<SEC-DOCUMENT>0001140361-26-029162.txt : 20260721
<SEC-HEADER>0001140361-26-029162.hdr.sgml : 20260721
<ACCEPTANCE-DATETIME>20260721172242
ACCESSION NUMBER:		0001140361-26-029162
CONFORMED SUBMISSION TYPE:	S-4
PUBLIC DOCUMENT COUNT:		167
FILED AS OF DATE:		20260721
DATE AS OF CHANGE:		20260721

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Passage BIO, Inc.
		CENTRAL INDEX KEY:			0001787297
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				822729751
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-297601
		FILM NUMBER:		261191135

	BUSINESS ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		2678660312

	MAIL ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4
<SEQUENCE>1
<FILENAME>ny20077915x1_s4.htm
<DESCRIPTION>S-4
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2025" xmlns:sic="http://xbrl.sec.gov/sic/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:exch="http://xbrl.sec.gov/exch/2025" xmlns:cef="http://xbrl.sec.gov/cef/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:pasg="http://passagebio.com/20260721" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_723110b0c7b24db4b051c4943c1e8143" contextRef="c20260101to20260331" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_9946e5eddb1a49729ff626a6ca5e08e2" contextRef="c20260101to20260331">0001787297</ix:nonNumeric><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_369a8940b23142559db48644f0c7b55d" contextRef="c20260101to20260331">Non-accelerated Filer</ix:nonNumeric><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_87ff84423c1d4358a1dd1652b1ad4132" contextRef="c20250714to20250714" unitRef="U004" decimals="2">0.05</ix:nonFraction><ix:nonFraction name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Fact_9c4ae5c452f740698340777ae9877470" contextRef="c20250714to20250714" unitRef="U004" decimals="2">0.05</ix:nonFraction><ix:nonNumeric name="us-gaap:IncomeTaxExaminationDescription" id="Fact_bf46da9b45834552bfbf43a7fff05a75" contextRef="c20250101to20251231">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December 31, 2025, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations. Tax years from 2022 and after remain subject to examination by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized.</ix:nonNumeric><ix:nonNumeric name="us-gaap:IncomeTaxExaminationYearUnderExamination" id="Fact_76a8a6c10938470cb53d52e197480e2e" contextRef="c20250101to20251231">2021 2022 2023 2024 2025</ix:nonNumeric><ix:nonFraction name="us-gaap:NumberOfReportableSegments" id="Fact_6fcb045ac6ef441986cb7c4046a9cae6" contextRef="c20250101to20251231" unitRef="U008" decimals="0">1</ix:nonFraction><ix:nonFraction name="us-gaap:NumberOfReportableSegments" id="Fact_54f55c66f3b44146b30493895e843cea" contextRef="c20260101to20260331" unitRef="U008" decimals="0">1</ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_ddc4c321df544d6ab525cd8234db36c3" contextRef="c20251231" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_3ede8ec3df2f4c6594e8b1e4cf743bf7" contextRef="c20241231" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_84393bbafad4493585cb473ec6ceb36d" contextRef="c20251231" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_37943eae796244c0bb11517d9e8ac664" contextRef="c20241231" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_b0ea0c10802147e1aace77035d2e4588" contextRef="c20260331" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_aae3abcfe7c54022ae82a6d996c01274" contextRef="c20251231" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_6cc7532afaff475eb890c1213316a0a2" contextRef="c20260331" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_fc17000e5373490cbae15a0831b04236" contextRef="c20251231" unitRef="U001" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="pasg-20260721.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20260101to20260331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentAndCertainOtherAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:PropertyPlantAndEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">pasg:LaboratoryEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260131_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">pasg:LaboratoryEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250714to20250714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-14</xbrli:startDate><xbrli:endDate>2025-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_CashAndCashEquivalentsAxis_DemandDepositsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CashAndCashEquivalentsAxis_DemandDepositsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FinancialInstrumentAxis_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_DisposalGroupClassificationAxis_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-31</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:MarketStreetSubleaseAgreement1835Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-29</xbrli:startDate><xbrli:endDate>2023-09-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240220to20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:MarketStreetSubleaseAgreement1835Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-20</xbrli:startDate><xbrli:endDate>2024-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-07</xbrli:startDate><xbrli:endDate>2023-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-04</xbrli:startDate><xbrli:endDate>2024-09-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200201to20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PlanNameAxis_EquityInducementPlan2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250131_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260131_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PlanNameAxis_EquityInducementPlan2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260501to20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-01</xbrli:startDate><xbrli:endDate>2026-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_IncomeTaxAuthorityAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_IncomeTaxAuthorityAxis_DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_TaxCreditCarryforwardAxis_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_TaxCreditCarryforwardAxis_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_OrphanDrugMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pasg:OrphanDrugMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260214to20260214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-14</xbrli:startDate><xbrli:endDate>2026-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260304to20260304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-03-04</xbrli:startDate><xbrli:endDate>2026-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PlanNameAxis_EquityInducementPlan2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260331_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_PlanNameAxis_EquityInducementPlan2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260428to20260428_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-04-28</xbrli:startDate><xbrli:endDate>2026-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260428_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20260522to20260522_PropertyPlantAndEquipmentByTypeAxis_MarketStreetLeaseAgreement2005Member_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:MarketStreetLeaseAgreement2005Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-05-22</xbrli:startDate><xbrli:endDate>2026-05-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20260624to20260624_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-06-24</xbrli:startDate><xbrli:endDate>2026-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U003"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>pasg:item</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>pasg:plan</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>pasg:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
<div style="line-height: initial;">

  <div style="color: #000000;">
    <!--Begin Page 1-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; position: relative; width: 540pt;"><a id="ny20077915x1_s4_100-regcov_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 540pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 25pt; text-align: center;">As filed with the Securities and Exchange Commission on July&#160;21, 2026. </div>

          <div class="BRDSX_regno" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 1pt; text-align: right;">Registration No. 333-&#8195;&#8195;&#8195;&#8195; </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 540pt; margin-left: 0pt;">
        <div>
          <div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>

          <div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-main" style="width: 540pt; margin-left: 0pt;">
        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 9.5pt; text-align: center;">UNITED STATES <br/>
        </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">SECURITIES AND EXCHANGE COMMISSION <br/>
        </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><span style="font-size: 12pt;">Washington, D.C. 20549 </span></div>

        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div>

        </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 16pt; font-weight: bold; margin-top: 10pt; text-align: center;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_ffd8b3e949cd48aba981e97fd7327022" contextRef="c20260101to20260331">S-4</ix:nonNumeric> </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><span style="font-size: 12pt;">REGISTRATION STATEMENT </span><br/>
        </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><span style="font-size: 12pt; font-style: italic;">UNDER </span><br/>
        </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 12pt;"><span style="font-size: 12pt; font-style: italic;">THE SECURITIES ACT OF 1933</span><span style="font-size: 12pt; font-weight: normal;"> </span></div>

        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div>

        </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold; margin-top: 10pt; text-align: center;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_a1fdc0d923ce49cba4f21e91dd7488c9" contextRef="c20260101to20260331">PASSAGE BIO, INC.</ix:nonNumeric><br/>
        </div>

        <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold; margin-top: 0pt; text-align: center; font-size: 10pt;"><span style="font-size: 10pt; font-weight: normal;">(Exact name of registrant as
            specified in its Charter)</span></div>

        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div>

        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div>

        <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 172pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 172pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 172pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 172pt; text-align: left; vertical-align: top;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Delaware<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(State or other jurisdiction of <br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">incorporation or organization) </div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 172pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">2836<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Primary Standard Industrial <br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Classification Code Number) </div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 172pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">82-2729751 <br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(I.R.S. Employer Identification No.)</div>
              </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3pt; width: 172pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 172pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 172pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

  </tr>


</table>
        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 2pt; text-align: center;">(267) 866-0311<br/>
        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Address, including zip code, and telephone number, including area code, of
          registrant&#8217;s principal executive offices) </div>

        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div>

        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 4pt; text-align: center;">William Chou, M.D. <br/>
        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Chief Executive Officer <br/>
        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Passage Bio, Inc. <br/>
        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Address Not Applicable<sup>1</sup> (267) 866-0311<br/>
        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Registrant&#8217;s telephone number, including area code) </div>

        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div>

        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-style: italic; font-weight: bold; margin-top: 4pt; text-align: center;">Copies to:<span style="font-style: normal; font-weight: normal;"> </span></div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div>

        <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 264pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 264pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 264pt; text-align: left; vertical-align: top;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Robert Freedman, Esq.<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">David Michaels, Esq.<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ryan Mitteness, Esq.<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fenwick &amp; West LLP<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">401 Union Street, 5<sup>th</sup> Floor<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Seattle, WA 98101<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(206) 389-4510</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 264pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Peter N. Handrinos, Esq.<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Leah R. Sauter, Esq.<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Elisabeth M. Martin, Esq.<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Latham &amp; Watkins LLP<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">200 Clarendon Street<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">Boston, MA 02116<br/>
                </div>
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; text-align: center;">(617) 948-6000</div>
              </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3pt; width: 264pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 264pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

  </tr>


</table>
        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div>

        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 4pt; text-align: center;">Approximate date of commencement of proposed sale to the public: </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 2pt; margin-left: 0pt; text-align: justify;">As soon as practicable after the effectiveness of this
          registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: justify;">If the securities being registered on this Form are being offered in connection
          with the formation of a holding company and there is compliance with General Instruction G, check the following box <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span></div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: justify;">If this Form is filed to register additional securities for an offering pursuant
          to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span></div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: justify;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under
          the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an
          accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2
          of the Exchange Act. </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"> </div>

        <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 0pt; width: 540pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 216pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 12pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 264pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 6pt; width: 12pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Large accelerated filer</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 12pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<span style="font-size: 9pt; font-family: Arial, Helvetica, sans-serif;">&#9744;</span></div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 264pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accelerated filer</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 12pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 1pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<span style="font-size: 9pt; font-family: Arial, Helvetica, sans-serif;">&#9744;</span><span style="font-size: 9pt;"> </span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: top;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="-sec-ix-hidden:Fact_369a8940b23142559db48644f0c7b55d">Non-accelerated filer</span><br/>
                </div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 12pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#9746;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 264pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Smaller reporting company</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 12pt; padding-top: 0.17pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_8a5466b72b744501b30bfdec44f2379c" contextRef="c20260101to20260331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
                </div>
              </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 0.17pt; text-align: left; vertical-align: top;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 12pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 264pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Emerging growth company</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="width: 12pt; padding-top: 0.46pt; text-align: left; vertical-align: bottom;">
                <div class="BRDSX_fpara" style="margin: 0pt 0px 0px 0pt; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_b69d9f57028d411898fbb83f8f542477" contextRef="c20260101to20260331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
                </div>
              </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3pt; width: 216pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 12pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 264pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 6pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

    <td style="height: 3pt; width: 12pt;">
                <div style="font-size: 1pt;">&#8194;</div>
              </td>

  </tr>


</table>
        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has
          elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;<span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span></div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: left;">If applicable, place an X in the box to designate the appropriate rule provision
          relied upon in conducting this transaction: </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: left;">Exchange Act Rule 13e-4(i) (Cross-Border Issuer Tender Offer) <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span></div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 2pt; margin-left: 0pt; text-align: left;">Exchange Act Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> </div>

        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 3.75pt;"> </div>

        </div>

        <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 2pt; margin-left: 0pt; text-align: justify;">The registrant hereby amends this registration statement on
          such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of
          the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</div>

      </div>

      <div class="BRDSX_block-footnote" style="width: 540pt; margin-left: 0pt;">
        <div>
          <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 3pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-footnote" style="width: 540pt; margin-left: 0pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 10pt; text-align: left; vertical-align: top;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;"><span style="position: relative; top: -3.25pt;">1</span><br/>
                </div>
              </td>

    <td style="vertical-align: top;">
                <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: justify; font-size: 8pt;"><span style="font-size: 8pt;">We are a remote-only company. Accordingly, we do not maintain a headquarters. For purposes of
                    compliance with applicable requirements of the Securities Act and Securities Exchange Act of 1934, as amended, any stockholder communication required to be sent to our principal executive offices may be directed to P.O. Box 7, Hopewell,
                    New Jersey 08525.</span></div>
              </td>

  </tr>


</table>
      </div>

      <div class="BRDSX_block-frill" style="width: 540pt; margin-top: 12pt; margin-left: 0pt;">
        <div>
          <div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div>

          <div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div>

        </div>

      </div>

    </div>

    <!--End Page 1-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 2-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 504pt;"><a id="ny20077915x1_s4_101-cov_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 504pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #FC0014; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">
            <div style="font-family: Arial, Helvetica, sans-serif; text-align: left; margin-bottom: 12pt;">The information in this preliminary proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the
              registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the
              offer or sale is not permitted. </div>
<div>
            SUBJECT TO COMPLETION, JULY&#160;21, 2026<span style="color: #000000;"> </span></div>
</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 43px; width: 220px;" src="logo_passagebio.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 14pt; text-align: center;">PROPOSED MERGER<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 0pt; text-align: center;">YOUR VOTE IS VERY IMPORTANT<span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">To the Stockholders of Passage Bio, Inc.,</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio, Inc., a Delaware corporation (&#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio</span>&#8221;), and Remix Therapeutics, Inc., a Delaware corporation (&#8220;<span style="font-style: italic; font-weight: bold;">Remix</span>&#8221;) have entered into an Agreement and Plan of Merger, dated June&#160;24, 2026 (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger Agreement</span>&#8221;), pursuant to which, among other matters, Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Passage Bio (&#8220;<span style="font-style: italic; font-weight: bold;">Merger Sub</span>&#8221;), will merge with and into Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio (such transaction, the &#8220;<span style="font-style: italic; font-weight: bold;">Merger</span>&#8221;). In
            connection with the Merger, Passage Bio will change its name to Remix Therapeutics, Inc. (together with its subsidiaries following the Merger, the &#8220;<span style="font-style: italic; font-weight: bold;">combined company</span>&#8221;).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the effective time of the merger (the &#8220;<span style="font-style: italic; font-weight: bold;">Effective Time&#8221;</span>), (a) each outstanding share of Remix common stock, par value $0.0001&#160;per share (&#8220;<span style="font-style: italic; font-weight: bold;">Remix Common Stock</span>&#8221;), and each share of Remix preferred
            stock, par value $0.0001 per share (&#8220;<span style="font-style: italic; font-weight: bold;">Remix Preferred Stock</span>&#8221; and, together with the Remix Common Stock, &#8220;<span style="font-style: italic; font-weight: bold;">Remix Capital Stock</span>&#8221;)

            (excluding shares held by Remix stockholders who have exercised and perfected appraisal rights, shares of Remix Capital Stock held as treasury stock by Remix or held or owned by Passage Bio, Merger Sub or any subsidiary of Passage Bio or Remix,
            and any shares described in the following clause (b)) will be converted into the right to receive approximately &#8195;&#8195;&#8195; shares of common stock of Passage Bio, par value $0.0001 per share (&#8220;<span style="font-style: italic; font-weight: bold;">Passage

              Bio Common Stock</span>&#8221;), based on an assumed exchange ratio of 0.1734 (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger</span> <span style="font-style: italic; font-weight: bold;">Exchange Ratio</span>&#8221;), assuming a reverse
            stock split of Passage Bio Common Stock at a ratio of &#8195;&#8195;-for-&#8195;&#8195; to be implemented prior to the closing of the Merger (the &#8220;<span style="font-style: italic; font-weight: bold;">Closing</span>&#8221;) as may be adjusted and as discussed in the
            accompanying proxy statement/prospectus, and which is further subject to certain adjustments as described below, and (b)&#160;each share of Remix Common Stock issued in the Concurrent Financing (as defined and described in more detail below) will be
            converted into the right to receive a number of shares of Passage Bio Common Stock calculated in accordance with the exchange ratio formula set forth in the Merger Agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Concurrent
              Financing Exchange Ratio</span>&#8221;), which is assumed to be &#8195;&#8195;&#8195; and is subject to the same assumptions as the Merger Exchange Ratio described above and below. Passage Bio will assume outstanding and unexercised options to purchase shares of
            Remix Common Stock, and in connection with the Merger such options will be converted into options to purchase shares of Passage Bio Common Stock based on the Merger Exchange Ratio.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each share of Passage Bio Common Stock issued and outstanding at the time of the
            Merger will remain issued and outstanding, and, subject to the proposed reverse stock split, will be unaffected by the Merger. In addition, on June&#160;24, 2026, Remix entered into a subscription agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Subscription Agreement</span>&#8221;) with certain investors, pursuant to which Remix has agreed to sell, and such investors have agreed to purchase, shares of Remix Common Stock for an aggregate purchase price of approximately
            $70.0&#160;million, immediately prior to the Effective Time of the Merger. The transactions contemplated by the Subscription Agreement, together with the issuance by Remix of approximately $30.0&#160;million of convertible promissory notes pursuant to a
            convertible promissory note purchase agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Remix Note&#160;Purchase Agreement (2026)</span>&#8221;), comprises the concurrent financing (such transactions, collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">Concurrent Financing</span>&#8221;), which is expected to result in aggregate gross proceeds of approximately $100.0&#160;million. The closing of the portion of the Concurrent Financing contemplated by the
            Subscription Agreement is conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. The Concurrent Financing is more fully described in the section titled &#8220;<span style="font-style: italic;">Questions and Answers&#8212;What is the Concurrent Financing?</span>&#8221; and &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Subscription Agreement</span> <span style="font-style: italic;">and Registration Rights
              Agreement</span>.&#8221;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Merger Exchange Ratio and Concurrent Financing Exchange Ratio formulas
            in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon the number of shares of Passage Bio Common Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Remix (other than
            investors in the Concurrent Financing) are expected to own approximately 65% of the combined company, pre-Merger equityholders of Passage Bio are expected to own approximately 6% of the combined company and the investors in the Concurrent
            Financing are expected to own approximately 29% of the combined company (assuming proceeds from the Concurrent Financing of approximately $100.0&#160;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and
            subject to certain assumptions, including (i) a valuation for Passage Bio of approximately $20.0 million (assuming Passage Bio has net cash (&#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio Net Cash</span>&#8221;) of $5.0 million as
            of the Closing), (ii) an equity value for Remix of $226.0&#160;million, and (iii) the relative capitalization of Passage Bio and Remix. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject
            to certain adjustments (as described in more detail in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Merger Consideration and Merger Exchange Ratio</span>&#8221;), including the amount of the final Passage Bio Net Cash at
            the Closing.</div>

        </div>

      </div>

    </div>

    <!--End Page 2-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 3-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 504pt;"><a id="ny20077915x1_s4_101-cov_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 504pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Shares of Passage Bio Common Stock are currently listed on The Nasdaq Capital
            Market (&#8220;<span style="font-style: italic; font-weight: bold;">Nasdaq</span>&#8221;) under the symbol &#8220;PASG.&#8221; Remix will file an initial listing application for the combined company with Nasdaq. After completion of the Merger, Passage Bio will be
            renamed &#8220;Remix Therapeutics, Inc.&#8221;, and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;RMTX.&#8221; On July&#160;20, 2026, the last trading day before the date of the accompanying proxy
            statement/prospectus, the closing sale price of Passage Bio Common Stock was $4.81 per share.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio stockholders are cordially invited to attend a special meeting of
            Passage Bio stockholders (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio special meeting</span>&#8221;). The Passage Bio special meeting is being held on &#8195;&#8195;&#8195;, 2026 unless postponed or adjourned to a later date, in order to
            obtain the stockholder approvals necessary to complete the Merger and related matters. The Passage Bio special meeting will be held entirely online. Passage Bio stockholders will be able to attend and participate in the Passage Bio special
            meeting by registering at &#8195;&#8195;&#8195; where they will be able to listen to the meeting live, submit questions and vote.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After careful consideration, each of Passage Bio&#8217;s board of directors (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio Board</span>&#8221;) and Remix&#8217;s board of directors (the &#8220;<span style="font-style: italic; font-weight: bold;">Remix Board</span>&#8221;) have approved the Merger Agreement and the Contemplated
            Transactions (as defined below) and have determined that it is advisable to consummate the Merger. The Passage Bio Board has approved the proposals described in the accompanying proxy statement/prospectus and unanimously recommends that its
            stockholders vote &#8220;FOR&#8221; the proposals described in the accompanying proxy statement/prospectus.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">At the Passage Bio special meeting, Passage Bio will ask its stockholders to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve the issuance of shares of Passage Bio Common Stock to the securityholders of Remix, pursuant to the terms of the Merger
                    Agreement, a copy of which is attached as <span style="text-decoration: underline;">Annex&#160;A</span><span style="font-style: italic;"> </span>to the accompanying proxy statement/prospectus, which will (a) represent more than 20% of the shares of Passage Bio Common Stock
                    outstanding immediately prior to the Merger and (b) result in the change of control of Passage Bio, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively (the &#8220;<span style="font-style: italic; font-weight: bold;">Nasdaq
                      Stock Issuance Proposal</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Proposal&#160;No.&#160;1</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve an amendment to Passage Bio&#8217;s amended and restated certificate of incorporation to effect, prior to the Effective Time,
                    a reverse stock split of Passage Bio&#8217;s issued and outstanding common stock at a ratio in the range from 1-for-&#8195;&#8195; to 1-for-&#8195;&#8195;, inclusive, with the final ratio to be mutually agreed to by Passage Bio and Remix, in the form attached as <span style="text-decoration: underline;">Annex&#160;I</span><span style="font-style: italic;"> </span>to the accompanying proxy statement/prospectus (the &#8220;<span style="font-style: italic; font-weight: bold;">Reverse Stock Split Proposal</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Proposal No. 2</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve the amendment and restatement of Passage Bio&#8217;s amended and restated certificate of incorporation, effective as of the
                    Effective Time, to (i) change the name of Passage Bio to &#8220;Remix Therapeutics, Inc.,&#8221; and (ii)&#160;make certain other changes, in the form attached as <span style="text-decoration: underline;">Annex&#160;J</span> to the accompanying proxy statement/prospectus (the &#8220;<span style="font-style: italic; font-weight: bold;">Charter Proposal</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Proposal No. 3</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve, on an advisory and non-binding basis, certain material amendments to Passage Bio&#8217;s amended and restated certificate of
                    incorporation reflected in the Proposed Restated Charter, presented as separate subproposals (the &#8220;<span style="font-style: italic; font-weight: bold;">Governance Proposals</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Proposal No. 4</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve the adoption of the Remix Therapeutics, Inc. 2026 Equity Incentive Plan in the form attached as <span style="text-decoration: underline;">Annex </span><span style="text-decoration: underline;">K</span>
                    to the accompanying proxy statement/prospectus (the &#8220;<span style="font-style: italic; font-weight: bold;">2026 Plan Proposal</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Proposal No. 5</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve the adoption of the Remix Therapeutics, Inc. 2026 Employee Stock Purchase Plan in the form attached as <span style="text-decoration: underline;">Annex </span><span style="text-decoration: underline;">L</span>
                    to the accompanying proxy statement/prospectus (the &#8220;<span style="font-style: italic; font-weight: bold;">2026 ESPP Proposal</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Proposal No. 6</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve on an advisory, non-binding basis certain compensation arrangements for Passage Bio&#8217;s named executive officers in
                    connection with the Merger (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger Compensation Proposal</span>&#8221; <span style="font-style: italic;">or &#8220;</span><span style="font-style: italic; font-weight: bold;">Proposal No. 7</span><span style="font-style: italic;">&#8221;</span>); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Approve an adjournment of the Passage Bio special meeting, if necessary, to solicit additional proxies if there are not
                    sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Charter Proposal, the Governance Proposals, the 2026 Plan Proposal, the 2026 ESPP Proposal and/or the Merger Compensation Proposal
                    (the &#8220;<span style="font-style: italic; font-weight: bold;">Adjournment Proposal</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Proposal No. 8</span>&#8221;); and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Transact such other business as may properly come before the stockholders at the Passage Bio special meeting or any adjournment
                    or postponement thereof. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As described in the accompanying proxy statement/prospectus, certain Passage Bio
            stockholders who in the aggregate beneficially owned approximately 1% of the outstanding shares of Passage Bio Common Stock as of June&#160;24, 2026, and certain Remix stockholders who in the aggregate beneficially owned approximately 93% of the
            outstanding shares of Remix Capital Stock as of June&#160;24, 2026, are parties to support agreements with Passage Bio and Remix, respectively, whereby such stockholders have agreed to vote (i)&#160;in the case of Passage Bio stockholders, in favor of
            the Merger and the other transactions and actions contemplated by the Merger Agreement (collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">Contemplated Transactions</span>&#8221;), including (a)&#160;the Nasdaq Stock Issuance
            Proposal, (b)&#160;the Reverse Stock Split Proposal, (c)&#160;the Charter Proposal, and (d)&#160;the other transactions </div>

        </div>

      </div>

    </div>

    <!--End Page 3-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 4-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 504pt;"><a id="ny20077915x1_s4_101-cov_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 504pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and actions contemplated by the Merger Agreement, including the Concurrent
            Financing (as defined in the Merger Agreement), and (ii)&#160;in the case of Remix stockholders, in favor of adopting the Merger Agreement and approving the Merger and the other Contemplated Transactions, in each case, subject to the terms of the
            support agreements. Following the effectiveness of the registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part, and pursuant to the Merger Agreement, Remix shall seek to obtain approval for the Merger
            Agreement and the Contemplated Transactions from stockholders holding a sufficient number of shares of Remix Capital Stock to adopt and approve such matters.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">More information about Passage Bio, Remix, the Merger
            Agreement and Contemplated Transactions, and the foregoing proposals is contained in the accompanying proxy statement/prospectus. Passage Bio urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN
            PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;<span style="text-decoration: underline;">RISK FACTORS</span>&#8221; BEGINNING ON PAGE <a href="#tRF">23</a> OF THE ACCOMPANYING PROXY STATEMENT/ PROSPECTUS.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is excited about the opportunities the Merger brings to Passage Bio&#8217;s
            stockholders and thanks you for your consideration and continued support. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">William Chou, M.D.<span style="font-weight: normal;"> </span><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><span style="font-style: italic; font-weight: normal;">President and Chief
              Executive Officer</span><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><span style="font-weight: normal;">Passage Bio, Inc.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Neither the Securities and Exchange Commission nor any state
            securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy statement/prospectus. Any representation to the contrary is a criminal offense.<span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying proxy statement/prospectus is dated &#8195;&#8195;&#8195;,
            2026, and is first being mailed to Passage Bio&#8217;s stockholders on or about &#8195;&#8195;&#8195;, 2026.</div>

        </div>

      </div>

    </div>

    <!--End Page 4-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 5-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_102-notice_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PASSAGE BIO, INC.<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">P.O. Box 7<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Hopewell, New Jersey 08525<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">To the stockholders of Passage Bio, Inc.:</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On behalf of the Passage Bio Board, we are pleased to deliver this proxy
            statement/prospectus for the proposed Merger between Passage Bio and Remix pursuant to which, among other matters, Merger Sub will merge with and into Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio special meeting will be held on &#8195;&#8195;&#8195;, 2026 unless postponed or
            adjourned to a later date. The Passage Bio special meeting will be held entirely online. You will be able to attend and participate in the Passage Bio special meeting by registering at &#8195;&#8195;&#8195;. Upon entry of your control number and other required
            information, you will receive further instructions via email that provide you access to the Passage Bio special meeting and to vote and submit questions during the Passage Bio special meeting. The Passage Bio special meeting will be held for
            the following purposes, which are collectively referred to as the &#8220;<span style="font-style: italic; font-weight: bold;">Proposals</span>&#8221;: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the issuance of shares of Passage Bio Common Stock to the securityholders of Remix, pursuant to the terms of the
                    Merger Agreement, a copy of which is attached as <span style="text-decoration: underline;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, which will (a) represent more than 20% of the shares of Passage Bio Common Stock outstanding immediately prior to the
                    Merger and (b) result in the change of control of Passage Bio, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve an amendment to Passage Bio&#8217;s amended and restated certificate of incorporation to effect a reverse stock split of
                    Passage Bio&#8217;s issued and outstanding common stock at a ratio in the range from 1-for-&#8195;&#8195; to 1-for-&#8195;&#8195;, inclusive, with the final ratio to be mutually agreed to by Passage Bio and Remix, in the form attached as <span style="text-decoration: underline;">Annex&#160;I</span> to the
                    accompanying proxy statement/prospectus; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the amendment and restatement of to Passage Bio&#8217;s amended and restated certificate of incorporation to (i)&#160;change the
                    name of Passage Bio to &#8220;Remix Therapeutics, Inc.,&#8221; and (ii)&#160;make certain other changes, in the form attached as <span style="text-decoration: underline;">Annex&#160;J</span> to the accompanying proxy statement/prospectus; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve, on an advisory and non-binding basis, certain material amendments to Passage Bio&#8217;s certificate of incorporation
                    reflected in the Proposed Restated Charter, presented as separate subproposals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the adoption of the Remix Therapeutics, Inc. 2026 Equity Incentive Plan; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve the adoption of the Remix Therapeutics, Inc. 2026 Employee Stock Purchase Plan; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve on an advisory, non-binding basis certain compensation arrangements for Passage Bio&#8217;s named executive officers in
                    connection with the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To approve an adjournment of the Passage Bio special meeting, if necessary, to solicit additional proxies if there are not
                    sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Charter Proposal, the Governance Proposals, the 2026 Plan Proposal, the 2026 ESPP Proposal and/or the Merger Compensation Proposal;
                    and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To transact such other business as may properly come before the stockholders at the Passage Bio special meeting or any
                    adjournment or postponement thereof. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Board has fixed &#8195;&#8195;&#8195;, 2026 as the record date for the
            determination of stockholders entitled to notice of, and to vote at, the Passage Bio special meeting and any adjournment or postponement thereof. Only holders of record of shares of Passage Bio Common Stock at the close of business on the
            record date are entitled to notice of, and to vote at, the Passage Bio special meeting. At the close of business on the record date, Passage Bio had &#8195;&#8195;&#8195; shares of Passage Bio Common Stock outstanding and entitled to vote.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Your vote is important. The affirmative vote of the holders of a majority of the
            voting power of all outstanding shares of Passage Bio Common Stock entitled to vote thereon is required for the approval of Proposal Nos. 2 and 3. The affirmative approval of a majority of the votes cast on the proposal by the holders of
            Passage Bio Common Stock entitled to vote at the Passage Bio special meeting, assuming a quorum is present, is required for the approval of Proposal Nos. 1, 4, 5, 6, 7 and 8. Each of Proposal Nos. 1, 2 and 3 is a condition to completion of the
            Merger. The </div>

        </div>

      </div>

    </div>

    <!--End Page 5-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 6-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_102-notice_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">closing of the Concurrent Financing is conditioned upon the satisfaction or
            waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Merger and the Concurrent Financing cannot be consummated without the approval of Proposal Nos. 1, 2 and 3. The issuance of Passage Bio Common
            Stock in connection with the Merger and the change of control of Passage Bio resulting from the Merger will not take place unless Proposal Nos. 1, 2 and 3 are approved by Passage Bio stockholders and the reverse stock split is effected, Passage
            Bio&#8217;s name is changed to &#8220;Remix Therapeutics, Inc.&#8221; and the Merger is consummated. The approval of Proposal Nos. 4, 5, 6, 7 and 8 is not a condition to the completion of the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Even if you plan to virtually attend the Passage Bio special meeting, Passage Bio
            requests that you sign and return the enclosed proxy or vote by mail, by phone or online to ensure that your shares will be represented at the Passage Bio special meeting if you are unable to virtually attend. You may change or revoke your
            proxy at any time before it is voted at the Passage Bio special meeting.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">THE PASSAGE BIO BOARD HAS UNANIMOUSLY DETERMINED AND BELIEVES
            THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, ADVISABLE AND IN THE BEST INTERESTS OF PASSAGE BIO AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL. THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS THAT PASSAGE BIO STOCKHOLDERS VOTE
            &#8220;FOR&#8221; EACH SUCH PROPOSAL.</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">The proxy statement/prospectus is available at &#8195;&#8195;&#8195;&#8195;&#8195;</div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">By Order of the Passage Bio Board of Directors, </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">William Chou, M.D.<span style="font-weight: normal;"> </span><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="font-style: italic; font-weight: normal;">President

              and Chief Executive Officer</span><span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8195;&#8195;&#8195;, <span style="font-style: italic;">2026</span></div>

        </div>

      </div>

    </div>

    <!--End Page 6-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 7-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_102-notice_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">EXPLANATORY NOTE</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The issuances of (i) all shares of Passage Bio Common Stock in exchange for
            shares of Remix Common Stock, including the shares of Remix Common Stock to be issued in the Subscription Financing immediately prior to the Effective Time, after giving effect to (A) the conversion of all outstanding shares of Remix preferred
            stock into shares of Remix Common Stock, (B) the conversion of the 2025 Convertible Notes and the associated warrants into shares of Remix Common Stock, and (C) the conversion of the 2026 Convertible Notes into shares of Remix Common Stock,
            (ii) shares of Passage Bio Common Stock issuable upon exercise of warrants issued in exchange for Remix warrants, and (iii) shares of Passage Bio Common Stock issuable upon exercise of options to purchase shares of Passage Bio Common Stock in
            exchange for options to purchase shares of Remix Common Stock outstanding under the Remix 2019 Plan, are intended to be covered by this registration statement on Form S-4 of which this proxy statement/prospectus is a part.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There is no difference between (i) the shares of Passage Bio Common Stock that
            will be issued in exchange for each share of Remix Common Stock, (ii) the shares of Passage Bio Common Stock that will be issuable upon the exercise of Passage Bio Warrants issued in exchange for Remix Warrants, (iii) the shares of Passage Bio
            Common Stock that will be issuable upon the exercise of options to purchase shares of Passage Bio Common Stock issued in exchange for Remix Options.</div>

        </div>

      </div>

    </div>

    <!--End Page 7-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 8-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_104-toc_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <a id="TOC"><!--Anchor--></a>
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 432pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tQA">QUESTIONS AND ANSWERS</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tQA"><span style="padding-left: 10pt;">1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS">PROSPECTUS SUMMARY</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPS"><span style="padding-left: 5pt;">10</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTCOMP">The Companies</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTCOMP"><span style="padding-left: 5pt;">10</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tMERG">The Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tMERG"><span style="padding-left: 5pt;">10</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM2">Passage Bio&#8217;s Reasons for the Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM2"><span style="padding-left: 5.37pt;">11</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM3">Remix&#8217;s Reasons for the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM3"><span style="padding-left: 5.37pt;">11</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM4">Recommendation of the Passage Bio Board</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM4"><span style="padding-left: 5.37pt;">11</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM5">Interests of Passage Bio&#8217;s Directors and Executive
                      Officers in the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM5"><span style="padding-left: 5pt;">12</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM6">Interests of Remix&#8217;s Directors and Executive Officers in
                      the Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM6"><span style="padding-left: 5pt;">12</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM7">Opinion of Redwood Valuation Partners, LLC</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM7"><span style="padding-left: 5pt;">13</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM8">The Merger Agreement</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM8"><span style="padding-left: 5pt;">13</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM9">Management Following the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM9"><span style="padding-left: 5pt;">18</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM10">Material U.S. Federal Income Tax Consequences of the
                      Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM10"><span style="padding-left: 5pt;">18</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM11">Risk Factors</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM11"><span style="padding-left: 5pt;">18</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM12">Regulatory Approvals</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM12"><span style="padding-left: 5pt;">21</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM13">Nasdaq Listing</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM13"><span style="padding-left: 5pt;">21</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM14">Anticipated Accounting Treatment</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM14"><span style="padding-left: 5pt;">22</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM15">Appraisal Rights</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM15"><span style="padding-left: 5pt;">22</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTM16">Comparison of Stockholder Rights</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM16"><span style="padding-left: 5pt;">22</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRF"><span style="padding-left: 5pt;">23</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tRF1">Risks Related to the Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRF1"><span style="padding-left: 5pt;">23</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tRF2">Risks Related to the Reverse Stock Split</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRF2"><span style="padding-left: 5pt;">29</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tRF3">Risks Related to Passage Bio</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRF3"><span style="padding-left: 5pt;">30</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tRF4">Risks Related to Remix</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRF4"><span style="padding-left: 5pt;">36</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tRF5">Risks Related to the Combined Company</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRF5"><span style="padding-left: 5pt;">94</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMPDI">MARKET PRICE AND DIVIDEND INFORMATION</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tMPDI">102</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tDIV">Dividends</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tDIV">102</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tFLS">103</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTM">THE MERGER</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTM">106</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tBOTM">Background of the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tBOTM">106</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMPB">Passage Bio&#8217;s Reasons for the Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMPB"><span style="padding-left: 0.37pt;">112</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMRR">Remix&#8217;s Reasons for the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMRR"><span style="padding-left: 0.37pt;">115</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMORV">Opinion of Redwood (Passage Bio&#8217;s Financial Advisor)</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMORV"><span style="padding-left: 0.37pt;">119</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMIPB">Interests of Passage Bio&#8217;s Directors and Executive
                      Officers in the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMIPB">125</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTOSPB">Treatment of Shares of Passage Bio Common Stock</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTOSPB">126</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMIRD">Interests of Remix&#8217;s Directors and Executive Officers
                      in the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMIRD">129</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTORO">Treatment of Remix Options</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTORO">131</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tETOTM">Effective Time of the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tETOTM">131</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMMFI">Material U.S. Federal Income Tax Consequences of the
                      Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMMFI">132</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tNLIS">Nasdaq Stock Market Listing</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tNLIS">132</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMAAT">Anticipated Accounting Treatment</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMAAT">132</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMARI">Appraisal Rights</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMARI">132</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tTMA">THE MERGER AGREEMENT</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMA">137</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tSTRUC">Structure</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tSTRUC">137</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tCOEOTM">Completion and Effectiveness of the Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tCOEOTM">137</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTORCNAR">Treatment of Remix Convertible Notes and Remix
                      Preferred Stock</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTORCNAR">137</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMAMC">Merger Consideration and Merger Exchange Ratio</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMAMC">137</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tCOPBNC">Calculation of Passage Bio Net Cash</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tCOPBNC">140</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tDPBNCS">Delivery of Passage Bio Net Cash Schedule</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tDPBNCS">140</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTORMO">Treatment of Remix Options and Remix Equity Plan</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTORMO">141</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br/>
        </div>

      </div>

    </div>

    <!--End Page 8-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 9-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_104-toc_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 432pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTORW">Treatment of Remix Warrants</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTORW">141</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tDAEOCCF">Directors and Executive Officers of the Combined
                      Company Following the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tDAEOCCF">141</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tAOTRC">Amendment of the Restated Certificate of Incorporation
                      of Passage Bio</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tAOTRC">142</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPAS">Potential Asset Sale</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPAS">142</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tRAW">Representations and Warranties</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRAW">142</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tCCOBPM">Covenants; Conduct of Business Pending the Merger</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tCCOBPM">143</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tCVR">Contingent Value Rights</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tCVR">146</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMANS">Non-Solicitation</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMANS">146</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tBRC">Board Recommendation Change</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tBRC">148</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tMOPBSAWORS">Meeting of Passage Bio&#8217;s Stockholders and Written
                      Consent of Remix&#8217;s Stockholders</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tMOPBSAWORS">150</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMARA">Regulatory Approvals</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMARA">151</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tIAIFDAO">Indemnification and Insurance for Directors and
                      Officer</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tIAIFDAO">151</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tS16M">Section&#160;16 Matters</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tS16M">152</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#t2P2E">2026 Plan and 2026 ESPP</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#t2P2E">152</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPB4P">Passage Bio 401(K) Plan</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPB4P">152</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTOE">Termination of Employees</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTOE">152</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tS2G">Section&#160;280G</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tS2G">152</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tAA">Additional Agreements</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tAA">153</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMACC">Conditions to the Completion of the Merger</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMACC">154</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tTMATT">Termination and Termination Fees</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tTMATT">156</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tAW">Amendment and Waiver</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tAW">158</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tFE">Fees and Expenses</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tFE">158</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tARM">AGREEMENTS RELATED TO THE MERGER</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tARM">159</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tARMSA">Support Agreements</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tARMSA">159</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tARMLA">Lock-Up Agreements</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tARMLA">160</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tARM1">The Concurrent Financing</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tARM1">160</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tARMSAR">Registration Rights Agreement</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tARMSAR">161</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tARMCVR">Contingent Value Rights Agreement</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tARMCVR">161</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPEOC">PASSAGE BIO EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPEOC">169</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPEOD">PASSAGE BIO EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPEOD">173</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tREOD">REMIX EXECUTIVE OFFICER AND DIRECTOR COMPENSATION</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tREOD">181</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMAT">MATTERS BEING SUBMITTED TO A VOTE OF PASSAGE BIO
                      STOCKHOLDERS</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tMAT">187</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP1">PROPOSAL NO. 1&#8212;THE NASDAQ STOCK ISSUANCE PROPOSAL</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP1">187</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP2">PROPOSAL NO. 2&#8212;THE REVERSE STOCK SPLIT PROPOSAL</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP2">189</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP3">PROPOSAL NO. 3&#8212;THE CHARTER PROPOSAL</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP3">195</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP4">PROPOSAL NO. 4&#8212;THE GOVERNANCE PROPOSALS</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP4">197</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP5">PROPOSAL NO. 5&#8212;THE 2026 EQUITY INCENTIVE PLAN PROPOSAL</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP5">201</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP6">PROPOSAL NO. 6&#8212;THE 2026 EMPLOYEE STOCK PURCHASE PLAN
                      PROPOSAL</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP6">208</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP7">PROPOSAL NO. 7&#8212;THE MERGER COMPENSATION PROPOSAL</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP7">212</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tPROP8">PROPOSAL NO. 8&#8212;THE ADJOURNMENT PROPOSAL</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPROP8">213</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPBB">PASSAGE BIO&#8217;S BUSINESS</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tPBB">214</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRB">REMIX&#8217;S BUSINESS</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tRB">219</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tMDA">PASSAGE BIO MANAGEMENT&#8217;S DISCUSSION
                      AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tMDA">256</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tMDAR">REMIX&#8217;S MANAGEMENT&#8217;S DISCUSSION AND
                      ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tMDAR">267</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tMFTM">MANAGEMENT FOLLOWING THE MERGER</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tMFTM">284</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCRRP">CERTAIN RELATIONSHIPS AND RELATED
                      PARTY TRANSACTIONS OF THE COMBINED COMPANY</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tCRRP">289</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUFC">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
                      INFORMATION</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tUFC">293</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNUP">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL
                      INFORMATION</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.5pt; text-align: left;"><a href="#tNUP">299</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">ii<br/>
        </div>

      </div>

    </div>

    <!--End Page 9-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 10-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_104-toc_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 432pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDPBC">DESCRIPTION OF PASSAGE BIO CAPITAL STOCK</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tDPBC"><span style="padding-left: 2.22pt;">304</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCRHP">COMPARISON OF RIGHTS OF HOLDERS OF
                      PASSAGE BIO CAPITAL STOCK AND REMIX CAPITAL STOCK</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tCRHP"><span style="padding-left: 2.22pt;">308</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSAR">SECURITIES ACT RESTRICTIONS ON RESALE OF COMBINED COMPANY
                      COMMON STOCK</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tSAR"><span style="padding-left: 2.22pt;">315</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSPB">PRINCIPAL STOCKHOLDERS OF PASSAGE BIO</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tPSPB"><span style="padding-left: 2.22pt;">316</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSR">PRINCIPAL STOCKHOLDERS OF REMIX</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tPSR"><span style="padding-left: 2.22pt;">318</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPSC">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tPSC"><span style="padding-left: 2.22pt;">320</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">LEGAL MATTERS</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tLM"><span style="padding-left: 2.22pt;">322</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">EXPERTS</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tEXP"><span style="padding-left: 2.22pt;">322</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCD2">CHANGES AND DISAGREEMENTS WITH
                      ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tCD2"><span style="padding-left: 2.22pt;">322</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tWYC"><span style="padding-left: 2.22pt;">322</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSPN">STOCKHOLDER PROPOSALS</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tSPN"><span style="padding-left: 2.22pt;">324</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tSPN1">Contacting the Passage Bio Board</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tSPN1"><span style="padding-left: 2.22pt;">324</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tSPN2">Householding of Proxy Statement/Prospectus</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tSPN2"><span style="padding-left: 2.22pt;">324</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><a href="#tSPN3">Other Matters</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tSPN3"><span style="padding-left: 2.22pt;">324</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tIFS">INDEX TO FINANCIAL STATEMENTS</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tIFS"><span style="padding-left: 3.33pt;">F-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXA">Annex&#160;A&#8212;Merger Agreement</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXA"><span style="padding-left: 1.67pt;">A-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXB">Annex&#160;B&#8212;Opinion of Passage Bio Financial Advisor</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXB"><span style="padding-left: 2.22pt;">B-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXC">Annex&#160;C&#8212;Form&#160;of Passage Bio Support Agreement</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXC"><span style="padding-left: 2.22pt;">C-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXD">Annex&#160;D&#8212;Form&#160;of Company Support Agreement</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXD"><span style="padding-left: 1.67pt;">D-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXE">Annex&#160;E&#8212;Form&#160;of Lock-Up Agreement</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXE"><span style="padding-left: 2.78pt;">E-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXF">Annex&#160;F&#8212;Form&#160;of CVR Agreement</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXF"><span style="padding-left: 3.33pt;">F-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXG">Annex&#160;G&#8212;Subscription Agreement</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXG"><span style="padding-left: 1.67pt;">G-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXH">Annex&#160;H&#8212;Form&#160;of Registration Rights Agreement</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXH"><span style="padding-left: 1.67pt;">H-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tANXI">Annex&#160;I&#8212;Certificate of Amendment of
                      Amended and Restated Certificate of Incorporation of Passage Bio to Provide for the Reverse Stock Split</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXI"><span style="padding-left: 5.56pt;">I-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXJ">Annex&#160;J&#8212;Proposed Amended and Restated Certificate of
                      Incorporation of the Combined Company</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXJ"><span style="padding-left: 5pt;">J-2</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXL">Annex&#160;K&#8212;2026 Equity Incentive Plan</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXL"><span style="padding-left: 1.67pt;">K-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXM">Annex&#160;L&#8212;2026 Employee Stock Purchase Plan</a></div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXM"><span style="padding-left: 2.78pt;">L-1</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXN">Annex&#160;M&#8212;Form&#160;of Proxy Card</a></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.39pt; text-align: left;"><a href="#tANXN">M-1</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3.25pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">iii<br/>
        </div>

      </div>

    </div>

    <!--End Page 10-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 11-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tQA"><!--Anchor--></a>QUESTIONS AND ANSWERS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Except where specifically noted, the following information
            and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No. 2 of this proxy statement/prospectus.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following section provides answers to frequently asked questions about the
            Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross-referenced sections. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What is the Merger? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio, Merger Sub, and Remix entered into the Merger Agreement on June&#160;24, 2026. The Merger Agreement contains the terms
                    and conditions of the proposed merger transaction among Passage Bio, Merger Sub, and Remix. Under the Merger Agreement, Merger Sub will merge with and into Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio. This
                    transaction is referred to as the Merger. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why are the two companies proposing to merge? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio and Remix believe that combining the two companies will result in a substantially capitalized, clinical-stage
                    biotechnology company advancing a leading portfolio of RNA-processing and small-molecule therapeutics. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<span style="font-style: italic;">The
                      Merger&#8212;Passage Bio&#8217;s Reasons for the Merger</span>&#8221; and &#8220;<span style="font-style: italic;">The Merger&#8212;Remix&#8217;s Reasons for the Merger</span>&#8221; of this proxy statement/prospectus. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Why am I receiving this proxy statement/prospectus? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You are receiving this proxy statement/prospectus because you have been identified as a stockholder of Passage Bio as of the
                    record date. This document serves as: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a proxy statement of Passage Bio used to solicit proxies for the Passage Bio special meeting to vote on the matters set forth
                    herein; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a prospectus of Passage Bio used to offer shares of Passage Bio Common Stock in exchange for shares of Remix Capital Stock in
                    the Merger. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What is the Concurrent Financing? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">This proxy statement/prospectus collectively refers to the transactions contemplated by the Subscription Agreement and the Remix
                    Note Purchase Agreement (2026) as the &#8220;Concurrent Financing.&#8221; The Concurrent Financing is expected to result in aggregate gross proceeds of approximately $100.0 million. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">On June&#160;24, 2026, Remix entered into the Subscription Agreement with certain
            accredited investors (the &#8220;<span style="font-style: italic; font-weight: bold;">Investors</span>&#8221;), pursuant to which Remix agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares of Remix Common
            Stock for an aggregate purchase price of approximately $70.0&#160;million. On June 29, 2026, Remix issued approximately $30&#160;million of convertible promissory notes pursuant to the Remix Note PurchaseAgreement (2026). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Shares of Remix Common Stock issued pursuant to the Concurrent Financing will be
            converted into shares of Passage Bio Common Stock in accordance with the Concurrent Financing Exchange Ratio in the Merger Agreement. Remix and Passage Bio have also agreed to enter into a registration rights agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Registration Rights Agreement</span>&#8221;) with the Investors at the closing of the Concurrent Financing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Immediately after the Closing, under the Merger Exchange Ratio and Concurrent
            Financing Exchange Ratio formulas in the Merger Agreement, on a pro forma basis and based upon the number of shares of Passage Bio Common Stock expected to be issued in connection with the Merger, the Investors are expected to own approximately
            29% of the combined company, calculated on a fully diluted basis, using the treasury stock method and subject to certain assumptions (as described in more detail in the section titled &#8220;<span style="font-style: italic;">The Merger
              Agreement&#8212;Merger Consideration and Merger Exchange Ratio</span>&#8221;). </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br/>
        </div>

      </div>

    </div>

    <!--End Page 11-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 12-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">How many shares must be present to hold the Passage Bio special meeting? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The presence of the holders of a majority of the shares of Passage Bio Common Stock entitled to vote, present in person or
                    represented by proxy, at the Passage Bio special meeting is necessary to constitute a quorum at the meeting for the Proposals. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What proposals must be approved by Passage Bio stockholders in order for the Merger to close? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The following proposals must be approved by the Required Passage Bio Stockholder Vote (as defined in the Merger Agreement) at
                    the Passage Bio special meeting in order for the Merger to close: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 1</span>&#8212;<span style="font-weight: bold;">The Nasdaq Stock Issuance Proposal </span>to

                    approve the issuance of shares of Passage Bio Common Stock to the securityholders of Remix, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span style="text-decoration: underline;">Annex&#160;A</span><span style="font-style: italic;"> </span>to this
                    proxy statement/prospectus, which will (a) represent more than 20% of the shares of Passage Bio Common Stock outstanding immediately prior to the Merger and (b) result in the change of control of Passage Bio, pursuant to Nasdaq Listing
                    Rules 5635(a) and 5635(b), respectively; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 2</span>&#8212;<span style="font-weight: bold;">The Reverse Stock Split Proposal </span>to

                    approve an amendment to Passage Bio&#8217;s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding Passage Bio Common Stock at a ratio in the range from 1-for-&#8195;&#8195; to 1-for-&#8195;&#8195;, inclusive,
                    with the final ratio to be mutually agreed to by Passage Bio and Remix, in the form attached as <span style="text-decoration: underline;">Annex&#160;I</span><span style="font-style: italic;"> </span>to this proxy statement/prospectus; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 3</span>&#8212;<span style="font-weight: bold;">The Charter Proposal </span>to approve
                    an amendment and restatement of Passage Bio&#8217;s amended and restated certificate of incorporation to (i) change the name of Passage Bio to &#8220;Remix Therapeutics, Inc.,&#8221; and (ii) make certain other changes, in the form attached as <span style="text-decoration: underline;">Annex&#160;J</span>
                    to this proxy statement/prospectus. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The approval of each of Proposal Nos. 1, 2 and 3 by Passage Bio's stockholders
            is a condition to the completion of the Merger. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What other proposals are to be voted on at the Passage Bio special meeting? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">At the Passage Bio special meeting, the holders of Passage Bio Common Stock will also be asked to consider the following
                    proposals: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 4&#8212;The Governance Proposals</span> to approve on a non-binding advisory basis,
                    certain material amendments to the Passage Bio amended and restated certificate of incorporation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 5&#8212;The 2026 Plan Proposal </span>to approve the adoption of the Remix
                    Therapeutics, Inc. 2026 Equity Incentive Plan. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 6&#8212;The 2026 ESPP Proposal </span>to approve the adoption of the Remix
                    Therapeutics, Inc. 2026 Employee Stock Purchase Plan. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 7&#8212;The Merger Compensation Proposal </span>to approve on a non-binding advisory
                    basis, certain compensation arrangements for Passage Bio&#8217;s named executive officers in connection with the Merger. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Proposal No. 8&#8212;The Adjournment Proposal </span>to approve an adjournment of the Passage Bio
                    special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Charter Proposal, the Governance Proposals, the 2026
                    Plan Proposal, the 2026 ESPP Proposal and/or the Merger Compensation Proposal. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">The approval of Proposal Nos. 4, 5, 6, 7 and 8 is not a condition to the
            Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As of the date of this proxy statement/prospectus, the Passage Bio Board does
            not know of any business to be presented at the Passage Bio special meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the Passage Bio special meeting, it
            is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br/>
        </div>

      </div>

    </div>

    <!--End Page 12-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 13-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What stockholder votes are required to approve the Proposals at the Passage Bio special meeting? </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The affirmative vote of the holders of a majority of the voting power of all
            outstanding shares of Passage Bio Common Stock entitled to vote thereon is required for the approval of Proposal Nos. 2 and 3. The affirmative approval of a majority of the votes cast on the proposal by the holders of Passage Bio Common Stock
            entitled to vote at the Passage Bio special meeting, assuming a quorum is present, is required for the approval of Proposal Nos. 1, 4, 5, 6, 7 and 8. Each of Proposal Nos. 1, 2 and 3 is a condition to completion of the Merger. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will count the votes at the Passage Bio special Meeting? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR&#8221; and &#8220;AGAINST&#8221;
                    votes, abstentions and broker non-votes. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What is an abstention and a broker non-vote, and how do they count for purposes of determining a quorum? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An &#8220;abstention&#8221; represents a shareholder's affirmative choice to decline to vote on a proposal. Broker non-votes occur when
                    shares held by a broker in &#8220;street name&#8221; for a beneficial owner are not voted with respect to a particular proposal because the broker (1) has not received voting instructions from the beneficial owner and (2) lacks discretionary voting
                    power to vote those shares. A broker is entitled to vote shares held for a beneficial owner on routine matters. However, each proposal to be voted on at the Passage Bio special meeting is a non-routine matter and, absent instructions
                    from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on any matters to be voted on at the Passage Bio special meeting. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Abstentions and broker non-votes will be treated as shares present for the
            purpose of determining the presence of a quorum for the transaction of business at the Passage Bio special meeting. With respect to Proposal Nos. 1, 4, 5, 6, 7 and 8, abstentions and broker non-votes will not be counted as votes cast and will
            have no effect on the outcome of the vote. With respect to Proposal Nos. 2 and 3, which require the affirmative vote of a majority of all outstanding shares of Passage Bio Common Stock thereon, abstentions and broker non-votes will count as
            votes against such proposals.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">As of &#8195;&#8195;&#8195;, 2026, the directors and executive officers of Passage Bio owned or
            controlled &#8195;&#8195;&#8195; outstanding shares of Passage Bio Common Stock entitled to vote at the Passage Bio special meeting. As of June&#160;24, 2026, the Passage Bio stockholders that are party to a support agreement, including the directors and executive
            officers of Passage Bio, owned an aggregate number of shares of Passage Bio Common Stock representing approximately 1% of the outstanding shares of Passage Bio Common Stock. Each stockholder that entered into a Passage Bio support agreement has
            agreed to vote all shares of Passage Bio Common Stock owned by him, her or it as of the Record Date (i) in favor of approving the Merger and the other transactions and actions contemplated by the Merger Agreement, including the Nasdaq Stock
            Issuance Proposal, Reverse Stock Split Proposal, Charter Proposal, and the Concurrent Financing (collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">Contemplated Transactions</span>&#8221;), (ii) against any proposal made in
            opposition to, or in competition with, the Merger Agreement or the Merger and (iii) against any acquisition proposal involving a third party. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who is entitled to vote? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Only holders of record of Passage Bio Common Stock at the close of business on the record date of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, are entitled to
                    notice of, and to vote at, the Passage Bio special meeting. At the close of business on the record date, there were &#8195;&#8195;&#8195; registered holders of record of Passage Bio Common Stock and there were &#8195;&#8195;&#8195; shares of Passage Bio Common Stock
                    issued and outstanding. Each share of Passage Bio Common Stock entitles the holder thereof to one vote on each matter submitted for stockholder approval. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">As a Passage Bio stockholder, how does the Passage Bio Board recommend that I vote? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">After careful consideration, the Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; each of the Proposals. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the Nasdaq Stock Issuance Proposal. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br/>
        </div>

      </div>

    </div>

    <!--End Page 13-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 14-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the Reverse Stock Split Proposal. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the Charter Proposal. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the Governance Proposals. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the 2026 Plan Proposal. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the 2026 ESPP Proposal. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the Merger Compensation Proposal. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221;
                    the Adjournment Proposal, if necessary. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will Passage Bio securityholders receive in the Merger? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio stockholders will continue to own and hold their existing shares of Passage Bio Common Stock. Each share of Passage
                    Bio Common Stock issued and outstanding at the time of the Merger will remain issued and outstanding, and, subject to the proposed reverse stock split, will be unaffected by the Merger. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Further, holders of Passage Bio Common Stock of record as of the close of
            business on the last business day prior to the day on which the Effective Time occurs will receive one Passage Bio CVR for each outstanding share of Passage Bio Common Stock held by such stockholder on such date, as described in more detail in
            the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Passage Bio Contingent Value Rights Agreement.</span>&#8221; </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The Merger Agreement provides that, prior to the Closing, Passage Bio will take
            all actions necessary to provide that (i) all Passage Bio Options will be fully vested and exercisable as of immediately prior to the Effective Time and will continue on the same terms and conditions in effect as of immediately prior to the
            Effective Time, and (ii)&#160;all Passage Bio Restricted Stock Unit Awards will be fully vested and settled in shares of Passage Bio Common Stock no later than the day immediately prior to the record date for the Pre-Closing Distribution (which is
            the distribution of the contingent value rights to Passage Bio stockholders). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For a more complete description of the treatment of Passage Bio securities in
            the Merger, please see the sections titled &#8220;<span style="font-style: italic;">The Merger Agreement</span>&#8212;<span style="font-style: italic;">Merger Consideration and Merger Exchange Ratio</span>&#8221; and &#8220;<span style="font-style: italic;">Market
              Price and Dividend Information</span>&#8221; of this proxy statement/prospectus. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are Passage Bio contingent value rights? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">At the Effective Time, Passage Bio and a third party rights agent will enter into a Contingent Value Rights Agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio CVR Agreement</span>&#8221;), pursuant to which holders of record of Passage Bio Common Stock as of the close of business on the last business day prior to the day on which the
                    Effective Time occurs will receive one contingent value right (each, a &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio CVR</span>&#8221;) for each outstanding share of Passage Bio Common Stock held by such stockholder on
                    such date. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Each Passage Bio CVR will represent the contractual right to receive payments
            from Passage Bio upon the actual receipt by Passage Bio or its subsidiaries of certain contingent proceeds derived from Passage Bio&#8217;s existing license arrangements with Gemma Biotherapeutics, Inc. relating to its GM1 and MLD programs, net of
            certain tax, transaction costs and certain other expenses. The contingent payments under the Passage Bio CVR Agreement, if they become payable, will become payable to the rights agent for subsequent distribution to the holders of the Passage
            Bio CVRs. There can be no assurance that any holders of Passage Bio CVRs will receive payments with respect thereto. For more detail, see the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Passage Bio
              Contingent Value Rights Agreement</span>.&#8221; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What will Remix securityholders receive in the Merger? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix stockholders will receive shares of Passage Bio Common Stock, and Remix optionholders&#8217; outstanding </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br/>
        </div>

      </div>

    </div>

    <!--End Page 14-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 15-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">and unexercised options to purchase shares of Remix Common Stock (a &#8220;<span style="font-style: italic; font-weight: bold;">Remix Option</span>&#8221;) as of immediately prior to the Effective Time will be assumed by Passage Bio and will be converted into options to purchase shares of Passage Bio Common Stock, with
            appropriate adjustments to reflect the Merger Exchange Ratio, as determined in accordance with the Merger Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Under the Merger Exchange Ratio and Concurrent Financing Exchange Ratio formulas
            in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon the number of shares of Passage Bio Common Stock expected to be issued in connection with the Merger and the Concurrent Financing, pre-Merger
            equityholders of Remix (other than investors in the Concurrent Financing) are expected to own approximately 65% of the combined company, pre-Merger equityholders of Passage Bio are expected to own approximately 6% of the combined company and
            the investors in the Concurrent Financing are expected to own approximately 29% of the combined company (assuming proceeds from the Concurrent Financing of approximately $100.0&#160;million), in each case, calculated on a fully diluted basis, using
            the treasury stock method, and subject to certain assumptions, including (i) a valuation for Passage Bio of approximately $20.0 million (assuming Passage Bio Net Cash of $5.0 million as of the Closing), (ii) an equity value for Remix of
            $226.0&#160;million, and (iii) the relative capitalization of Passage Bio and Remix. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail
            in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Merger Consideration and Merger Exchange Ratio</span>&#8221;), including the amount of the final Passage Bio Net Cash at the Closing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">For a more complete description of the treatment of Remix Common Stock and Remix
            Options in the Merger, please see the sections titled &#8220;<span style="font-style: italic;">The Merger Agreement</span>&#8212;<span style="font-style: italic;">Merger Consideration and Merger Exchange Ratio</span>&#8221; of this proxy statement/prospectus.
            For a description of the effect of the Concurrent Financing on Remix&#8217;s current securityholders, please see the sections titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger</span>&#8212;<span style="font-style: italic;">Subscription

              Agreement&#8221;</span> and &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Registration Rights Agreement</span>&#8221; of this proxy statement/prospectus. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Will the common stock of the combined company trade on an exchange? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">At the Effective Time, Passage Bio will be renamed &#8220;Remix Therapeutics, Inc.&#8221; and it is expected that the common stock of the
                    combined company will trade on Nasdaq under the symbol &#8220;RMTX&#8221;; however, the parties may waive the closing condition in the Merger Agreement that the common stock of the combined company be approved for listing on Nasdaq prior to the
                    Closing. For a description of the effect of a waiver of the Nasdaq listing closing condition, please see the section titled &#8220;<span style="font-style: italic;">Risk Factors&#8212;Risks Related to the Combined Company</span>&#8221; of this proxy
                    statement/prospectus. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will be the directors of the combined company following the Merger? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger Agreement provides that the parties will take all necessary action so that immediately after the Effective Time, the
                    board of directors of the combined company comprises six members, with each member designated by Remix. Remix currently expects that immediately following the Effective Time, the combined company board of directors will consist of:
                    Linda C. Bain, Scott Biller, Ph.D., Peter Colabuono, Maria Koehler, M.D., Ph.D., Matthew R. Patterson, and Peter G. Smith, Ph.D. For a more complete discussion of the expected members of the combined company board of directors, please
                    see the section titled &#8220;<span style="font-style: italic;">Management Following the Merger</span>&#8221; of this proxy statement/prospectus. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who will be the executive officers of the combined company immediately following the Merger? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger Agreement provides that the parties will take all necessary action so that immediately after the Effective Time, the
                    persons designated by Remix are appointed to the positions of officers of the combined company. Remix currently expects that the following individuals will serve as the executive officers of the combined company following the Merger: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 448pt; margin-left: 20pt; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 168pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 268pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 268pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">TITLE </div>
                </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 268pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer<span style="font-style: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 268pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Operating Officer and Chief Business Officer<span style="font-style: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mythili Koneru, M.D., Ph.D.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 268pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Medical Officer<span style="font-style: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 268pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Scientific Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 168pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 268pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br/>
        </div>

      </div>

    </div>

    <!--End Page 15-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 16-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What risks should I consider in deciding whether to vote in favor of the Merger? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You should carefully review the section titled &#8220;<span style="font-style: italic;">Risk Factors</span>&#8221; of this proxy
                    statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks
                    and uncertainties to which each of Passage Bio and Remix, as independent companies, are subject. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">When do you expect the Merger to be consummated? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger is expected to close in the fourth quarter of 2026, subject to the satisfaction of customary closing conditions,
                    including, among others, approval by the stockholders of each company and the effectiveness of the registration statement. However, the exact timing cannot be predicted. For more information, please see the section titled &#8220;<span style="font-style: italic;">The Merger Agreement</span>&#8212;<span style="font-style: italic;">Conditions to the Completion of the Merger</span>&#8221; of this proxy statement/prospectus. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax consequences of the Merger to holders of Passage Bio Common
                    Stock? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio stockholders will not sell, exchange or dispose of any shares of Passage Bio Common Stock as a result of the Merger.
                    Thus, there will be no material U.S. federal income tax consequences to Passage Bio stockholders as a result of the Merger. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax consequences of the issuance of the Passage Bio CVRs, including
                    any distributions of Passage Bio Common Stock under the Passage Bio CVRs? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Although the U.S. federal income tax treatment of the Passage Bio CVRs is uncertain and the matter is not free from doubt,
                    Passage Bio intends to treat a holder&#8217;s receipt of the Passage Bio CVRs as not constituting a current distribution of property with respect to the holder&#8217;s existing shares of Passage Bio Common Stock for U.S. federal income tax purposes
                    and future cash payments (if any) on the CVRs being reported as dividends to the extent of the combined company&#8217;s current and accumulated earnings and profits in the year(s) in which such payments are made. Please review the information
                    in the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Passage Bio Contingent</span><span style="font-style: italic; font-weight: bold;"> </span><span style="font-style: italic;">Value Rights
                      Agreement</span>&#8221; for a discussion of the material U.S. federal income tax consequences of the Passage Bio CVRs to holders of Passage Bio Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are the material U.S. federal income tax consequences of the reverse stock split to holders of Passage
                    Bio Common Stock? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A holder of Passage Bio Common Stock should not recognize gain or loss upon the reverse stock split, except to the extent such
                    holder receives cash in lieu of a fractional share of Passage Bio Common Stock, and subject to the discussion in the section titled &#8220;<span style="font-style: italic;">Proposal No. 2&#8212;The Reverse Stock Split Proposal</span>.&#8221; Please
                    review the information in the section titled &#8220;<span style="font-style: italic;">Proposal No. 2&#8212;The Reverse Stock Split Proposal&#8212;Material U.S. Federal Income Tax Consequences of the Reverse Stock Split</span>&#8221; for a more complete
                    description of the material U.S.&#160;federal income tax consequences of the reverse stock split to holders of Passage Bio Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What do I need to do now? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by
                    reference, and to consider how the Merger affects you. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you are a Passage Bio stockholder of record, as of the record date, you may
            provide your proxy instructions in one of four different ways: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can vote using the proxy card; simply complete, sign and date the accompanying proxy card and return it promptly in the
                    envelope provided. If you return your signed proxy card before the Passage Bio special meeting, Passage Bio will vote your shares in accordance with the proxy card. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can vote by proxy over the internet by following the instructions provided on the proxy card. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can vote by telephone by calling the toll-free number found on the proxy card. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can attend the Passage Bio special meeting online and vote by registering at &#8195;&#8195;&#8195;. Upon entry of your control number and
                    other required information, you will receive further instructions via email that provide you access to the Passage Bio special meeting and information on how to vote and submit questions during the Passage Bio special meeting. Simply
                    attending the Passage Bio special meeting will not, by itself, vote your shares or revoke your proxy. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br/>
        </div>

      </div>

    </div>

    <!--End Page 16-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 17-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">We provide internet proxy voting to allow you to vote your shares online,
            with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access
            providers and telephone companies.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you hold your shares in &#8220;street name&#8221; (as described below), you may provide
            your proxy instructions by following the instructions on your vote instruction form provided by your broker, bank or other agent. Please provide your proxy instructions only once, unless you are revoking a previously delivered proxy
            instruction, and as soon as possible so that your shares can be voted at the Passage Bio special meeting.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If you are a beneficial owner of shares registered in the name of your broker,
            bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from Passage Bio. Simply complete and mail the voting instruction card to ensure that
            your vote is counted. To vote at the Passage Bio special meeting, you may visit &#8195;&#8195;&#8195;, press the &#8220;Attend Meeting&#8221; button and follow the instructions. You may be instructed to obtain a legal proxy from your broker, bank, or other nominee and
            submit a copy in advance of the meeting. Further instructions will be provided to you via email.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Whether or not you plan to attend the Passage Bio special meeting, Passage Bio
            encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the Passage Bio special meeting, you may still attend the Passage Bio special meeting and vote. In such case, your previously submitted
            proxy will be disregarded. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What does it mean if I receive more than one set of proxy materials? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If you receive more than one set of proxy materials, your shares may be registered in more than one name or in different
                    accounts. For example, if you hold your shares of Passage Bio Common Stock in more than one brokerage account, you will receive a separate voting instruction form for each brokerage account in which you hold shares. If you are a
                    stockholder of record and your shares are registered in more than one name, you will receive more than one proxy card. Please complete, sign, date and return each proxy card and voting instruction form that you receive, or otherwise
                    follow the voting instructions set forth in this proxy statement/prospectus, to ensure that you vote every share of Passage Bio Common Stock that you own. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What happens if I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If you are a Passage Bio stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions will
                    reduce the aggregate number of votes required to approve each of the Proposals. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What if I return a proxy card or otherwise vote but do not make specific choices? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If you are a Passage Bio stockholder of record and you return a signed and dated proxy card or otherwise submit a proxy without
                    marking voting selections, your shares will be voted &#8220;FOR&#8221; the Nasdaq Stock Issuance Proposal, &#8220;FOR&#8221; the Reverse Stock Split Proposal, &#8220;FOR&#8221; the Charter Proposal, &#8220;FOR&#8221; the Governance Proposals, &#8220;FOR&#8221; the 2026 Plan Proposal, &#8220;FOR&#8221; the
                    2026 ESPP Proposal, &#8220;FOR&#8221; the Merger Compensation Proposal, and &#8220;FOR&#8221; the Adjournment Proposal, in accordance with the recommendations of the Passage Bio Board. If any other matter is properly presented at the Passage Bio special
                    meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. If you are a beneficial owner of shares held in &#8220;street name&#8221; and do not provide your broker, bank or
                    other agent with voting instructions, please see the question <span style="font-style: italic;">&#8220;If my shares of Passage Bio Common Stock are held in &#8220;street name&#8221; by my broker, will my broker vote my shares for me?</span>&#8221; below. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">May I attend the Passage Bio special meeting and vote? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Stockholders of record as of &#8195;&#8195;&#8195;, 2026 will be able to attend and participate in the Passage Bio special meeting online by
                    accessing. To join the Passage Bio special meeting, you will need to have your control number which is included on your proxy card. If your shares are held in &#8220;street name,&#8221; you should contact your bank, broker or other nominee if you
                    did not receive a control number. If your shares are held in &#8220;street name&#8221; you will also need to provide a legal proxy to vote during the meeting. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who counts the votes? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Broadridge Financial Solutions (&#8220;<span style="font-style: italic; font-weight: bold;">Broadridge</span>&#8221;) has been engaged as
                    Passage Bio&#8217;s inspector of election. If you </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br/>
        </div>

      </div>

    </div>

    <!--End Page 17-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 18-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">are a stockholder of record, your executed proxy card is returned directly to
            Broadridge for tabulation. If you hold your shares through a broker, your broker returns one proxy card to Broadridge on behalf of all its clients. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Where can I find the voting results of the Passage Bio special meeting? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Preliminary voting results are expected to be announced at the Passage Bio special meeting and may be set forth in a press
                    release of Passage Bio after the Passage Bio special meeting. Final voting results for the Passage Bio special meeting are expected to be published in a Current Report on Form&#160;8-K to be filed by Passage Bio with the SEC within four
                    business days after the Passage Bio special meeting. If final voting results are not available within four business days after the Passage Bio special meeting, Passage Bio intends to file a Current Report on Form&#160;8-K to publish the
                    preliminary results and, within four business days after the final results are known, file an additional Current Report on Form&#160;8-K to publish the final results. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">If my shares of Passage Bio Common Stock are held in &#8220;street name&#8221; by my broker, will my broker vote my
                    shares for me? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If you hold shares beneficially in street name and do not provide your broker or other agent with voting instructions, your
                    shares may constitute &#8220;broker non-votes.&#8221; A &#8220;broker non-vote&#8221; occurs when shares held by a broker or other agent are not voted with respect to a particular proposal because the broker or other agent does not have or did not exercise
                    discretionary authority to vote on the matter and has not received voting instructions from its clients. Matters for which the broker does not have discretionary authority to vote are referred to as &#8220;non-routine&#8221; matters. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Passage Bio expects that Proposal Nos. 1, 2, 3, 4, 5, 6, 7 and 8 will be
            considered to be &#8220;non-routine&#8221; matters, and thus a Passage Bio stockholder&#8217;s broker, bank or other agent may not vote shares on those Proposals in the absence of such holders&#8217; voting instructions. To make sure that your vote is counted, you
            should instruct your broker or other agent to vote your shares, following the procedures provided by your broker. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">What are broker non-votes and do they count for determining a quorum? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Generally, a &#8220;broker non-vote&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because
                    the broker does not have or did not exercise discretionary authority to vote on the matter and has not received voting instructions from its clients.</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">It is anticipated that all of the proposals currently scheduled for
            consideration at the Passage Bio special meeting will be considered &#8220;non-routine&#8221; matters, and a broker will lack the authority to vote shares at its discretion on such proposals. Consequently, Passage Bio expects that there will not be any
            broker non-votes at the Passage Bio special meeting. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">Broker non-votes, if any, will be treated as shares present for the purpose of
            determining the presence of a quorum for the transaction of business at the Passage Bio special meeting. With respect to Proposal Nos. 1, 4, 5, 6, 7 and 8, broker non-votes will not be counted as votes cast and will have no effect on the
            outcome of the vote. With respect to Proposal Nos. 2 and 3, which require the affirmative vote of a majority of all outstanding shares of Passage Bio Common Stock entitled to vote thereon, broker non-votes will count as votes against such
            proposals. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">May I change my vote after I have submitted a proxy or provided proxy instructions? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may change their vote at
                    any time before their proxy is voted at the Passage Bio special meeting in one of four ways: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may submit another properly completed proxy with a later date by mail or via the internet. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You can provide your proxy instructions via telephone at a later date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may send an instrument in writing revoking the proxy or another duly executed proxy bearing a later date to Passage Bio&#8217;s
                    corporate secretary. Any written notice of revocation or subsequent proxy card must be received by the corporate secretary prior to the taking of the vote at the special meeting. Such written notice of revocation or subsequent proxy
                    card should be sent to Passage Bio&#8217;s Corporate Secretary at Passage Bio, Inc., P.O. Box 7, Hopewell, New Jersey 08525, Attention: Secretary. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br/>
        </div>

      </div>

    </div>

    <!--End Page 18-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 19-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_105-qa_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">You may attend the Passage Bio special meeting online and vote by registering at &#8195;&#8195;&#8195;. Upon entry of your control number and
                    other required information, you will receive further instructions via email that provide you access to the Passage Bio special meeting and information on how to vote and submit questions during the Passage Bio special meeting. Simply
                    attending the Passage Bio special meeting will not, by itself, vote your shares or revoke your proxy. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">All properly executed proxies that are not revoked will be voted at the Passage
            Bio special meeting and at any adjournments or postponements of the Passage Bio special meeting in accordance with the instructions contained in the proxy. <span style="font-weight: bold;">If a holder of Passage Bio Common Stock executes and
              returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the Proposals in accordance with the recommendations of the Passage Bio Board.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">If a Passage Bio stockholder who owns shares of Passage Bio Common Stock in
            &#8220;street name&#8221; has instructed a broker to vote its shares of Passage Bio Common Stock, the stockholder must follow directions received from its broker to change those instructions. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who is soliciting and paying for this proxy solicitation? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio and Remix are paying &#8195;&#8194;% and &#8195;&#8194;%, respectively, of the cost of (i) filing and printing of this proxy
                    statement/prospectus and any amendments and supplements hereto and paid to the financial printer or the SEC and (ii) the proxy solicitation firm engaged in connection with the Passage Bio special meeting. Arrangements will also be made
                    with brokerage firms and other custodians, nominees and fiduciaries who are record holders of Passage Bio Common Stock for the forwarding of solicitation materials to the beneficial owners of Passage Bio Common Stock. Passage Bio will
                    reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out-of-pocket expenses they incur in connection with the forwarding of solicitation materials. Passage Bio has retained &#8195;&#8195;&#8195; (&#8220;<span style="font-style: italic; font-weight: bold;">&#8195;&#8195;&#8195;</span>&#8221;) to assist it in soliciting proxies using the means referred to above. Passage Bio and Remix will pay the fees of &#8195;&#8195;&#8195;, which Passage Bio expects to be approximately $&#8195;&#8195;&#8195;, plus reimbursement of
                    reasonable and customary out-of-pocket expenses. In addition to solicitation by mail, the directors, officers, employees and agents of Passage Bio may solicit proxies from Passage Bio stockholders by personal interview, telephone,
                    email, fax or otherwise. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Q:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Who can help answer my questions? </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A:<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If you are a Passage Bio stockholder and would like additional copies of this proxy statement/prospectus without charge or if
                    you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact Passage Bio&#8217;s proxy solicitor, &#8195;&#8195;&#8195;, at the following address, telephone number or email address: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">Call Toll Free:<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Email: </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br/>
        </div>

      </div>

    </div>

    <!--End Page 19-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 20-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPS"><!--Anchor--></a>PROSPECTUS SUMMARY </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">This summary highlights selected information from this
              proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the Passage Bio special meeting, you should read this entire proxy
              statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the
              section titled &#8220;Where You Can Find More Information&#8221; beginning on page <a href="#tWYC">322</a> of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy
              statement/prospectus does not give effect to the proposed reverse stock split described in Proposal No. 2 of this proxy statement/prospectus.<span style="font-style: normal;"> </span></div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;"><a id="tTCOMP"><!--Anchor--></a>The Companies </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Passage Bio </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is a clinical stage genetic medicines company that has historically
              focused on improving the lives of patients with neurodegenerative diseases through the development and advancement of cutting-edge, one-time therapies designed to target critical underlying pathologies in these conditions. As described
              elsewhere in this proxy statement/prospectus, Passage Bio has determined to wind down its gene therapy programs and, on June&#160;24, 2026, entered into the Merger Agreement with Remix. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Remix </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is a clinical-stage biotechnology company developing novel small molecule
              therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix&#8217;s REMaster&#8482; technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally
              administered compounds that modulate gene expression. Remix&#8217;s innovative therapeutic approach led to the discovery of REM-422, an RNA processing modulator in oncology, now being evaluated in Phase 1/2 clinical studies to treat acute myeloid
              leukemia (&#8220;<span style="font-style: italic; font-weight: bold;">AML</span>&#8221;), high-risk myelodysplastic syndrome (&#8220;<span style="font-style: italic; font-weight: bold;">HR-MDS</span>&#8221;) and adenoid cystic carcinoma (&#8220;<span style="font-style: italic; font-weight: bold;">ACC</span>&#8221;).</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s principal executive offices are located at 100 Forge Road Suite 400,
              Watertown, MA 02472, and its telephone number is (781) 827-0901. Remix&#8217;s website address is www.remixtx.com. Remix&#8217;s website is included as an inactive textual reference and the information contained on, or that can be accessed through,
              Remix&#8217;s website is not a part of this proxy statement/prospectus. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Merger Sub </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Merger Sub is a direct, wholly owned subsidiary of Passage Bio and was formed
              solely for the purpose of carrying out the Merger. Merger Sub is a remote-only company. Accordingly, it does not maintain a headquarters. Its telephone number is (267) 866-0311.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;"><a id="tMERG"><!--Anchor--></a>The Merger <span style="font-weight: normal;">(see page <a href="#tTM">106</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;24, 2026, Passage Bio, Merger Sub, and Remix entered into the Merger
              Agreement. Subject to the terms and conditions in the Merger Agreement, at the Effective Time, Merger Sub will merge with and into Remix, with Remix surviving as a wholly owned subsidiary of Passage Bio (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger</span><span style="font-style: italic;">&#8221;</span>). This transaction is referred to as the Merger.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger will become effective at the time the Certificate of Merger has been
              duly filed with and accepted by the Secretary of State of the State of Delaware or such other date and time as is agreed upon by Passage Bio and Remix and specified in the Certificate of Merger in accordance with the DGCL, subject to the
              satisfaction or waiver of certain conditions to the closing, including, among other things, approval by Passage Bio&#8217;s stockholders of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal and the Charter Proposal.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Merger Exchange Ratio and Concurrent Financing Exchange Ratio
              formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon the number of shares of Passage Bio Common Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Remix
              (other than investors in the Concurrent Financing) are expected to own approximately 65% of the combined company, pre-Merger equityholders of Passage Bio are expected to own approximately 6% of the combined company and the investors in </div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br/>
        </div>

      </div>

    </div>

    <!--End Page 20-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 21-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the Concurrent Financing are expected to own approximately 29% (assuming
              proceeds from the Concurrent Financing of approximately $100.0&#160;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i) a valuation for Passage Bio of
              approximately $20.0 million (assuming Passage Bio Net Cash of $5.0 million as of the Closing), (ii) an equity value for Remix of $226.0&#160;million, and (iii) the relative capitalization of Passage Bio and Remix. The percentage of the combined
              company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Merger Consideration and
                Merger Exchange Ratio</span>&#8221;), including the amount of the final Passage Bio Net Cash at the Closing.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;"><a id="tTM2"><!--Anchor--></a>Passage Bio&#8217;s Reasons for the
              Merger <span style="font-weight: normal;">(see page <a href="#tTMPB">112</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After careful consideration, at a meeting of the Passage Bio Board on June&#160;23,
              2026, the Passage Bio Board unanimously (i) determined that the Merger Agreement and the Contemplated Transactions are fair to, advisable and in the best interests of Passage Bio and its stockholders, (ii) approved the Merger Agreement and
              the Contemplated Transactions, including the issuance of shares of Passage Bio Common Stock pursuant to the Merger Agreement, and (iii) determined to recommend that the Passage Bio stockholders vote &#8220;FOR&#8221; the Proposals, including the Nasdaq
              Stock Issuance Proposal, at the Passage Bio special meeting.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For additional information, please see the section titled &#8220;<span style="font-style: italic;">The Merger&#8212;Passage Bio&#8217;s Reasons for the Merger</span>&#8221; of this proxy statement/prospectus.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;"><a id="tTM3"><!--Anchor--></a>Remix&#8217;s Reasons for the Merger<span style="font-weight: normal;"> (see page <a href="#tTMRR">115</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After careful consideration, at a meeting of the Remix Board on June&#160;23, 2026,
              the Remix Board unanimously (i)&#160;determined that the Contemplated Transactions were fair to, advisable and in the best interests of Remix and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Contemplated
              Transactions and (iii) recommended, upon the terms and subject to the conditions set forth in the Merger Agreement, that the stockholders of Remix vote to adopt the Merger Agreement and thereby approve the Contemplated Transactions.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For a discussion of certain factors considered by the Remix Board in making
              such recommendation, please see the section titled &#8220;<span style="font-style: italic;">The Merger&#8212;Remix&#8217;s Reasons for the Merger</span>&#8221; of this proxy statement/prospectus. </div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;"><a id="tTM4"><!--Anchor--></a>Recommendation of the
              Passage Bio Board </div>

            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that the issuance of shares of Passage Bio Common Stock pursuant to the
                      Merger Agreement is fair to, advisable and in the best interests of Passage Bio and its stockholders and has approved such issuance. The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the Nasdaq Stock Issuance Proposal. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that it is fair to, advisable and in the best interests of Passage Bio and
                      its stockholders to approve the amendment to Passage Bio&#8217;s amended and restated certificate of incorporation to effect the reverse stock split, as described in this proxy statement/prospectus. The Passage Bio Board unanimously
                      recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the Reverse Stock Split Proposal. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that it is fair to, advisable and in the best interests of Passage Bio and
                      its stockholders to approve the amendment and restatement of Passage Bio&#8217;s amended and restated certificate of incorporation to (i) change its name to &#8220;Remix Therapeutics, Inc.&#8221;, and (ii) make certain other changes, as described in
                      this proxy statement/prospectus. The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the Charter Proposal. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that it is fair to, advisable and in the best interests of Passage Bio and
                      its stockholders to approve, on an advisory and non-binding basis, the material amendments to Passage Bio&#8217;s certificate of incorporation reflected in the Proposed Restated Charter, as described in this proxy statement/prospectus. The
                      Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the Governance Proposals. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that it is fair to, advisable and in the best interests of Passage Bio and
                      its stockholders to approve the adoption of the Remix Therapeutics, Inc. 2026 Equity Incentive Plan, as described in this proxy statement/prospectus. The Passage Bio Board unanimously recommends that Passage Bio stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the 2026 Plan Proposal. </div>
                  </td>

  </tr>


</table>
          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br/>
        </div>

      </div>

    </div>

    <!--End Page 21-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 22-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that it is fair to, advisable and in the best interests of Passage Bio and
                      its stockholders to approve the adoption of the Remix Therapeutics, Inc. 2026 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. The Passage Bio Board unanimously recommends that Passage Bio stockholders
                      vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the 2026 ESPP Proposal. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that it is fair to, advisable and in the best interests of Passage Bio and
                      its stockholders to approve on a non-binding advisory basis, certain compensation arrangements for Passage Bio&#8217;s named executive officers in connection with the Merger, as described in this proxy statement/prospectus. The Passage Bio
                      Board unanimously recommends that Passage Bio stockholders vote <span style="font-weight: bold;">&#8220;FOR&#8221;</span> the Merger Compensation Proposal. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio Board has determined and believes that adjourning the Passage Bio special meeting, if necessary, to solicit
                      additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Charter Proposal, the Governance Proposals, the 2026 Plan Proposal, the 2026 ESPP Proposal
                      and/or the Merger Compensation Proposal is fair to, advisable and in the best interests of Passage Bio and its stockholders and has approved and adopted the proposal. The Passage Bio Board unanimously recommends that Passage Bio
                      stockholders vote &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary. </div>
                  </td>

  </tr>


</table>
            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"><a id="tTM5"><!--Anchor--></a>Interests of Passage Bio&#8217;s
              Directors and Executive Officers in the Merger <span style="font-weight: normal;">(see page <a href="#tTMIPB">125</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In considering the recommendation of the Passage Bio Board with respect to
              issuing shares of Passage Bio Common Stock in the Merger and other matters to be acted upon by the Passage Bio stockholders at the Passage Bio special meeting, the Passage Bio stockholders should be aware that Passage Bio&#8217;s directors and
              executive officers have interests in the Merger that are different from, or in addition to, the interests of Passage Bio stockholders generally. These interests include the following: </div>

            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Under the Merger Agreement, Passage Bio&#8217;s directors and executive officers are entitled to continued indemnification, expense
                      advancements and insurance coverage. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In connection with the Merger, each outstanding and unvested option to purchase shares of Passage Bio Common Stock (a &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio Option</span>&#8221;) will be accelerated in full, effective as of immediately prior to the Effective Time; following the Closing, each unexpired and unexercised Passage Bio
                      Option will continue on the same terms and conditions in effect as of immediately prior to the Effective Time. The vesting of each outstanding and unvested restricted stock unit award covering shares of Passage Bio Common Stock (a &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio Restricted Stock Unit Award</span>&#8221;) will be accelerated in full effective no later than the day immediately prior to the record date for the Pre-Closing Distribution (which
                      is the distribution of the contingent value rights to Passage Bio stockholders), and each such award will be settled in shares of Passage Bio Common Stock (net of applicable tax withholding). </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In connection with the Merger, Passage Bio&#8217;s executive officers may receive an extension of the post-termination exercise
                      period of their Passage Bio Options, subject to their agreement to certain conditions. </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s executive officers are expected to have their employment terminated at the closing of the Merger, and to receive
                      the severance benefits set forth in their employment agreements in connection with such termination. </div>
                  </td>

  </tr>


</table>
            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These interests are discussed in more detail in the section titled &#8220;<span style="font-style: italic;">The Merger&#8212;Interests of Passage Bio&#8217;s Directors and Executive Officers in the Merger</span>&#8221; of this proxy statement/prospectus. The Passage Bio Board was aware of these potential conflicts of interests and
              considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Passage Bio stockholders approve the proposals to be presented to the Passage Bio stockholders for
              consideration at the Passage Bio special meeting as contemplated by this proxy statement/prospectus.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"><a id="tTM6"><!--Anchor--></a>Interests of Remix&#8217;s
              Directors and Executive Officers in the Merger<span style="font-weight: normal;"> (see page <a href="#tTMIRD">129</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In considering the recommendation of the Remix Board with respect to approving
              the Merger, stockholders should be aware that certain of Remix&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Remix stockholders generally.</div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br/>
        </div>

      </div>

    </div>

    <!--End Page 22-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 23-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">As described elsewhere in this proxy statement/prospectus, including in the
              section captioned &#8220;<span style="font-style: italic;">Management Following the Merger</span>,&#8221; seven of Remix&#8217;s directors and all of Remix&#8217;s executive officers are expected to become the directors and executive officers, respectively, of the
              combined company upon the Closing, in connection with which the executive officers may enter into employment agreements comparable to those of applicable executive officers of a publicly traded company. Following completion of the Merger, it
              is expected that the combined company will provide compensation to non-employee directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing, and which will be designed to enable the
              combined company to attract and retain, on a long-term basis, highly qualified non-employee directors.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These interests are discussed in more detail in the section titled &#8220;<span style="font-style: italic;">The Merger&#8212;Interests of Remix&#8217;s Directors and Executive Officers in the Merger</span>&#8221; of this proxy statement/prospectus. The Remix Board was aware of these potential conflicts of interests and considered them,
              among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Remix stockholders approve the Merger as contemplated by this proxy statement/prospectus. </div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTM7"><!--Anchor--></a>Opinion of Redwood Valuation
              Partners, LLC <span style="font-weight: normal;">(see page <a href="#tTMORV">119</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio retained Redwood Valuation Partners, LLC (&#8220;<span style="font-style: italic; font-weight: bold;">Redwood</span>&#8221;) as a financial advisor to deliver an opinion in respect of the fairness of the Merger Consideration in connection with the Merger. The Passage Bio Board selected Redwood to act as Passage Bio&#8217;s
              financial advisor to deliver such opinion based on Redwood&#8217;s qualifications, reputation and experience. Redwood is a valuation firm that has substantial experience in financial analyses relating to transactions similar to this transaction.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;23, 2026, Redwood delivered to the Passage Bio Board its written
              opinion that, as of such date and based upon and subject to the various assumptions made, and the qualifications and limitations upon the review undertaken by Redwood in preparing its opinion, the Merger Consideration to be paid by Passage
              Bio pursuant to the terms of the Merger Agreement is fair, from a financial point of view, to Passage Bio. The full text of the written opinion of Redwood, which describes the assumptions made and the qualifications and limitations upon the
              review undertaken by Redwood in preparing its opinion, is attached as <span style="text-decoration: underline;">Annex&#160;B</span> to this proxy statement/prospectus and is incorporated herein by reference.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood provided its financial advisory services and opinion for the
              information and assistance of the Passage Bio Board (in its capacity as such and not in any other capacity) in connection with and for purposes of the Passage Bio Board&#8217;s consideration of the Merger and the opinion of Redwood addressed only
              the fairness, from a financial point of view, as of the date thereof, to Passage Bio of the Merger Consideration to be paid by Passage Bio pursuant to the terms of the Merger Agreement. The opinion of Redwood did not address any other term or
              aspect of the Merger Agreement or the Merger and did not and does not constitute a recommendation to any stockholder of Passage Bio or Remix as to whether or how such holder should vote with respect to the Merger or the Proposals or otherwise
              act with respect to the Merger or any other matter.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The full text of the written opinion of Redwood should be read carefully in its
              entirety for a description of the assumptions made and qualifications and limitations upon the review undertaken by Redwood in preparing its opinion. </div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTM8"><!--Anchor--></a>The Merger Agreement </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Merger Consideration and Merger Exchange
              Ratio (see page <a href="#tTMAMC">137</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time, each outstanding share of Remix Capital Stock (excluding
              shares held by stockholders who have exercised and perfected appraisal rights, shares held as treasury stock by Remix or held or owned by Passage Bio, Merger Sub or any subsidiary of Passage Bio or Remix, and shares issued in the Concurrent
              Financing) will be converted into the right to receive a number of shares of Passage Bio Common Stock equal to the Merger Exchange Ratio. Additionally, shares of Remix Capital Stock issued in the Concurrent Financing will be converted solely
              into the right to receive a number of shares of Passage Bio Common Stock equal to the Concurrent Financing Exchange Ratio, which is calculated by multiplying the total amount of Concurrent Financing Merger Shares (as defined below) by the
              percentage of the proceeds resulting from the Concurrent Financing (&#8220;<span style="font-style: italic; font-weight: bold;">Concurrent Financing Proceeds</span>&#8221;) (as defined below) represented by the applicable stockholder&#8217;s investment in the
              Concurrent Financing, as set forth on the Allocation Certificate (as defined in the Merger Agreement).</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">No fractional shares of Passage Bio Common Stock will be issued in connection
              with the Merger, and any holder of Remix Capital Stock who would otherwise be entitled to receive a fraction of a share of Passage Bio Common Stock </div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br/>
        </div>

      </div>

    </div>

    <!--End Page 23-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 24-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">(after aggregating all fractional shares of Passage Bio Common Stock
              issuable to such holder) will not receive any fraction of a share, and the number of shares of Passage Bio Common Stock issued to such holder will be rounded down to the nearest whole share, with no cash being paid for any fractional share
              eliminated by such rounding.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Based on an assumed Merger Exchange Ratio of 0.1734, which assumes (i) a
              reverse stock split of Passage Bio Common Stock of 1-for-&#8195;, to be implemented immediately prior to the Closing, as may be adjusted, (ii) a valuation of Passage Bio of approximately $20.0 million (assuming Passage Bio Net Cash at the Closing
              of $5.0 million), (iii) a fixed valuation of Remix of $226.0&#160;million, (iv) the relative capitalization of Passage Bio and Remix, and (v)&#160;proceeds from the Concurrent Financing of approximately $100.0&#160;million, Passage Bio expects that it will
              issue approximately 27,012,093 shares of Passage Bio Common Stock in the Merger, excluding any shares that may be subsequently issued in connection with the exercise of the stock options of Remix that will be assumed by Passage Bio and become
              options to purchase shares of Passage Bio Common Stock (&#8220;<span style="font-style: italic; font-weight: bold;">Remix Options</span>&#8221;) and assuming no stockholders of Remix exercise and perfect their appraisal rights.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Exchange Ratio and Concurrent Financing Exchange Ratio Formulas
              pursuant to which shares of Remix Capital Stock will be converted into shares of Passage Bio Common Stock is derived based on (i) a Remix fixed valuation of $226.0&#160;million and (ii) an initial Passage Bio valuation of approximately $20.0
              million, subject to certain adjustments based on Passage Bio Net Cash at the Closing. The Passage Bio valuation used to determine the Merger Exchange Ratio will be decreased on a dollar-for-dollar basis to reflect the amount by which
              $5.0&#160;million exceeds Passage Bio Net Cash if Passage Bio Net Cash is less than $4.5&#160;million, and will be increased on a dollar-for-dollar basis to reflect the amount by which Passage Bio Net Cash exceeds $5.0&#160;million if Passage Bio Net Cash
              is greater than $5.5&#160;million.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Immediately after the Closing, under the Merger Exchange Ratio and Concurrent
              Financing Exchange Ratio formulas in the Merger Agreement, on a pro forma basis and based upon the number of shares of Passage Bio Common Stock expected to be issued in connection with the Merger, the pre-Merger equityholders of Remix (other
              than holders of shares issued in connection with the Concurrent Financing) are expected to own approximately 65% of the combined company, the pre-Merger equityholders of Passage Bio are expected to own approximately 6% of the combined
              company, and the holders of shares issued in connection with the Concurrent Financing are expected to own approximately 29% of the combined company (assuming proceeds from the Concurrent Financing of $100.0&#160;million), in each case, calculated
              on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i) a valuation for Passage Bio of approximately $20.0 million (assuming Passage Bio Net Cash of $5.0 million as of the Closing), (ii) a
              fixed valuation for Remix of $226.0&#160;million and (iii) the relative capitalization of Passage Bio and Remix. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain
              adjustments. The Merger Exchange Ratio and Concurrent Financing Exchange Ratio formulas assume an implied value of the combined company of approximately $346 million, subject to certain adjustments.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For more information about the Merger Consideration and Merger Exchange Ratio,
              see the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Merger Consideration and Merger Exchange Ratio</span>&#8221; of this proxy statement/prospectus. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Treatment of Passage Bio Equity Awards
              (see page <a href="#tTMTPB">127</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement provides that, prior to the Closing, Passage Bio will take
              all actions necessary to provide that (i)&#160;all then-outstanding Passage Bio Options will be fully vested and exercisable as of immediately prior to the Effective Time and will continue on the same terms and conditions in effect as of
              immediately prior to the Effective Time, and (ii)&#160;all the then-outstanding Passage Bio Restricted Stock Unit Awards will be fully vested and settled in shares of Passage Bio Common Stock no later than the day immediately prior to the record
              date for the Pre-Closing Distribution (which is the distribution of the contingent value rights to Passage Bio stockholders). </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Treatment of Remix Options (see page <a href="#tTMTRS">130</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the terms of the Merger Agreement, each Remix Option that is outstanding
              and unexercised immediately prior to the Effective Time under the Remix 2019 Stock Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">Remix 2019 Plan</span>&#8221;), whether or not vested, will be converted into and become an option to
              purchase shares of Passage Bio Common Stock at the Effective Time. Passage Bio will assume the Remix 2019 Plan and all such Remix Options in accordance with the terms of the Remix 2019 Plan and the terms of the stock option agreement by which
              such Remix Option is evidenced. </div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br/>
        </div>

      </div>

    </div>

    <!--End Page 24-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 25-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Conditions to the Completion of the
              Merger (see page <a href="#tTMACC">154</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The obligations of Passage Bio and Remix to consummate the Merger are subject
              to the satisfaction or waiver, on or prior to the Effective Time, of the conditions set forth in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Conditions to the Completion of the Merger</span>&#8221; below. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Non-Solicitation (see page <a href="#tTMANS">146</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Capitalized terms in this section are as defined in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Non-Solicitation.</span>&#8221;</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio and its respective representatives are prohibited by the terms of
              the Merger Agreement from, directly or indirectly, (i) soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry or
              taking any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii) furnishing any non-public information regarding Passage Bio or any of its subsidiaries to any person in connection with or in
              response to an Acquisition Proposal or Acquisition Inquiry; (iii) engaging in discussions (other than to inform any person of the existence of these prohibitions) or negotiations with any person with respect to any Acquisition Proposal or
              Acquisition Inquiry; (iv) approving, endorsing or recommending any Acquisition Proposal; (v) executing or entering into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction (as defined below)
              (other than a confidentiality agreement permitted as described below); or (vi) publicly proposing to do any of the foregoing. </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Notwithstanding the foregoing, subject to compliance with the non-solicitation
              obligations set forth in the Merger Agreement, and prior to obtaining the Required Passage Bio Stockholder Vote, Passage Bio and its subsidiaries may furnish non-public information regarding Passage Bio to, and enter into discussions or
              negotiations with, any person in response to a bona fide Acquisition Proposal by such person, which the Passage Bio Board has determined in good faith, after consultation with Passage Bio&#8217;s outside financial advisors and outside legal
              counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) none of Passage Bio, any of its subsidiaries or any of their respective representatives shall have breached the applicable
              non-solicitation restrictions in the Merger Agreement in any material respect, (B) the Passage Bio Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would be inconsistent with the
              fiduciary duties of the Passage Bio Board under applicable law; (C) Passage Bio receives from such person an executed confidentiality agreement containing provisions, in the aggregate, at least as favorable to Passage Bio as those contained
              in the Mutual Confidential Disclosure Agreement, dated as of April&#160;29, 2026, by and between Passage Bio and Remix (the &#8220;<span style="font-style: italic; font-weight: bold;">Confidentiality Agreement</span>&#8221;); and (D) substantially
              contemporaneously with furnishing any such non-public information to such person, Passage Bio gives Remix notice of Passage Bio&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such person and furnishes such
              non-public information to Remix (to the extent such information has not been previously furnished by Passage Bio to Remix).</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix and its subsidiaries and their respective representatives are prohibited
              by the terms of the Merger Agreement from, directly or indirectly, (i) soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any Acquisition Proposal or Acquisition
              Inquiry or taking any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; (ii)&#160;furnishing any non-public information regarding Remix or any of its subsidiaries to any person in connection with
              or in response to an Acquisition Proposal or Acquisition Inquiry; (iii) engaging in discussions (other than to inform any person of the existence of these prohibitions) or negotiations with any person with respect to any Acquisition Proposal
              or Acquisition Inquiry; (iv) approving, endorsing or recommending any Acquisition Proposal; (v) executing or entering into any letter of intent or any contract contemplating or otherwise relating to any Acquisition Transaction; or (vi)
              publicly proposing to do any of the foregoing.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Notwithstanding the foregoing, subject to compliance with the non-solicitation
              obligations set forth in the Merger Agreement, and prior to obtaining the Required Remix Stockholder Vote (as defined in the Merger Agreement), Remix and its subsidiaries may furnish non-public information regarding Remix or any of its
              subsidiaries to, and enter into discussions or negotiations with, any person in response to a bona fide Acquisition Proposal by any person, which the Remix Board has determined in good faith, after consultation with Remix&#8217;s outside financial
              advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer if: (A) none of Remix, any of its subsidiaries or any of their respective representatives shall have breached the applicable
              non-solicitation restrictions in the Merger Agreement in any material respect, (B) the Remix Board concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be </div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br/>
        </div>

      </div>

    </div>

    <!--End Page 25-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 26-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">expected to result in a breach of the fiduciary duties of the Remix Board
              under applicable law; (C) Remix gives Passage prior written notice of Remix&#8217;s intention to furnish non-public information to, or enter into discussions with, such person; (D) Remix receives from such person an executed Acceptable
              Confidentiality Agreement (which need not contain standstill, non-solicitation or no-hire provisions); and (E) substantially concurrently with furnishing any such non-public information to such person, Remix furnishes such non-public
              information to Passage (to the extent such information has not been previously furnished by Remix to Passage). For the avoidance of doubt, Remix may engage in ordinary-course business development activities, including responding to inquiries
              from, or furnishing information to, third parties with respect to Remix or its business, in each case without complying with the foregoing non-solicitation restrictions. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Termination and Termination Fees (see page
              <a href="#tTMATT">156</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of Remix or Passage Bio may terminate the Merger Agreement under certain
              circumstances, which would prevent the Merger from being consummated.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Merger Agreement is terminated under certain circumstances, Passage Bio
              will be required to pay Remix a termination fee of approximately $1.5&#160;million and if the Merger Agreement is terminated under certain other circumstances, Remix may be required to pay Passage Bio a termination fee of up to $17.5&#160;million. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Support Agreements (see page <a href="#tARMSA">159</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain stockholders of Remix, who as of June&#160;24, 2026 held approximately 93%
              of the outstanding shares of Remix Capital Stock, entered into support agreements with Passage Bio, pursuant to which such stockholders agreed, solely in their capacities as Remix stockholders, to vote all of their shares of Remix Capital
              Stock in favor of (i) the adoption of the Merger Agreement and the approval of the Merger and the other Contemplated Transactions, (ii) the conversion of each share of Remix preferred stock into shares of Remix common stock immediately prior
              to, and contingent upon, the Closing, and (iii) the other Remix Stockholder Matters (as defined in the Merger Agreement), and against any competing acquisition proposal or any other action that would reasonably be expected to impede or
              adversely affect the Merger. In addition, such stockholders agreed not to transfer their shares of Remix Capital Stock, subject to certain exceptions, until the earlier of the termination of the Merger Agreement and the completion of the
              Merger.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain stockholders of Passage Bio, who as of June&#160;24, 2026 held approximately
              1% of the outstanding shares of Passage Bio Common Stock, entered into support agreements with Remix, pursuant to which such stockholders agreed, solely in their capacities as Passage Bio stockholders, to vote all of their shares of Passage
              Bio Common Stock in favor of (i) the approval of the Merger Agreement and the transactions contemplated thereby, including the issuance of shares of Passage Bio Common Stock to Remix stockholders in the Merger, (ii) an amendment to Passage
              Bio&#8217;s certificate of incorporation to effect the Reverse Stock Split and (iii) the other Passage Bio Stockholder Matters (as defined in the Merger Agreement), and against any competing acquisition proposal or any other action that would
              reasonably be expected to impede or adversely affect the Merger. In addition, such stockholders agreed not to transfer their shares of Passage Bio Common Stock, subject to certain exceptions, until the earlier of the termination of the Merger
              Agreement and the completion of the Merger. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Lock-Up Agreements (see page <a href="#tARMLA">160</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain of Remix&#8217;s executive officers, directors and stockholders, who as of
              June&#160;24, 2026 collectively owned approximately 99% of the outstanding shares of Remix Capital Stock, have entered into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge,
              sell, contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of any shares of Passage Bio Common Stock beneficially held by them, including, as applicable, shares received in the Merger and shares
              issuable upon the exercise of options, warrants or convertible securities, until 180 days after the Closing. In addition, certain of Passage Bio&#8217;s officers, who as of June&#160;24, 2026 collectively owned approximately 0.34% of the outstanding
              shares of Passage Bio Common Stock, have entered into lock-up agreements on substantially the same terms with respect to the shares of Passage Bio Common Stock beneficially held by them. </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Subscription Agreement and Registration
              Rights Agreement (see page <a href="#tARMSAR">161</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;24, 2026, concurrently with the execution and delivery of the Merger
              Agreement, Remix entered into a subscription agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Subscription Agreement</span>&#8221;) with certain accredited investors named therein (the &#8220;<span style="font-style: italic; font-weight: bold;">Investors</span>&#8221;), pursuant to which the Investors agreed to purchase shares of Remix Common Stock for aggregate </div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br/>
        </div>

      </div>

    </div>

    <!--End Page 26-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 27-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">gross proceeds of approximately $70.0&#160;million. The Subscription Agreement,
              together with the issuance by Remix of approximately $30.0&#160;million of convertible promissory notes pursuant to the Remix Note&#160;Purchase Agreement (2026), comprises the Concurrent Financing (the &#8220;<span style="font-style: italic; font-weight: bold;">Concurrent Financing</span>&#8221;), which is expected to result in aggregate gross proceeds of approximately $100.0&#160;million. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of the conditions to the
              Merger, as well as certain other conditions. The shares of Remix Common Stock issued in the Concurrent Financing will convert into shares of Passage Bio Common Stock in the Merger and, immediately following the Merger, are expected to
              represent approximately 29% of the outstanding shares of the combined company.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the closing of the Concurrent Financing, Remix, Passage Bio and the
              Investors will enter into a registration rights agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Registration Rights Agreement</span>&#8221;), pursuant to which the combined company will agree to prepare and file with the SEC a
              registration statement to register for resale the shares of Passage Bio Common Stock issued to the Investors in connection with the Concurrent Financing, to use commercially reasonable efforts to cause such registration statement to be
              declared effective no later than the 90th calendar day following the Effective Time (or, in the event of a full review by the SEC, a later date specified in the Registration Rights Agreement) and to keep such registration statement
              continuously effective until the shares covered thereby may be sold without restriction under Rule&#160;144 or otherwise cease to be registrable securities. For a more complete description of these agreements, see the sections titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;The Concurrent Financing&#8221; and &#8220;Agreements Related to the Merger&#8212;Registration Rights Agreement</span>.&#8221; </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Passage Bio Contingent Value Rights
              Agreement (see page <a href="#tARMCVR">161</a>) </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As provided in the Merger Agreement, Passage Bio will declare a distribution to
              the holders of record of Passage Bio Common Stock, determined as of the close of business on the last business day prior to the day on which the Effective Time occurs, of the right to receive one CVR for each outstanding share of Passage Bio
              Common Stock held by such holder as of such date, each representing the non-transferable contractual right to receive certain contingent payments from Passage Bio upon the occurrence of certain events. The CVRs will be governed by the terms
              of the CVR Agreement, which will be entered into at or prior to the Effective Time by Passage Bio and Computershare Trust Company, N.A., as the Rights Agent.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the CVR Agreement, each CVR holder will be entitled to certain
              contingent cash payments, which are payable by Passage Bio to the Rights Agent for subsequent distribution to the CVR holders (such payments, the &#8220;<span style="font-style: italic; font-weight: bold;">CVR Payments</span>&#8221;), of the CVR
              Proceeds. The &#8220;<span style="font-style: italic; font-weight: bold;">CVR Proceeds</span>&#8221; will equal the net amount, calculated in accordance with GAAP consistently applied, of (i) 80% of the cash proceeds received by Passage Bio or its
              subsidiaries from Gemma Biotherapeutics, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">Gemma</span>&#8221;) in respect of the product purchase fee under Passage Bio&#8217;s exclusive license agreement with Gemma relating to its GM1 program
              (the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Sublicense (GM1)</span>&#8221;), to the extent received prior to July&#160;31, 2028 (the &#8220;<span style="font-style: italic; font-weight: bold;">GM1 CVR Period</span>&#8221;), and (ii) 100% of the
              cash proceeds received by Passage Bio or its subsidiaries from Gemma in respect of the upfront fees under Passage Bio&#8217;s exclusive license agreement with Gemma relating to its MLD program (the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Sublicense (MLD)</span>&#8221; and, together with the Gemma Sublicense (GM1), the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Sublicenses</span>&#8221;), to the extent received prior to December&#160;31, 2027 (the &#8220;<span style="font-style: italic; font-weight: bold;">MLD CVR Period</span>&#8221;), in each case less certain permitted deductions (the &#8220;<span style="font-style: italic; font-weight: bold;">Permitted Deductions</span>&#8221;), including applicable taxes on
              such proceeds, reasonable and documented out-of-pocket costs and expenses incurred by Passage Bio or its subsidiaries in performing the CVR Agreement and the Gemma Sublicenses (including the costs of storing and maintaining MLD product supply
              materials) and the costs of collecting such proceeds. The cash proceeds described in clauses (i) and (ii) are referred to, collectively, as the &#8220;<span style="font-style: italic; font-weight: bold;">Legacy Asset Payments,</span>&#8221; and each of
              the GM1 CVR Period and the MLD CVR Period is referred to as a &#8220;<span style="font-style: italic; font-weight: bold;">CVR Period</span>.&#8221;</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The CVR Payments, if any, will become payable only if and when the applicable
              Legacy Asset Payments are actually received during the applicable CVR Period. If no such proceeds are received during the applicable CVR Period, the CVR holders will not receive any payment under the CVR Agreement, and the CVRs will expire
              without any consideration or compensation therefor. There can be no assurance that the CVR holders will receive any CVR Payments.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The CVRs are not transferable, except in the limited circumstances specified in
              the CVR Agreement, will not be evidenced by any certificate or other instrument and will not be registered with the SEC. The CVRs will not have any voting or dividend rights, will not accrue interest on any amounts that may become payable in
              respect of the CVRs and will not represent any equity or ownership interest in Passage Bio or any of its subsidiaries. Passage Bio&#8217;s obligation to make any CVR Payment, if one becomes due, is neither secured nor guaranteed by Passage Bio or
              any of its subsidiaries.</div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br/>
        </div>

      </div>

    </div>

    <!--End Page 27-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 28-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a id="tTM9"><!--Anchor--></a>Management Following the
              Merger <span style="font-weight: normal;">(see page <a href="#tMFTM">284</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Effective as of the Closing, the combined company&#8217;s executive officers are
              expected to be the individuals designated by Remix, including: </div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

            <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 168pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="height: 6pt; width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="height: 6pt; width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="height: 6pt; width: 288pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                  </td>

    <td style="width: 6pt; border-bottom: none;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 6pt; border-bottom: none;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">TITLE </div>
                  </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D.</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer </div>
                  </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Operating Officer and Chief Business Officer
                    </div>
                  </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mythili Koneru, M.D., Ph.D.</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Medical Officer </div>
                  </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D.</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="width: 288pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                    <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Scientific Officer</div>
                  </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 168pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="height: 2.75pt; width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="height: 2.75pt; width: 6pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

    <td style="height: 2.75pt; width: 288pt;">
                    <div style="font-size: 1pt;">&#8194;</div>
                  </td>

  </tr>


</table>
            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTM10"><!--Anchor--></a>Material U.S. Federal Income
              Tax Consequences of the Merger<span style="font-weight: normal;"> (see page <a href="#tTMMFI">132</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Since the Passage Bio stockholders will not sell, exchange or dispose of any
              shares of Passage Bio Common Stock as a result of the Merger, there will be no material U.S. federal income tax consequences to Passage Bio stockholders as a result of the Merger.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTM11"><!--Anchor--></a>Risk Factors <span style="font-weight: normal;">(see page <a href="#tRF">23</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Both Passage Bio and Remix are subject to various risks associated with their
              businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks: </div>

            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to the Merger </div>

            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger Exchange Ratio will not be adjusted based on the market price of Passage Bio Common Stock, so the consideration at
                      the Closing may have a greater or lesser value than at the time the Merger Agreement was signed; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the conditions to the Closing are not met, the Merger may not occur; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger,
                      industry-wide changes and/or other causes; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Some executive officers and directors of Passage Bio have interests in the Merger that are different from the stockholders of
                      Passage Bio and that may influence them to support or approve the Merger without regard to the interests of the stockholders of Passage Bio; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will
                      experience in connection with the Merger; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the Merger is not completed, Passage Bio&#8217;s stock price may decline significantly; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio and Remix equityholders will have a reduced ownership and voting interest in, and will exercise less influence
                      over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Merger may not be completed on the terms or timeline currently contemplated, or at all; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Lawsuits may be filed against Passage Bio and the members of the Passage Bio Board arising out of the proposed Merger, which
                      may delay or prevent the proposed Merger; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">During the pendency of the Merger Agreement, Passage Bio and Remix may not be able to enter into a business combination with
                      another party at a favorable price due to specific restrictions in the Merger Agreement; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals for either Remix
                      or Passage Bio, including proposals that may be superior to the arrangements contemplated by the Merger Agreement; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Because the lack of a public market for the shares of Remix Capital Stock makes it difficult to evaluate the fairness of the
                      Merger, the stockholders of Remix may receive consideration in the Merger that is less than the fair market value of such Remix Capital Stock or Passage Bio may pay more than the fair market value of such Remix Capital Stock; </div>
                  </td>

  </tr>


</table>
          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br/>
        </div>

      </div>

    </div>

    <!--End Page 28-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 29-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The opinion delivered by Redwood to the Passage Bio Board prior to the entry into the Merger Agreement does not reflect
                      changes in circumstances that may occur after the date thereof; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio or Remix may waive one or more of the conditions to the Merger without recirculation of this proxy
                      statement/prospectus or resoliciting stockholder approval; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Transfers of the combined company&#8217;s securities utilizing Rule&#160;144 (&#8220;<span style="font-style: italic; font-weight: bold;">Rule&#160;144</span>&#8221;)

                      of the Securities Act of 1933, as amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Securities Act</span>&#8221;) may be limited; and </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s wind-down of its historical operations, the sale of assets, the suspension of development activities and the
                      proposed Merger, resulting in the conversion of Remix into a public company, will make Passage Bio subject to the SEC requirements applicable to reporting shell company business combinations. As a result, the combined company will be
                      subject to more stringent reporting requirements, offering limitations and resale restrictions. </div>
                  </td>

  </tr>


</table>
            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Risks Related to Passage Bio </div>

            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio has incurred significant losses since its inception and anticipates that it will continue to incur losses in the
                      foreseeable future. Passage Bio has not commercialized any products and has never generated revenue from the commercialization of any product. Passage Bio is not currently profitable, and may never achieve or sustain profitability; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Raising additional capital may cause dilution to Passage Bio&#8217;s stockholders or restrict its operations; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s failure to meet the listing standards of Nasdaq could result in the delisting of its common stock. Delisting
                      could adversely affect the liquidity of Passage Bio&#8217;s common stock and the market price of Passage Bio&#8217;s common stock could decrease, and Passage Bio&#8217;s ability to obtain sufficient additional capital to fund its operations and to
                      continue to operate as a going concern would be substantially impaired; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the Merger is not completed, Passage Bio&#8217;s board of directors may decide to pursue an alternative strategic transaction, or
                      other alternatives, which may include a dissolution and liquidation, in which case the amount, if any, distributed to Passage Bio&#8217;s stockholders may be minimal; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio is substantially dependent on its remaining employees to facilitate the consummation of the Merger; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio depends on its remaining license arrangements, and the loss of, or disputes under, those arrangements could
                      adversely affect Passage Bio which may also impact the value of any potential CVR; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio equityholders may not receive any payment on the Passage Bio CVRs and the Passage Bio CVRs may otherwise expire
                      valueless; and </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The tax treatment of the CVRs is uncertain. </div>
                  </td>

  </tr>


</table>
            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Risks Related to Remix </div>

            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix is a clinical stage biotechnology company with a limited operating history and have no history of commercializing
                      products, which may make it difficult for investors to evaluate Remix&#8217;s current business and likelihood of success and future viability; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix has incurred significant net losses in each period since Remix&#8217;s inception, and expects to continue to incur significant
                      net losses for the foreseeable future; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix has never generated revenue from product sales and may never achieve or maintain profitability; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix only has one product candidate in clinical development: REM-422. All of Remix&#8217;s other development programs are in the
                      preclinical or discovery stage. If Remix is are unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately commercialize its product candidates, or experience significant delays in
                      doing so, its business will be materially harmed; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials,
                      and the results of Remix&#8217;s clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities; </div>
                  </td>

  </tr>


</table>
          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br/>
        </div>

      </div>

    </div>

    <!--End Page 29-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 30-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix has limited resources and is currently focusing its efforts on REM-422 for development in particular indications and
                      advancing its other research programs. As a result, Remix may fail to capitalize on programs, product candidates or indications that may be more profitable or for which there is a greater likelihood of success; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">As an organization, Remix has never submitted an NDA or other marketing application, and may be unable to do so for any of its
                      product candidates; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix is conducting, and plans to conduct, some of its clinical trials outside of the United States. However, the FDA and
                      other foreign equivalents may not accept data from such trials, in which case its development plans will be delayed, which could materially harm its business; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others
                      in the medical community necessary for commercial success; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix has never commercialized a product candidate as a company before and currently lacks the necessary expertise, personnel
                      and resources to successfully commercialize any products on Remix&#8217;s own or together with suitable collaborators; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Obtaining and maintaining regulatory approval of Remix&#8217;s product candidates in one jurisdiction does not mean that Remix will
                      be successful in obtaining regulatory approval of Remix&#8217;s product candidates in other jurisdictions; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix will need to grow the size and capabilities of its organization, and Remix may experience difficulties in managing this
                      growth; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If Remix is unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market
                      Remix&#8217;s product candidates, Remix may not be able to successfully sell or market Remix&#8217;s product candidates that obtain regulatory approval; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s success depends on its ability to protect its intellectual property rights and its proprietary technologies. If Remix
                      is unable to obtain, maintain, defend and enforce patent or other intellectual property protection for its product candidates or technology, or if the scope of the patent or other intellectual property protection obtained is not
                      sufficiently broad, its competitors or other third parties could develop and commercialize products similar or identical to Remix&#8217;s, and its ability to successfully commercialize its product candidates may be adversely affected; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix relies on third parties to conduct preclinical studies and clinical trials and those third parties may not perform
                      satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix contracts with third parties for the manufacture of its product candidates for preclinical studies and clinical trials
                      and expects to do so ultimately for commercialization, and the loss of these third parties or their inability to supply Remix with sufficient quality and quantities of its product candidates or such quantities at an acceptable cost
                      could delay, prevent or impair its development or commercialization efforts; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix has entered a collaboration with Roche for the development and commercialization of product candidates. Remix may in the
                      future enter additional collaborations. If those collaborations are not successful, Remix may not be able to capitalize on the market potential of these product candidates; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix does not anticipate that Remix will pay any cash dividends in the foreseeable future; and </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix will need substantial additional funding before Remix can complete the development of its product candidates. If Remix
                      is unable to obtain such additional capital on favorable terms, on a timely basis or at all, Remix would be forced to delay, reduce or eliminate its product development and clinical programs and may not have the capital required to
                      otherwise operate Remix&#8217;s business. </div>
                  </td>

  </tr>


</table>
            <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Combined Company </div>

            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Following the Merger, the combined company may be unable to successfully integrate the businesses of Passage Bio and Remix and
                      realize some or all of the anticipated benefits of the Merger; </div>
                  </td>

  </tr>


</table>
          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br/>
        </div>

      </div>

    </div>

    <!--End Page 30-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 31-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock
                      may drop following the Merger; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The combined company will incur costs and increased demands upon management as a result of complying with the laws, rules and
                      regulations affecting public companies; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the proceeds subject to the CVR Agreement are not received in a timely manner, the combined company may have to incur time
                      and resources to recover such proceeds; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Nasdaq may delist the combined company&#8217;s securities from trading on its exchange, which could limit investors&#8217; ability to make
                      transactions in its securities and subject the combined company to additional trading restrictions; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Provisions in the combined company&#8217;s amended and restated certificate of incorporation, the combined company&#8217;s amended and
                      restated bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of the combined company by others, even if an acquisition would be beneficial to the combined company&#8217;s stockholders, and may prevent
                      attempts by the combined company&#8217;s stockholders to replace or remove the combined company&#8217;s current management; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If approved by the stockholders, the combined company&#8217;s restated certificate of incorporation will provide that the Court of
                      Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between the combined company and the combined company&#8217;s stockholders and that the federal district courts shall be the exclusive forum for
                      the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit the combined company&#8217;s stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company
                      or its directors, officers or employees; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to
                      resell their shares of common stock for a profit, if at all; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined
                      company, its business or its market, its stock price and trading volume could decline; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The unaudited pro forma condensed combined financial statements included in this proxy statement/prospectus are presented for
                      illustrative purposes only and may not be an indication of the combined company&#8217;s financial condition or results of operations following the completion of the Merger; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial
                      statements on a timely basis could be impaired; </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to
                      successfully develop or commercialize its drug candidates or otherwise implement its business plan; and </div>
                  </td>

  </tr>


</table>
            <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                  </td>

    <td style="vertical-align: top;">
                    <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Changes in tax laws or regulations that are applied adversely to the combined company may materially and adversely affect its
                      business, results of operations and financial condition. </div>
                  </td>

  </tr>


</table>
            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTM12"><!--Anchor--></a>Regulatory Approvals <span style="font-weight: normal;">(see page <a href="#tTMARA">151</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the United States, Passage Bio must comply with applicable federal and state
              securities laws and the rules and regulations of Nasdaq in connection with (i) the issuance of shares of Passage Bio Common Stock to Remix stockholders in connection with the transactions contemplated by the Merger Agreement and the change of
              control resulting from the Merger and (ii) the filing of this proxy statement/prospectus with the SEC.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Completion of the Merger is conditioned on the absence of any law or order
              restraining, enjoining, or otherwise prohibiting the consummation of the Merger.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTM13"><!--Anchor--></a>Nasdaq Listing <span style="font-weight: normal;">(see page <a href="#tNLIS">132</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the Merger Agreement, Passage Bio has agreed to use commercially
              reasonable efforts, (i) to maintain its existing listing on Nasdaq until the Closing and to obtain approval of the listing of the combined company on Nasdaq, (ii) to the extent required by the rules and regulations of Nasdaq, prepare and
              submit to Nasdaq a </div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br/>
        </div>

      </div>

    </div>

    <!--End Page 31-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 32-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a id="ny20077915x1_s4_106-summary_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;">
        <div class="BRDSX_page-content" style="margin-left: 12pt;">
          <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">notification form for the listing of the shares of Passage Bio Common Stock
              being issued in connection with the Merger and Contemplated Transactions, (iii) use commercially reasonable efforts to cause such shares to be approved for listing (subject to official notice of issuance) on the Nasdaq market at or prior to
              the Effective Time, (iv) to effect the reverse stock split, and (v)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, to file an initial Nasdaq Listing Application for the Passage Bio Common Stock on Nasdaq and to use commercially
              reasonable efforts to cause such listing application to be conditionally approved prior to the Effective Time.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a id="tTM14"><!--Anchor--></a>Anticipated Accounting
              Treatment <span style="font-weight: normal;">(see page <a href="#tTMAAT">132</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is expected to be accounted for under accounting principles
              generally accepted in the United States of America (&#8220;<span style="font-style: italic; font-weight: bold;">GAAP</span>&#8221;) as an in-substance reverse recapitalization. For accounting purposes, Remix is expected to be considered the accounting
              acquirer. The treatment as an in-substance reverse recapitalization is based on the assessment that as a result of Passage Bio&#8217;s discontinuation of its research and development activities and settlement of its other remaining operating assets
              and liabilities, immediately prior to the Closing, Passage Bio is expected to have nominal assets, apart from cash and cash equivalents and marketable securities. Under a reverse recapitalization, Remix is considered to effect a financing
              transaction in exchange for issuing equity.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a id="tTM15"><!--Anchor--></a>Appraisal Rights <span style="font-weight: normal;">(see page <a href="#tTMARI">132</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Holders of Passage Bio Common Stock are not entitled to appraisal rights in
              connection with the Merger under the DGCL.</div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix stockholders are entitled to appraisal rights in connection with the
              Merger under Section&#160;262 of the DGCL. See the section titled &#8220;<span style="font-style: italic;">The Merger&#8212;Appraisal Rights</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</div>

            <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a id="tTM16"><!--Anchor--></a>Comparison of Stockholder
              Rights <span style="font-weight: normal;">(see page <a href="#tCRHP">308</a>)</span></div>

            <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Both Passage Bio and Remix are incorporated under the laws of the State of
              Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the DGCL. If the Merger is completed, Remix stockholders will become Passage Bio stockholders, and their rights will be
              governed by the DGCL, the amended and restated bylaws of the combined company and the amended and restated certificate of incorporation of the combined company, as amended, as more fully described under the section titled &#8220;<span style="font-style: italic;">Comparison of Rights of Holders of Passage Bio Capital Stock and Remix Capital Stock</span>&#8221; of this proxy statement/prospectus. </div>

          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br/>
        </div>

      </div>

    </div>

    <!--End Page 32-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 33-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tRF"><!--Anchor--></a>RISK FACTORS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company will be faced with a market environment that cannot be
            predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material
            risks described below before deciding how to vote your shares of Passage Bio Common Stock. You should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;<span style="font-style: italic;">Where You Can Find More Information</span>&#8221; beginning on page <a href="#tWYC">322</a> of this proxy statement/prospectus for further information. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;"><a id="tRF1"><!--Anchor--></a>Risks Related to the Merger </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Merger Exchange Ratio will not be
            adjusted based on the market price of Passage Bio Common Stock, so the consideration at the Closing may have a greater or lesser value than at the time the Merger Agreement was signed. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Exchange Ratio will not change based on changes in the trading price
            of Passage Bio Common Stock. Therefore, if before the completion of the Merger, the market price of Passage Bio Common Stock increases from the market price on the date of the Merger Agreement, Remix stockholders could then receive merger
            consideration with substantially higher value for their shares of Remix common stock than the parties had negotiated when they established the Merger Exchange Ratio. The Merger Agreement does not include a price-based termination right. Under
            the Merger Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon the number of shares of Passage Bio Common Stock expected to be issued in
            connection with the Merger, pre-Merger equityholders of Remix (other than investors in the Concurrent Financing) are expected to own approximately 65% of the combined company, pre-Merger equityholders of Passage Bio are expected to own
            approximately 6% of the combined company and the investors in the Concurrent Financing are expected to own approximately 29% of the combined company (assuming proceeds from the Concurrent Financing of $100.0&#160;million), in each case, calculated
            on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (i) a valuation for Passage Bio of approximately $20.0 million (assuming Passage Bio Net Cash of $5.0 million as of the Closing), (ii) a
            fixed valuation for Remix of $226.0&#160;million, and (iii) the relative capitalization of Passage Bio and Remix. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments
            (as described in more detail in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Merger Consideration and Merger Exchange Ratio</span>&#8221;), including the amount of the final Passage Bio Net Cash at the Closing. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">If the conditions to the Closing are not
            met, the Merger may not occur. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Even if Proposal Nos. 1, 2 and 3 are approved by the stockholders of Passage Bio,
            specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and each material condition to the completion of the Merger is described
            in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Conditions to the Completion of the Merger</span>&#8221; of this proxy statement/prospectus. Passage Bio and Remix cannot assure you that all of the conditions will be
            satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or will be delayed, and Passage Bio and Remix each may lose some or all of the intended benefits of the Merger. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Merger may be completed even though a
            material adverse effect may result from the announcement of the Merger, industry-wide changes and/or other causes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In general, either Passage Bio or Remix can refuse to complete the Merger if
            there is a Passage Bio Material Adverse Effect (as defined in the Merger Agreement) or a Remix Material Adverse Effect (as defined in the Merger Agreement), as applicable, between June&#160;24, 2026, the date of the Merger Agreement, and the
            Closing. However, certain types of changes do not permit either party to refuse to complete the Merger, even if such change could be said to have a material adverse effect on Passage Bio or Remix, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general business, political or economic conditions generally affecting the industries in which Passage Bio or Remix operate; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acts of war, the outbreak or escalation of armed hostilities, acts of terrorism, earthquakes, wildfires, hurricanes or other
                    natural disasters, health emergencies, including pandemics and related or associated epidemics, disease outbreaks or quarantine restrictions; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br/>
        </div>

      </div>

    </div>

    <!--End Page 33-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 34-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in financial, banking or securities markets; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any failure by Passage Bio to meet internal or analysts&#8217; expectations or projections or the results of operations of Passage Bio
                    (it being understood, however, that any effect causing or contributing to the failure of Passage Bio to meet internal or analysts&#8217; expectations or projections or the results of operations of Passage Bio may be taken into account in
                    determining whether a material adverse effect with respect to Passage Bio has occurred, unless such effects are otherwise excepted from the definition of Passage Bio Material Adverse Effect); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any change in, or any compliance with or action taken for the purpose of complying with, any applicable law or GAAP (or
                    interpretations of any applicable law or GAAP); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the announcement of the Merger Agreement or the pendency of the Contemplated Transactions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the taking of any action required to be taken by the Merger Agreement; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any change in the cash position of Passage Bio and its subsidiaries resulting from operations in the ordinary course of business
                    or from expenditures reasonably required to effect the wind-down, discontinuation, suspension or termination of any clinical, pre-clinical or development program or trial of Passage Bio or its subsidiaries (including the PBFT02 program
                    and the upliFT-D trial). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a material adverse change occurs with respect to either party or both parties
            and Passage Bio and Remix still complete the Merger, the stock price of the combined company following the Closing may suffer and may reduce the value of the Merger to the stockholders of Passage Bio, Remix or both.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Some executive officers and directors of
            Passage Bio have interests in the Merger that are different from those of the stockholders of Passage Bio and that may influence them to support or approve the Merger without regard to the interests of Passage Bio stockholders.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain executive officers and directors of Passage Bio are parties to
            arrangements that provide them with interests in the Merger that are different from, or in addition to, the interests of Passage Bio stockholders generally. With respect to Passage Bio&#8217;s directors and executive officers, these interests may
            include severance or other separation payments and benefits, the acceleration of their outstanding Passage Bio equity awards, the extension of the post-termination exercise period of certain Passage Bio Options held by executive officers, and
            rights to continued indemnification, expense advancement and directors&#8217; and officers&#8217; liability insurance coverage. With respect to Remix&#8217;s directors and executive officers, these interests may include the conversion of their Remix Options into
            options to purchase shares of combined company common stock, the expected continuation of certain Remix executive officers and directors with the combined company following the Effective Time, and rights to indemnification and liability
            insurance coverage under the Merger Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Board was aware of and considered these interests, among other
            matters, in reaching its determination (i) that the terms of the Merger Agreement and the Merger and the other Contemplated Transactions are fair to, advisable and in the best interest of Passage Bio and its stockholders, (ii) to approve and
            declare advisable the Merger Agreement and the Contemplated Transactions, including the Merger and the issuance of shares of Passage Bio Common Stock to the stockholders of Remix pursuant to the Merger Agreement and (iii) to recommend, upon the
            terms and subject to the terms and conditions set forth in the Merger Agreement, that the stockholders of Passage Bio vote to approve Proposal Nos. 1, 2 and 3. These interests, among other factors, may have influenced the directors and
            executive officers of Passage Bio to support or approve the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For more information regarding the interests of Passage Bio&#8217;s and Remix&#8217;s
            executive officers and directors in the Merger, see the sections titled &#8220;The Merger&#8212;Interests of Passage Bio&#8217;s Directors and Executive Officers in the Merger&#8221; and &#8220;The Merger&#8212;Interests of Remix<span style="font-style: italic;">&#8217;s Directors and
              Executive Officers in the Merger</span>.&#8221; </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Passage Bio stockholders may not realize
            a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the combined company is unable to realize the full strategic and financial
            benefits currently anticipated from the Merger, Passage Bio stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to
            the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br/>
        </div>

      </div>

    </div>

    <!--End Page 34-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 35-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">If the Merger is not completed, Passage
            Bio&#8217;s stock price may decline significantly. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The market price of Passage Bio Common Stock is subject to significant
            fluctuations. During the 12-month period ended June&#160;24, 2026, the closing per share sales price of Passage Bio Common Stock on Nasdaq ranged from a high of $19.85 on January&#160;9, 2026 to a low of $4.08 on May&#160;7, 2026. Market prices for securities
            of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of Passage Bio Common Stock will likely be volatile based on whether stockholders and other investors
            believe that Passage Bio can complete the Merger or otherwise raise additional capital to support Passage Bio&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a
            timely manner, if at all.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Additional factors that may cause the market price of Passage Bio Common Stock
            to fluctuate include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the entry into, or termination of, key agreements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant
                    contracts, commercial relationships or capital commitments; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the loss of key employees; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">future sales of its common stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general and industry-specific economic conditions that may affect its research and development expenditures; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the failure to meet industry analyst expectations; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">period-to-period fluctuations in financial results. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Moreover, the stock markets in general have experienced substantial volatility
            that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of Passage Bio Common Stock. In the past, following periods of volatility in the
            market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Passage Bio and Remix equityholders
            will have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the
            respective companies.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After the completion of the Merger, the current stockholders of Passage Bio and
            Remix will own a smaller percentage of the combined company than their ownership of their respective companies prior to the Merger. <span style="font-style: italic;">For the expected pro forma ownership percentages of the combined company and
              the assumptions on which they are based, see the risk factor above titled &#8220;&#8212;The Merger Exchange Ratio will not be adjusted based on the market price of Passage Bio Common Stock, so the consideration at the Closing may have a greater or lesser
              value than at the time the Merger Agreement was signed&#8221; and the section titled &#8220;The Merger Agreement&#8212;Merger Consideration and Merger Exchange Ratio.&#8221;</span> </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The Merger may not be completed on the
            terms or timeline currently contemplated, or at all. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consummation of the Merger is subject to numerous conditions, including (1)
            the effectiveness of the registration statement of which this proxy statement/prospectus forms a part, (2) the approval by Passage Bio&#8217;s stockholders of the Passage Bio Stockholder Matters, (3) the approval by Remix&#8217;s stockholders of the Remix
            Stockholder Matters, and (4) other customary closing conditions and there can be no assurance that the Merger will be consummated. See the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Conditions to the Completion of
              the Merger</span>.&#8221;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Merger is not completed for any reason, the price of Passage Bio Common
            Stock may decline to the extent that the market price of Passage Bio Common Stock reflects or previously reflected positive market assumptions that the Merger would be completed and the related benefits would be realized. In addition, Passage
            Bio and Remix have expended and will continue to expend significant management time and resources and have incurred and will continue to incur significant expenses due to legal, advisory, printing and financial services fees related to the
            Merger. These expenses must be paid regardless of whether the Merger is consummated.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br/>
        </div>

      </div>

    </div>

    <!--End Page 35-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 36-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Lawsuits may be filed against Passage
            Bio and the members of the Passage Bio Board arising out of the proposed Merger, which may delay or prevent the proposed Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Putative stockholder complaints, including stockholder class action complaints,
            and other complaints may be filed against Passage Bio, the Passage Bio Board, Remix, the Remix Board and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and Passage Bio
            may not be successful in defending against any such future claims. Lawsuits that may be filed against Passage Bio, the Passage Bio Board, Remix, or the Remix Board could delay or prevent the Merger, divert the attention of Passage Bio&#8217;s
            management and employees from Passage Bio&#8217;s day-to-day business and otherwise adversely affect Passage Bio&#8217;s financial condition.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">During the pendency of the Merger
            Agreement, Passage Bio and Remix may not be able to enter into a business combination with another party at a favorable price because of restrictions in the Merger Agreement, which could adversely affect their respective businesses.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Covenants in the Merger Agreement impede the ability of Passage Bio and Remix to
            make acquisitions, subject to specified exceptions relating to fiduciary duties, or complete other mergers, sales of assets or other business combinations pending completion of the Merger. As a result, if the Merger is not completed, the
            parties may be at a disadvantage to their competitors during that period. In addition, while the Merger Agreement is in effect, each party is generally prohibited from soliciting, initiating, knowingly encouraging or entering into specified
            extraordinary transactions, such as a merger, sale of assets or other business combination, with any third party, subject to specified exceptions, even if any such transaction could be favorable to such party&#8217;s stockholders, as applicable. For
            a more complete description of the restrictions on pursuing alternative transactions please see the section titled &#8220;<span style="font-style: italic;">The Merger Agreement</span>.&#8221;</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Certain provisions of the Merger
            Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the arrangements contemplated by the Merger Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The terms of the Merger Agreement prohibit each of Passage Bio and Remix from
            soliciting competing proposals or cooperating with persons making unsolicited takeover proposals, except in certain limited circumstances. With respect to Passage Bio, the Passage Bio Board may respond to an unsolicited competing proposal if it
            determines in good faith, after consultation with its outside financial advisor and outside legal counsel, that the unsolicited competing proposal constitutes, or is reasonably likely to result in, a superior competing proposal and, after
            consultation with its outside legal counsel, that failure to take such action would be inconsistent with the fiduciary duties of the Passage Bio Board. With respect to Remix, following receipt of a bona fide acquisition proposal by any person
            that the Remix Board has determined constitutes, or is reasonably likely to result in, a superior offer, Remix may solicit acquisition proposals and furnish information to, and enter into discussions with, any person (including persons not
            making such proposal) if the Remix Board concludes in good faith, after consultation with its outside legal counsel and financial advisor, that failure to take such action would be inconsistent with the fiduciary duties of the Remix Board.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In certain circumstances, and subject to compliance with the Merger Agreement,
            the Passage Bio Board or the Remix Board may change its recommendation to its respective stockholders if it determines such recommendation change is required to avoid a breach of its fiduciary duties. Additionally, subject to compliance with
            the procedures set forth in the Merger Agreement, including paying the applicable termination fee, Remix may terminate the Merger Agreement in order to enter into an agreement with respect to a Superior Offer.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon termination of the Merger Agreement in certain circumstances, Remix may be
            required to pay to Passage Bio a termination fee of (x) $17.5&#160;million, including (i) where the Remix Board changes or withdraws its recommendation in favor of the Merger or recommends to enter into an alternative transaction, (ii) in certain
            circumstances where Remix enters into a Permitted Alternative Agreement (as defined in the Merger Agreement); or (iii) if (a) the Merger Agreement is terminated because Remix (1) fails to obtain the requisite stockholder approval of the Merger
            Agreement and the transactions contemplated thereby or (2) breaches the Merger Agreement, (b) an alternative acquisition proposal was announced or disclosed prior to obtaining Remix&#8217;s stockholder approval, and (c)&#160;within 12 months of the
            termination of the Merger Agreement, Remix enters into a definitive agreement with respect to an alternative transaction; or (iv) if (a) the Merger Agreement is terminated because the Merger has not been consummated by the Outside Date, (b) an
            alternative acquisition proposal was announced or disclosed prior to obtaining the Required Remix Stockholder Vote, and (c) within 12 months of such termination, Remix enters into a definitive agreement with respect to an alternative
            transaction (for which the applicable termination fee is also $17.5&#160;million).</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br/>
        </div>

      </div>

    </div>

    <!--End Page 36-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 37-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Upon termination of the Merger Agreement in certain circumstances, a
            termination fee of $1.5 million may be payable by Passage Bio to Remix if (i)(a) the Merger Agreement is terminated because the Merger has not been consummated by the Outside Date (as defined in the Merger Agreement) or Passage Bio (1) fails to
            obtain the requisite stockholder approval of the Passage Bio Stockholder Matters or (2) breaches the Merger Agreement, (b) an alternative acquisition proposal was announced or disclosed prior to such termination, and (c) within 12 months of the
            termination of the Merger Agreement, Passage Bio enters into a definitive agreement with respect to an alternative transaction, (ii) Passage Bio fails to include its board recommendation in this proxy statement/prospectus, or (iii) the Passage
            Bio Board of directors changes or withdraws its recommendation in favor of the Merger or approves an alternative transaction, or willfully and intentionally breaches its non-solicitation or certain other obligations under the Merger Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These termination fees may discourage third parties from submitting competing
            proposals to Passage Bio or Remix or their respective stockholders and may cause the Passage Bio Board or the Remix Board, as the case may be, to be less inclined to recommend a competing proposal. For more information regarding the potential
            termination fees, see the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Termination and Termination Fees</span>.&#8221;</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Because the lack of a public market for
            the shares of Remix Capital Stock makes it difficult to evaluate the fairness of the Merger, the stockholders of Remix may receive consideration in the Merger that is less than the fair market value of such Remix Capital Stock or Passage Bio
            may pay more than the fair market value of such Remix Capital Stock.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The outstanding shares of Remix Capital Stock are privately held and are not
            traded in any public market. The lack of a public market makes it extremely difficult to determine the fair market value of the shares of Remix Capital Stock. Because the percentage of Passage Bio equity to be issued to Remix stockholders was
            determined based on negotiations between the parties, it is possible that the value of the Passage Bio Common Stock to be received by Remix stockholders will be less than the fair market value of the shares of Remix Capital Stock, or Passage
            Bio may pay more than the aggregate fair market value for the shares of Remix Capital Stock.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The opinion delivered by Redwood to the
            Passage Bio Board prior to the entry into the Merger Agreement does not reflect changes in circumstances that may occur after the date thereof.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Board has not obtained an updated opinion either as of the date
            of this proxy statement/prospectus or as of any other date subsequent to the date of the opinion of Redwood, Passage Bio&#8217;s financial advisor. Changes in circumstances, including without limitation the operations and prospects of Passage Bio or
            Remix, stock prices, general market and economic conditions and other factors, some or all of which may be beyond the control of Passage Bio and Remix, are not reflected in the opinion of Redwood. The opinion of Redwood does not speak as of any
            date other than the date thereof. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Passage Bio or Remix may waive one or
            more of the conditions to the Merger without recirculation of this proxy statement/prospectus or resoliciting stockholder approval. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Conditions to Passage Bio&#8217;s or Remix&#8217;s obligations to complete the Merger may be
            waived, in whole or in part, to the extent permitted by law, in certain circumstances unilaterally or by agreement of Passage Bio and Remix. In the event of a waiver of a condition, the Passage Bio Board will evaluate the materiality of any
            such waiver to determine whether amendment of this proxy statement/prospectus and re-solicitation of stockholder approval is necessary.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event that the Passage Bio Board, in its own reasonable discretion,
            determines any such waiver is not significant enough to require recirculation of this proxy statement/prospectus and re-solicitation of its stockholders, it will have the discretion to complete the Merger without seeking further stockholder
            approval, which decision may have a material adverse effect on Passage Bio stockholders. For example, if Passage Bio and Remix agree to waive the requirement that the shares of Passage Bio Common Stock to be issued in the Merger have been
            approved for listing (subject to official notice of issuance) on Nasdaq as of the Closing, and their respective boards of directors elect to proceed with the Closing, Nasdaq may notify the combined company of its determination to delist the
            combined company&#8217;s securities based upon the failure to satisfy the initial inclusion criteria in the Nasdaq application. The combined company may appeal the determination to a hearings panel but such appeal will not stay the suspension and
            delisting action and Nasdaq may notify the combined company that its common stock will be immediately suspended from trading and delisted.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, in order to meet the initial listing requirements of Nasdaq or as
            otherwise determined in the discretion of the combined company board pursuant to the terms of the Lock-Up Agreements, the Passage Bio Board or combined </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br/>
        </div>

      </div>

    </div>

    <!--End Page 37-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 38-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">company board may release stockholders from their Lock-Up Agreements and waive
            the requirement that such Lock-Up Agreements be in full force and effect immediately following the Effective Time. Such release would increase the number of shares that may be sold in the public market immediately after the Merger and any such
            sales could cause the combined company&#8217;s stock price to decline. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfers of the combined company&#8217;s
            securities utilizing Rule&#160;144 may be limited. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A significant portion of the combined company&#8217;s securities will be restricted
            from immediate resale. Holders should be aware that transfers of Passage Bio&#8217;s securities pursuant to Rule&#160;144 may be limited as Rule&#160;144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell
            companies (other than business combination related shell companies) or issuers that have previously been a shell company. Passage Bio&#8217;s wind-down of its general and administrative operations that will not be needed after Closing and the
            proposed Merger (including the issuance of the Passage Bio CVRs in connection therewith) will make Passage Bio subject to the SEC requirements applicable to reporting shell company business combinations. Passage Bio anticipates that following
            the consummation of the Merger, the combined company will no longer be a shell company. As a result, Passage Bio anticipates that holders of restricted securities of the combined company, including affiliates of the combined company, will not
            be able to sell such securities pursuant to Rule&#160;144 without registration until one year after the combined company files Form&#160;10 information with the SEC. For more information, see the section titled &#8220;<span style="font-style: italic;">Securities
              Act Restrictions on Resale of Combined Company Common Stock</span>.&#8221;</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s wind-down of its historical
            operations, the sale of assets, the suspension of development activities and the proposed Merger, resulting in the conversion of Remix into a public company, will make Passage Bio subject to the SEC requirements applicable to reporting shell
            company business combinations. As a result, the combined company will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">According to SEC guidance, the requirements applicable to reporting shell company
            business combinations apply to any company that sells or otherwise disposes of its historical assets or operations in connection with or as part of a plan to combine with a non-shell private company in order to convert the private company into
            a public one. Passage Bio has taken steps to wind-down its general and administrative operations that will not be needed after Closing and expects to issue the Passage Bio CVRs in connection with the Closing and, as such, Passage Bio&#8217;s plan to
            merge with Remix, resulting in the conversion of Remix into a public company, will be subject to the SEC requirements applicable to reporting shell company business combinations, which are as follows: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company will need to file a Current Report on Form&#160;8-K to report the Form&#160;10 type information (&#8220;<span style="font-style: italic; font-weight: bold;">Super 8-K</span>&#8221;) after the Closing reflecting its status as an entity that is not a shell company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company will not be eligible to use a Form&#160;S-3 until 12 full calendar months after the Closing; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company will need to wait at least 60 calendar days after the filing of the Super 8-K to file a Form&#160;S-8 for any
                    equity plans or awards, such as the 2026 Plan and the 2026 ESPP and the assumed Remix 2019 Plan; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company will be an &#8220;ineligible issuer&#8221; for three years following the Closing, which will prevent the combined
                    company from (i) incorporating by reference in its Form&#160;S-1 filings, (ii) using a free writing prospectus or (iii) taking advantage of well-known seasoned issuer (&#8220;<span style="font-style: italic; font-weight: bold;">WKSI</span>&#8221;)
                    status, even if otherwise eligible based on its public float; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">investors who (i) were affiliates of Remix at the time the Merger was submitted for the vote or consent of Remix&#8217;s stockholders,
                    (ii) receive securities of the combined company in the Merger and (iii) publicly offer or sell such securities will be deemed to be engaged in a distribution of such securities, and therefore would be underwriters with respect to
                    resales of those securities; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Rule&#160;144(i)(2) will limit the ability of holders of restricted securities, and any affiliates of the public company to publicly
                    resell Rule&#160;145(c) securities per Rule&#160;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company per Rule&#160;144, until one year after the Form&#160;10 information is filed with the SEC. Non-affiliate Passage Bio
                    stockholders prior to the Merger will not be subject to such restrictions on public resales of their shares. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br/>
        </div>

      </div>

    </div>

    <!--End Page 38-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 39-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The foregoing SEC requirements will increase the combined company&#8217;s time and
            cost of raising capital, offering stock under equity plans, and complying with securities laws. Furthermore, such requirements will add burdensome restrictions on the resale of the combined company common stock by affiliates of Remix and any
            holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For more information about the conditions to the completion of the Merger, see
            the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Conditions to the Completion of the Merger</span>.&#8221; </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Passage Bio stockholders may not receive
            any payment on the Passage Bio CVRs and the Passage Bio CVRs may otherwise expire valueless. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The right of Passage Bio stockholders to receive any payment in respect of, or to
            derive any value from, the Passage Bio CVRs is contingent on Passage Bio or the combined company actually receiving the Legacy Asset Payments &#8212; the GM1 Payments and the MLD Payments payable by Gemma Biotherapeutics, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">Gemma</span>&#8221;) under Passage Bio&#8217;s sublicense arrangements with Gemma relating to its GM1 and MLD programs (the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Sublicenses</span>&#8221;) &#8212;
            during the applicable CVR Period, and on the amount of any such payments remaining after the permitted deductions specified in the Passage Bio CVR Agreement. The GM1 Payments may give rise to a Passage Bio CVR Payment only if received during
            the GM1 CVR Period, which ends on July&#160;31, 2028, and the MLD Payments only if received during the MLD CVR Period, which ends on December&#160;31, 2027; any amounts received after the applicable CVR Period will not give rise to any Passage Bio CVR
            Payment. In addition, the GM1 Payments depend on the continued effectiveness of Passage Bio&#8217;s underlying license, which requires Passage Bio to make the GM1 2027 License Payment (as defined in the Passage Bio CVR Agreement) to The Trustees of
            the University of Pennsylvania to extend that license; if that payment is not made, the GM1 Payments may not be realized. If the applicable payments are not made, are not received during the applicable CVR Period, or are not sufficient to
            result in any Passage Bio CVR Payment after giving effect to the permitted deductions, no payments will be made in respect of the Passage Bio CVRs, and the Passage Bio CVRs will expire valueless.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following the effective time, the combined company will have sole authority over
            whether and how to monetize the Legacy Assets (if at all), and the combined company&#8217;s only obligations will be to carry out the obligations set forth in the Passage Bio CVR Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Furthermore, the Passage Bio CVRs will be unsecured contractual obligations of
            the combined company. The Passage Bio CVRs will not be transferable except in the limited circumstances specified in the Passage Bio CVR Agreement, will not be evidenced by any certificate or other instrument, will not be registered with the
            SEC and will not be listed on any exchange. The Passage Bio CVRs will not have any voting or dividend rights, will not represent any equity or ownership interest in the combined company, and will not accrue interest. As a result, there will be
            no public market for the Passage Bio CVRs, and holders may not be able to realize any value from the Passage Bio CVRs other than through the payments, if any, made under the Passage Bio CVR Agreement. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">The tax treatment of the CVRs is
            uncertain. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio intends to treat a holder&#8217;s receipt of the Passage Bio CVRs as not
            constituting a current distribution of property with respect to the holder&#8217;s existing shares of Passage Bio Common Stock for U.S. federal income tax purposes, and future cash payments (if any) on the CVRs being reported as dividends to the
            extent of the combined company&#8217;s current and accumulated earning and profits in the year(s) in which such payments are made. However, the U.S. federal income tax treatment of the Passage Bio CVRs is uncertain. There is no legal authority
            directly addressing the U.S. federal income tax treatment of the receipt of, and payments under, the Passage Bio CVRs, and there can be no assurance that the Internal Revenue Service (&#8220;<span style="font-style: italic; font-weight: bold;">IRS</span>&#8221;)

            would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the Passage Bio CVRs. For more information regarding the U.S. federal income tax consequences of the
            CVRs, see the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Passage Bio Contingent Value Rights Agreement</span>.&#8221; </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;"><a id="tRF2"><!--Anchor--></a>Risks Related to the Reverse Stock Split</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">The reverse stock split may not increase
            the price of the combined company&#8217;s common stock over the long term. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The principal purposes of the reverse stock split are to increase the per share
            market price of Passage Bio Common Stock so that the combined company is able to satisfy the minimum bid price requirement and the other initial listing standards of Nasdaq in connection with the Merger, and to increase the number of authorized
            but unissued shares of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">29<br/>
        </div>

      </div>

    </div>

    <!--End Page 39-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 40-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">common stock available for future issuance. The combined company cannot assure
            you, however, that the reverse stock split will accomplish any sustained increase in the per share market price of its common stock. While it is expected that the reduction in the number of outstanding shares of common stock will proportionally
            increase the market price of the combined company&#8217;s common stock, the combined company cannot assure you that the reverse stock split will increase the market price of its common stock by a multiple of the reverse stock split ratio, or result
            in any permanent or sustained increase in the market price, which depends on many factors, including the combined company&#8217;s business and financial performance, general market conditions and prospects for future success. Accordingly, even if the
            market price of the combined company&#8217;s common stock satisfies the applicable Nasdaq listing requirements initially following the reverse stock split, the combined company cannot assure you that it will continue to do so. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">The reverse stock split may decrease
            the liquidity of the combined company&#8217;s common stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Although the Passage Bio Board believes that the anticipated increase in the
            market price of the combined company&#8217;s common stock resulting from the reverse stock split could encourage interest in the common stock and possibly promote greater liquidity for the combined company&#8217;s stockholders, that liquidity could also be
            adversely affected by the reduced number of shares of common stock that would be outstanding after the reverse stock split, particularly if the per share market price does not increase as a result of the reverse stock split. The reduction in
            the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock, and may make it more difficult to effect transactions in the common stock. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">The reverse stock split may lead to a
            decrease in the combined company&#8217;s overall market capitalization. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Should the market price of the combined company&#8217;s common stock decline after the
            reverse stock split, the percentage decline, as an absolute number and as a percentage of the combined company&#8217;s overall market capitalization, may be greater than would occur in the absence of the reverse stock split. A reverse stock split is
            sometimes viewed negatively by the market and, consequently, can lead to a decrease in the combined company&#8217;s overall market capitalization. If the per share market price of the combined company&#8217;s common stock does not increase in proportion to
            the reverse stock split ratio, or declines to its pre-split level, the combined company&#8217;s overall market capitalization will be reduced. In some cases, the per share stock price of companies that have effected reverse stock splits has
            subsequently declined back to or below pre-split levels, and there can be no assurance that the total market value of the combined company&#8217;s common stock will not decline as a result of the reverse stock split. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; text-align: center;"><a id="tRF3"><!--Anchor--></a>Risks Related to Passage Bio </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise indicated or the context otherwise requires, references in this
            section to &#8220;Passage Bio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Passage Bio and its subsidiaries. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Risks Related to Passage Bio&#8217;s Financial
            Position and Need for Additional Capital </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has a history of operating
            losses, has wound down its development programs and has limited remaining operations, and does not expect to generate revenue or achieve profitability. Passage Bio anticipates that it will continue to incur losses for the foreseeable future.
            Its limited operating history may make it difficult for you to evaluate the success of its business to date and to assess its future viability.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has wound down its development programs and has limited remaining
            operations. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. Its operations to date have been limited primarily to staffing its company, business planning, raising capital,
            entering into collaboration and vendor agreements for conducting preclinical research and clinical development activities for its product candidates, and performing clinical development activities and manufacturing clinical supply. Passage Bio
            has outlicensed or discontinued its product candidates and is no longer advancing a development pipeline. Passage Bio has no products approved for commercial sale and has not generated any revenue from commercial product sales, and it expects
            to incur costs associated with the proposed Merger. It has generally funded its operations to date through proceeds from sales of convertible preferred stock and public offerings, and does not expect to receive revenue from commercial product
            sales, for many years, if ever. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has incurred net losses since its inception in 2017. Passage Bio
            incurred net losses of $45.5&#160;million and $64.8&#160;million for the years ended December&#160;31, 2025 and 2024, respectively and incurred net losses of $7.6&#160;million </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">30<br/>
        </div>

      </div>

    </div>

    <!--End Page 40-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 41-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and $15.4&#160;million for the three months ended March&#160;31, 2026 and 2025,
            respectively. As of December&#160;31, 2025 and March&#160;31, 2026, Passage Bio had an accumulated deficit of $704.8&#160;million and $712.3&#160;million, respectively. Substantially all of its operating losses have resulted from expenses incurred in connection
            with its research and development programs, acquiring the rights to its product candidates, and from general and administrative expenses associated with its operations. Passage Bio expects to continue to incur significant expenses and operating
            losses over the next several years and for the foreseeable future in connection with the wind-down of its operations and the proposed Merger, which expenses, together with anticipated general and administrative expenses, will likely result in
            it incurring significant losses for the foreseeable future. Its prior losses, combined with expected future losses, have had and will continue to have an adverse effect on its stockholders&#8217; equity and working capital.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If the Merger is not completed, Passage
            Bio&#8217;s board of directors may decide to pursue an alternative strategic transaction, or a dissolution and liquidation, in which case the amount, if any, distributed to its stockholders may be minimal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There can be no assurance that the Merger will be completed. Passage Bio has
            wound down its historical development operations, and it has outlicensed or discontinued its product programs and has not and will continue to not generate revenue from operations. If the Merger is not completed and it is unable to identify and
            complete an alternative strategic transaction, Passage Bio&#8217;s board of directors may decide to pursue a dissolution and liquidation. In that event, the amount of cash available for distribution to its stockholders will depend heavily on the
            timing of, and costs related to, such dissolution and liquidation, as well as the amount of cash required to settle its remaining obligations and to establish reserves for contingent liabilities. Passage Bio may also become subject to
            litigation or other claims in connection with a dissolution and liquidation. As a result of these and other factors, its stockholders could lose all or a significant portion of their investment in the event of a dissolution and liquidation. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Passage Bio is substantially dependent on
            its remaining employees to facilitate the consummation of the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the wind-down of its development programs, Passage Bio reduced
            its workforce and ceased its laboratory operations, and its ability to consummate the Merger or any alternative strategic transaction depends on its ability to retain its remaining employees. The uncertainty associated with the Merger, together
            with its cash-conservation efforts, may make it more difficult to retain these employees, and the loss of their services could adversely affect its ability to complete the Merger. Passage Bio may not be able to retain its remaining employees on
            acceptable terms, or at all. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Passage Bio depends on its remaining
            license arrangements, and the loss of, or disputes under, those arrangements could adversely affect it. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Passage Bio breaches any of the agreements under which it licenses the use,
            development and commercialization rights to its product candidates or technology from third parties, it could lose license rights that are important to its business. Passage Bio has provided notice terminating the Penn License Agreement with
            respect to PBFT02, its former lead product candidate, while the Penn License Agreement otherwise remains in effect with respect to its other licensed products. Under the Penn License Agreement, Passage Bio is subject to various obligations,
            including payment obligations, diligence obligations such as development and commercialization obligations, as well as potential royalty payments and other obligations. If Passage Bio fails to comply with any of these obligations or otherwise
            breaches its license agreements, its licensors may have the right to terminate the applicable license in whole or in part. Generally, the loss of any one of its current licenses, or any other license it may acquire in the future, could harm its
            business, prospects, financial condition and results of operations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Licensing of intellectual property is of critical importance to its business and
            involves complex legal, business and scientific issues. Disputes may arise between Passage Bio and its licensors regarding intellectual property subject to a license agreement, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope of rights granted under the license agreement and other interpretation-related issues; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether and the extent to which its technology and processes infringe on intellectual property of the licensor that is not
                    subject to the licensing agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its right to sublicense patent and other intellectual property rights to third parties under collaborative development
                    relationships; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its diligence obligations with respect to the use of the licensed technology in relation to its development and
                    commercialization of its product candidates, and what activities satisfy those diligence obligations; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">31<br/>
        </div>

      </div>

    </div>

    <!--End Page 41-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 42-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by its licensors and
                    Passage Bio and its partners; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether and the extent to which inventors are able to contest the assignment of their rights to its licensors. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If disputes over intellectual property that Passage Bio has licensed prevent or
            impair its ability to maintain its current licensing arrangements on acceptable terms or at all, it may be unable to realize the value of the affected license rights. In addition, if disputes arise as to ownership of licensed intellectual
            property, its ability to pursue or enforce the licensed patent rights may be jeopardized. If Passage Bio or its licensors fail to adequately protect this intellectual property, the value of its remaining license rights could suffer. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Risks Related to Passage Bio&#8217;s Common Stock</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The price of Passage Bio&#8217;s common stock
            may be volatile and fluctuate substantially, which could result in substantial losses for holders of its common stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s stock price has been and is likely to continue to be volatile. The
            stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for its common stock may
            be influenced by many factors, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its ability to complete the Merger or any alternative transaction; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the level of expenses related to its operations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">market conditions in the biotechnology sector; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unanticipated or serious safety concerns related to the use of any of its product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the recruitment or departure of key personnel; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">actual or anticipated changes in estimates as to financial results; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">variations in its financial results or those of companies that are perceived to be similar to it; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">health pandemics could disrupt its operations and adversely impact its business,; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general economic, industry and market conditions, including fluctuating interest rates, tariffs, market volatility, a potential
                    federal government shutdown and inflation; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general economic uncertainty and capital markets disruptions, which has been substantially impacted by geopolitical instability
                    due to the ongoing military conflicts around the world; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other factors, including those described in this &#8220;Risk Factors&#8221; section, many of which are beyond its control. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Passage Bio fails to establish and
            maintain proper and effective internal control over financial reporting in the future, its ability to produce accurate and timely financial statements could be impaired, which could harm its operating results, investors&#8217; views of it and, as a
            result, the value of its common stock.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act of 2002 (the &#8220;<span style="font-style: italic; font-weight: bold;">Sarbanes-Oxley Act</span>&#8221;), Passage Bio is required to furnish a report by its management on its internal control over financial reporting within its Form&#160;10-K. However, while Passage Bio
            remains a smaller reporting company, it will not be required to include an attestation report on internal control over financial reporting issued by its independent registered public accounting firm. Ensuring that Passage Bio has adequate
            internal financial and accounting controls and procedures in place so that it can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be frequently evaluated. Its failure to maintain
            the effectiveness of its internal controls in accordance with the requirements of the Sarbanes-Oxley Act could have a material adverse effect on its business. If Passage Bio identifies one or more material weaknesses, it could result in an
            adverse reaction in the financial markets due to a loss of confidence in the reliability of its financial statements. In addition, if Passage Bio is not able to continue to meet these requirements, it may not be able to remain listed on Nasdaq.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio may hire additional personnel and may utilize external temporary
            resources to implement, document and modify policies and procedures to maintain effective internal controls. However, it is possible that it may </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">32<br/>
        </div>

      </div>

    </div>

    <!--End Page 42-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 43-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">identify deficiencies and weaknesses in its internal controls. If material
            weaknesses or deficiencies in its internal controls exist and go undetected or unremediated, its financial statements could contain material misstatements that, when discovered in the future, could cause it to fail to meet its future reporting
            obligations and cause the price of its common stock to decline.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Passage Bio will continue to incur
            increased costs as a result of operating as a public company and its management will continue to be required to devote substantial time to new compliance initiatives.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a public company Passage Bio will continue to incur significant legal,
            accounting and other expenses. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure
            and financial controls and corporate governance practices. Its management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase its legal and
            financial compliance costs and will make some activities more time-consuming and costly. Passage Bio is a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make its common stock
            less attractive to investors. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is a &#8220;smaller reporting company,&#8221; meaning that the market value of
            its stock held by non-affiliates is less than $700.0&#160;million and its annual revenue is less than $100.0&#160;million during the most recently completed fiscal year. Passage Bio will continue to be a smaller reporting company if either (i) the market
            value of its stock held by non-affiliates is less than $250.0&#160;million or (ii) its annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of its stock held by non-affiliates is less than
            $700.0&#160;million. Passage Bio may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company it may choose to present only the two most
            recent fiscal years of audited financial statements in its Annual Report on Form&#160;10-K and have reduced disclosure obligations regarding executive compensation.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">The exclusive forum provisions in its
            restated certificate of incorporation and amended and restated bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with it or any of its directors, officers, or other employees,
            which may discourage lawsuits with respect to such claims.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s restated certificate of incorporation, to the fullest extent
            permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on its behalf; any action asserting a breach of fiduciary duty; any action asserting a
            claim against it arising pursuant to the Delaware General Corporation Law (the &#8220;<span style="font-style: italic; font-weight: bold;">DGCL&#8221;), its restated certificate of incorporation, or its restated bylaws; any action to interpret</span>,
            apply, enforce, or determine the validity of its restated certificate of incorporation or its restated bylaws; or any action asserting a claim against it that is governed by the internal affairs doctrine. This exclusive forum provision does not
            apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Exchange Act</span>&#8221;). It could apply, however, to a suit that falls
            within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section&#160;22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all
            suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and
            its stockholders will not be deemed to have waived its compliance with the federal securities laws and the rules and regulations thereunder.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated bylaws also provide that the federal district
            courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Its decision to
            adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the
            holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by its stockholders to enforce any duty or
            liability created by the Securities Act must be brought in federal court and cannot be brought in state court.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a
            claim in a judicial forum that it finds favorable for disputes with it or any of its directors, officers, or other employees, which may discourage lawsuits </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">33<br/>
        </div>

      </div>

    </div>

    <!--End Page 43-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 44-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">with respect to such claims. Alternatively, if a court were to find the choice
            of forum provisions contained in its restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, it may incur additional costs associated with resolving such action in other
            jurisdictions, which could harm its business, results of operations and financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Section&#160;203 of the DGCL may discourage, delay or prevent a change in
            control of Passage Bio. Section&#160;203 imposes certain restrictions on mergers, business combinations and other transactions between it and holders of 15% or more of its common stock.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Provisions in its corporate charter
            documents and under Delaware law could make an acquisition of it, which may be beneficial to its stockholders, more difficult and may prevent attempts by its stockholders to replace or remove its current management.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Provisions in its restated certificate of incorporation and its restated bylaws
            may discourage, delay or prevent a merger, acquisition or other change in control of Passage Bio that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions
            could also limit the price that investors might be willing to pay in the future for shares of its common stock, thereby depressing the market price of its common stock. In addition, because its board of directors is responsible for appointing
            the members of its management team, these provisions may frustrate or prevent any attempts by its stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of its board of
            directors. Among other things, these provisions: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish a classified board of directors so that not all members of its board are elected at one time; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">permit only the board of directors to establish the number of directors and fill vacancies on the board; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide that directors may only be removed &#8220;for cause&#8221; and only by the affirmative vote of the holders of at least two-thirds of
                    the voting power of its outstanding shares of capital stock entitled to vote thereon; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">require super-majority voting to amend some provisions of its restated certificate of incorporation and restated bylaws; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">authorize the issuance of &#8220;blank check&#8221; preferred stock that its board could use to implement a stockholder rights plan, also
                    known as a &#8220;poison pill&#8221;; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">eliminate the ability of its stockholders to call special meetings of stockholders; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of its
                    stockholders; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">do not provide for cumulative voting in the election of directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish advance notice requirements for nominations for election to its board or for proposing matters that can be acted upon
                    by stockholders at annual stockholder meetings. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Moreover, Passage Bio is governed by the provisions of Section&#160;203 of the DGCL,
            which prohibits a person who owns in excess of 15% of its outstanding voting stock from merging or combining with it for a period of three years after the date of the transaction in which the person acquired in excess of 15% of its outstanding
            voting stock, unless the merger or combination is approved in a prescribed manner.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any of these provisions of its charter documents or Delaware law could, under
            certain circumstances, depress the market price of its common stock. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">General Risk Factors</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio may be subject to securities
            litigation, which could result in substantial expenses and could divert management attention. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The market price of its common stock has been and may continue to be volatile.
            The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In
            the past, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">34<br/>
        </div>

      </div>

    </div>

    <!--End Page 44-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 45-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">companies that have experienced volatility in the market price of their stock
            have been subject to securities class action litigation. Passage Bio may be the target of this type of litigation in the future. Securities litigation against it could result in substantial costs and divert its management&#8217;s attention from other
            business concerns, which could seriously harm its business.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If securities analysts do not publish
            research or reports about its business or if they publish negative evaluations of its stock, the price of its stock could decline.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The trading market for its common stock relies in part on the research and
            reports that industry or financial analysts publish about it or its business. Passage Bio does not have any control over the analysts, or the content and opinions included in their reports. If one or more of the analysts covering its business
            downgrades their evaluations of its stock, the trading price of its stock would likely decrease. Even if Passage Bio does obtain analyst coverage, if one or more of the analysts covering its business downgrade their evaluations of its stock,
            the price of its stock could decline. If one or more of these analysts cease to cover its stock, it could lose visibility in the market for its stock, which in turn could cause its stock price to decline. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Unfavorable global economic conditions
            could adversely affect its business, financial condition or results of operations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s results of operations could be adversely affected by general
            conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets, and, in recent months, the global economy has been
            impacted by fluctuating interest rates, tariffs, and inflation. Likewise, the capital and credit markets may be adversely affected by ongoing military conflicts around the world, global sanctions imposed in response thereto, and potential
            recessions. Moreover, Passage Bio may also be impacted by turmoil in the global banking system. Passage Bio regularly maintains cash balances at third-party financial institutions in excess of the FDIC insurance limit and there is no guarantee
            that the federal government would guarantee all depositors if such financial institutions were to fail, in the event of bank closures and continued instability in the global banking system. A severe or prolonged economic downturn, such as the
            global financial crisis, could result in a variety of risks to its business, including its ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain its suppliers, possibly
            resulting in operational disruption, or cause its sublicense partners to delay making payments for its services. Any of the foregoing could harm its business and Passage Bio cannot anticipate all of the ways in which the current economic
            climate and financial market conditions could adversely impact its business. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">35<br/>
        </div>

      </div>

    </div>

    <!--End Page 45-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 46-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tRF4"><!--Anchor--></a>Risks Related to Remix </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Risks Related to Remix&#8217;s Limited Operating History, Financial
            Position and need for Additional Capital </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is a clinical stage biotechnology
            company with a limited operating history and has no history of commercializing products, which may make it difficult for investors to evaluate Remix&#8217;s current business and likelihood of success and future viability.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is a clinical stage biopharmaceutical company with a limited operating
            history upon which investors can evaluate its business and prospects.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix commenced operations in July&#160;2019, has no products approved for commercial
            sale and has never generated any revenue from sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, Remix has devoted substantially all of its resources to developing REM-422, its research
            and development activities, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has not yet demonstrated its ability to complete pivotal clinical trials,
            obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more
            difficult for investors to accurately predict Remix&#8217;s likelihood of success and viability than it could be if Remix had a longer operating history.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix may encounter unforeseen expenses, difficulties,
            complications, delays and other known and unknown factors and risks frequently experienced by biopharmaceutical companies in rapidly evolving fields. Remix also expects that, as it advances its product candidates, it will need to transition
            from a company with a research and development focus to a company capable of supporting commercial activities. Remix has not yet demonstrated an ability to successfully overcome such risks and difficulties, or to make such a transition. If
            Remix does not adequately address these risks and difficulties or successfully make such a transition, its business will suffer. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Remix has incurred significant net losses
            in each period since Remix&#8217;s inception, and expects to continue to incur significant net losses for the foreseeable future. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix incurred significant net losses in each reporting period since its
            inception, has not generated any products revenue to date and has financed its operations principally through private placements of its preferred stock and convertible notes. Remix expects that it will be many years, if ever, before it has
            commercialized a product and can generate revenue from product sales. Even if Remix succeeds in receiving marketing approval for and commercializing one or more of its product candidates, it expects to continue to incur substantial research and
            development and other expenses in order to discover, develop and market additional potential products.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix expects to continue to incur significant expenses and increasing operating
            losses for the foreseeable future. The net losses Remix incurs may fluctuate significantly from quarter to quarter such that a period-to-period comparison of Remix&#8217;s results of operations may not be a good indication of its future performance.
            The size of Remix&#8217;s future net losses will depend, in part, on the rate of future growth of its expenses and its ability to generate revenue. Remix&#8217;s prior losses and expected future losses have had and will continue to have an adverse effect
            on its working capital, its ability to fund the development of its product candidates and its ability to achieve and maintain profitability and the performance of its stock. Remix&#8217;s future funding requirements will depend on many factors,
            including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress, costs, design, results of and timing of Remix&#8217;s planned and ongoing preclinical studies and clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the willingness of the United States Food and Drug Administration (FDA) or applicable foreign authorities to accept the data
                    from clinical trials, as well as data from Remix&#8217;s planned and ongoing preclinical studies and clinical trials and other work, as the basis for review and approval of Remix&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the outcome, costs and timing of seeking and obtaining FDA and applicable foreign regulatory approvals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and characteristics of product candidates that Remix pursue; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">36<br/>
        </div>

      </div>

    </div>

    <!--End Page 46-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 47-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s need to expand its research and development (&#8220;<span style="font-style: italic; font-weight: bold;">R&amp;D</span>&#8221;)
                    capabilities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs and timing associated with manufacturing Remix&#8217;s product candidates, and if such product candidates receive regulatory
                    approval, establishing commercial supplies and sales, marketing, and distribution capabilities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and
                    adequate market share and revenue for any approved products; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">patients&#8217; willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement
                    from third-party payors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s efforts to maintain, expand, and defend the scope of Remix&#8217;s intellectual property portfolio, including the amount and
                    timing of any payments Remix may be required to make, or that Remix may receive, in connection with the licensing, filing, prosecution, defense, and enforcement of any patents or other intellectual property rights; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s need and ability to retain key management and hire scientific, technical, business, and medical personnel; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s need to implement additional internal systems and infrastructure, including financial and reporting systems; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with operating as a public company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the economic and other terms, timing of and success of Remix&#8217;s current and any future collaborations, licensing or other
                    arrangements which Remix may enter in the future; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, receipt, and amount of sales from Remix&#8217;s product candidates, if approved. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Remix is unable to raise additional capital when needed, Remix may be required
            to delay, limit, reduce or terminate Remix&#8217;s product development or future commercialization efforts or grant rights to develop and market product candidates that Remix would otherwise prefer to develop and market itself, and Remix&#8217;s ability to
            grow and support its business and to respond to market challenges could be significantly limited, which could have a material adverse effect on Remix&#8217;s business, financial condition and results of operations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix&#8217;s management has evaluated adverse conditions and events that
            raise substantial doubt about Remix&#8217;s ability to continue as a going concern, and its independent registered public accounting firm included an explanatory paragraph in its report on its financial statements as of and for the year ended
            December 31, 2025 included in this proxy statement/prospectus with respect to this uncertainty. This substantial doubt about Remix&#8217;s ability to continue as a going concern could materially limit its ability to raise additional funds through the
            issuance of new debt or equity securities or otherwise. Future reports on its financial statements may include an explanatory paragraph with respect to its ability to continue as a going concern. Even if the Merger and Concurrent Financing are
            successfully completed, there is no assurance that adequate additional financing needed to allow Remix to continue as a going concern will be available to it on acceptable terms, or at all. The perception that Remix may not be able to continue
            as a going concern may cause others to choose not to do business with Remix due to concerns about its ability to meet its contractual obligations. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix has never generated revenue from
            product sales and may never achieve or maintain profitability. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has never generated any revenue from commercial product sales. To become
            and remain profitable, Remix must develop and eventually commercialize product candidates with significant market potential, which will require Remix to be successful in a range of challenging activities. These activities can include completing
            preclinical studies and clinical trials of Remix&#8217;s product candidates, obtaining regulatory approval for these product candidates, manufacturing, marketing and selling those products that are approved and satisfying any postmarketing
            requirements. Remix does not anticipate generating any revenue from product sales for many years, if ever. Remix&#8217;s ability to generate revenue and achieve profitability depends significantly on its ability to achieve several objectives,
            including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">successful and timely completion of clinical development of REM-422 and preclinical and clinical development of other research
                    programs and any other future programs; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">37<br/>
        </div>

      </div>

    </div>

    <!--End Page 47-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 48-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishing and maintaining relationships with contract research organizations (CROs) and clinical sites for the clinical
                    development of REM-422 and any other future programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">timely receipt of regulatory approvals from applicable regulatory authorities for any product candidates for which Remix
                    successfully complete clinical development; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developing an efficient and scalable manufacturing process for Remix&#8217;s product candidates, including obtaining finished products
                    that are appropriately packaged for sale; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide
                    adequate, in both amount and quality, products and services to support clinical development and meet the market demand for Remix&#8217;s product candidates, if approved; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">successful commercial launch following any regulatory approval, including the development of a commercial infrastructure,
                    whether in-house or with one or more collaborators; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a continued acceptable safety profile following any regulatory approval of Remix&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">commercial acceptance of Remix&#8217;s product candidates by patients, the medical community and third-party payors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfying any required post-marketing approval commitments to applicable regulatory authorities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">identifying, assessing and developing new product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United
                    States and internationally; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">defending against third-party interference or infringement claims, if any; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to
                    develop, manufacture or commercialize Remix&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining and maintaining coverage and adequate reimbursement by third-party payors for Remix&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">addressing any competing therapies and technological and market developments; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">attracting, hiring and retaining qualified personnel. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may never be successful in achieving its objectives and, even if it does,
            may never generate revenue that is significant or large enough to achieve profitability. Even if Remix successfully obtains regulatory approval to market a product candidate, its revenue will depend, in part, upon the size of the markets in the
            territories for which it receives regulatory approval and has commercial rights, the availability of competitive therapies and whether there are sufficient levels of reimbursement and adoption by physicians. If Remix does achieve profitability,
            it may not be able to sustain or increase profitability on a quarterly or annual basis. Remix&#8217;s failure to become and remain profitable would decrease the value of the company and could impair its ability to maintain or further its research and
            development efforts, raise additional necessary capital, grow its business and continue its operations. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Risks Related to the Discovery, Development and Regulatory
            Approval of Remix&#8217;s Product Candidates </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix only has one product candidate in
            clinical development: REM-422. All of Remix&#8217;s other development programs are in the preclinical or discovery stage. If Remix is unable to advance its product candidates in clinical development, obtain regulatory approval and ultimately
            commercialize its product candidates, or experience significant delays in doing so, its business will be materially harmed.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is substantially dependent on the success of its lead product candidate
            REM-422, which is in clinical development. Remix&#8217;s other programs are still in the preclinical or discovery stages. Remix will need to progress REM-422, through Remex&#8217;s ongoing and planned clinical trials and progress its other current and
            future development programs through preclinical studies and submit Investigational New Drug applications (INDs) to the FDA or comparable submissions to applicable foreign authorities prior to initiating their clinical development. Remix&#8217;s
            ability to generate product revenues, which it does not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of its product candidates. The success of Remix&#8217;s product
            candidates will depend on several factors, including the following: </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">38<br/>
        </div>

      </div>

    </div>

    <!--End Page 48-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 49-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">completion of preclinical studies with favorable results; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">allowance to proceed with clinical trials under INDs by the FDA or under similar regulatory submissions by applicable foreign
                    authorities for the conduct of clinical trials of Remix&#8217;s product candidates and Remix&#8217;s proposed design of future clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">successful enrollment in, and completion of, clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sufficiency of Remix&#8217;s financial and other resources to complete the necessary preclinical studies and clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">demonstrating the safety and efficacy, of Remix&#8217;s product candidates to the satisfaction of applicable regulatory authorities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">receipt of regulatory approvals from applicable regulatory authorities, including New Drug Applications (&#8220;<span style="font-style: italic; font-weight: bold;">NDAs</span>&#8221;) from the FDA and equivalent approvals from comparable foreign regulatory authorities and maintaining such approvals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">making arrangements with third-party manufacturers, or establishing clinical and commercial manufacturing capabilities for
                    Remix&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishing sales, marketing and distribution capabilities and launching commercial sales of Remix&#8217;s products, if and when
                    approved, whether alone or in collaboration with others; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishing and maintaining patent and trade secret protection or regulatory exclusivity for Remix&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">acceptance of any products Remix develops and their benefits and uses, if and when approved, by patients, the medical community
                    and third-party payors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">effectively competing with other therapies; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintaining an acceptable safety profile of Remix&#8217;s products following approval, if and when approved; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">building and maintaining an organization of people who can successfully develop Remix&#8217;s product candidates. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has not yet succeeded and may not succeed in demonstrating efficacy and
            safety for any product candidates in clinical trials or in obtaining regulatory approval thereafter. Given its stage of development, it will take several years before Remix can demonstrate the safety or efficacy of a product candidate
            sufficient to warrant approval for commercialization, if it can do so at all. If Remix is unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize its product candidates, Remix may not be able to
            generate sufficient revenue to continue its business.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">The outcome of preclinical testing and
            early clinical trials may not be predictive of the success of later clinical trials, and the results of Remix&#8217;s clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix will be required to demonstrate with substantial evidence through
            well-controlled clinical trials that its product candidates are safe and effective for their intended uses before it can seek regulatory approvals for their commercial sale. Preclinical and clinical testing is expensive and can take many years
            to complete, and Remix&#8217;s outcome is inherently uncertain. Failure can occur at any time during the preclinical study and clinical trial processes, and, because Remix&#8217;s product candidates are in early stages of developments, there is a high risk
            of failure and it may never succeed in developing marketable products.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The results of preclinical studies may not be predictive of the results of
            clinical trials of Remix&#8217;s product candidates. Moreover, the results of early clinical trials may not be predictive of the results of later-stage clinical trials. Although product candidates may demonstrate promising results in preclinical
            studies and early clinical trials, they may not </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">39<br/>
        </div>

      </div>

    </div>

    <!--End Page 49-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 50-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">prove to be safe or effective in subsequent clinical trials. Favorable results
            from certain animal studies may not accurately predict the results of other animal studies or of human trials, due to the inherent biologic differences in species, the differences between testing conditions in animal studies and human trials,
            and the particular goals, purposes, and designs of the relevant studies and trials.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There is typically an extremely high rate of attrition from the failure of
            product candidates proceeding through preclinical studies and clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies
            and initial clinical trials. Likewise, early, smaller-scale clinical trials may not be predictive of eventual safety or effectiveness in large-scale pivotal clinical trials. Moreover, preclinical and clinical data are often susceptible to
            varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their drugs. A
            number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results
            in earlier trials. Most product candidates that commence preclinical studies and clinical trials are never approved as products. The development of Remix&#8217;s product candidates and its stock price may also be impacted by inferences, whether
            correct or not, that are drawn between the success or failure of preclinical studies or clinical trials of Remix&#8217;s competitors or other companies in the biopharmaceutical industry, in addition to its own preclinical studies and clinical trials.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In some instances, there can be significant variability in safety and efficacy
            results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing
            regimen and other trial protocols and the rate of dropout among clinical trial participants. This variability can increase the uncertainty of, and adversely impact, Remix&#8217;s clinical trial outcomes. As a result, Remix does not know whether any
            preclinical studies or clinical trials it may conduct will demonstrate consistent or adequate efficacy or safety sufficient to obtain approval to market any of its product candidates.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix has limited resources and is
            currently focusing its efforts on REM-422 for development in particular indications and advancing its other research programs. As a result, Remix may fail to capitalize on programs, product candidates or indications that may be more profitable
            or for which there is a greater likelihood of success.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is currently focusing its resources and efforts on REM-422 and advancing
            its other research programs. Because it has limited financial and managerial resources, Remix must focus on a limited number of research programs and product candidates and on specific indications. As a result, Remix may forgo or delay pursuit
            of opportunities for other target indications or with other product candidates that may have greater commercial potential. Remix&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable
            market opportunities. Its spending on current and future research and development activities for REM-422 and its other research programs may not yield any commercially viable products. If Remix does not accurately evaluate the commercial
            potential or target markets for REM-422 and its other research programs, or the product candidates it is currently developing in these programs, it may relinquish valuable rights to its product candidates or programs through collaboration,
            licensing or other strategic arrangements in cases in which it would have been more advantageous for Remix to retain sole development and commercialization rights to such product candidate or program.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">As an organization, Remix has never
            submitted an NDA or other marketing application, and may be unable to do so for any of its product candidates.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix will need to successfully complete pivotal clinical trials in order to seek
            FDA or applicable foreign authority approval to market REM-422 and any future product candidates it may develop. Carrying out clinical trials and the preparation and submission of NDA and comparable marketing applications is complicated, and
            its experience is limited. Remix is concurrently conducting a Phase 1/2 clinical trial of REM-422 in ACC and a Phase 1 trial of REM-422 in AML. Remix has not yet completed any pivotal clinical trials, and has limited experience as a company in
            preparing, submitting and prosecuting regulatory applications and has not previously submitted an NDA or other applicable foreign regulatory submission for any product candidate. Remix also plans to conduct a number of clinical trials for in
            parallel over the next several years. This may be a difficult process to manage with its limited resources and may divert the attention of management. Consequently, it may be unable to successfully and efficiently execute and complete necessary
            clinical trials in a way that leads to regulatory submission and approval </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">40<br/>
        </div>

      </div>

    </div>

    <!--End Page 50-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 51-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of any of its product candidates. Remix may require more time and incur
            greater costs than its competitors and may not succeed in obtaining regulatory approvals of product candidates that it develops. Failure to commence or complete, or delays in, its planned clinical trials, could prevent Remix from or delay it in
            submitting marketing applications for and commercializing its product candidates.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Clinical and preclinical development
            involves a lengthy and expensive process with an uncertain outcome. Any difficulties or delays in the commencement or completion, or the termination or suspension, of Remix&#8217;s current or planned clinical trials could result in increased costs to
            Remix, delay or limit Remix&#8217;s ability to generate revenue or adversely affect Remix&#8217;s commercial prospects.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Before obtaining approval from regulatory authorities for the commercialization
            of any of its product candidates, Remix must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidate in humans. Before it can initiate clinical trials for any product candidates, Remix must submit the
            results of preclinical studies to the FDA or comparable foreign regulatory authorities along with other information, including information about product candidate chemistry, manufacturing and controls and its proposed clinical trial protocol,
            as part of an IND or similar regulatory submission. The FDA or comparable foreign regulatory authorities may require Remix to conduct additional preclinical studies for any product candidate before it allows Remix to initiate clinical trials
            under any IND or similar regulatory submission, which may lead to delays and increase the costs of its preclinical development programs. Moreover, even if Remix commences clinical trials, issues may arise that could cause regulatory authorities
            to suspend or terminate such clinical trials. Any such delays in the commencement or completion of Remix&#8217;s ongoing and planned clinical trials for its product candidates could significantly affect its product development timelines and product
            development costs and harm its financial position.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may experience delays in initiating or completing clinical trials or
            reporting data readouts for such trials, due to unforeseen events or otherwise, that could delay or prevent its ability to receive regulatory approval or commercialize its current and any future product candidates, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulators, such as the FDA or comparable foreign regulatory authorities, Institutional Review Boards (&#8220;<span style="font-style: italic; font-weight: bold;">IRBs</span>&#8221;) or ethics committees may impose additional requirements before permitting Remix to initiate a clinical trial, may not authorize Remix or its investigators to commence or conduct a clinical
                    trial at a prospective trial site, may not allow Remix to amend trial protocols or regulators may disagree as to the design or implementation of its clinical trials and require that Remix modify or amend its clinical trial protocols or
                    statistical analysis plans; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may experience delays in reaching, or fail to reach, agreement on acceptable terms with CROs or with individual clinical
                    trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among trial sites; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">delays in identifying, recruiting and training suitable clinical investigators; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional
                    participants or withdrawing their approval of the trial; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes or amendments to Remix&#8217;s clinical trial protocols; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trial sites may deviate from the trial protocol, fail to ensure the integrity of the data being collected at the site
                    or drop out of a trial; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by any of Remix&#8217;s third-party contractors to perform in accordance with good clinical practices (&#8220;<span style="font-style: italic; font-weight: bold;">GCP</span>&#8221;) requirements or applicable regulatory rules and guidelines in other countries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of participants required for clinical trials may be larger than Remix anticipates, Remix may experience difficulty in
                    finding and enrolling sufficient qualified patients for its trials, enrollment in clinical trials may be slower than it anticipates or participants may drop out or fail to return for post-treatment follow-up at a higher rate than it
                    anticipates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">participants may fail to enroll or remain in Remix&#8217;s trials at the rate it expects, or fail to return for post-treatment
                    follow-up, including participants failing to remain in its trials due to movement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">patients choosing an alternative product for the indications for which Remix is developing its product candidates, or
                    participating in competing clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of clinical trials may be greater than Remix anticipates; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">41<br/>
        </div>

      </div>

    </div>

    <!--End Page 51-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 52-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the quality or quantity of data relating to Remix&#8217;s product candidates or other materials necessary to conduct its clinical
                    trials may be inadequate to initiate or complete a given clinical trial; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may experience difficulties in manufacturing, or fail to manufacture, sufficient quantities of its product candidates for
                    use in clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">participants experiencing severe or serious unexpected drug-related adverse events; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reports from clinical testing conducted by other companies of other therapies in the same class of agents that could be
                    considered similar to Remix&#8217;s product candidates may raise safety, tolerability or efficacy concerns about its product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may lack adequate funding to initiate or continue one or more of its clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">selection of clinical endpoints that require prolonged periods of clinical observation or extended analysis of the resulting
                    data; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a facility manufacturing Remix&#8217;s product candidates or any of their components may violate current Good Manufacturing Practice
                    (cGMP) regulations or other applicable requirements, which could lead to adverse FDA or other regulatory authority action or otherwise delay its development programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes to Remix&#8217;s manufacturing processes may be necessary or desired; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">third-party contractors being unwilling or unable to satisfy their contractual obligations to Remix in a timely or accurate
                    manner; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">third-party contractors could become debarred or suspended or otherwise penalized by the FDA or other government or regulatory
                    authorities for violations of regulatory requirements, in which case Remix may need to find a substitute contractor, and Remix may not be able to use some or all of the data produced by such contractors in support of its planned
                    marketing applications; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical trials of Remix&#8217;s product candidates may fail to show appropriate safety, tolerability or efficacy, may produce
                    negative or inconclusive results or may otherwise fail to improve on the existing standard of care, and Remix may decide, or regulators may require it, to conduct additional clinical trials or Remix may decide to abandon product
                    development programs. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Clinical trials must be conducted in accordance with the FDA and other applicable
            regulatory authorities&#8217; legal requirements, regulations and guidelines, and remain subject to oversight by these governmental agencies as well as ethics committees or IRBs responsible for overseeing the conduct of clinical trials and ensuring
            the welfare of the research participants. Remix could similarly encounter delays if a clinical trial is suspended or terminated by it, the IRBs of the institutions in which such trials are being conducted, the FDA or comparable foreign
            regulatory authorities or the Data Safety Monitoring Board for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or its
            clinical trial protocols, adverse findings from inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to establish or achieve
            clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and Remix
            may need to amend clinical trial protocols to comply with these changes. Amendments may require Remix to resubmit its clinical trial protocols to regulators or to IRBs for reexamination, which may impact the costs, timing or successful
            completion of a clinical trial. Clinical trials may also be delayed or terminated as a result of ambiguous or negative interim results.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Further, conducting clinical trials in foreign countries, as Remix may do for its
            product candidates, presents additional risks that may delay completion of its clinical trials. These risks include the failure of enrolled subjects in foreign countries to adhere to clinical protocols as a result of differences in healthcare
            services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, and political and economic risks, including war, relevant to such foreign countries.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Many of the factors that cause, or lead to, a delay in the commencement or
            completion of, or the termination or suspension of clinical trials may also ultimately lead to the denial of regulatory approval of Remix&#8217;s product candidates. Further, the FDA may disagree with its interpretation of data from clinical trials
            or may change the requirements for approval even after it has reviewed and commented on the design for its clinical trials.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">42<br/>
        </div>

      </div>

    </div>

    <!--End Page 52-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 53-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Ultimately, Remix&#8217;s product development costs will increase if Remix
            experiences delays in clinical testing or in seeking regulatory approvals. Remix does not know whether any of its clinical trials will begin as planned, will need to be redesigned or will be completed on schedule, or at all. Significant
            clinical trial delays also could shorten any periods during which Remix may have the exclusive right to commercialize its product candidates and may allow its competitors to bring products to market before Remix does, potentially impairing its
            ability to successfully commercialize its product candidates, if approved. Any delays or increase in costs in Remix&#8217;s clinical development programs may harm its business, financial condition, results of operations and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Enrollment and retention of patients in
            clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Remix&#8217;s control, which could adversely affect its business, operating results and prospects.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Patient enrollment is a significant factor impacting the duration of Remix&#8217;s
            clinical trials, along with treatment duration and completion of required follow-up periods. Clinical trials may be prolonged, or Remix may not be able to initiate or continue clinical trials for its product candidates if it is unable to locate
            and enroll a sufficient number of eligible patients to participate as required by the FDA or applicable foreign authorities. Remix also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for its
            planned clinical trials and monitoring such patients adequately during and after treatment. Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which
            may make it more difficult to fully enroll Remix&#8217;s clinical trials. In addition, the process of finding and diagnosing patients may prove costly.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The eligibility criteria of Remix&#8217;s clinical trials, once established, may
            further limit the pool of available trial participants. If the actual number of patients with these diseases is smaller than Remix anticipates, it may encounter difficulties in enrolling patients in its clinical trials, thereby delaying or
            preventing development and approval of its product candidates. Even once enrolled, Remix may be unable to retain a sufficient number of patients to complete any of its trials.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The timely completion of clinical trials in accordance with their protocols
            depends on, among other things, Remix&#8217;s ability to enroll a sufficient number of patients who remain in the study until its conclusion. Remix may experience difficulties in patient enrollment or retention in its clinical trials for a variety of
            reasons. Patient enrollment and retention in clinical trials depends on many factors, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the size and nature of the patient population; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the severity of the disease or condition under investigation; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the design of the trial protocol; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the existing body of safety and efficacy data for the product candidate; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">efforts by Remix and its CROs to facilitate timely enrollment in clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">patient referral practices of physicians; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the proximity of patients to clinical sites; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the eligibility criteria for the trial; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability to adequately monitor patients during a trial; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that patients will drop out of a trial before completing all site visits; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available
                    therapies. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Furthermore, Remix&#8217;s efforts to build relationships with patient communities may
            not succeed, which could result in delays in patient enrollment in its clinical trials. If Remix encounters any delays in enrolling such additional </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">43<br/>
        </div>

      </div>

    </div>

    <!--End Page 53-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 54-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">participants, this may further delay its clinical trial. In addition, any
            negative results Remix may report in clinical trials of its product candidate may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient
            enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on Remix&#8217;s ability to develop its product candidates, or could render further development impossible. Further, if patients drop out
            of its clinical trials, miss scheduled doses or follow-up visits, or otherwise fail to follow clinical trial protocols, the integrity of data from its clinical trials may be compromised or not accepted by the FDA or applicable foreign
            authorities, which would represent a significant setback for the applicable program. In addition, Remix may rely on CROs and clinical trial sites to ensure proper and timely conduct of its future clinical trials and, while it has entered and
            intends to enter into agreements governing their services, it will be limited in its ability to compel their actual performance. Such delays or failures could adversely affect its business, operating results, financial condition and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Serious adverse events, undesirable side
            effects or other unexpected properties of Remix&#8217;s product candidates may be identified during development or after approval, which could lead to the discontinuation or failure of its clinical development programs, refusal by regulatory
            authorities to approve its product candidates or, if discovered following regulatory approval, revocation of marketing authorizations or limitations on the use of its product candidates, any of which would limit the commercial potential of such
            product candidate.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As is the case with oncology drugs generally, it is likely that there may be side
            effects and adverse events associated with use of Remix&#8217;s product candidates. Results of Remix&#8217;s clinical trials could reveal a high and unacceptable severity and prevalence of expected or unexpected adverse events or unexpected
            characteristics. Undesirable effects caused by its product candidates when used alone or in combination with other therapies could cause Remix or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more
            restrictive label, or lead to the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Any drug-related adverse events could affect patient recruitment or the ability of enrolled patients to complete
            the trial or result in potential product liability claims. Any of these occurrences may harm Remix&#8217;s business, financial condition, results of operations, and prospects significantly.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">It is possible that as Remix tests its product candidates in larger, longer, and
            more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread following any regulatory approval, more illnesses, injuries, discomforts, and other adverse events than
            were observed in earlier trials, as well as new conditions that did not occur or went undetected in previous trials, may be discovered. If such side effects become known later in development or upon approval, if any, such findings may harm its
            business, financial condition, and prospects significantly.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix may decide to study its product candidates in combination with
            other therapies, which may exacerbate adverse events associated with such product candidates. Patients treated with its product candidates may also be undergoing surgical, radiation, and/or chemotherapy treatments, which can cause side effects
            or adverse events that are unrelated to its product candidates but may still impact the success of its clinical trials. The inclusion of critically ill patients in its clinical trials may result in deaths or other adverse medical events due to
            other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, Remix expects that some of the patients enrolled in its clinical trials will die or experience major clinical events
            either during the course of its clinical trials or after participating in such trials.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Remix&#8217;s product candidates are associated with undesirable side effects in
            clinical trials or have characteristics that are unexpected, Remix may elect to halt or abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics
            are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial value for the product candidate if approved. Many compounds that initially showed promise in early-stage testing have later been
            found to cause side effects that prevented further development of the compound. In addition, regulatory authorities may draw different conclusions or require additional testing to confirm these determinations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, if any of Remix&#8217;s product candidates receive regulatory approval,
            the FDA could require it to include a black box warning in the product label or adopt a Risk Evaluation and Mitigation Strategy (REMS), to ensure that the benefits of the product outweigh its risks, which may include a medication guide
            outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners. For example, the FDA could require Remix to adopt a REMS to ensure that the benefits of treatment with such product candidates
            outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">44<br/>
        </div>

      </div>

    </div>

    <!--End Page 54-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 55-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">controlled, restrictive and more costly than what is typical for the industry.
            Furthermore, if Remix or others later identify undesirable side effects caused by its product candidates, several other potentially significant negative consequences could result, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory authorities may suspend or withdraw approvals of such product candidate; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">regulatory authorities may require additional warnings on the label, including &#8220;boxed&#8221; warnings, or issue safety alerts, Dear
                    Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may be required to change the way a product candidate is administered or conduct additional clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix could be sued and held liable for harm caused to patients; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix could be subject to fines, injunctions, or the imposition of criminal or civil penalties; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if approved, Remix may need to conduct a recall, market withdrawal or similar post-market action; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if approved, Remix may be forced to suspend marketing of that product, or decide to remove the product from the marketplace; and
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if approved, the product may become less competitive, and Remix&#8217;s reputation may suffer. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any of these events could prevent Remix from achieving or maintaining market
            acceptance of its product candidates and could significantly harm its business, prospects, financial condition and results of operations.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The regulatory approval processes of the
            FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if Remix is ultimately unable to obtain regulatory approval for its product candidates, its business will be substantially harmed.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The clinical development, manufacturing, labeling, storage, recordkeeping,
            advertising, promotion, import, export, marketing and distribution of Remix&#8217;s product candidates are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., Remix
            is not permitted to market its product candidates in the U.S. until it receives regulatory approval of an NDA from the FDA. The process of obtaining such regulatory approval is expensive, often takes many years following the commencement of
            clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA and
            comparable regulatory have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product
            candidates, regulatory approval of a product candidate is never guaranteed. Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to obtaining approval to commercialize a product candidate in the U.S. or
            abroad, Remix must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for
            their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if Remix believes available nonclinical or clinical data support the safety and/or efficacy of its product candidates, such
            data may not be sufficient to obtain approval from the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require Remix to conduct additional preclinical studies
            or clinical trials for its product candidates either prior to or post-approval, or may object to elements of its clinical development program.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA or comparable foreign regulatory authorities can delay, limit or deny
            approval of a product candidate for many reasons, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such authorities may disagree with the design or execution of Remix&#8217;s clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">negative or ambiguous results from Remix&#8217;s clinical trials or results may not meet the level of statistical significance or
                    persuasiveness required by the FDA or comparable foreign regulatory agencies for approval; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">serious and unexpected drug-related side effects may be experienced by participants in Remix&#8217;s clinical trials or by individuals
                    using drugs similar to its product candidates; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">45<br/>
        </div>

      </div>

    </div>

    <!--End Page 55-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 56-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full
                    population for which Remix seek approval; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the
                    standard of care is potentially different from that of their own country; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such authorities may disagree with Remix&#8217;s interpretation of data from preclinical studies or clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such authorities may not agree that the data collected from clinical trials of Remix&#8217;s product candidates are acceptable or
                    sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such authorities may disagree with Remix regarding the formulation, labeling and/or the product specifications of its product
                    candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval may be granted only for indications that are significantly more limited than those sought by Remix, and/or may include
                    significant restrictions on distribution and use; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers with which
                    Remix contract for clinical and commercial supplies; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">With respect to foreign markets, approval procedures vary among countries and, in
            addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. Even if Remix eventually completes clinical trials and receives approval of an NDA or comparable
            foreign marketing application for its product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials and/or the implementation of a REMS, which may be
            required because the FDA believes it is necessary to ensure safe use of the product after approval. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product
            candidate and would materially adversely impact Remix&#8217;s business and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">A Fast Track Designation from the FDA,
            even if granted for any of Remix&#8217;s product candidates, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that its product candidates will receive regulatory approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In March&#160;2026, the FDA granted Fast Track designation for REM-422 for the
            treatment of patients with recurrent, metastatic or unresectable ACC whose tumors express MYB transcripts containing a poison exon. Depending on the data from its preclinical and clinical studies, Remix may decide to seek such designation for
            some or all of its other product candidates. The Fast Track program is intended to expedite or facilitate the process for reviewing product candidates that meet certain criteria. Specifically, drugs and biologics are eligible for Fast Track
            designation if they are intended, alone or in combination with one or more drugs or biologics, to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or
            condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a Fast Track product candidate has opportunities for more frequent interactions with
            the applicable FDA review team during product development and, once an NDA is submitted, the application may be eligible for priority review. An NDA submitted for a Fast Track product candidate may also be eligible for rolling review, where the
            FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and
            determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA has broad discretion whether or not to grant this designation. Even if
            Remix believes a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to grant it. Even if Remix does receive Fast Track Designation for any of its product candidates, such product
            candidates may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track Designation if it believes that the designation is no longer supported by data from </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">46<br/>
        </div>

      </div>

    </div>

    <!--End Page 56-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 57-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix&#8217;s clinical development program. Furthermore, such a designation does not
            increase the likelihood that REM-422 or any other product candidate that may be granted Fast Track designation will receive regulatory approval in the U.S. Many product candidates that have received Fast Track Designation have ultimately failed
            to obtain approval.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix may attempt to secure approval from
            the FDA through the use of the accelerated approval pathway. If it is unable to obtain such approval, Remix may be required to conduct additional preclinical studies or clinical trials beyond those that it contemplates, which could increase the
            expense of obtaining, and delay the receipt of, necessary regulatory approvals. Even if Remix receives accelerated approval from the FDA, if its confirmatory trials do not verify clinical benefit, or if it does not comply with rigorous
            post-marketing requirements, the FDA may seek to withdraw any accelerated approval it has obtained.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may in the future seek accelerated approval for one or more of its product
            candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies
            upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic
            effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic
            image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on
            irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accelerated approval pathway may be used in cases in which the advantage of a
            new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement
            to conduct, in a diligent manner, additional confirmatory studies to verity and describe the drug&#8217;s predicted clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit or are not completed in a timely manner,
            the FDA may withdraw its approval of the drug on an expedited basis. In addition, the Food and Drug Omnibus Reform Act of 2022, among other things, provided FDA additional statutory authority to mitigate potential risks to patients from
            continued marketing of ineffective drugs previously granted accelerated approval. Under these provisions, the FDA may require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being
            granted.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to seeking accelerated approval for any of its product candidates, Remix
            intends to seek feedback from the FDA and will otherwise evaluate its ability to seek and receive accelerated approval. There can be no assurance that after its evaluation of the feedback and other factors Remix will decide to pursue or submit
            an NDA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if Remix decides to submit an application for accelerated approval for its product candidates, there can be no assurance that such
            application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA could also require Remix to conduct further studies prior to considering its application or granting
            approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for its product candidates would result in a longer time period to commercialization of such product candidate, if
            any, could increase the cost of development of such product candidate and could harm Remix&#8217;s competitive position in the marketplace.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix is required by the FDA to obtain
            approval of a companion diagnostic in connection with approval of any of its product candidates, and it does not obtain, or faces delays in obtaining, FDA approval of such companion diagnostic, Remix will not be able to commercialize such
            product candidate and its ability to generate revenue will be materially impaired.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">According to FDA guidance, if the FDA determines that a companion diagnostic in
            vitro device is essential to the safe and effective use of a novel therapeutic product or indication, the FDA generally will not approve the therapeutic product or therapeutic product indication if the companion diagnostic is not also approved
            or cleared for that indication. Depending on the data from its clinical trials, Remix may decide to collaborate with diagnostic companies during its clinical trial enrollment process to help identify patients with characteristics that it
            believes will be most likely to respond to its product candidates. If a satisfactory companion diagnostic is not commercially </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">47<br/>
        </div>

      </div>

    </div>

    <!--End Page 57-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 58-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">available in this situation, Remix may be required to develop or obtain such
            test, which would be subject to regulatory approval requirements. The process of obtaining or creating such diagnostic is time consuming and costly.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Companion diagnostics are developed in conjunction with clinical programs for the
            associated product and are subject to regulation as medical devices by the FDA and comparable foreign regulatory authorities, and the FDA has generally required premarket approval of companion diagnostics for cancer therapies. The approval or
            clearance of a companion diagnostic as part of the therapeutic product&#8217;s further labeling limits the use of the therapeutic product to only those patients who express the specific characteristic that the companion diagnostic was developed to
            detect.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Further, in December&#160;2025, the FDA proposed reclassifying certain nucleic
            acid-based in vitro tests intended as companion diagnostics for oncology therapeutics from Class&#160;III into Class&#160;II. If such reclassification proposals become finalized, any companion diagnostics that are the subject of the down-classification
            may no longer require premarket approval, but rather may be marketed pursuant to the generally less burdensome 510(k) clearance process. However, there is no assurance that any companion diagnostic required for Remix&#8217;s pharmaceutical
            development programs will benefit from the reclassification, or that the reclassification, even if it does occur, will result in a shorter timeline to development or marketing of the companion diagnostic.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the FDA or a comparable foreign regulatory authority requires approval or
            clearance of a companion diagnostic for any of Remix&#8217;s product candidates, whether before or after the product candidate obtains regulatory approval, Remix and/or third-party collaborators may encounter difficulties in developing and obtaining
            approval or clearance for these companion diagnostics. Any delay or failure by Remix or third-party collaborators to develop or obtain regulatory approval or clearance of a companion diagnostic could delay or prevent approval or continued
            marketing of the relevant product. Remix or its collaborators may also experience delays in developing a sustainable, reproducible and scalable manufacturing process for the companion diagnostic or in transferring that process to commercial
            partners or negotiating insurance reimbursement plans, all of which may prevent Remix from completing its clinical trials or commercializing its product candidates, if approved, on a timely or profitable basis, if at all.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interim, topline and preliminary data
            from Remix&#8217;s preclinical studies and clinical trials that it announces or publishes from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the
            final data.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From time to time, Remix may publicly disclose preliminary, interim, or topline
            data from its preclinical studies and clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive
            review of the data related to the particular study or trial. For example, Remix may report responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up
            evaluations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix also makes assumptions, estimations, calculations and conclusions as part
            of its analyses of data, and may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that Remix reports may differ from future results of the same studies or trials, or different
            conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially
            different from the preliminary data it previously published. As a result, topline data should be viewed with caution until the final data are available.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix may report interim analyses of only certain endpoints rather
            than all endpoints. Interim data from clinical trials that it may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse
            changes between interim data and final data could significantly harm its business and prospects. Further, additional disclosure of interim data by Remix or by its competitors in the future could result in volatility in the price of its common
            stock.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the information Remix chooses to publicly disclose regarding a
            particular study or trial is typically selected from a more extensive amount of available information. Investors may not agree with what Remix determines is the material or otherwise appropriate information to include in its disclosure, and any
            information it determines not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or its business. If the preliminary or topline
            data that </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">48<br/>
        </div>

      </div>

    </div>

    <!--End Page 58-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 59-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg27"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix reports differ from late, final or actual results, or if others,
            including regulatory authorities, disagree with the conclusions reached, its ability to obtain approval for, and commercialize, any of its product candidates may be harmed, which could harm its business, financial condition, results of
            operations and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Issues relating to our use of artificial
            intelligence (&#8220;AI&#8221;) in the discovery and development of our product candidates could adversely affect our business and operating results.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We incorporate AI solutions into our platform technologies. There are significant
            risks involved in utilizing AI, including that AI-generated content, analyses, or recommendations we utilize could be deficient, that our competitors may more quickly or effectively adopt AI capabilities, or that our use of AI or other emerging
            technologies increases regulatory, cybersecurity and other significant risks. If our AI systems fail to achieve their intended purposes, such as identifying viable therapeutic candidates or targets, predicting biological outcomes, producing
            reproducible results, and other similar or related purposes, our product development efforts may be delayed or unsuccessful. If we are unable to successfully integrate and manage AI within our business, or if AI fails to deliver the expected
            benefits, our ability to develop our product candidates could be materially adversely affected.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Issues relating to the use of new and evolving technologies such as AI may cause
            us to experience brand or reputational harm, competitive harm, legal liability and new or enhanced governmental or regulatory scrutiny, and we may incur additional costs to resolve such issues. Known risks of AI currently include inaccuracy,
            bias, toxicity, intellectual property infringement or misappropriation, data privacy and cybersecurity issues and data provenance disputes. Perceived or actual technical, legal, compliance, privacy, security, ethical or other issues relating to
            the use of AI may cause public confidence in AI to be undermined, which could slow market acceptance of products discovered and developed using AI. In addition, litigation or government regulation related to the use of AI may also adversely
            impact our and others&#8217; abilities to discover and develop products using AI, as well as increase the cost and complexity of doing so. For example, regulators may limit our ability to develop or implement our proprietary AI algorithms and/or may
            eliminate or restrict the confidentiality of our proprietary technology, which could have an adverse effect on our business, results of operations and financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We also face increased competition from other companies that are using AI and
            related methods for drug discovery and development, some of which have more resources than we do and may have developed more effective methods than we and any third-party collaborators have, which may reduce our and any third-party
            collaborators&#8217; effectiveness in identifying potential product candidates and attracting additional collaborators to work with us. If our competitors are able to utilize new technologies more effectively (including but not limited to those that
            may involve AI or be created using AI) to discover, develop and commercialize products that compete with any of our product candidates or potential commercial products, such technologies could adversely impact our ability to compete.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Further, AI presents additional risks and challenges, especially as the use of
            these technologies becomes more important to our operations over time. AI may have or produce errors or inadequacies that are not easily detectable. The quality of AI outputs depends heavily on the quality and quantity of input data. If the
            data used to train AI or the content, analyses or recommendations that AI applications assist in producing are or are alleged to be deficient, inaccurate, incomplete, overbroad or biased, our business, financial condition and results of
            operations may be adversely affected. Developing, testing and deploying AI systems may also increase the cost profile of our product offerings due to the nature of the computing costs involved in such systems, which could impact our project
            margin and adversely affect our business and operating results.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The legal landscape and subsequent legal protection for the use of AI remains
            uncertain, and the increasing use of AI in drug discovery and development introduces new and evolving risks related to ownership, inventorship and protection of intellectual property generated by or with the assistance of AI technologies. For
            example, generative AI may be used improperly or inappropriately, which could lead to the tainting of our proprietary information and render us unable to qualify for certain patent or trade secret protection. Its use by people, including our
            vendors, employees, suppliers and contractors, with access to our proprietary and confidential information, including know-how, may continue to increase and may lead to the release of such information, which may impact our ability to realize
            the benefit of our intellectual property. If we do not have sufficient rights to collect or use the data on which our AI relies or to the outputs produced by our platform, we may incur liability through the alleged violation of certain laws,
            third-party privacy rights, online terms of service or other contracts to which we or our data providers are a party. Regulatory and legal frameworks governing inventions created with or using AI are still developing and may create uncertainty
            regarding our ability to secure and enforce rights in such inventions. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">49<br/>
        </div>

      </div>

    </div>

    <!--End Page 59-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 60-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg28"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">AI presents risks and challenges that
            can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Issues in the development and use of AI, combined with an uncertain regulatory
            environment, may result in reputational harm, liability or other adverse consequences to our business operations. As with many technological innovations, AI presents risks and challenges that could impact our business. In addition to our
            platform technologies, we have adopted and integrated, and in the future may adopt and integrate, generative AI tools into our systems for specific use cases reviewed by legal and information security. Our vendors may incorporate generative AI
            tools into their offerings without disclosing this use to us, and the providers of these generative AI tools may not meet existing or rapidly evolving regulatory or industry standards with respect to privacy and data protection and may inhibit
            our or our vendors&#8217; ability to maintain an adequate level of service and experience. If we, our vendors or our third-party partners experience an actual or perceived breach or privacy or security incident because of the use of generative AI, we
            may lose valuable intellectual property and confidential information and our reputation and the public perception of the effectiveness of our security measures could be harmed. Further, bad actors around the world use increasingly sophisticated
            methods, including the use of AI, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these outcomes could damage our reputation, result in the loss
            of valuable property and information, and adversely impact our business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our use of AI may also lead to novel and urgent cybersecurity and privacy risks,
            which may adversely affect our operations and reputation, as well as the operations of any third-party collaborators. Emerging ethical issues surround the use of AI, and we may be subject to reputational and legal risk if our deployment or use
            of AI becomes controversial. Our use of AI may also, in the future, result in cybersecurity incidents that implicate the personal data of customers or patients. Any such cybersecurity incidents related to our use of AI could adversely affect
            our reputation and results of operations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A growing number of legislators and regulators are adopting laws and regulations
            and have focused enforcement efforts on the adoption of AI, and use of such technologies in compliance with ethical standards and societal expectations. These developments may increase our compliance burden and costs in connection with use of
            AI and lead to legal liability if we fail to meet evolving legal standards or if use of such technologies results in harms or other causes of action we did not predict. For example, the EU&#8217;s Artificial Intelligence Act entered into force on
            August 1, 2024, with most provisions becoming effective on August 2, 2026. This legislation imposes significant obligations on providers and deployers of AI systems, and encourages providers and deployers of AI systems to account for EU ethical
            principles in their development and use of these systems. Likewise, in the U.S., several states, including Colorado and California, passed laws to regulate various AI uses, including AI used to make consequential decisions. In addition, various
            federal regulators have issued guidance and focused enforcement efforts on the use of AI in regulated sectors. The FDA, for example, issued draft guidance on the use of AI in regulatory decision-making for drug and biological products that
            centers on the context of use while establishing a credibility assessment framework for establishing and evaluating AI model outputs intended to support regulatory decision-making. If we develop or use AI systems governed by these laws or
            regulations, including as informed by regulatory guidance, we would need to meet higher standards of data quality, transparency, monitoring and human oversight, and we would need to adhere to specific and potentially burdensome and costly
            ethical, accountability and administrative requirements, with the potential for significant enforcement or litigation in the event of any perceived non-compliance. We expect other jurisdictions will adopt similar laws. Uncertainty in the legal
            regulatory regime may require significant resources to modify and maintain business practices to comply with U.S. and non-U.S. laws, the nature of which cannot be determined at this time. The scope of requirements depends on legal and risk
            determinations that rely on novel legal provisions that have not yet been interpreted by courts or regulators, and non-compliance can lead to significant fines.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">We utilize third-party open source
            software (&#8220;OSS&#8221;), which presents risks that could adversely affect our business and subject us to possible litigation.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We utilize software that is licensed from third parties under open source
            licenses, and we expect to continue to use such OSS in the future. We cannot ensure that we have effectively monitored our use of OSS, validated the quality or source of such software, or are in compliance with the terms of the applicable open
            source licenses or our policies and procedures. Use of OSS may entail greater risks than use of third-party commercial software because open source licensors generally do not provide support, updates or warranties or other contractual
            protections regarding infringement claims or the quality of the code. OSS may also be more susceptible to security vulnerabilities. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">50<br/>
        </div>

      </div>

    </div>

    <!--End Page 60-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 61-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg29"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Third-party OSS providers could experience service outages, data loss, privacy
            breaches, cyber-attacks and other events relating to the applications and services they provide, which could diminish the utility of these services and harm our business. We also could be subject to lawsuits by third parties claiming that what
            we believe to be licensed OSS infringes such parties&#8217; intellectual property rights, which could be costly for us to defend and require us to devote additional research and development resources to change our solutions. Some OSS licenses contain
            requirements that we make available source code for modifications or derivative works we create based upon the type of OSS we use. If we combine our proprietary software with OSS in a certain manner, we could, under certain of the OSS licenses,
            be required to release the source code of our proprietary software to the public. This could allow our competitors to create similar products with lower development effort and time, and ultimately could result in a loss of product sales for us.
            Although we monitor our use of OSS, the terms of many OSS licenses have not been interpreted by U.S. courts, and there is a risk that those licenses could be construed in a manner that could impose unanticipated conditions or restrictions on
            our ability to commercialize our product candidates. We could be required to seek licenses from third parties in order to continue using our software, to re-engineer our software or to discontinue use of our software in the event re-engineering
            cannot be accomplished on a timely basis, any of which could materially and adversely affect our business, financial condition, results of operations and prospects. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix faces substantial competition which
            may result in others discovering, developing or commercializing products before or more successfully than Remix does. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The pharmaceutical and biotechnology industries are characterized by rapidly
            advancing technologies, intense competition and a strong emphasis on proprietary products. In particular, precision oncology is a very competitive space and Remix has chosen to prioritize addressing well-validated biological targets, and
            therefore expects to face competition from existing products and products in development for each of its product candidates. While Remix believes that its technology, the expertise of its team, and its development experience and scientific
            knowledge provide it with competitive advantages, it faces increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research
            institutions. Product candidates that Remix successfully develops and commercializes may compete with existing therapies and new therapies that may become available in the future.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Many of Remix&#8217;s competitors, either alone or with their collaborators, have
            significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved
            products than Remix does. These competitors also compete with Remix in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in
            acquiring technologies complementary to, or necessary for, its programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
            Additional mergers and acquisitions may result in even more resources being concentrated in its competitors. As a result of all of these factors, Remix&#8217;s competitors may succeed in obtaining approval from the FDA or other comparable foreign
            regulatory authorities or in discovering, developing and commercializing product candidates in its field before Remix does.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s commercial potential could be reduced or eliminated if its competitors
            develop and commercialize products that are safer or more effective, have fewer or less severe side effects, and are more convenient or less expensive than products that it may develop. Its competitors also may obtain FDA or other regulatory
            approval for their products more rapidly than Remix can, which could result in its competitors establishing a strong market position before Remix is able to enter the market or could otherwise make its development more complicated. Remix
            believes the key competitive factors affecting the success of all of its programs are likely to be efficacy, safety and patient convenience. Even if the product candidates it develops obtain regulatory approval, they may be priced at a
            significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There are no FDA-approved drugs for ACC. However, there are competitors
            developing therapies for ACC, including Emi-Le, which is in development by Les Laboratoires Servier SAS (&#8220;<span style="font-style: italic; font-weight: bold;">Servier</span>&#8221;), and RGT-61159, which is in development by Rgenta Therapeutics, Inc.
            (&#8220;<span style="font-style: italic; font-weight: bold;">Rgenta</span>&#8221;).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Finally, there are numerous other investigational therapies, spanning many
            modalities, that are being evaluated preclinically and in clinical trials for various subtypes of AML.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Technological advances or products developed by Remix&#8217;s competitors may render
            its technologies or product candidates obsolete, less competitive or not economical. If Remix is unable to compete effectively, its opportunity to generate revenue from the sale of its products it may develop, if approved, could be adversely
            affected. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">51<br/>
        </div>

      </div>

    </div>

    <!--End Page 61-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 62-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg30"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Changes in methods of product candidate
            manufacturing or formulation may result in additional costs or delay. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As product candidates progress through preclinical and clinical trials to
            regulatory approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size,
            minimize costs and achieve consistent quality and results. For example, Remix may introduce an alternative formulation of one or more of its product candidates during the course of its clinical trials. Such changes carry the risk that they will
            not achieve these intended objectives.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any of these changes could cause Remix&#8217;s product candidates to perform
            differently and affect the results of clinical trials conducted with the altered materials, or adversely affect a product&#8217;s safety or profile that has been previously established. In particular, such changes could delay completion of clinical
            trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of Remix&#8217;s product candidates and jeopardize or impair its ability to commercialize its
            product candidates, if approved, and generate revenue. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Remix may develop its current or future
            product candidates in combination with other therapies, which would expose it to additional risks. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may develop or seek strategic collaborations to develop its current or
            future product candidates in combination with one or more currently approved cancer therapies or therapies in development. Even if any of its current or future product candidates were to receive regulatory approval or be commercialized for use
            in combination with other existing therapies, Remix would continue to be subject to the risks that the FDA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with any of its product
            candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which its product candidates are approved for use could themselves fall out of
            favor or be relegated to later lines of treatment. Such events could result in the need to identify other combination therapies for its product candidates or its own products being removed from the market or being less successful commercially.
            In addition, developing combination regimens may require that Remix adequately demonstrate the safety and efficacy of each therapy within the combination regimen, which may prove difficult, and otherwise require it to generate more data than it
            would in connection with a monotherapy program.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the FDA, or other comparable foreign regulatory authorities do not approve or
            withdraw their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies Remix chooses to evaluate in combination with any of its current or future product
            candidates, Remix may be unable to obtain approval of or successfully market any one or all of the current or future product candidates it develops. Additionally, if the third-party providers of therapies or therapies in development used in
            combination with its current or future product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of its current or future product candidates, or if the cost of combination therapies are
            prohibitive, its development and commercialization efforts would be impaired, which would have an adverse effect on its business, financial condition, results of operations and growth prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Remix is conducting, and plans to
            conduct, some of its clinical trials outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case its development plans will be delayed, which could materially harm its
            business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has conducted or is conducting clinical trials for REM-422 in France, and
            will likely conduct additional clinical trials for REM-422 and its other product candidates at sites outside of the United States. The acceptance of study data from clinical trials conducted outside the United States or another jurisdiction by
            the FDA or applicable foreign authority may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States,
            regardless of whether the trials were conducted pursuant to an IND, the FDA will generally not approve an NDA on the basis of foreign data alone unless (i)&#160;the data are applicable to the U.S. population and U.S. medical practice; (ii) the
            trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection
            to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, if the trial was not
            otherwise subject to an IND, the FDA will not accept the data as support for a submission unless the study was conducted in accordance with GCP requirements </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">52<br/>
        </div>

      </div>

    </div>

    <!--End Page 62-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 63-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg31"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and the FDA is able to validate the data from the study through an onsite
            inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted.
            There can be no assurance that the FDA or any applicable foreign authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or applicable foreign authorities do not accept any such
            data, Remix would likely be required to conduct additional clinical trials, which would be costly and time consuming, and delay aspects of its development plan, which could harm its business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Conducting clinical trials outside the United States exposes Remix to
            additional risks, including risks associated with: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additional foreign regulatory requirements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">foreign exchange fluctuations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with foreign manufacturing, customs, shipment and storage requirements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">cultural differences in medical practice and clinical research; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">diminished protection of intellectual property in some countries. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Risks Related to the Commercialization of Remix&#8217;s Product
            Candidates </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s product candidates may not achieve
            adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Even if Remix&#8217;s product candidates receive regulatory approval, they may not gain
            adequate market acceptance among physicians, patients, third-party payors and others in the medical community. The degree of market acceptance of any of Remix&#8217;s approved product candidates will depend on a number of factors, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing of market introduction of the product candidate as well as competitive products; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the clinical indications for which a product candidate is approved; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or
                    contraindications in labeling, or a risk evaluation and mitigation strategy, if any, which may not be required of alternative treatments and competitor products; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential and perceived advantages of Remix&#8217;s product candidates over alternative treatments; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of treatment in relation to alternative treatments; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of coverage and adequate reimbursement by third-party payors, including government authorities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of an approved product candidate for use as a combination therapy; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">relative convenience and ease of administration; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the willingness of the target patient population to try new therapies and undergo required diagnostic screening to determine
                    treatment eligibility and of physicians to prescribe these therapies and diagnostic tests; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effectiveness of sales and marketing efforts; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unfavorable publicity relating to Remix&#8217;s product candidates; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the approval of other new therapies for the same indications. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If any of Remix&#8217;s product candidates are approved but do not achieve an adequate
            level of acceptance by physicians, hospitals, healthcare payors and patients, Remix may not generate or derive sufficient revenue from that product candidate and its financial results could be negatively impacted.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">53<br/>
        </div>

      </div>

    </div>

    <!--End Page 63-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 64-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg32"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The market opportunities for any
            product candidates Remix develops, if approved, may be limited to certain smaller patient subsets and may be smaller than it estimates them to be.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">When cancer is detected early (referred to as localized disease), conventional
            treatments which include chemotherapy, hormone therapy, surgery and radiation therapy and/or selected targeted therapies may be adequate to cure the patient in many cases. However, once cancer has spread to other areas (advanced or metastatic
            disease), cancer treatments may not be sufficient to provide a cure but often can significantly prolong life without curing the cancer. First-line (1L) therapies designate treatments that are initially administered to patients with advanced or
            metastatic disease, while second-line (2L) and third or later line (3L+) therapies are administered to patients when the prior therapies lose their effectiveness. The FDA and other comparable foreign regulatory bodies often approve cancer
            therapies for a particular line of treatment. Typically, drug approvals are initially granted for use in later lines of treatment, but with additional evidence of significant efficacy from clinical trials, biopharmaceutical companies can
            successfully seek and gain approval for use in earlier lines of treatment.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix plans to initially seek approval of its product candidates in most
            instances at least as a second- or third-line therapy, for use in patients with advanced or metastatic cancer where at least one prior therapy has limited clinical benefit or has lost its effectiveness. For those product candidates that prove
            to be sufficiently safe and effective, if any, Remix would expect to seek approval as a 2L therapy and potentially ultimately as a 1L therapy. There is no guarantee that its product candidates, even if approved as a second, third or subsequent
            line of therapy would be approved for an earlier line of therapy, and prior to any such approvals Remix may have to conduct additional clinical trials that may be costly, time-consuming and subject to risk.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s projections of both the number of people who have the cancers it is
            targeting, as well as the subset of people with these cancers in a position to receive a particular line of therapy and who have the potential to benefit from treatment with its product candidates, are based on its beliefs and estimates. These
            estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or
            prevalence of the cancers that Remix is targeting. The potentially addressable patient population for Remix&#8217;s product candidates may be limited or may not be amenable to treatment with its product candidates. Consequently, even if Remix&#8217;s
            product candidates are approved, the number of patients that may be eligible for treatment with its product candidates may turn out to be much lower than expected. In addition, Remix has not yet conducted market research to determine how
            treating physicians would expect to prescribe a product that is approved for multiple tumor types if there are different lines of approved therapies for each such tumor type. Even if Remix obtains significant market share for its products, if
            approved, if the potential target populations are small, it may never achieve profitability without obtaining regulatory approval for additional indications. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Any product candidates Remix develops may
            become subject to unfavorable third-party coverage and reimbursement policies, as well as pricing regulations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The availability and extent of coverage and adequate reimbursement by third-party
            payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of
            Remix&#8217;s product candidates that receive regulatory approval will depend substantially, both in the United States and internationally, on the extent to which the costs of such product candidates will be covered and reimbursed by third-party
            payors. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow Remix to establish or maintain pricing sufficient to realize an adequate return on its investment. Coverage and reimbursement may impact the
            demand for, or the price of, any product candidate for which Remix obtains regulatory approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, Remix may not successfully commercialize any
            product candidate for which it obtains regulatory approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There is significant uncertainty related to third-party payor coverage and
            reimbursement of newly approved products. In the United States, no uniform policy for coverage and reimbursement for products exists among third-party payors. Third-party payors often rely upon Medicare coverage policy and payment limitations
            in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. One third-party
            payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This
            process will require Remix to provide scientific and clinical support for the use of its products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the
            first instance.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">54<br/>
        </div>

      </div>

    </div>

    <!--End Page 64-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 65-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg33"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">As federal and state governments implement additional health care cost
            containment measures, including measures to lower prescription drug pricing, Remix cannot be sure that its products, if approved, will be covered by private or public payors, and if covered, whether the reimbursement will be adequate or
            competitive with other marketed products. Any actions by federal and state governments and health plans aimed at putting additional downward pressure on pharmaceutical pricing and health care costs could negatively impact coverage and
            reimbursement for Remix&#8217;s product candidates if approved, its revenue, and its ability to compete with other marketed products and to recoup the costs of its research and development. For further discussion, see &#8220;<span style="font-style: italic;">&#8212; Remix may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on its business and results of
              operations.</span>&#8221;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Increasingly, third-party payors are requiring that drug companies provide them
            with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of
            medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a
            formulary, which might not include all FDA-approved drugs for a particular indication. Remix may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of its products. Nonetheless,
            Remix&#8217;s product candidates may not be considered medically necessary or cost effective. Remix cannot be sure that coverage and reimbursement will be available for any product that it commercializes and, if reimbursement is available, what the
            level of reimbursement will be.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, companion diagnostic tests require coverage and reimbursement
            separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to
            companion diagnostics. Additionally, if any companion diagnostic provider is unable to obtain reimbursement or is inadequately reimbursed, that may limit the availability of such companion diagnostic, which would negatively impact prescriptions
            for Remix&#8217;s product candidates, if approved.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Outside the United States, the commercialization of therapeutics is generally
            subject to extensive governmental price controls and other market regulations, and Remix believes the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing
            and usage of therapeutics such as its product candidates. In many countries, particularly the countries of the European Union (EU), medical product prices are subject to varying price control mechanisms as part of national health systems. In
            these countries, pricing negotiations with governmental authorities can take considerable time after a product receives regulatory approval. To obtain reimbursement or pricing approval in some countries, Remix may be required to conduct a
            clinical trial that compares the cost-effectiveness of its product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix
            their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that Remix is able to charge for its product candidates. Accordingly, in
            markets outside the United States, the reimbursement for Remix products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Remix is unable to establish or sustain coverage and adequate reimbursement
            for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved.
            Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which Remix receives regulatory approval, less favorable coverage
            policies and reimbursement rates may be implemented in the future.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix&#8217;s business entails a significant
            risk of product liability and if Remix is unable to obtain sufficient insurance coverage such inability could have an adverse effect on Remix&#8217;s business and financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s business exposes Remix to significant product liability risks inherent in
            the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of Remix&#8217;s development programs. If Remix succeeds in marketing products, such claims could result in an
            FDA or other regulatory authority investigation of the safety and effectiveness of Remix&#8217;s products, Remix&#8217;s manufacturing processes and facilities or Remix&#8217;s marketing programs. FDA or other regulatory authority investigations could
            potentially lead to a recall of Remix&#8217;s products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">55<br/>
        </div>

      </div>

    </div>

    <!--End Page 65-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 66-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg34"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">eventual outcome, liability claims may also result in decreased demand for
            Remix&#8217;s products, injury to Remix&#8217;s reputation, costs to defend the related litigation, a diversion of management&#8217;s time and Remix&#8217;s resources and substantial monetary awards to trial participants or patients. Remix currently has product
            liability insurance that Remix believes is appropriate for Remix&#8217;s stage of development and may need to obtain higher levels prior to advancing Remix&#8217;s product candidates into clinical trials or marketing any of Remix&#8217;s product candidates, if
            approved. Any insurance Remix has or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, Remix may be unable
            to obtain sufficient insurance at a reasonable cost to protect Remix against losses caused by product liability claims that could have an adverse effect on Remix&#8217;s business and financial condition.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix has never commercialized a product
            candidate as a company before and currently lacks the necessary expertise, personnel and resources to successfully commercialize any products on Remix&#8217;s own or together with suitable collaborators.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has never commercialized a product candidate as a company. Remix may
            license certain rights with respect to Remix&#8217;s product candidates to collaborators, and, if so, Remix will rely on the assistance and guidance of those collaborators. For product candidates for which Remix retains commercialization rights and
            obtains regulatory approval, Remix will have to develop Remix&#8217;s own sales, marketing and supply organization or outsource these activities to a third party.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Factors that may affect Remix&#8217;s ability to commercialize its product candidates,
            if approved, on Remix&#8217;s own include recruiting and retaining adequate numbers of effective sales and marketing personnel, developing adequate educational and marketing programs to increase public acceptance of Remix&#8217;s approved product
            candidates, ensuring regulatory compliance of Remix&#8217;s company, employees and third parties under applicable healthcare laws, and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales
            and marketing organization will be expensive and time consuming and could delay the launch of Remix&#8217;s product candidates upon approval. Remix may not be able to build an effective sales and marketing organization. If Remix is unable to build
            its own distribution and marketing capabilities or to find suitable partners for the commercialization of its product candidates, Remix may not generate revenues from them or be able to reach or sustain profitability.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining regulatory
            approval of Remix&#8217;s product candidates in one jurisdiction does not mean that Remix will be successful in obtaining regulatory approval of Remix&#8217;s product candidates in other jurisdictions.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining regulatory approval of Remix&#8217;s product candidates in
            one jurisdiction does not guarantee that Remix will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities
            in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a
            negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional
            preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved
            for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that Remix intends to charge for Remix&#8217;s products is also subject to approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Obtaining foreign regulatory approvals and establishing and maintaining
            compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for Remix and could delay or prevent the introduction of Remix&#8217;s products in certain countries. If Remix or any future collaborator fails
            to comply with the regulatory requirements in international markets or fails to receive applicable regulatory approvals, Remix&#8217;s target market will be reduced and Remix&#8217;s ability to realize the full market potential of Remix&#8217;s potential product
            candidates will be harmed. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Even if Remix&#8217;s product candidates
            receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For any regulatory approvals that Remix may receive for Remix&#8217;s product
            candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for Remix&#8217;s product candidates will be subject to extensive and ongoing
            regulatory requirements. These </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">56<br/>
        </div>

      </div>

    </div>

    <!--End Page 66-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 67-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg35"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">requirements include submissions of safety and other post-marketing
            information and reports, registration, as well as ongoing compliance with cGMPs and GCPs for any clinical trials. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced
            inspections by the FDA and other regulatory authorities for compliance with cGMPs and other applicable regulations and standards. In addition, any regulatory approvals Remix may receive will require the submission of periodic reports to
            regulatory authorities and ongoing surveillance to monitor the safety and efficacy of the product. Such approvals may also contain significant limitations related to use restrictions for specified age groups, warnings, precautions or
            contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS as a condition of approval of Remix&#8217;s product candidates, which could limit their commercial potential.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Remix or a regulatory agency discover previously unknown problems with a
            product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or Remix,
            including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject Remix&#8217;s company to administrative
            or judicially imposed sanctions, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the marketing or manufacturing of Remix&#8217;s products, withdrawal of the product from the market or voluntary or
                    mandatory product recalls; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal by the FDA to approve pending applications or supplements to approved applications submitted, or suspension or
                    revocation of approvals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizures or detentions, or refusal to permit the import or export of Remix&#8217;s products; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of civil or criminal penalties. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The occurrence of any event or penalty described above may inhibit Remix&#8217;s
            ability to commercialize its product candidates and generate revenue and could require Remix to expend significant time and resources in response and could generate negative publicity.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and
            additional government regulations may be promulgated that could prevent, limit or delay marketing authorization of any product candidates Remix develops. Remix also cannot predict the likelihood, nature or extent of government regulation that
            may arise from future legislation or administrative action, either in the United States or abroad. If Remix is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if Remix is not able
            to maintain regulatory compliance, Remix may be subject to enforcement action and Remix may not achieve or sustain profitability. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The FDA and other regulatory agencies
            actively enforce the laws and regulations prohibiting the promotion of off-label uses. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA strictly regulates marketing, labeling, advertising and promotion of
            prescription drugs. These regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the internet and off-label promotion. Any
            regulatory approval that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe and effective by FDA. While physicians in the United States may choose, and are generally permitted, to
            prescribe drugs for uses that are not described in the product&#8217;s labeling and for uses that differ from those tested in clinical trials and approved by the regulatory authorities, Remix&#8217;s ability to promote any products will be narrowly limited
            to those indications that are specifically approved by the FDA.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If any of Remix&#8217;s product candidates are approved and it is found to have
            improperly promoted off-label uses of those products, Remix may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as
            Remix&#8217;s product candidates, if approved. If Remix is found to have promoted such off-label uses, it may become subject to significant liability. The United States federal government has levied large civil and criminal fines against companies
            for alleged </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">57<br/>
        </div>

      </div>

    </div>

    <!--End Page 67-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 68-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg36"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">improper promotion of off-label use and has enjoined several companies from
            engaging in off-label promotion. The government has also required companies to enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If Remix cannot successfully manage the
            promotion of its product candidates, if approved, it could become subject to significant liability, which would materially adversely affect its business and financial condition.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix may fail to obtain orphan drug
            designations from the FDA for Remix&#8217;s product candidates, and even where Remix has obtained such designations, Remix may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Regulatory authorities in some jurisdictions, including the U.S., may designate
            drugs designed to address relatively small patient populations as &#8220;orphan drugs.&#8221; Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is defined as one occurring in
            a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States, where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in
            the United States. In the U.S., orphan designation entitles a party to financial incentives such as opportunities for grant funding for clinical trial costs, tax advantages and user-fee waivers. In addition, if a product candidate that has
            orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications,
            including an NDA, to market the same drug for the same approved use or indication within such rare disease or condition for seven years, except in limited circumstances.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has received the FDA Orphan Drug Designations for REM-422 for the treatment
            of ACC and for the treatment of acute AML. Remix may seek Orphan Drug Designations for REM-422 in other diseases or conditions or for its other product candidates. There can be no assurances that Remix will be able to obtain such designations.
            Even if Remix, or any future collaborators, obtain orphan drug designation for a product candidate, Remix, or they, may not be able to obtain or maintain orphan drug exclusivity for that product candidate. Further, even if Remix, or any future
            collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active ingredients may be approved for the same uses or indications.
            Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same use or indication within the same rare disease or condition if the FDA concludes that the later drug is clinically superior in that it is shown
            to be safer, more effective or makes a major contribution to patient care with respect to the exclusivity-protected use or indication, or if the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product
            quantity to meet the needs relating to the relevant indication or use. Orphan drug designation neither shortens the development or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix may face difficulties from changes
            to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on Remix&#8217;s business and results of operations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Existing regulatory policies may change, and additional government regulations
            may be enacted that could prevent, limit or delay regulatory approval of Remix&#8217;s product candidates. Remix cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action,
            either in the United States or abroad. If Remix is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if it is not able to maintain regulatory compliance, Remix may lose any
            regulatory approval that it may have obtained, and it may not achieve or sustain profitability.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For example, in March&#160;2010, the Patient Protection and Affordable Care Act of
            2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and continues to
            significantly impact the United States pharmaceutical industry. The ACA, which, among other things, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations;
            subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Since its enactment, there have been
            executive, judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law.
            For example, on August&#160;16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">58<br/>
        </div>

      </div>

    </div>

    <!--End Page 68-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 69-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg37"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">into law, which among other things, extended enhanced subsidies for
            individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminated the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary
            maximum out-of-pocket cost and creating a new manufacturer discount program.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, other legislative changes have been proposed and adopted in the
            United States since the ACA was enacted. For example, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in aggregate reductions to Medicare payments to providers, effective April&#160;1, 2013, which, due to
            subsequent legislative amendments, will stay in effect through 2032. In addition, the American Rescue Plan Act of 2021, effective January&#160;1, 2024, was signed into law, which eliminated the statutory cap on Medicaid Drug Rebate Program rebates
            that manufacturers pay to state Medicaid programs. The cap was previously capped at 100% of the Average Manufacturer Price (AMP) for a covered outpatient drug.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2025, the One Big Beautiful Bill Act, or OBBBA, was signed into law,
            which is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. OBBBA also
            narrowed access to ACA marketplace exchange enrollment and declined to extend the ACA enhanced advanced premium tax credits, which expired at the end of 2025. The OBBBA is anticipated to reduce the number of Americans with health insurance.
            Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expired ACA subsidies.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Moreover, there has been heightened governmental scrutiny recently over the
            manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to
            product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The IRA included prescription drug provisions that have significant
            implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single-source Medicare drugs, imposing penalties and excise tax for
            manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part&#160;B and Part&#160;D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning
            Medicare Part&#160;D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one or more orphan
            designations and for which the only approved indication or indications are for rare diseases or conditions. Since the IRA&#8217;s passage, the government selected and negotiated two rounds of drugs and has announced a third round of drugs that have
            been selected for negotiation, which is currently the subject to several constitutional challenges. The outcome of these challenges on the IRA, and the effect of IRA on Remix&#8217;s business and the healthcare industry in general are not yet known.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May&#160;12, 2025, President Trump signed an executive order directing the
            Secretary of HHS to set and communicate most-favored-nation, or MFN, price targets to manufacturers and propose a rulemaking plan to impose MFN pricing if &#8220;significant progress&#8221; is not made, and also directing the federal government to support
            regulatory paths to allow direct-to-patient sales for companies that meet these targets. The executive order further states that the Administration will take additional action (for example, examining whether marketing approvals should be
            modified or rescinded or considering individual drug importation waiver authorities) should manufacturers fail to offer American consumers the MFN lowest price. In July&#160;2025, President Trump sent letters to certain pharmaceutical companies
            demanding that these companies extend MFN pricing to Medicaid and newly launched drugs as well as move to direct-to-consumer models priced at MFN pricing, and soliciting binding commitments by September&#160;29, 2025. Since this time, multiple drug
            manufacturers have announced plans to, for certain of their drugs, lower prices to reflect similar pricing around the world, and to sell these reduced-price drugs on a direct-to-consumer purchasing platform developed by the federal government;
            however, it is not known what results will occur to the extent the recipients of these letters do not reduce their U.S. prices. In April&#160;2026, the Trump administration issued a proclamation imposing tariffs under Section&#160;232 of the Trade
            Expansion Act on imports of brand pharmaceuticals, biologics and associated pharmaceutical ingredients, beginning July&#160;31, 2026. Exempted from these tariffs, among others, are companies that have executed or are negotiating agreements with the
            federal government regarding most favored nation pricing and onshoring of production and research and development.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On December&#160;19, 2025, CMS released two proposed rules that would incorporate MFN
            pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">59<br/>
        </div>

      </div>

    </div>

    <!--End Page 69-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 70-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg38"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Model, or GLOBE, for Medicare Part&#160;B, would require manufacturers of specified
            single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS&#8217;s spending and eligibility criteria. The second proposal, the Guarding U.S.
            Medicare Against Rising Drug Costs, or GUARD, model for Medicare Part&#160;D, would similarly mandate manufacturer rebates for qualifying sole source drugs where the Medicare net price exceeds an MFN benchmark derived from international reference
            pricing methodologies. As proposed, GLOBE would begin a five year performance period on October&#160;1, 2026 and GUARD would begin its performance period in 2027. These proposals, if finalized, will likely be subject to legal challenges that could
            delay their implementation or modify their impact on manufacturer pricing and revenue. Additionally, in November&#160;2025, CMS introduced the GENErating cost Reductions for U.S. Medicaid, or GENEROUS Model, a voluntary MFN framework for
            manufacturers participating in the Medicaid Drug Rebate Program. Although it is voluntary, the GENEROUS Model could also impact the drug pricing landscape for manufacturers.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the state level, legislatures have increasingly passed legislation and
            implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
            some cases, designed to encourage importation from other countries and bulk purchasing. In 2021, many states have passed or are considering state drug price transparency and reporting laws that substantially increase the compliance burdens on
            pharmaceutical manufacturers. The impact of these legislative, executive, and administrative actions and any future healthcare measures and agency rules implemented by the Trump administration on Remix and the pharmaceutical industry as a whole
            is unclear. The implementation of cost containment measures or other healthcare reforms may prevent Remix from being able to generate revenue, attain profitability, or commercialize its product candidates if approved. Complying with any new
            legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on its business, and expose it to greater liability.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is unable to predict the future course of federal or state healthcare
            legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare, particularly as a result of the recent presidential election. These and any further changes in the law or
            regulatory framework that reduce Remix&#8217;s revenue or increase its costs could also have a material and adverse effect on its business, financial condition and results of operations. The continuing efforts of the government, insurance companies,
            managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the demand for Remix&#8217;s product candidates, if it obtains regulatory approval; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to set a price that it believes is fair for its products; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to obtain coverage and reimbursement approval for a product; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to generate revenue and achieve or maintain profitability; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the level of taxes that Remix is required to pay; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the availability of capital. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix expects that other healthcare reform measures that may be adopted in the
            future may result in more rigorous coverage criteria and in additional downward pressure on the price that it receives for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar
            reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent Remix from being able to generate revenue, attain profitability or commercialize its product candidates.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Legislative and regulatory proposals have been made to expand post-approval
            requirements and restrict sales and promotional activities for biotechnology products. Remix cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what
            the impact of such changes on the regulatory approvals of its product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent regulatory approval, as well as
            subject Remix to more stringent product labeling and post-marketing testing and other requirements.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">60<br/>
        </div>

      </div>

    </div>

    <!--End Page 70-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 71-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg39"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Inadequate funding for the FDA, the SEC
            and other United States government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized
            in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of Remix&#8217;s business may rely, which could negatively impact its business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The ability of the FDA or comparable foreign regulatory authorities to review and
            approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average
            review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which Remix&#8217;s operations may rely, including those that fund research and development
            activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or
            approved by necessary government agencies, which would adversely affect Remix&#8217;s business. For example, in recent years, the U.S.&#160;government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough
            critical FDA employees and stop critical activities. In addition, the current U.S. Presidential administration has issued certain policies and Executive Orders directed towards reducing the employee headcount and costs associated with
            U.S.&#160;administrative agencies, including the FDA, which have led to substantial personnel changes, and it remains unclear the degree to which these efforts or the resulting changes in FDA personnel may limit or otherwise adversely affect the
            FDA&#8217;s ability to conduct routine activities.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a prolonged government shutdown occurs, or if funding shortages, staffing
            limitations or similar factors hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, such events could significantly impact the ability of the FDA or other
            such regulatory authorities to timely review and process Remix&#8217;s regulatory submissions, which could have a material adverse effect on its business.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Remix&#8217;s relationships with employees,
            independent contractors, consultants, commercial collaborators, healthcare professionals, clinical investigators, CROs, suppliers, vendors and third-party payors in connection with Remix&#8217;s current and future business activities may be subject
            to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and government price reporting, which could expose Remix to significant losses, including, among other things, criminal sanctions, civil penalties,
            contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is exposed to the risk that its employees, independent contractors,
            consultants, commercial collaborators, healthcare professionals, clinical investigators, CROs, suppliers, vendors and third-party payors may engage in misconduct or other improper activities. Healthcare providers and third-party payors play a
            primary role in the recommendation and prescription of any product candidates for which Remix obtains regulatory approval. Remix&#8217;s current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors
            and customers may expose it to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which Remix researches, as well as markets, sells
            and distributes its product candidates for which it obtains regulatory approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The laws that may affect Remix&#8217;s ability to operate include, but are not limited
            to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting,
                    receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
                    purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does
                    not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
                    prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe
                    harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of Remix&#8217;s facts and circumstances;
                  </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">61<br/>
        </div>

      </div>

    </div>

    <!--End Page 71-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 72-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg40"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">federal civil and criminal false claims laws, including the False Claims Act, or FCA, which can be enforced through civil &#8220;qui
                    tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, including the Civil Monetary Penalties Law, impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing
                    to be presented, claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false or fraudulent, knowingly making or causing a false statement material to a false or fraudulent claim or an
                    obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims
                    directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal
                    Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the
                    FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from
                    participation in Medicare, Medicaid and other federal healthcare programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic
                    and Clinical Health Act, or HITECH, and the regulations that implement both laws (collectively, HIPAA), which created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or
                    attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any
                    healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in
                    connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without
                    actual knowledge of the statute or specific intent to violate it; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations, which require applicable
                    manufacturers of drugs, devices, biologics and medical supplies for which reimbursement is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS in HHS
                    information related to payments or other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician healthcare providers
                    (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and
                    unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services
                    reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance
                    promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding
                    pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the
                    registration of pharmaceutical sales representatives. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may also be subject to federal consumer protection and unfair competition
            laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Efforts to ensure that Remix&#8217;s current and future business arrangements with
            third parties will comply with applicable healthcare regulatory laws and regulations will involve ongoing substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is
            possible that governmental authorities will conclude that Remix&#8217;s business practices, including certain advisory and consulting agreements it has entered into with physicians who are paid, in part, in the form of stock or stock options, do not
          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">62<br/>
        </div>

      </div>

    </div>

    <!--End Page 72-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 73-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg41"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">comply with current or future statutes, regulations, agency guidance or case
            law involving applicable fraud and abuse or other healthcare laws and regulations. If Remix&#8217;s operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that
            apply to Remix, it may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as
            Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, exclusion, debarment or refusal to allow Remix to enter into government contracts, contractual damages,
            reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if Remix becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of
            non-compliance with these laws, and the curtailment or restructuring of Remix&#8217;s operations, any of which could adversely affect its ability to operate its business and its results of operations. Defending against any such actions can be costly,
            time-consuming and may require significant financial and personnel resources. Therefore, even if Remix is successful in defending against any such actions that may be brought against it, its business may be impaired. Further, if any of the
            physicians or other healthcare providers or entities with whom Remix expects to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including
            exclusions from government funded healthcare programs.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Actual or perceived failures to comply
            with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect Remix&#8217;s business, results of operations, and financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The global data protection landscape is rapidly evolving, and Remix is or may
            become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that Remix may collect in connection with
            clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and Remix cannot yet determine the impact future laws, regulations, standards, or perception
            of their requirements may have on its business. This evolution may create uncertainty in its business, affect its ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the
            acceptance of more onerous obligations in Remix&#8217;s contracts, result in liability or impose additional costs on it. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or
            perceived failure by Remix to comply with federal, state or foreign laws or regulations, its internal policies and procedures or its contracts governing its processing of personal information could result in negative publicity, government
            investigations and enforcement actions, claims by third parties and damage to Remix&#8217;s reputation, any of which could have a material adverse effect on Remix&#8217;s business, results of operation, and financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As Remix&#8217;s operations and business grow, it may become subject to or affected by
            new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and
            breach reporting of individually identifiable health information. Remix may obtain health information from third parties, such as research institutions with which it collaborates, that are subject to privacy and security requirements under
            HIPAA. Although Remix does not believe that it is directly subject to HIPAA, other than potentially with respect to providing certain employee benefits, Remix could be subject to criminal penalties if it knowingly obtains or discloses
            individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA. Certain states have also adopted comparable privacy and security laws and regulations, which govern the
            privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance
            issues for Remix and its future customers and strategic partners. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act (collectively, the CCPA) requires covered businesses that process the
            personal information of California residents to, among other things: (i) provide certain disclosures to California residents regarding the business&#8217;s collection, use, and disclosure of their personal information; (ii) receive and respond to
            requests from California residents to access, delete, and correct their personal information, or to opt out of certain disclosures of their personal information; and (iii) enter into specific contractual provisions with service providers that
            process California resident personal information on the business&#8217;s behalf. Additional compliance investment and potential business process changes may also be required. Similar laws have been passed in other states, and are continuing to be
            proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. For example, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">63<br/>
        </div>

      </div>

    </div>

    <!--End Page 73-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 74-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg42"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Washington State enacted the Washington My Health My Data Act, which broadly
            defines consumer health data, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent consent requirements, and grants consumers certain rights with respect to their health data, including to
            request deletion of their information. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that Remix is subject to or affected by HIPAA, the CCPA, or other domestic
            privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect its financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s operations abroad may also be subject to increased scrutiny or attention
            from data protection authorities. For example, in Europe, the European Union General Data Protection Regulation (the EU GDPR) and in the United Kingdom, the United Kingdom General Data Protection Regulation and Data Protection Act 2018 (the UK
            GDPR and together with the EU GDPR, referred to as the GDPR) impose strict requirements for processing the personal data of individuals within the European Economic Area (EEA) and the United Kingdom (UK). Companies that must comply with the
            GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance under both the EU GDPR and UK GDPR of up to &#8364;20&#160;million/ GBP 17.5&#160;million or
            4% of the annual global revenues of the noncompliant company, whichever is greater. In addition to fines, a breach of the GDPR may result in regulatory investigations, reputational damage, orders to cease/ change Remix&#8217;s data processing
            activities, enforcement notices, assessment notices (for a compulsory audit) and/ or civil claims (including class actions). Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that
            have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA, and the United States remains uncertain. Case law from the
            Court of Justice of the European Union (CJEU) states that reliance on the standard contractual clauses a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism alone may not necessarily be
            sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On July&#160;10, 2023, the European Commission adopted its Adequacy Decision in relation to the new EU-US Data Privacy Framework (DPF), rendering the DPF
            effective as a GDPR transfer mechanism to U.S.&#160;entities self-certified under the DPF.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In relation to such cross border transfers of personal data, Remix expects the
            existing legal complexity and uncertainty regarding international personal data transfers to continue, and international transfers to the United States, China, and to other jurisdictions more generally to continue to be subject to enhanced
            scrutiny by regulators. As the regulatory guidance and enforcement landscape in relation to data transfers continue to develop, Remix could suffer additional costs, complaints and/or regulatory investigations or fines; Remix may have to stop
            using certain tools and vendors and make other operational changes; Remix may have to implement alternative data transfer mechanisms under the GDPR and/or take additional compliance and operational measures; and/or it could otherwise affect the
            manner in which Remix operates its business, and could adversely affect its business, operations and financial condition. As Remix continues to expand into other foreign countries and jurisdictions, it may be subject to additional laws and
            regulations that may affect how it conducts business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Even though Remix believes it and its vendors are generally in compliance with
            applicable laws, rules and regulations relating to privacy and data security, these laws are in some cases relatively new and the interpretation and application of these laws are uncertain. Any failure or perceived failure by Remix to comply
            with data privacy laws, rules, regulations, industry standards and other requirements could result in proceedings or actions against it by individuals, government agencies, or others. It could incur significant costs in investigating and
            defending such claims and, if found liable, pay significant damages or fines or be required to make changes to its business. Further, these proceedings and any subsequent adverse outcomes may subject it to significant negative publicity and an
            erosion of trust. If any of these events were to occur, its business, results of operations, and financial condition could be materially adversely affected.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix&#8217;s business activities may be
            subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws and anti-money laundering laws, including laws of other countries in which Remix operates, as well as U.S. and certain foreign export
            controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit Remix&#8217;s ability to compete in foreign markets and subject Remix to liability if Remix violates them.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is subject to the FCPA, the U.S. domestic public corruption and commercial
            bribery statutes contained in 18&#160;U.S.C. &#167; 201, the U.S. Travel Act and possibly other anti-bribery and anti-corruption laws and anti-money laundering laws in countries outside of the United States in which where Remix conducts its activities. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">64<br/>
        </div>

      </div>

    </div>

    <!--End Page 74-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 75-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg43"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Anti-corruption and anti-bribery laws have been enforced aggressively in
            recent years and are interpreted broadly to generally prohibit companies, their employees, agents, representatives, business partners, and third-party intermediaries from authorizing, offering, or providing, directly or indirectly, improper
            payments or benefits to recipients in the public or private sector.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may leverage third parties to sell its products and conduct its business
            abroad. Remix and its employees, agents, representatives, business partners and third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned or affiliated entities and
            may be held liable for the corrupt or other illegal activities of these employees, agents, representatives, business partners or third-party intermediaries even if Remix does not explicitly authorize such activities. Remix&#8217;s business activities
            may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which Remix operates. The FCPA generally prohibits companies and their employees and third-party intermediaries from
            offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires
            public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Remix&#8217;s business is heavily regulated and
            therefore may involve significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, hospitals are owned and operated by the government, and doctors and other hospital
            employees would be considered foreign officials under the FCPA. Recently, the SEC and DOJ have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There can be no assurance that all of Remix&#8217;s
            employees, agents, representatives, business partners or third-party intermediaries will not take actions in violation of applicable law for which Remix may be ultimately held responsible. As Remix commercializes its product candidates and
            increases its international sales and business, its risks under these laws may increase. There is no certainty that all of Remix&#8217;s employees, agents or contractors, or those of its affiliates, will comply with all applicable laws and
            regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against Remix, its officers or its employees, disgorgement, and other sanctions and
            remedial measures, and prohibitions on the conduct of its business. Any such violations could include prohibitions on Remix&#8217;s ability to offer its products in one or more countries and could materially damage its reputation, its brand, its
            international activities, its ability to attract and retain employees and its business, prospects, operating results and financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These laws also require that Remix keep accurate books and records and maintain
            internal controls and compliance procedures designed to prevent any such actions. While Remix has policies and procedures to address compliance with such laws, there can be no assurance that none of its employees, agents, representatives,
            business partners or third-party intermediaries will take actions in violation of its policies and applicable law, for which Remix may be ultimately held responsible.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any allegations or violation of the FCPA or other applicable anti-bribery and
            anti-corruption laws and anti-money laundering laws could result in whistleblower complaints, sanctions, settlements, prosecution, enforcement actions, fines, damages, adverse media coverage, investigations, loss of export privileges, severe
            criminal or civil sanctions, or suspension or debarment from government contracts, all of which may have an adverse effect on Remix&#8217;s reputation, business, results of operations, and prospects. Responding to any investigation or action will
            likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense costs and other professional fees.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix&#8217;s products may be subject to U.S. and foreign export controls,
            trade sanctions and import laws and regulations. Governmental regulation of the import or export of Remix&#8217;s products, or its failure to obtain any required import or export authorization for its products, when applicable, could harm Remix&#8217;s
            international or domestic sales and adversely affect its revenue. Compliance with applicable regulatory requirements regarding the export of Remix&#8217;s products may create delays in the introduction of its products in international markets or, in
            some cases, prevent the export of its products to some countries altogether. Furthermore, United States export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons
            targeted by United States sanctions. If Remix fails to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or
            import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or products targeted by such regulations, could result in </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">65<br/>
        </div>

      </div>

    </div>

    <!--End Page 75-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 76-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg44"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">decreased use of Remix&#8217;s products by, or in its decreased ability to export
            its products to, existing or potential customers with international operations. Any decreased use of Remix&#8217;s products or limitation on its ability to export or sell its products would likely adversely affect its business.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix fails to comply with
            environmental, health and safety laws and regulations, Remix could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of Remix&#8217;s business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is subject to numerous environmental, health and safety laws and
            regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s operations involve the use of hazardous and flammable materials,
            including chemicals and biological and radioactive materials. Remix&#8217;s operations also produce hazardous waste products. Remix generally contracts with third parties for the disposal of these materials and wastes. Remix cannot eliminate the risk
            of contamination or injury from these materials. In the event of contamination or injury resulting from its use of hazardous materials, Remix could be held liable for any resulting damages, and any liability could exceed its resources. Remix
            also could incur significant costs associated with civil or criminal fines and penalties.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Although Remix maintains workers&#8217; compensation insurance to cover it for costs
            and expenses it may incur due to injuries to its employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Remix does not maintain insurance for environmental
            liability or toxic tort claims that may be asserted against it in connection with its storage or disposal of biological, hazardous or radioactive materials. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Any legal proceedings or claims against
            Remix could be costly and time-consuming to defend and could harm Remix&#8217;s reputation regardless of the outcome. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may in the future become subject to legal proceedings and claims that arise
            in the ordinary course of business, including intellectual property, product liability, employment, class action, whistleblower and other litigation claims, and governmental and other regulatory investigations and proceedings. For example,
            Remix was involved in a legal proceeding in connection with the Merger, which was voluntarily dismissed by the plaintiff on January&#160;19, 2023. Such matters can be time-consuming, divert management&#8217;s attention and resources, cause Remix to incur
            significant expenses or liability, or require it to change its business practices. In addition, the expense of litigation and the timing of this expense from period to period are difficult to estimate, subject to change, and could adversely
            affect Remix&#8217;s financial condition and results of operations. Because of the potential risks, expenses, and uncertainties of litigation, Remix may, from time to time, settle disputes, even where it has meritorious claims or defenses, by
            agreeing to settlement agreements. Any of the foregoing could adversely affect its business, financial condition, and results of operations. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Risks Related to Employee Matters, Managing Remix&#8217;s Growth and
            Other Risks Related to Remix&#8217;s Business </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s success is highly dependent on its
            ability to attract, hire and retain highly skilled executive officers and employees. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix currently has a small team focused on research and development of small
            oncology therapies. Remix&#8217;s ability to discover and develop any product candidates is dependent on its chemists. To succeed, Remix must recruit, hire, retain, manage and motivate qualified clinical, scientific, technical and management
            personnel, and Remix faces significant competition for experienced personnel. Remix is highly dependent on the principal members of its management and scientific and medical staff, particularly Peter Smith, its President, Chief Executive
            Officer and director and Dominic Reynolds, its Chief Scientific Officer. If Remix does not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect Remix&#8217;s ability to execute its
            business plan and harm its operating results. In particular, the loss of one or more of its executive officers could be detrimental to Remix if it cannot recruit suitable replacements in a timely manner. Remix does not maintain &#8220;Key Person&#8221;
            insurance for any of its executives or other employees. Remix could in the future have difficulty attracting and retaining experienced personnel and may be required to expend significant financial resources in its employee recruitment and
            retention efforts.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Many of the other biotechnology companies that Remix competes against for
            qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than Remix does. They also may provide higher compensation, more diverse opportunities and better prospects for career
            advancement. Some of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">66<br/>
        </div>

      </div>

    </div>

    <!--End Page 76-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 77-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg45"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">these characteristics may be more appealing to high-quality candidates than
            what Remix has to offer. If Remix is unable to continue to attract and retain high-quality personnel, the rate and success at which it can discover, develop and commercialize its product candidates will be limited and the potential for
            successfully growing Remix&#8217;s business will be harmed.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s scientific and clinical advisors and consultants typically will not enter
            into non-compete agreements with us. If a conflict of interest arises between their work for Remix and their work for another entity, Remix may lose their services. Furthermore, Remix&#8217;s advisors may have arrangements with other companies to
            assist those companies in developing products or technologies that may compete with Remix. In particular, if Remix is unable to maintain consulting or employment relationships with its scientific founders and other scientific and clinical
            advisors and consultants, or if they provide services to Remix&#8217;s competitors, Remix&#8217;s development and commercialization efforts will be impaired and its business will be significantly harmed.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix&#8217;s reliance on a limited number of
            employees who provide various administrative, research and development, and other services across Remix&#8217;s organization presents operational challenges that may adversely affect Remix&#8217;s business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of June 23, 2026, Remix had 37 full-time employees. Of these employees, 29
            were engaged in research or product development and clinical activities. The small size of Remix&#8217;s centralized team may limit its ability to devote adequate personnel, time, and resources to support its operations or research and development
            activities, and the management of financial, accounting, and reporting matters. If Remix&#8217;s team fails to provide adequate administrative, research and development, or other services across Remix&#8217;s organization, its business, financial
            condition, and results of operations could be harmed. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix will need to grow the size and
            capabilities of its organization, and Remix may experience difficulties in managing this growth. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In order to successfully implement Remix&#8217;s development and commercialization
            plans and strategies, it expects to need significant additional managerial, operational, sales, marketing, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">identifying, recruiting, integrating, maintaining, retaining and motivating Remix&#8217;s current and additional employees; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">managing Remix&#8217;s internal development efforts effectively, including the preclinical, clinical, FDA, EMA and other comparable
                    foreign regulatory agencies&#8217; review process for REM-422, while complying with any contractual obligations to contractors and other third parties; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">managing increasing operational and managerial complexity; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">improving Remix&#8217;s operational, financial and management controls, reporting systems and procedures. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s future financial performance and its ability to successfully develop and,
            if approved, commercialize REM-422 and other research programs will depend, in part, on its ability to effectively manage any future growth, and its management may also have to divert a disproportionate amount of its attention away from
            day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix currently relies, and for the foreseeable future will continue to rely, in
            substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of research, clinical development and manufacturing. There can be no assurance that the services of independent
            organizations, advisors and consultants will continue to be available to Remix on a timely basis when needed, or that it can find qualified replacements. In addition, if Remix is unable to effectively manage its outsourced activities or if the
            quality or accuracy of the services provided by third-party service providers is compromised for any reason, its preclinical studies and clinical trials may be extended, delayed or terminated, and Remix may not be able to obtain regulatory
            approval for any of its product candidates or otherwise advance its business. There can be no assurance that Remix will be able to manage its existing third-party service providers or find other competent outside contractors and consultants on
            economically reasonable terms, or at all.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Remix is not able to effectively expand its organization by hiring new
            employees and/or engaging additional third-party service providers, Remix may not be able to successfully implement the tasks necessary to further develop and commercialize REM-422 and any other product candidates and, accordingly, may not
            achieve its research, development and commercialization goals. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">67<br/>
        </div>

      </div>

    </div>

    <!--End Page 77-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 78-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg46"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix&#8217;s business and operations may
            suffer in the event of information technology system failures, cyberattacks or deficiencies in its cybersecurity. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix collects and maintains information in digital form that is necessary to
            conduct its business, and Remix is increasingly dependent on information technology systems and infrastructure to operate its business. In the ordinary course of its business, Remix collects, stores and transmits confidential information,
            including intellectual property, proprietary business information, preclinical and clinical trial data, and personal information (collectively, Confidential Information). It is critical that Remix does so in a secure manner to maintain the
            confidentiality and integrity of such Confidential Information.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s information technology systems and those of Remix&#8217;s third-party service
            providers, strategic partners and other contractors or consultants are vulnerable to attack, damage and interruption from computer viruses and malware (<span style="font-style: italic;">e.g.</span>, ransomware), misconfigurations, &#8220;bugs&#8221; or
            other vulnerabilities, malicious code, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, cyberattacks, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud,
            denial or degradation of service attacks and sophisticated nation-state and nation-state-supported actors. Remix has also outsourced elements of its information technology infrastructure, and as a result a number of third-party vendors may or
            could have access to Remix&#8217;s confidential information.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The risk of a security breach or disruption, particularly through cyberattacks or
            cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased and evolved.
            If Remix or Remix&#8217;s third-party vendors were to experience a significant cybersecurity breach of Remix&#8217;s or their information systems or data, the costs associated with the investigation, remediation and potential notification of the breach to
            counterparties and data subjects could be material. In addition, Remix&#8217;s remediation efforts may not be successful. If Remix does not allocate and effectively manage the resources necessary to build and sustain the proper technology and
            cybersecurity infrastructure, Remix could suffer significant business disruption, including data loss or the loss of or damage to intellectual property or other proprietary information. There can also be no assurance that Remix&#8217;s and Remix&#8217;s
            third-party service providers&#8217;, strategic partners&#8217;, contractors&#8217;, consultants&#8217;, CROs&#8217; and collaborators&#8217; cybersecurity risk management program and processes, including policies, controls or procedures, will be fully implemented, complied with
            or effective in protecting Remix&#8217;s systems, networks and Confidential Information.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix and certain of its service providers are from time to time subject to
            cyberattacks and security incidents. While Remix does not believe that it has experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in its operations, it could
            result in a material disruption of Remix&#8217;s development programs and its business operations, whether due to a loss, corruption or unauthorized disclosure of its trade secrets, personal information or other proprietary or sensitive information
            or other similar disruptions. For example, the loss of clinical trial data from completed or ongoing clinical trials for any of Remix&#8217;s therapeutic candidates could result in delays in its development and regulatory approval efforts and
            significantly increase its costs to recover or reproduce the data.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a security breach or other incident were to result in the unauthorized access
            to or unauthorized use, disclosure, release or other processing of personal information, it may be necessary to notify individuals, governmental authorities, supervisory bodies, and other parties pursuant to privacy and security laws. Any
            security compromise affecting us, Remix&#8217;s service providers, strategic partners, other contractors, consultants, or Remix&#8217;s industry, whether real or perceived, could harm Remix&#8217;s reputation, erode confidence in the effectiveness of its
            security measures and lead to regulatory scrutiny. To the extent that any disruption or security breach were to result in a loss of, or damage to, Remix&#8217;s data or systems, or inappropriate disclosure of confidential or proprietary or personal
            information, Remix could incur liability, including litigation exposure, penalties and fines, Remix could become the subject of regulatory action or investigation, its competitive position could be harmed and the further development and
            commercialization of its products and services could be delayed. If such an event were to occur and cause interruptions in Remix&#8217;s operations, it could result in a material disruption of Remix&#8217;s business. Furthermore, federal, state and
            international laws and regulations can expose Remix to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties, fines and significant legal liability, if its information technology
            security efforts fail. Any adverse impact to the availability, integrity or confidentiality of Remix&#8217;s or third-party systems or Confidential Information can result in legal claims or proceedings (such as class actions), regulatory
            investigations and enforcement actions, fines and penalties, negative reputational impacts that </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">68<br/>
        </div>

      </div>

    </div>

    <!--End Page 78-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 79-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg47"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">cause Remix to lose existing or future customers, and/or significant incident
            response, system restoration or remediation and future compliance costs. Remix may also be exposed to a risk of loss or litigation and potential liability, which could materially and adversely affect its business, results of operations or
            financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Attacks upon information technology systems are increasing in their frequency,
            levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized
            access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, Remix may be unable to anticipate these techniques or implement adequate preventative measures. Remix may also experience
            security breaches that may remain undetected for an extended period. Even if identified, Remix may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques &#8212; including
            artificial intelligence &#8212; that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s existing general liability and cyber liability insurance policies may not
            cover, or may cover only a portion of, any potential claims related to security breaches to which it is exposed or may not be adequate to indemnify it for all or any portion of liabilities that may be imposed. Remix also cannot be certain that
            its existing insurance coverage will continue to be available on acceptable terms or in amounts sufficient to cover the potentially significant losses that may result from a security incident or breach or that the insurer will not deny coverage
            of any future claim. Accordingly, if Remix&#8217;s cybersecurity measures, and those of its service providers, fail to protect against unauthorized access, attacks (which may include sophisticated cyberattacks) and the mishandling of data by Remix&#8217;s
            employees and third-party service providers, then its reputation, results of operations and financial condition could be adversely affected.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">If Remix is unable to establish sales
            or marketing capabilities or enter into agreements with third parties to sell or market Remix&#8217;s product candidates, Remix may not be able to successfully sell or market Remix&#8217;s product candidates that obtain regulatory approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix currently does not have and has never had a marketing or sales team. In
            order to commercialize any product candidates, if approved, Remix must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the
            territories in which Remix may have approval to sell or market its product candidates. Remix may not be successful in accomplishing these required tasks.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Establishing an internal sales or marketing team with technical expertise and
            supporting distribution capabilities to commercialize Remix&#8217;s product candidates will be expensive and time-consuming and will require significant attention of its executive officers to manage. Any failure or delay in the development of Remix&#8217;s
            internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of its product candidates that Remix obtains approval to market if Remix does not have arrangements in place with third parties to
            provide such services on its behalf. Alternatively, if Remix chooses to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment
            its own sales force and distribution systems or in lieu of its own sales force and distribution systems, Remix will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration and such
            arrangements may prove to be less profitable than commercializing the product on its own. If Remix is unable to enter into such arrangements when needed, on acceptable terms or at all, Remix may not be able to successfully commercialize any of
            its product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If Remix is unable to successfully commercialize its approved product candidates, either on its own or through
            collaborations with one or more third parties, Remix&#8217;s future product revenue will suffer, and it may incur significant additional losses. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">69<br/>
        </div>

      </div>

    </div>

    <!--End Page 79-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 80-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg48"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">A variety of risks associated with
            marketing Remix&#8217;s product candidates internationally could materially adversely affect Remix&#8217;s business. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may seek regulatory approval of its product candidates outside of the
            United States and, accordingly, Remix expects that it will be subject to additional risks related to operating in foreign countries if it obtains the necessary approvals, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">differing regulatory requirements and reimbursement regimes in foreign countries, such as the lack of pathways for accelerated
                    drug approval, may result in foreign regulatory approvals taking longer and being more costly than obtaining approval in the United States; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">foreign regulatory authorities may disagree with the design, implementation or results of Remix&#8217;s clinical trials or its
                    interpretation of data from nonclinical studies or clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval policies or regulations of foreign regulatory authorities may significantly change in a manner rendering Remix&#8217;s
                    clinical data insufficient for approval; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">impact of the COVID-19 virus or future pandemic and epidemic on Remix&#8217;s ability to produce its product candidates and conduct
                    clinical trials in foreign countries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">economic weakness, including inflation, or political instability in particular foreign economies and markets; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with legal requirements applicable to privacy, data protection, information security and other matters; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">foreign taxes, including withholding of payroll taxes; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations
                    incident to doing business in another country; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">difficulties staffing and managing foreign operations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">complexities associated with managing multiple payor reimbursement regimes and government payors in foreign countries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">workforce uncertainty in countries where labor unrest is more common than in the United States; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential liability under the FCPA or comparable foreign regulations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">challenges enforcing Remix&#8217;s contractual and intellectual property rights, especially in those foreign countries that do not
                    respect and protect intellectual property rights to the same extent as the United States; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">business interruptions resulting from geo-political actions, including war and terrorism, trade policies, treaties and tariffs.
                  </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These and other risks associated with international operations may materially
            adversely affect Remix&#8217;s ability to attain or maintain profitable operations. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Risks Related to Remix&#8217;s Intellectual Property Rights </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s success depends on its ability to
            protect its intellectual property rights and its proprietary technologies. If Remix is unable to obtain, maintain, defend and enforce patent or other intellectual property protection for its product candidates or technology, or if the scope of
            the patent or other intellectual property protection obtained is not sufficiently broad, its competitors or other third parties could develop and commercialize products similar or identical to Remix&#8217;s, and its ability to successfully
            commercialize its product candidates may be adversely affected. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix relies, and may in the future rely, upon a combination of patent, trade
            secret and trademark protection for its product candidates and proprietary technologies to prevent third parties from exploiting its achievements, thus </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">70<br/>
        </div>

      </div>

    </div>

    <!--End Page 80-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 81-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg49"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">eroding its competitive position in its market. These legal measures afford
            only limited protection, and competitors or others may gain access to or use Remix&#8217;s intellectual property and proprietary information. Remix&#8217;s success depends in large part on its ability to obtain, maintain, expand, enforce, and defend the
            scope, ownership or control, validity and enforceability of its intellectual property protection in the United States and other countries with respect to its product candidates and other proprietary technologies it may develop. Remix generally
            seeks, and may in the future seek, to protect its proprietary position, in part, by filing patent applications in the United States and abroad relating to its product candidates and technology, manufacturing processes and methods of use. Remix
            may also seek to protect its proprietary position by acquiring or in-licensing relevant issued patents or pending patent applications from third parties. If Remix is unable to obtain, maintain, expand, enforce and defend the scope, ownership or
            control, validity and enforceability of its intellectual property protection, its business, financial condition, results of operations and prospects could be materially harmed. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Changes in either the patent laws or their interpretation in the United States
            and other jurisdictions may diminish Remix&#8217;s ability to protect its intellectual property, obtain, maintain, expand, enforce and defend its intellectual property rights and, more generally, could affect the value of its intellectual property or
            narrow the scope of its protection. Remix cannot predict whether the patent applications it currently or may in the future pursue or may in-license will issue as patents in any particular jurisdiction, whether the claims of any issued patents
            will provide sufficient protection against competitors or other third parties, or if these patents are challenged by its competitors, whether the patents will be found to be invalid, unenforceable, or not infringed or not owned or controlled by
            Remix. The patent prosecution process is expensive, time-consuming, and complex, and Remix may not be able to file, prosecute, maintain, enforce, defend or license all necessary or desirable patent applications or patents at a reasonable cost
            or in a timely manner or in all jurisdictions. It is also possible that Remix will fail to identify patentable aspects of its research and development output in time to obtain patent protection. Although Remix enters into non-disclosure and
            confidentiality agreements with parties who have access to confidential or patentable aspects of its research and development output, such as its employees, licensees, third-party collaborators, CROs, contract manufacturers, consultants,
            advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing Remix&#8217;s ability to seek patent protection. Consequently, Remix may not be able
            to prevent any third party from using any of its technology that is in the public domain to compete with its product candidates or technologies. In addition, Remix&#8217;s ability to obtain and maintain valid and enforceable patents depends on
            whether the differences between its inventions and the prior art allow its inventions to be patentable in light of the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and
            patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, Remix cannot be certain that it or its licensors were the first to invent the
            inventions claimed in any of its licensed patents or pending patent applications, or that Remix was the first to make the inventions claimed in those owned or licensed patents or pending patent applications, or that Remix or its licensors were
            the first to file for patent protection of such other inventions. If a third party can establish that Remix was not the first to make or the first to file for patent protection of such other inventions, its owned and licensed patents and patent
            applications may not issue as patents and even if issued, may be challenged and invalidated or rendered unenforceable. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The patent position of biopharmaceutical companies generally is highly uncertain,
            involves complex legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of Remix&#8217;s patent rights are highly uncertain. Its
            current and future patent applications may not result in patents being issued. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any issued patents may not afford sufficient protection of Remix&#8217;s product
            candidates or their intended uses against competitors, nor can there be any assurance that the issued patents will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive
            technologies, products or product candidates. Further, even if these patents are granted, they may be difficult to enforce. Obtaining and maintaining Remix&#8217;s patent protection depends on compliance with various procedural, document submission,
            information disclosure, fee payment and other requirements imposed by governmental patent agencies, and its patent protection could be reduced or eliminated if Remix fails to comply with these requirements. In the event Remix experiences
            noncompliance events that cannot be corrected and it loses its patent rights, competitors could enter the market, which would have a material adverse effect on its business. Further, any issued patents that Remix owns or may license in the
            future covering its product candidates could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or other countries, including the U.S. Patent and Trademark Office (USPTO).
            Grounds for a validity challenge could be an alleged failure to meet any of several </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">71<br/>
        </div>

      </div>

    </div>

    <!--End Page 81-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 82-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg50"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">statutory requirements, including lack of novelty, obviousness, written
            description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid
            for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
            withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Also, patent terms, including any extensions or adjustments that may or may not be available to Remix, may be inadequate to
            protect its competitive position on its product candidates for an adequate amount of time, and Remix may be subject to claims challenging the inventorship, ownership, validity, enforceability of its patents and/or other intellectual property.
            Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing Remix&#8217;s ability to protect its product candidates. Further, if Remix encounters delays in its development and testing of
            its product candidates, clinical trials or regulatory review and approval of its product candidates, the period of time during which it could market its product candidates under patent protection may be reduced, since any patents protecting
            such product candidates might expire before or shortly after such product candidates are commercialized. Thus, Remix&#8217;s patents may not provide it with sufficient rights to exclude others from commercializing products similar or identical to its
            own or afford it any meaningful competitive advantage. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Moreover, the claim coverage in a patent application can be significantly reduced
            before the corresponding patent is granted. Even if Remix&#8217;s owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide it with any meaningful protection, prevent competitors or other third parties
            from competing with it or otherwise provide it with any competitive advantage. Any patents issuing from Remix&#8217;s owned or in-licensed patent applications may be challenged, narrowed, circumvented or invalidated by third parties. Consequently,
            Remix does not know whether its product candidates and other proprietary technology will be protectable or remain protected by valid and enforceable patents. Even if a patent is granted, Remix&#8217;s competitors or other third parties may be able to
            circumvent the patent by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect its business, financial condition, results of operations and prospects. Furthermore, Remix&#8217;s
            competitors or other third parties may avail themselves of safe harbors under the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Amendments) to conduct research and clinical trials. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The issuance of a patent is not conclusive as to its inventorship, ownership,
            scope, validity, or enforceability and Remix&#8217;s owned or in-licensed patent rights may be challenged in the courts or patent offices in the United States and abroad. Remix may be subject to a post-grant proceeding at the USPTO challenging the
            validity of one or more claims of its patents or patents it may license in the future. Third-party submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on Remix&#8217;s pending patent application or
            patent application it may license in the future. A third party may also claim that Remix&#8217;s patent rights are invalid or unenforceable in a litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
            In addition, Remix may become involved in opposition, derivation, revocation, reexamination, reissue, interference proceedings or other similar proceedings in the United States and/or foreign jurisdictions challenging its patent rights. An
            adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, Remix&#8217;s patent rights, and may allow third parties, including generic drug companies, to commercialize its
            product candidates and other proprietary technologies it may develop and compete directly with Remix. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">It is also possible that defects of form in the preparation or filing of Remix&#8217;s
            patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form,
            preparation, prosecution, or enforcement of Remix&#8217;s patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair
            Remix&#8217;s ability to prevent competition from third parties, which may have an adverse impact on its business. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Moreover, in the future, some of Remix&#8217;s patent rights may be co-owned with third
            parties. In the United States, each co-owner has the freedom to license and exploit the technology. If Remix is unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patent rights, such co-owners may be able
            to license their rights to other third parties, including Remix&#8217;s competitors, and its competitors could market competing products </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">72<br/>
        </div>

      </div>

    </div>

    <!--End Page 82-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 83-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg51"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">and technology. In addition, Remix may need the cooperation of any such
            co-owners of such patent rights in order to enforce such patent rights against third parties, and such cooperation may not be provided to it. Any of the foregoing could have a material adverse effect on Remix&#8217;s competitive position, business,
            financial condition, results of operations and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix&#8217;s commercial success depends
            significantly on its ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that Remix infringes their proprietary rights may result in liability for damages or prevent or delay
            its developmental and commercialization efforts.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s commercial success depends in part on its ability to avoid infringing,
            misappropriating and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation involving patents and other intellectual property rights in the biotechnology and
            pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign
            jurisdictions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Numerous U.S. and foreign-issued patents and pending patent applications owned by
            third parties exist in the fields in which Remix plans to commercialize its programs and in which it is developing other proprietary technologies. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as
            Remix gains greater visibility and market exposure as a public company, the risk increases that its therapeutic programs and commercializing activities may give rise to claims of infringement of the patent rights of others. Remix cannot
            guarantee that its therapeutic programs and other proprietary technologies it develops will not infringe existing or future patents owned by third parties. Remix may not be aware of patents that have already been issued for which a third party,
            such as a competitor in the fields in which it is developing its therapeutic programs, might assert as infringed by Remix. It is also possible that patents owned by third parties of which Remix is aware, but which it does not believe it
            infringes or that it believes it has valid defenses to any claims of patent infringement, could be found to be infringed by Remix. It is not unusual that corresponding patents issued in different countries have different scopes of coverage,
            such that in one country a third-party patent does not pose a material risk, but in another country, the corresponding third-party patent may pose a material risk to Remix&#8217;s products or product candidates. In addition, because patent
            applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that Remix may infringe. For example, pending patent applications that have been published can, subject to
            certain limitations, be later amended in a manner that could cover Remix&#8217;s product candidates or the use any such product candidates. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event that any third-party claims that Remix infringes their patents or
            that Remix is otherwise employing their proprietary technology without authorization and initiates litigation against it, even if Remix believes such claims are without merit, a court could hold that such patents are valid, enforceable and
            infringed by Remix. Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from Remix&#8217;s business, and may impact
            its reputation. In the event of a successful claim of infringement against Remix, it may be enjoined from further developing or commercializing the infringing products or technologies. In addition, Remix may be required to pay substantial
            damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign its infringing products or technologies, which may be impossible or require
            substantial time and monetary expenditure. Such licenses may not be available on commercially reasonable terms or at all. Even if Remix is able to obtain a license, the license would likely obligate it to pay license fees or royalties or both,
            and the rights granted to it might be nonexclusive, which could result in its competitors gaining access to the same intellectual property. If Remix is unable to obtain a necessary license to a third-party patent on commercially reasonable
            terms or at all, it may be unable to commercialize the infringing products or technologies or such commercialization efforts may be significantly delayed, which could in turn significantly harm its business. In addition, Remix may in the future
            pursue patent challenges with respect to third-party patents, including as a defense against the foregoing infringement claims. The outcome of such challenges is unpredictable. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Even if resolved in Remix&#8217;s favor, the foregoing proceedings could be very
            expensive, particularly for a company of Remix&#8217;s size, and time-consuming. Such proceedings could substantially increase its operating losses and reduce the resources available for development activities or any future sales, marketing or
            distribution activities. Remix may not have sufficient financial or other resources to conduct such proceedings adequately. Some of its competitors may be able to sustain the costs of litigation or administrative proceedings more effectively
            than Remix can because of greater financial resources. Such proceedings may also absorb significant time of Remix&#8217;s technical and </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">73<br/>
        </div>

      </div>

    </div>

    <!--End Page 83-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 84-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg52"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">management personnel and distract them from their normal responsibilities.
            Uncertainties resulting from such proceedings could impair Remix&#8217;s ability to compete in the marketplace. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if
            securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of Remix&#8217;s common stock. The occurrence of any of the foregoing could have a material adverse effect on Remix&#8217;s
            business, financial condition, results of operations and prospects.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may in the future pursue invalidity proceedings with respect to third-party
            patents. The outcome following legal assertions of invalidity is unpredictable. Even if resolved in Remix&#8217;s favor, these legal proceedings may cause it to incur significant expenses, and could distract its technical and management personnel
            from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative,
            it could have a substantial adverse effect on the price of Remix&#8217;s common stock. Such proceedings could substantially increase its operating losses and reduce the resources available for development activities or any future sales, marketing or
            distribution activities. Remix may not have sufficient financial or other resources to conduct such proceedings adequately. Some of these third parties may be able to sustain the costs of such proceedings more effectively than Remix can because
            of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent proceedings could compromise Remix&#8217;s ability to compete in the marketplace. If Remix does not prevail in the patent proceedings the
            third parties may assert a claim of patent infringement directed at its product candidates.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix may be involved in lawsuits to
            protect or enforce its patents or its future licensors&#8217; patents, which could be expensive, time consuming and unsuccessful. Further, its issued patents or its future licensors&#8217; patents could be found invalid or unenforceable if challenged in
            court or before administrative bodies in the United States or abroad.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s patent rights may be subject to priority, validity, inventorship,
            ownership and enforceability disputes. Legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and likely to divert significant resources from Remix&#8217;s core
            business, including distracting its management and scientific personnel from their normal responsibilities and generally harm its business. If Remix or its licensors are unsuccessful in any of these proceedings, such patents and patent
            applications may be narrowed, invalidated or held unenforceable. Any of the foregoing could have a material adverse effect on Remix&#8217;s business, financial condition, results of operations and prospects. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Remix initiates legal proceedings against a third party to enforce a patent
            covering its product candidates, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds
            for a validity challenge could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement, lack of sufficient written description, failure to claim patent-eligible subject
            matter or obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading or
            inconsistent statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of a patent before administrative bodies in the United States or abroad, even outside the context of litigation. Such
            mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in
            the revocation of, cancellation of, shortening the term of or amendment to Remix&#8217;s owned or in-licensed patent rights or any patent rights it may obtain or license in the future in such a way that they no longer cover its product candidates or
            prevent third parties from competing with its product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, Remix cannot be certain that there
            is no invalidating prior art, of which it or its licensing partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, Remix would lose at least
            part, and perhaps all, of the patent protection for its product candidates. Such a loss of patent protection would have a material adverse impact on Remix&#8217;s business, financial condition, results of operations and prospects. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, if the breadth or strength of protection provided by Remix&#8217;s patents
            and patent applications or the patents and patent applications of its future licensors is threatened, it could dissuade companies from collaborating with Remix to license, develop or commercialize current or future product candidates. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">74<br/>
        </div>

      </div>

    </div>

    <!--End Page 84-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 85-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg53"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Furthermore, because of the substantial amount of discovery required in
            connection with intellectual property litigation or other legal proceedings relating to Remix&#8217;s intellectual property rights, there is a risk that some of its confidential information could be compromised by disclosure during this type of
            litigation or other proceedings. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Finally, the issuance of a patent does not give Remix the right to practice the
            patented invention. Third parties may have blocking patents that could prevent Remix from marketing its own patented product and practicing its own patented technology. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Intellectual property litigation may
            lead to unfavorable publicity that harms Remix&#8217;s reputation and causes the market price of its common shares to decline. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the course of any intellectual property litigation, there could be public
            announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings or developments in the litigation. If securities analysts or investors regard these announcements as negative,
            the perceived value of Remix&#8217;s existing product candidates, approved products, programs or intellectual property could be diminished. Accordingly, the market price of shares of Remix&#8217;s common stock may decline. Such announcements could also
            harm Remix&#8217;s reputation or the market for its future products, which could have a material adverse effect on its business.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix may not identify relevant
            third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect its ability to develop and market its products and product candidates.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix cannot guarantee that any of its or its licensors&#8217; patent searches or
            analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are or will be complete or thorough, nor can Remix be certain that it or its licensors have identified or will
            identify each and every third-party patent and pending patent application in the United States and abroad that is relevant to or necessary for the commercialization of its current and future products and product candidates in any jurisdiction.
            Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date.
            Therefore, patent applications covering Remix&#8217;s product candidates could have been filed by others without its knowledge. The scope of a patent claim is determined by the interpretation of the law, the words of a patent claim, the written
            disclosure in a patent and the patent&#8217;s prosecution history. Remix&#8217;s interpretation of the relevance or the scope of a patent or a pending patent application may be incorrect, which may negatively impact its ability to market its products.
            Remix may incorrectly determine that its products or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope.
            Alternatively, Remix may incorrectly determine that the Hatch-Waxman Amendments are a defense for a safe harbor to infringement of a patent it considers relevant to the research or clinical development of its product candidates. Remix&#8217;s
            determination of the expiration date of any patent in the United States or abroad that it considers relevant may be incorrect, and Remix may incorrectly conclude that a third-party patent is invalid and unenforceable or not infringed. Remix&#8217;s
            failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products and product candidates. If Remix fails to identify and correctly interpret relevant patents, it may be subject to
            infringement claims. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that Remix infringes. As the number
            of competitors in the market grows and the number of patents issued in this area increases, the possibility of patent infringement claims escalates. Moreover, in recent years, individuals and groups that are non-practicing entities, commonly
            referred to as &#8220;patent trolls,&#8221; have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, Remix may receive threatening letters, notices or
            &#8220;invitations to license,&#8221; or may be the subject of claims that its products and business operations infringe or violate the intellectual property rights of others. Remix cannot guarantee that it will be able to successfully settle or otherwise
            resolve such infringement claims. If Remix fails in any such dispute, in addition to being forced to pay damages, it may be temporarily or permanently prohibited from commercializing any of its product candidates that are held to be infringing.
            Remix might, if possible, also be forced to redesign product candidates or services so that it no longer infringes the third-party intellectual property rights. Any of these events, even if Remix were ultimately to prevail, could require it to
            divert substantial financial and management resources that it would otherwise be able to devote to its business.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">75<br/>
        </div>

      </div>

    </div>

    <!--End Page 85-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 86-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg54"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Changes in United States patent law, or
            laws in other countries, could diminish the value of patents in general, thereby impairing Remix&#8217;s ability to protect its product candidates.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As is the case with other pharmaceutical companies, Remix&#8217;s success is heavily
            dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing pharmaceutical patents is
            costly, time consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of Remix&#8217;s intellectual property and may increase the
            uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Remix cannot predict the breadth of claims that may be allowed or enforced in its patents or in third-party patents. In
            addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to Remix. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Assuming that other requirements for patentability are met, prior to March&#160;2013,
            in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith America
            Invents Act (the America Invents Act) enacted in September&#160;2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent
            application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March&#160;2013, but before Remix or its
            licensors could therefore be awarded a patent covering an invention of Remix or its licensors even if Remix or its licensors had made the invention before it was made by such third party. This requires Remix to be cognizant of the time from
            invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, Remix cannot be certain that it or its licensors are the
            first to either (i) file any patent application related to its product candidates and other proprietary technologies it may develop or (ii) invent any of the inventions claimed in its patents or patent applications. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The America Invents Act also included a number of significant changes that affect
            the way patent applications filed after March&#160;2013 are prosecuted and also affect patent litigation. These include allowing third party protests and submission of prior art to the USPTO during patent prosecution and additional procedures to
            attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
            standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient
            to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate Remix&#8217;s owned or in-licensed patent claims or any patent claims it may license in the future
            that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the patent positions of companies in the development and
            commercialization of pharmaceuticals are particularly uncertain. Recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
            situations. For example, the U.S.&#160;Supreme Court held in Amgen v. Sanofi (2023) that a functionally claimed genus was invalid for failing to comply with the enablement requirement of the Patent Act. As such, Remix&#8217;s patent rights with functional
            claims may be vulnerable to third party challenges seeking to invalidate these claims for lacking enablement or adequate support in the specification. In addition to increasing uncertainty with regard to Remix&#8217;s ability to obtain patents in the
            future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the United States federal courts, the USPTO, or similar authorities in foreign
            jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken Remix&#8217;s ability to obtain new patents or to enforce its existing patent and the patents it might obtain or license in the future.
            Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken
            Remix&#8217;s ability to obtain new patents or to enforce patents that it has or may obtain or license in the future. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For example, on June&#160;1, 2023, the European Union Patent Package (EU Patent
            Package) regulations were implemented with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (UPC) for litigation involving European patents. As a result, all European patents, including those
            issued prior </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">76<br/>
        </div>

      </div>

    </div>

    <!--End Page 86-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 87-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg55"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to ratification of the EU Patent Package, now by default automatically fall
            under the jurisdiction of the UPC, unless otherwise opted out. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries. Remix&#8217;s European patent applications, if issued, could be
            challenged in the UPC. During the first seven years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. Remix may decide to opt out its future European patents from
            the UPC, but doing so may preclude it from realizing the benefits of the UPC. Moreover, if Remix does not meet all of the formalities and requirements for opt-out under the UPC, its future European patents could remain under the jurisdiction of
            the UPC. The UPC will provide Remix&#8217;s competitors with a new forum to centrally revoke its European patents, and allow for the possibility of a competitor to obtain pan-European injunction. Such a loss of patent protection could have a material
            adverse impact on Remix&#8217;s business and its ability to commercialize its technology and its product candidates due to increased competition and, resultantly, on its business, financial condition, results of operations and prospects. The UPC and
            Unitary Patent are significant changes in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation in the UPC. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix may be subject to claims
            challenging the inventorship or ownership of its patents and other intellectual property. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may also be subject to claims that former employees or other third parties
            have an ownership interest in its patents or other intellectual property. Remix may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing its
            product candidates. Although it is Remix&#8217;s policy to require its employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to Remix, Remix
            may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that Remix regards as its own, and Remix cannot be certain that its agreements with such parties will be upheld in the
            face of a potential challenge, or that they will not be breached, for which Remix may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and
            litigation may be necessary to defend against these and other claims challenging inventorship or ownership. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If Remix fails in defending
            any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on its business. Even if Remix is successful in defending against such claims,
            litigation could result in substantial costs and distraction to management and other employees. Any of the foregoing could have a material adverse effect on Remix&#8217;s business, financial condition, results of operations and prospects.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The USPTO has taken the position that inventors and joint inventors named on U.S.
            patents and patent applications must be natural persons, and that, for AI-assisted inventions, patent protection may be available only where one or more natural persons made a legally sufficient contribution to the claimed invention. The
            USPTO&#8217;s guidance requires the inventorship analysis to focus on human contributions to the conception of the claimed invention, and not merely on the use, operation or ownership of an AI system. As a result, if an AI system materially
            contributes to the conception of an invention and no natural person can be shown to have made the required contribution to one or more claims, we may be unable to obtain patent protection for those claims, or any patents that issue could be
            challenged as invalid or unenforceable. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Patent terms may be inadequate to
            protect Remix&#8217;s competitive position on its product candidates for an adequate amount of time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Patents have a limited lifespan. In the United States, if all maintenance fees
            are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.
            Even if patents covering Remix&#8217;s product candidates are obtained, once the patent life has expired, Remix may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review
            of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, Remix&#8217;s patent portfolio may not provide it with sufficient rights to exclude others from
            commercializing products similar or identical to its own. If Remix does not have sufficient patent life to protect its products, its business, financial condition, results of operations and prospects will be adversely affected.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">77<br/>
        </div>

      </div>

    </div>

    <!--End Page 87-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 88-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg56"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">If Remix does not obtain patent term
            extension and equivalent extensions outside of the United States for its product candidates, its business may be materially harmed.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Depending upon the timing, duration and specifics of FDA marketing approval of
            Remix&#8217;s product candidates, one&#160;or more of its United States patents or those of its future licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman
            Act). The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved
            product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims
            covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of Remix&#8217;s product candidates.
            However, Remix may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover,
            the applicable time period or the scope of patent protection afforded could be less than Remix requests. If Remix is unable to obtain patent term extension or restoration or the term of any such extension is less than it requests, its
            competitors may obtain approval of competing products following its patent expiration, and its revenue could be reduced, possibly materially. Further, if this occurs, Remix&#8217;s competitors may take advantage of its investment in development and
            trials by referencing its clinical and preclinical data and launch their product earlier than might otherwise be the case. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Remix may not be able to protect its
            intellectual property rights throughout the world. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Although Remix has pending patent applications in the United States and will have
            pending patent applications in other countries in the future, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and its intellectual property rights in some countries outside the
            United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. For example,
            other countries may impose substantial restrictions on the scope of claims, including limiting patent protection to specifically disclosed embodiments. Consequently, Remix may not be able to prevent third parties from practicing its inventions
            in all countries outside the United States, or from selling or importing products made using its intellectual property in and into the United States or other jurisdictions. Consequently, Remix may not be able to prevent third parties from
            practicing its inventions in all countries outside the United States or from selling or importing products made using its inventions in and into the United States or other jurisdictions. Competitors may use Remix&#8217;s technologies in jurisdictions
            where it has not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where Remix has patent protection, but enforcement is not as strong as that in the United States.
            These products may compete with Remix&#8217;s product candidates, and its current patents, the patents of its future licensors, or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Many companies have encountered significant problems in protecting and defending
            intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for Remix to stop the
            infringement of its patents or its future licensors&#8217; patents or marketing of competing products in violation of its proprietary rights generally. In addition, some jurisdictions, such as Europe, Japan and China, may have a heightened standard
            for patentability than in the United States, including, for example, the requirement of claims having literal support in the original patent filing and the limitation on using supporting data that is not in the original patent filing. Under
            those heightened patentability requirements, Remix may not be able to obtain sufficient patent protection in certain jurisdictions even though the same or similar patent protection can be secured in the United States and other jurisdictions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Proceedings to enforce Remix&#8217;s patent rights in foreign jurisdictions could
            result in substantial costs and divert its efforts and attention from other aspects of its business, could put its patents or the patents of its future licensors at risk of being invalidated or interpreted narrowly and its patent applications
            or the patent applications of its future licensors at risk of not issuing and could provoke third parties to assert claims against Remix. Remix may not prevail in any lawsuits that it initiates, and the damages or other remedies awarded, if
            any, may not be commercially meaningful. Accordingly, Remix&#8217;s efforts to enforce its intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that it develops or
            licenses. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">78<br/>
        </div>

      </div>

    </div>

    <!--End Page 88-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 89-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg57"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Many countries have compulsory licensing laws under which a patent owner may
            be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could
            materially diminish the value of such patent. If Remix is forced to grant a license to third parties with respect to any patents relevant to its business, its competitive position may be impaired, and its business, financial condition, results
            of operations and prospects may be adversely affected. In addition, geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of Remix&#8217;s patent
            applications or those of any future licensors and the maintenance, enforcement or defense of its issued patents which could impair its competitive intellectual property position. For example, the United States and foreign government actions
            related to Russia&#8217;s conflict in Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. In addition, a decree was adopted by the Russian government in March&#160;2022, allowing Russian companies and
            individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, Remix would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing
            products made using its inventions in and into Russia.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Obtaining and maintaining Remix&#8217;s patent
            protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and its patent protection could be reduced or eliminated for non-compliance with
            these requirements.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The USPTO and various non-U.S. government agencies require compliance with
            several procedural, documentary, fee payment and other similar provisions during the patent application process. In some circumstances, Remix is dependent on its licensors to take the necessary action to comply with these requirements with
            respect to its licensed intellectual property. For example, periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent
            agencies outside of the United States over the lifetime of Remix&#8217;s owned or licensed patents and applications. In certain circumstances, Remix may rely on its licensing partners to pay these fees due to the U.S. and non-U.S. patent agencies. In
            some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent
            application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a
            material adverse effect on Remix&#8217;s business, financial condition, results of operations and prospects.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The USPTO and various non-U.S. government agencies require compliance with
            certain foreign filing requirements during the patent application process. For example, in some countries, including the United States, China, India and some European countries, a foreign filing license is required before certain patent
            applications are filed. The foreign filing license requirements vary by country and depend on various factors, including where the inventive activity occurred, citizenship status of the inventors, the residency of the inventors and the
            invention owner, the place of business for the invention owner and the nature of the subject matter to be disclosed (e.g., items related to national security or national defense). In some, but not all cases, for example in China and India, a
            foreign filing license cannot be obtained retroactively in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment of a pending patent application or can be grounds for revoking or
            invalidating an issued patent, resulting in the loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the relevant markets with similar or identical products or technology, which
            could have a material adverse effect on Remix&#8217;s business, financial condition, results of operations and prospects. Remix may also be dependent on its licensors to take the necessary actions to comply with these requirements with respect to its
            licensed intellectual property. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Public health pandemics (such as the COVID-19 pandemic), geopolitical instability
            (war and terrorism), natural disasters, or similar events may impair Remix&#8217;s and its licensors&#8217; ability to comply with these procedural, document submission, fee payment, and other requirements imposed by government patent agencies, which may
            materially and adversely affect Remix&#8217;s ability to obtain or maintain patent protection for its product candidates.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix&#8217;s trademarks and trade names are
            not adequately protected, then it may not be able to build name recognition in its markets of interest and its business may be adversely affected.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix intends to use trademarks or trade names to brand its products. Its
            trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. Remix may not be able to protect its rights to these trademarks and trade names, which it needs to build
            name recognition among </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">79<br/>
        </div>

      </div>

    </div>

    <!--End Page 89-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 90-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg58"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">potential partners or customers in its markets of interest. During trademark
            registration proceedings, Remix may receive rejections of its applications by the USPTO or in other foreign jurisdictions. Although Remix is given an opportunity to respond to such rejections, it may be unable to overcome them. In the event
            that Remix&#8217;s trademarks are successfully challenged or determined to be infringing, misappropriating or violating other marks, it could be forced to rebrand its products, which could result in loss of brand recognition, and could require it to
            devote resources to advertising and marketing new brands. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel
            registered trademarks. Opposition or cancellation proceedings may be filed against Remix&#8217;s trademarks, which may not survive such proceedings. Moreover, any name Remix may propose to use with its product candidates in the United States must be
            approved by the FDA, regardless of whether it has registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of
            potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of Remix&#8217;s proposed proprietary product names, it may be required to expend significant additional
            resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe, misappropriate or otherwise violate the existing rights of third parties and be acceptable to the FDA. Furthermore,
            in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may not be able to obtain, protect or enforce its rights to these
            trademarks and trade names, which it needs to build name recognition among potential partners or customers in its markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to Remix&#8217;s, thereby
            impeding its ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, misappropriation, dilution or other claims brought by owners of other registered
            trademarks or trademarks that incorporate variations of Remix&#8217;s registered or unregistered trademarks or trade names. Over the long term, if Remix is unable to establish name recognition based on its trademarks and trade names, then it may not
            be able to compete effectively and its business may be adversely affected. Remix&#8217;s efforts to obtain, enforce or protect its proprietary rights related to trademarks, trade names, domain name, or other intellectual property may be ineffective
            and could result in substantial costs and diversion of resources and could adversely affect its business, financial condition, results of operations and prospects. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix is unable to protect the
            confidentiality of its trade secrets, its business and competitive position would be harmed. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition to seeking patent protection for its product candidates and
            proprietary technologies, Remix may rely on trade secret protection and confidentiality agreements to protect its unpatented know-how, technology, and other proprietary information and to maintain its competitive position. Remix seeks to
            protect these trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as its employees, licensees, third-party collaborators, CROs,
            contract manufacturers, consultants, advisors and other third parties. Remix also enters into confidentiality and invention or patent assignment agreements with its employees and consultants. Trade secrets and know-how can be difficult to
            protect. Remix cannot guarantee that it has entered into applicable agreements with each party that may have or have had access to its trade secrets or proprietary technology and processes. Despite these efforts, any of these parties may breach
            the agreements and disclose Remix&#8217;s proprietary information, including its trade secrets, and Remix may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures is difficult, and Remix does not
            know whether the steps it has taken to protect its proprietary technologies will be effective. Remix cannot guarantee that any potential trade secrets and other proprietary and confidential information will not be disclosed or that competitors
            will not otherwise gain access to trade secrets. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside
            and outside the United States are less willing or unwilling to protect trade secrets. If any of Remix&#8217;s trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, Remix would have no right to
            prevent them from using that technology or information to compete with it. Furthermore, others may independently discover similar trade secrets and proprietary information. Remix may also need to share its trade secrets and proprietary know-how
            with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or
            controlled by state actors. As a result, Remix may encounter significant problems in protecting and defending its intellectual property </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">80<br/>
        </div>

      </div>

    </div>

    <!--End Page 90-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 91-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg59"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">both in the United States and abroad. If any of Remix&#8217;s trade secrets were to
            be disclosed or misappropriated or if any such information were to be independently developed by a competitor or other third party, its competitive position would be materially and adversely harmed. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may be subject to claims that third parties have an ownership interest in
            its trade secrets. For example, Remix may have disputes arise from conflicting obligations of its employees, consultants or others who are involved in developing its product candidates. Litigation may be necessary to defend against these and
            other claims challenging ownership of Remix&#8217;s trade secrets. If Remix fails in defending any such claims, in addition to paying monetary damages, it may lose valuable trade secret rights, such as exclusive ownership of, or right to use, trade
            secrets that are important to its product candidates and other proprietary technologies it may develop. Such an outcome could have a material adverse effect on Remix&#8217;s business. Even if Remix is successful in defending against such claims,
            litigation could result in substantial costs and be a distraction to its management and other employees. Any of the foregoing could have a material adverse effect on Remix&#8217;s business, financial condition, results of operations and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix may be subject to claims that it
            or its employees, consultants or advisors have wrongfully used or disclosed alleged confidential information or trade secrets of their current or former employers or claims asserting ownership of what Remix regards as its own intellectual
            property.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Some of Remix&#8217;s employees, consultants and advisors are currently or were
            previously employed at universities or other biotechnology or pharmaceutical companies, including its competitors or potential competitors. Although Remix tries to ensure that its employees, consultants and advisors do not use the proprietary
            information or know-how of others in their work for Remix, Remix may be subject to claims that it or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such
            individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If Remix fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights or
            personnel. Even if Remix is successful in defending against such claims, litigation could result in substantial costs and be a distraction to its management. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, while it is Remix&#8217;s policy to require its employees and contractors
            who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to Remix, Remix may be unsuccessful in executing such an agreement with each party who, in fact, conceives
            or develops intellectual property that Remix regards as its own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and Remix may be forced to bring claims against third
            parties, or defend claims that they may bring against Remix, to determine the ownership of what Remix regards as its intellectual property. Such claims could have a material adverse effect on Remix&#8217;s business, financial condition, results of
            operations and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Because Remix&#8217;s development programs
            may in the future require the use of proprietary rights held by third parties, the growth of its business may depend in part on its ability to acquire, in-license, or use these third-party proprietary rights. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Because Remix&#8217;s development programs may in the future require the use of
            proprietary rights held by third parties, the growth of its business may depend in part on its ability to acquire, in-license, or use these third-party proprietary rights. Remix may be unable to acquire or in-license any compositions, methods
            of use, processes or other third-party intellectual property rights from third parties that it identifies as necessary for development and commercialization of its product candidates. The licensing and acquisition of third-party intellectual
            property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that Remix may consider attractive or necessary. These established companies
            may have a competitive advantage over Remix due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Remix to be a competitor may be unwilling to assign or
            license rights to it. Remix also may be unable to license or acquire third-party intellectual property rights on terms that would allow it to make an appropriate return on its investment or at all. If Remix is unable to successfully obtain
            rights to required third-party intellectual property rights or maintain the existing intellectual property rights it has, it may have to abandon development of the relevant program or product candidate, which could have a material adverse
            effect on its business, financial condition, results of operations, and prospects.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">81<br/>
        </div>

      </div>

    </div>

    <!--End Page 91-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 92-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg60"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix&#8217;s rights to develop and
            commercialize its technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to it by others.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may enter into license agreements in the future with others to advance its
            existing or future research or allow commercialization of its existing or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all
            territories in which Remix may wish to develop or commercialize its technology and products in the future. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, subject to the terms of any such license agreements, Remix may not
            have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that it licenses from third parties. In such an event, Remix cannot be certain that
            these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of its business. If Remix&#8217;s future licensors fail to prosecute, maintain, enforce, and
            defend such patents or patent applications, or lose rights to those patents or patent applications, the rights Remix has licensed may be reduced or eliminated, and its right to develop and commercialize any of its future product candidates that
            are subject of such licensed rights could be adversely affected. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s future licensors may rely on third-party consultants or collaborators or
            on funds from third parties such that Remix&#8217;s future licensors are not the sole and exclusive owners of the patents they in-license. If other third parties have ownership rights to Remix&#8217;s future in-licensed patents, they may be able to license
            such patents to Remix&#8217;s competitors, and its competitors could market competing products and technology. This could have a material adverse effect on Remix&#8217;s competitive position, business, financial conditions, results of operations, and
            prospects. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">It is possible that Remix may be unable to obtain licenses at a reasonable cost
            or on reasonable terms, if at all. Even if Remix is able to obtain a license, it may be non-exclusive, thereby giving its competitors access to the same technologies licensed to Remix. In that event, Remix may be required to expend significant
            time and resources to redesign its technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Remix is unable to
            do so, it may be unable to develop or commercialize the affected product candidates, which could harm its business, financial condition, results of operations, and prospects significantly. Remix cannot provide any assurances that third-party
            patents do not exist which might be enforced against its current technology, manufacturing methods, product candidates, or future methods or products resulting in either an injunction prohibiting its manufacture or future sales, or, with
            respect to its future sales, an obligation on its part to pay royalties and/or other forms of compensation to third parties, which could be significant.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix fails to comply with its
            obligations in the agreements under which it licenses intellectual property rights from third parties or otherwise experiences disruptions to its business relationships with its future licensors, it could lose license rights that are important
            to its business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Disputes may arise between Remix and its future licensors regarding intellectual
            property subject to a license agreement, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the scope of rights granted under the license agreement and other interpretation-related issues; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether and the extent to which Remix&#8217;s technology and processes infringe on intellectual property of the licensor that is not
                    subject to the licensing agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s right to sublicense patents and other rights to third parties under its license arrangements or collaborative
                    development relationships; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s diligence obligations with respect to the use of the l icensed technology in relation to its development and
                    commercialization of its product candidates and what activities satisfy those diligence obligations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s right to transfer or assign the license; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by
                    Remix&#8217;s future licensors and Remix and its partners; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The priority of invention of patented technology. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the agreements under which Remix licenses intellectual property or
            technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">82<br/>
        </div>

      </div>

    </div>

    <!--End Page 92-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 93-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg61"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">any contract interpretation disagreement that may arise could narrow what
            Remix believes to be the scope of its rights to the relevant intellectual property or technology, or increase what Remix believes to be its financial or other obligations under the relevant agreement, either of which could have a material
            adverse effect on its business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that Remix licenses in the future prevent or impair its ability to maintain its licensing arrangements
            on commercially acceptable terms, it may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on its business, financial conditions, results of operations, and
            prospects. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Despite Remix&#8217;s best efforts, its future licensors might conclude that Remix
            materially breached its license agreements and might therefore terminate the license agreements, thereby removing its ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are
            terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to Remix&#8217;s. This could have a material adverse effect on
            Remix&#8217;s competitive position, business, financial conditions, results of operations, and prospects. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">The patent protection and patent
            prosecution for some of Remix&#8217;s product candidates may be dependent on third parties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">While Remix normally seeks to obtain the right to control prosecution,
            maintenance and enforcement of the patents relating to its product candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to its product candidates are controlled by its future
            licensors or collaboration partners. If any of Remix&#8217;s future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of its business,
            including by payment of all applicable fees for patents covering its product candidates, Remix could lose its rights to the intellectual property or its exclusivity with respect to those rights, its ability to develop and commercialize those
            product candidates may be adversely affected and Remix may not be able to prevent competitors from making, using and selling competing products. In addition, even where Remix has the right to control patent prosecution of patents and patent
            applications it has licensed to and from third parties, Remix may still be adversely affected or prejudiced by actions or inactions of its licensees, its future licensors and their counsel that took place prior to the date upon which Remix
            assumed control over patent prosecution.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Intellectual property discovered
            through government funded programs may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for United States-based companies. Compliance with such regulations may limit Remix&#8217;s exclusive
            rights and limit its ability to contract with non-United States manufacturers.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Although Remix does not currently own issued patents or pending patent
            applications that have been generated through the use of United States government funding, it may acquire or license in the future intellectual property rights that have been generated through the use of United States government funding or
            grants. Pursuant to the Bayh-Dole Act of 1980, the United States government has certain rights in inventions developed with government funding. These United States government rights include a non-exclusive, non-transferable, irrevocable
            worldwide license to use inventions for any governmental purpose. In addition, the United States government has the right, under certain limited circumstances, to require Remix to grant exclusive, partially exclusive, or non-exclusive licenses
            to any of these inventions to a third party if it determines that: (1) adequate steps have not been taken to commercialize the invention; (2) government action is necessary to meet public health or safety needs; or (3)&#160;government action is
            necessary to meet requirements for public use under federal regulations, also referred to as march-in rights. If the United States government exercised its march-in rights in Remix&#8217;s future intellectual property rights that are generated
            through the use of United States government funding or grants, Remix could be forced to license or sublicense intellectual property developed by it or that it licenses on terms unfavorable to it, and there can be no assurance that Remix would
            receive compensation from the United States government for the exercise of such rights. The United States government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government
            or fails to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may
            require Remix to expend substantial resources. In addition, the United States government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the
            United States. This preference for United States industry may be waived by the federal agency that provided the funding if the owner or assignee of the intellectual </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">83<br/>
        </div>

      </div>

    </div>

    <!--End Page 93-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 94-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg62"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">property can show that reasonable but unsuccessful efforts have been made to
            grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States
            industry may limit Remix&#8217;s ability to contract with non-United States product manufacturers for products covered by such intellectual property. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Intellectual property rights do not
            necessarily address all potential threats to Remix&#8217;s competitive advantage. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The degree of future protection afforded by Remix&#8217;s intellectual property rights
            is uncertain because intellectual property rights have limitations and may not adequately protect its business or permit it to maintain its competitive advantage. For example: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may be able to develop products that are similar to Remix&#8217;s product candidates but that are not covered by the claims of
                    the patents that Remix owns or licenses; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix or its future licensors or collaborators might not have been the first to make the inventions covered by the issued
                    patents or patent application that Remix owns or licenses; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix or its future licensors or collaborators might not have been the first to file patent applications covering certain of its
                    inventions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">others may independently develop similar or alternative technologies or duplicate any of Remix&#8217;s technologies without infringing
                    its intellectual property rights; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">it is possible that the pending patent applications Remix owns or licenses will not lead to issued patents; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issued patents that Remix owns or licenses may be held invalid or unenforceable as a result of legal challenges by its
                    competitors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s competitors might conduct research and development activities in countries where it does not have patent rights and then
                    use the information learned from such activities to develop competitive products for sale in its major commercial markets; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may not develop additional proprietary technologies that are patentable; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix or its licensors may fail to meet obligations to the U.S. government with respect to any future in-licensed patents and
                    patent applications funded by U.S. government grants, leading to the loss of patent rights; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may not be able to generate sufficient data to support full patent applications that protect the entire breadth of
                    developments in one or more of its programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may not successfully commercialize the product candidates, if approved, before its relevant patents expire; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The patents of others or pending or future applications of others may have an adverse effect of Remix&#8217;s business; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently
                    file a patent covering such intellectual property.&#8195;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Should any of these events occur, it could significantly harm Remix&#8217;s business,
            results of operations and prospects. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Risks Related to Remix&#8217;s Dependence on Third Parties </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix relies on third parties to conduct
            preclinical studies and clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is dependent on third parties to conduct its clinical trials and
            preclinical studies. Specifically, Remix relies on, and will continue to rely on, medical institutions, clinical investigators, CROs and consultants to conduct preclinical studies and clinical trials, in each case in accordance with trial
            protocols and regulatory requirements. These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. Though Remix expects to carefully manage
            its relationships with such CROs, investigators and other third parties, there can be no assurance that Remix will not encounter challenges or </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">84<br/>
        </div>

      </div>

    </div>

    <!--End Page 94-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 95-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg63"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">delays in the future, or that these delays or challenges will not have a
            material adverse impact on its business, financial condition and prospects. Further, while Remix has and will have agreements governing the activities of its third-party contractors, Remix has limited influence over their actual performance.
            Nevertheless, Remix is responsible for ensuring that each of its clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards and requirements, and Remix&#8217;s reliance on its CROs and other
            third parties does not relieve it of its regulatory responsibilities.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix and its CROs are required to comply with Good Laboratory
            Practice (&#8220;<span style="font-style: italic; font-weight: bold;">GLP</span>&#8221;) and GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities, for Remix&#8217;s product candidates in
            clinical development. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If Remix or any of its CROs or trial sites fail to comply with applicable GLP, GCP or other
            requirements, the data generated in its clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require Remix to perform additional clinical trials before approving its marketing applications, if
            ever. Furthermore, Remix&#8217;s clinical trials must be conducted with materials manufactured in accordance with cGMP regulations. Failure to comply with these regulations may require Remix to repeat clinical trials, which would delay the regulatory
            approval process.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There is no guarantee that any of Remix&#8217;s CROs, investigators or other third
            parties will devote adequate time and resources to such trials or studies or perform as contractually required. If any of these third parties fails to meet expected deadlines, adhere to Remix&#8217;s clinical protocols or meet regulatory
            requirements, or otherwise perform in a substandard manner, Remix&#8217;s clinical trials may be extended, delayed or terminated. In addition, many of the third parties with whom Remix contracts may also have relationships with other commercial
            entities, including its competitors, for whom they may also be conducting clinical trials or other activities that could harm Remix&#8217;s competitive position.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, principal investigators for Remix&#8217;s clinical trials may be asked to
            serve as scientific advisors or consultants to Remix from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of
            interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial
            itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA Remix submits. Any such delay or rejection could prevent Remix from commercializing its product candidates.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix&#8217;s CROs have the right to terminate their agreements with Remix
            in the event of an uncured material breach and under other specified circumstances. If any of Remix&#8217;s relationships with these third parties terminate, it may not be able to enter into arrangements with alternative third parties on commercially
            reasonable terms or at all. Switching or adding additional CROs, investigators and other third parties involves additional cost and requires Remix&#8217;s management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO
            commences work. As a result, delays occur, which can materially impact Remix&#8217;s ability to meet its desired clinical development timelines. Though Remix works to carefully manage its relationships with its CROs, investigators and other third
            parties, there can be no assurance that it will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on its business, financial condition and prospects.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix contracts with third parties for
            the manufacture of its product candidates for preclinical studies and clinical trials and expects to do so ultimately for commercialization, and the loss of these third parties or their inability to supply Remix with sufficient quality and
            quantities of its product candidates or such quantities at an acceptable cost could delay, prevent or impair its development or commercialization efforts.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix does not currently have the infrastructure or internal capability to
            manufacture supplies of its product candidates for use in development and commercialization. Remix relies, and expects to continue to rely, on third-party manufacturers for the production of its product candidates for preclinical studies and
            clinical trials under the guidance of members of its organization. Any supply interruption in limited or sole sourced materials could materially harm Remix&#8217;s ability to manufacture its product candidates until a new source of supply, if any,
            could be identified and qualified. Remix may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. To date, Remix has obtained active pharmaceutical ingredients (API) and drug
            product for its product candidates from certain single-source contract manufacturing organizations (CMOs). Any performance failures by such CMOs could materially harm Remix&#8217;s business. Remix does not have long-term supply agreements, and it
            purchases its required drug product on a purchase order basis, which means that aside </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">85<br/>
        </div>

      </div>

    </div>

    <!--End Page 95-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 96-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg64"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">from any binding purchase orders it has from time to time, its supplier could
            cease supplying to Remix or change the terms on which it is willing to continue supplying to Remix at any time. If Remix were to experience an unexpected loss of supply of any of its product candidates for any reason, whether as a result of
            manufacturing, supply or storage issues or otherwise, it could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing preclinical studies or clinical trials.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix expects to continue to rely on third-party manufacturers for the commercial
            supply of any of its product candidates for which it obtains regulatory approval. Remix may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if Remix is able to
            establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the failure of the third party to manufacture Remix&#8217;s product candidates according to Remix&#8217;s schedule and specifications, or at
                    all, including if Remix&#8217;s third-party contractors give greater priority to the supply of other products over its product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between Remix and
                    them; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the reduction or termination of production or deliveries by suppliers, or the raising or prices or renegotiation of terms; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the termination or nonrenewal of arrangements or agreements by Remix&#8217;s third-party contractors at a time that is costly or
                    inconvenient for Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the breach by the third-party contractors of Remix&#8217;s agreements with them; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the failure of third-party contractors to comply with applicable regulatory requirements, including cGMPs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the breach by the third-party contractors of Remix&#8217;s agreements with them; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the failure of the third party to manufacture Remix&#8217;s product candidates according to its specifications; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo
                    not being properly identified; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies
                    not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the misappropriation of Remix&#8217;s proprietary information, including its trade secrets and know how. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix does not have complete control over all aspects of the manufacturing
            process of its contract manufacturing partners and is dependent on these contract manufacturing partners for compliance with cGMP regulations for manufacturing both APIs and finished drug products. To date, Remix has obtained API and drug
            product for its product candidates from single-source third party CMOs. Remix is in the process of developing its supply chain for each of its product candidates and intends to put in place framework agreements under which third-party CMOs will
            generally provide Remix with necessary quantities of API and drug product on a project-by-project basis based on its development needs. As Remix advances its product candidates through development, it will consider its lack of redundant supply
            for the API and drug product for each of its product candidates to protect against any potential supply disruptions. However, Remix may be unsuccessful in putting in place such framework agreements or protecting against potential supply
            disruptions.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Third-party manufacturers may not be able to comply with cGMP regulations or
            similar regulatory requirements outside of the United States. If Remix&#8217;s CMOs cannot successfully manufacture material that conforms to its specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities,
            they will not be able to secure and/or maintain approval for use of their manufacturing facilities in connection with Remix&#8217;s product candidates. In addition, Remix does not have control over the ability of its CMOs to maintain adequate quality
            control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of Remix&#8217;s product candidates or if it withdraws any such approval in the future,
            Remix will need to find alternative manufacturing facilities, and those new facilities would need to be inspected and approved by FDA or comparable regulatory authority prior to commencing manufacturing, which would significantly impact Remix&#8217;s
            ability to develop, obtain regulatory approval for or market its product candidates, if approved. Remix&#8217;s failure, or the failure of its third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on
            Remix, including fines, injunctions, civil penalties, delays, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">86<br/>
        </div>

      </div>

    </div>

    <!--End Page 96-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 97-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg65"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">suspension or withdrawal of approvals, license revocation, seizures or recalls
            of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Remix&#8217;s product candidates or drugs and harm its business and results of operations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, certain CMOs and CROs outside of the U.S. could become subject to
            U.S. legislation, sanctions, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement or supply of such material or have an adverse effect
            on our ability to secure significant commitments from governments to purchase our potential therapies. For example, the U.S. BIOSECURE Act, which was enacted in December 2025, prohibits federal agencies from procuring or using any biotechnology
            equipment or services from &#8220;biotechnology companies of concern&#8221;, or entering into, extending, or renewing any contracts with entities that use such biotechnology equipment or services from &#8220;biotechnology companies of concern&#8221;. Congress has
            interpreted a &#8220;biotechnology company of concern&#8221; as an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic
            information). While the U.S. BIOSECURE Act has a grandfathering period of five years for existing contracts, and has carveouts for manufacture of drugs for supply under Medicaid and Medicare Part B, subject to the Secretary of Veteran Affairs&#8217;
            discretion, the impact of the U.S. BIOSECURE Act on the biotechnology industry is uncertain. If the foreign CROs and CMOs we rely on in the future become subject to trade restrictions, sanctions, increased tariffs or other regulatory
            requirements by the U.S. government (including designation as a &#8220;biotechnology company of concern&#8221; under the U.S. BIOSECURE Act), or if the U.S. or other foreign governments take retaliatory actions due to recent or increased tensions between
            the U.S. and other countries, it may have the potential to severely restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain &#8220;biotechnology companies of
            concern&#8221; without losing the ability to contract with, or otherwise receive funding from, the U.S. government.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s current and anticipated future dependence upon others for the manufacture
            of its product candidates may adversely affect its future profit margins and its ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix&#8217;s third-party manufacturers use
            hazardous materials in a manner that causes injury or violates applicable law, Remix may be liable for damages. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s research and development activities involve the controlled use of
            potentially hazardous substances, including chemical materials, by its third-party manufacturers. Remix&#8217;s manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage,
            handling and disposal of medical and hazardous materials. Although Remix believes that its manufacturers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, it cannot completely
            eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, Remix may incur liability or local, city, state or federal authorities may curtail the use of these
            materials and interrupt its business operations. In the event of an accident, Remix could be held liable for damages or penalized with fines, and the liability could exceed its resources. Remix does not have any insurance for liabilities
            arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair Remix&#8217;s research, development and production efforts, which
            could harm its business, prospects, financial condition or results of operations.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix engages in future acquisitions
            or strategic partnerships, this may increase Remix&#8217;s capital requirements, dilute Remix&#8217;s stockholders, cause Remix to incur debt or assume contingent liabilities, and subject Remix to other risks.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From time to time, Remix evaluates various acquisition opportunities and
            strategic partnerships, including licensing or acquiring complementary products, product candidates, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks,
            including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">increased operating expenses and cash requirements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the assumption of additional indebtedness or contingent liabilities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuance of Remix&#8217;s equity securities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assimilation of operations, intellectual property, products and product candidates of an acquired company, including
                    difficulties associated with integrating new personnel; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">87<br/>
        </div>

      </div>

    </div>

    <!--End Page 97-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 98-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg66"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the diversion of Remix&#8217;s management&#8217;s attention from its existing programs and initiatives in pursuing such a strategic merger
                    or acquisition; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">retention of key employees, the loss of key personnel and uncertainties in Remix&#8217;s ability to maintain key business
                    relationships; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their
                    existing products, product candidates and regulatory approvals; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s inability to generate revenue from acquired technology and/or products sufficient to meet its objectives in undertaking
                    the acquisition or even to offset the associated acquisition and maintenance costs. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, if Remix undertakes acquisitions or pursues partnerships in the
            future, it may issue dilutive securities, assume or incur debt obligations, incur large onetime expenses and acquire intangible assets that could result in significant future amortization expense.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">If Remix decides to establish
            additional collaborations but is not able to establish those collaborations on commercially reasonable terms, Remix may have to alter its development and commercialization plans.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s drug development programs, and the potential commercialization of its
            product candidates will require substantial additional cash to fund expenses. Remix may seek to selectively form additional collaborations to expand its capabilities, potentially accelerate research and development activities and provide for
            commercialization activities by third parties. Remix may also seek strategic collaborations to develop combination therapy strategies for its portfolio products, and/or maximize portfolio value globally through selective co-development and/or
            commercialization collaborations. Any of these relationships may require Remix to incur non-recurring and other charges, increase its near-and long-term expenditures, issue securities that dilute its existing stockholders, or disrupt its
            management and business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix faces significant competition in seeking appropriate collaborators and the
            negotiation process is time-consuming and complex. Whether Remix reaches a definitive agreement for a collaboration depends, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the
            proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical studies or clinical trials, the likelihood of approval by the FDA or comparable foreign
            regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with
            respect to Remix&#8217;s ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to
            collaborate on and whether such collaboration could be more attractive than the one with Remix for its product candidate. Further, Remix may not be successful in its efforts to establish a collaboration or other alternative arrangements for
            product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, there have been a significant number of recent business combinations
            among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if Remix is successful in entering into a collaboration, the terms and conditions of that collaboration may restrict it from
            entering into future agreements on certain terms with potential collaborators.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If and when Remix seeks to enter into collaborations, it may not be able to
            negotiate collaborations on a timely basis, on acceptable terms, or at all. If Remix is unable to do so, it may have to curtail the development of a product candidate, reduce or delay its development program or one or more of its other research
            programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase its expenditures and undertake development or commercialization activities at its own expense. If Remix elects to increase its
            expenditures to fund development or commercialization activities on its own, it may need to obtain additional capital, which may not be available to Remix on acceptable terms or at all. If Remix does not have sufficient funds, it may not be
            able to further develop its product candidates or bring them to market and generate product revenue.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">88<br/>
        </div>

      </div>

    </div>

    <!--End Page 98-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 99-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg67"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix has entered a collaboration with
            Roche for the development and commercialization of product candidates. Remix may in the future enter additional collaborations. If those collaborations are not successful, Remix may not be able to capitalize on the market potential of these
            product candidates.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has entered into a collaboration with Roche and may enter into additional
            collaborations and licenses with other third parties in the future. For some programs, Remix also depends on, or may in the future depend on, third party collaborators to design and conduct its research development program. Remix will likely
            have limited control over the amount and timing of resources that its collaborators dedicate to the development or commercialization of its product candidates. Remix&#8217;s ability to generate revenue from these arrangements will depend on its
            collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving Remix&#8217;s product candidates would pose numerous risks to Remix, including the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations
                    and may not perform their obligations as expected; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may deemphasize or not pursue development and commercialization of Remix&#8217;s product candidates or may elect not to
                    continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a business combination or sale or disposition of a business unit or
                    development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or
                    abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
                    Remix&#8217;s product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Remix&#8217;s; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing
                    and distribution of Remix&#8217;s product relative to other products; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix may grant exclusive rights to its collaborators that would prevent it from collaborating with others; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may not properly obtain, maintain, defend or enforce Remix&#8217;s intellectual property rights or may use its
                    proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate its proprietary information and intellectual property or
                    expose Remix to potential litigation or other intellectual property related proceedings; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disputes may arise between the collaborators and Remix that result in the delay or termination of the research, development or
                    commercialization of Remix&#8217;s product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development
                    or commercialization of the applicable product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or
                    at all; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may not provide Remix with timely and accurate information regarding development progress and activities under the
                    collaboration or may limit Remix&#8217;s ability to share such information, which could adversely impact its ability to report progress to its investors and otherwise plan its own development of its product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">collaborators may own or co-own intellectual property covering Remix&#8217;s products or product candidates that result from Remix
                    collaborating with them, and in such cases, Remix would not have the exclusive right to develop or commercialize such intellectual property; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in
                    civil or criminal proceedings. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">89<br/>
        </div>

      </div>

    </div>

    <!--End Page 99-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 100-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg68"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks Related to Remix&#8217;s Common Stock </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s operating results may fluctuate
            significantly, which makes its future operating results difficult to predict and could cause Remix&#8217;s operating results to fall below expectations or its guidance.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s quarterly and annual operating results may fluctuate significantly in the
            future, which makes it difficult for Remix to predict its future operating results. From time to time, Remix may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and
            significant upfront and milestone payments and/or royalties, which may become an important source of Remix&#8217;s revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a
            significant fluctuation in Remix&#8217;s operating results from one period to the next.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Remix measures compensation cost for stock-based awards made to
            employees at the grant date of the award, based on the fair value of the award as determined by its board of directors, and recognizes the cost as an expense over the employee&#8217;s requisite service period. As the variables that Remix uses as a
            basis for valuing these awards change over time, the magnitude of the expense that it must recognize may vary significantly.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Furthermore, Remix&#8217;s operating results may fluctuate due to a variety of other
            factors, many of which are outside of its control and may be difficult to predict, including the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and cost of, and level of investment in, research and development activities relating to Remix&#8217;s programs, which will
                    change from time to time; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to enroll patients in clinical trials and the timing of enrollment; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of manufacturing Remix&#8217;s current product candidates and any future product candidates, which may vary depending on FDA
                    or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of Remix&#8217;s agreements with manufacturers; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expenditures that Remix will or may incur to acquire or develop additional product candidates and technologies or other assets;
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing and outcomes of preclinical studies and clinical trials for REM-422 and any product candidates from Remix&#8217;s research
                    programs, or competing product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">competition from existing and potential future products that compete with REM-422, or any of Remix&#8217;s research programs, and
                    changes in the competitive landscape of its industry, including consolidation among Remix&#8217;s competitors or partners; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any delays in regulatory review or approval of REM-422, or any of Remix&#8217;s other research programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the level of demand for any of Remix&#8217;s product candidates, if approved, which may fluctuate significantly and be difficult to
                    predict; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk/benefit profile, cost and reimbursement policies with respect to Remix&#8217;s product candidates, if approved, and existing
                    and potential future products that compete with REM-422, or any of Remix&#8217;s other research programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to commercialize REM-422, or any of its research programs, if approved, inside and outside of the United States,
                    either independently or working with third parties; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to establish and maintain collaborations, licensing or other arrangements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s ability to adequately support future growth; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential unforeseen business disruptions that increase Remix&#8217;s costs or expenses; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">future accounting pronouncements or changes in Remix&#8217;s accounting policies; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the changing and volatile global economic and political environment. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The cumulative effect of these factors could result in large fluctuations and
            unpredictability in Remix&#8217;s quarterly and annual operating results. As a result, comparing Remix&#8217;s operating results on a period-to-period basis may not be meaningful. Investors should not rely on Remix&#8217;s past results as an indication of its
            future performance. This </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">90<br/>
        </div>

      </div>

    </div>

    <!--End Page 100-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 101-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg69"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">variability and unpredictability could also result in Remix&#8217;s failing to meet
            the expectations of industry or financial analysts or investors for any period. If Remix&#8217;s revenue or operating results fall below the expectations of analysts or investors or below any forecasts it may provide to the market, or if the
            forecasts Remix provides to the market are below the expectations of analysts or investors, the price of Remix&#8217;s common stock could decline substantially. Such a stock price decline could occur even when Remix has met any previously publicly
            stated guidance it may provide. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix will need substantial additional
            funding before Remix can complete the development of its product candidates. If Remix is unable to obtain such additional capital on favorable terms, on a timely basis or at all, Remix would be forced to delay, reduce or eliminate its product
            development and clinical programs and may not have the capital required to otherwise operate Remix&#8217;s business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Developing pharmaceutical products, including conducting preclinical studies and
            clinical trials, is expensive. Remix has not generated any revenues from the commercial sale of products and will not be able to generate any product revenues until, and only if, Remix receives approval to sell its product candidates from the
            FDA or other regulatory authorities. Remix expects its current cash, together with the net proceeds from the Transaction and related financing, to fund operations into early 2028. However, as Remix has not generated any revenue from commercial
            sales to date and does not expect to generate any revenue for several years, if ever, Remix will need to raise substantial additional capital in order to fund its general corporate activities and to fund Remix&#8217;s research and development,
            including its currently planned clinical trials and plans for new clinical trials and product development.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may seek to raise additional funds through various potential sources, such
            as equity and debt financings, or through strategic collaborations and license agreements. Remix can give no assurances that it will be able to secure such additional sources of funds to support its operations or, if such funds are available,
            that such additional financing will be sufficient to meet its needs. Moreover, to the extent that Remix raises additional funds by issuing equity securities, Remix&#8217;s stockholders may experience additional significant dilution and new investors
            could gain rights, preferences and privileges senior to the holders of common stock. Debt financing, if available, may involve restrictive covenants. To the extent that it raises additional funds through collaboration and licensing
            arrangements, Remix may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Given Remix&#8217;s capital constraints, Remix will need to prioritize spending on its
            clinical and preclinical programs. If Remix is unable to raise sufficient funds to support its current and planned operations, Remix may elect to discontinue certain of its ongoing activities or programs. Remix&#8217;s inability to raise additional
            funds could also prevent it from taking advantage of opportunities to pursue promising new or existing programs in the future.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s forecasts regarding its beliefs in the sufficiency of Remix&#8217;s financial
            resources to support its current and planned operations are forward-looking statements and involve significant risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere
            in this &#8220;Risk Factors&#8221; section. These estimates are based on assumptions that may prove to be wrong, and Remix could utilize its available capital resources sooner than currently expected. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix will incur additional costs and
            increased demands upon management as a result of complying with the laws and regulations affecting public companies. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix will incur significant legal, accounting and other expenses as a public
            company that it did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. Some of Remix&#8217;s management team have not previously managed and operated a public company. These
            executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that it complies with all of these
            requirements. Any changes Remix makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled
            with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for Remix to attract and retain qualified persons to serve on the board of directors or on--board committees or to
            serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">91<br/>
        </div>

      </div>

    </div>

    <!--End Page 101-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 102-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg70"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Once Remix is no longer a smaller
            reporting company or otherwise no longer qualifies for applicable exemptions, Remix will be subject to additional laws and regulations affecting public companies that will increase Remix&#8217;s costs and the demands on management and could harm its
            operating results.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is subject to the reporting requirements of the Exchange Act, which
            requires, among other things, that Remix file with the SEC, annual, quarterly and current reports with respect to Remix&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a smaller
            reporting company, Remix may take advantage of exemptions from various requirements such as an exemption from the requirement to have Remix&#8217;s independent auditors attest to its internal control over financial reporting under Section&#160;404 of the
            Sarbanes Oxley Act as well as an exemption from the &#8220;say on pay&#8221; voting requirements pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. Once Remix is no longer a smaller reporting company or otherwise qualifies
            for these exemptions, it will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If Remix is not able to comply
            with the requirements in a timely manner or at all, Remix&#8217;s financial condition or the market price of its common stock may be harmed. For example, if Remix or Remix&#8217;s independent auditor identifies deficiencies in its internal control over
            financial reporting that are deemed to be material weaknesses Remix could face additional costs to remedy those deficiencies, the market price of Remix&#8217;s stock could decline or Remix could be subject to sanctions or investigations by the SEC or
            other regulatory authorities, which would require additional financial and management resources. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix does not anticipate that it will
            pay any cash dividends in the foreseeable future. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The current expectation is that Remix will retain its future earnings, if any, to
            fund the growth of its business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of Remix will be investors&#8217; sole source of gain, if any, for the foreseeable future.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">There may not be an active trading market
            for Remix&#8217;s common stock may and Remix&#8217;s stockholders may not be able to resell their shares of common stock for a profit, if at all.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">An active trading market for Remix&#8217;s shares of common stock may not be sustained.
            If an active market for Remix&#8217;s common stock is not sustained, it may be difficult for Remix&#8217;s stockholders to sell their shares at an attractive price or at all. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix&#8217;s executive officers, directors and
            principal stockholders will have the ability to control or significantly influence all matters submitted to Remix&#8217;s stockholders for approval. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s executive officers, directors and principal stockholders, in the
            aggregate, beneficially own approximately 93.3% of Remix&#8217;s outstanding shares of common stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to
            Remix&#8217;s stockholders for approval, as well as Remix&#8217;s management and affairs. For example, these persons, if they choose to act together, would control or significantly influence the election of directors and approval of any merger,
            consolidation or sale of all or substantially all of Remix&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of Remix on terms that other stockholders may desire. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix may be exposed to increased
            litigation, including stockholder litigation, which could have an adverse effect on Remix&#8217;s business and operations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix may be exposed to increased litigation from stockholders, suppliers and
            other third parties due to the combination of Remix&#8217;s business. Such litigation may have an adverse impact on Remix&#8217;s business and results of operations or may cause disruptions to its operations. In addition, in the past, stockholders have
            initiated class action lawsuits against biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against Remix, could cause Remix to incur substantial costs and
            divert management&#8217;s attention and resources, which could have a material adverse effect on its business, financial condition and results of operations.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If equity research analysts do not
            publish research or reports, or publish unfavorable research or reports, about Remix, Remix&#8217;s business or Remix&#8217;s market, Remix&#8217;s stock price and trading volume could decline.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The trading market for Remix&#8217;s common stock will be influenced by the research
            and reports that equity research analysts publish about Remix and Remix&#8217;s business. Equity research analysts may elect not to provide research coverage of Remix&#8217;s common stock, and such lack of research coverage may adversely affect the market
            price of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">92<br/>
        </div>

      </div>

    </div>

    <!--End Page 102-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 103-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg71"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix&#8217;s common stock. In the event Remix does have equity research analyst
            coverage, Remix will not have any control over the analysts or the content and opinions included in their reports. The price of Remix&#8217;s common stock could decline if one or more equity research analysts downgrade Remix&#8217;s stock or issue other
            unfavorable commentary or research. If one or more equity research analysts ceases coverage of Remix or fails to publish reports on Remix regularly, demand for Remix&#8217;s common stock could decrease, which in turn could cause Remix&#8217;s stock price
            or trading volume to decline.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If Remix fails to maintain proper and
            effective internal control over financial reporting, Remix&#8217;s ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in Remix&#8217;s financial reporting, and the trading price of Remix&#8217;s common
            stock may decline.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to Section&#160;404 of Sarbanes-Oxley, Remix&#8217;s management will be required to
            report upon the effectiveness of Remix&#8217;s internal control over financial reporting. When Remix no longer qualifies as a &#8220;smaller reporting company&#8221;, Remix&#8217;s independent registered public accounting firm will be required to attest to the
            effectiveness of Remix&#8217;s internal control over financial reporting. The rules governing the standards that must be met for Remix&#8217;s management to assess Remix&#8217;s internal control over financial reporting are complex and require significant
            documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, Remix may need to upgrade its information technology systems; implement additional financial and management
            controls, reporting systems and procedures; and hire additional accounting and finance staff. If Remix or, if required, Remix&#8217;s auditors are unable to conclude that Remix&#8217;s internal control over financial reporting is effective, investors may
            lose confidence in Remix&#8217;s financial reporting and the trading price of Remix&#8217;s common stock may decline.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There can be no assurance that there will not be material weaknesses or
            significant deficiencies in Remix&#8217;s internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit Remix&#8217;s ability to accurately report its financial condition,
            results of operations or cash flows. If Remix is unable to conclude that its internal control over financial reporting is effective, or if its independent registered public accounting firm determines Remix has a material weakness or significant
            deficiency in its internal control over financial reporting once that firm begins its Section&#160;404 reviews, investors may lose confidence in the accuracy and completeness of Remix&#8217;s financial reports, the market price of its common stock could
            decline, and Remix could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in its internal control over financial reporting, or to implement or maintain other
            effective control systems required of public companies, could also restrict its future access to the capital markets. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">General Risk Factors </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s operations are vulnerable to
            interruption by flood, fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond Remix&#8217;s control, which could harm Remix&#8217;s business.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s office facilities are located in Massachusetts. Remix has not undertaken
            a systematic analysis of the potential consequences to its business and financial results from a major blizzard, flood, fire, earthquake, power loss, telecommunications failure, terrorist activity, pandemics or other disasters and do not have a
            recovery plan for such disasters. In addition, Remix does not carry sufficient insurance to compensate Remix for actual losses from interruption of its business that may occur, and any losses or damages incurred by Remix could harm its
            business. The occurrence of any of these business disruptions could seriously harm Remix&#8217;s operations and financial condition and increase its costs and expenses. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">93<br/>
        </div>

      </div>

    </div>

    <!--End Page 103-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 104-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg72"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tRF5"><!--Anchor--></a>Risks Related to the Combined Company </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">In determining whether you should approve the proposals
            contained in this proxy statement/prospectus, you should carefully read the following risk factors in addition to the risks described above.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following completion of the Merger, the combined company will be susceptible to
            many of the risks described in the sections titled &#8220;<span style="font-style: italic;">Risk Factors&#8212;Risks Related to Passage Bio</span>&#8221; and &#8220;<span style="font-style: italic;">Risk Factors&#8212;Risks Related to Remix </span>&#8221; in this proxy
            statement/prospectus. To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the combined company could
            be adversely affected in a material way. This could cause the market price of the combined company&#8217;s common stock to decline.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Following the Merger, the combined
            company may be unable to successfully integrate the businesses of Passage Bio and Remix and realize some or all of the anticipated benefits of the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger involves the combination of two companies which currently operate as
            independent companies. Following the Merger, the combined company will be required to devote significant management attention and resources to integrating its business practices and operations. The combined company may fail to realize some or
            all of the anticipated benefits of the Merger if the integration process takes longer than expected or is more costly than expected. Potential difficulties the combined company may encounter in the integration process include the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the inability to successfully combine the businesses of Passage Bio and Remix in a manner that permits the combined company to
                    achieve the anticipated benefits from the Merger, which would result in the anticipated benefits of the Merger not being realized partly or wholly in the time frame currently anticipated or at all; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">creation of uniform standards, controls, procedures, policies and information systems; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Merger. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Passage Bio and Remix have operated and, until the completion of the
            Merger, will continue to operate, independently. It is possible that the integration process also could result in the diversion of each company&#8217;s management&#8217;s attention, the disruption or interruption of, or the loss of momentum in, each
            company&#8217;s ongoing businesses or inconsistencies in standards, controls, procedures and policies, any of which could adversely affect the combined company&#8217;s ability to maintain its business relationships or the ability to achieve the anticipated
            benefits of the merger, or could otherwise adversely affect the business and financial results of the combined company.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">The market price of the combined
            company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The market price of the combined company&#8217;s common stock following the Merger
            could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the
            market price of the combined company&#8217;s common stock to fluctuate include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of the combined company to obtain regulatory approvals for its drug candidates, and delays or failures to obtain
                    such approvals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure of any of the combined company&#8217;s drug candidates, if approved, to achieve commercial success; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by the combined company to maintain its existing third-party license and supply agreements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure by the combined company or its licensors to prosecute, maintain, or enforce its intellectual property rights; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in laws or regulations applicable to the combined company&#8217;s drug candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any inability to obtain adequate supply of the combined company&#8217;s drug candidates or the inability to do so at acceptable
                    prices; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adverse regulatory authority decisions; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">94<br/>
        </div>

      </div>

    </div>

    <!--End Page 104-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 105-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg73"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">introduction of new products, services or technologies by the combined company&#8217;s competitors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to meet or exceed financial and development projections the combined company may provide to the public; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to meet or exceed the financial and development projections of the investment community; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined
                    company or its competitors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s
                    ability to obtain patent protection for its technologies; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions or departures of key personnel; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">significant lawsuits, including patent or stockholder litigation; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue an
                    adverse or misleading opinion regarding its business and stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the market valuations of similar companies; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">general market or macroeconomic conditions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sales of its common stock by the combined company or its stockholders in the future; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">trading volume of the combined company&#8217;s common stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">failure to maintain compliance with the listing requirements of Nasdaq; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof,
                    significant contracts, commercial relationships or capital commitments; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adverse publicity generally, including with respect to other products and potential products in such markets; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the introduction of technological innovations or new therapies that compete with potential products of the combined company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in the structure of health care payment systems; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">and period-to-period fluctuations in the combined company&#8217;s financial results. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Moreover, the stock markets in general have experienced substantial volatility
            that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the past, following periods of volatility in the market price of a company&#8217;s
            securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could
            significantly harm the combined company&#8217;s profitability and reputation.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Additionally, a decrease in the stock price of the combined company may cause the
            combined company&#8217;s common stock to no longer satisfy the continued listing standards of Nasdaq. If the combined company is not able to maintain the requirements for listing on Nasdaq, it could be delisted, which could have a materially adverse
            effect on its ability to raise additional funds as well as the price and liquidity of its common stock. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The combined company will incur costs and
            demands upon management as a result of complying with the laws, rules and regulations affecting public companies. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company will incur significant legal, accounting and other expenses
            that Remix did not incur as a private company, including costs associated with public company reporting requirements.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company will also incur costs associated with corporate governance
            requirements, including requirements under the laws, rules and regulations of the SEC as well as the Nasdaq rules. These laws, rules and </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">95<br/>
        </div>

      </div>

    </div>

    <!--End Page 105-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 106-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg74"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">regulations are expected to increase the combined company&#8217;s legal and
            financial compliance costs and to make some activities more time consuming and costly. These laws, rules and regulations also may make it difficult and expensive for the combined company to obtain directors&#8217; and officers&#8217; liability insurance.
            As a result, it may be more difficult for the combined company to attract and retain qualified individuals to serve on the combined company board of directors or as executive officers of the combined company, which may adversely affect investor
            confidence in the combined company and could cause the combined company&#8217;s business or stock price to suffer.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If the proceeds subject to the CVR
            Agreement are not received in a timely manner, the combined company may have to incur time and resources to recover such proceeds.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time, Passage Bio and a third party rights agent, will enter
            into the CVR Agreement, pursuant to which Passage Bio&#8217;s common stockholders of record as of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one contingent value right (each, a &#8220;<span style="font-style: italic; font-weight: bold;">CVR</span>&#8221;) for each outstanding share of Passage Bio Common Stock held by such stockholder on such date. Each CVR will represent the contractual right to receive payments from Passage Bio upon
            the actual receipt by Passage Bio or its subsidiaries of certain contingent proceeds derived from certain existing license agreements of Passage Bio, net of certain tax, transaction costs and certain other expenses. For additional information,
            please see the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Passage Bio Contingent Value Rights Agreement</span>.&#8221;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Passage Bio does not receive such proceeds prior to the Closing, the combined
            company may need to allocate time and resources to recover such proceeds. As a result, the combined company&#8217;s stockholders may receive no or limited benefits from any time or resources allocated to recovering such proceeds and such activities
            may be a distraction to the combined company&#8217;s management and employees. As a result, the combined company&#8217;s operations and financial condition may be adversely affected.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Nasdaq may delist the combined company&#8217;s
            securities from trading on its exchange, which could limit investors&#8217; ability to make transactions in its securities and subject the combined company to additional trading restrictions.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Currently, Passage Bio&#8217;s common stock is publicly traded on Nasdaq. In connection
            with the proposed Merger, Remix will file an initial listing application with Nasdaq pursuant to Nasdaq&#8217;s &#8220;reverse merger&#8221; rules. The combined company will be required to meet the initial listing requirements for its securities to be listed on
            Nasdaq.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the combined company fails to meet the Nasdaq listing requirements and their
            respective boards choose to close the Merger without Nasdaq&#8217;s approval, then Nasdaq may notify the combined company of its determination to delist the company&#8217;s securities based upon the failure to satisfy the criteria in the Nasdaq
            application. For more information, refer to the section titled &#8220;<span style="font-style: italic;">Risk Factors&#8212;Risks Related to the Merger&#8212;Passage Bio or Remix may waive one or more of the conditions to the Merger without recirculation of this
              proxy statement/prospectus or resoliciting stockholder approval</span>&#8221;.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We cannot assure you that the combined company will be able to meet those initial
            listing requirements. Even if the combined company&#8217;s securities are so listed, the combined company may be unable to maintain the listing of its securities in the future. In order to continue listing its securities on Nasdaq following the
            proposed Merger, the combined company will be required to maintain certain financial, distribution and stock price levels. If Nasdaq delists the combined company&#8217;s securities from trading on its exchange at the Closing (or thereafter) and the
            combined company is not able to list its securities on another national securities exchange or regain compliance with Nasdaq, the combined company&#8217;s securities could be quoted on an over-the-counter market. If this were to occur, the combined
            company could face significant material adverse consequences, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a limited availability of market quotations for its securities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reduced liquidity for its securities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a determination that the combined company&#8217;s common stock is a &#8220;penny stock&#8221; which will require brokers trading in the combined
                    company&#8217;s common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a limited amount of news and analyst coverage; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decreased ability to issue additional securities or obtain additional financing in the future. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The National Securities Markets Improvement Act of 1996, which is a federal
            statute, prevents or preempts states from regulating the sale of certain securities, which are referred to as &#8220;covered securities.&#8221; Since the Passage Bio </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">96<br/>
        </div>

      </div>

    </div>

    <!--End Page 106-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 107-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg75"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Common Stock is listed on Nasdaq, they are covered securities. Although states
            are preempted from regulating the sale of covered securities, the federal statute does allow states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then states can regulate or bar
            the sale of covered securities in a particular case. If Passage Bio was no longer listed on Nasdaq, its securities would not be covered securities and it would be subject to regulation in each state in which it offers its securities, including
            in connection with the Merger.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Provisions in the combined company&#8217;s
            amended and restated certificate of incorporation, the combined company&#8217;s amended and restated bylaws and Delaware law may have anti-takeover effects that could discourage an acquisition of the combined company by others, even if an acquisition
            would be beneficial to the combined company&#8217;s stockholders, and may prevent attempts by the combined company&#8217;s stockholders to replace or remove the combined company&#8217;s current management.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The amended and restated certificate of incorporation and amended and restated
            bylaws of the combined company will be the amended and restated certificate of incorporation and amended and restated bylaws of Passage Bio, which, along with Delaware law will contain provisions that may have the effect of discouraging,
            delaying or preventing a change in control of the combined company or changes in the combined company&#8217;s management that stockholders may consider favorable, including transactions in which the combined company&#8217;s stockholders might otherwise
            receive a premium for their shares. The combined company&#8217;s amended and restated certificate of incorporation and bylaws will include provisions that: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">authorize &#8220;blank check&#8221; preferred stock, which could be issued by the combined company&#8217;s board of directors without stockholder
                    approval and may contain voting, liquidation, dividend and other rights superior to the combined company&#8217;s common stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create a classified board of directors whose members serve staggered three-year terms; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">specify that special meetings of the combined company&#8217;s stockholders can be called only by the combined company&#8217;s board of
                    directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">prohibit stockholder action by written consent; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of the combined company&#8217;s
                    stockholders, including proposed nominations of persons for election to the combined company&#8217;s board of directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide that vacancies on the combined company&#8217;s board of directors may be filled only by a majority of directors then in
                    office, even though less than a quorum; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide that the combined company&#8217;s directors may be removed only for cause; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">specify that no stockholder is permitted to cumulate votes at any election of directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expressly authorize the combined company&#8217;s board of directors to modify, alter or repeal the combined company&#8217;s amended and
                    restated bylaws; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">require supermajority votes of the holders of the combined company&#8217;s common stock to amend specified provisions of the combined
                    company&#8217;s amended and restated certificate of incorporation and amended and restated bylaws. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These provisions, alone or together, could delay or prevent hostile takeovers and
            changes in control or changes in the combined company&#8217;s management. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the
            market price of the combined company&#8217;s common stock.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, because the combined company will be incorporated in the State of
            Delaware, the combined company will be governed by the provisions of Section&#160;203 of the DGCL which will prohibit a person who owns in excess of 15% of the combined company&#8217;s outstanding voting stock from merging or combining with the combined
            company for a period of three years after the date of the transaction in which the person acquired in excess of 15% of the combined company&#8217;s outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any provision of the combined company&#8217;s amended and restated certificate of
            incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">97<br/>
        </div>

      </div>

    </div>

    <!--End Page 107-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 108-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg76"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">for the combined company&#8217;s stockholders to receive a premium for their shares
            of our common stock, and could also affect the price that some investors are willing to pay for the combined company&#8217;s common stock.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If approved by the stockholders, the
            combined company&#8217;s restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between the combined company and the combined company&#8217;s
            stockholders and that the federal district courts shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, which could limit the combined company&#8217;s stockholders&#8217; ability to
            obtain a favorable judicial forum for disputes with the combined company or its directors, officers or employees.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s restated certificate of incorporation, which will be
            Passage Bio&#8217;s restated certificate of incorporation, will provide that the Court of Chancery of the State of Delaware is the exclusive forum for (1) any derivative action or proceeding brought on the combined company&#8217;s behalf, (2) any action
            asserting a breach of fiduciary duty, (3) any action asserting a claim against the combined company arising pursuant to the Delaware General Corporation Law, the combined company&#8217;s amended and restated certificate of incorporation or the
            combined company&#8217;s amended and restated bylaws, or (4) any action asserting a claim against the combined company that is governed by the internal affairs doctrine. Furthermore, the combined company&#8217;s amended and restated certificate of
            incorporation will also provide that unless the combined company consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint
            asserting a cause of action arising under the Securities Act. These choice of forum provisions may result in increased costs to the combined company&#8217;s stockholders to bring a claim, limit a combined company&#8217;s stockholder&#8217;s ability to bring a
            claim in a judicial forum that it finds favorable for disputes with the combined company or its directors, officers or other employees, and may generally have the effect of discouraging lawsuits against the combined company and its directors,
            officers and other employees. By agreeing to this provision, however, the combined company&#8217;s stockholders will not be deemed to have waived the combined company&#8217;s compliance with the federal securities laws and the rules and regulations
            thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions
            to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in the combined company&#8217;s amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, the combined company may
            incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect the combined company&#8217;s business and financial condition.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">An active trading market for the combined
            company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the Merger, there had been no public market for Remix&#8217;s common stock. An
            active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for its common stock does not develop or is not sustained, it may be difficult for its stockholders to sell their
            shares at an attractive price or at all. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Future sales of shares by existing
            stockholders could cause the combined company&#8217;s stock price to decline. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If existing stockholders of Passage Bio and Remix sell, or indicate an intention
            to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, including upon the expiration or release of lock-up restrictions
            pursuant to the terms of the Lock-Up Agreements, the trading price of the common stock of the combined company could decline. Neither Passage Bio nor Remix is able to predict the effect that sales may have on the prevailing market price of the
            combined company&#8217;s common stock.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If equity research analysts do not
            publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The trading market for the combined company&#8217;s common stock will be influenced by
            the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect not to provide research coverage of the combined company&#8217;s common stock after the completion of the Merger, and such
            lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts, or the content and opinions </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">98<br/>
        </div>

      </div>

    </div>

    <!--End Page 108-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 109-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg77"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">included in their reports. The price of the combined company&#8217;s common stock
            could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it
            regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed
            combined financial statements included in this proxy statement/prospectus are presented for illustrative purposes only and may not be an indication of the combined company&#8217;s financial condition or results of operations following the completion
            of the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed combined financial statements contained in this
            proxy statement/prospectus are presented for illustrative purposes only and may not be an indication of the combined company&#8217;s financial condition or results of operations following the Merger for several reasons. The unaudited pro forma
            condensed combined financial statements have been derived from the historical audited financial statements of Passage Bio and Remix as of and for the three months ended March&#160;31, 2026 and for the year ended December&#160;31, 2025 and certain
            adjustments and assumptions have been made regarding the combined company after giving effect to the Merger. The information upon which these adjustments and assumptions have been made is preliminary, and these kinds of adjustments and
            assumptions are difficult to make with accuracy. Moreover, the unaudited pro forma condensed combined financial statements do not reflect all costs that are expected to be incurred by the combined company in connection with the Merger. For
            example, the impact of any incremental costs incurred in integrating the two companies is not reflected in the unaudited pro forma condensed combined financial statements. As a result, the actual financial condition of the combined company
            following the Merger may not be consistent with, or evident from, these unaudited pro forma condensed combined financial statements. The assumptions used in preparing the unaudited pro forma condensed combined financial statements may not prove
            to be accurate, and other factors may affect the combined company&#8217;s financial condition following the Merger. For more information, please see the section titled &#8220;<span style="font-style: italic;">Unaudited Pro Forma Condensed Combined
              Financial Information</span>&#8221; in this proxy statement/prospectus.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">If the combined company fails to maintain
            proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company will be subject to the reporting requirements of the
            Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over
            financial reporting. The combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial
            reporting in its Annual Report on Form&#160;10-K filing for that year, as required by Section&#160;404 of the Sarbanes-Oxley Act. As a private company, Remix has never been required to test its internal controls within a specified period. This will
            require that the combined company incur substantial professional fees and internal costs to expand its accounting and finance functions and that it expends significant management efforts. The combined company may experience difficulty in
            meeting these reporting requirements in a timely manner.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company may discover weaknesses in its system of internal financial
            and accounting controls and procedures that could result in a material misstatement of its financial statements. The combined company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control
            system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can
            provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the combined company is not able to comply with the requirements of
            Section&#160;404 of the Sarbanes-Oxley Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of
            its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The combined company is expected to take
            advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in its common stock being less attractive to investors.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following the Merger, the combined company is expected to continue to be eligible
            to use the reduced disclosure requirements appliable to smaller reporting companies until the next determination date, in accordance with the rules </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">99<br/>
        </div>

      </div>

    </div>

    <!--End Page 109-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 110-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg78"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of the SEC. As a smaller reporting company, the combined company will be able
            to take advantage of reduced disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements in its SEC filings. Decreased disclosures in the combined company&#8217;s SEC filings
            due to its status as a smaller reporting company may make it harder for investors to analyze its results of operations and financial prospects. Passage Bio and Remix cannot predict if investors will find the combined company&#8217;s common stock less
            attractive if it relies on these exemptions. If some investors find its common stock less attractive as a result, there may be a less active trading market for its common stock and its stock price may be more volatile. The combined company may
            take advantage of the reporting exemptions applicable to a smaller reporting company until it is no longer a smaller reporting company, which status would end once it has a public float greater than $250&#160;million as of the last business day of
            the combined company&#8217;s second fiscal quarter. In that event, the combined company could still be a smaller reporting company if its annual revenues were below $100&#160;million and it has a public float of less than $700&#160;million as of the last
            business day of the combined company&#8217;s second fiscal quarter. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Changes in tax laws or regulations that
            are applied adversely to the combined company may materially and adversely affect its business, results of operations and financial condition. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">New income, sales, use or other tax laws, statutes, rules, regulations or
            ordinances could be enacted at any time, or interpreted, changed, modified or applied adversely to us, any of which could adversely affect our business, results of operations and financial condition. In particular, presidential, congressional,
            state and local elections in the United States could result in significant changes in, and uncertainty with respect to, tax legislation, regulation and government policy directly affecting our business or indirectly affecting us because of
            impacts on our customers, suppliers and manufacturers. For example, the United States government has, from time to time, proposed and may enact significant changes to the taxation of business entities including, among others, an increase in the
            corporate income tax rate and the imposition of minimum taxes or surtaxes on certain types of income. The likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur
            and, if so, the ultimate impact on our business. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes may materially and adversely affect our business, results of operations
            and financial condition.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, we are subject to the examination of our income and other tax
            returns by the IRS and other taxing authorities. We regularly assess the likelihood of adverse outcomes resulting from such examinations to determine the adequacy of our provision for income taxes. Although we believe we have made appropriate
            provisions for taxes in the jurisdictions in which we operate, changes in the tax laws or challenges from taxing authorities under existing tax laws could adversely affect our business, financial condition, and results of operations. </div>

          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s ability to use net
            operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of Passage Bio and Remix has incurred losses during its history, and the
            combined company does not expect to become profitable in the near future and may never achieve profitability. To the extent that the combined company continues to generate taxable losses, unused losses will carry forward to offset future
            taxable income, if any, until such unused losses expire, if at all. Historically, Passage Bio has not done an analysis to determine whether or not ownership changes have occurred since inception. As of December&#160;31, 2025, Passage Bio had U.S.
            federal NOL carryforwards and state NOL carryforwards of $ 398.0&#160;million and $ 277.8&#160;million, respectively, and Remix had U.S. federal and state NOL carryforwards of approximately $124.8 million and $62.0 million, respectively. Under current
            law, U.S. federal NOL carryforwards generated in taxable periods beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of such NOL carryforwards is limited to 80% of taxable income. It is uncertain if and
            to what extent various states will conform to federal law. In addition, under Sections 382 and 383 of the Code, federal NOL carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative
            changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage
            points over their lowest ownership percentage within a rolling three-year period. The combined company&#8217;s ability to utilize its NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a
            result of ownership changes, including potential changes in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased
            future income tax liability to the combined company, and the combined company&#8217;s future cash flows could be adversely affected. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">100<br/>
        </div>

      </div>

    </div>

    <!--End Page 110-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 111-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_107-risk_pg79"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_frisk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Unfavorable global economic conditions
            could adversely affect the combined company&#8217;s business, financial condition, results of operations or cash flows. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s results of operations could be adversely affected by
            general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the combined company&#8217;s business, including weakened demand for the combined company&#8217;s
            product candidates and the combined company&#8217;s ability to raise additional capital when needed on acceptable terms, or at all. A weak or declining economy could also strain the combined company&#8217;s suppliers, possibly resulting in supply
            disruption. Any of the forgoing could harm the combined company&#8217;s business and the combined company cannot anticipate all the ways in which the current economic climate and financial market conditions could adversely affect its business. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">101<br/>
        </div>

      </div>

    </div>

    <!--End Page 111-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 112-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_108-market_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tMPDI"><!--Anchor--></a>MARKET PRICE AND DIVIDEND INFORMATION </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio Common Stock is currently listed on Nasdaq under the symbol &#8220;PASG.&#8221;
            The closing price of the Passage Bio Common Stock on June&#160;23, 2026, the last day of trading prior to the announcement of the Merger, as reported on Nasdaq, was $6.12 per share. The closing price of the Passage Bio Common Stock on &#8195;&#8195;&#8195;&#8195;&#8195;, 2026,
            the last practicable date before the date of this proxy statement/prospectus, as reported on Nasdaq, was $&#8195;&#8195;&#8195;&#8195;&#8195; per share. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Because the market price of the Passage Bio Common Stock is subject to
            fluctuation, the market value of the shares of the Passage Bio Common Stock that the Remix stockholders will be entitled to receive in the Merger may increase or decrease.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Remix is a private company and shares of Remix Capital Stock are not publicly
            traded.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Assuming approval of Proposal Nos. 1, 2 and 3 and the Closing, following the
            consummation of the Merger, the Passage Bio Common Stock will trade on The Nasdaq Capital Market under Passage Bio&#8217;s new name, &#8220;Remix Therapeutics, Inc.&#8221; and new trading symbol &#8220;RMTX&#8221;.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, the record date for the Passage Bio special meeting, there
            were approximately &#8195;&#8195;&#8195;&#8195;&#8195; registered holders of record of Passage Bio Common Stock. As of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, Remix had &#8195;&#8195;&#8195;&#8195;&#8195; holders of record of Remix Common Stock and &#8195;&#8195;&#8195;&#8195;&#8195; holders of record of Remix Preferred Stock. For detailed information
            regarding the beneficial ownership of certain Passage Bio stockholders and Remix stockholders, see the sections of this proxy statement/prospectus titled &#8220;<span style="font-style: italic;">Principal Stockholders of Passage Bio</span>&#8221; and &#8220;<span style="font-style: italic;">Principal Stockholders of Remix.</span>&#8221; </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tDIV"><!--Anchor--></a>Dividends </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has never declared or paid any cash dividends on Passage Bio Common
            Stock and does not anticipate paying cash dividends on Passage Bio Common Stock for the foreseeable future. Any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined company&#8217;s then-current board
            of directors and will depend upon a number of factors, including the combined company&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the
            then-current board of directors deems relevant.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has never paid or declared any cash dividends on Remix Capital Stock, does
            not anticipate paying any cash dividends on the Remix Capital Stock in the foreseeable future, and intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to
            pay dividends will be at the discretion of the Remix Board and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable
            laws and other factors the Remix Board deems relevant. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">102<br/>
        </div>

      </div>

    </div>

    <!--End Page 112-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 113-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_109-fls_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tFLS"><!--Anchor--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
            STATEMENTS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This proxy statement/prospectus contains or incorporates statements that
            constitute forward-looking statements within the meaning of the federal securities laws in relation to Passage Bio, Remix, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate
            to historical or current facts or matters are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are
            forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221;
            &#8220;projects,&#8221; &#8220;forecasts,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These
            forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Passage Bio, Remix or the proposed transaction
            will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Passage Bio&#8217;s or Remix&#8217;s control) or other assumptions that may cause actual results or performance to
            be materially different from those expressed or implied by these forward-looking statements. In addition to other factors and matters contained in or incorporated by reference in this document, Passage Bio believes the following factors could
            cause actual results to differ materially from those discussed in the forward-looking statements: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the conditions to the Closing of the transaction are not satisfied, including the failure to timely obtain
                    stockholder approval for the Merger Agreement and the transactions contemplated thereby, if at all; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s and Remix&#8217;s ability to meet expectations regarding the timing and completion of the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the Concurrent Financing is not completed in a timely manner or at all; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">uncertainties as to the timing of the consummation of the Merger and the ability of each of Passage Bio and Remix to consummate
                    the Merger and the other Contemplated Transactions, including the Concurrent Financing; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expectations regarding the strategies, prospects, plans, expectations and objectives of management of Remix for future
                    operations of the combined company following the Closing; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of the combined company to recognize the benefits that may be derived from the Merger, including the commercial or
                    market opportunity of the product candidates of Remix and the combined company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">uncertainties regarding the anticipated tax treatment of the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that Passage Bio CVR holders may never receive any proceeds pursuant to the Passage Bio CVR Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that as a result of adjustments to the Merger Exchange Ratio, Passage Bio stockholders and Remix stockholders could own
                    more or less of the combined company than is currently anticipated; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to the market price of Passage Bio Common Stock relative to the value suggested by the Merger Exchange Ratio; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to Passage Bio&#8217;s and Remix&#8217;s ability to correctly estimate their respective operating expenses and expenses
                    associated with the transaction, uncertainties regarding the impact any delay in the closing would have on the anticipated cash resources of the combined company upon Closing and other events and unanticipated spending and costs that
                    could reduce the combined company&#8217;s cash resources; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger
                    Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that under the terms of the Merger Agreement, Passage Bio and Remix are restrained from soliciting other acquisition
                    proposals during the pendency of the Merger, except in certain circumstances; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">103<br/>
        </div>

      </div>

    </div>

    <!--End Page 113-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 114-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_109-fls_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effect of the announcement or pendency of the Merger on Passage Bio&#8217;s or Remix&#8217;s business relationships, operating results
                    and business generally, including disruption of Passage Bio&#8217;s and Remix&#8217;s management&#8217;s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the
                    announcement or completion of the transaction; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the Merger Agreement may be terminated in circumstances that require Passage Bio or Remix to pay a termination
                    fee; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the outcome of any legal proceedings that may be instituted against Passage Bio, Remix or any of their respective directors or
                    officers related to the Merger Agreement or the transactions contemplated thereby; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of Remix to maintain and protect its intellectual property rights; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">competitive responses to the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">legislative, regulatory, political and economic developments beyond the parties&#8217; control; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s public securities&#8217; potential liquidity and trading; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks related to the failure to realize any value from product candidates and preclinical programs being developed and
                    anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing drug candidates to market; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">success in recruiting and retaining, or changes required in, Remix&#8217;s officers, key employees or directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the early stage of the combined company&#8217;s development efforts; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that unforeseen events during clinical trials could cause delays or other adverse consequences; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">risks relating to the regulatory approval process for the combined company&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that interim, topline and preliminary data may change as more patient data become available and are subject to audit
                    and verification procedures that could result in material changes in the final data; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the combined company&#8217;s product candidates may cause serious adverse side effects; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk of failure to obtain U.S. or international marketing approval for the combined company&#8217;s product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the combined company&#8217;s need for additional funding, which may not be available; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that Remix, or its CROs, CDMOs, service providers, current and potential future partners or other third parties upon
                    which it relies, could experience a security incident, system disruption or failure, data loss, cyberattack, or similar event that could compromise the confidentiality, integrity and availability of systems and data; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the sufficiency of Remix&#8217;s internal controls and procedures and its ability to remediate any material weaknesses; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developments and projections relating to Remix&#8217;s competitors, its industry or the market opportunities for REM-422 or any future
                    product candidates; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">economic, regulatory, political, geopolitical (including military conflicts and threatened hostilities), environmental and
                    public health developments in the United States and foreign countries. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Should one or more of these risks or uncertainties materialize or should any of
            Passage Bio&#8217;s or Remix&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that Passage Bio considers immaterial or which are
            unknown. You are urged to carefully review the disclosures Passage Bio and Remix make concerning these risks and other factors that may affect Passage Bio&#8217;s and Remix&#8217;s business and operating results under the section titled &#8220;<span style="font-style: italic;">Risk&#160;Factors</span>&#8221; of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed
            with the SEC by </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">104<br/>
        </div>

      </div>

    </div>

    <!--End Page 114-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 115-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_109-fls_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Passage Bio. Please see the section titled &#8220;<span style="font-style: italic;">Where

              You Can Find More Information</span>&#8221; of this proxy statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected
            benefits of the Merger will be realized.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If any of these risks or uncertainties materialize or any of these assumptions
            prove incorrect, the results of Passage Bio, Remix or the combined company could differ materially from the forward-looking statements. Any public statements or disclosures by Passage Bio and Remix following this proxy statement/prospectus that
            modify or impact any of the forward-looking statements contained in this proxy statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these
            forward-looking statements, which speak only as of the date of this document. Passage Bio and Remix do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this
            document or to reflect the occurrence of unanticipated events, unless required by law to do so. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">105<br/>
        </div>

      </div>

    </div>

    <!--End Page 115-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 116-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tTM"><!--Anchor--></a>THE MERGER </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Background of the Merger<a id="tBOTM"><!--Anchor--></a> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following chronology summarizes the material meetings and
            events that led to the execution of the Merger Agreement. It does not purport to catalog every discussion or interaction among the Passage Bio Board, members of Passage Bio&#8217;s senior management or Passage Bio&#8217;s advisors or other parties and
            their respective financial advisors, legal advisors, affiliates or other representatives.<span style="font-style: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to January 2026, Passage was a clinical stage genetic medicines company
            focused on the development and advancement of cutting-edge, one-time gene therapies designed to improve the lives of patients with neurodegenerative diseases. During this period, and in furtherance of this strategy, the Passage Board of
            Directors and Passage management would, from time to time, review and discuss Passage&#8217;s business, financial condition, operations and strategic priorities and consider various strategic business initiatives intended to strengthen Passage&#8217;s
            business and enhance stockholder value. As part of these discussions, the Passage Board of Directors regularly evaluated appropriate steps for the Company to consider if it were not able to receive sufficient investor support to conduct its
            clinical trials, including reverse merger alternatives.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage historically focused on the clinical development of its lead product
            candidate, PBFT02, a gene replacement therapy targeting frontotemporal dementia (&#8220;FTD&#8221;) caused by progranulin deficiency (&#8220;FTD-GRN&#8221;) and was conducting a multi-center, open-label, single-arm Phase 1/2 clinical trial to evaluate PBFT02 in
            patients with a symptomatic diagnosis of FTD-GRN. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In 2026, PBFT02 was Passage&#8217;s only clinical stage program. As of December 31,
            2025, Passage had cash and cash equivalents of $46.3 million, which it expected to be sufficient to fund its operating expenses and capital expenditures through the end of the first quarter of 2027. In January 2026, Passage conducted a meeting
            with FDA to gain feedback on the likely registrational clinical trial design for PBFT02 in FTD-GRN. At this meeting, FDA provided initial feedback regarding Passage&#8217;s proposed trial design and the potential need for a randomized controlled
            registrational trial. Passage continued to engage in discussions with FDA regarding this initial feedback following the meeting. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In February 2026, Passage engaged an investment bank with which it had previously
            engaged for financing transactions to explore potential financing alternatives for Passage, given its current cash position and anticipated capital requirements for the continued clinical development of PBFT02.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On February 12, 2026, the Passage Board of Directors met, with Passage senior
            management and representatives of this investment bank and Fenwick &amp; West LLP (&#8220;Fenwick,&#8221; the Company&#8217;s outside counsel) attending, to discuss a potential financing process. At this meeting, the Passage Board of Directors authorized
            management, in advance of receipt of final FDA minutes from the January 2026 meeting, to begin confidential outreach to potential investors regarding a financing intended to extend Passage&#8217;s cash runway and enable commencement of a Phase 2/3
            clinical trial for PBFT02. At this meeting, the Passage Board of Directors also considered potential alternatives if a financing were not successful.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Between February 17, 2026, and April 7, 2026, 26 investors were contacted, all 26
            either executed a confidentiality agreement directly with Passage or agreed to terms of confidentiality, and meetings were held with 16 investors. Through this process, one term sheet was received. This term sheet contemplated a multiple tiered
            financing that would require significant additional investor support to lead to a viable financing path.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On March 27, 2026, Passage senior management initiated discussions with Wedbush
            PacGrow (&#8220;Wedbush&#8221;) regarding a potential engagement to advise Passage in connection with a strategic review process, in light of Wedbush&#8217;s experience in the life sciences industry and with reverse merger transactions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On April 3, 2026, Passage received final minutes from FDA (reflecting FDA&#8217;s
            definitive written statement regarding the topics discussed at the January 2026 meeting) in which the FDA confirmed that it would require a randomized controlled arm for a registrational clinical trial for PBFT02.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On April 7, 2026, the Passage Board of Directors met, with Passage senior
            management and representatives of Fenwick attending, to summarize the investor feedback received as a result of Passage&#8217;s outreach, the terms of the single term sheet received and the likelihood of it leading to a financing, and the expected
            challenges to funding continued development of the PBFT02 program. The Passage Board and its advisors also discussed conducting a strategic review process and soliciting proposals for an acquisition or &#8220;reverse&#8221; merger transaction and the
            potential </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">106<br/>
        </div>

      </div>

    </div>

    <!--End Page 116-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 117-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">additional advisors that the Passage Board of Directors would engage as part
            of that process. Following discussion, the Board (i) determined the one term sheet provided did not provide a reasonable path for a financing, (ii) determined to cease further investor outreach for a financing, and (iii) directed Passage senior
            management to engage Wedbush as its financial advisor to conduct a strategic review process to solicit proposals for an acquisition of Passage or a &#8220;reverse merger&#8221; transaction, with terms consistent with the proposal presented at the meeting.
            Also at this meeting, the Passage Board of Directors established a Transaction Committee to enable more efficient review on behalf of the Board, and delegated to the Transaction Committee, consisting of directors Athena Countouriotis, Maxine
            Gowen, and Sandip Kapadia, the power and authority of the Passage Board of Directors to supervise the Company&#8217;s management in this process and to review and evaluate proposals received from third parties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On April 10, 2026, Passage entered into an engagement letter with Wedbush, with
            terms consistent with those previously approved by the Passage Board of Directors, under which it engaged Wedbush to act as its financial advisor to conduct a strategic review process.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On April 20, 2026, Passage issued a press release and filed a Current Report on
            Form 8-K with the SEC disclosing feedback from the Type C meeting with the FDA regarding key elements of a future registrational trial design of PBFT02 in FTD-GRN in which FDA indicated that a randomized controlled registrational study design
            would be required for PBFT02 in this indication. Given the substantial cost of such a registrational study and the challenges posed by a randomized controlled study design, Passage announced in this press release that it was evaluating
            potential next steps in the clinical development of PBFT02. On April 17, 2026, the trading day prior to the issuance of the press release and filing of the Form 8-K, the closing price of Passage Bio Common Stock was $11.67. On April 20, 2026,
            the closing price of Passage Bio Common Stock was $6.25.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Also on April 20, 2026, following issuance of the press release, consistent with
            the discussion by the Board at the April 7, 2026 Board meeting, management authorized Wedbush to initiate outreach to potential counterparties, requesting non-binding indications of interests by May 5, 2026. In this initial outreach, Wedbush
            contacted 148 potential strategic and reverse merger counterparties to gauge interest in a potential acquisition or reverse merger with Passage. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Additionally, following April 20, 2026, Passage made PBFT02 program information
            available under confidentiality to three parties (a large pharmaceutical company, a midsize biotech company and an investment fund) that expressed interest in potentially purchasing or licensing the PBFT02 program from Passage. Following review
            of diligence materials, none of these parties expressed interest in acquiring or licensing the PBFT02 program.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On April 22, 2026, the Passage Transaction Committee met, with Passage senior
            management and representatives of Wedbush and Fenwick attending. At this meeting, a representative of Wedbush presented an overview of the reverse merger process, and the committee members, senior management, and representatives discussed
            criteria for evaluating bids, including: (i) the counterparty&#8217;s product candidate pipeline, (ii) the stage of clinical development for such counterparty&#8217;s product candidates, (iii) the anticipated timeline to intermediate catalysts for such
            counterparty&#8217;s product candidates, (iv) the size of market opportunity for such counterparty&#8217;s product candidates, (v) the counterparty&#8217;s existing investor base and public company readiness, (vi) the quality of the counterparty&#8217;s management
            team, (vii) the counterparty&#8217;s cash runway and status of any required concurrent financing, and (viii) the counterparty&#8217;s intellectual property portfolio and freedom to operate. At this meeting, the Passage Transaction Committee authorized
            management to do an initial review of bids based on the criteria discussed to determine parties to advance with, including to initiate term sheet discussions as appropriate.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On April 27, 2026, the Passage Board approved a restructuring of its workforce to
            decrease operating expenses by reducing the workforce by approximately 75%. On April 28, Passage filed a Current Report on Form 8-K with the SEC disclosing this decision. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">107<br/>
        </div>

      </div>

    </div>

    <!--End Page 117-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 118-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Between April 22, 2026, and May 5, 2026, 21 potential reverse merger
            counterparties submitted an initial indication of interest. No strategic acquirors submitted an indication of interest.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage senior management, in consultation with Wedbush, evaluated each of the
            received bids based on the criteria outlined at the April 22 Transaction Committee meeting. Through such evaluation, 10 potential counterparties were invited to present to the Passage Transaction Committee (other than Dr. Countouriotis, who was
            affiliated with one of these counterparties). Prior to each presentation, Passage executed a mutual confidentiality agreement with each potential counterparty, each of which contained a customary standstill provision that provided for an
            automatic fall-away upon a transaction of the type contemplated by the Merger Agreement. A summary of the initial proposals from those 10 potential counterparties is provided below:</div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 22, 2026, Passage received an indication of interest for a reverse merger from Remix. Remix&#8217;s indication of interest
                    proposed an equity valuation of Passage of $8 million and valued Remix at a range between $250-350 million equity valuation, with a $100 million PIPE financing, and proposed that Remix&#8217;s current stockholders would own 69.8%-76.4% of the
                    total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 1.7%-2.2% of the outstanding common stock of the combined company, and the investors in such PIPE financing would own 21.8%-27.9% of the
                    outstanding common stock of the combined company. Any remaining cash balance of Passage would be paid to Passage stockholders as a dividend at the time the proposed merger would close.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 27, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company A. Company A&#8217;s indication of interest proposed an equity valuation of Passage of $10 million and valued Company A at a range between $135-150 million equity valuation, with a $100 million PIPE financing,
                    and proposed that Company A&#8217;s current stockholders would own 57.7% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 3.8%-4.1% of the outstanding common stock of the combined
                    company, and the investors in such PIPE financing would own 38.5%-40.8% of the outstanding common stock of the combined company. Any remaining cash balance of Passage would be paid to Passage stockholders as a dividend at the time the
                    proposed merger would close.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 28, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company B. Company B&#8217;s indication of interest proposed an equity valuation of Passage of $15 million and valued Company B at a $150 million equity valuation, with a $200 million PIPE financing, and proposed that
                    Company B&#8217;s current stockholders would own 41.1% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 4.1% of the outstanding common stock of the combined company, and the investors in
                    such PIPE financing would own 54.8% of the outstanding common stock of the combined company.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 29, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company C. Company C&#8217;s indication of interest proposed an equity valuation of Passage of $8 million and valued Company C at a $125 million equity valuation, with a $250 million PIPE financing, and proposed that
                    Company C&#8217;s current stockholders would own 32.6% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 2.1% of the outstanding common stock of the combined company, and the investors in
                    such PIPE financing would own 65.3% of the outstanding common stock of the combined company. Any remaining cash balance of Passage would be paid to Passage stockholders as a dividend at the time the proposed merger would close.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 30, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company D. Company D&#8217;s indication of interest proposed an equity valuation of Passage of $20 million and valued Company D at a $500 million equity valuation, with a $100 million PIPE financing, and proposed that
                    Company D&#8217;s current stockholders would own 80.6% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 3.2% of the outstanding common stock of the combined company, and the investors in
                    such PIPE financing would own 16.1% of the outstanding common stock of the combined company.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On April 27, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company E. Company E&#8217;s indication of interest proposed an equity valuation of Passage of $13 million and valued Company E at a $590 million equity valuation, with </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">108<br/>
        </div>

      </div>

    </div>

    <!--End Page 118-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 119-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">a $200 million PIPE financing, and proposed that Company E&#8217;s current
            stockholders would own 73.5% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 1.6% of the outstanding common stock of the combined company, and the investors in such PIPE financing would
            own 24.9% of the outstanding common stock of the combined company.</div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On May 4, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company F. Company F&#8217;s indication of interest proposed an equity valuation of Passage of $20 million and valued Company F at a $280 million equity valuation, with a $100 million PIPE financing, and proposed that
                    Company F&#8217;s current stockholders would own 70.0% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 5.0% of the outstanding common stock of the combined company, and the investors in
                    such PIPE financing would own 25.0% of the outstanding common stock of the combined company.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On May 5, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company G. Company G&#8217;s indication of interest proposed an equity valuation of Passage of $8 million and valued Company G at a $250 million equity valuation, with a $320 million PIPE financing, and proposed that
                    Company G&#8217;s current stockholders would own 43.3% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 1.4% of the outstanding common stock of the combined company, and the investors in
                    such PIPE financing would own 55.4% of the outstanding common stock of the combined company. Any remaining cash balance of Passage would be paid to Passage stockholders as a dividend at the time the proposed merger would close.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On May 5, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company H. Company H&#8217;s indication of interest proposed an equity valuation of Passage of $15 million and valued Company H at a $150 million equity valuation, with a $90 million PIPE financing, and proposed that
                    Company H&#8217;s current stockholders would own 58.8% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 5.9% of the outstanding common stock of the combined company, and the investors in
                    such PIPE financing would own 35.3% of the outstanding common stock of the combined company.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">On May 5, 2026, Passage received an indication of interest for a reverse merger from a privately-held biotechnology company
                    referred to herein as Company I. Company I&#8217;s indication of interest proposed an equity valuation of Passage of $15 million and valued Company I at a $435 million equity valuation, with a $200 million PIPE financing, and proposed that
                    Company I&#8217;s current stockholders would own 66.9% of the total outstanding common stock of the combined company, Passage&#8217;s current stockholders would own 2.3% of the outstanding common stock of the combined company, and the investors in
                    such PIPE financing would own 30.8% of the outstanding common stock of the combined company.</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Between April 30, 2026 and May 8, 2026, representatives of each of these
            potential counterparties described above met with the Passage Transaction Committee (other than Dr. Countouriotis) and representatives of Passage senior management and Wedbush and made presentations regarding their businesses, strategies and
            product pipelines.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following these presentations, the Passage Transaction Committee and Passage
            senior management conferred, with input from Wedbush, to determine the potential counterparties with which Passage should enter into initial term sheet negotiations. Wedbush indicated to Passage senior management and the Passage Transaction
            Committee where they were acting as financial advisor to any potential counterparty. In evaluating each proposal, the Transaction Committee assessed, among other things, each party&#8217;s clinical pipeline, valuation of their own company as well as
            their proposed valuation of Passage. After evaluating all of the outstanding proposals, Passage determined to engage in such negotiations with Companies C, E, D, F, G, I and Remix.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 2, 2026, the Passage Board of Directors approved a change to composition
            of its Transaction Committee, removing Athena Countouriotis (due to her affiliation with one of these potential counterparties) and adding Thomas Kassberg.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 6, 2026, Passage senior management, representatives of Wedbush, and
            Company E senior management held a financial due diligence call.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">On May 6, 2026, Passage initiated term sheet negotiations with Company E,
            Company G and Remix.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">109<br/>
        </div>

      </div>

    </div>

    <!--End Page 119-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 120-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">On May 8, 2026, Passage senior management, representatives of Wedbush, and
            Remix senior management held a follow-up due diligence call to address Passage&#8217;s questions about Remix&#8217;s strategy and lead program.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">On May 7, 2026, Passage initiated term sheet negotiations with Company I.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">On May 8, 2026, Company C withdrew its bid submission from the strategic review
            process.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 11, 2026, the Passage Transaction Committee met, with Passage senior
            management and representatives of Wedbush and Fenwick attending. A representative of Fenwick reviewed the fiduciary duties of the Transaction Committee members in evaluating proposals that had been received. A representative of Wedbush then
            reviewed the 20 proposals for reverse merger transactions that had been received, and indicated that Wedbush was acting as financial advisor to certain of the companies presenting proposals (including Remix), and the Transaction Committee
            members discussed the relative prioritization of these proposals based on the criteria that had been established at the April 22 meeting of the Passage Transaction Committee, and the status of initial term sheet negotiations with Company E,
            Company G, Company I, and Remix. At this meeting, the Passage Transaction Committee authorized management to enter into a term sheet with Company E on the terms discussed at this meeting proposing a valuation for Passage of $14 million, plus
            net cash and a 21-day exclusivity period to negotiate a definitive merger agreement, based on Passage Transaction Committee&#8217;s favorable view of the clinical pipeline, stage of development and management team of Company E.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 13, 2026, Company E notified Passage that it was withdrawing its bid
            submission from the strategic review process.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">On May 16, 2026, Passage initiated term sheet negotiations with Company D and
            Company F.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 19, 2026, the Passage Board of Directors met, with Passage senior
            management and representatives of Fenwick present. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage senior management provided an update to the Board on the status of the
            strategic review process, including the status of term sheet negotiations and discussions with counterparties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 20, 2026, Passage senior management held a due diligence call with the
            lead private placement investor of Remix, along with Remix senior management and representatives of Wedbush.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">On May 21, 2026, Passage initiated term sheet negotiations with Company B.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 24, 2026, senior management at Passage and Remix discussed the terms of
            the exclusivity provisions in the term sheet.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 27, 2026, Passage filed a Current Report on Form 8-K with the SEC
            disclosing that it provided written notice to Gemma Biotherapeutics, Inc. (&#8220;Gemma&#8221;) of termination of the research, collaboration and license agreement, dated July 31, 2024, by and between Gemma and Passage. In addition, the 8-K disclosed that
            Passage and Commerce Square Partners &#8211; Philadelphia Plaza, L.P. (the &#8220;Landlord&#8221;) entered into a lease termination agreement with respect to a lease agreement dated April 10, 2020 between Passage and the Landlord for Passage&#8217;s prior headquarters
            in Philadelphia, in view of the fact that Passage Bio had reduced its workforce by 75% and its focus going forward on a reverse merger transaction.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Also on May 27, 2026, Passage, Fenwick, Remix, Latham &amp; Watkins LLP
            (&#8220;Latham&#8221;), and Wedbush met to discuss the exclusivity provisions in the term sheet between Passage and Remix. Following this meeting, Remix and Passage finalized the form of the term sheet between the parties, which provided for an equity
            valuation of Passage of $20 million (subject to adjustment based on Passage&#8217;s net cash at closing) and valued Remix at a range of $250 million and $350 million, with a $100 million PIPE financing. In addition, Passage was provided access to a
            virtual data room which included clinical data that Remix planned to present at the upcoming ASCO meeting. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Also on May 27, 2026, Passage senior management, representatives of Wedbush, and
            Company B senior management held a follow-up due diligence call to address Passage&#8217;s questions about Company B&#8217;s clinical program status and status of certain business development agreements.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Also on May 27, 2026, the Transaction Committee met, together with Passage senior
            management and representatives of Wedbush and Fenwick present to discuss the revised term sheet under consideration with Remix, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">110<br/>
        </div>

      </div>

    </div>

    <!--End Page 120-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 121-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">including the exclusivity terms therein. The Transaction Committee discussed
            the proposed terms set forth in this term sheet (as described above), and, following discussion, the Transaction Committee authorized Passage senior management to finalize and execute the term sheet, including the exclusivity provisions
            therein. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">On May 28, 2026, Passage and Remix executed this term sheet. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 29, 2026, Passage&#8217;s senior management and representatives of Fenwick and
            Wedbush met with representatives of Remix and Latham, outside counsel to Remix, to discuss key steps in the proposed reverse merger and concurrent private placement transactions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May 30, 2026, Wedbush informed Passage that it would not be able to issue a
            fairness opinion in a merger with Remix because as previously disclosed, it was acting as financial advisor to Remix. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From June 2, 2026 through June 7, 2026, Passage senior management engaged with
            discussions with five potential financial advisors regarding delivery of a fairness opinion.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June 3, 2026, representatives of Passage provided access to a data room that
            included due diligence materials to representatives of Remix.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June 4, 2026, Latham provided to Fenwick a Remix company presentation to be
            used to market the concurrent private placement of Remix.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June 5, 2026, Passage&#8217;s senior management and Remix senior management met to
            discuss and negotiate elements of the proposed CVR Agreement. During this discussion, Passage&#8217;s senior management described contractual obligations of agreements between Passage and Gemma Biotherapeutics and between Passage and The Trustees of
            the University of Pennsylvania, including financial obligations and enabling operational requirements.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">On June 5, 2026, Latham delivered to Fenwick an initial draft of the Merger
            Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">On June 8, 2026, Latham delivered to Fenwick an initial draft of the Support
            Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June 9, 2026, the Transaction Committee discussed firms that could provide a
            fairness opinion to the Passage Board with respect to the transaction, and after discussion of the qualifications of several such firms, approved the engagement of Redwood Valuation to provide a fairness opinion to the Passage Board with
            respect to the transaction. Management engaged Redwood Valuation on June 11, 2026.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">On June 10, 2026, Fenwick delivered a revised draft of the Support Agreement to
            Latham.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Between June 10 and June 22, 2026, Latham and Fenwick exchanged drafts of the
            Merger Agreement, the CVR Agreement and other ancillary agreements, and the disclosure schedules to the Merger Agreement, negotiating, among other things, provisions in the Merger Agreement regarding the calculation of net cash and transaction
            expenses, the representations and warranties and covenants of the parties, the closing conditions to the Merger, and the non-solicitation and related provisions, and, in the CVR Agreement, the covenants requiring use of commercially reasonable
            efforts to achieve the CVR milestones, and the calculation of permitted deductions from the amounts to be paid under the CVR Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">On June 15, 2026, Latham delivered to Fenwick an initial draft of the CVR
            Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Throughout June 22, 2026 and June 23, 2026, Latham and Fenwick continued to
            discuss, and finalized, the Merger Agreement, the CVR Agreement and other ancillary agreements, and the disclosure schedules to the Merger Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June 23, 2026, the Passage Board of Directors met, together with Fenwick and
            senior management. In advance of the meeting (in the morning of June 23, 2026) the members of the Board of Directors received the final forms of Merger Agreement and CVR Agreement. Representatives of Wedbush joined the meeting, provided an
            overview of the strategic outreach conducted in May, and left the meeting. A representative of Fenwick then reviewed the fiduciary duties of the Board of Directors in evaluating the Transaction, and described the key terms of the Merger
            Agreement and CVR Agreement. Representatives of Redwood then joined the meeting and, at the request of the Passage Board of Directors, Redwood reviewed its financial analysis of the Merger Consideration with the Passage Board of Directors and
            delivered an oral opinion, confirmed by delivery of a written opinion dated June 23, 2026, to the Passage Board of Directors to the effect that, based on and subject to the various assumptions made, procedures followed, matters considered and
            limitations and qualifications on the review undertaken by Redwood as set forth in such opinion, as of June 23, 2026 the Exchange Ratio provided for pursuant to the Merger Agreement was fair, from </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">111<br/>
        </div>

      </div>

    </div>

    <!--End Page 121-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 122-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">a financial point of view, to Passage. Redwood also reconfirmed its
            independence at this meeting with respect to each of Passage and Remix. After discussion, the Passage Board of Directors unanimously determined that the Merger Agreement and the other transactions contemplated thereby were advisable and in the
            best interests of Passage and its stockholders, approved and declared advisable the Merger and the other transactions contemplated under the Merger Agreement, and recommended that Passage&#8217;s stockholders vote to approve the issuance of Passage
            common stock in the Merger. Additionally, the Directors voted unanimously in favor of terminating its agreement under the Second ARCA with Penn with respect to PBFT02 and in favor of terminating the Amended and Restated Development Services and
            Clinical Supply Agreement with Catalent. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Shortly after the close of trading on Nasdaq on June 24, 2026, representatives of
            Passage and Remix executed the Merger Agreement. Following execution, Passage issued a press release announcing the transaction and filed a Current Report on Form 8-K with the SEC disclosing the Merger Agreement and the termination of its
            agreements with Penn and Catalent.</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTMPB"><!--Anchor--></a>Passage Bio&#8217;s Reasons for the
            Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the course of its evaluation of the Merger, the Merger Agreement and the
            Contemplated Transactions, the Passage Bio Board held numerous meetings, consulted with Passage Bio management, its legal counsel and its financial advisors and reviewed and assessed a significant amount of information. In reaching its decision
            to approve the Merger, the Merger Agreement and the Contemplated Transactions, the Passage Bio Board considered the following factors, among others and not necessarily presented in any order of relative importance: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s business, available capital, market capitalization and the need for future capital, business and strategic
                    objectives, as well as the risks of accomplishing those objectives, including if Passage Bio were to remain an independent company, including in light of; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s decision, announced in April&#160;2026, to initiate a review of strategic alternatives to maximize shareholder value,
                    following final feedback received from the FDA regarding PBFT02; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of investor interest, with respect to investment in Passage Bio, to provide funds for possible further development of
                    its programs, and probability of success and time required for development in relation to the requisite time and costs; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the negative results of the business development efforts by Passage Bio with respect to sale or licensing of assets that could
                    result in meaningful new capital or shared future development costs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possible alternatives to the Merger available to Passage Bio, the range of possible benefits and risks to the Passage Bio
                    stockholders of those alternatives and the timing and the likelihood of accomplishing the goal of any of such alternatives, and the Passage Bio Board&#8217;s assessment that the Merger presented a superior opportunity for Passage Bio
                    stockholders to any such alternatives; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio Board&#8217;s assessment of potential candidates for a strategic transaction, and in particular, the Passage Bio
                    Board&#8217;s view that Remix was the most attractive and promising candidate and the Passage Bio Board&#8217;s belief that the Merger would create more value for Passage Bio&#8217;s stockholders than any of the other proposals that the Passage Bio Board
                    had received or Passage Bio could create as a standalone company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the comprehensive process undertaken by the Passage Bio Board and Passage Bio&#8217;s financial advisors of reviewing and analyzing
                    potential strategic alternatives and merger partner candidates in pursuit of a strategic transaction, including the proposed Merger, in each case considering the current market dynamics; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic transaction
                    with Passage Bio based on the business, scientific, regulatory, intellectual property, financial, accounting and legal due diligence conducted by Passage Bio management and Passage Bio&#8217;s advisors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio Board&#8217;s belief, based in part on the clinical and scientific diligence process conducted by Passage Bio&#8217;s
                    management and reviewed with the Passage Bio Board, that Remix&#8217;s product candidates present a market opportunity with the potential to create meaningful value for the stockholders of the combined company and an opportunity for Passage
                    Bio&#8217;s stockholders to participate in the future potential growth of the combined company; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">112<br/>
        </div>

      </div>

    </div>

    <!--End Page 122-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 123-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential for Passage Bio&#8217;s equityholders to receive certain cash payments following the Closing pursuant to the Passage Bio
                    CVR Agreement, which the Passage Bio Board believed preserves for Passage Bio&#8217;s existing equityholders the potential value from collection of amounts owed by Gemma under certain agreements and obligates the combined company to use
                    commercially reasonable efforts following the Closing to collect such amounts; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s current market capitalization and the potential dilution from any financings required to support its plans and
                    objectives were it to remain an independent company, as well as well as the uncertainty regarding the availability of such financing on terms acceptable to Passage Bio; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">financial market conditions at the time of the signing of the Merger Agreement, including market prices, volatility and trading
                    information with respect to Passage Bio Common Stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the financial analysis presented by Redwood to the Passage Bio Board on June&#160;23, 2026 and Redwood&#8217;s opinion, dated June&#160;23,
                    2026, to the Passage Bio Board that, as of such date and based upon and subject to the qualifications, limitations, assumptions and other matters set forth therein, the Merger Consideration was fair, from a financial point of view, to
                    Passage Bio (as more fully described in the section titled &#8220;<span style="font-style: italic;">The Merger&#8212;Opinion of Passage Bio&#8217;s Financial Advisor</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the strength of the balance sheet of the combined organization, which includes Passage Bio&#8217;s anticipated Passage Bio Net Cash at
                    Closing of approximately $5.0 million, plus the aggregate commitment represented in the Concurrent Financing of approximately $100&#160;million; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio Board&#8217;s belief that the terms of the Merger Agreement and the related agreements, including the parties&#8217;
                    respective representations, warranties and covenants, the conditions to their respective obligations to close the Merger and the termination rights of the parties, are reasonable under the circumstances, including: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the belief that, as a result of arm&#8217;s-length negotiations with Remix, Passage Bio and its representatives negotiated the most
                    favorable Merger Exchange Ratio to which Remix was willing to agree, and that the other terms of the Merger Agreement include the most favorable terms to Passage Bio in the aggregate to which Remix was willing to agree; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the calculation of the Merger Exchange Ratio, Passage Bio Net Cash at the Closing and the estimated number of shares of Passage
                    Bio Common Stock to be issued in the Merger, and the fact that the relative valuation of Passage Bio, and thus the relative percentage ownership of Passage Bio&#8217;s stockholders immediately following the Closing, is subject to change based
                    on the amount of Passage Bio net cash at the Closing; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and customary nature of the conditions to Passage Bio&#8217;s and Remix&#8217;s respective obligations to complete the Merger and
                    the likelihood that the Merger will be completed on a timely basis; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the ability of Passage Bio under the Merger Agreement to consider unsolicited acquisition proposals under certain circumstances
                    and for the Passage Bio Board to potentially change its recommendation in favor of such a proposal should Passage Bio determine such proposal to constitute, or be reasonably likely to result in, a superior offer; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the belief by the Passage Bio Board of the reasonableness of the potential termination fee of $1.5&#160;million, payable by Passage
                    Bio if the Merger Agreement is terminated in certain circumstances; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the belief by the Passage Bio Board of the reasonableness of the potential termination fee of $17.5&#160;million payable by Remix in
                    certain circumstances of termination, which the Passage Bio Board believed would provide deterrence for competing acquisition proposals and provide Passage Bio with compensation for the time, expense and disruption associated with
                    negotiating the transaction if the Merger is not completed under such specified circumstances; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Lock-Up Agreements, pursuant to which certain executive officers, directors and stockholders of Remix who beneficially own
                    an aggregate of approximately 99% of the outstanding Remix Capital Stock as of June&#160;24, 2026, and certain executive officers of Passage Bio have agreed not to transfer their shares of common stock of the combined company for the 180-day
                    period after the effective time of the Merger; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">113<br/>
        </div>

      </div>

    </div>

    <!--End Page 123-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 124-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix support agreements, pursuant to which certain executive officers, directors and stockholders of Remix who beneficially
                    own an aggregate of approximately 93% of the outstanding Remix Capital Stock as of June&#160;24, 2026, solely in their capacities as stockholders, have agreed to execute a written consent or vote all of their shares of Remix Capital Stock in
                    favor of the Merger and against any alternative acquisition proposals, and the fact that stockholders holding the necessary votes to adopt the Merger Agreement and approve the Merger have entered into Remix support agreements; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio support agreements, pursuant to which certain executive officers and directors of Passage Bio, solely in their
                    capacities as stockholders, have agreed, to vote all of their shares of Passage Bio Common Stock in favor of the Proposals and against any alternative acquisition proposals. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In the course of its deliberations, the Passage Bio Board also considered, among other things, a variety of risks and other
                    countervailing factors related to entering into the Merger, the Merger Agreement and the Contemplated Transactions, including: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that the Merger will not be consummated in a timely manner or at all; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential adverse effect of the public announcement of the Merger on Passage Bio&#8217;s business, including potential volatility
                    of the trading price of Passage Bio Common Stock following the announcement of the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that the GM1 Payments and the MLD Payments are not received during the applicable CVR Period, or are
                    insufficient after permitted deductions, or that any other Legacy Assets remaining after the Closing are not otherwise monetized and the consequential potential that Passage Bio equityholders will not receive any consideration under the
                    Passage Bio CVRs and the Passage Bio CVRs may otherwise expire valueless; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that Remix will not be able to complete the Concurrent Financing on the terms or amounts contemplated or at all;
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that certain provisions of the Merger Agreement could have the effect of discouraging competing proposals involving
                    Passage Bio, including the restrictions on Passage Bio&#8217;s ability to solicit alternative acquisition proposals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that under certain circumstances Passage Bio may be required to pay to Remix a termination fee of $1.5&#160;million, and the
                    potential effects of such termination fee; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the provisions of the Merger Agreement that permit the Remix Board, subject to specified conditions, to consider and engage with
                    third parties regarding alternative acquisition proposals and to change its recommendation if the Remix Board determines that such proposal constitutes, or is reasonably likely to result in, a superior offer; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the combined company&#8217;s board will not include a representative of the current Passage Bio Board; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">that the combined company&#8217;s management is not expected to include any current Passage Bio officers; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the early-stage nature of Remix&#8217;s product candidates and the risks and uncertainties associated with development and
                    commercialization of Remix&#8217;s product candidates, including that such product candidates may not generate acceptable clinical data in the future or be successfully developed into products that are marketed and sold, as well as other
                    scientific, technical and regulatory risks and uncertainties; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the substantial fees and expenses incurred or that may be incurred by Passage Bio or the combined company associated with
                    completing the Merger, including the costs associated with any potential transaction related litigation; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility of disruptive stockholder demands or litigation following announcement of the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the Merger may not be completed despite the parties&#8217; efforts or that the Closing may be unduly delayed and the
                    effects on Passage Bio as a standalone company because of such failure or delay, including that a more limited range of alternative strategic transactions may be available to Passage Bio in such an event and that Passage Bio may
                    experience additional significant challenges associated with its need to raise additional capital through the public or private sale of equity securities; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">114<br/>
        </div>

      </div>

    </div>

    <!--End Page 124-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 125-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that under certain circumstances, Passage Bio will not be entitled to receive a termination fee from Remix even in the
                    event that the Merger is not consummated as a result of circumstances which are not under Passage Bio&#8217;s control; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Wedbush, Passage Bio&#8217;s financial advisor, served as financial advisor for Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the dilution to the existing stockholders of Passage Bio upon the consummation of the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the possibility that Passage Bio Net Cash, as more fully described below under the caption &#8220;<span style="font-style: italic;">The

                      Merger Agreement&#8212;Calculation of Passage Bio&#8217;s Net Cash</span>&#8221; in this proxy statement/prospectus, may be lower at the determination time than currently anticipated, which would reduce the relative percentage ownership of Passage
                    Bio&#8217;s existing equityholders in the combined company; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the various other risks associated with the combined company and the Merger, including those described in the section entitled &#8220;<span style="font-style: italic;">Risk Factors</span>&#8221; in this proxy statement/prospectus. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In light of the variety of factors considered in connection with its evaluation
            of the Merger and the complexity of these matters, the Passage Bio Board did not find it useful or practicable to and did not attempt to, quantify, assign or rank any relative or specific weights to the various factors that it considered in
            reaching its determination that the Merger, the Merger Agreement and the Contemplated Transactions are advisable and in best interests of Passage Bio and Passage Bio&#8217;s stockholders. In addition, the Passage Bio Board did not undertake to make
            any specific determination as to whether any particular factor, or any aspect of any particular factor, was favorable or unfavorable to the ultimate determination of the Passage Bio Board, but rather the Passage Bio Board conducted an overall
            analysis of the factors described above, including discussions with and questioning of Passage Bio management and representatives of the Passage Bio&#8217;s legal and financial advisors. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a id="tTMRR"><!--Anchor--></a>Remix&#8217;s Reasons for the Merger
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After careful consideration, at a meeting of the Remix Board on June&#160;23, 2026,
            the Remix Board unanimously (i)&#160;determined that the Contemplated Transactions were fair to, advisable and in the best interests of Remix and its stockholders, (ii) approved and declared advisable the Merger Agreement and the Contemplated
            Transactions and (iii)&#160;recommended, upon the terms and subject to the conditions set forth in the Merger Agreement, that the stockholders of Remix vote to adopt the Merger Agreement and thereby approve the Contemplated Transactions (the &#8220;<span style="font-style: italic; font-weight: bold;">Remix Board Recommendation</span>&#8221;).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In evaluating the Merger Agreement and the Contemplated Transactions, the Remix
            Board consulted with its financial and legal advisors and members of Remix&#8217;s management and considered a number of factors in making the Remix Board Recommendation, including the following factors that it believed generally weighed in favor of
            the Merger and the Contemplated Transactions (which are not presented in a particular order and were neither ranked nor weighted in any manner by the Remix Board). </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Business, Financial Condition and Prospects of Remix as a Private Company</span>. The Remix
                    Board believed that the Contemplated Transactions were more favorable to Remix and its stockholders than the potential value that might result from other alternatives reasonably available to Remix, including the continued operation of
                    Remix on a standalone basis as a private company, in light of a number of factors, including: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix Board&#8217;s assessment of Remix&#8217;s business, operations, financial condition, strategic and competitive positioning,
                    historical and projected cash burn rate and financial performance, preclinical and clinical data, and the risks in achieving Remix&#8217;s prospects and plans; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the potential benefits to Remix and its stockholders that could result from consummating a reverse merger transaction with a
                    publicly listed company, including increased public visibility, enhanced market awareness of Remix&#8217;s business and product pipeline, and improved access to the public capital markets. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Access to Capital</span>. The Remix Board considered: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its belief that Remix would require additional capital to fund its ongoing operations and advance its product development
                    initiatives; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the uncertainty regarding the availability, timing, and terms of such financing available to Remix in the private markets as a
                    standalone private company; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">115<br/>
        </div>

      </div>

    </div>

    <!--End Page 125-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 126-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its belief that investors would be more willing to commit capital to Remix when a defined path to liquidity existed, such as the
                    prospect of becoming a publicly traded company through a reverse merger transaction; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its belief that the Merger with Passage, together with the funding committed in the Concurrent Financing, would be a higher
                    probability and more efficient means to access capital than other potential options considered, including engaging in a similar transaction with other publicly-listed companies or pursuing a private financing or initial public offering&#894;
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cash resources of the combined company, including the Passage Net Cash, expected to be available upon the closing of the
                    Concurrent Financing and consummation of the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">its belief that such cash resources would support Remix&#8217;s current and planned clinical trials and operations into 2028 and
                    provide runway through key clinical milestones&#894; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the access, as a public company, to a broader range of investors to support the development of Remix&#8217;s pipeline than if Remix
                    continued to operate as a privately held company. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Results of Negotiations with Passage; Highest Price Reasonably Available; Risk of Loss of Opportunity. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">The Remix Board considered that Remix and its advisors had engaged in extensive arm&#8217;s-length
                      negotiations with Passage since April&#160;21, 2026 and determined that the expected relative percentage ownership of Passage equityholders and Remix equityholders in the combined company represented the highest relative percentage
                      ownership in the combined company reasonably obtainable for Remix, based on the Remix Board&#8217;s judgment and assessment of the approximate valuations of Passage (including the value the Passage Net Cash is expected to provide to the
                      combined company) and Remix (including the value of the amount of proceeds from the Concurrent Financing). </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">The Remix Board considered the risk that prolonging the process for evaluating other alternatives
                      available to Remix in an effort to increase the relative percentage ownership of Remix equityholders in the combined company prior to executing a definitive merger agreement with Passage both presented a significant risk of the loss
                      of the opportunity to consummate the Contemplated Transactions on the terms and conditions negotiated by Remix and the Remix Board as of June&#160;23, 2026, and was unlikely to yield a proposal that would be a material improvement to the
                      Contemplated Transactions. </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Results of Process Conducted</span>. The Remix Board considered: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the fact that it evaluated a range of strategic alternatives, including remaining a private
                      company, pursuing private financings or an initial public offering or engaging in a similar transaction with other publicly-listed companies; </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the fact that Remix and its advisors contacted a range of potential transaction counterparties
                      during the months leading up to the execution of the Merger Agreement; </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">its belief that, after reviewing various financing options to enhance stockholder value, the
                      Contemplated Transactions represented the most favorable alternative reasonably available to Remix&#894; and </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">its belief that no alternative transactions were reasonably likely to create greater value for
                      Remix&#8217;s stockholders than the Contemplated Transactions, taking into account market conditions, execution risk, timing considerations and the potential dilution associated with such alternatives. </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">High Likelihood of Completion</span>. The Remix Board considered the likelihood of completion
                    of the Contemplated Transactions to be high, particularly in light of the terms of the Merger Agreement and closing conditions, including: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the fact that, substantially concurrently with the execution of the Merger Agreement, certain
                      directors, officers and stockholders of Remix executed the Remix Support Agreements and certain directors and officers of Passage executed the Passage Support Agreements, pursuant to </span></div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">116<br/>
        </div>

      </div>

    </div>

    <!--End Page 126-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 127-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_ebl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 80pt; text-align: left;">which those Persons have agreed, solely in their capacity as stockholders of
            Passage and Remix, respectively, to vote all of their shares of Passage Common Stock or Remix Capital Stock, respectively, in favor of the adoption and approval of the Passage Stockholder Matters and the Remix Stockholder Matters, respectively;
          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the absence of any conditions to the consummation of the Merger that are unlikely to be
                      satisfied, including the absence of a financing condition due to the nature of the consideration; and </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the commitment of Passage to use its commercially reasonable efforts to consummate the
                      Contemplated Transactions. </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Continuity of Remix Business in the Combined Company. The Remix Board considered its expectation that: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the combined company&#8217;s operations would comprise Remix&#8217;s existing business; </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">substantially all of Remix&#8217;s employees, including its management, will serve in similar roles at
                      the combined company&#894; and </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the combined company would adopt the name &#8220;Remix Therapeutics, Inc.&#8221; at the Closing. </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Stockholder Access to Liquidity</span>. The Remix Board considered that: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">the Contemplated Transactions would provide Remix&#8217;s current stockholders with greater liquidity
                      by owning publicly-traded stock than if Remix continued to operate as a privately held company; and </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">that shares of Passage Common Stock issued to Remix stockholders will be registered on a Form&#160;S-4
                      registration statement and will become freely tradable for Remix stockholders who are not affiliates of Remix and who are not parties to the Lock-Up Agreements. </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Opportunity to Engage with Third Parties</span>. The Remix Board considered the terms of the
                    Merger Agreement permitting Remix, under certain specified circumstances prior to the approval of the Remix Stockholder Matters by the Required Remix Stockholder Vote, to furnish non-public information regarding Remix to, and enter into
                    discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal of Remix which the Remix Board determines in good faith, after consultation with Remix&#8217;s financial advisors and outside legal counsel,
                    constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Ability to Terminate the Merger Agreement in Order to Accept a Superior Proposal</span>. The
                    Remix Board considered the terms of the Merger Agreement permitting Remix, under certain specified circumstances prior to the approval of the Remix Stockholder Matters by the Required Remix Stockholder Vote, to terminate the Merger
                    Agreement to enter into an Alternative Acquisition Agreement with respect to a Superior Proposal, subject to certain conditions, including that Remix pay Passage the $17.5 million termination fee. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Other Terms of the Merger Agreement. The Remix Board considered: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">that the Merger Agreement and other transaction documents were negotiated at arm&#8217;s length between
                      Remix, on the one hand, and Passage, on the other hand, with the assistance of their respective financial and legal advisors; </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">its belief that the material terms of the Merger Agreement, taken as a whole, were reasonable to
                      Remix based on the applicable facts and circumstances; </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">its belief that the $17.5&#160;million termination fee payable under the Merger Agreement if Remix
                      terminates the Merger Agreement to enter into an Alternative Acquisition Agreement with respect to a Superior Proposal was reasonable in amount and not preclusive of alternative proposals; </span></div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">117<br/>
        </div>

      </div>

    </div>

    <!--End Page 127-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 128-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">that the terms of the Merger Agreement permit Remix, under circumstances specified in the Merger
                      Agreement, to obtain an injunction, specific performance and other equitable relief to prevent breaches of the Merger Agreement and to enforce specifically the terms and provisions thereof, without any requirement to post a bond,
                      surety or other security; and </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">that the terms of the Merger Agreement provide Remix sufficient operating flexibility to conduct
                      its business in the ordinary course until the earlier of the consummation of the Merger or the termination of the Merger Agreement. </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Potential Tax Consequences for Remix Stockholders</span>. The Remix Board considered its
                    expectation that the Merger will be treated as a reorganization for U.S. federal income tax purposes, with the result that the Remix stockholders will generally not recognize taxable gain or loss for U.S. federal income tax purposes
                    with respect to the Merger. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Appraisal Rights</span>. The Remix Board considered the availability of appraisal rights under
                    Section&#160;262 of the DGCL, which permits holders of Remix Capital Stock who properly exercise such rights to seek judicial determination of the fair value of their shares of Remix Capital Stock. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the course of its deliberations, the Remix Board also considered a variety of
            uncertainties, risks and potentially negative factors (which are not presented in a particular order and were neither ranked nor weighted in any manner by the Remix Board), including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the potential benefits of the Contemplated Transactions may not be realized&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that the Contemplated Transactions might not be consummated in a timely manner or at all, including as a result of the
                    failure of Passage to obtain the Required Passage Stockholder Vote, and the potential adverse effect on the reputation of Remix and its ability to obtain future financing if the Merger and Concurrent Financing are not completed&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the risk that future sales of common stock by existing Passage stockholders may cause the price of Passage Common Stock to fall,
                    thus reducing the value of Passage Common Stock received by Remix&#8217;s stockholders in the Merger&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the size of the termination fees payable by Remix to Passage upon the occurrence of certain events, and the potential effect of
                    such termination fees in deterring potential acquirers from proposing an alternative transaction that may be more advantageous to Remix stockholders&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the exchange ratio used to establish the number of shares of Passage Common Stock to be issued to Remix stockholders in the
                    Merger is fixed, except for adjustments due to the amount of Passage Net Cash, the amount of proceeds received by Remix in the Concurrent Financing and changes in the parties&#8217; outstanding capital stock at Closing, and thus the relative
                    percentage ownership of Passage stockholders and Remix stockholders in the combined company immediately following the consummation of the Merger is similarly fixed&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Wedbush, Remix&#8217;s financial advisor, served as the exclusive financial advisor for the Merger; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the right of Passage, under certain specified circumstances prior to the approval of the Passage Stockholder Matters by the
                    Required Passage Stockholder Vote, to furnish non-public information regarding Passage to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal of Passage which the Passage
                    Board determines in good faith, after consultation with Passage&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the right of Passage, under certain specified circumstances prior to the approval of the Passage Stockholder Matters by the
                    Required Passage Stockholder Vote, to terminate the Merger Agreement to enter into an Alternative Acquisition Agreement with respect to a Superior Proposal, subject to certain conditions, including that Passage pay Remix the
                    $1.5&#160;million termination fee; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the expenses incurred and anticipated to be incurred in connection with the Merger and related administrative costs associated
                    with combining the organizations, including pursuant to the CVR Agreement&#894; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">118<br/>
        </div>

      </div>

    </div>

    <!--End Page 128-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 129-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the additional costs and compliance obligations Remix will incur that are associated with operating as a public company
                    following the consummation of the Merger&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the fact that Passage&#8217;s representations and warranties in the Merger Agreement do not survive the Closing, and the potential
                    risk of liabilities that may arise after the Closing&#894; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">various other risks associated with the combined company and the Merger, including the risks described in the section of this
                    proxy statement/prospectus entitled &#8220;<span style="font-style: italic;">Risk Factors</span>&#8221;. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After taking into account all of the factors set forth above, as well as others,
            the Remix Board (i) concluded that the potential benefits of the Contemplated Transactions outweighed any negative or unfavorable considerations, (ii)&#160;determined that the Contemplated Transactions were fair to, advisable and in the best
            interests of Remix and its stockholders and (iii) made the Remix Board Recommendation to Remix&#8217;s stockholders.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This discussion of the information and factors considered by the Remix Board
            includes the material positive and negative factors considered by the Remix Board, but it is not intended to be exhaustive and may not include all the factors considered by the Remix Board. The Remix Board did not quantify or assign any
            specific weights to the various factors that it considered in reaching its determination to approve the Merger Agreement and the Contemplated Transactions. Rather, the Remix Board viewed its position and recommendation as being based on the
            totality of the information presented to, and factors considered by, it. In addition, individual members of the Remix Board may have given differing weights to different factors.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The explanation of the reasoning of the Remix Board and certain information
            presented in this section is forward-looking in nature and should be read in light of the factors set forth in the section of this proxy statement/prospectus entitled &#8220;<span style="font-style: italic;">Cautionary Note&#160;Regarding Forward-Looking
              Statements</span>.&#8221; </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tTMORV"><!--Anchor--></a>Opinion of Redwood (Passage
            Bio&#8217;s Financial Advisor) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio retained Redwood to provide an opinion to the Passage Bio Board as to
            the fairness, from a financial point of view, to Passage Bio of the Merger Consideration (as defined below) proposed to be paid pursuant to the terms of the Merger Agreement. The Passage Bio Board selected Redwood to act as Passage Bio&#8217;s
            financial advisor to deliver such opinion based on Redwood&#8217;s qualifications, reputation and experience. Redwood is a valuation firm that has substantial experience in financial analyses relating to transactions similar to this transaction. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;23, 2026, Redwood rendered to the Passage Bio Board (in its capacity as
            such) its oral opinion, which was subsequently confirmed by delivery of a written opinion dated as of June&#160;23, 2026 addressed to the Passage Bio Board, that, as of such date and based upon and subject to various assumptions made, procedures
            followed, matters considered, and qualifications and limitations upon the review undertaken by Redwood in preparing its opinion, the Merger Consideration to be paid by Passage Bio in the proposed Merger is fair, from a financial point of view,
            to Passage Bio. The Passage Bio Board considered the financial analyses of Redwood and the opinion of Redwood as one of several factors in making its determination to approve the Merger Agreement and the Merger. Redwood&#8217;s opinion was not the
            sole factor considered by the Passage Bio Board and should not be viewed as determinative of the views of the Passage Bio Board or Passage Bio&#8217;s management with respect to the Merger Consideration or the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The full text of Redwood&#8217;s written opinion, dated June&#160;23, 2026, which describes
            the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Redwood in preparing its opinion, is attached as Annex&#160;B to this proxy statement/prospectus and is incorporated
            herein by reference. The summary of the written opinion of Redwood set forth below is qualified in its entirety by the full text of Redwood&#8217;s written opinion. Passage Bio stockholders are urged to read the opinion in its entirety. Redwood
            provided its financial advisory services and opinion for the information and assistance of the Passage Bio Board (in its capacity as such and not in any other capacity) in connection with and for purposes of its consideration of the Merger and
            Redwood&#8217;s opinion addressed only the fairness, from a financial point of view, as of the date thereof, to Passage Bio of the Merger Consideration to be paid pursuant to the Merger Agreement. Redwood&#8217;s opinion did not address any other term or
            aspect of the Merger Agreement or the Merger and does not constitute a recommendation to any stockholder of Passage Bio or Remix as to how such holder should vote in connection with the Merger or the Proposals, or any other person as to how
            such stockholder or other person should vote with respect to any matter relating to the Merger or otherwise act with respect to the Merger or any other matter. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">119<br/>
        </div>

      </div>

    </div>

    <!--End Page 129-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 130-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The full text of Redwood&#8217;s written opinion should be read
            carefully in its entirety for a description of the assumptions made, procedures followed, matters considered, and qualifications and limitations upon the review undertaken by Redwood in preparing its opinion. The summary of the opinion of
            Redwood set forth in this proxy statement/prospectus is qualified in its entirety by reference to the full text of the opinion.<span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Scope of Redwood&#8217;s Analysis </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with preparing its opinion, Redwood (i) reviewed a draft dated
            June&#160;22, 2026 of the Merger Agreement, which, for purposes of its opinion, Redwood assumed to be in all material respects identical to the agreement to be executed by the parties; (ii) reviewed drafts of the agreements governing the Concurrent
            Financing, including (A) a draft dated June&#160;23, 2026 of the Subscription Agreement and (B) a draft dated June&#160;17, 2026 of the term sheet for the Convertible Promissory Note&#160;Purchase Agreement (the &#8220;Convertible Note&#160;Term Sheet&#8221;), which set forth
            the principal terms on which certain investors will purchase convertible promissory notes of Remix pursuant to the Remix Note&#160;Purchase Agreement (2026) (as defined in the Merger Agreement); (iii) reviewed the form of CVR attached as Exhibit&#160;F
            to the draft Merger Agreement; (iv) reviewed certain publicly available business and financial information concerning Passage Bio and Remix, and the industries in which they operate; (v) reviewed the current and historical market prices of
            Passage Bio Common Stock and certain publicly traded securities of other companies that Redwood deemed relevant; (vi) at Passage Bio&#8217;s direction, reviewed and relied upon for Redwood&#8217;s opinion and analysis (A) the estimated balance sheet of
            Passage Bio corresponding with the estimated closing date of the Merger, (B) the pro forma capitalization table and option ledger of Passage Bio and Remix corresponding with the proposed closing date of the Merger, and (C) the illustrative
            example of the calculation of the Remix Merger Shares (as defined in the Merger Agreement) set forth in Section&#160;1.1(a)(iii) of the Passage Disclosure Schedule to the draft Merger Agreement; (vii)&#160;reviewed summaries prepared internally by
            Passage Bio of its efforts to solicit interest from third parties with respect to a possible acquisition or business combination of Passage Bio; and (viii) performed such other financial studies and analyses and considered such other
            information as Redwood deemed appropriate for the purposes of its opinion. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Redwood held discussions with certain members of the management of
            Passage Bio with respect to certain aspects of the Merger, the past and current business operations of Passage Bio, Merger Sub and Remix, the financial condition and future prospects and operations of Passage Bio, Merger Sub and Remix, the
            effects of the Merger on the financial condition and future prospects of Passage Bio, and certain other matters Redwood believed necessary or appropriate to its inquiry. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In giving its opinion, Redwood relied upon and assumed the accuracy and
            completeness of all information that was publicly available or was furnished to or discussed with it by Passage Bio or otherwise reviewed by or for Redwood, and Redwood did not assume any responsibility for independent verification of any such
            information. Redwood did not independently verify any such information or its accuracy or completeness and, pursuant to its engagement letter with Passage Bio, dated June&#160;11, 2026 (the &#8220;<span style="font-style: italic; font-weight: bold;">Engagement

              Letter</span>&#8221;), Redwood did not assume any obligation to undertake any such independent verification. Redwood did not conduct nor was Redwood provided with any valuation or appraisal of any assets or liabilities, nor did Redwood evaluate the
            solvency, creditworthiness or fair value of Passage Bio, Merger Sub, Remix or the Surviving Corporation under any applicable laws relating to bankruptcy, insolvency, fraudulent conveyance or similar matters. Redwood did not express any view or
            render any opinion regarding the legal, regulatory or tax consequences of the Merger or any portion thereof to Passage Bio, its stockholders or any other party, and Redwood relied on the assessments made by legal, regulatory and tax advisors to
            Passage Bio with respect to such issues. In relying on the estimated balance sheet and pro forma capitalization table of Passage Bio and other financial data, analyses and projections provided to Redwood or discussed with Redwood by the Passage
            Bio Board or Passage Bio&#8217;s management, Redwood assumed with the Passage Bio Board&#8217;s consent that they had been reasonably prepared based on assumptions reflecting the best currently available estimates and judgments by Passage Bio&#8217;s management.
            Redwood expressed no view as to such estimates or projections or the assumptions on which they were based. Redwood assumed that the Merger will be consummated on the terms set forth in the draft Merger Agreement, and that the definitive Merger
            Agreement will not differ in any material respects from the draft thereof furnished to it or have any waiver, modification or amendment of any term or condition that is material to its analysis. Redwood assumed that the Allocation Certificate
            (as defined in the Merger Agreement) will be prepared in good faith and in accordance with the terms of the Merger Agreement and the organizational documents of Remix and the contracts applicable to Remix Capital Stock. Redwood assumed that the
            Concurrent Financing would be consummated on the terms and conditions described in the Subscription Agreement and the Convertible Note&#160;Term Sheet, with aggregate gross cash proceeds of at least the Concurrent </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">120<br/>
        </div>

      </div>

    </div>

    <!--End Page 130-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 131-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Investment Amount (as defined in the Merger Agreement). Redwood assumed that
            any Reverse Stock Split (as defined in the Merger Agreement) effected in connection with the Merger will not affect the relative economic interests of the stockholders. Redwood assumed that the Merger will qualify as a reorganization within the
            meaning of Section&#160;368(a) of the Code. Redwood also assumed that the representations and warranties made by Passage Bio, Merger Sub and Remix in the Merger Agreement and the related agreements are and will be true and correct in all respects
            material to its analysis. Redwood further assumed that all material governmental, regulatory or other consents and approvals necessary for the consummation of the Merger will be obtained without any adverse effect on Passage Bio, Merger Sub or
            Remix or on the contemplated benefits of the Merger. Redwood did not express any opinion as to the Concurrent Financing Merger Shares. At the direction of Passage Bio&#8217;s management, Redwood did not analyze the value of the Passage Bio CVRs or
            ascribe value to any Legacy Assets (as defined in the Merger Agreement), and Redwood expressed no opinion with respect thereto. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood&#8217;s opinion was necessarily based on economic, market and other conditions
            as in effect on, and the information made available to Redwood as of, the date thereof. Subsequent developments may affect Redwood&#8217;s opinion and Redwood does not have any obligation to update, revise, or reaffirm its opinion. Redwood&#8217;s opinion
            is limited solely to the fairness, from a financial point of view, to Passage Bio of the Merger Consideration to be paid in the proposed Merger. Redwood was not asked to opine as to, and its opinion does not in any manner address, (i)&#160;the
            fairness of the Merger to the holders of any class of securities, creditors or other constituencies of Passage Bio or Remix, (ii) the underlying decision by Passage Bio to engage in the Merger, (iii) the terms, structure or fairness of the
            Concurrent Financing, including the Subscription Agreement, the Convertible Note&#160;Term Sheet, the Remix Convertible Notes (2026) (as defined in the Merger Agreement) or any other agreement or instrument entered into in connection with the
            Concurrent Financing, or the fairness thereof to any party, (iv) the terms, value or fairness of the Passage Bio CVRs, the CVR Agreement or the Legacy Asset Dispositions (each as defined in the Merger Agreement), (v) the terms or fairness of
            any Stockholder Support Agreement, Lock-Up Agreement, Passage Equity Plan (each as defined in the Merger Agreement), employment or severance arrangement, or any other agreement, arrangement or understanding entered into in connection with, or
            contemplated by, the Merger, (vi) the relative merits of the Merger as compared to any alternative business strategies or transactions that might have been available to Passage Bio, or (vii) the prices at which shares of Passage Bio Common
            Stock or any other securities may trade at any time. Furthermore, Redwood expressed no opinion with respect to the amount or nature of any compensation to any officers, directors, or employees of any party to the Merger, or any class of such
            persons, relative to the Merger Consideration or with respect to the fairness of any such compensation. The opinion should not be construed as creating any fiduciary duty on the part of Redwood to any party. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood was not authorized to, and did not, solicit any expressions of interest
            from any other parties with respect to the sale of all or any part of Passage Bio, any alternative transaction involving Passage Bio, or any other transaction. Redwood did not participate in negotiations with respect to the terms of the Merger,
            the Merger Agreement, the Concurrent Financing or any related transactions, nor did Redwood participate in the determination of the Merger Consideration or the allocation methodology. Redwood was not asked to opine on, and expressed no opinion
            as to, whether the Merger Consideration represents the highest or best price reasonably attainable by Passage Bio. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">The opinion of Redwood was approved by the fairness opinion
            committee of Redwood Valuation Partners, LLC, and was provided to the Passage Bio Board (in its capacity as such) in connection with and for the purposes of its evaluation of the Merger. The opinion of Redwood does not constitute a
            recommendation to any stockholder of Passage Bio, Merger Sub or Remix as to how such stockholder should vote or act with respect to the Merger, the Proposals or any other matter.<span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Summary of Redwood Financial Analysis </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a summary of the material financial analyses performed by
            Redwood in connection with rendering its opinion that were included in Redwood&#8217;s presentation reviewed by the Passage Bio Board, and is not a complete description of the fairness opinion or the underlying analyses, or of the factors considered
            in connection with, the analyses or the fairness opinion. The preparation of a fairness opinion is a complex analytical process involving various determinations as to the most appropriate and relevant methods of financial analysis and the
            application of those methods to the particular circumstances and, therefore, a fairness opinion is not readily susceptible to partial analysis or summary description. Redwood arrived at its opinion based on the results of all analyses
            undertaken by it and factors assessed as a whole, and it did not draw, in isolation, conclusions from or with regard to any one factor or method of analysis for purposes of its opinion. Accordingly, Redwood believes that its analyses must be
            considered as a whole and that selecting portions of such analyses and factors, without considering all analyses and </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">121<br/>
        </div>

      </div>

    </div>

    <!--End Page 131-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 132-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">factors, could create a misleading or incomplete view of the processes
            underlying Redwood&#8217;s analyses and its opinion. While this summary describes the analyses and factors that Redwood deemed material in its presentations to the Passage Bio Board and its opinion, it does not purport to be a comprehensive
            description of all analyses and factors considered by Redwood. The opinion is based on the comprehensive consideration of the various analyses performed. This summary is qualified in its entirety by reference to the full text of the opinion
            attached as Annex&#160;B to this proxy statement/prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In performing its analyses, Redwood conducted such research as it deemed relevant
            and made numerous assumptions with respect to Passage Bio, Remix, Merger Sub, their respective industries, general business and economic conditions and other matters, many of which are beyond the control of Passage Bio or any other parties to
            the Merger. None of Passage Bio, Merger Sub, Remix, Redwood, nor any other person or entity assumes responsibility if future results differ materially from the information Passage Bio furnished to or discussed with Redwood or that Redwood
            otherwise reviewed. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition,
            analyses relating to the value of Passage Bio, Remix or the Surviving Corporation do not represent appraisals or reflect the prices at which any entity may actually be sold or its securities traded. The assumptions and estimates used in the
            financial analyses, and subsequent results, are inherently uncertain. Except as otherwise noted, the following quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before June&#160;22,
            2026 (the last trading day before the issuance of Redwood&#8217;s opinion to the Passage Bio Board) and is not necessarily indicative of current or future market conditions.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial analyses summarized below include information presented in tabular
            format. In order for Redwood&#8217;s financial analyses to be fully understood, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data
            below without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of Redwood&#8217;s financial analyses. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Analysis of Merger Consideration </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood conducted an analysis of the Merger Consideration to be paid by Passage
            Bio pursuant to the Merger Agreement. The aggregate number of shares of Passage Bio Common Stock issuable to holders of Remix Common Stock in the Merger (other than the shares issued in the Concurrent Financing) is referred to herein as the &#8220;<span style="font-style: italic; font-weight: bold;">Merger Consideration</span>.&#8221; For a description of the terms of the Merger, including the allocation methodology used to determine the Merger Consideration, see the section entitled &#8220;<span style="font-style: italic;">The Merger Agreement</span>&#8221; beginning on page <a href="#tTMA">137</a> of this proxy statement/prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In preparing its analysis, with the consent and knowledge of the Passage Bio
            Board, Redwood took into account certain information and representations that Passage Bio&#8217;s management provided, including that (i) the amount of the Concurrent Financing would be no less than $100.0&#160;million and would occur immediately prior to
            the Effective Time, (ii) Passage Bio Net Cash (as defined in the Merger Agreement) would be approximately $10.6&#160;million at the Effective Time, (iii) the Remix Equity Value (as defined in the Merger Agreement) prior to the Concurrent Financing
            was estimated to be $226.0&#160;million, (iv) the total invested capital of Remix prior to the Concurrent Financing was $245.8&#160;million, and (v) the number of fully diluted outstanding shares of Passage Bio Common Stock was 3,238,579&#160;shares.
            Additionally, Redwood was advised by Passage Bio that holders of Passage Bio Common Stock, will receive Passage Bio CVR relating to contingent proceeds derived from certain existing license agreements of Passage Bio (net of certain expenses)
            and that Passage Bio is not expected to have any continuing business operations on a standalone basis other than those incidental to Passage Bio&#8217;s status as a publicly traded company on Nasdaq. Therefore, Redwood did not ascribe any value to
            the existing business operations of Passage Bio or the Passage Bio CVRs. Further, Passage Bio&#8217;s management provided Redwood with short-term forecasts created to estimate Passage Bio Net Cash at Closing. No long-term financial forecasts were
            provided to Redwood, nor were otherwise publicly available, for Passage Bio, Merger Sub or Remix. As a result, Redwood did not perform a discounted cash flow analysis with respect to Passage Bio, Merger Sub or Remix. In addition, Redwood did
            not make any independent evaluation or appraisal of any of the assets or liabilities (contingent, derivative, off-balance-sheet or otherwise) of Passage Bio, Merger Sub or Remix, nor was Redwood furnished with any such evaluation or appraisal,
            and Redwood was not asked to conduct, and did not conduct, a physical inspection of the properties or assets of Passage Bio, Merger Sub or Remix. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">122<br/>
        </div>

      </div>

    </div>

    <!--End Page 132-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 133-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Premium to Net Cash </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood reviewed publicly available information relating to the financial terms
            of life sciences reverse mergers between June&#160;23, 2023 and June&#160;22, 2026. Redwood reviewed the total premium, defined as the total consideration amount less net cash of the target company, offered as consideration for each public target, along
            with other quantitative metrics. The table below shows the close date, surviving company, public company target, and premium. The selected group listed below was chosen based on the business operations of each target company, industry of the
            target company, financial information of the target company, recency of the respective transaction, and other factors. Redwood also made qualitative judgments when performing its analysis, based on its experience and professional judgment,
            concerning differences between the operational, business or financial characteristics of Passage Bio to the companies listed below that could affect the public trading, acquisition or other values of each in order to provide a context in which
            to consider the results of the quantitative analysis. Although the target companies in the reverse mergers listed below were used for comparison purposes, none of the target companies is directly comparable to Passage Bio. These companies may
            have characteristics that are materially different than Passage Bio, and Redwood did not have access to non-public information on any of the transactions listed below. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 66pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 156pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Close Date</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surviving Company</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Public Company</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Value, Net<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">of Cash <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">($MM) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October-25</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oncoinvent ASA</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BerGenBio ASA (OB:BGBIO)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July-25</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ImageneBio, Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ikena Oncology, Inc. (NasdaqGM:IKNA)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">20 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June-25</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Crescent Biopharma, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">GlycoMimetics (Nasdaq: GLYC)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April-25</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jade Biosciences, Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aerovate Therapeutics (Nasdaq: AVTE)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April-25</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tvardi Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cara Therapeutics (Nasdaq: CARA)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">20 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December-24</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Palvella Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pieris Pharmaceuticals (Nasdaq: PIRS)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October-24</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">TuHURA Biosciences, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kintara Therapeutics (Nasdaq: KTRA)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">11 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October-24</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Wex Pharmaceuticals Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Virios Therapeutics (Nasdaq: VIRI)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">September-24</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Oruka Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ARCA Biopharma (Nasdaq: ABIO)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August-24</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Firefly Neurosciences, Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">WaveDancer (Nasdaq: WAVD)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">14 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June-24</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tetonic Therapeutics</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AVROBIO (Nasdaq: AVRO)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">13 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">April-24</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tawsfynydd Therapeutics</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Onconova Therapeutics (Nasdaq: ONTX)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">11 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March-24</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Serina Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AgeX Therapeutics (Nasdaq: AGE)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March-24</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Q32 Bio Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Homology Medicines (Nasdaq: FIXX)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">20 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March-24</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">LENZ Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Graphite Bio (Nasdaq: GRPH)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">12 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March-24</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ImmunogenX, LLC</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">First Wave BioPharma (FWBI)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">15 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December-23</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cyclo Therapeutics (Nasdaq: CYTH)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Applied Molecular Transport (Nasdaq: AMTI)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">December-23</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Neurogene Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Neoleukin Therapeutics (Nasdaq: NLTX)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">14 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November-23</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cartesian Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Selecta Biosciences (Nasdaq: RNAC)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">13 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">November-23</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Korro Bio, Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Frequency Therapeutics (Nasdaq: FREQ)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">15 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October-23</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lung Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aileron Therapeutics (Nasdaq: ALRN)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October-23</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Notable Labs, Ltd.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vascular Biogenics Ltd. (Nasdaq: VBLT)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">20 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">September-23</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dianthus Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Magenta Therapeutics (Nasdaq: MGTA)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">20 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August-23</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">EIP Pharma (CervoMed)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Diffusion Pharmaceuticals (Nasdaq: DFFN)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">10 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June-23</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">TeraImmune Inc.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Baudax Bio (Nasdaq: BXRX)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 66pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June-23</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 156pt; padding-top: 1.01pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spyre Therapeutics, Inc.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aeglea BioTherapeutics (Nasdaq: AGLE)</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">25</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 66pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 156pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood reviewed the value delivered for the public entity, net of cash, from the
            selected transactions, of which the median was $12&#160;million and range from 25th percentile to 75th percentile measured $8.5&#160;million to $15&#160;million, respectively. These observations compare to the premium in the proposed Merger of $15&#160;million as
            set forth in the Merger Agreement. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Initial Public Offering Multiples </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood considered certain financial data and financial terms of selected initial
            public offerings (&#8220;IPOs&#8221;) that, in its view, were deemed comparable to Remix in consideration of Remix&#8217;s industry, diversification, clinical stage of development for its lead asset, underlying technology, target of therapeutics, and other
            factors. The financial data </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">123<br/>
        </div>

      </div>

    </div>

    <!--End Page 133-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 134-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reviewed by Redwood included the value of capital raised prior to each
            selected IPO and the related market value of the invested capital (&#8220;MVIC&#8221;) as indicated by each offering, of which Redwood derived implied multiples (&#8220;MVIC Multiples&#8221;). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The selected IPOs listed below were chosen based on the business operations of
            each company, its industry, diversification, financial information, technology, therapeutic target, recency of the respective transaction, and other factors. Redwood also made qualitative judgments when performing its analysis, based on its
            experience and professional judgment, concerning differences between the operational, business or financial characteristics of Remix to the companies listed below that could affect the public trading or relative values of each in order to
            provide a context in which to consider the results of the quantitative analysis. Although the companies participating in an initial public offering listed below were used for comparison purposes, none of the target companies is directly
            comparable to Remix. These companies may have characteristics that are materially different than Remix, and Redwood did not have access to non-public information on any of the transactions listed below. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 126pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">IPO Date</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 126pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Target</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Phase</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">MVIC Multiple </div>
                </td>

  </tr>

  <tr>

    <td style="width: 108pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;2026</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 126pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Parabilis Medicines</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.6x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">February&#160;2026</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Generate Biomedicines</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.8x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;2025</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maze Therapeutics</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">0.8x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;2024</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rapport Therapeutics</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.9x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">June&#160;2024</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 126pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alumis</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.0x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 108pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">February&#160;2024</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 126pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Metagenomi</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1.3x</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 126pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood reviewed the above transactions, of which the median MVIC Multiple was
            1.6x, and the range from the 25<sup>th</sup> percentile to 75<sup>th</sup> percentile measured 1.1x to 1.8x. These observations were compared to an MVIC Multiple for Remix implied in the proposed Merger of 0.9x based upon the aforementioned
            information provided to Redwood. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Merger and Acquisition Proposals </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood considered certain financial data and financial terms of selected merger
            and acquisition transactions that, in its view, were deemed comparable to Remix in consideration of their industry, diversification, clinical stage of development for its lead asset, underlying technology, target of therapeutics, recency of the
            respective transaction, and other factors. The financial data reviewed included the value of capital raised prior to each selected transaction and the related MVIC as indicated by the transaction, of which Redwood derived implied MVIC
            Multiples. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood also made qualitative judgments when performing its analysis, based on
            its experience and professional judgment, concerning differences between the operational, business or financial characteristics of Remix to the transactions listed below that could affect relative values of each in order to provide a context in
            which to consider the results of the quantitative analysis. Although the companies subject to each transaction below were used for comparison purposes, none of the target companies is directly comparable to Remix. These companies may have
            characteristics that are materially different than Remix, and Redwood did not have access to non-public information on any of the transactions listed below. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The selected transactions were as follows: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 120pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 72pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Close Date</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Target</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Acquirer</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Phase</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">MVIC Multiple </div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">October&#160;2025</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Orbital Therapeutics</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bristol Myers Squibb</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preclinical</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.6x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">August&#160;2024</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Morphic Holding</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Eli Lilly</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.4x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">May&#160;2024</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Alpine Immune Sciences</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vertex Pharmaceuticals</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.6x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March&#160;2024</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Harpoon Therapeutics</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Merck</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.2x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">February&#160;2024</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">RayzeBio</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Bristol Myers Squibb</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">9.8x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">February&#160;2024</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Gracell Biotechnologies</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AstraZeneca</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.2x </div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.01pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">January&#160;2024</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Carmot Therapeutics</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Roche</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">7.0x</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 120pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 108pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 72pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood reviewed the above transactions, of which the median MVIC Multiple was
            5.6x, and the range from the 25<sup>th</sup> percentile to 75<sup>th</sup> percentile measured 5.3x to 8.3x . These observations were compared to an MVIC Multiple for Remix implied in the proposed Merger of 0.9x based upon the aforementioned
            information provided to Redwood. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">124<br/>
        </div>

      </div>

    </div>

    <!--End Page 134-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 135-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Other Factors </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood described for the Board certain additional factors solely for reference
            and informational purposes only, including, among other things, the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Historical Stock Trading Price Analysis. Redwood reviewed the market capitalization implied by the closing trading prices of
                    publicly traded shares of Passage Bio during the 30 trading days ended June&#160;22, 2026, which reflected a high of $19.4&#160;million and low of $13.6&#160;million, respectively, during the period; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Public Comparable Companies. In connection with Redwood&#8217;s financial analysis, Redwood analyzed publicly available information
                    pertaining to the enterprise values of certain publicly traded companies deemed comparable to the Surviving Company. Redwood identified seven publicly traded companies, of which enterprise value ranged from $233&#160;million to $1.6&#160;billion,
                    with a median of $439&#160;million. This was compared to the calculated enterprise of the Surviving Company of $248&#160;million based upon the terms of the Merger Agreement and information provided by Passage Bio. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Redwood Valuation Partners, LLC operates as a valuation advisory firm, delivering
            financial analyses to meet the needs of investors, board members, executive and finance teams. Other than services in connection with the Merger, in the past two years, Redwood has not provided financial advisory or other services to, or
            received compensation from, Passage Bio, Merger Sub or Remix. Redwood may provide financial advisory services to, or with respect to, Passage Bio, Merger Sub, Remix, the Surviving Corporation or their affiliates in the future, and would expect
            to receive fees for providing such services. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio engaged Redwood to act as financial advisor to the Passage Bio Board
            in connection with the Merger based on Redwood&#8217;s qualifications, experience, and reputation, as well as extensive experience working in the biotechnology sector. Redwood regularly engages with clients to provide independent assessments of value
            in connection with mergers and acquisitions, divestitures, change of control and other purposes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio and Remix determined the Merger Consideration through arm&#8217;s-length
            negotiations and was approved by the Passage Bio Board. Redwood&#8217;s financial analyses and opinion represented just one of several factors the Passage Bio Board considered in evaluating the Merger. The analyses summarized above should not be
            interpreted as determinative of the Passage Bio Board&#8217;s or Passage Bio management&#8217;s views regarding the Merger Consideration, nor should they be seen as an indication as to whether the Passage Bio Board would have been willing to approve a
            different consideration as fair. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio agreed to pay Redwood a fee of $200,000 for the delivery of its
            fairness opinion, no portion of which was contingent on the completion of the Merger or the conclusions set forth in its opinion. In addition, Passage Bio agreed to indemnify Redwood and its related parties against certain liabilities and
            expenses resulting from any claims related to or arising out of the Merger or Redwood&#8217;s engagement to provide its opinion. Redwood&#8217;s liability in connection with its opinion is limited in accordance with the terms set forth in its Engagement
            Letter with Passage Bio. Redwood and its affiliates do not hold any investment stake in Passage Bio, Merger Sub, Remix or any party to the Concurrent Financing. Redwood also does not have, and has not had during the two years preceding the date
            of its opinion, any material financial advisory or other material commercial or financial relationship with any party to the Concurrent Financing that was material to its opinion. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTMIPB"><!--Anchor--></a>Interests of Passage Bio&#8217;s
            Directors and Executive Officers in the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In considering the recommendation of the Passage Bio Board with respect to
            issuing shares of Passage Bio Common Stock in the Merger and other matters to be acted upon by the Passage Bio stockholders at the Passage Bio special meeting, the Passage Bio stockholders should be aware that Passage Bio&#8217;s directors and
            executive officers have interests in the Merger that are different from, or in addition to, the interests of Passage Bio stockholders generally. The Passage Bio Board was aware of these potential conflicts of interest and considered them, among
            other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Passage Bio stockholders approve the proposals to be presented to the Passage Bio stockholders for consideration at the Passage
            Bio special meeting as contemplated by this proxy statement/prospectus. These interests include the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Under the Merger Agreement, Passage Bio&#8217;s directors and executive officers are entitled to continued indemnification, expense
                    advancements and insurance coverage; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">125<br/>
        </div>

      </div>

    </div>

    <!--End Page 135-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 136-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In connection with the Merger, each then-outstanding and unvested Passage Bio Option will be accelerated in full, effective as
                    of immediately prior to the Effective Time; following the Closing, each unexpired and unexercised Passage Bio Option will continue on the same terms and conditions in effect as of immediately prior to the Effective Time. The vesting of
                    each outstanding and unvested Passage Bio Restricted Stock Unit Award will be accelerated in full effective no later than the day immediately prior to the record date for the Pre-Closing Distribution, and each such award will be settled
                    in shares of Passage Bio Common Stock (net of applicable tax withholding); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">In connection with the Merger, Passage Bio&#8217;s executive officers may receive an extension of the post-termination exercise period
                    of their outstanding Passage Bio Options, subject to their agreement to certain conditions; and. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s executive officers are expected to have their employment terminated at the closing of the Merger, and to receive
                    the severance benefits set forth in their employment agreements in connection with such termination. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">These interests are discussed in more detail below. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tTOSPB"><!--Anchor--></a>Treatment of Shares of
            Passage Bio Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each share of Passage Bio Common Stock issued and outstanding at the time of the
            Merger will remain issued and outstanding, and, subject to the proposed reverse stock split, will be unaffected by the Merger. Passage Bio&#8217;s directors and executive officers will continue to hold their existing shares of Passage Bio Common
            Stock following the consummation of the Merger. In addition, holders of Passage Bio Common Stock as of the close of business on the last business day prior to the day on which the Effective Time occurs will receive one Passage Bio CVR for each
            outstanding share of Passage Bio Common Stock held by such holder on such date (as described in more detail in the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Passage Bio Contingent Value Rights Agreement</span>&#8221;).

            For more information regarding the beneficial ownership of Passage Bio Common Stock by Passage Bio&#8217;s directors and executive officers, see the section titled &#8220;<span style="font-style: italic;">Principal Stockholders of Passage Bio</span>&#8221; of
            this proxy statement/prospectus. As of June&#160;30, 2026, the directors and executive officers of Passage Bio and their affiliates beneficially owned, in the aggregate, approximately 7.4% of the outstanding shares of Passage Bio Common Stock
            (including shares issuable upon exercise of stock options exercisable within 60 days of such date).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth, for each current Passage Bio director and
            executive officer, the number of shares of Passage Bio Common Stock beneficially owned as of June&#160;30, 2026, as well as the number of shares of Passage Bio Common Stock held directly (excluding shares issuable upon exercise of stock options
            exercisable within 60 days of such date and shares held through affiliated investment funds): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 469.77pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 252pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 90pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 115.77pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 252pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHARES OF COMMON<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">STOCK BENEFICIALLY<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OWNED<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)<sup>(1)</sup></div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHARES OF COMMON STOCK<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">HELD DIRECTLY<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(EXCLUDING OPTIONS)<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)<sup>(2)</sup> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 0.37pt;">112,342 </span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 5pt;">6,724 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Athena Countouriotis, M.D.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 5pt;">18,357</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 12.5pt;">945 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maxine Gowen, Ph.D.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 5pt;">18,794</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sandip Kapadia</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 5pt;">19,765</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Kassberg</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 5pt;">12,755</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derrell Porter, M.D.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 5pt;">16,567</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dolan Sondhi, Ph.D.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 5pt;">14,446</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;"><span style="padding-left: 5pt;">25,781</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;"><span style="padding-left: 5pt;">5,403 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All directors and executive officers as a group (8 persons)</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 90pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 28.75pt; text-align: left;">238,807</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 115.77pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 44.13pt; text-align: left;">13,072</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 252pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 90pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 115.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes shares of Passage Bio Common Stock issuable upon the exercise of stock options exercisable within 60 days of June&#160;30,
                    2026. See &#8220;<span style="font-style: italic;">Principal Stockholders of Passage Bio</span>&#8221; for additional information regarding beneficial ownership. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents shares of Passage Bio Common Stock held directly, excluding shares issuable upon exercise of stock options exercisable
                    within 60&#160;days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">126<br/>
        </div>

      </div>

    </div>

    <!--End Page 136-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 137-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a id="tTMTPB"><!--Anchor--></a>Treatment

            of Passage Bio Equity Awards </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement provides that, prior to the Closing, Passage Bio will take
            all actions necessary to provide that (i)&#160;all then-outstanding Passage Bio Options will be fully vested and exercisable as of immediately prior to the Effective Time and will continue on the same terms and conditions in effect as of immediately
            prior to the Effective Time, and (ii)&#160;all then-outstanding Passage Bio Restricted Stock Unit Awards will be fully vested and settled in shares of Passage Bio Common Stock no later than the day immediately prior to the record date for the
            Pre-Closing Distribution (which is the distribution of the contingent value rights to Passage Bio stockholders). As a result, all unvested stock options held by Passage Bio&#8217;s directors and executive officers will become fully vested as of the
            Effective Time, subject to the director or executive officer&#8217;s continued service through the Effective Time, and all unvested restricted stock units held by such persons will vest and be settled in shares of Passage Bio Common Stock prior to
            the record date for the Pre-Closing Distribution of the Passage Bio CVRs, subject to the director or executive officer&#8217;s continued service through such date.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth, for each Passage Bio director and executive
            officer, the number of Passage Bio Options and Passage Bio Restricted Stock Unit Awards outstanding as of June&#160;30, 2026, and the estimated intrinsic value of accelerated vesting in connection with the Merger, calculated based on a per share
            price of $4.67 (the average closing market price of Passage Bio Common Stock on the Nasdaq Capital Market over the first five trading days following the first public announcement of the transactions contemplated by the Merger Agreement, without
            giving effect to the proposed reverse stock split. The value for the Passage Bio Restricted Stock Unit Awards do not include any additional value that may be received for the Passage Bio CVRs. As of June&#160;30, 2026, the Passage Bio Options held
            by Passage Bio&#8217;s executive officers had exercise prices ranging from $7.64 to $135 per share and the Passage Bio Options held by Passage Bio&#8217;s directors had exercise prices ranging from $5.08 to $36, all of which are higher than $4.67 per share
            and, accordingly, no value is ascribed to the Passage Bio Options. The actual amounts payable in respect of Passage Bio equity awards held by directors and executive officers of Passage Bio will depend on the number of shares of Passage Bio
            Common Stock subject to Passage Bio equity awards held by such persons as of the Effective Time, which may differ from the amounts set forth in the table below as a result of vesting or forfeitures. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 73.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 81.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 89.33pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 204pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 3.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNVESTED STOCK<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OPTIONS<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div>
                </td>

    <td style="width: 3.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNVESTED<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">RESTRICTED STOCK<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNITS<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div>
                </td>

    <td style="width: 3.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ESTIMATED VALUE OF<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ACCELERATED<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">VESTING<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers<br/>
                  </div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D.</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;">103,134</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.18pt; text-align: left;">10,000</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.93pt; text-align: left;">46,700</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;"><span style="padding-left: 5pt;">29,948</span></div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.18pt; text-align: left;"><span style="padding-left: 5pt;">5,000</span></div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.93pt; text-align: left;">23,350 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Employee Directors<span style="font-weight: normal;"> </span><br/>
                  </div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maxine Gowen, Ph.D.</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;"><span style="padding-left: 5pt;">10,539</span></div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Athena Countouriotis, M.D.</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;"><span style="padding-left: 5pt;">10,539</span></div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derrell D. Porter, M.D.</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;"><span style="padding-left: 5pt;">10,539</span></div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dolan Sondhi, Ph.D.</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;"><span style="padding-left: 5pt;">10,605</span></div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sandip Kapadia</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;"><span style="padding-left: 5pt;">10,539</span></div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Kassberg</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.4pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.46pt; text-align: left;"><span style="padding-left: 5pt;">14,163</span></div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 81.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 89.33pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 73.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 81.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 89.33pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Extension of Post-Termination Exercise
            Period of Passage Bio Options </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the Merger, the Passage Bio Board approved extending to two
            (2) years the post-termination exercise period for all outstanding Passage Bio Options held by Passage Bio&#8217;s current employees, including its executive officers, upon a termination of service by Passage Bio for any reason other than for cause.
            The extension is subject to the applicable employee&#8217;s waiver of any rights relating to the CVR Distribution with respect to Passage Bio Options, the employee&#8217;s agreement (if requested by Remix prior to the Closing) to provide up to ten (10)
            hours per month of transition advisory services for additional reasonable compensation, and the other terms of the applicable award agreement and Passage Bio Equity Plan. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Executive Employment Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has entered into written employment agreements with each of its named
            executive officers that provide for severance benefits upon a qualifying termination of employment, including a termination of employment in connection with a change in control of Passage Bio, which includes the Merger. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">127<br/>
        </div>

      </div>

    </div>

    <!--End Page 137-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 138-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">William Chou, M.D. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the terms of the employment agreement, in the event Dr.&#160;Chou is
            terminated without &#8220;cause&#8221; or resigns for &#8220;good reason&#8221; (as such terms are defined in his employment agreement), within two months prior to, or 12&#160;months following, a &#8220;change in control,&#8221; which includes the Merger, Dr.&#160;Chou would be entitled to
            a lump-sum cash amount equal to (i) 18 months of his base salary at that time; (ii) 150% of his annual target bonus for the year in which such termination occurs; and (iii) the amount of COBRA premiums he would be required to pay to maintain
            group healthcare coverage as in effect on the date of his termination for 18 months. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, in the event that a successor company does not assume or substitute
            equity awards held by Dr.&#160;Chou in connection with a &#8220;change in control,&#8221; which includes the Merger, or Dr.&#160;Chou experiences a qualifying termination as described above within two months prior to, or 12 months following a &#8220;change in control,&#8221;
            Dr.&#160;Chou&#8217;s then-outstanding equity awards will become fully vested and exercisable, as applicable, and forfeiture restrictions thereon will lapse. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of the foregoing severance payments and benefits are subject to Dr.&#160;Chou&#8217;s
            execution of a general release of claims against Passage Bio, and his compliance with certain non-competition and non-solicitation provisions set forth in his employment agreement or Passage Bio&#8217;s standard confidentiality and inventions
            assignment agreement. To the extent such severance payments and benefits would result in excise taxes imposed by Section&#160;4999 of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Code</span>&#8221;),

            then pursuant to his employment agreement, Dr.&#160;Chou would be entitled to receive (i) the full payment of such payments and benefits or (ii) such lesser amount as would result in no portion of those payments and benefits being subject to the
            excise tax, whichever results in the greater net after-tax position for Dr.&#160;Chou. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the terms of her employment agreement, in the event that
            Ms.&#160;Borthwick is terminated without &#8220;cause&#8221; or resigns for &#8220;good reason&#8221; (as such terms are defined in her employment agreement), within two months prior to, or 12&#160;months following, a &#8220;change in control,&#8221; which includes the Merger,
            Ms.&#160;Borthwick would be entitled to a lump-sum cash amount equal to (i) 12 months of her base salary; (ii) 100% her annual target bonus for the year in which such termination occurs; and (iii) the amount of COBRA premiums she would be required
            to pay to maintain group healthcare coverage as in effect on the date of her termination for 12 months. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, in the event that a successor company does not assume or substitute
            equity awards held by Ms.&#160;Borthwick in connection with a &#8220;change in control,&#8221; which includes the Merger, or Ms.&#160;Borthwick experiences a qualifying termination as described above within two months prior to, or 12 months following a &#8220;change in
            control&#8221;, Ms.&#160;Borthwick&#8217;s then-outstanding equity awards will become fully vested and exercisable, as applicable, and forfeiture restrictions thereon will lapse. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of the foregoing severance payments and benefits are subject to
            Ms.&#160;Borthwick&#8217;s execution of a general release of claims against Passage Bio, and her compliance with certain non-competition and non-solicitation provisions set forth in her employment agreement or Passage Bio&#8217;s standard confidentiality and
            inventions assignment agreement. To the extent such severance payments and benefits would result in excise taxes imposed by Section&#160;4999 of the Code, then pursuant to her employment agreement, Ms.&#160;Borthwick would be entitled to receive (i) the
            full payment of such payments and benefits or (ii) such lesser amount as would result in no portion of those payments and benefits being subject to the excise tax, whichever results in the greater net after-tax position for Ms.&#160;Borthwick. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Quantification of Potential Payments and
            Benefits to Passage Bio&#8217;s Named Executive Officers </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table and related footnotes set forth the information required by
            Item&#160;402(t) of Regulation S-K regarding the payments and benefits that are based on or otherwise relate to the Merger and that Passage Bio&#8217;s named executive officers may receive in connection with the Merger, which is sometimes referred to as
            &#8220;golden parachute&#8221; compensation. It is currently expected that each of Dr.&#160;Chou and Ms.&#160;Borthwick will have their employment terminated without cause upon the closing of the Merger. It is possible that one or both of them will provide
            transitional consulting services to the combined company for some period post-Merger, although no agreement with respect to any such services has been entered into. Consequently, no arrangements with Remix are included in the table below.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The amounts below are estimates based on multiple assumptions that may or may not
            actually occur or be accurate, and do not reflect certain compensation actions that may occur before the Effective Time. As a result, the actual amounts, if any, that a named executive officer may receive may differ materially from the amounts
            set forth below.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">128<br/>
        </div>

      </div>

    </div>

    <!--End Page 138-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 139-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">For purposes of the table below, the following assumptions were used: (i) the
            Effective Time occurs on October&#160;15, 2026, the assumed date of the completion of the Merger solely for purposes of this disclosure; (ii) the base salary and bonus opportunities for each named executive officer were those in effect as of
            June&#160;30, 2026 (iii) the price per share of Passage Bio Common Stock is $4.67, based on the average closing market price of Passage Common Stock over the first&#160;five trading days following the first public announcement of the Merger, without
            giving effect to the proposed reverse stock split; (iv) the number of outstanding and unvested Passage Bio Options and Passage Bio Restricted Stock Unit Awards held by each named executive officer is based on such awards outstanding as of
            June&#160;30, 2026, the latest practicable date before the filing of the Form&#160;S-4, rather than as of the Effective Time; and (v) except as otherwise indicated, each named executive officer experiences a termination by the combined company without &#8220;<span style="font-style: italic; font-weight: bold;">cause</span>&#8221; or the named executive officer resigns for &#8220;good reason&#8221; (as defined in the named executive officer&#8217;s employment agreement) (in each case, a &#8220;Qualifying Termination&#8221;) upon the
            closing of the Merger and completes all conditions for receiving severance. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 252pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 39.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 252pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div>
                </td>

    <td style="width: 6.71pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.71pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cash<sup>(1)</sup> <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 6.71pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.71pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity<sup>(2)</sup> <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 6.7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Perquisites/<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Benefits<sup>(3)</sup><br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 6.7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(4)</sup> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D.</div>
                </td>

    <td style="width: 6.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$1,593,020</div>
                </td>

    <td style="width: 6.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$84,500</div>
                </td>

    <td style="width: 6.7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.67pt; text-align: left;">$49,572</div>
                </td>

    <td style="width: 6.7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$1,727,092 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 252pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick</div>
                </td>

    <td style="width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">696,920</span></div>
                </td>

    <td style="width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$42,250</div>
                </td>

    <td style="width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.67pt; text-align: left;">$33,000</div>
                </td>

    <td style="width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 7.5pt;">&#8203;772,170</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 252pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 39.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Cash. Represents the estimated cash severance payable to the named executive officer upon a Qualifying Termination occurring
                    within two&#160;months prior to, or twelve months following, a change in control, which includes the Merger. Under each named executive officer&#8217;s employment agreement, upon such Qualifying Termination, Dr.&#160;Chou would be entitled to a
                    lump-sum amount equal to 18 months of his base salary plus 150% of his annual target bonus, and Ms.&#160;Borthwick would be entitled to a lump-sum amount equal to 12 months of her base salary plus 100% of her annual target bonus. These
                    payments are &#8220;double-trigger,&#8221; meaning that both the completion of the Merger and a qualifying termination must occur, and such payments are conditioned on the named executive officer&#8217;s execution and non-revocation of a general release
                    of claims and continued compliance with non-competition and non-solicitation covenants. The estimated components are: (i) for Dr. Chou, $1,027,755 representing 18 months of his base salary, plus $565,265 representing 150% of his annual
                    target bonus; and (ii) for Ms. Borthwick, $497,800 representing 12&#160;months of her base salary, plus $199,120 representing 100% of her annual target bonus.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Equity. Represents the estimated value of the accelerated vesting of the named executive officer&#8217;s outstanding and unvested
                    Passage Bio Options and Passage Bio Restricted Stock Unit Awards. Under the Merger Agreement, each outstanding and unvested Passage Bio Option will accelerate in full effective immediately prior to the Effective Time, and each
                    outstanding and unvested Passage Bio Restricted Stock Unit Award will accelerate in full no later than the day immediately prior to the record date for the Pre-Closing Distribution; accordingly, these amounts are &#8220;single-trigger&#8221; and
                    would become payable upon completion of the Merger without regard to a termination of employment. The value of accelerated Passage Bio Options is based on the excess, if any, of $4.67 per share over the applicable exercise price, and
                    the value of accelerated Passage Bio Restricted Stock Unit Awards is based on $4.67 per share. This amount does not include any additional value attributable to the contingent extension of the post-termination exercise period of certain
                    Passage Bio Options held by the named executive officer. Depending on when the Effective Time occurs, certain Passage Bio Options and/or Passage Bio Restricted Stock Unit Awards may vest in accordance to their terms prior to the
                    Closing, or may be exercised or forfeited prior to that time.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Perquisites/Benefits. Represents the estimated cost of continued group health coverage (through reimbursement of COBRA premiums)
                    provided upon a Qualifying Termination of employment in connection with a change in control &#8212; 18 months for Dr.&#160;Chou and 12 months for Ms.&#160;Borthwick. These benefits are &#8220;double-trigger.&#8221;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Tax Reimbursement. Passage Bio&#8217;s named executive officers are not entitled to any tax gross-up or excise tax reimbursement in
                    connection with the Merger. Each named executive officer&#8217;s employment agreement contains a Section&#160;280G &#8220;better-of&#8221; provision, pursuant to which any payments that would constitute &#8220;parachute payments&#8221; within the meaning of Section&#160;280G
                    of the Code will be reduced to the extent necessary to avoid the excise tax under Section&#160;4999 of the Code, but only if such reduction would result in a greater after-tax benefit to the named executive officer. This does not include any
                    previous earnings for the annual bonus, salary increase, or other previously taxed earnings. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTMIRD"><!--Anchor--></a>Interests of Remix&#8217;s Directors
            and Executive Officers in the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In considering the recommendation of the Remix Board with respect to approving
            the Merger, Passage Bio stockholders should be aware that certain of Remix&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Remix&#8217;s stockholders generally. These
            interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Remix Board was aware of these potential conflicts of interest and considered
            them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Remix stockholders approve the Merger. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Ownership Interests </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of June 30, 2026, the directors and executive officers of Remix as a group
            beneficially owned in the aggregate approximately 8.3% of the outstanding shares of Remix Capital Stock, which for purposes of this subsection excludes any Remix shares issuable upon exercise of Remix Options held by such individuals. Such
            shares of Remix </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">129<br/>
        </div>

      </div>

    </div>

    <!--End Page 139-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 140-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Capital Stock will be converted into shares of Passage Bio Common Stock at the
            Effective Time. In addition, each of Remix&#8217;s directors and executive officers or their respective affiliates who beneficially own any shares of Remix Capital Stock have also entered into a support agreement in connection with the Merger. For a
            more detailed discussion of the support agreements, please see the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Support Agreements.</span>&#8221; </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tTMTRS"><!--Anchor--></a>Treatment

            of Remix Stock Options </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s directors and executive officers currently hold options to purchase
            shares of Remix Common Stock. Under the terms of the Merger Agreement, at the Effective Time, each Remix Option that is outstanding and unexercised immediately prior to the Effective Time under the Remix 2019 Plan (as amended, the &#8220;<span style="font-style: italic; font-weight: bold;">Remix 2019 Plan</span>&#8221;) will automatically be converted into an option to purchase shares of Passage Bio Common Stock equal to the number of shares of Remix Common Stock subject to such option
            multiplied by the Merger Exchange Ratio and rounding that result down to the nearest whole number of shares at a per share exercise price equal to the existing exercise price of such option multiplied by the Merger Exchange Ratio, rounded up to
            the nearest whole cent. Passage Bio will assume the Remix 2019&#160;Plan. All rights with respect to Remix Common Stock subject to Remix Options assumed by Passage Bio will be converted into rights with respect to Passage Bio Common Stock. The term,
            exercisability, vesting schedules and other provisions of assumed Remix options will generally remain unchanged. See the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Treatment of Remix Stock Options.</span>&#8221;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table details the outstanding options held by Remix&#8217;s directors and
            executive officers as of June&#160;30, 2026: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.65pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 48.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options (#)</div>
                </td>

    <td style="width: 10.71pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Volume <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise Price </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Executive Officers<br/>
                  </div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D.</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;">5,815,999</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$0.72 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman, Ph.D.</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;">1,719,273</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$0.69 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mythili Koneru, M.D., Ph.D.</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;">1,839,960</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$1.17 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D.</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;">1,001,849</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$0.84 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Employee Directors<br/>
                  </div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Linda C. Bain</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><span style="padding-left: 7.5pt;">220,000</span></div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$0.94 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Scott Biller, Ph.D.</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><span style="padding-left: 7.5pt;">148,435</span></div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$0.84 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kevin Bitterman, Ph.D.</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;"><span style="padding-left: 12.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">James Jeffrey Goater, Jr.</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;"><span style="padding-left: 12.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maria Koehler, M.D., Ph.D.</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><span style="padding-left: 7.5pt;">280,000</span></div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$1.09 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Matthew R. Patterson</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.32pt; text-align: left;"><span style="padding-left: 7.5pt;">684,967</span></div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">$0.70</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.65pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.71pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 48.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Management Following the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As described in the section captioned &#8220;<span style="font-style: italic;">Management

              Following the Merger</span>&#8221;, Remix&#8217;s executive officers and directors are currently expected to become the executive officers and directors of the combined company. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Indemnification and Insurance </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For a discussion of the indemnification and insurance provisions related to
            Remix&#8217;s executive officers and directors under the Merger Agreement, please see the sections titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Other Agreements&#8212;Director Indemnification and Insurance</span>&#8221; and &#8220;<span style="font-style: italic;">Certain Relationships and Related Party Transactions of the Combined Company&#8212;Remix Related Party Transactions-Indemnification Agreements.</span>&#8221; </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">130<br/>
        </div>

      </div>

    </div>

    <!--End Page 140-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 141-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Executive Officers of the Combined Company
            Following the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Effective as of the Closing, the combined company&#8217;s executive officers are
            expected to be the individuals designated by Remix. Remix currently expects that the following individuals will serve as the executive officers of the combined company following the Merger: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 168pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 296pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 168pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 296pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">TITLE </div>
                </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D.</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 296pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer </div>
                </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 296pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Operating Officer and Chief Business Officer </div>
                </td>

  </tr>

  <tr>

    <td style="width: 168pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D.</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 296pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Scientific Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 168pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 296pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Merger Consideration </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time, each share of Remix Capital Stock outstanding immediately
            prior thereto (excluding shares held by stockholders who have exercised and perfected appraisal rights, shares held as treasury stock by Remix or held or owned by Passage Bio, Merger Sub or any subsidiary of Passage Bio or Remix and shares
            issued in the Concurrent Financing), will be converted into the right to receive a number of shares of Passage Bio Common Stock equal to the Merger Exchange Ratio. Additionally, the Remix Common Stock issued in the Concurrent Financing will be
            converted solely into the right to receive a number of shares of Passage Bio Common Stock equal to the total amount of Concurrent Financing Merger Shares multiplied by the percentage of the Concurrent Financing Proceeds represented by the
            applicable stockholder&#8217;s investment in the Concurrent Financing, in each case as set forth on the Allocation Certificate.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">No fractional shares of Passage Bio Common Stock will be issued in connection
            with the Merger, and no certificates or scrip for any such fractional shares will be issued, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Passage Bio Common Stock a holder of Remix
            Common Stock would otherwise be entitled to receive shall be aggregated together first prior to eliminating any remaining fractional share. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"><a id="tTORO"><!--Anchor--></a>Treatment of Remix Options </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the terms of the Merger Agreement, each Remix Option that is outstanding
            and unexercised immediately prior to the Effective Time under the Remix 2019 Plan, whether or not vested, will be converted into and become an option to purchase shares of Passage Bio Common Stock at the Effective Time. Passage Bio will assume
            the Remix 2019 Plan and all such Remix Options in accordance with the terms of the Remix 2019 Plan and the terms of the stock option agreement by which such option is evidenced.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Accordingly, from and after the Effective Time: (i) each outstanding Remix Option
            assumed by Passage Bio may be exercised solely for shares of Passage Bio Common Stock; (ii) the number of shares of Passage Bio Common Stock subject to each outstanding Remix Option assumed by Passage Bio will be determined by multiplying (A)
            the number of shares of Remix Common Stock that were subject to such Remix Option, by (B) the Merger Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Passage Bio Common Stock; (iii) the per share
            exercise price for the Passage Bio Common Stock issuable upon exercise of each Remix Option assumed by Passage Bio will be determined by dividing (A) the per share exercise price of such Remix Option, by (B) the Merger Exchange Ratio and
            rounding the resulting exercise price up to the nearest whole cent; and (iv) any restriction on the exercise of any Remix Option assumed by Passage Bio will continue in full force and effect and the term, exercisability, vesting schedule and
            any other provisions of such Remix Option will otherwise remain unchanged; provided, however, that the combined company&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of the Remix Board or any
            committee thereof with respect to each Remix Option assumed by Passage Bio. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"><a id="tETOTM"><!--Anchor--></a>Effective Time of the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger will be completed no later than the second business day after all of
            the conditions to the Closing are satisfied or waived, including the approval of the stockholders of Passage Bio, other than those conditions that by their nature are to be satisfied at the closing of the Merger, unless earlier terminated in
            accordance with the terms of the Merger Agreement. For more information on termination rights, see the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Termination and Termination Fees.</span>&#8221; The Merger is anticipated to
            occur after the Passage Bio special meeting. Neither Passage Bio nor Remix can predict the exact timing of the consummation of the Merger. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">131<br/>
        </div>

      </div>

    </div>

    <!--End Page 141-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 142-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg27"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a id="tTMMFI"><!--Anchor--></a>Material U.S. Federal Income
            Tax Consequences of the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio stockholders will not sell, exchange or dispose of any shares of
            Passage Bio Common Stock as a result of the Merger. Thus, there will be no material U.S. federal income tax consequences to Passage Bio stockholders as a result of the Merger. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a id="tNLIS"><!--Anchor--></a>Nasdaq Stock Market Listing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio Common Stock is currently listed on Nasdaq under the symbol &#8220;PASG.&#8221;
            Pursuant to the Merger Agreement, Passage Bio has agreed to (a) use commercially reasonable efforts to maintain its existing listing on Nasdaq until the Closing, (b)(i) to the extent required by the rules and regulations of Nasdaq, prepare and
            submit to Nasdaq a notification form for the listing of the shares of Passage Bio Common Stock being issued in the Merger, and (ii) use commercially reasonable efforts to cause such shares to be approved for listing (subject to official notice
            of issuance) on the Nasdaq market at or prior to the Effective Time, and (c) to the extent required by Nasdaq Marketplace Rule&#160;5110, to file an initial Nasdaq Listing Application for the Passage Bio Common Stock on Nasdaq and to use
            commercially reasonable efforts to cause such listing application to be conditionally approved prior to the Effective Time.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each party will reasonably promptly inform the other party of all verbal or
            written communications between Nasdaq and such party or its representatives. Each party will cooperate with the other party as reasonably requested with respect to the Nasdaq listing application and promptly furnish to such party all
            information concerning itself, its members and its stockholders that may be reasonably requested in connection with any action contemplated by the foregoing paragraph.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Nasdaq listing application is accepted, Passage Bio anticipates that the
            common stock of the combined company will be listed on Nasdaq following the Closing under the trading symbol &#8220;RMTX.&#8221; In order for the Nasdaq listing application to be accepted, among other requirements, the combined company must maintain a bid
            price of $4.00 or higher for a certain period of time following the proposed reverse stock split. As of &#8195;&#8195;&#8195;&#8195;&#8195;, 2026, the bid price of Passage Bio Common Stock was $&#8195;&#8195;&#8195;&#8195;&#8195;. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a id="tTMAAT"><!--Anchor--></a>Anticipated Accounting
            Treatment </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is expected be accounted for under GAAP as an in-substance reverse
            recapitalization. For accounting purposes, Remix is expected to be considered the accounting acquirer. The treatment as an in-substance reverse recapitalization is based on the assessment that as a result of Passage Bio&#8217;s discontinuation of its
            research and development activities and settlement of its other remaining operating assets and liabilities, immediately prior to the Closing, Passage Bio is expected to have nominal assets, apart from cash and cash equivalents and marketable
            securities. Under a reverse recapitalization, Remix is considered to effect a financing transaction in exchange for issuing equity. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"><a id="tTMARI"><!--Anchor--></a>Appraisal Rights </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Passage Bio </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Under the DGCL, Passage Bio stockholders are not entitled to appraisal rights in
            connection with the Merger. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Merger is consummated, holders of shares of Remix Common Stock (including
            beneficial owners of shares of Remix Common Stock) who (i) did not consent to the adoption of the Merger Agreement pursuant to Section&#160;228 of the DGCL, (ii)&#160;properly demand an appraisal of their shares of Remix Common Stock, (iii)&#160;continuously
            hold of record or beneficially own their shares of Remix Common Stock through the effective date of the Merger, and (iv)&#160;do not properly withdraw their demands or otherwise lose their rights to appraisal will be entitled to appraisal rights in
            connection with the Merger under Section&#160;262 ( of the DGCL (&#8220;<span style="font-style: italic; font-weight: bold;">Section&#160;262</span>&#8221;), so long as they comply with the conditions established by Section&#160;262. Unless the context requires
            otherwise, all references in Section&#160;262 and in this summary to a &#8220;<span style="font-style: italic; font-weight: bold;">stockholder</span>&#8221; mean a record holder of Remix Common Stock, all references in Section&#160;262 and in this summary to &#8220;<span style="font-style: italic; font-weight: bold;">beneficial owner</span>&#8221; mean a person who is the beneficial owner of shares of Remix Common Stock held either in voting trust or by a nominee on behalf of such person, and all references in
            Section&#160;262 and in this summary to the word &#8220;person&#8221; mean any individual, corporation, partnership, unincorporated association or other entity.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">132<br/>
        </div>

      </div>

    </div>

    <!--End Page 142-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 143-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg28"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The following discussion is not a complete statement of the law pertaining to
            appraisal rights under the DGCL and is qualified in its entirety by the full text of Section&#160;262, which can be accessed without subscription or cost at the following URL, and is incorporated herein by reference:
            https://www.delcode.delaware.gov/title8/c001/sc09/index.html#262. Failure to precisely follow any of the statutory procedures set forth in Section&#160;262 will result in the loss or waiver of your appraisal rights. The following summary does not
            constitute any legal or other advice nor does it constitute a recommendation that stockholders or beneficial owners exercise their appraisal rights under Section&#160;262.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under Section&#160;262, if the Merger is completed, stockholders and beneficial owners
            of Remix Common Stock who (i) have not consented to the adoption of the Merger Agreement pursuant to Section&#160;228 of the DGCL, (ii) make the demand described below with respect to such shares within twenty days of the mailing of a notice of the
            availability of appraisal rights from Remix, (iii) continuously hold of record or beneficially own such shares through the effective date of the Merger, and (iv) otherwise comply with the statutory requirements of Section&#160;262 will be entitled
            to an appraisal of their shares of Remix Common Stock and to receive payment in cash, in lieu of the shares of Passage Bio Common Stock otherwise issuable to such stockholder or beneficial owner pursuant to terms and conditions of the Merger
            Agreement, for the fair value of their shares of Remix Common Stock as of the Effective Time, exclusive of any element of value arising from the accomplishment or expectation of the Merger, as determined by the Delaware Court of Chancery (the &#8220;<span style="font-style: italic; font-weight: bold;">Court</span>&#8221;). Such payment shall include interest on the amount determined by the Court to be the fair value from the effective date of the Merger through the date of payment of the judgment,
            unless the Court in its discretion determines otherwise for good cause shown. In certain circumstances described below, interest shall accrue on the difference between the amount determined to be the fair value and the amount paid by the
            surviving entity prior to the entry of judgment in the appraisal proceeding. The &#8220;fair value&#8221; of shares of Remix Common Stock as determined by the Court may be more than, less than, or equal to the value of the shares of Passage Bio Common
            Stock that persons seeking appraisal are otherwise entitled to receive under the terms of the Merger Agreement. Stockholders and beneficial owners should be aware that an investment banking opinion as to the fairness, from a financial point of
            view, of the consideration payable in a transaction, such as the Merger, is not an opinion as to, and does not otherwise necessarily address &#8220;fair value&#8221; under Section&#160;262.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">When a merger agreement is approved by written consent without a meeting pursuant
            to Section&#160;228 of the DGCL, as is contemplated to be the case with the Merger Agreement, Section&#160;262 requires that either a constituent corporation before, or the surviving corporation within 10 days after, the effective date of the merger
            notify each stockholder of the constituent corporation who is entitled to appraisal rights, that appraisal rights are available for any and all shares thereof and must include in each such notice a copy of Section&#160;262 or information directing
            the stockholders to a publicly available electronic resource at which Section&#160;262 may be accessed without subscription or cost. Remix will separately provide notice to Remix&#8217;s stockholders that appraisal rights are available in connection with
            the Merger, and the full text of Section&#160;262 can be accessed without subscription or cost at the following URL, and is incorporated herein by reference: https://www.delcode.delaware.gov/title8/c001/sc09/index.html#262. Failure to comply timely
            and properly with the requirements of Section&#160;262 will result in the loss of appraisal rights under the DGCL.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Stockholders and beneficial owners of Remix Common Stock who wish to exercise
            their appraisal rights must, within 20 days after the date of receiving such notice, demand in writing the appraisal of such stockholder&#8217;s or beneficial owner&#8217;s shares. In addition, such person must continuously hold of record or beneficially
            own the shares of Remix Common Stock from the date the written demand for appraisal is made through the effective date of the Merger. All demands for appraisal should be addressed to Peter Smith, Chief Executive Officer at Remix Therapeutics,
            Inc., 100 Forge Road, Suite 400, Watertown, MA 02472. A stockholder&#8217;s or beneficial owner&#8217;s failure to demand in writing the appraisal of such stockholder&#8217;s or beneficial owner&#8217;s shares on or before the expiration of such 20-day period will
            result in the loss of his, her or its appraisal rights.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the case of a written demand for appraisal made by a stockholder of record,
            the demand must reasonably inform Remix of the identity of the stockholder and that the stockholder intends thereby to demand an appraisal of such stockholder&#8217;s shares of Remix Common Stock. If shares of Remix Common Stock are owned of record
            in a fiduciary or representative capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal must be made on behalf of the record owner in that capacity. If the shares of Remix Common Stock are owned of record by
            more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal on
            behalf of a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he, she or it is acting as agent for the record owner. A record owner, such as a
            broker, bank or other nominee who holds shares of Remix Common Stock as a </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">133<br/>
        </div>

      </div>

    </div>

    <!--End Page 143-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 144-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg29"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">nominee or intermediary for others, may exercise appraisal rights with respect
            to the shares of Remix Common Stock held for one or more beneficial owners, while not exercising appraisal rights for other beneficial owners. In that case, the written demand should state the number of shares of Remix Common Stock as to which
            appraisal is sought. Where no number of shares of Remix Common Stock is expressly mentioned, the demand will be presumed to cover all shares of Remix Common Stock held in the name of the record owner.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the case of a written demand for appraisal made by a beneficial owner, the
            demand must reasonably identify the record holder of the shares for which the demand is made, be accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of such stock and a statement that such documentary evidence is
            a true and correct copy of what it purports to be and provide an address at which such beneficial owner consents to receive notices given by the surviving corporation and to be set forth on the verified list (as defined below). Although not
            expressly required by Section&#160;262, the surviving corporation reserves the right to take the position that it may require the submission of all information required of a beneficial owner under subsection (d)(3) of Section&#160;262 with respect to any
            person sharing beneficial ownership of the shares of Remix Common Stock for which such demand is submitted.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Beneficial owners who hold their shares of Remix Common Stock through a broker,
            bank or other nominee and who wish to exercise appraisal rights should consult with their broker, bank or other nominee as soon as possible to determine the appropriate procedures for, and any internal deadlines that the broker, bank or other
            nominee may impose in connection with, making a demand for appraisal, so that a valid demand may be made within the time period described above.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Merger is consummated, within 10 days after the effective date of the
            Merger, Remix, as the surviving corporation in the Merger, must notify each stockholder or beneficial owner who is entitled to appraisal rights of the date that the Merger has become effective; provided, however, that if such notice is sent
            more than 20 days following the sending of the notice of appraisal rights to Remix stockholders, such notice need only be sent to each stockholder or beneficial owner who is entitled to appraisal rights and who has demanded appraisal of his,
            her or its shares of Remix Common Stock in accordance with Section&#160;262.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At any time within 60 days after the effective date of the Merger, any person
            entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party will have the right to withdraw their demand for appraisal and to accept the terms offered in the Merger by delivering to the
            surviving corporation a written withdrawal of such person&#8217;s demand for appraisal; after this period, the person may withdraw such demand for appraisal only with the written consent of the surviving corporation. Notwithstanding the foregoing, no
            appraisal proceeding in the Court shall be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such terms as the Court deems just, including, without limitation, a reservation of jurisdiction
            (a &#8220;<span style="font-style: italic; font-weight: bold;">reservation</span>&#8221;) for any application (as defined below); provided, however, that this provision shall not affect the right of any person who has not commenced an appraisal proceeding
            or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the Merger within 60 days after the effective date of the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Within 120 days after the effective date of the Merger, but not thereafter,
            either the surviving corporation or any person who has complied with the requirements of Section&#160;262 and is otherwise entitled to appraisal rights under Section&#160;262 may commence an appraisal proceeding by filing a petition in the Court
            demanding a determination of the value of the shares of Remix Common Stock held by all persons entitled to appraisal. Upon the filing of the petition by any person other than the surviving corporation, service of a copy of such petition shall
            be made upon the surviving corporation. The surviving corporation has no obligation to file such petition and has no present intention to file a petition and holders should not assume that the surviving corporation will file a petition. In the
            event that the surviving corporation does not file such petition, it is the obligation of the stockholders or beneficial owners of Remix Common Stock to initiate all necessary action to perfect their appraisal rights with respect to shares of
            Remix Common Stock within the time prescribed in Section&#160;262. If, within 120 days after the effective date of the Merger, no petition has been filed as provided above, all rights to appraisal will be lost and those shares will be deemed to have
            been converted at the Effective Time into the right to receive shares of Passage Bio Common Stock as set forth in the Merger Agreement. In addition, within 120 days after the effective date of the Merger, any person who has theretofore complied
            with the applicable provisions of Section&#160;262 will be entitled to receive from the surviving corporation, upon written request, a statement setting forth the aggregate number of shares of Remix Common Stock not consenting in writing in favor of
            the Merger and with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that where </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">134<br/>
        </div>

      </div>

    </div>

    <!--End Page 144-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 145-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg30"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">a beneficial owner makes a demand for appraisal directly, the record holder of
            such shares shall not be considered a separate stockholder holding such shares for purposes of this aggregate number). The statement must be given within 10 days after such written request has been received by the surviving corporation or
            within 10 days after expiration of the period for delivery of demands for appraisal under Section&#160;262(d), whichever is later.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a petition for appraisal is duly filed by a stockholder or beneficial owner of
            Remix Common Stock and a copy of the petition is delivered to the surviving corporation, then the surviving corporation will be obligated, within 20 days after receiving service of a copy of the petition, to file with the Delaware Register in
            Chancery in which the petition was filed a duly verified list (the &#8220;<span style="font-style: italic; font-weight: bold;">verified list</span>&#8221;) containing the names and addresses of all persons who have demanded an appraisal of their shares of
            Remix Common Stock and with whom agreements as to the value of their shares of Remix Common Stock have not been reached. If the petition was filed by the surviving corporation, the petition shall be accompanied by such a duly verified list. The
            Register in Chancery, if so ordered by the Court, must give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving corporation in the Merger and to the persons shown on the verified
            list at the addresses therein stated. The forms of the notices by mail and by publication must be approved by the Court, and the costs thereof shall be borne by the surviving corporation in the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a petition for an appraisal is timely filed, at the hearing on such petition,
            the Court will determine which persons have complied with Section&#160;262 and are entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares of Remix Common Stock, and who hold shares represented
            by certificates, to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with that direction, the Court may dismiss the proceedings as
            to that person.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon application by the surviving corporation or by any person entitled to
            participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the verified list may
            participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under Section&#160;262.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After determination of the persons entitled to appraisal of their shares of Remix
            Common Stock, the appraisal proceeding shall be conducted in accordance with the rules of the Court, including any rules specifically governing appraisal proceedings. Through such proceeding the Court will appraise the shares of Remix Common
            Stock, determining their fair value as of the Effective Time, exclusive of any element of value arising from the accomplishment or expectation of the Merger, together with interest, if any, to be paid upon the amount determined to be the fair
            value. When the fair value has been determined, the Court will direct the payment of such value (together with any applicable interest) by the surviving corporation to the persons entitled thereto. Payment will be so made to each such person
            upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in such Court may be enforced. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in
            the following sentence, interest from the effective date of the Merger through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as
            established from time to time during the period between the effective date of the Merger and the date of payment of the judgment. At any time before the entry of judgment in the appraisal proceeding, the surviving corporation may pay to each
            person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided in the preceding sentence only upon the sum of (i) the difference, if any, between the amount so paid and the fair value of shares as
            determined by the Court and (ii)&#160;interest theretofore accrued, unless paid at that time.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix reserves the right to assert, in any appraisal proceeding, that, for
            purposes of Section&#160;262, the &#8220;fair value&#8221; of a share of Remix Common Stock is less than the value that Remix stockholders are entitled to receive under the terms of the Merger Agreement. In determining &#8220;fair value,&#8221; the Court is required to
            take into account all relevant factors. In <span style="font-style: italic;">Weinberger v. UOP, Inc.</span>, 457 A.2d 701 (Del. 1983), the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an
            appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered and that &#8220;[f]air price obviously
            requires consideration of all relevant factors involving the value of a company.&#8221; The Delaware Supreme Court has stated that in making this determination of fair value, the court must consider market value, asset value, dividends, earnings
            prospects, the nature of the enterprise and any other facts that could be ascertained as of the date of the merger that throw any light on future prospects of the merged corporation. Section&#160;262 provides that fair value is to be &#8220;exclusive of
            any </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">135<br/>
        </div>

      </div>

    </div>

    <!--End Page 145-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 146-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_110-merger_pg31"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">element of value arising from the accomplishment or expectation of the
            merger.&#8221; In <span style="font-style: italic;">Cede &amp; Co. v. Technicolor, Inc.</span>, 684 A.2d 289 (Del. 1996), the Delaware Supreme Court stated that such exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of
            value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In <span style="font-style: italic;">Weinberger</span>, the Delaware Supreme Court also stated that &#8220;elements of future
            value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221; Although Remix believes that the value ascribed to each share of Remix
            Common Stock pursuant to the terms of the Merger is fair, no representation is made as to the outcome of the appraisal of fair value, and the persons seeking appraisal should recognize that such an appraisal could result in a determination of a
            value higher or lower than, or the same as, the value that Remix Stockholders are entitled to receive under the terms of the Merger Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Costs of the appraisal proceeding (which do not include attorneys&#8217; fees or the
            fees and expenses of experts) may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon the application of a person whose name appears on the verified list who participated in the
            proceeding and incurred expenses in connection therewith (an &#8220;<span style="font-style: italic; font-weight: bold;">application</span>&#8221;), the Court may order all or a portion of such expenses, including, without limitation, reasonable attorneys&#8217;
            fees and the fees and expenses of experts used in the appraisal proceeding, to be charged pro rata against the value of all shares of Remix Common Stock entitled to appraisal that were not dismissed pursuant to the terms of Section&#160;262 or
            subject to an award pursuant to a reservation. In the absence of such an order, each party bears its own fees and expenses.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If any person who demands appraisal under Section&#160;262 fails to perfect, or loses
            or validly withdraws, such person&#8217;s right to appraisal, such person&#8217;s shares of Remix Common Stock will be deemed to have been converted at the Effective Time into the right to receive the shares of Passage Bio Common Stock otherwise issuable
            to such person in connection with the Merger. Any person who demanded and perfected appraisal rights will not, after the Effective Time, be entitled to vote the shares of Remix Common Stock subject to that demand for any purpose or to receive
            payments of dividends or any other distribution with respect to those shares of Remix Common Stock (except dividends or other distributions payable to stockholders of record at a date which is prior to the Effective Time).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Failure to comply strictly with all of the procedures set forth in Section&#160;262
            will result in the loss of a stockholder&#8217;s or beneficial owner&#8217;s statutory appraisal rights. Consequently, any person wishing to exercise appraisal rights is encouraged to consult legal counsel before attempting to exercise those rights. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">136<br/>
        </div>

      </div>

    </div>

    <!--End Page 146-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 147-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tTMA"><!--Anchor--></a>THE MERGER AGREEMENT </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a summary of the material terms of the Merger Agreement. A copy
            of the Merger Agreement is attached as <span style="text-decoration: underline;">Annex&#160;A</span> to this proxy statement/prospectus and is incorporated by reference. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its
            terms. It is not intended to provide any other factual information about Passage Bio, Remix or Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger
            Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement contains representations and warranties that Passage Bio and
            Merger Sub, on the one hand, and Remix, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and were made for the
            purpose of allocating contractual risk between the parties rather than establishing matters as facts, and may be subject to standards of materiality applicable to the parties that differ from those applicable to investors. In addition, the
            assertions made in the representations and warranties are qualified by the information in confidential disclosure schedules exchanged by the parties in connection with the signing of the Merger Agreement, which contains information that
            modifies, qualifies and creates exceptions to the representations and warranties set forth in the Merger Agreement. Moreover, information concerning the subject matter of the representations, warranties and covenants may have changed (and may
            continue to change) after the date of the Merger Agreement, which subsequent information may or may not be fully reflected in the Company&#8217;s public disclosures. Accordingly, you should not rely on the representations, warranties or covenants as
            current characterizations of factual information about Passage Bio, Remix or Merger Sub, and you should read the information provided elsewhere in this proxy statement/prospectus and in Passage Bio&#8217;s filings with the SEC regarding its business.
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a id="tSTRUC"><!--Anchor--></a>Structure </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Merger Agreement, Merger Sub, a wholly owned subsidiary of Passage Bio
            formed in connection with the Merger, will merge with and into Remix at the Effective Time, with Remix surviving as a wholly owned subsidiary of Passage Bio. Substantially concurrently with the completion of the Merger, Passage Bio will be
            renamed &#8221;Remix&#160;Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;RMTX.&#8221; </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a id="tCOEOTM"><!--Anchor--></a>Completion and Effectiveness
            of the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger will be completed no later than the second business day after all of
            the conditions to the Closing are satisfied or waived, including the approval of the stockholders of Passage Bio, other than those conditions that by their nature are to be satisfied at the closing of the Merger (so long as such conditions
            would be so satisfied), unless earlier terminated in accordance with the terms of the Merger Agreement. The Closing may also occur at such other time, date and place as Remix and Passage Bio mutually agree in writing. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"><a id="tTORCNAR"><!--Anchor--></a>Treatment of Remix
            Convertible Notes and Remix Preferred Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">All Remix Convertible Notes will be converted into shares of Remix Common Stock
            as of immediately prior to the Effective Time in accordance with, and pursuant to the terms and conditions of, the Remix Convertible Notes.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">All Remix Preferred stock will be converted into shares of Remix Common Stock as
            of immediately prior to the Effective Time in accordance with, and pursuant to the terms and conditions of, the organizational documents of Remix (the &#8220;<span style="font-style: italic; font-weight: bold;">Remix Preferred Stock Conversion</span>&#8221;).
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"><a id="tTMAMC"><!--Anchor--></a>Merger Consideration and
            Merger Exchange Ratio </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Merger Consideration </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time (after giving effect to the Remix Preferred Stock
            Conversion and the Remix Convertible Notes Conversion), the Remix Common Stock outstanding immediately prior to the Effective Time (excluding (i)&#160;Remix Common Stock issued in the Concurrent Financing, (ii) Remix Treasury Shares and (iii)
            Dissenting Remix Shares) will be converted solely into the right to receive a number of shares of Passage Bio Common Stock equal to the total number of Remix Merger Shares described in the section titled &#8220;<span style="font-style: italic;">The
              Merger Agreement&#8212;Remix Merger Shares</span>&#8221; multiplied by the applicable Remix stockholder&#8217;s percentage interest in Remix Outstanding Shares as set </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">137<br/>
        </div>

      </div>

    </div>

    <!--End Page 147-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 148-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">forth on the Allocation Certificate and, if any such Remix Common Stock is
            unvested or is subject to a repurchase option or a risk of forfeiture under any applicable restricted stock, restricted stock unit award agreement or other similar agreement with Remix, then the shares of Passage Bio Common Stock issued in
            exchange for such Remix Common Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time, by virtue of the Merger, upon the terms and subject to the
            conditions set forth in the Merger Agreement, each share of Remix Common Stock issued in the Concurrent Financing will be converted solely into the right to receive a number of shares of Passage Bio Common Stock equal to the amount of
            Concurrent Financing Merger Shares described in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Merger Consideration and Merger Exchange Ratio</span>&#8221; multiplied by the percentage of the Concurrent Financing Proceeds
            represented by the applicable stockholder&#8217;s investment in the Concurrent Financing, as set forth on the Allocation Certificate. Remix Treasury Shares will automatically be cancelled and extinguished without any conversion thereof or
            consideration paid therefore.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">No fractional shares of Passage Bio Common Stock will be issued in connection
            with the Merger, and no certificates or scrip for any such fractional shares will be issued, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Passage Bio Common Stock resulting from the
            conversion of Remix capital stock into the right to receive a number of Passage Bio Common Stock a holder of Remix Common Stock would otherwise be entitled to receive shall be aggregated together first prior to eliminating any remaining
            fractional share.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time, by virtue of the Merger, upon the terms and subject to the
            conditions set forth in the Merger Agreement, each share of common stock, $0.001 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and exchanged for one validly issued,
            fully paid and nonassessable share of common stock, $0.0001 par value per share, of the Surviving Corporation. If applicable, each stock certificate of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time, evidence
            ownership of such shares of common stock of the Surviving Corporation until presented for transfer or exchange. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Allocation Certificate </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In accordance with the Merger Agreement, at least two Business Days prior to the
            closing date, Remix will prepare and deliver to Passage Bio a certificate signed by an executive officer of Remix, setting forth (as of immediately prior to the Effective Time): (a) each holder of Remix Capital Stock (after giving effect to the
            Remix Preferred Stock Conversion, the Remix Convertible Notes Conversion and the treatment of the Remix Warrants in accordance with their terms and conditions), (b) such holder&#8217;s name and address, (c), the number and type of Remix Capital Stock
            held as of the Closing Date for each such holder, (d) the number of shares of Passage Bio Common Stock to be issued to such holder pursuant to the Merger Agreement in respect of the Remix Capital Stock held by such holder as of immediately
            prior to the Effective Time and (e) for each investor in the Concurrent Financing, the total investment to be made by such investor in the Concurrent Financing, the percentage of the Concurrent Financing Proceeds represented by such
            stockholder&#8217;s investment in the Concurrent Financing, and the number of shares of Passage Bio Common Stock to be issued to such holder pursuant to the Merger Agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Allocation
              Certificate</span>&#8221;). </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Remix Merger Shares </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The formula to calculate Remix Merger Shares, subject to the terms and conditions
            of the Merger Agreement, is the product determined by multiplying (i) the Post-Closing Passage Shares by (ii) the Remix Allocation Percentage, in which: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Aggregate Valuation&#8221; means the sum of (A) the Remix Equity Value, (B) the Passage Bio Valuation and (C)&#160;the Concurrent
                    Financing Proceeds. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Passage Allocation Percentage&#8221; means the quotient (rounded to four decimal places) determined by dividing (A) the Passage
                    Valuation by (B) the Aggregate Valuation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Passage Bio Equity Value&#8221; means $20,000,000. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Passage Outstanding Shares&#8221; means, subject to the terms and conditions of the Merger Agreement (including, if applicable and
                    without limitation, the effects of the Reverse Stock Split and filing the Proposed Restated Charter), the total number of shares of Passage Common Stock outstanding immediately prior to the Effective Time expressed on a fully-diluted
                    basis, and assuming, without </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">138<br/>
        </div>

      </div>

    </div>

    <!--End Page 148-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 149-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">limitation or duplication, (A) the issuance of shares of Passage Common Stock in
            respect of all Passage ITM Options that will be outstanding as of immediately prior to the Effective Time calculated on a &#8220;treasury method&#8221; basis (and, for the avoidance of doubt, excluding any shares of Passage Common Stock in respect of
            Passage Bio Options that are not Passage ITM Options), (B) the settlement in shares of Passage Common Stock of Passage Restricted Stock Unit Awards outstanding as of immediately prior to the Effective Time on a net settlement basis as provided
            in the Merger Agreement (which, for the avoidance of doubt, excludes the shares of Passage Common Stock withheld under the RSU Withholding Amount) and (C) the exclusion of shares of Passage Common Stock held by Passage as treasury stock or
            owned by Remix or any of its Subsidiaries or any Subsidiary of Passage immediately prior to the Effective Time. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Passage Valuation&#8221; means (A) the Passage Equity Value minus (B) the Passage Net Cash Deficiency (if any) plus (C) the Passage
                    Net Cash Surplus (if any). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Remix Allocation Percentage&#8221; means the quotient (rounded to four decimal places) determined by dividing (A) the Remix Equity
                    Value by (B) the Aggregate Valuation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Remix Equity Value&#8221; means $226,000,000. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Passage Bio Net Cash Deficiency&#8221; means, if Passage Bio Net Cash is less than $4,500,000, the amount (if&#160;any) by which
                    $5,000,000 exceeds Passage Bio Net Cash, calculated as of 12:01 a.m. Eastern Time on the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Post-Closing Passage Shares&#8221; means the quotient determined by dividing (A) the Passage Outstanding Shares by (B) the Passage
                    Allocation Percentage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Passage Bio Net Cash Surplus&#8221; means, if Passage Bio Net Cash is greater than $5,500,000, the amount (if&#160;any) by which Passage
                    Bio Net Cash exceeds $5,000,000, calculated as of 12:01 a.m. Eastern Time on the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Remix Merger Shares&#8221; means the product of (i) the Post-Closing Passage Shares multiplied by (ii) the Remix Allocation
                    Percentage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Remix Outstanding Shares&#8221; means, (i) the total number of shares of Remix Common Stock outstanding immediately prior to the
                    Effective Time (after giving effect to the Remix Preferred Stock Conversion and the Remix Convertible Notes Conversion) as expressed on a fully-diluted basis and as-converted to Remix Common Stock on a &#8220;treasury method&#8221; basis and
                    assuming, without limitation or duplication, the issuance of all shares of Remix Common Stock that would be issued assuming the acceleration and exercise of all Remix Options and Remix Warrants outstanding as of immediately prior to the
                    Effective Time, but, (ii)&#160;notwithstanding the foregoing, excluding all shares of Remix Common Stock issuable in connection with the Concurrent Financing, including, without limitation, the shares of Remix Common Stock issued pursuant to
                    (x) the conversion of the Remix Convertible Notes (2026) in the Remix Convertible Notes Conversion and (y) the Subscription Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Concurrent Financing Proceeds&#8221; means the proceeds resulting from the Concurrent Financing, which are not expected to be less
                    than the Concurrent Investment Amount of $99,929,000.00.</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Concurrent Financing Merger Shares </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The formula to calculate Concurrent Financing Merger Shares, subject to the terms
            and conditions of the Merger Agreement, is the product determined by multiplying (i) the Post-Closing Passage Shares by (ii) the Concurrent Financing Allocation Percentage, in which: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Post-Closing Passage Shares&#8221; is defined above. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Concurrent Financing Allocation Percentage&#8221; means the quotient (rounded to four decimal places) determined by dividing (A) the
                    Concurrent Financing Proceeds by (B) the Aggregate Valuation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;Aggregate Valuation&#8221; is defined above. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">139<br/>
        </div>

      </div>

    </div>

    <!--End Page 149-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 150-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a id="tCOPBNC"><!--Anchor--></a>Calculation of Passage Bio
            Net Cash </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the terms of the Merger Agreement, Passage Bio&#8217;s &#8220;Net Cash&#8221; means the
            sum (without duplication) of the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with
                    GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Passage Balance
                    Sheet; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">plus</span>: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all prepaid expenses set forth in the Passage disclosure schedule; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">minus</span>: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">accrued accounts payable due and payable as of the Closing in accordance with GAAP, including, without limitation, all lease
                    termination costs and all other fees and expenses of Passage incurred in connection with the Contemplated Transactions, including, for the avoidance of doubt, Transaction Expenses of Passage Bio; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">contractual commitments for future cash payments, whether absolute, contingent or otherwise, under Passage Real Estate Leases,
                    netted against cash amounts received or reasonably expected to be received pursuant to sublease arrangements with respect to Passage Real Estate Leases </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expenses (including Taxes) of Passage Bio incurred in connection with, related to or associated with the disposition of Legacy
                    Assets and any contingent obligations or liabilities (including the full amount of any indemnity obligations) arising from such dispositions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any liabilities of Passage (A) for any cash payment to or for the benefit of any current or former employee, officer, director,
                    individual independent contractor or other individual non-employee service provider of Passage Bio or any of its subsidiaries for change in control or transaction bonuses, retention bonuses, severance or similar compensatory payments or
                    benefits that are payable under the terms of Passage contracts in effect prior to the Effective Time as a result of, or in connection with, the completion of the Contemplated Transactions, whether alone or together with any other event
                    (including payments with &#8220;<span style="font-style: italic; font-weight: bold;">double trigger</span>&#8221; provisions related to terminations occurring at or prior to the Closing) (in each case, including the employer portion of any payroll
                    or similar taxes payable with respect thereto), (B) with respect to the unfunded or underfunded portion of any accrued employer contributions to a defined contribution or any post-retirement health and welfare benefit plan that remain
                    unpaid as of Closing, and (C) accrued but unpaid bonuses, severance and vacation or paid time off (including the employer portion of any payroll or similar taxes payable with respect thereto; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the RSU Withholding Amount and the employer portion of any payroll or similar taxes payable as a result of the vesting and
                    settlement of each outstanding and unvested Passage Bio Restricted Stock Unit Award in accordance with the Merger Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the avoidance of doubt, (1) the cash and cash equivalents received in the
            Concurrent Financing will be excluded from the calculation of Passage Net Cash and (2) the cash, cash equivalents and marketable securities received from the disposition of Legacy Assets will be included in the calculation of Passage Net Cash.
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;"><a id="tDPBNCS"><!--Anchor--></a>Delivery of Passage Bio Net
            Cash Schedule </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Not less than ten business days prior to the anticipated Closing Date as mutually
            agreed to in good faith by Passage Bio and Remix, Passage Bio will deliver to Remix a net cash schedule (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio Net Cash Schedule</span>&#8221;) setting forth, in reasonable detail,
            Passage Bio&#8217;s good faith estimated calculation of Passage Bio Net Cash (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio Net Cash Calculation</span>&#8221;) as of the close of business on the Closing Date, prepared and certified
            by Passage Bio&#8217;s Chief Financial Officer (or if there is no Chief Financial Officer, the principal financial and accounting officer of Passage Bio) together with the relevant work papers and back-up materials used or useful in preparing the
            Passage Bio Net Cash schedule as reasonably requested by Remix.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Within five business days after delivery of such Passage Bio Net Cash Schedule
            (the last day of such period referred to as the &#8220;<span style="font-style: italic; font-weight: bold;">response date</span>&#8221;), Remix will have the right to dispute any part of the Passage Bio Net Cash schedule by </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">140<br/>
        </div>

      </div>

    </div>

    <!--End Page 150-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 151-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">delivering a written notice to that effect to Passage Bio (referred to herein
            as a &#8220;<span style="font-style: italic; font-weight: bold;">dispute notice</span>&#8221;). Any dispute notice will identify in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to the Passage Bio&#8217;s Net Cash
            Calculation.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Remix disputes the Passage Bio Net Cash Schedule on or prior to the response
            date, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed-upon determination of Net Cash. If the parties are unable to negotiate an agreed-upon determination of Net Cash or any component thereof within
            two calendar days after the delivery of Remix&#8217;s dispute notice, any remaining disagreements as to the calculation of Net Cash will be referred to an independent auditor of recognized national standing jointly selected by Passage Bio and Remix
            or another independent auditor of recognized national standing mutually agreed upon by Passage Bio and Remix. The determination of the amount of Net Cash made by such accounting firm shall be final and binding on Passage Bio and Remix. The
            parties will delay the closing of the Merger until the resolution of the calculation of Net Cash.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s Net Cash balance is subject to numerous factors, some of which are
            outside of Passage Bio&#8217;s control. The actual amount of Net Cash will depend significantly on the timing of the closing of the Merger. As noted above, the closing of the Merger could be delayed if Passage Bio and Remix are not able to agree upon
            the amount of Passage Bio&#8217;s Net Cash as of the close of business on the Closing Date. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTORMO"><!--Anchor--></a>Treatment of Remix Options and
            Remix Equity Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the terms of the Merger Agreement, each Remix Option that is outstanding
            and unexercised immediately prior to the Effective Time under the Remix 2019 Plan, whether or not vested, will be converted into and become an option to purchase shares of Passage Bio Common Stock at the Effective Time. Passage Bio will assume
            the Remix 2019 Plan and all such Remix Option in accordance with the terms of the Remix 2019 Plan and the terms of the stock option agreement by which such Remix Option is evidenced.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Accordingly, from and after the Effective Time: (i) each outstanding Remix Option
            assumed by Passage Bio may be exercised solely for shares of Passage Bio Common Stock; (ii) the number of shares of Passage Bio Common Stock subject to each outstanding Remix Option assumed by Passage Bio will be determined by multiplying (A)
            the number of shares of Remix Common Stock that were subject to such Remix Option, by (B) the Merger Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Passage Bio Common Stock; (iii) the per&#160;share
            exercise price for the Passage Bio Common Stock issuable upon exercise of each Remix Option assumed by Passage Bio will be determined by dividing (A) the per share exercise price of such Remix Option, by (B) the Merger Exchange Ratio and
            rounding the resulting exercise price up to the nearest whole cent; and (iv) any restriction on the exercise of any Remix Option assumed by Passage Bio will continue in full force and effect and the term, exercisability, vesting schedule and
            any other provisions of such Remix Option will otherwise remain unchanged; provided, however, that the combined company&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of the Remix Board or any
            committee thereof with respect to each Remix Option assumed by Passage Bio.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As soon as reasonably practicable following the Closing Date (but in no event
            later than five (5) Business Days after Passage Bio first becomes eligible to use Form&#160;S-8 for the assumed Remix Options), Passage Bio will file an appropriate registration statement on Form&#160;S-8 (or such other appropriate form, if required)
            with respect to the offering of the shares of Passage Bio Common Stock issuable upon the exercise of the assumed Remix Options and will use reasonable best efforts to maintain the effectiveness of registration statement thereafter for so long
            as any of such Remix Options remain outstanding. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tTORW"><!--Anchor--></a>Treatment of Remix Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time, each Remix Warrant that is issued and outstanding as of
            immediately prior to the Effective Time shall be treated in accordance with its terms and conditions. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tDAEOCCF"><!--Anchor--></a>Directors and Executive
            Officers of the Combined Company Following the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the Merger Agreement, each of the directors and officers of Passage
            will resign effective as of the Effective Time. The Merger Agreement provides that Passage Bio will cause, effective as of the Effective Time, the board of directors of the combined company to consist of six members, with each member designated
            by Remix. The parties currently anticipate that Linda C. Bain, Scott Biller, Ph.D., Maria&#160;Koehler, M.D., Ph.D., Matthew R. Patterson, Peter G. Smith, Ph.D., and Peter&#160;Colabuono will serve on the board of directors of the combined company. For
            more information about the directors and executive officers of the combined company following the Merger, please see the section titled &#8220;<span style="font-style: italic;">Management Following the Merger.</span>&#8221; </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">141<br/>
        </div>

      </div>

    </div>

    <!--End Page 151-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 152-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a id="tAOTRC"><!--Anchor--></a>Amendment of the Restated
            Certificate of Incorporation of Passage Bio </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio agreed to amend its certificate of incorporation prior to the
            Effective Time to effect the Reverse Stock Split and to amend its certificate of incorporation at the Effective Time to be in the form of the Amended and Restated Passage Bio Charter. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;"><a id="tPAS"><!--Anchor--></a>Potential Asset Sale </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the closing of the Merger, Passage Bio is entitled, but is under no
            obligation, to sell, transfer, license, assign or otherwise divest any or all of the assets and rights primarily relating to Passage Bio&#8217;s full AAV particle purification method or other inventions generated by Passage Bio in connection with its
            PBFT02 clinical studies (the &#8220;<span style="font-style: italic; font-weight: bold;">Legacy Assets</span>&#8221;) in a transaction or series of transactions (the &#8220;<span style="font-style: italic; font-weight: bold;">Legacy Asset Disposition</span>&#8221;).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">However, Passage Bio may not enter into any agreement with respect to the Legacy
            Asset Disposition that would result in a continuing obligation or liability to Passage Bio or the Surviving Corporation without the prior written consent of Remix (such consent not to be unreasonably withheld, conditioned or delayed). Passage
            Bio will provide Remix with a copy of any agreement with respect to a Legacy Asset Disposition at least five business days prior to entry into such agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a Legacy Asset is sold on or prior to the Closing Date, the cash, cash
            equivalents and marketable securities received from such disposition will be included in the calculation of Passage Bio Net Cash pursuant to the Merger Agreement, which will have the effect of decreasing the number of shares issuable as
            consideration to the Remix securityholders as of immediately prior to the Merger and proportionately increasing the relative ownership of Passage Bio (following the Closing) by Passage Bio&#8217;s pre-closing securityholders. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;"><a id="tRAW"><!--Anchor--></a>Representations and Warranties </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement contains customary representations and warranties of Passage
            Bio and Remix for a transaction of this type relating to, among other things: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">due organization; subsidiaries, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">organizational documents, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">authority; binding nature of the Merger Agreement, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">vote required, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">non-contravention; consents, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">capitalization, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">financial statements, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">absence of changes, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">absence of undisclosed liabilities, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">title to assets, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real property; leasehold, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">intellectual property, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">agreements, contracts and commitments, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compliance; permits; restrictions, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">legal proceedings; orders, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax matters, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">employee and labor matters; benefit plans, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">environmental matters, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">insurance, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transactions with affiliates, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">no financial advisors, and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">privacy and data security. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">142<br/>
        </div>

      </div>

    </div>

    <!--End Page 152-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 153-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix makes additional representations and warranties relating to, among other
            things, the Concurrent Financing.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio makes additional representations and warranties relating to, among
            other things, SEC filings and the valid issuance of Passage Bio Common Stock in connection with the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The representations and warranties are, in many respects, qualified by
            materiality and knowledge of the representing party, and will not survive the Merger, but their accuracy forms the basis of one of the conditions to the obligations of Passage Bio and Remix to complete the Merger. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a id="tCCOBPM"><!--Anchor--></a>Covenants; Conduct of
            Business Pending the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has agreed that until the earlier of the Effective Time and the termination
            of the Merger Agreement, except as set&#160;forth in the Remix disclosure schedule, as required by applicable law, as otherwise provided by the Merger Agreement and the transactions contemplated thereby or with Passage Bio&#8217;s prior written consent
            (not to be unreasonably withheld, conditioned or delayed), Remix will, and will cause its subsidiaries to, use their commercially reasonable efforts to conduct its operations in the ordinary course of its business and to preserve intact the
            present business organizations and goodwill of the business and the present relationships of the business with material customers and suppliers. Without limiting the generality of the foregoing, until the earlier of the Effective Time and the
            termination of the Merger Agreement, except as set forth in the Remix disclosure schedule, as required by applicable law, as otherwise provided by the Merger Agreement and the transactions contemplated thereby or with Passage Bio&#8217;s prior
            written consent (not to be unreasonably withheld, conditioned or delayed), Remix will not, and will cause its subsidiaries not to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sell, lease, license or otherwise dispose of any material assets of Remix, or in either case, any interests therein, except (i)
                    pursuant to existing contracts, (ii) for sales or licensing of products to customers or (iii)&#160;otherwise in the ordinary course of its business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take any action with respect to any equity interests of Remix or any of its subsidiaries, including any issuance, sale,
                    transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issue, deliver, sell, grant, pledge, transfer, subject to any encumbrance or dispose of any Remix capital stock or the
                    securities of any subsidiary of Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create or otherwise incur any encumbrance on any material asset of Remix or any of its subsidiaries, other than permitted
                    encumbrances pursuant to the Merger Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make any loans, advances or capital contributions to, or investments in, any person other than Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance with
                    its terms) any material contract, other than any amendment or modification entered into in the ordinary course of its business and containing terms not materially less favorable to Remix or any of its Subsidiaries than the terms of such
                    contract in effect as of the date of the Merger Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any contract that would be required to be disclosed as a material contract in the Remix disclosure schedule if such
                    contract were in effect as of the date of the Merger Agreement, other than any such contract entered into in the ordinary course of its business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">except as required by any Remix employee plan, (i) increase any salary, wage or other compensation or benefit to, or enter into
                    or amend any employment, retention, change-in-control, termination or severance agreement with, any current or former employee, officer, director, individual independent contractor or other individual non-employee service provider of
                    Remix or any of its subsidiaries, other than annual increases in base compensation in the ordinary course of its business with respect to employees whose annual base compensation is less than $500,000 and provided that such increases do
                    not, individually or in the aggregate, result in any material increase in costs, obligations or liabilities for Remix and its subsidiaries, (ii) grant or pay any bonuses to any current or former employee, officer, director, individual
                    independent contractor or other individual non-employee service provider of Remix or any of its subsidiaries, other than in the ordinary course of its business, (iii) establish, enter into or adopt any new material Remix employee plan
                    or any plan, program, policy, agreement or arrangement that would be a </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">143<br/>
        </div>

      </div>

    </div>

    <!--End Page 153-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 154-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">material Remix employee plan if it was in effect on the date of the Merger
            Agreement or amend or modify, in a manner that would, individually or in the aggregate, materially increase costs, obligations or liabilities for Remix and its subsidiaries or the combined company, any existing Remix employee plan or accelerate
            the vesting of any compensation (including stock options, restricted stock, restricted stock units, phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of capital stock or equity-based awards) for
            the benefit of any current or former employee, officer, director, individual independent contractor or other individual non-employee service provider of Remix or any of its subsidiaries, other than any such acceleration occurring in the
            ordinary course of its business, (iv) take any action to accelerate any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any current or former employee, officer, director, individual independent
            contractor or other individual non-employee service provider of Remix or any of its subsidiaries, other than in the ordinary course of its business, (v) grant any new long-term incentive or equity-based awards, or amend or modify the terms of
            any such outstanding awards under any Remix employee plan or (vi)&#160;hire, terminate (other than for cause), promote or change the employment status or title of any current or former employee, officer, director, individual independent contractor
            or other individual non-employee service provider of Remix or any of its subsidiaries, other than in the ordinary course of its business; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt, enter into, amend or terminate any collective bargaining agreement or contract with any labor union, works council or
                    labor organization; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">settle any material legal proceeding involving Remix or any of its subsidiaries or relating to the transactions contemplated by
                    the Merger Agreement, in either case, for more than $100,000 individually or $250,000 in the aggregate; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make or change any material tax election or tax accounting method, change any annual tax accounting period, amend any material
                    tax return, enter into any closing agreement with a governmental authority with respect to material taxes or settle any tax claim with respect to material taxes; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to
                    prevent the Merger from qualifying as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code and Treasury Regulations, with respect to which each of Passage Bio, Merger Sub and Remix are a &#8220;party to a reorganization&#8221; under
                    Section&#160;368(b) of the Code, and the Merger Agreement from qualifying as a &#8220;plan of reorganization&#8221; for purposes of Sections 354, 361 and 368 of the Code and within the meaning of Section&#160;368 of the Code and Treasury Regulations
                    Section&#160;1.368-2(g) (the &#8220;<span style="font-style: italic; font-weight: bold;">Intended Tax Treatment</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make any material change in any method of financial accounting or financial accounting practice of Remix or any of its
                    subsidiaries, except for any such change required by reason of a change in GAAP or other applicable financial accounting standards; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other than in connection with actions contemplated by the Merger Agreement, adopt, approve, consent to or propose any change in
                    the organizational documents of Remix or any of its subsidiaries; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">agree or commit to do any of the foregoing. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has agreed that until the earlier of the Effective Time and the
            termination of the Merger Agreement, except as required by applicable law, as otherwise provided by the Merger Agreement and the transactions contemplated thereby or with Remix&#8217;s prior written consent (not to be unreasonably withheld,
            conditioned or delayed), Passage Bio will, and will cause its subsidiaries to, use their commercially reasonable efforts to conduct its operations in the ordinary course of its business and to preserve intact the present business organizations
            and goodwill of the business and the present relationships of the business with material customers and suppliers. Without limiting the generality of the foregoing, until the earlier of the Effective Time and the termination of the Merger
            Agreement, except as set forth in the Passage Bio disclosure schedule, as required by applicable law, as otherwise provided by the Merger Agreement and the transactions contemplated thereby or with Remix&#8217;s prior written consent (not to be
            unreasonably withheld, conditioned or delayed), Passage Bio will not, and will cause its subsidiaries not to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">sell, lease, license or otherwise dispose of any material assets of Passage Bio, or in either case, any interests therein,
                    except (i) pursuant to existing contracts, (ii) for sales or licensing of products to customers or (iii)&#160;otherwise in the ordinary course of its business; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">144<br/>
        </div>

      </div>

    </div>

    <!--End Page 154-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 155-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">except for the issuance of securities under the Merger Agreement, take any action with respect to any equity interests of
                    Passage Bio or any of its subsidiaries, including any issuance, sale, transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issue, deliver, sell, grant, pledge, transfer, subject to any encumbrance or dispose of any Passage Bio Common Stock or the
                    securities of any subsidiary of Passage Bio; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create or otherwise incur any encumbrance on any material asset of Passage Bio or any of its subsidiaries, other than permitted
                    encumbrances pursuant to the Merger Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make any loans, advance or capital contributions to, or investments in, any person other than Passage Bio; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance with
                    its terms) any material contract, other than any amendment or modification entered into in the ordinary course of its business and containing terms, not materially less favorable to Passage Bio or any of its Subsidiaries than the terms
                    of such contract in effect as of the date of the Merger Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">enter into any contract that would be required to be disclosed as a material contract in the Passage Bio disclosure schedule if
                    such contract were in effect as of the date the Merger Agreement, other than any such contract entered into in the ordinary course of its business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">except as required by any Passage Bio employee plan, (i) increase any salary, wage or other compensation or benefit to, or enter
                    into or amend any employment, retention, change-in-control, termination or severance agreement with, any current or former employee, officer, director, individual independent contractor or other individual non-employee service provider
                    of Passage Bio or any of its subsidiaries, (ii)&#160;grant or pay any bonuses to any current or former employee, officer, director, individual independent contractor or other individual non-employee service provider of Passage Bio or any of
                    its subsidiaries, (iii)&#160;establish, enter into or adopt any new Passage Bio employee plan or any plan, program, policy, agreement or arrangement that would be a material Passage Bio employee plan if it was in effect on the date of the
                    Merger Agreement or amend or modify, in a manner that would, individually or in the aggregate, materially increase costs, obligations or liabilities for Passage Bio and its subsidiaries or the combined company, any existing Passage Bio
                    employee plan or accelerate the vesting of any compensation (including stock options, restricted stock, restricted stock units, phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of
                    capital stock or equity-based awards) for the benefit of any current or former employee, officer, director, individual independent contractor or other individual non-employee service provider of Passage Bio or any of its subsidiaries,
                    (iv)&#160;grant any current or former employee, officer, director, individual independent contractor or other individual non-employee service provider of Passage Bio or any of its subsidiaries any right to receive, or pay to any current or
                    former employee, officer, director, individual independent contractor or other individual non-employee service provider of Passage Bio or any of its subsidiaries any severance, change in control, transaction, retention, termination or
                    similar compensation or benefits or increases therein, (v)&#160;take any action to accelerate any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any current or former employee, officer, director,
                    individual independent contractor or other individual non-employee service provider of Passage Bio or any of its subsidiaries, (vi) grant any new long-term incentive or equity-based awards, or amend or modify the terms of any such
                    outstanding awards under any Passage Bio employee plan or (vii) hire, terminate (other than for cause), promote or change the employment status or title of any current or former employee, officer, director, individual independent
                    contractor or other individual non-employee service provider of Passage Bio or any of its subsidiaries other than terminations of any current or former employee, officer, director, individual independent contractor or other individual
                    non-employee service provider of Passage Bio who is not an officer of Passage Bio; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt, enter into, amend or terminate any collective bargaining agreement or contract with any labor union, works council or
                    labor organization; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">settle any material legal proceeding involving Passage Bio or relating to the transactions contemplated by the Merger Agreement;
                  </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">145<br/>
        </div>

      </div>

    </div>

    <!--End Page 155-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 156-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make or change any material tax election or tax accounting method, change any annual tax accounting period, amend any material
                    tax return, enter into any closing agreement with a governmental authority with respect to material taxes or settle any tax claim with respect to material taxes; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to
                    prevent the Merger from qualifying for the Intended Tax Treatment; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make any material change in any method of financial accounting or financial accounting practice of Passage Bio, except for any
                    such change required by reason of a change in GAAP or other applicable financial accounting standards; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other than in connection with actions contemplated by the Merger Agreement, adopt, approve, consent to or propose any change in
                    the organizational documents of Passage Bio; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">agree or commit to do any of the foregoing. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"><a id="tCVR"><!--Anchor--></a>Contingent Value Rights </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the Effective Time, Passage Bio will declare a distribution of one CVR
            to the holders of record of Passage Bio Common Stock as of the record date for such distribution. Each such holder shall be entitled to receive one CVR for each outstanding share of Passage Bio Common Stock held by such stockholder as of the
            record date (less applicable withholding taxes), each representing the right to receive contingent payments upon the occurrence of certain events set&#160;forth in, and subject to and in accordance with the terms and conditions of, the CVR
            Agreement, discussed in greater detail under the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger-Contingent Value Rights Agreement</span>.&#8221; The record date for such distribution will be the close of business
            on the last business day prior to the day on which the Effective Time occurs and the payment date for which will be three business days after the Effective Time; provided that the payment of such distribution may be conditioned upon the
            occurrence of the Effective Time. In connection with such distribution, Passage Bio will cause the CVR Agreement to be duly authorized, executed and delivered by Passage Bio and Computershare Trust Company, N.A. (or such other nationally
            recognized rights agent agreed to between Passage Bio and Remix). </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"><a id="tTMANS"><!--Anchor--></a>Non-Solicitation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of Passage Bio and Remix have agreed that until the earlier of the Effective
            Time and the termination of the Merger Agreement, except as described below, Passage Bio and Remix and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize or permit any of the directors,
            officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any
                    Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">furnish any non-public information regarding such party to any person (other than Remix or Passage Bio) in connection with or in
                    response to an Acquisition Proposal or Acquisition Inquiry; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">engage in discussions or negotiations with any person with respect to such Acquisition Proposal or Acquisition Inquiry; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approve, endorse or recommend any Acquisition Proposal (other than in accordance with the Merger Agreement); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">other than in accordance with the Merger Agreement, execute or enter into any letter of intent or any contract contemplating or
                    otherwise relating to any Acquisition Transaction, other than an acceptable confidentiality agreement in accordance with the Merger Agreement; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">publicly propose to do any of the foregoing. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the avoidance of doubt, Remix may engage in ordinary course business
            development activities, including responding to inquiries or furnishing third parties information with respect to Remix or its business, without complying with the requirements set forth above. An &#8220;Acquisition Inquiry&#8221; means, with respect to a
            party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">146<br/>
        </div>

      </div>

    </div>

    <!--End Page 156-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 157-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">information made or submitted by Remix, on the one hand, or Passage Bio, on
            the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal, other than, as applicable, with respect to the Legacy Asset Disposition or the Concurrent Financing.&#8221;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">An &#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal,
            whether written or oral (other than an offer or proposal made or submitted by or on behalf of Remix or any of its affiliates, on the one hand, or by or on behalf of Passage Bio or any of its affiliates, on the other hand, to the other party)
            contemplating or otherwise relating to any Acquisition Transaction with such party, other than, as applicable, with respect to the Legacy Asset Disposition or the Concurrent Financing.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related
            transactions (other than, as applicable, with respect to the Legacy Asset Disposition or the Concurrent Financing) involving: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of
                    securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (A) in which a party is a constituent entity, (B) in which a person or &#8220;group&#8221; (as defined in the Exchange Act and the rules
                    promulgated thereunder) of persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a party or any of its
                    subsidiaries or (C) in which a party or any of its subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute
                    or account for 20% or more of the consolidated book value or the fair market value of the assets of a party and its subsidiaries, taken as a whole. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Notwithstanding the foregoing, before obtaining the applicable approvals of the
            Passage Bio stockholders required to consummate the Merger, Passage Bio may furnish non-public information regarding Passage Bio or its subsidiaries to, and may enter into discussions or negotiations with, any person in response to a bona fide
            written Acquisition Proposal with respect to Passage Bio, which Passage Bio&#8217;s board of directors determines in good faith, after consultation with Passage Bio&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely
            to result in, a Superior Offer (and is not withdrawn) if: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">neither Passage Bio nor any Representative of Passage Bio shall have breached the non-solicitation provisions of the Merger
                    Agreement in any material respect; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio board of directors concludes in good faith based on the advice of outside legal counsel, that failure to take
                    such action would reasonably be expected to result in a breach of the fiduciary duties of the Passage Bio board of directors under applicable law; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio gives Remix prior written notice of Passage Bio&#8217;s intention to furnish non-public information to, or enter into
                    discussions with, such person; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio receives from such person an executed confidentiality agreement in accordance with the terms and conditions of the
                    Merger Agreement; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">substantially concurrently with furnishing any such non-public information to such person, Passage Bio furnishes such non-public
                    information to Remix (to the extent such information has not been previously furnished by Passage Bio to Remix). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has acknowledged and agreed that if any Passage Bio Representative
            takes any action in its capacity as a Passage Bio Representative that, if taken by Passage Bio, would constitute a breach of the non-solicitation provisions of the Merger Agreement, the taking of such action by such Passage Bio Representative
            will be deemed a breach of such non-solicit provisions by Passage Bio.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">147<br/>
        </div>

      </div>

    </div>

    <!--End Page 157-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 158-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Notwithstanding the foregoing, before obtaining the applicable approvals of
            the Remix stockholders required to consummate the Merger, Remix may furnish non-public information regarding Remix or its subsidiaries to, and may enter into discussions or negotiations with, any person in response to a bona fide written
            Acquisition Proposal with respect to Remix, which Remix&#8217;s board of directors determines in good faith, after consultation with Remix&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in, a Superior
            Offer (and is not withdrawn) if: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">neither Remix nor any Representative of Remix shall have breached the non-solicitation provisions of the Merger Agreement in any
                    material respect; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix board of directors concludes in good faith based on the advice of outside legal counsel, that the failure to take such
                    action would reasonably be expected to result in a breach of the fiduciary duties of the Remix board of directors under applicable law; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix gives Passage Bio prior written notice of Remix&#8217;s intention to furnish non-public information to, or enter into
                    discussions with, such person; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix receives from such person an executed confidentiality agreement in accordance with the terms and conditions of the Merger
                    Agreement; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">substantially concurrently with furnishing any such non-public information to such person, Remix furnishes such non-public
                    information to Passage Bio (to the extent such information has not been previously furnished by Remix to Passage Bio). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has acknowledged and agreed that if any Remix Representative takes any
            action in its capacity as a Remix Representative that, if taken by Remix, would constitute a breach of the non-solicitation provisions of the Merger Agreement, the taking of such action by such Remix Representative will be deemed a breach of
            such non-solicit provisions by Remix.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A &#8220;Superior Offer&#8221; means an unsolicited bona fide written Acquisition Proposal
            (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (i) was not obtained or made as a direct or indirect result of a breach of (or in violation of) the Merger
            Agreement and (ii) is on terms and conditions that the Remix board of directors or the Passage Bio board of directors, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of
            consummation thereof, the financing terms and any termination or break-up fees and conditions to consummation thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and
            following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Remix&#8217;s stockholders or Passage Bio&#8217;s stockholders, as applicable, than the terms of the Merger
            Agreement and the transactions contemplated thereby and is not subject to any financing conditions.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement also provides that if any party or any representative of
            such party receives an Acquisition Proposal or Acquisition Inquiry at any time prior to the earlier of the Effective Time and the termination of the Merger Agreement, then such party shall promptly (and in no event later than one business day
            after such party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other party orally and in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the person making or submitting such
            Acquisition Proposal or Acquisition Inquiry, and provide a copy of the Acquisition Proposal or Acquisition Inquiry, or if the Acquisition Proposal or Acquisition Inquiry is not written, the terms thereof). The Merger Agreement provides that
            such party shall keep the other party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"><a id="tBRC"><!--Anchor--></a>Board Recommendation Change </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Merger Agreement, subject to certain exceptions described below,
            Passage Bio agreed that its board of directors may not take any of the following actions, each of which are referred to in this proxy statement/prospectus as a &#8220;Passage Bio Board Adverse Recommendation Change&#8221;: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of the
                    Passage Bio board of directors in a manner adverse to Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, or have any committee of the Passage Bio board of directors resolve, to withdraw or modify the recommendation of the
                    Passage Bio board of directors in a manner adverse to Remix; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 4pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">148<br/>
        </div>

      </div>

    </div>

    <!--End Page 158-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 159-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">However, notwithstanding the foregoing, at any time prior to the approval of
            the proposals to be considered at the Passage Bio stockholder meeting by the necessary vote of Passage Bio stockholders, if Passage Bio has received a bona&#160;fide written Superior Offer, the Passage Bio board of directors may make a Passage Bio
            Board Adverse Recommendation Change if, but only if, following the receipt of and on account of such Superior Offer: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio board of directors determines in good faith, after consultation with its outside legal counsel, that the failure
                    to make a Passage Bio Board Adverse Recommendation Change would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio has, and has caused its financial advisors and outside legal counsel to, during a three business day period
                    commencing on the date that the Passage Bio board of directors notifies Remix in writing of its intent to make a Passage Bio Board Adverse Recommendation Change, negotiated with Remix in good faith to make such adjustments to the terms
                    and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if after Remix shall have delivered to Passage Bio a written offer to alter the terms or conditions of the Merger Agreement
                    during the three business day period commencing on the date that the Passage Bio board of directors notifies Remix in writing of its intent to make a Passage Bio Board Adverse Recommendation Change (or if Remix declines to do so), the
                    Passage Bio board of directors shall have determined in good faith, after consultation with its outside legal counsel, that the failure to withhold, amend, withdraw or modify the recommendation of the Passage Bio board of directors
                    would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement, if any); provided that (x) Remix receives
                    written notice from Passage Bio confirming that the Passage Bio board of directors has determined to change its recommendation during such three business day period, which notice shall include written copies of any relevant proposed
                    transaction agreements with any party making a potential Superior Offer, (y) during any such three business day period, Remix shall be entitled to deliver to Passage Bio one or more counterproposals to such Acquisition Proposal and
                    Passage Bio will, and cause its representatives to, negotiate with Remix in good faith (to the extent Remix desires to negotiate) to make such adjustments in the terms and conditions of the Merger Agreement so that the applicable
                    Acquisition Proposal ceases to constitute a Superior Offer and (z) in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the combined company that Passage Bio&#8217;s stockholders would
                    receive as a result of such potential Superior Offer), Passage Bio shall be required to provide Remix with notice of such material amendment and such three business day period shall be extended, if applicable, to ensure that at least
                    two business days remain in the requisite notice period following such notification during which the parties shall comply again with the requirements of the Merger Agreement and the Passage Bio board of directors shall not make a
                    Passage Bio Board Adverse Recommendation Change prior to the end of such notice period as so extended (it being understood that there may be multiple extensions). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Merger Agreement, subject to certain exceptions described below, Remix
            has agreed that its board of directors may not take any of the following actions: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of the Remix
                    board of directors in a manner adverse to Passage Bio; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">resolve, or have any committee of the Remix board of directors resolve, to withdraw or modify the recommendation of the Remix
                    board of directors in a manner adverse to Passage Bio; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">However, notwithstanding the foregoing, at any time prior to the approval of the
            Remix Stockholder Matters by the necessary vote of Remix stockholders, if Remix has received a bona fide written Superior Offer, the Remix board of directors may make a Remix Board Adverse Recommendation Change if, but only if, following the
            receipt of and on account of such Superior Offer: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix board of directors determines in good faith, after consultation with its outside legal counsel, that the failure to
                    make a Remix Board Adverse Recommendation Change would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">149<br/>
        </div>

      </div>

    </div>

    <!--End Page 159-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 160-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix has, and has caused its financial advisors and outside legal counsel to, during a three business day period commencing on
                    the date that the Remix board of directors notifies Passage Bio in writing of its intent to make a Remix Board Adverse Recommendation Change, negotiated with Passage Bio in good faith to make such adjustments to the terms and conditions
                    of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if after Passage Bio shall have delivered to Remix a written offer to alter the terms or conditions of the Merger Agreement
                    during the three business day period commencing on the date that the Remix board of directors notifies Passage Bio in writing of its intent to make a Remix Board Adverse Recommendation Change (or if Passage Bio declines to do so), the
                    Remix board of directors shall have determined in good faith, after consultation with its outside legal counsel, that the failure to withhold, amend, withdraw or modify the recommendation of the Remix board of directors would reasonably
                    be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement, if any); provided that (x) Passage Bio receives written
                    notice from Remix confirming that the Remix board of directors has determined to change its recommendation during such three business day period, which notice shall include written copies of any relevant proposed transaction agreements
                    with any party making a potential Superior Offer, (y) during any such three business day period, Passage Bio shall be entitled to deliver to Remix one or more counterproposals to such Acquisition Proposal and Remix will, and cause its
                    representatives to, negotiate with Passage Bio in good faith (to the extent Passage Bio desires to negotiate) to make such adjustments in the terms and conditions of the Merger Agreement so that the applicable Acquisition Proposal
                    ceases to constitute a Superior Offer and (z) in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the combined company that Remix&#8217;s stockholders would receive as a result of
                    such potential Superior Offer), Remix shall be required to provide Passage Bio with notice of such material amendment and such three business day period shall be extended, if applicable, to ensure that at least two business days remain
                    in the requisite notice period following such notification during which the parties shall comply again with the requirements of the Merger Agreement and the Remix board of directors shall not make a Remix Board Adverse Recommendation
                    Change prior to the end of such notice period as so extended (it being understood that there may be multiple extensions). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a id="tMOPBSAWORS"><!--Anchor--></a>Meeting of Passage Bio&#8217;s
            Stockholders and Written Consent of Remix&#8217;s Stockholders </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is obligated under the Merger Agreement to take all action necessary
            under applicable law to call, give notice of and hold a meeting of the holders of Passage Bio Common Stock to consider and vote to approve the Merger Agreement and the transactions contemplated thereby, including the issuance of the shares of
            Passage Bio Common Stock to the stockholders of Remix pursuant to the terms of the Merger Agreement and the adoption of the amendments to the Restated Certificate of Incorporation of Passage Bio described in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Amendment of the Restated Certificate of Incorporation of Passage Bio</span>&#8221;. The Passage Bio stockholder meeting shall be held as promptly as practicable after the date that the Registration
            Statement is declared effective under the Securities Act, and in any event no later than 45 days after the effective date of the Registration Statement. Passage Bio shall take reasonable measures to ensure that all proxies solicited in
            connection with the Passage Bio stockholder meeting are solicited in compliance with all applicable law.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Notwithstanding anything to the contrary contained in the Merger Agreement, if on
            the date of the Passage Bio stockholder meeting, or a date preceding the date on which the Passage Bio stockholder meeting is scheduled, Passage Bio reasonably believes that (i) it will not receive proxies sufficient to obtain the requisite
            Passage Bio stockholder vote, whether or not a quorum would be present or (ii) it will not have sufficient shares of Passage Bio Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business
            of the Passage Bio stockholder meeting, Passage Bio may postpone or adjourn, or make one or more successive postponements or adjournments of, the Passage Bio stockholder meeting as long as the date of the Passage Bio stockholder meeting is not
            postponed or adjourned more than an aggregate of 30 calendar days in connection with any postponements or adjournments.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Promptly after the Registration Statement has been declared effective under the
            Securities Act, and in any event no later than two business days thereafter, Remix shall prepare, with the cooperation of Passage Bio, and cause to be mailed to the stockholders of Remix an information statement, which shall include a copy of
            the Proxy Statement, and the Remix stockholder written consent, in order to solicit the approval of Remix&#8217;s stockholders, including but not limited to Remix&#8217;s stockholders sufficient for the requisite Remix stockholder vote in lieu of a meeting
            pursuant </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">150<br/>
        </div>

      </div>

    </div>

    <!--End Page 160-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 161-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to Section&#160;228 of Delaware law, for purposes of (i) adopting and approving the
            Merger Agreement and the transaction contemplated thereby, (ii) acknowledging that the approval given thereby is irrevocable, ((i) and (ii)&#160;together, the &#8220;<span style="font-style: italic; font-weight: bold;">Required Remix Stockholder Vote</span>&#8221;).

            Remix shall use its reasonable best efforts to cause Remix stockholders sufficient for the Required Remix Stockholder Vote to execute and deliver to Remix the Remix stockholder written consent promptly following delivery thereof, and in any
            event no later than fifteen days after the Registration Statement has been declared effective. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tTMARA"><!--Anchor--></a>Regulatory Approvals </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of the parties will use commercially reasonable efforts to file or otherwise
            submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority
            with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with, and without limiting, the efforts referenced above, Passage
            and Remix shall (i) furnish, or cause to be furnished, to the other party, such necessary information and reasonable assistance as the other party may request in connection with its preparation of any filing or submission that is required to be
            filed by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, (ii) permit the other party and its counsel to review any filing or submission prior to forwarding to the governmental
            authorities (except where such material is reasonably determined by a party to be competitively sensitive to such party in which case it will be provided, subject to applicable law, to the other party&#8217;s counsel on an &#8220;<span style="font-style: italic; font-weight: bold;">external counsel only</span>&#8221; basis) and consider in good faith any comments made by such other party, (iii) keep each other reasonably apprised of the status of, and provide the other party with copies of (to the
            extent made in writing), any communications with, and any inquiries or requests for additional information from, any governmental authorities and comply as promptly as practicable with any such inquiry or request and (iv) not participate in any
            meeting or discussion, either in person or by telephone or videoconference, with any governmental authority in connection with the transactions contemplated by the Merger Agreement, unless (A) it provides the other party with reasonable advance
            notice and (B) gives the other party and its counsel the opportunity to attend and participate; provided that a party shall not be required to give the other party the opportunity to attend and participate to the extent prohibited by such
            governmental authority </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"><a id="tIAIFDAO"><!--Anchor--></a>Indemnification and
            Insurance for Directors and Officers </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Merger Agreement, from the Effective Time through the sixth anniversary
            of the date on which the Effective Time occurs (or, if a director or officer of Passage Bio or Remix, respectively, asserts a claim for indemnification or other protections pursuant to the Merger Agreement prior to the end of such six-year
            period, then until the date that such claim is resolved and all Costs associated therewith have been indemnified), each of Passage Bio and the combined company agreed to indemnify and hold harmless each person who is now, or has been at any
            time prior to the date of the Merger Agreement, or who becomes prior to the Effective Time, a director or officer of Passage Bio or Remix, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees,
            costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the
            fact that the indemnified officer or director is or was a director or officer of Passage Bio or of Remix, whether asserted or claimed prior to, at or after the Effective Time. Each indemnified officer or director will be entitled to advancement
            of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Passage Bio and the combined company, jointly and severally, upon receipt by Passage Bio or the combined company from such indemnified
            officer or director of a request therefor; provided that any such person to whom expenses are advanced provides an undertaking to Passage Bio, to the extent then required by Delaware law, to repay such advances if it is ultimately determined
            that such person is not entitled to indemnification.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement also provides that the provisions of the certificate of
            incorporation and bylaws of Passage Bio with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of Passage Bio that are presently set forth in the certificate of incorporation and
            bylaws of Passage Bio will not be amended modified or repealed for a period of six years from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers
            or directors of Passage Bio, unless such modification is required by applicable law. The certificate of incorporation and bylaws </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">151<br/>
        </div>

      </div>

    </div>

    <!--End Page 161-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 162-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of the combined company will contain, and Passage Bio will cause the
            certificate of incorporation and bylaws of the combined company to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently
            set forth in the certificate of incorporation and bylaws of Remix.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From and after the Effective Time, Passage Bio will maintain directors&#8217; and
            officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Passage Bio. In addition,
            Passage Bio will purchase a six year &#8220;tail policy&#8221; on Passage Bio&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the Merger. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tS16M"><!--Anchor--></a>Section&#160;16 Matters </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the Effective Time, Passage Bio will take all such steps as may be
            required to cause any acquisitions of Passage Bio Common Stock and any options to purchase Passage Bio Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the
            reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Passage Bio, to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="t2P2E"><!--Anchor--></a>2026 Plan and 2026 ESPP </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the effectiveness of the Form&#160;S-4, Passage Bio will use commercially
            reasonable efforts to cause the Passage Bio Board to adopt the 2026 Plan and the 2026 ESPP, each in form and substance as agreed to by Passage Bio and Remix, reserving for issuance a number of shares of Passage Bio Common Stock to be mutually
            agreed upon by Remix and Passage Bio. Approval of the 2026 Plan and the 2026 ESPP by Passage Bio&#8217;s stockholders is not a condition to closing. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tPB4P"><!--Anchor--></a>Passage Bio 401(k) Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless Remix requests otherwise at least 10 business days prior to the Closing
            Date, the Passage Bio Board or an authorized committee thereof will, effective as of at least one day prior to the Closing Date but subject to the closing of the Merger, take (or cause to be taken) all actions to adopt such resolutions as may
            be necessary or appropriate to (a)&#160;terminate any Passage Bio employee plan that is intended to meet the requirements of Section&#160;401(k) of the Code or, if applicable, (b) withdraw as a participating employer in such 401(k) plan, spin-off the
            portion of such 401(k) plan maintained by Passage Bio and terminate the spun-off portion of such 401(k) plan maintained by Passage Bio. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tTOE"><!--Anchor--></a>Termination of Employees </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the Closing Date, the Passage Bio Board shall adopt appropriate
            resolutions and Passage Bio will take all such steps as may be required to cause the employment of each employee of Passage Bio to be terminated as of the Closing Date. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tS2G"><!--Anchor--></a>Section&#160;280G </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Within 15 business days of the signing of the Merger Agreement, Passage Bio will
            deliver a list of disqualified individuals (within the meaning of Section&#160;280G of the Code) to Remix along with an estimate of the parachute payments (within the meaning of Section&#160;280G of the Code) that could be paid to such disqualified
            individual as a result of the Merger, which estimate shall be updated and delivered to Remix not later than 5 business days prior to the Closing Date. Passage Bio shall cooperate with Remix to limit potential adverse tax consequences of
            Section&#160;280G and shall not engage in any action outside the ordinary course of business that is primarily intended to reduce or mitigate a potential parachute payment or excise taxes under Section&#160;280G without prior consultation with Remix, and
            with respect to the valuing of any non-competition agreements or commission of any reasonable compensation studies, without the prior approval by Remix (such approval not to be unreasonably withheld, conditioned of delayed).</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">152<br/>
        </div>

      </div>

    </div>

    <!--End Page 162-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 163-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><a id="tAA"><!--Anchor--></a>Additional Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of Passage Bio and Remix has agreed to use commercially reasonable efforts
            to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in
                    connection with the transactions contemplated by the Merger Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any
                    applicable law or contract, or otherwise) by such party in connection with the transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use commercially reasonable efforts to obtain and maintain as promptly as practicable the expiration or termination of any
                    applicable waiting period under any applicable antitrust, competition, investment or similar laws; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated
                    by the Merger Agreement; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Pursuant to the Merger Agreement, Passage Bio and Remix have further agreed,
            among other things, that: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">At or prior to the Effective Time, Passage Bio will use commercially reasonable efforts to (a) maintain a listing on Nasdaq
                    until the Effective Time and, to the extent required by the rules and regulations of Nasdaq, obtain approval of the listing of the combined company on Nasdaq, (b) to the extent required by the rules and regulations of Nasdaq, prepare
                    and submit to Nasdaq a notification form for the listing of the shares of Passage Bio Common Stock to be issued in connection with the transactions contemplated by the Merger Agreement and to cause such shares to be approved for
                    listing; (c) prepare and timely submit to Nasdaq a notification form of the Reverse Stock Split and a copy of the amendment to Passage Bio&#8217;s certificate of incorporation to effect the Reverse Stock Split and other amendments
                    contemplated by the Merger Agreement certified by the Secretary of State of the State of Delaware, to Nasdaq on or before the closing date of the Merger; and (d) to the extent required by Nasdaq Marketplace Rule&#160;5110, assist Remix in
                    preparing and filing an initial listing application for the Passage Bio Common Stock on Nasdaq. Passage Bio and Remix will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations.
                    The party not filing the Nasdaq listing application will cooperate with the other party as reasonably requested by such filing party with respect to the Nasdaq listing application and promptly furnish to such filing party all
                    information concerning itself and its stockholders that may be required or reasonably requested in connection with any action contemplated by the foregoing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Prior to the Effective Time, Passage Bio will provide Remix with reasonably prompt notice of any stockholder litigation against
                    Passage Bio or any of its directors relating to the Merger Agreement or the transactions contemplated by the Merger Agreement, including by providing copies of all pleadings with respect thereto, and will keep Remix reasonably informed
                    with respect to the status thereof. Prior to the closing of the Merger, Passage will, to the extent that the attorney-client privilege is not undermined or otherwise adversely affected, (a) provide Remix the opportunity to review and
                    propose comments with respect to all filings, pleadings and responses proposed to be filed or submitted by or on behalf of Passage prior to such filing or submission, and Passage shall consider such comments in good faith, (b) give
                    Remix a reasonable opportunity to review in advance all materials proposed to be delivered by or on behalf of Passage in connection with any discovery or document production with respect to such stockholder litigation, (c) give Remix
                    the right to participate in the defense, settlement or prosecution of any such stockholder litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected) and (d)&#160;reasonably consult with
                    Remix with respect to the defense, settlement and prosecution of any stockholder litigation. Passage may not compromise or settle, or come to an arrangement regarding, or agree to compromise, settle or come to an arrangement regarding,
                    any stockholder litigation unless Remix has consented thereto in writing (which consent will not be unreasonably withheld, conditioned or delayed). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">153<br/>
        </div>

      </div>

    </div>

    <!--End Page 163-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 164-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each party intends that for United States federal income tax purposes, the Merger will qualify for the Intended Tax Treatment.
                    Each party will for all tax purposes report consistently with the foregoing, and no party will take any position on any tax return that is inconsistent with the foregoing, unless otherwise required by a governmental authority as a
                    result of a &#8220;determination&#8221; within the meaning of Section&#160;1313(a) of the Code. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"><a id="tTMACC"><!--Anchor--></a>Conditions to the Completion
            of the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each party&#8217;s obligation to effect the Merger and otherwise consummate the
            Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the Closing, of each of the following conditions: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">No temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the
                    Contemplated Transactions shall have been issued by any court of competent jurisdiction or other governmental authority of competent jurisdiction and remain in effect and there shall not be any law which has the effect of making the
                    consummation of the Contemplated Transactions illegal. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Required Passage Bio Stockholder Vote and the Required Remix Stockholder Vote shall have been obtained. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The approval of the listing of the additional shares of Passage Bio Common Stock on Nasdaq shall have been obtained and the
                    shares of Passage Bio Common Stock to be issued in the Merger pursuant to the Merger Agreement shall have been approved for listing (subject to official notice of issuance) on Nasdaq and the Proposed Restated Charter shall have been
                    duly filed with the Secretary of State of the State of Delaware. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Remix Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Subscription Agreement and the Remix Note&#160;Purchase Agreement (2026) shall each be in full force and effect and cash proceeds
                    of not less than the Concurrent Investment Amount shall have been received by Remix, or will be received by Remix prior to or substantially simultaneously with the Closing, in connection with the Concurrent Financing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Passage Bio and Remix lock-up agreements will continue to be in full force and effect as of immediately following the
                    Effective Time. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be
                    subject to any stop order or proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix shall have effected the Remix Preferred Stock Conversion. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The obligations of Remix to effect the Merger and otherwise consummate the
            Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the Closing, of each of the following conditions: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The representations and warranties of each of Passage Bio with respect to due organization, subsidiaries, organizational
                    documents, authority, the binding nature of the Merger Agreement, required vote and no financial advisors shall have been true and correct in all respects as of the date of the Merger Agreement and shall be true and correct in all
                    material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such
                    representations and warranties shall be true and correct as of such date). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The representations and warranties of Passage Bio with respect to capitalization shall have been true and correct in all
                    respects as of the date of the Merger Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de
                    minimis, individually or in the aggregate or (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the
                    qualifications as set forth in the preceding clause (x), as of such particular date). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">154<br/>
        </div>

      </div>

    </div>

    <!--End Page 164-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 165-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The remaining representations and warranties of Passage Bio and Merger Sub in the Merger Agreement shall have been true and
                    correct in all respects as of the date of the Merger Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on such date except (i)&#160;in each case, or in the aggregate, where the
                    failure to be so true and correct would not reasonably be expected to have a Passage Bio Material Adverse Effect (without giving effect to any references therein to any Passage Bio Material Adverse Effect, or other materiality
                    qualifications) or (ii) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding
                    clause (i), as of such particular date). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio and Merger Sub shall have performed and complied in all material respects with all covenants and agreements required
                    to be performed or complied with by them under the Merger Agreement at or prior to the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A Passage Bio Material Adverse Effect shall not have occurred since the date of the Merger Agreement and be continuing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio shall have delivered to Remix a customary closing certificate signed by an executive officer of Passage Bio in
                    accordance with the terms and conditions of the Merger Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The existing shares of Passage Bio Common Stock will have been continually listed on Nasdaq as of and from the date of the
                    Merger Agreement through the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix will have received true and complete copies of all documentation for each Legacy Asset Disposition reasonably evidencing
                    that Passage Bio has received or will receive into one or more bank accounts the proceeds (or, in the case of any Legacy Asset Disposition which will be consummated substantially contemporaneously with the closing of the Merger, that
                    such proceeds are in irrevocable transit to Passage Bio) of all Legacy Asset Dispositions which are included in Passage Bio&#8217;s estimated Net Cash calculation. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The obligations of Passage Bio and Merger Sub to effect the Merger and otherwise
            consummate the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the Closing, of each of the following conditions: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The representations and warranties of Remix with respect to due organization, subsidiaries, organizational documents, authority,
                    the binding nature of the Merger Agreement, required vote and no financial advisors shall have been true and correct in all respects as of the date of the Merger Agreement and shall be true and correct in all material respects on and as
                    of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and
                    warranties shall be true and correct as of such date). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The representations and warranties of Remix with respect to capitalization shall have been true and correct in all respects as
                    of the date of the Merger Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis,
                    individually or in the aggregate or (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as
                    set forth in the preceding clause (x), as of such particular date). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The remaining representations and warranties of Remix in the Merger Agreement shall have been true and correct in all respects
                    as of the date of the Merger Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on such date except (i) in each case, or in the aggregate, where the failure to be so true and
                    correct would not reasonably be expected to have a Remix Material Adverse Effect (without giving effect to any references therein to any Remix Material Adverse Effect, or other materiality qualifications) or (ii) for those
                    representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause (i), as of such particular
                    date). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">155<br/>
        </div>

      </div>

    </div>

    <!--End Page 165-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 166-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix shall have performed and complied in all material respects with all covenants and agreements required to be performed or
                    complied with by it under the Merger Agreement at or prior to the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">A Remix Material Adverse Effect shall not have occurred since the date of the Merger Agreement and be continuing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix shall have delivered to Passage Bio a customary closing certificate signed by an executive officer of Remix in accordance
                    with the terms and conditions of the Merger Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"><a id="tTMATT"><!--Anchor--></a>Termination and Termination
            Fees </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Termination of the Merger Agreement</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement may be terminated, and the Merger and the transactions
            contemplated by the Merger Agreement may be abandoned, at any time before the Effective Time, whether before or after the required stockholder approvals to consummate the Merger have been obtained, as set forth below:</div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by mutual written consent of Passage Bio and Remix;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Passage Bio or Remix, if the Merger has not been consummated by December&#160;24, 2026 (subject to possible extension as
                    provided in the Merger Agreement); provided, however, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur
                    on or before December&#160;24, 2026 and such action or failure to act constitutes a breach of the Merger Agreement; and provided, further, that such date will be extended by 90&#160;days upon request of either party in the event that the SEC has
                    not declared effective the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, by the date which is 25 days prior to December&#160;24, 2026;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Passage Bio or Remix if a court of competent jurisdiction or other governmental authority has issued a final and
                    non-appealable order or has taken any other action that permanently restrains, enjoins or otherwise prohibits the Merger or any of the other transactions contemplated by the Merger Agreement;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Passage Bio, if the required Remix Stockholder Vote has not been obtained and evidence thereof delivered to Passage Bio
                    within fifteen days of the registration statement on Form&#160;S-4, of which this proxy statement/prospectus is a part, becoming effective; provided that this right to terminate the Merger Agreement will not be available to Passage Bio once
                    Remix obtains such stockholder consent;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by either Passage Bio or Remix, if the Passage Bio stockholder meeting has been held and completed and Passage Bio stockholders
                    have taken a final vote on the proposals set forth in the Merger Agreement to be considered at the Passage Bio stockholder meeting, and the Required Passage Bio Stockholder Vote has not been obtained; provided, however, that the right
                    to terminate the Merger Agreement under this clause (e) shall not be available to Passage where the failure to obtain the Required Passage Bio Stockholder Vote shall have been caused by the action or failure to act of Passage Bio and
                    such action or failure to act constitutes a material breach by Passage Bio of this Agreement;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Remix, at any time prior to the Required Passage Bio Stockholder Vote being obtained, if any of the following circumstances
                    shall occur:</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio fails to include in this proxy statement/prospectus the Passage Bio board of directors&#8217; recommendation that Passage
                    Bio stockholders vote to approve the Passage Bio Stockholder Matters;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio board of directors, or any committee thereof evaluating any Acquisition Proposal, makes a recommendation change
                    adverse to Remix or approves, endorses or recommends any Acquisition Proposal (other than with Remix);</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other
                    than a confidentiality agreement permitted pursuant to the terms and conditions of the Merger Agreement; or</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio board of directors or any committee thereof evaluating any Acquisition Proposal shall have failed to recommend
                    against any Acquisition Proposal that is a tender offer or exchange offer within 10 business days after the commencement thereof;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">156<br/>
        </div>

      </div>

    </div>

    <!--End Page 166-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 167-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Passage Bio, at any time prior to the Required Remix Stockholder Vote being obtained, if any of the following circumstances
                    shall occur:</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix fails to include in the Information Statement the Remix Board Recommendation</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix board of directors or any committee thereof evaluating any Acquisition Proposal has made a Remix Board Adverse
                    Recommendation Change or approves, endorses or recommends any Acquisition Proposal (other than with Passage Bio);</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a
                    confidentiality agreement permitted pursuant to the terms and conditions of the Merger Agreement; or</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix board of directors or any committee thereof evaluating any Acquisition Proposal fails to recommend against any
                    Acquisition Proposal that is a tender offer or exchange offer within 10&#160;business days after the commencement thereof;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Remix (at any time prior to the approval of the Remix Stockholder Matters by the Required Remix Stockholder Vote) in order to
                    substantially concurrently enter into an Alternative Acquisition Agreement with respect to a Superior Offer, so long as Remix has complied in all material respects with obligations under the Merger Agreement and concurrently with such
                    termination Remix pays the termination fee due to Passage in accordance with the Merger Agreement;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Passage (at any time prior to the approval of the Passage Stockholder Matters by the Required Passage Stockholder Vote) in
                    order to substantially concurrently enter into an Alternative Acquisition Agreement with respect to a Superior Offer, so long as Passage has complied in all material respects with obligations under the Merger Agreement and concurrently
                    with such termination Passage pays the termination fee due to Remix in accordance with the Merger Agreement;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Remix, if Passage Bio or Merger Sub has breached any of its representations, warranties, covenants or agreements contained in
                    the Merger Agreement or if any representation or warranty of Passage Bio or Merger Sub has become inaccurate, in either case, such that the conditions to the closing set forth in the Merger Agreement would not be satisfied as of the
                    time of such breach or inaccuracy; provided that Remix is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement; provided, further, that if such breach or inaccuracy is curable by
                    Passage Bio or Merger Sub at least one business day prior to the Outside Date, then the Merger Agreement will not terminate pursuant to this paragraph as a result of a particular breach or inaccuracy until the expiration of a 30-day
                    period commencing upon delivery of written notice, from Remix to Passage Bio or Merger Sub, of such breach or inaccuracy and Remix&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will
                    not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Passage Bio or Merger Sub is cured prior to such termination becoming effective); or</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by Passage Bio, if Remix has breached any of its representations, warranties, covenants or agreements contained in the Merger
                    Agreement or if any representation or warranty of Remix has become inaccurate, in either case, such that the conditions to the closing set forth in the Merger Agreement would not be satisfied as of the time of such breach or inaccuracy;
                    provided that Passage Bio is not then in material breach of any representation, warranty, covenant or agreement under the Merger Agreement; provided, further, that if such breach or inaccuracy is curable by Remix at least one business
                    day prior to the Outside Date, then the Merger Agreement will not terminate pursuant to this paragraph as a result of a particular breach or inaccuracy until the expiration of a 30-day period commencing upon delivery of written notice,
                    from Passage Bio to Remix, of such breach or inaccuracy and Passage Bio&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such
                    particular breach or inaccuracy if such breach by Remix is cured prior to such termination becoming effective).</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The party desiring to terminate the Merger Agreement will give the other party
            notice of such termination, specifying the provisions thereof pursuant to which such termination is made and the basis for termination described in reasonable detail.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">157<br/>
        </div>

      </div>

    </div>

    <!--End Page 167-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 168-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Termination Fees Payable by Passage Bio</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio must pay Remix a nonrefundable termination fee of $1.5 million within
            two business days after termination of the Merger Agreement (or, if applicable, upon entry into a definitive agreement and/or consummation of a Subsequent Transaction) if (i) the Merger Agreement is terminated by (A) Passage Bio or Remix
            pursuant to clause (e) above, (B) at any time after the date of the Merger Agreement and prior to the Passage Bio stockholder meeting an Acquisition Proposal with respect to Passage Bio will have been publicly announced, disclosed or otherwise
            communicated to the Passage Bio board of directors (and will not have been withdrawn), and (C) within 12 months after the date of such termination, Passage Bio enters into a definitive agreement with respect to a Subsequent Transaction or
            consummates a Subsequent Transaction, or (ii) the Merger Agreement is terminated by Remix pursuant to clause (f) or clause (j) above.</div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Termination Fees Payable by Remix</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix must pay Passage Bio a nonrefundable termination fee of $17.5&#160;million
            within two business days after termination of the Merger Agreement (or, if applicable, upon entry into a definitive agreement and/or consummation of a Subsequent Transaction) if (i) the Merger Agreement is terminated by (A) Passage Bio pursuant
            to clause (d) above, (B) at any time after the date of the Merger Agreement and prior to the termination of the Merger Agreement, an Acquisition Proposal with respect to Remix will have been publicly announced, disclosed or otherwise
            communicated to the Remix board of directors (and will not have been withdrawn), and (C) within 12 months after the date of such termination, Remix enters into a definitive agreement with respect to a Subsequent Transaction or consummates a
            Subsequent Transaction, or (ii) the Merger Agreement is terminated by Passage Bio pursuant to clause (g) or (h) above. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tAW"><!--Anchor--></a>Amendment and Waiver </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement may not be amended except by an instrument in writing signed
            on behalf of each of Remix, Merger Sub and Passage Bio. Such amendment requires the approval of the respective boards of directors of Remix, Merger Sub and Passage Bio at any time, except that after the Merger Agreement has been adopted and
            approved by the Remix stockholders or Passage Bio stockholders, no amendment which by law requires further approval of the Remix stockholders or Passage Bio stockholders, as the case may be, may be made without such further approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any provision of the Merger Agreement may be waived by any party solely on that
            party&#8217;s behalf, without the consent of any other party. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be applicable and have any effect in the specific
            instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right, privilege or remedy under the Merger Agreement will operate as a waiver of such power, right, privilege or remedy
            under the Merger Agreement. Furthermore, no single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tFE"><!--Anchor--></a>Fees and Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement provides that all fees and expenses incurred in connection
            with the Merger Agreement and the transactions contemplated thereby shall be paid by the party incurring such expenses, whether or not the Merger is consummated, except as described above in the section titled &#8220;<span style="font-style: italic;">The

              Merger Agreement&#8212;Termination and Termination Fees</span>,&#8221; and except that Passage Bio and Remix will pay the costs and expenses incurred in relation to the filings by the parties under any antitrust law applicable to the Merger Agreement and
            the transactions contemplated by the Merger Agreement, and Passage Bio and Remix will share equally in all fees and expenses incurred in relation to the printing and filing with the SEC of the registration statement on Form&#160;S-4 (including any
            financial statements and exhibits) and any amendments or supplements thereto. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">158<br/>
        </div>

      </div>

    </div>

    <!--End Page 168-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 169-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tARM"><!--Anchor--></a>AGREEMENTS RELATED TO THE MERGER </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"><a id="tARMSA"><!--Anchor--></a>Support Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In order to induce Passage Bio to enter into the Merger Agreement, certain Remix
            executive officers, directors and stockholders, including certain investors in the Concurrent Financing, are party to support agreements with Passage Bio pursuant to which, among other things, each such stockholder has agreed, solely in his,
            her or its capacity as a Remix stockholder, to vote all of his, her or its shares of Remix capital stock in favor of (i) the adoption of the Merger Agreement and approval of the Merger, (ii) the approval of the related transactions contemplated
            by the Merger Agreement, (iii) to the extent applicable, the conversion of each share of Remix preferred stock into shares of Remix common stock immediately prior to and contingent upon the closing and (iv) the approval of certain additional
            proposals in connection with the Merger that the Remix board of directors may recommend, including, if applicable, to approve any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the adoption of
            the Merger Agreement on the date on which a meeting of such stockholders is held. These Remix executive officers, directors and stockholders also agreed to vote against (i) any action or agreement that would result in a breach of any
            representation, warranty, covenant or obligation of Remix in the Merger Agreement, (ii) any competing Acquisition Proposal with respect to Remix and (iii) any agreement, transaction or other matter that is intended to, or would reasonably be
            expected to, impede, interfere with, delay, postpone, discourage or materially and adversely affect the Merger or any of the other transactions contemplated by the Merger Agreement, subject to certain specified exceptions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These Remix executive officers, directors and stockholders have also granted
            Remix an irrevocable proxy to vote their respective shares of Remix common stock or Remix preferred stock in accordance with the support agreements if a stockholder fails to timely vote its shares on the matters covered by the support
            agreements. The Remix stockholders may vote their shares of Remix common stock or Remix preferred stock on all other matters not referred to in such proxy.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of June&#160;24, 2026, the Remix stockholders that are party to support agreements
            with Passage Bio owned an aggregate of approximately 93% of the outstanding shares of Remix common stock and Remix preferred stock. These stockholders include executive officers and directors of Remix, as well as certain other stockholders
            owning a significant portion of the outstanding shares of Remix capital stock. Following the effectiveness of the registration statement on Form&#160;S-4 of which this proxy statement/prospectus is a part and pursuant to the Merger Agreement, Remix
            stockholders holding a sufficient number of shares of Remix capital stock to adopt the Merger Agreement and approve the Merger and related transactions will execute written consents providing for such adoption and approval. Therefore, holders
            of a sufficient number of shares of Remix capital stock required to adopt the Merger Agreement and approve the Merger and related transactions that are contractually obligated to adopt the Merger Agreement are expected to adopt the Merger
            Agreement via written consent.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under these support agreements, subject to certain exceptions, such stockholders
            have also agreed not to sell or transfer their shares of Remix capital stock and securities convertible into shares of Remix capital stock held by them, or any voting rights with respect thereto, until the earlier to occur of (a) the Effective
            Time, (b) such date and time as the Merger Agreement shall be terminated pursuant to Article&#160;VIII thereof or otherwise, (c) any amendment to the Merger Agreement that is effected without the supporting stockholder&#8217;s written consent that
            decreases the amount, or changes the form, of consideration payable to all stockholders of Remix pursuant to the terms of the Merger Agreement or (d)&#160;the mutual written agreement of the parties to terminate the Remix Support Agreement. To the
            extent that any such sale or transfer is permitted pursuant to the exceptions included in the support agreement, each person to which any shares of Remix capital stock or securities convertible into shares of Remix capital stock are so sold or
            transferred must agree in writing to be bound by the terms and provisions of the support agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, in order to induce Remix to enter into the Merger Agreement, certain
            Passage Bio stockholders have entered into support agreements with Remix pursuant to which, among other things, each such stockholder has agreed, solely in his, her or its capacity as a Passage Bio stockholder, to vote all of his, her or its
            shares of Passage Bio Common Stock in favor of (i) the approval of the Merger Agreement, (ii) the transactions contemplated thereby, including the issuance of Passage Bio Common Stock to Remix stockholders, (iii) an amendment to the restated
            certificate of incorporation of Passage Bio to effect the proposed Reverse Stock Split, (iv) any proposal to adjourn or postpone the meeting to a later date, if there are not sufficient votes for the approval of the Merger Agreement and the
            transactions contemplated therein and (v) the approval of certain additional proposals in connection with the Merger that the Passage Bio board of directors may recommend. These Passage Bio stockholders also agreed to vote against (i) any
            action or agreement that would result in a breach of any representation, warranty, covenant or </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">159<br/>
        </div>

      </div>

    </div>

    <!--End Page 169-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 170-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">obligation of Passage Bio in the Merger Agreement, (ii) any competing
            Acquisition Proposal with respect to Passage Bio and (iii) any action, proposal, agreement, transaction or proposed transaction that would reasonably be expected to materially impede, interfere with, delay, postpone, discourage or adversely
            affect the Merger or any of the other transactions contemplated by the Merger Agreement, subject to certain specified exceptions.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These Passage Bio Stockholders have also granted Passage Bio an irrevocable proxy
            to vote their respective shares of Passage Bio Common Stock in accordance with the support agreements. Passage Bio stockholders may vote their shares of Passage Bio Common Stock on all other matters not referred to in such proxy.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of June&#160;24, 2026, the Passage Bio stockholders that are party to a support
            agreement owned approximately 1% of the outstanding shares of Passage Bio Common Stock. These stockholders include certain executive officers and directors of Passage Bio.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under these support agreements, subject to certain exceptions, such stockholders
            have also agreed not to sell or transfer their shares of Passage Bio Common Stock and securities convertible into shares of Passage Bio Common Stock held by them until the earlier to occur of (a) the Effective Time, (b) such date and time as
            the Merger Agreement shall be terminated pursuant to Article&#160;VIII thereof or otherwise, (c) any amendment to the Merger Agreement that is effected without the supporting stockholder&#8217;s written consent that increases the amount, or changes the
            form, of consideration payable to all stockholders of Remix pursuant to the terms of the Merger Agreement or (d) the mutual written agreement of the parties to terminate the Passage Support Agreement. To the extent that any such sale or
            transfer is permitted pursuant to the exceptions included in the support agreements, each person to which any shares of Passage Bio Common Stock or securities convertible into shares of Passage Bio Common Stock are so sold or transferred must
            agree in writing to be bound by the terms and provisions of the support agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The foregoing description of the support agreements does not purport to be
            complete and is qualified in its entirety by the full text of the forms of support agreements, which are attached hereto as Annex&#160;C and Annex&#160;D. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"><a id="tARMLA"><!--Anchor--></a>Lock-Up Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain of Remix&#8217;s executive officers, directors and stockholders have entered
            into lock-up agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
            option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Passage Bio&#8217;s common stock, including, as applicable, shares received in the Merger and shares issuable upon exercise of
            options, warrants or convertible securities, until 180 days after the Closing Date.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Remix stockholders who have executed lock-up agreements as of June&#160;24, 2026,
            owned in the aggregate, approximately 99% of the outstanding shares of Remix common stock and Remix preferred stock.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain of Passage Bio&#8217;s officers have entered into lock-up agreements, pursuant
            to which such stockholders have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
            purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Passage Bio Common Stock, until 180 days after the Closing Date.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio stockholders who have executed lock-up agreements as of June&#160;24, 2026
            owned, in the aggregate, 0.34%&#160;of the shares of outstanding Passage Bio Common Stock.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The foregoing description of the lock-up agreements does not purport to be
            complete and is qualified in its entirety by the full text of the form of lock-up agreements, which are attached as Annexes E and F hereto. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"><a id="tARM1"><!--Anchor--></a>The Concurrent Financing</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June 24, 2026, concurrently with the execution and delivery of the Merger
            Agreement, Remix entered into (i) a subscription agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Subscription Agreement</span>&#8221;) for the sale of shares of Remix common stock for an aggregate purchase price of approximately
            $70.0 million and (ii) a convertible promissory note purchase agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Remix Note Purchase Agreement (2026)</span>&#8221;) for the sale of approximately $30.0 million aggregate principal
            amount of convertible notes (the &#8220;<span style="font-style: italic; font-weight: bold;">2026 Notes</span>&#8221;) that will convert into shares of Remix common stock based on the same aggregate equity value of Remix being used in the Merger. The sale
            of shares of Remix common stock pursuant to the Subscription Agreement and the issuance of the 2026 Notes pursuant to the Remix Note Purchase </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">160<br/>
        </div>

      </div>

    </div>

    <!--End Page 170-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 171-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Agreement (2026) are expected to result in aggregate gross proceeds to Remix
            of approximately $100 million (the &#8220;<span style="font-style: italic; font-weight: bold;">Concurrent Financing</span>&#8221;). The issuance of Remix common stock pursuant to the Subscription Agreement and the conversion of the 2026 Notes into shares
            of Remix common stock are contingent on, and will occur immediately prior to, the Effective Time of the Merger. Shares of Remix common stock issued in the Concurrent Financing will be converted into shares of Passage Bio common stock at the
            Effective Time in accordance with the terms of the Merger Agreement. The Company received $30.0 million in proceeds from the 2026 Notes in June 2026.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The foregoing description of the Subscription Agreement and the Remix Note
            Purchase Agreement (2026) does not purport to be complete and is qualified in its entirety by the full text of the Subscription Agreement and the Remix Note Purchase Agreement (2026), the former which is attached hereto as Annexes G.</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;"><a id="tARMSAR"><!--Anchor--></a>Registration Rights
            Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the closing of the Concurrent Financing, Remix, Passage Bio and the investors
            participating in the Concurrent Financing will enter into a registration rights agreement (the <span style="font-style: italic; font-weight: bold;">&#8220;Registration Rights Agreement&#8221;</span>). Pursuant to the Registration Rights Agreement, the
            combined company will agree to prepare and file with the SEC a registration statement to register for resale the shares of Passage Bio Common Stock issued to such investors in connection with the Concurrent Financing within 30 calendar days
            following the Effective Time, and, to use commercially reasonable efforts to cause such registration statement to be declared effective no later than the 90th calendar day following the Effective Time (or, in the event of a full review by the
            SEC, a later date specified in the Registration Rights Agreement), and to keep such registration statement continuously effective until the earlier of (a) the date that all registrable securities covered by such registration statement (i) have
            been sold, thereunder or pursuant to rule&#160;144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the combined company to be in compliance with the current public information
            requirement under Rule 144 and (b) three years after the date of the Registration Rights Agreement. The Registration Rights Agreement also contains customary provisions relating to, among other things, indemnification and the payment of
            registration expenses by the combined company.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The foregoing description of the Registration Rights Agreement does not purport
            to be complete and is qualified in its entirety by the full text of the form of Registration Rights Agreement, which is attached hereto as Annex&#160;H. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;"><a id="tARMCVR"><!--Anchor--></a>Contingent Value Rights
            Agreement </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">CVR Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As provided in the Merger Agreement and discussed under the section titled &#8220;<span style="font-style: italic;">The Merger Agreement -Contingent Value Rights</span>&#8221; in this proxy statement/prospectus, Passage Bio will declare a distribution of contingent value rights (each, a &#8220;<span style="font-style: italic; font-weight: bold;">CVR</span>&#8221;) to its common stockholders of record (determined as of the close of business on the last business day prior to the day on which the Effective Time occurs). Each such holder will be entitled to receive one CVR for each
            outstanding share of Passage Bio Common Stock held by such stockholder as of such date, each representing the non-transferable contractual right to receive certain contingent payments from Passage Bio upon the occurrence of certain events.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The CVRs will be governed by the terms of the CVR Agreement, which will be
            entered into at or prior to the Effective Time by Passage Bio and Computershare Trust Company, N.A. (or such other nationally recognized rights agent agreed to between Passage Bio and Remix), as the Rights Agent. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Characteristics of the CVRs; Restrictions on
            Transfer </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The CVRs may not be transferred, pledged, hypothecated, encumbered, assigned or
            otherwise disposed of (whether by sale, merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise), in whole or in part, other than pursuant to any of the following permitted transfers: (i) upon death, by will or
            intestacy; (ii) by instrument to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (iii)&#160;pursuant to a court order of a court of competent jurisdiction (such as in connection
            with divorce, bankruptcy or liquidation); (iv) by operation of law (including a consolidation or merger) or without consideration in connection with the dissolution, liquidation or termination of any corporation, limited liability company,
            partnership or other entity; (v)&#160;in the case of CVRs payable to a nominee, from a nominee to a beneficial owner (and, if applicable, through an intermediary) or from such nominee to another nominee for the same beneficial owner, in each case as
            permitted by The Depository Trust Company; (vi) to Passage Bio or its subsidiaries; or (vii) upon abandonment of a CVR by the holder thereof in accordance with the CVR Agreement.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">161<br/>
        </div>

      </div>

    </div>

    <!--End Page 171-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 172-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The CVRs will not be evidenced by a certificate or any other instrument. The
            CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of the CVRs. The CVRs will not represent any equity or ownership interest in Passage Bio or any of its subsidiaries, including the
            Surviving Corporation. The Rights Agent will maintain an up-to-date register (the <span style="font-style: italic; font-weight: bold;">&#8220;CVR Register&#8221;</span>) for the purposes of (i)&#160;identifying the holders of CVRs, (ii) determining holders&#8217;
            entitlement to CVRs, and (iii) registering the CVRs and permitted transfers thereof. Passage Bio&#8217;s obligation to make the CVR payment, if any becomes due, is neither secured nor guaranteed by Passage Bio or any of its subsidiaries. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">CVR Payments </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the CVR Agreement, each CVR holder is entitled to certain contingent
            cash payments, which are payable by Passage Bio to the Rights Agent for subsequent distribution to the CVR holders (such payments, the CVR Payments), of the CVR Proceeds, which will equal the net amount (calculated in accordance with GAAP
            consistently applied) of: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">eighty percent (80%) of the cash proceeds received by Passage Bio or its subsidiaries from Gemma Biotherapeutics, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">Gemma</span>&#8221;) for the portion of the one-time, non-refundable, non-creditable product purchase fee contemplated by Section&#160;5.1 of the Exclusive License Agreement (GM1), dated as of
                    July&#160;31, 2024, as amended on May&#160;7, 2025 (the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Sublicense (GM1)</span>&#8221;), between Passage Bio and Gemma which has not already been paid to Passage on or prior to the date of the
                    CVR Agreement and prior to July&#160;31, 2028 (the <span style="font-style: italic; font-weight: bold;">&#8220;GM1 CVR Period&#8221;</span> and collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">GM1 Payments</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">one hundred percent (100%) of the cash proceeds received by Passage Bio or its subsidiaries from Gemma for the one-time,
                    non-refundable, non-creditable upfront fees contemplated by the Exclusive License Agreement (MLD), dated as of July&#160;31, 2024, as amended on May&#160;7, 2025 (the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Sublicense (MLD)</span>&#8221;
                    and, together with the Gemma Sublicense (GM1), the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Sublicenses</span>&#8221;), between Passage Bio and Gemma which has not already been paid to Passage on or prior to the date of the
                    CVR Agreement and prior to December&#160;31, 2027 (the &#8220;<span style="font-style: italic; font-weight: bold;">MLD CVR Period</span>&#8221; and collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">MLD Payments</span>&#8221; and,
                    together with the GM1 Payments, the &#8220;<span style="font-style: italic; font-weight: bold;">Legacy Asset Payments</span>&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">less </span>all applicable permitted deductions (collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">Permitted Deductions</span>&#8221;), which include, without duplication: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">any applicable and non-recoverable value added, sales or similar taxes imposed upon the Legacy
                      Asset Payments and payable in cash by Passage Bio or any of its subsidiaries and any income or other similar taxes required to be paid by Passage Bio or any of its subsidiaries as a result of the receipt of the Legacy Asset Payments;
                    </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">any reasonable, documented out-of-pocket costs and expenses incurred by Passage Bio or its
                      subsidiaries in respect of its performance of the CVR Agreement, or in respect of its performance of the Gemma Sublicenses (to the extent related to the Legacy Asset Payments, and including the documented out-of-pocket costs and
                      expenses paid or payable by Passage Bio or any of its subsidiaries to Catalent Pharma Solutions, LLC for the storage and maintenance of MLD product supply materials) or any other agreement to which Passage Bio or any of its
                      subsidiaries is a party that is in effect as of the date of the CVR Agreement and related to the Legacy Asset Payments; and </span></div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 6pt;">&#9675;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; text-align: left; font-size: 10pt;"><span style="font-size: 10pt;">any reasonable, documented out-of-pocket costs and expenses incurred or accrued by Passage Bio or
                      its subsidiaries in respect of the collection or receipt of any Legacy Asset Payment. </span></div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Withholding </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The CVR Agreement provides that the combined company and the Rights Agent will be
            entitled to deduct and withhold, or cause to be deducted and withheld, from any payment payable to CVR holders pursuant to the CVR Agreement, such amounts as they are required to deduct and withhold with respect to the making of such payment
            under any provision of applicable law relating to taxes. To the extent that amounts are so deducted and withheld and paid over to the appropriate governmental authority, such deducted and withheld amounts will be treated for all purposes of the
            CVR Agreement as having been paid to the CVR holder in respect of which such deduction and withholding was made. Prior to making any such tax deductions or withholdings or causing any such tax deductions or withholdings to be made with respect
            to any CVR holder, the Rights Agent will, to the extent reasonably practicable, provide notice to the CVR holder of such potential tax deduction or withholding and a reasonable </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">162<br/>
        </div>

      </div>

    </div>

    <!--End Page 172-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 173-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg27"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">opportunity for the CVR holder to provide any necessary tax forms in order to
            avoid or reduce such withholding amounts. However, the time period for the payment of amounts payable to such CVR holder in accordance with the CVR Agreement will be extended by a period equal to any delay caused by the CVR holder in providing
            such forms, and in no event will such period be extended for more than ten business days (unless otherwise requested by the CVR holder for the purpose of delivering such forms and agreed to by the Rights Agent). </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Payment Procedures </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As promptly as practicable after CVR Proceeds are actually received, but no later
            than 20 days following Passage Bio&#8217;s or its subsidiaries&#8217; receipt of any Legacy Asset Payment, Passage Bio will (i) deliver to the Rights Agent an officer&#8217;s certificate certifying the aggregate amount of (a) the CVR Proceeds received by Passage
            Bio or its subsidiaries in respect of such Legacy Asset Payment (or, in the case of the first delivery of such certificate, all CVR Proceeds received through the date of such certificate), (b) the Permitted Deductions reflected in such CVR
            Proceeds and (c) the CVR payment payable to the CVR holders, if any, and (d) deliver to the Rights Agent, or as the Rights Agent directs, the CVR payments (if any) by wire transfer of immediately transferable funds to an account designated by
            the Rights Agent. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly (and in any event, within ten business days) pay, by check mailed, first-class postage prepaid, to the address of each
            CVR holder set&#160;forth in the CVR Register at such time or by other method of delivery as specified by the applicable holder in writing to the Rights Agent, an amount equal to the product determined by multiplying (i) the quotient determined by
            dividing (A) the applicable CVR Payment by (B) the total number of CVRs registered in the CVR Register at such time, by (ii)&#160;the number of CVRs registered to such holder in the CVR Register at such time. For the avoidance of doubt Passage Bio
            shall have no further liability in respect of the relevant CVR Payment upon delivery of such CVR Payment to the Rights Agent and the satisfaction of each of Passage Bio&#8217;s obligations set forth hereunder. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Amendment and Termination of the CVR
            Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio may, at any time and from time to time, unilaterally enter into one
            or more amendments to the CVR Agreement for any of the following purposes, without the consent of any of the holders of CVRs or the Rights Agent: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to evidence the appointment of another person as a successor Rights Agent and the assumption by any successor Rights Agent of
                    the covenants and obligations of the Rights Agent pursuant to the CVR Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to evidence the succession of another person to Passage Bio and the assumption of any such successor of the covenants of Passage
                    Bio pursuant to the CVR Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to add to the covenants of Passage Bio further covenants, restrictions, conditions or provisions for the protection and benefit
                    of the holders of CVRs, provided that in each case, such provisions shall not adversely affect the rights of the holders of CVRs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to cure any ambiguity, to correct or supplement any provision in the CVR Agreement that may be defective or inconsistent with
                    any other provision in the CVR Agreement, or to make any other provisions with respect to matters or questions arising under the CVR Agreement, provided that in each case, such provisions shall not adversely affect the rights of the
                    holders of CVRs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as may be necessary or appropriate to ensure that CVRs are not subject to registration under the Securities Act or the Exchange
                    Act and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as may be necessary or appropriate to ensure that Passage Bio is not required to produce a prospectus or an admission document
                    in order to comply with applicable law; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to cancel CVRs (i) in the event that any holder of CVRs has abandoned its rights to such CVRs or (ii)&#160;following a transfer of
                    such CVRs to Passage Bio or its subsidiaries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as may be necessary or appropriate to ensure that Passage Bio complies with applicable law; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to effect any other amendment to the CVR Agreement that would provide any additional rights or benefits to the holders of CVRs
                    or that does not adversely affect the legal rights under the CVR Agreement of any such holder of CVRs. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">With the consent of the Acting Holders, meaning the registered holders of more
            than 35% of the outstanding CVRs, Passage Bio and the Rights Agent may enter into any amendment to the CVR Agreement, even if such amendment is adverse to the interests of the holders of the CVRs.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">163<br/>
        </div>

      </div>

    </div>

    <!--End Page 173-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 174-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg28"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Passage Bio will (or will cause the Rights Agent to) provide notice in general
            terms of the substance of any amendment to the CVR Agreement to the holders of the CVRs promptly after execution by Passage Bio and the Rights Agent, if applicable, of such amendment.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The CVR Agreement will terminate automatically, and the parties will have no
            liability thereunder, with respect to each Legacy Asset Payment upon the earlier of the payment of the CVR Payment (if any) in respect of such Legacy Asset Payment and the expiration of the applicable CVR Period, and will terminate in its
            entirety following the expiration of both the MLD CVR Period (which ends on December&#160;31, 2027) and the GM1 CVR Period (which ends on July&#160;31, 2028), after which the CVRs will expire without any consideration or compensation therefor. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other Provisions of the CVR Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The CVR Agreement also provides, among other things, for: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the duties, responsibilities, rights and immunities of the Rights Agent, and procedures for the resignation or removal of the
                    Rights Agent and appointment of a successor; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a prohibition on Passage Bio granting any lien, security interest, pledge or similar interest in any CVR Proceeds, and
                    restrictions on Passage Bio&#8217;s ability to amend, waive, terminate or assign the Gemma Sublicenses or the Penn License Agreement in a manner materially adverse to the rights of holders of CVRs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the application of laws of the State of Delaware, exclusive jurisdiction over the parties by the Chancery Court of the State of
                    Delaware, County of New Castle, or, if under applicable law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof), and waiver of trial by
                    jury. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The foregoing description of the CVR Agreement does not purport to be complete
            and is qualified in its entirety by the full text of the form of CVR Agreement, which is attached hereto as Annex&#160;F. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax
            Consequences of the CVRs to Holders of Passage Bio Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following discussion is a summary of the material U.S. federal income tax
            consequences of the issuance of the CVRs and payments (if any) thereon to holders of Passage Bio Common Stock, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as
            estate and gift tax laws, and any applicable state, local, or non-U.S. tax laws are not discussed. Furthermore, the following discussion does not address any tax consequences of transactions effectuated before, after or at the same time as the
            issuance of the CVRs (except, to the limited extent discussed below, the Reverse Stock Split), whether or not they are in connection with the issuance of the CVRs. The CVRs generally may not be transferred or assigned except for certain
            permitted transfers; accordingly, this discussion assumes the CVRs are not transferable or assignable and does not address any consequences of transferring, assigning or otherwise disposing of the CVRs or any interest therein.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This discussion is based on the Code, Treasury Regulations promulgated
            thereunder, judicial decisions, and published rulings and administrative pronouncements of the IRS, in each case, as in effect as of the date hereof.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These authorities may change or be subject to differing interpretations. Any such
            change or differing interpretation may be applied retroactively in a manner that could adversely affect a holder of Passage Bio Common Stock. Passage Bio has not sought and will not seek an opinion of counsel or any rulings from the IRS
            regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to that discussed below regarding the tax consequences of the issuance of the CVRs and payments (if any) thereon.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This discussion is limited to holders of Passage Bio Common Stock who hold their
            Passage Bio Common Stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to the particular
            circumstances of a holder of Passage Bio Common Stock, including the impact of the Medicare contribution tax on net investment income and any alternative minimum tax. In addition, it does not address consequences relevant to holders of Passage
            Bio Common Stock that are subject to particular rules, including, without limitation: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">U.S. expatriates or former citizens or long-term residents of the United States; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons holding Passage Bio Common Stock as part of a hedge, straddle, or other risk-reduction strategy or as part of a
                    conversion transaction or other integrated investment; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">164<br/>
        </div>

      </div>

    </div>

    <!--End Page 174-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 175-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg29"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">banks, insurance companies, and other financial institutions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate investment trusts or regulated investment companies; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers, or traders in securities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">S corporations, partnerships, or other entities or arrangements treated as pass-through entities for U.S. federal income tax
                    purposes (and investors therein); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">tax-exempt organizations, qualified retirement plans, individual retirement accounts or other tax deferred accounts, or
                    governmental organizations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons deemed to sell Passage Bio Common Stock under the constructive sale provisions of the Code; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold shares of Passage Bio Common Stock that may constitute &#8220;qualified small business stock&#8221; under Section&#160;12023 of
                    the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their shares of Passage Bio Common Stock in a transaction subject to the gain rollover provisions of
                    Section&#160;1045 of the Code; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold or receive Passage Bio Common Stock pursuant to the exercise of any employee stock options or otherwise as
                    compensation; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">controlled foreign corporations, passive foreign investment companies, and corporations that accumulate earnings to avoid U.S.
                    federal income tax; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">&#8220;qualified foreign pension funds&#8221; as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are
                    held by one or more qualified foreign pension funds; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons subject to special tax accounting rules as a result of any item of gross income with respect to the Passage Bio Common
                    Stock or the CVRs being taken into account in an applicable financial statement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a partnership, or an entity treated as a partnership for U.S. federal income
            tax purposes, holds Passage Bio Common Stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly,
            partnerships holding Passage Bio Common Stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">THIS DISCUSSION IS NOT TAX ADVICE. HOLDERS OF PASSAGE BIO
            COMMON STOCK SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE ISSUANCE OF THE CVRS, AND PAYMENTS (IF ANY) THEREON,
            ARISING UNDER OTHER U.S. FEDERAL TAX LAWS (INCLUDING ESTATE AND GIFT TAX LAWS), UNDER THE LAWS OF ANY STATE, LOCAL, OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY.<span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax
            Consequences for U.S. Holders </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For purposes of this discussion, a &#8220;U.S. Holder&#8221; is any beneficial owner of
            Passage Bio Common Stock that, for U.S.&#160;federal income tax purposes, is or is treated as: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an individual who is a citizen or resident of the United States; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a corporation created or organized in or under the laws of the United States, any state thereof, or the District of Columbia; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a trust that (1) is subject to the primary supervision of a U.S. court and all substantial decisions of which are subject to the
                    control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code), or (2) has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">165<br/>
        </div>

      </div>

    </div>

    <!--End Page 175-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 176-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg30"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Tax Treatment of the CVRs and the Proposed
            Reverse Stock Split </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Although the matter is not free from doubt, Passage Bio intends to treat the
            issuance of the CVRs (together with any payments on the CVRs) and the proposed Reverse Stock Split as separate transactions for U.S. federal income tax purposes, and the following discussion (except as discussed below under &#8220;-<span style="font-style: italic;">Alternative Treatment of the CVRs and the Reverse Stock Split as a Single Recapitalization</span>&#8221;) assumes this treatment will be respected. The IRS could successfully challenge this position, however. Passage Bio
            urges you to consult your tax advisor with respect to whether the issuance of the CVRs (and any payments on the CVRs), on the one hand, and the proposed Reverse Stock Split, on the other, constitute separate transactions. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Tax Treatment of the CVRs </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There is no authority that directly addresses whether contingent value rights
            with characteristics similar to the CVRs should be treated for federal income tax purposes as a distribution of property with respect to Passage Bio stock, an &#8220;open transaction,&#8221; or in some other manner, and such questions are inherently
            factual in nature. Accordingly, holders are urged to consult with their tax advisors regarding this issue.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">However, based on the specific characteristics of the CVRs, and unless otherwise
            required by a change in law after the date of the CVR Agreement, Passage Bio intends to take the position that the fair market value of the CVRs cannot be reasonably ascertained on the date of the issuance of the CVRs (the <span style="font-style: italic; font-weight: bold;">&#8220;CVR Distribution Date&#8221;</span>), and, accordingly, the issuance of the CVRs constitutes an &#8220;open transaction.&#8221; Accordingly, absent a change in law requiring otherwise, the combined company will
            not report the issuance of the CVRs as a current distribution of property with respect to its stock and will instead report each future cash payment (if any) on the CVRs as a distribution by the combined company for U.S. federal income tax
            purposes, with each such payment being reported as a dividend to the extent of the combined company&#8217;s current and accumulated earnings and profits in the year in which such payment is made.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Passage Bio&#8217;s intended reporting position is correct, a U.S. Holder would
            generally not recognize income in respect of the CVRs on the CVR Distribution Date and would take no tax basis in the CVRs. Any future cash payments would constitute a dividend to the extent of Passage Bio&#8217;s current and accumulated earnings and
            profits (as determined for U.S.&#160;federal income tax purposes) in the taxable year of such payment, then as a non-taxable return of capital to the extent of such holder&#8217;s basis in its Passage Bio Common Stock, and finally as capital gain from the
            sale or exchange of Passage Bio Common Stock. Dividends received by individual U.S. Holders are generally eligible for reduced rates of taxation applicable to long-term capital gains, provided certain requirements are met.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">However, the IRS could instead assert that the issuance of the CVRs should be
            treated as a &#8220;closed transaction.&#8221; Under &#8220;closed transaction&#8221; treatment, a U.S. Holder would be treated as receiving a distribution equal to the fair market value (determined on the CVR Distribution Date) of the CVRs issued to such U.S. Holder
            on the CVR Distribution Date. The amount of this distribution generally would be treated first as a taxable dividend to the extent of the U.S. Holder&#8217;s pro rata share of Passage Bio&#8217;s current or accumulated earnings and profits (as determined
            for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the U.S. Holder&#8217;s basis in its Passage Bio Common Stock, and finally as capital gain from the sale or exchange of Passage Bio Common Stock. A U.S.
            Holder&#8217;s tax basis in the CVRs received would equal the fair market value of the CVRs on the CVR Distribution Date and the holding period of the CVRs received would begin on the day following the CVR Distribution Date. Although not free from
            doubt, a future cash payment under a CVR would likely be treated as a non-taxable return of a U.S. Holder&#8217;s adjusted tax basis in the CVR to the extent thereof, although the timing of the recovery of a U.S. Holder&#8217;s tax basis is unclear. A
            payment in excess of such amount may be treated as a payment with respect to a sale of a capital asset, ordinary income or a dividend. Additionally, it is possible that a portion of future cash payments would constitute imputed interest and
            taxed as such. A U.S. Holder might recognize loss, which might be a capital loss and could be a long-term capital loss, upon the expiration of the CVR to the extent cash payments ultimately received pursuant to such CVR were less than the U.S.
            Holder&#8217;s adjusted tax basis in the CVRs, but whether and when such a loss would be recognized is unclear. The deductibility of capital losses is subject to limitations.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">It is possible, although Passage Bio believes unlikely, that the issuance of the
            CVRs could be treated as one or more &#8220;debt instruments&#8221; or as a distribution of equity.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">U.S. Holders are urged to consult their tax advisors with respect to the proper
            characterization of the CVRs and the tax consequences thereof (including any future cash payments made under the CVRs). </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">166<br/>
        </div>

      </div>

    </div>

    <!--End Page 176-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 177-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg31"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Alternative Treatment of the CVRs and the
            Proposed Reverse Stock Split as a Single Recapitalization </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Notwithstanding Passage Bio&#8217;s position that the CVRs and the proposed Reverse
            Stock Split are appropriately treated as separate transactions, it is possible that the IRS or a court could determine that the issuance of the CVRs (and/or any payments thereon) and the proposed Reverse Stock Split constitute a single
            &#8220;recapitalization&#8221; for U.S. federal income tax purposes with the CVRs constituting taxable &#8220;boot&#8221; received in such recapitalization exchange. In such case, the tax consequences of the CVRs and the proposed Reverse Stock Split would differ from
            those described above, including the timing and character of income, which would depend in part on many of the same considerations described above.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">DUE TO THE SUBSTANTIAL UNCERTAINTY REGARDING THE TAX TREATMENT
            OF THE CVRS (AND ANY FUTURE CASH PAYMENTS UNDER THE CVRS) AND THE POSSIBLE INTEGRATION OF THE CVRS AND THE PROPOSED REVERSE STOCK SPLIT, U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS CONCERNING THE RECOGNITION OF GAIN, INCOME AND/OR LOSS
            IN CONNECTION WITH THE CVRS AND THE PROPOSED REVERSE STOCK SPLIT AND THE APPLICABILITY OF INFORMATION REPORTING AND BACKUP WITHHOLDING.<span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax
            Consequences for Non-U.S. Holders </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The discussion below applies to beneficial owners of Passage Bio Common Stock
            that are not U.S. Holders or entities treated as partnerships or other pass-through entities for U.S. federal income tax purposes (such beneficial owners, Non-U.S. Holders).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As discussed above under &#8220;<span style="font-style: italic;">Material U.S. Federal
              Income Tax Consequences for U.S. Holders&#8212;Tax Treatment of the CVRs and the Proposed Reverse Stock Split</span>&#8221; and &#8220;<span style="font-style: italic;">Material U.S. Federal Income Tax Consequences for U.S.&#160;Holders&#8212;Tax Treatment of the CVRs</span>,&#8221;

            Passage Bio intends to take the position that any future cash payments on the CVRs are distributions with respect to Passage Bio Common Stock and that such distributions constitute dividends to the extent payable out of the combined company&#8217;s
            current and accumulated earnings and profits (as determined under U.S. federal income tax principles) in the taxable year of such future cash payment. Assuming such position is correct, it is expected that Non-U.S. Holders would generally be
            subject to U.S. federal withholding tax at a rate of 30% on any future cash payments on the CVRs that constitute dividends. Such withholding may be reduced if the Non-U.S. Holder properly certifies qualification for a lower withholding rate
            under an applicable tax treaty or an exemption from withholding as a result of dividends on the Passage Bio Common Stock being effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if
            required by an applicable tax treaty, the Non-U.S. Holder maintains a permanent establishment in the United States to which such dividends are attributable). A Non-U.S. Holder that is a corporation also could be subject to a branch profits tax
            at a rate of 30% (or such lower rate specified by an applicable tax treaty) on income attributable to the CVRs. If you are eligible for a reduced rate of U.S. withholding tax under an income tax treaty, you may also be able to obtain a refund
            or credit of any excess amounts withheld by timely filing an appropriate claim for a refund with the IRS.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Payments in excess of the combined company&#8217;s current and accumulated earnings and
            profitse (as determined under U.S. federal income tax principles) in the taxable year of such future cash payment would constitute a return of capital and first be applied against and reduce a Non-U.S. Holder&#8217;s adjusted tax basis in its common
            stock, but not below zero, and any excess would be treated as capital gain with respect to such Non-U.S. Holder&#8217;s Passage Bio Common Stock. However, this intended position is subject to substantial uncertainty, and, accordingly, Non-U.S.
            Holders are urged to consult their tax advisors with respect to the proper characterization of the CVRs and the tax consequences thereof (including any future cash payments made under the CVRs). A Non-U.S. holder generally will not be subject
            to U.S.&#160;federal income tax on gain realized on future cash payments made on the CVRs unless: (1) the gain (a) is effectively connected with a trade or business of the Non-U.S. Holder in the United States, subject to an applicable treaty
            providing otherwise and (b) if an applicable income tax treaty applies between the United States and the Non-U.S. Holder&#8217;s country of residence, is attributable to a permanent establishment maintained by the Non-U.S. Holder in the United States
            (in which case the special rules described below apply), or (2) Passage Bio (or the combined company, as applicable) is or has been a &#8220;United States real property holding corporation&#8221; (&#8220;<span style="font-style: italic; font-weight: bold;">USRPHC</span>&#8221;)

            and certain other requirements are met. Passage Bio does not believe that it currently is or has ever been a USRPHC.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the IRS instead asserts that the issuance of the CVRs should be treated as a
            &#8220;closed transaction,&#8221; a Non-U.S. Holder would be treated as receiving a distribution equal to the fair market value (determined on the CVR </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">167<br/>
        </div>

      </div>

    </div>

    <!--End Page 177-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 178-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_111-agreement_pg32"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Distribution Date) of the CVRs issued to such Non-U.S. Holder on the CVR
            Distribution Date. The amount of this distribution generally would be treated first as a taxable dividend to the extent of the Non-U.S. Holder&#8217;s pro rata share of the combined company&#8217;s current or accumulated earnings and profits (as determined
            for U.S. federal income tax purposes), then as a non-taxable return of capital to the extent of the Non-U.S. Holder&#8217;s basis in its Passage Bio Common Stock, and finally as capital gain from the sale or exchange of Passage Bio Common Stock
            (taxed to a Non-U.S. Holder in the same manner as described above). A Non-U.S. Holder&#8217;s tax basis in the CVRs received would equal the fair market value of the CVRs on the CVR Distribution Date and the holding period of the CVRs received would
            begin on the day following the CVR Distribution Date. Although not free from doubt, a future cash payment under a CVR would likely be treated as a non-taxable return of a Non-U.S. Holder&#8217;s adjusted tax basis in the CVR to the extent thereof,
            although the timing of the recovery of a Non-U.S. Holder&#8217;s tax basis is unclear. A payment in excess of such amount may be treated as a dividend or other payment subject to U.S. withholding tax.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">DUE TO THE LEGAL AND FACTUAL UNCERTAINTY REGARDING THE TAX
            TREATMENT OF THE CVRS (AND ANY FUTURE CASH PAYMENTS UNDER THE CVRS), NON-U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS CONCERNING THE RECOGNITION OF GAIN, INCOME AND/OR LOSS OR WITHHOLDING THAT MAY APPLY IN CONNECTION WITH THE CVRS.
            NON-U.S. HOLDERS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE APPLICABILITY OF INFORMATION REPORTING AND BACKUP WITHHOLDING AND/OR WITHHOLDING UNDER THE FOREIGN ACCOUNT TAX COMPLIANCE ACT WITH RESPECT TO THE CVRS AND ANY FUTURE CASH PAYMENTS
            UNDER THE CVRS, PARTICULARLY IN LIGHT OF THE UNCERTAINTY UNDER U.S. FEDERAL INCOME TAX LAW RELATING TO THE TAX TREATMENT OF THE CVRS.<span style="font-weight: normal;"> </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">168<br/>
        </div>

      </div>

    </div>

    <!--End Page 178-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 179-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_112-executive_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPEOC"><!--Anchor--></a>PASSAGE BIO EXECUTIVE OFFICERS AND CORPORATE
            GOVERNANCE </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise indicated or the context otherwise requires, references in this
            section to &#8220;Passage Bio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Passage Bio and its subsidiaries. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Executive Officers </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table identifies our executive officers, and sets forth their
            current positions at Passage Bio, Inc. and their ages as of June&#160;24, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 204pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AGE</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">POSITION </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D.</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">53</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President, Chief Executive Officer, and Director </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">50</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Financial Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Biographical information for our executive officers, as of June&#160;24, 2026, is set
            forth below.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">William Chou, M.D., <span style="font-style: normal; font-weight: normal;">has served as Passage Bio&#8217;s President and Chief Executive Officer and member of its board of directors since October&#160;2022. Dr.&#160;Chou is an accomplished executive with nearly 20 years of
              healthcare experience across a range of development and commercialization roles. Dr.&#160;Chou previously served as CEO of Aruvant Sciences (&#8220;</span>Aruvant<span style="font-style: normal; font-weight: normal;">&#8221;), a clinical-stage
              biopharmaceutical company focused on developing gene therapies for rare disease, from November&#160;2019 to October&#160;2022. Prior to joining Aruvant, from May&#160;2008 to October&#160;2019, Dr.&#160;Chou served in a variety of leadership roles at Novartis Pharma
              AG (&#8220;</span>Novartis<span style="font-style: normal; font-weight: normal;">&#8221;), including Vice President and Global Disease Lead for Novartis&#8217; Cell and Gene Therapy, where he oversaw the global commercial launch of Kymriah&#174;, the first CAR-T
              cell therapy. Prior to that role, Dr.&#160;Chou led the Kymriah<sup>&#174;</sup> lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr.&#160;Chou worked at the Boston
              Consulting Group where he focused on commercial and clinical pharmaceutical strategy. Dr.&#160;Chou holds an M.B.A. from the Yale School of Management, an M.D. from the University of Pittsburgh School of Medicine, and an A.B. in politics and
              economics from Princeton University. Dr.&#160;Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick <span style="font-style: normal; font-weight: normal;">has served as Passage Bio&#8217;s Chief Financial Officer since March&#160;2024. From November&#160;2021 to March&#160;2024, Ms.&#160;Borthwick served as Passage Bio&#8217;s Interim Chief Financial Officer and Vice President
              of Finance. From June&#160;1997 to October&#160;2021, Ms.&#160;Borthwick served in various leadership roles of increasing responsibility at Johnson &amp; Johnson Services, Inc. During her tenure at Johnson &amp; Johnson, she worked in Finance in support of
              Research &amp; Development, Manufacturing, Business Development, Treasury and commercial operations for the global Pharmaceutical and Medical Technology business segments. Ms.&#160;Borthwick earned her B.S. in Economics with concentrations in
              Accounting and Health Care Management at the Wharton School at the University of Pennsylvania, and her M.B.A. from the Tuck School of Business at Dartmouth College.</span></div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Director Independence </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the rules of the Nasdaq Stock Market, independent directors must comprise a
            majority of a listed company&#8217;s board of directors. In addition, the rules of the Nasdaq Stock Market require that, subject to specified exceptions, each member of a listed company&#8217;s audit and compensation committees be independent and that
            director nominees be selected or recommended for the board&#8217;s selection by independent directors constituting a majority of the independent directors or by a nominating and corporate governance committee comprised solely of independent
            directors. Under the rules of the Nasdaq Stock Market, a director will only qualify as &#8220;independent&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of
            independent judgment in carrying out the responsibilities of a director and that such person is &#8220;independent&#8221; as defined under Nasdaq Stock Market and the rules under the Exchange Act.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Audit committee members must also satisfy the independence criteria set forth in
            Rule&#160;10A-3 under the Exchange Act. In order to be considered independent for purposes of Rule&#160;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of
            directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2) be an affiliated person of the listed company or any of its
            subsidiaries.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Based upon information requested from and provided by each director concerning
            his or her background, employment and affiliations, including family relationships, our Board has determined that each of our directors, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">169<br/>
        </div>

      </div>

    </div>

    <!--End Page 179-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 180-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_112-executive_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">with the exception of Dr.&#160;Chou, is an &#8220;independent director&#8221; as defined under
            applicable rules of the Nasdaq Stock Market. In addition, all members of our audit committee satisfy the independence criteria set forth in Rule&#160;10A-3 under the Exchange Act, and all members of our Compensation Committee satisfy the
            independence criteria set forth in Rule&#160;10C-1 under the Exchange Act and are &#8220;non-employee directors&#8221; as defined in Section&#160;16b-3 of the Exchange Act, and all members of the Nominating and Corporate Governance Committee are &#8220;independent&#8221; as
            defined under the applicable listing standards of Nasdaq. In making such determination, our Board considered the relationships that each such non-employee director has with our Company and all other facts and circumstances that our Board deemed
            relevant in determining his or her independence, including the beneficial ownership of our capital stock by each non-employee director. Dr.&#160;Chou is not an independent director under these rules because he is an employee of Passage Bio. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Board Meetings and Attendance </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Board held five meetings during the year ended December&#160;31, 2025.
            Each of the directors attended at least seventy-five percent (75%) of the meetings of the Passage Bio Board and the committees of the Passage Bio Board on which he or she served during the year ended December&#160;31, 2025 (in each case, which were
            held during the period for which he or she was a director and/or a member of the applicable committee and excluding any meetings in which a director was an interested party).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">All members of Passage Bio&#8217;s board of directors attended Passage Bio&#8217;s 2025
            Annual Meeting of Stockholders. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Board of Directors Leadership Structure </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The positions of Chief Executive Officer and chairperson of our board of
            directors are held by two different individuals (William Chou, M.D. and Maxine Gowen, Ph.D., respectively). This structure allows our Chief Executive Officer to focus on our day-to-day business while our chairperson leads our board of directors
            in its fundamental role of providing advice to and independent oversight of management. Dr.&#160;Chou&#8217;s deep medical knowledge as well as his experience in various executive positions in life sciences companies makes him well-suited for this
            day-to-day operational role, while Dr.&#160;Gowen&#8217;s extensive experience in leadership roles at life sciences companies with respect to drug discovery, corporate strategy, and operations allows her to perform an oversight function separate from
            management. Our board of directors believes such separation is appropriate, as it enhances the accountability of the Chief Executive Officer to the board of directors and strengthens the independence of the board of directors from management. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Board Committees </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio board of directors has a standing Audit, Compensation and
            Nominating and Corporate Governance Committee. Each of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee is comprised solely of independent directors and is described more fully below. Each committee
            operates pursuant to a written charter and each reviews and assesses the adequacy of its charter periodically. The charters for each committee are all available on our website (www.passagebio.com) under the &#8220;Investors&#8221; section. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Audit Committee </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our audit committee is composed of Dr.&#160;Countouriotis, Mr.&#160;Kapadia, and
            Mr.&#160;Kassberg, with Mr.&#160;Kapadia serving as the Chair of the committee. The Passage Bio Board has determined that each member of the audit committee meets the independence requirements of Rule&#160;10A-3 under the Exchange Act and the applicable
            listing standards of Nasdaq. The Passage Bio Board has determined that Mr.&#160;Kapadia is an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act and the applicable listing
            standards of Nasdaq. The audit committee&#8217;s responsibilities include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">selecting and hiring Passage Bio&#8217;s independent registered public accounting firm; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the qualifications, independence, and performance of Passage Bio&#8217;s independent auditors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the preparation of the audit committee report to be included in Passage Bio&#8217;s annual proxy statement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s compliance with certain legal and regulatory requirements, including disclosure controls; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing Passage Bio&#8217;s cybersecurity risk management program; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">170<br/>
        </div>

      </div>

    </div>

    <!--End Page 180-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 181-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_112-executive_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">assisting the board of directors with risk assessment and management; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s accounting and financial reporting processes, including Passage Bio&#8217;s financial statement audits and the integrity
                    of its financial statements; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and approving related-person transactions. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, the audit committee met four times. The
            report of the audit committee is included in this proxy statement/prospectus under &#8220;<span style="font-style: italic;">Audit Committee Report</span>.&#8221; </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Nominating and Corporate Governance
            Committee </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Nominating and Corporate Governance Committee is composed of Dr.&#160;Gowen,
            Dr.&#160;Porter, and Dr.&#160;Sondhi, with Dr.&#160;Gowen serving as Chair of the committee. The Passage Bio Board has determined that each member of the Nominating and Corporate Governance Committee is &#8220;independent&#8221; as defined under the applicable listing
            standards of Nasdaq. The Nominating and Corporate Governance Committee&#8217;s responsibilities include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">identifying, considering, and recommending candidates for membership on the Passage Bio board of directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing the process of evaluating the performance of the Passage Bio board of directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advising the Passage Bio board of directors on corporate governance matters, including environmental, social and governance
                    issues. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, the Nominating and Governance Committee
            met four times. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Compensation Committee </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Compensation Committee is composed of Dr.&#160;Countouriotis,
            Dr.&#160;Gowen, and Dr.&#160;Porter, with Dr.&#160;Countouriotis serving as Chair of the committee. The Passage Bio board of directors has determined that each member of the Compensation Committee is &#8220;independent&#8221; as defined under the applicable listing
            standards of Nasdaq and meets the independence criteria set forth in Rule&#160;10C-1 under the Exchange Act. The Compensation Committee&#8217;s responsibilities include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">evaluating, recommending, approving, and reviewing executive officer compensation arrangements, plans, policies, and programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">evaluating and recommending non-employee director compensation arrangements for determination by the Passage Bio board of
                    directors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">administering Passage Bio&#8217;s cash-based and equity-based compensation plans; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing Passage Bio&#8217;s compliance with regulatory requirements associated with the compensation of directors, officers, and
                    employees. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Compensation Committee has the sole authority and responsibility, subject to
            any approval by the board of directors which the Compensation Committee or legal counsel determines to be desirable or required by applicable law or the Nasdaq rules, to determine all aspects of executive compensation packages for the Chief
            Executive Officer and other executive officers. The Compensation Committee also makes recommendations to the Passage Bio board of directors regarding the form and amount of compensation for non-employee directors. The Compensation Committee may
            take into account the recommendations of the Chief Executive Officer with respect to compensation of the other executive officers, and the recommendations of the board of directors or any member of the board of directors with respect to
            compensation of the Chief Executive Officer and other executive officers. During the year ended December&#160;31, 2025, the Compensation Committee met six times. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Compensation Consultant </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Compensation Committee has engaged Pearl Meyer and Partners, LLC (&#8220;<span style="font-style: italic; font-weight: bold;">Pearl Meyer</span>&#8221;), as its independent executive compensation consultant to evaluate Passage Bio&#8217;s executive compensation and board of directors compensation program and practices and to
            provide advice and ongoing assistance on these matters. Specifically, Pearl Meyer was engaged to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide compensation-related data for a peer group of companies to serve as a basis for assessing competitive compensation
                    practices; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">171<br/>
        </div>

      </div>

    </div>

    <!--End Page 181-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 182-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_112-executive_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review and assess Passage Bio&#8217;s current executive compensation program relative to the market to identify any potential changes
                    or enhancements to be brought to the attention of the Compensation Committee; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">review market practices regarding base salary, bonus, and equity programs. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Representatives of Pearl Meyer met informally with the Chair of the Compensation
            Committee and attended the regular meetings of the Compensation Committee, including executive sessions from time to time without any members of management present. During the fiscal year ended December&#160;31, 2025, Pearl Meyer worked directly
            with the Compensation Committee (and not on behalf of management) to assist the committee in satisfying its responsibilities and undertook no projects for management without the committee&#8217;s prior approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Compensation Committee has determined that none of the work performed by
            Pearl Meyer during the fiscal year ended December&#160;31, 2025 raised any conflict of interest. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Code of Business Conduct and Ethics </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio board of directors has adopted a Code of Conduct and Ethics that
            applies to all of its employees, officers, and directors, including the Chief Executive Officer, Chief Financial Officer and other executive and senior financial officers. The full text of the Code of Conduct and Ethics is posted on the
            investor relations section of our website at www.passagebio.com We intend to disclose future amendments to certain provisions of our Code of Conduct and Ethics, or waivers of these provisions, on our website or in public filings to the extent
            required by the applicable rules. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Social Responsibility </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio believes that corporate social responsibility initiatives are
            important to its business and to creating sustainable value for its stockholders and wider stakeholder group. The Passage Bio board of directors and management are committed to these initiatives and believe these efforts will benefit Passage
            Bio employees, partners, and the communities in which it operates. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">172<br/>
        </div>

      </div>

    </div>

    <!--End Page 182-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 183-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPEOD"><!--Anchor--></a>PASSAGE BIO EXECUTIVE OFFICER AND DIRECTOR
            COMPENSATION </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise indicated or the context otherwise requires,
            references in this section to &#8220;Passage Bio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Passage Bio and its subsidiaries.<span style="font-style: normal;"> </span></div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Executive Compensation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s named executive officers for the year ended December&#160;31, 2025 are:
          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">William Chou, M.D., President and Chief Executive Officer; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Kathleen Borthwick, Chief Financial Officer; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Edgar B. (Chip) Cale, former General Counsel and Corporate Secretary*. </div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Mr.&#160;Cale served as Passage Bio&#8217;s General Counsel and Corporate Secretary until his passing in June&#160;2025.</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">2025 Summary Compensation Table </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth the compensation awarded to, earned by or paid to
            each of our named executive officers for the fiscal years ended December&#160;31, 2025 and December&#160;31, 2024. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 132pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 22.65pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 33.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 33.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 40pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 132pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME AND PRINCIPAL POSITION</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.65pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">YEAR</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.59pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SALARY<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">STOCK <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AWARDS <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(1)</sup></div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OPTION <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AWARDS <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(2)</sup></div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">NON-EQUITY <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">INCENTIVE <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">COMPENSATION <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PLAN <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(3)</sup></div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ALL OTHER <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">COMPENSATION <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(4)</sup></div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TOTAL <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td rowspan="2" style="width: 132pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D. <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><span style="font-style: italic;">President and Chief Executive Officer</span><br/>
                  </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.65pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.33pt; text-align: left;">2025</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.59pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;">660,985</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;">234,040</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;">239,266</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.55pt; text-align: left;">334,972</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.06pt; text-align: left;">17,500</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,486,763 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.33pt; text-align: left;">2024</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;">638,461</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;">646,659</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.55pt; text-align: left;">334,400</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.06pt; text-align: left;">17,250</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">1,636,770 </div>
                </td>

  </tr>

  <tr>

    <td rowspan="2" style="width: 132pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><span style="font-style: italic;">Chief Financial Officer</span><br/>
                  </div>
                </td>

    <td style="width: 3pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.65pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.33pt; text-align: left;">2025</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.59pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;">450,627</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;"><span style="padding-left: 0.37pt;">117,020</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;"><span style="padding-left: 5pt;">85,440</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.55pt; text-align: left;">181,252</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.06pt; text-align: left;">17,500</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 7.5pt;">851,839 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.33pt; text-align: left;">2024</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;">420,692</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;">256,971</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.55pt; text-align: left;">166,785</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.06pt; text-align: left;">17,250</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 7.5pt;">861,698 </span></div>
                </td>

  </tr>

  <tr>

    <td rowspan="2" style="width: 132pt; height: 12.75pt; padding-top: 1.01pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Edgar B. (Chip) Cale<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><span style="font-style: italic;">General Counsel and Corporate
                      Secretary</span><br/>
                  </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.65pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.33pt; text-align: left;">2025</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.59pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;">221,860</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;">197,080</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;">156,850</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.55pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.06pt; text-align: left;">17,500</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 7.5pt;">593,290 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.65pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.33pt; text-align: left;">2024</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.59pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.05pt; text-align: left;">436,754</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.63pt; text-align: left;">255,143</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.55pt; text-align: left;">172,773</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.06pt; text-align: left;">17,250</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 7.5pt;">881,920</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 132pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 22.65pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 33.76pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 33.76pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 9.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents the grant date fair value of restricted stock units awarded during the applicable year as computed in accordance with
                    FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the restricted stock units reported in the Stock awards column are set forth in Note&#160;13 to our 2025 financial statements included with our 2025 Annual
                    Report under Form&#160;10-K. Note&#160;that the amounts reported in this column reflect the aggregate accounting cost, under generally accepted accounting principles, for these awards and do not necessarily correspond to the actual economic value
                    that may be received by each named executive officer from the restricted stock units. The reported amount for Mr.&#160;Cale&#8217;s fiscal year 2025 awards also includes $80,060 due to the incremental fair value, computed in accordance with FASB
                    ASC Topic 718, of the modification to accelerate the vesting of outstanding restricted stock units following the termination of employment due to the employee&#8217;s death. This treatment applied to all outstanding restricted stock units
                    held by Mr.&#160;Cale. No additional restricted stock units were granted as part of the modification. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents the grant date fair value of options awarded during the applicable year as computed in accordance with FASB ASC Topic
                    718. The assumptions used in calculating the grant date fair value of the stock options reported in the Option awards column are set forth in Note&#160;13 to our financial statements included with our 2025 Annual Report under Form&#160;10-K.
                    Note&#160;that the amounts reported in this column reflect the aggregate accounting cost, under generally accepted accounting principles, for these awards and do not necessarily correspond to the actual economic value that may be received by
                    each named executive officer from the options. The reported amount for Mr.&#160;Cale&#8217;s fiscal year 2025 awards also includes $71,410 due to the incremental fair value, computed in accordance with FASB ASC Topic 718, of the modification to
                    accelerate the vesting of outstanding stock options following the termination of employment due to the employee&#8217;s death and provide that vested stock options may be exercised until the option expiration date set forth in the
                    individual&#8217;s stock option award agreement. This treatment applied to all outstanding stock options held by Mr.&#160;Cale. No additional stock options were granted as part of the modification and the exercise price of the stock options did
                    not change in connection with the modification. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts shown in the &#8220;Nonequity Incentive Plan Compensation&#8221; column represent annual bonuses earned with respect to fiscal
                    years 2025 and 2024 under our annual bonus program as described below under the section titled &#8220;<span style="font-style: italic;">&#8212;Non-Equity Incentive Plan Compensation.</span>&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts shown in the &#8220;All Other Compensation&#8221; column for fiscal years 2025 and 2024 reflect 401(k) plan matching
                    contributions, described below under &#8220;<span style="font-style: italic;">Employee and Retirement Benefits.</span>&#8221; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Executive Compensation Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio endeavors to maintain sound compensation governance standards
            consistent with the Company&#8217;s executive compensation policies and practices. The Company&#8217;s Compensation Committee regularly reviews all compensation components to ensure that they are consistent with the Company&#8217;s short-term and long-term
            goals, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">173<br/>
        </div>

      </div>

    </div>

    <!--End Page 183-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 184-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">including base salary, bonus, benefits, equity incentives, and other
            perquisites, as well as severance arrangements, change-in-control benefits, and other forms of executive officer compensation. In addition, the Compensation Committee also considers matters related to individual compensation, such as
            compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of the Company&#8217;s compensation strategy, potential modifications to that strategy, and new trends, plans, or approaches to compensation, at
            various meetings throughout the year. When considering the total variable pay-mix for Passage Bio&#8217;s executive officers, the Company seeks to design and implement a competitive executive compensation program that combines both cash and incentive
            elements based on annual performance objectives and long-term equity elements that will be flexible and complementary to meet the Company&#8217;s compensation objectives. The Compensation Committee also has the authority to administer the Company&#8217;s
            equity-based plans, both directly and through delegated authority to the Chief Executive Officer.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company&#8217;s Compensation Committee provides a recommendation on the
            compensation of the Chief Executive Officer to the board of directors and approves the compensation of the Company&#8217;s other executive officers.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the fall of 2024, the Compensation Committee engaged Pearl Meyer to evaluate
            the Company&#8217;s executive compensation program and provide a market frame of reference for setting compensation for the 2025 fiscal year. In evaluating the total compensation of Passage Bio&#8217;s executive officers, the Compensation Committee, with
            the assistance of Pearl Meyer, established a peer group of twenty publicly traded companies in the biopharmaceutical industry whose market capitalization, operating size, maturity of product development pipeline or area of therapeutic focus
            were similar to Passage Bio at that time. In the fall of 2025, Pearl Meyer again assisted the Compensation Committee for the evaluation of the Company&#8217;s executive compensation program for the 2026 fiscal year. As part of its advice, Pearl Meyer
            developed a new peer group of twenty publicly traded companies in the biopharmaceutical industry to evaluate the Company&#8217;s executive compensation program and provide a market frame of reference for setting compensation for the 2026 fiscal year,
            which accounted for the evolution of the Company between 2024 and 2025 and reflected the characteristics of the Company at that time. Pearl Meyer used this peer group to assist the Compensation Committee in conducting a competitive compensation
            assessment for Passage Bio&#8217;s executive officers for the fiscal year ended December&#160;31, 2025 and for fiscal year 2026 compensation planning. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Employment Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have entered into written employment agreements with each of our named
            executive officers. Each of these agreements provides for at-will employment and includes each officer&#8217;s base salary, a discretionary annual incentive bonus opportunity that may be based on individual and Company performance, and standard
            employee benefit plan participation. These agreements also provide for severance benefits upon termination of employment or a change in control of the Company. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">William Chou, M.D. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Effective as of October&#160;10, 2022, William Chou, M.D. was appointed as the
            Company&#8217;s Chief Executive Officer and a member of the Passage Bio Board. Dr.&#160;Chou&#8217;s employment agreement provides for at-will employment and included his initial base salary, discretionary annual incentive bonus opportunity, certain initial
            equity incentive awards and standard employee benefit plan participation. The details of Dr.&#160;Chou&#8217;s compensation for the years ended December&#160;31, 2025 and 2024 are included in the Summary Compensation Table above. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">See section <span style="font-style: italic;">Interests of Passage Bio&#8217;s
              Directors and Executive Officers in the Merger&#8212;Executive Employment Agreements</span> above for a description of Dr.&#160;Chou&#8217;s severance and change in control rights. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On March&#160;1, 2024, Kathleen Borthwick was appointed the Company&#8217;s Chief Financial
            Officer. Ms.&#160;Borthwick&#8217;s employment agreement provides for at-will employment and includes her initial base salary, discretionary annual incentive bonus opportunity, certain initial equity incentive awards, and standard employee benefit plan
            participation. The details of Ms.&#160;Borthwick&#8217;s compensation for the years ended December&#160;31, 2025 and 2024 are included in the Summary Compensation Table above. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">See section <span style="font-style: italic;">Interests of Passage Bio&#8217;s
              Directors and Executive Officers in the Merger&#8212;Executive Employment Agreements</span> above for a description of Ms.&#160;Borthwick&#8217;s severance and change in control rights. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">174<br/>
        </div>

      </div>

    </div>

    <!--End Page 184-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 185-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Base Salaries </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Base salaries are reviewed annually and may be adjusted to realign salaries with
            market levels of compensation paid by Passage Bio&#8217;s peer companies, after considering individual responsibilities and performance over the past year. In 2025, the base salary of Passage Bio&#8217;s continuing executive officers increased by 3.5% to
            7% to better align them with market practices. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Non-Equity Incentive Plan Compensation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Annual bonuses for Passage Bio&#8217;s executive officers are based on the achievement
            of individual performance objectives and corporate objectives established by the Passage Bio Board that are based on goals related to research and development, regulatory, financial, and other general corporate goals. The 2025 target bonus
            amounts, expressed as a percentage of annual base salary, were 55% for Dr.&#160;Chou and 40% for Ms.&#160;Borthwick. In February&#160;2026, based on the achievement of these corporate and personal performance objectives, the Passage Bio Board determined to
            award bonuses at 92% and 100% of the targeted amount as reflected in the table above to Dr.&#160;Chou and Ms.&#160;Borthwick, respectively. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employee and retirement benefits </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company provides broad-based health and welfare benefits that are available
            to all of our employees, including our named executive officers, including health, life and AD&amp;D, disability, vision and dental insurance. The Company maintains a tax-qualified retirement plan (the &#8220;<span style="font-style: italic; font-weight: bold;">401(k) Plan</span>&#8221;), for our full-time employees, including our named executive officers. The 401(k) Plan provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Insider Trading Policy </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has adopted an Insider Trading Policy that applies to all of its
            employees, officers and directors, including the Chief Executive Officer and other executive officers, to establish policies and procedures to promote compliance with applicable U.S. securities laws, rules and regulations and applicable Nasdaq
            listing standards and prohibit the purchase, sale and/or other dispositions of Company securities while in the possession of material nonpublic information related to the Company and the disclosure of material nonpublic information related to
            the Company to any outside person. Passage Bio&#8217;s Insider Trading Policy further prohibits such individuals from purchasing financial instruments, or otherwise engaging in transactions, that hedge or offset, or are designed to hedge or offset,
            any decrease in the market value of Passage Bio&#8217;s common stock, such as prepaid variable forward contracts, equity swaps, collars, forward sale contracts and exchange funds.</div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Compensation Recovery Policy </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On October&#160;12, 2023, the Passage Bio Board adopted, and Passage Bio&#8217;s
            Compensation Committee administers, a compensation recovery policy (the &#8220;<span style="font-style: italic; font-weight: bold;">Clawback Policy</span>&#8221;) to comply with new rules and regulations promulgated by the SEC, including Rule&#160;10D-1 of the
            Exchange Act that is applicable to the Company&#8217;s executive officers and all employees who are officers for purposes of Section&#160;16 of the Exchange Act, including current and former executive officers and Section&#160;16 officers (the &#8220;<span style="font-style: italic; font-weight: bold;">Covered Employees</span>&#8221;). The Clawback Policy allows the Company to recover, or claw back, certain incentive-based compensation from Covered Employees in the event of a restatement of the
            Company&#8217;s financial statements due to material noncompliance with any financial reporting requirements under the federal securities laws. Under the Company&#8217;s Clawback Policy, if a restatement would result in any incentive-based compensation
            paid during the three years preceding the restatement to have been lower had it been calculated based on such restated results, the Company must recover the amounts in excess of what would have been paid under the restatement from any Covered
            Employee who received such incentive-based compensation. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Equity Awards </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In 2025, Passage Bio granted stock options and restricted stock units to its
            named executive officers as a way to incentivize them and as a retention vehicle. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">175<br/>
        </div>

      </div>

    </div>

    <!--End Page 185-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 186-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 528pt;"><a id="ny20077915x1_s4_113-compensation_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 30pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Outstanding Equity Awards at Fiscal 2025
            Year-End </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table presents, for each of the Company&#8217;s named executive officers,
            information regarding outstanding stock options and restricted stock units held as of December&#160;31, 2025. Awards to date have been granted under Passage Bio&#8217;s 2018 Equity Incentive Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">2018

              EIP</span>&#8221;), 2020 Equity Incentive Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">2020 EIP</span>&#8221;), and the 2021 Equity Inducement Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">2021 EIP</span>&#8221;). </div>

        </div>

        <div class="BRDSX_block-main" style="width: 528pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 528pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 80pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 38.87pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 43.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 226.1pt;" colspan="13">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 118.7pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 80pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="13" style="width: 226.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option Awards</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 118.7pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock Awards </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 80pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Grant Date</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Plan</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vesting <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Commencement <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">date</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">underlying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unexercised <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercisable</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">underlying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unexercised <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">options <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unexercisable</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">expiration <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">date</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Grant Date</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares or <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">restricted <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">units that <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">have not <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vested<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Market <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">value of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares or <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">restricted <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">units that <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">have not <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">vested<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td rowspan="6" style="width: 80pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D. </div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;" rowspan="6">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;">10/10/2022</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(1)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;">10/10/2022</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">8,695</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 4pt;">2,280</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">26.40</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">10/10/2032</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 12.5pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;">10/10/2022</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2021 EIP<sup>(1)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;">10/10/2022</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;">26,344</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 4pt;">6,930</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">26.40</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">10/10/2032</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2023</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(2)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2023</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;">20,922</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 4pt;">9,507</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">21.60</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2033</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2024</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(2)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2024</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;">12,579</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;">16,170</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">30.00</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2034</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;">1/15/2025</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;">20,000<sup>(4)</sup></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;">236,000 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2025</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(2)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2025</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">7,308</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;">31,668</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 8pt;">7.74</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2035</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td rowspan="7" style="width: 80pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick</div>
                </td>

    <td style="width: 2.55pt;" rowspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;">12/15/2021</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(1)</sup></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4.3pt;">11/1/2021</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">2,799</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;">135.00</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">12/15/2031</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">6/13/2022</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(3)</sup></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">6/13/2022</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">1,043</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">45.80</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/13/2032</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2023</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(2)</sup></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2023</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">1,893</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 10pt;">856</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">21.60</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2033</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">7/28/2023</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(1)</sup></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">7/28/2023</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 10pt;">604</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 10pt;">395</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">17.55</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">7/28/2033</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2024</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(2)</sup></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2024</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">4,966</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 4pt;">6,384</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">30.00</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2034</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;">1/15/2025</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;">10,000<sup>(4)</sup></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"><span style="padding-left: 0.3pt;">118,000 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2025</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(2)</sup></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2025</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">2,610</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 0.3pt;">11,308</span></div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 8pt;">7.74</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2035</span></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td rowspan="10" style="width: 80pt; height: 11.25pt; padding-top: 1.33pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Edgar B.(Chip) Cale</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;" rowspan="10">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;">10/23/2019</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; white-space: nowrap; margin-left: -0.01pt; text-align: left;">2018<sup>(1)</sup> EIP<sup>(5)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">9/23/2019</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;">13,712</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;">161.37</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">2/27/2020</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; white-space: nowrap; margin-left: -0.01pt; text-align: left;">2020<sup>(1)</sup> EIP<sup>(5)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">2/27/2020</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">4,986</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;">360.00</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">2/16/2021</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; white-space: nowrap; margin-left: -0.01pt; text-align: left;">2020<sup>(1)</sup> EIP<sup>(5)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">2/15/2021</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">8,549</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;">437.00</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">2/10/2022</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020<sup>(5)</sup> EIP<sup>(6)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">2/10/2022</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">5,299</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">90.40</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">5/31/2022</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020<sup>(5)</sup> EIP<sup>(7)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">5/31/2022</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">5,000</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">36.00</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">6/13/2022</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020<sup>(3)</sup> EIP<sup>(5)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">6/13/2022</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">5,299</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">45.80</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2023</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020<sup>(5)</sup> EIP<sup>(6)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2023</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">8,749</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">21.60</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2024</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020<sup>(5)</sup> EIP<sup>(6)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/15/2024</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;">10,149</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">30.00</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">9/30/2024</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(5)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 8pt;">8/1/2024</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;"><span style="padding-left: 4pt;">2,499</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 4pt;">14.00</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.22pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 7.48pt; text-align: left;"></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; height: 11.25pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 3.36pt; text-align: left;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 1.21pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2025</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 43.98pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">2020 EIP<sup>(5)</sup></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.54pt; text-align: left;"><span style="padding-left: 4pt;">3/17/2025</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.29pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 9.15pt; text-align: left;">13,918</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.51pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 12.26pt; text-align: left;"><span style="padding-left: 14pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.95pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 2.48pt; text-align: left;"><span style="padding-left: 8pt;">7.74</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 4pt;">6/16/2026</span></div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38.87pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.72pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3.25pt; width: 80pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 38.87pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 43.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 55.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 40.29pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 46.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.55pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 26.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 36.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 38.87pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 36.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 2.54pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 32.72pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 30pt;">
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-top: 3pt; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The option vests as to 25% of the total shares on the first anniversary date of the vesting commencement date and then 2.0833% of
                    the total shares vest monthly thereafter, with 100% of the total shares vested on the fourth anniversary of the vesting commencement date subject to the reporting person&#8217;s provision of service to the Company on each vesting date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The option vests 2.0833% of the total shares monthly with 100% of the total shares vested on the fourth anniversary of the
                    vesting commencement date, subject to the reporting person&#8217;s provision of service to the Company on each vesting date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The option vests 2.7778% of the total shares monthly with 100% of the total shares vested on the third anniversary of the vesting
                    commencement date, subject to the reporting person&#8217;s provision of service to the Company on each vesting date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents restricted stock units, which 50% vested on January&#160;8, 2026, and the remaining 50% vest on January&#160;8, 2027. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The post-termination exercise period applicable to the option expires in June&#160;2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Under the original terms of the option agreement, the option vests 2.0833% of the total shares monthly with 100% of the total
                    shares vested on the fourth anniversary of the vesting commencement date, subject to the executive&#8217;s provision of service to the Company on each vesting date. Upon the executive&#8217;s passing in June&#160;2025, all unvested shares subject to
                    this option were accelerated as of June&#160;16, 2025. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The option vested 8.3333% of the total shares on June&#160;30, 2022, and then 8.3333% of the total shares vested monthly thereafter,
                    with 100% of the total shares vested on May&#160;31, 2023, subject to the executive&#8217;s provision of service to the Company on each vesting date. The option was granted in connection with Mr.&#160;Cale&#8217;s appointment to interim Chief Executive
                    Officer. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 30pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">176<br/>
        </div>

      </div>

    </div>

    <!--End Page 186-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 187-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the year ended December&#160;31, 2025, Passage Bio&#8217;s non-employee directors
            received the following compensation (as approved by the Passage Bio Board):</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Cash Compensation. <span style="font-style: normal;">Each
              non-employee director received an annual cash retainer of $40,000. Additionally, the Chair of the Passage Bio Board received an additional annual payment of $30,000; the Chair of the Audit, Compensation, and Nominating and Governance
              Committees each received an additional annual payment of $15,000, $12,000 and $8,000, respectively; and the members of the Company&#8217;s Audit, Compensation, and Nominating and Governance Committees received an additional annual payment of
              $7,500, $5,500, and $4,000, respectively. Cash compensation was paid quarterly in arrears and was pro-rated for partial quarters served.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Equity Compensation.<span style="font-style: normal;"> Each
              new, non-employee director who joined the Passage Bio Board would receive an initial option grant for the purchase of shares of Passage Bio Common Stock with a value of $110,000 upon election to the Passage Bio Board, which vest in equal
              monthly installments for three years after the grant date, subject to the director&#8217;s continued service on the Passage Bio Board. No new non-employee directors joined the Passage Bio Board during the year ended December&#160;31, 2025. On the date
              of the 2025 annual meeting of stockholders, each non-employee director who continued to serve on the Passage Bio Board immediately following such meeting received an option grant to purchase of shares of Passage Bio Common Stock with a value
              of $55,000, which vest on the one-year anniversary of the grant date, subject to the director&#8217;s continued service on the Passage Bio Board. In addition, equity awards for non-employee directors will vest in full in the event that Passage Bio
              is subject to a change in control or upon certain other events. Non-employee directors receive no other form of remuneration, perquisites or benefits, but are reimbursed for their reasonable travel expenses incurred in attending board and
              committee meetings.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth the compensation earned by or paid to the
            Company&#8217;s non-employee directors for services provided during the year ended December&#160;31, 2025. Dr.&#160;Chou, the Company&#8217;s President and Chief Executive Officer, did not receive additional compensation for his service as a director during 2025.
            Saqib Islam resigned from the Passage Bio Board effective September&#160;16, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 40.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">FEES EARNED OR <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PAID IN CASH <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OPTION <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AWARDS<sup>(1)</sup><br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">ALL OTHER <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">COMPENSATION <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TOTAL <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maxine Gowen, Ph.D. </div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.13pt; text-align: left;">83,500</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.62pt; text-align: left;">55,000</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.8pt; text-align: left;">&#8212;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">138,500 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Athena Countouriotis, M.D. </div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.13pt; text-align: left;">54,181</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.62pt; text-align: left;">55,000</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.8pt; text-align: left;">&#8212;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">109,181 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Saqib Islam</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.13pt; text-align: left;">35,340</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.62pt; text-align: left;">55,000</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.8pt; text-align: left;">&#8212;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">90,340 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sandip Kapadia</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.13pt; text-align: left;">55,000</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.62pt; text-align: left;">55,000</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.8pt; text-align: left;">&#8212;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 0.37pt;">110,000 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Kassberg</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.13pt; text-align: left;">47,500</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.62pt; text-align: left;">39,176</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.8pt; text-align: left;">&#8212;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">86,676 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derrell Porter, M.D. </div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.13pt; text-align: left;">49,500</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.62pt; text-align: left;">55,000</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.8pt; text-align: left;">&#8212;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">104,500 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dolan Sondhi, Ph.D. </div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.76pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.13pt; text-align: left;">44,000</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.76pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.62pt; text-align: left;">55,000</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.61pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 27.8pt; text-align: left;">&#8212;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">99,000</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 228pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.76pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.76pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts reported in this column represent the aggregate grant date fair value of the stock options granted to our
                    non-employee directors during the year ended December&#160;31, 2025, as computed in accordance with the Financial Accounting Standards Board Accounting Standards Codification (&#8220;<span style="font-style: italic; font-weight: bold;">FASB ASC</span>&#8221;)
                    Topic 718. The assumptions used in calculating the aggregate grant date fair value of the stock options reported in this column are set forth in Note&#160;13 to our financial statements included in our Annual Report on Form&#160;10-K for the year
                    ended December&#160;31, 2025. The amounts reported in this column reflect the accounting cost of these stock options, and do not correspond to the actual economic value that may be received by the Company&#8217;s directors from the stock options.
                    For information regarding the number of stock options held by each non-employee director as of December&#160;31, 2025, see the table below. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 448pt; margin-left: 20pt; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 33.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 3.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OPTION <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AWARDS <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maxine Gowen, Ph.D. </div>
                </td>

    <td style="width: 3.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 2.08pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.88pt; text-align: left;">18,794 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Athena Countouriotis, M.D. </div>
                </td>

    <td style="width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.88pt; text-align: left;">17,412 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sandip Kapadia</div>
                </td>

    <td style="width: 3.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.88pt; text-align: left;">19,765 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Kassberg</div>
                </td>

    <td style="width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.88pt; text-align: left;">15,895 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derrell Porter, M.D. </div>
                </td>

    <td style="width: 3.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.33pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.88pt; text-align: left;">16,567 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.33pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dolan Sondhi, Ph.D. </div>
                </td>

    <td style="width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.76pt; padding-top: 1.33pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 0pt; margin-left: 5.88pt; text-align: left;">14,446</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3.25pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 3.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 33.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">177<br/>
        </div>

      </div>

    </div>

    <!--End Page 187-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 188-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation Policy
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In April&#160;2024, the Passage Bio Board adopted a written Non-Employee Director
            Compensation Policy (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Bio Director Compensation Policy</span>&#8221;). The Passage Bio Director Compensation Policy covers the elements and amounts of compensation that the Company&#8217;s
            non-employee directors receive, as well as certain process and governance requirements. In particular, the Passage Bio Director Compensation Policy requires the Compensation Committee to annually retain a compensation consultant to conduct an
            analysis of non-employee director compensation for purposes of setting future compensation. The analysis is based on a group of comparable companies (the &#8220;<span style="font-style: italic; font-weight: bold;">Director Compensation Peer Group</span>&#8221;),

            as recommended by the compensation consultant, as well as any resulting recommendations for director compensation.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Director Compensation Policy requires that the Director
            Compensation Peer Group be determined on an annual basis, based on the recommendations of the compensation consultant, and shall be limited to companies with market capitalizations of 0.4 to 2.25 times that of Passage Bio&#8217;s market
            capitalization, except that if Passage Bio&#8217;s market capitalization is less than $250&#160;million, the constituent companies may have a market capitalization of 0.333 to 3 times that of Passage Bio&#8217;s market capitalization.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In accordance with the Passage Bio Director Compensation Policy, Passage Bio&#8217;s
            Compensation Committee retained Pearl Meyer as its compensation consultant for the determination of the Passage Bio&#8217;s 2026 non-employee director compensation program. Pearl Meyer established a peer group of twenty publicly traded companies for
            the purpose of informing non-employee director compensation decisions. The peer group reflected companies with the following characteristics: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Publicly traded and listed on a major exchange; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Primary business operations in the biotechnology or pharmaceutical industry; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Completed an initial public offering prior to January&#160;1, 2024; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Currently in a pre-commercial status; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Market capitalization between $13&#160;million and $113&#160;million; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Total full-time employee count between 20 and 150; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Last twelve months operating expenses between $20&#160;million and $160&#160;million. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following peer group was selected based on the above-mentioned criteria (the
            &#8220;<span style="font-style: italic; font-weight: bold;">2026 Director Compensation Peer Group</span>&#8221;).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the table below, (i) &#8220;Full Time Employees&#8221; was compiled using information from
            each peer group company&#8217;s human capital disclosure included in the applicable peer group company&#8217;s most recently filed Form&#160;10-K as of the date of the analysis and (ii) &#8220;Last Twelve Months Operating Expenses&#8221; was compiled using information from
            each peer group company&#8217;s financial statements included in the applicable peer group company&#8217;s most recently filed Form&#160;10-K or 10-Q, as applicable, as of the date of the analysis. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 76.2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Market Capitalization <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">at 12/31/2025 <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in millions) <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Full Time <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Employees</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Last Twelve <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Months <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Operating <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expenses <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in millions) <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Actinium Pharmaceuticals, Inc.</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">42</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">37</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;"><span style="padding-left: 5pt;">37 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Aligos Therapeutics, Inc.</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">57</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">70</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;"><span style="padding-left: 5pt;">89 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ALX Oncology Holdings Inc. </div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">61</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">80</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;">108 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">AN2 Therapeutics, Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">31</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">22</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;"><span style="padding-left: 5pt;">37 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">BioAlta, Inc. </div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">34</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">61</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;"><span style="padding-left: 5pt;">66 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Celularity Inc.</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">32</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;">123</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;"><span style="padding-left: 5pt;">89 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Century Therapeutics, Inc. </div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">87</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;">140</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;">136 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clene Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">61</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">75</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;"><span style="padding-left: 5pt;">24 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Immunic, Inc. </div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">64</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">91</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;">106 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jasper Therapeutics, Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 33.1pt; text-align: left;">51</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">64</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.05pt; text-align: left;"><span style="padding-left: 5pt;">93 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 76.2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">178<br/>
        </div>

      </div>

    </div>

    <!--End Page 188-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 189-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 76.2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Company</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Market Capitalization <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">at 12/31/2025 <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in millions) <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Full Time <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Employees</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Last Twelve <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Months <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Operating <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expenses <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in millions) <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">KALA BIO, Inc. </div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">13</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">38</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">42 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kezar Life Sciences, Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">46</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">55</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">65 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lantern Pharma Inc. </div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">34</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">24</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">20 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">LeonaBio, Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">30</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">26</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">39 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lisata Therapeutics, Inc. </div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">16</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">26</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">21 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">NextCure, Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">50</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">43</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">62 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PDS Biotechnology Corporation</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">42</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">24</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">32 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Precision BioSciences, Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;">100</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;">108</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">90 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Rallybio Corporation</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">29</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">25</span></div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">39 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Xilio Therapeutics, Inc. </div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.2pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30.6pt; text-align: left;"><span style="padding-left: 5pt;">34</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.88pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.94pt; text-align: left;"><span style="padding-left: 5pt;">64</span></div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.11pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.55pt; text-align: left;">76</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 76.2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Director Compensation Policy also includes the following
            limitations on the amounts of compensation that may be paid to non-employee directors: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Continuing Directors. </span>The total average annual compensation of all continuing
                    non-employee directors for any calendar year shall not exceed the 62.5<sup>th</sup> percentile of Passage Bio&#8217;s Director Compensation Peer Group. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">New Directors.</span> The average annual compensation for any new director&#8217;s total annual cash
                    compensation shall not exceed the 62.5<sup>th</sup> percentile of Passage Bio&#8217;s Director Compensation Peer Group. Each new director&#8217;s initial equity award shall not exceed two times the value of the annual award granted to continuing
                    directors in that year. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Market Capitalization Limitation. </span>If Passage Bio&#8217;s market capitalization is below
                    $100.0&#160;million, measured as of the last day of the fiscal quarter immediately preceding the date on which the board of directors approves annual non-employee director compensation, the total average non-employee director compensation
                    shall not exceed $125,000, excluding any initial equity award granted to new directors as described above. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Compensation for Other Service. </span>Any compensation awarded to non-employee directors for
                    service as an officer, employee or consultant of the Company shall be excluded from the calculation of total average annual director compensation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Equity Awards to be Granted by Value.</span> Equity awards to non-employee directors shall be
                    calculated and granted in terms of a designated value, and not in terms of a fixed number of shares. Value (for the purposes of determining the number of shares that will be subject to an award) means the grant date fair value of the
                    award determined in accordance with FASB ASC Topic 718. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation for 2026
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pearl Meyer recommended, and after review and recommendation by Passage Bio&#8217;s
            Compensation Committee, the Passage Bio Board approved the 2026 non-employee director compensation program based on the analysis of the Peer Group and application of the provisions of the Passage Bio Director Compensation Policy: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Cash Compensation.</span> An annual cash retainer of $40,000 to each non-employee director.
                    Additionally, the Chair of the Passage Bio Board receives an additional annual payment of $30,000; the Chair of the Audit, Compensation and Nominating and Governance Committees receive an additional annual payment of $15,000, $12,000
                    and $8,000 respectively; and the members of the Audit, Compensation and Nominating and Governance Committees receive an additional annual payment of $7,500, $6,000 and $4,000, respectively. Cash compensation is paid quarterly in arrears
                    and is pro-rated for partial quarters served. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Equity Compensation. </span>Each new, non-employee director who joins the Passage Bio Board
                    will receive an initial option grant for the purchase of shares of Passage Bio common stock with a value of $80,000 upon election to the Passage Bio Board. Equity awards for new directors will vest in equal monthly installments for
                    three years after the grant date if the director has served continuously as a member of the Passage Bio </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">179<br/>
        </div>

      </div>

    </div>

    <!--End Page 189-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 190-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">Board through the applicable vesting date. On the date of each annual meeting of
            stockholders, each non-employee director who continues to serve on the Passage Bio Board immediately following such meeting will receive an option grant for the purchase of shares of our common stock with a value of $40,000, or such other
            amount as determined by the board of directors. Annual equity grants for directors will vest on the one-year anniversary after the grant date if the director has served continuously as a member of the Passage Bio Board through the applicable
            vesting date. In addition, equity awards for non-employee directors will vest in full in the event that we are subject to a change in control or upon certain other events. Non-employee directors receive no other form of remuneration,
            perquisites, or benefits, but are reimbursed for their reasonable travel expenses incurred in attending board and committee meetings. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following completion of the Merger, it is expected that the combined company will
            provide compensation to the non-employee directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing, and which will be designed to enable the combined company to attract and retain, on a
            long-term basis, highly qualified non-employee directors. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">180<br/>
        </div>

      </div>

    </div>

    <!--End Page 190-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 191-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tREOD"><!--Anchor--></a>REMIX EXECUTIVE OFFICER AND DIRECTOR
            COMPENSATION </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">2025 Director Compensation Table </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table presents the total compensation for each person who served as
            a non-employee director of the Remix Board during 2025. Peter G. Smith, Ph.D., Remix&#8217;s Chief Executive Officer, did not receive any additional compensation from Remix for his service on the Remix Board in 2025. The compensation received by
            Dr.&#160;Smith as a named executive officer, or NEO, is set forth below in &#8220;<span style="font-style: italic;">Executive Compensation&#8212;2025 Summary Compensation Table.</span>&#8221; </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div>
                </td>

    <td style="width: 4.19pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fees Paid <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">or Earned <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in Cash <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 4.19pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Linda C. Bain<sup>(1)</sup></div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;">$26,250</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$26,250 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Scott Biller, Ph.D.<sup>(2)</sup></div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;">$35,000</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$35,000 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kevin Bitterman, Ph.D.<sup>(3)</sup></div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;">$<span style="padding-left: 22.5pt;">0</span></div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 22.5pt;">0 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Jeff Goater<sup>(4)</sup></div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;">$<span style="padding-left: 22.5pt;">0</span></div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 22.5pt;">0 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maria Koehler, M.D., Ph.D.<sup>(5)</sup></div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;">$35,000</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$35,000 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Matthew R. Patterson<sup>(6)</sup></div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;">$65,000</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$65,000 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Rome, Ph.D.<sup>(7)</sup></div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.12pt; text-align: left;">$<span style="padding-left: 22.5pt;">0</span></div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 22.5pt;">0</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.19pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of December&#160;31, 2025, Ms.&#160;Bain held options to purchase 110,000 shares of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of December&#160;31, 2025, Dr.&#160;Biller held options to purchase 148,435 shares of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of December&#160;31, 2025, Dr.&#160;Bitterman did not hold any options to purchase shares of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of December&#160;31, 2025, Mr.&#160;Goater did not hold any options to purchase shares of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of December&#160;31, 2025, Dr.&#160;Koehler held options to purchase 155,000 shares of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of December&#160;31, 2025, Mr.&#160;Patterson held options to purchase 684,967 shares of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of December&#160;31, 2025, Dr.&#160;Rome did not hold any options to purchase shares of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Narrative to 2025 Director Compensation Table </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix does not currently have a formal non-employee director compensation
            program. No non-employee director received any equity grants in 2025 or other compensation from Remix for 2025.</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Executive Compensation Prior to the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless the context otherwise requires, any reference in this section of this
            proxy statement/prospectus to &#8220;Remix&#8221; refers to Remix and its consolidated subsidiaries prior to the consummation of the Merger and to Remix and its consolidated subsidiaries following the Merger. Remix has opted to comply with the executive
            compensation disclosure rules applicable to &#8220;smaller reporting companies&#8221; as such term is defined in the rules promulgated under the Securities Act, which require compensation disclosure for its principal executive officer and its two other
            most highly compensated executive officers.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This section discusses the material components of the executive compensation
            program offered to the executive officers of Remix who would have been &#8220;named executive officers&#8221; for 2025. Such executive officers consist of the following persons, referred to herein as our NEOs: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Peter G. Smith, Ph.D., Remix&#8217;s Chief Executive Officer; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Heather Wasserman, Ph.D., Remix&#8217;s Chief Operating Officer and Chief Business Officer; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Dominic Reynolds, Ph.D., Remix&#8217;s Chief Science Officer. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each of Remix&#8217;s NEOs will serve the combined company in the same capacities after
            the consummation of the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This discussion may contain forward-looking statements that are based on Remix&#8217;s
            current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that Remix adopts following the consummation of the Merger could vary significantly from Remix&#8217;s historical
            practices and currently planned programs summarized in this discussion. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">181<br/>
        </div>

      </div>

    </div>

    <!--End Page 191-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 192-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">2025 Summary Compensation Table </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth information concerning the compensation of Remix&#8217;s
            named executive officers for the year ended December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 20pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name and Principal Position</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 20pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Salary <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Awards <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(1)</sup></div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Non-Equity <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Incentive <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(2)</sup></div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">All Other <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)<sup>(3)</sup></div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D. <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><span style="font-style: italic;">Chief Executive Officer</span><br/>
                  </div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 20pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2025</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$525,300</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$415,344</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.91pt; text-align: left;">$188,388</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">$13,789</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,142,821 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman, Ph.D. <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><span style="font-style: italic;">Chief Operating Officer and Chief
                      Business Officer</span><br/>
                  </div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 20pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2025</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$459,230</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 27.5pt;">0</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.91pt; text-align: left;">$184,657</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">$<span style="padding-left: 5pt;">9,433</span></div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: top; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">653,320 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D. <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"><span style="font-style: italic;">Chief Science Officer</span><br/>
                  </div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 20pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2025</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$443,700</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 27.5pt;">0</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.91pt; text-align: left;">$139,766</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.32pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 8.41pt; text-align: left;">$12,756</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: top; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">596,222</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 20pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Amounts reflect the full grant-date fair value of stock options granted during 2025 computed in accordance with ASC Topic 718,
                    rather than the amounts paid to or realized by the NEO. We provide information regarding the assumptions used to calculate the value of all stock options made to executive officers in Note&#160;15 to the consolidated financial statements
                    included in this registration statement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts reflect non-equity incentive plan awards paid in 2026 for performance during 2025. Please refer to &#8220;<span style="font-style: italic;">2025 Bonuses</span>&#8221; below for further detail. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The amounts reflect 401(k) employer matching contributions. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">NARRATIVE TO SUMMARY COMPENSATION TABLE </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">2025 Salaries </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The named executive officers receive a base salary to compensate them for
            services rendered to Remix. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. None of the named
            executive officers received a base salary increase in 2025. As of the end of the fiscal year ended December&#160;31, 2025, the base salaries for Dr.&#160;Smith, Dr.&#160;Wasserman and Dr.&#160;Reynolds were $525,300, $459,230 and $443,700 respectively. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">2025 Annual Bonuses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each NEO is eligible to earn an annual incentive bonus for each year the NEO is
            employed by Remix, with the target amount of such bonus opportunity set as a percentage of the NEO&#8217;s annual base salary and based on achievement of certain corporate goals. Actual bonus amounts are determined by the Remix Board in its
            discretion. For the fiscal year ended December&#160;31, 2025, the target annual bonuses for Dr.&#160;Smith, Dr.&#160;Wasserman and Dr.&#160;Reynolds were 45%, 35% and 35% of base salary, respectively. Annual performance bonuses of our NEOs for 2025 were weighted
            100% on corporate objectives that generally related to Remix&#8217;s drug development programs, financing and culture objectives and third party collaboration efforts.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The actual annual cash bonuses awarded to each named executive officer for 2025
            performance are set forth above in the 2025 Summary Compensation Table in the column entitled &#8220;Non-Equity Incentive Plan Compensation.&#8221; </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Equity Compensation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In 2025, Dr.&#160;Smith was granted options to purchase 984,047 shares of Remix Common
            Stock. The options vest as to 492,024 shares in 48 substantially equal monthly installments upon Dr.&#160;Smith&#8217;s completion of each full month of service after December&#160;23, 2023 and as to the remaining 492,023 shares (the &#8220;<span style="font-style: italic; font-weight: bold;">Performance Option</span>&#8221;) in 48&#160;substantially monthly installments upon Dr.&#160;Smith&#8217;s completion of each full month of service after the consummation of predetermined financing criteria, subject in each case, to
            potential accelerated vesting as described in the section titled &#8220;<span style="font-style: italic;">Executive Compensation Arrangements</span>.&#8221; The stock options were granted under the Remix 2019 Plan, the terms of which are described below
            under the subsection titled &#8220;<span style="font-style: italic;">&#8212;Equity Incentive Plan</span>.&#8221; </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">No other NEO was granted equity awards in 2025. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">182<br/>
        </div>

      </div>

    </div>

    <!--End Page 192-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 193-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Other Elements of Compensation </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Retirement Plans </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We currently maintain a 401(k) retirement savings plan for our employees,
            including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. The Internal Revenue Code allows
            eligible employees to defer a portion of their compensation, within prescribed limits, through elective contributions to the 401(k) plan. Currently, we match contributions made by participants in the 401(k) plan up to a specified percentage of
            the employee contributions, and these matching contributions are fully vested as of the date on which the contribution is made. We believe that providing a vehicle for tax-deferred retirement savings through our 401(k) plan, and making fully
            vested matching contributions, adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employee Benefits and Perquisites and
            Other Personal Benefits </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Health/Welfare Plans<span style="font-style: normal;">. All
              of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans, including: </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">medical, dental and vision benefits; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a health savings account (HSA); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">short-term and long-term disability insurance; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">life and accidental death and dismemberment insurance. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We believe the benefits described above are necessary and appropriate to provide
            a competitive compensation package to our named executive officers. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We did not provide any perquisites or special personal benefits to our named
            executive officers in fiscal year 2025, but our compensation committee may from time to time approve them in the future when our compensation committee determines that such perquisites are necessary or advisable to fairly compensate or
            incentivize our employees. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">No Tax Gross-Ups </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We do not make gross-up payments to cover our named executive officers&#8217; personal
            income taxes that may pertain to any of the compensation or perquisites paid or provided by our company. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">183<br/>
        </div>

      </div>

    </div>

    <!--End Page 193-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 194-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Outstanding Equity Awards at 2025 Fiscal Year-End </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table summarizes the number of shares of Remix Common Stock
            underlying outstanding equity incentive plan awards for each named executive officer as of December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 55.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 252.84pt;" colspan="13">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="13" style="width: 252.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option Awards </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name</div>
                </td>

    <td style="width: 3.91pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Vesting <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Commencement <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date</div>
                </td>

    <td style="width: 3.91pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options (#) <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercisable</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options (#) <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercisable</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Equity Incentive <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Plan Awards: <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Underlying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unexercised <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unearned Options <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Option <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Expiration <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Date </div>
                </td>

  </tr>

  <tr>

    <td rowspan="6" style="width: 144pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D. </div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;" rowspan="6">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;">492,023<sup>(1)</sup></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$1.17</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 0.37pt;">2/11/2035</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;">12/23/2023<sup>(2)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 7.5pt;">246,012</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">246,012</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$1.17</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 0.37pt;">2/11/2035 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;"><span style="padding-left: 5pt;">7/26/2024</span><sup>(3)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 7.5pt;">104,476</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><span style="padding-left: 0.37pt;">116,768</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.70</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">7/17/2032 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;"><span style="padding-left: 5pt;">8/28/2023</span><sup>(3)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 7.5pt;">172,078</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><span style="padding-left: 5pt;">49,166</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.70</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">7/17/2032 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;"><span style="padding-left: 5pt;">3/24/2022</span><sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;">1,808,404</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">120,560</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.70</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">7/17/2032 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;"><span style="padding-left: 10pt;">8/7/2021</span><sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;">2,460,500</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.56</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">8/6/2031 </span></div>
                </td>

  </tr>

  <tr>

    <td rowspan="3" style="width: 144pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman, Ph.D. </div>
                </td>

    <td style="width: 3.91pt;" rowspan="3">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;">12/22/2023<sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 7.5pt;">168,250</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">168,250</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$1.02</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">4/8/2034 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;"><span style="padding-left: 5pt;">3/24/2022</span><sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 7.5pt;">501,978</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><span style="padding-left: 5pt;">33,465</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.70</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">7/17/2032 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;"><span style="padding-left: 5pt;">8/24/2020</span><sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 7.5pt;">847,330</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.56</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">3/8/2031 </span></div>
                </td>

  </tr>

  <tr>

    <td rowspan="3" style="width: 144pt; height: 12.75pt; padding-top: 1.01pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D. </div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;" rowspan="3">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;">&#8203;<span style="padding-left: 5pt;">1/22/2024</span><sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;">&#8203;<span style="padding-left: 7.5pt;">262,726</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8203;285,573</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$1.02</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">4/8/2034 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;">&#8203;<span style="padding-left: 5pt;">3/24/2022</span><sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;">&#8203;<span style="padding-left: 7.5pt;">178,421</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;">&#8203;<span style="padding-left: 5.37pt;">11,895</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.70</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; height: 12.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">7/17/2032 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.52pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.86pt; text-align: left;">&#8203;<span style="padding-left: 5pt;">9/16/2020</span><sup>(4)</sup></div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.62pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.81pt; text-align: left;"><span style="padding-left: 7.5pt;">263,234</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.67pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.88pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.19pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 28.74pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.12pt; text-align: left;">$0.56</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.56pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">3/8/2031</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 62.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 28.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.9pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Option vests in 48 equal monthly installments upon Dr.&#160;Smith&#8217;s completion of each full month of service after the consummation of
                    predetermined financing criteria, which will be met by the Merger, subject to potential accelerated vesting as described in the section titled &#8220;<span style="font-style: italic;">Executive Compensation Arrangements</span>.&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Option vests in 48 equal monthly installments following the vesting commencement date, subject to potential accelerated vesting
                    as described in the section titled &#8220;<span style="font-style: italic;">Executive Compensation Arrangements</span>.&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Option vests in 36 equal monthly installments following the vesting commencement date, subject to potential accelerated vesting
                    as described in the section titled &#8220;<span style="font-style: italic;">Executive Compensation Arrangements</span>.&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Option vested as to 25% on the first anniversary of the vesting commencement date and as to the remainder in 36 equal monthly
                    installments thereafter, subject to potential accelerated vesting as described in the section titled &#8220;<span style="font-style: italic;">Executive Compensation Arrangements</span>.&#8221; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Executive Compensation Arrangements </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In August&#160;2019, Remix entered into an offer letter with Dr.&#160;Smith for his prior
            position as Remix&#8217;s President and Chief Scientific Officer, which was subsequently amended by the Remix Board (as amended, the &#8220;<span style="font-style: italic; font-weight: bold;">Smith Agreement</span>&#8221;). While Dr.&#160;Smith now serves as Remix&#8217;s
            Chief Executive Officer, the terms of the Smith Agreement continue to govern his employment. Pursuant to the Smith Agreement, Dr.&#160;Smith is entitled to (i) an initial annual base salary of $375,000, which has been increased to $543,700 and (ii)
            an initial annual performance bonus targeted at 30% of his annual base salary, which has been increased to 45% of his annual base salary. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon a termination of Dr.&#160;Smith&#8217;s employment by the Company without &#8220;cause,&#8221; his
            resignation for &#8220;good reason&#8221; or the occurrence of a &#8220;change in control&#8221; (each as defined in the Smith Agreement), Dr.&#160;Smith is entitled to receive (a) 12 months of base salary continuation payments following his separation and (b) payment of
            Remix&#8217;s portion of his monthly premium under COBRA for up to 12 months following his separation. Receipt of severance is conditioned upon Dr.&#160;Smith&#8217;s execution (and non-revocation) of a general release of claims. Dr.&#160;Smith is subject to
            non-competition and non-solicitation restrictions during the term of his employment and for one year thereafter, subject to applicable laws. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">With respect to Dr.&#160;Smith&#8217;s option grants other than the Performance Option, if
            he is terminated without &#8220;cause&#8221; or he resigns for &#8220;good reason,&#8221; in each case, within 12 months following a &#8220;change in control&#8221; (each as defined in the Remix 2019 Plan or the applicable stock option agreement), the unvested options will become
            immediately vested and exercisable upon such qualifying termination. The Merger will not constitute a change in control for purposes of the stock options. The Performance Option is subject to accelerated vesting upon the earliest to occur of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">184<br/>
        </div>

      </div>

    </div>

    <!--End Page 194-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 195-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">(i) a deemed liquidation event that results in an implied enterprise value of
            at least a predetermined amount, (ii) the closing of a firm commitment underwritten public offering of shares of Remix Capital Stock with at least a predetermined share price or (iii) the discretion of the Remix Board. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Heather Wasserman, Ph.D. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In August&#160;2020, Remix entered into an offer letter with Dr.&#160;Wasserman pursuant to
            which she serves as Remix&#8217;s Chief Operating Officer and Chief Business Officer (as amended, the &#8220;<span style="font-style: italic; font-weight: bold;">Wasserman Agreement</span>&#8221;). The Wasserman Agreement provides that Dr.&#160;Wasserman is entitled
            to (i) an initial annual base salary of $350,000, which has been increased to $459,230 and (ii) an initial annual performance bonus targeted at 35% of her annual base salary. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon a termination of Dr.&#160;Wasserman&#8217;s employment by the Company without &#8220;cause&#8221;
            or her resignation for &#8220;good reason&#8221; (each as defined in the Wasserman Agreement), Dr.&#160;Wasserman is entitled to receive (a) 9 months of base salary continuation payments following her separation and (b) payment of Remix&#8217;s portion of her monthly
            premium under COBRA for up to 9 months following her separation. Receipt of severance is conditioned upon Dr.&#160;Wasserman&#8217;s execution (and non-revocation) of a general release of claims. Dr.&#160;Wasserman is subject to non-competition and
            non-solicitation restrictions during the term of her employment and for one year thereafter, subject to applicable laws. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the Wasserman Agreement and the option award agreements governing
            Dr.&#160;Wasserman&#8217;s option grants provide that upon a termination without &#8220;cause&#8221; or Dr.&#160;Wasserman&#8217;s resignation for &#8220;good reason,&#8221; in each case, within 12 months following a &#8220;change in control&#8221; (each as defined in the Remix 2019 Plan or the
            applicable stock option agreement), the unvested options will become immediately vested and exercisable upon such qualifying termination. The Merger will not constitute a change in control for purposes of the stock options. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2019, Remix entered into an offer letter with Dr.&#160;Reynolds for his prior
            position as Remix&#8217;s Vice President, which was subsequently amended by the Remix Board in connection with his promotion to Chief Science Officer (as amended, the &#8220;<span style="font-style: italic; font-weight: bold;">Reynolds Agreement</span>&#8221;).
            Pursuant to the Reynolds Agreement, Dr.&#160;Reynolds is entitled to (i) an initial annual base salary of $285,000, which has been increased to $443,700 and (ii) an initial annual performance bonus targeted at 30% of his annual base salary, which
            has been increased to 35% of his annual base salary. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon a termination of Dr.&#160;Reynolds&#8217; employment by the Company without &#8220;cause&#8221; or
            his resignation for &#8220;good reason&#8221; (each as defined in substantially the same manner as in the Wasserman Agreement), Dr.&#160;Reynolds is entitled to receive (a) 9 months of base salary continuation payments following his separation and (b) payment
            of Remix&#8217;s portion of his monthly premium under COBRA for up to 9 months following his separation. Receipt of severance is conditioned upon Dr.&#160;Reynolds&#8217; execution (and non-revocation) of a general release of claims. Dr.&#160;Reynolds is subject to
            non-competition and non-solicitation restrictions during the term of his employment and for one year thereafter, subject to applicable laws. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the option award agreements governing Dr.&#160;Reynolds&#8217; option grants
            provide that upon a termination without &#8220;cause&#8221; or Dr.&#160;Reynolds&#8217; resignation for &#8220;good reason,&#8221; in each case, within 12 months following a &#8220;change in control&#8221; (each as defined in the Remix 2019 Plan or the applicable stock option agreement),
            the unvested options will become immediately vested and exercisable upon such qualifying termination. The Merger will not constitute a change in control for purposes of the stock options. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following the closing of the Merger, it is expected that the combined company may
            enter into new employment agreements with Dr.&#160;Smith, Dr.&#160;Wasserman and Dr.&#160;Reynolds, the terms of which have not yet been determined. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Equity Incentive Plans </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix 2019 Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Remix 2019 Plan was initially adopted by the Remix Board, and subsequently
            approved by Remix&#8217;s stockholders, on July&#160;26, 2019.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Authorized Shares<span style="font-style: normal;">. Under
              the Remix 2019 Plan, Remix has reserved for issuance an aggregate of 23,696,650 shares of Remix Common Stock, which number is subject to adjustment in the event of a reorganization, stock split, reverse stock split, stock dividend,
              recapitalization, reclassification or other similar change in capitalization or event. The shares of Remix Common Stock underlying any awards granted under the Remix 2019 Plan that are forfeited, </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">185<br/>
        </div>

      </div>

    </div>

    <!--End Page 195-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 196-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_113-compensation_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">cancelled, repurchased by Remix, satisfied without the issuance of common
            stock or otherwise terminated (other than by exercise) and shares that are withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding are currently added to the shares of Remix Common Stock
            available for issuance under the Remix 2019 Plan.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Eligibility and Administration<span style="font-style: normal;">. Employees, officers, directors and consultants to Remix, its parent and its subsidiaries are eligible to receive awards under the Remix 2019 Plan. Subject to the express terms and conditions of the Remix 2019 Plan, the plan
              administrator has the authority to make all determinations and interpretations under the plan, prescribe all forms of award agreements for use with the plan, and adopt, amend, and repeal rules, guidance, and practices for the administration
              of the Remix 2019 Plan. The Remix Board administers the Remix 2019 Plan and may delegate authority and functions to one or more committees of the Remix Board to administer the Remix 2019 Plan. The plan administrator also sets the terms and
              conditions of all awards under the Remix 2019 Plan, including any vesting and vesting acceleration conditions, subject to the conditions and limitations in the Remix 2019 Plan.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Awards<span style="font-style: normal;">. The Remix 2019 Plan
              provides for the grant of options, restricted stock units and restricted stock awards, however, only options are currently outstanding. Options provide for the future acquisition of shares of Remix Common Stock at an exercise price determined
              by the Remix Board at the date of grant.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Sale Events<span style="font-style: normal;">. The Remix 2019
              Plan provides that if Remix is a party to a merger or consolidation, or in the event of a sale of all or substantially all of Remix&#8217;s stock or assets, all shares acquired under the Remix 2019 Plan and all outstanding awards will be treated in
              the manner described in the definitive transaction agreement (or in a manner determined by the Remix Board if there is no definitive agreement), which treatment may include the continuation, assumption or substitution of awards, the
              cancellation of awards in exchange for cash consideration, or if no cash consideration is provided, the opportunity to exercise any outstanding options prior to the consummation of the transaction, or the acceleration of any vesting and
              exercisability provisions.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Adjustments<span style="font-style: normal;">. In the event
              of certain capitalization events (including a stock split, a stock dividend, a reverse split or a reclassification), proportionate adjustments shall automatically be made, as applicable, to (i) the number and kind of shares of Remix Common
              Stock available for issuance under the Remix 2019 Plan, (ii) the number and kind of shares of Remix Common Stock covered by each outstanding award, (iii) the exercise price under each outstanding option and the purchase price applicable to
              any unexercised stock purchase right and (iv) any repurchase price that applies to shares granted under the Remix 2019 Plan. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Transferability<span style="font-style: normal;">. Awards
              under the Remix 2019 Plan are transferable by participants only by (i) a beneficiary designation, (ii) a will, (iii) the laws of descent and distribution or (iv) other than with respect to incentive stock options, to the extent permitted by
              Rule 701 of the Securities Act if the Remix Board provides.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Amendment and Termination.<span style="font-style: normal;">
              The Remix Board may amend, suspend or terminate the Remix 2019 Plan at any time, subject to stockholder approval where required by applicable law. The Remix Board may also amend or cancel any outstanding award, provided that no amendment to
              an award may adversely affect a participant&#8217;s rights without his or her consent. The Remix Board is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options or effect the repricing of such
              awards through cancellation and re-grants.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025, options to purchase up to 16,928,609 shares of Remix
            Common Stock were outstanding under the Remix 2019 Plan. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">186<br/>
        </div>

      </div>

    </div>

    <!--End Page 196-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 197-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_114-prop1_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tMAT"><!--Anchor--></a>MATTERS BEING SUBMITTED TO A VOTE OF PASSAGE
            BIO STOCKHOLDERS</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;"><a id="tPROP1"><!--Anchor--></a>PROPOSAL NO. 1&#8212;THE NASDAQ STOCK ISSUANCE
            PROPOSAL </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Passage Bio special meeting, Passage Bio stockholders will be asked to
            approve the issuance of shares of Passage Bio Common Stock to (i) the securityholders of Remix, pursuant to the terms of the Merger Agreement, and (ii) certain investors in the Concurrent Financing, pursuant to the terms of the subscription
            agreement, which will (a)&#160;represent more than 20% of the shares of Passage Bio Common Stock outstanding immediately prior to the Merger and (b) result in the change of control of Passage Bio, pursuant to Nasdaq Listing Rules 5635(a) and
            5635(b), respectively.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Merger Exchange Ratio and Concurrent Financing Exchange Ratio formulas
            in the Merger Agreement, immediately after the Closing, on a pro forma basis and based upon the number of shares of Passage Bio Common Stock expected to be issued in connection with the Merger, pre-Merger equityholders of Remix (other than
            investors in the Concurrent Financing) are expected to own approximately 65% of the combined company, pre-Merger equityholders of Passage Bio are expected to own approximately 6% of the combined company and the investors in the Concurrent
            Financing are expected to own approximately 29% of the combined company (assuming proceeds from the Concurrent Financing of $100.0&#160;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to
            certain assumptions, including (i) a valuation for Passage Bio of approximately $20.0 million (assuming Passage Bio Net Cash of $5.0 million as of the Closing), (ii) a fixed valuation for Remix of $226.0&#160;million, and (iii) the relative
            capitalization of Passage Bio and Remix. The percentage of the combined company that each party&#8217;s equityholders will own following the Closing is subject to certain adjustments (as described in more detail in the section titled &#8220;<span style="font-style: italic;">The Merger Agreement&#8212;Merger Consideration and Merger Exchange Ratio</span>&#8221;), including the amount of the final Passage Bio Net Cash at the Closing.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The terms of, reasons for and other aspects of the Merger Agreement, the Merger
            and the issuance of Passage Bio Common Stock in the Merger are described in detail in the other sections in this proxy statement/prospectus. A copy of the Merger Agreement is attached as <span style="text-decoration: underline;">Annex&#160;A</span> to this proxy statement/prospectus. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Reason for the Proposal </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to
            obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of
            shares of common stock then outstanding. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), Passage Bio must obtain the approval of Passage Bio stockholders for the issuance of these shares of common stock in the
            Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to
            obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. Nasdaq has determined that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to
            ensure compliance with Nasdaq Listing Rule&#160;5635(b), Passage Bio must obtain the approval of Passage Bio stockholders of the change of control of Passage Bio resulting from the Merger. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Required Vote </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The affirmative approval of a majority of the votes cast on the proposal by the
            holders of Passage Bio Common Stock entitled to vote at the Passage Bio special meeting, assuming a quorum is present, is required to approve the Nasdaq Stock Issuance Proposal. Abstentions and broker non-votes (if any) will have no effect on
            the outcome of the vote on the Nasdaq Stock Issuance Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal
            (or the waiver thereof in accordance with the terms of the Merger Agreement). Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock
            Issuance Proposal will not be effected. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Concurrent Financing
            cannot be consummated without the approval of the Nasdaq Stock Issuance Proposal (or the waiver thereof).</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">187<br/>
        </div>

      </div>

    </div>

    <!--End Page 197-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 198-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_114-prop1_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Certain of Passage Bio&#8217;s stockholders have agreed to vote any shares of
            Passage Bio Common Stock owned by them in favor of the Contemplated Transactions including: (a) the Nasdaq Stock Issuance Proposal, (b) the Reverse Stock Split Proposal, (c) the Charter Proposal, and (d) the other actions contemplated by the
            Merger Agreement, against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and against any alternative acquisition proposals. See the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Support Agreements</span>&#8221; for more information.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the
            accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the approval of the Nasdaq Stock Issuance Proposal. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE NASDAQ STOCK ISSUANCE PROPOSAL</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">188<br/>
        </div>

      </div>

    </div>

    <!--End Page 198-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 199-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_115-prop2_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPROP2"><!--Anchor--></a>PROPOSAL NO. 2&#8212;THE REVERSE STOCK SPLIT
            PROPOSAL </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Passage Bio special meeting, Passage Bio stockholders will be asked to
            approve an amendment to Passage Bio&#8217;s amended and restated certificate of incorporation that will implement a reverse stock split of the issued and outstanding shares of Passage Bio Common Stock at a ratio in the range between 1-for-&#8195;&#8195; to
            1-for-&#8195;&#8195; inclusive, with the final ratio to be mutually agreed to by Passage Bio and Remix, for the purposes of maintaining compliance with Nasdaq listing standards or for the combined company to meet the initial listing standards of Nasdaq or
            otherwise if deemed advisable by Remix. Upon the effectiveness of such amendment to Passage Bio&#8217;s amended and restated certificate of incorporation to effect the reverse stock split (the &#8220;<span style="font-style: italic; font-weight: bold;">reverse

              stock split effective time</span>&#8221;), the issued and outstanding shares of Passage Bio Common Stock immediately prior to the reverse stock split effective time will be reclassified into a smaller number of shares such that a Passage Bio
            stockholder will own a ratio ranging from one new share of Passage Bio Common Stock for every &#8195;&#8195;&#8195; to &#8195;&#8195; shares of issued common stock held by such stockholder immediately prior to the reverse stock split effective time, as specified. Based upon
            the reverse stock split ratio selected by Passage Bio and Remix, proportionate adjustments will be made to the per share exercise price, and/or the number of shares issuable upon the exercise or vesting of all then outstanding Passage Bio
            Options, which will result in a proportional decrease in the number of shares of Passage Bio Common Stock reserved for issuance upon exercise or vesting of such stock options, and a proportional increase in the exercise price of all such stock
            options.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed form of certificate of amendment to Passage Bio&#8217;s amended and
            restated certificate of incorporation, a copy of which is attached as <span style="text-decoration: underline;">Annex&#160;I</span> to this proxy statement/prospectus, will affect the reverse stock split but <span style="font-style: italic; font-weight: bold;">will not </span>change the
            number of authorized shares of Passage Bio Common Stock, or the par value of Passage Bio Common Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Board may determine to effect the reverse stock split, if it is
            approved by the stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the Nasdaq Stock Issuance Proposal. In addition, notwithstanding approval of this proposal by Passage Bio stockholders, the
            Passage Bio Board may, in its sole discretion, abandon the proposed amendment and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the reverse stock split, as permitted under
            Section&#160;242(c) of the DGCL. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Reasons for the Proposal </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Board approved the proposal approving the amendment to Passage
            Bio&#8217;s amended and restated certificate of incorporation effecting the reverse stock split for the following reasons: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio Board believes effecting the reverse stock split will result in an increase in the minimum bid price of Passage
                    Bio Common Stock, thereby increasing the ability of the combined company to satisfy the Nasdaq initial listing requirements for the combined company common stock and reducing the risk of a delisting of Passage Bio Common Stock from
                    Nasdaq in the future; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio Board believes that the resulting increase in the number of authorized and unissued shares available for future
                    issuance will facilitate the issuance of shares to the stockholders of Remix pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, and ultimately the consummation of the Merger, and the issuance of shares
                    to the investors in the Concurrent Financing pursuant to the Subscription Agreement; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Bio Board believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the
                    desired results of the reverse stock split. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Requirements for Listing on Nasdaq </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio Common Stock is listed on Nasdaq under the symbol &#8220;PASG.&#8221; Remix will
            file an initial listing application pursuant to the terms of the Merger Agreement for the combined company with Nasdaq.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">According to the Nasdaq rules, an issuer must, in a case such as this, apply for
            initial inclusion following a transaction whereby the issuer combines with a non-Nasdaq entity, resulting in a change of control of the issuer and potentially allowing the non-Nasdaq entity to obtain a Nasdaq listing. Accordingly, the listing
            standards of Nasdaq </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">189<br/>
        </div>

      </div>

    </div>

    <!--End Page 199-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 200-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_115-prop2_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">will require Passage Bio to have, among other things, a $4.00 per share
            minimum bid price for a certain number of trading days preceding the Closing. Therefore, the reverse stock split may be necessary in order to consummate the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, it is a condition to the Closing that the shares of Passage Bio
            Common Stock to be issued in the Merger pursuant to the Merger Agreement having been approved for listing on Nasdaq.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">One of the effects of the reverse stock split will be to effectively increase the
            proportion of authorized shares which are unissued relative to those which are issued. This could result in Passage Bio&#8217;s management being able to issue more shares without further stockholder approval. The reverse stock split will not affect
            the number of authorized shares of Passage Bio capital stock, which will continue to be authorized pursuant to Passage Bio&#8217;s amended and restated certificate of incorporation. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Potential Increased Investor Interest </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The closing price of the Passage Bio Common Stock on &#8195;&#8195;&#8195;, 2026, as reported on
            Nasdaq, was $&#8195;&#8195;&#8195; per share. An investment in Passage Bio Common Stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced
            stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of
            lower priced stocks. Also, the Passage Bio Board believes that most investment funds are reluctant to invest in lower priced stocks.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There are risks associated with the reverse stock split, including that the
            reverse stock split may not result in an increase in the per share price of Passage Bio Common Stock at the levels expected or at all.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio cannot predict whether the reverse stock split will increase the
            market price for Passage Bio Common Stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market price per share of Passage Bio Common Stock after the reverse stock split will rise in proportion to the reduction in
                    the number of shares of Passage Bio Common Stock outstanding before the reverse stock split; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower
                    priced stocks; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the reverse stock split will result in a per share price that will increase the ability of Passage Bio to attract and retain
                    employees; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for
                    continued listing; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the reverse stock split will or increase trading volume in Passage Bio Common Stock and facilitate future financings by the
                    combined company; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of time for
                    the combined company&#8217;s common stock to be approved for listing by Nasdaq. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The market price of Passage Bio Common Stock will also be based on the
            performance of Passage Bio, and after the Merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of
            Passage Bio Common Stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of Passage Bio may be greater than would occur in the absence of a reverse stock split. Furthermore, the
            liquidity of Passage Bio Common Stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Principal Effects of the Reverse Stock Split </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The reverse stock split will be realized simultaneously for all shares of Passage
            Bio Common Stock and Passage Bio Options outstanding immediately prior to the reverse stock split effective time. The reverse stock split will affect all holders of shares of Passage Bio Common Stock outstanding immediately prior to the reverse
            stock split effective </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">190<br/>
        </div>

      </div>

    </div>

    <!--End Page 200-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 201-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_115-prop2_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">time uniformly and each such stockholder will hold the same percentage of
            Passage Bio Common Stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for immaterial adjustments that may result from the treatment of fractional shares
            as described below. The reverse stock split will not change the par value of Passage Bio Common Stock or preferred stock and will not reduce the number of authorized shares of Passage Bio Common Stock or preferred stock. Passage Bio Common
            Stock issued pursuant to the reverse stock split will remain fully paid and nonassessable. The reverse stock split will not affect Passage Bio continuing to be subject to the periodic reporting requirements of the Exchange Act. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Procedure for Effecting Reverse Stock Split and Exchange of
            Stock Certificates </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Passage Bio stockholders approve the amendment to Passage Bio&#8217;s amended
            and restated certificate of incorporation effecting the reverse stock split, and if the Passage Bio Board still believes that a reverse stock split is in the best interests of Passage Bio and its stockholders, Passage Bio will file the
            certificate of amendment to Passage Bio&#8217;s amended and restated certificate of incorporation with the Secretary of State of the State of Delaware at such time as the Passage Bio Board has determined to be the appropriate reverse stock split
            effective time. The Passage Bio Board may delay effecting the reverse stock split without resoliciting stockholder approval.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Beginning at the reverse stock split effective time, each stock certificate
            representing pre-split shares will be deemed for all corporate purposes to evidence ownership of post-split shares.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Beneficial Owners of Common Stock<span style="font-style: normal;">. Upon the implementation of the reverse stock split, Passage Bio intends to treat shares held by stockholders in &#8220;street name&#8221; (</span>i.e.<span style="font-style: normal;">, through a bank, broker, custodian or other nominee), in
              the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding Passage Bio Common
              Stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder
              holds shares of Passage Bio Common Stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee.</span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Registered Holders of Common Stock in Book-Entry Form<span style="font-style: normal;">. Passage Bio registered holders of common stock hold their shares electronically in book-entry form with Passage Bio transfer agent, Computershare Trust Company, N.A. These stockholders do not hold physical stock
              certificates evidencing their ownership of Passage Bio Common Stock. However, they are provided with a statement reflecting the number of shares of Passage Bio Common Stock registered in their accounts. No action needs to be taken to receive
              post-reverse stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record
              indicating the number of shares of Passage Bio Common Stock held following the reverse stock split. </span></div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Fractional Shares </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">No fractional shares will be issued in connection with the reverse stock split.
            Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre-split shares not evenly divisible by the number of pre-split shares for which each post-split share is to be reclassified,
            will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the certificate
            of amendment to Passage Bio&#8217;s amended and restated certificate of incorporation effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one
            fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefore as described herein.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio stockholders should be aware that, under the escheat laws of the
            various jurisdictions where stockholders reside, where Passage Bio is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be
            paid to the designated agent for each such jurisdiction, unless correspondence has been received by Passage Bio or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders
            otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">191<br/>
        </div>

      </div>

    </div>

    <!--End Page 201-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 202-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_115-prop2_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Potential Anti-Takeover Effect </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Although the increased proportion of unissued authorized shares to issued shares
            could, under certain circumstances, have an anti-takeover effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Passage Bio Board or contemplating a
            tender offer or other transaction for the combination of Passage Bio with another company, the Reverse Stock Split Proposal is not being proposed in response to any effort of which Passage Bio is aware to accumulate shares of Passage Bio Common
            Stock or obtain control of Passage Bio, other than in connection with the Merger and the Concurrent Financing, nor is it part of a plan by management to recommend a similar amendment to the Passage Bio Board and stockholders. Other than the
            proposals being submitted to the Passage Bio stockholders for their consideration at the Passage Bio special meeting, the Passage Bio Board does not currently contemplate recommending the adoption of any other actions that could be construed to
            affect the ability of third parties to take over or change control of Passage Bio. For more information, please see the section titled &#8220;<span style="font-style: italic;">Risk Factors&#8212;Risks Related to the Combined Company</span>&#8221; of this proxy
            statement/prospectus. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Material U.S. Federal Income Tax Consequences of the Reverse
            Stock Split to U.S. Holders of Passage Bio Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a discussion of the material U.S. federal income tax
            consequences of the reverse stock split that are applicable to U.S. holders (which, for purposes of this discussion, has the same meaning as in &#8220;<span style="font-style: italic;">Material U.S. Federal Income Tax Consequences of the Passage Bio
              CVRs to holders of </span>Passage Bio<span style="font-style: italic;"> Common Stock</span>&#8221;) of Passage Bio Common Stock. This discussion does not purport to be a complete analysis of all potential tax consequences and is based upon current
            provisions of the Code, existing Treasury regulations, judicial decisions and published rulings and administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or
            change. Any such change or differing interpretation, which may be retroactive, could alter the tax consequences to holders of Passage Bio Common Stock as described in this summary.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This discussion assumes that any cash distributed pursuant to a cash dividend
            will be treated for U.S. federal income tax purposes as separate and distinct from the reverse stock split.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Additionally, this discussion does not address all U.S. federal income tax
            consequences relevant to holders of Passage Bio Common Stock. In addition, it does not address consequences relevant to holders of Passage Bio Common Stock that are subject to particular U.S. or non-U.S. tax rules, including, without
            limitation, to holders of Passage Bio Common Stock that are: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who do not hold their Passage Bio Common Stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">real estate investment trusts; regulated investment companies; tax-exempt organizations or governmental organizations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pass-through entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited
                    liability companies (and investors therein); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to the alternative minimum tax provisions of the Code; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction or other integrated
                    transaction; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons that have a functional currency other than the U.S. dollar; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">traders in securities who elect to apply a mark-to-market method of accounting; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who hold shares of Passage Bio Common Stock that may constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of
                    the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their shares of Passage Bio Common Stock in a transaction subject to the gain rollover provisions of
                    Section&#160;1045 of the Code; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">192<br/>
        </div>

      </div>

    </div>

    <!--End Page 202-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 203-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_115-prop2_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Passage Bio Common Stock
                    being taken into account in an &#8220;applicable financial statement&#8221; (as defined in the Code); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons deemed to sell Passage Bio Common Stock under the constructive sale provisions of the Code; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">persons who acquired their shares of Passage Bio Common Stock pursuant to the exercise of options or otherwise as compensation
                    or through a tax-qualified retirement plan or through the exercise of a warrant or conversion rights under convertible instruments; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expatriates or former citizens or long-term residents of the United States. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Holders of Passage Bio Common Stock subject to particular U.S. or non-U.S. tax
            rules, including those that are described in the preceding paragraph, are urged to consult their own tax advisors regarding the consequences to them of the reverse stock split.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If an entity that is treated as a partnership for U.S. federal income tax
            purposes (or any other pass-through entity) holds Passage Bio stock, the U.S. federal income tax treatment of a partner in the partnership or other pass-through entity will generally depend upon the status of the partner, the activities of the
            partnership or other pass-through entity and certain determinations made at the partner level. If you are a partner of a partnership or other pass-through entity holding Passage Bio Common Stock, you should consult your tax advisors regarding
            the tax consequences of the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the following discussion does not address (a) any tax consequences
            of transactions effectuated before, after or at the same time as the reverse stock split, whether or not they are in connection with the reverse stock split, except as specifically provided below; (b) the tax consequences of the reverse stock
            split under state, local and foreign tax laws; (c)&#160;any U.S. federal non-income tax consequences of the reverse stock split, including estate, gift or other tax consequences; or (d) the Medicare contribution tax on net investment income. No
            ruling from the IRS has been or will be requested in connection with the reverse stock split. Passage Bio stockholders should be aware that the IRS could adopt a position contrary to that set forth in this discussion and which could be
            sustained by a court.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">STOCKHOLDERS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF
            THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING
            JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Tax Consequences of the Reverse Stock
            Split </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed reverse stock split is intended to constitute a &#8220;recapitalization&#8221;
            for U.S. federal income tax purposes pursuant to Section&#160;368(a)(1)(E) of the Code. As a result, a U.S. holder is not expected to recognize gain or loss upon the proposed reverse stock split, except with respect to cash received in lieu of a
            fractional share of Passage Bio Common Stock, as discussed below. A U.S. holder&#8217;s aggregate adjusted tax basis in the shares of Passage Bio Common Stock received pursuant to the proposed reverse stock split should equal the aggregate adjusted
            tax basis of the shares of the Passage Bio Common Stock surrendered (excluding any portion of such basis that is allocated to any fractional share of Passage Bio Common Stock), and such U.S. holder&#8217;s holding period in the shares of Passage Bio
            Common Stock received should include the holding period in the shares of Passage Bio Common Stock surrendered. U.S.&#160;Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of Passage Bio Common
            Stock surrendered to the shares of Passage Bio Common Stock received in a recapitalization pursuant to the proposed reverse stock split. U.S. holders of shares of Passage Bio Common Stock acquired on different dates and at different prices
            should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares. It is possible that the IRS or a court could determine that the issuance of the Passage Bio CVRs (and/or any payments thereon) and
            the proposed reverse stock split constitute a single &#8220;recapitalization&#8221; for U.S. federal income tax purposes with the Passage Bio CVRs constituting taxable &#8220;boot&#8221; received in such recapitalization exchange. In such case, the tax consequences of
            the Passage Bio CVRs and the proposed reverse stock split would differ from those described above, including with respect to the timing and character of income. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Cash in Lieu of Fractional Shares </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A U.S. holder that receives cash in lieu of a fractional share of Passage Bio
            Common Stock pursuant to the proposed reverse stock split should recognize capital gain or loss in an amount equal to the difference between the amount of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">193<br/>
        </div>

      </div>

    </div>

    <!--End Page 203-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 204-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_115-prop2_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">cash received and the U.S. holder&#8217;s tax basis in the shares of Passage Bio
            Common Stock surrendered that is allocated to such fractional share of Passage Bio Common Stock. Such capital gain or loss should be long-term capital gain or loss if the U.S. holder&#8217;s holding period for Passage Bio Common Stock surrendered
            exceeded one&#160;year at the reverse stock split effective time. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Tax Reporting Regarding the Reverse Stock
            Split </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Assuming the reverse stock split qualifies as a recapitalization within the
            meaning of Section&#160;368(a) of the Code, each U.S. Holder who receives shares of Passage Bio Common Stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to
            any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished
            as part of such reorganization. Each U.S. Holder who owned at least five percent (by vote or value) of the total outstanding stock of Passage Bio or who owned securities in Passage Bio with a basis of $1,000,000 or more are required to attach a
            statement to their tax returns for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulations Section&#160;1.368-3(b). Such statement must include the holder&#8217;s tax basis in the U.S.&#160;Holder&#8217;s
            Passage Bio Common Stock and the fair market value of such stock. Each U.S. Holder is urged to consult with its tax advisor to comply with these rules. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Information Regarding Backup Withholding </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Payments of cash made in lieu of a fractional share of Passage Bio Common Stock
            may, under certain circumstances, be subject to information reporting and backup withholding. To avoid backup withholding, each holder of Passage Bio Common Stock that does not otherwise establish an exemption should furnish its taxpayer
            identification number and comply with the applicable certification process. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Backup withholding is not an additional tax. Any amounts withheld will be allowed
            as a credit against the holder&#8217;s U.S.&#160;federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. Holders of Passage Bio Common Stock should consult their tax advisors
            regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Required Vote </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The affirmative vote of the holders of a majority of the voting power of all
            outstanding shares of Passage Bio Common Stock entitled to vote thereon is required to approve the Reverse Stock Split Proposal. Abstentions and broker non-votes will count as votes against the Reverse Stock Split Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is conditioned upon the approval of the Reverse Stock Split Proposal
            (or the waiver thereof in accordance with the terms of the Merger Agreement). If the Merger is not consummated for any reason, the actions contemplated by the Reverse Stock Split Proposal may still be effected if the Reverse Stock Split
            Proposal is approved. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Concurrent Financing cannot be consummated
            without the approval of the Reverse Stock Split Proposal (or the waiver thereof). Passage Bio may still elect to proceed with the reverse stock split if the Reverse Stock Split Proposal is approved by Passage Bio stockholders even if Proposal
            No. 1 is not approved, or even if approved, the Merger is not consummated.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain of Passage Bio&#8217;s stockholders have agreed to vote any shares of common
            stock owned by them in favor of the Contemplated Transactions including (a) the Nasdaq Stock Issuance Proposal, (b) the Reverse Stock Split Proposal, (c)&#160;the Charter Proposal, and (d) the other actions contemplated by the Merger Agreement,
            against approval of any proposal made in opposition to, or in competition with, the Merger Agreement or the consummation of the Merger, and against any alternative acquisition proposals. See the section titled &#8220;<span style="font-style: italic;">Agreements

              Related to the Merger&#8212;Support Agreements</span>&#8221; for more information.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the
            accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the approval of the Reverse Stock Split Proposal. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE REVERSE STOCK SPLIT PROPOSAL</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">194<br/>
        </div>

      </div>

    </div>

    <!--End Page 204-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 205-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_116-prop3_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPROP3"><!--Anchor--></a>PROPOSAL NO. 3&#8212;THE CHARTER PROPOSAL </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Passage Bio special meeting, Passage Bio stockholders will be asked to
            approve, as separate subproposals, the material amendments reflected in the proposed restated certificate of incorporation of Passage Bio, which will become the certificate of incorporation of the combined company upon completion of the Merger
            (the &#8220;<span style="font-style: italic; font-weight: bold;">Proposed Restated Charter</span>&#8221;). The Charter Proposal includes the name change and the other material changes described in Proposal No. 4&#8212;The Governance Proposals, each of which will
            be effective only upon completion of the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The form of the Proposed Restated Charter, a copy of which is attached as <span style="text-decoration: underline;">Annex&#160;J</span>
            to this proxy statement/prospectus, will amend and restate the Passage Bio charter in its entirety. The following descriptions are qualified in their entirety by reference to the full text of the Proposed Restated Charter. See the section
            titled &#8220;<span style="font-style: italic;">Description of Passage Bio Capital Stock</span>&#8221; for a summary of principal terms of the Proposed Restated Charter. All stockholders and other interested parties are encouraged to read the Proposed
            Restated Charter in its entirety for a more complete description of its terms.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a summary of the material differences between the existing
            Passage Bio charter and the Proposed Restated Charter, each of which would be effected by the filing of the Proposed Restated Charter: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would change the corporate name of Passage Bio from &#8220;Passage Bio, Inc.&#8221; to &#8220;Remix Therapeutics,
                    Inc.&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would opt out of a separate class vote under Section&#160;242(b)(2) of the DGCL for changes in the
                    number of shares of common stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would remove the supermajority voting requirement for changes to the number of authorized shares
                    of preferred stock and would instead subject such changes to the voting standard generally applicable to charter amendments under the DGCL. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would provide for a supermajority stockholder voting requirement for adopting, amending or
                    repealing the Bylaws, and eliminate the lower majority voting threshold for certain Board-approved stockholder bylaw amendments. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would change the directors and officers authorized to call special meetings of stockholders to
                    only: the Board, the Chairperson of the Board, the Chief Executive Officer or, in the absence of a Chief Executive Officer, the President.&#8195;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would contain a provision authorizing the combined company to provide indemnification and
                    advancement of expenses to current and former officers, directors, employees and agents.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would designate the federal district courts as the exclusive forum for claims under the Securities
                    Act of 1933, and a provision that deems stockholders who file claims in a court outside of Delaware to have consented to jurisdiction in Delaware. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The Proposed Restated Charter would provide for a supermajority stockholder voting requirement for amending or repealing only
                    certain enumerated provisions of the Proposed Restated Charter, while other provisions would no longer require a supermajority vote to amend in the future. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would also make conforming, clarifying and
            administrative changes, including reorganizing the charter, updating the registered office provisions, expressly stating certain common stock dividend and liquidation rights subject to the rights of any Preferred Stock, expressly stating that
            there will be no cumulative voting and omitting historical provisions relating to the prior reverse stock split. Passage Bio does not expect these other changes to materially affect stockholder rights, and these other changes are not being
            presented as separate subproposals. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Required Vote </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The affirmative vote of the holders of a majority of the voting power of all
            outstanding shares of Passage Bio Common Stock entitled to vote thereon is required to approve the Charter Proposal. Abstentions and broker non-votes will count as votes against the Charter Proposal.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">195<br/>
        </div>

      </div>

    </div>

    <!--End Page 205-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 206-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_116-prop3_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The Merger is conditioned upon the approval of the Charter Proposal (or the
            waiver thereof in accordance with the terms of the Merger Agreement). Notwithstanding the approval of the Charter Amendment Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Charter Amendment Proposal
            will not be effected. The closing of the Concurrent Financing is conditioned upon the satisfaction or waiver of each of the conditions to the Closing as well as certain other conditions. Therefore, the Concurrent Financing cannot be consummated
            without the approval of the Charter Proposal (or the waiver thereof).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the
            accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight: bold;">FOR</span>&#8221; each of the Charter Proposal. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE CHARTER PROPOSAL</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">196<br/>
        </div>

      </div>

    </div>

    <!--End Page 206-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 207-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_117-prop4_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPROP4"><!--Anchor--></a>PROPOSAL NO. 4&#8212;THE GOVERNANCE PROPOSALS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition to the approval of the Proposed Restated Charter as a whole pursuant
            to the Charter Amendment Proposal, Passage Bio&#8217;s stockholders are being asked to separately approve certain material amendments to the Passage Bio certificate of incorporation that will be effected by the Proposed Restated Charter pursuant to
            the eight&#160;governance proposals described below.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is requesting that its stockholders vote upon the Governance
            Proposals on a non-binding advisory basis. Approval of the Governance Proposals is not otherwise required by Delaware law separate and apart from the approval of the Charter Amendment Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Set forth below under Proposals 4A to 4H is a summary of each material amendment,
            as well as the Passage Bio Board&#8217;s reasons for proposing each amendment. These summaries are qualified by reference to the complete text of the Proposed Restated Charter. The Proposed Restated Charter, as will be in effect upon consummation of
            the Business Combination and filing with the Secretary of State of the State of Delaware, is attached to this proxy statement/prospectus as <span style="text-decoration: underline;">Annex&#160;J</span>. All stockholders are encouraged to read the governance proposals in their entirety for
            a more complete description of their terms. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposal No. 4A&#8212;Name Change Amendment </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would change the corporate name of Passage Bio from
            &#8220;Passage Bio, Inc.&#8221; to &#8220;Remix Therapeutics, Inc.&#8221; </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Proposal No. 4B&#8212;Change to Opt Out of Separate Class&#160;Vote
            Requirement of Section&#160;242(b)(2) for Changes to Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would opt out of a separate class vote under
            Section&#160;242(b)(2) of the DGCL for changes in the number of shares of common stock. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposal No. 4C&#8212;Change to Voting Standard to Change the
            Authorized Number of Shares of Preferred Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would remove the supermajority voting requirement
            for changes to the number of authorized shares of preferred stock and would instead subject such changes to the voting standard generally applicable to charter amendments under the DGCL. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposal No. 4D&#8212;Changes to Stockholder Bylaw Amendment Voting
            Standard </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would provide for a supermajority stockholder
            voting requirement for adopting, amending or repealing the Bylaws, and eliminate the lower majority voting threshold for certain Board-approved stockholder bylaw amendments. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposal No. 4E&#8212;Changes to Directors and Officers Authorized to
            Call Special Meetings </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would change the directors and officers authorized
            to call special meetings of stockholders to only: the Board, the Chairperson of the Board, the Chief Executive Officer or, in the absence of a Chief Executive Officer, the President.</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposal No. 4F&#8212;Indemnification Provision </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would contain a provision authorizing the combined
            company to provide indemnification and advancement of expenses to current and former officers, directors, employees and agents.</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposal No. 4G&#8212;Changes to the Exclusive Forum Provisions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would designate the federal district courts as the
            exclusive forum for claims under the Securities Act of 1933, and a provision that deems stockholders who file claims in a court outside of Delaware to have consented to jurisdiction in Delaware. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Proposal No. 4H&#8212;Changes to Charter Amendment Voting Standard </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would provide for a supermajority stockholder
            voting requirement for amending or repealing only certain enumerated provisions of the Proposed Restated Charter, while other provisions would no longer require a supermajority vote to amend in the future. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">197<br/>
        </div>

      </div>

    </div>

    <!--End Page 207-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 208-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_117-prop4_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Other Changes </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would also make conforming, clarifying and
            administrative changes, including reorganizing the charter, updating the registered office provisions, expressly stating certain common stock dividend and liquidation rights subject to the rights of any Preferred Stock, expressly stating that
            there will be no cumulative voting and omitting historical provisions relating to the prior reverse stock split. Passage Bio does not expect these other changes to materially affect stockholder rights, and these other changes are not being
            presented as separate subproposals. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Reasons for the Proposals</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Proposal No. 4A&#8212;Name Change Amendment </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Changing the corporate name from &#8220;Passage Bio, Inc.&#8221; to &#8220;Remix Therapeutics,
            Inc.&#8221; is desirable to clearly identify Remix as the publicly traded entity following the Merger.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Passage Bio stockholders approve the Charter Amendment Proposal and the
            Merger is completed, Passage Bio will file the Proposed Restated Charter with the Secretary of State of the State of Delaware upon the completion of the Merger. Following the name change, the common stock of the combined company is expected to
            trade on Nasdaq under the symbol &#8220;RMTX.&#8221; Following the effective date of the name change, all new stock certificates issued by the Company will use the new name. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Proposal No. 4B&#8212;Change to Opt Out of Separate Class&#160;Vote
            Requirement of Section&#160;242(b)(2) for Changes to Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would provide that, subject to the rights of any
            holders of any outstanding series of Preferred Stock, the number of authorized shares of Common Stock may be increased or decreased, but not below the number of shares then outstanding, by the requisite vote of the stockholders entitled to vote
            thereon, voting as a single class, irrespective of Section&#160;242(b)(2) of the DGCL. The current Passage Bio charter does not contain a corresponding common stock class-vote opt-out provision. The effect of this change is that, to the extent
            permitted by the DGCL, future increases or decreases in the number of authorized shares of Common Stock could be approved without a separate class vote and allow all stockholders to vote upon such matters, which could simplify future
            stockholder votes on these matters. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Proposal No. 4C&#8212;Change to Voting Standard to Change the
            Authorized Number of Shares of Preferred Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the current Passage Bio charter, such an increase or decrease in the
            authorized shares of preferred stock requires the affirmative vote of holders of two-thirds of the voting power of the then-outstanding shares entitled to vote thereon, voting together as a single class, unless two-thirds of the &#8220;Whole Board&#8221;
            (defined in the current Passage Bio charter as the total number of authorized directors including vacancies) has approved the change, in which case approval by a majority of the voting power of the then-outstanding shares entitled to vote
            generally in the election of directors is required. The Proposed Restated Charter would remove this supermajority voting requirement, such that changes in the number of authorized shares of preferred stock would instead be subject to the voting
            standard generally applicable to charter amendments under the DGCL. This change is desirable because it brings the combined company&#8217;s governance framework into conformity with current Delaware law and market practice, thereby simplifying vote
            execution for future changes to the number of authorized shares of preferred stock. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Proposal No. 4D&#8212;Changes to Stockholder Bylaw Amendment Voting
            Standard </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The current Passage Bio charter permits stockholders to adopt, amend or repeal
            the bylaws with the affirmative vote of holders of at least two-thirds of the voting power of the then-outstanding shares entitled to vote generally in the election of directors, voting together as a single class, but if two-thirds of the Whole
            Board has approved a proposed bylaw adoption, amendment or repeal, the current Passage Bio charter requires only approval by a majority of stockholder voting power. The Proposed Restated Charter would require the affirmative vote of holders of
            at least two-thirds of the voting power of all then-outstanding shares of voting stock for any adoption, amendment or repeal of the bylaws, in addition to any other required vote. The effect of this change is to eliminate the lower majority
            voting threshold for Board-approved stockholder bylaw amendments, and require a supermajority voting threshold in all cases. This change is desirable because the supermajority voting provisions are intended to improve the likelihood of
            continued stability in the combined companies policies, and to discourage certain tactics that may be used in proxy fights. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">198<br/>
        </div>

      </div>

    </div>

    <!--End Page 208-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 209-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_117-prop4_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Proposal No. 4E&#8212; Changes to Directors and Officers Authorized
            to Call Special Meetings </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The current Passage Bio charter provides that special meetings of stockholders
            may be called only by the Chairperson of the Board, the Chief Executive Officer, the Lead Independent Director, the President or the Board acting pursuant to a resolution adopted by a majority of the Whole Board, and may not be called by
            stockholders or any other person or persons. The Proposed Restated Charter would provide that, subject to the special rights of holders of one or more series of Preferred Stock, special meetings may be called only by or at the direction of the
            Board, the Chairperson of the Board, the Chief Executive Officer or, in the absence of a Chief Executive Officer, the President, and may not be called by any other person or persons. The effect of this change is to (i) allow the Board to call a
            special meeting with a majority vote, as long as there is a quorum and (ii) remove the ability of the Lead Independent Director to call a special meeting and (iii) provide that the President may call a special meeting only when a Chief
            Executive Officer is not in office. This change is desirable because it aligns the directors and officers authorized to call special meetings with the contemplated governance framework for the combined company. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Proposal No. 4F&#8212;Indemnification Provision </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Proposed Restated Charter would add a provision stating that the corporation
            has the power to provide rights to indemnification and advancement of expenses to its current and former officers, directors, employees and agents and to any person who is or was serving at the request of the corporation as a director, officer,
            employee or agent of another corporation, partnership, joint venture, trust or other enterprise. The current Passage Bio bylaws have an indemnification provision, which, if the Charter Amendment Proposal is approved by stockholders and the
            Merger closes, would be included in the Proposed Restated Charter instead of the combined company&#8217;s bylaws. This change is desirable because it places these provisions in the Proposed Restated Charter, where they cannot be amended without
            stockholder approval under Section&#160;242 of the DGCL, which offers greater protection to officers, directors, employees and agents of the combined company. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Proposal No. 4G&#8212;Changes to the Exclusive Forum Provisions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The current Passage Bio charter provides that, unless Passage Bio consents in
            writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for specified internal corporate claims. The Proposed Restated Charter would revise the exclusive forum provision
            to add a federal forum provision designating the federal district courts of the United States of America as the exclusive forum for complaints asserting causes of action arising under the Securities Act of 1933, as amended. A federal forum
            provision is desirable because it eliminates the ability of plaintiffs to choose state courts for Securities Act claims, ensures corporations receive the benefit of federal procedural protections like the PSLRA, and avoids duplicative and
            inconsistent litigation across state and federal courts. The Proposed Restated Charter would also add a provision that stockholders who file claims in a court outside of Delaware will be deemed to have consented to jurisdiction in Delaware. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Proposal No. 4H&#8212;Changes to Charter Amendment Voting Standard </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The current Passage Bio charter generally requires the affirmative vote of
            holders of at least two-thirds of the voting power of all then-outstanding shares entitled to vote generally in the election of directors, voting together as a single class, to amend or repeal any charter provision; however, if two-thirds of
            the Whole Board has approved the amendment or repeal, the current Passage Bio charter requires only approval by holders of at least a majority of such voting power. The Proposed Restated Charter would instead require the affirmative vote of
            holders of at least two-thirds of the total voting power of all then-outstanding shares entitled to vote thereon, voting together as a single class, to amend, alter, repeal or rescind, or adopt any provision inconsistent with the following
            specified provisions: Part&#160;B of Article&#160;V (preferred stock terms), Article&#160;VI (board of directors), Article&#160;VII (stockholder actions and meetings), Article&#160;VIII (director and officer exculpation), Article&#160;IX (indemnification and advancement of
            expenses), Article&#160;X (forum&#160;selection), and Article&#160;XI (charter amendments). The remaining provisions, Article&#160;I (name), Article&#160;II (registered office), Article&#160;III (purpose), Article&#160;IV (total authorized stock and Part&#160;A of Article&#160;V (common
            stock terms), would no longer require a supermajority vote to amend in the future. The effect of this change is to narrow the set of charter provisions subject to a supermajority stockholder approval standard, while eliminating the lower
            majority voting threshold for Board-approved amendments to the specified provisions. This change would also permit amendments to the common stock, including amendments to reclassify the common stock via a reverse stock split, to be approved
            subject to the voting standard generally applicable to charter amendments under the DGCL. This change is desirable because it strikes a balance between requiring supermajority voting for </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">199<br/>
        </div>

      </div>

    </div>

    <!--End Page 209-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 210-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_117-prop4_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">certain provisions that are most important to stability of the corporation
            while allowing for flexibility to amend other provisions in the charter. It brings the combined company&#8217;s governance framework into conformity with current Delaware law and market practice, thereby simplifying vote execution for future changes
            to the number of shares of common stock. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Required Vote </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The Closing is not conditioned upon the approval of the Governance Proposals.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Approval of the Governance Proposals requires the affirmative approval of a
            majority of the votes cast on the proposal by holders of Passage Bio Common Stock entitled to vote and actually cast thereon at the special meeting of stockholders. Failure to vote by proxy or to vote in person at the special meeting of
            stockholders, an abstention from voting, or a broker non-vote will have no effect on the outcome of the vote on the Governance Proposals.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As discussed above, a vote to approve each of the Governance Proposals is an
            advisory vote, and therefore, is not binding on Passage Bio, Remix or their respective boards of directors. Accordingly, regardless of the outcome of the non-binding advisory vote, Passage Bio and Remix intend that the Proposed Restated
            Charter, in the form attached to this proxy statement as Annex&#160;J will take effect at the Closing of the Business Combinations, assuming approval of the Charter Amendment Proposal (Proposal No. 3). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#8220;FOR&#8221; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE GOVERNANCE PROPOSALS</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">200<br/>
        </div>

      </div>

    </div>

    <!--End Page 210-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 211-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_118-prop5_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPROP5"><!--Anchor--></a>PROPOSAL NO. 5&#8212;THE 2026 EQUITY INCENTIVE
            PLAN PROPOSAL </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are requesting Passage Bio stockholders to consider and approve the Remix
            Therapeutics, Inc. 2026 Equity Incentive Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">2026 Plan</span>&#8221;). The Passage Board has approved the 2026 Plan, subject to shareholder approval and effective upon the Effective Time.
            The 2026 Plan is intended to replace the 2018 EIP, the 2020 EIP and the Remix 2019&#160;Plan (together with the 2018 EIP and 2020 EIP, the &#8220;<span style="font-style: italic; font-weight: bold;">Prior Plans</span>&#8221;). The Remix 2019 Plan, together with
            all outstanding awards thereunder, will be assumed by Passage Bio in the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the 2026 Plan is approved, the number of shares reserved for issuance under
            the 2026 Plan will equal the sum of (i)&#8195;&#8195; shares; (ii) any shares that are subject to awards under the Prior Plans which are forfeited or lapse unexercised and which are not issued under the Prior Plans; and (iii) an annual increase on the
            first day of each calendar year beginning January&#160;1, 2027 and ending on and including January&#160;1, 2036, equal to the lesser of (A)&#8195;&#8195;% of the aggregate number of shares outstanding on the final day of the immediately preceding calendar year and
            (B) such smaller number of shares as is determined by the board of directors of the combined company or the compensation committee of such board. Upon the effective date of the 2026 Plan, no new awards will be granted under the Prior Plans, but
            any awards previously granted under a Prior Plan will remain subject to the terms of the applicable Prior Plan. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If this Proposal No. 5 is not approved by the Passage Bio stockholders, or if the
            consummation of the Merger does not occur for any reason, the 2026 Plan will not become effective, and the Prior Plans will remain in effect. However, we may need to consider alternative compensation structures to achieve the objectives for
            which the Prior Plans were designed. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">2026 Plan </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Background</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The purpose of the 2026 Plan is to enhance our ability to attract, retain and
            motivate persons who make (or are expected to make) important contributions to the combined company by providing these individuals with equity-based compensatory opportunities. Equity awards are intended to motivate high levels of performance
            and align the interests of our directors, employees and consultants with those of our stockholders by giving directors, employees and consultants the perspective of an owner with an equity stake in the combined company and providing a means of
            recognizing their contributions to our success. Our ability to grant equity awards is critical to our ability to be competitive and to attract, retain and motivate the talent we need to best position the combined company for success. The use of
            equity awards as compensation also allows us to conserve cash resources for other important purposes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to approving the 2026 Plan, the Passage Bio Board and Compensation
            Committee considered the equity grant objectives of the combined company and determined that approval of the 2026 Plan would be the most effective tool in achieving our employee retention and incentive goals, and aligning employee interests
            with those of the stockholders, because it provides a direct and straightforward means of incentivizing employees. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A total of &#8195;&#8195; shares will initially be reserved for issuance under the 2026 Plan.
            As of &#8195;&#8195;, 2026, the closing price on Nasdaq per share of Passage Bio Common Stock was $<span style="text-decoration: underline;">&#8195;</span>. Based upon a price per share of $&#8195;&#8194;, the maximum aggregate market value that could potentially be issued under the 2026 Plan as of the Effective
            Time is $&#8195;&#8194;. </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Determination of Adoption of 2026 Plan</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We believe that the adoption of the 2026 Plan is reasonable, appropriate and in
            the best interests of the combined company and its stockholders at this time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Accordingly, the Passage Bio Board recommends that Passage Bio stockholders vote
            for approval of this Proposal&#160;No.&#160; 5. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Summary of the 2026 Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This section summarizes certain principal features of the 2026 Plan, subject to
            shareholder approval and effective upon the Effective Time. The summary is qualified in its entirety by reference to the complete text of the 2026 Plan, which is attached to this proxy statement/prospectus as Annex&#160;K. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">201<br/>
        </div>

      </div>

    </div>

    <!--End Page 211-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 212-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_118-prop5_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Eligibility and Administration</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our employees, consultants and directors, and employees, consultants and
            directors of our subsidiaries will be eligible to receive awards under the 2026 Plan. Immediately following the Merger, the combined company is expected to have &#8195;&#8195; employees,&#8195;&#8195; non-employee directors and &#8195;&#8195; consultants who will be eligible for
            awards under the 2026&#160;Plan. The 2026 Plan will generally be administered by the board of directors of the combined company with respect to awards to non-employee directors and by the compensation committee of such board with respect to other
            participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed under
            Section&#160;16 of the Exchange Act, and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the
            administration of, the 2026 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2026 Plan, including any vesting and vesting acceleration conditions. </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Limitation on Awards and Shares Available for Awards</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the 2026 Plan is approved and the Merger is completed, the number of shares
            reserved for issuance under the 2026&#160;Plan will equal the sum of (i)&#8195;&#8195; shares; (ii) any shares that are subject to awards under the Prior Plans which are forfeited or lapse unexercised and which are not issued under the Prior Plans; and (iii) an
            annual increase on the first day of each calendar year beginning January&#160;1, 2027 and ending on and including January&#160;1, 2036, equal to the lesser of (A)&#160;<span style="text-decoration: underline;">&#8195;&#8195;</span>% of the aggregate number of shares outstanding on the final day of the
            immediately preceding calendar year and (B) such smaller number of shares as is determined by the board of directors of the combined company or the compensation committee of such board. No more than &#8195;&#8195; shares may be issued under the 2026 Plan
            upon the exercise of incentive stock options. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of &#8195;&#8195;, 2026, there were (a)&#8195;&#8195; shares of Passage Bio Common Stock subject to
            awards outstanding under the 2018 EIP, (b)&#8195;&#8195; shares of Passage Bio Common Stock subject to awards outstanding under the 2020 EIP and (c)&#8195;&#8195; shares of Remix Common Stock subject to awards outstanding under the Remix 2019 Plan. Under the terms of
            the Merger Agreement, at the Effective Time, each Remix stock option that is outstanding and unexercised immediately prior to the Effective Time under the Remix 2019 Plan will automatically be converted into an option to purchase shares of
            Passage Bio Common Stock based on the Merger Exchange Ratio. Shares issued under the 2026 Plan may be authorized but unissued shares, including shares authorized but unissued under the Prior Plans, shares purchased on the open market, or
            treasury shares. Upon the effective date of the 2026 Plan, no new awards will be granted under the Prior Plans, but any awards previously granted under a Prior Plan will remain subject to the terms of the Prior Plan. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If an award under the Prior Plans or the 2026 Plan expires, lapses or is
            terminated, exchanged for or settled for cash, surrendered, repurchased, cancelled without having been fully exercised or forfeited, any shares subject to such award may, to the extent of such forfeiture, expiration or cash settlement, be used
            again for new grants under the 2026 Plan. Further, shares delivered to us to satisfy the applicable exercise or purchase price of an award under the Prior Plans or the 2026 Plan and/or to satisfy any applicable tax withholding obligations
            (including shares retained by us from the award under the Prior Plans or the 2026 Plan being exercised or purchased and/or creating the tax obligation) will become or again be available for grants of awards under the 2026 Plan. The payment of
            dividend equivalents in cash in conjunction with any awards under the Prior Plans or the 2026 Plan will not reduce the shares available for grant under the 2026 Plan. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Awards granted under the 2026 Plan upon the assumption of, or in substitution
            for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under the 2026 Plan. The 2026 Plan
            provides that the sum of any cash compensation and the aggregate grant date fair value (determined as of the date of the grant under ASC Topic 718, or any successor thereto) of all awards granted to a non-employee director as compensation for
            services as a non-employee director during any fiscal year may not exceed the amount equal to $&#8195;&#8194;, increased to $&#8195;&#8195; in the fiscal year in which the effective date of the 2026 Plan occurs or in the fiscal year of a non-employee director&#8217;s
            initial year of service as a non-employee director (in each case, excluding any compensation awarded prior to the effective date of the 2026 Plan). </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">202<br/>
        </div>

      </div>

    </div>

    <!--End Page 212-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 213-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_118-prop5_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Awards</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2026 Plan provides for the grant of options, including incentive stock
            options (&#8220;<span style="font-style: italic; font-weight: bold;">ISOs</span>&#8221;) and nonqualified stock options (&#8220;<span style="font-style: italic; font-weight: bold;">NSOs</span>&#8221;), restricted stock, dividend equivalents, restricted stock units (&#8220;<span style="font-style: italic; font-weight: bold;">RSUs</span>&#8221;), performance shares, other incentive awards, stock appreciation rights (&#8220;<span style="font-style: italic; font-weight: bold;">SARs</span>&#8221;) and cash awards. No determination has
            been made as to the types or amounts of awards that will be granted to specific individuals pursuant to the 2026 Plan. Certain awards under the 2026 Plan may constitute or provide for a deferral of compensation, subject to Section&#160;409A of the
            Code, which may impose additional requirements on the terms and conditions of such awards. All awards under the 2026&#160;Plan will be set forth in award agreements, which will detail all terms and conditions of the awards, including any applicable
            vesting and payment terms and post-termination exercise limitations. Awards other than cash awards generally will be settled in shares of our common stock, but the plan administrator may provide for cash settlement of any award. A brief
            description of each award type follows. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;"><span style="text-decoration: underline;">Options</span></span>. Options provide for the purchase of shares of our common stock in the
                    future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the
                    Code are satisfied. Unless determined otherwise by the plan administrator, the exercise price of an option may not be less than 100% of the fair market value of the underlying share on the date of grant, except with respect to certain
                    substitute options granted in connection with a corporate transaction. In the case of ISOs granted to certain significant stockholders, however, the exercise price of such ISOs may not be less than 110% of the fair market value of the
                    underlying shares on the date of grant. The term of an option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined by the plan administrator may
                    apply to options and may include continued service, performance and/or other conditions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;"><span style="text-decoration: underline;">SARs</span></span>. SARs entitle their holder, upon exercise, to receive from us an amount
                    equal to the appreciation of the shares subject to the award between the grant date and the exercise date. Unless determined otherwise by the plan administrator, the exercise price of a SAR may not be less than 100% of the fair market
                    value of the underlying share on the date of grant, except with respect to certain substitute SARs granted in connection with a corporate transaction. The term of a SAR may not be longer than ten years. Vesting conditions determined by
                    the plan administrator may apply to SARs and may include continued service, performance and/or other conditions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;"><span style="text-decoration: underline;">Restricted Stock and RSUs</span></span>. Restricted stock is an award of nontransferable
                    shares of our common stock that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which may
                    also remain forfeitable unless and until specified conditions are met, and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares.
                    Delivery of the shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be
                    based on continuing service, the attainment of performance goals and/or such other conditions as the plan administrator may determine. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;"><span style="text-decoration: underline;">Other Stock or Cash Based Awards</span></span>. Other stock or cash based awards may be awards
                    of cash, fully vested shares and other awards valued wholly or partially by referring to, or otherwise based on, shares. Other stock or cash based awards may be granted to participants and may also be available as a payment form in the
                    settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise payable to any individual who is eligible to receive awards. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;"><span style="text-decoration: underline;">Dividend Equivalents</span></span>. Dividend equivalents represent the right to receive the
                    equivalent value of dividends paid on shares and may be granted alone or in tandem with awards other than options or SARs. Unless otherwise determined by the plan administrator, dividend equivalents with respect to an award shall only
                    be paid to a participant to the extent that the vesting conditions are subsequently satisfied. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;"><span style="text-decoration: underline;">Performance Awards</span></span>. Performance awards include any of the foregoing awards that
                    are granted subject to vesting and/or payment based on the attainment of specified performance goals or other criteria the plan administrator may determine, which may or may not be objectively determinable. Performance criteria upon
                    which performance goals are established by the plan administrator may include but are not limited to: net earnings (either before or after one&#160;or more of the following: (a) interest, (b) taxes, (c) depreciation, </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">203<br/>
        </div>

      </div>

    </div>

    <!--End Page 213-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 214-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_118-prop5_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">(d) amortization and (e) non-cash equity-based compensation expense); gross or
            net sales or revenue; net income (either before or after taxes); adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operating profit or economic profit); profit return ratios or operating
            margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including, but not limited to, operating cash flow and free cash flow or cash flow return on capital);
            return on assets; return on capital or invested capital; return on shareholders&#8217; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share;
            adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating
            to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer
            service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring
            liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any
            of which may be measured in absolute terms or as compared to any incremental increase or decrease. </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Certain Transactions</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The plan administrator has broad discretion to take action under the 2026 Plan,
            as well as make adjustments to the terms and conditions of existing and future awards, to prevent the dilution or enlargement of intended benefits and facilitate necessary or desirable changes in the event of certain transactions and events
            affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions, consolidations and other corporate transactions. This includes canceling awards for cash or property, accelerating the vesting of awards, providing for
            the assumption or substitution of awards by a successor entity, and adjusting the number and type of shares subject to outstanding awards or with respect to which awards may be granted under the 2026 Plan. In addition, in the event of certain
            non-reciprocal transactions with the stockholders known as &#8220;equity restructurings,&#8221; the plan administrator will make equitable adjustments to the 2026 Plan and outstanding awards. </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Foreign Participants, Claw-Back Provisions, Transferability and Participant
              Payments</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The plan administrator may modify award terms, establish subplans and/or adjust
            other terms and conditions of awards, subject to the share limits described above, in order to facilitate grants of awards subject to the laws and/or stock exchange rules of countries outside of the United States. All awards will be subject to
            the provisions of any claw-back policy implemented by the combined company to the extent set forth in such claw-back policy and/or in the applicable award agreement. With limited exceptions for estate planning, domestic relations orders,
            certain beneficiary designations and the laws of descent and distribution, awards under the 2026 Plan are generally non-transferable prior to vesting, and are exercisable only by the participant. With regard to tax withholding, exercise price
            and purchase price obligations arising in connection with awards under the 2026 Plan, the plan administrator may, in its discretion, accept cash, check or wire transfer, shares of our common stock, a &#8220;market sell order&#8221;, delivery of a
            promissory note or other property, or any combination of the foregoing. </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Repricing of Awards without Stockholder Approval</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The plan administrator may reduce the exercise price of an option or SAR or
            cancel an option or SAR in exchange for cash, another award under the 2026 Plan or an option or SAR with an exercise price that is less than the exercise price of the original option or SAR without the approval of the stockholders. </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Plan Amendment and Termination</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The plan administrator may amend, suspend or terminate the 2026 Plan at any time;
            provided that no amendment, other than an increase to the overall share limit, may materially and adversely affect any award outstanding at the time of such amendment without the affected participant&#8217;s consent. </div>

          <div class="BRDSX_h5" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Effective Date and Term of Plan</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2026 Plan was approved by the Passage Bio Board to be effective upon the
            Effective Time, subject to approval of the 2026 Plan by the stockholders. Unless earlier terminated by the board of directors of the combined company, the 2026 </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">204<br/>
        </div>

      </div>

    </div>

    <!--End Page 214-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 215-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_118-prop5_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Plan will remain effective until the tenth anniversary of the date the Passage
            Bio Board adopted the 2026&#160;Plan. If the 2026 Plan is not approved by the stockholders or the Merger is not consummated, the 2026 Plan will not become effective, no awards will be granted under the 2026 Plan and the Prior Plans will continue in
            full force and effect. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Federal Income Tax Consequences </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a general summary of the current federal income tax consequences
            to the combined company and to U.S. participants for awards granted under the 2026 Plan. The federal tax laws may change and the tax consequences for any participant will depend upon his or her individual circumstances. Tax consequences for any
            particular individual may be different. This summary does not purport to be complete, and does not discuss state, local or non-U.S. tax consequences. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Non-Qualified Options</span>. The grant of a non-qualified option under the 2026
            Plan is not expected to result in any federal income tax consequences to the participant or to the combined company. Generally, upon exercise of a non-qualified option, the participant will realize ordinary income, and the combined company will
            be entitled to a tax deduction, in an amount equal to the difference between the option exercise price and the fair market value of the shares at the time of exercise. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Incentive Stock Options</span>. The grant or exercise of an ISO under the 2026
            Plan is not expected to result in any federal income tax consequences to the participant or to the combined company. However, the amount by which the fair market value of the shares at the time of exercise exceeds the option price will be an
            &#8220;item of adjustment&#8221; for participants for purposes of the alternative minimum tax, unless the shares are sold or otherwise disposed of in the same year the ISO is exercised. Gain realized by participants on the sale of shares underlying an ISO
            is taxable at capital gains rates, and no tax deduction is available to the combined company, unless the participant disposes of the shares within (i) two years after the date of grant of the option or (ii) within one year of the date the
            shares were transferred to the participant. If the shares are sold or otherwise disposed of before the end of the one-year and two-year periods specified above, the difference between the option exercise price and the fair market value of the
            shares on the date of the option&#8217;s exercise (or the date of sale, if less) will be taxed at ordinary income rates, and the combined company will be entitled to a deduction to the extent that the participant recognizes ordinary income. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Stock Appreciation Rights</span>. The grant of a SAR under the 2026 Plan is not
            expected to result in any federal income tax consequences to either the participant or the combined company. Generally, upon exercise of the SAR, the fair market value of the shares received, determined on the date of exercise of the SAR, or
            the amount of cash received in lieu of shares, will be treated as compensation taxable as ordinary income to the participant in the year of such exercise. The combined company will be entitled to a deduction for compensation paid in the same
            amount which the participant realized as ordinary income. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Restricted Stock</span>. A participant generally will not have taxable income on
            the grant of restricted stock under the 2026&#160;Plan, nor will the combined company then be entitled to a deduction, unless the participant makes a valid election under Section&#160;83(b) of the Code. However, when restrictions on shares of restricted
            stock lapse, such that the shares are no longer subject to a substantial risk of forfeiture, the participant generally will recognize ordinary income, and the combined company will be entitled to a corresponding deduction, for an amount equal
            to the difference between the fair market value of the shares on the date such restrictions lapse over the purchase price for the restricted stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Restricted Stock Units</span>. A participant generally will not realize taxable
            income at the time of the grant of RSUs under the 2026 Plan, and the combined company will not be entitled to a deduction at that time. When RSUs are settled, whether in cash or shares, the participant will have ordinary income, and the
            combined company will be entitled to a corresponding deduction. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Stock Awards</span>. If a participant receives a stock award under the 2026 Plan
            in lieu of a cash payment that would otherwise have been made, the participant generally will be taxed as if the cash payment has been received, and the combined company will have a deduction in the same amount. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Dividend Equivalents</span>. A participant generally will not realize taxable
            income at the time of the grant of dividend equivalents under the 2026 Plan, and the combined company will not be entitled to a deduction at that time. When a dividend equivalent is paid, the participant will recognize ordinary income, and the
            combined company will be entitled to a corresponding deduction. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Application of Section&#160;409A of the Code</span>. Section&#160;409A of the Code imposes
            an additional 20% tax and interest on an individual receiving non-qualified deferred compensation under a plan that fails to satisfy certain requirements. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">205<br/>
        </div>

      </div>

    </div>

    <!--End Page 215-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 216-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_118-prop5_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">For purposes of Section&#160;409A, &#8220;non-qualified deferred compensation&#8221; includes
            equity-based incentive programs, including some options, SARs and RSU programs. Generally speaking, Section 409A does not apply to ISOs, non-discounted non-qualified options and SARs if no deferral is provided beyond exercise, or restricted
            stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The awards made pursuant to the 2026 Plan are designed in a manner intended to
            comply with the requirements of Section&#160;409A to the extent the awards granted under the 2026 Plan are not exempt from Section&#160;409A. However, if the 2026 Plan fails to comply with Section&#160;409A in operation, a participant could be subject to the
            additional taxes and interest. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"><span style="text-decoration: underline;">Limitations on the Company&#8217;s Compensation Deduction</span>. Section&#160;162(m) of the
            Code limits the deduction certain employers may take for otherwise deductible compensation payable to certain current and former executive officers of the combined company to the extent the compensation paid to such an officer for the year
            exceeds $1&#160;million U.S.&#160;dollars. Additionally, under Section&#160;280G of the Code, in connection with a change in control, certain compensatory payments in excess of prescribed limits made to &#8220;disqualified individuals&#8221; in connection with the change
            in control may not be deductible by the combined company. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">New Plan Benefits </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The future awards, if any, that will be made to eligible persons under the 2026
            Plan are subject to the discretion of the plan administrator, and therefore, the benefits or number of shares subject to awards that may be granted in the future to our executive officers, employees and directors is not currently determinable.
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Equity Compensation Plan Information </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table sets forth information concerning Passage Bio&#8217;s equity
            compensation plans as of December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 156pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 80.93pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 66.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 67.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 70.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 156pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 80.93pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Securities to <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">be Issued upon <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding Options <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 66.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted Average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Options and Rights <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">($)</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 67.11pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities to be <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued upon vesting <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">and settlement of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">restricted Stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Units <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#)</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 70.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Securities <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remaining Available <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">for Future Issuance <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Under Equity <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Compensation <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Plans <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(#) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 156pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity Compensation Plans Approved by Stockholders</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 80.93pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.21pt; text-align: left;">621,389<sup>(1)</sup></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 66.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.37pt; text-align: left;">$50.66<sup>(2)</sup></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 67.11pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.8pt; text-align: left;">50,000</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 70.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.13pt; text-align: left;">492,727<sup>(3)</sup> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 156pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Equity Compensation Plans Not Approved by
                    Stockholders</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 80.93pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.21pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">37,584</span><span style="padding-bottom: 1.5pt;"><sup>(4)</sup></span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 66.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.37pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">28.25</span><span style="padding-bottom: 1.5pt;"><sup>(5)</sup></span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 67.11pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt; padding-right: 22.5pt;">0</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 70.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">87,166</span><span style="padding-bottom: 1.5pt;"><sup>(6)</sup> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 156pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 80.93pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 24.21pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 66.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.37pt; text-align: left;">$49.38</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 67.11pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.8pt; text-align: left;">50,000</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 70.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.13pt; text-align: left;">579,893</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 156pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 80.93pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 66.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 67.11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 70.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes outstanding awards under the 2018 EIP and the 2020 EIP. Excludes purchase rights accruing under the Passage Bio 2020
                    Employee Stock Purchase Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">2020 ESPP</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">This value is calculated based on the exercise price of options outstanding under the 2018 EIP and the 2020 EIP and does not take
                    into account outstanding RSUs, which have no exercise price. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) no shares available for future issuance under the 2018 EIP, (ii) 433,624 shares available for issuance under the
                    2020 EIP, and (iii)&#160;59,103 shares available for issuance under the 2020 ESPP. While there are no shares of common stock available for issuance under the 2018&#160;EIP, the plan continues to govern the terms of stock options granted
                    thereunder. Any shares of common stock that are subject to outstanding awards under the 2018 EIP that are issuable upon the exercise of stock options that expire or become unexercisable for any reason without having been exercised in
                    full will generally be available for future grant and issuance under the 2020 EIP. In addition, the 2020 EIP provides for an automatic increase in the number of shares reserved for issuance thereunder on January&#160;1 of each year for the
                    remaining term of the plan equal to the lesser of (i) 5.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (ii) an amount as approved by the Passage Bio Board each
                    year. Pursuant to this provision, the number of shares reserved for grant and issuance under our 2020 Plan increased by 159,141 on January&#160;1, 2026. Also, the 2020 ESPP provides for an automatic annual increase in the number of shares
                    reserved for issuance thereunder on January&#160;1 of each year for the remaining term of the plan equal to (i) 1.0% of the number of issued and outstanding shares of common stock on December&#160;31 of the immediately preceding year, or (ii) a
                    lesser amount as approved by the Passage Bio Board each year. Pursuant to this provision, the number of shares reserved for grant and issuance under the 2020&#160;ESPP increased by 0 shares on January&#160;1, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects outstanding options under the 2021 EIP. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">This value is calculated based on the exercise price of options outstanding under the 2021 EIP and does not take into account
                    outstanding RSUs, which have no exercise price. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects shares that remain available for grant under the 2021 EIP. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">206<br/>
        </div>

      </div>

    </div>

    <!--End Page 216-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 217-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_118-prop5_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Consequences of Failing to Approve the Proposal </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2026 Plan will not be implemented unless approved by the stockholders. If the
            2026 Plan is not approved by the Shareholders, the Prior Plans will remain in effect, and the combined company will continue to grant awards under the Prior Plans until the share reserve under the Prior Plans is exhausted or the terms of the
            Prior Plans expire. Once the remaining share reserve is exhausted, the combined company may elect to provide compensation through other means, such as cash-settled awards or other cash compensation, to assure that the combined company and its
            affiliates can attract and retain qualified personnel. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Vote Required and Recommendation of Board </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Approval of the 2026 Plan, which is subject to and conditional upon the
            consummation of the Merger, requires the affirmative approval of a majority of the votes cast on the proposal. If the stockholders approve the 2026&#160;Plan, it will become effective upon the Effective Time. If the Passage Bio Board determines, in
            its sole discretion, not to proceed with the Merger, the 2026 Plan will not become effective. The Passage Bio Board has reserved the right to terminate or abandon the 2026 Plan at any time prior to the Effective Time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS THAT THE PASSAGE BIO <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE 2026 PLAN PROPOSAL.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">207<br/>
        </div>

      </div>

    </div>

    <!--End Page 217-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 218-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_119-prop6_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPROP6"><!--Anchor--></a>PROPOSAL NO. 6&#8212;THE 2026 EMPLOYEE STOCK
            PURCHASE PLAN PROPOSAL </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In Proposal No. 6, Passage Bio stockholders are being asked to approve the Remix
            Therapeutics, Inc. 2026&#160;Employee Stock Purchase Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">2026 ESPP</span>&#8221;) and the material terms thereunder. The Passage Bio Board approved the 2026&#160;ESPP, subject to stockholder approval
            at the Passage Bio special meeting. The 2026 ESPP will become effective upon the Effective Time.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2026 ESPP is described in more detail below. A copy of the 2026 ESPP is
            attached to this proxy statement/prospectus as Annex&#160;L. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">The 2026 ESPP </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2026 ESPP is designed to allow eligible employees of the combined company to
            purchase shares of our common stock at a discount with their accumulated payroll deductions. The 2026 ESPP is divided into two&#160;components: the &#8220;Section&#160;423 Component&#8221; and the &#8220;Non-Section&#160;423 Component&#8221;. The Section&#160;423 Component is intended to
            qualify under Section&#160;423 of the Internal Revenue Code (the &#8220;<span style="font-style: italic; font-weight: bold;">Code</span>&#8221;). The Non-Section&#160;423 Component will be used to grant rights to certain non-U.S. employees which need not qualify as
            rights granted pursuant to an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. The material terms of the 2026 ESPP are summarized below. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Why Stockholders Should Vote to Approve the 2026 ESPP </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2026 ESPP will authorize the issuance of &#8195;&#8195; shares of our common stock, plus
            an annual increase on the first day of each calendar year beginning January&#160;1, 2027 and ending on and including January&#160;1, 2036, equal to the lesser of (A)&#160;&#8195;&#8195;% of the aggregate number of shares outstanding on the final day of the immediately
            preceding calendar year and (B) such smaller number of shares as is determined by the board of directors of the combined company or the compensation committee of such board.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The primary purpose of the 2026 ESPP will be to provide eligible employees with
            an opportunity to participate in the ownership of the combined company by purchasing shares of our common stock at a discounted price through payroll deductions so that they may increase their proprietary interest in our success and to align
            employee interests to those of our stockholders. The 2026 ESPP is intended to benefit the combined company as well as its stockholders and employees.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We firmly believe that the 2026 ESPP is a powerful incentive and retention tool
            that will benefit all of our stockholders. Specifically, the 2026 ESPP will enable the combined company to: (1) provide eligible employees with a convenient means of acquiring an equity interest in the combined company through payroll
            deductions, (2)&#160;enhance such employees&#8217; sense of participation in the affairs of the combined company, and (3) provide an incentive for continued employment. The 2026 ESPP will also align the interests of employees with those of stockholders
            through increased stock ownership. Accordingly, the Passage Bio Board believes that approval of the 2026 ESPP is in the best interests of the combined company and recommends that Passage Bio stockholders vote for approval of the 2026 ESPP.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In determining whether to approve the 2026 ESPP, the Passage Bio Board considered
            that the combined company expects the proposed aggregate share reserve under the 2026 ESPP to provide us with enough shares for the operation of the 2026 ESPP for the next 10 years, noting that future circumstances, including employee
            participation rates and changes in our stock price, may change this. We cannot predict our future share usage under the 2026&#160;ESPP, the future price of our shares of common stock or future hiring activity with any degree of certainty at this
            time, and the share reserve under the 2026 ESPP could last for a shorter or longer time. The Passage Bio Board has determined that the size of the share reserve under the 2026 ESPP is reasonable and appropriate at this time. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Summary of the 2026 ESPP </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This section summarizes certain principal features of the 2026 ESPP. The summary
            is qualified in its entirety by reference to the complete text of the 2026 ESPP. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Administration </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subject to the terms and conditions of the 2026 ESPP, the compensation committee
            of the board of directors of the combined company will administer the 2026 ESPP. The compensation committee can delegate administrative tasks </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">208<br/>
        </div>

      </div>

    </div>

    <!--End Page 218-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 219-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_119-prop6_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">under the 2026 ESPP to the services of an agent and/or employees to assist in
            the administration of the 2026 ESPP. The administrator will have the discretionary authority to administer and interpret the 2026 ESPP. Interpretations and constructions of the administrator of any provision of the 2026 ESPP or of any rights
            thereunder will be conclusive and binding on all persons. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Shares Available for Awards </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The maximum number of shares of our common stock which will be authorized for
            sale under the 2026 ESPP is &#8195;&#8195; shares of common stock, subject to the adjustment provisions contained in the 2026 ESPP. The shares reserved for issuance under the 2026 ESPP may be authorized and unissued shares, treasury shares and/or shares
            purchased on the open market. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Eligibility </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Employees eligible to participate in the 2026 ESPP for a given offering period
            generally include employees who are employed by the combined company or one of our designated subsidiaries on the first trading day of the offering period. The administrator may provide that our employees (and, if applicable, any employees of
            our designated subsidiaries) who are highly compensated employees, have been employed less than two years, customarily work less than five&#160;months in a calendar year or are customarily scheduled to work less than 20 hours per week may not be
            eligible to participate in the 2026 ESPP. Finally, an employee who owns (or is deemed to own through attribution) 5% or more of the combined voting power or value of all our classes of stock or of one of our subsidiaries will not be permitted
            to participate in the 2026 ESPP.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of &#8195;&#8195;, we had approximately &#8195;&#8195; employees who would be eligible to participate
            in the 2026 ESPP. Immediately following the Merger, the combined company is expected to have &#8195;&#8195; employees who will be eligible to participate in the 2026 ESPP. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Participation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Employees will enroll under the 2026 ESPP by completing a subscription agreement
            permitting the deduction from their compensation of at least 1% of their compensation but not more than 15% of their compensation (or such other maximum percentage as may be designated by the administrator). Such payroll deductions shall be
            expressed as a whole number percentage (except as otherwise determined by the administrator), and the accumulated deductions will be applied to the purchase of shares of common stock on each purchase date. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Offering </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the 2026 ESPP, participants are offered the option to purchase shares of
            our common stock at a discount during a series of successive offering periods, the duration and timing of which will be determined by the administrator. However, in no event may an offering period be longer than 27 months in length. The
            offering periods are each comprised of one or more equal length or shorter purchase periods.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The option purchase price will be the lower of 85% of the closing trading price
            per share of our common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date. As of &#8195;&#8195;, 2026, the closing price on Nasdaq per share of
            Passage Bio Common Stock was $&#8195;&#8195;.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Section&#160;423 Component, participants may not purchase shares of our
            common stock at a rate which exceeds $25,000 of the fair market value of our stock (determined at the time the option to purchase shares under the 2026 ESPP is granted) for each calendar year in which the option is outstanding (as determined in
            accordance with Section&#160;423 of the Code).</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless a participant has previously canceled his or her participation in the 2026
            ESPP before the purchase date, the participant will be deemed to have exercised his or her option in full as of each purchase date. Upon exercise, the participant will purchase the number of whole shares that his or her accumulated payroll
            deductions will buy at the option purchase price, subject to the participation limitations listed above. Participation will end automatically upon a participant&#8217;s termination of employment.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A participant may withdraw all of his or her payroll deductions credited to his
            or her account that have not yet been used to purchase shares of our common stock at any time by giving written notice to the combined company no later </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">209<br/>
        </div>

      </div>

    </div>

    <!--End Page 219-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 220-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_119-prop6_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">than 15&#160;days prior to the end of the offering period or, if earlier, the end
            of the purchase period (or such shorter or longer period of time specified by the administrator in an offering document). Upon withdrawal, the participant will receive a refund of the participant&#8217;s account balance in cash without interest, and
            such participant&#8217;s rights for the offering period shall be automatically terminated, and no further payroll deductions for the purchase of shares shall be made for such offering period. A participant may increase, decrease or suspend his or her
            payroll deductions at any time during an offering period; provided, however, that the administrator may limit the number of changes a participant may make to his or her payroll deduction elections during each offering period in the applicable
            offering document (and in the absence of any specific designation by the administrator, a participant shall be allowed to decrease (but not increase) or suspend his or her payroll deduction elections one time during each offering period). In
            addition, if a participant wants to increase or decrease the rate of payroll deductions, he or she may do so effective for the next offering period by submitting a new subscription agreement before the offering period for which such change is
            to be effective.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A participant may not transfer rights granted under the 2026 ESPP other than by
            will, the laws of descent and distribution or as otherwise provided under the 2026 ESPP. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Adjustments </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event of certain transactions or events affecting the shares of our common
            stock, such as any stock dividend or other distribution, change in control, reorganization, merger, consolidation or other corporate transaction, the administrator will make equitable adjustments to the 2026 ESPP and outstanding rights if the
            administrator determines it is appropriate to prevent dilution or enlargement of rights. In addition, in the event of the foregoing transactions or events or certain significant transactions, including a change in control, the administrator may
            provide for (i) either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (ii) the assumption or substitution of outstanding rights by the successor or survivor
            corporation or parent or subsidiary thereof, (iii) the adjustment in the number and type of shares of stock subject to outstanding rights, (iv) the use of participants&#8217; accumulated payroll deductions to purchase stock on a new purchase date
            prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (v) the termination of all outstanding rights. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Amendment and Termination </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The administrator may amend, suspend or terminate the 2026 ESPP at any time.
            However, stockholder approval will be needed to either (i) increase the aggregate number, or change the type, of shares that may be sold pursuant to rights under the 2026 ESPP (other than an adjustment that is permitted under the 2026 ESPP) or
            (ii) change the corporations or classes of corporations whose employees may be granted rights under the 2026 ESPP. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Federal Income Tax Consequences </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a general summary under current law of the principal U.S.
            federal income tax consequences related to the purchase of shares under the 2026 ESPP. This summary deals with the general federal income tax principles that apply and is provided only for general information. Some kinds of taxes, such as
            state, local and foreign income taxes and federal employment taxes, are not discussed. As such, tax consequences for employees participating in the Non-Section 423 Component of the 2026 ESPP are not discussed. This summary is not intended as
            tax advice to participants, who should consult their own tax advisors.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Section&#160;423 Component of the 2026 ESPP, and the right of participants to make
            purchases thereunder, is intended to qualify under the provisions of Section&#160;423 of the Code. Under the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the
            2026&#160;ESPP. This means that an eligible employee will not recognize taxable income on the date the employee is granted an option under the 2026&#160;ESPP. In addition, the employee will not recognize taxable income upon the purchase of shares.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon such a sale or disposition, the participant generally will be subject to tax
            in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed of more than two years from the date of grant and more than one year from the date of
            purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income measured as the lesser of (i) the excess of the fair market value of the shares at the time of such sale or
            disposition (or death) over the purchase price or (ii) an amount equal to the applicable discount from the fair market value of the shares as of the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">210<br/>
        </div>

      </div>

    </div>

    <!--End Page 220-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 221-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_119-prop6_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">date of grant. If the shares are held for the holding periods described above
            but are sold for a price that is less than the purchase price, there is no ordinary income. The amount of such ordinary income recognized by the participant will be added to the participant&#8217;s basis in the shares for purposes of determining
            capital gain or loss upon the sale or disposition of the shares by the participant.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the shares are sold or otherwise disposed of before the expiration of the
            holding periods described above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased over the purchase price. The amount of such ordinary
            income recognized by the participant will be added to the participant&#8217;s basis in the shares for purposes of determining capital gain or loss upon the sale or disposition of the shares by the participant. Any additional gain or loss on such sale
            or disposition will be long-term or short-term capital gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of them.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company generally will not be entitled to a tax deduction with
            respect to the shares purchased under the Section&#160;423 Component of the 2026 ESPP, unless the participant disposes of the shares before the expiration of the holding periods described above, in which case the combined company will be entitled to
            a tax deduction equal to the corresponding amount of ordinary income recognized by the participant. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">New Plan Benefits </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Because the number of shares that may be purchased under the 2026 ESPP will
            depend on each employee&#8217;s voluntary election to participate and on the fair market value of our common stock at various future dates, the actual number of shares that may be purchased by any individual cannot be determined in advance. No shares
            of our common stock have been issued under the 2026 ESPP as it is not yet effective. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS THAT THE PASSAGE BIO <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">STOCKHOLDERS VOTE &#8220;FOR&#8221; THE APPROVAL OF THE 2026 ESPP PROPOSAL.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">211<br/>
        </div>

      </div>

    </div>

    <!--End Page 221-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 222-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_120-prop7_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPROP7"><!--Anchor--></a>PROPOSAL NO. 7&#8212;THE MERGER COMPENSATION
            PROPOSAL </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to Section&#160;14A of the Exchange Act and Rule&#160;14a-12(c) thereunder,
            Passage Bio is seeking non-binding, advisory shareholder approval of certain compensation arrangements for Passage Bio named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t) of
            Regulation S-K in the subsection titled &#8220;<span style="font-style: italic;">Quantification of Potential Payments and Benefits to Passage Bio&#8217;s Named Executive Officers</span>&#8221; in the section titled &#8220;<span style="font-style: italic;">The
              Merger&#8212;Interests of Passage Bio&#8217;s Directors and Executive Officers in the Merger</span>&#8221; in this proxy statement/prospectus. At the Passage Bio Special Meeting, Passage Bio will therefore ask its stockholders to adopt the following
            resolution: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">RESOLVED:<span style="font-weight: normal;"> that certain
              compensation arrangements for Passage Bio named executive officers in connection with the Merger, as disclosed pursuant to Item&#160;402(t) of Regulation S-K in the subsection titled &#8220;</span><span style="font-style: italic; font-weight: normal;">Quantification

              of Potential Payments and Benefits to Passage Bio&#8217;s Named Executive Officers</span><span style="font-weight: normal;">&#8221; in the section titled &#8220;</span><span style="font-style: italic; font-weight: normal;">The Merger&#8212;Interests of Passage Bio&#8217;s
              Directors and Executive Officers in the Merger</span><span style="font-weight: normal;">&#8221; in the proxy statement/prospectus, are hereby </span>APPROVED<span style="font-weight: normal;"> on a non-binding, advisory basis. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Because the vote is advisory in nature only, it will not be binding on Passage
            Bio. Accordingly, to the extent Passage Bio is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed,
            regardless of the outcome of this advisory vote. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the
            accompanying proxy </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Required Vote </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The affirmative approval of a majority of the votes cast on the proposal by the
            holders of Passage Bio Common Stock entitled to vote at the Passage Bio special meeting, assuming a quorum is present, is required to approve the Merger Compensation Proposal. Abstentions and broker non-votes (if any) will have no effect on the
            outcome of the vote on the Merger Compensation Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The Merger is <span style="font-weight: bold;">not</span> conditioned upon the
            approval of the Merger Compensation Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the
            accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the approval of the Merger Compensation Proposal. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE MERGER COMPENSATION PROPOSAL</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">212<br/>
        </div>

      </div>

    </div>

    <!--End Page 222-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 223-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_121-prop8_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPROP8"><!--Anchor--></a>PROPOSAL NO. 8&#8212;THE ADJOURNMENT PROPOSAL </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If Passage Bio fails to receive a sufficient number of votes to approve the
            Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Charter Proposal, the Governance Proposals, the 2026 Plan Proposal , the 2026&#160;ESPP Proposal and/or the Merger Compensation Proposal, Passage Bio may propose to adjourn the
            Passage&#160;Bio special meeting, for a period of not more than 60 days, for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Charter Proposal, the Governance
            Proposals, the 2026 Plan Proposal , the 2026 ESPP Proposal and/or the Merger Compensation Proposal. Passage Bio currently does not intend to propose adjournment at the Passage Bio special meeting if there are sufficient votes to approve the
            Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal, the Charter Proposal, the Governance Proposals, the 2026 Plan Proposal , the 2026 ESPP Proposal and the Merger Compensation Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a quorum is not present at the Passage Bio special meeting, under Passage
            Bio&#8217;s bylaws, the chairperson of the Passage Bio special meeting will have the power to adjourn the Passage Bio special meeting until a quorum is present or represented. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Required Vote </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The affirmative approval of a majority of the votes cast on the proposal by the
            holders of Passage Bio Common Stock entitled to vote at the Passage Bio special meeting, assuming a quorum is present, is required to approve the Adjournment Proposal. Abstentions and broker non-votes (if any) will have no effect on the outcome
            of the vote on the Adjournment Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The Merger is <span style="font-weight: bold;"><span style="text-decoration: underline;">not</span></span> conditioned
            upon the approval of the Adjournment Proposal.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise instructed, it is the intention of the persons named in the
            accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span style="font-weight: bold;">FOR</span>&#8221; the approval of the Adjournment Proposal. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; text-align: center;">THE PASSAGE BIO BOARD UNANIMOUSLY RECOMMENDS A VOTE &#8220;FOR&#8221; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE ADJOURNMENT PROPOSAL, IF NECESSARY</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">213<br/>
        </div>

      </div>

    </div>

    <!--End Page 223-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 224-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPBB"><!--Anchor--></a>PASSAGE BIO&#8217;S BUSINESS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless the context otherwise requires, all references in this
            section to &#8220;Passage Bio,&#8221; &#8220;it&#8221; and &#8220;their&#8221; refer to Passage Bio, Inc. prior to the consummation of the Merger<span style="font-style: normal;">. </span></div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is a clinical stage genetic medicines company that has historically
            focused on improving the lives of patients with neurodegenerative diseases through the development and advancement of cutting-edge, one-time therapies designed to target critical underlying pathologies in these conditions. As described in the
            section titled &#8220;Recent Developments,&#8221; Passage Bio has determined to wind down its gene therapy programs and, on June&#160;24, 2026, entered into the Merger Agreement with Remix. In connection with the wind-down, Passage Bio has terminated its
            development services and clinical supply arrangements with Catalent, its collaboration agreement with Gemma Biotherapeutics, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">Gemma</span>&#8221;), and has given notice to terminate its
            license with Penn with respect to PBFT02, its former lead product candidate. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Recent Developments </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;24, 2026, Passage Bio entered into an Agreement and Plan of Merger and
            Reorganization (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger Agreement</span>&#8221;) with Remix Therapeutics, Inc., a Delaware corporation (&#8220;<span style="font-style: italic; font-weight: bold;">Remix</span>&#8221;), and Merger Sub,
            Inc., a Delaware&#160;corporation and wholly-owned subsidiary of Passage Bio (&#8220;<span style="font-style: italic; font-weight: bold;">Merger Sub</span>&#8221;). Upon the terms and subject to the satisfaction of the conditions described in the Merger
            Agreement, Merger Sub will be merged with and into Remix, with Remix surviving as a wholly-owned subsidiary of Passage Bio. The Merger is intended to qualify for the Intended Tax Treatment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Concurrently with the execution and delivery of the Merger Agreement, certain
            investors entered into the Subscription Agreement with Remix, pursuant to which such investors have agreed to purchase, immediately prior to the Merger, shares of Remix Common Stock representing an aggregate commitment of approximately
            $100&#160;million in the Concurrent Financing. The shares of Remix Common Stock that are issued in the Concurrent Financing will be or will have the right to be, respectively, converted into shares of Passage Bio Common Stock in the Merger. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s Pipeline </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is a clinical-stage genetic medicines company that has historically
            focused on developing one-time, adeno-associated virus (&#8220;<span style="font-style: italic; font-weight: bold;">AAV</span>&#8221;) based gene therapies designed to treat neurodegenerative diseases. Passage Bio&#8217;s lead product candidate was PBFT02, and
            Passage Bio has also pursued additional preclinical and outlicensed programs. As described above under &#8220;&#8212;Recent Developments,&#8221; Passage Bio has terminated or wound down its principal program, collaboration, license and manufacturing
            arrangements. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s Approach </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s historical approach combined its selection of AAV capsids and
            transgenes with administration into the cerebrospinal fluid by intra-cisterna magna (&#8220;<span style="font-style: italic; font-weight: bold;">ICM&#8221;</span>) delivery, intended to achieve broad distribution of its product candidates throughout the
            central nervous system. Passage Bio advanced its programs through a research collaboration with the Trustees of the University of Pennsylvania&#8217;s Gene Therapy Program (&#8220;<span style="font-style: italic; font-weight: bold;">GTP</span>&#8221;). </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Genetic Medicines Background </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Genetic medicines seek to treat the underlying genetic causes of disease. Each
            person&#8217;s genome consists of DNA organized into genes, and mutations in a single gene can alter the amount or activity of the protein that the gene encodes, which can result in disease. One gene therapy approach is to deliver a new, functional
            copy of a defective or missing gene to affected cells, frequently using an AAV vector. Passage Bio&#8217;s programs applied this approach to neurodegenerative diseases of the central nervous system. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">PBFT02 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s lead product candidate was PBFT02, a gene replacement therapy that
            used an AAV1 capsid to deliver a functional copy of the granulin gene (&#8220;<span style="font-style: italic; font-weight: bold;">GRN</span>&#8221;) encoding progranulin (&#8220;<span style="font-style: italic; font-weight: bold;">PGRN</span>&#8221;). PBFT02&#8217;s lead
            indication was frontotemporal dementia caused by progranulin deficiency (&#8220;<span style="font-style: italic; font-weight: bold;">FTD-GRN</span>&#8221;) an inheritable form of FTD resulting </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">214<br/>
        </div>

      </div>

    </div>

    <!--End Page 224-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 225-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">from reduced PGRN production, for which there are no approved
            disease-modifying therapies; Passage Bio estimated the prevalence of FTD-GRN in the United States and Europe to be approximately 18,000. Passage Bio was also evaluating PBFT02 in additional adult neurodegenerative diseases in which it believed
            elevated PGRN levels could provide benefit, including FTD due to mutations in the C9orf72 gene (&#8220;<span style="font-style: italic; font-weight: bold;">FTD-C9orf72</span>&#8221;), and amyotrophic lateral sclerosis (&#8220;<span style="font-style: italic; font-weight: bold;">ALS</span>&#8221;) based on PGRN&#8217;s potential to ameliorate TDP-43 pathology, as well as Alzheimer&#8217;s disease (&#8220;<span style="font-style: italic; font-weight: bold;">AD</span>&#8221;), in carriers of the GRN rs5848 polymorphism
            associated with reduced PGRN levels. Passage Bio had initiated clinical development of PBFT02 in patients with FTD-GRN and FTD-C9orf72 in its upliFT-D clinical trial. As described above under &#8220;&#8212;Recent Developments,&#8221; Passage Bio provided notice
            terminating the Penn License Agreement, as defined below, with respect to PBFT02. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Clinical Development of PBFT02 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">PBFT02 was selected as Passage Bio&#8217;s development candidate following preclinical
            proof-of-concept studies in adult non-human primates (&#8220;<span style="font-style: italic; font-weight: bold;">NHPs</span>&#8221;) in which intra-cisterna magna administration of an AAV1 vector encoding human PGRN produced elevated PGRN levels in
            cerebrospinal fluid (&#8220;<span style="font-style: italic; font-weight: bold;">CSF</span>&#8221;). In a 90-day GLP-compliant toxicology study in NHPs, PBFT02 was generally well-tolerated at the doses evaluated, with vector distribution to the CSF and
            gene transfer detected in the brain and spinal cord. Passage Bio initiated the upliFT-D trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with symptomatic FTD-GRN, and subsequently
            FTD-C9orf72, conducted as a dose-ranging study. In April&#160;2026, Passage Bio reported updated interim data suggesting that PBFT02 may slow neurodegeneration in patients with FTD-<span style="font-style: italic;">GRN </span>and reported that it
            completed a Type C meeting with the FDA to seek guidance on key elements of a future registrational trial of PBFT02 for FTD-<span style="font-style: italic;">GRN</span> patients, following which the FDA indicated that a randomized controlled
            registrational study design is required for PBFT02 in this indication. A randomized controlled registrational trial poses substantial ethical concerns for patients and their families as well as logistical and financial challenges. As such, the
            Company evaluated potential next steps in the clinical development of PBFT02 in FTD-<span style="font-style: italic;">GRN</span> and FTD-C9orf72 in the uplift-D trial, including the sale or outlicensing of the program to a third party, and,
            following such evaluation, determined to discontinue its research and development activities related for PBFT02. On June&#160;23, 2026, the Company delivered written notice to The Trustees of the University of Pennsylvania (&#8220;<span style="font-style: italic; font-weight: bold;">Penn</span>&#8221;) of the Company&#8217;s election to terminate, pursuant to Section&#160;10.2 therein, the Second Amended and Restated Research, Collaboration and License Agreement between Penn and the Company, dated as of
            July&#160;31, 2024 (the &#8220;<span style="font-style: italic; font-weight: bold;">Penn Agreement</span>&#8221;), solely with respect to the licensed product referred to by the Company as &#8220;PBFT02&#8221; and all indications licensed to the Company under the Penn
            Agreement for PBFT02, including frontotemporal dementia with granulin mutations (the &#8220;<span style="font-style: italic; font-weight: bold;">PBFT02 Termination</span>&#8221;). Following the effectiveness of the PBFT02 Termination, the Company will no
            longer have rights under the Penn Agreement to develop or commercialize PBFT02. The PBFT02 Termination will become effective ninety (90) days following Penn&#8217;s receipt of such notice. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Manufacturing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio had maintained a relationship with Catalent Maryland, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">Catalent</span>&#8221;) for process development, manufacturing, supply chain and analytical testing under a collaboration agreement and an amended and restated development services and clinical supply
            agreement (together, the &#8220;<span style="font-style: italic; font-weight: bold;">Amended Catalent Agreements</span>&#8221;) for process development, manufacturing, supply chain, and analytical testing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;23, 2026, Passage Bio delivered written notice to Catalent to terminate,
            pursuant to Section&#160;20.1(b)(ii) thereof, the amended and restated development services and clinical supply agreement, dated November&#160;9, 2023 (one of the Amended Catalent Agreements), in its entirety, effective as of June&#160;23, 2026. Passage Bio
            determined to terminate this agreement in connection with the wind-down of its gene therapy programs and the proposed Merger, and Passage Bio is not obligated to pay Catalent any termination fee in connection with the termination. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Competition </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The biotechnology and pharmaceutical industries, including the genetic medicines
            field, are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual property. Passage Bio&#8217;s programs faced competition from companies developing gene therapies and other modalities for
            neurodegenerative diseases, as well as from pharmaceutical and biotechnology companies, academic and research institutions and government agencies. For the treatment of FTD, there are no approved disease-modifying therapies. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">215<br/>
        </div>

      </div>

    </div>

    <!--End Page 225-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 226-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">License Agreements </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">University of Pennsylvania </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a result of the Outlicense Transaction Agreements, Passage Bio restructured
            its research, collaboration and licensing agreement with Penn, as amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Penn License Agreement</span>&#8221;). Pursuant to the Penn License Agreement, as of July&#160;31, 2024, Passage Bio (i)
            terminated the funding of discovery research programs; (ii)&#160;terminated the research and exploratory research programs; (iii) terminated the remaining eight options it had for future CNS indications; (iv) terminated the transaction fee payable
            to Penn in the event of certain corporate transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1 Gangliosidosis (<span style="font-style: italic; font-weight: bold;">GM1,</span>&#8221; Krabbe
            disease (&#8220;<span style="font-style: italic; font-weight: bold;">Krabbe</span>&#8221;), and metachromatic leukodystrophy (&#8220;<span style="font-style: italic; font-weight: bold;">MLD</span>&#8221;), and certain platform technologies resulting from the discovery
            programs that the Company funded. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;23, 2026, Passage Bio delivered written notice to Penn to terminate the
            Penn License Agreement, pursuant to Section&#160;10.2 thereof, solely with respect to its product candidate referred to as PBFT02 for all indications licensed to Passage Bio thereunder for such product candidate, including frontotemporal dementia
            with granulin mutations. This partial termination will become effective on the date that is 90 days following Penn&#8217;s receipt of the notice, after which Passage Bio will no longer have any rights under the Penn License Agreement to develop or
            commercialize PBFT02. The Penn License Agreement will remain in effect with respect to all non-terminated licensed products. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Gemma &#8211; Research, Collaboration and License
            Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            Passage Bio entered into the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma conducted certain preclinical and IND-enabling work for Passage Bio&#8217;s Huntington&#8217;s disease program and a paused research
            program in temporal lobe epilepsy (&#8220;<span style="font-style: italic; font-weight: bold;">TLE&#8221;</span>), which were previously conducted by Penn under the Penn License Agreement; and (ii) Gemma granted Passage Bio Options to conduct mutually
            agreed research programs in four new CNS indications. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On May&#160;21, 2026, Passage Bio provided written notice to Gemma to terminate the
            Gemma Collaboration Agreement, which termination will become effective in accordance with the terms of the Gemma Collaboration Agreement. Following the effectiveness of the termination, Passage Bio will no longer have any rights to the research
            programs or the options for new CNS indications previously available to it under the Gemma Collaboration Agreement. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Gemma &#8211; Sublicense Agreements and Transition
            Services Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the transfer of the Outlicensed Programs to Gemma, in
            July&#160;2024, Passage Bio entered into the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs (the &#8220;<span style="font-style: italic; font-weight: bold;">Amended Gemma Sublicenses</span>&#8221;). Pursuant to the Amended Gemma Sublicenses, Passage Bio is entitled to receive (i) an aggregate total of $15.0&#160;million in initial payments for licenses and clinical product supply, of
            which $10.0 million has been received as of May&#160;19, 2026, and $5.0&#160;million of which was due in March&#160;2026; (ii) an additional $5.0&#160;million contingent on Gemma completing certain business milestones; (iii) up to an additional $114.0&#160;million in
            development and commercial milestone payments; and (iv) single digit royalties as a percentage of annual worldwide net sales in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical
            trial materials and product supply related to the Outlicensed Programs. In addition, Gemma is responsible for all payments to Penn related to the Outlicensed Programs under the Penn License Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Passage Bio entered into the Transition Services Agreement, as
            amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which, the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for transitional
            services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. As of May&#160;19, 2026, Passage Bio had collected $10.0 million in initial payments and $4.8 million in transition services payments under
            these agreements. In addition, the Company has applied $1.5&#160;million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts due to Passage Bio for transition services. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Intellectual Property </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s commercial success depends in part on its ability to obtain and
            maintain intellectual property protection for product candidates and core technologies, including manufacturing know-how. Passage Bio seeks to </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">216<br/>
        </div>

      </div>

    </div>

    <!--End Page 226-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 227-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">protect its programs through a combination of owned and in-licensed patents
            and patent applications, together with trade secrets and proprietary know-how. Passage Bio&#8217;s rights in the intellectual property relating to PBFT02 and its other programs were held under its license and collaboration agreements with the
            University of Pennsylvania and Gemma, which agreements have been terminated or partially terminated as described above under &#8220;&#8212;License Agreements.&#8221; </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Government Regulation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The development and commercialization of gene therapy product candidates are
            subject to extensive regulation by the FDA in the United States and by comparable regulatory authorities in other jurisdictions. In the United States, human gene therapy products are regulated as biological products under the Public Health
            Service Act and the Federal Food, Drug, and Cosmetic Act, and require, among other things, an effective IND before clinical testing may begin and approval of a biologics license application (&#8220;<span style="font-style: italic; font-weight: bold;">BLA</span>&#8221;)

            before a product may be marketed. Gene therapy products are also subject to additional FDA oversight and guidance, including with respect to manufacturing, labeling, and post-approval safety reporting. Comparable requirements apply in the
            European Union and other jurisdictions in which clinical trials are conducted or marketing authorizations are sought. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Employees and Human Capital Resources</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of June&#160;30, 2026, Passage Bio had six full-time employees. None of Passage
            Bio&#8217;s employees is represented by a labor union or covered by a collective bargaining agreement. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Legal Proceedings </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From time to time, Passage Bio may be involved in legal proceedings arising in
            the ordinary course of its business. Passage Bio is the defendant in litigation with a former employee, who filed a lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the
            Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended that Passage Bio entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of
            company stock and additional compensation. Specifically, he contended that before the announcement of Passage Bio&#8217;s initial public offering in February&#160;2020, he was promised 150,000 shares of stock as part of the settlement, and that those
            shares were not subject to the reverse stock split that was implemented for all shareholders. Passage Bio responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement
            been finalized, the plaintiff would have been entitled to 33,836 shares (1,692 shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it
            agreed with Passage Bio that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what Passage Bio contended had been offered to the plaintiff before the
            initial public offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in Passage Bio&#8217;s favor, finding that no binding agreement was reached and that the plaintiff
            was not entitled to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate court affirmed the entry of judgment in favor of the Company and on
            October&#160;7, 2025, the plaintiff filed an Application for Reargument to the Superior Court of Pennsylvania. In December&#160;2025, the Superior Court of Pennsylvania denied the Application for Reargument. In December&#160;2025, the plaintiff petitioned for
            review of their appeal to the Pennsylvania Supreme Court. In July 2026, the Pennsylvania Supreme Court denied the petition for review with respect to the plaintiff&#8217;s challenge to the post-trial rulings in favor of Passage Bio, but it agreed to
            hear the question of whether certain communications between lawyers and the mediator were appropriately excluded from evidence at trial under Pennsylvania&#8217;s mediation privilege. The Pennsylvania Supreme Court timing for this hearing is
            currently pending. Passage Bio intends to continue to defend against this claim. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other than the above, Passage Bio is not presently a party to any legal
            proceedings that, in the opinion of management, would, if decided against the Company, have a material adverse effect on its business. Regardless of outcome, litigation can have an adverse impact on Passage Bio due to defense and settlement
            costs, diversion of management resources, negative publicity and reputational harm, and other factors. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Corporate Information </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio was incorporated under the laws of the State of Delaware in July&#160;2017
            under the name Passage Bio, Inc. Passage Bio is a remote-only company. Accordingly, it does not maintain a headquarters. For purposes of compliance with applicable requirements of the Securities Act and the Exchange Act, as amended, any
            stockholder </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">217<br/>
        </div>

      </div>

    </div>

    <!--End Page 227-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 228-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">communication required to be sent to the Company&#8217;s principal executive offices
            may be directed to P.O. Box 7, Hopewell, New Jersey 08525. Passage Bio&#8217;s telephone number is (267) 866-0311 and its website address is www.passagebio.com. The information contained on, or that can be accessed through, the Company&#8217;s website is
            not part of, and is not incorporated by reference into, this proxy statement/prospectus. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Available Information </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio files annual, quarterly and current reports, proxy statements and
            other documents with the Securities and Exchange Commission (&#8220;<span style="font-style: italic; font-weight: bold;">SEC</span>&#8221;) under the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Exchange

              Act</span>&#8221;). The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including Passage Bio, that file electronically with the SEC. The public can obtain any
            documents that Passage Bio files with the SEC at www.sec.gov. Copies of each of the Company&#8217;s filings with the SEC can also be viewed and downloaded free of charge at its website, https://investors.passagebio.com/, after the reports and
            amendments are electronically filed with or furnished to the SEC. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">218<br/>
        </div>

      </div>

    </div>

    <!--End Page 228-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 229-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tRB"><!--Anchor--></a>REMIX&#8217;S BUSINESS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise indicated or the context otherwise requires, references in this
            section to &#8220;Remix,&#8221; the &#8220;Company&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and other similar terms refer to Remix and its subsidiary. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is a clinical stage biopharmaceutical company focused on small molecule
            approaches to reprograming RNA, potentially offering new treatment options to patients with devastating diseases. Remix&#8217;s proprietary approach identifies small molecules that have the potential to impact the expression of disease driving
            messenger RNA (mRNA) and proteins, which could allow Remix to address previously undruggable targets.&#8195;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s lead program, REM-422, is an investigational, orally available mRNA
            degrader of the MYB oncogenic transcription factor, which is thought to be a key driver of Adenoid Cystic Carcinoma (&#8220;<span style="font-style: italic; font-weight: bold;">ACC</span>&#8221;), myeloid malignancies (Acute Myelogenous Leukemia (&#8220;<span style="font-style: italic; font-weight: bold;">AML</span>&#8221;) and myelodysplastic syndromes (&#8220;<span style="font-style: italic; font-weight: bold;">MDS</span>&#8221;) and other cancers. REM-422 has completed the Phase 1 dose escalation portion of a
            Phase 1/2 study, in ACC, a rare malignancy affecting 13,000 - 15,000 individuals in the United States and with over 1,500 new cases annually in the United States ACC is characterized by relentless growth, high rates of metastasis and no
            FDA-approved therapies. Available systemic treatments have demonstrated overall response rates (&#8220;<span style="font-style: italic; font-weight: bold;">ORR</span>&#8221;) of 0&#8211;15% and median progression-free survival of approximately seven months,
            representing a significant unmet medical need. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Recommended Phase 2 Dose (&#8220;<span style="font-style: italic; font-weight: bold;">RP2D</span>&#8221;) of 24mg, as of April&#160;24, 2026 REM-422 demonstrated an ORR of 43%, based on best overall tumor response, and a Disease Control Rate (&#8220;<span style="font-style: italic; font-weight: bold;">DCR</span>&#8221;) of 100% in
            biomarker-positive patients. Responses have been durable as of the data cutoff, with median duration of response not yet reached and patients remaining on therapy for up to two years. No dose-limiting toxicities have been observed at any dose
            level, and the rate of Grade 3 or higher treatment-related adverse events at the RP2D was low at 7% (Gr3 noted in 1&#160;patient and was reversible). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix completed an End-of-Phase 1 (&#8220;<span style="font-style: italic; font-weight: bold;">EOP1</span>&#8221;) meeting with the FDA. The FDA authorized Remix to proceed with an ongoing Phase 2 study with proposed key elements, including: recommended dose, the use of the MYB poison exon biomarker as a potential companion diagnostic
            (developed in collaboration with Tempus AI), and single-arm study design for potential registration. At the EOP1 meeting, FDA provided recommendations that have been incorporated into the study including using patient-reported outcome measures.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The potentially registrational Phase 2 portion of the ARIA study of REM-422 in
            ACC is actively enrolling. The Phase 2 study will enroll 40&#8211;50 patients with recurrent, metastatic, or locally advanced unresectable ACC whose tumors are biomarker-positive for the MYB poison exon. Enrollment is more than 60% complete, with
            full enrollment anticipated by year-end 2026. ORR and DoR data are expected approximately in mid-2027. Subject to the results of the Phase 2 study, NDA submission is targeted as early as the second half of 2027 and Remix is preparing for
            potential commercial readiness in 2028. REM-422 has been granted Orphan Drug Designation for the treatment of ACC, and Fast Track Designation for the treatment of patients with recurrent or metastatic ACC whose tumors express MYB transcripts
            containing poison exon by the FDA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">REM-422 is also being evaluated in a Phase 1 dose escalation study in relapsed or
            refractory AML and High-Risk MDS, malignancies affecting approximately 25,000 patients annually in the United States in which MYB dysregulation plays a well-characterized role in disease progression. REM-422 has been generally well tolerated
            across dose levels studied as of February&#160;22, 2026, and clinical responses have been observed. Dose escalation is ongoing with the objective of identifying an RP2D; RP2D determination and top-line data are expected by approximately mid-2027.
            REM-422 has been granted Orphan Drug Designation for the treatment of AML by the FDA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Beyond REM-422, Remix is advancing a pipeline of RNA processing-targeted
            candidates for oncology, including a program targeting MYC-dysregulated cancers, a driver implicated in approximately 25% of all human malignancies. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">219<br/>
        </div>

      </div>

    </div>

    <!--End Page 229-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 230-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">In January&#160;2024, Remix announced a multi-year strategic collaboration with
            Roche for the discovery and development of small molecule therapeutics modulating RNA processing, with the potential for up to $1&#160;billion in milestone payments and tiered royalties. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Pipeline Summary </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 184px; width: 597px;" src="ny20077915x1_table01.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix&#8217;s Strategy </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix intends to become a leading biopharmaceutical company focused on the
            development and commercialization of small molecule therapies that reprogram RNA processing to address previously undruggable oncogenic targets. Remix&#8217;s strategy is to: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Advance REM-422 toward a potential near term approval in ACC.
            <span style="font-weight: normal;">Remix completed an End-of-Phase 1 (&#8220;EOP1&#8221;) meeting with the FDA. The FDA authorized Remix to proceed with an ongoing Phase 2 study with proposed key elements, including recommended dose, the use of the MYB
              poison exon biomarker as a potential companion diagnostic (developed in collaboration with Tempus AI), and single arm study design for potential registration. At the EOP1 meeting, FDA provided recommendations that have been incorporated into
              the study including using patient-reported outcome measures. REM-422 has been granted Fast Track Designation and Orphan Drug Designations in ACC. The potentially registrational Phase 2 portion of the ARIA study is actively enrolling, with
              more than 60% of patients enrolled and full enrollment anticipated by year-end 2026. ORR and Duration of Response data are expected by approximately mid-2027. Based on the data from the Phase 2 trial a potential NDA submission could be
              targeted for as early as the second half of 2027 and Remix will prepare for potential commercial readiness in 2028. </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Maximize the potential value of REM-422 by expanding development into AML, High-Risk MDS, and additional MYB-driven indications.
                    REM-422 is currently being evaluated in a Phase 1 dose escalation study in relapsed or refractory AML and High-Risk MDS, diseases in which MYB dysregulation plays a well-characterized role in driving malignant proliferation. REM-422 has
                    been generally well tolerated across dose levels studied as of February&#160;22, 2026 and clinical responses have been observed. RP2D determination and top-line data are expected by approximately mid-2027. Beyond AML and MDS, MYB
                    dysregulation is implicated in several additional hematological malignancies and solid tumor indications, including breast cancer, lymphoma, T-cell acute lymphoblastic leukemia, and colorectal cancer, representing a broad opportunity to
                    extend the clinical development of REM-422 beyond the lead target indications. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Advance Remix&#8217;s preclinical and discovery programs into clinical development. </span>Remix is
                    progressing chemical matter for several potential high value oncology and neurology targets, including an mRNA degrader approach for MYC-dysregulated cancers with nomination of a Development Candidate expected in 2027. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Continue to invest in REMaster technology platform and discovery efforts to identify new
                      targets. </span>Remix will continue to invest in its data analytic, novel high through-put screening technologies, structural biology and next-generation chemistry capabilities to identify and design molecules to address new targets
                    and therapeutic areas. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-weight: bold;">Evaluate strategic partnerships and collaborations to maximize the potential of Remix&#8217;s
                      platform. </span>Given the broad applicability of Remix&#8217;s approach, Remix may enter into strategic collaborations intended </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">220<br/>
        </div>

      </div>

    </div>

    <!--End Page 230-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 231-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_bl" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">to advance and accelerate its development programs, expand into new therapeutic
            areas and enhance capabilities of its platform. In 2022, Remix announced a multi-year strategic collaboration with Janssen for three targets in oncology and immunology. In 2024, Remix announced a multi-year strategic collaboration with Roche
            for an undisclosed number of targets across multiple therapeutic areas. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Unmet Need in ACC </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There is a critical need for a precision therapy that targets the molecular
            driver of ACC, a rare malignancy affecting more than 1,500 new patients per year in the United States and approximately 13,000&#8211;15,000 patients living with the disease. ACC has no FDA-approved therapies despite the high rate of metastases.
            Surgery is currently the standard of care, but disease will recur in 50-75% of patients, nearly all of whom will eventually require systemic treatment. TKIs (Tyrosine kinase inhibitors) and chemotherapeutic agents offer low response rates and
            tolerability challenges. Most patients will eventually require systemic therapy, however available systemic treatments demonstrate ORR of only 0&#8211;15% and median progression-free survival of approximately seven months, representing a significant
            unmet medical need. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">REM-422 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s lead product candidate, REM-422, is an investigational, orally available,
            potent and selective small molecule mRNA degrader of MYB, a transcription factor and key oncogenic driver of multiple solid tumors and hematological malignancies (Cicir&#242; 2021). Though MYB has been classically regarded as &#8220;undruggable&#8221;,
            (George&#160;2014; Tao 2017), Remix has identified a poison exon (&#8220;<span style="font-style: italic; font-weight: bold;">PE</span>&#8221;) that has the potential to be modulated by REM-422 and thereby significantly reduce MYB expression through inducing
            degradation of its mRNA. While the primary role of MYB in normal cells is to regulate differentiation and proliferation of hematopoietic cells and a subset of epithelial tissues (Zhou 2011), recurrent genetic lesions and evidence of
            dysregulation have been observed for MYB in a variety of cancers, including ACC and acute myelogenous leukemia (AML) (Cicir&#242; 2021). MYB dysregulation is a defining characteristic of ACC, with &gt;90% of patients exhibiting genomic or molecular
            activation of MYB (Persson 2022; Wagner 2022). Remix is currently developing REM-422 initially in ACC and AML/MDS. Remix has an ongoing Phase 1/2 study in ACC, with full ORR and DOR data anticipated in the second half of 2027. As of April&#160;24,
            2026, the study has demonstrated a favorable ORR of 43%, based on best overall tumor response which has exceeded historical third party benchmarks of available standard of care agents. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Adenoid Cystic Carcinoma Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">ACC is a rare malignant tumor of secretory (glandular) tissue. It most commonly
            forms in the salivary glands but can also occur in other glands, like the tear or sweat glands (Cleveland Clinic, 2024), and arises outside the head and neck in the esophagus, breast, lung, and vulva, among other sites (Li et al., Cancer
            2012)). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">ACC is notorious for its propensity for neural invasion, local recurrence, and
            distant metastasis (Jia et al., 2024), and is otherwise characterized by relentless growth and frequent local recurrence that can appear many years after treatment (Ouyang et al., 2017). </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Prevalence </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Worldwide, the yearly incidence of ACC is 3-4.5 cases per million with
            approximately 5,500 new cases of ACC annually and in the U.S. there are estimated to be &gt;1,500 new cases annually with over 13,000-15,000 people living with ACC in US. Relapse after definitive local surgery is continuous over time with up to
            70% of patients developing recurrence or metastatic disease. There is an estimated incidence of &gt;1,500, and a projected prevalent population of approximately 13,000 &#8211; 15,000 patients in the U.S. MYB translocations are present in
            approximately 75% of ACCs, predominantly MYB-NFIB fusions. The majority of patients without MYB -fusions have overexpression of wild-type MYB, making the overall frequency of MYB dysregulation &gt;90% (Persson, 2022). </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Treatments for ACC </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">ACC currently has no approved systemic therapies. Surgery is the current standard
            of care for patients who are surgical candidates, but disease will recur in 50-75% of patients following surgery, with many patients having multiple recurrences and surgeries. After recurrence, patients are then treated with TKIs or
            chemotherapy; however, these options have only an 11-15% ORR with 7-9 month mPFS or 13% ORR with 5-20 month mPFS, respectively. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">221<br/>
        </div>

      </div>

    </div>

    <!--End Page 231-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 232-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix&#8217;s Proposed Solution, REM-422, for ACC </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix believes REM-422, as an orally delivered drug that is designed to target
            the underlying MYB-regulated biology that drives ACC, has the potential to meaningfully transform the standard of care in recurrent, metastatic or locally advanced unresectable ACC. REM-422 is an investigational, potent and selective small
            molecule mRNA degrader of the MYB oncogene, designed to address &gt;60-65% of the ACC population that are poison exon positive. The pharmacokinetic (PK) properties of REM-422 were optimized via medicinal chemistry in effort to achieve a profile
            that would result in drug exposures sufficient to drive the desired pharmacodynamic (PD) effect of reducing MYB mRNA levels <span style="font-style: italic;">in vivo</span> in order to elicit anti-tumor activity. Multiple third-party <span style="font-style: italic;">in vitro</span> and <span style="font-style: italic;">in vivo </span>preclinical studies provide evidence that MYB can be a driver oncogene in both hematologic and solid tumors (Pattabiraman 2013; Takao 2021;
            Zuber 2011). Collectively, Remix believes these observations illustrate the fundamental importance of MYB in a variety of malignancies and support the hypothesis that targeting MYB is a viable therapeutic strategy for treating cancer. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The MYB pre-mRNA contains a PE normally not included in the mature MYB mRNA.
            REM-422 is designed to facilitate an interaction between the U1 spliceosome complex and the 5&#8242; splice site associated with a normally unused PE in the MYB pre-mRNA transcript. The PE is normally not included in mature MYB mRNA as the
            unfavorable interaction between the U1snRNP complex and the weak 5&#8217; splice site causes an exclusion of the PE when the U1snRNP complex is unable to bind. Addition of REM-422 has the potential to lead to PE inclusion and consequent MYB mRNA
            degradation via the Nonsense-Mediated Decay (NMD) pathway.</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; text-align: center;">Schematic showing proposed mechanism of REM-422 resulting in M&amp;B mRNA
            degradation</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; text-align: center;"><img style="height: 310px; width: 593px;" src="ny20077915x1_flowchart01.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">AML Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Acute myeloid leukemia (AML) is a heterogenous hematologic disease that causes
            the body to produce too many myeloblasts, limiting space for healthy blood cells to form. This begins in the bone marrow with the potential to move quickly into the blood, as well. AML generally does not form solid tumor masses but is
            widespread throughout the bone marrow and can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord) and testicles. Myelodysplastic syndrome with excess blasts
            (high-blast MDS) is a subgroup of MDS, which represents a group of blood disorders characterized by abnormal development of blood cells within the bone marrow. According to the American Cancer Society, approximately 1 in 3 MDS patients see
            their condition evolve into AML. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Prevalence </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix estimates there are approximately 25,000 treatable AML and high-blast MDS
            patients in the United States. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">222<br/>
        </div>

      </div>

    </div>

    <!--End Page 232-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 233-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Treatments for AML </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The primary treatment for most types of AML during the remission induction phase
            is chemotherapy, sometimes along with targeted therapies depending on the genetic mutation. This might be followed by a stem cell transplant. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix&#8217;s Proposed Solution, REM-422, for
            AML </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix believes there is potential for broad activity for REM-422 across AML and
            MDS, both as a single agent or in combination with other therapies, given its highly differentiated proposed mechanism of action. MYB is overexpressed in nearly all AML patient samples, and Remix believes the lack of
            translocations/rearrangements in MYB in this disease suggests that patient selection based on PE status will not be necessary, as nearly all AML patient cells will express MYB containing the PE, and are thereby targetable by REM-422. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">REM-422 Clinical Studies </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is evaluating REM-422 in a Phase 1/2 study in recurrent or metastatic ACC
            and a Phase 1 study in relapsed or refractory AML and HR-MDS as summarized in the table below. In Q3 2023, Remix was allowed to proceed by the FDA in ACC under an Investigational New Drug Application (&#8220;<span style="font-style: italic; font-weight: bold;">IND</span>&#8221;). The Phase 1/2 study, also known as ARIA, is a first-in-human, open-label, multicenter dose-escalation study in recurrent/metastatic ACC and began patient enrollment in the Phase 1 portion in 1Q2024. ARIA
            included a starting dose of 3 mg once daily, selected based on the results from Good Laboratory Practice (&#8220;<span style="font-style: italic; font-weight: bold;">GLP</span>&#8221;) toxicology studies. Remix completed an End-of-Phase 1 (&#8220;EOP1&#8221;) meeting
            with the FDA. The FDA authorized Remix to proceed with an ongoing Phase 2 study with proposed key elements, including: recommended dose, the use of the MYB poison exon biomarker as a potential companion diagnostic (developed in collaboration
            with Tempus AI), and single arm study design for potential registration. At the EOP1 meeting, FDA provided recommendations that have been incorporated into the study including using patient-reporting outcome measures. In addition, Remix agreed
            to include Patient Reported Outcomes in a subset of the Phase 2 cohort to provide supportive evidence of potential clinical benefit. Remix believes this provides a potential path to an NDA submission based on the results from the Phase 2
            portion of the ARIA study, potentially as early as the second half of 2027. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-top: 1pt solid #000000; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 76.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 76.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 76.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 108pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 76.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Program / Target</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Proposed Mechanism</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: justify;">Primary Target </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Indications</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stage / Status</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Development Focus </div>
                </td>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 2.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">REM-422 / MYB</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 2.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Small-molecule MYB mRNA degrader via poison-exon inclusion</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 2.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adenoid cystic carcinoma</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 2.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical; Phase 1/2 with Phase 2 cohort in biomarker-positive ACC ongoing</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 2.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Advance biomarker-selected development and generate ORR and durability
                    data </div>
                </td>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">REM-422 / MYB</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Small-molecule MYB mRNA degrader</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Relapsed/refractory AML and HR-MDS (no biomarker needed)</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 108pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Clinical; Phase 1 dose escalation ongoing</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 76.25pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Define RP2D and evaluate monotherapy and combination potential</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 76.25pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 76.25pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 76.25pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 108pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 76.25pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">223<br/>
        </div>

      </div>

    </div>

    <!--End Page 233-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 234-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Clinical Trials and Data in ACC </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Phase 1/2 ARIA Study Overview</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: Arial, Helvetica, sans-serif; font-size: 11.5pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">Phase 1/2 ARIA (<span style="text-decoration: underline;">A</span> Study Overview of <span style="text-decoration: underline;">R</span>EM-422 <span style="text-decoration: underline;">i</span>n <span style="text-decoration: underline;">A</span>denoid

            Cystc Carcinoma) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.25pt; text-align: center;"><img style="height: 257px; width: 613px;" src="ny20077915x1_flowchart0x2.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Phase 1 cohort enrolled 69 all-comer ACC patients across dose levels from 3
            mg to 48 mg QD with additional patients enrolled in 18 mg and 24 mg to identify the RP2D. The primary objectives included safety and identification of the RP2D; secondary objectives included PK, PD, and efficacy evaluations. The patients&#8217; tumor
            biopsies were evaluated retrospectively to determine MYB status. Radiographic response was assessed by RECIST v1.1. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At ASCO 2026, Phase 1 data were presented (data-cut April&#160;24, 2026). Data as of
            the cutoff date showed 69 patients were treated with no dose-limiting toxicities (DLTs) reported across 3&#8211;48 mg and no study-treatment-related deaths. Additionally, the ORR was 43% and DCR was 100% at the RP2D in biomarker positive patients,
            based on best overall tumor response. The median age was 57 years, with 75% of patients receiving 1 or more prior lines of systemic therapy. The majority of patients (78%) had salivary gland tumor as the primary site. Additionally, 16% had
            solid histology or high-grade transformation indicating more aggressive disease, while 26% were also ACC subtype I (indicating a more aggressive phenotype). As of the data cut off date, biomarker positivity in the study was 51%. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 284px; width: 613px;" src="ny20077915x1_table02x1.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">224<br/>
        </div>

      </div>

    </div>

    <!--End Page 234-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 235-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ARIA Safety Data </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of the April&#160;24, 2026 data cut-off there were no dose-limiting toxicities
            reported at any of dose levels tested (3-48 mg), and REM-422 was described as well tolerated at 24 mg QD, the selected RP2D. PK and PD results supported 24mg dosing. REM-422 PK data showed dose proportional increase in exposure, and PD data
            showed more than 80% target engagement at &#8805;24 mg indicating MYB mRNA levels decreasing, leading to subsequent MYB protein level decrease in the example tumor biopsy provided.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 208px; width: 613px;" src="ny20077915x1_charts01x1.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of the April&#160;24, 2026 data cutoff date, the RP2D was generally well tolerated
            relative to higher doses and demonstrated limited Grade 3&#8211;4 TRAEs at 24 mg, supporting 24 mg QD as the RP2D based on the combined PK/PD, efficacy and safety results. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of the April&#160;24, 2026 data cutoff date, eighteen (26.1%) participants
            experienced TRAEs &#8805; Grade 3 as indicated in slide below. There was a steep increase in the frequency of more severe toxicity in the 38 mg and 48 mg starting dose levels. The combined higher frequency of related hematologic and non-hematologic
            toxicity events in the 30&#160;mg, 38 mg and 48 mg dose levels underscores the intolerability for long-term dosing at these higher dose levels in ACC. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 163px; width: 613px;" src="ny20077915x1_table03x2.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">225<br/>
        </div>

      </div>

    </div>

    <!--End Page 235-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 236-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">ARIA Preliminary Clinical Activity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The data cutoff date was April&#160;24, 2026 for the preliminary clinical activity
            discussed below. The waterfall plot showing change in tumor size from baseline by biomarker status indicates that biomarker positive patients demonstrated robust anti-tumor activity with many remaining on treatment at the time of data cutoff.
            An exemplary radiographic image is included for one patient that suggests lung nodules noted have improved notably by month&#160;5&#160;on-treatment scan.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 223px; width: 613px;" src="ny20077915x1_barchart01x2.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 158px; width: 613px;" src="ny20077915x1_barchart02x1.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the waterfall plot is further divided by dose level showing only biomarker
            positive patients, the anti-tumor activity was predominant at the 24 mg dose level. Furthermore, the ORR was 43% and DCR was 100% at RP2D in biomarker positive patients, based on best overall response. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The spider plot shows objective responses were noted in both ACC subtypes, across
            histologies and irrespective of prior lines of therapy as shown below. Responses were durable, with many patients with responses still on therapy at the time of data cutoff. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 163px; width: 613px;" src="ny20077915x1_linechart0x4.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is currently conducting the potentially registrational Phase 2 portion of
            the study with approximately 40-50 patients dosed at RP2D with metastatic, recurrent, or unresectable ACC who are prospectively confirmed MYB PE positive by central investigational use only (IUO) assay. The eligibility criteria include
            measurable disease by RECIST v1.1 and radiographic progression within 12 months prior to enrollment. The primary objective of the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">226<br/>
        </div>

      </div>

    </div>

    <!--End Page 236-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 237-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Phase 2 is ORR by RECIST 1.1 by BICR. Secondary objectives include, but not
            limited to, progression-free survival, duration of response, overall survival, disease control rate, and safety. The potentially registrational Phase 2 study is currently &gt;60% enrolled with full enrollment expected in 2H 2026. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Phase 1 Trial of REM-422 in AML/HR-MDS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Phase 1 trial in AML/HR-MDS is currently enrolling patients with relapsed and
            refractory disease. The primary objective of the dose escalation is to evaluate the safety and tolerability of REM-422. Dose expansion of up to 125&#160;patients is planned to evaluate safety at RP2D and preliminary antitumor activity including rate
            of CR/CRh.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 303px; width: 613px;" src="ny20077915x1_flowchart0x3.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of the February 22, 2026 data cut, 62 AML/HR-MDS patients have been treated in
            Phase 1 study exploring doses ranging from 1mg to 30mg. As of the data cutoff, Remix believes the safety results have been acceptable for an R/R AML/HR-MDS Phase 1 population. There was one 1 DLT: ALT increase observed at the 6 mg dose level.
            This cohort was subsequently expanded and no additional DLTs have been noted at that or other dose levels. No REM-422-related deaths occurred. PD data suggest MYB mRNA reduction in bone marrow that was noted with increased doses of REM-422.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">227<br/>
        </div>

      </div>

    </div>

    <!--End Page 237-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 238-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">As of the data cutoff, TEAEs in &gt;10% of patients included fatigue,
            diarrhea, epistaxis, pneumonia, decreased appetite, dyspnea, febrile neutropenia and nausea. Grade &#8805;3 REM-422-related TEAEs occurred in 12/62 patients, 19.4%, with the highest number in the 30 mg starting dose group. Two patients, 3.2%, had
            REM-422-related SAEs: colitis and differentiation syndrome, both Grade 3. As of 22 February&#160;2026 datacut, early activity was observed in patients with relative reductions in blast counts and multiple responses at various dose levels and with
            various cytogenetics in heavily pre-treated patients including CR, CRi, CRuni and MLFS as indicated in table below. Dose escalation is currently ongoing and the RP2D has not been determined. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 223px; width: 613px;" src="ny20077915x1_table04x1.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">REM-422 Preclinical Data </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has evaluated the specificity, selectivity, and anti-tumor activity of
            REM-422 in preclinical models of both ACC and AML. Remix also has a robust NHP dataset showing acceptable non-clinical safety results. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">REM-422 has observed high specificity and selectivity for the MYB PE. In an <span style="font-style: italic;">in vitro</span> assay system REM-422 increased the binding affinity of the MYB poison exon to the U1 snRNP complex but not to a closely related non-MYB PE. Experiments carried out in leukemia cells demonstrate that
            REM-422 treatment promoted inclusion of the PE which led to degradation and reduced expressed of the mature MYB mRNA transcript, as assessed by quantitative polymerase chain reaction (qPCR). RNAseq experiments demonstrated that REM-422
            treatment led to gene expression changes similar to those observed after genetic knockdown (shRNA) of MYB in the same leukemia cell line. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">228<br/>
        </div>

      </div>

    </div>

    <!--End Page 238-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 239-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">REM-422 treatment led to the reduction of
            MYB mRNA and phenocopies genetic knockdown of MYB in human cancer cell lines</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 368px; width: 409px;" src="ny20077915x1_linechart0x1.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 261px; width: 500px;" src="ny20077915x1_linechart0x2.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Oral dosing of REM-422 in ACC
            patient-derived xenograft (PDX) models demonstrated anti-tumor activity and reduction of MYB mRNA and protein levels selectively in models that express the PE targeted by REM-422<span style="font-style: normal; font-weight: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Oral dosing of REM-422 to mice bearing human tumor xenografts derived from an ACC
            patient tumor with a MYB fusion that contains the PE (ACCX11 model) led to tumor regressions, with IHC staining for MYB demonstrating strongly reduced staining after REM-422 treatment. In contrast, dosing of REM-422 in mice bearing tumors
            derived from the ACCX20M1 model, which expresses a MYB fusion that excludes the PE, demonstrated no meaningful anti-tumor activity and no effect on MYB protein levels after treatment. These data support Remix&#8217;s view that MYB is a driver
            oncogene in ACC and REM-422 has the potential to address ACC patients whose tumors express MYB transcripts that contain the PE targeted by REM-422.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">229<br/>
        </div>

      </div>

    </div>

    <!--End Page 239-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 240-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 285px; width: 614px;" src="ny20077915x1_linechart0x5.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">REM-422 demonstrated monotherapy and
            combination activity in AML models </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">REM-422 also has been evaluated in a number of AML cell models <span style="font-style: italic;">in vitro</span> and <span style="font-style: italic;">in vivo</span>. The figure below (left) shows the activity in a disseminated human AML PDX model, in which leukemic blasts are taken from AML patients and
            engrafted into immunodeficient mice. Oral administration of REM-422 resulted in a significant reduction in human AML cells (hCD45+) in both the bone marrow and periphery compared to vehicle treatment. The vehicle-treated mice also showed a
            steady reduction in body weight during the course of the study which would have required euthanasia. In contrast, the REM-422 treated animals maintained a normal body weight, reflecting the potential survival benefit in this model. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The figure also shows the results of <span style="font-style: italic;">in vitro
            </span>studies of REM-422 in combination with multiple chemotherapy and targeted agents used in AML treatment. Twelve AML cell lines were treated with REM-422 or each agent in dose response as monotherapy or in combination and cell viability
            was assessed for additive, synergistic, or antagonistic relationships between the two agents. As seen in the bar graph, nearly all combinations were assessed as additive or synergistic, consistent with the highly differentiated proposed
            mechanism of action of REM-422. These results support REM-422&#8217;s potential for development as a combination therapy in AML.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 299px; width: 613px;" src="ny20077915x1_charts02x2.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has conducted 28-day GLP IND-enabling safety studies with once-daily oral
            dosing of REM-422 in rats and cynomolgus monkeys. Dose-limiting toxicities were hematological and gastrointestinal in nature; the findings are </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">230<br/>
        </div>

      </div>

    </div>

    <!--End Page 240-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 241-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">considered monitorable and reversible. Exposures associated with PD modulation
            of MYB were well-tolerated. Remix believes REM-422 demonstrated an acceptable non-clinical safety profile for clinical development. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Companion Diagnostic </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Companion diagnostic development is a key component of the REM-422 clinical
            strategy, with the goal of enabling prospective identification of patients most likely to benefit from MYB mRNA degradation. In the ACC program, biomarker work has focused on detecting MYB PE status in tumor tissue, with central testing used to
            support patient selection for expansion cohorts. In ACC, the Phase 2 cohort requires biomarker-positive disease by a central IUO assay, reflecting Phase 1 data showing that clinical activity was enriched in biomarker-positive patients. In
            AML/HR-MDS study, MYB PE testing is not necessary since all patients have the PE in this patient population. Efforts are ongoing to align REM-422 ACC clinical development with a fit-for-purpose diagnostic path that can identify eligible
            patients, support regulatory interactions and potentially enable a precision-medicine label. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">With an estimated prevalence of 75% of ACC cases having MYB translocations, and
            the majority of patients with overexpression of wild-type MYB are without MYB-fusions. A companion diagnostic is in parallel development with REM-422 in an effort to prospectively define the ACC patient population that are MYB poison exon
            positive and that Remix believes is suitable for treatment with REM-422. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under contract with Remix&#8217;s diagnostic partner, Remix is further developing the
            IUO clinical trial assay used in Remix&#8217;s Phase 2 trial as a potential companion diagnostic. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the additional Phase 2 centers in France, Remix has a Clinical Performance
            Study (&#8220;<span style="font-style: italic; font-weight: bold;">CPS</span>&#8221;) in place through its diagnostic partner to enable prospective testing using the same IUO assay, with the goal of eventually obtaining CE Marking in Europe. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Discovery Programs </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s proprietary REMaster&#8482; technology platform is designed to enable the
            identification of compounds that control RNA processing and correct dysregulation or eliminate deleterious mRNAs altogether. The <span style="font-style: italic;">REMaster&#8482; </span>Platform comprises a suite of <span style="font-style: italic;">in silico</span> and experimental capabilities. Sequential deployment of these tools makes it possible to identify, validate and prioritize PE targets, and to screen and optimize small molecules that have the potential drive the
            inclusion of these PEs within mRNA transcripts to promote degradation of high value/genetically validated gene targets for potential therapeutic benefit. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The oncoprotein MYC is a pleiotropic transcription factor that modulates global
            gene expression and regulates critical cellular processes including proliferation, differentiation, cell cycle, metabolism and apoptosis. Strong evidence supports aberrant MYC expression as a driver of both tumor initiation and maintenance, and
            it is associated with all the &#8220;hallmark&#8221; features of cancer. However, despite significant effort, targeting MYC with small molecules still represents a substantial challenge, particularly at the protein level. MYC has no enzymatic activity or
            active site and is intrinsically disordered with limited options for ligand binding, precluding structure-guided drug design; as such the protein is considered undruggable. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has developed a novel strategy to tackling MYC dependent cancers that has
            the potential to address many of the challenges with MYC. Using the REMaster&#8482; platform, Remix has identified a PE inclusion event in a key MYC-regulator protein, validated to be NMD sensitive and modulable by small molecules. Remix&#8217;s
            MYC-dependent cancer drug discovery program builds on this observation to directly tackle aberrant MYC transcriptional activity. Remix believes that the preclinical data generated to date support that Remix&#8217;s investigational MYC-regulator
            protein mRNA degraders have potential to address patients whose tumors are MYC-amplified or activated. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix continues to explore other small molecules that have the potential to
            selectively degrade mRNA and prevent protein expression and is upstream from more traditional therapeutic approaches that attempt to drug proteins. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Collaboration Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We leverage our REMaster&#8482; drug discovery platform to expand the potential
            applications for modulating RNA processing through strategic collaborations with our partners. These collaborations are intended to combine Remix&#8217;s platform and RNA processing expertise with Remix&#8217;s partners&#8217; disease-area, development and
            commercialization capabilities. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">231<br/>
        </div>

      </div>

    </div>

    <!--End Page 241-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 242-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Janssen Research Collaboration Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In February&#160;2022, we and Janssen Pharmaceutica NV (&#8220;<span style="font-style: italic; font-weight: bold;">Janssen</span>&#8221;) entered into a research collaboration agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Janssen Agreement</span>&#8221;), for the discovery and development of small molecule
            therapeutics that modulate RNA processing using Remix&#8217;s REMaster drug discovery platform. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As consideration for the licenses granted under the Janssen Agreement, Janssen
            paid an upfront payment of $45.0&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On July&#160;1, 2026, Janssen gave notice of termination of the Janssen Agreement,
            which will be effective on August&#160;30, 2026. Remix will have no further obligations under the Janssen Agreement upon its termination. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Roche Research Collaboration and License
            Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, we and F. Hoffmann-La Roche Ltd. (&#8220;<span style="font-style: italic; font-weight: bold;">Roche</span>&#8221;) entered into a research collaboration and license agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Roche Agreement</span>&#8221;) for the discovery and development of small molecule
            therapeutics that modulate RNA processing using the REMaster drug discovery platform, pursuant to which we granted Roche: (a) an exclusive license under certain of our intellectual property rights to develop, manufacture and commercialize
            compounds, any products containing such compounds and any companion diagnostics for such products for all fields of use worldwide, provided that such license excludes any rights to our platform technology; and (b) an exclusive license under any
            jointly developed intellectual property solely in conjunction with the development, manufacture or commercialization of such product. We are responsible for certain discovery and preclinical activities, and Roche will be responsible for
            development and commercialization of any licensed compounds and licensed products arising under each research program. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other than as required to complete the research activities under a research
            program, from the effective date of the Roche Agreement until the earliest of: (a) the initiation of the first phase 2 study for the first licensed compound or licensed product directed to a collaboration target; (b) expiration of the
            applicable research program for such collaboration target; and (c) termination of the applicable research program for such collaboration target, we agreed not to exploit any compound that has its primary mechanism of action against such
            collaboration target. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As consideration for the licenses granted under the Roche Agreement, Roche made
            an upfront payment of $30.0&#160;million. We are also eligible to receive from Roche (a) preclinical, clinical, commercial and sales milestone payments of up to $1.0&#160;billion and (b) tiered royalties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2024, Remix announced that a near-term preclinical milestone under the
            Roche Agreement had been achieved. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless earlier terminated, the Roche Agreement will remain in effect for each
            licensed product until expiration of the royalty term for such licensed product. The parties have included termination provisions in the agreement, allowing termination of the Roche Agreement in its entirety or on a research program-by-research
            program, licensed product-by-licensed product or country-by-country basis. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Tempus Master Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In August&#160;2023, we and Tempus AI, Inc. entered into a master agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Tempus Agreement</span>&#8221;), pursuant to which Tempus will provide us with certain analytical and companion diagnostic development services. In connection with the services provided by Tempus,
            Tempus grants us a non-exclusive license under certain of Tempus&#8217; de-identified data cohorts to use for our research and development of indications of interest for REM-422. Under the Tempus Agreement, we are leveraging Tempus&#8217; de-identified,
            multimodal data and its Lens data analytics platform to interrogate specific patient cohorts. The services under the Tempus Agreement also include next-generation sequencing support for the REM-422 clinical trial. In particular, we are also
            utilizing Tempus&#8217; xT and xR assays to capture DNA and RNA data. Unless earlier terminated, the Tempus Agreement will continue subject to automatic one-year renewals. Either party may terminate the Tempus Agreement for the material breach of the
            other party, subject to specified cure periods. Either party may also terminate the Tempus Agreement without cause at any time, subject to a specified notice period. The Tempus Agreement may terminate if either party determines in good faith
            that a change in applicable law or regulation makes part of the Tempus Agreement illegal or unenforceable or materially changes the economic benefit or cost of performing the Agreement, subject to a specified period to negotiate amendments to
            resolve such changes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In March&#160;2026, we entered into an order form under the Tempus Agreement setting
            forth the terms for the co-development with Tempus of companion diagnostics for REM-422 (the &#8220;<span style="font-style: italic; font-weight: bold;">Work Order</span>&#8221;). Unless earlier </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">232<br/>
        </div>

      </div>

    </div>

    <!--End Page 242-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 243-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">terminated in accordance with the terms of the Tempus Agreement or the terms
            of the Work Order, the Work Order will continue until all milestones set forth therein have been achieved. We have the right to terminate the Work Order for convenience, subject to a cancellation fee based on work conducted by Tempus to achieve
            the subsequent milestones. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Remix&#8217;s Team </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix was co-founded by Pete Smith, Remix&#8217;s President and CEO, and Atlas Venture.
            Remix is led by seasoned industry drug discovery veterans with proven track records, as well as extensive experience and deep knowledge in: RNA biology and processing, small molecule RNA processing modulators, oncology, neurology,
            bioinformatics and data sciences, chemistry, multiplexed assay systems, biophysics and biochemistry, structural biology, translational medicine, and clinical development. In addition, Remix&#8217;s executive leadership team has a successful track
            record of company building and leading biotech companies including Pete Smith, Ph.D., President and CEO, an experienced executive and company builder with over 25 years of diverse industry experience including research, business and strategy;
            Heather Wasserman, Ph.D., Chief Operating Officer and Chief Business Officer, a seasoned executive with over 25 years in business development, strategy, finance and operations; Mythili Koneru, MD, Chief Medical Officer, who has over 20 years of
            successful drug development, medical affairs and medical practice experience; and Dominic Reynolds, Chief Scientific Officer, a 25 year industry veteran with roles across research and drug discovery. The management team is complemented by a
            world class scientific advisory group and close collaborators with expertise in RNA biology and processing, structural biology, oncology, neurology and translational medicine. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Since inception and prior to the announcement of its merger with Passage Bio,
            Remix has raised more than $200 million in equity capital from premier life sciences investors, including Atlas Ventures, The Column Group, Foresite Capital, Arch Venture Partners, Surveyor Citadel, Casdin Capital and Alexandria Ventures. On
            June&#160;24<sup>th</sup>, 2026, Remix announced it entered into a reverse merger transaction with Passage Bio, a publicly traded biotech company, to create a new public company with the sole focus of advancing Remix&#8217;s pipeline. In support of the
            merger, Remix has secured commitments for a $100 million investment in Remix&#8217;s common stock from premier venture capital funds, healthcare-dedicated funds, major mutual funds and other leading investors, that is expected to close immediately
            prior to completion of the merger. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Background </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Aberrantly expressed proteins are a fundamental driver of many diseases,
            particularly cancer, where inappropriate activation, overexpression, or ectopic expression of oncogenic proteins can promote uncontrolled proliferation, metastasis, immune evasion and therapeutic resistance. While these proteins represent
            compelling therapeutic targets, many remain &#8220;undruggable&#8221; because they lack well-defined binding pockets or function through protein-protein interactions that are difficult to inhibit with conventional small molecules. An alternative strategy
            is to selectively reduce production of these disease-causing proteins by targeting processing of their underlying mRNAs for degradation, thereby preventing protein synthesis regardless of the protein&#8217;s structural tractability. Remix believes
            that small-molecule mRNA degraders have the potential to expand the therapeutic landscape by enabling selective modulation of disease drivers that have historically been inaccessible to traditional drug discovery approaches. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">RNA Processing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">RNA processing comprises a series of steps that occur after transcription of DNA
            into precursor-messenger RNA (pre-mRNA) and before mRNA translation into protein. These processes regulate the composition, abundance, localization and stability of RNA molecules and are critical determinants of gene expression. Key RNA
            processing mechanisms include alternative splicing, exon inclusion or exclusion, intron removal, alternative polyadenylation, RNA editing and pathways that govern RNA stability and degradation. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">233<br/>
        </div>

      </div>

    </div>

    <!--End Page 243-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 244-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">One important regulatory mechanism involves the inclusion of PEs which are
            naturally occurring exons that contain premature termination codons (&#8220;<span style="font-style: italic; font-weight: bold;">PTC</span>&#8221;). Inclusion of a PE can render the resulting mRNA transcript susceptible to degradation through the
            nonsense-mediated decay (&#8220;<span style="font-style: italic; font-weight: bold;">NMD</span>&#8221;) pathway, a cellular quality-control mechanism that identifies and degrades transcripts containing PTCs. Through coordinated control of PE inclusion and
            NMD, cells can modulate the expression levels of specific genes and proteins.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 367px; width: 593px;" src="ny20077915x1_flowchart04.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s platform is designed to identify and develop small molecules that
            modulate RNA processing pathways, including alternative splicing and PE regulation. By selectively altering RNA processing decisions, Remix&#8217;s approach is intended to increase, decrease or otherwise modify the expression of disease-associated
            genes. Remix believes that targeting RNA processing may provide a therapeutic strategy for addressing disease drivers that are difficult to modulate using conventional approaches directed at proteins, including targets that have historically
            been considered undruggable. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Remix&#8217;s Approach and the Opportunity to Use mRNA Degradation
            for Unlocking Undruggable Targets </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s proprietary REMaster&#8482; technology platform is designed to enable the
            identification of compounds that control RNA processing and correct dysregulation or eliminate deleterious mRNAs altogether. Remix believes that small molecule induced mRNA degradation presents an opportunity to address the limitations of other
            therapies and transform the treatment paradigm for a variety of diseases. Remix built its proprietary REMaster&#8482; platform to have visibility into multiple steps of the RNA processing cascade for target discovery and modulation and expands to
            boosting RNA expression or skipping over mutations in exons. This technology identifies small molecules that selectively degrade mRNA and prevent protein expression and is upstream from more traditional therapeutic approaches that attempt to
            drug proteins. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Remix&#8217;s approach to co-opting RNA processing with small molecules is outlined
            below: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The U1snRNP complex is part of the spliceosome machinery, that initiates mRNA splicing, which is the process of editing newly
                    transcribed pre-mRNA by excising non-coding regions (&#8220;<span style="font-style: italic; font-weight: bold;">introns</span>&#8221;) and stitching together coding regions (&#8220;<span style="font-style: italic; font-weight: bold;">exons</span>&#8221;) to
                    generate a mature mRNA for translation into functional protein </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The U1snRNP complex binding to 5&#8217; splice site is an important step that facilitates exon recognition and inclusion into a mature
                    mRNA </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PEs are naturally occurring exons that contain premature termination codons (&#8220;<span style="font-style: italic; font-weight: bold;">PTCs</span>&#8221;) and are normally not included in mature mRNA allowing for normal protein expression </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">234<br/>
        </div>

      </div>

    </div>

    <!--End Page 244-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 245-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">PEs are excluded from mature mRNA due to the unfavorable interaction between the U1snRNP complex and the weak 5&#8217; splice site + a
                    PE</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 262px; width: 594px;" src="ny20077915x1_graphic01.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The REMaster&#8482; platform identifies small molecule RNA glue compounds (blue diamond below) that induce the interaction between the
                    U1snRNP complex and the weak 5&#8217; splice site of a PE leading to PE inclusion in the mature mRNA and subsequent degradation via the NMD pathway. Thereby providing a mechanism with the potential to enhance PE use by increasing the
                    recognition of weak 5&#8217; splice sites with small molecules.</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 266px; width: 594px;" src="ny20077915x1_graphic02.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Accordingly, this mechanism that uses PEs to control gene expression can be
            co-opted and controlled with small molecules that Remix discovers leading to the potential to potentially degrade targets of known importance in various diseases (Neil et. Al, 2022; Love et. Al., 2023; Ewa Rogalska, Vivori and Vaclcarcel,
            2023). The REMaster&#8482; platform scans the transcriptome and locates PE targets; Remix then designs assays to identify small molecules that force their inclusion and selectively degrade the corresponding mRNA in a controlled manner. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">235<br/>
        </div>

      </div>

    </div>

    <!--End Page 245-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 246-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix&#8217;s REMaster&#8482; Drug Discovery Platform</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 334px; width: 594px;" src="ny20077915x1_graphic03.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The <span style="font-style: italic;">REMaster&#8482; </span>Platform comprises a
            suite of <span style="font-style: italic;">in silico</span> and experimental capabilities. Sequential deployment of these tools makes it possible to identify, validate and prioritize PE targets, and to screen and optimize small molecules that
            drive the inclusion of these PEs within mRNA transcripts to promote degradation of high value/genetically validated gene targets for therapeutic benefit. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Initially, an extensive transcriptomic database comprised of terabytes of RNA-Seq
            and next-generation sequencing (&#8220;<span style="font-style: italic; font-weight: bold;">NGS</span>&#8221;) data is mined via machine learning to identify potential PE targets. Genetic and functional assays, which repair mismatches between the U1snRNP
            complex and 5&#8217; splice sites, are then employed to determine the extent to which each PE can be included within a mRNA transcript of interest. This step provides key empirical conviction for each PE target site. Remix then screens a proprietary
            chemical library enriched in compounds designed to target RNA/RBPs (&#8220;<span style="font-style: italic; font-weight: bold;">RNA-Binding Proteins</span>&#8221;) using multiplexed screening assays to identify chemical matter that modulates the inclusion
            levels of the various PE targets; the multiplexed nature of the assays allows for high throughput screening (&#8220;<span style="font-style: italic; font-weight: bold;">HTS</span>&#8221;) and an early assessment of selectivity. Subsequently, structural
            biology and biophysical assays, as well as cellular and biochemical profiling assays, allow for the optimization of lead compounds. Remix focuses on disease driver targets for genetically defined diseases and with clear patient stratification
            criteria to facilitate rapid POC in the clinic. Collectively, the various aspects of the REMaster platform allow Remix to identify the most compelling targets and exonization events for a given target indication, and then identify potent and
            selective chemical matter, which can be developed into potential product candidates. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">The REMaster&#8482; platform has identified a large number of PEs that have distinct 5&#8217; splice site sequences,
                    which exhibit different types of mismatches within the U1snRNP complex<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has an extensive knowledgebase relevant to identifying potential druggable
            nodes of RNA processing. Amassing large numbers of public and internally curated RNA-Seq and NGS sequencing samples has allowed Remix to mine for tractable PEs across the transcriptome and a variety of indications. For example: Remix has
            identified a large universe of potential PE target sites &#8211; approximately 1.5&#160;million PEs, compared to publicly annotated data sets, which contain &lt;5% of this number. Importantly, Remix has determined that approximately 50%&#160;of all multi-exon
            mammalian genes contain at least one PE, providing multiple opportunities for modulating gene expression. Target sites have unique sequences and bulge/shape characteristics, and Remix is identifying chemical matter that is specific and
            selective for a given bulge type. This will greatly expand the toolkit of available small molecule splice modulators and will continue to augment Remix&#8217;s ability to prosecute a wide variety of targets. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">236<br/>
        </div>

      </div>

    </div>

    <!--End Page 246-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 247-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix has developed a systematic strategy for identifying the best target
            sites for prosecution. This involves a stepwise approach beginning with database identification of possible target motifs, and the computation and experimental validation of the exon. This paves the way for developing and optimizing assays for
            screening the Remix chemical library. Collectively, this approach allows Remix to focus on the most promising PEs for compound identification. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">The Remix small molecule library is uniquely biased towards compounds that bind RNA/RNA-binding protein
                    (RBPs) complexes </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unlike many small molecules utilized in HTS campaigns, Remix&#8217;s proprietary
            chemical library is heavily enriched in compounds that bind RNA and RNA-binding proteins (&#8220;<span style="font-style: italic; font-weight: bold;">RBP</span>s&#8221;). This is a collection of &gt;180,000 compounds enriched in chemical matter designed to
            bind RNA/RBPs but also includes substantial representation of other diversity subsets. The bias for compounds that bind RNA-protein complexes is a unique advantage that makes it possible to identify RNA processing modulators. Remix&#8217;s curated
            chemical library continues to evolve over time, and cutting-edge computational chemistry analysis ensures the library diversity is sufficient for identification of lead chemical matter for drug discovery programs. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; text-align: left;">Biology and Biomolecular Sciences: Functional target validation and multiplexed HTS </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has developed a proprietary genetic toolkit to validate that novel PE
            targets can be modulated in cells and lead to functional outcomes on gene and protein expression. The validation process ensures that biologically meaningful targets are selected for progression into HTS campaigns. In the multiplexed REMseq<sup>TM</sup>
            cellular screening assay format, hundreds of PE targets can be screened in parallel to identify novel compounds that modulate exon use with high specificity and selectivity. The REMseq<sup>TM</sup> HTS assay format is a minigene-based system
            that accurately measures exon modulation by small molecules. After design and synthesis, hundreds of exon-containing minigenes are pooled or multiplexed together and screened. The screens are designed to identify compounds from the Remix
            chemical library that lead to a change in exon usage in the final spliced RNA product. When such compounds are identified, modulation of the exon is confirmed using orthogonal assay technologies.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A cell-free biochemical Fluorescence Polarization assay system (&#8220;<span style="font-style: italic; font-weight: bold;">FP assay</span>&#8221;) is also available for HTS. In this system, a reconstituted U1snRNP particle generated <span style="font-style: italic;">in vitro</span> is used to identify chemical matter that
            increases the affinity of the exon 5&#8217; splice site to the U1snRNP particle. This is achieved by designing a fluorescently labelled oligonucleotide with the corresponding 5&#8217;-splice site sequence. By introducing additional 5&#8217; splice site
            oligonucleotides with distinct fluorescent labels, FP screen multiplexing is also possible using this assay technology. Additionally, kinetic characterization of splice modulator binding to PE sequences can be conducted using the engineered
            U1snRNP particle. For example, advanced binding kinetics and residence time determination studies can be performed using orthogonal assay technologies such as Surface Plasmon Resonance (&#8220;<span style="font-style: italic; font-weight: bold;">SPR</span>&#8221;)

            and Micro Scale Thermophoresis (&#8220;<span style="font-style: italic; font-weight: bold;">MST</span>&#8221;). Collectively, this suite of biophysical and biochemical assays provides Remix with multiple options for identifying and confirming novel
            chemical matter emerging from HTS campaigns. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has also developed extensive expertise determining high resolution Cryo-EM
            and X-Ray crystallographic structures of the reconstituted U1snRNP particle bound to 5&#8217; splice site oligonucleotides in the presence or absence of small molecule splice modulator ligands. Collectively, these structural biology tools can be used
            to computationally guide compound potency and selectivity optimization, enable virtual HTS campaigns and to understand the mechanistic role of the various accessory proteins associated with the U1snRNP complex and splice site binding. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Together with the cellular, biochemical and biophysical assays described above,
            these structural biology capabilities provide Remix with key mechanistic insights into compound binding properties. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">237<br/>
        </div>

      </div>

    </div>

    <!--End Page 247-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 248-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">MYC-Dependent cancers program </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The oncoprotein MYC is a pleiotropic transcription factor that modulates global
            gene expression and regulates critical cellular processes including proliferation, differentiation, cell cycle, metabolism and apoptosis. The MYC oncogene family includes c-MYC, MYCN (N-MYC) and MYCL (L-MYC). All three paralogs (hereafter
            collectively referred to as MYC) have a similar function but show distinct expression timings and tissue specificities. Strong evidence supports aberrant MYC expression as a driver of both tumor initiation and maintenance, and it is associated
            with all the &#8220;hallmark&#8221; features of cancer. MYC activity is usually tightly controlled at the transcriptional and protein level but is estimated to be aberrantly amplified or activated in ~28% of all human cancers. As such MYC considered one of
            the most enticing targets for cancer drug development.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 15.25pt; text-align: center;"><img style="height: 227px; width: 594px;" src="ny20077915x1_graphic04x1.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">However, despite significant effort, targeting MYC with small molecules still
            represents a substantial challenge, particularly at the protein level. MYC has no enzymatic activity or active site and is intrinsically disordered with limited options for ligand binding, precluding structure-guided drug design; as such the
            protein is considered undruggable. Additional challenges to the design of effective MYC inhibitors include the high affinity interaction between MYC and its obligate heterodimerization partner MAX and the partial functional redundancy of the
            three MYC paralogs. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has developed a novel strategy to tackling MYC dependent cancers that Remix
            believes has the potential to address many of the challenges articulated above. Using the REMaster&#8482; platform, Remix has identified a PE inclusion event in a key MYC-regulator protein, validated to be NMD sensitive and modulable by small
            molecules. Remix&#8217;s MYC-dependent cancer drug discovery program builds on this observation to directly tackle aberrant MYC transcriptional activity. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Experiments carried out in a c-MYC amplified gastric cancer cell line demonstrate
            that treatment with Remix mRNA degrader small molecules, exemplified by RXSM-1244, promoted concentration-dependent inclusion of a PE, which led to degradation and reduced expression of the mature mRNA transcript, as assessed by qPCR, and to
            reductions in protein levels as assessed by Western Blotting, for the MYC-regulator protein (figure below, left). In a whole transcriptome RNA sequencing (RNA-seq) experiment in a c-MYC amplified gastric cancer cell line, analysis of known
            MYC-dependent upregulated and MYC-dependent downregulated pathways showed that treatment with a small molecule mRNA degrader phenocopied siRNA mediated knockdown of either MYC or the MYC-regulator protein, reversing the aberrant gene expression
            patterns (figure below, right). These findings are consistent with the proposed mechanism of action wherein Remix small molecule mRNA degraders are designed to deplete the mRNA and protein expression of a MYC-regulator protein essential for
            oncogenic MYC transcriptional activity.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">238<br/>
        </div>

      </div>

    </div>

    <!--End Page 248-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 249-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;"><img style="height: 297px; width: 618px;" src="ny20077915x1_charts03x2.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following medicinal chemistry optimization, the pharmacokinetic (PK) properties
            observed for RXSM-1244 provided sufficient drug exposures to evaluate oral dosing in mice bearing a c-MYC amplified gastric cancer cell line derived xenograft. The tumor bearing mice received three consecutive daily oral doses of RXSM-1244
            then, six&#160;hours post the final dose, tumors were harvested and analyzed for mRNA (qPCR) and protein (Western Blot) expression. Consistent with the earlier <span style="font-style: italic;">in vitro</span> data, RXSM-1244 promoted the inclusion
            of a PE which led to depletion of both the mature mRNA transcript and protein levels of the MYC-regulator protein (figure below, left). Additionally, daily oral administration of RXSM-1244 for 28 days in the same mouse xenograft model resulted
            in robust tumor growth inhibition when compared to vehicle-dosed mice (figure below, right). These data support Remix&#8217;s belief that Remix MYC-regulator protein mRNA degraders may be applicable to patients whose tumors are MYC-amplified or
            activated. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.75pt; text-align: center;"><img style="height: 266px; width: 601px;" src="ny20077915x1_charts04x2.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Manufacturing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix believes that REM-422 can be reliably and efficiently manufactured. To date
            Remix has developed a manufacturing process that Remix believes is scalable for clinical supply and commercial production and have established a network of contract manufacturers that Remix believes is capable of reliably and efficiently
            supplying REM-422 for clinical trials and, ultimately, commercialization. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix does not currently own or operate, and has no plans to build, any
            manufacturing facilities. Remix relies, and expects to continue to rely, on third parties for the manufacture of REM-422 for clinical testing, as well as ultimately </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">239<br/>
        </div>

      </div>

    </div>

    <!--End Page 249-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 250-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg27"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">for potential commercial use. Remix also relies, and expects to continue to
            rely, on third parties to package, label, store and distribute Remix&#8217;s REM-422. Remix believes that this strategy allows it to maintain a more efficient infrastructure by eliminating the need for it to invest in its own manufacturing
            facilities, equipment and personnel while also enabling it to focus its expertise and resources on the research and development of Remix&#8217;s pipeline products. To date, for REM-422, Remix has contracted to obtain active pharmaceutical ingredients
            (API), drug product, and packaging and distribution services from Anthem Biosciences Limited, Catalent Pharma Solutions, LLC and Fisher Clinical Services Inc, respectively, upon whom Remix currently relies as single-source contract
            manufacturing organizations, or CMOs. As Remix advances REM-422 through development and expand manufacturing volumes, Remix will explore adding backup suppliers for the API, drug product, packaging and formulation to protect against any
            potential supply disruptions. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Intellectual Property </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Intellectual property, including patents, trade secrets, trademarks and
            copyrights, is important to our business. Our commercial success depends in part on our ability to obtain and maintain proprietary intellectual property protection for our current products as well as for future product candidates and novel
            discoveries, product development technologies, and know-how. Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary
            rights. We seek to maintain our proprietary position by, among other means, filing United States and foreign patent application to obtain issued patents that cover our products (including REM-422), product candidates, technology, inventions,
            and improvements that are important to the development and implementation of our business. We may also license from third parties certain patent rights and proprietary know-how that we believe to be necessary or useful to our business.
            Additionally, we protect our proprietary know-how that may not be patentable, and other confidential information, by maintaining and implementing appropriate policies and procedures for ensuring secrecy and confidentiality. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our patent portfolio of exclusively owned patent families, which includes patent
            families covering REM-422. As of July 16, 2026, our owned patent estate consisted of 41 patent families comprising 5 issued foreign patents in Japan Taiwan and Saudi Arabia, 34 pending U.S. non-provisional patent applications, and 272 pending
            applications in various jurisdictions outside of the U.S., including Europe, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Eurasia, Egypt, Guatemala, Hong Kong, India, Israel, Japan, Korea, Mexico, New Zealand,
            Russia, Peru, Saudi Arabia, Singapore, South Africa, Taiwan, and United Arab Emirates, as well as Patent Cooperation Treaty (&#8220;<span style="font-style: italic; font-weight: bold;">PCT</span>&#8221;) applications. Our patent estate includes
            applications and patents directed to compositions of matter, formulations, methods of making, and methods of treatment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">With respect to the composition of matter for REM-422, as of July 16, 2026, we
            owned 3 issued non-United States patents in Japan and Saudi Arabia, which are expected to expire in 2041, in each instance provided that all appropriate maintenance fees are paid and without taking into account any patent term adjustment,
            patent term extension, or supplementary protection certificates that may be available on a country-by-country basis. We also own 7 pending U.S.&#160;non-provisional patent applications and 101 pending patent applications in various jurisdictions
            outside of the U.S., including Europe, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Eurasia, Egypt, Guatemala, Hong Kong, India, Israel, Japan, Korea, Mexico, New Zealand, Russia, Peru, Saudi Arabia, Singapore,
            South Africa, Taiwan, and United Arab Emirates, which, if issued, will be expected to expire between 2041 and 2047, in each instance provided that all appropriate maintenance fees are paid and without taking into account any patent term
            adjustment, patent term extension, or supplementary protection certificates that may be available on a country-by-country basis. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The patent positions of biopharmaceutical companies are generally uncertain and
            involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do
            not know whether the product candidates we own will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction, and
            furthermore, we cannot determine whether the claims of any issued patents will provide sufficient proprietary protection to protect us from competitors, or will be challenged, circumvented or invalidated by third parties. Because patent
            applications in the United States and certain other jurisdictions are maintained in secrecy for 18&#160;months, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of
            the priority of inventions covered by pending patent applications. Moreover, we may have to participate in other proceedings declared by the United States Patent and Trademark Office </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">240<br/>
        </div>

      </div>

    </div>

    <!--End Page 250-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 251-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg28"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">(&#8220;<span style="font-style: italic; font-weight: bold;">USPTO</span>&#8221;) or a
            foreign patent office, such as post-grant proceedings and oppositions, that challenge the validity of a granted patent. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Although we currently have issued patents directed to a number of different
            attributes of our products, and pending applications on others, there can be no assurance that any issued patents would be held valid by a court of competent jurisdiction. An adverse outcome could subject us to significant liabilities to third
            parties, require disputed rights to be licensed from third parties or require us to cease using specific compounds or technology. To the extent prudent, we intend to bring litigation against third parties that we believe are infringing our
            patents. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The term of individual patents depends upon the legal term of the patents in the
            countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term
            adjustment, which compensates a patentee for administrative delays by the USPTO in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent with an earlier expiration date. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As mentioned above, in the United States, the patent term of a patent that covers
            an FDA-approved drug may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. REM-422 has not received FDA approval and we have been
            awarded patent term extension on that product. In the future, if and when our other pharmaceutical products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term
            adjustments and extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of
            whether such extensions should be granted, and even if granted, the length of such adjustments or extensions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">To protect our rights to any of our issued patents and proprietary information,
            we may need to litigate against infringing third parties, or avail ourselves of the courts, or participate in hearings to determine the scope and validity of those patents or other proprietary rights. These types of proceedings are often costly
            and could be very time-consuming to us, and we cannot be certain that the deciding authorities will rule in our favor. An unfavorable decision could result in the invalidation or a limitation in the scope of our patents or forfeiture of the
            rights associated with our patents or pending patent applications. Any such decision could result in our key technologies not being protectable, allowing third parties to use our technology without being required to pay us licensing fees or may
            compel us to license needed technologies from third parties to avoid infringing third-party patent and proprietary rights. Such a decision could even result in the invalidation, or a limitation in the scope, of our patents or could cause us to
            lose our rights under existing issued patents or not to have rights granted under our pending patent applications. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We also rely on trade secret protection for our confidential and proprietary
            information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, no assurances can be given that others will not independently develop
            substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. It is our policy to require our employees,
            consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all
            confidential information developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of
            employees, the confidentiality agreements further provide that all inventions conceived by the individual will be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate
            remedies for our trade secrets in the event of unauthorized use or disclosure of such information. See the section titled &#8220;Risk factors&#8212;Risks Related to Our Intellectual Property Rights&#8221; for a more comprehensive description of risks related to
            our intellectual property.</div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Competition</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The biotechnology and pharmaceutical industries, and the oncology sector, are
            characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property rights. While we believe that our discovery programs, technology, knowledge, experience, and scientific resources provide us with
            competitive advantages, we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">241<br/>
        </div>

      </div>

    </div>

    <!--End Page 251-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 252-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg29"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Any product candidates that we may successfully develop and commercialize will
            compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience
            of our products and the ease of use and effectiveness of any complementary diagnostics and/or companion diagnostics.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There are a large number of companies developing or marketing treatments for
            cancer, including many major pharmaceutical and biotechnology companies. These treatments consist of small molecule drug products, biologics, cell-based therapies and traditional chemotherapy. There are also several programs in development
            targeting ACC, including those clinical programs run by Servier Pharmaceuticals and Rgenta. There are also several programs in development targeting AML, including clinical programs being conducted by Kura Oncology, Syndax, Taiho, Jansen, Ipsen
            and Aptose. Smaller and other early stage companies may also prove to be significant competitors. In addition, academic research departments and public and private research institutions may be conducting research on compounds that could prove
            to be competitive.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The availability of coverage and reimbursement from government and other
            third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which
            could result in our competitors establishing a strong market position before we are able to enter the market.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Many of the companies against which we may compete have significantly greater
            financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also
            prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and
            establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Government Regulation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Government authorities in the United States at the federal, state and local level
            and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and
            reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory
            authority, submitted for review and approved by the regulatory authority. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">U.S. Drug Development Process </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the United States, the FDA regulates drugs under the federal Food, Drug, and
            Cosmetic Act (FDCA) and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and
            financial resources. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">completion of certain preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory
                    Practice regulations (GLPs) and other applicable regulations; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">submission to the FDA of an Investigational New Drug application (IND), which must become effective before human clinical trials
                    may begin; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">approval by an independent institutional review board (IRB), or ethics committee at each clinical site before each trial may be
                    initiated; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice regulations (&#8220;<span style="font-style: italic; font-weight: bold;">GCPs</span>&#8221;) to evaluate the safety and efficacy of the product candidate for its intended use; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preparation and submission to the FDA of an NDA; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfactory completion of an FDA advisory committee review, if applicable; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">242<br/>
        </div>

      </div>

    </div>

    <!--End Page 252-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 253-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg30"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess
                    compliance with current Good Manufacturing Practice requirements (cGMPs) to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfactory completion of potential inspection of selected clinical investigation sites to assess compliance with GCPs; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the
                    United States. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Once a product candidate is identified for development, it enters the preclinical
            testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information
            and analytical data, to the FDA as part of an IND. An IND is a request for allowance from the FDA to administer an investigational drug product to humans. An IND will also include a protocol detailing, among other things, the objectives of the
            clinical trial, the parameters to be used in monitoring safety, and any effectiveness criteria to be evaluated. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt
            by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also
            may be imposed by the FDA at any time before or during clinical trials due to safety concerns about on-going or proposed clinical trials or non-compliance with specific FDA requirements, and the trials may not begin or continue until the FDA
            notifies the sponsor that the hold has been lifted. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">All clinical trials must be conducted under the supervision of one or more
            qualified investigators in accordance with GCPs, which include, among other things, the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials must be
            conducted under protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the
            IND, and a separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. While the IND is active, progress reports summarizing the
            results of the clinical trials and nonclinical studies performed since the last progress report, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and
            investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or in vitro testing suggesting a significant risk
            to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Furthermore, an independent IRB covering the institutions participating in the
            clinical trial must review and approve each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her
            legal representative, monitor the study until completed and otherwise comply with IRB regulations. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients
            are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug
            has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending
            on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. There are also requirements governing the reporting of ongoing clinical studies and clinical
            study results to public registries, including clinicaltrials.gov. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Human clinical trials are typically conducted in three sequential phases that
            may overlap or be combined: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 1: The product candidate is initially introduced into healthy human subjects, or in some cases, patients with the target
                    disease or condition, and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">243<br/>
        </div>

      </div>

    </div>

    <!--End Page 253-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 254-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg31"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 2: The product candidate is administered to a limited patient population with a specified disease or condition to identify
                    possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Phase 3: The product candidate is administered to an expanded patient population to further evaluate dosage, to provide
                    substantial evidence of efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product
                    candidate and provide an adequate basis for product labeling. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted
            after initial regulatory approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials
            as a condition of approval of an NDA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Concurrent with clinical trials, companies usually complete additional animal
            studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMPs. The manufacturing process
            must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate
            packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">U.S. Review and Approval Process </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The results of product development, including results from preclinical and other
            non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA
            requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the Pediatric Research Equity Act (PREA), requires a sponsor to
            conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, NDAs and certain supplements must contain a pediatric assessment
            unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration
            for each pediatric subpopulation for which the product is deemed safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several
            reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin.
            The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Once an NDA has been submitted, the FDA conducts a preliminary review of the
            application within the first 60 days after submission, before accepting it for filing, to determine whether it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for
            filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once filed, the FDA reviews an NDA to determine, among other things,
            whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (PDUFA),
            guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the
            NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after it the application is submitted. The FDA&#8217;s review of the application may also be extended for a three-month period to enable the FDA to
            respond to new information deemed a &#8220;major amendment&#8221; to the application. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA may refer an application for a novel drug to an advisory committee. An
            advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA
            is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">244<br/>
        </div>

      </div>

    </div>

    <!--End Page 254-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 255-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg32"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Before approving an NDA, the FDA will typically inspect the facility or
            facilities where the product is manufactured. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCPs. After the FDA evaluates an NDA and conducts any required inspections of
            clinical trial sites or the manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response Letter (CRL). An approval letter authorizes
            commercial marketing of the drug with prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL usually describes
            the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a CRL is issued, the
            sponsor must resubmit the NDA addressing all of the deficiencies identified in the letter, or otherwise withdraw the application. Even if responsive data and information are submitted, the FDA may decide that the resubmitted NDA does not
            satisfy the criteria for approval. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If a product receives regulatory approval, the approved indications for use may
            more be limited than those initially sought by the Sponsor, which may restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct post-marketing studies to further evaluate the safety or efficacy of the
            product, and may require additional testing and surveillance programs to monitor the safety of the commercialized product. The FDA may also place other conditions on approval, including the requirement for a Risk Evaluation and Mitigation
            Strategy (REMS), to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS, which could include medication guides, physician communication plans or elements to assure safe use,
            such as restricted distribution methods, patient registries and other risk minimization tools. The FDA will not approve an NDA without an approved REMS, if required. Any of these limitations on approval or marketing could restrict the
            commercial promotion, distribution, prescription or dispensing of drug products. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Orphan drug designation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug
            intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable
            expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA.
            After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation entitles a party to financial incentives such as opportunities for grant funding
            towards clinical trial costs, tax advantages and user-fee waivers, but does not convey any advantage in or shorten the duration of the regulatory review and approval process. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Additionally, if a product that has orphan designation subsequently receives the
            first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same
            approved indication or use within the applicable rare disease or condition for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity within the protected indication or
            use, or inability to manufacture the product in sufficient quantities to meet the needs relating to the approved indication or use of patients with the relevant orphan disease or condition. Orphan exclusivity can block the approval of a
            competing product within the exclusivity-protected indications for seven years if a competitor obtains approval of the &#8220;same drug,&#8221; as defined by the FDA, for the same indications or uses. However, competitors may obtain approval of different
            drugs for the same indications or uses for which the orphan product has exclusivity, or obtain approval of the same drug for different indications or uses. In addition, if an orphan designated product receives regulatory approval for a disease
            or condition broader than what is designated, it may not be entitled to orphan exclusivity. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Expedited Development and Review Programs
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA has a number of programs intended to expedite the development or review
            of a marketing application for an investigational drug. For example, the fast track designation program is intended to expedite or facilitate the process for developing and reviewing product candidates that meet certain criteria. Specifically,
            investigational drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. The
            sponsor of a fast track product candidate has opportunities for more frequent interactions with the applicable FDA review team during product development and, once an NDA is submitted, the application may be eligible for priority review. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">245<br/>
        </div>

      </div>

    </div>

    <!--End Page 255-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 256-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg33"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">With regard to a fast track product candidate, the FDA may consider for review
            sections of the NDA on a rolling basis before the complete application is submitted if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule
            is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A product candidate intended to treat a serious or life-threatening disease or
            condition may also be eligible for breakthrough therapy designation to expedite its development if preliminary clinical evidence indicates that the product candidate, whether alone or in combination with one or more other drugs or biologics,
            may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track
            program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior FDA
            managers. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, an NDA may also be eligible for priority review if the underlying
            product candidate is designed to treat a serious condition, and if approved, would provide a significant improvement in safety or efficacy compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of
            a NDA designated for priority review in an effort to facilitate the review. The FDA endeavors to review priority review applications within six months of the filing date as compared to ten months for review of new molecular entity NDAs under
            current PDUFA review goals. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, depending on the design of the applicable clinical trials, a product
            candidate may be eligible for accelerated approval. Specifically, drugs intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product candidate has an effect
            on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
            morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA generally requires that a
            sponsor of a drug receiving accelerated approval perform adequate and well-controlled confirmatory clinical trials, and may require that such confirmatory trials be underway prior to granting accelerated approval. Drugs receiving accelerated
            approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required confirmatory trials in a timely manner or if such trials fail to verify the predicted clinical benefit. In addition, the FDA requires as a
            condition of accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Fast track designation, breakthrough therapy designation, priority review, and
            accelerated approval do not change the standards for approval but may expedite the development or approval process. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product no longer
            meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Post-approval requirements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any products manufactured or distributed pursuant to FDA approvals are subject to
            pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of
            the product. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Drug manufacturers and other entities involved in the manufacture and
            distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other
            laws and regulations. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. Accordingly, manufacturers must continue to expend
            time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA may withdraw approval if compliance with regulatory requirements and
            standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing
            processes, or failure </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">246<br/>
        </div>

      </div>

    </div>

    <!--End Page 256-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 257-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg34"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">to comply with regulatory requirements, may result in revisions to the
            approved labeling to add new safety information; imposition of requirements for post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other
            potential consequences include, among other things: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product
                    recalls; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">fines, warning letters, or untitled letters; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">clinical holds on ongoing or planned clinical studies; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of
                    approvals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product seizure or detention, or refusal to permit the import or export of products; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">mandated modification of promotional materials and labeling and the issuance of corrective information; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or
                    other safety information about the product; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">injunctions or the imposition of civil or criminal penalties. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the FDA closely regulates the marketing, labeling, advertising and
            promotion of drug products. A company can make only those claims relating to safety and efficacy that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and
            regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.
            Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians
            may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s
            communications on the subject of off-label use of their products. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Marketing exclusivity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Regulatory exclusivity provisions under the FDCA can delay the submission or the
            approval of certain marketing applications that seek to reference an FDA-approved product. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to obtain approval of an NDA for a
            new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the
            exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application (&#8220;<span style="font-style: italic; font-weight: bold;">ANDA</span>&#8221;), or an NDA submitted under section 505(b)(2) of the FDCA (505(b)(2) NDA) for another
            version of such drug where the applicant does not own or have a legal right of reference to such data, if required for approval. However, such applications may be submitted after four years if it contains &#8220;Paragraph IV&#8221; certification attesting
            that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDCA alternatively provides three years of non-patent exclusivity for an NDA,
            505(b)(2) NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for
            example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from
            approving ANDAs or 505(b)(2) NDAs referencing the approved application for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a
            full NDA that does not reference the approved application. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
            trials necessary to demonstrate safety and effectiveness. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pediatric exclusivity is another type of marketing exclusivity available in the
            United States. If granted, pediatric exclusivity provides for the attachment of an additional six months of marketing exclusivity to the term of any </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">247<br/>
        </div>

      </div>

    </div>

    <!--End Page 257-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 258-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg35"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">existing regulatory exclusivity or certain listed patents. Pediatric
            exclusivity is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve certain applications. A product candidate may be eligible for this six-month period of exclusivity if the NDA
            sponsor conducts clinical trials in children and submits information requested in writing by the FDA, referred to as a Written Request, relating to the use of the product&#8217;s active moiety in children. The issuance of a Written Request does not
            require the sponsor to undertake the described clinical trials. In addition, the clinical trial data do not need to show the product to be effective in the pediatric population studied; rather, the additional protection is granted if the
            pediatric clinical trial is deemed to have fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that
            information relating to that use of a product candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">FDA Regulation of Companion Diagnostics </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix believes that certain of its product candidates may require an in vitro
            diagnostic to identify appropriate patient populations for investigation and/or use of Remix&#8217;s product candidates. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FDCA
            and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and
            listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA
            prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (&#8220;<span style="font-style: italic; font-weight: bold;">PMA</span>&#8221;). Most companion diagnostics for oncology product candidates utilize the PMA pathway. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If use of companion diagnostic is deemed essential to the safe and effective use
            of a drug product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the therapeutic product. According to FDA guidance, for novel product candidates, a companion diagnostic
            device and its corresponding drug candidate should be approved or cleared contemporaneously by FDA for the use indicated in the therapeutic product labeling. FDA guidance also explains that a companion diagnostic device used to make treatment
            decisions in clinical trials of a drug generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as
            patient selection, the diagnostic device may be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (&#8220;<span style="font-style: italic; font-weight: bold;">IDE</span>&#8221;) regulations. In which case, the sponsor of
            the diagnostic device will be required to submit and obtain approval of an IDE application, and subsequently comply with the IDE regulations. However, according to the guidance, if a diagnostic device and a drug are to be studied together to
            support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of applicable IDE regulations and the IND regulations. The guidance provides that, depending on the
            details of the study plan and degree of risk posed to subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The FDA has generally required companion diagnostics intended to select the
            patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic simultaneously with approval of the therapeutic. The PMA process, including the gathering of clinical and preclinical data and the submission to and
            review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about
            the device and its components regarding, among other things, device design, manufacturing and labeling. In addition, PMAs for certain devices must generally include the results from extensive preclinical and adequate and well-controlled
            clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when
            the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality Management System Regulation (&#8220;<span style="font-style: italic; font-weight: bold;">QMSR</span>&#8221;), which imposes elaborate testing, control, documentation and other quality assurance requirements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the FDA&#8217;s evaluation of the PMA application is favorable, the FDA may issue an
            approvable letter requiring the applicant&#8217;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#8217;s
            evaluation of the PMA or </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">248<br/>
        </div>

      </div>

    </div>

    <!--End Page 258-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 259-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg36"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">manufacturing facilities is not favorable, the FDA will deny approval of the
            PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical
            trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If and when the FDA concludes that the applicable criteria
            have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and
            effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval
            or other regulatory standards are not maintained or problems are identified following initial marketing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After a device is commercialized, it remains subject to significant regulatory
            requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s
            manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QMSR, which represents FDA&#8217;s cGMP requirements for medical devices. Domestic and foreign facility records and manufacturing processes
            are subject to periodic unscheduled inspections by the FDA. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other U.S. Regulatory Matters </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pharmaceutical companies are subject to additional healthcare regulation and
            enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, U.S. federal and state anti-kickback, fraud and abuse, false claims,
            pricing reporting, and transparency laws and regulations with respect to payments and other transfers of value made to physicians and other healthcare professionals, as well as similar foreign laws in the jurisdictions outside the U.S.
            Violation of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative civil and criminal penalties, damages, disgorgement fines, additional reporting
            requirements and oversight obligations, contractual damages, the curtailment or restructuring of operations, exclusion from participation in government healthcare programs, and imprisonment. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">European Union Drug Development </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Similar to the United States, the various phases of non-clinical and clinical
            research in the European Union (EU) are subject to significant regulatory controls. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the principles of good laboratory practice (GLP) as set forth in EU Directive
            2004/10/EC. Clinical trials of medicinal products in the EU must be conducted in accordance with EU and national regulations and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH)
            guidelines on Good Clinical Practices (GCP) as well as the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If the sponsor of the clinical trial is not established within the
            EU, it must appoint an EU entity to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU member states, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject
            injured in the clinical trial.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The EU Clinical Trials Regulation (Regulation EU No 536/2014 - CTR), which was
            adopted in April&#160;2014 and repealed the EU Clinical Trials Directive, became applicable on January 31, 2022. Unlike directives, the CTR is directly applicable in all EU member states without the need for member states to further implement it
            into national law. The CTR notably harmonizes the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, which contains a centralized EU portal and database. While the EU Clinical
            Trials Directive required a separate clinical trial application (CTA), to be submitted in each member state, the CTR introduces a centralized process and only requires the submission of a single application for multi-center trials. The CTR
            allows sponsors to make a single submission to both the competent authority and an ethics committee in each member state, leading to a single decision per member state. The assessment procedure of the CTA has been harmonized as well, including
            a joint assessment by all member states concerned, and a separate assessment by each member state with respect to specific requirements related to its own territory, including ethics rules. Each member state&#8217;s decision is communicated to the
            sponsor via the centralized EU portal. Once the CTA is approved, clinical study development may proceed. The CTR transition period ended on January&#160;31, 2025, and all clinical trials (and related applications) are now fully subject to the
            provisions of the CTR. Medicines used in clinical trials must be manufactured in accordance with Good Manufacturing Practice (GMP). </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">249<br/>
        </div>

      </div>

    </div>

    <!--End Page 259-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 260-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg37"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">European Union Drug Review and Approval </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In order to market our product candidates in the EU, we must obtain a marketing
            authorization (MA). In the EEA, which is comprised of the 27 member states of the EU plus Norway, Iceland, and Liechtenstein, medicinal products can only be commercialized after obtaining an MA. There are two types of marketing authorizations:
            (i) centralized MAs issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the EMA, which are valid throughout the entire territory of the EEA;
            and (ii) national MAs issued by the competent authorities of individual EU member states through the mutual recognition or decentralized procedures, which are available for products not falling within the mandatory scope of the centralized
            procedure. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The centralized procedure is based on the opinion of the CHMP of the EMA. The
            maximum timeframe for the evaluation of a marketing authorization application (MAA), by the EMA under the centralized procedure is 210 days, excluding clock stops. The centralized procedure is mandatory for certain types of products, including
            orphan medicinal products and medicinal products containing a new active substance indicated for the treatment of cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized
            procedure is also optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health
            in the EU.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Before granting the MA, the EMA makes an assessment of the risk-benefit balance
            of the product on the basis of scientific criteria concerning its quality, safety and efficacy. MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the
            risk-benefit balance. In exceptional cases, the CHMP might perform an accelerated review of a MAA in no more than 150 days (not including clock stops) instead of the standard 210-day timeframe.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Innovative products that target an unmet medical need and are expected to be of
            major public health interest may be eligible for a number of expedited development and review programs, such as the PRIority MEdicines (PRIME) scheme, which provides incentives similar to the Breakthrough Therapy designation in the United
            States. PRIME is a voluntary scheme aimed at enhancing the EMA&#8217;s support for the development of medicines that target unmet medical needs. It is based on increased interaction and early dialogue with companies developing promising medicines, to
            optimize their product development plans and speed up their evaluation to help them reach patients earlier. The benefits of a PRIME designation include the appointment of a rapporteur before submission of a marketing authorization application,
            early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated assessment. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">European Union Drug Data and Marketing
            Exclusivity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the EU, new products authorized for marketing (i.e., reference products)
            generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period prevents generic and biosimilar applicants from relying on the preclinical and clinical trial
            data contained in the dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity
            period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have elapsed from the initial MA of the reference product in the EU. The overall ten-year market exclusivity period can be
            extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains an authorization for one or more new therapeutic indications, which, during the scientific evaluation prior to their authorization,
            are held to bring a significant clinical benefit in comparison with existing therapies. Similar to the U.S. patent term-restoration, Supplementary Protection Certificates (SPCs) serve as an extension to a patent right in Europe for up to five
            years. SPCs apply to specific pharmaceutical products to offset the loss of patent protection due to the lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">European Union Orphan Medicinal Products </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the EU, orphan designation is granted by the European Commission based on a
            scientific opinion of the EMA&#8217;s Committee for Orphan Medicinal Products. A medicinal product may be designated as orphan if its sponsor can establish that (i) the product is intended for the diagnosis, prevention or treatment of a
            life-threatening or chronically debilitating condition; (ii) either (a) such condition affects no more than 5 in 10,000 persons in the EU when the application is made, or (b) the product, without the benefits derived from orphan status, would
            not generate </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">250<br/>
        </div>

      </div>

    </div>

    <!--End Page 260-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 261-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg38"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">sufficient return in the EU to justify investment; and (iii) there exists no
            satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the medicinal product will be of significant benefit to those affected by the condition. The application
            for orphan designation must be submitted before the application for marketing authorization. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the EU, orphan designation entitles a party to financial incentives such as
            reduction of fees, fee waivers, protocol assistance, and access to the centralized marketing authorization procedure. Moreover, upon grant of a marketing authorization, orphan medicinal products are entitled to ten years of market exclusivity
            for the approved therapeutic indication. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed Pediatric Investigation Plan. However, during such period, marketing
            authorizations may be granted to a similar medicinal product with the same orphan indication if: (i) the applicant can establish that the second medicinal product, although similar to the orphan medicinal product already authorized, is safer,
            more effective or otherwise clinically superior; (ii) the marketing authorization holder for the orphan medicinal product grants its consent; or (iii) the marketing authorization holder of the orphan medicinal product is unable to supply
            sufficient quantities of product. The exclusivity period may be reduced to six years if, at the end of the fifth year, it is established that the medicine no longer meets the criteria for orphan designation, including where it is shown that the
            product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Orphan designation does not convey any advantage in, or shorten the duration of, the
            regulatory review and approval process.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The EU pharmaceutical legislation has been undergoing a complete review process,
            in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November&#160;2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products was
            published on April&#160;26, 2023. The proposed changes were since discussed and negotiated by the European Parliament and the Council of the EU as part of the EU ordinary legislative process. A provisional agreement has been reached by the European
            Parliament and Council of the EU on the proposed revisions on December&#160;11, 2025. Following positive votes by Member States and the European Parliament on the provisional agreement in March&#160;2026, the proposed revisions (affecting the duration of
            regulatory data protection and market protection, including for orphan medicinal products, revising the eligibility for expedited pathways, etc.) must now be formally adopted by the Ministers of Health in the Employment, Social Policy, Health
            and Consumer Affairs Council (EPSCO) and the European Parliament Plenary, currently anticipated in Q4 2026. The proposed changes are not expected to become applicable before Q4 2028 and may however have a significant impact on the
            pharmaceutical industry and our business in the long term. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Post-Approval Requirements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Similar to the United States, both MA holders and manufacturers of medicinal
            products are subject to comprehensive regulatory oversight by the EMA and the European Commission. The holder of a MA must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance (QPPV)
            who is responsible for the establishment and maintenance of that system, and oversees the safety profiles of medicinal products and any emerging safety concerns. Key obligations include expedited reporting of suspected serious adverse reactions
            and submission of periodic safety update reports (PSURs). All new MAAs must include a risk management plan (RMP) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks
            associated with the product. The EMA may also impose specific obligations as a condition of the MA. The advertising and promotion of medicinal products are also subject to EU laws concerning promotion of medicinal products, interactions with
            physicians, misleading and comparative advertising and unfair commercial practices. All advertising and promotional activities for the product must be consistent with the approved summary of product characteristics, and therefore all off-label
            promotion is prohibited. Direct-to-consumer advertising of prescription medicines is also prohibited in the EU. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The aforementioned EU rules are generally applicable in the EEA. Failure to
            comply with EU and member state laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of the MA, manufacturing of pharmaceutical products,
            statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of
            clinical trials, or to grant MAs, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating
            restrictions, injunctions, suspension of licenses, fines and criminal penalties.</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">251<br/>
        </div>

      </div>

    </div>

    <!--End Page 261-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 262-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg39"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Moreover, in the EU, a &#8220;conditional&#8221; MA may be granted in cases where all the
            required safety and efficacy data are not yet available. A conditional MA is subject to conditions to be fulfilled for generating the missing data or ensuring increased safety measures. It is valid for one year and has to be renewed annually
            until fulfillment of all the conditions. Once the pending studies are provided, it can become a &#8220;standard&#8221; MA. However, if the conditions are not fulfilled within the timeframe set by the EMA, the MA ceases to be renewed. Furthermore, MAs may
            also be granted &#8220;under exceptional circumstances&#8221; when the applicant can show that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use even after the product has been authorized and subject to
            specific procedures being introduced. This may arise in particular when the intended indications are very rare and, in the present state of scientific knowledge, it is not possible to provide comprehensive information. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Regulation of Companion Diagnostics in the
            EU </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The EU regulatory landscape concerning in vitro diagnostic medical devices
            recently evolved, and continues to undergo legislative changes. On May&#160;26, 2022, the EU In Vitro Diagnostic Medical Devices Regulation (Regulation (EU) No 2017/746 &#8211; IVDR), entered into force, repealing and replacing the EU In Vitro Diagnostic
            Medical Devices Directive. Unlike directives, the IVDR is directly applicable in all EU member states without the need for member states to further implement it into national law, and is intended to establish a uniform, transparent, predictable
            and sustainable regulatory framework across the EU for in vitro diagnostic medical devices and ensure a high level of safety and health while supporting innovation. Following subsequent legislative changes, European institutions adopted a
            &#8220;progressive&#8221; roll-out of the IVDR to prevent disruption in the supply of in vitro diagnostic medical devices. Therefore, the IVDR applies since May&#160;26, 2022 but there is a tiered system extending the grace period for many devices (depending on
            their risk classification) before they have to be fully compliant with the regulation. These requirements are in active implementation and may change as the European Commission adopts additional implementing acts and considers targeted
            revisions to related IVD rules. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">All in vitro diagnostic medical devices placed on the market in the EU must meet
            the general safety and performance requirements laid down in Annex&#160;I to the IVDR, including the requirement that a device must be designed and manufactured in such a way that, during normal conditions of use, it is suitable for its intended
            purpose. Compliance with the general safety and performance requirements of the IVDR is a prerequisite for European conformity marking (CE mark) without which in vitro diagnostic medical devices cannot be marketed or sold in the EU. To
            demonstrate compliance with the general safety and performance requirements, manufacturers must undergo a conformity assessment procedure, which varies according to the type of in vitro diagnostic medical device and its (risk) classification. A
            conformity assessment procedure generally requires the intervention of a notified body. Notified bodies are independent organizations designated by EU member states to assess the conformity of devices before being placed on the market. A
            notified body would typically audit and examine a product&#8217;s technical dossiers and the manufacturer&#8217;s quality system. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body
            issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the EU. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The regulation of companion diagnostics is subject to further requirements since
            the IVDR became applicable. The IVDR introduced a new classification system for companion diagnostics, which are now specifically defined as diagnostic tests that support the safe and effective use of a specific medicinal product, by
            identifying patients that are suitable or unsuitable for treatment. Companion diagnostics must undergo a conformity assessment by a notified body. Before it can issue an EU certificate, the notified body must seek a scientific opinion from the
            EMA on the suitability of the companion diagnostic to the medicinal product concerned where the medicinal product falls exclusively within the scope of the centralized procedure for the authorization of medicines, or the medicinal product is
            already authorized through the centralized procedure, or a marketing authorization application for the medicinal product has been submitted through the centralized procedure. Where a product falls within the scope of the centralized procedure,
            the EMA opinion on the suitability of the companion diagnostic is required. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, the EU regulatory landscape concerning in vitro diagnostic medical
            devices continues to undergo legislative changes. On December&#160;16, 2025, the European Commission published a targeted revision proposal of both the EU Medical Devices Regulation and the IVDR to address structural issues, certification delays,
            and burdens on small and medium-sized enterprises. The proposal entered the ordinary legislative procedure and is currently not </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">252<br/>
        </div>

      </div>

    </div>

    <!--End Page 262-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 263-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg40"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">expected to be adopted before late 2026 or early 2027. If adopted, the revised
            framework may impact the conformity assessment process for our companion diagnostic, including potential changes to notified body procedures, the role of expert panels, and the EMA consultation process for companion diagnostics linked to
            centrally authorized medicinal products. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Coverage and Reimbursement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Significant uncertainty exists as to the coverage and reimbursement status of any
            product candidate for which Remix may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health
            programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which Remix or its customers seek reimbursement for Remix&#8217;s product candidates can be
            subject to challenge, reduction or denial by third-party payors. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The process for determining whether a third-party payor will provide coverage for
            a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. A third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate
            will be available. Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and
            reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate reimbursement are not available, or are
            available only at limited levels, successful commercialization of, and obtaining a satisfactory financial return on, any product Remix develops may not be possible. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Third-party payors are increasingly challenging the price and examining the
            medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, Remix may need to conduct
            expensive studies in order to demonstrate the medical necessity and cost- effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider Remix&#8217;s product
            candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable Remix to maintain price
            levels sufficient to realize an appropriate return on Remix&#8217;s investment in drug development.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the EU, pricing and reimbursement schemes vary widely from country to country.
            The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. In the EU,
            governments influence the price of products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Member states are free to restrict the range
            of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate positive and negative
            list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. Member states may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt
            a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms. To obtain reimbursement or
            pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies (Health Technology Assessment - HTA). The outcome of HTA
            regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU member states. There can be no assurance that any country that has
            price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. The downward pressure on healthcare costs in general, particularly prescription
            medicines, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On December 13, 2021, Regulation No 2021/2282 on HTA, amending Directive
            2011/24/EU, was adopted. The Regulation entered into force in January 2022 and has been applicable since January 2025, with phased implementation based on the type of product, i.e., oncology and advanced therapy medicinal products as of 2025,
            orphan medicinal products as of 2028, and all other new medicinal products by 2030. The Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products, and </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">253<br/>
        </div>

      </div>

    </div>

    <!--End Page 263-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 264-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg41"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">provide the basis for cooperation at the EU level for joint clinical
            assessments in these areas. It will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies
            with the highest potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing
            voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Healthcare Reform </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the United States and certain foreign jurisdictions, there have been, and
            Remix expects there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
            (collectively the &#8220;<span style="font-style: italic; font-weight: bold;">ACA</span>&#8221;) was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. The ACA
            contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the ACA increased the minimum level of Medicaid rebates payable by
            manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain
            &#8220;branded prescription drugs&#8221; to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
            implanted, or injected; expanded eligibility criteria for Medicaid programs; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with
            funding for such research; and established a Center for Medicare &amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.
            Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June&#160;17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA without specifically ruling on
            the constitutionality of the ACA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other legislative changes have been proposed and adopted since the ACA was
            enacted. On March&#160;11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminates the statutory cap on drug manufacturers&#8217; Medicaid drug rebate program liability, beginning January&#160;1, 2024. The rebate was previously capped
            at 100% of a drug&#8217;s average manufacturer price. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Moreover, there has recently been heightened governmental scrutiny over the
            manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review
            the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. On August&#160;16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law.
            Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part&#160;B and Medicare Part&#160;D to penalize price
            increases that outpace inflation (first due in 2023); and replaces the Part&#160;D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services (&#8220;<span style="font-style: italic; font-weight: bold;">HHS</span>&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. CMS has published the negotiated prices for the initial ten drugs, which went
            into effect in January&#160;2026, and the subsequent 15 drugs, which will first be effective in 2027, as well as the next set of 15 drugs that will be subject to price negotiations. HHS has issued and will continue to issue guidance implementing the
            IRA, although the Medicare drug price negotiation program is currently subject to legal challenges. While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The One Big Beautiful Bill Act, which was enacted in July&#160;2025, imposes
            significant reductions in the funding of the Medicaid program. Such reductions are expected to decrease the number of persons enrolled in Medicaid and reduce the services covered by Medicaid, which could adversely affect Remix&#8217;s sales of any
            product candidate that Remix commercializes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Trump administration is also pursuing a two-fold strategy to reduce drug
            costs in the U.S. While it is unclear whether and how the Trump proposals will be implemented, the Trump policies are likely to have a negative impact on the pharmaceutical industry and on Remix&#8217;s ability to receive adequate revenues for any
            product candidate that </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">254<br/>
        </div>

      </div>

    </div>

    <!--End Page 264-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 265-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_122-bus_pg42"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Remix commercializes. On the one hand, President Trump threatened to impose
            significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most favored nation pricing, which would tie the price for drugs in the U.S. to the lowest price in a group of other countries. In response, multiple
            manufacturers entered into confidential pricing agreements with the federal government. In April&#160;2026, the Trump administration issued a proclamation imposing tariffs under Section&#160;232 of the Trade Expansion Act on imports of brand
            pharmaceuticals, biologics and associated pharmaceutical ingredients, beginning July&#160;31, 2026. Exempted from these tariffs, among others, are companies that have executed or are negotiating agreements with the federal government regarding most
            favored nation pricing and onshoring of production and research and development. On the other hand, the Trump administration is pursuing traditional regulatory pathways to impose drug pricing policies, and published two proposed regulations in
            December&#160;2025, referred to as Globe and Guard. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the
            units of their drugs that are reimbursed by Medicare, with the rebate amount based on most favored nation pricing. While the impact of the Globe and Guard proposed regulations, if finalized, cannot yet be determined, it is likely to be
            significant. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and Remix&#8217;s business. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Individual states in the United States have also become increasingly active in
            implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, marketing cost disclosure, drug price reporting and other
            transparency measures. Some states have enacted legislation creating so-called prescription drug affordability boards, which ultimately may attempt to impose price limits on certain drugs in these states, and at least one state board is
            imposing an upper payment limit. Some states are also seeking to implement general, across the board price caps for pharmaceuticals, or are seeking to regulate drug distribution. Some measures are designed to encourage importation from other
            countries. These types of initiatives may result in additional reductions in Medicare, Medicaid, and other healthcare funding, and may otherwise affect the prices Remix may obtain for its investigational products that receive approval.
            Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. Adoption of other new legislation or regulation at the federal, state,
            or foreign level could further limit reimbursement for pharmaceuticals, including Remix&#8217;s product candidates if approved. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employees and Human Capital Resources </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of June&#160;23, 2026 , Remix had 37 full-time employees. Of these employees, 29
            were engaged in research or product development and clinical activities. None of Remix&#8217;s employees are represented by a labor union or covered by a collective bargaining agreement. Remix considers its relationship with its employees to be good.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our human capital resources objectives include identifying, recruiting,
            retaining, incentivizing and integrating our existing and new employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based
            compensation awards and cash-based performance bonus awards. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Facilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s corporate headquarters are located in Watertown, Massachusetts where
            Remix leases approximately 43,417&#160;square feet of office and laboratory space pursuant to a lease agreement that expires in December&#160;2032. Remix believes that its facility will be adequate for its long-term needs. If required, Remix believes
            that suitable additional or alternative space would be available in the future on commercially reasonable terms. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Legal Proceedings </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From time to time, Remix may become involved in legal proceedings or be subject
            to claims arising in the ordinary course of its business. Remix is not currently a party to any legal proceedings. Regardless of outcome, any proceedings or claims can have an adverse impact on Remix because of defense and settlement costs,
            diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">255<br/>
        </div>

      </div>

    </div>

    <!--End Page 265-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 266-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tMDA"><!--Anchor--></a>PASSAGE BIO MANAGEMENT&#8217;S DISCUSSION AND
            ANALYSIS OF FINANCIAL CONDITION <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AND RESULTS OF OPERATIONS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following discussion and analysis of Passage Bio&#8217;s financial condition and
            results of operations should be read together with the section titled &#8220;Unaudited Pro Forma Condensed Combined Financial Information&#8221; and<span style="font-style: italic;"> </span>Passage Bio&#8217;s consolidated financial statements for the years
            ended December&#160;31, 2025 and 2024, the three months ended March&#160;31, 2026 and 2025, and the related notes appearing elsewhere in this proxy statement/prospectus. This discussion and other parts of this proxy statement/prospectus contain
            forward-looking statements that involve risks and uncertainties, such as statements regarding Passage Bio&#8217;s plans, objectives, expectations, intentions and projections. Passage Bio&#8217;s actual results could differ materially from those described
            in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the &#8220;<span style="font-style: italic;">Risk Factors</span>&#8221; section of this proxy
            statement/prospectus. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is a clinical stage genetic medicines company that has historically
            focused on improving the lives of patients with neurodegenerative diseases through the development and advancement of cutting-edge, one-time therapies designed to target critical underlying pathologies in these conditions. As described in the
            section titled &#8220;Recent Developments,&#8221; Passage Bio has determined to wind-down its gene therapy programs and, on June&#160;24, 2026, entered into the Merger Agreement with Remix. In connection with the wind-down, Passage Bio has terminated its
            development services and clinical supply arrangements with Catalent and has given notice to terminate its license with Penn with respect to PBFT02, its former lead product candidate. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Financial Operations Overview </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">License Agreements </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">University of Pennsylvania </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a result of the Outlicense Transaction Agreements, as discussed below, Passage
            Bio restructured its research, collaboration and licensing agreement with the Trustees of the University of Pennsylvania (&#8220;<span style="font-style: italic; font-weight: bold;">Penn</span>&#8221;), as amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Penn License Agreement</span>&#8221;). Pursuant to the Penn License Agreement, as of July&#160;31, 2024, Passage Bio (i)&#160;terminated the funding of discovery research programs&#894; (ii) terminated the research and exploratory research
            programs&#894; (iii) terminated the remaining eight options Passage Bio had for future central nervous system (&#8220;<span style="font-style: italic; font-weight: bold;">CNS</span>&#8221;) indications&#894; (iv) terminated the transaction fee payable to Penn in the
            event of certain corporate transactions&#894; and (v)&#160;retained its then-current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe, and MLD, and certain platform technologies resulting from the discovery programs that Passage
            Bio funded. As described below, Passage Bio subsequently gave notice to terminate the Penn License Agreement with respect to PBFT02 and its FTD indications. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;23, 2026, Passage Bio delivered written notice to Penn to terminate the
            Penn License Agreement, pursuant to Section&#160;10.2 thereof, solely with respect to its product candidate referred to as PBFT02 for all indications licensed to Passage Bio thereunder for such product candidate, including frontotemporal dementia
            with granulin mutations (the &#8220;<span style="font-style: italic; font-weight: bold;">PBFT02 Termination</span>&#8221;). The PBFT02 Termination will become effective on the date that is 90 days following Penn&#8217;s receipt of the notice, after which Passage
            Bio will no longer have any rights under the Penn License Agreement to develop or commercialize PBFT02. The Penn License Agreement will remain in effect with respect to all non-terminated licensed products. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Gemma - Research, Collaboration and License
            Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            Passage Bio entered into a research, collaboration and license agreement with Gemma (the &#8220;<span style="font-style: italic; font-weight: bold;">Gemma Collaboration Agreement</span>&#8221;). Pursuant to the Gemma Collaboration Agreement, (i) Gemma
            conducted certain preclinical and IND application enabling work for Passage Bio&#8217;s research program in Huntington&#8217;s disease and a paused research program in Temporal Lobe Epilepsy (&#8220;<span style="font-style: italic; font-weight: bold;">TLE</span>&#8221;)

            which were previously being conducted by Penn under the Penn License Agreement and (ii) Gemma granted Passage Bio Options to conduct mutually agreed research programs in four new CNS indications. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Gemma Collaboration Agreement provided for potential development and sales
            milestone payments, tiered royalties on net sales of any resulting products, and option exercise fees payable by Passage Bio, in each case contingent on the achievement of future development or commercial events. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">256<br/>
        </div>

      </div>

    </div>

    <!--End Page 266-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 267-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">On May&#160;21, 2026, Passage Bio provided written notice to Gemma to terminate the
            Gemma Collaboration Agreement, which termination will become effective in accordance with the terms of the Gemma Collaboration Agreement. Following the effectiveness of the termination, Passage Bio will no longer have any rights to the research
            programs or the options for new CNS indications previously available to it under the Gemma Collaboration Agreement. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Gemma - Sublicense Agreements and Transition
            Services Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the transfer of the Outlicensed Programs to Gemma, in
            July&#160;2024, Passage Bio entered into the Gemma Sublicenses. On May&#160;7, 2025, Passage Bio agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs (the &#8220;<span style="font-style: italic; font-weight: bold;">Amended Gemma Sublicenses</span>&#8221;). Pursuant to the Amended Gemma Sublicenses, Passage Bio is entitled to receive (i) an aggregate total of $15.0&#160;million in initial payments for licenses and clinical product supply, of
            which $10.0 million has been received as of May 19, 2026, and $5.0&#160;million of which was due in March&#160;2026&#894; (ii) an additional $5.0&#160;million contingent on Gemma completing certain business milestones&#894; (iii) up to an additional $114.0&#160;million in
            development and commercial milestone payments&#894; and (iv)&#160;single digit royalties as a percentage of annual worldwide net sales in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical
            trial materials and product supply related to the Outlicensed Programs. In addition, Gemma is responsible for all payments to Penn related to the Outlicensed Programs under the Penn License Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, Passage Bio entered into the Transition Services Agreement, as
            amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which, Passage Bio provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for transitional
            services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. As of December&#160;31, 2025 and March&#160;31, 2026, Passage Bio collected $7.5&#160;million in initial payments and $4.8&#160;million in transition services
            payments under these agreements. In addition, Passage Bio has applied $1.5&#160;million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts due to Passage Bio for transition services. On May 19, 2026, Passage Bio received
            another $2.5 million from Gemma. The Transition Services Agreement and the Gemma Collaboration Agreement have each been terminated by Passage&#160;Bio. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio refers to the Amended Gemma Sublicenses, the Transition Services
            Agreement, and the Gemma Collaboration Agreement, collectively, as the Outlicense Transaction Agreements. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Collaboration and Manufacturing and Supply
            Agreements </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Catalent </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio had previously entered into a collaboration agreement and a
            development services and clinical supply agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Amended Catalent Agreements</span>&#8221;) with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S (&#8220;<span style="font-style: italic; font-weight: bold;">Catalent</span>&#8221;) to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for its gene therapy product candidates. Under the terms of the Amended Catalent
            Agreements, Catalent agreed to manufacture batches of drug product for its gene therapy product candidates. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;23, 2026, Passage Bio delivered written notice to Catalent to terminate,
            pursuant to Section&#160;20.1(b)(ii) thereof, the amended and restated development services and clinical supply agreement, dated November&#160;9, 2023 (one of the Amended Catalent Agreements), in its entirety, effective as of June&#160;23, 2026. Passage Bio
            determined to terminate this agreement in connection with the wind-down of its gene therapy programs and the proposed Merger, and Passage Bio was not obligated to pay Catalent any termination fee in connection with the termination. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Components of Results of Operations </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Research and Development </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development expenses consist primarily of costs incurred in
            connection with the development of its product candidates. These expenses include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Personnel expenses, including salaries, benefits and share-based compensation expense for employees engaged in research and
                    development functions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Expenses incurred at and for its lab facilities, including rent, utilities, depreciation, amortization and maintenance; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">257<br/>
        </div>

      </div>

    </div>

    <!--End Page 267-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 268-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval,
                    including payments to clinical research organizations, &#8220;<span style="font-style: italic; font-weight: bold;">CROs</span>&#8221;, and payments to Gemma and Penn for preclinical research and development; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Expenses and fees paid to consultants who assist with contract development and manufacturing organizations (&#8220;<span style="font-style: italic; font-weight: bold;">CDMOs</span>&#8221;), including the cost of acquiring and manufacturing preclinical trial and clinical trial materials. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio tracks outsourced development expenses and other external research
            and development expenses to specific product candidates on a program-by-program basis, such as fees paid to CROs, CDMOs and research laboratories in connection with its preclinical development, process development, manufacturing and clinical
            development activities, expenses incurred under its prior collaboration with Penn, and expenses incurred under the Gemma Collaboration Agreement. However, Passage Bio does not track its internal research and development expenses on a program by
            program basis as they primarily relate to compensation, lab operations and lab facility costs, and other expenses which are deployed across multiple projects under development. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development activities are central to its business model. Product
            candidates in later stages of clinical development generally have higher development expenses than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">General and administrative expenses consist primarily of personnel expenses,
            including salaries, benefits and share-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology, product strategy, quality, regulatory, operations and human resource functions.
            General and administrative expenses also include professional and consulting services, headquarters facility costs, including rent, utilities, depreciation, amortization and maintenance, legal expenses related to intellectual property,
            litigation and corporate matters, insurance expense, expenses related to contract modifications or terminations, software expenses, expenses incurred to engage with patient advocacy organizations, and recruitment related expenses. Passage Bio
            expects its general and administrative expenses to decrease in the future due to the reduction of leased office facilities and associated asset depreciation, reductions in staff and reductions in professional and consulting services. Passage
            Bio also expects to incur increased legal and professional fees in the near term in connection with the proposed Merger and related transaction activities. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Impairment of Long-Lived Assets </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets consists of non-cash impairment charges recorded
            to its assets. Passage Bio reviews long-lived assets, such as the right of use assets (&#8220;<span style="font-style: italic; font-weight: bold;">ROU Assets</span>&#8221;), or property and equipment, for impairments when events or changes in circumstances
            indicate the carrying amount of the assets may not be recoverable. During the year ended December&#160;31, 2025, Passage Bio recognized impairment expenses related to the ROU assets, property and equipment, net, and certain other assets. During the
            three months ended March&#160;31, 2026, Passage Bio did not recognize any impairment expenses. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a result of the announcement in January&#160;2025 to reduce its workforce by 55%
            and cease its lab operations in Hopewell, New Jersey, Passage Bio reassessed asset groups and evaluated such asset groups for impairment. Passage Bio determined the laboratory equipment was a separate asset group based on management&#8217;s
            implemented plans to sell the laboratory equipment and estimated the fair value of the laboratory equipment based on the estimated future cash flows from the sale of such equipment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2025, Passage Bio determined an impairment indicator was present for
            the asset groups related to the Laboratory Lease Agreement at Hopewell, New Jersey. Passage Bio compared the estimated total future undiscounted cash flows to the carrying values, which includes ROU assets and leasehold improvements allocable
            to the laboratory space for those asset groups. Passage Bio concluded the carrying value was not recoverable for one&#160;asset group as it exceeded the estimated undiscounted cash flows. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other income (expense), net consists of interest earned on its cash equivalents
            and marketable securities, amortization of premium and discount on its marketable securities, income from subleases, and the sale of certain tax credits. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">258<br/>
        </div>

      </div>

    </div>

    <!--End Page 268-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 269-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Results of Operations </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Comparison of the Years Ended December&#160;31,
            2025 and 2024 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table sets forth its results of operations for the years ended
            December&#160;31, 2025 and 2024. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 79.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 79.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

    <td style="width: 4.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br/>
                  </div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 3.33pt;">23,276</span></div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 3.33pt;">40,179</span></div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(16,903) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">19,875</span></div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">24,988</span></div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10.37pt;">(5,113) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,145</span></div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,233</span></div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">912 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">(49,296)</span></div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">(70,400)</span></div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">21,104 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,774</span></div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,633</span></div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,859</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(45,522</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(64,767</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">19,245</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development expenses decreased by $16.9&#160;million to $23.3&#160;million for
            the year ended December&#160;31, 2025 from $40.2&#160;million for the year ended December&#160;31, 2024. The decrease was primarily due to the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $4.8&#160;million in wages and benefits due to a lower headcount from its restructuring in January&#160;2025; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $3.7&#160;million in preclinical research expenses primarily related to the termination of its discovery research
                    obligation under the Penn License Agreement and reduced Huntington&#8217;s disease program expenses; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $2.6&#160;million in facility and other expenses related primarily to decreased depreciation expenses in connection
                    with the disposal of its laboratory equipment; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $1.9&#160;million in chemistry, manufacturing and control expenses primarily related to reduced costs in connection
                    with the restructuring and ceased operations of the lab in Hopewell, New Jersey; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $1.7&#160;million in share-based compensation expense related to reductions in headcount; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $1.3&#160;million in professional fees and consulting expenses; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $0.9&#160;million in clinical operations expenses due to decreased activity in the GM1 program partially offset by
                    increased activity supporting the FTD program. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">General and administrative expenses decreased by $5.1&#160;million to $19.9&#160;million
            for the year ended December&#160;31, 2025 from $25.0&#160;million for the year ended December&#160;31, 2024. The decrease was primarily due to the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $2.6&#160;million in professional fees and consulting expenses; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $1.5&#160;million and $1.1&#160;million in wages and benefits and share-based compensation expense, respectively, related to
                    reductions in headcount; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $0.8&#160;million in facility and other expenses. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The decrease was partially offset by: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an increase of $0.9&#160;million in accruals for the GM1 divestiture fee due to Catalent. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Impairment of Long-Lived Assets </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, Passage Bio recorded $6.1&#160;million of
            impairment expenses related to the Hopewell laboratory space. The impairment charges consisted of $2.6&#160;million of impairment expenses related to laboratory equipment and certain other assets which were revalued and subsequently sold in
            March&#160;2025&#894; and $2.6&#160;million and $0.9&#160;million related to ROU assets and leasehold improvements, respectively, in connection with impairment testing in December&#160;2025. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">259<br/>
        </div>

      </div>

    </div>

    <!--End Page 269-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 270-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, Passage Bio recorded $5.2&#160;million of
            impairment expenses related to the Hopewell laboratory space. The impairment charges consisted of $2.5&#160;million and $2.3&#160;million recorded to the ROU assets and property and equipment, net, respectively. In addition, Passage Bio recorded
            $0.4&#160;million of impairment expenses related to property and equipment for certain other assets Passage Bio no longer planned to deploy. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other income (expense), net decreased by $1.8&#160;million to $3.8&#160;million for the
            year ended December&#160;31, 2025 from $5.6&#160;million for the year ended December&#160;31, 2024. The decrease was primarily due to the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $2.0&#160;million attributable to interest income and the amortization of premium and discount on its marketable
                    securities; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $0.3&#160;million related to the sale of certain tax credits in 2024. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">These decreases were partially offset by: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an increase of $0.5&#160;million attributable to income from subleases. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Comparison of the Three Months Ended March&#160;31, 2026 and 2025 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth the Company&#8217;s results of operations for the three
            months ended March&#160;31, 2026 and 2025: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 78.16pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 30.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 78.16pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three months ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Change</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br/>
                  </div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 3.33pt;">4,093</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 8.33pt;">7,737</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(3,644) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">4,787</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">6,085</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">(1,298) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">2,637</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">(2,637) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 5pt;">(8,247)</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">(16,459)</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">8,212 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">688</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,054</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(366</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(7,559</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(15,405</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7,846</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development expenses decreased by $3.6&#160;million to $4.1&#160;million for
            the three months ended March&#160;31, 2026 from $7.7&#160;million for the three months ended March&#160;31, 2025. The decrease was primarily due to the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $2.1&#160;million in wages and benefits due to a lower headcount following its restructuring in January&#160;2025; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $1.0&#160;million in facility and other expenses related to decreased rent expenses in connection with the Hopewell
                    Lease Termination Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $0.6&#160;million in clinical operations expenses due to decreased activity in the GM1 program partially offset by
                    increased activity supporting the FTD program; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $0.1&#160;million in share-based compensation expense related to reductions in headcount. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">These decreases were partially offset by: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an increase of $0.2&#160;million in preclinical research expenses related to Huntington&#8217;s disease program expenses. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">260<br/>
        </div>

      </div>

    </div>

    <!--End Page 270-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 271-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">General and administrative expenses decreased by $1.3&#160;million to $4.8&#160;million for
            the three months ended March&#160;31, 2026 from $6.1&#160;million for the three months ended March&#160;31, 2025. The decrease was primarily due to the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $0.9&#160;million and $0.2&#160;million in wages and benefits and share-based compensation expense, respectively, related to
                    reductions in headcount; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a decrease of $0.3&#160;million in facility and other expenses. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">These decreases were partially offset by: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an increase of $0.1&#160;million in professional fees. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Impairment of Long-Lived Assets </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2026, the Company did not record any
            impairment expense. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2025, the Company recorded $2.6&#160;million
            of impairment expense related to laboratory equipment and certain other assets which were revalued and subsequently sold from the Hopewell laboratory space. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Net Gain on Lease Termination </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2026, the Company recorded a $0.6&#160;million
            net gain on the termination of the Hopewell Laboratory Lease. The net gain was comprised of a $3.8&#160;million gain on the write-off of assets and liabilities for operating leases offset by a $3.2&#160;million loss on disposal of property and equipment.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2025, the Company did not record any
            lease termination gain or loss. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other income (expense), net decreased by $0.4&#160;million to $0.7&#160;million for the
            three months ended March&#160;31, 2026 from $1.1&#160;million for the three months ended March&#160;31, 2025. The decrease was due to a $0.4&#160;million decrease in the amortization of premium and discount on the Company&#8217;s marketable securities. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Liquidity and Capital Resources </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has incurred significant operating losses and negative cash flows
            from operations since its inception and, as of March&#160;31, 2026, had an accumulated deficit of $712.3&#160;million. Passage Bio expects to continue to incur net losses and negative cash flows from operations for the foreseeable future. As of March&#160;31,
            2026, Passage Bio had cash and cash equivalents of $33.3&#160;million, which Passage Bio expects may not be sufficient to fund its operating expenses and capital expenditure requirements for at least the twelve months following the date its
            financial statements are issued. As a result, substantial doubt exists about Passage Bio&#8217;s ability to continue as a going concern within one year after the date that the financial statements included elsewhere in this proxy statement/prospectus
            are issued. Passage Bio&#8217;s ability to continue as a going concern will depend on its ability to complete the Merger and the Concurrent Financing or otherwise obtain substantial additional funding. There can be no assurance that Passage Bio will
            be able to complete the Merger or the Concurrent Financing on a timely basis, on acceptable terms, or at all. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Funding Requirements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s primary use of cash is to fund operating expenses, most
            significantly research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when Passage Bio pays these expenses, as reflected in the change in its outstanding accounts payable, accrued expenses and
            prepaid expenses. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Because of the numerous risks and uncertainties associated with research,
            development and commercialization of pharmaceutical products, Passage Bio is unable to estimate the exact amount of its operating capital requirements. Passage Bio&#8217;s future funding requirements will depend primarily on its ability to complete
            the proposed transaction with Remix. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">261<br/>
        </div>

      </div>

    </div>

    <!--End Page 271-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 272-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Passage Bio will need additional funds to meet operational needs and capital
            requirements for clinical trials, other research and development expenditures, and business development activities. Passage Bio currently has no credit facility or committed sources of capital. Because of the numerous risks and uncertainties
            associated with the development and commercialization of its product candidates, Passage Bio is unable to estimate the amounts of increased capital outlays and operating expenditures associated with its current and anticipated clinical studies.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the Company does not complete the proposed transaction with Remix and until
            such time, if ever, as Passage Bio can generate substantial product revenue, Passage Bio expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing,
            distribution or licensing arrangements. To the extent that Passage Bio raises additional capital through the sale of equity or convertible debt securities, existing stockholders&#8217; ownership interest will be diluted, and the terms of these
            securities may include liquidation or other preferences that adversely affect existing stockholders&#8217; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants
            limiting or restricting its ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If Passage Bio raises additional funds through collaborations, strategic
            alliances or marketing, distribution or licensing arrangements with third parties, Passage Bio may have to relinquish valuable rights to its technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms
            that may not be favorable to Passage Bio. If Passage Bio is unable to raise additional funds through equity or debt financings or other arrangements when needed, Passage Bio may be required to delay, limit, further reduce or terminate its
            research, product development or future commercialization efforts, or grant rights to develop and market product candidates that Passage Bio would otherwise prefer to develop and market itself. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On March&#160;5, 2021, Passage Bio entered into a Sales Agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Sales Agreement</span>&#8221;) with Cowen and Company, LLC (&#8220;<span style="font-style: italic; font-weight: bold;">Cowen</span>&#8221;) relating to the applicable terms of at-the-market equity offerings (the
            &#8220;<span style="font-style: italic; font-weight: bold;">ATM Facility</span>&#8221;), pursuant to which Passage Bio may, but are not obligated to, offer and sell, from time to time, shares of its common stock with an aggregate offering price up to
            $125.0&#160;million through Cowen, as sales agent in the ATM Facility. Passage Bio issued 300,000 shares of common stock under the ATM Facility, resulting in net proceeds of $8.7&#160;million, after deducting offering costs of $0.3&#160;million in March&#160;2024.
            As a result of its public float, Passage Bio is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3,
            filed on March&#160;5, 2025. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Cash Flows </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table shows a summary of its cash flows for the periods indicated:
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 264pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 86.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 86.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 264pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 86.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 86.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 264pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash provided by (used in) operating activities</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(12,987)</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(13,847)</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(31,509)</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(47,956) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash provided by (used in) investing activities</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">20</span></div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">39,631</span></div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">40,216</span></div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">54,946 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash provided by (used in) financing activities</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">23</span></div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">8,874 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase (decrease) in cash and cash equivalents</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(12,967</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">25,784</span></div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">8,730</span></div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">15,864</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 264pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Net Cash Provided by (Used in) Operating
            Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, Passage Bio used $31.5&#160;million of net
            cash in operating activities, primarily to fund its operations related to the development of its product candidates and related general and administrative support activities. Cash used in operating activities reflected its net loss of
            $45.5&#160;million, which was partially offset by a net decrease in its operating assets of $4.0&#160;million and net non-cash charges of $10.0&#160;million primarily related to depreciation, amortization, share-based compensation, amortization of premium and
            discount, net, impairment of long-lived assets, and other non-cash items. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, Passage Bio used $48.0&#160;million of net
            cash in operating activities, primarily to fund its operations related to the development of its product candidates and related general and administrative support activities. Cash used in operating activities reflected its net loss of
            $64.8&#160;million, which was partially offset by a net decrease in its operating assets of $4.2&#160;million and net non-cash charges of $12.6&#160;million primarily related to depreciation, amortization, share-based compensation, amortization of premium and
            discount, net, and impairment of long-lived assets. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">262<br/>
        </div>

      </div>

    </div>

    <!--End Page 272-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 273-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2026, Passage Bio used $13.0&#160;million
            of net cash in operating activities. Cash used in operating activities reflected a net loss of $7.6&#160;million and a decrease in its operating assets of $5.5&#160;million offset by non-cash charges of $0.1&#160;million related to depreciation, amortization,
            share-based compensation, loss recognized on disposal of long-lived assets, and other non-cash items. The primary uses of cash were to fund its operations related to the development of its product candidates and the payment of the lease
            termination fee in connection with the Hopewell Lease Termination Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2025, Passage Bio used $13.8&#160;million of
            net cash in operating activities. Cash used in operating activities reflected a net loss of $15.4&#160;million and a decrease in its operating assets of $2.2&#160;million, partially offset by non-cash charges of $3.8&#160;million related to depreciation,
            amortization, share-based compensation, amortization of premium and discount, net, and impairment of long-lived assets. The primary use of cash was to fund its operations related to the development of its product candidates. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Net Cash Provided by (Used in) Investing
            Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, Passage Bio had sales and maturities of
            $39.0&#160;million in marketable securities and received $1.2&#160;million related to the sale of property and equipment in connection with ceased operations of the lab in Hopewell, New Jersey. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, Passage Bio purchased $88.2&#160;million in
            marketable securities and had sales and maturities of $143.2&#160;million in marketable securities. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2026, Passage Bio received de minimis
            cash proceeds related to the sale of property and equipment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2025, Passage Bio had sales and
            maturities of $39.0&#160;million in marketable securities and received cash proceeds of $0.6&#160;million related to the sale of property and equipment and certain other assets. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Net Cash Provided by (Used in) Financing
            Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, Passage Bio received de minimis proceeds
            from the issuance of common stock under its Employee Stock Purchase Plan (the &#8220;<span style="font-style: italic; font-weight: bold;">ESPP</span>&#8221;). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, Passage Bio received $8.7&#160;million in net
            proceeds from the issuance of common stock under the ATM Facility. Passage Bio received gross proceeds of $9.0&#160;million, net of offering costs of $0.3&#160;million. Passage Bio received $0.2&#160;million in proceeds from the issuance of common stock under
            the ESPP and exercises of employee stock options. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2026 and 2025, Passage Bio had no gross
            receipts or outflows of cash related to financing activities. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Contractual Obligations and Other
            Commitments </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio previously leased approximately 37,000 square feet of office space in
            Philadelphia, Pennsylvania, under a lease dated April&#160;10, 2020 (the &#8220;<span style="font-style: italic; font-weight: bold;">Market Street Lease Agreement</span>&#8221;). On May&#160;22, 2026, Passage Bio and the landlord entered into a lease termination
            agreement pursuant to which the 2005 Market Street Lease Agreement was terminated and Passage Bio paid a termination fee of $2.3&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio previously leased approximately 62,000 square feet of laboratory
            space in Hopewell, New Jersey under a lease dated December&#160;15, 2020 (the &#8220;<span style="font-style: italic; font-weight: bold;">Hopewell Lease</span>&#8221;). On March&#160;4, 2026, Passage Bio and the landlord entered into a lease termination agreement
            pursuant to which the Hopewell Lease was terminated and Passage Bio agreed to pay a termination fee of approximately $4.8&#160;million, plus accrued rent through February&#160;14, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following the termination of the 2005 Market Street Lease Agreement and the
            Hopewell Lease, Passage Bio has no material remaining obligations under real property leases. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the exclusive relationship under the Amended Catalent Agreements, following
            certain conditional events related to the divestiture by Passage Bio of either FTD or GM1, Passage Bio would pay Catalent certain fees. In the event of certain transactions, Passage Bio may terminate the Amended Catalent Agreements for
            convenience with respect to such products, in which case, Passage Bio would pay Catalent a certain termination fee. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">263<br/>
        </div>

      </div>

    </div>

    <!--End Page 273-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 274-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements, is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, Passage Bio is required to make payment of $0.9&#160;million to Catalent which has been accrued as of and during the year ended
            December&#160;31, 2025 and accrued for as of the three months ended March&#160;31, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These contractual obligations and commitments are associated with contracts that
            are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Payments due
            upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of its service providers, up to the date of cancellation are not included as the amount and timing of such payments
            are not known. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The contractual obligations and commitments above do not include any potential
            milestone or royalty payments that Passage Bio may be required to make under the Penn License Agreement. Under the Amended Gemma Sublicenses, Gemma will be responsible for all potential milestone and royalty payments to Penn for the Outlicensed
            Programs. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The contractual obligations and commitments above do not include any potential
            milestone or royalty payments that Passage Bio may be required to make under the Gemma Collaboration Agreement. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Critical Accounting Policies and Estimates </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s management&#8217;s discussion and analysis of its financial condition and
            results of operations are based on its financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The preparation of these financial statements requires Passage Bio to make
            estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in its financial statements. On an ongoing basis, Passage Bio evaluate its estimates and
            judgments, including those related to long-lived assets and accrued expenses. Passage Bio base its estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the
            circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different
            assumptions or conditions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">While its significant accounting policies are described in more detail in Note&#160;3
            to its audited financial statements included elsewhere in this proxy statement/prospectus, Passage Bio believes the following accounting policies are the most critical to the judgments and estimates used in the preparation of its financial
            statements. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Long-Lived Assets </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio assesses long-lived assets for impairment when events or changes in
            circumstances indicate that the carrying value of the assets or the asset group may not be recoverable. Passage Bio measures the recoverability of assets that Passage Bio will continue to use in its operations by comparing the carrying value of
            the asset groups to its estimate of the related total future undiscounted net cash flows. If an asset group&#8217;s carrying value is not recoverable through the related undiscounted cash flows, the asset group is considered to be impaired. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event the carrying value exceeds the future undiscounted net cash flows,
            Passage Bio estimates the fair values using either the income approach, market approach, or a combination of the two. The income approach is based on the present value of future cash flows of each asset group, while the market approach is based
            on industry and economic conditions, including estimates on prevailing prices and rates for similar assets. The approaches are asset group specific and may incorporate a number of market participant assumptions in assessing fair value including
            future growth rates, discount rates, and market activity. Passage Bio measures the impairment by comparing the difference between the asset group&#8217;s carrying value and its fair value. Long-lived assets are considered a non-financial asset and
            are recorded at fair value only if an impairment charge is recognized. Impairments are determined for groups of assets related to the lowest level of identifiable independent cash flows. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, Passage Bio recorded impairments of
            long-lived assets (ROU asset, property and equipment, net, and certain other assets) of $6.1&#160;million. The impairment charges consisted of $2.6&#160;million of impairment expenses to property and equipment, net, and certain other assets in connection
            with the January&#160;2025 restructuring and ceasing its lab operations in Hopewell, New Jersey and $2.6&#160;million and $0.9&#160;million recorded to the ROU assets and property and equipment, net, respectively in connection with the December&#160;2025
            impairment testing related to the Hopewell laboratory space. As of December&#160;31, 2025, Passage Bio had property and equipment, net of $4.1&#160;million and ROU assets of $10.2&#160;million recorded on its balance sheet. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">264<br/>
        </div>

      </div>

    </div>

    <!--End Page 274-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 275-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, Passage Bio recorded impairments of
            long-lived assets (ROU assets, property and equipment, net, and certain other assets) of $5.2&#160;million primarily due to impairment testing in connection with the Hopewell laboratory space. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company did not recognize any impairment expenses for long-lived assets
            during the three months ended March&#160;31, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Actual future net cash flows are uncertain, subject to risks, and may change
            depending upon several factors, including industry or economic trends. If its estimates of future net cash flows differ from actual future net cash flows, its estimates of fair value could materially change. Additionally, future events or
            changes in circumstances could indicate the carrying value of its long-lived assets may not be recoverable and lead to future impairments. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development costs are expensed as incurred and consist primarily of
            employee-related expenses, including salaries, benefits, and share-based compensation, as well as expenses incurred with contract research organizations, contract manufacturing organizations, internal analytical and testing activities, and
            preclinical and discovery expenses through its collaboration arrangements with Penn and Gemma. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio makes estimates of its external accrued research and development
            expenses, which primarily relates to activities performed by its contract research organizations and contract manufacturing organizations, as of each balance sheet date in its financial statements based on an estimate of progress to completion
            of specific tasks using facts and circumstances known to Passage Bio at that time. Passage Bio determines the estimates by reviewing contracts, vendor agreements and change orders, invoicing to date, reviewing vendor provided supporting
            documentation and through discussions with its internal personnel and external service providers as to the progress to completion of services and the agreed-upon fee to be paid for such services. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Actual costs and estimates of progress to completion of its contract research
            organizations and contract manufacturing organizations are uncertain, subject to risks and may change depending upon a number of factors, including its enrollment levels and status of its clinical trials, and timing of its manufacturing
            activities. Such estimates are uncertain given the level of visibility Passage Bio has towards the activities of its contract research organizations and contract manufacturing organizations. If the actual timing of the performance of services
            or the level of effort varies from the estimate, Passage Bio will adjust the accrual and related expenses accordingly. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio may enter into license agreements and transition services agreements
            under which Passage Bio may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may include
            non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio applies the Financial Accounting Standards Board&#8217;s Accounting
            Standards Codification Topic 606, <span style="font-style: italic;">Revenue from Contracts with Customers </span>(&#8220;<span style="font-style: italic; font-weight: bold;">ASC 606</span>&#8221;) when all of the following criteria are met, to determine
            a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations&#894; (ii) Passage Bio can identify each party&#8217;s rights regarding the goods or services to be transferred&#894; (iii)&#160;Passage
            Bio can identify the payment terms for the goods or services to be transferred&#894; (iv) the contract has commercial substance&#894; and (v) Passage Bio will collect substantially all of the consideration to which Passage Bio will be entitled in
            exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, Passage Bio performs the following steps: (i) identification of the promised goods or services in the contract&#894;
            (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract&#894; (iii) measurement of the transaction price, including consideration of the constraint
            on variable consideration&#894; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis&#894; and (v) recognition of revenue when (or as) Passage Bio satisfy each performance obligation. As
            part of the accounting for these arrangements, Passage Bio must use its judgment to determine the number of performance obligations, the transaction price, the stand-alone selling price for each performance obligation identified in the contract
            for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. Passage Bio uses judgment to determine whether milestones or other variable consideration, except for certain sales-based
            milestone payments and royalties, should be included in the transaction price as described further below. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">265<br/>
        </div>

      </div>

    </div>

    <!--End Page 275-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 276-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">At the inception of each arrangement that includes milestone payments, Passage
            Bio evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within its control or the licensee, such as those subject to regulatory approvals, are not considered
            probable of being achieved until those approvals are received. Passage Bio evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this
            assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, Passage Bio reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations in the period of
            adjustment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For customer contracts in the scope of ASC 606, amounts due to Passage Bio are
            recorded as accounts receivable on its balance sheet when its right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on its balance sheet as current deferred revenue if
            expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months following the balance sheet
            date. Passage Bio does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Recent Accounting Pronouncements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">See Note&#160;3 to its financial statements included elsewhere in this proxy
            statement/prospectus for a description of recent accounting pronouncements applicable to its financial statements. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Quantitative and Qualitative Disclosure about Market Risk </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is exposed to market risks in the ordinary course of its business.
            Passage Bio&#8217;s primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because its investments are in marketable securities. Passage Bio&#8217;s marketable
            securities are subject to interest rate risk and could fall in value if market interest rates increase. However, Passage Bio believes that its exposure to interest rate risk is not significant as the majority of its investments are short-term
            in duration and due to the low risk profile of its investments, a 10% change in interest rates would not have a material effect on the total market value of its investment portfolio. Passage Bio has the ability to hold its marketable securities
            until maturity, and therefore Passage Bio would not expect its operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on its investments. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025 and March&#160;31, 2026, Passage Bio held $46.3&#160;million and
            $33.3&#160;million, respectively, in cash and cash equivalents, all of which was denominated in U.S. dollar assets, and consisting primarily of cash accounts in banking institutions and investments in money market funds. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is exposed to market risk related to changes in foreign currency
            exchange rates, as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, Passage Bio does not utilize any forward exchange contracts.
            All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. For the year ended December&#160;31, 2025 and the three months ended March&#160;31, 2026, a majority of its expenditures were denominated in U.S.
            dollars. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on its financial statements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Inflation may affect Passage Bio by increasing its cost of labor, cost of
            external services, and cost of external goods and raw materials. Passage Bio does not believe that inflation has had a material effect on its business, financial condition or results of operations for any period presented herein. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">266<br/>
        </div>

      </div>

    </div>

    <!--End Page 276-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 277-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tMDAR"><!--Anchor--></a>REMIX&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS
            OF <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following discussion and analysis of our financial
            condition and results of operations should be read with our audited consolidated financial statements as of and for the years ended December&#160;31, 2025 and 2024, and our unaudited condensed consolidated financial statements as of and for the
            three months ended March&#160;31, 2026, and the related notes thereto included elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus,
            including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the
            &#8220;Risk Factors&#8221; section of this proxy statement/prospectus, our actual results may differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.<span style="font-style: normal;"> </span></div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Overview </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix is a clinical stage biopharmaceutical company focused on small molecule
            approaches to reprogramming ribonucleic acid (&#8220;RNA&#8221;), potentially offering new treatment options to patients with devastating diseases. Remix's proprietary approach identifies small molecules that have the potential to impact the expression of
            disease driving messenger RNA (&#8220;mRNA&#8221;) and proteins, which could allow Remix to address previously undruggable targets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We received clearance from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for
            our Investigational New Drug (&#8220;IND&#8221;) applications for REM-422 in adenoid cystic carcinoma (&#8220;ACC&#8221;) and acute myeloid leukemia (&#8220;AML&#8221;). REM-422 is currently being evaluated in a Phase 1/2 clinical trial in patients with recurrent, metastatic or
            unresectable ACC and in a Phase 1 clinical trial in patients with AML or high-risk myelodysplastic syndrome (&#8220;HR-MDS&#8221;). In May&#160;2024, we announced that the first patients had been enrolled and dosed in both trials. In October&#160;2025, we announced
            positive preliminary data from the Phase 1 portion of our ACC clinical trial, and in March&#160;2026, the FDA granted Fast Track designation to REM-422 for the treatment of patients with recurrent, metastatic or unresectable ACC whose tumors express
            Myeloblastosis (&#8220;MYB&#8221;) transcripts containing a poison exon. Remix completed an End-of-Phase 1 (&#8220;EOP1&#8221;) meeting with the FDA on March 27, 2026. The FDA authorized Remix to proceed with an ongoing Phase 2 study with proposed key elements,
            including: recommended dose, the use of the MYB poison exon biomarker as a potential companion diagnostic (developed in collaboration with Tempus AI), and single arm study design for potential registration. At the EOP1 meeting, FDA provided
            recommendations that have been incorporated into the study including using patient-reported outcome measures. Subject to the results of the Phase 2 study, an NDA submission is targeted as early as the second half of 2027 and Remix is preparing
            for potential commercial readiness in 2028. In May&#160;2026, we announced positive data from the Phase 1/2 ARIA study of REM-422 in patients with ACC. Beyond REM-422, we have discovery and preclinical efforts across oncology, immunology and
            neurodegenerative targets, including targets being pursued through collaboration arrangements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Since our inception in 2019, we have devoted substantially all of our efforts and
            financial resources to organizing and staffing, business planning, raising capital, discovering product candidates, establishing and protecting our intellectual property portfolio, and conducting discovery, research and development activities
            for our current or future product candidates. We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from issuances of our convertible
            preferred stock and convertible promissory notes, and revenue received under our collaboration arrangements. Through December&#160;31, 2025, we have received gross proceeds of $154.8 million from issuances of our convertible preferred stock, $75.1
            million of proceeds received in connection with convertible promissory notes, $42.0&#160;million from our collaboration agreement with F. Hoffmann-La Roche Ltd (&#8220;Roche Basel&#8221;) and Hoffmann-La Roche Inc. (&#8220;Roche US&#8221;), together referred to as Roche,
            and $45.8 million from our collaboration agreement with Janssen Pharmaceutica NV (&#8220;Janssen&#8221;). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have incurred significant operating losses since inception. Our ability to
            generate product revenue sufficient to achieve profitability will depend on the successful development and eventual commercialization of one or more of our current or future product candidates. We reported net losses of $16.6&#160;million and
            $21.4&#160;million for the three months ended March&#160;31, 2026 and 2025, respectively. We had net losses of $73.7 million and $69.1 million for the years ended December&#160;31, 2025 and 2024, respectively. As of March&#160;31, 2026, we had cash and cash
            equivalents of $24.0&#160;million and an accumulated deficit of $308.6 million. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. In addition, we expect that our expenses and
            capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we: </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">267<br/>
        </div>

      </div>

    </div>

    <!--End Page 277-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 278-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advance our MYB program through clinical development; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">advance the development of our other small molecule research programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expand our pipeline of product candidates through our own research and development efforts; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek to discover and develop additional product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">contract to manufacture any approved product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expand our clinical, scientific, management and administrative teams; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintain, expand, protect, and enforce our intellectual property portfolio, including patents, trade secrets and know how; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">implement operational, financial and management systems; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">operate as a public company. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will not generate revenue from product sales unless and until we successfully
            complete clinical development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur
            significant expenses to develop our internal commercialization capability to support commercial sales, marketing and distribution. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the
            timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not achieve or sustain profitability. If we fail to become profitable or are unable
            to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and may be forced to reduce or terminate our operations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have limited capital resources and expect that our cash and cash equivalents,
            including amounts received from issuances of convertible promissory notes, will not be sufficient to fund our operating expenses, capital expenditure requirements and obligations, for the twelve months following the date the consolidated
            financial statements are issued. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year from the date that these consolidated financial statements were issued. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our plans to obtain additional funding include (1) a reverse merger and
            concurrent private placement in public equity (&#8220;PIPE&#8221;) financing, (2) financing alternatives (e.g., equity financing, royalty arrangements, business development financing, etc.), or (3) both. Refer to Note&#160;23 of our consolidated financial
            statements included elsewhere in this proxy/prospectus for further information. Although we continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient financing on terms acceptable to us to fund
            continuing operations, if at all. If we are unable to obtain financing, we may be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or future commercialization efforts, which
            could adversely affect our business prospects, or we may be unable to continue operations. As a result, we have concluded that our plans do not alleviate the substantial doubt about our ability to continue as a going concern. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2026, we had cash and cash equivalents of $24.0&#160;million. As of
            July&#160;21, 2026, the issuance date of the unaudited condensed consolidated financial statements as of and for the three months ended March&#160;31, 2026, we expect our cash and cash equivalents will fund our operating expenses and capital expenditure
            requirements into the fourth quarter of 2026 without giving effect to the Merger and Concurrent Financing, as defined below. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Beyond that point, we will need to raise additional capital to finance our
            operations, which cannot be assured. Although management believes that the Merger and Concurrent Financing, if completed, would provide sufficient liquidity to fund the combined company&#8217;s operations beyond the one-year look-forward period,
            management cannot conclude that the completion of these transactions is probable as of the financial statement issuance date, as their successful execution depends on approvals and actions by third parties that are outside of management&#8217;s
            control. This raises substantial doubt about our ability to continue as a going concern within one year of the issuance date of unaudited condensed consolidated financial statements. See Note&#160;1 of our unaudited condensed consolidated financial
            statements included elsewhere in this proxy statement/prospectus for additional information on our </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">268<br/>
        </div>

      </div>

    </div>

    <!--End Page 278-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 279-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">assessment. Similarly, in our consolidated financial statements for the year
            ended December&#160;31, 2025, our independent registered public accounting firm included an explanatory paragraph stating that our recurring losses from operations since inception, expectation of generating operating losses for the foreseeable
            future and need for additional capital to finance our future operations raise substantial doubt about our ability to continue as a going concern. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Proposed Merger and Concurrent Financing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;24, 2026, Remix entered into an Agreement and Plan of Merger (the &#8220;Merger
            Agreement&#8221;) with Passage Bio, Inc. (&#8220;Passage Bio&#8221;) and Peregrine Merger Sub, Inc., a wholly owned subsidiary of Passage Bio (&#8220;Merger Sub&#8221;). Subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub
            will merge with and into Remix, with Remix continuing as a wholly owned subsidiary of Passage Bio and the surviving corporation of the merger (the &#8220;Merger&#8221;). In connection with the Merger, Passage Bio will change its name to &#8220;Remix
            Therapeutics, Inc.&#8221; Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each then outstanding share of Remix&#8217;s common stock (including shares of common stock issued upon
            conversion of Remix&#8217;s preferred stock, shares of Remix&#8217;s common stock issued upon conversion of Remix&#8217;s convertible notes and warrants and shares of Remix&#8217;s common stock issued in the Concurrent Financing described below) will be converted into
            the right to receive a number of shares of Passage Bio&#8217;s common stock calculated in accordance with the Merger Agreement. The combined company is expected to be led by Remix&#8217;s management team and will focus on developing small molecule
            therapeutics to modulate RNA processing and address the underlying drivers of disease. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Concurrently with entering into the Merger Agreement, Remix entered into (i) a
            subscription agreement (the &#8220;Subscription Agreement&#8221;) for the sale of shares of Remix common stock for an aggregate purchase price of approximately $70.0 million and (ii) a convertible promissory note purchase agreement (the &#8220;2026
            Note&#160;Agreement&#8221;) for the sale of approximately $30.0&#160;million aggregate principal amount of convertible notes (the &#8220;2026 Notes&#8221;) that will convert into shares of Remix common stock based on the same aggregate equity value of Remix being used in
            the Merger. In June&#160;2026, we received $30.0&#160;million in proceeds from the 2026 Notes related to the 2026 Notes Agreement. The notes remained outstanding as of the financial statement issuance date, and conversion is contingent upon the closing
            of the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The sale of common stock pursuant to the Subscription Agreement and the issuance
            of the 2026 Notes pursuant to the 2026 Note&#160;Agreement are expected to result in aggregate gross proceeds to Remix of approximately $100.0 million (the &#8220;Concurrent Financing&#8221;). The issuance of Remix common stock pursuant to the Subscription
            Agreement and the conversion of the 2026 Notes into shares of Remix common stock are contingent on and will occur immediately prior to the Effective Time. Shares of Remix common stock issued in the Concurrent Financing will be converted into
            shares of Passage Bio common stock at the Effective Time in accordance with the terms of the Merger Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is expected to close in the fourth quarter of 2026 and is subject to
            approval by the stockholders of Remix and Passage Bio as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the transaction. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Macroeconomic and Geopolitical Considerations </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Uncertainty in the global economy presents significant risks to our business. We
            are subject to continuing risks and uncertainties in connection with the current macroeconomic environment including, but not limited to, rising inflation, rising interest rates, the risk of a recession and other ongoing global conflicts.
            Inflationary pressures and broader macroeconomic conditions have not had a material impact on our R&amp;D expenses or clinical trial costs during the periods presented, though we continue to monitor these conditions. While we are closely
            monitoring the impact of the current macroeconomic conditions on all aspects of our business, including the impacts on our clinical trial participants, employees, suppliers, vendors and collaboration partners, the ultimate extent of the
            long-term impact on our business remains highly uncertain and will depend on future developments and factors that continue to evolve. We will continue to evaluate the nature and extent of the potential impacts to our business, results of
            operations, liquidity and capital resources. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">269<br/>
        </div>

      </div>

    </div>

    <!--End Page 279-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 280-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Components of Our Results of Operations </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Collaboration Revenue </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">To date, we have not generated any revenue from product sales as we do not
            currently have any product candidates approved for commercial sales in any country. All revenue to date has been derived from our collaboration agreements. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Collaboration Revenue, Janssen </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In February&#160;2022, we entered into an exclusive collaboration and license
            agreement with Janssen to discover small molecule compounds that modulate targets for the treatment of diseases and conditions in the fields of oncology and immunology. We entered into this agreement with the intention of utilizing our
            proprietary drug discovery platform to identify compounds for collaboration targets. We received an upfront cash payment of $45.0&#160;million upon execution of the agreement, and were eligible to receive additional development, regulatory, and
            sales-based milestone payments as well as tiered royalties upon the achievement of specific events. We received an additional $0.8&#160;million as reimbursement for costs incurred as part of the collaboration related to a specific target that was
            subsequently reimbursed by Janssen. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We concluded that the arrangement was within the scope of Accounting Standards
            Codification (&#8220;ASC&#8221;) 606&#160;(&#8220;ASC 606&#8221;), <span style="font-style: italic;">Revenue from Contracts with Customers</span>, and not ASC 808, <span style="font-style: italic;">Collaborative Arrangements </span>(&#8220;ASC&#160;808&#8221;), because the relationship
            represents a vendor-customer relationship. We identified one combined performance obligation consisting of the license and research services, including related participation in joint governance activities and information-sharing obligations, as
            the promises were not distinct within the context of the contract. See &#8220;Critical Accounting Policies and Significant Judgments and Estimates &#8212; Revenue Recognition for Collaboration Arrangements&#8221; for further information.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We terminated the agreement with Janssen (the &#8220;Janssen Agreement&#8221;) in July&#160;2026
            following the formal notice that the targets would not be advanced further under the collaboration. As such, we will recognize the remaining deferred revenue balance associated with the Janssen Agreement during the quarter ending September&#160;30,
            2026. We will not recognize any additional collaboration revenue under the Janssen Agreement. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Collaboration Revenue, Roche </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, we and F. Hoffmann-La Roche Ltd. (&#8220;Roche&#8221;) entered into a
            research collaboration and license agreement (the &#8220;Roche Agreement&#8221;) for the discovery and development of small molecule therapeutics that modulate RNA processing using the REMaster drug discovery platform, pursuant to which we granted Roche:
            (a) an exclusive license under certain of our intellectual property rights to develop, manufacture and commercialize compounds, any products containing such compounds and any companion diagnostics for such products for all fields of use
            worldwide, provided that such license excludes any rights to our platform technology; and (b) an exclusive license under any jointly developed intellectual property solely in conjunction with the development, manufacture or commercialization of
            such product. We are responsible for certain discovery and preclinical activities, and Roche will be responsible for development and commercialization of any licensed compounds and licensed products arising under each research program. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As consideration for the licenses granted under the Roche Agreement, Roche made
            an upfront payment of $30.0 million. We are also eligible to receive from Roche (a) preclinical, clinical, commercial and sales milestone payments of up to $1.0 billion and (b) tiered royalties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We concluded that the relationship represents a vendor-customer relationship, and
            that ASC 606 is the appropriate accounting literature to apply. See &#8220;Critical Accounting Policies and Significant Judgments and Estimates &#8212; Revenue Recognition for Collaboration Arrangements&#8221; for further information. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">270<br/>
        </div>

      </div>

    </div>

    <!--End Page 280-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 281-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Operating Expenses </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development expenses consist primarily of costs incurred in
            connection with the discovery and development of our product candidates and the development of our programs and platform. Research and development expenses also include the costs incurred by us under the Janssen Agreement and Roche Agreement.
            We expense research and development costs as incurred. These expenses include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">employee-related expenses, including salaries, related benefits and stock-based compensation expense, for employees engaged in
                    research and development functions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">expenses incurred in connection with research and the preclinical development of our product candidates, including under
                    agreements with third parties, such as consultants and contract research organizations (&#8220;CROs&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the cost of manufacturing drug products for use in our clinical trials and preclinical studies, including under agreements with
                    third parties, such as consultants and contract manufacturing organizations (&#8220;CMOs&#8221;); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">laboratory supplies and other research materials; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">facilities, depreciation and other expenses related to research and development activities, which include direct or allocated
                    expenses for rent, utilities and maintenance of facilities and insurance.</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We separately track the direct research and development expenses for our MYB
            program, which primarily consist of external costs and fees paid to consultants, CROs and research laboratories in connection with our clinical development activities. To date, external research and development costs for any individual program
            or product candidate have been tracked commencing when we nominate the first product candidate in the program. Prior to that time, such costs are classified as unallocated platform and discovery external costs. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We do not allocate employee-related costs, external costs associated with our
            platform and discovery efforts, costs of laboratory supplies, and other internal or indirect costs to specific product development programs because these costs are deployed across multiple programs under development and our platform technology
            and, as such, are not separately classified. The total costs of our discovery efforts and projects are included in unallocated employee-related expenses as well as platform and discovery external costs. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We utilize CROs for our research and development activities and CMOs for our
            manufacturing activities, as we do not have our own manufacturing facilities. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service
            providers. This process involves reviewing open contracts and purchase orders, communicating with the respective personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the
            associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities
            are recorded as prepaid expenses. Such amounts are recognized as an expense when the goods have been delivered or the services have been performed, or when it is no longer expected that the goods will be delivered or the services rendered. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Product candidates in later stages of development generally have higher
            development costs than those in earlier stages. As a result, we expect that our research and development expenses will increase substantially over the next several years as we advance our current or future product candidates through preclinical
            studies into and through clinical trials, continue to discover and develop additional product candidates, expand, maintain, protect and enforce our intellectual property portfolio, and hire additional research and development personnel. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">271<br/>
        </div>

      </div>

    </div>

    <!--End Page 281-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 282-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The successful development of our current and future product candidates is
            highly uncertain, and we do not believe it is possible at this time to accurately project the nature, timing and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, any of our current or
            future product candidates. To the extent our product candidates continue to advance into initial clinical trials as well as advance into larger and later-stage clinical trials, our expenses will increase substantially and may become more
            variable. The duration, costs and timing of preclinical studies and clinical trials and development of our current product candidates are subject to numerous uncertainties and will depend on a variety of factors, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">successful and timely completion of clinical development of REM-422 and preclinical and clinical development of other research
                    programs and any other future programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishing and maintaining relationships with CROs and clinical sites for the clinical development of REM-422 and any other
                    future programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">timely receipt of regulatory approvals from applicable regulatory authorities for any product candidates for which we
                    successfully complete clinical development; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developing an efficient and scalable manufacturing process for our product candidates, including obtaining finished products
                    that are appropriately packaged for sale; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">establishing and maintaining commercially viable supply and manufacturing relationships with third&#160;parties that can provide
                    products and services adequate in both quantity and quality to support clinical development and meet the market demand for our product candidates, if approved; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">successful commercial launch following any regulatory approval, including the development of a commercial infrastructure,
                    whether in-house or with one or more collaborators; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a continued acceptable safety profile following any regulatory approval of our product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">commercial acceptance of our product candidates by patients, the medical community and third-party payors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">satisfying any required post-marketing approval commitments to applicable regulatory authorities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">identifying, assessing and developing new product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United
                    States and internationally; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">defending against third-party interference or infringement claims, if any; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to
                    develop, manufacture or commercialize our product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining and maintaining coverage and adequate reimbursement by third-party payors for our product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">addressing any competing therapies and technological and market developments; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">attracting, hiring and retaining qualified personnel. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any of these factors could significantly impact the costs, timing and viability
            associated with the development of our current or future product candidates. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. In addition, we may never succeed in obtaining regulatory
            approval for any of our product candidates. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">General and administrative expenses consist primarily of salaries and
            personnel-related costs, including stock-based compensation for our personnel in executive, finance and administrative functions; professional fees for accounting, auditing, tax, intellectual property and legal services; and consultant fees.
            General and administrative expenses also include facilities, depreciation and other expenses related to general and administrative activities, which include direct or allocated expenses for rent, utilities, infrastructure, corporate insurance,
            information technology and office expenses. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We anticipate that our general and administrative expenses will increase in the
            future as we increase our headcount to support our continued research and development of our current and future product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director
            and officer insurance costs as well as investor and public relations expenses associated with being a public company. We expect to incur additional intellectual property-related expenses as we file patent applications to protect our innovations
            resulting from research and development activities. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">272<br/>
        </div>

      </div>

    </div>

    <!--End Page 282-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 283-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">2025 Restructuring </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2025, we implemented a strategic restructuring and reprioritization plan
            to reduce operating costs and preserve capital, which included a reduction of approximately 20% of our workforce (the &#8220;2025 Restructuring&#8221;). We recognized $0.9 million of restructuring charges, consisting primarily of severance and related
            benefits, which are included in general and administrative expenses and research and development expenses in the consolidated statements of operations and comprehensive loss<span style="font-weight: bold;"> </span>for the year ended
            December&#160;31, 2025. The 2025 Restructuring was completed as of December&#160;31, 2025. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other (Expense) Income </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Change in Fair Value of Convertible Notes Payable, Warrant
            Liabilities, and Contingent Tranche Liability<span style="font-style: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, we entered into a convertible promissory note and warrant
            purchase agreement (the &#8220;2023 Notes Agreement&#8221;) with multiple investors pursuant to which we agreed to issue and sell to the lenders convertible promissory notes (the &#8220;2023 Notes&#8221;) and warrants to purchase common stock (the &#8220;2023 Warrants&#8221;).
            The 2023 Notes Agreement provided for multiple closings, including the initial closing of up to $25.0&#160;million and the milestone closing of up to $40.1&#160;million (the &#8220;Milestone Closing&#8221;), which was contingent upon achievement of certain
            development milestones prescribed by the 2023 Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We accounted for the 2023 Notes under the fair value method of accounting, with
            changes in fair value recorded in the consolidated statements of operations and comprehensive loss at each reporting date. Therefore, no bifurcation of embedded features within the 2023 Notes is required. The convertible notes payable, the
            warrant liability and the contingent tranche liability were each determined to be separate freestanding financial instruments under ASC 480, <span style="font-style: italic;">Distinguishing Liabilities from Equity </span>(&#8220;ASC 480&#8221;). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;14, 2025, we entered into the first amendment to the 2023 Notes
            Agreement pursuant to which the maturity date of the 2023 Notes was amended to the earlier of December&#160;22, 2025 or immediately prior to the initial closing under the 2025 Notes Agreement, as defined below. As a result, the outstanding 2023
            Notes converted into shares of Series&#160;B preferred stock immediately prior to the initial closing of the 2025 Notes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Additionally, on November&#160;14, 2025, we entered into a convertible promissory note
            and warrant purchase agreement (the &#8220;2025 Notes Agreement&#8221;), with multiple investors pursuant to which we agreed to issue and sell to the lenders convertible promissory notes (&#8220;2025 Notes&#8221;) and warrants to purchase shares (the &#8220;2025 Warrants&#8221;).
            The 2025 Notes Agreement provided for multiple closings, including an initial tranche of $15.0&#160;million in December&#160;2025 (the &#8220;First Tranche Closing&#8221;) and a second tranche of $15.0&#160;million in March&#160;2026 (the &#8220;Second Tranche Closing&#8221;). The second
            tranche represented an obligation to issue additional notes and warrants upon the satisfaction of the milestone closing conditions and was initially recorded at its fair value of $0.5 million, estimated using a Monte Carlo simulation model, and
            was presented as a contingent tranche liability on the consolidated balance sheets as of December&#160;31, 2025. The Second Tranche Closing was completed in March&#160;2026, at which time the contingent tranche liability was settled. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We accounted for the 2025 Notes under the fair value method of accounting, with
            changes in fair value recorded in the consolidated statements of operations and comprehensive loss at each reporting date. Therefore, no bifurcation of embedded features within the 2025 Notes is required. The convertible notes payable, the
            warrant liability and the contingent tranche liability were each determined to be separate freestanding financial instruments under ASC 480. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Interest Income </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Interest income consists of interest earned on our cash, cash equivalents and
            restricted cash, which include unrestricted deposits with financial institutions in checking and money market accounts. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20pt; margin-left: 0pt; text-align: left;">Other (Expense) Income, Net </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other (expense) income, net consists of an insignificant amount of miscellaneous
            income and expense items unrelated to our core operations. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Income Taxes </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">We maintain a full valuation allowance against deferred tax assets, but may
            record current tax expense or benefit. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">273<br/>
        </div>

      </div>

    </div>

    <!--End Page 283-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 284-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Results of Operations </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Comparison of the three months ended March
            31, 2026 and 2025 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table summarizes our results of operations for the three months
            ended March 31, 2026 and 2025 (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 93.04pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 300pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 93.04pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div>
                </td>

    <td style="width: 10.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 32.22pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 300pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 10.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

    <td style="width: 10.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 15.83pt;">831 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 15.83pt;">690 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;">$<span style="padding-left: 10.83pt;">141 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br/>
                  </div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">12,100 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">15,555 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt;">(3,455) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,072 </span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,275 </span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(203</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">16,172 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,830 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,658</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(15,341</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(19,140</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,799 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (expense) income:<br/>
                  </div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Change in fair value of convertible notes payable, warrant liabilities
                    and <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">contingent tranche liability, related party</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">(1,375)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">(2,770)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 8.33pt;">1,395 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest income</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 21.2pt;">114 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 20.83pt;">551 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 12.5pt;">(437) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other expense, net</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total other expense, net</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,264</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,227</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">963 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(16,605</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(21,367</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,762 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15 </span></div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss and comprehensive loss</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(16,615</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(21,382</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,767</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes our research and development expenses for the
            periods indicated (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 85.76pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 85.76pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,</div>
                </td>

    <td style="width: 9.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 32.22pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 9.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

    <td style="width: 9.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Direct research and development:<br/>
                  </div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">MYB program</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;">$<span style="padding-left: 5pt;">6,258 </span></div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;">$<span style="padding-left: 5pt;">5,324 </span></div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;">$<span style="padding-left: 10.83pt;">934 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other preclinical programs</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="padding-left: 10pt;">1,222 </span></div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="padding-left: 10pt;">3,868 </span></div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt;">(2,646) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unallocated research and development expenses: <br/>
                  </div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs (including stock-based compensation)</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="padding-left: 10pt;">2,579 </span></div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="padding-left: 10pt;">4,062 </span></div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt;">(1,483) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Facilities, laboratory supplies and other</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,041 </span></div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,301 </span></div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(260</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$12,100 </span></div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.43pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,555 </span></div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(3,455</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 33.37pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 33.37pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development expenses were $12.1 million for the three months ended
            March 31, 2026, compared to $15.6 million for the three months ended March 31, 2025. The decrease in total research and development expenses of $3.5 million was primarily attributable to the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The decrease of $2.6&#160;million in other preclinical and collaboration programs was primarily due to the 2025 Restructuring and
                    reprioritization of our preclinical programs from 2025 to further support our MYB program; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The decrease in personnel-related costs of $1.5&#160;million, including a decrease of $0.2&#160;million in stock-based compensation
                    expense, was primarily due to the 2025 Restructuring, which reduced our workforce by approximately 20% period over period; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The decrease of $0.3&#160;million in facilities, laboratory supplies and other costs which was primarily due to decreased spending on
                    laboratory supplies in line with the prioritization of resources to our MYB program; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Partially offsetting these decreases was an increase of $0.9&#160;million in direct research and development costs related to our MYB
                    program due to increased clinical spend to support our Phase 1/2 clinical trial activities, partially offset by lower biological discovery costs. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">274<br/>
        </div>

      </div>

    </div>

    <!--End Page 284-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 285-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">General and administrative expenses were $4.1 million for the three months ended
            March 31, 2026, compared to $4.3 million for the three months ended March 31, 2025. The decrease of approximately $0.2 million was primarily attributable to a decrease of $0.4&#160;million in personnel-related costs due to the 2025 Restructuring,
            partially offset by an increase of $0.1&#160;million in professional fees. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other (Expense) Income </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Change in Fair Value of Convertible Notes Payable, Warrant
            Liabilities and Contingent Tranche Liability </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, November&#160;2025 and March&#160;2026, we issued convertible notes and
            corresponding warrants and contingent tranches to various new and existing investor groups (see Note&#160;9 of our consolidated financial statements included elsewhere in this proxy statement/prospectus). We elected to record the convertible notes,
            warrants, and contingent tranche liabilities at fair value upon issuance and to subsequently remeasure each freestanding instrument at fair value at the end of each reporting period with the change in fair value being recorded as a component of
            other (expense) income in our consolidated statements of operations and comprehensive loss. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The change in fair value of the convertible promissory notes, warrant liability
            and settlement of the contingent tranche liability was $1.4 million for the three months ended March&#160;31, 2026, compared to $2.8&#160;million for the three months ended March&#160;31, 2025. The decrease in the change in fair value was primarily
            attributable to the change in fair value of the convertible notes payable due to market conditions, in addition to the contingent tranche liability related to the Second Tranche Closing settling in March&#160;2026. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Interest Income </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Interest income was $0.1 million for the three months ended March 31, 2026,
            compared to $0.6 million for the three months ended March 31, 2025. The decrease was primarily due to a decrease in our cash, cash equivalents and restricted cash balance. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Comparison of the years ended December&#160;31,
            2025 and 2024 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table summarizes our results of operations for the years ended
            December&#160;31, 2025 and 2024 (in&#160;thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 85.04pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 85.04pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">For the year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div>
                </td>

    <td style="width: 6.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 32.22pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

    <td style="width: 6.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,310 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 8.33pt;">4,827 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;">$(1,517) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br/>
                  </div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">52,593 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">58,492 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt;">(5,899) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,056 </span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,152 </span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(96</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">67,649 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">73,644 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,995</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(64,339</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(68,817</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,478 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (expense) income:<br/>
                  </div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Change in fair value of convertible notes payable,
                    warrant liabilities and contingent tranche liability, related party</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">(10,814)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">(3,518)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt;">(7,296) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest income</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">1,293 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">3,224 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt;">(1,931) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other (expense) income, net</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(27</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">22 </span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(49</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total other expense, net</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,548</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(272</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,276</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(73,887</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(69,089</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(4,798</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax benefit (expense)</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">182 </span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(50</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">232 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss and comprehensive loss</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(73,705</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(69,139</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.69pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(4,566</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">275<br/>
        </div>

      </div>

    </div>

    <!--End Page 285-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 286-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The following table summarizes our research and development expenses for the
            periods indicated (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 84.6pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 84.6pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,</div>
                </td>

    <td style="width: 9.8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 32.22pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">$ Change</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

    <td style="width: 9.8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Direct research and development:<br/>
                  </div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">MYB program</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$20,095 </div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$18,877 </div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;">$<span style="padding-left: 3.33pt;">1,218 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other preclinical programs</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">9,983 </span></div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 5pt;">13,948 </span></div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><span style="padding-left: 5pt;">(3,965) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unallocated research and development expenses: <br/>
                  </div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs (including stock-based compensation)</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">13,321 </span></div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 5pt;">14,902 </span></div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><span style="padding-left: 5pt;">(1,581) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Facilities, laboratory supplies and other</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">9,194 </span></div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10,765 </span></div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,571</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$52,593

                    </span></div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$58,492 </span></div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.22pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.7pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(5,899</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development expenses were $52.6 million for the year ended
            December&#160;31, 2025, compared to $58.5 million for the year ended December&#160;31, 2024. The decrease in total research and development expenses of $5.9 million was primarily attributable to the following: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The decrease of $4.0&#160;million in collaboration programs and other preclinical programs was primarily due to prioritization of
                    resources to our MYB program to further advance our clinical trial over our platform programs; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The decrease in personnel-related costs of $1.6&#160;million, including a decrease of $0.4&#160;million in stock-based compensation
                    expense, was primarily due to the 2025 Restructuring, which reduced our workforce by approximately 20%; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The decrease of $1.6&#160;million in facilities, laboratory supplies and other costs which was primarily due to decreased spending on
                    laboratory supplies in line with the prioritization of resources to our clinical program; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Partially offsetting these decreases was an increase of $1.2&#160;million in direct external costs of our MYB program due to
                    increased clinical spend from our Phase 1 clinical trial activities, partially offset by decreases in preclinical and manufacturing activities. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">General and Administrative Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">General and administrative expenses were $15.1 million for the year ended
            December&#160;31, 2025, compared to $15.2&#160;million for the year ended December&#160;31, 2024. The decrease of $0.1 million was primarily attributable to a decrease of $0.2 million in professional fees, primarily due to decreases in legal fees, partially
            offset by an increase of $0.1&#160;million in personnel-related costs due to the 2025 Restructuring. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other (Expense) Income </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Change in Fair Value of Convertible Notes Payable, Warrant
            Liabilities and Contingent Tranche Liability </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023 and November&#160;2025, we issued convertible notes and corresponding
            warrants and contingent tranches to various new and existing investor groups (see Note&#160;9 of our consolidated financial statements included elsewhere in this proxy statement/prospectus). We elected to record the convertible notes, warrants, and
            contingent tranche liabilities at fair value upon issuance and to subsequently remeasure each freestanding instrument at fair value at the end of each reporting period with the change in fair value being recorded as a component of other
            (expense) income in our consolidated statements of operations and comprehensive loss. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The change in fair value of the convertible promissory notes, warrant liability
            and contingent tranche liability was $10.8 million for the year ended December 31, 2025, compared to $3.5 million for the year ended December 31, 2024. The increase in the change in fair value was primarily attributable to the conversion of the
            convertible notes payable in November&#160;2025, compared to the change in fair value of the contingent tranche liability prior to settlement in the comparable period in 2024. See Note&#160;9 of our consolidated financial statements for further
            information on the changes in fair value during the periods presented. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">276<br/>
        </div>

      </div>

    </div>

    <!--End Page 286-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 287-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Interest Income </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Interest income was $1.3 million for the year ended December&#160;31, 2025, compared
            to $3.2 million for the year ended December&#160;31, 2024. The decrease was primarily due to a decrease in our cash, cash equivalents and restricted cash balance. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Liquidity and Capital Resources </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Sources of Liquidity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Since our inception, we have devoted substantially all of our efforts and
            financial resources to organizing and staffing our company, raising capital, discovering product candidates, protecting our intellectual property portfolio, and conducting discovery, research and development activities. We do not have any
            products approved for sale and have not generated any revenue from product sales. We have funded our operations to date primarily with proceeds from issuances of our convertible preferred stock and convertible promissory notes, and revenue
            received under our collaboration arrangements. As of March&#160;31, 2026, we had cash and cash equivalents of $24.0 million and an accumulated deficit of $308.6 million. We expect our cash and cash equivalents will fund our operating expenses and
            capital expenditure requirements into the fourth quarter of 2026 without giving effect to the Merger and Concurrent Financing, after which we will need to raise additional capital to finance our operations, which cannot be assured and raises
            substantial doubt about our ability to continue as a going concern. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our recent financing activities include the issuance of convertible promissory
            notes and related warrants to existing investors, including investors affiliated with members of our board of directors who are deemed to be related parties. In December&#160;2023, we entered into the 2023 Notes Agreement with multiple investors,
            including existing related-party investors. In November&#160;2025, the outstanding 2023 Notes converted into shares of Series&#160;B Preferred Stock pursuant to their contractual terms, and we entered into the 2025 Notes Agreement exclusively with
            existing related-party investors, which was recorded at fair value. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We entered into the 2023 Notes Agreement and the 2025 Notes Agreement to fund our
            operating expenses and capital expenditure requirements, including our discovery, research and development activities, at times when we determined that these financing structures represented available sources of capital. Through December&#160;31,
            2025, we received $15.0&#160;million in proceeds from related parties under the 2025 Notes Agreement, and during the three months ended March&#160;31, 2026, we received an additional $15.0&#160;million in proceeds from related parties upon the second tranche
            closing under the 2025 Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In June 2026, we entered into the 2026 Note Agreement and the Subscription
            Agreement for the Concurrent Financing. See &#8220;&#8212; Proposed Merger and Concurrent Financing.&#8221; We expect that we may seek additional financing from these or other related parties in the future, on terms that have not yet been determined, to fund our
            operations beyond the fourth quarter of 2026. There can be no assurance that any such financing will be available on acceptable terms, or at all. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash flows for the three months ended March
            31, 2026 and 2025 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes our sources and uses of cash for each of the
            periods presented (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 95.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.84pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(14,783)</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(21,065) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by investing activities</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">26 </span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by financing activities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,012 </span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">42 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase (decrease) in cash, cash equivalents and restricted cash</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 15.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">255 </span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(21,023</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17pt; margin-left: 0pt; text-align: left;">Operating Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2026, net cash used in operating
            activities of $14.8&#160;million was primarily due to a net loss of $16.6&#160;million and changes in operating assets and liabilities of $0.8&#160;million, partially offset by adjustments for non-cash items of $2.6&#160;million. The change in operating assets and
            liabilities was largely driven by the decrease in deferred revenue of $0.8&#160;million upon recognition of revenue related to the collaboration agreements </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">277<br/>
        </div>

      </div>

    </div>

    <!--End Page 287-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 288-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">during the period. The non-cash items included $1.4&#160;million for the change in
            fair value of convertible notes payable, warrant liabilities and contingent tranche liability, as well as $0.7&#160;million in depreciation and amortization expense and $0.4&#160;million in stock-based compensation expense. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2025, net cash used in operating
            activities of $21.1&#160;million was primarily due to a net loss of $21.4&#160;million and changes in operating assets and liabilities of $4.0&#160;million, partially offset by adjustments for non-cash items of $4.3&#160;million. The change in operating assets and
            liabilities was largely driven by the decrease in accounts payable and accrued expenses and other current liabilities of $1.2 million and $2.1 million, respectively, and the decrease in deferred revenue of $0.7&#160;million upon recognition of
            revenue related to the collaboration agreements during the period. The non-cash items included $2.8&#160;million for the change in fair value of convertible notes payable, warrant liabilities and contingent tranche liability, as well as $0.8 million
            in depreciation and amortization expense and $0.7&#160;million in stock-based compensation expense. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Investing Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March 31, 2026, net cash provided by investing
            activities was less than $0.1 million, consisting of proceeds from the sale of property and equipment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">During the three months ended March 31, 2025, no cash was provided by or used in
            investing activities. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Financing Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March 31, 2026, net cash provided by financing
            activities was $15.0 million, consisting of the net proceeds from issuance of the second tranche of the 2025 Notes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the three months ended March 31, 2025, net cash provided by financing
            activities was less than $0.1&#160;million and related to proceeds from the exercise of stock options. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash flows for the years ended December&#160;31,
            2025 and 2024 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes our sources and uses of cash for each of the
            periods presented (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 95.65pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.65pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Years Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.18pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.46pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in operating activities</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(64,053)</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.46pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$(22,113) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash used in investing activities</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">(48)</span></div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.13pt;">(449) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by financing activities</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">14,755 </span></div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.46pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 7.96pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">48,502 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net (decrease) increase in cash, cash equivalents and restricted cash</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(49,346</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.46pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 2.96pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">25,940</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.46pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Operating Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, net cash used in operating activities of
            $64.1&#160;million was primarily due to a net loss of $73.7&#160;million and changes in operating assets and liabilities of $6.7&#160;million, partially offset by adjustments for non-cash items of $16.3&#160;million. The change in operating assets and liabilities
            was largely driven by the decrease in deferred revenue of $3.3&#160;million upon recognition of revenue related to the collaboration agreements during the period, as well as decreases of $2.5&#160;million and $1.1&#160;million related to accrued expenses and
            other liabilities and operating lease liabilities, respectively. The non-cash items included $10.8&#160;million for the change in fair value of convertible notes payable, warrant liabilities and contingent tranche liability, as well as $3.2&#160;million
            in depreciation and amortization expense and $2.1&#160;million in stock-based compensation expense. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, net cash used in operating activities of
            $22.1&#160;million was primarily due to a net loss of $69.1&#160;million, partially offset by changes in operating assets and liabilities of $38.0&#160;million and adjustments for non-cash items of $9.0&#160;million. The change in operating assets and liabilities
            was largely driven by a decrease in accounts receivable of $29.8&#160;million and an increase in deferred revenue of $7.2&#160;million, both related to collaboration agreements. The non-cash items included $3.5&#160;million for the change in fair value of
            convertible notes payable, warrant liabilities and contingent tranche liability, as well as $3.3&#160;million in depreciation and amortization expense and $2.3&#160;million in stock-based compensation expense. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">278<br/>
        </div>

      </div>

    </div>

    <!--End Page 288-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 289-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Investing Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, net cash used in investing activities
            was less than $0.1 million, resulting from purchases of property and equipment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, net cash used in investing activities
            was $0.4 million due to purchases of property and equipment partially offset by proceeds from the sale of property and equipment. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Financing Activities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2025, net cash provided by financing
            activities was $14.8 million, consisting primarily of net proceeds from the issuance of the 2025 convertible notes payable, warrants, and contingent tranche liability. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the year ended December&#160;31, 2024, net cash provided by financing
            activities was $48.5 million, consisting primarily of net proceeds from the issuance and sale of the second tranche of our 2023 convertible notes payable and warrants. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Funding Requirements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We expect our expenses to increase substantially in connection with our ongoing
            activities, particularly as we advance our preclinical activities and planned clinical trials for our current or future product candidates in development. We are seeking to complete the proposed Merger with Passage Bio as well as complete the
            issuance of Remix common stock in the Concurrent Financing to raise additional capital. Following the completion of the proposed Merger and the Concurrent Financing, we expect to incur additional costs associated with operating as a public
            company. The timing and amount of our operating expenditures will depend largely on the progress, costs, design, results of and timing of our planned and ongoing preclinical studies and clinical trials; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the willingness of the FDA or applicable foreign authorities to accept the data from clinical trials, as well as data from our
                    planned and ongoing preclinical studies and clinical trials and other work, as the basis for review and approval of our product candidates; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the outcome, costs and timing of seeking and obtaining FDA and applicable foreign regulatory approvals; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number and characteristics of product candidates that we pursue; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our need to expand our R&amp;D capabilities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs and timing associated with manufacturing our product candidates, and if such product candidates receive regulatory
                    approval, establishing commercial supplies and sales, marketing, and distribution capabilities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third party payors and adequate
                    market share and revenue for any approved products; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">patients&#8217; willingness to pay out of pocket for any approved products in the absence of coverage and/or adequate reimbursement
                    from third party payors; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our efforts to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of
                    any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense, and enforcement of any patents or other intellectual property rights; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our need and ability to retain key management and hire scientific, technical, business, and medical personnel; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the costs associated with operating as a public company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the economic and other terms, timing of and success of our current and any future collaborations, licensing or other
                    arrangements into which we may enter in the future; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the timing, receipt, and amount of sales from our product candidates, if approved. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">279<br/>
        </div>

      </div>

    </div>

    <!--End Page 289-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 290-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Accordingly, we will require substantial additional funding to continue our
            operations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon the completion of the proposed Merger and the Concurrent Financing, based on
            our current operating plan, we believe that our existing cash and cash equivalents should be sufficient to fund the combined company&#8217;s operations into 2028. Management based its projections of operating capital requirements on our current
            operating plan, which includes several assumptions that may prove to be incorrect, and we may use all of our available capital resources sooner than we expect. Until such time, if ever, as we can generate sufficient product revenue to support
            our operations, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. We may be required to
            raise additional funds sooner than planned. However, there can be no assurance that we will be able to raise additional capital on favorable terms, or at all. To the extent that we raise additional capital through the sale of equity or
            convertible debt securities, the ownership interest of our stockholders may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect the rights of our common stockholders and
            the rights of the stockholders of the combined organization. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Debt financing and preferred equity financing, if available, may involve
            agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances
            or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
            favorable to us. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise
            additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product
            candidates that we would otherwise prefer to develop and market ourselves. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Off-Balance Sheet Arrangements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We do not have any off-balance sheet arrangements as defined in Item&#160;303(b) of
            Regulation S-K that have or are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures, or capital resources. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Contractual Obligations and Commitments </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Leases </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of March 31, 2026 and December&#160;31, 2025, we had future minimum operating lease
            payment obligations under non-cancelable leases of $32.7 million and $33.8&#160;million, respectively. Our operating lease expires in December&#160;2032. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Other Contractual Obligations </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We enter into contracts in the normal course of business with CROs, CMOs and
            other third parties for preclinical research studies, drug supply, clinical trials, manufacturing, testing and other services. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice.
            Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation. The amount and timing of such payments are not
            known. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Critical Accounting Policies and Significant Judgments and
            Estimates </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our consolidated financial statements are prepared in accordance with U.S.
            Generally Accepted Accounting Principles (&#8220;GAAP&#8221;). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue,
            costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the
            circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our
            actual results may differ from these estimates under different assumptions or conditions. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">280<br/>
        </div>

      </div>

    </div>

    <!--End Page 290-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 291-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">While our significant accounting policies are described in more detail in
            Note&#160;2 to our consolidated financial statements included elsewhere in this proxy statement/prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our
            consolidated financial statements. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Convertible Notes Payable, Warrant
            Liabilities and Contingent Tranche Liability </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We elected to account for our convertible promissory notes and associated
            instruments at fair value under ASC 825, <span style="font-style: italic;">Financial Instruments</span>. We also classify certain warrants and contingent tranches issued in connection with our convertible note financings and line of credit as
            liabilities. The convertible notes payable, warrant liabilities, and contingent tranche liabilities are recorded at fair value at issuance and remeasured at fair value at each reporting date, with changes in fair value recognized in other
            (expense) income, net in the consolidated statements of operations and comprehensive loss. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We estimate the fair value of our convertible notes payable and associated
            freestanding instruments using a Monte Carlo simulation model until such time as the number of underlying shares is fixed or determinable. The Monte Carlo simulation model requires significant judgment and the use of unobservable inputs,
            including assumptions related to the timing and probability of potential conversion, financing, liquidity or other exit events, the fair value of our underlying equity securities, expected volatility, expected term, risk-free interest rates and
            expected dividends. Because we are a privately held company, certain of these assumptions are inherently subjective and may differ materially from actual results. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We consider the fair value measurement of our convertible notes payable, warrant
            liabilities, and contingent tranche liabilities to be a critical accounting estimate because changes in the assumptions used in the valuation models could have a material impact on the fair value of the liabilities and the amount of non-cash
            gains or losses recognized in our results of operations. A significant increase in the probability or timing of a financing, conversion or liquidity event, an increase in the fair value of our underlying equity securities, an increase in
            expected volatility or a change in the expected term or risk-free interest rate could result in materially different fair value measurements. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Revenue Recognition </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We account for the Janssen Agreement and Roche Agreement in accordance with ASC
            606 to measure progress of the collaborations over time. We measure progress using a proportional performance measure based on actual research and development costs incurred relative to total estimated research and development costs to be
            incurred by us under the respective agreements. We account for the consideration we receive under the Janssen Agreement and Roche Agreement as collaboration revenue in our consolidated statements of operations and comprehensive loss based on
            our progress towards completion of our research activities under the research plan. The unrecognized portion of consideration received under the Janssen Agreement and Roche Agreement is recorded as deferred revenue in our consolidated balance
            sheets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The critical estimate in measuring such progress is the estimation of the total
            costs to complete our remaining obligations under the Janssen Agreement and Roche Agreement. This includes a number of estimates and assumptions which contemplate both objective and subjective factors. Primary inputs to the estimate to complete
            our remaining performance obligations include the estimated internal personnel costs and third-party costs to support research and development activities of multiple potential targets. We forecast third-party costs to support research and
            development activities based on the requirements under the research plan, historical experience and negotiated rates with vendors. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our estimates may vary relative to actual costs incurred for various reasons
            including the number of targets being pursued, changes in scope, feedback from regulators, developments in the science over the term of the research plan and changes in costs for supplies, consumables and other materials needed for the
            collaboration. We actively monitor these estimates relative to actual costs incurred and update our forecasts when and as necessary. These variances represent changes in estimates and may result in material changes in recognition of deferred
            revenue over the term of the collaboration. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As part of the process of preparing our consolidated financial statements, we are
            required to estimate our accrued research and development expenses. This process involves estimating the level of services performed and the associated cost incurred for services when we have not yet been invoiced or otherwise notified of
            actual costs. The </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">281<br/>
        </div>

      </div>

    </div>

    <!--End Page 291-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 292-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg27"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">majority of our service providers invoice us in arrears for services performed
            on a predetermined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and
            circumstances known to us at that time. At each period end, we corroborate the accuracy of such estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include
            those related to fees paid to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">vendors in connection with discovery and preclinical development activities; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CROs in connection with preclinical studies, testing and planned clinical trials; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">CMOs in connection with the production of preclinical and clinical trial materials. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We record the expense and accrual related to external research and development
            based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research and development activities; invoicing to date under contracts;
            communication from our vendors, including CROs, CMOs and other companies of any actual costs incurred during the period that have not been invoiced; and the costs included in the contracts and purchase orders. The financial terms of these
            agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of
            the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies
            from the estimate, we adjust the accrual or the amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services
            performed relative to the actual status and timing of services may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of
            accrued research and development expenses. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Stock-Based Compensation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We measure all stock-based awards granted to employees, directors and
            non-employees based on the award&#8217;s fair value on the date of grant. We issue stock-based awards to employees and directors with both service-based vesting conditions and performance-based vesting conditions. We recognize the expense for
            service-based awards on a straight-line basis over each award&#8217;s requisite service period, which is generally the vesting period. For awarded stock options with performance-based vesting conditions, we recognize expense over the requisite
            service period commencing when the achievement of the related performance condition is first estimated to be probable, with a cumulative catch-up adjustment recognized in the period such change occurs. For stock-based awards granted to
            non-employee consultants, compensation expense is recognized in the same manner as if we had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The fair value of each stock option is estimated on the date of grant using the
            Black-Scholes option pricing model, which uses as inputs the fair value of our common stock and assumptions that we make for the volatility of our common stock, the expected term of the stock options, the risk-free interest rate for a period
            that approximates the expected term of the stock options and the expected dividend yield. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Due to the lack of a public market for the trading of our common stock prior to
            the completion of our transaction, and a lack of company-specific historical and implied volatility data, we base the estimate of expected volatility on the historical volatilities of a representative group of publicly traded guideline
            companies. For these analyses, we select companies with comparable characteristics and with historical share price information that approximates the expected term of the stock-based awards. We compute the historical volatility data using the
            daily closing prices for the selected companies&#8217; shares during the equivalent period that approximates the calculated expected term of our stock options. We will continue to apply this method until a sufficient amount of historical information
            regarding the volatility of our own stock price becomes available. We estimate the expected term of our stock options granted to employees and directors using the simplified method, whereby the expected term equals the average of the vesting
            term and the original contractual term of the option. We utilize this method as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is assumed to
            be zero as we have no current plans to pay any dividends on common stock. We have elected to use the expected term for stock options granted to non-employees, using the simplified method, as the basis for the expected term assumption. However,
            we may elect to use either the contractual term or the expected term for stock options granted to non-employees on an award-by-award basis. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">282<br/>
        </div>

      </div>

    </div>

    <!--End Page 292-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 293-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_123-mda_pg28"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A description of recently issued accounting pronouncements that may potentially
            impact our financial position and results of operations is disclosed in Note&#160;2 of our consolidated financial statements included elsewhere in this proxy statement/prospectus. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Quantitative and Qualitative Disclosures About Market Risk </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Interest Rate Risk </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our cash and cash equivalents consist of cash held in readily available checking
            accounts, money market funds and money market accounts. We are exposed to market risk related to fluctuations in interest rates and market prices. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in
            the general level of United States interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial
            condition or results of operations. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Foreign Currency </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We contract with vendors in foreign countries, including countries in Europe and
            the Asia Pacific. We are therefore subject to fluctuations in foreign currency rates in connection with these agreements. We do not hedge our foreign currency exchange rate risk. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Net realized and unrealized gains and losses from foreign currency transactions
            are reported in other (expense) income, net, in the statements of operations and comprehensive loss. The impact of foreign currency costs on our operations has been nominal for all periods presented. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Inflation Risk </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Inflation generally affects us by increasing our labor and clinical trial costs.
            We do not believe that inflation has had a material effect on our results of operations during the periods presented. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Financial instruments that potentially subject us to concentrations of credit
            risk consist principally of cash and cash equivalents. We maintain cash and cash equivalents at financial institutions that we believe have high credit quality and we do not believe that such funds are exposed to any unusual credit risk beyond
            the normal credit risk associated with commercial banking relationships. We place our cash with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to the limit of $250,000. Deposits held
            may exceed the amount of insurance provided by the FDIC. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">283<br/>
        </div>

      </div>

    </div>

    <!--End Page 293-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 294-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_124-management_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tMFTM"><!--Anchor--></a>MANAGEMENT FOLLOWING THE MERGER </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Executive Officers and Directors </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Executive Officers and Directors of the
            Combined Company Following the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s board of directors will initially consist of Linda C.
            Bain, Scott Biller, Ph.D., Maria Koehler, M.D., Ph.D., Matthew&#160;R.&#160;Patterson, and Peter G. Smith, Ph.D., who currently serve on the Remix board of directors, and Peter Colabuono. The staggered structure of the current Passage Bio board of
            directors will remain in place for the combined company following the completion of the Merger. The Remix board of directors has determined that each of the directors, other than Dr.&#160;Smith, meet the Nasdaq independence requirements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table lists the names and ages, as of June&#160;30, 2026, and positions
            of the individuals who are expected to serve as executive officers and directors of the combined company upon completion of the Merger: </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Executive Officers: </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AGE</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">POSITION</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">50</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President, Chief Executive Officer, and Director</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman, Ph.D.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">52</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Operating Officer and Chief Business Officer</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Mythili Koneru, M.D., Ph.D.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">48</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Medical Officer</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D.</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">50</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Scientific Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Non-Employee Directors:</div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">AGE</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">POSITION </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Matthew R. Patterson</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">55</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chairman </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Linda C. Bain</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">55</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Scott Biller, Ph.D.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">70</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Colabuono</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">44</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maria Koehler, M.D., Ph.D.</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13pt; text-align: left;">69</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Executive Officers </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D.<span style="font-style: normal; font-weight: normal;"> has served as the President of Remix since July&#160;2019 and as the Chief Executive Officer since August 2021. From August 2019 to August 2021, he also served as the Chief Scientific Officer. He
              has served as a member of the Board of Directors of Remix since March&#160;2020. He previously served as Chief Scientific Officer at H3 Biomedicine, a precision oncology company. Prior to H3 Biomedicine, Dr.&#160;Smith was at Takeda and Millennium
              Pharmaceuticals from 2004 to 2011. He received his Ph.D. from Newcastle University and completed post-doctoral training at Dana Farber Cancer Institute and the University of Leeds. He also sits on the Board of Directors of Ryvu Therapeutics
              and is an advisor to several drug discovery companies. Dr.&#160;Smith&#8217;s leadership experience at Remix and his expertise in biotechnology and oncology drug discovery and development qualify him to serve on the combined company&#8217;s board of
              directors. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Heather Wasserman, Ph.D.<span style="font-style: normal; font-weight: normal;"> has served as the Chief Business Officer of Remix since March&#160;2021. She is responsible for corporate business development and operations at Remix. She joined Remix after seven years at Eli
              Lilly, where she gained extensive business knowledge while heading up immunology search and evaluation, emerging technologies and innovations and most recently global corporate business development during her tenure there. Prior to Eli Lilly,
              she was a research scientist at Human Genome Sciences. Dr.&#160;Wasserman received a Ph.D. from the University of Georgia, and went on to complete a postdoctoral fellowship at Emory University. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Mythili Koneru, M.D., Ph.D. <span style="font-style: normal; font-weight: normal;">has served as Remix&#8217;s Chief Medical Officer since January&#160;2026. She was most recently Chief Medical Officer at Legend Biotech from April&#160;2023 to October&#160;2025 where she was responsible for
              overseeing all clinical development and medical affairs activities. Prior to that role, Dr.&#160;Koneru was initially SVP of Clinical Development February&#160;2019 to November&#160;2019 before becoming the Chief Medical Officer of Marker Therapeutics from
              December&#160;2019 to April&#160;2023, leading development of cellular therapies and peptide vaccines in its immune-oncology portfolio. Dr.&#160;Koneru served as Associate Vice President of Immuno-Oncology at Eli Lilly and also served as Senior Medical
              Director of Early Phase Clinical Development at Eli Lilly. Prior to Eli Lilly, </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">284<br/>
        </div>

      </div>

    </div>

    <!--End Page 294-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 295-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_124-management_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Dr.&#160;Koneru was an oncology fellow in the laboratory of Dr.&#160;Renier Brentjens at
            Memorial Sloan-Kettering Cancer Center, where she developed adoptive T cell therapies for both leukemia and solid tumors in early phase clinical trials. Dr.&#160;Koneru earned her bachelor&#8217;s degree in biology from the University of Chicago, her
            doctorate degree in Tumor Biology from New York University, and her medical degree from Robert Wood Johnson Medical School. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph. D. <span style="font-style: normal; font-weight: normal;">has served as Chief Scientific Officer of the Company since February&#160;2024, as SVP Head of Drug Discovery from May&#160;2022 to February&#160;2024 and started at Remix at its inception as SVP Head of
              Chemistry from September&#160;2019 to May&#160;2022. Prior to joining Remix, Dr.&#160;Reynolds served as a consultant to two seed-stage companies at Third Rock Ventures and as VP, Head of Chemistry at H3 Biomedicine, a company he joined on day one. Prior to
              that, Mr.&#160;Reynolds worked at Forma Therapeutics, where he also joined on the first day, and he started his career at Millennium Pharmaceuticals. He received his Ph.D. in synthetic chemistry from the University of Cambridge and conducted
              postdoctoral training at Harvard University where he focused on natural product synthesis. </span></div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Non-Employee Directors </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Matthew R. Patterson<span style="font-style: normal; font-weight: normal;"> has served as Chairman of Remix&#8217;s board of directors since June of 2024. He previously served as Executive Chairman from March&#160;2021 until June of 2024. He is Chairman of the Board of Directors
              at Addition Therapeutics, Inc., Chairman of the Board of Directors at Rezo Therapeutics, Inc. and a Venture Partner at SR One. In 2012 Matt co-founded Audentes Therapeutics and served as Chief Executive Officer from the Company&#8217;s inception
              until its acquisition by Astellas Pharma Inc. in January&#160;2020. Mr.&#160;Patterson was also Chairman of the Board of Directors at Audentes and formerly served as President until May&#160;2018. Previously Mr.&#160;Patterson worked for Genzyme Corporation,
              BioMarin Pharmaceutical, Amicus Therapeutics, and Iris Medicine. Prior to Audentes he was an Entrepreneur-In-Residence with OrbiMed. He also served as a member of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the
              international advocacy organization representing the gene and cell therapy and broader regenerative medicine sector, from 2015-2021, and was Chairman in 2019 and 2020. Mr.&#160;Patterson received his Bachelor&#8217;s degree in Biochemistry from Bowdoin
              College. Mr.&#160;Patterson&#8217;s extensive leadership and board experience in the biotechnology industry, including his service as our Chairman and former Executive Chairman, qualify him to serve on the combined company&#8217;s board of directors. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Linda C. Bain <span style="font-style: normal; font-weight: normal;">has served as a member of Remix&#8217;s board of directors since April&#160;2025. She has been a Venture Partner at Atlas Venture since April&#160;2025. Prior to Atlas Venture, Ms.&#160;Bain served as Chief Operating Officer and
              Chief Financial Officer of Mariana Oncology, Inc., a Novartis Company April&#160;2025. Ms.&#160;Bain also served as Chief Financial Officer of Codiak BioSciences from December&#160;2015 to April&#160;2023; as Chief Financial Officer of Avalanche Biotechnologies,
              and Vice President of Finance, Business Operations, and Treasurer at bluebird bio. She previously held senior roles at Genzyme Corporation, including Vice President of Finance, Global Manufacturing and Operations, and Vice President of
              Finance, Genzyme Genetics. Earlier in her career, she held senior roles at Fidelity Investments, AstraZeneca and Deloitte &amp; Touche. She is currently on the Board of Directors of Arvinas, Autolus Therapeutics and Hemab Therapeutics.
              Ms.&#160;Bain holds a B.S. in Accounting and Business Administration from the University of the Free State, Bloemfontein South Africa and an Honors Degree in Accounting and Business Administration. Ms.&#160;Bain&#8217;s extensive executive financial and
              operational leadership experience in the biopharmaceutical industry and her current service on the boards of directors of several life sciences companies qualify her to serve on the board of directors of the combined company. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Scott Biller, Ph.D. <span style="font-style: normal; font-weight: normal;">has served as a member of Remix&#8217;s board of directors since July&#160;2020. Since 2021, Dr.&#160;Biller has served as Executive Venture Partner at the venture capital fund GV. He previously served as the
              Chief Scientific Officer of Agios Pharmaceuticals from September&#160;2010 to December&#160;2019. Dr.&#160;Biller is also currently the sole proprietor of Biller Consulting, a consulting company serving the biopharmaceutical industry since 2020. Since&#160;2020,
              Dr.&#160;Biller has served on the Board of Directors of Foghorn Therapeutics, Inc. and, from February&#160;2021 to December&#160;2025, served on the Board of Directors of Rome Therapeutics. In 2022, Dr.&#160;Biller joined the Board of Directors of OMass
              Therapeutics in Oxford, U.K and since 2023, he served as a board observer for Gate Biosciences. Dr.&#160;Biller earned a S.B. degree from the Massachusetts Institute of Technology, a Ph.D. from Caltech and was an NIH Postdoctoral Fellow at
              Columbia University in natural product synthesis. Dr.&#160;Biller&#8217;s extensive scientific leadership experience and knowledge of the biopharmaceutical industry qualify him to serve on the combined company&#8217;s board of directors. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Peter Colabuono<span style="font-style: normal; font-weight: normal;"> is expected to serve on the board of directors of the combined company upon completion of the merger. Mr.&#160;Colabuono is a Managing Director at Decheng Capital and has been with the firm since October&#160;2016. </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">285<br/>
        </div>

      </div>

    </div>

    <!--End Page 295-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 296-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_124-management_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">He is currently serving as a board member and leading the operations of
            Ariagen. Mr.&#160;Colabuono is also a director of ConjugateBio, Firefly Biologics and Solve Therapeutics. From August&#160;2019 to May&#160;2022, he served as a member of the board of directors of Checkmate Pharmaceuticals, Inc. (acquired by Regeneron). From
            March&#160;2017 to August&#160;2021, he served as a member of the board of AADi Bioscience (NASDAQ: AADI). From February&#160;2018 to November&#160;2020, he served as a member of the board at Velos Biopharma (acquired by Merck). Prior to joining Decheng,
            Mr.&#160;Colabuono served as Senior Director, Business Development at Ironwood Pharmaceuticals, Inc., a public commercial biotech company, from September&#160;2015 to October&#160;2016. As an Associate at Frazier Healthcare Ventures, he led the investment and
            company formation for Silvergate Pharmaceuticals (acquired by CutisPharma), a pediatric rare disease company that to date has launched four internally developed and proprietary products. From 2011 to May&#160;2014, Mr.&#160;Colabuono served as Vice
            President of Business Development &amp; Managed Care and a member of the Operations Committee of Silvergate, playing essential roles in the success of the Company. At Frazier, he was involved in and served as a board observer for Calistoga
            Pharmaceuticals (acquired by Gilead Sciences), VentiRx (acquired by Celgene), Alnara Pharma (acquired by Eli Lilly) and Oceana Therapeutics (acquired by Salix), as well as several of the firm&#8217;s public investments. Prior to Frazier, he served in
            the Morgan Stanley and Cowen Healthcare Investment Banking groups. He is an inventor and author on issued patents and journal articles, and he is active with the Head &amp; Neck Cancer Alliance. Mr.&#160;Colabuono holds a B.A. in Molecular Biology
            and Biochemistry from Dartmouth College. Mr.&#160;Colabuono&#8217;s extensive experience in healthcare investing, business development in the life sciences industry, and service on the boards of multiple biopharmaceutical companies qualify him to serve on
            the combined company&#8217;s board of directors. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Maria Koehler, M.D., Ph.D.<span style="font-style: normal; font-weight: normal;"> has served on Remix&#8217;s board of directors since May&#160;2024. Dr.&#160;Koehler has served on the board of directors of Orum Therapeutics since April&#160;2026, and previously on boards of directors for
              Abdera Therapeutics from July&#160;2023 until May&#160;2026, Ikena Therapeutics from April&#160;2021 to July&#160;2026, Celyad Oncology SA from March&#160;2020 to March&#160;2021, and Silverback Therapeutics, Inc. from March&#160;2021 to November&#160;2022. From May&#160;2019 to
              March&#160;2025, Dr.&#160;Koehler served as Chief Medical Officer at Repare Therapeutics, Inc. (Repare), a public precision oncology company. Dr.&#160;Koehler is currently Chief Development Officer in Hightop Therapeutics (Stealth), a partner in Omega funds
              (since May&#160;2025) and Senior Scientific Advisor to Viking Global investors (since May&#160;2025). Prior to joining Repare, Dr.&#160;Koehler was Chief Medical Officer at Bicycle Therapeutics Limited, a public biopharmaceutical company, from
              September&#160;2017 to April&#160;2019, and before that had roles of increasing responsibility at Pfizer from 2009 through 2017, most recently as Vice President of Oncology Strategy, Innovation and Collaborations. Dr.&#160;Koehler earned an M.D., and a
              Ph.D. in Toxicology from Silesian School of Medicine, Katowice, Poland. She received her initial training in immunology/oncology at the University of Heidelberg in Heidelberg, Germany, and additional training at St. Jude Children&#8217;s Research
              Hospital in the department of virology and molecular biology. Dr.&#160;Koehler&#8217;s extensive executive leadership and board experience in the biotechnology industry and her medical and scientific training qualify her to serve on the combined
              company&#8217;s board of directors. </span></div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Family Relationships </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There are no family relationships among any of Remix&#8217;s current directors and
            executive officers, and there are no family relationships among any of the combined company&#8217;s proposed directors and executive officers. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Composition of the Board of Directors
            Following the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio board of directors is divided into three classes. The classified
            structure of the Passage Bio board of directors will remain in place for the combined company following the completion of the Merger. Each class has a three-year term, with one class elected at each annual meeting. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the Merger Agreement, each of the directors and officers of Passage
            Bio shall resign effective as of the Effective Time. Following the completion of the Merger, Remix anticipates that the combined company board of directors will consist of nine directors, all of whom will be designated by Remix. Remix currently
            expects that all of its current directors will continue to serve as directors on the combined company board of directors following the Merger. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Committees of the Combined Company&#8217;s Board
            of Directors </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the completion of the Merger, the standing committees of the
            board of directors of the combined company will continue to be the following: audit committee, compensation committee and a nominating and corporate governance committee, and each will continue to operate pursuant to a charter, which is
            expected to be amended and restated by the combined company&#8217;s board of directors in connection with the completion of the Merger. The combined company&#8217;s board of directors may establish other committees from time to time to assist it and its
            board of directors. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">286<br/>
        </div>

      </div>

    </div>

    <!--End Page 296-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 297-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_124-management_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Audit Committee </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s audit committee will oversee its corporate accounting and
            financial reporting process. Among other matters, the audit committee&#8217;s responsibilities will include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from
                    such firm; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements
                    and related disclosures; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">coordinating our board of directors&#8217; oversight of our internal control over financial reporting, disclosure controls and
                    procedures and code of business conduct and ethics; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">discussing our risk assessment and management policies; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">meeting independently with our internal auditing staff, if any, registered public accounting firm and management; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and approving or ratifying any related person transactions&#894; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preparing the audit committee report required by SEC rules. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following the consummation of the Merger, the members of the audit committee are
            expected to be &#8195;&#8195;,&#8195;&#8195; and &#8195;&#8195;. &#8195;&#8195;&#8195;&#8195; is expected to be the chair of the audit committee and is a financial expert under the rules of the SEC. To qualify as independent to serve on the combined company&#8217;s audit committee, listing standards of Nasdaq
            and the applicable SEC rules require that a director not accept any consulting, advisory or other compensatory fee from the combined company, other than for service as a director, or be an affiliated person of the combined company. Passage Bio
            and Remix believe that, following the completion of the Merger, the composition of the audit committee will comply with the applicable requirements of the rules and regulations of Nasdaq and the SEC. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Compensation Committee </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The combined company&#8217;s compensation committee will oversee policies relating to
            compensation and benefits of its officers and employees. Among other matters, the compensation committee&#8217;s responsibilities include: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and approving, or recommending for approval by the board of directors, the compensation of our Chief Executive Officer
                    and our other executive officers&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">administering and overseeing our cash and equity incentive plans&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and making recommendations to our board of directors with respect to director compensation&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis,&#8221; to the extent required&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">administering and overseeing our compliance with the compensation recover policy required by appliable SEC and Nasdaq rules&#894; and
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preparing the annual compensation committee report required by SEC rules, to the extent required. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following the consummation of the Merger, the members of the compensation
            committee are expected to be &#8195;&#8194;,&#8195;&#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;&#8195;. &#8195;&#8195;&#8195;&#8195; is expected to be the chair of the compensation committee. Each member of the combined company&#8217;s compensation committee is expected to be a &#8220;non-employee&#8221; director within the meaning of
            Rule&#160;16b-3 of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. Passage Bio and Remix believe that, following the completion of the Merger, the composition of the
            compensation committee will comply with the applicable requirements of the rules and regulations of Nasdaq. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Nominating and Corporate Governance
            Committee </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The nominating and corporate governance committee&#8217;s responsibilities will
            include: </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">287<br/>
        </div>

      </div>

    </div>

    <!--End Page 297-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 298-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_124-management_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">identifying individuals qualified to become board members&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recommending to our board of directors the persons to be nominated for election as directors and to each board committee&#894; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">developing and recommending to our board of directors corporate governance guidelines, and reviewing and recommending to our
                    board of directors proposed changes to our corporate governance guidelines from time to time&#894; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">overseeing a periodic evaluation of our board of directors. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Following the consummation of the Merger, the members of the nominating and
            corporate governance committee are expected to be &#8195;&#8195;&#8195;&#8195;&#8194;,&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;, and &#8195;&#8195;&#8195;&#8195;&#8195;. &#8195;&#8195;&#8195;&#8195;&#8195;&#8195; is expected be the chair of the nominating and corporate governance committee. Passage Bio and Remix believe that, after the completion of the Merger, the
            composition of the nominating and corporate governance committee will meet the requirements for independence under, and the functioning of such nominating and corporate governance committee will comply with, any applicable requirements of the
            rules and regulations of Nasdaq. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Compensation Committee Interlocks and
            Insider Participation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each member of the compensation committee will be a &#8220;non-employee&#8221; director
            within the meaning of Rule&#160;16b-3 of the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. None of the proposed combined company&#8217;s executive officers serves as a member
            of the board of directors or compensation committee of any entity that has one or more executive officers who is proposed to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to the Merger, Remix did not have a formal policy to provide any cash or
            equity compensation to its non-employee directors for their service on the Remix Board or committees of the Remix Board, nor did any non-employee director receive any compensation for serving on Remix&#8217;s board of directors. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the closing of the Merger, it is expected that the combined
            company will provide compensation to non-employee directors pursuant to a new non-employee director compensation policy that is expected to be adopted post-closing. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">288<br/>
        </div>

      </div>

    </div>

    <!--End Page 298-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 299-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_125-certain_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCRRP"><!--Anchor--></a>CERTAIN RELATIONSHIPS AND RELATED PARTY
            TRANSACTIONS <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF THE COMBINED COMPANY </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition to the compensation arrangements, including employment, termination
            of employment and change in control arrangements, with Passage Bio&#8217;s and Remix&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<span style="font-style: italic;">Management Following the Merger</span>,&#8221; &#8220;<span style="font-style: italic;">Passage Bio Executive Officer and Director Compensation and Corporate Governance</span>&#8221; and &#8220;<span style="font-style: italic;">Remix Executive Officer and Director Compensation</span>&#8221;, the following is a
            description of each transaction involving Passage Bio since January&#160;1, 2023, each transaction involving Remix since January&#160;1, 2023, and each current proposed transaction in which: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">either Passage Bio or Remix has been or is to be a participant; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Passage Bio&#8217;s or Remix&#8217;s total
                    assets at year-end for the last two completed fiscal years, as applicable; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any of Passage Bio&#8217;s, Remix&#8217;s or the combined company&#8217;s expected directors, executive officers or holders of more than 5% of the
                    outstanding shares of Passage Bio Capital Stock, Remix Capital Stock, or the combined company&#8217;s common stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.
                  </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Passage Bio Related Party Transactions </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Certain Relationships and Transactions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other than the compensation agreements and other arrangements described under
            &#8220;Passage Bio Executive Officer and Director Compensation and Corporate Governance&#8221; in this proxy statement/prospectus and the transactions described below, from January&#160;1, 2023 to the present, there have been no transactions, and there are
            currently no proposed transactions, in which the amount involved exceeded or will exceed, the lesser of $120,000 and 1% of the average of Passage Bio&#8217;s total assets at year-end for the prior two completed fiscal years and in which any director,
            executive officer, holders of more than 5% of Passage Bio&#8217;s common stock, or other persons as may be required to be disclosed pursuant to Item&#160;404 of Regulation S-K, had a direct or indirect material interest. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Director and Officer Indemnification and
            Insurance </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has agreed to indemnify each of its directors and executive officers
            against certain liabilities, costs and expenses, and has purchased directors&#8217; and officers&#8217; liability insurance. Passage Bio also maintains a general liability insurance policy which covers certain liabilities of directors and officers arising
            out of claims based on acts or omissions in their capacities as directors or officers. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Agreements Related to the Merger </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Support Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Concurrently with the execution of the Merger Agreement, certain stockholders of
            Passage Bio holding approximately 1% of the outstanding shares of Passage Bio Common Stock entered into support agreements with Passage Bio to vote all of their shares of Passage Bio Common Stock in favor of (a) the Nasdaq Stock Issuance
            Proposal, (b) the Reverse Stock Split Proposal, and (c) the Charter Proposal. For additional information regarding the support agreements, see the section titled &#8220;<span style="font-style: italic;">Agreements Related to the Merger&#8212;Support
              Agreements.</span>&#8221; </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Indemnification Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with Passage Bio&#8217;s initial public offering in February&#160;2020,
            Passage Bio entered into agreements to indemnify its directors and executive officers. These agreements, among other things, require Passage Bio to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines
            and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in its right, on account of any services undertaken by such person on its behalf or that person&#8217;s status as a member of Passage
            Bio&#8217;s Board of Directors to the maximum extent allowed under Delaware law. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Policies and Procedures for Related-Party
            Transactions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s board of directors has adopted a written related person
            transactions policy. Under this policy, Passage Bio&#8217;s executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of Passage Bio&#8217;s common stock, and any members of the immediate family of and any entity
            affiliated with any of the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">289<br/>
        </div>

      </div>

    </div>

    <!--End Page 299-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 300-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_125-certain_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">foregoing persons, are not permitted to enter into a material related person
            transaction with Passage Bio without the review and approval of the Audit Committee, or a committee composed solely of independent directors in the event it is inappropriate for the Audit Committee to review such transaction due to a conflict
            of interest. The policy provides that any request for Passage Bio to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of Passage Bio&#8217;s common stock or with any of
            their immediate family members or affiliates in which the amount involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Passage Bio&#8217;s total assets at year-end for the prior two completed fiscal years will be presented
            to the Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, the Audit Committee will consider the relevant facts and circumstances available and deemed relevant to the Audit Committee, including,
            but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person&#8217;s interest in the transaction.
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Remix Related Party Transactions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following is a description of transactions or series of transactions since
            January&#160;1, 2023, to which Remix was or will be a party, in which: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amount involved in the transaction exceeds, or will exceed, the lesser of $120,000 or one percent of the average of Remix&#8217;s
                    total assets for the last two completed fiscal years; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in which any of Remix&#8217;s directors or executive officers who will become directors or executive officers of the combined company,
                    or holders of more than 5% of Remix&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Compensation arrangements for Remix named executive officers and directors are
            described elsewhere in this proxy statement/prospectus in the section titled &#8220;<span style="font-style: italic;">Remix Executive and Director Compensation</span>.&#8221; </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Private Placements of Securities </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">2023 Convertible Note&#160;Financing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, Remix entered into a note and warrant purchase agreement with
            certain investors to purchase up to an aggregate of $75.0&#160;million in convertible notes, or the 2023 Notes, on or prior to December&#160;31, 2024. In connection with the 2023 Notes, Remix issued warrants to purchase capital stock with an aggregate
            exercise amount equal to 20% of the principal amount of each 2023 Note. The 2023 Notes bore interest at 5.25% per annum. Remix issued $11.4&#160;million of 2023 Notes in December&#160;2023, $8.6&#160;million of 2023 Notes in January&#160;2024 and $40.1&#160;million of
            2023 Notes in July&#160;2024, for an aggregate total principal amount of approximately $60&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2025, Remix entered into an amendment to the 2023 Notes with the
            requisite noteholder majority to convert the 2023 Notes into Series&#160;B Preferred Stock. The associated warrants remained outstanding and became exercisable at the Series&#160;B Preferred Stock price. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes the aggregate amount of 2023 Notes and warrants
            purchased by related persons. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 62.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.68pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participant<sup>(1)</sup></div>
                </td>

    <td style="width: 6.95pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Principal Amount</div>
                </td>

    <td style="width: 6.95pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate Exercise <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount (Warrant) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ARCH Venture Fund XI, L.P.</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">2,017,504.91</span></div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$<span style="padding-left: 7.5pt;">403,500.98 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Atlas Venture Opportunity Fund II, L.P.</div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">8,566,795.73</span></div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$1,713,359.15 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Citadel Credit Master Fund LLC</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">3,592,814.08</span></div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$<span style="padding-left: 7.5pt;">718,562.82 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Foresite Capital Fund V, L.P., Foresite Capital
                    Opportunity Fund V, L.P. and Foresite Capital Fund VI LP</div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">6,586,340.53</span></div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$<span style="padding-left: 0.37pt;">1,317,268.11 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Column Group IV, LP and The Column Group IV-A, LP</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 62.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$14,733,641.02</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$2,946,728.20</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 62.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.68pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Additional details regarding these stockholders and their equity holdings are provided in this proxy statement/prospectus under
                    the caption &#8220;Principal Stockholders of Remix.&#8221; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">2025 Convertible Note&#160;Financing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2025, Remix entered into a note and warrant purchase agreement with
            certain investors to purchase up to an aggregate of $30.0&#160;million in convertible notes, or the 2025 Notes, on or prior to May&#160;31, 2027. In connection with the 2025 Notes, Remix issued warrants to purchase capital stock with an aggregate
            exercise amount equal to 20% of the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">290<br/>
        </div>

      </div>

    </div>

    <!--End Page 300-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 301-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_125-certain_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">principal amount of each 2025 Note. The 2025 Notes bear interest at 8.0% per
            annum. Remix issued $12.1&#160;million of 2025 Notes in November&#160;2025, $2.9&#160;million of 2025 Notes in December&#160;2025, less than $0.1&#160;million of 2025 Notes in January&#160;2026 and $15&#160;million of 2025 Notes in March&#160;2026, for an aggregate total principal
            amount of approximately $30&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2025 Notes contain mandatory conversion features whereby the total
            outstanding amount of principal and accrued and unpaid interest of the 2025 Notes shall automatically convert into shares of Remix&#8217;s preferred stock or common stock, as applicable, (i) upon a Qualified Financing (as defined therein), (ii)&#160;upon
            the closing of a Non-Qualified Financing (as defined therein), (iii) upon the occurrence of a Public Company Event (as defined therein), or (iv) upon maturity of the 2025 Notes on November&#160;30, 2027. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In June&#160;2026, in connection with the 2026 Convertible Note&#160;Financing and the
            Subscription Financing (each as described below), Remix entered into an omnibus amendment to the 2025 Notes with the requisite noteholder majority to, among other things, provide that the 2025 Notes will convert in connection with the
            Subscription Financing (as described below) at 80% of the price of the Subscription Financing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes the aggregate amount of 2025 Notes and warrants
            purchased by related persons. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 61.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.68pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participant<sup>(1)</sup></div>
                </td>

    <td style="width: 7.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.11pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Principal Amount <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Note)</div>
                </td>

    <td style="width: 7.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate Exercise <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount (Warrant) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ARCH Venture Fund XI, L.P.</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.11pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.81pt; text-align: left;">$1,724,892.94</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$<span style="padding-left: 7.5pt;">344,978.59 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Atlas Venture Opportunity Fund II, L.P.</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.11pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.81pt; text-align: left;">$7,323,323.04</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$1,464,664.60 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Citadel Credit Master Fund LLC </div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.11pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.81pt; text-align: left;">$1,653,338.89</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$<span style="padding-left: 7.5pt;">330,667.77 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foresite Capital Fund VI, L.P.</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.11pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.81pt; text-align: left;">$5,640,196.60</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$1,128,039.32 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">The Column Group IV, LP, The Column Group IV-A, LP
                    and The Column Group Opportunity III, LP</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.11pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.81pt; text-align: left;">$9,329,233.72</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.68pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.09pt; text-align: left;">$1,865,846.74</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 61.11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.68pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Additional details regarding these stockholders and their equity holdings are provided in this proxy statement/prospectus under
                    the caption &#8220;Principal Stockholders of Remix.&#8221; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">2026 Convertible Note&#160;Financing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In June&#160;2026, Remix entered into a note purchase agreement with certain investors
            in which Remix received a total aggregate amount of $30.0&#160;million in exchange for the issuance of convertible notes, or the 2026 Notes. The 2026 Notes bear interest at 8.0% per annum. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2026 Notes contain mandatory conversion features whereby the total
            outstanding amount of principal and accrued and unpaid interest of the 2026 Notes shall automatically convert into shares of Remix&#8217;s preferred stock or common stock, as applicable, (i) upon a Qualified Financing (as defined therein), (ii)&#160;upon
            the closing of a Non-Qualified Financing (as defined therein), (iii) upon the consummation of a PIPE Offering (as defined therein), (iv) upon the occurrence of a Public Company Event (as defined therein), or (v) upon maturity of the 2026 Notes
            on June&#160;29, 2027. The 2026 Notes will convert into shares of common stock immediately prior to the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes the aggregate amount of 2026 Notes purchased by
            related persons. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.79pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.79pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 84.41pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participant<sup>(1)</sup></div>
                </td>

    <td style="width: 11.79pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.79pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 84.41pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Principal Amount (Note) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">ARCH Venture Fund XI, L.P.</div>
                </td>

    <td style="width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 84.41pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">$<span style="padding-left: 7.5pt;">966,940.10 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Atlas Venture Opportunity Fund III, L.P.</div>
                </td>

    <td style="width: 11.79pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.79pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 84.41pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">$3,000,000.00 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foresite Capital Fund V, L.P. and Foresite Capital Fund VI LP</div>
                </td>

    <td style="width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 84.41pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">$3,156,669.65 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Column Group IV, LP and The Column Group IV-A, LP</div>
                </td>

    <td style="width: 11.79pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.79pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 84.41pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">$8,244,444.72 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 0.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Decheng Capital Global Life Sciences Fund V, L.P.,
                    Decheng Capital Global Life Sciences Fund V-A, L.P. and Decheng Capital Global Life Sciences Fund V-B, L.P.</div>
                </td>

    <td style="width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 84.41pt; padding-top: 0.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 13.46pt; text-align: left;">$<span style="padding-left: 7.5pt;">10,000,000</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.79pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 84.41pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 10.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Additional details regarding these stockholders and their equity holdings are provided in this proxy statement/prospectus under
                    the caption &#8220;Principal Stockholders of Remix.&#8221; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Subscription Financing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the Merger Agreement, Remix entered into a Subscription
            Agreement in June&#160;2026 with certain investors, which combined with the 2026 Convertible Note&#160;Financing, represents the Concurrent Financing. Pursuant to the Subscription Agreement, the investors agreed to purchase approximately $70.0&#160;million in
            shares of Remix common stock. The closing of the Subscription Financing is conditioned upon the satisfaction or waiver of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">291<br/>
        </div>

      </div>

    </div>

    <!--End Page 301-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 302-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_125-certain_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the conditions to the Merger as well as certain other conditions. Four of the
            investors or their affiliates are beneficial holders of more than 5% of Remix&#8217;s capital stock, and the table below sets forth their respective subscription amounts for shares of Remix common stock expected at the closing of the Subscription
            financing: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 73.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participant<sup>(1)</sup></div>
                </td>

    <td style="width: 5.45pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.45pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.11pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Subscription Amount </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Atlas Venture Opportunity Fund III, L.P.</div>
                </td>

    <td style="width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.11pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;">$<span style="padding-left: 5pt;">1,000,000.00 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Citadel Ceme Investments Ltd.</div>
                </td>

    <td style="width: 5.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;">$<span style="padding-left: 5pt;">4,000,000.00 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foresite Capital Fund V, L.P. and Foresite Capital Fund VI LP</div>
                </td>

    <td style="width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;">$10,843,330.00 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">The Column Group IV, LP, The Column Group IV-A, LP
                    and The Column Group Opportunity&#160;III, LP</div>
                </td>

    <td style="width: 5.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;">$<span style="padding-left: 0.37pt;">11,755,555.28 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Decheng Capital Global Life Sciences Fund V, L.P.,
                    Decheng Capital Global Life Sciences Fund V-A, L.P. and Decheng Capital Global Life Sciences Fund V-B, L.P.</div>
                </td>

    <td style="width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.11pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;">$20,000,000.00</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 73.11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Additional details regarding these stockholders and their equity holdings are provided in this proxy statement/prospectus under
                    the caption &#8220;Principal Stockholders of Remix.&#8221; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Certain of Remix&#8217;s directors are employed by Remix&#8217;s principal stockholders, as
            indicated in the table below: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Director</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholder </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Linda C. Bain</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Atlas Venture Life Science Advisors, LLC </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kevin Bitterman, Ph.D.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Atlas Venture Life Science Advisors, LLC </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Colabuono</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Decheng Capital </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">James Jeffrey Goater, Jr.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">The Column Group</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Other Agreements with Remix Stockholders </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with Remix&#8217;s 2025 Convertible Note&#160;Financing, Remix entered into
            investors&#8217; rights, voting and right of first refusal and co-sale agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of Remix preferred stock and
            certain holders of Remix common stock. These stockholder agreements will terminate upon the closing of the Merger. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Indemnification Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has entered into agreements to indemnify its directors and executive
            officers. These agreements will, among other things, require Remix to indemnify these individuals for certain expenses (including attorneys&#8217; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or
            proceeding, including any action by or in Remix&#8217;s right, on account of any services undertaken by such person on Remix&#8217;s behalf or that person&#8217;s status as a member of Remix&#8217;s board of directors to the maximum extent allowed under Delaware law.
          </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Policies for Approval of Related Party
            Transactions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s board of directors reviews and approves transactions with its directors,
            officers and holders of 5% or more of its voting securities and their affiliates, each a related party. Prior such transaction, the material facts as to the related party&#8217;s relationship or interest in the transaction are disclosed to Remix&#8217;s
            board of directors prior to their consideration of such transaction, and the transaction is not considered approved by the board of directors unless a majority of the directors who are not interested in the transaction approve the transaction.
            Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#8217;s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in
            good faith. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">292<br/>
        </div>

      </div>

    </div>

    <!--End Page 302-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 303-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tUFC"><!--Anchor--></a>UNAUDITED PRO FORMA CONDENSED COMBINED
            FINANCIAL INFORMATION </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;24, 2026, Passage Bio entered into the Merger Agreement with Remix and
            Merger Sub. Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Remix, with Remix surviving the merger as a wholly owned subsidiary of Passage Bio.
            Following the Merger, Passage Bio will change its corporate name to &#8220;Remix Therapeutics, Inc.&#8221; and Remix, as the surviving corporation, will be renamed &#8220;Remix Operations, Inc.&#8221; The combined company following the Merger, which will operate under
            the name Remix Therapeutics, Inc., is referred to herein as the &#8220;Combined Company&#8221;. The Combined Company will be led by Remix&#8217;s management team and is expected to continue Remix&#8217;s business as a biotechnology company focused on developing small
            molecule therapies designed to modulate RNA processing and address the underlying drivers of disease. The following unaudited pro forma condensed combined financial information and related notes have been prepared to give effect to the Merger
            and the related transactions described below. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed combined financial information has been
            prepared in accordance with Article&#160;11 of Regulation S-X, <span style="font-style: italic;">Pro Forma Financial Information</span>, as amended, which is herein referred to as (&#8220;Article&#160;11&#8221;). Article&#160;11 provides simplified requirements to
            depict the accounting for the transaction (&#8220;Transaction Accounting Adjustments&#8221;) and the option to present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (&#8220;Management&#8217;s
            Adjustments&#8221;). Passage Bio has elected not to present Management&#8217;s Adjustments in the unaudited pro forma condensed combined financial information. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2026
            gives effect to the Merger and related transactions as if they had occurred on March&#160;31, 2026. The unaudited pro forma condensed combined statement of operations for the year ended December&#160;31, 2025 and the three months ended March&#160;31, 2026
            give effect to the Merger and related transactions as if they had occurred on January&#160;1, 2025, the beginning of the earliest period presented. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">The Merger and Related Transactions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Immediately prior to the Effective Time and subject to the conditions set forth
            in the Merger Agreement: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all Remix convertible notes, including the 2026 Notes, will convert into shares of Remix common stock in accordance with their
                    terms; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all outstanding shares of Remix preferred stock will convert into shares of Remix common stock pursuant to the organizational
                    documents of Remix (the &#8220;Remix Preferred Stock Conversion&#8221;). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">At the Effective time and subject to the conditions set forth in the Merger
            Agreement: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each outstanding share of Remix common stock (excluding (a) shares of Remix common stock issued in the Concurrent Financing, as
                    defined below, (b) Dissenting Shares, and (c) Remix Treasury Shares) will convert into the right to receive a number of shares of Passage Bio Common Stock, calculated in accordance with the Merger Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the shares of Remix common stock issued in the Concurrent Financing (as defined below) will convert into the right to receive a
                    number of shares of Passage Bio Common Stock calculated in accordance with the Merger Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each outstanding Remix stock option that has not previously been exercised prior to the Closing will be assumed by Passage Bio
                    and become an option to purchase a number of shares of Passage Bio Common Stock; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each outstanding Remix warrant will be treated in accordance with its terms and conditions. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The shares of Passage Bio Common Stock that will be issued to stockholders of
            Remix will be calculated using a formula in the Merger Agreement based on the equity value of each of Remix and Passage Bio. Remix has been ascribed an aggregate equity value of $226.0 million and Passage Bio&#8217;s equity value is expected to be
            approximately $20.0 million (assuming Passage Bio Net Cash of $5.0 million as of the Closing), subject to adjustment based on the amount of Passage Bio Net Cash at the Closing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Concurrently with the execution of the Merger Agreement, Remix entered into the
            Subscription Agreement, pursuant to which certain investors agreed to purchase shares of Remix common stock for aggregate gross proceeds </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">293<br/>
        </div>

      </div>

    </div>

    <!--End Page 303-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 304-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of approximately $70.0&#160;million immediately prior to the Effective Time (the &#8220;<span style="font-style: italic; font-weight: bold;">Subscription Financing</span>&#8221;). On June&#160;24, 2026, certain lenders entered into the Remix Note&#160;Purchase Agreement (2026) with Remix and, on June&#160;29, 2026, purchased convertible promissory notes
            of Remix in an aggregate principal amount of $30.0&#160;million (the &#8220;<span style="font-style: italic; font-weight: bold;">2026 Notes</span>,&#8221; and such financing, the &#8220;<span style="font-style: italic; font-weight: bold;">2026 Convertible
              Note&#160;Financing</span>&#8221;). In connection with the Merger, the 2026 Notes will convert into shares of Remix common stock at a conversion price equal to the price per share paid by investors in the Subscription Financing ($1.39 per share). The
            Subscription Financing and the 2026 Convertible Note&#160;Financing are collectively referred to in this section of this proxy statement/prospectus as the &#8220;Concurrent Financing,&#8221; and are expected to result in aggregate gross cash proceeds of
            $100.0&#160;million upon the closing of the Subscription Financing immediately prior to the Effective Time. The closing of the Subscription Financing is conditioned upon the satisfaction or waiver of the conditions set forth in the Merger Agreement.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix has outstanding warrants issued in its 2023 and 2025 note financings (the &#8220;<span style="font-style: italic; font-weight: bold;">2023 Warrants</span>&#8221; and &#8220;<span style="font-style: italic; font-weight: bold;">2025 Warrants</span>&#8221;, respectively). In connection with the Merger: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the 2023 Warrants, which are exercisable for Remix preferred stock and are out of the money, will terminate in accordance with
                    their terms; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the 2025 Warrants, which are exercisable at 80% of the Subscription Financing price (<span style="font-style: italic;">i.e.</span>,
                    $1.11) and are in the money, will be net exercised for shares of Remix common stock (which convert into Passage Bio Common Stock in the Merger); and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix additionally has an outstanding warrant issued in 2024 in connection with the Letter Agreement. This warrant will be
                    assumed by Passage Bio and converted into a warrant to purchase Passage Bio Common Stock. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Additionally, at the Effective Time, Passage Bio will enter into the CVR
            Agreement. Each CVR issued in connection with the CVR Agreement represents the right to receive payments from proceeds actually received by Passage Bio under certain existing license agreements, net of certain taxes, transaction costs, and
            other expenses. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Accounting for the Merger </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For accounting purposes, Remix is expected to be treated as the accounting
            acquirer and Passage Bio as the accounting acquiree. This determination is based primarily on the expectation that, immediately following the Merger, Remix equity holders will hold a substantial majority of the voting interests in the Combined
            Company, Remix designees are expected to comprise a majority of the board of directors of the Combined Company, Remix&#8217;s senior management will comprise the senior management of the Combined Company, the Combined Company will operate under the
            Remix name, and Remix&#8217;s business will be the ongoing business of the Combined Company. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is expected to be accounted for as a reverse recapitalization in
            accordance with U.S. GAAP. Under reverse recapitalization accounting, the financial statements of the Combined Company will represent a continuation of the financial statements of Remix. The Merger will be treated as the equivalent of Remix
            issuing equity to acquire the net assets of Passage Bio, accompanied by a recapitalization of Remix&#8217;s equity. The historical operating results of the Combined Company prior to the Merger will be those of Remix. The net assets of Passage Bio, to
            the extent retained by the Combined Company, are expected to be stated at historical carrying value, with no goodwill or other intangible assets recorded. Any difference between the consideration deemed issued by Remix and the historical
            carrying value of Passage Bio&#8217;s net assets is expected to be recorded as an adjustment to additional paid-in capital. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 0pt; text-align: left;">Pro Forma Capitalization </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table summarizes the estimated ownership of the Combined Company
            immediately following the Merger and the Concurrent Financing, based on a Remix Equity Value of $226.0&#160;million, a Passage Valuation of $20.0&#160;million (assuming Passage Bio Net Cash of $5.0 million as of the Closing) and Concurrent Financing
            Proceeds of $100.0&#160;million, resulting in an implied aggregate valuation of approximately $346.0&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 22.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix historical shareholders</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">27,012,092 </div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">63.2% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Investors in Concurrent Financing</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">12,509,562 </div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">29.3% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Bio historical shareholders</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,232,810 </span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7.5</span><span style="padding-bottom: 1.5pt;">% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated total shares of Passage Bio Common Stock</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">42,754,464 </span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 22.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">100.0</span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 22.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">294<br/>
        </div>

      </div>

    </div>

    <!--End Page 304-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 305-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The estimated ownership percentages and share amounts are preliminary and
            subject to change based on, among other things, the final calculation of Passage Bio Net Cash, the final amount of Concurrent Financing proceeds, the final number of outstanding Remix and Passage Bio shares, the final exchange ratios, and any
            reverse stock split effected prior to the Effective Time. The table excludes the impact of any shares reserved for future issuance under the Combined Company&#8217;s equity incentive plans. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other Information </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed combined financial information and related
            notes have been derived from and should be read in conjunction with: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical unaudited interim financial statements of Remix as of and for the three months ended March&#160;31, 2026, the
                    historical audited financial statements of Remix as of and for the year ended December&#160;31, 2025, and the related notes included elsewhere in this proxy statement/prospectus; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the historical unaudited interim financial statements of Passage Bio as of and for the three months ended March&#160;31, 2026, the
                    historical audited financial statements of Passage Bio as of and for the year ended December&#160;31, 2025, and the related notes included elsewhere in this proxy statement/prospectus. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Management has performed a preliminary review of the accounting policies of
            Passage Bio and Remix and is not aware of any material differences. Following the Closing, management of the Combined Company will complete a final review of Passage Bio&#8217;s policies to conform its presentation to Remix&#8217;s; any differences
            identified could materially affect the unaudited pro forma condensed combined financial information. Passage Bio and Remix have no historical relationship requiring the elimination of intercompany transactions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed combined financial information is based on
            assumptions and estimates described in the accompanying notes. The Transaction Accounting Adjustments are preliminary and subject to further revision as additional information becomes available and additional analyses are performed. The
            unaudited pro forma condensed combined financial information is presented for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized had Passage Bio and
            Remix been a combined organization during the periods presented, nor is it necessarily indicative of the future financial position or results of operations of the Combined Company. The unaudited pro forma condensed combined financial
            information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies, synergies, cost savings, other benefits or expenses that may be associated with the integration of Passage Bio
            and Remix. Actual results reported in periods following the Effective Time may differ significantly from those reflected in the unaudited pro forma condensed combined financial information presented herein. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">295<br/>
        </div>

      </div>

    </div>

    <!--End Page 305-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 306-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Unaudited Pro Forma Condensed Combined Balance Sheet <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of March&#160;31, 2026 <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468.98pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 85.66pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.33pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 40.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 204pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 85.66pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">As of March&#160;31, 2026</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 204pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 85.66pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 126.5pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction Accounting Adjustments</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 204pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remix</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Passage</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Merger<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financing <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br/>
                  </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br/>
                  </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 8.33pt;">24,022</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 8.33pt;">33,336</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;">$<span style="padding-left: 10pt;">(9,382)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 0.56pt;">C</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;">$65,226 </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.56pt; text-align: left;">A</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 3.33pt;">132,161</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 15pt;">(8,995)</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 0.56pt;">D</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 5pt;">27,954</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.56pt; text-align: left;"><span style="padding-left: 0.55pt;">B</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Prepaid expenses and other current assets</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt;">940</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt;">682</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 18.33pt;">1,000</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 0.56pt;">D</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">2,622</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Prepaid research and development</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">723</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">723</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">24,962</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">34,741</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 10pt;">(17,377)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 5pt;">93,180</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">135,506</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">2,409</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">2,409</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease right-of-use assets</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">14,678</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt;">651</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">15,329</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.7pt;">11,716</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt;">826</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">12,542</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid expenses and other non-current assets</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,471</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">244</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,715</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total assets</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">55,236 </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">36,462 </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(17,377</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$93,180 </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">167,501</span><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Liabilities, Convertible
                    Preferred Stock and Stockholders' (Deficit) Equity<br/>
                  </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities:<br/>
                  </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 13.33pt;">2,979 </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 13.33pt;">1,310 </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;">$<span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 13.33pt;">4,289</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.7pt;">4,115</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">3,895</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">8,010</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liability, current portion</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">1,770</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">1,149</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">2,919</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Non-refundable sublicense and transition services
                    payment</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">13,750</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 10pt;">(13,750)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 1.11pt;">E</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred revenue, current portion </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,286</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,286</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">26,150</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">20,104</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 10pt;">(13,750)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">32,504</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible notes payable (related party)</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">29,400</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 10pt;">(29,400)</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 1.67pt;">F</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2023 Warrants and Letter <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Warrant liability (related party) </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">5,661</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 15pt;">(5,661)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;">G</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2025 Warrant liability (related party)</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">2,588</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 15pt;">(2,588)</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;">H</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease liability, net of current portion</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">21,155</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">4,606</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">25,761</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue, net of current portion</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">56,490</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">56,490</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total liabilities</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">141,444</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">24,710</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 10pt;">(51,399)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.7pt;">114,755</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and contingencies<br/>
                  </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible preferred stock</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">200,865</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 5pt;">(200,865)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 3.89pt;">I</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders' (deficit) equity:<br/>
                  </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Common stock - historical</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35.83pt;">1</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 32.5pt;">(1)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 3.89pt;">I</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Common stock - NewCo</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 1.67pt;">F</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 27.5pt;">1</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.56pt; text-align: left;">A</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35.83pt;">4</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;">H</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 35.83pt;">2</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 3.89pt;">I</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 27.5pt;">1</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.56pt; text-align: left;"><span style="padding-left: 0.55pt;">B</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital - historical</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">21,537</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">724,068</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 15pt;">(7,995)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 0.56pt;">D</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">372,707</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital - NewCo</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 13.33pt;">13,750</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 1.11pt;">E</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 5pt;">65,225</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.56pt; text-align: left;">A</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 13.33pt;">29,400</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 1.67pt;">F</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 18.33pt;">5,661</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;">G</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 8.33pt;">200,864</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 3.89pt;">I</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 5pt;">27,953</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.56pt; text-align: left;"><span style="padding-left: 0.55pt;">B</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 18.33pt;">2,588</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;">H</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 5pt;">(712,316)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 2.78pt;">J</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 18.33pt;">1,972</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;">K</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5.37pt;">(308,611)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">(712,316)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 15pt;">(9,382)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 0.56pt;">C</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">(319,965)</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 8.33pt;">712,316</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;"><span style="padding-left: 2.78pt;">J</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span> </div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,972</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 1.55pt; text-align: left;">K</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total stockholders' (deficit) equity:</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(287,073</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.7pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">11,752</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">234,887</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">93,180</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">52,746</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Total liabilities, convertible preferred stock and
                    stockholders' (deficit) equity:</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">55,236 </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">36,462 </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.9pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(17,377</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.89pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.64pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.07pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$93,180 </span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.33pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">167,501</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 204pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.89pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.33pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">296<br/>
        </div>

      </div>

    </div>

    <!--End Page 306-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 307-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Unaudited Pro Forma Condensed Combined Statements of Operations <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, 2026 <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except share and per share data) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 173pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 96.76pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 15.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 173pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 96.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 173pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 96.76pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 128.02pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction Accounting Adjustments</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 173pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remix</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Passage</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Merger <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financing <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined </div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 25pt;">831</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;">$<span style="padding-left: 12.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 30pt;">831 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">12,100</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">4,093</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">16,193 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">4,072</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">4,787</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt;">8,859 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">16,172</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">8,247</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,419 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(15,341</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8,247</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(23,588</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense):<br/>
                  </div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Change in fair value of convertible notes payable
                    and warrant liabilities</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 19.17pt;">(1,375)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 5pt;">1,875</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3pt; text-align: left;">M</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35pt;">500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest income</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.37pt;">114</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35.37pt;">114 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">688</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">685 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total other income (expense)</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,264</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">688</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,875</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,299 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(16,605</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(7,559</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,875</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(22,289</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 40pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(16,615</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(7,559</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.02pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,875</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(22,299</span><span style="padding-bottom: 0.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net loss per share of common stock, basic and
                    diluted</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 19.17pt;">(2.12)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 19.17pt;">(2.36)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 24.17pt;">(0.52) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted-average common shares outstanding, basic
                    and diluted</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">7,825,834</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 5pt;">3,205,866</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">42,746,109</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 173pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.53pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 15.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.53pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">297<br/>
        </div>

      </div>

    </div>

    <!--End Page 307-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 308-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Unaudited Pro Forma Condensed Combined Statements of Operations <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December 31, 2025 <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except share and per share data) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 173pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 96.76pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 15.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 173pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 96.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 173pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 96.76pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Historical</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 128.02pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Transaction Accounting Adjustments</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 173pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remix</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Passage</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Merger <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Financing <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Adjustments</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pro Forma <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Combined </div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 17.5pt;">3,310</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;">$<span style="padding-left: 15.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 22.5pt;">3,310 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br/>
                  </div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">52,593</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">23,276</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">75,869 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">15,056</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">19,875</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">36,903 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 8.33pt;">1,972</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3pt; text-align: left;"><span style="padding-left: 2.77pt;">L</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,145</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,145 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">67,649</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,296</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,972</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.87pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">118,917 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(64,339</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(49,296</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,972</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(115,607</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense):<br/>
                  </div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Change in fair value of convertible notes payable
                    and warrant liabilities</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt;">(10,814)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 8.33pt;">2,150</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3pt; text-align: left;">M</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 24.17pt;">(8,664) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest income</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">1,293</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt;">1,293 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(27</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,774</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,747 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total other income (expense)</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,548</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,774</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,150</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 24.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,624</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(73,887</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(45,522</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">178</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.54pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(119,231</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax benefit</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(182</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(182</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(73,705</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(45,522</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.36pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">178</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.27pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.54pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(119,049</span><span style="padding-bottom: 0.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Net loss per share of common stock, basic and
                    diluted</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 19.17pt;">(9.57)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">$<span style="padding-left: 14.17pt;">(14.35)</span></div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 24.17pt;">(2.79) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 173pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Weighted-average common shares outstanding, basic
                    and diluted</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">7,700,621</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 5pt;">3,172,870</span></div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 15.44pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.53pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">42,691,401</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 173pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 15.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">298<br/>
        </div>

      </div>

    </div>

    <!--End Page 308-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 309-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tNUP"><!--Anchor--></a>Notes to Unaudited Pro Forma Condensed
            Combined Financial Information </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Description of the Merger and Related Transactions </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger and the related transactions are described above under &#8220;The Merger and
            Related Transactions,&#8221; &#8220;Accounting for the Merger,&#8221; and &#8220;Pro Forma Capitalization.&#8221; Capitalized terms used but not defined in these notes have the meanings given to them above or elsewhere in this proxy statement/prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the Effective Time, each outstanding share of Remix common stock &#8211; after
            giving effect to the Remix Preferred Stock Conversion, the Remix Convertible Notes Conversion, and other than Dissenting Shares, Remix Treasury Shares and the shares issued in the Concurrent Financing &#8211; will be converted into the right to
            receive shares of Passage Bio Common Stock based on the Merger Exchange Ratio (estimated to be 0.1734), determined in accordance with the formula in the Merger Agreement and adjusted for any reverse stock split effected prior to the Effective
            Time. At the Effective Time, each share of Remix Common Stock issued in the Concurrent Financing will be converted into the right to receive Passage Bio Common Stock based on the Concurrent Financing Exchange Ratio (estimated to be 0.1734),
            determined in accordance with the formula in the Merger Agreement and adjusted for any reverse stock split effected prior to the Effective Time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The estimated aggregate consideration deemed transferred, calculated for purposes
            of this unaudited pro forma condensed combined financial information, is as follows (in thousands, except share and per share amounts): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Estimated shares of Passage Bio Common Stock to be
                    owned by pre-Closing Passage Bio stockholders<sup>(i)</sup></div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">3,232,810 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Passage Bio equity awards vesting upon Closing<sup>(ii)</sup></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">727,544 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Estimated total shares of Passage Bio Common Stock
                    outstanding immediately following the Closing attributable to pre-Closing Passage Bio stockholders and holders of Passage Bio equity awards</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">3,960,354 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated price per share of Passage Bio common stock<sup>(iii)</sup></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4.91 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated aggregate consideration deemed transferred</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 12.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">19,445</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects the number of shares of Passage Bio Common Stock that pre-Closing Passage Bio stockholders are expected to own of the
                    Combined Company as of the Closing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects the number of shares underlying outstanding Passage Bio equity awards that vest in full upon the Closing. Because these
                    awards contain no remaining service condition following the Closing, the shares underlying such awards are included in full in the estimated total shares used to calculate the estimated aggregate consideration deemed transferred. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Reflects the assumed price per share of Passage Bio common stock, based on the closing price of Passage Bio common stock as of
                    July&#160;15, 2026. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The estimated aggregate consideration is based on the number of shares of Passage
            Bio Common Stock that pre-Closing Passage Bio stockholders will own of the Combined Company. No amount is attributed to the CVRs, which are accounted for as a contingency with no amount recognized (see Note&#160;2). Because the Merger will be
            accounted for as a reverse recapitalization, any difference between the consideration deemed transferred and the fair value of Passage Bio&#8217;s net assets will be recorded as an adjustment to additional paid-in capital when the Merger occurs. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Basis of Presentation </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed combined financial information has been
            prepared in accordance with Article&#160;11 and presents Transaction Accounting Adjustments only &#8211; no Management&#8217;s Adjustments are presented. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2026
            gives effect to the Merger and related transactions as if they had occurred on March&#160;31, 2026. The unaudited pro forma condensed combined statement of operations for the year ended December&#160;31, 2025 and the three months ended March&#160;31, 2026
            give effect to the Merger and related transactions as if they had occurred on January&#160;1, 2025, the beginning of the earliest period presented. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For accounting purposes, Remix is treated as the accounting acquirer and Passage
            Bio as the accounting acquiree, and the Merger will be accounted for as a reverse recapitalization. This determination reflects that, immediately following the Merger: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix equity holders will hold a substantial majority of the voting interests in the Combined Company, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix designees will comprise a majority of the board of directors, </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">299<br/>
        </div>

      </div>

    </div>

    <!--End Page 309-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 310-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s senior management will comprise the senior management of the Combined Company, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix&#8217;s business will be the ongoing business of the Combined Company; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage Bio&#8217;s pre-combination assets consist primarily of cash and other non-operating assets. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under reverse recapitalization accounting, the financial statements of the
            Combined Company represent a continuation of Remix&#8217;s financial statements, and the Merger is treated as the equivalent of Remix issuing equity to acquire the net assets of Passage Bio, accompanied by a recapitalization of Remix&#8217;s equity.
            Passage Bio&#8217;s net assets, to the extent retained by the Combined Company, will be stated at historical carrying value, with no goodwill or intangible assets recorded. Any difference between the consideration deemed issued by Remix and the
            historical carrying value of Passage Bio&#8217;s net assets will be recorded as an adjustment to additional paid-in capital. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the Merger, Passage Bio will distribute one CVR per share of
            Passage Bio Common Stock to pre-Closing Passage Bio stockholders. Passage Bio has elected to early adopt Accounting Standards Update (&#8220;ASU&#8221;) 2025-07, under which a contract whose settlement is based on the operations or activities specific to
            one party to the contract is not accounted for as a derivative under Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;815, <span style="font-style: italic;">Derivatives and Hedging</span>. Because the CVRs settle based on proceeds derived from
            Passage Bio&#8217;s legacy license agreements, they qualify for this scope exception and are accounted for as a contingency under ASC&#160;Topic&#160;450, <span style="font-style: italic;">Contingencies</span>. Because no payment is currently probable and
            estimable, no liability has been recognized and no pro forma adjustment has been recorded in respect of the CVRs. A liability will be recognized if and when payment becomes probable and estimable. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Shares of Passage Bio Common Stock Issued in Connection with the Merger and Concurrent Financing </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Immediately prior to the Merger, all outstanding Remix convertible notes and all
            outstanding shares of Remix preferred stock will be converted into shares of Remix common stock, and the 2025 Warrants will be net exercised for shares of Remix common stock, each of which will be exchanged for shares of Passage Bio Common
            Stock based on the Merger Exchange Ratio. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Exchange Ratio for purposes of this unaudited pro forma condensed
            combined financial information was derived using a stipulated equity value for Remix of $326.0&#160;million (including the Concurrent Financing) and for Passage Bio of $20.0&#160;million (assuming Passage Bio Net Cash of $5.0 million as of the Closing).
            The estimated number of shares of Passage Bio Common Stock issuable to Remix&#8217;s common stockholders, preferred stockholders, and convertible note holders, ignoring the impact of any reverse stock split and fractional-share rounding, is
            determined as follows: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 396pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 50pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock outstanding</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">7,833,976 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued upon conversion of Remix preferred
                    stock</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 0.37pt;">118,136,265 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued upon conversion of the 2025
                    convertible notes</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">28,727,129 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued upon net exercise of the 2025
                    Warrants</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">1,081,712 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated total shares of Remix common stock issued in
                    the Merger</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">155,779,082 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Merger Exchange Ratio</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">0.1734 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated total shares of Passage Bio common stock
                    issued to Remix Stockholders</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">27,012,092 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued in the Subscription Financing</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">50,499,963 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued upon conversion of the 2026 Notes</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">21,642,840 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated total shares of Remix common stock issued in
                    the Concurrent Financing</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">72,142,803 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Concurrent Financing Exchange Ratio</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">0.1734 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Estimated total shares of Passage
                    Bio common stock issued to Remix Stockholders as a result of the Concurrent Financing</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12,509,562 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated total shares of Passage Bio Common Stock
                    issued to Remix stockholders</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">39,521,654</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 396pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">300<br/>
        </div>

      </div>

    </div>

    <!--End Page 310-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 311-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Pro Forma Adjustments </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The pro forma adjustments, which are based on preliminary estimates that could
            change materially as additional information is obtained, are described below. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Adjustments to the Unaudited Pro Forma Condensed Combined
            Balance Sheet </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the net cash proceeds of $65.2&#160;million received in the Subscription Financing, consisting of gross proceeds of
                    $70.0&#160;million less estimated issuance costs of $4.8&#160;million. Shares issued in the Subscription Financing are shares of Remix common stock that convert immediately into shares of Passage Bio Common Stock in the Merger. Accordingly, the
                    proceeds are reflected directly in Passage Bio Common Stock (par value) and additional paid-in capital, based on an estimated 8,756,693 shares of Passage Bio Common Stock issued. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">B.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the net cash proceeds of $28.0&#160;million from issuance of the 2026 Notes, consisting of gross proceeds of $30.0&#160;million
                    less estimated issuance costs of $2.0 million. In connection with the Merger, the 2026 Notes convert into shares of Remix common stock, which immediately convert into Passage Bio Common Stock. Accordingly, the proceeds are reflected
                    directly in Passage Bio Common Stock (par value) and additional paid-in capital, based on an estimated 3,752,869 shares of Passage Bio Common Stock issued. Because the issuance and conversion occur simultaneously at the Closing, for
                    purposes of the pro forma adjustments no interest accrues on the 2026 Notes. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">C.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the cash settlement of $9.4&#160;million of estimated Passage Bio transaction costs incurred in connection with the Merger
                    that were not recognized in the historical financial statements. Because Remix is the accounting acquirer, Passage Bio&#8217;s transaction costs are not treated as costs of the equity transaction. Consistent with reverse recapitalization
                    accounting, these transaction costs are expensed as incurred. Accordingly, the $9.4&#160;million is reflected as a cash payment with a corresponding increase to accumulated deficit in the pro forma condensed combined balance sheet. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">D.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the cash settlement of $9.0&#160;million of estimated Remix transaction costs incurred in connection with the Merger that
                    were not recognized in the historical financial statements. Of this amount, $1.0&#160;million relates to a prepaid directors&#8217; and officers&#8217; insurance policy, which is recorded as a prepaid expense in the pro forma condensed combined balance
                    sheet. The remaining $8.0&#160;million represents Remix&#8217;s transaction costs, which, consistent with reverse recapitalization accounting, are recorded as a reduction of additional paid-in capital to the extent of cash received from Passage
                    Bio, with any excess recognized as expense. As of March&#160;31, 2026, Passage Bio&#8217;s cash balance exceeded Remix&#8217;s transaction costs; accordingly, the full $8.0&#160;million was charged to additional paid-in capital. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">E.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the removal of Passage Bio's non-refundable sublicense and transition services payment accrual as the remaining
                    obligations thereunder are nominal and do not represent an obligation of the Combined Company.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the conversion of Remix&#8217;s 2025 convertible notes into shares of Remix common stock in connection with the Merger, which
                    immediately convert into shares of Passage Bio Common Stock. The 2025 convertible notes are carried at fair value, and their carrying value of $29.4 million as of March&#160;31, 2026 is reflected as Passage Bio Common Stock (par value) and
                    additional paid-in capital, based on an estimated 4,981,284 shares of Passage Bio Common Stock issued on conversion. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">G.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the termination of the 2023 Warrants in connection with the Merger in accordance with their terms. This adjustment
                    reflects the derecognition of the warrant liability of $5.7 million, with the offset recorded to additional paid-in capital. The related change in fair value recognized in Remix&#8217;s historical statements of operations is eliminated (see
                    Adjustment M). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">H.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the net exercise of the 2025 Warrants in connection with the Merger into shares of Remix common stock, which
                    immediately convert into shares of Passage Bio Common Stock, based on an estimated 187,569 shares of Passage Bio Common Stock issued. This adjustment reflects the reclassification of the warrant liability of $2.6 million to Passage Bio
                    Common Stock (par value) and additional paid-in capital. No cash is received on the net exercise, and the related change in fair value recognized in Remix&#8217;s historical statements of operations is eliminated (see Adjustment M). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">301<br/>
        </div>

      </div>

    </div>

    <!--End Page 311-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 312-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the recapitalization of Remix&#8217;s historical equity in connection with the Merger based on the estimated Merger Exchange
                    Ratio, including: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The conversion of all outstanding shares of Remix preferred stock into Passage Bio Common Stock. Remix preferred stock first
                    converts into shares of Remix common stock, which immediately converts into Passage Bio Common Stock in the Merger. Accordingly, the adjustment is reflected directly in Passage Bio Common Stock (par value) and additional paid-in
                    capital. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The conversion of all outstanding shares of Remix common stock (excluding shares issued in the Concurrent Financing and upon
                    conversion of the 2025 convertible notes addressed in Adjustments A, B, and F) into shares of Passage Bio Common Stock. The adjustment is reflected directly in Passage Bio Common Stock (par value) and additional paid-in capital. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">J.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the elimination of Passage Bio&#8217;s historical accumulated deficit. Because the Merger is accounted for as a reverse
                    recapitalization, Passage Bio&#8217;s historical equity balances are not carried forward, and Passage Bio&#8217;s accumulated deficit of $712.3 million was eliminated against additional paid-in capital. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">K.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the charge to additional paid-in capital and accumulated deficit related to $2.0&#160;million of stock-based compensation
                    expense associated with the Merger, consisting of: (a) $1.7&#160;million of expense related to acceleration of certain unvested stock options pursuant to pre-existing grant agreements that provide for acceleration upon a change in control,
                    which will be triggered by the Merger; and (b) $0.3&#160;million of incremental expense related to the extension of exercise periods for certain stock options pursuant to the terms of the Merger Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Adjustments to the Unaudited Pro Forma Condensed Combined
            Statements of Operations </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">L.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects nonrecurring stock-based compensation expense of $2.0 million associated with the Merger, consisting of: (a) $1.7
                    million of expense from acceleration of unvested stock options under pre-existing grant agreements that provide for acceleration upon a change in control, which will be triggered by the Merger; and (b)&#160;$0.3&#160;million of incremental
                    expense related to the extension of exercise periods for certain stock options pursuant to the terms of the Merger Agreement. The affected employees are all classified in general and administrative functions; accordingly, the aggregate
                    charge is recorded in general and administrative expense in the unaudited pro forma condensed combined statement of operations. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: left;">The acceleration described in (a) occurs pursuant to the pre-existing terms of
            the original award agreements and is not accounted for as a modification; upon the change in control, the remaining unrecognized compensation cost for the affected awards is recognized in full. The extension of exercise periods described in (b)
            is accounted for as a modification under ASC 718, with the incremental fair value of the affected awards, measured as of the modification date, recognized immediately because the underlying awards are fully vested. Because these costs are
            nonrecurring and directly attributable to the Merger, the aggregate charge is reflected in the pro forma statement of operations for the year ended December&#160;31, 2025. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">M.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Reflects the elimination of changes in fair value recognized in Remix&#8217;s historical statements of operations related to the 2023
                    Warrants, the 2025 Warrants, and the 2025 Convertible Notes. Because the 2023 Warrants, 2025 Warrants, and 2025 Convertible Notes are assumed to have been terminated, net exercised, and converted respectively as of January&#160;1, 2025 the
                    related fair value remeasurements recognized in Remix&#8217;s historical results have been eliminated for the periods presented, as follows (in thousands): </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 448pt; margin-left: 20pt; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 72.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 5.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72.73pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Change in fair value - 2025 convertible notes</div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 12.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72.73pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.62pt; text-align: left;">$2,800 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Change in fair value - 2025 Warrants</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72.73pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.62pt; text-align: left;"><span style="padding-left: 9.17pt;">(300) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Change in fair value - 2023 Warrants</div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,150</span></div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72.73pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.62pt; text-align: left;"><span style="padding-left: 9.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(625</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total pro forma adjustment</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$ 2,150</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72.73pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.62pt; text-align: left;">$ 1,875</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.69pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 72.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Pro Forma Loss per Share </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The pro forma combined basic and diluted loss per share has been adjusted to
            reflect the pro forma net loss for the year ended December&#160;31, 2025 and the three months ended March 31, 2026. The weighted-average shares outstanding for the periods presented has been adjusted to give effect to both: (i) the conversion of
            Remix&#8217;s </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">302<br/>
        </div>

      </div>

    </div>

    <!--End Page 312-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 313-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_126-unaudited_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">historical weighted-average shares outstanding based on the estimated Merger
            Exchange Ratio; and (ii) the shares issued in the Merger and related transactions, as if they had been outstanding as of January&#160;1, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Because the Combined Company is in a net loss position, any adjustment for
            potentially dilutive shares would be anti-dilutive; accordingly, basic and diluted loss per share are the same. The following table sets forth the computation of pro forma net loss per share (in thousands, except share and per share amounts): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 470.68pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 339pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 59.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 339pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Ended March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average Remix common shares outstanding - basic and diluted</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 10pt;">7,700,621</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 10pt;">7,825,834 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued upon conversion of Remix preferred
                    stock</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 0.37pt;">118,136,265</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 0.37pt;">118,136,265 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Shares of Remix common stock issued upon conversion
                    of the 2025 convertible notes</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 5pt;">28,727,129</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 5pt;">28,727,129 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued upon net exercise of the 2025
                    Warrants</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,081,712</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,081,712</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Estimated weighted-average shares of Remix common
                    stock outstanding as of immediately prior to the Closing</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;">155,645,727</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;">155,770,940 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Merger Exchange Ratio</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">0.1734</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">0.1734 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Estimated total shares of Passage
                    Bio common stock issued to Remix Stockholders in the Merger </div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 5pt;">26,988,969</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 5pt;">27,010,681 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued in the Subscription Financing</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 5pt;">50,499,963</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 5pt;">50,499,963 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Remix common stock issued upon conversion of the 2026 Notes</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">21,642,840</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">21,642,840 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 5pt;">72,142,803</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 5pt;">72,142,803 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Estimated Concurrent Financing Exchange Ratio</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">0.1734</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">0.1734 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Estimated total shares of Passage
                    Bio common stock issued to Remix Stockholders as a result of the Concurrent Financing</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 5pt;">12,509,562</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 5pt;">12,509,562 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares of Passage Bio common stock issued upon acceleration of RSUs</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 22.5pt;">20,000</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 22.5pt;">20,000 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average Passage Bio common shares outstanding&#8212;basic and diluted</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,172,870</span></div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,205,866 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 339pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Pro forma combined
                    weighted-average common shares outstanding &#8212;basic and diluted</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 7.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">42,691,401</span></div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 59.18pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 4.6pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">42,746,109</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 339pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 59.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">303<br/>
        </div>

      </div>

    </div>

    <!--End Page 313-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 314-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_127-description_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tDPBC"><!--Anchor--></a>DESCRIPTION OF PASSAGE BIO CAPITAL STOCK </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following description of Passage Bio Capital Stock and provisions of Passage
            Bio&#8217;s amended and restated certificate of incorporation (as will be in effect if the Charter Proposal is approved) and Passage Bio&#8217;s amended and restated bylaws are summaries and are qualified by reference to such charter (which is attached as
            Annex J) and bylaws (which has been publicly filed with the SEC) and applicable provisions of the DGCL. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s authorized capital stock will consist of 300,000,000 shares of
            common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Holders of Passage Bio&#8217;s common stock are entitled to one vote for each share
            held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by Passage Bio&#8217;s stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote
            on the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of Passage Bio&#8217;s stockholders having a majority in voting power of the votes cast by the stockholders present or
            represented and voting on such matter. Passage Bio&#8217;s amended and restated certificate of incorporation and amended and restated bylaws also provide that Passage Bio&#8217;s directors may be removed only for cause and only by the affirmative vote of
            the holders of at least two-thirds in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least two-thirds in voting power of the outstanding shares of capital
            stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of Passage Bio&#8217;s amended and restated certificate of incorporation. See below under &#8220;Anti-Takeover Effects of
            Delaware Law and Passage Bio&#8217;s Certificate of Incorporation and Bylaws&#8212;Amendment of Charter Provisions.&#8221; Holders of common stock are entitled to receive proportionately any dividends as may be declared by Passage Bio&#8217;s board of directors,
            subject to any preferential dividend rights of any series of preferred stock that Passage Bio may designate and issue in the future. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event of Passage Bio&#8217;s liquidation or dissolution, the holders of common
            stock are entitled to receive proportionately Passage Bio&#8217;s net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders
            of common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any
            series of preferred stock that we may designate and issue in the future. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Preferred Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the terms of Passage Bio&#8217;s amended and restated certificate of
            incorporation that will become effective upon the closing of the Merger, Passage Bio&#8217;s board of directors is authorized to direct Passage Bio to issue shares of preferred stock in one or more series without stockholder approval. Passage Bio&#8217;s
            board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred
            stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The purpose of authorizing Passage Bio&#8217;s board of directors to issue preferred
            stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future
            financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of Passage Bio&#8217;s outstanding voting stock. Upon the
            closing of the Merger, there will be no shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Anti-takeover effects of Delaware law and
            Passage Bio&#8217;s amended and restated certificate of incorporation and amended and restated bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Some provisions of Delaware law, Passage Bio&#8217;s amended and restated certificate
            of incorporation and Passage Bio&#8217;s amended and restated bylaws could make the following transactions more difficult: an acquisition of Passage Bio by means of a tender offer; an acquisition of Passage Bio by means of a proxy contest or
            otherwise; or the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">304<br/>
        </div>

      </div>

    </div>

    <!--End Page 314-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 315-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_127-description_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">removal of Passage Bio&#8217;s incumbent officers and directors. It is possible that
            these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in Passage Bio&#8217;s best interests, including transactions which provide for payment
            of a premium over the market price for Passage Bio&#8217;s shares. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These provisions, summarized below, are intended to discourage coercive takeover
            practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of Passage Bio to first negotiate with Passage Bio&#8217;s board of directors. Passage Bio believes that the benefits of the
            increased protection of Passage Bio&#8217;s potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure Passage Bio outweigh the disadvantages of discouraging these proposals because
            negotiation of these proposals could result in an improvement of their terms. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 0pt; text-align: left;">Undesignated preferred stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The ability of Passage Bio&#8217;s board of directors, without action by the
            stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by Passage Bio&#8217;s board of directors could impede the success of any attempt to change control of Passage
            Bio. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of Passage Bio. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 0pt; text-align: left;">Stockholder meetings </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated bylaws provide that a special meeting of
            stockholders may be called only by Passage Bio&#8217;s chair of the board, chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of Passage Bio&#8217;s board of directors. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13pt; margin-left: 0pt; text-align: left;">Requirements for advance notification of stockholder
            nominations and proposals </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated bylaws establish advance notice procedures
            with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the
            board of directors. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Elimination of stockholder action by written consent </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated certificate of incorporation eliminates the
            right of stockholders to act by written consent without a meeting. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Staggered board </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s board of directors is divided into three classes. The directors in
            each class will serve for a three-year term, one class being elected each year by Passage Bio&#8217;s stockholders. This system of electing and removing directors may tend to discourage a third-party from making a tender offer or otherwise attempting
            to obtain control of Passage Bio, because it generally makes it more difficult for stockholders to replace a majority of the directors. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Removal of directors </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated certificate of incorporation provides that no
            member of Passage Bio&#8217;s board of directors may be removed from office by Passage Bio&#8217;s stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of
            the outstanding shares of stock entitled to vote in the election of directors. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Stockholders not entitled to cumulative voting </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated certificate of incorporation does not permit
            stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of Passage Bio&#8217;s common stock entitled to vote in any election of directors can elect all of the directors
            standing for election, if they choose, other than any directors that holders of Passage Bio&#8217;s preferred stock may be entitled to elect. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Delaware anti-takeover statute </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is subject to Section&#160;203 of the General Corporation Law of the State
            of Delaware, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders
            unless the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">305<br/>
        </div>

      </div>

    </div>

    <!--End Page 315-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 316-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_127-description_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">business combination is, or the transaction in which the person became an
            interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the
            determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the
            interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Choice of forum </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated certificate of incorporation provides that,
            unless Passage Bio consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1) any derivative action, suit or proceeding brought on Passage Bio&#8217;s
            behalf; (2) any action, suit or proceeding asserting a claim of breach of a fiduciary duty by any of Passage Bio&#8217;s directors, officers, or stockholders; (3) any action, suit or proceeding asserting a claim against Passage Bio arising pursuant
            to any provision of the General Corporation Law of the State of Delaware or Passage Bio&#8217;s certificate of incorporation or bylaws; or (4) any action, suit or proceeding asserting a claim governed by the internal affairs doctrine; provided that
            the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction, including all causes of
            action asserted against any defendant to such complaint. For instance, the provision would not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities Act,
            Exchange Act, or the rules and regulations thereunder. Passage Bio&#8217;s amended and restated certificate of incorporation further provides that, unless Passage Bio consents in writing to the selection of an alternative forum, the federal district
            courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Passage Bio&#8217;s amended and
            restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of Passage Bio&#8217;s capital stock will be deemed to have notice of and to have consented to this choice of forum
            provision. It is possible that a court of law could rule that the choice of forum provision contained in Passage Bio&#8217;s amended and restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or
            otherwise. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Amendment of charter provisions </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The amendment of any of the above provisions, except for the provision making it
            possible for Passage Bio&#8217;s board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote
            thereon. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The provisions of Delaware law, Passage Bio&#8217;s amended and restated certificate of
            incorporation and Passage Bio&#8217;s amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of Passage Bio&#8217;s
            common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of Passage Bio&#8217;s board and management. It is possible that these provisions
            could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Limitations on liability and indemnification
            of officers and directors </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated certificate of incorporation provides that no
            director or officer will be personally liable to Passage Bio or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except as required by applicable law, as in effect from time to time. Section&#160;102(b)(7)
            of the DGCL permits a corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary
            duty as a director or officer, except for liability for: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any breach of the director&#8217;s or officer&#8217;s duty of loyalty to Passage Bio or its stockholders; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any act or omission not in good faith or which involved intentional misconduct or a knowing violation of law; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">306<br/>
        </div>

      </div>

    </div>

    <!--End Page 316-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 317-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_127-description_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&#160;174 of the DGCL; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any transaction from which the director or officer derived an improper personal benefit. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a result, neither Passage Bio nor its stockholders have the right, through
            stockholders&#8217; derivative suits on Passage Bio&#8217;s behalf, to recover monetary damages against a director or officer for breach of fiduciary duty as a director, including breaches resulting from grossly negligent behavior, except in the situations
            described above. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s amended and restated certificate of incorporation also provides
            that, to the fullest extent permitted by law, Passage Bio will indemnify any director or officer of Passage Bio against all damages, claims and liabilities arising out of the fact that the person is or was Passage Bio&#8217;s director or officer, or
            served any other enterprise at Passage Bio&#8217;s request as a director or officer. Amending this provision will not reduce Passage Bio&#8217;s indemnification obligations relating to actions taken before an amendment. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The transfer agent and registrar for Passage Bio Common Stock is Computershare
            Trust Company, N.A. The transfer agent&#8217;s address is 250 Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) 962-4284. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Nasdaq Capital Market Listing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio&#8217;s common stock is listed on the Nasdaq Capital Market under the
            symbol &#8220;PASG.&#8221; Following the closing of the Merger, the combined company&#8217;s common stock is expected to be listed on the Nasdaq Capital Market under the symbol &#8220;RMTX.&#8221; </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">307<br/>
        </div>

      </div>

    </div>

    <!--End Page 317-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 318-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_128-comparison_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCRHP"><!--Anchor--></a>COMPARISON OF RIGHTS OF HOLDERS OF PASSAGE
            BIO CAPITAL STOCK <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AND REMIX CAPITAL STOCK </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix and Passage Bio are both incorporated under the laws of the State of
            Delaware. The rights of Remix stockholders and Passage Bio stockholders are generally governed by the DGCL. Upon completion of the Merger, Remix stockholders will become Passage Bio stockholders, and their rights will be governed by the DGCL,
            the amended and restated bylaws of the combined company and the restated certificate of incorporation of the combined company. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The material differences between the current rights of Remix stockholders under
            Remix&#8217;s amended and restated certificate of incorporation and bylaws and their rights as stockholders of the combined company, after the Merger, under the proposed restated certificate of incorporation and the amended and restated bylaws, both
            as will be in effect immediately following the completion of the Merger, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the proposed
            restated certificate of incorporation and amended and restated bylaws. You should carefully read this entire document and the other referenced documents, including the proposed restated certificate of incorporation and amended and restated
            bylaws, for a more complete understanding of the differences between being a stockholder of Remix or Passage Bio before the Merger and being a stockholder following the completion of the Merger. For more information on how to obtain these
            documents, see the section titled &#8220;<span style="font-style: italic;">Where You Can Find More Information</span>&#8221; of this proxy statement/prospectus. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Authorized Common Stock </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s authorized capital stock consists of (i) 162,000,000 shares of Common
            Stock, $0.0001 par value per share, and (ii) 124,133,326 shares of Preferred Stock, $0.0001 par value per share (consisting of 17,964,705 shares of Series&#160;Seed Preferred Stock, 35,714,365 shares of Series&#160;A Preferred Stock, and 70,454,256
            shares of Series&#160;B Preferred Stock). </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will authorize 310,000,000
            shares, consisting of (i) 300,000,000 shares of Common Stock, $0.0001 par value per share, and (ii) 10,000,000 shares of Preferred Stock, $0.0001 par value per share. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement contemplates an amendment to Passage Bio&#8217;s restated
            certificate of incorporation in connection with the Closing to implement the reverse stock split. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Conversion Rights, Liquidation Preferences, and Protective
            Provisions </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Holders of Remix Common Stock have no preemptive rights to subscribe for any
            shares of any class of Remix stock. The voting, dividend and liquidation rights of the holders of Remix Common Stock are subject to and qualified by the rights, powers and preferences of the holders of Remix Preferred Stock. The holders of
            Remix Preferred Stock are entitled to receive dividends prior and in preference to any declaration or payment of any dividend on Remix Common Stock. Upon the liquidation, dissolution or winding up of Remix, the holders of Remix Preferred Stock
            are entitled to be paid out of the assets of Remix available for distribution to its stockholders before any payment is made to the holders of Remix Common Stock. Each share of Remix Preferred Stock is convertible into shares of Remix Common
            Stock at the option of the holder thereof at any time. The Remix Board is authorized, subject to limitations prescribed by Delaware law and the required consent of the holders of Remix Preferred Stock, to issue preferred stock with voting
            powers, designations, preferences and relative, participating, optional or other rights, and qualifications, limitations or restrictions as set forth in Remix&#8217;s amended and restated certificate of incorporation. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide for no preemptive
            rights to subscribe for any shares of any class of stock nor conversion rights to convert common stock into or exchange common stock for shares of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">308<br/>
        </div>

      </div>

    </div>

    <!--End Page 318-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 319-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_128-comparison_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">any other class or classes or of any other series of the same class of capital
            stock. The rights, preferences and privileges of the holders of the combined company&#8217;s common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of the combined company&#8217;s preferred stock that
            may be designated in the future. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon the dissolution, liquidation or winding up of the combined company, whether
            voluntary or involuntary, the funds and assets of the combined company that may be legally distributed to the stockholders shall be distributed among the holders of the then outstanding common stock pro rata in accordance with the number of
            shares of common stock held by each such holder, subject to the rights and preferences of any holders of any shares of any outstanding series of preferred stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that shares of
            preferred stock may be issued from time to time in one or more series, each of such series to have such terms as stated in the resolution or resolutions providing for the creation and issuance of such series adopted by the board of directors.
            The board of directors will be expressly authorized to issue the Preferred Stock in one or more series from time to time, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance
            of the shares thereof and by filing a certificate of designation, to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and relative
            participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, and to
            increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series as shall be stated and expressed in such resolutions, all to the fullest extent now or hereafter permitted by the DGCL.
            The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change of control and may
            adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Number of Directors </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s amended and restated certificate of incorporation provides that the
            number of directors of Remix shall be determined in the manner set forth in the bylaws. Remix&#8217;s bylaws provide that the number of directors that shall constitute the whole Remix Board of Directors shall be determined by resolution of the Remix
            Board of Directors or by the stockholders at the annual meeting of the stockholders, and each director elected shall hold office until his or her successor is elected and qualified. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation and amended and restated
            bylaws will provide that, subject to any special rights of the holders of any series of preferred stock to elect directors, the number of directors which shall constitute the whole board of directors shall be fixed exclusively by one or more
            resolutions adopted from time to time by the board of directors. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Stockholder Nominations and Proposals </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix&#8217;s bylaws do not contain specific advance notice provisions for stockholder
            nominations or proposals. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed amended and restated bylaws will provide that stockholders seeking
            to present proposals before an annual meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide written notice on a timely basis and also specify requirements as to the form and
            content of a stockholder&#8217;s notice. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Classification of Board of Directors </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix&#8217;s amended and restated certificate of incorporation does not provide for a
            classified board of directors. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">309<br/>
        </div>

      </div>

    </div>

    <!--End Page 319-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 320-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_128-comparison_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that the
            directors shall be divided into three classes, with each class having a three-year term expiring on a staggered basis. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Election of Directors </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each director elected shall hold office until his or her successor is elected and
            qualified. The holders of record of the shares of Series&#160;Seed Preferred Stock, exclusively and as a separate class, are entitled to elect two directors. The holders of record of the shares of Series&#160;A Preferred Stock, exclusively and as a
            separate class, are entitled to elect one director. The holders of record of the shares of Remix Common Stock, exclusively and as a separate class, are entitled to elect one director. The holders of record of the shares of Remix Common Stock
            and of any other class or series of voting stock are entitled to elect the balance of the total number of directors. Each director elected shall hold office until his or her successor is duly elected and qualified. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Other than any directors elected by the separate vote of the holders of any class
            or series of preferred stock, the board of directors will be divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III. At each annual meeting of stockholders of the combined company, subject to any special rights of the holders
            of one or more outstanding series of preferred stock to elect directors, the successors of the class of directors whose term expires at that meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders held
            in the third&#160;year following the year of their election. Each director shall hold office until his or her successor is duly elected and qualified or until his or her earlier death, resignation, disqualification or removal. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Removal of Directors </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s amended and restated certificate of incorporation provides that any
            director elected by the holders of a specific class or series of capital stock entitled to elect such director may be removed with or without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of
            capital stock entitled to elect such director. Remix&#8217;s bylaws provide that any director or the entire Remix Board of Directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of
            directors. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that, subject to
            the special rights of the holders of one or more outstanding series of preferred stock to elect directors, the board of directors or any individual director may be removed from office at any time, but only for cause and only by the affirmative
            vote of the holders of at least two-thirds of the voting power of all of the then outstanding shares of voting stock entitled to vote at an election of directors. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Vacancies on the Board of Directors </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s bylaws provide that, unless otherwise provided in Remix&#8217;s certificate of
            incorporation, vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director,
            and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held
            in the manner provided by statute. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation and amended and restated
            bylaws will provide that, subject to the special rights of the holders of one or more outstanding series of preferred stock to elect directors, except as otherwise provided by law, any vacancies on the board of directors resulting from death,
            resignation, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">310<br/>
        </div>

      </div>

    </div>

    <!--End Page 320-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 321-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_128-comparison_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">disqualification, retirement, removal or other causes and any newly created
            directorships resulting from any increase in the number of directors shall be filled exclusively by the affirmative vote of a majority of the directors then in office, even though less than a quorum, or by a sole remaining director (other than
            any directors elected by the separate vote of one or more outstanding series of preferred stock), and shall not be filled by the stockholders. Any director appointed in accordance with the preceding sentence shall hold office until the
            expiration of the term of the class to which such director shall have been appointed or until his or her earlier death, resignation, retirement, disqualification or removal. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Voting Stock </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s amended and restated certificate of incorporation provides that the
            holders of Remix Common Stock are entitled to one vote for each share of Remix Common Stock held at all meetings of stockholders. The holders of each series of Remix Preferred Stock are entitled to cast the number of votes equal to the number
            of whole shares of Remix Common Stock into which the shares of Remix Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that each holder
            of common stock, as such, shall be entitled to vote on each matter submitted to a vote of stockholders and shall be entitled to one vote for each share of common stock held of record by such holder as of the record date for determining
            stockholders entitled to vote on such matter. There shall be no cumulative voting. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Stockholder Action by Written Consent </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s bylaws provide that, unless otherwise provided by Remix&#8217;s certificate of
            incorporation, any action required or permitted to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing setting forth the action so taken
            is signed in a manner permitted by law by the holders of outstanding stock having not less than the number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present
            and voted. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that any action
            required or permitted to be taken by the stockholders must be effected at an annual or special meeting of stockholders, and shall not be taken by written consent in lieu of a meeting. Notwithstanding the foregoing, any action required or
            permitted to be taken by the holders of any series of preferred stock, voting separately as a series or separately as a class with one or more other such series, may be taken without a meeting, without prior notice and without a vote, to the
            extent expressly so provided by the applicable certificate of designation relating to such series of preferred stock. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Notice of Stockholder Meeting </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s bylaws provide that written notice of any stockholder meeting stating the
            place, if any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, shall be given to each stockholder entitled to vote
            at such meeting not fewer than 10 nor more than 60 days before the date of the meeting. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed amended and restated bylaws will provide that, unless otherwise
            provided by law, the certificate of incorporation or the bylaws, the notice of any meeting of stockholders shall be sent or otherwise given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to
            vote at such meeting. The </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">311<br/>
        </div>

      </div>

    </div>

    <!--End Page 321-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 322-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_128-comparison_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">notice shall specify the place, if any, date and time of the meeting, the
            means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting of stockholders, the purpose or purposes for which such meeting
            is called. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Special Stockholder Meetings </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s bylaws provide that special meetings of the stockholders, for any purpose
            or purposes, unless otherwise prescribed by statute or by the certificate of incorporation, may be called by the Chief Executive Officer and shall be called by the Chief Executive Officer or secretary at the request in writing of a majority of
            the Remix Board of Directors, or at the request in writing of stockholders owning at least 50% in amount of the entire capital stock of Remix issued and outstanding and entitled to vote. Such request shall state the purpose or purposes of the
            proposed meeting. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation and amended and restated
            bylaws will provide that, subject to the special rights of the holders of one or more series of preferred stock, special meetings of stockholders may be called, for any purpose or purposes, at any time only by or at the direction of the board
            of directors, the Chairperson of the board of directors, the Chief Executive Officer or, in the absence of a Chief Executive Officer, the President, and shall not be called by any other person or persons. No business may be transacted at any
            special meeting of stockholders other than the business specified in the notice of such meeting. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Indemnification </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s amended and restated certificate of incorporation provides that, to the
            fullest extent permitted by law, a director of Remix shall not be personally liable to Remix or its stockholders for monetary damages for breach of fiduciary duty as a director. Remix is authorized to provide indemnification of (and advancement
            of expenses to) directors, officers and agents (and any other persons to which the DGCL permits Remix to provide indemnification) through bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested
            directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&#160;145 of the DGCL. Remix&#8217;s bylaws provide that Remix shall, to the fullest extent authorized under the laws of the State of Delaware, as those
            laws may be amended and supplemented from time to time, indemnify any director made, or threatened to be made, a party to an action or proceeding, whether criminal, civil, administrative or investigative, by reason of being a director of Remix;
            provided, however, that Remix shall indemnify any such director in connection with a proceeding initiated by such director only if such proceeding was authorized by the Board of Directors. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that no director
            or officer shall have any personal liability to the combined company or its stockholders for monetary damages for any breach of fiduciary duty as a director or officer, except to the extent such exemption from liability or limitation thereof is
            not permitted under the DGCL as the same exists or hereafter may be amended. The proposed restated certificate of incorporation also will provide that the combined company will have the power to provide rights to indemnification and advancement
            of expenses to its current and former officers, directors, employees and agents and to any person who is or was serving at the request of the combined company as a director, officer, employee or agent of another corporation, partnership, joint
            venture, trust or other enterprise. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed amended and restated bylaws will provide that the combined company
            will indemnify and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any director or officer who was or is made or is threatened to be made a party or is otherwise involved in any
            action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer or, while serving as a
            director or officer of the combined company, is or was serving at the request of the combined company as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or non-profit entity,
            including service with respect to employee benefit plans, against all liability and loss suffered and expenses </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">312<br/>
        </div>

      </div>

    </div>

    <!--End Page 322-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 323-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_128-comparison_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">(including attorneys&#8217; fees, judgments, fines and amounts paid in settlement)
            reasonably incurred by such person in connection with any such proceeding. The proposed amended and restated bylaws also will provide that the combined company will pay the expenses (including attorneys&#8217; fees) incurred by any covered person in
            defending any proceeding in advance of its final disposition. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Amendment of Certificate of Incorporation </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Amendments to Remix&#8217;s amended and restated certificate of incorporation are
            governed by the DGCL, which generally requires approval by the Remix Board and by a majority of the outstanding shares entitled to vote on such amendment. However, Remix&#8217;s amended and restated certificate of incorporation provides that the
            affirmative vote of the Requisite Holders (the holders of a majority of the then outstanding shares of Remix Preferred Stock, voting together as a single class and on an as-converted basis) shall be required to amend, alter, waive or repeal any
            provision of Remix&#8217;s certificate of incorporation or bylaws in a manner that adversely affects the powers, preferences or rights of the Remix Preferred Stock or any series thereof. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that,
            notwithstanding anything contained therein to the contrary, in addition to any vote required by applicable law, the following provisions in the proposed restated certificate of incorporation may be amended, altered, repealed or rescinded, in
            whole or in part, or any provision inconsistent therewith may be adopted, only by the affirmative vote of the holders of at least two-thirds of the total voting power of all the then outstanding shares of stock entitled to vote thereon, voting
            together as a single class: Part&#160;B of Article&#160;V (Capital Stock), Article&#160;VI (Management), Article&#160;VII (Stockholder Meetings and Action), Article&#160;VIII (Exculpation), Article&#160;IX (Indemnification), Article&#160;X (Forum Selection), and Article&#160;XI
            (Amendments). </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Amendment of Bylaws </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s amended and restated certificate of incorporation provides that, subject
            to any additional vote required by the certificate of incorporation or bylaws, the Remix Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the bylaws. Remix&#8217;s bylaws provide that the bylaws may be altered,
            amended or repealed, or new bylaws may be adopted by the stockholders or by the Remix Board, when such power is conferred upon the Remix Board by the certificate of incorporation at any regular meeting of the stockholders or of the Remix Board
            or at any special meeting of the stockholders or of the Remix Board if notice of such alteration, amendment, repeal or adoption of new bylaws be contained in the notice of such special meeting. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation and amended and restated
            bylaws will provide that the board of directors is expressly authorized to adopt, amend or repeal the bylaws. In addition to any vote of the holders of any class or series of stock required by applicable law or by the restated certificate of
            incorporation or the bylaws, the adoption, amendment or repeal of the bylaws by the stockholders shall require the affirmative vote of the holders of at least two-thirds of the voting power of all of the then outstanding shares of voting stock
            entitled to vote generally in an election of directors. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Forum Selection </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Remix </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix&#8217;s amended and restated certificate of incorporation provides that, unless
            Remix consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder to bring (i) any derivative action or proceeding brought on behalf of
            Remix, (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Remix to Remix or Remix&#8217;s stockholders, (iii) any action asserting a claim against Remix, its directors, officers or
            employees arising pursuant to any provision of the DGCL or Remix&#8217;s certificate of incorporation or bylaws, or (iv) any action asserting a claim against Remix, its directors, officers or employees governed by the internal affairs doctrine,
            except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">313<br/>
        </div>

      </div>

    </div>

    <!--End Page 323-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 324-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_128-comparison_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">indispensable party not subject to the jurisdiction of the Court of Chancery
            (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within 10 days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of
            Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Proposed Certificate of Incorporation and
            Bylaws </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The proposed restated certificate of incorporation will provide that, unless
            Passage Bio consents in writing to the selection of an alternative forum, (a) the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the other state courts of the State of
            Delaware or the United States District Court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action, suit or proceeding brought on behalf of the combined
            company, (ii) any action, suit or proceeding asserting a claim of breach of a fiduciary duty owed by any director, officer or stockholder of the combined company to the combined company or its stockholders, (iii) any action, suit or proceeding
            arising pursuant to any provision of the DGCL or the bylaws or the restated certificate of incorporation (as either may be amended from time to time), or (iv) any action, suit or proceeding asserting a claim against the combined company
            governed by the internal affairs doctrine; and (b) subject to the preceding provisions, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of
            action arising under the Securities Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">314<br/>
        </div>

      </div>

    </div>

    <!--End Page 324-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 325-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_129-security_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tSAR"><!--Anchor--></a>SECURITIES ACT RESTRICTIONS ON RESALE OF
            COMBINED COMPANY COMMON STOCK </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to Rule&#160;144, a person who has beneficially owned restricted combined
            company common stock for at least six months would be entitled to sell their securities provided that (i) such person is not deemed to have been an affiliate of the combined company at the time of, or at any time during the three months
            preceding, a sale and (ii)&#160;combined company is subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&#160;13 or 15(d) of the Exchange Act during the
            12&#160;months (or such shorter period as combined company was required to file reports) preceding the sale. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Persons who have beneficially owned restricted combined company common stock
            shares for at least six months but who are affiliates of combined company at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell
            within any three-month period only a number of securities that does not exceed the greater of: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">1% of the total number of combined company common stock then outstanding; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the average weekly reported trading volume of the combined company common stock during the four calendar weeks preceding the
                    filing of a notice on Form&#160;144 with respect to the sale. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Sales by affiliates of combined company under Rule&#160;144 are also limited by manner
            of sale provisions and notice requirements and to the availability of current public information about the combined company. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Restrictions on the Use of Rule&#160;144 by Shell Companies or
            Former Shell Companies </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Rule&#160;144 is not available for the resale of securities initially issued by shell
            companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule&#160;144 also includes an important exception to this prohibition if the following conditions are
            met: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuer of the securities that was formerly a shell company has ceased to be a shell company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuer of the securities is subject to the reporting requirements of Section&#160;13 or 15(d) of the Exchange Act; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the
                    preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form&#160;8-K reports; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at least one year has elapsed from the time that the issuer filed current Form&#160;10 type information with the SEC reflecting its
                    status as an entity that is not a shell company. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We anticipate that following the consummation of the Merger, the combined company
            will no longer be a shell company, and so, once the conditions set forth in the exceptions listed above are satisfied, Rule&#160;144 will become available for the resale of the above noted restricted securities. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">315<br/>
        </div>

      </div>

    </div>

    <!--End Page 325-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 326-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_130-principal_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPSPB"><!--Anchor--></a>PRINCIPAL STOCKHOLDERS OF PASSAGE BIO </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of June&#160;30, 2026, Passage Bio had 3,217,810 shares of Passage Bio Common Stock
            issued and outstanding. The table below shows certain information about the beneficial ownership of Passage Bio Common Stock, as of June&#160;30, 2026, by: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person, or group of affiliated persons, known by Passage Bio to beneficially own more than 5% of the outstanding shares of
                    Passage Bio Common Stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of Passage Bio&#8217;s directors, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of Passage Bio&#8217;s named executive officers, and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of Passage Bio&#8217;s directors and executive officers as a group. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In accordance with SEC rules, Passage Bio has included in the column &#8220;Number of
            Shares Beneficially Owned&#8221; all shares of Passage Bio Common Stock over which the person has sole or shared voting or investment power as of June&#160;30, 2026, and all shares of Passage Bio Common Stock that the person has the right to acquire
            within 60 days after June&#160;30, 2026 through the exercise of any stock options. All shares that a person has a right to acquire within 60 days of June&#160;30, 2026 are deemed outstanding for the purpose of computing the percentage beneficially owned
            by the person, but are not deemed outstanding for the purpose of computing the percentage beneficially owned by any other person. Unless otherwise indicated, each person has the sole power (or shares the power with a spouse) to invest and vote
            the shares of Passage Bio Common Stock listed opposite the person&#8217;s name. Where applicable, ownership is subject to community property laws. Inclusion of shares in this table as beneficially owned is not an admission of beneficial ownership of
            those shares by the person listed in the table. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 39.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 39.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div>
                </td>

    <td style="width: 7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div>
                </td>

    <td style="width: 7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% Stockholders:<br/>
                  </div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lynx1 Capital Management LP<sup>(1)</sup></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;">673,759</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;">20.9%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vestal Point Capital, LP<sup>(2)</sup></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;">305,000</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 5pt;">9.5%</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Baselake Partners, LP<sup>(3)</sup></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;">235,058</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 5pt;">7.3%</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors and Named Executive Officers:<br/>
                  </div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D.<sup>(4)</sup></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 0.37pt;">112,342</span></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 5pt;">3.5% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Athena Countouriotis, M.D.<sup>(5)</sup></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 5pt;">18,357</span></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 17.5pt;">*% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maxine Gowen, Ph.D.<sup>(6)</sup></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 5pt;">18,794</span></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 17.5pt;">*% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sandip Kapadia<sup>(7)</sup></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 5pt;">19,765</span></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 17.5pt;">*% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thomas Kassberg<sup>(8)</sup></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 5pt;">12,755</span></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 17.5pt;">*% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Derrell Porter, M.D.<sup>(9)</sup></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 5pt;">16,567</span></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 17.5pt;">*% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dolan Sondhi, Ph.D.<sup>(10)</sup></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 5pt;">14,446</span></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 17.5pt;">*% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kathleen Borthwick<sup>(11)</sup></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.75pt; text-align: left;"><span style="padding-left: 5pt;">25,789</span></div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 17.5pt;">*% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">All executive officers and directors as a group (8
                    persons)<sup>(12)</sup></div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 3.75pt; text-align: left;">238,807</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.25pt; text-align: left;"><span style="padding-left: 5pt;">7.4%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 39.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 39.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div>

          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">* Represents beneficial ownership of less than one percent of outstanding Passage
            Bio Common Stock. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based solely on a Schedule 13D filed on July 2, 2026. Represents 673,759 shares of common stock held by Lynx1 Capital Management
                    LP. The address for Lynx1 Capital Management LP is 151 Calle de San Francisco, Suite 200, PMB 1237, San Juan, PR 00901-1607.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based solely on a Schedule 13G filed on November 14, 2024. Represents 305,000 shares of common stock held by Vestal Point
                    Capital, LP. The address for Vestal Point Capital, LP is 632 Broadway, Suite 602, New York, NY 10012.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Based solely on a Schedule 13G filed on June 25, 2026. Represents 235,058 shares of common stock held by Baselake Partners, LP.
                    The address for Baselake Partners, LP is 3155 W. Big Beaver Road, Suite 207, Troy, Michigan 48084.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 6,724 shares of common stock and (ii) 105,618 shares underlying options to purchase common stock that are
                    exercisable within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 945 shares of common stock and (ii) 17,412 shares underlying options to purchase common stock that are exercisable
                    within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 18,794 shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 19,765 shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 12,755 shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">316<br/>
        </div>

      </div>

    </div>

    <!--End Page 326-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 327-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_130-principal_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 5.25pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 16,567 shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents 14,446 shares underlying options to purchase common stock that are exercisable within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 5,403 shares of common stock and (ii) 20,378 shares underlying options to purchase common stock that are
                    exercisable within 60 days of June 30, 2026.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents (i) 13,072 shares of common stock and (ii) 225,735 shares underlying options to purchase common stock that are
                    exercisable within 60 days of June 30, 2026, by our directors and executive office.</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">317<br/>
        </div>

      </div>

    </div>

    <!--End Page 327-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 328-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_130-principal_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPSR"><!--Anchor--></a>PRINCIPAL STOCKHOLDERS OF REMIX </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The table below shows certain information about the beneficial ownership of Remix
            Common Stock, as of June&#160;30, 2026, by: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person, or group of affiliated persons, known by Remix to beneficially own more than 5% of the outstanding shares of Remix
                    Common Stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of Remix&#8217;s directors, </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each of Remix&#8217;s named executive officers, and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of Remix&#8217;s directors and executive officers as a group. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The number of shares beneficially owned by each stockholder is determined under
            rules issued by the Securities and Exchange Commission. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power. Applicable percentage ownership is
            based on 125,970,241 shares of common stock outstanding as of June&#160;30, 2026, giving effect to the conversion of all outstanding shares of our preferred stock into shares of our common stock. In computing the number of shares beneficially owned
            by an individual or entity and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60 days of June&#160;30,
            2026 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. Where applicable, ownership is subject to community property laws. Inclusion of shares
            in this table as beneficially owned is not an admission of beneficial ownership of those shares by the person listed in the table. Except as otherwise noted below, the address for each person or entity listed in the table is c/o Remix
            Therapeutics, Inc., 400 Technology Square, Cambridge, MA&#160;02139. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 39.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Beneficial Owner</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percentage <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">of Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Beneficially <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Owned </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% Stockholders:<br/>
                  </div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with The Column Group<sup>(1)</sup></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">39,490,577</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;">31.0% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Atlas<sup>(2)</sup></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">30,999,572</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;">24.4% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Foresite<sup>(3)</sup></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">23,836,323</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;">18.8% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with ARCH<sup>(4)</sup></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">7,301,459</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 5pt;">5.8% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Entities Affiliated with Citadel<sup>(5)</sup></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">6,987,260</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 5pt;">5.4% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Directors and Named Executive Officers:<br/>
                  </div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D.<sup>(6)</sup></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">6,578,875</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 5pt;">5.0% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Linda C. Bain<sup>(7)</sup></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">146,666</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 17.5pt;">* </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Scott Biller, Ph.D.<sup>(8)</sup></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">331,342</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 17.5pt;">* </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Kevin Bitterman, Ph.D.</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 7.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">James Jeffrey Goater, Jr.</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 7.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Maria Koehler, M.D., Ph.D.<sup>(9)</sup></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">130,833</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 17.5pt;">* </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Matthew R. Patterson<sup>(10)</sup></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">984,967</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 17.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dominic Reynolds, Ph.D.<sup>(11)</sup></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">935,500</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 17.5pt;">* </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Michael Rome, Ph.D.</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 7.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Heather Wasserman, Ph.D.<sup>(12)</sup></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">1,607,106</span></div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 5pt;">1.3% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">All executive officers and directors as a group (12
                    persons)<sup>(13)</sup></div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">10,715,289</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.99pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 11.24pt; text-align: left;"><span style="padding-left: 5pt;">8.3%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 39.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 11.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents beneficial ownership of less than one percent of outstanding Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (A)(i) 483,500 shares of common stock held by The Column Group IV, LP (TCG IV); (ii) 9,196,872 shares of common stock
                    issuable upon conversion of Series&#160;Seed preferred stock held by TCG IV; (iii) 9,679,170 shares of common stock issuable upon conversion of Series&#160;A preferred stock held by TCG IV; (iv) 17,463,154 shares of common stock issuable upon
                    conversion of Series&#160;B preferred stock held by TCG IV; and (v) 1,364,695 shares of common stock issuable upon conversion of Series&#160;B warrants held by TCG IV; and (B)(i)&#160;16,500 shares of common stock held by The Column Group IV,-A, LP
                    (TCG IV-A); (ii) 313,854 shares of common stock issuable upon conversion of Series&#160;Seed preferred stock held by TCG IV-A; (iii) 330,313 shares of common stock issuable upon conversion of Series&#160;A preferred stock held by TCG IV-A; (iv)
                    595,949 shares of common stock issuable upon conversion of Series&#160;B preferred stock held by TCG IV-A; and (v) 46,570 shares of common stock issuable upon conversion of Series&#160;B warrants held by TCG IV-A. TCG IV and </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">318<br/>
        </div>

      </div>

    </div>

    <!--End Page 328-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 329-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_130-principal_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_ftnote" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; margin-top: 5.25pt; margin-left: 20pt; text-align: left;">TCG IV-A are venture capital investment entities. The Column Group IV GP, LP
            (TCG IV GP) is the general partner of each of TCG IV and TCG IV-A. Tim Kutzkey and Peter Svennilson are the managing partners of TCG IV GP and are engaged through venture capital investment entities in acquiring, holding and disposing of
            interests in various companies for investment purposes . The address of the entities affiliated with The Column Group is 1 Letterman Drive, Building D, San Francisco, CA, 94129. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (A)(i) 2,500,000 shares of common stock held by Atlas Venture Fund XI, L.P. (AVF XI); (ii) 8,453,979 shares of common
                    stock issuable upon conversion of Series&#160;Seed preferred stock held by AVF XI; (iii) 9,057,529 shares of common stock issuable upon conversion of Series&#160;A preferred stock held by AVF XI; (B)(i) 2,873,563 shares of common stock issuable
                    upon conversion of Series&#160;B preferred stock held by Atlas Venture Opportunity Fund I, L.P. (AVOF I); (C)(i) 7,293,928 shares of common stock issuable upon conversion of Series&#160;B preferred stock held by Atlas Venture Opportunity Fund II,
                    L.P. (AVOF II); and (ii) 820,573 shares of common stock issuable upon conversion of Series&#160;B warrants held by AVOF II. Atlas Venture Associates XI, L.P. (AVA XI LP) is the general partner of AVF XI and Atlas Venture Associates XI, LLC
                    (AVA XI LLC) is the general partner of AVA XI LP. Each of AVF XI, AVA XI LP and AVA XI LLC may be deemed to share voting and dispositive power over, and, may be deemed to beneficially own, the securities held by AVF XI. Kevin Bitterman,
                    Ph.D. is a member of AVA XI LLC and a member of our board of directors. Dr.&#160;Bitterman disclaims beneficial ownership of the securities held by AVF XI, except to the extent of his pecuniary interest therein, if any. Atlas Venture
                    Associates Opportunity I, L.P. (AVAO I LP) is the general partner of AVOF I, and Atlas Venture Associates Opportunity I, LLC (AVAO I LLC) is the general partner of AVAO I LP. Each of AVOF I, AVAO I LP and AVAO I LLC may be deemed to
                    share voting and dispositive power over, and may be deemed to beneficially own, the securities held by AVOF I. Dr.&#160;Bitterman is a member of AVAO I LLC and a member of our board of directors. Dr.&#160;Bitterman disclaims beneficial ownership
                    of the securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. Atlas Venture Associates Opportunity II, L.P. (AVAO II LP) is the general partner of AVOF II, and Atlas Venture Associates Opportunity II,
                    LLC (AVAO II LLC) is the general partner of AVAO II LP. Each of AVOF II, AVAO II LP, and AVAO II, LLC may be deemed to share voting and dispositive power over, and may be deemed to beneficially own, the securities held by AVOF II.
                    Dr.&#160;Bitterman is a member of AVAO II LLC and a member of our board of directors. Dr.&#160;Bitterman disclaims beneficial ownership of the securities owned by AVOF II, except to the extent of his pecuniary interest therein, if any. The
                    address for each of these entities and individuals is 300 Technology Square, 8th Floor, Cambridge, MA 02139. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (A)(i) 8,429,038 shares of common stock issuable upon conversion of Series&#160;A preferred stock held by Foresite Capital
                    Fund V, L.P. (Foresite Fund V); (ii) 7,990,419 shares of common stock issuable upon conversion of Series&#160;B preferred stock held by Foresite Fund&#160;V; (iii)&#160;363,763 shares of common stock issuable upon conversion of Series&#160;B warrants held
                    by Foresite Fund V; (B)(i) 3,574,840 shares of common stock issuable upon conversion of Series&#160;B preferred stock held by Foresite Capital Fund VI LP (Foresite Fund VI); (ii)&#160;234,893 shares of common stock issuable upon conversion of
                    Series&#160;B warrants held by Foresite Fund VI; (C)(i) 2,107,260 shares of common stock issuable upon conversion of Series&#160;A preferred stock held by Foresite Capital Opportunity Fund V, L.P. (Foresite Opportunity); (ii) 1,103,893 shares of
                    common stock issuable upon conversion of Series&#160;B preferred stock held by Foresite Opportunity; and (iii) 32,217 shares of common stock issuable upon conversion of Series&#160;B warrants held by Foresite Opportunity. Foresite Capital
                    Management V, LLC (FCM V) is the general partner of Foresite Fund V and may be deemed to have sole voting and dispositive power over the securities held by Foresite Fund V. Foresite Capital Management VI, LLC (FCM VI) is the general
                    partner of Foresite Fund VI and may be deemed to have sole voting and dispositive power over the securities held by Foresite Fund VI. Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Foresite Opportunity
                    and may be deemed to have sole voting and dispositive power over the shares held by Foresite Opportunity. James B. Tananbaum, M.D., is the sole managing member of FCM V, FCM VI, and FCOM V, and may be deemed to have sole voting and
                    dispositive power over the securities held by Foresite Fund V, Foresite Fund VI, and Foresite Opportunity, respectively. Each of Foresite Fund V, Foresite Fund VI, Foresite Opportunity, and Dr.&#160;Tananbaum disclaims beneficial ownership
                    of such securities except to the extent of its or his respective pecuniary interests therein. The principal business address of Dr.&#160;Tananbaum and each of the foregoing entities is 9200 Sunset Boulevard, PH1, West Hollywood, CA 90069. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 3,951,112 shares of common stock issuable upon conversion of Series&#160;A preferred stock held by ARCH Venture Fund XI,
                    L.P. (ARCH Fund XI); (ii) 3,157,101 shares of common stock issuable upon conversion of Series&#160;B preferred stock held by ARCH Fund XI; (iii) 193,246 shares of common stock issuable upon conversion of Series&#160;B warrants held by ARCH Fund
                    XI. ARCH Venture Partners XI, L.P. (&#8220;AVP XI LP&#8221;) is the sole general partner of ARCH Fund XI, and ARCH Venture Partners XI, LLC (&#8220;AVP XI LLC&#8221;) is the sole general partner of AVP XI LP, and each of them may be deemed to beneficially own
                    securities directly held of record by ARCH Fund XI. AVP XI LLC exercises voting and investment power through an investment committee comprised of Kristina M. Burow, Keith Crandell, Steven Gillis, and Robert Nelsen. The address for each
                    of these entities and individuals is c/o ARCH Venture Partners, 8755 West Higgins Road, Suite 1025, Chicago, IL 60631. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (A)(i) 1,853,849 shares of common stock issuable upon conversion of Series B preferred stock held by Citadel Credit
                    Master Fund LLC (&#8220;CMFC&#8221;); (ii) 344,139 shares of common stock issuable upon conversion of Series B warrants held by CMFC; and (B)(i)&#160;4,789,272&#160;shares of common stock issuable upon conversion of Series B preferred stock held by Citadel
                    Multi-Strategy Equities Master Fund Ltd (&#8220;CEMF&#8221;). Citadel Advisors LLC (&#8220;Citadel Advisors&#8221;) is the portfolio manager of CMFC and CEMF. Citadel Advisors Holdings LP (&#8220;CAH&#8221;) is the sole member of Citadel Advisors. Citadel GP LLC (&#8220;CGP&#8221;)
                    is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr. Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to
                    dispose or to direct the disposition of, the shares held by CMFC and CEMF. This response is not and shall not be construed as an admission that Mr. Griffin or any of the Citadel related entities listed above is the beneficial owner of
                    any securities of Remix other than the securities actually owned by such person (if any). The address of the entities affiliated with Citadel: c/o Citadel Enterprise Americas, 830 Brickell Plaza, Floor 15, Miami, FL 33131. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 1,486,610 shares of common stock held in the name of the Peter G. Smith 2023 Trust and (ii) 5,092,265 shares, held
                    in the name of Peter G. Smith, underlying options to purchase common stock that are exercisable within 60 days of June 30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 146,666 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 124,768 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 130,833 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 984,967 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 807,659 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 1,607,106 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(13)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 2,171,025 shares of common stock and (ii) 8,544,264 shares underlying options to purchase common stock that are
                    exercisable within 60 days of June&#160;30, 2026, by our directors and executive officers. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">319<br/>
        </div>

      </div>

    </div>

    <!--End Page 329-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 330-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_130-principal_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tPSC"><!--Anchor--></a>PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth information regarding beneficial ownership of the
            combined company&#8217;s capital stock immediately after consummation of the Merger and the Concurrent Financing, assuming the consummation of the Merger occurred as of June 30, 2026, by: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person, or group of affiliated persons, expected by Passage Bio and Remix to become the beneficial owners of more than 5%
                    of the combined company&#8217;s outstanding common stock; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person expected to be a director of the combined company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">each person expected to be a named executive officer of the combined company; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">all of the combined company&#8217;s expected executive officers and directors as a group. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The table lists applicable percentage ownership based on 42,426,611 shares of
            combined company common stock expected to be outstanding immediately following the consummation of the Merger, is based on Passage Bio&#8217;s and Remix&#8217;s capitalization as of June 30, 2026, prior to giving effect to the proposed reverse stock split
            of Passage Bio Common Stock and assumes (i) no exercise of outstanding options to purchase shares of Remix Common Stock, outstanding options to purchase Passage Bio Common Stock prior to the Closing and (ii) the Closing on June 30, 2026.
            Immediately after the Closing, under the Merger Exchange Ratio and Concurrent Financing Exchange Ratio formulas in the Merger Agreement, pre-Merger equityholders of Remix (other than Investors in the Concurrent Financing) are expected to own
            approximately 65% of the combined company, pre-Merger equityholders of Passage Bio are expected to own approximately 6% of the combined company and the Investors in the Concurrent Financing are expected to own approximately 29% of the combined
            company (assuming a Concurrent Financing of $100.0&#160;million), in each case, calculated on a fully diluted basis, using the treasury stock method, and subject to certain assumptions, including (a) a valuation for Passage Bio of approximately
            $20.0&#160;million (assuming Passage Bio Net Cash of $5.0 million as of the Closing), (b) a fixed valuation for Remix of $226.0&#160;million, (c)&#160;proceeds from the Concurrent Financing of $100 million and (d) the relative capitalization of Passage Bio
            and Remix. The table below assumes that the Exchange Ratio is estimated to be approximately 0.1734 shares of Passage Bio Common Stock for each share of Remix Common Stock, prior to giving effect to the proposed reverse stock split. The exchange
            ratio and the percentage of the combined company that each party&#8217;s equity holders will own following the Closing is subject to certain adjustments as described in the Merger Agreement, including the amount of the final Passage Bio Net Cash at
            Closing. There can be no assurances any of these assumptions will be accurate at the Closing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Beneficial ownership is determined in accordance with the rules of the SEC. These
            rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, the rules include shares of common stock issuable pursuant to the
            exercise of stock options that are either immediately exercisable or exercisable within 60 days after June 30, 2026. These securities are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of
            computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless otherwise indicated, Passage Bio and Remix believe based on information
            provided to Passage Bio and Remix, the persons or entities identified in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Except as otherwise noted below, the address for each person or entity listed in
            the table is c/o Remix Therapeutics, Inc., 400 Technology Square, Cambridge, MA 02139. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468.28pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME AND ADDRESS OF BENEFICIAL OWNER</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">NUMBER OF<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHARES<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BENEFICIALLY<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OWNED (#)<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OFFERING</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PERCENTAGE<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF SHARES<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BENEFICIALLY<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OWNED (%) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">5% or Greater Stockholders<br/>
                  </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Entities Affiliated with The Column Group<sup>(1)</sup></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.57pt; text-align: left;">10,674,425</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.32pt; text-align: left;">25.2% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Entities Affiliated with Atlas<sup>(2)</sup></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.57pt; text-align: left;"><span style="padding-left: 5pt;">6,965,033</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.32pt; text-align: left;">16.4 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Entities Affiliated with Foresite<sup>(3)</sup></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.57pt; text-align: left;"><span style="padding-left: 5pt;">6,724,045</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.32pt; text-align: left;">15.8 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Entities Affiliated with Decheng Capital<sup>(4)</sup></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.57pt; text-align: left;"><span style="padding-left: 5pt;">3,754,250</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.32pt; text-align: left;"><span style="padding-left: 5pt;">8.8</span> </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">320<br/>
        </div>

      </div>

    </div>

    <!--End Page 330-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 331-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_130-principal_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468.28pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">NAME AND ADDRESS OF BENEFICIAL OWNER</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">NUMBER OF<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHARES<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BENEFICIALLY<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OWNED (#)<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OFFERING</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">PERCENTAGE<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF SHARES<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">BENEFICIALLY<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">OWNED (%) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Named Executive Officers, Other Officers, and
                    Directors:<br/>
                  </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Peter G. Smith, Ph.D.<sup>(5)</sup></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;">1,140,697 </div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;">2.6% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Linda C. Bain<sup>(6)</sup></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 12.5pt;">25,430</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;"><span style="padding-left: 12.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Peter Colabuono</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;"><span style="padding-left: 12.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Scott Biller, Ph.D.<sup>(7)</sup></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 12.5pt;">57,451</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;"><span style="padding-left: 12.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Maria Koehler, M.D., Ph.D.<sup>(8)</sup></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 12.5pt;">22,685</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;"><span style="padding-left: 12.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Matthew R. Patterson<sup>(9)</sup></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 7.5pt;">170,781</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;"><span style="padding-left: 12.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Dominic Reynolds, Ph.D.<sup>(10)</sup></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 7.5pt;">162,204</span></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;"><span style="padding-left: 12.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Heather Wasserman, Ph.D.<sup>(11)</sup></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 7.5pt;">278,653</span></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;"><span style="padding-left: 12.5pt;">*</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">All current executive officers and directors as a group (12 persons)<sup>(12)</sup></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;">1,857,901</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.14pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.82pt; text-align: left;">4.7%</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 16pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Represents beneficial ownership of less than 1%. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 8,354,046 shares of common stock held by The Column Group IV, LP (TCG IV); (ii) 285,088 shares of common stock held
                    by The Column Group IV-A, LP (TCG IV-A) and (iii) 2,035,291 shares of common stock held by The Column Group Opportunity III, LP (TCG Opp III). TCG IV, TCG IV-A and TCG Opp III are venture capital investment entities. The Column Group IV
                    GP, LP (TCG IV GP) is the general partner of each of TCG IV and TCG IV-A, and The Column Group Opportunity III GP, LP (TCG Opp III GP) the general partner of TCG Opp III. Tim Kutzkey and Peter Svennilson are the managing partners of TCG
                    IV GP and TCGP Opp III GP and are engaged through venture capital investment entities in acquiring, holding and disposing of interests in various companies for investment purposes. The address of the entities affiliated with The Column
                    Group is 1 Letterman Drive, Building D, San Francisco, CA, 94129.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 3,469,752 shares of common stock held by Atlas Venture Fund XI, L.P. (AVF XI); (ii) 498,240 shares of common stock
                    held by Atlas Venture Opportunity Fund I, L.P. (AVOF I); (iii) 2,496,201 shares of common stock held by Atlas Venture Opportunity Fund II, L.P. (AVOF II) and (iv) 500,840 shares of common stock held by Atlas Venture Opportunity Fund
                    III, L.P. (AVOF III). Atlas Venture Associates XI, L.P. (AVA XI LP) is the general partner of AVF XI and Atlas Venture Associates XI, LLC (AVA XI LLC) is the general partner of AVA XI LP. Each of AVF XI, AVA XI LP and AVA XI LLC may be
                    deemed to share voting and dispositive power over, and, may be deemed to beneficially own, the securities held by AVF XI. Atlas Venture Associates Opportunity I, L.P. (AVAO I LP) is the general partner of AVOF I, and Atlas Venture
                    Associates Opportunity I, LLC (AVAO I LLC) is the general partner of AVAO I LP. Each of AVOF I, AVAO I LP and AVAO I LLC may be deemed to share voting and dispositive power over, and may be deemed to beneficially own, the securities
                    held by AVOF I. Atlas Venture Associates Opportunity II, L.P. (AVAO II LP) is the general partner of AVOF II, and Atlas Venture Associates Opportunity II, LLC (AVAO II LLC) is the general partner of AVAO II LP. Each of AVOF II, AVAO II
                    LP, and AVAO II LLC may be deemed to share voting and dispositive power over, and may be deemed to beneficially own, the securities held by AVOF II. Atlas Venture Associates Opportunity III, L.P. (AVAO III LP) is the general partner of
                    AVOF III, and Atlas Venture Associates Opportunity III, LLC (AVAO III LLC) is the general partner of AVAO III LP. Each of AVOF III, AVAO III LP, and AVAO III LLC may be deemed to share voting and dispositive power over, and may be
                    deemed to beneficially own, the securities held by AVOF II. The address for each of these entities and individuals is 300 Technology Square, 8th Floor, Cambridge, MA 02139.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 3,722,802 shares of common held by Foresite Capital Fund V, L.P. (Foresite Fund V); (ii) 2,444,470 shares of common
                    stock held by Foresite Capital Fund VI LP (Foresite Fund VI); and (iii) 556,774 shares of common stock held by Foresite Capital Opportunity Fund V, L.P. (Foresite Opportunity). Foresite Capital Management V, LLC (FCM V) is the general
                    partner of Foresite Fund V and may be deemed to have sole voting and dispositive power over the securities held by Foresite Fund V. Foresite Capital Management VI, LLC (FCM VI) is the general partner of Foresite Fund VI and may be
                    deemed to have sole voting and dispositive power over the securities held by Foresite Fund VI. Foresite Capital Opportunity Management V, LLC (FCOM V) is the general partner of Foresite Opportunity and may be deemed to have sole voting
                    and dispositive power over the shares held by Foresite Opportunity. James B. Tananbaum, M.D., is the sole managing member of FCM V, FCM VI, and FCOM V, and may be deemed to have sole voting and dispositive power over the securities held
                    by Foresite Fund V, Foresite Fund VI, and Foresite Opportunity, respectively. Each of Foresite Fund V, Foresite Fund VI, Foresite Opportunity, and Dr.&#160;Tananbaum disclaims beneficial ownership of such securities except to the extent of
                    its or his respective pecuniary interests therein. The principal business address of Dr.&#160;Tananbaum and each of the foregoing entities is 9200 Sunset Boulevard, PH1, West Hollywood, CA 90069.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 3,385,641 shares of common held by Decheng Capital Global Life Sciences Fund V, L.P. (Decheng Fund V)&#894; (ii) 221,163
                    shares of common stock held by Decheng Capital Global Life Sciences Fund VA, L.P. (Decheng Fund VA)&#894; and (iii) 147,445 shares of common stock held by Decheng Capital Global Life Sciences Fund VB, L.P. (Decheng Fund VB). Decheng Capital
                    Management V (Cayman), LLC (&#8220;Decheng GP V&#8221;) is the sole general partner of each of Decheng Fund V, Decheng Fund VA and Decheng Fund VB. Dr.&#160;Xiangmin Cui is the manager of Decheng GP V. The address of the entities affiliated with Decheng
                    is 3000 Sand Hill Road, Building 2, Suite 110, Menlo Park, CA 94025. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(5)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 257,663 shares of common stock held in the name of the Peter G. Smith 2023 Trust and (ii) 882,937 shares, held in
                    the name of Peter G. Smith, underlying options to purchase common stock that are exercisable within 60 days of June 30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(6)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 25,430 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(7)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 21,633 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(8)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 22,685 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(9)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 110,096 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(10)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 140,038 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026 </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(11)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes 278,653 shares underlying options to purchase common stock that are exercisable within 60 days of June&#160;30, 2026. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(12)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes (i) 376,429 shares of common stock and (ii) 1,481,472 shares underlying options to purchase common stock that are
                    exercisable within 60 days of June&#160;30, 2026, by our directors and executive officers.</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">321<br/>
        </div>

      </div>

    </div>

    <!--End Page 331-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 332-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_131-legal_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tLM"><!--Anchor--></a>LEGAL MATTERS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Fenwick &amp; West LLP, Seattle, Washington, will pass upon the validity of
            Passage Bio&#8217;s Common Stock offered by this proxy statement/prospectus. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; text-align: center;"><a id="tEXP"><!--Anchor--></a>EXPERTS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial statements of Passage Bio, Inc. as of December&#160;31, 2025 and 2024,
            and for the years then ended, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as
            experts in accounting and auditing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial statements of Remix Therapeutics, Inc. as of December 31, 2025 and
            2024, and for the years then ended, included in this Prospectus, have been audited by Deloitte &amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance
            upon the report of such firm given their authority as experts in accounting and auditing. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; text-align: center;"><a id="tCD2"><!--Anchor--></a>CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON
            ACCOUNTING AND <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">FINANCIAL DISCLOSURE </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On March&#160;3, 2026, Remix dismissed PricewaterhouseCoopers LLP (&#8220;PwC&#8221;) as its
            independent accountants. On May&#160;13, 2026, Remix engaged Deloitte &amp; Touche LLP as its independent registered public accounting firm for the fiscal years ended December&#160;31, 2025 and 2024. Remix&#8217;s board of directors approved the decision to
            change Remix&#8217;s independent registered public accounting firm. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The reports of PwC on Remix&#8217;s financial statements for the fiscal years ended
            December&#160;31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles, except for the explanatory paragraph about the substantial
            doubt about the Company's ability to continue as a going concern. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the fiscal years ended December&#160;31, 2024 and 2023 and the subsequent
            period through March&#160;3, 2026, there were no disagreements, as defined in Item&#160;304(a)(1)(iv) of Regulation S-K, between Remix and PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or
            procedure, which disagreements, if not resolved to PwC's satisfaction, would have caused PwC to make reference to the subject matter of the disagreements in connection with its reports on Remix&#8217;s financial statements for such fiscal years. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the fiscal years ended December&#160;31, 2024 and 2023 and the subsequent
            period through March&#160;3, 2026, there were no reportable events, as described in Item&#160;304(a)(1)(v) of Regulation S-K. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix provided PwC with a copy of the foregoing disclosures and requested a
            letter addressed to the SEC stating whether PwC agrees with the statements made by Remix in this section and, if not, stating the respects in which it does not agree. A copy of PwC's letter, dated July 21, 2026, is filed as Exhibit&#160;16.1 to the
            registration statement of which this proxy statement/prospectus forms a part. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">During the fiscal years ended December&#160;31, 2025 and 2024 and the subsequent
            period through May 13, 2026, neither Remix nor anyone acting on its behalf consulted with Deloitte &amp; Touche LLP regarding either: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the
            type of audit opinion that might be rendered on Remix&#8217;s financial statements, and neither a written report nor oral advice was provided to Remix by Deloitte &amp; Touche LLP that Deloitte &amp; Touche LLP concluded was an important factor
            considered by Remix in reaching a decision as to any accounting, auditing, or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as defined in Item&#160;304(a)(1)(iv) of Regulation S-K, or a reportable
            event, as described in Item&#160;304(a)(1)(v) of Regulation S-K. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; text-align: center;"><a id="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio is subject to the informational requirements of the Exchange Act and
            in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains Passage Bio&#8217;s filings as well as reports, proxy and
            information statements, and other information issuers file electronically with the SEC at www.sec.gov. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio also makes available free of charge on or through its website at
            www.passagebio.com, its Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and amendments to those </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">322<br/>
        </div>

      </div>

    </div>

    <!--End Page 332-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 333-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_131-legal_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange
            Act as soon as reasonably practicable after Passage Bio electronically files such material with or otherwise furnishes it to the SEC. The website addresses for the SEC and Passage Bio are inactive textual references and except as specifically
            incorporated by reference into this proxy statement/prospectus, information on or accessible from those websites is not part of this proxy statement/prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has filed with the SEC a registration statement on Form&#160;S-4, of which
            this proxy statement/prospectus is a part, under the Securities Act to register the shares of Passage Bio Common Stock to be issued to Remix stockholders in the Merger. This proxy statement/prospectus is a part of that registration statement
            and constitutes a prospectus of Passage Bio, as well as a proxy statement of Passage for its special meeting. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about
            Passage Bio and Passage Bio Common Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has supplied all information contained in this proxy
            statement/prospectus relating to Passage Bio and Remix has supplied all information contained in this proxy statement/prospectus relating to Remix. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If you would like to request documents from Passage Bio or Remix, please send a
            request in writing or by telephone to either Passage Bio or Remix at the following addresses: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Passage Bio, Inc.<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">P.O. Box 7, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Hopewell, New Jersey 08525<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attn: Kathleen Borthwick<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Email: kborthwick@passagebio.com</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Remix Therapeutics, Inc.100 Forge Road, Suite 400<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Watertown, MA 02472<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attn: Molly Heydt<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Email: mvonderheydt@remixtx.com</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio stockholders may submit a written request for a copy of Passage Bio&#8217;s
            most recently filed Annual Report on Form&#160;10-K to the above address or email address, which will be provided without charge. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If you are a Passage Bio stockholder and would like additional copies, without
            charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact Passage Bio&#8217;s proxy solicitor, &#8195;&#8195;&#8195;&#8195;, at the following address, telephone number or
            email&#160;address: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Call Toll Free:<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Email:</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">323<br/>
        </div>

      </div>

    </div>

    <!--End Page 333-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 334-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_132-stockholder_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tSPN"><!--Anchor--></a>STOCKHOLDER PROPOSALS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio special meeting is a special meeting of stockholders called
            solely for the purposes described in this proxy statement/prospectus. Business transacted at the Passage Bio special meeting is limited to the matters described in the notice of the meeting. Accordingly, stockholders may not present proposals
            or nominations for consideration at the Passage Bio special meeting. Stockholders who wish to submit proposals for nominations for inclusion in, or to be brought before, a future annual meeting of stockholders of Passage Bio, or, if the Merger
            has been consummated, the combined company, must comply with the applicable requirements of the SEC&#8217;s proxy rules and the then-governing bylaws of Passage Bio or the combined company, as applicable. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tSPN1"><!--Anchor--></a>Contacting the Passage Bio
            Board </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Stockholders wishing to communicate with the Passage Bio Board may do so by
            writing to the Passage Bio Board or to the non-employee members of the Passage Bio Board as a group, at: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">P.O. Box 7, Hopewell, New Jersey 08525 <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attention: Secretary </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The communication must prominently display the legend &#8220;BOARD COMMUNICATION&#8221; in
            order to indicate to the Secretary that it is a communication for Passage Bio Board. Upon receiving such a communication, the Secretary will promptly forward the communication to the relevant individual or group to which it is addressed.
            Certain items that are unrelated to the Passage Bio Board&#8217;s duties and responsibilities may be excluded, such as spam, junk mail and mass mailings, resumes and other forms of job inquiries, surveys and business solicitations or advertisements.
            The Secretary will not forward any communication determined in his good faith belief to be frivolous, unduly hostile, threatening, illegal or similarly unsuitable. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tSPN2"><!--Anchor--></a>Householding of Proxy
            Statement/Prospectus </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">SEC rules concerning the delivery of annual disclosure documents allow Passage
            Bio or your broker to send a single&#160;Notice of Proxy Materials or, if applicable, a single set of our proxy materials to any household at which two&#160;or more of our stockholders reside, if Passage Bio or your broker believes that the stockholders
            are members of the same family, unless Passage Bio or your broker has received contrary instructions from one or more of the stockholders. This practice, referred to as &#8220;householding,&#8221; benefits both you and Passage Bio. It reduces the volume of
            duplicate information received at your household and helps to reduce our expenses. The rule applies to Passage Bio&#8217;s Notices of Proxy Materials, annual reports, proxy statements and information statements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio will undertake to deliver promptly, upon written or oral request, a
            separate copy to a stockholder at a shared address to which a single copy of the Notice of Proxy Materials or proxy materials was delivered. You may make a written or oral request by sending a notification to Passage Bio&#8217;s Secretary at the
            address or telephone number above, providing your name, your shared address, and the address to which Passage Bio should direct the additional copy of the Notice of Proxy Materials or proxy materials. Multiple stockholders sharing an address
            who have received one copy of a mailing and would prefer Passage Bio to mail each stockholder a separate copy of future mailings should contact us at our principal executive offices. Additionally, if current stockholders with a shared address
            received multiple copies of a mailing and would prefer Passage Bio to mail one copy of future mailings to stockholders at the shared address, notification of that request may also be made through Passage Bio&#8217;s principal executive offices.
            Stockholders who participate in householding will continue to have access to and utilize separate proxy voting instructions. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"><a id="tSPN3"><!--Anchor--></a>Other Matters </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Passage Bio Board does not presently intend to bring any other business
            before the Passage Bio special meeting and, so far as is known to the Passage Bio Board, no matters are to be brought before the Passage Bio special meeting except as specified in the notice of the meeting. As to any business that may arise and
            properly come before the Passage Bio special meeting, however, it is intended that proxies, in the form enclosed, will be voted in respect thereof in accordance with the judgment of the persons voting such proxies. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">324<br/>
        </div>

      </div>

    </div>

    <!--End Page 334-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 335-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_200-fintoc_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tIFS"><!--Anchor--></a>PASSAGE BIO, INC.<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Index to Financial Statements </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Years ended December&#160;31, 2025 and 2024 <br/>
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Financial Statements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 432pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.44pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRO">Report of Independent Registered Public Accounting Firm</a></div>
                </td>

    <td style="width: 9.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.44pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.28pt; text-align: left;"><a href="#tRO">F-2 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tBS">Balance Sheets</a></div>
                </td>

    <td style="width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.28pt; text-align: left;"><a href="#tBS">F-4 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSO">Statements of Operations and Comprehensive Loss</a></div>
                </td>

    <td style="width: 9.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.28pt; text-align: left;"><a href="#tSO">F-5 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSE">Statements of Stockholders&#8217; Equity</a></div>
                </td>

    <td style="width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.28pt; text-align: left;"><a href="#tSE">F-6 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCF">Statements of Cash Flows</a></div>
                </td>

    <td style="width: 9.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.44pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.28pt; text-align: left;"><a href="#tCF">F-7</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNF">Notes to the Financial Statements</a></div>
                </td>

    <td style="width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.44pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.28pt; text-align: left;"><a href="#tNF">F-8</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 16.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Three Months Ended March&#160;31, 2026 and 2025<br/>
          </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Interim Financial Statements (unaudited)</div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 18.89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 432pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCBS1">Balance Sheets</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCBS1">F-29 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSO1">Statements of Operations and Comprehensive Loss</a></div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSO1">F-30 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSS1">Condensed Statements of Stockholders&#8217; Equity</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSS1">F-31 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSCF1">Statements of Cash Flows</a></div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSCF1">F-32</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNS1">Notes to Unaudited Interim Financial Statements</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tNS1">F-33</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 432pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 18.89pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">REMIX THERAPEUTICS, INC<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Index to Consolidated Financial Statements </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 18.89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 432pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRIR2">Report of Independent Registered Public Accounting Firm</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tRIR2">F-49</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCBS2">Consolidated Balance Sheets as of December 31, 2025 and
                      2024</a></div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCBS2">F-50</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSO2">Consolidated Statements of
                      Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSO2">F-51</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSC2">Consolidated Statements of
                      Convertible Preferred Stock and Stockholders&#8217; Deficit for the years ended December 31, 2025 and 2024</a></div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSC2">F-52</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSCF2">Consolidated Statements of Cash Flows for the years
                      ended December 31, 2025 and 2024</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSCF2">F-53</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNCF2">Notes to Consolidated Financial Statements </a></div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tNCF2">F-54</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 18.89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Index to Interim Financial Statements (Unaudited) </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 432pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 18.89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 432pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCBS3">Consolidated Balance Sheets as of March 31, 2026 and
                      December 31, 2025</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCBS3">F-85 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSO3">Consolidated Statements of
                      Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025</a></div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSO3">F-86 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;"><a href="#tCSC3">Consolidated Statements of
                      Convertible Preferred Stock and Stockholders&#8217; Deficit for the three months ended March 31, 2026 and 2025</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSC3">F-87 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tCSCF3">Consolidated Statements of Cash Flows for the three
                      months ended March 31, 2026 and 2025</a></div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tCSCF3">F-88 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tNCFS3">Notes to Consolidated Financial Statements</a></div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 18.89pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#tNCFS3">F-89</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 432pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 18.89pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 335-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 336-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_201-fintab_pg1"><!--Anchor--></a> </div>

    <div><br/></div>

  </div>


  <div style="color: #000000;">
    <!--Begin Page 1-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">To the Stockholders and Board of Directors <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Bio, Inc.: </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Opinion on the Financial Statements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have audited the accompanying balance sheets of Passage Bio, Inc. (the
            Company) as of December 31, 2025 and 2024, the related statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our
            opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity
            with U.S. generally accepted accounting principles. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Basis for Opinion </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These financial statements are the responsibility of the Company&#8217;s management.
            Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be
            independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We conducted our audits in accordance with the standards of the PCAOB. Those
            standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
            engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on
            the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our audits included performing procedures to assess the risks of material
            misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
            statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
            reasonable basis for our opinion. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Critical Audit Matter </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The critical audit matter communicated below is a matter arising from the
            current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our
            especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
            matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Evaluation of long-lived assets for impairment </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As discussed in Notes 3 and 10 to the financial statements, the Company
            assesses long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets or the asset group may not be recoverable. The Company&#8217;s property and equipment, net, and right of use assets &#8211;
            operating leases as of December&#160;31, 2025 were $4.1&#160;million and $10.2&#160;million, respectively. The Company measures the recoverability of assets by comparing the carrying value of the asset groups to an estimate of the related total future
            undiscounted net cash flows. If an asset group&#8217;s carrying value is not recoverable through the related undiscounted net cash flows, the asset group is considered impaired. The Company measures the impairment by comparing the difference between
            the asset group&#8217;s carrying value and its fair value which is estimated using either an income approach based on the present value of estimated future cash flows or a market approach based on industry and economic conditions including estimates
            on prevailing prices and rates for similar assets. The approaches are asset group specific and may incorporate a number of market participant assumptions in assessing fair value including future growth rates, discount rates, and market
            activity. The Company recognized impairment charges for long-lived assets of $6.1&#160;million during the year ended December&#160;31, 2025. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 1-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 2-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_201-fintab_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">We identified the evaluation of the impairment of an asset group related to
            the Company&#8217;s laboratory space as a critical audit matter. Challenging auditor judgment, and specialized skills and knowledge, were required to evaluate certain assumptions used in the determination of the fair value of the asset group,
            including sublease market activity and the discount rate. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following are the primary procedures we performed to address this critical
            audit matter. We involved valuation professionals with specialized skills and knowledge, who assisted in 1) evaluating sublease market activity used in determining the fair value of the asset group by comparing it to publicly available market
            data and 2) evaluating the discount rate used by management by comparing it to a range of independently developed discount rates. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">/s/ KPMG LLP </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We have served as the Company&#8217;s auditor since 2019. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Philadelphia, Pennsylvania <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">March 3, 2026 </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 2-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 3-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_201-fintab_pg3"><!--Anchor--></a></div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_h1">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">Balance Sheets </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> </div>

          <table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 94.84pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 94.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands, except share and per share data)</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2025</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Assets </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Current assets: </div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Cash and cash equivalents</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_1608a05412ea4dcfa782e814b07711c0" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,303</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_c887f241d20b42e4842fde32f15fdeec" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,573</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Marketable securities</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" id="Fact_932e5c244e184316a00d9a8c5f1bb417" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" id="Fact_a9efeb9bd03544468507e2bbfec71a9c" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,183</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Prepaid expenses and other current assets</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_7595bec57fbd4f2aa92ef3b52ec406cb" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_08aecb5c3ddb49c487d64df757f3f8ab" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">838</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Prepaid research and development</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" id="Fact_d0ad8120e42f4be0941f0367112106ff" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" id="Fact_ceb698037e264f56ae704c081c1ce251" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,221</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total current assets</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_bd5b616bc58f44e0a45f8c10668f61db" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,762</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_dd563fcc23564cc79daacd759eeb53d1" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,815</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Property and equipment, net</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_627e3a4a24ce4afe83400c10dc3e8513" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,107</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_96e9dab067a54115ba48e73f570cba11" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,331</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Right of use assets - operating leases</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_cdbe7d439ca645639ee2df2f1c8bd1cb" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,168</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_1a518e77be6446a1bf351fa4bd6dafa7" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,803</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Other assets</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_85ea212a26e748698778280f5b9bebe4" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_10fe436b128d42af999dd28f6f10275f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">463</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total assets</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_0d661250bf4b42709dc40fe9672039f0" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,281</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_c0177b115ed84e48be6b7af8450e9114" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">102,412</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Liabilities and stockholders&#8217; equity </div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Current liabilities: </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Accounts payable</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 13.7pt;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_204590269fdb45e6a6a42eb1aa1585c4" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,113</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_7df1eab2688047f5aa99b51b2ecf7751" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">742</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_81c9a7f2a8d4476cbcd3040f5efb00af" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,653</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_ecef7056e5554435a6c65d1c01c976f6" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,707</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Non-refundable sublicense and transition services payments</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_13fbfe7cebc7454ca44bf6e069d34e16" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,750</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_abba2b3cb12f422a9654eb314307cd69" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,226</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Operating lease liabilities</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_4127d285dab44e44a70da091b2148f77" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,567</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_02900ee9c22b462fa2b245226ceac11b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,688</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total current liabilities</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_88cf06fcc7f7480b8e75088ece7312a0" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,083</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_03eb1fcb731942a29b52fc50291980c2" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,363</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Operating lease liabilities - noncurrent</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_77a1daa8c1794d9b930c47cc58e2b005" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,443</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_7a7f3494f7c148999a09e2e49a1527dd" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,788</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total liabilities</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_5d8722bf4ee54a89b635aa6b6e42c71c" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,526</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_4d807a3bc80a4eea969da57ecacf918f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,151</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Commitments and contingencies (note 11) </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara"><span style="-sec-ix-hidden:Fact_ddc4c321df544d6ab525cd8234db36c3"> </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara"><span style="-sec-ix-hidden:Fact_3ede8ec3df2f4c6594e8b1e4cf743bf7"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Stockholders&#8217; equity: </div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Preferred stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_7756d5f9acf4477a8751ae833c6643ec" contextRef="c20241231" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_ec60ab55909d4a1d82221e0ddb202020" contextRef="c20251231" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value: <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_6f5eb69035b4453ca3f0e5a7e537783e" contextRef="c20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_27a28f3217ac44a184949dba4d25804b" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span>
                    shares authorized; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_c73212cfb0024bf7bf71b8623aa0cc83" contextRef="c20241231" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_899857c6492a47bfb90aae6d82ea51f4" contextRef="c20241231" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_5c21a44574fb4ed8aa123d628d3fab54" contextRef="c20251231" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_036609dd09fe44dd8bfa8fa9b114633a" contextRef="c20251231" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at both December&#160;31, 2025 and December&#160;31, 2024</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"> <span style="padding-left: 30.83pt;"><span style="-sec-ix-hidden:Fact_84393bbafad4493585cb473ec6ceb36d">&#8212;</span></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;"><span style="-sec-ix-hidden:Fact_37943eae796244c0bb11517d9e8ac664">&#8212;</span> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_21ba0d99aa1b45e9a1eea27dbf435633" contextRef="c20241231" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_141128e9599e4fdd96a48127d0ffcdce" contextRef="c20251231" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value: <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_c22dc72a100e40b1b25e1a54924d9d39" contextRef="c20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_48a92c530fd14870a3ea35c1ae1153af" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span>
                    shares authorized; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_b7d573a085364ca0a22275f13b77b180" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_04d21bdb2dc14b7085638353903eb339" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,182,810</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at December&#160;31, 2025 and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_ff08e3e4c29749aa9c2a1e842e40492e" contextRef="c20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_b8709531b8b645c1aaae1bc0cebd42c3" contextRef="c20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,161,503</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at December&#160;31, 2024</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Additional paid-in capital</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_63230078ab2b43d28995e3f09acaab9a" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">723,512</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_ac81376ed19a46a8a1fbb2dc7b0c1e2d" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">720,488</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Accumulated other comprehensive income (loss)</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 35.83pt;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" id="Fact_ca7de7b76f14427a99a6590bd8e9b770" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Accumulated deficit</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_2bc83809162c4c0a9ea547e234dcdd8b" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">704,757</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_8176dd341744403ea8aa1f7d4eaa2330" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">659,235</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total stockholders&#8217; equity</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8730030a74b64b3d960eea44f723102c" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,755</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_638affc09ca846d59ba106a5d178ee04" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,261</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total liabilities and stockholders&#8217; equity</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_b274b32963b24a509563feeaeb248fba" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,281</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_252cf0467897495f952826583b0c7bb4" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">102,412</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">See accompanying notes to financial statements.<span style="font-style: normal;"> </span><br/>
        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 3-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 4-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_201-fintab_pg4"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Statements of Operations and Comprehensive Loss </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.5pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.5pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 105pt; white-space: nowrap;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.5pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 105pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands, except share and per share data)</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses: </div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 12.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_152b9f8606e3451da90114ba61b9c824" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,276</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 12.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_cf5cc5abdbe248a68680d95ce80edf07" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,179</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_ad5478d6f1ec458689aba63a402c2b93" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,875</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_107e8dc38be4437e80aa6092b76d72b0" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,988</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_2b550ea33ac34914bb0b26b232e55242" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,145</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_194cf261268c421b8e086fef65ef1dad" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,233</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_f7afedf0f469436898bcbbda7258cb15" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">49,296</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_f34738da80d54c50920d17d3eed093dc" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">70,400</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_7ca418cbf4164f679473fefcde6d7453" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,774</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_b683c0823d2946dea0db014a6fb9936f" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,633</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_adf4a316455f4aa99e1bab94fb47a632" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,522</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_1f95564c1cc04578954b9ea6380dffe0" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,767</ix:nonFraction>)</span><span style="padding-bottom: 0.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Per share information: </div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share of common stock, basic and diluted</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_444734cc52454f7eb7131f3c321288c3" contextRef="c20250101to20251231" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_10e43fef19104c41b83c347cb26e465f" contextRef="c20250101to20251231" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">14.35</ix:nonFraction></ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_7dfe283d90164b1d80b51eebea8a1387" contextRef="c20240101to20241231" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_2583a5c42d0f4733b579cce8ed584519" contextRef="c20240101to20241231" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">21.04</ix:nonFraction></ix:nonFraction>)</span><span style="padding-bottom: 0.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted average common shares outstanding, basic and diluted</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_b30d5e9d70c04ba899076b0be6d0f3fa" contextRef="c20250101to20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_2b4da21d98874ff7af659a0cdf31f0d7" contextRef="c20250101to20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,172,870</ix:nonFraction></ix:nonFraction> </span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_89157f08401b4345bacd39daeb5d4f76" contextRef="c20240101to20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_5f842b8a289947de888145d47b6afe89" contextRef="c20240101to20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,078,665</ix:nonFraction></ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Comprehensive loss: </div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 9.17pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e23c12f7454a4a9390b302cf54bcedfc" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,522</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 9.17pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_39f73fe0e5f4468d8984a46d75addf5a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,767</ix:nonFraction>) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unrealized gain (loss) on marketable securities</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_0b2376cfa19a4fe69448001379f72ea1" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_6ab96f57709b4d27979374478f317ba0" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Comprehensive loss</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_4f1f79b7febe409586084ca60b899653" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,530</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_af1b4475a9744533b51ffac3384b901c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,716</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">See accompanying notes to financial statements.<span style="font-style: normal;"> </span><br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 4-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 5-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_201-fintab_pg5"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Statements of Stockholders&#8217; Equity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 72.53pt; white-space: nowrap;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.56pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 97.16pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45.32pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.76pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.27pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 72.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common stock</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 49.56pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">paid-in capital</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 97.16pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated other </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">comprehensive income (loss)</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 45.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">deficit</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 36.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands, except share data)</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div>
                </td>

    <td style="width: 2.27pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at January&#160;1, 2024</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a34defea973d4aa68f42f4eaf5e73d07" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">2,805,618</ix:nonFraction></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_65496520abe94d8abf0286bab1029424" contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">705,794</ix:nonFraction></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_50bf9694df9a4c4e80385630d7e6e2d0" contextRef="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">43</ix:nonFraction>)</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_60391dabfafb4c9989f1c6c69dfa057b" contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">594,468</ix:nonFraction>)</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e6aa24ad461a4aadb5feaa808bbaf4b7" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,283</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Issuance of common stock under the ATM Facility, net
                    of offering costs</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 7.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_1f667ded66324aeb85e18433a62f827b" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_fc1ce62aa5a0487db42ff7c8a7da6974" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,742</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;"><span style="padding-left: 8.33pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.26pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_f94f436125ea49d08fe82e361ad8a679" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,742</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Exercise of stock options and vesting of restricted
                    stock units</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_452d01bc1f9e45f499ce72828cf6e6f5" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">45,649</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><span style="padding-left: 27.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" id="Fact_6fe5c5a475894cd0af807450ef5e9f41" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;"><span style="padding-left: 8.33pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 26.76pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" id="Fact_15320d855b9c4a3a9a94dc82c08e87a8" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Issuance of shares in connection with employee stock
                    purchase plan</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" id="Fact_9373b5469599456fb38a52263a12e19a" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">10,236</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><span style="padding-left: 27.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_65f5932f1cb442c5a80b0edabed5c971" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;"><span style="padding-left: 8.33pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 26.76pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_c66ef19f593b404baf66ca2659aadb7a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Unrealized gain (loss) on marketable securities</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_0be72dfdd3324caf9485065ba8eedb7b" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 26.76pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_12b414ab1883475685dab18aa25839c1" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Share-based compensation expense</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_7334c3efca9f482c81f7c7cc0c72efcd" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,820</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;"><span style="padding-left: 8.33pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.26pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_c5e40ed208f64f8e84ac6e8cb3c7d189" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,820</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c1c30a57d58f4f3eac7cc34c6a75e746" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,767</ix:nonFraction>) </div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_84e429571b1e4de9944a5837bc90d96d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,767</ix:nonFraction>)<span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2024</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_89918d7417c042689bc54daef89e6352" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,161,503</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.02pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_71ecde895d9c4d7da56053511dc8eeaa" contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">720,488</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 39.41pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d868233e309743c4a1896e9e635a5b42" contextRef="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2449be1a21224d3cb4682503a8359ca8" contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">659,235</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.76pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 4.26pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_74103f990f3449c984e237a86d71acf9" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,261</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 97.16pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.27pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 72.69pt; white-space: nowrap;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.56pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 97.15pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45.31pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 72.69pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common stock</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 49.56pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">paid-in capital</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 97.15pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated other </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">comprehensive income (loss)</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 45.31pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">deficit</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands, except share data)</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at January&#160;1, 2025</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_b14fe65c2cbd41f6be807c9e12575aa7" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,161,503</ix:nonFraction></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3b73ad9b2e664aaeb020262d34088a9e" contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">720,488</ix:nonFraction></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_a6bae5f10dd14a768c564e731dd3b5f2" contextRef="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_964b441779c5454b9304903f2c4d1bdf" contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">659,235</ix:nonFraction>)</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: right;">$<span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2c9af7fc267a430f9f6ccc6b31767dcf" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,261</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Exercise of stock options and vesting of restricted
                    stock units</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 12.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_fb70c5bc997a4e05afd5d1712f86c739" contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">16,825</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: right;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Issuance of shares in connection with employee stock
                    purchase plan</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" id="Fact_fc67e7011e4a4e5cb70b104a2cab3f32" contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">4,482</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;"><span style="padding-left: 27.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_db5811826d7c47dca294259a5925cbed" contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: right;"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" id="Fact_31111d30bf744add98f7897032f27001" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Unrealized gain (loss) on marketable securities</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;"><span style="padding-left: 6.67pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_051efc7b99c84e4abe5dd9a09d8c87d2" contextRef="c20250101to20251231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: right;"><span style="padding-left: 27.5pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_b0e331e67d6647fc92d05f71ea53867a" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Share-based compensation expense</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_a58377578ff94c1c84013c6c00a2ab59" contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: right;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_4ba3e4e3451b4fe1b77caf3e96907f5e" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d70dd6b7e100432f8f93335e200e3a46" contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,522</ix:nonFraction>) </div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b875eb6a46f44d32b064ebbed261f3e0" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,522</ix:nonFraction>)<span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_2f449928750144d5a4c4477853b5d8fe" contextRef="c20251231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,182,810</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_7eee63aa4df94b019d12d82b4bae5ce1" contextRef="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">723,512</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1cfa13f645044718adfcf7db6303f68a" contextRef="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">704,757</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: right;"><span style="border-bottom: 3pt double rgb(0, 0, 0); padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double rgb(0, 0, 0); padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_07b47e8838354d66b93583d808a45592" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,755</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.99pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 97.15pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.31pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">See accompanying notes to financial statements.<span style="font-style: normal;"> </span><br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 5-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 6-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_201-fintab_pg6"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Statements of Cash Flows </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 368pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 91.29pt; white-space: nowrap;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 368pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 91.29pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 368pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 4.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 4.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows used in operating activities: </div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;">$(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cb4f4c506f794cf3873d8c0208fd4179" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,522</ix:nonFraction>)</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;">$<span style="padding-left: 1.67pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ab27a0316591466ebdce43df513aa4ae" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,767</ix:nonFraction>) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to reconcile net loss to net cash provided by (used in)
                    operating activities: </div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_6569275f3381453c8966ffaf82489b57" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">728</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_1335e44ed8c34a779b7ac363b0bf4681" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,081</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_96cb8cbe4d0746a2bdb8910559ccdb5b" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_93a7e33dfc574f9892c2ae1de1ae7dcc" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,820</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Amortization of premium and discount on marketable securities, net</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_b6ea1a19e0054b039dd59ca6aaae4cf1" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 11.67pt;">(<ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_792a54745cd640b2af8653609bdf8825" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,527</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_7d23d03bbb8e402d8dde73fd57ec8acf" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,145</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_90bea641633149b09db39bb2238357f8" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,233</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other non-cash items</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:OtherNoncashExpense" id="Fact_6912bfc5ba794f86a384bf0e9c3e2d84" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities: </div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid expenses and other current assets, and other assets</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_64e8208d53334d408177a6f428325a35" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">228</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 22.5pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_881435f1a7b84965a4febb2659f490c0" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">255</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid research and development</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" id="Fact_86f0714dce8a48178802f0cabf119338" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">391</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" id="Fact_0db1f77eaf284505a5e8a00fdcc6b471" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,521</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Non-refundable sublicense and transition services payments received</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" id="Fact_a6a6856d609b40469d4529cc26907148" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,015</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" id="Fact_d9438c1b68674fc38e12611de7ada864" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,226</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Right of use assets and operating lease liabilities</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 17.5pt;">(<ix:nonFraction name="pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" id="Fact_73538a4e663a4df8819aa51be0bc7ab4" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">464</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 19.17pt;">(<ix:nonFraction name="pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" id="Fact_22f4d662f62842d884d754c7b252eb1b" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">279</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" id="Fact_69f7b75d3f2f4657b4f780c7fe1fa517" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,880</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 19.17pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" id="Fact_6ed04e427b6040078b6acfbc61f3ae0c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">556</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_72c767f143cf470380294b05cb793b37" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,054</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 11.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_c704a975ea5b4e1f928a26e2ae335a6e" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,963</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in) operating activities</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_df41db104f0f4bb8a6074da2f2b6a2a4" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31,509</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_d94245b660ea4885b885556d04719692" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,956</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows provided by (used in) investing activities: </div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Purchases of marketable securities</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 6.67pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" id="Fact_49d805c50d4a44aaa7d7a6c4dc36bccb" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,170</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Sales or maturities of marketable securities</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" id="Fact_c28d788ac38846cab526a5da130015ec" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,046</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" id="Fact_f8c72b78f63f461492437d072cbe9791" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143,150</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Purchases of property and equipment and other assets</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 24.17pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" id="Fact_60d4f77aec614d5f86059003f182ef4f" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Sales of property and equipment and other assets</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" id="Fact_ecd268bca1cd4506b093957a06d7fb27" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,170</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in) investing activities</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_5747e2f331ef4f0c96d9eb9ea4958e08" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,216</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_f98dca241c8247a08116c3e606423f4c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,946</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows provided by (used in) financing activities: </div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from issuance of common stock under the ATM Facility, net of
                    offering costs</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" id="Fact_2db2fb3eb58c476e8e935e22e04c3c57" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,742</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from the exercise of stock options</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 27.5pt;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_b3e2dcb1345c4f1881cc3dec6d5f9024" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">35</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Proceeds from the issuance of common stock under employee stock purchase
                    plan</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" id="Fact_0cd0c1044c254467a99ca91631c9466b" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ProceedsFromStockPlans" id="Fact_98fb95edf9574e62b758f13e2e607ee5" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in) financing activities</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_944d7f84956441dfa90e21431440f18a" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_d3ba1b87ca4946d8b341f5c4d8b43e34" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,874</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase (decrease) in cash and cash equivalents</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_c368a82784ba4993ba587171a1b4c85c" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,730</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_844ec8b1e4eb4ba4924c19ccf57c5a93" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,864</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of year</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_3c721680743e4495bbf4f8bcda77b31c" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,573</ix:nonFraction> </span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_5ae862670ac148cca4413db950840f6e" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,709</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of year</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_aa676b4407c845dfb10172a8f108b345" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,303</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_9179363e8d6446cca876933ff661e101" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,573</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental disclosure of non-cash activities: </div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unrealized gain (loss) on marketable securities</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" id="Fact_970b25ce13e9477cafb094a4ed97725b" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" id="Fact_81e4e0f180b0406d99e1905ae83bf1ce" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right of use assets recognized upon the commencement of sublease</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_9311ef85c6e14343acaa11187fb3a4fc" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">422</ix:nonFraction>)</span><span style="padding-bottom: 0.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 368pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liabilities recognized upon the commencement of sublease</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.31pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.12pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="pasg:OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" id="Fact_7e116678a10c4814a0d0cdc8e72141df" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">422</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 368pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 42.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">See accompanying notes to financial statements.<span style="font-style: normal;"> </span><br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 6-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 7-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg1"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_h1">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">Notes to Financial Statements </div>


          <ix:nonNumeric name="us-gaap:NatureOfOperations" id="Text_e1ee21d341264b828ba139f91408ccd2" contextRef="c20250101to20251231" escape="true" continuedAt="Text_1647c40b1c544b3db59ec5d46287640b1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">1. Nature of Operations </div>
</ix:nonNumeric>
          <ix:continuation id="Text_1647c40b1c544b3db59ec5d46287640b1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#8217;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#8217;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-<span style="font-style: italic;">GRN</span>,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="pasg:RisksAndLiquidityTextBlock" id="Text_f57d5e5afeca418eb7fd8408a6796027" contextRef="c20250101to20251231" escape="true" continuedAt="Text_ea38cb609b124d009c2b936fc1510f541">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">2. Risks and Liquidity </div>
</ix:nonNumeric>
          <ix:continuation id="Text_ea38cb609b124d009c2b936fc1510f541" continuedAt="Text_ea38cb609b124d009c2b936fc1510f542">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_6cba1d7c84034023918e592f1853c1a1" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">704.8</ix:nonFraction> million as of December 31, 2025. The Company anticipates
            incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop
            its product candidates. </div>
</ix:continuation>
          <ix:continuation id="Text_ea38cb609b124d009c2b936fc1510f542" continuedAt="Text_ea38cb609b124d009c2b936fc1510f543">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company&#8217;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div>
</ix:continuation>
          <ix:continuation id="Text_ea38cb609b124d009c2b936fc1510f543" continuedAt="Text_ea38cb609b124d009c2b936fc1510f544">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_7b54d3222ec14b829d5c16a073d7a766" contextRef="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">125.0</ix:nonFraction> million through Cowen, as sales agent in the ATM Facility. The Company
            issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_82abdd0edae4439795aa7abd514c3334" contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction> shares of its common stock under the ATM Facility, resulting in net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_928b13df4d8e4c63bbf38e4d4a9112f6" contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.7</ix:nonFraction> million, after deducting offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_6732f9d7795f4da9ac65de4ef7065a4f" contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>
            million in March&#160;2024. The Company is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on
            March&#160;5, 2025. </div>
</ix:continuation>
          <ix:continuation id="Text_ea38cb609b124d009c2b936fc1510f544" continuedAt="Text_ea38cb609b124d009c2b936fc1510f545">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company plans to seek additional funding through public or private equity
            offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances
            or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding or prospects of funding are unfavorable,
            the Company could be required to further delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div>
</ix:continuation>
          <ix:continuation id="Text_ea38cb609b124d009c2b936fc1510f545">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">In accordance with the Financial Accounting Standards Board&#8217;s, or FASB,
            Accounting Standards Codification, or ASC, Topic 205-40, <span style="font-style: italic;">Presentation of Financial Statements &#8211; Going Concern</span>, the Company has evaluated whether there are certain conditions and events, considered in
            the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company
            expects that its cash and cash equivalents will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these financial statements. </div>
</ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 7-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 8-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg2"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_9cb80479c5684973813880a1aaf5bb69" contextRef="c20250101to20251231" escape="true" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d61">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">3. Summary of Significant Accounting Policies </div>
</ix:nonNumeric>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d61" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d62"><ix:nonNumeric name="pasg:BasisOfPresentationPolicyTextBlock" id="Text_ce43ed643c64417cbffdfc18a128623c" contextRef="c20250101to20251231" escape="true" continuedAt="Text_6b7424a886b84d6284c85495c1d57cd51">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Basis of Presentation </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d62" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d63"><ix:continuation id="Text_6b7424a886b84d6284c85495c1d57cd51" continuedAt="Text_6b7424a886b84d6284c85495c1d57cd52">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The accompanying financial statements have been prepared in accordance with
            generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP&#160;as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d63" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d64"><ix:continuation id="Text_6b7424a886b84d6284c85495c1d57cd52">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_87ff84423c1d4358a1dd1652b1ad4132">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" id="Fact_419ff5da80084795bfee3f8abba8b05d" contextRef="c20250714to20250714" unitRef="U003" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of shares of Common
            Stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity, have been adjusted
            retroactively to reflect the Reverse Stock Split for all periods presented. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d64" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d65"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_336ce045db334f54b2124a91e296d99b" contextRef="c20250101to20251231" escape="true" continuedAt="Text_3e3562bee48e4a54abeb37c3f722cb641">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Use of Estimates </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d65" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d66"><ix:continuation id="Text_3e3562bee48e4a54abeb37c3f722cb641" continuedAt="Text_3e3562bee48e4a54abeb37c3f722cb642">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d66" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d67"><ix:continuation id="Text_3e3562bee48e4a54abeb37c3f722cb642">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d67" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d68"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_5c0187fade50459fb24e02190d3ceef2" contextRef="c20250101to20251231" escape="true" continuedAt="Text_e330abf0a7f54c74b1c47833d589ebb41">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Fair Value of Financial Instruments </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_e330abf0a7f54c74b1c47833d589ebb41"><ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d68" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d69">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d69" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d610"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="Text_d4d0fe9c4ed84af6beaa831961870d13" contextRef="c20250101to20251231" escape="true" continuedAt="Text_f5604ccd45e346bfb0ad236443d99d261">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Concentration of Credit Risk </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d610" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d611"><ix:continuation id="Text_f5604ccd45e346bfb0ad236443d99d261">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which dictates the allocation of funds within its portfolio of money market funds. The Company has
            not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money market funds. </div>
</ix:continuation></ix:continuation>


          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d611" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d612"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_e8f6a9cafd72470984a70fe4b7f6b488" contextRef="c20250101to20251231" escape="true" continuedAt="Text_885f875ade6342d3bf6750e723eba3f81">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Cash and Cash Equivalents </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d612" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d613"><ix:continuation id="Text_885f875ade6342d3bf6750e723eba3f81">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of December 31, 2025 consisted of money market funds. Cash consists of cash deposits at banking institutions. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d613" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d614"><ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" id="Text_8255baa722d944b49918c420a2872198" contextRef="c20250101to20251231" escape="true" continuedAt="Text_20db786475294a8a8f21a198310ca9b41">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Marketable Securities </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d614" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d615"><ix:continuation id="Text_20db786475294a8a8f21a198310ca9b41">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. The Company held <ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" id="Fact_ebef65929cfb43208e94ce483dbcd85a" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> marketable securities as of December 31, 2025. Marketable
            securities as of December 31, 2024 consisted of various securities as described in Note&#160;4. Marketable securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other
            comprehensive income (loss) within stockholders&#8217; equity. Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable
            securities sold are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund
            operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet. </div>
</ix:continuation></ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 8-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 9-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d615" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d616"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Text_42dd64e891964538aa09f73b8715a6d2" contextRef="c20250101to20251231" escape="true" continuedAt="Text_d8e3ea8ef44a4e20952e169cb4c7b33a1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Property and Equipment, Net </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d616" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d617"><ix:continuation id="Text_d8e3ea8ef44a4e20952e169cb4c7b33a1" continuedAt="Text_d8e3ea8ef44a4e20952e169cb4c7b33a2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_474247f28f1d460d8ec86fcd1e76c30c" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric> for computer hardware and software, <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_f54daa09bbfb48d0b0bca8fb1252a407" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> for office
            equipment, <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_3d8577570d664890aa67c4aa76c2c2e9" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> for laboratory equipment, and <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_348877d82be34e77be502204cab78717" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric> for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d617" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d618"><ix:continuation id="Text_d8e3ea8ef44a4e20952e169cb4c7b33a2" continuedAt="Text_d8e3ea8ef44a4e20952e169cb4c7b33a3">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. The Company recognized de minimis losses on disposals of property and equipment for the year ended
            December 31, 2025. The Company did <ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" id="Fact_3874194f809e4db8860eca77b2f3b14a" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="5" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any losses on disposals of property and equipment for the year ended December 31,
            2024. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d618" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d619"><ix:continuation id="Text_d8e3ea8ef44a4e20952e169cb4c7b33a3" continuedAt="Text_d8e3ea8ef44a4e20952e169cb4c7b33a4">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company recognized impairment expenses for property and equipment of $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_2ac3d5614881474a9ec01ca06c7c8f23" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million for the year ended December 31, 2025, $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_292fc42baece40d3939aa7de9d46cdcf" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>
            million of which was for lab equipment, $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_fd01ce4d433044e09d336faa10531aff" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> of which was for leasehold improvements, and $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_f3616a53216e424ca8c88038595c16f9" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million of which was for certain other assets. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d619" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d620"><ix:continuation id="Text_d8e3ea8ef44a4e20952e169cb4c7b33a4" continuedAt="Text_d8e3ea8ef44a4e20952e169cb4c7b33a5">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">As a result of the Company&#8217;s January&#160;2025 announcement to reduce its overall
            workforce and cease its lab operations, the Company reassessed asset groups at its lab in Hopewell, New Jersey, and evaluated such asset groups for impairment under FASB ASC Topic 360, <span style="font-style: italic;">Long-lived assets:
              Impairment or disposal of long-lived assets</span>. The Company determined the laboratory equipment was a separate asset group based on management&#8217;s implemented plans to sell the laboratory equipment and estimated the fair value of the
            laboratory equipment based on the estimated future cash flows from the sale of such equipment, resulting in impairment of laboratory equipment and certain other assets of $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_d56e2fee856e44d1b52e2db326cd1cbd" contextRef="c20250101to20251231_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction> million. Subsequent to recording the impairment, the Company sold substantially all the laboratory equipment and certain other assets for $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" id="Fact_f94b37ce674245cba7f909c88351333e" contextRef="c20260101to20260131_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d620" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d621"><ix:continuation id="Text_d8e3ea8ef44a4e20952e169cb4c7b33a5" continuedAt="Text_d8e3ea8ef44a4e20952e169cb4c7b33a6">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement and an estimated market participant subtenant borrowing rate and compared that to the carrying value of the asset group, resulting in impairment to leasehold improvements of $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_865d0ec7e9c74958929153b0bc133c2b" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million. The impairment expense for the leasehold improvements relate to the proportional allocation of total impairment recognized for the asset group subject to
            impairment testing. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d621" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d622"><ix:continuation id="Text_d8e3ea8ef44a4e20952e169cb4c7b33a6">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company recognized impairment expenses for property and equipment and
            certain other assets of $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_d738b25b96e04d4b846f823b6400d717" contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction> million for the year ended December&#160;31, 2024, which primarily relates to the proportional allocation of
            total impairments recognized for asset groups subject to impairment testing as further described in Note&#160;10. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d622" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d623"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="Text_c8a01f07e1be44beb46247ce73c79d59" contextRef="c20250101to20251231" escape="true" continuedAt="Text_92294e9ab45d49f891960b87163798851">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Leasing </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d623" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d624"><ix:continuation id="Text_92294e9ab45d49f891960b87163798851" continuedAt="Text_92294e9ab45d49f891960b87163798852">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of December 31, 2025, the Company has classified all leases with terms greater than one year, as operating leases. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d624" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d625"><ix:continuation id="Text_92294e9ab45d49f891960b87163798852" continuedAt="Text_92294e9ab45d49f891960b87163798853">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>
</ix:continuation></ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 9-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 10-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d625" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d626"><ix:continuation id="Text_92294e9ab45d49f891960b87163798853">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company recognized impairment expenses for ROU assets of $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_23f6859a3fc345c0b43818d2955e1eb3" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_87d6ae83626d4885a57f2786ec3447bc" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction> million in the years ended December 31, 2025 and 2024,
            respectively. These impairment expenses include the proportional allocation of total impairments recognized for the asset groups subject to impairment testing as further described in Note&#160;10. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d626" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d627"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_93ac640af2c6454ba76a29c750a58c17" contextRef="c20250101to20251231" escape="true" continuedAt="Text_79f6a6ef73ac4f5f910232c2aca569e91">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Research and Development </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d627" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d628"><ix:continuation id="Text_79f6a6ef73ac4f5f910232c2aca569e91">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d628" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d629"><ix:nonNumeric name="pasg:OtherIncomeAndOtherExpensePolicyPolicyTextBlock" id="Text_2f702f06a54542a98f070865d1766077" contextRef="c20250101to20251231" escape="true" continuedAt="Text_ced6e8a05f82480eb68fb79e613153f11">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Other Income (Expense), Net </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d629" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d630"><ix:continuation id="Text_ced6e8a05f82480eb68fb79e613153f11" continuedAt="Text_ced6e8a05f82480eb68fb79e613153f12">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, income from subleases, and the sale of certain tax credits. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d630" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d631"><ix:continuation id="Text_ced6e8a05f82480eb68fb79e613153f12" continuedAt="Text_ced6e8a05f82480eb68fb79e613153f13">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company recorded $<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_f8d2d4098fea460fa3682f74e3de06f5" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.8</ix:nonFraction> million to other income (expense), net for the year ended December 31, 2025, which consisted of $<ix:nonFraction name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" id="Fact_2f46959b3ad94ae380462b8a0ec6e98d" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction> million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_d78f0a2470c442709a74eb4c4e134243" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction> million from sublease income. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d631" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d632"><ix:continuation id="Text_ced6e8a05f82480eb68fb79e613153f13">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company recorded $<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_a502ec31a7a84cd28b0a8415ebcf6ec9" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.6</ix:nonFraction> million to other income (expense), net for the year ended December 31, 2024, which consisted of $<ix:nonFraction name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" id="Fact_2a225adab2e34ccab3772e95498e2378" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.3</ix:nonFraction> million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities, $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_ca17523a8a6d4b30b60955350abbe144" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million from sublease income, and $<ix:nonFraction name="pasg:GainLossOnSaleOfTaxCredits" id="Fact_df4731bbc440490a81147559be1e19ad" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million related to the sale of
            certain tax credits. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d632" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d633"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_35a88f9995fb4176ab5854ea155965b1" contextRef="c20250101to20251231" escape="true" continuedAt="Text_e66c296a19094f3aa2109e4a2f9e1d551">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Share-Based Compensation </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d633" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d634"><ix:continuation id="Text_e66c296a19094f3aa2109e4a2f9e1d551" continuedAt="Text_e66c296a19094f3aa2109e4a2f9e1d552">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d634" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d635"><ix:continuation id="Text_e66c296a19094f3aa2109e4a2f9e1d552" continuedAt="Text_e66c296a19094f3aa2109e4a2f9e1d553">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d635" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d636"><ix:continuation id="Text_e66c296a19094f3aa2109e4a2f9e1d553" continuedAt="Text_e66c296a19094f3aa2109e4a2f9e1d554">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d636" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d637"><ix:continuation id="Text_e66c296a19094f3aa2109e4a2f9e1d554" continuedAt="Text_e66c296a19094f3aa2109e4a2f9e1d555">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The expected term of the stock options is estimated using the &#8220;simplified
            method,&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the
            midpoint between the vesting period and the contractual term of the option. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d637" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d638"><ix:continuation id="Text_e66c296a19094f3aa2109e4a2f9e1d555" continuedAt="Text_e66c296a19094f3aa2109e4a2f9e1d556">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">For stock price volatility, the Company uses a composite of comparable public
            company data as a basis for its expected volatility and considers the historic volatility of its common stock from its initial public offering to date to calculate the fair value of option grants. The selection of comparable public company data
            requires the application of management&#8217;s judgement. </div>
</ix:continuation></ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-11<br/>
        </div>

      </div>

    </div>

    <!--End Page 10-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 11-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d638" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d639"><ix:continuation id="Text_e66c296a19094f3aa2109e4a2f9e1d556">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d639" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d640"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Text_47115dbd2f2840328a5778ab75c9966d" contextRef="c20250101to20251231" escape="true" continuedAt="Text_6321ebef90a14687892425dc0b0a77f01">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">License and Other Revenue </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d640" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d641"><ix:continuation id="Text_6321ebef90a14687892425dc0b0a77f01" continuedAt="Text_6321ebef90a14687892425dc0b0a77f02">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company may enter into license agreements and transition services
            agreements (see Note&#160;8) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d641" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d642"><ix:continuation id="Text_6321ebef90a14687892425dc0b0a77f02" continuedAt="Text_6321ebef90a14687892425dc0b0a77f03">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue







              from Contracts with Customers</span>, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d642" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d643"><ix:continuation id="Text_6321ebef90a14687892425dc0b0a77f03" continuedAt="Text_6321ebef90a14687892425dc0b0a77f04">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d643" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d644"><ix:continuation id="Text_6321ebef90a14687892425dc0b0a77f04">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d644" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d645"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_631b0384b8b6447c896c5fdfef6402e2" contextRef="c20250101to20251231" escape="true" continuedAt="Text_6604b10ef8864cc6b7d92da08397e5a41">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Income Taxes </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d645" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d646"><ix:continuation id="Text_6604b10ef8864cc6b7d92da08397e5a41" continuedAt="Text_6604b10ef8864cc6b7d92da08397e5a42">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Income taxes are accounted for under the asset-and-liability method as
            required by FASB ASC Topic 740, <span style="font-style: italic;">Income Taxes</span>, or ASC 740. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
            carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
            the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period </div>
</ix:continuation></ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-12<br/>
        </div>

      </div>

    </div>

    <!--End Page 11-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 12-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d646" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d647"><ix:continuation id="Text_6604b10ef8864cc6b7d92da08397e5a42" continuedAt="Text_6604b10ef8864cc6b7d92da08397e5a43">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">corresponding to the enactment date. Under ASC 740, a valuation allowance is
            required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d647" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d648"><ix:continuation id="Text_6604b10ef8864cc6b7d92da08397e5a43">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">FASB ASC Subtopic 740-10, <span style="font-style: italic;">Accounting for
              Uncertainty of Income Taxes</span>, or ASC 740-10, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The
            Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax
            position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.
            In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income,
            net, within other income (expense), net. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d648" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d649"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_9a2490101f8e4e2cb8f6b23776bffbac" contextRef="c20250101to20251231" escape="true" continuedAt="Text_b0839426b9144f57b805b09da7af70841">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Net Loss Per Share </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d649" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d650"><ix:continuation id="Text_b0839426b9144f57b805b09da7af70841" continuedAt="Text_b0839426b9144f57b805b09da7af70842">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d650" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d651"><ix:continuation id="Text_b0839426b9144f57b805b09da7af70842" continuedAt="Text_b0839426b9144f57b805b09da7af70843">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d651" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d652"><ix:continuation id="Text_b0839426b9144f57b805b09da7af70843" continuedAt="Text_b0839426b9144f57b805b09da7af70844">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d652" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d653"><ix:continuation id="Text_b0839426b9144f57b805b09da7af70844"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_8ef8738e0bf44e4b9375fd93779f1b49" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Stock options</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_da6fd82c1f3b448498c155ac2f69157b" contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">658,973</ix:nonFraction></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_35444f43d93643288fa4cfc5cb99f803" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">577,581</ix:nonFraction></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Unvested restricted stock units</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_cc9c246d952c460aa3a2075eef3e1d3e" contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_988d3413b97b41daa83c3686b35e9e5f" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">7,093</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Employee stock purchase plan</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8c4f9c012f8743cd89eeeafe78fabcca" contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">696</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8d29dd197eb44968a4a7bd48d225284a" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">2,636</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_f355596633e145ef949ce883936b5eff" contextRef="c20250101to20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">709,669</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ff1f335ee6c44a5e871baaa89ab64454" contextRef="c20240101to20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">587,310</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation></ix:continuation>

          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d653" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d654"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_debea71f797f4c758a06b1580069d248" contextRef="c20250101to20251231" escape="true" continuedAt="Text_98f2e68141d04a599c4f79b9e1d8421c1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Recently Issued Accounting Pronouncements
            Not Yet Adopted </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d654" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d655"><ix:continuation id="Text_98f2e68141d04a599c4f79b9e1d8421c1" continuedAt="Text_98f2e68141d04a599c4f79b9e1d8421c2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income&#160;&#8211;&#160;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d655" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d656"><ix:continuation id="Text_98f2e68141d04a599c4f79b9e1d8421c2" continuedAt="Text_98f2e68141d04a599c4f79b9e1d8421c3">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed, and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d656" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d657"><ix:continuation id="Text_98f2e68141d04a599c4f79b9e1d8421c3" continuedAt="Text_98f2e68141d04a599c4f79b9e1d8421c4">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim </div>
</ix:continuation></ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-13<br/>
        </div>

      </div>

    </div>

    <!--End Page 12-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 13-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d657" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d658"><ix:continuation id="Text_98f2e68141d04a599c4f79b9e1d8421c4" continuedAt="Text_98f2e68141d04a599c4f79b9e1d8421c5">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">periods. ASU 2025-11 is effective for the Company for interim periods within
            annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement
            disclosures. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d658" continuedAt="Text_c4a42e6cd1a9445c989df014f41d49d659"><ix:continuation id="Text_98f2e68141d04a599c4f79b9e1d8421c5" continuedAt="Text_98f2e68141d04a599c4f79b9e1d8421c6">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Recently Adopted Accounting Pronouncements </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c4a42e6cd1a9445c989df014f41d49d659"><ix:continuation id="Text_98f2e68141d04a599c4f79b9e1d8421c6">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">In December&#160;2023, the FASB issued ASU No. 2023-09, <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>, or ASU 2023-09, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and
            income taxes paid. The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU&#160;are effective for annual periods beginning after December&#160;15, 2024 with
            early adoption permitted. The Company adopted this new accounting pronouncement retrospectively during the year ended December&#160;31, 2025. Refer to Note&#160;14 for additional disclosures. </div>
</ix:continuation></ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Text_0ebc5bbd31f14b0cb567f764a589206e" contextRef="c20250101to20251231" escape="true" continuedAt="Text_855b84fe6feb42bbbec591653224664a1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">4. Cash, Cash Equivalents, and Marketable Securities </div>
</ix:nonNumeric>
          <ix:continuation id="Text_855b84fe6feb42bbbec591653224664a1" continuedAt="Text_855b84fe6feb42bbbec591653224664a2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">The following table provides details regarding the Company&#8217;s portfolio of cash
            and cash equivalents: </div>
</ix:continuation>
          <ix:continuation id="Text_855b84fe6feb42bbbec591653224664a2" continuedAt="Text_855b84fe6feb42bbbec591653224664a3">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_855b84fe6feb42bbbec591653224664a3" continuedAt="Text_855b84fe6feb42bbbec591653224664a4"><ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Text_5024e8bfbd4444379e398e3a6e7def8c" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Cost or </div>
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Amortized cost</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Unrealized gains</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Unrealized losses</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">December&#160;31, 2025: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Cash accounts in banking institutions</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_a05bcf81049748999d8031ba613e1167" contextRef="c20251231_CashAndCashEquivalentsAxis_DemandDepositsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_e5c57736c32440c48ab37bcd654a067e" contextRef="c20251231_CashAndCashEquivalentsAxis_DemandDepositsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,500</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Money market funds</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_a6dc6c79dd6b4c44ba5664f05a4acb7d" contextRef="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,803</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_406fce4119f341cdb62e134aea895fa2" contextRef="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,803</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_f434cdf1cce145ba927efbe3c3f2a2d6" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,303</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_12c7e5164c214fde842ea44566e28142" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,303</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">December&#160;31, 2024: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Cash accounts in banking institutions</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_8ea2e8a91e2542f9924bec00fa76d020" contextRef="c20241231_CashAndCashEquivalentsAxis_DemandDepositsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,527</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_585c2f7f6b504ee28711325e28a23301" contextRef="c20241231_CashAndCashEquivalentsAxis_DemandDepositsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,527</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Money market funds</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_7fdf9dbd73d042e9a45238ff23fac95e" contextRef="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,058</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_19992400100445018c90b7b98c8c0f35" contextRef="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,058</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Commercial paper</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_3b203f93fa314d64baef6248c838c80b" contextRef="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,988</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_cf836b247437409283182761a1485421" contextRef="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,988</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_741c8f6707ad4ce6b47b947d5381a070" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,573</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_4ae10ababb2e46b4bc960eb6fa78fcdf" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,573</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 56.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_855b84fe6feb42bbbec591653224664a4" continuedAt="Text_855b84fe6feb42bbbec591653224664a5">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">The following table provides details regarding the Company&#8217;s portfolio of
            marketable securities: </div>
</ix:continuation>
          <ix:continuation id="Text_855b84fe6feb42bbbec591653224664a5" continuedAt="Text_855b84fe6feb42bbbec591653224664a6">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_855b84fe6feb42bbbec591653224664a6" continuedAt="Text_855b84fe6feb42bbbec591653224664a7"><ix:nonNumeric name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Text_240290ae2d0b4ecb8dbf65a9dd23d926" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Amortized cost</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Unrealized gains</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Unrealized losses</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">December&#160;31, 2025: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Certificates of deposit</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Commercial paper</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Corporate debt securities</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">U.S. government securities</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">December&#160;31, 2024: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Certificates of deposit</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_84d7be86d2f040d08e01cf83ba4ff3e8" contextRef="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,970</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_35e4035a7c414230aaa0b16097ecfd3d" contextRef="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_3b7e22efb5ba4e7baaeda0d664a34d55" contextRef="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,971</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Commercial paper</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_9c79dd73331d419681ae2b8aca19ef9e" contextRef="c20241231_FinancialInstrumentAxis_CommercialPaperMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,433</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_c8bfddd6d6fd45289dfaa9d736ad083e" contextRef="c20241231_FinancialInstrumentAxis_CommercialPaperMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_5160440ec6764c9a9deebfa9be5e8804" contextRef="c20241231_FinancialInstrumentAxis_CommercialPaperMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,439</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Corporate debt securities</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_4d4236fbcf2c4b35b62f1d85573dc05c" contextRef="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,864</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_1dc170488b4f4d5497b265a1be6d0cde" contextRef="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_71fbdeba7ba24be8bca6d5001179ace9" contextRef="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,865</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">U.S. government securities</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_f90153813c7f48c2a425952a10810047" contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,908</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_ae7da0a15f3f4853b78283b89d4bd1b6" contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction> </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_4d052f75045f46acb6dee4fc417c6b20" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction>) </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_5894d76495c84415911f2a689cec9db5" contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,908</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_1399264646ef4220a58d68b83c53595d" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,175</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_1e8a48a281e140d6998d4a7c6db848f7" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 1.67pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_946bff7e976b434497b3e148945c3ca3" contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_c074c9e30e7a498c98fc18375376fb0b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,183</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_855b84fe6feb42bbbec591653224664a7">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">As of December 31, 2025, all of the Company&#8217;s marketable securities matured
            and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#8217;s balance sheet. </div>
</ix:continuation>

        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_824aeb4535e54b93929ad1a7732d02e8" contextRef="c20250101to20251231" escape="true" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f81">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">5. Fair Value of Financial Instruments and Non-Financial
            Instruments </div>
</ix:nonNumeric>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f81" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f82">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Financial Instruments </div>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f82" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f83">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-14<br/>
        </div>

      </div>

    </div>

    <!--End Page 13-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 14-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f83" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f84">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <span style="font-style: italic;">Fair Value Measurement</span>, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: </div>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f84" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f85">
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;1:</span> Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. </div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f85" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f86">
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;2:</span> Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. </div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f86" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f87">
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;3:</span> Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f87" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f88">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following fair value hierarchy table presents information about the
            Company&#8217;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions: </div>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f88" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f89">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f89" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f810"><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Text_19ce8f64c3a34ac995c24f97422a318e" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 147.47pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.26pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 147.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement at </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reporting date using </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets for </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">identical </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_cbffef4cb6d64b2bbd5ddaa722db3b21" contextRef="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,803</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_1ff3ab7f713d4971a6f8ff96efae279d" contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,803</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_4f2530a0a3fe4a7e9b201e08c0d44533" contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,803</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;">$<ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_1b4c44a90a6f4a488dd5675ce76a97d6" contextRef="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,058</ix:nonFraction></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;">$&#8212; </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_39260886795d4a9996c4f2e5b840488a" contextRef="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,988</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_7b9156c059094770a41897feae27260d" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,058</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_49c78d1a02f242c0a27102236a612ad9" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,988</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Marketable securities: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_d80cbbe85c1f4994aa5f87b7d387cfe8" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CertificatesOfDepositMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,971</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_f554fcdc0d8148658f3f8ca34e96bc82" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CommercialPaperMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,439</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_4d7e4cedfa2649cb915cd22d01a90f45" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,865</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_d98b9e36867a4bc09da28d98cea0e7bd" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,908</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total marketable securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_9bd539657f60458ea687d697b4f130ba" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,183</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_dbd7584135444309a40296f688d86ded" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,058</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_e16656888d16415e829f76c4f06d4728" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,171</ix:nonFraction></span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.89pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f810" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f811">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Non-Financial Instruments </div>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f811" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f812">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 </div>
</ix:continuation>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-15<br/>
        </div>

      </div>

    </div>

    <!--End Page 14-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 15-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f812" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f813">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">inputs is determined by estimating the amount and timing of net future cash
            flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest. Significant increases or decreases in actual cash flows may result in valuation changes. </div>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f813" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f814">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following long-lived assets were measured at fair value, on a nonrecurring
            basis, during the years ended December 31, 2025 and 2024. Assets remeasured in 2024 or sold in 2025 are not included in the fair value presented as of December&#160;31, 2025. The significant assumptions utilized are further described in Notes 3 and
            10: </div>
</ix:continuation>
          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f814" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f815">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f815" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f816"><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="Text_c695bc53ec3f4490b8ca4743f7d255d3" contextRef="c20250101to20251231" escape="true" continuedAt="Text_819e2a6231e544578a4547f39412bf301">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 189.53pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2025 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2025</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" id="Fact_c9117365900644a98aeda30f601680fb" contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,155</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_0a1af8f2a4ae47c58da333ccc5e9aaeb" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,373</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:RightOfUseAssetsFairValueDisclosure" id="Fact_139fae85d2fe43149bf58fca7ef4eefa" contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,489</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_7668576fcf57451e963f6716772e227f" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,633</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" id="Fact_62929a5d62514c34a2d05b86f0c9f5b7" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">139</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_0d5d6c69164e415e9edd06cd62b4beb8" contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,644</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_2fdb4a2b04504beba7a7deceb2373949" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,145</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 61.43pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f816" continuedAt="Text_114b544ea90d4f0bb8218376a2d199f817">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_114b544ea90d4f0bb8218376a2d199f817"><ix:continuation id="Text_819e2a6231e544578a4547f39412bf301">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 189.54pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.54pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2024 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2024</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;">$<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentFairValueDisclosure" id="Fact_c8c12e334815498faad3a8ae2e575849" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,668</ix:nonFraction></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_242ef526ec1748f1b87d225acf5df6ea" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,279</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="pasg:RightOfUseAssetsFairValueDisclosure" id="Fact_161717718d0d44eaa1314bd75c62f320" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,642</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_55ac05c4e573494396724c34e8d652f6" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,516</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherAssetsFairValueDisclosure" id="Fact_a493bd27150643dfb3ce5ebf682c30e8" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">200</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" id="Fact_9079a3be7b3142c9b216f4003628dfdd" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">438</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_619390e3bf834028866053368dc6fce6" contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,510</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_7602d219fb9a4113855eb3b0e8ac667c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,233</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_0db423afdcc64514b58b1bad8522d337" contextRef="c20250101to20251231" escape="true" continuedAt="Text_2fa78d0ace584d42810424707ce11d221">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">6. Property and Equipment, Net </div>
</ix:nonNumeric>
          <ix:continuation id="Text_2fa78d0ace584d42810424707ce11d221" continuedAt="Text_2fa78d0ace584d42810424707ce11d222">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Property and equipment, net, consists of the following: </div>
</ix:continuation>
          <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_00a755d3d1f648259f0a45c4ab434de2" contextRef="c20250101to20251231" escape="true" continuedAt="Text_26ec792f097b40aaa7642eeb64c125171"><ix:continuation id="Text_2fa78d0ace584d42810424707ce11d222" continuedAt="Text_2fa78d0ace584d42810424707ce11d223">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_26ec792f097b40aaa7642eeb64c125171"><ix:continuation id="Text_2fa78d0ace584d42810424707ce11d223" continuedAt="Text_2fa78d0ace584d42810424707ce11d224">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Laboratory equipment</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 15.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_95ba2779709c422a92652b2696b5cb94" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,020</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Office equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_bdb296821c7f40bebafe7f0401eabaed" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.87pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a4dc1c758a20468c9f4e0a9a648a5d25" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Computer hardware and software</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_47659c04fd0e475f9591a37ab1045740" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">988</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10.74pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a2cbd7ad71764989a29cf17238cce67c" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,111</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Furniture and fixtures</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_84746eb22c5a40ab8c779cb1f968223d" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_d8f2350fc07f41c1b61c85e81f1aa9a6" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Leasehold improvements</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_5351e41ed87f484a8c5cec877b703d5c" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,510</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_ccdfbfd88b6b474788262d9c71172c2a" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,386</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total property and equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_662f0311873741b28c6154f4011e8c6e" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,024</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_36ef555e66074d32990d9cbcc5fdc11a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,055</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_5d0d071fa09b45ae87b021eb9bcf9d9b" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,917</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_d4b407797e9547bea184f72d6249b4c5" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,724</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_c0acffe08f5f4f93bb748697dd7be168" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,107</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_f196ed8b6c704e49888368bf48243143" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,331</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_2fa78d0ace584d42810424707ce11d224" continuedAt="Text_2fa78d0ace584d42810424707ce11d225">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">In connection with the Company&#8217;s January&#160;2025 announcement to reduce its
            overall workforce by <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" id="Fact_35a4892984ed409395c4035e056c13f6" contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>% and cease its lab operations in Hopewell, New Jersey, management implemented plans to sell substantially
            all the laboratory equipment and certain other assets and estimated the fair value of the assets based on the estimated future cash flows from the sale of such assets. Subsequent to recording the impairment of $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_edc63f19a99f41718523833f6501430e" contextRef="c20250101to20251231_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction> million, the Company sold substantially all the laboratory equipment and certain other assets for $<ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" id="Fact_b5d1deb63dd6448d8523ff6dad1a04a6" contextRef="c20260101to20260131_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million. As a result, the Company did <ix:nonFraction name="us-gaap:Depreciation" id="Fact_3181b42a5fee45ec85553b8389521bec" contextRef="c20250101to20251231_DisposalGroupClassificationAxis_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction>t record any
            depreciation on the impaired and disposed laboratory equipment during the year ended December&#160;31, 2025 as the equipment was considered held-for-sale in January&#160;2025. Neither laboratory equipment nor accumulated depreciation related to such
            equipment are recorded on the balance sheet as of December&#160;31, 2025. </div>
</ix:continuation>
          <ix:continuation id="Text_2fa78d0ace584d42810424707ce11d225">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Depreciation and amortization expense was $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_f001388c831c43e4bc166b8e3621c02f" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_51a029c2c40d4bf68b6e25fbb9902667" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction> million for the
            years ended December 31, 2025 and 2024, respectively. </div>
</ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-16<br/>
        </div>

      </div>

    </div>

    <!--End Page 15-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 16-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg10"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:nonNumeric name="pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="Text_fea37eaf2402449ab3beebffb24f16c5" contextRef="c20250101to20251231" escape="true" continuedAt="Text_1c848da772104d3aa0c28830eaded9811">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">7. Accrued Expenses and Other Current Liabilities </div>
</ix:nonNumeric>
          <ix:continuation id="Text_1c848da772104d3aa0c28830eaded9811" continuedAt="Text_1c848da772104d3aa0c28830eaded9812">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Accrued expenses and other current liabilities consisted of the following: </div>
</ix:continuation>
          <ix:continuation id="Text_1c848da772104d3aa0c28830eaded9812" continuedAt="Text_1c848da772104d3aa0c28830eaded9813">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_1c848da772104d3aa0c28830eaded9813"><ix:nonNumeric name="pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="Text_1fbbc0625e634c3fb40cf744aac6f484" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Professional fees</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 7.5pt;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_0061632e9afe4eba96fb166c5db30013" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">347</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 7.5pt;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_c728b099a7444d75aa3d48ba45bbef7a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">406</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Compensation and related benefits</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_e113660ef9ef46e39194a35d869f94ae" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,740</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_5eb48edd151e426fb662d70508a6e180" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,405</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Research and development</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 12.5pt;"><ix:nonFraction name="pasg:AccruedResearchAndDevelopmentExpense" id="Fact_cf513611705548818f5b287744d44943" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">642</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="pasg:AccruedResearchAndDevelopmentExpense" id="Fact_796093cede2d4b14944b85c45248de32" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,896</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:AccruedDivestitureFeesCurrent" id="Fact_dec777de22784b4bb24fecf85b1f0980" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_1bd1f4380fb44b549d32d996de6e0719" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,653</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_af2e0205b4154320bc6f79f3e38d4923" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,707</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>
            </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Text_4f81f5d8c94a4dcfb4a40fd153d8c63e" contextRef="c20250101to20251231" escape="true" continuedAt="Text_55dbdc48dd614bc6b1204bc3d8e3049f1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">8. Gemma License Agreement </div>
</ix:nonNumeric>
          <ix:continuation id="Text_55dbdc48dd614bc6b1204bc3d8e3049f1" continuedAt="Text_55dbdc48dd614bc6b1204bc3d8e3049f2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $<ix:nonFraction name="pasg:UpfrontLicenseFeeReceivable" id="Fact_6893b3cd8a104d1c9aca44f4fa057f77" contextRef="c20240731" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million in
            initial payments for licenses and clinical product supply, of which $<ix:nonFraction name="pasg:ProceedsFromNonRefundableSublicensePayments" id="Fact_fac334603d5a4e5788a3e21ef5d1f2aa" contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.5</ix:nonFraction> million was previously received, $<ix:nonFraction name="pasg:ShortTermLicenseFeeDueAndReceivable" id="Fact_9a1f6325fd2c4cce8061d1554bf5e4e1" contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction> million of which was due in May&#160;2025, and $<ix:nonFraction name="pasg:LongTermLicenseFeeDueAndReceivable" id="Fact_309fc47be1b9427fbe1ae0db2c5663e2" contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction>
            million of which is due in March&#160;2026; (ii) an additional $<ix:nonFraction name="pasg:ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" id="Fact_ad7eb28ff5824ec4a711a19c60c9dc4f" contextRef="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million contingent on Gemma completing certain business milestones;
            (iii) up to an additional $<ix:nonFraction name="pasg:MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" id="Fact_69ba06ed5f814a1d9f9af963b74af3b5" contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">114.0</ix:nonFraction> million in development and commercial milestone payments; and (iv) single digit royalties as a
            percentage of annual worldwide net sales, in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will
            be responsible for all payments due to the Trustees of the University of Pennsylvania&#8217;s, or Penn, under the Company&#8217;s research, collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs.
            On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which,
            the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. As of
            December 31, 2025, the Company has collected $<ix:nonFraction name="pasg:ProceedsFromNonRefundableSublicensePayments" id="Fact_a2731203382c411f8c743ea377b8cade" contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.5</ix:nonFraction> million in initial payments, $<ix:nonFraction name="pasg:ProceedsFromNonRefundableTransitionServicesPayments" id="Fact_853c821bd68d44b5865057d3a32e7640" contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction> million in transition services payments, and applied $<ix:nonFraction name="pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments" id="Fact_92371728ffbd46d5866b80d3e44b1ed5" contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction>
            million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts due to the Company for transition services under these agreements. </div>
</ix:continuation>
          <ix:continuation id="Text_55dbdc48dd614bc6b1204bc3d8e3049f2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of December 31, 2025, the Company has received initial payments of $<ix:nonFraction name="pasg:ProceedsFromNonRefundableSublicensePayments" id="Fact_448ba42fe6f5449bb08894427debb023" contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.5</ix:nonFraction> million associated with the aggregate $<ix:nonFraction name="pasg:UpfrontLicenseFeeReceivable" id="Fact_6934c7d0abe4406baac9ec6483d368a2" contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million of
            initial payments to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $<ix:nonFraction name="pasg:ProceedsFromNonRefundableTransitionServicesPayments" id="Fact_c5f687a1f0aa4e238d64b6a175a7351c" contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction> million associated
            with the Transition Services Agreement and applied $<ix:nonFraction name="pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments" id="Fact_6ffe3eaaafd8440ab4256a5f287e1514" contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction> million in amounts owed to Gemma for the Huntington&#8217;s disease program against
            amounts due to the Company for transition services under these agreements. The Company recorded these amounts ($<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_d93ea224c4e24e839852b20ed48f13fb" contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.8</ix:nonFraction> million) as
            non-refundable sublicense and transition services payments on the balance sheet as of December 31, 2025, as the criteria set forth above have not yet been met. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Text_5680eb51727a433c96bb9b204e0e295a" contextRef="c20250101to20251231" escape="true" continuedAt="Text_4c5e12a314e847119d9a46974db5d6021">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">9. Severance </div>
</ix:nonNumeric>
          <ix:continuation id="Text_4c5e12a314e847119d9a46974db5d6021" continuedAt="Text_4c5e12a314e847119d9a46974db5d6022">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" id="Fact_6607b0e795e349c6985707181d26b5a7" contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>%.
          </div>
</ix:continuation>
          <ix:continuation id="Text_4c5e12a314e847119d9a46974db5d6022">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with ASC 420, <span style="font-style: italic;">Exit and
              Disposal Activities</span>, the Company recorded severance and termination-related costs of $<ix:nonFraction name="us-gaap:SeveranceCosts1" id="Fact_2fd1851e266346be9b8dd78571e52d62" contextRef="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million in general and
            administrative expenses and $<ix:nonFraction name="us-gaap:SeveranceCosts1" id="Fact_1e54d4050021494b833ad11dcaee9dce" contextRef="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction> million in research and development expenses for the year ended December 31, 2025. During the year
            ended December 31, 2024, the Company recorded <ix:nonFraction name="us-gaap:SeveranceCosts1" id="Fact_c78d97c07cd946f891e3554399406966" contextRef="c20240101to20241231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> severance and termination-related costs. As of December 31, 2025, there were <ix:nonFraction name="us-gaap:RestructuringReserve" id="Fact_e50ba9b12fd6446c995e15cfeda3d70f" contextRef="c20251231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> unpaid severance and termination-related costs. </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-17<br/>
        </div>

      </div>

    </div>

    <!--End Page 16-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 17-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg11"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_3b508a4265244397a68a874ae16f7a8e" contextRef="c20250101to20251231" escape="true" continuedAt="Text_73e1bde7b6704599a39db603191bb63d1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">10. Leases </div>
</ix:nonNumeric>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d1" continuedAt="Text_73e1bde7b6704599a39db603191bb63d2">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2005 Market Street Lease Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d2" continuedAt="Text_73e1bde7b6704599a39db603191bb63d3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_c4ab2e1a31bd4bebadcee4036a9835e8" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">37,000</ix:nonFraction>
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact_e4e497d21a4a4b89be2334b08a2d66e1" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt:fixed-true">extend</ix:nonNumeric> the term of the 2005 Market Street Lease Agreement by <ix:nonFraction name="pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions" id="Fact_57ba9d62f9364166a2e80973a574379a" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" unitRef="U006" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> additional terms of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Fact_8f2cae5e68934b998459e9418b77770b" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> each. The Company has an option to early <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="Fact_9f888cc6f6f341808ceaa5c472ce2e8d" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt:fixed-true">terminate</ix:nonNumeric>
            the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than <ix:nonNumeric name="pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease" id="Fact_f58e1ae79bbe4671bbfbee8ea428ed44" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt-sec:durwordsen">fifteen months</ix:nonNumeric> prior
            to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#8217;s measurement of the ROU asset and operating lease liability as of December 31, 2025. During 2023 the Company subleased all of the space at
            2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d3" continuedAt="Text_73e1bde7b6704599a39db603191bb63d4">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement A </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d4" continuedAt="Text_73e1bde7b6704599a39db603191bb63d5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_2b9cd9ea26854127b269a9f086090870" contextRef="c20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">8,000</ix:nonFraction> square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact_0b4b22fb0b664f07883c8cbc7add1e0c" contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" format="ixt:fixed-true">extend</ix:nonNumeric> the sublease agreement through November&#160;30, 2031. The base sublease rent is $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_8a9d0c97bcdd4596a93e9ab95ec7ba0b" contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million per year and increases by <ix:nonFraction name="pasg:PercentageOfAnnualIncreaseInSubleaseRent" id="Fact_5bea738f5e3c40ee8447201ab92e1da8" contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.75</ix:nonFraction>% annually through
            the expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses, and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d5" continuedAt="Text_73e1bde7b6704599a39db603191bb63d6">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC Topic 842, <span style="font-style: italic;">Leases</span>,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d6" continuedAt="Text_73e1bde7b6704599a39db603191bb63d7">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement B </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d7" continuedAt="Text_73e1bde7b6704599a39db603191bb63d8">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_9abc0e3faf90493f9af45cedff960fd3" contextRef="c20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">29,000</ix:nonFraction> square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024, and continues through August&#160;2026. Sublessee B has an option to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact_84906cd581804c97ba2c43fb95bef060" contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember" format="ixt:fixed-true">extend</ix:nonNumeric> the
            term of the sublease agreement through March&#160;31, 2029. The base sublease rent is $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_2b40ab65489a4419be239c96d168e124" contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million per year for the entire term of the
            sublease. Additionally, Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005
            Market Street Lease Agreement. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d8" continuedAt="Text_73e1bde7b6704599a39db603191bb63d9">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d9" continuedAt="Text_73e1bde7b6704599a39db603191bb63d10">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1835 Market Street Sublease Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d10" continuedAt="Text_73e1bde7b6704599a39db603191bb63d11">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February&#160;20, 2024, the Company entered into a sublease agreement with a
            counterparty, or the 1835 Market Street Sublease Agreement. Under the 1835 Market Street Sublease Agreement, the Company subleased approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_4c5837a1527e4d799018e512ad943948" contextRef="c20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">16,000</ix:nonFraction>
            square feet of office space in Philadelphia, Pennsylvania. The sublease term began on March&#160;26, 2024 and expired on September&#160;30, 2025. The Company had the option but did not elect to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact_45b6c202eb5a4a3cae4f988fc4f50da0" contextRef="c20240220to20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member" format="ixt:fixed-true">extend</ix:nonNumeric> the term of the sublease agreement through February&#160;28, 2029. The base sublease rent was $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_56ebaadcbc314fa49860135f09c52940" contextRef="c20240220to20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million per year for the original <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_61eab1a6d29f496fa620b102181bf567" contextRef="c20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member" format="ixt-sec:durwordsen">18-month</ix:nonNumeric> term of the
            sublease. Additionally, the Company was required to pay utility costs associated with the subleased premises. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d11" continuedAt="Text_73e1bde7b6704599a39db603191bb63d12">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Laboratory Lease Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d12" continuedAt="Text_73e1bde7b6704599a39db603191bb63d13">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and is expected to expire in March&#160;2036. The </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-18<br/>
        </div>

      </div>

    </div>

    <!--End Page 17-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 18-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d13" continuedAt="Text_73e1bde7b6704599a39db603191bb63d14">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">Company has an option to early <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="Fact_d9e208f2913343f2a253acf7fc7a515d" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember" format="ixt:fixed-true">terminate</ix:nonNumeric> the Laboratory Lease Agreement as of March&#160;2032 given notice is provided to the landlord no less than <ix:nonNumeric name="pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease" id="Fact_da4da20e455149c9877a4ca10bef4fc2" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> prior to March&#160;2032. The Company has an option to extend the term of the Laboratory Lease Agreement by up to&#160;<ix:nonFraction name="pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions" id="Fact_2136f8a98b844994a3f5a2455286938e" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember" unitRef="U006" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> <ix:nonNumeric name="pasg:NewLeaseAgreementOperatingLeaseRenewalTerm" id="Fact_c0366e3a9fdc42dea8c511cd64fcc915" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> terms. These options were not recognized as
            part of the Company&#8217;s measurement of the ROU asset and operating lease liability as of December 31, 2025. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d14" continuedAt="Text_73e1bde7b6704599a39db603191bb63d15">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company implemented a restructuring plan which included
            ceasing lab operations. As a result, the Company is no longer using any of the space covered by the Laboratory Lease Agreement and is actively pursuing opportunities to sublease all remaining space in the Laboratory Lease Agreement as well as
            discussing with the landlord potential alternatives. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d15" continuedAt="Text_73e1bde7b6704599a39db603191bb63d16">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Hopewell Sublease Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d16" continuedAt="Text_73e1bde7b6704599a39db603191bb63d17">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately <ix:nonFraction name="pasg:AreaSubleased" id="Fact_f0cf17f4750e4ee5bc7284ae78a09bfa" contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">3,200</ix:nonFraction> square feet, or <ix:nonFraction name="pasg:AreaOfLandSubleasedPercentage" id="Fact_dea06821f8ff4360922ddb914db50f9f" contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of its approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_cd3cf65e93c84402ae5ac72df2cd9910" contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">62,000</ix:nonFraction> square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and expires on December&#160;31, 2029. Sublessee C has the option to extend the term of the sublease through
            December&#160;2032. The base sublease rent is $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_59d3791e2e68498abcb42d2f8cecce06" contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million per year and increases by <ix:nonFraction name="pasg:PercentageOfAnnualIncreaseInSubleaseRent" id="Fact_def797da785c4a05b7f77d5ed80ae2a5" contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C is required to pay the portion of the common area maintenance expenses,
            operating expenses, and use and occupancy taxes that the Company is required to pay under the Laboratory Lease Agreement. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d17" continuedAt="Text_73e1bde7b6704599a39db603191bb63d18">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the Laboratory Lease Agreement. The Company continues to account for the Laboratory Lease Agreement as a lessee and in the same manner as prior to the execution of the Hopewell
            Sublease Agreement. The Company accounted for the Hopewell Sublease Agreement as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d18" continuedAt="Text_73e1bde7b6704599a39db603191bb63d19">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2024, the Company determined triggering events were present and reassessed
            the asset groups related to its laboratory space under the Laboratory Lease Agreement, which resulted in changes to the Company&#8217;s identified asset groups. The Company determined whether an impairment indicator was present for each of the new
            asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying values, which includes ROU assets, leasehold improvements, and other property and equipment allocable to the
            laboratory space for those asset groups. The Company concluded the carrying values of certain asset groups were not recoverable as they exceeded the estimated undiscounted cash flows. The Company calculated the amount of impairment on those
            asset groups using a discounted cash flow model to calculate the fair value of the asset group which incorporated the net identifiable cash flows for the term of the Hopewell Sublease Agreement, including an estimate for cash flows in the
            residual period, and an estimated borrowing rate of a market participant subtenant. As a result, certain asset groups were impaired and the Company recognized impairment expense of $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_12fa6df3d2a04613884170f6ec411b77" contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.2</ix:nonFraction> million, including $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_241534d11f754be8b4f92c003d8720eb" contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction> million for the ROU assets, $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_82a1ba97743141bfb2fb02edb0270f18" contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction> million for the property and equipment, net, and $<ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" id="Fact_b753048cf5c34e02ac1fffdce873f77d" contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>
            million for certain other assets during the year ended December&#160;31, 2024. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d19" continuedAt="Text_73e1bde7b6704599a39db603191bb63d20">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the January&#160;2025 announcement to reduce its overall
            workforce by <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" id="Fact_44daeb3f54984e53b821f5a444665808" contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>% and cease its lab operations in Hopewell, New Jersey, the Company determined triggering events were present and
            reassessed its asset groups related to its laboratory space under the Laboratory Lease Agreement. Laboratory equipment was separated from the ROU assets and leasehold improvements allocable to the laboratory space as the equipment was no longer
            being used in operations and the Company had implemented a plan to sell those assets. For the ROU assets and allocable leasehold improvements, the Company compared the estimated undiscounted cash flows from subleasing to the carrying value and
            determined there was no impairment. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d20" continuedAt="Text_73e1bde7b6704599a39db603191bb63d21">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement based upon sublease market activity and an estimated market </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-19<br/>
        </div>

      </div>

    </div>

    <!--End Page 18-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 19-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d21" continuedAt="Text_73e1bde7b6704599a39db603191bb63d22">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">participant subtenant borrowing rate and compared that to the carrying value
            of the asset group. As a result, the Company recognized impairment expense of $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_616990bd921a4fd2bc283b81336d3d8d" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction> million, including $<ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_50fc5d51c350470c91b262a944a2a79e" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction> million for the ROU assets and $<ix:nonFraction name="us-gaap:ImpairmentOfLeasehold" id="Fact_f3bfda529c78425bb3feff116b9a3a5d" contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction>
            million for the leasehold improvements during the year ended December 31, 2025. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d22" continuedAt="Text_73e1bde7b6704599a39db603191bb63d23">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes future minimum lease payments for the Company&#8217;s
            lessee operating leases, which comprises of the 2005 Market Street Lease Agreement and the Laboratory Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A, Sublease Agreement B, and the
            Hopewell Sublease Agreement as the Company was not relieved of its primary obligation under the 2005 Market Street Lease Agreement and Laboratory Lease Agreement: </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d23" continuedAt="Text_73e1bde7b6704599a39db603191bb63d24">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d24" continuedAt="Text_73e1bde7b6704599a39db603191bb63d25"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_bf968286b91a4b78bfd0f780bf688228" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_f4e71201efa1462c89992eefe27ec609" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,757</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_17fdd0550d964e578c2295e154e9d31a" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,863</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_4e4f23db07674f63a619a9d295b1b38e" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,973</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_5298105745ac4bacb3d48f7727555f02" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,085</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" id="Fact_fc73701c558c4d758e36a774cfdf0d93" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,200</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" id="Fact_46d3443eff654f03b09e83b6618694a2" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,421</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_3e43248efd7348af968de60a6366a5ee" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,299</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_f5f6706f1bc24457bfc34a2cf1675aa0" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,289</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_11373ac715fb4b0382ff8881b9637ec4" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,010</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d25" continuedAt="Text_73e1bde7b6704599a39db603191bb63d26">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes lease expense by lease type that was recognized
            during the years ended December&#160;31, 2025 and 2024: </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d26" continuedAt="Text_73e1bde7b6704599a39db603191bb63d27">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d27" continuedAt="Text_73e1bde7b6704599a39db603191bb63d28"><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" id="Text_3d5d856da87441e2abf02d2dd296ec6e" contextRef="c20250101to20251231" escape="true" continuedAt="Text_26a7524a9d214ec19006d73f5183b86b1">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 142.48pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease cost</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_7c3ae0119e7f40c6a7f5ccc1cbed5477" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,419</ix:nonFraction></div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_1e82f8a729b84953b25adc94acd23f6a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,505</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease cost</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_6d31e17f62474dc8afb6a21a904e8670" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,103</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_cc1641009a70479ba6bbe76b602cd603" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,127</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:LeaseCost" id="Fact_d5bdce0728034a44bb4c99b22a8d0f89" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,522</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:LeaseCost" id="Fact_e5c668418cae4a5a93c5d7079eb4b601" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,632</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d28" continuedAt="Text_73e1bde7b6704599a39db603191bb63d29">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d29" continuedAt="Text_73e1bde7b6704599a39db603191bb63d30">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d30" continuedAt="Text_73e1bde7b6704599a39db603191bb63d31"><ix:continuation id="Text_26a7524a9d214ec19006d73f5183b86b1" continuedAt="Text_26a7524a9d214ec19006d73f5183b86b2">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 142.48pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_0c3847f98fc045dbb81514880ef5d40f" contextRef="c20251231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.7</ix:nonFraction>% </div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_936dd2aae7cd46ed8fdfd61a6f796ba4" contextRef="c20241231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.7</ix:nonFraction>% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_9ac06680dc194f0b9749214fa2666d81" contextRef="c20251231" format="ixt-sec:duryear">9.3</ix:nonNumeric> </div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_019dcb92d12f49879e8383b7e1c89088" contextRef="c20241231" format="ixt-sec:duryear">10.2</ix:nonNumeric> </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d31" continuedAt="Text_73e1bde7b6704599a39db603191bb63d32">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The cash paid for amounts included in the measurement of the Company&#8217;s
            operating lease liabilities for the years ended December&#160;31, 2025 and 2024 were $<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" id="Fact_744ddf2613744807b0e7fc1d858d2a45" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" id="Fact_1629a6b4c77e439a9e269d21052cf1ad" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.8</ix:nonFraction> million, respectively, recorded in operating cash flows. </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d32" continuedAt="Text_73e1bde7b6704599a39db603191bb63d33">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes sublease income that was recognized in other
            income (expense), net during the years ended December 31, 2025 and 2024: </div>
</ix:continuation>
          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d33" continuedAt="Text_73e1bde7b6704599a39db603191bb63d34">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_73e1bde7b6704599a39db603191bb63d34"><ix:continuation id="Text_26a7524a9d214ec19006d73f5183b86b2">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 142.48pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_1fd2bcc3a4f14c79bebdd23fabea1872" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,467</ix:nonFraction></div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.25pt; text-align: left;">$<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_99935ac63ed2490ab09337e30981a3aa" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">987</ix:nonFraction></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
            </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_528cb9f8536842b3a82c8a9b13e46873" contextRef="c20250101to20251231" escape="true" continuedAt="Text_c592faaa6d5043c397414a9192c162ed1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">11. Commitments and Contingencies </div>
</ix:nonNumeric>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed1" continuedAt="Text_c592faaa6d5043c397414a9192c162ed2">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Amended and Restated Research, Collaboration
            and License Arrangement with Penn </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed2" continuedAt="Text_c592faaa6d5043c397414a9192c162ed3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-20<br/>
        </div>

      </div>

    </div>

    <!--End Page 355-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 356-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed3" continuedAt="Text_c592faaa6d5043c397414a9192c162ed4">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">(i)&#160;terminated the funding of discovery research programs; (ii) terminated the
            research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS, indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate
            transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe, and MLD and certain platform technologies resulting from the discovery programs that it funded. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed4" continuedAt="Text_c592faaa6d5043c397414a9192c162ed5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the Company&#8217;s licensed programs in FTD, GM1, Krabbe, and MLD, the Penn
            License Agreement requires that it make payments of up to $<ix:nonFraction name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" id="Fact_aaf759282d1a4fe0a9c5759de8d59689" contextRef="c20251231_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction> million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications, and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $<ix:nonFraction name="pasg:CollaborationAgreementSalesMilestonePaymentsPayable" id="Fact_f61799dbeb364d88adec6a5c8c3a8f23" contextRef="c20251231_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction> million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed5" continuedAt="Text_c592faaa6d5043c397414a9192c162ed6">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed6" continuedAt="Text_c592faaa6d5043c397414a9192c162ed7">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Gemma - Research, Collaboration and
            License Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed7" continuedAt="Text_c592faaa6d5043c397414a9192c162ed8">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New
            Drug-enabling work for the Company&#8217;s active research program in Huntington&#8217;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and (ii)
            Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed8" continuedAt="Text_c592faaa6d5043c397414a9192c162ed9">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $<ix:nonFraction name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" id="Fact_4db0797560ec49e8b9686cc2bcdb54b2" contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction> million per product candidate in the aggregate for Huntington&#8217;s disease and any future CNS indications available to the
            Company under its four options and (ii) $<ix:nonFraction name="pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" id="Fact_07c2926a68de4aab8aa64d3998e591a0" contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">39.0</ix:nonFraction> million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $<ix:nonFraction name="pasg:CollaborationAgreementSalesMilestonePaymentsPayable" id="Fact_b81775e259974eab990d4c7c4c54c8e7" contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction>
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed9" continuedAt="Text_c592faaa6d5043c397414a9192c162ed10">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed10" continuedAt="Text_c592faaa6d5043c397414a9192c162ed11">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $<ix:nonFraction name="pasg:NonRefundableAggregateFeesPayablePerProductIndication" id="Fact_e9571fae85e24a75bf0fce469a649604" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million per product indication, with $<ix:nonFraction name="pasg:NonRefundableUpfrontFeesPayablePerProductIndication" id="Fact_1627cec58d8e4ac5b326d5ebb72f211f" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million due upfront and another $<ix:nonFraction name="pasg:NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" id="Fact_b057ade5794e4649adf988deb16170c9" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>
            million fee owed upon a further developmental milestone. </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-21<br/>
        </div>

      </div>

    </div>

    <!--End Page 356-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 357-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed11" continuedAt="Text_c592faaa6d5043c397414a9192c162ed12">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;8. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed12" continuedAt="Text_c592faaa6d5043c397414a9192c162ed13">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed13" continuedAt="Text_c592faaa6d5043c397414a9192c162ed14">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Catalent Agreements </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed14" continuedAt="Text_c592faaa6d5043c397414a9192c162ed15">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed15" continuedAt="Text_c592faaa6d5043c397414a9192c162ed16">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#8217;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed16" continuedAt="Text_c592faaa6d5043c397414a9192c162ed17">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements, is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $<ix:nonFraction name="pasg:AccruedDivestitureFeesCurrent" id="Fact_1cdebbde6e9546849c22f52be49fcde0" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million to Catalent which has been accrued as of and during the year ended December&#160;31, 2025. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed17" continuedAt="Text_c592faaa6d5043c397414a9192c162ed18">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Litigation </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed18" continuedAt="Text_c592faaa6d5043c397414a9192c162ed19">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" id="Fact_939ab66caae941a3b0cfdef429d8d983" contextRef="c20251231" unitRef="U001" decimals="-5" scale="5" format="ixt-sec:numwordsen">no</ix:nonFraction>t recorded any amounts for loss contingencies as of December 31, 2025. </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed19" continuedAt="Text_c592faaa6d5043c397414a9192c162ed20">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#8217;s initial
            public offering in February&#160;2020, he was promised <ix:nonFraction name="pasg:StockIssuedDuringPeriodSettlementOfLitigation" id="Fact_5b4770cc238746feae94c8d8864cbd5b" contextRef="c20200201to20200229" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction> shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to <ix:nonFraction name="pasg:LossContingencySharesAgreedByDefendant" id="Fact_a202af6bb36b42faa336d2a4707c15fc" contextRef="c20200201to20200229" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">33,836</ix:nonFraction> shares (<ix:nonFraction name="pasg:LossContingencySharesAgreedByDefendant" id="Fact_8fd59443fffc4c69b3979d0ac5f27a0c" contextRef="c20250101to20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">1,692</ix:nonFraction> shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it
            agreed with the Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the
            initial public offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#8217;s favor, finding that no binding agreement was reached and that the plaintiff
            was not entitled to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate court affirmed the entry of judgment in favor of the Company and on
            October&#160;7, 2025, the plaintiff filed an Application for Reargument to the Superior Court <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">of Pennsylvania. In December 2025, the Superior Court of Pennsylvania denied the Application for Reargument. In December 2025,</span> the plaintiff petitioned for review of their appeal to the Pennsylvania
            Supreme Court which is currently pending. The Company intends to continue to defend against this claim. </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-22<br/>
        </div>

      </div>

    </div>

    <!--End Page 357-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 358-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed20" continuedAt="Text_c592faaa6d5043c397414a9192c162ed21">
<div class="BRDSX_h3" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Other than the above, we are not presently a party to any legal proceedings
              that, in the opinion of management, would, if decided against us, have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management
              resources, negative publicity and reputational harm, and other factors. </span></div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed21" continuedAt="Text_c592faaa6d5043c397414a9192c162ed22">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Employment Agreements </div>
</ix:continuation>
          <ix:continuation id="Text_c592faaa6d5043c397414a9192c162ed22">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to <ix:nonFraction name="pasg:PercentageOfTargetAnnualBonusAmounts" id="Fact_892b2c23c98341e7bb6f5ce264e114b2" contextRef="c20250101to20251231" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">150</ix:nonFraction>% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_f564bf0f512b48abaec4658c5e728db2" contextRef="c20250101to20251231" escape="true" continuedAt="Text_a731bd63205c4e409dc3af4b5db774de1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">12. Common Stock </div>
</ix:nonNumeric>
          <ix:continuation id="Text_a731bd63205c4e409dc3af4b5db774de1" continuedAt="Text_a731bd63205c4e409dc3af4b5db774de2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_b759239f388b4887811c1e3f86e753fc" contextRef="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">125.0</ix:nonFraction> million through Cowen, as sales agent in the ATM Facility. The Company
            issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_4fb68306e6e74e238b627c5a362ea8e3" contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction> shares of common stock under the ATM Facility, resulting in net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_8b21952e8b92480bbdb8aa56ce2a2d82" contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.7</ix:nonFraction> million, after deducting offering costs of $<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_e64ccddae1b344a0ada9dbe1f9e8b078" contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million
            in March&#160;2024. The Company is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on March&#160;5,
            2025. </div>
</ix:continuation>
          <ix:continuation id="Text_a731bd63205c4e409dc3af4b5db774de2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On July&#160;14, 2025, the Company effected the Reverse Stock Split. The Reverse
            Stock Split did not reduce the number of authorized shares of the common stock and did not change the par value of the common stock. In addition, proportionate adjustments were made to the number of shares of common stock available for issuance
            under the Company&#8217;s equity inducement and incentive plans; the number of shares underlying, and the exercise prices of outstanding equity awards under such plans. All share information in these financial statements has been adjusted for this
            Reverse Stock Split. </div>
</ix:continuation>
        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_b280b2bae9534450a605d9beab9f0e1b" contextRef="c20250101to20251231" escape="true" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">13. Share-Based Compensation </div>
</ix:nonNumeric>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f1" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f2">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f2" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has <ix:nonFraction name="pasg:NumberOfEquityIncentivePlans" id="Fact_8a4422aa0db54255bd0e752dc5131602" contextRef="c20250101to20251231" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020&#160;Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f3" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f4">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The total number of shares authorized under the Incentive Plan as of December
            31, 2025 was <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_91aa82385f444dd6be5198c42aed083b" contextRef="c20251231_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">947,598</ix:nonFraction>. Additionally, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_5bf7fce0581a4e5cbd6152936038a8e0" contextRef="c20251231_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">204,732</ix:nonFraction>
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of December 31, 2025, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_ac49e5e2f9294cc6bb4b4db936dbd6f2" contextRef="c20251231_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">433,624</ix:nonFraction>
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January 1st of each
            year, commencing on January 1, 2021 and continuing for <ix:nonNumeric name="pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Fact_2c7df563d86c4eb58ee9af3730b23a3f" contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, in an amount equal to <ix:nonFraction name="pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" id="Fact_8acec2b7c36c43b791c8162048c4bc9d" contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member" unitRef="U004" decimals="2" scale="-2" format="ixt-sec:numwordsen">five </ix:nonFraction>percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by <ix:nonFraction name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" id="Fact_f166fa3c87cc4ffcbbc973b98f83be6a" contextRef="c20260101to20260131_PlanNameAxis_EquityIncentivePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">159,141</ix:nonFraction> and <ix:nonFraction name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" id="Fact_1e67ddab33ca4a8d997159821e11b4fd" contextRef="c20250101to20250131_PlanNameAxis_EquityIncentivePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">155,155</ix:nonFraction> shares in January&#160;2026 and 2025,
            respectively. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f4" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_7f0ce76302b749aca94ae32edf65845e" contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> periods, and have a term of <ix:nonNumeric name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="Fact_363e6eac101d4b6889f8ffb289129d7f" contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f5" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f6">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Inducement Plan was approved by the Company&#8217;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of December 31, 2025 was <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_5122329a0e1d40728f439bbde26c7e46" contextRef="c20251231_PlanNameAxis_EquityInducementPlan2021Member" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>. Of this amount, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_20409e4c49304194a291c6532e8fc625" contextRef="c20251231_PlanNameAxis_EquityInducementPlan2021Member" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">87,166</ix:nonFraction> shares were </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f6" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f7">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> available for future grants as of December 31, 2025. The Inducement Plan
            provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest
            based on requisite service period and have a term of <ix:nonNumeric name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="Fact_1e39c8a1c89f4e508bacabde2ed9e1b8" contextRef="c20250101to20251231_PlanNameAxis_EquityInducementPlan2021Member" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. The Company&#8217;s restricted stock units awarded to date under the
            Inducement Plan vest based on requisite service period and have a term based on each award agreement. </div>
</ix:continuation>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">  </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-23<br/>
        </div>

      </div>

    </div>

    <!--End Page 358-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 359-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>


          <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_d72cd2c19b0341ed9849ce7fcfb1e0a0" contextRef="c20250101to20251231" escape="true" continuedAt="Text_e4e5dc4411374a5692eb5d2ac685dd1b1">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">The
            Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense
            categories in its accompanying statements of operations and comprehensive loss for the period presented:</div>
</ix:nonNumeric>
        </div>

        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f7" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f8"><ix:continuation id="Text_e4e5dc4411374a5692eb5d2ac685dd1b1">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 107.28pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 7.5pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d2b104b3f140419894ac38499e64a502" contextRef="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">842</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f2066bf12ea04470bdae85076816fb37" contextRef="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,529</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_1f408cfee014428981935b46448ba157" contextRef="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,159</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_6384068b3afd4a26ab7a128b90073cb6" contextRef="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,291</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_7a656d1779cd4b4f8c58d4f592cde7fa" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,001</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_9ee7f83ffadb439090af56039355155a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,820</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f8" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f9">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The following table summarizes stock option activity for the year ended
            December 31, 2025: </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f9" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f10">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f10" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f11"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_898291d9d77a4cde8a80adf92addc91e" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_45b065f0a57c4191abd6fa3153d460fa" contextRef="c20241231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">577,581</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_ac7e4eb9ea744e0abb5bf5d570288bcf" contextRef="c20241231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">77.56</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_af6cec3c43d44fbfb0090ad82f6edd4f" contextRef="c20240101to20241231" format="ixt-sec:duryear">7.5</ix:nonNumeric></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_c098e8952a7146b4affb5bc0e99dce83" contextRef="c20250101to20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">248,208</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_27a47536a72c4a47a7d2b165e9ee1096" contextRef="c20250101to20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">7.78</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" id="Fact_56efd0c892c1409690153e21b127d203" contextRef="c20250101to20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">125,526</ix:nonFraction>)</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_955eb1ba20a14cadb4e7cab66ce682eb" contextRef="c20250101to20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">82.56</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" id="Fact_5ad40d4e9adf450bbc3974aced06a512" contextRef="c20250101to20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">41,290</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" id="Fact_e4dee399761744ce8cd7aad0fabd2d6f" contextRef="c20250101to20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">175.24</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_ea8ecc6d462e446897cc9925644c5333" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">658,973</ix:nonFraction><br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_c1c423c453204155a78ac3bc0d28e5ae" contextRef="c20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">44.20</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_a38a64d2ab204fdfa21fb5fd5655e16b" contextRef="c20250101to20251231" format="ixt-sec:duryear">7.1</ix:nonNumeric></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_b82ed796f0f04403bda23f40111ed0e7" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">357,766</ix:nonFraction><br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_946c0a7b27e04de5bd6c9f307c52b7c8" contextRef="c20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">78.82</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_5097ffe2eae54528a658a01d129233c2" contextRef="c20250101to20251231" format="ixt-sec:duryear">5.6</ix:nonNumeric></div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_8ba460f28b744c8b9a541fe9b9514312" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">658,973</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_efcd13e7d2444f56894f962096307251" contextRef="c20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">44.20</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_c134529c866248abaa4e5584b3f1c57e" contextRef="c20250101to20251231" format="ixt-sec:duryear">7.1</ix:nonNumeric></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f11" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f12">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The weighted-average grant date fair value of options granted was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_b136cc86df1f47388ef4e4ee297941cb" contextRef="c20250101to20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">6.07</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_71ab0f8898d449ceac898ba1a75f3359" contextRef="c20240101to20241231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">20.20</ix:nonFraction> for the years ended
            December 31, 2025 and 2024, respectively. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f12" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f13">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The aggregate intrinsic value of options outstanding was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_df8aa066a5084113af97a409f74d04ee" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million at December 31, 2025 and was de minimis at December 31, 2024. The aggregate intrinsic value of options exercisable was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_e1d292e9947143c9996e2fab60da3a1d" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million at December 31, 2025 and was de minimis at December 31, 2024. There were <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_49b0fff8399f4c74b3c689455349da50" contextRef="c20250101to20251231" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> options exercised during the year ended December 31, 2025 and the aggregate intrinsic value of options exercised during the year ended December 31, 2024 was de minimis.
          </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f13" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f14">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the total unrecognized compensation expense related
            to unvested stock option awards was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_5eb2d7d37f794fc99b9188c97d4f615c" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_bacc2541ad344e3da35501471eb22ebc" contextRef="c20250101to20251231" format="ixt-sec:duryear">2.2</ix:nonNumeric> years. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f14" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f15">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f15" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f16">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f16" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f17"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_9e392f53478042f5bb5d184ec076e0a0" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 95.28pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_4c266c34c0f94bef86947be24f2ea533" contextRef="c20250101to20251231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">93.7</ix:nonFraction>%</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_eb2d393bd1cc4bb195058c00266f2cd5" contextRef="c20240101to20241231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">88.4</ix:nonFraction>%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_ecc965bd11234b28b9b394489b8a4e38" contextRef="c20250101to20251231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.1</ix:nonFraction>%</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_bf0248a0f04a4423a77f38f8843d33f3" contextRef="c20240101to20241231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.2</ix:nonFraction>%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_1ac58e93742a4c4cb5eb3081e26cca90" contextRef="c20250101to20251231" format="ixt-sec:duryear">5.9</ix:nonNumeric> years</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_35400f2d0d014f7da6f9ac048cbd36ef" contextRef="c20240101to20241231" format="ixt-sec:duryear">6.0</ix:nonNumeric> years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_5a0dc34f8e9b4eecb2853a5bcca387bd" contextRef="c20250101to20251231" unitRef="U004" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_b0186d6b23d34501a355109da4e967ba" contextRef="c20240101to20241231" unitRef="U004" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <div>
            <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f17" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f18">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Restricted Stock Units </div>
</ix:continuation>
            <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f18" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f19">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company issues restricted stock units, or RSUs, to employees that vest
              over periods of time as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant.
              Compensation expense is recognized on a straight-line basis over the vesting period of the RSUs. </div>
</ix:continuation>
          </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-24<br/>
        </div>

      </div>

    </div>

    <!--End Page 359-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 360-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f19" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f20">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following table summarizes activity related to RSU awards during the year
            ended December 31, 2025: </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f20" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f21">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f21" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f22"><ix:nonNumeric name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Text_dcbfd101faef4ecb8bfc6b4460abb94e" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_13f6639f0522449487b4f2a70845a20d" contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">7,093</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_26b9c824cfe148c2a134d4beb0ab95bf" contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">44.80</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_abaf8b269954426c8fc2a3a25c8fd7d9" contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_e238b71526164e96ad10587979cff368" contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">11.70</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_7b52f661896d47cf9c54668eeadd2983" contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">16,825</ix:nonFraction>)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_88d69d1b0d7740e6a15aa71251957b0a" contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">27.92</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_2820809321754b06b322326f97a95cf1" contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">268</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_269339ade09545b5abd66e7f99dabc4e" contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">90.40</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_799b94c51ff447e89f9f49e2a69b7e83" contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction><br/>
                    </span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_806a8eed7f3041f7b48004719bfb6f49" contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">10.52</ix:nonFraction></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f22" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f23">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the total unrecognized expense related to all RSUs
            was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_96cf1445405645c8ade283f8537e9735" contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Fact_c230c76de13d4da3b28ac3a16ef04a29" contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">1.0</ix:nonNumeric> years. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f23" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f24">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employee Stock Purchase Plan </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f24" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f25">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_0afe79a01adb4bd69f905ffa0a81c755" contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">99,088</ix:nonFraction> shares of the Company&#8217;s common stock. Of this amount, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_614c1d5ca57140f49f936aebf4069924" contextRef="c20251231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">59,103</ix:nonFraction> were available for future grants as of December 31, 2025. The number of shares of the Company&#8217;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January&#160;1st of each year and continuing for <ix:nonNumeric name="pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Fact_fa9d02b9390644cd98b2233904fdb5ab" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, in an amount
            equal to <ix:nonFraction name="pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" id="Fact_dc3e48ec26df470c88655f5a53a97cbe" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="2" scale="-2" format="ixt-sec:numwordsen">one </ix:nonFraction>percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP was not increased. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f25" continuedAt="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f26">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock
            through accumulated payroll deductions at such times as are established by the board of director&#8217;s Compensation Committee. Eligible employees may purchase the Company&#8217;s common stock at <ix:nonFraction name="pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage" id="Fact_a4e4f275cd634469bf47a710ea2122c9" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="INF" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to <ix:nonFraction name="pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" id="Fact_473de1307fea4d14aefff4877e86b76b" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $<ix:nonFraction name="pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" id="Fact_c8a02dd939e4413a8dd5b7f081e012f5" contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction>
            worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than <ix:nonFraction name="pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" id="Fact_513a3dd570af45e78e6679b3818903f9" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">200</ix:nonFraction> shares of
            the Company&#8217;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from <ix:nonFraction name="pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" id="Fact_dc3ed54840894071b3134b6ce56d0140" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">200</ix:nonFraction> shares to <ix:nonFraction name="pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" id="Fact_a5f5a4e533e641679c988bb8388956e8" contextRef="c20260501to20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">2,000</ix:nonFraction> shares in any single offering period, not to exceed $<ix:nonFraction name="pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" id="Fact_8d4dc96fac544b9e9938f2d15a1422b8" contextRef="c20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> in any calendar year. </div>
</ix:continuation>
          <ix:continuation id="Text_6b6bc5ccaa41475bbe6d6dc5692dfb9f26">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the guidance in ASC Topic 718-50,<span style="font-style: italic;"> Compensation &#8211; Stock Compensation</span>, the ability to purchase shares of the Company&#8217;s common stock at <ix:nonFraction name="pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage" id="Fact_ed866bcdd2d04d8584451b9a18b745b9" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="INF" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the
            lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and<span style="font-weight: bold;">, </span>therefore, the ESPP is a compensatory plan under this
            guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f199ba375c0c45c8a7f7d23743d18fbc" contextRef="c20240101to20241231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_dbecac16ef614fb0bf59ce3c0f411f71" contextRef="c20250101to20251231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> share-based compensation expense related to the ESPP was recorded during the years ended December 31, 2025 and 2024. </div>
</ix:continuation>
        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_3822bad715044d959d44a011b4f19698" contextRef="c20250101to20251231" escape="true" continuedAt="Text_325615726879467d9c942997190aac8e1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">14. Income Taxes </div>
</ix:nonNumeric>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e1" continuedAt="Text_325615726879467d9c942997190aac8e2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The tax effects of temporary differences that gave rise to significant
            portions of the deferred tax assets and liabilities were as follows: </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e2" continuedAt="Text_325615726879467d9c942997190aac8e3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_325615726879467d9c942997190aac8e3" continuedAt="Text_325615726879467d9c942997190aac8e4"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Text_18cdc19081024323b420349013328872" contextRef="c20250101to20251231" escape="true" continuedAt="Text_65e126b863eb482fb8eec7b62c77c4be1">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 89pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets:<br/>
                  </div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net operating loss carryforwards</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_8323423f0e8f41de86b48269e4216f6d" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">105,425</ix:nonFraction></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_91aebc5f5e12450fade0c59d32372140" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">94,923</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development credits</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" id="Fact_6da378c7f2c940279ae42027ba57fa1f" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,020</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" id="Fact_8f1044e9d70d46089f53f95e2671e8c0" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,842</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration and license agreement</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 15pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement" id="Fact_d02d92cf76dc467aa4567e78ae3854e0" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,832</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement" id="Fact_9cd0150bfd46424996f62befa2d4e522" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-25<br/>
        </div>

      </div>

    </div>

    <!--End Page 360-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 361-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_325615726879467d9c942997190aac8e4" continuedAt="Text_325615726879467d9c942997190aac8e5"><ix:continuation id="Text_65e126b863eb482fb8eec7b62c77c4be1">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 11.25pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 89pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Capitalized research and development</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment" id="Fact_9eba2b4c6b1b4b138f7a40f925a67ed8" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,041</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment" id="Fact_760c017e982349deaefd9db5a984799f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,803</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_3fbe55c454074507b13eb69fd44ec3d9" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,329</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_3397f2a69e194c85bf6d007acf272508" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,863</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses and other</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" id="Fact_edd047796804445ea1b1b9dfc1bf686a" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,581</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" id="Fact_3df4e946f78e429dad911ea71e5f46ee" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,404</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liabilities</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsOperatingLeaseLiabilities" id="Fact_97c4932987cc49e0b076e5de243f2605" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,520</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsOperatingLeaseLiabilities" id="Fact_719945a60519400d8bc5d11a12fbd24b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,560</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsDepreciationAndAmortization" id="Fact_2a4219c63a904b228a285b98e3749773" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,048</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:DeferredTaxAssetsDepreciationAndAmortization" id="Fact_c48edbf799c94712b48437aa37b56560" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total gross deferred tax assets before valuation allowance</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_a83fd552a95a487483e82e4ca4d6ac3b" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">225,796</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_ad526a50fa9140aeb6f71c1545645796" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">224,278</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valuation allowance</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_06020a90aec0443fa72eef6dcd1406c5" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">222,752</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_4b951fb4635341dcaa9e595cbe74854d" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219,833</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Net deferred tax assets</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_25395b998d364a7fb9c143541d30639d" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,044</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_c86a8657c65e487f909a4af078cea44f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,445</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax liabilities:<br/>
                  </div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right of use assets - operating leases</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" id="Fact_ac89ef03169048a495414cba3bb11f00" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,044</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" id="Fact_3b19f29d9ce94bdd9a13d74964a10962" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,445</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total deferred tax liabilities</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" id="Fact_9c5e362b4a4e4f888cd6372d303dfb20" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,044</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" id="Fact_527ce2e7d616412e871264b2807c329b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,445</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Net deferred taxes</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_bdac3f41a6a047bf831c18c8f1daa73e" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_76ae474e54b049d49d4e737ef1aa0a95" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_325615726879467d9c942997190aac8e5" continuedAt="Text_325615726879467d9c942997190aac8e6">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In assessing the need for a valuation allowance, management must determine
            that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined the deferred tax assets do not meet the more-likely-than-not
            threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December 31, 2025 and 2024. The valuation allowance increased by $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" id="Fact_4c5c8bdcb49e491588b899b1b6017381" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" id="Fact_65a12505bffc4211a69831f785ce5dbe" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.1</ix:nonFraction> million during
            the years ended December 31, 2025 and 2024, respectively. </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e6" continuedAt="Text_325615726879467d9c942997190aac8e7">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the year ended December&#160;31, 2025, the Company adopted ASU No. 2023-09,
            <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span> retrospectively. A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e7" continuedAt="Text_325615726879467d9c942997190aac8e8">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_325615726879467d9c942997190aac8e8" continuedAt="Text_325615726879467d9c942997190aac8e9"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Text_67b5e1f66f7c4acdb597df2538091232" contextRef="c20250101to20251231" escape="true" continuedAt="Text_f2cbc3e15d014374964505e304ade4bb1">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 165.09pt;" colspan="10">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 165.09pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 73.44pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 76.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">US federal statutory tax rate</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 1.67pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_fdcd6efca63e4a5e9257ddb5c3f41701" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,560</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_c05dd176c0ae41f9b288c6269e729664" contextRef="c20250101to20251231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction>%<br/>
                    </span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_d861656a247c46e987f3515461d229ff" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,601</ix:nonFraction>)</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_8b483eede7b747c19be8706024a32a16" contextRef="c20240101to20241231" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction>%</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Federal:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Tax credits:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Research and development tax credits</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" id="Fact_ad7f4d71827c4438a2acd3149b84c768" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" id="Fact_15a3c7540a7548d290f25136237c3498" contextRef="c20250101to20251231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" id="Fact_d1a26b11e4a74db5b9fee6b8410356ca" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">626</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" id="Fact_e88b9e3b8e0945aab7f90976998699b8" contextRef="c20240101to20241231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Orphan drug tax credits</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 6.67pt;">(<ix:nonFraction name="pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" id="Fact_82aaa4a9221843b6916924e73c581722" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,003</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" id="Fact_e294a6ebffb240e59c2d4741c13f89c3" contextRef="c20250101to20251231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">8.8</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(<ix:nonFraction name="pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" id="Fact_be58a5acf8b64bfd9c47a5db645bce56" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,896</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" id="Fact_9ae53492f60746bfbac71bbdeef1e12d" contextRef="c20240101to20241231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in valuation allowances</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_f9ba5a37e0494569999b58d99cc0ccee" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,334</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_0f40f26e8f6d46e2b17673a2bfce5eda" contextRef="c20250101to20251231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">27.2</ix:nonFraction>)</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_fff59c56d7824dc5bc13694f48c14a4f" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,422</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_082289dd25fa40ad87a6add21e15a0f2" contextRef="c20240101to20241231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">27.0</ix:nonFraction>)</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Nontaxable or nondeductible items:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Share-based payment awards</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" id="Fact_0e133f5c507e4b3da83e962354139c03" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">241</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 5pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" id="Fact_1d8046d6cc234a5593f9cdcb7f921475" contextRef="c20250101to20251231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.5</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" id="Fact_1755d38c70c444e0a775784e4a512390" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 5pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" id="Fact_a96bbee22d19486092a3a3dbac2b3c61" contextRef="c20240101to20241231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.7</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Expiration of share-based payment awards</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_1e2f04a60938463884065ee477fa41a2" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,159</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 5pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_61e3b64dd42d4b8684f562c185892a20" contextRef="c20250101to20251231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_b5750ff937784aeb99a1be30b220933d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 5pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_421cc73fc425446ea2c3589f400f1cc6" contextRef="c20240101to20241231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">1.9</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Other</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" id="Fact_fbbbb487c0394a22a886c6921af84307" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" id="Fact_dc693fb67ad94b9db60d9b03a3f2027f" contextRef="c20250101to20251231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" id="Fact_99243719aeb440f1bfbcf0aacf6a0f92" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" id="Fact_9016768f60194f26b3f0ebebe4a5a516" contextRef="c20240101to20241231" unitRef="U004" decimals="3" sign="-" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State and local income taxes, net of federal income tax effect<sup>1</sup></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective tax rate</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_873120e2011d48d989606558a7b10414" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_f96dedb2b0e14ef89481beb35364b697" contextRef="c20250101to20251231" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_a4a50b54568f409ba68599f459819ef6" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_9addc95db57c40d395969e6264800fd9" contextRef="c20240101to20241231" unitRef="U004" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 26.06pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 26.06pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <div>
            <ix:continuation id="Text_325615726879467d9c942997190aac8e9" continuedAt="Text_325615726879467d9c942997190aac8e10">
<div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> <br/></div>
</ix:continuation>
          </div>


          <ix:continuation id="Text_325615726879467d9c942997190aac8e10" continuedAt="Text_325615726879467d9c942997190aac8e11"><ix:continuation id="Text_f2cbc3e15d014374964505e304ade4bb1">
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic;">1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; text-align: justify;">In 2025 and 2024, state and local income taxes in Pennsylvania and Philadelphia comprise the majority of
                    the state and local income taxes, net of federal income tax effect category.<span style="font-style: normal;"> </span></div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_325615726879467d9c942997190aac8e11" continuedAt="Text_325615726879467d9c942997190aac8e12">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December&#160;31, 2025 and 2024, the Company made <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_cf781248de6748e9be75c34c717e6e8a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_3585b94c69714555aeb8f1589728d43b" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> income tax payments. Additionally, the Company generated <ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" id="Fact_a9d2b67203404d1a821eaca2a80ac225" contextRef="c20250101to20251231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" id="Fact_095107ebd20b45c0bee1e104a36f3b88" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> foreign pre-tax income or losses during these periods, as all operations were conducted within the United States. </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-26<br/>
        </div>

      </div>

    </div>

    <!--End Page 361-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 362-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_202-finnotes_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_325615726879467d9c942997190aac8e12" continuedAt="Text_325615726879467d9c942997190aac8e13">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The following table summarizes carryforwards of federal, state and local net
            operating losses, or NOL, and research and development and orphan drug tax credits: </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e13" continuedAt="Text_325615726879467d9c942997190aac8e14">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_325615726879467d9c942997190aac8e14" continuedAt="Text_325615726879467d9c942997190aac8e15"><ix:nonNumeric name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="Text_5e0d470cf8e643c39f279ec97ffdae31" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 91.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 91.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Federal</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_f99fec03bceb44d69b320638e3110176" contextRef="c20251231_IncomeTaxAuthorityAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">398,039</ix:nonFraction></div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_7c88dfeca3024284bfac89a78119d3ec" contextRef="c20241231_IncomeTaxAuthorityAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">339,055</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_2bb492ec56c1499e8b6412b5d3f2c233" contextRef="c20251231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">398,035</ix:nonFraction></span></div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_f3516b2362894cc1b233da5a89a068c3" contextRef="c20241231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">339,051</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Local</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_618b9b6af59a4b8094803769a0527625" contextRef="c20251231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">277,828</ix:nonFraction></span></div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_f7180588a5f74b1f98448d7528675ac5" contextRef="c20241231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">218,844</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research tax credits</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_3d596e912cc14fa9babd3d4afa18e38e" contextRef="c20251231_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,020</ix:nonFraction></span></div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_5546a465f4e643189210239552794a79" contextRef="c20241231_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,842</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_325615726879467d9c942997190aac8e15" continuedAt="Text_325615726879467d9c942997190aac8e16">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For federal income tax purposes, $<ix:nonFraction name="pasg:OperatingLossCarryforwardSubjectToExpiration" id="Fact_deadf62dfb2544d2bb68c0fd647b9979" contextRef="c20251231_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million of NOL carryforwards expire in 2037. The remaining federal NOL carryforwards were generated subsequent to January&#160;1, 2018, and therefore, are able to be carried
            forward indefinitely. </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e16" continuedAt="Text_325615726879467d9c942997190aac8e17">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">For state income tax purposes, NOL carryforwards begin expiring in 2037, and
            expire through 2045. </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e17" continuedAt="Text_325615726879467d9c942997190aac8e18">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For local income tax purposes related to the city of Philadelphia, NOL
            carryforwards begin expiring in 2042, and expire through 2045. </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e18" continuedAt="Text_325615726879467d9c942997190aac8e19">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the Company also had $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_ba68e86d28e640fa8f94b364f6f95062" contextRef="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.6</ix:nonFraction> million of federal research and development and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_97b3030478ab48b68834ea68376d1c23" contextRef="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_OrphanDrugMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">43.4</ix:nonFraction>
            million orphan drug tax credit carryforwards that will begin to expire in 2038 and 2040, respectively, unless previously utilized. </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e19" continuedAt="Text_325615726879467d9c942997190aac8e20">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The NOL and tax credit carryforwards are subject to review and possible
            adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders
            over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually
            to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in
            future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOL carryforwards may also be limited, including Pennsylvania, which limits NOL utilization as a
            percentage of apportioned taxable income. </div>
</ix:continuation>
          <ix:continuation id="Text_325615726879467d9c942997190aac8e20">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"><span style="-sec-ix-hidden:Fact_bf46da9b45834552bfbf43a7fff05a75">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net.</span> As of December 31, 2025, the Company had <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" id="Fact_0c019b42a10f465d94a7eefa03ac3f66" contextRef="c20251231" unitRef="U001" decimals="-5" scale="5" format="ixt-sec:numwordsen">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" id="Fact_d987024a26fa4143a993c02b9513e960" contextRef="c20250101to20251231" unitRef="U001" decimals="-5" scale="5" format="ixt-sec:numwordsen">no</ix:nonFraction>
            amounts have been recognized in the Company&#8217;s statement of operations. <span style="-sec-ix-hidden:Fact_76a8a6c10938470cb53d52e197480e2e">Tax years from 2022</span> and after remain subject to examination
            by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized. </div>
</ix:continuation>
        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_9742994bf92f4ad7a6f30665c90e0a45" contextRef="c20250101to20251231" escape="true" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">15. Segment Reporting </div>
</ix:nonNumeric>
          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a1" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a2">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a <span style="-sec-ix-hidden:Fact_6fcb045ac6ef441986cb7c4046a9cae6">single</span> reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. </div>
</ix:continuation>
          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a2" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a3">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies. The Company&#8217;s CODM is its chief executive officer. </div>
</ix:continuation>
          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a3" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a4">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The measure of segment assets is reported on the balance sheet as total
            assets. All assets are located within the United&#160;States. </div>
</ix:continuation>
          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a4" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a5">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara"> The CODM uses net loss as reported on the Company&#8217;s statement of operations
            to assess the Company&#8217;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses
            exclude certain non-cash items such as share-based compensation and depreciation and amortization expenses. </div>
</ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-27<br/>
        </div>

      </div>

    </div>

    <!--End Page 362-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 363-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_202-finnotes_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_fpara">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Notes to Financial Statements<span style="padding-left: 4pt;">(cont.) </span><br/>
          </div>


          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a5" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a6">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">The following table summarizes significant segment expenses: </div>
</ix:continuation>
          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a6" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a7">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a7" continuedAt="Text_94c893dfd9c24093aa8d92bd4fe4282a8"><ix:nonNumeric name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Text_3506ba8ede0c40ecabbea17553c3c669" contextRef="c20250101to20251231" escape="true">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 12.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Research and development<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentLaborAndRelatedExpenses" id="Fact_3fd6f1cd904042d3b20e6c667e4b0c19" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,462</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="pasg:ResearchAndDevelopmentLaborAndRelatedExpenses" id="Fact_81abfc315ce34662a68b7a26ff77e986" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,265</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentThirdPartyCosts" id="Fact_961359f9bb6d46aba24ac633cea6baf4" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,532</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentThirdPartyCosts" id="Fact_29d962d9a1e84b5d8e1e43fbbb8c3d97" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,691</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentShareBasedCompensation" id="Fact_776044df752b4242ae4ca60ec7ed1b7f" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">842</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentShareBasedCompensation" id="Fact_c7d0394254a5495ca03213022dbd1394" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,529</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentDepreciationAndAmortization" id="Fact_e9f3c02413df48259cda1695b10802cb" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">440</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentDepreciationAndAmortization" id="Fact_121e637bb4384ac2ac7fa5be75e964ae" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,694</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total research and development expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_f55f1fcb81ce404abaecf92524b1d2ca" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,276</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_f85e68dccde24bde84b7937d67a417c4" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,179</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">General and administrative<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeLaborAndRelatedExpenses" id="Fact_74f5e6a8136f483499d1a04e9127d1c2" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,784</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeLaborAndRelatedExpenses" id="Fact_0d3e5dec0cec46e88c8541ca1f9f3576" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,255</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeThirdPartyCosts" id="Fact_d80159027deb457a94f193cac6cd75b4" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,644</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeThirdPartyCosts" id="Fact_cb1eb4de7bf4448f8d53e61308ccd85e" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,055</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeShareBasedCompensation" id="Fact_c21bbc4fa24549b99ba6b0775469992f" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,159</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeShareBasedCompensation" id="Fact_86a4508f02a2428e8b7fd056ca562c30" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,291</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeDepreciationAndAmortization" id="Fact_e7f24888938b4e48b0fc35d979a67aee" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">288</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeDepreciationAndAmortization" id="Fact_b5472040dc934ae0a1ca2a2ae682cb9e" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">387</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total general and administrative expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_3ef49bde238e4ab6ab5dff3788a4758b" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,875</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_564cb9ae79324daa813af94cbb5a146a" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,988</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Impairment of long-lived assets</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_4b71f524ce4140c9bd40eb5e592cf74e" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,145</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_a2891305c71c48b19d1a66322374b040" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,233</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Loss from operations</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_7055b6997b9a458ba417af2d593d1de7" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">49,296</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_2149e04d80cf4dc98150f94f92a01532" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">70,400</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Other (income) expense, net</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_9ae7c6fcdf01448e84aa36d6b238ed34" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,774</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_0b3e33bc765b468d958947c564a637bb" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,633</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Net loss</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_43ceea284e014699a2e74661cde072d8" contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,522</ix:nonFraction></span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_50e14a6f3ed64720ba6dc11d107bb709" contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">64,767</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_94c893dfd9c24093aa8d92bd4fe4282a8">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">The components of Other (income) expense, net are further described in note 3
            to the financial statements.</div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_6863ed48a63d44b0a8696795a5d8cb8c" contextRef="c20250101to20251231" escape="true" continuedAt="Text_d5201c3bdb4348b0a0eae1f27f6256de1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">16. Subsequent Events </div>
</ix:nonNumeric>
          <ix:continuation id="Text_d5201c3bdb4348b0a0eae1f27f6256de1">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">None. </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-28<br/>
        </div>

      </div>

    </div>

    <!--End Page 27-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 28-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_203-fintab01_pg1"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;" class="BRDSX_h1">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">Balance Sheets<br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">(Unaudited) </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> </div>

          <table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands, except share and per share data)</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March&#160;31, 2026</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Assets </div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Current assets: </div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Cash and cash equivalents</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_baca7cafd3794351a910e440dbfedef2" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,336</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_737a2058fd6c4e0a9ab5fb9a8609b5ed" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,303</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Prepaid expenses and other current assets</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_e3d66196cdb14bce9ebe46aa9b3cb7f3" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_dd157cec4eff437898738a757d7e227f" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">629</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Prepaid research and development</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" id="Fact_04c70b6c419f4520a32ade088d36aade" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">723</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" id="Fact_b51f2dd458cb4b79a4b7de229183f33f" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total current assets</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_c54f1af76c4c413689ca95cb42199b43" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,741</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_8bd48b9bcc85499db52e307b224f577a" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,762</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Property and equipment, net</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_6fd229ebc8e540529b8d6bfd0c4ea0ea" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">826</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_2758f48ba9914fe89b03129424133708" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,107</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Right of use assets - operating leases</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_a1aa9d4a02d4458f9f4c23e558e91cc2" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">651</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_43f6e99446c04ba499ce589b826597f7" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,168</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Other assets</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_2d627cfc67744369a47a3d8c12bcfe5e" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_4b32cbcbc4ee47e293a34a5961da7196" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total assets</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_f9e856ab45e04451ac139ef129503527" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,462</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_ef531f1ee8be4287ab60da189e0375f4" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,281</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Liabilities and stockholders&#8217; equity </div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Current liabilities: </div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Accounts payable</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_d54f371363e9488f9fd51c48b341649b" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,310</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 13.7pt;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_d09400df388b4c1ead8ce6f5a20d3b14" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,113</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_3cbb6ccdf0e74d9598eba256c7790387" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,895</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt;"><ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_65d3409b7cab43b6a94a7ccb412d0085" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,653</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Non-refundable sublicense and transition services payments</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_8f7ffdf4390d4f508bcb004bed6b0cfd" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,750</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_2a111f91023b4a0f8249c367561cf0b3" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,750</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Operating lease liabilities</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_6d50bcbbff8a4b6f9c48fe3323073a9d" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,149</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_45052f4ba9334c5d9f085bea8aea5fcd" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,567</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total current liabilities</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_b75a68170c024705bbc13608802bf93a" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,104</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_82c405676db041f68e156add2e64ff09" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,083</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Operating lease liabilities - noncurrent</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_74195e706c40453da7b3ef1a31f8d95b" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,606</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_5039b200ac9e43b9873143cc3aa65c6b" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,443</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total liabilities</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_39d42c322055480a90b5d08992997ebe" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,710</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_d047bfc1332741c2b8b52d968625fd96" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,526</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Commitments and contingencies (note 10) </div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><span style="-sec-ix-hidden:Fact_b0ea0c10802147e1aace77035d2e4588"> </span></td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><span style="-sec-ix-hidden:Fact_aae3abcfe7c54022ae82a6d996c01274"> </span></td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Stockholders&#8217; equity: </div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Preferred stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_be731cf726cf4132abea5f891ddbed01" contextRef="c20260331" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_559697deb2af486e9814bd17aeca554b" contextRef="c20251231" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value: <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_d0dec8ea1db7456c94780bf9a19c0f9a" contextRef="c20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_4aa32106aa6f4e12b74c83dc07f7d959" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span>
                    shares authorized; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_3f2dfde085a348c7ae3bf0939f35d1f8" contextRef="c20260331" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_259a4b6c1c1742a3b021f20e9400afff" contextRef="c20251231" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_198c6ce0d4cb42b3a6eca4aac61d53e4" contextRef="c20251231" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_05169ecaafac4626a0a3545e253d9165" contextRef="c20260331" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at both March&#160;31, 2026 and December&#160;31, 2025</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;"><span style="-sec-ix-hidden:Fact_6cc7532afaff475eb890c1213316a0a2">&#8212;</span></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;"><span style="-sec-ix-hidden:Fact_fc17000e5373490cbae15a0831b04236">&#8212;</span> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Common stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_a5e1a6f3ad78467f8445bb6560b4e7b3" contextRef="c20260331" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_1ed9b55a8c6d4939bec0bb1c0b0dacc7" contextRef="c20251231" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value: <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_39194d1243a84f82bf9265d568bdc7e1" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_320e8d1703394f169b12212f1fee6443" contextRef="c20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span>
                    shares authorized; <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_e53fc8338b134444adcba5cf45a9e5e1" contextRef="c20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_880532351558425a8f586df286f6801d" contextRef="c20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,207,810</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at March&#160;31, 2026 and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_d1f634250a4843e19223b1afb4a32537" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_183b90fa5d754215a77a690896c8c055" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,182,810</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Additional paid-in capital</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_7b1bd9c7572c46a7aca3f826243ecfa6" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">724,068</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_3f7f8f53f47e440f97702e8e3fc6f206" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">723,512</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Accumulated deficit</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_a965e46c82ea4ee59cfab93e59bfbaaa" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">712,316</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_8c5b8394d9414efa9a55aae9cfe7812b" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">704,757</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total stockholders&#8217; equity</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.7pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_531d66ecf4d540369b1efe4b06d02939" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,752</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_a0e117115a0c425383c397ed154a9eea" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,755</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Total liabilities and stockholders&#8217; equity</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.06pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_34daa57d15c846e4a055a03ae1f2523f" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,462</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.84pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_97a8f5030e1842f6bf566114e5fc3991" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,281</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara"> </div>

        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">See accompanying notes to unaudited interim financial statements.<br/>
        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-29<br/>
        </div>

      </div>

    </div>

    <!--End Page 28-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 29-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_203-fintab01_pg2"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_h1">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">Statements of Operations and Comprehensive Loss <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">(Unaudited) </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> </div>

          <table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands, except share and per share data)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Operating expenses: </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Research and development</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_73964263e3a0417bb5eac10cc1b4e019" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,093</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_3bb671550ef8455d84276a7546ddcaed" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,737</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">General and administrative</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_6f268f3daf5b45aa9b56ebe4bba94586" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,787</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_dda45b9342724a429816cbd58cc1d079" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,085</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Impairment of long-lived assets</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_4971bd6e20844486a18d73e5347bb07b" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,637</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Net gain on lease termination</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 26.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:GainLossOnTerminationOfLease" id="Fact_23e0ad2e78b14a1cbab9a6857bbfa19b" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;" class="BRDSX_fpara">Loss from operations</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 19.17pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_5131882999e94245950ae08c3c019f17" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,247</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 14.17pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_8610e6090c06424088644082f5e57d8e" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16,459</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Other income (expense), net</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_5144dc288c4a4ff0b791f46c6d063b59" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">688</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_8358688a84534310801b8cdecc92981d" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,054</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Net loss</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f578e337b450429da14285b31dc8724b" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,559</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4a3cfab7aed24869b72750468d4e55f4" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,405</ix:nonFraction>)</span><span style="padding-bottom: 0.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Per share information: </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Net loss per share of common stock, basic and diluted</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_510a6e6e2dbe4a0496a4181240e7645c" contextRef="c20260101to20260331" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_0a5849c24c3540f780a4accb1db74dd8" contextRef="c20260101to20260331" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">2.36</ix:nonFraction></ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_ee2a7d0c8b5941ce9a9e08516a151a01" contextRef="c20250101to20250331" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_e203fd703e0f43aeb36f3eb9309baaf3" contextRef="c20250101to20250331" unitRef="U002" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">4.87</ix:nonFraction></ix:nonFraction>)</span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Weighted average common shares outstanding, basic and diluted</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_fe3ab6034f19452684f52e26e3170402" contextRef="c20260101to20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_e5d22873e84244fb89d7dd630ea2a0a9" contextRef="c20260101to20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,205,866</ix:nonFraction></ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_e16fb4b85bbf45bf92f69cc765915ed4" contextRef="c20250101to20250331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_dc8c42d10306473da164228a33c1660e" contextRef="c20250101to20250331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,163,914</ix:nonFraction></ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Comprehensive loss: </div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Net loss</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 14.17pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_54c74b94447440ca99ede9283666a28a" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,559</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 9.17pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3b0c88e6d23840499d7334b272bc644b" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,405</ix:nonFraction>) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;" class="BRDSX_fpara">Unrealized gain (loss) on marketable securities</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_ef0ff808302943adac208a2b5cc0973e" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>)</span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Comprehensive loss</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 14.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_5261cea89f454636a5b2eb42c318f96b" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,559</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.42pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_1565b40a52b8441cbb7e3cd6414ed5e2" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,413</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">See accompanying notes to unaudited interim financial statements.<br/>
        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-30<br/>
        </div>

      </div>

    </div>

    <!--End Page 29-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 30-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_203-fintab01_pg3"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_h1">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">Statements of Stockholders&#8217; Equity <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">(Unaudited) </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> </div>

          <table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.63pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.63pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 73.25pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.56pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 97.16pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45.32pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.62pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 32.5pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 2.63pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 73.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Common stock</div>
                </td>

    <td style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Additional </div>
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">paid-in capital</div>
                </td>

    <td rowspan="2" style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Accumulated other </div>
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">comprehensive income (loss)</div>
                </td>

    <td rowspan="2" style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Accumulated </div>
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">deficit</div>
                </td>

    <td rowspan="2" style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.62pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Total </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands, except share data)</div>
                </td>

    <td style="width: 2.63pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Shares</div>
                </td>

    <td style="width: 2.63pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Amount </div>
                </td>

    <td style="width: 2.62pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Balance at January&#160;1, 2026</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_9f4674a68da948b58e065dfbfc5d1f79" contextRef="c20251231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,182,810</ix:nonFraction> </div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.03pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_09cc79da126e462789c8ba6c547e7ec8" contextRef="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">723,512</ix:nonFraction></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;" class="BRDSX_fpara">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_72cd475cad4d47c597d8db01d3cc5ca1" contextRef="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">704,757</ix:nonFraction>)</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_467f3ceefb9046b7bd74f1b74f752bea" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,755</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Exercise of stock options and vesting of restricted
                    stock units</div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 12.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_1babbc723d5a488e951e86b80dc67300" contextRef="c20260101to20260331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.03pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Share-based compensation expense</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.03pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_0418d71e8d874401a1bfa09676769d1b" contextRef="c20260101to20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">556</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_13eac2d0ce1f487db0a1d0250b5ca726" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">556</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Net loss</div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.03pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c2c27d2dc7a148dfb937266a8b92a69a" contextRef="c20260101to20260331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,559</ix:nonFraction>) </span></div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b2c8311489b146028601c0e527afe016" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,559</ix:nonFraction>) </span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_635730bd39b74254abbcd213e935960c" contextRef="c20260331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,207,810</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.49pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.03pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8f5b135425ed4374b8d7841529914ede" contextRef="c20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">724,068</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.16pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.24pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_081a74f81f3148fda55d099edf0497f6" contextRef="c20260331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">712,316</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 0.37pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8db4feafaff44f968d1d4f667697d1ff" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,752</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.99pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.56pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 97.16pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.62pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> </div>

          <table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 72.69pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 49.56pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 97.15pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45.31pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 2.35pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72.69pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Common stock</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Additional </div>
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">paid-in capital</div>
                </td>

    <td rowspan="2" style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Accumulated other </div>
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">comprehensive income (loss)</div>
                </td>

    <td rowspan="2" style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Accumulated </div>
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">deficit</div>
                </td>

    <td rowspan="2" style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 2.35pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" rowspan="2">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Total </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands, except share data)</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Shares</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Amount </div>
                </td>

    <td style="width: 2.35pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Balance at January&#160;1, 2025</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_e96612d5ce0a4d18937e33aaab4e5db0" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,161,503</ix:nonFraction> </div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;" class="BRDSX_fpara">$&#8212;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2a9e83f0dff54dd9baa1da2b1487382f" contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">720,488</ix:nonFraction></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_94060ce6eda4403b9273727dc2327338" contextRef="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;" class="BRDSX_fpara">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0c9164c371dd43e5816eee6d87d61592" contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">659,235</ix:nonFraction>)</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_035b67ac3de64fc79eb91922b2dd8a9a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,261</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Exercise of stock options and vesting of restricted
                    stock units</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 17.5pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_0daf2d6f528145da903fde531c071b26" contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">4,325</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Unrealized gain (loss) on marketable securities</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 6.67pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_8b4f0b52c0c041a4a6f790fb233e1dbd" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>) </span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 27.5pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" id="Fact_bdc564e0e6264adf85be233ab162d80c" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;" class="BRDSX_fpara">Share-based compensation expense</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 22.5pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_71f698419a424dcc9db060f2d6ca426b" contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">858</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_ebbf29a6202a4358b57ef7fd382a3678" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">858</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Net loss</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6fd23e64b787436f8121ddbb67789687" contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,405</ix:nonFraction>) </span></div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cf7b5bfd952a45318d6219ca20666c7c" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,405</ix:nonFraction>) </span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Balance at March&#160;31, 2025</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f1dc144d556f47cc8b19eecd305dd8a4" contextRef="c20250331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">3,165,828</ix:nonFraction> </span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.56pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.04pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_bedb26746b31452092c7687b97bdbc66" contextRef="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">721,346</ix:nonFraction></span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 97.15pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 41.08pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_a53661cae021489fae0606c3afa62522" contextRef="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">674,640</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4f5a87ba13c74076adb082be3adab9f4" contextRef="c20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,706</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.56pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 97.15pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.31pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.35pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">See accompanying notes to unaudited interim financial statements.<br/>
        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-31<br/>
        </div>

      </div>

    </div>

    <!--End Page 30-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 31-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_203-fintab01_pg4"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Statements of Cash Flows <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Unaudited) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 77.84pt; white-space: nowrap;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 77.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 3.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows used in operating activities: </div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_06866935a11a4f48800dcc7c1fdb05f9" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,559</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_167ada6afb344bc6bda428923e19f334" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,405</ix:nonFraction>) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to reconcile net loss to net cash provided by (used in)
                    operating activities: </div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_a3234483f678475494db6cc9e900eb40" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_d4b25415761441318de8d5a2623b5675" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">201</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_d96961153a1f43fb86b853c514c9ff4e" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">556</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_d44b4f3ae98f4d278f7f53205af6c5fc" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Amortization of premium and discount on marketable securities, net</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_13ba4a5c43ee466591edd34ccc667e9e" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">129</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(<ix:nonFraction name="us-gaap:GainLossOnTerminationOfLease" id="Fact_35c859b89a2e4d8cbb7661c17b4f96b9" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">633</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_f3022c33b8e445a89c00789cc1b02ef1" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,637</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities: </div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid expenses and other current assets, and other assets</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_7829b53d3b084b31ad103cc58699e240" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">53</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_20a9320556ac4cef80f07a618b6768ea" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">709</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid research and development</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" id="Fact_9f613d07bfae41e4ae406e1ff86b3629" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;"><ix:nonFraction name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" id="Fact_8e67b90ee6ab42e2959944b780f3a99e" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Non-refundable sublicense and transition services payments received</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" id="Fact_0d153bfd4e744c318c208c7e96b687db" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">506</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Right of use assets and operating lease liabilities</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(<ix:nonFraction name="pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" id="Fact_3dc16583a93948b0aca59381fc730a72" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,973</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">(<ix:nonFraction name="pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" id="Fact_023592fceb0b49d58120f79d664b1d1f" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" id="Fact_5695fc21fd89498e89a4b30e9491d873" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">197</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" id="Fact_b5eb567c66904b50bf633c52c1b003bb" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">716</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_71831830d3444369a2ba6a0978df2fa0" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">758</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" id="Fact_ac1e0e411dd54fe4a3fb4e7a3db25068" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,713</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in) operating activities</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_e69530fa2728495b9f0c7e889fbe7810" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,987</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_54304b9b5000432cad36dbf7e5260c93" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,847</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows provided by (used in) investing activities: </div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Sales or maturities of marketable securities</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" id="Fact_3c5a83ed15c14e6982b33034792fa602" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,046</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Sales of property and equipment and other assets</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" id="Fact_bdcef3ed5f0a4d5f85903010343293e1" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfProductiveAssets" id="Fact_dcdd6c236b2e4f528d9f4def02ce5c9e" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">585</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in) investing activities</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_5f895841a48d48a2b0a5e5ca1e71c525" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_7b36403e56e44f5d849a01601e8a3d88" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,631</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows provided by (used in) financing activities: </div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net cash provided by (used in) financing activities</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase (decrease) in cash and cash equivalents</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_d66fc2ee5f8c4bbe8172094d1acfb4ea" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,967</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_496d609746574e3ca0c5dd54fbe1a56d" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,784</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at beginning of period</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_84b136414fac42688b06ccb6856dcbba" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,303</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_186eee3260a74e2fa11ba4e57c32c901" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,573</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents at end of period</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_db9d6ada9ece4cf7bcd1a1c22787dfe0" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,336</ix:nonFraction></span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_f0d0be25a2584356940ed59cb33ed8b3" contextRef="c20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,357</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental disclosure of non-cash activities: </div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Unrealized gain (loss) on marketable securities</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 22.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" id="Fact_50249c6099854b3ebb62b1ce7b0a25a8" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction>)</span><span style="padding-bottom: 0.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred proceeds from equipment sale in other current assets</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(<ix:nonFraction name="pasg:DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" id="Fact_46b186032a174035918e77db7595a21f" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">585</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">See accompanying notes to unaudited interim financial statements.<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-32<br/>
        </div>

      </div>

    </div>

    <!--End Page 31-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 32-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg1"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;" class="BRDSX_h1">Passage Bio, Inc. <br/>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_h1">Notes to Unaudited Interim Financial Statements </div>


          <ix:nonNumeric name="us-gaap:NatureOfOperations" id="Text_2b766c4664334617b6188ccc87e1d49e" contextRef="c20260101to20260331" escape="true" continuedAt="Text_0e9db704024f4fb2915f6eac78c401bc1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">1. Nature of Operations </div>
</ix:nonNumeric>
          <ix:continuation id="Text_0e9db704024f4fb2915f6eac78c401bc1">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#8217;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#8217;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-<span style="font-style: italic;">GRN</span>,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. </div>
</ix:continuation>
        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="pasg:RisksAndLiquidityTextBlock" id="Text_f1cc5cc1bd44436c89eb346335870528" contextRef="c20260101to20260331" escape="true" continuedAt="Text_c72ded625a854625818615fa1d88c78e1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">2. Risks, Liquidity, and Going Concern </div>
</ix:nonNumeric>
          <ix:continuation id="Text_c72ded625a854625818615fa1d88c78e1" continuedAt="Text_c72ded625a854625818615fa1d88c78e2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_acf14738350f429b9539927e18bf46fb" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">712.3</ix:nonFraction> million as of March 31, 2026. The Company anticipates incurring
            additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its
            product candidates. </div>
</ix:continuation>
          <ix:continuation id="Text_c72ded625a854625818615fa1d88c78e2" continuedAt="Text_c72ded625a854625818615fa1d88c78e3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div>
</ix:continuation>
          <ix:continuation id="Text_c72ded625a854625818615fa1d88c78e3" continuedAt="Text_c72ded625a854625818615fa1d88c78e4">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_b44f4ce92ada4ee3ba025445c5b9524a" contextRef="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">125.0</ix:nonFraction> million through Cowen, as sales agent in the ATM Facility. The Company
            is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on March&#160;4, 2024. As of March 31, 2026, $<ix:nonFraction name="pasg:RemainingCapacityOfValueOfSharesAvailableToBeSold" id="Fact_6e47240646da4623aa5e81f6c0a07c8a" contextRef="c20260331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.8</ix:nonFraction> million of capacity remains available to be sold under the ATM Facility. </div>
</ix:continuation>
          <ix:continuation id="Text_c72ded625a854625818615fa1d88c78e4" continuedAt="Text_c72ded625a854625818615fa1d88c78e5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These financial statements have been prepared in accordance with U.S.
            generally accepted accounting principles, or GAAP, assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In
            accordance with the Financial Accounting Standards Board&#8217;s, or FASB, Accounting Standards Codification, or ASC, Subtopic 205-40, <span style="font-style: italic;">Presentation of Financial Statements - Going Concern</span>, the Company has
            evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
            issued. The Company incurred net losses of approximately $<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_61ed3feee4df487bb06b3b6b41896579" contextRef="c20260101to20260331" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">7.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cd8f78fac37d4f3fafb4eba11fba9e5c" contextRef="c20250101to20250331" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">15.4</ix:nonFraction> million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, the Company had cash and cash equivalents totaling $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_f509dc230d6e4435be02bcd0dea85b8a" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">33.3</ix:nonFraction> million, which the Company does not expect to be sufficient to meet the Company&#8217;s capital requirements over the next 12 months. </div>
</ix:continuation>
          <ix:continuation id="Text_c72ded625a854625818615fa1d88c78e5" continuedAt="Text_c72ded625a854625818615fa1d88c78e6">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result, there is substantial doubt about the Company&#8217;s ability to
            continue as a going concern within one year after the date that these financial statements are issued. The financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported
            expenses that may be necessary if the Company were unable to continue as a going concern. </div>
</ix:continuation>
          <ix:continuation id="Text_c72ded625a854625818615fa1d88c78e6" continuedAt="Text_c72ded625a854625818615fa1d88c78e7">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April&#160;20, 2026, the Company announced that it has initiated a review of
            strategic alternatives to maximize shareholder value (see Note&#160;13). These strategic alternatives may include, but are not limited to, merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships,
            licensing opportunities, or other potential paths. The Company does not intend to provide updates on the strategic review until the board of directors approves a specific action or otherwise determines that disclosure is appropriate or
            required. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances </div>
</ix:continuation>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-33<br/>
        </div>

      </div>

    </div>

    <!--End Page 32-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 33-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_c72ded625a854625818615fa1d88c78e7">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">or other arrangements on favorable terms, or at all. The terms of any
            financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, or prospects of funding are unfavorable, the Company could be required to further delay, reduce or eliminate
            research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div>
</ix:continuation>
        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_5c335827d7c942fe803d9f1d6483992c" contextRef="c20260101to20260331" escape="true" continuedAt="Text_d43b426244ec4f0683467a683705afbf1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">3. Summary of Significant Accounting Policies </div>
</ix:nonNumeric>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf1" continuedAt="Text_d43b426244ec4f0683467a683705afbf2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s complete summary of significant accounting policies can be found
            in &#8220;Note&#160;3. Summary of Significant Accounting Policies&#8221; in the audited financial statements included in the Company&#8217;s Annual Report filed on Form&#160;10-K for the year ended December 31, 2025. </div>
</ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf2" continuedAt="Text_d43b426244ec4f0683467a683705afbf3"><ix:nonNumeric name="pasg:BasisOfPresentationPolicyTextBlock" id="Text_9900b853e4fd4930834c30cb1f722ae7" contextRef="c20260101to20260331" escape="true" continuedAt="Text_70090237b6e042f68d2a8b4de65415881">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf3" continuedAt="Text_d43b426244ec4f0683467a683705afbf4"><ix:continuation id="Text_70090237b6e042f68d2a8b4de65415881" continuedAt="Text_70090237b6e042f68d2a8b4de65415882">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited financial statements have been prepared in
            accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf4" continuedAt="Text_d43b426244ec4f0683467a683705afbf5"><ix:continuation id="Text_70090237b6e042f68d2a8b4de65415882">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_9c4ae5c452f740698340777ae9877470">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" id="Fact_1f617be7dfb8470bad4fc64b6a7a284b" contextRef="c20250714to20250714" unitRef="U003" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of
            shares of common stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity,
            have been adjusted retroactively to reflect the Reverse Stock Split for all periods presented. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf5" continuedAt="Text_d43b426244ec4f0683467a683705afbf6"><ix:nonNumeric name="pasg:InterimFinancialStatementsPolicyTextBlock" id="Text_2db19ac0e23642d3b7c93a3baef523da" contextRef="c20260101to20260331" escape="true" continuedAt="Text_c9f027e9f522447bb0983d859012f8521">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Interim Financial Statements </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf6" continuedAt="Text_d43b426244ec4f0683467a683705afbf7"><ix:continuation id="Text_c9f027e9f522447bb0983d859012f8521">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited interim financial statements have been prepared
            from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the SEC, which permits reduced disclosures for interim periods. All adjustments, consisting only
            of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets, statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows have been made. Although these interim financial
            statements do not include all of the information and notes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of
            operations and cash flows are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and notes should be read in conjunction with the audited financial statements and notes
            included in the Company&#8217;s 2025 Annual Report filed on Form&#160;10-K. </div>
</ix:continuation></ix:continuation>


          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf7" continuedAt="Text_d43b426244ec4f0683467a683705afbf8"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_44216349385c4476a0266584440beed9" contextRef="c20260101to20260331" escape="true" continuedAt="Text_a2ea8d1883984caaa5b30859221f25121">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf8" continuedAt="Text_d43b426244ec4f0683467a683705afbf9"><ix:continuation id="Text_a2ea8d1883984caaa5b30859221f25121" continuedAt="Text_a2ea8d1883984caaa5b30859221f25122">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a2ea8d1883984caaa5b30859221f25122"><ix:continuation id="Text_d43b426244ec4f0683467a683705afbf9" continuedAt="Text_d43b426244ec4f0683467a683705afbf10">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf10" continuedAt="Text_d43b426244ec4f0683467a683705afbf11"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_e2a059f2461946b0a2a2bee09b46e5cb" contextRef="c20260101to20260331" escape="true" continuedAt="Text_5169e99d2f9a44faa27df170655d72db1">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5169e99d2f9a44faa27df170655d72db1"><ix:continuation id="Text_d43b426244ec4f0683467a683705afbf11" continuedAt="Text_d43b426244ec4f0683467a683705afbf12">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf12" continuedAt="Text_d43b426244ec4f0683467a683705afbf13"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="Text_8a987435b0fc463490f745ee4e7b931a" contextRef="c20260101to20260331" escape="true" continuedAt="Text_5ba4b74a4c24479ea1caa3d76ed132de1">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf13" continuedAt="Text_d43b426244ec4f0683467a683705afbf14"><ix:continuation id="Text_5ba4b74a4c24479ea1caa3d76ed132de1" continuedAt="Text_5ba4b74a4c24479ea1caa3d76ed132de2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which </div>
</ix:continuation></ix:continuation>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-34<br/>
        </div>

      </div>

    </div>

    <!--End Page 33-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 34-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf14" continuedAt="Text_d43b426244ec4f0683467a683705afbf15"><ix:continuation id="Text_5ba4b74a4c24479ea1caa3d76ed132de2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">dictates the allocation of funds within its portfolio of money market
            funds. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money
            market funds.
          </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf15" continuedAt="Text_d43b426244ec4f0683467a683705afbf16"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_fdfdf5e9710c425799a4c30f0db20294" contextRef="c20260101to20260331" escape="true" continuedAt="Text_53c23b8821554353942cd3d654210b4f1">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf16" continuedAt="Text_d43b426244ec4f0683467a683705afbf17"><ix:continuation id="Text_53c23b8821554353942cd3d654210b4f1" continuedAt="Text_53c23b8821554353942cd3d654210b4f2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2026 consisted of money market funds. Cash consists of cash deposits at banking institutions. As of March&#160;31, 2025, all of the Company&#8217;s marketable
            securities matured and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#8217;s balance sheet. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf17" continuedAt="Text_d43b426244ec4f0683467a683705afbf18"><ix:continuation id="Text_53c23b8821554353942cd3d654210b4f2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company had cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_53fee346efe74341884f2ff80d1000bc" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">33.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_5b6e91543c464b98823663a6ce8b1a95" contextRef="c20251231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">46.3</ix:nonFraction> million as of
            March 31, 2026 and December 31, 2025, respectively. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf18" continuedAt="Text_d43b426244ec4f0683467a683705afbf19"><ix:nonNumeric name="us-gaap:MarketableSecuritiesPolicy" id="Text_44153f8fe9a7480b9c1c656d00ed3f4e" contextRef="c20260101to20260331" escape="true" continuedAt="Text_a7e9bff7d105480da402ec21c16eef3e1">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf19" continuedAt="Text_d43b426244ec4f0683467a683705afbf20"><ix:continuation id="Text_a7e9bff7d105480da402ec21c16eef3e1">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity.
            Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable securities sold are recognized as a component of other
            income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all
            marketable securities as current assets within the balance sheet. As of March 31, 2026, the Company had <ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" id="Fact_71d6355f396247388882d9e1c7dbff55" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> marketable securities. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf20" continuedAt="Text_d43b426244ec4f0683467a683705afbf21"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Text_2a5cb37ec6674a5e908a9ce87047fd8b" contextRef="c20260101to20260331" escape="true" continuedAt="Text_59324010232d4d7c93e97a3db023b8191">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf21" continuedAt="Text_d43b426244ec4f0683467a683705afbf22"><ix:continuation id="Text_59324010232d4d7c93e97a3db023b8191" continuedAt="Text_59324010232d4d7c93e97a3db023b8192">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_4001efaf22034039b8a26f19fee9e393" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric> for computer hardware and software, <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_f0cffa7a259340d493482beb3c48d367" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric>
            for office equipment, <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_e1b93eb40dbe4fc6b9dc5b0d54730f3c" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> for laboratory equipment, and <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_7c76562f330d4c3bbddff4d0b952f78c" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric> for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf22" continuedAt="Text_d43b426244ec4f0683467a683705afbf23"><ix:continuation id="Text_59324010232d4d7c93e97a3db023b8192" continuedAt="Text_59324010232d4d7c93e97a3db023b8193">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf23" continuedAt="Text_d43b426244ec4f0683467a683705afbf24"><ix:continuation id="Text_59324010232d4d7c93e97a3db023b8193">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company did not recognize any impairment expenses for long-lived assets for the three months ended March 31, 2026. The
            Company recognized impairment expenses for laboratory equipment and certain other assets of $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_a0f0e81ee4954b4e8daa9d559b4d0866" contextRef="c20250101to20250331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction> million for the three months ended
            March 31, 2025. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf24" continuedAt="Text_d43b426244ec4f0683467a683705afbf25"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="Text_0c8c3c7890d84a2f867622b9a23caedd" contextRef="c20260101to20260331" escape="true" continuedAt="Text_e0e9259d24f2458b8966a447e23601261">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Leasing </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf25" continuedAt="Text_d43b426244ec4f0683467a683705afbf26"><ix:continuation id="Text_e0e9259d24f2458b8966a447e23601261" continuedAt="Text_e0e9259d24f2458b8966a447e23601262">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of March 31, 2026, the Company has classified all leases with terms greater than one year, as operating leases. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf26" continuedAt="Text_d43b426244ec4f0683467a683705afbf27"><ix:continuation id="Text_e0e9259d24f2458b8966a447e23601262" continuedAt="Text_e0e9259d24f2458b8966a447e23601263">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf27" continuedAt="Text_d43b426244ec4f0683467a683705afbf28"><ix:continuation id="Text_e0e9259d24f2458b8966a447e23601263" continuedAt="Text_e0e9259d24f2458b8966a447e23601264">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When assets and liabilities for operating leases are written off, the balances
            are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>
</ix:continuation></ix:continuation>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-35<br/>
        </div>

      </div>

    </div>

    <!--End Page 34-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 35-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf28" continuedAt="Text_d43b426244ec4f0683467a683705afbf29"><ix:continuation id="Text_e0e9259d24f2458b8966a447e23601264">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company did <ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_9b05e14b2ecc4527ba39c569c6e73599" contextRef="c20250101to20250331" unitRef="U001" decimals="-5" scale="5" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:OperatingLeaseImpairmentLoss" id="Fact_2e451f68e47140f796b48fde0814a26f" contextRef="c20260101to20260331" unitRef="U001" decimals="-5" scale="5" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t
            recognize any impairment expenses for ROU assets for the three months ended March 31, 2026 or 2025. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf29" continuedAt="Text_d43b426244ec4f0683467a683705afbf30"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_9d3640017f8a43d7bbdafe027243784c" contextRef="c20260101to20260331" escape="true" continuedAt="Text_5bcdbacb019849009395c61ea0d201a71">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Research and Development </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf30" continuedAt="Text_d43b426244ec4f0683467a683705afbf31"><ix:continuation id="Text_5bcdbacb019849009395c61ea0d201a71">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relate to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf31" continuedAt="Text_d43b426244ec4f0683467a683705afbf32"><ix:nonNumeric name="pasg:OtherIncomeAndOtherExpensePolicyPolicyTextBlock" id="Text_265e550c4dca4673af040818b46e1b04" contextRef="c20260101to20260331" escape="true" continuedAt="Text_7efef806582e4789a57788594d5405fb1">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf32" continuedAt="Text_d43b426244ec4f0683467a683705afbf33"><ix:continuation id="Text_7efef806582e4789a57788594d5405fb1" continuedAt="Text_7efef806582e4789a57788594d5405fb2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, and income from subleases. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf33" continuedAt="Text_d43b426244ec4f0683467a683705afbf34"><ix:continuation id="Text_7efef806582e4789a57788594d5405fb2" continuedAt="Text_7efef806582e4789a57788594d5405fb3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_40e3889a964045189c9fc4508c4b3b01" contextRef="c20260101to20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million to other income (expense), net for the three months ended March 31, 2026, which consisted of $<ix:nonFraction name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" id="Fact_f41ccb0e7229473092a85f69093ce23a" contextRef="c20260101to20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction> million attributable to interest income and $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_588f62f4f15a40d78acd524ec9d02cf5" contextRef="c20260101to20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million
            related to income from subleases. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf34" continuedAt="Text_d43b426244ec4f0683467a683705afbf35"><ix:continuation id="Text_7efef806582e4789a57788594d5405fb3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_bc72406a730e4fdcba6d07ff88d66b97" contextRef="c20250101to20250331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction> million to other income (expense), net for the three months ended March&#160;31, 2025, which consisted of $<ix:nonFraction name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" id="Fact_de3bd440f9fd46c7a0916529a1756c36" contextRef="c20250101to20250331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_f0c6fb6579134fcb944e9ef90dbeb9d2" contextRef="c20250101to20250331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million related to income from subleases. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf35" continuedAt="Text_d43b426244ec4f0683467a683705afbf36"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_39f92fa049bf434f92d9cb2df40a2ee3" contextRef="c20260101to20260331" escape="true" continuedAt="Text_2f297bd3ff9848719f65c43a6e3ac3da1">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf36" continuedAt="Text_d43b426244ec4f0683467a683705afbf37"><ix:continuation id="Text_2f297bd3ff9848719f65c43a6e3ac3da1" continuedAt="Text_2f297bd3ff9848719f65c43a6e3ac3da2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf37" continuedAt="Text_d43b426244ec4f0683467a683705afbf38"><ix:continuation id="Text_2f297bd3ff9848719f65c43a6e3ac3da2" continuedAt="Text_2f297bd3ff9848719f65c43a6e3ac3da3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf38" continuedAt="Text_d43b426244ec4f0683467a683705afbf39"><ix:continuation id="Text_2f297bd3ff9848719f65c43a6e3ac3da3" continuedAt="Text_2f297bd3ff9848719f65c43a6e3ac3da4">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf39" continuedAt="Text_d43b426244ec4f0683467a683705afbf40"><ix:continuation id="Text_2f297bd3ff9848719f65c43a6e3ac3da4" continuedAt="Text_2f297bd3ff9848719f65c43a6e3ac3da5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to 2026, the Company estimated the expected term of the stock options
            using the &#8220;simplified method,&#8221; as the Company had limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The
            Company now has sufficient historical exercise data and has determined it is no longer appropriate to use the &#8220;simplified method&#8221;. Additionally, the Company no longer uses comparable public company data to estimate expected volatility and
            instead bases its expected volatility assumption on the historical volatility of its own stock price. The Company will apply this methodology prospectively and the change in estimates did not have a material impact for the three months ended
            March 31, 2026. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf40" continuedAt="Text_d43b426244ec4f0683467a683705afbf41"><ix:continuation id="Text_2f297bd3ff9848719f65c43a6e3ac3da5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur.
          </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf41" continuedAt="Text_d43b426244ec4f0683467a683705afbf42"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Text_4d1c285f316b48cc91c5d78bb692fe63" contextRef="c20260101to20260331" escape="true" continuedAt="Text_6e0e67371f6c4c52825aced87c856d251">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf42" continuedAt="Text_d43b426244ec4f0683467a683705afbf43"><ix:continuation id="Text_6e0e67371f6c4c52825aced87c856d251" continuedAt="Text_6e0e67371f6c4c52825aced87c856d252">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;7) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>
</ix:continuation></ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-36<br/>
        </div>

      </div>

    </div>

    <!--End Page 35-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 36-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf43" continuedAt="Text_d43b426244ec4f0683467a683705afbf44"><ix:continuation id="Text_6e0e67371f6c4c52825aced87c856d252" continuedAt="Text_6e0e67371f6c4c52825aced87c856d253">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue





































              from Contracts with Customer</span>s, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf44" continuedAt="Text_d43b426244ec4f0683467a683705afbf45"><ix:continuation id="Text_6e0e67371f6c4c52825aced87c856d253" continuedAt="Text_6e0e67371f6c4c52825aced87c856d254">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf45" continuedAt="Text_d43b426244ec4f0683467a683705afbf46"><ix:continuation id="Text_6e0e67371f6c4c52825aced87c856d254">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf46" continuedAt="Text_d43b426244ec4f0683467a683705afbf47"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_891e5895b38441af8b347814ac8a1699" contextRef="c20260101to20260331" escape="true" continuedAt="Text_983bccfcace541a5828e769f205af3061">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf47" continuedAt="Text_d43b426244ec4f0683467a683705afbf48"><ix:continuation id="Text_983bccfcace541a5828e769f205af3061" continuedAt="Text_983bccfcace541a5828e769f205af3062">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf48" continuedAt="Text_d43b426244ec4f0683467a683705afbf49"><ix:continuation id="Text_983bccfcace541a5828e769f205af3062" continuedAt="Text_983bccfcace541a5828e769f205af3063">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf49" continuedAt="Text_d43b426244ec4f0683467a683705afbf50"><ix:continuation id="Text_983bccfcace541a5828e769f205af3063" continuedAt="Text_983bccfcace541a5828e769f205af3064">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf50" continuedAt="Text_d43b426244ec4f0683467a683705afbf51"><ix:continuation id="Text_983bccfcace541a5828e769f205af3064"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_95d493bcef2e46fe984f118665f28ecd" contextRef="c20260101to20260331" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 117.85pt; white-space: nowrap;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ba3d6fba1c3d4f9ea5267cc145ea5b8a" contextRef="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">846,107</ix:nonFraction></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4ea5f3f6b2fd44e1b96091136deedb84" contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">704,699</ix:nonFraction></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_d80f0ff5d19f4fffbd8dae3f738975ae" contextRef="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_bb62a3b2d44f4af9a1e9559827956d18" contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">62,500</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2695fb3b335242f29426ef55c24f6f96" contextRef="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">1,593</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_e01e9331415d4ec6b6da19db465a8b14" contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">848</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_03bf821f130448d584801821d9a3bd41" contextRef="c20260101to20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">872,700</ix:nonFraction> </span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_a840ec7de3c647f1ae318928c25f8bea" contextRef="c20250101to20250331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">768,047</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation></ix:continuation>
             </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-37<br/>
        </div>

      </div>

    </div>

    <!--End Page 36-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 37-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf51" continuedAt="Text_d43b426244ec4f0683467a683705afbf52"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_481db3a20a0c4a8b9f5e0999cc91663c" contextRef="c20260101to20260331" escape="true" continuedAt="Text_45a91efaba9045a0a8fe83dc47d776141">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
          </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf52" continuedAt="Text_d43b426244ec4f0683467a683705afbf53"><ix:continuation id="Text_45a91efaba9045a0a8fe83dc47d776141" continuedAt="Text_45a91efaba9045a0a8fe83dc47d776142">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf53" continuedAt="Text_d43b426244ec4f0683467a683705afbf54"><ix:continuation id="Text_45a91efaba9045a0a8fe83dc47d776142" continuedAt="Text_45a91efaba9045a0a8fe83dc47d776143">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_d43b426244ec4f0683467a683705afbf54"><ix:continuation id="Text_45a91efaba9045a0a8fe83dc47d776143">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim periods. ASU 2025-11 is effective for the Company for interim periods within annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be
            applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement disclosures. </div>
</ix:continuation></ix:continuation>
        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" id="Text_f605d606d39849ce93545310d0b767f3" contextRef="c20260101to20260331" escape="true" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">4. Fair Value of Financial Instruments and Non-Financial
            Instruments </div>
</ix:nonNumeric>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd1" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd2">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Financial Instruments </div>
</ix:continuation>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd2" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expenses and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <span style="font-style: italic;">Fair Value Measurement</span>, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: </div>
</ix:continuation>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd3" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd4">
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 1: </span>Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. </div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd4" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd5">
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 2: </span>Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. </div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd5" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd6">
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 3: </span>Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd6" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd7">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents include money market funds that are carried at cost, which approximates their fair value. The fair values are based on quoted market prices in active markets for
            identical assets and therefore are classified within Level&#160;1 of the fair value hierarchy. </div>
</ix:continuation>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd7" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd8">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Non-Financial Instruments </div>
</ix:continuation>
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd8" continuedAt="Text_963c1dd760284a27bd73ea66f4cd38dd9">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 inputs is determined by estimating the amount and timing of net future cash flows (which
            are unobservable inputs) and </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-38<br/>
        </div>

      </div>

    </div>

    <!--End Page 37-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 38-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_963c1dd760284a27bd73ea66f4cd38dd9">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">discounting them using a risk-adjusted rate of interest. Significant
            increases or decreases in actual cash flows may result in valuation changes. There were no assets remeasured in the three months ended March 31, 2026. Assets remeasured in the three months ended March 31, 2025 included laboratory equipment and
            certain other assets which were sold prior to March&#160;31, 2025 and were not included in the balance sheet as of March&#160;31, 2025. The impairment related to the remeasurement of $<ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" id="Fact_c39ea8a1ab284c6eaffbe359f155aa7c" contextRef="c20260101to20260331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction> million is included in the statement of operations for the three months ended March&#160;31, 2025. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_aecfc78749574a559761528a9cc29a16" contextRef="c20260101to20260331" escape="true" continuedAt="Text_01f91692c1594c95b751b186dd3b9ed11">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">5. Property and Equipment, Net </div>
</ix:nonNumeric>
          <ix:continuation id="Text_01f91692c1594c95b751b186dd3b9ed11" continuedAt="Text_01f91692c1594c95b751b186dd3b9ed12">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Property and equipment, net, consists of the following: </div>
</ix:continuation>
          <ix:continuation id="Text_01f91692c1594c95b751b186dd3b9ed12" continuedAt="Text_01f91692c1594c95b751b186dd3b9ed13">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_01f91692c1594c95b751b186dd3b9ed13" continuedAt="Text_01f91692c1594c95b751b186dd3b9ed14"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_2cb494f093514aad82c29480d2bd18db" contextRef="c20260101to20260331" escape="true">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Office equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_eea6129bbe944886b987d2390b6107e8" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">55</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 10.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_d66246b73a664b19abdd0ee5df61f840" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Computer hardware and software</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c51a37cede0143289da28b6957d7c8e0" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">959</ix:nonFraction> </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_bf6091ad5db849cf9162face7abe5189" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">988</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Furniture and fixtures</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_7c738874ea844270b7428215e0eb755c" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">306</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 15.83pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c67c9f915a2f4d48a706531d5ee63afa" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">419</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Leasehold improvements</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_6a582bd3327b41cf9d45a483c040f81f" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,564</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_8da914b34e874cf8b1714d2d361adc46" contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,510</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total property and equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c39f8a4639b846e8ae47084564f8d504" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,884</ix:nonFraction> </span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_29ef8fd9a7554edd9003f53cff2d78b0" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,024</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_1def950e44a14cfb8e8bbf08195b4b06" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,058</ix:nonFraction>) </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_5b484891f1a34d3c8b93faa5fe58be2b" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,917</ix:nonFraction>) </span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_e96c8ae250be475788b57f77120ef5fd" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">826</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_fad700a15569499b86eb1769716d8972" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,107</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_01f91692c1594c95b751b186dd3b9ed14" continuedAt="Text_01f91692c1594c95b751b186dd3b9ed15">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On March&#160;4, 2026, the Company entered into the Hopewell Lease Termination
            Agreement. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $<ix:nonFraction name="pasg:EarlyLeaseTerminationFee" id="Fact_e2f987609c6a46c6a69dd67b70ad7b41" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="pasg:EarlyLeaseTerminationFee" id="Fact_8858bd784a2e40fbbbadc93e6a778ce8" contextRef="c20260214to20260214" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction></ix:nonFraction>
            million as well as accrued rent through February&#160;14, 2026. As a result of the Hopewell Lease Termination Agreement, the Company recognized a net gain of $<ix:nonFraction name="us-gaap:GainLossOnTerminationOfLease" id="Fact_d9acabbd87b14ddd9406338998e469d7" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million on the lease termination for the three months ended March 31, 2026. The net gain is comprised of a $<ix:nonFraction name="pasg:GainLossOnWriteOffOfOperatingLeases" id="Fact_5b1d818f89b54a4bb763e9c70d104378" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.8</ix:nonFraction>
            million gain on the write-off of assets and liabilities for operating leases offset by a $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" id="Fact_b6104c3bb9d54706a258c8a273fff0af" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction> million net loss on disposal of
            property and equipment. The assets disposed of as part of the termination included office equipment, leasehold improvements, furniture and fixtures, and computer hardware and software. </div>
</ix:continuation>
          <ix:continuation id="Text_01f91692c1594c95b751b186dd3b9ed15">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Depreciation and amortization expense was $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_0c8bc34da66d4a17a100ad85665c318b" contextRef="c20260101to20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_5c7ad5c5b522465eb0b1df55f0905e9a" contextRef="c20250101to20250331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million for the
            three months ended March 31, 2026 and 2025, respectively. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="Text_61818a45ed0f4be4bdea6f0a9863e926" contextRef="c20260101to20260331" escape="true" continuedAt="Text_323eb4ce37bb4ff79dc16ae09a2dd02f1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">6. Accrued Expenses and Other Current Liabilities </div>
</ix:nonNumeric>
          <ix:continuation id="Text_323eb4ce37bb4ff79dc16ae09a2dd02f1" continuedAt="Text_323eb4ce37bb4ff79dc16ae09a2dd02f2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses and other current liabilities consisted of the following: </div>
</ix:continuation>
          <ix:continuation id="Text_323eb4ce37bb4ff79dc16ae09a2dd02f2" continuedAt="Text_323eb4ce37bb4ff79dc16ae09a2dd02f3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_323eb4ce37bb4ff79dc16ae09a2dd02f3"><ix:nonNumeric name="pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="Text_079b562fb0f34a1799d1ed43f83dcbde" contextRef="c20260101to20260331" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;">$<span style="padding-left: 7.5pt;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_1907e8ab81af45db8b2809a920076dbd" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_85ec014f58054d2987da1305c85debfa" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">347</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_cca50877b1f74c4cacd32d032514a019" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,297</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_d87ce4b868bc4d889800b4049512c7b3" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,740</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="pasg:AccruedResearchAndDevelopmentExpense" id="Fact_1bff2efaa92448c19471ab49fbb6214b" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,174</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;"><ix:nonFraction name="pasg:AccruedResearchAndDevelopmentExpense" id="Fact_e76c86f3baf24424b81fb5e698977bb7" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">642</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:AccruedDivestitureFeesCurrent" id="Fact_b2ee8e67c6514b00af86fc3195e37629" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:AccruedDivestitureFeesCurrent" id="Fact_2bd32c3e7841485d9fbcdb265812911b" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_366d793b61cc4f068ae36e01912f8ba1" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,895</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="pasg:AccruedExpensesAndOtherCurrentLiabilities" id="Fact_62ee0f1c7c454397bc5b3a900cdd0f12" contextRef="c20251231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,653</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Text_6740f125cb9846df93081ba6e95823ee" contextRef="c20260101to20260331" escape="true" continuedAt="Text_cd4389beb7ee429694ac314f4111e0051">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">7. Gemma License Agreement </div>
</ix:nonNumeric>
          <ix:continuation id="Text_cd4389beb7ee429694ac314f4111e0051" continuedAt="Text_cd4389beb7ee429694ac314f4111e0052">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $<ix:nonFraction name="pasg:UpfrontLicenseFeeReceivable" id="Fact_d721e387add64a879c7f51dae06e3c87" contextRef="c20240731" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million in
            initial payments for licenses and clinical product supply, of which $<ix:nonFraction name="pasg:ProceedsFromNonRefundableSublicensePayments" id="Fact_47a55d363a9d4a5fa1df902812153907" contextRef="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million was previously received, $<ix:nonFraction name="pasg:LicenseFeeDueAndReceivable" id="Fact_ddb0b3a132c747f9919aede502cf26b2" contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million of which was due in May&#160;2025, of which $<ix:nonFraction name="pasg:ProceedsFromShortTermLicenseFee" id="Fact_6e9eec9c1bee47899933c74e8c9ef125" contextRef="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>
            million has been received, and $<ix:nonFraction name="pasg:LongTermLicenseFeeDueAndReceivable" id="Fact_990cffc51caa4950a9e9b408211e54c9" contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million of which was due in March&#160;2026, and has not yet been received; (ii) an additional $<ix:nonFraction name="pasg:ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" id="Fact_c3f5e81fc2d54bec92ca01906daf3f46" contextRef="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million contingent on Gemma completing certain business milestones; (iii) up to an additional $<ix:nonFraction name="pasg:MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" id="Fact_1f1af82c259a460099e800234e577b27" contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">114.0</ix:nonFraction> million in development and commercial milestone payments; and (iv) single digit royalties as a percentage of annual worldwide net sales, in exchange for sublicenses
            to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will be responsible for all payments due to the Trustees of </div>
</ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-39<br/>
        </div>

      </div>

    </div>

    <!--End Page 38-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 39-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_204-finnotes01_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:continuation id="Text_cd4389beb7ee429694ac314f4111e0052" continuedAt="Text_cd4389beb7ee429694ac314f4111e0053">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">the University of Pennsylvania&#8217;s, or Penn, under the Company&#8217;s research,
            collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs. On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services
            Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which, the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for
            transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. </div>
</ix:continuation>
          <ix:continuation id="Text_cd4389beb7ee429694ac314f4111e0053">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of March 31, 2026, the Company has received initial payments of $<ix:nonFraction name="pasg:ProceedsFromNonRefundableSublicensePayments" id="Fact_2f610da5d1c84b9dba7f4638ab4f43b5" contextRef="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.5</ix:nonFraction> million associated with the aggregate $<ix:nonFraction name="pasg:UpfrontLicenseFeeReceivable" id="Fact_769fadbb18274ef48374baffc5ce0550" contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million of initial payments
            to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $<ix:nonFraction name="pasg:ProceedsFromNonRefundableTransitionServicesPayments" id="Fact_34269150cf894e5b9aae1b2ff4b6d377" contextRef="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction> million associated with the
            Transition Services Agreement and applied $<ix:nonFraction name="pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments" id="Fact_d77c0d9d2b1946e38c03d9f3600fd988" contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction> million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts
            due to the Company for transition services under these agreements. The Company recorded these amounts ($<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_4bc309b0b56c495788390beb7d775d06" contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.8</ix:nonFraction> million) as
            non-refundable sublicense and transition services payments on the balance sheet as of March 31, 2026, as the criteria set forth above have not yet been met. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Text_be025be6753c4d5e84fc6c429f004662" contextRef="c20260101to20260331" escape="true" continuedAt="Text_195aa969c6c7493b86aba9846dca0d541">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">8. Severance </div>
</ix:nonNumeric>
          <ix:continuation id="Text_195aa969c6c7493b86aba9846dca0d541" continuedAt="Text_195aa969c6c7493b86aba9846dca0d542">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the three months ended March 31, 2026, the Company did <ix:nonFraction name="us-gaap:SeveranceCosts1" id="Fact_aee9ab359d934fa78a5c7d85071b3a9a" contextRef="c20260101to20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction>t record any severance and termination-related costs (see Note&#160;13). </div>
</ix:continuation>
          <ix:continuation id="Text_195aa969c6c7493b86aba9846dca0d542" continuedAt="Text_195aa969c6c7493b86aba9846dca0d543">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately <ix:nonFraction name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" id="Fact_767f6686be7e4cc9951951297fa245c2" contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">55</ix:nonFraction>%.





            In accordance with ASC 420, <span style="font-style: italic;">Exit and Disposal Activities</span>, the Company recorded severance and termination-related costs of $<ix:nonFraction name="us-gaap:SeveranceCosts1" id="Fact_b4f0c40e22514232bcd8e94fe96ebb1a" contextRef="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million in general and administrative expenses and $<ix:nonFraction name="us-gaap:SeveranceCosts1" id="Fact_6c2700fb88dc4672aae472eefb71b003" contextRef="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction> million in
            research and development expenses for the three months ended March 31, 2025. </div>
</ix:continuation>
          <ix:continuation id="Text_195aa969c6c7493b86aba9846dca0d543">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">As of March 31, 2026, there were <ix:nonFraction name="us-gaap:RestructuringReserve" id="Fact_f62e1f40e4d44e0cbb7491123707e518" contextRef="c20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> unpaid severance and termination-related costs. </div>
</ix:continuation>
        </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_9197aad69ea541df9f9604e168bbb26c" contextRef="c20260101to20260331" escape="true" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a601">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">9. Leases </div>
</ix:nonNumeric>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a601" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a602">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">2005 Market Street Lease Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a602" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a603">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_b8db6bbe266d4815bbaa92aa9209bca3" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">37,000</ix:nonFraction>
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact_3287ce56016d49cd9671859453abefec" contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt:fixed-true">extend</ix:nonNumeric> the term of the 2005 Market Street Lease Agreement by <ix:nonFraction name="pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions" id="Fact_0bee9a223a464a819bf749d6c47753d1" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" unitRef="U006" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction>
            additional terms of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Fact_182333cf5b64412582167b938bf83e1a" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> each. The Company has an option to early <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" id="Fact_615a49a6c10b4490b4c22b851f5622a1" contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt:fixed-true">terminate</ix:nonNumeric> the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than <ix:nonNumeric name="pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease" id="Fact_9c7a58674cc541c3a790492419d6de9b" contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember" format="ixt-sec:durwordsen">fifteen months</ix:nonNumeric> prior to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#8217;s measurement of the ROU asset and operating lease liability
            as of March 31, 2026. During 2023, the Company subleased all of the space at 2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a603" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a604">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Sublease Agreement A </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a604" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a605">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_530297f723c342daabc6164f17fc18c2" contextRef="c20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">8,000</ix:nonFraction> square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact_7b97529228e84a30a70fa0bf22ebefe8" contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" format="ixt:fixed-true">extend</ix:nonNumeric> the sublease agreement through November&#160;30, 2031. The base sublease rent is $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_c16a229e9f1f426eae79626ab2ea1f03" contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million per year and increases by <ix:nonFraction name="pasg:PercentageOfAnnualIncreaseInSubleaseRent" id="Fact_dca8a11809904b2fa366f34207f44221" contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember" unitRef="U004" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.75</ix:nonFraction>% annually through the
            expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a605" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a606">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Pursuant to ASC Topic 842, <span style="font-style: italic;">Leases</span>,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. </div>
</ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-40<br/>
        </div>

      </div>

    </div>

    <!--End Page 39-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 40-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_204-finnotes01_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a606" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a607">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Sublease Agreement B </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a607" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a608">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_7ec0bd04eff1479b827738a6630d064e" contextRef="c20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">29,000</ix:nonFraction> square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024 and Sublessee B has elected the option to <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Fact_3ead746fc9b44234adb809338ac3de15" contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember" format="ixt:fixed-true">extend</ix:nonNumeric> the term of the sublease
            agreement through March&#160;31, 2029. The base sublease rent is $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_ec13e867913345c7ac44700f0eb85e82" contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million per year for the entire term of the sublease. Additionally,
            Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005 Market Street Lease
            Agreement. </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a608" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a609">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a609" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6010">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Laboratory Lease Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6010" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6011">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The Company was also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and was expected to expire in March&#160;2036 with an option to extend the term of the Laboratory Lease Agreement by up to&#160;<ix:nonFraction name="pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions" id="Fact_040e5881400c45a4a27a053d62db93e1" contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember" unitRef="U006" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> <ix:nonNumeric name="pasg:NewLeaseAgreementOperatingLeaseRenewalTerm" id="Fact_8c9afa3885474ef3ab8fc3e2129bff4c" contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> terms. On March&#160;4,
            2026, the Company entered into the Hopewell Lease Termination Agreement with the Landlord. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $<ix:nonFraction name="pasg:EarlyLeaseTerminationFee" id="Fact_5dfb43c1248e461d8842fe34064e24dc" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction> million as well as accrued rent through February&#160;14, 2026. The Company has no further obligations under the Laboratory Lease Agreement
            subsequent to the effective date of the Hopewell Lease Termination Agreement. As of March&#160;4, 2026, the Company recognized a net gain of $<ix:nonFraction name="us-gaap:GainLossOnTerminationOfLease" id="Fact_d830beb8dee94e6dafa72baa6d4547d9" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>
            million on the lease termination comprised of a $<ix:nonFraction name="pasg:GainLossOnWriteOffOfOperatingLeases" id="Fact_3c8e9fe1a5c54e10ac1b99dcbfa26b6e" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.8</ix:nonFraction> million gain on the write-off of assets and liabilities for operating leases
            offset by a $<ix:nonFraction name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" id="Fact_44b86cd44fe3413dac35002b57cb70fe" contextRef="c20260304to20260304" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction> million net loss on disposal of property and equipment, which was primarily leasehold improvements. As a result of
            the Hopewell Lease Termination Agreement, ROU assets decreased $<ix:nonFraction name="pasg:RightOfUsePeriodDecreaseDueToLeaseTermination" id="Fact_3776b3e8fec2446faa427fff6937e18b" contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.4</ix:nonFraction> million and lease liabilities for operating leases decreased $<ix:nonFraction name="pasg:LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" id="Fact_c160bcb70aee4989bd8d6dfeae9f3cea" contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">18.0</ix:nonFraction> million during the three months ended March 31, 2026. </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6011" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6012">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;" class="BRDSX_h3">Hopewell Sublease Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6012" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6013">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately <ix:nonFraction name="pasg:AreaSubleased" id="Fact_4cf1e4cc4ba641bfb5ad26d9d29c1fb2" contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">3,200</ix:nonFraction> square feet, or <ix:nonFraction name="pasg:AreaOfLandSubleasedPercentage" id="Fact_e4dd28c9f08946eba9251c0781e96303" contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of its approximately <ix:nonFraction name="us-gaap:AreaOfLand" id="Fact_3eea5202f60d4290b8ad1d8c712c5e80" contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U005" decimals="0" scale="0" format="ixt:num-dot-decimal">62,000</ix:nonFraction> square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and was scheduled to expire on December&#160;31, 2029, with an option for Sublessee C to extend the term of the
            sublease through December&#160;2032. The base sublease rent was $<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_e2363683c0944824b71c3add3d072e81" contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million per year and increased by <ix:nonFraction name="pasg:PercentageOfAnnualIncreaseInSubleaseRent" id="Fact_14a3452b86f641cb928be1c244b97b92" contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C was required to pay the portion of the common
            area maintenance expenses, operating expenses, and use and occupancy taxes that the Company was required to pay under the Laboratory Lease Agreement. In connection with the Hopewell Lease Termination Agreement on March&#160;4, 2026, the Hopewell
            Sublease Agreement was concurrently terminated. The Company has no ongoing sublease arrangements related to the Hopewell, New Jersey laboratory space. </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6013" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6014">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The following table summarizes future minimum lease payments for the Company&#8217;s
            lessee operating lease, which comprises of the 2005 Market Street Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A and Sublease Agreement B, as the Company was not relieved of its primary
            obligation under the 2005 Market Street Lease Agreement: </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6014" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6015">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6015" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6016"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_13cd0d9e70eb49e6b37b6f379fb4b961" contextRef="c20260101to20260331" escape="true">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 420pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 30.83pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 420pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 8.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">2026</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 10.83pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_4b1e94dcaad448a2aa54b9a0ce83c085" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">900</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">2027</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_7647b0e7bd4e4027addd8406bba979c4" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">2028</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_28dba370fd474cd491304d997d8a61a4" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,270</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">2029</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_c19c0c4de1e94b30af9df827bad56223" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,308</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">2030</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_f0cce44f040644929acaf3b328aa54e3" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,348</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Thereafter</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" id="Fact_11940c42ca184781a12113f65f4abe25" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,388</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total undiscounted lease payments</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 8.33pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_7b416108109f441da01142339a1d3470" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,447</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Less: imputed interest</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_4808fa4eca574b519fe5422173f34179" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,692</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Total lease liabilities</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_828336aa6e554776b52a970921cc22b1" contextRef="c20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,755</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 420pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>
            </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-41<br/>
        </div>

      </div>

    </div>

    <!--End Page 40-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 41-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_204-finnotes01_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6016" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6017">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The following table summarizes lease expense by lease type that was
            recognized during the three months ended March&#160;31, 2026 and 2025: </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6017" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6018">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6018" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6019"><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" id="Text_fd8bf6aaa04c42f1b6386cd7317328e1" contextRef="c20260101to20260331" escape="true" continuedAt="Text_286bb3b50c9e4d279ec46c8a21e6247e1">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara"></div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March 31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March 31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Operating lease expense</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_3bdc1dc74dbc4be28233ab8093e88b20" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">476</ix:nonFraction></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;" class="BRDSX_fpara">$<span style="padding-left: 7.5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" id="Fact_2e489b19bda541a28b240741d82b11ee" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">880</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Variable lease expense</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_e4c39687eabd4a54ab7e13601eab3491" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction> </span></td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:VariableLeaseCost" id="Fact_b79439e5e0ce417a839c5a5d23f15e91" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;" class="BRDSX_fpara"></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:LeaseCost" id="Fact_023a2bb8d1b44382a3f0f7dc6cace75c" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;" class="BRDSX_fpara"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:LeaseCost" id="Fact_f94787c4bb90451f944051bdaf1653b8" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,418</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6019" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6020">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6020" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6021">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6021" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6022"><ix:continuation id="Text_286bb3b50c9e4d279ec46c8a21e6247e1" continuedAt="Text_286bb3b50c9e4d279ec46c8a21e6247e2">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;" class="BRDSX_fpara"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_2f1ba15a7db44d27804f7879a7d616ae" contextRef="c20260331" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.0</ix:nonFraction>% </div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;" class="BRDSX_fpara"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_9da1647fab19446f84156846e8b04a22" contextRef="c20250331" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.7</ix:nonFraction>% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;" class="BRDSX_fpara"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_edfd780a8c2a49258f6538a5f55c1a1f" contextRef="c20260331" format="ixt-sec:duryear">5.8</ix:nonNumeric> </div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;" class="BRDSX_fpara"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_b2b03d86cc0141f9a69bc39ef14524f5" contextRef="c20250331" format="ixt-sec:duryear">10.0</ix:nonNumeric> </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6022" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6023">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The cash paid for amounts included in the measurement of the Company&#8217;s
            operating lease liabilities for the three months ended March 31, 2026 and 2025 were $<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" id="Fact_ea47e46017bc42bba0ac08183a289cd8" contextRef="c20260101to20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeasePaymentsUse" id="Fact_5c81ea4924ed48c49fd7b3f8c13b6b7f" contextRef="c20250101to20250331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million, respectively, recorded in operating cash flows. </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6023" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6024">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">The following table summarizes sublease income that was recognized in other
            income (expense), net during the three months ended March 31, 2026 and 2025: </div>
</ix:continuation>
          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6024" continuedAt="Text_6cac7dec09d34d1bb46f60139ff32a6025">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_6cac7dec09d34d1bb46f60139ff32a6025"><ix:continuation id="Text_286bb3b50c9e4d279ec46c8a21e6247e2">
<table cellspacing="0" cellpadding="0" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;" class="BRDSX_fintab">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;" class="BRDSX_fpara">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;" colspan="4">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;" class="BRDSX_fpara">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;" class="BRDSX_fpara">Sublease rental income</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_e479181a948b4296807e7d5b742daddf" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">356</ix:nonFraction></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;" class="BRDSX_fpara">$<ix:nonFraction name="us-gaap:SubleaseIncome" id="Fact_fe6c4dfd9e8246f88c3d38a48c7b4830" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">367</ix:nonFraction></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
            </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_fe20e307efce454ea5e2c2713bf1b014" contextRef="c20260101to20260331" escape="true" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">10. Commitments and Contingencies </div>
</ix:nonNumeric>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b1" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b2">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Amended and Restated Research, Collaboration
            and License Arrangement with Penn </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b2" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company (i)&#160;terminated the funding of discovery research programs; (ii) terminated the research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS,
            indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe and MLD and certain platform
            technologies resulting from the discovery programs that it funded. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b3" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b4">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the Company&#8217;s licensed programs in FTD, GM1, Krabbe and MLD, the Penn
            License Agreement requires that it make payments of up to $<ix:nonFraction name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" id="Fact_feac6bc678d642e1ad4f073912607e1c" contextRef="c20260331_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction> million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $<ix:nonFraction name="pasg:CollaborationAgreementSalesMilestonePaymentsPayable" id="Fact_9a22ab6d6d8b428e8aa0bd36d8b24559" contextRef="c20260331_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction> million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b4" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-42<br/>
        </div>

      </div>

    </div>

    <!--End Page 41-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 42-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b5" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b6">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Gemma - Research, Collaboration and
            License Agreement </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b6" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b7">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New Drug,
            or IND, enabling work for the Company&#8217;s active research program in Huntington&#8217;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and
            (ii)&#160;Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b7" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b8">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $<ix:nonFraction name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" id="Fact_3d5a6dd3557346adaf511f6e73a1d121" contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction> million per product candidate in the aggregate for Huntington&#8217;s disease and any future CNS indications available to the
            Company under its four options and (ii) $<ix:nonFraction name="pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" id="Fact_2f288be71db6437e912ad1cd2e6b8b2d" contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">39.0</ix:nonFraction> million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $<ix:nonFraction name="pasg:CollaborationAgreementSalesMilestonePaymentsPayable" id="Fact_33dadb7e92b3424ca778bcac7d87f5a2" contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction>
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b8" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b9">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b9" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b10">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $<ix:nonFraction name="pasg:NonRefundableAggregateFeesPayablePerProductIndication" id="Fact_4aaaf0040153465c984bb7e12f3dbec4" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million per product indication, with $<ix:nonFraction name="pasg:NonRefundableUpfrontFeesPayablePerProductIndication" id="Fact_d5cccc6390d34574872145dabde45655" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million due upfront and another $<ix:nonFraction name="pasg:NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" id="Fact_7b2fc4a170604f31902119b897be6bd6" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>
            million fee owed upon a further developmental milestone. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b10" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b11">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;7. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b11" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b12">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b12" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b13">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Catalent Agreements </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b13" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b14">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b14" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b15">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#8217;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b15" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b16">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $<ix:nonFraction name="pasg:AccruedDivestitureFeesCurrent" id="Fact_60a7f80684d24054b0ad1c65b357994b" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction> million to Catalent which is accrued as of March 31, 2026. </div>
</ix:continuation>
           </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-43<br/>
        </div>

      </div>

    </div>

    <!--End Page 42-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 43-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b16" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b17">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Litigation </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b17" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b18">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has <ix:nonFraction name="us-gaap:LossContingencyAccrualAtCarryingValue" id="Fact_ff1c236195c24eafb1e1916b77dc5813" contextRef="c20260331" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction>t recorded any amounts for loss contingencies as of March 31, 2026. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b18" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b19">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#8217;s initial
            public offering in February&#160;2020, he was promised <ix:nonFraction name="pasg:StockIssuedDuringPeriodSettlementOfLitigation" id="Fact_9d8cd52857db497d8beb5565e79b3065" contextRef="c20200201to20200229" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction> shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to <ix:nonFraction name="pasg:LossContingencySharesAgreedByDefendant" id="Fact_d10ca8f024ea4f9793496d0d26f8d831" contextRef="c20200201to20200229" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">33,836</ix:nonFraction> shares (<ix:nonFraction name="pasg:LossContingencySharesAgreedByDefendant" id="Fact_2d59f3fb9bfb401d924f566e722a5698" contextRef="c20260101to20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">1,692</ix:nonFraction> shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it agreed with the
            Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the initial public
            offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#8217;s favor, finding that no binding agreement was reached and that the plaintiff was not entitled
            to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate co<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">urt affirmed the entry of judgment in favor of the Company and on October&#160;7, 2025, the plaintiff filed an Application for Reargument to the
              Superior Court of Pennsylvania. In December&#160;2025, the plaintiff petitioned for review of their appeal to the Pennsylvania Supreme Court. The Company intends to continue to defend against this claim. </span></div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b19" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b20">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other than the above, the Company is not presently a party to any legal
            proceedings that, in the opinion of management, would, if decided against the Company, have a material adverse effect on the Company&#8217;s business. Regardless of outcome, litigation can have an adverse impact on the Company due to defense and
            settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b20" continuedAt="Text_61c6c38c22064930a4a7db3372e00c3b21">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Employment Agreements </div>
</ix:continuation>
          <ix:continuation id="Text_61c6c38c22064930a4a7db3372e00c3b21">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to <ix:nonFraction name="pasg:PercentageOfTargetAnnualBonusAmounts" id="Fact_80298b39b5f04a53aa113e7d5c78251a" contextRef="c20260101to20260331" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">150</ix:nonFraction>% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Text_ad515e99e2e146ed801f2975eb7781c0" contextRef="c20260101to20260331" escape="true" continuedAt="Text_3b57384df5394133af2d69b43c0955031">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">11. Stockholder&#8217;s Equity and Share-Based Compensation </div>
</ix:nonNumeric>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c0955031" continuedAt="Text_3b57384df5394133af2d69b43c0955032">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected the Reverse Stock Split. The Reverse
            Stock Split did not reduce the number of authorized shares of the common stock and did not change the par value of the common stock. In addition, proportionate adjustments were made to the number of shares of common stock available for issuance
            under the Company&#8217;s equity inducement and incentive plans; the number of shares underlying, and the exercise prices of outstanding equity awards under such plans. All share information in these financial statements has been adjusted for this
            Reverse Stock Split. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c0955032" continuedAt="Text_3b57384df5394133af2d69b43c0955033">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c0955033" continuedAt="Text_3b57384df5394133af2d69b43c0955034">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has <ix:nonFraction name="pasg:NumberOfEquityIncentivePlans" id="Fact_2a58113f0b1349ba92b432995f065c62" contextRef="c20260101to20260331" unitRef="U007" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c0955034" continuedAt="Text_3b57384df5394133af2d69b43c0955035">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The total number of shares authorized under the Incentive Plan as of March 31,
            2026 was <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_e99b45a98fbf4f1d8ac73b95c5b38dde" contextRef="c20260331_PlanNameAxis_EquityIncentivePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">1,106,739</ix:nonFraction>. Additionally, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_71fac20ef33b4ae8a73f1caca75e6c9e" contextRef="c20260331_PlanNameAxis_EquityIncentivePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">204,732</ix:nonFraction>
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of March 31, 2026, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_5e5cebfad00541098d44e01b71b03b64" contextRef="c20260331_PlanNameAxis_EquityIncentivePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">405,163</ix:nonFraction>
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January&#160;1st of each
            year, commencing on January&#160;1, 2021 and continuing for <ix:nonNumeric name="pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Fact_34166b18522e4978a9533c7294886e47" contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, in an amount equal to <ix:nonFraction name="pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" id="Fact_825535d307514b1483afa0b767ba9a9b" contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember" unitRef="U004" decimals="2" scale="-2" format="ixt-sec:numwordsen">five </ix:nonFraction>percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by <ix:nonFraction name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" id="Fact_7d26f85d3e994537aafe1ae6ede70f43" contextRef="c20260101to20260131_PlanNameAxis_EquityIncentivePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">159,141</ix:nonFraction> and <ix:nonFraction name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" id="Fact_2b33ccb23d7d49609915e4d28a2e5ef1" contextRef="c20250101to20250131_PlanNameAxis_EquityIncentivePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">155,155</ix:nonFraction> shares in January&#160;2026 and 2025,
            respectively. </div>
</ix:continuation>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-44<br/>
        </div>

      </div>

    </div>

    <!--End Page 379-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 380-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_3b57384df5394133af2d69b43c0955035" continuedAt="Text_3b57384df5394133af2d69b43c0955036">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_2685e68de1a949c28bb3e55ba79ef614" contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> periods, and have a term of <ix:nonNumeric name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="Fact_18f02e80074e474bac3d4c0059d3924e" contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c0955036" continuedAt="Text_3b57384df5394133af2d69b43c0955037">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Inducement Plan was approved by the Company&#8217;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of March 31, 2026 was <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_88f7c0964749400cba81dfed0c08f92f" contextRef="c20260331_PlanNameAxis_EquityInducementPlan2021Member" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>. Of this amount, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_5c4ca4b6a9bf4c0cb0596a55ce504018" contextRef="c20260331_PlanNameAxis_EquityInducementPlan2021Member" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">87,634</ix:nonFraction> shares were available for future grants as of March 31, 2026. The Inducement Plan provides for the granting of nonqualified stock options and
            restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest based on requisite service period and have a term of <ix:nonNumeric name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="Fact_f73b5682026941038fa437674c858847" contextRef="c20260101to20260331_PlanNameAxis_EquityInducementPlan2021Member" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. The Company&#8217;s restricted stock units awarded to date under the Inducement Plan vest based on requisite service period and have a term
            based on each award agreement. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c0955037" continuedAt="Text_3b57384df5394133af2d69b43c0955038">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at their grant-date fair value and
            records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations and
            comprehensive loss for the period presented:</div>
</ix:continuation>
          <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_0b3ff716410e4f2a9b3c18c24982954e" contextRef="c20260101to20260331" escape="true" continuedAt="Text_71a0e031bce540fb8696cb52bbdbaa3b1"><ix:continuation id="Text_3b57384df5394133af2d69b43c0955038" continuedAt="Text_3b57384df5394133af2d69b43c0955039">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> <br/></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_71a0e031bce540fb8696cb52bbdbaa3b1" continuedAt="Text_71a0e031bce540fb8696cb52bbdbaa3b2"><ix:continuation id="Text_3b57384df5394133af2d69b43c0955039" continuedAt="Text_3b57384df5394133af2d69b43c09550310">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_71a0e031bce540fb8696cb52bbdbaa3b2"><ix:continuation id="Text_3b57384df5394133af2d69b43c09550310" continuedAt="Text_3b57384df5394133af2d69b43c09550311">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 117.85pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_0e48072e30c0457d991f10fb38395128" contextRef="c20260101to20260331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">142</ix:nonFraction></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_41df688023ea410eadebe79e4b0a0cc0" contextRef="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_3ecfcf4ffd374fa4b1c8c0684528fd8b" contextRef="c20260101to20260331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">414</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f075694dec9c434bad6680e58bd73c3b" contextRef="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">614</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_ed2ecf6d19c74e378c1f900c75899ba5" contextRef="c20260101to20260331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">556</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_d72d1fdff783451ea3b1f3d1d56fdb28" contextRef="c20250101to20250331" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">858</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550311" continuedAt="Text_3b57384df5394133af2d69b43c09550312">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The following table summarizes stock option activity for the three months ended
            March 31, 2026: </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550312" continuedAt="Text_3b57384df5394133af2d69b43c09550313">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550313" continuedAt="Text_3b57384df5394133af2d69b43c09550314"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_c08f539b44794ae0be2ad8207fcae901" contextRef="c20260101to20260331" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.14pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_47d5665cbf3c419da30c30823d8ea926" contextRef="c20251231" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">658,973</ix:nonFraction></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_716c2ea03f9040d19e4dff99ec7a1175" contextRef="c20251231" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">44.20</ix:nonFraction></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_3ebdc1ee5a6245c1a4f3ef70abf31622" contextRef="c20250101to20251231" format="ixt-sec:duryear">7.1</ix:nonNumeric></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_09eb3b98306a4ae1934a1b34afe56e4f" contextRef="c20260101to20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">191,510</ix:nonFraction></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_f42f836bd76f488b84f2e61ce450c135" contextRef="c20260101to20260331" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">7.64</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 6.67pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" id="Fact_2ae5f659115a4d2c837314e3ce3f6068" contextRef="c20260101to20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">4,376</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_4ae32069cd6648539ed4698a924d2ac9" contextRef="c20260101to20260331" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">10.99</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_8d4bb9ab37d64555b9b57b01efac95a3" contextRef="c20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">846,107</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_2d5585421a6644ffad761fe8023c6e0e" contextRef="c20260331" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">40.13</ix:nonFraction></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_e27bcd744be141c78b55a3a70602b810" contextRef="c20260101to20260331" format="ixt-sec:duryear">7.5</ix:nonNumeric></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_d1b0ff019f0e4689ada4032fba084354" contextRef="c20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">387,675</ix:nonFraction></span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_d2394f763baf4108a8f9e78b78371c2e" contextRef="c20260331" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">74.20</ix:nonFraction></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_74fbc1efca2e4391ba22c08ccf89c8b6" contextRef="c20260101to20260331" format="ixt-sec:duryear">5.6</ix:nonNumeric></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_9f24968af9bb4b4880fc4a55db82e9e4" contextRef="c20260331" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">846,107</ix:nonFraction></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_5d2776ad0f1d4142acbe21cfd12c2fcd" contextRef="c20260331" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">40.13</ix:nonFraction></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_4a85db7c7b5c47a4911c43b5b45eae20" contextRef="c20260101to20260331" format="ixt-sec:duryear">7.5</ix:nonNumeric></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550314" continuedAt="Text_3b57384df5394133af2d69b43c09550315">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The weighted average grant date fair value of options granted was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_a4a73941316e419aa44a4bef1bc0dfc1" contextRef="c20260101to20260331" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">5.81</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_62ecb9cb986a406cbf885986634cebf8" contextRef="c20250101to20250331" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">6.20</ix:nonFraction> for the three months
            ended March&#160;31, 2026 and 2025, respectively. As of March 31, 2026, the total unrecognized compensation expense related to unvested stock option awards was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_95890eea2e4342f79b29844136bb7404" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.6</ix:nonFraction> million, which the Company expects to recognize over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_08c0ae6b9b754b7d904fa264db0e44b2" contextRef="c20260101to20260331" format="ixt-sec:duryear"><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_57577a0471e242aa8f1a194eb44c4f7c" contextRef="c20260101to20260331" format="ixt-sec:duryear">2.6</ix:nonNumeric></ix:nonNumeric>
            years. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550315" continuedAt="Text_3b57384df5394133af2d69b43c09550316">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The aggregate intrinsic value of options outstanding was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_ceded439fb6c47ca99e586c59efd40dd" contextRef="c20260331" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million at March 31, 2026 and was de minimis at March&#160;31, 2025. The aggregate intrinsic value of options exercised and options exercisable were
            each de minimis during the three months ended March 31, 2026 and 2025. </div>
</ix:continuation>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-45<br/>
        </div>

      </div>

    </div>

    <!--End Page 380-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 381-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550316" continuedAt="Text_3b57384df5394133af2d69b43c09550317">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: </div>
</ix:continuation>
          <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_9e91f614c71d4b6cb3438a13756da5f9" contextRef="c20260101to20260331" escape="true" continuedAt="Text_b67981fad5004452a66051929e69093e1"><ix:continuation id="Text_3b57384df5394133af2d69b43c09550317" continuedAt="Text_3b57384df5394133af2d69b43c09550318">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_b67981fad5004452a66051929e69093e1"><ix:continuation id="Text_3b57384df5394133af2d69b43c09550318" continuedAt="Text_3b57384df5394133af2d69b43c09550319">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 117.85pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_994ec3ae968141ebb9db854f723c5ac2" contextRef="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">92.4</ix:nonFraction>%</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_4e5353bf9a3549f8b945862c878f00eb" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">93.8</ix:nonFraction>%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_737afc3b303b46bb9b6ea9068f5dd39f" contextRef="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.9</ix:nonFraction>%</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_83855d5969ed45d5bc7c438749a9ef4c" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U004" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.1</ix:nonFraction>%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_1bd70ae9e4914bd498db52766bcf52d5" contextRef="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">5.8</ix:nonNumeric> years</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_4aed6500676b44e79ac1d6cc9296c884" contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6</ix:nonNumeric>.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550319" continuedAt="Text_3b57384df5394133af2d69b43c09550320">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Restricted Stock Units </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550320" continuedAt="Text_3b57384df5394133af2d69b43c09550321">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company issues RSUs to employees that vest over periods of time as
            determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant. Compensation expense is
            recognized on a straight-line basis over the vesting period of the RSUs. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550321" continuedAt="Text_3b57384df5394133af2d69b43c09550322">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes activity related to RSU awards during the three
            months ended March 31, 2026: </div>
</ix:continuation>
          <ix:nonNumeric name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Text_d87b4b9f2e004776a61a102db1ddc619" contextRef="c20260101to20260331" escape="true" continuedAt="Text_737617535b014b6daf9b513e3bb7c0231"><ix:continuation id="Text_3b57384df5394133af2d69b43c09550322" continuedAt="Text_3b57384df5394133af2d69b43c09550323">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_737617535b014b6daf9b513e3bb7c0231"><ix:continuation id="Text_3b57384df5394133af2d69b43c09550323" continuedAt="Text_3b57384df5394133af2d69b43c09550324">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_c57921ca7f5a465cbb337557cbd0b319" contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_b741a79e011d4861a50c0953a90aeb58" contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">10.52</ix:nonFraction> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_dbd3f842b47541a881e2aefec0f659ef" contextRef="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction>)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_c66a157d3ee34ed3a4adaa470bdaec9d" contextRef="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">11.70</ix:nonFraction></span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_bd1fae84ce08459aa6a2484b5a4956ff" contextRef="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_e8ee539028a3470d82efb3d6228d6baa" contextRef="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="2" scale="0" format="ixt:num-dot-decimal">11.70</ix:nonFraction></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550324" continuedAt="Text_3b57384df5394133af2d69b43c09550325">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2026, the total unrecognized expense related to all RSUs was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_f54ee35392674129a6fe5dd5b67e8bec" contextRef="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_01f8a434997945efa8f1b7ecebefe9df" contextRef="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">0.8</ix:nonNumeric> years. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550325" continuedAt="Text_3b57384df5394133af2d69b43c09550326">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Employee Stock Purchase Plan </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550326" continuedAt="Text_3b57384df5394133af2d69b43c09550327">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_ba4c74a37d6f4c71989cac83c8d04b3f" contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">99,088</ix:nonFraction> shares of the Company&#8217;s common stock. Of this amount, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_6776f1af908f4bd4919070c16fbb6052" contextRef="c20260331_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">59,103</ix:nonFraction> were available for future grants as of March 31, 2026. The number of shares of the Company&#8217;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for <ix:nonNumeric name="pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Fact_9c911b0cd506418d9ae319d90989df88" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, in an amount
            equal to <ix:nonFraction name="pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" id="Fact_4e54c823e31d43018f6f953e601476c1" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="2" scale="-2" format="ixt-sec:numwordsen">one </ix:nonFraction>percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP were not increased. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550327" continuedAt="Text_3b57384df5394133af2d69b43c09550328">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock
            through accumulated payroll deductions at such times as are established by the board of directors&#8217; Compensation Committee. Eligible employees may purchase the Company&#8217;s common stock at <ix:nonFraction name="pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage" id="Fact_8799123dba9249fcad58511d4a3a3788" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to <ix:nonFraction name="pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" id="Fact_aaa2d91a2e134f9cb72db425c35cd487" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $<ix:nonFraction name="pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" id="Fact_2da43c57fdac48bcad3511dc17ed9185" contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction>
            worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than <ix:nonFraction name="pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" id="Fact_642c949577c34b2a9575d957b46bc896" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">200</ix:nonFraction> shares of
            the Company&#8217;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from <ix:nonFraction name="pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" id="Fact_dff1908d5f6545bebcebe563ddc57c19" contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">200</ix:nonFraction> shares to <ix:nonFraction name="pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" id="Fact_9d224bd754c64472bd774ac4de059739" contextRef="c20260501to20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="0" scale="0" format="ixt:num-dot-decimal">2,000</ix:nonFraction> shares in any single offering period, not to exceed $<ix:nonFraction name="pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" id="Fact_e9cdbc14166241cdb74bbd44a790d0a1" contextRef="c20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> in any calendar year. </div>
</ix:continuation>
          <ix:continuation id="Text_3b57384df5394133af2d69b43c09550328">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the guidance in ASC Topic 718-50,<span style="font-style: italic;"> Compensation &#8211; Stock Compensation</span>, the ability to purchase shares of the Company&#8217;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the
            purchase date) represents an option and<span style="font-weight: bold;">, </span>therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair
            value as estimated by applying the Black-Scholes option-pricing model and is recognized over the withholding period. <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_8a044c6ae3b24f599b612a0d35aaa128" contextRef="c20250101to20250331_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_4aa2144f0fa2412081929b93ffad0840" contextRef="c20260101to20260331_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction>
            share-based compensation expense related to the ESPP was recorded during the three months ended March&#160;31, 2026 and 2025. </div>
</ix:continuation>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-46<br/>
        </div>

      </div>

    </div>

    <!--End Page 381-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 382-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_204-finnotes01_pg15"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_b3d57ceda17f4e5fb5f3483971688bcc" contextRef="c20260101to20260331" escape="true" continuedAt="Text_a73e7cf18f9442a6925bf05e72bf874b1">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">12. Segment Reporting </div>
</ix:nonNumeric>
          <ix:continuation id="Text_a73e7cf18f9442a6925bf05e72bf874b1" continuedAt="Text_a73e7cf18f9442a6925bf05e72bf874b2">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a <span style="-sec-ix-hidden:Fact_54f55c66f3b44146b30493895e843cea">single</span> reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. </div>
</ix:continuation>
          <ix:continuation id="Text_a73e7cf18f9442a6925bf05e72bf874b2" continuedAt="Text_a73e7cf18f9442a6925bf05e72bf874b3">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies in the Company&#8217;s 2025 Annual Report filed on Form&#160;10-K. The Company&#8217;s CODM is its chief executive officer. The measure of segment assets is reported on the balance sheet as total assets. All
            assets are located within the United States. </div>
</ix:continuation>
          <ix:continuation id="Text_a73e7cf18f9442a6925bf05e72bf874b3" continuedAt="Text_a73e7cf18f9442a6925bf05e72bf874b4">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The CODM uses net loss as reported on the Company&#8217;s statement of operations to
            assess the Company&#8217;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses exclude
            certain non-cash items such as share-based compensation and depreciation and amortization expenses. </div>
</ix:continuation>
          <ix:continuation id="Text_a73e7cf18f9442a6925bf05e72bf874b4" continuedAt="Text_a73e7cf18f9442a6925bf05e72bf874b5">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes significant segment expenses: </div>
</ix:continuation>
          <ix:continuation id="Text_a73e7cf18f9442a6925bf05e72bf874b5" continuedAt="Text_a73e7cf18f9442a6925bf05e72bf874b6">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>
</ix:continuation>

          <ix:continuation id="Text_a73e7cf18f9442a6925bf05e72bf874b6" continuedAt="Text_a73e7cf18f9442a6925bf05e72bf874b7"><ix:nonNumeric name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Text_4d9727421a81487994f3e25bd39a759f" contextRef="c20260101to20260331" escape="true">
<table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 117.85pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 3.33pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentLaborAndRelatedExpenses" id="Fact_6fcdf625ea22434c9d0aaaa8241c009f" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,458</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 8.33pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentLaborAndRelatedExpenses" id="Fact_e13382fd4c0d43a7b6562457929dcd84" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,589</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentThirdPartyCosts" id="Fact_e43f6b3435304cb1aabcfd6d84fa65a7" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,432</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentThirdPartyCosts" id="Fact_5dc5ea02ee3a4fe69fed6bc3a3276d66" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,794</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentShareBasedCompensation" id="Fact_88b71e25afe042a8960f21aa2397edb2" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">142</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentShareBasedCompensation" id="Fact_9c8338005f004ae7b218924f44f645b5" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentDepreciationAndAmortization" id="Fact_fca85ae1cf264f5fabf87ee2a2d8d07b" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:ResearchAndDevelopmentDepreciationAndAmortization" id="Fact_3cf0fa17fae04539a7c908b689ab5687" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">110</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_2fd3ed61081743b98a47fa54afd70657" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,093</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_5dea6130f5b14247a20b8146ed7566a8" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,737</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeLaborAndRelatedExpenses" id="Fact_32df42db8ac24025a09c7efafe972bbb" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,891</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeLaborAndRelatedExpenses" id="Fact_a40c9f42fbc143f7b2d2639b41de1fd5" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,790</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeThirdPartyCosts" id="Fact_d5ccbb0d01764bc79b955410e38a5183" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,415</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeThirdPartyCosts" id="Fact_0ab2dd98645142f9bc0c5c3aff8ee60a" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,603</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeShareBasedCompensation" id="Fact_448b761a506d469a927d27e0bb0b5a72" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">414</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeShareBasedCompensation" id="Fact_ba029c30b0b442f7b7cabe770196280b" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">614</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeDepreciationAndAmortization" id="Fact_bb4af7102c284069b880326d7e082044" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="pasg:GeneralAndAdministrativeDepreciationAndAmortization" id="Fact_f33ad63c13f54e23ba65542c3ef97fb7" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">78</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_faefffcf7db94fb88ebbaa377b65707b" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,787</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_65818292169d4f8aa9dd143fba695759" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,085</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_c97de7d39c784d0c9fcfddb7d5337d2d" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,637</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:GainLossOnTerminationOfLease" id="Fact_e9465e41853b469a88855d93fdd40ffd" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">633</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c901f272c7124cf0888e95a7b8aebdf0" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,247</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_e47337846f3e4ebfab6dae21f58abd15" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,459</ix:nonFraction>)</span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_44e02b34bef94b7b9079cb0434a42c71" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">688</ix:nonFraction></span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_aaddde2c00a749bba3ceed1c6ff9f724" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,054</ix:nonFraction> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_9bde39fc75ea4532b7d31484d9c3ba31" contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,559</ix:nonFraction>)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7810d7d4369340ca93681f129b71e5d4" contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,405</ix:nonFraction>)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 54.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
</ix:nonNumeric></ix:continuation>

          <ix:continuation id="Text_a73e7cf18f9442a6925bf05e72bf874b7">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The components of Other (income) expense, net are further described in Note&#160;3 to
            the financial statements. </div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="color: #000000;">
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_bccb8136b6c74517a91af1fb6892a0ce" contextRef="c20260101to20260331" escape="true" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a31">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;" class="BRDSX_h2">13. Subsequent Events </div>
</ix:nonNumeric>
          <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a31" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a32">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On April&#160;20, 2026, the Company announced it has initiated a review of
            strategic alternatives to maximize shareholder value. These strategic alternatives may include merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships, licensing opportunities, or other
            potential paths. </div>
</ix:continuation>
          <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a32" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a33">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On April&#160;28, 2026, in connection with the Company&#8217;s review of strategic
            alternatives, the Company announced a restructuring of its workforce, or the Restructuring Plan, to decrease operating expenses by reducing the workforce by approximately <ix:nonFraction name="pasg:RestructuringPlanReductionInWorkforcePercentage" id="Fact_9eb8286cf3d84c4d9c9bab64602e5a63" contextRef="c20260428to20260428_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U004" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>%. The implementation of the Restructuring Plan should be substantially complete in the second and third quarters of 2026. The Company estimates the aggregate severance and related
            costs for the Restructuring Plan will be approximately $<ix:nonFraction name="pasg:EstimatedSeveranceAndRelatedCosts" id="Fact_938ee3f34987438b823136167661ab2e" contextRef="c20260428_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.3</ix:nonFraction> million, which will be recorded primarily in the second quarter of 2026.
            These estimates are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with,
            the Restructuring Plan as well as the Company&#8217;s review of strategic alternatives. </div>
</ix:continuation>
           </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-47<br/>
        </div>

      </div>

    </div>

    <!--End Page 46-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 47-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_300-annexa_pg1"><!--Anchor--></a> </div>

    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div style="width: 468pt; margin-left: 0pt;" class="BRDSX_block-main">
          <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a33" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a34">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On May 21, 2026, the Company provided written notice to Gemma to terminate
            the Gemma Collaboration Agreement, which termination will become effective in accordance with the terms of the Gemma Collaboration Agreement. Following the effectiveness of the termination, the Company will no longer have any rights to the
            research programs or the options for new CNS indications previously available to it under the Gemma Collaboration Agreement.</div>
</ix:continuation>
          <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a34" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a35">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On May 22, 2026, the Company and the landlord entered into a lease termination
            agreement pursuant to which the 2005 Market Street Lease Agreement was terminated and the Company paid a termination fee of $<ix:nonFraction name="pasg:PaymentOfLeaseTerminationFee" id="Fact_239b7988048f48318dd830e290a2461d" contextRef="c20260522to20260522_PropertyPlantAndEquipmentByTypeAxis_MarketStreetLeaseAgreement2005Member_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction>
            million.</div>
</ix:continuation>
          <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a35" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a36">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On June 23, 2026, the Company delivered written notice to Penn to terminate
            the Penn License Agreement, pursuant to Section 10.2 thereof, solely with respect to the Company&#8217;s product candidate referred to as PBFT02 for all indications licensed to the Company thereunder for such product candidate, including
            frontotemporal dementia with granulin mutations, or the <span style="font-style: italic; font-weight: bold;">PBFT02 Termination</span>. The PBFT02 Termination will become effective on the date that is 90 days following Penn&#8217;s receipt of the
            notice, after which the Company will no longer have any rights under the Penn License Agreement to develop or commercialize PBFT02. The Penn License Agreement will remain in effect with respect to all non-terminated licensed products.</div>
</ix:continuation>
          <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a36" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a37">
<div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">On June 23, 2026, the Company delivered written notice to Catalent to
            terminate, pursuant to Section 20.1(b)(ii) thereof, the amended and restated development services and clinical supply agreement, dated November 9, 2023 (one of the Amended Catalent Agreements), in its entirety, effective as of June 23, 2026.
            The Company determined to terminate this agreement in connection with the wind-down of our gene therapy programs and the proposed Merger (as defined below), and the Company was not obligated to pay Catalent any termination fee in connection <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">with the termination.</span></div>
</ix:continuation>
          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara">
            <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a37" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a38">
<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 24, 2026, the Company entered into
              an Agreement and Plan of Merger and Reorganization, or the Merger Agreement, with Remix Therapeutics, Inc., a Delaware corporation, or Remix, and Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, or Merger
              Sub. Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Remix, with Remix continuing as a wholly-owned subsidiary of the Company and the surviving
              corporation of the merger. Upon termination of the Merger Agreement under specified circumstances the Company will be required to make a payment to Remix equal to $<ix:nonFraction name="pasg:MergerAgreementTerminationPaymentAmount" id="Fact_46d381260a5647aa85af78b2f5861409" contextRef="c20260624to20260624_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction> million in cash.</div>
</ix:continuation>
            <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a38" continuedAt="Text_de56e5cf8fee4db3a96f1dbb1791c2a39">
<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
            </div>
</ix:continuation>
            <ix:continuation id="Text_de56e5cf8fee4db3a96f1dbb1791c2a39">
<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> In July 2026, the Pennsylvania Supreme
              Court denied the petition for review with respect to the plaintiff&#8217;s challenge to the post-trial rulings in favor of Passage Bio, but it agreed to hear the question of whether certain communications between lawyers and the mediator were
              appropriately excluded from evidence at trial under Pennsylvania&#8217;s mediation privilege. The Pennsylvania Supreme Court timing for this hearing is currently pending.<br/>
            </div>
</ix:continuation>
          </div>

          <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;" class="BRDSX_fpara"> </div>

        </div>

      </div>

      <div style="width: 468pt; margin-top: 12pt; margin-left: 0pt;" class="BRDSX_block-frill">
        <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;" class="BRDSX_unknown">F-48<br/>
        </div>

      </div>

    </div>

    <!--End Page 373-->
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 374-->
    <div style="text-align: left; margin: auto; line-height: initial; width: 468pt;" class="BRDSX_page"><a id="ny20077915x1_s4_206-fintab02_pg1"><!--Anchor--></a> </div>

  </div>


  <div style="color: #000000;">
    <!--Begin Page 1-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; position: relative; width: 540pt;"> </div>

    <!--Begin Page 383-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tRIR2"><!--Anchor--></a>REPORT OF INDEPENDENT REGISTERED PUBLIC
            ACCOUNTING FIRM </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">To the Stockholders and Board of Directors of Remix Therapeutics, Inc. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Opinion on the Financial Statements</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have audited the accompanying consolidated balance sheets of Remix
            Therapeutics, Inc. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders' deficit, and cash flows, for the
            years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025
            and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Going Concern</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying financial statements have been prepared assuming that the
            Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred recurring losses from operations and recurring cash used in operations, has an accumulated deficit, and has limited capital
            resources to sustain operations that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments
            that might result from the outcome of this uncertainty.</div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Basis for Opinion</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These financial statements are the responsibility of the Company's management.
            Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be
            independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We conducted our audits in accordance with the standards of the PCAOB and in
            accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
            misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of
            internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our audits included performing procedures to assess the risks of material
            misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
            statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
            reasonable basis for our opinion.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">/s/ Deloitte &amp; Touche LLP<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, Massachusetts<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">July 21, 2026</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We have served as the Company's auditor since 2026. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-49<br/>
        </div>

      </div>

    </div>

    <!--End Page 383-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 384-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_206-fintab02_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCBS2"><!--Anchor--></a>REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED BALANCE SHEETS <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(In thousands, except share and per share amounts)</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 94.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 94.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br/>
                  </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br/>
                  </div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">24,147 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">73,424 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts receivable</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212; </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">353 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Prepaid expenses and other current assets</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,208 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,547</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">25,355 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">77,324 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">2,029 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">2,098 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease right-of-use assets</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">14,959 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">15,969 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">12,595 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">15,706 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid expenses and other non-current assets</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,431 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">265 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total assets</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">56,369 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 4.07pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">111,362 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities, Convertible Preferred Stock and
                    Stockholders&#8217; Deficit<br/>
                  </div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities:<br/>
                  </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 13.33pt;">3,383 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 13.33pt;">4,572 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">3,707 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">6,306 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liability, current portion</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">1,682 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">1,724 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred revenue, current portion </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">14,464 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,046 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">23,236 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">19,648 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible notes payable (includes $13,100 and $39,667 from related
                    parties)</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">13,100 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">59,600 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">2023 Warrants and Letter Warrant liability (includes
                    $6,170 and $2,753 from related parties)</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">6,286 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">4,020</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2025 Warrant liability, related party</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 18.33pt;">1,388 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contingent tranche liability, related party</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">500 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease liability, net of current portion</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">21,736 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">23,786 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue, net of current portion</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">60,143 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">70,871</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other liabilities</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 26.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">116</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total liabilities</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">126,389 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">178,041 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and contingencies (Note&#160;18)<br/>
                  </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Convertible preferred stock (Series&#160;Seed, A and B),
                    $0.0001 par value; 124,133,326&#160;shares and 87,347,523 shares authorized at December&#160;31, 2025 and 2024, respectively; 118,136,265 and 87,203,974 shares issued and outstanding at December&#160;31, 2025 and 2024, respectively; aggregate
                    liquidation preference of $219,390 and $154,793 at December&#160;31, 2025 and 2024, respectively</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">200,865 </span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">132,793 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders&#8217; deficit:<br/>
                  </div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common stock, $0.0001 par value; 162,000,000 and
                    116,000,000 shares authorized at December&#160;31, 2025 and 2024, respectively; 7,811,834 and 7,626,774 shares issued and outstanding at December&#160;31, 2025 and 2024, respectively</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35.83pt;">1</span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 35.83pt;">1 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.7pt;">21,110 </span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">18,818 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(291,996</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(218,291</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total stockholders&#8217; deficit</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(270,885</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(199,472</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">56,369</span></div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 4.07pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">111,362</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-50<br/>
        </div>

      </div>

    </div>

    <!--End Page 384-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 385-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_206-fintab02_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCSO2"><!--Anchor--></a>REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(In thousands) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 98.81pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 98.81pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 17.5pt;">3,310 </span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 17.13pt;">4,827 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br/>
                  </div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;">52,593 </span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.13pt;">58,492 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,056 </span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,152 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">67,649 </span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">73,644 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(64,339</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(68,817</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (expense) income:<br/>
                  </div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Change in fair value of convertible notes payable,
                    warrant liabilities and contingent tranche liability, related party</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt;">(10,814)</span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.8pt;">(3,518) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest income</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">1,293 </span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.13pt;">3,224 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other (expense) income, net</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 31.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(27</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 34.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">22 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total other expense, net</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,548</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 26.3pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(272</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(73,887</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.8pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(69,089</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax benefit (expense)</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">182 </span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 31.3pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(50</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss and comprehensive loss</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(73,705</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.8pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(69,139</span><span style="padding-bottom: 0.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share of common stock, basic and diluted</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 19.17pt;">(9.57)</span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 18.8pt;">(9.08) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average common shares outstanding, basic and diluted</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">7,700,621 </span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">7,611,340</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 44.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-51<br/>
        </div>

      </div>

    </div>

    <!--End Page 385-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 386-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_206-fintab02_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCSC2"><!--Anchor--></a>REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND&#160;STOCKHOLDERS&#8217;&#160;DEFICIT
            <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(In thousands, except share amounts)</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 97.77pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 71.21pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45.31pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 97.77pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series Seed, A and B <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Convertible Preferred Stock</div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 71.21pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 36.45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital </div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 45.31pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 47.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217; <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares </div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div>
                </td>

    <td style="width: 2.61pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at January&#160;1, 2024</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 4.4pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">87,203,974 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$132,793 </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,570,827 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$16,390 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$(149,152</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$(132,761</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise of stock options</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 37.65pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 26.13pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 11.88pt;">55,947 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 21.38pt;">39 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 29.29pt;">39 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Vesting of restricted common stock from
                    early-exercised stock options </div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 37.65pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 26.13pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 28.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 21.38pt;">54 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 29.29pt;">54 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock-based compensation</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 37.65pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 26.13pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 28.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 9.5pt;">2,335 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 17.41pt;">2,335 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 37.65pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 28.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 21.38pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(69,139</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(69,139</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2024</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 4.4pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">87,203,974 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$132,793 </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7,626,774 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 4.75pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$18,818 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(218,291</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.27pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(199,472</span><span style="padding-bottom: 0.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Issuance of Series&#160;B convertible preferred stock
                    in exchange for 2023 Notes</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 4.4pt;">31,029,131 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 9.5pt;">68,264 </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 28.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 21.38pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 3.27pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 9.5pt; text-indent: -9.5pt; text-align: left;">Conversion of Series&#160;A and Series&#160;B convertible
                    preferred stock to common stock from the 2025 notes agreement</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 17.86pt;">(96,840)</span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 18.21pt;">(192)</span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 11.88pt;">96,840 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 16.63pt;">192 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 24.54pt;">192 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise of stock options</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 37.65pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 26.13pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 11.88pt;">88,220 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 21.38pt;">49 </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 29.29pt;">49 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock-based compensation</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 37.65pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 26.13pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 28.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 9.5pt;">2,051 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 29.29pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.02pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 17.41pt;">2,051 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="padding-left: 37.65pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="padding-left: 26.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 28.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="padding-left: 4.75pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="padding-left: 21.38pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(73,705</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.02pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="padding-left: 9.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(73,705</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.27pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.04pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.44pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.51pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.45pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$200,865 </span></div>
                </td>

    <td style="width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 38pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 0.35pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7,811,834 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 6.87pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 4.75pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 2.79pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 0.35pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">21,110 </span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.31pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 3.27pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(291,996</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.27pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0pt; margin-left: 4.16pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(270,885</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.04pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.36pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.31pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.61pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9.5pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-52<br/>
        </div>

      </div>

    </div>

    <!--End Page 386-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 387-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_206-fintab02_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCSCF2"><!--Anchor--></a>REMIX THERAPEUTICS, INC.<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 83.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 83.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from operating activities:<br/>
                  </div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(73,705)</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$ (69,139) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to reconcile net loss to net cash used in operating
                    activities:<br/>
                  </div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization expense</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,170 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,293 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,051 </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,335 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Non-cash issuance expense</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">267 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Change in fair value of convertible notes payable,
                    warrant liability and contingent tranche liability</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">10,814 </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,518 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Gain on sale of property and equipment</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(141) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities:<br/>
                  </div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts receivable</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">353 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">29,754 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid expenses and other assets</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">896 </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(1,653) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(999)</span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">1,883 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Deferred revenue</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(3,310)</span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">7,173 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Operating lease liabilities</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(1,083)</span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(574) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued expenses and other liabilities</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,507</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,438 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net cash used in operating activities</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(64,053</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(22,113</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from investing activities:<br/>
                  </div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchases of property and equipment</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt;">(48)</span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(647) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from sales of property and equipment</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">198 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net cash used in investing activities</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(48</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(449</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from financing activities:<br/>
                  </div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance costs related to convertible notes payable</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(282) </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Issuance costs to obtain a line of credit</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(204)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from issuance of convertible notes payable and warrant liability</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">14,988 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">48,667 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from exercise of stock options</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49 </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">39 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net cash provided by financing activities</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">14,755 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">48,502 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net (decrease) increase in cash, cash equivalents and
                    restricted cash</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">(49,346)</span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">25,940 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents and restricted cash, beginning of period</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">75,522 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,582 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents and restricted cash, end of period</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">26,176 </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">75,522 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental disclosures of non-cash information:<br/>
                  </div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Conversion of convertible notes payable to Series&#160;B preferred stock</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 3.33pt;">68,264 </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 20.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Conversion of Series&#160;A, Series&#160;B preferred stock to common stock</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">192 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax refund received</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(229)</span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sale of property, plant and equipment in prepaid expenses and other
                    current assets</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 26.2pt;">11 </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vesting of restricted common stock from early-exercised stock options</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">54 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Settlement of contingent tranche liability from the convertible notes
                    payable</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">5,660 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warrants issued to obtain a line of credit</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 21.2pt;">116</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 372pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-53<br/>
        </div>

      </div>

    </div>

    <!--End Page 387-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 388-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tNCF2"><!--Anchor--></a>REMIX THERAPEUTICS, INC.<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1. Description of Business, Organization and Liquidity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix Therapeutics, Inc. (together with its consolidated subsidiary, the
            &#8220;Company&#8221;) is focused on developing small molecule therapeutics to modulate ribonucleic acid (&#8220;RNA&#8221;) processing and address the underlying drivers of disease. The Company was incorporated in July&#160;2019 under the laws of the State of Delaware and
            is located in Massachusetts. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company is subject to risks and uncertainties common to early-stage companies
            in the biotechnology industry, including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing.
            Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts will
            require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company
            will realize revenue from product sales. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Going Concern </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying consolidated financial statements are prepared in accordance
            with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has incurred recurring operating losses and negative cash flows from
            operations since its inception and has an accumulated deficit. Net losses totaled $73.7&#160;million and $69.1&#160;million for the years ended December&#160;31, 2025 and 2024, respectively, and cash flows used in operations totaled $64.1&#160;million and
            $22.1&#160;million for the years ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, the Company had an accumulated deficit of $292.0&#160;million. The Company expects to continue to incur significant operating losses and negative
            cash flows from operations for the foreseeable future until such time, if ever, it generates a level of revenue that is sufficient to support its cost structure. The Company has limited capital resources and expects that its cash and cash
            equivalents, including amounts received from issuances of convertible promissory notes, will not be sufficient to fund its operating expenses, capital expenditure requirements and obligations, for the twelve months following the date the
            consolidated financial statements are issued. As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year from the date that these consolidated financial statements
            were issued. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Management&#8217;s plans to obtain additional funding include (1) a reverse merger and
            concurrent private placement in public equity (&#8220;PIPE&#8221;) financing, (2) financing alternatives (e.g., equity financing, royalty arrangements, business development financing, etc.), or (3) both. Refer to Note&#160;23 for more information. Although
            management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company to fund continuing operations, if at all. If the Company is unable to
            obtain financing, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business
            prospects, or the Company may be unable to continue operations. As a result, the Company has concluded that management&#8217;s plans do not alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consolidated financial statements do not include any adjustments relating to
            the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">2. Summary of Significant Accounting Policies </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying consolidated financial statements have been prepared in
            conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). All adjustments considered necessary for a fair presentation have been included. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-54<br/>
        </div>

      </div>

    </div>

    <!--End Page 388-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 389-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Principles of Consolidation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying consolidated financial statements include the accounts of Remix
            Therapeutics, Inc., and its wholly owned subsidiary, Remix Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The preparation of the Company&#8217;s consolidated financial statements in conformity
            with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the
            reported amounts of revenue and expenses during the reporting periods. The Company bases its estimates on historical experience, known trends, and various other assumptions that are believed to be reasonable under the circumstances. On an
            ongoing basis, management evaluates its estimates as there are changes in circumstances, facts, and experience. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Segment Information </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has one reportable segment focused on developing small molecule
            therapeutics to modulate ribonucleic acid (&#8220;RNA&#8221;) processing and address the underlying drivers of disease. Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by
            the chief operating decision-maker (the &#8220;CODM&#8221;) in deciding how to allocate resources and assess performance. The Company&#8217;s CODM, its Chief Executive Officer (&#8220;CEO&#8221;), manages the Company&#8217;s operations on a consolidated basis for the purposes of
            making operating decisions, assessing financial performance, and allocating resources. For additional information, see Note&#160;22<span style="font-style: italic;">, Segment Information</span>. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Cash Equivalents </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company considers all highly liquid investments with a remaining maturity
            when purchased of three months or less to be cash equivalents. Cash equivalents are comprised of money market funds as of December&#160;31, 2025 and 2024. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Restricted Cash </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Restricted cash represents cash held by a financial institution as collateral for
            letters of credit, which secure the Company&#8217;s operating leases for office and laboratory space. Restricted cash amounts are reported as non-current assets on the consolidated balance sheets unless restrictions are expected to be released within
            twelve months of the respective balance sheet date. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Financial instruments that potentially subject the Company to concentrations of
            credit risk consist principally of cash and cash equivalents. The Company maintains its cash and cash equivalents in financial institutions that it believes have high credit quality and does not believe that such funds are exposed to any
            unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company places its cash with reputable financial institutions that are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to
            the limit of $250,000. Deposits held may exceed the amount of insurance provided by the FDIC. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company is dependent on third-party contract manufacturing organizations
            (&#8220;CMOs&#8221;) to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of CMOs to supply it with its requirements for the active pharmaceutical
            ingredients related to these programs. Although the Company is not currently selling products to customers, these research and development programs could be adversely affected by a significant interruption in the supply of active pharmaceutical
            ingredients. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Fair Value Measurements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair
            value is defined as the price that would be received for an asset or paid to transfer a liability between market participants at the measurement date. Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, <span style="font-style: italic;">Fair
              Value Measurement</span> (&#8220;ASC 820&#8221;), establishes a </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-55<br/>
        </div>

      </div>

    </div>

    <!--End Page 389-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 390-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">three-level valuation hierarchy for instruments measured at fair value. The
            hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of inputs, of which the first two are considered observable and the last is considered
            unobservable: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or
                    liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity and that are significant to determining the
                    fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company&#8217;s cash equivalents, contingent tranche liabilities, warrant
            liabilities and convertible promissory notes payable are carried at fair value, determined according to the fair value hierarchy described above (see Note&#160;3). The carrying values of the Company&#8217;s accounts payable and accrued expenses
            approximate their fair values due to the short-term nature of these liabilities. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Convertible Promissory Notes Payable </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As permitted under ASC 825, <span style="font-style: italic;">Financial
              Instruments</span> (&#8220;ASC 825&#8221;), the Company elects to account for its convertible promissory notes (the &#8220;convertible notes payable&#8221;), which meet the required criteria, at fair value at inception and at each subsequent reporting date.
            Subsequent changes in fair value are recorded as a component of non-operating loss in other income (expense) in the consolidated statements of operations and comprehensive loss. As a result of electing the fair value option, direct costs and
            fees related to the convertible notes payable are expensed as incurred. The Company elected as an accounting policy to not present interest expense separately from changes in the fair value of the convertible notes payable. The proceeds from
            the sale of the convertible promissory notes are allocated to the identified freestanding instruments, including warrants and contingent tranches, based on their fair value at inception (see Note&#160;9). </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Warrant Liability </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounts for issued warrants either as a liability or equity in
            accordance with ASC 480-10, <span style="font-style: italic;">Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity</span> (&#8220;ASC 480-10&#8221;) or ASC 815-40, <span style="font-style: italic;">Accounting
              for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock</span> (&#8220;ASC 815-40&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480<span style="font-style: italic;">, Distinguishing Liabilities from Equity </span>(&#8220;ASC 480&#8221;), meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815,
            including whether the warrants are indexed to the Company&#8217;s own stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity
            classification. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Warrants issued with convertible promissory notes<span style="font-style: normal;"> &#8211; Warrants that are classified as liabilities are recorded at fair value and remeasured each period until settled or until classified as equity, with changes in the fair value recorded in other income (expense) in
              the consolidated statements of operations and comprehensive loss. As the warrant liabilities associated with the convertible notes payable are contingently redeemable outside of the control of the Company, the warrants were determined to be
              classified as a liability. Changes in the Company&#8217;s inputs and assumptions, such as the volatility of comparable companies or changes in interest rates, could result in material changes in the warrants valuation in future periods. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Warrants issued to obtain a line of credit<span style="font-style: normal;"> &#8211; In certain instances, warrants may be issued by the Company to obtain access to a line of credit with a third-party creditor. As the warrants are contingently redeemable outside of the control of the Company,
              the warrants were determined to be classified as a liability and are recorded on the balance sheet at the date of the line of credit&#8217;s inception. Warrants issued to obtain a line of credit are recorded within the 2023 Warrant and Letter
              Warrant liability line on the Company&#8217;s consolidated balance sheets. The Company estimates the fair value of the warrants issued to obtain a line of credit using the Black-Scholes pricing model at the date of the line of credit&#8217;s inception
              and subsequently adjusts the fair value at each reporting date (see Note&#160;10). </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-56<br/>
        </div>

      </div>

    </div>

    <!--End Page 390-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 391-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Contingent Tranche Liabilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company determined that its obligations to issue, and the Company&#8217;s
            investors&#8217; rights to purchase, additional convertible promissory notes and warrants pursuant to a milestone closing or the satisfaction of other specified tranche closing conditions (see Note&#160;9) represent freestanding financial instruments (the
            &#8220;contingent tranche liabilities&#8221;). The contingent tranche liabilities are initially recorded at fair value using valuation models that incorporate significant unobservable inputs and are remeasured at fair value at each reporting date and upon
            settlement, exercise, or expiration of the related obligations. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Property and Equipment </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Property and equipment are stated at cost, net of accumulated depreciation and
            amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset, as follows: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 95.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer equipment and software</div>
                </td>

    <td style="width: 12.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 95.23pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">3 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment</div>
                </td>

    <td style="width: 12.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 95.23pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">5 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures </div>
                </td>

    <td style="width: 12.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 95.23pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">5 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 12.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 95.23pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">Shorter of useful life or<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;">term of associated lease</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 95.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Costs for capital assets not yet placed into service are capitalized as
            construction-in-process and depreciated once put into service. Upon the sale or disposal of property and equipment, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheets and any
            resulting gain or loss is reflected in loss from operations. Expenditures for repairs and maintenance are expensed as incurred, while expenditures for major renewals and betterments that extend the useful life of an asset or provide additional
            utility are capitalized. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Impairment of Long-Lived Assets </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company evaluates its long-lived assets, including property and equipment and
            operating lease right-of-use (&#8220;ROU&#8221;) assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Factors that the Company considers in deciding when to
            perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. The
            recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset or asset group to the future undiscounted cash flows expected to be generated by the asset or asset group and its eventual disposition.
            If an asset is determined to be impaired, the loss is measured based on the excess of the asset or asset group&#8217;s carrying value and its quoted market prices in active markets, if available. If quoted market prices are not available, the
            estimate of fair value is based on various valuation techniques, including a discounted value of estimated future cash flows. The Company did not identify any assessment triggering events and did not record any impairment losses on long-lived
            assets during the years ended December&#160;31, 2025 or 2024. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Leases </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company determines whether the arrangement is or contains a lease at
            inception based on the unique facts and circumstances present in the arrangement, including the use of an identified asset or group of assets and the Company&#8217;s control over the use of that identified asset or group of assets. If determined to
            be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as of the date on which the leased asset is made available for use by the Company, based on the
            economic characteristics of the lease. For each lease with a term greater than 12 months, the Company records a right-of-use asset and current and non-current lease liabilities. As of December&#160;31, 2025 and 2024, the Company did not have any
            financing leases. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company&#8217;s leases of laboratory and office space are classified as operating
            leases. In determining the appropriate lease classification, ASU 2016-02, <span style="font-style: italic;">Leases</span> (&#8220;ASC 842&#8221;) allows for the use of judgment in determining whether (i) the lease transfers ownership of the underlying
            asset to the Company, (ii) the lease grants an option for the Company to purchase the underlying asset, (iii) the assumed lease term is for a major part of the remaining economic life of the underlying asset or (iv) whether the present value of
            lease payments represents substantially all </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-57<br/>
        </div>

      </div>

    </div>

    <!--End Page 391-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 392-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">of the fair value of the underlying asset. If one or more of these factors are
            not present, the lease is considered to be an operating lease. Lease terms may include the impact of options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The aforementioned factors
            are applied consistently to the Company&#8217;s entire portfolio of leases. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A right-of-use asset represents the economic benefit conveyed to the Company by
            the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the lease. The Company elected to apply the package of practical expedients, which allows the Company to
            not reassess (i)&#160;whether existing or expired arrangements contain a lease, (ii) the lease classification of existing or expired leases, or (iii) whether previous initial direct costs would qualify for capitalization under the new lease
            standard. The Company also elected to not group lease and non-lease components as a single component. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are
            excluded. Lease liabilities are measured at lease commencement and calculated as the present value of the future lease payments in the contract using the rate implicit in the contract, when available. If an implicit rate is not readily
            determinable, the Company will use an incremental borrowing rate measured as the rate at which the Company could borrow, on a fully collateralized basis, a commensurate loan in the same currency over a period consistent with the lease term at
            the commencement date. The determination of the incremental borrowing rate is a management judgment, which is based on an analysis that includes the credit rating of the Company, geographical risk and U.S. Treasury and corporate bond yields.
            Right-of-use assets are measured as the lease liability plus initial direct costs and prepaid lease payments, less lease incentives granted by the lessor. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The lease term is measured as the non-cancellable period in the contract,
            adjusted for any options to extend or terminate when it is reasonably certain the Company will extend the lease term via such options based on an assessment of economic factors present as of the lease commencement date. Lease expense is
            recognized on a straight-line basis over the lease term. The Company has elected not to recognize on the balance sheet leases with terms of one year or less, but payments are recognized as expense on a straight-line basis over the lease term. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Classification and Accretion of Convertible
            Preferred Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has classified its convertible preferred stock (the &#8220;preferred
            stock&#8221;) as mezzanine equity in the accompanying consolidated balance sheets due to terms that allow for redemption of the shares in cash upon certain change of control events that are outside of the Company&#8217;s control, including a sale or
            transfer of control of the Company as holders of the preferred stock could cause redemption of the shares in these situations. The Company did not accrete the carrying values of the preferred stock to their respective redemption values since a
            liquidation event was not considered probable for the years ended December&#160;31, 2025 and 2024. Subsequent adjustments of the carrying values of the preferred stock to the ultimate redemption values will be made only when it becomes probable that
            such a liquidation event will occur. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Revenue Recognition </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company records revenue in accordance with ASC Topic 606, <span style="font-style: italic;">Revenue from Contracts</span> with <span style="font-style: italic;">Customers </span>(&#8220;ASC 606&#8221;). Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in
            an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company
            performs the following five steps: (i) identifies the contract(s) with a customer, (ii)&#160;identifies the performance obligations in the contract, (iii) determines the transaction price, (iv) allocates the transaction price to the performance
            obligations in the contract, and (v) recognizes revenue when, or as, the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration
            it is entitled to in exchange for the goods or services it transfers to the customer. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has entered into multiple collaboration agreements that are within
            the scope of ASC 606, under which it (i) has licensed exclusive rights to research, develop, manufacture and commercialize product candidates and (ii)&#160;provides research and development services to third parties (see Note&#160;8). The terms of these
            arrangements include payments to the Company of non-refundable upfront fees as well as research, development and sales milestone payments upon achieving the specified milestones, as well as potential future royalty payments. As part of the
            accounting for this type of arrangement, the Company must use judgment to determine: (a) the performance obligations, (b) the transaction prices, (c) the standalone selling price for each performance obligation identified in the contracts for
            the allocation of the transaction prices, and (d) the timing of revenue recognition. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-58<br/>
        </div>

      </div>

    </div>

    <!--End Page 392-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 393-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Performance Obligations </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At contract inception, once the contract is determined to be within the scope of
            ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations by assessing whether each promised good or service is distinct. In assessing whether promised goods or
            services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own and whether the required expertise
            is readily available. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the remaining promises, whether the value of the promise is dependent on the unsatisfied
            promises, whether there are other vendors that could provide the remaining promises, and whether it is separately identifiable from the remaining promises. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If an arrangement is determined to contain customer options that allow the
            customer to acquire additional goods or services, the Company evaluates the customer options to determine if they are material rights at the outset of each arrangement. Options to acquire additional goods or services for free or at a discount
            are deemed to be material rights. If the goods and services underlying the customer options are not determined to be material rights, these customer options are not considered to be performance obligations in the arrangement because they are
            contingent upon exercise of the option and are accounted for as separate contracts. If the customer options are determined to be a material right, the material right is recognized as a separate performance obligation at the outset of the
            arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option.
            Amounts allocated to any material right are recognized as revenue when or as the related future goods or services are transferred or when the option expires. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Transaction Price </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In determining transaction price, the Company uses judgment to determine whether
            milestone payments or other variable consideration should be included in the transaction price. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction
            price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable
            consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If an arrangement includes development and regulatory milestone payments, the
            Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount. If it is probable that a significant revenue reversal would not
            occur, the associated milestone payment amount is included in the transaction price. Milestone events that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are generally not considered probable of
            being achieved until such events have actually been achieved. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For arrangements with licenses of intellectual property that include sales-based
            royalties or milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties or milestone payments relate, the Company recognizes royalty revenue and sales-based milestones at the
            later of (i) when the related sales occur, or (ii) when the performance obligation to which the royalty or milestone payment has been allocated has been satisfied. To date, the Company has not recognized any royalty revenue from its existing
            collaboration arrangements. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 15pt; margin-left: 0pt; text-align: left;">Standalone Selling Prices </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The standalone selling price is the price at which an entity would sell a
            promised good or service separately to a customer. Management estimates the standalone selling price of each of the identified performance obligations in the Company&#8217;s customer contracts, maximizing the use of observable inputs. Because the
            Company has not sold the same goods or services in its contracts separately to any customers on a standalone basis and there are no similar observable transactions in the marketplace, the Company estimates the standalone selling price of each
            performance obligation in its customer arrangement based on its estimate of costs to be incurred to fulfill its obligations associated with the performance, plus a reasonable margin, unless it is unnecessary for the Company to determine the
            standalone selling prices because only one performance obligation is deemed to exist in the arrangement. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-59<br/>
        </div>

      </div>

    </div>

    <!--End Page 393-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 394-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Timing of Revenue Recognition </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company recognizes as revenue the amount of the transaction price that is
            allocated to the respective performance obligation when, or as, the performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an input method. The Company evaluates the measure of progress
            each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. The measure of progress, and the resulting periods over which revenue should be recognized, are subject to estimates by management and may
            change over the course of the research, development and licensing arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Under the Company&#8217;s existing collaboration agreements, the
            Company has concluded that the transfer of control to the customers occurs over the time period that the research and development services are to be provided by the Company, and this cost-to-cost method is, in management&#8217;s judgment, the best
            measure of progress towards satisfying the performance obligations relating to its collaboration agreements. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Contract Balances </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upfront payments received prior to satisfaction of the Company&#8217;s contracted
            performance obligations are recorded as deferred revenue and recognition of revenue is deferred to the future period(s) in which the Company performs its performance obligations. Amounts expected to be recognized as revenue within the 12 months
            following the balance sheet date are classified as deferred revenue, current portion in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are
            classified as deferred revenue, net of current portion. Alternatively, if the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, the Company will then record a
            contract asset. Other than accounts receivable, no contract assets existed as of December&#160;31, 2025 and 2024 and no revenue was recognized from contract assets that existed in prior periods. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Research and Development Expenses </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Research and development costs are expensed as incurred. Research and development
            expenses are comprised of costs incurred in performing research and development activities, including personnel-related expenses such as salaries, payroll taxes, benefits and stock-based compensation; external costs of outside vendors engaged
            to conduct research, preclinical development activities and trials; laboratory supplies; manufacturing; depreciation and maintenance of research equipment; and the allocable portions of facilities costs, such as rent, utilities, repairs and
            maintenance. Additionally, research and development costs include the costs incurred related to the collaboration revenue generated during the years ended December&#160;31, 2025 and 2024 (see Note&#160;8). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has entered into various research and development related contracts
            with external parties. Costs for certain development activities are recognized based on the evaluation of progress to completion of events, invoices received, and contracted costs. Payment for these activities is based on the terms of
            individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development. Significant judgments and estimates are made in determining
            the accrued and prepaid balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. The Company&#8217;s historical estimates have not been materially different from the actual costs. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Patent-Related Costs </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Patent-related costs incurred in connection with patent applications are expensed
            as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">General and Administrative </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">General and administrative expenses consist primarily of payroll and employee
            related costs, including stock-based compensation; professional fees for accounting, tax and legal services; consultant fees; information technology costs; depreciation and maintenance of property and equipment; and the allocated portion of
            rent and utilities, infrastructure, corporate insurance and office expenses. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Stock-Based Compensation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounts for stock-based awards in accordance with ASC Topic 718, <span style="font-style: italic;">Compensation&#8212;Stock Compensation</span> (&#8220;ASC 718&#8221;). ASC 718 requires all stock-based awards issued to employees, nonemployees and members of the Company&#8217;s board of directors (the &#8220;Board&#8221;) for their services on the
            Board to be recognized as </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-60<br/>
        </div>

      </div>

    </div>

    <!--End Page 394-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 395-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">expense in the consolidated statements of operations and comprehensive loss.
            The Company measures and recognizes stock-based compensation for both employee and non-employee awards based on the grant-date fair value of the awards. The Company measures restricted common stock awards using the difference, if any, between
            the purchase price per share of the award and the fair value of the Company&#8217;s common stock at the date of grant. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company estimates the fair value of stock options using the Black-Scholes
            option pricing model. The Company has elected to use the expected term for stock options granted to non-employees, using the simplified method, as the basis for the expected term assumption. However, the Company may elect to use either the
            contractual term or the expected term for stock options granted to non-employees on an award-by-award basis. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For stock options and time-based restricted stock awards, the Company expenses
            the fair value of the awards on a straight-line basis over each award&#8217;s requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Compensation expense for awards to non-employees with
            service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. For awarded stock options with performance-based
            vesting conditions, the Company recognizes expense based on the grant-date fair value of the performance award over the requisite service period to the extent the achievement of the related performance condition is estimated to be probable. At
            each reporting date, the Company evaluates whether any performance conditions related to a performance-based award have changed. The effect of any change in performance conditions is recognized as a cumulative catch-up adjustment in the period
            such change occurs. Any remaining unrecognized compensation expense would be recognized using the accelerated attribution method over the remaining requisite service period. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company classifies stock-based compensation expense in its consolidated
            statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Determination of the Fair Value of Stock-Based Awards </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company estimates the fair value of stock options using the Black-Scholes
            option pricing model, which requires inputs of subjective assumptions, including: (i) the expected volatility of the Company&#8217;s common stock, (ii) the expected term of the award, (iii) the risk-free interest rate, (iv) expected dividends and (v)
            the fair value of the Company&#8217;s common stock. Due to the lack of a public market for the trading of the Company&#8217;s common stock and a lack of company-specific historical and implied volatility data, management bases the estimate of expected
            volatility on the historical volatilities of a representative group of publicly traded guideline companies. For these analyses, the Company selects companies with comparable characteristics and with historical share price information that
            approximates the expected term of the equity-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies&#8217; shares during the equivalent period that approximates the calculated
            expected term of the Company&#8217;s stock options. The Company will continue to apply this method until a sufficient amount of historical information regarding the volatility of the Company&#8217;s own stock price becomes available. The Company estimates
            the expected term of its stock options granted to employees and directors using the simplified method, whereby the expected term equals the average of the vesting term and the original contractual term of the option. The Company utilizes this
            method as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected dividend yield is assumed to be zero as the Company has no current plans to pay any dividends on
            common stock. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">Determination of Fair Value of Common Stock on Grant Dates </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Given the absence of an active market for the Company&#8217;s common stock, the Board
            is required to determine the fair value of the Company&#8217;s common stock at the time of each grant of a stock-based award. In order to do so, the Company engages a third-party valuation specialist to estimate the fair value of its common stock in
            accordance with the framework of the American Institute of Certified Public Accountants&#8217; Technical Practice Aid, <span style="font-style: italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span>. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition to this estimate, the Board considers a number of various objective
            and subjective factors in determining the fair value of the Company&#8217;s equity instruments as of each grant date, including: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the lack of liquidity of the Company&#8217;s equity as a private company; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the prices of the Company&#8217;s preferred stock sold to outside investors in arm&#8217;s length transactions and the rights, preferences
                    and privileges of that preferred stock as compared to those of its common stock, including the liquidation preferences of the Company&#8217;s preferred stock; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-61<br/>
        </div>

      </div>

    </div>

    <!--End Page 395-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 396-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the progress of the Company&#8217;s research and development efforts, including the status of preclinical studies and planned clinical
                    trials for its product candidate; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Company&#8217;s stage of development and business strategy and the material risks related to its business and industry; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the achievement of enterprise milestones, including entering into collaborative agreements; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company in light of
                    prevailing market conditions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the valuation of publicly traded companies in the life sciences and biotechnology sectors, as well as recently completed mergers
                    and acquisitions of peer companies; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any external market conditions affecting the biotechnology industry and trends within the biotechnology industry. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Income Taxes </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounts for income taxes using the asset and liability method. Under
            the asset and liability method, deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the financial statement basis of existing assets and liabilities and their
            respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
            assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. A valuation allowance against deferred
            tax assets is recorded with a charge to income tax expense if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounts for income taxes in accordance with authoritative accounting
            guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained upon examination by the relevant taxing authority. There are no unrecognized tax benefits
            included in the Company&#8217;s consolidated balance sheet as of December&#160;31, 2025 and 2024. The Company&#8217;s policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. The Company has not recognized tax
            interest or penalties in its statements of operations and comprehensive loss for the years ended December&#160;31, 2025 and 2024. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Comprehensive Loss </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217;
            deficit that result from transactions and economic events other than those with stockholders. For the years ended December&#160;31, 2025 and 2024, there were no differences between net loss and comprehensive loss. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Loss per Share </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company follows the two-class method when computing net loss per share
            attributable to common stockholders as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to
            dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires loss available to common stockholders for the period to be allocated between common and participating securities based on their
            respective rights to receive dividends as if all income for the period had been distributed. The Company&#8217;s non-cumulative convertible preferred stock is a participating security. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Basic net loss per share attributable to common stockholders is computed by
            dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable
            to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities, and by dividing the diluted net loss attributable to common stockholders by the weighted-average number of common shares and
            potential common shares outstanding, if dilutive, during each period. For the purpose of this calculation, potential dilutive common shares include shares of convertible preferred stock, stock options, and restricted common stock. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-62<br/>
        </div>

      </div>

    </div>

    <!--End Page 396-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 397-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Pronouncements
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU
            2023-09, <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span>(&#8220;ASU 2023-09&#8221;), which requires a company to expand its existing income tax disclosures, specifically related to the rate
            reconciliation and income taxes paid. ASU 2023-09 is effective for the Company for annual periods beginning after December&#160;15, 2024, and was adopted prospectively. The adoption of this standard resulted in additional disclosures around income
            taxes but did not have a material impact on the Company&#8217;s consolidated financial statements. See Note&#160;16<span style="font-style: italic;">, Income Taxes</span>, for additional information. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2023, the FASB issued ASU 2023-07, <span style="font-style: italic;">Segment

              Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span> (&#8220;ASU 2023-07&#8221;), which enhances segment disclosure requirements, primarily through expanded disclosures related to significant segment expenses and information
            regularly provided to the chief operating decision maker (&#8220;CODM&#8221;). ASU 2023-07 became effective for the Company for annual periods beginning after December&#160;15, 2023, and the Company adopted the standard retrospectively. Adoption of the standard
            resulted in expanded segment disclosures but did not have a material impact on the Company&#8217;s consolidated financial statements. See Note&#160;22,<span style="font-style: italic;"> Segment Information</span>, for additional information. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Accounting Pronouncements Not Yet Adopted
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2025, the FASB issued ASU 2025-12, <span style="font-style: italic;">Codification

              Improvements</span>. The amendments include technical corrections, clarifications, and other minor improvements to various Topics within the ASC. The ASU is effective for all entities for annual reporting periods beginning after December&#160;15,
            2026, and interim periods within those annual reporting periods. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2025-12 on its consolidated financial statements and related disclosures. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2024, the FASB issued ASU 2024-04, <span style="font-style: italic;">Debt&#8212;Debt

              with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments</span>, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted
            for as an induced conversion or a debt extinguishment. ASU 2024-04 is effective for the Company for annual reporting periods beginning after December&#160;15, 2025, with early adoption permitted. The Company is currently evaluating the impact of
            adopting ASU 2024-04 on its consolidated financial statements and related disclosures. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2024, the FASB issued ASU 2024-03, <span style="font-style: italic;">Income

              Statement&#8212;Reporting Comprehensive Income (Topic 220): Disaggregation of Income Statement Expenses,</span> to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation,
            depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December&#160;15, 2026, and for interim periods within fiscal years
            beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior
            periods presented in the financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and related disclosures. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In September&#160;2025, the FASB issued ASU 2025-07, <span style="font-style: italic;">Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</span>,
            which refines the scope of derivative accounting for certain contracts with underlying terms based on operations or activities specific to one of the parties to the contract and clarifies the accounting for share-based noncash consideration
            received from a customer in a revenue contract. ASU 2025-07 is effective for the Company beginning in fiscal year 2027, including interim periods within that fiscal year. Early adoption is permitted. The Company is currently evaluating the
            impact of adopting this ASU on its consolidated financial statements and related disclosures. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In May&#160;2025, the FASB issued ASU 2025-03, <span style="font-style: italic;">Business

              Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity</span>, which amends the guidance for determining the accounting acquirer in certain transactions
            involving the acquisition of a variable interest entity that meets the definition of a business. ASU 2025-03 requires an entity to consider the factors in ASC 805-10-55-12 through 55-15 in determining which entity is the accounting acquirer
            when a legal acquiree is a variable interest entity and the transaction is not primarily effected by transferring cash or other assets or by incurring liabilities. ASU&#160;2025-03 is effective for the Company for annual reporting periods beginning
            after December&#160;15, 2026, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-63<br/>
        </div>

      </div>

    </div>

    <!--End Page 397-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 398-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">including interim reporting periods within those annual reporting periods.
            Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and related disclosures. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">3. Fair Value Measurements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following tables present the Company&#8217;s fair value hierarchy for its assets
            and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 147.54pt;" colspan="10">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 147.54pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets:<br/>
                  </div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash equivalents:<br/>
                  </div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$15,433

                    </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212;

                    </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$15,433

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,433

                    </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,433

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities:<br/>
                  </div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible notes payable</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;">$&#8212; </div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$13,100 </div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$13,100 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">2023 Warrant liability*</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">6,286 </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">6,286 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">2025 Warrant liability</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">1,388 </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">1,388 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Contingent tranche liability</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">500 </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$21,274

                    </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$21,274</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24.66pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 3.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The table includes warrants issued to obtain a line of credit amounting to $0.1&#160;million as of December 31, 2025. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 1pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 147.54pt;" colspan="10">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 147.54pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.08pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets:<br/>
                  </div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash equivalents:<br/>
                  </div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$46,166

                    </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212;

                    </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$46,166

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$46,166

                    </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$46,166

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities:<br/>
                  </div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible notes payable</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;">$&#8212; </div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$59,600 </div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$59,600 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">2023 Warrant liability**</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,136 </span></div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,136 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$63,736

                    </span></div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$63,736</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24.66pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 3.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">**<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The table includes warrants issued to obtain a line of credit amounting to $0.1&#160;million as of December 31, 2024. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">During the years ended December&#160;31, 2025 and 2024, there were no transfers
            between levels. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The table below presents changes in the Company&#8217;s liabilities with significant
            unobservable inputs (Level&#160;3 liabilities) during the years ended December&#160;31, 2025 and 2024 (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 54.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Convertible <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">notes payable</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 Warrant <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">liability*</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 Warrant <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">liability</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contingent <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">tranche liability </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ending balance at December&#160;31, 2023</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;">$<span style="padding-left: 3.33pt;">10,121 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;">$<span style="padding-left: 7.5pt;">953 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;">$<span style="padding-left: 12.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 1.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;">$<span style="padding-left: 10.83pt;">361 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issuances</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="padding-left: 8.33pt;">50,304 </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 5pt;">3,867 </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="padding-left: 15.83pt;">272 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Adjustments to estimated fair value</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="padding-left: 17.5pt;">(825)</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 9.17pt;">(684)</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="padding-left: 8.33pt;">5,027 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Settlements</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,660</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ending balance at December&#160;31, 2024</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">59,600 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,136 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 12.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 1.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 15.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issuances</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="padding-left: 8.33pt;">13,100 </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 5pt;">1,388 </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 2.26pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="padding-left: 15.83pt;">500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Adjustments to estimated fair value</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="padding-left: 13.33pt;">8,664 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 5pt;">2,150 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.01pt; padding-bottom: 0.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Settlements</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(68,264</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.01pt; padding-bottom: 1.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ending balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.31pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">13,100 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,286 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,388 </span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 1.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.81pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">500</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 54.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 3.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of both December&#160;31, 2025 and 2024, the table includes warrants issued to obtain a line of credit amounting to $0.1&#160;million. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Money Market Funds </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">U.S. government money market funds were valued by the Company based on quoted
            market prices, which represent a Level&#160;1 measurement within the fair value hierarchy. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-64<br/>
        </div>

      </div>

    </div>

    <!--End Page 398-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 399-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Convertible Notes Payable, Warrant
            Liabilities and Contingent Tranche Liabilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The convertible notes payable, warrant liabilities and contingent tranche
            liabilities (see Note&#160;9) are measured at fair value using a Monte Carlo simulation model. After issuance at the Series&#160;B Preferred Stock price ($2.088) in November&#160;2025, the 2023 Warrant liability (see Note&#160;12) is measured at fair value using a
            Black-Scholes option pricing model. Both valuation models use significant unobservable Level&#160;3 inputs and reflect management&#8217;s judgments about assumptions that market participants would use to determine a current transaction price. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company estimates the volatility of its common stock based on historical
            volatility of comparable companies. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the instruments valued. The expected life of the
            instruments is determined based on expected timing of potential conversion scenarios associated with the instruments through discussions with management. The dividend rate is based on the historical rate, which the Company anticipates will
            remain at zero. Significant increases or decreases in the selected discount rate, volatility, or other significant unobservable inputs could result in a significantly lower or higher fair value measurement. The Company evaluates these inputs at
            each reporting date based on market participant assumptions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Monte Carlo simulation valuation model includes key assumptions that project
            multiple potential future scenarios based on the Company&#8217;s stock price (common and preferred) valuations, the likelihood of various financing events (such as Qualified Public Offerings or changes of control), and the probability of the
            conversion scenarios include the fair value of the underlying common and preferred stock, estimated time to liquidity and the estimated probabilities of conversion scenarios. Additional key assumptions for the convertible notes payable, warrant
            liability and contingent tranche liability for which the number of underlying shares are not fixed or determinable as of the periods presented include: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 166pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 276pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 166pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 276pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 13.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.62% - 3.90%</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.16% - 4.28% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend rate</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00%</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected stock price volatility</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">48.00% - 94.00%</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">71.00% - 90.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (years)</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.25 - 2.00</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.28 - 0.98</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the year ended December&#160;31, 2025, the key assumptions using the Black-Scholes
            option-pricing model included the following inputs for the 2023 Warrants and Letter Warrants. For the year ended December&#160;31, 2024, the key assumptions using the Black-Scholes option-pricing model included the following inputs for the Letter
            Warrants: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 160pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 160pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.60% - 3.70% </div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.09% - 4.58% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend rate</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00%</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected stock price volatility</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">85.90% - 95.00%</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">86.17% - 87.66% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.51pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (years)</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1.00 - 2.00</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.51pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">9.92 - 10.00</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">4. Cash, Cash Equivalents and Restricted Cash </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table provides a reconciliation of cash, cash equivalents and
            restricted cash reported on the consolidated balance sheets to the same such amounts shown on the consolidated statements of cash flows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 80.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 80.5pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.58pt; padding-bottom: 1.88pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents</div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$24,147 </div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.51pt; padding-bottom: 0.88pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$73,424 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash</div>
                </td>

    <td style="width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,029 </span></div>
                </td>

    <td style="width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.51pt; padding-bottom: 2.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,098 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$26,176

                    </span></div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$75,522</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 372pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-65<br/>
        </div>

      </div>

    </div>

    <!--End Page 399-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 400-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">5. Prepaid Expenses and Other Current Assets </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes the Company&#8217;s prepaid expenses and other current
            assets (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 75.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 75.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid research and development costs</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 7.5pt;">742 </span></div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$2,276 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other prepaid expenses and other current assets</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">346 </span></div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">1,033 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid software and subscription costs</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">120 </span></div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">238 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,208

                    </span></div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,547</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">6. Property and Equipment, Net </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Property and equipment, net consisted of the following (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 82.17pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 82.17pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 3.33pt;">14,100 </span></div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$14,100 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">7,523 </span></div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">7,609 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 20.83pt;">798 </span></div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;">798 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer equipment and software</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">250 </span></div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">244 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">22,671 </span></div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">22,751 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(10,076</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(7,045</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">12,595 </span></div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,706</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 372pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.92pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Depreciation and amortization expense for the years ended December&#160;31, 2025 and
            2024 was $3.2 million and $3.3 million, respectively. Depreciation and amortization expense is classified in both research and development expense and general and administrative expense within the consolidated statements of operations and
            comprehensive loss. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">7. Accrued Expenses and Other Current Liabilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses and other current liabilities consisted of the following (in
            thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 75.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 75.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 372pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued research and development costs</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,862 </div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$3,020 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued employee compensation and benefits</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">1,414 </span></div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">2,924 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued professional services and other</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">431 </span></div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">362 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 372pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,707

                    </span></div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,306</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 372pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">8. Collaboration Agreements </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Janssen Pharmaceutica NV, 2022 Collaboration
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In February&#160;2022, the Company entered into an exclusive collaboration and license
            agreement with Janssen Pharmaceutica NV (&#8220;Janssen&#8221;), a Belgian pharmaceutical and research company, to discover small molecule compounds that modulate targets for the treatment of diseases and conditions in the fields of oncology and immunology
            (the &#8220;Janssen Agreement&#8221;). The parties entered into this agreement with the intention to utilize the Company&#8217;s proprietary drug discovery platform to identify compounds for collaboration targets. The Company received an upfront cash payment of
            $45.0&#160;million upon execution of the agreement, and was eligible to receive additional development, regulatory, and sales-based milestone payments as well as tiered royalties upon the achievement of specific events. The Company received an
            additional $0.8&#160;million as reimbursement for costs incurred as part of the collaboration related to a specific target that were subsequently reimbursed by Janssen. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company concluded that the Janssen Agreement was within the scope of ASC 606
            (&#8220;ASC 606&#8221;), <span style="font-style: italic;">Revenue from Contracts with Customers</span>, and not ASC 808, <span style="font-style: italic;">Collaborative Arrangements </span>(&#8220;ASC 808&#8221;) because the relationship </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-66<br/>
        </div>

      </div>

    </div>

    <!--End Page 400-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 401-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">represents a vendor-customer relationship. The Company identified one combined
            performance obligation consisting of the license and research services, including related participation in joint governance activities and information-sharing obligations, as the promises were not distinct within the context of the contract. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025 and 2024, the Company determined that the total
            transaction price was $45.8 million, consisting of the non-refundable upfront payment received at contract inception as well as specific costs that were reimbursed by Janssen. The Company excluded milestone payments and royalties from the
            transaction price because the related amounts were constrained or otherwise not probable of achievement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The transaction price was allocated to the single combined performance obligation
            of the license and research services. The Company&#8217;s expected costs relating to the project were the measure that best depicted the transfer of services to Janssen. The Company recognizes revenue in proportion to the actual incurred costs to
            date compared to the total budgeted costs expected to be incurred, a cost-to-cost input method. The Company recognized $1.0 million and $3.0&#160;million of collaboration revenue for the years ended December&#160;31, 2025 and 2024, respectively, all of
            which was derived from amounts included in deferred revenue at the beginning of each period. As of December&#160;31, 2025, the Company recorded deferred revenue of $8.0 million within current liabilities and $28.8 million within non-current
            liabilities in the accompanying consolidated balance sheets. As of December&#160;31, 2024, the Company recorded deferred revenue of $4.4 million within current liabilities and $33.4 million within non-current liabilities in the accompanying
            consolidated balance sheets. As of December&#160;31, 2025, the license and research services related to the single combined performance obligation were expected to be performed over a remaining period of approximately three years. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As further discussed in Note&#160;23, <span style="font-style: italic;">Subsequent
              Events,</span> the Janssen Agreement was terminated in July 2026 following the formal notice that the targets would not be advanced further under the collaboration. As a result, the Company expects to recognize the remaining deferred revenue
            balance associated with the Janssen Agreement during the quarter ending September&#160;30, 2026 and does not expect to recognize any additional collaboration revenue under the Janssen Agreement thereafter. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">F. Hoffmann-La Roche Ltd and Hoffmann-La
            Roche Inc., Collaboration </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December 2023, the Company and F. Hoffmann-La Roche Ltd (&#8220;Roche&#8221;) entered into
            a research collaboration and license agreement (the &#8220;Roche Agreement&#8221;) for the discovery and development of small molecule therapeutics that modulate RNA processing using the REMaster drug discovery platform, pursuant to which the Company
            granted Roche: (a) an exclusive license under certain of our intellectual property rights to develop, manufacture, and commercialize compounds, any products containing such compounds and any companion diagnostics for such products for all
            fields of use worldwide, provided that such license excludes any rights to our platform technology; and (b) an exclusive license under any jointly developed intellectual property solely in conjunction with the development, manufacture or
            commercialization of such product. The Company is responsible for certain discovery and preclinical activities, and Roche will be responsible for development and commercialization of any licensed compounds and licensed products arising under
            each research program. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As consideration for the licenses granted under the Roche Agreement, Roche made
            an upfront payment of $30.0 million. The Company is also eligible to receive from Roche (a) preclinical, clinical, commercial and sales milestone payments of up to $1.0 billion and (b) tiered royalties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company concluded that the arrangement is not within the scope of ASC Topic
            808, <span style="font-style: italic;">Collaborative Arrangements </span>(&#8220;ASC 808&#8221;). The Company concluded that the relationship represents a vendor-customer relationship, and that ASC 606 is the appropriate accounting literature to apply.
            The Company identified the following promises under the arrangement: (1) research services through the lead optimization phase as defined by the research plan; (2) a non-exclusive license under the Remix research program IP to conduct the Roche
            research activities under such research program; (3) an exclusive worldwide program license, with the right to grant sublicenses, under the licensed intellectual property and the Company&#8217;s interest in the joint collaboration IP to research,
            develop, make, use, import, export, obtain regulatory approval, sell, offer to sell, commercialize and otherwise exploit any compound or product with respect to such program in the territory; (4) the Company&#8217;s participation in a Joint Research
            Committee (&#8220;JRC&#8221;), Joint Operation Team (&#8220;JOT&#8221;) and Joint Patent Coordination Team (&#8220;JPCT&#8221;); and (5) sharing of information on a quarterly basis to update the JRC. The Company determined that the listed promises were not distinct from each
            other in the contract. Roche is unable to benefit from the license individually, as it only serves for performance of Roche -designated research activities during the research term. The Company also concluded that the licensed intellectual
            property and the research and development activities were not </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-67<br/>
        </div>

      </div>

    </div>

    <!--End Page 401-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 402-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">distinct from each other because the research and development activities
            customize and significantly modify the underlying technology. The participation in the JRC, JOT, JPCT and sharing of information cannot be considered distinct, as the promises are highly interrelated with the research activities. As such, these
            promises are combined into a single performance obligation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025 and 2024, the Company determined that the total
            transaction price is $42.0&#160;million, which represents the $30.0&#160;million non-refundable upfront payment, as well as $12.0&#160;million in nomination milestone payments achieved in June&#160;2024. The Company reviewed each preclinical and development
            milestone and concluded that none of the other milestones were deemed probable to be achieved. The commercial and sales milestones and royalties will be recognized at the later of (i) when the related sales occur, or (ii) when the performance
            obligation to which the royalty or milestone payment has been allocated has been satisfied, and as such, will be excluded from the transaction price. The Company will continue to evaluate the probability of achievement of the specified
            milestones in the agreement and will adjust the estimate of overall transaction price, as necessary. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The transaction price was allocated to the single combined performance
            obligation. The Company&#8217;s expected costs relating to the project are the measure that best depicts the progress toward satisfaction of the performance obligation. The Company recognizes revenue in proportion to the actual incurred costs to date
            compared to the total budgeted costs expected to be incurred, a cost-to-cost input method. The Company recognized $2.3 million and $1.8&#160;million as collaboration revenue in the consolidated statements of operations and comprehensive loss for the
            year ended December&#160;31, 2025 and 2024, respectively. As of December&#160;31, 2025, the Company recorded deferred revenue of $6.4 million within current liabilities and $31.4 million within non-current liabilities in the accompanying consolidated
            balance sheets. As of December&#160;31, 2024, the Company recorded deferred revenue of $2.6 million within current liabilities and $37.5 million within non-current liabilities in the accompanying consolidated balance sheets. The revenue related to
            the single combined performance obligation is recognized as the related research services are performed, which is expected to be over approximately three years as of December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As the Company progresses towards satisfaction of the performance obligation
            under the Roche Agreement, the estimated costs associated with the remaining effort required to complete the performance obligation may change, as well as the estimated amount of variable consideration included in the transaction price, which
            may materially impact revenue recognition. The Company regularly evaluates and, when necessary, updates the costs associated with the remaining effort under the collaboration. Accordingly, revenue may fluctuate from period to period due to
            revisions to estimated costs, resulting in a change in the measure of progress. Such changes can also impact the allocation of deferred revenue between current and non-current based on changes in expected timing of the satisfaction of the
            performance obligation, but would have no impact on cash flows from operations. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">9. Convertible Notes Payable, Warrant Liabilities and Contingent
            Tranche Liabilities<span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2023 Convertible Notes Payable<span style="font-style: normal; font-weight: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December 2023, the Company entered into a convertible notes and warrant
            purchase agreement (the &#8220;2023 Notes Agreement&#8221;) with multiple investors according to which the Company agreed to issue and sell to the lenders convertible promissory notes (the &#8220;2023 Notes&#8221;) and warrants to purchase capital stock of the Company
            (the &#8220;2023 Warrants&#8221; as further described below). The 2023 Notes Agreement provided for multiple closings, including the initial closing of up to $25.0&#160;million and the milestone closing of up to $40.1&#160;million which was contingent upon
            achievement of certain development milestones relating to REM-422, prescribed by the 2023 Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The initial closing commenced on December&#160;22, 2023 and was completed on
            January&#160;12, 2024. Through December&#160;31, 2023, the Company issued $11.4&#160;million aggregate principal amount of 2023 Notes, and issued the remaining $8.6&#160;million aggregate principal amount of 2023 Notes, in January&#160;2024. Total issuance costs were
            $0.2&#160;million and $0.1&#160;million in December&#160;2023 and January&#160;2024, respectively and expensed as incurred. In July&#160;2024, upon achievement of the applicable milestone conditions, the Company completed the Milestone Closing and issued an additional
            $40.1&#160;million aggregate principal amount of the 2023 Notes. The 2023 Notes accrued interest at an annual rate of 5.25% (with an effective interest rate of 5.32% through settlement in 2025, and during 2024). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2023 Notes were convertible into the conversion shares, as defined in the
            2023 Notes Agreement, with the applicable class of shares and conversion price determined based on the conversion scenario. If the 2023 Notes were converted upon a next equity financing, which would result in gross proceeds of at least
            $50.0&#160;million (&#8220;Qualified Financing&#8221;), all unpaid principal and accrued interest would be convertible into shares of preferred stock identical to </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-68<br/>
        </div>

      </div>

    </div>

    <!--End Page 402-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 403-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">the class of preferred stock issued in such financing at a conversion price
            equal to 80% of the lowest cash price per share paid by investors in the Qualified Financing. Upon an equity financing that did not constitute a Qualified Financing (a &#8220;Non-Qualified Financing&#8221;), all unpaid principal and accrued interest would
            automatically convert into shares of preferred stock identical to the class of preferred stock issued in such financing at a conversion price equal to 80% of the lowest cash price per share paid by investors in the Non-Qualified Financing. Upon
            conversion at maturity, upon certain corporate events, or upon an event of default, in each case as defined in the 2023 Notes Agreement, all unpaid principal and accrued interest would convert into shares of preferred stock at a conversion
            price of $2.0880 per share (&#8220;Series&#160;B Preferred Stock&#8221;). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounted for the 2023 Notes under the fair value method of
            accounting, with changes in fair value recorded in other income (expense) in the consolidated statements of operations and comprehensive loss at each reporting date. Therefore, no bifurcation of embedded features within the 2023 Notes was
            required. The fair value of the 2023 Notes as of December&#160;31, 2024 was $59.6&#160;million and was calculated using a Monte Carlo simulation (see Note&#160;3). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;14, 2025, the Company entered into the first amendment to the 2023
            Notes Agreement (the &#8220;2023&#160;Notes First Amendment&#8221;). Pursuant to the 2023 Notes First Amendment, the lenders waived the Non-Qualified Financing conversion provisions applicable to the 2023 Notes, and the maturity date of the 2023&#160;Notes was
            amended to the earlier of December&#160;22, 2025 or immediately prior to the initial closing under the 2025 Notes Agreement, as defined below. The Company entered into the 2025 Notes Agreement on November&#160;14, 2025, immediately following execution of
            the 2023 Notes First Amendment. As a result, the outstanding 2023 Notes converted into shares of Series&#160;B Preferred Stock immediately prior to the initial closing of the 2025 Notes. The fair value of the 2023 Notes immediately prior to
            conversion was $68.3 million. The total change in fair value of the 2023 Notes was $8.7&#160;million and ($0.8) million for the years ended December&#160;31, 2025 and 2024, respectively. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">2023 Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each investor that participated in the 2023 Notes financing received a 2023
            Warrant. The 2023 Warrants were exercisable for the class of preferred stock into which the related 2023 Notes convert, at a per share exercise price equal to the applicable Qualified Financing conversion price or Non-Qualified Financing
            conversion price. If the related 2023 Notes were repaid in cash or immediately available funds, the 2023 Warrants would become exercisable for shares of Series&#160;B Preferred Stock at an exercise price equal to the Series&#160;B original issue price of
            $2.0880 per share. Each 2023 Warrant had a contractual term of seven years, unless earlier terminated upon the closing of a corporate event, including a change in control, an initial public offering or a reverse merger, as defined in the 2023
            Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company concluded that the 2023 Warrants represent freestanding financial
            instruments and classified the 2023 Warrants as liabilities in accordance with ASC 480. Accordingly, the 2023 Warrants were initially recorded at fair value using a Monte Carlo simulation model (see Note&#160;3) and remeasured at each reporting
            date, with changes in fair value recognized in other income (expense) in the consolidated statements of operations and comprehensive loss. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon execution of the 2023 Notes First Amendment, the outstanding 2023 Notes
            converted into shares of Series&#160;B Preferred Stock immediately prior to the initial closing of the 2025 Notes. In accordance with the terms of the related 2023 Warrants, following conversion of the corresponding 2023 Notes, the 2023 Warrants
            remained outstanding and became exercisable for the same conversion shares into which the corresponding 2023 Notes converted, which in this case were shares of Series&#160;B preferred stock, at the applicable exercise price. Accordingly, the 2023
            Warrants did not terminate or convert into equity upon execution of the agreements but continued as warrants exercisable for Series&#160;B Preferred Stock, subject to termination in the event the holder became a non-participating investor under the
            2025 Notes Agreement (described below). The fair value of the 2023 Warrants, including the Letter Warrants, as of December&#160;31, 2025 and 2024 was $6.3 million and $4.1 million, respectively. The total change in fair value of the 2023 Warrants
            was $2.1&#160;million and ($0.7) million for the years ended December&#160;31, 2025 and 2024, respectively. The 2023 Warrants remain outstanding as of December&#160;31, 2025. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">2023 Milestone Tranche Liability </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2023 Milestone Tranche Liability is a contingent tranche liability
            representing the Company&#8217;s obligation to issue an additional $40.1&#160;million aggregate principal amount of 2023 Notes and the related 2023 Warrants upon achievement of specified milestone conditions. The Company determined that the contractual
            rights and obligations associated with the tranche represented a separate freestanding financial instrument and classified the related </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-69<br/>
        </div>

      </div>

    </div>

    <!--End Page 403-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 404-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">instrument as a liability under ASC 480. The liability was initially recorded
            at fair value using a Monte Carlo simulation model (see Note&#160;3) and subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in other income (expense) in the consolidated statements of operations and
            comprehensive loss. Upon the milestone closing in July&#160;2024, the liability was settled. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">2025 Convertible Notes Payable<span style="font-style: normal; font-weight: normal;"> </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;14, 2025, the Company entered into a convertible promissory note and
            warrant purchase agreement (the &#8220;2025 Notes Agreement&#8221;) with certain investors (a &#8220;Lender&#8221;, or the &#8220;Lenders&#8221;), pursuant to which the Company agreed to issue and sell convertible promissory notes (the &#8220;2025 Notes&#8221;) and warrants to purchase
            shares, as further described below. The 2025 Notes Agreement provides for multiple closings, including an initial tranche of up to $15.0&#160;million (the &#8220;First Tranche Closing&#8221;) and a second tranche of up to $15.0&#160;million, the funding of which is
            subject to approval by the Company&#8217;s Board based on specified conditions set forth in the 2025 Notes Agreement (the &#8220;Second Tranche Closing&#8221;). Through December&#160;31, 2025, the Company issued $15.0&#160;million aggregate principal amount of 2025 Notes.
            Total issuance costs of $0.3&#160;million were expensed as incurred during 2025. The First Tranche Closing commenced on November&#160;14, 2025 and was substantially completed as of December&#160;31, 2025. A nominal amount of funding was received in
            January&#160;2026 to close the first tranche. The Second Tranche Closing was completed in March 2026. The 2025 Notes mature on November&#160;30, 2027 and bear interest at 8.00% per annum, which resulted in an effective interest rate of 8.00% for the year
            ended December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2025 Notes are convertible into conversion shares, as defined in the 2025
            Notes Agreement, with the applicable class of shares and conversion price determined based on the applicable conversion scenario. Upon a Qualified Financing, defined as the next equity financing resulting in gross proceeds of at least
            $50.0&#160;million, all unpaid principal and accrued interest under the 2025 Notes automatically convert into shares of preferred stock identical to the class of preferred stock issued in such financing. Upon a Non-Qualified Financing, all unpaid
            principal and accrued interest under the 2025 Notes may convert into shares of preferred stock identical to the class of preferred stock issued in such financing. Upon conversion in connection with an initial public offering (&#8220;IPO&#8221;),
            non-traditional IPO or a special purpose acquisition company (&#8220;SPAC&#8221;) transaction, certain corporate events, or, for purposes of the related warrants, upon an event of default, in each case as defined in the 2025 Notes Agreement (a &#8220;Public
            Company Event&#8221;), the applicable conversion shares consist of shares of Series&#160;B Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the terms of the 2025 Notes Agreement, if a Lender fails to fund its
            required commitment in either tranche, such Lender may be deemed a non-participating investor. In such event, all shares of preferred stock then held by such investor are subject to automatic conversion into common stock pursuant to the
            applicable special mandatory conversion provisions, and any applicable warrants held by such investor automatically terminate and cease to be exercisable. Any unfunded tranche amounts may be reallocated among participating Lenders in accordance
            with the terms of the 2025 Notes Agreement. Pursuant to the terms of the 2025 Notes Agreement, any 2023 Warrants previously issued to a non-participating investor automatically terminate and cease to be exercisable. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon a change of control, as defined in the 2025 Notes Agreement, each holder of
            the 2025 Notes was entitled to receive, upon consummation of such transaction, the greater of (i) a specified repayment amount or (ii) the amount such holder would have received assuming conversion of the 2025 Notes into shares of Series&#160;B
            Preferred Stock, in each case in accordance with the terms of the 2025 Notes Agreement. If the 2025 Notes remain outstanding at the maturity date and have not otherwise been converted or repaid, the Company is required to repay all unpaid
            principal and accrued interest, unless the requisite holders elect conversion in accordance with the 2025 Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The applicable conversion price of the 2025 Notes varies depending on the
            conversion event. The conversion price for a Public Company Event, certain corporate events, event of default scenarios and certain maturity-related conversions is $2.0880 per share. The conversion price for a Qualified Financing is equal to
            80% of the applicable cash price per share paid by investors in such financing, and the conversion price for a Non-Qualified Financing is equal to 80% of the applicable cash price per share paid by investors in such financing, in each case as
            defined in the 2025 Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company elected the fair value option to account for the 2025 Notes, with
            changes in fair value recognized in other income (expense) in the consolidated statements of operations and comprehensive loss at each reporting date. As a result, separate accounting for embedded features within the 2025 Notes was not
            required. The fair value of the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-70<br/>
        </div>

      </div>

    </div>

    <!--End Page 404-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 405-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">2025 Notes at issuance was $13.1 million and was estimated using a Monte Carlo
            simulation. As a result of the issuance date of the 2025 Notes being in close proximity to December&#160;31, 2025, the Company concluded that any change in fair value between the issuance date and December&#160;31, 2025 was not material. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Second Tranche Closing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Second Tranche Closing represented the Company&#8217;s obligation to issue an
            additional $15.0&#160;million aggregate principal amount of 2025 Notes and the related 2025 Warrants upon satisfaction of the applicable second tranche closing conditions. Pursuant to the 2025 Notes Agreement, the Lenders&#8217; obligations to purchase
            the 2025 Notes and related 2025 Warrants at the Second Tranche Closing were subject to the Company&#8217;s receipt, on or before May&#160;31, 2027, of a funding request by the Board of Directors, including a majority of the directors designated by holders
            of preferred stock, after the Company&#8217;s aggregate cash balance fell below $15.0&#160;million. The Company determined that the contractual rights and obligations to issue additional notes and warrants associated with the Second Tranche Closing
            represented a separate freestanding financial instrument and classified the related instrument as a liability in accordance with ASC 480. The liability was initially recorded at its fair value of $0.5 million, estimated using a Monte Carlo
            simulation model, and is presented as a contingent tranche liability on the consolidated balance sheets. Because the initial recognition date was in close proximity to December&#160;31, 2025, the Company concluded that any change in fair value
            between the initial recognition date and December&#160;31, 2025 was not material. The Second Tranche Closing was completed in March&#160;2026, at which time the contingent tranche liability was settled. See Note&#160;3 for information regarding the valuation
            methodology and significant assumptions. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">2025 Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each investor participating in the 2025 Notes financing received a warrant (the
            &#8220;2025 Warrants&#8221;) with an aggregate exercise amount equal to 20% of the original principal amount of each related 2025 Note&#160;purchased. Pursuant to the terms of the 2025 Notes Agreement, each 2025 Warrant is exercisable for the same conversion
            shares into which the corresponding 2025 Note&#160;converts, at a per share exercise price equal to the applicable conversion price. In the event the corresponding 2025 Note&#160;converts in connection with a Public Company Event or at maturity, or is
            repaid in cash or immediately available funds, the related 2025 Warrant is exercisable for shares of Series&#160;B Preferred Stock at an exercise price equal to the Series&#160;B original issue price of $2.0880 per share. In addition, upon the occurrence
            of an event of default under the 2025 Notes Agreement, the conversion price for purposes of the 2025 Warrants is the Series&#160;B original issue price. Each 2025 Warrant has a contractual term of seven years, unless earlier terminated upon the
            closing of a corporate event, including a change in control, an initial public offering or a reverse merger, as defined in the 2025 Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company concluded that the 2025 Warrants represent freestanding financial
            instruments and classified the 2025&#160;Warrants as liabilities in accordance with ASC 480. Accordingly, the 2025 Warrants were initially recorded at fair value and are remeasured at each reporting date, with changes in fair value recognized in
            other income (expense) in the consolidated statements of operations and comprehensive loss. The fair value of the 2025 Warrant liability at issuance was $1.4 million using a Monte Carlo simulation model (see Note&#160;3). As the issuance date of the
            2025 Warrants was in close proximity to December&#160;31, 2025, the Company concluded that any change in fair value between the issuance date and December&#160;31, 2025 was not material. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">10. Line of Credit </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On October&#160;10, 2024, the Company entered into the Loan and Security Agreement
            (the &#8220;Letter Agreement&#8221;) with the Banc of California (the &#8220;Bank&#8221;), pursuant to which the Bank agreed to provide the Company with a term loan facility of up to $40.0&#160;million, subject to the terms and conditions of the agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company could request, but was not required to draw upon, a term loan at any
            time from October&#160;10, 2024 through December&#160;31, 2025. In a scenario where certain funding requirements had been satisfied based on predetermined criteria in the Letter Agreement (the &#8220;Interest-Only Extension Milestone&#8221;), the availability date
            would have been automatically extended to June&#160;30, 2026 (the &#8220;Availability End Date&#8221;). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon a drawdown by the Company, a total term loan not to exceed $40.0&#160;million
            could have been issued in two tranches (each tranche a &#8220;Term Loan&#8221; and collectively the &#8220;Term Loans&#8221;). The first tranche would not exceed $35.0&#160;million through the Availability End Date (&#8220;Tranche I&#8221;). The second tranche would not exceed
            $5.0&#160;million upon achievement of the Tranche II milestone through the Availability End Date (&#8220;Tranche II&#8221;). The Tranche II </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-71<br/>
        </div>

      </div>

    </div>

    <!--End Page 405-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 406-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">milestone was based on a predetermined development milestone, or the
            occurrence of the Interest-Only Extension Milestone. Interest would have accrued from the date of each Term Loan at a variable annual rate equal to the greater of the prime rate then in effect or 5.50% through the Availability End Date for the
            applicable Term Loans. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Letter Agreement contained certain customary affirmative and negative
            covenants and events of default. The affirmative covenants include, among others, covenants requiring the Company to deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding minimum balances
            within its bank accounts. The negative covenants include, among others, limitations on the Company&#8217;s ability to incur additional indebtedness, merge with other companies or consummate certain changes of control, acquire other companies or
            businesses, or enter into various specified transactions. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is 5.00% above the rate
            effective immediately before the event of default and may be declared immediately due and payable by the Bank. The Company concurrently issued warrants to purchase 143,549 shares of Series&#160;B preferred stock in connection with the Line of Credit
            (the &#8220;Letter Warrants&#8221;). The Letter Warrants were issued as an additional incentive for the Bank and classified as a liability and recorded at fair value using a Black-Scholes option-pricing model (see Note&#160;3) and remeasured at each reporting
            date. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Issuance costs and facility fees associated with the Letter Agreement totaled
            $0.2&#160;million through the year ended December&#160;31, 2024. The Company views costs associated with entering into a revolving Line of Credit arrangement as costs incurred in exchange for access to capital. Therefore, these costs are capitalized as a
            deferred asset in other assets and amortized on a straight-line basis within other income (expense) in the consolidated statements of operations and comprehensive loss, over the access period of the Line of Credit. The issuance costs were fully
            amortized as of December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company did not draw upon the Line of Credit as of December&#160;31, 2025, and the
            Letter Agreement subsequently expired with the Bank (see Note&#160;23). There were no other material accounting considerations associated with the expiration of the Letter Agreement. The Letter Warrants issued upon execution of the Letter Agreement
            remain outstanding and were initially recorded at fair value upon issuance, and will be remeasured at each reporting date with changes in fair value recorded in the consolidated statement of operations and comprehensive loss (see Note&#160;12). </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">11. One-Time Employee Termination Benefits </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On July 22, 2025, the Company announced the implementation of a strategic
            restructuring and reprioritization plan (the &#8220;2025 Restructuring&#8221;). As part of this restructuring, the Company incurred restructuring charges of approximately $0.9&#160;million, primarily related to severance and employee benefit costs. These costs
            totaled less than $0.1&#160;million in general and administrative expenses and $0.8&#160;million in research and development expenses in the consolidated statements of operations and comprehensive loss. The Company paid all associated benefit expenses in
            cash during the year ended December 31, 2025. The 2025 Restructuring was completed as of December&#160;31, 2025. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">12. Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has issued warrants in connection with the 2023 Notes (see Note&#160;9),
            as well as its credit arrangements, which are classified as liabilities and measured at fair value at each reporting date. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each investor that participated in the 2023 Notes financing received a 2023
            Warrant. The 2023 Warrants were not exercisable for a fixed number of shares until the conversion of the 2023 Notes. Upon conversion of the 2023 Notes into shares of Series&#160;B Preferred Stock on November&#160;14, 2025, with approval of the Board, the
            2023 Warrants became exercisable for an aggregate of 5,756,672 shares of Series&#160;B Preferred Stock at a share price of $2.088 (see&#160;Note&#160;9). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In October&#160;2024, the Company issued 143,549 Letter Warrants as an additional
            incentive to the Bank providing the Line of Credit at a share price of $2.088 (see Note&#160;10). The fair value of the Letter Warrants was $0.1&#160;million as of December&#160;31, 2025 and 2024 (see Note&#160;3). The balance of the Letter Warrants was included
            as a component of other liabilities as of December 31, 2024, and included as a component of 2023 Warrants and Letter Warrant liability as of December 31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the 2025 Notes financing, the Company issued warrants to
            lenders that purchased 2025 Notes. Each 2025 Warrant has an aggregate exercise amount equal to 20% of the original principal amount of the related 2025 Note. The 2025 Warrants are exercisable for the same conversion shares into which the
            corresponding 2025 </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-72<br/>
        </div>

      </div>

    </div>

    <!--End Page 406-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 407-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Notes convert, at a per share exercise price equal to the applicable
            conversion price. As of December&#160;31, 2025, the number of shares underlying the 2025 Warrants was not fixed or determinable because the 2025 Notes may convert at different prices depending on the applicable conversion event. Accordingly, the
            2025 Warrants are excluded from the warrant roll forward below (see Note&#160;9). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2025, upon the First Tranche Closing of the 2025 Notes, certain
            Lenders did not fund their principal amounts (&#8220;Tranche Default&#8221;). As a result of the Tranche Default, their respective 2023 Warrants, totaling 2,957 shares, were cancelled. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table summarizes the activity for the 2023 Warrants classified as
            liabilities for which the number of underlying shares was fixed or determinable as of the periods presented: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 396pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 396pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 Warrant <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares </div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2023</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.82pt; text-align: left;"><span style="padding-left: 30pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issuances</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.82pt; text-align: left;"><span style="padding-left: 7.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">143,549 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2024</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.82pt; text-align: left;"><span style="padding-left: 7.5pt;">143,549 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Underlying shares became determinable</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.82pt; text-align: left;">5,756,672 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cancellations</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.82pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,957</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 396pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.82pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">5,897,264</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 396pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.18pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounts for the warrants as liabilities and remeasures them to fair
            value at each reporting date, with changes in fair value recognized in other income (expense), net. See Note&#160;3 for information regarding the valuation methodology and significant assumptions used to estimate the fair value of the warrant
            liabilities. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">13. Convertible Preferred Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has issued Series&#160;Seed preferred stock (the &#8220;Series&#160;Seed Preferred
            Stock&#8221;), Series&#160;A preferred stock (the &#8220;Series&#160;A Preferred Stock&#8221;) and Series&#160;B preferred stock (the &#8220;Series&#160;B Preferred Stock&#8221;), collectively referred to as Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In March&#160;2020, the Company entered into a Series&#160;Seed preferred stock financing
            for 16,907,958 shares, raising approximately $11.0&#160;million at $0.9463 per share, in conjunction with previously issued convertible notes of $5.0&#160;million. In connection with the financing, the investors received customary rights including
            registration rights, pro rata participation rights in future financings, information and inspection rights for major investors, and call options. In September&#160;2020, the Company authorized the issuance of an additional 1,056,747 shares of
            Series&#160;Seed Preferred Stock, raising approximately $1.0&#160;million at $0.9463 per share. In connection with the financing, the investors received customary rights including registration rights, pro rata participation rights in future financings,
            information and inspection rights for major investors, and call options. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In September&#160;2020, the Company entered into a Series&#160;A Preferred Stock Purchase
            Agreement (&#8220;Series&#160;A Agreement&#8221;) authorizing the issuance of Series&#160;A Preferred Stock at $1.8982 per share. Through the initial closing and two subsequent tranches (January and November&#160;2021), the Company issued a total of 35,714,365 shares for
            aggregate gross proceeds of $67.8&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The second tranche right of the Series&#160;A Preferred Stock met the definition of a
            freestanding financial instrument and was recorded as a $5.2&#160;million liability at inception. The obligation was remeasured through settlement in November&#160;2021, with the $5.2&#160;million decrease in fair value recognized as other income. Proceeds in
            excess of fair value of $4.5 million were recorded as a capital contribution to additional paid-in capital. In December&#160;2025, upon the First Tranche Closing of the 2025 Notes, certain Lenders incurred a Tranche Default by failing to fund their
            principal amounts. As a result, 52,682 shares of their Series&#160;A Preferred Stock were converted to common stock on a one-for-one basis (see Note&#160;9). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In March&#160;2022, the Company entered into a Series&#160;B Preferred Stock Purchase
            Agreement (&#8220;Series&#160;B Agreement&#8221;) with investors by authorizing the issuance of shares of Series&#160;B Preferred Stock at a price of $2.0880 per share in two separate tranches. In connection with the initial issuance of Series&#160;B Preferred Stock, the
            Company had the obligation to sell additional shares of Series&#160;B Preferred Stock at a price of $2.0880 per share. Upon execution of the Series&#160;B Agreement in March&#160;2022, the first tranche closed and the Company issued 16,762,450 shares of
            Series&#160;B Preferred Stock for gross cash proceeds of $35.0&#160;million. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-73<br/>
        </div>

      </div>

    </div>

    <!--End Page 407-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 408-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">In January&#160;2023, the Company issued 16,762,454 shares of Series&#160;B Preferred
            Stock in the second tranche closing of the Series&#160;B Agreement for gross proceeds of $35.0&#160;million. Proceeds in excess of fair value of $6.1&#160;million were recorded as a capital contribution to additional paid-in capital. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2025, in connection with the amended maturity and conversion of the
            2023 Notes (see Note&#160;9), the Board authorized an increase of 36,785,803 shares to the Series&#160;B preferred stock pool and issued 31,029,131 shares of Series&#160;B Preferred Stock upon conversion. In December&#160;2025, certain Lenders incurred a Tranche
            Default upon the First Tranche Closing of the 2025 Notes by failing to fund their principal amounts. As a result (see Note&#160;9), 44,158 shares of their Series&#160;B Preferred Stock were converted to common stock on a one-for-one basis. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">Preferred stock consisted of the following (in thousands, except share
            amounts): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 276.47pt;" colspan="13">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="13" style="width: 276.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued and <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Liquidation <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preference</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issuable Upon <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conversion </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;Seed Preferred Stock</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">17,964,705 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt;">17,964,705 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">16,700 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;">$<span style="padding-left: 5pt;">17,000 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt;">17,964,705 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A Preferred Stock</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">35,714,365 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt;">35,661,683 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">57,856 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 10pt;">67,693 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt;">35,661,683 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;B Preferred Stock</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,454,256 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">64,509,877 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">126,309 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">134,697 </span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">64,509,877 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">124,133,326 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$200,865 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$219,390 </span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.65pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 274.52pt;" colspan="13">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="13" style="width: 274.52pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued and <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Liquidation <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preference</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issuable Upon <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conversion </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;Seed Preferred Stock</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">17,964,705 </div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">17,964,705 </div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 5pt;">16,700 </span></div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;">$<span style="padding-left: 5pt;">17,000 </span></div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.83pt; text-align: left;">17,964,705 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A Preferred Stock</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">35,714,365 </div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">35,714,365 </div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">57,956 </span></div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 10pt;">67,793 </span></div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.83pt; text-align: left;">35,714,365 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;B Preferred Stock</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">33,668,453

                    </span></div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">33,524,904

                    </span></div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">58,137 </span></div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,000 </span></div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.83pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">33,524,904

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">87,347,523

                    </span></div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">87,203,974

                    </span></div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$132,793

                    </span></div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$154,793 </span></div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">87,203,974</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.65pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The rights and privileges of the preferred stock are as follows: </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Voting </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The holders of preferred stock are entitled to vote on any matters brought before
            stockholders and shall have the number of votes equal to the number of shares of common stock into which such shares of preferred stock are convertible. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Dividends </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The holders of preferred stock are entitled to an 8% non-cumulative dividend.
            Dividends are payable only when, as, and if declared by the Board. Through December&#160;31, 2025 and 2024, no dividends have been declared. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Liquidation Preference </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event of any voluntary or involuntary liquidation, dissolution, or winding
            up of the Company, holders of the preferred stock then outstanding shall be entitled to receive, in preference to all common stockholders, the greater of: (i) an amount per share equal to the preferred stock original issue price for each
            respective series, plus any dividends declared but unpaid thereon or (ii) the amount that would be received if the preferred stock was converted into common stock just prior to the liquidation event. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless the holders of the majority of the outstanding shares of preferred stock,
            voting together as a single class, elected otherwise, a &#8220;Deemed Liquidation Event&#8221; includes: (i) a merger or consolidation (other than one in which stockholders of the Company owning a majority by voting power of the outstanding shares of the
            Company prior to the merger or consolidation continue to own a majority by voting power of the outstanding shares of the surviving or acquiring corporation), or (ii) a sale, lease, transfer, exclusive license, or other disposition by the
            Company of all or substantially all assets, taken as a whole. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-74<br/>
        </div>

      </div>

    </div>

    <!--End Page 408-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 409-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Conversion </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each share of preferred stock is convertible into shares of common stock at the
            option of the holder at any time after the date of issuance. The number of shares of common stock to be issued in the event of a conversion is determined by dividing the original issuance price for each respective series by the applicable
            conversion price at the time of conversion. The conversion price for each of the Series&#160;Seed Preferred Stock, Series&#160;A Preferred Stock and Series&#160;B Preferred Stock are $0.9463, $1.8982 and $2.0880 per share, respectively. The preferred stock
            automatically converts into common stock upon the earlier of (i) the closing of an initial public offering of the Company&#8217;s common stock resulting in net proceeds of at least $75.0&#160;million or (ii) upon the election by the holders of at least
            two-thirds of the voting power of the then outstanding shares of preferred stock. The Company&#8217;s preferred stock is expected to convert into shares of common stock as described above as part of the reverse merger, as discussed in Note&#160;23,<span style="font-style: italic;"> Subsequent Events</span>. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Redemption </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The preferred stock is not subject to redemption. The preferred stockholders only
            have redemption rights in the event of a deemed liquidation, as defined above, which is not within the control of the Company and therefore the preferred stock is classified outside of permanent equity. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">14. Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025, the Company had 162,000,000 shares of $0.0001 par value
            common stock authorized with 7,811,834 shares issued and outstanding. As of December&#160;31, 2024, the Company had 116,000,000 shares of $0.0001 par value common stock authorized with 7,626,774 shares issued and outstanding. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company had reserved the following shares of common stock for the potential
            conversion of preferred stock, the exercise of outstanding stock options and the future issuance of awards available for grant under the Company&#8217;s 2019 Remix Therapeutics Stock Incentive Plan, as amended from time to time (the &#8220;2019 Plan&#8221;): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 110pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 110pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares reserved for the conversion of authorized Series&#160;Seed Preferred
                    Stock</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">17,964,705 </span></div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">17,964,705 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares reserved for the conversion of authorized Series&#160;A Preferred Stock</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">35,714,365 </span></div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">35,714,365 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares reserved for the conversion of authorized Series&#160;B Preferred
                    Stock*</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">70,454,256 </span></div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">33,668,453 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock options available for grant under the 2019 Plan</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">4,553,047 </span></div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;">781,486 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock options outstanding under the 2019 Plan</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">16,928,609 </span></div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,083,279 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">145,614,982</span></div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">107,212,288</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes shares of 2023 Warrants and Letter Warrants as of December&#160;31, 2025, and Letter Warrants as of December&#160;31, 2024 </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Voting </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The holders of shares of common stock are entitled to one vote for each share of
            common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Liquidation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After payment to the holders of shares of preferred stock of their liquidation
            preferences, the remaining assets of the Company are distributed to the holders of common stock. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">15. Stock-Based Compensation </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2019 Stock Incentive Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2019, the Board adopted the 2019 Plan. Under terms of the 2019 Plan,
            incentive stock options (&#8220;ISOs&#8221;) may be granted to employees of the Company and nonqualified stock options, or restricted stock awards may be granted to directors, consultants, employees, and officers of the Company. The exercise price of ISOs
            cannot be less than the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-75<br/>
        </div>

      </div>

    </div>

    <!--End Page 409-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 410-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">fair value in the case of employees holding 10% or more of the voting stock of
            the Company. The options vest over a period determined by the Board, typically over four years, with the first 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting in 12 equal quarterly installments
            and expire not more than ten years from the date of grant. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From 2021 through 2023, the Company amended the 2019 Plan on multiple occasions
            to increase the number of shares of common stock reserved for issuance thereunder from 8,144,063 to 20,265,036 shares. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In March&#160;2024, the 2019 Plan was amended to increase the number of shares of
            common stock reserved for issuance under the 2019 Plan from 20,265,036 shares to 21,991,539 shares. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In January&#160;2025, the 2019 Plan was amended to increase the number of shares of
            common stock reserved for issuance under the 2019 Plan from 21,991,539 shares to 23,696,650 shares. As of December&#160;31, 2025, there were 4,553,047 shares remaining available for future grants under the 2019 Plan. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Performance-Based Stock Options </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2022, the Company&#8217;s Board granted options to purchase common stock to an
            employee that will commence vesting upon the achievement of certain financing and research and developmental milestones and once achieved, generally vest monthly over 36 months (the &#8220;Performance Awards&#8221;). The Company issued Performance Awards
            for the purchase of 442,488 shares of common stock with an exercise price of $0.70 per share, which had an aggregate fair value at date of grant of $0.3&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company determined that the performance conditions associated with these
            awards were achieved during the years ended December&#160;31, 2024 and 2023. Stock-based compensation expense of less than $0.1&#160;million was recognized for each of the years ended December&#160;31, 2025 and 2024 related to these awards. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In February&#160;2025, the Board granted options to purchase common stock to an
            employee that will commence vesting upon the achievement of certain financing criteria (the &#8220;2025 Performance Awards&#8221;). The 2025 Performance Awards have an exercise price of $1.17 per share, which had an aggregate fair value at date of grant of
            $0.4 million. Once achieved, the 492,023 shares of granted options will vest monthly over 48 months. As of December&#160;31, 2025, the Company determined that the 2025 Performance Awards criteria had not been met, and as such no expense was
            recognized. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Stock Option Activity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes the Company&#8217;s stock option activity: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 264pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 48.66pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 264pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 4.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted-<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price</div>
                </td>

    <td style="width: 4.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted-<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Life</div>
                </td>

    <td style="width: 4.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Intrinsic<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 264pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in years)</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2024</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">19,083,279 </div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.69</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">7.34 </div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$9,066 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">2,306,497 </span></div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$1.17</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt;">(88,220)</span></div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.56</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited or canceled</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(4,372,947</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.75</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">16,928,609

                    </span></div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.75</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">5.94 </div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$7,179 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and expected to vest at December&#160;31, 2025</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">16,436,586 </div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.73</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">5.84 </div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$7,179 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 264pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable at December&#160;31, 2025</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">13,572,909 </div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.67</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">5.30 </div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$6,724</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 264pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 48.66pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The weighted-average grant-date fair value of the stock options granted during
            the years ended December&#160;31, 2025 and 2024 amounted to $0.85 per share and $0.72 per share, respectively. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The aggregate intrinsic value of stock options is calculated as the difference
            between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had exercise prices lower than the fair value of the Company&#8217;s common stock. The total intrinsic value of stock
            options exercised during the years ended December&#160;31, 2025 and 2024 amounted to less than $0.1&#160;million. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-76<br/>
        </div>

      </div>

    </div>

    <!--End Page 410-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 411-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Stock Option Valuation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The assumptions used to value stock options granted using the Black-Scholes
            option-pricing model were as follows: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 148pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 148pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 4.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.86% - 4.52%</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.70% - 4.69% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend rate</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00%</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected stock price volatility</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">83.83% - 86.10%</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">78.46% - 79.59% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (years)</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.0 - 6.1</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.9 - 6.1</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Stock-Based Compensation Expense </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Total stock-based compensation expense recorded for employees, directors,
            non-employees and founders for the years ended December&#160;31, 2025 and 2024 was as follows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 69.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expense</div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,252 </div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1,170 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense</div>
                </td>

    <td style="width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">799 </span></div>
                </td>

    <td style="width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,165 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$2,051

                    </span></div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$2,335</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025, the total unrecognized stock-based compensation balance
            for unvested options was $2.0 million, which is expected to be recognized over 1.6 years. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">16. Income Taxes </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For financial reporting purposes, loss before income taxes for the year ended
            December&#160;31, 2025 and 2024 includes the following components (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 89.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Domestic</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(73,887)</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(69,089) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(73,887</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(69,089</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The significant components of the provision for income tax expense attributable
            to income from continuing operations for the years ended December&#160;31, 2025 and 2024 are as follows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 62.25pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 62.25pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 10.88pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current:<br/>
                  </div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Federal </div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.29pt; text-align: left;">$(199)</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;">$21 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">State</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.29pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17 </span></div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Current (Provision) Benefit</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.29pt; text-align: left;"><span style="padding-left: 5pt;">(182)</span></div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><span style="padding-left: 5pt;">50 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred:<br/>
                  </div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Federal </div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.29pt; text-align: left;"><span style="padding-left: 13.33pt;">&#8212; </span></div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">State</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.29pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total Deferred Provision</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.29pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total (Provision) Benefit</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 23.91pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.29pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(182</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.8pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$50</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 23.91pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.88pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 16.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-77<br/>
        </div>

      </div>

    </div>

    <!--End Page 411-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 412-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">A reconciliation of the federal statutory income tax rate to the effective
            rate for the year ended December&#160;31, 2025 is as follows (in thousands, except percentages): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 71.26pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 71.26pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">U.S. Federal statutory income tax (benefit)</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;">$(15,516)</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 3.33pt;">21.0% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Domestic federal<br/>
                  </div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Tax credits<br/>
                  </div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">R&amp;D credit</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 17.5pt;">(726)</span></div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 8.33pt;">1.0 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Nontaxable or nondeductible items<br/>
                  </div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Preferred revaluation</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 13.33pt;">2,271 </span></div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 5pt;">(3.3) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Other</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 20.83pt;">143 </span></div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 5pt;">(0.2) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Changes in valuation allowance</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 8.33pt;">13,629 </span></div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;">(18.2) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other reconciling items<br/>
                  </div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Domestic state<br/>
                  </div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">State income taxes, net of federal effect</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 25.83pt;">17 </span></div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 8.33pt;">0.0 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Foreign Tax effects</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.75pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 12.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(182</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 21.75pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.46pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">0.2</span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.38pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 21.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A reconciliation of the federal statutory income tax rate to the effective rate
            for the year ended December&#160;31, 2024 is as follows (in thousands, except percentages): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Federal statutory income tax rate</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;"><span style="padding-left: 3.33pt;">21.0% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes from statutory rate:<br/>
                  </div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State taxes, net of federal benefit</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;"><span style="padding-left: 8.33pt;">7.4 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Tax credits</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;"><span style="padding-left: 8.33pt;">3.1 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;"><span style="padding-left: 5pt;">(0.5) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Change in valuation allowance</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;">(29.9) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preferred Revaluation</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;"><span style="padding-left: 5pt;">(1.1) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other adjustments</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(0.1</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective income tax rate</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(0.1</span><span style="padding-bottom: 0.5pt;">)%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounts for income taxes under ASC 740, <span style="font-style: italic;">Income Taxes</span> (&#8220;ASC 740&#8221;). The Company&#8217;s loss before income taxes consists solely of a domestic loss. The state jurisdiction that contributes to the majority (greater than 50%) of the tax effect in this category is
            Massachusetts. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Income tax refunds received were all at the federal level and totaled $0.2
            million for the year ended December&#160;31, 2025. No refunds were received nor taxes paid for the year ended December&#160;31, 2024. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Deferred tax assets and liabilities reflect the net tax effects of net operating
            loss carryovers and temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities
            were as follows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 86.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 86.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets:<br/>
                  </div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net operating loss carryforwards</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$30,135 </div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 5pt;">9,260 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Capitalized research and development expenses</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">24,677 </span></div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">31,464 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred revenue</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">20,383 </span></div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">18,516 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Lease liability</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">6,398 </span></div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">6,969 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development tax credit carryforwards</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">12,001 </span></div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">8,613 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accruals and reserves</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;">518 </span></div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;">775 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">712 </span></div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">545 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total deferred tax assets</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">94,824 </span></div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">76,142 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-78<br/>
        </div>

      </div>

    </div>

    <!--End Page 412-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 413-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 86.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 86.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax liabilities:<br/>
                  </div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right-of-use asset</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -2.96pt; text-align: left;"><span style="padding-left: 9.63pt;">(4,087)</span></div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 10pt;">(4,363) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Property and equipment</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -2.96pt; text-align: left;"><span style="padding-left: 9.63pt;">(1,725)</span></div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 10pt;">(2,066) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other deferred tax liabilities</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -2.96pt; text-align: left;"><span style="padding-left: 27.13pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total deferred tax liabilities</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -2.96pt; text-align: left;"><span style="padding-left: 9.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,813</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(6,430</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valuation allowance</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -2.96pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(89,011</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(69,712</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Net deferred tax assets</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -2.96pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.46pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 13.75pt; margin-left: 0pt; text-align: left;">In determining the need for a valuation allowance, the Company has given
            consideration to its cumulative book income and loss positions. The Company has assessed the available means of recovering deferred tax assets, including the ability to carryback net operating losses, the existence of reversing taxable
            temporary differences, the availability of tax planning strategies and forecasted future taxable income. As of December&#160;31, 2025, the Company maintains a full valuation allowance against its net deferred tax assets. A valuation allowance of
            $89.0 million and $69.7 million was recorded as of December&#160;31, 2025 and 2024, respectively. The valuation allowance increased primarily as a result of tax credits and net operating losses generated. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025, the Company had U.S. federal net operating loss
            carryforwards of approximately $124.8 million. U.S. federal net operating loss carryforwards generated in the tax years beginning after December&#160;31, 2017 do not expire. All of the Company&#8217;s net operating losses were generated in 2019 and after.
            As such, all of the U.S. federal net operating losses have an indefinite life carryforward. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025, the Company had state net operating loss carryforwards
            of approximately $62.0&#160;million that expire at various dates through 2039. As of December&#160;31, 2025, the Company had U.S. federal credit carryforwards of approximately $7.1&#160;million that expire at various dates through 2044. As of December&#160;31,
            2025, the Company had U.S. state tax credit carryforwards of approximately $6.2 million that expire at various dates through 2036. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under Sections 382 and 383 of the U.S. Internal Revenue Code, if a corporation
            undergoes an ownership change, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change attributes, such as net operating losses and research tax credits, to offset its post-change income and taxes
            may be limited. In general, an ownership change generally occurs if there is a cumulative change in ownership by 5% stockholders that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under U.S. state tax
            laws. The Company has experienced an ownership change in the past and may experience ownership changes in the future as a result of future transactions in its share capital, some of which may be outside the control of the Company. As a result,
            if the Company earns net taxable income, its ability to use its pre-change net operating loss carryforwards, or other pre-change tax attributes, to offset U.S. federal and state taxable income and taxes is subject to significant limitations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounted for uncertain tax positions using a more likely than not
            threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be
            taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates uncertain tax positions on an annual basis and adjusts the
            level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.
            For the years ended December&#160;31, 2025, and 2024, there were no accrued interest or penalties in the consolidated statements of operations. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company is subject to taxation only for federal and state purposes. At
            December&#160;31, 2025, the Company is subject to examination by these taxing authorities for all years since its 2019 incorporation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On July&#160;4, 2025, the One Big Beautiful Bill (&#8220;OB3&#8221;) was enacted. As a result of
            the tax law changes under OB3, the requirements for capitalization of research and development expenditures changed. The impact of the changes under OB3 are reflected in the Company&#8217;s tax provision. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-79<br/>
        </div>

      </div>

    </div>

    <!--End Page 413-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 414-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg27"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">17. Leases </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">100 Forge </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In May&#160;2021, the Company became a party to a ten-year, non-cancellable lease for
            a 43,417 square foot laboratory and office facility in Watertown, Massachusetts with the term commencing in May&#160;2022. The lease agreement provides for escalating monthly rental payments, and a tenant improvement allowance up to a maximum of
            $195 per square foot of rentable area in the premises, which amounts to a maximum of $8.5&#160;million in improvement allowances, based on the 43,417 rental square feet leased to the Company. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has the option to extend the lease for an additional term of five
            years. The Company is not reasonably certain that it will exercise this renewal option and it is, therefore, not included in the measurement of the lease. The lease does not include any restrictions or covenants that had to be accounted for
            under the lease guidance. In accordance with the lease agreement, the Company has obtained a letter of credit in the amount of $2.0 million, which is included in the non-current restricted cash balance within the consolidated balance sheets as
            of December&#160;31, 2025 and 2024. </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">Summary of Lease Costs Recognized </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following tables contain a summary of the lease costs recognized under ASC
            842 and other information pertaining to the Company&#8217;s operating leases for the years ended December&#160;31, 2025 and 2024. Variable lease expense relates primarily to office lease common area maintenance and property taxes, which is expensed as
            incurred, and is excluded from the calculation of lease liabilities and right-of-use assets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The components of lease cost under ASC 842 were as follows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 81.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 81.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease cost</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$3,569 </div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$3,575 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease cost</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,672 </span></div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,724 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$
                      5,241 </span></div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$
                      5,299</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Supplemental disclosure of information related to leases was as follows (in
            thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 81.5pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 81.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash paid for amounts included in the measurement of lease liabilities:<br/>
                  </div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating cash flows from operating leases</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$4,284 </div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$4,159 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right-of-use assets obtained in exchange for new operating lease
                    liabilities</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 12.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 12.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term&#8212;operating leases (in years)</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">7.01 </span></div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">8.01 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate&#8212;operating leases</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">10.50%</span></div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">10.50%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 13.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Future lease payments for non-cancellable operating leases and a reconciliation
            to the carrying amount of the operating lease liabilities presented on the consolidated balance sheet as of December&#160;31, 2025 were as follows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Year Ending December&#160;31:</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">4,412 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,545 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,681 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,821 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,966 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10,383 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">33,808 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Less: interest</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(10,390</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Present value of lease liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">23,418</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-80<br/>
        </div>

      </div>

    </div>

    <!--End Page 414-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 415-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg28"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">18. Commitments and Contingencies </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Legal Proceedings </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the ordinary course of business, the Company may be subject to legal
            proceedings, claims and litigation, as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable.
            Legal costs associated with these matters are expensed when incurred. As of December&#160;31, 2025 and 2024, the Company was not a party to any legal proceedings. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Indemnification Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the ordinary course of business, the Company enters into various agreements
            containing standard indemnification provisions. The Company&#8217;s indemnification obligations under such provisions are typically in effect from the date of execution of the applicable agreement through the end of the applicable statute of
            limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of December&#160;31, 2025 and 2024, no amounts have been accrued related to such indemnification provisions. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Other Contracts </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company enters into contracts in the normal course of business with various
            third parties for preclinical research studies, clinical trials, testing, manufacturing and other services. These contracts generally provide for termination upon notice and are cancelable without significant penalty or payment, and do not
            contain any minimum purchase commitments. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">19. Related Parties </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has multiple investors affiliated with members of the Company&#8217;s Board
            of Directors who are deemed to be related parties. During the years ended December&#160;31, 2025 and 2024, the Company entered into or was party to the following transactions with related parties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, the Company entered into the 2023 Notes Agreement with multiple
            investors, including existing related party investors (see Note&#160;9). In July&#160;2024, the milestone tranche closing of $40.1&#160;million was funded entirely by existing related party investors. As of December&#160;31, 2024, the fair value of the 2023 Notes
            was $59.6&#160;million and is reflected in the notes payable line on the consolidated balance sheets. In November&#160;2025, the outstanding 2023 Notes converted into Series&#160;B Preferred Stock pursuant to their contractual terms, resulting in the issuance
            of 31,029,131 shares to related party investors, and the Company entered into the 2025 Notes Agreement exclusively with existing related party investors (see Note&#160;9). During the year ended December&#160;31, 2025, the Company received $15.0&#160;million
            in proceeds from related parties under the 2025 Notes Agreement, as allocated to the convertible notes payable, warrant liability and contingent tranche liability lines on the consolidated balance sheets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the 2023 Notes Agreement and 2025 Notes Agreement, the Company
            issued warrants to related party investors exercisable for shares equal to 20% of the principal amount of each note purchased. The fair value of warrants held by related party investors was $7.6 million and $2.8 million as of December&#160;31, 2025
            and 2024, respectively, and are reflected on the respective warrant liability lines on the consolidated balance sheets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the years ended December&#160;31, 2025 and 2024, the Company received
            $15.0&#160;million and $31.9 million, respectively, in cash proceeds from related parties in connection with the convertible promissory note financings. There were no other amounts due to or from related parties as of December&#160;31, 2025 and 2024. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-81<br/>
        </div>

      </div>

    </div>

    <!--End Page 415-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 416-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg29"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">20. Net Loss per Share </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Basic and diluted net loss per share attributable to common stockholders was
            calculated as follows (in thousands, except share and per share amounts): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 98.81pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 98.81pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator: <br/>
                  </div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss attributable to common stockholders</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(73,705</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.8pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(69,139</span><span style="padding-bottom: 0.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator: <br/>
                  </div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Weighted-average common shares outstanding, basic and diluted</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7,700,621 </span></div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 1.01pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7,611,340 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share attributable to common stockholders, basic and diluted</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 19.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(9.57</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 44.63pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 18.8pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(9.08</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 44.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth the number of shares underlying instruments
            outstanding at the end of the reporting period that have potential dilutive impacts but have been excluded from the calculation of net loss per share attributable to common stockholders because their effect would have been anti-dilutive: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 113.31pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 113.31pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible preferred stock (as converted to common stock)</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">118,136,265 </div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">87,203,974 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options to purchase common stock </div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 4.63pt;">16,928,609 </span></div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">19,083,279 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warrants issued in relation to a line of credit</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.13pt;">143,549 </span></div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">143,549 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warrants issued in relation to 2023 convertible promissory notes payable</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 9.63pt;">5,753,715 </span></div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company also had certain other financial instruments outstanding as of
            December&#160;31, 2025 which could obligate the Company to issue shares of common stock upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future events. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the year ended December&#160;31, 2025, these instruments included convertible
            promissory notes and warrants issued as part of the 2025 Notes Agreement (see Note&#160;9). As the necessary conditions for the conversion or exercise of these instruments had not been satisfied as of December&#160;31, 2025, the Company has excluded
            these instruments from the table above. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">21. Retirement Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company sponsors a defined contribution plan covering substantially all its
            employees who meet certain eligibility requirements. The Company matches 50% up to 6% of employee contributions. The Company, at the discretion of the Board, may make contributions to the plan. During the years ended December&#160;31, 2025 and 2024,
            the Company made matching contributions of $0.3&#160;million and $0.4&#160;million, respectively. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">22. Segment Information </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company&#8217;s CODM, its CEO, regularly reviews consolidated net loss and
            significant income and expense categories and compares to the budget when evaluating the Company&#8217;s financial performance. The significant expense categories and amounts regularly provided to the CODM and included in consolidated net loss are
            presented in the table below. The CODM allocates resources based on the Company&#8217;s available cash resources and forecasted expenditures on a consolidated basis. Segment information regularly provided to the CODM is consistent with that reported
            on the consolidated balance sheets, with particular emphasis on the Company&#8217;s available liquidity, including its cash and cash equivalents balances. The accounting policies of the single reportable segment are identical to those described in
            Note&#160;2,<span style="font-style: italic;"> Summary of Significant Accounting Policies.</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of December&#160;31, 2025 and 2024, all of the Company&#8217;s long-lived assets are
            located in the U.S., and the Company&#8217;s collaboration revenue was attributed to Switzerland for Roche and to the U.S. for Janssen (see Note&#160;8). As of the termination of the Janssen Agreement in July&#160;2026, all collaboration revenue is expected to
            be derived in Switzerland (see Note&#160;23). </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-82<br/>
        </div>

      </div>

    </div>

    <!--End Page 416-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 417-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg30"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The following table presents certain financial data for the Company&#8217;s
            reportable segment (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 2pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 0pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 89.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,310 </span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">4,827 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses:<br/>
                  </div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">13,321 </span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">14,902 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">MYB program</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">20,095 </span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">18,877 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other preclinical programs</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">9,983 </span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">13,948 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Facilities, laboratory supplies and other</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">9,194 </span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">10,765 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses:<br/>
                  </div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">5,142 </span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">5,001 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Facilities, laboratory supplies and other</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">9,914 </span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">10,151 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other segment items*</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">9,366 </span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">322 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss and comprehensive loss</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(73,705</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(69,139</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Other segment items consist of other expense, net, and income tax benefit (expense). Other expense primarily consists of the
                    change in fair value of convertible notes payable, warrant liabilities and contingent tranche liabilities partially offset by interest income. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">23. Subsequent Events </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For its consolidated financial statements as of and for the year ended
            December&#160;31, 2025, the Company evaluated subsequent events through July&#160;21, 2026, the date on which those financial statements were issued. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Expiration of Line of Credit </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In January&#160;2026, the Letter Agreement with the Bank was formally terminated
            relating to the Line of Credit with the Bank. The termination created an additional collateral balance of $0.4&#160;million required by the Bank for the letter of credit associated with the Company&#8217;s lease agreement. The transfer of the new letter
            of credit balance was completed in January&#160;2026. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Issuance of Additional Convertible
            Promissory Notes and Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In March&#160;2026, the Company received an additional $15.0&#160;million in proceeds from
            the Second Tranche Closing related to the 2025 Notes Agreement (see Note&#160;9). Each investor participating in the 2025 Notes financing received a warrant with an aggregate exercise amount equal to 20% of the original principal amount of each
            related 2025 Note&#160;purchased. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Proposed Merger and Concurrent Financing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;24, 2026, Remix entered into an Agreement and Plan of Merger (the &#8220;Merger
            Agreement&#8221;) with Passage Bio, Inc. (&#8220;Passage Bio&#8221;) and Peregrine Merger Sub, Inc., a wholly owned subsidiary of Passage Bio (&#8220;Merger Sub&#8221;). Subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub
            will merge with and into Remix, with Remix continuing as a wholly owned subsidiary of Passage Bio and the surviving corporation of the merger (the &#8220;Merger&#8221;). In connection with the Merger, Passage Bio will change its name to &#8220;Remix
            Therapeutics, Inc.&#8221; Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each then outstanding share of Remix&#8217;s common stock (including shares of common stock issued upon
            conversion of Remix&#8217;s preferred stock, shares of Remix&#8217;s common stock issued upon conversion of Remix&#8217;s convertible notes and warrants and shares of Remix&#8217;s common stock issued in the Concurrent Financing described below) will be converted into
            the right to receive a number of shares of Passage Bio&#8217;s common stock calculated in accordance with the Merger Agreement. The combined company is expected to be led by Remix&#8217;s management team and will focus on developing small molecule
            therapeutics to modulate RNA processing and address the underlying drivers of disease. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Concurrently with entering into the Merger Agreement, Remix entered into (i) a
            subscription agreement (the &#8220;Subscription Agreement&#8221;) for the sale of shares of Remix common stock for an aggregate purchase price of approximately $70.0 million and (ii) a convertible promissory note purchase agreement (the &#8220;2026 </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-83<br/>
        </div>

      </div>

    </div>

    <!--End Page 417-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 418-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_207-finnotes02_pg31"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Note&#160;Agreement&#8221;) for the sale of approximately $30.0 million aggregate
            principal amount of convertible notes (the &#8220;2026 Notes&#8221;) that will convert into shares of Remix common stock based on the same aggregate equity value of Remix being used in the Merger. The sale of common stock pursuant to the Subscription
            Agreement and the issuance of the 2026 Notes pursuant to the 2026 Note&#160;Agreement are expected to result in aggregate gross proceeds to Remix of approximately $100.0 million (the &#8220;Concurrent Financing&#8221;). The issuance of Remix common stock
            pursuant to the Subscription Agreement and the conversion of the 2026 Notes into shares of Remix common stock are contingent on and will occur immediately prior to the Effective Time. Shares of Remix common stock issued in the Concurrent
            Financing will be converted into shares of Passage Bio common stock at the Effective Time in accordance with the terms of the Merger Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is expected to close in the fourth quarter of 2026 and is subject to
            approval by the stockholders of Remix and Passage Bio as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the transaction. Under certain circumstances, the
            Company could be required to pay Passage Bio a termination fee of $17.5 million, and Passage Bio could be required to pay the Company a termination fee of $1.5 million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In June 2026, the Company received $30.0&#160;million in proceeds from the 2026 Notes
            related to the 2026 Notes Agreement. The notes remained outstanding as of the issuance date, and conversion is contingent upon merger closing. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Termination of the Janssen Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On July 1, 2026, Janssen gave notice of termination of the Janssen Agreement,
            which will be effective on August 30, 2026. Remix will have no further obligations under the Janssen Agreement upon its termination. Accordingly, the Company expects to recognize the remaining deferred revenue balance associated with the
            Janssen Agreement during the period ending September&#160;30, 2026. The Company will not recognize any additional collaboration revenue under the Janssen Agreement after recognition of the remaining deferred revenue balance. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-84<br/>
        </div>

      </div>

    </div>

    <!--End Page 418-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 419-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_208-fintab03_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCBS3"><!--Anchor--></a>REMIX THERAPEUTICS, INC.<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 40.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31,<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 5.17pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31,<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets<br/>
                  </div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current assets:<br/>
                  </div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash and cash equivalents</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 8.33pt;">24,022 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;">$<span style="padding-left: 8.33pt;">24,147 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Prepaid expenses and other current assets</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">940 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,208 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current assets</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">24,962 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt;">25,355 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">2,409 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 18.33pt;">2,029 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease right-of-use assets</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">14,678 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt;">14,959 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net </div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.7pt;">11,716 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt;">12,595 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Prepaid expenses and other non-current assets</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,471 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,431 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total assets</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">55,236 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">56,369 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities, Convertible Preferred Stock and
                    Stockholders&#8217; Deficit<br/>
                  </div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Current liabilities:<br/>
                  </div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accounts payable</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 13.33pt;">2,979 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;">$<span style="padding-left: 13.33pt;">3,383 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.7pt;">4,115 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 18.33pt;">3,707 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liability, current portion</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">1,770 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 18.33pt;">1,682 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Deferred revenue, current portion </div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,286 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">14,464 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total current liabilities</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">26,150 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt;">23,236 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible notes payable, related party</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">29,400 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt;">13,100 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">2023 Warrants and Letter Warrant liability (includes
                    $5,545 and $6,170 from related parties)</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">5,661 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 18.33pt;">6,286 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2025 Warrant liability, related party</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 18.33pt;">2,588 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 18.33pt;">1,388 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Contingent tranche liability, related party</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212; </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 25.83pt;">500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease liability, net of current portion</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">21,155 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt;">21,736 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred revenue, net of current portion</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">56,490 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">60,143 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total liabilities</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">141,444 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 8.33pt;">126,389 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Commitments and contingencies (Note&#160;16)<br/>
                  </div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible preferred stock (Series&#160;Seed, A and B), $0.0001 par value; <br/>
                  </div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">124,133,326 shares authorized at both March&#160;31, 2026
                    and December&#160;31, 2025; 118,136,265 shares issued and outstanding at both March&#160;31, 2026 and December&#160;31, 2025; aggregate liquidation preference of $219,390 at both March&#160;31, 2026 and December&#160;31, 2025</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">200,865 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 8.33pt;">200,865 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholders&#8217; deficit:<br/>
                  </div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Common stock, $0.0001 par value; 162,000,000 shares
                    authorized at both March&#160;31, 2026 and December&#160;31, 2025; 7,831,834 and 7,811,834 shares issued and outstanding at March&#160;31, 2026 and December&#160;31, 2025, respectively</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35.83pt;">1 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 35.83pt;">1 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Additional paid-in capital</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">21,537 </span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 13.7pt;">21,110 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accumulated deficit</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(308,611</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(291,996</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total stockholders&#8217; deficit</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(287,073</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(270,885</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">55,236 </span></div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">56,369</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.17pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated
          financial statements. <br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-85<br/>
        </div>

      </div>

    </div>

    <!--End Page 419-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 420-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_208-fintab03_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCSO3"><!--Anchor--></a>REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
            <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 111pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 111pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 10.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">831</span></div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 25pt;">690 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating expenses:<br/>
                  </div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;">12,100</span></div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt;">15,555 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,072</span></div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,275 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total operating expenses</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">16,172</span></div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,830 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(15,341</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(19,140</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (expense) income:<br/>
                  </div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Change in fair value of convertible notes payable,
                    warrant liabilities and contingent tranche liability, related party</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 19.17pt;">(1,375)</span></div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 19.17pt;">(2,770) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Interest income</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30.37pt;">114</span></div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 30pt;">551 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other expense, net</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 36.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total other expense, net</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,264</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 19.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,227</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss before income taxes</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(16,605</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(21,367</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Income tax expense</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">10</span></div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss and comprehensive loss</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(16,615</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 9.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(21,382</span><span style="padding-bottom: 0.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share of common stock, basic and diluted</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 19.17pt;">(2.12)</span></div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 19.17pt;">(2.80) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average common shares outstanding, basic and diluted</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">7,825,834</span></div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">7,649,176</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated
          financial statements. <br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-86<br/>
        </div>

      </div>

    </div>

    <!--End Page 420-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 421-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_208-fintab03_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCSC3"><!--Anchor--></a>REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND
            STOCKHOLDERS&#8217; DEFICIT <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands, except share amounts) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 97.07pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.26pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 73.01pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 97.07pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series&#160;Seed, A and B <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Convertible Preferred Stock</div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 73.01pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 36.45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 45.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 47.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217; <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.09pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.09pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">118,136,265</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.96pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$200,865</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 0.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,811,834</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 0.37pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">21,110</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$(291,996</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$(270,885</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.09pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="padding-left: 39.63pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 10pt;">(16,615)</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="padding-left: 10pt;">(16,615) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Stock-based compensation expense</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.09pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="padding-left: 39.63pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="padding-left: 17.5pt;">415</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="padding-left: 25.83pt;">415 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise of stock options</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.09pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="padding-left: 39.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">20,000</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.09pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 39.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$200,865</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7,831,834</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$21,537</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 0.37pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(308,611</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(287,073</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 39.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.99pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.1pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 97.08pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.26pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 73.01pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 97.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Series&#160;Seed, A and B <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Convertible Preferred Stock</div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 73.01pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 36.45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Additional <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Paid-In <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Capital</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 45.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Accumulated <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 47.1pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholders&#8217; <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Deficit </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.78pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount </div>
                </td>

    <td style="width: 2.51pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2024</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.78pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.38pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">87,203,974</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.28pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.39pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$132,793</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,626,774</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$18,818</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$(218,291</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$(199,472</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.78pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.38pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.39pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 10pt;">(21,382)</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="padding-left: 10pt;">(21,382) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Stock-based compensation expense</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.78pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.38pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.39pt; text-align: left;"><span style="padding-left: 27.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 30pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="padding-left: 17.5pt;">676</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="padding-left: 25.83pt;">676 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise of stock options</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.78pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.38pt; text-align: left;"><span style="padding-left: 35pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.39pt; text-align: left;"><span style="padding-left: 27.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">61,627</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">42</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="padding-left: 30.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">42 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at March&#160;31, 2025</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.78pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">87,203,974</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 42.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$132,793</span></div>
                </td>

    <td style="width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">7,688,401</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 27.99pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">1</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$19,536</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.32pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(239,673</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.14pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(220,136</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 42.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.26pt; border-right: 1pt solid #000000; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 27.99pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 2.51pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.1pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: justify;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated
          financial statements. <br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-87<br/>
        </div>

      </div>

    </div>

    <!--End Page 421-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 422-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_208-fintab03_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tCSCF3"><!--Anchor--></a>REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 95.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from operating activities:<br/>
                  </div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(16,615)</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(21,382) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Adjustments to reconcile net loss to net cash used in operating
                    activities:<br/>
                  </div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization expense</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">731</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">809 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Stock-based compensation expense</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">415</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">676 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Change in fair value of convertible notes payable,
                    warrant liabilities and contingent tranche liability, related party</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">1,375</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,770 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Non-cash issuance expense</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">70 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Loss on sale of property and equipment</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 21.57pt;">111</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in operating assets and liabilities:</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts receivable</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">106 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Prepaid expenses and other assets</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">239</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">339 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accounts payable</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(404)</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(1,152) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Accrued expenses and other current liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">408</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(2,075) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Operating lease liabilities</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(212)</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(536) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Deferred revenue</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(831</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(690</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net cash used in operating activities</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(14,783</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(21,0</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">65</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from investing activities:<br/>
                  </div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Purchases of property and equipment</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt;">(6)</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from sales of property and equipment</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">32</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net cash provided by investing activities</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">26</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash flows from financing activities:<br/>
                  </div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from issuance of convertible notes payable</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">15,000</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds from exercise of stock options</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">12</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">42 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net cash provided by financing activities</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">15,012</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">42 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net increase (decrease) in cash, cash equivalents and
                    restricted cash</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">255</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">(21,023) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents and restricted cash, beginning of period</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">26,176</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">75,522 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash, cash equivalents and restricted cash, end of period</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">26,431</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">54,499</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Supplemental disclosures of non-cash information:<span style="font-weight: normal;"> </span><br/>
                  </div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Income tax refund received </div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 17.5pt;">(60)</span></div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sale of property, plant and equipment in prepaid expenses and other
                    current assets</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt;">6</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">The accompanying notes are an integral part of these unaudited condensed consolidated
          financial statements. <br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-88<br/>
        </div>

      </div>

    </div>

    <!--End Page 422-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 423-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tNCFS3"><!--Anchor--></a>REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">1. Description of Business, Organization and Liquidity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Remix Therapeutics, Inc. (together with its consolidated subsidiary, the
            &#8220;Company&#8221;) is focused on developing small molecule therapeutics to modulate ribonucleic acid (&#8220;RNA&#8221;) processing and address the underlying drivers of disease. The Company was incorporated in July&#160;2019 under the laws of the State of Delaware and
            is located in Massachusetts. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company is subject to risks and uncertainties common to early-stage companies
            in the biotechnology industry, including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing.
            Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts will
            require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company
            will realize revenue from product sales. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">Going Concern </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying unaudited condensed consolidated financial statements are
            prepared in accordance with generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has incurred recurring operating losses and negative cash flows from
            operations since its inception and has an accumulated deficit. Net losses totaled $16.6&#160;million and $21.4&#160;million for the three months ended March&#160;31, 2026 and 2025, respectively, and cash flows used in operations totaled $14.8&#160;million and
            $21.1&#160;million for the three months ended March&#160;31, 2026 and 2025, respectively. As of March&#160;31, 2026, the Company had an accumulated deficit of $308.6&#160;million. The Company expects to continue to incur significant operating losses and negative
            cash flows from operations for the foreseeable future until such time, if ever, it generates a level of revenue that is sufficient to support its cost structure. The Company has limited capital resources and expects that its cash and cash
            equivalents, including amounts received from issuances of convertible promissory notes, will not be sufficient to fund its operating expenses, capital expenditure requirements and obligations, for the twelve months following the date the
            audited consolidated financial statements included elsewhere in this proxy/prospectus are issued. As a result, the Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year from the
            date that the audited consolidated financial statements were issued. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Management&#8217;s plans to obtain additional funding include (1) a reverse merger and
            concurrent private placement in public equity (&#8220;PIPE&#8221;) financing, (2) financing alternatives (e.g., equity financing, royalty arrangements, business development financing, etc.), or (3) both. Refer to Note&#160;21 for more information. Although
            management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company to fund continuing operations, if at all. If the Company is unable to
            obtain financing, the Company may be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business
            prospects, or the Company may be unable to continue operations. As a result, the Company has concluded that management&#8217;s plans do not alleviate the substantial doubt about the Company&#8217;s ability to continue as a going concern. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These unaudited condensed consolidated financial statements do not include any
            adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">2. Summary of Significant Accounting Policies </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These unaudited condensed consolidated financial statements have been prepared in
            conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-89<br/>
        </div>

      </div>

    </div>

    <!--End Page 423-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 424-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial
            reporting. Any reference in these notes to applicable guidance refers to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Principles of Consolidation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The accompanying unaudited condensed consolidated financial statements include
            the accounts of Remix Therapeutics, Inc. and its wholly owned subsidiary, Remix Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Unaudited Condensed Consolidated Financial
            Statements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These unaudited condensed consolidated financial statements have been prepared on
            the same basis as the annual financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair statement of the Company&#8217;s financial position as of March&#160;31, 2026 and
            its results of operations and cash flows for the three months ended March&#160;31, 2026 and 2025. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or
            omitted from these unaudited condensed consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the
            year ended December&#160;31, 2025 included elsewhere in this filing. There have been no material changes to the Company&#8217;s significant accounting policies from those described therein. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The preparation of the Company&#8217;s unaudited condensed consolidated financial
            statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed
            consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. The Company bases its estimates on historical experience, known trends, and various other assumptions that are believed to be
            reasonable under the circumstances. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Convertible Promissory Notes Payable </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As permitted under ASC 825, <span style="font-style: italic;">Financial
              Instruments</span> (&#8220;ASC 825&#8221;), the Company elects to account for its convertible promissory notes (the &#8220;convertible notes payable&#8221;), which meet the required criteria, at fair value at inception and at each subsequent reporting date.
            Subsequent changes in fair value are recorded as a component of non-operating loss in other (expense) income in the unaudited condensed consolidated statements of operations and comprehensive loss. As a result of electing the fair value option,
            direct costs and fees related to the convertible notes payable are expensed as incurred. The Company elected as an accounting policy to not present interest expense separately from changes in the fair value of the convertible notes payable. The
            proceeds from the sale of the convertible promissory notes were allocated to the identified freestanding instruments, including warrants and contingent tranches, based on their fair value at inception (see Note&#160;8). </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Warrant Liabilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company classifies warrants as liabilities when they are contingently
            redeemable outside of the Company&#8217;s control or otherwise do not meet the criteria for equity classification under ASC 480-10, <span style="font-style: italic;">Distinguishing Liabilities from Equity</span> (&#8220;ASC 480-10&#8221;) or ASC 815-40, <span style="font-style: italic;">Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity</span> (&#8220;ASC&#160;815-40&#8221;). Warrant liabilities are recorded at fair value at inception and remeasured at each reporting date, with changes in fair value
            recognized in other (expense) income on the unaudited condensed consolidated statements of operations and comprehensive loss. The Company estimates the fair value of its warrant liabilities using a Monte Carlo simulation model for warrants
            issued in connection with the convertible promissory notes and the Black-Scholes pricing model for warrants when the number of underlying shares is fixed or determinable (see Note&#160;3 and Note&#160;10). </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Contingent Tranche Liabilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company determined that its obligations to issue, and the Company&#8217;s
            investors&#8217; rights to purchase, additional convertible promissory notes and warrants pursuant to a milestone closing or the satisfaction of other specified tranche closing conditions (see Note&#160;8) represent freestanding financial instruments (the
            &#8220;contingent tranche </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-90<br/>
        </div>

      </div>

    </div>

    <!--End Page 424-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 425-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">liabilities&#8221;). The contingent tranche liabilities are initially recorded at
            fair value using valuation models that incorporate significant unobservable inputs and are remeasured at fair value at each reporting date and upon settlement, exercise, or expiration of the related obligations. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Revenue Recognition </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company recognizes revenue in accordance with ASC 606. The Company&#8217;s revenues
            consist of collaboration agreements under which it licenses intellectual property and provides research and development services (see Note&#160;7). For ongoing arrangements, revenue is recognized using a cost-to-cost input method over the
            performance period, which best depicts the transfer of services to the customer. Variable consideration, including development milestones, is included in the transaction price only to the extent it is probable that a significant reversal of
            cumulative revenue will not occur. Upfront payments received prior to satisfaction of performance obligations are recorded as deferred revenue, classified as current or non-current based on expected timing of recognition. When a collaboration
            agreement is terminated and remaining performance obligations are extinguished, any remaining deferred revenue balance is recognized in full in the period of termination. There have been no material changes to the Company&#8217;s revenue recognition
            policies from those described in the Company&#8217;s annual financial statements for the year ended December&#160;31, 2025 included elsewhere in this filing. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Pronouncements
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In September&#160;2025, the FASB issued ASU 2025-07, <span style="font-style: italic;">Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</span>,
            which refines the scope of derivative accounting for certain contracts with underlying terms based on operations or activities specific to one of the parties to the contract and clarifies the accounting for share-based noncash consideration
            received from a customer in a revenue contract. ASU 2025-07 is effective for the Company beginning in fiscal year 2027, including interim periods within that fiscal year. Early adoption is permitted. The Company early adopted ASU 2025-07 as of
            January&#160;1, 2026 using the prospective method. The adoption did not have a material impact on the Company&#8217;s consolidated balance sheets or statements of operations. The Company considered the guidance in ASU 2025-07 in connection with its
            evaluation of certain financial instruments issued or converted in connection with the Merger and Concurrent Financing discussed elsewhere in this proxy statement/prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In May&#160;2025, the FASB issued ASU 2025-03, <span style="font-style: italic;">Business

              Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity</span>, which amends the guidance for determining the accounting acquirer in certain transactions
            involving the acquisition of a variable interest entity that meets the definition of a business. ASU 2025-03 requires an entity to consider the factors in ASC 805-10-55-12 through 55-15 in determining which entity is the accounting acquirer
            when a legal acquiree is a variable interest entity and the transaction is not primarily effected by transferring cash or other assets or by incurring liabilities. ASU&#160;2025-03 is effective for the Company for annual reporting periods beginning
            after December&#160;15, 2026, including interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of an interim or annual reporting period. The Company adopted ASU 2025-03 as of January&#160;1, 2026
            in connection with its evaluation of the accounting acquirer in the Merger discussed elsewhere in this proxy statement/prospectus. The adoption did not have a material impact on the Company&#8217;s consolidated balance sheets or statements of
            operations, but was considered in determining that Remix is the accounting acquirer for accounting purposes. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2024, the FASB issued ASU 2024-04, <span style="font-style: italic;">Debt&#8212;Debt

              with Conversion and Other Options (Subtopic&#160;470-20): Induced Conversions of Convertible Debt Instruments</span>, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted
            for as an induced conversion or a debt extinguishment. The Company adopted ASU 2024-04 on January&#160;1, 2026. The adoption did not have a material impact on the Company&#8217;s unaudited condensed consolidated financial statements or related
            disclosures. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Accounting Pronouncements Not Yet Adopted </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2024, the FASB issued ASU 2024-03, <span style="font-style: italic;">Income

              Statement&#8212;Reporting Comprehensive Income (Topic&#160;220): Disaggregation of Income Statement Expenses</span>, to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation,
            depreciation, amortization, and depletion) </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-91<br/>
        </div>

      </div>

    </div>

    <!--End Page 425-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 426-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">included in certain expense captions presented on the face of the income
            statement. This ASU is effective for fiscal years beginning after December&#160;15, 2026, and for interim periods within fiscal years beginning after December&#160;15, 2027. Early adoption is permitted. The amendments may be applied either (1)
            prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of
            adopting this ASU on its consolidated financial statements and related disclosures. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">3. Fair Value Measurements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following tables present the Company&#8217;s fair value hierarchy for its assets
            and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 174.54pt;" colspan="10">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 276pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 174.54pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 276pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets:<br/>
                  </div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash equivalents:<br/>
                  </div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$16,530</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$16,530

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$16,530</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$16,530

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities:<br/>
                  </div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible notes payable</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$29,400</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$29,400 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">2023 Warrant liability*</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">5,661</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">5,661 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">2025 Warrant liability</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,588</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,588 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$37,649</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$37,649</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 276pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24.66pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The table includes warrants issued to obtain a line of credit amounting to $0.1&#160;million as of March&#160;31, 2026. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 174.54pt;" colspan="10">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 276pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 174.54pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 276pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.83pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assets:<br/>
                  </div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash equivalents:<br/>
                  </div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$15,433</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$15,433

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,433</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 3.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$15,433

                    </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liabilities:<br/>
                  </div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 3.01pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Convertible notes payable</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$13,100</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$13,100 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">2023 Warrant liability*</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">6,286</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">6,286 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">2025 Warrant liability</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">1,388</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">1,388 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Contingent tranche liability</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">500</span></div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24.66pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.83pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$21,274</span></div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$21,274</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24.66pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.73pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 8.25pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The table includes warrants issued to obtain a line of credit amounting to $0.1&#160;million as of December&#160;31, 2025. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">During the three months ended March&#160;31, 2026 and 2025, there were no transfers
            between levels. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The table below presents changes in the Company&#8217;s liabilities with significant
            unobservable inputs (Level&#160;3 liabilities) during the three months ended March&#160;31, 2026 and 2025 (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 54.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Convertible <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">notes payable</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 Warrant <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">liability*</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 Warrant <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">liability</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contingent <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">tranche liability </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;">$13,100</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;">$6,286</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;">$1,388</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.56pt; text-align: left;">$<span style="padding-left: 3.33pt;">500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issuances</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="padding-left: 5pt;">13,500</span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 5pt;">1,500</span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.56pt; text-align: left;"><span style="padding-left: 13.33pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Adjustments to estimated fair value</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="padding-left: 10pt;">2,800</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 9.17pt;">(625)</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 9.17pt;">(300)</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.56pt; text-align: left;"><span style="padding-left: 13.33pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Settlements</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.56pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(500</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$29,400</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.06pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,661</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$2,588</span></div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.44pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.56pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 8.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.98pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 54.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-92<br/>
        </div>

      </div>

    </div>

    <!--End Page 426-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 427-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 47.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Convertible <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">notes payable</div>
                </td>

    <td style="width: 9.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2023 Warrant <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">liability* </div>
                </td>

    <td style="width: 9.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at December&#160;31, 2024</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;">$59,600</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;">$4,136 </div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;&#8195;&#8195;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195;&#8195;&#8195;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Issuances</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Adjustments to estimated fair value</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="padding-left: 10pt;">3,460</span></div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 9.17pt;">(690)</span></div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Settlements</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 0.76pt; padding-bottom: 2.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Balance at March&#160;31, 2025</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.44pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.97pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$63,060</span></div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.63pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.07pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,446</span></div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.63pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 20pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">As of both March&#160;31, 2026 and 2025, the table includes warrants issued to obtain a line of credit amounting to $0.1&#160;million. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Money Market Funds </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">U.S. government money market funds were valued by the Company based on quoted
            market prices, which represent a Level&#160;1 measurement within the fair value hierarchy. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Convertible Notes Payable, Warrant
            Liabilities and Contingent Tranche Liabilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The convertible notes payable, warrant liabilities and contingent tranche
            liabilities (see Note&#160;8) are measured at fair value using a Monte Carlo simulation model. After issuance at the Series&#160;B Preferred Stock price ($2.0880) in November&#160;2025, the 2023 Warrant liability (see Note&#160;10) is measured at fair value using
            a Black-Scholes option pricing model. Both valuation models use significant unobservable Level&#160;3 inputs and reflect management&#8217;s judgments about assumptions that market participants would use to determine a current transaction price. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company estimates the volatility of its common stock based on historical
            volatility of comparable companies. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the instruments valued. The expected life of the
            instruments is determined based on expected timing of potential conversion scenarios associated with the instruments through discussions with management. The dividend rate is based on the historical rate, which the Company anticipates will
            remain at zero. Significant increases or decreases in the selected discount rate, volatility, or other significant unobservable inputs could result in a significantly lower or higher fair value measurement. The Company evaluates these inputs at
            each reporting date based on market participant assumptions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Monte Carlo simulation valuation model includes key assumptions that project
            multiple potential future scenarios based on the Company&#8217;s stock price (common and preferred) valuations, the likelihood of various financing events (such as Qualified Public Offerings or changes of control), and the probability of the
            conversion scenarios. include the fair value of the underlying common and preferred stock, estimated time to liquidity and the estimated probabilities of conversion scenarios. Additional key assumptions for the convertible notes payable,
            warrant liability and contingent tranche liability for which the number of underlying shares are not fixed or determinable as of the periods presented include: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.70% - 3.81%</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.62% - 3.90% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend rate</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00%</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected stock price volatility</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">54.00% - 86.00%</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">48.00% - 94.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (years)</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.27 - 1.65</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.25 - 2.00</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Black-Scholes option-pricing model is used when the number of underlying
            shares is fixed or determinable as of the periods presented, which applied to the 2023 Warrants and Letter Warrants (both defined below) as of both March&#160;31, 2026 and December&#160;31, 2025. The key assumptions for both periods included the
            following inputs: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.80%</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 1.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.60% - 3.70% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend rate</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00%</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected stock price volatility</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">74.00% - 85.30%</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; padding-bottom: 1.13pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">85.90% - 95.00% </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 0.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term (years)</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">0.64 - 1.65</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.99pt; padding-top: 0.76pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">1.00 - 2.00</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 10.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.99pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-93<br/>
        </div>

      </div>

    </div>

    <!--End Page 427-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 428-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">4. Cash, Cash Equivalents and Restricted Cash </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table provides a reconciliation of cash, cash equivalents and
            restricted cash reported on the consolidated balance sheets to the amounts presented in the unaudited condensed consolidated statements of cash flows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 276pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash and cash equivalents</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;">$24,022</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">$24,147</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;">$52,401</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;">$73,424 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restricted cash</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,409</span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,029</span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,098</span></div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,098 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 276pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.22pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$26,431</span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$26,176</span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$54,499</span></div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$75,522</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 276pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">5. Property and Equipment, Net </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Property and equipment, net consisted of the following (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 12.42pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 3.33pt;">14,100</span></div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.33pt; text-align: left;">$<span style="padding-left: 3.33pt;">14,100 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 13.33pt;">7,374</span></div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.33pt; text-align: left;"><span style="padding-left: 13.33pt;">7,523 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 20.83pt;">798</span></div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.33pt; text-align: left;"><span style="padding-left: 20.83pt;">798 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer equipment and software</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">250</span></div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.33pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">250 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 8.33pt;">22,522</span></div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.33pt; text-align: left;"><span style="padding-left: 8.33pt;">22,671 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(10,806</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.33pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(10,076</span><span style="padding-bottom: 1.5pt;">) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.7pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">11,716</span></div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 5.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">12,595</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.42pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Depreciation and amortization expense for the three months ended March&#160;31, 2026
            and 2025 was $0.7&#160;million and $0.8&#160;million, respectively. Depreciation and amortization expense is classified in both research and development expense and general and administrative expense within the unaudited condensed consolidated statements
            of operations and comprehensive loss. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">6. Accrued Expenses and Other Current Liabilities </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses and other current liabilities consisted of the following (in
            thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 9.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued research and development costs</div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.72pt; text-align: left;">$2,913</div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;">$1,862 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued employee compensation and benefits</div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.72pt; text-align: left;"><span style="padding-left: 12.5pt;">787</span></div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;"><span style="padding-left: 5pt;">1,414 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accrued professional services</div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.72pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">415</span></div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">431 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 3.72pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 0.37pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,115</span></div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,707</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">7. Collaboration Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company&#8217;s collaboration revenue is generated from license and research
            collaboration arrangements. The following disclosures summarize material interim activity and contract balances; additional information about the Company&#8217;s collaboration agreements is included in the audited consolidated financial statements
            for the year ended December&#160;31, 2025. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Janssen Pharmaceutica NV, 2022 Collaboration
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In February&#160;2022, the Company and Janssen Pharmaceutica NV (&#8220;Janssen&#8221;), a Belgian
            pharmaceutical and research company, entered into an exclusive collaboration and license agreement to discover small molecule compounds that modulate targets for the treatment of diseases and conditions in the fields of oncology and immunology
            (the &#8220;Janssen Agreement&#8221;). The Company received a non-refundable upfront payment of $45.0&#160;million upon execution of the agreement, which represented the initial transaction price. The Company received an additional $0.8&#160;million as reimbursement
            for costs incurred as part of the collaboration related to a specific target that was subsequently </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-94<br/>
        </div>

      </div>

    </div>

    <!--End Page 428-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 429-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">reimbursed by Janssen. The promises under the arrangement, including research
            services, licenses, and joint committee participation, are not distinct from one another and are therefore combined into a single performance obligation. Revenue is recognized over the performance period using a cost-to-cost input method. The
            Company excludes milestone payments and royalties from the transaction price because the related amounts are constrained or otherwise not probable of achievement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the three months ended March&#160;31, 2026 and March&#160;31, 2025, the Company
            recognized $0.2&#160;million and $0.1&#160;million of collaboration revenue, respectively, all of which was derived from amounts included in deferred revenue at the beginning of the respective period. As of March&#160;31, 2026, the Company had deferred
            revenue related to the Janssen Agreement of $8.8&#160;million within current liabilities and $27.8&#160;million within non-current liabilities in the condensed consolidated balance sheets. As of December&#160;31, 2025, the Company had deferred revenue related
            to the Janssen Agreement of $8.0&#160;million within current liabilities and $28.8&#160;million within non-current liabilities in the condensed consolidated balance sheets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As further discussed in Note&#160;21, <span style="font-style: italic;">Subsequent
              Events,</span> the Janssen Agreement was terminated in July&#160;2026 following the determination by both parties that the targets would not be advanced further under the collaboration. As a result, the Company expects to recognize the remaining
            deferred revenue balance associated with the Janssen Agreement during the quarter ending September&#160;30, 2026 and does not expect to recognize any additional collaboration revenue under the Janssen Agreement thereafter. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">F. Hoffmann-La Roche Ltd and Hoffmann-La
            Roche Inc., Collaboration </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December 2023, the Company and F. Hoffmann-La Roche Ltd (&#8220;Roche&#8221;) entered into
            a research collaboration and license agreement (the &#8220;Roche Agreement&#8221;) for the discovery and development of small molecule therapeutics that modulate RNA processing using the REMaster drug discovery platform. As of March&#160;31, 2026 and
            December&#160;31, 2025, the transaction price was $42.0&#160;million, consisting of a $30.0&#160;million upfront payment received in January&#160;2024 and $12.0&#160;million in nomination milestone payments achieved in June&#160;2024. The promises under the arrangement were
            not distinct from one another and were therefore combined into a single performance obligation. Revenue is recognized over the performance period using a cost-to-cost input method. The Company will continue to evaluate the probability of
            achievement of the remaining specified milestones at each reporting date and will adjust the estimate of the transaction price as necessary. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company recognized $0.7&#160;million and $0.6&#160;million of collaboration revenue
            under the Roche Agreement for the three months ended March&#160;31, 2026 and 2025, respectively. As of March&#160;31, 2026, the Company recorded deferred revenue related to the Roche Agreement of $8.5&#160;million within current liabilities and $28.7&#160;million
            within non-current liabilities in the accompanying unaudited condensed consolidated balance sheets. As of December&#160;31, 2025, the Company recorded deferred revenue related to the Roche Agreement of $6.4&#160;million within current liabilities and
            $31.4&#160;million within non-current liabilities in the condensed consolidated balance sheets. The revenue related to the single combined performance obligation is expected to be recognized over approximately three years as of March&#160;31, 2026. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">8. Convertible Notes Payable, Warrant Liabilities and Contingent
            Tranche Liabilities </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2023 Convertible Notes Payable </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, the Company entered into the 2023 Notes Agreement, pursuant to
            which it issued $65.1&#160;million aggregate principal amount of convertible promissory notes (the &#8220;2023 Notes&#8221;) in multiple tranches, bearing interest at 5.25% per annum. The 2023 Notes were convertible into shares of preferred stock at varying
            prices depending on the conversion scenario, as fully described in the Company&#8217;s audited financial statements for the year ended December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2023 Notes were convertible into the conversion shares, as defined in the
            2023 Notes Agreement, with the applicable class of shares and conversion price determined based on the conversion scenario. If the 2023 Notes were converted upon a next equity financing, which would result in gross proceeds of at least
            $50.0&#160;million (&#8220;Qualified Financing&#8221;), all unpaid principal and accrued interest would be convertible into shares of preferred stock identical to the class of preferred stock issued in such financing at a conversion price equal to 80% of the
            lowest cash price per share paid by investors in the Qualified Financing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company accounted for the 2023 Notes under the fair value method of
            accounting, with changes in fair value recorded in other (expense) income in the unaudited condensed consolidated statements of operations and comprehensive loss at each reporting date. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-95<br/>
        </div>

      </div>

    </div>

    <!--End Page 429-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 430-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">On November&#160;14, 2025, the Company entered into the first amendment to the 2023
            Notes Agreement. As a result, the 2023 Notes converted into 31,029,131 shares of Series&#160;B Preferred Stock in November&#160;2025. The fair value of the 2023 Notes immediately prior to conversion was $68.3&#160;million. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">2023 Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In connection with the 2023 Notes Agreement, the Company issued warrants to
            purchase capital stock of the Company (the &#8220;2023 Warrants&#8221;) with an aggregate exercise amount equal to 20% of the principal amount of each note purchased. The 2023 Warrants are classified as liabilities under ASC 480 and remeasured at each
            reporting date with changes in fair value recognized in other (expense) income. Following conversion of the 2023 Notes in November&#160;2025, the 2023 Warrants remained outstanding and became exercisable for shares of Series&#160;B Preferred Stock at
            $2.0880 per share, subject to termination if the holder became a non-participating investor under the 2025&#160;Notes Agreement. The 2023 Warrants remain outstanding as of March&#160;31, 2026. See Note&#160;3 and Note&#160;10 for current period fair value
            information and warrant activity, respectively, and the Company&#8217;s audited financial statements for the year ended December&#160;31, 2025 for a complete description of the 2023 Warrants. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">2025 Convertible Notes Payable </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;14, 2025, the Company entered into a Convertible Promissory Note&#160;and
            Warrant Purchase Agreement (the &#8220;2025 Notes Agreement&#8221;) with certain investors (a &#8220;Lender&#8221;, or the &#8220;Lenders&#8221;), pursuant to which the Company agreed to issue and sell convertible promissory notes (the &#8220;2025 Notes&#8221;) and warrants to purchase
            shares of the Company&#8217;s common stock, as further described below. The 2025 Notes Agreement provides for multiple closings, including an initial tranche of up to $15.0&#160;million (the &#8220;First Tranche Closing&#8221;) and a second tranche of up to
            $15.0&#160;million, the funding of which was subject to approval by the Company&#8217;s Board based on specified conditions set forth in the 2025 Notes Agreement (the &#8220;Second Tranche Closing&#8221;). Through December&#160;31, 2025, the Company issued $15.0&#160;million
            aggregate principal amount of 2025 Notes, less issuance costs of $0.3&#160;million. The First Tranche Closing commenced on November&#160;14, 2025 and was substantially completed as of December&#160;31, 2025. A nominal amount of funding was received in
            January&#160;2026 to close the first tranche. The Second Tranche Closing of $15.0&#160;million was completed in March&#160;2026. The 2025 Notes mature on November&#160;30, 2027 and bear interest at 8.00% per annum, which resulted in an effective interest rate of
            8.00% for the three months ended March&#160;31, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The 2025 Notes are convertible into conversion shares, as defined in the 2025
            Notes Agreement, with the applicable class of shares and conversion price determined based on the applicable conversion scenario. If a Lender fails to fund its required tranche commitment and is deemed a non-participating investor, its
            preferred stock is subject to mandatory conversion to common stock and its warrants (including any 2023 Warrants) automatically terminate. Upon a change of control, holders are entitled to the greater of a specified repayment amount or the
            value assuming conversion into Series&#160;B Preferred Stock. The conversion price is $2.0880 per share for a public company-related event, certain corporate events, event of default, or maturity-related conversion, and 80% of the applicable cash
            price per share in a Qualified or Non-Qualified Financing. See the Company&#8217;s audited financial statements for the year ended December&#160;31, 2025 for a complete description of the 2025 Notes conversion terms. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company elected the fair value option to account for the 2025 Notes, with
            changes in fair value recognized in other (expense) income in the unaudited condensed consolidated statements of operations and comprehensive loss at each reporting date. As a result, separate accounting for embedded features within the 2025
            Notes was not required. The fair value of the 2025 Notes at issuance was $13.1&#160;million and was estimated using a Monte Carlo simulation. Because the issuance date of the 2025 Notes was in close proximity to December&#160;31, 2025, the Company
            concluded that any change in fair value between the issuance date and December&#160;31, 2025 was not material. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Second Tranche Closing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Second Tranche Closing represented the Company&#8217;s obligation to issue an
            additional $15.0&#160;million aggregate principal amount of 2025 Notes and the related 2025 Warrants upon satisfaction of the applicable second tranche closing conditions. Pursuant to the 2025 Notes Agreement, the Lenders&#8217; obligations to purchase
            the 2025 Notes and related 2025 Warrants at the Second Tranche Closing were subject to the Company&#8217;s receipt, on or before May&#160;31, 2027, of a funding request by the Board of Directors, including a majority of the directors designated by holders
            of preferred stock after the Company&#8217;s aggregate cash balance fell below $15.0&#160;million. The Company determined that the contractual rights and obligations to issue additional notes and warrants associated with the Second Tranche </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-96<br/>
        </div>

      </div>

    </div>

    <!--End Page 430-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 431-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Closing represented a separate freestanding financial instrument and
            classified the related instrument as a liability in accordance with ASC 480. The liability was initially recorded at its fair value of $0.5&#160;million, estimated using a Monte Carlo simulation model, and was presented as a contingent tranche
            liability on the consolidated balance sheets as of December&#160;31, 2025. The Second Tranche Closing was completed in March&#160;2026, at which time the contingent tranche liability was settled. See Note&#160;3 for information regarding the valuation
            methodology and significant assumptions. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">2025 Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each investor participating in the 2025 Notes financing received a warrant (the
            &#8220;2025 Warrants&#8221;) with an aggregate exercise amount equal to 20% of the original principal amount of each related 2025 Note&#160;purchased. Pursuant to the terms of the 2025 Notes Agreement, each 2025 Warrant is exercisable for the same conversion
            shares into which the corresponding 2025 Note&#160;converts, at a per share exercise price equal to the applicable conversion price. In the event the corresponding 2025 Notes convert in connection with a Public Company Event or at maturity or are
            repaid in cash or immediately available funds, the related 2025 Warrants are exercisable for shares of Series&#160;B Preferred Stock at an exercise price equal to the Series&#160;B original issue price of $2.0880 per share. In addition, upon the
            occurrence of an event of default under the 2025 Notes Agreement, the conversion price for purposes of the 2025 Warrants is the Series&#160;B original issue price. Each 2025 Warrant has a contractual term of seven years, unless earlier terminated
            upon the closing of a corporate event, including a change in control, an initial public offering or a reverse merger, as defined in the 2025 Notes Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company concluded that the 2025 Warrants represent freestanding financial
            instruments and classified the 2025 Warrants as liabilities in accordance with ASC 480. Accordingly, the 2025 Warrants were initially recorded at fair value and are remeasured at each reporting date, with changes in fair value recognized in
            other (expense) income in the unaudited condensed consolidated statements of operations and comprehensive loss. The fair value of the 2025 Warrants at issuance was $1.4&#160;million using a Monte Carlo simulation model. As the issuance date of the
            2025 Warrants was in close proximity to December&#160;31, 2025, the Company concluded that any change in fair value between the issuance date and December&#160;31, 2025 was not material. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">9. Line of Credit </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On October&#160;10, 2024, the Company entered into the Loan and Security Agreement
            (the &#8220;Letter Agreement&#8221;) with Banc of California (the &#8220;Bank&#8221;) that provided for a term loan facility of up to $40.0&#160;million at the Company&#8217;s option until December&#160;31, 2025 (the &#8220;Line of Credit&#8221;). The Company concurrently issued 143,549 warrants
            to purchase shares of Series&#160;B preferred stock in connection with the Line of Credit (the &#8220;Letter Warrants&#8221;). The Letter Warrants were issued as an additional incentive for the Bank and were determined to be classified as a liability (see
            Note&#160;10). Issuance costs of $0.2&#160;million were capitalized and amortized on a straight-line basis over the access period and were fully amortized as of December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company did not draw upon the Line of Credit as of December&#160;31, 2025, and the
            Letter Agreement was formally terminated in January&#160;2026. As part of the termination, the Bank required an additional $0.4&#160;million in collateral for the letter of credit associated with the Company&#8217;s lease agreement, which was funded in
            January&#160;2026. No borrowings were outstanding as of March&#160;31, 2026 or December&#160;31, 2025. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">10. Warrants </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In October&#160;2024, the Company issued Letter Warrants to purchase 143,549 shares of
            Series&#160;B Preferred Stock as an additional incentive to the Bank providing the Line of Credit at a share price of $2.088 (see Note&#160;9). The fair value of the Letter Warrants was $0.1&#160;million as of March&#160;31, 2026 and 2025 (see Note&#160;3). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;14, 2025, upon approval of the Board, the Company issued additional
            2023 Warrants to purchase 5,756,672 shares of Series&#160;B Preferred Stock as part of the conversion of the 2023 Notes (see Note&#160;8). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2025, upon the First Tranche Closing of the 2025 Notes, certain
            Lenders did not fund their principal amounts (&#8220;Tranche Default&#8221;). As part of the Tranche Default, their respective 2023 Warrants totaling 2,957 shares were subsequently cancelled. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There was no 2023 Warrant activity from December&#160;31, 2025 to March&#160;31, 2026, and
            the warrants outstanding remained 5,897,264, inclusive of the warrants related to the letter of credit. As of March&#160;31, 2026 and December&#160;31, 2025, the Company determined the fair value of all outstanding 2023 Warrants to be $5.6 million and
            $6.2 million, respectively. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-97<br/>
        </div>

      </div>

    </div>

    <!--End Page 431-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 432-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">The Company estimates the fair value of 2023 Warrants using the Black-Scholes
            option-pricing model as of March&#160;31, 2026. This model incorporates various assumptions, including the expected volatility, expected term, and interest rates. See Note&#160;3 for assumptions used in determining fair values. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">11. Convertible Preferred Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has issued Series&#160;Seed preferred stock (the &#8220;Series&#160;Seed Preferred
            Stock&#8221;), Series&#160;A preferred stock (the &#8220;Series&#160;A Preferred Stock&#8221;) and Series&#160;B preferred stock (the &#8220;Series&#160;B Preferred Stock&#8221;), collectively referred to as Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Preferred stock consisted of the following (in thousands, except share amounts):
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 276.47pt;" colspan="13">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="13" style="width: 276.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued and <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Liquidation <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preference</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issuable Upon <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conversion </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;Seed Preferred Stock</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">17,964,705</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt;">17,964,705</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">16,700</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;">$<span style="padding-left: 5pt;">17,000</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt;">17,964,705 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A Preferred Stock</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">35,714,365</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt;">35,661,683</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">57,856</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 10pt;">67,693</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt;">35,661,683 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;B Preferred Stock</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,454,256</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">64,509,877</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">126,309</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">134,697</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">64,509,877 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">124,133,326</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$200,865</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$219,390</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.65pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 276.47pt;" colspan="13">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="13" style="width: 276.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 180pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Authorized</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issued and <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Outstanding</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Carrying <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Liquidation <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preference</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Issuable Upon <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Conversion </div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;Seed Preferred Stock</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">17,964,705</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt;">17,964,705</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 5pt;">16,700</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;">$<span style="padding-left: 5pt;">17,000</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt;">17,964,705 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;A Preferred Stock</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">35,714,365</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt;">35,661,683</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">57,856</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 10pt;">67,693</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt;">35,661,683 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Series&#160;B Preferred Stock</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,454,256</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">64,509,877</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">126,309</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">134,697</span></div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="padding-left: 4.63pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">64,509,877 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">124,133,326</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$200,865</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 40.45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$219,390</span></div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.65pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.51pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">118,136,265</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 40.45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.78pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.65pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There were no material changes to the rights, preferences, and terms of the
            Company&#8217;s convertible preferred stock during the three months ended March&#160;31, 2026. No dividends were declared or paid during the three months ended March&#160;31, 2026 or 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">See the Company&#8217;s audited financial statements for the year ended December&#160;31,
            2025 for a complete description of the voting rights, dividend rights, liquidation preferences, conversion terms, and redemption features of each series. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">12. Common Stock </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2026, the Company had 162,000,000 shares of $0.0001 par value
            common stock authorized with 7,831,834 shares issued and outstanding. As of December&#160;31, 2025, the Company had 162,000,000 shares of $0.0001 par value common stock authorized with 7,811,834 shares issued and outstanding. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has reserved the following shares of common stock for the potential
            conversion of preferred stock, the exercise of outstanding stock options, and the future issuance of awards available for grant under the Company&#8217;s 2019 Remix Therapeutics Stock Incentive Plan, as amended from time to time (the &#8220;2019 Plan&#8221;): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares reserved for the conversion of authorized Series&#160;Seed Preferred
                    Stock</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">17,964,705</span></div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">17,964,705 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares reserved for the conversion of authorized Series&#160;A Preferred Stock</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">35,714,365</span></div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">35,714,365 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares reserved for the conversion of authorized Series&#160;B Preferred
                    Stock*</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">70,454,256</span></div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">70,454,256 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock options available for grant under the 2019 Plan</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">4,061,639</span></div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">4,553,047</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Common stock options outstanding under the 2019 Plan</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,382,106</span></div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">16,928,609 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">145,577,071</span></div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 50pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">145,614,982</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 50pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Includes shares of 2023 Warrants and Letter Warrants at both March&#160;31, 2026 and December&#160;31, 2025. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-98<br/>
        </div>

      </div>

    </div>

    <!--End Page 432-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 433-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Voting </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The holders of shares of common stock are entitled to one vote for each share of
            common stock held at all meetings of stockholders and written action in lieu of meetings; there is no cumulative voting. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Liquidation </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">After payment to the holders of shares of preferred stock of their liquidation
            preferences, the remaining assets of the Company are distributed to the holders of common stock. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">13. Stock-Based Compensation </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2019 Stock Incentive Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2019, the Board adopted the 2019 Plan. Under terms of the 2019 Plan,
            incentive stock options (&#8220;ISOs&#8221;) may be granted to employees of the Company and nonqualified stock options or restricted stock awards may be granted to directors, consultants, employees, and officers of the Company. See the Company&#8217;s audited
            financial statements for the year ended December&#160;31, 2025 for a complete description of the 2019 Plan terms. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2026, 23,696,650 shares were reserved for issuance under the 2019
            Plan, of which 4,061,639 shares remained available for future grants. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Performance-Based Stock Options </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In July&#160;2022, the Company granted performance-based stock options (the
            &#8220;Performance Awards&#8221;) to an employee for 442,488 shares at an exercise price of $0.70 per share. The Performance Awards vest upon achievement of specified milestones followed by monthly vesting over 36 months. See the Company&#8217;s audited
            financial statements for the year ended December&#160;31, 2025 for a complete description of the Performance Award terms. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company determined that the performance conditions associated with these
            awards were achieved during the years ended December&#160;31, 2024 and 2023. Stock-based compensation expense of less than $0.1&#160;million was recognized for each of the three months ended March&#160;31, 2026 and 2025 related to these awards. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In February&#160;2025, the Board granted options to purchase common stock to an
            employee that will commence vesting upon the achievement of certain financing criteria (the &#8220;2025 Performance Awards&#8221;). The 2025 Performance Awards have an exercise price of $1.17 per share, which had an aggregate fair value at date of grant of
            $0.4&#160;million. Once achieved, the 492,023 shares of granted options will vest monthly over 48 months. As of March&#160;31, 2026, the Company determined that the 2025 Performance Awards criteria had not been met, and as such, no expense was
            recognized. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Stock Option Activity </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table summarizes the Company&#8217;s stock option activity: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.11pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 48.66pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares</div>
                </td>

    <td style="width: 7.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted- <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Exercise <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Price</div>
                </td>

    <td style="width: 7.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted- <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remaining <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Contractual <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Life</div>
                </td>

    <td style="width: 7.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Aggregate <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Intrinsic <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Value </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in years)</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 2.08pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(in thousands) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">16,928,609</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.75</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">5.94</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$7,179 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">2,382,960</span></div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$1.17</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 14.17pt;">(20,000)</span></div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.56</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited or canceled</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 1.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,909,463</span><span style="padding-bottom: 1.5pt;">)</span></div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.71</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at March&#160;31, 2026</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">17,382,106</span></div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.81</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">6.85</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$6,293 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and expected to vest at March&#160;31, 2026</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">16,890,083</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.80</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">6.79</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$6,293 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercisable at March&#160;31, 2026</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">12,242,281</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.11pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.3pt; text-align: left;">$0.68</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.32pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.9pt; text-align: left;">5.94</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48.66pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10.58pt; text-align: left;">$5,945</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.11pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 48.66pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The weighted-average grant-date fair value of the stock options granted during
            the three months ended March&#160;31, 2026 and 2025 amounted to $0.88 per share and $0.84 per share, respectively. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-99<br/>
        </div>

      </div>

    </div>

    <!--End Page 433-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 434-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Stock-Based Compensation Expense </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Total stock-based compensation expense recorded for employees, directors,
            non-employees and founders for the three months ended March&#160;31, 2026 and 2025 was as follows (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 75.38pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 75.38pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 384pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 4.32pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expense</div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;">$203</div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;">$422 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expense</div>
                </td>

    <td style="width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">212</span></div>
                </td>

    <td style="width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">254 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 384pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$415</span></div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 33.37pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.69pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$676</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 33.37pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 33.37pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2026, the total unrecognized stock-based compensation balance for
            unvested options was $3.6&#160;million, which is expected to be recognized over 1.9 years. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">14. Income Taxes </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the three months ended March&#160;31, 2026, the Company recorded a nominal income
            tax provision. As of March&#160;31, 2026 and December&#160;31, 2025, the Company recorded a full valuation allowance against its net deferred tax assets, as the Company believed it was more likely than not it would not be able to utilize its deferred tax
            assets prior to their expiration. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Since the Company&#8217;s inception, it has not recorded any income tax benefits for
            the net losses it has incurred in each year or for its research and development tax credits, as it believes, based upon the weight of available evidence, that it is more likely than not that all of the Company&#8217;s net operating loss carryforwards
            and tax credits will not be realized. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">15. Leases </div>

          <div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">100 Forge </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company leases a 43,417 square foot laboratory and office facility in
            Watertown, Massachusetts under a ten-year non-cancellable operating lease that commenced in May&#160;2022. In accordance with the lease agreement, the Company has obtained a letter of credit of $2.0&#160;million, which is included in non-current
            restricted cash as of March&#160;31, 2026 and December&#160;31, 2025. There were no material changes to the lease terms during the three months ended March&#160;31, 2026. See the Company&#8217;s audited financial statements for the year ended December&#160;31, 2025 for
            additional detail on lease terms. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">16. Commitments and Contingencies </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Legal Proceedings </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the ordinary course of business, the Company may be subject to legal
            proceedings, claims and litigation, as the Company operates in an industry susceptible to patent legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such losses are probable and estimable.
            Legal costs associated with these matters are expensed when incurred. As of March&#160;31, 2026 and December&#160;31, 2025, the Company was not a party to any legal proceedings. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Indemnification Agreements </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the ordinary course of business, the Company enters into various agreements
            containing standard indemnification provisions. The Company&#8217;s indemnification obligations under such provisions are typically in effect from the date of execution of the applicable agreement through the end of the applicable statute of
            limitations. The aggregate maximum potential future liability of the Company under such indemnification provisions is uncertain. As of March&#160;31, 2026 and December&#160;31, 2025, no amounts have been accrued related to such indemnification
            provisions. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Other Contracts </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company enters into contracts in the normal course of business with various
            third parties for preclinical research studies, clinical trials, testing, manufacturing and other services. These contracts generally provide for termination upon notice and are cancelable without significant penalty or payment, and do not
            contain any minimum purchase commitments. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-100<br/>
        </div>

      </div>

    </div>

    <!--End Page 434-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 435-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">17. Related Parties </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company has multiple investors affiliated with members of the Company&#8217;s Board
            of Directors who are deemed to be related parties. As of and during the three months ended March&#160;31, 2026 and 2025, the Company entered into or was party to the following transactions with related parties. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In December&#160;2023, the Company entered into the 2023 Notes Agreement with multiple
            investors, including existing related party investors (see Note&#160;8). The portion of the 2023 Warrants with related parties is separately presented on the unaudited condensed consolidated balance sheets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company entered into the 2025 Notes Agreement exclusively with existing
            related party investors (see Note&#160;8). During the year ended December&#160;31, 2025, the Company received $15.0&#160;million in proceeds from related parties under the 2025 Notes Agreement, as allocated to the convertible notes payable, warrant liability,
            and contingent tranche liability lines on the unaudited condensed consolidated balance sheets based on relative fair value (see Note&#160;3). Upon the Second Tranche Closing in March&#160;2026, the remaining $15.0&#160;million was received and similarly
            accounted for on the unaudited condensed consolidated balance sheets. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">There were no other amounts due to or from related parties as of March&#160;31, 2026
            or December&#160;31, 2025. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">18. Net Loss per Share </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Basic and diluted net loss per share attributable to common stockholders was
            calculated as follows (in thousands, except share and per share amounts): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 348pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 105pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 105pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 348pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Numerator:<br/>
                  </div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net loss attributable to common stockholders</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 9.17pt;">(16,615)</span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<span style="padding-left: 9.17pt;">(21,382) </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Denominator:<br/>
                  </div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Weighted-average common shares outstanding, basic and diluted</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,825,834</span></div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,649,176 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 348pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss per share attributable to common stockholders, basic and diluted</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 19.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(2.12</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 19.17pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(2.80</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 348pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table sets forth the number of shares underlying instruments
            outstanding at the end of the reporting period that have potential dilutive impacts but have been excluded from the calculation of net loss per share attributable to common stockholders because their effect would have been anti-dilutive: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 113.31pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 113.31pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible preferred stock (as converted to common stock)</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">118,136,265</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">87,203,974 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options to purchase common stock</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 4.63pt;">17,382,106</span></div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">20,257,345 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warrants issued in relation to a line of credit</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 17.13pt;">143,549</span></div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 12.5pt;">143,549</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Warrants issued in relation to 2023 convertible promissory notes payable</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.63pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 9.63pt;">5,753,715</span></div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 35pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.63pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.34pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company also had certain other financial instruments outstanding as of
            March&#160;31, 2026 which could obligate the Company to issue shares of common stock upon the occurrence of various future events at prices and in amounts that are not determinable until the occurrence of those future events. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For the three months ended March&#160;31, 2026, these instruments included convertible
            promissory notes and warrants issued as part of the 2025 Notes Agreement (see Note&#160;8). As the necessary conditions for the conversion or exercise of these instruments had not been satisfied as of March&#160;31, 2026, the Company has excluded these
            instruments from the table above. </div>

          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">19. Retirement Plan </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company sponsors a defined contribution plan covering substantially all its
            employees who meet certain eligibility requirements. The Company matches 50% up to 6% of employee contributions. The Company, at the discretion of the Board, may make contributions to the plan. The Company made contributions of $0.1&#160;million for
            both the three months ended March&#160;31, 2026 and 2025. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-101<br/>
        </div>

      </div>

    </div>

    <!--End Page 435-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 436-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">20. Segment Information </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company manages its operations on a consolidated basis as a single reportable
            segment focused on developing small molecule therapeutics to modulate RNA processing and address the underlying drivers of disease. The accounting policies of the single reportable segment are identical to those described in Note&#160;2,<span style="font-style: italic;"> Summary of Significant Accounting Policies, </span>of the Company&#8217;s audited financial statements for the year ended December&#160;31, 2025 included elsewhere in this proxy statement/prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Company&#8217;s chief operating decision-maker (the &#8220;CODM&#8221;), its Chief Executive
            Officer, regularly reviews consolidated net loss and significant income and expense categories and compares to the budget when evaluating the Company&#8217;s financial performance. The significant expense categories and amounts regularly provided to
            the CODM and included in consolidated net loss are presented in the table below. The CODM allocates resources based on the Company&#8217;s available cash resources and forecasted expenditures on a consolidated basis. Segment information regularly
            provided to the CODM is consistent with that reported on the unaudited condensed consolidated balance sheets, with particular emphasis on the Company&#8217;s available liquidity, including its cash and cash equivalents balances. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of March&#160;31, 2026 and December&#160;31, 2025, all of the Company&#8217;s long-lived
            assets are located in the U.S., and the Company&#8217;s collaboration revenue was attributed to Switzerland for Roche and to the U.S. for Janssen (see Note&#160;7). As of the termination of the Janssen Agreement in July&#160;2026, all collaboration revenue is
            expected to be derived in Switzerland (see Note&#160;21). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table presents certain financial data for the Company&#8217;s reportable
            segment (in thousands): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 89.84pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Collaboration revenue</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="font-weight: normal; padding-left: 15.83pt;">831</span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 15.83pt;">690 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development expenses:<br/>
                  </div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,579</span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,062 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">MYB program</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">6,258</span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">5,324 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Other preclinical programs</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">1,222</span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,868 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Facilities, laboratory supplies and other</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,041</span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,301 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative expenses:<br/>
                  </div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Personnel costs</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">1,230</span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">1,630 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Facilities, laboratory supplies and other</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,842</span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">2,645 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other segment items*</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,274</span></div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,242</span><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss and comprehensive loss</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(16,615</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(21,382</span><span style="padding-bottom: 0.5pt;">)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 12.75pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Other segment items consist of other (expense) income and income tax expense. Other (expense) income primarily consists of
                    interest income and the change in fair value of convertible notes payable, warrant liabilities and contingent tranche liability. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">21. Subsequent Events </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For its unaudited condensed consolidated financial statements as of and for the
            three months ended March&#160;31, 2026, the Company evaluated subsequent events through July&#160;21, 2026, the date on which those financial statements were issued. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Proposed Merger and Concurrent Financing </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On June&#160;24, 2026, Remix entered into an Agreement and Plan of Merger (the &#8220;Merger
            Agreement&#8221;) with Passage Bio, Inc. (&#8220;Passage Bio&#8221;) and Peregrine Merger Sub, Inc., a wholly owned subsidiary of Passage Bio (&#8220;Merger Sub&#8221;). Subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub
            will merge with and into Remix, with Remix continuing as a wholly owned subsidiary of Passage Bio and the surviving corporation of the merger (the &#8220;Merger&#8221;). In connection with the Merger, Passage Bio will change its name to &#8220;Remix
            Therapeutics, Inc.&#8221; Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each then outstanding share of Remix&#8217;s common stock (including shares of common stock issued upon
            conversion of Remix&#8217;s preferred stock, shares of Remix&#8217;s common stock issued upon </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-102<br/>
        </div>

      </div>

    </div>

    <!--End Page 436-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 437-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_209-finnotes03_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">conversion of Remix&#8217;s convertible notes and warrants and shares of Remix&#8217;s
            common stock issued in the Concurrent Financing described below) will be converted into the right to receive a number of shares of Passage Bio&#8217;s common stock calculated in accordance with the Merger Agreement. The combined company is expected
            to be led by Remix&#8217;s management team and will focus on developing small molecule therapeutics to modulate RNA processing and address the underlying drivers of disease. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Concurrently with entering into the Merger Agreement, Remix entered into (i) a
            subscription agreement (the &#8220;Subscription Agreement&#8221;) for the sale of shares of Remix common stock for an aggregate purchase price of approximately $70.0 million and (ii) a convertible promissory note purchase agreement (the &#8220;2026
            Note&#160;Agreement&#8221;) for the sale of approximately $30.0&#160;million aggregate principal amount of convertible notes (the &#8220;2026 Notes&#8221;) that will convert into shares of Remix common stock based on the same aggregate equity value of Remix being used in
            the Merger. The sale of common stock pursuant to the Subscription Agreement and the issuance of the 2026 Notes pursuant to the 2026 Note&#160;Agreement are expected to result in aggregate gross proceeds to Remix of approximately $100.0 million (the
            &#8220;Concurrent Financing&#8221;). The issuance of Remix common stock pursuant to the Subscription Agreement and the conversion of the 2026 Notes into shares of Remix common stock are contingent on and will occur immediately prior to the Effective Time.
            Shares of Remix common stock issued in the Concurrent Financing will be converted into shares of Passage Bio common stock at the Effective Time in accordance with the terms of the Merger Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger is expected to close in the fourth quarter of 2026 and is subject to
            approval by the stockholders of Remix and Passage Bio as well as other customary closing conditions, including the effectiveness of a registration statement filed with the SEC in connection with the transaction. Under certain circumstances, the
            Company could be required to pay Passage Bio a termination fee of $17.5&#160;million, and Passage Bio could be required to pay the Company a termination fee of $1.5&#160;million. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In June&#160;2026, the Company received $30.0&#160;million in proceeds from the 2026 Notes
            related to the 2026 Notes Agreement. The notes remained outstanding as of the financial statement issuance date, and conversion is contingent upon the closing of the Merger. </div>

          <div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Termination of the Janssen Agreement </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On July 1, 2026, Janssen gave notice of termination of the Janssen Agreement,
            which will be effective on August 30, 2026. Remix will have no further obligations under the Janssen Agreement upon its termination. Accordingly, the Company expects to recognize the remaining deferred revenue balance associated with the
            Janssen Agreement during the period ending September&#160;30, 2026. The Company will not recognize any additional collaboration revenue under the Janssen Agreement after recognition of the remaining deferred revenue balance. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-103<br/>
        </div>

      </div>

    </div>

    <!--End Page 437-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 438-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;">
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANNEXA"><!--Anchor--></a>Annex&#160;A<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: right;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: right;"><span style="font-style: italic;">EXECUTION VERSION</span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">AGREEMENT AND PLAN OF MERGER <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">by and among: <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">PASSAGE BIO, INC.; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">PEREGRINE MERGER SUB, INC.; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">and <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Dated as of June&#160;24, 2026 </div>

        </div>

      </div>

    </div>

    <!--End Page 438-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 439-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 378pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA1">ARTICLE&#160;I DEFINITIONS AND INTERPRETATIVE PROVISIONS</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA1"><span style="padding-left: 4.5pt;">A-2 </span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS11">1.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS11">Definitions</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS11"><span style="padding-left: 4.5pt;">A-2</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS12">1.2</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS12">Other Definitional and Interpretative Provisions</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS12">A-14 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA2">ARTICLE&#160;II THE MERGER</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA2">A-15</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS21">2.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS21">The Merger</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS21">A-15 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS22">2.2</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS22">Closing</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS22">A-15 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS23">2.3</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS23">Organizational Documents; Directors and Officers</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS23">A-16 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS24">2.4</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS24">Conversion of Remix Convertible Notes; Effect on
                      Shares; Treatment of Remix Options and Remix Warrants</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS24">A-16 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS25">2.5</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS25">Contingent Value Right.</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS25">A-18 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS26">2.6</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS26">Closing of Remix&#8217;s Transfer Books</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS26">A-18 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS27">2.7</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS27">Surrender of Remix Common Stock</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS27">A-18</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS28">2.8</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS28">Calculation of Net Cash</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS28">A-19</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS29">2.9</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS29">Further Action</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS29">A-20</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS210">2.10</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS210">Withholding</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS210">A-20</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS211">2.11</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS211">Statutory Rights of Appraisal</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS211">A-20</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA3">ARTICLE&#160;III REPRESENTATIONS AND WARRANTIES OF REMIX</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA3">A-21 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS31">3.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS31">Due Organization; Subsidiaries</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS31">A-21</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS32">3.2</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS32">Organizational Documents</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS32">A-21</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS33">3.3</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS33">Authority; Binding Nature of Agreement</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS33">A-21</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS34">3.4</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS34">Vote Required</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS34">A-21 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS35">3.5</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS35">Non-Contravention; Consents</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS35">A-22 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS36">3.6</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS36">Capitalization</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS36">A-22 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS37">3.7</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS37">Financial Statements</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS37">A-23 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS38">3.8</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS38">Absence of Changes</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS38">A-24</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS39">3.9</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS39">Absence of Undisclosed Liabilities</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS39">A-24</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS310">3.10</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS310">Title to Assets</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS310">A-25</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS311">3.11</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS311">Real Property; Leasehold</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS311">A-25 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS312">3.12</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS312">Intellectual Property</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS312">A-25 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS313">3.13</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS313">Agreements, Contracts and Commitments</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS313">A-29 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS314">3.14</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS314">Compliance; Permits; Restrictions</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS314">A-30 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS315">3.15</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS315">Legal Proceedings; Orders</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS315">A-32 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS316">3.16</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS316">Tax Matters</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS316">A-32 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS317">3.17</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS317">Employee and Labor Matters; Benefit Plans</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS317">A-33 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS318">3.18</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS318">Environmental Matters</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS318">A-35 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS319">3.19</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS319">Insurance</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS319">A-35</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS320">3.20</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS320">Transactions with Affiliates</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS320">A-35 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS321">3.21</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS321">No Financial Advisors</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS321">A-36 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS322">3.22</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS322">Privacy and Data Security</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS322">A-36 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS323">3.23</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS323">Concurrent Financing</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS323">A-36 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS324">3.24</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS324">No Other Representations or Warranties</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS324">A-37 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA4">ARTICLE&#160;IV REPRESENTATIONS AND WARRANTIES OF PASSAGE
                      AND MERGER SUB</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA4">A-37 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS41">4.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS41">Due Organization; Subsidiaries</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS41">A-37 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS42">4.2</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS42">Organizational Documents</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS42">A-37</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS43">4.3</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS43">Authority; Binding Nature of Agreement</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS43">A-37</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS44">4.4</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS44">Vote Required</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS44">A-38 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS45">4.5</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS45">Non-Contravention; Consents</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS45">A-38 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS46">4.6</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS46">Capitalization</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS46">A-39</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 378pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-i<br/>
        </div>

      </div>

    </div>

    <!--End Page 439-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 440-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 378pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS47">4.7</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS47">SEC Filings; Financial Statements</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS47">A-40 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS48">4.8</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS48">Absence of Changes</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS48">A-41 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS49">4.9</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS49">Absence of Undisclosed Liabilities</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS49">A-42 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS410">4.10</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS410">Title to Assets</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS410">A-42</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS411">4.11</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS411">Real Property; Leasehold</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS411">A-42</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS412">4.12</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS412">Intellectual Property</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS412">A-42 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS413">4.13</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS413">Agreements, Contracts and Commitments</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS413">A-46 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS414">4.14</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS414">Compliance; Permits; Restrictions</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS414">A-47 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS415">4.15</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS415">Legal Proceedings; Orders</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS415">A-49 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS416">4.16</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS416">Tax Matters</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS416">A-49 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS417">4.17</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS417">Employee and Labor Matters; Benefit Plans</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS417">A-50 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS418">4.18</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS418">Environmental Matters</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS418">A-52 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS419">4.19</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS419">Insurance</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS419">A-52 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS420">4.20</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS420">Transactions with Affiliates</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS420">A-53 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS421">4.21</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS421">No Financial Advisors</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS421">A-53</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS422">4.22</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS422">Valid Issuance; No Bad Actor</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS422">A-53 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS423">4.23</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS423">Privacy and Data Security</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS423">A-53</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS424">4.24</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS424">No Other Representations or Warranties</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS424">A-53</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA5">ARTICLE&#160;V COVENANTS</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA5">A-54 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS51">5.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS51">Conduct of Remix&#8217;s Business</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS51">A-54 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS52">5.2</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS52">Conduct of Passage&#8217;s Business</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS52">A-55 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS53">5.3</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS53">Access and Investigation.</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS53">A-57 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS54">5.4</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS54">No Solicitation.</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS54">A-57 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS55">5.5</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS55">Notification of Certain Matters</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS55">A-59 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS56">5.6</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS56">Legacy Asset Disposition</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS56">A-59</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS57">5.7</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS57">Registration Statement; Proxy Statement</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS57">A-59 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS58">5.8</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS58">Remix Stockholder Written Consent.</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS58">A-60 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS59">5.9</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS59">Passage Stockholder Meeting.</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS59">A-62 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS510">5.10</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS510">Efforts; Regulatory Approvals.</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS510">A-63</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS511">5.11</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS511">Disclosures</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS511">A-64 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS512">5.12</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS512">Passage Options</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS512">A-64</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS513">5.13</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS513">Passage Restricted Stock Unit Awards</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS513">A-64 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS514">5.14</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS514">Passage SPP</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS514">A-65</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS515">5.15</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS515">Indemnification of Officers and Directors</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS515">A-65 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS516">5.16</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS516">Tax Matters</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS516">A-66 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS517">5.17</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS517">Listing</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS517">A-66</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS518">5.18</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS518">Legends</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS518">A-67 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS519">5.19</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS519">Officers and Directors</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS519">A-67 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS520">5.20</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS520">Termination of Certain Agreements and Rights</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS520">A-67 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS521">5.21</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS521">Section&#160;16 Matters</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS521">A-67 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS522">5.22</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS522">Allocation Certificate</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS522">A-68 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS523">5.23</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS523">Obligations of Merger Sub</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS523">A-68 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS524">5.24</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS524">Takeover Statutes</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS524">A-68 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS525">5.25</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS525">Stockholder Litigation</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS525">A-68</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS526">5.26</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS526">Concurrent Financing</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS526">A-68 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS527">5.27</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS527">Passage Equity Plans</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS527">A-69 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS528">5.28</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS528">Passage 401(k) Plan</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS528">A-69</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS529">5.29</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS529">Employees</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS529">A-70 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS530">5.30</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS530">Section&#160;280G</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS530">A-70 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA6">ARTICLE&#160;VI CONDITIONS TO CONSUMMATION OF THE MERGER</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA6">A-70</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS61">6.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS61">Conditions Precedent to Obligations of Each Party</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS61">A-70 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS62">6.2</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS62">Conditions Precedent to Obligations of Remix</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS62">A-71 </a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 378pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-ii<br/>
        </div>

      </div>

    </div>

    <!--End Page 440-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 441-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 378pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS63">6.3</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS63">Conditions Precedent to Obligations of Passage</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.79pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS63">A-72 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS64">6.4</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS64">Frustration of Closing Conditions</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS64">A-72 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA7">ARTICLE&#160;VII CLOSING DELIVERIES</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA7">A-72</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS71">7.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS71">Closing Deliveries of Remix</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS71">A-72 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS72">7.2</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS72">Closing Deliveries of Passage</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS72">A-73 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA8">ARTICLE&#160;VIII TERMINATION</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA8">A-73</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS81">8.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS81">Termination</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS81">A-73 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS82">8.2</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS82">Effect of Termination</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS82">A-74 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS83">8.3</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS83">Expenses; Termination Fees.</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS83">A-74 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAA9">ARTICLE&#160;IX GENERAL PROVISIONS</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAA9">A-76</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS91">9.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS91">Non-Survival of Representations and Warranties</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS91">A-76</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS92">9.2</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS92">Amendment</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS92">A-76</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS93">9.3</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS93">Waiver</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS93">A-76 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS94">9.4</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS94">Entire Agreement; Counterparts; Exchanges by
                      Electronic Transmission or Facsimile</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS94">A-76 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS95">9.5</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS95">Applicable Law; Jurisdiction</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS95">A-76 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS96">9.6</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS96">Assignability</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS96">A-77</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS97">9.7</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS97">Notices</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS97">A-77</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS98">9.8</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS98">Cooperation</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS98">A-77</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS99">9.9</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS99">Severability</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS99">A-77 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS910">9.10</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS910">Other Remedies; Specific Performance</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; padding-bottom: 1.25pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS910">A-78 </a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS911">9.11</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 378pt; padding-top: 0.92pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXAS911">No Third-Party Beneficiaries</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 0.92pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 2.75pt; text-align: left;"><a href="#tANXAS911">A-78</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 378pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 21.5pt; margin-left: 0pt; text-align: left;">EXHIBITS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 60pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 396pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 60pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;A</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 396pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Passage Stockholder Support Agreement </div>
                </td>

  </tr>

  <tr>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;B </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Remix Stockholder Support Agreement </div>
                </td>

  </tr>

  <tr>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;C</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Passage Lock-Up Agreement </div>
                </td>

  </tr>

  <tr>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;D</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Remix Lock-Up Agreement </div>
                </td>

  </tr>

  <tr>

    <td style="width: 60pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;E</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 396pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Certificate of Incorporation of the Surviving Corporation </div>
                </td>

  </tr>

  <tr>

    <td style="width: 60pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit&#160;F</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 396pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of CVR Agreement</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 60pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 396pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-iii<br/>
        </div>

      </div>

    </div>

    <!--End Page 441-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 442-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tANXA"><!--Anchor--></a><a id="tANA"><!--Anchor--></a>AGREEMENT AND
            PLAN OF MERGER </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This <span style="font-variant: small-caps;">Agreement And Plan Of Merger</span>
            (this &#8220;<span style="font-weight: bold;">Agreement</span>&#8221;) is made and entered into as of June&#160;24, 2026, by and among <span style="font-variant: small-caps;">Passage Bio, Inc.,</span> a Delaware corporation (&#8220;<span style="font-weight: bold;">Passage</span>&#8221;),

            <span style="font-variant: small-caps;">Peregrine Merger Sub, Inc.</span>, a Delaware corporation and a direct, wholly owned subsidiary of Passage (&#8220;<span style="font-weight: bold;">Merger Sub</span>&#8221;), and <span style="font-variant: small-caps;">Remix Therapeutics, Inc., </span>a Delaware corporation (&#8220;<span style="font-weight: bold;">Remix</span>&#8221;). Certain capitalized terms used in this Agreement are defined in <span style="text-decoration: underline;">Section&#160;1.1</span>. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">RECITALS </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage and Remix intend to effect a merger of Merger Sub with and into Remix (the &#8220;<span style="font-weight: bold;">Merger</span>&#8221;)

                    in accordance with this Agreement and Delaware Law. Upon consummation of the Merger, Merger Sub will cease to exist, and Remix will become a wholly owned subsidiary of Passage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">B.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The board of directors of Passage (the &#8220;<span style="font-weight: bold;">Passage Board</span>&#8221;) has (i) determined that the
                    Contemplated Transactions are fair to, advisable and in the best interests of Passage and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of
                    Passage Common Stock to the stockholders of Remix pursuant to the terms of this Agreement, the change of control of Passage and the other actions contemplated by this Agreement, and (iii) determined to recommend, upon the terms and
                    subject to the conditions set forth in this Agreement, that the stockholders of Passage vote to (a) approve the issuance of Passage Common Stock in the Merger and the change of control resulting from the Merger in accordance with Nasdaq
                    Listing Rule&#160;5635 (the &#8220;<span style="font-weight: bold;">Nasdaq Issuance Proposal</span>&#8221;) and (b) adopt the Amended and Restated Passage Charter (the &#8220;<span style="font-weight: bold;">Passage Charter Amendment Proposal</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">C.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The board of directors of Merger Sub (the &#8220;<span style="font-weight: bold;">Merger Sub Board</span>&#8221;) has (i)&#160;determined that
                    the Contemplated Transactions are fair to, advisable, and in the best interests of Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to
                    recommend, upon the terms and subject to the conditions set forth in this Agreement, that Passage, in its capacity as the sole stockholder of Merger Sub, vote to adopt this Agreement and thereby approve the Contemplated Transactions.
                    Immediately prior to the execution and delivery of this Agreement, Passage, in its capacity as the sole stockholder of Merger Sub, duly executed and delivered a written consent approving and adopting this Agreement in accordance with
                    Delaware Law, which written consent, by its terms, will be effective immediately following the execution of this Agreement (the &#8220;<span style="font-weight: bold;">Merger Sub Stockholder Approval</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">D.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The board of directors of Remix (the &#8220;<span style="font-weight: bold;">Remix Board</span>&#8221;) has (i) determined that the
                    Contemplated Transactions are fair to, advisable and in the best interests of Remix and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the
                    terms and subject to the conditions set forth in this Agreement, that the stockholders of Remix vote to adopt this Agreement and thereby approve the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">E.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Remix&#8217;s willingness to
                    enter into this Agreement, the stockholders, officers and directors of Passage set forth on <span style="text-decoration: underline;">Section&#160;A</span> of the Passage Disclosure Schedule (solely in their capacity as stockholders of Passage) are executing support agreements in
                    favor of Remix in substantially the form attached hereto as <span style="text-decoration: underline;">Exhibit&#160;A</span> (the &#8220;<span style="font-weight: bold;">Passage Stockholder Support Agreement</span>&#8221;), pursuant to which such Persons have, subject to the terms and
                    conditions set forth therein, agreed to vote all of their shares of Passage Common Stock in favor of the Passage Stockholder Matters. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Passage&#8217;s willingness to
                    enter into this Agreement, the officers, directors and stockholders of Remix set forth on <span style="text-decoration: underline;">Section&#160;A</span> of the Remix Disclosure Schedule (solely in their capacity as stockholders of Remix) are executing support agreements in favor
                    of Passage in substantially the form attached hereto as <span style="text-decoration: underline;">Exhibit&#160;B</span> (the &#8220;<span style="font-weight: bold;">Remix Stockholder Support Agreement</span>&#8221;), pursuant to which such Persons have, subject to the terms and conditions set
                    forth therein, agreed to vote all of their shares of Remix Capital Stock in favor of this Agreement and an amendment to Remix&#8217;s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Remix
                    Common Stock from 162,000,000 to 300,000,000 (the &#8220;<span style="font-weight: bold;">Remix Charter Amendment</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">G.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Remix&#8217;s willingness to
                    enter into this Agreement, the officers and directors of Passage set forth on <span style="text-decoration: underline;">Section&#160;B</span> of the Passage Disclosure Schedule are executing lock-up agreements in substantially the form attached hereto as <span style="text-decoration: underline;">Exhibit&#160;C</span>
                    (collectively, the &#8220;<span style="font-weight: bold;">Passage Lock-Up Agreements</span>&#8221;). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 442-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 443-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">H.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Passage&#8217;s willingness to
                    enter into this Agreement, the officers, directors and stockholders of Remix set forth on <span style="text-decoration: underline;">Section&#160;B</span> of the Remix Disclosure Schedule are executing lock-up agreements in substantially the form attached hereto as <span style="text-decoration: underline;">Exhibit&#160;D</span>
                    (collectively, the &#8220;<span style="font-weight: bold;">Remix Lock-Up Agreements</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">It is expected that promptly after the Registration Statement is declared effective under the Securities Act, the
                    stockholders of Remix sufficient to adopt and approve this Agreement and the Merger as required under Delaware Law and Remix&#8217;s Organizational Documents will execute and deliver an action by written consent constituting the Required
                    Remix Stockholder Vote, in a form and substance reasonably acceptable to Passage and Remix (each, a &#8220;<span style="font-weight: bold;">Remix Stockholder Written Consent</span>&#8221; and collectively, the &#8220;<span style="font-weight: bold;">Remix
                      Stockholder Written Consents</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">J.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement, certain investors have executed a Subscription Agreement by
                    and among Remix and the Persons named therein, pursuant to which such Persons have agreed to purchase the number of shares of Remix Capital Stock set forth therein immediately prior to the Effective Time in connection with the
                    Concurrent Financing (the &#8220;<span style="font-weight: bold;">Subscription Agreement</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">K.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Concurrently with the execution and delivery of this Agreement, certain investors have executed a Convertible Promissory
                    Note&#160;Purchase Agreement by and among Remix and the lenders party thereto, pursuant to which such lenders have agreed to purchase the convertible promissory notes concurrently with the execution and delivery of this Agreement in
                    connection with the Concurrent Financing, which convertible promissory notes shall convert into shares of Remix Common Stock in connection with the Remix Convertible Notes Conversion (the &#8220;<span style="font-weight: bold;">Remix
                      Note&#160;Purchase Agreement (2026)</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">L.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of the parties hereto intends that, for United States federal income tax purposes, the Merger will qualify as a
                    &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-weight: bold;">Code</span>&#8221;) and the Treasury Regulations, with respect to which each of Passage, Merger Sub,
                    and Remix are a &#8220;party to a reorganization&#8221; under Section&#160;368(b) of the Code, and this Agreement is intended to constitute a &#8220;plan of reorganization&#8221; for purposes of Sections 354, 361 and 368 of the Code and within the meaning of
                    Section&#160;368 of the Code and Treasury Regulations Section&#160;1.368-2(g) (the &#8220;<span style="font-weight: bold;">Intended Tax Treatment</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;">AGREEMENT </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The Parties, intending to be legally bound, agree as follows: </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;"><a id="tANXAA1"><!--Anchor--></a>ARTICLE I<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">DEFINITIONS AND INTERPRETATIVE PROVISIONS </div>

          <a id="tANXAS11"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Definitions</span>. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">For purposes of this Agreement (including this <span style="text-decoration: underline;">Section 1.1</span>): </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">2026 Equity Incentive Plan</span>&#8221; shall
            mean an equity incentive plan of Passage in form and substance as agreed to by Passage and Remix (such agreement not to be unreasonably withheld, conditioned or delayed by either Party), reserving for issuance a number of shares of Passage
            Common Stock to be mutually agreed upon by Passage and Remix (such agreement not to be unreasonably withheld, conditioned or delayed by either Party). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">2026 ESPP</span>&#8221; shall mean an &#8220;employee
            stock purchase plan&#8221; of Passage in form and substance as agreed to by Passage and Remix (such agreement not to be unreasonably withheld, conditioned or delayed by either Party), reserving for issuance a number of shares of Passage Common Stock
            to be mutually agreed upon by Passage and Remix (such agreement not to be unreasonably withheld, conditioned or delayed by either Party). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">2026 Plans</span>&#8221; shall mean both the 2026
            ESPP and the 2026 Equity Incentive Plan. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Acceptable Confidentiality Agreement</span>&#8221;
            means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any
            standstill, non-solicitation or no hire provisions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Acquisition Inquiry</span>&#8221; means, with
            respect to a Party, an inquiry, indication of interest or request for information (other than an inquiry, indication of interest or request for information made or submitted by Remix, on the one hand, or Passage, on the other hand, to the other
            Party) that would reasonably be expected to lead to an Acquisition Proposal, other than, as applicable, with respect to the Legacy Asset Disposition and the Concurrent Financing. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 443-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 444-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Acquisition Proposal</span>&#8221; means, with
            respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Remix or any of its Affiliates, on the one hand, or by or on behalf of Passage or any of its Affiliates, on
            the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party, other than, as applicable, with respect to the Legacy Asset Disposition and the Concurrent Financing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Acquisition Transaction</span>&#8221; means any
            transaction or series of related transactions (other than, as applicable, the Legacy Asset Disposition and the Concurrent Financing) involving: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of
                    securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (A) in which a Party is a constituent entity, (B) in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules
                    promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its
                    Subsidiaries or (C) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that
                    constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Affiliate</span>&#8221; means, with respect to any
            Person, any other Person directly or indirectly controlling, controlled by, or under common control with such other Person. For purposes of this definition, &#8220;<span style="text-decoration: underline;">control</span>&#8221; when used with respect to any Person means the power to direct the
            management and policies of such Person, directly or indirectly, whether through the ownership of voting securities or partnership or other ownership interests, by contract or otherwise, and the terms &#8220;<span style="text-decoration: underline;">controlling</span>&#8221; and &#8220;<span style="text-decoration: underline;">controlled</span>&#8221;
            have correlative meanings. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Antitrust Laws</span>&#8221; means the Sherman
            Act, the Clayton Act, the Federal Trade Commission Act, the HSR Act, all applicable foreign antitrust Laws and all other applicable Laws issued by a Governmental Authority that are designed or intended to prohibit, restrict or regulate actions
            having the purpose or effect of monopolization or restraint of trade or lessening of competition through merger or acquisition. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Business Day</span>&#8221; means any day other
            than a day on which banks in the State of New York or the State of Pennsylvania are authorized or obligated to be closed. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Cash and Cash Equivalents</span>&#8221; means all
            (i) cash and cash equivalents and (ii) marketable securities, in each case determined in accordance with GAAP. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">COBRA</span>&#8221; means the Consolidated Omnibus
            Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Part&#160;6 of Title I of ERISA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Code</span>&#8221; means the Internal Revenue Code
            of 1986, as amended. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Concurrent Financing</span>&#8221; means (i) the
            issuance and sale of convertible promissory notes to be consummated concurrently with the execution and delivery of this Agreement pursuant to the Remix Note&#160;Purchase Agreement (2026) (such convertible promissory notes, the &#8220;<span style="font-weight: bold;">Remix Convertible Notes (2026)</span>&#8221;), and the issuance of Remix Common Stock resulting from the conversion of the Remix Convertible Notes (2026) into shares of Remix Common Stock pursuant to the Remix Convertible
            Notes Conversion and (ii) the issuance and sale of shares of Remix Capital Stock in a private placement to be consummated immediately prior to the Effective Time pursuant to the Subscription Agreement, with aggregate gross cash proceeds
            pursuant to the transactions described in clause (i) and (ii) of, in the aggregate, at least the Concurrent Investment Amount. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Concurrent Financing Allocation Percentage</span>&#8221;
            means the quotient (rounded to four decimal places) determined by <span style="font-style: italic;">dividing</span> (i) the Concurrent Financing Proceeds <span style="font-style: italic;">by</span> (ii) the Aggregate Valuation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Concurrent Financing Merger Shares</span>&#8221;
            means, subject to <span style="text-decoration: underline;">Section&#160;2.4(g)</span>, the product determined by <span style="font-style: italic;">multiplying</span> (i)&#160;the Post-Closing Passage Shares <span style="font-style: italic;">by</span> (ii) the Concurrent Financing Allocation
            Percentage (rounded down to the nearest whole share). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Concurrent Financing Proceeds</span>&#8221; means the
            proceeds resulting from the Concurrent Financing. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 444-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 445-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Concurrent Investment Amount</span>&#8221; means
            $99,929,000. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Confidentiality Agreement</span>&#8221; means the
            Mutual Confidential Disclosure Agreement, dated as of April&#160;29, 2026, by and between Remix and Passage. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Consent</span>&#8221; means any approval, consent,
            ratification, permission, waiver or authorization (including any Governmental Authorization). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Contemplated Transactions</span>&#8221; means the
            Merger and the other transactions contemplated by this Agreement, including the Remix Preferred Stock Conversion, the Concurrent Financing, the transactions contemplated by the CVR Agreement, the filing of the Amended and Restated Passage
            Charter with the Secretary of State of the State of Delaware and the filing of the Remix Charter Amendment with the Secretary of State of the State of Delaware. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Contract</span>&#8221; means, with respect to any
            Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or
            any of its assets are bound or affected under applicable Law. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Delaware Law</span>&#8221; means the General
            Corporation Law of the State of Delaware. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Effect</span>&#8221; means any effect, change,
            event, circumstance, or development. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Employee Plan</span>&#8221; means (i) each
            &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA whether or not subject to ERISA; (ii) any other plan, program, policy, agreement or arrangement providing for stock options, stock purchases, restricted stock, restricted stock
            units, phantom equity, other equity or equity-based incentives, employment agreements, bonuses, commissions, severance, retention, deferred compensation, change in control, transaction, supplemental income arrangements, vacation, retirement,
            pension, profit-sharing, post-retirement health and welfare, fringe, life insurance, perquisites, health, medical, dental, vision, welfare, employee assistance or similar benefits; and (iii) all other plans, programs, policies, agreements or
            arrangements (whether written or unwritten) providing compensation or benefits to any current or former employee, officer, director, individual independent contractor and other non-employee service provider. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Encumbrance</span>&#8221; means any lien, pledge,
            hypothecation, charge, mortgage, security interest, lease, license, option, easement, reservation, servitude, adverse title, claim, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of
            any similar nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any
            asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Enforceability Exceptions</span>&#8221; means the
            (i) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Entity</span>&#8221; means any corporation
            (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability
            company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Environmental Law</span>&#8221; means any federal,
            state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions,
            discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">ERISA</span>&#8221; means the Employee Retirement
            Income Security Act of 1974, as amended. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">ERISA Affiliate</span>&#8221; means, with respect
            to any Entity, any other Person that would be treated as a single employer with such Entity, part of the same &#8220;controlled group&#8221; as such Entity or under common control with such Entity under Sections 414(b), (c), (m) or (o) of the Code, as
            applicable. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Excepted Contract</span>&#8221; means any and all
            (a)&#160;non-exclusive licenses for generally unmodified and commercially available shrink-wrap, click wrap and off-the-shelf software or software as a service, (b)&#160;Contracts that (i)&#160;have expired on their own terms and have no continuing
            obligations, rights or interests (other than obligations to maintain confidentiality in the ordinary course of business), (ii)&#160;have been assigned to a third party (and to which Remix or </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 445-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 446-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Passage, as applicable, and each of its Subsidiaries is no longer a party
            and has no obligations, rights or interests (other than obligations to maintain confidentiality in the ordinary course of business)) or (iii)&#160;were terminated prior to the date hereof that do not have any continuing obligations, rights or
            interests (other than obligations to maintain confidentiality in the ordinary course of business), (c)&#160;non-disclosure agreements entered into (i)&#160;in the Ordinary Course of Business by Remix or Passage, as applicable, or any of its Subsidiaries
            or (ii)&#160;in connection with discussions, negotiations, and transactions related to this Agreement or any transactions that were evaluated or pursued as an alternative to the transactions contemplated hereby or (d)&#160;materials transfer agreements
            and clinical trial agreements with individual clinical sites, in each case, entered into in the Ordinary Course of Business and that do not transfer ownership of material Intellectual Property to any Person other than Remix or Passage, as
            applicable, or any of its Subsidiaries, or grant rights to use material Intellectual Property for the research, supply, manufacturing, development or commercialization of products (other than on behalf of, or for the benefit of, Remix or
            Passage, as applicable, or any of its Subsidiaries). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Exchange Act</span>&#8221; means the Securities
            Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">GAAP</span>&#8221; means United States generally
            accepted accounting principles. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Governmental Authority</span>&#8221; means any:
            (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (ii) federal, state, local, municipal, foreign, supra-national or other government or institution, (iii) governmental or
            quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other
            tribunal, and for the avoidance of doubt, any taxing authority) or (iv) self-regulatory organization (including Nasdaq). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Governmental Authorization</span>&#8221; means
            any: (i) permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any
            Governmental Authority or pursuant to any Law or (ii) right under any Contract with any Governmental Authority. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Hazardous Materials</span>&#8221; means any
            pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to
            regulation, control or remediation under any Environmental Law, including, without limitation, crude oil or any fraction thereof, and petroleum products or by-products. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">HSR Act</span>&#8221; means the Hart-Scott-Rodino
            Antitrust Improvements Act of 1976, as amended. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Intellectual Property</span>&#8221; means any and
            all intellectual property and similar proprietary rights throughout the world, including any and all state, United States, international and/or foreign or other territorial or regional rights in, arising out of or associated with any of the
            following: (i)&#160;United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisional, continuations, continuations-in-part, reissues, renewals, extensions, supplementary
            protection certificates, reexaminations, term extensions, confirmations, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures and inventions (collectively, &#8220;<span style="font-weight: bold;">Patents</span>&#8221;), (ii) trademarks, service marks, trade names, domain names, corporate names, brand names, URLs or other names and locators associated with the internet, trade dress, logos and other source
            identifiers, including registrations and applications for registration thereof and goodwill associated therewith and symbolized thereby (collectively, &#8220;<span style="font-weight: bold;">Trademarks</span>&#8221;), (iii) works of authorship (whether or
            not copyrightable) and all copyrights, copyrightable works, derivative works, including registrations and applications for registration thereof, and all renewals, extensions, restorations or reversions of the foregoing, including all rights of
            authorship, use, publication, publicity, reproduction, distribution, income, performance and transformation, (iv)&#160;software, including all source code, object code, firmware, development tool files, all media on which any of the foregoing is
            recorded, and all related documentation, (v) all inventions, invention disclosures, improvements, formulae, customer lists, trade secrets, know-how (including recipes, specifications, formulae, manufacturing and other processes, operating
            procedures, methods, techniques and all research and development information), technology, technical data, rights in databases and data collections, and other proprietary rights and intellectual property, whether patentable or not, and all
            documentation relating to any of the foregoing, and (vi) all rights to sue or recover and retain damages and costs and attorneys&#8217; fees for the past, present or future infringement, dilution, misappropriation, or other violation of any of the
            foregoing anywhere in the world. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">IRS</span>&#8221; means the United States Internal
            Revenue Service. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 446-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 447-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Key Employee</span>&#8221; means, with respect
            to any Person, (i) an executive officer of such Person; and (ii) any employee of such Person that reports directly to the chief executive officer of such Person. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Knowledge</span>&#8221; means, (i) of Remix, with
            respect to any matter in question, the actual knowledge of the individuals set forth in <span style="text-decoration: underline;">Section&#160;1.1</span> of the Remix Disclosure Schedule, in each case after reasonable inquiry of those employees who would reasonably be expected to have
            actual knowledge of the matter in question and (ii) of Passage or Merger Sub, with respect to any matter in question, the actual knowledge of individuals set forth in <span style="text-decoration: underline;">Section&#160;1.1(a)(i)</span> of the Passage Disclosure Schedule or the knowledge
            such individual would reasonably be expected to have of such matter in question in the ordinary course of the performance of such individual&#8217;s employment responsibilities. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Law</span>&#8221; means any federal, state,
            national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated,
            implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Legal Proceeding</span>&#8221; means any action,
            suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or
            otherwise involving, any court or other Governmental Authority or any arbitrator or arbitration panel, excluding any office actions and other ex parte proceedings in the ordinary course of prosecuting or maintaining of any registration or
            application for registration of any Patent or Trademark. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Multiemployer Plan</span>&#8221; means a
            &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001 (a)(3) of ERISA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Multiple Employer Plan</span>&#8221; means a
            &#8220;multiple employer plan&#8221; as described in Section&#160;413(e) of ERISA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Multiple Employer Welfare Arrangement</span>&#8221;
            means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Nasdaq</span>&#8221; means The Nasdaq Stock Market.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Notice Period</span>&#8221; means a period of at
            least three (3) Business Days commencing on the date the (i) Passage Board notifies Remix in writing of its intent to make a Passage Board Adverse Recommendation Change or (ii) Remix Board notifies Passage in writing of its intent to make a
            Remix Board Adverse Recommendation Change. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Order</span>&#8221; means any judgment, order,
            writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement, or deferred prosecution agreement with, or any settlement under the jurisdiction of, any
            court or Governmental Authority. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Ordinary Course of Business</span>&#8221; means,
            in the case of each of Remix and Passage, such actions taken in the ordinary course of its normal operations and consistent with its past practices. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Organizational Documents</span>&#8221; means, with
            respect to any Person (other than an individual), (i)&#160;the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating
            or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (ii) all bylaws, regulations and similar documents or agreements relating to the organization or
            governance of such Person, in each case, as amended or supplemented from time to time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Party</span>&#8221;<span style="font-weight: bold;">
              or </span>&#8220;<span style="font-weight: bold;">Parties</span>&#8221; means Remix, Passage and Merger Sub. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Associate</span>&#8221; means any current
            or former employee, officer, director, individual independent contractor or other individual non-employee service provider of Passage or any of its Subsidiaries. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Balance Sheet</span>&#8221; means the
            audited balance sheet of Passage as of December&#160;31, 2024 and December&#160;31, 2025. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Capitalization Representations</span>&#8221;
            means the representations and warranties of Passage and Merger Sub set forth in <span style="text-decoration: underline;">Sections 4.6(a)</span> and <span style="text-decoration: underline;">4.6(d)</span>. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 447-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 448-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Contract</span>&#8221; means any
            Contract: (i) to which Passage or any of its Subsidiaries is a party, (ii) by which Passage or any of its Subsidiaries or any Passage IP Rights or any other asset of Passage or any of its Subsidiaries is or may become bound or under which
            Passage or any of its Subsidiaries has, or may become subject to, any obligation or (iii)&#160;under which Passage or any of its Subsidiaries has or may acquire any right or interest. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Covered Person</span>&#8221; means, with
            respect to Passage as an &#8220;issuer&#8221; for purposes of Rule&#160;506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule&#160;506(d)(1). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Employee Plan</span>&#8221; means any
            Employee Plan that Passage or any of its Subsidiaries (i)&#160;sponsors, maintains, administers, or contributes to, (ii) provides benefits under or through, (iii) has any obligation to contribute to or provide benefits under or through, (iv) may
            reasonably be expected to have any Liability with respect to, or (v) utilizes to provide benefits to or otherwise cover any Passage Associate. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Equity Plans</span>&#8221; means the
            Passage Amended and Restated 2018 Equity Incentive Plan, the Passage 2020 Equity Incentive Plan, and the Passage 2021 Equity Inducement Plan, each as amended from time to time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage ESPP</span>&#8221; means the Passage
            Amended and Restated 2020 Employee Stock Purchase Plan, as amended from time to time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Fundamental Representations</span>&#8221;
            means the representations and warranties of Passage and Merger Sub set forth in <span style="text-decoration: underline;">Sections 4.1(a)</span>, <span style="text-decoration: underline;">4.1(b)</span>, <span style="text-decoration: underline;">4.2</span>, <span style="text-decoration: underline;">4.3</span>, <span style="text-decoration: underline;">4.4</span> and <span style="text-decoration: underline;">4.21</span>. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage IP Rights</span>&#8221; means all
            Intellectual Property that is (i) owned by or purported to be owned, whether wholly or jointly with others, by Passage or any of its Subsidiaries (&#8220;<span style="font-weight: bold;">Passage Owned IP Rights</span>&#8221;), or (ii) licensed or
            sublicensed to Passage or any of its Subsidiaries (&#8220;<span style="font-weight: bold;">Passage Licensed IP Rights</span>&#8221;), in each case, that is necessary for, or used or held for use in, the operation of the business of Passage and its
            Subsidiaries as presently conducted. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage IP Rights Agreement</span>&#8221; means
            any Contract governing, related to or pertaining to any Passage IP Rights, other than any confidential information provided under confidentiality agreements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage ITM Option</span>&#8221; means each
            Passage Option with an exercise price per share less than the closing trading price of a share of Passage Common Stock on the last full trading day on which the Passage Common Stock is traded prior to the date on which the Effective Time
            occurs. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Material Adverse Effect</span>&#8221;
            means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Passage Material Adverse Effect, has had or would reasonably be expected to have a material adverse
            effect on the business, assets, liabilities, financial condition or results of operations of Passage or its Subsidiaries, taken as a whole; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>,
            that Effects arising or resulting from the following, alone or in combination, shall not be taken into account in determining whether there has been a Passage Material Adverse Effect: (i) the announcement of this Agreement, the pendency or the
            consummation of the Contemplated Transactions, including any adverse change in customer, supplier, governmental, landlord, employee or similar relationships resulting therefrom or with respect thereto (other than, in the case of this clause
            (i), for purposes of <span style="text-decoration: underline;">Section&#160;4.3</span>, <span style="text-decoration: underline;">Section&#160;4.4</span>, or <span style="text-decoration: underline;">Section&#160;4.5</span>), (ii) the taking of any action, or the failure to take any action, by Passage that is expressly required under the terms of this Agreement, (iii) any natural
            disasters or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the
            world or any governmental or other response or reaction to any of the foregoing, (iv) any change in GAAP or applicable Law or the interpretation thereof, (v) general economic, financial and capital markets, or political conditions, including
            any instability in the banking sector, including the failure or placement into receivership of any financial institution, in each case generally affecting the industries in which Passage and its Subsidiaries operate, (vi) any change in the cash
            position of Passage and its Subsidiaries which results from operations in the Ordinary Course of Business or expenditures which are reasonably required to effect the wind-down, discontinuation, suspension or termination of any clinical,
            pre-clinical or development program or trial of Passage or any of its Subsidiaries (including the PBFT02 program and the upliFT-D trial), or (vii) any failure of Passage to meet any projections, business plans or forecasts (<span style="font-style: italic;">provided</span> that this clause (vii)&#160;shall not prevent a determination that any change or effect underlying such failure to meet projections, business plans or forecasts has resulted in a Passage Material Adverse
            Effect (to the extent such change or effect is not otherwise excluded from this definition of Passage Material Adverse Effect)); except in each case with respect to clauses (iii), (iv) and (v), to the extent disproportionately affecting Passage
            and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Passage and its Subsidiaries operate. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 448-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 449-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Net Cash</span>&#8221; means, without
            duplication, (i) Passage&#8217;s unrestricted Cash and Cash Equivalents determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial
            statements (including any related notes) contained or incorporated by reference in the Passage Balance Sheet, <span style="font-style: italic;"><span style="text-decoration: underline;">plus</span></span> (ii) all prepaid expenses set forth on Section&#160;1.1(a)(ii) of the Passage
            Disclosure Schedule, <span style="font-style: italic;"><span style="text-decoration: underline;">minus</span></span> (iii) accrued accounts payable due and payable as of the Closing in accordance with GAAP, including, without limitation, all lease termination costs and all other fees
            and expenses of Passage incurred in connection with the Contemplated Transactions, including, for the avoidance of doubt, Transaction Expenses of Passage, <span style="font-style: italic;"><span style="text-decoration: underline;">minus</span></span> (iv) contractual commitments for
            future cash payments, whether absolute, contingent or otherwise, under Passage Real Estate Leases, netted against cash amounts received or reasonably expected to be received pursuant to sublease arrangements with respect to Passage Real Estate
            Leases, <span style="font-style: italic;"><span style="text-decoration: underline;">minus</span></span> (v) expenses (including Taxes) of Passage incurred in connection with, related to or associated with the disposition of Legacy Assets and any contingent obligations or liabilities
            (including the full amount of any indemnity obligations) arising from such dispositions, <span style="font-style: italic;"><span style="text-decoration: underline;">minus</span> </span>(vi) any Liabilities of Passage (A) for any cash payment to or for the benefit of any Passage
            Associate for change in control or transaction bonuses, retention bonuses, severance or similar compensatory payments or benefits that are payable under the terms of Passage Contracts in effect prior to the Effective Time as a result of, or in
            connection with, the completion of the Contemplated Transactions, whether alone or together with any other event (including payments with &#8220;double trigger&#8221; provisions related to terminations occurring at or prior to the Closing) (in each case,
            including the employer portion of any payroll or similar Taxes payable with respect thereto), (B) with respect to the unfunded or underfunded portion of any accrued employer contributions to a defined contribution or any post-retirement health
            and welfare benefit plan that remain unpaid as of Closing, and (C) accrued but unpaid bonuses, severance and vacation or paid time off (including the employer portion of any payroll or similar Taxes payable with respect thereto), and <span style="font-style: italic;"><span style="text-decoration: underline;">minus</span></span> (vii) the RSU Withholding Amount and the employer portion of any payroll or similar Taxes payable as a result of the vesting and settlement of each outstanding and unvested Passage Restricted
            Stock Unit Award pursuant to <span style="text-decoration: underline;">Section&#160;5.13</span>. For the avoidance of doubt, (1) the Cash and Cash Equivalents received in the Concurrent Financing will be excluded from the calculation of Passage Net Cash and (2) the Cash and Cash
            Equivalents received from the disposition of Legacy Assets will be included in the calculation of Passage Net Cash. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Options</span>&#8221; means options to
            purchase shares of Passage Common Stock granted by Passage, including, without limitation, under the Passage Equity Plans, but, for the avoidance of doubt, excluding the Passage ESPP. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Registered IP</span>&#8221; means all
            Passage IP Rights that are owned or exclusively licensed by Passage or any of its Subsidiaries that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all Patents, registered copyrights and
            registered trademarks and all applications for any of the foregoing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Restricted Stock Unit Awards</span>&#8221;
            means restricted stock unit awards covering shares of Passage Common Stock granted by Passage, including, without limitation, restricted stock unit awards granted under the Passage 2020 Equity Incentive Plan and the Passage 2021 Equity
            Inducement Plan. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Triggering Event</span>&#8221; shall be
            deemed to have occurred if: (i) Passage shall have failed to include in the Proxy Statement the Passage Board Recommendation, (ii) the Passage Board or any committee thereof evaluating any Acquisition Proposal shall have made a Passage Board
            Adverse Recommendation Change or approved, endorsed or recommended any Acquisition Proposal (other than with Remix), (iii) Passage shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition
            Proposal (other than an Acceptable Confidentiality Agreement pursuant to <span style="text-decoration: underline;">Section&#160;5.4</span>) or (iv) the Passage Board or any committee thereof evaluating any Acquisition Proposal shall have failed to recommend against any Acquisition Proposal
            that is a tender offer or exchange offer within 10 Business Days after the commencement thereof. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Permitted Encumbrance</span>&#8221; means (i) any
            statutory liens for Taxes not yet due and payable or for Taxes that are being contested in good faith and for which adequate reserves have been made on the Remix Unaudited Balance Sheet or the Passage Balance Sheet, as applicable, in accordance
            with GAAP, (ii) liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of Remix or Passage,
            as applicable, (iii) statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements, (iv) deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment
            insurance or similar programs mandated by Law, (v)&#160;statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies, (vi) imperfections of title and (vii) liens arising under
            applicable securities Laws. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Person</span>&#8221; means any individual, Entity or
            Governmental Authority. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 449-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 450-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Personal Information</span>&#8221; means any
            information concerning an identified or identifiable natural person. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Privacy Laws</span>&#8221; mean Laws relating to
            privacy, security and/or collection, use or other processing of Personal Information. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Associate</span>&#8221; means any current or
            former employee, officer, director, individual independent contractor or other individual non-employee service provider of Remix or any of its Subsidiaries. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Remix Balance Sheet</span>&#8221; means the audited
            balance sheet of Remix as of December&#160;31, 2024<span style="font-weight: bold;">.</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Remix Capital Stock</span>&#8221; means Remix
            Common Stock and Remix Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Capitalization Representations</span>&#8221;
            means the representations and warranties of Remix set forth in <span style="text-decoration: underline;">Sections&#160;3.6(a)</span> and <span style="text-decoration: underline;">3.6(d)</span>. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Remix Common Stock</span>&#8221; means the common
            stock, $0.0001 par value per share, of Remix. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Contract</span>&#8221; means any Contract:
            (i) to which Remix or any of its Subsidiaries is a party, (ii) by which Remix or any of its Subsidiaries, any Remix IP Rights or any other asset of Remix or any of its Subsidiaries is or may become bound or under which Remix or any of its
            Subsidiaries has, or may become subject to, any obligation or (iii) under which Remix or any of its Subsidiaries has or may acquire any right or interest. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Convertible Notes</span>&#8221; means the
            outstanding unsecured convertible promissory notes, issued by Remix pursuant to the Remix Note&#160;Purchase Agreements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Employee Plan</span>&#8221; means any
            Employee Plan that Remix or any of its Subsidiaries (i)&#160;sponsors, maintains, administers, or contributes to, (ii) provides benefits under or through, (iii) has any obligation to contribute to or provide benefits under or through, (iv) may
            reasonably be expected to have any Liability with respect to, or (v) utilizes to provide benefits to or otherwise cover any Remix Associate (or their spouses, dependents, or beneficiaries). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Remix Equity Plan</span>&#8221; means the Remix 2019
            Stock Plan, as amended from time to time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Exchange Ratio</span>&#8221; means the
            quotient obtained by dividing (i) the number of Remix Merger Shares by (ii) the number of Remix Outstanding Shares. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Fundamental Representations</span>&#8221;
            means the representations and warranties of Remix set forth in <span style="text-decoration: underline;">Sections&#160;3.1(a)</span>, <span style="text-decoration: underline;">3.1(b)</span>, <span style="text-decoration: underline;">3.2</span>, <span style="text-decoration: underline;">3.3</span>, <span style="text-decoration: underline;">3.4</span> and <span style="text-decoration: underline;">3.20</span>. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix IP Rights</span>&#8221; means all
            Intellectual Property that is (i) owned by or purported to be owned, whether wholly or jointly with others, by Remix or any of its Subsidiaries (&#8220;<span style="font-weight: bold;">Remix Owned IP Rights</span>&#8221;), or (ii) licensed or sublicensed
            to Remix or any of its Subsidiaries (&#8220;<span style="font-weight: bold;">Remix Licensed IP Rights</span>&#8221;), in each case, that is necessary for, or used or held for use in, the operation of the business of Remix and its Subsidiaries as presently
            conducted. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix IP Rights Agreement</span>&#8221; means any
            Contract governing, related to or pertaining to any Remix IP Rights other than any confidential information provided under confidentiality agreements. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Material Adverse Effect</span>&#8221; means
            any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Remix Material Adverse Effect, has had or would reasonably be expected to have a material adverse effect on
            the business, assets, liabilities, financial condition or results of operations of Remix or its Subsidiaries, taken as a whole; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that Effects
            arising or resulting from the following, alone or in combination, shall not be taken into account in determining whether there has been a Remix Material Adverse Effect: (i) the announcement of this Agreement, the pendency or the consummation of
            the Contemplated Transactions, including any adverse change in customer, supplier, governmental, landlord, employee or similar relationships resulting therefrom or with respect thereto (other than, in the case of this clause (i), for purposes
            of <span style="text-decoration: underline;">Section&#160;3.3</span>, <span style="text-decoration: underline;">Section&#160;3.4</span>, or <span style="text-decoration: underline;">Section&#160;3.5</span>), (ii) the taking of any action, or the failure to take any action, by Remix that is expressly required under the terms of this Agreement, (iii) any natural disasters or
            epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any
            governmental or other response or reaction to any of the foregoing, (iv) any change in GAAP or applicable Law or the interpretation thereof, (v) general economic, financial and capital markets, or political conditions, including any instability
            in the banking sector, including the failure or placement into receivership of any financial institution, in each case generally affecting the industries in which Remix and its Subsidiaries operate, (vi)&#160;any change in the cash position of Remix
            and its Subsidiaries which results from operations in the Ordinary Course of Business, or (vii) any failure of Remix to meet any </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 450-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 451-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">projections, business plans or forecasts (<span style="font-style: italic;">provided</span>
            that, this clause (vii) shall not prevent a determination that any change or effect underlying such failure to meet projections, business plans or forecasts has resulted in a Remix Material Adverse Effect (to the extent such change or effect is
            not otherwise excluded from this definition of Remix Material Adverse Effect)); except in each case with respect to clauses (iii), (iv) and (v), to the extent disproportionately affecting Remix and its Subsidiaries, taken as a whole, relative
            to other similarly situated companies in the industries in which Remix and its Subsidiaries operate. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Merger Shares</span>&#8221; means, subject
            to <span style="text-decoration: underline;">Section&#160;2.4(g)</span>, the product determined by <span style="font-style: italic;"><span style="text-decoration: underline;">multiplying</span></span> (i) the Post-Closing Passage Shares <span style="font-style: italic;">by </span>(ii) the Remix Allocation Percentage, in which:
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Aggregate Valuation</span>&#8221; means the sum
            of (A) the Remix Equity Value, <span style="font-style: italic;">plus</span> (B)&#160;the Passage Valuation, <span style="font-style: italic;">plus</span> (C)&#160;the Concurrent Financing Proceeds. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Allocation Percentage</span>&#8221; means
            the quotient (rounded to four decimal places) determined by <span style="font-style: italic;"><span style="text-decoration: underline;">dividing</span></span> (A) the Passage Valuation <span style="font-style: italic;"><span style="text-decoration: underline;">by</span></span> (B) the Aggregate Valuation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-weight: bold;">Passage Equity Value</span>&#8221; means
            $20,000,000. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Outstanding Shares</span>&#8221; means,
            subject to <span style="text-decoration: underline;">Section&#160;2.4(g)</span> (including, if applicable and without limitation, the effects of the Reverse Stock Split and filing the Amended and Restated Passage Charter), the total number of shares of Passage Common Stock outstanding
            immediately prior to the Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication, (A) the issuance of shares of Passage Common Stock in respect of all Passage ITM Options that will be outstanding as of
            immediately prior to the Effective Time calculated on a &#8220;treasury method&#8221; basis (and, for the avoidance of doubt, excluding any shares of Passage Common Stock in respect of Passage Options that are not Passage ITM Options), (B) the settlement
            in shares of Passage Common Stock of Passage Restricted Stock Unit Awards outstanding as of immediately prior to the Effective Time on a net settlement basis as provided in <span style="text-decoration: underline;">Section&#160;5.13</span> (which, for the avoidance of doubt, excludes the
            shares of Passage Common Stock withheld under the RSU Withholding Amount) and (C) the exclusion of shares of Passage Common Stock held by Passage as treasury stock or owned by Remix or any of its Subsidiaries or any Subsidiary of Passage
            immediately prior to the Effective Time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Valuation</span>&#8221; means (A) the
            Passage Equity Value <span style="font-style: italic;"><span style="text-decoration: underline;">minus</span></span> (B) the Passage Net Cash Deficiency (if any) <span style="font-style: italic;"><span style="text-decoration: underline;">plus</span></span> (C) the Passage Net Cash Surplus (if any). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Allocation Percentage</span>&#8221; means
            the quotient (rounded to four decimal places) determined by <span style="font-style: italic;"><span style="text-decoration: underline;">dividing</span></span> (A)&#160;the Remix Equity Value <span style="font-style: italic;"><span style="text-decoration: underline;">by</span></span> (B) the Aggregate Valuation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-weight: bold;">Remix Equity Value</span>&#8221; means
            $226,000,000. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Net Cash Deficiency</span>&#8221; means,
            if Passage Net Cash is less than $4,500,000, then the amount, if any, that $5,000,000 exceeds the Passage Net Cash, calculated as of 12:01 am Eastern time on the Closing Date. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Post-Closing Passage Shares</span>&#8221; means
            the quotient determined by <span style="font-style: italic;"><span style="text-decoration: underline;">dividing</span></span> (A) the Passage Outstanding Shares <span style="font-style: italic;">by</span> (B) the Passage Allocation Percentage. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Passage Net Cash Surplus</span>&#8221; means, if
            Passage Net Cash is greater than $5,500,000, then the amount, if any, that the Passage Net Cash exceeds $5,000,000, calculated as of 12:01 am Eastern time on the Closing Date. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">For the avoidance of doubt, the Concurrent Financing Proceeds shall not be
            included in the calculation or determination of the Passage Valuation or any component thereof. Set forth on Section&#160;1.1(a)(iii) of the Passage Disclosure Schedule is an illustrative example of the calculation of the Remix Merger Shares
            calculation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Note&#160;Purchase Agreement (2025)</span>&#8221;
            means the Convertible Promissory Note&#160;and Warrant Purchase Agreement, by and among Remix and the lenders party thereto, dated as of November&#160;14, 2025, as amended by that certain Omnibus Amendment No. 1 to Convertible Promissory Note&#160;and Warrant
            Purchase Agreement and Notes, dated as of the date hereof, and as may be further amended or supplemented from time to time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Note&#160;Purchase Agreements</span>&#8221;
            means, collectively, the Remix Note&#160;Purchase Agreement (2025) and the Remix Note&#160;Purchase Agreement (2026). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Options</span>&#8221; means options to
            purchase shares of Remix Common Stock granted by Remix under the Remix Equity Plan. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 451-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 452-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Outstanding Shares</span>&#8221; means,
            (i) the total number of shares of Remix Common Stock outstanding immediately prior to the Effective Time (after giving effect to the Remix Preferred Stock Conversion and the Remix Convertible Notes Conversion) as expressed on a fully-diluted
            basis and as-converted to Remix Common Stock on a &#8220;treasury method&#8221; basis and assuming, without limitation or duplication, the issuance of all shares of Remix Common Stock that would be issued assuming the acceleration and exercise of all Remix
            Options and Remix Warrants outstanding as of immediately prior to the Effective Time, but, (ii) notwithstanding the foregoing, <span style="font-style: italic;">excluding</span> all shares of Remix Common Stock issuable in connection with the
            Concurrent Financing, including, without limitation, the shares of Remix Common Stock issued pursuant to (x) the conversion of the Remix Convertible Notes (2026) in the Remix Convertible Notes Conversion and (y) the Subscription Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Preferred Stock</span>&#8221; means,
            collectively, the Remix Series&#160;Seed Preferred Stock, Remix Series&#160;A Preferred Stock and Remix Series&#160;B Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Registered IP</span>&#8221; means all Remix
            IP Rights that are owned or exclusively licensed by Remix or any of its Subsidiaries that are registered, filed, issued or otherwise granted under the authority of, with or by any Governmental Authority, including all patents, registered
            copyrights and registered trademarks and all applications and registrations for any of the foregoing. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Series&#160;A Preferred Stock</span>&#8221; means
            the preferred stock, $0.0001 par value per share, of Remix, designated as Series&#160;A Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Series&#160;B Preferred Stock</span>&#8221; means
            the preferred stock, $0.0001 par value per share, of Remix, designated as Series&#160;B Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Series&#160;Seed Preferred Stock</span>&#8221;
            means the preferred stock, $0.0001 par value per share, of Remix, designated as Series&#160;Seed Preferred Stock. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Service Provider</span>&#8221; means each
            Person who, as of the Effective Time, is an employee, non-employee director, advisor or independent contractor of Remix or any of its Subsidiaries or who is otherwise an &#8220;employee&#8221; of Passage or its Subsidiaries for purposes of a registration
            statement on Form&#160;S-8, in each case, as of the Effective Time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Triggering Event</span>&#8221; shall be
            deemed to have occurred if: (i) Remix shall have failed to include in the Information Statement the Remix Board Recommendation, (ii) the Remix Board or any committee thereof evaluating any Acquisition Proposal shall have made a Remix Board
            Adverse Recommendation Change or approved, endorsed or recommended any Acquisition Proposal (other than with Passage), (iii) Remix shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition
            Proposal (other than an Acceptable Confidentiality Agreement pursuant to <span style="text-decoration: underline;">Section&#160;5.4</span>) or (iv) the Remix Board or any committee thereof evaluating any Acquisition Proposal shall have failed to recommend against any Acquisition Proposal
            that is a tender offer or exchange offer within 10 Business Days after the commencement thereof. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Remix Warrants</span>&#8221; means outstanding
            warrants to purchase shares of capital stock of Remix, issued pursuant to (i) the Remix Note&#160;Purchase Agreements and (ii) that certain Convertible Promissory Note&#160;and Warrant Purchase Agreement, dated as of December&#160;22, 2023, by and among Remix
            and the lenders party thereto, as amended. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Representatives</span>&#8221; means, with respect
            to any Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and representatives. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Reverse Stock Split</span>&#8221; means a reverse
            stock split of all outstanding shares of Passage Common Stock at a reverse stock split ratio as mutually agreed to by Passage and Remix that is effected by Passage prior to the Effective Time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Sarbanes-Oxley Act</span>&#8221; means the
            Sarbanes-Oxley Act of 2002. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">SEC</span>&#8221; means the United States
            Securities and Exchange Commission. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Securities Act</span>&#8221; means the
            Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Subsequent Transaction</span>&#8221; means any
            Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Subsidiary</span>&#8221; means, with respect to a
            Person, an Entity of which more than 50% of the voting power of the equity securities or equity interests is owned, directly or indirectly, by such Person. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-11<br/>
        </div>

      </div>

    </div>

    <!--End Page 452-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 453-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Superior Offer</span>&#8221; means an
            unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (i) was not obtained or made as a direct or indirect result
            of a breach of (or in violation of) this Agreement and (ii) is on terms and conditions that the Remix Board or the Passage Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of
            consummation thereof and the financing terms and any termination or break-up fees and conditions to consummation thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following
            consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Remix&#8217;s stockholders or Passage&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions
            and is not subject to any financing conditions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Tax</span>&#8221; means (i) any U.S. federal,
            state or local or non-U.S. tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, unemployment tax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax,
            property tax, business tax, withholding tax, imputed underpayment amount, payroll tax, customs duty, escheat, unclaimed property, alternative or add-on minimum or other tax or similar charge (whether imposed directly or through withholding and
            whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof) and (ii)&#160;any liability for payment of
            amounts described in clause (i) whether as a result of transferee or successor liability, of being a member of an affiliated, consolidated, combined or unitary group for any period, pursuant to a Contract, through operation of Law or otherwise.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Tax Return</span>&#8221; means any return
            (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the
            foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or
            enforcement of or compliance with any Law relating to any Tax. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Transaction Expenses</span>&#8221; means, with
            respect to a Party, the aggregate amount (without duplication) of all costs, fees, Taxes and expenses incurred by such Party or any of its Subsidiaries (including Merger Sub), or for which such Party or any of its Subsidiaries are or may become
            liable in connection with the Contemplated Transactions and the negotiation, preparation and execution of this Agreement or any other agreement, document, instrument, filing, certificate, schedule, exhibit, letter or other document prepared or
            executed in connection with the Contemplated Transactions, including (i) any fees and expenses of legal counsel and accountants, the maximum amount of fees and expenses payable to financial advisors, investment bankers, brokers, consultants,
            tax advisors, transfer agents, proxy solicitor and other advisors of such Party; (ii) the premiums, commissions and other fees paid or payable in connection with obtaining Passage&#8217;s D&amp;O tail policy as set forth in <span style="text-decoration: underline;">Section&#160;5.15(d)</span>;
            and (iii) the CVR Fees. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-weight: bold;">Treasury Regulations</span>&#8221; means the United
            States Treasury regulations promulgated under the Code. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-weight: bold;">WARN Act</span>&#8221; means the Worker Adjustment
            and Retraining Notification Act of 1988, as amended, and any similar or related law. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Each of the following terms is defined in the Section&#160;set forth opposite such term: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 37.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Term</div>
                </td>

    <td style="width: 11.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Section </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Access Exceptions</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Access Exception Efforts</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.3(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accounting Firm</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(e) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Allocation Certificate</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.22 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Passage Charter </div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.3(c) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Anticipated Closing Date</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Assumed Option</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.4(h) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Capitalization Date</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.6(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Cash Determination Time</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Certificate of Merger</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.1 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.2 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Closing Date</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.2 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.76pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-12<br/>
        </div>

      </div>

    </div>

    <!--End Page 453-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 454-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 37.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Term</div>
                </td>

    <td style="width: 11.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Section </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Code</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Costs</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.15(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR Agreement</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">CVR Fees</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">D&amp;O Indemnified Parties</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.15(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">D&amp;O tail policy</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.15(d) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Delivery Date</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dispute Notice</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Disqualifying Event</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.22 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Drug Regulatory Agency</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(c) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective Time</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.1 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exchange Agent</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FDA</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(c) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">FDCA</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(c) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Final Passage Net Cash</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(c) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form S-4</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Information Statement</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.8(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Intended Tax Treatment</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legacy Assets</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.6(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Legacy Asset Disposition</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.6(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Liability</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.9 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Merger</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Merger Sub</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Merger Sub Board</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Nasdaq Issuance Proposal</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Ordinary Course Agreement</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.16(f) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outside Date</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">8.1(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Board</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Board Adverse Recommendation Change</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.9(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Board Recommendation</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.9(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Certifications</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Charter Amendment Proposal</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Closing Certificate</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.2(d) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Common Stock</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.6(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Designee</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.19(a)(i) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Disclosure Schedule</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Article&#160;IV </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage IT Systems</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.23(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Lock-Up Agreements </div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Material Contract</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.13(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Net Cash Calculation</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Net Cash Schedule</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Permits</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.14(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Preferred Stock </div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.6(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Privacy Policies</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.23(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Product Candidates</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.14(d) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Real Estate Leases</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.11 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Regulatory Permits</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.14(d) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Stockholder Matters</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.9(a) </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-13<br/>
        </div>

      </div>

    </div>

    <!--End Page 454-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 455-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 37.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Term</div>
                </td>

    <td style="width: 11.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Section </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Stockholder Meeting</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.9(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Stockholder Support Agreement</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage 401(k) Plan</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.28 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PHSA</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(c) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-Closing Distribution</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.5(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Pre-Closing Period</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.1 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proxy Statement</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Registration Statement</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Preamble </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Board</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Board Recommendation</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.8(c) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Certification</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Charter Amendment</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Closing Certificate</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">6.3(d) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Convertible Notes Conversion</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.4(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Disclosure Schedule</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Article&#160;III </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Financial Statements</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix IT Systems</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.22(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Lock-Up Agreements </div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Material Contract</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.13(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Permits</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Note&#160;Purchase Agreement (2026)</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Preferred Stock Conversion</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.4(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Privacy Policies</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.22(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Product Candidates</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(d) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Real Estate Leases</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.11 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Regulatory Permits</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.14(d) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Stockholder Support Agreement</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Stockholder Written Consents</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Unaudited Balance Sheet</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Unaudited Financial Statements</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.7(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Required Passage Stockholder Vote</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">4.4 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Required Remix Stockholder Vote</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">3.4 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Response Date</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.8(b) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Reverse Stock Split Proposal</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.9(a) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">RSU Withholding Amount</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.13 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Spun-Off Plan</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.28 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subscription Agreement</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Recitals </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Surviving Corporation</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2.1 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transfer Tax </div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.76pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.16(a)</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 11.12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.76pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <a id="tANXAS12"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Other Definitional and Interpretative Provisions</span>. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like
                    import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or
                    interpretation hereof. References to Sections, Exhibits and Schedules are to Sections, Exhibits and Schedules of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit&#160;or Schedule but not otherwise defined
                    therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter
                    genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include the masculine and feminine genders. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement,
                    they shall be deemed to be followed by the words &#8220;without </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-14<br/>
        </div>

      </div>

    </div>

    <!--End Page 455-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 456-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">limitation,&#8221; whether or not they are in fact followed by those words or
            words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or
            Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References
            to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, and substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the
            United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless
            otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of
            measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur
            in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this
            Agreement. The Parties agree that the Remix Disclosure Schedule or the Passage Disclosure Schedule shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in <span style="text-decoration: underline;">Article&#160;III</span>
            or <span style="text-decoration: underline;">Article&#160;IV</span> respectively. The disclosures in any section or subsection of the Remix Disclosure Schedule or the Passage Disclosure Schedule shall qualify other sections and subsections in <span style="text-decoration: underline;">Article&#160;III</span> or <span style="text-decoration: underline;">Article&#160;IV</span>
            respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation,
            (a) that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been posted to and made available by a Party to the other Party and its Representatives in the
            electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions or (b) delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail prior to
            the execution of this Agreement. The inclusion of any information in the Remix Disclosure Schedule or Passage Disclosure Schedule (or any update thereto) shall not be deemed to be an admission or acknowledgement, in and of itself, that such
            information is required by the terms hereof to be disclosed, is material, has resulted in or would result in a Remix Material Adverse Effect or Passage Material Adverse Effect, as the case may be, or is outside the Ordinary Course of Business.
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a id="tANXAA2"><!--Anchor--></a>ARTICLE II<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE MERGER </div>

          <a id="tANXAS21"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">The Merger</span>. Upon the terms and subject to the conditions set forth in this Agreement and subject to the applicable
                    provisions of Delaware Law, at the Closing, Passage and Remix shall cause Merger Sub to be merged with and into Remix, whereupon the separate existence of Merger Sub shall cease and Remix shall continue as the Surviving Corporation of
                    the Merger and as a wholly owned subsidiary of Passage (the &#8220;<span style="font-weight: bold;">Surviving Corporation</span>&#8221;). At the Closing, Passage and Remix shall cause the Merger to be consummated and effective under Delaware Law by
                    executing and filing with the Secretary of State of the State of Delaware a certificate of merger, satisfying the applicable requirements of Delaware Law and in a form to be mutually agreed upon by the Parties prior to the Closing (the
                    &#8220;<span style="font-weight: bold;">Certificate of Merger</span>&#8221;). The Merger shall become effective at the time of the filing of such Certificate of Merger and the acceptance by the Secretary of State of the State of Delaware, or at
                    such later time as may be specified in such Certificate of Merger with the consent of Passage and Remix (the time as of which the Merger becomes effective being referred to as the &#8220;<span style="font-weight: bold;">Effective Time</span>&#8221;).
                  </div>
                </td>

  </tr>


</table>
          <a id="tANXAS22"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Closing</span>. Subject to the satisfaction or waiver of the conditions set forth in this Agreement, the consummation of the
                    Merger (the &#8220;<span style="font-weight: bold;">Closing</span>&#8221;) shall take place remotely, (a) no later than the second Business Day after all the conditions precedent set forth in <span style="text-decoration: underline;">Article&#160;VI</span> shall have been satisfied or waived </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-15<br/>
        </div>

      </div>

    </div>

    <!--End Page 456-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 457-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">(other than those conditions that, by their nature, are to be satisfied at
            the Closing (provided such conditions would be so satisfied)) or (b) at such other time, date and place as the Parties may mutually agree upon in writing. The date on which the Closing actually takes place is referred to as the &#8220;<span style="font-weight: bold;">Closing Date</span>&#8221;. </div>

          <a id="tANXAS23"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Organizational Documents; Directors and Officers</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Certificate of Incorporation of the Surviving Corporation</span>. At the Effective Time, the Amended and Restated Certificate
                    of Incorporation of Remix as in effect immediately prior to the Effective Time shall be amended and restated in its entirety to read as set forth in <span style="text-decoration: underline;">Exhibit&#160;E</span>, and as so amended and restated shall be the certificate of
                    incorporation of the Surviving Corporation until thereafter amended as provided by Delaware Law. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Bylaws of the Surviving Corporation</span>. Passage and Remix shall take all actions necessary so that, at the Effective
                    Time, the bylaws of Merger Sub, as in effect immediately prior to the Effective Time, shall become the bylaws of the Surviving Corporation (with the name of Remix Operations, Inc. as the Surviving Corporation&#8217;s name) until thereafter
                    amended in accordance with Delaware Law and as provided in the Surviving Corporation&#8217;s Organizational Documents. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Certificate of Incorporation of Passage</span>. At the Effective Time, Passage shall file an amended and restated certificate
                    of incorporation to (i) change the name of Passage to &#8220;Remix Therapeutics, Inc.,&#8221; (ii) if Passage and Remix mutually agree to complete the Reverse Stock Split, effect the Reverse Stock Split and (iii) make such other changes as shall be
                    mutually agreed upon by Passage and Remix and adopted at the Passage Stockholder Meeting (the certificate of incorporation, as amended and restated, the &#8220;<span style="font-weight: bold;">Amended and Restated Passage Charter</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Bylaws of Passage</span>. At the Effective Time, the Passage and the Passage Board shall take all actions necessary to amend
                    and restate its Amended and Restated Bylaws in the form agreed to by Passage and Remix. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Directors and Officers</span>. The directors and officers, each to hold office in accordance with the provisions of Delaware
                    Law and the Surviving Corporation&#8217;s Organizational Documents immediately after the Effective Time, shall be as set forth in <span style="text-decoration: underline;">Section&#160;5.19</span>. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS24"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conversion of Remix Convertible Notes; Effect on Shares; Treatment of Remix Options and Remix </span><span style="text-decoration: underline;">Warrants</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All Remix Convertible Notes shall be converted into shares of Remix Common Stock as of immediately prior to the Effective
                    Time in accordance with, and pursuant to the terms and conditions of, the Remix Convertible Notes (the &#8220;<span style="font-weight: bold;">Remix Convertible Notes Conversion</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All Remix Preferred Stock shall be converted into shares of Remix Common Stock as of immediately prior to the Effective Time
                    in accordance with, and pursuant to the terms and conditions of, the Organizational Documents of Remix (the &#8220;<span style="font-weight: bold;">Remix Preferred Stock Conversion</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">At the Effective Time (after giving effect to the Remix Preferred Stock Conversion and the Remix Convertible Notes
                    Conversion), by virtue of the Merger and without any further action on the part of Passage, Merger Sub, Remix or any stockholder of Remix, subject to <span style="text-decoration: underline;">Section&#160;2.4(e)</span>, the Remix Common Stock outstanding immediately prior to the
                    Effective Time (excluding (i) Remix Common Stock issued in the Concurrent Financing, (ii) Remix Common Stock held by Remix as treasury stock or by Passage or any of its direct or indirect subsidiaries as of immediately prior to the
                    Effective Time (&#8220;<span style="font-weight: bold;">Remix Treasury Shares</span>&#8221;) and (iii) Dissenting Remix Shares) shall be converted solely into the right to receive a number of shares of Passage Common Stock equal to the amount of
                    Remix Merger Shares multiplied by the applicable stockholder&#8217;s percentage interest in Remix Outstanding Shares as set forth on the Allocation Certificate and, if any such Remix Common Stock is unvested or is subject to a repurchase
                    option or a risk of forfeiture under any applicable restricted stock, restricted stock unit award agreement or other similar agreement with Remix, then the shares of Passage Common Stock issued in exchange for such Remix Common Stock
                    will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">At the Effective Time, by virtue of the Merger and without further action on the part of Passage, Merger Sub, Remix or any
                    stockholder of Remix, (i) subject to <span style="text-decoration: underline;">Section&#160;2.4(e)</span>, the Remix Common Stock issued in the Concurrent Financing shall be converted solely into the right to receive a number of shares of Passage </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-16<br/>
        </div>

      </div>

    </div>

    <!--End Page 457-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 458-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Common Stock equal to the amount of Concurrent Financing Merger Shares
            multiplied by the percentage of the Concurrent Financing Proceeds represented by the applicable stockholder&#8217;s investment in the Concurrent Financing, as set forth on the Allocation Certificate and (ii) the Remix Treasury Shares will
            automatically be cancelled and extinguished without any conversion thereof or consideration paid therefor. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No fractional shares of Passage Common Stock shall be issued in connection with the Merger, and no certificates or scrip for
                    any such fractional shares shall be issued, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Passage Common Stock a holder of Remix Common Stock would otherwise be entitled to
                    receive shall be aggregated together first prior to eliminating any remaining fractional share. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">At the Effective Time, by virtue of the Merger and without any further action on the part of Passage, Merger Sub, Remix or
                    any stockholder of Remix, each share of common stock, $0.001 par value per share, of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and exchanged for one validly issued, fully paid and
                    nonassessable share of common stock, $0.0001 par value per share, of the Surviving Corporation. If applicable, each stock certificate of Merger Sub evidencing ownership of any such shares shall, as of the Effective Time, evidence
                    ownership of such shares of common stock of the Surviving Corporation until presented for transfer or exchange. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If, between the date of this Agreement and the Effective Time, the outstanding Remix Common Stock or Passage Common Stock
                    shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split, combination (including the effects of the
                    Reverse Stock Split and the filing the Amended and Restated Passage Charter, to the extent the effects of the Reverse Stock Split and the effects of filing the Amended and Restated Passage Charter have not previously been taken into
                    account in calculating the Remix Merger Shares) or exchange of shares or other like change, Remix Merger Shares shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders
                    of Remix Common Stock and Passage Common Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or
                    other like change; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that nothing herein will be construed to permit Remix or Passage to take any action with respect to Remix Common
                    Stock or Passage Common Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Remix Option outstanding immediately prior to the Effective Time and held by a Remix Service Provider shall
                    automatically without any further action on the part of Passage, Merger Sub, Remix or any holder of a Remix Option, be converted, at the Effective Time, into an option (an &#8220;<span style="font-weight: bold;">Assumed Option</span>&#8221;) to
                    acquire, on the same terms and conditions (including the same vesting and exercisability terms and conditions) as were applicable under the Remix Equity Plan and option agreement applicable to such Remix Option immediately prior to the
                    Effective Time, the number of shares of Passage Common Stock determined by multiplying the number of shares of Remix Common Stock subject to such Remix Option immediately prior to the Effective Time by the Remix Exchange Ratio, rounding
                    down to the nearest whole number of shares, at a per share exercise price determined by dividing the per share exercise price of such Remix Option immediately prior to the Effective Time by the Remix Exchange Ratio, rounding up to the
                    nearest whole cent; <span style="font-style: italic;">provided</span> that the conversion of the Remix Options will be made in a manner consistent with Treasury Regulations Section&#160;1.424-1, such that the conversion will not constitute
                    a &#8220;modification&#8221; of such Remix Options for purposes of Section&#160;409A or Section&#160;424 of the Code. As of the Effective Time, Passage will assume the Remix Equity Plan. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">At the Effective Time, each Remix Warrant that is issued and outstanding as of immediately prior to the Effective Time shall
                    be treated in accordance with its terms and conditions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As soon as reasonably practicable following the Closing Date (but in no event later than five (5) Business Days after Passage
                    first becomes eligible to use Form&#160;S-8 for the assumed Remix Options), Passage will file an appropriate registration statement on Form&#160;S-8 (or such other appropriate form, if required) with respect to the offering of the shares of
                    Passage Common Stock issuable upon the exercise of the assumed Remix Options and will use reasonable best efforts to maintain the effectiveness of registration statement thereafter for so long as any of such Remix Options remain
                    outstanding. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-17<br/>
        </div>

      </div>

    </div>

    <!--End Page 458-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 459-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS25"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.5<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Contingent Value Right</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Prior to the Effective Time, Passage shall declare a distribution (the &#8220;<span style="font-weight: bold;">Pre-Closing
                      Distribution</span>&#8221;) of contingent value rights (each, a &#8220;<span style="font-weight: bold;">CVR</span>&#8221;) to the holders of record of Passage Common Stock as of the record date for the Pre-Closing Distribution. Each such holder shall
                    be entitled to receive one CVR for each outstanding share of Passage Common Stock held by such holder as of such date (less applicable withholding Taxes). Each CVR shall represent the right to receive contingent payments upon the
                    occurrence of certain events set forth in, and subject to and in accordance with the terms and conditions of, the Contingent Value Rights Agreement in the form attached hereto as <span style="text-decoration: underline;">Exhibit&#160;F</span>, to be entered into between Passage and
                    Computershare Trust Company, N.A. (or such other nationally recognized rights agent agreed to between Passage and Remix) (the &#8220;<span style="font-weight: bold;">Rights Agent</span>&#8221;), with such revisions thereto requested by the Rights
                    Agent that are not, individually or in the aggregate, materially detrimental to the holders of CVRs and reasonably acceptable to Passage and Remix (the &#8220;<span style="font-weight: bold;">CVR Agreement</span>&#8221;). The record date for the
                    Pre-Closing Distribution shall be the close of business on the last Business Day prior to the day on which the Effective Time occurs and the payment date for the Pre-Closing Distribution shall be three (3) Business Days after the
                    Effective Time; <span style="font-style: italic;">provided</span> that the payment of such distribution may be conditioned upon the occurrence of the Effective Time. In connection with the Pre-Closing Distribution, Passage shall cause
                    the CVR Agreement to be duly authorized, executed and delivered by Passage and the Exchange Agent. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage agrees to pay all costs and fees associated with any action contemplated by this <span style="text-decoration: underline;">Section&#160;2.5</span> (the &#8220;<span style="font-weight: bold;">CVR Fees</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <a id="tANXAS26"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.6<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Closing of Remix&#8217;s Transfer Books</span>. At the Effective Time: (a) all Remix Common Stock outstanding immediately prior to
                    the Effective Time shall be treated in accordance with <span style="text-decoration: underline;">Section&#160;2.4(c)</span> and <span style="text-decoration: underline;">Section&#160;2.4(d)</span>, as applicable, and all holders of certificates representing Remix Common Stock that were outstanding immediately prior to the
                    Effective Time shall cease to have any rights as stockholders of Remix (other than the right to receive Remix Merger Shares or, in the case of Dissenting Remix Shares, the rights pursuant to <span style="text-decoration: underline;">Section&#160;2.11</span>) and (b) the stock
                    transfer books of Remix shall be closed with respect to all Remix Common Stock outstanding immediately prior to the Effective Time. No further transfer of any such Remix Common Stock shall be made on such stock transfer books after the
                    Effective Time. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS27"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.7<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Surrender of Remix Common Stock</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">On or prior to the Closing Date, Passage and Remix shall jointly select a reputable bank, transfer agent or trust company to
                    act as exchange agent in the Merger (the &#8220;<span style="font-weight: bold;">Exchange Agent</span>&#8221;). At the Effective Time, Passage shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Passage
                    Common Stock issuable pursuant to <span style="text-decoration: underline;">Section&#160;2.4(c)</span> and <span style="text-decoration: underline;">Section&#160;2.4(d)</span>, as applicable, in exchange for Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Promptly after the Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders
                    of Remix Common Stock that were converted into the right to receive Remix Merger Shares: (i) a letter of transmittal in customary form and containing such provisions as Passage may reasonably specify and (ii) instructions for effecting
                    the surrender of Remix Common Stock in exchange for book-entry shares of Passage Common Stock. Upon delivery of a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or
                    Passage, the holder of such Remix Common Stock shall be entitled to receive in exchange therefor book-entry shares representing Remix Merger Shares (in a number of whole shares of Passage Common Stock) that such holder has the right to
                    receive pursuant to the provisions of <span style="text-decoration: underline;">Section&#160;2.4(c)</span> and <span style="text-decoration: underline;">Section&#160;2.4(d)</span>, as applicable. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No dividends or other distributions declared or made with respect to Passage Common Stock with a record date after the
                    Effective Time shall be paid to the holder of any Remix Common Stock with respect to the shares of Passage Common Stock that such holder has the right to receive in the Merger until such holder delivers a duly executed letter of
                    transmittal (at which time (or, if later, on the applicable payment date) such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions,
                    without interest). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any shares of Passage Common Stock deposited with the Exchange Agent that remain undistributed to holders of Remix Common
                    Stock as of the date that is 180 days after the Closing Date shall be delivered to </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-18<br/>
        </div>

      </div>

    </div>

    <!--End Page 459-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 460-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Passage upon demand, and any holders of Remix Common Stock who have not
            theretofore delivered a duly executed letter of transmittal in accordance with this <span style="text-decoration: underline;">Section&#160;2.7</span> (other than holders of Remix Treasury Shares or Dissenting Remix Shares) shall thereafter look only to Passage for satisfaction of their
            claims for Passage Common Stock and any dividends or distributions with respect to shares of Passage Common Stock. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No Party shall be liable to any holder of any Remix Common Stock or to any other Person with respect to any shares of Passage
                    Common Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS28"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.8<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Calculation of Net Cash</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Not less than ten (10) Business Days prior to the anticipated date for Closing as mutually agreed to in good faith by Passage
                    and Remix (the &#8220;<span style="font-weight: bold;">Anticipated Closing Date</span>&#8221;), Passage will deliver to Remix a schedule (the &#8220;<span style="font-weight: bold;">Passage Net Cash Schedule</span>&#8221;, and the date of delivery of the
                    Passage Net Cash Schedule, the &#8220;<span style="font-weight: bold;">Delivery Date</span>&#8221;) setting forth, in reasonable detail, Passage&#8217;s good faith, estimated calculation of Passage Net Cash (the &#8220;<span style="font-weight: bold;">Passage
                      Net Cash Calculation</span>&#8221;) as of the close of business on the Closing Date (the &#8220;<span style="font-weight: bold;">Cash Determination Time</span>&#8221;) prepared and certified by Passage&#8217;s chief financial officer (or if there is no chief
                    financial officer at such time, the principal financial and accounting officer for Passage). Passage shall make available to Remix (electronically to the greatest extent possible), as reasonably requested by Remix, the work papers and
                    back-up materials used or useful in preparing the Passage Net Cash Schedule (including, with respect to Transaction Expenses, estimated final invoices and current accounts receivable from each advisor to Passage) and, if reasonably
                    requested by Remix, Passage&#8217;s accountants and counsel at reasonable times and upon reasonable notice. The Passage Net Cash Calculation shall include Passage&#8217;s determination, as of the Cash Determination Time, of the defined terms in <span style="text-decoration: underline;">Section&#160;1.1</span>
                    necessary to calculate Remix Merger Shares. Set forth on <span style="text-decoration: underline;">Section&#160;2.8(a)</span> of the Passage Disclosure Schedule is an illustrative example of a Passage Net Cash calculation calculated on a hypothetical basis as of the date described
                    therein. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Within five (5) Business Days after the Delivery Date (the last day of such period, the &#8220;<span style="font-weight: bold;">Response

                      Date</span>&#8221;), Remix shall have the right to dispute any part of the Passage Net Cash Calculation by delivering a written notice to that effect to Passage (a &#8220;<span style="font-weight: bold;">Dispute Notice</span>&#8221;). Any Dispute
                    Notice shall identify in reasonable detail, to the extent known, the nature and amounts of any proposed revisions to the Passage Net Cash Calculation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If, on or prior to the Response Date, Remix notifies Passage in writing that it has no objections to the Passage Net Cash
                    Calculation or, if prior to 5:00 p.m. (New York City time) on the Response Date, Remix has failed to deliver a Dispute Notice as provided in <span style="text-decoration: underline;">Section&#160;2.8(b)</span>, then the Passage Net Cash Calculation as set forth in the Passage Net
                    Cash Schedule shall be deemed to have been finally determined for purposes of this Agreement and to represent the Passage Net Cash at the Cash Determination Time (the &#8220;<span style="font-weight: bold;">Final Passage Net Cash</span>&#8221;) for
                    purposes of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If Remix delivers a Dispute Notice on or prior to 5:00 p.m. (New York City time) on the Response Date, then Representatives
                    of Passage and Remix shall promptly, and in no event later than one calendar day after the Response Date, meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Passage Net Cash,
                    which agreed upon Passage Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Final Passage Net Cash for purposes of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If Representatives of Passage and Remix are unable to negotiate an agreed-upon determination of Final Passage Net Cash
                    pursuant to <span style="text-decoration: underline;">Section&#160;2.8(d)</span> within two (2) calendar days after delivery of the Dispute Notice (or such other period as Passage and Remix may mutually agree upon), then any remaining disagreements as to the calculation of Passage
                    Net Cash shall be referred to an independent auditor of recognized national standing jointly selected by Passage and Remix or another independent auditor of recognized national standing mutually agreed upon by Passage and Remix (the &#8220;<span style="font-weight: bold;">Accounting Firm</span>&#8221;). Passage shall promptly deliver to the Accounting Firm all work papers and back-up materials used in preparing the Passage Net Cash Schedule, and Passage and Remix shall use
                    commercially reasonable efforts to cause the Accounting Firm to make its determination within five (5) calendar days of accepting its selection. Passage and Remix shall be afforded the opportunity to present to the Accounting Firm any
                    material related to the unresolved disputes and to discuss the issues with the Accounting Firm; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that no such presentation or
                    discussion shall occur without the presence of a Representative of each of Passage and Remix. The determination of the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-19<br/>
        </div>

      </div>

    </div>

    <!--End Page 460-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 461-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Accounting Firm shall be limited to the disagreements submitted to the
            Accounting Firm. The determination of the amount of Passage Net Cash made by the Accounting Firm shall be made in writing delivered to each of Passage and Remix, shall be final and binding on Passage and Remix and shall be deemed to have been
            finally determined for purposes of this Agreement and to represent the Final Passage Net Cash for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this <span style="text-decoration: underline;">Section&#160;2.8(e)</span>. The
            fees and expenses of the Accounting Firm shall be allocated between Passage and Remix in the same proportion that the disputed amount of the Passage Net Cash that was unsuccessfully disputed by such Party (as finally determined by the
            Accounting Firm) bears to the total disputed amount of the Passage Net Cash amount and such portion of the costs and expenses of the Accounting Firm borne by Remix and any other fees, costs or expenses incurred by Remix following the
            Anticipated Closing Date in connection with the procedures set forth in this <span style="text-decoration: underline;">Section&#160;2.8(e)</span> shall be deducted from the final determination of the amount of Passage Net Cash. If this <span style="text-decoration: underline;">Section 2.8(e)</span> applies as to the determination
            of the Final Passage Net Cash described in <span style="text-decoration: underline;">Section&#160;2.8(a)</span>, upon resolution of the matter in accordance with this <span style="text-decoration: underline;">Section&#160;2.8(e)</span>, the Parties shall not be required to determine Passage Net Cash again even though the Closing Date
            may occur later than the Anticipated Closing Date. </div>

          <a id="tANXAS29"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.9<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Further Action</span>. If, at any time after the Effective Time, any further action is determined by the Surviving
                    Corporation to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Corporation with full right, title and possession of and to all rights and property of Remix, then the officers and managers
                    of the Surviving Corporation shall be fully authorized, and shall use their commercially reasonable efforts (in the name of Remix, in the name of Merger Sub, in the name of the Surviving Corporation and otherwise) to take such action. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS210"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Withholding</span>. Each of the Exchange Agent, Passage and the Surviving Corporation and any other applicable withholding
                    agent (each, a &#8220;<span style="font-weight: bold;">Withholding Agent</span>&#8221;) shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement (including the Pre-Closing Distribution) such amounts as
                    are required to be deducted or withheld from such consideration under the Code or under any other applicable Law; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that if a
                    Withholding Agent determines that any payment in connection with the Contemplated Transactions is subject to deduction and/or withholding, then, except with respect to compensatory payments, the Pre-Closing Distribution or as a result
                    of a failure to deliver the certificate described in <span style="text-decoration: underline;">Section&#160;5.16(b)</span>, such Withholding Agent shall use commercially reasonable efforts to (i) provide reasonable advance notice to such recipient of any required deduction or
                    withholding and (ii) reasonably cooperate with such recipient to reduce or eliminate any such deduction and/or withholding. To the extent such amounts are so deducted or withheld, such amounts shall be (i) timely remitted to the
                    appropriate Governmental Authority, and (ii)&#160;treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS211"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Statutory Rights of Appraisal</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything to the contrary set forth in this Agreement, if required by Delaware Law (but only to the extent
                    required thereby), all shares of Remix Common Stock that are issued and outstanding as of immediately prior to the Effective Time (other than the Remix Treasury Shares) and held by any Person (or beneficially owned by a &#8220;beneficial
                    owner&#8221; of shares of Remix Common Stock held either in a voting trust or by a nominee on behalf of the beneficial owner) who has neither voted in favor of the Merger nor consented thereto in writing and who is entitled to demand and has
                    properly and validly exercised their statutory rights of appraisal in respect of such shares of Remix Common Stock in accordance with Section&#160;262 of Delaware Law (collectively, the &#8220;<span style="font-weight: bold;">Dissenting Remix
                      Shares</span>&#8221;) will not be converted into, or represent the right to receive, the shares of Passage Common Stock that such holder has the right to receive in the Merger pursuant to <span style="text-decoration: underline;">Section&#160;2.4</span>. Holders or beneficial owners of
                    Dissenting Remix Shares will be entitled to receive payment of the appraised value of such Dissenting Remix Shares in accordance with the provisions of Section&#160;262 of Delaware Law (it being understood and acknowledged that such
                    Dissenting Remix Shares shall no longer be outstanding, shall automatically be cancelled and shall cease to exist, and such holder or beneficial owner shall cease to have any rights with respect thereto other than the right to receive
                    the appraised value of such Dissenting Remix Shares to the extent afforded by Section&#160;262 of Delaware Law), except that all Dissenting Remix Shares held or beneficially owned by any Person who shall have failed to perfect or who shall
                    have effectively withdrawn, waived or lost their rights to appraisal of such Dissenting Remix Shares pursuant to </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-20<br/>
        </div>

      </div>

    </div>

    <!--End Page 461-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 462-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Section&#160;262 of Delaware Law will thereupon be deemed to have been
            converted into, and to have become exchangeable for, as of the Effective Time, the right to receive the shares of Passage Common Stock that such holder has the right to receive in the Merger, without interest thereon, upon such holder&#8217;s
            compliance with the requirements set forth in <span style="text-decoration: underline;">Section&#160;2.7(b)</span>. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix will give Passage prompt notice of any demands for appraisal received by Remix, withdrawals of such demands and any
                    other instruments served pursuant to Delaware Law and received by Remix in respect of Dissenting Remix Shares or otherwise asserting any dissenters&#8217; rights or rights of appraisal in respect of Remix Common Stock. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a id="tANXAA3"><!--Anchor--></a>ARTICLE III<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF REMIX </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Except as set forth in the written disclosure schedule
            delivered by Remix to Passage (the &#8220;<span style="font-weight: bold;">Remix Disclosure Schedule</span>&#8221;),<span style="font-weight: bold;"> </span>Remix represents and warrants to Passage and Merger Sub as follows: </div>

          <a id="tANXAS31"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Due Organization; Subsidiaries</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing
                    under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and
                    use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Remix and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent
                    applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business and the manner in which its business is currently being conducted requires such licensing or qualification other than in
                    jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Remix Material Adverse Effect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;3.1(c)</span> of the Remix Disclosure Schedule, Remix has no Subsidiaries and Remix does not
                    directly or indirectly own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control, directly or indirectly, any other Entity. Remix is not and has not otherwise been, directly or indirectly,
                    a party to, member of or participant in any partnership, joint venture or similar business entity. Remix has not agreed and is not obligated to make, nor is Remix bound by any Contract under which it may become obligated to make, any
                    future investment in or capital contribution to any other Entity. Remix has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited
                    partnership or other Entity. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS32"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Organizational Documents</span>. Remix has delivered to Passage accurate and complete copies of Remix&#8217;s Organizational
                    Documents. Remix is not in breach or violation of its Organizational Documents in any material respect. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS33"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Authority; Binding Nature of Agreement</span>. Remix has all necessary corporate power and authority to enter into and,
                    subject to obtaining the Required Remix Stockholder Vote, to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Remix Board (at meetings duly called and held) has (a)&#160;determined that the
                    Contemplated Transactions are fair to, advisable and in the best interests of Remix and its stockholders, (b) approved and declared advisable this Agreement and the Contemplated Transactions and (c) determined to recommend the Remix
                    Board Recommendation to the stockholders of Remix. This Agreement has been duly executed and delivered by Remix and assuming the due authorization, execution and delivery by Passage and Merger Sub, constitutes the legal, valid and
                    binding obligation of Remix, enforceable against Remix in accordance with its terms, subject to the Enforceability Exceptions. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS34"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Vote Required</span>. The affirmative vote of the holders of at least (i) a majority in voting power of the shares of Remix
                    Capital Stock outstanding on the record date and (ii) a majority in voting power of the shares of Remix Preferred Stock, voting together as a single class on an as-converted basis, outstanding on the record date (together, the &#8220;<span style="font-weight: bold;">Required Remix</span> <span style="font-weight: bold;">Stockholder Vote</span>&#8221;), is the only vote of the holders of any class or series of Remix Capital Stock necessary to adopt and approve this Agreement
                    and approve the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-21<br/>
        </div>

      </div>

    </div>

    <!--End Page 462-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 463-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS35"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.5<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Non-Contravention; Consents</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to obtaining the Required Remix Stockholder Vote and the filing of the Certificate of Merger and the Remix Charter
                    Amendment as required by Delaware Law, neither (x) the execution, delivery or performance of this Agreement by Remix, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or
                    lapse of time): </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Remix or its
                    Subsidiaries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right
                    to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Remix or its Subsidiaries, or any of the assets owned or used by Remix or its Subsidiaries, is subject; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental
                    Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Remix or its Subsidiaries or that otherwise relates to the business of Remix, or any of the assets owned,
                    leased or used by Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Remix
                    Material Contract, or give any Person the right to: (A) declare a default or exercise any remedy under any Remix Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any such
                    Remix Material Contract, (C) accelerate the maturity or performance of any Remix Material Contract or (D) cancel, terminate or modify any term of any Remix Material Contract, except in the case of any nonmaterial breach, default,
                    penalty or modification; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Remix or its
                    Subsidiaries (except for Permitted Encumbrances). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except for (i) any Consent set forth on <span style="text-decoration: underline;">Section&#160;3.5(a)</span> of the Remix Disclosure Schedule under any Remix Contract,
                    (ii) the Required Remix Stockholder Vote, (iii) the filing of the Certificate of Merger and the Remix Charter Amendment with the Secretary of State of the State of Delaware pursuant to Delaware Law, (iv) any filing that may be required
                    under the HSR Act and any other applicable Antitrust Laws or competition, investment or similar Laws and (v) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under
                    applicable federal and state securities laws, neither Remix nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the
                    execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Remix Board has taken and will take all actions necessary to ensure that the restrictions applicable to business
                    combinations contained in Section&#160;203 of Delaware Law are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute
                    or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS36"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.6<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Capitalization</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The authorized capital stock of Remix consists of (i) 162,000,000 shares of Remix Common Stock, of which 7,833,976 shares
                    have been issued and are outstanding as of the close of business on June&#160;22, 2026 (the &#8220;<span style="font-weight: bold;">Capitalization Date</span>&#8221;), and (ii) 124,133,326 shares of Remix Preferred Stock, of which (A) 17,964,705 shares
                    have been designated Remix Series&#160;Seed Preferred Stock, all of which shares have been issued and are outstanding as of the Capitalization Date, (B) 35,714,365 shares have been designated Remix Series&#160;A Preferred Stock, of which
                    35,661,683 shares have been issued and are outstanding as of the Capitalization Date and (C) 70,454,256 shares have been designated Remix Series&#160;B Preferred Stock, of which 64,509,877 shares have been issued and are outstanding as of
                    the Capitalization Date. Remix does not hold any shares of its capital stock in its treasury as of the Capitalization Date. Since the Capitalization Date through the date of this Agreement, other than in connection with the settlement
                    or exercise, as applicable, of Remix Options outstanding as of the Capitalization Date and included in <span style="text-decoration: underline;">Section&#160;&#8206;3.6(c)</span> of the Remix Disclosure Schedule, </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-22<br/>
        </div>

      </div>

    </div>

    <!--End Page 463-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 464-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg27"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">neither Remix nor any of its Subsidiaries has issued any shares of capital
            stock or other securities of Remix. Each share of Remix Preferred Stock is convertible into one share of Remix Common Stock. There are no declared or accrued but unpaid dividends with respect to any shares of the Remix Capital Stock and Remix
            has never declared or paid any dividend or other distribution. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All of the outstanding shares of Remix Capital Stock have been duly authorized and validly issued, are fully paid and
                    nonassessable and are free of any Encumbrances other than under applicable securities Laws. None of the outstanding shares of Remix Capital Stock is entitled or subject to any preemptive right, right of participation, right of
                    maintenance or any similar right. None of the outstanding shares of Remix Capital Stock is subject to any right of first refusal in favor of Remix. Except as contemplated herein, there is no Remix Contract relating to the voting or
                    registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Remix Capital Stock. Remix is not under any obligation, nor
                    is Remix bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Remix Capital Stock or other securities. <span style="text-decoration: underline;">Section&#160;3.6(b)</span> of the Remix Disclosure
                    Schedule accurately and completely describes all repurchase rights held by Remix with respect to shares of Remix Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase
                    rights are currently exercisable. The shares of Remix Capital Stock are uncertificated. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except for the Remix Equity Plan and the Remix Options granted thereunder, Remix does not have any stock incentive plan or
                    any other plan, program, agreement or arrangement providing for any equity or equity-based compensation for any Person and there were no other equity or equity-based awards outstanding as of the date of this Agreement. As of the date of
                    this Agreement, Remix has reserved 23,696,650 shares of Remix Common Stock for issuance under the Remix Equity Plan, of which 260,796 shares of Remix Common Stock have been issued and are outstanding pursuant to restricted stock
                    purchase agreements, 1,976,340 shares of Remix Common Stock have been issued and are outstanding pursuant to the exercise of Remix Options, 17,638,267 shares of Remix Common Stock are subject to outstanding Remix Options, and 3,821,247
                    shares of Remix Common Stock remain available for future grant pursuant to the Remix Equity Plan. <span style="text-decoration: underline;">Section&#160;&#8206;3.6(c)</span> of the Remix Disclosure Schedule sets forth a true and complete list, as of the date of this Agreement, of each
                    outstanding Remix Option, including: (i) the name of the holder, (ii) the number of shares of Remix Common Stock subject to such Remix Option, (iii) the exercise price of each Remix Option, (iv) the date on which such Remix Option was
                    issued, (v) the applicable vesting schedule, including any acceleration provisions, and the number of vested and unvested shares, (vi) the expiration date, as applicable, and (vii) whether the Remix Option is intended to be an
                    &#8220;incentive stock option&#8221; (as defined in the Code) or a non-qualified stock option. Remix has made available to Passage accurate and complete copies of the following: (A) the Remix Equity Plan, (B) the standard form of agreement
                    evidencing Remix Options; and (C) each agreement evidencing a Remix Option that does not conform in all material respects to the standard form agreement. <span style="text-decoration: underline;">Section&#160;3.6(c)</span> of the Remix Disclosure Schedule sets forth, as of the date
                    of this Agreement, the type and amount of Remix Capital Stock issuable upon exercise of the outstanding Remix Warrants. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;3.6(c)</span> of the Remix Disclosure Schedule, as of the Capitalization Date there is no:
                    (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Remix, (ii) outstanding security, instrument or obligation that is or
                    may become convertible into or exchangeable for any shares of the capital stock or other securities of Remix, (iii) stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Remix is or
                    may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect
                    that such Person is entitled to acquire or receive any shares of capital stock or other securities of Remix. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All outstanding shares of Remix Capital Stock, Remix Options, Remix Warrants, Remix Convertible Notes and other securities of
                    Remix have been issued and granted in compliance with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS37"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.7<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Financial Statements</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.7(a)</span> of the Remix Disclosure Schedule includes true and complete copies of (i) the Remix Balance Sheet and
                    the related audited statement of income, cash flow and changes in stockholders&#8217; equity for the year </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-23<br/>
        </div>

      </div>

    </div>

    <!--End Page 464-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 465-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg28"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">ended December&#160;31, 2024 (the &#8220;<span style="font-weight: bold;">Remix
              Audited Financial Statements</span>&#8221;), (ii) Remix&#8217;s unaudited balance sheet and the related unaudited statement of income, cash flow and changes in stockholders&#8217; equity for the year ended December&#160;31, 2025 (the &#8220;<span style="font-weight: bold;">Remix Unaudited Financial Statements</span>&#8221;), and (iii) Remix&#8217;s unaudited balance sheet (the &#8220;<span style="font-weight: bold;">Remix Unaudited Balance Sheet</span>&#8221;) and the related unaudited statement of income, cash flow and changes
            in stockholders&#8217; equity for the three (3) months ended March&#160;31, 2026 (the &#8220;<span style="font-weight: bold;">Remix Interim Financial Statements</span>&#8221; and collectively, with the Remix Audited Financial Statements and the Remix Unaudited
            Financial Statements, the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Financial Statements</span>&#8221;). </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Remix Financial Statements (i) were prepared in accordance with GAAP (except (x) as may be indicated in the notes
                    thereto, (y) the Remix Unaudited Financial Statements and the Remix Interim Financial Statements may not contain all footnotes required by GAAP, and (z) the Remix Interim Financial Statements are subject to normal and recurring year-end
                    adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (ii)&#160;fairly present, in all material respects, the financial
                    position of Remix as of the respective dates thereof and the results of operations and cash flows of Remix for the periods covered thereby. The Remix Audited Financial Statements required by applicable Law to be included in the
                    Registration Statement shall, when delivered by Remix for inclusion in the Registration Statement for filing with the SEC following the date of this Agreement in accordance with <span style="text-decoration: underline;">Section&#160;5.7</span>, comply in all material respects with
                    the applicable accounting requirements and with the rules and regulations of the SEC, the Exchange Act and the Securities Act applicable to a registrant, in effect as of the respective dates thereof. Other than as expressly disclosed in
                    the Remix Financial Statements, there has been no material change in Remix&#8217;s accounting methods or principles that would be required to be disclosed in Remix&#8217;s financial statements in accordance with GAAP. The books of account and other
                    financial records of Remix and each of its Subsidiaries are true and complete in all material respects. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There have been no formal internal investigations regarding financial reporting or accounting policies and practices
                    discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, or general counsel of Remix, the Remix Board or any committee thereof, other than ordinary course audits or reviews of
                    accounting policies and practices or internal controls. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix and its Subsidiaries maintain a system of internal accounting controls designed to provide reasonable assurance that
                    (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the financial statements of Remix and its Subsidiaries in conformity
                    with GAAP and to maintain accountability of Remix&#8217;s and its Subsidiaries&#8217; assets, (iii) access to Remix&#8217;s and its Subsidiaries&#8217; assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv) the
                    recorded accountability for Remix and its Subsidiaries&#8217; assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. Remix and each of its Subsidiaries maintains
                    internal control over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public
                    accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Remix, &#8220;independent&#8221; with respect to Remix within the meaning of Regulation S-X under the Exchange Act and (iii) to the Knowledge of
                    Remix, in compliance with subsections (g) through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS38"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.8<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Absence of Changes</span>. Except as set forth on <span style="text-decoration: underline;">Section&#160;3.8</span> of the Remix Disclosure Schedule, since January&#160;1,
                    2025, Remix and its Subsidiaries have conducted their business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and
                    there has not been any (a) Remix Material Adverse Effect or (b) action, event or occurrence that would have required the consent of Remix pursuant to <span style="text-decoration: underline;">Sections 5.1(a)</span>, <span style="text-decoration: underline;">5.1(c)</span>, <span style="text-decoration: underline;">5.1(e)</span>, <span style="text-decoration: underline;">5.1(k)</span>, <span style="text-decoration: underline;">5.1(l)</span>,
                    <span style="text-decoration: underline;">5.1(m)</span>, <span style="text-decoration: underline;">5.1(n)</span>, and <span style="text-decoration: underline;">5.1(p)</span> (only with respect to the foregoing Sections) of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS39"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.9<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Absence of Undisclosed Liabilities</span>. Neither Remix nor any of its Subsidiaries has any liability, indebtedness,
                    obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-24<br/>
        </div>

      </div>

    </div>

    <!--End Page 465-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 466-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg29"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;<span style="font-weight: bold;">Liability</span>&#8221;), in each case, of a type required to be reflected or reserved for on a balance sheet prepared in accordance with GAAP, except for: (a) Liabilities disclosed, reflected or reserved against in the
            Remix Unaudited Balance Sheet, (b) normal and recurring current Liabilities that have been incurred by Remix or its Subsidiaries since the date of the Remix Unaudited Balance Sheet in the Ordinary Course of Business (none of which relates to
            any breach of contract, breach of warranty, tort, infringement, or violation of Law), (c)&#160;Liabilities for performance of obligations of Remix or any of its Subsidiaries under Remix Contracts, (d) Liabilities incurred in connection with the
            Contemplated Transactions and the Subscription Agreement and (e)&#160;Liabilities described in <span style="text-decoration: underline;">Section&#160;3.9</span> of the Remix Disclosure Schedule. </div>

          <a id="tANXAS310"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Title to Assets.</span> Each of Remix and its Subsidiaries has good and valid title to, or, in the case of leased properties
                    and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the
                    Remix Unaudited Balance Sheet and (b) all other tangible assets reflected in the books and records of Remix as being owned by Remix. All of such assets are owned or, in the case of leased assets, leased by Remix or any of its
                    Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS311"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Real Property; Leasehold.</span> Neither Remix nor any of its Subsidiaries owns or has ever owned any real property, nor is
                    Remix or any of its Subsidiaries party to any agreement to purchase or sell any real property. Remix has made available to Passage (a) an accurate and complete list of all real properties with respect to which Remix directly or
                    indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Remix or any of its Subsidiaries and (b) copies of all leases under which any such real property is possessed (the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Real Estate Leases</span>&#8221;), each of which is in full force and effect, with no existing material default thereunder by Remix or to the Knowledge of Remix, the
                    other party thereto. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS312"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.12<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Intellectual Property</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.12(a)</span> of the Remix Disclosure Schedule is an accurate, true and complete listing of all Remix Registered IP
                    (other than domain names), including for each item the record owner (and name of any other Person with an ownership interest in such item of Remix Registered IP, if any, and the nature of such ownership interest), jurisdiction, status,
                    date of registration or application, and registration or application number of each item, as applicable. <span style="text-decoration: underline;">Section&#160;3.12(a)</span> of the Remix Disclosure Schedule also sets forth, as of the date of this Agreement, a list of all internet
                    domain names in Remix Registered IP or with respect to which Remix or any of its Subsidiaries is the registrant and, with respect to each domain name, the record owner of such domain name and if different, the legal and beneficial
                    owner(s) of such domain name and the applicable domain name registrar. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.12(b)</span> of the Remix Disclosure Schedule accurately identifies all Remix Contracts pursuant to which any
                    material Remix IP Rights are licensed to Remix or any of its Subsidiaries (other than to the extent such Remix IP Rights are non-exclusively licensed and are (A) any non-customized software that (1) is licensed solely in executable or
                    object code form, or provided as a service, pursuant to a nonexclusive license to such software and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development,
                    manufacturing, or distribution of, any of Remix&#8217;s or its Subsidiaries&#8217; products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other
                    materials, (C) any confidential information provided subject to confidentiality obligations, (D) proprietary information and inventions assignment agreements or consulting agreements between Remix or its Subsidiaries and their
                    respective employees or individual independent contractors that are substantially on Remix&#8217;s standard form thereof, (E) ancillary to a sale of products or services to customers or (F) incidental to the provision of services from
                    contract manufacturers, suppliers, distributors or other service providers to Remix or any of its Subsidiaries). To the Knowledge of Remix, each Remix Contract listed in <span style="text-decoration: underline;">Section&#160;3.12(b)</span> of the Remix Disclosure Schedule is in
                    full force and effect and constitutes a legal, valid, and binding obligation of Remix, its Subsidiaries and each other party thereto, and is enforceable against Remix, its Subsidiaries and each other party thereto in accordance with its
                    terms. To the Knowledge of Remix, neither Remix, its Subsidiaries, nor any other party to any Remix Contract listed in </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-25<br/>
        </div>

      </div>

    </div>

    <!--End Page 466-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 467-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg30"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.12(b)</span> of the Remix Disclosure Schedule has been or is, or
            has been or is alleged to be, in material default under, or has provided or received any notice of breach under, or intention to terminate (including by non-renewal), any Remix Contract listed in <span style="text-decoration: underline;">Section&#160;3.12(b)</span> of the Remix Disclosure
            Schedule. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.12(c)</span> of the Remix Disclosure Schedule accurately identifies each Remix Contract pursuant to which any
                    Person other than Remix or any of its Subsidiaries has been granted any material license under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Remix IP Rights (other than (i)
                    any confidential information provided subject to confidentiality obligations and (ii)&#160;any Remix IP Rights to the extent nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling
                    such academic collaborator, supplier or service providers to provide services for Remix&#8217;s or its Subsidiaries&#8217; benefit). To the Knowledge of Remix, each Remix Contract listed in <span style="text-decoration: underline;">Section&#160;3.12(c)</span> of the Remix Disclosure Schedule
                    is in full force and effect and constitutes a legal, valid, and binding obligation of Remix, its Subsidiaries and each other party thereto, and is enforceable against Remix, its Subsidiaries and each other party thereto in accordance
                    with its terms. Neither Remix, its Subsidiaries nor, to the Knowledge of Remix, any other party to any Remix Contract listed in <span style="text-decoration: underline;">Section&#160;3.12(c)</span> of the Remix Disclosure Schedule has provided or received any written notice or
                    allegation of breach under, or intention to terminate (including by non-renewal), any Remix Contract listed in <span style="text-decoration: underline;">Section&#160;3.12(c)</span> of the Remix Disclosure Schedule. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as identified on <span style="text-decoration: underline;">Section&#160;3.12(d)</span> of the Remix Disclosure Schedule, neither Remix nor any of its Subsidiaries
                    is bound by, no Remix Owned IP Rights are subject to, and to the Knowledge of Remix, no Remix Licensed IP Rights that are exclusively licensed to Remix or any of its Subsidiaries are subject to (other than the rights of the applicable
                    licensors), any Contract containing any covenant or other provision that materially limits or restricts the ability of Remix or any of its Subsidiaries to use, exploit, assert, or enforce any Remix Registered IP anywhere in the world. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Remix Owned IP Rights (other
                    than co-owned rights identified in <span style="text-decoration: underline;">Section&#160;3.12(b)</span> of the Remix Disclosure Schedule), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">(i) All documents and instruments necessary to register or apply for or renew registration of Remix Registered IP owned by
                    Remix or any of its Subsidiaries, and (ii) to the Knowledge of Remix, all documents and instruments necessary to register or apply for or renew registration of Remix Registered IP exclusively licensed to Remix or any of its
                    Subsidiaries, have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority. (A) Remix or its Subsidiaries have paid all renewal and maintenance fees, annuities and other fees with
                    respect to the Remix Registered IP owned by Remix or any of its Subsidiaries and (B) to the Knowledge of Remix, Remix or its Subsidiaries have executed all documents and instruments necessary to register or apply for or renew
                    registration of Remix Registered IP exclusively licensed to Remix or any of its Subsidiaries, in each case (A) and (B) that are due and payable as of the date of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Person who is or was an employee, contractor or consultant of Remix or any of its Subsidiaries and who is or was
                    involved in the creation, discovery, reduction to practice or development of any material Intellectual Property for Remix or any of its Subsidiaries has signed a valid, enforceable written agreement containing a present assignment of
                    all rights, title and interests in and to such Intellectual Property to Remix or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Remix and its Subsidiaries. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Remix, no current or former member, officer, director, or employee of Remix or any of its Subsidiaries
                    has any claim, right (whether or not currently exercisable), or interest to or in any Remix Owned IP Rights. To the Knowledge of Remix, no employee of Remix or any of its Subsidiaries is (A)&#160;bound by or otherwise subject to any Contract
                    restricting him or her from performing his or her duties for Remix or such Subsidiary or (B) in breach of any Contract with any former employer or other Person concerning Remix Owned IP Rights purported to be owned by Remix or such
                    Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Remix Owned IP Rights purported to be owned by Remix or such Subsidiary. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;3.12(i)</span> of the Remix Disclosure Schedule, no funding, facilities, or personnel of any
                    Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-26<br/>
        </div>

      </div>

    </div>

    <!--End Page 467-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 468-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg31"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Remix Owned IP Rights, or, to the Knowledge of Remix, any Remix Licensed
            IP Rights that are exclusively licensed to Remix or any of its Subsidiaries, and no educational institution has any right to, or right to royalties for, or to impose any requirement on the manufacture or commercialization of any product
            incorporating, any Remix Owned IP Rights, or, to the Knowledge of Remix, any Remix Licensed IP Rights that are exclusively licensed to Remix or any of its Subsidiaries. To the Knowledge of Remix, no Governmental Authority has any right to
            (including any &#8220;step-in&#8221; or &#8220;march-in&#8221; rights with respect to), ownership of, commercialization of, or right to royalties or other payments for any Remix Owned IP Rights, or, to the Knowledge of Remix, any Remix Licensed IP Rights that are
            exclusively licensed to Remix or any of its Subsidiaries. Without limiting the generality of the foregoing, to the Knowledge of Remix, no invention claimed or covered by any Patent within the Remix Owned IP Rights, or, to the Knowledge of
            Remix, any Remix Licensed IP Rights that are exclusively licensed to Remix or any of its Subsidiaries, (A) was conceived or reduced to practice in connection with any research activities funded, in whole or in part, by the federal government of
            the United States or any agency thereof, (B) is a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. Section&#160;201(e), or (C) is otherwise subject to the provisions of the Bayh-Dole Act or any similar Law of any other jurisdiction,
            including with respect to any Patents that are part of the Remix IP Rights. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect,
                    maintain and enforce its rights in all proprietary information that Remix or such Subsidiary holds, or purports to hold, as confidential or a trade secret. To the Knowledge of Remix, neither Remix nor any of its Subsidiaries has made
                    any of its trade secrets or other material confidential or proprietary information that it intended to maintain as confidential information available to any other Person except pursuant to written agreements requiring such Person to
                    maintain the confidentiality of such trade secrets or confidential information. To the Knowledge of Remix, there have been no material security breaches, outages, violations or unauthorized access to any of the proprietary information
                    that Remix or any of its Subsidiaries holds, or purports to hold, as confidential or a trade secret, except as would not have, individually or in the aggregate, a Remix Material Adverse Effect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;3.12(k)</span> of the Remix Disclosure Schedule, neither Remix nor any of its Subsidiaries
                    has assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Remix IP Rights to any other Person. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Remix, neither Remix nor any of its Subsidiaries has taken or failed to take any action that could be
                    reasonably expected to result in the abandonment, invalidity, cancellation, forfeiture, relinquishing, invalidation or unenforceability of any Remix Registered IP (including with respect to any Trademark, a failure to exercise adequate
                    quality controls or an assignment in gross without the accompanying goodwill), other than in the Ordinary Course of Business by Remix for Patent or Trademark prosecution. To the Knowledge of Remix, each item of Remix Registered IP has
                    been duly maintained and is not expired, abandoned or cancelled. To the Knowledge of Remix, each of the Patents included in the Remix Registered IP accurately identifies each and every inventor of the claims thereof as determined in
                    accordance with the applicable laws of the jurisdiction in which such Patent is issued or pending. To the Knowledge of Remix, neither Remix nor any of its Subsidiaries has engaged in patent or copyright misuse or any fraud or
                    inequitable conduct in connection with any Remix Registered IP. Each of Remix and its Subsidiaries and their respective counsel have complied with their duties of candor and disclosure and have made no material misrepresentations in the
                    filings submitted to the applicable Governmental Authorities with respect to any of the Remix Registered IP. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Remix, the Remix IP Rights constitute all Intellectual Property necessary for Remix and each of its
                    Subsidiaries to conduct its business as currently conducted or proposed to be conducted; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that the foregoing representation is not a
                    representation with respect to non-infringement of Intellectual Property. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix has delivered, or made available to Passage, a complete and accurate copy of all material Remix IP Rights Agreements. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Remix, the manufacture, marketing, offering for sale, sale, importation, use or intended use or other
                    disposal of any product under development by Remix or any of its Subsidiaries does not violate, and, since June&#160;1, 2023, has not violated, any license or agreement between Remix or its Subsidiaries and any third party in any material
                    respect, and, to the Knowledge of Remix, does not violate, infringe or </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-27<br/>
        </div>

      </div>

    </div>

    <!--End Page 468-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 469-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg32"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">misappropriate, and, since June&#160;1, 2023, has not violated, infringed or
            misappropriated, any valid and issued Patent or other Intellectual Property of any other Person. To the Knowledge of Remix, no third party is violating, infringing or misappropriating or, since June&#160;1, 2023, has violated, infringed or
            misappropriated any Remix IP Rights, or otherwise is breaching or, since June&#160;1, 2023, has breached any material Remix IP Rights Agreement. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As of the date of this Agreement, neither Remix nor any of its Subsidiaries is, or, since June&#160;1, 2023, has been, a party to
                    any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of
                    any Remix Registered IP. None of the Remix Owned IP Rights, and to the Knowledge of Remix, the Remix Licensed IP Rights that are exclusively licensed to Remix or any of its Subsidiaries, have been adjudged invalid or unenforceable in
                    whole or part, and all Remix Owned IP Rights, and to the Knowledge of Remix, all Remix Licensed IP Rights that are exclusively licensed to Remix or any of its Subsidiaries, are in full force and effect. No Patents within the Remix
                    Registered IP owned by Remix or any of its Subsidiaries, or to the Knowledge of Remix, no Patents within the Remix Registered IP exclusively licensed to Remix or any of its Subsidiaries, have been subject to any interference,
                    derivation, reexamination (including ex parte reexamination, inter partes reexamination, inter partes review, or post grant review), reissue, cancellation, opposition, claim, allegation or other action, including any proceeding in which
                    the scope, validity, inventorship, ownership or enforceability of any such Patent is being or has been contested or challenged. Since June&#160;1, 2023, neither Remix nor any of its Subsidiaries have received any written notice asserting
                    that any Remix Registered IP or the proposed use, sale, offer for sale, license or disposition of products, methods, or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or
                    that Remix or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(q)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;3.12(q)</span> of the Remix Disclosure Schedule, to the Knowledge of Remix, no registered
                    trademark or trade name owned, used, or applied for by Remix or any of its Subsidiaries conflicts or interferes with any registered trademark or trade name owned, used, or applied for by any other Person except as would not have a Remix
                    Material Adverse Effect. To the Knowledge of Remix, none of the goodwill associated with or inherent in any registered trademark in which Remix or its Subsidiaries has or purports to have an ownership interest has been impaired as
                    determined by Remix in accordance with GAAP. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(r)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except (i) as would not have a Remix Material Adverse Effect or (ii) as contained in license, distribution or service
                    agreements entered into in the Ordinary Course of Business by Remix or any of its Subsidiaries, to the Knowledge of Remix, (A) neither Remix nor any of its Subsidiaries is bound by any Contract to indemnify, defend, hold harmless, or
                    reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to Remix or any of its Subsidiaries, taken as a whole and (B) neither Remix nor any of its
                    Subsidiaries has ever assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which
                    assumption, agreement or responsibility remains in force as of the date of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(s)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Remix, neither Remix nor any of its Subsidiaries is party to any Contract that, as a result of such
                    execution, delivery and performance of this Agreement, will (i) cause the grant, assignment, or transfer to any other third party of any license or other right to or in any Remix Registered IP, (ii)&#160;result in breach of, default under,
                    termination of, or acceleration or modification of such Contract with respect to any Remix Registered IP, (iii) alter, encumber, impair or extinguish, or result in any Encumbrance with respect to the right of Remix or the Surviving
                    Corporation and its Subsidiaries to use, sell or license or enforce any Remix Registered IP or portion thereof, or (iv) result in Remix or any of its Subsidiaries being bound by or subject to any exclusivity obligations, non-compete or
                    other restrictions on the operation or scope of their respective businesses, or to any obligation to grant any rights in or to any Remix Registered IP, except, in each of (i), (ii), (iii) and (iv), for the occurrence of any such grant
                    or impairment that would not, individually or in the aggregate, result in a Remix Material Adverse Effect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(t)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding any other provisions of this Agreement, Passage acknowledges and agrees that the representations and
                    warranties contained in this <span style="text-decoration: underline;">Section&#160;3.12</span> are the only representations or warranties made by Remix or any of its Subsidiaries with respect to Intellectual Property, and no other provisions of this Agreement shall be interpreted
                    as containing any representation or warranty with respect thereto. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-28<br/>
        </div>

      </div>

    </div>

    <!--End Page 469-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 470-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg33"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS313"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Agreements, Contracts and Commitments</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Other than Excepted Contracts, <span style="text-decoration: underline;">Section&#160;3.13(a)</span> of the Remix Disclosure Schedule lists the following Remix Contracts
                    in effect as of the date of this Agreement, other than the Subscription Agreement (each, a &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Material Contract</span>&#8221; and collectively, the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Material Contracts</span>&#8221;): </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract that is a collective bargaining agreement or other agreement or arrangement with any labor union, works
                    council or labor organization; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract for the employment or engagement of any individual on an employee, consulting or other basis that
                    provides for annual base compensation in excess of $500,000; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract with any Remix Associate that provides for retention, change in control, transaction or other similar
                    payments or benefits, whether or not payable as a result of the Contemplated Transactions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of
                    Business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract containing (A) any covenant limiting the freedom of Remix or any of its Subsidiaries or the Surviving
                    Corporation to engage in any line of business or compete with any Person, or limiting the development, manufacture, or distribution of Remix&#8217;s or any of its Subsidiaries&#8217; products or services, (B) any most-favored pricing arrangement,
                    (C) any exclusivity provision or (D) any non-solicitation provision (excluding such provisions to the extent they provide for non-solicitation of employees, consultants or individual independent contractors); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vi)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract (A) pursuant to which any Person granted Remix or any of its Subsidiaries an exclusive license under any
                    Intellectual Property, (B) pursuant to which Remix or any of its Subsidiaries granted any Person an exclusive license to any Remix IP Rights or (C) that is or should be listed in Section&#160;3.12(b) or 3.12(c) of the Remix Disclosure
                    Schedule; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of
                    $1,000,000 in the aggregate pursuant to its express terms and not cancelable without penalty; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(viii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in
                    each case, involving payments in excess of $1,000,000 in the aggregate after the date of this Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ix)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other
                    agreements or instruments relating to the borrowing of money or extension of credit in excess of $500,000 individually or in excess of $1,000,000 in the aggregate, or creating any material Encumbrances with respect to any assets of
                    Remix or any of its Subsidiaries or any loans or debt obligations with officers or directors of Remix or any of its Subsidiaries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(x)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract that is: (A) a distribution agreement that contains any exclusivity provision, (B)&#160;an agreement involving
                    provision of services or products with respect to any pre-clinical or clinical development activities of Remix or any of its Subsidiaries requiring payment by or to Remix or any of its Subsidiaries after the date of this Agreement in
                    excess of $500,000 pursuant to its express terms, (C) a dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Remix or any of its Subsidiaries has
                    continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Remix or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned,
                    in whole or in part, by Remix or such Subsidiary or (D) a Contract containing a license under any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture
                    or produce any product, service or technology of Remix or any of its Subsidiaries (except to the extent such license is granted by Remix or any of its Subsidiaries to its service providers for provision of goods or services to Remix or
                    any of its Subsidiaries) or any Contract to sell, distribute or commercialize any products or service of Remix or any of its Subsidiaries, in each case of clause (D), except for Remix Contracts entered into in the Ordinary Course of
                    Business; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-29<br/>
        </div>

      </div>

    </div>

    <!--End Page 470-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 471-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg34"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xi)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person,
                    providing advisory services to Remix or any of its Subsidiaries in connection with the Contemplated Transactions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Remix Contract to which Remix or any of its Subsidiaries is a party or by which any of their assets and properties is
                    currently bound, which involves annual obligations of payment by, or annual payments to, Remix or such Subsidiary in excess of $500,000; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xiii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a Remix Real Estate Lease; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xiv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">a Contract disclosed in or required to be disclosed in <span style="text-decoration: underline;">Section&#160;3.12(a)</span> or <span style="text-decoration: underline;">Section&#160;3.12(b)</span> of the Remix
                    Disclosure Schedule; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any other Remix Contract that is not terminable at will (with no penalty or payment) by Remix or any of its Subsidiaries, and
                    (A) which involves payment or receipt by Remix or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $1,000,000 in the aggregate, or obligations after the date of this
                    Agreement in excess of $1,000,000 in the aggregate or (B) that is material to the business or operations of Remix and its Subsidiaries taken as a whole. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix has delivered or made available to Passage accurate and complete copies of all Remix Material Contracts, including all
                    amendments thereto. There are no Remix Material Contracts that are not in written form. Neither Remix nor any of its Subsidiaries has, nor to the Knowledge of Remix, as of the date of this Agreement, has any other party to a Remix
                    Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any such Remix Material Contract in such manner as would permit any party to
                    cancel or terminate any such Remix Material Contract, or would permit any party to seek material damages thereunder. As to Remix and its Subsidiaries, as of the date of this Agreement, each Remix Material Contract is valid, binding,
                    enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Remix Material Contract to change, any material amount paid or payable to Remix
                    or any of its Subsidiaries under any Remix Material Contract or any other material term or provision of any Remix Material Contract. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS314"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.14<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Compliance; Permits; Restrictions</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix and each of its Subsidiaries is, and since June&#160;1, 2023 has been, in material compliance with all applicable Laws. No
                    investigation, claim, suit, proceeding, audit, Order, or other action by any Governmental Authority is pending or, to the Knowledge of Remix, threatened against Remix or any of its Subsidiaries. There is no agreement or Order binding
                    upon Remix or any of its Subsidiaries which (i) could reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Remix or any of its Subsidiaries, any acquisition of material property by
                    Remix or any of its Subsidiaries or the conduct of business by Remix or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Remix&#8217;s ability to comply with or perform any covenant or
                    obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Remix and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the
                    business of Remix as currently conducted (collectively, the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Permits</span>&#8221;).<span style="font-weight: bold;"> </span><span style="text-decoration: underline;">Section&#160;3.14(b)</span> of the Remix
                    Disclosure Schedule identifies each such Remix Permit. Each of Remix and its Subsidiaries is in material compliance with the terms of such Remix Permits. No Legal Proceeding is pending or, to the Knowledge of Remix, threatened, which
                    seeks to revoke, substantially limit, suspend, or materially modify any Remix Permit. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There are no Legal Proceedings pending or, to the Knowledge of Remix, threatened in writing with respect to an alleged
                    material violation by Remix or any of its Subsidiaries of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.) and the rules and regulations promulgated by the United States Food and Drug Administration (&#8220;<span style="font-weight: bold;">FDA</span>&#8221;) thereunder (the &#8220;<span style="font-weight: bold;">FDCA</span>&#8221;), similar Laws promulgated by any other Governmental Authority responsible for regulation of the research, development, testing,
                    manufacturing, packaging, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug products (&#8220;<span style="font-weight: bold;">Drug Regulatory Agency</span>&#8221;). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-30<br/>
        </div>

      </div>

    </div>

    <!--End Page 471-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 472-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg35"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Remix and its Subsidiaries holds all required material Governmental Authorizations issuable by any Drug Regulatory
                    Agency necessary for the conduct of the business of Remix as currently conducted, and, as applicable, for the research, development, testing, manufacturing, packaging, processing, storage, labeling, sale, marketing, advertising,
                    distribution and importation or exportation, in each case as currently conducted, of any of its product candidates (the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Product Candidates</span>&#8221;)<span style="font-weight: bold;"> </span>(collectively, the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Regulatory Permits</span>&#8221;)<span style="font-weight: bold;"> </span>and since June&#160;1, 2023, no
                    such Remix Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii)&#160;modified in any material, adverse manner. Since June&#160;1, 2023, Remix has maintained and is in compliance in all material respects
                    with the terms of such Remix Regulatory Permits and neither Remix nor any of its Subsidiaries has, since June&#160;1, 2023, received any written notice or other written communication from any Drug Regulatory Agency regarding (A) any material
                    violation of or failure to comply materially with any term or requirement of any Remix Regulatory Permit or (B)&#160;any revocation, withdrawal, suspension, cancellation, termination or material modification of any Remix Regulatory Permit. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Remix or its
                    Subsidiaries, in which Remix or its Subsidiaries or their respective product candidates, including the Remix Product Candidates, have participated (collectively, &#8220;<span style="font-weight: bold;">Remix Studies</span>&#8221;), were and, if
                    still pending, are being conducted in compliance in all material respects with any applicable regulations of the Drug Regulatory Agencies and other applicable Law to which such Remix Studies are or were subject, including, without
                    limitation, 21 C.F.R. Parts 50, 54, 56, 58 and 312. Neither Remix nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug Regulatory Agency requiring, or, to the Knowledge of
                    Remix, any action to place a clinical hold order on, or otherwise terminate, delay, or suspend any such Remix Studies, other than ordinary course communications regarding the design and implementation of such Remix Studies. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries, nor, to the Knowledge of Remix, any contract manufacturer with respect to any
                    Remix Product Candidate, is the subject of any pending or, to the Knowledge of Remix, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and
                    Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September&#160;10, 1991) and any amendments thereto (the &#8220;<span style="font-weight: bold;">Application Integrity Policy</span>&#8221;), or any other similar Law. To the Knowledge of
                    Remix, none of Remix, any of its Subsidiaries or any contract manufacturer with respect to any Remix Product Candidate has committed any acts, made any statement, or failed to make any statement, in each case in respect of Remix&#8217;s
                    business or products that would violate the Application Integrity Policy, or any other similar Law. Since June&#160;1, 2023, none of Remix, any of its Subsidiaries, or, to the Knowledge of Remix, any of their respective officers, employees,
                    agents, or contract manufacturers with respect to any Remix Product Candidate, has been convicted of any crime that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a, (ii)&#160;42 U.S.C. &#167; 1320a-7, or (iii) any other
                    applicable Law. To the Knowledge of Remix, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Remix, any of its Subsidiaries, any
                    contract manufacturer with respect to any Remix Product Candidate, or any of its respective officers, employees or agents. Neither Remix nor any of its Subsidiaries is a party to or has any reporting obligations under any corporate
                    integrity agreements, monitoring agreements, deferred or non-prosecution agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Authority. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All manufacturing operations conducted by, or to the Knowledge of Remix, for the benefit of, Remix or its Subsidiaries in
                    connection with any Remix Product Candidate, since June&#160;1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDCA, and to the extent applicable, the respective
                    counterparts thereof promulgated by Governmental Authorities in countries outside the United States. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">None of Remix, its Subsidiaries, or, to the Knowledge of Remix, any manufacturing site of a contract manufacturer, in each
                    case with respect to such parties&#8217; or such site&#8217;s activities conducted with respect to any Remix Product Candidate, (i) is subject to a Drug Regulatory Agency shutdown or import or export prohibition or (ii) has since June&#160;1, 2023
                    received any unresolved Form&#160;FDA 483, notice of violation, warning letter, untitled letter, or similar correspondence or notice from the FDA or other Governmental Authority alleging or asserting material noncompliance with any
                    applicable Law, and, to the Knowledge of Remix, neither the FDA nor any other Governmental Authority has threatened such action. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-31<br/>
        </div>

      </div>

    </div>

    <!--End Page 472-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 473-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg36"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS315"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.15<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Legal Proceedings; Orders</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There is no pending Legal Proceeding and, to the Knowledge of Remix, no Person has threatened in writing to commence any
                    Legal Proceeding: (i) that involves Remix or any of its Subsidiaries or any Remix Associate (in his or her capacity as such) or any of the material assets owned or used by Remix or any of its Subsidiaries or (ii) that challenges, or
                    that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There is no Order to which Remix or any of its Subsidiaries, or any of the material assets owned or used by Remix or any of
                    its Subsidiaries, is subject. To the Knowledge of Remix, no officer or other Key Employee of Remix or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing any conduct,
                    activity or practice relating to the business of Remix or any of its Subsidiaries or to any material assets owned or used by Remix or any of its Subsidiaries. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS316"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.16<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Tax Matters</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Remix and each of its Subsidiaries has timely filed all income Tax Returns and all other material Tax Returns that
                    were required to be filed by or with respect to it under applicable Law. All such Tax Returns were correct and complete in all material respects and have been prepared in substantial compliance with all applicable Law. Subject to
                    exceptions as would not be material, no claim has ever been made by a Governmental Authority in a jurisdiction where Remix or any of its Subsidiaries does not file a particular type of Tax Return that Remix or any of its Subsidiaries is
                    subject to taxation by that jurisdiction that would require the filing of such a Tax Return. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All material amounts of Taxes due and owing by Remix and each of its Subsidiaries (whether or not shown on any Tax Return)
                    have been timely paid. The unpaid Taxes of Remix and each of its Subsidiaries for periods (or portions thereof) ending on or prior to the date of the Remix Unaudited Balance Sheet do not materially exceed the accruals for current Taxes
                    set forth on the Remix Unaudited Balance Sheet. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Remix and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes
                    required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There are no Encumbrances for material Taxes (other than Encumbrances described in clause (i) of the definition of &#8220;Permitted
                    Encumbrances&#8221;) upon any of the assets of Remix or any of its Subsidiaries. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No deficiencies for a material amount of Taxes with respect to Remix or any of its Subsidiaries have been claimed, proposed
                    or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to
                    any Liability in respect of Taxes of Remix or any of its Subsidiaries. Neither Remix nor any of its Subsidiaries has waived any statute of limitations in respect of material Taxes or agreed to any extension of time with respect to a
                    material Tax assessment or deficiency. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries has been a United States real property holding corporation within the meaning of
                    Section&#160;897(c)(2) of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii) of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries is a party to any material Tax allocation, Tax sharing or similar agreement
                    (including indemnity arrangements), other than customary indemnification provisions in commercial Contracts entered into in the Ordinary Course of Business that do not relate primarily to Tax (an &#8220;<span style="font-weight: bold;">Ordinary

                      Course Agreement</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income
                    Tax Return (other than a group the common parent of which is Remix). Neither Remix nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Remix) under Treasury Regulations Section&#160;1.1502-6 (or any
                    similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries has been a party to any joint venture, partnership, or other arrangement that is
                    treated as a partnership for U.S. federal income Tax purposes.<br/>
                  </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-32<br/>
        </div>

      </div>

    </div>

    <!--End Page 473-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 474-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg37"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries has a permanent establishment (within the meaning of an applicable Tax treaty) or
                    other office or fixed place of business in a country other than the country in which it is organized. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by
                    another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes
                    of Treasury Regulations Section&#160;1.6011-4(b)(2). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries will be required to include any material item of income or gain in, or exclude any
                    material item of deduction or loss from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i) change in, or use of improper, method of accounting for a taxable period ending on
                    or prior to the Closing Date; (ii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax law) executed on or prior to the Closing Date;
                    (iii)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&#160;prepaid amount, advance payments or deferred revenue received or accrued on or prior to the Closing Date; (v) intercompany transaction or
                    excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law); or (vi) application of Section&#160;367(d) of the Code to any transfer
                    of intangible property on or prior to the Closing Date. Remix has not made any election under Section&#160;965(h) of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.16(n)</span> of the Remix Disclosure Schedule sets forth the entity classification of Remix and each of its
                    Subsidiaries for U.S. federal income tax purposes. Neither Remix nor any of its Subsidiaries has made an election or taken any other action to change its federal and state income tax classification from such existing classification. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries has taken or knowingly failed to take any action, nor to the Knowledge of Remix,
                    are there any facts or circumstances, in each case, that would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS317"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.17<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Employee and Labor Matters; Benefit Plans</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.17(a)</span> of the Remix Disclosure Schedule contains a complete and accurate list of all Remix employees as of
                    the date of this Agreement, setting forth for each employee: job title; classification as exempt or non-exempt for wage and hour purposes; annual base salary, hourly rate or other rates of compensation; bonus potential; full-time or
                    part-time status; date of hire; business location; status (i.e., active or inactive and if inactive, the type of leave and estimated duration); and any visa or work permit status and the date of expiration, if applicable. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;3.17(b)</span> of the Remix Disclosure Schedule contains a complete and accurate list as of the date hereof of all of
                    the independent contractors, consultants, temporary employees, leased employees or other agents employed or used by Remix and classified by Remix as other than employees, or compensated other than through wages paid by Remix through
                    Remix&#8217;s payroll department (&#8220;<span style="text-decoration: underline;">Remix Contingent Workers</span>&#8221;), showing for each Remix Contingent Worker such individual&#8217;s engagement date, role in the business, work location, and fee or compensation arrangements. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix nor any of its Subsidiaries is a party to, bound by the terms of, or has a duty to bargain under, any
                    collective bargaining agreement or other Contract with a labor union, works council or labor organization representing any Remix Associate, and there are no labor unions, works council or labor organizations representing or, to the
                    Knowledge of Remix, purporting to represent or seeking to represent any Remix Associates, including through the filing of a petition for representation election. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Section&#160;3.17(d)</span> of the Remix Disclosure Schedule lists all material Remix Employee Plans. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As applicable with respect to each material Remix Employee Plan, Remix has made available to Passage true and complete copies
                    of (i) the plan document, including all amendments thereto, and in the case of an unwritten Employee Plan, a written description of all material terms thereof, (ii) all related trust instruments or other funding-related documents and
                    insurance contracts, (iii) the summary plan description and each summary of material modifications thereto, (iv) the financial statements for the most recent year for which </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-33<br/>
        </div>

      </div>

    </div>

    <!--End Page 474-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 475-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg38"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">such financial statements are available (in audited form, if available or
            required by ERISA) and, where applicable, annual reports with any Governmental Authority (<span style="font-style: italic;">e.g.</span>,<span style="font-style: italic;"> </span>Form&#160;5500 and all schedules thereto), (v)&#160;the most recent IRS
            determination or opinion letter, (vi)&#160;written results of any required compliance testing for the three most recent plan years, and (vii) all material, non-routine notices, filings or correspondence during the past three years with any
            Governmental Authority. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Remix Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable
                    determination letter or may rely on a favorable opinion letter with respect to such qualified status from the IRS to the effect that such plan is qualified under Section&#160;401(a) of the Code and the related trust is exempt from federal
                    income Taxes under Section&#160;501(a) of the Code. To the Knowledge of Remix, nothing has occurred that would reasonably be expected to cause the loss of the qualified status of any such Remix Employee Plan or the Tax exempt status of any
                    related trust. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Remix Employee Plan has been established, maintained and operated in compliance, in all material respects, with its
                    terms and all applicable Laws, including, without limitation, the Code and ERISA. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Remix, threatened with respect to any
                    Remix Employee Plan. All material payments and/or contributions required to have been made with respect to all Remix Employee Plans have been made in accordance with the terms of the applicable Remix Employee Plan and applicable Law in
                    all material respects and neither Remix nor any Remix ERISA Affiliate has any material Liability for any such unpaid contributions with respect to any Remix Employee Plan. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Remix, any of its Subsidiaries nor any of their ERISA Affiliates maintains, contributes to, is required to contribute
                    to or has any Liability with respect to (i) any &#8220;employee benefit plan&#8221; (within the meaning of Section&#160;3(2) of ERISA) that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan,
                    (iii) any Multiple Employer Plan, or (iv) any Multiple Employer Welfare Arrangement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No Remix Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service
                    or retirement, other than (i) pursuant to COBRA or an analogous state law requirement (the full cost of which is borne by such Person or such Person&#8217;s dependents or beneficiaries) or (ii)&#160;continuation coverage through the end of the
                    month in which such termination or retirement occurs. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">No Remix Employee Plan is subject to any law of a foreign jurisdiction outside of the United States. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Remix Employee Plan that constitutes in any part a nonqualified deferred compensation plan within the meaning of
                    Section&#160;409A of the Code has complied in all material respects with Section&#160;409A of the Code, to the extent applicable, and no compensation has been or would reasonably be expected to be includable in the gross income of any Remix
                    Associate as a result of the operation of Section&#160;409A of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix and its Subsidiaries are, and since June&#160;1, 2023 have been, in compliance in all material respects with all applicable
                    Laws respecting labor, employment and employment practices, including terms and conditions of employment, worker classification, tax withholding, unemployment compensation, workers&#8217; compensation, prohibited discrimination, harassment,
                    equal employment, fair employment practices, meal and rest periods, work authorization and immigration status, employee safety and health, wages (including overtime wages), pay equity, affirmative action, restrictive covenants,
                    compensation, and hours of work. There are no Legal Proceedings pending or, to the Knowledge of Remix, threatened against Remix or any of its Subsidiaries relating to any labor or employment matters or any Remix Associate. Remix is not
                    a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state, or local agency or Governmental Authority with respect to employment practices. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Since June&#160;1, 2023, (i) Remix has not taken any action which would constitute a &#8220;plant closing&#8221;, &#8220;collective dismissal&#8221;,
                    &#8220;group dismissal&#8221;, &#8220;group termination&#8221;, &#8220;mass termination&#8221;, or &#8220;mass layoff&#8221; within the meaning of the WARN Act, (ii) issued any written notification of a plant closing or mass layoff required by the WARN Act (nor has Remix or any of
                    its Subsidiaries been under any requirement or obligation to issue any such notification), or (iii) incurred any Liability or obligation under the WARN Act that remains unsatisfied. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Since June&#160;1, 2023, there has never been, nor to the Knowledge of Remix has there been any threat of, any strike, slowdown,
                    work stoppage, lockout, job action, union, organizing activity, question concerning </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-34<br/>
        </div>

      </div>

    </div>

    <!--End Page 475-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 476-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg39"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">representation or any similar activity or dispute, affecting Remix or its
            Subsidiaries. No event has occurred within the past six (6) months, and, to the Knowledge of Remix, no condition or circumstance exists, that would reasonably be expected to give rise to or provide a basis for the commencement of any such
            strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There is no contract, agreement, plan or arrangement to which Remix or any of its Subsidiaries is a party or by which it is
                    bound to make any payment or compensate any Remix Associate for Taxes incurred pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither the execution and delivery of this Agreement, the shareholder approval of this Agreement, nor the consummation of the
                    Contemplated Transactions (either alone or in conjunction with any other event, including without limitation, a termination of employment) will result in any (i) payment (including severance, forgiveness of indebtedness or otherwise) or
                    benefit becoming due to a Remix Associate, (ii)&#160;increase in any benefits or the compensation payable under any Remix Employee Plan, (iii)&#160;acceleration of the time of payment, funding or vesting of any such compensation or benefits or
                    any loan forgiveness, (iv)&#160;restriction on the right of Remix or any of its Subsidiaries or, after the consummation of Contemplated Transactions, the Surviving Corporation, to merge, amend, terminate or transfer any Remix Employee Plan,
                    or (v)&#160;&#8220;excess parachute payment&#8221; (within the meaning of Section&#160;280G of the Code). </div>
                </td>

  </tr>


</table>
          <a id="tANXAS318"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.18<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Environmental Matters</span>. Since June&#160;1, 2023, Remix and each of its Subsidiaries has complied with all applicable
                    Environmental Laws, which compliance includes the possession by Remix of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any
                    failure to be in compliance that, individually or in the aggregate, would not result in a Remix Material Adverse Effect. Neither Remix nor any of its Subsidiaries has received since June&#160;1, 2023, any written notice or other
                    communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Remix or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the
                    Knowledge of Remix, there are no circumstances that may prevent or interfere with Remix&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not have a Remix
                    Material Adverse Effect. To the Knowledge of Remix: (a)&#160;no current or prior owner of any property leased or controlled by Remix or any of its Subsidiaries has received since June&#160;1, 2023, any written notice or other communication
                    relating to property owned or leased at any time by Remix or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Remix or any of its
                    Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (b)&#160;neither Remix nor any of its Subsidiaries has any material Liability under any Environmental Law. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS319"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.19<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Insurance</span>. Remix has made available to Passage accurate and complete copies of all material insurance policies and all
                    material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Remix and its Subsidiaries. Each of such insurance policies is in full force and effect and Remix and its Subsidiaries are
                    in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since June&#160;1, 2023, neither Remix nor any of its Subsidiaries has received any notice or other
                    communication regarding any actual or possible: (a) cancellation or invalidation of any insurance policy or (b) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each
                    of Remix and its Subsidiaries has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Remix or such Subsidiary for which Remix or such Subsidiary has insurance coverage, and no
                    such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Remix of its intent to do so. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS320"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.20<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Transactions with Affiliates</span>. <span style="text-decoration: underline;">Section&#160;3.20</span> of the Remix Disclosure Schedule describes any material
                    transactions or relationships, since June&#160;1, 2023, between, on one hand, Remix and, on the other hand, any (a) executive officer or director of Remix or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b) owner
                    of more than five percent of the voting power of the outstanding shares of Remix Capital Stock or (c) to the Knowledge of Remix, any &#8220;related person&#8221; (within the meaning of </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-35<br/>
        </div>

      </div>

    </div>

    <!--End Page 476-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 477-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg40"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">Item&#160;404 of Regulation S-K under the Securities Act) of any such officer,
            director or owner (other than Remix) in the case of each of (a), (b) or (c) that is of the type that would be required to be disclosed under Item&#160;404 of Regulation S-K under the Securities Act. </div>

          <a id="tANXAS321"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.21<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Financial Advisors</span>. Except as set forth on <span style="text-decoration: underline;">Section&#160;3.21</span> of the Remix Disclosure Schedule, no broker, finder
                    or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of
                    Remix. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS322"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.22<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Privacy and Data Security</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix and its Subsidiaries have complied with all applicable Privacy Laws and the applicable terms of any Remix Contracts
                    relating to privacy, security, collection or use of Personal Information of any individuals (including clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care
                    professionals, clinical trial investigators, researchers, pharmacists) that interact with Remix or any of its Subsidiaries in connection with the operation of Remix&#8217;s and its Subsidiaries&#8217; business, except for such noncompliance as has
                    not had, and would not have, individually or in the aggregate, a Remix Material Adverse Effect. To the Knowledge of Remix, Remix has implemented and maintains reasonable written policies and procedures, satisfying the requirements of
                    applicable Privacy Laws and Remix Contracts, concerning the privacy, security, collection and use of Personal Information (the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Privacy Policies</span>&#8221;)
                    and has complied with the same, except for such noncompliance as has not to the Knowledge of Remix had, and would not have, individually or in the aggregate, a Remix Material Adverse Effect. To the Knowledge of Remix, as of the date
                    hereof, no claims have been asserted or threatened against Remix by any Person alleging a violation of Privacy Laws, Remix Privacy Policies and/or the applicable terms of any Remix Contracts relating to privacy, security, collection or
                    use of Personal Information of any individuals and Remix has not received written notice of any of the same. To the Knowledge of Remix, there have been no data security incidents, personal data breaches or other adverse events or
                    incidents related to Personal Information or Remix data in the custody or control of Remix or any service provider acting on behalf of Remix, in each case where such incident, breach or event would result in a notification obligation to
                    any Person under applicable law or pursuant to the terms of any Remix Contract. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The information technology assets and equipment of Remix and its Subsidiaries (collectively, &#8220;<span style="font-weight: bold;">Remix IT Systems</span>&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of Remix and its Subsidiaries as currently conducted, and to the
                    Knowledge of Remix, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Remix and its Subsidiaries have implemented and maintain commercially reasonable physical, technical and
                    administrative safeguards to protect Personal Information processed by or on behalf of Remix and its Subsidiaries, any other material confidential information and the integrity and security of Remix IT Systems used in connection with
                    their businesses, and during the past three years, there have been no breaches, violations, outages or unauthorized uses of or accesses to the same, except for those that have been remedied without material cost or Liability or the duty
                    to notify any other Person. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS323"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.23<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Concurrent Financing</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix has delivered to Passage true, correct and complete copies of all Contracts related to the Concurrent Financing,
                    including the Subscription Agreement, pursuant to which the Purchasers (as defined in the Subscription Agreement) party thereto (collectively, the &#8220;<span style="font-weight: bold;">Purchasers</span>&#8221;) have agreed, subject to the terms
                    and conditions set forth therein, to purchase the number of shares of Remix Common Stock set forth therein in connection with the transactions contemplated by this Agreement. The Subscription Agreement has not been amended or modified
                    prior to the date of this Agreement and as of the date hereof, no such amendment or modification is contemplated (other than amendments or modifications that are permitted by <span style="text-decoration: underline;">Section&#160;5.26</span>), and as of the date hereof, the
                    respective obligations and commitments contained in the Subscription Agreement have not been withdrawn or rescinded in any respect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As of the date hereof, the Subscription Agreement is in full force and effect and is the legal, valid, binding and
                    enforceable obligation of Remix, and, to the Knowledge of Remix, each of the Purchasers. There are no conditions precedent or other contingencies related to the funding of the full amount of the Concurrent Financing, other than as
                    expressly set forth in the Subscription Agreement. As of the date hereof, no event has occurred which, with or without notice, lapse of time or both, would reasonably be expected to constitute a </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-36<br/>
        </div>

      </div>

    </div>

    <!--End Page 477-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 478-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg41"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">default or breach on the part of Remix or, to the Knowledge of Remix, any
            Purchaser under the Subscription Agreement. As of the date hereof, Remix has no reason to believe that any of the conditions to the Concurrent Financing as contemplated by the Subscription Agreement will not be satisfied. </div>

          <a id="tANXAS324"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.24<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Other Representations or Warranties</span>. Remix hereby acknowledges and agrees that, except for the representations and
                    warranties contained in this Agreement, neither Passage nor any other person on behalf of Passage makes any express or implied representation or warranty with respect to Passage or with respect to any other information provided to
                    Remix, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Passage set forth in <span style="text-decoration: underline;">Article&#160;IV</span> (in each case
                    as qualified and limited by the Passage Disclosure Schedule)) none of Remix, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;"><a id="tANXAA4"><!--Anchor--></a>ARTICLE IV<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REPRESENTATIONS AND WARRANTIES OF PASSAGE AND MERGER SUB </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Except (i) as set forth in the written disclosure schedule delivered by
            Passage to Remix (the &#8220;<span style="font-weight: bold;">Passage Disclosure Schedule</span>&#8221;) or (ii) as disclosed in the Passage SEC Documents filed with the SEC on or before the day that is one&#160;(1)&#160;Business Day prior to the date hereof and
            publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A) without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B) excluding any disclosures
            contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or
            forward-looking in nature), it being understood that any matter disclosed in the Passage SEC Documents shall not be deemed disclosed for purposes of <span style="text-decoration: underline;">Section&#160;4.1(a)</span>, <span style="text-decoration: underline;">4.1(b)</span> or <span style="text-decoration: underline;">4.3</span>, Passage and Merger Sub represent and
            warrant to Remix as follows: </div>

          <a id="tANXAS41"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Due Organization; Subsidiaries</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Passage and its Subsidiaries (including Merger Sub) is a corporation or other legal entity duly incorporated or
                    otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i) to conduct its business in the manner in which its
                    business is currently being conducted, (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts
                    by which it is bound. Since the date of its formation, Merger Sub has not engaged in any activities other than in connection with or as contemplated by this Agreement. All of Passage&#8217;s Subsidiaries are wholly owned by Passage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Passage and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent
                    applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business and the manner in which its business is currently being conducted requires such licensing or qualification other than in
                    jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Passage Material Adverse Effect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;4.1(c)</span> of the Passage Disclosure Schedule, Passage has no Subsidiaries other than
                    Merger Sub and Passage does not directly or indirectly own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity other than Merger Sub. Passage is
                    not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Passage has not agreed and is not obligated to make, nor is Passage bound by any
                    Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Passage has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts
                    or other obligations of, any general partnership, limited partnership or other Entity. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS42"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Organizational Documents</span>. Passage has delivered to Remix accurate and complete copies of the Organizational Documents
                    of Passage and Merger Sub. Neither Passage nor Merger Sub is in breach or violation of its Organizational Documents in any material respect. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS43"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Authority; Binding Nature of Agreement</span>. Each of Passage and Merger Sub has all necessary corporate power and authority
                    to enter into and, subject to receiving the Required Passage Stockholder Vote and </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-37<br/>
        </div>

      </div>

    </div>

    <!--End Page 478-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 479-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg42"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">the effectiveness of the Merger Sub Stockholder Approval, to perform its
            obligations under this Agreement and to consummate the Contemplated Transactions. The Passage Board (at meetings duly called and held) has (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of
            Passage and its stockholders, (b) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Passage Common Stock to the stockholders of Remix pursuant to the terms of this Agreement
            and (c)&#160;determined to recommend the Passage Board Recommendation to the stockholders of Passage. The Merger Sub Board (by unanimous written consent) has: (x) determined that the Contemplated Transactions are fair to, advisable, and in the best
            interests of Merger Sub and its sole stockholder, (y) deemed advisable and approved this Agreement and the Contemplated Transactions and (z) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that
            the sole stockholder of Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by Passage and Merger Sub and, assuming the due authorization, execution and
            delivery by Remix, constitutes the legal, valid and binding obligation of Passage and Merger Sub, enforceable against each of Passage and Merger Sub in accordance with its terms, subject to the Enforceability Exceptions. </div>

          <a id="tANXAS44"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Vote Required</span>. The affirmative votes of (a) holders of a majority of the votes cast for or against the Nasdaq Issuance
                    Proposal and (b) holders of a majority of the voting power of the outstanding shares of Passage Common Stock entitled to vote on the adoption of the Amended and Restated Passage Charter, in each case, at the Passage Stockholder Meeting
                    are the only votes of the holders of any class or series of Passage Common Stock necessary to approve this Agreement and the Contemplated Transactions, including the issuance of the Remix Merger Shares to the stockholders of Remix in
                    the Merger and the adoption of the Amended and Restated Passage Charter (such vote, the &#8220;<span style="font-weight: bold;">Required Passage Stockholder Vote</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <a id="tANXAS45"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.5<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Non-Contravention; Consents</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to obtaining the Required Passage Stockholder Vote, the effectiveness of the Merger Sub Stockholder Approval and the
                    filing of the Certificate of Merger and the Amended and Restated Passage Charter as required by Delaware Law, neither (x) the execution, delivery or performance of this Agreement by Passage or Merger Sub, nor (y) the consummation of the
                    Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time): </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Passage or its
                    Subsidiaries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right
                    to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Passage or its Subsidiaries, or any of the assets owned or used by Passage or its Subsidiaries, is subject; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental
                    Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Passage or its Subsidiaries or that otherwise relates to the business of Passage, or any of the assets owned,
                    leased or used by Passage; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Passage
                    Material Contract, or give any Person the right to: (A) declare a default or exercise any remedy under any Passage Material Contract, (B)&#160;any material payment, rebate, chargeback, penalty or change in delivery schedule under any such
                    Passage Material Contract, (C) accelerate the maturity or performance of any Passage Material Contract or (D) cancel, terminate or modify any term of any Passage Material Contract, except in the case of any nonmaterial breach, default,
                    penalty or modification; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Passage or its
                    Subsidiaries (except for Permitted Encumbrances). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except for (i) any Consent set forth on <span style="text-decoration: underline;">Section&#160;4.5</span> of the Passage Disclosure Schedule under any Passage Contract,
                    (ii) the Required Passage Stockholder Vote, (iii) the filing of the Certificate of Merger and the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-38<br/>
        </div>

      </div>

    </div>

    <!--End Page 479-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 480-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg43"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Amended and Restated Passage Charter with the Secretary of State of the
            State of Delaware pursuant to Delaware Law, (iv) any filing that may be required under the HSR Act and any other applicable Antitrust Laws or competition, investment or similar Laws and (v) such consents, waivers, approvals, orders,
            authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, neither Passage nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice
            to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Passage Board and the Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions
                    applicable to business combinations contained in Section&#160;203 of Delaware Law are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other
                    state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS46"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Capitalization</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The authorized capital stock of Passage consists of (i) 300,000,000 shares of common stock, par value $0.0001 per share (&#8220;<span style="font-weight: bold;">Passage Common Stock</span>&#8221;) and (ii)&#160;10,000,000 shares of preferred stock, par value $0.0001&#160;per share (&#8220;<span style="font-weight: bold;">Passage Preferred Stock</span>&#8221;). As of the Capitalization Date,
                    (x) 3,212,810 shares of Passage Common Stock were issued and outstanding and (y) 0 shares of Passage Preferred Stock were issued and outstanding. Passage does not hold any shares of its capital stock in its treasury. Since the
                    Capitalization Date through the date of this Agreement, other than in connection with the settlement or exercise, as applicable, of Passage Options or Passage Restricted Stock Unit Awards outstanding as of the Capitalization Date and
                    included in <span style="text-decoration: underline;">Section&#160;4.6(c)</span> of the Passage Disclosure Schedule, neither Passage nor any of its Subsidiaries has issued any shares of capital stock or other securities of Passage. There are no declared or accrued but unpaid
                    dividends with respect to any shares of the Passage Common Stock and Passage has never declared or paid any dividend or other distribution. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All of the outstanding shares of Passage Common Stock have been duly authorized and validly issued, and are fully paid and
                    nonassessable and are free of any Encumbrances other than under applicable securities Laws. None of the outstanding shares of Passage Common Stock is entitled or subject to any preemptive right, right of participation, right of
                    maintenance or any similar right. None of the outstanding shares of Passage Common Stock is subject to any right of first refusal in favor of Passage. Except as contemplated herein, there is no Passage Contract relating to the voting or
                    registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Passage Common Stock. Passage is not under any obligation,
                    nor is Passage bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Passage Common Stock or other securities. <span style="text-decoration: underline;">Section&#160;4.6(b)</span> of the Passage
                    Disclosure Schedule accurately and completely lists all repurchase rights held by Passage with respect to shares of Passage Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those
                    repurchase rights are currently exercisable. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except for the Passage Equity Plans and the Passage Options and Passage Restricted Stock Unit Awards granted thereunder,
                    Passage does not have any stock incentive plan or any other plan, program, agreement or arrangement providing for any equity or equity-based compensation for any Person and there were no other equity or equity-based awards outstanding
                    as of the date of this Agreement. As of the Capitalization Date, 59,103 shares of Passage Common Stock were reserved and available for purchase under the Passage ESPP, Passage has reserved 4,571,714 shares of Passage Common Stock for
                    issuance under the Passage Equity Plans, of which 1,530,984&#160;shares have been issued and are outstanding pursuant to the exercise of Passage Options or settlement of Passage Restricted Stock Unit Awards, 649,384 shares are subject to
                    outstanding Passage Options, 20,000&#160;shares are subject to outstanding Passage Restricted Stock Unit Awards, and 172,080 shares remain available for future grant pursuant to the Passage Equity Plans. <span style="text-decoration: underline;">Section&#160;4.6(c)</span> of the Passage
                    Disclosure Schedule sets forth a true and complete list, as of the Capitalization Date, of each outstanding Passage Option and Passage Restricted Stock Unit Award, including: (i) the name of the holder, (ii) the number of shares of
                    Passage Common Stock subject to such Passage Option and/or Passage Restricted Stock Unit Award, (iii) the exercise price of each Passage Option, (iv) the date of grant, (v) the applicable vesting schedule, including any acceleration
                    provisions and the number of vested and unvested shares, (vi)&#160;the expiration date, as applicable, and (vii) whether the Passage Option is intended to be an &#8220;incentive </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-39<br/>
        </div>

      </div>

    </div>

    <!--End Page 480-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 481-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg44"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">stock option&#8221; (as defined in the Code) or a non-qualified stock option.
            Passage has made available to Remix accurate and complete copies of the following (except for such documents that are filed as an exhibit to a Passage SEC Document): (A) the standard form of agreement evidencing Passage Options and Passage
            Restricted Stock Unit Awards; and (B) each agreement evidencing a Passage Option or Passage Restricted Stock Unit Award that does not conform in all material respects to the standard form agreement. As of the date hereof, there are no ongoing
            offering periods or purchase periods under the Passage ESPP, and there are no outstanding rights to purchase shares under the ESPP. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;4.6(c)</span> of the Passage Disclosure Schedule, there is no: (i) outstanding subscription,
                    option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Passage, (ii) outstanding security, instrument or obligation that is or may become convertible into
                    or exchangeable for any shares of the capital stock or other securities of Passage, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Passage is or may become obligated to
                    sell or otherwise issue any shares of its capital stock or any other securities or (iv)&#160;condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is
                    entitled to acquire or receive any shares of capital stock or other securities of Passage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All outstanding shares of Passage Common Stock and other securities of Passage have been issued and granted in material
                    compliance with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS47"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.7<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">SEC Filings; Financial Statements</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents
                    required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act since June&#160;1, 2024 (the &#8220;<span style="font-weight: bold;">Passage SEC Documents</span>&#8221;). As of the time it was filed with the SEC (or, if
                    amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Passage SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the
                    Exchange Act (as the case may be) and as of the time they were filed, none of the Passage SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in
                    order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i) Rule&#160;13a-14 under the Exchange Act and (ii)&#160;18&#160;U.S.C. &#167;1350 (Section&#160;906
                    of the Sarbanes-Oxley Act) relating to the Passage SEC Documents (collectively, the &#8220;<span style="font-weight: bold;">Passage Certifications</span>&#8221;) are accurate and complete and comply as to form and content with all applicable Laws.
                    As used in this <span style="text-decoration: underline;">Section&#160;4.7</span>, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The financial statements (including any related notes) contained or incorporated by reference in the Passage SEC Documents:
                    (i) complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii) were prepared in accordance with GAAP (except as
                    may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form&#160;10-Q of the SEC, and except that the unaudited financial statements are subject to normal and recurring
                    year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii)&#160;fairly present, in all material respects, the
                    financial position of Passage as of the respective dates thereof and the results of operations and cash flows of Passage for the periods covered thereby. Other than as expressly disclosed in the Passage SEC Documents filed prior to the
                    date hereof, there has been no material change in Passage&#8217;s accounting methods or principles that would be required to be disclosed in Passage&#8217;s financial statements in accordance with GAAP. The books of account and other financial
                    records of Passage and each of its Subsidiaries are true and complete in all material respects. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public
                    accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-40<br/>
        </div>

      </div>

    </div>

    <!--End Page 481-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 482-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg45"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Passage, &#8220;independent&#8221; with respect to Passage within the meaning of
            Regulation S-X under the Exchange Act and (iii) to the Knowledge of Passage, in compliance with subsections (g) through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company
            Accounting Oversight Board thereunder. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;4.7(d)</span> of the Passage Disclosure Schedule, Passage has not received any comment letter
                    from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of Passage Common Stock on Nasdaq. Passage has not disclosed any unresolved comments in the
                    Passage SEC Documents. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There have been no formal internal investigations regarding financial reporting or accounting policies and practices
                    discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer, or general counsel of Passage, the Passage Board or any committee thereof, other than ordinary course audits or reviews
                    of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth on <span style="text-decoration: underline;">Section&#160;4.7(f)</span> of the Passage Disclosure Schedule, Passage is in compliance in all material
                    respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage maintains a system of internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the
                    Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and
                    procedures sufficient to provide reasonable assurance (i) that Passage maintains records that in reasonable detail accurately and fairly reflect Passage&#8217;s transactions and dispositions of assets, (ii) that transactions are recorded as
                    necessary to permit preparation of financial statements in accordance with GAAP, (iii)&#160;that receipts and expenditures are made only in accordance with authorizations of management and the Passage Board and (iv) regarding prevention or
                    timely detection of the unauthorized acquisition, use or disposition of Passage&#8217;s assets that could have a material effect on Passage&#8217;s financial statements. Passage has evaluated the effectiveness of Passage&#8217;s internal controls over
                    financial reporting and, to the extent required by applicable Law, presented in any applicable Passage SEC Document that is a report on Form&#160;10-K or Form&#160;10-Q (or any amendment thereto) its conclusions about the effectiveness of the
                    internal controls over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Passage has disclosed to Passage&#8217;s auditors and the Audit Committee of the Passage Board (and made
                    available to Remix a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting that are reasonably likely to
                    adversely affect Passage&#8217;s ability to record, process, summarize and report financial information and (B) any known fraud, whether or not material, that involves management or other employees who have a significant role in Passage or
                    its Subsidiaries&#8217; internal controls over financial reporting. Except as disclosed in the Passage SEC Documents filed prior to the date hereof, Passage&#8217;s internal controls over financial reporting is effective and Passage has not
                    identified any material weaknesses in the design or operation of Passage&#8217;s internal controls over financial reporting. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed
                    to ensure that all information (both financial and nonfinancial) required to be disclosed by Passage in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods
                    specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Passage&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding
                    required disclosure and to make the Passage Certifications and such disclosure controls and procedures are effective. Passage has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by
                    Rule&#160;13a-15 of the Exchange Act. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage has not been and is not currently a &#8220;shell company&#8221; as defined under Section&#160;12b-2 of the Exchange Act. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS48"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.8<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Absence of Changes</span>. Except as set forth on <span style="text-decoration: underline;">Section&#160;4.8</span> of the Passage Disclosure Schedule, since March&#160;31,
                    2026, Passage and its Subsidiaries have conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-41<br/>
        </div>

      </div>

    </div>

    <!--End Page 482-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 483-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg46"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">negotiations and transactions related thereto) and there has not been any
            (a)&#160;Passage Material Adverse Effect or (b) action, event or occurrence that would have required the consent of Remix pursuant to <span style="text-decoration: underline;">Sections 5.2(a)</span>, <span style="text-decoration: underline;">5.2(c)</span>, <span style="text-decoration: underline;">5.2(e)</span>, <span style="text-decoration: underline;">5.2(k)</span>, <span style="text-decoration: underline;">5.2(l)</span>, <span style="text-decoration: underline;">5.2(m)</span>, <span style="text-decoration: underline;">5.2(n)</span>,
            and <span style="text-decoration: underline;">5.2(p)</span> (only with respect to the foregoing Sections) of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement. </div>

          <a id="tANXAS49"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.9<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Absence of Undisclosed Liabilities</span>. Neither Passage nor any of its Subsidiaries has any Liability of a type required
                    to be reflected or reserved for on a balance sheet prepared in accordance with GAAP, except for: (a) Liabilities disclosed, reflected or reserved against in the Passage Balance Sheet, (b)&#160;normal and recurring current Liabilities that
                    have been incurred by Passage or its Subsidiaries since the date of the Passage Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement, or violation of
                    Law), (c) Liabilities for performance of obligations of Passage or any of its Subsidiaries under Passage Contracts, (d)&#160;Liabilities incurred in connection with the Contemplated Transactions and the Subscription Agreement and
                    (e)&#160;Liabilities described in <span style="text-decoration: underline;">Section&#160;4.9</span> of the Passage Disclosure Schedule. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS410"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Title to Assets</span>. Each of Passage and its Subsidiaries owns, and has good and valid title to, or, in the case of leased
                    properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets
                    reflected on the Passage Balance Sheet and (b) all other tangible assets reflected in the books and records of Passage as being owned by Passage. All of such assets are owned or, in the case of leased assets, leased by Passage or any of
                    its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS411"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Real Property; Leasehold</span>. Neither Passage nor any of its Subsidiaries owns or has ever owned any real property, nor is
                    Passage or any of its Subsidiaries party to any agreement to purchase or sell any real property. Passage has made available to Remix (a) an accurate and complete list of all real properties with respect to which Passage directly or
                    indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Passage or any of its Subsidiaries and (b) copies of all leases under which any such real property is possessed (the
                    &#8220;<span style="font-weight: bold;">Passage Real Estate Leases</span>&#8221;), each of which is in full force and effect, with no existing material default thereunder by Passage or to the Knowledge of Passage, the other party thereto. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS412"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.12<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Intellectual Property</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;4.12(a)</span> of the Passage Disclosure Schedule is an accurate, true and complete listing of all Passage Registered
                    IP (other than domain names), including for each item the record owner (and name of any other Person with an ownership interest in such item of Passage Registered IP, if any, and the nature of such ownership interest), jurisdiction,
                    status, date of registration or application and registration or application number of each item, as applicable. <span style="text-decoration: underline;">Section&#160;4.12(a)</span> of the Passage Disclosure Schedule also sets forth, as of the date of this Agreement, a list of all
                    internet domain names in Passage Registered IP or with respect to which Passage or any of its Subsidiaries are the registrant and, with respect to each domain name, the record owner of such domain name and if different, the legal and
                    beneficial owner(s) of such domain name and the applicable domain name registrar. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;4.12(b)</span> of the Passage Disclosure Schedule accurately identifies all Passage Contracts pursuant to which any
                    material Passage IP Rights are licensed to Passage or any of its Subsidiaries (other than to the extent such Passage IP Rights are non-exclusively licensed and are (A) any non-customized software that (1) is licensed solely in
                    executable or object code form pursuant to a nonexclusive license to such software and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or
                    distribution of, any of Passage&#8217;s or its Subsidiaries&#8217; products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any
                    confidential information provided subject to confidentiality obligations, (D) proprietary information and inventions assignment agreements or consulting agreements between Passage or its Subsidiaries and their respective employees or
                    individual independent contractors that are substantially on Passage&#8217;s standard form thereof, (E) ancillary to a sale of products or services to customers or (F) incidental to the provision of services from contract manufacturers,
                    suppliers, distributors or other service providers to Passage or any of its Subsidiaries). To the Knowledge of Passage, each Passage </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-42<br/>
        </div>

      </div>

    </div>

    <!--End Page 483-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 484-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg47"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Contract listed in <span style="text-decoration: underline;">Section&#160;4.12(b) </span>of the Passage Disclosure
            Schedule is in full force and effect and constitutes a legal, valid, and binding obligation of Passage, its Subsidiaries and each other party thereto, and is enforceable against Passage, its Subsidiaries and each other party thereto in
            accordance with its terms. To the Knowledge of Passage, neither Passage, its Subsidiaries, nor any other party to any Passage Contract listed in <span style="text-decoration: underline;">Section&#160;4.12(b)</span> of the Passage Disclosure Schedule has been or is, or has been or is
            alleged to be, in material default under, or has provided or received any notice of breach under, or intention to terminate (including by non-renewal), any Passage Contract listed in <span style="text-decoration: underline;">Section&#160;4.12(b)</span> of the Passage Disclosure Schedule. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;4.12(c)</span> of the Passage Disclosure Schedule accurately identifies each Passage Contract pursuant to which any
                    Person other than Passage or any of its Subsidiaries has been granted any material license under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Passage IP Rights (other than
                    (i) any confidential information provided subject to confidentiality obligations and (ii) any Passage IP Rights to the extent nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of
                    enabling such academic collaborator, supplier or service providers to provide services for Passage&#8217;s or its Subsidiaries&#8217; benefit). To the Knowledge of Passage, each Passage Contract listed in <span style="text-decoration: underline;">Section&#160;4.12(c)</span> of the Passage
                    Disclosure Schedule is in full force and effect and constitutes a legal, valid, and binding obligation of Passage, its Subsidiaries and each other party thereto, and is enforceable against Passage, its Subsidiaries and each other party
                    thereto in accordance with its terms. Neither Passage, its Subsidiaries nor, to the Knowledge of Passage, any other party to any Passage Contract listed in <span style="text-decoration: underline;">Section&#160;4.12(c)</span> of the Passage Disclosure Schedule has provided or
                    received any written notice or allegation of breach under, or intention to terminate (including by non-renewal), any Passage Contract listed in <span style="text-decoration: underline;">Section&#160;4.12(c)</span> of the Passage Disclosure Schedule. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as identified on <span style="text-decoration: underline;">Section&#160;4.12(d)</span> of the Passage Disclosure Schedule, neither Passage nor any of its
                    Subsidiaries is bound by, no Passage Owned IP Rights are subject to, and to the Knowledge of Passage, no Passage Licensed IP Rights that are exclusively licensed to Passage or any of its Subsidiaries are subject to (other than the
                    rights of the applicable licensors), any Contract containing any covenant or other provision that materially limits or restricts the ability of Passage or any of its Subsidiaries to use, exploit, assert, or enforce any Passage
                    Registered IP anywhere in the world. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Passage Owned IP Rights
                    (other than co-owned rights identified in <span style="text-decoration: underline;">Section&#160;4.12(c)</span> of the Passage Disclosure Schedule), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">(i) All documents and instruments necessary to register or apply for or renew registration of Passage Registered IP owned by
                    Passage or one of its Subsidiaries, and (ii) to the Knowledge of Passage, all documents and instruments necessary to register or apply for or renew registration of Passage Registered IP exclusively licensed to Passage or any of its
                    Subsidiaries, have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority. (A) Passage or any of its Subsidiaries has filed all statements of use and paid all renewal and maintenance
                    fees, annuities and other fees with respect to the Passage Registered IP owned by Passage or any of its Subsidiaries, and (B) To the Knowledge of Passage, Passage or its Subsidiaries have executed all documents and instruments necessary
                    to register or apply for or renew registration of Passage Registered IP exclusively licensed to Passage or any of its Subsidiaries, in each case, that are due and payable as of the date of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Person who is or was an employee, contractor or consultant of Passage or any of its Subsidiaries and who is or was
                    involved in the creation, discovery, reduction to practice or development of any material Intellectual Property for Passage or any of its Subsidiaries has signed a valid, enforceable written agreement containing a present assignment of
                    all rights, title and interests in and to such Intellectual Property to Passage or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Passage and its Subsidiaries. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Passage, no current or former member, officer, director, or employee of Passage or any of its
                    Subsidiaries has any claim, right (whether or not currently exercisable), or interest to or in any Passage Owned IP Rights. To the Knowledge of Passage, no employee of Passage or any of its Subsidiaries is (A)&#160;bound by or otherwise
                    subject to any Contract restricting him or her from performing his or her duties for Passage or such Subsidiary or (B) in breach of any Contract with any former employer or other Person </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-43<br/>
        </div>

      </div>

    </div>

    <!--End Page 484-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 485-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg48"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">concerning Passage Owned IP Rights purported to be owned by Passage or
            such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Passage Owned IP Rights purported to be owned by Passage or such Subsidiary. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No funding, facilities, or personnel of any Governmental Authority were used, directly or indirectly, to develop or create,
                    in whole or in part, any Passage Owned IP Rights, or, to the Knowledge of Passage, any Passage Licensed IP Rights that are exclusively licensed to Passage or any of its Subsidiaries, and no educational institution has any right to, or
                    right to royalties for, or to impose any requirement on the manufacture or commercialization of any product incorporating, any Passage Owned IP Rights, or, to the Knowledge of Passage, any Passage Licensed IP Rights that are exclusively
                    licensed to Passage. To the Knowledge of Passage, no Governmental Authority has any right to (including any &#8220;step-in&#8221; or &#8220;march-in&#8221; rights with respect to), ownership of, commercialization of, or right to royalties or other payments for
                    any Passage Owned IP Rights, or, to the Knowledge of Passage, any Passage Licensed IP Rights that are exclusively licensed to Passage or any of its Subsidiaries. Without limiting the generality of the foregoing, to the Knowledge of
                    Passage, no invention claimed or covered by any Patent within the Passage Owned IP Rights, or, to the Knowledge of Passage, any Passage Licensed IP Rights that are exclusively licensed to Passage or any of its Subsidiaries, (A) was
                    conceived or reduced to practice in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, (B) is a &#8220;subject invention&#8221; as that term is described in 35
                    U.S.C. Section&#160;201(e), or (C) is otherwise subject to the provisions of the Bayh-Dole Act or any similar Law of any other jurisdiction, including with respect to any Patents that are part of the Passage IP Rights. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect,
                    maintain and enforce its rights in all proprietary information that Passage or such Subsidiary holds, or purports to hold, as confidential or a trade secret. To the Knowledge of Passage, neither Passage nor any of its Subsidiaries has
                    made any of its trade secrets or other material confidential or proprietary information that it intended to maintain as confidential information available to any other Person except pursuant to written agreements requiring such Person
                    to maintain the confidentiality of such trade secrets or confidential information. To the Knowledge of Passage, there have been no material security breaches, outages, violations or unauthorized access to any of the proprietary
                    information that Passage or any of its Subsidiaries holds, or purports to hold, as confidential or a trade secret, except as would not have, individually or in the aggregate, a Passage Material Adverse Effect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has assigned or otherwise transferred ownership of, or agreed to assign or
                    otherwise transfer ownership of, any Passage IP Rights to any other Person. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Passage, neither Passage nor any of its Subsidiaries has taken or failed to take any action that could be
                    reasonably expected to result in the abandonment, invalidity, cancellation, forfeiture, relinquishing, invalidation or unenforceability of any Passage Registered IP (including with respect to any Trademark, a failure to exercise
                    adequate quality controls or an assignment in gross without the accompanying goodwill), other than in the Ordinary Course of Business by Passage or any of its Subsidiaries for Patent or Trademark prosecution. To the Knowledge of
                    Passage, each item of Passage Registered IP has been duly maintained and is not expired, abandoned or cancelled. To the Knowledge of Passage, each of the Patents included in the Passage Registered IP accurately identifies each and every
                    inventor of the claims thereof as determined in accordance with the applicable laws of the jurisdiction in which such Patent is issued or pending. To the Knowledge of Passage, neither Passage nor any of its Subsidiaries has engaged in
                    patent or copyright misuse or any fraud or inequitable conduct in connection with any Passage Registered IP. Each of Passage and its Subsidiaries and their respective counsel have complied with their duties of candor and disclosure and
                    have made no material misrepresentations in the filings submitted to the applicable Governmental Authorities with respect to any of the Passage Registered IP. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Passage, the Passage IP Rights constitute all Intellectual Property necessary for Passage or any of its
                    Subsidiaries to conduct its business as currently conducted or proposed to be conducted; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that the foregoing representation is not a
                    representation with respect to non-infringement of Intellectual Property. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage has delivered, or made available to Remix, a complete and accurate copy of all material Passage IP Rights Agreements.
                  </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-44<br/>
        </div>

      </div>

    </div>

    <!--End Page 485-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 486-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg49"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Passage, the manufacture, marketing, offering for sale, sale, importation, use or intended use or other
                    disposal of any product under development by Passage or any of its Subsidiaries does not violate, and, since June&#160;1, 2023, has not violated, any license or agreement between Passage or its Subsidiaries and any third party in any
                    material respect, and, to the Knowledge of Passage, does not violate, infringe or misappropriate, and, since June&#160;1, 2023, has not violated, infringed or misappropriated, any valid and issued Patent or other Intellectual Property of any
                    other Person. To the Knowledge of Passage, no third party is breaching, violating, infringing or misappropriating or, since June&#160;1, 2023, has violated, infringed or misappropriated, any Passage Owned IP Rights, or otherwise is breaching
                    or, since June&#160;1, 2023, has breached any material Passage IP Rights Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As of the date of this Agreement, neither Passage nor any of its Subsidiaries is a party to any Legal Proceeding (including,
                    but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Passage Registered IP. None
                    of the Passage Owned IP Rights, and to the Knowledge of Passage, the Passage Licensed IP Rights that are exclusively licensed to Passage or any of its Subsidiaries, have been adjudged invalid or unenforceable in whole or part, and all
                    Passage Owned IP Rights, and to the Knowledge of Passage, all Passage Licensed IP Rights that are exclusively licensed to Passage or any of its Subsidiaries, are in full force and effect. No Patents within the Passage Registered IP
                    owned by Passage, or to the Knowledge of Passage, no Patents within the Passage Registered IP exclusively licensed to Passage or any of its Subsidiaries, have been subject to any interference, derivation, reexamination (including ex
                    parte reexamination, inter partes reexamination, inter partes review, or post grant review), reissue, cancellation, opposition, claim, allegation or other action, including any proceeding in which the scope, validity, inventorship,
                    ownership or enforceability of any such Patent is being or has been contested or challenged. Since June&#160;1, 2023, neither Passage nor any of its Subsidiaries have received any written notice asserting that any Passage Registered IP or
                    the proposed use, sale, offer for sale, license or disposition of products, methods, or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Passage or any of its
                    Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(q)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Passage, no registered trademark or trade name owned, used, or applied for by Passage or any of its
                    Subsidiaries conflicts or interferes with any registered trademark or trade name owned, used, or applied for by any other Person except as would not have a Passage Material Adverse Effect. To the Knowledge of Passage, none of the
                    goodwill associated with or inherent in any registered trademark in which Passage or its Subsidiaries has or purports to have an ownership interest has been impaired as determined by Passage in accordance with GAAP. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(r)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except (i) as would not have a Passage Material Adverse Effect or (ii) as contained in license, distribution or service
                    agreements entered into in the Ordinary Course of Business by Passage or any of its Subsidiaries, to the Knowledge of Passage, (A) neither Passage nor any of its Subsidiaries is bound by any Contract to indemnify, defend, hold harmless,
                    or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to Passage or any of its Subsidiaries, taken as a whole and (B) neither Passage nor any of its
                    Subsidiaries has ever assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which
                    assumption, agreement or responsibility remains in force as of the date of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(s)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">To the Knowledge of Passage, neither Passage nor any of its Subsidiaries is party to any Contract that, as a result of such
                    execution, delivery and performance of this Agreement, will (i) cause the grant, assignment or transfer to any other third party of any license or other right to or in any Passage Registered IP, (ii)&#160;result in a breach of, default under
                    termination of, or acceleration or modification of such Contract with respect to any Passage Registered IP, (iii) alter, encumber impair or extinguish, or result in any Encumbrance with respect to the right of Passage or the Surviving
                    Corporation and its Subsidiaries to use, sell or license or enforce any Passage Registered IP or portion thereof or (iv) result in Passage or any of its Subsidiaries being bound by or subject to any exclusivity obligations, non-compete
                    or other restrictions on the operation or scope of their respective businesses, or to any obligation to grant any rights in or to any Passage Registered IP, except, in each of (i), (ii), (iii) and (iv), for the occurrence of any such
                    grant or impairment that would not individually or in the aggregate, result in a Passage Material Adverse Effect. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-45<br/>
        </div>

      </div>

    </div>

    <!--End Page 486-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 487-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg50"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(t)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding any other provisions of this Agreement, Remix acknowledges and agrees that the representations and warranties
                    contained in this <span style="text-decoration: underline;">Section&#160;4.12</span> are the only representations or warranties made by Passage or any of its Subsidiaries with respect to Intellectual Property, and no other provisions of this Agreement shall be interpreted as
                    containing any representation or warranty with respect thereto. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS413"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Agreements, Contracts and Commitments</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Other than Excepted Contracts, <span style="text-decoration: underline;">Section&#160;4.13</span> of the Passage Disclosure Schedule lists the following Passage Contracts
                    in effect as of the date of this Agreement other than the Subscription Agreement (each, a &#8220;<span style="font-weight: bold;">Passage Material Contract</span>&#8221;<span style="font-weight: bold;"> </span>and collectively, the &#8220;<span style="font-weight: bold;">Passage Material Contracts</span>&#8221;): </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract that is a collective bargaining agreement or other agreement or arrangement with any labor union, works
                    council or labor organization; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract for the employment or engagement of any individual on an employee, consulting or other basis that
                    provides for annual base compensation in excess of $250,000; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract with any Passage Associate that provides for retention, change in control, transaction or other similar
                    payments or benefits, whether or not payable as a result of the Contemplated Transactions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of
                    Business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract containing (A) any covenant limiting the freedom of Passage or any of its Subsidiaries or the Surviving
                    Corporation to engage in any line of business or compete with any Person, or limiting the development, manufacture, or distribution of Passage&#8217;s or any of its Subsidiaries&#8217; products or services, (B) any most-favored pricing arrangement,
                    (C)&#160;any exclusivity provision or (D)&#160;any non-solicitation provision (excluding such provisions to the extent they provide for non-solicitation of employees, consultants or individual independent contractors); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vi)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract (A) pursuant to which any Person granted Passage or any of its Subsidiaries an exclusive license to any
                    Intellectual Property, or (B) pursuant to which Passage or any of its Subsidiaries granted any Person an exclusive license to any Passage IP Rights or (C) that is or should be listed in Section&#160;4.12(b) or 4.12(c) of the Passage
                    Disclosure Schedule; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of
                    $250,000 in the aggregate pursuant to its express terms and not cancelable without penalty; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(viii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity,
                    in each case, involving payments in excess of $250,000 in the aggregate after the date of this Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ix)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other
                    agreements or instruments relating to the borrowing of money or extension of credit in excess of $250,000 in the aggregate or creating any material Encumbrances with respect to any assets of Passage or any of its Subsidiaries or any
                    loans or debt obligations with officers or directors of Passage or any of its Subsidiaries; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(x)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract that is: (A) a distribution agreement (identifying any that contain exclusivity provisions), (B) an
                    agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Passage or any of its Subsidiaries requiring payment by or to Passage or any of its Subsidiaries after the date
                    of this Agreement in excess of $250,000 pursuant to its express terms, (C) a dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Passage or any of its
                    Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Passage or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that
                    will not be owned, in whole or in part, by Passage or such Subsidiary or (D) a Contract containing a license under any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third
                    party to manufacture or </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-46<br/>
        </div>

      </div>

    </div>

    <!--End Page 487-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 488-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg51"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 70pt; text-align: justify;">produce any product, service or technology of Passage or any of its
            Subsidiaries (except to the extent such license is granted by Passage or any of its Subsidiaries to its service providers for provision of goods or services to Passage or any of its Subsidiaries) or any Contract to sell, distribute or
            commercialize any products or service of Passage or any of its Subsidiaries, in each case of clause (D), except for Passage Contracts entered into in the Ordinary Course of Business; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xi)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person,
                    providing advisory services to Passage or any of its Subsidiaries in connection with the Contemplated Transactions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">each Passage Contract to which Passage or any of its Subsidiaries is a party or by which any of their assets and properties
                    is currently bound, which involves annual obligations of payment by, or annual payments to, Passage or such Subsidiary in excess of $250,000; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xiii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a Passage Real Estate Lease; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xiv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">a Contract disclosed in or required to be disclosed in <span style="text-decoration: underline;">Section&#160;4.12(b)</span> or <span style="text-decoration: underline;">Section&#160;4.12(c)</span> of the Passage
                    Disclosure Schedule; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(xv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any other Passage Contract that is not terminable at will (with no penalty or payment) by Passage or any of its Subsidiaries,
                    and (A) which involves payment or receipt by Passage or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $250,000 in the aggregate, or obligations after the date of this
                    Agreement in excess of $500,000 in the aggregate or (B) that is material to the business or operations of Passage and its Subsidiaries taken as a whole. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage has delivered or made available to Remix accurate and complete copies of all Passage Material Contracts, including
                    all amendments thereto. There are no Passage Material Contracts that are not in written form. Neither Passage nor any of its Subsidiaries has, nor, to the Knowledge of Passage, as of the date of this Agreement, has any other party to a
                    Passage Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any such Passage Material Contract in such manner as would permit any
                    party to cancel or terminate any such Passage Material Contract, or would permit any party to seek material damages thereunder. As to Passage and its Subsidiaries, as of the date of this Agreement, each Passage Material Contract is
                    valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Passage Material Contract to change, any material amount paid or
                    payable to Passage or any of its Subsidiaries under any Passage Material Contract or any other material term or provision of any Passage Material Contract. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS414"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.14<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Compliance; Permits; Restrictions</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage and each of its Subsidiaries is, and since June&#160;1, 2023 has been, in material compliance with all applicable Laws. No
                    investigation, claim, suit, proceeding, audit, Order, or other action by any Governmental Authority is pending or, to the Knowledge of Passage, threatened against Passage or any of its Subsidiaries. There is no agreement or Order
                    binding upon Passage or any of its Subsidiaries which (i) could reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Passage or any of its Subsidiaries, any acquisition of material
                    property by Passage or any of its Subsidiaries or the conduct of business by Passage or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Passage&#8217;s ability to comply with or perform
                    any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Passage and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the
                    business of Passage and Merger Sub as currently conducted (collectively, the &#8220;<span style="font-weight: bold;">Passage Permits</span>&#8221;).<span style="font-weight: bold;"> </span><span style="text-decoration: underline;">Section&#160;4.14(b)</span> of the Passage Disclosure Schedule
                    identifies each Passage Permit. Each of Passage and its Subsidiaries is in material compliance with the terms of such Passage Permits. No Legal Proceeding is pending or, to the Knowledge of Passage, threatened, which seeks to revoke,
                    substantially limit, suspend, or materially modify any Passage Permit. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-47<br/>
        </div>

      </div>

    </div>

    <!--End Page 488-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 489-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg52"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There are no Legal Proceedings pending or, to the Knowledge of Passage, threatened in writing with respect to an alleged
                    material violation by Passage or any of its Subsidiaries of the FDCA or any other similar Law promulgated by a Drug Regulatory Agency. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Passage and its Subsidiaries holds all required material Governmental Authorizations issuable by any Drug Regulatory
                    Agency necessary for the conduct of the business of Passage and Merger Sub as currently conducted, and, as applicable, the research, development, testing, manufacturing, packaging, processing, storage, labeling, sale, marketing,
                    advertising, distribution and importation or exportation, in each case as currently conducted, of any of its product candidates (the &#8220;<span style="font-weight: bold;">Passage Product Candidates</span>&#8221;) (collectively, the &#8220;<span style="font-weight: bold;">Passage Regulatory Permits</span>&#8221;)<span style="font-weight: bold;"> </span>and, since June&#160;1, 2023, no such Passage Regulatory Permit has been (i)&#160;revoked, withdrawn, suspended, cancelled or terminated or
                    (ii)&#160;modified in any material, adverse manner. Since June&#160;1,&#160;2023, Passage has maintained and is in compliance in all material respects with the terms of such Passage Regulatory Permits and neither Passage nor any of its Subsidiaries
                    has, since June&#160;1, 2023, received any written notice or other written communication from any Drug Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Passage
                    Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Passage Regulatory Permit. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth in Section&#160;4.14(e) of the Passage Disclosure Schedule, all clinical, pre-clinical and other studies and
                    tests conducted by or on behalf of, or sponsored by, Passage or its Subsidiaries, in which Passage or its Subsidiaries or their respective product candidates, including the Passage Product Candidates, have participated (collectively, &#8220;<span style="font-weight: bold;">Passage Studies</span>&#8221;), were and, if still pending, are being conducted in compliance in all material respects with any applicable regulations of the Drug Regulatory Agencies and other applicable Law to
                    which such Passage Studies are or were subject, including, without limitation, 21&#160;C.F.R. Parts 50, 54, 56, 58 and 312. Neither Passage nor any of its Subsidiaries has received any written notices, correspondence, or other communications
                    from any Drug Regulatory Agency requiring, or, to the Knowledge of Passage, any action to place a clinical hold order on, or otherwise terminate, delay, or suspend any such Passage Studies, other than ordinary course communications
                    regarding the design and implementation of such Passage Studies. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries, nor, to the Knowledge of Passage, any contract manufacturer with respect to any
                    Passage Product Candidate, is the subject of any pending or, to the Knowledge of Passage, threatened investigation in respect of its business or products by the FDA pursuant to the Application Integrity Policy or any other similar Law.
                    To the Knowledge of Passage, neither Passage nor any of its Subsidiaries nor any contract manufacturer with respect to any Passage Product Candidate has committed any acts, made any statement, or failed to make any statement, in each
                    case in respect of Passage&#8217;s business or products that would violate the Application Integrity Policy or any other similar Law. Since June&#160;1, 2023, none of Passage, any of its Subsidiaries, or to the Knowledge of Passage, any of their
                    respective officers, employees, agents or contract manufacturers with respect to any Passage Product Candidate has been convicted of any crime that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a, (ii) 42
                    U.S.C. &#167; 1320a-7, or (iii) any other applicable Law. To the Knowledge of Passage, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against
                    Passage, any of its Subsidiaries, any contract manufacturer with respect to any Passage Product Candidate, or any of its respective officers, employees or agents. Neither Passage nor any of its Subsidiaries is a party to or has any
                    reporting obligations under any corporate integrity agreements, monitoring agreements, deferred or non-prosecution agreements, consent decrees, settlement orders, or similar agreements with or imposed by any Governmental Authority. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All manufacturing operations conducted by, or to the Knowledge of Passage, for the benefit of, Passage or its Subsidiaries in
                    connection with any Passage Product Candidate, since June&#160;1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDCA, and to the extent applicable, the respective
                    counterparts thereof promulgated by Governmental Authorities in countries outside the United States. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">None of Passage, its Subsidiaries or, to the Knowledge of Passage, any manufacturing site of a contract manufacturer, in each
                    case with respect to such parties&#8217; or such site&#8217;s activities conducted with respect to any Passage Product Candidate, (i) is subject to a Drug Regulatory Agency shutdown or import or export prohibition or (ii) has since June&#160;1, 2023,
                    received any unresolved Form&#160;FDA 483, notice of violation, </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-48<br/>
        </div>

      </div>

    </div>

    <!--End Page 489-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 490-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg53"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">warning letter, untitled letter, or similar correspondence or notice from
            the FDA or other Governmental Authority alleging or asserting material noncompliance with any applicable Law, and, to the Knowledge of Passage, neither the FDA nor any other Governmental Authority has threatened such action. </div>

          <a id="tANXAS415"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.15<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Legal Proceedings; Orders</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth in <span style="text-decoration: underline;">Section&#160;4.15</span> of the Passage Disclosure Schedule, there is no pending Legal Proceeding and, to
                    the Knowledge of Passage, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves Passage or any of its Subsidiaries or any Passage Associate (in his or her capacity as such) or any of the material assets
                    owned or used by Passage or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There is no Order to which Passage or any of its Subsidiaries, or any of the material assets owned or used by Passage or any
                    of its Subsidiaries is subject. To the Knowledge of Passage, no officer or other Key Employee of Passage or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing any
                    conduct, activity or practice relating to the business of Passage or any of its Subsidiaries or to any material assets owned or used by Passage or any of its Subsidiaries. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS416"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.16<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Tax Matters</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Passage and each of its Subsidiaries has timely filed all income Tax Returns and all other material Tax Returns that
                    were required to be filed by or with respect to it under applicable Law. All such Tax Returns were correct and complete in all material respects and have been prepared in substantial compliance with all applicable Law. Subject to
                    exceptions as would not be material, no claim has ever been made by a Governmental Authority in a jurisdiction where Passage or any of its Subsidiaries does not file a particular type of Tax Return that Passage or any of its
                    Subsidiaries is subject to taxation by that jurisdiction that would require the filing of such a Tax Return. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All material amounts of Taxes due and owing by Passage and each of its Subsidiaries (whether or not shown on any Tax Return)
                    have been timely paid. The unpaid Taxes of Passage and each of its Subsidiaries for periods (or portions thereof) ending on or prior to the date of the Passage Balance Sheet do not materially exceed the accruals for current Taxes set
                    forth on the Passage Balance Sheet. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Passage and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material
                    Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There are no Encumbrances for material Taxes (other than Encumbrances described in clause (i) of the definition of &#8220;Permitted
                    Encumbrances&#8221;) upon any of the assets of Passage or any of its Subsidiaries. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No deficiencies for a material amount of Taxes with respect to Passage or any of its Subsidiaries have been claimed, proposed
                    or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to
                    any Liability in respect of Taxes of Passage or any of its Subsidiaries. Neither Passage nor any of its Subsidiaries has waived any statute of limitations in respect of material Taxes or agreed to any extension of time with respect to a
                    material Tax assessment or deficiency. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has been a United States real property holding corporation within the meaning of
                    Section&#160;897(c)(2) of the Code during the applicable period specified in Section&#160;897(c)(1)(A)(ii) of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries is a party to any material Tax allocation, Tax sharing or similar agreement
                    (including indemnity arrangements), other than Ordinary Course Agreements. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S.&#160;federal
                    income Tax Return (other than a group the common parent of which is Passage). Neither Passage nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Passage and Merger Sub) under Treasury
                    Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-49<br/>
        </div>

      </div>

    </div>

    <!--End Page 490-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 491-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg54"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has been a party to any joint venture, partnership, or other arrangement that is
                    treated as a partnership for U.S. federal income Tax purposes. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has a permanent establishment (within the meaning of an applicable Tax treaty) or
                    other office or fixed place of business in a country other than the country in which it is organized. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by
                    another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for
                    purposes of Treasury Regulations Section&#160;1.6011-4(b)(2). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries will be required to include any material item of income or gain in, or exclude
                    any material item of deduction or loss from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i) change in, or use of improper, method of accounting for a taxable period
                    ending on or prior to the Closing Date; (ii)&#160;&#8220;closing agreement&#8221; as described in Section&#160;7121 of the Code (or any corresponding or similar provision of state, local or foreign income Tax law) executed on or prior to the Closing Date;
                    (iii)&#160;installment sale or open transaction disposition made on or prior to the Closing Date; (iv)&#160;prepaid amount, advance payments or deferred revenue received or accrued on or prior to the Closing Date; (v)&#160;intercompany transaction or
                    excess loss amount described in Treasury Regulations under Section&#160;1502 of the Code (or any corresponding or similar provision of state, local or foreign income Tax Law); or (vi) application of Section&#160;367(d) of the Code to any transfer
                    of intangible property on or prior to the Closing Date. Passage has not made any election under Section&#160;965(h) of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;4.16(n)</span> of the Passage Disclosure Schedule sets forth the entity classification of Passage and each of its
                    Subsidiaries for U.S. federal income tax purposes. Neither Passage nor any of its Subsidiaries has made an election or taken any other action to change its federal and state income tax classification from such existing classification. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries has taken or knowingly failed to take any action, nor to the Knowledge of
                    Passage, are there any facts or circumstances, in each case, that would reasonably be expected to prevent or impede the Merger from qualifying for the Intended Tax Treatment. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS417"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.17<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Employee and Labor Matters; Benefit Plans</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;4.17(a)</span> of the Passage Disclosure Schedule contains a complete and accurate list of all Passage employees as
                    of the date of this Agreement, setting forth for each employee: job title; classification as exempt or non-exempt for wage and hour purposes; annual base salary, hourly rate or other rates of compensation; bonus potential; full-time or
                    part-time status; date of hire; business location; status (i.e., active or inactive and if inactive, the type of leave and estimated duration); and any visa or work permit status and the date of expiration, if applicable. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;4.17(b)</span> of the Passage Disclosure Schedule contains a complete and accurate list as of the date hereof of all
                    of the independent contractors, consultants, temporary employees, leased employees or other agents employed or used by Passage and classified by Passage as other than employees, or compensated other than through wages paid by Passage
                    through Passage&#8217;s payroll department (&#8220;<span style="text-decoration: underline;">Passage Contingent Workers</span>&#8221;), showing for each Passage Contingent Worker such individual&#8217;s engagement date, role in the business, work location, and fee or compensation arrangements. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage nor any of its Subsidiaries is a party to, bound by the terms of, or has a duty to bargain under, any
                    collective bargaining agreement or other Contract with a labor union, works council or labor organization representing any Passage Associate, and there are no labor unions, works council or labor organizations representing or, to the
                    Knowledge of Passage, purporting to represent or seeking to represent any Passage Associates, including through the filing of a petition for representation election. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Section&#160;4.17(d)</span> of the Passage Disclosure Schedule lists all material Passage Employee Plans. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As applicable with respect to each material Passage Employee Plan, Passage has made available to Remix, true and complete
                    copies of (i) the plan document, including all amendments thereto, and in the case of an </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-50<br/>
        </div>

      </div>

    </div>

    <!--End Page 491-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 492-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg55"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">unwritten Employee Plan, a written description of all material terms
            thereof, (ii) all related trust instruments or other funding-related documents and insurance contracts, (iii) the summary plan description and each summary of material modifications thereto, (iv) the financial statements for the most recent
            year for which such financial statements are available (in audited form, if available or required by ERISA) and, where applicable, annual reports with any Governmental Authority (<span style="font-style: italic;">e.g.</span>,<span style="font-style: italic;"> </span>Form&#160;5500 and all schedules thereto), (v)&#160;the most recent IRS determination or opinion letter, (vi) written results of any required compliance testing for the three most recent plan years, and (vii) all
            material, non-routine notices, filings or correspondence during the past three years with any Governmental Authority. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Passage Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable
                    determination letter or may rely on a favorable opinion letter with respect to such qualified status from the IRS to the effect that such plan is qualified under Section&#160;401(a) of the Code and the related trust is exempt from federal
                    income Taxes under Section&#160;501(a) of the Code. To the Knowledge of Passage, nothing has occurred that would reasonably be expected to cause the loss of the qualified status of any such Passage Employee Plan or the Tax exempt status of
                    any related trust. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Passage Employee Plan has been established, maintained and operated in compliance, in all material respects, with its
                    terms and all applicable Laws, including, without limitation, the Code and ERISA. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Passage, threatened with respect to any
                    Passage Employee Plan. All material payments and/or contributions required to have been made with respect to all Passage Employee Plans have been made in accordance with the terms of the applicable Passage Employee Plan and applicable
                    Law in all material respects and neither Passage nor any Passage ERISA Affiliate has any material Liability for any such unpaid contributions with respect to any Passage Employee Plan. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither Passage, any of its Subsidiaries nor any of their ERISA Affiliates maintains, contributes to, is required to
                    contribute to or has any Liability with respect to (i) any &#8220;employee benefit plan&#8221; (within the meaning of Section&#160;3(2) of ERISA) that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer
                    Plan, (iii) any Multiple Employer Plan, or (iv) any Multiple Employer Welfare Arrangement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No Passage Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service
                    or retirement, other than (i) pursuant to COBRA or an analogous state law requirement (the full cost of which is borne by such Person or such Person&#8217;s dependents or beneficiaries) or (ii)&#160;continuation coverage through the end of the
                    month in which such termination or retirement occurs. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">No Passage Employee Plan is subject to any law of a foreign jurisdiction outside of the United States. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Passage Employee Plan that constitutes in any part a nonqualified deferred compensation plan within the meaning of
                    Section&#160;409A of the Code has complied in all material respects with Section&#160;409A of the Code, to the extent applicable, and no compensation has been or would reasonably be expected to be includable in the gross income of any Passage
                    Associate as a result of the operation of Section&#160;409A of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage and its Subsidiaries are, and since June&#160;1, 2023 have been, in compliance in all material respects with all
                    applicable Laws respecting labor, employment and employment practices, including terms and conditions of employment, worker classification, tax withholding, unemployment compensation, workers&#8217; compensation, prohibited discrimination,
                    harassment, equal employment, fair employment practices, meal and rest periods, work authorization and immigration status, employee safety and health, wages (including overtime wages), pay equity, affirmative action, restrictive
                    covenants, compensation, and hours of work. There are no Legal Proceedings pending or, to the Knowledge of Passage, threatened against Passage or any of its Subsidiaries relating to any labor or employment matters or any Passage
                    Associate. Passage is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state, or local agency or Governmental Authority with respect to employment practices. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Since June&#160;1, 2023, (i) Passage has not taken any action which would constitute a &#8220;plant closing&#8221;, &#8220;collective dismissal&#8221;,
                    &#8220;group dismissal&#8221;, &#8220;group termination&#8221;, &#8220;mass termination&#8221;, or &#8220;mass layoff&#8221; within the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-51<br/>
        </div>

      </div>

    </div>

    <!--End Page 492-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 493-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg56"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">meaning of the WARN Act, (ii) issued any written notification of a plant
            closing or mass layoff required by the WARN Act (nor has Passage or any of its Subsidiaries been under any requirement or obligation to issue any such notification), or (iii) incurred any Liability or obligation under the WARN Act that remains
            unsatisfied. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Since June&#160;1, 2023, there has never been, nor to the Knowledge of Passage has there been any threat of, any strike, slowdown,
                    work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, affecting Passage or its Subsidiaries. No event has occurred within the past six (6) months, and, to
                    the Knowledge of Passage, no condition or circumstance exists, that would reasonably be expected to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing
                    activity, question concerning representation or any similar activity or dispute. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">There is no contract, agreement, plan or arrangement to which Passage or any of its Subsidiaries is a party or by which it is
                    bound to make any payment or compensate any Passage Associate for Taxes incurred pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Neither the execution and delivery of this Agreement, the shareholder approval of this Agreement, nor the consummation of the
                    Contemplated Transactions (either alone or in conjunction with any other event, including without limitation, a termination of employment) will result in any (i) payment (including severance, forgiveness of indebtedness or otherwise) or
                    benefit becoming due to a Passage Associate, (ii)&#160;increase in any benefits or the compensation payable under any Passage Employee Plan, (iii)&#160;acceleration of the time of payment, funding or vesting of any such compensation or benefits
                    or any loan forgiveness, (iv)&#160;restriction on the right of Passage or any of its Subsidiaries or, after the consummation of Contemplated Transactions, the Surviving Corporation, to merge, amend, terminate or transfer any Passage Employee
                    Plan, or (v)&#160;&#8220;excess parachute payment&#8221; (within the meaning of Section&#160;280G of the Code). </div>
                </td>

  </tr>


</table>
          <a id="tANXAS418"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.18<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Environmental Matters</span>. Since June&#160;1, 2023, Passage and each of its Subsidiaries has complied with all applicable
                    Environmental Laws, which compliance includes the possession by Passage of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for
                    any failure to be in compliance that, individually or in the aggregate, would not result in a Passage Material Adverse Effect. Neither Passage nor any of its Subsidiaries has received since June&#160;1, 2023, any written notice or other
                    communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Passage or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the
                    Knowledge of Passage, there are no circumstances that may prevent or interfere with Passage&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not have a Passage
                    Material Adverse Effect. To the Knowledge of Passage: (a) no current or prior owner of any property leased or controlled by Passage or any of its Subsidiaries has received since June&#160;1, 2023, any written notice or other communication
                    relating to property owned or leased at any time by Passage or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Passage or any of its
                    Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (b) neither Passage nor any of its Subsidiaries has any material Liability under any Environmental Law. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS419"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.19<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Insurance</span>. Passage has made available to Remix accurate and complete copies of all material insurance policies and all
                    material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Passage and its Subsidiaries (including Merger Sub). Each of such insurance policies is in full force and effect and
                    Passage and its Subsidiaries (including Merger Sub) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since June&#160;1, 2023, neither Passage nor any
                    of its Subsidiaries has received any notice or other communication regarding any actual or possible: (a}&#160;cancellation or invalidation of any insurance policy or (b) refusal or denial of any coverage, reservation of rights or rejection
                    of any material claim under any insurance policy. Each of Passage and its Subsidiaries (including Merger Sub) has provided timely written notice to the appropriate insurance carrier(s) of each </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-52<br/>
        </div>

      </div>

    </div>

    <!--End Page 493-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 494-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg57"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">Legal Proceeding pending against Passage or such Subsidiary for which
            Passage or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Passage or any of its Subsidiaries of its intent to do so.
          </div>

          <a id="tANXAS420"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.20<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Transactions with Affiliates</span>. Except as set forth in the Passage SEC Documents filed prior to the date of this
                    Agreement, since the date of Passage&#8217;s last proxy statement filed in 2026 with the SEC, no event has occurred that would be required to be reported by Passage pursuant to Item&#160;404 of Regulation S-K promulgated by the SEC. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS421"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.21<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Financial Advisors</span>. Except as set forth on <span style="text-decoration: underline;">Section&#160;4.21</span> of the Passage Disclosure Schedule, no broker,
                    finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on
                    behalf of Passage. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS422"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.22<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Valid Issuance; No Bad Actor</span>. The Passage Common Stock to be issued in the Merger will, when issued in accordance with
                    the provisions of this Agreement, be validly issued, fully paid and nonassessable. To the Knowledge of Passage, as of the date of this Agreement and as of the Closing, no &#8220;bad actor&#8221; disqualifying event described in
                    Rule&#160;506(d)(l)(i)-(viii) of the Securities Act (a &#8220;<span style="font-weight: bold;">Disqualifying Event</span>&#8221;)<span style="font-weight: bold;"> </span>is applicable to Passage or, to Passage&#8217;s Knowledge, any Passage Covered Person,
                    except for a Disqualifying Event as to which Rule&#160;506(d)(2)(ii-iv) or (d)(3) of the Securities Act is applicable. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS423"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.23<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Privacy and Data Security</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage and its Subsidiaries have complied with all applicable Privacy Laws and the applicable terms of any Passage Contracts
                    relating to privacy, security, collection or use of Personal Information of any individuals (including clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care
                    professionals, clinical trial investigators, researchers, pharmacists) that interact with Passage or any of its Subsidiaries in connection with the operation of Passage&#8217;s and its Subsidiaries&#8217; business, except for such noncompliance as
                    has not had, and would not have, individually or in the aggregate, a Passage Material Adverse Effect. To the Knowledge of Passage, Passage has implemented and maintains reasonable written policies and procedures, satisfying the
                    requirements of applicable Privacy Laws and Passage Contracts, concerning the privacy, security, collection and use of Personal Information (&#8220;<span style="font-weight: bold;">Passage Privacy Policies</span>&#8221;) and has complied with the
                    same, except for such noncompliance as has not to the Knowledge of Passage had, and would not have, individually or in the aggregate, a Passage Material Adverse Effect. To the Knowledge of Passage, as of the date hereof, no claims have
                    been asserted or threatened against Passage by any Person alleging a violation of Privacy Laws, Passage Privacy Policies and/or the applicable terms of any Passage Contracts relating to privacy, security, collection or use of Personal
                    Information of any individuals and Passage has not received written notice of any of the same. To the Knowledge of Passage, there have been no data security incidents, personal data breaches or other adverse events or incidents related
                    to Personal Information or Passage data in the custody or control of Passage or any service provider acting on behalf of Passage, in each case where such incident, breach or event would result in a notification obligation to any Person
                    under applicable law or pursuant to the terms of any Passage Contract. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The information technology assets and equipment of Passage and its Subsidiaries (collectively, &#8220;<span style="font-weight: bold;">Passage IT Systems</span>&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of Passage and its Subsidiaries as currently conducted, and to the
                    Knowledge of Passage, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Passage and its Subsidiaries have implemented and maintain commercially reasonable physical, technical
                    and administrative safeguards to protect Personal Information processed by or on behalf of Passage and its Subsidiaries, any other material confidential information and the integrity and security of Passage IT Systems used in connection
                    with their businesses, and during the past three years, there have been no breaches, violations, outages or unauthorized uses of or accesses to the same, except for those that have been remedied without material cost or Liability or the
                    duty to notify any other Person. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS424"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.24<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Other Representations or Warranties</span>. Passage hereby acknowledges and agrees that, except for the representations
                    and warranties contained in this Agreement, neither Remix nor any of its Subsidiaries nor any other person on behalf of Remix or its Subsidiaries makes any express or implied representation or warranty with respect to Remix or its
                    Subsidiaries or with respect to any other information provided </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-53<br/>
        </div>

      </div>

    </div>

    <!--End Page 494-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 495-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg58"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">to Passage, any of its stockholders or any of their respective Affiliates
            in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Remix set forth in Article&#160;III (in each case as qualified and limited by the Remix Disclosure Schedule)) none of Passage, or any of
            its Representatives, stockholders or members, has relied on any such information (including the accuracy or completeness thereof). </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;"><a id="tANXAA5"><!--Anchor--></a>ARTICLE V<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">COVENANTS </div>

          <a id="tANXAS51"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conduct of Remix&#8217;s Business</span>. From the date hereof until the earlier of the Effective Time and the termination of this
                    Agreement in accordance with <span style="text-decoration: underline;">Article&#160;VIII</span> (the &#8220;<span style="font-weight: bold;">Pre-Closing Period</span>&#8221;), except as set forth on <span style="text-decoration: underline;">Section&#160;5.1</span> of the Remix Disclosure Schedule, as required by applicable Law, as
                    otherwise provided by this Agreement and the Contemplated Transactions or with Passage&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Remix shall, and shall cause its Subsidiaries to, use their
                    commercially reasonable efforts to conduct its operations in the Ordinary Course of Business and to preserve intact the present business organizations and goodwill of the business and the present relationships of the business with
                    material customers and suppliers. Without limiting the generality of the foregoing, during the Pre-Closing Period, except as set forth in <span style="text-decoration: underline;">Section&#160;5.1</span> of the Remix Disclosure Schedule, as required by applicable Law, as otherwise
                    specifically provided by this Agreement and the Contemplated Transactions or with Passage&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed), Remix shall not, and shall cause its Subsidiaries not to: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">sell, lease, license or otherwise dispose of any material assets of Remix, or in either case, any interests therein, except
                    (i) pursuant to existing Contracts, (ii) for sales or licensing of products to customers or (iii)&#160;otherwise in the Ordinary Course of Business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">take any action with respect to any equity interests of Remix or any of its Subsidiaries, including any issuance, sale,
                    transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">issue, deliver, sell, grant, pledge, transfer, subject to any Encumbrance or dispose of any Remix Capital Stock or the
                    securities of any Subsidiary of Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">create or otherwise incur any Encumbrance on any material asset of Remix or any of its Subsidiaries, other than Permitted
                    Encumbrances; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make any loans, advances or capital contributions to, or investments in, any Person other than Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance
                    with its terms) any Contract listed in <span style="text-decoration: underline;">Section&#160;3.13</span> of the Remix Disclosure Schedule, other than any amendment or modification entered into in the Ordinary Course of Business and containing terms not materially less favorable to
                    Remix or any of its Subsidiaries than the terms of such Contract in effect as of the date of this Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">enter into any Contract that would be required to be disclosed in <span style="text-decoration: underline;">Section&#160;3.13(a)</span> of the Remix Disclosure Schedule if
                    such Contract were in effect as of the date of this Agreement, other than any such Contract entered into in the Ordinary Course of Business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">except as required by any Remix Employee Plan, (i) increase any salary, wage or other compensation or benefit to, or enter
                    into or amend any employment, retention, change-in-control, termination or severance agreement with, any Remix Associate, other than annual increases in base compensation in the Ordinary Course of Business with respect to employees
                    whose annual base compensation is less than $500,000 and provided that such increases do not, individually or in the aggregate, result in any material increase in costs, obligations or liabilities for Remix and its Subsidiaries, (ii)
                    grant or pay any bonuses to any Remix Associate other than in the Ordinary Course of Business, (iii) establish, enter into or adopt any new material Remix Employee Plan or any plan, program, policy, agreement or arrangement that would
                    be a material Remix Employee Plan if it was in effect on the date hereof or amend or modify, in a manner that would, individually or in the aggregate, materially increase costs, obligations or liabilities for Remix and its Subsidiaries
                    or the Surviving Corporation, any existing Remix Employee Plan or accelerate the vesting of any compensation </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-54<br/>
        </div>

      </div>

    </div>

    <!--End Page 495-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 496-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg59"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">(including stock options, restricted stock, restricted stock units,
            phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of capital stock or equity-based awards) for the benefit of any Remix Associate, other than any such acceleration occurring in the Ordinary
            Course of Business, (iv)&#160;take any action to accelerate any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any Remix Associate, other than in the Ordinary Course of Business, (v) grant any new
            long-term incentive or equity-based awards, or amend or modify the terms of any such outstanding awards under any Remix Employee Plan or (vi) hire, terminate (other than for cause), promote or change the employment status or title of any Remix
            Associate, other than in the Ordinary Course of Business; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">adopt, enter into, amend or terminate any collective bargaining agreement or Contract with any labor union, works council or
                    labor organization; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">settle any material Legal Proceeding involving Remix or any of its Subsidiaries or relating to the transactions contemplated
                    by this Agreement, in either case, for more than $100,000 individually or $250,000 in the aggregate; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">make or change any material Tax election or Tax accounting method, change any annual Tax accounting period, amend any
                    material Tax Return, enter into any closing agreement with a Governmental Authority with respect to material Taxes or settle any Tax claim with respect to material Taxes; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to
                    prevent the Merger from qualifying for the Intended Tax Treatment; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">make any material change in any method of financial accounting or financial accounting practice of Remix or any of its
                    Subsidiaries, except for any such change required by reason of a change in GAAP or other applicable financial accounting standards; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">other than in connection with actions contemplated by this Agreement, adopt, approve, consent to or propose any change in the
                    Organizational Documents of Remix or any of its Subsidiaries; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">agree or commit to do any of the foregoing. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">Notwithstanding the generality of the foregoing, nothing set forth in this <span style="text-decoration: underline;">Section

              5.1</span> shall restrict Remix&#8217;s rights to effectuate the Concurrent Financing upon the terms set forth in the Subscription Agreement on the date hereof. Nothing contained in this Agreement shall give Passage, directly or indirectly, the right
            to control or direct the operations of Remix prior to the Effective Time. Prior to the Effective Time, Remix shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its
            business operations. </div>

          <a id="tANXAS52"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conduct of Passage&#8217;s Business</span>. During the Pre-Closing Period, except as set forth on <span style="text-decoration: underline;">Section&#160;5.2</span> of the
                    Passage Disclosure Schedule, as required by applicable Law, as otherwise provided by this Agreement and the Contemplated Transactions or with Remix&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed),
                    Passage shall, and shall cause its Subsidiaries to, use their commercially reasonable efforts to conduct its operations in the Ordinary Course of Business and to preserve intact the present business organizations and goodwill of the
                    business and the present relationships of the business with material customers and suppliers. Without limiting the generality of the foregoing, during the Pre-Closing Period, except as set forth in <span style="text-decoration: underline;">Section&#160;5.2</span> of the Passage
                    Disclosure Schedule, as required by applicable Law, as otherwise specifically provided by this Agreement and the Contemplated Transactions or with Remix&#8217;s prior written consent (not to be unreasonably withheld, conditioned or delayed),
                    Passage shall not, and shall cause its Subsidiaries not to: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">sell, lease, license or otherwise dispose of any material assets of Passage, or in either case, any interests therein, except
                    (i) pursuant to existing Contracts, (ii) for sales or licensing of products to customers or (iii)&#160;otherwise in the Ordinary Course of Business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">except for the issuance of securities under this Agreement, take any action with respect to any equity interests of Passage
                    or any of its Subsidiaries, including any issuance, sale, transfer, redemption, repurchase, recapitalization, adjustment, split, combination, reclassification, dividend, distribution or any other action in respect thereof; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">create, incur, assume, guarantee or repay (other than any mandatory repayments) any indebtedness; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-55<br/>
        </div>

      </div>

    </div>

    <!--End Page 496-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 497-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg60"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">issue, deliver, sell, grant, pledge, transfer, subject to any Encumbrance or dispose of any Passage Common Stock or the
                    securities of any Subsidiary of Passage; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">create or otherwise incur any Encumbrance on any material asset of Passage, other than Permitted Encumbrances; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">make any loans, advances or capital contributions to, or investments in, any Person other than Passage; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">adversely amend or otherwise adversely modify in any material respect or terminate (excluding any expiration in accordance
                    with its terms) any Contract listed in <span style="text-decoration: underline;">Section&#160;4.13</span> of the Passage Disclosure Schedule, other than any amendment or modification entered into in the Ordinary Course of Business and containing terms, not materially less favorable
                    to Passage or any of its Subsidiaries than the terms of such Contract in effect as of the date of this Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">enter into any Contract that would be required to be disclosed in <span style="text-decoration: underline;">Section&#160;4.13</span> of the Passage Disclosure Schedule if
                    such Contract were in effect as of the date of this Agreement, other than any such Contract entered into in the Ordinary Course of Business; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">except as required by any Passage Employee Plan, (i) increase any salary, wage or other compensation or benefit to, or enter
                    into or amend any employment, retention, change-in-control, termination or severance agreement with, any Passage Associate, (ii) grant or pay any bonuses to any Passage Associate, (iii) establish, enter into or adopt any new Passage
                    Employee Plan or any plan, program, policy, agreement or arrangement that would be a material Passage Employee Plan if it was in effect on the date hereof or amend or modify, in a manner that would, individually or in the aggregate,
                    materially increase costs, obligations or liabilities for Passage and its Subsidiaries or the Surviving Corporation, any existing Passage Employee Plan or accelerate the vesting of any compensation (including stock options, restricted
                    stock, restricted stock units, phantom units, warrants, other shares of capital stock or rights of any kind to acquire any shares of capital stock or equity-based awards) for the benefit of any Passage Associate, (iv) grant to any
                    Passage Associate any right to receive, or pay to any Passage Associate, any severance, change in control, transaction, retention, termination or similar compensation or benefits or increases therein, (v) take any action to accelerate
                    any payment or benefit, or the funding of any payment or benefit, payable or to be provided to any Passage Associate, (vi) grant any new long-term incentive or equity-based awards, or amend or modify the terms of any such outstanding
                    awards under any Passage Employee Plan or (vii) hire, terminate (other than for cause), promote or change the employment status or title of any Passage Associate other than terminations of any Passage Associate who is not an officer of
                    Passage; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">adopt, enter into, amend or terminate any collective bargaining agreement or Contract with any labor union, works council or
                    labor organization; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">settle any material Legal Proceeding involving Passage or relating to the transactions contemplated by this Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">make or change any material Tax election or Tax accounting method, change any annual Tax accounting period, amend any
                    material Tax Return; enter into any closing agreement with a Governmental Authority with respect to material Taxes or settle any Tax claim with respect to material Taxes; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">take any action, or knowingly fail to take any action, where such action or failure to act would reasonably be expected to
                    prevent the Merger from qualifying for the Intended Tax Treatment; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">make any material change in any method of financial accounting or financial accounting practice of Passage, except for any
                    such change required by reason of a change in GAAP or other applicable financial accounting standards; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">other than in connection with actions contemplated by this Agreement, adopt, approve, consent to or propose any change in the
                    Organizational Documents of Passage; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">agree or commit to do any of the foregoing. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-56<br/>
        </div>

      </div>

    </div>

    <!--End Page 497-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 498-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg61"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Notwithstanding the generality of the foregoing, nothing set forth in this
            <span style="text-decoration: underline;">Section 5.2</span> shall restrict Passage&#8217;s right to effectuate the Legacy Asset Disposition. Nothing contained in this Agreement shall give Remix, directly or indirectly, the right to control or direct the operations of Passage prior to the
            Effective Time. Prior to the Effective Time, Passage shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations. </div>

          <a id="tANXAS53"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Access and Investigation.</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date
                    of this Agreement, during the Pre-Closing Period, upon reasonable notice, Passage, on the one hand, and Remix, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (i) provide
                    the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and
                    other documents and information relating to such Party and its Subsidiaries, (ii) provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data,
                    and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably
                    request, (iii) permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such
                    Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem reasonably necessary or appropriate, in each case of clauses (i), (ii) and (iii), solely for the purpose of
                    consummating the Contemplated Transactions, and (iv) provide the other Party with copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the
                    Contemplated Transactions. Any investigation conducted by either Passage or Remix pursuant to this <span style="text-decoration: underline;">Section 5.3</span> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other
                    Party. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything herein to the contrary in this <span style="text-decoration: underline;">Section&#160;5.3</span>, no access or examination contemplated by this <span style="text-decoration: underline;">Section&#160;5.3</span>
                    shall be permitted to the extent that it would (i) require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, (ii) result in the disclosure of any trade secrets of any Party or any
                    of its Subsidiaries, (iii) result in the disclosure of any documents or information reasonably pertinent to any adverse Legal Proceeding between Remix or any of its Affiliates, on the one hand, and Passage or any of its Affiliates, on
                    the other hand, or (iv) violate any applicable Law or the terms or conditions of any Remix Contract or Passage Contract (the exceptions set forth in clauses (i)-(iv), collectively, the &#8220;<span style="font-weight: bold;">Access Exceptions</span>&#8221;);

                    <span style="font-style: italic;">provided</span> that such Party or its Subsidiary (A) shall be entitled to withhold only such information that may not be provided without causing such violation, disclosure or waiver, (B) shall provide
                    to the other Party all related information that may be provided without causing such violation, disclosure or waiver (including, to the extent permitted, redacted versions of any such information) and (C) shall enter into such effective
                    and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation, disclosure
                    or waiver (the requirements set forth in clauses (A)-(C), collectively, the &#8220;<span style="font-weight: bold;">Access Exception Efforts</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <a id="tANXAS54"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">No Solicitation.</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of Passage and Remix agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall
                    it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any
                    Acquisition Proposal or Acquisition Inquiry or take any action that could reasonably be expected to lead to an Acquisition Proposal or Acquisition Inquiry, (ii) furnish any non-public information regarding such Party to any Person
                    (other than Remix or Passage) in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition
                    Inquiry, (iv) approve, endorse or recommend any Acquisition Proposal (subject to <span style="text-decoration: underline;">Sections 5.8</span> and <span style="text-decoration: underline;">5.9</span>), (v) subject to <span style="text-decoration: underline;">Sections 5.8</span> and <span style="text-decoration: underline;">5.9</span>, execute or enter into any letter of intent or any Contract
                    contemplating or otherwise relating to any Acquisition Transaction, other than an Acceptable Confidentiality Agreement entered into in compliance with <span style="text-decoration: underline;">Section&#160;5.4(b)</span> (such letter of intent or Contract, an &#8220;<span style="font-weight: bold;">Alternative Acquisition Agreement</span>&#8221;) or </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-57<br/>
        </div>

      </div>

    </div>

    <!--End Page 498-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 499-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg62"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">(vi)&#160;publicly propose to do any of the foregoing. For the avoidance of
            doubt, Remix may engage in ordinary-course business development activities, including responding to inquiries or furnishing third parties information with respect to Remix or its business, in each case, without complying with the requirements
            of this <span style="text-decoration: underline;">Section 5.4</span>. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything contained in <span style="text-decoration: underline;">Section&#160;5.4(a)</span> and subject to compliance with <span style="text-decoration: underline;">Section&#160;5.4(a)</span>, prior to
                    the approval of this Agreement by Passage&#8217;s stockholders (i.e., the Required Passage Stockholder Vote), Passage may furnish non-public information regarding Passage and its Subsidiaries to, and enter into discussions or negotiations
                    with, any Person in response to a bona fide written Acquisition Proposal of Passage which the Passage Board determines in good faith, after consultation with Passage&#8217;s financial advisors and outside legal counsel, constitutes, or is
                    reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) neither Passage nor any Representative of Passage shall have breached <span style="text-decoration: underline;">Section&#160;5.4(a)</span> in any material respect, (B)&#160;the Passage Board concludes in
                    good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to result in a breach of the fiduciary duties of the Passage Board under applicable Law, (C) Passage gives Remix
                    prior written notice of Passage&#8217;s intention to furnish non-public information to, or enter into discussions with, such Person, (D) Passage receives from such Person an executed Acceptable Confidentiality Agreement and (E) substantially
                    concurrently with furnishing any such non-public information to such Person, Passage furnishes such non-public information to Remix (to the extent such information has not been previously furnished by Passage to Remix). Without limiting
                    the generality of the foregoing, Passage acknowledges and agrees that, in the event any Representative of Passage takes any action in its capacity as a Representative of Passage that, if taken by Passage, would constitute a breach of <span style="text-decoration: underline;">Section&#160;5.4(a)</span>
                    by Passage, the taking of such action by such Representative shall be deemed to constitute a breach of <span style="text-decoration: underline;">Section&#160;5.4(a)</span> by Passage for purposes of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything contained in <span style="text-decoration: underline;">Section&#160;5.4(a)</span> and subject to compliance with <span style="text-decoration: underline;">Section&#160;5.4(a)</span>, prior to
                    the approval of this Agreement by Remix&#8217;s stockholders (i.e., the Required Remix Stockholder Vote), Remix may furnish non-public information regarding Remix and its Subsidiaries to, and enter into discussions or negotiations with, any
                    Person in response to a bona fide written Acquisition Proposal of Remix which the Remix Board determines in good faith, after consultation with Remix&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely
                    to result in, a Superior Offer (and is not withdrawn) if: (A) neither Remix nor any Representative of Remix shall have breached <span style="text-decoration: underline;">Section&#160;5.4(a)</span> in any material respect, (B)&#160;the Remix Board concludes in good faith based on the
                    advice of outside legal counsel, that the failure to take such action would reasonably be expected to result in a breach of the fiduciary duties of the Remix Board under applicable Law, (C)&#160;Remix gives Passage prior written notice of
                    Remix&#8217;s intention to furnish non-public information to, or enter into discussions with, such Person, (D) Remix receives from such Person an executed Acceptable Confidentiality Agreement and (E) substantially concurrently with furnishing
                    any such non-public information to such Person, Remix furnishes such non-public information to Passage (to the extent such information has not been previously furnished by Remix to Passage). Without limiting the generality of the
                    foregoing, Remix acknowledges and agrees that, in the event any Representative of Remix takes any action in its capacity as a Representative of Remix that, if taken by Remix, would constitute a breach of <span style="text-decoration: underline;">Section&#160;5.4(a)</span> by Remix,
                    the taking of such action by such Representative shall be deemed to constitute a breach of <span style="text-decoration: underline;">Section&#160;5.4(a)</span> by Remix for purposes of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during
                    the Pre-Closing Period, then such Party shall promptly (and in no event later than one Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party orally and in writing of such
                    Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and provide a copy of the Acquisition Proposal or Acquisition Inquiry, or if the
                    Acquisition Proposal or Acquisition Inquiry is not written, the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and
                    any material modification or material proposed modification thereto.<br/>
                  </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-58<br/>
        </div>

      </div>

    </div>

    <!--End Page 499-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 500-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg63"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with
                    any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any non-public information provided to such Person. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS55"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.5<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Notification of Certain Matters</span>. During the Pre-Closing Period, each of Remix, on the one hand, and Passage, on the
                    other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (i) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be
                    required in connection with any of the Contemplated Transactions, (ii) any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against
                    such Party or, to the Knowledge of such Party, any director, officer or Key Employee of such Party, (iii) such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (iv) the
                    failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in <span style="text-decoration: underline;">Article&#160;VI</span> impossible or
                    materially less likely. No such notice shall be deemed to supplement or amend the Remix Disclosure Schedule or the Passage Disclosure Schedule for the purpose of (A)&#160;determining the accuracy of any of the representations and warranties
                    made by Remix or Passage in this Agreement or (B)&#160;determining whether any condition set forth in <span style="text-decoration: underline;">Article&#160;VI</span> has been satisfied. Any failure by either Party to provide notice pursuant to this <span style="text-decoration: underline;">Section&#160;5.5</span> shall not be
                    deemed to be a breach for purposes of <span style="text-decoration: underline;">Section&#160;6.2(b)</span> or <span style="text-decoration: underline;">6.3(b)</span>, as applicable, unless such failure to provide such notice was knowing and intentional. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS56"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.6<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Legacy Asset Disposition</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Prior to the Closing Date, Passage shall be entitled, but under no obligation, to sell, transfer, license, assign or
                    otherwise divest any or all of the assets and rights primarily relating to Passage&#8217;s full AAV particle purification method or other inventions generated by Passage Bio in connection with its PBFT02 clinical studies (the &#8220;<span style="font-weight: bold;">Legacy Assets</span>&#8221;) in a transaction or series of transactions (the &#8220;<span style="font-weight: bold;">Legacy Asset Disposition</span>&#8221;); <span style="font-style: italic;">provided</span> that Passage (i)
                    keeps Remix reasonably informed with respect to the status and terms of any potential Legacy Asset Disposition, (ii) does not provide any non-public information of Passage to any third parties unless such third party has executed an
                    Acceptable Confidentiality Agreement, (iii) furnishes such non-public information to be provided such third party to Remix (to the extent such information has not been previously furnished by Passage to Remix) substantially concurrently
                    with furnishing any such non-public information to such third party, (iv) provides Remix with a copy of any definitive agreement providing for a Legacy Asset Disposition at least five Business Days prior to entry into such agreement and
                    (v) as promptly as practicable after the consummation of any Legacy Asset Disposition, notifies Remix of any such consummation. Passage may not enter into any agreement with respect to the Legacy Asset Disposition that would result in a
                    continuing obligation or liability to Passage, the Surviving Corporation or any of their respective Affiliates without the prior written consent of Remix (which consent shall not be unreasonably withheld, conditioned or delayed). Each
                    Party acknowledges that Passage may, in contemplation of the Legacy Asset Disposition, (A) establish one or more Subsidiaries to hold the Legacy Assets, (B) transfer to any such Subsidiary any or all of the Legacy Assets and the
                    liabilities and obligations related thereto and (C)&#160;take such other steps that are reasonably necessary to prepare for the Legacy Asset Disposition. If Passage transfers the Legacy Assets to one or more Subsidiaries, the terms of this <span style="text-decoration: underline;">Section&#160;5.6(a)</span>
                    shall apply to such Subsidiaries in addition to Passage. Each Party further acknowledges that Passage may not be successful in completing, or may determine not to proceed, with the Legacy Asset Disposition. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">For the avoidance of doubt, any sale, transfer, license, assignment or other divestiture of Legacy Assets on or after the
                    Closing Date shall be governed by the terms and conditions of the CVR Agreement. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS57"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.7<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Registration Statement; Proxy Statement</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As promptly as practicable (but in any event, no later than twenty (20) Business Days) after the date of this Agreement, (i)
                    Passage, in cooperation with Remix, shall prepare and file with the SEC a proxy statement relating to the Passage Stockholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto,
                    the &#8220;<span style="font-weight: bold;">Proxy Statement</span>&#8221;) and (ii) Passage, in cooperation with Remix, shall prepare and file with the SEC a registration statement on Form&#160;S-4 (the &#8220;<span style="font-weight: bold;">Form&#160;S-4</span>&#8221;),

                    in which the Proxy Statement shall be included as a part (the Proxy Statement and the Form&#160;S-4, collectively, the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-59<br/>
        </div>

      </div>

    </div>

    <!--End Page 500-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 501-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg64"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Registration Statement</span>&#8221;), in
            connection with the registration under the Securities Act of the shares of Passage Common Stock to be issued by virtue of the Merger. Each of Passage and Remix shall use their commercially reasonable efforts to respond promptly to any comments
            of the SEC or its staff and to cause the Registration Statement to become effective as promptly as practicable, and shall take all or any action required under any applicable federal, state, securities and other Laws in connection with the
            issuance of shares of Passage Common Stock pursuant to the Merger. Each of the Parties shall furnish all information concerning itself and their Affiliates, as applicable, to the other Parties as the other Parties may reasonably request in
            connection with such actions and the preparation of the Registration Statement and Proxy Statement. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of
                    proxy included therewith) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances
                    under which they were made, not misleading. Remix covenants and agrees that the information supplied by or on behalf of Remix and its Subsidiaries to Passage for inclusion in the Registration Statement (including the Remix Audited
                    Financial Statements) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which
                    they were made, not misleading. Notwithstanding the foregoing, Passage makes no covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and
                    form of proxy included therewith) based on information provided by Remix or its Subsidiaries or any of their Representatives for inclusion therein. Remix and its legal counsel shall be given reasonable opportunity to review and comment
                    on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments on the SEC prior to the filing thereof with the SEC; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that the foregoing shall not apply to any amendment to the Registration Statement pertaining to a Passage Board Adverse Recommendation
                    Change. Each of the Parties shall use commercially reasonable efforts to cause the Registration Statement to comply with the applicable rules and regulations promulgated by the SEC, to respond promptly to any comments of the SEC or its
                    staff and to have the Registration Statement declared effective under the Securities Act as promptly as practicable after it is filed with the SEC. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of the Parties shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Passage&#8217;s
                    stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If Passage, Merger Sub or Remix become aware of any event or information that, pursuant to the Securities Act or
                    the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall
                    cooperate with such other Parties in filing such amendment or supplement with the SEC and, if appropriate, in mailing such amendment or supplement to the Passage stockholders. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix shall reasonably cooperate with Passage and provide, and cause its Representatives to provide, Passage and its
                    Representatives, with all true, correct and complete information regarding Remix and its Subsidiaries that is required by Law to be included in the Registration Statement or reasonably requested by Passage to be included in the
                    Registration Statement. Remix will use commercially reasonable efforts to cause Remix&#8217;s independent accounting firm to deliver any consent that Passage is required to file with the SEC with respect to the inclusion of the independent
                    accounting firm&#8217;s opinion on the audited financial statements of Remix in any filing of the Registration Statement with the SEC. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS58"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.8<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Remix Stockholder Written Consent.</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later
                    than two (2) Business Days thereafter, Remix shall prepare, with the cooperation of Passage, and cause to be mailed to its stockholders an information statement, which shall include a copy of the Proxy Statement (the &#8220;<span style="font-weight: bold;">Information Statement</span>&#8221;), and the Remix Stockholder Written Consent, in order to solicit the approval of Remix&#8217;s stockholders, including but not limited to Remix&#8217;s stockholders sufficient for the
                    Required Remix Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of Delaware Law, for purposes of (i) adopting and approving this Agreement and the Contemplated Transactions, and (ii) acknowledging that the approval given
                    thereby is irrevocable. Remix shall use its reasonable best efforts to cause Remix&#8217;s </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-60<br/>
        </div>

      </div>

    </div>

    <!--End Page 501-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 502-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg65"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">stockholders sufficient for the Required Remix Stockholder Vote to execute
            and deliver to Remix the Remix Stockholder Written Consent promptly following delivery thereof, and in any event no later than fifteen&#160;(15)&#160;days after the Registration Statement has been declared effective. Promptly following receipt of the
            duly executed Remix Stockholder Written Consent, Remix shall deliver a copy of the duly executed Remix Stockholder Written Consent to Passage. Under no circumstances shall Remix assert that any other approval or consent is necessary by its
            stockholders to approve this Agreement and the Contemplated Transactions. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Promptly following receipt of the Required Remix Stockholder Vote, Remix shall prepare and mail a notice to every stockholder
                    of Remix that did not execute the Remix Stockholder Written Consent. Such notice shall (i) be a statement to the effect that the Remix Board determined that the Merger is advisable in accordance with Section&#160;251(b) of Delaware Law and
                    in the best interests of the stockholders of Remix and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, and (ii) provide the stockholders of Remix to whom it is sent with notice of the actions
                    taken in the Remix Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of Delaware Law and Remix&#8217;s Organizational
                    Documents. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix agrees that, subject to <span style="text-decoration: underline;">Section&#160;5.8(d)</span>: (i) the Remix Board shall recommend that the holders of Remix Capital
                    Stock vote to adopt and approve this Agreement and the Contemplated Transactions, including the Merger, the Remix Preferred Stock Conversion, and the Remix Charter Amendment, as required under Delaware Law and Remix&#8217;s Organizational
                    Documents (the &#8220;<span style="font-weight: bold;">Remix Stockholder Matters</span>&#8221;) and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <span style="text-decoration: underline;">Section&#160;5.8(a)</span>, (ii)&#160;the Information
                    Statement shall include a statement to the effect that the Remix Board recommends that Remix&#8217;s stockholders vote to approve the Remix Stockholder Matters (the recommendation of the Remix Board being referred to as the &#8220;<span style="font-weight: bold;">Remix Board Recommendation</span>&#8221;) and (iii) the Remix Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Remix Board shall not publicly propose to withhold, amend, withdraw
                    or modify the Remix Board Recommendation) in a manner adverse to Passage, and no resolution by the Remix Board or any committee thereof to withdraw or modify the Remix Board Recommendation in a manner adverse to Passage or to adopt,
                    approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a &#8220;<span style="font-weight: bold;">Remix

                      Board Adverse Recommendation Change</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything to the contrary contained in <span style="text-decoration: underline;">Section&#160;5.8(c)</span>, and subject to compliance with <span style="text-decoration: underline;">Section&#160;5.4</span>
                    and <span style="text-decoration: underline;">Section&#160;5.8</span>, if at any time prior to the approval of the Remix Stockholder Matters by the Required Remix Stockholder Vote, Remix receives a bona fide written Superior Offer, the Remix Board may make a Remix Board Adverse
                    Recommendation Change if, but only if, in the receipt of and on account of such Superior Offer, (i) the Remix Board determines in good faith, after consultation with its outside legal counsel, that the failure to make a Remix Board
                    Adverse Recommendation Change would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) Remix has, and has caused its financial advisors and outside legal counsel to, during the Notice Period,
                    negotiate with Passage in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if after Passage shall have delivered to Remix
                    a written offer to alter the terms or conditions of this Agreement during the Notice Period (or if Passage declines to do so), the Remix Board shall have determined in good faith, after consultation with its outside legal counsel, that
                    the failure to withhold, amend, withdraw or modify the Remix Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms
                    and conditions of this Agreement, if any); <span style="font-style: italic;">provided </span>that (x) Passage receives written notice from Remix confirming that the Remix Board has determined to change its recommendation during the
                    Notice Period, which notice shall include written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (y) during any Notice Period, Passage shall be entitled to deliver to Remix one
                    or more counterproposals to such Acquisition Proposal and Remix will, and cause its Representatives to, negotiate with Passage in good faith (to the extent Passage desires to negotiate) to make such adjustments in the terms and
                    conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z) in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the
                    combined company that Remix&#8217;s stockholders would receive as a result of such potential Superior Offer), Remix shall be required to provide Passage with notice of such material </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-61<br/>
        </div>

      </div>

    </div>

    <!--End Page 502-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 503-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg66"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">amendment and the Notice Period shall be extended, if applicable, to
            ensure that at least two (2) Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration: underline;">Section&#160;5.8(d)</span> and the Remix Board shall not make a Remix Board
            Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions). </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to <span style="text-decoration: underline;">Section&#160;8.1</span>, Remix&#8217;s obligation to solicit the consent of its stockholders to sign the Remix Stockholder
                    Written Consent in accordance with <span style="text-decoration: underline;">Section&#160;5.8(a)</span> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry,
                    or by any Remix Board Adverse Recommendation Change. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS59"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.9<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Passage Stockholder Meeting.</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of
                    Passage Common Stock to consider and vote to approve this Agreement and the Contemplated Transactions, including the issuance of the shares of Passage Common Stock to the stockholders of Remix pursuant to the terms of this Agreement (<span style="font-style: italic;">i.e.</span>, the Nasdaq Issuance Proposal) and<span style="font-weight: bold;"> </span>the adoption of the Amended and Restated Passage Charter, and, if the Passage Board determines to complete the Reverse
                    Stock Split, an amendment to Passage&#8217;s certificate of incorporation to effect the Reverse Stock Split (the &#8220;<span style="font-weight: bold;">Reverse Stock Split Proposal</span>&#8221;) (collectively, the &#8220;<span style="font-weight: bold;">Passage</span>
                    <span style="font-weight: bold;">Stockholder Matters</span>&#8221; and such meeting, the &#8220;<span style="font-weight: bold;">Passage Stockholder Meeting</span>&#8221;). The Passage Stockholder Meeting shall be held as promptly as practicable after
                    the date that the Registration Statement is declared effective under the Securities Act, and in any event no later than forty-five (45) days after the effective date of the Registration Statement. Passage shall take reasonable measures
                    to ensure that all proxies solicited in connection with the Passage Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Passage
                    Stockholder Meeting, or a date preceding the date on which the Passage Stockholder Meeting is scheduled, Passage reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Passage Stockholder Vote,
                    whether or not a quorum would be present or (ii) it will not have sufficient shares of Passage Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Passage Stockholder
                    Meeting, Passage may postpone or adjourn, or make one or more successive postponements or adjournments of, the Passage Stockholder Meeting as long as the date of the Passage Stockholder Meeting is not postponed or adjourned more than an
                    aggregate of thirty (30) calendar days in connection with any postponements or adjournments. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage agrees that, subject to <span style="text-decoration: underline;">Section&#160;5.9(c)</span>: (i) the Passage Board shall recommend that the holders of Passage
                    Common Stock vote to approve the Passage Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in <span style="text-decoration: underline;">Section&#160;5.9(a)</span> above, (ii) the Proxy Statement shall include a
                    statement to the effect that the Passage Board recommends that Passage&#8217;s stockholders vote to approve the Passage Stockholder Matters (the recommendation of the Passage Board being referred to as the &#8220;<span style="font-weight: bold;">Passage

                      Board Recommendation</span>&#8221;) and (iii) the Passage Board Recommendation shall not be withheld, amended, withdrawn or modified (and the Passage Board shall not publicly propose to withhold, amend, withdraw or modify the Passage Board
                    Recommendation) in a manner adverse to Remix, and no resolution by the Passage Board or any committee thereof to withdraw or modify the Passage Board Recommendation in a manner adverse to Remix or to adopt, approve or recommend (or
                    publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed (the actions set forth in the foregoing clause (iii), collectively, a &#8220;<span style="font-weight: bold;">Passage Board Adverse
                      Recommendation Change</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything to the contrary contained in <span style="text-decoration: underline;">Section&#160;5.9(b)</span>, and subject to compliance with <span style="text-decoration: underline;">Section&#160;5.4</span>
                    and <span style="text-decoration: underline;">Section&#160;5.9</span>, if at any time prior to the approval of Passage Stockholder Matters by the Required Passage Stockholder Vote, Passage receives a bona fide written Superior Offer, the Passage Board may make a Passage Board
                    Adverse Recommendation Change if, but only if, in the receipt of and on account of such Superior Offer, (i) the Passage Board determines in good faith, after consultation with its outside legal counsel, that the failure to make a
                    Passage Board Adverse Recommendation Change would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) Passage has, and has caused its financial advisors and outside legal counsel to, during the
                    Notice Period, negotiate with Remix in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if after Remix shall have
                    delivered to Passage a written offer to alter the terms or conditions of this Agreement during the Notice Period (or if Remix declines to do so), the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-62<br/>
        </div>

      </div>

    </div>

    <!--End Page 503-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 504-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg67"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Passage Board shall have determined in good faith, after consultation with
            its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Passage Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such
            alterations of the terms and conditions of this Agreement, if any); <span style="font-style: italic;">provided </span>that (x) Remix receives written notice from Passage confirming that the Passage Board has determined to change its
            recommendation during the Notice Period, which notice shall include written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (y)&#160;during any Notice Period, Remix shall be entitled to
            deliver to Passage one or more counterproposals to such Acquisition Proposal and Passage will, and cause its Representatives to, negotiate with Remix in good faith (to the extent Remix desires to negotiate) to make such adjustments in the terms
            and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (z) in the event of any material amendment to any Superior Offer (including any revision in price or percentage of the
            combined company that Passage&#8217;s stockholders would receive as a result of such potential Superior Offer), Passage shall be required to provide Remix with notice of such material amendment and the Notice Period shall be extended, if applicable,
            to ensure that at least two&#160;(2)&#160;Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this <span style="text-decoration: underline;">Section&#160;5.9(c)</span> and the Passage Board shall not make a
            Passage Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions). </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage&#8217;s obligation to call, give notice of and hold the Passage Stockholder Meeting in accordance with <span style="text-decoration: underline;">Section&#160;5.9(a)</span>
                    shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or Acquisition Proposal, or by any withdrawal or modification of the Passage Board Recommendation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Nothing contained in this Agreement shall prohibit Passage or the Passage Board from (i) complying with Rules 14d-9 and
                    14e-2(a) promulgated under the Exchange Act; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that any disclosure made by Passage or the Passage Board pursuant to Rules 14d-9 and
                    14e-2(a) shall be limited to a statement that Passage is unable to take a position with respect to the bidder&#8217;s tender offer unless the Passage Board determines in good faith, after consultation with its outside legal counsel, that such
                    statement would result in a breach of its fiduciary duties under applicable Law, (ii) informing any Person of the existence of the provisions contained in <span style="text-decoration: underline;">Section&#160;5.4</span> or (iii) making any disclosure that the Passage Board (or a
                    committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law or by any listing or trading rules or regulations of Nasdaq; <span style="font-style: italic;">provided</span>
                    that, in the case of (iii),&#160;Passage shall provide Remix with a reasonable opportunity to review any such disclosure prior to the making thereof (to the extent practicable) and shall consider in good faith any comments from Remix
                    thereto; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">further</span>, that any such disclosures (other than a &#8220;stop, look and listen&#8221; communication or similar communication of the type
                    contemplated by Section&#160;14d-9(f) under the Exchange Act) that constitutes a Passage Board Adverse Recommendation Change shall be subject to <span style="text-decoration: underline;">Section&#160;5.9(c)</span>. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS510"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Efforts; Regulatory Approvals.</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Parties shall use commercially reasonable efforts to consummate the Contemplated Transactions. Without limiting the
                    generality of the foregoing, each Party: (i)&#160;shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii) shall
                    use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such
                    Contract to remain in full force and effect, (iii)&#160;shall use commercially reasonable efforts to obtain and maintain as promptly as practicable the expiration or termination of any applicable waiting period under any applicable
                    antitrust, competition, investment or similar Laws, (iv) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (v) shall use commercially reasonable
                    efforts to satisfy the conditions precedent to the consummation of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise
                    submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental
                    Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-63<br/>
        </div>

      </div>

    </div>

    <!--End Page 504-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 505-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg68"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In connection with, and without limiting, the efforts referenced in <span style="text-decoration: underline;">Section&#160;5.10(a)</span>, Passage and Remix shall (i)
                    furnish, or cause to be furnished, to the other Party, such necessary information and reasonable assistance as the other Party may request in connection with its preparation of any filing or submission that is required to be filed by
                    such Party to any Governmental Authority with respect to the Contemplated Transactions (subject to clause (i) of the definition of Access Exceptions and the requirements of the Access Exception Efforts), (ii)&#160;permit the other Party and
                    its counsel to review any filing or submission prior to forwarding to the Governmental Authorities (except where such material is reasonably determined by a Party to be competitively sensitive to such Party in which case it will be
                    provided, subject to applicable Law, to the other Party&#8217;s counsel on an &#8220;external counsel only&#8221; basis) and consider in good faith any comments made by such other Party, (iii)&#160;keep each other reasonably apprised of the status of, and
                    provide the other Party with copies of (to the extent made in writing), any communications with, and any inquiries or requests for additional information from, any Governmental Authorities and comply as promptly as practicable with any
                    such inquiry or request and (iv)&#160;not participate in any meeting or discussion, either in person or by telephone or videoconference, with any Governmental Authority in connection with the Contemplated Transactions, unless (A)&#160;it provides
                    the other Party with reasonable advance notice and (B)&#160;gives the other Party and its counsel the opportunity to attend and participate; <span style="font-style: italic;">provided</span> that a Party shall not be required to give the
                    other Party the opportunity to attend and participate to the extent&#160;prohibited by such Governmental Authority. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS511"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Disclosures</span>. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no
                    Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any disclosure (to any customers or employees of such Party, to the public or otherwise) regarding the Contemplated Transactions
                    unless: (a)&#160;the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b) such Party shall have determined in good faith, upon the advice
                    of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other
                    Party regarding, the text of such press release or disclosure; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that each of Remix and Passage may make any statement in response to
                    questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public
                    statements made by Remix and Passage in compliance with this <span style="text-decoration: underline;">Section&#160;5.11</span>. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or
                    filing to be issued or made with respect to (i) an Acquisition Proposal, (ii) a Passage Board Adverse Recommendation Change with respect to Passage only pursuant to <span style="text-decoration: underline;">Section&#160;5.9(e)</span> or (iii) a Remix Board Adverse Recommendation
                    Change with respect to Remix. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS512"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.12<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Passage Options</span>. Prior to the Closing, the Passage Board shall adopt appropriate resolutions and take all other
                    actions necessary and appropriate to cause the vesting and exercisability of each unexpired, unexercised and unvested Passage Option to be accelerated in full, effective as of immediately prior to the Effective Time. Following the
                    Closing, each unexpired and unexercised Passage Option shall continue on the same terms and conditions in effect as of immediately prior to the Effective Time. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS513"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Passage Restricted Stock Unit Awards</span>. Prior to the record date for the Pre-Closing Distribution, the Passage Board
                    shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide that (a) the vesting of each outstanding and unvested Passage Restricted Stock Unit Award shall be accelerated in full effective
                    as of no later than the day immediately prior to the record date for the Pre-Closing Distribution, and (b) for each outstanding and unsettled Passage Restricted Stock Unit Award, the holder thereof shall receive, no later than the day
                    immediately prior to the record date for the Pre-Closing Distribution, a number of shares of Passage Common Stock equal to the number of vested and unsettled shares of Passage Common Stock underlying such Passage Restricted Stock Unit
                    Award. Notwithstanding anything herein to the contrary, the Tax withholding obligations for each holder receiving shares of Passage Common Stock in accordance with the preceding sentence shall be satisfied by Passage withholding from
                    issuance that number of shares of Passage Common Stock calculated by multiplying the maximum statutory withholding rate for such holder in connection with such issuance by the number of shares of Passage Common Stock to be issued in
                    accordance with the preceding sentence, and rounding up to the nearest whole share and remitting such withholding in cash to the appropriate taxing authorities (the amount of such cash, the &#8220;<span style="text-decoration: underline;">RSU Withholding Amount</span>&#8221;). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-64<br/>
        </div>

      </div>

    </div>

    <!--End Page 505-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 506-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg69"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS514"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.14<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Passage ESPP</span>. As soon as reasonably practicable (and within five days) following the date of this Agreement, the
                    Passage Board shall adopt appropriate resolutions and take all other necessary actions to provide that (a) no new offering periods or purchase periods under the Passage ESPP shall be commenced and (b) the Passage ESPP shall be
                    terminated effective on the day prior to the Closing Date. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS515"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.15<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Indemnification of Officers and Directors </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">From the Effective Time through the sixth anniversary of the date on which the Effective Time occurs (or, if a D&amp;O
                    Indemnified Party (defined below) asserts a claim for indemnification or other protections pursuant to this <span style="text-decoration: underline;">Section&#160;5.15</span> prior to the end of such six-year period, then until the date that such claim is resolved and all Costs
                    associated therewith have been indemnified), each of Passage and the Surviving Corporation shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective
                    Time, a director or officer of Passage or Remix, respectively (the &#8220;<span style="font-weight: bold;">D&amp;O Indemnified Parties</span>&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and
                    expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;<span style="font-weight: bold;">Costs</span>&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal,
                    administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Passage or of Remix, whether asserted or claimed prior to, at or after the Effective Time,
                    in each case, to the fullest extent permitted under Delaware Law. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each
                    of Passage and the Surviving Corporation, jointly and severally, upon receipt by Passage or the Surviving Corporation from the D&amp;O Indemnified Party of a request therefor; <span style="font-style: italic;">provided</span> that any
                    such person to whom expenses are advanced provides an undertaking to Passage, to the extent then required by Delaware Law, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The provisions of Passage&#8217;s Organizational Documents with respect to indemnification, advancement of expenses and exculpation
                    of present and former directors and officers of Passage that are presently set forth in Passage&#8217;s Organizational Documents shall not be amended, modified or repealed for a period of six years from the Effective Time in a manner that
                    would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of Passage, unless such modification is required by applicable Law. The Surviving Corporation&#8217;s
                    Organizational Documents shall contain, and Passage shall cause the certificate of incorporation of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and
                    exculpation of present and former directors and officers as those presently set forth in Remix&#8217;s Organizational Documents. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">From and after the Effective Time, (i) the Surviving Corporation shall fulfill and honor in all respects the obligations of
                    Remix to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Remix&#8217;s Organizational Documents and pursuant to any indemnification agreements between Remix and such
                    D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii) Passage shall fulfill and honor in all respects the obligations of Passage to its D&amp;O Indemnified
                    Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Passage&#8217;s Organizational Documents and pursuant to any indemnification agreements between Passage and such D&amp;O Indemnified Parties, with
                    respect to claims arising out of matters occurring at or prior to the Effective Time. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">From and after the Effective Time, Passage shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an
                    effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Passage. In addition, Passage shall purchase, prior to the
                    Effective Time, a six-year prepaid &#8220;<span style="font-weight: bold;">D&amp;O tail policy</span>&#8221; for the non-cancellable extension of directors&#8217; and officers&#8217; liability coverage of Passage&#8217;s existing directors&#8217; and officers&#8217; insurance
                    policies for a claims reporting or discovery period of at least six years from and after the Effective Time with respect to any claim related to any period of time at or prior to the Effective Time with terms, conditions, retentions and
                    limits of liability that are no less favorable than the coverage provided under Passage&#8217;s existing policies as of the date of this Agreement with respect to any actual or alleged error, misstatement, misleading statement, act, omission,
                    neglect, breach of duty or any matter claimed against a director or officer of Passage by reason of him or her serving in such capacity that existed or occurred at or prior to the Effective Time (including in connection with this
                    Agreement or the Contemplated Transactions or in connection with Passage&#8217;s initial public offering of shares of Passage Common Stock). </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-65<br/>
        </div>

      </div>

    </div>

    <!--End Page 506-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 507-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg70"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The provisions of this <span style="text-decoration: underline;">Section&#160;5.15</span> are intended to be in addition to the rights otherwise available to the current
                    and former officers and directors of Passage and Remix by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their
                    Representatives. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In the event Passage or the Surviving Corporation or any of their respective successors or assigns (i)&#160;consolidates with or
                    merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii)&#160;transfers all or substantially all of its properties and assets to any Person, then, and in each
                    such case, proper provision shall be made so that the successors and assigns of Passage or the Surviving Corporation, as the case may be, shall succeed to the obligations set forth in this <span style="text-decoration: underline;">Section&#160;5.15</span>. Passage shall cause the
                    Surviving Corporation to perform all of the obligations of the Surviving Corporation under this <span style="text-decoration: underline;">Section 5.15</span>. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS516"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.16<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Tax Matters </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All transfer, documentary, sales, use, stamp, registration, excise, recording, registration value added and other such
                    similar Taxes and fees (including any penalties and interest) that become payable in connection with or by reason of the execution of this Agreement and the transactions contemplated hereby (collectively, &#8220;<span style="font-weight: bold;">Transfer Taxes</span>&#8221;) shall be borne and paid 50% by Passage and 50% by Remix. The Person required by applicable law shall timely file any Tax Return or other document with respect to such Transfer Taxes. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">At the Closing, Remix shall deliver to Passage a certificate pursuant to Treasury Regulations Sections 1.1445-2(c) and
                    1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&#160;1.897-2(h), in each case, in form and substance reasonably acceptable to Passage; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that Passage&#8217;s only remedy for Remix&#8217;s failure to provide such form or certificate will be to withhold from the payments to be made pursuant to this
                    Agreement any required withholding Tax under Section&#160;1445 of the Code, and Remix&#8217;s failure to provide any such form or certificate will not be deemed to be a failure of the conditions set forth in <span style="text-decoration: underline;">Article&#160;VI</span> to have been met. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The parties intend that, for United States federal income tax purposes, the Merger will qualify for the Intended Tax
                    Treatment. The Merger shall be reported by the parties for all Tax purposes in accordance with the foregoing, unless otherwise required by a Governmental Authority as a result of a &#8220;determination&#8221; within the meaning of Section&#160;1313(a)
                    of the Code. The parties shall cooperate with each other and their respective counsel to document and support the Tax treatment of the Merger as qualifying for the Intended Tax Treatment. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If, in connection with the preparation and filing of the Registration Statement or any other filing required by applicable
                    Law or the SEC&#8217;s review thereof, the SEC requests or requires that a tax opinion with respect to the U.S.&#160;federal income tax consequences of the Merger and the Intended Tax Treatment be prepared and submitted (a &#8220;<span style="font-weight: bold;">Tax Opinion</span>&#8221;), (i) Passage and Remix shall each use their respective reasonable best efforts to deliver to Fenwick &amp; West LLP, counsel to Passage, and to Latham &amp; Watkins LLP, counsel to
                    Remix, customary Tax representation letters satisfactory to each such counsel, dated and executed as of such date(s) as determined to be reasonably necessary by each such counsel in connection with the preparation and filing of such
                    Registration Statement or any other filing required by applicable Law, (ii) Passage shall use its reasonable best efforts to cause Fenwick &amp; West LLP to furnish a Tax Opinion addressed to Passage, subject to customary assumptions
                    and limitations, satisfactory to the SEC and (iii)&#160;Remix shall use its reasonable best efforts to cause Latham &amp; Watkins LLP to furnish a Tax Opinion addressed to Remix, subject to customary assumptions and limitations, satisfactory
                    to the SEC. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS517"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.17<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Listing</span>. At or prior to the Effective Time, Passage shall use commercially reasonable efforts to (a)&#160;maintain a
                    listing on Nasdaq until the Effective Time and, to the extent required by the rules and regulations of Nasdaq, to obtain approval of the listing of the combined company on Nasdaq; (b) to the extent required by the rules and regulations
                    of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Passage Common Stock to be issued in connection with the Contemplated Transactions and to cause such shares to be approved for listing; (c)
                    prepare and timely submit to Nasdaq a notification form of the Reverse Stock Split (if applicable) and a copy of the Amended and Restated Passage Charter, certified by the Secretary of State of the State of Delaware, to Nasdaq on or
                    before the Closing Date; and (d) to the extent required by Nasdaq Marketplace Rule&#160;5110, assist Remix in preparing and filing an initial listing application for the Passage Common Stock on Nasdaq (the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-66<br/>
        </div>

      </div>

    </div>

    <!--End Page 507-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 508-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg71"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">&#8220;<span style="font-weight: bold;">Nasdaq Listing Application</span>&#8221;).
            Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its Representatives. The Parties will use commercially reasonable efforts to coordinate with respect to
            compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly
            furnish to such filing Party all information concerning itself and its stockholders that may be required or reasonably requested in connection with any action contemplated by this <span style="text-decoration: underline;">Section&#160;5.17</span>. </div>

          <a id="tANXAS518"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.18<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Legends</span>. Passage shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any
                    shares of Passage Common Stock to be received in the Merger by equityholders of Remix who may be considered &#8220;affiliates&#8221; of Passage for purposes of Rules 144 and 145 under the Securities Act reflecting the restrictions set forth in
                    Rules 144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for Passage Common Stock. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS519"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.19<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Officers and Directors </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Directors and Officers of Passage</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage shall cause, effective as of the Effective Time, the Passage Board to consist of nine individuals, each as set forth
                    on <span style="text-decoration: underline;">Section&#160;5.19(a)(i)</span> of the Passage Disclosure Schedule. If any individual set forth on <span style="text-decoration: underline;">Section&#160;5.19(a)(i)</span> of the Passage Disclosure Schedule is unable or unwilling to serve as a director of Passage, Remix shall
                    designate a successor designee. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage shall cause the directors and officers of Passage listed on <span style="text-decoration: underline;">Section&#160;5.19(a)(ii)</span> of the Passage Disclosure
                    Schedule to sign written resignations in forms reasonably satisfactory to Remix, dated on or before the Closing Date and effective as of the Effective Time. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Immediately following the Effective Time, Passage shall take all necessary action to appoint the officers of Remix to become
                    the equivalent officers of Passage until the earlier of their resignation or removal or until their respective successors are duly elected or appointed and qualified, as the case may be. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Directors and Officers of the Surviving Corporation</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Parties shall take all actions necessary (A) so that from and after the Effective Time, the Surviving Corporation&#8217;s board
                    of directors shall be constituted with those members as set forth on <span style="text-decoration: underline;">Section&#160;5.19(b)</span> of the Passage Disclosure Schedule and (B)&#160;to secure the resignations of the existing members of the committees of the Surviving Corporation,
                    if any. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Parties shall take all actions necessary so that the officers of Remix immediately prior to the Effective Time shall,
                    from and after the Effective Time, be the officers of the Surviving Corporation, until the earlier of their resignation or removal or until their respective successors are duly elected or appointed and qualified, as the case may be. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">On the Closing Date, the Surviving Corporation shall enter into customary indemnification agreements reasonably satisfactory
                    to Remix with each individual to be appointed to, or serving on, the board of directors of the Surviving Corporation upon the Closing, which indemnification agreements shall continue to be effective following the Closing. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS520"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.20<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Termination of Certain Agreements and Rights</span>. Remix shall cause any stockholder agreements, voting agreements,
                    registration rights agreements, co-sale agreements and any other similar Contracts between Remix and any holders of Remix Capital Stock, including any such Contract granting any Person investor rights, rights of first refusal,
                    registration rights or director registration rights to be terminated immediately prior to the Effective Time, without any liability being imposed on the part of Passage or the Surviving Corporation. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS521"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.21<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;16 Matters</span>. Prior to the Effective Time, Passage shall take all such steps as may be required to cause any
                    acquisitions of Passage Common Stock and any options to purchase Passage Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of
                    Section&#160;16(a) of the Exchange Act with respect to Passage, to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-67<br/>
        </div>

      </div>

    </div>

    <!--End Page 508-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 509-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg72"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS522"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.22<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Allocation Certificate</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix will prepare and deliver to Passage at least two (2) Business Days prior to the Closing Date a certificate signed by an
                    executive officer of Remix in a form reasonably acceptable to Passage setting forth (as of immediately prior to the Effective Time) (a) each holder of Remix Capital Stock (after giving effect to the Remix Preferred Stock Conversion, the
                    Remix Convertible Notes Conversion and the treatment of the Remix Warrants in accordance with their terms and conditions), (b) such holder&#8217;s name and address, (c) the number and type of Remix Capital Stock held as of the Closing Date
                    for each such holder, (d) the number of shares of Passage Common Stock to be issued to such holder pursuant to this Agreement in respect of the Remix Capital Stock held by such holder as of immediately prior to the Effective Time, and
                    (e) each investor in the Concurrent Financing, the total investment to be made by such investor in the Concurrent Financing, the percentage of the Concurrent Financing Proceeds represented by such stockholder&#8217;s investment in the
                    Concurrent Financing, and the number of shares of Passage Common Stock to be issued to such holder pursuant to this Agreement (the &#8220;<span style="font-weight: bold;">Allocation Certificate</span>&#8221;). For the avoidance of doubt, the
                    Allocation Certificate shall be prepared in good faith, in accordance with the Organizational Documents of Remix and contracts applicable to Remix Capital Stock, Remix Options and Remix Warrants, and shall show each holder&#8217;s percentage
                    ownership interest in Remix on a fully diluted basis. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage will prepare and deliver to Remix at least two (2) Business Days prior to the Closing Date a certificate signed by an
                    executive officer of Passage in a form reasonably acceptable to Remix setting forth (as of immediately prior to the Effective Time) the Passage Outstanding Shares (the &#8220;<span style="font-weight: bold;">Passage Outstanding Shares
                      Certificate</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <a id="tANXAS523"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.23<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Obligations of Merger Sub</span>. Passage will take all action necessary to cause Merger Sub to perform its obligations under
                    this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS524"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.24<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Takeover Statutes</span>. If any takeover statute is or may become applicable to the Contemplated Transactions, each of
                    Remix, the Remix Board, Passage and the Passage Board, as applicable, shall grant such approvals and take such actions as are necessary, to the extent permitted by Law, so that the Contemplated Transactions may be consummated as
                    promptly as practicable on the terms contemplated by this Agreement and otherwise act to eliminate or minimize the effects of such statute or regulation on the Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS525"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.25<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Stockholder Litigation</span>. Prior to the Effective Time, Passage shall provide Remix with reasonably prompt notice of any
                    stockholder litigation against Passage or any of its directors relating to this Agreement or the Contemplated Transactions (&#8220;<span style="font-weight: bold;">Transaction Litigation</span>&#8221;), including by providing copies of all
                    pleadings with respect thereto, and shall keep Remix reasonably informed with respect to the status thereof. Prior to the Effective Time, Passage will, to the extent that the attorney-client privilege is not undermined or otherwise
                    adversely affected, (a)&#160;provide Remix the opportunity to review and propose comments with respect to all filings, pleadings and responses proposed to be filed or submitted by or on behalf of Passage prior to such filing or submission,
                    and Passage shall consider such comments in good faith, (b)&#160;give Remix a reasonable opportunity to review in advance all materials proposed to be delivered by or on behalf of Passage in connection with any discovery or document
                    production with respect to such Transaction Litigation, (c) give Remix the right to participate in the defense, settlement or prosecution of any Transaction Litigation and (d) reasonably consult with Remix with respect to the defense,
                    settlement and prosecution of any Transaction Litigation. Passage may not compromise or settle, or come to an arrangement regarding, or agree to compromise, settle or come to an arrangement regarding, any Transaction Litigation unless
                    Remix has consented thereto in writing (which consent will not be unreasonably withheld, conditioned or delayed). For purposes of this <span style="text-decoration: underline;">Section&#160;5.25</span>, &#8220;participate&#8221; means that Passage shall keep Remix reasonably apprised of the
                    proposed strategy and other significant decisions with respect to any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected), and Remix may offer comments or
                    suggestions with respect to such Transaction Litigation which Passage shall consider in good faith. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS526"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.26<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Concurrent Financing</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the terms and conditions of this Agreement, Remix shall use commercially reasonable efforts to obtain the
                    Concurrent Financing on the terms and conditions described in the Subscription Agreement and </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-68<br/>
        </div>

      </div>

    </div>

    <!--End Page 509-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 510-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg73"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">satisfy the conditions to the Concurrent Financing as described in the
            Subscription Agreement and shall not permit any termination, amendment or modification to be made to, or any waiver of any provision under, or any replacement of, the Subscription Agreement if such termination, amendment, modification, waiver
            or replacement (i) reduces the aggregate amount of the Concurrent Financing or (ii) imposes new or additional conditions or otherwise expands, amends or modifies any of the conditions to the receipt of the Concurrent Financing, or otherwise
            expands, amends or modifies any other provision of the Subscription Agreement, in a manner that would reasonably be expected to (x) delay or prevent the funding of the Concurrent Financing (or satisfaction of the conditions to the Concurrent
            Financing) at or substantially simultaneously with the Closing or (y) adversely impact the ability of Remix to enforce its rights against other parties to the Subscription Agreement. Remix shall promptly deliver to Passage copies of any such
            termination, amendment, modification, waiver or replacement. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix shall use commercially reasonable efforts (i) to maintain in effect the Subscription Agreement, (ii) to enforce its
                    rights under the Subscription Agreement and (iii) to comply with its obligations under the Subscription Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix shall give Passage prompt notice (i) of any breach or default by any party to the Subscription Agreement or definitive
                    agreements related to the Concurrent Financing of which Remix becomes aware, (ii)&#160;of the receipt of any written notice or other written communication from any Purchaser with respect to any (x)&#160;actual breach, default, termination or
                    repudiation by any party to the Subscription Agreement or definitive agreements related to the Concurrent Financing of any provisions of the Subscription Agreement or definitive agreements related to the Concurrent Financing or (y)
                    material dispute or disagreement relating to the Concurrent Financing with respect to the obligation to fund the Concurrent Financing at or substantially simultaneously with the Closing, and (iii) if at any time for any reason Remix
                    believes in good faith that it will not be able to obtain all or any portion of the Concurrent Financing on the terms and conditions, in the manner or from the sources contemplated by the Subscription Agreement or definitive agreements
                    related to the Concurrent Financing. Remix shall promptly provide information reasonably requested by Passage relating to the circumstances referred to in clauses (i), (ii) or (iii) of the immediately preceding sentence. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS527"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.27<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Passage Equity Plans</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Prior to the effectiveness of the Form&#160;S-4, Passage will use commercially reasonable efforts to cause the Passage Board to
                    adopt the 2026 Equity Incentive Plan, effective as of the Effective Time and subject to the Closing and the approval of the stockholders of Passage prior to the Closing, and will include provisions in the Proxy Statement for the
                    stockholders of Passage to approve the 2026 Equity Incentive Plan. Subject to the approval of the 2026 Equity Incentive Plan by the stockholders of Passage prior to the Effective Time, Passage shall file with the SEC, promptly after the
                    Effective Time and at Remix&#8217;s expense, a registration statement on Form&#160;S-8 (or any successor form), if available for use by Passage, relating to the shares of Passage Common Stock issuable with respect to the 2026 Equity Incentive
                    Plan. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Prior to the effectiveness of the Form&#160;S-4, Passage will use commercially reasonable efforts to cause the Passage Board to
                    adopt the 2026 ESPP, effective as of the Effective Time and subject to the Closing and approval of the stockholders of Passage prior to the Closing, and will include provisions in the Proxy Statement for the stockholders of Passage to
                    approve the 2026 ESPP. Subject to the approval of the 2026 ESPP by the stockholders of Passage prior to the Effective Time, Passage shall file with the SEC, promptly after the Effective Time and at Remix&#8217;s expense, a registration
                    statement on Form&#160;S-8 (or any successor form), if available for use by Passage, relating to the shares of Passage Common Stock issuable with respect to the 2026 ESPP. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">For the avoidance of doubt, approval of the 2026 Plans by the stockholders of Passage shall not be a condition to Closing. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS528"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.28<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Passage 401(k) Plan</span>. Unless otherwise requested by Remix in writing at least ten (10) business days prior to the
                    Closing Date, the Passage Board or an authorized committee thereof shall take (or cause to be taken) all actions to adopt such resolutions as may be necessary or appropriate to (a) terminate, effective no later than the day prior to the
                    Closing Date but subject to the Closing, any Passage Employee Plan that contains a cash or deferred arrangement intended to qualify under Section&#160;401(k) of the Code (a &#8220;<span style="font-weight: bold;">Passage 401(k) Plan</span>&#8221;) or,
                    if applicable, (b) withdraw as a participating employer in the Passage 401(k) Plan, spin-off the portion of the Passage 401(k) Plan maintained by Passage (the &#8220;<span style="font-weight: bold;">Spun-Off </span></div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-69<br/>
        </div>

      </div>

    </div>

    <!--End Page 510-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 511-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg74"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">Plan<span style="font-weight: normal;">&#8221;) and terminate
              the Spun-Off Plan, effective no later than the day prior to the Closing Date but subject to the Closing. If Passage is required to terminate any Passage 401(k) Plan or Spun-Off Plan, then Passage shall provide to Remix prior to the Closing
              Date written evidence of the adoption by the Passage Board or an authorized committee thereof of resolutions authorizing the termination of such Passage 401(k) Plan or Spun-Off Plan (the form and substance of which shall be subject to the
              reasonable prior review and approval of Remix). </span></div>

          <a id="tANXAS529"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.29<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Employees</span>. Prior to the Closing, the Passage Board shall adopt appropriate resolutions and Passage and the Passage
                    Board shall take all other actions necessary and appropriate to cause the employment of each employee of Passage to be terminated as of the Closing. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS530"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.30<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Section&#160;280G</span>. As promptly as practicable (and in any event within fifteen (15) Business Days)<sup> </sup>following
                    the date of this Agreement, Passage shall deliver to Remix a list of each &#8220;disqualified individual&#8221; (as defined in Section&#160;280G of the Code) of Passage and (i) Passage&#8217;s reasonable, good faith estimate of the &#8220;parachute payments&#8221;
                    (within the meaning of Section&#160;280G of the Code) that could be paid to such disqualified individual as a result of any of the transactions contemplated by this Agreement (alone or in combination with any other event), (ii) the &#8220;base
                    amount&#8221; (as defined in Section&#160;280G(b)(3) of the Code) for each such disqualified individual and (iii) the underlying documentation on which such calculations are based. Such information shall be updated and delivered to Remix not later
                    than five (5) Business Days prior to the Closing Date. From and after the date hereof, Passage shall reasonably cooperate with Remix to limit potential adverse Tax consequences under Section&#160;280G of the Code and shall not engage in any
                    action outside the ordinary course of business that is primarily intended to reduce or mitigate a potential parachute payment or excise taxes under Section&#160;280G of the Code without prior consultation with Remix, and with respect to the
                    valuing of any non-competition agreements or commission of any reasonable compensation studies, without the prior approval by Remix (such approval not to be unreasonably withheld, conditioned or delayed). In connection with the
                    foregoing, Remix shall provide Passage with any agreement, arrangement or Contract entered into or negotiated by Remix and a disqualified individual prior to the Closing Date that could reasonably be considered to be or provide for
                    &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Code and shall cooperate with the Passage in good faith in order to calculate or determine the value (for purposes of Section&#160;280G of the Code) of any such parachute
                    payments. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a id="tANXAA6"><!--Anchor--></a>ARTICLE&#160;VI<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONDITIONS TO CONSUMMATION OF THE MERGER </div>

          <a id="tANXAS61"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conditions Precedent to Obligations of Each Party</span>. The obligations of each Party to effect the Merger and otherwise
                    consummate the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No temporary restraining order, preliminary or permanent injunction or other Order preventing the consummation of the
                    Contemplated Transactions shall have been issued by any court of competent jurisdiction or other Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the
                    consummation of the Contemplated Transactions illegal. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Passage shall have obtained the Required Passage Stockholder Vote. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix shall have obtained the Required Remix Stockholder Vote. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The approval of the listing of the additional shares of Passage Common Stock on Nasdaq shall have been obtained and the
                    shares of Passage Common Stock to be issued in the Merger pursuant to this Agreement shall have been approved for listing (subject to official notice of issuance) on Nasdaq and the Amended and Restated Passage Charter shall have been
                    duly filed with the Secretary of State of the State of Delaware. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Remix Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Subscription Agreement and the Remix Note&#160;Purchase Agreement (2026) shall each be in full force and effect and cash
                    proceeds of not less than the Concurrent Investment Amount shall have been received by Remix, or will be received by Remix prior to or substantially simultaneously with the Closing, in connection with the Concurrent Financing. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-70<br/>
        </div>

      </div>

    </div>

    <!--End Page 511-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 512-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg75"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Passage Lock-Up Agreements and Remix Lock-Up Agreements will continue to be in full force and effect as of immediately
                    following the Effective Time. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not
                    be subject to any stop order or proceeding seeking a stop order with respect to such Registration Statement that has not been withdrawn. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Remix shall have effected the Remix Preferred Stock Conversion. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS62"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conditions Precedent to Obligations of Remix</span>. The obligations of Remix to effect the Merger and otherwise consummate
                    the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by Remix, at or prior to the Closing, of each of the following conditions: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of the Passage Fundamental Representations shall have been true and correct in all respects as of the date of this
                    Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically
                    made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Passage Capitalization Representations shall have been true and correct in all respects as of the date of
                    this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the
                    aggregate or (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the
                    preceding clause (x), as of such particular date). The representations and warranties of Passage and Merger Sub contained in this Agreement (other than the Passage Fundamental Representations and the Passage Capitalization
                    Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (i) in
                    each case, or in the aggregate, where the failure to be true and correct would not reasonably be expected to have a Passage Material Adverse Effect (without giving effect to any references therein to any Passage Material Adverse Effect
                    or other materiality qualifications) or (ii) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth
                    in the preceding clause (i), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Passage Disclosure Schedule made
                    or purported to have been made after the date of this Agreement shall be disregarded). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage and Merger Sub shall have performed and complied in all material respects with all covenants and agreements required
                    to be performed or complied with by them under this Agreement at or prior to the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">A Passage Material Adverse Effect shall not have occurred since the date of this Agreement and be continuing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The existing shares of Passage Common Stock shall have been continually listed on Nasdaq as of and from the date of this
                    Agreement through the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage shall have delivered to Remix a certificate (the &#8220;<span style="font-weight: bold;">Passage Closing Certificate</span>&#8221;),

                    dated the Closing Date and signed by an executive officer of Passage, certifying to the effect that (i) the conditions set forth in <span style="text-decoration: underline;">Sections 6.2(a),</span> <span style="text-decoration: underline;">6.2(b)</span> and <span style="text-decoration: underline;">6.2(c)</span> have been satisfied and (ii) the information
                    set forth in the Passage Outstanding Shares Certificate delivered by Passage in accordance with <span style="text-decoration: underline;">Section&#160;5.22(b)</span> is true and accurate in all respects as of the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix shall have received true and complete copies of all documentation for each Legacy Asset Disposition reasonably
                    evidencing that Passage has received or will receive into one or more bank account the proceeds (or, in the case of any Legacy Asset Disposition which will be consummated substantially contemporaneously with the Closing, that such
                    proceeds are in irrevocably transit to Passage) of all Legacy Asset Disposition which are included in Passage&#8217;s estimated Passage Net Cash Calculation. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-71<br/>
        </div>

      </div>

    </div>

    <!--End Page 512-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 513-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg76"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS63"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conditions Precedent to Obligations of Passage</span>. The obligations of Passage and Merger Sub to effect the Merger and
                    otherwise consummate the Contemplated Transactions are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by Passage, at or prior to the Closing, of each of the following conditions: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of the Remix Fundamental Representations shall have been true and correct in all respects as of the date of this
                    Agreement and shall be true and correct in all material respects on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically
                    made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Remix Capitalization Representations (disregarding any effects of the Remix Charter Amendment and the
                    Concurrent Financing) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date,
                    except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate or (y) for those representations and warranties which address matters only as of a particular date (which representations and
                    warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause (x), as of such particular date). The representations and warranties of Remix contained in this Agreement (other than the
                    Remix Fundamental Representations and the Remix Capitalization Representations) shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same
                    force and effect as if made on the Closing Date except (i) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Remix Material Adverse Effect (without giving effect to
                    any references therein to any Remix Material Adverse Effect or other materiality qualifications) or (ii) for those representations and warranties which address matters only as of a particular date (which representations shall have been
                    true and correct, subject to the qualifications as set forth in the preceding clause (i), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update
                    of or modification to the Remix Disclosure Schedule made or purported to have been made after the date of this Agreement shall be disregarded). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix shall have performed and complied in all material respects with all covenants and agreements required to be performed
                    or complied with by it under this Agreement at or prior to the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">A Remix Material Adverse Effect shall not have occurred since the date of this Agreement and be continuing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Remix shall have delivered to Passage a certificate (the &#8220;<span style="font-weight: bold;">Remix</span> <span style="font-weight: bold;">Closing Certificate</span>&#8221;), dated the Closing Date and signed by an executive officer of Remix, certifying to the effect that (i) the conditions set forth in <span style="text-decoration: underline;">Sections 6.3(a)</span>, <span style="text-decoration: underline;">6.3(b)</span> and <span style="text-decoration: underline;">6.3(c)</span>
                    have been satisfied and (ii) the information set forth in the Allocation Certificate delivered by Remix in accordance with <span style="text-decoration: underline;">Section&#160;5.22(a)</span> is true and accurate in all respects as of the Closing Date. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS64"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Frustration of Closing Conditions</span>. Neither Passage nor Merger Sub may rely on the failure of any conditions set forth
                    in <span style="text-decoration: underline;">Sections 6.1</span> or <span style="text-decoration: underline;">6.3</span> to be satisfied if the primary cause of such failure was the failure of Passage or Merger Sub to perform any of its obligations under this Agreement. Remix may not rely on the failure of any
                    conditions set forth in <span style="text-decoration: underline;">Sections 6.1</span> or <span style="text-decoration: underline;">6.2</span> to be satisfied if the primary cause of such failure was the failure of Remix to perform any of its obligations under this Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a id="tANXAA7"><!--Anchor--></a>ARTICLE&#160;VII<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CLOSING DELIVERIES </div>

          <a id="tANXAS71"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Closing Deliveries of Remix. The obligations of Passage and Merger Sub to effect the Merger and otherwise consummate the
                    Contemplated Transactions are subject to Passage receiving the following documents, each of which shall be in full force and effect, or the written waiver by Passage of delivery: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix Stockholder Written Consents; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Allocation Certificate; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Remix Closing Certificate. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-72<br/>
        </div>

      </div>

    </div>

    <!--End Page 513-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 514-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg77"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS72"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Closing Deliveries of Passage</span>. The obligations of Remix to effect the Merger and otherwise consummate the Contemplated
                    Transactions are subject to Remix receiving the following documents, each of which shall be in full force and effect, or the written waiver by Remix of delivery: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Net Cash Schedule; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Closing Certificate; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the Passage Outstanding Shares Certificate;<br/>
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to <span style="text-decoration: underline;">Section&#160;2.5</span>, the executed CVR Agreement; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">written resignations in forms satisfactory to Remix, dated as of the Closing Date and effective as of the Closing executed by
                    the officers and directors of Passage who are not to continue as officers or directors of Passage pursuant to <span style="text-decoration: underline;">Section&#160;5.19</span> hereof. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a id="tANXAA8"><!--Anchor--></a>ARTICLE&#160;VIII<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">TERMINATION </div>

          <a id="tANXAS81"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Termination</span>. This Agreement may be terminated, and the Merger and the Contemplated Transactions may be abandoned at
                    any time prior to the Effective Time, whether before or (subject to the terms hereof) after approval of the Passage Stockholder Matters by Passage&#8217;s stockholders, unless otherwise specified below: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">by mutual written consent of Passage and Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by either Passage or Remix if the Merger shall not have been consummated by December&#160;24, 2026 (subject to possible extension
                    as provided in this <span style="text-decoration: underline;">Section&#160;8.1(b)</span>, the &#8220;<span style="font-weight: bold;">Outside Date</span>&#8221;); <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that the right to terminate
                    this Agreement under this <span style="text-decoration: underline;">Section&#160;8.1(b)</span> shall not be available to Passage or Remix if such Party&#8217;s action or failure to act has been a principal cause of the failure of the Merger to occur on or before the Outside Date and such
                    action or failure to act constitutes a breach of this Agreement, <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">further</span>, that, in the event that the SEC has not declared effective under the
                    Securities Act the Registration Statement by the date which is twenty-five (25) days prior to the Outside Date, then either Passage or Remix shall be entitled to extend the Outside Date for an additional ninety (90) days; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by either Passage or Remix if a court of competent jurisdiction or other Governmental Authority shall have issued a final and
                    nonappealable Order, or shall have taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by Passage if the Required Remix Stockholder Vote shall not have been obtained and evidence thereof delivered to Passage
                    within fifteen (15) days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>,
                    that once the Required Remix Stockholder Vote has been obtained, Passage may not terminate this Agreement pursuant to this <span style="text-decoration: underline;">Section&#160;8.1(d)</span>; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by either Passage or Remix if (i) the Passage Stockholder Meeting (including any adjournments and postponements thereof)
                    shall have been held and completed and Passage&#8217;s stockholders shall have taken a final vote on the Passage Stockholder Matters and (ii) the Passage Stockholder Matters shall not have been approved at the Passage Stockholder Meeting (or
                    at any adjournment or postponement thereof) by the Required Passage Stockholder Vote; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that the right to terminate this Agreement
                    under this <span style="text-decoration: underline;">Section&#160;8.1(e)</span> shall not be available to Passage where the failure to obtain the Required Passage Stockholder Vote shall have been caused by the action or failure to act of Passage and such action or failure to act
                    constitutes a material breach by Passage of this Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by Remix (at any time prior to the approval of the Passage Stockholder Matters by the Required Passage Stockholder Vote) if a
                    Passage Triggering Event shall have occurred; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by Passage (at any time prior to the approval of the Remix Stockholder Matters by the Required Remix Stockholder Vote) if a
                    Remix Triggering Event shall have occurred; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by Remix (at any time prior to the approval of the Remix Stockholder Matters by the Required Remix </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-73<br/>
        </div>

      </div>

    </div>

    <!--End Page 514-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 515-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg78"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Stockholder Vote) in order to substantially concurrently enter into an
            Alternative Acquisition Agreement with respect to a Superior Offer, so long as Remix has complied in all material respects with obligations under <span style="text-decoration: underline;">Section&#160;5.4</span> and <span style="text-decoration: underline;">Section&#160;5.8</span> and concurrently with such termination Remix pays the
            termination fee due to Passage in accordance with <span style="text-decoration: underline;">Section&#160;8.3(e)</span>; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by Passage (at any time prior to the approval of the Passage Stockholder Matters by the Required Passage Stockholder Vote) in
                    order to substantially concurrently enter into an Alternative Acquisition Agreement with respect to a Superior Offer, so long as Passage has complied in all material respects with obligations under <span style="text-decoration: underline;">Section&#160;5.4</span> and <span style="text-decoration: underline;">Section&#160;5.9</span>
                    and concurrently with such termination Passage pays the termination fee due to Remix in accordance with <span style="text-decoration: underline;">Section&#160;8.3(d)</span>; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by Remix, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Passage or
                    Merger Sub or if any representation or warranty of Passage or Merger Sub shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration: underline;">Section&#160;6.2(a)</span> or <span style="text-decoration: underline;">Section&#160;6.2(b)</span> would not be satisfied as of
                    the time of such breach or as of the time such representation or warranty shall have become inaccurate; <span style="font-style: italic;">provided</span> that Remix is not then in material breach of any representation, warranty,
                    covenant or agreement under this Agreement; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">further</span>, that if such inaccuracy in Passage&#8217;s or Merger Sub&#8217;s representations and warranties or
                    breach by Passage or Merger Sub is curable by Passage or Merger Sub at least one Business Day prior to the Outside Date, then this Agreement shall not terminate pursuant to this <span style="text-decoration: underline;">Section&#160;8.1(j)</span> as a result of such particular
                    breach or inaccuracy until the expiration of a 30-day period commencing upon delivery of written notice from Remix to Passage or Merger Sub of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration: underline;">Section&#160;8.1(j)</span>
                    (it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration: underline;">Section&#160;8.1(j)</span> as a result of such particular breach or inaccuracy if such breach by Passage or Merger Sub is cured prior to such termination becoming
                    effective); or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">by Passage, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Remix or if
                    any representation or warranty of Remix shall have become inaccurate, in either case, such that the conditions set forth in <span style="text-decoration: underline;">Section&#160;6.3(a)</span> or <span style="text-decoration: underline;">Section&#160;6.3(b)</span> would not be satisfied as of the time of such breach or as of
                    the time such representation or warranty shall have become inaccurate; <span style="font-style: italic;">provided</span> that Passage is not then in material breach of any representation, warranty, covenant or agreement under this
                    Agreement; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">further</span>, that if such inaccuracy in Remix&#8217;s representations and warranties or breach by Remix is curable by Remix at least one
                    Business Day prior to the Outside Date, then this Agreement shall not terminate pursuant to this <span style="text-decoration: underline;">Section&#160;8.1(k)</span> as a result of such particular breach or inaccuracy until the expiration of a 30-day period commencing upon delivery
                    of written notice from Passage to Remix of such breach or inaccuracy and its intention to terminate pursuant to this <span style="text-decoration: underline;">Section&#160;8.1(k)</span> (it being understood that this Agreement shall not terminate pursuant to this <span style="text-decoration: underline;">Section&#160;8.1(k)</span>
                    as a result of such particular breach or inaccuracy if such breach by Remix is cured prior to such termination becoming effective). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">The Party desiring to terminate this Agreement pursuant to this <span style="text-decoration: underline;">Section&#160;8.1</span>
            (other than pursuant to <span style="text-decoration: underline;">Section&#160;8.1(a)</span>) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail. </div>

          <a id="tANXAS82"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Effect of Termination</span>. In the event of the termination of this Agreement as provided in <span style="text-decoration: underline;">Section&#160;8.1</span>, this
                    Agreement shall be of no further force or effect; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that (a)&#160;<span style="text-decoration: underline;">Section&#160;1.2</span>, this <span style="text-decoration: underline;">Section&#160;8.2</span>, <span style="text-decoration: underline;">Section&#160;5.11</span>, <span style="text-decoration: underline;">Section&#160;8.3</span>
                    and <span style="text-decoration: underline;">Article&#160;IX</span> (and the definitions of all defined terms in such Sections) shall survive the termination of this Agreement and shall remain in full force and effect and (b) the termination of this Agreement and the provisions of
                    <span style="text-decoration: underline;">Section&#160;8.3</span> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS83"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Expenses; Termination Fees</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as set forth in this <span style="text-decoration: underline;">Section&#160;8.3</span> all fees and expenses incurred in connection with this Agreement and the
                    Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that (i)
                    Passage and Remix shall pay the costs and expenses incurred in relation to the filings by the Parties under any antitrust Law applicable to this Agreement and the transactions </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-74<br/>
        </div>

      </div>

    </div>

    <!--End Page 515-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 516-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg79"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">contemplated hereby, and (ii) Passage and Remix shall share equally all
            fees and expenses incurred in relation to the printing and filing with the SEC of the Registration Statement (including any financial statements and exhibits) and any amendments or supplements thereto and paid to a financial printer or the SEC.
          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If (i) this Agreement is terminated by Passage or Remix pursuant to <span style="text-decoration: underline;">Section&#160;8.1(e)</span>, (ii) at any time after the date
                    of this Agreement and prior to the Passage Stockholder Meeting an Acquisition Proposal with respect to Passage shall have been publicly announced, disclosed or otherwise communicated to the Passage Board (and shall not have been
                    withdrawn) and (iii) within twelve (12) months after the date of such termination, Passage enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Passage shall pay to
                    Remix, within two (2) Business Days after termination (or, if applicable, upon such entry into a definitive agreement and/or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $1,548,000. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If (i) this Agreement is terminated by Passage pursuant to <span style="text-decoration: underline;">Section&#160;8.1(d)</span>, (ii) at any time after the date of this
                    Agreement, and prior to the termination of this Agreement, an Acquisition Proposal with respect to Remix shall have been publicly announced, disclosed or otherwise communicated to the Remix Board (and shall not have been withdrawn) and
                    (iii) within twelve (12) months after the date of such termination, Remix enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Remix shall pay to Passage, within two
                    (2) Business Days after termination (or, if applicable, upon such entry into a definitive agreement and/or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $17,500,000. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If this Agreement is terminated by Remix pursuant to <span style="text-decoration: underline;">Section&#160;8.1(f)</span> or by Passage pursuant to <span style="text-decoration: underline;">Section&#160;8.1(i)</span>,
                    then Passage shall pay to Remix within two (2) Business Days after termination, a nonrefundable fee in an amount equal to $1,548,000. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If this Agreement is terminated by Passage pursuant to <span style="text-decoration: underline;">Section&#160;8.1(g)</span> or by Remix pursuant to <span style="text-decoration: underline;">Section&#160;8.1(h)</span>,
                    then Remix shall pay to Passage, within two (2) Business Days after termination, a nonrefundable fee in an amount equal to $17,500,000. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If either Party fails to pay when due any amount payable by it under this <span style="text-decoration: underline;">Section&#160;8.3</span>, then (i) such Party shall
                    reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights
                    under this <span style="text-decoration: underline;">Section&#160;8.3</span> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such
                    overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be
                    paid plus three percent. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Parties agree that, subject to <span style="text-decoration: underline;">Section&#160;8.2</span>, the payment of the fees and expenses set forth in this <span style="text-decoration: underline;">Section&#160;8.3</span>
                    shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this <span style="text-decoration: underline;">Section&#160;8.3</span> that result in the payment of such fees, it being understood that in no event
                    shall either Passage or Remix be required to pay the individual fees or damages payable pursuant to this <span style="text-decoration: underline;">Section&#160;8.3</span> on more than one occasion. Subject to <span style="text-decoration: underline;">Section&#160;8.2</span>, following the termination of this Agreement under
                    the circumstances described in this <span style="text-decoration: underline;">Section&#160;8.3</span> and the payment of the fees set forth in this <span style="text-decoration: underline;">Section&#160;8.3</span> by a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of
                    this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii) no other Party or their respective
                    Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder,
                    director, officer, employee, Subsidiary, affiliate, agent or other representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or
                    the failure of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise,
                    in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges
                    that (x) the agreements contained in this <span style="text-decoration: underline;">Section&#160;8.3</span> are an integral part of the Contemplated Transactions, (y)&#160;without </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-75<br/>
        </div>

      </div>

    </div>

    <!--End Page 516-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 517-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg80"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">these agreements, the Parties would not enter into this Agreement and (z)
            any amount payable pursuant to this <span style="text-decoration: underline;">Section&#160;8.3</span> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a id="tANXAA9"><!--Anchor--></a>ARTICLE&#160;IX<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL PROVISIONS </div>

          <a id="tANXAS91"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Non-Survival of Representations and Warranties</span>. The representations and warranties of Remix, Passage and Merger Sub
                    contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the Effective Time, and only the covenants that by their terms survive the Effective Time and this <span style="text-decoration: underline;">Article&#160;IX</span>
                    shall survive the Effective Time. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS92"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Amendment</span>. This Agreement may be amended with the approval of the respective boards of directors of Remix, Merger Sub
                    and Passage at any time (whether before or after obtaining the Required Remix Stockholder Vote and the Required Passage Stockholder Vote); <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>,
                    that after any such approval of this Agreement by a Party&#8217;s stockholders or members, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This
                    Agreement may not be amended except by an instrument in writing signed on behalf of each of Remix, Merger Sub and Passage. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS93"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Waiver</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other
                    Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall
                    operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege
                    or remedy. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy
                    under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or
                    have any effect except in the specific instance in which it is given. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS94"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span>. This Agreement and the other
                    schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the
                    Parties with respect to the subject matter hereof and thereof; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that (a) the Confidentiality Agreement shall not be superseded and
                    shall remain in full force and effect in accordance with its terms and (b) the Remix Disclosure Schedule and the Passage Disclosure Schedule shall not, pursuant to Section&#160;268(b) of Delaware Law, be deemed part of this Agreement for
                    purposes of any provision of Delaware Law, but shall have the effects provided in this Agreement. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one
                    and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this
                    Agreement. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS95"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.5<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Applicable Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the laws of the
                    State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the
                    Contemplated Transactions, each of the Parties: irrevocably and unconditionally (a) consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not
                    have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b) agrees that all claims in respect of such action or proceeding shall be heard and
                    determined exclusively in accordance with clause (a) of this <span style="text-decoration: underline;">Section&#160;9.5</span>, (c) waives any objection to laying venue in any such action or proceeding in such courts, (d) waives any objection that such courts are an inconvenient
                    forum or do not have jurisdiction over any Party, (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration: underline;">Section&#160;9.7</span> of this Agreement and
                    (f)&#160;irrevocably and unconditionally waives the right to trial by jury. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-76<br/>
        </div>

      </div>

    </div>

    <!--End Page 517-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 518-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg81"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="tANXAS96"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.6<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of,
                    the Parties and their respective successors and permitted assigns; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that neither this Agreement nor any of a Party&#8217;s rights or
                    obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party
                    without the other Party&#8217;s prior written consent shall be void and of no effect. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS97"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.7<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Notices</span>. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
                    delivered and received hereunder (a) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b) upon delivery in the case of delivery by hand or (c)
                    on the date delivered to the place of delivery if sent by email (with a written or electronic confirmation of delivery) prior to 6:00 p.m. New York City time, otherwise on the next succeeding Business Day, in each case to the intended
                    recipient as set forth below: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 408pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 408pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Passage or Merger Sub: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Bio, Inc. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">P.O. Box 7</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hopewell, NJ 08525</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Will Chou M.D.</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[****] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy to (which shall not constitute notice): </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Fenwick &amp; West LLP </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">401 Union Street, Floor 5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Seattle, WA 98101 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effie Toshav; David Michaels; Ryan Mitteness </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[****] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Remix: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Therapeutics, Inc.</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">100 Forge Road, Suite 400 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Watertown, MA 02472</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Smith </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[****] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy to (which shall not constitute notice): </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Latham &amp; Watkins LLP </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">200 Clarendon Street </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02116</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter Handrinos; Leah Sauter </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[****]</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <a id="tANXAS98"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.8<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Cooperation</span>. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further
                    documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this
                    Agreement. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS99"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.9<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any
                    jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other
                    jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-77<br/>
        </div>

      </div>

    </div>

    <!--End Page 518-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 519-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg82"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">or provision of this Agreement is invalid or unenforceable, the Parties
            agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes
            closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence,
            the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable
            term or provision. </div>

          <a id="tANXAS910"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly
                    conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other
                    remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance
                    with their specific terms (including failing to take such actions as are required of each Party hereunder to consummate this Agreement and the Contemplated Transactions) or were otherwise breached. It is accordingly agreed that the
                    Parties shall be entitled to an injunction or injunctions, specific performance and other equitable relief to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court of the United
                    States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other
                    Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that
                    any award of specific performance is not an appropriate remedy for any reason at law or in equity. </div>
                </td>

  </tr>


</table>
          <a id="tANXAS911"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Third-Party Beneficiaries</span>. Nothing in this Agreement, express or implied, is intended to or shall confer upon any
                    Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to <span style="text-decoration: underline;">Section&#160;5.15</span>) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">[<span style="font-style: italic;">Remainder of page intentionally left blank</span>] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-78<br/>
        </div>

      </div>

    </div>

    <!--End Page 519-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 520-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg83"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">IN WITNESS WHEREOF<span style="font-weight: normal;">,
              the Parties have caused this Agreement to be executed as of the date first above written. </span></div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 240pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PASSAGE BIO, INC.<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ William Chou</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, MD </div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and CEO </div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PEREGRINE MERGER SUB, INC.<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ William Chou</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, MD </div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and CEO</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 204pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">[Signature Page to Merger Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-79<br/>
        </div>

      </div>

    </div>

    <!--End Page 520-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 521-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg84"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 240pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Peter G. Smith</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 204pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 5.75pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">[Signature Page to Merger Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-80<br/>
        </div>

      </div>

    </div>

    <!--End Page 521-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 522-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg85"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Exhibit&#160;A <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><span style="font-weight: normal;">Form&#160;of Passage Stockholder Support Agreement
            </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; text-align: center;">[Intentionally Omitted] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-81<br/>
        </div>

      </div>

    </div>

    <!--End Page 522-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 523-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg86"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Exhibit&#160;B<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><span style="font-weight: normal;">Form&#160;of Remix Stockholder Support Agreement </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; text-align: center;">[Intentionally Omitted] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-82<br/>
        </div>

      </div>

    </div>

    <!--End Page 523-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 524-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg87"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Exhibit&#160;C<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><span style="font-weight: normal;">Form&#160;of Passage Lock-Up Agreement</span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 19.5pt; text-align: center;">[Intentionally Omitted] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-83<br/>
        </div>

      </div>

    </div>

    <!--End Page 524-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 525-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg88"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Exhibit&#160;D </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; text-align: center;">Form&#160;of Remix Lock-Up Agreement </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">[Intentionally Omitted] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-84<br/>
        </div>

      </div>

    </div>

    <!--End Page 525-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 526-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg89"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Exhibit&#160;E </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; text-align: center;">Form&#160;of Certificate of Incorporation of the Surviving Corporation </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">[Intentionally Omitted] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-85<br/>
        </div>

      </div>

    </div>

    <!--End Page 526-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 527-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_300-annexa_pg90"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Exhibit&#160;F </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; text-align: center;">Form&#160;of CVR Agreement </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 20.5pt; text-align: center;">[Intentionally Omitted] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">A-86<br/>
        </div>

      </div>

    </div>

    <!--End Page 527-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 528-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_301-annexb_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXB"><!--Anchor--></a>Annex&#160;B</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.75pt; text-align: right;"><img style="height: 72px; width: 240px;" src="logo_redwood.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">June&#160;23, 2026<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Board of Directors <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">P.O. Box 7 <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hopewell, New Jersey 08525<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Members of the Board of Directors, </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">You have requested our opinion as to the fairness, from a financial point of
            view, to Passage Bio, Inc., a Delaware corporation (&#8220;Passage&#8221; or the &#8220;Company&#8221;), of the Merger Consideration (as defined below) to be paid by the Company pursuant to the terms of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), to be
            entered into by and among the Company, Peregrine Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Passage (&#8220;Merger Sub&#8221;), and Remix Therapeutics, Inc., a Delaware corporation (&#8220;Remix&#8221;). The Merger Agreement
            provides for a transaction (the &#8220;Transaction&#8221;) pursuant to which, on the terms and subject to the conditions set forth therein and in accordance with the General Corporation Law of the State of Delaware (&#8220;Delaware Law&#8221;), Merger Sub will be
            merged with and into Remix, with Remix surviving such merger as a wholly owned subsidiary of Passage (the &#8220;Merger&#8221;). Immediately prior to the time that the Merger becomes effective (the &#8220;Effective Time&#8221;), all outstanding Remix convertible notes
            will be converted into shares of Remix common stock in accordance with their terms (the &#8220;Remix Convertible Notes Conversion&#8221;) and all outstanding shares of Remix preferred stock will be converted into shares of Remix common stock in accordance
            with Remix&#8217;s organizational documents (the &#8220;Remix Preferred Stock Conversion&#8221;). At the Effective Time, each issued and outstanding share of Remix common stock (after giving effect to the Remix Convertible Notes Conversion and the Remix
            Preferred Stock Conversion and other than shares held by Remix as treasury stock or by Passage or any of its direct or indirect subsidiaries (&#8220;Remix Treasury Shares&#8221;) and shares as to which appraisal rights have been properly exercised
            (&#8220;Dissenting Remix Shares&#8221;)) will be converted into the right to receive shares of common stock, par value $0.0001 per share, of Passage (&#8220;Passage Common Stock&#8221;), in an amount determined pursuant to the allocation methodology set forth in the
            Merger Agreement, including, without limitation, based on agreed equity values of Passage and Remix and an allocation certificate to be prepared in accordance with the Merger Agreement (the &#8220;Allocation Certificate&#8221;). The aggregate number of
            shares of Passage Common Stock issuable to holders of Remix common stock in the Merger (other than shares issued in the Concurrent Financing (as defined below)) is referred to herein as the &#8220;Merger Consideration.&#8221; We are not expressing any
            opinion as to the Concurrent Financing Merger Shares (as defined in the Merger Agreement), being the shares of Passage Common Stock issuable to participants in the Concurrent Financing. At the direction of management of the Company, we have not
            analyzed the value of certain contingent value rights (&#8220;CVRs&#8221;) to be distributed to holders of record of Passage Common Stock prior to the Effective Time, or ascribed value to any Legacy Assets (as defined in the Merger Agreement), and we
            express no opinion with respect thereto. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with preparing our opinion, we have (i) reviewed a draft dated
            June 22, 2026 of the Merger Agreement, which, for purposes of this opinion, we have assumed to be in all material respects identical to the agreement to be executed by the parties; (ii) reviewed drafts of the agreements governing the concurrent
            financing of the Transaction (the &#8220;Concurrent Financing&#8221;), including (A) a draft dated June 23, 2026 of the Subscription Agreement, by and among Remix and the investors party thereto (the &#8220;Subscription Agreement&#8221;) and (B) a draft dated June 17,
            2026 of the term sheet for the Convertible Note&#160;Purchase Agreement (the &#8220;Convertible Note&#160;Term Sheet&#8221;), which sets forth the principal terms on which certain investors will purchase convertible promissory notes of Remix pursuant to the Remix
            Note&#160;Purchase Agreement (2026) (as defined in the Merger Agreement); (iii) reviewed the form of Contingent Value Rights Agreement attached as Exhibit&#160;F to the draft Merger Agreement; (iv) reviewed certain publicly available business and
            financial information concerning the Company and Remix, and the industries in which they operate; (v)&#160;reviewed the current and historical market prices of the Company&#8217;s common stock and certain publicly traded securities of other companies that
            we deemed relevant; (vi) at the Company&#8217;s direction, reviewed and relied upon for our opinion and analysis (A) the estimated balance sheet of the Company corresponding with the estimated closing date of the Transaction, (B) the pro forma
            capitalization table and option ledger of the Company and Remix corresponding with the proposed closing date of the Transaction, and (C) the illustrative example of </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 528-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 529-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_301-annexb_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><img style="height: 72px; width: 240px;" src="logo_redwood.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">the calculation of the Remix Merger Shares (as defined in the Merger
            Agreement) set forth in Section&#160;1.1(a)(iii) of the Passage Disclosure Schedule to the draft Merger Agreement; (vii) reviewed summaries prepared internally by the Company of its efforts to solicit interest from third parties with respect to a
            possible acquisition or business combination of the Company; and (viii)&#160;performed such other financial studies and analyses and considered such other information as we deemed appropriate for the purposes of this opinion. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition, we have held discussions with certain members of the management
            of the Company with respect to certain aspects of the Transaction, the past and current business operations of the Company, Merger Sub and Remix, the financial condition and future prospects and operations of the Company, Merger Sub and Remix,
            the effects of the Transaction on the financial condition and future prospects of the Company, and certain other matters we believed necessary or appropriate to our inquiry. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In giving our opinion, we have relied upon and assumed the accuracy and
            completeness of all information that was publicly available or was furnished to or discussed with us by the Company or otherwise reviewed by or for us, and we have not assumed any responsibility for independent verification of any such
            information. We have not independently verified any such information or its accuracy or completeness and, pursuant to our engagement letter with the Company, we did not assume any obligation to undertake any such independent verification. We
            have not conducted or been provided with any valuation or appraisal of any assets or liabilities, nor have we evaluated the solvency, creditworthiness or fair value of the Company, Merger Sub, Remix or the Surviving Corporation (as defined in
            the Merger Agreement) under any applicable laws relating to bankruptcy, insolvency, fraudulent conveyance or similar matters. We are not expressing any view or rendering any opinion regarding the legal, regulatory or tax consequences of the
            Transaction or any portion thereof to the Company, its stockholders or any other party, and we have relied on the assessments made by legal, regulatory and tax advisors to the Company with respect to such issues. In relying on the estimated
            balance sheet and pro forma capitalization table of the Company and other financial data, analyses and projections provided to us or discussed with us by the Company or its management, we have assumed with your consent that they have been
            reasonably prepared based on assumptions reflecting the best currently available estimates and judgments by management of the Company. We express no view as to such estimates or projections or the assumptions on which they were based. We have
            assumed that the Merger will be consummated on the terms set forth in the draft Merger Agreement, and that the definitive Merger Agreement will not differ in any material respects from the draft thereof furnished to us or have any waiver,
            modification or amendment of any term or condition that is material to our analysis. We have assumed that the Allocation Certificate will be prepared in good faith and in accordance with the terms of the Merger Agreement and the organizational
            documents of Remix and contracts applicable to Remix&#8217;s capital stock. We have assumed that the Concurrent Financing will be consummated on the terms and conditions described in the Subscription Agreement and the Convertible Note&#160;Term Sheet,
            with aggregate gross cash proceeds of at least the Concurrent Investment Amount (as defined in the Merger Agreement). We have assumed that any Reverse Stock Split (as defined in the Merger Agreement) effected in connection with the Transaction
            will not affect the relative economic interests of the stockholders. We have assumed that the Merger will qualify as a reorganization within the meaning of Section&#160;368(a) of the Internal Revenue Code of 1986, as amended. We have also assumed
            that the representations and warranties made by the Company, Merger Sub and Remix in the Merger Agreement and the related agreements are and will be true and correct in all respects material to our analysis. We have further assumed that all
            material governmental, regulatory or other consents and approvals necessary for the consummation of the Transaction will be obtained without any adverse effect on the Company, Merger Sub or Remix or on the contemplated benefits of the
            Transaction. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our opinion is necessarily based on economic, market and other conditions as
            in effect on, and the information made available to us as of the date hereof. It should be understood that subsequent developments may affect this opinion and that we do not have any obligation to update, revise, or reaffirm this opinion. Our
            opinion is limited solely to the fairness, from a financial point of view, to the Company of the Merger Consideration to be paid in the proposed Transaction. We have not been asked to opine as to, and this opinion does not in any manner
            address, (i) the fairness of the Transaction to the holders of any class of securities, creditors or other constituencies of the Company or Remix, (ii)&#160;the underlying decision by the Company to engage in the Transaction, (iii) the terms,
            structure or fairness of the Concurrent Financing, including the Subscription Agreement, the Convertible Note&#160;Term Sheet, the Remix Convertible Notes or any other agreement or instrument entered into in connection with the Concurrent Financing,
            or the fairness </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 529-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 530-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_301-annexb_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><img style="height: 72px; width: 240px;" src="logo_redwood.jpg" alt="graphic"/><br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">thereof to any party, (iv) the terms, value or fairness of the CVRs, the CVR
            Agreement, the Legacy Assets or the Legacy Asset Disposition (each as defined in the Merger Agreement), (v) the terms or fairness of any Stockholder Support Agreement, Lock-Up Agreement, Passage Equity Plan (each as defined in the Merger
            Agreement), employment or severance arrangement, or any other agreement, arrangement or understanding entered into in connection with, or contemplated by, the Transaction, (vi) the relative merits of the Transaction as compared to any
            alternative business strategies or transactions that might be available to the Company, or (vii) the prices at which shares of Passage Common Stock or any other securities may trade at any time. Furthermore, we express no opinion with respect
            to the amount or nature of any compensation to any officers, directors, or employees of any party to the Transaction, or any class of such persons, relative to the Merger Consideration or with respect to the fairness of any such compensation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We have acted as financial advisor to the Company with respect to the proposed
            Transaction and will receive a fee from the Company for our services, no portion of which is contingent on the consummation of the proposed Transaction or on the conclusions reached in this opinion. In addition, the Company has agreed to
            indemnify us for certain liabilities arising out of our engagement. Please be advised that during the two years preceding the date of this letter, neither we nor our affiliates have had any other material financial advisory or other material
            commercial relationships with the Company, Merger Sub or Remix. In addition, we and our affiliates do not hold any investment stake in the Company, Merger Sub or Remix. We do not currently have, and during the two years preceding the date of
            this letter have not had, any material financial advisory or other material commercial or financial relationship with any party to the Concurrent Financing that is material to this opinion. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our financial advisory services and the opinion expressed herein are provided
            for the information and assistance of the Board of Directors of the Company (in their capacity as directors and not in any other capacity) in connection with and for purposes of its consideration of the Transaction. This opinion is not intended
            to be and does not constitute a recommendation to the Board of Directors as to whether the Company should enter into the Merger Agreement or consummate the Transaction. This opinion does not address the relative merits of the Merger as compared
            to other business or financial strategies that might be available to the Company, nor does it address the underlying business decision of the Company to engage in the Transaction. We were not authorized to, and did not, solicit any expressions
            of interest from any other parties with respect to the sale of all or any part of the Company, any alternative transaction involving the Company, or any other transaction. We did not participate in negotiations with respect to the terms of the
            Transaction, the Merger Agreement, the Concurrent Financing or any related transactions, nor did we participate in the determination of the Merger Consideration or the allocation methodology. We were not asked to opine on, and express no
            opinion as to, whether the Merger Consideration represents the highest or best price reasonably attainable by the Company. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On the basis of and subject to the foregoing, it is our opinion as of the date
            hereof that the Merger Consideration to be paid by the Company in the proposed Transaction is fair, from a financial point of view, to the Company. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This opinion has been approved by the fairness opinion committee of Redwood
            Valuation Partners, LLC. This opinion is solely that of Redwood Valuation Partners, LLC, and our liability in connection with this opinion shall be limited in accordance with the terms set forth in our engagement letter with the Company. This
            letter is provided to the Board of Directors of the Company (in its capacity as such) in connection with and for the purposes of its evaluation of the Transaction. This opinion does not constitute a recommendation to any stockholder of the
            Company or Remix as to how such stockholder should vote or act with respect to the Transaction or any other matter. This opinion may not be disclosed, referred to, or communicated (in whole or in part) to any third party for any purpose
            whatsoever except with our prior written approval, except as required by legal and regulatory authorities. This opinion may be reproduced in full, and referenced, in any proxy or information statement or registration statement on Form&#160;S-4
            distributed to stockholders of the Company in connection with the Transaction, and any description or summary of this opinion or reference to us in such document shall be in a form pre-approved by us in writing; provided that this opinion may
            not otherwise be disclosed publicly in any manner without our prior written approval. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Very truly yours,<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ Redwood Valuation<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Redwood Valuation Partners, LLC </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">B-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 530-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 531-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXC"><!--Anchor--></a>Annex&#160;C </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">PASSAGE BIO, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">SUPPORT AGREEMENT </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">THIS SUPPORT AGREEMENT<span style="font-weight: normal;">
              (this &#8220;<span style="text-decoration: underline;">Agreement</span>&#8221;), dated as of June&#160;24, 2026, is made by and among Passage Bio, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline;">Passage</span>&#8221;), Remix Therapeutics, Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;), and the undersigned holders
              (each a &#8220;<span style="text-decoration: underline;">Stockholder</span>&#8221;) of shares of common stock (the &#8220;<span style="text-decoration: underline;">Shares</span>&#8221;) of Passage. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, Passage,
              Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Passage (&#8220;<span style="text-decoration: underline;">Merger Sub</span>&#8221;), and the Company, have entered into an Agreement and Plan of Merger, dated as of even date herewith (the &#8220;<span style="text-decoration: underline;">Merger Agreement</span>&#8221;),

              providing for the merger of Merger Sub with and into the Company (the &#8220;<span style="text-decoration: underline;">Merger</span>&#8221;); </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, each
              Stockholder beneficially owns and has sole or shared voting power with respect to the number of Shares, and holds Passage Options to acquire the number of Shares, indicated opposite such Stockholder&#8217;s name on <span style="text-decoration: underline;">Schedule 1</span> attached
              hereto; </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, as an
              inducement and a condition to the willingness of Passage to enter into the Merger Agreement, each Stockholder has agreed to enter into and perform this Agreement; and </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, all capitalized
              terms used in this Agreement without definition herein shall have the meanings ascribed to them in the Merger Agreement. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NOW, THEREFORE<span style="font-weight: normal;">, in
              consideration of, and as a condition to, Passage&#8217;s entering into the Merger Agreement, each Stockholder, Passage and the Company agree as follows: </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Agreement to Vote Shares</span>. Each Stockholder agrees that, prior to the Expiration Date (as defined in <span style="text-decoration: underline;">Section&#160;2</span>
                    below), at any meeting of the stockholders of Passage or any adjournment or postponement thereof, or in connection with any written consent of the stockholders (or any class or series of stockholders, as applicable) of Passage, with
                    respect to the Merger, the Merger Agreement or any Acquisition Proposal, such Stockholder shall: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">appear at such meeting or otherwise cause the Shares and any New Shares (as defined in <span style="text-decoration: underline;">Section&#160;3</span> below) to be counted
                    as present thereat for purposes of calculating a quorum; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">from and after the date hereof until the Expiration Date, vote (or cause to be voted), or deliver a written consent (or cause
                    a written consent to be delivered) covering all of the Shares and any New Shares that Stockholder shall be entitled to so vote: (i) in favor of (A) all of the Passage Stockholder Matters and (B)&#160;any matter that could reasonably be
                    expected to facilitate the Merger, the Concurrent Financing and the Contemplated Transactions; (ii) against any action or agreement that would result in a breach of any representation, warranty, covenant or obligation of Passage in the
                    Merger Agreement; (iii) against any Acquisition Proposal, or any agreement, transaction or other matter or action that is intended to, or would reasonably be expected to, impede, interfere with, delay, postpone, discourage or materially
                    and adversely affect the consummation of the Merger, the Concurrent Financing and all of the other Contemplated Transactions; and (iv) to approve any proposal to adjourn or postpone the meeting to a later date, if there are not
                    sufficient votes for the adoption of the Merger Agreement on the date on which such meeting is held. Stockholder shall not take or commit or agree to take any action inconsistent with the foregoing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Expiration Date</span>. As used in this Agreement, the term &#8220;<span style="text-decoration: underline;">Expiration Date</span>&#8221; shall mean the earlier to occur of
                    (a)&#160;the Effective Time, (b) such date and time as the Merger Agreement shall be terminated pursuant to <span style="text-decoration: underline;">Article&#160;VIII</span> thereof or otherwise, (c) any amendment to the Merger Agreement that is effected without the Stockholder&#8217;s
                    written consent that increases the amount, or changes the form, of consideration payable to all stockholders of the Company pursuant to the terms of the Merger Agreement or (d) the mutual written agreement of the parties to terminate
                    this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Additional Acquisitions</span>. Each Stockholder agrees that any shares of capital stock or other equity securities of
                    Passage that such Stockholder acquires or with respect to which such Stockholder otherwise acquires sole or shared voting power (including any proxy) after the execution of this Agreement and prior to the Expiration Date, whether by the
                    exercise of any Passage Options or otherwise, including, without limitation, upon the vesting of any applicable restricted stock unit award agreement or by gift, succession, in the event of a stock </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 531-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 532-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">split or as a dividend or distribution of any Shares (&#8220;<span style="text-decoration: underline;">New Shares</span>&#8221;),

            shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Shares. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Agreement to Retain Shares</span>. From and after the date hereof until the Expiration Date, each Stockholder shall not,
                    directly or indirectly, (a) sell, assign, transfer, tender, or otherwise dispose of (including, without limitation, by the creation of any Liens (as defined in <span style="text-decoration: underline;">Section&#160;5(d)</span> below)) any Shares or any New Shares, (b)&#160;deposit any
                    Shares or New Shares into a voting trust or enter into a voting agreement or similar arrangement with respect to such Shares or New Shares or grant any proxy or power of attorney with respect thereto (other than this Agreement), (c)
                    enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect sale, transfer, assignment or other disposition of (including, without limitation, by the creation of any Liens)
                    any Shares or New Shares, or (d) take any action that would make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of preventing or disabling such Stockholder from performing such
                    Stockholder&#8217;s obligations under this Agreement. Any action taken in violation of the foregoing sentence shall be null and void <span style="font-style: italic;">ab initio</span>. Notwithstanding the foregoing, each Stockholder may make
                    (1) transfers by will or by operation of Law or other transfers for estate-planning purposes, in which case this Agreement shall bind the transferee, (2) with respect to such Stockholder&#8217;s Passage Options (and any Shares underlying such
                    Passage Options) which expire on or prior to the Expiration Date, transfers, sale, or other disposition of Shares to Passage (or effecting a &#8220;net exercise&#8221; of a Passage Option) as payment for the (i) exercise price of such Stockholder&#8217;s
                    Passage Options and (ii) taxes applicable to the exercise of such Stockholder&#8217;s Passage Options, (3) if Stockholder is an entity, partnership or limited liability company, a transfer to one or more equityholders, partners or members of
                    Stockholder or to an Affiliated person, corporation, trust or other Entity controlling or under common control with Stockholder, or if Stockholder is a trust, a transfer to a beneficiary, provided that in each such case the applicable
                    transferee has signed a voting agreement in substantially the form hereof, (4) make transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement, and (5) transfers,
                    sales or other dispositions as Passage may otherwise agree in writing in its sole discretion. If any voluntary or involuntary transfer of any Shares covered hereby shall occur (including a transfer or disposition permitted by <span style="text-decoration: underline;">Section&#160;4(1)</span>
                    through <span style="text-decoration: underline;">Section&#160;4(5)</span>, sale by a Stockholder&#8217;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#8217;s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent
                    transferees of the initial transferee) shall take and hold such Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect, notwithstanding that such transferee
                    is not a Stockholder and has not executed a counterpart hereof or joinder hereto. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Representations and Warranties of Stockholder</span>. Each Stockholder hereby, severally but not jointly, represents and
                    warrants to Passage and the Company as follows: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If such Stockholder is an Entity: (i) such Stockholder is duly organized, validly existing and in good standing under the
                    laws of the jurisdiction in which it is incorporated, organized or constituted, (ii) such Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and
                    to consummate the transactions contemplated hereby, and (iii) the execution and delivery of this Agreement, performance of such Stockholder&#8217;s obligations hereunder and the consummation of the transactions contemplated hereby by such
                    Stockholder have been duly authorized by all necessary action on the part of such Stockholder and no other proceedings on the part of such Stockholder are necessary to authorize this Agreement, or to consummate the transactions
                    contemplated hereby. If such Stockholder is an individual, such Stockholder has the legal capacity to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions
                    contemplated hereby; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">this Agreement has been duly executed and delivered by or on behalf of such Stockholder and, to such Stockholder&#8217;s knowledge
                    and assuming this Agreement constitutes a valid and binding agreement of the Company and Passage, constitutes a valid and binding agreement with respect to such Stockholder, enforceable against such Stockholder in accordance with its
                    terms, except as enforcement may be limited by general principles of equity whether applied in a court of Law or a court of equity and by bankruptcy, insolvency and similar Laws affecting creditors&#8217; rights and remedies generally; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of Stockholder&#8217;s own
                    choosing. Stockholder has had an opportunity to review with its own tax advisors </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 532-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 533-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">the tax consequences of the Merger and the Contemplated Transactions.
            Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Passage, the Company or any of their respective agents or representatives. Stockholder understands that such Stockholder (and
            not Passage, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the transactions contemplated by the Merger Agreement. Stockholder understands and
            acknowledges that the Company, Passage and Merger Sub are entering into the Merger Agreement in reliance upon Stockholder&#8217;s execution, delivery and performance of this Agreement; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">such Stockholder beneficially owns the number of Shares, and holds Passage Options to acquire the number of Shares, indicated
                    opposite such Stockholder&#8217;s name on <span style="text-decoration: underline;">Schedule 1</span>, which constitute all of the Shares owned by the Stockholder as of the date hereof. Such Stockholder will own any New Shares, free and clear of any liens, claims, charges or other
                    encumbrances or restrictions of any kind whatsoever (&#8220;<span style="text-decoration: underline;">Liens</span>&#8221;), and has sole or shared, and otherwise unrestricted, voting power with respect to such Shares or New Shares and none of the Shares or New Shares is subject to any
                    voting trust or other agreement, arrangement or restriction with respect to the voting of the Shares or the New Shares, except as contemplated by this Agreement and the stockholder agreements and arrangements referenced in the Merger
                    Agreement and except for customary arrangements with the Stockholder&#8217;s prime broker and/or custodian; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to the knowledge of such Stockholder, the execution and delivery of this Agreement by such Stockholder does not, and the
                    performance by such Stockholder of his, her or its obligations hereunder and the compliance by such Stockholder with any provisions hereof will not, violate or conflict with, result in a material breach of or constitute a default (or an
                    event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of any Liens on any Shares or New
                    Shares pursuant to, any agreement, instrument, note, bond, mortgage, Contract, lease, license, permit or other obligation or any order, arbitration award, judgment or decree to which such Stockholder is a party or by which such
                    Stockholder is bound, or any Law, statute, rule or regulation to which such Stockholder is subject or, in the event that such Stockholder is a corporation, partnership, trust or other Entity, any bylaw or other Organizational Document
                    of such Stockholder; except for any of the foregoing as would not reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the execution and delivery of this Agreement by such Stockholder does not, and the performance of this Agreement by such
                    Stockholder does not and will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority or regulatory authority by such Stockholder except for applicable requirements,
                    if any, of the Exchange Act, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by such Stockholder of his,
                    her or its obligations under this Agreement in any material respect; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">no investment banker, broker, finder or other intermediary is entitled to a fee or commission from Passage or the Company in
                    respect of this Agreement based upon any Contract made by or on behalf of such Stockholder; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">as of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of such Stockholder, threatened
                    against such Stockholder that would reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Irrevocable Proxy</span>. Subject to the penultimate sentence of this <span style="text-decoration: underline;">Section&#160;6</span>, by execution of this Agreement, each
                    Stockholder does hereby appoint Passage and any of its designees with full power of substitution and resubstitution, as such Stockholder&#8217;s true and lawful attorney and irrevocable proxy, to the fullest extent of such Stockholder&#8217;s
                    rights with respect to the Shares, to vote and exercise all voting and related rights, including the right to sign such Stockholder&#8217;s name (solely in its capacity as a stockholder) to any Stockholder consent, if such Stockholder fails
                    to vote his, her or its Shares solely with respect to the matters set forth in <span style="text-decoration: underline;">Section&#160;1</span> hereof by 5:00 p.m. (Eastern Time) on the day immediately preceding the meeting date (or date </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 533-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 534-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">upon which written consents are requested to be submitted), provided the
            Stockholder has received information regarding the meeting or request for written consent at least five (5) Business Days before such stockholder meeting or any consent solicitation or other vote taken of Passage&#8217;s stockholders. Each
            Stockholder intends this proxy to be irrevocable and coupled with an interest hereunder until the Expiration Date, hereby revokes any proxy previously granted by such Stockholder with respect to the Shares and represents that none of such
            previously-granted proxies are irrevocable. The Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration: underline;">Section&#160;6</span> is given in connection with, and granted in consideration of, and as an inducement to the Company, Passage and Merger
            Sub to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <span style="text-decoration: underline;">Section&#160;1</span>. The irrevocable proxy and power of attorney granted herein shall survive the death or incapacity of such
            Stockholder and the obligations of such Stockholder shall be binding on such Stockholder&#8217;s heirs, personal representatives, successors, transferees and assigns. Each Stockholder hereby agrees not to grant any subsequent powers of attorney or
            proxies with respect to any Shares with respect to the matters set forth in <span style="text-decoration: underline;">Section&#160;1</span> until after the Expiration Date. With respect to any Shares that are owned beneficially by Stockholder but are not held of record by Stockholder
            (other than shares beneficially owned by Stockholder that are held in the name of a bank, broker or nominee), Stockholder shall take all action necessary to cause the record holder of such Shares to grant the irrevocable proxy and take all
            other actions provided for in this <span style="text-decoration: underline;">Section&#160;6</span> with respect to such Shares. Notwithstanding anything contained herein to the contrary, this irrevocable proxy shall automatically terminate upon the Expiration Date. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Legal Actions</span>. Each Stockholder will not in its capacity as a Passage security holder bring, commence, institute,
                    maintain, prosecute or voluntarily aid or participate in any Legal Proceeding which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of
                    this Agreement by such Stockholder, either alone or together with the other voting agreements and proxies to be delivered in connection with the execution of the Merger Agreement, or the approval of the Merger Agreement and the
                    Contemplated Transactions by the Passage Board, constitutes a breach of any fiduciary duty of the Passage Board or any member thereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly
                    conferred upon a party will be deemed cumulative with, and not exclusive of, any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any
                    other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is
                    accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof without the need of posting bond in any court of the
                    United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at Law or in equity. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Directors, Officers, Trustees and Fiduciaries</span>. This Agreement shall apply to each Stockholder solely in such
                    Stockholder&#8217;s capacity as a stockholder of Passage and not in such Stockholder&#8217;s capacity as a director, officer or employee of Passage or any of its Subsidiaries or in such Stockholder&#8217;s capacity as a trustee or fiduciary of any
                    employee benefit plan or trust. Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall (or require Stockholder to attempt to) limit or restrict a director and/or officer of Passage in the
                    exercise of his or her fiduciary duties consistent with the terms of the Merger Agreement as a director and/or officer of Passage or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be
                    construed to create any obligation on the part of any director and/or officer of Passage or any trustee or fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee
                    and/or fiduciary. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Ownership Interest</span>. Nothing contained in this Agreement shall be deemed to vest in Passage any direct or indirect
                    ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to such Stockholder, and Passage does not have authority
                    to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of Passage or exercise any power or authority to direct such Stockholder in the voting of any of the Shares, except as otherwise
                    provided herein. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Termination</span>. This Agreement shall terminate and shall have no further force or effect as of the Expiration Date.
                    Notwithstanding the foregoing, upon termination or expiration of this Agreement, no party shall have </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 534-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 535-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">any further obligations or liabilities under this Agreement; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that nothing set forth in this <span style="text-decoration: underline;">Section&#160;11</span> or elsewhere in this Agreement shall relieve any party from liability for any fraud or for any
            willful and material breach of this Agreement prior to termination hereof. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Further Assurances</span>. Each Stockholder shall, from time to time, execute and deliver, or cause to be executed and
                    delivered, such additional or further consents, documents and other instruments as the Company or Passage may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the
                    Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Disclosure</span>. Each Stockholder hereby agrees that Passage and the Company may publish and disclose in the Registration
                    Statement, any prospectus filed with any regulatory authority in connection with the Contemplated Transactions and any related documents filed with such regulatory authority and as otherwise required by Law, such Stockholder&#8217;s identity
                    and ownership of Shares and Passage Options and the nature of such Stockholder&#8217;s commitments, arrangements and understandings under this Agreement and may further file this Agreement as an exhibit to the Registration Statement or
                    prospectus or in any other filing made by Passage or the Company as required by Law or the terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the Contemplated Transactions, all subject to
                    prior review and a reasonable opportunity to comment by Stockholder&#8217;s counsel. Prior to the Closing, each Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or indirectly, make
                    any press release, public announcement or other public communication regarding the Merger without the prior written consent of Passage and the Company, <span style="font-style: italic;">provided</span> that the foregoing shall not
                    limit or affect any actions taken by such Stockholder (or any affiliated officer or director of such Stockholder) that would be permitted to be taken by such Stockholder, Passage or the Company pursuant to the Merger Agreement; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">further</span>, that the foregoing shall not affect any actions of Stockholder the prohibition of which would be prohibited under applicable Law and shall
                    not prohibit Stockholder or its affiliates from making any publicly-available filings required by applicable law, regulation or legal process. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Notice</span>. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered
                    personally or sent by overnight courier (providing proof of delivery), by facsimile transmission (providing confirmation of transmission) or by electronic transmission (providing confirmation of transmission) to the Company or Passage,
                    as the case may be, in accordance with <span style="text-decoration: underline;">Section&#160;9.7</span> of the Merger Agreement and to each Stockholder at his, her or its address or email address (providing confirmation of transmission) set forth on <span style="text-decoration: underline;">Schedule 1</span> attached
                    hereto (or at such other address for a party as shall be specified by like notice). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any
                    jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other
                    jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the
                    power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or
                    unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the parties hereto agree to replace such invalid
                    or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of,
                    the parties hereto and their respective successors and assigns; <span style="font-style: italic;">provided, however</span>, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated
                    by such party without the prior written consent of the other parties hereto, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent
                    shall be void and of no effect. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of
                    this Agreement. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 535-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 536-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Waivers</span>. No waivers of any breach of this Agreement extended by the Company or Passage to such Stockholder shall be
                    construed as a waiver of any rights or remedies of the Company or Passage, as applicable, with respect to any other stockholder of Passage who has executed an agreement substantially in the form of this Agreement with respect to Shares
                    held or subsequently held by such stockholder or with respect to any subsequent breach of Stockholder or any other such stockholder of Passage. No waiver of any provisions hereof by any party shall be deemed a waiver of any other
                    provisions hereof by any such party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such party. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Applicable Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the Laws of the
                    state of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties arising out of or relating to this Agreement, each of
                    the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the state of Delaware or to the extent such court does not have subject matter jurisdiction, the
                    Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance
                    with clause (i) of this <span style="text-decoration: underline;">Section&#160;18</span>, (iii)&#160;waives any objection to laying venue in any such action or Legal Proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have
                    jurisdiction over any party, and (v)&#160;agrees that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <span style="text-decoration: underline;">Section&#160;14</span> of this Agreement. Each party
                    irrevocably consents to service of process inside or outside the territorial jurisdiction of the courts referred to in this <span style="text-decoration: underline;">Section&#160;18</span> in the manner provided for notices in <span style="text-decoration: underline;">Section&#160;14</span>. Nothing in this Agreement will
                    affect the right of any party to serve process in any other manner permitted by applicable Law. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Waiver of Jury Trial</span>. The parties hereto hereby waive any right to trial by jury with respect to any action or Legal
                    Proceeding related to or arising out of this Agreement, any document executed in connection herewith and the matters contemplated hereby and thereby. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Agreement Until Executed</span>. Irrespective of negotiations among the parties or the exchanging of drafts of this
                    Agreement, this Agreement shall not constitute or be deemed to evidence a Contract, agreement, arrangement or understanding between the parties hereto unless and until (a) the Passage Board has approved, for purposes of any applicable
                    anti-takeover Laws and regulations and any applicable provision of the certificate of incorporation of Passage, the Merger Agreement and the Contemplated Transactions, (b) the Merger Agreement is executed by all parties thereto, and (c)
                    this Agreement is executed by all parties hereto. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</span>. This Agreement and the other agreements referred
                    to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. This Agreement
                    may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties
                    by electronic transmission via &#8220;.pdf&#8221; shall be sufficient to bind the parties to the terms and conditions of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Amendment</span>. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be modified or
                    waived, except by an instrument in writing signed on behalf of each party hereto; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that the rights or obligations of any Stockholder
                    may be waived, amended or otherwise modified in a writing signed by Passage, the Company and such Stockholder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Fees and Expenses</span>. Except as otherwise specifically provided herein, the Merger Agreement or any other agreement
                    contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Voluntary Execution of Agreement</span>. This Agreement is executed voluntarily and without any duress or undue influence on
                    the part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i) it has read and fully understood (x) the Merger Agreement, (y) this Agreement, and (z) the implications and consequences
                    thereof; (ii) it has been represented in the preparation, negotiation, and execution of this Agreement by legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii) it is
                    fully aware of the legal and binding effect of this Agreement. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 536-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 537-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">25.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Definition of Merger Agreement</span>. For purposes of this Agreement, the term &#8220;<span style="text-decoration: underline;">Merger Agreement</span>&#8221; may include such
                    agreement as amended or modified as long as such amendments or modifications (a) do not (i)&#160;change the form or amount of consideration payable under the Merger Agreement, (ii) extend the Outside Date past December&#160;24, 2026 (other than
                    any extension provided for in <span style="text-decoration: underline;">Section&#160;8.1(b)</span> of the Merger Agreement with respect to the Registration Statement), or (iii) otherwise change the terms and conditions of the Merger, the Concurrent Financing or the other
                    Contemplated Transactions in a manner materially adverse to such Stockholder or (b) have been agreed to in writing by such Stockholder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Construction.</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa;
                    the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting
                    party shall not be applied in the construction or interpretation of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of
                    limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; and &#8220;Schedules&#8221; are intended to refer to
                    Sections of this Agreement and Schedules to this Agreement, respectively. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part
                    of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; text-align: center;">[Remainder of Page has Intentionally Been Left Blank]<span style="font-style: normal;"> </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 537-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 538-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 228pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">EXECUTED as of the date first above written.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[STOCKHOLDER]</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Signature:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 180pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 5.75pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">Signature Page to Passage Support Agreement<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 538-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 539-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">EXECUTED as of the date first above written. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 228pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PASSAGE BIO, INC.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 192pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">Signature Page to Passage Support Agreement<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 539-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 540-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_302-annexc_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SCHEDULE 1 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 228pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name, Address and Email Address of Stockholder</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of Passage Common Stock</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3.25pt; width: 228pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3.25pt; width: 228pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">C-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 540-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 541-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXD"><!--Anchor--></a>Annex&#160;D<span style="font-weight: normal;">
            </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; text-align: center;">REMIX THERAPEUTICS, INC. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; text-align: center;">SUPPORT AGREEMENT </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">THIS SUPPORT AGREEMENT<span style="font-weight: normal;">
              (this &#8220;<span style="text-decoration: underline;">Agreement</span>&#8221;), dated as of [&#8226;], is made by and among Passage Bio, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline;">Passage</span>&#8221;), Remix Therapeutics, Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;), and the undersigned holders (each a &#8220;<span style="text-decoration: underline;">Stockholder</span>&#8221;)

              of shares of capital stock (the &#8220;<span style="text-decoration: underline;">Shares</span>&#8221;) of the Company. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, Passage,
              Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Passage (&#8220;<span style="text-decoration: underline;">Merger Sub</span>&#8221;), and the Company, have entered into an Agreement and Plan of Merger, dated as of even date herewith (the &#8220;<span style="text-decoration: underline;">Merger Agreement</span>&#8221;),

              providing for the merger of Merger Sub with and into the Company (the &#8220;<span style="text-decoration: underline;">Merger</span>&#8221;); </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, each
              Stockholder beneficially owns and has sole or shared voting power with respect to the number of Shares, and holds Remix Options and Remix Warrants to acquire the number of Shares, indicated opposite such Stockholder&#8217;s name on <span style="text-decoration: underline;">Schedule 1</span>
              attached hereto; </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, as an
              inducement and a condition to the willingness of the Company to enter into the Merger Agreement, each Stockholder has agreed to enter into and perform this Agreement; and </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS<span style="font-weight: normal;">, all capitalized
              terms used in this Agreement without definition herein shall have the meanings ascribed to them in the Merger Agreement. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NOW, THEREFORE<span style="font-weight: normal;">, in
              consideration of, and as a condition to, the Company&#8217;s entering into the Merger Agreement, each Stockholder, Passage and the Company agree as follows: </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Agreement to Vote Shares</span>. Each Stockholder agrees that, prior to the Expiration Date (as defined in <span style="text-decoration: underline;">Section&#160;2</span>
                    below), at any meeting of the stockholders of the Company or any adjournment or postponement thereof, or in connection with any written consent of the stockholders (or any class or series of stockholders, as applicable) of the Company,
                    with respect to the Merger, the Merger Agreement or any Acquisition Proposal, such Stockholder shall: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">appear at such meeting or otherwise cause the Shares and any New Shares (as defined in <span style="text-decoration: underline;">Section&#160;3</span> below) to be counted
                    as present thereat for purposes of calculating a quorum; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">from and after the date hereof until the Expiration Date, vote (or cause to be voted), or deliver a written consent (or cause
                    a written consent to be delivered) covering all of the Shares and any New Shares that Stockholder shall be entitled to so vote: (i) in favor of (A) all of the matters set forth in the Remix Stockholder Written Consent and (B) any matter
                    that could reasonably be expected to facilitate the Merger, the Concurrent Financing and the Contemplated Transactions; (ii) against any action or agreement that would result in a breach of any representation, warranty, covenant or
                    obligation of the Company in the Merger Agreement; (iii) against any Acquisition Proposal, or any agreement, transaction or other matter or action that is intended to, or would reasonably be expected to, impede, interfere with, delay,
                    postpone, discourage or materially and adversely affect the consummation of the Merger, the Concurrent Financing and all of the other Contemplated Transactions; (iv) to approve any proposal to adjourn or postpone the meeting to a later
                    date, if there are not sufficient votes for the adoption of the Merger Agreement on the date on which such meeting is held; and (v) to the extent applicable, in favor of an election to convert all of the Remix Preferred Stock held by
                    Stockholder into Remix Common Stock. Stockholder shall not take or commit or agree to take any action inconsistent with the foregoing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Expiration Date</span>. As used in this Agreement, the term &#8220;<span style="text-decoration: underline;">Expiration Date</span>&#8221; shall mean the earlier to occur of
                    (a)&#160;the Effective Time, (b) such date and time as the Merger Agreement shall be terminated pursuant to <span style="text-decoration: underline;">Article&#160;VIII</span> thereof or otherwise, (c) any amendment to the Merger Agreement that is effected without the Stockholder&#8217;s
                    written consent that decreases the amount, or changes the form, of consideration payable to all stockholders of the Company pursuant to the terms of the Merger Agreement or (d) the mutual written agreement of the parties to terminate
                    this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Additional Acquisitions</span>. Each Stockholder agrees that any shares of capital stock or other equity securities of the
                    Company that such Stockholder acquires or with respect to which such Stockholder otherwise acquires </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 541-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 542-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">sole or shared voting power (including any proxy) after the execution of
            this Agreement and prior to the Expiration Date, whether by the exercise of any Remix Options or Remix Warrants or otherwise, including, without limitation, upon the vesting of any applicable restricted stock unit award agreement or by gift,
            succession, in the event of a stock split or as a dividend or distribution of any Shares (&#8220;<span style="text-decoration: underline;">New Shares</span>&#8221;), shall be subject to the terms and conditions of this Agreement to the same extent as if they constituted the Shares. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Agreement to Retain Shares</span>. From and after the date hereof until the Expiration Date, each Stockholder shall not,
                    directly or indirectly, (a) sell, assign, transfer, tender, or otherwise dispose of (including, without limitation, by the creation of any Liens (as defined in <span style="text-decoration: underline;">Section&#160;5(d)</span> below)) any Shares or any New Shares, (b)&#160;deposit any
                    Shares or New Shares into a voting trust or enter into a voting agreement or similar arrangement with respect to such Shares or New Shares or grant any proxy or power of attorney with respect thereto (other than this Agreement), (c)
                    enter into any Contract, option, commitment or other arrangement or understanding with respect to the direct or indirect sale, transfer, assignment or other disposition of (including, without limitation, by the creation of any Liens)
                    any Shares or New Shares, or (d) take any action that would make any representation or warranty of such Stockholder contained herein untrue or incorrect or have the effect of preventing or disabling such Stockholder from performing such
                    Stockholder&#8217;s obligations under this Agreement. Any action taken in violation of the foregoing sentence shall be null and void <span style="font-style: italic;">ab initio</span>. Notwithstanding the foregoing, each Stockholder may make
                    (1) transfers by will or by operation of Law or other transfers for estate-planning purposes, in which case this Agreement shall bind the transferee, (2) with respect to such Stockholder&#8217;s Remix Options (and any Shares underlying such
                    Remix Options) which expire on or prior to the Expiration Date, transfers, sale, or other disposition of Shares to the Company (or effecting a &#8220;net exercise&#8221; of a Remix Option) as payment for the (i) exercise price of such Stockholder&#8217;s
                    Remix Options and (ii) taxes applicable to the exercise of such Stockholder&#8217;s Remix Options, (3) if Stockholder is an entity, partnership or limited liability company, a transfer to one or more equityholders, partners or members of
                    Stockholder or to an Affiliated person, corporation, trust or other Entity controlling or under common control with Stockholder, or if Stockholder is a trust, a transfer to a beneficiary, provided that in each such case the applicable
                    transferee has signed a voting agreement in substantially the form hereof, (4) make transfers that occur by operation of law pursuant to a qualified domestic relations order or in connection with a divorce settlement, and (5) transfers,
                    sales or other dispositions as the Company may otherwise agree in writing in its sole discretion. If any voluntary or involuntary transfer of any Shares covered hereby shall occur (including a transfer or disposition permitted by <span style="text-decoration: underline;">Section&#160;4(1)</span>
                    through <span style="text-decoration: underline;">Section&#160;4(5)</span>, sale by a Stockholder&#8217;s trustee in bankruptcy, or a sale to a purchaser at any creditor&#8217;s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent
                    transferees of the initial transferee) shall take and hold such Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect, notwithstanding that such transferee
                    is not a Stockholder and has not executed a counterpart hereof or joinder hereto. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Representations and Warranties of Stockholder</span>. Each Stockholder hereby, severally but not jointly, represents and
                    warrants to Passage and the Company as follows: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If such Stockholder is an Entity: (i) such Stockholder is duly organized, validly existing and in good standing under the
                    laws of the jurisdiction in which it is incorporated, organized or constituted, (ii) such Stockholder has all necessary power and authority to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and
                    to consummate the transactions contemplated hereby, and (iii) the execution and delivery of this Agreement, performance of such Stockholder&#8217;s obligations hereunder and the consummation of the transactions contemplated hereby by such
                    Stockholder have been duly authorized by all necessary action on the part of such Stockholder and no other proceedings on the part of such Stockholder are necessary to authorize this Agreement, or to consummate the transactions
                    contemplated hereby. If such Stockholder is an individual, such Stockholder has the legal capacity to execute and deliver this Agreement, to perform such Stockholder&#8217;s obligations hereunder and to consummate the transactions
                    contemplated hereby; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">this Agreement has been duly executed and delivered by or on behalf of such Stockholder and, to such Stockholder&#8217;s knowledge
                    and assuming this Agreement constitutes a valid and binding agreement of the Company and Passage, constitutes a valid and binding agreement with respect to such Stockholder, </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 542-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 543-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">enforceable against such Stockholder in accordance with its terms, except
            as enforcement may be limited by general principles of equity whether applied in a court of Law or a court of equity and by bankruptcy, insolvency and similar Laws affecting creditors&#8217; rights and remedies generally; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Stockholder has had the opportunity to review the Merger Agreement, including the provisions relating to the payment and
                    allocation of the consideration to be paid to the stockholders of the Company, and this Agreement with counsel of Stockholder&#8217;s own choosing. Stockholder has had an opportunity to review with its own tax advisors the tax consequences of
                    the Merger and the Contemplated Transactions. Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Passage, the Company or any of their respective agents or
                    representatives, except as set forth in the Subscription Agreement (with respect to those Stockholders executing the Subscription Agreement). Stockholder understands that such Stockholder (and not Passage, the Company or the Surviving
                    Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the transactions contemplated by the Merger Agreement. Stockholder understands and acknowledges that the Company, Passage
                    and Merger Sub are entering into the Merger Agreement in reliance upon Stockholder&#8217;s execution, delivery and performance of this Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">such Stockholder beneficially owns the number of Shares, and holds Remix Options and Remix Warrants to acquire the number of
                    Shares, indicated opposite such Stockholder&#8217;s name on <span style="text-decoration: underline;">Schedule 1</span>, which constitute all of the Shares owned by the Stockholder as of the date hereof. Such Stockholder will own any New Shares, free and clear of any liens, claims,
                    charges or other encumbrances or restrictions of any kind whatsoever (&#8220;<span style="text-decoration: underline;">Liens</span>&#8221;), and has sole or shared, and otherwise unrestricted, voting power with respect to such Shares or New Shares and none of the Shares or New Shares is
                    subject to any voting trust or other agreement, arrangement or restriction with respect to the voting of the Shares or the New Shares, except as contemplated by this Agreement and the stockholder agreements and arrangements referenced
                    in the Merger Agreement and except for customary arrangements with the Stockholder&#8217;s prime broker and/or custodian; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to the knowledge of such Stockholder, the execution and delivery of this Agreement by such Stockholder does not, and the
                    performance by such Stockholder of his, her or its obligations hereunder and the compliance by such Stockholder with any provisions hereof will not, violate or conflict with, result in a material breach of or constitute a default (or an
                    event that with notice or lapse of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of any Liens on any Shares or New
                    Shares pursuant to, any agreement, instrument, note, bond, mortgage, Contract, lease, license, permit or other obligation or any order, arbitration award, judgment or decree to which such Stockholder is a party or by which such
                    Stockholder is bound, or any Law, statute, rule or regulation to which such Stockholder is subject or, in the event that such Stockholder is a corporation, partnership, trust or other Entity, any bylaw or other Organizational Document
                    of such Stockholder; except for any of the foregoing as would not reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the execution and delivery of this Agreement by such Stockholder does not, and the performance of this Agreement by such
                    Stockholder does not and will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority or regulatory authority by such Stockholder except for applicable requirements,
                    if any, of the Exchange Act, and except where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or delay the performance by such Stockholder of his,
                    her or its obligations under this Agreement in any material respect; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">no investment banker, broker, finder or other intermediary is entitled to a fee or commission from Passage or the Company in
                    respect of this Agreement based upon any Contract made by or on behalf of such Stockholder; and </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 543-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 544-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">as of the date of this Agreement, there is no Legal Proceeding pending or, to the knowledge of such Stockholder, threatened
                    against such Stockholder that would reasonably be expected to prevent or delay the performance by such Stockholder of his, her or its obligations under this Agreement in any material respect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Irrevocable Proxy</span>. Subject to the penultimate sentence of this <span style="text-decoration: underline;">Section&#160;6</span>, by execution of this Agreement, each
                    Stockholder does hereby appoint the Company and any of its designees with full power of substitution and resubstitution, as such Stockholder&#8217;s true and lawful attorney and irrevocable proxy, to the fullest extent of such Stockholder&#8217;s
                    rights with respect to the Shares, to vote and exercise all voting and related rights, including the right to sign such Stockholder&#8217;s name (solely in its capacity as a stockholder) to any Stockholder consent, if such Stockholder fails
                    to vote his, her or its Shares solely with respect to the matters set forth in <span style="text-decoration: underline;">Section&#160;1</span> hereof by 5:00 p.m. (Eastern Time) on the day immediately preceding the meeting date (or date upon which written consents are requested to
                    be submitted), provided the Stockholder has received information regarding the meeting or request for written consent at least five (5) Business Days before such stockholder meeting or any consent solicitation or other vote taken of the
                    Company&#8217;s stockholders. Each Stockholder intends this proxy to be irrevocable and coupled with an interest hereunder until the Expiration Date, hereby revokes any proxy previously granted by such Stockholder with respect to the Shares
                    and represents that none of such previously-granted proxies are irrevocable. The Stockholder hereby affirms that the proxy set forth in this <span style="text-decoration: underline;">Section&#160;6</span> is given in connection with, and granted in consideration of, and as an
                    inducement to the Company, Passage and Merger Sub to enter into the Merger Agreement and that such proxy is given to secure the obligations of the Stockholder under <span style="text-decoration: underline;">Section&#160;1</span>. The irrevocable proxy and power of attorney granted
                    herein shall survive the death or incapacity of such Stockholder and the obligations of such Stockholder shall be binding on such Stockholder&#8217;s heirs, personal representatives, successors, transferees and assigns. Each Stockholder
                    hereby agrees not to grant any subsequent powers of attorney or proxies with respect to any Shares with respect to the matters set forth in <span style="text-decoration: underline;">Section&#160;1</span> until after the Expiration Date. With respect to any Shares that are owned
                    beneficially by Stockholder but are not held of record by Stockholder (other than shares beneficially owned by Stockholder that are held in the name of a bank, broker or nominee), Stockholder shall take all action necessary to cause the
                    record holder of such Shares to grant the irrevocable proxy and take all other actions provided for in this <span style="text-decoration: underline;">Section&#160;6</span> with respect to such Shares. Notwithstanding anything contained herein to the contrary, this irrevocable proxy
                    shall automatically terminate upon the Expiration Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Waiver of Appraisal Rights</span>. Each Stockholder hereby waives, and agrees not to exercise or assert, any appraisal rights
                    under applicable Law, including Section&#160;262 of Delaware Law, in connection with the Merger. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Legal Actions</span>. Each Stockholder will not in its capacity as a Company security holder bring, commence, institute,
                    maintain, prosecute or voluntarily aid or participate in any Legal Proceeding which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of
                    this Agreement by such Stockholder, either alone or together with the other voting agreements and proxies to be delivered in connection with the execution of the Merger Agreement, or the approval of the Merger Agreement and the
                    Contemplated Transactions by the Remix Board, constitutes a breach of any fiduciary duty of the Remix Board or any member thereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Other Remedies; Specific Performance</span>. Except as otherwise provided herein, any and all remedies herein expressly
                    conferred upon a party will be deemed cumulative with, and not exclusive of, any other remedy conferred hereby, or by Law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any
                    other remedy. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is
                    accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof without the need of posting bond in any court of the
                    United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at Law or in equity. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Directors, Officers, Trustees and Fiduciaries</span>. This Agreement shall apply to each Stockholder solely in such
                    Stockholder&#8217;s capacity as a stockholder of the Company and/or holder of Remix Options and/or Remix Warrants not in such Stockholder&#8217;s capacity as a director, officer or employee of the Company or any of its Subsidiaries or in such
                    Stockholder&#8217;s capacity as a trustee or fiduciary of any employee benefit plan or trust. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 544-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 545-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Notwithstanding any provision of this Agreement to the contrary, nothing
            in this Agreement shall (or require Stockholder to attempt to) limit or restrict a director and/or officer of the Company in the exercise of his or her fiduciary duties consistent with the terms of the Merger Agreement as a director and/or
            officer of the Company or in his or her capacity as a trustee or fiduciary of any employee benefit plan or trust or prevent or be construed to create any obligation on the part of any director and/or officer of the Company or any trustee or
            fiduciary of any employee benefit plan or trust from taking any action in his or her capacity as such director, officer, trustee and/or fiduciary. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Ownership Interest</span>. Nothing contained in this Agreement shall be deemed to vest in the Company any direct or
                    indirect ownership or incidence of ownership of or with respect to any Shares. All rights, ownership and economic benefits of and relating to the Shares shall remain vested in and belong to such Stockholder, and the Company does not
                    have authority to manage, direct, superintend, restrict, regulate, govern, or administer any of the policies or operations of the Company or exercise any power or authority to direct such Stockholder in the voting of any of the Shares,
                    except as otherwise provided herein. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Termination</span>. This Agreement shall terminate and shall have no further force or effect as of the Expiration Date.
                    Notwithstanding the foregoing, upon termination or expiration of this Agreement, no party shall have any further obligations or liabilities under this Agreement; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that nothing set forth in this <span style="text-decoration: underline;">Section&#160;12</span> or elsewhere in this Agreement shall relieve any party from liability for any fraud or for any willful and material breach of this Agreement
                    prior to termination hereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Further Assurances</span>. Each Stockholder shall, from time to time, execute and deliver, or cause to be executed and
                    delivered, such additional or further consents, documents and other instruments as the Company or Passage may reasonably request for the purpose of effectively carrying out the transactions contemplated by this Agreement and the
                    Contemplated Transactions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Disclosure</span>. Each Stockholder hereby agrees that Passage and the Company may publish and disclose in the Registration
                    Statement, any prospectus filed with any regulatory authority in connection with the Contemplated Transactions and any related documents filed with such regulatory authority and as otherwise required by Law, such Stockholder&#8217;s identity
                    and ownership of Shares, Remix Options and Remix Warrants and the nature of such Stockholder&#8217;s commitments, arrangements and understandings under this Agreement and may further file this Agreement as an exhibit to the Registration
                    Statement or prospectus or in any other filing made by Passage or the Company as required by Law or the terms of the Merger Agreement, including with the SEC or other regulatory authority, relating to the Contemplated Transactions, all
                    subject to prior review and a reasonable opportunity to comment by Stockholder&#8217;s counsel. Prior to the Closing, each Stockholder shall not, and shall use its reasonable best efforts to cause its representatives not to, directly or
                    indirectly, make any press release, public announcement or other public communication regarding the Merger without the prior written consent of Passage and the Company, <span style="font-style: italic;">provided</span> that the
                    foregoing shall not limit or affect any actions taken by such Stockholder (or any affiliated officer or director of such Stockholder) that would be permitted to be taken by such Stockholder, Passage or the Company pursuant to the Merger
                    Agreement; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">further</span>, that the foregoing shall not affect any actions of Stockholder the prohibition of which would be prohibited under
                    applicable Law and shall not prohibit Stockholder or its affiliates from making any publicly-available filings required by applicable law, regulation or legal process. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Notice</span>. All notices and other communications hereunder shall be in writing and shall be deemed given if delivered
                    personally or sent by overnight courier (providing proof of delivery), by facsimile transmission (providing confirmation of transmission) or by electronic transmission (providing confirmation of transmission) to the Company or Passage,
                    as the case may be, in accordance with <span style="text-decoration: underline;">Section&#160;9.7</span> of the Merger Agreement and to each Stockholder at his, her or its address or email address (providing confirmation of transmission) set forth on <span style="text-decoration: underline;">Schedule 1</span> attached
                    hereto (or at such other address for a party as shall be specified by like notice). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Severability</span>. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any
                    jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other
                    jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the parties hereto agree that the court making such determination shall have the
                    power to limit such term or provision, to delete specific words or phrases or to </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 545-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 546-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">replace such term or provision with a term or provision that is valid and
            enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to
            it in the prior sentence, the parties hereto agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of
            such invalid or unenforceable term or provision. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Assignability</span>. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of,
                    the parties hereto and their respective successors and assigns; <span style="font-style: italic;">provided, however</span>, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated
                    by such party without the prior written consent of the other parties hereto, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent
                    shall be void and of no effect. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the parties hereto) any right, benefit or remedy of any nature whatsoever under or by reason of
                    this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Waivers</span>. No waivers of any breach of this Agreement extended by the Company or Passage to such Stockholder shall be
                    construed as a waiver of any rights or remedies of the Company or Passage, as applicable, with respect to any other stockholder of the Company who has executed an agreement substantially in the form of this Agreement with respect to
                    Shares held or subsequently held by such stockholder or with respect to any subsequent breach of Stockholder or any other such stockholder of the Company. No waiver of any provisions hereof by any party shall be deemed a waiver of any
                    other provisions hereof by any such party, nor shall any such waiver be deemed a continuing waiver of any provision hereof by such party. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Applicable Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the Laws of the
                    state of Delaware, regardless of the Laws that might otherwise govern under applicable principles of conflicts of Laws. In any action or Legal Proceeding between any of the parties arising out of or relating to this Agreement, each of
                    the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the state of Delaware or to the extent such court does not have subject matter jurisdiction, the
                    Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or Legal Proceeding shall be heard and determined exclusively in accordance
                    with clause (i) of this <span style="text-decoration: underline;">Section&#160;19</span>, (iii)&#160;waives any objection to laying venue in any such action or Legal Proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have
                    jurisdiction over any party, and (v)&#160;agrees that service of process upon such party in any such action or Legal Proceeding shall be effective if notice is given in accordance with <span style="text-decoration: underline;">Section&#160;15</span> of this Agreement. Each party
                    irrevocably consents to service of process inside or outside the territorial jurisdiction of the courts referred to in this <span style="text-decoration: underline;">Section&#160;19</span> in the manner provided for notices in <span style="text-decoration: underline;">Section&#160;15</span>. Nothing in this Agreement will
                    affect the right of any party to serve process in any other manner permitted by applicable Law. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Waiver of Jury Trial</span>. The parties hereto hereby waive any right to trial by jury with respect to any action or Legal
                    Proceeding related to or arising out of this Agreement, any document executed in connection herewith and the matters contemplated hereby and thereby. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Agreement Until Executed</span>. Irrespective of negotiations among the parties or the exchanging of drafts of this
                    Agreement, this Agreement shall not constitute or be deemed to evidence a Contract, agreement, arrangement or understanding between the parties hereto unless and until (a) the Remix Board has approved, for purposes of any applicable
                    anti-takeover Laws and regulations and any applicable provision of the certificate of incorporation of the Company, the Merger Agreement and the Contemplated Transactions, (b)&#160;the Merger Agreement is executed by all parties thereto, and
                    (c) this Agreement is executed by all parties hereto. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission</span>. This Agreement and the other agreements referred
                    to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the parties with respect to the subject matter hereof and thereof. This Agreement
                    may be executed in several counterparts, each of which shall be </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 546-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 547-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">deemed an original and all of which shall constitute one and the same
            instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by electronic transmission via &#8220;.pdf&#8221; shall be sufficient to bind the parties to the terms and conditions of this Agreement. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Amendment</span>. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be modified or
                    waived, except by an instrument in writing signed on behalf of each party hereto; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that the rights or obligations of any Stockholder
                    may be waived, amended or otherwise modified in a writing signed by Passage, the Company and such Stockholder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Fees and Expenses</span>. Except as otherwise specifically provided herein, the Merger Agreement or any other agreement
                    contemplated by the Merger Agreement to which a party hereto is a party, each party hereto shall bear its own expenses in connection with this Agreement and the transactions contemplated hereby. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">25.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Voluntary Execution of Agreement</span>. This Agreement is executed voluntarily and without any duress or undue influence on
                    the part or behalf of the parties. Each of the parties hereby acknowledges, represents and warrants that (i) it has read and fully understood (x) the Merger Agreement, including the provisions relating to the payment and allocation of
                    the consideration to be paid to stockholders of the Company and holders of Remix Options and Remix Warrants, (y) this Agreement, and (z) the implications and consequences thereof; (ii) it has been represented in the preparation,
                    negotiation, and execution of this Agreement by legal counsel of its own choice, or it has made a voluntary and informed decision to decline to seek such counsel; and (iii)&#160;it is fully aware of the legal and binding effect of this
                    Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Definition of Merger Agreement</span>. For purposes of this Agreement, the term &#8220;<span style="text-decoration: underline;">Merger Agreement</span>&#8221; may include such
                    agreement as amended or modified as long as such amendments or modifications (a) do not (i)&#160;change the form or amount of consideration payable under the Merger Agreement, (ii) extend the Outside Date past [&#8226;] (other than any extension
                    provided for in <span style="text-decoration: underline;">Section&#160;8.1(b)</span> of the Merger Agreement with respect to the Registration Statement), or (iii) otherwise change the terms and conditions of the Merger, the Concurrent Financing or the other Contemplated
                    Transactions in a manner materially adverse to such Stockholder or (b) have been agreed to in writing by such Stockholder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Construction.</span> </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">For purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa;
                    the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine genders. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The parties hereto agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting
                    party shall not be applied in the construction or interpretation of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be deemed to be terms of
                    limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as otherwise indicated, all references in this Agreement to &#8220;Sections,&#8221; and &#8220;Schedules&#8221; are intended to refer to
                    Sections of this Agreement and Schedules to this Agreement, respectively. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The underlined headings contained in this Agreement are for convenience of reference only, shall not be deemed to be a part
                    of this Agreement and shall not be referred to in connection with the construction or interpretation of this Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; text-align: center;">[Remainder of Page has Intentionally Been Left Blank]<span style="font-style: normal;"> </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 547-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 548-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 228pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">EXECUTED as of the date first above written.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[STOCKHOLDER]</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Signature:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 180pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 5.75pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">Signature Page to Remix Support Agreement<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 548-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 549-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">EXECUTED as of the date first above written. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 468pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PASSAGE BIO, INC.<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 468pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">Signature Page to Remix Support Agreement<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 549-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 550-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_303-annexd_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; text-align: center;">SCHEDULE 1 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 120pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 55.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 55.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.32pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Name, Address and <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Email Address of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stockholder</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of Remix <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of Remix <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.32pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remix Options</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Remix Warrants</div>
                </td>

  </tr>

  <tr>

    <td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.32pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.32pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.32pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.95pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 120pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 55.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 55.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.32pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 16.01pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.95pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">D-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 550-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 551-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXE"><!--Anchor--></a>Annex&#160;E</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; text-align: center;">LOCK-UP AGREEMENT </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; text-align: right;">June&#160;24, 2026 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Passage Bio, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">P.O. Box 7 <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Hopewell, NJ 08525 <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Therapeutics, Inc. <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">100 Forge Road, Suite 400 <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Watertown, MA 02472 </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Ladies and Gentlemen: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The undersigned signatory of this lock-up agreement (this &#8220;<span style="font-style: italic; font-weight: bold;">Lock-Up Agreement</span>&#8221;) understands that Passage Bio, Inc., a Delaware corporation (including any successor thereto, &#8220;<span style="font-style: italic; font-weight: bold;">Passage</span>&#8221;), has
            entered into an Agreement and Plan of Merger, dated as of June&#160;24, 2026 (as the same may be amended from time to time, the &#8220;<span style="font-style: italic; font-weight: bold;">Merger Agreement</span>&#8221;) with Peregrine Merger Sub, Inc., a
            Delaware corporation and a direct, wholly owned subsidiary of Passage, and Remix Therapeutics, Inc., a Delaware corporation (including any successor thereto, &#8220;<span style="font-style: italic; font-weight: bold;">Remix</span>&#8221;). Capitalized
            terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a condition and inducement to each of the parties to enter into the Merger
            Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent
            of Passage and, solely prior to the Closing, Remix, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;<span style="font-style: italic; font-weight: bold;">Restricted Period</span>&#8221;): </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
                    grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Passage Common Stock held by the Undersigned immediately after the Closing issued pursuant to the Merger
                    Agreement in respect of any shares of Remix Common Stock, Remix Preferred Stock, Remix Convertible Notes, Remix Options or Remix Warrants that were held by the Undersigned immediately prior to the Closing (collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">Undersigned&#8217;s Shares</span>&#8221;), or publicly disclose the intention to make any such offer, sale, pledge, grant, transfer or disposition (for the avoidance of doubt, in no event will the
                    Concurrent Financing Released Shares or Passage Released Shares constitute &#8220;Undersigned&#8217;s Shares&#8221; for purposes of this Lock-Up Agreement); </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic
                    consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (i) above or this clause (ii) is to be settled by delivery of the Undersigned&#8217;s Shares or other securities, in cash or
                    otherwise; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">make any demand for, or exercise any right with respect to, the registration of any of the Undersigned&#8217;s Shares (other than
                    such rights set forth in the Merger Agreement or the obligations of Remix or the combined company under the Registration Rights Agreement (as defined in the Subscription Agreement, dated as of the date hereof, by and among Remix and
                    each of the purchasers listed on the Schedule of Purchasers attached thereto)). </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The restrictions and obligations contemplated by this Lock-Up Agreement shall not
            apply to: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers of the Undersigned&#8217;s Shares: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">if the undersigned is a <span style="text-decoration: underline;">natural person</span>, (A) to any person related to the undersigned by blood or adoption who is an
                    immediate family member of the undersigned, or by marriage or domestic partnership (a&#160;&#8220;<span style="font-style: italic; font-weight: bold;">Family Member</span>&#8221;), or to a trust formed for the direct or indirect benefit of the
                    undersigned or any of the undersigned&#8217;s Family Members, (B) to the undersigned&#8217;s estate, following the death of the undersigned, by will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, as such
                    term is described in Section&#160;501(c)(3) of the Internal Revenue Code of 1986, as amended, (D) by operation of Law pursuant to a qualified domestic relations order or in connection with a divorce settlement, or (E) to any partnership,
                    corporation or limited liability company which is controlled by the undersigned and/or by any such Family Member(s); </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 551-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 552-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">if the undersigned is a <span style="text-decoration: underline;">corporation</span>, <span style="text-decoration: underline;">partnership</span>, <span style="text-decoration: underline;">limited liability company</span> or <span style="text-decoration: underline;">other entity</span>,
                    (A) to another corporation, partnership, limited liability company, or other entity that is an affiliate (as defined under Rule&#160;12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities under common
                    control or management or advisement with the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such
                    partnership), (B) as a distribution or dividend to equity holders, including, without limitation, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the
                    undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution, as such term is
                    described in Section&#160;501(c)(3) of the Internal Revenue Code of 1986, as amended, (D) transfers or dispositions not involving a change in beneficial ownership or (E) with prior written consent of Passage; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the undersigned is a <span style="text-decoration: underline;">trust</span>, to any grantors or beneficiaries of the trust; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;"><span style="text-decoration: underline;">provided that</span><span style="font-style: normal;">, in
              the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value and each donee, heir, beneficiary or other transferee or distributee shall, prior to or concurrently with such transfer or distribution, sign
              and deliver to Passage a lock-up agreement in the form of this Lock-Up Agreement with respect to the Undersigned&#8217;s Shares that have been so transferred or distributed; </span></div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the exercise of an option to purchase Passage Common Stock (including a net or cashless exercise of an option to purchase
                    Passage Common Stock), and any related transfer of shares of Passage Common Stock to Passage or the sale of Passage Common Stock in the open market, in each case, for the purpose of paying the exercise price of such options or for
                    paying taxes (including estimated taxes) during the Restricted Period due as a result of the exercise of such options; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span><span style="text-decoration: underline;"> </span><span style="font-style: italic;"><span style="text-decoration: underline;">that</span></span>,
                    for the avoidance of doubt, the underlying shares of Passage Common Stock held by the undersigned following such exercise or open market sales shall continue to be subject to the restrictions on transfer set forth in this Lock-Up
                    Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the disposition (including a forfeiture or repurchase) to Passage of any shares of restricted stock granted pursuant to the
                    terms of any employee benefit plan or restricted stock purchase agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the vesting of any restricted stock unit or settlement of any other equity award that represents the right to receive shares
                    of Passage Common Stock, and transfers to Passage, or sales of Passage Common Stock in the open market, in connection with the vesting of any restricted stock unit or settlement of any other equity award that represents the right to
                    receive shares of Passage Common Stock settled in Passage Common Stock, in each case, to pay any tax withholding obligations due during the Restricted Period; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span><span style="text-decoration: underline;"> </span><span style="font-style: italic;"><span style="text-decoration: underline;">that</span></span>, for the avoidance of doubt, the underlying shares of Passage Common Stock held by the undersigned following such vesting or settlement and any such open market sales shall continue to be
                    subject to the restrictions on transfer set forth in this Lock-Up Agreement; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the establishment of a trading plan pursuant to Rule&#160;10b5-1 under the Exchange Act (a &#8220;<span style="font-style: italic; font-weight: bold;">10b5-1 Plan</span>&#8221;) for the transfer of Passage Common Stock; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span><span style="text-decoration: underline;"> </span><span style="font-style: italic;"><span style="text-decoration: underline;">that</span></span> (i) such plan does not provide
                    for any transfers of Passage Common Stock during the Restricted Period and (ii) no sales, transfers or other dispositions of shares of Passage Common Stock shall be made pursuant to a 10b5-1 Plan existing as of the date of the Merger
                    Agreement (which, for clarity, shall not be amended during the Restricted Period, but may be terminated during the Restricted Period); and <span style="font-style: italic;"><span style="text-decoration: underline;">provided further</span></span> that no public announcement or
                    filing under the Exchange Act or otherwise shall be required or voluntarily made by any party in connection with the establishment of such plan during the Restricted Period; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">transfers, sales, dispositions, or the entering into of transactions (including, without limitation, any swap, hedge, short
                    sale or similar agreement) or public announcements by the undersigned of or relating to shares of capital stock or other securities of Passage purchased or acquired by the undersigned on the open market, in other transactions following
                    the Closing or in a public offering by Passage or that do not involve or relate to the Undersigned&#8217;s Shares (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Released Shares</span>&#8221;); <span style="font-style: italic;"><span style="text-decoration: underline;">provided

                        that</span></span> this clause (f) shall not apply to any shares of Passage Common Stock issued pursuant to the Merger Agreement in respect of shares, or any securities convertible into or exercisable or exchangeable for shares, of
                    Remix; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">transfers of the Undersigned&#8217;s Shares pursuant to a bona fide third-party tender offer, merger, consolidation or other
                    similar transaction made to all holders of Passage&#8217;s capital stock involving a change of control of </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 552-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 553-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Passage that has been approved by Passage&#8217;s Board of Directors, <span style="font-style: italic;"><span style="text-decoration: underline;">provided that</span></span> in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this
            Lock-Up Agreement. For purposes of this clause (g), a &#8220;<span style="font-style: italic; font-weight: bold;">change of control</span>&#8221; means the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one
            transaction or a series of related transactions, to a person or group of affiliated persons, of Passage&#8217;s voting securities if, after such transfer, Passage&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the
            outstanding voting securities of Passage (or the surviving entity); </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">transfers of the Undersigned&#8217;s Shares pursuant to an order of a court or regulatory agency; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">transfers, sales, dispositions, or the entering into of transactions (including, without limitation, any swap, hedge, short
                    sale or similar agreement) or public announcements by the undersigned relating to shares of Passage Common Stock issued pursuant to the Merger Agreement in respect of shares of Remix or Passage, as the case may be, if any, purchased
                    pursuant to the Concurrent Financing (as defined in the Merger Agreement) or issued in exchange for, or on conversion or exercise of, any securities issued as part of the Concurrent Financing (the &#8220;<span style="font-style: italic; font-weight: bold;">Concurrent Financing Released Shares</span>&#8221;). For the avoidance of doubt and without limiting any of the foregoing exceptions, the number of Concurrent Financing Released Shares to be issued to the undersigned at
                    the Closing is set forth, solely for informational purposes, opposite his, her or its name on <span style="text-decoration: underline;">Schedule I</span> to this Lock-Up Agreement under the heading &#8220;Concurrent Financing Released Shares&#8221;; </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: justify;"><span style="text-decoration: underline;">provided, further</span><span style="font-style: normal;">,
              that, with respect to each of (a), (b), (c), and (d) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section&#160;16 of the Exchange Act or other public announcement shall be
              made voluntarily in connection with such transfer or disposition during the Restricted Period; </span><span style="text-decoration: underline;">provided that</span><span style="font-style: normal;"> (i) any filing under Section&#160;16 of the Exchange Act made during the Restricted
              Period shall clearly indicate in the footnotes thereto that such filing relates to the circumstances described in (a), (b), (c), or (d), as applicable, and that the shares of Passage Common Stock subject thereto remain subject to this Lock-Up
              Agreement and (ii) the foregoing shall not prevent the undersigned from filing a Form&#160;13F, Schedule 13G or Schedule 13D, or any amendment thereto, or from disclosing its holdings in Passage to the extent required by applicable Law. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any attempted transfer in violation of this Lock-Up Agreement will be of no
            effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Passage. In
            furtherance of the foregoing, the undersigned agrees that Passage and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if
            such transfer would constitute a violation or breach of this Lock-Up Agreement. Passage may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or
            instruments evidencing the undersigned&#8217;s ownership of Passage Common Stock: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AND MAY ONLY BE
            TRANSFERRED IN COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF REMIX THERAPEUTICS, INC. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Remix hereby represents and warrants that all Remix Lock-Up Agreements (as
            defined in the Merger Agreement) being executed by holders of Remix Capital Stock are in the same form as this Lock-Up Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The undersigned hereby represents and warrants that the undersigned has full
            power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the
            undersigned. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The parties hereto understand and agree that if the Merger Agreement is
            terminated for any reason, the undersigned shall be immediately and automatically released from all obligations under this Lock-Up Agreement. The undersigned understands that Passage and Remix are proceeding with the Contemplated Transactions
            in reliance upon this Lock-Up Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any and all remedies herein expressly conferred upon Passage or Remix will be
            deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity, and the exercise by Passage or Remix of any one remedy will not preclude the exercise of any other remedy. The undersigned agrees that
            irreparable damage, for which monetary damages, even if available, would not be an adequate remedy, would occur to Passage and/or Remix in the event that any provision of this Lock-Up Agreement were not performed in accordance with its specific
            terms or were otherwise breached. It is accordingly agreed that Passage and Remix shall be entitled to seek an injunction or </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 553-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 554-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">injunctions, specific performance and other equitable relief to prevent
            breaches of this Lock-Up Agreement and to seek to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which Passage or Remix is
            entitled at law or in equity, and the undersigned waives any bond, surety or other security that might be required of Passage or Remix with respect thereto. The undersigned further agrees that it will not oppose the granting of an injunction,
            specific performance or other equitable relief on the basis that Passage or Remix has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the event that any holder of Passage&#8217;s securities that are subject to a
            substantially similar lock-up agreement entered into by such holder, other than the undersigned, is permitted by Passage (and/or Remix), including, but not limited to, through any written consent granted under subparagraph (a)(ii)(E) above, to
            sell or otherwise transfer or dispose of shares of Passage Common Stock for value other than as permitted by this or a substantially similar lock-up agreement entered into by such holder or is granted an early release or waiver from the lock-up
            restrictions contained in such other lock-up agreement, the same percentage of shares of the Undersigned&#8217;s Shares shall be automatically, immediately and fully released and waived at the same time and on the same terms from any remaining
            restrictions set forth herein (the &#8220;<span style="font-style: italic; font-weight: bold;">Pro-Rata Release</span>&#8221;); <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span>, <span style="font-style: italic;"><span style="text-decoration: underline;">however</span></span>, that such
            Pro-Rata Release shall not be applied unless and until permission or early release has been granted by Passage, and solely prior to the Closing, Remix, to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a
            portion of such equity holder&#8217;s shares of Passage Common Stock that, when combined with all other permissions and early releases, represent an aggregate amount in excess of 1% of the number of shares of Passage Common Stock originally subject
            to substantially similar agreements; <span style="font-style: italic;"><span style="text-decoration: underline;">provided, </span><span style="text-decoration: underline;">further</span></span>, that Passage will promptly (and in any event within two business days prior to the effective date of any such Pro-Rata Release)
            notify the undersigned in writing of the terms and effective date of such Pro-Rata Release (including, without limitation, the percentage of the Undersigned&#8217;s Shares to be released in connection with such Pro-Rata Release); <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span>, <span style="font-style: italic;"><span style="text-decoration: underline;">however</span></span>, that if the undersigned is an executive officer or director of Passage and such permission or early release was granted solely for
            the purpose of meeting the initial listing standards of Nasdaq or another applicable national securities exchange, then such permission or early release shall not trigger, and the undersigned shall not be entitled to, the Pro-Rata Release. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up
            Agreement, Passage will promptly cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned&#8217;s Shares without the restrictive legend above or the withdrawal of any stop transfer
            instructions. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The undersigned understands that this Lock-Up Agreement is irrevocable and is
            binding upon the undersigned&#8217;s heirs, successors and assigns. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This Lock-Up Agreement and any claim, controversy or dispute arising under or
            related to this Lock-Up Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to the conflict of Laws principles thereof. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">IN ANY ACTION OR PROCEEDING BETWEEN THE UNDERSIGNED, ON THE ONE HAND, AND
            PASSAGE, REMIX OR ANY OF THEIR SUBSIDIARIES, ON THE OTHER HAND, ARISING OUT OF OR RELATING TO THIS LOCK-UP AGREEMENT, EACH OF THE UNDERSIGNED, PASSAGE AND REMIX: (A) IRREVOCABLY AND UNCONDITIONALLY CONSENTS AND SUBMITS TO THE EXCLUSIVE
            JURISDICTION AND VENUE OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE OR, TO THE EXTENT SUCH COURT DOES NOT HAVE SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE OR THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF
            DELAWARE, (B) AGREES THAT ALL CLAIMS IN RESPECT OF SUCH ACTION OR PROCEEDING SHALL BE HEARD AND DETERMINED EXCLUSIVELY IN ACCORDANCE WITH THIS PARAGRAPH AND THE PRECEDING PARAGRAPH, (C)&#160;WAIVES ANY OBJECTION TO LAYING VENUE IN ANY SUCH ACTION OR
            PROCEEDING IN SUCH COURTS, (D) WAIVES ANY OBJECTION THAT SUCH COURTS ARE AN INCONVENIENT FORUM OR DO NOT HAVE JURISDICTION OVER ANY PARTY, (E) AGREES THAT IF NOTICE IS GIVEN IN WRITING, WITH RESPECT TO THE UNDERSIGNED, TO THE ADDRESS OF THE
            UNDERSIGNED SET FORTH ON THE SIGNATURE PAGES HERETO, AND WITH RESPECT TO PASSAGE OR REMIX, TO THE ADDRESS SET FORTH ABOVE, SERVICE OF PROCESS UPON SUCH PARTY IN ANY SUCH ACTION OR PROCEEDING SHALL BE EFFECTIVE (I) FOUR BUSINESS DAYS AFTER BEING
            SENT BY REGISTERED OR CERTIFIED MAIL, RETURN RECEIPT REQUESTED, POSTAGE PREPAID, (II) ONE BUSINESS DAY AFTER BEING SENT </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 554-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 555-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">VIA A REPUTABLE NATIONWIDE OVERNIGHT COURIER SERVICE GUARANTEEING NEXT
            BUSINESS DAY DELIVERY, OR (III) WHEN RECEIPT IS ACKNOWLEDGED, IN THE CASE OF EMAIL, AND (F) IRREVOCABLY WAIVES THE RIGHT TO TRIAL BY JURY. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This Lock-Up Agreement may be executed in several counterparts, each of which
            shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Lock-Up Agreement (in counterparts or otherwise) by Passage, Remix and the undersigned by electronic mail (including any
            electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., <span style="text-decoration: underline;">www.docusign.com</span>) or electronic transmission in .pdf
            format shall be sufficient to bind such parties to the terms and conditions of this Lock-Up Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 8.5pt; text-align: center;">(Signature Page Follows)<span style="font-style: normal;"> </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 555-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 556-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 233pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 223pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 233pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accepted and Agreed<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By Passage Bio, Inc.:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 233pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accepted and Agreed by <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Therapeutics, Inc.: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 5pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 223pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 223pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3.25pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[Signature Page to Lock-Up Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 556-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 557-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Very truly yours,</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Print Name of Stockholder (Individual):</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Address:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 240pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 5.75pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[Signature Page to Lock-Up Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 557-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 558-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 240pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Very truly yours,</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Print Name of Stockholder (Entity):</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;]</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Address:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 3.25pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">[Signature Page to Lock-Up Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 558-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 559-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_304-annexe_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><span style="text-decoration: underline;">SCHEDULE I</span><br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Concurrent Financing Released Shares </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-top: 1pt solid #000000; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 353pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 1.75pt; text-align: left;">Stockholder</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 353pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Concurrent Financing Released Shares</div>
                </td>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 96pt; padding-top: 2.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 353pt; padding-top: 2.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 96pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 353pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 96pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 5.75pt; border-right: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 353pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 96pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.75pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 353pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; text-align: center;">[Schedule I] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">E-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 559-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 560-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXF"><!--Anchor--></a>Annex&#160;F </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; text-align: center;">FORM OF<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">CONTINGENT VALUE RIGHTS AGREEMENT<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">BETWEEN<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">PASSAGE BIO, INC.<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">and<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">[&#8226;], as Rights Agent<br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Dated as of [&#8226;] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 560-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 561-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 354pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 24pt; padding-bottom: 2.28pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-bottom: 2.28pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-bottom: 2.28pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-bottom: 2.28pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Page </div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.94pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAA1">ARTICLE 1 DEFINITIONS</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.94pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAA1"><span style="padding-left: 4.5pt;">F-3</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS11">Section&#160;1.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS11">Definitions</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS11"><span style="padding-left: 4.5pt;">F-3</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAA2">ARTICLE 2 CONTINGENT VALUE RIGHTS</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAA2"><span style="padding-left: 4.5pt;">F-6</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS21">Section&#160;2.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS21">Holders of CVRs; Appointment of Rights Agent</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS21"><span style="padding-left: 4.5pt;">F-6</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS22">Section&#160;2.2</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS22">Non-transferable</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS22"><span style="padding-left: 4.5pt;">F-6</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS23">Section&#160;2.3</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS23">No Certificate; Registration; Registration of
                      Transfer; Change of Address</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS23"><span style="padding-left: 4.5pt;">F-6</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS24">Section&#160;2.4</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS24">Payment Procedures</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS24"><span style="padding-left: 4.5pt;">F-7</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS25">Section&#160;2.5</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS25">No Voting, Dividends or Interest; No Equity or
                      Ownership Interest</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS25"><span style="padding-left: 4.5pt;">F-8</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS26">Section&#160;2.6</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS26">Ability to Abandon CVR</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS26"><span style="padding-left: 4.5pt;">F-8</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAA3">ARTICLE 3 THE RIGHTS AGENT</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAA3"><span style="padding-left: 4.5pt;">F-8</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS31">Section&#160;3.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS31">Certain Duties and Responsibilities</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS31"><span style="padding-left: 4.5pt;">F-8</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS32">Section&#160;3.2</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS32">Certain Rights of Rights Agent</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS32"><span style="padding-left: 4.5pt;">F-9</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS33">Section&#160;3.3</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS33">Resignation and Removal; Appointment of Successor</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS33"><span style="padding-left: 0.33pt;">F-11</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS34">Section&#160;3.4</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS34">Acceptance of Appointment by Successor</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS34"><span style="padding-left: 0.33pt;">F-11</span></a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAA4">ARTICLE 4 COVENANTS </a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAA4">F-12</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS41">Section&#160;4.1</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS41">List of Holders</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS41">F-12</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS42">Section&#160;4.2</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS42">Efforts</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS42">F-12</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS43">Section&#160;4.3</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS43">Prohibited Actions</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS43">F-12</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS44">Section&#160;4.4</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS44">Audit Rights.</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS44">F-13</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAA5">ARTICLE 5 AMENDMENTS </a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAA5">F-14</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS51">Section&#160;5.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS51">Amendments Without Consent of Holders or Rights Agent</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS51">F-14</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS52">Section&#160;5.2</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS52">Amendments with Consent of Holders</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS52">F-14</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS53">Section&#160;5.3</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS53">Effect of Amendments</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS53">F-14</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAA6">ARTICLE 6 CONSOLIDATION, MERGER, SALE OR CONVEYANCE </a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAA6">F-15</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS61">Section&#160;6.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS61">Successor Substituted</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS61">F-15</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 438pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAA7">ARTICLE 7 MISCELLANEOUS </a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAA7">F-15</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS71">Section&#160;7.1</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS71">Notices to Rights Agent and to Passage</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS71">F-15</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS72">Section&#160;7.2</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS72">Notice to Holders</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS72">F-15</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS73">Section&#160;7.3</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS73">Entire Agreement</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS73">F-16</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS74">Section&#160;7.4</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS74">Merger or Consolidation or Change of Name of Rights
                      Agent</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS74">F-16</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS75">Section&#160;7.5</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS75">Successors and Assigns</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS75">F-16</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS76">Section&#160;7.6</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS76">Benefits of Agreement; Action by Acting Holders</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS76">F-16</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS77">Section&#160;7.7</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS77">Governing Law</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS77">F-16</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS78">Section&#160;7.8</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS78">Jurisdiction</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS78">F-16</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS79">Section&#160;7.9</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS79">WAIVER OF JURY TRIAL</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS79">F-17</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS710">Section&#160;7.10</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS710">Severability Clause</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS710">F-17</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS711">Section&#160;7.11</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS711">Counterparts; Effectiveness</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS711">F-17</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS712">Section&#160;7.12</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS712">Termination</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS712">F-17</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS713">Section&#160;7.13</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS713">Force Majeure</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; padding-bottom: 1.4pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS713">F-17</a></div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.07pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 48pt; padding-top: 1.07pt; text-align: center; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS714">Section&#160;7.14</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 354pt; padding-top: 1.07pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#fANXAS714">Construction</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 24pt; padding-top: 1.07pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 3.5pt; text-align: left;"><a href="#fANXAS714">F-18</a></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 3pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 48pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 354pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 3pt; width: 24pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 561-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 562-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">This <span style="font-weight: bold;">CONTINGENT VALUE RIGHTS AGREEMENT</span>
            (this &#8220;<span style="text-decoration: underline;">Agreement</span>&#8221;), dated as of [ &#8226; ], is entered into by and between Passage Bio, Inc., a Delaware corporation (&#8220;<span style="text-decoration: underline;">Passage</span>&#8221;), and [ &#8226; ], a [ &#8226; ], as initial Rights Agent (as defined herein). </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; text-align: center;">PREAMBLE </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, Passage, Peregrine Merger Sub, Inc., a Delaware corporation and a
            wholly-owned subsidiary of Passage (&#8220;<span style="text-decoration: underline;">Merger Sub</span>&#8221;), and Remix Therapeutics, Inc., a Delaware corporation (the &#8220;<span style="text-decoration: underline;">Company</span>&#8221;), have entered into an Agreement and Plan of Merger, dated as of June&#160;24, 2026 (as it may be amended,
            supplemented or otherwise modified from time to time pursuant to the terms thereof, the &#8220;<span style="text-decoration: underline;">Merger Agreement</span>&#8221;), pursuant to which Merger Sub will merge with and into the Company (the &#8220;<span style="text-decoration: underline;">Merger</span>&#8221;), with the Company surviving the Merger
            as a wholly-owned subsidiary of Passage (the &#8220;<span style="text-decoration: underline;">Surviving Corporation</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, in connection with the Merger Agreement, Passage has agreed to
            provide to the Holders (as defined herein) certain contingent value rights as hereinafter described; </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, the parties to this Agreement have done all things necessary to make
            the contingent value rights, when issued pursuant to this Agreement, the valid obligations of Passage and to make this Agreement a valid and binding agreement of Passage, in accordance with its terms; and </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NOW, THEREFORE, in consideration of the premises and the consummation of the
            transactions referred to above, it is mutually covenanted and agreed, for the proportionate benefit of all Holders, as follows: </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a id="fANXAA1"><!--Anchor--></a>ARTICLE&#160;1 <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">DEFINITIONS </div>

          <a id="fANXAS11"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;1.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Definitions</span>. Capitalized terms used but not otherwise defined herein have the
                    meanings ascribed thereto in the Merger Agreement. The following terms have the meanings ascribed to them as follows: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Acting Holders</span>&#8221; means, at any time, the registered Holders of more
            than thirty-five percent (35%) of the total number of CVRs outstanding at such time, as set forth on the CVR Register. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Affiliate</span>&#8221; means, with respect to any Person, any other Person
            directly or indirectly controlling, controlled by, or under common control with such other Person. For purposes of this definition, &#8220;control&#8221; when used with respect to any Person means the power to direct the management and policies of such
            Person, directly or indirectly, whether through the ownership of voting securities or partnership or other ownership interests, by contract or otherwise, and the terms &#8220;controlling&#8221; and &#8220;controlled&#8221; have correlative meanings. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Catalent</span>&#8221; means Catalent Pharma Solutions, LLC. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Catalent Storage Costs</span>&#8221; means any documented out-of-pocket costs and
            expenses paid or payable by Passage or any of its Subsidiaries to Catalent for the storage and maintenance of MLD product supply materials. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Closing</span>&#8221; means the closing of the Merger. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Closing Date</span>&#8221; means the date on which the Closing actually takes place.
          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Commercially Reasonable Efforts</span>&#8221; means, with respect to the
            collection of Legacy Asset Payments, carrying out those obligations and tasks in a good faith and diligent manner; taking into account all commercial and other relevant factors that Passage, exercising good faith, would normally take into
            account with a collection of amounts receivable from a commercial counterparty, <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that, notwithstanding the foregoing, such level of efforts and resources shall not require Passage to
            advance, expend or commit any funds (other than <span style="font-style: italic;">de minimis</span> administrative costs and the GM1&#160;2027 License Payment) in connection with the collection of any Legacy Asset Payments; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span>, <span style="font-style: italic;"><span style="text-decoration: underline;">further</span></span>, that such level of efforts and resources shall be determined without taking into account the CVR Payment payable in accordance with,
            and subject to, the terms hereof. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">CVR</span>&#8221; means a contingent contractual right of Holders to receive CVR
            Payments under this Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">CVR Payment</span>&#8221; means, with respect to each Legacy Asset Payment, the
            CVR Proceeds attributable to such Legacy Asset Payment. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">CVR Payment Period</span>&#8221; means an annual period (or portion thereof)
            beginning on the Closing Date and ending on December&#160;31 of any given calendar year during the CVR Period&#894; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that if the last CVR Payment Period would end subsequent to the expiration of
            the CVR Period, such CVR Payment Period will end on the last day of the CVR&#160;Period. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 562-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 563-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">CVR Period</span>&#8221; means the GM1 CVR Period or the MLD CVR Period, as
            applicable. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">CVR Proceeds</span>&#8221; means a cash payment equal to one hundred percent
            (100%) of the Legacy Asset Payments actually received by Passage or any of its Subsidiaries during a CVR Payment Period, less Permitted Deductions with respect to such Legacy Asset Payments, in each case as calculated in accordance with GAAP
            consistently applied. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Gemma</span>&#8221; means Gemma Biotherapeutics, Inc. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Gemma Sublicense (GM1)</span>&#8221; means the Exclusive License Agreement (GM1),
            dated as of July&#160;31, 2024, as amended on May&#160;7, 2025, by and between Passage and Gemma. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Gemma Sublicense (MLD)</span>&#8221; means the Exclusive License Agreement (MLD),
            dated as of July&#160;31, 2024, as amended on May&#160;7, 2025, by and between Passage and Gemma. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Gemma Sublicenses</span>&#8221; means, collectively, the Gemma Sublicense (GM1) and
            the Gemma Sublicense (MLD). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">GM1 2027 License Payment</span>&#8221; means the License Maintenance Fee (as
            defined in the Penn License Agreement) payable by Passage to The Trustees of the University of Pennsylvania pursuant to the Penn License Agreement to extend the license granted under the Penn License Agreement through June&#160;30, 2028. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">GM1 CVR Period</span>&#8221; means the period beginning on the Closing Date and
            ending on July&#160;31, 2028. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">GM1 Payments</span>&#8221; means eighty percent (80%) of the payments received by
            Passage or any of its Subsidiaries from Gemma for the portion of the one-time, non-refundable, non-creditable product purchase fee contemplated by Section&#160;5.1 of the Gemma Sublicense (GM1) which has not already been paid to Passage on or prior
            to the date of this Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Holder</span>&#8221; means, at the relevant time, a Person in whose name CVRs are
            registered in the CVR Register. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Legacy Asset Payments</span>&#8221; means the receipt of cash consideration by
            Passage or its Subsidiaries with respect to the MLD Payments or the GM1 Payments, in each case, during the applicable CVR Period. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">MLD CVR Period</span>&#8221; means the period beginning on the Closing Date and
            ending on December&#160;31, 2027. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">MLD Payments</span>&#8221; means the payments received by Passage or any of its
            Subsidiaries from Gemma for the one-time, non-refundable, non-creditable upfront fees contemplated by Section&#160;5.1 of the Gemma Sublicense (MLD). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Officer&#8217;s Certificate</span>&#8221; means a certificate signed by the chief
            executive officer or the chief financial officer of Passage, in their respective official capacities. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Penn License Agreement</span>&#8221; means that certain Second Amended and
            Restated Research, Collaboration and License Agreement by and between Passage and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, dated as of July&#160;31, 2024, as amended as of the date of this Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Permitted Deductions</span>&#8221; means the following costs or expenses, without
            duplication: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any applicable and non-recoverable value added, sales or similar Taxes imposed on the Legacy Asset Payments and payable in
                    cash by Passage or any of its Subsidiaries and any income or other similar Taxes required to be paid by Passage or any of its Subsidiaries, in each case, with respect to the taxable year in which such Legacy Asset Payments were received
                    which Taxes would not have been required to be paid by Passage or its applicable Subsidiary but for its receipt of Legacy Asset Payments and any applicable Tax imposed on or otherwise payable in connection with making any CVR Payment or
                    the issuance of any CVR (including, without limitation, (i) the employer portion of any employment, payroll, or other similar Taxes in respect of CVR Payments (including in respect of Passage ITM Options granted to employees or Passage
                    Restricted Stock Unit Awards) and (ii) any withholding Taxes (including interest and penalties) relating to the issuance of a CVR or any CVR Payment); <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that, for purposes of
                    calculating any income Taxes of Passage or any of its Subsidiaries for this purpose, (a)&#160;such income Taxes shall be computed after taking into account any net operating loss carryforwards or other Tax attributes (including Tax credits)
                    of Passage or any of its Subsidiaries that are available to offset income or gain, after taking into account any limits of the usability of such attributes under applicable Law, including under Section&#160;382 of the Code, as reasonably
                    determined by a nationally </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 563-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 564-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">recognized tax advisor, which Tax attributes were generated either (I)
            prior to the Closing Date or (II)&#160;after the Closing Date, in the case of this clause (II) if such Tax attributes relate to the Legacy Asset Payments, (b) for the avoidance of doubt, any item(s) of income or gain resulting or arising from such
            Legacy Asset Payments shall be treated as the first item(s) of income or gain, as applicable, in the applicable taxable year and (c) Taxes shall not be taken into account under this clause (i), to the extent such Taxes are taken into account in
            the determination of Passage Net Cash; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any reasonable, documented out-of-pocket costs and expenses incurred or accrued by Passage or any of its Subsidiaries in
                    respect of its performance of this Agreement following the Closing Date or in respect of its negotiation, execution, delivery or performance of the Gemma Sublicenses (to the extent related to the Legacy Asset Payments, and including the
                    Catalent Storage Costs) or any other agreement to which Passage or any of its Subsidiaries is a party that is in effect as of the date of this Agreement and related to the Legacy Asset Payments, including (i) any costs related to the
                    prosecution, maintenance or enforcement by Passage or any of its Subsidiaries of intellectual property rights to the extent required by the terms of the Gemma Sublicenses (but excluding any costs related to a breach of this Agreement by
                    Passage, including costs incurred in litigation in respect of the same), (ii) any reasonable, documented out of pocket costs incurred in order to comply with the terms of the Gemma Sublicenses or any other agreement to which Passage or
                    any of its Subsidiaries is a party that is in effect as of the date of this Agreement and related to the Legacy Asset Payments that remain with Passage following the receipt of any Legacy Asset Payment, to the extent such costs relate
                    to any Legacy Asset Payment (but excluding the GM1 2027 License Payment), (iii) any Losses incurred and paid or payable by Passage or any of its Subsidiaries arising out of any claims, demands, actions or other proceedings, in each
                    case, brought by a third party, relating to or in connection with the Gemma Sublicenses or the Legacy Asset Payments or (iv) any documented out-of-pocket fees of the Rights Agent in connection with this Agreement; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">any reasonable documented out-of-pocket costs incurred or accrued by Passage or any of its Subsidiaries in connection with
                    the collection or receipt of any Legacy Asset Payment, including any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee, service fee, regulatory and other filing fees, or other fee, commission or expense owed to any
                    broker, finder, investment bank, auditor, accountant, counsel, advisor or other third party in relation thereto, in each case, pursuant to any Contract to which Passage or any of its Subsidiaries is a party that is in effect as of the
                    date of this Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Permitted Transfer</span>&#8221; means a Transfer of one or more CVRs (i) upon
            death of a Holder by will or intestacy; (ii)&#160;by&#160;instrument to an <span style="font-style: italic;">inter vivos</span> or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death of the trustee; (iii) made pursuant
            to a court order of a court of competent jurisdiction (such as in connection with divorce, bankruptcy or liquidation); (iv) made by operation of law (including a consolidation or merger) or without consideration in connection with the
            dissolution, liquidation or termination of any corporation, limited liability company, partnership or other entity; (v) in the case of CVRs payable to a nominee, from a nominee to a beneficial owner (and, if applicable, through an intermediary)
            or from such nominee to another nominee for the same beneficial owner, in each case as permitted by The Depository Trust Company; (vi) to Passage or its Subsidiaries; or (vii) as provided in <span style="text-decoration: underline;">Section&#160;2.6</span>. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Person</span>&#8221; means any individual, partnership, joint venture, limited
            liability company, firm, corporation, unincorporated association or organization, trust or other entity, and shall include any successor (by merger or otherwise) of any such Person. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Record Date</span>&#8221; means the close of business on the last Business Day
            prior to the day on which the Effective Time occurs. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Rights Agent</span>&#8221; means the Rights Agent named in the first paragraph of
            this Agreement, until a successor Rights Agent shall have been appointed pursuant to <span style="text-decoration: underline;">Article&#160;3</span> of this Agreement, and thereafter &#8220;Rights Agent&#8221; will mean such successor Rights Agent. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-align: left;">&#8220;<span style="text-decoration: underline;">Securities Act</span>&#8221; means the Securities Act of 1933, as amended. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="text-decoration: underline;">Transfer</span>&#8221; means transfer, pledge, hypothecation, encumbrance,
            assignment or other disposition (whether by sale, merger, consolidation, liquidation, dissolution, dividend, distribution or otherwise), the offer to make such a transfer or other disposition, and each contract, arrangement or understanding,
            whether or not in writing, to effect any of the foregoing. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 564-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 565-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="fANXAA2"><!--Anchor--></a>ARTICLE 2 <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONTINGENT VALUE RIGHTS </div>

          <a id="fANXAS21"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;2.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Holders of CVRs; Appointment of Rights Agent</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The CVRs shall be issued to the holders of shares of Passage Common Stock as of the Record Date. One CVR will be issued with
                    respect to each share of Passage Common Stock that is outstanding as of the close of business on the Record Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage hereby appoints the Rights Agent to act as rights agent for Passage in accordance with the express terms and
                    conditions set forth in this Agreement, and the Rights Agent hereby accepts such appointment. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS22"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;2.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Non-transferable</span>. A Holder may not at any time Transfer CVRs, other than pursuant to
                    a Permitted Transfer. Any attempted Transfer that is not a Permitted Transfer, in whole or in part, will be void <span style="font-style: italic;">ab initio</span> and of no effect. The CVRs will not be listed on any quotation system
                    or traded on any securities exchange. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS23"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;2.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">No Certificate; Registration; Registration of Transfer; Change of Address</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Holders&#8217; rights and obligations in respect of CVRs derive solely from this Agreement; CVRs will not be evidenced by a
                    certificate or other instrument. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent will create and maintain an up-to-date register (the &#8220;<span style="text-decoration: underline;">CVR Register</span>&#8221;) for the purposes of
                    (i)&#160;identifying the Holders of CVRs, (ii) determining Holders&#8217; entitlement to CVRs and (iii) registering the CVRs and Permitted Transfers thereof. The CVR Register will initially show one position for The Depository Trust Company (or
                    its nominee) representing all of the CVRs provided to the holders of shares of Passage Common Stock held as of the close of business on the Record Date. The CVR Register will be created, and CVRs will be distributed, pursuant to written
                    instructions from Passage to the Rights Agent. Except as expressly provided herein with respect to the rights of the Rights Agent, neither Passage nor its Subsidiaries will have any responsibility or liability whatsoever to any person
                    other than the Holders. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the restrictions on transferability set forth in <span style="text-decoration: underline;">Section&#160;2.2</span>, every request made to Transfer CVRs must be
                    in writing and accompanied by a written instrument of Transfer reasonably acceptable to the Rights Agent, together with the signature guarantee of a guarantor institution which is a participant in a signature guarantee program approved
                    by the Securities Transfer Association (a &#8220;signature guarantee&#8221;) and other requested documentation in a form reasonably satisfactory to the Rights Agent, duly executed and properly completed, as applicable, by the Holder or Holders
                    thereof, or by the duly appointed legal representative, personal representative or survivor of such Holder or Holders, setting forth in reasonable detail the circumstances relating to the Transfer. Upon receipt of such written notice,
                    the Rights Agent will, subject to its reasonable determination in accordance with its own internal procedures that the Transfer instrument is in proper form and the Transfer is a Permitted Transfer and otherwise complies on its face
                    with the other terms and conditions of this Agreement, register the Transfer of the applicable CVRs in the CVR Register. All Transfers of CVRs registered in the CVR Register will be the valid obligations of Passage, evidencing the same
                    right, and entitling the transferee to the same benefits and rights under this Agreement, as those held by the transferor. Each of Passage and the Rights Agent may require payment (without duplication) by the applicable Holder of a sum
                    sufficient to cover any stamp or other transfer Tax or governmental charge that is imposed in connection with (and would not have been imposed but for) any such registration of Transfer, unless the transferee shall have established to
                    the reasonable satisfaction of Passage or the Rights Agent, as applicable, that such Tax or governmental charge, if any, has been paid. No Transfer of CVRs shall be valid until registered in the CVR Register and any Transfer not duly
                    registered in the CVR Register shall be void. Passage shall not be responsible for any costs and expenses related to any transfer or assignment of the CVRs (including the cost of any transfer tax). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">A Holder may make a written request to the Rights Agent to change such Holder&#8217;s address of record in the CVR Register. Such
                    written request must be duly executed by such Holder and conform to such other reasonable requirements as the Rights Agent may establish from time to time. Upon receipt of such written notice, the Rights Agent shall promptly record the
                    change of address in the CVR Register. The Acting Holders </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 565-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 566-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">may, without duplication, make a written request to the Rights Agent for a
            list containing the names, addresses and number of CVRs of the Holders that are registered in the CVR Register. Upon receipt of such written request from the Acting Holders, the Rights Agent shall promptly deliver a copy of such list to the
            Acting Holders. </div>

          <a id="fANXAS24"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;2.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Payment Procedures</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As promptly as practicable (and, in any event, within twenty (20) days) following the receipt by Passage or any of its
                    Subsidiaries of any Legacy Asset Payment, Passage shall (i) deliver to the Rights Agent, an Officer&#8217;s Certificate certifying the aggregate amount of (A) the CVR Proceeds (if any) actually received by Passage or its Subsidiaries during
                    such fiscal quarter (or, in the case of the first delivery of such an Officer&#8217;s Certificate hereunder, all CVR Proceeds actually received through the end of such fiscal quarter); (B) the Permitted Deductions reflected in such CVR
                    Proceeds; and (C) the CVR Payment payable to Holders, if any, in respect of such CVR Proceeds, and (ii) deliver to the Rights Agent, or to the Rights Agent&#8217;s designee, the CVR Payment (if any) by wire transfer of immediately available
                    funds to an account designated in writing by the Rights Agent. Upon receipt of the wire transfer referred to in the foregoing sentence, the Rights Agent shall promptly (and in any event, within ten (10) Business Days) pay, by check
                    mailed, first-class postage prepaid, to the address of each Holder set forth in the CVR Register at such time or by other method of delivery as specified by the applicable Holder in writing to the Rights Agent, an amount equal to the
                    product determined by multiplying (x) the quotient determined by dividing (I) the applicable CVR Payment by (II) the total number of CVRs registered in the CVR Register at such time, by (y) the number of CVRs registered to such Holder
                    in the CVR Register at such time. For the avoidance of doubt Passage shall have no further liability in respect of the relevant CVR Payment upon delivery of such CVR Payment in accordance with this <span style="text-decoration: underline;">Section&#160;2.4(a)</span> and the
                    satisfaction of each of Passage&#8217;s obligations set forth in this <span style="text-decoration: underline;">Section 2.4(a)</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except to the extent otherwise required pursuant to a change in applicable Law after the date hereof, the parties hereto
                    agree to treat the issuance of the CVRs as not constituting a current distribution and all CVR Payments for U.S. federal (and applicable state and local) income Tax purposes as distributions of money governed by Section&#160;301 of the U.S.
                    Internal Revenue Code of 1986, as amended (the &#8220;<span style="text-decoration: underline;">Code</span>&#8221;), which will constitute a dividend to the extent payable out of Passage and its Subsidiaries&#8217; current and accumulated &#8220;earnings and profits&#8221; (pursuant to Section&#160;316 of the
                    Code) in the taxable year in which any such CVR Payment is made. The parties hereto will not take any position to the contrary on any Tax Return or for other Tax purposes except as required by a change in applicable Law after the date
                    hereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage and the Rights Agent will be entitled to deduct and withhold, or cause to be deducted and withheld, from any CVR
                    Payment otherwise payable pursuant to this Agreement, such amounts as Passage or the Rights Agent reasonably determines it is required to deduct and withhold with respect to the making of such payment under any provision of applicable
                    Law relating to Taxes. To the extent that amounts are so deducted and withheld and paid over to the appropriate Governmental Authority, such deducted and withheld amounts will be treated for all purposes of this Agreement as having been
                    paid to the Holder in respect of which such deduction and withholding was made. Prior to making any such deductions or withholdings or causing any such deductions or withholdings to be made with respect to any Holder, the Rights Agent
                    will, to the extent reasonably practicable, provide notice to the Holder of such potential Tax deduction or withholding and a reasonable opportunity for the Holder to provide any necessary Tax forms in order to avoid or reduce such
                    withholding amounts; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that the time period for payment of a CVR Payment by the Rights Agent set forth in <span style="text-decoration: underline;">Section&#160;2.4(a)</span> will be extended by a period equal to any delay
                    caused by the Holder providing such forms; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span>, <span style="font-style: italic;"><span style="text-decoration: underline;">further</span></span>, that in no event shall such period be extended for more than ten (10)
                    Business Days, unless otherwise requested by the Holder for the purpose of delivering such forms and agreed to by the Rights Agent. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any portion of a CVR Payment that remains undistributed to the Holders on the date that is six (6) months after the
                    applicable fiscal quarter end (including by means of uncashed checks or invalid addresses on the CVR Register) will be delivered by the Rights Agent to Passage or a Person nominated in writing by Passage (with written notice thereof
                    from Passage to the Rights Agent), and any Holder will thereafter look only to Passage for payment of such CVR Payment (which shall be without interest). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If any CVR Payment (or portion thereof) remains unclaimed by a Holder on the date that is one year after the date on which
                    such CVR Proceeds were required to be paid to Holders (or immediately prior to such earlier </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 566-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 567-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">date on which such CVR Payment would otherwise escheat to or become the
            property of any governmental authority), then: (i) such CVR Payment (or portion thereof) will, to the extent permitted by applicable Law, become the property of Passage and will be transferred to Passage or a Person nominated in writing by
            Passage (with written notice thereof from Passage to the Rights Agent), free and clear of all claims or interest of any Person previously entitled thereto, and no consideration or compensation shall be payable therefor, and (ii) the CVRs to
            which such payment relate shall be deemed abandoned in accordance with <span style="text-decoration: underline;">Section&#160;2.6</span> and shall no longer be deemed outstanding for any purpose (including for the purposes of calculating, for any CVR Payment payable following such
            abandonment, the total number of CVRs registered in the CVR Register and the number of CVRs registered to such Holder in the CVR Register). Neither Passage nor the Rights Agent will be liable to any Person in respect of any CVR Payment amount
            delivered to a public official pursuant to any applicable abandoned property, escheat or similar legal requirement under applicable law. In addition to and not in limitation of any other indemnity obligation herein, Passage agrees to indemnify
            and hold harmless the Rights Agent with respect to any liability, penalty, cost or expense the Rights Agent may incur or be subject to in connection with transferring such property to Passage or a public official. </div>

          <a id="fANXAS25"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;2.5<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">No Voting, Dividends or Interest; No Equity or Ownership Interest</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">CVRs will not have any voting or dividend rights, and interest will not accrue on any amounts payable in respect of CVRs. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">CVRs will not represent any equity or ownership interest in Passage or any of its Subsidiaries or in the Surviving
                    Corporation. The sole right of the Holders to receive property hereunder is the right to receive CVR Payments, if any, in accordance with the terms hereof. It is hereby acknowledged and agreed that a CVR shall not constitute a security
                    of Passage or any of its Subsidiaries or of the Surviving Corporation. Nothing contained in this Agreement shall be construed as conferring upon any Holder, by virtue of the CVRs, any rights or obligations of any kind or nature
                    whatsoever as a stockholder or equityholder of Passage or any of its Subsidiaries or of the Surviving Corporation, either at law or in equity. The rights of any Holder and the obligations of Passage and its Affiliates and their
                    respective officers, directors and controlling Persons are contract rights and obligations limited to those expressly set forth in this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">It is hereby acknowledged and agreed that the CVRs and the possibility of any payment hereunder with respect thereto are
                    highly speculative and subject to numerous factors outside of Passage&#8217;s control, and there is no assurance that Holders will receive any payments under this Agreement or in connection with the CVRs. Each Holder acknowledges that it is
                    highly possible that (i) no Legacy Asset Payments will be collected prior to the expiration of the applicable CVR Period and (ii) there will not be any Legacy Asset Payments that may be the subject of a CVR Payment. It is further
                    acknowledged and agreed that neither Passage nor its Affiliates owe, by virtue of their obligations under this Agreement, a fiduciary duty or any implied duties to the Holders and the parties hereto intend solely the express provisions
                    of this Agreement to govern their contractual relationship with respect to the CVRs. It is acknowledged and agreed that this <span style="text-decoration: underline;">Section&#160;2.5(c)</span> is an essential and material term of this Agreement. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS26"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;2.6<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Ability to Abandon CVR</span>. A Holder may at any time, at such Holder&#8217;s option or upon
                    the failure to claim payment under <span style="text-decoration: underline;">Section&#160;2.4(e)</span>, abandon all of such Holder&#8217;s remaining rights represented by CVRs by transferring such CVR to Passage or a Person nominated in writing by Passage (with written notice thereof
                    from Passage to the Rights Agent) without consideration or compensation therefor, and such rights will be cancelled, with the Rights Agent being promptly notified in writing by Passage of such transfer and cancellation. No such notice
                    to the Rights Agent shall be required in the case of abandonment due to the failure to claim payment under <span style="text-decoration: underline;">Section&#160;2.4(e)</span>. Nothing in this Agreement is intended to prohibit Passage or its Subsidiaries from offering to acquire or
                    acquiring CVRs, in private transactions or otherwise, for consideration in its sole discretion. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;"><a id="fANXAA3"><!--Anchor--></a>ARTICLE 3 <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">THE RIGHTS AGENT </div>

          <a id="fANXAS31"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;3.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Certain Duties and Responsibilities</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent will not have any liability for any actions taken or not taken in connection with this Agreement, except to
                    the extent such liability arises as a result of the willful misconduct, bad faith, fraud or gross negligence of the Rights Agent (in each case as determined by a final non-appealable judgment of a court of competent jurisdiction).
                    Notwithstanding anything in this Agreement to the contrary, any liability of </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 567-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 568-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">the Rights Agent under this Agreement will be limited to the amount of
            annual fees paid by Passage to the Rights Agent during the twelve (12) months immediately preceding the event for which recovery from the Rights Agent is being sought, except in the case of the willful misconduct, bad faith or fraud of the
            Rights Agent (in each case as determined by a final non-appealable judgment of a court of competent jurisdiction). Anything to the contrary notwithstanding, in no event will the Rights Agent be liable for special, punitive, indirect, incidental
            or consequential loss or damages of any kind whatsoever (including, without limitation, lost profits), even if the Rights Agent has been advised of the likelihood of such loss or damages, and regardless of the form of action. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holder
                    with respect to any action or default by any person or entity, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any
                    demand upon Passage, the Company or the Surviving Corporation. All rights of action under this Agreement may be enforced (but shall not be required to be enforced) by the Rights Agent, any claim, action, suit, audit, investigation or
                    proceeding instituted by the Rights Agent will be brought in its name as the Rights Agent and any recovery in connection therewith will be for the proportionate benefit of all the Holders, as their respective rights or interests may
                    appear on the CVR Register. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS32"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;3.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Certain Rights of Rights Agent</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent undertakes to perform such duties and only such duties as are specifically set forth in this Agreement, and
                    no implied covenants or obligations will be read into this Agreement against the Rights Agent. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent may rely and will be protected by Passage in acting or refraining from acting upon any resolution,
                    certificate, statement, instrument, opinion, report, notice, request, direction, consent, order or other paper or document reasonably believed by it in the absence of bad faith to be genuine and to have been signed or presented by or on
                    behalf of Passage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent may engage and consult with counsel of its selection, and the written advice or opinion of such counsel
                    will, in the absence of bad faith, gross negligence, fraud or willful misconduct (in each case, as determined by a final, non-appealable judgment of a court of competent jurisdiction) on the part of the Rights Agent, be full and
                    complete authorization and protection in respect of any action taken or not taken by the Rights Agent in reliance thereon. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any permissive rights of the Rights Agent hereunder will not be construed as a duty. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent will not be required to give any note or surety in respect of the execution of its powers or otherwise under
                    this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage agrees to indemnify the Rights Agent for, and to hold the Rights Agent harmless from and against, any loss,
                    liability, damage, judgment, fine, penalty, cost or expense (each, a &#8220;<span style="text-decoration: underline;">Loss</span>&#8221;) suffered or incurred by the Rights Agent and arising out of or in connection with the Rights Agent&#8217;s performance of its obligations under this
                    Agreement, including the reasonable and documented costs and expenses of defending the Rights Agent against any claims, charges, demands, actions or suits arising out of or in connection with the execution, acceptance, administration,
                    exercise and performance of its duties under this Agreement, including the costs and expenses of defending against any claim of liability arising therefrom, directly or indirectly, or enforcing its rights hereunder, except to the extent
                    such Loss has been determined by a final non-appealable decision of a court of competent jurisdiction to have resulted from the Rights Agent&#8217;s gross negligence, bad faith, fraud or willful misconduct (in each case, as determined by a
                    final, non-appealable judgment of a court of competent jurisdiction); <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that this <span style="text-decoration: underline;">Section&#160;3.2(f)</span> shall not apply to (i) income, receipt, franchise or similar Taxes, (ii)
                    any Taxes imposed due to the Rights Agent&#8217;s connection with the jurisdiction imposing such Taxes (other than any connection caused solely by this Agreement or the Rights Agent performing, enforcing or receiving payments under this
                    Agreement), or (iii) any Taxes imposed due to the failure of the Rights Agent to provide any form, document or certificate that would have reduced or eliminated the amount of withholding taxes (&#8220;<span style="text-decoration: underline;">Excluded Taxes</span>&#8221;). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In addition to the indemnification provided under <span style="text-decoration: underline;">Section&#160;3.2(f)</span>, Passage agrees (i) to pay the fees of the Rights
                    Agent in connection with the Rights Agent&#8217;s performance of its obligations hereunder, as agreed upon in writing by the Rights Agent and Passage on or prior to the date of this Agreement, and (ii) to reimburse the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 568-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 569-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Rights Agent for all reasonable and properly documented out-of-pocket
            expenses and other disbursements incurred in the preparation, delivery, negotiation, amendment, administration and execution of this Agreement and the exercise and performance of its duties hereunder, including all taxes (other than Excluded
            Taxes) and governmental charges, incurred by the Rights Agent in the performance of its obligations under this Agreement, except that Passage will have no obligation to pay the fees of the Rights Agent or reimburse the Rights Agent in
            connection with any lawsuit initiated by the Rights Agent on behalf of itself or the Holders, except in the case of any suit enforcing the provisions of <span style="text-decoration: underline;">Section&#160;2.4(a)</span>, <span style="text-decoration: underline;">Section&#160;2.4(b)</span> or <span style="text-decoration: underline;">Section&#160;3.2(f)</span>, if Passage is
            found by a court of competent jurisdiction to be liable to the Rights Agent or the Holders, as applicable in such suit. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No provision of this Agreement shall require the Rights Agent to expend or risk its own funds or otherwise incur any
                    financial liability in the performance of any of its duties hereunder or in the exercise of any of its rights or powers if it believes that repayment of such funds or adequate indemnification against such risk or liability is not
                    reasonably assured to it. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent will not be deemed to have knowledge of any event of which it was supposed to receive notice hereunder but
                    has not received written notice of such event, and the Rights Agent will not incur any liability for failing to take action in connection therewith, in each case, unless and until it has received such notice in writing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent may execute and exercise any of the rights or powers hereby vested in it or perform any duty hereunder
                    either itself or by or through its attorney or agents and the Rights Agent shall not be answerable or accountable for any act, default, neglect or misconduct of any such attorney or agents or for any loss to Passage resulting from any
                    such act, default, neglect or misconduct, absent gross negligence, bad faith or willful misconduct (each as determined by a final non-appealable judgment of a court of competent jurisdiction) in the selection and continued employment
                    thereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage shall perform, acknowledge and deliver or cause to be performed, acknowledged and delivered all such further and
                    other acts, documents, instruments and assurances as may be reasonably required by the Rights Agent for the carrying out or performing by the Rights Agent of the provisions of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent shall not be liable for or by reason of any of the statements of fact or recitals contained in this
                    Agreement (except its countersignature thereof) or be required to verify the same, and all such statements and recitals are and shall be deemed to have been made by Passage only. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent shall act hereunder solely as agent for Passage and shall not assume any obligations or relationship of
                    agency or trust with any of the owners or holders of the CVRs. The Rights Agent shall not have any duty or responsibility in the case of the receipt of any written demand from any Holders with respect to any action or default by
                    Passage, including, without limiting the generality of the foregoing, any duty or responsibility to initiate or attempt to initiate any proceedings at law or otherwise or to make any demand upon Passage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent may rely on and be fully authorized and protected in acting or failing to act upon (i) any guaranty of
                    signature by an &#8220;eligible guarantor institution&#8221; that is a member or participant in the Securities Transfer Agents Medallion Program or other comparable &#8220;signature guarantee program&#8221; or insurance program in addition to, or in
                    substitution for, the foregoing; or (ii) any law, act, regulation or any interpretation of the same even though such law, act, or regulation may thereafter have been altered, changed, amended or repealed. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent shall not be liable or responsible for any failure of Passage to comply with any of its obligations relating
                    to any registration statement filed with the Securities and Exchange Commission or this Agreement, including without limitation obligations under applicable Law. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Whenever the Rights Agent deems it desirable that a matter be proved or established prior to taking or omitting any action
                    hereunder, the Rights Agent may (i) rely upon an Officer&#8217;s Certificate and (ii) in the absence of bad faith, gross negligence, fraud or willful misconduct on its part, incur no liability and be held harmless by Passage for or in respect
                    of any action taken or omitted to be taken by it under the provisions of this Agreement in reliance upon such Officer&#8217;s Certificate. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(q)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">All funds received by the Rights Agent under this Agreement that are to be distributed or applied by the Rights Agent in the
                    performance of services hereunder (the &#8220;<span style="text-decoration: underline;">Funds</span>&#8221;) shall be held by the Rights Agent as agent for </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 569-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 570-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Passage and deposited in one or more bank accounts to be maintained by the
            Rights Agent in its name as agent for Passage. Until paid pursuant to the terms of this Agreement, the Rights Agent will hold the Funds through such accounts in: deposit accounts of commercial banks with Tier 1 capital exceeding $1&#160;billion or
            with an average rating above investment grade by S&amp;P (LT Local Issuer Credit Rating), Moody&#8217;s (Long Term Rating) and Fitch Ratings, Inc. (LT Issuer Default Rating) (each as reported by Bloomberg Finance L.P.). The Rights Agent shall, in the
            absence of bad faith, gross negligence, fraud or willful misconduct (each as determined by a final, non-appealable judgment of a court of competent jurisdiction), have no responsibility or liability for any diminution of the Funds that may
            result from any deposit made by the Rights Agent in accordance with this paragraph, including any losses resulting from a default by any bank, financial institution or other third party. The Rights Agent may from time to time receive interest,
            dividends or other earnings in connection with such deposits. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(r)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The obligations of Passage and the rights of the Rights Agent under this <span style="text-decoration: underline;">Section&#160;3.2</span>, <span style="text-decoration: underline;">Section&#160;3.1</span> and <span style="text-decoration: underline;">Section&#160;2.4</span>
                    shall survive the expiration of the CVRs and the termination of this Agreement and the resignation, replacement or removal of the Rights Agent. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS33"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;3.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Resignation and Removal; Appointment of Successor</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent may resign at any time by written notice to Passage. Any such resignation notice shall specify the date on
                    which such resignation will take effect (which shall be at least thirty (30) days following the date that such resignation notice is delivered), and such resignation will be effective on the earlier of (i)&#160;the date so specified and (ii)
                    the appointment of a successor Rights Agent. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage will have the right to remove the Rights Agent at any time by written notice to the Rights Agent, specifying the date
                    on which such removal will take effect. Such notice will be given at least thirty (30) days prior to the date so specified (or, if earlier, the appointment of the successor Rights Agent). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If the Rights Agent resigns, is removed or becomes incapable of acting, Passage will promptly appoint a qualified successor
                    Rights Agent. Notwithstanding the foregoing, if Passage fails to make such appointment within a period of thirty (30) days after giving notice of such removal or after it has been notified in writing of such resignation or incapacity by
                    the resigning or incapacitated Rights Agent, then the incumbent Rights Agent may apply to any court of competent jurisdiction for the appointment of a new Rights Agent. The successor Rights Agent so appointed will, upon its acceptance
                    of such appointment in accordance with this <span style="text-decoration: underline;">Section&#160;3.3(c)</span> and <span style="text-decoration: underline;">Section&#160;3.4</span>, become the Rights Agent for all purposes hereunder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage will give notice to the Holders of each resignation or removal of the Rights Agent and each appointment of a
                    successor Rights Agent in accordance with <span style="text-decoration: underline;">Section&#160;7.2</span>. Each notice will include the name and address of the successor Rights Agent. If Passage fails to send such notice within ten (10) Business Days after acceptance of
                    appointment by a successor Rights Agent, the successor Rights Agent will cause the notice to be mailed at the expense of Passage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything to the contrary in this <span style="text-decoration: underline;">Section&#160;3.3</span>, unless consented to in writing by the Acting Holders,
                    Passage will not appoint as a successor Rights Agent any Person that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Rights Agent will reasonably cooperate with Passage and any successor Rights Agent in connection with the transition of
                    the duties and responsibilities of the Rights Agent to the successor Rights Agent, including the transfer of all relevant data, including the CVR Register, to the successor Rights Agent, but such predecessor Rights Agent shall not be
                    required to make any additional expenditure or assume any additional liability in connection with the foregoing. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS34"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;3.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Acceptance of Appointment by Successor</span>. Every successor Rights Agent appointed
                    hereunder will, at or prior to such appointment, execute, acknowledge and deliver to Passage and to the resigning or removed Rights Agent an instrument accepting such appointment and a counterpart of this Agreement, and such successor
                    Rights Agent, without any further act, deed or conveyance, will become vested with all the rights, powers, trusts and duties of the Rights Agent; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that upon the request of Passage
                    or the successor Rights Agent, such resigning or removed Rights Agent will execute and deliver an instrument transferring to such successor Rights Agent all the rights, powers and trusts of such resigning or removed Rights Agent. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-11<br/>
        </div>

      </div>

    </div>

    <!--End Page 570-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 571-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="fANXAA4"><!--Anchor--></a>ARTICLE 4<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">COVENANTS </div>

          <a id="fANXAS41"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;4.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">List of Holders</span>. Passage will furnish or cause to be furnished to the Rights Agent,
                    in such form as Passage receives from Passage&#8217;s transfer agent (or other agent performing similar services for Passage), the names and addresses of the Holders within fifteen (15) Business Days following the Closing Date. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS42"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;4.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Efforts</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">During the applicable CVR Period, Passage will, and will cause its Subsidiaries to, use Commercially Reasonable Efforts to
                    collect the Legacy Asset Payments, to the extent payable to Passage. For the avoidance of doubt, during and after the applicable CVR Period, Passage shall not be required to use any efforts to pursue the collection of any Legacy Asset
                    Payments, except as required by this <span style="text-decoration: underline;">Section 4.2(a)</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything herein to the contrary, but subject to <span style="text-decoration: underline;">Section&#160;4.2(a)</span> and <span style="text-decoration: underline;">Section&#160;4.3</span>, (i) Passage
                    and its Affiliates shall have the power and right to control all aspects of their businesses and operations (and all of their assets and products), and subject to Passage&#8217;s compliance with the terms of this Agreement, Passage and its
                    Affiliates may exercise or refrain from exercising such power and right as it may deem appropriate and in the best overall interests of Passage and its Affiliates and its and their stockholders, rather than the interest of the Holders,
                    (ii) none of Passage or any of its Affiliates (or any director, officer, employee, or other representative of the foregoing) owes any fiduciary duty or similar duty or any other implied duties to any Holder in respect of the CVRs, the
                    Legacy Asset Payments or the Gemma Sublicenses, (iii) except as specifically provided in <span style="text-decoration: underline;">Section&#160;4.2(a)</span>, Passage shall have no obligation to take any action in order to obtain, maximize or expedite the receipt of any Legacy
                    Asset Payments or to minimize Permitted Deductions, (iv)&#160;except as expressly set forth in <span style="text-decoration: underline;">Article&#160;3</span> and <span style="text-decoration: underline;">Section&#160;4.2(a)</span>, none of Passage or any of its Subsidiaries shall have any obligation or liability whatsoever to any
                    Person relating to or in connection with any action, or failure to act, with respect to the collection of any Legacy Asset Payment, and (v) in no event shall Passage or any of its Subsidiaries be required to make any payment or advance
                    any funds to Gemma or any other Person (other than <span style="font-style: italic;">de minimis</span> administrative costs) in order to obtain, facilitate, accelerate or otherwise further the receipt of any Legacy Asset Payment. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the requirements of <span style="text-decoration: underline;">Section&#160;4.2(a)</span> and the other contractual obligations of Passage expressly set forth in
                    this Agreement, (i) the Holders acknowledge that Passage has a fiduciary obligation to operate its business in the best interests of its stockholders, and any potential obligation to pay CVR Payments will not create any express or
                    implied obligation to operate its business in any particular manner in order to maximize CVR Proceeds, (ii) except as expressly set forth in this Agreement, the Holders are not relying on any representation of Passage or any other
                    Person with regard to any Legacy Asset Payments or other action involving the Gemma Sublicenses following the Closing, and neither Passage nor any other Person has provided, or can provide, any assurance to the Holders that any CVR
                    Proceeds will in fact be earned and paid, and (iii) none of Passage or any of its Subsidiaries, officers, directors or Affiliates shall have any obligation or liability whatsoever to any Person relating to or in connection with any
                    action, or failure to act, with respect to the collection of any Legacy Asset Payments, and in no event shall any of Passage, its Subsidiaries, directors, officers and Affiliates be deemed to have any fiduciary or similar duties to any
                    Holder by virtue of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Following the expiration of the applicable CVR Period, Passage shall be permitted to take any action in respect of the Gemma
                    Sublicenses in its sole and absolute discretion. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage shall make the GM1 2027 License Payment when due and payable under the Penn License Agreement. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS43"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;4.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Prohibited Actions</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">During the applicable CVR Period, Passage shall not (i) terminate, amend or waive provision of any Gemma Sublicense in a
                    manner that would reasonably be expected to materially and adversely affect Passage&#8217;s ability to collect any Legacy Asset Payments or the rights of the Holders hereunder; (ii) transfer or assign the Gemma Sublicenses, or any rights to
                    receive payments thereunder, to any other Person (other than a Subsidiary of Passage), unless such Person assumes all of Passage&#8217;s obligations under this Agreement; (iii) grant any lien, security interest, pledge or similar interest in
                    any Legacy Asset Payments (other than liens, security interests, pledges or similar interests generally granted with respect to all assets of Passage, and not specific to the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-12<br/>
        </div>

      </div>

    </div>

    <!--End Page 571-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 572-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Legacy Asset Payments, and which do not prohibit the ability of Passage to
            collect any Legacy Asset Payments and, in connection therewith, to distribute the CVR Payments resulting from such Legacy Asset Payments to the Holders, free and clear of such liens and security interests) or any CVR Proceeds; or (iv)&#160;terminate
            the Gemma Sublicenses or the Penn License Agreement, other than a termination by Passage of any Gemma Sublicense or the Penn License Agreement in response to a material breach by Gemma of any Gemma Sublicense (other than a breach by Gemma of
            any payment obligations under the Gemma Sublicenses (including with respect to patent and prosecution costs required to be paid to The Trustees of the University of Pennsylvania under the Penn License Agreement)) or a material breach by The
            Trustees of the University of Pennsylvania of the Penn License Agreement, in each case, that remains uncured following any applicable cure period, if such termination would be reasonable under the circumstances. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything in this Agreement to the contrary, (x) the covenants of Passage set forth in <span style="text-decoration: underline;">Section&#160;4.2</span>
                    shall not be deemed breached on account of Passage&#8217;s failure to (i) hire or retain any new employees specifically for the purpose of collecting the Legacy Asset Payments or (ii) initiate, prosecute or maintain any litigation against
                    Gemma or any other Person in connection with the Legacy Asset Payments; and (y) any exercise by the Acting Holders of enforcement rights under <span style="text-decoration: underline;">Section&#160;7.6</span> with respect to <span style="text-decoration: underline;">Article&#160;4</span> shall be subject to the foregoing
                    limitation. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS44"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;4.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Audit Rights</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Until the termination of this Agreement and for a period of two (2) years thereafter, Passage shall keep, and shall require
                    its Affiliates to keep, complete and accurate books and records to the extent necessary to calculate the CVR Payments payable under this Agreement. The Acting Holders shall have the right to cause an independent certified public
                    accounting firm of nationally recognized standing reasonably acceptable to Passage (the &#8220;<span style="text-decoration: underline;">Independent Accountant</span>&#8221;) to audit such books and records for the sole purpose of confirming the CVR Payments payable hereunder, subject to
                    (x) the prior execution and delivery of a reasonable confidentiality agreement by such Independent Accountant in form and substance reasonably satisfactory to Passage and (y) such access not unreasonably interfering with the conduct of
                    the business of Passage or any of its Affiliates. Upon at least fifteen (15) Business Days&#8217; prior written notice from the Acting Holders, such audit shall be conducted during regular business hours in such a manner as to not
                    unnecessarily interfere with Passage&#8217;s normal business activities. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Such audit shall not be performed more frequently than once per calendar year, and no CVR Payment Period that has been the
                    subject of a prior audit may be audited more than once. The Independent Accountant shall disclose to the Rights Agent or the Acting Holders, as applicable, only whether the calculations are correct or not and the specific details
                    concerning any discrepancies. No other information shall be shared, and in no event shall Passage be required to provide any Tax returns or any other Tax information it deems confidential to the Holders or any other party (other than
                    the Independent Accountant, subject to the confidentiality agreement referenced above). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If the audit reveals an overpayment, Passage shall be entitled to withhold such amount from future CVR Payments. If the audit
                    reveals an underpayment, Passage shall promptly (and in any event within thirty&#160;(30)&#160;days) remit such amount to the Rights Agent for distribution to the Holders. The Acting Holders shall bear the full cost and expense of such audit
                    unless such audit discloses an underpayment by Passage of ten percent (10%) or more of the CVR Payment due under this Agreement for the applicable period, in which case Passage shall bear the full cost and expense of such audit. The
                    Rights Agent shall be entitled to rely on any audit report delivered by the Independent Accountant pursuant to this <span style="text-decoration: underline;">Section 4.4</span> and shall have no duty or liability with respect to, and shall not be deemed to have knowledge of,
                    any adjustment or any event relating thereto unless and until it shall have received such report. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-13<br/>
        </div>

      </div>

    </div>

    <!--End Page 572-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 573-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="fANXAA5"><!--Anchor--></a>ARTICLE 5<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AMENDMENTS </div>

          <a id="fANXAS51"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;5.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Amendments Without Consent of Holders or Rights Agent</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Passage, at any time and from time to time, may enter into one or more amendments to this Agreement for any of the following
                    purposes, without the consent of any of the Holders or the Rights Agent (subject to <span style="text-decoration: underline;">Section&#160;5.3</span>): </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to evidence the appointment of another Person as a successor Rights Agent and the assumption by any successor Rights Agent of
                    the covenants and obligations of the Rights Agent herein in accordance with the provisions hereof; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to evidence the succession of another Person to Passage and the assumption of any such successor of the covenants of Passage
                    outlined herein in a transaction contemplated by <span style="text-decoration: underline;">Section&#160;6.1</span>; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to add to the covenants of Passage such further covenants, restrictions, conditions or provisions for the protection and
                    benefit of the Holders; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that in each case, such provisions shall not adversely affect the rights of the Holders; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to cure any ambiguity, to correct or supplement any provision in this Agreement that may be defective or inconsistent with
                    any other provision in this Agreement, or to make any other provisions with respect to matters or questions arising under this Agreement; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that in each case, such provisions shall
                    not adversely affect the rights of the Holders; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(v)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">as may be necessary or appropriate to ensure that CVRs are not subject to registration under the Securities Act or the
                    Exchange Act and the rules and regulations made thereunder, or any applicable state securities or &#8220;blue sky&#8221; laws; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vi)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">as may be necessary or appropriate to ensure that Passage is not required to produce a prospectus or an admission document in
                    order to comply with applicable Law; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(vii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to cancel CVRs (i) in the event that any Holder has abandoned its rights in accordance with <span style="text-decoration: underline;">Section&#160;2.6</span>, or (ii)
                    following a transfer of such CVRs to Passage or its Subsidiaries in accordance with <span style="text-decoration: underline;">Section&#160;2.2</span> or <span style="text-decoration: underline;">Section&#160;2.3</span>; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(viii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as may be necessary or appropriate to ensure that Passage complies with applicable Law; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ix)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">to effect any other amendment to this Agreement that would provide any additional rights or benefits to the Holders or that
                    does not adversely affect the legal rights under this Agreement of any such Holder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Promptly after the execution by Passage of any amendment pursuant to this <span style="text-decoration: underline;">Section&#160;5.1</span>, Passage will (or will cause
                    the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration: underline;">Section&#160;7.2</span>. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS52"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;5.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Amendments with Consent of Holders</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In addition to any amendments to this Agreement that may be made by Passage without the consent of any Holder or the Rights
                    Agent pursuant to <span style="text-decoration: underline;">Section&#160;5.1</span>, with the consent of the Acting Holders, Passage and the Rights Agent may enter into one or more amendments to this Agreement for the purpose of adding, eliminating or amending any provisions of
                    this Agreement, even if such addition, elimination or amendment is adverse to the interests of the Holders. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Promptly after the execution by Passage and the Rights Agent of any amendment pursuant to the provisions of this <span style="text-decoration: underline;">Section&#160;5.2</span>,
                    Passage will (or will cause the Rights Agent to) notify the Holders in general terms of the substance of such amendment in accordance with <span style="text-decoration: underline;">Section&#160;7.2</span>. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS53"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;5.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Effect of Amendments</span>. Upon the execution of any amendment under this <span style="text-decoration: underline;">Article&#160;5</span>,
                    this Agreement will be modified in accordance therewith, such amendment will form a part of this Agreement for all purposes and every Holder will be bound thereby. Upon the delivery of a certificate from an appropriate officer of
                    Passage which states that the proposed supplement or amendment is in compliance with the terms of this <span style="text-decoration: underline;">Article&#160;5</span>, the Rights Agent shall execute such supplement or amendment. Notwithstanding anything in this Agreement to the
                    contrary, the Rights Agent shall not be required to execute any </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-14<br/>
        </div>

      </div>

    </div>

    <!--End Page 573-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 574-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">supplement or amendment to this Agreement that it has determined would
            adversely affect its own rights, duties, obligations or immunities under this Agreement. No supplement or amendment to this Agreement shall be effective unless duly executed by the Rights Agent. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a id="fANXAA6"><!--Anchor--></a>ARTICLE 6<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">CONSOLIDATION, MERGER, SALE OR CONVEYANCE </div>

          <a id="fANXAS61"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;6.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Successor Substituted</span>. Upon any consolidation of or merger by Passage with or into
                    any other Person, or any conveyance, transfer or lease of substantially all of the properties and assets of Passage to any Person, the surviving Person or acquiring Person (as applicable) shall succeed to, and be substituted for, and
                    may exercise every right and power of, and shall assume all of the obligations of Passage under this Agreement with the same effect as if such Person had been named as Passage herein. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a id="fANXAA7"><!--Anchor--></a>ARTICLE 7<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">MISCELLANEOUS </div>

          <a id="fANXAS71"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Notices to Rights Agent and to Passage</span>. All notices, requests and other
                    communications (each, a &#8220;<span style="text-decoration: underline;">Notice</span>&#8221;) to any party hereunder shall be in writing. Such Notice shall be deemed given (a) on the date of delivery, if delivered in person, by FedEx or other internationally recognized overnight courier
                    service or, (except with respect to any Person other than the Rights Agent), by e-mail (upon confirmation of receipt) prior to 5:00 p.m. in the time zone of the receiving party or on the next Business Day, if delivered after 5:00 p.m.
                    in the time zone of the receiving party or (b) on the first Business Day following the date of dispatch, if delivered by FedEx or by other internationally recognized overnight courier service (upon proof of delivery), addressed as
                    follows: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 432pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Rights Agent, to: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to Passage, to: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Passage Bio, Inc. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">100 Forge Road, Suite 400 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Watertown, MA 02472 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: [&#8226;] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [***] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy, which shall not constitute notice, to: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Latham &amp; Watkins LLP </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">200 Clarendon Street </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02116 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention: Peter Handrinos; Leah Sauter </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 403pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [***]</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 403pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">or to such other address or facsimile number as such party may hereafter
            specify for the purpose by notice to the other parties hereto. </div>

          <a id="fANXAS72"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.2<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Notice to Holders</span>. All Notices required to be given to the Holders will be given
                    (unless otherwise herein expressly provided) in writing and mailed, first-class postage prepaid, to each Holder at such Holder&#8217;s address as set forth in the CVR Register, not later than the latest date, and not earlier than the earliest
                    date, prescribed for the sending of such Notice, if any, and will be deemed given on the date of mailing. In any case where notice to the Holders is given by mail, neither the failure to mail such Notice, nor any defect in any Notice so
                    mailed, to any particular Holder will affect the sufficiency of such Notice with respect to other Holders. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-15<br/>
        </div>

      </div>

    </div>

    <!--End Page 574-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 575-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="fANXAS73"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.3<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Entire Agreement</span>. As between Passage and the Rights Agent, this Agreement
                    constitutes the entire agreement between the parties with respect to the subject matter of this Agreement, notwithstanding the reference to any other agreement herein, and supersedes all prior agreements and understandings, both written
                    and oral, among or between any of the parties with respect to the subject matter of this Agreement. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS74"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.4<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Merger or Consolidation or Change of Name of Rights Agent</span>. Any Person into which the
                    Rights Agent or any successor Rights Agent may be merged or with which it may be consolidated, or Person resulting from any merger or consolidation to which the Rights Agent or any successor Rights Agent shall be a party, or any Person
                    succeeding to the stock transfer or other shareholder services business of the Rights Agent or any successor Rights Agent, shall be the successor to the Rights Agent under this Agreement without the execution or filing of any paper or
                    any further act on the part of any of the parties hereto, <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that such Person would be eligible for appointment as a successor Rights Agent under the provisions of <span style="text-decoration: underline;">Section&#160;3.3</span>.
                    The purchase of all or substantially all of the Rights Agent&#8217;s assets employed in the performance of transfer agent activities shall be deemed a merger or consolidation for purposes of this <span style="text-decoration: underline;">Section&#160;7.4</span>. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS75"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.5<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Successors and Assigns</span>. This Agreement will be binding upon, and will be enforceable
                    by and inure solely to the benefit of, the Holders, Passage and the Rights Agent and their respective successors and assigns. Except for assignments pursuant to <span style="text-decoration: underline;">Section&#160;7.4</span>, the Rights Agent may not assign this Agreement without
                    Passage&#8217;s prior written consent. Subject to <span style="text-decoration: underline;">Section&#160;5.1(a)(ii)</span> and <span style="text-decoration: underline;">Article&#160;6</span> hereof, Passage may assign, in its sole discretion and without the consent of any other party, any or all of its rights, interests and
                    obligations hereunder to one or more of its Affiliates or to any Person with whom Passage is merged or consolidated, or any entity resulting from any merger or consolidation to which Passage shall be a party (each, an &#8220;<span style="text-decoration: underline;">Assignee</span>&#8221;);

                    <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span>, <span style="font-style: italic;"><span style="text-decoration: underline;">however</span></span>, that in connection with any assignment to an Assignee, Passage shall agree to remain liable for the performance by
                    Passage of its obligations hereunder (to the extent Passage exists following such assignment). Passage or an Assignee may not otherwise assign this Agreement without the prior consent of the Acting Holders (such consent not to be
                    unreasonably withheld, conditioned or delayed). Any attempted assignment of this Agreement in violation of this <span style="text-decoration: underline;">Section&#160;7.5</span> will be void <span style="font-style: italic;">ab initio</span> and of no effect. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS76"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.6<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Benefits of Agreement; Action by Acting Holders</span>. Nothing in this Agreement, express
                    or implied, will give to any Person (other than Passage, the Rights Agent, the Holders and their respective permitted successors and assigns hereunder) any benefit or any legal or equitable right, remedy or claim under this Agreement or
                    under any covenant or provision herein contained, all such covenants and provisions being for the sole benefit of Passage, the Rights Agent, the Holders and their permitted successors and assigns. The Holders will have no rights
                    hereunder except as are expressly set forth herein (including the right of the Acting Holders to enforce the obligations of Passage pursuant to <span style="text-decoration: underline;">Article&#160;4</span>, on behalf of the Holders, as third-party beneficiaries of such
                    obligations). Except for the rights of the Rights Agent set forth herein, the Acting Holders will have the sole right, on behalf of all Holders, by virtue of or under any provision of this Agreement, to institute any action or
                    proceeding at law or in equity with respect to this Agreement, and no individual Holder or other group of Holders will be entitled to exercise such rights. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS77"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.7<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Governing Law</span>. This Agreement and the CVRs will be governed by, and construed in
                    accordance with, the laws of the State of Delaware (without giving effect to any rule or principle that would result in application of the law of any other jurisdiction) and for all purposes shall be governed by and construed in
                    accordance with the laws of such State applicable to contracts to be made and performed entirely within such State. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS78"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.8<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Jurisdiction</span>. In any action or proceeding between any of the parties hereto arising
                    out of or relating to this Agreement or any of the transactions contemplated hereby, each of the parties hereto: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery
                    of the State of Delaware or, if under applicable Law exclusive jurisdiction is vested in the Federal courts, the United States District Court for the District of Delaware (and appellate courts thereof); (b) agrees that all claims in
                    respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (a) of this <span style="text-decoration: underline;">Section&#160;7.8</span>; (c) waives any objection to laying venue in any such action or proceeding in such courts; (d)
                    waives any objection that such courts are an </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-16<br/>
        </div>

      </div>

    </div>

    <!--End Page 575-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 576-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 60pt; text-align: justify;">inconvenient forum or do not have jurisdiction over any party hereto; and
            (e) agrees that service of process upon such party hereto in any such action or proceeding shall be effective if notice is given in accordance with <span style="text-decoration: underline;">Section&#160;7.1</span> or <span style="text-decoration: underline;">Section&#160;7.2</span> of this Agreement. </div>

          <a id="fANXAS79"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.9<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic; font-weight: bold;">WAIVER OF JURY TRIAL</span>. <span style="font-weight: bold;">EACH OF
                      THE PARTIES HERETO (AND BY ACCEPTING THE CVRS, THE HOLDERS) HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. EACH
                      PARTY HERETO CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE
                      FOREGOING WAIVER, (II) EACH PARTY HERETO UNDERSTANDS AND HAS CONSIDERED THE IMPLICATION OF THIS WAIVER, (III) EACH PARTY HERETO MAKES THIS WAIVER VOLUNTARILY, AND (IV)&#160;EACH PARTY HERETO HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
                      BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS <span style="text-decoration: underline;">SECTION 7.9</span>.</span> </div>
                </td>

  </tr>


</table>
          <a id="fANXAS710"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Severability Clause</span>. In the event that any provision of this Agreement, or the
                    application of any such provision to any Person or set of circumstances, is for any reason determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision
                    to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, will not be impaired or otherwise affected and will continue to be valid and enforceable to the fullest extent
                    permitted by applicable Law. Upon such a determination, the parties hereto will negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner
                    in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span>, <span style="font-style: italic;"><span style="text-decoration: underline;">however</span></span>,
                    that if an excluded provision shall affect the rights, immunities, liabilities, duties or obligations of the Rights Agent, the Rights Agent shall be entitled to resign immediately upon written notice to Passage. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS711"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Counterparts; Effectiveness</span>. This Agreement may be signed in any number of
                    counterparts, each of which will be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement or any counterpart may be executed and delivered by electronic
                    communications by portable document format (.pdf), each of which shall be deemed an original. This Agreement will become effective when each party hereto will have received a counterpart hereof signed by the other party hereto. Until
                    and unless each party hereto has received a counterpart hereof signed by the other party hereto, this Agreement will have no effect and no party will have any right or obligation hereunder (whether by virtue of any oral or written
                    agreement or any other communication). </div>
                </td>

  </tr>


</table>
          <a id="fANXAS712"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.12<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Termination</span>. This Agreement will automatically terminate with respect to an
                    applicable Legacy Asset Payment and be of no further force or effect and, except as provided in <span style="text-decoration: underline;">Section&#160;3.2</span>, the parties hereto will have no further liability hereunder, and the CVRs will expire without any consideration or
                    compensation therefor with respect to the applicable Legacy Asset Payment, upon the earlier of (a) the expiration of the applicable CVR Period and (b) the date on which all Legacy Asset Payments have been received and all CVR Payments
                    in respect thereof have been distributed to the Holders. The termination of this Agreement will not affect or limit the right of Holders to receive the CVR Payments under <span style="text-decoration: underline;">Section&#160;2.4</span> to the extent earned prior to the termination
                    of this Agreement, and the provisions applicable thereto will survive the expiration or termination of this Agreement; <span style="font-style: italic;"><span style="text-decoration: underline;">provided</span></span> that, notwithstanding anything to the contrary herein, if
                    the MLD Payments remain invoiced to Gemma but unpaid as of December&#160;31, 2027, the Holders shall have no right to CVR Payments related to MLD Payments following such date. </div>
                </td>

  </tr>


</table>
          <a id="fANXAS713"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Force Majeure</span>. Notwithstanding anything to the contrary contained herein, none of
                    the Rights Agent, Passage or any of its Subsidiaries (except as it relates to the obligations of the Company (and the Surviving Corporation) under <span style="text-decoration: underline;">Article&#160;3</span>) will be liable for any delays or failures in performance resulting
                    from acts beyond its reasonable control including acts of God, pandemics (including COVID-19), terrorist acts, shortage of supply, breakdowns or malfunctions, interruptions or malfunctions of computer facilities, or loss of data due to
                    power failures or mechanical difficulties with information storage or retrieval systems, labor difficulties, war or civil unrest. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-17<br/>
        </div>

      </div>

    </div>

    <!--End Page 576-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 577-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <a id="fANXAS714"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Section&#160;7.14<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="font-style: italic;">Construction</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">For purposes of this Agreement, whenever the context requires: singular terms will include the plural, and vice versa; the
                    masculine gender will include the feminine and neuter genders; the feminine gender will include the masculine and neuter genders; and the neuter gender will include the masculine and feminine genders. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, will not be deemed to be terms of
                    limitation, but rather will be deemed to be followed by the words &#8220;without limitation.&#8221; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The headings contained in this Agreement are for convenience of reference only, will not be deemed to be a part of this
                    Agreement and will not be referred to in connection with the construction or interpretation of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any reference in this Agreement to a date or time shall be deemed to be such date or time in New York City, United States,
                    unless otherwise specified. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as
                    if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any Person by virtue of the authorship of any provision of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">All references herein to &#8220;$&#8221; are to United States Dollars. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">[<span style="font-style: italic;">Remainder of page intentionally left blank</span>] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-18<br/>
        </div>

      </div>

    </div>

    <!--End Page 577-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 578-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_305-annexf_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">IN WITNESS WHEREOF, each of the parties has caused this Agreement to be
            executed as of the day and year first&#160;above written. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 468pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 468pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">PASSAGE BIO, INC.</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 468pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="7" style="width: 468pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;], as Rights Agent </div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">[Signature Page to CVR Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">F-19<br/>
        </div>

      </div>

    </div>

    <!--End Page 578-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 579-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXG"><!--Anchor--></a>Annex&#160;G </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; text-align: center;">SUBSCRIPTION AGREEMENT </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This Subscription Agreement (this &#8220;<span style="font-style: italic; font-weight: bold;">Agreement</span>&#8221;) is made and entered into as of June&#160;24, 2026 (the &#8220;<span style="font-style: italic; font-weight: bold;">Effective Date</span>&#8221;) by and among Remix Therapeutics, Inc., a Delaware corporation (the &#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221;), and each of the purchasers listed on the <span style="text-decoration: underline;">Schedule of Purchasers </span>attached hereto, severally and not jointly (each a &#8220;<span style="font-style: italic; font-weight: bold;">Purchaser</span>&#8221;
            and together the &#8220;<span style="font-style: italic; font-weight: bold;">Purchasers</span>&#8221;). Certain terms used and not otherwise defined in the text of this Agreement are defined in <span style="text-decoration: underline;">Section&#160;8</span> hereof. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; text-align: center;">RECITALS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, the Company is party to that certain Agreement and Plan of Merger by
            and among the Company, Peregrine Merger Sub, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">Merger Sub</span>&#8221;), and Passage Bio, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">Passage</span>&#8221;), dated on or about the
            date hereof (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger Agreement</span>&#8221;), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Passage (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, the Company desires to sell to the Purchasers, and the Purchasers,
            severally and not jointly, desire to purchase from the Company, an aggregate amount equal to $69,999,999.28 (the &#8220;<span style="font-style: italic; font-weight: bold;">Total Subscription Amount</span>&#8221;) of shares of the Company&#8217;s Common Stock,
            par value $0.0001 per share (the &#8220;<span style="font-style: italic; font-weight: bold;">Common Stock</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, the Company and each Purchaser is executing and delivering this
            Agreement in reliance upon the exemption from securities registration afforded by Section&#160;4(a)(2) of the 1933 Act and/or in reliance upon any of the safe harbors set forth in Regulation D thereunder; and </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, at the Effective Time (as defined in the Merger Agreement) by virtue
            of the Merger, the shares of Common Stock shall be automatically converted into the right to receive a number of shares of common stock par value $0.0001&#160;per share, of Passage (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage
              Common Stock</span>&#8221;), in accordance with Section&#160;2.4(d) of the Merger Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NOW, THEREFORE, in consideration of the foregoing and the mutual
            representations, warranties and covenants herein contained, the parties hereto hereby agree as follows: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Authorization of Securities</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company has authorized the sale and issuance of shares of Common Stock on the terms and subject to the conditions set
                    forth in this Agreement. The shares of Common Stock sold hereunder at the Closing (as defined below) shall be referred to as the &#8220;<span style="font-style: italic; font-weight: bold;">Securities</span>&#8221;. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Sale and Purchase of the Securities</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Upon the terms and subject to the conditions herein contained (including the satisfaction or waiver of the closing conditions
                    set forth in <span style="text-decoration: underline;">Section&#160;6</span>), the Company agrees to sell and issue to each Purchaser, and each Purchaser agrees, severally and not jointly, to purchase from the Company, at a closing to take place remotely via exchange of executed
                    documents (the &#8220;<span style="font-style: italic; font-weight: bold;">Closing</span>&#8221; and the date of the Closing, the &#8220;<span style="font-style: italic; font-weight: bold;">Closing Date</span>&#8221;) to occur immediately prior to the
                    Effective Time (as such term is defined in the Merger Agreement), that number of Securities equal to (rounded down to the nearest whole share) (i) the aggregate commitment amount set forth under the heading &#8220;Subscription Amount&#8221; and
                    opposite such Purchaser&#8217;s name on the Schedule of Purchasers (the &#8220;<span style="font-style: italic; font-weight: bold;">Subscription Amount</span>&#8221;) divided by (ii) the Purchase Price (as may be adjusted pursuant to <span style="text-decoration: underline;">Section&#160;2.04</span>
                    hereof). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.02<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Upon written notice from (or on behalf of) the Company to the Purchasers (the &#8220;<span style="font-style: italic; font-weight: bold;">Wire Instructions Notice</span>&#8221;) at least three Business Days prior to the date that the Company reasonably expects all conditions to the closing of the Merger to be satisfied, each Purchaser will pay the Subscription Amount
                    set forth opposite such Purchaser&#8217;s name on the Schedule of Purchasers by wire transfer of immediately available funds in accordance with the Wire Instructions Notice at least two Business Days prior to the Closing. The Wire
                    Instructions Notice shall include an express acknowledgement that the Company reasonably expects all conditions to the closing of the Merger under the Merger Agreement to be satisfied on the Closing Date. If so requested by the Company
                    in the Wire Instructions Notice and agreed by the applicable Purchaser, the Subscription Amount of each Purchaser shall be paid into an escrow fund or trust account designated by the Company in writing (the &#8220;<span style="font-style: italic; font-weight: bold;">Escrow Account</span>&#8221;) to be released to the Company only upon satisfaction of each </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 579-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 580-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">of the closing conditions set forth in <span style="text-decoration: underline;">Section&#160;6</span> below. In the
            event the Closing does not occur within three Business Days of the Closing Date specified in the Wire Instructions Notice, unless otherwise agreed by the Company and such Purchaser, the Company shall, or shall cause the escrow agent for the
            Escrow Account to, promptly (but not later than one Business Day thereafter) return the aggregate Subscription Amount to each Purchaser by wire transfer of U.S. dollars in immediately available funds to the account specified by such Purchaser.
            On the Closing Date, the Company will deliver, against payment by each Purchaser of its Subscription Amount, the Securities in book-entry form registered in the name of the Purchaser (or its nominee as instructed by the Purchaser) free and
            clear of any liens or other restrictions (other than those arising under applicable securities laws, and shall provide evidence of such issuance from Passage&#8217;s transfer agent as of the Closing Date to each Purchaser. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.03<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything to the contrary in this Agreement, the (i) Schedule of Purchasers and (ii) the aggregate
                    Subscription Amount may be amended by the Company and the affected Purchaser (which may be a new Purchaser) prior to the effectiveness of the Registration Statement, without the consent of the other parties hereto, to reflect the actual
                    number of Securities purchased by each Purchaser at the Closing, <span style="font-style: italic;">provided</span> that (x) the Company shall provide to Purchasers such updated Schedule of Purchasers, (y) the aggregate Subscription
                    Amount of all Purchasers after giving effect to such amendment shall not be less than the Total Subscription Amount and (z) no Purchaser&#8217;s Subscription Amount be increased without such Purchaser&#8217;s prior written consent. For the
                    avoidance of doubt, the Company may, with the approval of the Purchaser Majority, add additional purchasers (each of whom shall execute a joinder to this Agreement and make the representations set forth in <span style="text-decoration: underline;">Section&#160;3</span>) at any time
                    prior to the effectiveness of the Registration Statement, provided that the Purchase Price paid by such additional purchasers is equal to or greater than the Purchase Price. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.04<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In the event of any stock split, subdivision, dividend or distribution payable in shares of Common Stock (or other securities
                    or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing, each
                    reference in this Agreement to a number of shares or a price per share shall be deemed to be amended to appropriately account for such event. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Representations and Warranties of the Purchasers</span>. Each Purchaser, severally and not jointly, represents and warrants
                    to the Company and the Placement Agents that: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Organization</span>. The Purchaser is duly organized, validly existing and in good standing under the laws of the
                    jurisdiction of its organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.02<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Validity</span>. The execution, delivery and performance of this Agreement and the consummation by the Purchaser of the
                    transactions contemplated hereby have been duly authorized by all necessary corporate, partnership, limited liability or similar actions, as applicable, on the part of such Purchaser. This Agreement has been duly executed and delivered
                    by the Purchaser and, assuming that this Agreement constitutes the valid and binding obligation of the Company, constitutes a valid and binding obligation of the Purchaser, enforceable against it in accordance with its terms, except as
                    limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditors&#8217; rights generally, and as limited by laws relating to the
                    availability of specific performance, injunctive relief, or other equitable remedies. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.03<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Brokers</span>. There is no broker, investment banker, financial advisor, finder or other person which has been retained by
                    or is authorized to act on behalf of the Purchaser who is entitled to any fee or commission for which the Company will be liable in connection with the execution of this Agreement and the consummation of the transactions contemplated
                    hereby. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.04<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Investment Representations and Warranties</span>. The Purchaser understands and agrees that the offering and sale of the
                    Securities has not been registered under the 1933 Act or any applicable state securities laws or the securities laws of any other jurisdiction and is being made in reliance upon federal and state exemptions for transactions not
                    involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser&#8217;s representations as expressed herein. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 580-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 581-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.05<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Acquisition for Own Account</span>. The Purchaser is acquiring the Securities for its own account for investment purposes and
                    not with a view towards distribution in a manner which would violate the 1933&#160;Act or any applicable state or federal securities laws. The Purchaser has not been formed for the specific purpose of acquiring the Securities. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.06<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No General Solicitation</span>. The Purchaser is not purchasing the Securities as a result of any advertisement, article,
                    notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general
                    advertisement. The purchase of the Securities by the Purchaser has not been solicited by or through anyone other than the Company or, on the Company&#8217;s behalf, Goldman Sachs &amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. (the &#8220;<span style="font-style: italic; font-weight: bold;">Placement Agents</span>&#8221;), who have been engaged as joint placement agents for the offering of the Securities; provided that the Company may engage additional Placement Agents from time
                    to time in its sole discretion. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.07<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Ability to Protect Its Own Interests and Bear Economic Risks</span>. The Purchaser is a sophisticated institutional investor,
                    has the capacity to protect its own interests in connection with the transactions contemplated by this Agreement, and has sufficient knowledge and experience in investing in investments similar to the Securities to properly evaluate the
                    merits and risks of the investment in the Securities. The Purchaser is able to bear the substantial risks of an investment in the Securities including but not limited to loss of the Purchaser&#8217;s entire investment therein. The Purchaser
                    has exercised independent judgment in evaluating its participation in the purchase of the Securities, and has determined based on its own independent review and such professional advice as it deems appropriate that its purchase of the
                    Securities and participation in the transactions contemplated by this Agreement (i) are consistent with the Purchaser&#8217;s financial needs, objectives and applicable investment policies or guidelines, (ii) do not and will not violate or
                    constitute a default under the Purchaser&#8217;s charter, bylaws or other constituent document or under any law, rule, regulation, agreement or other obligation by which it is bound, except to the extent such non-compliance, violation or
                    default would not materially and adversely affect the Purchaser&#8217;s ability to consummate the transactions contemplated by this Agreement, and (iii) is a fit, proper and suitable investment for the Purchaser, notwithstanding the
                    substantial risks inherent in investing in or holding the Securities. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.08<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Accredited Investor</span>. The Purchaser is (i) a qualified institutional buyer (as defined in Rule&#160;144A of the 1933 Act),
                    or (ii) an &#8220;accredited investor&#8221; within the meaning of Rule&#160;501(a) (1), (2), (3) or (7) under the 1933 Act. Accordingly, the Purchaser understands that the offering meets the exemptions from filing under FINRA Rule&#160;5123(b)(1)(C) or (J).
                    The Purchaser is an institutional account as defined in FINRA Rule&#160;4512(c). Accordingly, the Purchaser has also been advised that the offering meets (i) the exemptions from filing under FINRA Rule&#160;5123(b)(1)(A) and (ii) the
                    institutional customer exemption under FINRA Rule&#160;2111(b). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.09<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Restricted Securities</span>. The Purchaser understands that the Securities are being offered in a transaction not involving
                    any public offering within the meaning of the 1933 Act in a transaction exempt from the registration requirements of the 1933 Act, and will be characterized as &#8220;restricted securities&#8221; under the federal securities laws inasmuch as they
                    are being acquired from the Company in a private placement under Section&#160;4(a)(2) of the 1933 Act and that, under such laws and applicable regulations, such Securities may be resold without registration under the 1933 Act only in certain
                    limited circumstances. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Review and Advisors</span>. The Purchaser has had the opportunity to review with the Purchaser&#8217;s own tax advisors the
                    federal, state and local tax consequences of its purchase of the Securities set forth opposite such Purchaser&#8217;s name on the Schedule of Purchasers and the transactions contemplated by this Agreement. The Purchaser is relying solely on
                    the Purchaser&#8217;s own determination as to tax consequences, and on the Purchaser&#8217;s own sources of information and advisors with respect to all tax matters, and not on any statements or representations of the Company (other than the
                    representations and warranties in this Agreement), the Placement Agents or any of their respective agents, and understands that the Purchaser (and not the Company) shall be responsible for the Purchaser&#8217;s own tax liability that may
                    arise as a result of the transactions contemplated by this Agreement. Based on such information as the Purchaser deemed appropriate and without reliance upon the Placement Agents, the Purchaser has independently made its own analysis
                    and decision to purchase the Securities. The Purchaser has (i) had the opportunity to ask questions of and receive answers directly with respect to its purchase of Securities, and (ii) conducted and completed its own </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 581-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 582-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">independent due diligence with respect to the purchase of Securities.
            Neither such inquiries nor any other due diligence investigation conducted by the Purchaser shall modify, limit or otherwise affect such Purchaser&#8217;s right to reasonably rely on the Company&#8217;s representations and warranties contained in this
            Agreement. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Residency</span>. Such Purchaser&#8217;s residence (if an individual) or offices in which its investment decision with respect to
                    the Securities was made (if an entity) are located at the address immediately below such Purchaser&#8217;s name on the Schedule of Purchasers, or as otherwise noted on the Schedule of Purchasers. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.12<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Disclosure of Information</span>. The Purchaser has had an opportunity to review Passage&#8217;s 1934 Act filings, such audited
                    financial information of Passage for the years ended December&#160;31, 2024 and December&#160;31, 2025, the Company&#8217;s &#8220;PIPE Presentation&#8221;, including the risk factors in the &#8220;PIPE Presentation&#8221;, as most recently provided to such Purchaser in
                    connection herewith, and such other information as the undersigned deems necessary in order to make an investment decision with respect to the Securities, and discuss the Company&#8217;s business, management, financial affairs and the terms
                    and conditions of the offering of the Securities and the terms and related risks of the Merger with the Company&#8217;s management. The foregoing, however, does not limit or modify the representations and warranties of the Company in <span style="text-decoration: underline;">Section&#160;4</span>
                    of this Agreement or the right of the Purchasers to rely thereon. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Placement Agents</span>. Such Purchaser hereby acknowledges and agrees that it has independently evaluated the merits of its
                    decision to purchase the Securities, and that (a) the Placement Agents are acting solely as placement agents in connection with the execution, delivery and performance of this Agreement, the Registration Rights Agreement or the Merger
                    Agreement and are not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for such Purchaser, the Company or any other Person in connection with the execution, delivery and performance
                    of this Agreement, the Registration Rights Agreement or the Merger Agreement, (b) the Placement Agents have not made and will not make any representation or warranty, whether express or implied, of any kind or character and has not
                    provided any advice or recommendation in connection with the execution, delivery and performance of this Agreement, the Registration Rights Agreement or the Merger Agreement and (c) the Placement Agents will not have any responsibility
                    with respect the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.14<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Conflicts</span>. The execution, delivery and performance of this Agreement by the Purchaser, the purchase of the
                    Securities in accordance with their terms and the consummation by the Purchaser of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by such Purchaser (with or without
                    notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material benefit under (i) any provision of the
                    organizational documents of the Purchaser, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii) any agreement or instrument,
                    undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Purchaser or its respective properties or assets, except, in the case of clause (ii), as would
                    not, individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of the Purchaser to perform its obligations under this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Representations and Warranties by the Company</span>. The Company represents and warrants to the Purchasers and the Placement
                    Agents that: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Absence of Changes</span>. The Company has conducted its business only in the ordinary course of business (except for the
                    execution and performance of this Agreement and the Merger Agreement, and the discussions, negotiations, and transactions related thereto) and since the incorporation of the Company (i) there has not been any change, condition, event,
                    circumstance, occurrence, result, state of facts or development that has or would reasonably be expected to have a materially adverse effect on the business, condition (financial or otherwise), general affairs, management, prospects,
                    assets, liabilities, operations, results of operations, stockholders&#8217; equity or financial performance of the Company and its subsidiaries, taken as a whole (a &#8220;<span style="font-style: italic; font-weight: bold;">Material Adverse Effect</span>&#8221;);

                    provided, however, that none of the following, alone or in combination, shall be deemed to constitute, or shall be taken into account in determining whether there has been, a Material Adverse Effect: (A) changes in general economic,
                    regulatory or political conditions in the United States or changes in conditions in the U.S. financial, credit or securities markets generally (including changes in interest rates and </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 582-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 583-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">exchange rates) provided that the Company is not disproportionately
            affected thereby, (B) changes, conditions or developments in the industries in which the Company operates provided that the Company is not disproportionately affected thereby, (C) material changes in applicable law or in GAAP or in accounting
            standards, or any material changes in the interpretation or enforcement of any of the foregoing, (D) acts of war (whether or not declared), sabotage, terrorism, natural disasters, epidemics, pandemics or other force majeure events provided that
            the Company is not disproportionately affected thereby, (E) changes resulting from the announcement or pendency of the Merger or any of the transactions contemplated by this Agreement or the Merger Agreement, and (F) any failure by the Company
            to meet any internal or published projections, forecasts or revenue or earnings predictions for any period (provided that the underlying causes of such failure may be taken into account in determining whether there is a Material Adverse Effect
            to the extent not otherwise excluded by this proviso), (ii) there have been no transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of business (which shall include entering into material
            licensing and collaboration agreements and preferred stock and convertible note financings) and except as contemplated in this Agreement and the Merger Agreement, which are material with respect to the Company and its subsidiaries considered as
            one enterprise, and (iii) there has been no dividend or distribution of any kind declared, paid or made by the Company on any class of its capital stock. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.02<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Organization and Good Standing of the Company</span>. The Company and its subsidiaries have been duly organized or
                    incorporated (as applicable) and are validly existing and in good standing (as applicable) under the laws of their respective jurisdictions of organization or incorporation, and have all necessary power and authority (i) to conduct the
                    business in which they are engaged in all material respects in the manner in which their respective business is currently being conducted, (ii) to own or lease and use their respective property and assets in the manner in which their
                    respective property and assets are currently owned or leased and used in all material respects and (iii) to perform their respective obligations under all contracts by which they are bound in all material respects. The Company and its
                    subsidiaries are each duly qualified as a foreign corporation (or other applicable entity) to transact business and are in good standing in each other jurisdiction in which such qualification is required, whether by ownership or leasing
                    of property or the conduct of business, except where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.03<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Subsidiaries</span>. The Company does not have any subsidiaries, other than the Remix Securities Corporation, and does not
                    otherwise own any shares of capital stock or any interest in any other Person. The Company does not control directly or indirectly or have any direct or indirect equity participation or similar interest in any corporation, partnership,
                    limited liability company, joint venture, trust or other business association or entity. The Company owns 100% of the equity interests of each of its subsidiaries. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.04<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Validity; Valid Issuance of Securities</span>. The Company has all requisite corporate power and authority to enter into this
                    Agreement, the Registration Rights Agreement and the Merger Agreement and to consummate the transactions contemplated by this Agreement, the Registration Rights Agreement and the Merger Agreement, subject only to (i) the adoption of the
                    Merger Agreement in accordance with the terms thereof and an amendment to the Company&#8217;s certificate of incorporation by the Company&#8217;s stockholders under the Delaware General Corporation Law, (ii) the filing of an amendment to the
                    Company&#8217;s certificate of incorporation, and (iii) the consent required by the Company&#8217;s stockholders to terminate the Company&#8217;s investor agreements. The execution and delivery of this Agreement, the Registration Rights Agreement and the
                    Merger Agreement and the consummation of the transactions contemplated by this Agreement, the Registration Rights Agreement and the Merger Agreement by the Company have been duly authorized by all necessary corporate action on the part
                    of the Company, subject to obtaining the stockholder approvals set forth above. Assuming the due authorization, execution and delivery by each Purchaser, this Agreement the Registration Rights Agreement and the Merger Agreement each
                    constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance,
                    and any other laws of general application affecting enforcement of creditors&#8217; rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. The Securities
                    are duly authorized and, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free and clear of any liens or other
                    restrictions, other than restrictions on transfer under applicable state and federal securities laws or such restrictions as the Purchaser has agreed to in writing with the Company, and will not have been issued in </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 583-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 584-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">violation of or subject to any preemptive or similar rights created under
            the Company&#8217;s certificate of incorporation, as amended by the certificate of amendment to be filed immediately prior to the Closing, or bylaws or the Delaware General Corporation Law. All of the issued and outstanding shares of capital stock of
            the Company have been issued in compliance in all material respects with applicable federal and state securities laws. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.05<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Governmental Consents and Filings</span>. Assuming the accuracy of the representations made by the Purchasers in <span style="text-decoration: underline;">Section&#160;3</span>
                    hereof and except as set forth in the Merger Agreement and the Registration Rights Agreement and the filing of the certificate of amendment to the Company&#8217;s certificate of incorporation, no material consent, approval, order or
                    authorization of, or registration, qualification, designation, declaration or filing with, any Governmental Entity (as defined below) is required on the part of the Company in connection with the consummation of the transactions
                    contemplated by this Agreement, except for filings pursuant to Regulation D of the 1933 Act and applicable state securities laws, which have been made or will be made in a timely manner. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.06<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Absence of Violations, Defaults and Conflicts</span>. Neither the Company nor any of its subsidiaries is (i) in violation of
                    its charter, bylaws or similar organizational document, (ii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit
                    agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound or to which any of the properties or assets of the Company or any subsidiary
                    is subject (collectively, &#8220;<span style="font-style: italic; font-weight: bold;">Agreements and Instruments</span>&#8221;), except for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (iii) in
                    violation of any law, statute, rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company
                    or any of its subsidiaries or any of their respective properties, assets or operations (each, a &#8220;<span style="font-style: italic; font-weight: bold;">Governmental Entity</span>&#8221;), except for such violations that would not, singly or in
                    the aggregate, result in a Material Adverse Effect. Subject to obtaining the Required Remix Stockholder Vote (as defined in the Merger Agreement), the execution, delivery and the performance of this Agreement and the Merger Agreement
                    and the consummation of the transactions contemplated herein (including the issuance and sale of the Securities) and compliance by the Company with its obligations hereunder do not and will not, whether with or without the giving of
                    notice or passage of time or both, (1) conflict with or constitute a breach of, or default under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of the Company or any subsidiary
                    pursuant to, the Agreements and Instruments, (2) result in any violation of the provisions of the certificate of incorporation, by-laws or similar organizational document of the Company or any of its subsidiaries or (3) result in any
                    violation of any applicable law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity, except in the case of clauses&#160;(1)&#160;and (3), for such violations as would not, singly or in the aggregate, have or
                    reasonably be expected to have a Material Adverse Effect, or materially affect the validity of the Securities or the legal authority of the Company to perform its obligations hereunder and timely comply in all material respects with the
                    terms of this Agreement or the Merger Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.07<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Absence of Proceedings</span>. There is no action, suit, proceeding or, to the knowledge of the Company, inquiry or
                    investigation, before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which would have or reasonably be expected to be
                    material to the Company and its subsidiaries, taken as a whole, or materially and adversely affect the validity of the Securities or the legal authority of the Company to perform its obligations hereunder and timely comply in all
                    material respects with the terms of this Agreement or the Merger Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.08<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Possession of Licenses and Permits</span>. The Company and its subsidiaries possess such permits, licenses, approvals,
                    consents and other authorizations (collectively, &#8220;<span style="font-style: italic; font-weight: bold;">Governmental Licenses</span>&#8221;) issued by the appropriate Governmental Entities necessary to conduct the business now operated by
                    them, except where the failure so to possess would not, singly or in the aggregate, reasonably be expected to be material to the Company or any of its subsidiaries, taken as a whole. The Company and its subsidiaries are in compliance
                    with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, reasonably be expected to be material to the Company or any of its subsidiaries, taken as a whole.
                    All of the Governmental Licenses are valid and in full force and effect, except when the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 584-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 585-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">invalidity of such Governmental Licenses or the failure of such
            Governmental Licenses to be in full force and effect would not, singly or in the aggregate, reasonably be expected to be material to the Company or any of its subsidiaries, taken as a whole. Neither the Company nor any of its subsidiaries has
            received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would reasonably be expected to be
            material to the Company or any of its subsidiaries, taken as a whole. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.09<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Payment of Taxes</span>. All United States federal income tax returns of the Company and its subsidiaries required by law to
                    be filed have been filed and all U.S. federal income taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to
                    which adequate reserves have been provided. No assessment in connection with United States federal tax returns has been made against the Company. The Company and its subsidiaries have filed all other material tax returns that are
                    required to have been filed by them or have timely requested extensions thereof pursuant to applicable foreign, state, local or other law, and has paid all material taxes due pursuant to such returns or all material taxes due and
                    payable pursuant to any assessment received by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by the Company or its
                    subsidiaries. There are no (i)&#160;examinations or audits of any tax return of the Company or its subsidiaries that are pending or in progress involving any material taxes or (ii) unresolved written claims that have been received by the
                    Company or its subsidiaries from any governmental body in any jurisdiction where the Company or any such subsidiary, as applicable, does not file tax returns that the Company or any such subsidiary is or may be subject to taxes in that
                    jurisdiction. No extension or waiver of the statute of limitation period applicable to any material tax returns of the Company or material tax has been granted and is currently in effect other than automatic extensions of the time in
                    which to file a tax return of the Company obtained in the ordinary course of business. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Insurance</span>. The Company and the subsidiaries carry or are entitled to the benefits of insurance, with what the Company
                    reasonably believes to be financially sound and reputable insurers, in such amounts and covering such risks as is adequate for the conduct of their respective businesses and the value of their respective properties and assets, and all
                    such insurance is in full force and effect. The Company has no reason to believe that it or any of the subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain
                    comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not reasonably be expected to be material to the Company or any of its subsidiaries,
                    taken as a whole. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Investment Company Act</span>. The Company is not required, and immediately after the sale of the Securities hereunder will
                    not be required, to be registered as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.12<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Studies, Tests and Preclinical and Clinical Trials</span>. The pre-clinical studies and clinical trials conducted by or, to
                    the Company&#8217;s knowledge, on behalf of or sponsored by the Company and its subsidiaries with respect to the Company&#8217;s product candidates (collectively &#8220;<span style="font-style: italic; font-weight: bold;">Studies</span>&#8221;) were, and if
                    still pending are, being conducted in all material respects in accordance with all Applicable Laws (as defined below) to which such Studies are or were subject. Neither the Company nor its subsidiaries has received any written notices
                    or correspondence from any Governmental Entity requiring or threatening the termination, adverse modification or suspension of any ongoing or proposed Studies other than in connection with ordinary course communications with respect to
                    modifications in connection with the design and implementation of such Studies, and, to the Company&#8217;s knowledge, there are no reasonable grounds for the same. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Regulatory Matters</span>. Except in each case as would not, singly or in the aggregate, have or reasonably be expected to
                    have a Material Adverse Effect, since June&#160;1, 2023: (i) neither the Company nor any of its subsidiaries has received any FDA Form&#160;483, notice of adverse finding, warning letter or other correspondence or written notice from the U.S.
                    Food and Drug Administration (&#8220;<span style="font-style: italic; font-weight: bold;">FDA</span>&#8221;) or any other Governmental Entity alleging or asserting noncompliance with (x) any statutes, laws, ordinances, rules and regulations
                    applicable to the Company and its subsidiaries for the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of
                    any product or product candidate manufactured or distributed by the Company, including without limitation, the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. &#167; 301, et seq., similar laws enforced by other Governmental Entities and the
                    regulations promulgated pursuant to such laws </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 585-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 586-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">(collectively, &#8220;<span style="font-style: italic; font-weight: bold;">Applicable

              Laws</span>&#8221;) or (y) any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws and/or to carry on its businesses as now conducted (&#8220;<span style="font-style: italic; font-weight: bold;">Authorizations</span>&#8221;) and (ii) the Company and each of its subsidiaries has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims,
            submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete, correct
            and not misleading on the date filed (or were corrected or supplemented by a subsequent submission). </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.14<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Compliance With Laws</span>. The Company has complied in all material respects with, is not in material violation of, and has
                    not received any written notice alleging any violation with respect to, any applicable provisions of any statute, law or regulation with respect to the conduct of its business, or the ownership or operation of its properties or assets.
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.15<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Information Provided</span>. The information to be supplied by or on behalf of the Company for inclusion or incorporation by
                    reference in the Registration Statement (as defined in the Merger Agreement), or supplied by or on behalf of the Company for inclusion in any filing pursuant to Rule&#160;165 and Rule&#160;425 under the 1933 Act or Rule&#160;14a-12 under the 1934 Act,
                    including the Company Presentation (each a &#8220;<span style="font-style: italic; font-weight: bold;">Regulation M-A Filing</span>&#8221;), shall not, at the time the Registration Statement or any such Regulation M-A Filing is filed with the
                    Securities and Exchange Commission (the &#8220;<span style="font-style: italic; font-weight: bold;">Commission</span>&#8221;), at any time it is amended or supplemented or at the time the Registration Statement is declared effective by the
                    Commission, as applicable, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein not misleading. The information to be
                    supplied by or on behalf of the Company for inclusion in the Registration Statement to be sent to the stockholders of Passage in connection with the meeting of Passage&#8217;s stockholders (the &#8220;<span style="font-style: italic; font-weight: bold;">Public Company Meeting</span>&#8221;), shall not, on the date the proxy statement/prospectus included in the Registration Statement is first mailed to stockholders of Passage, at the time of the Public Company Meeting or at the
                    Effective Time, contain any statement that, at such time and in light of the circumstances under which it shall be made, is false or misleading with respect to any material fact, or omit to state any material fact necessary in order to
                    make the statements made in the Registration Statement not false or misleading; or omit to state any material fact necessary to correct any statement in any earlier communication with respect to the solicitation of proxies for the
                    Public Company Meeting that has become false or misleading. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.16<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Additional Agreements</span>. The Company does not have any agreement or understanding with any Purchaser or any other
                    person with respect to the transactions contemplated by this Agreement other than as specified in this Agreement. The Company has no other agreements or understandings (including, without limitation, side letters) with any Purchaser to
                    purchase any of the Securities on terms more favorable to such Purchaser than as set forth herein. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.17<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Private Placement</span>. None of the Company, its subsidiaries or any person acting on its or their behalf, has, directly or
                    indirectly, made any offers or sales of any security or solicited any offers to buy any security under any circumstances that would require registration under the 1933 Act of the Securities being sold pursuant to this Agreement.
                    Assuming the accuracy of the representations and warranties of the Purchasers contained in <span style="text-decoration: underline;">Section&#160;3</span> hereof, the issuance and sale of the Securities is exempt from registration under the 1933 Act. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.18<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Disqualification Events</span>. No &#8220;bad actor&#8221; disqualifying event described in Rule&#160;506(d)(1)(i)-(viii) of the 1933 Act
                    (a &#8220;<span style="font-style: italic; font-weight: bold;">Disqualification Event</span>&#8221;) is applicable to the Company or, to the Company&#8217;s knowledge, any Company Covered Person (as defined below), except for a Disqualification Event as
                    to which Rule&#160;506(d)(2)(ii&#8211;iv) or (d)(3) is applicable. &#8220;<span style="font-style: italic; font-weight: bold;">Company Covered Person</span>&#8221; means, with respect to the Company as an &#8220;issuer&#8221; for purposes of Rule&#160;506 promulgated under
                    the 1933 Act, any person listed in the first paragraph of Rule&#160;506(d)(1). The Company is not aware of any Person (other than any Company Covered Person) that has been or will be paid (directly or indirectly) remuneration for
                    solicitation of purchasers in connection with the sale of the Securities pursuant to this Agreement. The Company has complied, to the extent applicable, with its disclosure obligations under Rule&#160;506(e). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.19<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No General Solicitation</span>. Neither the Company nor, to the Company&#8217;s knowledge, any person acting on behalf of the
                    Company has, directly or indirectly, offered or sold any of the Securities by any form of general solicitation or general advertising. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 586-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 587-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.20<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Integrated Offering</span>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in <span style="text-decoration: underline;">Section&#160;3</span>
                    hereof, none of the Company, its subsidiaries nor, to the Company&#8217;s knowledge, any of its or their Affiliates or any Person acting on its or their behalf has, directly or indirectly, at any time within the past six (6) months, made any
                    offers or sales of any Company security or solicited any offers to buy any security under circumstances that would (i) eliminate the availability of the exemption from registration under Section&#160;4(a)(2) and/or Regulation D under the
                    1933 Act in connection with the offer and sale by the Company of the Securities as contemplated hereby or (ii) cause the offering of the Securities pursuant to this Agreement to be integrated with prior offerings by the Company for
                    purposes of any applicable law, regulation or stockholder approval provisions. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.21<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Brokers</span>. Other than the Placement Agents, there is no broker, investment banker, financial advisor, finder or other
                    person which has been retained by or is authorized to act on behalf of the Company that is entitled to any fee or commission in connection with the execution of this Agreement and the consummation of the transactions contemplated hereby
                    (other than the Merger), other than RBC Capital Markets L.L.C. and Canaccord Genuity, capital markets advisors to the Company. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.22<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Additional Representations and Warranties</span>. The Company&#8217;s representations and warranties set forth in the Merger
                    Agreement in Sections 3.3 (Authority; Binding Nature of Agreement), 3.6 (Capitalization), 3.7&#160;(Financial Statements), 3.10 (Title to Assets), 3.11 (Real Property; Leasehold), 3.12 (Intellectual Property), 3.13 (Agreements, Contracts and
                    Commitments), 3.14 (Compliance; Permits; Restrictions) (except with respect to the first sentence of clause (a) thereof and with respect to clauses (e) and (h)&#160;thereof), 3.17 (Employee and Labor Matters; Benefit Plans), 3.18
                    (Environmental Matters), 3.20&#160;(Transactions with Affiliates) and 3.22 (Privacy and Data Security) are hereby incorporated by reference and made by the Company, as qualified by the disclosures in the Remix Disclosure Schedule (as defined
                    in the Merger Agreement). As of the Effective Date, to the knowledge of the Company, the representations and warranties of Passage in the Merger Agreement and in any certificate or other writing delivered by Passage pursuant thereto are
                    true and correct. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.23<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Merger Agreement</span>. The Purchasers have been provided with true, complete and correct copies of the Merger Agreement and
                    the Remix Disclosure Schedule (as defined in the Merger Agreement) in the form originally executed, and there have been no amendments or waivers thereto other than those as to which the Purchasers have been advised in writing. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.24<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Employee Agreements</span>. To the Company&#8217;s knowledge, each current and former employee, consultant and officer of the
                    Company has executed an agreement with the Company regarding confidentiality, proprietary information and assignment of inventions and intellectual property rights (the &#8220;<span style="font-style: italic; font-weight: bold;">Confidential
                      Information Agreements</span>&#8221;). To the Company&#8217;s knowledge, no current or former employee or consultant has excluded works or inventions from his or her assignment of inventions pursuant to such person&#8217;s Confidential Information
                    Agreement. To the Company&#8217;s knowledge, no employee or consultant is in violation of any agreement described in this <span style="text-decoration: underline;">Section 4.24</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.25<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Anti-Bribery and Anti-Money Laundering Laws; Sanctions</span>. Each of the Company, its subsidiaries and, to the knowledge of
                    the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws,
                    including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public
                    Officials in International Business Transactions, signed December&#160;17, 1997, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope, (B)
                    anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US.
                    Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money
                    Laundering, of which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant
                    to the authority of any of the foregoing, or any orders or licenses issued thereunder, or (C) except as would not reasonably be expected, individually or in the aggregate, to result in a </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 587-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 588-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Material Adverse Effect, any laws with respect to import and export
            control and economic sanctions, including the U.S. Export Administration Regulations, the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the
            Treasury Office of Foreign Asset Control. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.26<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Reliance by Purchasers</span>. The Company acknowledges that each Purchaser will rely upon the truth and accuracy of, and the
                    Company&#8217;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth in this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Covenants</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Further Assurances</span>. At or prior to Closing, each party agrees to cooperate and generally do such reasonable acts and
                    things in good faith as may be necessary to timely satisfy each of the conditions to be satisfied by it as provided in <span style="text-decoration: underline;">Section&#160;6</span> of this Agreement and effectuate the intents and purposes of this Agreement subject to the terms
                    and conditions hereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.02<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Disclosure of Transactions and Other Material Information</span>. The Company shall or shall cause Passage to, (i)&#160;on or
                    before 9:00 a.m., New York City time, within one Business Day immediately following the Effective Date (or if this Agreement is executed between midnight and 9:00 a.m., New York City time, on any Business Day, no later than 9:01 a.m. on
                    the Effective Date), issue one or more press releases and/or file with the Commission a Current Report on Form&#160;8-K (collectively with the press release, the &#8220;<span style="font-style: italic; font-weight: bold;">Disclosure Document</span>&#8221;,

                    and the actual issuance or acceptance (as applicable) of the filing of such press releases or Current Report on Form&#160;8-K, the &#8220;<span style="font-style: italic; font-weight: bold;">Disclosure Time</span>&#8221;) disclosing all material terms
                    of the transactions contemplated hereby and by the Merger Agreement and any other material nonpublic information within the meaning of the federal securities laws that the Company, Passage or their respective officers, directors,
                    employees, agents or any other person acting at the direction of the Company or Passage has provided to the Purchasers in connection with the transactions contemplated by this Agreement and by the Merger Agreement prior to the filing of
                    the Disclosure Document. The Company represents and warrants that, from and after the issuance of the Disclosure Document, no Purchaser shall be in possession of any material nonpublic information received from the Company, Passage or
                    their respective officers, directors, employees, agents or other person acting at their direction. In addition, effective upon the Disclosure Time, the Company acknowledges and agrees that any and all confidentiality obligations agreed
                    to pursuant to the wall cross procedures for the Offering shall terminate and be of no further force or effect. The Company understands and confirms that each of the Purchasers will rely on the foregoing representations in effecting
                    transactions in securities of the Company. The Company shall not, and shall cause its officers, directors, employees and agents not to, publicly disclose the name of any Purchaser or any affiliate or investment adviser of any Purchaser,
                    or include the name of any Purchaser or any affiliate or investment adviser of any Purchaser without the prior written consent (including by e-mail) of such Purchaser (i) in any press release, marketing materials or any other public
                    announcement, or (ii) in any filing with the Commission or any regulatory agency or trading market, except (A) as required by the federal securities laws, rules or regulations, (B)&#160;to the extent such disclosure is required by other
                    laws, rules or regulations, at the request of the staff of the Commission or regulatory agency or under regulations of any national securities exchange on which Passage&#8217;s securities are listed for trading or (C) to the extent such
                    disclosure contains only information previously approved in accordance with this <span style="text-decoration: underline;">Section&#160;5.02</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.03<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Concurrent Financing Restructuring</span>. In the event the structure of the Concurrent Financing (as defined in the Merger
                    Agreement) either violates applicable Law (as defined in the Merger Agreement) or materially and adversely affects Passage&#8217;s ability to cause the Registration Statement to become effective in a timely manner, and in any event 60 days
                    prior to the Outside Date (as defined in, and as may be extended in accordance with, the Merger Agreement), then the Company and Purchasers shall cooperate and use commercially reasonable efforts to cause the Concurrent Financing to be
                    amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Passage Common Stock (as defined in the Merger Agreement) substantially contemporaneously with the Closing in a manner which
                    preserves to the extent possible, the amount of funds ultimately received by Passage and its subsidiaries, and the number of shares of Passage Common Stock ultimately held by each Purchaser in respect of such amounts as though the
                    Concurrent Financing and the Merger pursuant to the Merger Agreement have been consummated according to their respective terms. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 588-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 589-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.04<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Expenses</span>. The Company and each Purchaser is liable for, and will pay, its own expenses incurred in connection with the
                    negotiation, preparation, execution and delivery of this Agreement, including, without limitation, attorneys&#8217; and consultants&#8217; fees and expenses. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.05<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Form&#160;S-4</span>. From the date hereof until the Closing Date, the Company shall use commercially reasonable efforts to ensure
                    the Registration Statement will register the issuance of the shares of Passage Common Stock to be issued in exchange for the Securities, subject to and in accordance with the terms of the Merger Agreement, to the Purchasers that are not
                    affiliates of the Company. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.06<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Blue Sky Laws</span>. The Company, on or before the Closing Date, shall take such action as the Company shall reasonably
                    determine is necessary in order to obtain an exemption for or to qualify the Securities for sale to each Purchaser at the Closing pursuant to this Agreement under applicable securities or &#8220;blue sky&#8221; laws of the states of the United
                    States (or to obtain an exemption from such qualification). The Company shall make all filings and reports relating to the offer and sale of the Securities required under applicable securities or &#8220;blue sky&#8221; laws of the states of the
                    United States following the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.07<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Amendment or Waiver of Merger Agreement Terms</span>. The Company shall not amend, modify or waive (or approve an
                    amendment, modification or a waiver requested by Passage of, or fail to contest an action regarding a breach of) any provision of the Merger Agreement in a manner that would reasonably be expected to materially and adversely affect the
                    benefits that the Purchaser would reasonably expect to receive pursuant to this Agreement without the consent of each Purchaser, it being agreed that any amendment or modification to the definitions of &#8220;Remix Equity Value,&#8221; &#8220;Remix
                    Outstanding Shares,&#8221; &#8220;Concurrent Financing Merger Shares,&#8221; &#8220;Concurrent Financing Allocation Percentage,&#8221; &#8220;Concurrent Investment Amount&#8221; and &#8220;Concurrent Financing Proceeds&#8221; in the Merger Agreement shall be deemed materially adverse to
                    the Purchasers. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.08<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Equal Treatment of Purchasers</span>. No consideration shall be offered or paid to any Purchaser to amend or consent to a
                    waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the Purchasers. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the
                    Company and negotiated separately by each Purchaser and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of shares of Common Stock or otherwise. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.09<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Indemnification</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company agrees to indemnify and hold harmless each Purchaser and its Affiliates, and their respective directors,
                    officers, trustees, members, stockholders, partners, managers, employees, investment advisers and agents (collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">Indemnified Persons</span>&#8221;), from and against any and all
                    losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorneys&#8217; fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with
                    investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Indemnified Person may become subject as a result of any breach of representation,
                    warranty, covenant or agreement made by or to be performed on the part of the Company under this Agreement or the Registration Rights Agreement, and will reimburse any such Indemnified Person for all such amounts as they are incurred by
                    such Indemnified Person. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim
                    with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to
                    indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying
                    party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of
                    any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing
                    that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the
                    failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-11<br/>
        </div>

      </div>

    </div>

    <!--End Page 589-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 590-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">obligations hereunder, except to the extent that such failure to give
            notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for
            fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld,
            conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete,
            explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability,
            wrongdoing, or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of
            any judgment or enter into any settlement. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;6.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Conditions of Closing</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 30pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conditions of the Purchasers&#8217; Obligations at the Closing</span>. The obligations of each Purchaser under <span style="text-decoration: underline;">Section&#160;2</span>
                    hereof are subject to the fulfillment, at or prior to the Closing, of all of the following conditions, unless otherwise waived by such Purchaser solely as to itself. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Representations and Warranties</span>. The representations and warranties of the Company contained in this Agreement shall be
                    true and correct in all material respects on the Effective Date, and shall be true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on
                    and as of the Closing Date (except (i) to the extent expressly made as of an earlier date in which case as of such earlier date and (ii) the Fundamental Representations and representations and warranties that are qualified as to
                    materiality or Material Adverse Effect, which representations and warranties shall be true in all respects). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Performance</span>. The Company shall have performed and complied in all material respects with all covenants, agreements,
                    obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or prior to the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Compliance Certificate</span>. The Chief Executive Officer of the Company shall have delivered to the Purchasers at the
                    Closing Date a certificate, in form and substance reasonably acceptable to the Purchasers, certifying that the conditions specified in <span style="text-decoration: underline;">Sections 6.01(a)</span>, <span style="text-decoration: underline;">6.01(b)</span>, <span style="text-decoration: underline;">6.01(f)</span>, <span style="text-decoration: underline;">6.01(j)</span>, <span style="text-decoration: underline;">6.01(k)</span> and <span style="text-decoration: underline;">6.01(l)
                    </span>of this Agreement have been fulfilled. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Qualification under Securities Laws</span>. All registrations, qualifications, permits and approvals, if any, required under
                    applicable securities laws shall have been obtained for the lawful execution, delivery and performance of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Secretary&#8217;s Certificate</span>. The Secretary of the Company shall have delivered to the Purchasers at the Closing a
                    certificate, in form and substance reasonably acceptable to the Purchasers (such consent not to be unreasonably withheld, conditioned or delayed), certifying (i) the certificate of incorporation and bylaws of the Company, (ii)
                    authorization of the Board of Directors of the Company approving this Agreement and the transactions contemplated under this Agreement (including the Merger Agreement) and (iii) as to a certificate evidencing the good standing of the
                    Company in Delaware issued by the Secretary of State of Delaware, as of a date within five Business Days of the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Merger</span>. All conditions to the closing of the Merger shall have been satisfied or waived (other than the Closing
                    hereunder and other than those conditions which, by their nature, are to be satisfied at the closing of the transactions contemplated by the Merger Agreement, but subject to the satisfaction of such conditions as of the closing of the
                    transactions contemplated by the Merger Agreement), and the closing of the Merger shall be set to occur substantially concurrently with the Closing hereunder. The Merger Agreement or any provision thereof shall not have been amended,
                    modified, or waived in contravention of <span style="text-decoration: underline;">Section&#160;5.07</span> hereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Injunction</span>. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
                    entered, promulgated or endorsed by any Governmental Entity of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by this Agreement. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-12<br/>
        </div>

      </div>

    </div>

    <!--End Page 590-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 591-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Registration Rights Agreement</span>. The Company shall have delivered the fully executed Registration Rights Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Opinion of Company Counsel</span>. The Purchasers and the Placement Agents shall have received from Latham &amp; Watkins LLP,
                    counsel for the Company, an opinion, dated as of the Closing, in the form and substance typical for transactions of this nature. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Registration Statement; Proxy Statement/Prospectus</span>. The Registration Statement shall have become effective under the
                    1933 Act and no stop order suspending the effectiveness of the Registration Statement shall have been issued and no proceeding for that purpose, and no similar proceeding with respect to the Registration Statement shall have been, to
                    the Company&#8217;s knowledge, initiated or threatened in writing by the Commission or its staff. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Nasdaq</span>. The shares of Passage&#8217;s common stock, par value $0.0001 per share (the &#8220;<span style="font-style: italic; font-weight: bold;">Passage Common Stock</span>&#8221;) to be issued in the Merger (including, for the avoidance of doubt, shares of Passage Common Stock issued in exchange for the Securities issued hereunder) shall have been approved for
                    listing (subject to official notice of issuance) on Nasdaq. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Financing Amount</span>. The Company shall receive at Closing aggregate proceeds from the purchase of Securities pursuant to
                    this Agreement of not less than the Total Subscription Amount. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">No Material Adverse Effect</span>. Since the Effective Date, no Material Adverse Effect shall have occurred. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.02<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conditions of the Company&#8217;s Obligations</span>. The obligations of the Company under <span style="text-decoration: underline;">Section&#160;2</span> hereof are subject to
                    the fulfillment, at or prior to the Closing, of all of the following conditions, any of which may be waived in whole or in part by the Company in its absolute discretion. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Representations and Warranties</span>. The representations and warranties of the Purchasers contained in this Agreement shall
                    be true and correct as of the Effective Date and true and correct in all material respects on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of the Closing Date
                    (except to the extent expressly made as of an earlier date in which case shall be as of such earlier date). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Performance</span>. Each Purchaser shall have performed and complied with all covenants, agreements, obligations and
                    conditions contained in this Agreement that are required to be performed or complied with by it on or prior to the Closing Date. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Qualification under Securities Laws</span>. All registrations, qualifications, permits and approvals, if any, required under
                    applicable securities laws shall have been obtained for the lawful execution, delivery and performance of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Merger</span>. All conditions to the closing of the Merger shall have been satisfied or waived (other than the Closing
                    hereunder and other than those conditions which, by their nature, are to be satisfied at the closing of the transactions contemplated by the Merger Agreement), and the closing of the Merger shall be set to occur substantially
                    concurrently with the Closing hereunder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Payment</span>. The Company shall have received payment, by wire transfer of immediately available funds, in the full amount
                    of the Subscription Amount of each Purchaser at the Closing as set forth on the Schedule of Purchasers. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Injunction</span>. The purchase of and payment for the Securities by each Purchaser shall not be prohibited or enjoined by
                    any law or governmental or court order or regulation. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;7.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Transfer Restrictions; Restrictive Legend</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Transfer Restrictions</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Purchaser understands that the Company may, as a condition to the transfer of any of the Securities, require that the
                    request for transfer be accompanied by a certificate and/or an opinion of counsel reasonably satisfactory to the Company, to the effect that the proposed transfer does not result in a violation of the 1933&#160;Act, unless such transfer is
                    covered by an effective registration statement or is exempt from the registration requirements of the 1933 Act, including under Rule&#160;144. It is understood that the certificates evidencing the Securities may bear substantially the
                    following legend: </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-13<br/>
        </div>

      </div>

    </div>

    <!--End Page 591-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 592-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">&#8220;THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
            1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER SUCH ACT OR APPLICABLE STATE
            SECURITIES LAWS OR A VALID EXEMPTION FROM REGISTRATION UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS.&#8221; </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Upon request by a Purchaser, the Company shall use commercially reasonable efforts to cause the transfer agent to remove any
                    restrictive legend as promptly as reasonably practicable in connection with any sale of any Securities bearing such restrictive legend pursuant to Rule&#160;144 or any other applicable exemption from the registration requirements of the
                    Securities Act; provided the Company has received customary representations and other documentation reasonably acceptable to the Company in connection therewith. The Company shall be responsible for the fees of its transfer agent and
                    counsel to the Company associated with such issuances. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;8.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Definitions</span>. Unless the context otherwise requires, the terms defined in this <span style="text-decoration: underline;">Section&#160;8</span> shall have the
                    meanings specified for all purposes of this Agreement. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">1933 Act</span>&#8221; means
            the Securities Act of 1933, as amended. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">1934 Act</span>&#8221; means
            the Securities Exchange Act of 1934, as amended. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Affiliate</span>&#8221; shall
            have the meaning ascribed to such term in Rule&#160;12b-2 of the General Rules and Regulations under the 1934 Act. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Business Day</span>&#8221;
            means any day other than Saturday, Sunday or other day on which commercial banks in the City of New York are authorized or required by law to remain closed. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Company Presentation</span>&#8221;
            means that certain Investor Presentation, dated June&#160;2026, as provided to the Purchasers prior to the Effective Date and filed by Passage on a Current Report on Form&#160;8-K after the Effective Date. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Good Clinical Practices</span>&#8221;
            means the FDA&#8217;s standards for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials contained in 21 C.F.R. Parts 50, 54, 56 and 312. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Good Laboratory
              Practices</span>&#8221; means the FDA&#8217;s standards for conducting non-clinical laboratory studies contained in 21 C.F.R. Part&#160;58. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Engagement Letter</span>&#8221;
            means the Engagement Letter by and between the Company and the Placement Agents, dated June&#160;17, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic;">Fundamental
              Representations</span>&#8221; <span style="font-weight: normal;">means the representations and warranties made by the Company in Sections 4.02 (Organization and Good Standing of the Company), 4.04 (Validity; Valid Issuance of Securities), 4.05
              (Governmental Consents and Filings), 4.06 (Absence of Violations, Defaults and Conflicts), 4.07 (Absence of Proceedings), 4.11&#160;(Investment Company Act), 4.14 (Compliance with Laws), 4.18 (No Disqualification Events), 4.19 (No General
              Solicitation), 4.20 (No Integrated Offering) and 4.21 (Brokers). </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">National Exchange</span>&#8221;
            means the Nasdaq Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market, or the New York Stock Exchange. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Person</span>&#8221; means an
            individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Purchase Price</span>&#8221;
            means an amount equal to (i) the Remix Equity Value (as defined in the Merger Agreement), divided by (ii) the number of Remix Outstanding Shares (as defined in the Merger Agreement but which, for the avoidance of doubt, excludes (x) the
            Securities being issued hereunder and (y) the shares of Remix Common Stock issued pursuant to the conversion of the Remix Convertible Notes (2026) (as defined in the Merger Agreement)) as of immediately prior to the closing of the offering of
            the Securities hereunder. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Purchaser Majority</span>&#8221;
            means, prior to the Closing, the Purchasers committed to purchase a majority of the Securities and, following the Closing, the Purchasers who hold a majority of the Securities (including any Passage Common Stock issued in exchange therefor)
            still held by the Purchasers, which majority must include Purchasers who purchased at least $15,000,000 in Securities at the Closing. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-14<br/>
        </div>

      </div>

    </div>

    <!--End Page 592-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 593-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Registration Rights
              Agreement</span>&#8221; means the Registration Rights Agreement, in the form attached hereto as <span style="text-decoration: underline;">Exhibit&#160;A</span>, to be entered into at the Closing among the Company and each Purchaser. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Rule&#160;144</span>&#8221; means
            Rule&#160;144 promulgated by the Commission pursuant to the 1933 Act, as such Rule&#160;may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as Rule&#160;144. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 60pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SECTION&#160;9.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Miscellaneous</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.01<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Waivers and Amendments</span>. Neither this Agreement, nor any provision hereof, may be changed, waived, amended or modified
                    orally or by course of dealing, but only by an instrument in writing executed by the Company and the Purchaser Majority, <span style="font-style: italic;">provided</span> that, (a) if any, change, waiver, amendment, modification
                    disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall be required and (b) the consent of each Purchaser shall be required
                    for any change in the Purchase Price or applicable Purchaser&#8217;s Subscription Amount, any change in the type of security to be issued to Purchasers at Closing, or the amendment or waiver of <span style="text-decoration: underline;">Section&#160;9.12 </span>or <span style="text-decoration: underline;">9.13</span> or of any
                    of the closing conditions set forth in <span style="text-decoration: underline;">Sections 6.01(a)</span>, <span style="text-decoration: underline;">6.01(f)</span>, <span style="text-decoration: underline;">6.01(j)</span>, <span style="text-decoration: underline;">6.01(k)</span>, or <span style="text-decoration: underline;">6.01(l)</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.02<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Notices</span>. All notices, requests, consents, and other communications under this Agreement shall be in writing and shall
                    be deemed delivered (a) when delivered, if delivered personally, (b) four Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (c) one Business Day after being sent via a reputable
                    nationwide overnight courier service guaranteeing next Business Day delivery, or (d)&#160;when receipt is acknowledged, in the case of email, in each case to the intended recipient as set forth below, with respect to the Company, and to the
                    addresses set forth on the Schedule of Purchasers with respect to the Purchasers. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 408pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">if to the Company: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Therapeutics, Inc. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">100 Forge Road, Suite 400 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Watertown, MA 02472 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention:Peter Smith </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [ *** ] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">with a copy to (which shall not constitute notice): </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Latham &amp; Watkins LLP </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">200 Clarendon Street </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Boston, MA 02215 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Attention:Peter Handrinos; Leah Sauter; Elisabeth Martin </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 408pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Email: [ *** ]</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 408pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">or at such other address as the Company or each Purchaser may specify by
            written notice to the other parties hereto in accordance with this <span style="text-decoration: underline;">Section&#160;9.02</span>. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.03<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Cumulative Remedies</span>. None of the rights, powers or remedies conferred upon each Purchaser, on the one hand, or the
                    Company, on the other hand, shall be mutually exclusive, and each such right, power or remedy shall be cumulative and in addition to every other right, power or remedy, whether conferred by this Agreement or now or hereafter available
                    at law, in equity, by statute or otherwise. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.04<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Successors and Assigns</span>. All the terms and provisions of this Agreement shall be binding upon and inure to the benefit
                    of and be enforceable by the respective parties hereto, the successors and permitted assigns of each Purchaser and the successors of the Company, whether so expressed or not. None of the Purchasers may assign its rights or obligations
                    hereof without the prior written consent of the Company, except that a Purchaser may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder to any of its affiliates or to any other investment
                    funds or accounts managed or advised by the investment manager who acts on behalf of Purchaser (<span style="font-style: italic;">provided</span> each such assignee agrees to be bound by the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-15<br/>
        </div>

      </div>

    </div>

    <!--End Page 593-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 594-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">terms of this Agreement and makes the same representations and warranties
            set forth in <span style="text-decoration: underline;">Section&#160;3</span> hereof). The Company may not assign its rights or obligations hereof without the consent of the Purchaser Majority. This Agreement shall not inure to the benefit of or be enforceable by any other person. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.05<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Exculpation and Acknowledgement of Placement Agents</span>. Each party hereto agrees for the express benefit of each of the
                    Placement Agents, its affiliates and its representatives that: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each of the Placement Agents is acting solely as financial advisor to the Company in connection with the sale of the
                    Securities and is not acting in any other capacity and is not and shall not be construed as a fiduciary for the Purchaser, or any other person or entity in connection with the sale of Securities. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">No Placement Agent or any of its affiliates or any of its representatives (i) shall be liable for any improper payment made
                    in accordance with the information provided by the Company, (ii) has made or will make any representation or warranty, express or implied, of any kind or character, and has not provided any advice or recommendation to the Purchasers in
                    connection with the purchase or sale of the Securities, (iii) has any responsibilities as to the validity, accuracy, completeness, value or genuineness, as of any date, of any information, certificates or documentation delivered by or
                    on behalf of the Company pursuant to this Agreement, the Registration Rights Agreement or the Merger Agreement, or in connection with any of the transactions contemplated by such agreements, including any valuation, offering or
                    marketing materials, or any omissions from such materials; or (iv) shall be liable or have any obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards,
                    liabilities, costs, expenses or disbursements incurred by the Purchaser, the Company or any other person or entity), whether in contract, tort or otherwise to the Purchaser or to any person claiming through the Purchaser, (x) for any
                    action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by this Agreement, the Registration Rights Agreement or the Merger
                    Agreement or (y) for anything which any of them may do or refrain from doing in connection with this Agreement, the Registration Rights Agreement or the Merger Agreement, except for such party&#8217;s own gross negligence, willful misconduct
                    or bad faith. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Placement Agents, their respective affiliates and their respective representatives shall be entitled to rely on, and
                    shall be protected in acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any of them by or on behalf of the Company. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Purchaser acknowledges that each of the Placement Agents is acting as a placement agent on a &#8220;best efforts&#8221; basis for
                    the Securities being offered hereby and will be compensated by the Company for acting in such capacity. Each Purchaser represents that such Purchaser was contacted regarding the sale of the Securities by a Placement Agent or the Company
                    (or an authorized agent or representative thereof) with whom the Purchaser entered into a verbal or written confidentiality agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Purchaser represents that it is making this investment based on the results of its own due diligence investigation of
                    the Company, and has not relied on any information or advice furnished by or on behalf of either of the Placement Agents in connection with the transactions contemplated hereby. Each Purchaser acknowledges that neither of the Placement
                    Agents has made, and will not make, any representations and warranties with respect to the Company or the transactions contemplated hereby, and the Purchaser will not rely on any statements made by either of the Placement Agents, orally
                    or in writing, to the contrary. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.06<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Headings</span>. The headings of the Sections and paragraphs of this Agreement have been inserted for convenience of
                    reference only and do not constitute a part of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.07<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Governing Law; Jurisdiction</span>. This Agreement shall be governed by, and construed in accordance with, the laws of the
                    State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. IN ANY ACTION OR PROCEEDING BETWEEN ANY OF THE PARTIES ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE
                    CONTEMPLATED TRANSACTIONS, EACH OF THE PARTIES: (A) IRREVOCABLY AND UNCONDITIONALLY CONSENTS AND SUBMITS TO THE EXCLUSIVE JURISDICTION AND VENUE OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE OR, TO THE EXTENT SUCH COURT DOES NOT
                    HAVE SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE OR THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE, (B) AGREES THAT ALL CLAIMS IN RESPECT OF SUCH ACTION OR PROCEEDING SHALL BE HEARD AND </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-16<br/>
        </div>

      </div>

    </div>

    <!--End Page 594-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 595-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">DETERMINED EXCLUSIVELY IN ACCORDANCE WITH CLAUSE (A) OF THIS <span style="text-decoration: underline;">SECTION
              9.07</span>, (C)&#160;WAIVES ANY OBJECTION TO LAYING VENUE IN ANY SUCH ACTION OR PROCEEDING IN SUCH COURTS, (D) WAIVES ANY OBJECTION THAT SUCH COURTS ARE AN INCONVENIENT FORUM OR DO NOT HAVE JURISDICTION OVER ANY PARTY, (E) AGREES THAT SERVICE OF
            PROCESS UPON SUCH PARTY IN ANY SUCH ACTION OR PROCEEDING SHALL BE EFFECTIVE IF NOTICE IS GIVEN IN ACCORDANCE WITH <span style="text-decoration: underline;">SECTION 9.02</span> OF THIS AGREEMENT AND (F)&#160;IRREVOCABLY WAIVES THE RIGHT TO TRIAL BY JURY. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.08<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Survival</span>. The representations and warranties of the Company and the Purchasers contained in <span style="text-decoration: underline;">Sections 3</span> and <span style="text-decoration: underline;">4</span>
                    and the agreements and covenants set forth in <span style="text-decoration: underline;">Sections 5</span> and <span style="text-decoration: underline;">9</span> shall survive the Closing for the applicable statute of limitations (unless such covenant or agreement terminates earlier in accordance with its terms),
                    which shall not be extended by Section&#160;8106(c) of Title 10 of the Delaware Code or any similar law. Each Purchaser shall be responsible only for its own representations, warranties, agreements and covenants hereunder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.09<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Confidential Information</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Purchaser covenants that until such time as the transactions contemplated by this Agreement and any material non-public
                    information provided to such Purchaser are publicly disclosed by the Company in accordance with <span style="text-decoration: underline;">Section&#160;5.02</span> (or earlier termination of this Agreement), such Purchaser will maintain the confidentiality of all disclosures made to
                    it in connection with this transaction (including the existence and terms of this transaction), other than to such Purchaser&#8217;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation
                    of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company may request from the Purchasers such reasonable and customary additional information as the Company may deem
                    necessary to evaluate the eligibility of a Purchaser to acquire the Securities, and such Purchaser shall promptly provide such information as may reasonably be requested to the extent readily available; provided, that the Company agrees
                    to keep any such information provided by such Purchaser confidential, except (i) as required by the federal securities laws, rules or regulations and (ii) to the extent such disclosure is required by other laws, rules or regulations, at
                    the request of the staff of the Commission or regulatory agency or under the regulations of Nasdaq. The Purchaser acknowledges that the Company or Passage may file a copy of this Agreement and the Registration Rights Agreement with the
                    Commission as exhibits to a periodic report, current report or a registration statement of the Company or Passage. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.10<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Counterparts; Effectiveness</span>. This Agreement may be executed in any number of counterparts and by different parties
                    hereto in separate counterparts, with the same effect as if all parties had signed the same document. All such counterparts (including counterparts delivered by facsimile or other electronic format) shall be deemed an original, shall be
                    construed together and shall constitute one and the same instrument. This Agreement shall become effective when each party hereto shall have received counterparts hereof signed by all of the other parties hereto. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.11<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Entire Agreement</span>. This Agreement, together with the Registration Rights Agreement, contains the entire agreement among
                    the parties hereto with respect to the subject matter hereof and, except as set forth&#160; below, this agreement supersedes and replaces all other prior agreements, written or oral, among the parties hereto with respect to the subject
                    matter hereof. Notwithstanding the foregoing or anything to the contrary in this Agreement and subject to <span style="text-decoration: underline;">Section&#160;5.02</span>, this Agreement shall not supersede any confidentiality or other non-disclosure agreements that may be in
                    place between the Company and any Purchaser as of the date hereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.12<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Severability</span>. If any provision of this Agreement shall be found by any court of competent jurisdiction to be invalid
                    or unenforceable, the parties hereby waive such provision to the extent that it is found to be invalid or unenforceable. Such provision shall, to the maximum extent allowable by law, be modified by such court so that it becomes
                    enforceable, and, as modified, shall be enforced as any other provision hereof, all the other provisions hereof continuing in full force and effect. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.13<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Independent Nature of Purchasers&#8217; Obligations and Rights</span>. The obligations of each Purchaser under this Agreement are
                    several and not joint with the obligations of any other Purchaser, and no Purchaser shall be </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-17<br/>
        </div>

      </div>

    </div>

    <!--End Page 595-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 596-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">responsible in any way for the performance of the obligations of any other
            Purchaser under this Agreement. Nothing contained herein, and no action taken by any Purchaser pursuant hereto, shall be deemed to constitute the Purchasers as, and the Company acknowledges that the Purchasers do not so constitute, a
            partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such
            obligations or the transactions contemplated by this Agreement, and the Company acknowledges that the Purchasers are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement. The
            Company acknowledges and each Purchaser confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Purchaser shall be entitled to independently
            protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. The Company
            has elected to provide all Purchasers with the same terms for the convenience of the Company and not because it was required or requested to do so by any Purchaser. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.14<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Termination</span>. This Agreement shall terminate and be void and of no further force and effect, and all obligations of the
                    parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earlier to occur of (a) such date and time that the Merger Agreement is terminated in accordance with its terms, (b)
                    upon the mutual written agreement of the Company and the Purchaser, (c) if, on the Closing Date, any of the conditions of Closing set forth in <span style="text-decoration: underline;">Section&#160;6</span> have not been satisfied as of the time required hereunder to be so
                    satisfied or waived by the party entitled to grant such waiver and, as a result thereof, the transactions contemplated by this Agreement are not consummated, or (d) if the Closing has not occurred on or before the Outside Date (as
                    defined in the Merger Agreement), other than as a result of a Willful Breach of a Purchaser&#8217;s obligations hereunder, provided however, that the Outside Date may not be extended to any date that is more than eighteen months following the
                    date hereof without each Purchaser&#8217;s prior written consent; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that nothing herein shall relieve any party to this Agreement of any
                    liability for common law fraud or for any Willful Breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement. Upon any termination hereof prior to the issuance of the Securities, any
                    amounts paid by a Purchaser to the Company in connection with the transactions contemplated herein shall promptly (and in any event within one Business Day) be returned in full to such Purchaser by wire transfer of immediately available
                    funds to the account specified by such Purchaser, without any deduction for or on account of any tax withholding, charges or set-off. &#8220;<span style="font-style: italic; font-weight: bold;">Willful Breach</span>&#8221; means a deliberate act or
                    deliberate failure to act, taken with the actual knowledge that such act or failure to act would result in or constitute a material breach of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 40pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.15<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Third-Party Beneficiaries</span>. This Agreement is intended for the benefit of the parties hereto and their respective
                    successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person; <span style="font-style: italic;">provided</span>, <span style="font-style: italic;">however</span>, that
                    each of the Placement Agents will be entitled to rely, as an express third-party beneficiary, on the representations and warranties of the Purchasers and the Company set forth in <span style="text-decoration: underline;">Section&#160;3</span> and <span style="text-decoration: underline;">Section&#160;4</span> hereof, the
                    covenants set forth in <span style="text-decoration: underline;">Section&#160;5</span> hereof and <span style="text-decoration: underline;">Sections&#160;9.04</span>, <span style="text-decoration: underline;">9.05</span>, <span style="text-decoration: underline;">9.08</span>, <span style="text-decoration: underline;">9.13</span> and <span style="text-decoration: underline;">9.14</span> hereof. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">[<span style="font-style: italic;">Signature pages follow</span>] </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-18<br/>
        </div>

      </div>

    </div>

    <!--End Page 596-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 597-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">IN WITNESS WHEREOF<span style="font-weight: normal;">, the
              parties hereto have executed this Agreement as of the date first written above. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">COMPANY:<span style="font-weight: normal;"> </span></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.<span style="font-weight: normal;"> </span></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">a Delaware corporation </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:Peter Smith </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title: President and Chief Executive Officer</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">[Signature Page to the Subscription Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-19<br/>
        </div>

      </div>

    </div>

    <!--End Page 597-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 598-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">IN WITNESS WHEREOF<span style="font-weight: normal;">, the
              parties hereto have executed this Agreement as of the date first written above. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PURCHASER:<span style="font-weight: normal;"> </span></div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 216pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 216pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">[Signature Page to the Subscription Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-20<br/>
        </div>

      </div>

    </div>

    <!--End Page 598-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 599-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">SCHEDULE OF PURCHASERS</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 9.47pt; text-align: center;">[Signature Page to the Subscription Agreement]<br/>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-21<br/>
        </div>

      </div>

    </div>

    <!--End Page 599-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 600-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_306-annexg_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">Exhibit&#160;A<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;"><span style="text-decoration: underline;">Form&#160;of Registration Rights Agreement</span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">G-22<br/>
        </div>

      </div>

    </div>

    <!--End Page 600-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 601-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXH"><!--Anchor--></a>Annex&#160;H <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; text-align: center;">FORM OF REGISTRATION RIGHTS AGREEMENT </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">This Registration Rights Agreement (this &#8220;<span style="font-style: italic; font-weight: bold;">Agreement</span>&#8221;) is made and entered into as of [&#8226;] 2026, among Remix Therapeutics, Inc., a Delaware corporation (&#8220;<span style="font-style: italic; font-weight: bold;">Remix</span>&#8221;), Passage Bio, Inc., a Delaware
            corporation (&#8220;<span style="font-style: italic; font-weight: bold;">Passage</span>&#8221;), and each of the several investors signatory hereto. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, Remix and Passage are party to that certain Agreement and Plan of
            Merger by and among Remix, Peregrine Merger Sub, Inc., and Passage, dated as of June&#160;24, 2026 (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger Agreement</span>&#8221;), pursuant to which the Company will become a wholly-owned
            subsidiary of Passage (the &#8220;<span style="font-style: italic; font-weight: bold;">Merger</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, following the Effective Time (as defined in the Merger Agreement),
            Passage will change its name to Remix Therapeutics, Inc. (&#8220;<span style="font-style: italic; font-weight: bold;">TopCo</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, the Company and certain investors (the &#8220;<span style="font-style: italic; font-weight: bold;">Purchasers</span>&#8221;) are parties to a Subscription Agreement, dated as of June&#160;24, 2026 (the &#8220;<span style="font-style: italic; font-weight: bold;">Purchase Agreement</span>&#8221;), pursuant to which such Purchasers,
            severally and not jointly, are purchasing, prior to the Effective Time, shares of common stock of Remix (the &#8220;<span style="font-style: italic; font-weight: bold;">Purchased Shares</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, pursuant to that certain Convertible Promissory Note&#160;Purchase
            Agreement, dated as of June&#160;24, 2026 (the &#8220;<span style="font-style: italic; font-weight: bold;">Bridge Note&#160;Purchase Agreement</span>&#8221;), Remix has issued $[&#8226;] aggregate principal amount of convertible promissory notes (the &#8220;<span style="font-style: italic; font-weight: bold;">Bridge Notes</span>&#8221;) to certain lenders (the &#8220;<span style="font-style: italic; font-weight: bold;">Bridge Note&#160;Lenders</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, pursuant to that certain Convertible Promissory Note&#160;Purchase
            Agreement, dated as of November&#160;14, 2025, as amended by the Omnibus Amendment No. 1 to Convertible Promissory Note&#160;and Warrant Purchase Agreement and Notes, dated as of June&#160;24, 2026 (as amended, the &#8220;<span style="font-style: italic; font-weight: bold;">2025 Note&#160;Purchase Agreement</span>&#8221;), Remix has issued $29,988,211.99 aggregate principal amount of convertible promissory notes (the &#8220;<span style="font-style: italic; font-weight: bold;">2025 Notes</span>&#8221;) to certain
            lenders (the &#8220;<span style="font-style: italic; font-weight: bold;">2025 Notes Lenders</span>&#8221; and together with the Bridge Note&#160;Lenders, the &#8220;<span style="font-style: italic; font-weight: bold;">Lenders</span>&#8221;); </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, the Bridge Note&#160;Purchase Agreement and the 2025 Note&#160;Purchase
            Agreement provide that if, prior to the maturity date of the Bridge Notes and the 2025 Notes, as applicable, a PIPE Offering (as defined in each of the Bridge Note&#160;Purchase Agreement and the 2025 Note&#160;Purchase Agreement) is consummated, then
            the outstanding amount under each Bridge Note&#160;and each 2025 Note&#160;will be converted automatically and concurrently into a number of shares of common stock of Remix (the &#8220;<span style="font-style: italic; font-weight: bold;">Conversion Shares</span>&#8221;);

          </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, at the Effective Time by virtue of the Merger, the shares of common
            stock of Remix shall be automatically converted into the right to receive a number of shares of common stock, par value $0.0001 per share, of TopCo (the &#8220;<span style="font-style: italic; font-weight: bold;">Common Stock</span>&#8221;), in accordance
            with Section&#160;2.4(d) of the Merger Agreement; and </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">WHEREAS, in connection with the consummation of the transactions contemplated
            by the Purchase Agreement, and pursuant to the terms of the Purchase Agreement, the parties desire to enter into this Agreement in order to grant certain rights to the Purchasers and the Lenders as set forth below. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">NOW, THEREFORE, in consideration of the covenants and promises set forth
            herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Definitions</span>. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In addition to the terms defined herein, capitalized terms used and not
            otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given to such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221; means
            Remix Therapeutics, Inc. for all periods prior to the Effective Time and TopCo for all periods after the Effective Time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Effectiveness Date</span>&#8221;
            means, with respect to the Initial Registration Statement required to be filed hereunder, the 90th calendar day following the Effective Time (or, in the event of a &#8220;full review&#8221; by the Commission, the 120th&#160;calendar day following the Effective
            Time) and with respect to any additional Registration Statements that may be required pursuant to Sections 2(b) and 2(c) or Section&#160;3(c), the 60th calendar day following the date on which an additional Registration Statement is required to be
            filed hereunder (or, in the event of a &#8220;full review&#8221; by the Commission, the 90th calendar day following the date thereof); <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that in the event the Company is notified by the Commission (orally or in writing)
            that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 601-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 602-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">to such Registration Statement shall be the second (2nd) Trading Day
            following the date on which the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the
            next succeeding Trading Day. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Effectiveness Period</span>&#8221;
            shall have the meaning set forth in Section&#160;2(a). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Filing Date</span>&#8221;
            means, with respect to the Initial Registration Statement required hereunder, the 30th calendar day following the Effective Time, and, with respect to any additional Registration Statements that may be required pursuant to Sections 2(b) and
            2(c) or Section&#160;3(c), the 20th calendar day following the later of (i) the date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities and (ii) the date on which
            the Company becomes aware of the necessity of filing such additional Registration Statement related to the Registrable Securities. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Holder</span>&#8221; or &#8220;<span style="font-style: italic; font-weight: bold;">Holders</span>&#8221; means the holder or holders, as the case may be, from time to time of Registrable Securities. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Indemnified Party</span>&#8221;
            shall have the meaning set forth in Section&#160;5(c). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Indemnifying Party</span>&#8221;
            shall have the meaning set forth in Section&#160;5(c). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Initial Registration
              Statement</span>&#8221; means the initial Registration Statement filed pursuant to this Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Losses</span>&#8221; shall
            have the meaning set forth in Section&#160;5(a). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Plan of Distribution</span>&#8221;
            shall have the meaning set forth in Section&#160;2(a). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Prospectus</span>&#8221;
            means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon
            Rule&#160;430A or Rule&#160;430B promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a
            Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Registrable Securities</span>&#8221;
            means, as of any date of determination, (a) all shares of TopCo common stock issued to the Purchaser and/or their respective affiliates at the closing of the Merger in respect of the Purchased Shares, (b)&#160;all shares of TopCo common stock issued
            to the Lenders and/or their respective affiliates at the closing of the Merger in respect of the Conversion Shares, (c) all shares of TopCo issued at the closing of the Merger to the Purchasers and the Lenders and/or their respective affiliates
            in respect of all other shares of capital stock of Remix held by the Purchasers and the Lenders and/or their respective affiliates as of immediately prior to the Effective Time, and (d) any securities issued or then issuable upon any stock
            split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not
            be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) upon the earliest to occur of (i) a Registration Statement with respect to the sale of such Registrable Securities is
            declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (ii) such Registrable Securities have been previously
            sold in accordance with Rule&#160;144, (iii) such time as Rule&#160;144 or another similar exemption under the Securities Act is available for the sale of all of such Holder&#8217;s shares without limitation during a three-month period without registration,
            (iv) with respect to Registrable Securities held by a Holder that is not an affiliate of the Company, upon exchange of such Registrable Securities for unrestricted shares under an effective registration statement on Form&#160;S-4, if available and
            assuming any applicable legends (if any) are removed from such Registrable Securities, and (v) three years after the date of this Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Registration Statement</span>&#8221;
            means any registration statement required to be filed hereunder pursuant to Section&#160;2(a) and any additional registration statements contemplated by Section&#160;2(c) or Section&#160;3(c), including (in each case) the Prospectus, amendments and
            supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration
            statement. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 602-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 603-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Rule&#160;415</span>&#8221;
            means Rule&#160;415 promulgated by the Commission pursuant to the Securities Act, as such Rule&#160;may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same
            purpose and effect as such Rule. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">Rule&#160;424</span>&#8221; means
            Rule&#160;424 promulgated by the Commission pursuant to the Securities Act, as such Rule&#160;may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and
            effect as such Rule. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;<span style="font-style: italic; font-weight: bold;">SEC Guidance</span>&#8221;
            means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff (whether or not publicly-available); provided, that any such oral guidance, comments,
            requirements or requests are reduced to writing by the Commission and (ii) the Securities Act. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Selling Stockholder
              Questionnaire</span>&#8221; shall have the meaning set forth in Section&#160;3(a). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-align: left;">&#8220;<span style="font-style: italic; font-weight: bold;">Trading Day</span>&#8221;
            means any day on which the TopCo&#8217;s common stock is traded on a National Exchange. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Shelf Registration</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the
                    resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule&#160;415. Each Registration Statement filed hereunder shall
                    contain (unless otherwise directed by Holders holding at least 85% of Registrable Securities) disclosure substantially in the form of the &#8220;<span style="font-style: italic; font-weight: bold;">Plan of Distribution</span>&#8221; attached hereto
                    as <span style="text-decoration: underline;">Annex&#160;A</span> and substantially in the form of the &#8220;<span style="font-style: italic; font-weight: bold;">Selling Stockholder</span>&#8221; section attached hereto as <span style="text-decoration: underline;">Annex&#160;B</span>. Subject to the terms of this Agreement, the Company
                    shall use commercially reasonable efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under Section&#160;3(c)) to be declared effective under the Securities Act as promptly as possible after
                    the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities Act, and to be
                    supplemented and amended to the extent necessary to ensure that such Registration Statement is available or, if not available, that another Registration Statement is available, for the resale of all Registrable Securities held by the
                    Holders until the earlier of (a) the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule&#160;144, or (ii) may be sold without volume or manner-of-sale restrictions
                    pursuant to Rule&#160;144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule&#160;144 and (b) three years after the date of this Agreement (the &#8220;<span style="font-style: italic; font-weight: bold;">Effectiveness Period</span>&#8221;). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall notify the Holders
                    via e-mail of the effectiveness of a Registration Statement no more than one (1) Trading Day following confirmation of effectiveness with the Commission. The Company shall, in accordance with SEC Guidance, file a final Prospectus with
                    the Commission as required by Rule&#160;424. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding the registration obligations set forth in Section&#160;2(a), if the Commission informs the Company that all of the
                    Registrable Securities cannot, as a result of the application of Rule&#160;415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly inform each of the Holders thereof and use
                    commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on Form&#160;S-3 or
                    such other form available to register for resale the Registrable Securities as a secondary offering; with respect to filing on Form&#160;S-3 or other appropriate form; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that prior to filing such amendment,
                    the Company shall be obligated to use commercially reasonable efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If at any time the Commission takes the position that the offering of some or all of the Registrable Securities in a
                    Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule&#160;415 under the Securities Act (provided, however, the Company shall be obligated to use commercially reasonable efforts to
                    advocate with the Commission for the registration of all of the Registrable Securities) or requires any Holder to be named as an &#8220;underwriter,&#8221; the Company shall (i) promptly notify each holder of Registrable Securities thereof and (ii)
                    make commercially reasonable efforts to persuade the Commission that </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 603-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 604-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">the offering contemplated by such Registration Statement is a valid
            secondary offering and not an offering &#8220;by or on behalf of the issuer&#8221; as defined in Rule&#160;415 and that none of the Holders is an &#8220;underwriter.&#8221; Each Holder shall have the right to have its legal counsel, at such Holder&#8217;s expense, to review and
            oversee any registration or matters pursuant to this Section&#160;2(c), including to comment on any written submission made to the Commission with respect thereto. In the event that, despite the Company&#8217;s commercially reasonable efforts and
            compliance with the terms of this Section&#160;2(c), the Commission refuses to alter its position, the Company shall (i) remove from such Registration Statement such portion of the Registrable Securities and/or (ii) agree to such restrictions and
            limitations on the registration and resale of the Registrable Securities as the Commission may require to assure the Company&#8217;s compliance with the requirements of Rule&#160;415 (collectively, the &#8220;<span style="font-style: italic; font-weight: bold;">SEC
              Restrictions</span>&#8221;)&#894; provided, however, that the Company shall not name any Holder as an &#8220;underwriter&#8221; in such Registration Statement without the prior written consent of such Holder (provided that, in the event an Holder withholds such
            consent, the Company shall have no obligation hereunder to include any Registrable Securities of such Holder in any Registration Statement covering the resale thereof until such time as the Commission no longer requires such Holder to be named
            as an &#8220;underwriter&#8221; in such Registration Statement or such Holder otherwise consents in writing to being so named). Any cutback imposed on the Holders pursuant to this Section&#160;2(c) shall be allocated among the Holders by reducing Registrable
            Securities represented by shares of Common Stock (applied, in the case that some of such shares of Common Stock may be registered, to the Holders on a pro rata basis based on the total number of such unregistered shares of Common Stock held by
            such Holders, but excluding from such pro rata calculation any unregistered shares of Common Stock held by a Holder that the Commission has deemed to be an &#8220;underwriter&#8221; or otherwise requires such Holder to sell its shares of Common Stock in a
            primary offering). In the event of a cutback hereunder, the Company shall give the Holder at least two (2) Trading Days prior written notice along with the calculations as to such Holder&#8217;s allotment. In the event the Company amends the Initial
            Registration Statement in accordance with the foregoing, the Company will use its commercially reasonable efforts to file with the Commission, as promptly as allowed by the Commission or SEC Guidance provided to the Company or to registrants of
            securities in general, one or more registration statements on Form&#160;S-3 or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If Form&#160;S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i)
                    register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form&#160;S-3 promptly as practicable after such form is available, provided that the Company shall
                    maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form&#160;S-3 covering the Registrable Securities has been declared effective by the Commission. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Registration Procedures</span>. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">In connection with the Company&#8217;s registration obligations hereunder, the Company
            shall: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As far in advance as reasonably practicable, but in any event not less than five (5) Trading Days prior to the filing of each
                    Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto, the Company shall (i) furnish to each Holder copies of all such documents proposed to be
                    filed, which documents will be subject to the review of such Holders, and (ii) use commercially reasonable efforts to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries
                    as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act, provided that the Company shall redact any sections of such documents
                    that may contain material non-public information unless the Holder consents in writing to receive such information and agrees to hold it in confidence. The Company shall not file a Registration Statement or any such Prospectus or any
                    amendments or supplements thereto (A) containing information regarding any Holder to which such Holder reasonably objects in good faith, provided that the Company is notified of such objection in writing no later than three (3)&#160;Trading
                    Days after the Holders have been so furnished copies of a Registration Statement or one (1)&#160;Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto, or (B) to which the
                    Required Holders shall reasonably (x) object or (y) believe contains an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the
                    circumstances under which they were made, not misleading, </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 604-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 605-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">unless such information is required (in the good faith opinion of the
            Company) to comply with any applicable law or regulation or SEC Guidance. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as <span style="text-decoration: underline;">Annex&#160;C</span> or such other form as reasonably
            acceptable to the Company (a &#8220;<span style="font-style: italic; font-weight: bold;">Selling Stockholder Questionnaire</span>&#8221;) on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the third (3rd) Trading
            Day following the date on which such Holder receives draft materials in accordance with this Section. The Company shall not be required to include any Registrable Securities in the Registration Statement for any Holder that has not provided
            such Selling Stockholder Questionnaire. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Each Holder shall cooperate with the Company as reasonably requested in connection with the preparation of each Registration
                    Statement, including responding promptly to any comments from the Commission relating to information provided by or concerning such Holder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement
                    and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the
                    Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus
                    supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule&#160;424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a
                    Registration Statement or any amendment thereto and, upon request of Holders, provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration
                    Statement (provided that, the Company shall excise any information contained therein that would constitute material non-public information regarding the Company or any of its subsidiaries), and (iv) comply in all material respects with
                    the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of
                    this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of
                    Common Stock then registered in a Registration Statement, then the Company shall, subject to Sections 2(b) and 2(c), if applicable, file as soon as reasonably practicable, an additional Registration Statement covering the resale by the
                    Holders of not less than the number of such Registrable Securities. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (v)&#160;hereof, be
                    accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1)&#160;Trading Day prior to such filing)
                    and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is
                    proposed to be filed, (B) when the Commission notifies the Company whether there will be a &#8220;review&#8221; of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a
                    Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration
                    Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any
                    or all of the Registrable Securities or the initiation of any Proceeding for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any
                    of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity (a &#8220;<span style="font-style: italic; font-weight: bold;">Proceeding</span>&#8221;) for such purpose, and (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any
                    statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement,
                    Prospectus or other documents so that, in the case of a Registration </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 605-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 606-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Statement or the Prospectus, as the case may be, it will not contain any
            untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>,
            that in no event shall any such notice contain any information that would constitute material, non-public information regarding the Company or any of its subsidiaries. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Use its commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order
                    stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest
                    practicable moment. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If requested by a Holder, furnish to each Holder, without charge, an electronic copy of the conformed copy of each such
                    Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to
                    the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item that is available on the EDGAR system
                    (or successor thereto) need not be furnished. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or
                    supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant
                    to Section&#160;3(d). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or
                    cooperate with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky
                    laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other
                    acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally to do
                    business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In connection with any sale pursuant to an effective Registration Statement, if requested by a Holder, promptly (and in any
                    event within five (5) Trading Days of such request) deliver to Holder certificates or book entry statements, as applicable, representing Registrable Securities to be delivered to a transferee pursuant to such effective Registration
                    Statement, which certificates shall be free of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in the name of the transferee as such Holder may reasonably request. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Upon the occurrence of any event contemplated by Section&#160;3(d)(iii) through (v), as promptly as reasonably possible under the
                    circumstances taking into account the Company&#8217;s good faith determination of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a
                    post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter
                    delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of
                    the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (v) of Section&#160;3(d) above to suspend the use of any Prospectus until the requisite changes to
                    such Prospectus have been made, then the Holders shall suspend use of such Prospectus; provided that the Company shall only be entitled to exercise its right under this Section&#160;3(k) to suspend the availability of a Registration
                    Statement and Prospectus up to two (2) occasions in any 12-month period for a period not to exceed forty five (45) consecutive days or a total of ninety (90) calendar days, in each case in any such 12-month period. The Company will use
                    its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is reasonably practicable. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 606-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 607-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the
                    Securities Act and the Exchange Act, including, without limitation, Rule&#160;172 under the Securities Act, file any final Prospectus, including any supplement or amendment thereof, with the Commission pursuant to Rule&#160;424 under the
                    Securities Act, promptly inform the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule&#160;172 and, as a result thereof, the Holders are required to deliver a
                    Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company shall use its commercially reasonable efforts to maintain eligibility for use of Form&#160;S-3 (or any successor form
                    thereto) for the registration of the resale of the Registrable Securities once eligible to use such form. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of
                    Common Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(o)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company shall use its reasonable best efforts to cause all Registrable Securities to be listed on each securities
                    exchange or market, if any, on which the shares of Passage common stock are listed. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(p)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company shall, at its sole expense, upon appropriate notice from a Holder stating that Registrable Securities have been
                    sold or transferred pursuant to an effective Registration Statement, promptly (and in any event within five (5) Trading Days of such notice) prepare and deliver certificates or evidence of book-entry positions representing the
                    Registrable Securities to be delivered to a transferee pursuant to such Registration Statement, which certificates or book-entry positions shall be free of any restrictive legends and in such denominations and registered in such names
                    as the undersigned may request. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(q)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery
                    of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule&#160;144 free of any restrictive legends and representing such number of shares of Common Stock and
                    registered in such names as the holders of the Registrable Securities may reasonably request to the extent permitted by such Registration Statement or Rule&#160;144 to effect sales of Registrable Securities, provided that the Company has
                    timely received from the holder customary representations and other documentation, including broker representation letters reasonably acceptable to the Company and the transfer agent; for the avoidance of doubt, the Company may satisfy
                    its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company&#8217;s Direct Registration System. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Registration Expenses</span>. All fees and expenses incident to the performance of or compliance with this Agreement by the
                    Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all
                    registration and filing fees (including, without limitation, fees and expenses of the Company&#8217;s counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B)&#160;with respect to filings
                    required to be made with any National Exchange on which the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including,
                    without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing
                    certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, (vi)
                    fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement, including the Company&#8217;s transfer agent, and (vii) solely in connection with the
                    review and filing of the initial Registration Statement, the reasonable fees and expenses, not to exceed $50,000, of one counsel for the selling Holders selected by the Holders of a majority of the Registrable Securities to be
                    registered. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and
                    expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 607-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 608-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">incurred in connection with the listing of the Registrable Securities on
            any securities exchange as required hereunder. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Holder or, except to the extent provided for in the Purchase Agreement or this
            Agreement, any legal fees or other costs of the Holders. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Indemnification</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Indemnification by the Company</span>. The Company shall, notwithstanding any termination of this Agreement, indemnify and
                    hold harmless each Holder and its affiliates, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under
                    a margin call of Common Stock), investment advisors and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each
                    Person who controls any such Holder (within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons
                    with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and
                    all losses, claims, damages, liabilities, costs (including, without limitation, reasonable and documented attorneys&#8217; fees) and expenses (collectively, &#8220;<span style="font-style: italic; font-weight: bold;">Losses</span>&#8221;), as incurred,
                    arising out of or based solely upon (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any
                    preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto,
                    in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
                    in connection with the performance of its obligations under this Agreement (the matters in the foregoing clauses (1) and (2) being, collectively, &#8220;<span style="font-style: italic; font-weight: bold;">Violations</span>&#8221;), except to the
                    extent, but only to the extent, that (i) such untrue statements or omissions are based upon information regarding such Holder furnished in writing to the Company by such Holder or indemnified person expressly for use therein and that
                    has not been corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the Person asserting the claim, (ii) in the case of an occurrence of an event of the type specified in
                    Section&#160;3(d)(iii)-(v), such Losses result from the use by such Holder or indemnified person of an outdated, defective or otherwise unavailable prospectus if the untrue statement or omission of material fact contained in such prospectus
                    was corrected in a revised prospectus, as then amended or supplemented, and the Holder or indemnified person was promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a
                    Violation&#894; (iii) shall not be available to the extent such claim is based on a failure of the relevant Holder or indemnified person to deliver, or cause to be delivered, if required, the prospectus to the Persons asserting an untrue
                    statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of Registrable Securities&#894; and (iv) shall not apply to amounts paid in settlement of any claim if such settlement is
                    effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding
                    arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such
                    indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section&#160;6(f). </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Indemnification by Holders</span>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its
                    directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section&#160;15 of the Securities Act and Section&#160;20 of the Exchange Act), and the directors, officers, agents or employees of such
                    controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon any untrue or alleged untrue statement of a material fact contained in
                    any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein
                    or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading to the extent, but only to the extent, that (i) such untrue
                    statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion in such </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 608-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 609-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">Registration Statement or such Prospectus, including information provided
            in the Selling Stockholder Questionnaire and that has not been corrected in a subsequent writing prior to or concurrently with the sale of Registrable Securities to the Person asserting the claim, or (ii) such Losses arise from such Holder&#8217;s
            violation of its obligations under this Agreement. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to
            this Section&#160;5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable Securities included in the Registration
            Statement giving rise to such indemnification obligation. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Conduct of Indemnification Proceedings</span>. If any Proceeding shall be brought or asserted against any Person entitled to
                    indemnity hereunder (an &#8220;<span style="font-style: italic; font-weight: bold;">Indemnified Party</span>&#8221;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#8220;<span style="font-style: italic; font-weight: bold;">Indemnifying Party</span>&#8221;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the
                    payment of all reasonable fees and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities
                    pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have
                    materially and adversely prejudiced the Indemnifying Party. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">An Indemnified Party shall have the right to employ separate counsel in any
            such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and
            expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such
            Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a conflict of interest is likely to exist if the same counsel were
            to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the
            Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). Notwithstanding anything in this Section 5,
            the Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written
            consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on
            claims that are the subject matter of such Proceeding. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">Subject to the terms of this Agreement, all reasonable and documented fees
            and expenses of the Indemnified Party (including reasonable and documented fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be
            paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and
            expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Contribution</span>. If the indemnification under Section&#160;5(a) or 5(b) is unavailable to an Indemnified Party or insufficient
                    to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the
                    Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and
                    Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been
                    taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or
                    omission; </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 609-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 610-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">provided, however, that no Person guilty of fraudulent misrepresentation
            (within the meaning of Section&#160;11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The amount paid or payable by a party as a result of any Losses shall be
            deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&#8217; or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for
            such fees or expenses if the indemnification provided for in this Section&#160;5 was available to such party in accordance with its terms. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">The parties hereto agree that it would not be just and equitable if
            contribution pursuant to this Section&#160;5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. In no event
            shall the contribution obligation of a Holder of Registrable Securities, when combined with any amounts owed under Section&#160;5(b) be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection
            with any claim relating to this Section&#160;5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the
            Registrable Securities giving rise to such contribution obligation. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">The indemnity and contribution agreements contained in this Section&#160;5(d) are
            in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">Miscellaneous</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Remedies</span>. In the event of a breach by the Company or by a Holder of any of their respective obligations under this
                    Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its
                    rights under this Agreement. Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and
                    that the obligations of the parties hereunder shall be specifically enforceable. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Piggyback on Registrations; Prohibition on Filing Other Registration Statements</span>. Neither the Company nor any of its
                    securityholders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statement filed pursuant to this Agreement other than the Registrable Securities The Company shall not
                    file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, provided that this Section&#160;6(b) shall not prohibit the Company
                    from filing amendments to registration statements filed prior to the date of this Agreement so long as no new securities are registered on any such existing registration statements, nor preparing and filing with the Commission a
                    registration statement on Form&#160;S-8 relating to its equity incentive plans, nor filing a shelf registration statement on Form&#160;S-3 for securities held by stockholders who are parties to separate registration rights agreements entered into
                    prior to the date hereof or in connection with the Merger, nor filing any registration statement required by the terms of the Merger Agreement in connection with the issuance of securities as merger consideration, nor filing any
                    registration statement as may be required to comply with applicable law or the rules of any national securities exchange. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Discontinued Disposition</span>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a
                    notice from the Company of the occurrence of any event of the kind described in Section&#160;3(d)(iii) through (v), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is
                    advised in writing (the &#8220;<span style="font-style: italic; font-weight: bold;">Advice</span>&#8221;) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use
                    its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Amendments and Waivers</span>. The provisions of this Agreement, including the provisions of this sentence, may not be
                    amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Required Holders, provided that, (i) if any
                    amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall be required, (ii) any amendment, modification
                    or waiver of the definition of Registrable Securities, Filing Date, Effectiveness Date, Effectiveness Period, Section&#160;5 or this Section&#160;6(d) shall require the consent </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 610-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 611-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">of each Holder affected by such amendment, modification or waiver, (iii)
            the consent of all Holders is required for any amendment or modification that creates or imposes new or additional obligations on the Holders, including, without limitation, any lockup agreement, and (iv) any amendment, modification or waiver
            that would increase the Company&#8217;s obligations or liabilities hereunder or shorten any time period for Company performance shall require the prior written consent of the Company. If a Registration Statement does not register all of the
            Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall
            have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates
            exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or consent
            relates; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section&#160;6(d). No consideration shall be
            offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement. As used herein, &#8220;<span style="font-style: italic; font-weight: bold;">Required Holders</span>&#8221; means Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes any securities issuable upon conversion or exercise of any
            Registrable Security). </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Notices</span>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
                    shall be delivered as set forth in the Purchase Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Successors and Assigns</span>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted
                    assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger or other transaction in which the Registrable Securities are converted into the equity securities of another
                    Person, in which case such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder) its rights or obligations hereunder without the prior written consent of the Required Holders.
                    Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under Section&#160;9.04 of the Purchase Agreement, provided each such assignee agrees to be bound by the terms of this Agreement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">No Inconsistent Agreements</span>. Neither the Company nor any of its subsidiaries has entered, as of the date hereof, nor
                    shall the Company or any of its subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement
                    or otherwise conflicts with the provisions hereof. Neither the Company nor any of its subsidiaries has previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that have
                    not been satisfied in full; provided that the Company shall not be deemed to be in breach of this Section&#160;6(g) solely by reason of any registration rights agreement entered into in connection with the Merger Agreement or any equity
                    incentive plan of the Company. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Execution and Counterparts</span>. This Agreement may be executed in two or more counterparts, all of which when taken
                    together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same
                    counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; format data file or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g.,
                    www.docusign.com), such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page was an
                    original thereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Governing Law</span>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement
                    shall be determined in accordance with the provisions of the Purchase Agreement and Section&#160;9.07 is hereby incorporated herein <span style="font-style: italic;">mutatis mutandis</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Cumulative Remedies</span>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by
                    law. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Severability</span>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent
                    jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-11<br/>
        </div>

      </div>

    </div>

    <!--End Page 611-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 612-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">restrictions set forth herein shall remain in full force and effect and
            shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by
            such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that
            may be hereafter declared invalid, illegal, void or unenforceable. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(l)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Headings</span>. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall
                    not be deemed to limit or affect any of the provisions hereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(m)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Independent Nature of Holders&#8217; Obligations and Rights</span>. The obligations of each Holder hereunder are several and not
                    joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document
                    delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of group or entity, or create a
                    presumption that the Holders are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the
                    Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including without
                    limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the
                    obligations of the Company contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by any
                    Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the Holders collectively and not between and among Holders. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(n)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Non-Recourse</span>. Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants,
                    agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, stockholder, general or
                    limited partner or member of any Holder or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it
                    being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or
                    member of any Holder or of any affiliates or assignees thereof, as such for any obligation of any Holder under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect
                    of or by reason of such obligations or their creation. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">(<span style="font-style: italic;">Signature Pages Follow</span>) </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-12<br/>
        </div>

      </div>

    </div>

    <!--End Page 612-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 613-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">IN WITNESS WHEREOF<span style="font-weight: normal;">,
              the parties have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the date first written above. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 468pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 252pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-13<br/>
        </div>

      </div>

    </div>

    <!--End Page 613-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 614-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">IN WITNESS WHEREOF<span style="font-weight: normal;">,
              the parties have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the date first written above. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 468pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PASSAGE BIO, INC. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 252pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-14<br/>
        </div>

      </div>

    </div>

    <!--End Page 614-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 615-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">IN WITNESS WHEREOF<span style="font-weight: normal;">,
              the parties have caused their respective signature page to this Registration Rights Agreement to be duly executed as of the date first written above. </span></div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 468pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">INVESTOR: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[&#8226;] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

  </tr>

  <tr>

    <td style="width: 204pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 252pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 252pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-15<br/>
        </div>

      </div>

    </div>

    <!--End Page 615-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 616-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><span style="text-decoration: underline;">Annex&#160;A</span><span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 12pt; text-align: center;"><span style="text-decoration: underline;">Plan of Distribution</span> </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Each Selling Stockholder (the &#8220;<span style="font-style: italic; font-weight: bold;">Selling Stockholders</span>&#8221;) of the securities and any of their pledgees, assignees, donees (including charitable organizations), transferees or other successors-in-interest may, from time to time, sell, transfer or otherwise dispose
            of any or all of their securities covered hereby either directly by such person, through underwriters, dealers or agents, on any principal Trading Market or any other stock exchange, market or trading facility on which the securities are
            traded, in the over-the-counter market or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of
                    the block as principal to facilitate the transaction, or in crosses, in which the same broker acts as agent on both sides of the trade; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an exchange distribution in accordance with the rules of the applicable exchange; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the pledge of securities for any loan or obligation </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">privately negotiated transactions; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through the writing or settlement of short sales entered into after the effective date of the registration statement of which
                    the prospectus will form a part; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through distribution by a Selling Stockholder or its successor in interest to its members, general or limited partners or
                    stockholders (or their respective members, general or limited partners, beneficiaries or stockholders) </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities
                    at a stipulated price per security; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
                  </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a combination of any such methods of sale; or </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other method permitted pursuant to applicable law. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Selling Stockholders may also sell securities under Rule&#160;144 or any other
            exemption from registration under the Securities Act of 1933, as amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Securities Act</span>&#8221;), if available, or otherwise as permitted pursuant to applicable law, rather than under
            this prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Selling Stockholders may distribute the securities covered by this
            prospectus from time to time in one or more transactions: (i) at a fixed price or prices, which may be changed from time to time; (ii) at market prices prevailing at the time of sale; (iii) at prices related to the prevailing market prices; or
            (iv) at negotiated prices. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Broker-dealers engaged by the Selling Stockholders may arrange for other
            brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated,
            but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule&#160;2121; and in the case of a principal transaction a markup or
            markdown in compliance with FINRA Rule&#160;2121. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the sale of the securities or interests therein, the
            Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders
            may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or
            other transactions with broker-dealers or other financial institutions or create one or more derivative securities that require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which
            securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-A-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 616-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 617-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Selling Stockholders also may from time to time pledge or grant a
            security interest in some or all of the securities owned by them that are subject to this prospectus, and the pledgees or secured parties will, upon foreclosure in the event of default, be deemed to be Selling Stockholders. If and to the extent
            such foreclosure occurs, the number of securities under this prospectus on behalf of such Selling Stockholder will decrease by the number of securities subject to any such foreclosure. The Selling Stockholders also may transfer the securities
            in other circumstances, in which case the transferees, pledgees, donees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">A Selling Stockholder that is an entity may elect to make an in-kind
            distribution of securities to its members, general or limited partners, beneficiaries or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Selling Stockholders and any broker-dealers or agents that are involved in
            selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any discounts, commissions or concessions received by such broker-dealers or agents and any profit
            on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed us that it does not have any written or oral agreement or understanding,
            directly or indirectly, with any person to distribute the securities. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are required to pay certain fees and expenses incurred by us incident to
            the registration of the securities. We have agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We agreed to keep this prospectus effective until the earlier of (a) the date
            that the securities (i) have been sold, pursuant to this prospectus or pursuant to Rule&#160;144, or (ii) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or
            manner-of-sale limitations by reason of Rule&#160;144, and without the requirement for us to be in compliance with the current public information under Rule&#160;144 under the Securities Act or any other rule of similar effect and (b) [&#8226;]. The resale
            securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been
            registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under applicable rules and regulations under the Exchange Act, any person
            engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the
            distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common
            stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the
            time of the sale (including by compliance with Rule&#160;172 under the Securities Act). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">To the extent required, this prospectus may be amended or supplemented from
            time to time to describe a specific plan of distribution. There can be no assurances that the Selling Stockholders will sell any or all of the securities offered under this prospectus. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-A-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 617-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 618-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><span style="text-decoration: underline;">Annex&#160;B</span> </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">SELLING STOCKHOLDERS </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For additional information regarding the issuances of those shares of common
            stock being registered for resale in this registration statement, see &#8220;Private Placement of Shares of Common Stock&#8221; and &#8220;Business Combination of [&#8226;] and [&#8226;]&#8221; above. We are registering the shares of common stock in order to permit the selling
            stockholders to offer the shares for resale from time to time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The table below lists the selling stockholders and other information regarding
            the beneficial ownership of the shares of common stock by each of the selling stockholders. The second column lists the number of shares of common stock beneficially owned by each selling stockholder, based on its ownership of the shares of
            common stock, as of ________, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The third column lists the shares of common stock being offered by this
            prospectus by the selling stockholders. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fourth column reflects the number of shares of common stock beneficially
            owned by each selling stockholder, assuming the sale of all of the shares offered by the selling stockholders pursuant to this prospectus. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The selling stockholders may sell all, some or none of their shares in this
            offering. See &#8220;Plan of Distribution&#8221;. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 120pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 79.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 74.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 79.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 120pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name of Selling <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stockholder </div>
                </td>

    <td style="width: 19.22pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 79.09pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock Owned <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Prior to Offering </div>
                </td>

    <td style="width: 19.22pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 74.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Maximum Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Shares of Common<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Stock to be Sold<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pursuant to this<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Prospectus </div>
                </td>

    <td style="width: 19.22pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 79.09pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of Shares of <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock Owned<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">After Offering</div>
                </td>

  </tr>

  <tr>

    <td style="width: 120pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 19.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 79.09pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 19.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 74.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 19.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 79.09pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 120pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 79.09pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 74.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 79.09pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 120pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 79.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 74.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 19.22pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 79.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-B-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 618-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 619-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><span style="text-decoration: underline;">Annex&#160;C</span><span style="font-weight: normal;"> </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;">Selling Stockholder Notice and Questionnaire </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The undersigned owner of Registrable Securities (as such term is defined in
            the Registration Rights Agreement) of Passage Bio, Inc., a Delaware corporation (the &#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221;) (to be renamed Remix Therapeutics, Inc.), understands that the Company has filed or
            intends to file with the Securities and Exchange Commission (the &#8220;<span style="font-style: italic; font-weight: bold;">Commission</span>&#8221;) a Registration Statement for the registration and resale under Rule&#160;415 of the Securities Act of 1933, as
            amended (the &#8220;<span style="font-style: italic; font-weight: bold;">Securities Act</span>&#8221;), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement dated as of [ &#8226; ], 2026 to which the Company and the
            undersigned are parties (the &#8220;<span style="font-style: italic; font-weight: bold;">Registration Rights Agreement</span>&#8221;). A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below.
            All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Certain legal consequences arise from being named as a selling stockholder in
            the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as
            a selling stockholder in the Registration Statement and the related prospectus. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;">NOTICE </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The undersigned beneficial owner (the &#8220;<span style="font-style: italic; font-weight: bold;">Selling Stockholder</span>&#8221;) of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The undersigned hereby provides the following information to the Company and
            represents and warrants that such information is accurate: </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;">QUESTIONNAIRE </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Name. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 444pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(a)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Full Legal Name of Selling Stockholder </div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(b)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Full Legal Name of Registered Holder (if not the same as (a) above)
                    through which Registrable Securities are held:</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(c)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Full Legal Name of Natural Control Person (which means a natural person
                    who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 12pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 444pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Address for Notices to Selling Stockholder: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 480pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 384pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Telephone: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 384pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Fax: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 384pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 84pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Contact Person:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 384pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 384pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Broker-Dealer Status: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 444pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(a)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Are you a broker-dealer? </div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Yes <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> &#8195;&#8195; No <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(b)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">If &#8220;yes&#8221; to Section&#160;3(a), did you receive your Registrable Securities as
                    compensation for investment banking services to the Company? </div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Yes <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> &#8195;&#8195; No <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Note:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">If &#8220;no&#8221; to Section&#160;3(b), the Commission&#8217;s staff has indicated that you
                    should be identified as an underwriter in the Registration Statement. </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 444pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-C-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 619-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 620-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 444pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(c)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Are you an affiliate of a broker-dealer? </div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Yes <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> &#8195;&#8195; No <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(d)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">If you are an affiliate of a broker-dealer, do you certify that you
                    purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to
                    distribute the Registrable Securities? </div>
                </td>

  </tr>

  <tr>

    <td colspan="4" style="width: 468pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Yes <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> &#8195;&#8195; No <span style="font-size: 1pt;">&#8201;</span><span style="font-family: Arial, Helvetica, sans-serif;">&#9744;</span> </div>
                </td>

  </tr>

  <tr>

    <td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Note:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 444pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">If &#8220;no&#8221; to Section&#160;3(d), the Commission&#8217;s staff has indicated that you
                    should be identified as an underwriter in the Registration Statement.</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 444pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Ownership of Securities of the Company Owned by the Selling Stockholder. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 420pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 420pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Except as set forth below in this Item&#160;4, the
                    undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.<span style="font-style: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">(a)</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Type and Amount of other Company securities owned by the Selling
                    Stockholder (including beneficially owned, as applicable): </div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 420pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 420pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 420pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Relationships with the Company: </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 420pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 420pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 0pt; margin-left: 0pt; text-align: left;">Except as set forth below, neither the undersigned
                    nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company
                    (or its predecessors or affiliates) during the past three years.<span style="font-style: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State any exceptions here:</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 120pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 288pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 420pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 420pt; border-bottom: 1pt solid #000000;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-C-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 620-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 621-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_307-annexh_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The undersigned agrees to promptly notify the Company of any material
            inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company
            of any changes to the number of securities held or owned by the undersigned or its affiliates. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">By signing below, the undersigned consents to the disclosure of the
            information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such
            information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this
            Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 189pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 144pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 75pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Beneficial Owner: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 189pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 144pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 189pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 144pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 24pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 144pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 24pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED NOTICE
            AND QUESTIONNAIRE TO:</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">H-C-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 621-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 622-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_308-annexi_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXI"><!--Anchor--></a>Annex&#160;I </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">FORM OF CERTIFICATE OF AMENDMENT TO THE<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">RESTATED CERTIFICATE OF INCORPORATION<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195;<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">PASSAGE BIO, INC. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Passage Bio, Inc. (the &#8220;<span style="font-style: italic; font-weight: bold;">Corporation</span>&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;<span style="font-style: italic; font-weight: bold;">DGCL</span>&#8221;), does hereby
            certify as follows: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.&#8195;This Certificate of Amendment (this &#8220;<span style="font-style: italic; font-weight: bold;">Certificate of Amendment</span>&#8221;) amends the provisions of the Corporation&#8217;s Restated Certificate of Incorporation filed with the Delaware Secretary of State on May&#160;30, 2023, as amended by the
            Certificate of Amendment filed with the Delaware Secretary of State on November&#160;11, 2025 (the &#8220;<span style="font-style: italic; font-weight: bold;">Certificate of Incorporation</span>&#8221;). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.&#8195;Pursuant to Section&#160;242 of the DGCL, the Board of
            Directors of the Corporation has duly adopted this Certificate of Amendment, and the Corporation&#8217;s stockholders have duly approved this Certificate of Amendment. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.&#8195;Section&#160;1 of Article&#160;IV of the Certificate of
            Incorporation is hereby amended by adding the following paragraph to the end of such section: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">&#8220;Effective at 12:01 a.m. Eastern Time on &#8195;&#8195;, 2026 (the &#8220;<span style="font-style: italic; font-weight: bold;">Effective Time</span>&#8221;), each &#8195;&#8195; shares of Common Stock then issued and outstanding, or held in treasury of the Corporation, immediately prior to the Effective Time shall automatically be
            reclassified and converted into one (1) share of Common Stock, without any further action by the Corporation or the respective holders of such shares (the &#8220;<span style="font-style: italic; font-weight: bold;">Reverse</span> <span style="font-style: italic; font-weight: bold;">Stock Split</span>&#8221;). No fractional shares shall be issued in connection with the Reverse Stock Split. A holder of Common Stock who would otherwise be entitled to receive a fractional share of
            Common Stock as a result of the Reverse Stock Split will receive cash in lieu of such fractional share.&#8221; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.&#8195;The foregoing terms and provisions of this Certificate of
            Amendment shall be effective as of the Effective Time. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">5.&#8195;Except as herein amended, the Certificate of Incorporation
            shall remain in full force and effect. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 26.5pt; text-align: center;">[Signature appears on the following page.]<span style="font-style: normal;"> </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 622-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 623-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_308-annexi_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">IN WITNESS WHEREOF, the Corporation has caused this
            Certificate of Amendment to be signed by its duly authorized officer this &#8195;&#8195; day of &#8195;&#8195;, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 216pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 216pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PASSAGE BIO, INC.<span style="font-weight: normal;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 187pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 187pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 187pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 17pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 187pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 17pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 187pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">I-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 623-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 624-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_309-annexj_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXJ"><!--Anchor--></a>Annex&#160;J </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">FORM OF RESTATED CERTIFICATE OF INCORPORATION <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OF <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REMIX THERAPEUTICS, INC. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Remix Therapeutics, Inc. (the &#8220;<span style="text-decoration: underline;">Corporation</span>&#8221;), a corporation organized
            and&#160;existing under the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration: underline;">DGCL</span>&#8221;), does hereby certify as follows: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The name of the Corporation is Remix Therapeutics, Inc. The Corporation was incorporated under the name Passage Bio, Inc. by
                    the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on July&#160;26, 2017. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">This Restated Certificate of Incorporation (the &#8220;<span style="text-decoration: underline;">Restated Certificate</span>&#8221;), which amends, restates and further integrates
                    the certificate of incorporation of the Corporation as heretofore in effect, has been approved by the Board of Directors of the Corporation (the &#8220;<span style="text-decoration: underline;">Board of Directors</span>&#8221;) in accordance with Sections 242 and 245 of the DGCL, and has
                    been adopted by the written consent of the stockholders of the Corporation in accordance with Section&#160;228 of the DGCL. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The text of the certificate of incorporation of the Corporation, as heretofore amended, is hereby amended and restated by
                    this Restated Certificate to read in its entirety as set forth in <span style="text-decoration: underline;">EXHIBIT A</span> attached hereto. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">IN WITNESS WHEREOF, Remix Therapeutics, Inc. has caused this Restated
            Certificate to be signed by a duly authorized officer of the Corporation, on [&#8194;], 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 264pt;" colspan="7">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 264pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Therapeutics, Inc.<span style="font-weight: normal;">, a Delaware corporation</span></div>
                </td>

  </tr>

  <tr>

    <td colspan="10" style="width: 468pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 20pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 208pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 20pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 208pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Peter G. Smith, Ph.D. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 20pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 208pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">President and Chief Executive Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 20pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 208pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 624-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 625-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_309-annexj_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><span style="text-decoration: underline;">EXHIBIT A</span> </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">ARTICLE I </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The name of the corporation is Remix Therapeutics, Inc. (the &#8220;<span style="text-decoration: underline;">Corporation</span>&#8221;).

          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">ARTICLE II </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The address of the Corporation&#8217;s registered office in the State of Delaware is
            [1209 Orange Street, in the City of Wilmington, County of New Castle, 19801], and the name of its registered agent at such address is [The Corporation Trust Company]. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;">ARTICLE III </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The purpose of the Corporation is to engage in any lawful act or activity for
            which corporations may be organized under the General Corporation Law of the State of Delaware (the &#8220;<span style="text-decoration: underline;">DGCL</span>&#8221;) as it now exists or may hereafter be amended and supplemented. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;">ARTICLE IV </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Corporation is authorized to issue two classes of stock to be designated,
            respectively, &#8220;<span style="text-decoration: underline;">Common Stock</span>&#8221; and &#8220;<span style="text-decoration: underline;">Preferred Stock</span>.&#8221; The total number of shares of capital stock which the Corporation shall have authority to issue is 310,000,000. The total number of shares of Common Stock that the Corporation is
            authorized to issue is 300,000,000, having a par value of $0.0001 per share, and the total number of shares of Preferred Stock that the Corporation is authorized to issue is 10,000,000, having a par value of $0.0001 per share. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;">ARTICLE V </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The designations and the powers, privileges and rights, and the
            qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation are as follows: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">COMMON STOCK</span>. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">General</span>. The voting, dividend, liquidation and other rights and powers of the Common Stock are subject to and
                    qualified by the rights, powers and preferences of any series of Preferred Stock as may be designated by the Board of Directors of the Corporation (the &#8220;<span style="text-decoration: underline;">Board of Directors</span>&#8221;) and outstanding from time to time. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Voting</span>. Except as otherwise provided herein or expressly required by law, each holder of Common Stock, as such, shall
                    be entitled to vote on each matter submitted to a vote of stockholders and shall be entitled to one (1) vote for each share of Common Stock held of record by such holder as of the record date for determining stockholders entitled to
                    vote on such matter. Except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Restated Certificate (including any Certificate of Designation (as defined below)) that
                    relates solely to the rights, powers, preferences (or the qualifications, limitations or restrictions thereof) or other terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled,
                    either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Restated Certificate (including any Certificate of Designation) or pursuant to the DGCL. There shall be no cumulative
                    voting. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 60pt; text-align: justify;">Subject to the rights of any holders of any outstanding series of Preferred
            Stock, the number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the requisite vote of the stockholders entitled to vote thereon, voting as a single class,
            irrespective of the provisions of Section&#160;242(b)(2) of the DGCL. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Dividends</span>. Subject to applicable law and the rights and preferences of any holders of any outstanding series of
                    Preferred Stock, the holders of Common Stock, as such, shall be entitled to the payment of dividends on the Common Stock when, as and if declared by the Board of Directors in accordance with applicable law. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 625-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 626-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_309-annexj_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6.75pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="text-decoration: underline;">Liquidation</span>. Subject to the rights and preferences of any holders of any shares of any outstanding series of Preferred
                    Stock, in the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the funds and assets of the Corporation that may be legally distributed to the Corporation&#8217;s stockholders shall be
                    distributed among the holders of the then outstanding Common Stock <span style="text-decoration: underline;">pro</span> <span style="text-decoration: underline;">rata</span> in accordance with the number of shares of Common Stock held by each such holder. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">B.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><span style="text-decoration: underline;">PREFERRED STOCK</span> </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">Shares of Preferred Stock may be issued from time to time in one or more
            series, each of such series to have such terms as stated or expressed herein and in the resolution or resolutions providing for the creation and issuance of such series adopted by the Board of Directors as hereinafter provided. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">Authority&#160;is hereby expressly granted to the Board of Directors from time to
            time to issue the Preferred Stock in one or more series, and in connection with the creation of any such series, by adopting a resolution or resolutions providing for the issuance of the shares thereof and by filing a certificate of designation
            relating thereto in accordance with the DGCL (a &#8220;<span style="text-decoration: underline;">Certificate of Designation</span>&#8221;), to determine and fix the number of shares of such series and such voting powers, full or limited, or no voting powers, and such designations, preferences and
            relative participating, optional or other special rights, and qualifications, limitations or restrictions thereof, including without limitation thereof, dividend rights, conversion rights, redemption privileges and liquidation preferences, and
            to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series as shall be stated and expressed in such resolutions, all to the fullest extent now or hereafter permitted by the
            DGCL. Without limiting the generality of the foregoing, the resolution or resolutions providing for the creation and issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any
            other series of Preferred Stock to the extent permitted by law and this Restated Certificate (including any Certificate of Designation). Except as otherwise required by law, holders of any series of Preferred Stock shall be entitled only to
            such voting rights, if any, as shall expressly be granted thereto by this Restated Certificate (including any Certificate of Designation). </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-align: justify;">The number of authorized shares of Preferred Stock may be increased or
            decreased (but not below the number of shares thereof then outstanding) by the requisite vote of the stockholders of the Corporation entitled to vote thereon, voting as a single class, irrespective of the provisions of Section&#160;242(b)(2) of the
            DGCL, unless a separate vote of any such holders is required pursuant to the terms of any Certificate of Designation. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;">ARTICLE VI </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">For the management of the business and for the conduct of the affairs of the
            Corporation it is further provided that: </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the special rights of the holders of one or more outstanding series of Preferred Stock to elect directors, the
                    directors of the Corporation shall be classified with respect to the time for which they severally hold office into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III. Each class shall consist, as nearly as may be possible, of
                    one-third of the total number of directors constituting the entire Board of Directors. At each annual meeting of stockholders of the Corporation, subject to any special rights of the holders of one or more outstanding series of
                    Preferred Stock to elect directors, the successors of the class of directors whose term expires at that meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders held in the third year following
                    the year of their election. Each director shall hold office until his or her successor is duly elected and qualified or until his or her earlier death, resignation, disqualification or removal. No decrease in the number of directors
                    shall shorten the term of any incumbent director. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">B.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Except as otherwise expressly provided by the DGCL or this Restated Certificate, the business and affairs of the Corporation
                    shall be managed by or under the direction of the Board of Directors. The number of directors which shall constitute the whole Board of Directors shall be fixed exclusively by one or more resolutions adopted from time to time by the
                    Board of Directors. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">C.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the special rights of the holders of one or more outstanding series of Preferred Stock to elect directors, the
                    Board of Directors or any individual director may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least two-thirds of the voting power of all of the then outstanding shares of
                    voting stock of the Corporation entitled to vote at an election of directors. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">D.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the special rights of the holders of one or more outstanding series of Preferred Stock to elect </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 626-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 627-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_309-annexj_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: justify;">directors, except as otherwise provided by law, any vacancies on the Board
            of Directors resulting from death, resignation, disqualification, retirement, removal or other causes and any newly created directorships resulting from any increase in the number of directors shall be filled exclusively by the affirmative vote
            of a majority of the directors then in office, even though less than a quorum, or by a sole remaining director (other than any directors elected by the separate vote of one or more outstanding series of Preferred Stock), and shall not be filled
            by the stockholders. Any director appointed in accordance with the preceding sentence shall hold office until the expiration of the term of the class to which such director shall have been appointed or until his or her earlier death,
            resignation, retirement, disqualification or removal. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">E.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Whenever the holders of any one or more series of Preferred Stock issued by the Corporation shall have the right, voting
                    separately as a series or separately as a class with one or more such other series, to elect directors at an annual or special meeting of stockholders, the election, term of office, removal and other features of such directorships shall
                    be governed by the terms of this Certificate of Incorporation (including any Certificate of Designation). Notwithstanding anything to the contrary in this Article&#160;VI, the number of directors that may be elected by the holders of any
                    such series of Preferred Stock shall be in addition to the number fixed pursuant to paragraph B of this Article&#160;VI, and the total number of directors constituting the whole Board of Directors shall be automatically adjusted accordingly.
                    Except as otherwise provided in the Certificate of Designation(s) in respect of one or more series of Preferred Stock, whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of
                    such right pursuant to the provisions of such Certificate of Designation(s), the terms of office of all such additional directors elected by the holders of such series of Preferred Stock, or elected to fill any vacancies resulting from
                    the death, resignation, disqualification or removal of such additional directors, shall forthwith terminate (in which case each such director thereupon shall cease to be qualified as, and shall cease to be, a director) and the total
                    authorized number of directors of the Corporation shall automatically be reduced accordingly. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">In furtherance&#160;and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to
                    adopt, amend or repeal Bylaws of the Corporation (as amended and/or restated from time to time, the &#8220;<span style="text-decoration: underline;">Bylaws</span>&#8221;). In addition to any vote of the holders of any class or series of stock of the Corporation required by applicable law
                    or by this Certificate of Incorporation (including any Certificate of Designation in respect of one or more series of Preferred Stock) or the Bylaws of the Corporation, the adoption, amendment or repeal of the Bylaws of the Corporation
                    by the stockholders of the Corporation shall require the affirmative vote of the holders of at least two-thirds of the voting power of all of the then outstanding shares of voting stock of the Corporation entitled to vote generally in
                    an election of directors. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">G.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The directors of the Corporation need not be elected by written ballot unless the Bylaws so provide. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; text-align: center;">ARTICLE VII </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Any action required or permitted to be taken by the stockholders of the Corporation must be effected at an annual or special
                    meeting of stockholders of the Corporation, and shall not be taken by written consent in lieu of a meeting. Notwithstanding the foregoing, any action required or permitted to be taken by the holders of any series of Preferred Stock,
                    voting separately as a series or separately as a class with one or more other such series, may be taken without a meeting, without prior notice and without a vote, to the extent expressly so provided by the applicable Certificate of
                    Designation relating to such series of Preferred Stock, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding shares of the relevant series of Preferred Stock having not
                    less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with
                    the applicable provisions of the DGCL. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">B.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Subject to the special rights of the holders of one or more series of Preferred Stock, special meetings of stockholders of
                    the Corporation may be called, for any purpose or purposes, at any time only by or at the direction of the Board of Directors, the Chairperson of the Board of Directors, the Chief Executive Officer or, in the absence of a Chief
                    Executive Officer, the President, and shall not be called by any other person or persons. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">C.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Advance notice of stockholder nominations for the election of directors and of other business proposed to be brought by
                    stockholders before any meeting of stockholders of the Corporation shall be given in the manner provided in the Bylaws of the Corporation. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 627-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 628-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_309-annexj_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ARTICLE VIII </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">No director or officer of the Corporation shall have any personal liability to
            the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a director or officer, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL as the same exists or
            hereafter may be amended. Any amendment, repeal or modification of this Article&#160;VIII, or the adoption of any provision of the Restated Certificate inconsistent with this Article&#160;VIII, shall not adversely affect any right or protection of a
            director or officer of the Corporation with respect to any act or omission occurring prior to such amendment, repeal, modification or adoption. If the DGCL is amended after approval by the stockholders of this Article&#160;VIII to authorize
            corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL as so
            amended. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE IX </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Corporation shall have the power to provide rights to indemnification and
            advancement of expenses to its current and former officers, directors, employees and agents and to any person who is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership,
            joint venture, trust or other enterprise. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE X </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Unless the Corporation consents&#160;in writing to the selection of an alternative
            forum, (a) the Court of Chancery (the &#8220;<span style="text-decoration: underline;">Chancery Court</span>&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the other state courts of the State of Delaware or the United States District Court
            for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action, suit or proceeding brought on behalf of the Corporation, (ii) any action, suit or proceeding asserting a
            claim of breach of a fiduciary duty owed by any director, officer<span style="font-weight: bold;"> </span>or stockholder of the Corporation to the Corporation or to the Corporation&#8217;s stockholders, (iii) any action, suit or proceeding arising
            pursuant to any provision of the DGCL or the Bylaws of the Corporation or this Restated Certificate (as either may be amended from time to time) or (iv) any action, suit or proceeding asserting a claim against the Corporation governed by the
            internal affairs doctrine; and (b) subject to the preceding provisions of this Article&#160;X, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes
            of action arising under the Securities Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. If any action the subject matter of which is within the scope of clause (a) of the immediately
            preceding sentence is filed in a court other than the courts in the State of Delaware (a &#8220;<span style="text-decoration: underline;">Foreign Action</span>&#8221;) in the name of any stockholder, such stockholder shall be deemed to have consented to (x) the personal jurisdiction of the state
            and federal courts in the State of Delaware in connection with any action brought in any such court to enforce the provisions of clause (a) of the immediately preceding sentence and (y) having service of process made upon such stockholder in
            any such action by service upon such stockholder&#8217;s counsel in the Foreign Action as agent for such stockholder. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Any person or entity purchasing or otherwise acquiring any interest in any
            security of the Corporation shall be deemed to have notice of and consented to this Article&#160;X. This Article&#160;X is intended to benefit and may be enforced by the Corporation, its officers and directors, the underwriters to any offering giving
            rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If any provision or provisions of this Article&#160;X shall be held to be invalid,
            illegal or unenforceable as applied to any circumstance for any reason whatsoever, (a) the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article&#160;X (including, without
            limitation, each portion of any paragraph of this Article&#160;X containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired
            thereby and (b) the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 628-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 629-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_309-annexj_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ARTICLE XI </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Notwithstanding anything contained in this Restated Certificate to the contrary, in addition to any vote required by
                    applicable law, the following provisions in this Restated Certificate may be amended, altered, repealed or rescinded, in whole or in part, or any provision inconsistent therewith or herewith may be adopted, only by the affirmative vote
                    of the holders of at least two-thirds of the total voting power of all the then outstanding shares of stock of the Corporation entitled to vote thereon, voting together as a single class: Part&#160;B of Article&#160;V, Article&#160;VI, Article&#160;VII,
                    Article&#160;VIII, Article&#160;IX, Article&#160;X, and this Article&#160;XI. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">B.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">If any provision&#160;or provisions of this Restated Certificate shall be held to be invalid, illegal or unenforceable as applied
                    to any circumstance for any reason whatsoever: (i) the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Restated Certificate (including, without limitation, each
                    portion of any paragraph of this Restated Certificate containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not, to the fullest extent permitted
                    by applicable law, in any way be affected or impaired thereby and (ii) to the fullest extent permitted by applicable law, the provisions of this Restated Certificate (including, without limitation, each such portion of any paragraph of
                    this Restated Certificate containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation to protect its directors, officers, employees and agents from personal liability in
                    respect of their good faith service to or for the benefit of the Corporation to the fullest extent permitted by law. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">J-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 629-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 630-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXL"><!--Anchor--></a>Annex&#160;K</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; text-align: center;">REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REMIX THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; text-align: center;">ARTICLE I. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">PURPOSE</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Plan&#8217;s purpose is to enhance the Company&#8217;s ability to
            attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms
            used in the Plan are defined in Article&#160;XI. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; text-align: center;">ARTICLE II. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">ELIGIBILITY </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">Service Providers are eligible to be granted Awards under the
            Plan, subject to the limitations described herein. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; text-align: center;">ARTICLE III. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADMINISTRATION AND DELEGATION </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.1<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Administration</span>.
              The Plan is administered by the Administrator. The Administrator has authority to determine which Service Providers receive Awards, grant Awards and set Award terms and conditions, subject to the conditions and limitations in the Plan. The
              Administrator also has the authority to take all actions and make all determinations under the Plan, to interpret the Plan and Award Agreements and to adopt, amend and repeal Plan administrative rules, guidelines and practices as it deems
              advisable. The Administrator may correct defects and ambiguities, supply omissions and reconcile inconsistencies in the Plan or any Award Agreement as it deems necessary or appropriate to administer the Plan and any Awards. The
              Administrator&#8217;s determinations under the Plan are in its sole discretion and will be final and binding on all persons having or claiming any interest in the Plan or any Award. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.2<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Appointment

                of Committees</span>. To the extent Applicable Laws permit, the Board or an authorized Committee may delegate any or all of its powers under the Plan to one or more Committees or officers of the Company or any of its Subsidiaries; provided,
              however, that in no event shall an officer of the Company or any of its Subsidiaries be delegated the authority to grant Awards to, or amend Awards held by, the following individuals: (i) individuals who are subject to Section&#160;16 of the
              Exchange Act, or (ii) officers of the Company or any of its Subsidiaries or Directors to whom authority to grant or amend Awards has been delegated hereunder. The Board or an authorized Committee, as applicable, may rescind any such
              delegation, abolish any Committee or re-vest in itself any previously delegated authority at any time. </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13.5pt; text-align: center;">ARTICLE IV. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">STOCK AVAILABLE FOR AWARDS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.1<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Number

                of Shares</span>. Subject to adjustment under Article&#160;VIII and the terms of this Article&#160;IV, Awards may be made under the Plan covering up to the Overall Share Limit. As of the Plan&#8217;s effective date under Section&#160;10.3, the Company ceased
              granting awards under the Prior Plans; however, Prior Plan Awards remain subject to the terms of the applicable Prior Plan. Shares issued under the Plan may consist of authorized but unissued Shares, Shares purchased on the open market or
              treasury Shares. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.2<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Share

                Recycling</span>. If all or any part of an Award or Prior Plan Award expires, lapses or is terminated, exchanged for or settled in cash, surrendered, repurchased, canceled without having been fully exercised/settled or forfeited, in any case,
              in a manner that results in the Company acquiring Shares covered by the Award or Prior Plan Award at a price not greater than the price (as adjusted to reflect any Equity Restructuring) paid by the Participant for such Shares or not issuing
              any Shares covered by the Award or Prior Plan Award, the unused Shares covered by the Award or Prior Plan Award will, as applicable, become or again be available for Award grants under the Plan. Further, Shares delivered (either by actual
              delivery or attestation) to the Company by a Participant to satisfy the applicable exercise or purchase price of an Award or Prior Plan Award and/or to satisfy any applicable tax withholding obligation (including Shares retained by the
              Company from the Award or Prior Plan Award being exercised or purchased and/or creating the tax obligation) will, as applicable, become or again be available for Award grants under the Plan. The payment of Dividend Equivalents in cash in
              conjunction with any outstanding Awards or Prior Plan Awards shall not count against the Overall Share Limit. </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 630-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 631-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.3<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Incentive

                Stock Option Limitations</span>. Notwithstanding anything to the contrary herein, no more than [<span style="text-decoration: underline;">&#8195;&#8195;&#8195;</span>] Shares may be<sup> </sup>issued pursuant to the exercise of Incentive Stock Options. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.4 <span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Substitute

                Awards</span>. In connection with an entity&#8217;s merger or consolidation with the Company or the Company&#8217;s acquisition of an entity&#8217;s property or stock, the Administrator may grant Awards in substitution for any options or other stock or
              stock-based awards granted before such merger or consolidation by such entity or its affiliate. Substitute Awards may be granted on such terms as the Administrator deems appropriate, notwithstanding limitations on Awards in the Plan.
              Substitute Awards will not count against the Overall Share Limit (nor shall Shares subject to a Substitute Award be added to the Shares available for Awards under the Plan as provided above), except that Shares acquired by exercise of
              substitute Incentive Stock Options will count against the maximum number of Shares that may be issued pursuant to the exercise of Incentive Stock Options under the Plan. Additionally, in the event that a company acquired by the Company or any
              Subsidiary or with which the Company or any Subsidiary combines has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant
              pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable
              to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the Shares authorized for grant under the Plan (and Shares subject to such Awards shall not be
              added to the Shares available for Awards under the Plan as provided above); provided that Awards using such available shares shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan,
              absent the acquisition or combination, and shall only be made to individuals who were not Service Providers prior to such acquisition or combination. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.5<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Non-Employee

                Director Compensation</span>. Notwithstanding any provision to the contrary in the Plan, the Administrator may establish compensation for non-employee Directors from time to time, subject to the limitations in the Plan. The Administrator will
              from time to time determine the terms, conditions and amounts of all such non-employee Director compensation in its discretion and pursuant to the exercise of its business judgment, taking into account such factors, circumstances and
              considerations as it shall deem relevant from time to time; provided that, the sum of any cash compensation, or other compensation, and the value (determined as of the grant date in accordance with Financial Accounting Standards Board
              Accounting Standards Codification Topic 718, or any successor thereto) of Awards granted to a non-employee Director as compensation for services as a non-employee Director during any fiscal year of the Company may not exceed $[&#8226;], increased
              to $[&#8226;] in the fiscal year in which the Plan&#8217;s effective date occurs or in the fiscal year of a non-employee Director&#8217;s initial year of service as a non-employee Director (in each case, excluding any compensation awarded prior to the Plan&#8217;s
              effective date). Consulting fees or other compensation the Company or any of its Subsidiaries may pay or provide to any non-employee director for services in addition to the services normally performed by a non-employee director shall not be
              included in calculating compliance with such limits. The Administrator may make exceptions to these limits for individual non-employee Directors in extraordinary circumstances, as the Administrator may determine in its discretion, provided
              that the non-employee Director receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving non-employee Directors. </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE V. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">STOCK OPTIONS AND STOCK APPRECIATION RIGHTS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.1<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">General</span>.
              The Administrator may grant Options or Stock Appreciation Rights to Service Providers subject to the limitations in the Plan, including any limitations in the Plan that apply to Incentive Stock Options. The Administrator will determine the
              number of Shares covered by each Option and Stock Appreciation Right, the exercise price of each Option and Stock Appreciation Right and the conditions and limitations applicable to the exercise of each Option and Stock Appreciation Right. A
              Stock Appreciation Right will entitle the Participant (or other person entitled to exercise the Stock Appreciation Right) to receive from the Company upon exercise of the exercisable portion of the Stock Appreciation Right an amount
              determined by multiplying the excess, if any, of the Fair Market Value of one Share on the date of exercise over the exercise price per Share of the Stock Appreciation Right by the number of Shares with respect to which the Stock Appreciation
              Right is exercised, subject to any limitations of the Plan or that the Administrator may impose and payable in cash, Shares valued at Fair Market Value or a combination of the two as the Administrator may determine or provide in the Award
              Agreement.</span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.2<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Exercise

                Price</span>. The Administrator will establish each Option&#8217;s and Stock Appreciation Right&#8217;s exercise price and specify the exercise price in the Award Agreement. Unless otherwise determined by the Administrator, the exercise price will not be
              less than 100% of the Fair Market Value on the grant date of the Option or Stock Appreciation Right. </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 631-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 632-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.3<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Duration</span>.
              Each Option or Stock Appreciation Right will be exercisable at such times and as specified in the Award Agreement, provided that, unless otherwise determined by the Administrator, the term of an Option or Stock Appreciation Right will not
              exceed ten years. Notwithstanding the foregoing and unless determined otherwise by the Company, in the event that on the last business day of the term of an Option or Stock Appreciation Right (other than an Incentive Stock Option) (i)&#160;the
              exercise of the Option or Stock Appreciation Right is prohibited by Applicable Laws, as determined by the Company, or (ii) Shares may not be purchased or sold by the applicable Participant due to any Company insider trading policy (including
              blackout periods) or a &#8220;lock-up&#8221; agreement undertaken in connection with an issuance of securities by the Company, the term of the Option or Stock Appreciation Right shall be automatically extended until the date that is thirty (30) days
              after the end of the legal prohibition, black-out period or lock-up agreement, as determined by the Company; provided, however, in no event shall the extension last beyond the ten year term of the applicable Option or Stock Appreciation
              Right. Notwithstanding the foregoing, if the Participant, prior to the end of the term of an Option or Stock Appreciation Right, violates the non-competition, non-solicitation, confidentiality or other similar restrictive covenant provisions
              of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company or any of its Subsidiaries, the right of the Participant and the Participant&#8217;s transferees to exercise any
              Option or Stock Appreciation Right issued to the Participant shall terminate immediately upon such violation, unless the Company otherwise determines. In addition, if, prior to the end of the term of an Option or Stock Appreciation Right, the
              Participant is given notice by the Company or any of its Subsidiaries of the Participant&#8217;s Termination of Service by the Company or any of its Subsidiaries for Cause, and the effective date of such Termination of Service is subsequent to the
              date of the delivery of such notice, the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant shall be suspended from the time of the delivery of such notice
              until the earlier of (i) such time as it is determined or otherwise agreed that the Participant&#8217;s service as a Service Provider will not be terminated for Cause as provided in such notice or (ii)&#160;the effective date of the Participant&#8217;s
              Termination of Service by the Company or any of its Subsidiaries for Cause (in which case the right of the Participant and the Participant&#8217;s transferees to exercise any Option or Stock Appreciation Right issued to the Participant will
              terminate immediately upon the effective date of such Termination of Service). </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.4<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Exercise</span>.
              Options and Stock Appreciation Rights may be exercised by delivering to the Company a written notice of exercise, in a form the Administrator approves (which may be electronic), signed by the person authorized to exercise the Option or Stock
              Appreciation Right, together with, as applicable, payment in full (i) as specified in Section&#160;5.5 for the number of Shares for which the Award is exercised and (ii) as specified in Section&#160;9.5 for any applicable taxes. Unless the
              Administrator otherwise determines, an Option or Stock Appreciation Right may not be exercised for a fraction of a Share. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.5<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Payment

                Upon Exercise</span>. Subject to Section&#160;10.8, any Company insider trading policy (including blackout periods) and Applicable Laws, the exercise price of an Option must be paid by: </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;cash, wire transfer of immediately available funds or
            by check payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below is permitted; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;if there is a public market for Shares at the time of
            exercise, unless the Company otherwise determines, (i) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and unconditional undertaking by a broker acceptable to the Company to deliver
            promptly to the Company sufficient funds to pay the exercise price, or (ii) the Participant&#8217;s delivery to the Company of a copy of irrevocable and unconditional instructions to a broker acceptable to the Company to deliver promptly to the
            Company cash or a check sufficient to pay the exercise price; provided that such amount is paid to the Company at such time as may be required by the Administrator;</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;to the extent permitted by the Administrator, delivery
            (either by actual delivery or attestation) of Shares owned by the Participant valued at their fair market value; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;to the extent permitted by the Administrator,
            surrendering Shares then issuable upon the Option&#8217;s exercise valued at their fair market value on the exercise date; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(e)&#8195;to the extent permitted by the Administrator, delivery
            of a promissory note or any other property that the Administrator determines is good and valuable consideration; or </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;to the extent permitted by the Company, any combination
            of the above payment forms approved by the Administrator. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 632-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 633-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ARTICLE VI. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">RESTRICTED STOCK; RESTRICTED STOCK UNITS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.1<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">General</span>.
              The Administrator may grant Restricted Stock, or the right to purchase Restricted Stock, to any Service Provider, subject to the Company&#8217;s right to repurchase all or part of such Shares at their issue price or other stated or formula price
              from the Participant (or to require forfeiture of such Shares) if conditions the Administrator specifies in the Award Agreement are not satisfied before the end of the applicable restriction period or periods that the Administrator
              establishes for such Award. In addition, the Administrator may grant to Service Providers Restricted Stock Units, which may be subject to vesting and forfeiture conditions during the applicable restriction period or periods, as set forth in
              an Award Agreement. The Administrator will determine and set forth in the Award Agreement the terms and conditions for each Restricted Stock and Restricted Stock Unit Award, subject to the conditions and limitations contained in the Plan. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">6.2<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Restricted

                Stock</span>. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<span style="text-decoration: underline;">Dividends</span>. Participants holding shares of
            Restricted Stock will be entitled to all ordinary cash dividends paid with respect to such Shares, unless the Administrator provides otherwise in the Award Agreement. In addition, unless the Administrator provides otherwise, if any dividends or
            distributions are paid in Shares, or consist of a dividend or distribution to holders of Common Stock of property other than an ordinary cash dividend, the Shares or other property will be subject to the same restrictions on transferability and
            forfeitability as the shares of Restricted Stock with respect to which they were paid. Notwithstanding anything to the contrary herein, unless otherwise determined by the Administrator, with respect to any award of Restricted Stock, dividends
            which are paid to holders of Common Stock prior to vesting shall only be paid out to a Participant holding such Restricted Stock to the extent that the vesting conditions are subsequently satisfied. All such dividend payments will be made no
            later than March&#160;15 of the calendar year following the calendar year in which the right to the dividend payment becomes nonforfeitable, unless determined otherwise by the Administrator or unless deferred in a manner intended to comply with
            Section&#160;409A. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<span style="text-decoration: underline;">Stock Certificates</span>. The Company may require that
            the Participant deposit in escrow with the Company (or its designee) any stock certificates issued in respect of shares of Restricted Stock, together with a stock power endorsed in blank. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">6.3<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Restricted

                Stock Units</span>. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<span style="text-decoration: underline;">Settlement</span>. The Administrator may provide that
            settlement of Restricted Stock Units will occur upon or as soon as reasonably practicable after the Restricted Stock Units vest or will instead be deferred, on a mandatory basis or at the Participant&#8217;s election, in a manner intended to comply
            with Section&#160;409A. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<span style="text-decoration: underline;">Stockholder Rights</span>. A Participant will have no
            rights of a stockholder with respect to Shares subject to any Restricted Stock Unit unless and until the Shares are delivered in settlement of the Restricted Stock Unit. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<span style="text-decoration: underline;">Dividend Equivalents</span>. If the Administrator
            provides, a grant of Restricted Stock Units may provide a Participant with the right to receive Dividend Equivalents. Dividend Equivalents may be paid currently or credited to an account for the Participant, settled in cash or Shares and
            subject to the same restrictions on transferability and forfeitability as the Restricted Stock Units with respect to which the Dividend Equivalents are granted and subject to other terms and conditions as set forth in the Award Agreement.
            Notwithstanding anything to the contrary herein, unless otherwise determined by the Administrator, Dividend Equivalents with respect to an Award shall only be paid to a Participant to the extent that the vesting conditions are subsequently
            satisfied. All such Dividend Equivalent payments will be made no later than March&#160;15 of the calendar year following the calendar year in which the right to the Dividend Equivalent payment becomes nonforfeitable, unless determined otherwise by
            the Administrator or unless deferred in a manner intended to comply with Section&#160;409A. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">ARTICLE VII. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OTHER STOCK OR CASH BASED AWARDS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Other Stock or Cash Based Awards may be granted to
            Participants, including Awards entitling Participants to receive Shares to be delivered in the future and including annual or other periodic or long-term cash bonus awards (whether based on specified Performance Criteria or otherwise), in each
            case subject to any conditions and limitations in the Plan. Such Other Stock or Cash Based Awards will also be available as a payment form in the settlement of other Awards, as standalone payments and as payment in lieu of compensation to which
            a Participant is otherwise entitled. Other Stock or Cash Based Awards may be paid in Shares, cash or other property, or any combination of the foregoing, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 633-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 634-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">as the Administrator determines. Subject to the provisions of the Plan, the
            Administrator will determine the terms and conditions of each Other Stock or Cash Based Award, including any purchase price, performance goal(s) (which may be based on the Performance Criteria), transfer restrictions, and vesting conditions,
            which will be set forth in the applicable Award Agreement. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE VIII. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADJUSTMENTS FOR CHANGES IN COMMON STOCK <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AND CERTAIN OTHER EVENTS</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.1<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Equity

                Restructuring</span>. In connection with any Equity Restructuring, notwithstanding anything to the contrary in this Article&#160;VIII, the Administrator will equitably adjust each outstanding Award as it deems appropriate to reflect the Equity
              Restructuring, which may include adjusting the number and type of securities subject to each outstanding Award and/or the Award&#8217;s exercise price or grant price (if applicable), granting new Awards to Participants, and making a cash payment to
              Participants. The adjustments provided under this Section&#160;8.1 will be nondiscretionary and final and binding on the affected Participant and the Company; provided that the Administrator will determine whether an adjustment is equitable. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.2<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Corporate

                Transactions</span>. In the event of any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), reorganization, merger, consolidation, combination, amalgamation, repurchase,
              recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Common Stock or other securities of the Company, Change in Control,
              issuance of warrants or other rights to purchase Common Stock or other securities of the Company, other similar corporate transaction or event, other unusual or nonrecurring transaction or event affecting the Company or its financial
              statements or any change in any Applicable Laws or accounting principles, the Administrator, on such terms and conditions as it deems appropriate, either by the terms of the Award or by action taken prior to the occurrence of such transaction
              or event (except that action to give effect to a change in Applicable Laws or accounting principles may be made within a reasonable period of time after such change), is hereby authorized to take any one or more of the following actions
              whenever the Administrator determines that such action is appropriate in order to (x)&#160;prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any
              Award granted or issued under the Plan, (y) facilitate such transaction or event or (z) give effect to such changes in Applicable Laws or accounting principles:</span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;To provide for the cancellation of any such Award in
            exchange for either an amount of cash or other property with a value equal to the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights under the
            vested portion of such Award, as applicable; provided that, if the amount that could have been obtained upon the exercise or settlement of the vested portion of such Award or realization of the Participant&#8217;s rights, in any case, is equal to or
            less than zero, then the Award may be terminated without payment; provided, further, that Awards held by members of the Board will be settled in Shares on or immediately prior to the applicable event if the Administrator takes action under this
            clause&#160;(a);&#8195;</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;To provide that such Award shall vest and, to the
            extent applicable, be exercisable as to all Shares covered thereby, notwithstanding anything to the contrary in the Plan or the provisions of such Award; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;To provide that such Award be assumed by the successor
            or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by awards covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and
            kind of shares and/or applicable exercise or purchase price, in all cases, as determined by the Administrator;&#8195;</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;To make adjustments in the number and type of Shares
            (or other securities or property) subject to outstanding Awards and/or with respect to which Awards may be granted under the Plan (including, but not limited to, adjustments of the limitations in Article&#160;IV hereof on the maximum number and kind
            of shares which may be issued) and/or in the terms and conditions of (including the grant or exercise price or applicable performance goals), and the criteria included in, outstanding Awards;</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(e)&#8195;To replace such Award with other rights or property
            selected by the Administrator; and/or </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;To provide that the Award will terminate and cannot
            vest, be exercised or become payable after the applicable event. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 634-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 635-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.3<span style="font-weight: normal;">
              &#8195;<span style="text-decoration: underline;">Administrative Stand Still</span>. In the event of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders,
              or any other extraordinary transaction or change affecting the Shares or the share price of Common Stock, including any Equity Restructuring or any securities offering or other similar transaction, for administrative convenience, the
              Administrator may refuse to permit the exercise of any Award for up to sixty days before or after such transaction. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.4<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">General</span>.
              Except as expressly provided in the Plan or the Administrator&#8217;s action under the Plan, no Participant will have any rights due to any subdivision or consolidation of Shares of any class, dividend payment, increase or decrease in the number of
              Shares of any class or dissolution, liquidation, merger, or consolidation of the Company or other corporation. Except as expressly provided with respect to an Equity Restructuring under Section&#160;8.1 above or the Administrator&#8217;s action under
              the Plan, no issuance by the Company of Shares of any class, or securities convertible into Shares of any class, will affect, and no adjustment will be made regarding, the number of Shares subject to an Award or the Award&#8217;s grant or exercise
              price. The existence of the Plan, any Award Agreements and the Awards granted hereunder will not affect or restrict in any way the Company&#8217;s right or power to make or authorize (i) any adjustment, recapitalization, reorganization or other
              change in the Company&#8217;s capital structure or its business, (ii) any merger, consolidation dissolution or liquidation of the Company or sale of Company assets or (iii) any sale or issuance of securities, including securities with rights
              superior to those of the Shares or securities convertible into or exchangeable for Shares. The Administrator may treat Participants and Awards (or portions thereof) differently under this Article&#160;VIII. </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE IX. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL PROVISIONS APPLICABLE TO AWARDS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.1<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Transferability</span>.
              Except as the Administrator may determine or provide in an Award Agreement or otherwise for Awards other than Incentive Stock Options, Awards may not be sold, assigned, transferred, pledged or otherwise encumbered, either voluntarily or by
              operation of law, except by will or the laws of descent and distribution, or, subject to the Administrator&#8217;s consent, pursuant to a domestic relations order, and, during the life of the Participant, will be exercisable only by the
              Participant. References to a Participant, to the extent relevant in the context, will include references to a Participant&#8217;s authorized transferee that the Administrator specifically approves. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.2<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Documentation</span>.
              Each Award will be evidenced in an Award Agreement, which may be written or electronic, as the Administrator determines. Each Award may contain terms and conditions in addition to those set forth in the Plan. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.3<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Discretion</span>.
              Except as the Plan otherwise provides, each Award may be made alone or in addition or in relation to any other Award. The terms of each Award to a Participant need not be identical, and the Administrator need not treat Participants or Awards
              (or portions thereof) uniformly. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.4<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Termination

                of Status</span>. The Administrator will determine how a Participant&#8217;s disability, death, retirement, authorized leave of absence or any other change or purported change in a Participant&#8217;s Service Provider status affects an Award (including
              whether and when a Termination of Service has occurred and the effect of such change on any vesting restrictions) and the extent to which, and the period during which, the Participant, the Participant&#8217;s legal representative, conservator,
              guardian or Designated Beneficiary may exercise rights under the Award, if applicable. The Administrator shall, in its sole discretion, determine whether a Service Provider&#8217;s transfer of employment from the Company to a Subsidiary or vice
              versa shall result in a termination of the Service Provider&#8217;s status as a Service Provider. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.5<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Withholding</span>.
              Each Participant must pay the Company or a Subsidiary, if applicable, or make provision satisfactory to the Administrator for payment of, any taxes required by Applicable Laws to be withheld in connection with such Participant&#8217;s Awards by the
              date of the event creating the tax liability. The Company may deduct an amount sufficient to satisfy such tax obligations based on the applicable statutory withholding rates (or such other rate as may be determined by the Company after
              considering any accounting consequences or costs) from any payment of any kind otherwise due to a Participant. Subject to Section&#160;10.8 and any Company insider trading policy (including blackout periods), Participants may satisfy such tax
              obligations (i) in cash, by wire transfer of immediately available funds, by check made payable to the order of the Company, provided that the Company may limit the use of the foregoing payment forms if one or more of the payment forms below
              is permitted, (ii) to the extent permitted by the Administrator, in whole or in part by delivery of Shares, including Shares retained from the Award creating the tax obligation, in an amount necessary to cover such tax obligations, (iii) if
              there is a public market for Shares at the time the tax obligations are due, unless the Company otherwise determines, (A) delivery (including electronically or telephonically to the extent permitted by the Company) of an irrevocable and
              unconditional undertaking by a broker acceptable to the Company to deliver promptly to the Company sufficient funds to satisfy the tax obligations, or (B) delivery by the Participant to the </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 635-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 636-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">Company of a copy of irrevocable and unconditional instructions to a broker
            acceptable to the Company to deliver promptly to the Company cash or a check sufficient to satisfy the tax withholding; provided that such amount is paid to the Company at such time as may be required by the Administrator, or (iv) to the extent
            permitted by the Administrator, any combination of the foregoing payment forms approved by the Company. If any tax withholding obligation will be satisfied under clause (ii) of the immediately preceding sentence by the Company&#8217;s retention of
            Shares from the Award creating the tax obligation and there is a public market for Shares at the time the tax obligation is satisfied, the Company may elect to instruct any brokerage firm determined acceptable to the Company for such purpose to
            sell on the applicable Participant&#8217;s behalf some or all of the Shares retained and to remit the proceeds of the sale to the Company or its designee, and each Participant&#8217;s acceptance of an Award under the Plan will constitute the Participant&#8217;s
            authorization to the Company and instruction and authorization to such brokerage firm to complete the transactions described in this sentence. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.6<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Amendment

                of Award; Repricing</span>. The Administrator may amend, modify or terminate any outstanding Award, including by substituting another Award of the same or a different type, changing the exercise or settlement date, and converting an Incentive
              Stock Option to a Non-Qualified Stock Option. The Participant&#8217;s consent to such action will be required unless (i) the action, taking into account any related action, does not materially and adversely affect the Participant&#8217;s rights under the
              Award, or (ii) the change is permitted under Article&#160;VIII or pursuant to Section&#160;10.6. Further, the Administrator may, without the approval of the stockholders of the Company, reduce the exercise price per share of outstanding Options or
              Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, other Awards or Options or Stock Appreciation Rights with an exercise price per share that is less than the exercise price per share of
              the original Options or Stock Appreciation Rights. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.7<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Conditions

                on Delivery of Stock</span>. The Company will not be obligated to deliver any Shares under the Plan or remove restrictions from Shares previously delivered under the Plan until (i) all Award conditions have been met or removed to the Company&#8217;s
              satisfaction, (ii) as determined by the Company, all other legal matters regarding the issuance and delivery of such Shares have been satisfied, including any applicable securities laws and stock exchange or stock market rules and
              regulations, and (iii) the Participant has executed and delivered to the Company such representations or agreements as the Administrator deems necessary or appropriate to satisfy any Applicable Laws. The Company&#8217;s inability to obtain
              authority from any regulatory body having jurisdiction, which the Administrator determines is necessary to the lawful issuance and sale of any securities, will relieve the Company of any liability for failing to issue or sell such Shares as
              to which such requisite authority has not been obtained. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.8<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Acceleration</span>.
              The Administrator may at any time provide that any Award will become immediately vested and fully or partially exercisable, free of some or all restrictions or conditions, or otherwise fully or partially realizable. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.9<span style="font-weight: normal;">&#8195; <span style="text-decoration: underline;">Additional

                Terms of Incentive Stock Options</span>. The Administrator may grant Incentive Stock Options only to employees of the Company, any of its present or future parent or subsidiary corporations, as defined in Sections 424(e) or (f) of the Code,
              respectively, and any other entities the employees of which are eligible to receive Incentive Stock Options under the Code. If an Incentive Stock Option is granted to a Greater Than 10% Stockholder, the exercise price will not be less than
              110% of the Fair Market Value on the Option&#8217;s grant date, and the term of the Option will not exceed five years. All Incentive Stock Options will be subject to and construed consistently with Section&#160;422 of the Code. By accepting an Incentive
              Stock Option, the Participant agrees to give prompt notice to the Company of dispositions or other transfers (other than in connection with a Change in Control) of Shares acquired under the Option made within (i)&#160;two years from the grant date
              of the Option or (ii) one year after the transfer of such Shares to the Participant, specifying the date of the disposition or other transfer and the amount the Participant realized, in cash, other property, assumption of indebtedness or
              other consideration, in such disposition or other transfer. Neither the Company nor the Administrator will be liable to a Participant, or any other party, if an Incentive Stock Option fails or ceases to qualify as an &#8220;incentive stock option&#8221;
              under Section&#160;422 of the Code. Any Incentive Stock Option or portion thereof that fails to qualify as an &#8220;incentive stock option&#8221; under Section&#160;422 of the Code for any reason, including becoming exercisable with respect to Shares having a
              fair market value exceeding the $100,000 limitation under Treasury Regulation Section&#160;1.422-4, will be a Non-Qualified Stock Option. </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 636-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 637-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ARTICLE X. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">MISCELLANEOUS</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.1<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">No

                Right to Employment or Other Status</span>. No person will have any claim or right to be granted an Award, and the grant of an Award will not be construed as giving a Participant the right to continued employment or any other relationship with
              the Company or any of its Subsidiaries. The Company and its Subsidiaries expressly reserve the right at any time to dismiss or otherwise terminate their relationship with a Participant free from any liability or claim under the Plan or any
              Award, except as expressly provided in an Award Agreement or in the Plan. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.2<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">No

                Rights as Stockholder; Certificates</span>. Subject to the Award Agreement, no Participant or Designated Beneficiary will have any rights as a stockholder with respect to any Shares to be distributed under an Award until becoming the record
              holder of such Shares. Notwithstanding any other provision of the Plan, unless the Administrator otherwise determines or Applicable Laws require, the Company will not be required to deliver to any Participant certificates evidencing Shares
              issued in connection with any Award and instead such Shares may be recorded in the books of the Company (or, as applicable, its transfer agent or stock plan administrator). The Company may place legends on stock certificates issued under the
              Plan that the Administrator deems necessary or appropriate to comply with Applicable Laws. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.3<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Effective

                Date and Term of Plan</span>. The Plan will become effective at the Effective Time and unless terminated earlier by the Board, will remain in effect until the tenth anniversary of the date the Board adopted the Plan, but Awards previously
              granted may extend beyond that date in accordance with the Plan. If the Plan is not approved by the Company&#8217;s stockholders, the Plan will not become effective, and no Awards will be granted under the Plan. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.4<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Amendment

                of Plan</span>. The Administrator may amend, suspend or terminate the Plan at any time; provided that no amendment, other than an increase to the Overall Share Limit, may materially and adversely affect any Award outstanding at the time of
              such amendment without the affected Participant&#8217;s consent. No Awards may be granted under the Plan during any suspension period or after the Plan&#8217;s termination. Awards outstanding at the time of any Plan suspension or termination will
              continue to be governed by the Plan and the Award Agreement, as in effect before such suspension or termination. The Board will obtain stockholder approval of any Plan amendment to the extent necessary to comply with Applicable Laws. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.5<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Provisions

                for Foreign Participants</span>. The Administrator may modify Awards granted to Participants who are foreign nationals or employed outside the United States or establish subplans or procedures under the Plan to address differences in laws,
              rules, regulations or customs of such foreign jurisdictions with respect to tax, securities, currency, employee benefit or other matters. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">10.6<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Section&#160;409A</span>.</span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;<span style="text-decoration: underline;">General</span>. The Company intends that all Awards be
            structured to comply with, or be exempt from, Section&#160;409A, such that no adverse tax consequences, interest, or penalties under Section&#160;409A apply. Notwithstanding anything in the Plan or any Award Agreement to the contrary, the Administrator
            may, without a Participant&#8217;s consent, amend this Plan or Awards, adopt policies and procedures, or take any other actions (including amendments, policies, procedures and retroactive actions) as are necessary or appropriate to preserve the
            intended tax treatment of Awards, including any such actions intended to (A) exempt this Plan or any Award from Section&#160;409A, or (B) comply with Section&#160;409A, including regulations, guidance, compliance programs and other interpretative
            authority that may be issued after an Award&#8217;s grant date. The Company makes no representations or warranties as to an Award&#8217;s tax treatment under Section&#160;409A or otherwise. The Company will have no obligation under this Section&#160;10.6 or
            otherwise to avoid the taxes, penalties or interest under Section&#160;409A with respect to any Award and will have no liability to any Participant or any other person if any Award, compensation or other benefits under the Plan are determined to
            constitute noncompliant &#8220;nonqualified deferred compensation&#8221; subject to taxes, penalties or interest under Section&#160;409A. Notwithstanding any contrary provision of the Plan or any Award Agreement, any payment of &#8220;nonqualified deferred
            compensation&#8221; under the Plan that may be made in installments shall be treated as a right to receive a series of separate and distinct payments. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;<span style="text-decoration: underline;">Separation from Service</span>. If an Award constitutes
            &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A, any payment or settlement of such Award upon a termination of a Participant&#8217;s Service Provider relationship will, to the extent necessary to avoid taxes under Section&#160;409A, be made only
            upon the Participant&#8217;s &#8220;separation from service&#8221; (within the meaning of Section&#160;409A), whether such &#8220;separation from service&#8221; occurs </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 637-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 638-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">upon or after the termination of the Participant&#8217;s Service Provider
            relationship. For purposes of this Plan or any Award Agreement relating to any such payments or benefits, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms means a &#8220;separation from service.&#8221; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;<span style="text-decoration: underline;">Payments to Specified Employees</span>. Notwithstanding
            any contrary provision in the Plan or any Award Agreement, any payment(s) of &#8220;nonqualified deferred compensation&#8221; required to be made under an Award to a &#8220;specified employee&#8221; (as defined under Section&#160;409A and as the Administrator determines)
            due to his or her &#8220;separation from service&#8221; will, to the extent necessary to avoid taxes under Section&#160;409A(a)(2)(B)(i) of the Code, be delayed for the six-month period immediately following such &#8220;separation from service&#8221; (or, if earlier, until
            the specified employee&#8217;s death) and will instead be paid (as set forth in the Award Agreement) on the day immediately following such six-month period or as soon as administratively practicable thereafter (without interest). Any payments of
            &#8220;nonqualified deferred compensation&#8221; under such Award payable more than six months following the Participant&#8217;s &#8220;separation from service&#8221; will be paid at the time or times the payments are otherwise scheduled to be made. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.7<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Limitations

                on Liability</span>. Notwithstanding any other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, spouse,
              beneficiary, or any other person for any claim, loss, liability, or expense incurred in connection with the Plan or any Award, and such individual will not be personally liable with respect to the Plan because of any contract or other
              instrument executed in his or her capacity as an Administrator, director, officer, other employee or agent of the Company or any Subsidiary. To the extent allowable pursuant to Applicable Laws and the Company&#8217;s governing documents, the
              Company will indemnify and hold harmless each director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or
              interpretation, against any cost or expense (including attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from
              such person&#8217;s own fraud or bad faith. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.8<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Lock-Up

                Period</span>. The Company may, at the request of any underwriter representative or otherwise, in connection with registering the offering of any Company securities under the Securities Act, prohibit Participants from, directly or indirectly,
              selling or otherwise transferring any Shares or other Company securities during a period of up to one hundred eighty days following the effective date of a Company registration statement filed under the Securities Act, or such longer period
              as determined by the underwriter. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.9<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Data

                Privacy</span>. By accepting an Award, the Participant acknowledges and agrees that the Company (acting as data controller) may hold certain personal information about the Participant, including the Participant&#8217;s name, address and telephone
              number; birthdate; social security number, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and Award details (the &#8220;</span><span style="font-style: italic;">Data</span><span style="font-weight: normal;">&#8221;) to implement, manage and administer the Plan and Awards in accordance with this Plan and the Award Agreements and in the Company&#8217;s legitimate interests to operate a
              successful business. The Company may receive the Data from its Subsidiaries and affiliates or the Participant, and may share the Data with its Subsidiaries and with third parties assisting the Company with the Plan implementation,
              administration and management including a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. These recipients may be located outside of the Participant&#8217;s country (and outside of the United
              States, European Economic Area or United Kingdom), and in such cases the Data will be transferred in accordance with applicable law, including where required using approved international data transfer mechanisms such as standard contractual
              clauses. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. To the extent permitted under applicable law, a Participant may, at any time,
              exercise their right to request access to their Data, to delete or correct their Data, to object to the Company&#8217;s use of the Data, to request that the Company restrict the use of Data or shares the Data with another controller, or to raise
              any issues around the Company&#8217;s use of Data with the Company or any data privacy regulator. To contact the Company, request a copy of any international data transfer mechanism, exercise any data privacy right, or find out more information
              about how the Company uses the Data, a Participant may contact their local human resources representative. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.10<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Severability</span>.
              If any portion of the Plan or any action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or
              invalid provisions had been excluded, and the illegal or invalid action will be null and void. </span></div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 638-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 639-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.11<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Governing Documents</span>. If any contradiction occurs between the Plan and any Award Agreement or other written agreement between a Participant and the Company (or any Subsidiary) that the Administrator has approved, the Plan will
              govern, unless it is expressly specified in such Award Agreement or other written document that a specific provision of the Plan will not apply. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.12<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Governing

                Law</span>. The Plan and all Awards will be governed by and interpreted in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice-of-law principles requiring the application of a jurisdiction&#8217;s laws other than the
              State of Delaware. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.13<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Claw-back

                Provisions</span>. All Awards (including any proceeds, gains or other economic benefit the Participant actually or constructively receives upon receipt or exercise of any Award or the receipt or resale of any Shares underlying the Award) will
              be subject to any Company claw-back policy implemented by the Company, including any claw-back policy adopted to comply with Applicable Laws, including, without limitation, Rule&#160;10D-1 of the Exchange Act and any rules or regulations
              promulgated thereunder, as set forth in such claw-back policy and/or the Award Agreement. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.14<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Titles

                and Headings</span>. The titles and headings in the Plan are for convenience of reference only and, if any conflict, the Plan&#8217;s text, rather than such titles or headings, will control. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.15<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Conformity

                to Applicable Laws</span>. Participant acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Awards will be administered only in
              conformance with Applicable Laws. To the extent Applicable Laws permit, the Plan and all Award Agreements will be deemed amended as necessary to conform to Applicable Laws. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.16<span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Relationship

                to Other Benefits</span>. No payment under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary
              except as expressly provided in writing in such other plan or an agreement thereunder. </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">10.17 <span style="font-weight: normal;">&#8195;<span style="text-decoration: underline;">Broker-Assisted

                Sales</span>. In the event of a broker-assisted sale of Shares in connection with the payment of amounts owed by a Participant under or with respect to the Plan or Awards, including amounts to be paid under the final sentence of Section&#160;9.5:
              (a) any Shares to be sold through the broker-assisted sale will be sold on the day the payment first becomes due, or as soon thereafter as practicable; (b) such Shares may be sold as part of a block trade with other Participants in the Plan
              in which all participants receive an average price; (c) the applicable Participant will be responsible for all broker&#8217;s fees and other costs of sale, and by accepting an Award, each Participant agrees to indemnify and hold the Company
              harmless from any losses, costs, damages, or expenses relating to any such sale; (d) to the extent the Company or its designee receives proceeds of such sale that exceed the amount owed, the Company will pay such excess in cash to the
              applicable Participant as soon as reasonably practicable; (e) the Company and its designees are under no obligation to arrange for such sale at any particular price; and (f) in the event the proceeds of such sale are insufficient to satisfy
              the Participant&#8217;s applicable obligation, the Participant may be required to pay immediately upon demand to the Company or its designee an amount in cash sufficient to satisfy any remaining portion of the Participant&#8217;s obligation. </span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; text-align: center;">ARTICLE XI. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">DEFINITIONS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">As used in the Plan, the following words and phrases will have
            the following meanings: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.1&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Administrator</span>&#8221;
            means the Board or a Committee to the extent that the Board&#8217;s powers or authority under the Plan have been delegated to such Committee. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.2&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Applicable

              Laws</span>&#8221; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or
            quotation system on which the Common Stock is listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where Awards are granted. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.3&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Award</span>&#8221;
            means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Dividend Equivalents or Other Stock or Cash Based Awards. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.4&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Award

              Agreement</span>&#8221; means a written agreement evidencing an Award, which may be electronic, that contains such terms and conditions as the Administrator determines, consistent with and subject to the terms and conditions of the Plan. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 639-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 640-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.5&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Board</span>&#8221;
            means the Board of Directors of the Company. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.6&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Cause</span>&#8221;
            means (i) if a Participant is a party to a written employment or consulting agreement with the Company or any of its Subsidiaries in which the term &#8220;cause&#8221; is defined (a &#8220;<span style="font-style: italic; font-weight: bold;">Relevant Agreement</span>&#8221;),

            &#8220;Cause&#8221; as defined in the Relevant Agreement, and (ii) if no Relevant Agreement exists, (A) the Administrator&#8217;s determination that the Participant failed to substantially perform the Participant&#8217;s duties (other than a failure resulting from the
            Participant&#8217;s Disability); (B) the Administrator&#8217;s determination that the Participant failed to carry out, or comply with any lawful and reasonable directive of the Board or the Participant&#8217;s immediate supervisor; (C) the occurrence of any act
            or omission by the Participant that could reasonably be expected to result in (or has resulted in) the Participant&#8217;s conviction, plea of no contest, plea of nolo contendere, or imposition of unadjudicated probation for any felony or indictable
            offense or crime involving moral turpitude; (D) the Participant&#8217;s unlawful use (including being under the influence) or possession of illegal drugs on the premises of the Company or any of its Subsidiaries or while performing the Participant&#8217;s
            duties and responsibilities for the Company or any of its Subsidiaries; or (E) the Participant&#8217;s commission of an act of fraud, embezzlement, misappropriation, misconduct, or breach of fiduciary duty against the Company or any of its
            Subsidiaries. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.7&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Change

              in Control</span>&#8221; means and includes each of the following: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;A transaction or series of transactions (other than an
            offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission or a transaction or series of transactions that meets the requirements of clauses (i) and (ii) of subsection (c)
            below) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its Subsidiaries, an employee benefit plan maintained by the Company or any
            of its Subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of
            Rule&#160;13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition; or </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;During any period of two (2) consecutive years,
            individuals who, at the beginning of such period, constitute the Board together with any new Director(s) (other than a Director designated by a person who shall have entered into an agreement with the Company to effect a transaction described
            in subsections (a) or (c)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the Directors then still in office who either were Directors at the beginning of
            the two (2)-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof; or </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;The consummation by the Company (whether directly
            involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the
            Company&#8217;s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(i)&#8195;which results in the Company&#8217;s voting securities
            outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or
            indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;<span style="font-style: italic; font-weight: bold;">Successor Entity</span>&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 40pt; text-indent: 20pt; text-align: justify;">(ii)&#8195;after which no person or group beneficially owns
            voting securities representing 50% or more of the combined voting power of the Successor Entity; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that no person or group shall be treated for purposes of this clause (ii) as beneficially owning 50% or more of
            the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Notwithstanding the foregoing, if a Change in Control
            constitutes a payment event with respect to any Award (or portion of any Award) that provides for the deferral of compensation that is subject to Section&#160;409A, to the extent </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-11<br/>
        </div>

      </div>

    </div>

    <!--End Page 640-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 641-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">required to avoid the imposition of additional taxes under Section&#160;409A, the
            transaction or event described in subsection (a), (b) or (c) with respect to such Award (or portion thereof) shall only constitute a Change in Control for purposes of the payment timing of such Award (or portion thereof) if such transaction
            also constitutes a &#8220;change in control event,&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Administrator shall have full and final authority, which
            shall be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, the date of the occurrence of such Change in Control and any incidental matters relating thereto;
            provided that any exercise of authority in conjunction with a determination of whether a Change in Control is a &#8220;change in control event&#8221; as defined in Treasury Regulation Section&#160;1.409A-3(i)(5) shall be consistent with such regulation. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.8&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Code</span>&#8221;
            means the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.9&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Committee</span>&#8221;
            means one or more committees or subcommittees of the Board, which may include one or more Company directors or executive officers, to the extent Applicable Laws permit. To the extent required to comply with the provisions of Rule&#160;16b-3, it is
            intended that each member of the Committee will be, at the time the Committee takes any action with respect to an Award that is subject to Rule&#160;16b-3, a &#8220;non-employee director&#8221; within the meaning of Rule&#160;16b-3; however, a Committee member&#8217;s
            failure to qualify as a &#8220;non-employee director&#8221; within the meaning of Rule&#160;16b-3 will not invalidate any Award granted by the Committee that is otherwise validly granted under the Plan.</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.10&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Common

              Stock</span>&#8221; means the common stock of the Company. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.11&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221;
            means Remix Therapeutics, Inc., a Delaware corporation, or any successor. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.12&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Consultant</span>&#8221;
            means any person, including any adviser, engaged by the Company or its parent or Subsidiary to render services to such entity if the consultant or adviser: (i) renders bona fide services to the Company; (ii) renders services not in connection
            with the offer or sale of securities in a capital-raising transaction and does not directly or indirectly promote or maintain a market for the Company&#8217;s securities; and (iii) is a natural person. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.13&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Designated

              Beneficiary</span>&#8221; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s rights if the Participant dies or becomes incapacitated.
            Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.14&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Director</span>&#8221;
            means a Board member. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.15&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Disability</span>&#8221;
            means a permanent and total disability under Section&#160;22(e)(3) of the Code, as amended. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.16&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Dividend

              Equivalents</span>&#8221; means a right granted to a Participant under the Plan to receive the equivalent value (in cash or Shares) of dividends paid on Shares. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.17&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Effective

              Time</span>&#8221; means [<span style="text-decoration: underline;">&#8195;&#8195;&#8195;</span>]. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.18&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Employee</span>&#8221;
            means any employee of the Company or its Subsidiaries. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.19&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Equity

              Restructuring</span>&#8221; means, as determined by the Administrator, a nonreciprocal transaction between the Company and its stockholders, such as a stock dividend, stock split, spin-off or recapitalization, or other large, nonrecurring cash
            dividend, that affects the number or kind of Shares (or other Company securities) or the share price of Common Stock (or other Company securities) and causes a change in the per share value of the Common Stock underlying outstanding Awards. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.20&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Exchange

              Act</span>&#8221; means the Securities Exchange Act of 1934, as amended. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.21&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Fair

              Market Value</span>&#8221; means, as of any date, the value of a Share determined as follows: (i) if the Common Stock is listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Common Stock as quoted
            on such exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; (ii) if the Common
            Stock is not traded on a stock exchange but is quoted on a national market or other quotation system, the closing sales price on such date, or if no sales occurred on such date, then on the last date preceding such date during which a sale
            occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; or (iii)&#160;without an established market for the Common Stock, the Administrator will determine the Fair Market Value in its discretion. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-12<br/>
        </div>

      </div>

    </div>

    <!--End Page 641-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 642-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.22&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Greater Than 10% Stockholder</span>&#8221; means an individual then owning (within the meaning of Section&#160;424(d) of the Code) more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary
            corporation, as defined in Section&#160;424(e) and (f) of the Code, respectively. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.23&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Incentive

              Stock Option</span>&#8221; means an Option intended to qualify as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.24&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Non-Qualified

              Stock Option</span>&#8221; means an Option (or portion thereof) not intended or not qualifying as an Incentive Stock Option. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.25&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Option</span>&#8221;
            means an option to purchase Shares, which will either be an Incentive Stock Option or a Non-Qualified Stock Option. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.26&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Other

              Stock or Cash Based Awards</span>&#8221; means cash awards, awards of Shares, and other awards valued wholly or partially by referring to, or are otherwise based on, Shares or other property. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.27&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Overall

              Share Limit</span>&#8221; means the sum of (i) [&#8226;] Shares, (ii) any Shares which are subject to Prior Plan Awards which become available for issuance under the Plan pursuant to Article&#160;IV; and (iii) an increase commencing on January&#160;1, 2027 and
            continuing annually on each anniversary thereof through (and including) January&#160;1, 2036, equal to the lesser of (A) [&#8226;] % of the aggregate number of Shares outstanding on the last day of the immediately preceding calendar year and (B) such
            smaller number of Shares as determined by the Administrator. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.28&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Participant</span>&#8221;
            means a Service Provider who has been granted an Award. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.29&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Performance

              Criteria</span>&#8221; means the criteria (and adjustments) that the Administrator may select for an Award to establish performance goals for a performance period, which may include (but is not limited to) the following: net earnings or losses
            (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted
            net income; profits (including but not limited to gross profits, net profits, profit growth, net operating profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or
            before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on
            stockholders&#8217; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per
            share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic
            milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of
            personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or
            reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any
            incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#8217;s performance or the performance of a Subsidiary, division, business segment or business unit of the Company or a Subsidiary, or based
            upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. The Administrator may provide for exclusion of the impact of an event or
            occurrence which the Administrator determines should appropriately be excluded, including (a) restructurings, discontinued operations, extraordinary items, and other unusual, infrequently occurring or non-recurring charges or events, (b) asset
            write-downs, (c) litigation or claim judgments or settlements, (d) acquisitions or divestitures, (e) reorganization or change in the corporate structure or capital structure of the Company, (f) an event either not directly related to the
            operations of the Company, Subsidiary, division, business segment or business unit or not within the reasonable control of management, (g) foreign exchange gains and losses, (h) a change in the fiscal year of the Company, (i) the refinancing or
            repurchase of bank loans or debt securities, (j) unbudgeted capital expenditures, (k) the issuance or repurchase of equity securities and other changes in the number of outstanding shares, (l) conversion of some or all of convertible securities
            to Common Stock, (m) any business interruption event (n) the cumulative effects of tax or accounting changes in accordance with U.S.&#160;generally accepted accounting principles, or (o) the effect of changes in other laws or regulatory rules
            affecting reported results. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-13<br/>
        </div>

      </div>

    </div>

    <!--End Page 642-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 643-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg14"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.30&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Plan</span>&#8221;
            means this Remix Therapeutics, Inc. 2026 Equity Incentive Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.31&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Prior

              Plans</span>&#8221; means, collectively, the Passage Bio, Inc. Amended and Restated 2018 Equity Incentive Plan, the Passage Bio, Inc. 2020 Equity Incentive Plan and the Remix Therapeutics Inc. 2019 Stock Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.32&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Prior

              Plan Award</span>&#8221; means an award outstanding under the Prior Plans as of the Effective Time. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.33&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Restricted

              Stock</span>&#8221; means Shares awarded to a Participant under Article&#160;VI subject to certain vesting conditions and other restrictions. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.34&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Restricted

              Stock Unit</span>&#8221; means an unfunded, unsecured right to receive, on the applicable settlement date, one Share or an amount in cash or other consideration determined by the Administrator to be of equal value as of such settlement date awarded
            to a Participant under Article&#160;VI, subject to certain vesting conditions and other restrictions. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.35&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Rule&#160;16b-3</span>&#8221;
            means Rule&#160;16b-3 promulgated under the Exchange Act. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.36&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Section&#160;409A</span>&#8221;
            means Section&#160;409A of the Code and all regulations, guidance, compliance programs and other interpretative authority thereunder. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.37&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Securities

              Act</span>&#8221; means the Securities Act of 1933, as amended. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.38&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Service

              Provider</span>&#8221; means an Employee, Consultant or Director. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.39&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Shares</span>&#8221;
            means shares of Common Stock. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.40&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Stock

              Appreciation Right</span>&#8221; means a stock appreciation right granted under Article&#160;V. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.41&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Subsidiary</span>&#8221;
            means any entity (other than the Company), whether domestic or foreign, in an unbroken chain of entities beginning with the Company if each of the entities other than the last entity in the unbroken chain beneficially owns, at the time of the
            determination, securities or interests representing at least 50% of the total combined voting power of all classes of securities or interests in one of the other entities in such chain. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.42&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Substitute

              Awards</span>&#8221; means Awards granted or Shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the
            Company or any Subsidiary or with which the Company or any Subsidiary combines. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">11.43&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Termination

              of Service</span>&#8221; means a Participant ceasing to be a Service Provider. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">* * * * * </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-14<br/>
        </div>

      </div>

    </div>

    <!--End Page 643-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 644-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg15"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REMIX THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">STOCK OPTION GRANT NOTICE </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Capitalized terms not specifically defined in this Stock
            Option Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Grant Notice</span>&#8221;) have the meanings given to them in the Remix Therapeutics, Inc. 2026 Equity Incentive Plan (as amended and/or restated from time to time, the &#8220;<span style="font-style: italic; font-weight: bold;">Plan</span>&#8221;) of Remix Therapeutics, Inc. (the &#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221;). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company has granted to the participant listed below (&#8220;<span style="font-style: italic; font-weight: bold;">Participant</span>&#8221;) the stock option described in this Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Option</span>&#8221;), subject to the terms and conditions of the Plan
            and the Stock Option Agreement attached as <span style="font-weight: bold;">Exhibit&#160;A</span> (the &#8220;<span style="font-style: italic; font-weight: bold;">Agreement</span>&#8221;), both of which are incorporated into this Grant Notice by reference. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 264pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participant:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exercise Price per Share:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Shares Subject to the Option:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Final Expiration Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vesting Commencement Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vesting Schedule:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[To be specified in individual award agreements] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Type of Option:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 264pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[Incentive Stock Option/Non-Qualified Stock Option]</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 264pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">By Participant&#8217;s signature below, Participant agrees to be
            bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant
            Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising
            under the Plan, this Grant Notice or the Agreement.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td colspan="4" style="width: 228pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PARTICIPANT </div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[Participant Name] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 180pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-15<br/>
        </div>

      </div>

    </div>

    <!--End Page 644-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 645-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg16"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><span style="text-decoration: underline;">Exhibit A</span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; text-align: center;">STOCK OPTION AGREEMENT </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Capitalized terms not specifically defined in this Agreement
            have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">ARTICLE I. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.1&#8195;<span style="text-decoration: underline;">Grant of Option</span>. The Company has granted to
            Participant the Option effective as of the grant date set forth in the Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Grant Date</span>&#8221;). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.2&#8195;<span style="text-decoration: underline;">Incorporation of Terms of Plan</span>. The Option is
            subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; text-align: center;">ARTICLE II. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">PERIOD OF EXERCISABILITY </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.1&#8195;<span style="text-decoration: underline;">Commencement of Exercisability</span>. The Option will
            vest and become exercisable according to the vesting schedule in the Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Vesting Schedule</span>&#8221;) except that any fraction of a Share as to which the Option would be vested or
            exercisable will be accumulated and will vest and become exercisable only when a whole Share has accumulated. Notwithstanding anything in the Grant Notice, the Plan or this Agreement to the contrary, unless the Administrator otherwise
            determines, the Option will immediately expire and be forfeited as to any portion that is not vested and exercisable as of Participant&#8217;s Termination of Service for any reason. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.2&#8195;<span style="text-decoration: underline;">Duration of Exercisability</span>. The Vesting Schedule
            is cumulative. Any portion of the Option which vests and becomes exercisable will remain vested and exercisable until the Option expires. The Option will be forfeited immediately upon its expiration. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.3&#8195;<span style="text-decoration: underline;">Expiration of Option</span>. The Option may not be
            exercised to any extent by anyone after, and will expire on, the first of the following to occur: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;The final expiration date in the Grant Notice; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Except as the Administrator may otherwise approve, the
            expiration of three (3) months from the date of Participant&#8217;s Termination of Service, unless Participant&#8217;s Termination of Service is for Cause or by reason of Participant&#8217;s death or Disability; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Except as the Administrator may otherwise approve, the
            expiration of one (1) year from the date of Participant&#8217;s Termination of Service by reason of Participant&#8217;s death or Disability; and </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(d)&#8195;Except as the Administrator may otherwise approve,
            Participant&#8217;s Termination of Service for Cause. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; text-align: center;">ARTICLE III. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">EXERCISE OF OPTION </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.1&#8195;<span style="text-decoration: underline;">Person Eligible to Exercise</span>. During Participant&#8217;s
            lifetime, only Participant may exercise the Option. After Participant&#8217;s death, any exercisable portion of the Option may, prior to the time the Option expires, be exercised by Participant&#8217;s Designated Beneficiary as provided in the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.2&#8195;<span style="text-decoration: underline;">Partial Exercise</span>. Any exercisable portion of the
            Option or the entire Option, if then wholly exercisable, may be exercised, in whole or in part, according to the procedures in the Plan at any time prior to the time the Option or portion thereof expires, except that the Option may only be
            exercised for whole Shares. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.3&#8195;<span style="text-decoration: underline;">Tax Withholding</span>.</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company has the right and option, but not the
            obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Option as Participant&#8217;s election to satisfy all or any portion of the withholding tax by
            requesting the Company retain Shares otherwise issuable under the Option. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-16<br/>
        </div>

      </div>

    </div>

    <!--End Page 645-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 646-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg17"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Participant acknowledges that Participant is
            ultimately liable and responsible for all taxes owed in connection with the Option, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Option. Neither
            the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or exercise of the Option or the subsequent sale of Shares. The Company and the
            Subsidiaries do not commit and are under no obligation to structure the Option to reduce or eliminate Participant&#8217;s tax liability. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE IV. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OTHER PROVISIONS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.1&#8195;<span style="text-decoration: underline;">Adjustments</span>. Participant acknowledges that the
            Option is subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.2&#8195;<span style="text-decoration: underline;">Notices</span>. Any notice to be given under the terms
            of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number. Any notice to be given
            under the terms of this Agreement to Participant must be in writing and addressed to Participant (or, if Participant is then deceased, to the person entitled to exercise the Option) at Participant&#8217;s last known mailing address, email address or
            facsimile number in the Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received,
            when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally
            recognized express shipping company or upon receipt of a facsimile transmission confirmation. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.3&#8195;<span style="text-decoration: underline;">Titles</span>. Titles are provided herein for
            convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.4&#8195;<span style="text-decoration: underline;">Conformity to Securities Laws</span>. Participant
            acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable
            Laws. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.5&#8195;<span style="text-decoration: underline;">Successors and Assigns</span>. The Company may assign
            any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement
            will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.6&#8195;<span style="text-decoration: underline;">Limitations Applicable to Section&#160;16 Persons</span>.
            Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Option will be subject to any additional limitations set forth in
            any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are required for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be deemed amended
            as necessary to conform to such applicable exemptive rule. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.7&#8195;<span style="text-decoration: underline;">Entire Agreement</span>. The Plan, the Grant Notice and
            this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.8&#8195;<span style="text-decoration: underline;">Agreement Severable</span>. In the event that any
            provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the
            Grant Notice or this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.9&#8195;<span style="text-decoration: underline;">Limitation on Participant&#8217;s Rights</span>. Participation
            in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor
            any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Option, and rights
            no greater than the right to receive the Shares as a general unsecured creditor with respect to the Option, as and when exercised pursuant to the terms hereof. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.10&#8195;<span style="text-decoration: underline;">Not a Contract of Employment</span>. Nothing in the
            Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which
            rights are hereby expressly reserved, to discharge or </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-17<br/>
        </div>

      </div>

    </div>

    <!--End Page 646-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 647-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg18"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">terminate the services of Participant at any time for any reason whatsoever,
            with or without Cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Participant. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.11&#8195;<span style="text-decoration: underline;">Counterparts</span>. The Grant Notice may be executed
            in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. Delivery of an executed counterpart of a
            signature page to this Agreement by facsimile, &#8220;.pdf&#8221; format, scanned pages or other electronic means shall be effective as delivery of a manually executed counterpart to this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">4.12&#8195;<span style="text-decoration: underline;">Incentive Stock Options</span>. If the Option is
            designated as an Incentive Stock Option: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Participant acknowledges that to the extent the
            aggregate fair market value of shares (determined as of the time the option with respect to the shares is granted) with respect to which stock options intended to qualify as &#8220;incentive stock options&#8221; under Section&#160;422 of the Code, including the
            Option, are exercisable for the first time by Participant during any calendar year exceeds $100,000 or if for any other reason such stock options do not qualify or cease to qualify for treatment as &#8220;incentive stock options&#8221; under Section&#160;422 of
            the Code, such stock options (including the Option) will be treated as non-qualified stock options. Participant further acknowledges that the rule set forth in the preceding sentence will be applied by taking the Option and other stock options
            into account in the order in which they were granted, as determined under Section&#160;422(d) of the Code. Participant acknowledges that amendments or modifications made to the Option pursuant to the Plan that would cause the Option to become a
            Non-Qualified Stock Option will not materially or adversely affect Participant&#8217;s rights under the Option, and that any such amendment or modification shall not require Participant&#8217;s consent. Participant also acknowledges that if the Option is
            exercised more than three (3) months after Participant&#8217;s Termination of Service as an Employee, other than by reason of death or Disability, the Option will be taxed as a Non-Qualified Stock Option. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Participant will give prompt written notice to the
            Company of any disposition or other transfer of any Shares acquired under this Agreement if such disposition or other transfer is made (a) within two (2) years from the Grant Date or (b) within one (1) year after the transfer of such Shares to
            Participant. Such notice will specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant in such disposition or other transfer. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">* * * * * </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-18<br/>
        </div>

      </div>

    </div>

    <!--End Page 647-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 648-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg19"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REMIX THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">RESTRICTED STOCK GRANT NOTICE </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Capitalized terms not specifically defined in this
            Restricted Stock Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Grant Notice</span>&#8221;) have the meanings given to them in the Remix Therapeutics, Inc. 2026 Equity Incentive Plan (as amended and/or restated from time to
            time, the &#8220;<span style="font-style: italic; font-weight: bold;">Plan</span>&#8221;) of Remix Therapeutics, Inc. (the &#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221;). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company has granted to the participant listed below (&#8220;<span style="font-style: italic; font-weight: bold;">Participant</span>&#8221;)<span style="font-style: italic;"> </span>the shares of Restricted Stock described in this Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Restricted
              Shares</span>&#8221;), subject to the terms and conditions of the Plan and the Restricted Stock Agreement attached as <span style="font-weight: bold;">Exhibit&#160;A</span> (the &#8220;<span style="font-style: italic; font-weight: bold;">Agreement</span>&#8221;),
            both of which are incorporated into this Grant Notice by reference.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participant:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of Restricted Shares:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vesting Commencement Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 180pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vesting Schedule:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 276pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[To be specified in individual award agreements]</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 180pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 276pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">By Participant&#8217;s signature below, Participant agrees to be
            bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant
            Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising
            under the Plan, this Grant Notice or the Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td colspan="4" style="width: 228pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PARTICIPANT </div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[Participant Name] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 180pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 180pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-19<br/>
        </div>

      </div>

    </div>

    <!--End Page 648-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 649-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg20"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><span style="text-decoration: underline;">Exhibit A</span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; text-align: center;">RESTRICTED STOCK AGREEMENT </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Capitalized terms not specifically defined in this Agreement
            have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; text-align: center;">ARTICLE I. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.1&#8195;<span style="text-decoration: underline;">Issuance of Restricted Shares</span>. The Company will
            issue the Restricted Shares to Participant effective as of the grant date set forth in the Grant Notice and will cause (a) a stock certificate or certificates representing the Restricted Shares to be registered in Participant&#8217;s name or (b) the
            Restricted Shares to be held in book-entry form. If a stock certificate is issued, the certificate will be delivered to, and held in accordance with this Agreement by, the Company or its authorized representatives and will bear the restrictive
            legends required by this Agreement. If the Restricted Shares are held in book-entry form, then the book-entry will indicate that the Restricted Shares are subject to the restrictions of this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.2&#8195;<span style="text-decoration: underline;">Incorporation of Terms of Plan</span>. The Restricted
            Shares are subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; text-align: center;">ARTICLE II. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">VESTING, FORFEITURE AND ESCROW </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.1&#8195;<span style="text-decoration: underline;">Vesting</span>. The Restricted Shares will become vested
            Shares (the &#8220;<span style="font-style: italic; font-weight: bold;">Vested Shares</span>&#8221;) according to the vesting schedule in the Grant Notice except that any fraction of a Share that would otherwise become a Vested Share will be accumulated
            and will become a Vested Share only when a whole Vested Share has accumulated.&#8195;</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.2&#8195;<span style="text-decoration: underline;">Forfeiture</span>. In the event of Participant&#8217;s
            Termination of Service for any reason, Participant will immediately and automatically forfeit to the Company any Shares that are not Vested Shares (the &#8220;<span style="font-style: italic; font-weight: bold;">Unvested Shares</span>&#8221;) at the time
            of Participant&#8217;s Termination of Service, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. Upon forfeiture of Unvested Shares, the Company will become the legal
            and beneficial owner of the Unvested Shares and all related interests and Participant will have no further rights with respect to the Unvested Shares. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.3&#8195;<span style="text-decoration: underline;">Escrow</span>.</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Unvested Shares will be held by the Company or its
            authorized representatives until (i) they are forfeited, (ii) they become Vested Shares or (iii) this Agreement is no longer in effect. By accepting this Award, Participant appoints the Company and its authorized representatives as
            Participant&#8217;s attorney(s)-in-fact to take all actions necessary to effect any transfer of forfeited Unvested Shares (and Retained Distributions (as defined below), if any, paid on such forfeited Unvested Shares) to the Company as may be
            required pursuant to the Plan or this Agreement and to execute such representations or other documents or assurances as the Company or such representatives deem necessary or advisable in connection with any such transfer. The Company, or its
            authorized representative, will not be liable for any good faith act or omission with respect to the holding in escrow or transfer of the Restricted Shares. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;All cash dividends and other distributions made or
            declared with respect to Unvested Shares (&#8220;<span style="font-style: italic; font-weight: bold;">Retained Distributions</span>&#8221;) will be held by the Company until the time (if ever) when the Unvested Shares to which such Retained Distributions
            relate become Vested Shares. The Company will establish a separate Retained Distribution bookkeeping account (&#8220;<span style="font-style: italic; font-weight: bold;">Retained Distribution Account</span>&#8221;) for each Unvested Share with respect to
            which Retained Distributions have been made or declared in cash and credit the Retained Distribution Account (without interest) on the date of payment with the amount of such cash made or declared with respect to the Unvested Share. Retained
            Distributions (including any Retained Distribution Account balance) will immediately and automatically be forfeited upon forfeiture of the Unvested Share with respect to which the Retained Distributions were paid or declared. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;As soon as reasonably practicable following the date on
            which an Unvested Share becomes a Vested Share, the Company will (i) cause the certificate (or a new certificate without the legend required by this </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-20<br/>
        </div>

      </div>

    </div>

    <!--End Page 649-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 650-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg21"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">Agreement, if Participant so requests) representing the Share to be
            delivered to Participant or, if the Share is held in book-entry form, cause the notations indicating the Share is subject to the restrictions of this Agreement to be removed and (ii) pay to Participant the Retained Distributions relating to the
            Share. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.4&#8195;<span style="text-decoration: underline;">Rights as Stockholder</span>. Except as otherwise
            provided in this Agreement or the Plan, upon issuance of the Restricted Shares by the Company, Participant will have all the rights of a stockholder with respect to the Restricted Shares, including the right to vote the Restricted Shares and to
            receive dividends or other distributions paid or made with respect to the Restricted Shares.</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;">ARTICLE III. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">TAXATION AND TAX WITHHOLDING </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.1&#8195;<span style="text-decoration: underline;">Representation</span>. Participant represents to the
            Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of the Restricted Shares and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and
            not on any statements or representations of the Company or any of its agents. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.2&#8195;<span style="text-decoration: underline;">Tax Withholding</span>.</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company has the right and option, but not the
            obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the Restricted Shares as Participant&#8217;s election to satisfy all or any portion of the withholding
            tax by requesting the Company retain Shares otherwise deliverable under the Award. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Participant acknowledges that Participant is ultimately
            liable and responsible for all taxes owed in connection with the Restricted Shares, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the Restricted
            Shares. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the Restricted Shares or the subsequent sale of the
            Restricted Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure this Award to reduce or eliminate Participant&#8217;s tax liability. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; text-align: center;">ARTICLE IV. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">RESTRICTIVE LEGENDS AND TRANSFERABILITY </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.1&#8195;<span style="text-decoration: underline;">Legends</span>. Any certificate representing a
            Restricted Share will bear the following legend until the Restricted Share becomes a Vested Share: </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; width: 448pt; margin-top: 6pt; margin-left: 20pt; text-align: justify;">THE SHARES REPRESENTED BY THIS CERTIFICATE
            ARE SUBJECT TO FORFEITURE IN FAVOR OF THE COMPANY AND MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.<span style="font-style: normal;"> </span></div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.2&#8195;<span style="text-decoration: underline;">Transferability</span>. The Restricted Shares and any
            Retained Distributions are subject to the restrictions on transfer in the Plan and may not be sold, assigned or transferred in any manner unless and until they become Vested Shares. Any attempted transfer or disposition of Unvested Shares or
            related Retained Distributions prior to the time the Unvested Shares become Vested Shares will be null and void. The Company will not be required to (a) transfer on its books any Restricted Share that has been sold or otherwise transferred in
            violation of this Agreement or (b) treat as owner of such Restricted Share or accord the right to vote or pay dividends to any purchaser or other transferee to whom such Restricted Share has been so transferred. The Company may issue
            appropriate &#8220;stop transfer&#8221; instructions to its transfer agent, if any, or make appropriate notations to the same effect in its records. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; text-align: center;">ARTICLE V. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OTHER PROVISIONS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.1&#8195;<span style="text-decoration: underline;">Adjustments</span>. Participant acknowledges that the
            Restricted Shares are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.2&#8195;<span style="text-decoration: underline;">Notices</span>. Any notice to be given under the terms
            of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number. Any notice to be given
            under the terms of this Agreement to Participant </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-21<br/>
        </div>

      </div>

    </div>

    <!--End Page 650-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 651-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg22"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">must be in writing and addressed to Participant at Participant&#8217;s last known
            mailing address, email address or facsimile number in the Company&#8217;s personnel files. By a notice given pursuant to this Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed
            duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service,
            when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.3&#8195;<span style="text-decoration: underline;">Titles</span>. Titles are provided herein for
            convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.4 &#8195;<span style="text-decoration: underline;">Conformity to Securities Laws</span>. Participant
            acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable
            Laws. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.5&#8195;<span style="text-decoration: underline;">Successors and Assigns</span>. The Company may assign
            any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in this Agreement or the Plan,
            this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.6&#8195;<span style="text-decoration: underline;">Limitations Applicable to Section&#160;16 Persons</span>.
            Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement and the Restricted Shares will be subject to any additional limitations
            set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are required for the application of such exemptive rule. To the extent Applicable Laws permit, this Agreement will be
            deemed amended as necessary to conform to such applicable exemptive rule. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.7&#8195;<span style="text-decoration: underline;">Entire Agreement</span>. The Plan, the Grant Notice and
            this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.8&#8195;<span style="text-decoration: underline;">Agreement Severable</span>. In the event that any
            provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the
            Grant Notice or this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.9&#8195;<span style="text-decoration: underline;">Limitation on Participant&#8217;s Rights</span>. Participation
            in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor
            any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the Award. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.10&#8195;<span style="text-decoration: underline;">Not a Contract of Employment</span>. Nothing in the
            Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which
            rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the
            Company or a Subsidiary and Participant. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.11&#8195;<span style="text-decoration: underline;">Counterparts</span>. The Grant Notice may be executed
            in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. Delivery of an executed counterpart of a
            signature page to this Agreement by facsimile, &#8220;.pdf&#8221; format, scanned pages or other electronic means shall be effective as delivery of a manually executed counterpart to this Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">* * * * * </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-22<br/>
        </div>

      </div>

    </div>

    <!--End Page 651-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 652-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg23"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">REMIX THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">RESTRICTED STOCK UNIT GRANT NOTICE </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Capitalized terms not specifically defined in this
            Restricted Stock Unit Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Grant Notice</span>&#8221;) have the meanings given to them in the Remix Therapeutics, Inc. 2026 Equity Incentive Plan (as amended and/or restated from time
            to time, the &#8220;<span style="font-style: italic; font-weight: bold;">Plan</span>&#8221;) of Remix Therapeutics, Inc. (the &#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221;). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company has granted to the participant listed below (&#8220;<span style="font-style: italic; font-weight: bold;">Participant</span>&#8221;) the Restricted Stock Units described in this Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">RSUs</span>&#8221;), subject to the terms and conditions of the
            Plan and the Restricted Stock Unit Agreement attached as <span style="font-weight: bold;">Exhibit&#160;A</span> (the &#8220;<span style="font-style: italic; font-weight: bold;">Agreement</span>&#8221;), both of which are incorporated into this Grant Notice by
            reference.</div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Participant:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 312pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Grant Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Number of RSUs:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vesting Commencement Date:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vesting Schedule:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[To be specified in individual award agreements]</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">By Participant&#8217;s signature below, Participant agrees to be
            bound by the terms of this Grant Notice, the Plan and the Agreement. Participant has reviewed the Plan, this Grant Notice and the Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant
            Notice and fully understands all provisions of the Plan, this Grant Notice and the Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising
            under the Plan, this Grant Notice or the Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 216pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td colspan="4" style="width: 216pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">REMIX THERAPEUTICS, INC.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-bottom: 2.88pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PARTICIPANT </div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 168pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 2.51pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 168pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Name: </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 168pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.76pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">[Participant Name] </div>
                </td>

  </tr>

  <tr>

    <td style="width: 36pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Title:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 168pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 240pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 168pt; border-bottom: 1pt solid #000000;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-23<br/>
        </div>

      </div>

    </div>

    <!--End Page 652-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 653-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg24"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><span style="text-decoration: underline;">Exhibit A</span></div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">RESTRICTED STOCK UNIT AGREEMENT </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Capitalized terms not specifically defined in this Agreement
            have the meanings specified in the Grant Notice or, if not defined in the Grant Notice, in the Plan. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE I. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GENERAL </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">1.1&#8195;<span style="text-decoration: underline;">Award of RSUs and Dividend Equivalents</span>.</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company has granted the RSUs to Participant
            effective as of the grant date set forth in the Grant Notice (the &#8220;<span style="font-style: italic; font-weight: bold;">Grant Date</span>&#8221;). Each RSU represents the right to receive one Share or, at the option of the Company, an amount of cash,
            in either case, as set forth in this Agreement. Participant will have no right to the distribution of any Shares or payment of any cash until the time (if ever) the RSUs have vested. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;The Company hereby grants to Participant, with respect
            to each RSU, a Dividend Equivalent for ordinary cash dividends paid to substantially all holders of outstanding Shares with a record date after the Grant Date and prior to the date the applicable RSU is settled, forfeited or otherwise expires.
            Each Dividend Equivalent entitles Participant to receive the equivalent value of any such ordinary cash dividends paid on a single Share. The Company will establish a separate Dividend Equivalent bookkeeping account (a &#8220;<span style="font-style: italic; font-weight: bold;">Dividend Equivalent Account</span>&#8221;) for each Dividend Equivalent and credit the Dividend Equivalent Account (without interest) on the applicable dividend payment date with the amount of any such cash paid. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.2&#8195;<span style="text-decoration: underline;">Incorporation of Terms of Plan</span>. The RSUs are
            subject to the terms and conditions set forth in this Agreement and the Plan, which is incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan will control. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">1.3&#8195;<span style="text-decoration: underline;">Unsecured Promise</span>. The RSUs and Dividend
            Equivalents will at all times prior to settlement represent an unsecured Company obligation payable only from the Company&#8217;s general assets. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE II. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">VESTING; FORFEITURE AND SETTLEMENT </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.1&#8195;<span style="text-decoration: underline;">Vesting; Forfeiture</span>. The RSUs will vest according
            to the vesting schedule in the Grant Notice except that any fraction of an RSU that would otherwise be vested will be accumulated and will vest only when a whole RSU has accumulated. In the event of Participant&#8217;s Termination of Service for any
            reason, all unvested RSUs will immediately and automatically be cancelled and forfeited, except as otherwise determined by the Administrator or provided in a binding written agreement between Participant and the Company. Dividend Equivalents
            (including any Dividend Equivalent Account balance) will vest or be forfeited, as applicable, upon the vesting or forfeiture of the RSU with respect to which the Dividend Equivalent (including the Dividend Equivalent Account) relates. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.2&#8195;<span style="text-decoration: underline;">Settlement</span>. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;RSUs and Dividend Equivalents (including any Dividend
            Equivalent Account balance) will be paid in Shares or cash at the Company&#8217;s option as soon as administratively practicable after the vesting of the applicable RSU, but in no event more than sixty (60) days after the RSU&#8217;s vesting date.
            Notwithstanding the foregoing, the Company may delay any payment under this Agreement that the Company reasonably determines would violate Applicable Laws until the earliest date the Company reasonably determines the making of the payment will
            not cause such a violation (in accordance with Treasury Regulation Section&#160;1.409A-2(b)(7)(ii)), provided the Company reasonably believes the delay will not result in the imposition of excise taxes under Section&#160;409A. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;If an RSU is paid in cash, the amount of cash paid with
            respect to the RSU will equal the Fair Market Value of a Share on the day immediately preceding the payment date. If a Dividend Equivalent is paid in Shares, the number of Shares paid with respect to the Dividend Equivalent will equal the
            quotient, rounded down to the nearest whole Share, of the Dividend Equivalent Account balance divided by the Fair Market Value of a Share on the day immediately preceding the payment date. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-24<br/>
        </div>

      </div>

    </div>

    <!--End Page 653-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 654-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg25"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ARTICLE III. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">TAXATION AND TAX WITHHOLDING </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.1&#8195;<span style="text-decoration: underline;">Representation</span>. Participant represents to the
            Company that Participant has reviewed with Participant&#8217;s own tax advisors the tax consequences of this Award and the transactions contemplated by the Grant Notice and this Agreement. Participant is relying solely on such advisors and not on any
            statements or representations of the Company or any of its agents. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">3.2&#8195;<span style="text-decoration: underline;">Tax Withholding</span>. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;The Company has the right and option, but not the
            obligation, to treat Participant&#8217;s failure to provide timely payment in accordance with the Plan of any withholding tax arising in connection with the RSUs or Dividend Equivalents as Participant&#8217;s election to satisfy all or any portion of the
            withholding tax by requesting the Company retain Shares otherwise issuable under the Award. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Participant acknowledges that Participant is ultimately
            liable and responsible for all taxes owed in connection with the RSUs and the Dividend Equivalents, regardless of any action the Company or any Subsidiary takes with respect to any tax withholding obligations that arise in connection with the
            RSUs or Dividend Equivalents. Neither the Company nor any Subsidiary makes any representation or undertaking regarding the treatment of any tax withholding in connection with the awarding, vesting or payment of the RSUs or the Dividend
            Equivalents or the subsequent sale of Shares. The Company and the Subsidiaries do not commit and are under no obligation to structure the RSUs or Dividend Equivalents to reduce or eliminate Participant&#8217;s tax liability. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">ARTICLE IV. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OTHER PROVISIONS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.1&#8195;<span style="text-decoration: underline;">Adjustments</span>. Participant acknowledges that the
            RSUs, the Shares subject to the RSUs and the Dividend Equivalents are subject to adjustment, modification and termination in certain events as provided in this Agreement and the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.2&#8195;<span style="text-decoration: underline;">Notices</span>. Any notice to be given under the terms
            of this Agreement to the Company must be in writing and addressed to the Company in care of the Company&#8217;s Secretary at the Company&#8217;s principal office or the Secretary&#8217;s then-current email address or facsimile number. Any notice to be given
            under the terms of this Agreement to Participant must be in writing and addressed to Participant at Participant&#8217;s last known mailing address, email address or facsimile number in the Company&#8217;s personnel files. By a notice given pursuant to this
            Section, either party may designate a different address for notices to be given to that party. Any notice will be deemed duly given when actually received, when sent by email, when sent by certified mail (return receipt requested) and deposited
            with postage prepaid in a post office or branch post office regularly maintained by the United States Postal Service, when delivered by a nationally recognized express shipping company or upon receipt of a facsimile transmission confirmation. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.3&#8195;<span style="text-decoration: underline;">Titles</span>. Titles are provided herein for
            convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.4&#8195;<span style="text-decoration: underline;">Conformity to Securities Laws</span>. Participant
            acknowledges that the Plan, the Grant Notice and this Agreement are intended to conform to the extent necessary with all Applicable Laws and, to the extent Applicable Laws permit, will be deemed amended as necessary to conform to Applicable
            Laws. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.5&#8195;<span style="text-decoration: underline;">Successors and Assigns</span>. The Company may assign
            any of its rights under this Agreement to single or multiple assignees, and this Agreement will inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth in the Plan, this Agreement
            will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.6&#8195;<span style="text-decoration: underline;">Limitations Applicable to Section&#160;16 Persons</span>.
            Notwithstanding any other provision of the Plan or this Agreement, if Participant is subject to Section&#160;16 of the Exchange Act, the Plan, the Grant Notice, this Agreement, the RSUs and the Dividend Equivalents will be subject to any additional
            limitations set forth in any applicable exemptive rule under Section&#160;16 of the Exchange Act (including any amendment to Rule&#160;16b-3) that are required for the application of such exemptive rule. To the extent Applicable Laws permit, this
            Agreement will be deemed amended as necessary to conform to such applicable exemptive rule. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.7&#8195;<span style="text-decoration: underline;">Entire Agreement</span>. The Plan, the Grant Notice and
            this Agreement (including any exhibit hereto) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-25<br/>
        </div>

      </div>

    </div>

    <!--End Page 654-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 655-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_310-annexl_pg26"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.8&#8195;<span style="text-decoration: underline;">Agreement Severable</span>. In the event that any
            provision of the Grant Notice or this Agreement is held illegal or invalid, the provision will be severable from, and the illegality or invalidity of the provision will not be construed to have any effect on, the remaining provisions of the
            Grant Notice or this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.9&#8195;<span style="text-decoration: underline;">Limitation on Participant&#8217;s Rights</span>. Participation
            in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and may not be construed as creating a trust. Neither the Plan nor
            any underlying program, in and of itself, has any assets. Participant will have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs and Dividend
            Equivalents, and rights no greater than the right to receive cash or the Shares as a general unsecured creditor with respect to the RSUs and Dividend Equivalents, as and when settled pursuant to the terms of this Agreement. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.10&#8195;<span style="text-decoration: underline;">Not a Contract of Employment</span>. Nothing in the
            Plan, the Grant Notice or this Agreement confers upon Participant any right to continue in the employ or service of the Company or any Subsidiary or interferes with or restricts in any way the rights of the Company and its Subsidiaries, which
            rights are hereby expressly reserved, to discharge or terminate the services of Participant at any time for any reason whatsoever, with or without Cause, except to the extent expressly provided otherwise in a written agreement between the
            Company or a Subsidiary and Participant. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.11&#8195;<span style="text-decoration: underline;">Counterparts</span>. The Grant Notice may be executed
            in one or more counterparts, including by way of any electronic signature, subject to Applicable Law, each of which will be deemed an original and all of which together will constitute one instrument. Delivery of an executed counterpart of a
            signature page to this Agreement by facsimile, &#8220;.pdf&#8221; format, scanned pages or other electronic means shall be effective as delivery of a manually executed counterpart to this Agreement. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">K-26<br/>
        </div>

      </div>

    </div>

    <!--End Page 655-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 656-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXM"><!--Anchor--></a>Annex&#160;L <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">REMIX THERAPEUTICS, INC. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026 EMPLOYEE STOCK PURCHASE PLAN</div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE I. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">PURPOSE </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The purpose of this Plan is to assist Eligible Employees of
            the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Plan consists of two components: (i) the Section&#160;423
            Component and (ii) the Non-Section&#160;423 Component. The Section&#160;423 Component is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and shall be administered, interpreted and construed in a manner consistent
            with the requirements of Section&#160;423 of the Code. The Non-Section&#160;423 Component authorizes the grant of rights which need not qualify as rights granted pursuant to an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. Rights granted
            under the Non-Section&#160;423 Component shall be granted pursuant to separate Offerings containing such sub-plans, appendices, rules or procedures as may be adopted by the Administrator and designed to achieve tax, securities laws or other
            objectives for Eligible Employees and Designated Subsidiaries but shall not be intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. Except as otherwise determined by the Administrator or provided herein, the
            Non-Section&#160;423 Component will operate and be administered in the same manner as the Section&#160;423 Component. Offerings intended to be made under the Non-Section&#160;423 Component will be designated as such by the Administrator at or prior to the
            time of such Offering. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">For purposes of this Plan, the Administrator may designate
            separate Offerings under the Plan in which Eligible Employees will participate. The terms of these Offerings need not be identical, even if the dates of the applicable Offering Period(s) in each such Offering are identical, provided that the
            terms of participation are the same within each separate Offering under the Section&#160;423 Component (as determined under Section&#160;423 of the Code). Solely by way of example and without limiting the foregoing, the Company could, but shall not be
            required to, provide for simultaneous Offerings under the Section&#160;423 Component and the Non-Section&#160;423 Component of the Plan. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; text-align: center;">ARTICLE II. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">DEFINITIONS AND CONSTRUCTION </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Wherever the following terms are used in the Plan they shall
            have the meanings specified below, unless the context clearly indicates otherwise. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.1&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Administrator</span>&#8221;
            means the entity that conducts the general administration of the Plan as provided in Article&#160;XI. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.2&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Agent</span>&#8221;
            means the brokerage firm, bank or other financial institution, entity or person(s), if any, engaged, retained, appointed or authorized to act as the agent of the Company or an Employee with regard to the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.3&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Applicable

              Law</span>&#8221; means the requirements relating to the administration of equity incentive plans under U.S. federal and state securities, tax and other applicable laws, rules and regulations, the applicable rules of any stock exchange or quotation
            system on which Shares are listed or quoted and the applicable laws and rules of any foreign country or other jurisdiction where rights under this Plan are granted. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.4&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Board</span>&#8221;
            means the Board of Directors of the Company. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.5&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Code</span>&#8221;
            means the U.S. Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.6&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Common

              Stock</span>&#8221; means the common stock of the Company and such other securities of the Company that may be substituted therefor. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.7&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Company</span>&#8221;
            means Remix Therapeutics, Inc., a Delaware corporation, or any successor. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.8&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Compensation</span>&#8221;
            of an Eligible Employee means, unless otherwise determined by the Administrator, the gross base compensation or wages received by such Eligible Employee as compensation for services to the Company or any Designated Subsidiary, excluding
            overtime payments, vacation pay, holiday pay, jury duty pay, funeral leave pay, military leave pay, sales commissions, incentive compensation, bonuses, expense reimbursements, income received in connection with any compensatory equity awards,
            fringe benefits and other special payments. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 656-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 657-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.9&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Designated

              Beneficiary</span>&#8221; means the beneficiary or beneficiaries the Participant designates, in a manner the Administrator determines, to receive amounts due or exercise the Participant&#8217;s rights if the Participant dies or becomes incapacitated.
            Without a Participant&#8217;s effective designation, &#8220;Designated Beneficiary&#8221; will mean the Participant&#8217;s estate. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.10&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Designated

              Subsidiary</span>&#8221; means any Subsidiary designated by the Administrator in accordance with Section&#160;11.2(b), such designation to specify whether such participation is in the Section&#160;423 Component or Non-Section&#160;423 Component. A Designated
            Subsidiary may participate in either the Section&#160;423 Component or Non-Section&#160;423 Component, but not both; provided that a Subsidiary that, for U.S. tax purposes, is disregarded from the Company or any Subsidiary that participates in the
            Section&#160;423 Component shall automatically constitute a Designated Subsidiary that participates in the Section&#160;423 Component. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.11&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Effective</span>
            <span style="font-style: italic; font-weight: bold;">Time</span>&#8221; means [<span style="text-decoration: underline;">&#8195;&#8195;&#8195;&#8195;</span>], 2026. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.12&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Eligible

              Employee</span>&#8221; means: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;an Employee who does not, immediately after any rights
            under this Plan are granted, own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of Shares and other securities of the Company, a Parent or a Subsidiary (as determined
            under Section&#160;423(b)(3) of the Code). For purposes of the foregoing, the rules of Section&#160;424(d) of the Code with regard to the attribution of stock ownership shall apply in determining the stock ownership of an individual, and stock that an
            Employee may purchase under outstanding options shall be treated as stock owned by the Employee. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Notwithstanding the foregoing, the Administrator may
            provide in an Offering Document that an Employee shall not be eligible to participate in an Offering Period under the Section&#160;423 Component if: (i) such Employee is a highly compensated employee within the meaning of Section&#160;423(b)(4)(D) of the
            Code; (ii) such Employee has not met a service requirement designated by the Administrator pursuant to Section&#160;423(b)(4)(A) of the Code (which service requirement may not exceed two years); (iii) such Employee&#8217;s customary employment is for
            twenty hours per week or less; (iv) such Employee&#8217;s customary employment is for less than five months in any calendar year; and/or (v) such Employee is a citizen or resident of a foreign jurisdiction and the grant of a right to purchase Shares
            under the Plan to such Employee would be prohibited under the laws of such foreign jurisdiction or the grant of a right to purchase Shares under the Plan to such Employee in compliance with the laws of such foreign jurisdiction would cause the
            Plan to violate the requirements of Section&#160;423 of the Code, as determined by the Administrator in its sole discretion; <span style="text-decoration: underline;">provided</span>, that any exclusion in clauses (i), (ii), (iii), (iv) or (v) shall be applied in an identical manner under
            each Offering Period to all Employees, in accordance with Treasury Regulation Section&#160;1.423-2(e). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;Further notwithstanding the foregoing, with respect to
            the Non-Section&#160;423 Component, the first&#160;sentence in this definition shall not apply in determining who is an &#8220;Eligible Employee,&#8221; and the Administrator may limit eligibility further within the Company or a Designated Subsidiary so as to only
            designate certain Employees of the Company or a Designated Subsidiary as Eligible Employees. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.13&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Employee</span>&#8221;
            means any individual who renders services to the Company or any Designated Subsidiary in the status of an employee, and, with respect to the Section&#160;423 Component, a person who is an employee of the Company or any Designated Subsidiary within
            the meaning of Section&#160;3401(c) of the Code. For purposes of an individual&#8217;s participation in, or other rights under the Plan, all determinations by the Company shall be final, binding and conclusive, notwithstanding that any court of law or
            governmental agency subsequently makes a contrary determination. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company
            or Designated Subsidiary and meeting the requirements of Treasury Regulation Section&#160;1.421-1(h)(2). Where the period of leave exceeds three (3) months and the individual&#8217;s right to reemployment is not guaranteed either by statute or by
            contract, the employment relationship shall be deemed to have terminated on the first day immediately following such three (3)-month period. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.14&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Fair

              Market Value</span>&#8221; means, as of any date, the value of Shares determined as follows: (i) if the Shares are listed on any established stock exchange, its Fair Market Value will be the closing sales price for such Shares as quoted on such
            exchange for such date, or if no sale occurred on such date, the last day preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; (ii) if the Shares are not
            traded on a stock exchange but are quoted on a national market or other quotation system, the closing sales price on </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 657-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 658-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">such date, or if no sales occurred on such date, then on the last date
            preceding such date during which a sale occurred, as reported in The Wall Street Journal or another source the Administrator deems reliable; or (iii) without an established market for the Shares, the Administrator will determine the Fair Market
            Value in its discretion. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.15&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Non-Section&#160;423

              Component</span>&#8221; means those Offerings under the Plan, together with the sub-plans, appendices, rules or procedures, if any, adopted by the Administrator as a part of this Plan, in each case, pursuant to which rights to purchase Shares
            during an Offering Period may be granted to Eligible Employees that need not satisfy the requirements for rights to purchase Shares granted pursuant to an &#8220;employee stock purchase plan&#8221; that are set forth under Section&#160;423 of the Code. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.16&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Offering</span>&#8221;
            means an offer by the Company under the Plan to Eligible Employees of a right to purchase Shares that may be exercised during an Offering Period as further described in Article&#160;IV hereof. Unless otherwise specified by the Administrator, each
            Offering to the Eligible Employees of the Company or a Designated Subsidiary shall be deemed a separate Offering, even if the dates and other terms of the applicable Offering Periods of each such Offering are identical, and the provisions of
            the Plan will separately apply to each Offering. To the extent permitted by Treasury Regulation &#167; 1.423-2(a)(1), the terms of each separate Offering under the Section&#160;423 Component need not be identical, provided that the terms of the
            Section&#160;423 Component and an Offering thereunder together satisfy Treasury Regulation &#167; 1.423-2(a)(2) and (a)(3). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.17&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Offering

              Date</span>&#8221; means the first Trading Day of each Offering Period. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.18&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Offering

              Document</span>&#8221; has the meaning given to such term in Section&#160;4.1. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.19&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Offering

              Period</span>&#8221; has the meaning given to such term in Section&#160;4.1. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.20&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Parent</span>&#8221;
            means any corporation, other than the Company, in an unbroken chain of corporations ending with the Company if, at the time of the determination, each of the corporations other than the Company owns stock possessing 50% or more of the total
            combined voting power of all classes of stock in one of the other corporations in such chain. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.21&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Participant</span>&#8221;
            means any Eligible Employee who has executed a subscription agreement and been granted rights to purchase Shares pursuant to the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.22&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Payday</span>&#8221;
            means the regular and recurring established day for payment of Compensation to an Employee of the Company or any Designated Subsidiary. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.23&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Plan</span>&#8221;
            means this 2026 Employee Stock Purchase Plan, including both the Section&#160;423 Component and Non-Section&#160;423 Component and any other sub-plans or appendices hereto, as amended from time to time. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.24&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Purchase

              Date</span>&#8221; means the last Trading Day of each Purchase Period or such other date as determined by the Administrator and set forth in the Offering Document. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.25&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Purchase

              Period</span>&#8221; shall refer to one or more periods within an Offering Period, as designated in the applicable Offering Document; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that, in the event no Purchase Period is designated by the Administrator in the
            applicable Offering Document, the Purchase Period for each Offering Period covered by such Offering Document shall be the same as the applicable Offering Period. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.26&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Purchase

              Price</span>&#8221; means the purchase price designated by the Administrator in the applicable Offering Document (which purchase price, for purposes of the Section&#160;423 Component, shall not be less than 85% of the Fair Market Value of a Share on the
            Offering Date or on the Purchase Date, whichever is lower); <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that, in the event no purchase price is designated by the Administrator in the applicable Offering Document, the purchase price for the Offering
            Periods covered by such Offering Document shall be 85% of the Fair Market Value of a Share on the Offering Date or on the Purchase Date, whichever is lower; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">further</span>, that the Purchase Price may be adjusted by the
            Administrator pursuant to Article&#160;VIII and shall not be less than the par value of a Share. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.27&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Section&#160;423

              Component</span>&#8221; means those Offerings under the Plan, together with the sub-plans, appendices, rules or procedures, if any, adopted by the Administrator as a part of this Plan or any Offering(s), in each case, pursuant to which rights to
            purchase Shares during an Offering Period may be granted to Eligible Employees that are intended to satisfy the requirements for rights to purchase Shares granted pursuant to an &#8220;employee stock purchase plan&#8221; that are set forth under
            Section&#160;423 of the Code.&#8195;</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.28&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Securities

              Act</span>&#8221; means the U.S. Securities Act of 1933, as amended. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 658-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 659-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.29&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Share</span>&#8221;
            means a share of Common Stock. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.30&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Subsidiary</span>&#8221;
            means any corporation, other than the Company, in an unbroken chain of corporations beginning with the Company if, at the time of the determination, each of the corporations other than the last corporation in an unbroken chain owns stock
            possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain; <span style="text-decoration: underline;">provided</span>, however, that a limited liability company or partnership may be treated as a Subsidiary to the
            extent either (a) such entity is treated as a disregarded entity under Treasury Regulation Section&#160;301.7701-3(a) by reason of the Company or any other Subsidiary that is a corporation being the sole owner of such entity, or (b) such entity
            elects to be classified as a corporation under Treasury Regulation Section&#160;301.7701-3(a) and such entity would otherwise qualify as a Subsidiary. In addition, with respect to the Non-Section&#160;423 Component, Subsidiary shall include any corporate
            or non-corporate entity in which the Company has a direct or indirect equity interest or significant business relationship. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">2.31&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Trading

              Day</span>&#8221; means a day on which national stock exchanges in the United States are open for trading. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">2.32&#8195;&#8220;<span style="font-style: italic; font-weight: bold;">Treasury

              Regulations</span>&#8221; means U.S. Department of the Treasury regulations. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; text-align: center;">ARTICLE III. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">SHARES SUBJECT TO THE PLAN </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.1&#8195;<span style="text-decoration: underline;">Number of Shares</span>. Subject to Article&#160;VIII, the
            aggregate number of Shares that may be issued pursuant to rights granted under the Plan shall be [<span style="text-decoration: underline;">&#8195;&#8195;&#8195;</span>] Shares. In addition to the foregoing, subject to Article&#160;VIII, on the first&#160;day of each calendar year beginning on and including
            January&#160;1, 2027 and ending on and including January&#160;1, 2036, the number of Shares available for issuance under the Plan shall be increased by that number of Shares equal to the lesser of (a) [<span style="text-decoration: underline;">&#8195;&#8195;</span>]% of the aggregate number of Shares
            outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of Shares as determined by the Board or the Compensation Committee of the Board. If any right granted under the Plan shall for any reason
            terminate without having been exercised, the Shares not purchased under such right shall again become available for issuance under the Plan. Notwithstanding anything in this Section&#160;3.1 to the contrary, the number of Shares that may be issued
            or transferred pursuant to the rights granted under the Section&#160;423 Component of the Plan shall not exceed an aggregate of [<span style="text-decoration: underline;">&#8195;&#8195;&#8195;</span>] Shares, subject to Article&#160;VIII. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">3.2&#8195;<span style="text-decoration: underline;">Shares Distributed</span>. Any Shares distributed
            pursuant to the Plan may consist, in whole or in part, of authorized and unissued Shares, treasury shares or Shares purchased on the open market. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; text-align: center;">ARTICLE IV. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">OFFERING PERIODS; OFFERING DOCUMENTS; PURCHASE DATES </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.1&#8195;<span style="text-decoration: underline;">Offering Periods</span>. The Administrator may from time
            to time grant or provide for the grant of rights to purchase Shares under the Plan to Eligible Employees during one or more periods (each, an &#8220;<span style="font-style: italic; font-weight: bold;">Offering Period</span>&#8221;) selected by the
            Administrator. The terms and conditions applicable to each Offering Period shall be set forth in an &#8220;<span style="font-style: italic; font-weight: bold;">Offering Document</span>&#8221; adopted by the Administrator, which Offering Document shall be
            in such form and shall contain such terms and conditions as the Administrator shall deem appropriate and shall be incorporated by reference into and made part of the Plan and shall be attached hereto as part of the Plan. The Administrator shall
            establish in each Offering Document one or more Purchase Periods during such Offering Period during which rights granted under the Plan shall be exercised and purchases of Shares carried out during such Offering Period in accordance with such
            Offering Document and the Plan. The provisions of separate Offerings or Offering Periods under the Plan may be partially or wholly concurrent and need not be identical. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">4.2&#8195;<span style="text-decoration: underline;">Offering Documents</span>. Each Offering Document with
            respect to an Offering Period shall specify (through incorporation of the provisions of this Plan by reference or otherwise): </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(a)&#8195;the length of the Offering Period, which period shall not
            exceed twenty-seven months; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(b)&#8195;the length of the Purchase Period(s) within the Offering
            Period; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;the maximum number of Shares that may be purchased by
            any Eligible Employee during such Offering Period, which, in the absence of a contrary designation by the Administrator, shall be 25,000 Shares (and which, for the Section&#160;423 Component Offering Periods, shall be subject to the limitations
            described in Section&#160;5.5 below); </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;in connection with each Offering Period that contains
            more than one Purchase Period, the maximum aggregate number of Shares which may be purchased by any Eligible Employee during each Purchase Period, </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 659-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 660-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-align: justify;">which, in the absence of a contrary designation by the Administrator, shall
            be 25,000 Shares (and which, for the Section&#160;423 Component Offering Periods, shall be subject to the limitations described in Section&#160;5.5 below); and </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(e)&#8195;such other provisions as the Administrator determines
            are appropriate, subject to the Plan. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE V. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">ELIGIBILITY AND PARTICIPATION </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.1&#8195;<span style="text-decoration: underline;">Eligibility</span>. Any Eligible Employee who shall be
            employed by the Company or a Designated Subsidiary on the Offering Date for an Offering Period, and who has enrolled in such Offering Period in accordance with Section&#160;5.2(a) below, shall be eligible to participate in the Plan during such
            Offering Period, subject to the requirements of this Article&#160;V and, for the Section&#160;423 Component, the limitations imposed by Section&#160;423(b) of the Code. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">5.2&#8195;<span style="text-decoration: underline;">Enrollment in Plan</span>. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;Except as otherwise set forth in an Offering Document
            or determined by the Administrator, an Eligible Employee may become a Participant in the Plan for an Offering Period by delivering a subscription agreement to the Company by such time prior to the Offering Date for such Offering Period (or such
            other date specified in the Offering Document) designated by the Administrator and in such form as the Company provides. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Except as otherwise determined by the Administrator,
            each subscription agreement shall designate a whole percentage of such Eligible Employee&#8217;s Compensation to be withheld by the Company or the Designated Subsidiary employing such Eligible Employee on each Payday during the Offering Period as
            payroll deductions under the Plan. The percentage of Compensation designated by an Eligible Employee may not be less than 1% and may not be more than the maximum percentage specified by the Administrator in the applicable Offering Document
            (which percentage shall be 15% in the absence of any such designation) as payroll deductions. The payroll deductions made for each Participant shall be credited to an account for such Participant under the Plan and shall be deposited with the
            general funds of the Company. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;A Participant may increase or decrease the percentage
            of Compensation designated in his or her subscription agreement, subject to the limits of this Section&#160;5.2, or may suspend his or her payroll deductions, at any time during an Offering Period; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that the
            Administrator may limit the number of changes a Participant may make to his or her payroll deduction elections during each Offering Period in the applicable Offering Document (and in the absence of any specific designation by the Administrator,
            a Participant shall be allowed to decrease (but not increase) or suspend his or her payroll deduction elections one time during each Offering Period). Any such change or suspension of payroll deductions shall be effective with the first full
            payroll period following five business days after the Company&#8217;s receipt of the new subscription agreement (or such shorter or longer period as may be specified by the Administrator in the applicable Offering Document). In the event a
            Participant suspends his or her payroll deductions during an Offering Period, such Participant&#8217;s cumulative unapplied payroll deductions prior to the suspension (if any) shall remain in his or her account and shall be applied to the purchase of
            Shares on the next occurring Purchase Date and shall not be paid to such Participant unless he or she withdraws from participation in the Plan pursuant to Article&#160;VII. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;Except as otherwise set forth in an Offering Document
            or as otherwise determined by the Administrator, a Participant may participate in the Plan only by means of payroll deduction and may not make contributions by lump sum payment for any Offering Period. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.3&#8195;<span style="text-decoration: underline;">Payroll Deductions</span>. Except as otherwise provided
            in the applicable Offering Document or determined by the Administrator, payroll deductions for a Participant shall commence on the first Payday following the Offering Date and shall end on the last Payday in the Offering Period to which the
            Participant&#8217;s authorization is applicable, unless sooner terminated by the Participant as provided in Article&#160;VII or suspended by the Participant or the Administrator as provided in Section&#160;5.2 and Section&#160;5.6, respectively. Notwithstanding any
            other provisions of the Plan to the contrary, in any non-U.S. jurisdiction where participation in the Plan through payroll deductions is prohibited, the Administrator may provide that an Eligible Employee may elect to participate through
            contributions to the Participant&#8217;s account under the Plan in a form acceptable to the Administrator in lieu of or in addition to payroll deductions; provided, however, that, for any Offering under the Section&#160;423 Component, the Administrator
            shall take into consideration any limitations under Section&#160;423 of the Code when applying an alternative method of contribution. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 660-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 661-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.4&#8195;<span style="text-decoration: underline;">Effect of Enrollment</span>. A Participant&#8217;s
            completion of a subscription agreement will enroll such Participant in the Plan for each subsequent Offering Period on the terms contained therein until the Participant either submits a new subscription agreement, withdraws from participation
            under the Plan as provided in Article&#160;VII or otherwise becomes ineligible to participate in the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.5&#8195;<span style="text-decoration: underline;">Limitation on Purchase of Shares</span>. An Eligible
            Employee may be granted rights under the Section&#160;423 Component only if such rights, together with any other rights granted to such Eligible Employee under &#8220;employee stock purchase plans&#8221; of the Company, any Parent or any Subsidiary, as
            specified by Section&#160;423(b)(8) of the Code, do not permit such employee&#8217;s rights to purchase stock of the Company or any Parent or Subsidiary to accrue at a rate that exceeds $25,000 of the fair market value of such stock (determined as of the
            first day of the Offering Period during which such rights are granted) for each calendar year in which such rights are outstanding at any time. This limitation shall be applied in accordance with Section&#160;423(b)(8) of the Code. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.6&#8195;<span style="text-decoration: underline;">Suspension of Payroll Deductions</span>. Notwithstanding
            the foregoing, to the extent necessary to comply with Section&#160;423(b)(8) of the Code and Section&#160;5.5 (with respect to the Section&#160;423 Component) or the other limitations set forth in this Plan, a Participant&#8217;s payroll deductions may be suspended
            by the Administrator at any time during an Offering Period. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares by reason of Section&#160;423(b)(8) of the Code, Section&#160;5.5 or the
            other limitations set forth in this Plan shall be paid to such Participant in one lump sum in cash as soon as reasonably practicable, but not more than 30 days, after the Purchase Date. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.7&#8195;<span style="text-decoration: underline;">Foreign Employees</span>. In order to facilitate
            participation in the Plan, the Administrator may provide for such special terms, rules and procedures applicable to Participants who are citizens or residents of a foreign jurisdiction, or who are employed by a Designated Subsidiary outside of
            the United States, as the Administrator may consider necessary or appropriate to accommodate differences in local law, tax policy or custom. Except as permitted by Section&#160;423 of the Code, with respect to the Section&#160;423 Component, such special
            terms may not be more favorable than the terms of rights granted under the Section&#160;423 Component to Eligible Employees who are residents of the United&#160;States. Such special terms may be set forth in an addendum to the Plan in the form of an
            appendix or sub-plan (which appendix or sub-plan may be designed to govern Offerings under the Section&#160;423 Component or the Non-Section&#160;423 Component, as determined by the Administrator). To the extent that the terms and conditions set forth in
            an appendix or sub-plan conflict with any provisions of the Plan, the provisions of the appendix or sub-plan shall govern. The adoption of any such appendix or sub-plan shall be pursuant to Section&#160;11.2(g). Without limiting the foregoing, the
            Administrator is specifically authorized to adopt rules and procedures, with respect to Participants who are foreign nationals or employed in non-U.S. jurisdictions, regarding the exclusion of particular Subsidiaries from participation in the
            Plan, eligibility to participate, the definition of Compensation, handling of payroll deductions or other contributions by Participants, payment of interest, conversion of local currency, data privacy security, payroll tax, withholding
            procedures, establishment of bank or trust accounts to hold payroll deductions or contributions. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">5.8&#8195;<span style="text-decoration: underline;">Leave of Absence</span>. During leaves of absence
            approved by the Company meeting the requirements of Treasury Regulation Section&#160;1.421-1(h)(2) under the Code, unless otherwise set forth in the terms of an Offering Document, a Participant may continue participation in the Plan by making cash
            payments to the Company on his or her normal Payday equal to the Participant&#8217;s authorized payroll deduction. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE VI. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">GRANT AND EXERCISE OF RIGHTS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.1&#8195;<span style="text-decoration: underline;">Grant of Rights</span>. On the Offering Date of each
            Offering Period, each Eligible Employee participating in such Offering Period shall be granted a right to purchase the maximum number of Shares specified under Section&#160;4.2, subject to the limits in Section&#160;5.5, and shall have the right to buy,
            on each Purchase Date during such Offering Period (at the applicable Purchase Price), such number of whole Shares as is determined by dividing (a) such Participant&#8217;s payroll deductions accumulated prior to such Purchase Date and retained in the
            Participant&#8217;s account as of the Purchase Date, by (b) the applicable Purchase Price (rounded down to the nearest Share). The right shall expire on the earliest of: (x)&#160;the last Purchase Date of the Offering Period, (y) the last day of the
            Offering Period, and (z) the date on which the Participant withdraws in accordance with Section&#160;7.1 or Section&#160;7.3. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.2&#8195;<span style="text-decoration: underline;">Exercise of Rights</span>. On each Purchase Date, each
            Participant&#8217;s accumulated payroll deductions and any other additional payments specifically provided for in the applicable Offering Document will be applied to the purchase of whole Shares, up to the maximum number of Shares permitted pursuant
            to the terms of the Plan and the applicable Offering Document, at the Purchase Price. No fractional Shares shall be issued upon the exercise of rights granted under </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 661-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 662-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg7"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">the Plan, unless the Offering Document specifically provides otherwise. Any
            cash in lieu of fractional Shares remaining after the purchase of whole Shares upon exercise of a purchase right will be returned to the Participant in one lump sum payment in a subsequent payroll check, unless the Administrator provides that
            such amounts should be credited to a Participant&#8217;s account and carried forward (after taking into account &#8220;equal rights and privileges&#8221;, as described below). Shares issued pursuant to the Plan may be evidenced in such manner as the
            Administrator may determine and may be issued in certificated form or issued pursuant to book-entry procedures. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.3&#8195;<span style="text-decoration: underline;">Pro Rata Allocation of Shares</span>. If the
            Administrator determines that, on a given Purchase Date, the number of Shares with respect to which rights are to be exercised may exceed (a) the number of Shares that were available for issuance under the Plan on the Offering Date of the
            applicable Offering Period, or (b) the number of Shares available for issuance under the Plan on such Purchase Date, the Administrator may in its sole discretion provide that the Company shall make a pro rata allocation of the Shares available
            for purchase on such Offering Date or Purchase Date, as applicable, in as uniform a manner as shall be practicable and as it shall determine in its sole discretion to be equitable among all Participants for whom rights to purchase Shares are to
            be exercised pursuant to this Article&#160;VI on such Purchase Date, and shall either (i) continue all Offering Periods then in effect, or (ii) terminate any or all Offering Periods then in effect pursuant to Article&#160;IX. The Company may make pro
            rata allocation of the Shares available on the Offering Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional Shares for issuance under the Plan by the Company&#8217;s stockholders
            subsequent to such Offering Date. The balance of the amount credited to the account of each Participant that has not been applied to the purchase of Shares shall be paid to such Participant without interest in one lump sum in cash as soon as
            reasonably practicable after the Purchase Date, or such earlier date as determined by the Administrator. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.4&#8195;<span style="text-decoration: underline;">Withholding</span>. At the time a Participant&#8217;s rights
            under the Plan are exercised, in whole or in part, or at the time some or all of the Shares issued under the Plan is disposed of, the Participant must make adequate provision for the Company&#8217;s federal, state, or other tax withholding
            obligations, if any, that arise upon the exercise of the right or the disposition of the Shares. At any time, the Company may, but shall not be obligated to, withhold from the Participant&#8217;s compensation or withhold Shares received pursuant to
            the Plan (or cause a sale of such Shares) in the amount necessary for the Company to meet applicable withholding obligations, including any withholding required to make available to the Company any tax deductions or benefits attributable to
            sale or early disposition of Shares by the Participant, in any case, without the Participant&#8217;s prior consent. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">6.5&#8195;<span style="text-decoration: underline;">Conditions to Issuance of Shares</span>. The Company
            shall not be required to issue or deliver any certificate or certificates for, or make any book entries evidencing, Shares purchased upon the exercise of rights under the Plan prior to fulfillment of all of the following conditions: (a) the
            admission of such Shares to listing on all stock exchanges, if any, on which the Shares are then listed; (b) the completion of any registration or other qualification of such Shares under any state or federal law or under the rulings or
            regulations of the Securities and Exchange Commission or any other governmental regulatory body, that the Administrator shall, in its absolute discretion, deem necessary or advisable; (c)&#160;the obtaining of any approval or other clearance from
            any state or federal governmental agency that the Administrator shall, in its absolute discretion, determine to be necessary or advisable; (d) the payment to the Company of all amounts that it is required to withhold under federal, state or
            local law upon exercise of the rights, if any; and (e)&#160;the lapse of such reasonable period of time following the exercise of the rights as the Administrator may from time to time establish for reasons of administrative convenience. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE VII. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">WITHDRAWAL; CESSATION OF ELIGIBILITY </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">7.1&#8195;<span style="text-decoration: underline;">Withdrawal</span>. A Participant may withdraw all but
            not less than all of the payroll deductions credited to his or her account and not yet used to exercise his or her rights under the Plan at any time by giving written notice to the Company in a form acceptable to the Company no later than
            fifteen (15) days prior to the end of the Offering Period or, if earlier, the end of the Purchase Period (or such shorter or longer period as may be specified by the Administrator in the applicable Offering Document). All of the Participant&#8217;s
            payroll deductions credited to his or her account during an Offering Period and not yet used to exercise rights under the Plan shall be paid to such Participant as soon as reasonably practicable after receipt of notice of withdrawal without any
            interest thereon and such Participant&#8217;s rights for the Offering Period shall be automatically terminated, and no further payroll deductions for the purchase of Shares shall be made for such Offering Period. If a Participant withdraws from an
            Offering Period, payroll deductions shall not resume at the beginning of any subsequent Offering Period unless the Participant is an Eligible Employee and timely delivers to the Company a new subscription agreement by the applicable enrollment
            deadline for any such subsequent Offering Period, as determined by the Administrator. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 662-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 663-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg8"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">7.2&#8195;<span style="text-decoration: underline;">Future Participation</span>. A Participant&#8217;s
            withdrawal from an Offering Period shall not have any effect upon his or her eligibility to participate in any similar plan that may hereafter be adopted by the Company or a Designated Subsidiary or in any subsequent Offering Period that
            commences after the termination of the Offering Period from which the Participant withdraws. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">7.3&#8195;<span style="text-decoration: underline;">Cessation of Eligibility</span>. Upon a Participant&#8217;s
            ceasing to be an Eligible Employee for any reason, he or she shall be deemed to have elected to withdraw from the Plan pursuant to this Article&#160;VII and the payroll deductions credited to such Participant&#8217;s account during the Offering Period and
            not yet used to exercise rights under the Plan shall be paid to such Participant or, in the case of his or her death, to the person or persons entitled thereto under Section&#160;12.4, as soon as reasonably practicable without any interest thereon,
            and such Participant&#8217;s rights for the Offering Period shall be automatically terminated. If a Participant transfers employment from the Company or any Designated Subsidiary participating in the Section&#160;423 Component to any Designated Subsidiary
            participating in the Non-Section&#160;423 Component, such transfer shall not be treated as a termination of employment under the Plan, but the Participant shall immediately cease to participate in the Section&#160;423 Component; however, any
            contributions made for the then-current Purchase Period in which such transfer occurs shall be transferred to the Non-Section&#160;423 Component, and such Participant shall immediately join the then-current Offering under the Non-Section&#160;423
            Component upon the same terms and conditions in effect for the Participant&#8217;s participation in the Section&#160;423 Component, except for such modifications otherwise applicable for Participants in such Offering. A Participant who transfers
            employment from any Designated Subsidiary participating in the Non-Section&#160;423 Component to the Company or any Designated Subsidiary participating in the Section&#160;423 Component shall not be treated as terminating the Participant&#8217;s employment
            under the Plan and shall remain a Participant in the Non-Section&#160;423 Component until the earlier of (i) the end of the current Offering Period under the Non-Section&#160;423 Component or (ii) the Offering Date of the first Offering Period in which
            the Participant is eligible to participate following such transfer. Notwithstanding the foregoing, the Administrator may establish different rules to govern transfers of employment between entities participating in the Section&#160;423 Component and
            the Non-Section&#160;423 Component, consistent with the applicable requirements of Section&#160;423 of the Code or other Applicable Law. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; text-align: center;">ARTICLE VIII. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADJUSTMENTS UPON CHANGES IN SHARES </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.1&#8195;<span style="text-decoration: underline;">Changes in Capitalization</span>. Subject to
            Section&#160;8.3, in the event that the Administrator determines that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), change in control, reorganization, merger, amalgamation,
            consolidation, combination, repurchase, redemption, recapitalization, liquidation, dissolution, or sale, transfer, exchange or other disposition of all or substantially all of the assets of the Company, or sale or exchange of Shares or other
            securities of the Company, issuance of warrants or other rights to purchase Shares or other securities of the Company, or other similar corporate transaction or event, as determined by the Administrator, affects the Shares such that an
            adjustment is determined by the Administrator to be appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended by the Company to be made available under the Plan or with respect to any outstanding
            purchase rights under the Plan, the Administrator shall make equitable adjustments, if any, to reflect such change with respect to (a) the aggregate number and type of Shares (or other securities or property) that may be issued under the Plan
            (including, but not limited to, adjustments of the limitations in Section&#160;3.1 and the limitations established in each Offering Document pursuant to Section&#160;4.2 on the maximum number of Shares that may be purchased); (b) the class(es) and number
            of Shares and price per Share subject to outstanding rights; and (c) the Purchase Price with respect to any outstanding rights. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.2&#8195;<span style="text-decoration: underline;">Other Adjustments</span>. Subject to Section&#160;8.3, in the
            event of any transaction or event described in Section&#160;8.1 or any unusual or nonrecurring transactions or events affecting the Company, any affiliate of the Company, or the financial statements of the Company or any affiliate, or of changes in
            Applicable Law or accounting principles, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions whenever the Administrator determines
            that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan, to facilitate such transactions or
            events or to give effect to such changes in laws, regulations or principles: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;To provide for either (i) termination of any
            outstanding right in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such right had such right been currently exercisable or (ii) the replacement of such outstanding right with
            other rights or property selected by the Administrator in its sole discretion; </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-8<br/>
        </div>

      </div>

    </div>

    <!--End Page 663-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 664-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg9"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;To provide that the outstanding rights under the
            Plan shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for by similar rights covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof,
            with appropriate adjustments as to the number and kind of shares and prices; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;To make adjustments in the number and type of Shares
            (or other securities or property) subject to outstanding rights under the Plan and/or in the terms and conditions of outstanding rights and rights that may be granted in the future; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;To provide that Participants&#8217; accumulated payroll
            deductions may be used to purchase Shares prior to the next occurring Purchase Date on such date as the Administrator determines in its sole discretion and the Participants&#8217; rights under the ongoing Offering Period(s) shall be terminated; and </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(e)&#8195;To provide that all outstanding rights shall terminate
            without being exercised. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.3&#8195;<span style="text-decoration: underline;">No Adjustment Under Certain Circumstances</span>. Unless
            determined otherwise by the Administrator, no adjustment or action described in this Article&#160;VIII or in any other provision of the Plan shall be authorized to the extent that such adjustment or action would cause the Section&#160;423 Component of
            the Plan to fail to satisfy the requirements of Section&#160;423 of the Code. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">8.4&#8195;<span style="text-decoration: underline;">No Other Rights</span>. Except as expressly provided in
            the Plan, no Participant shall have any rights by reason of any subdivision or consolidation of shares of stock of any class, the payment of any dividend, any increase or decrease in the number of shares of stock of any class or any
            dissolution, liquidation, merger, or consolidation of the Company or any other corporation. Except as expressly provided in the Plan or pursuant to action of the Administrator under the Plan, no issuance by the Company of shares of stock of any
            class, or securities convertible into shares of stock of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number of Shares subject to outstanding rights under the Plan or the Purchase Price with
            respect to any outstanding rights. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE IX.<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">AMENDMENT, MODIFICATION AND TERMINATION</div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.1&#8195;<span style="text-decoration: underline;">Amendment, Modification and Termination</span>. The
            Administrator may amend, suspend or terminate the Plan at any time and from time to time; <span style="text-decoration: underline;">provided</span>, <span style="text-decoration: underline;">however</span>, that approval of the Company&#8217;s stockholders shall be required to amend the Plan to: (a) increase the aggregate number,
            or change the type, of shares that may be sold pursuant to rights under the Plan under Section&#160;3.1 (other than an adjustment as provided by Article&#160;VIII) or (b) change the corporations or classes of corporations whose employees may be granted
            rights under the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.2&#8195;<span style="text-decoration: underline;">Certain Changes to Plan</span>. Without stockholder
            consent and without regard to whether any Participant rights may be considered to have been adversely affected (and, with respect to the Section&#160;423 Component of the Plan, to the extent permitted by Section&#160;423 of the Code), the Administrator
            shall be entitled to change or terminate the Offering Periods, limit the frequency and/or number of changes in the amount withheld from Compensation during an Offering Period, establish the exchange ratio applicable to amounts withheld in a
            currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company&#8217;s processing of payroll withholding elections, establish reasonable
            waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Shares for each Participant properly correspond with amounts withheld from the Participant&#8217;s Compensation, and
            establish such other limitations or procedures as the Administrator determines in its sole discretion to be advisable that are consistent with the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.3&#8195;<span style="text-decoration: underline;">Actions In the Event of Unfavorable Financial
              Accounting Consequences</span>. In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary
            or desirable, modify or amend the Plan to reduce or eliminate such accounting consequence including, but not limited to: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;altering the Purchase Price for any Offering Period,
            including an Offering Period underway at the time of the change in Purchase Price; </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;shortening any Offering Period so that the Offering
            Period ends on a new Purchase Date, including an Offering Period underway at the time of the Administrator action; and </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(c)&#8195;allocating Shares. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-9<br/>
        </div>

      </div>

    </div>

    <!--End Page 664-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 665-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg10"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Such modifications or amendments shall not require
            stockholder approval or if the Administrator so determines, the consent of any Participant. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">9.4&#8195;<span style="text-decoration: underline;">Payments Upon Termination of Plan</span>. Upon
            termination of the Plan, the balance in each Participant&#8217;s Plan account shall be refunded as soon as practicable after such termination, without any interest thereon, or the Offering Period may be shortened so that the purchase of Shares occurs
            prior to the termination of the Plan. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE X. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">TERM OF PLAN </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Plan shall become effective at the Effective Time. The
            effectiveness of the Section&#160;423 Component of the Plan shall be subject to approval of the Plan by the Company&#8217;s stockholders within twelve months following the date the Plan is first approved by the Board. No right may be granted under the
            Section&#160;423 Component of the Plan prior to such stockholder approval. The Plan shall remain in effect until terminated under Section&#160;9.1. No rights may be granted under the Plan during any period of suspension of the Plan or after termination
            of the Plan. </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">ARTICLE XI. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">ADMINISTRATION </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.1&#8195;<span style="text-decoration: underline;">Administrator</span>. Unless otherwise determined by
            the Board, the Administrator of the Plan shall be the Compensation Committee of the Board (or another committee or a subcommittee of the Board to which the Board delegates administration of the Plan). The Board may at any time re-vest in itself
            any previously delegated authority or duties for administration of the Plan. The Administrator may delegate administrative tasks under the Plan to the services of an Agent or Employees to assist in the administration of the Plan, including
            establishing and maintaining an individual securities account under the Plan for each Participant. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.2&#8195;<span style="text-decoration: underline;">Authority of Administrator</span>. The Administrator
            shall have the power, subject to, and within the limitations of, the express provisions of the Plan: </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;To determine when and how rights to purchase Shares
            shall be granted and the provisions of each offering of such rights (which need not be identical). </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;To designate from time to time which Subsidiaries of
            the Company shall be Designated Subsidiaries, which designation may be made without the approval of the stockholders of the Company. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(c)&#8195;To impose a mandatory holding period pursuant to which
            Participants may not dispose of or transfer Shares purchased under the Plan for a period of time determined by the Administrator in its discretion. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(d)&#8195;To construe and interpret the Plan and rights granted
            under it, and to establish, amend and revoke rules and regulations for its administration. The Administrator, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it shall
            deem necessary or expedient to make the Plan fully effective. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 20pt; text-indent: 20pt; text-align: left;">(e)&#8195;To amend, suspend or terminate the Plan as provided in
            Article&#160;IX. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(f)&#8195;Generally, to exercise such powers and to perform such
            acts as the Administrator deems necessary or expedient to promote the best interests of the Company and its Subsidiaries and to carry out the intent that the Plan be treated as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423
            of the Code for the Section&#160;423 Component. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(g)&#8195;To adopt sub-plans applicable to particular Designated
            Subsidiaries or locations, which sub-plans may be designed to be outside the scope of Section&#160;423 of the Code. The rules of such sub-plans may take precedence over other provisions of this Plan, with the exception of Section&#160;3.1 hereof, but
            unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall govern the operation of such sub-plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">11.3&#8195;<span style="text-decoration: underline;">Decisions Binding</span>. The Administrator&#8217;s
            interpretation of the Plan, any rights granted pursuant to the Plan, any subscription agreement and all decisions and determinations by the Administrator with respect to the Plan are final, binding, and conclusive on all parties. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-10<br/>
        </div>

      </div>

    </div>

    <!--End Page 665-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 666-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg11"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">ARTICLE XII. <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">MISCELLANEOUS </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.1&#8195;<span style="text-decoration: underline;">Restriction upon Assignment</span>. A right granted
            under the Plan shall not be transferable other than by will or the Applicable Laws of descent and distribution, and is exercisable during the Participant&#8217;s lifetime only by the Participant. Except as provided in Section&#160;12.4 hereof, a right
            under the Plan may not be exercised to any extent except by the Participant. The Company shall not recognize and shall be under no duty to recognize any assignment or alienation of the Participant&#8217;s interest in the Plan, the Participant&#8217;s
            rights under the Plan or any rights thereunder. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.2&#8195;<span style="text-decoration: underline;">Rights as a Stockholder</span>. With respect to Shares
            subject to a right granted under the Plan, no Participant or Designated Beneficiary shall be deemed to be a stockholder of the Company, and no Participant or Designated Beneficiary shall have any of the rights or privileges of a stockholder,
            until such Shares have been issued to the Participant or the Designated Beneficiary following exercise of the Participant&#8217;s rights under the Plan. No adjustments shall be made for dividends (ordinary or extraordinary, whether in cash
            securities, or other property) or distribution or other rights for which the record date occurs prior to the date of such issuance, except as otherwise expressly provided herein or as determined by the Administrator. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.3&#8195;<span style="text-decoration: underline;">Interest</span>. No interest shall accrue on the
            payroll deductions or contributions of a Participant under the Plan. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">12.4&#8195;<span style="text-decoration: underline;">Designation of Beneficiary</span>. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(a)&#8195;A Participant may, in the manner determined by the
            Administrator, file a written designation of a beneficiary who is to receive any Shares and/or cash, if any, from the Participant&#8217;s account under the Plan in the event of such Participant&#8217;s death subsequent to a Purchase Date on which the
            Participant&#8217;s rights are exercised but prior to delivery to such Participant of such Shares and cash. In addition, a Participant may file a written designation of a beneficiary who is to receive any cash from the Participant&#8217;s account under the
            Plan in the event of such Participant&#8217;s death prior to exercise of the Participant&#8217;s rights under the Plan. If the Participant is married and resides in a community property state, a designation of a person other than the Participant&#8217;s spouse
            as his or her beneficiary shall not be effective without the prior written consent of the Participant&#8217;s spouse. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 20pt; text-indent: 20pt; text-align: justify;">(b)&#8195;Such designation of beneficiary may be changed by the
            Participant at any time by written notice to the Company. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#8217;s death, the Company shall
            deliver such Shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such
            Shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.5&#8195;<span style="text-decoration: underline;">Notices</span>. All notices or other communications by
            a Participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.6&#8195;<span style="text-decoration: underline;">Equal Rights and Privileges</span>. Subject to
            Section&#160;5.7, all Eligible Employees will have equal rights and privileges under the Section&#160;423 Component so that the Section&#160;423 Component of this Plan qualifies as an &#8220;employee stock purchase plan&#8221; within the meaning of Section&#160;423 of the
            Code. Subject to Section&#160;5.7, any provision of the Section&#160;423 Component that is inconsistent with Section&#160;423 of the Code will, without further act or amendment by the Company, the Board or the Administrator, be reformed to comply with the
            equal rights and privileges requirement of Section&#160;423 of the Code. Eligible Employees participating in the Non-Section&#160;423 Component need not have the same rights and privileges as other Eligible Employees participating in the Non-Section&#160;423
            Component or as Eligible Employees participating in the Section&#160;423 Component. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.7&#8195;<span style="text-decoration: underline;">Use of Funds</span>. All payroll deductions received or
            held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such payroll deductions. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.8&#8195;<span style="text-decoration: underline;">Reports</span>. Statements of account shall be given to
            Participants at least annually, which statements shall set forth the amounts of payroll deductions, the Purchase Price, the number of Shares purchased and the remaining cash balance, if any. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-11<br/>
        </div>

      </div>

    </div>

    <!--End Page 666-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 667-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg12"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.9&#8195;<span style="text-decoration: underline;">No Employment Rights</span>. Nothing in the Plan
            shall be construed to give any person (including any Eligible Employee or Participant) the right to remain in the employ or service of the Company or any Parent or Subsidiary or affect the right of the Company or any Parent or Subsidiary to
            terminate the employment or service of any person (including any Eligible Employee or Participant) at any time, with or without cause. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.10&#8195;<span style="text-decoration: underline;">Notice of Disposition of Shares</span>. Each
            Participant shall give prompt notice to the Company of any disposition or other transfer of any Shares purchased upon exercise of a right under the Section&#160;423 Component of the Plan if such disposition or transfer is made: (a) within two years
            from the Offering Date of the Offering Period in which the Shares were purchased or (b) within one year after the Purchase Date on which such Shares were purchased. Such notice shall specify the date of such disposition or other transfer and
            the amount realized, in cash, other property, assumption of indebtedness or other consideration, by the Participant in such disposition or other transfer. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.11&#8195;<span style="text-decoration: underline;">Limitations on Liability</span>. Notwithstanding any
            other provisions of the Plan, no individual acting as a director, officer, other employee or agent of the Company or any Subsidiary will be liable to any Participant, former Participant, Designated Beneficiary or any other person for any claim,
            loss, liability, or expense incurred in connection with the Plan or any Offering Period, and such individual will not be personally liable with respect to the Plan because of any contract or other instrument executed in his or her capacity as
            an Administrator, director, officer, other employee or agent of the Company or any Subsidiary. To the extent allowable pursuant to Applicable Laws and the Company&#8217;s governing documents, the Company will indemnify and hold harmless each
            director, officer, other employee and agent of the Company or any Subsidiary that has been or will be granted or delegated any duty or power relating to the Plan&#8217;s administration or interpretation, against any cost or expense (including
            attorneys&#8217; fees) or liability (including any sum paid in settlement of a claim with the Administrator&#8217;s approval) arising from any act or omission concerning this Plan unless arising from such person&#8217;s own fraud or bad faith. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.12&#8195;<span style="text-decoration: underline;">Data Privacy</span>. As a condition for participation
            in the Plan, the Participant acknowledges and agrees that the Company (acting as data controller) may hold certain personal information about the Participant, including the Participant&#8217;s name, address and telephone number; birthdate; social
            security number, insurance number or other identification number; salary; nationality; job title(s); any Shares held in the Company or its Subsidiaries and affiliates; and participation details (the &#8220;<span style="font-style: italic; font-weight: bold;">Data</span>&#8221;) to implement, manage and administer the Plan and any Offering Period(s). The Company may receive the Data from its Subsidiaries and affiliates or the Participant, and may share the Data with its Subsidiaries
            and to third parties assisting the Company with the Plan implementation, administration and management including to a broker or other third party with whom the Company or the Participant may elect to deposit any Shares. These recipients may be
            located outside of the Participant&#8217;s country (and outside of the United States, European Economic Area or United Kingdom), and in such cases the Data will be transferred in accordance with applicable law, including where required using approved
            international data transfer mechanisms such as standard contractual clauses. The Data related to a Participant will be held only as long as necessary to implement, administer, and manage the Participant&#8217;s participation in the Plan. To the
            extent permitted under applicable law, a Participant may, at any time, exercise their right to request access to their Data, to delete or correct their Data, to object to the Company&#8217;s use of the Data, to request that the Company restricts the
            use of Data or shares the Data with another controller, or to raise any issues around the Company&#8217;s use of Data with the Company or any data privacy regulator. To contact the Company, request a copy of any international data transfer mechanism,
            exercise any data privacy right, or find out more information about how the Company uses the Data, a Participant may contact their local human resources representative. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.13&#8195;<span style="text-decoration: underline;">Severability</span>. If any portion of the Plan or any
            action taken under it is held illegal or invalid for any reason, the illegality or invalidity will not affect the remaining parts of the Plan, and the Plan will be construed and enforced as if the illegal or invalid provisions had been
            excluded, and the illegal or invalid action will be null and void. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.14&#8195;<span style="text-decoration: underline;">Titles and Headings</span>. The titles and headings in
            the Plan are for convenience of reference only and, if any conflict, the Plan&#8217;s text, rather than such titles or headings, will control. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.15&#8195;<span style="text-decoration: underline;">Conformity to Applicable Laws</span>. Participant
            acknowledges that the Plan is intended to conform to the extent necessary with Applicable Laws. Notwithstanding anything herein to the contrary, the Plan and all Offering Periods will be administered only in conformance with Applicable Laws. To
            the extent Applicable Laws permit, the Plan and all Offering Periods will be deemed amended as necessary to conform to Applicable Laws. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.16&#8195;<span style="text-decoration: underline;">Relationship to Other Benefits</span>. No payment
            under the Plan will be taken into account in determining any benefits under any pension, retirement, savings, profit sharing, group insurance, welfare or other benefit plan of the Company or any Subsidiary except as expressly provided in
            writing in such other plan or an agreement thereunder. </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-12<br/>
        </div>

      </div>

    </div>

    <!--End Page 667-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 668-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_311-annexm_pg13"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.17&#8195;<span style="text-decoration: underline;">Governing Law</span>. The Plan and any agreements
            hereunder shall be administered, interpreted and enforced in accordance with the laws of the State of Delaware, disregarding any state&#8217;s choice of law principles requiring the application of a jurisdiction&#8217;s laws other than the State of
            Delaware. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.18&#8195;<span style="text-decoration: underline;">Electronic Forms</span>. To the extent permitted by
            Applicable Law and in the discretion of the Administrator, an Eligible Employee may submit any form or notice as set forth herein by means of an electronic form approved by the Administrator. Before the commencement of an Offering Period, the
            Administrator shall prescribe the time limits within which any such electronic form shall be submitted to the Administrator with respect to such Offering Period in order to be a valid election. </div>

          <div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">12.19&#8195;<span style="text-decoration: underline;">Section&#160;409A</span>. The Section&#160;423 Component of the
            Plan and the rights to purchase Shares granted pursuant to Offerings thereunder are intended to be exempt from the application of Section&#160;409A of the Code and the U.S.&#160;Department of Treasury Regulations and other interpretive guidance issued
            thereunder (collectively, &#8220;<span style="font-style: italic; font-weight: bold;">Section&#160;409A</span>&#8221;). Neither the Non-Section&#160;423 Component nor any right to purchase Shares granted pursuant to an Offering thereunder is intended to constitute
            or provide for &#8220;nonqualified deferred compensation&#8221; within the meaning of Section&#160;409A. Notwithstanding any provision of the Plan to the contrary, if the Administrator determines that any right to purchase Shares granted under the Plan may be
            or become subject to Section&#160;409A or that any provision of the Plan may cause a right to purchase Shares granted under the Plan to be or become subject to Section&#160;409A, the Administrator may adopt such amendments to the Plan and/or adopt other
            policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions as the Administrator determines are necessary or appropriate to avoid the imposition of taxes under Section&#160;409A, either
            through compliance with the requirements of Section&#160;409A or with an available exemption therefrom. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">* * * * *</div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">L-13<br/>
        </div>

      </div>

    </div>

    <!--End Page 668-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 669-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_312-annexn_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: right;"><a id="tANXN"><!--Anchor--></a>Annex&#160;M </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">FORM OF PROXY CARD </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">M-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 669-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 670-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_400-part2_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">PART II<br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br/>
          </div>

          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 50pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 20.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Indemnification of Directors and Officers. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As permitted by Section&#160;102(b)(7) of the DGCL, Passage Bio&#8217;s amended and restated
            certificate of incorporation includes a provision to eliminate the personal liability of Passage Bio&#8217;s directors and officers for monetary damages for breach of their fiduciary duties as directors or officers, as applicable, to the fullest
            extent permitted by applicable law. In addition, Passage Bio&#8217;s amended and restated bylaws provide that Passage Bio is required to indemnify its directors and officers to the fullest extent permitted by the DGCL, and Passage Bio is required to
            advance expenses to its directors and officers prior to the final disposition of any covered proceeding, subject to applicable conditions and limitations set forth in Passage Bio&#8217;s amended and restated bylaws and the DGCL. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Section&#160;145(a) of the DGCL provides that a corporation shall have the power to
            indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right
            of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
            corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or
            proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to
            believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did
            not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his
            conduct was unlawful. Section&#160;145(b) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in
            the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
            officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of
            such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation; except that no indemnification shall be made in respect of any claim, issue
            or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Delaware Court of Chancery (the &#8220;<span style="font-style: italic; font-weight: bold;">Court of Chancery</span>&#8221;)
            or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for
            such expenses which the Court of Chancery or such other court shall deem proper. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Passage Bio has entered into indemnification agreements with its directors and
            certain of its officers. These indemnification agreements provide broader indemnity rights than those provided under the DGCL and Passage Bio&#8217;s amended and restated certificate of incorporation. These indemnification agreements are not intended
            to deny or otherwise limit third-party or derivative suits against Passage Bio or its directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial
            burden of a third-party suit would be borne by Passage Bio, and Passage Bio would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to Passage Bio&#8217;s benefit but would be offset by Passage Bio&#8217;s
            obligations to the director or officer under the indemnification agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Passage Bio maintains directors&#8217; and officers&#8217; liability insurance for the
            benefit of its directors and officers. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The Merger Agreement provides that, subject to certain limitations as set forth
            in the Merger Agreement, from the Effective Time through the sixth anniversary of the date on which the Effective Time occurs, Passage Bio and the Surviving Corporation will indemnify each person who is, has been at any time prior to the date
            of the Merger Agreement, or who becomes prior to the Effective Time, a director, officer, fiduciary or agent of Passage Bio or Remix or their respective subsidiaries. The Merger Agreement also provides that the provisions relating to the
            indemnification, advancement of expenses and exculpation of present and former directors and officers of Passage </div>

        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-1<br/>
        </div>

      </div>

    </div>

    <!--End Page 670-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 671-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_400-part2_pg2"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Bio or any of its subsidiaries set forth in the organizational documents of
            Passage Bio or any of its subsidiaries will not be amended, modified or repealed for a period of six years from the Effective Time in any manner that would adversely affect the rights of individuals who, at or prior to the Effective Time, were
            officers or directors of Passage Bio or any of its subsidiaries, unless required by applicable law. After Closing, the organizational documents of the surviving corporation will contain provisions at least as favorable as the provisions
            relating to the indemnification, advancement of expenses and exculpation of present and former directors and officers presently set forth in Passage Bio&#8217;s organizational documents as of the date of the Merger Agreement. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From and after the Effective Time, (i) the Surviving Corporation shall fulfill
            and honor in all respects the obligations of Remix to each person who is or has served as a director or officer of Remix as of immediately prior to the Closing pursuant to any indemnification provisions under Remix&#8217;s amended and restated
            certificate of incorporation and bylaws and pursuant to any indemnification agreements between Remix and such directors and officers, with respect to claims arising out of matters occurring at or prior to the Effective Time and (ii) Passage Bio
            shall fulfill and honor in all respects the obligations of Passage Bio or any of its subsidiaries to each person who is or has served as a director or officer of Passage Bio as of immediately prior to the Closing pursuant to any indemnification
            provisions under Passage Bio&#8217;s amended and restated certificate of incorporation and amended and restated bylaws or any of its subsidiaries and pursuant to any indemnification agreements between Passage Bio or any of its subsidiaries and such
            directors and officers, with respect to claims arising out of matters occurring at or prior to the Effective Time. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From the Effective Time through the sixth (6th) anniversary of the date on which
            the Effective Time occurs, Passage Bio shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially available terms and conditions and with coverage limits customary for
            companies similarly situated to Passage Bio. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">From and after the Effective Time, Passage Bio shall pay all expenses, including
            reasonable attorneys&#8217; fees, that are incurred by indemnified persons in connection with their successful enforcement of the rights provided to such persons in the Merger Agreement. The director and officer indemnification provisions of the
            Merger Agreement are intended to be in addition to the rights otherwise available to the current and former officers and directors of Passage Bio and Remix by law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and
            shall be enforceable by, each of such indemnified persons, their heirs and their representatives. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event Passage Bio or the Surviving Corporation or any of their respective
            successors or assigns (i)&#160;consolidates with or merges into any other person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all or substantially all of its properties and
            assets to any person, then, and in each such case, proper provision shall be made so that the successors and assigns of Passage Bio or the Surviving Corporation, as the case may be, shall succeed to the indemnification obligations set forth in
            the Merger Agreement. Passage Bio shall cause the Surviving Corporation to perform all of the director and officer indemnification obligations of the Surviving Corporation under the Merger Agreement. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 50pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 21.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Exhibits and Financial Statement Schedules. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Exhibit&#160;Index </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A list of exhibits filed with this registration statement on Form&#160;S-4 is set
            forth on the Exhibit&#160;Index and is incorporated herein by reference. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Financial Statements </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The financial statements filed with this registration statement on Form&#160;S-4 are
            set forth on the Financial Statement Index and is incorporated herein by reference. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 12pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 50pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 22.<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-align: left;">Undertakings. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most
                    recent post-effective amendment thereof) which, individually or in the </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-2<br/>
        </div>

      </div>

    </div>

    <!--End Page 671-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 672-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_400-part2_pg3"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 80pt; text-align: left;">aggregate, represent a fundamental change in the information set forth in the
            registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high
            end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than a 20%
            change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To include any material information with respect to the plan of distribution not previously disclosed in the registration
                    statement or any material change to such information in the registration statement. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed
                    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at
                    the termination of the offering. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 40pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial
                    distribution of the securities, if a primary offering of securities of the undersigned registrant is deemed to occur pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the
                    purchaser, and if the securities are deemed to be offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell
                    such securities to such purchaser: </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to
                    Rule&#160;424; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(ii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred
                    to by the undersigned registrant; </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iii)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned
                    registrant or its securities provided by or on behalf of the undersigned registrant; and </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 60pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(iv)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes as follows: That, for purposes of determining any liability under the Securities
                    Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d) of the Exchange Act)
                    that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
                    initial bona fide offering thereof. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes as follows: That prior to any public reoffering of the securities registered
                    hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus
                    will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other Items of the applicable form. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes as follows: That every prospectus (i) that is filed pursuant to paragraph (g)(1) of
                    Item&#160;512 of Regulation S-K or (ii) that purports to meet the requirements of section&#160;10(a)(3) of the Securities Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to
                    the registration statement and will not be used until </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-3<br/>
        </div>

      </div>

    </div>

    <!--End Page 672-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 673-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_400-part2_pg4"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 40pt; text-align: left;">such amendment is effective, and that, for purposes of determining any
            liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
            initial bona fide offering thereof. </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the
                    prospectus pursuant to Items 4, 10(b), 11, or 13 of this form, within one business day of receipt of such request, and to send the incorporated documents by first-class mail or other equally prompt means. This includes information
                    contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The undersigned registrant hereby undertakes to supply by means of a post-effective amendment all information concerning a
                    transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
                    controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
                    expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or
                    controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
                    unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
                    Securities Act and will be governed by the final adjudication of such issue. </div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 414pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit Number</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Description </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANNEXA">2.1*&#x5E;</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Agreement and Plan of Merger and Reorganization among Passage Bio, Inc.,
                    Merger Sub, Inc. and Remix Therapeutics, Inc., dated as of June&#160;24, 2026 (included as Annex&#160;A to the proxy statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000110465925109180/pasg-20250930xex3d1.htm">3.1#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Restated Certificate of Incorporation, dated May&#160;30, 2023, as amended
                    (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on November&#160;10, 2025). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000110465922124102/tm2231891d1_ex3-1.htm">3.2#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated Bylaws, dated December&#160;1, 2022 (incorporated by
                    reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form&#160;8-K (File No. 001-39231), filed with the SEC on December&#160;2, 2022). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-4_1.htm">4.1#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Common Stock Certificate. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXF">4.2*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Contingent Value Rights Agreement (included as Annex&#160;F to the
                    proxy statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">5.1**</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Opinion of Fenwick &amp; West LLP, counsel to Passage Bio, Inc. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_1.htm">10.3#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Indemnification Agreement between the Registrant and its
                    directors and officers (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Registration Statement on Form&#160;S-1 (File No. 333-236214), filed with the SEC on February&#160;3, 2020). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_2.htm">10.4#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amended and Restated 2018 Equity Incentive Plan, as amended, and forms of
                    award agreements (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Registration Statement on Form&#160;S-1 (File No. 333-236214), filed with the SEC on February&#160;3, 2020). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/pasg-20251231xex10d5.htm">10.5#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2020 Equity Incentive Plan of the Registrant, and forms of award
                    agreements (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Annual Report on Form&#160;10-K (File No. 001-39231), filed with the SEC on March&#160;3, 2026). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000110465926022549/pasg-20251231xex10d6.htm">10.6#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2020 Employee Stock Purchase Plan of the Registrant (incorporated by
                    reference to Exhibit&#160;10.6 to the Company&#8217;s Annual Report on Form&#160;10-K (File No. 001-39231), filed with the SEC on March&#160;3, 2026). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837021008991/tmb-20210719xex99d1.htm">10.7#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2021 Equity Inducement Plan (incorporated by reference to Exhibit&#160;99.1 to
                    the Company&#8217;s Registration Statement on Form&#160;S-8 (File No. 333-258000), filed with the SEC on July&#160;19, 2021). </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 48pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 414pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-4<br/>
        </div>

      </div>

    </div>

    <!--End Page 673-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 674-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_400-part2_pg5"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 414pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit Number</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Description </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837022017285/pasg-20220930xex10d1.htm">10.8+&#8224;#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employment Agreement, dated October&#160;10, 2022 by and between the
                    Registrant and William Chou (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File&#160;No.&#160;001-39231), filed with the SEC on November&#160;10, 2022). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837023002833/pasg-20221231xex10d24.htm">10.9+&#8224;#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employment Agreement dated September&#160;10, 2019, as amended on February&#160;26,
                    2020, by and between the Registrant and Edgar B. (Chip) Cale (incorporated by reference to Exhibit&#160;10.24 to the Company&#8217;s Annual Report on Form&#160;10-K (File No. 001-39231), filed with the SEC on March&#160;6, 2023). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024002310/pasg-20231231xex10d28.htm">10.10+&#8224;#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employment Agreement, dated March&#160;1, 2024, by and between the Registrant
                    and Kathleen Borthwick (incorporated by reference to Exhibit&#160;10.28 to the Company&#8217;s Annual Report on Form&#160;10-K (File&#160;No.&#160;001-39231), filed with the SEC on March&#160;4, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024008058/pasg-20240331xex10d1.htm">10.11+#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Non-Employee Director Compensation Policy effective as of April&#160;4, 2024
                    (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on May&#160;14, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024015431/pasg-20240930xex10d1.htm">10.12&#8224;&#x5E;#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exclusive License Agreement (PBGM01), dated July&#160;31, 2024, by and between
                    the Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on November&#160;13, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024015431/pasg-20240930xex10d2.htm">10.13&#8224;&#x5E;#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exclusive License Agreement (PBKR03), dated July&#160;31, 2024, by and between
                    the Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on November&#160;13, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024015431/pasg-20240930xex10d3.htm">10.14&#8224;&#x5E;#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exclusive License Agreement (PBML04), dated July&#160;31, 2024, by and between
                    the Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on November&#160;13, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024015431/pasg-20240930xex10d4.htm">10.15&#8224;&#x5E;#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Transition Services Agreement, dated July&#160;31, 2024, by and between the
                    Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on November&#160;13, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024015431/pasg-20240930xex10d5.htm">10.16&#8224;&#x5E;#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research, Collaboration &amp; License Agreement, dated July&#160;31, 2024, by
                    and between the Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on November&#160;13, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837024015431/pasg-20240930xex10d6.htm">10.17&#8224;&#x5E;#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Second Amended and Restated Research, Collaboration &amp; License
                    Agreement, dated July&#160;31, 2024, by and between the Registrant and the Trustees of the University of Pennsylvania (incorporated by reference to Exhibit&#160;10.6 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with
                    the SEC on November&#160;13, 2024). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837025011146/pasg-20250630xex10d1.htm">10.18&#8224;&#x5E;#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to the Exclusive License Agreement (PBGM01), dated May&#160;7, 2025,
                    by and between the Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on August&#160;12, 2025). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837025011146/pasg-20250630xex10d2.htm">10.19&#x5E;#</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to the Exclusive License Agreement (PBKR03), dated May&#160;7, 2025,
                    by and between the Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on August&#160;12, 2025). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="https://www.sec.gov/Archives/edgar/data/1787297/000155837025011146/pasg-20250630xex10d3.htm">10.20&#x5E;#</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Amendment to the Exclusive License Agreement (PBML04), dated May&#160;7, 2025,
                    by and between the Registrant and Gemma Biotherapeutics, Inc. (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q (File No. 001-39231), filed with the SEC on August&#160;12, 2025). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXC">10.21*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Passage Bio Stockholder Support Agreement (included as Annex&#160;C to
                    the proxy statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXD">10.22*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Remix Stockholder Support Agreement (included as Annex&#160;D to the
                    proxy statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXE">10.23*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Lock-Up Agreement (included as Annex&#160;E to the proxy
                    statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXH">10.24*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Registration Rights Agreement (included as Annex&#160;H to the proxy
                    statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXG">10.25*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Subscription Agreement, by and among Remix Therapeutics, Inc. and the
                    investors party thereto (included as Annex&#160;G to the proxy statement/prospectus). </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 414pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-5<br/>
        </div>

      </div>

    </div>

    <!--End Page 674-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 675-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_400-part2_pg6"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 414pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Exhibit Number</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">Description </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-26.htm">10.26*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Convertible Promissory Note Purchase Agreement, dated June 24, 2026, by
                    and among Remix Therapeutics, Inc. and the lenders party thereto. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXL">10.27*+</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026 Equity Incentive Plan, and forms of award agreements (included as
                    Annex&#160;K to the proxy statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXM">10.28*+</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026 Employee Stock Purchase Plan (included as Annex&#160;L to the proxy
                    statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-29.htm">10.29*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form&#160;of Indemnification Agreement, by and between Remix Therapeutics,
                    Inc. and each of its directors and executive officers. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-30.htm">10.30&#8224;&#x5E;*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Lease, dated August&#160;23, 2021, by and between 100 Forge Holding LLC and
                    Remix Therapeutics, Inc. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-31.htm">10.31+*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Remix Therapeutics Inc. 2019 Stock Plan, and forms of award agreements. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-32.htm">10.32+*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Offer Letter, dated July&#160;25, 2019, by and between Remix Therapeutics,
                    Inc. and Dominic Reynolds. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-33.htm">10.33+*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Offer Letter, dated August&#160;1, 2019, by and between Remix Therapeutics,
                    Inc. and Peter Smith. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-34.htm">10.34+*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Offer Letter, dated August 3, 2020, by and between Remix Therapeutics,
                    Inc. and Heather Wasserman. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex10-35.htm">10.35&#8224;&#x5E;*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Master Agreement, dated August&#160;16, 2023, by and between Remix
                    Therapeutics, Inc. and Tempus AI, Inc., as amended by Amendment to Master Agreement, dated December&#160;18, 2023 and Amendment #2 to Master Agreement, dated December 18, 2023. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex16-1.htm">16.1*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Letter from PricewaterhouseCoopers LLP, dated July&#160;21, 2026. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex23-1.htm">23.1*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of KPMG LLP, independent registered public accounting firm of
                    Passage Bio, Inc. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex23-2.htm">23.2*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Deloitte &amp; Touche, LLP, independent registered public
                    accounting firm of Remix Therapeutics, Inc. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">23.3**</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Fenwick &amp; West LLP (included in Exhibit&#160;5.1). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tSIG">24.1*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Power of Attorney (included on the signature page of this registration
                    statement). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">99.1**</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Form of Proxy Card. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXI">99.2*</a></div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proposed form of Certificate of Amendment to the Restated Certificate of
                    Incorporation of Passage Bio, Inc. to Provide for the Reverse Stock Split (included as Annex I to the proxy statement/prospectus). </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tANXJ">99.3*</a> </div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proposed form of Amended and Restated Certificate of Incorporation of
                    Passage Bio, Inc. (included as Annex J to the proxy statement/prospectus).</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex99-4.htm">99.4*</a> </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Redwood Valuation Partners, LLC.</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex99-5.htm">99.5*</a> </div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Linda C. Bain to be named as a director. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex99-6.htm">99.6*</a> </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Maria Koehler, M.D., Ph.D. to be named as a director. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex99-7.htm">99.7*</a> </div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Matthew R. Patterson to be named as a director. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex99-8.htm">99.8*</a> </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Peter Colabuono to be named as a director. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex99-9.htm">99.9*</a> </div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Peter G. Smith, Ph.D. to be named as a director. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex99-10.htm">99.10*</a> </div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Consent of Scott Biller, Ph.D. to be named as a director.</div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">101.INS*</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inline XBRL Instance Document - the instance document does not appear in
                    the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">101.SCH*</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inline XBRL Taxonomy Extension Schema Document </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">101.CAL*</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inline XBRL Taxonomy Extension Calculation Linkbase Document </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">101.DEF*</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inline XBRL Taxonomy Extension Definition Linkbase Document </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">101.LAB*</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inline XBRL Taxonomy Extension Label Linkbase Document </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">101.PRE*</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Inline XBRL Taxonomy Extension Presentation Linkbase Document </div>
                </td>

  </tr>

  <tr>

    <td style="width: 48pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="ny20077915x1_ex107.htm">107*</a></div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 414pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Filing Fee Table</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 414pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div>
            <div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 16pt;"> </div>

          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Filed herewith. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">**<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">To be filed by amendment. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">+<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Indicates management contract or compensatory plan. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#8224;<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Registrant has omitted portions of the exhibit as permitted under Item&#160;601(b)(10) of Regulation S-K. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#x5E;<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">The annexes, schedules and/or certain exhibits to this agreement have been omitted pursuant to Item&#160;601(b)(2) or Item&#160;601(a)(5)
                    of Regulation S-K. </div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" border="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">#<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; text-align: left;">Previously filed. </div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-6<br/>
        </div>

      </div>

    </div>

    <!--End Page 675-->
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <!--Begin Page 676-->
    <div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a id="ny20077915x1_s4_401-sig_pg1"><!--Anchor--></a>
      <p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p>
      <div class="BRDSX_page-content">
        <div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;">
          <div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a id="tSIG"><!--Anchor--></a>SIGNATURES </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, as amended, the
            Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, Pennsylvania, on the 21<sup>st</sup> day of July, 2026. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 228pt;" colspan="4">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 228pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">PASSAGE BIO, INC.</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">By:</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">/s/ William Chou </div>
                </td>

  </tr>

  <tr>

    <td style="width: 228pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 204pt; padding-top: 1.76pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">William Chou, M.D. <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Chief Executive Officer</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 204pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears
            below constitutes and appoints William Chou, M.D. and Kathleen Borthwick, and each of them individually, as his or her true and lawful attorney-in-fact and agent, with full powers of substitution and resubstitution, for him or her and in his or
            her name, place and stead, in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments and any related registration statements filed pursuant to Rule&#160;462 and otherwise), and to
            file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent and full power and authority to do and perform each and every act
            and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or
            resubstitute, may lawfully do or cause to be done by virtue hereof. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Pursuant to the requirements of the Securities Act of 1933, as amended, this
            registration statement has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated. </div>

          <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div>

          <table cellspacing="0" cellpadding="0" class="BRDSX_txttab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 72pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 144pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">SIGNATURE</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">TITLE</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">DATE </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ William Chou</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">President, Chief Executive Officer, and Director <span style="font-style: italic;">(Principal

                      Executive Officer)</span></div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">William Chou, M.D. </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Kathleen Borthwick</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Chief Financial Officer <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"><span style="font-style: italic;">(Principal Accounting and Financial Officer)</span></div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Kathleen Borthwick </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Maxine Gowen</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Maxine Gowen, Ph.D. </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Athena Countouriotis</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Athena Countouriotis, M.D. </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Sandip Kapadia</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Sandip Kapadia </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Thomas Kassberg</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Thomas Kassberg </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Derrell Porter</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Derrell Porter, M.D. </div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 228pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 72pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; height: 14pt; padding-top: 1.01pt; padding-bottom: 2.13pt; text-align: left; vertical-align: top; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">/s/ Dolan Sondhi</div>
                </td>

    <td style="width: 6pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 228pt; height: 14pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Director</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6pt;" rowspan="2">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td rowspan="2" style="width: 72pt; height: 14pt; padding-top: 1.01pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">July&#160;21, 2026 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 144pt; padding-top: 1.76pt; text-align: left; vertical-align: top;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Dolan Sondhi, Ph.D.</div>
                </td>

    <td style="width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 144pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 228pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 72pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
        </div>

      </div>

      <div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;">
        <div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">II-7<br/>
        </div>

      </div>

    </div>

    <!--End Page 676-->
  </div>


</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>2
<FILENAME>ny20077915x1_ex10-26.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 10.26</div>
      <div style="text-align: right; font-weight: bold;"><font style="font-style: italic;">Execution Version</font><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This Convertible Promissory Note Purchase Agreement (&#8220;<u>Agreement</u>&#8221;) is entered into as of June 24, 2026, by and among Remix Therapeutics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;),
        and the lenders (each individually, a &#8220;<u>Lender</u>&#8221;, and collectively, the &#8220;<u>Lenders</u>&#8221; named on the Schedule of Lenders attached hereto as <u>Exhibit A</u> (the &#8220;<u>Schedule of Lenders</u>&#8221;) and any additional Lenders who become party
        hereto.&#160; The Company and the Lenders may be referred to herein individually as a &#8220;<u>Party</u>&#8221; and, collectively, as the &#8220;<u>Parties</u>&#8221;.&#160; Capitalized terms not otherwise defined in this Agreement shall have the meanings ascribed to them in <u>Section





          1</u> below.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">WHEREAS, the Parties wish to provide for the sale and issuance of Notes, as defined below, to the Lenders by the Company in return for the provision by the Lenders of the loan amounts to the
        Company as set forth for each Lender on the Schedule of Lenders; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">WHEREAS, the Parties intend for the Company to issue in return for such loan amounts one or more Notes.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">NOW, THEREFORE, the Parties hereto agree as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Definitions</u></font>. As used herein, the terms set forth below shall have the following definitions.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Affiliate</u></font>&#8221; means, with respect to any Person, any other Person who directly or indirectly, controls, is controlled by or is
        under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person, or any venture capital fund now or hereafter existing which is controlled by one or more general partners
        (or member thereof) or managing members of, or shares the same management company (or stockholder or member thereof) with, such Person, or a family member of such Person.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Board</u></font>&#8221; means the Company&#8217;s board of directors.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Business Day</u></font>&#8221; means a weekday that banks are open for business in the United States.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>CFIUS</u></font>&#8221; means the Committee on Foreign Investment in the United States.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>CFIUS-Impacted Lender</u></font>&#8221; means a Lender for which (i) it is required, in the reasonable determination of the Company and such
        Lender, for such Lender to make a notice or declaration filing with CFIUS pursuant to the DPA or (ii) CFIUS requests or requires that such Lender or the Company file a notice or declaration with CFIUS pursuant to the DPA with respect to the
        conversion of any Preferred Stock or Notes pursuant to <u>Section 4</u> (each of (i) and (ii), a &#8220;<font style="font-weight: bold;"><u>CFIUS Filing Requirement</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>CFIUS Satisfied Condition</u></font>&#8221; shall be achieved when (1) the Company and the CFIUS-Impacted Lender shall have received written
        notice from CFIUS stating that: (i) CFIUS has concluded that the proposed transaction does not constitute a &#8220;covered transaction&#8221; subject to review under the DPA; or (ii) the assessment, review or investigation of the proposed transaction under the
        DPA has concluded, and there are no unresolved national security concerns with respect to the proposed transaction; (2) CFIUS has sent a report to the President of the United States requesting the President&#8217;s decision with respect to the proposed
        transaction and either (x) the fifteen (15) day period under the DPA subsequent to the President&#8217;s receipt of the CFIUS report during which the President may announce his decision to take action to suspend, prohibit or place any limitations on the
        proposed transaction has expired without any such action being taken or (y) the President of the United States has announced a decision not to take any action to suspend, prohibit or place any limitations on the proposed transaction; or (3) CFIUS
        has provided written notice that it is not able to complete action under the DPA with respect to the proposed transaction on the basis of a CFIUS declaration, but CFIUS has not requested that the Company and the CFIUS-Impacted Lender submit a CFIUS
        notice and has not initiated a unilateral CFIUS review.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">1</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Change of Control</u></font>&#8221; means:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a merger or consolidation in which (i) the Company is a constituent party or (ii) a subsidiary of the Company is a constituent party and the
        Company issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Company or a subsidiary in which the shares of capital stock of the Company outstanding immediately prior to
        such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1)
        the surviving or resulting Company; or (2) if the surviving or resulting Company is a wholly owned subsidiary of another Company immediately following such merger or consolidation, the parent Company of such surviving or resulting Company;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the
        Company or any subsidiary of the Company of all or substantially all the assets, or of all or substantially all of the intellectual property assets, of the Company and its subsidiaries taken as a whole, or (ii) the sale or disposition (whether by
        merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Company if substantially all of the assets of the Company and its subsidiaries taken as a whole are held
        by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Company; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any other transaction which is a Deemed Liquidation Event, as defined in the Restated Certificate.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Common Stock</u></font>&#8221; shall have the meaning set forth in the Restated Certificate.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Conversion Price</u></font>&#8221; means:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted in a Qualified Financing pursuant to <u>Section 4.1</u> below, eighty percent (80%) of the lowest cash price per share of preferred stock paid by
        the investors in the Qualified Financing (excluding, for the avoidance of doubt, any deemed price per share resulting from conversion of the Prior 2025 Notes);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted in a Non-Qualified Financing pursuant to <u>Section 4.2</u> below, eighty percent (80%) of the lowest cash price per share of preferred stock
        paid by the investors in the Non-Qualified Financing (excluding, for the avoidance of doubt, any deemed price per share resulting from conversion of the Prior 2025 Notes);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted pursuant to <u>Section 4.3</u> below in connection with a Public Company Event, the Specified Conversion Price;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted pursuant to <u>Section 4.4</u> below at the Maturity Date, the Specified Conversion Price; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted pursuant to <u>Section 4.5</u> below in connection with a PIPE Offering, the price per share paid by investors in the PIPE Offering.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold;"><u>Conversion Shares</u></font>&#8221; means:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted in a Qualified Financing pursuant to <u>Section 4.1</u> below, the shares of preferred stock issued by the Company in the Qualified Financing;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted in a Non-Qualified Financing pursuant to <u>Section 4.2</u> below, the shares of preferred stock issued by the Company in the Non-Qualified
        Financing;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted in connection with a Public Company Event pursuant to <u>Section 4.3</u> below, shares of Series C Preferred Stock;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted as of immediately prior to the Maturity Date pursuant to <u>Section 4.4</u> below, shares of Series C Preferred Stock; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 142pt;">if the Notes are converted in connection with a PIPE Offering pursuant to <u>Section 4.5</u> below, shares of common stock of the PIPE Issuer.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>DPA</u></font>&#8221; means the Defense Production Act of 1950, as amended, including all implementing regulations thereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Initial Public Offering</u></font>&#8221; means the Company&#8217;s first underwritten public offering of its Common Stock pursuant to an effective
        registration statement under the Securities Act.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Investors&#8217; Rights Agreement</u></font>&#8221; means that certain Amended and Restated Investors&#8217; Rights Agreement, dated as of November 14,
        2025, by and among the Company and the stockholders party thereto, as may be amended and/or restated from time to time.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.14</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Maturity Date</u></font>&#8221; means June 29, 2027.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Net Proceeds</u></font>&#8221; means, in connection with a Change of Control, the total cash proceeds that, irrespective of these Notes and
        the Prior 2025 Notes, would have been paid or distributed to the holders of capital stock of the Company in connection with any Change of Control, in accordance with the Restated Certificate in respect of such capital stock, inclusive of any
        amounts subject to escrow release, but excluding all amounts that are otherwise payable upon satisfaction of future contingencies such as earnout or milestone payments, as determined by the Board.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.16</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Non-Qualified Financing</u></font>&#8221; means the next sale (or series of related sales) by the Company of its preferred stock or other
        equity securities of the Company (whether or not authorized as of the date hereof) for capital raising purposes following the date of this Agreement that is not (i) a Qualified Financing or (ii) a PIPE Offering.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.17</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Non-Traditional IPO</u></font>&#8221; means any business combination pursuant to which the Company is merged into, or otherwise combines with
        a company that has a class of capital stock that is registered pursuant to Section 12(b) or Section 12(g) of the Securities Exchange Act of 1934, as amended (a &#8220;<font style="font-weight: bold;"><u>Pubco</u></font>&#8221;), or a subsidiary of such Pubco,
        and the shares of capital stock of the Company outstanding immediately prior to such transaction represent, or are converted into or exchanged for, shares of capital stock (or securities convertible into or exchangeable for shares of capital stock)
        of such Pubco in connection with such transaction.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.18</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Note Holder Majority</u></font>&#8221; means the holders of Notes representing a majority of the outstanding principal amount of Notes.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.19</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Notes</u></font>&#8221; means one or more convertible promissory notes issued to the Lenders hereunder, the form of which is attached hereto
        as <u>Exhibit B</u>, and the aggregate maximum principal amount of which shall not exceed $30,000,000.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.20</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Outstanding Amount</u></font>&#8221; of a Note means, as of any date of determination, the then outstanding principal and accrued but unpaid
        interest thereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.21</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Person</u></font>&#8221; means an individual, firm, corporation, partnership, association, limited liability company, trust or any other
        entity.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.22</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Placement Agents</u></font>&#8221; means Goldman Sachs &amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.23</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>PIPE Offering</u></font>&#8221; means the closing of the transactions contemplated by the PIPE Subscription Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.24</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; </div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>PIPE Subscription Agreement</u></font>&#8221; means that certain Subscription Agreement, dated as of the date hereof, by and among the Company
        and the other parties thereto, to be entered into in connection with a Non-Traditional IPO, as contemplated by that certain Agreement and Plan of Merger, dated as of the date hereof, by and among the Company, Passage Bio, Inc. and Peregrine Merger
        Sub, Inc., pursuant to which the PIPE Issuer will issue common stock to investors.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.25</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>PIPE Issuer</u></font>&#8221; means the issuing entity in a Non-Traditional IPO that consummates a PIPE Offering.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.26</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Preferred Stock</u></font>&#8221; means shares of preferred stock, $0.0001 par value per share, of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.27</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Prior 2025 Notes</u></font>&#8221; means those certain Convertible Promissory Notes issued pursuant to the Prior 2025 NPA.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.28</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Prior 2025 NPA</u></font>&#8221; means that certain Convertible Promissory Note and Warrant Purchase Agreement, dated as of November 14, 2025,
        by and among the Company and the lenders set forth on <u>Exhibit A</u> thereto.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.29</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Prior 2025 Warrants</u></font>&#8221; means those certain Warrants to Purchase Capital Stock of the Company issued pursuant to the Prior 2025
        NPA.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.30</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Public Company Event</u></font>&#8221; means an Initial Public Offering, Non-Traditional IPO (excluding, for the avoidance of doubt, a PIPE
        Offering) or a SPAC Transaction.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.31</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Qualified Financing</u></font>&#8221; means the next sale (or series of related sales) by the Company of its preferred stock (whether or not
        authorized as of the date hereof) for capital raising purposes following the date of this Agreement (excluding, for the avoidance of doubt, a PIPE Offering) from which the Company receives gross proceeds of not less than $50,000,000 (excluding the
        aggregate Outstanding Amounts converted into such preferred stock upon conversion of the Notes and the aggregate Outstanding Amounts (as defined in the Prior 2025 NPA) converted into such preferred stock upon conversion of the Prior 2025 Notes).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.32</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Restated</u></font><u>&#160;</u><font style="font-weight: bold;"><u>Certificate</u></font>&#8221; means the Company&#8217;s Amended and Restated
        Certificate of Incorporation, as may be amended and/or restated from time to time in accordance with its terms.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.33</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Securities Act</u></font>&#8221; means the Securities Act of 1933, as amended from time to time.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.34</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Series B Preferred Stock</u></font>&#8221; means the Company&#8217;s Series B Preferred Stock, par value $0.0001 per share.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.35</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Series C Preferred Stock</u></font>&#8221; means a new series of the Company&#8217;s preferred stock, par value $0.0001 per share, to be designated
        as &#8220;Series C Preferred Stock&#8221; by an amendment to, or amendment and restatement of, the Restated Certificate and having substantially the same rights, preferences and privileges set forth in the Series C Term Sheet.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.36</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Series C Term Sheet</u></font>&#8221; means the term sheet setting forth the principal terms of the Series C Preferred Stock attached hereto
        as <u>Exhibit D</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.37</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Series B Original Issue Price</u></font>&#8221; means $2.0880, the Original Issue Price of the Series B Preferred Stock as determined pursuant
        to (and defined in) the Restated Certificate, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock in accordance with the
        Restated Certificate.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.38</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>SPAC Transaction</u></font>&#8221; means a transaction or series of related transactions (by merger, or consolidation, share exchange or
        otherwise) with a publicly-traded &#8220;special purpose acquisition company&#8221; or its subsidiary (collectively, a &#8220;<font style="font-weight: bold;"><u>SPAC</u></font>&#8221;) in which the common stock or share capital of the SPAC or its successor entity is
        listed on the New York Stock Exchange, NASDAQ Global Select Market or NASDAQ Global Market or other nationally or internationally recognized exchange as approved by the Board.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.39</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Specified Conversion Price</u></font>&#8221; means $1.00056 (representing a pre-money valuation of $226,000,000), subject to appropriate
        adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization affecting the Company&#8217;s capital stock occurring after the date hereof; provided, further, that such price shall be adjusted to reflect such
        pre-money valuation of the Company&#8217;s fully-diluted capitalization as of the date hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">1.40</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<font style="font-weight: bold;"><u>Transaction Documents</u></font>&#8221; means this Agreement and the Notes.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Agreement to Sell and Purchase</u></font>. Subject to the terms and conditions hereof, at the Closing (as
        hereinafter defined), the Company hereby agrees to issue and sell to each Lender, and each Lender agrees to purchase from the Company, severally and not jointly, a Note in principal amount as set forth opposite such Lender&#8217;s name on <u>Exhibit A</u>.</div>
      <div style="text-align: justify; margin-left: 36pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Closing, Delivery and Payment.</u></font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Closing</u></font>. Subject to the terms and conditions of this Agreement, including the satisfaction or waiver of each of the closing
        conditions set forth in <u>Section 8</u> and <u>Section 9</u> (other than those conditions that by their terms are to be satisfied at the Closing), the closing of the sale and purchase of the Notes under this Agreement (the &#8220;<font style="font-weight: bold;">Closing</font>&#8221;) shall take place remotely via the exchange of documents and signatures on June 29, 2026 (the &#8220;<font style="font-weight: bold;">Closing Date</font>&#8221;), or at such other time and place as the Company and
        the Note Holder Majority shall mutually agree upon in writing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Delivery</u></font>.&#160; At the Closing, subject to the terms and conditions hereof, the Company will deliver to each Lender a Note against
        payment of the purchase price therefor by check made payable to the order of the Company, wire transfer of immediately available funds to the Company, or any combination of the foregoing.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Conversion and Payment of the Notes; Change of Control</u></font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Qualified Financing</u></font>.&#160; If, prior to the Maturity Date and prior to the time when the Notes have been converted pursuant to <u>Section



          4.2</u>, <u>Section 4.3</u>, <u>Section 4.4</u> or <u>Section 4.5</u>, the Company issues shares of its preferred stock in a Qualified Financing, the Outstanding Amount <font style="color: #000000;">under each Note will be converted
          automatically into Conversion Shares pursuant to <u>Section 1.10(a)</u> above </font>upon the closing of such Qualified Financing. The number of Conversion Shares to be issued upon such conversion of each Note shall be equal to the quotient
        obtained by dividing the Outstanding Amount under such Note by the applicable Conversion Price.&#160; The issuance of Conversion Shares in a Qualified Financing pursuant to the conversion of each Note shall be upon and subject to the same terms and
        conditions applicable to the securities issued and sold by the Company in the Qualified Financing to investors investing new money in the Company in connection with such Qualified Financing (&#8220;<font style="font-weight: bold;"><u>Standard Preferred
            Stock</u></font>&#8221;), including identical rights, privileges, preferences and restrictions as the shares of Standard Preferred Stock (and, for the avoidance of doubt, not the rights, preferences or privileges set forth in the Series C Term
        Sheet), other than with respect to the basis for any dividend rights, which will be based on the Conversion Price; provided, however, that in no event shall the liquidation preference per share of the Conversion Shares exceed the Conversion Price.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Non-Qualified Financing</u></font>. If, prior to the Maturity Date and prior to the time when the Notes have been converted pursuant to <u>Section



          4.1</u>, <u>Section 4.3</u>, <u>Section 4.4</u> or <u>Section 4.5</u>, the Company issues shares of its preferred stock in a Non-Qualified Financing, then, upon written notice of a holder of one or more Notes electing to convert its Note(s)
        into Conversion Shares pursuant to <u>Section 1.10(b)</u> above delivered to the Company as set forth below (a &#8220;<font style="font-weight: bold;"><u>Conversion Election</u></font>&#8221;), the Outstanding Amount <font style="color: #000000;">under each
          Note held by such holder will be converted automatically </font>into Conversion Shares pursuant to <u>Section 1.10(b)</u> above. The number of Conversion Shares to be issued upon such conversion of a Note shall be equal to the quotient obtained
        by dividing the Outstanding Amount under such Note by the applicable Conversion Price.&#160; The issuance of Conversion Shares in a Non-Qualified Financing pursuant to the conversion of a Note shall be upon and subject to the same terms and conditions
        applicable to the securities sold in the Non-Qualified Financing to investors investing new money in the Company in connection with such Non-Qualified Financing (&#8220;<font style="font-weight: bold;"><u>Non-Qualified</u></font><u>&#160;</u><font style="font-weight: bold;"><u>Standard Preferred Stock</u></font>&#8221;), including identical rights, privileges, preferences and restrictions as the shares of Non-Qualified Standard Preferred Stock (and, for the avoidance of doubt, not the rights,
        preferences or privileges set forth in the Series C Term Sheet), other than with respect to the basis for any dividend rights, which will be based on the Conversion Price; provided, however, that in no event shall the liquidation preference per
        share of the Conversion Shares exceed the Conversion Price.&#160; The Company shall send written notice to each holder of a Note no later than ten (10) days prior to the closing of a Non-Qualified Financing setting forth in reasonable detail the
        material terms of the Non-Qualified Financing and the Company&#8217;s good faith forecast of the Company&#8217;s capitalization after the closing of such Non-Qualified Financing (the &#8220;<font style="font-weight: bold;"><u>Non-Qualified Financing Notice</u></font>&#8221;).&#160;





        Each holder of a Note shall have the right to elect the conversion of the Outstanding Amounts under all Notes held by such holder as set forth above in this <u>Section 4.2</u> by sending a Conversion Election to the Company no later than ten (10)
        days after receipt of the Non-Qualified Financing Notice.&#160; Any failure of a holder of a Note to send a Conversion Election in accordance with the terms of this <u>Section 4.2</u> shall be deemed to be an election by such holder not to have the
        Outstanding Amounts under its Notes convert into Conversion Shares in such Non-Qualified Financing.&#160; In the event a holder of a Note has delivered a Conversion Election no later than ten (10) days after receipt of the Non-Qualified Financing Notice
        in accordance with this <u>Section 4.2</u>, the Company shall fully and promptly comply therewith.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Public Company Event</u></font>.&#160; If, prior to the Maturity Date and prior to the time when the Notes have been converted pursuant to <u>Section



          4.1</u>, <u>Section 4.2</u>, <u>Section 4.4</u> or <u>Section 4.5</u>, the Company consummates a Public Company Event, the Outstanding Amount <font style="color: #000000;">under each Note will be converted automatically </font>into
        Conversion Shares pursuant to <u>Section 1.10(c)</u> above immediately prior to and contingent upon the consummation of such Public Company Event.&#160; The number of Conversion Shares to be issued upon such conversion of each Note shall be equal to
        the quotient obtained by dividing the Outstanding Amount under such Note by the applicable Conversion Price.&#160; To the extent practicable and permissible in accordance with applicable law, the Company shall send written notice to each holder of a
        Note no later than fifteen (15) days prior to the consummation of such Public Company Event setting forth in reasonable detail the material terms of the Public Company Event.&#160; In the event that the Notes convert in accordance with this <u>Section
          4.3</u>, the Company hereby agrees and covenants to use commercially reasonable efforts to take any and all actions, and execute, file and deliver all documents, necessary to authorize and issue the Series C Preferred Stock with such rights,
        preferences and privileges set forth in the Series C Term Sheet upon conversion of the Notes (including, without limitation, to amend the Restated Certificate to authorize the Series C Preferred Stock and obtain the requisite approval of the
        Company&#8217;s stockholders and the Board to amend the Restated Certificate accordingly).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>At Maturity</u></font>.&#160; If, by the Maturity Date, the Notes have not been paid in full nor converted into equity securities of the
        Company, unless elected otherwise by the Note Holder Majority pursuant to a written notice delivered to the Company at any time prior to the Maturity Date, each Note shall automatically convert as of immediately prior to the Maturity Date into a
        number of Conversion Shares pursuant to Section 1.10(d) equal to the quotient obtained by dividing the Outstanding Amount under such Note by the applicable Conversion Price. In the event that the Notes convert in accordance with this <u>Section
          4.4</u>, the Company hereby agrees and covenants to use commercially reasonable efforts to take any and all actions, and execute, file and deliver all documents, necessary to authorize and issue the Series C Preferred Stock with such rights,
        preferences and privileges set forth in the Series C Term Sheet upon conversion of the Notes (including, without limitation, to amend the Restated Certificate to authorize the Series C Preferred Stock and obtain the requisite approval of the
        Company&#8217;s stockholders and the Board to amend the Restated Certificate accordingly).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>PIPE Offering</u></font>. If, prior to the Maturity Date and prior to the time when the Notes have been converted pursuant to <u>Section
          4.1</u>, <u>Section 4.2</u>, <u>Section 4.3</u>, or <u>Section 4.4</u>, a PIPE Offering is consummated, the Outstanding Amount under each Note will be converted automatically and concurrently into a number of Conversion Shares pursuant to <u>Section



          1.10(e)</u> equal to the quotient obtained by dividing the Outstanding Amount under such Note by the price per share paid by investors in the PIPE Offering. Upon an automatic conversion pursuant to this <u>Section 4.5</u>, the Company and the
        Lenders will enter into the Registration Rights Agreement, in the form attached hereto as <u>Exhibit E</u> (the &#8220;<font style="font-weight: bold;"><u>Registration Rights Agreement</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Conversion Procedures</u></font>.&#160; Upon a conversion of the Outstanding Amounts under its Notes, each Lender agrees to (a) execute and
        deliver to the Company all transaction documents entered into by the other purchasers of such Conversion Shares with respect to the purchase and receipt of such Conversion Shares (other than the PIPE Subscription Agreement) (provided that if such
        Conversion Shares are Series B Preferred Stock, only if such Lender is not already a party to such transaction documents) and (b) deliver, at the closing of the Qualified Financing, Non-Qualified Financing, Public Company Event, PIPE Offering or at
        the Maturity Date, as applicable, the original (if one was delivered) of its Note(s) for cancellation (or a written notice to the effect that the original of its Note(s) have been lost, stolen or destroyed and an agreement acceptable to the Company
        whereby the Lender agrees to indemnify the Company from any loss incurred by it in connection with its Note(s)). Any such conversion of a Note shall be deemed to have been made concurrently with the closing of the Qualified Financing, Non-Qualified
        Financing or PIPE Offering, if applicable, immediately prior to the Public Company Event or upon the Maturity Date, as applicable, without regard to whether the Lender has then delivered to the Company its Note(s), or an affidavit of lost Note(s)
        and an indemnification agreement in favor of the Company with respect to any lost or stolen Note(s), or executed any other documents required to be executed by the Lender pursuant thereto.&#160; On and as of the date of such conversion, the Person
        entitled to receive the Conversion Shares issuable upon such conversion of any Note shall be treated for all purposes as the record holder of such shares and such Note shall be cancelled and deemed paid in full.&#160; Upon the conversion of a Note into
        Conversion Shares, in lieu of any fractional shares to which the holder of a Note would otherwise be entitled, the Company shall pay the holder of such Note cash equal to such fraction of a share not issued multiplied by the applicable Conversion
        Price.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Payments upon a Change of Control</u></font>.&#160;&#160; In the event of a Change of Control prior to the Maturity Date and prior to the time when
        the Notes have been converted pursuant to <u>Section 4.1</u>, <u>Section 4.2</u>, <u>Section 4.3</u>, <u>Section 4.4</u> or <u>Section 4.5</u>, each Lender shall be entitled to receive, upon the closing of the Change of Control, in respect and
        satisfaction of such Lender&#8217;s Note and prior to the payment of any liquidation preference to the holders of capital stock of the Company pursuant to the Restated Certificate, an amount equal to the greater of (i) an amount equal to the Outstanding
        Amount under such Lender&#8217;s Note and (ii) the aggregate amount such Lender would have received under the Restated Certificate assuming that, immediately prior to the consummation of the Change of Control, such Lender&#8217;s Note is converted into the
        number of shares of Series C Preferred Stock equal to the quotient obtained by dividing the Outstanding Amount under such Note by the Specified Conversion Price. To the extent practicable, the Company shall send written notice to each holder of a
        Note no later than fifteen (15) days prior to the consummation of the Change of Control setting forth in reasonable detail the material terms of the Change of Control. Notwithstanding anything to the contrary contained herein, all payments to the
        Lenders in connection with a Change of Control shall be subject to a management carve-out plan to be adopted and approved by the Board, if at all.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">4.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>S</u><u>eniority; Prepayment</u></font>.&#160; The Notes and the Prior 2025 Notes shall be senior to all other indebtedness of the Company,
        except for unsecured trade debt incurred in the ordinary course of the Company&#8217;s business.&#160; Except in connection with a Change of Control, the Notes may not be prepaid without the prior written consent of the Note Holder Majority.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Representations and Warranties of the Company</u></font>.&#160; The Company hereby makes the representations and
        warranties set forth in this <u>Section 5</u> below as of the date of this Agreement to the Lenders and the Placement Agents, except as set forth in the Disclosure Schedules attached hereto as <u>Exhibit C</u> (if any).</div>
      <div style="text-align: justify; margin-left: 72pt;"><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Organization, Good Standing and Qualification</u></font>.&#160; The Company is a corporation duly organized, validly existing, and in good
        standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted.&#160; The Company is duly qualified to transact business and is in good standing in each jurisdiction in
        which the failure to so qualify does, or would reasonably be expected to, have a material adverse effect on the Company, its business as now conducted or proposed to be conducted, assets (including intangible assets), liabilities, financial
        condition, property or results of operations of the Company, individually or in the aggregate (&#8220;<font style="font-weight: bold;"><u>Material Adverse Effect</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Authorization</u></font>.&#160; All corporate action has been taken on the part of the Company, its officers, directors and stockholders
        necessary for the authorization, execution, delivery and performance of the Transaction Documents; provided that the Company does not currently have sufficient authorized Conversion Shares to permit the conversion of the Notes and the Prior 2025
        Notes or the exercise of the Prior 2025 Warrants or sufficient authorized shares of Common Stock to permit the conversion of the Conversion Shares and the shares of preferred stock issuable upon conversion of the Prior 2025 Notes.&#160; Except as may be
        limited by applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors&#8217; rights, the Company has taken all corporate action required to make all of the obligations of the Company reflected
        in the provisions of the Transaction Documents, the valid and enforceable obligations they purport to be.</div>
      <div style="text-align: justify; margin-left: 72pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Valid Issuance of Preferred Stock and Common Stock</u></font>.&#160; The Conversion Shares to be issued, sold and delivered upon conversion of
        the Notes will be duly and validly issued, fully paid and nonassessable, assuming proper amendment of the Restated Certificate to authorize sufficient Conversion Shares, and, based in part upon the representations and warranties of the Lenders in
        this Agreement, will be issued in compliance with all applicable federal and state securities laws.&#160; The shares of Common Stock to be issued, sold and delivered upon conversion of the Conversion Shares in accordance with the terms of the Restated
        Certificate will be duly authorized and validly issued, fully paid and nonassessable, assuming proper amendment of the Restated Certificate to authorize sufficient shares of Common Stock, and, based in part upon the representations and warranties
        of the Lenders in this Agreement, will be issued in compliance with all applicable federal and state securities laws.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Capitalization</u></font>. Immediately prior to the Closing,</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The authorized capital of the Company consists of:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 144pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;162,000,000 shares of Common Stock, 7,833,976 shares of which are issued and outstanding immediately prior to the Closing. All of the outstanding shares of Common Stock have been duly
        authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. The Company holds no Common Stock in its treasury.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 144pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;124,133,326 shares of Preferred Stock, 17,964,705 of which shares have been designated Series Seed Preferred Stock, all<font style="font-weight: bold;">&#160;</font>of which are issued
        and outstanding immediately prior to the Closing, 35,714,365 of which shares have been designated Series A Preferred Stock, 35,661,683 of which are issued and outstanding immediately prior to the Closing and 70,454,256 of which shares have been
        designated Series B Preferred Stock, 64,509,877 of which are issued and outstanding immediately prior to the Closing.&#160; The rights, privileges and preferences of the Preferred Stock are as stated in the Restated Certificate and as provided by the
        Delaware General Corporation Law. Each share of Preferred Stock is convertible into one share of Common Stock. The Company holds no Preferred Stock in its treasury.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company has reserved 23,696,650 shares of Common Stock for issuance to officers, directors, employees and consultants of the Company
        pursuant to its 2019 Stock Plan duly adopted by the Board and approved by the Company&#8217;s stockholders (the &#8220;<font style="font-weight: bold;">Stock Plan</font>&#8221;). Of such reserved shares of Common Stock, 260,796 shares have been issued pursuant to
        restricted stock purchase agreements, 1,976,340 shares have been issued pursuant to option exercises, options to purchase 17,638,267 shares have been granted and are currently outstanding, and 3,821,247 shares of Common Stock remain available for
        issuance to officers, directors, employees and consultants pursuant to the Stock Plan. The Company has furnished to the Lenders complete and accurate copies of the Stock Plan and forms of agreements used thereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except for (A) the conversion privileges of the Notes to be issued under this Agreement, the Prior 2025 Notes and the Prior 2025 Warrants, (B)
        the rights provided in Section 4 of the Investors&#8217; Rights Agreement, and (C) the securities and rights described in <u>Section 5.4(b)</u> hereof or in Section 5.4(c) of the Disclosure Schedules, there are no outstanding options, warrants, rights
        (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any shares of Common Stock or Preferred Stock, or any securities convertible into
        or exchangeable for shares of Common Stock or Preferred Stock. All outstanding shares of the Company&#8217;s Common Stock and all shares of the Company&#8217;s Common Stock underlying outstanding options are subject to (i) a right of first refusal in favor of
        the Company upon any proposed transfer (other than transfers for estate planning purposes); and (ii) a lock-up or market standoff agreement of not less than one hundred eighty (180) days following the Company&#8217;s initial public offering pursuant to a
        registration statement filed with the Securities and Exchange Commission under the Securities Act.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Governmental Consents and Filings</u></font>.&#160; Based in part upon the representations and warranties of the Lenders in this Agreement, no
        consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state, local or foreign governmental authority is required on the part of the Company in connection with the
        consummation of the transactions contemplated by this Agreement or the issuance of the Notes, the Conversion Shares or the shares of Common Stock issued upon conversion of the Conversion Shares (collectively, the &#8220;<font style="font-weight: bold;"><u>Securities</u></font>&#8221;),



        except for filings pursuant to Regulation D under the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Litigation</u></font><u>.</u>&#160; There is no action, suit, proceeding, arbitration, mediation, complaint, claim, charge or investigation
        before any court, arbitrator, mediator or governmental agency or instrumentality pending or, to the Company&#8217;s knowledge, currently threatened (i) against the Company or any officer or director of the Company; (ii) that questions the validity of the
        Transaction Documents or the right of the Company to enter into them, or to consummate the transactions contemplated by this Agreement, including the sale and issuance of the Notes; or (iii) that would reasonably be expected to have, either
        individually or in the aggregate, a Material Adverse Effect.&#160; Neither the Company nor, to the Company&#8217;s knowledge, any officer or director of the Company is a party to, or is named as subject to the provisions of, any order, writ, injunction,
        judgment or decree of any court or government agency or instrumentality (in the case of officers or directors of the Company, such as would have a Material Adverse Effect.)</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Compliance with Laws and Other Instrument</u>s</font>.&#160; Assuming the truth and accuracy of the representations and warranties of the
        Lenders set forth in this Agreement, the execution, delivery and performance by the Company of the Transaction Documents and the consummation of the transactions contemplated thereby will not violate (x) the Restated Certificate or the Company&#8217;s
        Bylaws (the &#8220;<font style="font-weight: bold;"><u>Bylaws</u></font>&#8221;), each as in effect as of the date hereof (y) any material order, writ, injunction, judgment or decree of any governmental authority applicable to the Company (collectively, &#8220;<font style="font-weight: bold;"><u>Material Decrees</u></font>&#8221;), or (z) any statute, rule or regulation applicable to the Company (collectively, &#8220;<font style="font-weight: bold;"><u>Applicable Laws</u></font>&#8221;), in each case, except any such
        violation which could not reasonably be expected to have a Material Adverse Effect. Other than violations or defaults that would not (individually or in the aggregate) have a Material Adverse Effect, the Company and its subsidiaries are not in
        violation or default of (i) its Restated Certificate or Bylaws, each as in effect as of the date hereof, (ii) any provision of any Material Decree, or (iii) any Applicable Law.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Subsidiaries</u></font>. Other than Remix Securities Corporation, a Massachusetts corporation, the Company does not currently own or
        control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or
        similar arrangement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Preemptive Rights</u></font>.&#160; The issuance of the Securities is not subject to any preemptive or similar rights, or the Company has
        fully satisfied (including with respect to rights of timely notification) or obtained waivers in respect of any preemptive or similar rights directly or indirectly affecting any of its securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Financial Statements</u></font>.&#160; The Company has delivered to each Lender its unaudited financial statements for the fiscal year ended
        December 31, 2025 and its unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of March 31, 2026 (the &#8220;<font style="font-weight: bold;"><u>Balance Sheet Date</u></font>&#8221;) for the three-month
        period ended on the Balance Sheet Date (collectively, the &#8220;<font style="font-weight: bold;"><u>Financial Statements</u></font>&#8221;).&#160; The Financial Statements have been prepared in accordance with generally accepted accounting principles (&#8220;<font style="font-weight: bold;"><u>GAAP</u></font>&#8221;) applied on a consistent basis throughout the periods indicated, except that the unaudited Financial Statements may not contain all footnotes required by GAAP.&#160; The Financial Statements fairly
        present in all material respects the financial condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject in the case of the unaudited Financial Statements to normal year-end audit adjustments.&#160;
        Except as set forth in the Financial Statements, the Company has no material liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to the Balance Sheet Date; (ii)
        obligations under contracts and commitments incurred in the ordinary course of business; (iii) liabilities and obligations of a type or nature not required under GAAP to be reflected in the Financial Statements and (iv) the Prior 2025 Notes and the
        Prior 2025 Warrants, which, in all such cases, individually and in the aggregate would not have a Material Adverse Effect.&#160; The Company maintains and will continue to maintain a standard system of accounting established and administered in
        accordance with GAAP.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Changes</u></font>.&#160; Since the Balance Sheet Date, there has not been:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the Financial Statements,
        except changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse Effect;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any waiver or compromise by the Company of a valuable right or of a material debt owed to it;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except in the ordinary course of
        business and the satisfaction or discharge of which would not have a Material Adverse Effect;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any material change to a material contract or agreement by which the Company or any of its assets is bound or subject;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any material change in any compensation arrangement or agreement with any officer of the Company;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any resignation or termination of employment of any officer of the Company;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any of its material properties or
        assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company&#8217;s ownership or use of such property or assets;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any members of their immediate
        families, other than travel advances and other advances made in the ordinary course of its business;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any declaration, setting aside or payment or other distribution in respect of any of the Company&#8217;s equity securities, or any direct or indirect
        redemption, purchase, or other acquisition of any of such securities by the Company;</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result in a Material Adverse Effect;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the Company;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to the Company&#8217;s knowledge, any other event or condition of any character, other than events affecting the economy or the Company&#8217;s industry
        generally, that would reasonably be expected to result in a Material Adverse Effect; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(n)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any arrangement or commitment by the Company to do any of the things described in this <u>Section 5.11</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Tax Returns, Payments, and Elections</u></font>.&#160; The Company has filed all tax returns and reports (including information returns and
        reports) as required by law.&#160; Such tax returns and reports are true and correct in all material respects.&#160; The Company has paid all taxes due.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Insurance</u></font>.&#160; The Company has in full force and effect insurance policies concerning such casualties as would be reasonable and
        customary for companies like the Company, with extended coverage, sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.14</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Permits</u></font>. The Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its
        business, the lack of which could have a Material Adverse Effect. The Company is not in default in any material respect under any of such franchises, permits, licenses or other similar authority.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Preclinical Development and </u></font><font style="font-weight: bold; color: #282828;"><u>Clinical Trials</u></font>. The studies,
        tests, preclinical development and clinical trials, if any, conducted by or on behalf of the Company are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional
        and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable laws and regulations<font style="color: #282828;">, including </font>the Federal Food, Drug, and Cosmetic Act <font style="color: #282828;">and 21 C.F.R. parts 50, 54, 56, 58, 312, and 812</font>. The descriptions of, protocols for, and data and other results of, the studies, tests, development and trials conducted by or on behalf of the Company that have been
        furnished or made available to the Lenders are accurate and complete. The Company is not aware of any studies, tests, development or trials the results of which reasonably call into question the results of the studies, tests, development and trials
        conducted by or on behalf of the Company, and the Company has not received any written notices or correspondence from the FDA or any other governmental entity or any institutional review board or comparable authority requiring the termination,
        suspension or material modification of any studies, tests, preclinical development or clinical trials conducted by or on behalf of the Company.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.16</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>FDA Approvals</u></font>. The Company possesses all permits, licenses, registrations, certificates, authorizations, orders and approvals
        from the appropriate federal, state or foreign regulatory authorities necessary to conduct its business as now conducted, including all such permits, licenses, registrations, certificates, authorizations, orders and approvals required by the U.S.
        Food and Drug Administration (the &#8220;<font style="font-weight: bold;"><u>FDA</u></font>&#8221;) or any other federal, state or foreign agencies or bodies engaged in the regulation of <font style="color: #282828;">drug substances, </font>pharmaceuticals<font style="color: #282828;">, biologics, medical devices</font> or biohazardous materials. The Company has not received any notice of proceedings relating to the suspension, modification, revocation or cancellation of any such permit, license,
        registration, certificate, authorization, order or approval. Neither the Company nor, to the Company's knowledge, any officer, employee or agent of the Company has been convicted of any crime or engaged in any conduct that has previously caused or
        would reasonably be expected to result in (A) disqualification or debarment by the FDA under 21 U.S.C. Sections 335(a) or (b), or any similar law, rule or regulation of any other governmental entities, <font style="color: #282828;">(B) debarment,
          suspension, or exclusion under any federal healthcare programs or by the General Services Administration, </font>or (C) exclusion under 42 U.S.C. Section 1320a-7 or any similar law, rule or regulation of any governmental entities.&#160; Neither the
        Company nor any of its officers, employees, or, to the knowledge of the Company, any of its contractors or agents, is the subject of any pending or threatened investigation by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts,
        Bribery, and Illegal Gratuities&#8221; policy as stated at 56 Fed. Reg. 46191 (September 10, 1991) (the &#8220;<font style="font-weight: bold;"><u>FDA Application Integrity Policy</u></font>&#8221;) and any amendments thereto, or by any other similar governmental
        entity pursuant to any similar policy.&#160; Neither the Company nor any of its officers, employees, contractors, and agents has committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis
        for the FDA to invoke the FDA Application Integrity Policy or for any similar governmental entity to invoke a similar policy.&#160; Neither the Company nor any of its officers, employees, or, to the Company&#8217;s knowledge, any of its contractors or agents,
        has made any materially false statements on, or material omissions from, any notifications, applications, approvals, reports and other submissions to the FDA or any similar governmental entity.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.17</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>FDA Regulation</u></font>.&#160; The Company is and has been in material compliance with all applicable laws administered or issued by the FDA
        or any similar governmental entity, including the Federal Food, Drug, and Cosmetic Act and all other laws regarding developing, testing, manufacturing, marketing, distributing or promoting the products of the Company, or complaint handling or
        adverse event reporting.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.18</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Healthcare Laws</u></font>. The Company is and has been in material compliance with all applicable Healthcare Laws. &#8220;<font style="font-weight: bold;"><u>Healthcare Laws</u></font>&#8221; means all applicable federal, state, or local health care laws, each as amended, relating to the regulation of the Company, including but not limited to laws regarding fraud and abuse;
        kickbacks; self-referrals; fee-splitting; the operation of healthcare provider networks or risk bearing entities; beneficiary inducement, false claims, false billing, false coding, reimbursement, and reassignment; record retention; healthcare
        professional or entity licensure, qualifications, accreditations, or scope of practice requirements, including the practice of telehealth and healthcare professional supervision; the corporate practice of a learned or licensed healthcare
        profession; health information privacy laws, including those relating to mental health and substance abuse, including the Health Insurance Portability and Accountability Act of 1996; and all applicable implementing regulations, rules, ordinances,
        and orders related to any of the foregoing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.19</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>No &#8220;Bad Actor&#8221; Disqualification</u></font>.&#160; No &#8220;bad actor&#8221; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities
        Act (a &#8220;<font style="font-weight: bold;"><u>Disqualification Event</u></font>&#8221;) is applicable to the Company or, to the Company&#8217;s knowledge, any Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii&#8211;iv) or
        (d)(3), is applicable.&#160; &#8220;<font style="font-weight: bold;"><u>Company Covered Person</u></font>&#8221; means, with respect to the Company as an &#8220;issuer&#8221; for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the first
        paragraph of Rule 506(d)(1).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.20</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>CFIUS Representations</u></font>. The Company does not engage in (a) the design, fabrication, development, testing, production or
        manufacture of one (1) or more &#8220;critical technologies&#8221; within the meaning of the DPA; (b) the ownership, operation, maintenance, supply, manufacture, or servicing of &#8220;covered investment critical infrastructure&#8221; within the meaning of the DPA (where
        such activities are covered by column 2 of Appendix A to 31 C.F.R. Part 800); or (c) the maintenance or collection, directly or indirectly, of &#8220;sensitive personal data&#8221; of U.S. citizens within the meaning of the DPA.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">5.21</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Disclosure</u></font><u>.</u>&#160; The Company has made available to the Lenders all the information reasonably available to the Company that
        the Lenders have requested for deciding whether to acquire the Notes.&#160; No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure Schedules, and no certificate furnished or to be furnished to Lenders at
        the Closing contains any untrue statement of a material fact or, to the Company&#8217;s knowledge, omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under
        which they were made.&#160; It is understood that this representation is qualified by the fact that the Company has not delivered to the Lenders, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure
        of the types of information customarily furnished to purchasers of securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">6.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Representations and Warranties and Covenants of the Lenders</u></font>.&#160; Each Lender, severally and not
        jointly, hereby makes the representations and warranties set forth in this <u>Section 6</u> below as of the date of this Agreement to the Company and the Placement Agents.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Authorization</u></font>.&#160; This Agreement constitutes such Lender&#8217;s valid and legally binding obligation, enforceable in accordance with
        its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors&#8217; rights and (ii) laws relating to the availability of specific performance,
        injunctive relief or other equitable remedies.&#160; Each Lender represents that it has full power and authority to enter into this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Purchase Entirely for Own Account</u></font>. Each Lender acknowledges that this Agreement is made with Lender in reliance upon such
        Lender&#8217;s representation to the Company that the Securities will be acquired for investment for Lender&#8217;s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that such Lender has no
        present intention of selling, granting any participation in, or otherwise distributing the same.&#160; By executing this Agreement, each Lender further represents that such Lender does not have any contract, undertaking, agreement or arrangement with
        any person to sell, transfer or grant participations to such person or to any third person, with respect to the Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Disclosure of Information</u></font>.&#160; Each Lender acknowledges that it has received all the information it considers necessary or
        appropriate for deciding whether to acquire the Securities.&#160; Each Lender further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities,
        although nothing set forth herein shall limit the Company&#8217;s representations and warranties set forth in <u>Section 5</u> above nor any Lender&#8217;s right to rely thereon.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Investment Experience</u></font>.&#160; Each Lender is an investor in securities of companies in the development stage and acknowledges that
        it is able to fend for itself, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Securities.&#160; If other
        than an individual, each Lender also represents it has not been organized solely for the purpose of acquiring the Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Accredited Investor</u></font>.&#160; Each Lender is an &#8220;accredited investor&#8221; within the meaning of Rule 501 of Regulation D of the Securities
        and Exchange Commission (the &#8220;<font style="font-weight: bold;"><u>SEC</u></font>&#8221;), as presently in effect. The residency of each Lender is set forth on the Schedule of Lenders hereto.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Restricted Securities</u></font>.&#160; Each Lender understands that the Securities are characterized as &#8220;restricted securities&#8221; under the
        federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the
        Securities Act only in certain limited circumstances.&#160; Each Lender represents that it is familiar with SEC Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Tax Advisors</u></font>.&#160;&#160; Each Lender has reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax
        consequences of Lender&#8217;s purchase of the Securities and the transactions contemplated by this Agreement. With respect to such matters, such Lender relies solely on any such advisor and not on any statements or representations of the Company or any
        of its agents, written or oral. Such Lender understands that it (and not the Company) shall be responsible for its own tax liability that may arise as a result of the Notes and the transactions contemplated by this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Further Limitations on Disposition</u></font>. Without in any way limiting the representations and warranties set forth above, each
        Lender further agrees not to make any disposition of all or any portion of the Securities unless and until the transferee has agreed in writing for the benefit of the Company to be bound by this <u>Section 6.8</u> and:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in
        accordance with such registration statement; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) Lender has notified the Company of the proposed disposition and has furnished the Company with a detailed statement of the circumstances
        surrounding the proposed disposition and (ii) if reasonably requested by the Company, Lender shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of
        such shares under federal or state securities laws.&#160; It is agreed that the Company will not require opinions of counsel: (x) for transactions made pursuant to Rule 144 except in extraordinary circumstances, nor (y) for any transfer of the
        Securities by a Lender that is a partnership, limited liability company or other entity to (A) a partner of such partnership or member of such company, (B) a controlled affiliate of such partnership or company, or (C) a retired partner of such
        partnership or a retired member of such company who retires after the date hereof; provided that in each of the foregoing cases, the transferee agrees in writing to be subject to the terms of this <u>Section 6.8</u> to the same extent as if the
        transferee were an original Lender hereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The provisions of this <u>Section 6.8</u> shall terminate and be of no further force and effect upon an Initial Public Offering.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Market Stand-off</u>.</font> Each Lender hereby agrees that such Lender shall not sell or otherwise transfer, make any short sale of,
        grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any Common Stock (or other securities) of the Company held by the Lender (other than those included in the
        registration statement) during the one hundred eighty (180) day period following the effective date of the registration statement for the Company&#8217;s Initial Public Offering filed under the Securities Act, <font style="font-style: italic;">provided</font>
        that all officers and directors of the Company and holders of at least one percent (1%) of the Company&#8217;s voting securities are bound by and have entered into similar agreements. The obligations described in this section shall not apply to: (1) a
        registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated in the
        future, (2) to distributions to current or former partners, members or stockholders of a Lender or to the transfer of any shares owned by a Lender in the Company to its Affiliates or any of the Lender&#8217;s stockholders, members, partners or other
        equity holders; provided that the Affiliate, stockholder member, partner or other equity holder of the Holder agrees to be bound in writing by the restrictions set forth herein, or (3) transactions (including, without limitation, any swap, hedge or
        similar agreement or arrangement) or announcements, in each case, relating to securities acquired in the IPO (as defined in the Investors&#8217; Rights Agreement) or in open market or other transactions from and after the IPO or that otherwise do not
        involve or relate to shares of Common Stock owned by a Lender prior to the IPO. The Company may impose stop-transfer instructions and may stamp each certificate with a legend as substantially set forth in <u>Section 6.10</u> below with respect to
        the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of such one hundred eighty (180) day (or other) period. The Lender agrees to execute a market stand-off agreement with the underwriters in the
        offering in customary form consistent with the provisions of this section.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Legends</u></font>.&#160; It is understood that the Securities may bear the following legends:</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">&#8220;THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.&#160; THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO
        AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SUCH ACT.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 72pt;">&#8220;THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN A CONVERTIBLE PROMISSORY NOTE PURCHASE
        AGREEMENT, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Placement Agents</u></font>. Each Lender hereby acknowledges and agrees that it has independently evaluated the merits of its decision to
        purchase the Notes, and that (a) the Placement Agents are acting solely as placement agents in connection with the execution, delivery and performance of this Agreement, the Registration Rights Agreement or the Agreement and Plan of Merger, dated
        as of June 24, 2026, by and among the Company, Passage Bio, Inc. and Peregrine Merger Sub, Inc. (the &#8220;<font style="font-weight: bold;"><u>Merger Agreement</u></font>&#8221;) and are not acting as an underwriter or in any other capacity and are not and
        shall not be construed as fiduciaries for such Lender, the Company or any other Person in connection with the execution, delivery and performance of this Agreement, the Registration Rights Agreement or the Merger Agreement, (b) the Placement Agents
        have not made and will not make any representation or warranty, whether express or implied, of any kind or character and has not provided any advice or recommendation in connection with the execution, delivery and performance of this Agreement, the
        Registration Rights Agreement or the Merger Agreement and (c) the Placement Agents will not have any responsibility with respect to the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning
        the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">6.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Accredited Investor</u></font>. Each Lender is (i) a qualified institutional buyer (as defined in Rule 144A of the Securities Act), or
        (ii) an &#8220;accredited investor&#8221; within the meaning of Rule 501(a) (1), (2), (3) or (7) under the Securities Act. Accordingly, each Lender understands that the offering meets the exemptions from filing under FINRA Rule 5123(b)(1)(C) or (J). Each
        Lender is an institutional account as defined in FINRA Rule 4512(c). Accordingly, each Lender has also been advised that the offering meets (i) the exemptions from filing under FINRA Rule 5123(b)(1)(A) and (ii) the institutional customer exemption
        under FINRA Rule 2111(b).</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">7.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Defaults and Remedies</u></font>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">7.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Events of Default</u></font><u>.</u>&#160; Each of the following events shall be considered an Event of Default with respect to any and all
        Notes:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall default in the payment of any part of the Outstanding Amount of any Note for more than five (5) days after it receives
        written notice from the Note Holder Majority at any time on or after the Maturity Date or at a date fixed by acceleration or otherwise;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall make an assignment for the benefit of creditors, or shall admit in writing its inability to pay its debts as they become due,
        or shall file a voluntary petition for bankruptcy, or shall file any petition or answer seeking for itself any reorganization, arrangement, composition, readjustment, dissolution or similar relief under any present or future statute, law or
        regulation, or shall file any answer admitting the material allegations of a petition filed against the Company in any such proceeding, or shall seek or consent to or acquiesce in the appointment of any trustee, receiver or liquidator of the
        Company, or of all or any substantial part of the properties of the Company, or the Company, the Board or the Company&#8217;s majority stockholders shall take any action looking to the dissolution or liquidation of the Company;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Within thirty (30) days after the commencement of any proceeding against the Company seeking any bankruptcy reorganization, arrangement,
        composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, such proceeding shall not have been dismissed, or within thirty (30) days after the appointment without the consent or
        acquiescence of the Company of any trustee, receiver or liquidator of the Company or of all or any substantial part of the properties of the Company, such appointment shall not have been vacated; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall fail to observe or perform any other obligation to be observed or performed by it under any of the Transaction Documents and
        such failure shall continue for thirty (30) days after written notice from the Note Holder Majority to perform or observe the obligation.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">7.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Remedies</u></font>.&#160; Upon the occurrence of an Event of Default under <u>Section 7.1</u> hereof, at the option and upon the declaration
        of the Note Holder Majority, the entire unpaid principal and accrued and unpaid interest on the Notes shall, without presentment, demand, protest, or notice of any kind, all of which are hereby expressly waived, be forthwith due and payable, and
        the holders thereof may, immediately and without expiration of any period of grace, enforce payment of all amounts due and owing under such Notes and exercise any and all other remedies granted to them at law, in equity or otherwise.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">8.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Conditions of the Lenders&#8217; Obligations at the Closing</u></font>.&#160; The obligations of each Lender to purchase
        Notes at the Closing are subject to the fulfillment on or before the Closing of each of the following conditions:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">8.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Representations and Warranties</u></font>. The representations and warranties of the Company contained in <u>Section 5</u> of this
        Agreement (taking into account the Disclosure Schedules) shall be true and correct in all respects on and as of the Closing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">8.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Performance</u></font>.&#160; The Company shall have performed and complied with all covenants, agreements, obligations and conditions
        contained in this Agreement that are required to be performed or complied with by it on or before the Closing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">8.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Qualifications</u></font><u>.</u>&#160; All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of
        the United States or of any state that are required in connection with the lawful issuance and sale of the Securities pursuant to this Agreement shall be duly obtained and effective as of the Closing.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">8.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Proceedings and Documents</u></font>.&#160; All corporate and other proceedings in connection with the transactions contemplated at the
        Closing and all documents and instruments incident to such transactions shall be reasonably satisfactory in substance and form to the Lenders participating in the Closing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">8.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Loan Documents</u></font>.&#160; The Company shall have duly executed and delivered to each Lender participating in the Closing the following
        documents:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement (including the Disclosure Schedules and an up-to-date Schedule of Lenders); and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Note(s) to be issued to such Lender at the Closing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">9.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Conditions of the Company&#8217;s Obligations at the Closing</u></font>.&#160; The obligations of the Company to issue
        Notes to any Lender at the Closing are subject to the fulfillment on or before the Closing of each of the following conditions by such Lender participating in the Closing:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Representations and Warranties</u></font>.&#160; The representations and warranties of such Lender contained in
        <u>Section 6</u> of this Agreement shall be true and correct in all respects on and as of the Closing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Payment</u></font>.&#160; The Company shall have received payment for the Note(s) being purchased by such
        Lender.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Qualifications</u></font>.&#160; All authorizations, approvals, or permits, if any, of any governmental
        authority or regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Securities pursuant to this Agreement shall be duly obtained and effective as of the Closing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Loan Documents</u></font>.&#160; Each such Lender shall have duly executed and delivered to the Company the
        following documents:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 144pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Agreement; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 144pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Note(s) to be issued to such Lender at the Closing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">10.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Miscellaneous</u></font><u>.</u></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Governing Law</u></font>.&#160; This Agreement will be construed and enforced in accordance with the substantive laws of the State of Delaware
        without reference to principles of conflicts of law that would result in the application of any law other than the law of the State of Delaware.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>WAIVER </u><u>OF JURY TRIAL</u></font>.&#160; EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON
        OR ARISING OUT OF THIS AGREEMENT, THE SECURITIES OR THE SUBJECT MATTER HEREOF.&#160; THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS
        TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS.&#160; THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE
        PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS.&#160; EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS
        FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Dispute Resolution</u></font>.&#160; The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
        Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or
        other proceeding arising out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or
        otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is
        brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Survival</u></font>.&#160; Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Lenders
        contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the
        Lenders or the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Successors and Assigns</u></font>.&#160; The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
        respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or
        liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. This Agreement, and the rights and obligations of each Lender hereunder, may be assigned by such Lender only to (a) any person or entity to which such
        Notes are transferred by such Lender, or (b) any Affiliate of such Lender, and, in each case, such transferee shall be deemed a &#8220;Lender&#8221; for purposes of this Agreement. For the avoidance of doubt, the Company and the Lenders intend that and agree
        that this <u>Subsection 10.5</u> shall be interpreted so that none of the obligations of the Company or the Lenders hereunder shall be a freestanding financial instrument under ASC480 for financial reporting purposes.&#160; The Company may not assign
        its rights or obligation hereunder without the prior written consent of the Note Holder Majority.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Notices</u></font>.&#160; All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon
        personal delivery to the party to be notified, (ii) when sent by electronic mail if sent during normal business hours of the recipient, if not, then on the next business day, (iii) five (5) days after having been sent by registered or certified
        mail, return receipt requested, postage prepaid or (iv) one (1) Business Day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written identification of receipt; provided that if the recipient is not
        located in the United States, two (2) Business Days after deposit with an internationally recognized overnight courier, specifying next day delivery, with written identification of receipt.&#160; All communications shall be sent to a party hereto at the
        address set forth on the signature page hereto, the Schedule of Lenders, or at such other address or contact information as the Company or Lender may designate by written notice to the other parties hereto by written notice given in accordance with
        this <u>Section 10.6</u>.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">19</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Delays or Omissions</u></font>.&#160; No delay or omission to exercise any right, power or remedy accruing to any party upon any breach or
        default of any other party under this Agreement shall impair any such right, power or remedy of such party, nor shall it be construed to be a waiver of any such breach or default or an acquiescence therein, or of or in any similar breach or default
        thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring.&#160; Any waiver, permit, consent or approval of any kind or character on the part of any
        party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing or as
        provided in this Agreement.&#160; All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Entire Agreement; Amendments and Waivers</u></font>.&#160; This Agreement, the Notes and the other documents delivered pursuant hereto
        constitute the full and entire understanding and agreement among the parties hereto with regard to the subjects hereof and thereof.&#160; The Company&#8217;s agreements with each of the Lenders are separate agreements, and the sales of the Notes to each of
        the Lenders are separate sales.&#160; Nonetheless, any term of this Agreement and the Notes may be amended or modified and the observance of any term of this Agreement or the Notes may be waived (either generally or in a particular instance and either
        retroactively or prospectively), only with the written consent of the Company and the Note Holder Majority; provided that:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;in no event may any such amendment or waiver adversely affect any holder of Notes in a manner which is disproportionate to the outstanding
        principal of the Note held by such holder unless such amendment or waiver is agreed to in writing by such adversely affected holder;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;no amendment may increase the obligation of any Lender to purchase additional Notes or change the principal amount or interest of Notes
        pursuant to this Agreement without the prior written consent of such Lender;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Sections 5.20</u>, and <u>10.20</u>, the definitions in <u>Section 1</u> of &#8220;CFIUS&#8221;, &#8220;CFIUS-Impacted Lender&#8221;, &#8220;CFIUS Satisfied Condition&#8221;,
        &#8220;CFIUS Filing Requirement&#8221;, &#8220;DPA&#8221;, or this clause (c) of this <u>Section 10.8</u> with respect to a CFIUS-Impacted Lender may not be amended, modified, terminated or waived without the written consent of such CFIUS-Impacted Lender; and</div>
      <div><br>
      </div>
      <div style="text-align: justify;">Any waiver or amendment effected in accordance with this Section shall be binding upon each party hereto and any holder of any Note purchased under this Agreement at the time outstanding and each future holder of all
        such Notes, as applicable.&#160; No amendment to or waiver of any provision of any Note shall be made unless such amendment or waiver is made with respect to all Notes.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Pari Passu Interest</u></font>.&#160; The Company and the Lenders acknowledge and agree that the payment of all or any portion of the
        outstanding principal amount of any Note or Prior 2025 Note and all interest thereon shall be pari passu in right of payment and in all other respects, including but not limited to remedies available to Lenders pursuant to <u>Section 7</u> hereof,
        the Notes, the Prior 2025 Notes and applicable law.&#160; Upon repayment of any amounts on any Note, the Company shall send along with such repayment an accounting that sets forth the repayments made to all holders of Notes issued hereunder.&#160; In the
        event a Lender receives payments in excess of its pro rata share of the Company&#8217;s payments to the Lenders of all of the Notes and the Prior 2025 Notes, then such Lender shall hold in trust all such excess payments for the benefit of the holders of
        the other Notes and the Prior 2025 Notes and shall pay such amounts held in trust to such other holders upon demand by such holders.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Publicity</u></font>.&#160; Neither the Company nor any Lender will originate any publicity, news release or other public announcement,
        written or oral (a &#8220;<font style="font-weight: bold;"><u>Release</u></font>&#8221;), regarding any Lender&#8217;s involvement with the transactions contemplated by this Agreement without the Company and the Lender&#8217;s prior written consent, other than (i) the
        disclosure of this Agreement and the transactions contemplated hereby to potential investors of the Company, or (ii) where such Release is required by applicable law.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">20</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Finder&#8217;s Fee</u></font>.&#160; Each party represents that it neither is nor will be obligated to pay any brokerage or finder&#8217;s fee or
        commissions in connection with this transaction, other than the Company to the Placement Agents pursuant to the amended and restated engagement letter, dated as of June 17, 2026, by and among the Company and the Placement Agents (the &#8220;<font style="font-weight: bold;"><u>Engagement Letter</u></font>&#8221;).&#160; The Company shall indemnify and hold each of the Lenders harmless, and each Lender shall, severally and not jointly, indemnify and hold the Company harmless, from any liability for
        any commission or compensation in the nature of a brokerage or finder&#8217;s fee (including the costs, expenses, and legal fees of defending against such liability) for which the Company or such Lender, or any of their respective partners, employees or
        representatives, as the case may be, is responsible.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Fees and Expenses</u></font>. The Company shall pay the fees and expenses of (i) Cooley LLP, counsel for Decheng Capital Global Life
        Sciences Fund V, L.P. (or its Affiliates), in an amount not to exceed, in the aggregate, $150,000 and (ii) Goodwin Procter LLP, counsel for certain other Lenders, in an amount not to exceed, in the aggregate, $45,000, in each case incurred in
        connection with both (a) the Notes and (b) the consummation of a PIPE Offering and/or a Non-Traditional IPO, if any.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Corporate Securities Law</u></font>.&#160; THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
        COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS
        EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE.&#160; THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.14</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Aggregation of Rights</u></font>.&#160; All Notes or shares of Preferred Stock held or acquired by a Lender or its Affiliates shall be
        aggregated together for the purpose of determining the availability of any rights and imposition of any obligations under this Agreement, and a Lender and its Affiliates may apportion such rights and obligations as among themselves in any manner
        they deem appropriate.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.15</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Exculpation Among Lenders</u></font>.&#160; Each Lender acknowledges that it is not relying upon any person, firm, corporation or stockholder,
        other than the Company and its officers and directors in their capacities as such, in making its investment or decision to invest in the Company.&#160; Each Lender agrees that no other Lender nor the respective controlling persons, officers, directors,
        partners, agents, stockholders or employees of any other Lender shall be liable for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase and sale of the Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.16</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Construction</u></font>.&#160; The parties hereto agree that they have been represented by counsel during the negotiation, preparation and
        execution of this Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or
        document.&#160; Unless the context of this Agreement otherwise requires, to the extent necessary so that each clause will be given the most reasonable interpretation, the singular number will include the plural and vice versa, the verb will be construed
        as agreeing with the word so substituted, words importing the masculine gender will include the feminine and neuter genders, words importing persons will include firms and corporations and words importing firms and corporations will include
        individuals.&#160; As used in this Agreement, the term &#8220;or&#8221; shall be interpreted to mean &#8220;and/or&#8221; unless the context of the use plainly means otherwise.&#160; As used in this Agreement, the terms &#8220;includes&#8221; or &#8220;including&#8221; shall be interpreted to mean
        &#8220;includes without limitation&#8221; or &#8220;including, as applicable,&#8221; and shall not be interpreted to limit the scope of the provisions directly preceding such terms.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">21</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.17</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Counterparts</u></font>.&#160; This Agreement may be executed in any number of counterparts and signatures may be delivered via electronic
        mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <font style="font-style: italic;">e.g.</font>, www.docusign.com) or other transmission method, each of which may be executed by less than all
        parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.18</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Severability</u></font>.&#160; Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and
        valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the
        remainder of such provision or the remaining provisions of this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.19</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Titles and Subtitles</u></font>.&#160; The titles and subtitles used in this Agreement are used for convenience only and are not to be
        considered in construing or interpreting this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.20</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>CFIUS Filing Event</u></font>. In the event of a CFIUS Filing Requirement, the Company and such Lender shall, and shall cause any
        Affiliates to, cooperate and promptly make a CFIUS filing in the requested, required or advisable form in accordance with the DPA. For the avoidance of doubt, the Company and a CFIUS-Impacted Lender shall have no obligation to accept or take any
        action, condition or restriction with respect to the proposed transaction in order to achieve the CFIUS Satisfied Condition.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.21</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Exculpation and Acknowledgement of Placement Agents</u></font>. Each party hereto agrees for the express benefit of each of the Placement
        Agents, its affiliates and its representatives that:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the Placement Agents is acting solely as financial advisor to the Company in connection with the sale of the Notes and is not acting in
        any other capacity and is not and shall not be construed as a fiduciary for the Lender, or any other person or entity in connection with the sale of the Notes.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No Placement Agent or any of its affiliates or any of its representatives (i) shall be liable for any improper payment made in accordance with
        the information provided by the Company, (ii) has made or will make any representation or warranty, express or implied, of any kind or character, and has not provided any advice or recommendation to the Lenders in connection with the purchase or
        sale of the Notes, (iii) has any responsibilities as to the validity, accuracy, completeness, value or genuineness, as of any date, of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this
        Agreement, the Registration Rights Agreement or the Merger Agreement, or in connection with any of the transactions contemplated by such agreements, including any valuation, offering or marketing materials, or any omissions from such materials; or
        (iv) shall be liable or have any obligation (including, without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by the Lenders, the
        Company or any other person or entity), whether in contract, tort or otherwise to the Lenders or to any person claiming through the Lenders, (x) for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be
        authorized or within the discretion or rights or powers conferred upon it by this Agreement, the Registration Rights Agreement or the Merger Agreement or (y) for anything which any of them may do or refrain from doing in connection with this
        Agreement, the Registration Rights Agreement or the Merger Agreement, except for such party&#8217;s own gross negligence, willful misconduct or bad faith.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Placement Agents, their respective affiliates and their respective representatives shall be entitled to rely on, and shall be protected in
        acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any of them by or on behalf of the Company.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">22</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Lender acknowledges that each of the Placement Agents is acting as a placement agent on a &#8220;best efforts&#8221; basis for the Notes being offered
        hereby and will be compensated by the Company for acting in such capacity. Each Lender represents that such Lender was contacted regarding the sale of the Notes by a Placement Agent or the Company (or an authorized agent or representative thereof)
        with whom the Lender entered into a verbal or written confidentiality agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Lender represents that it is making this investment based on the results of its own due diligence investigation of the Company, and has
        not relied on any information or advice furnished by or on behalf of the Placement Agents in connection with the transactions contemplated hereby. Each Lender acknowledges that none of the Placement Agents have made, and will not make, any
        representations and warranties with respect to the Company or the transactions contemplated hereby, and such Lender will not rely on any statements made by any of the Placement Agents, orally or in writing, to the contrary.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;">10.22</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u></u></font></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><font style="font-weight: bold;"><u>Third-Party Beneficiaries</u></font>.&#160; Each of the Placement Agents will be entitled to rely, as an express third&#8209;party beneficiary, on
        the representations and warranties and covenants of the Lenders and the Company set forth in <u>Section 5</u>, <u>Section 6</u>, and <u>Section 10.21</u> hereof.</div>
      <div><br>
      </div>
      <div style="text-align: center;">[Signature pages follow.]</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">23</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z602adca4b40e422ba28dd3c4d94bd5e9" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">COMPANY:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;">REMIX THERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
            </td>
            <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-family: 'Times New Roman', Times, serif;">/s/ Peter G. Smith, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Peter G. Smith, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">President &amp; Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.</div>
      <div> <br>
      </div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="za009b6128d764befa249dcd6828dd792" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="font-weight: bold;">LENDERS</font>:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">By:&#160; </div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Its:&#160; </div>
            </td>
            <td style="width: 44%; vertical-align: top;"> <br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">By:&#160; </div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Its:&#160; </div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">By:</div>
            </td>
            <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;">Title:&#160; </div>
            </td>
            <td style="width: 44%; vertical-align: top;">
              <div style="color: #000000; font-family: 'Times New Roman', Times, serif;"><br>
              </div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <br>
      <div style="text-align: center; font-weight: bold;"><u>Exhibit A</u></div>
      <div><br>
      </div>
      <div style="text-align: center;">Schedule of Lenders</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>Exhibit B</u></div>
      <div><br>
      </div>
      <div style="text-align: center;">Form of Convertible Promissory Note</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>Exhibit C</u></div>
      <div><br>
      </div>
      <div style="text-align: center;">Disclosure Schedules</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>Exhibit D</u></div>
      <div><br>
      </div>
      <div style="text-align: center;">Series C Term Sheet</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><u>Exhibit E</u></div>
      <div><br>
      </div>
      <div style="text-align: center;">Form of Registration Rights Agreement</div>
      <div><br>
      </div>
    </div>
    <br>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>3
<FILENAME>ny20077915x1_ex10-29.htm
<DESCRIPTION>EXHIBIT 10.29
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-family: 'Times New Roman',Times,serif; font-style: normal; font-weight: bold;">Exhibit 10.29</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">INDEMNIFICATION AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">THIS INDEMNIFICATION AGREEMENT (the &#8220;<u>Agreement</u>&#8221;) is made and entered into as of [&#8226;] between Remix Therapeutics, Inc., a Delaware corporation (the &#8220;<u>Company</u>&#8221;), and [&#8226;] (&#8220;<u>Indemnitee</u>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">WITNESSETH THAT:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, highly competent persons have become more reluctant to serve corporations as officers and directors or in other capacities unless they are provided
        with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, the Board of Directors of the Company (the &#8220;<u>Board</u>&#8221;) has determined that, in order to attract and retain qualified individuals, the Company
        will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities.&#160; Although the furnishing of such insurance has been a customary and
        widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with
        more exclusions.&#160; At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that
        traditionally would have been brought only against the Company or business enterprise itself.&#160; The Bylaws of the Company require indemnification of the officers and directors of the Company.&#160; Indemnitee may also be entitled to indemnification
        pursuant to the General Corporation Law of the State of Delaware (&#8220;<u>DGCL</u>&#8221;).&#160; The Bylaws and Certificate of Incorporation and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby
        contemplate that contracts may be entered into between the Company and members of the Board, officers and other persons with respect to indemnification;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the
        Company&#8217;s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such
        persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, this Agreement is a supplement to and in furtherance of the Bylaws and Certificate of Incorporation of the Company and any resolutions adopted
        pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">WHEREAS</font>, Indemnitee does not regard the protection available under the Company&#8217;s Bylaws and Certificate of Incorporation and insurance as adequate in the
        present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity.&#160; Indemnitee is willing to serve, continue to serve and to take on additional
        service for or on behalf of the Company on the condition that Indemnitee be so indemnified[.][; and]</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">[<font style="font-weight: bold;">WHEREAS</font>, Indemnitee has certain rights to indemnification and/or insurance provided by [&#8226;] and its affiliates (&#8220;<u>[&#8226;]</u>&#8221;), which Indemnitee and [&#8226;]
        intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided herein, with the Company&#8217;s acknowledgement and agreement to the foregoing being a material condition to Indemnitee&#8217;s willingness to serve on the
        Board.]</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold;">NOW, THEREFORE</font>, in consideration of Indemnitee&#8217;s agreement to serve as a director or officer from and after the date hereof, the parties hereto agree as
        follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Indemnity of Indemnitee</u>.&#160; The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time
        to time.&#160; In furtherance of the foregoing indemnification, and without limiting the generality thereof:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><u>Proceedings Other Than Proceedings by or in the Right of the Company</u>.&#160; Indemnitee shall be entitled to the rights of indemnification provided in this <u>Section l(a)</u>
        if, by reason of such person&#8217;s Corporate Status (as hereinafter defined), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the
        Company.&#160; Pursuant to this <u>Section 1(a)</u>, Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by such person, or on such
        person&#8217;s behalf, in connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and
        with respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee&#8217;s conduct was unlawful.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><u>Proceedings by or in the Right of the Company</u>.&#160; Indemnitee shall be entitled to the rights of indemnification provided in this <u>Section 1(b)</u> if, by reason of
        such person&#8217;s Corporate Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company.&#160; Pursuant to this <u>Section 1(b)</u>, Indemnitee shall be indemnified against
        all Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee&#8217;s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to
        the best interests of the Company; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, if applicable law so provides, no indemnification against such Expenses shall be made in respect of any claim,
        issue or matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent that the Court of Chancery of the State of Delaware shall determine that such indemnification may be made.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><u>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</u>.&#160; Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is,
        by reason of such person&#8217;s Corporate Status, a party to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses
        actually and reasonably incurred by such person or on such person&#8217;s behalf in connection therewith.&#160; If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all
        claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by such person or on such person&#8217;s behalf in connection with each successfully resolved claim, issue or
        matter.&#160; For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;"><u>[Indemnification of Appointing Stockholder.</u> If (i) Indemnitee is or was affiliated with one or more venture capital funds that has invested in the Company (an &#8220;<u>Appointing


          Stockholder</u>&#8221;), (ii) the Appointing Stockholder is, or is threatened to be made, a party to or a participant in any Proceeding, and (iii) the Appointing Stockholder&#8217;s involvement in the Proceeding results from any claim based on the
        Indemnitee&#8217;s service to the Company as a director or other fiduciary of the Company, the Appointing Stockholder will be entitled to indemnification hereunder for Expenses to the same extent as Indemnitee, and the terms of this Agreement as they
        relate to procedures for indemnification of Indemnitee and advancement of Expenses shall apply to any such indemnification of Appointing Stockholder.]</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Additional Indemnity</u>.&#160; In addition to, and without regard to any limitations on, the indemnification provided for in <u>Section 1</u> of this Agreement, the Company
        shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by such person or on such person&#8217;s behalf if, by reason of such person&#8217;s
        Corporate Status, he is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability arising out of the negligence or active or
        passive wrongdoing of Indemnitee.&#160; The only limitation that shall exist upon the Company&#8217;s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined (under
        the procedures, and subject to the presumptions, set forth in <u>Sections 6</u> and <u>7</u> hereof) to be unlawful.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Contribution</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Whether or not the indemnification provided in <u>Sections 1</u> and <u>2</u> hereof is available, in respect of any threatened, pending or completed action, suit or
        proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit or
        proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee.&#160; The Company shall not enter into any settlement of any action, suit or
        proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Without diminishing or impairing the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall elect or be required to pay all
        or any portion of any judgment or settlement in any threatened, pending or completed action, suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall
        contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or
        employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction or events from which such
        action, suit or proceeding arose; <u>provided</u>, <u>however</u>, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the
        Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in
        connection with the transaction or events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered.&#160; The relative fault of the Company
        and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, shall be
        determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is
        active or passive.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers, directors, or employees of the
        Company, other than Indemnitee, who may be jointly liable with Indemnitee.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the
        Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim
        relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and
        Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or
        transaction(s).</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Indemnification for Expenses of a Witness</u>.&#160; Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of such person&#8217;s
        Corporate Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by such person or on such
        person&#8217;s behalf in connection therewith.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Advancement of Expenses</u>.&#160; Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in
        connection with any Proceeding by reason of Indemnitee&#8217;s Corporate Status within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to
        or after final disposition of such Proceeding.&#160; Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by or on behalf of Indemnitee to
        repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses.&#160; Any advances and undertakings to repay pursuant to this <u>Section 5</u> shall be unsecured and interest
        free.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Procedures and Presumptions for Determination of Entitlement to Indemnification</u>.&#160; It is the intent of this Agreement to secure for Indemnitee rights of indemnity that
        are as favorable as may be permitted under the DGCL and public policy of the State of Delaware.&#160; Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is
        entitled to indemnification under this Agreement:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information
        as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification.&#160; The Secretary of the Company shall, promptly upon receipt of such a request for
        indemnification, advise the Board in writing that Indemnitee has requested indemnification.&#160; Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion, shall
        not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Upon written request by Indemnitee for indemnification pursuant to the first sentence of <u>Section 6(a)</u> hereof, a determination with respect to Indemnitee&#8217;s
        entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board (1) by a majority vote of the disinterested directors, even though less than a quorum, (2) by a committee of
        disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum, (3) if there are no disinterested directors or if the disinterested directors so direct, by independent legal counsel in a written
        opinion to the Board, a copy of which shall be delivered to the Indemnitee, or (4) if so directed by the Board, by the stockholders of the Company.&#160; For purposes hereof, disinterested directors are those members of the Board who are not parties to
        the action, suit or proceeding in respect of which indemnification is sought by Indemnitee.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to <u>Section 6(b)</u> hereof, the Independent Counsel shall be
        selected as provided in this <u>Section 6(c)</u>.&#160; The Independent Counsel shall be selected by the Board. Indemnitee may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company a written
        objection to such selection; <u>provided</u>, <u>however</u>, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;<u>Independent Counsel</u>&#8221; as defined in <u>Section
          13</u> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.&#160; Absent a proper and timely objection, the person so selected shall act as Independent Counsel.&#160; If a written objection is made
        and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit.&#160; If, within twenty (20) days after submission by
        Indemnitee of a written request for indemnification pursuant to <u>Section 6(a)</u> hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Court of Chancery of the State of
        Delaware or other court of competent jurisdiction for resolution of any objection which shall have been made by the Indemnitee to the Company&#8217;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected
        by the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under <u>Section 6(b)</u> hereof.&#160; The Company shall
        pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to <u>Section 6(b)</u> hereof, and the Company shall pay all reasonable fees and expenses incident to the
        procedures of this <u>Section 6(c)</u>, regardless of the manner in which such Independent Counsel was selected or appointed.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee
        is entitled to indemnification under this Agreement.&#160; Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.&#160; Neither the failure of the Company (including by its
        directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of
        conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee
        has not met the applicable standard of conduct.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise (as hereinafter defined),
        including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the
        Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise.&#160; In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee
        of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.&#160; Whether or not the foregoing provisions of this <u>Section 6(e)</u> are satisfied, it shall in any event be
        presumed that Indemnitee has at all times acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company.&#160; Anyone seeking to overcome this presumption shall have the burden of proof and the
        burden of persuasion by clear and convincing evidence.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">If the person, persons or entity empowered or selected under <u>Section 6</u> to determine whether Indemnitee is entitled to indemnification shall not have made a
        determination within sixty (60) days after receipt by the Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification
        absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such
        indemnification under applicable law; <u>provided</u>, <u>however</u>, that such sixty (60) day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination
        with respect to entitlement to indemnification in good faith requires such additional time to obtain or evaluate documentation and/or information relating thereto; and <u>provided further</u>, that the foregoing provisions of this <u>Section 6(f)</u>
        shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to <u>Section 6(b)</u> of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such
        determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and
        such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after
        having been so called and such determination is made thereat.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to
        such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such
        determination.&#160; Any Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination regarding the Indemnitee&#8217;s entitlement to indemnification under this Agreement.&#160; Any costs
        or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s
        entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction,
        disruption and uncertainty.&#160; In the event that any action, claim or proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action,
        claim or proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding.&#160; Anyone seeking to overcome this presumption shall
        have the burden of proof and the burden of persuasion by clear and convincing evidence.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its
        equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he
        reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that such person&#8217;s conduct was unlawful.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Remedies of Indemnitee</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">In the event that (i) a determination is made pursuant to <u>Section 6</u> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii)
        advancement of Expenses is not timely made pursuant to <u>Section 5</u> of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to <u>Section 6(b)</u> of this Agreement within ninety (90) days after receipt by
        the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after receipt by the Company of a written request therefor, or (v) payment of indemnification is not made
        within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to <u>Section 6</u> of this Agreement, Indemnitee shall be entitled to an
        adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of Indemnitee&#8217;s entitlement to such indemnification.&#160; Indemnitee shall commence such proceeding seeking an adjudication within one
        hundred eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this <u>Section 7(a)</u>.&#160; The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">In the event that a determination shall have been made pursuant to <u>Section 6(b)</u> of this Agreement that Indemnitee is not entitled to indemnification, any judicial
        proceeding commenced pursuant to this <u>Section 7</u> shall be conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under <u>Section 6(b)</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">If a determination shall have been made pursuant to <u>Section 6(b)</u> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such
        determination in any judicial proceeding commenced pursuant to this <u>Section 7</u>, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s misstatement not materially
        misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">In the event that Indemnitee, pursuant to this <u>Section 7</u>, seeks a judicial adjudication of such person&#8217;s rights under, or to recover damages for breach of, this
        Agreement, or to recover under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, the Company shall pay on Indemnitee&#8217;s behalf, in advance, any and all expenses (of the types described in the definition of Expenses
        in <u>Section 13</u> of this Agreement) actually and reasonably incurred by such person in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or
        insurance recovery.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this <u>Section 7</u> that the procedures and presumptions of this Agreement
        are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the provisions of this Agreement.&#160; The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee,
        shall (within ten (10) days after receipt by the Company of a written request therefore) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee
        for indemnification or advance of Expenses from the Company under this Agreement or under any directors' and officers' liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled
        to such indemnification, advancement of Expenses or insurance recovery, as the case may be.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to
        the final disposition of the Proceeding.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Non-Exclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under
        applicable law, the Certificate of Incorporation, the By-laws, any agreement, a vote of stockholders, a resolution of directors of the Company, or otherwise.&#160; No amendment, alteration or repeal of this Agreement or of any provision hereof shall
        limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in such person&#8217;s Corporate Status prior to such amendment, alteration or repeal.&#160; To the extent that a change in the DGCL,
        whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Certificate of Incorporation, By-laws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this
        Agreement the greater benefits so afforded by such change.&#160; No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and
        remedy given hereunder or now or hereafter existing at law or in equity or otherwise.&#160; The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or
        remedy.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the
        Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its
        or their terms to the maximum extent of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies.&#160; If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company
        has directors&#8217; and officers&#8217; liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies.&#160; The Company shall
        thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">[The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by [&#8226;] and certain of its
        affiliates (collectively, the &#8220;<u>Fund Indemnitors</u>&#8221;).&#160; The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to
        provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all
        Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Certificate of Incorporation or Bylaws of the Company (or any other agreement between the
        Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for
        contribution, subrogation or any other recovery of any kind in respect thereof.&#160; The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought
        indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the
        Company.&#160; The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 8(c).]</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">[Except as provided in paragraph (c) above,] [I][i]n the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of
        the rights of recovery of Indemnitee [(other than against the Fund Indemnitors)], who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the
        Company to bring suit to enforce such rights.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">[Except as provided in paragraph (c) above,] [T][t]he Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if
        and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">[Except as provided in paragraph (c) above,] [T][t]he Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of
        the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or
        advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Exception to Right of Indemnification</u>.&#160; Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity
        in connection with any claim made against Indemnitee:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the
        amount paid under any insurance policy or other indemnity provision[, provided, that the foregoing shall not affect the rights of Indemnitee or the Fund Indemnitors set forth in Section 8(c) above]; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of <u>Section 16(b)</u> of
        the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee
        against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation, or (ii) the Company provides the indemnification, in its sole
        discretion, pursuant to the powers vested in the Company under applicable law.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Duration of Agreement</u>.&#160; All agreements and obligations of the Company contained herein shall continue during the period Indemnitee is an officer or director of the
        Company (or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so long as Indemnitee shall be
        subject to any Proceeding (or any proceeding commenced under <u>Section 7</u> hereof) by reason of such person&#8217;s Corporate Status, whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for
        which indemnification can be provided under this Agreement.&#160; This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by
        purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Security</u>.&#160; To the extent requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the
        Company&#8217;s obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.&#160; Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Enforcement</u>.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The Company expressly confirms and agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as
        an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as an officer or director of the Company.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings,
        oral, written and implied, between the parties hereto with respect to the subject matter hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">The Company shall not seek from a court, or agree to, a "bar order" which would have the effect of prohibiting or limiting the Indemnitee's rights to receive advancement of
        expenses under this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Definitions</u>.&#160; For purposes of this Agreement:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<u>Corporate Status</u>&#8221; describes the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of any other corporation,
        partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<u>Disinterested Director</u>&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<u>Enterprise</u>&#8221; shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was
        serving at the express written request of the Company as a director, officer, employee, agent or fiduciary.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<u>Expenses</u>&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs,
        printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating,
        participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding.&#160; Expenses also shall include Expenses incurred in connection with any appeal resulting from
        any Proceeding and any federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including without limitation the premium, security for, and other costs
        relating to any cost bond, supersede as bond, or other appeal bond or its equivalent.&#160; Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<u>Independent Counsel</u>&#8221; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five
        years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification
        agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.&#160; Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of
        professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.&#160; The Company agrees to pay the reasonable fees of the
        Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">&#8220;<u>Proceeding</u>&#8221; includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative
        hearing or any other actual, threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party
        or otherwise, by reason of his or her Corporate Status, by reason of any action taken by such person or of any inaction on such person&#8217;s part while acting in his or her Corporate Status; in each case whether or not he is acting or serving in any
        such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated by an Indemnitee pursuant to <u>Section



          7</u> of this Agreement to enforce such person&#8217;s rights under this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Severability</u>.&#160; The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.&#160; [Further, the
        invalidity or unenforceability of any provision hereof as to either Indemnitee or Appointing Stockholder shall in no way affect the validity or enforceability of any provision hereof as to the other.] Without limiting the generality of the
        foregoing, this Agreement is intended to confer upon Indemnitee&#160; [and Appointing Stockholder] indemnification rights to the fullest extent permitted by applicable laws.&#160; In the event any provision hereof conflicts with any applicable law, such
        provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such conflict.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Modification and Waiver</u>.&#160; No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties
        hereto.&#160; No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Notice By Indemnitee</u>.&#160; Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena,
        complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification covered hereunder.&#160; The failure to so notify the Company shall not relieve the Company of any obligation which it may
        have to Indemnitee under this Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Notices</u>.&#160; All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given (a) upon personal
        delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by
        registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.&#160; All communications shall
        be sent:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">To Indemnitee at the address set forth below Indemnitee signature hereto.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 108pt;">To the Company at:</div>
      <div><br>
      </div>
      <div style="margin-left: 108pt;">Remix Therapeutics, Inc.</div>
      <div style="margin-left: 108pt;">100 Forge Road, Suite 400</div>
      <div style="margin-left: 108pt;">Watertown, MA&#160; 02472</div>
      <div style="margin-left: 108pt;">Attn: Chief Executive Officer</div>
      <div><br>
      </div>
      <div>or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Counterparts</u>.&#160; This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one
        and the same instrument.&#160; Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, <font style="font-style: italic;">e.g.</font>, www.docusign.com)
        or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Headings</u>.&#160; The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect
        the construction thereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">20.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u></u></div>
      <div style="margin: -12pt 0px 0px; text-align: justify; text-indent: 72pt;"><u>Governing Law and Consent to Jurisdiction</u>.&#160; This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance
        with, the laws of the State of Delaware, without regard to its conflict of laws rules. The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement
        shall be brought only in the Chancery Court of the State of Delaware (the &#8220;<u>Delaware Court</u>&#8221;), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the
        exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and
        (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-style: italic; font-weight: bold;">SIGNATURE PAGE TO FOLLOW</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the day and year first above written.</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zd26e2f3d9d9a47d7bf196b73b4d8f16c" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 8%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">COMPANY:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" rowspan="1" style="width: 8%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">REMIX THERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-family: 'Times New Roman', Times, serif;">By:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">Title:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif; font-weight: bold;">INDEMNITEE:</div>
            </td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">
              <div style="font-family: 'Times New Roman', Times, serif;">[&#8226;]</div>
            </td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 42%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">
              <div style="font-family: 'Times New Roman', Times, serif;">Address:</div>
            </td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
    </div>
    <div>&#160;<br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>4
<FILENAME>ny20077915x1_ex10-30.htm
<DESCRIPTION>EXHIBIT 10.30
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <div style="text-align: right; font-style: italic; font-weight: bold;">Exhibit 10.30</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10) (iv) of Regulation S-K. The omitted information is (i) not material and (ii) treated by the
      Registrant as private or confidential.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">The Registrant undertakes to furnish a copy of all omitted information, schedules, and exhibits to the U.S. Securities and Exchange Commission upon its request.</div>
    <div><br>
    </div>
    <div style="text-align: center;"> <img src="ny20077915x1_ex10-33logo01.jpg"></div>
    <div>&#160;</div>
    <div>
      <hr style="height: 2px; width: 50%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
    <div style="text-align: center;"><u> <br>
      </u></div>
    <div style="text-align: center;"><u>LEASE</u></div>
    <div>&#160;</div>
    <div style="text-align: center;">From</div>
    <div>&#160;</div>
    <div style="text-align: center;">100 FORGE HOLDING LLC,</div>
    <div>&#160;</div>
    <div style="text-align: center;">Landlord</div>
    <div>&#160;</div>
    <div style="text-align: center;">To</div>
    <div>&#160;</div>
    <div style="text-align: center;">REMIX THERAPEUTICS INC.,</div>
    <div>&#160;</div>
    <div style="text-align: center;">Tenant</div>
    <div>&#160;</div>
    <div style="text-align: center;">100 Forge Road, Watertown, Massachusetts</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%LCR%1%%%-->
    <div style="text-align: center;">TABLE OF CONTENTS</div>
    <div>&#160;</div>
    <div style="text-align: right; font-weight: bold;"><u>Page</u></div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z26f3560521134856ad675201e961ead3" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div>ARTICLE 1:</div>
          </td>
          <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>BASIC TERMS</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 2:<br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top;">PREMISES; APPURTENANT RIGHTS; COMMON AREAS; PARKING; CHANGES TO DEVELOPMENT</td>
          <td style="width: 5%; vertical-align: top; text-align: right;">
            <div>5</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Lease of Premises; Appurtenant Rights</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>2.01(a)&#160; General</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.01(b)&#160; Exclusions</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>2.01(c)&#160; Appurtenant Rights</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.01(d)&#160; Reservations</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>2.01(e)&#160; Condominium; Title Matters</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.01(f)&#160; Measurement</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>2.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Common Areas; Parking</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.02(a)&#160; Common Areas</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>2.02(b)&#160; Parking Areas</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">9</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.02(c)&#160; Specific Parking Rights Granted to Tenant</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">9</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>2.02(d)&#160; Access to Common Areas</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">11</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>2.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Changes and Additions to Development</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">11</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 3:</div>
          </td>
          <td style="width: 85%; vertical-align: top;">
            <div>LEASE TERM</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">11</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>3.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Lease Term; Construction</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">11</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>3.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Hold Over</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>3.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Right to Extend</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>3.03(a)&#160; Extension Term</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>3.03(b)&#160; Extension Term Base Rent</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">13</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>3.03(c)&#160; Determination of Fair Market Rent</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">13</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>3.03(d)&#160; Rent Continuation</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">14</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div>ARTICLE 4:</div>
          </td>
          <td style="width: 85%; vertical-align: top;">
            <div>RENT</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">14</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>4.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Base Rent</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">14</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>4.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Additional Rent</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">14</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>4.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Late Charge</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">16</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>4.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Interest</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">16</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>4.05.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Method of Payment</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">16</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 5:</div>
          </td>
          <td style="width: 85%; vertical-align: top;">
            <div>TAXES</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">17</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>5.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Definition of &#8220;Taxes&#8221;</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">17</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>5.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Method of Payment of Taxes</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">18</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>5.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Personal Property Taxes</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">19</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 6:</div>
          </td>
          <td style="width: 85%; vertical-align: top;">
            <div>BUILDING SERVICES AND SPECIAL BUILDING FACILITIES</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">19</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>6.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Utility Services</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">19</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>6.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Building Services and Building Systems</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">21</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>6.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Service Interruptions</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">24</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 7:</div>
          </td>
          <td style="width: 85%; vertical-align: top;">
            <div>OPERATING EXPENSES</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">25</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>7.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Operating Expenses</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">25</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 9%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 8:</div>
          </td>
          <td style="width: 86%; vertical-align: top;">
            <div>INSURANCE</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">29</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>8.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Coverage</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">29</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">i</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>8.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Avoid Action Increasing Rates</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">31</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>8.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Waiver of Subrogation</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">32</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>8.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Landlord&#8217;s Insurance</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">32</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 9:</div>
          </td>
          <td style="width: 85%; vertical-align: top;">
            <div>USE OF PREMISES</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">32</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Permitted Uses</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">32</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>9.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Indemnification</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">33</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Compliance With Legal Requirements and Title Matters</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">34</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>9.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Hazardous Substances</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">35</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.05.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Signs</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">40</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>9.06.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Landlord&#8217;s Access</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">40</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.07.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Landlord&#8217;s Rules and Regulations</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">41</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>9.08.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Compliance With Insurance Requirements</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">41</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.09.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Floor Load; Heavy Machinery</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">41</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>9.10.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>LEED/Energy Conservation Measures</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">42</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.11.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Emergency Generator</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">43</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>9.12.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Rooftop Rights</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">44</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>9.13.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Neutralization System</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">46</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 10:&#160; <br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top;">CONDITION AND MAINTENANCE OF PREMISES AND PROPERTY</td>
          <td style="width: 5%; vertical-align: top; text-align: right;">46<br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Existing Conditions</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">46</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>10.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>No Landlord Liability</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">46</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Landlord&#8217;s Repair and Maintenance Obligations</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">47</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>10.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Tenant&#8217;s Obligations</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">48</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.04(a)&#160; Repair and Maintenance</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">48</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>10.04(b)&#160; Landlord&#8217;s Right to Cure</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">48</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.05.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Tenant Work</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">49</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>10.05(a)&#160; General</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">49</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.05(b)&#160; Construction Documents</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">50</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>10.05(c)&#160; Performance</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">51</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.05(d)&#160; Payment</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">52</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>10.05(e)&#160; Other</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">52</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.05(f)&#160; Removal at Conclusion of Term</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">53</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>10.05(g)&#160; Initial Tenant Work</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">54</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>10.06.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Condition Upon Termination</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">54</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>10.07.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Decommissioning of the Premises</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">54</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 11:&#160; <br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top;">DAMAGE OR DESTRUCTION; CONDEMNATION</td>
          <td style="width: 5%; vertical-align: top; text-align: right;">56<br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>11.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Damage or Destruction of Premises</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">56</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>11.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Right to Terminate in Event of Casualty</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">57</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>11.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Termination in Event of Taking</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">58</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>11.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Landlord Reserves Award</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">58</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>11.05.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Abatement of Rent</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">58</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>11.06.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Risk of Loss</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">58</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div>ARTICLE 12:&#160; <br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">ASSIGNMENT AND SUBLETTING</td>
          <td style="width: 5%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">
            <div>59</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>12.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Landlord&#8217;s Consent Required</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">59</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>12.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Terms</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">60</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>12.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Related Party Transfers</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">60</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">ii</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>12.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Recapture of Premises</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">61</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>12.05.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Procedures</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">61</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>12.06.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Excess Rents</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">62</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>12.07.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>No Release</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">62</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div>ARTICLE 13:&#160; <br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">EVENTS OF DEFAULT AND REMEDIES</td>
          <td style="width: 5%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">62<br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>13.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Events of Default</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">62</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>13.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Remedies for Default</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">65</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>13.02(a)&#160; Reletting Expenses Damages</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">65</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>13.02(b)&#160; Termination Damages</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">65</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>13.02(c)&#160; Lump Sum Liquidated Damages</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">65</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>13.02(d)&#160; Remedies Cumulative; Late Performance</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">66</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>13.02(e)&#160; Landlord&#8217;s Curing</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">66</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top; background-color: rgb(204, 238, 255);" nowrap="nowrap">
            <div>ARTICLE 14:&#160; <br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">SECURITY DEPOSIT</td>
          <td style="width: 5%; vertical-align: top; text-align: right; background-color: rgb(204, 238, 255);">66<br>
          </td>
        </tr>
        <tr>
          <td style="width: 10%; vertical-align: top;">
            <div>ARTICLE 15:&#160; <br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top;">PROTECTION OF LENDERS</td>
          <td style="width: 5%; vertical-align: top; text-align: right;">69<br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>15.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Rights of Mortgage Holders</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">69</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>15.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Subordination of Lease</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">69</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>15.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Mortgagee&#8217;s Consent and Right to Cure Defaults</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">70</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>15.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Estoppel Certificates</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">70</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>15.05.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Financial Condition</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">71</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 10%; vertical-align: top;" nowrap="nowrap">
            <div>ARTICLE 16:<br>
            </div>
          </td>
          <td style="width: 85%; vertical-align: top;">MISCELLANEOUS PROVISIONS</td>
          <td style="width: 5%; vertical-align: top; text-align: right;">72<br>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.01.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Landlord&#8217;s Consent Fees</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">72</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.02.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Landlord&#8217;s Default</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">72</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.03.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Quiet Enjoyment</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">72</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.04.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Interpretation</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">72</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.05.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Notices</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">73</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.06.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>No Recordation</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">73</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.07.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Corporate Authority</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">73</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.08.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Joint and Several Liability</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">73</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.09.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Force Majeure</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">74</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.10.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>No Warranties; Limitation of Liability</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">74</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.10(a)&#160; No Warranties</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">74</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>16.10(b)&#160; Limitation Of Liability</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">75</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.11.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>No Brokers</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">75</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.12.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>No Waiver; Accord and Satisfaction</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">75</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.13.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Applicable Law and Construction</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">76</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.14.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Waiver of Trial by Jury</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">77</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.15.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>No Representations or Inducements</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">77</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.16.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>No Surrender</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">77</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.17.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Arbitration</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">77</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">&#160;</td>
          <td style="width: 90%; vertical-align: top;">
            <div>16.17(a)&#160; Initial Construction Disputes</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">77</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.17(b)&#160; Arbitration Procedures</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">78</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.18.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>REIT/UBTI</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">79</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>16.19.</div>
          </td>
          <td style="width: 90%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Patriot Act</div>
          </td>
          <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">79</div>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>16.20.</div>
          </td>
          <td style="width: 90%; vertical-align: top;">
            <div>Confidentiality</div>
          </td>
          <td style="width: 5%; vertical-align: top;">
            <div style="text-align: right;">80</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">iii</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">LEASE</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 1: BASIC TERMS</div>
    <div>&#160;</div>
    <div style="text-align: justify;">The following terms used in this Lease shall have the meanings set forth below. Other terms are defined throughout this Lease and indexed on <u>Schedule 1</u> attached hereto and made a part hereof.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0b44d60bdf434ce1a188bc815e9756e3" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Date of Lease:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>As of <u>8/23/2021</u><br>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Landlord:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>100 Forge Holding LLC,</div>
            <div>a Delaware limited liability company</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Original Address of Landlord:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>c/o Boylston Properties</div>
            <div>800 Boylston Street, Suite 1390</div>
            <div>Boston, Massachusetts 02199</div>
            <div>Attention: Mark A. Deschenes</div>
            <div> <br>
            </div>
            <div>With a copy to:</div>
            <div> <br>
            </div>
            <div>Sherin and Lodgen, LLP</div>
            <div>101 Federal Street</div>
            <div>Boston Massachusetts 02110</div>
            <div>Attention: Peter Friedenberg, Esq.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Tenant:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>Remix Therapeutics Inc.,</div>
            <div>a Delaware corporation</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Original Address of Tenant:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>One Kendall Square, Suite B600</div>
            <div>Cambridge, Massachusetts 02139</div>
            <div>Attention: Heather Wasserman</div>
            <div> <br>
            </div>
            <div>With copies to:</div>
            <div> <br>
            </div>
            <div>[***]</div>
            <div> <br>
            </div>
            <div>and</div>
            <div> <br>
            </div>
            <div>[***]</div>
            <div> <br>
            </div>
            <div>and</div>
            <div> <br>
            </div>
            <div>Goodwin Procter LLP</div>
            <div>100 Northern Avenue</div>
            <div>Boston, Massachusetts 02210</div>
            <div>Attention: Nicole W. Riley, Esq.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Guarantor:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>N/A</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zaedf3051dddb46b5ae689ff14892b437" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Development:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>The mixed&#8209;use development commonly known as &#8220;Arsenal Yards&#8221;</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Address of Development:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>100 Forge Road</div>
            <div>Watertown, Massachusetts 02472</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Building:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">The building shown as &#8220;Building G&#8221; on <u><font style="font-weight: bold;">Exhibit A</font></u> attached hereto (the &#8220;<font style="font-weight: bold;">Building</font>&#8221;), to be constructed within the Development
              on a parcel of land (the &#8220;<font style="font-weight: bold;">Land</font>&#8221;) which is more particularly described on <u><font style="font-weight: bold;">Exhibit A&#8209;1</font></u> attached hereto. The Building will contain approximately [***]
              rentable square feet on the basement through ninth floors thereof.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Unit:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">Primary Unit 100 Forge Building G (or such other name given to such unit by Landlord), initially consisting of the entire Building. Unless and until Landlord elects to create additional Primary Condominium
              Units within the Building in accordance with the provisions of the Condominium Documents, the terms &#8220;Building&#8221; and &#8220;Unit&#8221; as used in this Lease shall both mean the entire Building.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Premises:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">Approximately 43,417 rentable square feet on the third (3rd) and fourth (4th) floors of the Building, including approximately 243 rentable square feet within Chemical Storage Room 105 on the first floor of the
              Building for Hazardous Material storage, together with any additional areas within the Building devoted to Tenant&#8217;s use, all as shown on <u><font style="font-weight: bold;">Exhibit B</font></u> attached hereto, as measured in accordance with
              the provisions of <u>Section 2.01(f)</u>.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Tenant&#8217;s Percentage Share:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>[***]. See <u>Section 5.02</u>.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Term Commencement Date:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">The earlier of (i) the date on which Tenant commences construction activities at the Premises with the written consent of Landlord, or (ii) the Delivery Date.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Term:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="font-weight: bold;"><br>
            </div>
          </td>
          <td style="width: 40%; vertical-align: top; font-weight: bold;">Initial Term:</td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">The period commencing on the Term Commencement Date and expiring on the day (&#8220;<font style="font-weight: bold;">Termination Date</font>&#8221;) before the day which is ten (10) years after the Rent Commencement Date.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zda094e49d1734d2cba0e979c19d95a4d" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 5%; vertical-align: top;"><br>
          </td>
          <td style="width: 40%; vertical-align: top;">
            <div style="font-weight: bold;">Extension Term:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">One (1) extension term of five (5) Lease Years. See <u>Section 3.03(a)</u>.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Rent Commencement Date:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">The earlier of (i) the date on which Tenant first occupies any portion of the Premises for the conduct of its business or (ii) six (6) months after the Delivery Date (as the Delivery Date may be adjusted by
              reason of Landlord Delay or Force Majeure, but not by reason of Tenant Delay, as provided in the Work Letter attached hereto as <u><font style="font-weight: bold;">Exhibit C</font></u>). Reference is made to <u>Paragraph A.11</u> of the
              Work Letter for further provisions relating to the adjustment of the Rent Commencement Date.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Lease Year:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">The first Lease Year begins at 12:01 a.m. on the Term Commencement Date and ends at 11:59 p.m. on the last day of the calendar month in which the first anniversary of the Rent Commencement Date occurs, except
              that if the Rent Commencement Date occurs on the first day of a calendar month then the first Lease Year shall end on the day before the first anniversary of the Rent Commencement Date occurs. Each subsequent Lease Year shall be a period of
              twelve (12) full calendar months commencing at 12:01 a.m. on the day after the expiration of the preceding Lease Year.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Estimated Delivery Date:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">May 1, 2022. Reference is made to the Work Letter attached hereto as <u><font style="font-weight: bold;">Exhibit C</font></u> for the description of the Delivery Date and other matters related thereto.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Permitted Uses:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">Laboratory and research and development use, including, but not limited to, life sciences, pharmaceuticals, micro&#8209;biology, chemistry, vivarium, and similar scientific research uses, which may also include
              ancillary support office and conference rooms, provided the area devoted to support office and conference rooms shall not in the aggregate exceed sixty percent (60%) of the rentable area of the Premises (collectively, &#8220;<font style="font-weight: bold;">Life Science Uses</font>&#8221;). In no event shall Tenant or any subtenant or other occupant of all or any portion of the Premises use the Premises or any portion thereof in a manner that includes activities that would
              qualify or be characterized as any biosafety level (&#8220;<font style="font-weight: bold;">BSL</font>&#8221;) other than BSL1 or BSL2.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Landlord&#8217;s Broker:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>Cushman &amp; Wakefield</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3f50d6a4df5c4d9d9508b694a447fd8f" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Tenant&#8217;s Broker:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>Colliers</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Security Deposit:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">Letter of Credit in the amount of [***] Dollars. See <u>Article 14</u>.</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" colspan="2">
            <div style="font-weight: bold;">Base Rent:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div style="font-weight: bold;"><br>
            </div>
          </td>
          <td style="width: 40%; vertical-align: top;">
            <div style="font-weight: bold;">Initial Term:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>The following amounts:</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="vertical-align: top;" rowspan="1">&#160;</td>
        </tr>

    </table>
    <div>
      <div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 22.03%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Lease Year</div>
              </td>
              <td style="width: 17%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Rate per</div>
                <div style="text-align: center;"> rentable s.f.</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Monthly</div>
                <div style="text-align: center;"> Amount</div>
              </td>
              <td style="width: 17%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Annual Amount</div>
              </td>
              <td style="width: 10%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">1</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">2</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">3</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">4</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">5</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">6</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">7</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">8</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">9</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 22.03%; vertical-align: top;">&#160;</td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">10</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 16.95%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 17%; vertical-align: bottom;">
                <div style="text-align: center;">[***]</div>
              </td>
              <td style="width: 10%; vertical-align: bottom;" colspan="1">&#160;</td>
            </tr>

        </table>
      </div>
    </div>
    <div></div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="3" style="vertical-align: top;">
            <div style="text-align: justify; margin-left: 36pt;">Note: Base Rent for Lease Year 1 does not accrue and is not due or payable until the Rent Commencement Date</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;"><br>
          </td>
          <td style="width: 40%; vertical-align: top;">
            <div style="font-weight: bold;">Extension Term:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div>Fair Market Rent (as defined in <u>Section 3.03(b)</u>.</div>
          </td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Initial Tenant Work:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">As set forth in <u><font style="font-weight: bold;">Exhibit C</font></u> attached hereto.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Base Building Work:</div>
          </td>
          <td style="width: 55%; vertical-align: top;">
            <div style="text-align: justify;">As set forth in <u><font style="font-weight: bold;">Exhibit C</font></u> attached hereto.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 55%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>

    </table>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 45%; vertical-align: top;">
            <div style="font-weight: bold;">Exhibits:</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div>Schedule 1:</div>
            <div>Exhibit A (<u>Art 1</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Index of Defined Terms</div>
            <div>Plan showing Development and the Building/Unit</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit A&#8209;1 (<u>Art. 1</u>):</div>
            <div>Exhibit A&#8209;2 (<u>Sec. 2.02(c)</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Legal Description of the Land</div>
            <div>Plan Showing Location of Dedicated Parking Spaces Plan Showing No Parking Areas</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit B (<u>Art. 1</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Floor Plan showing the Premises</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit C (<u>Sec. 3.01</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Work Letter</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit C&#8209;1 (<u>Sec. 2.01(e)</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>List of Base Building Plans and Specifications</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit C&#8209;2:</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Tenant&#8217;s Test&#8209;Fit Plan</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div></div>
    <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf85b988df5824ea3a4fb6dddea2961f5" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit C&#8209;3:</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Lab Shell Specifications Tenant/Landlord Matrix of Responsibility</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit D (<u>Sec. 2.01(e)</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Title Matters</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit E (<u>Sec. 6.02</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Cleaning Specification for Common Areas and Landlord Services</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit F (<u>Sec. 6.02</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Shuttle Service</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit G:</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Reserved</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit H (<u>Sec. 9.07</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Landlord&#8217;s Rules and Regulations</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit I (<u>Sec. 9.10</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>LEED Requirements</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit J (<u>Sec. 10.05(b)</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Construction Documents Requirements</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit K (<u>Sec. 10.05(c)</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Tenant Work Insurance Schedule</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit L (<u>Sec. 10.05(c)</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Landlord&#8217;s Guidelines for Tenant Work</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit M (<u>Sec. 15.02</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Form of SNDA</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit N (<u>Sec. 15.04</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Form of Estoppel Certificate</div>
          </td>
        </tr>
        <tr>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Exhibit O (<u>Sec. 16.06</u>):</div>
          </td>
          <td style="width: 35%; vertical-align: top;">
            <div>Form of Notice of Lease</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 2: PREMISES; APPURTENANT RIGHTS; COMMON AREAS; PARKING; CHANGES TO DEVELOPMENT</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.01.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Lease of Premises; Appurtenant Rights</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>General</u>. Landlord hereby leases the Premises to Tenant, and Tenant hereby leases the Premises from
        Landlord, for the Term. The Premises will be located in the Unit and may include additional areas within the Building as further shown on <font style="font-weight: bold;"><u>Exhibit B</u></font> attached hereto. The Land and the Building are shown
        on the preliminary site plan attached hereto as <font style="font-weight: bold;"><u>Exhibit A</u></font> (provided, however, that the site plan and any other applicable exhibit (including <font style="font-weight: bold;"><u>Exhibit A&#8209;1</u></font>)
        is attached hereto merely to identify the location of the Premises and the initial boundaries of the Development and not the identities of any actual tenants or occupants of the Development, and nothing contained therein or in this Lease shall
        obligate Landlord to construct any buildings or other improvements shown on said site plan, other than the Premises). Subject to Landlord&#8217;s Rules and Regulations and the provisions of this Lease, Tenant shall have access to the Premises, the
        parking areas serving the Premises, and the Common Areas necessary for Tenant&#8217;s use of, or access to and egress from, the Premises 24 hours a day, 7 days a week; <font style="font-style: italic;">provided, however,</font> that in times of
        emergency as determined by Landlord, Landlord shall have the right to limit access to the Building by Tenant and all other tenants, provided that any such limits on access shall cease as soon as the emergency is resolved. For purposes of this <u>Section








          2.01(a)</u>, an &#8220;<font style="font-weight: bold;">emergency</font>&#8221; shall mean an event, such as a natural disaster, pandemic or other public health emergency (including actions required by any governmental authority to be taken by Landlord or
        Tenant in connection with such pandemic or public health emergency), fire or act of terrorism, not within the reasonable control of either party hereto, that poses an immediate threat to life or property (including the Development).</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Exclusions</u>. The Premises exclude the perimeter walls thereof (other than the inner surfaces thereof),
        as well as all Common Areas, including the common stairways and stairwells, entranceways and the main lobby, elevators and elevator wells, fan rooms, roofs, off&#8209;floor electric and off&#8209;floor telephone closets, freight elevators, and pipes, ducts,
        conduits, wires and appurtenant fixtures serving other parts of the Building or the Development (exclusively or in common) and other common areas and facilities from time to time designated as such by Landlord. The Premises also exclude the common
        corridors, elevator lobby, and common toilets, as well as common on&#8209;floor electric, telephone and janitor closets, located within the Unit.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);"><u>Appurtenant Rights</u>. Tenant shall have, as appurtenant to the Premises, the right to use in common
        with others, and subject to the applicable provisions of the Condominium Documents and the provisions of this Lease (including Landlord&#8217;s Rules and Regulations): (i) the Condominium Common Areas, (ii) the common facilities of the Building,
        including the common loading docks, the Neutralization System, lobbies, hallways, stairways and elevators of the Building serving the Premises in common with other portions of the Building, and other Building amenities (including bicycle storage
        area, locker rooms and showers), common mechanical and utility rooms, common Building chases and risers, common driveways and parking areas, and trash enclosures, and (iii) if all or any portion of the Premises is located on a multi&#8209;tenant floor,
        the common corridors, elevator lobby, and common toilets, as well as common on&#8209;floor electric, telephone and janitor closets, located on such floor (the areas and facilities described in clauses (i) &#8211; (iii) are hereinafter referred to,
        collectively, as the &#8220;<font style="font-weight: bold;"><u>Common Areas</u></font>&#8221;). The ground floor lobby of the Building shall not be use as a senior center or community center, and shall not be used by Tenant for holding events or meetings open
        to the public without the prior written consent of Landlord in each instance, which consent may be withheld in accordance with the provisions of the Condominium Documents. Regularly scheduled deliveries/loading shall be restricted to the hours of
        7:00 a.m. to 5:00 p.m.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Reservations</u>. In addition to other rights reserved herein or by law, Landlord reserves the right from
        time to time, without incurring any liability to Tenant or otherwise affecting Tenant&#8217;s obligations under this Lease, provided that Landlord shall provide at least forty&#8209;eight (48) hours prior written notice to Tenant, which may be by e&#8209;mail to
        Tenant at eperry@remixtx.com (except in the case of an emergency, in which case notice shall be provided as soon as reasonably practicable) and shall use commercially reasonable efforts to avoid (except in emergency) interruption of Tenant&#8217;s use
        and access to the Premises for the Permitted Use: (i) to install, use, maintain, repair, replace and relocate for service to the Premises and other parts of the Building, or either, chases, shafts, pipes, ducts, conduits, wires and appurtenant
        fixtures wherever located in the Premises or the Building or elsewhere in the Development; (ii) to alter, eliminate or relocate any common area or facility of the Building or the Unit, including the lobbies and entrances (provided that Landlord
        shall provide a bicycle storage area, locker rooms and showers for use by all tenants of the Building throughout the Term of this Lease); and (iii) to grant easements and other rights with respect to the Development; <font style="font-style: italic;">provided that</font> (a) to the maximum extent practicable, no such installations, replacements or relocations in the Premises shall be placed below ceiling surfaces, above floor surfaces or to the inside of perimeter walls, (b) Tenant&#8217;s
        use of and access to the Premises, the Common Areas and its parking spaces shall not be adversely impacted by any such additions, alterations, improvements, repairs, installations, replacements, eliminations or relocations, and (c) all such work
        necessitating entry into the Premises shall be subject to the provisions of <u>Section 9.06</u>. Landlord shall have the exclusive rights: to use all or any part of the roof of the Building for any purpose, and to erect, in connection with
        repairs, maintenance or replacements with respect to the Building, temporary scaffolds and other aids to construction on the exterior of the Building, provided that access to the Premises shall not be denied thereby. Landlord may also make any use
        it desires of the side or rear walls of the Building, provided that such use shall not encroach on the interior of the Premises.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Condominium; Title Matters</u>. Tenant acknowledges and confirms that the Premises will be subject to and
        benefitted by:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">That certain Amended and Restated Master Deed of the Arsenal Condominium dated June 5, 2018
        and recorded in the Middlesex South District Registry of Deeds (the &#8220;<font style="font-weight: bold;">Registry</font>&#8221;) in Book 71113, Page 277, as amended by that certain Amendment to Amended and Restated Master Dees of the Arsenal Condominium
        (n/k/a Arsenal Yards Primary Condominium) dated as of January 4, 2021 recorded with the Registry in Book 76688, Page 393, as affected by that certain First Supplemental Declaration of Arsenal Yards Primary Condominium dated December 28, 2020
        recorded with the Registry in Book 76554, Page 403, and as affected by that certain Second Supplemental Declaration of Arsenal Yards Primary Condominium recorded with the Registry in Book 77151, Page 184 (aa the same may hereafter be amended,
        supplemented, restated or otherwise modified from time to time, collectively, the &#8220;<font style="font-weight: bold;">Primary Condominium Master Deed</font>&#8221;); and</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">That certain Declaration of Trust of Arsenal Yards Primary Condominium Trust dated as of
        June 5, 2018 and recorded in the Registry in Book 71113, Page 410, as amended by that certain First Amendment to Declaration of Trust of Arsenal Yards Primary Condominium Trust dated January 13, 2021 and recorded with the Registry in Book 76690,
        Page 426 (as the same may hereafter be amended, supplemented, restated or otherwise modified from time to time, collectively, the &#8220;<font style="font-weight: bold;">Primary Condominium Trust</font>&#8221;).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The Primary Condominium Master Deed has created the Arsenal Yards Primary Condominium (the &#8220;<font style="font-weight: bold;">Primary Condominium</font>&#8221;), which consists of several primary
      condominium units (collectively, the &#8220;<font style="font-weight: bold;">Primary Units</font>&#8221; and individually, a &#8220;<font style="font-weight: bold;">Primary Unit</font>&#8221;), as well as common elements and limited common elements as described therein. The
      Premises will be a portion of the Unit. The Primary Condominium Trust is the organization of holders of fee simple title to the Primary Units (the &#8220;<font style="font-weight: bold;">Primary Unit Owners</font>&#8221;) formed to manage and regulate the
      Primary Condominium. The affairs of the Primary Condominium are governed by the Primary Board of Trustees (the &#8220;<font style="font-weight: bold;">Primary Board</font>&#8221;), all as set forth in the Primary Condominium Master Deed and the Primary
      Condominium Trust. The Primary Condominium Master Deed and the Primary Condominium Trust and all Plans (defined in the Condominium Documents) related thereto, all as the same may be amended, supplemented, restated or otherwise modified, are herein
      collectively referred to as the &#8220;<font style="font-weight: bold;">Condominium Documents</font>&#8221;. Landlord agrees that it shall diligently enforce all of its rights under the Condominium Documents with respect to the Unit and the Premises throughout
      the Term of this Lease, including any extensions thereof.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">7</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;">Further, this Lease and Tenant&#8217;s rights hereunder are subject to and benefitted by all matters of record, including those set forth on <font style="font-weight: bold;"><u>Exhibit D</u></font>
      attached hereto and incorporated herein by reference, and all permits and approvals affecting the Premises, the Building or the Development, all as the same may be amended from time to time (collectively, the &#8220;<font style="font-weight: bold;">Title
        Matters</font>&#8221;). Landlord covenants that Landlord shall not enter into any modification, alteration or amendment of, the Condominium Documents or Title Matters (except for amendments pursuant to Supplemental Declarations (defined in the
      Condominium Documents) to implement Development Rights and Special Declarant Rights (both as defined in the Condominium Documents)), which would reduce the scope of the items that comprise the Permitted Use, materially increase any of Tenant&#8217;s
      obligations or materially reduce any of Tenant&#8217;s rights under this Lease. Landlord shall vote the percentage interest applicable to the Unit and any and all other Primary Units owned by Landlord in a manner consistent with the immediately preceding
      sentence.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Measurement</u>. The total rentable area of the Premises set forth in <u>Article 1</u> has been
        determined by (i) measuring the usable area of the same based on the proposed location of the demising walls of the Premises as shown on <font style="font-weight: bold;"><u>Exhibit B</u></font> attached hereto, using the BOMA International
        Standard Method of Measurement for Office Buildings (ANSI/BOMA Z65.1&#8209;2010) (the &#8220;<font style="font-weight: bold;">Measurement Standard</font>&#8221;), as modified by Landlord for use in connection with lab buildings. To the extent to which Landlord, in
        the exercise of its reserved rights pursuant to <u>Section 2.01(e)</u>, constructs or installs any chase, shaft or similar enclosures within the Premises for the exclusive use of other tenants, or grants to Tenant exclusive rights to use any
        portion of the Building situated outside the boundaries of the Premises, such areas shall be excluded or included in the Premises (as the case may be) and Landlord shall cause its architect to measure such areas in accordance with the Measurement
        Standard and either add them or subtract them to or from the total rentable area of the Premises as otherwise determined in accordance with the provisions of this Lease. If the rentable area changes on account of the provisions of this <u>Section
          2.01(f)</u>, Landlord and Tenant shall then enter into an amendment to this Lease confirming the rentable area, as modified, as well as any changes to the boundaries of the Premises, and proportional changes in the Base Rent and any other charges
        or rights under this Lease that are based upon the rentable square footage in question.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.02.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Common Areas; Parking</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>Common Areas</u>. Included within Tenant&#8217;s appurtenant right to use the Common Areas as described in <u>Section









          2.01(c)</u> is the right to use, in common with Landlord and all others entitled to the use thereof, the non&#8209;structural General Common Elements and Limited Common Elements (as defined in the Condominium Documents) allocated to the Unit or
        otherwise available to Landlord as owner of the Unit pursuant to the Condominium Documents (excluding Limited Common Elements designated by Landlord for the exclusive use by another tenant of the Unit and Limited Common Elements comprising portions
        of the exterior shell of the Building) (herein referred to as &#8220;<font style="font-weight: bold;"><u>Condominium Common Areas</u></font>&#8221;) for their intended use and in accordance with any applicable terms and provisions of the Condominium Documents
        and this Lease. Landlord shall not be liable for any inconvenience or interruption of business or other consequences resulting from the making of repairs, replacements, improvements, alterations or additions or from the doing of any other work, by
        or at the direction of Landlord, the Declarant and its successors, assigns and transferees, other Primary Unit Owners, or the Primary Board, to or upon any Common Areas, or from delay or failure to perform such maintenance, snow removal or other
        work with respect to any Common Areas. Tenant acknowledges and agrees that the size, location and nature of any Condominium Common Area may be changed from time to time in accordance with the Condominium Documents.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>Parking Areas</u>. All parking areas, access roads and facilities which may be furnished in the
        Development, as it shall be constituted from time to time, including employee parking areas, truck way or ways, driveways, loading docks and areas, delivery passages, package pickup stations, pedestrian sidewalks, malls, courts and ramps,
        landscaped and planting areas, retaining walls, stairways, bus stops, first&#8209;aid stations, lighting facilities, comfort stations, and other areas and improvements which may be provided by the Primary Board for the general use in common of tenants,
        their officers, agents, employees, invitees and customers, shall at all times be subject to the exclusive control and management of the Primary Board. The Landlord, Declarant (and its successors, assigns and transferees) and the Primary Board shall
        have the right from time to time, and at no cost to Tenant, to change the areas, locations, length of stay and arrangement of parking areas and all other Common Areas referred to in this <u>Section 2.02</u>; to construct surface or elevated
        parking areas and facilities; to establish and from time to time change the level of parking surfaces; to impose parking fees and charges for any and all parking facilities and parking spaces in the Development or elsewhere, and enforce such
        parking charges (by operation of meters or otherwise); to limit the use of certain parking areas to the exclusive use of certain tenants or occupants of the Development; to close all or any portion of said areas or facilities to such extent as may,
        in the opinion of Landlord&#8217;s counsel, be legally sufficient to prevent a dedication thereof or the accrual of any rights to any person or to the public therein; to close temporarily any or all portions of the parking areas or facilities; to
        discourage non&#8209;customer retail parking; to establish bicycle parking and storage areas and facilities and electric vehicle charging stations; and to do and perform such other acts in and to said areas and improvements as, in the use of good
        business judgment, Landlord or the Primary Board shall determine to be advisable with a view to the improvements of the convenience and use thereof by tenants, their officers, agents, employees, and customers. In the event that, in connection with
        any of the activities described in the immediately preceding sentence, Tenant&#8217;s right to use any or all of the parking spaces described in <u>Section 2.02(c)</u> below is interrupted or suspended by such activity for more than five (5) consecutive
        Business Days, Landlord shall make commercially reasonable efforts to provide alternative parking to Tenant. Tenant shall, if requested by Landlord, furnish Landlord with State automobile license or registration numbers assigned to Tenant&#8217;s car or
        cars and cars of its employees within five (5) Business Days after Tenant&#8217;s receipt of Landlord&#8217;s written demand. Landlord may implement parking passes or other means of identifying authorized users of Tenant&#8217;s parking rights.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Specific Parking Rights Granted to Tenant.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">During the Term, Tenant, its employees, guests and visitors shall have the appurtenant
        right to use, at no additional charge, up to [***] ([***] space per [***] rentable square feet in the Premises) parking spaces located in the lower level of the garage at 50 Forge Road and 100 Forge Road (which lower level is shown on <font style="font-weight: bold;"><u>Exhibit A&#8209;2</u></font> attached hereto) between the hours of 8:00 A.M. and 5:00 P.M. on Business Days (at other times/days such parking spaces shall be made available to the general public). No specific parking
        spaces shall be designated, identified or reserved for Tenant&#8217;s exclusive use.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">In addition, during the Term, Tenant, its employees, guests and visitors shall have the
        appurtenant right to use, at no additional charge, up to [***] ([***] space per [***] rentable square feet in the Premises) parking spaces located in the lower level of the garage at 50 Forge Road and 100 Forge Road, between the hours of 8:00 A.M.
        and 5:00 P.M. on Business Days (at other times/days such parking spaces shall be made available to the general public), which spaces shall be provided by means of a parking stacker or other mechanical parking equipment. No specific parking spaces
        shall be designated, identified or reserved for Tenant&#8217;s exclusive use.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">In addition, Tenant, its employees, guests and visitors shall have the right to use during
        the Term up to [***] ([***] space per [***] rentable square feet in the Premises) undesignated parking spaces in the parking areas within the Development in accordance with the provisions of this subsection (c)(iii). Use of these parking spaces
        shall be on a first come/first served, non&#8209;exclusive, non&#8209;reserved basis.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">The parking rights set forth above shall be at no additional cost to Tenant or any of Tenant&#8217;s employees, guests or visitors. Tenant shall cause all employees, guests and visitors
      to not park in the portion of the Home Depot parking lot marked &#8220;No Building G Employee Parking Area&#8221; on the site plan attached hereto as <font style="font-weight: bold;"><u>Exhibit A&#8209;2</u></font>. Tenant&#8217;s employees shall be prohibited from parking
      in any surface parking areas in the Development and Tenant shall enforce this prohibition against its employees. Tenant&#8217;s employees shall be permitted to park in the parking garage located in the Building and on the lower level of the parking garage
      located within Building F and, but only to the extent specifically permitted by Landlord in writing, also either elsewhere within the parking garage located within Building F or in the parking garage located within Building B. Tenant&#8217;s guests and
      visitors will be required to park either in the garage facilities identified in the preceding sentence or in the area identified on the site plan attached hereto as <font style="font-weight: bold;"><u>Exhibit A&#8209;2</u></font> Tenant&#8217;s guests and
      visitors shall be prohibited from parking in any other surface parking areas in the Development and Tenant shall enforce this prohibition.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">In the event that at any time more than sixty percent (60%) of the rentable area of the Premises is used for a use other than Life Science Use (a &#8220;<font style="font-weight: bold;">Non&#8209;Life








        Science Use</font>&#8221;, which term shall include all support offices and conference rooms otherwise included in the definition of &#8220;Life Science Use&#8221; set forth above), without hereby implying that such use would be permitted under this Lease, Tenant&#8217;s
      parking rights with respect to such &#8220;Non&#8209;Life Science Use&#8221; shall be limited to one (1) parking space per 1,000 square feet of space in the Premises used for such &#8220;Non&#8209;Life Science Use&#8221; in excess of sixty percent (60%) of the rentable area of the
      Premises.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">Landlord shall have the right to enforce the aforesaid parking limitations by any lawful means.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">All parking spaces shall be used only by Tenant and Tenant&#8217;s employees and visitors for the
        parking of passenger vehicles only. At no time may Tenant, its employees and visitors use more parking spaces in the Development than the aggregate number set forth in Sections 2.2(c)(i) &#8211; (iii).</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">The provisions of this Lease, including the Rules and Regulations, shall apply to all
        parking facilities and parking spaces situated within the Development and Tenant&#8217;s use thereof. Landlord shall have the right to temporarily close portions of surface parking lots and parking facilities time to time for maintenance, repair or
        improvement, as necessary; provided that reasonable alternative parking is made available to Tenant to the extent of such closure.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(vi)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant&#8217;s rights under this Section may not be assigned, Subleased or otherwise transferred
        except in connection with a Transfer effected in accordance with the provisions of <u>Article 12</u> below. Neither Landlord nor any operator of the parking facilities shall be responsible for any loss or damage due to fire or theft or otherwise
        to any automobile parked in any parking lot or parking facilities within the Development or to any personal property therein.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Access to Common Areas</u>. Landlord covenants that throughout the Term of this Lease, Landlord shall
        enforce the applicable provisions of the Condominium Documents and Title Matters to provide Tenant with non&#8209;exclusive access to and use of the Common Areas of the Development provided pursuant to the Condominium Documents and Title Matters.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">2.03.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">C</font><font style="font-weight: bold; color: rgb(0, 0, 0);">hanges and Additions to
        Development</font>. Landlord, for itself and on behalf of the Primary Board and the Declarant, and the Declarant&#8217;s successors, assigns and transferees, hereby reserves the right at any time and from time to time to: (a) construct other buildings or
      improvements in the Development, make alterations thereof or additions thereto, build additional stories or levels on any such building (including the Building) or buildings adjoining same; (b) make changes or revisions in the Development and Common
      Areas, and convey portions of the Development, Primary Units, and Common Areas to others for any reason including for the purpose of constructing thereon other buildings or improvements, including additions thereto and alterations thereof
      notwithstanding that such activities to be undertaken may necessitate the alteration or rearrangement of all or portions of the Common Areas; and (c) exercise Development Rights and Special Declarant Rights (as defined in the Condominium Documents);
      provided that none of the foregoing shall materially interfere with the rights granted to Tenant hereunder (including the use of the Premises for the Permitted Use) or shall preclude access to the Premises from a public road or reduce the number of
      parking spaces below that which is required by Applicable Law (taking into consideration all permits, approvals and other relief applicable to the Development).</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 3: LEASE TERM</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.01.</font>&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Lease Term; Construction</font>. The Initial Term of this Lease is set
      forth in <u>Article 1</u>. The Base Building and the Premises shall be constructed as provided in the Work Letter (the &#8220;<font style="font-weight: bold;">Work Letter</font>&#8221;) attached hereto as <font style="font-weight: bold;"><u>Exhibit</u></font><u>&#160;</u><font style="font-weight: bold;"><u>C</u></font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">11</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <div>
        <div>
          <div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.02.</font><font class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160; </font><font style="font-weight: bold; color: rgb(0, 0, 0);">Hold Over</font>. If Tenant
              (or anyone claiming by, through or under Tenant) shall remain in occupancy of the Premises or any part thereof after the expiration or early termination of the Term without a written agreement therefor executed and delivered by Landlord, then
              without limiting Landlord&#8217;s other rights and remedies the person or entity remaining in possession shall be deemed a tenant at sufferance, and Tenant shall thereafter pay a monthly use and occupancy charge (pro&#8209;rated for such portion of any
              partial month as Tenant (or anyone claiming by, through or under Tenant) shall remain in possession) at a rate equal to (i) one hundred fifty (150%) percent of the monthly amount payable as Base Rent for the 12&#8209;month period immediately prior
              to such expiration or termination, plus (ii) one hundred (100%) percent of all Additional Rent also payable as provided in this Lease. No acceptance by Landlord of any payment by Tenant pursuant to this Section shall constitute Tenant (or
              anyone claiming by, through or under Tenant) as a tenant at will, but Tenant or such other person or entity shall remain a tenant at sufferance subject to all of the provisions of this Lease. If Landlord desires to regain possession of the
              Premises at any time Tenant (or anyone claiming by, through or under Tenant) is holding over, Landlord may, at its option, forthwith re&#8209;enter and take possession of the Premises or any part thereof by any lawful means. In any case, and
              notwithstanding the provisions of <u>Section 16.10(b)</u> to the contrary, Tenant shall be liable to Landlord for all claims, liabilities, damages (including indirect and consequential damages), losses or costs (including reasonable
              attorneys&#8217; fees and costs) resulting from any failure by Tenant (or anyone claiming by, through or under Tenant) to vacate the Premises or any portion thereof when required hereunder, and shall hold Landlord, its agents and employees,
              harmless and defend and indemnify Landlord, its agents and employees, from and against any and all claims, liabilities, damages (including indirect and consequential damages), losses, losses or costs (including reasonable attorneys&#8217; fees and
              costs) which Landlord may pay, incur or suffer on account of any such hold&#8209;over in the Premises after the expiration or earlier termination of the Term.</div>
            <div style="text-align: justify;"> <br>
            </div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">3.03.</font><font style="text-indent: 0px;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-weight: bold; color: rgb(0, 0, 0);">Right









                to Extend</font>.</div>
            <div style="text-align: justify;"> <br>
            </div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font><font style="text-indent: 0px;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color: rgb(0, 0, 0);"><u>Extension Term</u>. Provided that,
                as of both the time Tenant gives the Extension Notice (as defined below) and the first day of the Extension Term, (i) Tenant is not in default hereunder beyond all applicable notice and grace periods (if any), and (ii) the Tenant named in <u>Article








                  1</u> above (or a Related Party Transferee) has not assigned, Subleased, transferred or otherwise permitted the occupancy by third parties of more than twenty&#8209;five percent (25%) of the Premises, then Tenant may extend the Term of this
                Lease for the Extension Term stated in <u>Article 1</u> by giving unconditional written notice (an &#8220;<font style="font-weight: bold;">Extension Notice</font>&#8221;) to Landlord at least twelve (12) months but not more than eighteen (18) months
                before the end of the Initial Term, time being of the essence. The Extension Notice shall be sufficient to extend the Term for the Extension Term, subject to all of the terms of this Lease except for the change in Base Rent as set forth
                below, and no additional writing or further action by the parties shall be required for such purpose (but upon the request of either party, the parties shall promptly execute and deliver an amendment to this Lease reflecting such extension
                of the Term). If Tenant fails to give the Extension Notice in strict accordance with the provisions of this <u>Section 3.03(a)</u>, Tenant shall be deemed to have waived all rights to extend the Term of this Lease. All references in this
                Lease to the &#8220;Term&#8221; shall mean the Initial Term as it may be so extended by the Extension Term.</font></div>
            <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
              </font></div>
            <div style="clear: both; margin-top: 9pt; margin-bottom: 9pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">12</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
            </div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font><font style="text-indent: 0px;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160; &#160;&#160; </font><font style="color: rgb(0, 0, 0);"><u>Extension Term Base Rent</u>. Base
                Rent for the Extension Term(s) shall be the Fair Market Rent of the Premises (as defined below), but in no event shall the annual Base Rent as so determined be less than the amount of Base Rent payable by Tenant hereunder during the first
                Lease Year of the Initial Term. Fair market rent of the Premises (the &#8220;<font style="font-weight: bold;">Fair Market Rent</font>&#8221;) for the Extension Term shall be based upon leases or agreements to lease then being negotiated or executed
                with respect to comparable space located in the Development, or if no such leases or agreements to lease are then being negotiated or executed with respect to comparable space in the Development, the Fair Market Rent shall be determined by
                reference to leases or agreements to lease then being negotiated or executed with respect to comparable first&#8209;class laboratory/R&amp;D space in in comparable first&#8209;class lab buildings with walkable retail amenities in Watertown and other
                comparable inner suburban and suburban lab/R&amp;D markets (excluding Kendall Square, but including Allston/Brighton and West Cambridge). In determining Fair Market Rent, all relevant factors shall be taken into account, including size,
                location and age and condition of premises, lease term (including renewal options), tenant&#8217;s obligations with respect to operating expenses and taxes, tenant improvement allowances, other inducements then being offered by landlords,
                condition of building, and services and amenities provided by the landlord. Fair Market Rent shall include provisions for increases or other adjustments during the Extension Term for which such determination is being made.</font></div>
            <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
              </font></div>
            <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font><font style="text-indent: 0px;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color: rgb(0, 0, 0);"><u>Determination of Fair Market Rent</u>.
                Fair Market Rent shall be determined as follows: Landlord shall give Tenant written notice (&#8220;<font style="font-weight: bold;">Landlord&#8217;s Fair Market Rent Notice</font>&#8221;) of Landlord&#8217;s determination of Fair Market Rent for the Extension Term
                within thirty (30) days of Tenant&#8217;s giving to Landlord the Tenant&#8217;s Extension Notice. Tenant shall thereafter notify Landlord within thirty (30) days of Landlord&#8217;s giving to Tenant Landlord&#8217;s Fair Market Rent Notice of its agreement with or
                objection to Landlord&#8217;s determination of the Fair Market Rent, whereupon in the case of Tenant&#8217;s objection, Fair Market Rent shall be determined by arbitration conducted in the manner set forth below. If Tenant does not notify Landlord
                within such thirty (30) day period of Tenant&#8217;s agreement with or objection to Landlord&#8217;s determination of the Fair Market Rent, then the Fair Market Rent for the Extension Term shall be deemed to be Landlord&#8217;s determination of the Fair
                Market Rent as set forth in Landlord&#8217;s Fair Market Rent Notice to Tenant. If Tenant does notify Landlord within such thirty (30) day period of Tenant&#8217;s objection to Landlord&#8217;s determination of the Fair Market Rent, then within ten (10) days
                of Tenant&#8217;s giving such notice of objection to Landlord, each of Tenant and Landlord shall choose an MAI real estate appraiser or commercial real estate broker with at least ten (10) years of professional experience dealing with properties
                similar to the Development in the vicinity of the Development (each a &#8220;<font style="font-weight: bold;">Real Estate Professional</font>&#8221;) and notify the other party of the person so selected. The Real Estate Professionals so selected shall
                each determine and promptly report (in no event later than the thirtieth (30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day following the giving of the notice of appointment of the second Real Estate
                Professional) to both Landlord and Tenant in writing his or her determination of the Fair Market Rent. If the higher of the Fair Market Rents reported by the two Real Estate Professionals is no more than ten (10%) percent more than the
                lower rate, then the Fair Market Rent will be an average of such amounts. However, if the higher amount is more than one hundred ten (110%) percent of the lower amount, then within ten (10) days after receipt of both reports, Landlord and
                Tenant will jointly appoint a third Real Estate Professional meeting the aforesaid criteria, and the third Real Estate Professional will determine the Fair Market Rent by selecting either Landlord&#8217;s Fair Market Rent determination or
                Tenant&#8217;s Fair Market Rent determination according to whichever of the two valuations as set forth in the reports from Landlord&#8217;s Real Estate Professional or Tenant&#8217;s Real Estate Professional, respectively, is closer to the actual Fair
                Market Rent in the opinion of such third Real Estate Professional. The third Real Estate Professional shall have no discretion other than to select one of the determinations of Fair Market Rent made by the first two Real Estate
                Professionals as aforesaid. Landlord and Tenant shall each pay the fees and expenses of the Real Estate Professional that it appoints, and shall share equally the fees and expenses of the third Real Estate Professional.</font></div>
            <div style="text-align: justify;"><font style="color: rgb(0, 0, 0);"> <br>
              </font></div>
            <div style="clear: both; margin-top: 9pt; margin-bottom: 9pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">13</font></div>
              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
            </div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Rent Continuation</u>. For any part of the Extension Term for which the amount of Base Rent has not
              finally been determined, Tenant shall make payment on account of Base Rent at the rate last paid under this Lease, and the parties shall adjust for any overpayments or underpayments upon the final determination of Fair Market Rent. The
              failure by the parties to complete the processes contemplated under this <u>Section 3.03</u> prior to the commencement of the Extension Term shall not affect the continuation of the Term or the parties&#8217; obligation to make any adjustments for
              any overpayments or underpayments for the Base Rent due for the applicable period promptly after the determination thereof is made.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 4: RENT</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.01.</font>&#160;&#160;&#160; &#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Base Rent</font>. Commencing as of the Rent Commencement Date and
            continuing thereafter on the first day of each month during the Term, Tenant shall pay Landlord the monthly installment of Base Rent, in advance, without notice or demand.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.02.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Additional Rent.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>General</u>. &#8220;<font style="font-weight: bold;">Rent</font>&#8221; means, collectively, Base Rent and all
              other amounts payable by Tenant under this Lease other than Base Rent, including Tenant&#8217;s Percentage Share of Taxes and Tenant&#8217;s Percentage Share of Operating Expenses, regardless of whether or not such amount is expressly described as
              &#8220;Additional Rent&#8221; in this Lease (collectively, &#8220;<font style="font-weight: bold;">Additional Rent</font>&#8221;). Landlord shall reasonably estimate in advance (i) all Taxes under <u>Article 5</u> and (ii) all Operating Expenses under <u>Article 7</u>
              (the items in clauses (i) and (ii), collectively, being &#8220;<font style="font-weight: bold;">Operating Costs</font>&#8221;) and Tenant shall pay one&#8209;twelfth (1/12th) of Tenant&#8217;s Percentage Share of such reasonably estimated Operating Costs monthly in
              advance, commencing on the Rent Commencement Date and continuing thereafter on the first day of each calendar month (or portion thereof) included within the Term. Landlord may reasonably adjust its estimates of Operating Costs at any time
              (but not more than twice per year) based upon its experience and reasonable anticipation of costs. Such adjustments shall be effective as of the next Rent payment date occurring at least fifteen (15) days after written notice to Tenant.
              Within one hundred eighty (180) days after the end of each calendar year (or portion thereof) included within the Term, Landlord shall give Tenant a reasonably detailed statement (an &#8220;<font style="font-weight: bold;">Annual Operating
                Statement</font>&#8221;) of the Operating Costs paid or incurred by Landlord during the preceding calendar year (pro&#8209;rated for partial calendar years included within the Term) and Tenant&#8217;s Percentage Share of such expenses: <font style="font-style: italic;">provided, however,</font> that Landlord may bill Tenant for any items omitted or underbilled with respect to the calendar year in question for a period of time not to exceed one (1) year from the last day of such
              calendar year. Within thirty (30) days after Landlord&#8217;s delivery of an Annual Operating Statement to Tenant, Tenant shall pay Landlord any underpayment, or Landlord shall credit Tenant with any overpayment (which credit shall be applied to
              any Rent due under this Lease next coming due after the delivery of the Annual Operating Statement (or if the Term has ended, Landlord shall pay Tenant the amount of any overpayment as provided below)), of Tenant&#8217;s Percentage Share of such
              Operating Costs.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">14</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">If Tenant wishes to dispute the determination of the Operating Costs charged to Tenant under this Lease, Tenant may do so provided (i) Tenant shall give Landlord written notice of such dispute
            within one hundred twenty (120) days after its receipt of the Annual Operating Statement being disputed and (ii) Tenant shall pay any overpayment due based on the Annual Operating Statement as provided in the foregoing paragraph, pending
            resolution of the dispute. If Landlord provides a revised Annual Operating Statement within the one (1) year period described in the preceding grammatical paragraph in response to a previously omitted or underbilled item of Operating Costs,
            Tenant shall have the same one hundred twenty (120) day period from its receipt of such revised Annual Operating Statement within which to give Landlord written notice that it disputes one or more of the revised items contained in such revised
            Annual Operating Statement (which shall be the only items then subject to dispute by Tenant). Promptly after the giving of such notice in either such case. Landlord shall allow Tenant&#8217;s representatives to examine and audit in Landlord&#8217;s offices
            (or the office of its managing agent) Landlord&#8217;s books and records with respect to the subject matter of the dispute, which review or audit shall be completed within ninety (90) days after Tenant gave such notice of dispute. Tenant agrees that
            the party selected by Tenant to perform such review or audit shall be compensated on the basis of hourly fees and not on a contingency or percentage basis. Tenant agrees to keep the results of any such review or audit conducted by Tenant
            confidential except for disclosures to its employees, attorneys, consultants, accountants and owners and except to the extent required to enforce Tenant&#8217;s rights hereunder. The cost of such audit shall be borne by Tenant; provided, however, in
            the event it is finally determined (by mutual agreement or other resolution of such dispute) that Tenant was overcharged by more than five percent (5%) for the immediately preceding calendar year, then, in such event, Landlord shall pay for
            Tenant&#8217;s reasonable out&#8209;of&#8209;pocket cost for the audit. If it is finally determined (by mutual agreement or other resolution of such dispute) that Landlord&#8217;s determination of any of the Operating Cost is (i) overstated, or (ii) understated, then
            in the case of (i) Landlord shall credit the difference against monthly installments of Rent next thereafter coming due (or refund the difference if the Term has ended and Tenant has no further obligation to Landlord), or in the case of (ii)
            Tenant shall pay to Landlord the amount of such excess. Landlord&#8217;s obligation under this paragraph shall survive the expiration of the Term or earlier termination of this Lease.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">If the Term expires or the Lease is terminated as of a date other than the last day of a calendar year, Tenant&#8217;s payment of Additional Rent pursuant to this Section for such partial calendar
            year shall be based on Landlord&#8217;s good faith estimate of the items otherwise includable in Operating Costs. Tenant&#8217;s payment of Additional Rent shall be made on or before ten (10) Business Days after Landlord delivers such estimate to Tenant,
            with an appropriate payment or refund to be made upon Tenant&#8217;s later receipt of Landlord&#8217;s Annual Operating Statement for such calendar year. This Section shall survive the expiration or earlier termination of the Term.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">This Lease requires Tenant to pay directly to suppliers, vendors, carriers, contractors, and other parties certain utility costs, personal property taxes, maintenance and repair costs and other
            expenses. If Tenant fails to make any such payments when due and Landlord thereafter receives notice of such failure on the part of Tenant, Landlord shall have the right (but no obligation) to do so on its behalf, and if Landlord so pays any of
            these amounts in accordance with this Lease, Tenant shall reimburse such costs in full, together with interest thereon at the Default Rate, to Landlord, as Additional Rent, within ten (10) Business Days of Landlord&#8217;s written demand.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">15</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">If, during any period for which Landlord&#8217;s Operating Costs are being computed, less than ninety&#8209;five
              (95%) percent of the rentable area of the Unit was leased and occupied by tenants, Operating Costs that are allocable to the entire Unit or the portion thereof in question and which vary by level of occupancy shall be reasonably estimated and
              extrapolated by Landlord to determine the Operating Costs that would have been incurred if the Unit or such portion in question were ninety&#8209;five (95%) leased and occupied by tenants for such year and such services were being supplied to all
              tenants, and such estimated and extrapolated amount shall be deemed to be the Operating Costs for such period: <font style="font-style: italic;">provided, however, </font>that Landlord shall not collect from Tenant and other tenants in the
              Unit in the aggregate more than one hundred (100%) percent of Operating Costs actually incurred by Landlord.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">Unless otherwise provided in this Lease, payments of Additional Rent other than recurring payments such
              as monthly payments of estimated Operating Costs, shall be due and payable within thirty (30) days after invoicing by Landlord.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.03.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Late Charge</font>. Tenant acknowledges that if it pays Rent late,
            Landlord will incur unanticipated costs which will be extremely difficult to ascertain exactly. Such costs include processing and accounting charges, and late charges that may be imposed on Landlord under a mortgage on the Unit, the Building or
            the Development. Accordingly, if Landlord does not receive any such payment within five (5) days following its due date, Tenant shall pay Landlord a late charge equal to [***] percent of the overdue amount as an administrative charge. The
            parties agree that this late charge represents a fair and reasonable estimate of the costs Landlord shall incur by reason of Tenant&#8217;s payment default. Payment of the late charge shall not cure Tenant&#8217;s payment default or prevent Landlord from
            exercising any other rights and remedies.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.04.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Interest</font>. Any late Rent payment shall bear interest from
            the date due (without regard to the 5&#8209;day grace period provided in <u>Section 4.03</u>) until paid at a rate equal to [***] per annum (the &#8220;<font style="font-weight: bold;">Default Rate</font>&#8221;), except to the extent such interest would cause
            the total interest to be in excess of that legally permitted (and then interest will be at the maximum rate legally permitted). The &#8220;<font style="font-weight: bold;">Prime Rate</font>&#8221; shall mean the prime lending rate per annum published in <u>The








              Wall Street Journal</u> from time to time, and the Default Rate shall be adjusted effective upon each change in the Prime Rate. Payment of interest shall not cure Tenant&#8217;s payment default or prevent Landlord from exercising any other rights
            and remedies.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">4.05.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Method of Payment</font>. Tenant shall make a pro rata payment of
            Base Rent and Additional Rent for any period of less than a month at the beginning or end of the Term. All payments of Base Rent, Additional Rent and other sums due shall be paid in current U.S. exchange by electronic transfer to an account
            designated from time to time by Landlord, in each case without demand, abatement, set&#8209;off or other deduction.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">Without limiting the foregoing, except as expressly otherwise set forth in this Lease, Tenant&#8217;s obligation so to pay Rent shall be absolute, unconditional, and independent and shall not be
            discharged or otherwise affected by any Legal Requirement now or hereafter applicable to the Premises, or any other restriction on Tenant&#8217;s use, or any Force Majeure, casualty or taking, or any failure by Landlord to perform, or any other
            occurrence.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">It is intended that Base Rent payable hereunder shall be a net return to Landlord throughout the Term, free of expense, charge, offset, diminution or other deduction whatsoever on account of
            the Premises (excepting Landlord&#8217;s financing expenses, federal and state income taxes of general application, and those expenses that this Lease expressly makes the responsibility of Landlord), and all provisions hereof shall be construed in
            terms of such intent.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">16</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 5: TAXES</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.01.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Definition of &#8220;Taxes&#8221;</font>. &#8220;<font style="font-weight: bold;">Taxes</font>&#8221;
            shall mean all taxes, assessments, betterments, excises, user fees imposed by governmental authorities, and all other governmental charges and fees of any kind or nature, or impositions or agreed payments in lieu thereof, or voluntary payments
            made in connection with the provision of governmental services or improvements of benefit to the Building, the Unit or the Development (including any so&#8209;called linkage, impact or voluntary betterment payments), assessed or imposed against the
            Land, the Building or any other buildings or improvements in the Development, and any Units, General Common Elements or Limited Common Elements (including any personal property taxes levied on personal property or fixtures or equipment (other
            than that owned by tenants) used in connection therewith). Furthermore, notwithstanding anything to the contrary herein, Taxes shall exclude (a) any interest, fines and/or penalties for late payments to the extent relating to a period in which
            Tenant was not in default (beyond any applicable notice and cure periods) of its obligations to pay Base Rent, Tenant&#8217;s Percentage Share of Operating Costs or other payments under this Lease, and (b) federal, state or local income or profit
            taxes, franchise, rental, capital, inheritance, estate, conveyance, transfer, gift, or corporate excise taxes or levies. The amount of any special taxes, special assessments, and agreed or governmentally imposed &#8220;in lieu of tax&#8221; or similar
            charges, shall be included in Taxes for any year but shall be limited to the amount of the installment (plus any interest, other than penalty interest, payable thereon) of such special tax, special assessment or such charge required to be paid
            during or with respect to the year in question. Betterments and assessments, whether or not paid in installments, shall be included in Taxes in any tax year as if the betterment or assessment were paid in installments over the longest period
            permitted by law, together with the interest thereon charged by the assessing authority for the payment of such betterment or assessment in installments.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">Notwithstanding the foregoing, if during the Term the present system of ad valorem taxation of property shall be changed so that, in lieu of or in addition to the whole or any part of such ad
            valorem tax there shall be assessed, levied or imposed on the Premises, the Unit, the Building or the Development, or on Landlord, any kind or nature of federal, state, county, municipal or other governmental capital levy, income, sales,
            franchise, excise or similar tax, assessment, charge or fee (as distinct from the federal and state income tax in effect on the Date of Lease) measured by or based in whole or in part upon valuation of the Premises, the Unit, the Building or
            the Development, or mortgage valuation, rents, services or any other incidents, benefits or measures of real property or real property operations, then any and all of such taxes, assessments, levies, charges and fees shall be included within
            the term &#8220;Taxes&#8221;, but only to the extent that the same would be payable if the Development were the only property of Landlord. Taxes shall also include reasonable out&#8209;of&#8209;pocket expenses, including reasonable fees of attorneys, appraisers and
            other consultants, incurred in connection with any efforts to obtain abatements or reduction of Taxes for any year wholly or partially included in the Term, whether or not successful and whether or not such efforts involved filing of actual
            abatement applications or initiation of formal proceedings.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">17</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.02.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Method of Payment of Taxes</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">Commencing as of the Rent Commencement Date and continuing thereafter throughout the Term of this
              Lease, Tenant covenants and agrees to pay to Landlord as Additional Rent, for each Tax Year, or ratable portion thereof, included in the Term, Tenant&#8217;s Percentage Share of all Taxes payable with respect to the Unit and any applicable Limited
              Common Elements (as defined in the Condominium Documents) assigned or allocated to the Unit pursuant to the Condominium Documents. As used in this Lease:</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt;">&#8220;<font style="font-weight: bold;"><u>Tenant&#8217;s Percentage Share</u></font>&#8221; shall mean the percentage computed by Landlord from time to time by dividing the gross rentable area of the Premises
            by the total gross rentable area of the Unit, as both are reasonably computed by Landlord, and in the event that either the gross rentable area of the Premises or the total gross rentable area of the Unit is changed, Tenant&#8217;s Percentage Share
            will be appropriately adjusted and, as to the Tax Year in which such change occurs, Tenant&#8217;s Percentage Share shall be determined on the basis of the number of days during such Tax Year at each such percentage, in the event Tenant leases all of
            the Unit the Tenant&#8217;s Percentage Share shall be one hundred percent (100%). The initial determination of Tenant&#8217;s Percentage Share is set forth in <u>Article 1</u> hereof.</div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt;">&#8220;<font style="font-weight: bold;"><u>Tax Year</u></font>&#8221; means each twelve (12) month period (deemed, for the purposes of this Section, to have 365 days) during the Term established as the
            real estate Tax Year by the taxing authorities having lawful jurisdiction over the Development.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">If Landlord receives a refund of any such Taxes, Landlord shall pay to Tenant Tenant&#8217;s Percentage Share of the refund after deducting Landlord&#8217;s reasonable out&#8209;of&#8209;pocket costs and expenses
            incurred in obtaining the refund, to the extent such costs and expenses were not previously included in, and actually paid as, Taxes pursuant to this <u>Section 5.02</u>. Tenant shall make estimated payments on account of Taxes in monthly
            installments on the first day of each month, in amounts estimated from time to time by Landlord pursuant to <u>Section 4.02(a)</u>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">In addition, in the event that the taxing authority now or hereafter separately assesses parking
              spaces (or Landlord is reasonably able to determine the portion of an assessment made against a unit that is attributable to the parking made available to such unit) or any land or improvements used for parking, including surface parking and
              parking situated within a building or other structure (the &#8220;<font style="font-weight: bold;"><u>Development Parking</u></font>&#8221;), and regardless of whether such Development Parking constitutes a condominium unit or General Common Element (but
              excluding any Development Parking that is now or hereafter designated under the Condominium Documents as a Limited Common Element or otherwise for the exclusive use of a particular unit or units), then Tenant shall also pay its pro rata share
              of such Taxes (hereinafter referred to as &#8220;<font style="font-weight: bold;"><u>Separately Assessed Parking Taxes</u></font>&#8221;). The Separately Assessed Parking Taxes shall not include Taxes assessed on or attributable to (as determined by
              Landlord) any Development Parking which is a Limited Common Element or otherwise designated for the exclusive use of a particular unit or units. Tenant&#8217;s pro rata share of Separately Assessed Parking Taxes shall be determined by multiplying
              the Separately Assessed Parking Taxes by a fraction, the numerator of which is the total number of parking spaces allocated to Tenant pursuant to <u>Section 2.02(c)</u> and the denominator of which is the total number of parking spaces in
              the Development used for office, laboratory/R&amp;D, retail, restaurant, residential, hotel, service or other uses typically found in mixed&#8209;use developments, but only to the extent such parking spaces are not separately assessed to other
              units.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">18</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Notwithstanding the foregoing or anything contained in this Lease to the contrary, in the event that
              the Town of Watertown and any other applicable taxing authorities do not initially separately assess the Unit as a condominium unit for taxation purposes, then, until such time as the Unit is so assessed as a separate taxable condominium
              unit, the term &#8220;<font style="font-weight: bold;"><u>Taxes</u></font>&#8221; shall mean all real estate taxes and other ad valorem taxes (including betterment and special assessments) assessed against and payable with respect to the Development
              (including all land, buildings, parking and improvements related thereto) and Tenant shall pay its pro rata share thereof (determined by multiplying such Taxes by a fraction, the numerator of which is the total gross rentable floor area of
              the Premises, and the denominator of which is the total gross rentable floor area of all non&#8209;residential buildings located in the Development, or by such other reasonable allocation that forms the basis of the valuation prepared by the taxing
              authority). In addition, in the event that at any time the Town of Watertown separately assesses any of the Condominium Common Areas as a taxable parcel, &#8220;Taxes&#8221; shall include all real estate taxes and other ad valorem taxes (including
              betterment and special assessments) assessed against and payable with respect thereto (including all land, buildings, parking and improvements related thereto) and Tenant shall pay its pro rata share thereof, calculated in the manner provided
              in the immediately preceding sentence.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">5.03.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Personal Property Taxes</font>. Tenant shall pay directly all
            taxes (if any) charged against Tenant&#8217;s Property (as defined in <u>Section 10.06</u>). Tenant shall use commercially reasonable efforts to have Tenant&#8217;s Property taxed separately from the Unit. Landlord shall notify Tenant if any of Tenant&#8217;s
            Property is taxed with the Unit, and Tenant shall pay such taxes to Landlord within thirty (30) days of such written notice.</div>
          <div><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 6: BUILDING SERVICES AND SPECIAL BUILDING FACILITIES</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.01.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Utility Services</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant shall make all arrangements for, and shall provide and pay all charges and deposits required by
              the provider for, water, sewer, gas, boiler water, electricity, telephone and any other utilities or services used or consumed on the Premises (collectively, &#8220;<font style="font-weight: bold;">Utility Services</font>&#8221;), whether called use
              charge, tax assessment, fee, or otherwise, as the same become due. Tenant shall reimburse Landlord, as Additional Rent, for the cost of installation of any additional metering of the Premises (which was not installed as part of the Base
              Building Work) for the purpose of measuring Tenant&#8217;s consumption of Utility Services, as well as the cost of installing (at any time prior to or during the Term) and maintaining any &#8220;check&#8221; or &#8220;sub&#8221; meters, within thirty (30) days after
              invoicing by Landlord. In addition, if Landlord shall install, at Tenant&#8217;s request, meters for any Utility Services requested by Tenant, Tenant shall reimburse Landlord, as Additional Rent, for the reasonable cost of installing such meters
              (and thereafter, for maintaining the same) within thirty (30) days after invoicing by Landlord.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">19</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">As part of the Base Building Work, Landlord will (i) install BTU meters to measure the aggregate Common
              Area usage in the Building and Tenant&#8217;s consumption of hot water, chilled water and condenser water. In accordance with the provisions of the Work Letter attached hereto as <font style="font-weight: bold;"><u>Exhibit C</u></font>, Tenant
              shall, at its own cost and expense, install BTU meters on all Building hot water, chilled water and condenser water service to the Premises to measure Tenant&#8217;s usage thereof, and any meters installed as part of such work shall be compatible
              with the Unit equipment and the Unit Building Management System (BMS)); (ii) provide space for a Tenant meter on the utility gas manifold so that Tenant can install (at its sole cost and expense) any gas service necessary to service the
              exclusive needs of Tenant&#8217;s Premises; and (iii) provide a connection to the Building potable and non&#8209;potable water services to the Premises. Tenant shall provide and install water meters at this connection with remote readers to record
              Tenant&#8217;s use of potable and non&#8209;potable domestic water within the Premises. Tenant shall install, as part of its electrical service switchgear, a CT cabinet with an electrical usage meter as required by the Utility Service Provider. If the
              Utility Service Provider will not allow individual direct metering for Tenant&#8217;s service, this meter shall be used to measure Tenant&#8217;s direct usage of electricity within the Premises, (including the electricity consumed in providing HVAC
              service to the Premises), for which Tenant shall reimburse Landlord at the direct billing rates charged to Landlord by the Utility Service Provider. Landlord shall bill Tenant monthly for such electrical consumption and water consumption as a
              recurring charge at no mark&#8209;up, and Tenant shall pay each such invoice, as Additional Rent, within thirty (30) days after receipt of an invoice therefor. All costs, charges and expenses associated with the commencement of the provision by a
              particular Utility Service Provider to Tenant or to the Premises at the request of Tenant (e.g., installation charges, service deposits) shall be the sole responsibility of Tenant.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant shall timely pay all costs and expenses associated with any directly and separately metered
              utilities provided exclusively to the Premises directly to the applicable service provider. Tenant shall pay all costs and expenses associated with utility charges that are based on sub&#8209;metering or check metering directly to Landlord, without
              mark&#8209;up by Landlord on account of Landlord&#8217;s administration of such charges, within thirty (30) days of invoice therefor by Landlord. With respect to any Utility Services that are not either separately metered or measured by a check meter or
              submeter (including HVAC service provided to any portion of the Premises by means of the Building HVAC system rather than HVAC units serving solely the Premises), Tenant shall pay the cost of the same as part of Operating Costs payable
              hereunder. Tenant may, no more than once per calendar year, conduct an engineering survey at its sole cost and expense to determine whether the submeters and/or check meters are accurately measuring the particular services to be measured
              thereby and, if Tenant discovers any metering inaccuracies as a result of such survey and such inaccuracies result in an error in the amount billed to Tenant, Landlord shall promptly refund the overpayment within ten (10) Business Days after
              receipt of notice from Tenant of such inaccuracy. If requested by Landlord, Tenant and the persons conducting the engineering survey for Tenant shall enter into a reasonable confidentiality agreement prior to inspecting such meters, which
              shall permit Tenant to disclose the results of such survey to the extent required to enforce its rights hereunder. If the survey shows any errors resulting in any underpayment for such services, Tenant shall reimburse Landlord for Tenant&#8217;s
              share of such underpayment, as Additional Rent, within ten (10) Business Days of demand. In no event shall Tenant engage any person in connection with such engineering survey whose fees or costs are payable, in whole or part or directly or
              indirectly, in a contingent manner or by means of any commission depending on the survey outcome. Any dispute regarding amounts due, or accuracy of the meters, under this paragraph shall be resolved in accordance with <u>Section 16.17</u> of
              this Lease at the request of Landlord or Tenant, which request shall be made with respect to disputes regarding amounts due, no later than one hundred eighty (180) days after Tenant receives Landlord&#8217;s Annual Operating Statement for the
              fiscal year in question (any bill not disputed within such one hundred eighty (180) day period shall be deemed final and conclusive). Landlord shall not be liable for any interruption or failure in the supply of any utilities or Utility
              Services.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">20</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">To the maximum extent permitted by law, Landlord shall have the right at any time and from time to time
              during the Term to contract for or purchase one or more Utility Services from any company or third party providing Utility Services (&#8220;<font style="font-weight: bold;">Utility Service Provider</font>&#8221;) to the Building, provided that the rates
              charged by such Utility Service Provider are competitive with the current market rates. Subject to <u>Section 9.06</u>, Tenant agrees reasonably to cooperate with Landlord and such Utility Service Providers and at all times as reasonably
              necessary, and on reasonable advance notice (except in the event of emergency), shall allow Landlord and the Utility Service Providers reasonable access to any utility lines, equipment, feeders, risers, ducts, shafts, fixtures, wiring and any
              other such machinery or personal property within the Premises and associated with the delivery of Utility Services.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Except for the Initial Tenant Work and the equipment and appliances being installed in connection
              therewith, Tenant agrees that it will not make any material alteration or material addition to the electrical equipment and/or appliances in the Premises which would require increased electrical service to the Premises or modifications to the
              structure of the Unit or the Building, without the prior written consent of Landlord in each instance, which consent will not be unreasonably withheld, conditioned or delayed, and using contractor(s) reasonably approved by Landlord, and will
              promptly advise Landlord of any other alteration or addition to such electrical equipment and/or appliances (as to which Landlord&#8217;s prior written consent shall not be required). Landlord agrees to respond to any request for approval made by
              Tenant pursuant to this subsection (c) within ten (10) Business Days after its receipt of such request.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.02.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Building Services and Building Systems</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">In addition to the services described in <u>Section 6.01</u>, Landlord shall provide the following
              services to common areas within the Unit, the costs of which are included within Operating Expenses:</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;"><font style="color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="color: rgb(0, 0, 0);">Janitorial services for the Unit common areas as described in <font style="font-weight: bold;"><u>Exhibit








                  E</u></font> attached hereto.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)</font>&#160;&#160; &#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Unit entry security consistent with similar &#8220;first&#8209;class&#8221; laboratory and R&amp;D
              buildings in the vicinity of the Unit as described in <font style="font-weight: bold;"><u>Exhibit E</u></font> attached hereto.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160; &#160; &#160; <font style="color: rgb(0, 0, 0);">Landlord shall arrange for and provide (as defined below) to the common areas of
              the Unit those services as set forth in <font style="font-weight: bold;"><u>Exhibit E</u></font> attached hereto.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(iv)</font>&#160;&#160; &#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Landlord shall provide HVAC service to the common areas of the Unit by means of the
              Unit mechanical system, during Normal Business Hours, at such temperatures and in such amounts as are reasonably deemed by Landlord to be in keeping with the first&#8209;class standards of the Unit.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">Landlord shall provide for the maintenance and repair of HVAC systems that are
              common to all tenants of the Unit.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(vi)</font>&#160;&#160; &#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Landlord shall provide for the maintenance and repair of the emergency backup
              electrical systems that are common to all tenants of the Unit.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">21</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; margin-left: 36pt; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(vii)</font>&#160;&#160; &#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Landlord shall provide for the servicing, maintenance and repair of the
              Neutralization System that is common to tenants of the Unit.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">Tenant acknowledges that Landlord has not made any warranty or representation to Tenant as to the efficacy of the security services that Landlord is required to provide under this Lease.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant shall, at its sole cost and expense, provide janitorial services to the Premises on each
              Business Day during the Term. In addition, Tenant shall arrange for the removal and disposal of its lab&#8209;related refuse by a licensed vendor, all at Tenant&#8217;s sole cost and expense, such removal and disposal to be accomplished in accordance
              with all applicable Legal Requirements.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">Landlord shall provide ventilation to the Premises through the Building mechanical system on a 24/7
              basis (the cost of which shall be included in Operating Expenses). Tenant shall have the ability to control the provision of heat, ventilation or air conditioning to the portions of the Premises served by the Building mechanical systems (as
              opposed to being provided by means of any HVAC equipment or system installed by or on behalf of Tenant and serving only the Premises). The electricity and natural gas consumed in providing HVAC services to the Premises through the Building
              mechanical system shall be measured by a submeter and charged back to Tenant by Landlord at Landlord&#8217;s actual cost, without mark&#8209;up. The chilled water, hot water and/or condenser water consumed in providing HVAC services to the Premises
              through the Building mechanical system shall be metered to Tenant. Landlord shall bill Tenant monthly for such electrical and natural gas consumption and water consumption as a recurring charge, and Tenant shall pay each such invoice, as
              Additional Rent, within thirty (30) days after receipt of an invoice therefor. Tenant agrees to cooperate fully with Landlord with regard to, and to abide by all the reasonable regulations and requirements which Landlord may prescribe for,
              the proper functioning and protection of the air conditioning system of general applicability to all occupants of the Building and provided such regulations and requirements are provided in writing to Tenant thirty (30) days in advance and
              the same do not materially interfere with Tenant&#8217;s use of the Premises for the Permitted Use.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">If Tenant desires HVAC service to a common area of the Building outside of Normal Business Hours,
              Landlord will use reasonable efforts, upon not less than twenty&#8209;four (24) hours&#8217; prior written notice from Tenant of its requirements in that regard, to furnish additional heat or air conditioning services to such common area during such
              requested times. Tenant will pay to Landlord Landlord&#8217;s hourly charge, as the same may be adjusted from time to time by Landlord, for any such additional heat or air conditioning service required by Tenant.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">Excluding any equipment to be installed as part of the Initial Tenant Work, in the event Tenant requires additional air conditioning for equipment or other special purposes, or because of
            occupancy or excess electrical loads, such additional air conditioning equipment shall be installed within the Tenant&#8217;s Premises and connected via Tenant&#8217;s BTU usage meters to the supplemental condenser water system installed as part of the
            Base Building Work, but only if, in Landlord&#8217;s reasonable judgment, the same will not cause damage or injury to the Building or any Building System, or exceed Tenant&#8217;s allocated pro&#8209;rata share of available condenser water capacity, or create a
            dangerous or hazardous condition.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">22</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Pursuant to <u>Section 10.03</u>, Landlord shall repair, maintain in good condition and order, and
              replace all Building Systems, including the HVAC, plumbing, electrical, mechanical and other systems, to the extent to which the same were installed as part of the Base Building Work, subject to casualty, condemnation and matters described in
              Section <u>16.09</u>, the cost of which shall be included in Operating Expenses to the extent provided in <u>Section 7.01</u>. Tenant shall be solely responsible, at its sole cost and expense, for repairing, maintaining and replacing all
              equipment which services solely the Premises, whether the same were initially installed by Landlord or Tenant, and whether the same were installed prior to the Rent Commencement Date or thereafter, except to the extent the need for such
              repair results from Landlord&#8217;s negligence or willful misconduct or the negligence or willful misconduct of its agents, employees and/or contractors. In no event shall Landlord be liable for any interruption or delay in providing any of the
              services described in this Section or in <font style="font-weight: bold;"><u>Exhibit E</u></font> attached hereto by reason of any accident, the making of repairs, alterations or improvements, labor difficulties, trouble in obtaining fuel,
              electricity, service or supplies from the sources from which they are usually obtained for the Unit, governmental restraints, or any cause beyond Landlord&#8217;s control.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Notwithstanding anything to the contrary contained in this <u>Article 6</u> or elsewhere in this
              Lease, Landlord may institute, and Tenant shall comply with, such policies, programs and measures as may reasonably be necessary, required, or expedient for the conservation and/or preservation of energy or energy services, or as may be
              necessary or required to comply with applicable Legal Requirements.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant acknowledges that the power identified in the Tenant/Landlord Matrix of Responsibility attached
              as <font style="font-weight: bold;"><u>Exhibit C&#8209;3</u></font> to this Lease will be adequate to supply its proposed permitted uses of the Premises. If, however, Tenant subsequently determines that it will require electric current for use in
              the Premises in excess of the quantity which, in Landlord&#8217;s reasonable judgment, Landlord&#8217;s facilities are capable of providing, then Landlord, upon written request and at the sole cost and expense of Tenant, will furnish and install such
              additional wire, conduits, feeders, switchboards and appurtenances as reasonably may be required to supply such additional requirements of Tenant if current therefor be available to Landlord, provided that the same shall be permitted by
              applicable Legal Requirements and Insurance Requirements, and shall not cause damage to the Unit or the Building or the Premises or cause or create a dangerous or hazardous condition or entail excessive or unreasonable alterations or repairs.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(h)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant shall have the right to install, at its sole cost and expense, a security system for its
              Premises provided that (i) such security system is compatible with any security system installed by Landlord with respect to the Unit or the Building as a whole, (ii) Tenant shall provide Landlord with access cards, keys or codes as required
              to gain entry into all parts of the Premises, subject to the provisions of <u>Section 9.06</u>, and (iii) upon request by Landlord (in its sole discretion), Tenant shall remove all components of such security system upon the expiration or
              earlier termination of the term of this Lease and repair to Landlord&#8217;s reasonable satisfaction all damage caused by such removal.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">For the Term of this Lease, Landlord shall contract for the provision of scheduled shuttle private bus
              service or other vehicular transportation for employees of Tenant and other tenants at the Development to and from the Development and the Harvard Square MBTA Red Line Station, as more particularly provided in <font style="font-weight: bold;"><u>Exhibit F</u></font> attached hereto.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">23</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">6.03.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Service Interruptions</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">When necessary by reason of accident or emergency, or upon not less than three (3) Business Days&#8217;
              prior written notice (which may be by e&#8209;mail) to Tenant for repairs, alterations, replacements or improvements which in the reasonable judgment of Landlord are desirable or necessary to be made, or by reason of event(s) of Force Majeure,
              Landlord reserves the right to interrupt, curtail, stop or suspend (i) the furnishing of heating, elevator, air conditioning, and cleaning services and (ii) the operation of the plumbing and electric systems. Landlord shall exercise
              reasonable diligence to eliminate the cause of any such interruption, curtailment, stoppage or suspension, but there shall be no diminution or abatement of rent or other compensation due from Landlord to Tenant hereunder, nor shall this Lease
              be affected or any of the Tenant&#8217;s obligations hereunder reduced, and Landlord shall have no responsibility or liability for any such interruption, curtailment, stoppage, or suspension of services or systems, except as provided herein.
              Landlord shall schedule all non&#8209;emergency interruptions, curtailments, stops or suspensions of services or systems in advance and shall notify Tenant thereof. In exercising its rights under this <u>Section 6.03</u>, Landlord shall make a
              commercially reasonable effort not to unreasonably interfere with Tenant&#8217;s use of the Premises for the Permitted Use.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Notwithstanding the foregoing, Tenant shall be entitled to a proportionate abatement of Base Rent in
              the event of a &#8220;Landlord Service Interruption&#8221; (as defined below). For the purposes hereof, a &#8220;<font style="font-weight: bold;">Landlord Service Interruption</font>&#8221; shall occur in the event (i) the Premises shall lack any service which
              Landlord is required to provide hereunder thereby rendering at least fifty (50%) percent of the usable area of the laboratory portion of the Premises unusable for the Permitted Use for the entirety of the Landlord Service Interruption Cure
              Period (as defined below), (ii) such lack of service was not caused by the act or omission of Tenant or any Tenant Party; (iii) Tenant, in fact, ceases to use at least fifty (50%) percent of the usable area of the laboratory portion of the
              Premises for the entirety of the Landlord Service Interruption Cure Period; and (iv) such interruption of service was the result of causes, events or circumstances within the Landlord&#8217;s reasonable control and the cure of such interruption is
              within Landlord&#8217;s reasonable control. During such Landlord Service Interruption Period, Landlord will, if reasonably practical, cooperate with Tenant to arrange for the provision of any interrupted services on an interim basis via temporary
              measures until final corrective measures can be accomplished and Tenant will permit Landlord the necessary access to the Premises to remedy such lack of service, subject to the provisions of <u>Section 9.06</u>. For the purposes hereof, the
              &#8220;<font style="font-weight: bold;">Landlord Service Interruption Cure Period</font>&#8221; shall be defined as seven (7) consecutive Business Days after Landlord&#8217;s receipt of written notice from Tenant of the Landlord Service Interruption. This <u>Section







                6.03(b)</u> shall be Tenant&#8217;s sole and exclusive remedy on account of an interruption of services or Landlord default resulting in an interruption of services other than Tenant&#8217;s right to obtain affirmative injunctive relief. This <u>Section







                6.03(b)</u> shall not apply to any interruption or failure of services required to be provided by Landlord under <u>Section 6.02(a)</u> or <font style="font-weight: bold;"><u>Exhibit E</u></font> attached hereto, which is caused in whole
              or in part by any act or omission of Tenant or any Tenant Party, or by any occurrence described in <u>Section 16.09</u>, or by any cause whatsoever other than those set forth in the first sentence of this <u>Section 6.03(b)</u>.
              Notwithstanding the foregoing, if either Landlord or Tenant disputes in good faith whether, or the extent to which, an event is subject to the provisions of this <u>Section 6.03(b)</u>, or the amount of Tenant&#8217;s abatement of Base Rent
              hereunder, such dispute shall be resolved in accordance with <u>Section 16.17</u> of this Lease; <font style="font-style: italic;">provided, however,</font> that in the event that it is ultimately determined that there was a Landlord
              Service Interruption, then Tenant shall have the right to a retroactive equitable abatement of Base Rent for the period as set forth above, provided that, if the Term expires before Tenant&#8217;s entire retroactive abatement has been effected,
              then Landlord shall immediately refund to Tenant any overpayment of Rent due under the Lease not yet received on account of the retroactive abatement.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">24</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 7: OPERATING EXPENSES</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">7.01.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Operating Expenses</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">&#8220;<font style="font-weight: bold;">Operating Expenses</font>&#8221; shall mean all costs and expenses of
              whatever nature associated with the ownership, operation, management, cleaning, maintenance or repair of the Unit, and of all Building Systems, together with all General Common Assessments (as defined in the Primary Condominium Master Deed)
              under the Primary Condominium Master Deed, and all special assessments under the Primary Condominium Master Deed, if any, all as described in the Condominium Documents and allocated to the Unit under the Condominium Documents or otherwise
              reasonably allocated to the Unit by Landlord. Operating Expenses include the costs and expenses incurred in connection with the following (subject to the limitations and exclusions set forth in this <u>Section 7.01</u>): compliance with
              Landlord&#8217;s obligations under <u>Sections 6.01</u>, <u>6.02</u>, <u>9.13</u> and <u>10.03</u>; Common Area charges of the Condominium; amenity expenses; utility, water and sewage services (in each case to the extent not metered to and
              payable by specific tenants of the Unit); maintenance of signs (excluding maintenance of tenant&#8209;specific signage which is charged to those tenants); supplies, materials and equipment purchased or rented; total wage and salary costs paid to,
              and all contract payments made on account of, all persons engaged in the management, operation, maintenance, security, cleaning and repair of the Unit or the Building or the Development including and below the level of property manager
              (including any parking management for tenant parking requirements), including Social Security, old age and unemployment taxes and so&#8209;called &#8220;fringe benefits&#8221;; services generally furnished to tenants of the Unit; maintenance, repair and
              replacement of Unit equipment and components; utilities consumed and expenses incurred in the operation, maintenance and repair of the Unit; costs incurred by Landlord to comply with the terms and conditions of any governmental approvals
              affecting operations at the Unit, the Building or the Development; workers&#8217; compensation insurance and property, liability and other insurance premiums; personal property taxes; rental or lease payments paid by Landlord for rented or leased
              personal property used in the operation or maintenance of the Unit (provided that any such payments made to Affiliates of Landlord shall not exceed the amount otherwise payable in an arm&#8217;s length transaction); fees for required licenses and
              permits; shuttle and other transportation services operated or contracted for by Landlord to provide transportation for employees of tenants of the Development between the Development and mass transit locations (which shuttle may service
              other locations owned or controlled by Landlord, in which case Landlord shall equitably allocate the costs of such shuttle between the various properties); and property management fees in an amount not to exceed three percent (3%) of gross
              revenue. Landlord may use third parties or Affiliates to perform any of these services, and the cost thereof shall be included in Operating Expenses, so long as such third parties are professional and such costs are comparable to market rate
              costs. Costs referred to in this Section shall be ascertained in accordance with generally accepted accounting principles and allocated to appropriate fiscal periods on the accrual method of accounting.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">25</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Operating Expenses shall only include capital expenditures that (A) will, in Landlord&#8217;s reasonable
              estimate, result in a reduction in Operating Expenses payable by Tenant, taking into account the amount of annual amortization on account of the capital expenditure in question, or (B) are required to replace any capital items which have
              become obsolete or non&#8209;functional or which Landlord otherwise reasonably determines are required to be replaced in order to maintain the Unit as a first&#8209;class laboratory facility, or (C) are required by changes in Legal Requirements or
              Insurance Requirements occurring after the Delivery Date. Any capital expenditures not excluded from Operating Expenses pursuant to this paragraph shall be amortized over the useful life of the item in question as reasonably determined by
              Landlord in accordance with the relevant provisions of the Internal Revenue Code and the regulations promulgated thereunder, as amended from time to time, together with interest at Landlord&#8217;s actual interest rate incurred in financing such
              capital expenditures, or, if no part of such expenditure is financed, at an imputed interest rate equal to the Prime Rate plus 2%; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, if a
              particular capital expenditure effects savings in other Operating Expenses, including, without limitation, energy related costs, and such savings, on an annual basis (&#8220;<font style="font-weight: bold;">Actual Annual Savings</font>&#8221;), exceed
              the annual depreciation therefor, then and in such event the amount of depreciation for such capital expenditure shall be increased to an amount equal to the Actual Annual Savings; and in such circumstance, the increased depreciation (in the
              amount of the Actual Annual Savings) shall be made for such period of time as it would take to fully amortize the cost of the item in question, together with interest thereon at the interest rate as aforesaid in equal monthly payments, each
              in the amount of 1/12th of the Actual Annual Savings, with such payment to be applied first to interest and the balance to principal.</font></div>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcffdede518444daeaef95b5b26e86ce0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;">&#160;</td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(1)</td>
                <td style="vertical-align: top; text-align: justify;">
                  <div>Notwithstanding anything contained herein to the contrary, in no event shall Operating Expenses include any of the following:</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1500072998844c34a2f13da6fd702fa9" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(2)</td>
                <td style="vertical-align: top; text-align: justify;">
                  <div>expenses incurred by Landlord to lease space to new tenants or to retain existing tenants including marketing costs, brokerage commissions and concessions and leasehold improvement costs, finders&#8217; fees, attorneys&#8217; fees and expenses,
                    entertainment costs and travel expenses;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z182a8efc2b16470d8bb1a6feb169363b" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(3)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>debt service;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z43f05d6c95b84411818812a3374e7bf9" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(4)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>attorneys&#8217; fees incurred in connection with lease negotiations or disputes with individual tenants, and other expenses and attorneys&#8217; fees to resolve disputes, enforce or negotiate lease terms with prospective or existing tenants or
                    in connection with any financing, sale or syndication of the Unit or the creation of any condominium unit within the Development;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d56751b90f94ef4998d68b68c2be1e0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(5)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>accountants&#8217; fees incurred in connection with disputes with individual tenants and/or the existence, maintenance or related operations of the legal entity or entities of which Landlord is comprised. Without limitation, the foregoing
                    shall not exclude the costs of preparing financial statements for Operating Expenses;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8e6a6999a8b34416a086b38805e5e1b1" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(6)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the cost of any special work or service performed for any tenant (including Tenant) or licensee, such as after&#8209;hours HVAC service, which is billable to such tenant or licensee, or any costs in connection with services or benefits
                    that are provided to or for the particular benefit of specific (but less than all of) the tenants and billable to them;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">26</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfad23dfa5a5d44258ecb829e33d0e978" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(7)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the cost of any items for which Landlord is reimbursed by insurance, condemnation, licensees, tenants (other than through general operating expense provisions), warranties or otherwise;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbdffbdc6a90b49a8bf5f00d53ebd46a4" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(8)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the cost of any additions, changes, replacements, painting, decorating, renovations and other items that are made solely in order to prepare tenant space for a new tenant&#8217;s occupancy, or the cost of any other work in any space leased
                    to an existing or prospective tenant or other occupant of the Unit;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z676ed343f0f64871b7b61c2c0b6b1897" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(9)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>interest, principal, points and fees, amortization or other costs and expenses associated with any debt or amortization payments on any mortgage or deed to secure debt and rental under any ground lease, master space lease or other
                    underlying lease;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ea3182f1ef84220bc8076fc07c55af3" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(10)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>any expenses for repairs or maintenance to the extent reimbursed due to warranties and service contracts;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb8a0df019034444ab32fd407d1e570c1" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(11)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>any cost that Tenant pays for directly (either to Landlord or a third party);</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z06881752dfc744c6bd22b8521af0cfde" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(12)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>any cost for which Landlord is reimbursed by a warranty that Landlord is required to obtain in connection with the Unit pursuant to this Lease or that Landlord otherwise obtains in connection with the Unit;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z981a7f2e671b4d5181d9edce37e1cc3d" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(13)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>any amounts paid to an Affiliate of Landlord for the performance of services that is in excess of the amount that would have been paid on an arm&#8217;s length basis in the absence of such relationship;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za060a47ececc400c990187eab3dee5b5" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(14)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>depreciation and amortization of the Unit or any part thereof (except as otherwise provided in <u>Section 7.01(b)</u> above);</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4c46c1e80d5e4cbfba5c9b88f502a89d" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(15)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>salaries and bonuses and benefits of officers, executives of Landlord and administrative employees above the grade of property manager or building supervisor, and if a property manager or building supervisor or any personnel below
                    such grades are shared with other buildings or has other duties not related to the building containing the Premises, only the allocable portion of such person&#8217;s or persons&#8217; salary, bonuses, and benefits shall be included in Operating
                    Expenses;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc5cd5033668646bd8524299a47b73cd0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(16)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Landlord&#8217;s general overhead and administrative expenses;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z832a359f31c84af1beefb37c0b0ebc3a" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(17)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>cost of alterations, capital improvements, equipment replacement and other items which under generally accepted accounting principles are properly classified as capital expenditures except as provided in <u>Section 7.01(b)</u>;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e77f99b89a34b04a2814f52c8bae8ef" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(18)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>expenses incurred by Landlord to the extent the same are chargeable to any other tenant or occupant of the Unit, or to any third party;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">27</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55d4e8d6a69542d39a706496dbc137f2" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(19)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>any cost incurred solely because of the negligence or willful misconduct of Landlord, its agents and employees, or the Indemnitees;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z89bd07418b8b42f9a57d724886cc4ca6" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(20)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>penalties, fines and other costs incurred due to violation by Landlord of any lease, the Condominium Documents, or any Legal Requirements or Title Matters applicable to the Building;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0feb2904cebc4f0c8bc2b9a49afe2c1f" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(21)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Taxes;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z288c140ae6f842bd85b5b636bcbc84a6" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(22)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>costs and expenses incurred by Landlord in connection with the repair of damage to the Building or the Unit caused by fire or other casualty, insured or required to be insured against hereunder, other than the deductible amount under
                    such insurance policies;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z69524aa1400747e6ace04bea05336b15" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(23)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the cost of correcting defects in the initial construction of the Building;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zae7a6eb4f20f45e9ba9f0bf7a022f877" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(24)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the cost of any item for which Landlord is reimbursed through condemnation awards;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6d39f3eb427f4474949a149e8f0aeee2" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(25)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>costs and expenses of investigating, monitoring and remediating hazardous materials which were present on or beneath the surface of the Land as of the Date of Lease;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd726f203f0124861925fbca8cec16706" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(26)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>charitable or political contributions and membership fees or other payments to trade organizations;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb28ebcf2385946d6bb8208876ce6bacb" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(27)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>costs in connection with services that are provided to another lessee or occupant of the Building, but are not offered to Tenant;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z553ab150312d428482b2aff64548f0f9" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(28)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>costs or expenses incurred in connection with the financing or sale of the Project or any portion thereof;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z37f3df048f0f43ec9314483069c494c1" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(29)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>fines, penalties, interest or other amounts imposed in connection with the Landlord&#8217;s failure to pay any tax when due;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1a9064545d1a411fa6f9015354fa202b" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(30)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>any item that, if included in Operating Expense, would involve a double collection for such item by Landlord;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5b12a13e3c445f7a4bc19fdacf70985" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(31)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the cost of any &#8220;tap fees&#8221; or one&#8209;time lump sum sewer or water connection fees for the Building payable in connection with the initial construction of the Building, but not including any such fees payable by any specific tenant in
                    connection with obtaining or maintaining any permit or license issued to such tenant in connection with its water or sewer connection or usage (e.g., a MWRA Industrial User Permit);</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze1dff9ae69384f21944ac65a40438823" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(32)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>reserves of any kind;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z17c725b2146c44e7918d3d134db2b39d" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(33)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>costs and expenses incurred in the design, permitting or initial construction, fixturing and furnishing of the Base Building Work, including the parking facilities and any amenities and any costs of any remodeling, redevelopment or
                    expansion of the Building, Unit or Development;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">28</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z646f4d9e635b4ce19bff6daeac05a48b" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(34)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>the cost of performing work or furnishing service to or for any tenant other than Tenant, at Landlord&#8217;s expense, to the extent such work or service is in excess of any work or service Landlord is obligated to provide to Tenant or
                    generally to other tenants in the Building at Landlord&#8217;s expense;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z762316b4121e4317b7b4e0dda4c922f5" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(35)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>cost of initial cleaning and rubbish removal from the Building or the Development to be performed before final completion of the Building or tenant space, to the extent such costs relate to the construction of the Building or tenant
                    space; and</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z330c6e6d60e44d06b47b80f79c8a9b71" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(36)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>cost to install the initial landscaping of the Building or Development.</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="text-align: justify;">Tenant shall pay Tenant&#8217;s Percentage Share of Operating Expenses in accordance with <u>Section 4.02</u>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 8: INSURANCE</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.01.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Coverage</font>. Tenant shall maintain throughout the Term, at its
            sole cost and expense, insurance for the benefit of Tenant and Landlord (as their interests may appear) from insurers authorized to do business in the state in which the Development is located, rated at least &#8220;A: VII&#8221; by A.M. Best, with terms
            and coverages reasonably satisfactory to Landlord, and with such increases in limits as the holder of any mortgage on the Unit (either alone or as part of a larger mortgaged property) may from time to time require, or as Landlord may from time
            to time reasonably require (provided that such limits are the same as those then being provided by similar types of tenants in the greater Boston area under leases of similar types of premises). Initially, Tenant shall maintain the following on
            an occurrence basis (except as otherwise expressly provided below):</div>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf429960d149a48d28bd83bc9d385c2ff" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(A)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">Commercial general liability insurance on an occurrence basis naming Landlord, Landlord&#8217;s managing agent and Landlord&#8217;s mortgagee(s) of which Tenant has received prior written notice from time to time as
                    additional insureds, insuring against all claims and demands for personal injury liability (including bodily injury, sickness, disease, and death) or damage to property, with combined single limits of not less than $5,000,000 per
                    occurrence and $5,000,000 in the aggregate, which coverages may be effected by primary or excess coverage. The policy shall not contain any intra&#8209;insured exclusions as between insured persons or organizations, but shall include coverage
                    for liability assumed under this Lease as an &#8220;insured contract&#8221; for the performance of Tenant&#8217;s indemnity obligations under this Lease. Such insurance shall be primary and not contributing to any insurance available to Landlord, and
                    Landlord&#8217;s insurance (if any) shall be in excess thereto;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">29</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbb6b2b3441dc40c69b7e822e255c4a95" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(B)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">Property insurance covering property damage and business interruption. Covered property shall include all Tenant improvements in the Premises other than the Initial Tenant Work, but including all other
                    Tenant Work, and Tenant&#8217;s Property. Such insurance, with respect only to Tenant Work, shall name Landlord and Landlord&#8217;s mortgagees of which Tenant has received written notice from time to time as additional loss payees as their
                    interests may appear. Such insurance shall be written on an &#8220;all risk&#8221; of physical loss or damage basis including the perils of fire, extended coverage, windstorm, vandalism, malicious mischief, sprinkler leakage, flood and earthquake,
                    and such other risks Landlord may from time to time designate (provided that insurance for such risks is then commercially available at commercially reasonable rates and is being carried by similar tenants for research and laboratory
                    facilities in the vicinity of the Unit), for the full replacement cost of the covered items (provided that coverage limits for flood and earthquake coverages may be in lesser but commercially reasonable amounts) and in amounts that meet
                    any co-insurance clause of the policies of insurance, with a deductible amount not to exceed a then&#8209;commercially reasonable deductible, which initially shall be no greater than $50,000 (other than for flood and earthquake, for which
                    such deductibles shall initially be no greater than $100,000);</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z68f91515462044bfa4d0a232e89b8e18" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(C)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">Workers&#8217; compensation insurance with statutory benefits and employers liability insurance in the following amounts: each accident, $1,000,000; disease (policy limit), $1,000,000; disease (each employee),
                    $1,000,000;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1d68bb3ebefb494b88b4203c865f3475" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(D)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">Pollution legal liability insurance covering first and third&#8209;party claims for clean&#8209;up costs, personal injury and property damage on an on&#8209;site and off&#8209;site basis, with a single claim and aggregate claim
                    amount of Three Million Dollars ($3,000,000.00), naming Landlord, Landlord&#8217;s managing agent and Landlord&#8217;s mortgagee(s) from time to time as additional insureds. The parties acknowledge and agree that the insurance required by this
                    paragraph (E) shall not include coverage for pre&#8209;existing environmental conditions at the Development as of the Date of Lease; and</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8b1fd87d3a1f4c66b54296d359a0166e" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(E)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0);">During all construction by Tenant, Tenant shall maintain with respect to the Premises and the Unit adequate builder&#8217;s risk insurance, in form and amount reasonably satisfactory to Landlord based upon the
                    scope of work, (and Landlord, its mortgagees of which Tenant has received written notice, and any ground or master lease lessors of which Tenant has received written notice shall be named as an additional insured party as their interest
                    may appear).</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">Tenant shall give Landlord certificate(s) evidencing (i) the coverages required by <u>Sections 8.1(A) &#8209; (D)</u> not later than thirty (30) days prior to the earlier of either (a) the Delivery
            Date or (b) the date on which Tenant anticipates that Tenant&#8217;s Contractor will commence its on&#8209;site mobilization for the performance of the Initial Tenant Work, which coverage shall be effective not later than the earlier of the dates set forth
            in the foregoing clauses (a) and (b), and (ii) the coverage required by <u>Section 8.1(D)</u> not later than thirty (30) days prior to the earlier of either (x) the first delivery of Hazardous Materials to the Premises for Tenant&#8217;s use, or (y)
            Tenant&#8217;s occupancy of any portion of the Premises for the conduct of business therein, which coverage shall be effective not later than the earlier of the dates set forth in the foregoing clauses (x) and (y). Thereafter, Tenant shall provide
            certificates of each insurance coverage required by this Section not less than twenty (20) days before the expiration of such insurance coverage. All insurance certificates required to be provided by Tenant shall state that such coverages may
            not be canceled without at least ten (10) days&#8217; prior written notice to Landlord and Tenant for cancellation due to non&#8209;payment and thirty (30) days&#8217; prior written notice to Landlord and Tenant for other cancellations. Tenant shall provide
            written notice to Landlord of any amendments to Tenant&#8217;s insurance policies which could materially and adversely affect Landlord&#8217;s interest not later than the effective date of such amendment. All deductible amounts or self&#8209;insured retentions
            shall be commercially reasonable in amount, and shall be the sole responsibility of Tenant. In addition, Tenant shall cause Tenant&#8217;s Contractor to provide to Tenant on or before the Date of Lease certificates evidencing the coverages required
            by <u>Sections 8.1(A) and (C) </u>maintained by Tenant&#8217;s Contractor, and naming as additional insureds Landlord, Landlord&#8217;s managing agent and Landlord&#8217;s mortgagee(s) of which Tenant has received prior written notice from time to time, which
            coverages shall be effective as of such date, and thereafter to provide to Landlord certificates of each such insurance coverage not less than thirty (30) days before the expiration of such insurance coverage.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">30</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">If Tenant does not procure the insurance required pursuant to this Section, or keep the same in full force and effect, Landlord may, but shall not be obligated to, take out the necessary
            insurance and pay the premium therefor after written notice thereof to Tenant, and Tenant shall repay to Landlord, as Additional Rent, the amount so paid (together with interest thereon at the Default Rate) within ten (10) days of Landlord&#8217;s
            written demand. In addition, Landlord may recover from Tenant, as Additional Rent, any and all reasonable expenses (including reasonable attorneys&#8217; fees) and damages which Landlord may sustain by reason of the failure by Tenant to obtain and
            maintain such insurance, it being expressly declared that the expenses and damages of Landlord shall not be limited to the amount of the premiums thereon. The foregoing rights and remedies of Landlord shall not be deemed to waive any default or
            Event of Default under this Lease resulting from any such failure by Tenant to procure or to maintain in full force and effect any insurance required by this Section.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.02.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Avoid Action Increasing Rates</font>. Tenant shall not use or
            permit any use of the Premises beyond the Permitted Use in any way that will make voidable any insurance on the Unit, the Building or the Development, or on the contents thereof, or which shall be contrary to any requirements from time to time
            established or made by Landlord&#8217;s insurer, or which increases the cost of Landlord&#8217;s insurance or requires additional insurance. Tenant shall cure any breach of this Section within ten (10) days after written notice from Landlord or Tenant
            otherwise learning of such by (i) stopping any use that jeopardizes any insurance coverage or increases its cost or (ii) paying the increased cost of insurance. Tenant shall have no further notice or cure right under <u>Article 13</u> for any
            such breach. Tenant shall reimburse Landlord within ten (10) days of Landlord&#8217;s written demand, as Additional Rent, for all of Landlord&#8217;s costs reasonably incurred in providing any insurance that is attributable to any special endorsement or
            increase in premium resulting from the business or operations of Tenant other than those customarily associated with laboratory/R&amp;D use for the type of medical research conducted by Tenant, and any special or extraordinary risks or hazards
            resulting therefrom, including any risks or hazards associated with the generation, storage and disposal of Hazardous Materials other than those customarily associated with laboratory/R&amp;D use for the type of medical research conducted by
            Tenant.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">31</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.03.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Waiver of Subrogation</font>. Landlord and Tenant each waive any
            and every claim for recovery from the other for any and all loss of or damage to the Unit or any part of it, or to any of its contents, which loss or damage is covered by valid and collectible property insurance. This mutual waiver precludes
            the assignment of any such claim by subrogation (or otherwise) to an insurance company (or any other person), and Landlord and Tenant each agree to give written notice of this waiver to each insurance company that has issued or shall issue any
            property insurance policy to it, and to have such policies properly endorsed, if necessary, to prevent invalidation of the insurance coverage because of this waiver. In consideration of the foregoing, each of the parties hereto agrees with the
            other party that such insurance policies as it may have in effect during the Term of this Lease shall include a clause or endorsement which provides in substance that the insurance company waives any right of subrogation which it might
            otherwise have against Landlord, Landlord&#8217;s managing agent, or Tenant.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">8.04.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Insurance</font>. Landlord shall maintain (or cause to
            be maintained) at all times during the Term: (a) special form property insurance coverage in an amount equal to the full replacement value of the Building (excluding Tenant&#8217;s trade fixtures, equipment, Tenant Work (other than the Initial Tenant
            Work, which shall be insured by Landlord), Tenant&#8217;s Property and property not owned by Landlord); and (b) commercial general liability insurance covering the Development, (i) in the minimum amounts of One Million Dollars ($1,000,000.00) per
            occurrence, with an annual aggregate limit of Two Million Dollars ($2,000,000.00) for personal or bodily injury and damage to property, and (ii) an umbrella policy in the minimum coverage amount of Five Million Dollars ($5,000,000.00) per
            occurrence, with an annual aggregate limit of Five Million Dollars ($5,000,000.00); and (iii) any and all other insurance required to be maintained by Landlord by the Condominium Documents. As set forth in <u>Section 4.02</u>, the cost of any
            such insurance shall be borne by Tenant and other tenants of the Development as part of Operating Costs.</div>
          <div><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 9: USE OF PREMISES</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.01.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Permitted Uses</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant shall use the Premises only for the Permitted Uses described in <u>Article 1</u> and for no
              other use. In furtherance, and not in limitation, of the foregoing, in no event shall any portion of the Premises be used for retail uses (including a restaurant or any caf&#233;, coffee shop or other eatery) or any high density office use. Tenant
              shall certify to Landlord, upon request from time to time, the aggregate rentable square footage in the Premises being used for Non&#8209;Life Science Uses. Tenant shall keep the Premises equipped with appropriate safety appliances to the extent
              required by applicable Legal Requirements or Insurance Requirements. Tenant shall not cause or permit any potentially harmful air emissions, odors of cooking or other processes, or other objectionable odors or emissions to emanate from the
              Premises. Tenant shall not conduct or permit any auctions or sheriff&#8217;s sales at the Premises.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">32</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">If Tenant intends at any time during the Term to conduct animal research within the Premises, such
              research shall be limited to biopharmaceutical research and development, including the handling and testing of laboratory mice, laboratory rats and other laboratory small mammals only (the &#8220;<font style="font-weight: bold;">Permitted Animals</font>&#8221;)







              in connection therewith, and for no other purpose or use; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that in no event shall Tenant bring into or maintain in the Premises any animal
              for research purposes other than those permitted by applicable Legal Requirements for use in the Permitted Use. If Tenant proposes to use any animals other than the Permitted Animals enumerated in the immediately preceding sentence in its
              operations, it shall first obtain the prior written consent of Landlord, which consent Landlord shall not unreasonably withhold. Animal research, solely of Permitted Animals, shall be permitted subject to the following: (a) all testing and
              research shall be conducted in strict compliance with all applicable Legal Requirements and with good scientific and medical practice; (b) all dead animals, any part thereof or any waste products related thereto, shall be disposed of, at
              Tenant&#8217;s sole cost and expense, in strict compliance with all applicable Legal Requirements and with good scientific and medical practice; (c) no odors, noises or any similar nuisance shall be permitted to emanate from the vivarium; and (d)
              Tenant&#8217;s use of research animals shall not interfere with the peaceable and quiet use and enjoyment by other tenants or occupants of the Unit or the Building of their respective demised premises. Tenant shall procure and deliver to Landlord
              copies of all permits and approvals necessary for the use and operation of the vivarium and the keeping of Permitted Animals before allowing any actual Permitted Animals into the Premises and shall maintain such permits and approvals in full
              force and effect at all times during the Term. Tenant shall indemnify, save harmless and defend the &#8220;Indemnitees&#8221; (as defined in <u>Section 9.02</u> hereof) from and against all liability, claim, damage, loss or cost (including reasonable
              attorneys&#8217; fees) arising out of or relating to the use and operation of the vivarium and the presence of the Permitted Animals in and about the Premises, except to the extent to which the same was caused by the negligence or willful
              misconduct of any of the Indemnitees.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.02.</font>&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Indemnification</font>. Tenant is responsible for the Premises and
            any Tenant&#8217;s improvements, equipment, facilities and installations, wherever located in the Building or the Land, and all liabilities, including tort liabilities, incident thereto, except to the extent caused by the negligence or willful
            misconduct of Landlord, Landlord&#8217;s agents, employees or contractors, or the Indemnitees. Except to the extent caused by the negligence or willful misconduct of Landlord, Landlord&#8217;s agents, employees or contractors, or the Indemnitees, Tenant
            shall indemnify, save harmless and defend Landlord and Landlord&#8217;s partners, trustees, beneficiaries, shareholders, members, managers, owners, officers, directors, mortgagees, ground lessors, agents, employees, independent contractors,
            Landlord&#8217;s managing agent and other persons acting under them (collectively, &#8220;<font style="font-weight: bold;">Indemnitees</font>&#8221;), from and against all liability, claim, damage, loss or cost (including reasonable attorneys&#8217; fees) arising in
            whole or part out of, or in any way related to, (i) any alleged or actual injury, loss, theft or damage to any person or property while on the Premises; (ii) any alleged or actual injury, loss, theft or damage to any person or property while on
            the Development (other than within the Premises) to the extent arising from the acts or omissions of Tenant or persons claiming by, through or under Tenant, or any of their respective officers, employees, agents, servants, contractors or
            invitees (collectively, &#8220;<font style="font-weight: bold;">Tenant Parties</font>&#8221;); (iii) any alleged or actual condition within the Premises (except to the extent caused by a person or entity other than Tenant or a Tenant Party, for which
            Tenant is not otherwise responsible, as to which Tenant shall have the burden of proof); or (iv) failure of Tenant or any Tenant Party to comply with any provision of this Lease or the Condominium Documents, in each case under (i) through (iv)
            above paying any cost to Landlord within ten (10) days of written demand as Additional Rent.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">The provisions of this <u>Section 9.02</u> shall survive the expiration or earlier termination of this Lease.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">33</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.03.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Compliance With Legal Requirements and Title Matters</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant shall not permit the Premises, or cause the Premises or the Unit or the Building, to be used in
              any way that violates any applicable law, code, ordinance, governmental regulation, determination, order, permit, approval or any other governmental consent (each a &#8220;<font style="font-weight: bold;">Legal Requirement</font>&#8221;) or any Title
              Matter or any provision of the Condominium Documents, or that unreasonably interferes with the use of other portions (i.e., other than the Premises) of the Unit, the Building or the Development by other tenants, or constitutes a nuisance or
              waste. Landlord hereby states that none of the existing Title Matters set forth on <font style="font-weight: bold;"><u>Exhibit D</u></font> attached hereto will prohibit the use of the Premises for the Permitted Uses set forth in <u>Article
                1</u>. Tenant shall, at its sole cost and expense, be responsible for compliance with all Legal Requirements and Title Matters applicable to the Premises (or to the Unit or the Building solely by reason of Tenant&#8217;s specific use of the
              Premises, as opposed to laboratory/research and development uses in general), including the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules dated April 2016 (as the same may be amended, restated or
              replaced). The foregoing notwithstanding, Landlord, and not Tenant, shall be responsible for making all improvements and alterations to the common areas of the Development, the Unit and the Building which are required to cause the same to
              comply with all present and future Legal Requirements (the cost of which shall be included in Operating Expenses to the extent allowable pursuant to <u>Section 7.01(b))</u>.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant shall be responsible, at its sole cost and expense, for procuring and maintaining in full force
              and effect, and complying at all times with, any and all necessary permits, certifications, permissions and the like and complying with any reporting requirements directly relating or incident to the conduct of its activities on the Premises.
              Within ten (10) Business Days of a request by Landlord, which request shall be made not more than once during each period of twelve (12) consecutive months during the Term hereof, unless otherwise requested by any mortgagee of Landlord or
              prospective purchaser of the Unit (either by itself or as part of a mortgage on or purchase of a larger portion of the Development), Tenant shall furnish Landlord with copies of all such permits that Tenant has obtained. Tenant shall promptly
              give notice to Landlord of any written warnings or violations delivered by any governmental authority relating to Tenant&#8217;s use or occupancy of, or any condition within, the Premises (including building code violations, fire safety code
              violations, wastewater management violations, OSHA violations, or violations of Legal Requirements (including Environmental Laws)) received from any federal, state, or municipal agency or any court of law within ten (10) Business Days after
              Tenant&#8217;s receipt of such notice and shall promptly cure the conditions causing any such violations. Tenant shall not be deemed to be in default of its obligations under the preceding sentence to promptly cure any condition causing any such
              violation in the event that, in lieu of such cure, Tenant shall contest the validity of such violation, or apply for a variance or permission to allow such use by appellate or other proceedings permitted under applicable Legal Requirements,
              provided that: (i) any such contest is made reasonably and in good faith, (ii) Tenant makes provisions reasonably acceptable to Landlord, including posting bond(s) or giving other security reasonably acceptable to Landlord, to protect
              Landlord and its mortgagees, and the Unit from any liability, costs, damages or expenses arising in connection with such violation and failure to cure, (iii) Tenant agrees to indemnify, defend (with counsel reasonably acceptable to Landlord)
              and hold Landlord and its mortgagees harmless from and against any and all liability, costs, damages, or expenses arising in connection with such condition and/or violation, except to the extent to which such condition was caused by the
              negligence or willful misconduct of Landlord or Landlord&#8217;s employees, agents or contractors, (iv) Tenant shall promptly cure any violation in the event that its appeal of such violation is overruled or rejected, (v) Tenant shall certify to
              Landlord&#8217;s and its mortgagees&#8217; reasonable satisfaction that Tenant&#8217;s decision to delay such cure will not result in any actual or threatened bodily injury or property damage to Landlord, any tenant or occupant of the Unit or the Building or
              any other person or entity, and (vi) this Lease is in full force and effect and no Event of Default has occurred and is then continuing.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">34</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">In order to encourage the use of alternative means of transportation to and from the Premises by
              Tenant&#8217;s employees, Tenant shall (i) provide to qualified employees monthly transit subsidies, such as subsidizing MBTA monthly passes and providing Bluebike annual memberships for employees who otherwise drive to work two or fewer days per
              week, (ii) promote ridesharing for employees, consistent with COVID&#8209;19 and other public health protocols, and (ii) permit employees to set aside a portion of their salaries on a pre&#8209;tax basis as allowable under the commuter choice provisions
              of the federal tax code (as amended from time to time).</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.04.</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Hazardous Materials</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">&#8220;<font style="font-weight: bold;">Environmental Law</font>&#8221; shall mean all statutes, laws, rules,
              regulations, codes, ordinances, standards, guidelines, authorizations and orders of federal, state or local public authorities now in force or hereafter enacted, modified, or amended pertaining to the protection of the environment or to
              health or safety risks arising therefrom, including, but not limited to, control of air pollution, water pollution, groundwater pollution, and the generation, manufacture, management, handling, use, sale, transportation, delivery, discharge,
              emission, treatment, storage, disposal, release or threatened release of Hazardous Materials. To the extent applicable, such laws include, but are not limited to: (1) the Clean Air Act, 42 U.S.C. &#167; 7401, et seq.; (2) the Clean Water Act, 33
              U.S.C. &#167; 1251, et seq.; (3) the Safe Drinking Water Act, 42 U.S.C. &#167; 300f, et seq.; (4) the Resource Conservation and Recovery Act, 42 U.S.C. &#167; 6901, et seq.; (5) the Comprehensive Environmental Response, Compensation and Liability Act, 42
              U.S.C. &#167; 9601, et seq.; (6) the Toxic Substances Control Act, 15 U.S.C. &#167; 2601, et seq.; (7) Title III of the Superfund Amendments and Reauthorization Act, also known as the Emergency Planning and Community Right&#8209;to&#8209;Know Act, 42 U.S.C. &#167;
              11001; (8) the Hazardous Materials Transportation Act, 49 U.S.C. &#167; 1801 et seq.; (9) federal regulations promulgated pursuant to any of the foregoing statutes; (10) Massachusetts laws and regulations enacted in order to implement federal
              environmental statutes and regulations; (11) the Massachusetts Hazardous Waste Management Act, M.G.L. c. 21C; (12) the Massachusetts Oil and Hazardous Materials Release Prevention and Response Act, M.G.L. c. 21E; (13) the Hazardous Substances
              Disclosure by Employers Act, M.G.L. c. 111F; (14) Massachusetts regulations promulgated pursuant to the authority of applicable state environmental laws; and (15) local ordinances and regulations.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Hazardous Materials</font>&#8221; shall mean, but shall not be limited to, any products, hazardous substances, hazardous waste, toxic substances, environmental,
            biological, pathological, chemical, radioactive materials, waste or substances, oil or petroleum products and any material, waste or substance, which because of its quantitative concentration, chemical, biological, radioactive, flammable,
            explosive, infectious, or other characteristics, constitutes or may reasonably be expected to constitute or contribute to a danger or hazard to public health, safety or welfare or to the environment, including any asbestos (whether or not
            friable) and any asbestos&#8209;containing materials, lead paint, waste oils, solvents and chlorinated oils, polychlorinated biphenyls (PCBs), toxic metals, etchants, pickling and plating wastes, explosives, reactive metals and compounds, pesticides,
            herbicides, radon gas, urea formaldehyde foam insulation and chemical, biological and radioactive wastes, or any other materials or substances that are mentioned under or regulated by any Environmental Law; and including any other products or
            materials subsequently found by an authority of competent jurisdiction to have adverse effects on the environment or the health and safety of persons.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">35</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="color: rgb(0, 0, 0);">Tenant, at its sole cost and expense, shall (i) except as otherwise expressly provided in <u>Section
                9.13</u> below with respect to the Neutralization System, obtain all required permits and approvals for, and (ii) comply with all Environmental Laws pertaining to, the transportation, use, storage, generation, disposal, release or discharge
              of Hazardous Materials to, from or at the Premises by Tenant or any Tenant Party, including those Environmental Laws and permit provisions applicable to Tenant&#8217;s use of the Neutralization System. Provided that the same is performed at all
              times in accordance with the provisions of this Lease, Tenant may generate, produce, bring upon, use, store or treat Hazardous Materials in the Premises which are (a) typically found in commercial construction sites (which shall apply only
              during such time as Tenant is performing construction at the Premises as provided for in this Lease), (b) cleaning products or office supplies typically used in laboratory/office space, and (c) materials otherwise used in the ordinary course
              of Tenant&#8217;s operations and typically found in other leased laboratory space used for comparable purposes, as reasonably needed for Tenant&#8217;s operations and research activities, and strictly in accordance with Environmental Laws. In all events
              Tenant shall comply with all applicable provisions of the standards of the U.S. Department of Health and Human Services as further described in the USDHHS publication Biosafety in Microbiological and Biomedical Laboratories (5th Edition,
              December 2009) as it may be further revised, or such nationally recognized new or replacement standards as may be reasonably selected by Landlord. Except as otherwise set forth above, Tenant shall not cause or permit any Hazardous Materials
              to be generated, produced, brought upon, used, stored, treated or disposed of to, from, or in or about the Premises by Tenant or any Tenant Party without Landlord&#8217;s prior written consent, which may be withheld in Landlord&#8217;s sole discretion.
              Any Hazardous Materials permitted to be stored on the Premises pursuant to this paragraph shall be stored in areas of the Premises exclusively designated by Tenant for such purpose to the extent required by Legal Requirements. All industrial
              gases shall be contained in designated secured and screened areas as approved by applicable governmental authorities. Tenant shall have the right to store Hazardous Materials in &#8220;Control Areas&#8221; capable of holding Hazardous Materials in
              accordance with applicable Legal Requirements, including 780 CMR and 527 CMR requirements for &#8220;Control Areas&#8221;, as follows: (i) Tenant shall have the right to use fifty (50%) percent of the &#8220;Control Area&#8221; within Chemical Storage Room 105 on
              the first floor of the Building in accordance with the plan of the Premises attached hereto as <font style="font-weight: bold;"><u>Exhibit B</u></font>, and (ii) Tenant shall have the right to use its pro&#8209;rata share (calculated on the basis
              of the rentable square footage in Tenant&#8217;s Premises divided by the total rentable square footage on any particular floor of the Unit) of the capacity of the &#8220;Control Area&#8221; on such floor of the Unit (or the aggregate capacity of the &#8220;Control
              Areas&#8221; if there is more than one on such floor of the Unit). Except as provided in the immediately preceding sentence, in no event shall any Hazardous Materials be generated, stored or used outside of the Premises. Tenant shall not dispose of
              Hazardous Materials from the Premises to any other location except in strict compliance with all applicable Environmental Laws, nor permit any persons acting under it to do so. Notwithstanding the foregoing, Tenant shall not, in any event, be
              responsible for any Hazardous Materials to the extent such Hazardous Materials are introduced to the Development by anyone other than Tenant or any Tenant Party.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">36</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Within five (5) Business Days after taking initial occupancy of the Premises, Tenant shall provide to
              Landlord a list of all Hazardous Materials used, stored or generated by Tenant in the Premises, including quantities of each anticipated to be used, stored or generated, together with the material safety data sheet (&#8220;<font style="font-weight: bold;">MSDS</font>&#8221;) for each such Hazardous Material. Thereafter, within ten (10) Business Days of Landlord&#8217;s written request, Tenant shall provide Landlord with an updated list of all Hazardous Materials used, stored or generated by
              Tenant in the Premises, including quantities of each, together with the MSDS for each such Hazardous Material. From time to time at Landlord&#8217;s written request, but not more than once in any twelve (12) month period unless either Tenant is in
              default of its obligations under this <u>Section 9.04</u> or Landlord has reason to believe that a release of Hazardous Materials has occurred on, at or from the Premises caused by Tenant or a Tenant Party, Tenant shall execute affidavits,
              certifications and the like, in form reasonably acceptable to Tenant, to the best of Tenant&#8217;s knowledge and belief, regarding the presence or absence of Hazardous Materials on the Premises or the Unit used, stored, generated, disposed of or
              released by Tenant or any Tenant Party. Furthermore, within fifteen (15) days after Landlord&#8217;s written request, Tenant shall make available to Landlord at the Premises, for review and audit by Landlord, all of Tenant&#8217;s books and records
              relating to the types and amounts of all Hazardous Materials being generated, produced, brought upon, used, stored or disposed of by or on behalf of Tenant at, on or from the Premises, together with copies of any federal, state or municipal
              filings or compliance reports made by Tenant with respect to such Hazardous Materials that are required by applicable Environmental Law. Tenant agrees to pay the cost of any environmental inspection or assessment requested by any governmental
              agencies, mortgagees of the Unit (either by itself or as part of a larger mortgaged property), or by any insurance carrier to the extent that such inspection or assessment pertains to any release, threat of release, contamination, claim of
              contamination, loss or damage or deterioration of condition in the Premises caused by or alleged to be caused by Tenant or any Tenant Party (collectively, &#8220;<font style="font-weight: bold;">Environmental Incidents</font>&#8221;). Notwithstanding
              anything to the contrary contained in this <u>Section 9.04</u>, to the extent that any disclosure, affidavit or similar document to be provided by Tenant to Landlord pursuant to this <u>Section 9.04</u> would otherwise be required to
              disclose proprietary information concerning chemicals, substances, or materials synthesized by Tenant from constituent Hazardous Materials, such disclosure may exclude such proprietary information provided that the constituent Hazardous
              Materials (but not the manner, quantities or concentrations in which they are combined to form such chemicals, substances or materials) are identified therein.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">37</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Landlord shall not be liable to Tenant or any Tenant Party or to any person or governmental authority
              whatsoever for any release of Hazardous Materials brought to the Premises by or on behalf of Tenant at any time during the Term, except to the extent caused by the negligence or willful misconduct of Landlord or its employees, agents or
              contractors. Landlord shall have the right, from time to time during the Term, but not more than once in any twelve (12) month period unless either Tenant is in default of its obligations under this <u>Section 9.04</u> or Landlord has reason
              to believe that a release of Hazardous Materials has occurred on, at or from the Premises caused by Tenant or a Tenant Party, to enter upon the Premises upon reasonable prior notice to Tenant to perform environmental audits relating to the
              operations of Tenant and all those claiming through Tenant on the Premises, including (i) reviewing records relating to compliance with Environmental Laws and industry standards applicable to the generation, handling, use, storage and
              disposal of Hazardous Materials, (ii) observing techniques for handling, storing, using and disposing of Hazardous Materials, (iii) reviewing documentation relating to the off&#8209;Premises disposal of Hazardous Materials from the Premises, and
              (iv) conducting such tests as Landlord reasonably deems appropriate, all such work to be performed at Landlord&#8217;s sole expense except as otherwise provided in the next sentence. In addition to, and not in limitation of the rights provided in
              the immediately preceding sentence, if required by any governmental agency or if Landlord reasonably believes that a release of Hazardous Materials has occurred on or from the Premises by Tenant or any Tenant Party or a threat of release
              exists arising from Hazardous Materials not being handled, stored, used or disposed of by Tenant or any Tenant Party in accordance with the requirements of this Lease and all applicable Environmental Laws, then Landlord may, but need not,
              perform appropriate testing and the reasonable costs thereof shall be reimbursed to Landlord by Tenant within ten (10) Business Days of demand, as Additional Rent, <u>except</u> that Landlord shall bear the cost of such testing if (i)
              Landlord (rather than a governmental agency) requested such testing and (ii) such testing determines that no such release has occurred as a result of the actions of Tenant or any Tenant Party and that Hazardous Materials are being handled,
              used, stored and disposed of in compliance with the terms of this Lease and all applicable Environmental Laws. Tenant shall cooperate with Landlord in connection with any environmental audits or other inspections or testing performed by
              Landlord pursuant to this Section. Landlord and any third parties conducting such audits and/or inspecting Tenant&#8217;s books and records shall enter into reasonable non&#8209;disclosure and confidentiality agreements with Tenant, in form reasonably
              acceptable to Landlord and Tenant.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">If any transportation, generation, storage, use or disposal of Hazardous Materials on or about the
              Premises or the Land by Tenant or any Tenant Party results in the release onto, or other contamination of, any portion of the Unit, the Building, the Land, or any other portion of the Development or adjacent areas, soil or surface or ground
              water, or any loss or damage to person(s) or property, Tenant agrees to: (a) notify Landlord immediately, once Tenant has knowledge or has received notice, of any release, contamination, claim of contamination, loss or damage, and (b) after
              consultation with Landlord, clean up the release or contamination in compliance with all applicable Environmental Laws or Legal Requirements. In the event of such contamination, Tenant agrees to cooperate fully with Landlord and to provide
              such documents, affidavits and information as may be reasonably requested by Landlord (1) to comply with any Environmental Law or Legal Requirement, and/or (2) to comply with the request of any lender, investor or purchaser with respect to
              Hazardous Materials. Tenant shall notify Landlord promptly in the event of any spill or other release of any Hazardous Material at, in, on, under or about the Premises, the Building or elsewhere within the Development by Tenant or any Tenant
              Party that is required to be reported to a governmental authority under any Environmental Law or Legal Requirement, shall promptly forward to Landlord copies of any written notices received by Tenant relating to alleged violations of any
              Environmental Law or Legal Requirement and shall promptly pay when due any fine or assessment against Landlord, Tenant, the Premises, the Unit or any other portion of the Development relating to any violation of any Environmental Law or Legal
              Requirement by Tenant or any Tenant Party. If any governmental authority files a lien against the Premises, the Unit, the Building or any other portion of the Development due to any act or omission, intentional or unintentional, of Tenant or
              any Tenant Party that results or has resulted in the releasing, spilling, leaking, leaching, pumping, emitting, pouring, emptying or dumping of any Hazardous Material, Tenant shall, within ten (10) Business Days from the date that Tenant is
              first given notice of such lien (or within such shorter period of time as may be specified by Landlord if such governmental authority takes steps to enforce such lien) either (A) pay the claim and remove the lien or (B) furnish a cash
              deposit, bond or such other security as is reasonably satisfactory in all respects to Landlord and sufficient to discharge the lien completely.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">38</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Any increase in the premium for necessary insurance on the Premises, the Unit or the Building which
              arises from Tenant&#8217;s use and/or storage of Hazardous Materials beyond those typically found in laboratory and office space used for comparable purposes shall be solely at Tenant&#8217;s expense. Tenant shall procure and maintain at its sole expense
              such additional insurance as may be required to comply with any requirement of any federal, state or local government agency with jurisdiction.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(g)</font>&#160; &#160; &#160; &#160; &#160; <font style="color: rgb(0, 0, 0);">Except to the extent caused by the negligence or willful misconduct of Landlord, its employees, agents
              or contractors, or the Indemnitees, Tenant shall indemnify, defend with counsel reasonably acceptable to Landlord and hold the Indemnitees fully harmless from and against any and all liability, loss, suits, claims, actions, causes of action,
              proceedings, judgments, demands, costs, penalties, damages (including indirect and consequential damages), fines and expenses, including reasonable attorneys&#8217; fees (including reasonable attorneys&#8217; fees of Landlord&#8217;s counsel and costs of
              litigation), consultants&#8217; fees, laboratory fees and clean&#8209;up costs, and the costs and expenses of investigating and defending any claims or proceedings, resulting from, or attributable to (i) the presence of any Hazardous Materials on or in
              the Premises, the Building or the Development arising from the act, omission or negligence of Tenant or any Tenant Party, or arising out of the generation, storage, treatment, handling, transportation, disposal or release by Tenant or any
              Tenant Party of any Hazardous Materials at or near the Premises or the remainder of the Development, (ii) any violation(s) by Tenant or any Tenant Party of any Environmental Laws, (iii) any Environmental Incidents (as defined above) and (iv)
              any breach by Tenant of its covenants and obligations under this <u>Section 9.04</u>, <u>Section 9.13</u> or <u>Section 10.07</u>.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(h)</font>&#160;&#160;&#160;&#160; &#160; &#160; <font style="color: rgb(0, 0, 0);">Landlord shall indemnify, defend and hold Tenant fully harmless from and against any and all liability,
              loss, suits, claims, actions, causes of action, proceedings, judgments, demands, costs, penalties, damages, fines and expenses, including reasonable attorneys&#8217; fees and costs of litigation, consultants&#8217; fees, laboratory fees and clean&#8209;up
              costs, and the costs and expenses of investigating and defending any claims or proceedings, resulting from, or attributable to the presence of any Hazardous Materials on or in the Premises, the Building or the Development which were present
              prior to the Date of Lease and which require remedial action under applicable Environmental Laws.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">Any permit application for laboratory/research use or occupancy which includes the use of chemical fume
              hoods shall include an &#8220;Exhaust Air Dispersion Report&#8221; which includes a detailed exhaust dispersion analysis demonstrating that each fume hood exhaust plume is directed upward sufficient to ensure that prevailing winds will not carry the
              exhaust plume into fresh air intakes, open windows, or into a pedestrian environment.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="color: rgb(0, 0, 0);">The provisions of this <u>Section 9.04</u> shall survive the expiration of the Term or the earlier
              termination of this Lease.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Reference is made to <u>Section 10.07</u> for provisions relating to the decommissioning of the
              Premises by Tenant upon the expiration of the Term or the earlier expiration of this Lease.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">39</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.05.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Signs</font>. Except as expressly otherwise provided in this
            Section and except for the Initial Tenant Work, no sign, antenna or other structure or thing shall be erected or placed on the Premises or on any part of the exterior of the Building or anywhere on the Land, or otherwise erected or installed so
            as to be visible from the exterior of the Building, without first securing the written consent of Landlord, which be withheld by Landlord in its sole and absolute discretion Landlord, at Landlord&#8217;s cost, shall provide building standard signage
            within the Unit lobby identifying Tenant. Landlord shall also provide to Tenant Tenant&#8217;s Percentage Share of entries on any directory maintained by Landlord from time to time within the Unit. If Landlord does consent to the installation by
            Tenant of any exterior signage (without hereby implying any obligation on the part of Landlord so to consent), then (i) such sign shall be installed at the location, and shall be mounted and illuminated, as so approved by Landlord, and (ii)
            Tenant shall be solely responsible, at its sole cost and expense, but with Landlord&#8217;s reasonable cooperation at no cost or expense to Landlord, for (A) obtaining and maintaining in full force and effect all licenses, permits and approvals
            required from any governmental authority in connection with the installation or maintenance of all exterior signage, (B) the installation, maintenance and repair of all exterior signage, and shall maintain the same in good condition at all
            times, and (C) removing all signage installed by Tenant upon the expiration or earlier termination of the Term, and repairing all damage caused by such removal to Landlord&#8217;s reasonable satisfaction. All signage installed by or on behalf of
            Tenant shall comply with all applicable Legal Requirements. In the event that Landlord elects in the future to install a monument sign for the Building upon which the names of tenants can be displayed (without hereby obligating Landlord to
            install any such monument sign), Landlord shall make available to Tenant for the display of its name thereon Tenant&#8217;s Percentage Share of the portion of the monument sign reserved for the display of the names of tenants in the Building.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.06.</font>&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Access</font>. Subject to the provisions of this
            Section, Landlord or its agents may enter the Premises at all reasonable times to show the Premises to potential buyers, investors, tenants (but with respect to potential tenants, only in the final twelve (12) months of the Term) or other
            parties; to inspect and conduct tests in order to monitor Tenant&#8217;s compliance with Legal Requirements governing Hazardous Materials; for purposes described in <u>Sections 2.01</u>, <u>9.04</u>, <u>10.03</u> and/or <u>10.04(b)</u>; or for
            any other purpose Landlord reasonably deems necessary. No prospective lender, purchaser, or tenant claiming through Landlord shall be permitted access to the Premises without a representative of Landlord present. Except in the event of an
            emergency posing an imminent threat of personal injury or damage to the Premises (in which event notice shall be provided as soon as reasonably practicable), Landlord shall give Tenant at least forty&#8209;eight (48) hours&#8217; prior notice (which may be
            by e&#8209;mail to Tenant at eperry@remixtx.com<u>)</u> of any entry by Landlord into the Premises. Tenant may reasonably designate by written notice to Landlord certain &#8220;secure areas&#8221; within the Premises as to which any entry by Landlord, other than
            in case of emergency, shall occur only with a representative of Tenant or its authorized designee present; provided that if Tenant or its authorized designee fails to appear for a scheduled inspection or access by Landlord, Landlord may
            nevertheless proceed with such scheduled inspection or access so long as Landlord complies with Tenant&#8217;s standard protocols for such access of which Tenant has given Landlord written notice at least five (5) Business Days prior to Landlord&#8217;s
            entry. Notwithstanding the preceding provisions of this Section, in case of emergency, Landlord may enter any part of the Premises at any time without prior notice to Tenant provided that Landlord provides Tenant with notice of such entry as
            soon as reasonably possible thereafter. Landlord shall use reasonable efforts not to interfere with Tenant&#8217;s use and occupancy of the Premises for the Permitted Use when exercising Landlord&#8217;s rights under this paragraph. Landlord agrees to
            comply with Tenant&#8217;s reasonable requirements (including requirements in connection with access, health, safety, and/or security checks) in connection with non&#8209;emergency access to the Premises to the extent to which the same are consistent with
            the provisions of this Section and have been provided to Landlord in writing prior to any such entry.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">40</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.07.</font>&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Rules and Regulations</font>. Tenant and all Tenant
            Parties shall observe Landlord&#8217;s rules and regulations (&#8220;<font style="font-weight: bold;">Landlord</font>&#8217;<font style="font-weight: bold;">s Rules and Regulations</font>&#8221;) promulgated (and amended from time to time) with respect to the
            occupation and use of the Unit, the Premises, the parking facilities or the Common Areas, and of general applicability to all tenants of the Building and the Unit (including all Landlord&#8217;s Rules and Regulations which are applicable only to
            tenants which are using their leased premises for laboratory purposes, such as Tenant), provided that (i) Tenant receives reasonable prior written notice of such Landlord&#8217;s Rules and Regulations, and (ii) the same are not inconsistent with the
            provisions of this Lease. In the event of a conflict between the Rules and Regulations and this Lease, this Lease shall control. Tenant and all Tenant Parties shall also comply with all rules and regulations adopted from time to time by the
            Primary Condominium Trust pursuant to the Condominium Documents (such rules and regulations, together with Landlord&#8217;s Rules and Regulations, are referred to herein, collectively, as the &#8220;<font style="font-weight: bold;">Rules and Regulations</font>&#8221;).







            The initial Landlord&#8217;s Rules and Regulations are set forth in <font style="font-weight: bold;"><u>Exhibit</u></font><u>&#160;</u><font style="font-weight: bold;"><u>H</u></font> attached hereto. Landlord&#8217;s Rules and Regulations may also include, if
            any portion of the Building is being used as an animal facility at any time, provisions specifically relating thereto. Nothing contained in this Lease shall be construed to impose upon Landlord any duty or obligation to enforce the Rules and
            Regulations, or the terms, covenants or conditions in any other lease as against any other tenant and Landlord shall not be liable to Tenant for violation of the same by any other tenant or such other tenant&#8217;s servants, employees, agents,
            contractors, visitors, invitees or licensees; <font style="font-style: italic;">provided, however,</font> that Landlord shall enforce the Rules and Regulations in a non&#8209;discriminatory manner.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.08.</font>&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Compliance With Insurance Requirements</font>. Tenant and all
            Tenant Parties shall at all times comply with (i) the terms of any policy of insurance maintained by Landlord, Tenant or the Primary Board and applicable to the Premises, the Unit, the Building or the Development, or any portion of any of the
            foregoing, provided that such terms either (x) are typical of those contained in insurance policies customarily issued with respect to properties similar to the Building or the Development, or (y) have been provided or described in writing to
            Tenant, (ii) all requirements of the issuer of any such policy, which requirements have been provided or described in writing to Tenant, and (iii) all orders, rules, regulations and other requirements of the National Board of Fire Underwriters
            (or any other body exercising similar functions, if any) (collectively, &#8220;<font style="font-weight: bold;">Insurance Requirements</font>&#8221;).</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.09.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Floor Load; Heavy Machinery</font>. Tenant shall not place a load
            upon any floor of the Premises exceeding the floor load per square foot of area which such floor was designed to carry and which is allowed by Legal Requirements. Tenant acknowledges receipt from Landlord of the foregoing floor load
            information. Landlord reserves the right to reasonably prescribe the weight and position of all heavy machinery and mechanical equipment, which shall be placed so as to distribute the weight. Heavy machinery and mechanical equipment shall be
            placed and maintained by Tenant at Tenant&#8217;s expense in settings sufficient in Landlord&#8217;s reasonable judgment to absorb and prevent vibration, noise and annoyance. Tenant shall schedule and coordinate the installation or moving of any heavy
            machinery, heavy equipment, freight, bulky matter, or other oversize fixtures into or out of the Building with Landlord or its property manager. If such machinery, equipment, freight, bulky matter or fixtures requires special handling, Tenant
            agrees to employ only persons holding a Master Rigger&#8217;s License to do said work, and that all work in connection therewith shall comply with applicable Legal Requirements. Any such moving shall be at the sole risk and hazard of Tenant and
            Tenant will defend, indemnify and save Landlord harmless against and from any liability, loss, injury, claim or suit resulting directly or indirectly from such moving. Proper placement of all such heavy machinery, etc., in the Premises shall be
            Tenant&#8217;s responsibility.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">41</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.10.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">LEED/Energy Conservation Measures</font>. Tenant acknowledges that
            Landlord is required by the terms of certain of the permits issued by the Town of Watertown for the Development to design and construct the Unit so as to be certifiable at a Silver level in the Leadership in Energy and Environmental Design Core
            &amp; Shell program (&#8220;<font style="font-weight: bold;">LEED&#8209;CS</font>&#8221;), and has designed and constructed the Building to achieve that goal. Tenant further acknowledges and agrees that such certification will require Tenant to comply with the
            following requirements in connection with the design, construction, use and operation of its Premises:</div>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z20f7c2cded824ae4855bd31c7ded655b" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(1)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;"><u>Mandatory Leadership in Energy and Environmental Design (LEED) Tenant Compliance</u></font><font style="font-size: 10pt;">. Tenant shall meet the following
                      design and construction requirements in support of and in compliance with the LEED&#8209;CS prerequisites and credits attempted within the base&#8209;building LEED&#8209;CS certification application:</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z651fb086b9ed49fc8136b7662f01d847" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 72pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37); font-weight: bold;">a.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">EAp3 Fundamental Refrigerant Management</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">: Any additional HVAC &amp;
                      Refrigeration equipment and/or systems installed by Tenant must comply with the following: </font><font style="font-size: 10pt; font-style: italic; color: rgb(0, 0, 0);">&#8220;zero use of chlorofluorocarbon (CFC)&#8209;based refrigerants in new
                      heating, ventilating, air conditioning and refrigeration (HVAC&amp;R) systems. Small HVAC units (defined as containing less than 0.5 pounds (228 grams) of refrigerant) and other equipment, such as standard refrigerators, small water
                      coolers and any other equipment that contains less than 0.5 pounds (228 grams) of refrigerant, are not subject to the requirements of this prerequisite&#8221;.</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb07a753e4666483cb4c263880a3b30b4" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 72pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37); font-weight: bold;">b.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">IEQp1 Minimum Air Quality Performance</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">: All mechanical ventilation systems
                      installed by Tenant must </font><font style="font-size: 10pt; font-style: italic; color: rgb(0, 0, 0);">&#8220;meet the minimum requirements of Sections 4 through 7 of ASHRAE Standard 62.1&#8209;2007, Ventilation for Acceptable Indoor Air
                      Quality. Mechanical ventilation systems must be designed using the ventilation rate procedure or the applicable local code, whichever is more stringent.&#8221;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"> Compliance must be
                      demonstrated through calculations performed in alignment with the Ventilation Rate Procedure methodology as per section 6.2 of the ASHRAE 62.1&#8209;2007 standard.</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za88ef8d5b4a54bbf80d6be9b9239168f" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 36pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(2)</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;"><u>Mandatory Tenant Energy Conservation Measures (ECMs)</u></font><font style="font-size: 10pt;">. Tenant shall adhere to the following performance
                      requirements to support and align with the Energy Conservation Measures incorporated in the base&#8209;building Core and Shell building systems and building envelope design and the LEED&#8209;CS whole building energy model:</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3353bdd65c1d4cc1a2c298206c9d0a44" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 72pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37); font-weight: bold;">a.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Lighting Power Density</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">: The installed interior lighting power in the Premises
                      must be designed to be equal to or less than 0.75 Watts/SF using the Building Area Calculation Method as referenced in ASHRAE 90.1&#8209;2007.</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">42</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8988e1bf652a4af88d39db0e3c5cf5a3" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 72pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37); font-weight: bold;">b.</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; color: rgb(0, 0, 0);">Lighting Controls</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">: Tenants are required to provide the following lighting
                      controls with respect to any office space contained within their respective leased premises:</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5da3ae2231b4ada872c76ba03d49de0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 108pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">Daylight dimming: </font><font style="font-size: 10pt;">The Premises shall be designed to meet the following daylight dimming requirements:</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1db32780d7f0438a830233fda17bb82a" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 144pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>Automatic daylight harvesting controls must be provided in all tenant spaces that are within 15 ft of the exterior walls.</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z513978da04b34ff09d30e8f658907f4e" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 144pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>All lighting in these areas must be automatically controlled based on available daylight and is dimmed from 100% to 30% of the light output with a proportional power input reduction (from 100% to 30% of the power input).</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2f63d00748ad47ef8b74c4d4e306f04c" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 144pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div>The light level setpoint shall be 50 fc at a horizontal plane that is 2.5 ft above the floor.</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb8c2565d81ed4b2597a94c8e51065698" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 108pt;"><br>
                </td>
                <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">Occupancy Sensors on Lighting: </font><font style="font-size: 10pt;">Occupancy sensors must be provided for light control in all tenant spaces.</font></div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="text-align: justify;">Beyond adhering to the requirements of the above listed LEED&#8209;CS prerequisites and credits, Tenant, at its own cost and expense, shall design and construct the Initial Tenant Work and all subsequent Tenant Work,
            and shall operate within the Premises, so as to render the Premises certifiable under the LEED 2009 program for Commercial Interiors at a Silver level. Even if third&#8209;party certification is not pursued, Tenant shall be required to comply with
            the aforementioned LEED prerequisites and credits. In addition to and without limiting any of the foregoing, Tenant shall comply with the LEED design, construction and performance requirements for Arsenal Yards set forth on <font style="font-weight: bold;"><u>Exhibit I</u></font> attached hereto and incorporated herein by reference (the &#8220;<font style="font-weight: bold;">LEED Requirements</font>&#8221;).</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.11.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Emergency Generator</font>. Tenant shall have the right to tie
            into and use the emergency generator to be installed by Landlord as part of the Base Building Work for use by tenants of the Unit (the &#8220;<font style="font-weight: bold;">Unit Generator</font>&#8221;). Tenant shall be responsible, at its sole cost and
            expense, for installing, maintaining, repairing and replacing its connection between the Premises and the Unit Generator, and all associated cabling. Tenant shall be permitted to use up to an average of three (3) watts per square foot of usable
            area in the Premises from the Unit Generator, and at no time shall Tenant exceed that use limitation with respect to the Unit Generator. Except to the extent that Tenant ties into the Unit Generator as part of the Initial Tenant Work in
            accordance with the provisions of the Work Letter, installation of such tie&#8209;in and any related cabling, conduit and appurtenances will be governed by the applicable provisions of this Lease relating to Tenant Work. Tenant will submit to
            Landlord at least thirty (30) days prior to the proposed installation date Tenant&#8217;s proposed plans and specifications relating to the tie&#8209;in to the Unit Generator and all associated lines. Tenant may not commence any work to tie into the Unit
            Generator until it has received Landlord&#8217;s prior written approval (not to be unreasonably withheld, delayed or conditioned) of such plans and specifications. Tenant, at its sole cost and expense, shall comply with all applicable Legal
            Requirements and Title Matters and Landlord&#8217;s reasonable directives relating to the installation, operation, maintenance and repair of such tie&#8209;in, including (i) obtaining and maintaining (or causing to be obtained and maintained) and complying
            with the provisions of all applicable permits relating to the tie into and use of the Unit Generator. Tenant may not use the Unit Generator for any purpose other than solely in connection with Tenant&#8217;s occupancy of the Premises for the
            Permitted Use and in accordance with any applicable permit(s) pertaining to the Unit Generator. Except for permitted subtenants and assignees. Tenant may not use the Unit Generator to serve other occupant(s) of the Development.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">43</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.12.</font>&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Rooftop Rights</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">Tenant shall be permitted, in locations on the roof of the Building as approved by Landlord in writing
              in advance, to install, operate, maintain, repair and remove, all at Tenant&#8217;s sole cost and expense and for use solely by Tenant in connection with its business operations conducted in the Premises and not for use by non&#8209;occupant third
              parties, telecommunications and data processing equipment (including but not limited to satellite dishes, cell boosters and antennae), and related wiring from the roof to the interior portions of the Premises to the extent reasonably
              necessary (collectively, the &#8220;<font style="font-weight: bold;"><u>Rooftop Communications Equipment</u></font>&#8221;), provided the same complies with all Legal Requirements, all Title Matters and the provisions of the Condominium Documents. No
              rooftop installations other than Rooftop Communications Equipment installed in accordance with the provisions of this <u>Section 9.12</u> shall be permitted. The Rooftop Communications Equipment shall be screened from exterior view in a
              manner reasonably acceptable to Landlord and as may be required by the Town of Watertown. Tenant shall be responsible for all costs and expenses associated with or relating to the Rooftop Communications Equipment, including installation,
              operation, maintenance, use, removal and insuring of the Rooftop Communications Equipment (same being deemed Tenant&#8217;s personal property for purposes of this Lease), and shall reimburse Landlord any reasonable, actual out&#8209;of&#8209;pocket costs
              incurred by Landlord in connection therewith, including, but not limited to any costs for electric power that Tenant uses in the Building for the Rooftop Communications Equipment, as separately metered. Landlord shall have the right to permit
              other tenants of the Building to lease space on the roof of the Building for such other party&#8217;s own rooftop antennae, satellite dishes and other telecommunications equipment to be used in the conduct of such tenant&#8217;s business operations in
              the Building and not elsewhere, provided that (i) Tenant shall continue to have full access to the Rooftop Communications Equipment, (ii) Tenant&#8217;s right to install, use, improve, add to and replace Rooftop Communications Equipment shall be
              non&#8209;exclusive and shall be shared on a pro rata basis with any such rights granted to other tenant(s) in the Buildings, (iii) Landlord shall not install, and shall prohibit the installation and/or operation by any other party of, any
              additional microwave dishes/earth satellite disks, antennae, towers and/or other structures on the roof which would, in Tenant&#8217;s reasonable judgment, interfere with Tenant&#8217;s use of the Rooftop Communications Equipment which is then in place.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">44</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160; &#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Prior to installing any Rooftop Communications Equipment, Tenant shall submit to Landlord for its
              approval plans and specifications that (i) specify in detail the design, location, size and operating frequency(ies) of the Rooftop Communications Equipment and (ii) are sufficiently detailed to allow for the installation of the Rooftop
              Communications Equipment in a good and workmanlike manner and in accordance with all Legal Requirements. Following Landlord&#8217;s written approval of such plans, Tenant shall obtain all permits required for the installation and operation thereof,
              and copies of all such permits must be submitted to Landlord before Tenant begins to install the Rooftop Communications Equipment. Tenant shall be permitted to select a contractor of its choice to undertake the installation of the Rooftop
              Communications Equipment, subject to Landlord&#8217;s approval. Tenant shall install all Rooftop Communications Equipment in a good and workmanlike manner, and shall maintain and use the Rooftop Communications Equipment in accordance with all
              applicable Legal Requirements, Title Matters and the provisions of the Condominium Documents. Tenant shall also have the right to install reasonably necessary conduit and sleeving from the roof to the points of connection within the Premises.
              Tenant shall be responsible for all costs of installation (including structural reinforcing or modifications required to be made to the roof in order to support Tenant&#8217;s Rooftop Communications Equipment), repair, maintenance and removal with
              respect to the Rooftop Communications Equipment. Tenant shall thereafter maintain all permits necessary for the maintenance and operation of the Rooftop Communications Equipment while it is on the Building. Tenant shall maintain the Rooftop
              Communications Equipment in good repair and condition and in such a manner so as not to interfere in any material respect with any other satellite, antennae or other transmission facility on the roof or elsewhere in the Building which is or
              was installed and operating either prior to or after Tenant&#8217;s installation of the Rooftop Communications Equipment. Tenant shall repair any damage to the Building caused by or relating to the Rooftop Communications Equipment, including that
              which is caused by its installation, maintenance, use or removal, and Tenant shall reimburse Landlord for any out&#8209;of&#8209;pocket costs and expenses incurred by Landlord for any actual damage to the Building, including any damage resulting from
              penetrations of the Roof with respect to such installation, maintenance or use.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">Unless otherwise expressly agreed by Landlord in writing as part of its approval of the installation of
              such Rooftop Communications Equipment, Tenant shall, at its expense, remove the Rooftop Communications Equipment prior to the expiration of the Term (or within thirty (30) days after the earlier termination of the Term). If Tenant fails to do
              so, Landlord may remove the Rooftop Communications Equipment and store or dispose of it in any manner Landlord deems appropriate without liability to Tenant; Tenant shall reimburse Landlord for all actual out&#8209;of&#8209;pocket costs and expenses
              incurred by Landlord in connection therewith within thirty (30) days after Landlord&#8217;s request therefor.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);">All work relating to the Rooftop Communications Equipment shall, at Landlord&#8217;s written request, be
              coordinated with Landlord&#8217;s roofing contractor so as not to void any warranty for the Roof.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">45</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">9.13.</font>&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Neutralization System</font>. Landlord shall install as part of the
            Base Building Work an acid neutralization system for use by tenants of the Unit (the &#8220;<font style="font-weight: bold;">Neutralization System</font>&#8221;) in a location within the Building selected by Landlord, together with piping to each floor of
            the Premises (piping on each floor of the Premises connecting the Premises to the Neutralization System shall be Tenant&#8217;s responsibility). Tenant shall have the right to connect to and use the Neutralization System for the purposes for which it
            is intended only, which usage shall be at all times in accordance with the provisions of this Lease and with all applicable Legal Requirements (including the provisions of all such permits and approvals obtained by Landlord with respect to the
            Neutralization System) and best industry, laboratory and scientific standards and practices. Landlord shall obtain (and renew as applicable) all permits and approvals required by any Legal Requirement for the installation and use of the
            Neutralization System. Tenant shall be responsible, at its sole cost and expense, for complying with all such permits and approvals with respect to Tenant&#8217;s use of the Neutralization System. Landlord shall operate, maintain, repair, service and
            replace the Neutralization System in accordance with all applicable Legal Requirements so as to keep the same in good operating condition, with the costs of such operation, maintenance, repair, servicing and replacement to be included within
            Operating Expenses to be paid by Tenant and other tenants of the Unit using the Neutralization System from time to time; <font style="font-style: italic;">provided, however,</font> that Tenant shall be solely responsible for, at its sole cost
            and expense, costs and expenses (including reasonable attorneys&#8217; fees) arising out of or in any way related to any alleged or actual violation of any provision of this Lease or any applicable Legal Requirement by Tenant in connection with
            Tenant&#8217;s use of the Neutralization System, which obligation of Tenant shall survive the expiration or earlier termination of this Lease.</div>
          <div><br>
          </div>
          <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;">ARTICLE 10: CONDITION AND MAINTENANCE OF PREMISES</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.01.</font>&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Existing Conditions</font>. Tenant acknowledges that except for any
            express representations contained in this Lease, neither Landlord nor any person acting under or on behalf of Landlord has made any representation as to the condition of the Premises, the Unit, the Building or the Development, or the
            suitability of the Premises, the Unit, the Building or the Development for Tenant&#8217;s intended use. Tenant represents and warrants that Tenant has made its own inspection and inquiry regarding the Premises, the Unit, the Building and the
            Development, and is not relying on any representations of Landlord or any broker or persons acting on behalf of Landlord other than as set forth in this Lease. Notwithstanding the foregoing, Landlord and Tenant understand and acknowledge that
            as of the date hereof the Building is under construction and that Landlord represents and warrants that the Building and its improvements will be completed substantially in conformity with the provisions of this Lease (including, but not
            limited to, <font style="font-weight: bold;"><u>Exhibit</u></font><u>&#160;</u><font style="font-weight: bold;"><u>A</u></font><u>,</u>&#160;<font style="font-weight: bold;"><u>Exhibit</u></font><u>&#160;</u><font style="font-weight: bold;"><u>B</u></font><u>,</u>&#160;<font style="font-weight: bold;"><u>Exhibit</u></font><u>&#160;</u><font style="font-weight: bold;"><u>C&#8209;1</u></font>) and the Work Letter, and in accordance, in all material respects, with all applicable Legal Requirements.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.02.</font>&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">No Landlord Liability</font>. Landlord shall not be liable for any
            damage or injury to the persons, property or business (including loss of revenue, profits or data) of Tenant or any Tenant Party. <font style="font-style: italic;">provided, however,</font> that this <u>Section 10.02</u> shall not exempt
            Landlord from liability for Landlord&#8217;s negligence or willful misconduct, or the negligence or willful misconduct of its agents, employees and/or contractors, or Landlord&#8217;s breach of its obligations herein. This exemption shall apply whether
            such damage or injury is caused by (among other things): (i) fire, steam, electricity, water, gas, air, sewage, sewer gas or odors, snow, ice, frost or rain; (ii) the breakage, leakage, obstruction or other defects of pipes, faucets,
            sprinklers, wires, appliances, plumbing, windows, air conditioning or lighting fixtures or any other cause; (iii) explosion, electrical or electromagnetic emissions; (iv) any casualty or Taking; (v) theft; (vi) conditions in or about the Unit
            or the Building; or (vii) any act or omission of any other tenant. Tenant hereby agrees that, to the maximum extent permitted by law, all merchandise, furniture, fixtures and property of every kind, nature and description of Tenant or any
            Tenant Party which may be in or upon the Premises, the Unit, the Building or the Development, shall be at the sole risk and hazard of Tenant, and that if the whole or any part thereof shall be damaged, destroyed, stolen or removed from any
            cause or reason whatsoever, no part of said damage or loss shall be charged to, or borne by, Landlord, except to the extent caused by Landlord&#8217;s negligence or willful misconduct or the negligence or willful misconduct of its agents, employees
            or contractors, or Landlord&#8217;s breach of its obligations herein.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">46</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.03.</font>&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Landlord&#8217;s Repair and Maintenance Obligations</font>. Subject to
            the provisions of <u>Section 16.09</u>, and except for damage caused by fire, other casualty or taking (which is dealt with below), and damage caused by the act or omission of Tenant or any Tenant Party, Landlord shall maintain, or cause to be
            maintained, the foundations of the Building, the exterior walls and windows and roof (including roof membrane) of the Unit, the Unit Generator, the Building Systems (including the HVAC, plumbing, electrical, mechanical and other systems, as
            well as the Neutralization System, serving the Premises in common with other portions of the Unit), to the extent not serving the Premises or another tenant&#8217;s premises exclusively, the common areas and facilities of the Building, and any other
            items constituting Limited Common Elements of the Unit pursuant to the Condominium Documents (excluding those items that Tenant is responsible for under <u>Article 11</u>) in good order, condition and repair; provided that Tenant shall give
            Landlord written notice of the necessity for such repairs; and, provided further, that damage caused by the act or omission of Tenant or any Tenant Party shall, unless otherwise specified by Landlord, be promptly repaired by Tenant at its sole
            cost and expense. Landlord shall make any repairs or replacements to the Premises, the Unit (including the Unit Generator) or the Building, to the extent such repair or replacement was necessitated by Landlord&#8217;s negligence or willful misconduct
            or the negligence or willful misconduct of its agents, employees and/or contractors, or Landlord&#8217;s breach of its obligations herein, at its sole cost and expense and not to be reimbursed as an Operating Expense. In addition, Landlord shall
            enforce the applicable provisions of the Condominium Documents with respect to the maintenance, repair or replacement of the General Common Elements and all other buildings in the Development. Except to the extent caused by Landlord&#8217;s
            negligence or willful misconduct or the negligence or willful misconduct of its agents, employees and/or contractors, or Landlord&#8217;s breach of its obligations herein, Landlord shall not be obligated to maintain, repair or replace any interior
            windows, interior doors, plate glass, or the surfaces of walls within the Premises, or any fixtures, components or equipment located within the Premises or elsewhere which serve the Premises exclusively, all of which shall be Tenant&#8217;s
            obligation. Tenant waives the benefit of any present or future law that provides Tenant the right to repair the Premises, the Unit or the Building at Landlord&#8217;s expense or to abate or reduce the Rent or to terminate this Lease because of the
            condition of the Premises, the Unit or the Building, to the extent such benefit of law may be waived by Tenant. Except to the extent caused by the negligence or willful misconduct of Landlord or that of its agents, employees and/or contractors,
            Tenant shall not be entitled to any abatement of Rent, nor shall Landlord incur any liability, by reason of inconvenience, annoyance or injury to Tenant arising from any repairs, alterations, additions, replacements or improvements made by
            Landlord, or any related work undertaken by Landlord in accordance with the provisions of this Lease provided Landlord complies with the terms of <u>Section 9.06</u> regarding access to the Premises. Notwithstanding the fact that Landlord may
            provide security services at the Unit or the Building at any time during the term of this Lease, (i) Tenant hereby releases Landlord from any claim for injury to persons or damage to property asserted by Tenant or any Tenant Party that is
            suffered or occurs in or about the Premises or in or about the Unit, the Building or the Development by reason of the act of any intruder or any other person, and (ii) Landlord shall not be deemed to owe Tenant or any other person any duty or
            standard of care as a result of Landlord&#8217;s provision of such security services. All costs and expenses incurred by Landlord in connection with the performance of any obligation set forth in this <u>Section 10.03</u> shall be included in
            Operating Expenses except to the extent otherwise expressly provided above in this Section.</div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">47</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.04.</font>&#160;&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Tenant&#8217;s Obligations</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="color: rgb(0, 0, 0);"><u>Repair and Maintenance</u>. Except for work that <u>Section 10.03</u> requires Landlord to do and
              subject to <u>Section 16.09</u>, Tenant, at its sole cost and expense: shall keep the Premises (including all Initial Tenant Work, other Tenant Work, Tenant Property, and all fixtures, systems and equipment now or hereafter on the Premises
              or elsewhere that exclusively serve the Premises regardless of whether or not the same are part of a Building System), together with any Limited Common Elements (or portions thereof) with respect to which Tenant has exclusive rights, and any
              interior windows, interior doors, interior plate glass, and the inner surfaces of walls within the Premises, in at least as good order, condition and repair as they are in on the Delivery Date or may be thereafter put in during the Term,
              reasonable wear and tear, damage caused by fire, other casualty or taking (which is dealt with below) and damage caused by the negligence or willful misconduct of Landlord, Landlord&#8217;s agents, employees, or contractors excepted; shall keep in
              a secure and sanitary condition all trash and rubbish temporarily stored at the Premises; and shall make all repairs and replacements and do all other work necessary for the foregoing purposes, whether the same may be ordinary or
              extraordinary, foreseen or unforeseen. Without limitation, Tenant shall be responsible for the maintenance, repair and replacement of all plumbing, heating, ventilating and air&#8209;conditioning systems and other mechanical systems (whether or not
              part of the Building Systems) wherever located that exclusively serve the Premises, and Tenant shall secure, pay for, and keep in force contracts with appropriate and reputable service companies approved by Landlord (which approval shall not
              be unreasonably withheld, conditioned or delayed) providing for the regular maintenance of such systems to the extent that such systems exclusively serve the Premises. All repairs and replacements required to be made by Tenant hereunder shall
              be equal in quality and class to the original work. No storage shall be permitted outside of the Premises except as otherwise expressly provided in this Lease. Storage inside the Premises shall be provided in a manner not visible from outside
              the Premises.</font></div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Landlord&#8217;s Right to Cure</u>. If Tenant does not perform any of its obligations under <u>Section
                10.04(a)</u>, Landlord upon ten (10) days&#8217; prior written notice to Tenant (or in the case of an emergency, with notice provided as soon as reasonably practicable) may perform such maintenance, repair or replacement on Tenant&#8217;s behalf, and
              Tenant shall reimburse Landlord, as Additional Rent, for all costs reasonably incurred, together with an Administrative Charge (as defined in <u>Section 13.02(e))</u>, within ten (10) days of Landlord&#8217;s written demand.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">48</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; color: rgb(0, 0, 0);">10.05.</font>&#160;&#160;&#160; <font style="font-weight: bold; color: rgb(0, 0, 0);">Tenant Work</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);"><u>General</u>. &#8220;<font style="font-weight: bold;">Tenant Work</font>&#8221; shall mean all work, demolition,
              installations, improvements, additions and alterations made by or on behalf of Tenant in or to the Premises or, when expressly permitted by Landlord in advance, on or to any other portion of the Unit or the Building. Without limitation,
              Tenant Work includes any penetrations in the walls, partitions, ceilings or floors and all attached carpeting, all signs visible from the exterior of the Premises, and all changes in the exterior appearance of the windows of the Premises
              (including shades, curtains and the like). All Tenant Work shall be subject to Landlord&#8217;s prior written approval (which approval shall not be unreasonably withheld, conditioned, or delayed) and shall be arranged and paid for by Tenant, all as
              provided herein; <font style="font-style: italic;">provided that</font> any interior non&#8209;structural Tenant Work (including any series of related Tenant Work projects) that (a) costs less than the &#8220;<font style="font-weight: bold;">Tenant Work
                Threshold Amount</font>&#8221; (which shall be $75,000 in each instance or series of related projects, <font style="font-style: italic;">provided that</font> from and after the point at which the aggregate cost of Tenant Work proposed by Tenant
              in any Lease Year exceeds $150,000, all Tenant Work proposed during such Lease Year shall be deemed to exceed the Tenant Work Threshold Amount and shall require Landlord&#8217;s prior written approval), (b) does not adversely affect any structural
              component of the Building or the Unit, or any elevators, fire&#8209;safety, telecommunications, curtain wall, electrical, heating, ventilation, plumbing or any other mechanical system of the Unit or the Neutralization System (collectively, the &#8220;<font style="font-weight: bold;">Building Systems</font>&#8221;), (c) does not adversely affect any penetrations in or otherwise adversely affect any walls, floors, roofs, or other structural elements of the Building or the Unit, or the curtain wall,
              (d) does not involve the removal of more than a de minimis amount of the laboratory furnishings, laboratory equipment or laboratory machinery which was installed as part of the Initial Tenant Work, and (e) does not include any signs visible
              from the exterior of the Premises or any change in the exterior appearance of the windows in the Premises (including shades, curtains and the like) shall not require Landlord&#8217;s prior approval if Tenant delivers the Construction Documents (as
              defined in <u>Section 10.05(b))</u> for such work to Landlord at least five (5) Business Days&#8217; prior to commencing such work. Without limiting Landlord&#8217;s rights hereunder, Landlord shall not be deemed unreasonable for withholding its
              approval as to any Tenant Work which would require unusual expense to re&#8209;adapt the Premises or any portion thereof to typical laboratory use upon the termination or expiration of this Lease. In any event, non&#8209;structural cosmetic work such as
              painting, carpeting and wall coverings within the Premises (&#8220;<font style="font-weight: bold;">Cosmetic Work</font>&#8221;) shall not require Landlord&#8217;s consent or be included in the calculation of the Tenant Work Threshold, and no prior notice to
              Landlord of such work is required. Whether or not Landlord&#8217;s approval is required, Tenant shall neither propose nor effect any Tenant Work that in Landlord&#8217;s reasonable judgment (i) adversely affects any structural component of the Building
              or the Unit, (ii) materially affects any Building System, (iii) affects the exterior or the exterior appearance of the Unit or the Building or common areas within or around the Building, (iv) includes the installation of equipment that will
              have an unreasonable acoustic impact on other tenants of the Building or the Unit when compared to similar equipment in first&#8209;class laboratory/research and development buildings, (v) diminishes the value of the Premises, the Unit or the
              Building, (vi) involves the removal of more than a de minimis amount of the laboratory furnishings, laboratory equipment or laboratory machinery which was installed as part of the Initial Tenant Work, or (vii) requires any unusual expense to
              readapt the Premises or any portion thereof to typical laboratory use upon the termination or expiration of this Lease. Any disputes regarding the scope and estimated cost of the work necessary to readapt the Premises or any portion thereof
              to typical laboratory use upon the termination or expiration of this Lease shall be resolved pursuant to <u>Section 16.17</u>. Prior to commencing any Tenant Work affecting air disbursement from ventilation systems serving the Premises,
              including the installation of Tenant&#8217;s exhaust systems, Tenant shall provide Landlord with a third&#8209;party report from a consultant, and in a form, reasonably acceptable to Landlord, showing that such work will not adversely affect the
              ventilation systems of the Unit (or of any other tenant in the Unit) and shall, upon completion of such work, provide Landlord with a certification reasonably satisfactory to Landlord from such consultant confirming that no such adverse
              effects have resulted from such work. Landlord shall have the right to require Tenant to provide to Landlord from time to time while Tenant&#8217;s Work is being performed, periodic lien waivers in statutory form from Tenant&#8217;s Contractor and such
              subcontractors and suppliers as Landlord may reasonably designate from time to time.</font></div>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">49</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Construction Documents</u>. No Tenant Work, other than Cosmetic Work, shall be effected except in
              accordance with complete, coordinated construction drawings and specifications (&#8220;<font style="font-weight: bold;">Construction Documents</font>&#8221;) prepared in accordance with <font style="font-weight: bold;"><u>Exhibit J</u></font> attached
              hereto. Before commencing any Tenant Work requiring Landlord&#8217;s approval hereunder, Tenant shall obtain Landlord&#8217;s prior written approval of the Construction Documents for such work, which approval shall not be unreasonably withheld,
              conditioned or delayed. Landlord shall be given a reasonable opportunity to consult with Tenant and review plans for any work under this Lease requiring Landlord&#8217;s consent as they are being prepared. The Construction Documents shall be
              prepared by an architect (&#8220;<font style="font-weight: bold;">Tenant&#8217;s Architect</font>&#8221;) registered in the Commonwealth of Massachusetts and experienced in the construction of tenant space improvements in comparable buildings in the area where
              the Premises are located and, if the value of such Tenant Work will equal or exceed the Tenant Work Threshold Amount or will affect any Building System, the identity of Tenant&#8217;s Architect (and also engineers if such work will affect any
              Building System) shall be approved by Landlord in advance, such approval not to be unreasonably withheld, conditioned or delayed. Tenant shall be solely responsible for the liabilities associated with and expenses of all architectural and
              engineering services relating to Tenant Work and for the adequacy, accuracy, and completeness of the Construction Documents even if approved by Landlord (and even if Tenant&#8217;s Architect has been otherwise engaged by Landlord in connection with
              the Base Building Work or the Initial Tenant Work). Construction Documents shall comply with all Legal Requirements and Title Matters applicable to the Development or the Premises, or Tenant&#8217;s use thereof, as well as with the provisions of
              the Condominium Documents. Construction Documents shall set forth in detail the requirements for construction of the Tenant Work and shall show all work necessary to complete the Tenant Work, including all cutting, fitting, and patching and
              all connections to the mechanical, electrical, and plumbing systems and components of the Unit or the Building. Submission of the Construction Documents to Landlord for approval shall be deemed a warranty by Tenant that all Tenant Work
              described in the Construction Documents (i) complies with all applicable Legal Requirements, Title Matters and the Condominium Documents, (ii) does not adversely affect any structural component of the Unit or the Building, (iii) is compatible
              with and does not adversely affect the Building Systems, (iv) conforms to floor loading limits specified by Landlord, and (v) with respect to all materials, equipment and special designs, processes or products, does not infringe on any patent
              or other proprietary rights of others. The Construction Documents shall comply with Landlord&#8217;s requirements for the uniform exterior appearance of the Unit, including the use of Landlord&#8217;s standard window blinds and standard light fixtures.
              Landlord&#8217;s approval of Construction Documents shall signify only Landlord&#8217;s consent to the Tenant Work shown and shall not result in any responsibility of Landlord concerning compliance of the Tenant Work with any Legal Requirements or Title
              Matters, or coordination or compatibility with any component or system of the Unit or the Building, or the feasibility of constructing the Tenant Work without damage or harm to the Unit or the Building, all of which shall be the sole
              responsibility of Tenant.</font></div>
          <br>
        </div>
      </div>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">50</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 36pt;">If, as a result of any Tenant Work performed or proposed to be performed by Tenant, Landlord is or will be obligated to comply with any Legal Requirement (including the Americans With Disabilities
        Act) which was not previously applicable to the Premises or the Unit (or which was previously applicable in a different manner or to a different extent), and such compliance requires Landlord to make any improvement or alteration to any portion of
        the Unit or the Building, then (i) when Landlord makes such determination prior to the performance of such Tenant Work, as a condition to Landlord&#8217;s consent, Landlord shall have the right to require Tenant to pay to Landlord prior to the
        performance of such Tenant Work, the entire cost of any improvement or alteration Landlord is obligated to complete by such Legal Requirement, or (ii) when Landlord makes such determination after such Tenant Work has commenced (regardless of
        whether or not the same has been completed), Tenant shall pay to Landlord, as Additional Rent, within ten (10) days of demand therefor by Landlord, the entire cost of any improvement or alteration Landlord is obligated to complete by reason of such
        Legal Requirement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Performance</u>. The identity of any person or entity (including any employee or agent of Tenant)
          performing any Tenant Work (&#8220;<font style="font-weight: bold;">Tenant Contractor</font>&#8221;) requiring Landlord&#8217;s approval hereunder shall be subject to Landlord&#8217;s prior written approval, which approval shall not be unreasonably withheld, conditioned
          or delayed. Once any Tenant Contractor has been approved, the same Tenant Contractor may thereafter be used by Tenant for the same type of work until Landlord notifies Tenant that such Tenant Contractor is no longer approved. Tenant shall procure
          at Tenant&#8217;s expense all necessary permits and licenses (and shall provide copies thereof to Landlord) before undertaking any Tenant Work, but shall not take any plans for Tenant Work to any governmental authority for review or approval without
          Landlord&#8217;s prior written authorization in each instance (which prior authorization shall not be unreasonably withheld, conditioned or delayed). Tenant shall perform (or shall cause Tenant&#8217;s Contractor to perform) all Tenant Work at Tenant&#8217;s risk,
          in compliance with the Rules and Regulations, all applicable Legal Requirements and Insurance Requirements, and the provisions of the Condominium Documents, and in a good and workmanlike manner, employing new materials of good quality and
          producing a result at least equal in quality to the other parts of the Premises. When any Tenant Work is in progress (including, for this purpose, the Initial Tenant Work), Tenant shall cause to be maintained insurance as described in the Tenant
          Work Insurance Schedule attached hereto as <font style="font-weight: bold;"><u>Exhibit K</u></font> and such other insurance as may be reasonably required by Landlord covering any additional hazards due to such Tenant Work. If the Tenant Work in
          any instance requires Landlord&#8217;s approval hereunder, Tenant shall reimburse Landlord within thirty (30) days of demand, as Additional Rent, for its reasonable third&#8209;party out&#8209;of&#8209;pocket costs of reviewing the proposed Tenant Work and inspecting
          the performance of such work (as well as all costs imposed upon Landlord by any mortgagee which reviews and/or inspects the same). During the performance of any Tenant Work, representatives of Tenant and Landlord shall meet periodically (not less
          frequently than monthly) to review and discuss the progress of the work and the schedule for the performance of the remaining work.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In addition to and without limiting any of the foregoing, any and all Tenant Work shall be subject to, and performed in accordance with: (i) the LEED Requirements set forth on <font style="font-weight: bold;"><u>Exhibit I</u></font> attached hereto and incorporated herein by reference, and (ii) Landlord&#8217;s construction, repair and remodeling guidelines for Tenant Work in the Building, as the same may be amended and
        supplemented by Landlord from time to time by written notice to Tenant (collectively, &#8220;<font style="font-weight: bold;">Landlord&#8217;s Guidelines for Tenant Work</font>&#8221;). In the event that the Landlord&#8217;s Guidelines for Tenant Work impose more
        stringent requirements or a higher standard than any other applicable provision of this Lease (including the other Exhibits attached hereto), the provisions of the Landlord&#8217;s Guidelines for Tenant Work shall control. A copy of the Landlord&#8217;s
        Guidelines for Tenant Work in effect on the date hereof is attached hereto as <font style="font-weight: bold;"><u>Exhibit L</u></font> and incorporated herein by reference.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">51</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Tenant shall cause each Tenant Contractor (i) to comply with, and to do nothing to impair, any guaranties or warranties applicable to any portion or component of the Unit or the Building of which
        Tenant is made aware, and (ii) to use commercially reasonable efforts to avoid delaying or otherwise interfering with the work of any contractor of Landlord or of any other tenant. Each Tenant Contractor working on the roof of the Unit shall
        coordinate with Landlord&#8217;s roofing contractor, shall comply with its requirements and shall not violate existing roof warranties. Tenant shall indemnify and hold the Indemnitees harmless from any claim, loss or expense based upon injury to persons
        or damage to property to the extent arising from the act or omission of Tenant&#8217;s Contractor or any subcontractor or supplier of any tier, while on or about the Premises, the Unit, the Building or elsewhere in the Development, except to the extent
        caused by the negligence or willful misconduct of Landlord or Landlord&#8217;s agents, employees and/or contractors.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>Payment</u>. Tenant shall pay the entire cost of all Tenant Work so that the Premises (including
          Tenant&#8217;s leasehold) and all other portions of the Development shall always be free of liens for labor or materials; <font style="font-style: italic;">provided, however,</font> that in the event that there is a dispute over whether payment is due
          and payable, Tenant may withhold payment so long as it files and records a bond sufficient to discharge any potential lien arising from the dispute or other security acceptable to Landlord and its mortgagees in their reasonable discretion within
          ten (10) Business Days after Tenant has notice from any source of such dispute. If any such lien is filed that is claimed to be attributable to Tenant or persons acting under Tenant, then Tenant shall promptly (and always within ten (10) Business
          Days) discharge the same by payment or filing any necessary bond. In the event that Tenant fails to discharge such lien within the time period set forth above, Landlord shall have the right, but not the obligation, to bond over or otherwise
          discharge such lien as further set forth in <u>Section 13.02</u> of this Lease: <font style="font-style: italic;">provided, however,</font> that no notice or cure period shall apply. In such case Tenant shall pay Landlord&#8217;s reasonable costs of
          discharging such lien within ten (10) Business Days of Landlord&#8217;s written demand as Additional Rent.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Other</u>. Tenant must schedule and coordinate all aspects of work with the property manager or other
          person or persons designated from time to time by Landlord, and shall make prior arrangements for elevator or temporary hoist use. Landlord shall provide Tenant and all other tenants requiring the use of freight elevators and temporary hoists
          with joint access and the parties shall use reasonable efforts to coordinate such joint access to avoid conflicts. If an operating engineer is required by any union regulations, Tenant shall pay for such engineer. If shutdown of risers and mains
          for electrical, mechanical or plumbing work is required, such work shall be supervised by Landlord&#8217;s representative at Tenant&#8217;s cost. If special security arrangements must be made (e.g., in connection with work outside Normal Business Hours),
          Tenant shall pay the actual cost of such security. No work shall be performed in Unit or Building mechanical or electrical equipment rooms without Landlord&#8217;s approval, which approval shall not be unreasonably withheld, conditioned or delayed, and
          all such work shall be performed under Landlord&#8217;s supervision. Except in case of emergency, at least five (5) days&#8217; prior notice must be given to the property manager prior to the proposed shutdown of fire, sprinkler or other alarm systems, and
          in case of emergency, prompt notice shall be given. In the event that such work unintentionally alerts the Fire or Police Department or any private alarm monitoring company through an alarm signal, Tenant shall be liable for any fees or charges
          levied by the Fire or Police Department or any private alarm monitoring company in connection with such alarm except to the extent such alert was caused by Landlord or Landlord&#8217;s agents, employees or contractors. All demolition, installations,
          removals or other work that is reasonably likely to inconvenience other tenants of the Unit or the Building or disturb their normal business operations must be scheduled with the Building manager at least five (5) days in advance.</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">52</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Any requirements of any Tenant Contractor for services from Landlord or Landlord&#8217;s Contractor, such as hoisting, electrical or mechanical needs, shall be paid for within thirty (30) days of billing
        after such costs are incurred, and arranged between such Tenant Contractor and Landlord or Landlord&#8217;s contractor. Tenant shall cause each Tenant Contractor performing work on the Premises to clean up regularly and remove its debris from the
        Premises, the Building and the Land. If any Tenant Contractor fails so to clean up, then Landlord may, after giving Tenant at least twenty&#8209;four (24) hours&#8217; prior written notice, cause its contractor to clean up and remove debris, and Tenant shall
        pay the reasonable out&#8209;of&#8209;pocket costs of such cleanup and removal upon demand.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Each contract with a Tenant Contractor shall require such Tenant Contractor to take all reasonable steps to assure that any work is carried out without disruption from labor disputes arising from
        whatever cause, including disputes concerning union jurisdiction and the affiliation of workers employed by said Tenant Contractor or its subcontractors. Tenant shall be responsible for, and shall reimburse Landlord, as Additional Rent, for, all
        actual costs and expenses, including reasonable attorneys&#8217; fees and costs incurred by Landlord in connection with the breach by any Tenant Contractor of such obligations. If Tenant does not promptly resolve any labor dispute caused by or relating
        to any Tenant Contractor, Landlord may in its sole discretion request that Tenant remove such Tenant Contractor from the Premises, and if such Tenant Contractor is not promptly removed, Landlord may prohibit such Tenant Contractor from entering the
        Development.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Upon completion of any Tenant Work and as a condition of such completion, Tenant shall give to Landlord (i) a permanent certificate of occupancy (if one is legally required), and any other final
        governmental approvals required for such work, (ii) copies of &#8220;as built&#8221; plans (other than for Cosmetic Work) in modifiable AutoCAD format and all construction contracts, and (iii) proof of payment for all labor and materials in the form of a final
        statutory lien waiver from Tenant&#8217;s Contractor or such other reasonable evidence as Landlord may require.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Removal at Conclusion of Term</u>. Except as set forth in the last sentence of this paragraph below, any
          Tenant Work that is permanently affixed to the Premises or affixed in a manner so that it cannot be removed without causing other than incidental and repairable damage to the Premises shall become property of the Landlord at the termination of
          occupancy as provided herein. If Landlord so notifies Tenant in writing at the time Landlord approves plans for any Tenant Work (or, if Landlord&#8217;s consent to the plans is not required, at the time Landlord receives notice of such work), Tenant
          shall remove such or all Tenant Work as so specified prior to the conclusion of the Term. Tenant Work that may be removed with only incidental and/or repairable damage, may be removed by Tenant in any case provided such disturbance or damage is
          restored and repaired so that the Premises are left in a clean and fully functional condition at least as good as they were in at the commencement of the Term or as they may be put in thereafter, reasonable wear and tear, damage caused by fire,
          other casualty or taking, and damage caused by the negligence or willful misconduct of Landlord, Landlord&#8217;s agents, employees, or contractors excepted; provided, however, that notwithstanding anything to the contrary contained in this Lease, in
          the event that this Lease is terminated by reason of the occurrence of an Event of Default prior to the expiration of the Term, all of the laboratory furnishings, laboratory equipment and laboratory machinery installed as part of the Initial
          Tenant Work shall remain in the Premises unless Landlord agrees otherwise in writing at the time of such termination.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">53</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Initial Tenant Work</u>. The provisions of this <u>Section 10.05</u> shall not apply to Initial Tenant
          Work except to the extent otherwise expressly provided in this Lease or in the Work Letter.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">10.06.&#160;&#160;&#160; Condition Upon Termination. </font><font style="font-size: 10pt;">At the expiration or earlier
          termination of the Term, Tenant (and all persons claiming by, through or under Tenant) shall without the necessity of notice deliver the Premises (including all Initial Tenant Work, none of which shall be removed by Tenant, and all other Tenant
          Work to the extent provided in <u>Section 10.05(f)</u> of this Lease) broom&#8209;clean, in compliance with the requirements of <u>Section 10.07</u> and in good order, repair and condition, excepting only damage caused by fire, other casualty, or
          taking, reasonable wear and tear, and damage caused by the negligence or willful misconduct of Landlord, Landlord&#8217;s agents, employees, or contractors. The Premises shall be surrendered to Landlord free and clear of any mechanic&#8217;s liens (or any
          similar lien related to labor or materials) or other lien or encumbrance (excluding liens or encumbrances existing as of the date hereof and liens or encumbrances granted by Landlord or related to work performed by or for Landlord) against any
          part of the Premises, equipment and/or any Initial Tenant Work or any other Tenant Work to be surrendered with the Premises. As part of such delivery, Tenant shall also provide all keys (or lock combinations, codes, access cards, passwords
          relating to BMS equipment or software, or electronic passes) to the Premises to Landlord; remove all signs wherever located; and, except as set forth in <u>Section 10.05(f)</u>, remove all Tenant&#8217;s Property and other personal property whether or
          not bolted or otherwise attached. As used herein, &#8220;<font style="font-weight: bold;">Tenant&#8217;s Property</font>&#8221; shall mean all trade fixtures, furnishings, equipment, inventory, cabling of any type, and other personal property owned by Tenant or
          any person acting under Tenant at the Premises. Tenant shall repair all damage that results from such removal and restore the Premises substantially to a fully functional and tenantable condition (including the filling of all floor and wall
          holes, the removal of all disconnected wiring back to junction boxes and the replacement of all damaged ceiling tiles). Any property not so removed shall be deemed abandoned, shall at once become the property of Landlord, and may be disposed of
          in such manner as Landlord shall see fit; and Tenant shall pay the reasonable cost of removal and disposal to Landlord within ten (10) days of Landlord&#8217;s written demand. The provisions of this Section shall survive the expiration or earlier
          termination of the Term.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">10.07.&#160;&#160; Decommissioning of the Premises. </font><font style="font-size: 10pt;">Prior to the expiration of this
          Lease (or within thirty (30) days after any earlier termination), Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters), piping, supply lines, waste lines, tanks, and plumbing in or
          serving the Premises, and all exhaust or other ductwork in or serving the Premises, in each case that has carried, released or otherwise been exposed to any Hazardous Materials, and shall otherwise clean the Premises so as to permit the report
          hereinafter called for by this <u>Section 10.07</u> to be issued. Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination), Tenant, at Tenant&#8217;s expense, shall obtain and provide to Landlord a report
          addressed to Landlord and Landlord&#8217;s designees prepared by a reputable licensed environmental engineer or certified industrial hygienist that is designated by Tenant and acceptable to Landlord in Landlord&#8217;s reasonable discretion, which report
          shall be based on such person&#8217;s inspection of the Premises (including visual inspection, airborne and surface monitoring, and, if Tenant or any Tenant Party at any time stored or used any radioactive materials in the Premises, Geiger counter
          evaluation), and shall show:</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">54</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">that the Hazardous Materials brought onto the Premises by or for the use by Tenant or
          any Tenant Party, if any, existing prior to such decommissioning, have been removed as necessary so that the interior surfaces of the Premises (including floors, walls, ceilings, and counters), piping, supply lines, waste lines, tanks, and
          plumbing, and all such exhaust or other ductwork in and/or serving the Premises, may be reused by a subsequent tenant or disposed of in compliance with applicable Environmental Laws without taking any special precautions for Hazardous Materials,
          without incurring special costs or undertaking special procedures for demolition, disposal, investigation, assessment, cleaning or removal of Hazardous Materials, and without incurring regulatory compliance requirements or giving notice pursuant
          to Environmental Laws;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">if Tenant or any Tenant Party at any time stored or used any radioactive materials in
          the Premises, that the Premises (and all piping, supply lines, waste lines, tanks, and plumbing, and all exhaust or other ductwork in and/or serving the Premises), have been decommissioned in accordance with the regulations of the U.S. Nuclear
          Regulatory Commission and/or the Massachusetts Department of Public Health for the control of radiation, and have accordingly been released for unrestricted use by the Radiation Control Program of the Massachusetts Department of Public Health for
          the control of radiation; and</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="color: rgb(0, 0, 0);">(iii)</font>&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">that the Premises may be reoccupied for laboratory/research and development use,
          demolished or renovated without taking any special precautions for Hazardous Materials, without incurring special costs or undertaking special procedures for disposal, investigation, assessment, cleaning or removal of Hazardous Materials, and
          without incurring regulatory requirements or giving notice pursuant to Environmental Laws.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;">For purposes of the preceding clauses (i) and (iii) &#8220;special costs&#8221; or &#8220;special procedures&#8221; shall mean costs or procedures, as the case may be, that would not be incurred but for the nature of the Hazardous Materials
        introduced to the Premises by or for the use by Tenant or any Tenant Party, as Hazardous Materials instead of non&#8209;Hazardous Materials. The report shall include reasonable detail concerning the clean&#8209;up locations, the tests run and the analytic
        results.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In addition, Tenant shall provide to Landlord prior to the expiration of the Term (or within thirty (30) days after any earlier termination), a copy of its most current chemical waste removal
        manifest and a certification from Tenant executed by an officer of Tenant that no Hazardous Materials or other potentially dangerous or harmful chemicals brought onto the Premises by Tenant or any Tenant Party from and after the date that Tenant
        first took occupancy of the Premises remain in the Premises.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">55</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If Tenant fails to perform its obligations under this <u>Section 10.07</u>, then without limiting any other right or remedy, Landlord may, on five (5) Business Days&#8217; prior written notice to
        Tenant, perform such obligations at Tenant&#8217;s expense, and Tenant shall within ten (10) days of demand reimburse Landlord, as Additional Rent, for all reasonable out&#8209;of&#8209;pocket costs and expenses incurred by Landlord in connection with such work,
        together with an Administrative Charge, as defined in <u>Section 13.02</u>. In addition, at Landlord&#8217;s election, Landlord may inspect the Premises and the Land for Hazardous Materials at Landlord&#8217;s cost and expense within sixty (60) days of
        Tenant&#8217;s surrender of the Premises at the expiration or earlier termination of this Lease. Tenant shall pay for all such costs and expenses incurred by Landlord in connection with such inspection if such inspection reveals that a release or threat
        of release of Hazardous Materials exists (a) at the Premises (except to the extent resulting from the acts or omissions of Landlord or Landlord&#8217;s agents, employees or contractors, or occupants of other portions of the Building), or (b) elsewhere on
        the Land as a result of the acts or omission of Tenant, its officers, employees, contractors, or agents.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The provisions of this <u>Section 10.07</u> shall survive the expiration of the Term or the earlier termination of this Lease.</div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><a name="z_Toc234589618"></a>ARTICLE 11: DAMAGE OR DESTRUCTION; CONDEMNATION</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">11.01.&#160;&#160; Damage or Destruction of Premises. </font><font style="font-size: 10pt;">If the Premises, the Unit or
          the Building or any part thereof shall be damaged or destroyed by fire or other casualty (a &#8220;casualty&#8221;), or ordered to be demolished by the action of any public authority in consequence of a casualty, or taken by any exercise of the right of
          eminent domain, Tenant shall immediately give notice thereof to Landlord. Unless this Lease is terminated as provided herein, this Lease shall remain in full force and effect and Landlord shall proceed (or shall cause the Primary Board to
          proceed) with diligence to repair or cause to be repaired such damage so as to restore the Premises, the Building and access thereto, or what may remain thereof (including the Initial Tenant Work but excluding any other Tenant Work), as nearly as
          practicable to the condition they were in immediately prior to such damage, destruction or taking, subject to then applicable Legal Requirements and Title Matters, but neither Landlord nor the Primary Board shall be required to expend in such
          repair or rebuilding more than the proceeds of insurance or award of damages, if any, recovered or recoverable with respect to such damage, destruction or taking (plus, in the case of casualty, the amount of any insurance deductibles (which shall
          be deemed Operating Costs)), less Landlord&#8217;s (or the Primary Board&#8217;s) reasonable expenses incurred in collecting such proceeds or award, as the case may be, but in the case of damage or destruction only to the extent Landlord was carrying the
          insurance required to be carried pursuant to this Lease at the time of such damage or destruction. All such repairs made necessary by any negligent act or omission or any willful misconduct of Tenant shall be made by Landlord (or the Primary
          Board) at Tenant&#8217;s expense to the extent that the cost of such repairs is not covered by insurance proceeds available therefor (including the payment by Tenant of any applicable deductible amount). Landlord shall not be liable for delays in the
          making of any such repairs that are due to Force Majeure, nor shall Landlord be liable for any inconvenience or annoyance to Tenant or injury to the business of Tenant resulting from delays in repairing such damage. All repairs to and
          replacements of Tenant Property and any Tenant Work other than the Initial Tenant Work shall be made by and at the expense of Tenant, which work Tenant shall promptly commence as soon as practicable and thereafter prosecute diligently to
          completion.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">56</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">11.02.&#160;&#160;&#160; Right to Terminate in Event of Casualty. </font><font style="font-size: 10pt;">In case (a) the Building
          in which the Premises are situated is destroyed or so damaged by fire or casualty insured under any fire and extended coverage insurance policy carried by Landlord or the Primary Board as to render more than seventy percent (70%) of the square
          footage of the Building, or seventy percent (70%) of the square footage of the Unit, untenantable, or (b) more than fifty percent (50%) of the square footage of the Premises is so damaged or destroyed as to be rendered untenantable, or (c) the
          Premises or the Unit or all reasonable means of access thereto are destroyed or materially damaged during the last two (2) years of the Term, then, and in any of such cases, Landlord or Tenant (as to Tenant, in the events covered by clauses (b)
          and (c) only) may at its election, exercisable by notice given to the other within thirty (30) days after such destruction or damage, terminate this Lease as of the date designated by Landlord or Tenant in such notice, which designated date shall
          not be less than fifteen (15) days nor more than thirty (30) days after the date of such notice. In case (x) the Premises, the Unit or the Building shall be destroyed or materially damaged by any casualty other than one covered by such insurance
          policy (provided that at the time of such damage or destruction Landlord carried the insurance required by this Lease), or (y) if Landlord reasonably estimates that the cost to repair the same will exceed the amount of proceeds actually received
          by Landlord or the Primary Board from Landlord&#8217;s or the Primary Board&#8217;s insurance by more than $100,000.00, then, and in any of such cases, Landlord may at its election, exercisable by notice given to Tenant within sixty (60) days after such
          destruction or damage, terminate this Lease as of the date designated by Landlord in such notice, which designated date shall be not less than fifteen (15) days nor more than thirty (30) days after the date of such notice.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt;">If Landlord does not so elect to terminate this Lease and instead elects to repair or rebuild the Premises, Landlord shall specify pursuant to written notice to Tenant the time within which repairs
        or construction will be completed (Landlord agreeing to make commercially reasonable efforts to provide such notice to Tenant within sixty (60) days following such casualty), and in the event that Landlord estimates that the Premises cannot
        reasonably be repaired or restored within two hundred seventy (270) days following such casualty, then Tenant shall have the option within thirty (30) days after the receipt of such notice from Landlord to elect to terminate this Lease by written
        notice to Landlord. If Tenant does not so elect to terminate this Lease by written notice to Landlord within said thirty (30) day period, then this Lease shall continue in full force and effect and Landlord shall restore (or cause to be restored)
        the Premises, or what may remain thereof (including the Initial Tenant Work but excluding any other Tenant Work), as nearly as practicable to the condition they were in immediately prior to such damage, destruction or taking, subject to then
        applicable Legal Requirements and Title Matters, within the time specified in Landlord&#8217;s aforesaid notice and Tenant shall be entitled to an abatement of Base Rent as hereinafter set forth. If Landlord fails to substantially complete restoration of
        the Premises within the specified time (subject to Force Majeure or any delays caused by Tenant), then Tenant at its election may terminate this Lease and quit the Premises at any time after the time specified by Landlord for substantial completion
        as aforesaid but prior to Landlord&#8217;s substantial completion of the restoration, upon sixty (60) days&#8217; advanced written notice to Landlord: <font style="font-style: italic;">provided, however,</font> if Landlord substantially completes such
        restoration within said sixty (60) day period, then Tenant&#8217;s election to terminate this Lease shall be null and void and this Lease shall continue in full force and effect in accordance with the terms hereof. Tenant acknowledges and agrees that if
        other portions of the Unit are damaged by casualty, and this Lease is not terminated in accordance with its terms, Landlord shall only be obligated to restore (or cause to be restored) such other portions of the Unit as are necessary for Tenant to
        use and enjoy the Premises, including the exterior fa&#231;ade of the Premises, access thereto and the parking areas required to provide Tenant with the number of parking spaces provided in Section 2.02(c) hereof in reasonable proximity to the Building.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">57</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">11.03. &#160;&#160; Termination in Event of Taking. </font><font style="font-size: 10pt;">If all the Premises are taken by
          eminent domain this Lease shall terminate when Tenant is required to vacate the Premises. If by a taking (i) the floor area of the Premises is reduced by more than fifteen percent (15%) thereof, or (ii) all access to the Premises from the
          adjacent public right of way is taken and reasonably comparable alternative access is not made available within sixty (60) days of such taking, then, in either such case, this Lease may at the option of either party be terminated, as of the date
          when Tenant is required to vacate the portion of the Premises so taken or upon the expiration of said sixty (60) day period, as the case may be, by notice given to the other not more than thirty (30) days after the date on which the party
          desiring to terminate receives notice of the taking in the case of situation (i) above, or within thirty (30) days after the expiration of said sixty (60) day period in the case of situation (ii) above. If by a taking the floor area of the Unit
          in which the Premises are situated is reduced by more than twenty&#8209;five percent (25%), this Lease may at the option of Landlord or Tenant be terminated, as of the date when the tenants or occupants of the portion of said Unit so taken are required
          to vacate the same, by giving notice to the other not more than thirty (30) days after the date on which Landlord receives notice of the taking.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">11.04.&#160;&#160;&#160; Landlord Reserves Award. </font><font style="font-size: 10pt;">Landlord reserves and excepts all rights
          to awards for damages to the Unit and the Premises and the leasehold hereby created now accrued or hereafter accruing (not including a separate award for Tenant&#8217;s moving expenses, if any, or awards for the unamortized value of the non&#8209;removable
          Initial Tenant Work installed by Tenant less the amount of the Tenant Allowance) as long as such separate awards do not reduce, delay or hinder Landlord&#8217;s award<a name="z_9kMHG5YVt7DA67B"></a>) by reason of any exercise of the right of eminent
          domain, or by reason of anything lawfully done in pursuance of any public or other authority; and by way of confirmation Tenant grants to Landlord all Tenant&#8217;s rights to such awards (except as expressly reserved above in this <u>Section 11.04</u>)
          and covenants to execute and deliver such further instruments of assignment thereof as Landlord may from time to time request. Tenant&#8217;s aforesaid leasehold improvements shall be amortized on a straight line basis over the initial term of this
          Lease.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">11.05.&#160;&#160;&#160; Abatement of Rent. </font><font style="font-size: 10pt;">In the event of any casualty or taking of the
          Premises (or the Unit or Building which actually affects the Premises), a just proportion of the Base Rent payable hereunder, according to the nature and extent of the injury, shall be abated until completion of repairs or rebuilding or
          termination of this Lease, as the case may be; and in the case of a taking which permanently reduces the area of the Premises, or if following a casualty the restored Premises are smaller in area than the original area of the Premises, a just
          proportion of the Base Rent shall be abated for the remainder of the Term.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">11.06.&#160;&#160;&#160; Risk of Loss. </font><font style="font-size: 10pt;">The risk of loss or damage to property of the
          Tenant on or about the Premises will be borne solely by the Tenant and neither the Landlord nor any other tenant will have any liability for loss thereof or damage thereto, except as otherwise expressly set forth in this Lease.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">58</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><a name="z_Toc234589625"></a>ARTICLE 12: ASSIGNMENT AND SUBLETTING</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">12.01.&#160;&#160;&#160; Landlord&#8217;s Consent Required. </font><font style="font-size: 10pt;">Except as set forth in this Article,
          Tenant shall not assign this Lease, or Sublease the Premises or any portion thereof, or advertise the Premises for assignment or Sublease, or permit the occupancy of all or any portion of the Premises or the use of any portion of the Initial
          Tenant Work by any person other than Tenant, or assign or otherwise transfer or permit the assignment or transfer of any ownership interest (direct or indirect) in Tenant which effects a change of control of Tenant (whether in one transaction or
          in a series of related transactions), including transfer by mortgage, pledge or other encumbrance <a name="z_9kMHG5YVt7DA67A"></a>(whether of all or any portion of Tenant&#8217;s interest under this Lease, or of any such ownership interest (direct or
          indirect) in Tenant (each of the foregoing actions are collectively referred to as a &#8220;<font style="font-weight: bold;">Transfer</font>&#8221;), without obtaining, on each occasion, the prior written consent of Landlord, which consent shall not be
          unreasonably withheld, conditioned or delayed, provided that Tenant complies with the provisions of this Article: <font style="font-style: italic;">provided, however,</font> that Tenant shall not mortgage, pledge, grant a security interest in,
          or otherwise encumber all or any portion of the Initial Tenant Work or any equipment, machinery, trade fixture or other property paid for in whole or in part by any portion of Landlord&#8217;s Allowance without obtaining the prior written consent of
          Landlord in each instance, which consent may be withheld by Landlord in its sole and absolute discretion. Notwithstanding the foregoing, Tenant shall have the right to (x) obtain financing from institutional or individual investors (including
          venture capital funding and corporate partners) which regularly invest in private biotechnology companies, provided that such transaction is not a subterfuge to avoid the restrictions on Transfer otherwise set forth in this <u>Article 12</u>,
          (y) undergo a public offering, or (z) if Tenant is a public company, transfer shares of Tenant effected through any recognized exchange or through the &#8220;over the counter&#8221; market, any of which results in a change in control of Tenant without such
          change of control constituting an assignment under this <u>Article 12</u> requiring Landlord consent, provided that (A) Tenant notifies Landlord in writing of the financing at least five (5) Business Days prior to the closing of the financing,
          (B) in no event shall such financing result in a change in the use of the Premises from the use contemplated by Tenant at the commencement of the Term, and (C) any such financing shall be subject to the proviso set forth in the immediately
          preceding sentence. An assignee, subtenant, licensee, or other occupant is referred to herein as a &#8220;<font style="font-weight: bold;">Transferee</font>&#8221;. It shall be reasonable for Landlord to withhold consent to a proposed Transfer (other than a
          Related Party Transfer) if, by way of illustration and not in limitation, the proposed Transferee of a Transfer other than a Sublease does not have a net worth equal to or in excess of that of Tenant at the Date of Lease or immediately prior to
          the proposed Transfer, whichever is greater (or, in the case of a proposed Sublease, the proposed Transferee thereunder does not have the financial resources (including liquid assets) sufficient to timely perform its obligations under the
          proposed Sublease), or if the use proposed to be made of the Premises (or the applicable portion thereof) by the proposed Transferee is not a Permitted Use hereunder; <font style="font-style: italic;">provided, however,</font> that, subject to
          the limitations on Transfers set forth in this Lease, the Premises may be used for Non&#8209;Life Science Uses following an assignment of this Lease or (with respect to the applicable portion of the Premises, a Sublease), so long as such assignment or
          Sublease (i) is to an entity not affiliated with Tenant; (ii) is for a valid business purpose; and (iii) is not a subterfuge to avoid the restrictions on use set forth in <font style="font-weight: bold;">Section 9.01</font> above. A &#8220;Transfer&#8221;
          shall include any transfer of Tenant&#8217;s interest in this Lease by operation of law, any &#8220;Related Party Transfer&#8221; (as defined below), and the grant of permission or license by Tenant to any other person or entity to use or occupy any portion of the
          Premises for any period of time or for any purpose whatsoever. Any Transfer shall be subject to this Lease, all of the provisions of which shall be conditions to such Transfer and be binding on any Transferee. No Transferee shall have any right
          further to Transfer its interest in the Premises, and nothing herein shall impose any obligation on Landlord with respect to a further Transfer.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">59</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Without limiting Landlord&#8217;s right to withhold its consent to any Transfer by Tenant, and regardless of whether Landlord shall have consented to any such Transfer, neither Tenant nor any other
        person or entity having an interest in the possession, use or occupancy of the Premises or any part thereof shall enter into any lease, Sublease, assignment or other Transfer or agreement for possession, use or occupancy of all or any portion of
        the Premises which provides for rent or other payment for such use, occupancy or utilization based, in whole or in part, on the net income or profits derived by any person or entity from the space so leased, used or occupied, and any such purported
        lease, Sublease, assignment or other Transfer or agreement shall be absolutely void and ineffective as a conveyance of any right or interest in the possession, use or occupancy of all or any part of the Premises. There shall be no deduction from
        the rent payable under any Sublease or other Transfer nor from the amount thereof passed on to any person or entity, for any expenses or costs related in any way to the subleasing or Transfer of such space.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">12.02.&#160;&#160;&#160; Terms. </font><font style="font-size: 10pt;">Tenant shall not offer to make a Transfer (i) to any
          tenant in the Development (or any Affiliate of such tenant) which is not a Related Party Transferee if, at the time of Tenant&#8217;s intended Transfer, Landlord then has comparable space in the Building available for lease for a comparable term, or
          (ii) to any person or entity that would be of such type, character or condition as to be inappropriate as a tenant of a building comparable to the Building.<br>
          <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">12.03.&#160;&#160;&#160; Related Party Transfers. </font><font style="font-size: 10pt;">Tenant may make a Related Party Transfer
          (as defined below) without the consent of Landlord provided that Tenant gives Landlord at least ten (10) days&#8217; prior written notice thereof together with evidence reasonably satisfactory to Landlord that the proposed Transfer is a Related Party
          Transfer; <font style="font-style: italic;">provided, however,</font> that if Tenant is prohibited from providing such advance notice by a Legal Requirement or pursuant to an enforceable confidentiality agreement, Tenant shall deliver the same
          to Landlord within five (5) days following the Transfer. A &#8220;<font style="font-weight: bold;">Related Party Transfer</font>&#8221; shall mean one or more of the following: (1) any assignment or Sublease to (A) a parent which owns (either directly or
          indirectly) substantially all of the voting stock of Tenant or otherwise exercises voting control over Tenant, or (B) a subsidiary of Tenant in which Tenant owns (directly or indirectly) substantially all of the voting stock or over which Tenant
          otherwise exercises voting control, or (C) any subsidiary of Tenant&#8217;s parent in which such parent owns (directly or indirectly) substantially all of the voting stock or over which such parent otherwise exercises voting control, or (D) any other
          Affiliate of Tenant, or (2) an assignment incident to the sale of all or substantially all of Tenant&#8217;s assets, or (3) a statutory merger or consolidation of Tenant with any other entity, provided that in any of the situations described in the
          preceding clauses (1)&#8209;(3), (a) the person or entity succeeding to Tenant&#8217;s interest immediately thereafter (the &#8220;<font style="font-weight: bold;">Related Party Transferee</font>&#8221;) has a net worth equal to or in excess of that of Tenant at the
          Date of Lease or immediately prior to the Related Party Transfer, whichever is greater, and (b) such Related Party Transferee agrees in writing, for the benefit of Landlord, to assume all of Tenant&#8217;s obligations under this Lease. Related Party
          Transfers shall not be subject to the provisions of (a) clause (i) of <u>Section 12.02</u>, (b) <u>Section 12.04</u>, (c) the first sentence of <u>Section 12.05</u>, or (d) <u>Section 12.06</u>.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">60</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">12.04.&#160;&#160; Recapture of Premises. </font><font style="font-size: 10pt;">If Tenant proposes either (i) an
          assignment, Sublease or other Transfer of the entire Premises, or (ii) a Sublease of either (x) more than fifty&#8209;five (55%) percent of the rentable square footage of the Premises, or (y) such portion of the Premises which, when taken together with
          all other portions of the Premises then subject to Subleases, will result in more than fifty&#8209;five (55%) percent of the rentable square footage of the Premises being subject to a Sublease, then Tenant shall so state in Tenant&#8217;s written request for
          consent under <u>Section 12.05</u>, Tenant&#8217;s request for Landlord&#8217;s consent shall entitle Landlord, at its sole election, either (A) in the case of a proposed assignment, Sublease or other Transfer of the entire Premises, to terminate this Lease
          in its entirety, or (B) in the case of a proposed Sublease described in the preceding clause (ii), to terminate this Lease as to the portion of the Premises proposed to be so Subleased. If Landlord elects in a written notice given to Tenant
          within thirty (30) days after receipt of such written notice from Tenant to terminate this Lease in whole or in part pursuant to this Section, then this Lease shall so terminate in whole or in part (as so elected by Landlord) on the date
          specified by Landlord in such written notice to Tenant (which date shall be not less than thirty (30) days after the date of such notice), and all of the provisions of this Lease applicable to the expiration of the Term shall apply to such space.
          If Landlord notifies Tenant in writing within such 30&#8209;day period that Landlord elects not to exercise its termination right pursuant to this Section, or if Landlord fails to provide written notice to Tenant within such 30&#8209;day period that it
          elects to exercise its termination right pursuant to this Section (which shall be deemed a waiver by Landlord of its right to terminate pursuant to this Section), Tenant shall then comply with the provisions of this Article applicable to a
          Transfer. Landlord shall have the right to separate any portion of the Premises recaptured pursuant to this <u>Section 12.04</u> from the remainder of the Premises by constructing demising walls and other improvements necessary to convert the
          applicable portion of the Premises and Building to multi&#8209;tenant use at Landlord&#8217;s sole cost and expense.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">12.05.&#160;&#160;&#160; Procedures. </font><font style="font-size: 10pt;">At least thirty (30) days prior to the effective date
          of any Transfer, Tenant shall give Landlord in writing the details of the proposed Transfer, including: (i) the name, business, and financial condition (including the most recent annual and quarterly financial statements, in form and content
          reasonably acceptable to Landlord) of the prospective Transferee, (ii) a true and complete copy of the proposed instrument containing all of the terms and conditions of such Transfer, (iii) a written agreement of the prospective Transferee, in
          form and content reasonably acceptable to Landlord, agreeing with Landlord to perform and observe all of the terms, covenants, and conditions of this Lease undertaken by such Transferee, and (iv) any other information Landlord reasonably
          requires. Tenant shall pay to Landlord, as Additional Rent, Landlord&#8217;s reasonable outside attorneys&#8217; fees in reviewing any Transfer. Tenant shall provide Landlord with a true and correct copy of the instrument effecting the Transfer on or before
          the date that it takes effect, except that with respect to a Related Party Transfer, Tenant shall, within fifteen (15) days after the Related Party Transfer, deliver to Landlord evidence of merger or such other evidence as is reasonably
          satisfactory to Landlord that such Related Party Transfer has occurred. Landlord shall make commercially reasonable efforts to respond in writing to a request for its consent to a Transfer made by Tenant in accordance with the provisions of this
          <u>Section 12.05</u> within fifteen (15) Business Days after receipt by Landlord of all materials and information relating to such proposed Transfer and proposed Transferee as are required to be provided to Landlord pursuant to this <u>Section
            12.05</u>, but Landlord&#8217;s failure to respond within such time period shall not constitute deemed approval of any proposed Transfer or proposed Transferee.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">61</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">12.06.&#160;&#160; Excess Rents. </font><font style="font-size: 10pt;">If the consideration, rent, or other amounts payable
          to Tenant under any sublease, license, concession, or other agreement for possession, use or occupancy of all or any portion of the Premises (collectively, a &#8220;<font style="font-weight: bold;">Sublease</font>&#8221;) or any assignment exceed the sum of
          (1) Rent and other charges to be paid hereunder (which amounts, in the case of a Sublease, shall be pro&#8209;rated based on the floor area intended to be subject to such Sublease), and (2) Tenant&#8217;s Expenses (which shall be (a) in the case of an
          assignment, amortized over the remaining Term of the Lease, and (b) in the case of a Sublease, (i) pro&#8209;rated based on the floor area intended to be subject to such Sublease, and (ii) amortized over the fixed term of the Sublease in question),
          then Tenant shall pay to Landlord, as Additional Rent, one&#8209;half (1/2) of the amount of such excess when and as received by Tenant. &#8220;<font style="font-weight: bold;">Tenant&#8217;s Expenses</font>&#8221; shall mean, collectively, (i) the necessary and
          reasonable expenses incurred by Tenant in good faith to third parties in connection with such an assignment or Sublease (as the case may be) on account of brokerage, legal, design, and demising and leasehold improvement costs in the portion of
          the Premises affected by, and specifically in connection with, such assignment or Sublease, and (iii) the unamortized out of pocket cost to Tenant of previously constructing Tenant Work in the Premises (or, in the case of a Sublease, in the
          portion of the Premises to be subject to such Sublease) and in either case with respect to the Initial Tenant Work, only the portion of the cost thereof paid out of pocket by Tenant, and not the portion of the cost thereof covered by Landlord&#8217;s
          Allowance pursuant to the Work Letter, shall be included as an &#8220;out of pocket cost to Tenant&#8221; for purposes of this calculation, with such amortization to be calculated on a straight line basis over the remaining Initial Term of the Lease as of
          the date such expense was incurred by Tenant. There shall be included in the calculation to be performed pursuant to the first sentence of this section any lump&#8209;sum payment or periodic payments made to Tenant for the purchase of so&#8209;called
          leasehold improvements, but all lump&#8209;sum or periodic payments made to Tenant on account of the leasing or mere use of Tenant&#8217;s equipment by the Transferee under such Sublease or assignment shall be excluded from such calculation. The provisions
          of this <u>Section 12.06</u> shall not apply to Related Party Transfers.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">12.07.&#160;&#160;&#160; No Release. </font><font style="font-size: 10pt;">Notwithstanding any Transfer and whether or not the
          same is a Related Party Transfer or is consented to, the liability of Tenant to Landlord shall remain direct and primary, to the extent that Tenant still exists as a separate entity after a Related Party Transfer. Any Transferee of all or
          substantially all of Tenant&#8217;s interest in the Premises, including any such Transferee under a Related Party Transfer, shall be jointly and severally liable with Tenant (to the extent that Tenant still exists as a separate entity after a Related
          Party Transfer) to Landlord for the performance of all of Tenant&#8217;s covenants under this Lease; and such Transferee shall upon written request from Landlord execute and deliver such instruments as Landlord reasonably requests in confirmation
          thereof (and agrees that its failure to do so shall be a default). During any period when there exists an Event of Default by Tenant which is then continuing, Tenant hereby irrevocably authorizes Landlord to collect Rent and other charges from
          any Transferee (and upon notice from Landlord any Transferee shall pay directly to Landlord) and apply the net amount collected to the Rent and other charges reserved under this Lease. No Transfer shall be deemed a waiver of the provisions of
          this Section, or the acceptance of the Transferee as a tenant, or a release of Tenant from direct and primary liability for the performance of all of the covenants of this Lease. The consent by Landlord to any Transfer shall not relieve Tenant or
          any Transferee from the obligation of obtaining the express consent of Landlord to any modification of such Transfer or a further Transfer by Tenant or such Transferee. Notwithstanding anything to the contrary in the documents effecting the
          Transfer, Landlord&#8217;s consent shall not alter in any manner whatsoever the terms of this Lease, to which any Transfer at all times shall be subject and subordinate.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><a name="z_Toc234589633"></a>ARTICLE 13: EVENTS OF DEFAULT AND REMEDIES</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">13.01.&#160;&#160;&#160; Events of Default. </font><font style="font-size: 10pt;">In the event that:</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><br>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 36pt;">&#160;</td>
              <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(A)</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-size: 12pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">Tenant shall default in the payment of any Base Rent, Additional Rent or other sum payable under this Lease, when and as the same shall become due and payable
                    hereunder, and such default shall continue for a period of five (5) days after Landlord gives Tenant written notice that such payment was not paid when due: </font><font style="font-size: 10pt; font-style: italic; color: rgb(0, 0, 0);">provided,






                    however,</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"> that after Landlord has given two (2) notices to Tenant of a default pursuant to this <u>Section 13.01.A</u> within a twelve (12) month period, then for a period of
                    twelve (12) months from the date of such second notice Tenant shall not be entitled to any notice of a further default under this <u>Section 13.01.A</u>, and Tenant&#8217;s failure at any time during such 12&#8209;month period to make any such
                    payment within five (5) days after the date on which such payment is due hereunder shall constitute an Event of Default without the necessity of any notice; or</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div> <br>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">62</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z86ae64417d0646089d6f782d97d5a63b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(B)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">Tenant shall (i) make any Transfer in violation of this Lease; or (ii) fail to (a) maintain all insurance as required hereunder, or (b) within five (5) days
                  after Landlord&#8217;s written request to deliver the same, provide Landlord with the certificates of insurance required pursuant to <u>Article 7</u> above, or (c) restore or replenish the amount of the Security Deposit following a draw by
                  Landlord upon the Security Deposit, as required by <u>Article 14</u> below, or (d) execute, acknowledge and deliver within the 10&#8209;Business Day period provided in <u>Section 15.02</u> below any instrument described therein regarding the
                  subordination or priority of this Lease relative to any mortgage encumbering the property of which the Premises is a part, or (e) provide Landlord with an estoppel certificate following the second written notice within the time provided
                  in <u>Section 15.04</u> below; or</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ed9c67388944c1b9b7d048f050ad300" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(C)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">Tenant shall file a voluntary petition in bankruptcy or shall be adjudicated a bankrupt or insolvent; or shall file any petition or answer seeking any reorganization, arrangement, composition, liquidation,
                dissolution or similar relief under any present or future federal, state or other statute, law or regulation relating to bankruptcy, insolvency or other relief for debtors; or shall seek, or consent to, or acquiesce in the appointment of
                any trustee, receiver or liquidator of Tenant; or shall make any general assignment for the benefit of creditors; or</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z20db56d583f34f14beee39630fc0dd96" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(D)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">any court enters an order, judgment or decree approving a petition filed against Tenant seeking any reorganization, arrangement, composition, liquidation, dissolution or similar relief under any present or
                future federal, state or other statute, law or regulation relating to bankruptcy, insolvency or other relief for debtors, or for the appointment of a receiver, and such order, judgment or decree shall remain unvacated or unstayed for an
                aggregate of ninety (90) days; or</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb37a9a69c5784b5ea852b1f4ba589c5b" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(E)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0);">any representation or warranty made by Tenant herein is untrue in any material respect when made; or</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z81cbe50b690d4cb9aba260166159d1bb" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; color: rgb(15, 3, 37);">(F)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-size: 12pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">Tenant shall default in the observance or performance of any of Tenant&#8217;s covenants, agreements or obligations hereunder, other than those referred to in the
                  foregoing clauses (A)&#8209;(E), and such default shall not be corrected within the cure period expressly provided in this Lease therefor (and if no cure period is expressly provided, then for thirty (30) days after notice is given, </font><font style="font-size: 10pt; font-style: italic; color: rgb(0, 0, 0);">provided</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">, </font><font style="font-size: 10pt; font-style: italic; color: rgb(0, 0, 0);">however</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"> that such period shall be reasonably extended in the case of a non&#8209;monetary default that cannot be cured within such thirty (30) day period through the use of diligent efforts but only if the
                  default can be cured and Tenant begins such cure within such thirty (30) day period and thereafter diligently prosecutes such cure continuously to completion);</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">63</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify;">then, and in any such case, Landlord and its agents lawfully may, in addition to any remedies for any preceding breach, immediately or at any time thereafter without demand or notice and with or without process of
        law, enter upon any part of the Premises in the name of the whole or mail or deliver a notice of termination of the Term of this Lease addressed to Tenant at the address provided for in <u>Section 16.05 </u>below, and thereby Terminate the Term
        and repossess the Premises as of Landlord&#8217;s former estate. Any default by Tenant continuing beyond applicable notice and cure periods is referred to herein as an &#8220;<font style="font-weight: bold;">Event of Default</font>&#8221;. Tenant waives any
        statutory notice to quit and equitable rights in the nature of further cure or redemption, and Tenant agrees that upon Landlord&#8217;s termination of this Lease, Landlord shall be entitled to re&#8209;entry and possession in accordance with the terms hereof.
        Tenant agrees that a notice by Landlord alleging any default shall, at Landlord&#8217;s option (the exercise of such option shall be indicated by the inclusion of the words &#8220;notice to quit&#8221; in such notice), constitute a statutory notice to quit. If
        Landlord exercises its option to designate a notice of default hereunder as a statutory notice to quit, any grace periods provided for herein shall run concurrently with any statutory notice periods. Tenant further agrees that it shall not
        interpose any counterclaim or set&#8209;off in any summary proceeding or in any action based in whole or in part on non&#8209;payment of Rent other than mandatory counterclaims.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Upon such entry or mailing the Term shall terminate, all executory rights of Tenant and all obligations of Landlord will immediately cease, and Landlord may expel Tenant and all persons claiming
        under Tenant and remove their effects without any trespass and without prejudice to any remedies for arrears of Rent or prior breach; and Tenant waives all statutory and equitable rights to its leasehold (including rights in the nature of further
        cure or redemption, if any). If Landlord engages attorneys in connection with any failure to perform by Tenant hereunder, Tenant shall reimburse Landlord within ten (10) days of demand, as Additional Rent, for the reasonable fees of such attorneys.
        Without implying that other provisions do not survive, the provisions of this Article shall survive the Term or earlier termination of this Lease.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Subject to the provisions of this <u>Article 13</u>, Tenant shall indemnify Landlord against all loss of Rent and other costs, expenses, loss and damages that Landlord may incur during what would
        otherwise have constituted the balance of the Term by reason of the termination of this Lease for Tenant&#8217;s Event of Default hereunder. Without limiting the generality of the foregoing, Tenant shall reimburse Landlord for all expenses incurred by
        Landlord arising out of such termination, including all costs incurred in collecting amounts due from Tenant under this Lease (including reasonable attorneys&#8217; fees, costs of litigation and the like); all expenses incurred by Landlord in good faith
        in attempting to relet the Premises or parts thereof (including advertisements, brokerage commissions, tenant allowances, costs of preparing space, and the like); and all other expenditures by Landlord arising out of or resulting from the
        termination. The reimbursement from Tenant shall be due and payable within ten (10) days from time to time upon written notice from Landlord that an expense has been incurred, without regard to whether the expense was incurred before or after the
        termination of this Lease.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">64</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: bold;">13.02.&#160;&#160;&#160; Remedies for Default</div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Reletting Expenses Damages</u>. If this Lease is terminated for Tenant&#8217;s Event of Default, Tenant
          covenants, as an additional cumulative obligation after such termination, to pay within ten (10) days of written demand by Landlord all of Landlord&#8217;s reasonable out of pocket costs, including reasonable attorneys&#8217; fees and costs, related to
          Tenant&#8217;s default and in collecting amounts due, and all reasonable expenses in connection with reletting, including tenant inducements to new tenants, brokerage commissions, fees for legal services, and expenses of preparing the Premises for
          reletting, together with an Administrative Charge as set forth in <u>Section 13.02(e)</u> (&#8220;<font style="font-weight: bold;">Reletting Expenses</font>&#8221;). It is agreed that Landlord may (i) relet the Premises or part or parts thereof for a term
          or terms that may be equal to, less than or exceed the period that would otherwise have constituted the balance of the Term, and may grant such tenant inducements, including free rent, as Landlord in its sole discretion considers advisable, and
          (ii) make such alterations to the Premises as Landlord in its sole discretion considers advisable, and no failure to relet or to collect rent under any reletting shall operate to reduce Tenant&#8217;s liability. Except to the extent imposed by
          applicable law, Landlord shall have no obligation to relet the Premises or any portion thereof, and any obligation to relet imposed by law will be subject to (i) Landlord&#8217;s right, at its option, to first lease other space in the Unit which is
          then (or which will soon thereafter become) available for lease, and (ii) Landlord&#8217;s reasonable objectives of developing its property in a harmonious manner with appropriate mixes of tenants, uses, floor areas, terms and the like.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Termination Damages</u>. If this Lease is terminated for Tenant&#8217;s Event of Default, then unless and
          until Landlord elects lump sum liquidated damages described in the next paragraph, Tenant covenants, as an additional, cumulative obligation after any such termination, to pay punctually to Landlord all the sums and perform all of its obligations
          hereunder at the same time and in the same manner as if this Lease had not been terminated. In calculating such amounts, Tenant will be credited with the net proceeds of any rent then actually received by Landlord from a re&#8209;letting of the
          Premises after deducting all Rent and Reletting Expenses that have not then been paid by Tenant, provided that Tenant shall never be entitled to receive any portion of the re&#8209;letting proceeds, even if the same exceed the Rent originally due
          hereunder.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Lump Sum Liquidated Damages</u>. If this Lease is terminated for Tenant&#8217;s Event of Default, Tenant
          covenants, as an additional, cumulative obligation after any such termination, to pay forthwith to Landlord at Landlord&#8217;s election made by written notice at any time after termination, as liquidated damages, a single lump sum payment equal to the
          sum of (i) all sums then due and owing from Tenant to Landlord at the time of such election, plus (ii) either, as Landlord elects, (A) the excess of the present value of all of the Rent reserved for the residue of the Term (with Additional Rent
          deemed to increase [***] percent in each year on a non&#8209;compounding basis) over the present value of the aggregate Fair Market Rent and Additional Rent payable on account of the Premises during such period, which Fair Market Rent shall be reduced
          by reasonable projections of vacancies and by Landlord&#8217;s Reletting Expenses described above to the extent not theretofore paid to Landlord, or (B) an amount equal to the sum of all of the Rent and other sums due under the Lease with respect to
          the [***] period immediately preceding the date of such termination. The Federal Reserve discount rate (or equivalent) shall be used in calculating such present values under clause (ii)(A).</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">65</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>Remedies Cumulative: Late Performance</u>. The remedies to which Landlord may resort under this Lease,
          and all other rights and remedies of Landlord, are cumulative (except as otherwise provided in the first sentence of <u>Section 13.02(b)</u> above), and any two or more may be exercised at the same time. Nothing in this Lease shall limit the
          right of Landlord to prove and obtain in proceedings for bankruptcy or insolvency an amount equal to the maximum allowed by any statute or rule of law in effect at the time. Tenant shall also indemnify and hold Landlord harmless in the manner
          provided elsewhere herein if Landlord shall become or be made a party to any claim or action (a) instituted by Tenant against any third party, or by any third party against Tenant, or by or against any person claiming by, through or under Tenant;
          (b) for foreclosure of any lien for labor or material furnished to or for Tenant or such other person; (c) otherwise arising out of or resulting from any act or transaction of Tenant or such other person; or (d) necessary to protect Landlord&#8217;s
          interest under this Lease in a bankruptcy proceeding, or other proceeding under Title 11 of the United States Code, as amended.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);"><u>Landlord&#8217;s Curing</u>. If Tenant fails to perform any covenant within the applicable cure period (if
          any), then Landlord at its option may (without waiving any right or remedy for Tenant&#8217;s non-performance) at any time thereafter perform the covenant for the account of Tenant. Tenant shall, within ten <a name="z_9kMIH5YVt7DA67A"></a>(10) days of
          Landlord&#8217;s written demand, reimburse, as Additional Rent. Landlord&#8217;s cost (including reasonable attorneys&#8217; fees) of so performing, together with an administrative charge equal to ten percent (10%) of such cost (&#8220;<font style="font-weight: bold;">Administrative






            Charge</font>&#8221;) as Additional Rent. Notwithstanding any other provision concerning cure periods, Landlord may cure any non&#8209;performance for the account of Tenant after such written notice to Tenant, if any, as is reasonable under the
          circumstances if curing prior to the expiration of the applicable cure period is reasonably necessary to prevent likely damage to the Premises, the Unit or the Building or possible injury to persons, or to protect Landlord&#8217;s interest in the
          Premises, the Unit and the Building.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><a name="z_Toc234589636"></a>ARTICLE 14: SECURITY DEPOSIT</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Upon the execution of this Lease, Tenant shall deposit with Landlord a Letter of Credit as described in this Section (the &#8220;<font style="font-weight: bold;">Letter of Credit</font>&#8221;), as security
        for the punctual performance of each and every obligation of Tenant under this Lease. In no event shall the Security Deposit be deemed to be a prepayment of Rent nor shall it be considered a measure of liquidated damages.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The Letter of Credit shall be an irrevocable standby letter of credit, in form and content and issued by a commercial bank satisfactory to Landlord in its reasonable discretion, which Letter of
        Credit shall provide that it may be drawn upon in Boston, Massachusetts or by facsimile (i) in part or in whole, upon the presentation of a sight draft accompanied by a certificate signed by a representative of Landlord, setting forth the amount
        due to Landlord by reason of the occurrence of an Event of Default by Tenant hereunder, or (ii) in whole, upon the presentation of a sight draft accompanied by a certificate signed by a representative of Landlord, stating that (a) such Letter of
        Credit will expire within thirty (30) days of such certificate, and (b) Tenant has not deposited a substitute Letter of Credit in the form, amount and issued by a bank as required by this Section. Landlord agrees that for purposes of this Section,
        First Republic Bank shall be an acceptable issuer of the Letter of Credit. Any payment drawn by Landlord under the Letter of Credit pursuant to clause (ii) of the preceding sentence shall be held by Landlord as a cash Security Deposit (&#8220;<font style="font-weight: bold;">Cash Security</font>&#8221;) pursuant to the provisions of this Article. Landlord may commingle any Cash Security with Landlord&#8217;s other funds, and no interest shall be due thereon. The Letter of Credit shall remain in full
        force and effect for a period of at least sixty (60) days beyond the expiration of the Term. Tenant shall deposit the original Letter of Credit with Landlord and shall keep the Letter of Credit in full force and in compliance with the provisions of
        this Lease throughout the Term. If required by the terms of any mortgage, pledge, security agreement or other encumbrance granted on the Unit or Landlord&#8217;s interest therein to secure financing provided to Landlord, Landlord may assign the Letter of
        Credit to the holder of such mortgage, pledge, security agreement or other encumbrance.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">66</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Landlord may apply the Security Deposit towards any default by Tenant which continues beyond the expiration of the applicable notice and cure period provided therefor in this Lease (if any), and
        damages sustained by Landlord as a result thereof. In the event that Landlord so draws upon and applies all or any portion of the proceeds of the Letter of Credit, or so applies all or any portion of the Cash Security, Tenant shall pay to Landlord,
        as Additional Rent, the amount so expended by Landlord (or shall deliver an amendment to the Letter of Credit increasing the amount of the Letter of Credit by the amount so drawn by Landlord) within five (5) Business Days of written notice given by
        Landlord so that at all times (subject to the 5&#8209;Business Day grace period herein referenced) Landlord shall be entitled to draw down upon the full aggregate amount of the Letter of Credit or hold the full Cash Security, or some combination thereof
        <a name="z_9kMJI5YVt7DA67A"></a>(in an amount not to exceed the amount of the Security Deposit specified in <u>Article 1</u> above (as such amount may be reduced in accordance with the provisions of the last two grammatical paragraphs of this <u>Article






          14)</u>. Notwithstanding anything contained in this Lease to the contrary, any failure of Tenant to restore any amount drawn under the Letter of Credit or expended from the Cash Security within the time and manner specified in this Section shall
        immediately constitute an Event of Default hereunder (without the necessity of any additional notice or the passage of any additional time) and entitle Landlord to immediately draw down the Letter of Credit then in force or effect and Landlord
        shall retain such cash amounts as a Security Deposit pursuant to the provisions of this Section. Tenant shall be solely responsible for the payment of all costs associated with obtaining, replacing (as necessary), transferring, extending and
        maintaining the Letter of Credit in accordance with the terms of this Section. The application of all or any part of the Security Deposit to any obligation or default of Tenant under this Lease shall not deprive Landlord of any other rights or
        remedies Landlord may have, nor shall such application by Landlord constitute a waiver by Landlord. In addition, in the event of a termination based upon an Event of Default of Tenant under this Lease, or a rejection of the Lease pursuant to the
        provisions of the Federal Bankruptcy Code, Landlord shall have the right to apply the Security Deposit (from time to time, if necessary) to cover up to the full amount of damages and other amounts due from Tenant to Landlord under the Lease. Any
        amounts so applied shall, at Landlord&#8217;s election, be applied first to any unpaid Rent and other charges which were due prior to the filing of the petition for protection under the Federal Bankruptcy Code.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Landlord shall assign the Security Deposit to any purchaser of the Unit, and thereafter Landlord shall have no further responsibility therefor. Upon request of Landlord or any such purchaser of the
        Building, Tenant shall, at its expense, cooperate with Landlord in obtaining an amendment to or replacement of any Letter of Credit which Landlord is then holding so that the amended or new Letter of Credit reflects the name of the new owner of the
        Unit.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">67</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Within sixty (60) days after the expiration or earlier termination of the Term, Landlord shall inspect the Premises, make such draw upon the Letter of Credit or apply all or any portion of the Cash
        Security as may be required to cure any default by Tenant hereunder or to make payment on account of damages suffered by Landlord, and, if no default is then continuing, Landlord shall redeliver the original Letter of Credit (as may have previously
        been drawn on by Tenant) or pay the balance of the Cash Security, as the case may be, to Tenant.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Notwithstanding the foregoing, Tenant shall be entitled to reduce the amount of the Letter of Credit in accordance with the following provisions:</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z206486365a8247fd9b636b43935e2995" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provided that (x) Tenant closes and receives the proceeds of a Series B financing in an amount not less than [***], and (y) as of the date of such closing (the &#8220;<font style="font-weight: bold;">First Reduction Date</font>&#8221;) (i) this
                Lease is in full force and effect, (ii) no Event of Default on the part of Tenant has occurred and is then continuing, and (iii) Tenant has not assigned the Lease or effected a Transfer of an ownership interest (direct or indirect) in
                Tenant which effects a change in control of Tenant, other than (A) a Related Party Transfer, or (B) as approved by Landlord pursuant to the provisions of <u>Article 12</u> hereof, then upon written request by Tenant, Landlord agrees to
                accept a reduction in the amount of the Letter of Credit which it is then holding so as to cause the total Security Deposit to be reduced to the amount of [***] Dollars; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z093a3dd1813642af9df6a1cb2f7fab82" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0);">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>provided that (x) the amount of the Letter of Credit has previously been reduced in accordance with the provisions of the immediately preceding paragraph (1), and (y) as of the last day of the third (3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>) Lease Year (the &#8220;<font style="font-weight: bold;">Second Reduction Date</font>&#8221;) (i) this Lease is in full force and effect, (ii) no Event of Default on the part of Tenant has
                occurred and is then continuing, (iii) Tenant has not entered into any Transfer of all or any portion of its interest in the Premises (including any Sublease or any transfer of any ownership interest (direct or indirect) in Tenant which
                effects a change in control of Tenant) other than a Related Party Transfer, and (iv) (A) if Tenant is then a publicly&#8209;traded company, Tenant has a market capitalization of not less than [***] Dollars, or (y) if Tenant is not then a
                publicly&#8209;traded company, Tenant has an enterprise value of not less than [***] Dollars, Landlord agrees to accept a reduction in the amount of the Letter of Credit which it is then holding so as to cause the total Security Deposit to be
                reduced as of the Reduction Date to an amount equal to [***] Dollars.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Any reduction in the Letter of Credit held by Landlord as the Security Deposit pursuant to the immediately preceding paragraph shall be accomplished by Tenant providing Landlord with a substitute
        Letter of Credit in the reduced amount in exchange for the existing Letter of Credit which Landlord is then holding, or by an amendment to the existing Letter of Credit then held by Landlord, in form and substance reasonably acceptable to Landlord,
        which is accepted by Landlord in writing (which acceptance may be evidenced by e&#8209;mail). If Tenant does not satisfy the requirements for a reduction in the amount of the Letter of Credit on the First Reduction Date as specified above, then Tenant
        shall be deemed to have irrevocably forfeited its right to any reduction in the amount of the Letter of Credit during the Term. If, having satisfied the requirements for a reduction in the amount of the Letter of Credit on the First Reduction Date,
        Tenant does not satisfy the requirements for a reduction in the amount of the Letter of Credit on the Second Reduction Date as specified above, then Tenant shall be deemed to have irrevocably forfeited its right to any reduction in the amount of
        the Letter of Credit on or after the Second Reduction Date for the balance of the Term.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">68</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><a name="z_Toc234589637"></a>ARTICLE 15: PROTECTION OF LENDERS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">15.01.&#160;&#160;&#160; Rights of Mortgage Holders. </font><font style="font-size: 10pt;">Until the holder of a mortgage shall
          enter and take possession of the Premises for the purpose of foreclosure, such holder shall have only such rights of Landlord as are necessary to preserve the integrity of this Lease as security. Upon entry and taking possession of the Premises
          for the purpose of foreclosure, such holder shall have all the rights of Landlord hereunder. Notwithstanding any other provision of this Lease to the contrary, no such holder of a mortgage shall be liable either as mortgagee, assignee or
          otherwise, to perform, or be liable in damages for failure to perform, any of the obligations of Landlord unless and until such holder shall succeed to the interests of the Landlord, by foreclosure or deed in lieu of foreclosure, and such holder
          shall not in any event be liable to perform or for failure to perform the obligations of Landlord under the Work Letter, in the event the holder of a mortgage shall succeed to the interest of the Landlord as aforesaid, such holder shall be liable
          to perform all of the obligations of Landlord accruing from and after succession in interest (except for the obligations under the Work Letter), subject to and with the benefit of all of the provisions of this Lease. No Base Rent, Additional Rent
          or any other charge shall be paid more than ten (10) days prior to the due dates thereof and payments made in violation of this provision shall (except to the extent that such payment are actually received by a mortgagee in possession or in the
          process of foreclosing its mortgage) be a nullity as against such mortgagee and Tenant shall be liable for the amount of such payments to such mortgagee.<br>
          <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">15.02.&#160;&#160;&#160; Subordination of Lease. </font><font style="font-size: 10pt;">It is agreed that the rights and interest
          of Tenant under this Lease shall be (i) subject or subordinate to any present or future mortgage or mortgages and to any and all advances to be made thereunder, and to the interest of the holder thereof in the Premises or any property of which
          the Premises are a part if such mortgagee shall elect by notice to Tenant to subject or subordinate the rights and interest of Tenant under this Lease to such mortgage or (ii) prior to any present or future mortgage or mortgages, if such
          mortgagee shall elect, by notice to Tenant, to give the rights and interest of Tenant under this Lease priority to such mortgage. in the event of either of such elections, and upon notification by mortgagee to that effect, the rights and interest
          of Tenant under this Lease shall be deemed to be subordinate to, or have priority over, as the case may be, said mortgage or mortgages, irrespective of the time of execution or time of recording of any such mortgage or mortgages. Tenant agrees it
          will, within ten (10) Business Days of Landlord&#8217;s or any such mortgagee&#8217;s written request therefor, execute, acknowledge and deliver any and all instruments deemed by Landlord, or by the requesting mortgagee, necessary or desirable to give effect
          to or notice of such subordination or priority. Any mortgage to which this Lease shall be subordinated may contain such terms, provisions and conditions as the holder, in its sole discretion, deems necessary or appropriate. Notwithstanding the
          foregoing, however, (a) Landlord shall deliver to Tenant promptly following the execution and delivery of this Lease a subordination, non&#8209;disturbance and attornment agreement (&#8220;<font style="font-weight: bold;">SNDA</font>&#8221;) reasonably
          satisfactory to Tenant and such mortgagee with respect to any existing mortgage encumbering the Building or the Unit as of the Date of Lease, pursuant to which the holder of such mortgage shall agree to recognize and not disturb Tenant&#8217;s rights
          under this Lease so long as Tenant is not in default under this Lease beyond the expiration of applicable notice and cure periods, if any, and (b) Tenant shall not be obligated to subordinate this Lease to any future mortgage encumbering the
          Building or the Unit unless the mortgagee provides Tenant with an SNDA reasonably satisfactory to Tenant and such mortgagee pursuant to which the holder of such mortgage agrees to recognize and not disturb Tenant&#8217;s rights under this Lease so long
          as Tenant is not in default under this Lease beyond the expiration of applicable notice and cure periods, if any. The current mortgagee&#8217;s form of SNDA as of the Date of Lease is attached hereto as <font style="font-weight: bold;"><u>Exhibit M</u></font>
          and is deemed to be acceptable to Tenant. Any mortgage recorded after the recording of the memorandum of lease referred to in <u>Section 27.2</u> shall be subject to this Lease unless the mortgagee elects under clause (i) of this Section to
          subordinate the rights and interest of Tenant to such mortgage and Tenant and such mortgagee execute a SNDA reasonably satisfactory to Tenant and such mortgagee with respect to this Lease. An election by a mortgagee under clause (i) of the first
          sentence of this Section to subordinate the rights and interest of Tenant to a mortgage shall not be valid unless consented to in writing by all the holders of record of all mortgages then outstanding secured by the Premises.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">69</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">15.03.&#160;&#160;&#160; Mortgagee&#8217;s Consent and Right to Cure Defaults. </font><font style="font-size: 10pt;">No agreement to
          make or accept any surrender, termination or cancellation of this Lease and no agreement to modify so as to reduce the rent, change the Term, or otherwise materially change the rights of Landlord under this Lease, or to relieve Tenant of any
          obligations or Liability under this Lease, shall be valid unless consented to by Landlord&#8217;s mortgagees of record, if any. No act or failure to act on the part of Landlord which would entitle Tenant under the terms of this Lease, or by law, to be
          relieved of Tenant&#8217;s obligations hereunder or to terminate this Lease, shall result in a release or termination of such obligations or a termination of this Lease unless (i) Tenant shall have first given written notice of Landlord&#8217;s act or
          failure to act to Landlord&#8217;s mortgagees of record, if any, specifying the act or failure to act on the part of Landlord which could or would give basis to Tenant&#8217;s rights; and (ii) such mortgagees, after receipt of such notice, have failed or
          refused to correct or cure the condition complained of within a reasonable time thereafter; but nothing contained in this Section shall be deemed to impose any obligation on any such mortgagees to correct or cure any such condition. &#8220;<font style="font-weight: bold;"><u>Reasonable time</u></font>&#8221; as used above means and includes a reasonable time to obtain possession of the mortgaged premises if the mortgagee elects to do so and a reasonable time to correct or cure the condition
          if such condition is determined to exist.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">15.04.&#160;&#160; Estoppel Certificates. </font><font style="font-size: 10pt;">Within ten (10) Business Days after
          Tenant&#8217;s receipt of the written request of Landlord, Tenant shall execute, acknowledge and deliver to Landlord a written statement in the form attached hereto as <font style="font-weight: bold;"><u>Exhibit N</u></font> or in such other form as
          may be reasonably requested by Landlord, certifying (i) that none of the terms or provisions of this Lease have been changed (or if they have been changed, stating how); (ii) that this Lease has not been canceled or terminated and is in full
          force and effect; (iii) the last date of payment of Base Rent and other charges and the time period covered; (iv) to the best of Tenant&#8217;s knowledge, that Landlord is not in default under this Lease (or if in default, describing it in reasonable
          detail); and (v) such other information with respect to Tenant as Landlord may reasonably request or which any prospective purchaser or encumbrancer of the Unit, the Building or the Development may reasonably require. Landlord may deliver any
          such statement by Tenant to any prospective purchaser or encumbrancer, which parties may rely conclusively upon such statement as true and correct. If Tenant does not deliver such statement to Landlord within such ten (10) Business Day period:</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">70</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">Landlord, and any such prospective purchaser or encumbrancer, may conclusively presume and rely upon the
          following facts: (i) that the terms and provisions of this Lease have not been changed except as represented by Landlord; (ii) that this Lease has not been canceled or terminated and is in full force and effect, except as otherwise represented by
          Landlord; (iii) that not more than one (1) month&#8217;s Base Rent or other charges have been paid in advance; and (iv) that Landlord is not in default under this Lease. In such event, Tenant shall be estopped from denying the truth of such facts; and</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0);">If Landlord gives written notice to Tenant of such failure and Tenant further fails to deliver such
          statement to Landlord within five (5) Business Days following the giving of such second written notice, then an Event of Default shall be deemed to have occurred pursuant to <u>Section 13.01(B)(ii)(d)</u> above.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Within ten (10) Business Days after Landlord&#8217;s receipt of the written request of Tenant, Landlord shall execute, acknowledge and deliver to Tenant a written statement in such form as may be
        reasonably requested by Tenant, certifying (i) that none of the terms or provisions of this Lease have been changed (or if they have been changed, stating how); (ii) that this Lease has not been canceled or terminated and is in full force and
        effect; (iii) the last date of payment of Base Rent and other charges and the time period covered; (iv) to the best of Landlord&#8217;s knowledge, that Tenant is not in default under this Lease (or if in default, describing it in reasonable detail); and
        (v) such other information with respect to Landlord as Tenant may reasonably request or which any prospective assignee of Tenant&#8217;s interest hereunder in accordance with the provisions of <u>Article 12</u> may reasonably require. Tenant may deliver
        any such statement by Landlord to any such prospective encumbrancer or investor, which parties may rely conclusively upon such statement as true and correct.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">15.05.&#160;&#160;&#160; Financial Condition. </font><font style="font-size: 10pt;">Tenant, within ten (10) Business Days after
          request from Landlord from time to time, but in no event more than once per twelve (12) month period (except in connection with a sale or refinance of the Unit), shall deliver to Landlord (i) Tenant&#8217;s annual audited (if available, otherwise
          certified by Tenant&#8217;s Chief Financial Officer) financial statements for the latest available fiscal year (provided that after Tenant first takes occupancy of any portion of the Premises for the conduct of its business, Tenant shall provide in
          response to such a request from Landlord financial statements for the two (2) latest available fiscal years, including the most recent fiscal year prior to Landlord&#8217;s request), and (ii) to the extent to which Tenant has otherwise prepared them
          (or caused them to be prepared) for any purpose, quarterly financial statements certified in writing by Tenant&#8217;s chief financial officer with respect to the then&#8209;current fiscal year. Landlord may deliver such financial statements to its
          mortgagees and lenders and prospective mortgagees, lenders, and purchasers on a confidential basis. Tenant represents and warrants to Landlord that each unaudited financial statement shall be prepared in accordance with generally accepted
          accounting principles (&#8220;<font style="font-weight: bold;">GAAP</font>&#8221;) (except that such financial statements may (i) be subject to normal year-end audit adjustments, and (ii) not contain all notes thereto that may be required in accordance with
          GAAP), consistently applied, and shall fairly and accurately represent the financial condition of Tenant as of the date of such statement. Except for publicly available information, financial statements shall be kept confidential, and Landlord
          and any parties to whom Landlord provides such statements shall enter into reasonable confidentiality agreements with Tenant, in form reasonably acceptable to both Landlord and Tenant, prior to Tenant&#8217;s delivery of such financial statements. The
          requirements of this <u>Section 15.05</u> shall be suspended during such time (if any) as Tenant is subject to the public reporting requirements of the Securities Act of 1934, as amended.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">71</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; color: rgb(0, 0, 0); font-weight: bold;"><a name="z_Toc234589643"></a>ARTICLE 16: MISCELLANEOUS PROVISIONS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.01.&#160;&#160; Landlord&#8217;s Consent Fees. </font><font style="font-size: 10pt;">In addition to fees and expenses in
          connection with Tenant Work as described in <u>Section 10.05</u> above, Tenant shall pay Landlord&#8217;s reasonable out&#8209;of&#8209;pocket third party fees and expenses, including legal, engineering and other consultants&#8217; fees and expenses, incurred in
          connection with Tenant&#8217;s request for Landlord&#8217;s consent under <u>Article 12</u> or in connection with any other request by Tenant for Landlord&#8217;s consent or approval under this Lease.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.02.&#160;&#160;&#160; Landlord&#8217;s Default. </font><font style="font-size: 10pt;">Landlord shall in no event be in default in
          the performance of any of Landlord&#8217;s obligations under this Lease unless and until Landlord shall have failed to perform such obligation within thirty (30) days after notice by Tenant to Landlord (&#8220;<font style="font-weight: bold;">Tenant&#8217;s
            Default Notice</font>&#8221;) specifying the manner in which Landlord has failed to perform any such obligation (provided that if correction of any such matter reasonably requires longer than thirty (30) days and Landlord so notifies Tenant within
          thirty (30) days after such Tenant&#8217;s Default Notice is given, Landlord shall be allowed such longer period, but only if cure is begun within such thirty (30) day period and thereafter diligently prosecuted to completion). In the event of any
          default by Landlord hereunder, Tenant shall have no right to perform such Landlord obligation and recover from Landlord any costs so incurred, or to abate or withhold Rent, but Tenant shall have the right, in the event of a default by Landlord
          hereunder, to commence and to prosecute an independent proceeding against Landlord for the recovery of damages or for equitable relief. This Lease shall be construed as though Landlord&#8217;s and Tenant&#8217;s covenants contained herein are independent and
          not dependent, and Tenant hereby waives the benefit of any statute or judicial law to the contrary. In no event shall Landlord ever be liable to Tenant for any indirect, special, consequential, or punitive damages.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.03.&#160;&#160;&#160; Quiet Enjoyment. </font><font style="font-size: 10pt;">Landlord agrees that, so long as no Event of
          Default has occurred and is then continuing under this Lease, Tenant shall peaceably and quietly hold, occupy and enjoy the Premises during the Term of this Lease without disturbance by Landlord or by any person claiming through or under
          Landlord, subject to the terms of this Lease, the Condominium Documents and Title Matters.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.04.&#160;&#160;&#160; Interpretation. </font><font style="font-size: 10pt;">In any provision relating to the conduct, acts or
          omissions of Tenant, the term &#8220;<font style="font-weight: bold;">Tenant</font>&#8221; includes Tenant&#8217;s agents, employees, contractors, invitees, or successors. In any provision relating to the conduct, acts or omissions of Landlord, the term &#8220;<font style="font-weight: bold;">Landlord</font>&#8221; includes Landlord&#8217;s agents, employees, invitees, contractors or successors.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">72</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.05.&#160;&#160;&#160; Notices. </font><font style="font-size: 10pt;">All notices, requests and other communications required
          under this Lease (a) shall be in writing unless otherwise expressly provided herein, addressed (i) to Landlord, as specified in <u>Article 1</u>, and (ii) to Tenant, as specified in <u>Article 1</u> until the Rent Commencement Date, and then
          from and after the Rent Commencement Date, to Tenant at the Premises, Attn: Heather Wasserman, with copies to hwasserman@remixtx.com and to eperry@remixtx.com, and (b) shall (unless otherwise expressly provided in this Lease) be (i) personally
          delivered, or (ii) sent by certified mail, return receipt requested, postage prepaid, or (iii) delivered by a national overnight delivery service that maintains delivery records. Any notice so addressed shall be effective upon the earlier of (A)
          actual receipt, or (B) first tender for delivery by the United States Postal Service or a national overnight courier (provided that such first tender occurs on a Business Day), or (C) on the third Business Day following the day of mailing if so
          mailed by certified mail, return receipt requested. Either party may change its notice address upon written notice to the other party. Whenever oral notice is expressly permitted to be provided by either party pursuant to the provisions of this
          Lease, such notice shall only be valid and effective if such party uses all reasonable efforts to provide confirmatory written notice to the other party within twenty&#8209;four (24) hours of the giving of such oral notice.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.06.&#160;&#160;&#160; No Recordation. </font><font style="font-size: 10pt;">Tenant shall not record this Lease or any
          portion(s) hereof, and immediately upon any such recording this Lease shall automatically (and without the necessity of any notice from or action by Landlord) terminate. Notwithstanding the foregoing, Landlord and Tenant agree to execute herewith
          a Notice of Lease in the form attached hereto as <font style="font-weight: bold;"><u>Exhibit O</u></font>, which shall be recorded with the appropriate Registry of Deeds, and agree to execute, upon termination of this Lease for whatever cause, a
          Notice of Termination of Lease in recordable form for recording with said Registry of Deeds.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.07.&#160;&#160;&#160; Corporate Authority. </font><font style="font-size: 10pt;">Each of Tenant and Landlord warrant and
          represent to the other that (a) such party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which such entity was organized; (b) such party has the authority to own its property and to carry on its
          business as contemplated under this Lease; (c) such party has duly executed and delivered this Lease; and (d) the execution, delivery and performance by such party of this Lease (i) are within the powers of such party, (ii) have been duly
          authorized by all requisite action, (iii) will not violate any provision of law or any order of any court or agency of government, or any agreement or other instrument to which such party is a party or by which it or any of its property is bound,
          and (iv) will not result in the imposition of any lien or charge on any of such party&#8217;s property, except by the provisions of this Lease. Each party agrees that breach of the foregoing warranties and representations shall at the other party&#8217;s
          election be a default under this Lease for which there shall be no cure. These warranties and representations shall survive the expiration of the Term or the earlier termination of this Lease. Upon execution of this Lease, Tenant shall provide to
          Landlord a certificate of a clerk, secretary or other authorized officer of Tenant, (i) certifying to the adoption of a board resolution or other entity vote authorizing the execution of this Lease on behalf of Tenant, and (ii) identifying the
          person authorized to execute this Lease on behalf of Tenant.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.08.&#160;&#160;&#160; Joint and Several Liability. </font><font style="font-size: 10pt;">If more than one party signs this
          Lease as Tenant, they shall be jointly and severally liable for all obligations of Tenant.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">73</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.09.&#160;&#160;&#160; Force Majeure. </font><font style="font-size: 10pt;">If either party is delayed or hindered in or
          prevented from the performance of any act required under this Lease to be performed by such party by reason of (i) strikes, lockouts, or labor disputes not attributable to the failure of the party claiming the benefit of a delay due to &#8220;Force
          Majeure&#8221; or any of its contractors (of any tier) to perform their obligations under any applicable labor contract or law; (ii) inability to obtain labor or materials, or reasonable substitutes therefor; (iii) acts of God; (iv) governmental
          action, orders, restrictions or controls; (v) civil commotion, terrorism, riots, insurrection, or war; (vi) condemnation, or fire or other casualty; (vii) pandemic or other public health emergency (including actions required by any governmental
          authority to be taken by Landlord or Tenant in connection with such pandemic or public health emergency); (viii) trouble in obtaining fuel, electricity, water, sewer, or telecommunication services or supplies from sources from which they are
          usually obtained, provided the party experiencing such trouble shall have used reasonable efforts to procure alternative sources; or (ix) other conditions similar to those hereinabove enumerated beyond the reasonable control of the party
          obligated to perform (collectively, &#8220;<font style="font-weight: bold;">Force Majeure</font>&#8221;), then performance of such act shall be excused for the period of the delay, and the period for the performance of any such act shall be extended for a
          period equivalent to the period of such delay. Notwithstanding the provisions of the immediately preceding sentence, financial failure, bankruptcy, lack of funds or financial inability to perform shall not constitute &#8220;Force Majeure&#8221; for purposes
          of this Lease. Subject to the provisions of the last sentence of this Section, in case either party is prevented or delayed from diligent construction of improvements, making any repairs, alterations or improvements, or furnishing any services or
          performing any other covenant or duty to be performed on the part of such party by reason of any cause reasonably beyond such party&#8217;s control, then notwithstanding any contrary provision of this Lease, such party shall not be liable to the other
          party therefor nor shall Tenant be entitled to any abatement or reduction of Rent by reason thereof, nor shall the same give rise to a claim in Tenant&#8217;s favor that such failure constitutes actual or constructive, total or partial, eviction from
          the Premises. In order to claim the benefit of a delay due to &#8220;Force Majeure&#8221;, the party experiencing such event or circumstance must (a) notify the other party within a reasonable time period after such delay commences, and (b) use all
          reasonable and diligent efforts to minimize the duration of such delay and the effect of the delay upon the progress of construction of its respective work as described in this Work Letter. Notwithstanding anything to the contrary contained in
          this Lease, no event of Force Majeure shall (i) excuse Tenant&#8217;s obligations to pay Rent and other charges due pursuant to this Lease, or (ii) be grounds for Tenant to abate any portion of Rent or any other charge due pursuant to this Lease or
          entitle Tenant to terminate this Lease, except as may be otherwise expressly provided in <font style="font-weight: bold;"><u>Article 11</u></font> hereof, or (iii) excuse Landlord&#8217;s obligations to pay Landlord&#8217;s Allowance or the Space Planning
          Allowance when due pursuant to the Work Letter.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: bold;">16.10.&#160;&#160;&#160;&#160; No Warranties; Limitation of Liability.</div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>No Warranties</u>. Landlord and Tenant expressly agree that there are and shall be no implied warranties
          of merchantability, habitability, suitability, fitness for a particular purpose or of any other kind arising out of this Lease, and there are no warranties which extend beyond those expressly set forth in this Lease.</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">74</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>Limitation of Liability</u>. Tenant agrees that Landlord shall be liable only for breaches of its
          covenants occurring while it is owner of the Unit: <font style="font-style: italic;">provided, however,</font> that if Landlord from time to time is lessee of the ground or improvements constituting the Building, then Landlord&#8217;s period of
          ownership of the Unit shall be deemed to mean only that period while Landlord holds such leasehold interest. Upon any sale or transfer of the Unit and the acceptance by the transferee Landlord of the obligations of the landlord hereunder first
          arising from and after such sale or transfer of the Unit, the transferor Landlord (including any mortgagee) shall be relieved of any liability or obligation thereafter arising and Tenant shall look solely to the transferee Landlord as aforesaid
          for satisfaction of such liability or obligation except for defaults by Landlord prior to such transfer (for which the transferor Landlord shall remain liable). Tenant and each person acting under Tenant agrees to look solely to Landlord&#8217;s
          interest in the Unit for satisfaction of any claim against Landlord. No owner, trustee, beneficiary, partner, member, manager, officer, director, agent, or employee of either Landlord (or of any mortgagee or any lender or ground or improvements
          lessor) or Tenant, nor any person acting under any of them shall ever be personally or individually liable to the other party to this Lease or any person claiming under or through such other party for or on account of any default hereunder or
          failure to perform any of its obligations hereunder, or for or on account of any amount or obligations that may be or become due under or in connection with this Lease or the Premises; nor shall it or they ever be answerable or liable in any
          equitable judicial proceeding or order beyond the extent of their interest in the Unit. No deficit capital account of any member or partner of Landlord shall be deemed to be a liability of such member or partner or an asset of Landlord. Any lien
          obtained to enforce any judgment against Landlord shall be subject and subordinate to any mortgage encumbering the Unit (either by itself or as part of a larger mortgaged property). In no event shall Landlord (or any such persons) ever be liable
          to Tenant, or anyone claiming through or on behalf of Tenant, for any special, indirect, punitive or consequential damages, including lost profits or revenues. Except with respect to claims arising under <u>Section 3.02</u> and <u>Section
            9.04(g)</u> hereof, in no event shall Tenant (or any such persons) ever be liable to Landlord, or anyone claiming through or on behalf of Landlord, for any special, indirect, punitive or consequential damages, including lost profits or
          revenues, in an aggregate amount in excess of [***] Dollars with respect to all claims therefor by Landlord against Tenant arising under or relating to this Lease.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.11.&#160;&#160;&#160; No Brokers. </font><font style="font-size: 10pt;">Landlord and Tenant represent and warrant to each
          other that the parties named in <u>Article 1</u> are the only agents, brokers, finders or other parties with whom such party has dealt who may be entitled to any commission or fee with respect to this Lease or the Premises. Landlord shall
          compensate Landlord&#8217;s Broker and Tenant&#8217;s Broker pursuant to a separate agreement between Landlord and such Brokers. Landlord and Tenant agree to indemnify and hold the other harmless from any claim, demand, cost or liability, including
          reasonable attorneys&#8217; fees and expenses, asserted by any party other than the parties named in <u>Article 1</u> based upon dealings of that party with the indemnifying party. The provisions of this Section shall survive the expiration of the
          Term or the earlier termination of this Lease.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.12.&#160;&#160;&#160; No Waiver; Accord and Satisfaction. </font><font style="font-size: 10pt;">No consent by Landlord or
          Tenant to any act or omission that otherwise would be a default shall be construed to permit other similar acts or omissions. Neither party&#8217;s failure to seek redress for violation or to insist upon the strict performance of any covenant, nor the
          receipt by Landlord of Rent with knowledge of any breach of covenant, shall be deemed a consent to or waiver of such breach. No breach of covenant shall be implied to have been waived unless such is in writing, signed by the party benefiting from
          such covenant and delivered to the other party. No acceptance by Landlord of a lesser sum than the Rent due shall be deemed to be other than on account of the earliest installment of such Rent; nor shall any endorsement or statement on any check
          or in any letter accompanying any check or payment be deemed an accord and satisfaction; and Landlord may accept such check or payment without prejudice to Landlord&#8217;s right to recover the balance of such installment or pursue any other right or
          remedy. The acceptance by Landlord of any Rent following the giving of any default and/or termination notice shall not be deemed a waiver of such notice. Tenant shall not interpose any counterclaim or counterclaims in a summary proceeding or in
          any action based on non&#8209;payment of Rent except to the extent that by failing to do so, Tenant will irrevocably lose the right to assert such claim in an independent action.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">75</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.13.&#160;&#160;&#160; Applicable Law and Construction. </font><font style="font-size: 10pt;">This Lease may be executed in
          counterparts, shall be construed as a sealed instrument, and shall be governed exclusively by the provisions hereof and by the laws of the state where the Development is located without regard to principles of choice of law or conflicts of law.
          This Lease may be executed by electronic signature, which shall be considered as an original signature for all purposes and shall have the same force and effect as a manual signature. Delivery of a copy of this Lease bearing an original or
          electronic signature by facsimile transmission, electronic mail in portable document format (&#8220;pdf&#8221;), digital signature software application (such as DocuSign), or any other electronic means intended to preserve the original graphic and pictorial
          appearance of a document, will have the same effect as physical delivery of the paper document bearing a manual or electronic signature. The covenants of Landlord and Tenant are independent, and such covenants shall be construed as such in
          accordance with the laws of The Commonwealth of Massachusetts. If any provision of this Lease or the application thereof to any person or circumstance is for any reason held to be invalid, the remainder of this Lease (or the remainder of such
          provision) and the application thereof to other persons or circumstances shall not be affected thereby. Other than contemporaneous instruments executed and delivered of even date, if any, this Lease contains all of the agreements between Landlord
          and Tenant relating in any way to the Premises and supersedes all prior agreements and dealings between them. There are no oral agreements between Landlord and Tenant relating to this Lease or the Premises. This Lease may be amended only by
          instrument in writing executed and delivered by both Landlord and Tenant. The provisions of this Lease shall bind Landlord and Tenant and their respective successors and assigns, and shall inure to the benefit of Landlord and its successors and
          assigns and of Tenant and its permitted successors and assigns, subject to <u>Article 12</u>. The titles are for convenience only and shall not be considered a part of this Lease. This Lease shall not be construed more strictly against one party
          than against the other merely by virtue of the fact that it may have been prepared primarily by counsel for one of the parties, it being recognized that both Landlord and Tenant have contributed substantially and materially to the preparation of
          this Lease. If Tenant is granted any extension or other option, to be effective the exercise (and notice thereof) shall be unconditional; and if Tenant purports to condition the exercise of any option or to vary its terms in any manner, then the
          option granted shall be void and the purported exercise shall be ineffective. Time is of the essence of this Lease and each of its provisions. The enumeration of specific examples of a general provision shall not be construed as a limitation of
          the general provision, and the term &#8220;including&#8221; shall be deemed to mean &#8220;including, without limitation&#8221;. As used in this Lease, the term &#8220;<font style="font-weight: bold;">Business Day</font>&#8221; shall mean any day other than a Saturday, Sunday, or
          day on which commercial banks in Boston, Massachusetts are authorized or required by law to remain closed. The submission of a form of this Lease or any summary of its terms shall not constitute an offer by Landlord to Tenant; but a leasehold
          shall only be created and the parties bound when this Lease is executed and delivered by both Landlord and Tenant and approved by the holder of any mortgage of the Premises having the right to approve this Lease. Nothing herein shall be construed
          as creating the relationship between Landlord and Tenant of principal and agent or of partners or joint venturers or any relationship other than landlord and tenant. This Lease and all consents, notices, approvals and all other related documents
          may be reproduced by any party by any electronic means or by facsimile, photographic, microfilm, microfiche or other reproduction process and the originals may be destroyed; and each party agrees that any reproductions shall be as admissible in
          evidence in any judicial or administrative proceeding as the original itself (whether or not the original is in existence and whether or not reproduction was made in the regular course of business), and that any further reproduction of such
          reproduction shall likewise be admissible. If any payment in the nature of interest provided for in this Lease shall exceed the maximum interest permitted under controlling law, as established by final judgment of a court, then such interest
          shall instead be at the maximum permitted interest rate as established by such judgment.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">76</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: bold;">16.14.&#160;&#160; Waiver of Trial by Jury. LANDLORD AND TENANT HEREBY WAIVE TRIAL BY JURY IN ANY ACTION TO WHICH THEY ARE PARTIES ARISING OUT OF OR RELATING TO THIS
        LEASE, THE PREMISES, THE UNIT, THE BUILDING OR THE DEVELOPMENT.</div>
      <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.15.&#160;&#160;&#160; No Representations or Inducements. </font><font style="font-size: 10pt;">In entering into this Lease
          Tenant acknowledges that Tenant is not relying on any representations, agreements, or promises of Landlord, or any inducements offered by Landlord to Tenant, not expressly set forth in this Lease.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.16.&#160;&#160;&#160; No Surrender. </font><font style="font-size: 10pt;">No act or thing done by Landlord shall be deemed an
          acceptance of a surrender of the Premises, and no agreement to accept such surrender shall be valid, unless in writing signed by Landlord. No employee of Landlord or of Landlord&#8217;s agents shall have any power to accept the keys of the Premises
          prior to the termination of this Lease. The delivery of keys to any employee of Landlord or of Landlord&#8217;s agents shall not operate as a termination of the Lease or a surrender of the Premises. In the event that Tenant at any time desires to have
          Landlord underlet the Premises for Tenant&#8217;s account, Landlord or Landlord&#8217;s agents are authorized to receive the keys or other access devices for such purposes upon written notice from Tenant without releasing Tenant from any of the obligations
          under this Lease, and Tenant hereby relieves Landlord of any liability for loss of or damage to any of Tenant&#8217;s effects in connection with such underletting.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.17.&#160;&#160;&#160; Arbitration. </font><font style="font-size: 10pt;">All disputes between the parties specifically
          referencing this <u>Section 16.17</u> shall be resolved in accordance with this <u>Section 16.17</u> except (i) Landlord shall have all of its rights and remedies at law or in equity in the event of a default by Tenant, (ii) Landlord shall have
          the right to obtain possession of the Premises by any lawful means following a valid termination of this Lease, and (iii) any arbitration decision under this <u>Section 16.17</u> shall be enforceable in accordance with applicable law in any
          court of proper jurisdiction.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>Initial Construction Disputes</u>. If the dispute is with respect to matters relating to the Base
          Building Work or Initial Tenant Work (&#8220;<font style="font-weight: bold;">Initial Construction Disputes</font>&#8221;), the dispute shall initially be submitted by either party to the Landlord Representative and the Tenant Representative for resolution.
          The initial representatives of the parties shall be as follows, until a party gives written notice to the other parties that it is replacing its Representative:</font></div>
      <div><br>
      </div>
      <div>&#160;</div>
      <table style="border-collapse: collapse; width: 50%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="zd9b4bd4f91f346019156ac2dc9301d8c" align="center" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div style="font-size: 12pt;"><u><font style="font-size: 10pt;">Landlord Representative:</font></u></div>
            </td>
            <td style="width: 25%; vertical-align: top;">
              <div style="font-size: 12pt;"><u><font style="font-size: 10pt;">Tenant Representative:</font></u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 25%; vertical-align: top;">
              <div>Mark A. Deschenes</div>
            </td>
            <td style="width: 25%; vertical-align: top;">
              <div>Emily Perry</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The Landlord and Tenant Representatives shall meet one or more times to attempt to resolve such dispute within the 5&#8209;Business Day period following the date that such dispute is submitted to them.
        If, after such meeting(s), the parties have been unable to resolve such dispute, then such dispute shall be resolved as set forth in <u>Section 16.17(b)</u>.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">77</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);"><u>Arbitration Procedures</u>. Either party may give written notice of the dispute requesting resolution
          under this Section and submit a reasonably detailed written statement of the position and reasons therefor with such notice. The other party will, within ten (10) days (five (5) days if an Initial Construction Dispute) of receiving such written
          statement, submit to the party initiating the dispute resolution its own detailed written statement of the position and reasons therefor. The president of Tenant and Mark A. Deschenes, on behalf of Landlord (or such other persons as Landlord or
          Tenant may designate by written notice to the other), shall meet at the earliest mutually acceptable time and place, but in any case within thirty (30) days (ten (10) days if an Initial Construction Dispute) of the date of the response statement
          to attempt to resolve the dispute. If the matter has not been resolved within thirty (30) days (ten (10) days if an Initial Construction Dispute) of the date of the response statement, then either party may initiate arbitration of such
          controversy by written notice to the other (the &#8220;<font style="font-weight: bold;">Arbitration Notice</font>&#8221;). The arbitration shall be held before a single arbitrator. The parties shall endeavor to agree upon and name the arbitrator within the
          15&#8209;day period following the giving of the Arbitration Notice. If the parties fail timely to agree upon and name the arbitrator, then unless the parties agree in writing to another procedure for designating the arbitrator, either party may by
          written notice given to the other and to the Boston office of the American Arbitration Association request that the arbitrator be promptly chosen by the Boston office of the American Arbitration Association. The arbitrator shall commence the
          arbitration hearing within ten (10) days after appointment, shall complete the arbitration hearing within thirty (30) days after the date the arbitration hearing commenced, and shall render a written arbitration decision within forty (40) days
          after the arbitration hearing commenced, which time periods may be extended by written agreement of the parties or by the arbitrator for good cause, except that any arbitration of Initial Construction Disputes shall be conducted on an expedited
          basis and shall be concluded, with a decision issued, no later than two (2) weeks after the date that such dispute was submitted for arbitration. The arbitration shall be conducted in accordance with then existing expedited procedures under the
          commercial arbitration rules of the American Arbitration Association; however, to the extent any provision of this paragraph is inconsistent with such procedures, the provisions of this paragraph shall govern. The decision of the arbitrator shall
          be final and binding upon the parties and judgment upon the decision rendered by the arbitrator may be entered in any court having jurisdiction thereof. The parties shall equally share and pay the costs of the arbitrator. Each party shall be
          afforded a reasonable opportunity to take discovery of the other prior to the commencement of such arbitration consistent with the expedited dispute resolution timetable set forth in this <u>Section 16.17(b)</u>; provided, however, that each
          party shall be limited to a maximum of twelve (12) deposition hours each. Notwithstanding the foregoing or anything herein to the contrary, the dispute resolution provisions of this Section shall not apply to a dispute, claim or controversy in
          which: (i) a party claiming in good faith a breach of any provision of this Lease by the other party seeks immediate equitable relief from a court of competent jurisdiction to enable the instituting party to prevent irreparable harm (alleged to
          arise from the alleged breach) pending agreed resolution or a grant of arbitral relief; or (ii) any claim by one party against the other party arises out of the subject matter of any court litigation or proceeding commenced by any third party
          against one party in which the other party is an indispensable party or third party defendant; or (iii) any claim is asserted with respect to which a third party, which is not bound and will not upon request of a party, agree to arbitrate, is an
          indispensable or necessary party.</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">78</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.18.&#160;&#160;&#160; REIT/UBTI. </font><font style="font-size: 10pt;">Tenant and Landlord intend that all amounts payable by
          Tenant to Landlord shall qualify as &#8220;rents from real property,&#8221; and will otherwise not constitute &#8220;impermissible tenant services income&#8221; within the meaning of Section 856(d) of the Internal Revenue Code of 1986, as amended (the &#8220;<font style="font-weight: bold;">Code</font>&#8221;) and the U.S. Department of Treasury Regulations promulgated thereunder (the &#8220;<font style="font-weight: bold;">Regulations</font>&#8221;). In the event that Landlord determines that there is any risk that any
          amount payable under the Lease shall not qualify as &#8220;rents from real property&#8221; or will otherwise constitute impermissible tenant services income within the meaning of Section 856(d) of the Code and the Regulations promulgated thereunder. Tenant
          agrees (a) to cooperate with Landlord by entering into such amendment or amendments as Landlord deems necessary to qualify all amounts payable under the Lease as &#8220;rents from real property&#8221; and (b) to permit (and, upon request, to acknowledge in
          writing) an assignment of certain services under the Lease, and, upon request, to enter into direct agreements with the parties furnishing such services. Notwithstanding the foregoing, Tenant shall not be required to take any action pursuant to
          the preceding sentence (including acknowledging in writing an assignment of services pursuant thereto) if such action would result in (A) Tenant&#8217;s incurring more than de minimis additional liability under the Lease or (B) more than a de minimis
          negative change in the quality or level of Building operations or services rendered to Tenant under the Lease. For the avoidance of doubt, (i) if Tenant does not acknowledge in writing an assignment as described in clause (b) above (it being
          agreed that Tenant shall not unreasonably withhold, condition or delay such acknowledgment so long as the criteria in clauses (A) and (B) are satisfied), then Landlord shall not be released from liability under the Lease with respect to the
          services so assigned; and (ii) nothing in this Section shall limit or otherwise affect Landlord&#8217;s ability to assign its entire interest in the Lease to any party as part of a conveyance of Landlord&#8217;s ownership interest in the Building.<br>
          <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.19.&#160;&#160;&#160; Patriot Act. </font><font style="font-size: 10pt;">Notwithstanding any other provision contained in
          this Lease to the contrary, Tenant shall not knowingly transfer or permit the transfer of any legal or beneficial interest in Tenant to, or assign, Sublease or otherwise Transfer all or any portion of its interest under this Lease or in all or
          any portion of the Premises to, or enter into any Sublease to, any of the following:</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">any person or entity (or any person or entity whose operations are directed or controlled by a person or
          entity) that has been convicted of or has pleaded guilty in a criminal proceeding to a felony or that is an on&#8209;going target of a grand jury investigation convened pursuant to applicable statutes concerning organized crime;</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">any entity organized in or controlled from a country, the activities with respect to which are regulated or
          controlled pursuant to the following United States laws and the regulations or executive orders promulgated thereunder: (1) the Trading with the Enemy Act of 1917, 50 U.S.C. App. &#167; 1, et <font style="font-style: italic;">seq.</font>, as amended;
          (2) the International Emergency Economic Powers Act of 1976, 50 U.S.C. &#167;1701, <font style="font-style: italic;">et seq.</font>, as amended; or (3) the Anti&#8209;Terrorism and Arms Export Amendments Act of 1989, codified at Section 6(j) of the Export
          Administration Act of 1979, 50 U.S.C. App. &#167;2405W, as amended; or</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">any person or entity with whom Landlord is restricted from doing business under either (1) Executive Order
          No. 13224 on Terrorist Financing <a name="z_9kMKJ5YVt7DA67A"></a>(effective September 24, 2001 (as amended or supplemented from time to time, the &#8220;<font style="font-weight: bold;">Executive Order</font>&#8221;), or (2) the Uniting and Strengthening
          America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Public Law 10756; as amended, from time to time, the &#8220;<font style="font-weight: bold;">Patriot Act</font>&#8221;), or (3) the regulations of the United
          States Department of the Treasury Office of Foreign Assets Control (including those Persons named on the list of &#8220;Specially Designated Nationals and Blocked Persons&#8221; as modified from time to time), or other governmental action; or</font></div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">79</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0);">any Affiliate of any of the persons or entities described in the preceding paragraphs (a), (b) or (c).</font></div>
      <div><br>
      </div>
      <div style="text-align: justify;">Tenant hereby represents and warrants to Landlord, as of the Date of Lease, that, to the best of Tenant&#8217;s knowledge, neither Tenant nor any of its constituent partners, investors, beneficiaries or Affiliates, are in
        violation of any Legal Requirements relating to terrorism or money laundering, including the Executive Order and the Patriot Act and that neither Tenant, nor its constituent partners, investors, beneficiaries or Affiliates, are listed on the United
        States Department of the Treasury Office of Foreign Assets Control list of &#8220;Specially Designated Nationals and Blocked Persons&#8221; as modified from time to time, and that none of them is otherwise subject to the provisions of the Executive Order or
        the Patriot Act, or any rules or regulations promulgated thereunder. Thereafter, Tenant shall from time to time, within ten (10) days after request by Landlord, deliver to Landlord a certification stating that, to the best of Tenant&#8217;s knowledge,
        neither Tenant nor any Transferee, nor any of their respective constituent partners, investors, beneficiaries or Affiliates, are in violation of any Legal Requirements relating to terrorism or money laundering, including the Executive Order and the
        Patriot Act and that neither Tenant nor any Transferee, nor any of their respective constituent partners, investors, beneficiaries or Affiliates, are listed on the United States Department of the Treasury Office of Foreign Assets Control list of
        &#8220;Specially Designated Nationals and Blocked Persons&#8221; as modified from time to time, and that none of them is otherwise subject to the provisions of the Executive Order or the Patriot Act, or any rules or regulations promulgated thereunder. As used
        in this Lease, the term &#8220;<font style="font-weight: bold;">Affiliate</font>&#8221; shall mean, with respect to any specific person or entity, any other person or entity which, directly or indirectly, controls or is controlled by or is under common control
        with such first&#8209;mentioned person or entity. For the purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;), as used with respect to any entity, shall mean the
        possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting stock or by contract or otherwise.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">16.20.&#160;&#160;&#160; Confidentiality. </font><font style="font-size: 10pt;">Landlord and Tenant each agrees to keep the
          terms and provisions of this Lease (including all exhibits hereto) confidential, and further agrees that neither it nor its partners, managers, members, shareholders, officers, directors, employees, brokers, or attorneys shall disclose such
          matters or information to any other person or entity; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>: (i) either party may provide a copy of this Lease (including all exhibits hereto) and/or
          disclose any of its terms, provisions, covenants, obligations and conditions to its attorneys, accountants, auditors and lenders in connection with the conduct of such party&#8217;s business; and (ii) disclosure of such matters or information shall be
          permitted (x) subject to the provisions of this Section set forth below, to the extent to which it is required by applicable laws (including, without limitation, in connection with any required governmental filings by or on behalf of Landlord or
          Tenant); (y) in connection with any litigation or other proceeding between Landlord and Tenant relating to this Lease and/or the Premises; and (z) by Tenant to prospective investors, subtenants or assignees under this Lease, or by Landlord to
          prospective lenders, investors or purchasers of the Building. Tenant hereby acknowledges that disclosure of the terms hereof could adversely affect the ability of Landlord to negotiate other leases with respect to the Building and may impair
          Landlord&#8217;s relationship with other tenants of the Building, and agrees that damages alone would be an inadequate remedy for the breach of this provision by Tenant, so that Landlord shall also have the right to seek specific performance of this
          provision and to seek injunctive relief to prevent its breach or continued breach. In the event that Tenant is required by any applicable law or regulation to provide to any governmental agency a copy or extract of this Lease (including any
          exhibits hereto), or any information relating to this Lease, (a) Tenant shall redact all economic terms from such copy or extract initially provided to such governmental agency, and (b) if, following its review of such redacted copy or extract,
          such governmental agency requires Tenant to provide to it some or all of the redacted economic terms and Tenant is advised by qualified competent legal counsel that Tenant is required by applicable law or regulation to provide such economic
          terms, then Tenant may provide such redacted economic terms; <font style="font-style: italic;">provided, however,</font> that in all events Tenant shall provide only such information concerning the economic terms of this Lease as it is so
          advised by counsel is required by such applicable law or regulation to be provided.</font></div>
      <div style="text-align: justify; text-indent: 36pt; color: #000000; font-size: 12pt;"><font style="font-size: 10pt;"> <br>
        </font></div>
      <div style="text-align: center;">(the next page is the signature page)</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">80</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Executed to take effect as a sealed instrument on the Date of Lease first set forth above.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z94727fd4ff4d487aa914448ba12a7457" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div style="font-weight: bold;">LANDLORD:</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div>100 FORGE HOLDING LLC,</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div>a Delaware limited liability company</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">&#160;</td>
            <td style="width: 37%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ William P. McQuillan</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 37%; vertical-align: top;">
              <div>William P. McQuillan</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 37%; vertical-align: top;">
              <div>Authorized Signatory</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb6478909106a4972bad81f60115c0e9f" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div style="font-weight: bold;">TENANT:</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div>REMIX THERAPEUTICS INC.,</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div>a Delaware corporation</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ Pete Smith</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 37%; vertical-align: top;">
              <div>Pete Smith</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 37%; vertical-align: top;">
              <div>President and CEO</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-size: 8pt;">81</font><br>
      </div>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>5
<FILENAME>ny20077915x1_ex10-31.htm
<DESCRIPTION>EXHIBIT 10.31
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right; font-weight: bold;">Exhibit 10.31</div>
    <div><br>
    </div>
    <div style="text-align: center; font-variant: normal; font-weight: bold;">REMIX THERAPEUTICS INC.<br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold;">2019 STOCK PLAN<br>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold;">ADOPTED ON JULY 26, 2019<br>
    </div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">TABLE OF CONTENTS</div>
    <div><br>
    </div>
    <div style="text-align: right; font-weight: bold;">Page</div>
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3913e9868e084d439e115fedd8d007a0" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 1.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">ESTABLISHMENT AND PURPOSE</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 2.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">ADMINISTRATION</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Committees of the Board of Directors</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Authority of the Board of Directors</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 3.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">ELIGIBILITY</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">General Rule</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Ten&#8209;Percent Stockholders</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">1</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 4.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">STOCK SUBJECT TO PLAN</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Basic Limitation</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Additional Shares</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 5.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">TERMS AND CONDITIONS OF AWARDS OR SALES</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Stock Grant or Purchase Agreement</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Duration of Offers and Nontransferability of Rights</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">2</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(c)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Purchase Price</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 6.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">TERMS AND CONDITIONS OF OPTIONS</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Stock Option Agreement</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Number of Shares</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(c)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Exercise Price</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(d)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Vesting and Exercisability</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">3</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(e)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Basic Term</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(f)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Termination of Service (Except by Death)</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(g)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Leaves of Absence</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(h)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Death of Optionee</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">4</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(i)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Restrictions on Transfer of Options</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(j)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">No Rights as a Stockholder</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(k)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Modification, Extension and Assumption of Options</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">5</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(l)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Company&#8217;s Right to Cancel Certain Options</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">5</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%LCR%2%%%-->
    <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 7.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">TERMS AND CONDITIONS OF RESTRICTED STOCK UNITS</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Restricted Stock Unit Agreement</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Payment for Restricted Stock Units</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(c)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Vesting Conditions</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(d)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Forfeiture</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(e)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Voting and Dividend Rights</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(f)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Form and Time of Settlement of Restricted Stock Units</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(g)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Death of Recipient</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(h)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Creditors&#8217; Rights</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">6</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(i)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Modification, Extension and Assumption of Restricted Stock Units</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(j)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Restrictions on Transfer of Restricted Stock Units</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 8.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">PAYMENT FOR SHARES</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">General Rule</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Services Rendered</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(c)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Promissory Note</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(d)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Surrender of Stock</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(e)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Cashless Exercise</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">7</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(f)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Net Exercise</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(g)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Other Forms of Payment</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 9.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">ADJUSTMENT OF SHARES</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">General</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Corporate Transactions</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">8</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(c)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Dissolution or Liquidation</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(d)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Reservation of Rights</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 10.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">MISCELLANEOUS PROVISIONS</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Securities Law Requirements</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">No Retention Rights</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(c)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Treatment as Compensation</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(d)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Governing Law</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(e)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Conditions and Restrictions on Shares</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">10</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(f)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Tax Matters</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">11</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 11.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">DURATION AND AMENDMENTS; STOCKHOLDER APPROVAL</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(a)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Term of the Plan</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(b)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Right to Amend or Terminate the Plan</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(c)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Effect of Amendment or Termination</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">(d)</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Stockholder Approval</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
        </tr>
        <tr>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 7%; vertical-align: top;">&#160;</td>
          <td style="width: 81%; vertical-align: top;">&#160;</td>
          <td style="width: 4.62%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">SECTION 12.</div>
          </td>
          <td style="width: 81%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">DEFINITIONS</div>
          </td>
          <td style="width: 4.62%; vertical-align: top;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif;">12</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">ii</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-variant: normal; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc. 2019 Stock Plan</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 1.<font style="font-weight: normal;">&#8195;</font>ESTABLISHMENT AND PURPOSE</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">The purpose of this Plan is to attract, incentivize and retain Employees, Outside Directors and Consultants through the grant of Awards.&#160; The Plan provides for the direct award or sale of Shares, the
      grant of Options to purchase Shares and the grant of Restricted Stock Units to acquire Shares.&#160; Options granted under the Plan may be ISOs intended to qualify under Code Section 422 or NSOs which are not intended to so qualify.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">Capitalized terms are defined in Section 12.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 2.<font style="font-weight: normal;">&#8195;</font>ADMINISTRATION</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman', Times, serif; font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>Committees of the Board of
        Directors</font>.&#160; The Plan may be administered by one or more Committees.&#160; Each Committee shall consist, as required by applicable law, of one or more members of the Board of Directors who have been appointed by the Board of Directors.&#160; Each
      Committee shall have such authority and be responsible for such functions as the Board of Directors has assigned to it.&#160; If no Committee has been appointed, the entire Board of Directors shall administer the Plan.&#160; Any reference to the Board of
      Directors in the Plan or an Award Agreement shall be construed as a reference to the Committee (if any) to whom the Board of Directors has assigned a particular function.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font>Authority of the Board of Directors</font>.&#160; Subject to the provisions of the Plan, the Board of Directors shall have
      full authority and discretion to take any actions it deems necessary or advisable for the administration of the Plan.&#160; Notwithstanding anything to the contrary in the Plan, with respect to the terms and conditions of awards granted to Participants
      outside the United States, the Board of Directors may vary from the provisions of the Plan to the extent it determines it necessary and appropriate to do so; provided that it may not vary from those Plan terms requiring stockholder approval pursuant
      to Section 11(d) below.&#160; All decisions, interpretations and other actions of the Board of Directors shall be final and binding on all Participants and all persons deriving their rights from a Participant.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 3.<font style="font-weight: normal;">&#8195;</font>ELIGIBILITY</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>General Rule</font>.&#160; Employees, Outside Directors and Consultants shall be eligible for the grant of Awards under the
      Plan.&#160; However, only Employees shall be eligible for the grant of ISOs.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font>Ten&#8209;Percent Stockholders</font>.&#160; A person who owns more than 10% of the total combined voting power of all classes of
      outstanding stock of the Company, its Parent or any of its Subsidiaries shall not be eligible for the grant of an ISO unless (i) the Exercise Price is at least 110% of the Fair Market Value of a Share on the Date of Grant and (ii) such ISO by its
      terms is not exercisable after the expiration of five years from the Date of Grant.&#160; For purposes of this Subsection (b), in determining stock ownership, the attribution rules of Code Section 424(d) shall be applied.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 4.<font style="font-weight: normal;">&#8195;</font>STOCK SUBJECT TO PLAN</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>Basic Limitation</font>.&#160; Not more than 23,696,650 Shares may be issued under the Plan, subject to Subsection (b) below
      and Section 9(a).&#160; All of these Shares may be issued upon the exercise of ISOs.&#160;&#160; The Company, during the term of the Plan, shall at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan.&#160; Shares offered under
      the Plan may be authorized but unissued Shares or treasury Shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font>Additional Shares</font>.&#160; In the event that Shares previously issued under the Plan are forfeited to or repurchased by
      the Company due to failure to vest, such Shares shall be added to the number of Shares then available for issuance under the Plan.&#160; In the event that Shares that otherwise would have been issuable under the Plan are withheld by the Company in payment
      of the Purchase Price, Exercise Price or withholding taxes, such Shares shall remain available for issuance under the Plan.&#160; In the event that an outstanding Option, Restricted Stock Unit or other right for any reason expires or is canceled, the
      Shares allocable to the unexercised or unsettled portion of such Option, Restricted Stock Unit or other right shall remain available for issuance under the Plan.&#160; To the extent an Award is settled in cash, the cash settlement shall not reduce the
      number of Shares remaining available for issuance under the Plan.&#160; Notwithstanding the foregoing, in the case of ISOs, this Subsection (b) shall be subject to any limitations imposed under Section 422 of the Code and the treasury regulations
      thereunder.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 5.<font style="font-weight: normal;">&#8195;</font>TERMS AND CONDITIONS OF AWARDS OR SALES</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>Stock Grant or Purchase Agreement</font>.&#160; Each award of Shares under the Plan shall be evidenced by a Stock Grant
      Agreement between the Grantee and the Company.&#160; Each sale of Shares under the Plan (other than upon exercise of an Option) shall be evidenced by a Stock Purchase Agreement between the Purchaser and the Company.&#160; Such award or sale shall be subject to
      all applicable terms and conditions of the Plan and may be subject to any other terms and conditions which are not inconsistent with the Plan and which the Board of Directors deems appropriate for inclusion in a Stock Grant Agreement or Stock
      Purchase Agreement.&#160; The provisions of the various Stock Grant Agreements and Stock Purchase Agreements entered into under the Plan need not be identical.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font>Duration of Offers and Nontransferability of Rights</font>.&#160; Any right to purchase Shares under the Plan (other than an
      Option) shall automatically expire if not exercised by the Purchaser within 30 days (or such other period as may be specified in the Award Agreement) after the grant of such right was communicated to the Purchaser by the Company.&#160; Such right is not
      transferable and may be exercised only by the Purchaser to whom such right was granted.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(c)&#8195;</font>Purchase Price</font>.&#160; The Board of Directors shall determine the Purchase Price of Shares to be offered under the Plan
      at its sole discretion.&#160; The Purchase Price shall be payable in a form described in Section 8.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 6.<font style="font-weight: normal;">&#8195;</font>TERMS AND CONDITIONS OF OPTIONS</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>Stock Option Agreement</font>.&#160; Each grant of an Option under the Plan shall be evidenced by a Stock Option Agreement
      between the Optionee and the Company.&#160; The Option shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and conditions that are not inconsistent with the Plan and that the Board of Directors deems
      appropriate for inclusion in a Stock Option Agreement.&#160; The provisions of the various Stock Option Agreements entered into under the Plan need not be identical.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font>Number of Shares</font>.&#160; Each Stock Option Agreement shall specify the number of Shares that are subject to the Option
      and shall provide for the adjustment of such number in accordance with Section 9.&#160; The Stock Option Agreement shall also specify whether the Option is an ISO or an NSO.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(c)&#8195;</font>Exercise Price</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>General</font>.&#160; Each Stock Option Agreement shall specify the Exercise Price, which shall be payable
      in a form described in Section 8.&#160; Subject to the remaining provisions of this Subsection (c), the Exercise Price shall be determined by the Board of Directors in its sole discretion.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>ISOs</font>.&#160; The Exercise Price of an ISO shall not be less than 100% of the Fair Market Value of a
      Share on the Date of Grant, and a higher percentage may be required by Section 3(b).&#160; This Subsection (c)(ii) shall not apply to an ISO granted pursuant to an assumption of, or substitution for, another incentive stock option in a manner that
      complies with Code Section 424(a).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>NSOs</font>.&#160; Except as specifically set forth in this Subsection (c)(iii), the Exercise Price of
      an NSO shall not be less than 100% of the Fair Market Value of a Share on the Date of Grant.&#160; This Subsection (c)(iii) shall not apply to an NSO granted to a person who is not a U.S. taxpayer on the Date of Grant or to an NSO that is intended either
      to be exempt from Code Section 409A as a &#8220;short-term deferral&#8221; or to comply with the requirements of Code Section 409A.&#160; In addition, this Subsection (c)(iii) shall not apply to an NSO granted pursuant to an assumption of, or substitution for,
      another stock option in a manner that complies with Code Section 409A.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(d)&#8195;</font>Vesting and Exercisability</font>.&#160; Each Stock Option Agreement shall specify the date when all or any installment of
      the Option is to become vested and exercisable.&#160; No Option shall be exercisable unless the Optionee (i) has delivered an executed copy of the Stock Option Agreement to the Company or (ii) otherwise agrees to be bound by the terms of the Stock Option
      Agreement.&#160; The Board of Directors shall determine the vesting and exercisability provisions of the Stock Option Agreement at its sole discretion.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(e)&#8195;</font>Basic Term</font>.&#160; The Stock Option Agreement shall specify the term of the Option.&#160; The term shall not exceed 10 years
      from the Date of Grant, and in the case of an ISO, a shorter term may be required by Section 3(b).&#160; Subject to the preceding sentence, the Board of Directors at its sole discretion shall determine when an Option is to expire.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">3</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(f)&#8195;</font>Termination of Service (Except by Death)</font>.&#160; If an Optionee&#8217;s Service terminates for any reason other than the
      Optionee&#8217;s death, then the Optionee&#8217;s Options shall expire on the earliest of the following dates:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The expiration date determined pursuant to Subsection (e) above;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date three months after the termination of the Optionee&#8217;s Service for any reason other
      than Disability, or such earlier or later date as the Board of Directors may determine (but in no event earlier than 30 days after the termination of the Optionee&#8217;s Service); or</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date six months after the termination of the Optionee&#8217;s Service by reason of Disability,
      or such later date as the Board of Directors may determine.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The Optionee may exercise all or part of the Optionee&#8217;s Options at any time before the expiration of such Options under the preceding sentence, but only to the extent that such Options had become exercisable before the
      Optionee&#8217;s Service terminated (or became exercisable as a result of the termination) and the underlying Shares had vested before the Optionee&#8217;s Service terminated (or vested as a result of the termination).&#160; In the event that the Optionee dies after
      the termination of the Optionee&#8217;s Service but before the expiration of the Optionee&#8217;s Options, all or part of such Options may be exercised (prior to expiration) by the executors or administrators of the Optionee&#8217;s estate or by any person who has
      acquired such Options directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that such Options had become exercisable before the Optionee&#8217;s Service terminated (or became exercisable as a result of the
      termination) and the underlying Shares had vested before the Optionee&#8217;s Service terminated (or vested as a result of the termination).&#160; In no event will an Option, or the Shares underlying an Option, become vested and/or exercisable after termination
      of the Optionee&#8217;s Service unless the Board of Directors takes affirmative action or unless expressly provided in a written agreement between the Company and the Optionee.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(g)&#8195;</font>Leaves of Absence</font>.&#160; For purposes of Subsection (f) above, Service shall be deemed to continue while the Optionee
      is on a bona fide leave of absence approved by the Company in writing.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(h)&#8195;</font>Death of Optionee</font>.&#160; If an Optionee dies while the Optionee is in Service, then the Optionee&#8217;s Options shall
      expire on the earlier of the following dates:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The expiration date determined pursuant to Subsection (e) above; or</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date 12 months after the Optionee&#8217;s death, or such earlier or later date as the Board of
      Directors may determine (but in no event earlier than six months after the Optionee&#8217;s death).</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">4</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">All or part of the Optionee&#8217;s Options may be exercised at any time before the expiration of such Options under the preceding sentence by the executors or administrators of the Optionee&#8217;s estate or by any person who has
      acquired such Options directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that such Options had become exercisable before the Optionee&#8217;s death (or became exercisable as a result of the death) and the
      underlying Shares had vested before the Optionee&#8217;s death (or vested as a result of the Optionee&#8217;s death).&#160; In no event will an Option, or the Shares underlying an Option, become vested and/or exercisable after the Optionee&#8217;s death unless the Board of
      Directors takes affirmative action or unless expressly provided in a written agreement between the Company and the Optionee.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(i)&#8195;</font>Restrictions on Transfer of Options</font>.&#160; An Option shall be transferable by the Optionee only by (i) a beneficiary
      designation, (ii) a will or (iii) the laws of descent and distribution, except as provided in the next sentence.&#160; If the Board of Directors so provides, in a Stock Option Agreement or otherwise, an NSO may be transferable to the extent permitted by
      Rule 701 under the Securities Act.&#160; An ISO may be exercised during the lifetime of the Optionee only by the Optionee or by the Optionee&#8217;s guardian or legal representative.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(j)&#8195;</font>No Rights as a Stockholder</font>.&#160; An Optionee, or a transferee of an Optionee, shall have no rights as a stockholder
      with respect to any Shares covered by the Optionee&#8217;s Option until such person submits a notice of exercise, pays the Exercise Price and satisfies all applicable withholding taxes pursuant to the terms of such Option.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(k)&#8195;</font>Modification, Extension and Assumption of Options</font>.&#160; Within the limitations of the Plan, the Board of Directors
      may modify, reprice, extend or assume outstanding Options or may accept the cancellation of outstanding options (whether granted by the Company or another issuer) in return for the grant of new Options or a different type of award for the same or a
      different number of Shares and at the same or a different Exercise Price (if applicable).&#160; The foregoing notwithstanding, no modification of an Option shall, without the consent of the Optionee, impair the Optionee&#8217;s rights or increase the Optionee&#8217;s
      obligations under such Option; provided, however, that a modification of an Option that is otherwise favorable to the Optionee (for example, providing the Optionee with additional time to exercise the Option after termination of employment or
      providing for additional forms of payment) but causes the Option to lose its tax-favored status (for example, as an ISO) shall not require the consent of the Optionee.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(l)&#8195;</font></font>Company&#8217;s Right to Cancel Certain Options</font>.&#160; Any other provision of the
      Plan or a Stock Option Agreement notwithstanding, the Company shall have the right at any time to cancel an Option that was not granted in compliance with Rule 701 under the Securities Act.&#160; Prior to canceling such Option, the Company shall give the
      Optionee not less than 30 days&#8217; notice in writing.&#160; If the Company elects to cancel such Option, it shall deliver to the Optionee consideration with an aggregate value equal to the excess of (i) the Fair Market Value of the Shares subject to such
      Option as of the time of the cancellation over (ii) the Exercise Price of such Option.&#160; The consideration may be delivered in the form of cash or cash equivalents, in the form of Shares, or a combination of both.&#160; If the consideration would be a
      negative amount, such Option may be cancelled without the delivery of any consideration.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">5</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="font-weight: bold;">SECTION 7.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>TERMS AND CONDITIONS OF RESTRICTED STOCK UNITS</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font></font>Restricted Stock Unit Agreement</font>. Each grant of Restricted Stock Units
      under the Plan shall be evidenced by a Restricted Stock Unit Agreement between the recipient and the Company.&#160; Such Restricted Stock Units shall be subject to all applicable terms and conditions of the Plan and may be subject to any other terms and
      conditions that are not inconsistent with the Plan and which the Board of Directors deems appropriate for inclusion in a Restricted Stock Unit Agreement.&#160; The provisions of the various Restricted Stock Unit Agreements entered into under the Plan need
      not be identical.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font></font>Payment for Restricted Stock Units</font>.&#160; No cash consideration shall be
      required of the recipient in connection with the grant of Restricted Stock Units.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(c)&#8195;</font></font>Vesting Conditions</font>.&#160; Each Restricted Stock Unit Agreement shall specify
      the vesting requirements applicable to the Restricted Stock Units subject thereto, which the Board of Directors shall determine in its sole discretion.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(d)&#8195;</font></font>Forfeiture</font>.&#160; Unless a Restricted Stock Unit Agreement provides otherwise,
      upon termination of the recipient&#8217;s Service and upon such other times specified in the Restricted Stock Unit Agreement, any unvested Restricted Stock Units shall be forfeited to the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(e)&#8195;</font></font>Voting and Dividend Rights</font>.&#160; The holders of Restricted Stock Units shall
      have no voting rights.&#160; Prior to settlement or forfeiture, any Restricted Stock Unit granted under the Plan may, at the discretion of the Board of Directors, carry with it a right to dividend equivalents.&#160; Such right entitles the holder to be
      credited with an amount equal to all cash dividends paid on one Share while the Restricted Stock Unit is outstanding.&#160; Dividend equivalents may be converted into additional Restricted Stock Units.&#160; Settlement of dividend equivalents may be made in
      the form of cash, in the form of Shares, or in a combination of both.&#160; Prior to distribution, any dividend equivalents that are not paid shall be subject to the same conditions and restrictions as the Restricted Stock Units to which they attach.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(f)&#8195;</font></font>Form and Time of Settlement of Restricted Stock Units</font>.&#160; Settlement of
      vested Restricted Stock Units may be made in the form of (i) cash, (ii) Shares or (iii) any combination of both, as determined by the Board of Directors.&#160; The actual number of Restricted Stock Units eligible for settlement may be larger or smaller
      than the number included in the original award, based on predetermined performance factors.&#160; Vested Restricted Stock Units shall be settled in such manner and at such time(s) as specified in the Restricted Stock Unit Agreement.&#160; Until Restricted
      Stock Units are settled, the number of Shares represented by such Restricted Stock Units shall be subject to adjustment pursuant to Section 9.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(g)&#8195;</font></font>Death of Recipient</font>.&#160; Any Restricted Stock Units that become distributable
      after the Participant&#8217;s death shall be distributed to the Participant&#8217;s estate or to any person who has acquired such Restricted Stock Units directly from the recipient by beneficiary designation, bequest or inheritance.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(h)&#8195;</font></font>Creditors&#8217; Rights</font>.&#160; A holder of Restricted Stock Units shall have no
      rights other than those of a general creditor of the Company.&#160; Restricted Stock Units represent an unfunded and unsecured obligation of the Company, subject to the terms and conditions of the applicable Restricted Stock Unit Agreement.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">6</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(i)&#8195;</font></font>Modification, Extension and Assumption of Restricted Stock Units</font>.&#160; Within
      the limitations of the Plan, the Board of Directors may modify, extend or assume outstanding restricted stock units (whether granted by the Company or a different issuer).&#160; The foregoing notwithstanding, no modification of a Restricted Stock Unit
      shall, without the consent of the Participant, impair the Participant&#8217;s rights or increase the Participant&#8217;s obligations under such Restricted Stock Unit.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(j)&#8195;</font></font>Restrictions on Transfer of Restricted Stock Units</font>.&#160; A Restricted Stock
      Unit shall be transferable by the Participant only by (i) a beneficiary designation, (ii) a will or (iii) the laws of descent and distribution, except as provided in the next sentence.&#160; In addition, if the Board of Directors so provides, in a
      Restricted Stock Unit Agreement or otherwise, a Restricted Stock Unit shall also be transferable to the extent permitted by Rule 701 under the Securities Act.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 8.<font style="font-weight: normal;">&#8195;</font>PAYMENT FOR SHARES</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>General Rule</font>.&#160; The entire Purchase Price or Exercise Price of Shares issued under the Plan shall be payable in
      cash or cash equivalents at the time when such Shares are purchased, except as otherwise provided in this Section 8.&#160; In addition, the Board of Directors in its sole discretion may also permit payment through any of the methods described in (b)
      through (g) below.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font>Services Rendered</font>.&#160; Shares may be awarded under the Plan in consideration of services rendered to the Company, a
      Parent or a Subsidiary prior to the award.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(c)&#8195;</font>Promissory Note</font>.&#160; All or a portion of the Purchase Price or Exercise Price (as the case may be) of Shares issued
      under the Plan may be paid with a promissory note.&#160; The Shares shall be pledged as security for payment of the principal amount of the promissory note and interest thereon.&#160; The interest rate payable under the terms of the promissory note shall not
      be less than the minimum rate (if any) required to avoid the imputation of additional interest under the Code.&#160; Subject to the foregoing, the Board of Directors in its sole discretion shall specify the term, interest rate, recourse, amortization
      requirements (if any) and other provisions of such note.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(d)&#8195;</font>Surrender of Stock</font>.&#160; All or any part of the Exercise Price may be paid by surrendering, or attesting to the
      ownership of, Shares that are already owned by the Optionee.&#160; Such Shares shall be surrendered to the Company in good form for transfer and shall be valued at their Fair Market Value as of the date when the Option is exercised.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(e)&#8195;</font>Cashless Exercise</font>.&#160; All or part of the Exercise Price and any withholding taxes may be paid pursuant to a
      cashless exercise arrangement (whether through a securities broker or otherwise) established by the Company whereby Shares subject to an Option are sold and all or part of the sale proceeds are delivered to the Company.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(f)&#8195;</font></font>Net Exercise</font>.&#160; An Option may permit exercise through a &#8220;net exercise&#8221;
      arrangement pursuant to which the Company will reduce the number of Shares issued upon exercise by the largest whole number of Shares having an aggregate Fair Market Value (determined by the Board of Directors as of the exercise date) that does not
      exceed the aggregate Exercise Price or the sum of the aggregate Exercise Price and any withholding taxes (with the Company accepting from the Optionee payment of cash or cash equivalents to satisfy any remaining balance of the aggregate Exercise
      Price and, if applicable, any additional withholding taxes not satisfied through such reduction in Shares); <font style="font-style: italic;">provided</font> that to the extent Shares subject to an Option are withheld in this manner, the number of
      Shares subject to the Option following the net exercise will be reduced by the sum of the number of Shares withheld and the number of Shares delivered to the Optionee as a result of the exercise.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(g)&#8195;</font>Other Forms of Payment</font>.&#160; To the extent that an Award Agreement so provides, the Purchase Price or Exercise Price
      of Shares issued under the Plan may be paid in any other form permitted by the Delaware General Corporation Law, as amended.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 9.<font style="font-weight: normal;">&#8195;</font>ADJUSTMENT OF SHARES</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>General</font>.&#160; In the event of a subdivision of the outstanding Stock, a declaration of a dividend payable in Shares,
      a combination or consolidation of the outstanding Stock into a lesser number of Shares, a reclassification, or any other increase or decrease in the number of issued shares of Stock effected without receipt of consideration by the Company,
      proportionate adjustments shall automatically be made, as applicable, in each of (i) the number and kind of Shares available under Section 4, (ii) the number and kind of Shares covered by each outstanding Option, Award of Restricted Stock Units and
      any outstanding and unexercised right to purchase Shares that has not yet expired pursuant to Section 5(b),&#160; (iii) the Exercise Price under each outstanding Option and the Purchase Price applicable to any unexercised stock purchase right described in
      clause (ii) above, and (iv) any repurchase price that applies to Shares granted under the Plan pursuant to the terms of a Company repurchase right under the applicable Award Agreement.&#160; In the event of a declaration of an extraordinary dividend
      payable in a form other than Shares in an amount that has a material effect on the Fair Market Value of the Stock, a recapitalization, a spin-off, or a similar occurrence, the Board of Directors at its sole discretion may make appropriate adjustments
      in one or more of the items listed in clauses (i) through (iv) above; provided, however, that the Board of Directors shall in any event make such adjustments as may be required by Section 25102(o) of the California Corporations Code to the extent the
      Company is relying on the exemption afforded thereunder with respect to an Award.&#160; No fractional Shares shall be issued under the Plan as a result of an adjustment under this Section 9(a), although the Board of Directors in its sole discretion may
      make a cash payment in lieu of fractional Shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font></font>Corporate Transactions</font>.&#160; In the event that the Company is a party to a
      merger or consolidation, or in the event of a sale of all or substantially all of the Company&#8217;s stock or assets, all Shares acquired under the Plan and all Awards outstanding on the effective date of the transaction shall be treated in the manner
      described in the definitive transaction agreement (or, in the event the transaction does not entail a definitive agreement to which the Company is party, in the manner determined by the Board of Directors in its capacity as administrator of the Plan,
      with such determination having final and binding effect on all parties), which agreement or determination need not treat all Awards (or all portions of an Award) in an identical manner. The treatment specified in the transaction agreement or as
      determined by the Board of Directors may include (without limitation) one or more of the following with respect to each outstanding Award:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The Company, the surviving corporation or a parent thereof may continue or assume the Award or
      substitute a comparable award for the Award (including, but not limited to, an award to acquire the same consideration paid to the holders of Shares in the transaction).&#160; For avoidance of doubt, a comparable award need not be the same type of award
      as the Award for which it is substituted, and, in the case of an Option, need not have the same tax-status (e.g., an NSO may be substituted for an ISO).</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">8</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The cancellation of the Award and a payment to the Participant with respect to each Share
      subject to the portion of the Award that is vested as of the transaction date equal to the excess of (A) the value, as determined by the Board of Directors in its absolute discretion, of the property (including cash) received by the holder of a share
      of Stock as a result of the transaction, over (if applicable) (B) the per-Share Exercise Price of the Award (such excess, the &#8220;<font style="font-weight: bold;">Spread</font>&#8221;).&#160; Such payment shall be made in the form of cash, cash equivalents, or
      securities of the surviving corporation or its parent having a value equal to the Spread.&#160; In addition, any escrow, indemnification, holdback, earn-out or similar provisions in the transaction agreement may apply to such payment to the same extent
      and in the same manner as such provisions apply to the holders of Stock.&#160; Receipt of the payment described in this Subsection (b)(ii) may be conditioned upon the Participant acknowledging such escrow, indemnification, holdback, earn-out or other
      provisions on a form prescribed by the Company.&#160; If the Spread applicable to an Award is zero or a negative number, then the Award may be cancelled without making a payment to the Participant.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>Even if the Spread applicable to an Option is a positive number, the Option may be cancelled
      without the payment of any consideration; provided that the Optionee shall be notified of such treatment and given an opportunity to exercise the Option (to the extent the Option is vested or becomes vested as of the effective date of the
      transaction) during a period of not less than five (5) business days preceding the effective date of the transaction, unless (A) a shorter period is required to permit a timely closing of the transaction and (B) such shorter period still offers the
      Optionee a reasonable opportunity to exercise the Option.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iv)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>In the case of an Option: (A) suspension of the Optionee&#8217;s right to exercise the Option
      during a limited period of time preceding the closing of the transaction if such suspension is administratively necessary to facilitate the closing of the transaction and/or (B)&#160; termination of any right the Optionee has to exercise the Option prior
      to vesting in the Shares subject to the Option (i.e., &#8220;early exercise&#8221;), such that following the closing of the transaction the Option may only be exercised to the extent it is vested.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">For the avoidance of doubt, the Board of Directors has discretion to accelerate, in whole or part, the vesting and exercisability of an Award in connection with a corporate transaction covered by this Section 9(b).</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">9</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(c)&#8195;</font></font>Dissolution or Liquidation</font>.&#160; To the extent not previously exercised or
      settled, Options, Restricted Stock Units and other rights to purchase Shares shall terminate immediately prior to the liquidation or dissolution of the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(d)&#8195;</font></font>Reservation of Rights</font>.&#160; Except as provided in Section 7(e) or this
      Section 9, a Participant shall have no rights by reason of (i) any subdivision or consolidation of shares of stock of any class, (ii) the payment of any dividend or (iii) any other increase or decrease in the number of shares of stock of any class.&#160;
      Any issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, shall not affect, and no adjustment by reason thereof shall be made with respect to, the number or Exercise Price of Shares
      subject to an Award.&#160; The grant of an Award pursuant to the Plan shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure, to merge or
      consolidate or to dissolve, liquidate, sell or transfer all or any part of its business or assets.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 10.<font style="font-weight: normal;">&#8195;</font>MISCELLANEOUS PROVISIONS</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font></font>Securities Law Requirements</font>.&#160; Shares shall not be issued under the Plan
      unless, in the opinion of counsel acceptable to the Board of Directors, the issuance and delivery of such Shares complies with (or is exempt from) all applicable requirements of law, including (without limitation) the Securities Act, the rules and
      regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company&#8217;s securities may then be traded.&#160; The Company shall not be liable for a failure to
      issue Shares as a result of such requirements. Without limiting the foregoing, the Company may suspend the exercise of some or all outstanding Options for a period of up to 60 days in order to facilitate compliance with Securities Act Rule 701(e).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font></font>No Retention Rights</font>.&#160; Nothing in the Plan or in any right or Award
      granted under the Plan shall confer upon the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or
      retaining the Participant) or of the Participant, which rights are hereby expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without cause.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(c)&#8195;</font></font>Treatment as Compensation</font>.&#160; Any compensation that an individual earns or
      is deemed to earn under this Plan shall not be considered a part of his or her compensation for purposes of calculating contributions, accruals or benefits under any other plan or program that is maintained or funded by the Company, a Parent or a
      Subsidiary.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(d)&#8195;</font>Governing Law</font>.&#160; The Plan and all awards, sales and grants under the Plan shall be governed by, and construed in
      accordance with, the laws of the State of Delaware (except its choice-of-law provisions), as such laws are applied to contracts entered into and performed in such State.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">10</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(e)&#8195;</font>Conditions and Restrictions on Shares</font>.&#160; Shares issued under the Plan shall be subject to such forfeiture
      conditions, rights of repurchase, rights of first refusal, other transfer restrictions and such other terms and conditions as the Board of Directors may determine.&#160; Such conditions and restrictions shall be set forth in the applicable Award Agreement
      and shall apply in addition to any restrictions that may apply to holders of Shares generally.&#160; In addition, Shares issued under the Plan shall be subject to conditions and restrictions imposed either by applicable law or by Company policy, as
      adopted from time to time, designed to ensure compliance with applicable law or laws with which the Company determines in its sole discretion to comply including in order to maintain any statutory, regulatory or tax advantage, which (for avoidance of
      doubt) need not be set forth in the applicable Award Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(f)&#8195;</font>Tax Matters</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>As a condition to the award, grant, issuance, vesting, purchase, exercise, settlement or
      transfer of any Award, or Shares issued pursuant to any Award, granted under this Plan, the Participant shall make such arrangements as the Board of Directors may require or permit for the satisfaction of any federal, state, local or foreign
      withholding tax obligations that may arise in connection with such event.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>Unless<font style="font-weight: bold;">&#160;</font>otherwise expressly set forth in an Award
      Agreement, it is intended that Awards shall be exempt from Code Section 409A, and any ambiguity in the terms of an Award Agreement and the Plan shall be interpreted consistently with this intent.&#160;&#160; To the extent an Award is not exempt from Code
      Section 409A (any such award, a &#8220;<font style="font-weight: bold;">409A Award</font>&#8221;), any ambiguity in the terms of such Award and the Plan shall be interpreted in a manner that to the maximum extent permissible supports the Award&#8217;s compliance with
      the requirements of that statute.&#160; Notwithstanding anything to the contrary permitted under the Plan, in no event shall a modification of an Award not already subject to Code Section 409A, or any subsequent action taken with respect to such Award, be
      given effect if such modification or action would cause the Award to become subject to Code Section 409A unless the parties explicitly acknowledge and consent to the modification or action as one having that effect. A 409A Award shall be subject to
      such additional rules and requirements as specified by the Board of Directors from time to time in order for it to comply with the requirements of Code Section 409A.&#160; In this regard, if any amount under a 409A Award is payable upon a &#8220;separation from
      service&#8221; to an individual who is considered a &#8220;specified employee&#8221; (as each term is defined under Code Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the Participant&#8217;s
      separation from service or (ii) the Participant&#8217;s death, but only to the extent such delay is necessary to prevent such payment from being subject to Section 409A(a)(1).&#160; In addition, if a transaction subject to Section 9(b) constitutes a payment
      event with respect to any 409A Award, then the transaction with respect to such award must also constitute a &#8220;change in control event&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(5) to the extent required by Code Section 409A.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>Neither the Company nor any member of the Board of Directors shall have any liability to a
      Participant in the event an Award held by the Participant fails to achieve its intended characterization under applicable tax law.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">11</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 11.<font style="font-weight: normal;">&#8195;</font>DURATION AND AMENDMENTS; STOCKHOLDER APPROVAL</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(a)&#8195;</font>Term of the Plan</font>.&#160; The Plan, as set forth herein, shall become effective on the date of its adoption by the Board
      of Directors, subject to approval of the Company&#8217;s stockholders under Subsection (d) below.&#160; The Plan shall terminate automatically 10 years after the later of (i) the date when the Board of Directors adopted the Plan or (ii) the date when the Board
      of Directors approved the most recent increase in the number of Shares reserved under Section 4 that was also approved by the Company&#8217;s stockholders.&#160; The Plan may be terminated on any earlier date pursuant to Subsection (b) below.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(b)&#8195;</font>Right to Amend or Terminate the Plan</font>.&#160; Subject to Subsection (d) below, the Board of Directors may amend, suspend
      or terminate the Plan at any time and for any reason.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: normal;">(c)&#8195;</font>Effect of Amendment or Termination</font>.&#160; No Shares shall be issued or sold and no Award granted under the Plan after
      the termination thereof, except upon exercise or settlement of an Award granted under the Plan prior to such termination.&#160; Except as expressly provided in Section 6(k) above, the termination of the Plan, or any amendment thereof, shall not affect any
      Share previously issued or any Award previously granted under the Plan.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-weight: normal;">(d)&#8195;</font></font>Stockholder Approval</font>.&#160; To the extent required by applicable law, the Plan
      will be subject to approval of the Company&#8217;s stockholders within 12 months of its adoption date. An amendment of the Plan will be subject to the approval of the Company&#8217;s stockholders only to the extent required by applicable laws, regulations or
      rules.</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">SECTION 12.<font style="font-weight: normal;">&#8195;</font>DEFINITIONS</font>.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Award</font>&#8221; means any award granted under the Plan, including as an Option,
      an award of Restricted Stock Units or the grant or sale of Shares pursuant to Section 5 of the Plan.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Award Agreement</font>&#8221; means a Restricted Stock Unit Agreement, Stock Grant
      Agreement, Stock Option Agreement or Stock Purchase Agreement or such other agreement evidencing an Award under the Plan.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221; means the Board of Directors of the Company, as
      constituted from time to time.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Code</font>&#8221; means the Internal Revenue Code of 1986, as amended.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Committee</font>&#8221; means a committee of the Board of Directors, as described in
      Section 2(a).</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">12</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Company</font>&#8221; means Remix Therapeutics Inc., a Delaware corporation.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Consultant</font>&#8221; means a person, excluding Employees and Outside Directors,
      who performs bona fide services for the Company, a Parent or a Subsidiary as a consultant or advisor<font style="font-weight: bold;">&#160;</font>and who qualifies as a consultant or advisor under Rule 701(c)(1) of the Securities Act or under Instruction
      A.1.(a)(1) of Form S-8 under the Securities Act.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Date of Grant</font>&#8221; means the date of grant specified in the Award Agreement,
      which date shall be the later of (i) the date on which the Board of Directors resolved to grant the Award or (ii) the first day of the Participant&#8217;s Service.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Disability</font>&#8221; means that the Optionee is unable to engage in any
      substantial gainful activity by reason of any medically determinable physical or mental impairment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(j)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Employee</font>&#8221; means any individual who is a common&#8209;law employee of the
      Company, a Parent or a Subsidiary.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(k)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(l)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Exercise Price</font>&#8221; means the amount for which one Share may be purchased
      upon exercise of an Option, as specified by the Board of Directors in the applicable Stock Option Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(m)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Fair Market Value</font>&#8221; means the fair market value of a Share, as determined
      by the Board of Directors in good faith.&#160; Such determination shall be conclusive and binding on all persons.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(n)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Grantee</font>&#8221; means a person to whom the Board of Directors has awarded
      Shares under the Plan.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(o)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">ISO</font>&#8221; means an Option that qualifies as an incentive stock option as
      described in Code Section 422(b).&#160; Notwithstanding its designation as an ISO, an Option that does not qualify as an ISO under applicable law shall be treated for all purposes as an NSO.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(p)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">NSO</font>&#8221; means an Option that does not qualify as an incentive stock option
      as described in Code Section 422(b) or 423(b).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(q)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Option</font>&#8221; means an ISO or NSO granted under the Plan and entitling the
      holder to purchase Shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(r)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Optionee</font>&#8221; means a person who holds an Option.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(s)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Outside Director</font>&#8221; means a member of the Board of Directors who is not an
      Employee.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(t)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Parent</font>&#8221; means any corporation (other than the Company) in an unbroken
      chain of corporations ending with the Company, if each of the corporations other than the Company owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.&#160; A
      corporation that attains the status of a Parent on a date after the adoption of the Plan shall be considered a Parent commencing as of such date.</div>
    <div style="text-align: justify;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">13</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(u)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Participant</font>&#8221; means the holder of an outstanding Award.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(v)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Plan</font>&#8221; means this Remix Therapeutics Inc. 2019 Stock Plan.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(w)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Purchase Price</font>&#8221; means the consideration for which one Share may be
      acquired under the Plan (other than upon exercise of an Option), as specified by the Board of Directors.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(x)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Purchaser</font>&#8221; means a person to whom the Board of Directors has offered the
      right to purchase Shares under the Plan (other than upon exercise of an Option).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(y)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Restricted Stock Unit</font>&#8221; means a bookkeeping entry representing the
      equivalent of one Share, as awarded under the Plan.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(z)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Restricted Stock Unit Agreement</font>&#8221; means the agreement between the Company
      and the recipient of a Restricted Stock Unit that contains the terms, conditions and restrictions pertaining to such Restricted Stock Unit.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(aa)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(bb)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Service</font>&#8221; means service as an Employee, Outside Director or Consultant.&#160;
      In case of any dispute as to whether and when Service has terminated, the Board of Directors shall have sole discretion to determine whether such termination has occurred and the effective date of such termination.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(cc)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Share</font>&#8221; means one share of Stock, as adjusted in accordance with Section
      9 (if applicable).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(dd)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Stock</font>&#8221; means the Common Stock of the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(ee)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Stock Grant Agreement</font>&#8221; means the agreement between the Company and a
      Grantee who is awarded Shares under the Plan that contains the terms, conditions and restrictions pertaining to the award of such Shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(ff)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Stock Option Agreement</font>&#8221; means the agreement between the Company and an
      Optionee that contains the terms, conditions and restrictions pertaining to the Optionee&#8217;s Option.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(gg)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Stock Purchase Agreement</font>&#8221; means the agreement between the Company and a
      Purchaser who purchases Shares under the Plan that contains the terms, conditions and restrictions pertaining to the purchase of such Shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(hh)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Subsidiary</font>&#8221; means any corporation (other than the Company) in an
      unbroken chain of corporations beginning with the Company, if each of the corporations other than the last corporation in the unbroken chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the
      other corporations in such chain.&#160; A corporation that attains the status of a Subsidiary on a date after the adoption of the Plan shall be considered a Subsidiary commencing as of such date.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;">14</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Exhibit A</div>
    <font style="text-transform: uppercase;"> </font>
    <div><font style="text-transform: uppercase;"><br>
      </font> </div>
    <font style="text-transform: uppercase;"> </font>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Schedule of Shares Reserved for Issuance under the Plan</div>
    <font style="text-transform: uppercase;"> </font>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold;"><font style="text-transform: uppercase;"> </font><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9894a6c3e6f048fcb2b30a6f233e1f40" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
            <div>
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Date of Board Approval</div>
            </div>
          </td>
          <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
            <div>
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Date of Stockholder Approval</div>
            </div>
          </td>
          <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
            <div>
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Number of</div>
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">&#160;Shares Added</div>
            </div>
          </td>
          <td style="width: 25%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); text-align: center;">
            <div>
              <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">Cumulative Number of Shares</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">July 26, 2019</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">July 26, 2019</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">Not Applicable</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">681,818</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2020</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2020</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">2,373,099</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">3,054,917</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">September 15, 2020</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">September 15, 2020</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">5,089,146</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">8,144,063</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">August 7, 2021</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">August 7, 2021</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">2,976,867</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">11,120,930</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2022</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">March 24, 2022</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">6,796,961</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">17,917,891</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">March 15, 2023</div>
          </td>
          <td style="width: 25%; vertical-align: top;">&#160;</td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">1,700,000</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">19,617,891</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">September 22, 2023</div>
          </td>
          <td style="width: 25%; vertical-align: top;">&#160;</td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">647,145</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">20,265,036</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">March 15, 2024</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">March 22, 2024</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">1,726,503</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">21,991,539</div>
          </td>
        </tr>
        <tr>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">December 12, 2024</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">January 31, 2025</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">1,705,111</div>
          </td>
          <td style="width: 25%; vertical-align: top;">
            <div style="text-align: center;">23,696,650</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc. 2019 Stock Plan</div>
      <font style="text-transform: uppercase;"> </font>
      <div><font style="text-transform: uppercase;"><br>
        </font> </div>
      <font style="text-transform: uppercase;"> </font>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Notice of Stock Option Grant (Early Exercise)</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The Optionee has been granted the following option to purchase shares of the Common Stock of Remix Therapeutics Inc. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;):</div>
      <div style="text-align: justify;">&#160; <br>
      </div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3980e716e2cd447b915e56cffdabf2cb" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Name of Optionee:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>&#171;Name&#187;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Total Number of Shares:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>&#171;TotalShares&#187;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Type of Option:</div>
            </td>
            <td style="width: 8%; vertical-align: top;">
              <div>&#171;ISO&#187;</div>
            </td>
            <td style="width: 54%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Incentive Stock Option (ISO)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">&#160;</td>
            <td style="width: 8%; vertical-align: top;">
              <div>&#171;NSO&#187;</div>
            </td>
            <td style="width: 54%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Nonstatutory Stock Option (NSO)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Exercise Price per Share:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>$&#171;PricePerShare&#187;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Date of Grant:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>&#171;DateGrant&#187;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Date Exercisable:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>This option may be exercised at any time after the Date of Grant for all or any part of the Shares subject to this option.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Vesting Commencement Date:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div>&#171;VestComDate&#187;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Vesting Schedule:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: justify;">This option shall vest, and the Right of Repurchase shall lapse, with respect to the first &#171;Percent&#187;% of the Shares subject to this option when the Optionee completes &#171;CliffPeriod&#187; months of continuous
                Service beginning with the Vesting Commencement Date set forth above.&#160; This option shall vest, and the Right of Repurchase shall lapse, with respect to an additional &#171;Fraction&#187;% of the Shares subject to this option when the Optionee
                completes each month of continuous Service thereafter.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 30%; vertical-align: top;">
              <div>Expiration Date:</div>
            </td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: justify;">&#171;ExpDate&#187;.&#160; This option expires earlier if the Optionee&#8217;s Service terminates earlier, as provided in Section 6 of the Stock Option Agreement, or if the Company engages in certain corporate transactions, as
                provided in Section 9 of the Plan.</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;"><br>
        By signing below or otherwise accepting this option in a manner acceptable to the Company, the Optionee and the Company agree that this option is granted under, and governed by the terms and conditions of, this Notice of Stock Option Grant, the
        2019 Stock Plan and the Stock Option Agreement.&#160; Both of the latter documents are attached to, and made a part of, this Notice of Stock Option Grant.&#160; Capitalized terms not otherwise defined herein or in the Stock Option Agreement shall have the
        meanings set forth in the Plan.&#160; <font style="font-weight: bold;">Section 15 of the Stock Option Agreement includes important acknowledgements of the Optionee</font>.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z3e9674d326f34f3e85d00d1e3290640f" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 44%; vertical-align: top;">
              <div style="text-align: justify; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Optionee:</div>
            </td>
            <td colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: justify; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
            <td style="width: 44%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">By:</div>
            </td>
            <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 44%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Title:</div>
            </td>
            <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div style="text-align: justify; font-weight: bold;">&#160; <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; font-weight: bold;">THE OPTION GRANTED PURSUANT TO THE NOTICE OF STOCK OPTION GRANT AND THIS AGREEMENT AND THE SHARES ISSUABLE UPON THE EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
        AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.</div>
      <div><font style="text-transform: uppercase;"><br>
        </font> </div>
      <font style="text-transform: uppercase;"> </font>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc. 2019 Stock Plan:</div>
      <font style="text-transform: uppercase;"> </font>
      <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Stock Option Agreement (Early Exercise)</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 1.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>GRANT OF OPTION.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font><font style="font-weight: bold; font-variant: small-caps;">O</font><font style="font-weight: bold;">ption</font>.&#160;



        On the terms and conditions set forth in the Notice of Stock Option Grant, this Agreement and the Plan, the Company has granted to the Optionee on the Date of Grant the option to purchase at the Exercise Price the number of Shares set forth in the
        Notice of Stock Option Grant.&#160; The Exercise Price is agreed to be at least 100% of the Fair Market Value per Share on the Date of Grant (110% of Fair Market Value if this option is designated as an ISO in the Notice of Stock Option Grant and
        Section 3(b) of the Plan applies).&#160; This option is intended to be an ISO or an NSO, as provided in the Notice of Stock Option Grant.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>$100,000 Limitation</font>.&#160; Even if this option is designated as an ISO in the Notice of Stock Option Grant, it shall
        be deemed to be an NSO to the extent (and only to the extent) required by the $100,000 annual limitation under Section 422(d) of the Code.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Stock Plan and Defined Terms</font>.&#160; This option is granted pursuant to the Plan, a copy of which the Optionee
        acknowledges having received.&#160; The provisions of the Plan are incorporated into this Agreement by this reference.&#160; Except as otherwise defined in this Agreement (including without limitation Section 16 hereof), capitalized terms shall have the
        meaning ascribed to such terms in the Plan.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 2.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>RIGHT TO EXERCISE.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Exercisability</font>.&#160; Subject to Subsection (b) below and the other conditions set forth in this Agreement, all or
        part of this option may be exercised prior to its expiration at the time or times set forth in the Notice of Stock Option Grant.&#160; Shares purchased by exercising this option may be subject to the Right of Repurchase under Section 7.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Stockholder Approval</font>.&#160; Any other provision of this Agreement notwithstanding, no portion of this option shall
        be exercisable at any time prior to the approval of the Plan by the Company&#8217;s stockholders.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; font-weight: bold;">SECTION 3.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>NO TRANSFER OR ASSIGNMENT OF OPTION.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">Except as otherwise provided in or pursuant to this Agreement or the Plan, this option and the rights and privileges conferred hereby shall not be sold, pledged or otherwise transferred (whether by
        operation of law or otherwise) and shall not be subject to sale under execution, attachment, levy or similar process.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 4.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>EXERCISE PROCEDURES.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Notice of Exercise</font>.&#160; The Optionee or the Optionee&#8217;s representative may exercise this option by: (i) signing and
        delivering written notice (on a form prescribed by the Company) to the Company pursuant to Section 14(c) specifying the election to exercise this option, the number of Shares for which it is being exercised and the form of payment, (ii) if
        requested by the Company, executing and delivering such stockholders agreements as apply to the holders of the Company&#8217;s preferred stock (including, without limitation, any right of first refusal and co-sale agreement and/or voting agreement of the
        Company) and (iii) delivering payment, in a form permissible under Section 5, for the full amount of the Purchase Price (together with any applicable withholding taxes under Subsection (b)).&#160; In the event that this option is being exercised by the
        representative of the Optionee, the notice shall be accompanied by proof (satisfactory to the Company) of the representative&#8217;s right to exercise this option.&#160; In the event of a partial exercise of this option, Shares shall be deemed to have been
        purchased in the order in which they vest in accordance with the Notice of Stock Option Grant.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Withholding Taxes</font>.&#160; In the event that the Company determines that it is required to withhold any tax (including
        without limitation any income tax, social insurance contributions, payroll tax, payment on account or other tax-related items arising in connection with the Optionee&#8217;s participation in the Plan and legally applicable to the Optionee (the &#8220;<font style="font-weight: bold;">Tax-Related Items</font>&#8221;)) as a result of the grant, vesting or exercise of this option, or as a result of the vesting or transfer of shares acquired upon exercise of this option, the Optionee, as a condition of this
        option, shall make arrangements satisfactory to the Company to enable it to satisfy all Tax-Related Items.&#160; The Optionee acknowledges that the responsibility for all Tax-Related Items is the Optionee&#8217;s and may exceed the amount actually withheld by
        the Company (or its affiliate or agent).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Issuance of Shares</font>.&#160; After satisfying all requirements for exercise of this option, the Company shall cause to
        be issued one or more certificates evidencing, or electronic notation representing, the Shares for which this option has been exercised.&#160; Such Shares shall be registered (i) in the name of the person exercising this option, (ii) in the names of
        such person and his or her spouse as community property or as joint tenants with the right of survivorship or (iii) with the Company&#8217;s consent, in the name of a revocable trust.&#160; Until the issuance of the Shares has been entered into the books and
        records of the Company or a duly authorized transfer agent of the Company, no right to vote, receive dividends or any other right as a stockholder will exist with respect to such Shares.&#160; In the case of Restricted Shares, the Company shall cause
        any certificates evidencing such Shares to be deposited in escrow under Section 7(c).&#160; In the case of other Shares, the Company shall cause any certificates evidencing such Shares to be delivered to or upon the order of the person exercising this
        option.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 5.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>PAYMENT FOR STOCK.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Cash</font>.&#160; All or part of the Purchase Price may be paid in cash or cash equivalents or pursuant to a form of
        electronic funds transfer acceptable to the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Surrender of Stock</font>.&#160; At the discretion of the Board of Directors, all or any part of the Purchase Price may be
        paid by surrendering, or attesting to the ownership of, Shares that are already owned by the Optionee.&#160; Such Shares shall be surrendered to the Company in good form for transfer and shall be valued at their Fair Market Value as of the date when
        this option is exercised.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Cashless Exercise</font>.&#160; All or part of the Purchase Price and any withholding taxes may be paid by the delivery (on
        a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales proceeds to the Company.&#160; However, payment pursuant to the preceding sentence shall
        be permitted only if (i) Stock then is publicly traded and (ii) such payment does not violate applicable law.&#160; At the discretion of the Board of Directors, all or part of the Purchase Price and any withholding taxes may be paid pursuant to another
        cashless exercise arrangement established by the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 6.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>TERM AND EXPIRATION.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Basic Term</font>.&#160; This option shall in any event expire on the expiration date set forth in the Notice of Stock
        Option Grant, which date is 10 years after the Date of Grant (five years after the Date of Grant if this option is designated as an ISO in the Notice of Stock Option Grant and Section 3(b) of the Plan applies).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Service (Except by Death)</font>.&#160; If the Optionee&#8217;s Service terminates for any reason other than
        death, then this option shall expire on the earliest of the following occasions:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The expiration date determined pursuant to Subsection (a) above;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date three months after the termination of the Optionee&#8217;s Service for any reason other
        than Disability; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date six months after the termination of the Optionee&#8217;s Service by reason of
        Disability.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">The Optionee may exercise all or part of this option at any time before its expiration under the preceding sentence, but only to the extent that this option had become vested before the Optionee&#8217;s Service terminated
        or becomes vested as a result of such termination.&#160; In the event that the Optionee dies after termination of Service but before the expiration of this option, all or part of this option may be exercised (prior to expiration) by the executors or
        administrators of the Optionee&#8217;s estate or by any person who has acquired this option directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that this option had become vested before the Optionee&#8217;s
        Service terminated or becomes vested as a result of such termination.&#160; Once this option (or portion thereof) has terminated, the Optionee shall have no further rights with respect to the option (or portion thereof) or to the underlying Shares.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Death of the Optionee</font>.&#160; If the Optionee dies while in Service, then this option shall expire on the earlier of
        the following dates:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The expiration date determined pursuant to Subsection (a) above; or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date 12 months after the Optionee&#8217;s death.</div>
      <div><br>
      </div>
      <div style="text-align: justify;">All or part of this option may be exercised at any time before its expiration under the preceding sentence by the executors or administrators of the Optionee&#8217;s estate or by any person who has acquired this option
        directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that this option had become vested before the Optionee&#8217;s death or becomes vested as a result of the Optionee&#8217;s death.&#160; Once this option (or
        portion thereof) has terminated, the Optionee shall have no further rights with respect to the option (or portion thereof) or to the underlying Shares.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Additional Vesting After Termination of Service</font>.&#160; The period of time beginning on the date that the Optionee&#8217;s
        Service terminates or the date that the Optionee dies while in Service and ending on the earliest of the occasions determined pursuant to Subsections (b) or (c) above, as applicable, is referred to as the &#8220;<font style="font-weight: bold;">post-termination



          exercise period</font>&#8221;.&#160; To the extent this option is not fully vested on the date the Optionee&#8217;s Service terminates or the date that the Optionee dies while in Service, the Board of Directors may, during the post-termination exercise period,
        take action to cause this option to become vested (in whole or in part).&#160; In no event will this option become vested after termination of the Optionee&#8217;s Service or death unless the Board of Directors takes affirmative action pursuant to the
        preceding sentence or unless expressly provided in a written agreement between the Company and the Optionee.&#160; In this regard, any provision of this Agreement or another agreement that provides for vesting upon an event (including, without
        limitation, a change in control) will be deemed to require Service through the occurrence of such event unless the agreement clearly provides otherwise.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Extension of Post-Termination Exercise Periods</font>.&#160; Following the date on which the Company&#8217;s Stock is first
        listed for trading on an established securities market, if during any part of the exercise period described in Subsections (b)(ii) or (iii) or Subsection (c)(ii) above the exercise of this option would be prohibited solely because the issuance of
        Shares upon such exercise would violate the registration requirements under the Securities Act or a similar provision of other applicable law, then instead of terminating at the end of such prescribed period, the then-vested portion of this option
        will instead remain outstanding and not expire until the earlier of (i) the expiration date determined pursuant to Section 6(a) above or (ii) the date on which the then-vested portion of this option has been exercisable without violation of
        applicable law for the aggregate period (which need not be consecutive) after termination of the Optionee&#8217;s Service specified in the applicable Subsection above.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Part-Time Employment and Leaves of Absence</font>.&#160; If the Optionee commences working on a part-time basis, then the
        Company may adjust the vesting schedule set forth in the Notice of Stock Option Grant.&#160; If the Optionee goes on a leave of absence, then, to the extent permitted by applicable law, the Company may adjust or suspend the vesting schedule set forth in
        the Notice of Stock Option Grant.&#160; Except as provided in the preceding sentence, Service shall be deemed to continue for any purpose under this Agreement while the Optionee is on a <font style="font-style: italic;">bona fide</font> leave of
        absence approved by the Company in writing.&#160; Service shall be deemed to terminate when such leave ends, unless the Optionee immediately returns to active work when such leave ends.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Notice Concerning ISO Treatment</font>.&#160; Even if this option is designated as an ISO in the Notice of Stock Option
        Grant, it ceases to qualify for favorable tax treatment as an ISO to the extent that it is exercised:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>More than three months after the date when the Optionee ceases to be an Employee for any
        reason other than death or permanent and total disability (as defined in Section 22(e)(3) of the Code);</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>More than 12 months after the date when the Optionee ceases to be an Employee by reason of
        permanent and total disability (as defined in Section 22(e)(3) of the Code); or</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>More than three months after the date when the Optionee has been on a leave of absence for
        three months, unless the Optionee&#8217;s reemployment rights following such leave were guaranteed by statute or by contract.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 7.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>RIGHT OF REPURCHASE.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Scope of Repurchase Right</font>.&#160; Until they vest in accordance with the Notice of Stock Option Grant and Subsection
        (b) below, the Shares acquired under this Agreement shall be Restricted Shares and shall be subject to the Company&#8217;s Right of Repurchase.&#160; The Company, however, may decline to exercise its Right of Repurchase or may exercise its Right of Repurchase
        only with respect to a portion of the Restricted Shares.&#160; The Company may exercise its Right of Repurchase only during the Repurchase Period following the termination of the Optionee&#8217;s Service, but the Right of Repurchase may be exercised
        automatically under Subsection (d) below.&#160; If the Right of Repurchase is exercised, the Company shall pay the Optionee an amount equal to the lower of (i) the Exercise Price of each Restricted Share being repurchased or (ii) the Fair Market Value
        of such Restricted Share at the time the Right of Repurchase is exercised.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Lapse of Repurchase Right</font>.&#160; The Right of Repurchase shall lapse with respect to the Restricted Shares in
        accordance with the vesting schedule set forth in the Notice of Stock Option Grant.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Escrow</font>.&#160; Upon issuance, any certificate(s) for Restricted Shares shall be deposited in escrow with the Company
        to be held in accordance with the provisions of this Agreement.&#160; Any additional or exchanged securities or other property described in Subsection (f) below shall immediately be delivered to the Company to be held in escrow.&#160; All ordinary cash
        dividends on Restricted Shares (or on other securities held in escrow) shall be paid directly to the Optionee and shall not be held in escrow.&#160; Restricted Shares, together with any other assets held in escrow under this Agreement, shall be (i)
        surrendered to the Company for repurchase upon exercise of the Right of Repurchase or the Right of First Refusal or (ii) if held in escrow, released to the Optionee upon his or her request to the extent that the Shares have ceased to be Restricted
        Shares (but not more frequently than once every six months).&#160; In any event, all Shares that have ceased to be Restricted Shares, together with any other vested assets held in escrow under this Agreement, shall be released within 90 days after the
        earlier of (i) the termination of the Optionee&#8217;s Service or (ii) the lapse of the Right of First Refusal.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Exercise of Repurchase Right</font>.&#160; The Company shall be deemed to have exercised its Right of Repurchase
        automatically for all Restricted Shares as of the commencement of the Repurchase Period, unless the Company during the Repurchase Period notifies the holder of the Restricted Shares pursuant to Section 14(c) that it will not exercise its Right of
        Repurchase for some or all of the Restricted Shares.&#160; The Company shall pay to the holder of the Restricted Shares the purchase price determined under Subsection (a) above for the Restricted Shares being repurchased.&#160; Payment shall be made in cash
        or cash equivalents and/or by canceling indebtedness to the Company incurred by the Optionee in the purchase of the Restricted Shares.&#160; If the Restricted Shares being repurchased are represented by certificate(s), any such certificate(s) shall be
        delivered to the Company.&#160; If the Restricted Shares being repurchased are not represented by certificate, the repurchase shall be effected by an appropriate book entry on the stock ledger for the Shares.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Rights as Stockholder</font>.&#160; If the Right of Repurchase is exercised in accordance with this Section
        7 and the Company makes available the consideration for the Restricted Shares being repurchased, then the person from whom the Restricted Shares are repurchased shall no longer have any rights as a holder of the Restricted Shares (other than the
        right to receive payment of such consideration).&#160; Such Restricted Shares shall be deemed to have been repurchased pursuant to this Section 7, whether or not any certificate(s) for such Restricted Shares have been delivered to the Company or the
        consideration for such Restricted Shares has been accepted.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Additional or Exchanged Securities and Property</font>.&#160; In the event of a merger or consolidation of the Company, a
        sale of all or substantially all of the Company&#8217;s stock or assets, any other corporate reorganization, a stock split, the declaration of a stock dividend, the declaration of an extraordinary dividend payable in a form other than stock, a spin&#8209;off,
        an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities, any securities or other property (including cash or cash equivalents) that are by reason of such transaction exchanged
        for, or distributed with respect to, any Restricted Shares shall immediately be subject to the Right of Repurchase.&#160; Appropriate adjustments to reflect the exchange or distribution of such securities or property shall be made to the number and/or
        class of the Restricted Shares.&#160; Appropriate adjustments shall also be made to the price per share to be paid upon the exercise of the Right of Repurchase, provided that the aggregate purchase price payable for the Restricted Shares shall remain
        the same.&#160; In the event of any transaction described in Section 9(b) of the Plan or any other corporate reorganization, the Right of Repurchase may be exercised by the Company&#8217;s successor.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Transfer of Restricted Shares</font>.&#160; The Optionee shall not transfer, assign, encumber or otherwise dispose of any
        Restricted Shares without the Company&#8217;s written consent, except as provided in the following sentence.&#160; The Optionee may transfer Restricted Shares to one or more members of the Optionee&#8217;s Immediate Family or to a trust or other entity established
        by the Optionee solely for the benefit of the Optionee and/or one or more members of the Optionee&#8217;s Immediate Family, provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions of
        this Agreement.&#160; If the Optionee transfers any Restricted Shares, then this Agreement shall apply to the Transferee to the same extent as to the Optionee.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Assignment of Repurchase Right</font>.&#160; The Board of Directors may freely assign the Company&#8217;s Right of Repurchase, in
        whole or in part.&#160; Any person who accepts an assignment of the Right of Repurchase from the Company shall be entitled to and assume all of the Company&#8217;s rights and obligations under this Section 7.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 8.&#160; RIGHT OF FIRST REFUSAL.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Right of First Refusal</font>.&#160; In the event that the Optionee proposes to sell, pledge or otherwise transfer to a
        third party any Shares acquired under this Agreement, or any interest in such Shares, the Company shall have the Right of First Refusal with respect to all (and not less than all) of such Shares.&#160; If the Optionee desires to transfer Shares acquired
        under this Agreement, the Optionee shall give a written Transfer Notice to the Company describing fully the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address of the
        proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any applicable federal, State or foreign securities laws.&#160; The Transfer Notice shall be signed both by the Optionee and by the proposed
        Transferee and must constitute a binding commitment of both parties to the transfer of the Shares.&#160; The Company shall have the right to purchase all, and not less than all, of the Shares on the terms of the proposal described in the Transfer Notice
        (subject, however, to any change in such terms permitted under Subsection (b) below) by delivery of a notice of exercise of the Right of First Refusal within 30 days after the date when the Transfer Notice was received by the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Transfer of Shares</font>.&#160; If the Company fails to exercise its Right of First Refusal within 30 days after the date
        when it received the Transfer Notice, the Optionee may, not later than 90 days following receipt of the Transfer Notice by the Company, conclude a transfer of the Shares subject to the Transfer Notice on the terms and conditions no less favorable
        to the Optionee than those described in the Transfer Notice, provided that any such sale is made in compliance with applicable federal, State and foreign securities laws and not in violation of any other contractual restrictions to which the
        Optionee is bound.&#160; Any proposed transfer on terms and conditions less favorable than those described in the Transfer Notice, as well as any subsequent proposed transfer by the Optionee, shall again be subject to the Right of First Refusal and
        shall require compliance with the procedure described in Subsection (a) above.&#160; If the Company exercises its Right of First Refusal, the parties shall consummate the sale of the Shares on the terms set forth in the Transfer Notice within 60 days
        after the date when the Company received the Transfer Notice (or within such longer period as may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the Shares was to be
        made in a form other than cash or cash equivalents paid at the time of transfer, the Company shall have the option of paying for the Shares with cash or cash equivalents equal to the present value of the consideration described in the Transfer
        Notice.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Additional or Exchanged Securities and Property</font>.&#160; In the event of a merger or consolidation of the Company, a
        sale of all or substantially all of the Company&#8217;s stock or assets, any other corporate reorganization, a stock split, the declaration of a stock dividend, the declaration of an extraordinary dividend payable in a form other than stock, a spin&#8209;off,
        an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities, any securities or other property (including cash or cash equivalents) that are by reason of such transaction exchanged
        for, or distributed with respect to, any Shares subject to this Section 8 shall immediately be subject to the Right of First Refusal.&#160; Appropriate adjustments to reflect the exchange or distribution of such securities or property shall be made to
        the number and/or class of the Shares subject to this Section 8.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Right of First Refusal</font>.&#160; Any other provision of this Section 8 notwithstanding, in the event
        that the Stock is readily tradable on an established securities market when the Optionee desires to transfer Shares, the Company shall have no Right of First Refusal, and the Optionee shall have no obligation to comply with the procedures
        prescribed by Subsections (a) and (b) above.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Permitted Transfers</font>.&#160; This Section 8 shall not apply to (i) a transfer by beneficiary designation, will or
        intestate succession or (ii) a transfer to one or more members of the Optionee&#8217;s Immediate Family or to a trust or other entity established by the Optionee solely for the benefit of the Optionee and/or one or more members of the Optionee&#8217;s
        Immediate Family, provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions of this Agreement.&#160; If the Optionee transfers any Shares acquired under this Agreement, either under
        this Subsection (e) or after the Company has failed to exercise the Right of First Refusal, then this Agreement shall apply to the Transferee to the same extent as to the Optionee.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Rights as Stockholder</font>.&#160; If the Company makes available, at the time and place and in the amount
        and form provided in this Agreement, the consideration for the Shares to be purchased in accordance with this Section 8, then after such time the person from whom such Shares are to be purchased shall no longer have any rights as a holder of such
        Shares (other than the right to receive payment of such consideration in accordance with this Agreement).&#160; Such Shares shall be deemed to have been purchased in accordance with the applicable provisions hereof, whether or not any certificate(s)
        therefor have been delivered as required by this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Assignment of Right of First Refusal</font>.&#160; The Board of Directors may freely assign the Company&#8217;s Right of First
        Refusal, in whole or in part.&#160; Any person who accepts an assignment of the Right of First Refusal from the Company shall be entitled to and assume all of the Company&#8217;s rights and obligations under this Section 8.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 9.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>LEGALITY OF INITIAL ISSUANCE.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">No Shares shall be issued upon the exercise of this option unless and until the Company has determined that:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>It and the Optionee have taken any actions required to register the Shares under the
        Securities Act or to perfect an exemption from the registration requirements thereof;</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>Any applicable listing requirement of any stock exchange or other securities market on which
        Stock is listed has been satisfied; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font> Any other applicable provision of federal, State or foreign law has been satisfied.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 10.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>NO REGISTRATION RIGHTS.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">The Company may, but shall not be obligated to, register or qualify the sale of Shares under the Securities Act or any other applicable law.&#160; The Company shall not be obligated to take any
        affirmative action in order to cause the sale of Shares under this Agreement to comply with any law.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 11.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>RESTRICTIONS ON TRANSFER OF SHARES.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>General Restrictions</font>.&#160; Unless the Stock is readily tradeable on an established securities market, the transfer
        of any of the Shares acquired pursuant to this Agreement (or any interest therein) shall, at the Company&#8217;s request, be conditioned upon (i) effecting such transfer pursuant to a form of stock transfer agreement prescribed by the Company and (ii)
        payment of a transfer fee not to exceed $5,000.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Securities Law Restrictions</font>.&#160; Regardless of whether the offer and sale of Shares under the Plan have been
        registered under the Securities Act or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such
        Shares (including the placement of appropriate legends on the stock certificates (or electronic equivalent) or the imposition of stop-transfer instructions) and may refuse (or may be required to refuse) to transfer Shares acquired hereunder (or
        Shares proposed to be transferred in a subsequent transfer) if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the Securities Act or other relevant securities or other
        laws, including without limitation under Regulation S of the Securities Act or pursuant to another available exemption from registration.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Market Stand-Off</font>.&#160; In connection with any underwritten public offering by the Company of its equity securities
        pursuant to an effective registration statement filed under the Securities Act, including the Company&#8217;s initial public offering, the Optionee or a Transferee shall not directly or indirectly sell, make any short sale of, loan, hypothecate, pledge,
        offer, grant or sell any option or other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the foregoing transactions with respect to, any Shares
        acquired under this Agreement without the prior written consent of the Company or its managing underwriter.&#160; Such restriction (the &#8220;Market Stand-Off&#8221;) shall be in effect for such period of time following the date of the final prospectus for the
        offering as may be requested by the Company or such underwriter.&#160; In no event, however, shall such period exceed 180 days plus such additional period as may reasonably be requested by the Company or such underwriter to accommodate regulatory
        restrictions on (i) the publication or other distribution of research reports or (ii) analyst recommendations and opinions, including (without limitation) the restrictions set forth in Rule 2711(f)(4) of the National Association of Securities
        Dealers and Rule 472(f)(4) of the New York Stock Exchange, as amended, or any similar successor rules.&#160; The Market Stand-Off shall in any event terminate two years after the date of the Company&#8217;s initial public offering.&#160; In the event of the
        declaration of a stock dividend, a spin&#8209;off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities without receipt of consideration, any new, substituted or
        additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately be subject to the Market Stand-Off.&#160; In
        order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off period.&#160; The Company&#8217;s underwriters shall be beneficiaries
        of the agreement set forth in this Subsection (b).&#160; This Subsection (b) shall not apply to Shares registered in the public offering under the Securities Act.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Investment Intent at Grant</font>.&#160; The Optionee represents and agrees that the Shares to be acquired upon exercising
        this option will be acquired for investment, and not with a view to the sale or distribution thereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Investment Intent at Exercise</font>.&#160; In the event that the sale of Shares under the Plan is not registered under the
        Securities Act but an exemption is available that requires an investment representation or other representation, the Optionee shall represent and agree at the time of exercise that the Shares being acquired upon exercising this option are being
        acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel, including (if applicable because the Company is
        relying on Regulation S under the Securities Act) that as of the date of exercise the Optionee is (i) not a U.S. Person; (ii) not acquiring the Shares on behalf, or for the account or benefit, of a U.S. Person; and (iii) is not exercising the
        option in the United States.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Legends</font>.&#160; Any certificates (or electronic equivalent) evidencing Shares purchased under this Agreement shall
        bear the following legend:</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">&#8220;THE SHARES REPRESENTED HEREBY (AND ANY INTEREST THEREIN) MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF THE STOCK OPTION
        AGREEMENT PURSUANT TO WHICH SUCH SHARES WERE ACQUIRED.&#160; SUCH AGREEMENT GRANTS TO THE COMPANY CERTAIN RIGHTS OF FIRST REFUSAL UPON AN ATTEMPTED TRANSFER OF THE SHARES AND CERTAIN REPURCHASE RIGHTS UPON TERMINATION OF SERVICE WITH THE COMPANY.&#160; IN
        ADDITION, THE SHARES ARE SUBJECT TO RESTRICTIONS ON TRANSFER AS SET FORTH IN SUCH STOCK OPTION AGREEMENT.&#160; THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH STOCK OPTION AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.&#8221;</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify;">Any certificates (or electronic equivalent) evidencing Shares purchased under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are required or
        deemed advisable under the provisions of any applicable law):</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">&#8220;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;) OR ANY SECURITIES LAWS OF ANY U.S. STATE, AND MAY NOT BE SOLD, REOFFERED, PLEDGED,
        ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.&#160; IN THE ABSENCE OF
        REGISTRATION OR THE AVAILABILITY (CONFIRMED BY OPINION OF COUNSEL) OF AN ALTERNATIVE EXEMPTION FROM REGISTRATION UNDER THE ACT (INCLUDING WITHOUT LIMITATION IN ACCORDANCE WITH REGULATION S UNDER THE ACT), THESE SHARES MAY NOT BE SOLD, REOFFERED,
        PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED OF.&#160; HEDGING TRANSACTIONS INVOLVING THESE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.&#8221;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Removal of Legends</font>.&#160; If, in the opinion of the Company and its counsel, any legend placed on a stock
        certificate representing Shares sold under this Agreement is no longer required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Administration</font>.&#160; Any determination by the Company and its counsel in connection with any of the matters set
        forth in this Section 11 shall be conclusive and binding on the Optionee and all other persons.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 12.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>DRAG ALONG RIGHT.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Required Actions</font>.&#160; If the Requisite Parties approve a Sale of the Company, then Optionee hereby agrees with
        respect to all Shares which the Optionee own(s) or over which the Optionee otherwise exercises voting or dispositive authority:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if such Sale of the Company requires stockholder approval under the Certificate, the Bylaws
        of the Company or any law, rule or regulation applicable to the Company, to vote (in person, by proxy or by action by written consent, as applicable) such Shares in favor of such Sale of the Company (it being understood that, within five (5) days
        after the delivery of a proxy or consent solicitation statement (or similar document requesting the consent or approval of stockholders) in respect of any Sale of the Company, the Stockholder shall duly execute and deliver a proxy or consent, as
        the case may be, in favor of such Sale of the Company);</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if such transaction is a Stock Sale, to sell the same proportion of shares of capital stock
        of the Company beneficially held by the Optionee as is being sold by the Selling Holders to the person to whom the Selling Holders propose to sell their Shares;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to refrain from exercising any dissenters&#8217; rights or rights of appraisal under applicable
        law at any time with respect to such Sale of the Company;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iv)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if the consideration for such Shares pursuant to the Sale of the Company includes any
        securities, accept in lieu thereof an amount of cash equal to the fair value (as determined in good faith by the Company) of such securities to the extent reasonably necessary (as determined in good faith by the Company) to comply with applicable
        federal and state securities laws;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(v)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if the Selling Holders appoint a stockholder representative (the &#8220;<font style="font-weight: bold;">Stockholder Representative</font>&#8221;) for matters affecting the stockholders of the Company under the applicable definitive transaction agreements, to consent to (i) the appointment of such Stockholder Representative, (ii) the establishment
        of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the payment of such Stockholder&#8217;s pro rata portion (from the applicable escrow or expense fund or otherwise) of any and all
        reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative&#8217;s services and duties in connection with such Sale of the Company and its related service as the representative of the Stockholders;</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(vi)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to agree to make representations and warranties and to agree to indemnity and other
        liability obligations in connection with the Sale of the Company on terms and conditions that, taken as a whole, are no less favorable to Optionee than to other holders of Common Stock of the Company; and</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(vii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to execute and deliver all related documentation and take such other action in support of
        the Sale of the Company, as reasonably requested by the Company, including a written consent, release and/or joinder, and to not take any action inconsistent with the Sale of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Exceptions</font>.&#160; Notwithstanding the foregoing, an Optionee will not be required to comply with Subsection (a)
        above in connection with any Sale of the Company unless (i) each holder of each class or series of the Company&#8217;s stock will receive the same form of consideration for their shares of such class or series as is received by other holders in respect
        of their shares of such same class or series of stock and (ii) each holder of Common Stock will receive the same amount of consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock, subject,
        in each case, to any &#8220;rollover&#8221; or similar arrangements provided in the definitive documents relating to such Sale of the Company.&#160; If the consideration to be paid in exchange for the Shares pursuant to such Sale of the Company includes any
        securities and due receipt thereof by the Optionee would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (y) the provision to
        any Optionee of any information other than such information as a prudent issuer would generally furnish in an offering made solely to &#8220;accredited investors&#8221; as defined in Regulation D promulgated under the Securities Act, the Company may cause to
        be paid to any such Optionee in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Optionee, an amount in cash equal to the fair value (as determined in good faith by the Company&#8217;s Board of Directors or the
        Requisite Parties, as applicable) of the securities which such Optionee would otherwise receive as of the date of the issuance of such securities in exchange for the Shares.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 13.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>ADJUSTMENT OF SHARES.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">In the event of any transaction described in Section 9(a) of the Plan, the terms of this option (including, without limitation, the number and kind of Shares subject to this option and the Exercise
        Price) shall be adjusted as set forth in Section 9(a) of the Plan.&#160; In the event that the Company is a party to a merger or consolidation or in the event of a sale of all or substantially all of the Company&#8217;s stock or assets, this option shall be
        subject to the treatment provided by the Board of Directors in its sole discretion, as provided in Section 9(b) of the Plan.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 14.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>MISCELLANEOUS PROVISIONS.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Rights as a Stockholder</font>.&#160; Neither the Optionee nor the Optionee&#8217;s representative shall have any rights as a
        stockholder with respect to any Shares subject to this option until the Optionee or the Optionee&#8217;s representative becomes entitled to receive such Shares by filing a notice of exercise and paying the Purchase Price pursuant to Sections 4 and 5.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>No Retention Rights</font>.&#160; Nothing in this option or in the Plan shall confer upon the Optionee any right to
        continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining the Optionee) or of the Optionee, which rights are hereby
        expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without cause.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Notice</font>.&#160; Any notice required by the terms of this Agreement shall be given in writing.&#160; It shall be deemed
        effective upon (i) personal delivery, (ii) deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, (iii) deposit with Federal Express Corporation, with shipping charges prepaid or (iv) deposit
        with any internationally recognized express mail courier service, with shipping charges prepaid.&#160; Notice shall be addressed to the Company at its principal executive office and to the Optionee at the address that he or she most recently provided to
        the Company in accordance with this Subsection (c).&#160; In addition, to the extent required or permitted pursuant to rules established by the Company from time to time, notices may be delivered electronically.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Modifications and Waivers</font>.&#160; No provision of this Agreement shall be modified, waived or discharged unless the
        modification, waiver or discharge is agreed to in writing and signed by the Optionee and by an authorized officer of the Company (other than the Optionee); provided, however, that a modification that is otherwise favorable to the Optionee (for
        example, providing the Optionee with additional time to exercise this option after termination of employment or providing for additional forms of payment) but causes this option to lose its tax-favored status (for example, as an ISO) shall not
        require the consent of the Optionee.&#160; No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same
        condition or provision at another time.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Entire Agreement</font>.&#160; The Notice of Stock Option Grant, this Agreement and the Plan constitute the entire contract
        between the parties hereto with regard to the subject matter hereof.&#160; They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Choice of Law</font>.&#160; This Agreement shall be governed by, and construed in accordance with, the laws of the State of
        Delaware, as such laws are applied to contracts entered into and performed in such State.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Severability</font>.&#160; Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be
        effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without
        invalidating the remainder of such provision or the remaining provisions of this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Binding Effect on Transferees, Heirs, Successors and Assigns</font>.&#160; This Agreement shall be binding upon Optionee&#8217;s
        permitted transferees, heirs, successors and assigns; provided that for any such transfer to be deemed effective, the transferee shall agree on a form prescribed by the Company to be bound by the terms and conditions of this Agreement, including
        the restrictions on transfer in Section 11 and the drag along right in Section 12.&#160; The Company shall not record any transfer of Shares on its books or issue a new certificate representing any such Shares unless and until such transferee shall have
        complied with the terms of this Subsection (h).</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 15.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>ACKNOWLEDGEMENTS OF THE OPTIONEE.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">In addition to the other terms, conditions and restrictions imposed on this option and the Shares issuable under this option pursuant to this Agreement and the Plan, the Optionee expressly
        acknowledges being subject to Sections 7 (Right of Repurchase), 8 (Right of First Refusal), 9 (Legality of Initial Issuance), 11 (Restrictions on Transfer of Shares, including without limitation the Market Stand-Off) and 12 (Drag Along Right), as
        well as the following provisions:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Tax Consequences</font>.&#160; The Optionee agrees that the Company does not have a duty to design or administer the Plan
        or its other compensation programs in a manner that minimizes the Optionee&#8217;s tax liabilities.&#160; The Optionee shall not make any claim against the Company or its Board of Directors, officers or employees related to tax liabilities arising from this
        option or the Optionee&#8217;s other compensation.&#160; In particular, any Optionee subject to U.S. taxation acknowledges that this option is exempt from Section 409A of the Code only if the Exercise Price is at least equal to the Fair Market Value per Share
        on the Date of Grant.&#160; Since Shares are not traded on an established securities market, the determination of their Fair Market Value is made by the Board of Directors or by an independent valuation firm retained by the Company.&#160; The Optionee
        acknowledges that there is no guarantee in either case that the Internal Revenue Service will agree with the valuation, and the Optionee shall not make any claim against the Company or its Board of Directors, officers or employees in the event that
        the Internal Revenue Service asserts that the valuation was too low.&#160; In addition, if this option is designated as an ISO, the Optionee acknowledges that there is no guarantee that the option in fact qualifies for incentive stock option treatment
        or that it will continue to qualify for incentive stock option treatment at the time of exercise.&#160; In this regard, the Optionee acknowledges that the Company may take actions that will cause the option to cease to be eligible for incentive stock
        option treatment and that such actions do not require the Optionee&#8217;s consent.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Electronic Delivery of Documents</font>.&#160; The Optionee acknowledges and agrees that the Company may, in its sole
        discretion, deliver all documents relating to the Company, the Plan or this option and all other documents that the Company is required to deliver to its security holders (including, without limitation, disclosures that may be required by the
        Securities and Exchange Commission) by email or other means of electronic transmission (including by posting them on a website maintained by the Company or a third party under contract with the Company).&#160; The Optionee acknowledges that he or she
        may incur costs in connection with any such delivery by means of electronic transmission, including the cost of accessing the internet and printing fees, and that an interruption of internet access may interfere with his or her ability to access
        the documents.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>No Notice of Expiration Date</font>.&#160; The Optionee agrees that the Company and its officers, employees, attorneys and
        agents do not have any obligation to notify him or her prior to the expiration of this option pursuant to Section 6, regardless of whether this option will expire at the end of its full term or on an earlier date related to the termination of the
        Optionee&#8217;s Service.&#160; The Optionee further agrees that he or she has the sole responsibility for monitoring the expiration of this option and for exercising this option, if at all, before it expires.&#160; This Subsection (c) shall supersede any contrary
        representation that may have been made, orally or in writing, by the Company or by an officer, employee, attorney or agent of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Waiver of Statutory Information Rights</font>.&#160; The Optionee acknowledges and agrees that, upon exercise of this
        option and until the first sale of the Company&#8217;s Stock to the general public pursuant to a registration statement filed under the Securities Act, he or she shall waive, and shall be deemed to have waived, any rights the Optionee would otherwise
        have under Section 220 of the Delaware General Corporation Law (or under similar rights pursuant to any other applicable law) to inspect for any purpose and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders and
        its other books and records or the books and records of any subsidiary of the Company (the &#8220;<font style="font-weight: bold;">Inspection Rights</font>&#8221;).&#160; The Optionee acknowledges and understands that, but for the waiver made herein, the Optionee
        would be entitled, upon compliance with the procedures set forth in Section 220 of the Delaware General Corporation Law, to Inspection Rights pursuant thereto, and further acknowledges and agrees that the waiver set forth herein is a knowing and
        voluntary waiver of such rights, that the Optionee has received sufficient consideration for such waiver and that the Company would not be willing to provide the benefits to the Optionee hereunder without the benefit of such waiver from the
        Optionee.&#160; This waiver applies only in the Optionee&#8217;s capacity as a stockholder and does not affect any other inspection rights the Optionee may have pursuant to any written agreement with the Company.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Plan Discretionary</font>.&#160; The Optionee understands and acknowledges that (i) the Plan is entirely discretionary,
        (ii) the Company and<font style="font-weight: bold;">&#160;</font>the Optionee&#8217;s employer have reserved the right to amend, suspend or terminate the Plan at any time, (iii) the grant of an option does not in any way create any contractual or other right
        to receive additional grants of options (or benefits in lieu of options) at any time or in any amount and (iv) all determinations with respect to any additional grants, including (without limitation) the times when options will be granted, the
        number of Shares offered, the Exercise Price and the vesting schedule, will be at the sole discretion of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Service</font>.&#160; The Optionee understands and acknowledges that participation in the Plan ceases upon
        termination of his or her Service for any reason, except as may explicitly be provided otherwise in the Plan or this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Extraordinary Compensation</font>.&#160; The value of this option shall be an extraordinary item of compensation outside
        the scope of the Optionee&#8217;s employment contract, if any, and shall not be considered a part of his or her normal or expected compensation for purposes of calculating severance, resignation, redundancy or end-of-service payments, bonuses,
        long-service awards, pension or retirement benefits or similar payments.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Authorization to Disclose</font>.&#160; The Optionee hereby authorizes and directs the Optionee&#8217;s employer to disclose to
        the Company or any Subsidiary any information regarding the Optionee&#8217;s employment, the nature and amount of the Optionee&#8217;s compensation and the fact and conditions of the Optionee&#8217;s participation in the Plan, as the Optionee&#8217;s employer deems
        necessary or appropriate to facilitate the administration of the Plan.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Personal Data Authorization</font>.&#160; The Optionee consents to the collection, use and transfer of personal data as
        described in this Subsection (i).&#160; The Optionee understands and acknowledges that the Company, the Optionee&#8217;s employer and the Company&#8217;s other Subsidiaries hold certain personal information regarding the Optionee for the purpose of managing and
        administering the Plan, including (without limitation) the Optionee&#8217;s name, home address, telephone number, date of birth, social insurance number, salary, nationality, job title, any Shares or directorships held in the Company and details of all
        options or any other entitlements to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Optionee&#8217;s favor (the &#8220;<font style="font-weight: bold;">Data</font>&#8221;).&#160; The Optionee further understands and acknowledges that the
        Company and/or its Subsidiaries will transfer Data among themselves as necessary for the purpose of implementation, administration and management of the Optionee&#8217;s participation in the Plan and that the Company and/or any Subsidiary may each
        further transfer Data to any third party assisting the Company in the implementation, administration and management of the Plan.&#160; The Optionee understands and acknowledges that the recipients of Data may be located in the United States or
        elsewhere.&#160; The Optionee authorizes such recipients to receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of administering the Optionee&#8217;s participation in the Plan, including a transfer to any broker or
        other third party with whom the Optionee elects to deposit Shares acquired under the Plan of such Data as may be required for the administration of the Plan and/or the subsequent holding of Shares on the Optionee&#8217;s behalf.&#160; The Optionee may, at any
        time, view the Data, require any necessary modifications of Data or withdraw the consents set forth in this Subsection (i) by contacting the Company in writing.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; font-weight: bold;">SECTION 16.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>DEFINITIONS.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Agreement</font>&#8221; shall mean this Stock Option Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221; shall mean the Board of Directors of the Company,
        as constituted from time to time or, if a Committee has been appointed, such Committee.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Certificate</font>&#8221; shall mean the Company&#8217;s amended and restated certificate
        of incorporation as in effect from time to time.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Company</font>&#8221; shall mean Remix Therapeutics Inc., a Delaware corporation.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Immediate Family</font>&#8221; shall mean any child, stepchild, grandchild, parent,
        stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law and shall include adoptive relationships.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Optionee</font>&#8221; shall mean the person named in the Notice of Stock Option
        Grant.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Plan</font>&#8221; shall mean the Remix Therapeutics Inc. 2019 Stock Plan, as in
        effect on the Date of Grant.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Purchase Price</font>&#8221; shall mean the Exercise Price multiplied by the number
        of Shares with respect to which this option is being exercised.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Repurchase Period</font>&#8221; shall mean a period of 90 consecutive days
        commencing on the date when the Optionee&#8217;s Service terminates for any reason, including (without limitation) death or disability.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(j)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Requisite Parties</font>&#8221; shall mean both the Board of Directors and the
        Selling Holders.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(k)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Restricted Share</font>&#8221; shall mean a Share that is subject to the Right of
        Repurchase.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(l)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Right of First Refusal</font>&#8221; shall mean the Company&#8217;s right of first
        refusal described in Section 8.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(m)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Right of Repurchase</font>&#8221; shall mean the Company&#8217;s right of repurchase
        described in Section 7.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(n)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Sale of the Company</font>&#8221; shall mean: (i) a transaction or series of
        related transactions in which a person, or a group of related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a &#8220;<font style="font-weight: bold;">Stock



          Sale</font>&#8221;), (ii) a sale of all or substantially all of the assets of the Company or (iii) any other transaction that qualifies as a &#8220;Liquidation Event&#8221; as defined in the Certificate.</div>
      <div><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">17</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(o)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Selling Holders</font>&#8221; shall mean the holders of a majority of the
        then-outstanding shares of Common Stock (voting together as a single class and on an as-converted basis).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(p)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Service</font>&#8221; shall mean service as an Employee, Outside Director or
        Consultant.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(q)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Transferee</font>&#8221; shall mean any person to whom the Optionee has directly or
        indirectly transferred any Share acquired under this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(r)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Transfer Notice</font>&#8221; shall mean the notice of a proposed transfer of
        Shares described in Section 8.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 72pt;">(s)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">U.S. Person</font>&#8221; shall mean a person described in Rule 902(k) of
        Regulation S of the Securities Act (or any successor rule or provision), which generally defines a U.S. person as any natural person resident in the United States, any estate of which any executor or administrator is a U.S. Person, or any trust of
        which of any trustee is a U.S. Person.</div>
      <div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">18</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc. 2019 Stock Plan</div>
        <font style="text-transform: uppercase;"> </font>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Notice of Stock Option Grant (Installment Exercise)</div>
        <div><br>
        </div>
        <div style="text-align: justify;">The Optionee has been granted the following option to purchase shares of the Common Stock of Remix Therapeutics Inc. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;):</div>
        &#160;
        <div>
          <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>Name of Optionee:</div>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div>&#171;Name&#187;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>Total Number of Shares:</div>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div>&#171;TotalShares&#187;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>Type of Option:</div>
                </td>
                <td style="width: 8%; vertical-align: top;">
                  <div>&#171;ISO&#187;</div>
                </td>
                <td style="width: 54%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Incentive Stock Option (ISO)</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div>&#171;NSO&#187;</div>
                </td>
                <td style="width: 54%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Nonstatutory Stock Option (NSO)</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>Exercise Price per Share:</div>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div>$&#171;PricePerShare&#187;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>Date of Grant:</div>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div>&#171;DateGrant&#187;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>Vesting Schedule/Date Exercisable:</div>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div style="text-align: justify;">
                    <div style="font-family: 'Times New Roman', Times, serif;">This option shall vest and become exercisable with respect to the first &#171;Percent&#187;% of the Shares subject to this option when the Optionee completes &#171;CliffPeriod&#187; months of
                      continuous Service beginning with the Vesting Commencement Date set forth below.&#160; This option shall vest and become exercisable with respect to an additional &#171;Fraction&#187;% of the Shares subject to this option when the Optionee completes
                      each month of continuous Service thereafter.</div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 30%; vertical-align: top;">Vesting Commencement Date:</td>
                <td rowspan="1" colspan="2" style="vertical-align: top;">
                  <div style="font-family: 'Times New Roman', Times, serif;">&#171;VestComDate&#187;</div>
                </td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" rowspan="1" style="width: 30%; vertical-align: top;">&#160;&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 30%; vertical-align: top;">
                  <div>Expiration Date:</div>
                </td>
                <td colspan="2" style="vertical-align: top;">
                  <div style="text-align: justify;">
                    <div style="font-family: 'Times New Roman', Times, serif;">&#171;ExpDate&#187;.&#160; This option expires earlier if the Optionee&#8217;s Service terminates earlier, as provided in Section 6 of the Stock Option Agreement, or if the Company engages in
                      certain corporate transactions, as provided in Section 9 of the Plan.</div>
                  </div>
                </td>
              </tr>

          </table>
          <br>
        </div>
        <div style="text-align: justify; color: #000000;">By signing below or otherwise accepting this option in a manner acceptable to the Company, the Optionee and the Company agree that this option is granted under, and governed by the terms and
          conditions of, this Notice of Stock Option Grant, the 2019 Stock Plan and the Stock Option Agreement.&#160; Both of the latter documents are attached to, and made a part of, this Notice of Stock Option Grant.&#160; Capitalized terms not otherwise defined
          herein or in the Stock Option Agreement shall have the meanings set forth in the Plan.&#160; <font style="font-weight: bold;">Section 14 of the Stock Option Agreement includes important acknowledgements of the Optionee</font>.</div>
        &#160;<br>
        <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 44%; vertical-align: top;">
                <div style="text-align: justify; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Optionee:</div>
              </td>
              <td colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
              <td colspan="2" style="vertical-align: top;">
                <div style="text-align: justify; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 44%; vertical-align: top;">&#160;</td>
              <td colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
              <td style="width: 6%; vertical-align: top;">&#160;</td>
              <td style="width: 44%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              <td colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">By:</div>
              </td>
              <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 44%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Title:</div>
              </td>
              <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>

        </table>
        <div style="text-align: justify; font-weight: bold;">&#160; </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; font-weight: bold;">THE OPTION GRANTED PURSUANT TO THE NOTICE OF STOCK OPTION GRANT AND THIS AGREEMENT AND THE SHARES ISSUABLE UPON THE EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
          AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.</div>
        <div><font style="text-transform: uppercase;"><br>
          </font> </div>
        <font style="text-transform: uppercase;"> </font>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc. 2019 Stock Plan:</div>
        <font style="text-transform: uppercase;"> </font>
        <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Stock Option Agreement (Installment Exercise)</div>
        <font style="text-transform: uppercase;"> </font>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 1.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>GRANT OF OPTION.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font><font style="font-weight: bold; font-variant: small-caps;">O</font><font style="font-weight: bold;">ption</font>.&#160;



          On the terms and conditions set forth in the Notice of Stock Option Grant, this Agreement and the Plan, the Company has granted to the Optionee on the Date of Grant the option to purchase at the Exercise Price the number of Shares set forth in
          the Notice of Stock Option Grant.&#160; The Exercise Price is agreed to be at least 100% of the Fair Market Value per Share on the Date of Grant (110% of Fair Market Value if this option is designated as an ISO in the Notice of Stock Option Grant and
          Section 3(b) of the Plan applies).&#160; This option is intended to be an ISO or an NSO, as provided in the Notice of Stock Option Grant.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>$100,000 Limitation</font>.&#160; Even if this option is designated as an ISO in the Notice of Stock Option Grant, it
          shall be deemed to be an NSO to the extent (and only to the extent) required by the $100,000 annual limitation under Section 422(d) of the Code.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Stock Plan and Defined Terms</font>.&#160; This option is granted pursuant to the Plan, a copy of which the Optionee
          acknowledges having received.&#160; The provisions of the Plan are incorporated into this Agreement by this reference.&#160; Except as otherwise defined in this Agreement (including without limitation Section 15 hereof), capitalized terms shall have the
          meaning ascribed to such terms in the Plan.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 2.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>RIGHT TO EXERCISE.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Exercisability</font>.&#160; Subject to Subsection (b) below and the other conditions set forth in this Agreement, all or
          part of this option may be exercised prior to its expiration at the time or times set forth in the Notice of Stock Option Grant.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Stockholder Approval</font>.&#160; Any other provision of this Agreement notwithstanding, no portion of this option shall
          be exercisable at any time prior to the approval of the Plan by the Company&#8217;s stockholders.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <!--PROfilePageNumberReset%Num%2%%%-->
        <div style="text-align: justify; font-weight: bold;">SECTION 3.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>NO TRANSFER OR ASSIGNMENT OF OPTION.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">Except as otherwise provided in or pursuant to this Agreement or the Plan, this option and the rights and privileges conferred hereby shall not be sold, pledged or otherwise transferred (whether
          by operation of law or otherwise) and shall not be subject to sale under execution, attachment, levy or similar process.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 4.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>EXERCISE PROCEDURES.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Notice of Exercise</font>.&#160; The Optionee or the Optionee&#8217;s representative may exercise this option by: (i) signing
          and delivering written notice (on a form prescribed by the Company) to the Company pursuant to Section 13(c) specifying the election to exercise this option, the number of Shares for which it is being exercised and the form of payment, (ii) if
          requested by the Company, executing and delivering such stockholders agreements as apply to the holders of the Company&#8217;s preferred stock (including, without limitation, any right of first refusal and co-sale agreement and/or voting agreement of
          the Company) and (iii) delivering payment, in a form permissible under Section 5, for the full amount of the Purchase Price (together with any applicable withholding taxes under Subsection (b)). In the event that this option is being exercised by
          the representative of the Optionee, the notice shall be accompanied by proof (satisfactory to the Company) of the representative&#8217;s right to exercise this option.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Withholding Taxes</font>.&#160; In the event that the Company determines that it is required to withhold any tax
          (including without limitation any income tax, social insurance contributions, payroll tax, payment on account or other tax-related items arising in connection with the Optionee&#8217;s participation in the Plan and legally applicable to the Optionee
          (the &#8220;<font style="font-weight: bold;">Tax-Related Items</font>&#8221;)) as a result of the grant, vesting or exercise of this option, or as a result of the transfer of shares acquired upon exercise of this option, the Optionee, as a condition of this
          option, shall make arrangements satisfactory to the Company to enable it to satisfy all Tax-Related Items.&#160; The Optionee acknowledges that the responsibility for all Tax-Related Items is the Optionee&#8217;s and may exceed the amount actually withheld
          by the Company (or its affiliate or agent).</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Issuance of Shares</font>.&#160; After satisfying all requirements for exercise of this option, the Company shall cause
          to be issued one or more certificates evidencing, or electronic notation representing, the Shares for which this option has been exercised.&#160; Such Shares shall be registered (i) in the name of the person exercising this option, (ii) in the names
          of such person and his or her spouse as community property or as joint tenants with the right of survivorship or (iii) with the Company&#8217;s consent, in the name of a revocable trust.&#160; Until the issuance of the Shares has been entered into the books
          and records of the Company or a duly authorized transfer agent of the Company, no right to vote, receive dividends or any other right as a stockholder will exist with respect to such Shares. The Company shall cause any certificates evidencing
          such Shares to be delivered to or upon the order of the person exercising this option.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 5.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>PAYMENT FOR STOCK.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Cash</font>.&#160; All or part of the Purchase Price may be paid in cash or cash equivalents or pursuant to a form of
          electronic funds transfer acceptable to the Company.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Surrender of Stock</font>.&#160; At the discretion of the Board of Directors, all or any part of the Purchase Price may
          be paid by surrendering, or attesting to the ownership of, Shares that are already owned by the Optionee.&#160; Such Shares shall be surrendered to the Company in good form for transfer and shall be valued at their Fair Market Value as of the date
          when this option is exercised.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Cashless Exercise</font>.&#160; All or part of the Purchase Price and any withholding taxes may be paid by the delivery
          (on a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales proceeds to the Company.&#160; However, payment pursuant to the preceding sentence
          shall be permitted only if (i) Stock then is publicly traded and (ii) such payment does not violate applicable law.&#160; At the discretion of the Board of Directors, all or part of the Purchase Price and any withholding taxes may be paid pursuant to
          another cashless exercise arrangement established by the Company.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 6.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>TERM AND EXPIRATION.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Basic Term</font>.&#160; This option shall in any event expire on the expiration date set forth in the Notice of Stock
          Option Grant, which date is 10 years after the Date of Grant (five years after the Date of Grant if this option is designated as an ISO in the Notice of Stock Option Grant and Section 3(b) of the Plan applies).</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Service (Except by Death)</font>.&#160; If the Optionee&#8217;s Service terminates for any reason other than
          death, then this option shall expire on the earliest of the following occasions:</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The expiration date determined pursuant to Subsection (a) above;</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date three months after the termination of the Optionee&#8217;s Service for any reason
          other than Disability; or</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date six months after the termination of the Optionee&#8217;s Service by reason of
          Disability.</div>
        <div><br>
        </div>
        <div style="text-align: justify; color: #000000;">The Optionee may exercise all or part of this option at any time before its expiration under the preceding sentence, but only to the extent that this option had become vested and exercisable before
          the Optionee&#8217;s Service terminated or becomes vested and exercisable as a result of such termination.&#160; In the event that the Optionee dies after termination of Service but before the expiration of this option, all or part of this option may be
          exercised (prior to expiration) by the executors or administrators of the Optionee&#8217;s estate or by any person who has acquired this option directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that
          this option had become vested and exercisable before the Optionee&#8217;s Service terminated or becomes vested and exercisable as a result of such termination. Once this option (or portion thereof) has terminated, the Optionee shall have no further
          rights with respect to the option (or portion thereof) or to the underlying Shares.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Death of the Optionee</font>.&#160; If the Optionee dies while in Service, then this option shall expire on the earlier
          of the following dates:</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The expiration date determined pursuant to Subsection (a) above; or</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The date 12 months after the Optionee&#8217;s death.</div>
        <div><br>
        </div>
        <div style="text-align: justify; color: #000000;">All or part of this option may be exercised at any time before its expiration under the preceding sentence by the executors or administrators of the Optionee&#8217;s estate or by any person who has
          acquired this option directly from the Optionee by beneficiary designation, bequest or inheritance, but only to the extent that this option had become vested and exercisable before the Optionee&#8217;s death or becomes vested and exercisable as a
          result of the Optionee&#8217;s death.&#160; Once this option (or portion thereof) has terminated, the Optionee shall have no further rights with respect to the option (or portion thereof) or to the underlying Shares.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Additional Vesting After Termination of Service</font>.&#160; The period of time beginning on the date that the
          Optionee&#8217;s Service terminates or the date that the Optionee dies while in Service and ending on the earliest of the occasions determined pursuant to Subsections (b) or (c) above, as applicable, is referred to as the &#8220;<font style="font-weight: bold;">post-termination exercise period</font>&#8221;.&#160; To the extent this option is not fully vested and exercisable on the date the Optionee&#8217;s Service terminates or the date that the Optionee dies while in Service, the Board of Directors may,
          during the post-termination exercise period, take action to cause this option to become vested and exercisable (in whole or in part).&#160; In no event will this option become vested or exercisable after termination of the Optionee&#8217;s Service or death
          unless the Board of Directors takes affirmative action pursuant to the preceding sentence or unless expressly provided in a written agreement between the Company and the Optionee.&#160; In this regard, any provision of this Agreement or another
          agreement that provides for vesting upon an event (including, without limitation, a change in control) will be deemed to require Service through the occurrence of such event unless the agreement clearly provides otherwise.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Extension of Post-Termination Exercise Periods</font>.&#160; Following the date on which the Company&#8217;s Stock is first
          listed for trading on an established securities market, if during any part of the exercise period described in Subsections (b)(ii) or (iii) or Subsection (c)(ii) above the exercise of this option would be prohibited solely because the issuance of
          Shares upon such exercise would violate the registration requirements under the Securities Act or a similar provision of other applicable law, then instead of terminating at the end of such prescribed period, the then-vested portion of this
          option will instead remain outstanding and not expire until the earlier of (i) the expiration date determined pursuant to Section 6(a) above or (ii) the date on which the then-vested portion of this option has been exercisable without violation
          of applicable law for the aggregate period (which need not be consecutive) after termination of the Optionee&#8217;s Service specified in the applicable Subsection above.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Part-Time Employment and Leaves of Absence</font>.&#160; If the Optionee commences working on a part-time basis, then the
          Company may adjust the vesting schedule set forth in the Notice of Stock Option Grant.&#160; If the Optionee goes on a leave of absence, then, to the extent permitted by applicable law, the Company may adjust or suspend the vesting schedule set forth
          in the Notice of Stock Option Grant.&#160; Except as provided in the preceding sentence, Service shall be deemed to continue for any purpose under this Agreement while the Optionee is on a <font style="font-style: italic;">bona fide</font> leave of
          absence approved by the Company in writing.&#160; Service shall be deemed to terminate when such leave ends, unless the Optionee immediately returns to active work when such leave ends.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Notice Concerning ISO Treatment</font>.&#160; Even if this option is designated as an ISO in the Notice of Stock Option
          Grant, it ceases to qualify for favorable tax treatment as an ISO to the extent that it is exercised:</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>More than three months after the date when the Optionee ceases to be an Employee for any
          reason other than death or permanent and total disability (as defined in Section 22(e)(3) of the Code);</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>More than 12 months after the date when the Optionee ceases to be an Employee by reason
          of permanent and total disability (as defined in Section 22(e)(3) of the Code); or</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>More than three months after the date when the Optionee has been on a leave of absence
          for three months, unless the Optionee&#8217;s reemployment rights following such leave were guaranteed by statute or by contract.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 7.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>RIGHT OF FIRST REFUSAL.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Right of First Refusal</font>.&#160; In the event that the Optionee proposes to sell, pledge or otherwise transfer to a
          third party any Shares acquired under this Agreement, or any interest in such Shares, the Company shall have the Right of First Refusal with respect to all (and not less than all) of such Shares.&#160; If the Optionee desires to transfer Shares
          acquired under this Agreement, the Optionee shall give a written Transfer Notice to the Company describing fully the proposed transfer, including the number of Shares proposed to be transferred, the proposed transfer price, the name and address
          of the proposed Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any applicable federal, State or foreign securities laws.&#160; The Transfer Notice shall be signed both by the Optionee and by the
          proposed Transferee and must constitute a binding commitment of both parties to the transfer of the Shares.&#160; The Company shall have the right to purchase all, and not less than all, of the Shares on the terms of the proposal described in the
          Transfer Notice (subject, however, to any change in such terms permitted under Subsection (b) below) by delivery of a notice of exercise of the Right of First Refusal within 30 days after the date when the Transfer Notice was received by the
          Company.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Transfer of Shares</font>.&#160; If the Company fails to exercise its Right of First Refusal within 30 days after the
          date when it received the Transfer Notice, the Optionee may, not later than 90 days following receipt of the Transfer Notice by the Company, conclude a transfer of the Shares subject to the Transfer Notice on the terms and conditions no less
          favorable to the Optionee than those described in the Transfer Notice, provided that any such sale is made in compliance with applicable federal, State and foreign securities laws and not in violation of any other contractual restrictions to
          which the Optionee is bound.&#160; Any proposed transfer on terms and conditions less favorable than those described in the Transfer Notice, as well as any subsequent proposed transfer by the Optionee, shall again be subject to the Right of First
          Refusal and shall require compliance with the procedure described in Subsection (a) above.&#160; If the Company exercises its Right of First Refusal, the parties shall consummate the sale of the Shares on the terms set forth in the Transfer Notice
          within 60 days after the date when the Company received the Transfer Notice (or within such longer period as may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the
          Shares was to be made in a form other than cash or cash equivalents paid at the time of transfer, the Company shall have the option of paying for the Shares with cash or cash equivalents equal to the present value of the consideration described
          in the Transfer Notice.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Additional or Exchanged Securities and Property</font>.&#160; In the event of a merger or consolidation of the Company, a
          sale of all or substantially all of the Company&#8217;s stock or assets, any other corporate reorganization, a stock split, the declaration of a stock dividend, the declaration of an extraordinary dividend payable in a form other than stock, a
          spin&#8209;off, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities, any securities or other property (including cash or cash equivalents) that are by reason of such transaction
          exchanged for, or distributed with respect to, any Shares subject to this Section 7 shall immediately be subject to the Right of First Refusal.&#160; Appropriate adjustments to reflect the exchange or distribution of such securities or property shall
          be made to the number and/or class of the Shares subject to this Section 7.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Right of First Refusal</font>.&#160; Any other provision of this Section 7 notwithstanding, in the event
          that the Stock is readily tradable on an established securities market when the Optionee desires to transfer Shares, the Company shall have no Right of First Refusal, and the Optionee shall have no obligation to comply with the procedures
          prescribed by Subsections (a) and (b) above.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Permitted Transfers</font>.&#160; This Section 7 shall not apply to (i) a transfer by beneficiary designation, will or
          intestate succession or (ii) a transfer to one or more members of the Optionee&#8217;s Immediate Family or to a trust or other entity established by the Optionee solely for the benefit of the Optionee and/or one or more members of the Optionee&#8217;s
          Immediate Family, provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions of this Agreement.&#160; If the Optionee transfers any Shares acquired under this Agreement, either under
          this Subsection (e) or after the Company has failed to exercise the Right of First Refusal, then this Agreement shall apply to the Transferee to the same extent as to the Optionee.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Rights as Stockholder</font>.&#160; If the Company makes available, at the time and place and in the
          amount and form provided in this Agreement, the consideration for the Shares to be purchased in accordance with this Section 7, then after such time the person from whom such Shares are to be purchased shall no longer have any rights as a holder
          of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement).&#160; Such Shares shall be deemed to have been purchased in accordance with the applicable provisions hereof, whether or not any
          certificate(s) therefor have been delivered as required by this Agreement.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Assignment of Right of First Refusal</font>.&#160; The Board of Directors may freely assign the Company&#8217;s Right of First
          Refusal, in whole or in part.&#160; Any person who accepts an assignment of the Right of First Refusal from the Company shall be entitled to and assume all of the Company&#8217;s rights and obligations under this Section 7.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 8.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>LEGALITY OF INITIAL ISSUANCE.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">No Shares shall be issued upon the exercise of this option unless and until the Company has determined that:</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>It and the Optionee have taken any actions required to register the Shares under the
          Securities Act or to perfect an exemption from the registration requirements thereof;</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>Any applicable listing requirement of any stock exchange or other securities market on
          which Stock is listed has been satisfied; and</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>Any other applicable provision of federal, State or foreign law has been satisfied.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 9.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>NO REGISTRATION RIGHTS.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">The Company may, but shall not be obligated to, register or qualify the sale of Shares under the Securities Act or any other applicable law.&#160; The Company shall not be obligated to take any
          affirmative action in order to cause the sale of Shares under this Agreement to comply with any law.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 10.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>RESTRICTIONS ON TRANSFER OF SHARES.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>General Restrictions</font>.&#160; Unless the Stock is readily tradeable on an established securities market, the
          transfer of any of the Shares acquired pursuant to this Agreement (or any interest therein) shall, at the Company&#8217;s request, be conditioned upon (i) effecting such transfer pursuant to a form of stock transfer agreement prescribed by the Company
          and (ii) payment of a transfer fee not to exceed $5,000.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Securities Law Restrictions</font>.&#160; Regardless of whether the offer and sale of Shares under the Plan have been
          registered under the Securities Act or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of such
          Shares (including the placement of appropriate legends on the stock certificates (or electronic equivalent) or the imposition of stop-transfer instructions) and may refuse (or may be required to refuse) to transfer Shares acquired hereunder (or
          Shares proposed to be transferred in a subsequent transfer) if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the Securities Act or other relevant securities or other
          laws, including without limitation under Regulation S of the Securities Act or pursuant to another available exemption from registration.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Market Stand-Off</font>.&#160; In connection with any underwritten public offering by the Company of its equity
          securities pursuant to an effective registration statement filed under the Securities Act, including the Company&#8217;s initial public offering, the Optionee or a Transferee shall not directly or indirectly sell, make any short sale of, loan,
          hypothecate, pledge, offer, grant or sell any option or other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the foregoing transactions with
          respect to, any Shares acquired under this Agreement without the prior written consent of the Company or its managing underwriter.&#160; Such restriction (the &#8220;<font style="font-weight: bold;">Market Stand-Off</font>&#8221;) shall be in effect for such
          period of time following the date of the final prospectus for the offering as may be requested by the Company or such underwriter.&#160; In no event, however, shall such period exceed 180 days plus such additional period as may reasonably be requested
          by the Company or such underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports or (ii) analyst recommendations and opinions, including (without limitation) the restrictions set forth in
          Rule 2711(f)(4) of the National Association of Securities Dealers and Rule 472(f)(4) of the New York Stock Exchange, as amended, or any similar successor rules.&#160; The Market Stand-Off shall in any event terminate two years after the date of the
          Company&#8217;s initial public offering.&#160; In the event of the declaration of a stock dividend, a spin&#8209;off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities
          without receipt of consideration, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible,
          shall immediately be subject to the Market Stand-Off.&#160; In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Shares acquired under this Agreement until the end of the applicable stand-off
          period.&#160; The Company&#8217;s underwriters shall be beneficiaries of the agreement set forth in this Subsection (b).&#160; This Subsection (b) shall not apply to Shares registered in the public offering under the Securities Act.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Investment Intent at Grant</font>.&#160; The Optionee represents and agrees that the Shares to be acquired upon
          exercising this option will be acquired for investment, and not with a view to the sale or distribution thereof.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Investment Intent at Exercise</font>.&#160; In the event that the sale of Shares under the Plan is not registered under
          the Securities Act but an exemption is available that requires an investment representation or other representation, the Optionee shall represent and agree at the time of exercise that the Shares being acquired upon exercising this option are
          being acquired for investment, and not with a view to the sale or distribution thereof, and shall make such other representations as are deemed necessary or appropriate by the Company and its counsel, including (if applicable because the Company
          is relying on Regulation S under the Securities Act) that as of the date of exercise the Optionee is (i) not a U.S. Person; (ii) not acquiring the Shares on behalf, or for the account or benefit, of a U.S. Person; and (iii) is not exercising the
          option in the United States.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Legends</font>.&#160; Any certificates (or electronic equivalent) evidencing Shares purchased under this Agreement shall
          bear the following legend:</div>
        <div><br>
        </div>
        <div style="text-align: justify; margin-left: 36pt; color: #000000;">&#8220;THE SHARES REPRESENTED HEREBY (AND ANY INTEREST THEREIN) MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF
          THE STOCK OPTION AGREEMENT PURSUANT TO WHICH SUCH SHARES WERE ACQUIRED.&#160; SUCH AGREEMENT GRANTS TO THE COMPANY CERTAIN RIGHTS OF FIRST REFUSAL UPON AN ATTEMPTED TRANSFER OF THE SHARES.&#160; IN ADDITION, THE SHARES ARE SUBJECT TO RESTRICTIONS ON
          TRANSFER AS SET FORTH IN SUCH STOCK OPTION AGREEMENT. THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH STOCK OPTION AGREEMENT TO THE HOLDER HEREOF WITHOUT CHARGE.&#8221;</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; color: #000000;">Any certificates (or electronic equivalent) evidencing Shares purchased under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as are
          required or deemed advisable under the provisions of any applicable law):</div>
        <div><br>
        </div>
        <div style="text-align: justify; margin-left: 36pt; color: #000000;">&#8220;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;) OR ANY SECURITIES LAWS OF ANY U.S. STATE, AND MAY NOT BE SOLD,
          REOFFERED, PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.&#160;
          IN THE ABSENCE OF REGISTRATION OR THE AVAILABILITY (CONFIRMED BY OPINION OF COUNSEL) OF AN ALTERNATIVE EXEMPTION FROM REGISTRATION UNDER THE ACT (INCLUDING WITHOUT LIMITATION IN ACCORDANCE WITH REGULATION S UNDER THE ACT), THESE SHARES MAY NOT BE
          SOLD, REOFFERED, PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED OF.&#160; HEDGING TRANSACTIONS INVOLVING THESE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.&#8221;</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Removal of Legends</font>.&#160; If, in the opinion of the Company and its counsel, any legend placed on a stock
          certificate representing Shares sold under this Agreement is no longer required, the holder of such certificate shall be entitled to exchange such certificate for a certificate representing the same number of Shares but without such legend.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Administration</font>.&#160; Any determination by the Company and its counsel in connection with any of the matters set
          forth in this Section 10 shall be conclusive and binding on the Optionee and all other persons.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 11.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>DRAG ALONG RIGHT.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Required Actions</font>.&#160; If the Requisite Parties approve a Sale of the Company, then Optionee hereby agrees with
          respect to all Shares which the Optionee own(s) or over which the Optionee otherwise exercises voting or dispositive authority:</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if such Sale of the Company requires stockholder approval under the Certificate, the
          Bylaws of the Company or any law, rule or regulation applicable to the Company, to vote (in person, by proxy or by action by written consent, as applicable) such Shares in favor of such Sale of the Company (it being understood that, within five
          (5) days after the delivery of a proxy or consent solicitation statement (or similar document requesting the consent or approval of stockholders) in respect of any Sale of the Company, the Stockholder shall duly execute and deliver a proxy or
          consent, as the case may be, in favor of such Sale of the Company);</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if such transaction is a Stock Sale, to sell the same proportion of shares of capital
          stock of the Company beneficially held by the Optionee as is being sold by the Selling Holders to the person to whom the Selling Holders propose to sell their Shares;</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to refrain from exercising any dissenters&#8217; rights or rights of appraisal under
          applicable law at any time with respect to such Sale of the Company;</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iv)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if the consideration for such Shares pursuant to the Sale of the Company includes any
          securities, accept in lieu thereof an amount of cash equal to the fair value (as determined in good faith by the Company) of such securities to the extent reasonably necessary (as determined in good faith by the Company) to comply with applicable
          federal and state securities laws;</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(v)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if the Selling Holders appoint a stockholder representative (the &#8220;<font style="font-weight: bold;">Stockholder Representative</font>&#8221;) for matters affecting the stockholders of the Company under the applicable definitive transaction agreements, to consent to (i) the appointment of such Stockholder Representative,
          (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the payment of such Stockholder&#8217;s pro rata portion (from the applicable escrow or expense fund or
          otherwise) of any and all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative&#8217;s services and duties in connection with such Sale of the Company and its related service as the
          representative of the Stockholders;</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(vi)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to agree to make representations and warranties and to agree to indemnity and other
          liability obligations in connection with the Sale of the Company on terms and conditions that, taken as a whole, are no less favorable to Optionee than to other holders of Common Stock of the Company; and</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(vii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to execute and deliver all related documentation and take such other action in support
          of the Sale of the Company, as reasonably requested by the Company, including a written consent, release and/or joinder, and to not take any action inconsistent with the Sale of the Company.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Exceptions</font>.&#160; Notwithstanding the foregoing, an Optionee will not be required to comply with Subsection (a)
          above in connection with any Sale of the Company unless (i) each holder of each class or series of the Company&#8217;s stock will receive the same form of consideration for their shares of such class or series as is received by other holders in respect
          of their shares of such same class or series of stock and (ii) each holder of Common Stock will receive the same amount of consideration per share of Common Stock as is received by other holders in respect of their shares of Common Stock,
          subject, in each case, to any &#8220;rollover&#8221; or similar arrangements provided in the definitive documents relating to such Sale of the Company.&#160; If the consideration to be paid in exchange for the Shares pursuant to such Sale of the Company includes
          any securities and due receipt thereof by the Optionee would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or (y) the
          provision to any Optionee of any information other than such information as a prudent issuer would generally furnish in an offering made solely to &#8220;accredited investors&#8221; as defined in Regulation D promulgated under the Securities Act, the Company
          may cause to be paid to any such Optionee in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Optionee, an amount in cash equal to the fair value (as determined in good faith by the Company&#8217;s Board of
          Directors or the Requisite Parties, as applicable) of the securities which such Optionee would otherwise receive as of the date of the issuance of such securities in exchange for the Shares.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 12.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>ADJUSTMENT OF SHARES.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">In the event of any transaction described in Section 9(a) of the Plan, the terms of this option (including, without limitation, the number and kind of Shares subject to this option and the
          Exercise Price) shall be adjusted as set forth in Section 9(a) of the Plan.&#160; In the event that the Company is a party to a merger or consolidation or in the event of a sale of all or substantially all of the Company&#8217;s stock or assets, this option
          shall be subject to the treatment provided by the Board of Directors in its sole discretion, as provided in Section 9(b) of the Plan.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 13.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>MISCELLANEOUS PROVISIONS.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Rights as a Stockholder</font>.&#160; Neither the Optionee nor the Optionee&#8217;s representative shall have any rights as a
          stockholder with respect to any Shares subject to this option until the Optionee or the Optionee&#8217;s representative becomes entitled to receive such Shares by filing a notice of exercise and paying the Purchase Price pursuant to Sections 4 and 5.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>No Retention Rights</font>.&#160; Nothing in this option or in the Plan shall confer upon the Optionee any right to
          continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining the Optionee) or of the Optionee, which rights are hereby
          expressly reserved by each, to terminate his or her Service at any time and for any reason, with or without cause.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Notice</font>.&#160; Any notice required by the terms of this Agreement shall be given in writing.&#160; It shall be deemed
          effective upon (i) personal delivery, (ii) deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, (iii) deposit with Federal Express Corporation, with shipping charges prepaid or (iv)
          deposit with any internationally recognized express mail courier service, with shipping charges prepaid.&#160; Notice shall be addressed to the Company at its principal executive office and to the Optionee at the address that he or she most recently
          provided to the Company in accordance with this Subsection (c).&#160; In addition, to the extent required or permitted pursuant to rules established by the Company from time to time, notices may be delivered electronically.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Modifications and Waivers</font>.&#160; No provision of this Agreement shall be modified, waived or discharged unless the
          modification, waiver or discharge is agreed to in writing and signed by the Optionee and by an authorized officer of the Company (other than the Optionee); provided, however, that a modification that is otherwise favorable to the Optionee (for
          example, providing the Optionee with additional time to exercise this option after termination of employment or providing for additional forms of payment) but causes this option to lose its tax-favored status (for example, as an ISO) shall not
          require the consent of the Optionee.&#160; No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the
          same condition or provision at another time.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Entire Agreement</font>.&#160; The Notice of Stock Option Grant, this Agreement and the Plan constitute the entire
          contract between the parties hereto with regard to the subject matter hereof.&#160; They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter
          hereof.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Choice of Law</font>.&#160; This Agreement shall be governed by, and construed in accordance with, the laws of the State
          of Delaware, as such laws are applied to contracts entered into and performed in such State.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Severability</font>.&#160; Whenever possible, each provision of this Agreement shall be interpreted in such manner as to
          be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity,
          without invalidating the remainder of such provision or the remaining provisions of this Agreement.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Binding Effect on Transferees, Heirs, Successors and Assigns</font>.&#160; This Agreement shall be binding upon
          Optionee&#8217;s permitted transferees, heirs, successors and assigns; provided that for any such transfer to be deemed effective, the transferee shall agree on a form prescribed by the Company to be bound by the terms and conditions of this Agreement,
          including the restrictions on transfer in Section 10 and the drag along right in Section 11.&#160; The Company shall not record any transfer of Shares on its books or issue a new certificate representing any such Shares unless and until such
          transferee shall have complied with the terms of this Subsection (h).</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 14.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>ACKNOWLEDGEMENTS OF THE OPTIONEE.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">In addition to the other terms, conditions and restrictions imposed on this option and the Shares issuable under this option pursuant to this Agreement and the Plan, the Optionee expressly
          acknowledges being subject to Sections 7 (Right of First Refusal), 8 (Legality of Initial Issuance), 10 (Restrictions on Transfer of Shares, including without limitation the Market Stand-Off) and 11 (Drag Along Right), as well as the following
          provisions:</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Tax Consequences</font>.&#160; The Optionee agrees that the Company does not have a duty to design or administer the Plan
          or its other compensation programs in a manner that minimizes the Optionee&#8217;s tax liabilities.&#160; The Optionee shall not make any claim against the Company or its Board of Directors, officers or employees related to tax liabilities arising from this
          option or the Optionee&#8217;s other compensation.&#160; In particular, any Optionee subject to U.S. taxation acknowledges that this option is exempt from Section 409A of the Code only if the Exercise Price is at least equal to the Fair Market Value per
          Share on the Date of Grant.&#160; Since Shares are not traded on an established securities market, the determination of their Fair Market Value is made by the Board of Directors or by an independent valuation firm retained by the Company.&#160; The
          Optionee acknowledges that there is no guarantee in either case that the Internal Revenue Service will agree with the valuation, and the Optionee shall not make any claim against the Company or its Board of Directors, officers or employees in the
          event that the Internal Revenue Service asserts that the valuation was too low. In addition, if this option is designated as an ISO, the Optionee acknowledges that there is no guarantee that the option in fact qualifies for incentive stock option
          treatment or that it will continue to qualify for incentive stock option treatment at the time of exercise.&#160; In this regard, the Optionee acknowledges that the Company may take actions that will cause the option to cease to be eligible for
          incentive stock option treatment and that such actions do not require the Optionee&#8217;s consent.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Electronic Delivery of Documents</font>.&#160; The Optionee acknowledges and agrees that the Company may, in its sole
          discretion, deliver all documents relating to the Company, the Plan or this option and all other documents that the Company is required to deliver to its security holders (including, without limitation, disclosures that may be required by the
          Securities and Exchange Commission) by email or other means of electronic transmission (including by posting them on a website maintained by the Company or a third party under contract with the Company).&#160; The Optionee acknowledges that he or she
          may incur costs in connection with any such delivery by means of electronic transmission, including the cost of accessing the internet and printing fees, and that an interruption of internet access may interfere with his or her ability to access
          the documents.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>No Notice of Expiration Date</font>.&#160; The Optionee agrees that the Company and its officers, employees, attorneys
          and agents do not have any obligation to notify him or her prior to the expiration of this option pursuant to Section 6, regardless of whether this option will expire at the end of its full term or on an earlier date related to the termination of
          the Optionee&#8217;s Service.&#160; The Optionee further agrees that he or she has the sole responsibility for monitoring the expiration of this option and for exercising this option, if at all, before it expires.&#160; This Subsection (c) shall supersede any
          contrary representation that may have been made, orally or in writing, by the Company or by an officer, employee, attorney or agent of the Company.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Waiver of Statutory Information Rights</font>. The Optionee acknowledges and agrees that, upon exercise of this
          option and until the first sale of the Company&#8217;s Stock to the general public pursuant to a registration statement filed under the Securities Act, he or she shall waive, and shall be deemed to have waived, any rights the Optionee would otherwise
          have under Section 220 of the Delaware General Corporation Law (or under similar rights pursuant to any other applicable law) to inspect for any purpose and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders
          and its other books and records or the books and records of any subsidiary of the Company (the &#8220;<font style="font-weight: bold;">Inspection Rights</font>&#8221;).&#160; The Optionee acknowledges and understands that, but for the waiver made herein, the
          Optionee would be entitled, upon compliance with the procedures set forth in Section 220 of the Delaware General Corporation Law, to Inspection Rights pursuant thereto, and further acknowledges and agrees that the waiver set forth herein is a
          knowing and voluntary waiver of such rights, that the Optionee has received sufficient consideration for such waiver and that the Company would not be willing to provide the benefits to the Optionee hereunder without the benefit of such waiver
          from the Optionee.&#160; This waiver applies only in the Optionee&#8217;s capacity as a stockholder and does not affect any other inspection rights the Optionee may have pursuant to any written agreement with the Company.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Plan Discretionary</font>.&#160; The Optionee understands and acknowledges that (i) the Plan is entirely discretionary,
          (ii) the Company and<font style="font-weight: bold;">&#160;</font>the Optionee&#8217;s employer have reserved the right to amend, suspend or terminate the Plan at any time, (iii) the grant of an option does not in any way create any contractual or other
          right to receive additional grants of options (or benefits in lieu of options) at any time or in any amount and (iv) all determinations with respect to any additional grants, including (without limitation) the times when options will be granted,
          the number of Shares offered, the Exercise Price and the vesting schedule, will be at the sole discretion of the Company.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Service</font>.&#160; The Optionee understands and acknowledges that participation in the Plan ceases upon
          termination of his or her Service for any reason, except as may explicitly be provided otherwise in the Plan or this Agreement.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Extraordinary Compensation</font>.&#160; The value of this option shall be an extraordinary item of compensation outside
          the scope of the Optionee&#8217;s employment contract, if any, and shall not be considered a part of his or her normal or expected compensation for purposes of calculating severance, resignation, redundancy or end-of-service payments, bonuses,
          long-service awards, pension or retirement benefits or similar payments.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Authorization to Disclose</font>.&#160; The Optionee hereby authorizes and directs the Optionee&#8217;s employer to disclose to
          the Company or any Subsidiary any information regarding the Optionee&#8217;s employment, the nature and amount of the Optionee&#8217;s compensation and the fact and conditions of the Optionee&#8217;s participation in the Plan, as the Optionee&#8217;s employer deems
          necessary or appropriate to facilitate the administration of the Plan.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Personal Data Authorization</font>.&#160; The Optionee consents to the collection, use and transfer of personal data as
          described in this Subsection (i).&#160; The Optionee understands and acknowledges that the Company, the Optionee&#8217;s employer and the Company&#8217;s other Subsidiaries hold certain personal information regarding the Optionee for the purpose of managing and
          administering the Plan, including (without limitation) the Optionee&#8217;s name, home address, telephone number, date of birth, social insurance number, salary, nationality, job title, any Shares or directorships held in the Company and details of all
          options or any other entitlements to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Optionee&#8217;s favor (the &#8220;<font style="font-weight: bold;">Data</font>&#8221;).&#160; The Optionee further understands and acknowledges that the
          Company and/or its Subsidiaries will transfer Data among themselves as necessary for the purpose of implementation, administration and management of the Optionee&#8217;s participation in the Plan and that the Company and/or any Subsidiary may each
          further transfer Data to any third party assisting the Company in the implementation, administration and management of the Plan.&#160; The Optionee understands and acknowledges that the recipients of Data may be located in the United States or
          elsewhere.&#160; The Optionee authorizes such recipients to receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of administering the Optionee&#8217;s participation in the Plan, including a transfer to any broker or
          other third party with whom the Optionee elects to deposit Shares acquired under the Plan of such Data as may be required for the administration of the Plan and/or the subsequent holding of Shares on the Optionee&#8217;s behalf.&#160; The Optionee may, at
          any time, view the Data, require any necessary modifications of Data or withdraw the consents set forth in this Subsection (i) by contacting the Company in writing.</div>
        <div><br>
        </div>
        <div style="text-align: justify; font-weight: bold;">SECTION 15.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>DEFINITIONS.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Agreement</font>&#8221; shall mean this Stock Option Agreement.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221; shall mean the Board of Directors of the
          Company, as constituted from time to time or, if a Committee has been appointed, such Committee.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Certificate</font>&#8221; shall mean the Company&#8217;s amended and restated
          certificate of incorporation as in effect from time to time.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Company</font>&#8221; shall mean Remix Therapeutics Inc., a Delaware corporation.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Immediate Family</font>&#8221; shall mean any child, stepchild, grandchild,
          parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law and shall include adoptive relationships.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Optionee</font>&#8221; shall mean the person named in the Notice of Stock Option
          Grant.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Plan</font>&#8221; shall mean the Remix Therapeutics Inc. 2019 Stock Plan, as in
          effect on the Date of Grant.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Purchase Price</font>&#8221; shall mean the Exercise Price multiplied by the
          number of Shares with respect to which this option is being exercised.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Requisite Parties</font>&#8221; shall mean both the Board of Directors and the
          Selling Holders.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(j)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Right of First Refusal</font>&#8221; shall mean the Company&#8217;s right of first
          refusal described in Section 7.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(k)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Sale of the Company</font>&#8221; shall mean: (i) a transaction or series of
          related transactions in which a person, or a group of related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a &#8220;<font style="font-weight: bold;">Stock



            Sale</font>&#8221;), (ii) a sale of all or substantially all of the assets of the Company or (iii) any other transaction that qualifies as a &#8220;Liquidation Event&#8221; as defined in the Certificate.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">15</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(l)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Selling Holders</font>&#8221; shall mean the holders of a majority of the
          then-outstanding shares of Common Stock (voting together as a single class and on an as-converted basis).</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(m)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Service</font>&#8221; shall mean service as an Employee, Outside Director or
          Consultant.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(n)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Transferee</font>&#8221; shall mean any person to whom the Optionee has directly
          or indirectly transferred any Share acquired under this Agreement.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(o)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Transfer Notice</font>&#8221; shall mean the notice of a proposed transfer of
          Shares described in Section 7.</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 72pt;">(p)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">U.S. Person</font>&#8221; shall mean a person described in Rule 902(k) of
          Regulation S of the Securities Act (or any successor rule or provision), which generally defines a U.S. person as any natural person resident in the United States, any estate of which any executor or administrator is a U.S. Person, or any trust
          of which of any trustee is a U.S. Person.</div>
        <div><br>
        </div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">16</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
        </div>
        <div>
          <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc. 2019 Stock Plan:</div>
          <font style="text-transform: uppercase;"> </font>
          <div><font style="text-transform: uppercase;"><br>
            </font> </div>
          <font style="text-transform: uppercase;"> </font>
          <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Summary of Stock Grant (for Services)</div>
          <font style="text-transform: uppercase;"> </font>
          <div><br>
          </div>
          <div style="text-align: justify;">The Transferee is acquiring shares of the Common Stock of Remix Therapeutics Inc. (the &#8220;Company&#8221;) on the following terms:</div>
          <div>&#160;
            <div>
              <div><br>
              </div>
              <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

                  <tr>
                    <td style="width: 8%; vertical-align: top;">&#160;</td>
                    <td style="width: 30%; vertical-align: top;">
                      <div>Name of Transferee:</div>
                    </td>
                    <td style="vertical-align: top;">
                      <div>
                        <div style="font-family: 'Times New Roman', Times, serif;">&#171;Name&#187;</div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 8%; vertical-align: top;">&#160;</td>
                    <td colspan="2" style="vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 8%; vertical-align: top;">&#160;</td>
                    <td style="width: 30%; vertical-align: top;">
                      <div>Total Number of Transferred Shares:</div>
                    </td>
                    <td style="vertical-align: top;">
                      <div>
                        <div style="font-family: 'Times New Roman', Times, serif;">&#171;TotalShares&#187;</div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 8%; vertical-align: top;">&#160;</td>
                    <td colspan="2" style="vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 8%; vertical-align: top;">&#160;</td>
                    <td style="width: 30%; vertical-align: top;">
                      <div>Date of Transfer:</div>
                    </td>
                    <td style="vertical-align: top;">
                      <div>
                        <div style="font-family: 'Times New Roman', Times, serif;">&#171;DateTransfer&#187;</div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 8%; vertical-align: top;">&#160;</td>
                    <td colspan="2" style="vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 30%; vertical-align: top;">Vesting Commencement Date:</td>
                    <td rowspan="1" style="vertical-align: top;">
                      <div style="font-family: 'Times New Roman', Times, serif;">&#171;VestComDate&#187;</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
                    <td rowspan="1" style="vertical-align: top;">&#160;</td>
                  </tr>
                  <tr>
                    <td style="width: 8%; vertical-align: top;">&#160;</td>
                    <td style="width: 30%; vertical-align: top;">
                      <div>Vesting Schedule:</div>
                    </td>
                    <td style="vertical-align: top;">
                      <div style="text-align: justify;">
                        <div style="font-family: 'Times New Roman', Times, serif;">
                          <div>&#171;Percent&#187;% of the Transferred Shares shall vest, and the Forfeiture Condition shall lapse with respect to such shares, when the Transferee completes &#171;CliffPeriod&#187; months of continu-ous Service beginning with the Vesting
                            Commencement Date set forth above.&#160; An additional &#171;Fraction&#187;% of the Transferred Shares shall vest, and the Forfeiture Condition shall lapse with respect to such shares, when the Transferee completes each month of continuous
                            Service thereafter.</div>
                        </div>
                      </div>
                    </td>
                  </tr>

              </table>
              <br>
            </div>
          </div>
          <div style="text-align: justify;">By signing below or otherwise accepting this award in a manner acceptable to the Company, the Transferee and the Company agree that the acquisition of the Transferred Shares is governed by the terms and
            conditions of this Summary of Stock Grant, the 2019 Stock Plan and the Stock Grant Agreement.&#160; Both of these latter documents are attached to, and made a part of, this Summary of Stock Grant.&#160; Capitalized terms not otherwise defined herein or
            in the Stock Grant Agreement shall have the meanings set forth in the Plan.</div>
          <div><br>
          </div>
          <div style="text-align: justify;">By signing below, the Transferee consents, with respect to all shares of capital stock of the Company held by the Transferee, to receive any notice given by the Company under its certificate of incorporation or
            bylaws, as the same may be amended and/or restated from time to time, the General Corporation Law of the State of Delaware (the &#8220;<font style="font-weight: bold;">General Corporation Law</font>&#8221;) or otherwise, by electronic transmission pursuant
            to Section 232 of the General Corporation Law at the email address set forth below.&#160; The Transferee further acknowledges and agrees that the Company may rely upon any expressions of the Transferee&#8217;s consent to proposed corporate actions
            received from the email address provided below.&#160; The Transferee hereby agrees to notify the Company of any change to his or her email address set forth below, and further agrees that the provision of such notice shall constitute the
            Transferee&#8217;s consent to receive notice and to provide the Transferee&#8217;s expression of consent as provided herein at such address.&#160; In the event that the Company is unable to deliver notice to the Transferee at the e-mail address set forth below,
            the Transferee shall, within five (5) days after a request by the Company, provide the Company with a valid e-mail address to which the Transferee consents to receive notice and to provide expressions of consent as provided herein.</div>
          &#160;<br>
          <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 44%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-variant: small-caps; font-weight: bold;">
                    <div style="text-align: left; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Transferee:</div>
                  </div>
                </td>
                <td colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
                <td colspan="2" style="vertical-align: top;">
                  <div style="text-align: justify; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 44%; vertical-align: top;">&#160;</td>
                <td colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
                <td style="width: 6%; vertical-align: top;">&#160;</td>
                <td style="width: 44%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">By:</div>
                </td>
                <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 44%; vertical-align: top; padding-bottom: 2px;">
                  <div style="font-family: 'Times New Roman', Times, serif;">Email Address:</div>
                </td>
                <td colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 6%; vertical-align: top; padding-bottom: 2px;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">Title:</div>
                </td>
                <td style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td rowspan="1" colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td rowspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td rowspan="1" style="width: 44%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 44%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman', Times, serif;">Mailing Address:</div>
                </td>
                <td rowspan="1" colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
                <td rowspan="1" style="width: 44%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td rowspan="1" style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td rowspan="1" colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td rowspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td rowspan="1" style="width: 44%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>

          </table>
          <div style="text-align: justify; font-weight: bold;">&#160; </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div><br>
          </div>
          <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics Inc. 2019 Stock Plan:</div>
          <font style="text-transform: uppercase;"> </font>
          <div><font style="text-transform: uppercase;"><br>
            </font> </div>
          <font style="text-transform: uppercase;"> </font>
          <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Stock Grant Agreement (for Services)</div>
          <div><br>
          </div>
          <div style="font-weight: bold;">SECTION 1.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>ACQUISITION OF SHARES.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Transfer</font>.&#160; On the terms and conditions set forth in the Summary of Stock Grant, this Agreement and the
            Plan, the Company agrees to transfer to the Transferee the number of Shares set forth in the Summary of Stock Grant.&#160; The transfer shall occur at the offices of the Company on the date of transfer set forth in the Summary of Stock Grant or at
            such other place and time as the parties may agree.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Consideration</font>.<font style="font-weight: bold;">&#160; </font>The Transferee and the Company agree that the
            Transferred Shares are being issued to the Transferee as consideration for a portion of the services performed by the Transferee for the Company.&#160; The value of such portion is agreed to be not less than 100% of the Fair Market Value of the
            Transferred Shares.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Stock Plan and Defined Terms</font>.&#160; The transfer of the Transferred Shares is subject to the Plan, a copy of
            which the Transferee acknowledges having received.&#160; The provisions of the Plan are incorporated into this Agreement by this reference.&#160; Except as otherwise defined in this Agreement (including without limitation Section 12 hereof), capitalized
            terms shall have the meaning ascribed to such terms in the Plan.</div>
          <div><br>
          </div>
          <div style="font-weight: bold;">SECTION 2.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>FORFEITURE CONDITION.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Scope of Forfeiture Condition</font>.&#160; Until they vest in accordance with Subsection (b) below, the Transferred
            Shares shall be subject to forfeiture to the Company and shall be referred to as &#8220;<font style="font-weight: bold;">Restricted Shares</font>.&#8221;&#160; The Transferee shall not transfer, assign, encumber or otherwise dispose of any Restricted Shares
            without the Company&#8217;s written consent, except as provided in the following sentence.&#160; The Transferee may transfer Restricted Shares to one or more members of the Transferee&#8217;s Immediate Family or to a trust or other entity established by the
            Transferee solely for the benefit of the Transferee and/or one or more members of the Transferee&#8217;s Immediate Family, provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions
            of this Agreement.&#160; If the Transferee transfers any Restricted Shares, then this Agreement shall apply to the Subsequent Transferee to the same extent as to the Transferee.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Vesting</font>.&#160; The Transferred Shares shall vest, and the Forfeiture Condition shall lapse with respect to the
            Transferred Shares, in accordance with the vesting schedule set forth in the Summary of Stock Grant.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Execution of Forfeiture</font>.&#160; The Forfeiture Condition shall be applicable only if the Transferee&#8217;s Service
            terminates for any reason, with or without cause, including (without limitation) death or disability, before all Transferred Shares have become vested.&#160; In the event that the Transferee&#8217;s Service terminates for any reason, any certificate(s)
            representing any remaining Restricted Shares shall be delivered to the Company.&#160; If the Restricted Shares are not represented by certificate, the forfeiture shall be effected by an appropriate book entry on the stock ledger for the Shares.&#160; The
            Company shall make no payment for Transferred Shares that are forfeited.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <!--PROfilePageNumberReset%Num%2%%%-->
          <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Additional or Exchanged Securities and Property</font>.&#160; In the event of a merger or consolidation of the Company,
            a sale of all or substantially all of the Company&#8217;s stock or assets, any other corporate reorganization, the declaration of a stock dividend, the declaration of an extraordinary dividend payable in a form other than stock, a spin&#8209;off, a stock
            split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities, any securities or other property (including cash or cash equivalents) that are by reason of such transaction
            exchanged for, or distributed with respect to, any Restricted Shares or into which such Restricted Shares thereby become convertible shall immediately be subject to the Forfeiture Condition.&#160; Appropriate adjustments to reflect the exchange or
            distribution of such securities or property shall be made to the number and/or class of the Restricted Shares.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Rights as Stockholder</font>.&#160; If Transferred Shares are forfeited in accordance with this Section
            2, then the person who is to forfeit such Transferred Shares shall no longer have any rights as a holder of such Transferred Shares.&#160; Such Transferred Shares shall be deemed to have been forfeited in accordance with the applicable provisions
            hereof, whether or not any certificate(s) therefor have been delivered as required by this Agreement.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Escrow</font>.&#160; Upon issuance, any certificates for Restricted Shares shall be deposited in escrow with the
            Company to be held in accordance with the provisions of this Agreement.&#160; Any new, substituted or additional securities or other property described in Subsection (d) above shall immediately be delivered to the Company to be held in escrow, but
            only to the extent the Transferred Shares are at the time Restricted Shares.&#160; All regular cash dividends on Restricted Shares (or other securities at the time held in escrow) shall be paid directly to the Transferee and shall not be held in
            escrow.&#160; Restricted Shares, together with any other assets or securities held in escrow hereunder, shall be (i) surrendered to the Company for forfeiture and cancellation in the event that the Forfeiture Condition or Right of First Refusal
            applies or (ii) released to the Transferee upon the Transferee&#8217;s request to the extent the Transferred Shares are no longer Restricted Shares (but not more frequently than once every six months).&#160; In any event, all Transferred Shares that have
            vested (and any other vested assets and securities attributable thereto) shall be released within 60 days after the earlier of (i) the termination of the Transferee&#8217;s Service or (ii) the lapse of the Right of First Refusal.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Part-Time Employment and Leaves of Absence</font>.&#160; If the Transferee commences working on a part-time basis, then
            the Company may adjust the vesting schedule set forth in the Summary of Stock Grant.&#160; If the Transferee goes on a leave of absence, then, to the extent permitted by applicable law, the Company may adjust or suspend the vesting schedule set
            forth in the Summary of Stock Grant.&#160; Except as provided in the preceding sentence, Service shall be deemed to continue while the Transferee is on a <font style="font-style: italic;">bona fide</font> leave of absence approved by the Company in
            writing.&#160; Service shall be deemed to terminate when such leave ends, unless the Transferee immediately returns to active work when such leave ends.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">2</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="font-weight: bold;">SECTION 3.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>RIGHT OF FIRST REFUSAL.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Right of First Refusal</font>.&#160; In the event that the Transferee proposes to sell, pledge or otherwise transfer to
            a third party any Transferred Shares, or any interest in Transferred Shares, the Company shall have the Right of First Refusal with respect to all (and not less than all) of such Transferred Shares.&#160; If the Transferee desires to transfer
            Transferred Shares, the Transferee shall give a written Transfer Notice to the Company describing fully the proposed transfer, including the number of Transferred Shares proposed to be transferred, the proposed transfer price, the name and
            address of the proposed Subsequent Transferee and proof satisfactory to the Company that the proposed sale or transfer will not violate any applicable federal, State or foreign securities laws.&#160; The Transfer Notice shall be signed both by the
            Transferee and by the proposed Subsequent Transferee and must constitute a binding commitment of both parties to the transfer of the Transferred Shares.&#160; The Company shall have the right to purchase all, and not less than all, of the
            Transferred Shares on the terms of the proposal described in the Transfer Notice (subject, however, to any change in such terms permitted under Subsection (b) below) by delivery of a notice of exercise of the Right of First Refusal within 30
            days after the date when the Transfer Notice was received by the Company.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Transfer of Shares</font>.&#160; If the Company fails to exercise its Right of First Refusal within 30 days after
            receiving the Transfer Notice, the Transferee may, not later than 90 days after the Company received the Transfer Notice, conclude a transfer of the Transferred Shares subject to the Transfer Notice on the terms and conditions no less favorable
            to the Transferee than those described in the Transfer Notice, provided that any such sale is made in compliance with applicable federal, State and foreign securities laws and not in violation of any other contractual restrictions to which the
            Transferee is bound.&#160; Any proposed transfer on terms and conditions less favorable than those described in the Transfer Notice, as well as any subsequent proposed transfer by the Transferee, shall again be subject to the Right of First Refusal
            and shall require compliance with the procedure described in Subsection (a) above.&#160; If the Company exercises its Right of First Refusal, the parties shall consummate the sale of the Transferred Shares on the terms set forth in the Transfer
            Notice within 60 days after the Company received the Transfer Notice (or within such longer period as may have been specified in the Transfer Notice); provided, however, that in the event the Transfer Notice provided that payment for the
            Transferred Shares was to be made in a form other than cash or cash equivalents paid at the time of transfer, the Company shall have the option of paying for the Transferred Shares with cash or cash equivalents equal to the present value of the
            consideration described in the Transfer Notice.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Additional or Exchanged Securities and Property</font>.&#160; In the event of a merger or consolidation of the Company,
            a sale of all or substantially all of the Company&#8217;s stock or assets, any other corporate reorganization, a stock split, the declaration of a stock dividend, the declaration of an extraordinary dividend payable in a form other than stock, a
            spin&#8209;off, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities, any securities or other property (including cash or cash equivalents) that are by reason of such
            transaction exchanged for, or distributed with respect to, any Transferred Shares subject to this Section 3 shall immediately be subject to the Right of First Refusal.&#160; Appropriate adjustments to reflect the exchange or distribution of such
            securities or property shall be made to the number and/or class of the Transferred Shares subject to this Section 3.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">3</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Right of First Refusal</font>.&#160; Any other provision of this Section 3 notwithstanding, in the event
            that the Stock is readily tradable on an established securities market when the Transferee desires to transfer Transferred Shares, the Company shall have no Right of First Refusal, and the Transferee shall have no obligation to comply with the
            procedures prescribed by Subsections (a) and (b) above.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Permitted Transfers</font>.&#160; This Section 3 shall not apply to (i) a transfer by beneficiary designation, will or
            intestate succession or (ii) a transfer to one or more members of the Transferee&#8217;s Immediate Family or to a trust or other entity established by the Transferee solely for the benefit of the Transferee and/or one or more members of the
            Transferee&#8217;s Immediate Family, provided in either case that the Transferee agrees in writing on a form prescribed by the Company to be bound by all provisions of this Agreement.&#160; If the Transferee transfers any Transferred Shares, either under
            this Subsection (e) or after the Company has failed to exercise the Right of First Refusal, then this Agreement shall apply to the Subsequent Transferee to the same extent as to the Transferee.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Rights as Stockholder</font>.&#160; If the Company makes available, at the time and place and in the
            amount and form provided in this Agreement, the consideration for the Shares to be purchased in accordance with this Section 3, then after such time the person from whom such Shares are to be purchased shall no longer have any rights as a
            holder of such Shares (other than the right to receive payment of such consideration in accordance with this Agreement).&#160; Such Shares shall be deemed to have been purchased in accordance with the applicable provisions hereof, whether or not any
            certificate(s) therefor have been delivered as required by this Agreement.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Assignment of Right of First Refusal</font>.&#160; The Board of Directors may freely assign the Company&#8217;s Right of
            First Refusal, in whole or in part.&#160; Any person who accepts an assignment of the Right of First Refusal from the Company shall be entitled to and assume all of the Company&#8217;s rights and obligations under this Section 3.</div>
          <div><br>
          </div>
          <div style="font-weight: bold;">SECTION 4.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>OTHER RESTRICTIONS ON TRANSFER.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Transferee Representations</font>.&#160; In connection with the issuance and acquisition of Shares under this
            Agreement, the Transferee hereby represents and warrants to the Company as follows:</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The Transferee is acquiring and will hold the Transferred Shares for investment for his
            or her account only and not with a view to, or for resale in connection with, any &#8220;distribution&#8221; thereof within the meaning of the Securities Act.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The Transferee understands that the Transferred Shares have not been registered under
            the Securities Act by reason of a specific exemption therefrom and that the Transferred Shares must be held indefinitely, unless their sale or other transfer is subsequently registered under the Securities Act or the Transferee obtains an
            opinion of counsel, in form and substance satisfactory to the Company and its counsel, that such registration is not required.&#160; The Transferee further acknowledges and understands that the Company is under no obligation to register the
            Transferred Shares.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">4</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The Transferee is aware of Rule 144 under the Securities Act, which permits limited
            public resales of securities acquired in a non-public offering, subject to the satisfaction of certain conditions.&#160; These conditions may include (without limitation) that certain current public information about the issuer be available, that
            the resale occur only after a holding period required by Rule 144 has been satisfied, that the sale occur through an unsolicited &#8220;broker&#8217;s transaction,&#8221; and that the amount of securities being sold during any three&#8209;month period not exceed
            specified limitations.&#160; The Transferee acknowledges and understands that the conditions for resale set forth in Rule 144 have not been satisfied as of the Date of Transfer and that the Company is not required to take action to satisfy any such
            conditions.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iv)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The Transferee will not sell, transfer or otherwise dispose of the Transferred Shares
            in violation of the Securities Act, the Securities Exchange Act of 1934, or the rules promulgated thereunder, including Rule 144 under the Securities Act.&#160; The Transferee agrees that he or she will not dispose of the Transferred Shares unless
            and until he or she has complied with all requirements of this Agreement applicable to the disposition of Transferred Shares and he or she has provided the Company with written assurances, in substance and form satisfactory to the Company, that
            (A) the proposed disposition does not require registration of the Transferred Shares under the Securities Act or all appropriate action necessary for compliance with the registration requirements of the Securities Act or with any exemption from
            registration available under the Securities Act (including Rule 144) has been taken and (B) the proposed disposition will not result in the contravention of any transfer restrictions applicable to the Transferred Shares under applicable state
            law.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(v)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The Transferee has received and has had access to such information as he or she
            considers necessary or appropriate for deciding whether to invest in the Transferred Shares, and the Transferee has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the issuance of
            the Transferred Shares.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(vi)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>The Transferee is aware that his or her investment in the Company is a speculative
            investment that has limited liquidity and is subject to the risk of complete loss.&#160; The Transferee is able, without impairing his or her financial condition, to hold the Transferred Shares for an indefinite period and to suffer a complete loss
            of his or her investment in the Transferred Shares.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>General Restrictions</font>.&#160; Unless the Stock is readily tradeable on an established securities market, the
            transfer of any Shares acquired pursuant to this Agreement (or any interest therein) shall, at the Company&#8217;s request, be conditioned upon (i) effecting such transfer pursuant to a form of stock transfer agreement prescribed by the Company and
            (ii) payment of a transfer fee not to exceed $5,000.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">5</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Securities Law Restrictions</font>.&#160; Regardless of whether the offer and sale of Shares under the Plan have been
            registered under the Securities Act or have been registered or qualified under the securities laws of any State or other relevant jurisdiction, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer of the
            Transferred Shares (including the placement of appropriate legends on the stock certificates (or electronic equivalent) or the imposition of stop&#8209;transfer instructions) and may refuse (or may be required to refuse) to transfer Shares acquired
            hereunder (or Shares proposed to be transferred in a subsequent transfer) if, in the judgment of the Company, such restrictions, legends or refusal are necessary or appropriate to achieve compliance with the Securities Act or other relevant
            securities or other laws, including without limitation under Regulation S of the Securities Act or pursuant to another available exemption from registration.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Market Stand-Off</font>.&#160; In connection with any underwritten public offering by the Company of its equity
            securities pursuant to an effective registration statement filed under the Securities Act, including the Company&#8217;s initial public offering, the Transferee or a Subsequent Transferee shall not directly or indirectly sell, make any short sale of,
            loan, hypothecate, pledge, offer, grant or sell any option or other contract for the purchase of, purchase any option or other contract for the sale of, or otherwise dispose of or transfer, or agree to engage in any of the foregoing
            transactions with respect to, any Transferred Shares without the prior written consent of the Company or its managing underwriter.&#160; Such restriction (the &#8220;Market Stand-Off&#8221;) shall be in effect for such period of time following the date of the
            final prospectus for the offering as may be requested by the Company or such underwriter.&#160; In no event, however, shall such period exceed 180 days plus such additional period as may reasonably be requested by the Company or such underwriter to
            accommodate regulatory restrictions on (i) the publication or other distribution of research reports or (ii) analyst recommendations and opinions, including (without limitation) the restrictions set forth in Rule 2711(f)(4) of the National
            Association of Securities Dealers and Rule 472(f)(4) of the New York Stock Exchange, as amended, or any similar successor rules.&#160; The Market Stand-Off shall in any event terminate two years after the date of the Company&#8217;s initial public
            offering.&#160; In the event of the declaration of a stock dividend, a spin&#8209;off, a stock split, an adjustment in conversion ratio, a recapitalization or a similar transaction affecting the Company&#8217;s outstanding securities without receipt of
            consideration, any new, substituted or additional securities which are by reason of such transaction distributed with respect to any Shares subject to the Market Stand-Off, or into which such Shares thereby become convertible, shall immediately
            be subject to the Market Stand-Off.&#160; In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the Transferred Shares until the end of the applicable stand-off period.&#160; The Company&#8217;s
            underwriters shall be beneficiaries of the agreement set forth in this Subsection (d).&#160; This Subsection (d) shall not apply to Shares registered in the public offering under the Securities Act.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Rights of the Company</font>.&#160; The Company shall not be required to (i) transfer on its books any Transferred
            Shares that have been sold or transferred in contravention of this Agreement or (ii) treat as the owner of Transferred Shares, or otherwise to accord voting, dividend or liquidation rights to, any Subsequent Transferee to whom Transferred
            Shares have been transferred in contravention of this Agreement.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">6</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="font-weight: bold;">SECTION 5.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>SUCCESSORS AND ASSIGNS.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">Except as otherwise expressly provided to the contrary, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and be
            binding upon the Transferee and the Transferee&#8217;s legal representatives, heirs, legatees, distributees, assigns and transferees by operation of law, whether or not any such person has become a party to this Agreement or has agreed in writing to
            join herein and to be bound by the terms, conditions and restrictions hereof.</div>
          <div><br>
          </div>
          <div style="font-weight: bold;">SECTION 6.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>NO RETENTION RIGHTS.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">Nothing in this Agreement or in the Plan shall confer upon the Transferee any right to continue providing services to the Company for any period of specific duration or interfere with or
            otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining the Transferee) or of the Transferee, which rights are hereby expressly reserved by each, to terminate his or her Service at any time
            and for any reason, with or without cause.</div>
          <div><br>
          </div>
          <div style="font-weight: bold;">SECTION 7.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>TAX ELECTION.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">The acquisition of the Transferred Shares may result in adverse tax consequences that may be avoided or mitigated by filing an election under Code Section 83(b).&#160; Such election may be filed
            only within 30 days after the date of transfer set forth in the Summary of Stock Grant.&#160; The form for making the Code Section 83(b) election is attached to this Agreement as an Exhibit.&#160; <font style="font-weight: bold;">The Transferee should
              consult with his or her tax advisor to determine the tax consequences of acquiring the Transferred Shares and the advantages and disadvantages of filing the Code Section 83(b) election.&#160; The Transferee acknowledges that it is his or her sole
              responsibility, and not the Company&#8217;s, to file a timely election under Code Section 83(b), even if the Transferee requests the Company or its representatives to make this filing on his or her behalf.</font></div>
          <div><br>
          </div>
          <div style="font-weight: bold;">SECTION 8.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>LEGENDS.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">Any certificates (or electronic equivalent) evidencing Transferred Shares shall bear the following legends:</div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt;">&#8220;THE SHARES REPRESENTED HEREBY (AND ANY INTEREST THEREIN) MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF, EXCEPT IN COMPLIANCE WITH THE TERMS OF THE STOCK GRANT
            AGREEMENT PURSUANT TO WHICH SUCH SHARES WERE ACQUIRED.&#160; SUCH AGREEMENT GRANTS TO THE COMPANY CERTAIN RIGHTS OF FIRST REFUSAL UPON AN ATTEMPTED TRANSFER OF THE SHARES AND IMPOSES CERTAIN FORFEITURE CONDITIONS UPON TERMINATION OF SERVICE WITH THE
            COMPANY.&#160; IN ADDITION, THE SHARES ARE SUBJECT TO RESTRICTIONS ON TRANSFER AS SET FORTH IN SUCH STOCK GRANT AGREEMENT.&#160; THE SECRETARY OF THE COMPANY WILL UPON WRITTEN REQUEST FURNISH A COPY OF SUCH STOCK GRANT AGREEMENT TO THE HOLDER HEREOF
            WITHOUT CHARGE.&#8221;</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">7</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify;">Any certificates (or electronic equivalent) evidencing the Transferred Shares acquired under this Agreement in an unregistered transaction shall bear the following legend (and such other restrictive legends as
            are required or deemed advisable under the provisions of any applicable law):</div>
          <div><br>
          </div>
          <div style="text-align: justify; margin-left: 36pt;">&#8220;THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;ACT&#8221;) OR ANY SECURITIES LAWS OF ANY U.S. STATE, AND MAY NOT BE SOLD, REOFFERED,
            PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.&#160; IN THE
            ABSENCE OF REGISTRATION OR THE AVAILABILITY (CONFIRMED BY OPINION OF COUNSEL) OF AN ALTERNATIVE EXEMPTION FROM REGISTRATION UNDER THE ACT (INCLUDING WITHOUT LIMITATION IN ACCORDANCE WITH REGULATION S UNDER THE ACT), THESE SHARES MAY NOT BE
            SOLD, REOFFERED, PLEDGED, ASSIGNED, ENCUMBERED OR OTHERWISE TRANSFERRED OR DISPOSED OF.&#160; HEDGING TRANSACTIONS INVOLVING THESE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE ACT.&#8221;</div>
          <div><br>
          </div>
          <div style="text-align: justify;">If required by the authorities of any State in connection with the issuance of the Transferred Shares, the legend or legends required by such State authorities shall also be endorsed on all such certificates.</div>
          <div><br>
          </div>
          <div><font style="font-weight: bold;">SECTION 9.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>DRAG ALONG RIGHT</font>.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Required Actions</font>.&#160; If the Requisite Parties approve a Sale of the Company, then Transferee hereby agrees
            with respect to all Shares which the Transferee own(s) or over which the Transferee otherwise exercises voting or dispositive authority:</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if such Sale of the Company requires stockholder approval under the Certificate, the
            Bylaws of the Company or any law, rule or regulation applicable to the Company, to vote (in person, by proxy or by action by written consent, as applicable) such Shares in favor of such Sale of the Company (it being understood that, within five
            (5) days after the delivery of a proxy or consent solicitation statement (or similar document requesting the consent or approval of stockholders) in respect of any Sale of the Company, the Stockholder shall duly execute and deliver a proxy or
            consent, as the case may be, in favor of such Sale of the Company);</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">8</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(ii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if such transaction is a Stock Sale, to sell the same proportion of shares of capital
            stock of the Company beneficially held by the Transferee as is being sold by the Selling Holders to the person to whom the Selling Holders propose to sell their Shares;</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to refrain from exercising any dissenters&#8217; rights or rights of appraisal under
            applicable law at any time with respect to such Sale of the Company;</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(iv)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if the consideration for such Shares pursuant to the Sale of the Company includes any
            securities, accept in lieu thereof an amount of cash equal to the fair value (as determined in good faith by the Company) of such securities to the extent reasonably necessary (as determined in good faith by the Company) to comply with
            applicable federal and state securities laws;</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(v)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>if the Selling Holders appoint a stockholder representative (the &#8220;<font style="font-weight: bold;">Stockholder Representative</font>&#8221;) for matters affecting the stockholders of the Company under the applicable definitive transaction agreements, to consent to (i) the appointment of such Stockholder Representative,
            (ii) the establishment of any applicable escrow, expense or similar fund in connection with any indemnification or similar obligations, and (iii) the payment of such Stockholder&#8217;s pro rata portion (from the applicable escrow or expense fund or
            otherwise) of any and all reasonable fees and expenses to such Stockholder Representative in connection with such Stockholder Representative&#8217;s services and duties in connection with such Sale of the Company and its related service as the
            representative of the Stockholders;</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(vi)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to agree to make representations and warranties and to agree to indemnity and other
            liability obligations in connection with the Sale of the Company on terms and conditions that, taken as a whole, are no less favorable to Transferee than to other holders of Common Stock of the Company; and</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(vii)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>to execute and deliver all related documentation and take such other action in support
            of the Sale of the Company, as reasonably requested by the Company, including a written consent, release and/or joinder, and to not take any action inconsistent with the Sale of the Company.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Exceptions</font>.&#160; Notwithstanding the foregoing, a Transferee will not be required to comply with Subsection (a)
            above in connection with any Sale of the Company unless (i) each holder of each class or series of the Company&#8217;s stock will receive the same form of consideration for their shares of such class or series as is received by other holders in
            respect of their shares of such same class or series of stock and (ii) each holder of Common Stock will receive the same amount of consideration per share of Common Stock as is received by other holders in respect of their shares of Common
            Stock, subject, in each case, to any &#8220;rollover&#8221; or similar arrangements provided in the definitive documents relating to such Sale of the Company.&#160; If the consideration to be paid in exchange for the Shares pursuant to such Sale of the Company
            includes any securities and due receipt thereof by the Transferee would require under applicable law (x) the registration or qualification of such securities or of any person as a broker or dealer or agent with respect to such securities; or
            (y) the provision to any Transferee of any information other than such information as a prudent issuer would generally furnish in an offering made solely to &#8220;accredited investors&#8221; as defined in Regulation D promulgated under the Securities Act,
            the Company may cause to be paid to any such Transferee in lieu thereof, against surrender of the Shares which would have otherwise been sold by such Transferee, an amount in cash equal to the fair value (as determined in good faith by the
            Company&#8217;s Board of Directors or the Requisite Parties, as applicable) of the securities which such Transferee would otherwise receive as of the date of the issuance of such securities in exchange for the Shares.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">9</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="font-weight: bold;">SECTION 10.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>MISCELLANEOUS PROVISIONS.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Choice of Law</font>. This Agreement shall be governed by, and construed in accordance with, the laws of the State
            of Delaware (except its choice-of-law provisions), as such laws are applied to contracts entered into and performed in such State.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Notice.&#160; </font>Any notice required by the terms of this Agreement shall be given in writing.&#160; It shall be deemed
            effective upon (i) personal delivery, (ii) deposit with the United States Postal Service, by registered or certified mail, with postage and fees prepaid, (iii) deposit with Federal Express Corporation, with shipping charges prepaid or (iv)
            deposit with any internationally recognized express mail courier service, with shipping charges prepaid.&#160; Notice shall be addressed to the Company at its principal executive office and to the Transferee at the address that he or she most
            recently provided to the Company in accordance with this Subsection (b).&#160; In addition, to the extent required or permitted pursuant to rules established by the Company from time to time, notices may be delivered electronically.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Entire Agreement</font>.&#160; The Summary of Stock Grant, this Agreement and the Plan constitute the entire contract
            between the parties hereto with regard to the subject matter hereof.&#160; They supersede any other agreements, representations or understandings (whether oral or written and whether express or implied) that relate to the subject matter hereof.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Modifications and Waivers</font>.&#160; No provision of this Agreement shall be modified, waived or discharged unless
            the modification, waiver or discharge is agreed to in writing and signed by the Transferee and an authorized officer of the Company (other than the Transferee).&#160; No waiver by either party of any breach of, or of compliance with, any condition
            or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision of or of the same condition or provision at another time.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Severability</font>.&#160; Whenever possible, each provision of this Agreement shall be interpreted in such manner as
            to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity,
            without invalidating the remainder of such provision or the remaining provisions of this Agreement.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">10</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Binding Effect on Transferees, Heirs, Successors and Assigns</font>.&#160; This Agreement shall be binding upon
            Transferee&#8217;s permitted transferees, heirs, successors and assigns; provided that for any such transfer to be deemed effective, the transferee shall agree on a form prescribed by the Company to be bound by the terms and conditions of this
            Agreement, including the forfeiture condition in Section 2, the right of first refusal in Section 3, the restrictions on transfer in Section 4 and the drag along right in Section 9.&#160; The Company shall not record any transfer of Shares on its
            books or issue a new certificate representing any such Shares unless and until such transferee shall have complied with the terms of this Subsection (f).</div>
          <div><br>
          </div>
          <div style="text-align: justify; font-weight: bold;">SECTION 11.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>ACKNOWLEDGEMENTS OF THE TRANSFEREE.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">In addition to the other terms, conditions and restrictions imposed on the Shares acquired pursuant to this Agreement, the Transferee expressly acknowledges being subject to Sections 2
            (Forfeiture Condition), 3 (Right of First Refusal), 4 (Other Restrictions on Transfer, including without limitation the Market Stand-Off) and 9 (Drag Along Right), as well as the following provisions:</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Electronic Delivery of Documents</font>.&#160; The Transferee acknowledges and agrees that the Company may, in its sole
            discretion, deliver all documents relating to the Company, the Plan or this award and all other documents that the Company is required to deliver to its security holders (including, without limitation, disclosures that may be required by the
            Securities and Exchange Commission) by email or other means of electronic transmission (including by posting them on a website maintained by the Company or a third party under contract with the Company).&#160; The Transferee acknowledges that he or
            she may incur costs in connection with any such delivery by means of electronic transmission, including the cost of accessing the internet and printing fees, and that an interruption of internet access may interfere with his or her ability to
            access the documents.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Tax Consequences and Withholding</font>.&#160; The Transferee agrees that the Company does not have a duty to design or
            administer the Plan or its other compensation programs in a manner that minimizes the Transferee&#8217;s tax liabilities.&#160; The Transferee shall not make any claim against the Company or its Board of Directors, officers or employees related to tax
            liabilities arising from this award or the Transferee&#8217;s other compensation.&#160; In the event that the Company determines that it is required to withhold any tax (including without limitation any income tax, social insurance contributions, payroll
            tax, payment on account or other tax-related items arising in connection with the Transferee&#8217;s participation in the Plan and legally applicable to the Transferee (the &#8220;<font style="font-weight: bold;">Tax-Related Items</font>&#8221;)) as a result of
            the grant or vesting of the Transferred Shares, the Transferee, as a condition of this award, shall make arrangements satisfactory to the Company to enable it to satisfy all Tax-Related Items.&#160; The Transferee acknowledges that the
            responsibility for all Tax-Related Items is the Transferee&#8217;s and may exceed the amount actually withheld by the Company (or its affiliate or agent).</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Waiver of Statutory Information Rights</font>. The Transferee acknowledges and agrees that, until the first sale
            of the Company&#8217;s Stock to the general public pursuant to a registration statement filed under the Securities Act, he or she shall waive, and shall be deemed to have waived, any rights the Transferee would otherwise have under Section 220 of the
            Delaware General Corporation Law (or under similar rights pursuant to any other applicable law) to inspect for any purpose and to make copies and extracts from the Company&#8217;s stock ledger, a list of its stockholders and its other books and
            records or the books and records of any subsidiary of the Company (the &#8220;<font style="font-weight: bold;">Inspection Rights</font>&#8221;).&#160; The Transferee acknowledges and understands that, but for the waiver made herein, the Transferee would be
            entitled, upon compliance with the procedures set forth in Section 220 of the Delaware General Corporation Law, to Inspection Rights pursuant thereto, and further acknowledges and agrees that the waiver set forth herein is a knowing and
            voluntary waiver of such rights, that the Transferee has received sufficient consideration for such waiver and that the Company would not be willing to provide the benefits to the Transferee hereunder without the benefit of such waiver from the
            Transferee.&#160; This waiver applies only in the Transferee&#8217;s capacity as a stockholder and does not affect any other inspection rights the Transferee may have pursuant to any written agreement with the Company.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">11</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Plan Discretionary</font>.&#160; The Transferee understands and acknowledges that (i) the Plan is entirely
            discretionary, (ii) the Company and<font style="font-weight: bold;">&#160;</font>the Transferee&#8217;s employer have reserved the right to amend, suspend or terminate the Plan at any time, (iii) the transfer of the Transferred Shares does not in any way
            create any contractual or other right to receive additional awards under the Plan at any time or in any amount and (iv) all determinations with respect to any additional awards, including (without limitation) the times when awards will be
            granted, the number of Shares offered and the vesting schedule, will be at the sole discretion of the Company.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Termination of Service</font>.&#160; The Transferee understands and acknowledges that participation in the Plan ceases
            upon termination of his or her Service for any reason, except as may explicitly be provided otherwise in the Plan or this Agreement.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Extraordinary Compensation</font>.&#160; The value of the Transferred Shares shall be an extraordinary item of
            compensation outside the scope of the Transferee&#8217;s employment contract, if any, and shall not be considered a part of his or her normal or expected compensation for purposes of calculating severance, resignation, redundancy or end-of-service
            payments, bonuses, long-service awards, pension or retirement benefits or similar payments.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Authorization to Disclose</font>.&#160; The Transferee hereby authorizes and directs the Transferee&#8217;s employer to
            disclose to the Company or any Subsidiary any information regarding the Transferee&#8217;s employment, the nature and amount of the Transferee&#8217;s compensation and the fact and conditions of the Transferee&#8217;s participation in the Plan, as the
            Transferee&#8217;s employer deems necessary or appropriate to facilitate the administration of the Plan.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font>Personal Data Authorization</font>.&#160; The Transferee consents to the collection, use and transfer of personal data
            as described in this Subsection (h).&#160; The Transferee understands and acknowledges that the Company, the Transferee&#8217;s employer and the Company&#8217;s other Subsidiaries hold certain personal information regarding the Transferee for the purpose of
            managing and administering the Plan, including (without limitation) the Transferee&#8217;s name, home address, telephone number, date of birth, social insurance number, salary, nationality, job title, any Shares or directorships held in the Company
            and details of all options or any other entitlements to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Transferee&#8217;s favor (the &#8220;<font style="font-weight: bold;">Data</font>&#8221;).&#160; The Transferee further understands and
            acknowledges that the Company and/or its Subsidiaries will transfer Data among themselves as necessary for the purpose of implementation, administration and management of the Transferee&#8217;s participation in the Plan and that the Company and/or
            any Subsidiary may each further transfer Data to any third party assisting the Company in the implementation, administration and management of the Plan.&#160; The Transferee understands and acknowledges that the recipients of Data may be located in
            the United States or elsewhere.&#160; The Transferee authorizes such recipients to receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of administering the Transferee&#8217;s participation in the Plan, including a
            transfer to any broker or other third party with whom the Transferee elects to deposit Shares acquired under the Plan of such Data as may be required for the administration of the Plan and/or the subsequent holding of Shares on the Transferee&#8217;s
            behalf.&#160; The Transferee may, at any time, view the Data, require any necessary modifications of Data or withdraw the consents set forth in this Subsection (h) by contacting the Company in writing.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">12</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="font-weight: bold;">SECTION 12.<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>DEFINITIONS.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(a)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Agreement</font>&#8221; shall mean this Stock Grant Agreement.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(b)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Board of Directors</font>&#8221; shall mean the Board of Directors of the
            Company, as constituted from time to time or, if a Committee has been appointed, such Committee.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(c)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Certificate</font>&#8221; shall mean the Company&#8217;s amended and restated
            certificate of incorporation, as in effect from time to time.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(d)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Company</font>&#8221; shall mean Remix Therapeutics Inc., a Delaware
            corporation.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(e)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Forfeiture Condition</font>&#8221; shall mean the forfeiture condition
            described in Section 2.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(f)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Immediate Family</font>&#8221; shall mean any child, stepchild, grandchild,
            parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law and shall include adoptive relationships.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(g)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Plan</font>&#8221; shall mean the Remix Therapeutics Inc. 2019 Stock Plan, as
            amended.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(h)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Requisite Parties</font>&#8221; shall mean both the Board of Directors and the
            Selling Holders.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(i)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Restricted Share</font>&#8221; shall mean a Transferred Share that is subject
            to the Forfeiture Condition.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(j)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Right of First Refusal</font>&#8221; shall mean the Company&#8217;s right of first
            refusal described in Section 3.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(k)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Sale of the Company</font>&#8221; shall mean: (i) a transaction or series of
            related transactions in which a person, or a group of related persons, acquires from stockholders of the Company shares representing more than fifty percent (50%) of the outstanding voting power of the Company (a &#8220;<font style="font-weight: bold;">Stock Sale</font>&#8221;), (ii) a sale of all or substantially all of the assets of the Company or (iii) any other transaction that qualifies as a &#8220;Liquidation Event&#8221; as defined in the Certificate.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">13</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(l)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Selling Holders</font>&#8221; shall mean the holders of a majority of the
            then-outstanding shares of Common Stock (voting together as a single class and on an as-converted basis).</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(m)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Service</font>&#8221; shall mean service as an Employee, Outside Director or
            Consultant.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(n)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Subsequent Transferee</font>&#8221; shall mean any person to whom the
            Transferee has directly or indirectly transferred any Transferred Shares.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(o)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Transferee</font>&#8221; shall mean the individual named in the Summary of
            Stock Grant.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(p)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Transfer Notice</font>&#8221; shall mean the notice of a proposed transfer of
            Transferred Shares described in Section 3.</div>
          <div><br>
          </div>
          <div style="text-align: justify; text-indent: 72pt;">(q)<font style="font-weight: bold;"><font style="font-weight: normal;">&#8195;</font></font>&#8220;<font style="font-weight: bold;">Transferred Shares</font>&#8221; shall mean the Shares acquired by the
            Transferee pursuant to this Agreement.</div>
          <div><br>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
          </div>
          <div style="text-align: right; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Exhibit I</div>
          <div><br>
          </div>
          <div style="text-align: center; font-weight: bold;"><font style="font-variant: small-caps; text-transform: uppercase;">Section 83</font><font style="text-transform: uppercase;">(<font style="text-transform: lowercase;">b</font>)<font style="font-variant: small-caps;"> Election</font></font></div>
          <div><br>
          </div>
          <div style="text-align: justify;">The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, and pursuant to Treasury Regulations Section 1.83-2, to include in gross income as compensation
            for services the fair market value of the shares described below.</div>
          <div style="text-align: justify;"> <br>
          </div>
          <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="za988d78f40f84062bef068fd3b707057" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman', Times, serif;">(1)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="font-family: 'Times New Roman', Times, serif;">The taxpayer who performed the services is:</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 12%; vertical-align: top; padding-bottom: 2px;">
                  <div style="font-family: 'Times New Roman', Times, serif;">Name:</div>
                </td>
                <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 20%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 12%; vertical-align: top; padding-bottom: 2px;">
                  <div style="font-family: 'Times New Roman', Times, serif;">Address:</div>
                </td>
                <td style="width: 12%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 20%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td colspan="3" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="3" style="vertical-align: top;">&#160;</td>
                <td style="width: 40%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align: top; padding-bottom: 2px;">
                  <div style="font-family: 'Times New Roman', Times, serif;">Social Security No.:</div>
                </td>
                <td style="width: 20%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td style="width: 40%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(2)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The property with respect to which the election is made is ______ shares of the common stock of Remix Therapeutics Inc.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(3)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The property was transferred to the taxpayer on __________ __, ____.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(4)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The taxable year for which the election is made is the calendar year ____.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(5)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The property is subject to forfeiture if for any reason taxpayer&#8217;s service with the issuer terminates.&#160; The forfeiture condition lapses in a series of
                    installments over a ____-year period ending on __________ __, ____.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(6)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The fair market value of such property at the time of transfer (determined without regard to any restriction other than a restriction that by its terms will
                    never lapse) is $______ per share x ______ shares = $__________.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(7)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">No amount was paid for such property.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(8)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">The amount to include in gross income is $______.&#160; <font style="font-weight: bold; font-style: italic;">[The amount in Line 6.]</font></div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(9)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">A copy of this statement was furnished to Remix Therapeutics Inc., for whom taxpayer rendered the services underlying the transfer of such property.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td colspan="4" style="vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 8%; vertical-align: top;">&#160;</td>
                <td style="width: 8%; vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">(10)</div>
                </td>
                <td colspan="4" style="vertical-align: top;">
                  <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;">This statement is executed on __________ __, ____.</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <table style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td rowspan="1" style="width: 44%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td rowspan="1" colspan="1" style="width: 6%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td rowspan="1" style="width: 50%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
              </tr>
              <tr>
                <td style="width: 44%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman', Times, serif;">Spouse (if any)</div>
                </td>
                <td colspan="1" style="width: 6%; vertical-align: top;">&#160;</td>
                <td style="width: 50%; vertical-align: top;">
                  <div style="font-family: 'Times New Roman', Times, serif;">Taxpayer</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <div style="text-align: justify; font-style: italic; font-weight: bold;">Within 30 days after the date of transfer of the property, this election must be filed with the Internal Revenue Service office where the taxpayer files his or her annual
            federal income tax return.&#160; The filing should be made by registered or certified mail, return receipt requested.&#160; The taxpayer must deliver a copy of the completed form to the Company.</div>
          <div><br>
          </div>
        </div>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
    <div> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>6
<FILENAME>ny20077915x1_ex10-32.htm
<DESCRIPTION>EXHIBIT 10.32
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <div style="text-align: center; color: #000000; font-size: 12pt;">
      <div style="text-align: right; color: rgb(0, 0, 0); font-size: 10pt; font-style: italic; font-weight: bold;">Exhibit 10.32</div>
    </div>
    <div style="text-align: center; color: #000000; font-size: 12pt;"> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="text-align: center; color: rgb(0, 0, 0);">REMIX THERAPEUTICS, INC.</div>
    <div>&#160;</div>
    <div style="color: rgb(0, 0, 0);">25th July 2019</div>
    <div>&#160;</div>
    <div style="color: rgb(0, 0, 0);"><u>PERSONAL AND CONFIDENTIAL</u></div>
    <div>&#160;</div>
    <div style="color: rgb(0, 0, 0);">Dear Dominic</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Remix Therapeutics, Inc. (the &#8220;<u>Company</u>&#8221;) is pleased to offer you the full-time position of Vice President.&#160; We are excited about the prospect of you joining our team, and look forward to the
      addition of your professionalism and experience to help the Company achieve its goals.&#160; As a full-time employee, you are expected to devote your full time and best efforts to the Company, and you may not engage in outside business activities without
      the Company&#8217;s prior written consent.&#160; Notwithstanding the foregoing, the Company acknowledges that, in the first year of your employment, you may engage in consulting or other business activities for other portfolio companies of Atlas Ventures (&#8220;<u>Atlas</u>&#8221;)
      up to a maximum of 25% of your business time, with the prior agreement of the Chief Scientific Officer.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Your salary will be paid at an initial rate of $285,000 annually (&#8220;<u>Base Salary</u>&#8221;) in accordance with the Company&#8217;s normal payroll practices, subject to withholding taxes and as may be modified
      from time to time.&#160; You will also be eligible to receive cash incentive compensation as determined by the Company&#8217;s Board of Directors (&#8220;<u>Board</u>&#8221;).&#160; Your target annual incentive compensation shall be 30% of your Base Salary.&#160; The actual amount
      of your annual incentive compensation, if any, shall be determined at the sole discretion of the Board.&#160; You may participate in the benefit programs offered by the Company to its employees from time to time, provided that you are eligible under (and
      subject to all provisions of) the plan documents that govern those programs.&#160; Benefits are subject to change at any time in the Company&#8217;s sole discretion.&#160; You will also be entitled to paid vacation each year in accordance with the terms and
      conditions set forth in the Company&#8217;s vacation policy as in effect from time to time.&#160; You shall also be entitled to receive reimbursement for all reasonable business expenses incurred by you in performing your services to the Company, in accordance
      with the policies and procedures then in effect and established by the Company.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Subject to the approval of the Company&#8217;s Board of Directors (the &#8220;<u>Board</u>&#8221;) and the execution by you of a restricted stock agreement, the Company shall grant to&#160; you a restricted stock award for
      127,841 shares of the Company&#8217;s common stock (the &#8220;Restricted Shares&#8221;), which shall vest as to twenty-five percent (25%) of the Restricted Shares on the first anniversary of the Start Date, and as to the balance shall vest in equal quarterly
      installments of 6.25% of the Restricted Shares thereafter until the fourth anniversary of the Start Date.&#160; The Restricted Shares will otherwise be subject to the terms and conditions of the restricted stock agreement and the Company&#8217;s 2019 Stock
      Incentive Plan (the &#8220;<u>Grant Documents</u>&#8221;).&#160; In addition, you may be entitled to additional stock option grants and/or awards of restricted shares of common stock (&#8220;<u>Additional Grants</u>&#8221;) that the Company may elect to grant to you in the
      future in its sole discretion.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">The Company requires you to verify that the performance of your position at Remix Therapeutics does not and will not breach any agreement entered into by you prior to employment with the Company
      (i.e., you have not entered into any agreements with previous employers that are in conflict with your obligations to Remix Therapeutics).&#160; Please provide us with a copy of any such agreements.&#160; You will also be required to sign the Company&#8217;s
      Proprietary Information and Inventions Agreement (the &#8220;<u>PIIA</u>&#8221;) as a condition of your employment with the Company.&#160; A copy of the PIIA is attached.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">Your employment is also conditioned on the completion the I-9 form, and sufficient documentation to demonstrate your eligibility to work in the United States.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">The above terms are not contractual.&#160; They are a summary of our initial employment relationship and are subject to later modification by the Company.&#160; Your employment with the Company will be
      &#8220;at-will,&#8221; meaning that either you or the Company may terminate your employment relationship at any time, for any reason, with or without prior notice.&#160; The Company does, however, require that you provide at least two weeks&#8217; written notice in the
      event you decide to resign.&#160; The at-will nature of your employment also means that your job duties, title and responsibility and reporting level, work schedule, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures,
      may be changed, with or without notice, at any time in the sole discretion of the Company.&#160; You represent that you have not been subject to any workplace investigation regarding allegations of your personal misconduct whether relating to allegations
      of harassment, discrimination or otherwise.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">It is intended that the benefits provided under this letter shall comply with the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (&#8220;<u>Section 409A</u>&#8221;) or qualify for an
      exemption to Section 409A, and this letter shall be construed and interpreted in accordance with such intent.&#160; Any payments that qualify for the &#8220;short term deferral&#8221; exception or another exception under Section 409A shall be paid under the
      applicable exception.&#160; Each payment provided under this letter shall be treated as a separate payment for Section 409A purposes.&#160; All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable
      withholding and payroll taxes and other deductions required by law.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">If you accept this offer, this letter and the PIIA will constitute the complete agreement between you and Company with respect to the terms and conditions of your employment.&#160; Any prior or
      contemporaneous representations (whether oral or written) pertaining to your employment with the Company not contained in this letter or the PIIA, or contrary to those contained in this letter or the PIIA, that may have been made to you are expressly
      cancelled and superseded by this offer.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0);">We are excited to have you join Remix Therapeutics.&#160; We look forward to receiving a response from you within 7 days acknowledging that you have accepted this offer of employment, by signing below and
      returning the original to me.</div>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 55%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">Sincerely,</td>
          </tr>
          <tr>
            <td style="width: 55%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 55%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 35%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="color: rgb(0, 0, 0);">/s/ Peter G. Smith</font><br>
            </td>
            <td style="width: 10%; padding-bottom: 2px;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 55%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">Peter G Smith</td>
          </tr>
          <tr>
            <td style="width: 55%;">
              <div>&#160;</div>
            </td>
            <td colspan="2">President and Chief Scientific Officer</td>
          </tr>

      </table>
      <div> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 30%;">Understood and Agreed:</td>
            <td style="width: 70%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30%;">
              <div>&#160;</div>
            </td>
            <td style="width: 70%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30%; border-bottom: 2px solid rgb(0, 0, 0);"><font style="color: rgb(0, 0, 0);">/s/ Dominic Reynolds</font></td>
            <td style="width: 70%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30%;">
              <div>&#160;</div>
            </td>
            <td style="width: 70%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 30%;">Name: Dominic Reynolds</td>
            <td style="width: 70%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exhibit A</div>
    <div>&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PIIA</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: right; color: rgb(0, 0, 0);"><u>Appendix A</u></div>
    <div>&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PRIOR MATTERS</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
    </div>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>7
<FILENAME>ny20077915x1_ex10-33.htm
<DESCRIPTION>EXHIBIT 10.33
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 9pt; text-align: left; color: rgb(0, 0, 0);" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-size: 10pt;"><font style="font-weight: bold; font-style: italic;"> Exhibit 10.33</font><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt;"> <br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt;">REMIX THERAPEUTICS INC.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt;">Aug 1, 2019</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="color: rgb(0, 0, 0); font-size: 10pt;">Dear Peter:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-size: 10pt;">Remix Therapeutics Inc. (the &#8220;Company&#8221;), is pleased to offer you employment on the following terms:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">1.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Position</font>.&#160; Your title will be President and Chief Scientific Officer, and you will report to the Company&#8217;s Board of Directors (the &#8220;Board&#8221;).&#160; This is a full-time position.&#160; You will undertake to perform, to the
        best of your ability, all the work related to the Company&#8217;s business that can reasonably be assigned to you by or on behalf of the Company consistent with this position.&#160; You will act in accordance with the instructions to be given to you by the
        Board.&#160; While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) without the prior consent of the Board and under no circumstances will you engage
        in activities that would create a conflict of interest with the Company.&#160; For the avoidance of doubt, the Company agrees that you may continue (i) in a consulting or advisory board capacity with Rodin Therapeutics and (ii) in a consulting or
        advisory board capacity with the Atlas seed Project Borg.&#160; By signing this Agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the
        Company.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">2.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Workplace Location</font>.&#160; You are expected to work for the Company at its offices in or around Cambridge MA, USA, as well as from time to time elsewhere, in accordance with the nature and needs of the work as deemed
        necessary by the Company.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">3.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Cash Compensation</font>.&#160; The Company will pay you an initial base salary at the rate of $375,000.00 per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to standard withholdings.&#160;
        Your annual base salary will be prorated for 2019 and any other year of partial employment.&#160; This position is considered an exempt position for purposes of federal wage and hour laws.&#160; You will be eligible for an annual performance bonus of up to
        30% of your annual base salary, subject to achievement of targets that will be established by mutual agreement between you and the Board upon hire and at the beginning of each of the subsequent performance years.&#160; Performance bonus goals will be
        evaluated and paid on an annual basis, with such payment, to the extent earned, to be made within 2&#189; months following the close of the applicable fiscal year.&#160; Any bonus for the fiscal year in which your employment begins will be prorated, based on
        the number of days you are employed by the Company during that fiscal year.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">4.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Employee Benefits</font>.&#160; As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits, as in effect from time to time.&#160; In addition, you will be entitled to
        vacation in accordance with the Company&#8217;s vacation policy, as in effect from time to time.&#160; You will be entitled to 20 vacation days annually and customary holidays.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">5.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Equity</font>.&#160; Subject to the approval of the Board, you will be issued 2,500,000 shares of the Company&#8217;s common stock, 2,250,000 of the issued shares shall be subject to the Company&#8217;s right of repurchase (the
        &#8220;Restricted Shares&#8221;).&#160; The shares will be subject to the terms and conditions described in the applicable Stock Purchase Agreement.&#160; The Company&#8217;s right of repurchase with respect to the Restricted Shares will lapse with respect to&#160; 25% of the
        shares after 12 months of continuous service, and the repurchase right with respect to the balance will lapse in equal monthly installments over the next 36 months of continuous service, as described in the applicable Stock Purchase Agreement.&#160; The
        Company&#8217;s right of repurchase shall lapse with respect to the Restricted Shares if (a) the Company is subject to a Change in Control before your service with the Company terminates and (b) you are subject to an Involuntary Termination within 12
        months following Change in Control.&#160; Subject to the approval of the Board, you will also be eligible to receive additional grants of equity, from time to time.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">6.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Reimbursement of Expenses</font>.&#160; The Company will reimburse business expenses reasonably incurred in the performance of your duties in accordance with the Company&#8217;s standard practice and expense policy in place at the
        time.&#160; Business expenses incurred in a calendar year shall be reimbursed no later than March 15<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> of the following year.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">7.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Severance Benefits.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(a)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">General</font>.&#160; If you are subject to an Involuntary Termination, then you will be entitled to the benefits described in Section 7(b).&#160; However, Section 7(b) will not apply unless you (i) have returned all Company
        property in your possession, (ii) have resigned as a member of the Board, to the extent applicable, and (iii) have executed a general release of all claims (with applicable carve-out for continued indemnification) that you may have against the
        Company or persons affiliated with the Company (the &#8220;Release&#8221;).&#160; You must execute and return the Release on the date specified by the Company in substantially the form provided by the Company (the &#8220;Release Deadline&#8221;).&#160; The Release Deadline will in
        no event be later than 50 days after your Separation.&#160; If you fail to return the Release on or before the Release Deadline, or if you revoke the Release, then you will not be entitled to the benefits described in Section 7(b).</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(b)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Severance Payment and COBRA</font>.&#160; If you are subject to an Involuntary Termination or there is a Change in Control, then the Company will continue to pay your Base Salary for nine (9) months following Separation
        (&#8220;Severance Period&#8221;), and if you elect to continue your health insurance coverage under COBRA following your Separation, then the Company will pay it&#8217;s portion of your monthly premium under COBRA until the earliest of (i) the close of the 9-month
        period following your Separation, (ii) the expiration of your continuation coverage under COBRA or (iii) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment.&#160;
        The salary continuation payments will commence on the first payroll date following your return of the release provided for in Section 7(a) and thereafter on the Company&#8217;s normal payroll schedule.&#160; However, if the 50-day period described in Section
        7(a) spans two calendar years, then the salary continuation payments will commence on the first payroll date in the second calendar year following expiration of the applicable revocation period.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(c)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Accrued Rights.</font>&#160; You will be entitled to receive the following upon termination of employment for any reason: (i) accrued and unpaid Base Salary through the date of termination of employment and any accrued but
        unused vacation; (ii) any earned but unpaid bonus (to the extent earned) as of the date of termination; (iii) reimbursement for any unreimbursed business expenses; and (iv) such employee benefits, if any, to which you may be entitled under the
        applicable Company plans upon termination of employment.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">8.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Documents and Company Property</font>.&#160; You are prohibited from keeping in your possession in any way any correspondence, documents, other information carriers, copies thereof, and other goods made available by the
        Company or its affiliates to you (including, but not limited to, credit cards, mobile communication devices, keys, documents, handbooks, financial data, plans, USB sticks or other information carriers, access cards and laptop computer), except to
        the extent that this is necessary for the performance of your work for the Company.&#160; In any event, you are obliged to immediately hand over such documents and other goods made available to you at the end of this Agreement or upon suspension of your
        active duties for any reason.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">9.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Proprietary Information and Inventions Agreement</font>.&#160; This Agreement is subject to your execution of the Proprietary Information and Inventions Agreement attached as <u>Exhibit A</u>.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">10.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Employment Relationship</font>.&#160; Employment with the Company is for no specific period of time.&#160; Your employment with the Company will be &#8220;at will,&#8221; meaning that either you or the Company may terminate your employment
        at any time and for any reason, with or without cause.&#160; Any contrary representations that may have been made to you are superseded by this letter agreement.&#160; This is the full and complete agreement between you and the Company on this term.&#160;
        Although your job duties, title, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may change from time to time, the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed
        by you and a duly authorized officer of the Company (other than you).&#160; You agree to truthfully change your status, job and position on social media including, but not limited to, LinkedIn, Facebook and Twitter, in such manner that it is clear that
        you have no further involvement with the Company (and its affiliated enterprises) as of the date of termination of your employment within one (1) month of your termination of employment with the Company.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">11.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Tax Matters.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(a)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Withholding</font>.&#160; All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(b)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Section 409A</font>.&#160; It is intended that payments under this Agreement satisfy, to the greatest extent possible, the exemption from the application of Section 409A of the Code (and any state law of similar effect)
        provided under Treasury Regulation Section 1.409A-1(b)(4)</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="color: rgb(0, 0, 0); font-size: 10pt;">(as a &#8220;short-term deferral&#8221;).&#160; For purposes of this Agreement, each amount to be paid or benefit to be provided, including a series of installment payments, will be construed as a separate identified
      payment for purposes of Section 409A.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(c)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Tax Advice</font>.&#160; You are encouraged to obtain your own tax advice regarding your compensation from the Company.&#160; You agree that the Company does not have a duty to design its compensation policies in a manner that
        minimizes your tax liabilities, and you will not make any claim against the Company or its Board related to tax liabilities arising from your compensation.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">12.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Interpretation, Amendment and Enforcement</font>.&#160; This letter agreement and <u>Exhibit A</u> constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company
        and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company.&#160; This letter agreement may not be amended or modified, except by an express written agreement signed by both you
        and a duly authorized officer of the Company.&#160; The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this letter agreement or arising out of, related to, or in any way connected
        with, this letter agreement, your employment with the Company or any other relationship between you and the Company will be governed by laws of the Commonwealth of Massachusetts, excluding laws relating to conflicts or choice of law.&#160; This
        Agreement is not subject to collective bargaining arrangements.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">13.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Defined Terms.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt; color: rgb(0, 0, 0); font-size: 10pt;">&#8220;<font style="font-weight: bold;">Cause</font>&#8221; shall mean</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(i)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">an unauthorized use or disclosure by you of the Company&#8217;s confidential information or trade secrets, which use or disclosure causes material harm to the Company;</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(ii)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">a material failure by you to comply with the Company&#8217;s written policies or rules after being provided written notice and 30 days&#8217; opportunity to cure;</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(iii)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">your conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a crime involving moral turpitude, deceit, dishonesty or fraud that has caused harm to the Company or any affiliate of the Company;</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(iv)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">your gross negligence or willful misconduct with respect to the Company or any affiliate of the Company which causes harm;</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(v)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">your willful and continued failure to substantially perform (other than by reason of disability) your duties and responsibilities assigned or delegated after receiving written notification of such failure from the Board and 30 days&#8217;
        opportunity to cure;</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(vi)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">any intentional act of dishonesty, deceit, fraud, moral turpitude, misconduct, breach of trust or acts intentionally against the financial or business interests of the Company by you, or your use or possession of illegal drugs in the
        workplace; or</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(vii)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">the material breach by you of any of your obligations under any agreement between you and the Company after being provided written notice and 30 days&#8217; opportunity to cure; or</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(viii)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">your failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested your cooperation.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-size: 10pt;">&#8220;<font style="font-weight: bold;">Change in Control</font>&#8221;&#160; shall mean (i) the consummation of a merger or consolidation of the Company with or into another entity, (ii) the sale of
      all or substantially all of the assets of the Company, either in one transaction or a series of related transactions or (iii) the dissolution, liquidation or winding up of the Company.&#160; The foregoing notwithstanding, a merger or consolidation of the
      Company shall not constitute a &#8220;Change in Control&#8221; if immediately after such merger or consolidation a majority of the voting power of the capital stock of the continuing or surviving entity, or any direct or indirect parent corporation of such
      continuing or surviving entity, will be owned by the persons who were the Company&#8217;s stockholders immediately prior to such merger or consolidation in substantially the same proportions as their ownership of the voting power of the Company&#8217;s capital
      stock immediately prior to such merger or consolidation.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-size: 10pt;">&#8220;<font style="font-weight: bold;">Involuntary Termination</font>&#8221; means either (a) your Termination Without Cause or (b) your Resignation for Good Reason.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-size: 10pt;">&#8220;<font style="font-weight: bold;">Resignation for Good Reason</font>&#8221; means a Separation as a result of your resignation within ninety (90) days after one of the following conditions
      has come into existence without your consent:</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 144pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(i)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; color: rgb(0, 0, 0);">A reduction in your base salary and/or annual bonus opportunity;</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 144pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(ii)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">With respect to your role as Chief Scientific Officer, a material diminution in your position, authority or responsibilities with respect to the Company or any successor or acquiring entity; or</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; margin-left: 144pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">(iii)</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);">Without your prior consent, a relocation of your principal workplace by more than fifty (50) miles away from the location which you were working immediately prior to the required relocation.</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-size: 10pt;">A Resignation for Good Reason will not be deemed to have occurred unless you give the Company written notice of the condition within 90 days after the condition comes into existence
      and you obtain actual knowledge of such condition, and the Company fails to remedy the condition within 30 days after receiving your written notice.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-size: 10pt;">&#8220;<font style="font-weight: bold;">Separation</font>&#8221; means a &#8220;separation from service,&#8221; as defined in the regulations under Section 409A of the Code.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-size: 10pt;">&#8220;<font style="font-weight: bold;">Termination Without Cause</font>&#8221; means a Separation as a result of a termination of your employment by the Company without Cause.</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-indent: 72pt;"><font style="font-size: 10pt; color: rgb(0, 0, 0);">14.</font><font style="text-indent: 0px; font-size: 10pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; color: rgb(0, 0, 0);"><font style="font-weight: bold;">Arbitration</font>.&#160; Any controversy or claim arising out of this letter agreement and any and all claims relating to your employment with the Company will be settled by final and binding arbitration.&#160; The arbitration
        will take place in the Commonwealth of Massachusetts.&#160; The arbitration will be administered by the American Arbitration Association under its National Rules for the Resolution of Employment Disputes.&#160; Any award or finding will be confidential.&#160; You
        and the Company agree to provide one another with reasonable access to documents and witnesses in connection with the resolution of the dispute.&#160; Each party will be responsible for its own attorneys&#8217; fees, and the arbitrator may not award
        attorneys&#8217; fees unless a statute or contract at issue specifically authorizes such an award.&#160; This Section 14 does not apply to claims for workers&#8217; compensation benefits or unemployment insurance benefits.&#160; This Section 14 also does not apply to
        claims concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential information, patent right, copyright, mask work, trademark or any other trade secret or intellectual property held
        or sought by either you or the Company (whether or not arising under the Proprietary Information and Inventions Agreement between you and the Company).</font></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-indent: 72pt; color: rgb(0, 0, 0); font-size: 10pt;">We hope that you will accept our offer to assume the role of President and Chief Scientific Officer.&#160; You may indicate your agreement with these terms and accept this offer by
      signing and dating the enclosed duplicate original of this agreement and returning it to me.&#160; This offer, if not accepted, will expire at 5:00 PM ET on Aug 1, 2019.&#160; Your start date will be Aug 1, 2019.&#160; As required by law, your employment with the
      Company is contingent upon your providing legal proof of your identity and authorization to work in the United States.</div>
    <div style="text-indent: 72pt; color: rgb(0, 0, 0); font-size: 10pt;"> <br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 9pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z46f02b8297f44bfeaa4960df8fce5ca9" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="1" rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Remix Therapeutics Inc.</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 47%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td colspan="1" style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
          <td style="width: 3%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">/s/ Kevin Bitterman</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Kevin Bitterman</div>
          </td>
        </tr>
        <tr>
          <td colspan="1" rowspan="1" style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td colspan="2" rowspan="1" style="vertical-align: top; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Member of Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <table style="font-family: 'Times New Roman'; font-size: 9pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z507bba0ced6e4971b51295a928d32797" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 52%; vertical-align: top; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">I have read and accept this employment offer:</div>
          </td>
          <td colspan="1" style="width: 48%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 52%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td colspan="1" rowspan="1" style="width: 48%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">/s/ Peter Smith</div>
          </td>
          <td colspan="1" style="width: 48%; vertical-align: top; padding-bottom: 2px; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52%; vertical-align: top; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Signature of Peter Smith</div>
          </td>
          <td colspan="1" style="width: 48%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 52%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 48%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52%; vertical-align: top; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0);">Dated:&#160; <u>August 1, 2019</u></div>
          </td>
          <td colspan="1" style="width: 48%; vertical-align: top; font-size: 10pt;">&#160;</td>
        </tr>

    </table>
    <div> <font style="font-size: 10pt;"><br>
      </font></div>
    <div style="clear: both; margin-top: 9pt; margin-bottom: 9pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">Exhibit A</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">PIIA</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="clear: both; margin-top: 9pt; margin-bottom: 9pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: right; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;"><u>Appendix A</u></div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 10pt; font-weight: bold;">PRIOR MATTERS</div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>8
<FILENAME>ny20077915x1_ex10-34.htm
<DESCRIPTION>EXHIBIT 10.34
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
  <div>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold;">
      <div style="text-align: right; font-style: italic; font-weight: bold; font-variant: normal;">Exhibit 10.34</div>
    </div>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Remix Therapeutics, Inc. </div>
    <font style="text-transform: uppercase;"> </font>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">400 Technology Square</div>
    <font style="text-transform: uppercase;"> </font>
    <div style="text-align: center; font-variant: small-caps; font-weight: bold; text-transform: uppercase;">Cambridge, MA&#160; 02139</div>
    <font style="text-transform: uppercase;"> </font>
    <div style="text-transform: uppercase;">&#160;</div>
    <font style="text-transform: uppercase;"> </font>
    <div style="text-align: center; font-weight: bold; text-transform: uppercase;">August 3rd, 2020</div>
    <div>&#160;</div>
    <div style="text-align: justify;">Dear Heather:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">Remix Therapeutics, Inc.&#160; (the &#8220;Company&#8221;) is pleased to offer you employment on the following terms:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Position</font>.&#160; Your initial title will be Chief Business Officer/Chief Operating Officer, and you will initially report to Peter Smith, the Company&#8217;s
      President and Chief Scientific Officer.&#160; This is a full-time position.&#160; You are required to relocate to, and maintain a residence in, the greater Boston area.&#160; While you render services to the Company, you will not engage in any other employment,
      consulting or other business activity (whether full&#8209;time or part-time) without the Company&#8217;s prior written consent.&#160; By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that
      would prohibit you from performing your duties for the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Cash Compensation</font>.&#160; The Company will pay you a starting salary at the rate of $350,000 per year, payable in accordance with the Company&#8217;s standard
      payroll schedule (the &#8220;Base Salary&#8221;).&#160; The Base Salary will be subject to adjustment pursuant to the Company&#8217;s employee compensation policies in effect from time to time.&#160; In addition, you will <font style="color: rgb(0, 0, 0);">be eligible to be
        considered for an incentive bonus</font> for each fiscal year of the Company. <font style="color: rgb(0, 0, 0);"> The bonus (if any) will be awarded based on objective or subjective criteria established by the Company&#8217;s </font>President and
      approved by the Company&#8217;s Board of Directors.&#160; Your target bonus will be equal to 35% of your Base Salary.&#160; Any bonus for the fiscal year in which your employment begins will be prorated, based on the number of days you are employed by the Company
      during that fiscal year.&#160; Any bonus for a fiscal year will be paid within 2&#189; months after the close of that fiscal year, but only if you are still employed by the Company at the time of payment.<font style="color: rgb(0, 0, 0);"> Should the Company
        be acquired during the period of time between the end of fiscal year and anticipated payment of the bonus, the bonus will be paid out accordingly. The determinations of the Company&#8217;s Board of Directors with respect to your bonus will be final and
        binding.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Relocation Assistance</font>.&#160; The Company will provide you with a relocation bonus in the form of a sign-on bonus of $100,000 (the &#8220;Relocation Bonus&#8221;),
      which will be paid to you within 60 days of your start date and will be subject to customary deductions and withholdings. You hereby acknowledge and agree, however, that if your employment with the Company terminates for any reason other than an
      Involuntary Termination prior to the one-year anniversary of your start date, you will be required to repay the full amount of the Relocation Bonus to the Company.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Signing Bonus.</font>&#160; The Company agrees to pay you a signing bonus equaling $61,250 (the &#8220;Signing Bonus&#8221;), payable upon your 12 month anniversary at the
      Company following your start date and subject to all applicable tax reporting and withholding requirements.&#160; In the event that your employment with the Company terminates for any reason other than an Involuntary Termination prior to the one-year
      anniversary of your start date, you will forfeit the right to the Signing Bonus.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Employee Benefits</font>.&#160; As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored benefits.&#160; In
      addition, you will be entitled to paid vacation in accordance with the Company&#8217;s vacation policy, as in effect from time to time.&#160; The Company agrees to pay a bonus equaling the employee&#8217;s share of COBRA health benefits for up to 3 months before you
      are eligible to begin participating in Company-sponsored health benefits.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;">Stock Options</font>.&#160; Subject to the approval of the Company&#8217;s Board of Directors, you will be granted an option to purchase 847,330 shares of the
      Company&#8217;s Common Stock (the &#8220;Option&#8221;) with a right to early exercise the Options.&#160; The exercise price per share of the Option will be determined by the Board of Directors when the Option is granted.&#160; The Option will be subject to the terms and
      conditions applicable to options granted under the Company&#8217;s 2019 Stock Plan (the &#8220;Plan&#8221;) including standard vesting, as described in the Plan and the applicable Stock Plan Option Agreement.&#160; You will vest in 25% of the Option after 12 months of
      continuous service, and the balance will vest in equal monthly installments over the next 36 months of continuous service, as described in the applicable Stock Plan Agreement.&#160; In addition, if you are subject to an Involuntary Termination within 12
      months after a Change in Control, then you will vest automatically in 100% of any remaining unvested shares subject to the Option.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Proprietary Information and Inventions Agreement</font>.&#160; Like all Company employees, you will be required, as a condition of your employment with the
      Company, to sign the Company&#8217;s standard Proprietary Information and Inventions Agreement, a copy of which is attached hereto as <font style="font-weight: bold;">Exhibit A</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Employment Relationship</font>.&#160; Employment with the Company is for no specific period of time.&#160; Your employment with the Company will be &#8220;at will,&#8221;
      meaning that either you or the Company may terminate your employment at any time and for any reason, with or without Cause.&#160; Any contrary representations that may have been made to you are superseded by this letter agreement.&#160; This is the full and
      complete agreement between you and the Company on this term.&#160; Although your job duties, title, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may change from time to time, the &#8220;at will&#8221; nature of your
      employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Tax Matters</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Withholding</font>.&#160; All forms of compensation referred to in this letter agreement are subject to reduction to reflect applicable withholding and payroll
      taxes and other deductions required by law.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Tax Advice</font>.&#160; You are encouraged to obtain your own tax advice regarding your compensation from the Company.&#160; You agree that the Company does not
      have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">10.&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Interpretation, Amendment and Enforcement</font>.&#160; This letter agreement and <font style="font-weight: bold;">Exhibit A</font> supersede and replace any&#160;
      prior agreements, representations or understandings (whether written, oral, implied or otherwise) between you and the Company and constitute the complete agreement between you and the Company regarding the subject matter set forth herein.&#160; This
      letter agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company.&#160; The terms of this letter agreement and the resolution of any disputes as to the meaning, effect,
      performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;Disputes&#8221;) will be
      governed by Massachusetts law, excluding laws relating to conflicts or choice of law.&#160; You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in Massachusetts in connection with any Dispute or any
      claim related to any Dispute.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;">Defined Terms</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Cause&#8221;</font><font style="font-size: 10pt;"> shall mean</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;an unauthorized use or disclosure by you of the Company&#8217;s confidential information or trade secrets, which use or disclosure causes material harm to the Company;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a material failure by you to comply with the Company&#8217;s written policies or rules after being provided written notice and 30 days&#8217; opportunity to cure;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160; your conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a crime involving moral turpitude, deceit, dishonesty or fraud that has caused harm to the Company or any affiliate of the
      Company;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;your gross negligence or willful misconduct with respect to the Company or any affiliate of the Company which causes harm;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160; your willful and continued failure to substantially perform (other than by reason of disability) your duties and responsibilities assigned or delegated after receiving written
      notification of such failure from the Board and 30 days&#8217; opportunity to cure;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any intentional act of dishonesty, deceit, fraud, moral turpitude, misconduct, breach of trust or acts intentionally against the financial or business interests of the Company by you,
      or your use or possession of illegal drugs in the workplace;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 108pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the material breach by you of any of your obligations under any agreement between you and the Company after being provided written notice and 30 days&#8217; opportunity to cure; or</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 108pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160; your failure to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested your
      cooperation.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">&#8220;Change in Control&#8221;</font><font style="font-size: 10pt;">&#160; shall mean (a) the consummation of a merger or consolidation of the
        Company with or into another entity, (b) the sale of all or substantially all of the assets of the Company, either in one transaction or a series of related transactions or (c) the dissolution, liquidation or winding up of the Company.&#160; The
        foregoing notwithstanding, a merger or consolidation of the Company shall not constitute a &#8220;Change in Control&#8221; if immediately after such merger or consolidation a majority of the voting power of the capital stock of the continuing or surviving
        entity, or any direct or indirect parent corporation of such continuing or surviving entity, will be owned by the persons who were the Company&#8217;s stockholders immediately prior to such merger or consolidation in substantially the same proportions as
        their ownership of the voting power of the Company&#8217;s capital stock immediately prior to such merger or consolidation.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Involuntary Termination</font>&#8221; means either (a) your Termination Without Cause or (b) your Resignation for Good Reason.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Resignation for Good Reason</font>&#8221; means a Separation as a result of your resignation within 90 days after one of the following conditions has come into existence
      without your consent:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;A reduction in your Base Salary and/or annual bonus opportunity;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160; With respect to your role as Chief Business Officer/Chief Operating Officer, a material diminution in your position, authority or responsibilities with respect to the
      Company or any successor or acquiring entity; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Without your prior consent, a relocation of your principal workplace by more than 50 miles away from the location which you were working immediately prior to the
      required relocation.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">A Resignation for Good Reason will not be deemed to have occurred unless you give the Company written notice of the condition within 90 days after the condition comes into existence and you obtain
      actual knowledge of such condition, and the Company fails to remedy the condition within 30 days after receiving your written notice.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Separation</font>&#8221; means a &#8220;separation from service,&#8221; as defined in the regulations under Section 409A of the Internal Revenue Code of 1986, as amended.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">&#8220;<font style="font-weight: bold;">Termination Without Cause</font>&#8221; means a Separation as a result of a termination of your employment by the Company without Cause.</div>
    <div>&#160;</div>
    <div style="text-align: center;">* * * * *</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;">We hope that you will accept our offer to join the Company.&#160; You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this
      letter agreement and the enclosed Proprietary Information and Inventions Agreement and returning them to me.&#160; This offer, if not accepted, will expire at the close of business on ________, 2020.&#160; As required by law, your employment with the Company
      is contingent upon your providing legal proof of your identity and authorization to work in the United States.&#160; Your employment is also contingent upon your starting work with the Company on or before August 31, 2020.</div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt;">If you have any questions, please call me at _____________.</div>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z2b2ca31cfa1f4e23babfdca58f5ec29e" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50.00%;"><br>
            </td>
            <td colspan="2">Very truly yours,</td>
          </tr>
          <tr>
            <td style="width: 50.00%;"><br>
            </td>
            <td colspan="2"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;"><br>
            </td>
            <td colspan="2">
              <div style="text-align: left; font-variant: small-caps;">Remix Therapeutics Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;"><br>
            </td>
            <td colspan="2"><br>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;"><br>
            </td>
            <td style="width: 3%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="width: 47%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Peter Smith<br>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;" rowspan="1">&#160;</td>
            <td rowspan="1" colspan="2">Peter Smith, President and CSO</td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">I have read and accept this employment offer:</div>
    <div>&#160;</div>
    <div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="ze5f4df3d700e466997dbb2232f295761" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Heather Wasserman&#160; <br>
            </td>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div style="margin-left: 9pt">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt">
                      <div style="margin-left: 9pt">Signature of Heather Wasserman</div>
                    </div>
                  </div>
                </div>
              </div>
            </td>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;">Dated:&#160; <u>August 5, 2020</u></td>
            <td style="width: 50.00%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Attachment</div>
    <div>&#160;</div>
    <div>Exhibit A:&#160; Proprietary Information and Inventions Agreement</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>9
<FILENAME>ny20077915x1_ex10-35.htm
<DESCRIPTION>EXHIBIT 10.35
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 10.35</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10) (iv) of Regulation S-K. The omitted information is (i) not material and (ii) treated by the
      Registrant as private or confidential.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">The Registrant undertakes to furnish a copy of all omitted information, schedules, and exhibits to the U.S. Securities and Exchange Commission upon its request.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">TEMPUS</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Master Agreement</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Master Agreement (the &#8220;<u>Agreement</u>&#8221;) is entered into by and between Tempus Labs, Inc., with its principal place of business at 600 West Chicago Ave., Suite 510, Chicago, IL 60654 (on behalf of itself and its
      affiliates, &#8220;<u>Tempus</u>&#8221;) and Remix Therapeutics Inc., with its principal place of business at 100 Forge Road, Watertown MA 02472 (&#8220;<u>Client</u>&#8221;). Tempus and Client are each individually a &#8220;Party&#8221; and are collectively the &#8220;Parties.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Background</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Tempus is a technology company dedicated to advancing precision medicine through its proprietary products and services. Client would like to use Tempus&#8217; technology as further described in this Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;">Agreement</div>
    <div><br>
    </div>
    <div style="text-align: justify;">In consideration of the mutual promises described below, the Parties agree as follows:</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc3c793bdc0204c3baa54b1320253a202" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">1.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">General. </font>During the Term, Tempus shall provide &#8220;<u>Services</u>&#8221; and &#8220;<u>Deliverables</u>,&#8221; in accordance with Applicable Law (as defined below), and any Exhibit or fully executed Order Form under
              this Agreement. Tempus may also grant Client a license to certain &#8220;<u>Licensed Data</u>&#8221; or &#8220;<u>Software</u>,&#8221; also to the extent included in an Exhibit or a fully executed &#8220;<u>Order Form</u>.&#8221; The activities contemplated as of the date of
              this Agreement are described in the attached Exhibit(s), which may be supplemented by the Parties from time to time in writing. Any changes to the Services or to the assumptions on which they are based (including, but not limited to, changes
              in an agreed starting date or suspension of Services) may require changes in the budget and/or timelines and shall require a written amendment to an Exhibit or Order Form (each, a &#8220;<u>Change Order</u>&#8221;). Each Change Order shall detail the
              changes to the Exhibit or Order Form and shall become effective only upon its execution by both Parties. Both Parties agree to act in good faith and promptly when considering a Change Order requested by the other Party.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z18b8f06dc96040499da8f2351b74b7a1" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Fees</font>. Client agrees to pay Tempus all undisputed fees agreed to in the applicable Exhibit or Order Form. Undisputed invoices under this Agreement are due and payable by Client within [***] of the
              invoice date. Interest will apply to any undisputed, overdue invoices at a rate of the lesser of (a) [***], and (b) the highest rate permitted by applicable law. Client is responsible for payment of any taxes arising out of or related to this
              Agreement, except for taxes based on Tempus&#8217;s income, or business operations.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze7f50a5d3e4248e4ac133ef2102f8b41" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">3.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Audits</font>; [***]. During the Term of this Agreement, after reasonable notice by Client to Tempus, Tempus will allow Client employees and representatives, during normal business hours and at mutually
              agreeable times, to: [***]. Any audit or inspection under this Section is limited to once per year without cause and Client will provide at least [***] prior written notice to Tempus. Any audit or inspection carried out in connection with
              this Agreement is subject to Tempus&#8217;s reasonable and applicable policies and requirements, including without limitation security requirements and confidentiality protections. In the event that Tempus receives an inspection notice from an
              applicable regulatory authority that directly relates to Services provided to Client (&#8220;Inspection Notice&#8221;), Tempus will: [***]. Client acknowledges that it is Tempus&#8217;s obligation to respond to an Inspection Notice directed to Tempus, and that
              Tempus must respond to the Inspection Notice; provided, however, that [***]. Client agrees to cooperate with all reasonable requests necessary to comply with an Inspection Notice.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3f79fe7ae2f44211853cbc50aee1235b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">4.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Data Verification, Reports, and Records</font>. Tempus shall maintain appropriate reasonably detailed written records of all Services performed under this Agreement necessary to demonstrate Tempus&#8217;s
              compliance with Applicable Laws and as otherwise necessary to comply with the terms of this Agreement (collectively, &#8220;Records&#8221;) in a secure area reasonably protected from fire, theft and destruction. Tempus will retain Records in accordance
              with Applicable Laws and its internal policies and procedures. Tempus must provide prior written notice to Client prior to discarding or destroying any Records and Client may request Tempus to store those Records for a longer period of time
              at Client&#8217;s expenses. During the Term of the Agreement and for a period of [***] thereafter or longer as required by law, Records will be made available to Client by Tempus for review [***].</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f562b30bed64859893e91db824fe081" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Regulatory Contacts</font>. To the extent legally permissible, Tempus will: [***].</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z92a2cf95e71d46b2ba55cd459c163b77" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Representations, Warranties and Covenants</font>. Tempus hereby represents, warrants and covenants to Client that:</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f80551003a640ef80128943fe3958ea" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-weight: bold;">Authority</font>. Tempus is and will remain duly organized, validly existing and in good standing under the laws of its jurisdiction of organization; the execution and delivery of
              this Agreement has been authorized by all requisite corporate or organizational action; this Agreement is and will remain a valid and binding obligation of Tempus, enforceable in accordance with its terms; Tempus is under no contractual or
              other obligation or restriction that conflicts with Tempus&#8217;s execution or performance of this Agreement, and will not enter into any agreement, either written or oral, that would conflict with Tempus&#8217;s responsibilities under this Agreement;
              and [***].</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z230a4aa946564f26bae19f5c1c1f6c32" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-weight: bold;">Qualifications of Tempus Personnel</font>. Tempus has, and will engage, employees, consultants and/or permitted subcontractors (&#8220;Tempus Personnel&#8221;) with the proper skill, training
              and experience to provide the Services. Tempus will be solely responsible for paying Tempus Personnel and providing any employee benefits that they are owed. Before providing Services, Tempus agrees that all Tempus Personnel have agreed in
              writing, prior to receipt of Confidential Information either as a condition of their employment or in order to obtain the Confidential Information, to obligations similar to the provisions hereof, and (b) written agreements that effectively
              vest in Tempus any and all rights that such personnel might otherwise have in the Deliverables provided hereunder.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z51c40b7b55a24099a200dccb17d23a9c" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">c.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-weight: bold;">Legal Compliance</font>. In performing the Services and activities under the Agreement, both Parties will comply with all applicable laws,, binding regulatory guidelines, or
              regulations established by any relevant governmental authority having jurisdiction over the Services, expressly including, to the extent applicable, the U.S. Food, Drug and Cosmetic Act and the regulations promulgated pursuant thereto; ICH
              GCP Guideline UK SI 2004; 1031 Part 2; GxP (including but not limited to current Good Laboratory Practices, Good Clinical Practices, and Good Manufacturing Practices, as those terms are defined under FDA and ICH guidelines); securities laws
              and regulations, and those related to data privacy (&#8220;Applicable Laws&#8221;). Tempus acknowledges that any materials provided by Client to Tempus may be of an experimental nature, and Tempus will comply with all Applicable Laws relating to the
              handling and use thereof. Tempus will comply with all reasonable and applicable Client guidelines and Client Requirements (as set forth below), such as standard operating procedures, that Client provides in writing to Tempus in advance.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z37280ef4583c4ab0b4539c764be2e911" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">7.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Insurance</font>. During the Term, each Party will maintain the following insurance at its own expense: (i) commercial general liability insurance with limits not less than [***]; and (ii) workers&#8217;
              compensation insurance at statutory limits [***]. The insurance required above may be maintained through umbrella and/or self-insurance.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0a06b89c5ffa4e838b2046ada1845787" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">8.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Research Use Only</font>. Client agrees that unless otherwise specified in the applicable Exhibit or Order Form, information provided by Tempus under this Agreement is for research use only. Subject to the
              terms and conditions herein, Client agrees that: (a) Tempus does not recommend, endorse, or make any representation about the efficacy or appropriateness of any therapy, procedure, or treatment described in any report or information made
              available by Tempus; (b) if reports and information provided by Tempus are reviewed by a treating clinician, that clinician (and not Tempus) is responsible for decisions regarding patient care; and (c) Client is solely responsible for its use
              of reports and information, including Deliverables, made available by Tempus. All information and reports provided by Tempus are subject to any notes, explanations, limitations, and disclaimers included therein.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zace11834b1874e24b90238ec78bfef2d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">9.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Client&#8217;s Policies</font>. Client agrees that Client shall comply with such policies, rules, guidelines, and similar requirements, including, where applicable, requirements that govern research subject
              consent; the collection, processing, transfer, analysis, use, and storage of research subject specimens and data; and laws and regulations that apply to Client or its affiliates (collectively, &#8220;<u>Client Requirements</u>&#8221;). Client will only
              provide specimens and data to Tempus to the extent such transfer complies with Client Requirements.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z39fe4f430c8c4eba8387b27843664f5e" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">10.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Privacy, Confidentiality, and Intellectual Property</font>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb405e8974a5543b58743c6f9ad583af7" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Privacy</font>. If Client provides Tempus with protected health information (as defined in the Health Insurance Portability and Accountability Act of 1996 and its implementing
              regulations (&#8220;<u>HIPAA</u>&#8221;)) (&#8220;<u>PHI</u>&#8221;) under this Agreement, the Parties will enter into a business associate agreement, which will be deemed incorporated into this Agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za8374068f82245248a62130fa8560784" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Non-disclosure</font>. Any non-public information provided by a Party (the &#8220;<u>Disclosing Party</u>&#8221;) to the other Party (the &#8220;<u>Receiving Party</u>&#8221;) in connection with this
              Agreement, including specific terms and pricing, is the Disclosing Party&#8217;s &#8220;<u>Confidential Information</u>.&#8221; During the Term and the subsequent [***] period, the Receiving Party will maintain all Confidential Information in confidence and
              use it only as reasonably necessary to perform its obligations and exercise its rights under this Agreement. Confidential Information excludes information that (i) is publicly available through no fault of the Receiving Party or anyone to
              whom the Receiving Party made such information available; (ii) was lawfully obtained by the Receiving Party on a non-confidential basis from a third party; (iii) the Receiving Party can conclusively demonstrate was legally in its possession
              before the Disclosing Party provided it to the Receiving Party; or (iv) was independently developed by the Receiving Party or on its behalf without the use of any information provided to the Receiving Party by the Disclosing Party. In
              addition and notwithstanding anything to the contrary, any aggregated or otherwise de-identified data stored in Tempus&#8217; technology platform is not Client&#8217;s Confidential Information under this Agreement. The Receiving Party acknowledges and
              agrees that any violation of this Section 10(b) may result in irreparable injury and damage to the Disclosing Party not adequately compensable in money damages, and for which the Disclosing Party may have no adequate remedy at law. The
              Receiving Party acknowledges and agrees, therefore, that if this Section 10(b) is breached, in addition to any and all other remedies, the Disclosing Party may need to seek to obtain injunctions, orders, or decrees in order to protect the
              Confidential Information and may be entitled to do so without having to post a bond.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0fc6dabd0a414c288e7a2e5d3e1f718a" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">c.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Intellectual Property</font>. Except to the extent expressly stated otherwise, this Agreement does not grant either Party a license to or any right in the other Party&#8217;s intellectual
              property. Without limiting the generality of the foregoing, Tempus reserves all rights in Tempus Materials, during the Term and otherwise. &#8220;<u>Tempus</u>&#160;<u>Materials</u>&#8221; means any data, technology, software, formulas, techniques or know-how
              and other tangible and intangible items that are owned or created by Tempus without incorporating Client&#8217;s Confidential Information. Tempus will be and remain, at all times, the sole owner of the Tempus Materials, including any replacements,
              improvements, updates, enhancements, derivative works, and other modifications to the same in each case without incorporating Client&#8217;s Confidential Information. To the extent explicitly defined as a Deliverable in a fully executed work form,
              all clinical or other data, documentation, reports, formulations, processes, methods, discoveries, improvements, and derivatives of the foregoing, together with all developments, records, work product (including works-in-process) and
              information collected, generated, or derived by or on behalf of Tempus (&#8220;Client Data&#8221;), and any inventions that may evolve from or improvements to any of the Client Data, shall be and remain the exclusive property of Company, and Tempus
              agrees to assign, and hereby assigns, its rights in all such Client Data, inventions and/or related patents to Client. Licensed Data is never a Deliverable. To the extent any Tempus Materials are incorporated into any Deliverables, Tempus
              hereby grants to Client a perpetual, revocable, fully paid-up, royalty-free, non-exclusive, worldwide license (with the full right to sublicense directly or indirectly through multiple tiers) to use Tempus Materials that are incorporated into
              Deliverables, solely as required for Client to use the Deliverables for only their intended purpose.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3ac01b785b6a4b15ae5c7fb743015d17" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">a.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Client Materials</font>. All documentation, information, and biological, chemical or other materials controlled by Client and furnished to Tempus (the &#8220;<u>Client Materials</u>&#8221;) for purposes of providing
              the Services hereunder, all derivatives of Client Materials, and all associated intellectual property rights will remain the exclusive property of Client. If Client provides Tempus with any Client Materials, Tempus will only use the Client
              Materials solely as necessary in connection with its performance of the Services. Unless otherwise agreed to by the Parties, upon the completion of each Order Form or the expiration or termination of this Agreement, or at the request of
              Client, Tempus will return or destroy any unused portion of the Client Materials provided by Client in accordance with Client&#8217;s instructions and at Client&#8217;s expense and subject to the parties&#8217; obligations set forth in this Agreement. Client
              grants to Tempus a worldwide, royalty-free, non-exclusive license for the Term of this Agreement to use, modify, adapt and copy any such Client Materials as necessary for the performance of Tempus&#8217; obligations in connection with this
              Agreement.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z862a70a5889c418f885038ebd2782b83" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">11.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Indemnification</font>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7099e59608c64338b8958975342f609b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Mutual</font>. Each Party will defend, indemnify, and hold harmless the other Party, its board, officers, employees, suppliers, agents, successors, and assigns from and against any
              costs, losses, damages, liabilities, expenses, demands and judgments, including court costs and attorney fees (collectively, &#8220;<u>Losses</u>&#8221;) that arise out of a third party claim based on the negligent acts or willful misconduct of the
              indemnifying Party&#8217;s employees or agents that directly cause bodily injury or tangible property damage, if the injury or damage directly arises out of performance of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za88961e672ac48bdb8ac79534ce981b2" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">By Tempus</font>. Tempus will defend, indemnify, and hold Client, its board, officers, employees, suppliers, agents, successors, and assigns harmless from and against any Losses
              that arise out of a third party claim alleging that the Tempus Materials used in providing the Services or any Software or Deliverable directly infringes a copyright, a U.S. patent issued as of the Effective Date, or any third party
              trademark, or out of a material breach of its obligations, representations and/or warranties under this Agreement. Tempus&#8217; obligations under this Subsection are Client&#8217;s sole and exclusive remedy and Tempus&#8217; sole obligation for any alleged
              infringement of intellectual property. Tempus does not have any obligations for infringement or misappropriation liability under this Subsection for claims of infringement or misappropriation based upon or arising out of: (i) any Deliverable,
              Software, or Tempus Materials modified without Tempus&#8217; approval; (ii) the use of any Deliverable, Software, or Tempus Materials in combination with materials not provided by Tempus; or (iii) the use of any Deliverable, Software, or Tempus
              Materials other than as permitted under this Agreement. Tempus does not have any obligations under this Subsection for Losses that would otherwise be based upon or arise out of the negligence or willful misconduct of, or that would otherwise
              be indemnified by, Client, its directors, officers, employees, suppliers, agents, successors, and/or assigns.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze9866001b6374289b3c438c738681ce8" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">c.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">By Client</font>. Client will defend, indemnify, and hold Tempus, its directors, officers, employees, suppliers, agents, successors, and assigns harmless from and against any Losses
              that arise out of a third party claim regarding Client&#8217;s negligence or willful misconduct in the use of any Software, Licensed Data, or Deliverables, or out of a material breach of its obligations, representations and/or warranties under this
              Agreement. Client does not have any obligations under this Subsection for Losses that would otherwise be based upon or arise out of the negligence or willful misconduct of, or that would otherwise be indemnified by, Tempus, its directors,
              officers, employees, suppliers, agents, successors, and/or assigns.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd08d35e91d8749eb8b46857965592f46" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">d.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Process</font>. The indemnification obligations in this Section are subject to the &#8220;<u>Indemnified Party</u>&#8221;: (i) giving prompt notice to the &#8220;<u>Indemnifying Party</u>&#8221; of the
              claim for which indemnification is sought; (ii) reasonably cooperating in its defense; and (iii) granting the Indemnifying Party control over its defense and settlement. Any delay in notice will only excuse the Indemnifying Party&#8217;s
              obligations under this Section to the extent its defense of the claim is adversely affected. The Indemnifying Party will not agree to any finding of fault, action, or forbearance by the Indemnified Party without its advance written consent.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4187b74e30ce4bdeaff1a5651d26e214" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">12.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Limitations</font>. UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE FOR ANY SPECIAL, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL, PUNITIVE, OR OTHER INDIRECT DAMAGES SUFFERED BY THE OTHER OR ANY OTHER PERSON
              ARISING FROM OR RELATED TO THIS AGREEMENT OR ANY SERVICES OR ACTIVITIES HEREUNDER, REGARDLESS OF WHETHER THE PARTY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR THEY WERE OTHERWISE FORESEEABLE. IN ADDITION, UNDER NO CIRCUMSTANCES WILL
              EITHER PARTY BE LIABLE FOR ANY INDIVIDUAL CLAIM, OR IN THE AGGREGATE FOR ALL CLAIMS, FOR ANY AMOUNT IN EXCESS OF THE GREATER OF THE FEES PAID BY CLIENT TO TEMPUS UNDER THIS AGREEMENT IN THE [***] PRECEDING THE CLAIM OR [***]. THE LIMITATIONS
              SET FORTH IN THIS SECTION DO NOT APPLY TO EITHER PARTY&#8217;S PAYMENT OBLIGATIONS.EACH PARTY DISCLAIMS ALL WARRANTIES AND REPRESENTATIONS NOT EXPRESSLY SET FORTH IN THIS AGREEMENT.</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z013d77bff2fe48528efca8f025431529" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">13.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Term and Termination</font>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf59b658a4c584d4f969ea841534c8933" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Term</font>. This Agreement is effective as of the Effective Date and will continue for two (2) years (the &#8220;<u>Initial</u>&#160;<u>Term</u>&#8221;). Thereafter, the Agreement will renew for
              additional, successive one (1) year terms (each, a &#8220;<u>Renewal</u>&#160;<u>Term</u>&#8221;) until terminated in accordance with this Section. The Initial Term with all Renewal Terms, if any, are the &#8220;<u>Term</u>&#8221;. Sections 2, 4, 5, 9, 10, 11, 12, 13,
              14(a), and 14(h) will survive termination of this Agreement for a period of [***].</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze8b0c4d172c647059cdf94ccfcbfc200" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Termination</font>. Either Party may terminate this Agreement if the other has committed a material breach that is not cured to the reasonable satisfaction of the non-breaching
              Party within [***] of receipt of written notice from the non-breaching Party. In addition, either Party may terminate this Agreement or any ongoing Order Form(s) at any time by providing at least [***] written notice to the other Party unless
              otherwise mutually agreed by the Parties. The applicable terms of the Agreement, along with all payment obligations owed to Tempus for Services provided to Client, will survive until the surviving Order Form(s) are completed or terminated.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zca45af25ba1e424a8f2aa800d1ac3af6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">c.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Regulatory Changes</font>. If either Party (the &#8220;<u>Noticing Party</u>&#8221;) determines in good faith that a change in applicable law or regulation, or a change in how a current law or
              regulation is interpreted, (i) makes any part of this Agreement illegal or unenforceable, or (ii) materially changes the economic benefit or cost of performing this Agreement, then the Noticing Party will provide the other Party with a
              proposed amendment to this Agreement to address such change. The Parties will negotiate such amendment in good faith. If the Parties are unable to reach agreement within [***] of the initial notice, this Agreement will terminate. No liability
              will accrue to either Party for failure to perform under this Agreement during the period between notice under this Subsection and any amendment to or termination of this Agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6b0e880426a34e64832eec99972b9572" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt; vertical-align: top; font-weight: bold;">14.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div><font style="font-weight: bold;">Miscellaneous</font>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5d8469bdf7d14126993984ab713c5fe4" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">a.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Governing Law and Disputes</font>. This Agreement will be governed exclusively by the laws of New York, without regard to its conflict of law principles. The parties consent to
              exclusive jurisdiction and venue of the federal and state courts in the City of New York, New York. The Parties will use good faith efforts to work together to resolve any disputes related to this Agreement, using mutually escalating
              discussions as needed.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3e348563df8d416dbebde97e974abfdd" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">b.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Force Majeure</font>. Neither Party will be liable for any failure or delay of performance to the extent resulting from a cause outside of its reasonable control, such as natural
              disaster, strike, fire, pandemic, governmental action, terrorism, or war, but only so long as such cause persists. Once the cause no longer persists, the Parties will resume performance under this Agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z51e96a1ff9c74065a4367585e700a212" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">c.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Anti-Corruption</font>. Neither Party has received or been offered any illegal or improper payment, bribe, kickback, gift, or other item of value from an employee or agent of the
              other Party in connection with this Agreement. The Parties intend for their relationship and interactions under this Agreement to comply with the following: (i) the federal anti-kickback statute (42 U.S.C. &#167; 1320a-7b(b)) and the associated
              safe harbor regulations; and (ii) the limitation on certain physician referrals (Stark Law) (42 U.S.C. &#167; 1395nn). Accordingly, no part of any remuneration provided under this Agreement or any other agreement between the Parties is a
              prohibited payment in exchange for recommending or arranging for the referral of business or the ordering of items or services, or otherwise intended to induce illegal referrals of business.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7183bf27d6dd4c1d91f0ef497b4c2d15" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">d.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Exclusion and Debarment</font>. As of the date of this Agreement and to the best of Tempus&#8217; knowledge, neither Tempus nor any Tempus personnel providing Services under this
              Agreement: (i) have been the subject of a debarment proceeding under 21 U.S.C. &#167; 335a; or (ii) are excluded from participation in Medicare, Medicaid, or any other federal or state health care program. If (i) or (ii) occur during the Term of
              this Agreement, the affected Party will promptly notify the other Party, which may immediately terminate this Agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z79f2008d0cc84216936f0a44e5327c34" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">e.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Notice</font>. Notice required under this Agreement will be in writing, delivered to the address for each Party listed above, and clearly identifiable as a legal notice. Client will
              designate its billing contact and invoice address, and any subsequent changes to such information, by email to <u>billing@Tempus.com</u>.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcc4dcc6596fd449c9374524de578e1bb" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">f.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Binding Effect; Assignment</font>. This Agreement is binding upon, and will inure to the benefit of, the successors and permitted assigns of the Parties. Either Party may assign its
              rights and responsibilities under this Agreement to any of its affiliates or in connection with a merger, acquisition, corporate reorganization or sale of all or substantially all of its assets to which this Agreement pertains. Any other
              purported assignment is void.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf6c2eb5dd1224f6b819c3c72f9053c07" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">g.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Subcontracting</font>. [***], Tempus may subcontract certain of its rights and obligations under this Agreement. Any Tempus subcontractor is subject to the terms of this Agreement
              that would otherwise apply to Tempus, and Tempus is responsible for the acts and omissions of its subcontractor to the same extent as it is responsible for its own acts and omissions.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3c425df89a1148dca67a6ec8ea431737" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">h.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Use of Name and Marks</font>. Neither Party has the right to make public statements regarding the existence of this Agreement and an accurate description of the Services without the
              consent of the other Party, including use of the other Party&#8217;s logo in a list of clients or suppliers. Neither Party may use the other Party&#8217;s name or marks for any other purpose without the other Party&#8217;s advance written consent.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc61387c4ec8448e3888de418c5e08086" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">i.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Relationship of the Parties</font>. The Parties are independent contractors. This Agreement does not create a partnership, franchise, joint venture, agency, fiduciary, or employment
              relationship between the Parties.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z837326009007428ea83f8ca97b79135d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">j.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Entire Agreement; Amendments and Waivers</font>. This Agreement, which includes all Exhibits and fully executed Order Forms and amendments, is the entire understanding between the
              Parties on its subject matter and supersedes all prior or contemporaneous discussions, representations, and agreements, oral or written, between the Parties. Tempus accepts Client&#8217;s purchase orders for convenience only, and the terms of any
              purchase order do not bind Tempus. There are no third party beneficiaries to this Agreement. If any provision in this Agreement is held invalid or unenforceable, the remainder of the Agreement will remain enforceable to the fullest extent
              permitted by law, so long as such change does not materially change the cost or benefit of the Agreement to a Party. Any term or provision of this Agreement may be amended, and the observance of any term of this Agreement may be waived, only
              by a writing signed by the Parties. Failure to enforce any term of this Agreement is not a waiver. The body of this Agreement will supersede the terms of any Exhibit or fully executed Order Form to the extent necessary to address a direct
              conflict.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e5a79ec36f5423cadf7e645f92dec48" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; color: #000000;">k.</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="color: #000000;"><font style="font-style: italic;">Counterparts</font>. This Agreement may be executed in any number of counterparts, each of which is deemed an original and all of which taken together constitute the Agreement.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center;">[<font style="font-style: italic;">Signature Page Follows</font>]</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">This Agreement is effective as of the later date of signature below (the &#8220;<u>Effective Date</u>&#8221;).</div>
    <div><br>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z016a8f054b7a4602b02bad82d69de0c0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="2" style="width: 45.24%; vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">Remix Therapeutics Inc.</div>
          </td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="width: 51.87%; vertical-align: top;">
            <div style="text-align: justify; font-weight: bold;">Tempus Labs, Inc.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 36.58%; vertical-align: top;">&#160;</td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 43.21%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="width: 45.24%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">/s/ Peter Smith</div>
          </td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="width: 51.87%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">/s/ Ryan Bartolucci</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 36.58%; vertical-align: top;">&#160;</td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 43.21%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: justify;">Name:</div>
          </td>
          <td style="width: 36.58%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">Peter Smith</div>
          </td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: justify;">Name:</div>
          </td>
          <td style="width: 43.21%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">Ryan Bartolucci</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 36.58%; vertical-align: top;">&#160;</td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 43.21%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: justify;">Title:</div>
          </td>
          <td style="width: 36.58%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">President and CEO</div>
          </td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: justify;">Title:</div>
          </td>
          <td style="width: 43.21%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">CAO</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 36.58%; vertical-align: top;">&#160;</td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td style="width: 8.66%; vertical-align: top;">&#160;</td>
          <td style="width: 43.21%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: justify;">Date:</div>
          </td>
          <td style="width: 36.58%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">15-Aug-2023</div>
          </td>
          <td style="width: 2.89%; vertical-align: top;">&#160;</td>
          <td style="width: 8.66%; vertical-align: top;">
            <div style="text-align: justify;">Date:</div>
          </td>
          <td style="width: 43.21%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">16-Aug-2023</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div>
      <div style="text-align: center; margin-left: 0.05pt; font-weight: bold;">Amendment to Master Agreement</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 35.95pt; margin-left: 18pt;">This Amendment (&#8220;<font style="font-weight: bold;">Amendment </font>) is made as of the date of the last signature below (&#8220;<font style="font-weight: bold;">Amendment Date</font>&#8221;)
        between Remix Therapeutics, Inc. (&#8220;<font style="font-weight: bold;">Client</font>&#8221;) and Tempus AI, Inc. (formerly known as Tempus Labs, Inc.) (&#8220;<font style="font-weight: bold;">Tempus</font>&#8221;, and collectively with Client, the &#8220;<font style="font-weight: bold;">Parties</font>&#8221; and each a &#8220;<font style="font-weight: bold;">Party</font>&#8221;) and amends that certain Master Agreement between the Parties, with the effective date of August 16, 2023 (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: center; margin-left: 0.1pt; font-weight: bold;">RECITALS</div>
      <div><br>
      </div>
      <div style="margin-left: 54pt;">WHEREAS, the Parties wish to amend the Agreement in order to add additional master terms.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 35.95pt; margin-left: 18pt;">NOW THEREFORE, in consideration of the mutual promises herein, the Parties, intending to be legally bound, hereby agree as follows:</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze634dce3901d459fb294a81a9b16f349" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-weight: bold;">A.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Parties agree that the content of Attachment A hereto is hereby attached to the Agreement as new Exhibit A and the content of Attachment B hereto is hereby attached to the Agreement as new Exhibit B.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc1ba33ffcc2e4e02958703641c9cc94c" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-weight: bold;">B.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Section 1 of the Agreement is hereby deleted in its entirety and replaced with the following Section 1:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">&#8220;<font style="font-weight: bold;">General. </font>During the Term, Tempus shall provide &#8220;Services&#8221; and &#8220;Deliverables,&#8221; in accordance with Applicable Law (as defined below) , and any Exhibit or
        fully executed Order Form under this Agreement. Tempus may also grant Client a license to certain &#8220;Licensed Data&#8221; or &#8220;Software,&#8221; also to the extent included in an Exhibit or a fully executed &#8220;Order Form.&#8221; The activities contemplated as of the date
        of this Agreement are described in the attached Exhibit(s), which may be supplemented by the Parties from time to time in writing. Tempus acknowledges that the Materials (as defined below) may be of an experimental nature, and Tempus will comply
        with all applicable laws, regulations and rules relating to the handling and use thereof. Tempus will comply with all reasonable and applicable Client guidelines, such as standard operating procedures, that Client provides in writing. All
        documentation, information, and biological, chemical or other materials controlled by Client and furnished to Tempus (the &#8220;<u>Materials</u>&#8221;), all derivatives of Materials, and all associated intellectual property rights will remain the exclusive
        property of Client. If Client provides Tempus with any Materials, Tempus will use the Materials solely as necessary in connection with its performance of the Services and agrees that the Materials will not be transferred or distributed to any third
        person without the prior written permission of Client.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za4228a8efea34aa1a122d4a6901a4589" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; font-weight: bold;">C.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Section 3 of the Agreement is hereby deleted in its entirety and replaced with the following Section 3:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">&#8220;<font style="font-weight: bold;">Audits; [***]. </font>During the Term of this Agreement, after reasonable notice by Client to Tempus, Tempus will allow Client employees and representatives,
        during normal business hours and at mutually agreeable times, to: <font style="font-weight: bold;">[***]</font>. Any audit or inspection under this Section is limited to once per year without cause and Client will provide at least <font style="font-weight: bold;">[***]</font> prior written notice to Tempus. Any audit or inspection carried out in connection with this Agreement is subject to Tempus&#8217;s reasonable and applicable policies and requirements, including without limitation
        security requirements and confidentiality protections. In the event that Tempus receives an inspection notice from an applicable regulatory authority that directly relates to Services provided to Client (&#8220;Inspection Notice&#8221;), Tempus will: <font style="font-weight: bold;">[***]</font>. Client acknowledges that it is Tempus&#8217;s obligation to respond to an Inspection Notice directed to Tempus, and that Tempus must respond to the Inspection Notice; provided, however, that <font style="font-weight: bold;">[***]</font>. Client agrees to cooperate with all reasonable requests necessary to comply with an Inspection Notice. <font style="font-weight: bold;">[***]</font>&#8221;</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc7392e38a9114ac7b1ec928c123ad735" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; font-weight: bold;">D.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Section 4 of the Agreement is hereby deleted in its entire and replaced with the following Section 4:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">&#8220;<font style="font-weight: bold;">Data Verification, Reports, and Records. </font>Tempus shall maintain appropriate reasonably detailed written records of all Services performed under this
        Agreement necessary to demonstrate Tempus&#8217;s compliance with Applicable Laws and as otherwise necessary to comply with the terms of this Agreement (collectively, &#8220;Records&#8221;) in a secure area reasonably protected from fire, theft and destruction.
        During the Term of the Agreement and for at least a period of <font style="font-weight: bold;">[***] </font>thereafter or longer as required by law, Records will be retained by Tempus and made available to Client by Tempus for review <font style="font-weight: bold;">[***]</font>. Subject to the foregoing, Tempus will retain Records in accordance with Applicable Laws and its internal policies and procedures. Tempus must provide prior written notice to Client prior to discarding or
        destroying any Records and Client may request Tempus to store those Records for a longer period of time at Client&#8217;s expenses.&#8221;</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf73dd93f1f64400f86d66586aa3f5ef9" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 17.95pt; vertical-align: top; font-weight: bold;">E.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Section 5 of the Agreement is hereby deleted in its entire and replaced with the following Section 5:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;">&#8220;<font style="font-weight: bold;">Regulatory Contacts. </font>Tempus and Client will reasonably cooperate with respect to developing and agreeing to a strategy for proactive communications with
        regulatory authorities regarding the Services provided to Client under this Agreement, and Tempus will use commercially reasonable efforts not to materially deviate from such strategy except to the extent necessary to comply with its legal
        obligations. Notwithstanding the foregoing, Tempus will maintain ultimate control (in its sole discretion) over the content of regulatory communications regarding Tempus medical devices (including investigational use only devices) and laboratory
        developed tests. To the extent legally permissible, Tempus will: <font style="font-weight: bold;">[***]</font>.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd7ee21f4419a4cd0a1bf3ae748d5d863" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-weight: bold;">F.</td>
            <td style="width: auto; vertical-align: top;">
              <div>Except as otherwise provided in this Amendment, all terms and conditions previously set forth in the Agreement will remain in effect as set forth in the Agreement. If this Amendment and the Agreement are inconsistent, the terms and
                provisions of this Amendment will supersede the terms and provisions of the Agreement, but only to the extent necessary to satisfy the purposes of this Amendment.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-indent: 35.95pt; margin-left: 18pt;">NOW THEREFORE, the Parties enter into this Amendment by signature of their authorized representatives below.</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5bee01c0f8b04f9691aa0d1d2b62a441" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 10.44%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="width: 28.33%; vertical-align: top;">
              <div>Remix Therapeutics Inc.</div>
            </td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 9.44%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="width: 47.44%; vertical-align: top;">
              <div>Tempus AI, Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10.44%; vertical-align: top;">&#160;</td>
            <td style="width: 24.11%; vertical-align: top;">&#160;</td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 9.44%; vertical-align: top;">&#160;</td>
            <td style="width: 34.11%; vertical-align: top;">&#160;</td>
            <td style="width: 13.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10.44%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 24.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ Peter Smith</div>
            </td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 9.44%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 34.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ Ryan Bartolucci</div>
            </td>
            <td style="width: 13.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10.44%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 24.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>Peter Smith</div>
            </td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 9.44%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 34.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>Ryan Bartolucci</div>
            </td>
            <td style="width: 13.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10.44%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 24.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>President and CEO</div>
            </td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 9.44%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 34.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>CAO</div>
            </td>
            <td style="width: 13.33%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10.44%; vertical-align: top;">
              <div>Date:</div>
            </td>
            <td style="width: 24.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>18-Dec-2023</div>
            </td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 4.22%; vertical-align: top;">&#160;</td>
            <td style="width: 9.44%; vertical-align: top;">
              <div>Date:</div>
            </td>
            <td style="width: 34.11%; vertical-align: top; border-bottom: 2px solid black;">
              <div>18-Dec-2023</div>
            </td>
            <td style="width: 13.33%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Attachment A</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT A:</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">LICENSED DATA AND EXPLORE PROGRAM (ANALYTICAL SERVICES)</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">[***]</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Attachment B</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT B:</div>
      <div><br>
      </div>
      <div style="text-align: center; margin-left: 0.1pt; font-weight: bold;">TERMS OF USE FOR TEMPUS SOFTWARE</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">[***]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div style="text-align: center; margin-left: 31.3pt; font-weight: bold;"> <br>
        </div>
        <div style="text-align: center; margin-left: 31.3pt; font-weight: bold;">AMENDMENT #2 TO MASTER AGREEMENT</div>
        <div><br>
        </div>
        <div style="text-align: justify; text-indent: 35.95pt; margin-left: 29.5pt;">This Amendment #2 (&#8220;<font style="font-weight: bold;">Amendment</font>&#8221;) is made as of the date of the last signature below (&#8220;<font style="font-weight: bold;">Amendment
            Date</font>&#8221;) between Remix Therapeutics, Inc. (&#8220;<font style="font-weight: bold;">Client</font>&#8221;) and Tempus AI, Inc. f/k/a Tempus Labs, Inc. (&#8220;<font style="font-weight: bold;">Tempus</font>&#8221;, and collectively with Client, the &#8220;<font style="font-weight: bold;">Parties</font>&#8221; and each a &#8220;<font style="font-weight: bold;">Party</font>&#8221;) and amends that certain Master Agreement between the Parties, with the effective date of August 16, 2023, as amended by the Amendment dated
          December 18, 2023 (the &#8220;<font style="font-weight: bold;">Agreement</font>&#8221;).</div>
        <div><br>
        </div>
        <div style="text-align: center; margin-left: 31.3pt; font-weight: bold;">RECITALS</div>
        <div><br>
        </div>
        <div style="margin-left: 47.5pt;">WHEREAS, the Parties wish to amend the Agreement in order to add additional privacy terms. NOW THEREFORE, in consideration of the mutual conditions and promises set out in this</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">Amendment and other good and valuable consideration, the receipt and sufficiency of which are acknowledged and with effect on and from the date of this Amendment, the Parties agree as follows:</div>
        <div><br>
        </div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e3d9ea9d3194868933c78cfb0121fcc" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.5pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The Parties agree to amend the Agreement so as to incorporate and append Schedule 1 attached to this Amendment as a new annex to the Agreement and both Parties will adhere to and comply with the requirements of Schedule 1 in relation
                  to their processing of Personal Data under the Agreement.</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z122b022fb52e45b1831b9f8bb069528d" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.5pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>In the event of a conflict or inconsistency between the terms of this Amendment and the Agreement, the terms of the Amendment shall prevail but only to the extent necessary to satisfy the purposes of this Amendment. Except as otherwise
                  provided in this Amendment, all terms and conditions previously set forth in the Agreement will remain in effect as set forth in the Agreement.</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z11d92bbbe16d46c3bdc1584666ab495e" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.5pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>This Amendment shall be governed by and construed in accordance with the governing law provision set out in the Agreement and any dispute shall be governed by the dispute resolution procedure set out in the Agreement.</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94aa619b96f445d78740c324d55eaeaa" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 47.5pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>This Amendment may be executed in counterparts, all of which shall constitute one and the same instrument and delivered via facsimile or other electronic transmission.</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div style="text-align: center; margin-left: 31.35pt;">[<font style="font-style: italic;">Signature pages follow</font>]</div>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">IN WITNESS whereof the Parties hereto have caused this Amendment to be duly executed on the last date of signature below.</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">SIGNED BY</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">Name: Heather Wasserman</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">Role: CBO/COO</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">Signature: <u>/s/ Heather Wasserman&#160;&#160;&#160;&#160; </u><br>
        </div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">For and on behalf of</div>
        <div style="margin-left: 29.5pt; font-weight: bold;">Remix Therapeutics Inc.</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">SIGNED BY</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">Name: Ryan Bartolucci</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">Role: CAO</div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">Signature: <u>/s/ Ryan Bartolucci&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u><br>
        </div>
        <div><br>
        </div>
        <div style="margin-left: 29.5pt;">For and on behalf of</div>
        <div style="margin-left: 29.5pt; font-weight: bold;">Tempus AI, Inc.</div>
        <div><br>
        </div>
        <div style="font-family: 'Times New Roman',Times,serif; text-align: center;">[<font style="font-style: italic;">Signature page to Amendment</font>]</div>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div><br>
        </div>
        <div style="text-align: center; margin-left: 31.35pt; font-weight: bold;">SCHEDULE 1</div>
        <div><br>
        </div>
        <div style="text-align: center; margin-left: 31.5pt; font-weight: bold;">Part A: Controller to Processor obligations</div>
        <div><br>
        </div>
        <div style="text-align: center; text-indent: -42.5pt; margin-left: 72pt; font-weight: bold;">[***]</div>
        <div style="text-align: center; text-indent: -42.5pt; margin-left: 72pt; font-weight: bold;"> <br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
        </div>
        <div><br>
        </div>
        <div style="text-align: center; margin-left: 31.25pt; font-weight: bold;">Part B: EU Standard Contractual Clauses</div>
        <div><br>
        </div>
        <div style="text-align: center; margin-left: 31.25pt; font-weight: bold;">[***]</div>
        <div style="text-align: center; margin-left: 31.25pt; font-weight: bold;"> <br>
        </div>
        <div>
          <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>10
<FILENAME>ny20077915x1_ex16-1.htm
<DESCRIPTION>EXHIBIT 16.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div style="text-align: right; font-weight: bold;">
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 16.1</div>
  <div><br>
  </div>
  <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0a00f072fcdb4dd99d951a8922456589" cellpadding="0" cellspacing="0">

      <tr>
        <td style="width: 19.41%; vertical-align: top; text-align: center;"><img src="ny20077915x1_ex16-1img01.jpg"></td>
        <td style="width: 47.26%; vertical-align: top;">&#160;</td>
        <td style="width: 33.33%; vertical-align: top;">&#160;</td>
      </tr>
      <tr>
        <td style="width: 19.41%; vertical-align: top;">
          <div><img src="ny20077915x1_ex16-1img02.jpg"></div>
        </td>
        <td style="width: 47.26%; vertical-align: top;">&#160;</td>
        <td style="width: 33.33%; vertical-align: top;">&#160;</td>
      </tr>

  </table>
  <div><br>
  </div>
  <div>July 21, 2026</div>
  <div><br>
  </div>
  <div>Securities and Exchange Commission 100 F Street, N.E.</div>
  <div>Washington, DC 20549</div>
  <div><br>
  </div>
  <div>Commissioners:</div>
  <div><br>
  </div>
  <div>We have read the statements made by Remix Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 304(a)(1) of Regulation S-K, as part of the Registration Statement on Form
    S-4 of Remix Therapeutics, Inc. dated July 21, 2026. We agree with the statements concerning our Firm contained therein.</div>
  <div><br>
  </div>
  <div>Very truly yours,</div>
  <div><br>
  </div>
  <div>/s/ PricewaterhouseCoopers LLP</div>
  <div>Boston, Massachusetts</div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
  </div>
  <div><br>
  </div>
  <div style="font-weight: bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</div>
  <div><br>
  </div>
  <div>On March 3, 2026, Remix dismissed PricewaterhouseCoopers LLP (&#8220;PwC&#8221;) as its independent accountants. On May 13, 2026, Remix engaged Deloitte &amp; Touche LLP as its independent registered public accounting firm for the fiscal year ending December
    31, 2025 and 2024.</div>
  <div><br>
  </div>
  <div>Remix&#8217;s board of directors approved the decision to change Remix&#8217;s independent registered public accounting firm.</div>
  <div>The reports of PwC on Remix&#8217;s financial statements for the fiscal year ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting
    principles, except for the explanatory paragraph about the substantial doubt about the Company&#8217;s ability to continue as a going concern.</div>
  <div><br>
  </div>
  <div>During the fiscal years ended December 31, 2024 and 2023 and the subsequent period through March 3, 2026, there were no disagreements, as defined in Item 304(a)(1)(iv) of Regulation S-K, between Remix and PwC on any matter of accounting principles
    or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to PwC&#8217;s satisfaction, would have caused PwC to make reference to the subject matter of the disagreements in connection with its reports
    on Remix&#8217;s financial statements for such fiscal years.</div>
  <div>During the fiscal years ended December 31, 2024 and 2023 and the subsequent period through March 3, 2026, there were no reportable events, as described in Item 304(a)(1)(v) of Regulation S-K.</div>
  <div><br>
  </div>
  <div>Remix provided PwC with a copy of the foregoing disclosures and requested a letter addressed to the SEC stating whether PwC agrees with the statements made by Remix in this section and, if not, stating the respects in which it does not agree. A copy
    of PwC&#8217;s letter is filed as Exhibit 16.1 to the registration statement of which this proxy statement/prospectus forms a part.</div>
  <div><br>
  </div>
  <div>During the fiscal years ended December 31, 2025 and 2024 and the subsequent period through May 13, 2026, neither Remix nor anyone acting on its behalf consulted with Deloitte &amp; Touche LLP regarding either: (i) the application of accounting
    principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on Remix&#8217;s financial statements, and neither a written report nor oral advice was provided to Remix by Deloitte &amp; Touche LLP
    that Deloitte &amp; Touche LLP concluded was an important factor considered by Remix in reaching a decision as to any accounting, auditing, or financial reporting issue; or (ii) any matter that was either the subject of a disagreement, as defined in
    Item 304(a)(1)(iv) of Regulation S-K, or a reportable event, as described in Item 304(a)(1)(v) of Regulation S-K.</div>
  <div><br>
  </div>
  <div>
    <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>11
<FILENAME>ny20077915x1_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div>
    <div style="text-align: right; font-weight: bold;">Exhibit 23.1</div>
    <div style="text-align: center; font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    <div style="text-align: center;">&#160;</div>
    <div>We consent to the use of our report dated March 3, 2026, with respect to the financial statements of Passage Bio, Inc., included herein, and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus.</div>
    <div>&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z327ee2fda7ab4d43964332004f4b312f" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 97.75%; vertical-align: top;">
            <div>/s/ KPMG LLP</div>
          </td>
          <td style="width: 2.25%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 97.75%; vertical-align: top;">
            <div>&#160;</div>
          </td>
          <td style="width: 2.25%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 97.75%; vertical-align: top;">
            <div>Philadelphia, Pennsylvania</div>
          </td>
          <td style="width: 2.25%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 97.75%; vertical-align: top;">
            <div>July 21, 2026</div>
          </td>
          <td style="width: 2.25%; vertical-align: top;">
            <div>&#160;</div>
          </td>
        </tr>

    </table>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>12
<FILENAME>ny20077915x1_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 23.2</font><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
      <div> <br>
      </div>
      <div>We consent to the use in this Registration Statement&#160; on Form S-4 of our report dated July 21, 2026, relating to the financial statements of Remix Therapeutics, Inc. We also consent to the reference to us under the heading "Experts" in such
        Registration Statement.</div>
      <div> <br>
      </div>
      <div>/s/ Deloitte &amp; Touche, LLP</div>
      <div> <br>
      </div>
      <div>Boston, Massachusetts</div>
      <div> <br>
      </div>
      <div>July 21, 2026</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>13
<FILENAME>ny20077915x1_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; margin-left: 324pt;">
      <div><font style="font-weight: bold;">Exhibit 99.4</font><br>
      </div>
      <div><br>
      </div>
      <img src="ny20077915x1_ex99-4img01.jpg" height="71" width="240"></div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>July 21, 2026</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="margin-right: 416.75pt;">Board of Directors </div>
    <div style="margin-right: 416.75pt;">Passage Bio, Inc.</div>
    <div>P.O. Box 7</div>
    <div>Hopewell, NJ 08525</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>Members of the Board of Directors,</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: justify; margin-right: 53.85pt;">We hereby consent to (i) references to our name, (ii) the use of our opinion letter dated June 23, 2026 to the Passage Bio, Inc. Board of Directors included in Annex B to the proxy
      statement/prospectus, which forms a part of the Registration Statement on Form S-4 relating to the proposed merger to be entered into by and among Passage Bio, Inc., Peregrine Merger Sub, Inc. and Remix Therapeutics, Inc. and (iii) the references to
      such opinion in such proxy statement/prospectus. In giving such consent, we do not admit that we come within the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of
      the Securities and Exchange Commission thereunder, nor do we hereby admit that we are experts with respect to any part of such Registration Statement within the meaning of the term &#8220;experts&#8221; as used in the Securities Act of 1933, as amended, or the
      rules and regulations of the Securities and Exchange Commission thereunder. Additionally, such consent does not cover any future amendments to the Registration Statement.</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>Very truly yours,</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>/s/ Redwood Valuation</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>Redwood Valuation Partners, LLC<br>
      <div><br>
      </div>
      <br>
    </div>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div><img src="ny20077915x1_ex99-4img02.jpg"> </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>14
<FILENAME>ny20077915x1_ex99-5.htm
<DESCRIPTION>EXHIBIT 99.5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 99.5</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Consent to be Named as a Director</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; color: #000000;">In connection with the filing by Passage Bio, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities
        Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Passage Bio, Inc. following the
        consummation of the merger with Remix Therapeutics, Inc., which will be renamed Remix Therapeutics, Inc. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</div>
      <div><br>
      </div>
      <div style="color: #000000;">Dated: July 20, 2026</div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za95c8ca32c9b44c789f80fc1201231d7" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 56.13%; vertical-align: middle;">&#160;</td>
            <td style="width: 43.81%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 56.13%; vertical-align: top;">
              <div style="text-align: right;">By:</div>
            </td>
            <td style="width: 43.81%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Linda C. Bain</div>
            </td>
          </tr>
          <tr>
            <td style="width: 56.13%; vertical-align: top;">
              <div style="text-align: right;">Name:</div>
            </td>
            <td style="width: 43.81%; vertical-align: bottom;">
              <div>Linda C. Bain</div>
            </td>
          </tr>
          <tr>
            <td style="width: 56.13%; vertical-align: middle;">&#160;</td>
            <td style="width: 43.81%; vertical-align: middle;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>15
<FILENAME>ny20077915x1_ex99-6.htm
<DESCRIPTION>EXHIBIT 99.6
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 99.6</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Consent to be Named as a Director</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; color: #000000;">In connection with the filing by Passage Bio, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities
        Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Passage Bio, Inc. following the
        consummation of the merger with Remix Therapeutics, Inc., which will be renamed Remix Therapeutics, Inc. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</div>
      <div><br>
      </div>
      <div style="color: #000000;">Dated: July 18, 2026</div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z16055ace81554786910dc6ea9788bf5f" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
            <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 55.83%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: right;">By:</div>
            </td>
            <td style="width: 0.56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 43.62%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Maria Koehler, M.D., Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 55.83%; vertical-align: top;">
              <div style="text-align: right;">Name:</div>
            </td>
            <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
            <td style="width: 43.62%; vertical-align: bottom;">
              <div>Maria Koehler, M.D., Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
            <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.7
<SEQUENCE>16
<FILENAME>ny20077915x1_ex99-7.htm
<DESCRIPTION>EXHIBIT 99.7
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; color: #000000; font-weight: bold;">Exhibit 99.7</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Consent to be Named as a Director</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt; color: #000000;">In connection with the filing by Passage Bio, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities
        Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a member of the board of directors of Passage Bio, Inc. following the
        consummation of the merger with Remix Therapeutics, Inc., which will be renamed Remix Therapeutics, Inc. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</div>
      <div><br>
      </div>
      <div style="color: #000000;">Dated: July 19, 2026</div>
      <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z51383a0bcd5b4207a8f1d0862f4d0934" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
            <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 55.83%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: right;">By:</div>
            </td>
            <td style="width: 0.56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
            <td style="width: 43.62%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Matthew R. Patterson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 55.83%; vertical-align: top;">
              <div style="text-align: right;">Name:</div>
            </td>
            <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
            <td style="width: 43.62%; vertical-align: bottom;">
              <div>Matthew R. Patterson</div>
            </td>
          </tr>
          <tr>
            <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
            <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
            <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.8
<SEQUENCE>17
<FILENAME>ny20077915x1_ex99-8.htm
<DESCRIPTION>EXHIBIT 99.8
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.8</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Consent to be Named as a Director</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">In connection with the filing by Passage Bio, Inc. of the Registration Statement on Form S-4 with the Securities and
        Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto
        as a member of the board of directors of Passage Bio, Inc. following the consummation of the merger with Remix Therapeutics, Inc., which will be renamed Remix Therapeutics, Inc. I also consent to the filing of this consent as an exhibit to such
        Registration Statement and any amendments thereto.</div>
    <div><br>
    </div>
    <div style="color: #000000;">Dated: July 20, 2026</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z10ba4344be394c569147e42d71f3e40b" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: right;">By:</div>
          </td>
          <td style="width: 0.56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 43.62%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Peter Colabuono</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: top;">
            <div style="text-align: right;">Name:</div>
          </td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: bottom;">
            <div>Peter Colabuono</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.9
<SEQUENCE>18
<FILENAME>ny20077915x1_ex99-9.htm
<DESCRIPTION>EXHIBIT 99.9
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.9</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Consent to be Named as a Director</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">In connection with the filing by Passage Bio, Inc. of the Registration Statement on Form S-4 with the Securities and
        Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto
        as a member of the board of directors of Passage Bio, Inc. following the consummation of the merger with Remix Therapeutics, Inc., which will be renamed Remix Therapeutics, Inc. I also consent to the filing of this consent as an exhibit to such
        Registration Statement and any amendments thereto.</div>
    <div><br>
    </div>
    <div style="color: #000000;">Dated: July 20, 2026</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z9ff71e398cf54668a0de7170d7227015" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: right;">By:</div>
          </td>
          <td style="width: 0.56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 43.62%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Peter G. Smith, Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: top;">
            <div style="text-align: right;">Name:</div>
          </td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: bottom;">
            <div>Peter G. Smith, Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.10
<SEQUENCE>19
<FILENAME>ny20077915x1_ex99-10.htm
<DESCRIPTION>EXHIBIT 99.10
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 26.3.2.5342
         Copyright 1995 - 2026 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; color: #000000; font-weight: bold;">
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">Exhibit 99.10</div>
    <div><br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">Consent to be Named as a Director</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt; color: #000000;">In connection with the filing by Passage Bio, Inc. of the Registration Statement on Form S-4 with the Securities and
        Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto
        as a member of the board of directors of Passage Bio, Inc. following the consummation of the merger with Remix Therapeutics, Inc., which will be renamed Remix Therapeutics, Inc. I also consent to the filing of this consent as an exhibit to such
        Registration Statement and any amendments thereto.</div>
    <div><br>
    </div>
    <div style="color: #000000;">Dated: July 18, 2026</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2ea0954474f14bc698458bb824f9b2a6" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: right;">By:</div>
          </td>
          <td style="width: 0.56%; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
          <td style="width: 43.62%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>/s/ Scott Biller, Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: top;">
            <div style="text-align: right;">Name:</div>
          </td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: bottom;">
            <div>Scott Biller, Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 55.83%; vertical-align: middle;">&#160;</td>
          <td style="width: 0.56%; vertical-align: bottom;">&#160;</td>
          <td style="width: 43.62%; vertical-align: middle;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>20
<FILENAME>ny20077915x1_ex107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by Broadridge Transform (tm) - http://www.broadridge.com -->
<!-- Created: Tue Jul 21 18:28:11 UTC 2026 -->
<!-- Created by CompSci Resources, LLC on Mon Oct 13 19:35:23 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
 <head>
  <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
 <body><div style="font-family: Times New Roman; font-size: 12pt;"><div>

  </div><hr style="border-top: 4px solid black; border-bottom: none; border-left: none; border-right: none; height: 2px; margin: 8px auto; width: 100%;"/><div style="text-align: right; margin-right: 0.75pt;">
   <span style="font-size: 10.0pt; color: #000000; font-weight: bold;">Exhibit 107</span>
  </div><div>

  </div><div style="margin-bottom: 10pt; margin-top: 10pt; text-align: center;">
   <span style="font-size: 10.0pt; font-weight: bold;"><b>Calculation of Filing Fee Tables</b></span>
  </div><div>
  </div><div style="text-align: center;"> <span style="font-size: 10pt; font-weight: bold;"><b>Form <ix:nonNumeric contextRef="c0" name="ffd:SubmissnTp" id="ixv-195"><ix:nonNumeric contextRef="c0" name="ffd:FormTp" id="ixv-196">S-4</ix:nonNumeric></ix:nonNumeric></b></span> </div><div style="text-align: center;">
   <span style="font-size: 10.0pt; color: #000000;">(Form Type)</span>
  </div><div>
  </div><div style="text-align: center; font-size: 10pt;">&#160;
  </div><div>

  </div><div style="text-align: center;"> <ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-25"><span style="font-size: 10pt; font-weight: bold;"><b>PASSAGE BIO, INC.</b></span></ix:nonNumeric> </div><div style="text-align: center;">
   <span style="font-size: 10.0pt; color: #000000;">(Exact Name of Registrant as Specified in its Charter)</span>
  </div><div>
  </div><div style="text-align: center; margin-right: 0.75pt; font-size: 10pt;">&#160;
  </div><div>
  </div><div style="text-align: center;">
   <span style="font-size: 10.0pt; color: #000000; font-weight: bold; text-decoration: underline;">Table 1: Newly Registered Securities</span>
  </div><div>
















  </div><table style="border-spacing: 0px; border-collapse: collapse; margin-left: -0.25pt; width: 100%; font-size: 10pt;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 2%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 9%;">&#160;</td><td style="width: 14%;">&#160;</td><td style="width: 11%;">&#160;</td><td style="width: 11%;">&#160;</td><td style="width: 11%;">&#160;</td><td style="width: 11%;">&#160;</td><td style="width: 11%;">&#160;</td><td style="width: 11%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td><td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="font-weight: bold;">Security Type</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 2pt 1px; vertical-align: bottom; text-align: center;"> <span style="font-weight: bold;">Security Class Title</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 2pt 1px; vertical-align: bottom; text-align: center;"> <span style="font-weight: bold;">Fee Calculation or Carry Forward Rule</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="font-weight: bold;">Amount Registered</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="font-weight: bold;">Proposed Maximum Offering Price Per Unit</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center;"> <span style="font-weight: bold;">Maximum Aggregate Offering Price</span> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; white-space: nowrap;"> <span style="font-weight: bold;">Fee Rate</span> </td> <td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;"> <span style="font-weight: bold;">Amount of Registration Fee</span> </td> </tr> <tr style="vertical-align: top;"> <td colspan="10" style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: center;"> <span style="font-weight: bold;">Newly Registered Securities</span> </td> </tr> <tr style="vertical-align: top; height: 11pt; background-color: rgb(204, 238, 255);"> <td style="border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">(1)</td><td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; height: 11pt;"> <div> <ix:nonNumeric contextRef="c1" format="ixt:fixed-false" name="ffd:PrevslyPdFlg" id="ixv-197">Fees to Be Paid</ix:nonNumeric> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c1" name="ffd:OfferingSctyTp" id="ixv-198">Equity</ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;">
<div style="margin: 0in; font-size: 12pt; break-after: avoid;"><ix:nonNumeric contextRef="c1" name="ffd:OfferingSctyTitl" id="ixv-77"><span style="font-size: 10pt">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></div></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c1" format="ixt:fixed-true" name="ffd:FeesOthrRuleFlg" id="ixv-199">Other</ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="ffd:AmtSctiesRegd" scale="0" unitRef="shares" id="ixv-200">42,605,021</ix:nonFraction></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> N/A </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="ffd:MaxAggtOfferingPric" scale="0" unitRef="usd" id="ixv-201">8,190.12</ix:nonFraction></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="ffd:FeeRate" scale="0" unitRef="pure" id="ixv-202">0.0001381</ix:nonFraction> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="ffd:FeeAmt" scale="0" unitRef="usd" id="ixv-203">1.14</ix:nonFraction></td> </tr><tr style="vertical-align: top; height: 11pt;"> <td style="border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">(2)</td><td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; height: 11pt;"> <div> <ix:nonNumeric contextRef="c2" format="ixt:fixed-false" name="ffd:PrevslyPdFlg" id="ixv-204">Fees to Be Paid</ix:nonNumeric> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c2" name="ffd:OfferingSctyTp" id="ixv-205">Equity</ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;">
<div style="margin: 0in; font-size: 12pt; break-after: avoid;"><ix:nonNumeric contextRef="c2" name="ffd:OfferingSctyTitl" id="ixv-92"><span style="font-size: 10pt">Warrants to purchase Common Stock</span></ix:nonNumeric></div></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c2" format="ixt:fixed-true" name="ffd:FeesOthrRuleFlg" id="ixv-206">Other</ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ffd:AmtSctiesRegd" scale="0" unitRef="shares" id="ixv-207">24,891</ix:nonFraction></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> N/A </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">N/A</span><sup> </sup></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> &#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ffd:FeeAmt" scale="0" unitRef="usd" id="ixv-208">0.00</ix:nonFraction></td> </tr><tr style="vertical-align: top; height: 11pt; background-color: rgb(204, 238, 255);"> <td style="border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; text-align: center;">(3)</td><td style="padding: 2pt 1.25pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; height: 11pt;"> <div> <ix:nonNumeric contextRef="c3" format="ixt:fixed-false" name="ffd:PrevslyPdFlg" id="ixv-209">Fees to Be Paid</ix:nonNumeric> </div> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c3" name="ffd:OfferingSctyTp" id="ixv-210">Equity</ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;">
<div style="margin: 0in; font-size: 12pt; break-after: avoid;"><ix:nonNumeric contextRef="c3" name="ffd:OfferingSctyTitl" id="ixv-109"><span style="font-size: 10pt">Options to purchase Common Stock</span></ix:nonNumeric></div></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonNumeric contextRef="c3" format="ixt:fixed-true" name="ffd:FeesOthrRuleFlg" id="ixv-211">Other</ix:nonNumeric> </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ffd:AmtSctiesRegd" scale="0" unitRef="shares" id="ixv-212">3,058,476</ix:nonFraction></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> N/A </td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <span style="letter-spacing: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">N/A</span><sup> </sup></td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> &#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ffd:FeeAmt" scale="0" unitRef="usd" id="ixv-213">0.00</ix:nonFraction></td> </tr> <tr style="vertical-align: top;"> <td style="border-width: 1pt; border-style: solid; border-color: black;">&#160;</td><td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; vertical-align: bottom;"> <span style="font-weight: bold;">Total Offering Amounts</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> $<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ffd:TtlOfferingAmt" scale="0" unitRef="usd" id="ixv-214">8,190.12</ix:nonFraction></td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ffd:TtlFeeAmt" scale="0" unitRef="usd" id="ixv-215">1.14</ix:nonFraction></td> </tr> <tr style="vertical-align: top; background-color: rgb(204, 238, 255);"> <td style="border-width: 1pt; border-style: solid; border-color: black;">&#160;</td><td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; vertical-align: bottom;"> <span style="font-weight: bold;">Total Fees Previously Paid</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="ffd:TtlPrevslyPdAmt" scale="0" unitRef="usd" id="ixv-216">&#8212;</ix:nonFraction> </td> </tr> <tr style="vertical-align: top; height: 11pt;"> <td style="border-width: 1pt; border-style: solid; border-color: black;">&#160;</td><td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; height: 11pt;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; height: 11pt; vertical-align: bottom;"> <span style="font-weight: bold;">Total Fee Offsets</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> <ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="ffd:TtlOffsetAmt" scale="0" unitRef="usd" id="ixv-217">&#8212;</ix:nonFraction> </td> </tr> <tr style="vertical-align: top; height: 11pt; background-color: rgb(204, 238, 255);"> <td style="border-width: 1pt; border-style: solid; border-color: black;">&#160;</td><td style="padding: 0px 5.4pt; border-width: 1pt; border-style: solid; border-color: black; height: 11pt;">&#160;</td> <td colspan="4" style="padding: 2pt 5.4pt 1.75pt 5.4pt; border-width: 1pt; border-style: solid; border-color: black; text-align: right; height: 11pt; vertical-align: bottom;"> <span style="font-weight: bold;">Net Fee Due</span> </td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="padding: 0px 1.25pt 0px 1px; border-width: 1pt; border-style: solid; border-color: black; vertical-align: bottom; font-size: 0px; height: 11pt;">&#160;</td> <td style="border-width: 1pt; border-style: solid; border-color: black; padding: 2pt 1.25pt 1.75pt 1px; vertical-align: bottom; text-align: center; height: 11pt;"> $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ffd:NetFeeAmt" scale="0" unitRef="usd" id="ixv-218">1.14</ix:nonFraction></td> </tr> </table><ix:nonNumeric contextRef="c1" escape="true" name="ffd:OfferingNote" id="ixv-155"><table style="font-size: 12pt; width:100%;"><tr style="height: 0px; font-size: 0px;"><td style="width: 1%; vertical-align: top; font-size: 10pt;">(1)</td><td style="width: 1%; vertical-align: top; font-size: 10pt;">(a)</td><td style="width: 98%; font-size: 10pt; text-align: left;">Represents the maximum
number of shares of Common Stock, par value $0.0001 per share (&#8220;Passage Bio
Common Stock&#8221;), of Passage Bio, Inc. (&#8220;Passage Bio&#8221;), that are expected to be
issued (or become issuable) to securityholders of Remix Therapeutics, Inc. (&#8220;Remix&#8221;)
pursuant to the merger and related transactions contemplated by the Agreement
and Plan of Merger, dated as of June&#160;24, 2026 (&#8220;Merger Agreement&#8221;), by and
among Passage Bio, Merger Sub, Inc., and Remix, with Remix continuing as a
wholly-owned subsidiary of Passage Bio and the surviving corporation of the
merger. The number of shares of Passage Bio Common Stock to be registered on
this registration statement (&#8220;Registration Statement&#8221;) consists of (i) the
estimated number of shares of Passage Bio Common Stock that are expected to be
issued in exchange for shares of Remix Common Stock (the &#8220;Remix Common Stock&#8221;)
outstanding immediately prior to the Effective Time (as defined in the Merger
Agreement), including the shares of Remix Common Stock to be issued in the PIPE
Financing, after giving effect to (A) the conversion of all outstanding shares
of Remix preferred stock into shares of Remix Common Stock, (B) the conversion
of the 2025 Convertible Notes (as defined in the Registration Statement) and
the associated warrants into shares of Remix Common Stock, and (C) the
conversion of the 2026 Convertible Notes into shares of Remix Common Stock,
each without taking into account the effect of a reverse stock split of Passage
Bio Common Stock and assuming a maximum pre-split exchange ratio of
approximately 0.1734 shares of Passage Bio Common Stock for each outstanding
share of Remix Common Stock (which is subject to adjustment prior to the
closing of the Merger), and (ii) shares of Passage Bio Common Stock issuable
upon exercise of warrants issued in the merger in exchange for Remix warrants,
without taking into account the effect of a reverse stock split of Passage Bio
Common Stock and assuming a maximum pre-split exchange ratio of approximately
0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix
Common Stock (which is subject to adjustment prior to the closing of the
Merger), and (iii) options to purchase shares of Passage Bio Common Stock in
exchange for options to purchase shares of Remix Common Stock outstanding under
the Remix 2019 Plan, without taking into account the effect of a reverse stock
split of Passage Bio Common Stock and assuming a maximum pre-split exchange
ratio of approximately 0.1734 shares of Passage Bio Common Stock for each
outstanding share of Remix Common Stock (which is subject to adjustment prior
to the closing of the Merger).</td></tr><tr><td>&#160;</td><td style="font-size: 10pt; vertical-align: top;">(b)</td><td style="text-align: left;"><span style="font-size: 10pt;">Estimated solely for the
purpose of calculating the registration fee under Rule 457(f)(2) under the
Securities Act of 1933, as amended. Remix is a private company, no market
exists for its securities, and Remix has an accumulated capital deficit.
Therefore, the proposed maximum aggregate offering price is calculated based on
an aggregate offering amount equal to one-third of the aggregate par value of
the Remix Common Stock that will be exchanged in the merger.</span></td></tr><tr><td>&#160;</td><td style="font-size: 10pt; vertical-align: top;">(c)</td><td style="text-align: left;"><span style="font-size: 10pt;">In accordance with Rule 416
under the Securities Act of 1933, as amended, this registration statement shall
be deemed to cover any securities that may from time to time be offered or
issued resulting from forward or reverse stock splits, stock dividends or
similar transactions.</span></td></tr></table></ix:nonNumeric><ix:nonNumeric contextRef="c2" escape="true" name="ffd:OfferingNote" id="ixv-171"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt; font-size: 10pt;"> <div style="margin-bottom: 4pt;"> (2) </div> </td> <td style="padding: 0px 5.4pt; font-size: 10pt; text-align: left;"> <div style="margin-bottom: 4pt;"> Consists of Passage Bio warrants issued in the merger in exchange for Remix warrants, without taking into account the effect of a reverse stock split of Passage Bio Common Stock and assuming a maximum pre-split exchange ratio of approximately 0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix Common Stock (which is subject to adjustment prior to the closing of the Merger). The registration fee with respect to the warrants has been allocated to the underlying shares of Passage Bio Common Stock issuable upon exercise of such Passage Bio warrants, as described in footnote (1). </div> </td> </tr> </table></ix:nonNumeric><ix:nonNumeric contextRef="c3" escape="true" name="ffd:OfferingNote" id="ixv-181"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt; font-size: 10pt;"> <div style="margin-bottom: 4pt;"> (3) </div> </td> <td style="padding: 0px 5.4pt; font-size: 10pt; text-align: left;"> <div style="margin-bottom: 4pt;"> Consists of Passage Bio stock options to purchase shares of Passage Bio Common Stock issued in exchange for Remix stock options to purchase shares of Remix Common Stock, without taking into account the effect of a reverse stock split of Passage Bio Common Stock and assuming a maximum pre-split exchange ratio of approximately 0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix Common Stock (which is subject to adjustment prior to the closing of the Merger). The registration fee with respect to the options to purchase shares of Passage Bio Common Stock has been allocated to the underlying shares of Passage Bio Common Stock issuable upon exercise of such options, as described in footnote (1). </div> </td> </tr> </table></ix:nonNumeric><div style="margin-right : 171.75pt; font-size : 8pt; width : 100%; ">&#160;
  </div><div>

 </div><hr style="border-top: 2px solid black; border-bottom: none; border-left: none; border-right: none; height: 2px; margin: 8px auto; width: 100%;"/><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" name="ffd:CombinedProspectusTableNa" id="ixv-221">N/A</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-222">0001787297</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="ffd:FeeExhibitTp" id="ixv-223">EX-FILING FEES</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="ffd:OffsetTableNa" id="ixv-224">N/A</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-21</xbrli:startDate>
    <xbrli:endDate>2026-07-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ffd:OfferingAxis">
        <dei:lineNo>1</dei:lineNo>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-21</xbrli:startDate>
    <xbrli:endDate>2026-07-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ffd:OfferingAxis">
        <dei:lineNo>2</dei:lineNo>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-07-21</xbrli:startDate>
    <xbrli:endDate>2026-07-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:typedMember dimension="ffd:OfferingAxis">
        <dei:lineNo>3</dei:lineNo>
      </xbrldi:typedMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV7][obisxT7a+z9g8+oGwTTQrOBrd0LP3/BNFlS/TQNn+EbW8SVOIL16/gQ4LIAatvNM+XGoOrqKvV1uwqPIHYcWE8Bsx3qTFQI3hDpGLQs2Nkr+NRF2RL+c2oyAvjUf2lz9OGmkWCJ5fyZXuMoVfOBTQLt9ubKhc9Gex+o0+ULtZqhPqnVs24JYY4D3PnLZaRCax/QIeAT/df31QH9QdZ7DGkKC0LbOo1kuCiYdaTHvIB2cB3qGIIwI9cMkusP8VKbx8WJ+WHwBof+yIwKXMex6wfIT+7AoUWWtHpO4ZjDSmqCAHidooRZShq8x0YFQya91OxZXwLBIvW1Dzju0xwamb0y6PzghITm3i0yxAq9GW/I=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2026-07-21</xbrli:startDate>
    <xbrli:endDate>2026-07-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>
</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>pasg-20260721.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<xs:schema targetNamespace="http://passagebio.com/20260721" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:pasg="http://passagebio.com/20260721" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:srt-types="http://fasb.org/srt-types/2025">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20260721_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20260721_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20260721_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20260721_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://passagebio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/BalanceSheetsFy" id="BalanceSheetsFy">
        <link:definition>010000 - Statement - Balance Sheets (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/BalanceSheetsFyParenthetical" id="BalanceSheetsFyParenthetical">
        <!--Parent Role: Balance Sheets (FY)-->
        <link:definition>010100 - Statement - Balance Sheets (FY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy" id="StatementsOfOperationsAndComprehensiveLossFy">
        <link:definition>020000 - Statement - Statements of Operations and Comprehensive Loss (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StatementsOfStockholdersEquityFy" id="StatementsOfStockholdersEquityFy">
        <link:definition>030000 - Statement - Statements of Stockholders' Equity (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StatementsOfCashFlowsFy" id="StatementsOfCashFlowsFy">
        <link:definition>040000 - Statement - Statements of Cash Flows (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/BalanceSheetsQ1" id="BalanceSheetsQ1">
        <link:definition>050000 - Statement - Balance Sheets (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/BalanceSheetsQ1Parenthetical" id="BalanceSheetsQ1Parenthetical">
        <!--Parent Role: Balance Sheets (Q1)-->
        <link:definition>050100 - Statement - Balance Sheets (Q1) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1" id="StatementsOfOperationsAndComprehensiveLossQ1">
        <link:definition>060000 - Statement - Statements of Operations and Comprehensive Loss (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StatementsOfStockholdersEquityQ1" id="StatementsOfStockholdersEquityQ1">
        <link:definition>070000 - Statement - Statements of Stockholders' Equity (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StatementsOfCashFlowsQ1" id="StatementsOfCashFlowsQ1">
        <link:definition>080000 - Statement - Statements of Cash Flows (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/NatureOfOperationsFy" id="NatureOfOperationsFy">
        <link:definition>090100 - Disclosure - Nature of Operations (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/RisksAndLiquidityFy" id="RisksAndLiquidityFy">
        <link:definition>090200 - Disclosure - Risks and Liquidity (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy" id="SummaryOfSignificantAccountingPoliciesFy">
        <link:definition>090300 - Disclosure - Summary of Significant Accounting Policies (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy" id="CashCashEquivalentsAndMarketableSecuritiesFy">
        <link:definition>090400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy" id="FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy">
        <link:definition>090500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFy" id="PropertyAndEquipmentNetFy">
        <link:definition>090600 - Disclosure - Property and Equipment, Net (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy" id="AccruedExpensesAndOtherCurrentLiabilitiesFy">
        <link:definition>090700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/GemmaLicenseAgreementFy" id="GemmaLicenseAgreementFy">
        <link:definition>090800 - Disclosure - Gemma License Agreement (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SeveranceFy" id="SeveranceFy">
        <link:definition>090900 - Disclosure - Severance (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesFy" id="LeasesFy">
        <link:definition>091000 - Disclosure - Leases (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CommitmentsAndContingenciesFy" id="CommitmentsAndContingenciesFy">
        <link:definition>091100 - Disclosure - Commitments and Contingencies (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CommonStockFy" id="CommonStockFy">
        <link:definition>091200 - Disclosure - Common Stock (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SharebasedCompensationFy" id="SharebasedCompensationFy">
        <link:definition>091300 - Disclosure - Share-Based Compensation (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/IncomeTaxesFy" id="IncomeTaxesFy">
        <link:definition>091400 - Disclosure - Income Taxes (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SegmentReportingFy" id="SegmentReportingFy">
        <link:definition>091500 - Disclosure - Segment Reporting (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SubsequentEventsFy" id="SubsequentEventsFy">
        <link:definition>091600 - Disclosure - Subsequent Events (FY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/NatureOfOperationsQ1" id="NatureOfOperationsQ1">
        <link:definition>091700 - Disclosure - Nature of Operations (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1" id="RisksLiquidityAndGoingConcernQ1">
        <link:definition>091800 - Disclosure - Risks, Liquidity, and Going Concern (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1" id="SummaryOfSignificantAccountingPoliciesQ1">
        <link:definition>091900 - Disclosure - Summary of Significant Accounting Policies (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1" id="FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1">
        <link:definition>092000 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1" id="PropertyAndEquipmentNetQ1">
        <link:definition>092100 - Disclosure - Property and Equipment, Net (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1" id="AccruedExpensesAndOtherCurrentLiabilitiesQ1">
        <link:definition>092200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/GemmaLicenseAgreementQ1" id="GemmaLicenseAgreementQ1">
        <link:definition>092300 - Disclosure - Gemma License Agreement (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SeveranceQ1" id="SeveranceQ1">
        <link:definition>092400 - Disclosure - Severance (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesQ1" id="LeasesQ1">
        <link:definition>092500 - Disclosure - Leases (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CommitmentsAndContingenciesQ1" id="CommitmentsAndContingenciesQ1">
        <link:definition>092600 - Disclosure - Commitments and Contingencies (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1" id="StockholderSEquityAndSharebasedCompensationQ1">
        <link:definition>092700 - Disclosure - Stockholder's Equity and Share-Based Compensation (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SegmentReportingQ1" id="SegmentReportingQ1">
        <link:definition>092800 - Disclosure - Segment Reporting (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SubsequentEventsQ1" id="SubsequentEventsQ1">
        <link:definition>092900 - Disclosure - Subsequent Events (Q1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies" id="SummaryOfSignificantAccountingPoliciesFyPolicies">
        <!--Parent Role: Summary of Significant Accounting Policies (FY)-->
        <link:definition>100300 - Disclosure - Summary of Significant Accounting Policies (FY) (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies" id="SummaryOfSignificantAccountingPoliciesQ1Policies">
        <!--Parent Role: Summary of Significant Accounting Policies (Q1)-->
        <link:definition>101900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables" id="SummaryOfSignificantAccountingPoliciesFyTables">
        <!--Parent Role: Summary of Significant Accounting Policies (FY)-->
        <link:definition>110300 - Disclosure - Summary of Significant Accounting Policies (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables" id="CashCashEquivalentsAndMarketableSecuritiesFyTables">
        <!--Parent Role: Cash, Cash Equivalents, and Marketable Securities (FY)-->
        <link:definition>110400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables" id="FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables">
        <!--Parent Role: Fair Value of Financial Instruments and Non-Financial Instruments (FY)-->
        <link:definition>110500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFyTables" id="PropertyAndEquipmentNetFyTables">
        <!--Parent Role: Property and Equipment, Net (FY)-->
        <link:definition>110600 - Disclosure - Property and Equipment, Net (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables" id="AccruedExpensesAndOtherCurrentLiabilitiesFyTables">
        <!--Parent Role: Accrued Expenses and Other Current Liabilities (FY)-->
        <link:definition>110700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesFyTables" id="LeasesFyTables">
        <!--Parent Role: Leases (FY)-->
        <link:definition>111000 - Disclosure - Leases (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SharebasedCompensationFyTables" id="SharebasedCompensationFyTables">
        <!--Parent Role: Share-Based Compensation (FY)-->
        <link:definition>111300 - Disclosure - Share-Based Compensation (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/IncomeTaxesFyTables" id="IncomeTaxesFyTables">
        <!--Parent Role: Income Taxes (FY)-->
        <link:definition>111400 - Disclosure - Income Taxes (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SegmentReportingFyTables" id="SegmentReportingFyTables">
        <!--Parent Role: Segment Reporting (FY)-->
        <link:definition>111500 - Disclosure - Segment Reporting (FY) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables" id="SummaryOfSignificantAccountingPoliciesQ1Tables">
        <!--Parent Role: Summary of Significant Accounting Policies (Q1)-->
        <link:definition>111900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables" id="PropertyAndEquipmentNetQ1Tables">
        <!--Parent Role: Property and Equipment, Net (Q1)-->
        <link:definition>112100 - Disclosure - Property and Equipment, Net (Q1) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables" id="AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables">
        <!--Parent Role: Accrued Expenses and Other Current Liabilities (Q1)-->
        <link:definition>112200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesQ1Tables" id="LeasesQ1Tables">
        <!--Parent Role: Leases (Q1)-->
        <link:definition>112500 - Disclosure - Leases (Q1) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables" id="StockholderSEquityAndSharebasedCompensationQ1Tables">
        <!--Parent Role: Stockholder's Equity and Share-Based Compensation (Q1)-->
        <link:definition>112700 - Disclosure - Stockholder's Equity and Share-Based Compensation (Q1) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SegmentReportingQ1Tables" id="SegmentReportingQ1Tables">
        <!--Parent Role: Segment Reporting (Q1)-->
        <link:definition>112800 - Disclosure - Segment Reporting (Q1) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/RisksAndLiquidityFyDetails" id="RisksAndLiquidityFyDetails">
        <!--Parent Role: Risks and Liquidity (FY)-->
        <link:definition>120200 - Disclosure - Risks and Liquidity (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails" id="SummaryOfSignificantAccountingPoliciesFyDetails">
        <!--Parent Role: Summary of Significant Accounting Policies (FY)-->
        <link:definition>120300 - Disclosure - Summary of Significant Accounting Policies (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails" id="CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails">
        <!--Parent Role: Cash, Cash Equivalents, and Marketable Securities (FY)-->
        <link:definition>120400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities - Portfolio of Cash and Cash Equivalents (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails" id="CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails">
        <!--Parent Role: Cash, Cash Equivalents, and Marketable Securities (FY)-->
        <link:definition>120402 - Disclosure - Cash, Cash Equivalents, and Marketable Securities - Portfolio of Marketable Securities (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails" id="FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails">
        <!--Parent Role: Fair Value of Financial Instruments and Non-Financial Instruments (FY)-->
        <link:definition>120500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Recurring basis) (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails" id="FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails">
        <!--Parent Role: Fair Value of Financial Instruments and Non-Financial Instruments (FY)-->
        <link:definition>120502 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Nonrecurring Basis) (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFyDetails" id="PropertyAndEquipmentNetFyDetails">
        <!--Parent Role: Property and Equipment, Net (FY)-->
        <link:definition>120600 - Disclosure - Property and Equipment, Net (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails" id="PropertyAndEquipmentNetNarrativeFyDetails">
        <!--Parent Role: Property and Equipment, Net (FY)-->
        <link:definition>120602 - Disclosure - Property and Equipment, Net - Narrative (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesFyDetails">
        <!--Parent Role: Accrued Expenses and Other Current Liabilities (FY)-->
        <link:definition>120700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/GemmaLicenseAgreementFyDetails" id="GemmaLicenseAgreementFyDetails">
        <!--Parent Role: Gemma License Agreement (FY)-->
        <link:definition>120800 - Disclosure - Gemma License Agreement (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SeveranceFyDetails" id="SeveranceFyDetails">
        <!--Parent Role: Severance (FY)-->
        <link:definition>120900 - Disclosure - Severance (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesFyDetails" id="LeasesFyDetails">
        <!--Parent Role: Leases (FY)-->
        <link:definition>121000 - Disclosure - Leases (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesFyDetailsCalc01" id="LeasesFyDetailsCalc01">
        <!--Parent Role: Leases (FY) (Details)-->
        <link:definition>121002 - Disclosure - Leases (FY) (Details) CALC 01</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails" id="LeasesOperatingLeaseCostFyDetails">
        <!--Parent Role: Leases (FY)-->
        <link:definition>121002 - Disclosure - Leases - Operating lease cost (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesSubleaseIncomeFyDetails" id="LeasesSubleaseIncomeFyDetails">
        <!--Parent Role: Leases (FY)-->
        <link:definition>121004 - Disclosure - Leases - Sublease income (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails" id="CommitmentsAndContingenciesCollaborationAgreementsFyDetails">
        <!--Parent Role: Commitments and Contingencies (FY)-->
        <link:definition>121100 - Disclosure - Commitments and Contingencies - Collaboration Agreements (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CommonStockFyDetails" id="CommonStockFyDetails">
        <!--Parent Role: Common Stock (FY)-->
        <link:definition>121200 - Disclosure - Common Stock (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails" id="SharebasedCompensationEquityIncentivePlanEsppFyDetails">
        <!--Parent Role: Share-Based Compensation (FY)-->
        <link:definition>121300 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails" id="SharebasedCompensationSharebasedCompensationExpenseFyDetails">
        <!--Parent Role: Share-Based Compensation (FY)-->
        <link:definition>121302 - Disclosure - Share-Based Compensation - Share-based compensation expense (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails" id="SharebasedCompensationStockOptionActivityFyDetails">
        <!--Parent Role: Share-Based Compensation (FY)-->
        <link:definition>121304 - Disclosure - Share-Based Compensation - Stock Option Activity (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails" id="SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails">
        <!--Parent Role: Share-Based Compensation (FY)-->
        <link:definition>121306 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails" id="SharebasedCompensationRestrictedStockUnitsFyDetails">
        <!--Parent Role: Share-Based Compensation (FY)-->
        <link:definition>121308 - Disclosure - Share-Based Compensation - Restricted Stock Units (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails">
        <!--Parent Role: Income Taxes (FY)-->
        <link:definition>121400 - Disclosure - Income Taxes - Deferred tax assets and liabilities (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" id="IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails">
        <!--Parent Role: Income Taxes (FY)-->
        <link:definition>121402 - Disclosure - Income Taxes - Reconciliation of the federal income tax rate to the effective tax rate (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/IncomeTaxesFyDetails" id="IncomeTaxesFyDetails">
        <!--Parent Role: Income Taxes (FY)-->
        <link:definition>121404 - Disclosure - Income Taxes (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails" id="IncomeTaxesNetOperatingLossesFyDetails">
        <!--Parent Role: Income Taxes (FY)-->
        <link:definition>121406 - Disclosure - Income Taxes - Net operating losses (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SegmentReportingFyDetails" id="SegmentReportingFyDetails">
        <!--Parent Role: Segment Reporting (FY)-->
        <link:definition>121500 - Disclosure - Segment Reporting (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SubsequentEventsFyDetails" id="SubsequentEventsFyDetails">
        <!--Parent Role: Subsequent Events (FY)-->
        <link:definition>121600 - Disclosure - Subsequent Events (FY) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details" id="RisksLiquidityAndGoingConcernQ1Details">
        <!--Parent Role: Risks, Liquidity, and Going Concern (Q1)-->
        <link:definition>121800 - Disclosure - Risks, Liquidity, and Going Concern (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details" id="SummaryOfSignificantAccountingPoliciesQ1Details">
        <!--Parent Role: Summary of Significant Accounting Policies (Q1)-->
        <link:definition>121900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details" id="FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details">
        <!--Parent Role: Fair Value of Financial Instruments and Non-Financial Instruments (Q1)-->
        <link:definition>122000 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1Details" id="PropertyAndEquipmentNetQ1Details">
        <!--Parent Role: Property and Equipment, Net (Q1)-->
        <link:definition>122100 - Disclosure - Property and Equipment, Net (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details" id="PropertyAndEquipmentNetNarrativeQ1Details">
        <!--Parent Role: Property and Equipment, Net (Q1)-->
        <link:definition>122102 - Disclosure - Property and Equipment, Net - Narrative (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details" id="AccruedExpensesAndOtherCurrentLiabilitiesQ1Details">
        <!--Parent Role: Accrued Expenses and Other Current Liabilities (Q1)-->
        <link:definition>122200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/GemmaLicenseAgreementQ1Details" id="GemmaLicenseAgreementQ1Details">
        <!--Parent Role: Gemma License Agreement (Q1)-->
        <link:definition>122300 - Disclosure - Gemma License Agreement (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SeveranceQ1Details" id="SeveranceQ1Details">
        <!--Parent Role: Severance (Q1)-->
        <link:definition>122400 - Disclosure - Severance (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesQ1Details" id="LeasesQ1Details">
        <!--Parent Role: Leases (Q1)-->
        <link:definition>122500 - Disclosure - Leases (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details" id="LeasesOperatingLeaseCostQ1Details">
        <!--Parent Role: Leases (Q1)-->
        <link:definition>122502 - Disclosure - Leases - Operating lease cost (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesQ1DetailsCalc01" id="LeasesQ1DetailsCalc01">
        <!--Parent Role: Leases (Q1) (Details)-->
        <link:definition>122502 - Disclosure - Leases (Q1) (Details) CALC 01</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/LeasesSubleaseIncomeQ1Details" id="LeasesSubleaseIncomeQ1Details">
        <!--Parent Role: Leases (Q1)-->
        <link:definition>122504 - Disclosure - Leases - Sublease income (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details" id="CommitmentsAndContingenciesCollaborationAgreementsQ1Details">
        <!--Parent Role: Commitments and Contingencies (Q1)-->
        <link:definition>122600 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details" id="StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details">
        <!--Parent Role: Stockholder's Equity and Share-Based Compensation (Q1)-->
        <link:definition>122700 - Disclosure - Stockholder's Equity and Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details" id="StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details">
        <!--Parent Role: Stockholder's Equity and Share-Based Compensation (Q1)-->
        <link:definition>122702 - Disclosure - Stockholder's Equity and Share-Based Compensation - Share-based compensation expense (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details" id="StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details">
        <!--Parent Role: Stockholder's Equity and Share-Based Compensation (Q1)-->
        <link:definition>122704 - Disclosure - Stockholder's Equity and Share-Based Compensation - Stock Option Activity (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details" id="StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details">
        <!--Parent Role: Stockholder's Equity and Share-Based Compensation (Q1)-->
        <link:definition>122706 - Disclosure - Stockholder's Equity and Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details" id="StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details">
        <!--Parent Role: Stockholder's Equity and Share-Based Compensation (Q1)-->
        <link:definition>122708 - Disclosure - Stockholder's Equity and Share-Based Compensation - Restricted Stock Units (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SegmentReportingQ1Details" id="SegmentReportingQ1Details">
        <!--Parent Role: Segment Reporting (Q1)-->
        <link:definition>122800 - Disclosure - Segment Reporting (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://passagebio.com/role/SubsequentEventsQ1Details" id="SubsequentEventsQ1Details">
        <!--Parent Role: Subsequent Events (Q1)-->
        <link:definition>122900 - Disclosure - Subsequent Events (Q1) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2025" schemaLocation="https://xbrl.sec.gov/exch/2025/exch-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2025" schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" />
  <xs:element name="CollaborativeArrangementDisclosureAbstract" id="pasg_CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedResearchAndDevelopmentExpense" id="pasg_AccruedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedDivestitureFeesCurrent" id="pasg_AccruedDivestitureFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedExpensesAndOtherCurrentLiabilities" id="pasg_AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromNonRefundableTransitionServicesPayments" id="pasg_ProceedsFromNonRefundableTransitionServicesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ShortTermLicenseFeeDueAndReceivable" id="pasg_ShortTermLicenseFeeDueAndReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="UpfrontLicenseFeeReceivable" id="pasg_UpfrontLicenseFeeReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LongTermLicenseFeeDueAndReceivable" id="pasg_LongTermLicenseFeeDueAndReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" id="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ProceedsFromNonRefundableSublicensePayments" id="pasg_ProceedsFromNonRefundableSublicensePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ArrangementWithGemmaBiotherapeuticsIncMember" id="pasg_ArrangementWithGemmaBiotherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" id="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" id="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInPrepaidResearchAndDevelopment" id="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" id="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" id="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="SubleaseAgreementCMember" id="pasg_SubleaseAgreementCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OperatingLeasesForOfficeSpaceMember" id="pasg_OperatingLeasesForOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SubleaseAgreementaMember" id="pasg_SubleaseAgreementaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MarketStreetSubleaseAgreement1835Member" id="pasg_MarketStreetSubleaseAgreement1835Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SubleaseAgreementBMember" id="pasg_SubleaseAgreementBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OperatingLeasesForLaboratorySpaceMember" id="pasg_OperatingLeasesForLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" id="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfAnnualIncreaseInSubleaseRent" id="pasg_PercentageOfAnnualIncreaseInSubleaseRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NewLeaseAgreementOperatingLeaseRenewalTerm" id="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NewLeaseAgreementOperatingLeaseNumberOfExtensions" id="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AreaSubleased" id="pasg_AreaSubleased" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AreaOfLandSubleasedPercentage" id="pasg_AreaOfLandSubleasedPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PrepaidResearchAndDevelopmentAssetCurrent" id="pasg_PrepaidResearchAndDevelopmentAssetCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" id="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BasisOfPresentationPolicyTextBlock" id="pasg_BasisOfPresentationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CashCashEquivalentsAndMarketableSecuritiesAbstract" id="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RisksAndLiquidityAbstract" id="pasg_RisksAndLiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RisksAndLiquidityTextBlock" id="pasg_RisksAndLiquidityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RisksAndLiquidityTable" id="pasg_RisksAndLiquidityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RisksAndLiquidityLineItems" id="pasg_RisksAndLiquidityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AttheMarketFacilityAgreementMember" id="pasg_AttheMarketFacilityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" id="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LaboratoryEquipmentMember" id="pasg_LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LaboratoryEquipmentAndCertainOtherAssetsMember" id="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GainLossOnSaleOfTaxCredits" id="pasg_GainLossOnSaleOfTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockOptionsIncludingSharesSubjectToRepurchaseMember" id="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RightOfUseAssetsFairValueDisclosure" id="pasg_RightOfUseAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ComputerHardwareAndSoftwareMember" id="pasg_ComputerHardwareAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GeneticMedicinesSegmentMember" id="pasg_GeneticMedicinesSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GeneralAndAdministrativeThirdPartyCosts" id="pasg_GeneralAndAdministrativeThirdPartyCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GeneralAndAdministrativeShareBasedCompensation" id="pasg_GeneralAndAdministrativeShareBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GeneralAndAdministrativeLaborAndRelatedExpenses" id="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ResearchAndDevelopmentDepreciationAndAmortization" id="pasg_ResearchAndDevelopmentDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ResearchAndDevelopmentLaborAndRelatedExpenses" id="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ResearchAndDevelopmentShareBasedCompensation" id="pasg_ResearchAndDevelopmentShareBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GeneralAndAdministrativeDepreciationAndAmortization" id="pasg_GeneralAndAdministrativeDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ResearchAndDevelopmentThirdPartyCosts" id="pasg_ResearchAndDevelopmentThirdPartyCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockholderSEquityAndShareBasedCompensationAbstract" id="pasg_StockholderSEquityAndShareBasedCompensationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" id="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" id="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" id="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" id="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" id="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" id="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeeStockPurchasePlanStockPurchasePricePercentage" id="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfEquityIncentivePlans" id="pasg_NumberOfEquityIncentivePlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" id="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" id="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeeStockPurchasePlanMember" id="pasg_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlanMember" id="pasg_EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityInducementPlan2021Member" id="pasg_EquityInducementPlan2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" id="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LossContingencySharesAgreedByDefendant" id="pasg_LossContingencySharesAgreedByDefendant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" id="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfTargetAnnualBonusAmounts" id="pasg_PercentageOfTargetAnnualBonusAmounts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NonRefundableAggregateFeesPayablePerProductIndication" id="pasg_NonRefundableAggregateFeesPayablePerProductIndication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CollaborationAgreementSalesMilestonePaymentsPayable" id="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSettlementOfLitigation" id="pasg_StockIssuedDuringPeriodSettlementOfLitigation" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NonRefundableUpfrontFeesPayablePerProductIndication" id="pasg_NonRefundableUpfrontFeesPayablePerProductIndication" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="EquityIncentivePlan2020Member" id="pasg_EquityIncentivePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" id="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RisksLiquidityAndGoingConcernAbstract" id="pasg_RisksLiquidityAndGoingConcernAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InterimFinancialStatementsPolicyTextBlock" id="pasg_InterimFinancialStatementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingLossCarryforwardSubjectToExpiration" id="pasg_OperatingLossCarryforwardSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LocalTaxAuthoritiesMember" id="pasg_LocalTaxAuthoritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StateTaxAuthorityMember" id="pasg_StateTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OrphanDrugMember" id="pasg_OrphanDrugMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RemainingCapacityOfValueOfSharesAvailableToBeSold" id="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="EarlyLeaseTerminationFee" id="pasg_EarlyLeaseTerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" id="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" id="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="RightOfUsePeriodDecreaseDueToLeaseTermination" id="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="GainLossOnWriteOffOfOperatingLeases" id="pasg_GainLossOnWriteOffOfOperatingLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="LicenseFeeDueAndReceivable" id="pasg_LicenseFeeDueAndReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ProceedsFromShortTermLicenseFee" id="pasg_ProceedsFromShortTermLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EstimatedSeveranceAndRelatedCosts" id="pasg_EstimatedSeveranceAndRelatedCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RestructuringPlanReductionInWorkforcePercentage" id="pasg_RestructuringPlanReductionInWorkforcePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PaymentOfLeaseTerminationFee" id="pasg_PaymentOfLeaseTerminationFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MergerAgreementTerminationPaymentAmount" id="pasg_MergerAgreementTerminationPaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MarketStreetLeaseAgreement2005Member" id="pasg_MarketStreetLeaseAgreement2005Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DeferredTaxAssetsCollaborationAndLicenseAgreement" id="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredTaxAssetsDepreciationAndAmortization" id="pasg_DeferredTaxAssetsDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" id="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DeferredTaxAssetsOperatingLeaseLiabilities" id="pasg_DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" id="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" id="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>pasg-20260721_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1DetailsCalc01" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1DetailsCalc01" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesOperatingLeaseCostFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyDetailsCalc01" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyDetailsCalc01" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfCashFlowsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfCashFlowsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfCashFlowsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfCashFlowsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfOperationsAndComprehensiveLossFy" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsFy" />
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="calculation: AssetsCurrent to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="PrepaidResearchAndDevelopmentAssetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="calculation: AssetsCurrent to PrepaidResearchAndDevelopmentAssetCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="CommitmentsAndContingencies" xlink:title="calculation: LiabilitiesAndStockholdersEquity to CommitmentsAndContingencies" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="AccruedExpensesAndOtherCurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="calculation: LiabilitiesCurrent to AccruedExpensesAndOtherCurrentLiabilities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to ContractWithCustomerLiabilityCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="calculation: ComprehensiveIncomeNetOfTax to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to OtherNonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="AssetImpairmentCharges" xlink:title="calculation: OperatingIncomeLoss to AssetImpairmentCharges" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GeneralAndAdministrativeExpense" xlink:title="calculation: OperatingIncomeLoss to GeneralAndAdministrativeExpense" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingIncomeLoss to ResearchAndDevelopmentExpense" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GainLossOnTerminationOfLease" xlink:title="calculation: OperatingIncomeLoss to GainLossOnTerminationOfLease" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="NetIncomeLoss" xlink:title="calculation: ComprehensiveIncomeNetOfTax to NetIncomeLoss" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfCashFlowsFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AssetImpairmentCharges" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AssetImpairmentCharges" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableTrade" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableTrade" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationDepletionAndAmortization" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense" xlink:label="OtherNoncashExpense" xlink:title="OtherNoncashExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OtherNoncashExpense" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OtherNoncashExpense" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="IncreaseDecreaseInPrepaidResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidResearchAndDevelopment" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInContractWithCustomerLiability" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfConvertiblePreferredStock" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="ProceedsFromStockPlans" xlink:title="ProceedsFromStockPlans" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockPlans" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockPlans" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireProductiveAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleAndMaturityOfMarketableSecurities" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfPropertyPlantAndEquipment" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="PaymentsToAcquireMarketableSecurities" xlink:title="PaymentsToAcquireMarketableSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireMarketableSecurities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireMarketableSecurities" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfProductiveAssets" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfCashFlowsQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfProductiveAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationDepletionAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationDepletionAndAmortization" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnTerminationOfLease" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnTerminationOfLease" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayableTrade" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayableTrade" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AssetImpairmentCharges" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AssetImpairmentCharges" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="IncreaseDecreaseInPrepaidResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidResearchAndDevelopment" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInContractWithCustomerLiability" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="calculation: AvailableForSaleDebtSecuritiesAmortizedCostBasis to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="calculation: AvailableForSaleDebtSecuritiesAmortizedCostBasis to AvailableForSaleSecuritiesDebtSecurities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="calculation: AvailableForSaleDebtSecuritiesAmortizedCostBasis to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="calculation: AssetsFairValueDisclosure to CashAndCashEquivalentsFairValueDisclosure" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="calculation: AssetsFairValueDisclosure to AvailableForSaleSecuritiesDebtSecurities" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetImpairmentCharges" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="calculation: AssetImpairmentCharges to ImpairmentOfLongLivedAssetsHeldForUse" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetImpairmentCharges" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="calculation: AssetImpairmentCharges to OperatingLeaseImpairmentLoss" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="OtherAssetImpairmentCharges" xlink:title="OtherAssetImpairmentCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetImpairmentCharges" xlink:to="OtherAssetImpairmentCharges" xlink:title="calculation: AssetImpairmentCharges to OtherAssetImpairmentCharges" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="PropertyPlantAndEquipmentFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="calculation: AssetsFairValueDisclosure to PropertyPlantAndEquipmentFairValueDisclosure" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="OtherAssetsFairValueDisclosure" xlink:title="OtherAssetsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="OtherAssetsFairValueDisclosure" xlink:title="calculation: AssetsFairValueDisclosure to OtherAssetsFairValueDisclosure" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RightOfUseAssetsFairValueDisclosure" xlink:label="RightOfUseAssetsFairValueDisclosure" xlink:title="RightOfUseAssetsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="RightOfUseAssetsFairValueDisclosure" xlink:title="calculation: AssetsFairValueDisclosure to RightOfUseAssetsFairValueDisclosure" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="AccruedExpensesAndOtherCurrentLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedExpensesAndOtherCurrentLiabilities to AccruedProfessionalFeesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: AccruedExpensesAndOtherCurrentLiabilities to EmployeeRelatedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="AccruedResearchAndDevelopmentExpense" xlink:title="AccruedResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="AccruedResearchAndDevelopmentExpense" xlink:title="calculation: AccruedExpensesAndOtherCurrentLiabilities to AccruedResearchAndDevelopmentExpense" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="AccruedDivestitureFeesCurrent" xlink:title="calculation: AccruedExpensesAndOtherCurrentLiabilities to AccruedDivestitureFeesCurrent" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiability" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiability" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyDetailsCalc01">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="VariableLeaseCost" xlink:title="calculation: LeaseCost to VariableLeaseCost" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="OperatingLeaseCost" xlink:title="calculation: LeaseCost to OperatingLeaseCost" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:title="DeferredTaxAssetsCapitalizedResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:title="DeferredTaxAssetsCollaborationAndLicenseAgreement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsCollaborationAndLicenseAgreement" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwards" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="DeferredTaxAssetsDepreciationAndAmortization" xlink:title="DeferredTaxAssetsDepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsDepreciationAndAmortization" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsDepreciationAndAmortization" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsInProcessResearchAndDevelopment" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:title="DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLeaseLiabilities" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsGross" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsGross" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsValuationAllowance" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxAssetsNet" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxAssetsNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="DeferredIncomeTaxLiabilitiesNet" xlink:title="DeferredIncomeTaxLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:title="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredIncomeTaxLiabilitiesNet" xlink:to="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:title="calculation: DeferredIncomeTaxLiabilitiesNet to DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredIncomeTaxLiabilitiesNet" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredIncomeTaxLiabilitiesNet" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="IncomeTaxReconciliationNondeductibleExpenseOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationNondeductibleExpenseOther" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="IncomeTaxReconciliationTaxCreditsResearch" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationTaxCreditsResearch" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:label="GeneralAndAdministrativeShareBasedCompensation" xlink:title="GeneralAndAdministrativeShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GeneralAndAdministrativeExpense" xlink:to="GeneralAndAdministrativeShareBasedCompensation" xlink:title="calculation: GeneralAndAdministrativeExpense to GeneralAndAdministrativeShareBasedCompensation" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:label="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="GeneralAndAdministrativeDepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GeneralAndAdministrativeExpense" xlink:to="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="calculation: GeneralAndAdministrativeExpense to GeneralAndAdministrativeDepreciationAndAmortization" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:label="GeneralAndAdministrativeThirdPartyCosts" xlink:title="GeneralAndAdministrativeThirdPartyCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GeneralAndAdministrativeExpense" xlink:to="GeneralAndAdministrativeThirdPartyCosts" xlink:title="calculation: GeneralAndAdministrativeExpense to GeneralAndAdministrativeThirdPartyCosts" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:label="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="GeneralAndAdministrativeLaborAndRelatedExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GeneralAndAdministrativeExpense" xlink:to="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="calculation: GeneralAndAdministrativeExpense to GeneralAndAdministrativeLaborAndRelatedExpenses" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:label="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="ResearchAndDevelopmentLaborAndRelatedExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="calculation: ResearchAndDevelopmentExpense to ResearchAndDevelopmentLaborAndRelatedExpenses" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:label="ResearchAndDevelopmentThirdPartyCosts" xlink:title="ResearchAndDevelopmentThirdPartyCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ResearchAndDevelopmentThirdPartyCosts" xlink:title="calculation: ResearchAndDevelopmentExpense to ResearchAndDevelopmentThirdPartyCosts" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:label="ResearchAndDevelopmentShareBasedCompensation" xlink:title="ResearchAndDevelopmentShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ResearchAndDevelopmentShareBasedCompensation" xlink:title="calculation: ResearchAndDevelopmentExpense to ResearchAndDevelopmentShareBasedCompensation" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:label="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="ResearchAndDevelopmentDepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ResearchAndDevelopmentExpense" xlink:to="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="calculation: ResearchAndDevelopmentExpense to ResearchAndDevelopmentDepreciationAndAmortization" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1DetailsCalc01">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="6.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>pasg-20260721_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesCollaborationAgreementsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesSubleaseIncomeQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesSubleaseIncomeQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1DetailsCalc01" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1DetailsCalc01" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesOperatingLeaseCostQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetNarrativeQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksLiquidityAndGoingConcernQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesNetOperatingLossesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationRestrictedStockUnitsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationStockOptionActivityFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationSharebasedCompensationExpenseFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationEquityIncentivePlanEsppFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CommonStockFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommonStockFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesCollaborationAgreementsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesSubleaseIncomeFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesSubleaseIncomeFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesOperatingLeaseCostFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyDetailsCalc01" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyDetailsCalc01" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetNarrativeFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksAndLiquidityFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksAndLiquidityFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1Policies" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFyPolicies" />
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksLiquidityAndGoingConcernQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/NatureOfOperationsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#NatureOfOperationsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingFy" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationFy" />
  <link:roleRef roleURI="http://passagebio.com/role/CommonStockFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommonStockFy" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceFy" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementFy" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetFy" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksAndLiquidityFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksAndLiquidityFy" />
  <link:roleRef roleURI="http://passagebio.com/role/NatureOfOperationsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#NatureOfOperationsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfCashFlowsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfCashFlowsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfStockholdersEquityQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfStockholdersEquityQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfOperationsAndComprehensiveLossQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsQ1Parenthetical" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsQ1Parenthetical" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfCashFlowsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfCashFlowsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfStockholdersEquityFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfStockholdersEquityFy" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfOperationsAndComprehensiveLossFy" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsFyParenthetical" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsFyParenthetical" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pasg-20260721.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsFyParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfStockholdersEquityFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueShareBasedCompensation" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesShareBasedCompensation" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="definition: StatementLineItems to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfCashFlowsFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsQ1Parenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfStockholdersEquityQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesShareBasedCompensation" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="definition: StatementLineItems to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfCashFlowsQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/NatureOfOperationsFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksAndLiquidityFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommonStockFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsFy" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/NatureOfOperationsQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsQ1" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingFyTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1Tables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingQ1Tables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksAndLiquidityFyDetails">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="RisksAndLiquidityLineItems" xlink:title="RisksAndLiquidityLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: RisksAndLiquidityLineItems to RetainedEarningsAccumulatedDeficit" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: RisksAndLiquidityLineItems to StockIssuedDuringPeriodValueNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: RisksAndLiquidityLineItems to StockIssuedDuringPeriodSharesNewIssues" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: RisksAndLiquidityLineItems to ProceedsFromIssuanceOfCommonStock" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="definition: RisksAndLiquidityLineItems to PaymentsOfStockIssuanceCosts" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTable" xlink:label="RisksAndLiquidityTable" xlink:title="RisksAndLiquidityTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RisksAndLiquidityLineItems" xlink:to="RisksAndLiquidityTable" xlink:title="definition: RisksAndLiquidityLineItems to RisksAndLiquidityTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RisksAndLiquidityTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: RisksAndLiquidityTable to SubsidiarySaleOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AttheMarketFacilityAgreementMember" xlink:label="AttheMarketFacilityAgreementMember" xlink:title="AttheMarketFacilityAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AttheMarketFacilityAgreementMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to AttheMarketFacilityAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RisksAndLiquidityTable" xlink:to="RangeAxis" xlink:title="definition: RisksAndLiquidityTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to GainLossOnSaleOfPropertyPlantEquipment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OperatingLeaseImpairmentLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ProceedsFromSaleOfPropertyPlantAndEquipment" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OtherNonoperatingIncomeExpense" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="SubleaseIncome" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to SubleaseIncome" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GainLossOnSaleOfTaxCredits" xlink:label="GainLossOnSaleOfTaxCredits" xlink:title="GainLossOnSaleOfTaxCredits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="GainLossOnSaleOfTaxCredits" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to GainLossOnSaleOfTaxCredits" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockIssuedDuringPeriodSharesReverseStockSplits" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="LeaseholdsAndLeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdsAndLeaseholdImprovementsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="PropertyPlantAndEquipmentOtherTypesMember" xlink:title="PropertyPlantAndEquipmentOtherTypesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PropertyPlantAndEquipmentOtherTypesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to PropertyPlantAndEquipmentOtherTypesMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:label="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:label="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:title="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to PropertyPlantAndEquipmentAndCertainOtherAssetsMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to StockOptionsIncludingSharesSubjectToRepurchaseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="LongLivedAssetsHeldForSaleByAssetTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to LongLivedAssetsHeldForSaleByAssetTypeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="LongLivedAssetsHeldForSaleNameDomain" xlink:title="LongLivedAssetsHeldForSaleNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="LongLivedAssetsHeldForSaleNameDomain" xlink:title="definition: LongLivedAssetsHeldForSaleByAssetTypeAxis to LongLivedAssetsHeldForSaleNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="LongLivedAssetsHeldForSaleNameDomain_2" xlink:title="LongLivedAssetsHeldForSaleNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="LongLivedAssetsHeldForSaleNameDomain_2" xlink:title="definition: LongLivedAssetsHeldForSaleByAssetTypeAxis to LongLivedAssetsHeldForSaleNameDomain_2" order="2.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongLivedAssetsHeldForSaleNameDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="definition: LongLivedAssetsHeldForSaleNameDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to SubsequentEventTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="CashAndCashEquivalentsLineItems" xlink:title="CashAndCashEquivalentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="definition: CashAndCashEquivalentsLineItems to CashAndCashEquivalentsAtCarryingValueAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="definition: CashAndCashEquivalentsLineItems to CashEquivalentsAtCarryingValue" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: CashAndCashEquivalentsLineItems to CashAndCashEquivalentsFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="ScheduleOfCashAndCashEquivalentsTable" xlink:title="ScheduleOfCashAndCashEquivalentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="ScheduleOfCashAndCashEquivalentsTable" xlink:title="definition: CashAndCashEquivalentsLineItems to ScheduleOfCashAndCashEquivalentsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCashAndCashEquivalentsTable" xlink:to="CashAndCashEquivalentsAxis" xlink:title="definition: ScheduleOfCashAndCashEquivalentsTable to CashAndCashEquivalentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DemandDepositsMember" xlink:label="DemandDepositsMember" xlink:title="DemandDepositsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="DemandDepositsMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to DemandDepositsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="MoneyMarketFundsMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to MoneyMarketFundsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="CommercialPaperMember" xlink:title="CommercialPaperMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="CommercialPaperMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to CommercialPaperMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="CashAndCashEquivalentsLineItems" xlink:title="CashAndCashEquivalentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="definition: CashAndCashEquivalentsLineItems to AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="definition: CashAndCashEquivalentsLineItems to AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="definition: CashAndCashEquivalentsLineItems to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="definition: CashAndCashEquivalentsLineItems to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="definition: CashAndCashEquivalentsLineItems to AvailableForSaleSecuritiesDebtSecurities" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="ScheduleOfCashAndCashEquivalentsTable" xlink:title="ScheduleOfCashAndCashEquivalentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="ScheduleOfCashAndCashEquivalentsTable" xlink:title="definition: CashAndCashEquivalentsLineItems to ScheduleOfCashAndCashEquivalentsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCashAndCashEquivalentsTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: ScheduleOfCashAndCashEquivalentsTable to FinancialInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="CertificatesOfDepositMember" xlink:title="CertificatesOfDepositMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CertificatesOfDepositMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CertificatesOfDepositMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="CommercialPaperMember" xlink:title="CommercialPaperMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CommercialPaperMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CommercialPaperMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CorporateDebtSecuritiesMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CorporateDebtSecuritiesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="USGovernmentDebtSecuritiesMember" xlink:title="USGovernmentDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USGovernmentDebtSecuritiesMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USGovernmentDebtSecuritiesMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AvailableForSaleSecuritiesDebtSecurities" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="CashAndCashEquivalentsAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to CashAndCashEquivalentsAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="MoneyMarketFundsMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to MoneyMarketFundsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="CommercialPaperMember" xlink:title="CommercialPaperMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="CommercialPaperMember" xlink:title="definition: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to CommercialPaperMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FinancialInstrumentAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="CertificatesOfDepositMember" xlink:title="CertificatesOfDepositMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CertificatesOfDepositMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CertificatesOfDepositMember" order="1.0" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CommercialPaperMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CommercialPaperMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CorporateDebtSecuritiesMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CorporateDebtSecuritiesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="USGovernmentDebtSecuritiesMember" xlink:title="USGovernmentDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USGovernmentDebtSecuritiesMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USGovernmentDebtSecuritiesMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="PropertyPlantAndEquipmentFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PropertyPlantAndEquipmentFairValueDisclosure" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RightOfUseAssetsFairValueDisclosure" xlink:label="RightOfUseAssetsFairValueDisclosure" xlink:title="RightOfUseAssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="RightOfUseAssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to RightOfUseAssetsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="OtherAssetsFairValueDisclosure" xlink:title="OtherAssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OtherAssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OtherAssetsFairValueDisclosure" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ImpairmentOfLongLivedAssetsHeldForUse" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OperatingLeaseImpairmentLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="OtherAssetImpairmentCharges" xlink:title="OtherAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OtherAssetImpairmentCharges" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OtherAssetImpairmentCharges" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetImpairmentCharges" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetImpairmentCharges" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerHardwareAndSoftwareMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerHardwareAndSoftwareMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="LeaseholdsAndLeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdsAndLeaseholdImprovementsMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="definition: PropertyPlantAndEquipmentLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="Depreciation" xlink:title="definition: PropertyPlantAndEquipmentLineItems to Depreciation" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ProceedsFromSaleOfPropertyPlantAndEquipment" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RestructuringCostAndReserveAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain_2" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain_2" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="definition: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="LongLivedAssetsHeldForSaleByAssetTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to LongLivedAssetsHeldForSaleByAssetTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="LongLivedAssetsHeldForSaleNameDomain" xlink:title="LongLivedAssetsHeldForSaleNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="LongLivedAssetsHeldForSaleNameDomain" xlink:title="definition: LongLivedAssetsHeldForSaleByAssetTypeAxis to LongLivedAssetsHeldForSaleNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="LongLivedAssetsHeldForSaleNameDomain_2" xlink:title="LongLivedAssetsHeldForSaleNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="LongLivedAssetsHeldForSaleNameDomain_2" xlink:title="definition: LongLivedAssetsHeldForSaleByAssetTypeAxis to LongLivedAssetsHeldForSaleNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongLivedAssetsHeldForSaleNameDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="definition: LongLivedAssetsHeldForSaleNameDomain to LaboratoryEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:label="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LongLivedAssetsHeldForSaleNameDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="definition: LongLivedAssetsHeldForSaleNameDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to SubsequentEventTypeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="DisposalGroupClassificationAxis" xlink:title="DisposalGroupClassificationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="DisposalGroupClassificationAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to DisposalGroupClassificationAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="DisposalGroupClassificationDomain" xlink:title="DisposalGroupClassificationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DisposalGroupClassificationAxis" xlink:to="DisposalGroupClassificationDomain" xlink:title="definition: DisposalGroupClassificationAxis to DisposalGroupClassificationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="DisposalGroupClassificationDomain_2" xlink:title="DisposalGroupClassificationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DisposalGroupClassificationAxis" xlink:to="DisposalGroupClassificationDomain_2" xlink:title="definition: DisposalGroupClassificationAxis to DisposalGroupClassificationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:title="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisposalGroupClassificationDomain" xlink:to="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:title="definition: DisposalGroupClassificationDomain to DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_UpfrontLicenseFeeReceivable" xlink:label="UpfrontLicenseFeeReceivable" xlink:title="UpfrontLicenseFeeReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontLicenseFeeReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontLicenseFeeReceivable" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableSublicensePayments" xlink:label="ProceedsFromNonRefundableSublicensePayments" xlink:title="ProceedsFromNonRefundableSublicensePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableSublicensePayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableSublicensePayments" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShortTermLicenseFeeDueAndReceivable" xlink:label="ShortTermLicenseFeeDueAndReceivable" xlink:title="ShortTermLicenseFeeDueAndReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ShortTermLicenseFeeDueAndReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ShortTermLicenseFeeDueAndReceivable" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LongTermLicenseFeeDueAndReceivable" xlink:label="LongTermLicenseFeeDueAndReceivable" xlink:title="LongTermLicenseFeeDueAndReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LongTermLicenseFeeDueAndReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LongTermLicenseFeeDueAndReceivable" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:label="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:label="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableTransitionServicesPayments" xlink:label="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="ProceedsFromNonRefundableTransitionServicesPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableTransitionServicesPayments" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:label="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PayableDecreaseFromAmountsReceivedTransitionServicesPayments" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiabilityCurrent" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="definition: RestructuringCostAndReserveLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="SeveranceCosts1" xlink:title="definition: RestructuringCostAndReserveLineItems to SeveranceCosts1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="RestructuringReserve" xlink:title="RestructuringReserve" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringReserve" xlink:title="definition: RestructuringCostAndReserveLineItems to RestructuringReserve" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="definition: RestructuringCostAndReserveLineItems to ScheduleOfRestructuringAndRelatedCostsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfRestructuringAndRelatedCostsTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="definition: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain_2" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain_2" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="definition: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaSubleased" xlink:label="AreaSubleased" xlink:title="AreaSubleased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaSubleased" xlink:title="definition: LesseeLeaseDescriptionLineItems to AreaSubleased" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaOfLandSubleasedPercentage" xlink:label="AreaOfLandSubleasedPercentage" xlink:title="AreaOfLandSubleasedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLandSubleasedPercentage" xlink:title="definition: LesseeLeaseDescriptionLineItems to AreaOfLandSubleasedPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLand" xlink:title="definition: LesseeLeaseDescriptionLineItems to AreaOfLand" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToExtend" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="definition: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseNumberOfExtensions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseRemainingLeaseTerm" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToTerminate" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:label="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseNoticePeriodForTerminationOfLease" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="SubleaseIncome" xlink:title="definition: LesseeLeaseDescriptionLineItems to SubleaseIncome" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfAnnualIncreaseInSubleaseRent" xlink:label="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="PercentageOfAnnualIncreaseInSubleaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="definition: LesseeLeaseDescriptionLineItems to PercentageOfAnnualIncreaseInSubleaseRent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="definition: LesseeLeaseDescriptionLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseTermOfContract" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="definition: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseRenewalTerm" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AssetImpairmentCharges" xlink:title="definition: LesseeLeaseDescriptionLineItems to AssetImpairmentCharges" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseImpairmentLoss" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="definition: LesseeLeaseDescriptionLineItems to ImpairmentOfLongLivedAssetsHeldForUse" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="OtherAssetImpairmentCharges" xlink:title="OtherAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OtherAssetImpairmentCharges" xlink:title="definition: LesseeLeaseDescriptionLineItems to OtherAssetImpairmentCharges" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="ImpairmentOfLeasehold" xlink:title="ImpairmentOfLeasehold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="ImpairmentOfLeasehold" xlink:title="definition: LesseeLeaseDescriptionLineItems to ImpairmentOfLeasehold" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiability" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to PropertyPlantAndEquipmentByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="OperatingLeasesForOfficeSpaceMember" xlink:title="OperatingLeasesForOfficeSpaceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForOfficeSpaceMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForOfficeSpaceMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementaMember" xlink:label="SubleaseAgreementaMember" xlink:title="SubleaseAgreementaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementaMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementaMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementBMember" xlink:label="SubleaseAgreementBMember" xlink:title="SubleaseAgreementBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementBMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementBMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MarketStreetSubleaseAgreement1835Member" xlink:label="MarketStreetSubleaseAgreement1835Member" xlink:title="MarketStreetSubleaseAgreement1835Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="MarketStreetSubleaseAgreement1835Member" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to MarketStreetSubleaseAgreement1835Member" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="OperatingLeasesForLaboratorySpaceMember" xlink:title="OperatingLeasesForLaboratorySpaceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForLaboratorySpaceMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForLaboratorySpaceMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementCMember" xlink:label="SubleaseAgreementCMember" xlink:title="SubleaseAgreementCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementCMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementCMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RestructuringCostAndReserveAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain_2" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain_2" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="definition: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyDetailsCalc01" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesSubleaseIncomeFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="CollaborationAgreementSalesMilestonePaymentsPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementSalesMilestonePaymentsPayable" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableAggregateFeesPayablePerProductIndication" xlink:label="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="NonRefundableAggregateFeesPayablePerProductIndication" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableAggregateFeesPayablePerProductIndication" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xlink:label="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="NonRefundableUpfrontFeesPayablePerProductIndication" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableUpfrontFeesPayablePerProductIndication" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:label="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AccruedDivestitureFeesCurrent" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to AccruedDivestitureFeesCurrent" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="LossContingencyAccrualAtCarryingValue" xlink:title="LossContingencyAccrualAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencyAccrualAtCarryingValue" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencyAccrualAtCarryingValue" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockIssuedDuringPeriodSettlementOfLitigation" xlink:label="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="StockIssuedDuringPeriodSettlementOfLitigation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to StockIssuedDuringPeriodSettlementOfLitigation" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LossContingencySharesAgreedByDefendant" xlink:label="LossContingencySharesAgreedByDefendant" xlink:title="LossContingencySharesAgreedByDefendant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencySharesAgreedByDefendant" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencySharesAgreedByDefendant" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfTargetAnnualBonusAmounts" xlink:label="PercentageOfTargetAnnualBonusAmounts" xlink:title="PercentageOfTargetAnnualBonusAmounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfTargetAnnualBonusAmounts" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PercentageOfTargetAnnualBonusAmounts" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommonStockFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodValueNewIssues" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: ClassOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="definition: ClassOfStockLineItems to PaymentsOfStockIssuanceCosts" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AttheMarketFacilityAgreementMember" xlink:label="AttheMarketFacilityAgreementMember" xlink:title="AttheMarketFacilityAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AttheMarketFacilityAgreementMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to AttheMarketFacilityAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfStockByClassTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfEquityIncentivePlans" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfEquityIncentivePlans" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockAdditionalCapitalSharesReservedForFutureIssuance" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanStockPurchasePricePercentage" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="17.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EmployeeStockPurchasePlanMember" xlink:title="definition: PlanNameDomain to EmployeeStockPurchasePlanMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityIncentivePlanMember" xlink:to="EquityIncentivePlan2020Member" xlink:title="definition: EquityIncentivePlanMember to EquityIncentivePlan2020Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityInducementPlan2021Member" xlink:label="EquityInducementPlan2021Member" xlink:title="EquityInducementPlan2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityIncentivePlanMember" xlink:to="EquityInducementPlan2021Member" xlink:title="definition: EquityIncentivePlanMember to EquityInducementPlan2021Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to SubsequentEventTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:label="OperatingLossCarryforwardSubjectToExpiration" xlink:title="OperatingLossCarryforwardSubjectToExpiration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardSubjectToExpiration" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardSubjectToExpiration" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="definition: OperatingLossCarryforwardsLineItems to TaxCreditCarryforwardAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="definition: OperatingLossCarryforwardsLineItems to IncomeTaxExaminationPenaltiesAndInterestAccrued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="definition: OperatingLossCarryforwardsLineItems to IncomeTaxExaminationPenaltiesAndInterestExpense" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="IncomeTaxExaminationDescription" xlink:title="IncomeTaxExaminationDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxExaminationDescription" xlink:title="definition: OperatingLossCarryforwardsLineItems to IncomeTaxExaminationDescription" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="IncomeTaxExaminationYearUnderExamination" xlink:title="IncomeTaxExaminationYearUnderExamination" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxExaminationYearUnderExamination" xlink:title="definition: OperatingLossCarryforwardsLineItems to IncomeTaxExaminationYearUnderExamination" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="definition: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_2" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_2" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="definition: IncomeTaxAuthorityDomain to DomesticCountryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DomesticCountryMember" xlink:to="US" xlink:title="definition: DomesticCountryMember to US" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DomesticCountryMember" xlink:to="StateAndLocalJurisdictionMember" xlink:title="definition: DomesticCountryMember to StateAndLocalJurisdictionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StateTaxAuthorityMember" xlink:label="StateTaxAuthorityMember" xlink:title="StateTaxAuthorityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StateAndLocalJurisdictionMember" xlink:to="StateTaxAuthorityMember" xlink:title="definition: StateAndLocalJurisdictionMember to StateTaxAuthorityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="LocalTaxAuthoritiesMember" xlink:title="LocalTaxAuthoritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StateAndLocalJurisdictionMember" xlink:to="LocalTaxAuthoritiesMember" xlink:title="definition: StateAndLocalJurisdictionMember to LocalTaxAuthoritiesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="definition: OperatingLossCarryforwardsTable to TaxCreditCarryforwardAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain_2" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain_2" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="definition: TaxCreditCarryforwardNameDomain to ResearchMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OrphanDrugMember" xlink:label="OrphanDrugMember" xlink:title="OrphanDrugMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="OrphanDrugMember" xlink:title="definition: TaxCreditCarryforwardNameDomain to OrphanDrugMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NumberOfReportableSegments" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NumberOfReportableSegments" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentExpenseAbstract" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentExpenseAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="GeneralAndAdministrativeExpenseAbstract" xlink:title="GeneralAndAdministrativeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeExpenseAbstract" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeExpenseAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to OtherNonoperatingIncomeExpense" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:label="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="GeneralAndAdministrativeLaborAndRelatedExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeLaborAndRelatedExpenses" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:label="GeneralAndAdministrativeThirdPartyCosts" xlink:title="GeneralAndAdministrativeThirdPartyCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeThirdPartyCosts" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeThirdPartyCosts" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:label="GeneralAndAdministrativeShareBasedCompensation" xlink:title="GeneralAndAdministrativeShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeShareBasedCompensation" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeShareBasedCompensation" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:label="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="GeneralAndAdministrativeDepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeDepreciationAndAmortization" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeExpense" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeExpense" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="AssetImpairmentCharges" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to AssetImpairmentCharges" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to OperatingIncomeLoss" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:label="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="ResearchAndDevelopmentLaborAndRelatedExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentLaborAndRelatedExpenses" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:label="ResearchAndDevelopmentThirdPartyCosts" xlink:title="ResearchAndDevelopmentThirdPartyCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentThirdPartyCosts" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentThirdPartyCosts" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:label="ResearchAndDevelopmentShareBasedCompensation" xlink:title="ResearchAndDevelopmentShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentShareBasedCompensation" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentShareBasedCompensation" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:label="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="ResearchAndDevelopmentDepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentDepreciationAndAmortization" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentExpense" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="18.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable to StatementBusinessSegmentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneticMedicinesSegmentMember" xlink:label="GeneticMedicinesSegmentMember" xlink:title="GeneticMedicinesSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="GeneticMedicinesSegmentMember" xlink:title="definition: SegmentDomain to GeneticMedicinesSegmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsFyDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="RisksAndLiquidityLineItems" xlink:title="RisksAndLiquidityLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: RisksAndLiquidityLineItems to RetainedEarningsAccumulatedDeficit" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: RisksAndLiquidityLineItems to StockIssuedDuringPeriodValueNewIssues" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:label="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:title="RemainingCapacityOfValueOfSharesAvailableToBeSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:title="definition: RisksAndLiquidityLineItems to RemainingCapacityOfValueOfSharesAvailableToBeSold" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: RisksAndLiquidityLineItems to NetIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RisksAndLiquidityLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: RisksAndLiquidityLineItems to CashAndCashEquivalentsAtCarryingValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTable" xlink:label="RisksAndLiquidityTable" xlink:title="RisksAndLiquidityTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RisksAndLiquidityLineItems" xlink:to="RisksAndLiquidityTable" xlink:title="definition: RisksAndLiquidityLineItems to RisksAndLiquidityTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RisksAndLiquidityTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: RisksAndLiquidityTable to SubsidiarySaleOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AttheMarketFacilityAgreementMember" xlink:label="AttheMarketFacilityAgreementMember" xlink:title="AttheMarketFacilityAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AttheMarketFacilityAgreementMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to AttheMarketFacilityAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RisksAndLiquidityTable" xlink:to="RangeAxis" xlink:title="definition: RisksAndLiquidityTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockIssuedDuringPeriodSharesReverseStockSplits" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to CashAndCashEquivalentsAtCarryingValue" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to PropertyPlantAndEquipmentUsefulLife" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OperatingLeaseImpairmentLoss" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OtherNonoperatingIncomeExpense" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="SubleaseIncome" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to SubleaseIncome" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to GainLossOnSaleOfPropertyPlantEquipment" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:label="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to StockOptionsIncludingSharesSubjectToRepurchaseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerHardwareAndSoftwareMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ComputerHardwareAndSoftwareMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="LeaseholdsAndLeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdsAndLeaseholdImprovementsMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_UpfrontLicenseFeeReceivable" xlink:label="UpfrontLicenseFeeReceivable" xlink:title="UpfrontLicenseFeeReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontLicenseFeeReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontLicenseFeeReceivable" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableSublicensePayments" xlink:label="ProceedsFromNonRefundableSublicensePayments" xlink:title="ProceedsFromNonRefundableSublicensePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableSublicensePayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableSublicensePayments" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LicenseFeeDueAndReceivable" xlink:label="LicenseFeeDueAndReceivable" xlink:title="LicenseFeeDueAndReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LicenseFeeDueAndReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LicenseFeeDueAndReceivable" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromShortTermLicenseFee" xlink:label="ProceedsFromShortTermLicenseFee" xlink:title="ProceedsFromShortTermLicenseFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromShortTermLicenseFee" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromShortTermLicenseFee" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LongTermLicenseFeeDueAndReceivable" xlink:label="LongTermLicenseFeeDueAndReceivable" xlink:title="LongTermLicenseFeeDueAndReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LongTermLicenseFeeDueAndReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LongTermLicenseFeeDueAndReceivable" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:label="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:label="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableTransitionServicesPayments" xlink:label="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="ProceedsFromNonRefundableTransitionServicesPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableTransitionServicesPayments" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:label="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PayableDecreaseFromAmountsReceivedTransitionServicesPayments" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiabilityCurrent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="definition: RestructuringCostAndReserveLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="SeveranceCosts1" xlink:title="definition: RestructuringCostAndReserveLineItems to SeveranceCosts1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="RestructuringReserve" xlink:title="RestructuringReserve" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringReserve" xlink:title="definition: RestructuringCostAndReserveLineItems to RestructuringReserve" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="definition: RestructuringCostAndReserveLineItems to ScheduleOfRestructuringAndRelatedCostsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfRestructuringAndRelatedCostsTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="definition: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain_2" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain_2" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="definition: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaSubleased" xlink:label="AreaSubleased" xlink:title="AreaSubleased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaSubleased" xlink:title="definition: LesseeLeaseDescriptionLineItems to AreaSubleased" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaOfLandSubleasedPercentage" xlink:label="AreaOfLandSubleasedPercentage" xlink:title="AreaOfLandSubleasedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLandSubleasedPercentage" xlink:title="definition: LesseeLeaseDescriptionLineItems to AreaOfLandSubleasedPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLand" xlink:title="definition: LesseeLeaseDescriptionLineItems to AreaOfLand" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToExtend" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="definition: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseNumberOfExtensions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseRemainingLeaseTerm" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToTerminate" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:label="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseNoticePeriodForTerminationOfLease" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="SubleaseIncome" xlink:title="definition: LesseeLeaseDescriptionLineItems to SubleaseIncome" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfAnnualIncreaseInSubleaseRent" xlink:label="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="PercentageOfAnnualIncreaseInSubleaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="definition: LesseeLeaseDescriptionLineItems to PercentageOfAnnualIncreaseInSubleaseRent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="definition: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseRenewalTerm" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EarlyLeaseTerminationFee" xlink:label="EarlyLeaseTerminationFee" xlink:title="EarlyLeaseTerminationFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="EarlyLeaseTerminationFee" xlink:title="definition: LesseeLeaseDescriptionLineItems to EarlyLeaseTerminationFee" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="GainLossOnTerminationOfLease" xlink:title="definition: LesseeLeaseDescriptionLineItems to GainLossOnTerminationOfLease" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GainLossOnWriteOffOfOperatingLeases" xlink:label="GainLossOnWriteOffOfOperatingLeases" xlink:title="GainLossOnWriteOffOfOperatingLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="GainLossOnWriteOffOfOperatingLeases" xlink:title="definition: LesseeLeaseDescriptionLineItems to GainLossOnWriteOffOfOperatingLeases" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="definition: LesseeLeaseDescriptionLineItems to GainLossOnSaleOfPropertyPlantEquipment" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:label="RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:title="RightOfUsePeriodDecreaseDueToLeaseTermination" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:title="definition: LesseeLeaseDescriptionLineItems to RightOfUsePeriodDecreaseDueToLeaseTermination" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:label="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:title="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:title="definition: LesseeLeaseDescriptionLineItems to LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiability" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="28.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to RangeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to PropertyPlantAndEquipmentByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="OperatingLeasesForOfficeSpaceMember" xlink:title="OperatingLeasesForOfficeSpaceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForOfficeSpaceMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForOfficeSpaceMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementaMember" xlink:label="SubleaseAgreementaMember" xlink:title="SubleaseAgreementaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementaMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementaMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementBMember" xlink:label="SubleaseAgreementBMember" xlink:title="SubleaseAgreementBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementBMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementBMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="OperatingLeasesForLaboratorySpaceMember" xlink:title="OperatingLeasesForLaboratorySpaceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForLaboratorySpaceMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForLaboratorySpaceMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementCMember" xlink:label="SubleaseAgreementCMember" xlink:title="SubleaseAgreementCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementCMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementCMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1DetailsCalc01" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesSubleaseIncomeQ1Details" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="CollaborationAgreementSalesMilestonePaymentsPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementSalesMilestonePaymentsPayable" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableAggregateFeesPayablePerProductIndication" xlink:label="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="NonRefundableAggregateFeesPayablePerProductIndication" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableAggregateFeesPayablePerProductIndication" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xlink:label="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="NonRefundableUpfrontFeesPayablePerProductIndication" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableUpfrontFeesPayablePerProductIndication" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:label="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AccruedDivestitureFeesCurrent" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to AccruedDivestitureFeesCurrent" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="LossContingencyAccrualAtCarryingValue" xlink:title="LossContingencyAccrualAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencyAccrualAtCarryingValue" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencyAccrualAtCarryingValue" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockIssuedDuringPeriodSettlementOfLitigation" xlink:label="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="StockIssuedDuringPeriodSettlementOfLitigation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to StockIssuedDuringPeriodSettlementOfLitigation" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LossContingencySharesAgreedByDefendant" xlink:label="LossContingencySharesAgreedByDefendant" xlink:title="LossContingencySharesAgreedByDefendant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencySharesAgreedByDefendant" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencySharesAgreedByDefendant" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfTargetAnnualBonusAmounts" xlink:label="PercentageOfTargetAnnualBonusAmounts" xlink:title="PercentageOfTargetAnnualBonusAmounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfTargetAnnualBonusAmounts" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PercentageOfTargetAnnualBonusAmounts" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfEquityIncentivePlans" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfEquityIncentivePlans" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockAdditionalCapitalSharesReservedForFutureIssuance" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanStockPurchasePricePercentage" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="17.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EmployeeStockPurchasePlanMember" xlink:title="definition: PlanNameDomain to EmployeeStockPurchasePlanMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityInducementPlan2021Member" xlink:label="EquityInducementPlan2021Member" xlink:title="EquityInducementPlan2021Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityIncentivePlanMember" xlink:to="EquityInducementPlan2021Member" xlink:title="definition: EquityIncentivePlanMember to EquityInducementPlan2021Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to SubsequentEventTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details" />
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NumberOfReportableSegments" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NumberOfReportableSegments" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentExpenseAbstract" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentExpenseAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="GeneralAndAdministrativeExpenseAbstract" xlink:title="GeneralAndAdministrativeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeExpenseAbstract" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeExpenseAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to OtherNonoperatingIncomeExpense" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:label="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="GeneralAndAdministrativeLaborAndRelatedExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeLaborAndRelatedExpenses" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:label="GeneralAndAdministrativeThirdPartyCosts" xlink:title="GeneralAndAdministrativeThirdPartyCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeThirdPartyCosts" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeThirdPartyCosts" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:label="GeneralAndAdministrativeShareBasedCompensation" xlink:title="GeneralAndAdministrativeShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeShareBasedCompensation" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeShareBasedCompensation" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:label="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="GeneralAndAdministrativeDepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeDepreciationAndAmortization" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeExpense" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeExpense" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="AssetImpairmentCharges" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to AssetImpairmentCharges" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GainLossOnTerminationOfLease" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GainLossOnTerminationOfLease" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to OperatingIncomeLoss" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:label="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="ResearchAndDevelopmentLaborAndRelatedExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentLaborAndRelatedExpenses" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:label="ResearchAndDevelopmentThirdPartyCosts" xlink:title="ResearchAndDevelopmentThirdPartyCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentThirdPartyCosts" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentThirdPartyCosts" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:label="ResearchAndDevelopmentShareBasedCompensation" xlink:title="ResearchAndDevelopmentShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentShareBasedCompensation" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentShareBasedCompensation" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:label="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="ResearchAndDevelopmentDepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentDepreciationAndAmortization" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentExpense" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="definition: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="19.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable to StatementBusinessSegmentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneticMedicinesSegmentMember" xlink:label="GeneticMedicinesSegmentMember" xlink:title="GeneticMedicinesSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="GeneticMedicinesSegmentMember" xlink:title="definition: SegmentDomain to GeneticMedicinesSegmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RestructuringPlanReductionInWorkforcePercentage" xlink:label="RestructuringPlanReductionInWorkforcePercentage" xlink:title="RestructuringPlanReductionInWorkforcePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="RestructuringPlanReductionInWorkforcePercentage" xlink:title="definition: SubsequentEventLineItems to RestructuringPlanReductionInWorkforcePercentage" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EstimatedSeveranceAndRelatedCosts" xlink:label="EstimatedSeveranceAndRelatedCosts" xlink:title="EstimatedSeveranceAndRelatedCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="EstimatedSeveranceAndRelatedCosts" xlink:title="definition: SubsequentEventLineItems to EstimatedSeveranceAndRelatedCosts" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PaymentOfLeaseTerminationFee" xlink:label="PaymentOfLeaseTerminationFee" xlink:title="PaymentOfLeaseTerminationFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PaymentOfLeaseTerminationFee" xlink:title="definition: SubsequentEventLineItems to PaymentOfLeaseTerminationFee" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MergerAgreementTerminationPaymentAmount" xlink:label="MergerAgreementTerminationPaymentAmount" xlink:title="MergerAgreementTerminationPaymentAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="MergerAgreementTerminationPaymentAmount" xlink:title="definition: SubsequentEventLineItems to MergerAgreementTerminationPaymentAmount" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: SubsequentEventTable to PropertyPlantAndEquipmentByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MarketStreetLeaseAgreement2005Member" xlink:label="MarketStreetLeaseAgreement2005Member" xlink:title="MarketStreetLeaseAgreement2005Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="MarketStreetLeaseAgreement2005Member" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to MarketStreetLeaseAgreement2005Member" order="1.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>pasg-20260721_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis" xml:lang="en-US" id="srt_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis" xlink:title="label: RangeAxis to srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember" xml:lang="en-US" id="srt_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember" xlink:title="label: RangeMember to srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_MaximumMember" xml:lang="en-US" id="srt_MaximumMember">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember" xlink:title="label: MaximumMember to srt_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl1" xml:lang="en-US" id="srt_MaximumMember_lbl1">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl1" xlink:title="label: MaximumMember to srt_MaximumMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:label xlink:type="resource" xlink:label="country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="country_US" xml:lang="en-US" id="country_US">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="US" xlink:to="country_US" xlink:title="label: US to country_US" />
    <link:label xlink:type="resource" xlink:label="country_US_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="country_US_lbl1" xml:lang="en-US" id="country_US_lbl1">UNITED STATES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="US" xlink:to="country_US_lbl1" xlink:title="label: US to country_US_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital">Additional paidin capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US" id="us-gaap_PaymentsToAcquireProductiveAssets">Purchases of property and equipment and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:title="label: PaymentsToAcquireProductiveAssets to us-gaap_PaymentsToAcquireProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireProductiveAssets_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireProductiveAssets_lbl1">Payments to Acquire Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl1" xlink:title="label: PaymentsToAcquireProductiveAssets to us-gaap_PaymentsToAcquireProductiveAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation" xml:lang="en-US" id="us-gaap_Depreciation">Depreciation on equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation" xlink:title="label: Depreciation to us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="ImpairmentOfLeasehold" xlink:title="ImpairmentOfLeasehold" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfLeasehold" xml:lang="en-US" id="us-gaap_ImpairmentOfLeasehold">Impairment of leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLeasehold" xlink:to="us-gaap_ImpairmentOfLeasehold" xlink:title="label: ImpairmentOfLeasehold to us-gaap_ImpairmentOfLeasehold" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLeasehold_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLeasehold_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfLeasehold_lbl1">Impairment of Leasehold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLeasehold" xlink:to="us-gaap_ImpairmentOfLeasehold_lbl1" xlink:title="label: ImpairmentOfLeasehold to us-gaap_ImpairmentOfLeasehold_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AssetImpairmentCharges" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetImpairmentCharges1" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges1">Total impairment losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges1" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentCharges_lbl2" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges_lbl2">Asset Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl2" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="OtherAssetImpairmentCharges" xlink:title="OtherAssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetImpairmentCharges" xml:lang="en-US" id="us-gaap_OtherAssetImpairmentCharges">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges" xlink:title="label: OtherAssetImpairmentCharges to us-gaap_OtherAssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetImpairmentCharges1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherAssetImpairmentCharges1" xml:lang="en-US" id="us-gaap_OtherAssetImpairmentCharges1">Impairment of certain other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges1" xlink:title="label: OtherAssetImpairmentCharges to us-gaap_OtherAssetImpairmentCharges1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetImpairmentCharges_lbl2" xml:lang="en-US" id="us-gaap_OtherAssetImpairmentCharges_lbl2">Other Asset Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl2" xlink:title="label: OtherAssetImpairmentCharges to us-gaap_OtherAssetImpairmentCharges_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract">Balance Sheets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasic" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic">Net loss per share of common stock, basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl1">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium">Amortization of premium and discount on marketable securities, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl1">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and Cash Equivalent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="label: CashAndCashEquivalentsAtCarryingValueAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1">Cash and Cash Equivalent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValueAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue">Cost or Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl1">Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="CertificatesOfDepositMember" xlink:title="CertificatesOfDepositMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CertificatesOfDepositMember" xml:lang="en-US" id="us-gaap_CertificatesOfDepositMember">Certificates of deposit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:title="label: CertificatesOfDepositMember to us-gaap_CertificatesOfDepositMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CertificatesOfDepositMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CertificatesOfDepositMember_lbl1" xml:lang="en-US" id="us-gaap_CertificatesOfDepositMember_lbl1">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl1" xlink:title="label: CertificatesOfDepositMember to us-gaap_CertificatesOfDepositMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US" id="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">Valuation allowance increased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xml:lang="en-US" id="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" xlink:title="label: ValuationAllowanceDeferredTaxAssetChangeInAmount to us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses and other current assets, and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableTrade">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:title="label: IncreaseDecreaseInAccountsPayableTrade to us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayableTrade to us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="CommercialPaperMember" xlink:title="CommercialPaperMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommercialPaperMember" xml:lang="en-US" id="us-gaap_CommercialPaperMember">Commercial paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember" xlink:title="label: CommercialPaperMember to us-gaap_CommercialPaperMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommercialPaperMember_lbl1" xml:lang="en-US" id="us-gaap_CommercialPaperMember_lbl1">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl1" xlink:title="label: CommercialPaperMember to us-gaap_CommercialPaperMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl1">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl1">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComputerEquipmentMember" xml:lang="en-US" id="us-gaap_ComputerEquipmentMember">Computer hardware</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember" xlink:title="label: ComputerEquipmentMember to us-gaap_ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US" id="us-gaap_ComputerEquipmentMember_lbl1">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1" xlink:title="label: ComputerEquipmentMember to us-gaap_ComputerEquipmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US" id="us-gaap_CorporateDebtSecuritiesMember">Corporate debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:title="label: CorporateDebtSecuritiesMember to us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CorporateDebtSecuritiesMember_lbl1" xml:lang="en-US" id="us-gaap_CorporateDebtSecuritiesMember_lbl1">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl1" xlink:title="label: CorporateDebtSecuritiesMember to us-gaap_CorporateDebtSecuritiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsGross" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross">Total gross deferred tax assets before valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="label: DeferredTaxAssetsInProcessResearchAndDevelopment to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xlink:title="label: DeferredTaxAssetsInProcessResearchAndDevelopment to us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsNet" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl1">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="DeferredTaxLiabilitiesAbstract" xlink:title="DeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesAbstract">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:title="label: DeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" xlink:title="label: DeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DemandDepositsMember" xlink:label="DemandDepositsMember" xlink:title="DemandDepositsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DemandDepositsMember" xml:lang="en-US" id="us-gaap_DemandDepositsMember">Cash accounts in banking institutions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DemandDepositsMember" xlink:to="us-gaap_DemandDepositsMember" xlink:title="label: DemandDepositsMember to us-gaap_DemandDepositsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DemandDepositsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DemandDepositsMember_lbl1" xml:lang="en-US" id="us-gaap_DemandDepositsMember_lbl1">Demand Deposits [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DemandDepositsMember" xlink:to="us-gaap_DemandDepositsMember_lbl1" xlink:title="label: DemandDepositsMember to us-gaap_DemandDepositsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted">Net loss per share of common stock, diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl1">Earnings Per Share, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">Foreign pre-tax income or losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">Changes in valuation allowances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">US federal statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">Expiration of share-based payment awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Percent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditsResearch to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditsResearch to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockMember" xml:lang="en-US" id="us-gaap_EmployeeStockMember">Employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember" xlink:title="label: EmployeeStockMember to us-gaap_EmployeeStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockMember_lbl1">Employee Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl1" xlink:title="label: EmployeeStockMember to us-gaap_EmployeeStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation" xml:lang="en-US" id="us-gaap_ShareBasedCompensation">Sharebased compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DomesticCountryMember" xml:lang="en-US" id="us-gaap_DomesticCountryMember">Domestic Tax Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember" xlink:title="label: DomesticCountryMember to us-gaap_DomesticCountryMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember">Furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl1">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="us-gaap_GainLossOnSaleOfPropertyPlantEquipment">Loss on disposal of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl1">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl1" xlink:title="label: GainLossOnSaleOfPropertyPlantEquipment to us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpense1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense1">Total general and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense1" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense_lbl2" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense_lbl2">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl2" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="GeneralAndAdministrativeExpenseAbstract" xlink:title="GeneralAndAdministrativeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseAbstract" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseAbstract">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:title="label: GeneralAndAdministrativeExpenseAbstract to us-gaap_GeneralAndAdministrativeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl1">General and Administrative Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl1" xlink:title="label: GeneralAndAdministrativeExpenseAbstract to us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember">General and administrative expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember1" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember1">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember1" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" xlink:title="label: GeneralAndAdministrativeExpenseMember to us-gaap_GeneralAndAdministrativeExpenseMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse1" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse1">Impairment expenses for property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse1" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl2" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl2">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl2" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">Impairment of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="label: ImpairmentOfLongLivedAssetsToBeDisposedOf to us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf1" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf1">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf1" xlink:title="label: ImpairmentOfLongLivedAssetsToBeDisposedOf to us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl2" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl2">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl2" xlink:title="label: ImpairmentOfLongLivedAssetsToBeDisposedOf to us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract">Statements of Operations and Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">Income tax examination, penalties and interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestExpense to us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl1">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl1" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestExpense to us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestAccrued to us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl1">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl1" xlink:title="label: IncomeTaxExaminationPenaltiesAndInterestAccrued to us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="label: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xlink:title="label: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">US federal statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="label: IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate to us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" xlink:title="label: IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate to us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="IncomeTaxReconciliationNondeductibleExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseOther to us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseOther to us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">Expiration of share-based payment awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="IncomeTaxReconciliationTaxCreditsAbstract" xlink:title="IncomeTaxReconciliationTaxCreditsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:title="label: IncomeTaxReconciliationTaxCreditsAbstract to us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl1" xlink:title="label: IncomeTaxReconciliationTaxCreditsAbstract to us-gaap_IncomeTaxReconciliationTaxCreditsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationTaxCreditsResearch">Research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:title="label: IncomeTaxReconciliationTaxCreditsResearch to us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl1" xlink:title="label: IncomeTaxReconciliationTaxCreditsResearch to us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxesPaidNet" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet">Income tax payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaidNet_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet_lbl1">Income Taxes Paid, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl1" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="MarketableSecuritiesPolicy" xlink:title="MarketableSecuritiesPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MarketableSecuritiesPolicy" xml:lang="en-US" id="us-gaap_MarketableSecuritiesPolicy">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy" xlink:title="label: MarketableSecuritiesPolicy to us-gaap_MarketableSecuritiesPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MarketableSecuritiesPolicy_lbl1" xml:lang="en-US" id="us-gaap_MarketableSecuritiesPolicy_lbl1">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl1" xlink:title="label: MarketableSecuritiesPolicy to us-gaap_MarketableSecuritiesPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities" xml:lang="en-US" id="us-gaap_Liabilities">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities" xlink:title="label: Liabilities to us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract">Liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="LossContingencyAccrualAtCarryingValue" xlink:title="LossContingencyAccrualAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LossContingencyAccrualAtCarryingValue" xml:lang="en-US" id="us-gaap_LossContingencyAccrualAtCarryingValue">Amount of loss contingency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:title="label: LossContingencyAccrualAtCarryingValue to us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingencyAccrualAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_LossContingencyAccrualAtCarryingValue_lbl1">Loss Contingency Accrual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl1" xlink:title="label: LossContingencyAccrualAtCarryingValue to us-gaap_LossContingencyAccrualAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MoneyMarketFundsMember" xml:lang="en-US" id="us-gaap_MoneyMarketFundsMember">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:title="label: MoneyMarketFundsMember to us-gaap_MoneyMarketFundsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MoneyMarketFundsMember_lbl1" xml:lang="en-US" id="us-gaap_MoneyMarketFundsMember_lbl1">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl1" xlink:title="label: MoneyMarketFundsMember to us-gaap_MoneyMarketFundsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities">Net cash provided by (used in) financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">Cash flows provided by (used in) financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">Cash flows provided by (used in) investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">Cash flows used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLoss" xml:lang="en-US" id="us-gaap_NetIncomeLoss">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss1" xml:lang="en-US" id="us-gaap_NetIncomeLoss1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss2" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_NetIncomeLoss2" xml:lang="en-US" id="us-gaap_NetIncomeLoss2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss3" xml:lang="en-US" id="us-gaap_NetIncomeLoss3">Net Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss3" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss3" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl4" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl4">Net Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl4" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="ProceedsFromStockPlans" xlink:title="ProceedsFromStockPlans" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockPlans" xml:lang="en-US" id="us-gaap_ProceedsFromStockPlans">Proceeds from the issuance of common stock under employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans" xlink:title="label: ProceedsFromStockPlans to us-gaap_ProceedsFromStockPlans" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockPlans_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockPlans_lbl1">Proceeds from Stock Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl1" xlink:title="label: ProceedsFromStockPlans to us-gaap_ProceedsFromStockPlans_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense" xlink:label="OtherNoncashExpense" xlink:title="OtherNoncashExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherNoncashExpense" xml:lang="en-US" id="us-gaap_OtherNoncashExpense">Other non-cash items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense" xlink:title="label: OtherNoncashExpense to us-gaap_OtherNoncashExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNoncashExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNoncashExpense_lbl1">Other Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl1" xlink:title="label: OtherNoncashExpense to us-gaap_OtherNoncashExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OfficeEquipmentMember" xml:lang="en-US" id="us-gaap_OfficeEquipmentMember">Office equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember" xlink:title="label: OfficeEquipmentMember to us-gaap_OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OfficeEquipmentMember_lbl1" xml:lang="en-US" id="us-gaap_OfficeEquipmentMember_lbl1">Office Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl1" xlink:title="label: OfficeEquipmentMember to us-gaap_OfficeEquipmentMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl1" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss1" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_OperatingIncomeLoss1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss1">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl2">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl2" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl1">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl1" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense">Other income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherNonoperatingIncomeExpense1" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense1">Other (income) expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense1" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl2" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl2">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl2" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl1">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesIssued" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl1">Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl1">Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">Proceeds from issuance of common stock under the ATM Facility, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="label: ProceedsFromIssuanceOfConvertiblePreferredStock to us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfConvertiblePreferredStock to us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US" id="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">Sales or maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="label: ProceedsFromSaleAndMaturityOfMarketableSecurities to us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl1">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl1" xlink:title="label: ProceedsFromSaleAndMaturityOfMarketableSecurities to us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromSaleOfProductiveAssets" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfProductiveAssets">Sales of property and equipment and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:title="label: ProceedsFromSaleOfProductiveAssets to us-gaap_ProceedsFromSaleOfProductiveAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl1">Proceeds from Sale of Productive Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl1" xlink:title="label: ProceedsFromSaleOfProductiveAssets to us-gaap_ProceedsFromSaleOfProductiveAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">Sale of property and equipment and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment1" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment1">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment1" xlink:title="label: ProceedsFromSaleOfPropertyPlantAndEquipment to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised">Proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl1">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet1">Total, property plant and equipment net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl2">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="PaymentsToAcquireMarketableSecurities" xlink:title="PaymentsToAcquireMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US" id="us-gaap_PaymentsToAcquireMarketableSecurities">Purchases of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:title="label: PaymentsToAcquireMarketableSecurities to us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireMarketableSecurities_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireMarketableSecurities_lbl1">Payments to Acquire Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl1" xlink:title="label: PaymentsToAcquireMarketableSecurities to us-gaap_PaymentsToAcquireMarketableSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchMember" xml:lang="en-US" id="us-gaap_ResearchMember">Research tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="us-gaap_ResearchMember" xlink:title="label: ResearchMember to us-gaap_ResearchMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchMember_lbl1">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="us-gaap_ResearchMember_lbl1" xlink:title="label: ResearchMember to us-gaap_ResearchMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">Severance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="label: RestructuringAndRelatedActivitiesDisclosureTextBlock to us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" xlink:title="label: RestructuringAndRelatedActivitiesDisclosureTextBlock to us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="RestructuringReserve" xlink:title="RestructuringReserve" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestructuringReserve" xml:lang="en-US" id="us-gaap_RestructuringReserve">Unpaid severance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringReserve" xlink:to="us-gaap_RestructuringReserve" xlink:title="label: RestructuringReserve to us-gaap_RestructuringReserve" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringReserve_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringReserve_lbl1" xml:lang="en-US" id="us-gaap_RestructuringReserve_lbl1">Restructuring Reserve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl1" xlink:title="label: RestructuringReserve to us-gaap_RestructuringReserve_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US" id="us-gaap_SaleOfStockNameOfTransactionDomain">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="label: SaleOfStockNameOfTransactionDomain to us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule of share-based compensation expense category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock">Schedule of property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="label: AvailableForSaleSecuritiesDebtSecuritiesCurrent to us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1">Debt Securities, Available-for-Sale, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtSecuritiesCurrent to us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock_lbl1">Segment Reporting Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl1" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xml:lang="en-US" id="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">Schedule of reconciliation of reported segment net loss to the statement of operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:title="label: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock to us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl1">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl1" xlink:title="label: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock to us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xml:lang="en-US" id="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="label: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl1">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl1" xlink:title="label: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xml:lang="en-US" id="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="label: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable to us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Granted, Weighted average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Unvested balance, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1">Unvested balance, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">Unvested balance, Weighted average grant date fair value, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1">Unvested balance, Weighted average grant date fair value, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">Vested, Weighted average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Shares available for future grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Weighted average grant date fair value of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Aggregate intrinsic value of options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">Outstanding, Ending of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1">Outstanding, Beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">Outstanding, Ending of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1">Outstanding, Beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Vested and exercisable at December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber1">Vested and exercisable at March 31, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Vested and exercisable at December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1">Vested and exercisable at March 31, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US" id="us-gaap_StateAndLocalJurisdictionMember">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:title="label: StateAndLocalJurisdictionMember to us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract">Statements of Cash Flows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract">Statements of Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts">Issuance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl1">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">Equity, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Equity [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsequentEventLineItems" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl1">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl1" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable" xml:lang="en-US" id="us-gaap_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract">Supplemental disclosure of noncash activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl1">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAmount">Research tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:title="label: TaxCreditCarryforwardAmount to us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAmount_lbl1" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAmount_lbl1">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl1" xlink:title="label: TaxCreditCarryforwardAmount to us-gaap_TaxCreditCarryforwardAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardNameDomain">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:title="label: TaxCreditCarryforwardNameDomain to us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAxis">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:title="label: TaxCreditCarryforwardAxis to us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent" xml:lang="en-US" id="us-gaap_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseAbstract" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseAbstract">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:title="label: ResearchAndDevelopmentExpenseAbstract to us-gaap_ResearchAndDevelopmentExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1">Research and Development Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseAbstract to us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="USGovernmentDebtSecuritiesMember" xlink:title="USGovernmentDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_USGovernmentDebtSecuritiesMember" xml:lang="en-US" id="us-gaap_USGovernmentDebtSecuritiesMember">U.S. government securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" xlink:title="label: USGovernmentDebtSecuritiesMember to us-gaap_USGovernmentDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_USGovernmentDebtSecuritiesMember_lbl1" xml:lang="en-US" id="us-gaap_USGovernmentDebtSecuritiesMember_lbl1">US Government Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl1" xlink:title="label: USGovernmentDebtSecuritiesMember to us-gaap_USGovernmentDebtSecuritiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted average common shares outstanding, diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Weighted average common shares outstanding, basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl1" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl1">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="PropertyPlantAndEquipmentOtherTypesMember" xlink:title="PropertyPlantAndEquipmentOtherTypesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentOtherTypesMember">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:title="label: PropertyPlantAndEquipmentOtherTypesMember to us-gaap_PropertyPlantAndEquipmentOtherTypesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl1">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentOtherTypesMember" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl1" xlink:title="label: PropertyPlantAndEquipmentOtherTypesMember to us-gaap_PropertyPlantAndEquipmentOtherTypesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="LeaseholdsAndLeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xml:lang="en-US" id="us-gaap_LeaseholdsAndLeaseholdImprovementsMember">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:title="label: LeaseholdsAndLeaseholdImprovementsMember to us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl1" xml:lang="en-US" id="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl1">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl1" xlink:title="label: LeaseholdsAndLeaseholdImprovementsMember to us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense1">Total research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl2" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl2">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl2" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecurities">Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:title="label: AvailableForSaleSecuritiesDebtSecurities to us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecurities1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecurities1">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities1" xlink:title="label: AvailableForSaleSecuritiesDebtSecurities to us-gaap_AvailableForSaleSecuritiesDebtSecurities1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl2" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl2">Debt Securities, Available-for-Sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl2" xlink:title="label: AvailableForSaleSecuritiesDebtSecurities to us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets" xml:lang="en-US" id="us-gaap_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets" xlink:title="label: Assets to us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="MarketableSecuritiesUnrealizedGainLoss" xlink:title="MarketableSecuritiesUnrealizedGainLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xml:lang="en-US" id="us-gaap_MarketableSecuritiesUnrealizedGainLoss">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:title="label: MarketableSecuritiesUnrealizedGainLoss to us-gaap_MarketableSecuritiesUnrealizedGainLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl1" xml:lang="en-US" id="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl1">Marketable Security, Unrealized Gain (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl1" xlink:title="label: MarketableSecuritiesUnrealizedGainLoss to us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="IncomeTaxExaminationDescription" xlink:title="IncomeTaxExaminationDescription" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationDescription">Income Tax Examination, Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription" xlink:title="label: IncomeTaxExaminationDescription to us-gaap_IncomeTaxExaminationDescription" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityDomain">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="label: IncomeTaxAuthorityDomain to us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US" id="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="label: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfRestructuringDomain" xml:lang="en-US" id="us-gaap_TypeOfRestructuringDomain">Type of Restructuring [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:title="label: TypeOfRestructuringDomain to us-gaap_TypeOfRestructuringDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EmployeeSeveranceMember" xml:lang="en-US" id="us-gaap_EmployeeSeveranceMember">Workforce reduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:title="label: EmployeeSeveranceMember to us-gaap_EmployeeSeveranceMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeSeveranceMember1" xml:lang="en-US" id="us-gaap_EmployeeSeveranceMember1">Employee Severance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember1" xlink:title="label: EmployeeSeveranceMember to us-gaap_EmployeeSeveranceMember1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeSeveranceMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeSeveranceMember_lbl2" xml:lang="en-US" id="us-gaap_EmployeeSeveranceMember_lbl2">Employee Severance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeSeveranceMember" xlink:to="us-gaap_EmployeeSeveranceMember_lbl2" xlink:title="label: EmployeeSeveranceMember to us-gaap_EmployeeSeveranceMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US" id="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable">Restructuring Cost [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="label: ScheduleOfRestructuringAndRelatedCostsTable to us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">Stockholder's Equity and Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock1" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock1">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock1" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl2" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl2">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl2" xlink:title="label: DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure">Fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure1">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure1" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl2" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl2">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl2" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable" xml:lang="en-US" id="us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable" xlink:title="label: StatementTable to us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract" xml:lang="en-US" id="us-gaap_AssetsAbstract">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems" xml:lang="en-US" id="us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems_lbl1" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems_lbl1">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl1" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xml:lang="en-US" id="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">Schedule of net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="label: SummaryOfOperatingLossCarryforwardsTextBlock to us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl1">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl1" xlink:title="label: SummaryOfOperatingLossCarryforwardsTextBlock to us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel1Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl1">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel2Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl1">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel3Member" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:label="FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:title="FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">Summary of non-financial instruments measured at fair value, on a nonrecurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:title="label: FairValueAssetsMeasuredOnNonrecurringBasisTextBlock to us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl1">Fair Value Measurements, Nonrecurring [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl1" xlink:title="label: FairValueAssetsMeasuredOnNonrecurringBasisTextBlock to us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="PropertyPlantAndEquipmentFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="label: PropertyPlantAndEquipmentFairValueDisclosure to us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl1">Property, Plant, and Equipment, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentFairValueDisclosure" xlink:to="us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl1" xlink:title="label: PropertyPlantAndEquipmentFairValueDisclosure to us-gaap_PropertyPlantAndEquipmentFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract" xml:lang="en-US" id="us-gaap_EquityAbstract">Common Stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock">Fair Value of Financial Instruments and Non-Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueDisclosuresTextBlock_lbl1">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl1" xlink:title="label: FairValueDisclosuresTextBlock to us-gaap_FairValueDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">Stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingExpensesAbstract" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpensesAbstract_lbl1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl1" xlink:title="label: OperatingExpensesAbstract to us-gaap_OperatingExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Amount of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems1">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems1" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract">Per share information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract_lbl1">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl1" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Schedule of antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xml:lang="en-US" id="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">Amortization of premium and discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="label: InvestmentIncomeNetAmortizationOfDiscountAndPremium to us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl1" xml:lang="en-US" id="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl1">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl1" xlink:title="label: InvestmentIncomeNetAmortizationOfDiscountAndPremium to us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="LongLivedAssetsHeldForSaleNameDomain" xlink:title="LongLivedAssetsHeldForSaleNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongLivedAssetsHeldForSaleNameDomain" xml:lang="en-US" id="us-gaap_LongLivedAssetsHeldForSaleNameDomain">Long-Lived Assets Held-for-Sale, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongLivedAssetsHeldForSaleNameDomain" xlink:to="us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:title="label: LongLivedAssetsHeldForSaleNameDomain to us-gaap_LongLivedAssetsHeldForSaleNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl1">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems1">Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems1" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="LongLivedAssetsHeldForSaleByAssetTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xml:lang="en-US" id="us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis">Long-Lived Asset, Held-for-Sale, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="label: LongLivedAssetsHeldForSaleByAssetTypeAxis to us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">Shares available for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity" xml:lang="en-US" id="us-gaap_StockholdersEquity">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity1" xml:lang="en-US" id="us-gaap_StockholdersEquity1">Balance at Beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity2" xml:lang="en-US" id="us-gaap_StockholdersEquity2">Balance at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">Changes in valuation allowances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAbstract">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:title="label: ComponentsOfDeferredTaxAssetsAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue" xml:lang="en-US" id="us-gaap_PreferredStockValue">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2025 and December 31, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PreferredStockValue1" xml:lang="en-US" id="us-gaap_PreferredStockValue1">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both March 31, 2026 and December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue1" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxAbstract">Comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTaxAbstract to us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember">Additional paidin capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl1" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsMember" xml:lang="en-US" id="us-gaap_RetainedEarningsMember">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl1" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeMember">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain" xml:lang="en-US" id="us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember">Employee Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl1">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues">Sale of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues1">Issuance of common stock under the ATM Facility, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues1" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">Exercise of stock options and vesting of restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensation to us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensation to us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">Issuance of shares in connection with employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="label: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan to us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl1">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl1" xlink:title="label: StockIssuedDuringPeriodValueEmployeeStockPurchasePlan to us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues1">Issuance of common stock under the ATM Facility, net of offering costs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">Exercise of stock options and vesting of restricted stock units (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">Issuance of shares in connection with employee stock purchase plan (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">Stock issued during period, Reverse stock splits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplits to us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesReverseStockSplits to us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US" id="us-gaap_CollaborativeArrangementDisclosureTextBlock">Gemma License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">Number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">Weighted average remaining contractual term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">Vested or expected to vest at December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1">Vested or expected to vest at March 31, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">Vested or expected to vest at December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1">Vested or expected to vest at March 31, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="OtherAssetsFairValueDisclosure" xlink:title="OtherAssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsFairValueDisclosure" xml:lang="en-US" id="us-gaap_OtherAssetsFairValueDisclosure">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure" xlink:title="label: OtherAssetsFairValueDisclosure to us-gaap_OtherAssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsFairValueDisclosure_lbl1">Other Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsFairValueDisclosure" xlink:to="us-gaap_OtherAssetsFairValueDisclosure_lbl1" xlink:title="label: OtherAssetsFairValueDisclosure to us-gaap_OtherAssetsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization1">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl2" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl2">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl2" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfStockLineItems" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl1" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl1">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl1" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable">Stock, Class of Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract" xml:lang="en-US" id="us-gaap_LeasesAbstract">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies">Commitments and contingencies (note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingencies1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies1">Commitments and contingencies (note 10)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies1" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NatureOfOperations" xml:lang="en-US" id="us-gaap_NatureOfOperations">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="us-gaap_NatureOfOperations" xlink:title="label: NatureOfOperations to us-gaap_NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NatureOfOperations_lbl1" xml:lang="en-US" id="us-gaap_NatureOfOperations_lbl1">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl1" xlink:title="label: NatureOfOperations to us-gaap_NatureOfOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl1" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent">Professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl1">Accrued Professional Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl1" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent">Compensation and related benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">Sharebased compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsFairValueDisclosure" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure">Total financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl1">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain" xml:lang="en-US" id="us-gaap_SegmentDomain">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember">Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl1">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementsNonrecurringMember" xml:lang="en-US" id="us-gaap_FairValueMeasurementsNonrecurringMember">Nonrecurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:title="label: FairValueMeasurementsNonrecurringMember to us-gaap_FairValueMeasurementsNonrecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1">Fair Value, Nonrecurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" xlink:title="label: FairValueMeasurementsNonrecurringMember to us-gaap_FairValueMeasurementsNonrecurringMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:title="CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xml:lang="en-US" id="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">Cash, Cash Equivalents, and Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:title="label: CashCashEquivalentsAndMarketableSecuritiesTextBlock to us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl1">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl1" xlink:title="label: CashCashEquivalentsAndMarketableSecuritiesTextBlock to us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding" xml:lang="en-US" id="us-gaap_SharesOutstanding">Balance at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding1" xml:lang="en-US" id="us-gaap_SharesOutstanding1">Balance at Beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Schedule of deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">Schedule of effective income tax rate reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:title="ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">Schedule of details regarding the Company's portfolio of cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:title="label: ScheduleOfCashAndCashEquivalentsTableTextBlock to us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" xlink:title="label: ScheduleOfCashAndCashEquivalentsTableTextBlock to us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract">Commitments and Contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="us-gaap_FairValueDisclosuresAbstract">Fair Value of Financial Instruments and Non-Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract" xlink:title="label: FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl1" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">Amortized cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="label: AvailableForSaleDebtSecuritiesAmortizedCostBasis to us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" xlink:title="label: AvailableForSaleDebtSecuritiesAmortizedCostBasis to us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Schedule of stock option activity plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock1">Schedule of stock option activity plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock1" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Schedule of weighted average assumptions applied to options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="label: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedActivitiesAbstract">Severance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:title="label: RestructuringAndRelatedActivitiesAbstract to us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates" xml:lang="en-US" id="us-gaap_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember">Unvested restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl1">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems1" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems1">Fair Value of Financial Instruments and Non-Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems1" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US" id="us-gaap_RestructuringCostAndReserveLineItems">Severance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" xlink:title="label: RestructuringCostAndReserveLineItems to us-gaap_RestructuringCostAndReserveLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringCostAndReserveLineItems_lbl1" xml:lang="en-US" id="us-gaap_RestructuringCostAndReserveLineItems_lbl1">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl1" xlink:title="label: RestructuringCostAndReserveLineItems to us-gaap_RestructuringCostAndReserveLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US" id="us-gaap_RestructuringCostAndReserveAxis">Restructuring Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:title="label: RestructuringCostAndReserveAxis to us-gaap_RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract">Subsequent Events.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:title="ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">Schedule of details regarding the Company's portfolio of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:title="label: ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock to us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl1">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl1" xlink:title="label: ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock to us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">Workforce reduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="label: RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent to us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent1" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent1">Number of positions eliminated, period percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent1" xlink:title="label: RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent to us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl2" xml:lang="en-US" id="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl2">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl2" xlink:title="label: RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent to us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US" id="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="label: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US" id="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems1" xml:lang="en-US" id="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems1">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems1" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityAxis">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="label: IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US" id="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="label: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Aggregate intrinsic value of options exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">Summary of assets measured at fair value on a recurring basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl1">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl1" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">Forfeited, Weighted average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Unrecognized compensation expense related to unvested stock option awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">Total unrecognized expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialInstrumentAxis" xml:lang="en-US" id="us-gaap_FinancialInstrumentAxis">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="label: FinancialInstrumentAxis to us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">Weighted average exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">Weighted-average remaining contractual term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis" xml:lang="en-US" id="us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain" xml:lang="en-US" id="us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis" xml:lang="en-US" id="us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="ScheduleOfCashAndCashEquivalentsTable" xlink:title="ScheduleOfCashAndCashEquivalentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xml:lang="en-US" id="us-gaap_ScheduleOfCashAndCashEquivalentsTable">Cash and Cash Equivalent [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:title="label: ScheduleOfCashAndCashEquivalentsTable to us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAxis">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:title="label: CashAndCashEquivalentsAxis to us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="CashAndCashEquivalentsLineItems" xlink:title="CashAndCashEquivalentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsLineItems" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsLineItems">Cash, cash equivalents and marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems" xlink:title="label: CashAndCashEquivalentsLineItems to us-gaap_CashAndCashEquivalentsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsLineItems1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsLineItems1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsLineItems1">Cash and Cash Equivalents [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems1" xlink:title="label: CashAndCashEquivalentsLineItems to us-gaap_CashAndCashEquivalentsLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember" xml:lang="en-US" id="us-gaap_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubsequentEventMember1" xml:lang="en-US" id="us-gaap_SubsequentEventMember1">Subsequent event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember1" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">Recently Issued Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock1">Recently Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="label: AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife">Useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Vested and exercisable at December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2">Vested and exercisable at March 31, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">Vested or expected to vest at December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2">Vested or expected to vest at March 31, 2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Weighted average period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NumberOfReportableSegments" xml:lang="en-US" id="us-gaap_NumberOfReportableSegments">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments" xlink:title="label: NumberOfReportableSegments to us-gaap_NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfReportableSegments_lbl1" xml:lang="en-US" id="us-gaap_NumberOfReportableSegments_lbl1">Number of Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl1" xlink:title="label: NumberOfReportableSegments to us-gaap_NumberOfReportableSegments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AreaOfLand" xml:lang="en-US" id="us-gaap_AreaOfLand">Area leased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfLand" xlink:to="us-gaap_AreaOfLand" xlink:title="label: AreaOfLand to us-gaap_AreaOfLand" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AreaOfLand_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AreaOfLand_lbl1" xml:lang="en-US" id="us-gaap_AreaOfLand_lbl1">Area of Land</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl1" xlink:title="label: AreaOfLand to us-gaap_AreaOfLand_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">Stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" xlink:title="label: StockholdersEquityNoteStockSplitConversionRatio1 to us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SeveranceCosts1" xml:lang="en-US" id="us-gaap_SeveranceCosts1">Severance and termination-related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1" xlink:title="label: SeveranceCosts1 to us-gaap_SeveranceCosts1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeveranceCosts1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeveranceCosts1_lbl1" xml:lang="en-US" id="us-gaap_SeveranceCosts1_lbl1">Severance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl1" xlink:title="label: SeveranceCosts1 to us-gaap_SeveranceCosts1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xml:lang="en-US" id="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">Schedule of activity related to restricted stock unit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="label: NonvestedRestrictedStockSharesActivityTableTextBlock to us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl1">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl1" xlink:title="label: NonvestedRestrictedStockSharesActivityTableTextBlock to us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">Number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">Weighted average grant date fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">Unrealized losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">Unrealized gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="label: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="DisposalGroupClassificationAxis" xlink:title="DisposalGroupClassificationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupClassificationAxis" xml:lang="en-US" id="us-gaap_DisposalGroupClassificationAxis">Disposal Group Classification [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis" xlink:title="label: DisposalGroupClassificationAxis to us-gaap_DisposalGroupClassificationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="DisposalGroupClassificationDomain" xlink:title="DisposalGroupClassificationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupClassificationDomain" xml:lang="en-US" id="us-gaap_DisposalGroupClassificationDomain">Disposal Group Classification [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain" xlink:title="label: DisposalGroupClassificationDomain to us-gaap_DisposalGroupClassificationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:title="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xml:lang="en-US" id="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember">Disposal group classified as held for sale or to be disposed of by sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:title="label: DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember to us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_lbl1" xml:lang="en-US" id="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_lbl1">Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_lbl1" xlink:title="label: DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember to us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="DeferredIncomeTaxLiabilitiesNet" xlink:title="DeferredIncomeTaxLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_DeferredIncomeTaxLiabilitiesNet" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilitiesNet">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:title="label: DeferredIncomeTaxLiabilitiesNet to us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl1">Deferred Income Tax Liabilities, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl1" xlink:title="label: DeferredIncomeTaxLiabilitiesNet to us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SubleaseIncome" xml:lang="en-US" id="us-gaap_SubleaseIncome">Sublease Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="us-gaap_SubleaseIncome" xlink:title="label: SubleaseIncome to us-gaap_SubleaseIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubleaseIncome1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SubleaseIncome1" xml:lang="en-US" id="us-gaap_SubleaseIncome1">Sublease rental income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="us-gaap_SubleaseIncome1" xlink:title="label: SubleaseIncome to us-gaap_SubleaseIncome1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubleaseIncome_lbl2" xml:lang="en-US" id="us-gaap_SubleaseIncome_lbl2">Sublease Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl2" xlink:title="label: SubleaseIncome to us-gaap_SubleaseIncome_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LeaseCost" xml:lang="en-US" id="us-gaap_LeaseCost">Lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCost" xlink:to="us-gaap_LeaseCost" xlink:title="label: LeaseCost to us-gaap_LeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCost_lbl1" xml:lang="en-US" id="us-gaap_LeaseCost_lbl1">Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCost" xlink:to="us-gaap_LeaseCost_lbl1" xlink:title="label: LeaseCost to us-gaap_LeaseCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseCost" xml:lang="en-US" id="us-gaap_OperatingLeaseCost">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseCost1" xml:lang="en-US" id="us-gaap_OperatingLeaseCost1">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost1" xlink:title="label: OperatingLeaseCost to us-gaap_OperatingLeaseCost1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableLeaseCost" xml:lang="en-US" id="us-gaap_VariableLeaseCost">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost" xlink:title="label: VariableLeaseCost to us-gaap_VariableLeaseCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_VariableLeaseCost1" xml:lang="en-US" id="us-gaap_VariableLeaseCost1">Variable lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost1" xlink:title="label: VariableLeaseCost to us-gaap_VariableLeaseCost1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnTerminationOfLease" xml:lang="en-US" id="us-gaap_GainLossOnTerminationOfLease">Net gain on lease termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease" xlink:title="label: GainLossOnTerminationOfLease to us-gaap_GainLossOnTerminationOfLease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainLossOnTerminationOfLease1" xml:lang="en-US" id="us-gaap_GainLossOnTerminationOfLease1">Net gain on lease termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease1" xlink:title="label: GainLossOnTerminationOfLease to us-gaap_GainLossOnTerminationOfLease1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnTerminationOfLease_lbl2" xml:lang="en-US" id="us-gaap_GainLossOnTerminationOfLease_lbl2">Gain (Loss) on Termination of Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl2" xlink:title="label: GainLossOnTerminationOfLease to us-gaap_GainLossOnTerminationOfLease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent">Non-refundable sublicense and transition services payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent1" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent1">Non-refundable sublicense payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent1" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent_lbl2" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent_lbl2">Contract with Customer, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl2" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset">Right of use assets - operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl1">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">Future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">Option to extend lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="label: LesseeOperatingLeaseExistenceOfOptionToExtend to us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl1">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl1" xlink:title="label: LesseeOperatingLeaseExistenceOfOptionToExtend to us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">Option to terminate lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="label: LesseeOperatingLeaseExistenceOfOptionToTerminate to us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl1">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl1" xlink:title="label: LesseeOperatingLeaseExistenceOfOptionToTerminate to us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable">Lessee, Lease, Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems">Lessee, Lease, Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">Cash and cash equivalents at beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1">Cash and cash equivalents at end</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="OperatingLeasePaymentsUse" xlink:title="OperatingLeasePaymentsUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasePaymentsUse" xml:lang="en-US" id="us-gaap_OperatingLeasePaymentsUse">Operating lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse" xlink:title="label: OperatingLeasePaymentsUse to us-gaap_OperatingLeasePaymentsUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePaymentsUse_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasePaymentsUse_lbl1">Operating Lease, Payments, Use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl1" xlink:title="label: OperatingLeasePaymentsUse to us-gaap_OperatingLeasePaymentsUse_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">Right of use assets recognized upon the commencement of sublease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">Total undiscounted lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths1">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">2030</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour1">2030</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree1">2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo1">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">Schedule of future minimum rental payments for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseImpairmentLoss" xml:lang="en-US" id="us-gaap_OperatingLeaseImpairmentLoss">Impairment expenses for right of use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" xlink:title="label: OperatingLeaseImpairmentLoss to us-gaap_OperatingLeaseImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseImpairmentLoss1" xml:lang="en-US" id="us-gaap_OperatingLeaseImpairmentLoss1">Right of use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss1" xlink:title="label: OperatingLeaseImpairmentLoss to us-gaap_OperatingLeaseImpairmentLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseImpairmentLoss_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseImpairmentLoss_lbl2">Operating Lease, Impairment Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl2" xlink:title="label: OperatingLeaseImpairmentLoss to us-gaap_OperatingLeaseImpairmentLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiability" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability">Total lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Operating Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent">Operating lease liabilities - noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1">Operating Lease, Liability, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="LeaseCostTableTextBlock" xlink:title="LeaseCostTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LeaseCostTableTextBlock" xml:lang="en-US" id="us-gaap_LeaseCostTableTextBlock">Summary of operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:title="label: LeaseCostTableTextBlock to us-gaap_LeaseCostTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseCostTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LeaseCostTableTextBlock_lbl1">Lease, Cost [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl1" xlink:title="label: LeaseCostTableTextBlock to us-gaap_LeaseCostTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock">Leasing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock_lbl1">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl1">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl1" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="IncomeTaxExaminationYearUnderExamination" xlink:title="IncomeTaxExaminationYearUnderExamination" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExaminationYearUnderExamination" xml:lang="en-US" id="us-gaap_IncomeTaxExaminationYearUnderExamination">Income Tax Examination, Year under Examination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExaminationYearUnderExamination" xlink:to="us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:title="label: IncomeTaxExaminationYearUnderExamination to us-gaap_IncomeTaxExaminationYearUnderExamination" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">Weighted-average remaining lease term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract">Term of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1">Lessee, Operating Lease, Term of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">Share-based payment awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="label: EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount to us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl1">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount to us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">Share-based payment awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:title="label: EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent to us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl1">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent to us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">License and Other Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="label: RevenueFromContractWithCustomerPolicyTextBlock to us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" xlink:title="label: RevenueFromContractWithCustomerPolicyTextBlock to us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInContractWithCustomerLiability">Non-refundable sublicense and transition services payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:title="label: IncreaseDecreaseInContractWithCustomerLiability to us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" xlink:title="label: IncreaseDecreaseInContractWithCustomerLiability to us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">Renewal term of lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="label: LesseeOperatingLeaseRemainingLeaseTerm to us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl1">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl1" xlink:title="label: LesseeOperatingLeaseRemainingLeaseTerm to us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory" xml:lang="en-US" id="dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness" xml:lang="en-US" id="dei_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" xlink:title="CollaborativeArrangementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborativeArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_CollaborativeArrangementDisclosureAbstract_lbl" xml:lang="en-US" id="pasg_CollaborativeArrangementDisclosureAbstract_lbl">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="pasg_CollaborativeArrangementDisclosureAbstract_lbl" xlink:title="label: CollaborativeArrangementDisclosureAbstract to pasg_CollaborativeArrangementDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborativeArrangementDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_CollaborativeArrangementDisclosureAbstract_lbl1" xml:lang="en-US" id="pasg_CollaborativeArrangementDisclosureAbstract_lbl1">Gemma License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="pasg_CollaborativeArrangementDisclosureAbstract_lbl1" xlink:title="label: CollaborativeArrangementDisclosureAbstract to pasg_CollaborativeArrangementDisclosureAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:title="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl">The entire disclosure of information pertaining to accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock to pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl1">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock to pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:title="label: AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock to pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="AccruedResearchAndDevelopmentExpense" xlink:title="AccruedResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="pasg_AccruedResearchAndDevelopmentExpense_lbl">The carrying balance as of the balance sheet of accrued research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpense" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_lbl" xlink:title="label: AccruedResearchAndDevelopmentExpense to pasg_AccruedResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AccruedResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="pasg_AccruedResearchAndDevelopmentExpense_lbl1">Accrued Research And Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpense" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_lbl1" xlink:title="label: AccruedResearchAndDevelopmentExpense to pasg_AccruedResearchAndDevelopmentExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_AccruedResearchAndDevelopmentExpense" xml:lang="en-US" id="pasg_AccruedResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedResearchAndDevelopmentExpense" xlink:to="pasg_AccruedResearchAndDevelopmentExpense" xlink:title="label: AccruedResearchAndDevelopmentExpense to pasg_AccruedResearchAndDevelopmentExpense" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedDivestitureFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AccruedDivestitureFeesCurrent_lbl" xml:lang="en-US" id="pasg_AccruedDivestitureFeesCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedDivestitureFeesCurrent" xlink:to="pasg_AccruedDivestitureFeesCurrent_lbl" xlink:title="label: AccruedDivestitureFeesCurrent to pasg_AccruedDivestitureFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedDivestitureFeesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AccruedDivestitureFeesCurrent_lbl1" xml:lang="en-US" id="pasg_AccruedDivestitureFeesCurrent_lbl1">Accrued Divestiture Fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedDivestitureFeesCurrent" xlink:to="pasg_AccruedDivestitureFeesCurrent_lbl1" xlink:title="label: AccruedDivestitureFeesCurrent to pasg_AccruedDivestitureFeesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedDivestitureFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_AccruedDivestitureFeesCurrent" xml:lang="en-US" id="pasg_AccruedDivestitureFeesCurrent">Divestiture fee due to Catalent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedDivestitureFeesCurrent" xlink:to="pasg_AccruedDivestitureFeesCurrent" xlink:title="label: AccruedDivestitureFeesCurrent to pasg_AccruedDivestitureFeesCurrent" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="AccruedExpensesAndOtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" id="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl">The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:title="label: AccruedExpensesAndOtherCurrentLiabilities to pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl1" xml:lang="en-US" id="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl1">Accrued Expenses and Other Current Liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl1" xlink:title="label: AccruedExpensesAndOtherCurrentLiabilities to pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_AccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US" id="pasg_AccruedExpensesAndOtherCurrentLiabilities">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:title="label: AccruedExpensesAndOtherCurrentLiabilities to pasg_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl2" xml:lang="en-US" id="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl2">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl2" xlink:title="label: AccruedExpensesAndOtherCurrentLiabilities to pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl">Tabular disclosure of information pertaining to accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock to pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl1">Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock to pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xml:lang="en-US" id="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">Schedule of accrued liabilities and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock to pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableTransitionServicesPayments" xlink:label="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="ProceedsFromNonRefundableTransitionServicesPayments" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl" xml:lang="en-US" id="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl">The cash inflow from non-refundable transition service payments received by the company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNonRefundableTransitionServicesPayments" xlink:to="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl" xlink:title="label: ProceedsFromNonRefundableTransitionServicesPayments to pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl1" xml:lang="en-US" id="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl1">Proceeds From Non Refundable Transition Services Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNonRefundableTransitionServicesPayments" xlink:to="pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl1" xlink:title="label: ProceedsFromNonRefundableTransitionServicesPayments to pasg_ProceedsFromNonRefundableTransitionServicesPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromNonRefundableTransitionServicesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ProceedsFromNonRefundableTransitionServicesPayments" xml:lang="en-US" id="pasg_ProceedsFromNonRefundableTransitionServicesPayments">Amount of transition services payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNonRefundableTransitionServicesPayments" xlink:to="pasg_ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="label: ProceedsFromNonRefundableTransitionServicesPayments to pasg_ProceedsFromNonRefundableTransitionServicesPayments" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShortTermLicenseFeeDueAndReceivable" xlink:label="ShortTermLicenseFeeDueAndReceivable" xlink:title="ShortTermLicenseFeeDueAndReceivable" />
    <link:label xlink:type="resource" xlink:label="pasg_ShortTermLicenseFeeDueAndReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ShortTermLicenseFeeDueAndReceivable_lbl" xml:lang="en-US" id="pasg_ShortTermLicenseFeeDueAndReceivable_lbl">Amount of license fee due and receivable in short-term as of the balance sheet date under the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLicenseFeeDueAndReceivable" xlink:to="pasg_ShortTermLicenseFeeDueAndReceivable_lbl" xlink:title="label: ShortTermLicenseFeeDueAndReceivable to pasg_ShortTermLicenseFeeDueAndReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ShortTermLicenseFeeDueAndReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ShortTermLicenseFeeDueAndReceivable_lbl1" xml:lang="en-US" id="pasg_ShortTermLicenseFeeDueAndReceivable_lbl1">Short-Term License Fee Due And Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLicenseFeeDueAndReceivable" xlink:to="pasg_ShortTermLicenseFeeDueAndReceivable_lbl1" xlink:title="label: ShortTermLicenseFeeDueAndReceivable to pasg_ShortTermLicenseFeeDueAndReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ShortTermLicenseFeeDueAndReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ShortTermLicenseFeeDueAndReceivable" xml:lang="en-US" id="pasg_ShortTermLicenseFeeDueAndReceivable">Short-term license fee due and receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermLicenseFeeDueAndReceivable" xlink:to="pasg_ShortTermLicenseFeeDueAndReceivable" xlink:title="label: ShortTermLicenseFeeDueAndReceivable to pasg_ShortTermLicenseFeeDueAndReceivable" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_UpfrontLicenseFeeReceivable" xlink:label="UpfrontLicenseFeeReceivable" xlink:title="UpfrontLicenseFeeReceivable" />
    <link:label xlink:type="resource" xlink:label="pasg_UpfrontLicenseFeeReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_UpfrontLicenseFeeReceivable_lbl" xml:lang="en-US" id="pasg_UpfrontLicenseFeeReceivable_lbl">Amount of upfront license fee that is receivable under the license arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontLicenseFeeReceivable" xlink:to="pasg_UpfrontLicenseFeeReceivable_lbl" xlink:title="label: UpfrontLicenseFeeReceivable to pasg_UpfrontLicenseFeeReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_UpfrontLicenseFeeReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_UpfrontLicenseFeeReceivable_lbl1" xml:lang="en-US" id="pasg_UpfrontLicenseFeeReceivable_lbl1">Upfront License Fee Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontLicenseFeeReceivable" xlink:to="pasg_UpfrontLicenseFeeReceivable_lbl1" xlink:title="label: UpfrontLicenseFeeReceivable to pasg_UpfrontLicenseFeeReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_UpfrontLicenseFeeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_UpfrontLicenseFeeReceivable" xml:lang="en-US" id="pasg_UpfrontLicenseFeeReceivable">Upfront license fee receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontLicenseFeeReceivable" xlink:to="pasg_UpfrontLicenseFeeReceivable" xlink:title="label: UpfrontLicenseFeeReceivable to pasg_UpfrontLicenseFeeReceivable" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LongTermLicenseFeeDueAndReceivable" xlink:label="LongTermLicenseFeeDueAndReceivable" xlink:title="LongTermLicenseFeeDueAndReceivable" />
    <link:label xlink:type="resource" xlink:label="pasg_LongTermLicenseFeeDueAndReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LongTermLicenseFeeDueAndReceivable_lbl" xml:lang="en-US" id="pasg_LongTermLicenseFeeDueAndReceivable_lbl">Amount of license fee due and receivable in long-term as of the balance sheet date under the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLicenseFeeDueAndReceivable" xlink:to="pasg_LongTermLicenseFeeDueAndReceivable_lbl" xlink:title="label: LongTermLicenseFeeDueAndReceivable to pasg_LongTermLicenseFeeDueAndReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LongTermLicenseFeeDueAndReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LongTermLicenseFeeDueAndReceivable_lbl1" xml:lang="en-US" id="pasg_LongTermLicenseFeeDueAndReceivable_lbl1">Long-Term License Fee Due And Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLicenseFeeDueAndReceivable" xlink:to="pasg_LongTermLicenseFeeDueAndReceivable_lbl1" xlink:title="label: LongTermLicenseFeeDueAndReceivable to pasg_LongTermLicenseFeeDueAndReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LongTermLicenseFeeDueAndReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LongTermLicenseFeeDueAndReceivable" xml:lang="en-US" id="pasg_LongTermLicenseFeeDueAndReceivable">Long-term license fee due and receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLicenseFeeDueAndReceivable" xlink:to="pasg_LongTermLicenseFeeDueAndReceivable" xlink:title="label: LongTermLicenseFeeDueAndReceivable to pasg_LongTermLicenseFeeDueAndReceivable" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:label="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" />
    <link:label xlink:type="resource" xlink:label="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl" xml:lang="en-US" id="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl">The amount of decrease in payable due to amounts received under transition service payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:to="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl" xlink:title="label: PayableDecreaseFromAmountsReceivedTransitionServicesPayments to pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl1" xml:lang="en-US" id="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl1">Payable, Decrease from Amounts Received Transition Services Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:to="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl1" xlink:title="label: PayableDecreaseFromAmountsReceivedTransitionServicesPayments to pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xml:lang="en-US" id="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments">Transition service payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:to="pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="label: PayableDecreaseFromAmountsReceivedTransitionServicesPayments to pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableSublicensePayments" xlink:label="ProceedsFromNonRefundableSublicensePayments" xlink:title="ProceedsFromNonRefundableSublicensePayments" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromNonRefundableSublicensePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ProceedsFromNonRefundableSublicensePayments_lbl" xml:lang="en-US" id="pasg_ProceedsFromNonRefundableSublicensePayments_lbl">The cash inflow from non-refundable sublicense payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNonRefundableSublicensePayments" xlink:to="pasg_ProceedsFromNonRefundableSublicensePayments_lbl" xlink:title="label: ProceedsFromNonRefundableSublicensePayments to pasg_ProceedsFromNonRefundableSublicensePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromNonRefundableSublicensePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ProceedsFromNonRefundableSublicensePayments_lbl1" xml:lang="en-US" id="pasg_ProceedsFromNonRefundableSublicensePayments_lbl1">Proceeds From Non-Refundable Sublicense Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNonRefundableSublicensePayments" xlink:to="pasg_ProceedsFromNonRefundableSublicensePayments_lbl1" xlink:title="label: ProceedsFromNonRefundableSublicensePayments to pasg_ProceedsFromNonRefundableSublicensePayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromNonRefundableSublicensePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ProceedsFromNonRefundableSublicensePayments" xml:lang="en-US" id="pasg_ProceedsFromNonRefundableSublicensePayments">Payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNonRefundableSublicensePayments" xlink:to="pasg_ProceedsFromNonRefundableSublicensePayments" xlink:title="label: ProceedsFromNonRefundableSublicensePayments to pasg_ProceedsFromNonRefundableSublicensePayments" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl" xml:lang="en-US" id="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl">Represents information pertaining to the arrangement with Gemma Biotherapeutics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:to="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl" xlink:title="label: ArrangementWithGemmaBiotherapeuticsIncMember to pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl1" xml:lang="en-US" id="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl1">Arrangement With Gemma Biotherapeutics Inc [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:to="pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl1" xlink:title="label: ArrangementWithGemmaBiotherapeuticsIncMember to pasg_ArrangementWithGemmaBiotherapeuticsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xml:lang="en-US" id="pasg_ArrangementWithGemmaBiotherapeuticsIncMember">Gemma License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:to="pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="label: ArrangementWithGemmaBiotherapeuticsIncMember to pasg_ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:label="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" />
    <link:label xlink:type="resource" xlink:label="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl" xml:lang="en-US" id="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl">Contingent proceeds upon completing certain business milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:to="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl" xlink:title="label: ContingentProceedsFromUponCompletionOfCertainBusinessMilestones to pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl1" xml:lang="en-US" id="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl1">Contingent Proceeds From Upon Completion of certain business milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:to="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl1" xlink:title="label: ContingentProceedsFromUponCompletionOfCertainBusinessMilestones to pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xml:lang="en-US" id="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones">Contingent proceeds upon completing certain business milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:to="pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="label: ContingentProceedsFromUponCompletionOfCertainBusinessMilestones to pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:label="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" />
    <link:label xlink:type="resource" xlink:label="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl" xml:lang="en-US" id="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl">The maximum additional amount in development and commercial milestone payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:to="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl" xlink:title="label: MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable to pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl1" xml:lang="en-US" id="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl1">Maximum Additional Amount in Development And Commercial Milestone Payments Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:to="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl1" xlink:title="label: MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable to pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xml:lang="en-US" id="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable">Maximum additional amount in development and commercial milestone payments receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:to="pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="label: MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable to pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="IncreaseDecreaseInPrepaidResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xml:lang="en-US" id="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl">The amount of increase (decrease) in prepaid research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xlink:title="label: IncreaseDecreaseInPrepaidResearchAndDevelopment to pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl1" xml:lang="en-US" id="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl1">Increase (Decrease) In Prepaid Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidResearchAndDevelopment to pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xml:lang="en-US" id="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment">Prepaid research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="label: IncreaseDecreaseInPrepaidResearchAndDevelopment to pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl">The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xlink:title="label: IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities to pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl1">Increase (Decrease) in Right of Use Assets and Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities to pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xml:lang="en-US" id="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities">Right of use assets and operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="label: IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities to pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:label="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:title="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" xml:lang="en-US" id="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl">The amount of lease liabilities recognized upon adoption of standard.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:to="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" xlink:title="label: OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard to pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl1" xml:lang="en-US" id="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl1">Operating Lease Liability Recognized Upon Adoption of Standard</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:to="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl1" xlink:title="label: OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard to pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xml:lang="en-US" id="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard">Operating lease liabilities recognized upon the commencement of sublease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:to="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:title="label: OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard to pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementCMember" xlink:label="SubleaseAgreementCMember" xlink:title="SubleaseAgreementCMember" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_SubleaseAgreementCMember_lbl" xml:lang="en-US" id="pasg_SubleaseAgreementCMember_lbl">Represents information pertaining to Sublease Agreement C.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementCMember" xlink:to="pasg_SubleaseAgreementCMember_lbl" xlink:title="label: SubleaseAgreementCMember to pasg_SubleaseAgreementCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_SubleaseAgreementCMember_lbl1" xml:lang="en-US" id="pasg_SubleaseAgreementCMember_lbl1">Sublease Agreement C [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementCMember" xlink:to="pasg_SubleaseAgreementCMember_lbl1" xlink:title="label: SubleaseAgreementCMember to pasg_SubleaseAgreementCMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_SubleaseAgreementCMember" xml:lang="en-US" id="pasg_SubleaseAgreementCMember">Sublease Agreement C</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementCMember" xlink:to="pasg_SubleaseAgreementCMember" xlink:title="label: SubleaseAgreementCMember to pasg_SubleaseAgreementCMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="OperatingLeasesForOfficeSpaceMember" xlink:title="OperatingLeasesForOfficeSpaceMember" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_OperatingLeasesForOfficeSpaceMember_lbl" xml:lang="en-US" id="pasg_OperatingLeasesForOfficeSpaceMember_lbl">Represents the operating lease agreement for office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesForOfficeSpaceMember" xlink:to="pasg_OperatingLeasesForOfficeSpaceMember_lbl" xlink:title="label: OperatingLeasesForOfficeSpaceMember to pasg_OperatingLeasesForOfficeSpaceMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_OperatingLeasesForOfficeSpaceMember_lbl1" xml:lang="en-US" id="pasg_OperatingLeasesForOfficeSpaceMember_lbl1">Operating Leases For Office Space [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesForOfficeSpaceMember" xlink:to="pasg_OperatingLeasesForOfficeSpaceMember_lbl1" xlink:title="label: OperatingLeasesForOfficeSpaceMember to pasg_OperatingLeasesForOfficeSpaceMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_OperatingLeasesForOfficeSpaceMember" xml:lang="en-US" id="pasg_OperatingLeasesForOfficeSpaceMember">Operating leases for office space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesForOfficeSpaceMember" xlink:to="pasg_OperatingLeasesForOfficeSpaceMember" xlink:title="label: OperatingLeasesForOfficeSpaceMember to pasg_OperatingLeasesForOfficeSpaceMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementaMember" xlink:label="SubleaseAgreementaMember" xlink:title="SubleaseAgreementaMember" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_SubleaseAgreementaMember_lbl" xml:lang="en-US" id="pasg_SubleaseAgreementaMember_lbl">Represents information pertaining to Sublease Agreement A.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementaMember" xlink:to="pasg_SubleaseAgreementaMember_lbl" xlink:title="label: SubleaseAgreementaMember to pasg_SubleaseAgreementaMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementaMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_SubleaseAgreementaMember_lbl1" xml:lang="en-US" id="pasg_SubleaseAgreementaMember_lbl1">Sublease Agreement A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementaMember" xlink:to="pasg_SubleaseAgreementaMember_lbl1" xlink:title="label: SubleaseAgreementaMember to pasg_SubleaseAgreementaMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_SubleaseAgreementaMember" xml:lang="en-US" id="pasg_SubleaseAgreementaMember">Sublease Agreement A</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementaMember" xlink:to="pasg_SubleaseAgreementaMember" xlink:title="label: SubleaseAgreementaMember to pasg_SubleaseAgreementaMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MarketStreetSubleaseAgreement1835Member" xlink:label="MarketStreetSubleaseAgreement1835Member" xlink:title="MarketStreetSubleaseAgreement1835Member" />
    <link:label xlink:type="resource" xlink:label="pasg_MarketStreetSubleaseAgreement1835Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_MarketStreetSubleaseAgreement1835Member_lbl" xml:lang="en-US" id="pasg_MarketStreetSubleaseAgreement1835Member_lbl">Represents the member information pertaining to 1835 Market Street Sublease Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketStreetSubleaseAgreement1835Member" xlink:to="pasg_MarketStreetSubleaseAgreement1835Member_lbl" xlink:title="label: MarketStreetSubleaseAgreement1835Member to pasg_MarketStreetSubleaseAgreement1835Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_MarketStreetSubleaseAgreement1835Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_MarketStreetSubleaseAgreement1835Member_lbl1" xml:lang="en-US" id="pasg_MarketStreetSubleaseAgreement1835Member_lbl1">1835 Market Street Sublease Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketStreetSubleaseAgreement1835Member" xlink:to="pasg_MarketStreetSubleaseAgreement1835Member_lbl1" xlink:title="label: MarketStreetSubleaseAgreement1835Member to pasg_MarketStreetSubleaseAgreement1835Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_MarketStreetSubleaseAgreement1835Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_MarketStreetSubleaseAgreement1835Member" xml:lang="en-US" id="pasg_MarketStreetSubleaseAgreement1835Member">1835 market street sublease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketStreetSubleaseAgreement1835Member" xlink:to="pasg_MarketStreetSubleaseAgreement1835Member" xlink:title="label: MarketStreetSubleaseAgreement1835Member to pasg_MarketStreetSubleaseAgreement1835Member" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementBMember" xlink:label="SubleaseAgreementBMember" xlink:title="SubleaseAgreementBMember" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_SubleaseAgreementBMember_lbl" xml:lang="en-US" id="pasg_SubleaseAgreementBMember_lbl">Represents information pertaining to Sublease Agreement B.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementBMember" xlink:to="pasg_SubleaseAgreementBMember_lbl" xlink:title="label: SubleaseAgreementBMember to pasg_SubleaseAgreementBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_SubleaseAgreementBMember_lbl1" xml:lang="en-US" id="pasg_SubleaseAgreementBMember_lbl1">Sublease Agreement B [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementBMember" xlink:to="pasg_SubleaseAgreementBMember_lbl1" xlink:title="label: SubleaseAgreementBMember to pasg_SubleaseAgreementBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_SubleaseAgreementBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_SubleaseAgreementBMember" xml:lang="en-US" id="pasg_SubleaseAgreementBMember">Sublease Agreement B</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubleaseAgreementBMember" xlink:to="pasg_SubleaseAgreementBMember" xlink:title="label: SubleaseAgreementBMember to pasg_SubleaseAgreementBMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="OperatingLeasesForLaboratorySpaceMember" xlink:title="OperatingLeasesForLaboratorySpaceMember" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xml:lang="en-US" id="pasg_OperatingLeasesForLaboratorySpaceMember_lbl">Represents the operating lease agreement for laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesForLaboratorySpaceMember" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xlink:title="label: OperatingLeasesForLaboratorySpaceMember to pasg_OperatingLeasesForLaboratorySpaceMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_OperatingLeasesForLaboratorySpaceMember_lbl1" xml:lang="en-US" id="pasg_OperatingLeasesForLaboratorySpaceMember_lbl1">Operating Leases For Laboratory Space [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesForLaboratorySpaceMember" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember_lbl1" xlink:title="label: OperatingLeasesForLaboratorySpaceMember to pasg_OperatingLeasesForLaboratorySpaceMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_OperatingLeasesForLaboratorySpaceMember" xml:lang="en-US" id="pasg_OperatingLeasesForLaboratorySpaceMember">Operating leases for laboratory space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasesForLaboratorySpaceMember" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember" xlink:title="label: OperatingLeasesForLaboratorySpaceMember to pasg_OperatingLeasesForLaboratorySpaceMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:label="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" />
    <link:label xlink:type="resource" xlink:label="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl" xml:lang="en-US" id="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl">Represents the notice period for termination of lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:to="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl" xlink:title="label: LesseeOperatingLeaseNoticePeriodForTerminationOfLease to pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl1" xml:lang="en-US" id="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl1">Lessee, Operating Lease, Notice Period for Termination of Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:to="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl1" xlink:title="label: LesseeOperatingLeaseNoticePeriodForTerminationOfLease to pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xml:lang="en-US" id="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease">Notice Period for termination lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:to="pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="label: LesseeOperatingLeaseNoticePeriodForTerminationOfLease to pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfAnnualIncreaseInSubleaseRent" xlink:label="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="PercentageOfAnnualIncreaseInSubleaseRent" />
    <link:label xlink:type="resource" xlink:label="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl" xml:lang="en-US" id="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl">Represents the percentage of annual increase in sublease rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAnnualIncreaseInSubleaseRent" xlink:to="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl" xlink:title="label: PercentageOfAnnualIncreaseInSubleaseRent to pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl1" xml:lang="en-US" id="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl1">Percentage of Annual Increase in Sublease Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAnnualIncreaseInSubleaseRent" xlink:to="pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl1" xlink:title="label: PercentageOfAnnualIncreaseInSubleaseRent to pasg_PercentageOfAnnualIncreaseInSubleaseRent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_PercentageOfAnnualIncreaseInSubleaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_PercentageOfAnnualIncreaseInSubleaseRent" xml:lang="en-US" id="pasg_PercentageOfAnnualIncreaseInSubleaseRent">Annual increase in sublease rent (as a percent)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfAnnualIncreaseInSubleaseRent" xlink:to="pasg_PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="label: PercentageOfAnnualIncreaseInSubleaseRent to pasg_PercentageOfAnnualIncreaseInSubleaseRent" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" id="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl">Represents the renewal term under new lease agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xlink:title="label: NewLeaseAgreementOperatingLeaseRenewalTerm to pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl1" xml:lang="en-US" id="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl1">New Lease Agreement, Operating Lease, Renewal Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl1" xlink:title="label: NewLeaseAgreementOperatingLeaseRenewalTerm to pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xml:lang="en-US" id="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm">Extended term of new lease agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="label: NewLeaseAgreementOperatingLeaseRenewalTerm to pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <link:label xlink:type="resource" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xml:lang="en-US" id="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl">Represents the number of extensions available under the new lease arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xlink:title="label: NewLeaseAgreementOperatingLeaseNumberOfExtensions to pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl1" xml:lang="en-US" id="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl1">New Lease Agreement, Operating Lease, Number Of Extensions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl1" xlink:title="label: NewLeaseAgreementOperatingLeaseNumberOfExtensions to pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xml:lang="en-US" id="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions">Number of extension terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="label: NewLeaseAgreementOperatingLeaseNumberOfExtensions to pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaSubleased" xlink:label="AreaSubleased" xlink:title="AreaSubleased" />
    <link:label xlink:type="resource" xlink:label="pasg_AreaSubleased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AreaSubleased_lbl" xml:lang="en-US" id="pasg_AreaSubleased_lbl">Area subleased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaSubleased" xlink:to="pasg_AreaSubleased_lbl" xlink:title="label: AreaSubleased to pasg_AreaSubleased_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AreaSubleased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AreaSubleased_lbl1" xml:lang="en-US" id="pasg_AreaSubleased_lbl1">Area Subleased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaSubleased" xlink:to="pasg_AreaSubleased_lbl1" xlink:title="label: AreaSubleased to pasg_AreaSubleased_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaOfLandSubleasedPercentage" xlink:label="AreaOfLandSubleasedPercentage" xlink:title="AreaOfLandSubleasedPercentage" />
    <link:label xlink:type="resource" xlink:label="pasg_AreaOfLandSubleasedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AreaOfLandSubleasedPercentage_lbl" xml:lang="en-US" id="pasg_AreaOfLandSubleasedPercentage_lbl">Represents are of land sub leased of the total area under lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfLandSubleasedPercentage" xlink:to="pasg_AreaOfLandSubleasedPercentage_lbl" xlink:title="label: AreaOfLandSubleasedPercentage to pasg_AreaOfLandSubleasedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AreaOfLandSubleasedPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AreaOfLandSubleasedPercentage_lbl1" xml:lang="en-US" id="pasg_AreaOfLandSubleasedPercentage_lbl1">Area of Land subleased, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfLandSubleasedPercentage" xlink:to="pasg_AreaOfLandSubleasedPercentage_lbl1" xlink:title="label: AreaOfLandSubleasedPercentage to pasg_AreaOfLandSubleasedPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_AreaOfLandSubleasedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_AreaOfLandSubleasedPercentage" xml:lang="en-US" id="pasg_AreaOfLandSubleasedPercentage">Subleased area of land</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AreaOfLandSubleasedPercentage" xlink:to="pasg_AreaOfLandSubleasedPercentage" xlink:title="label: AreaOfLandSubleasedPercentage to pasg_AreaOfLandSubleasedPercentage" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="PrepaidResearchAndDevelopmentAssetCurrent" />
    <link:label xlink:type="resource" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xml:lang="en-US" id="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl">Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidResearchAndDevelopmentAssetCurrent" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xlink:title="label: PrepaidResearchAndDevelopmentAssetCurrent to pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl1" xml:lang="en-US" id="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl1">Prepaid Research And Development Asset, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidResearchAndDevelopmentAssetCurrent" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl1" xlink:title="label: PrepaidResearchAndDevelopmentAssetCurrent to pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_PrepaidResearchAndDevelopmentAssetCurrent" xml:lang="en-US" id="pasg_PrepaidResearchAndDevelopmentAssetCurrent">Prepaid research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidResearchAndDevelopmentAssetCurrent" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="label: PrepaidResearchAndDevelopmentAssetCurrent to pasg_PrepaidResearchAndDevelopmentAssetCurrent" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:label="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:title="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl">Disclosure of accounting policy for other income or other expense items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:to="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl" xlink:title="label: OtherIncomeAndOtherExpensePolicyPolicyTextBlock to pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl1">Other Income and Other Expense Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:to="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl1" xlink:title="label: OtherIncomeAndOtherExpensePolicyPolicyTextBlock to pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xml:lang="en-US" id="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock">Other Income (Expense), Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:to="pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:title="label: OtherIncomeAndOtherExpensePolicyPolicyTextBlock to pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_BasisOfPresentationPolicyTextBlock" xlink:label="BasisOfPresentationPolicyTextBlock" xlink:title="BasisOfPresentationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" id="pasg_BasisOfPresentationPolicyTextBlock_lbl">Disclosure of accounting policy for basis of presentation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationPolicyTextBlock" xlink:to="pasg_BasisOfPresentationPolicyTextBlock_lbl" xlink:title="label: BasisOfPresentationPolicyTextBlock to pasg_BasisOfPresentationPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_BasisOfPresentationPolicyTextBlock_lbl1" xml:lang="en-US" id="pasg_BasisOfPresentationPolicyTextBlock_lbl1">Basis Of Presentation [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationPolicyTextBlock" xlink:to="pasg_BasisOfPresentationPolicyTextBlock_lbl1" xlink:title="label: BasisOfPresentationPolicyTextBlock to pasg_BasisOfPresentationPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_BasisOfPresentationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_BasisOfPresentationPolicyTextBlock" xml:lang="en-US" id="pasg_BasisOfPresentationPolicyTextBlock">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfPresentationPolicyTextBlock" xlink:to="pasg_BasisOfPresentationPolicyTextBlock" xlink:title="label: BasisOfPresentationPolicyTextBlock to pasg_BasisOfPresentationPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:title="CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:label xlink:type="resource" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US" id="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:title="label: CashCashEquivalentsAndMarketableSecuritiesAbstract to pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl1" xml:lang="en-US" id="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl1">Cash, Cash Equivalents, and Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl1" xlink:title="label: CashCashEquivalentsAndMarketableSecuritiesAbstract to pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="RisksAndLiquidityAbstract" xlink:title="RisksAndLiquidityAbstract" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RisksAndLiquidityAbstract_lbl" xml:lang="en-US" id="pasg_RisksAndLiquidityAbstract_lbl">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityAbstract" xlink:to="pasg_RisksAndLiquidityAbstract_lbl" xlink:title="label: RisksAndLiquidityAbstract to pasg_RisksAndLiquidityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RisksAndLiquidityAbstract_lbl1" xml:lang="en-US" id="pasg_RisksAndLiquidityAbstract_lbl1">Risks and Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityAbstract" xlink:to="pasg_RisksAndLiquidityAbstract_lbl1" xlink:title="label: RisksAndLiquidityAbstract to pasg_RisksAndLiquidityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTextBlock" xlink:label="RisksAndLiquidityTextBlock" xlink:title="RisksAndLiquidityTextBlock" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RisksAndLiquidityTextBlock_lbl" xml:lang="en-US" id="pasg_RisksAndLiquidityTextBlock_lbl">The entire disclosure of information pertaining to risk and liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityTextBlock" xlink:to="pasg_RisksAndLiquidityTextBlock_lbl" xlink:title="label: RisksAndLiquidityTextBlock to pasg_RisksAndLiquidityTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RisksAndLiquidityTextBlock_lbl1" xml:lang="en-US" id="pasg_RisksAndLiquidityTextBlock_lbl1">Risks And Liquidity [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityTextBlock" xlink:to="pasg_RisksAndLiquidityTextBlock_lbl1" xlink:title="label: RisksAndLiquidityTextBlock to pasg_RisksAndLiquidityTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pasg_RisksAndLiquidityTextBlock" xml:lang="en-US" id="pasg_RisksAndLiquidityTextBlock">Risks and Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityTextBlock" xlink:to="pasg_RisksAndLiquidityTextBlock" xlink:title="label: RisksAndLiquidityTextBlock to pasg_RisksAndLiquidityTextBlock" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_RisksAndLiquidityTextBlock_lbl2" xml:lang="en-US" id="pasg_RisksAndLiquidityTextBlock_lbl2">Risks, Liquidity, and Going Concern</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityTextBlock" xlink:to="pasg_RisksAndLiquidityTextBlock_lbl2" xlink:title="label: RisksAndLiquidityTextBlock to pasg_RisksAndLiquidityTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTable" xlink:label="RisksAndLiquidityTable" xlink:title="RisksAndLiquidityTable" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RisksAndLiquidityTable_lbl" xml:lang="en-US" id="pasg_RisksAndLiquidityTable_lbl">Schedule of information pertaining to risk and liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityTable" xlink:to="pasg_RisksAndLiquidityTable_lbl" xlink:title="label: RisksAndLiquidityTable to pasg_RisksAndLiquidityTable_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RisksAndLiquidityTable_lbl1" xml:lang="en-US" id="pasg_RisksAndLiquidityTable_lbl1">Risks And Liquidity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityTable" xlink:to="pasg_RisksAndLiquidityTable_lbl1" xlink:title="label: RisksAndLiquidityTable to pasg_RisksAndLiquidityTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="RisksAndLiquidityLineItems" xlink:title="RisksAndLiquidityLineItems" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RisksAndLiquidityLineItems_lbl" xml:lang="en-US" id="pasg_RisksAndLiquidityLineItems_lbl">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityLineItems" xlink:to="pasg_RisksAndLiquidityLineItems_lbl" xlink:title="label: RisksAndLiquidityLineItems to pasg_RisksAndLiquidityLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RisksAndLiquidityLineItems_lbl1" xml:lang="en-US" id="pasg_RisksAndLiquidityLineItems_lbl1">Risks And Liquidity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityLineItems" xlink:to="pasg_RisksAndLiquidityLineItems_lbl1" xlink:title="label: RisksAndLiquidityLineItems to pasg_RisksAndLiquidityLineItems_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksAndLiquidityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_RisksAndLiquidityLineItems" xml:lang="en-US" id="pasg_RisksAndLiquidityLineItems">Risks, Liquidity, and Going Concern</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndLiquidityLineItems" xlink:to="pasg_RisksAndLiquidityLineItems" xlink:title="label: RisksAndLiquidityLineItems to pasg_RisksAndLiquidityLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AttheMarketFacilityAgreementMember" xlink:label="AttheMarketFacilityAgreementMember" xlink:title="AttheMarketFacilityAgreementMember" />
    <link:label xlink:type="resource" xlink:label="pasg_AttheMarketFacilityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AttheMarketFacilityAgreementMember_lbl" xml:lang="en-US" id="pasg_AttheMarketFacilityAgreementMember_lbl">Represents the member information pertaining to at-the-market (ATM) facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AttheMarketFacilityAgreementMember" xlink:to="pasg_AttheMarketFacilityAgreementMember_lbl" xlink:title="label: AttheMarketFacilityAgreementMember to pasg_AttheMarketFacilityAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AttheMarketFacilityAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AttheMarketFacilityAgreementMember_lbl1" xml:lang="en-US" id="pasg_AttheMarketFacilityAgreementMember_lbl1">ATM Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AttheMarketFacilityAgreementMember" xlink:to="pasg_AttheMarketFacilityAgreementMember_lbl1" xlink:title="label: AttheMarketFacilityAgreementMember to pasg_AttheMarketFacilityAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_AttheMarketFacilityAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_AttheMarketFacilityAgreementMember" xml:lang="en-US" id="pasg_AttheMarketFacilityAgreementMember">ATM Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AttheMarketFacilityAgreementMember" xlink:to="pasg_AttheMarketFacilityAgreementMember" xlink:title="label: AttheMarketFacilityAgreementMember to pasg_AttheMarketFacilityAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:label="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:title="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" />
    <link:label xlink:type="resource" xlink:label="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl" xml:lang="en-US" id="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl">Represents information pertaining to property, plant and equipment and certain other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:to="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl" xlink:title="label: PropertyPlantAndEquipmentAndCertainOtherAssetsMember to pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl1" xml:lang="en-US" id="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl1">Property Plant And Equipment And Certain Other Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:to="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl1" xlink:title="label: PropertyPlantAndEquipmentAndCertainOtherAssetsMember to pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xml:lang="en-US" id="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember">Property and equipment and certain other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:to="pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:title="label: PropertyPlantAndEquipmentAndCertainOtherAssetsMember to pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="pasg_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LaboratoryEquipmentMember_lbl" xml:lang="en-US" id="pasg_LaboratoryEquipmentMember_lbl">Represents the information pertaining to Laboratory equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="pasg_LaboratoryEquipmentMember_lbl" xlink:title="label: LaboratoryEquipmentMember to pasg_LaboratoryEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LaboratoryEquipmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LaboratoryEquipmentMember_lbl1" xml:lang="en-US" id="pasg_LaboratoryEquipmentMember_lbl1">Laboratory equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="pasg_LaboratoryEquipmentMember_lbl1" xlink:title="label: LaboratoryEquipmentMember to pasg_LaboratoryEquipmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LaboratoryEquipmentMember" xml:lang="en-US" id="pasg_LaboratoryEquipmentMember">Laboratory equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentMember" xlink:to="pasg_LaboratoryEquipmentMember" xlink:title="label: LaboratoryEquipmentMember to pasg_LaboratoryEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:label="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:label xlink:type="resource" xlink:label="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl" xml:lang="en-US" id="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl">Represents information pertaining to laboratory equipment and certain other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:to="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl" xlink:title="label: LaboratoryEquipmentAndCertainOtherAssetsMember to pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl1" xml:lang="en-US" id="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl1">Laboratory Equipment And Certain Other Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:to="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl1" xlink:title="label: LaboratoryEquipmentAndCertainOtherAssetsMember to pasg_LaboratoryEquipmentAndCertainOtherAssetsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xml:lang="en-US" id="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember">Laboratory equipment and certain other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:to="pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="label: LaboratoryEquipmentAndCertainOtherAssetsMember to pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GainLossOnSaleOfTaxCredits" xlink:label="GainLossOnSaleOfTaxCredits" xlink:title="GainLossOnSaleOfTaxCredits" />
    <link:label xlink:type="resource" xlink:label="pasg_GainLossOnSaleOfTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_GainLossOnSaleOfTaxCredits_lbl" xml:lang="en-US" id="pasg_GainLossOnSaleOfTaxCredits_lbl">The amount of gain (loss) on sale of tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfTaxCredits" xlink:to="pasg_GainLossOnSaleOfTaxCredits_lbl" xlink:title="label: GainLossOnSaleOfTaxCredits to pasg_GainLossOnSaleOfTaxCredits_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_GainLossOnSaleOfTaxCredits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_GainLossOnSaleOfTaxCredits_lbl1" xml:lang="en-US" id="pasg_GainLossOnSaleOfTaxCredits_lbl1">Gain (Loss) on Sale of Tax Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfTaxCredits" xlink:to="pasg_GainLossOnSaleOfTaxCredits_lbl1" xlink:title="label: GainLossOnSaleOfTaxCredits to pasg_GainLossOnSaleOfTaxCredits_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_GainLossOnSaleOfTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_GainLossOnSaleOfTaxCredits" xml:lang="en-US" id="pasg_GainLossOnSaleOfTaxCredits">Gain (loss) on sale of tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnSaleOfTaxCredits" xlink:to="pasg_GainLossOnSaleOfTaxCredits" xlink:title="label: GainLossOnSaleOfTaxCredits to pasg_GainLossOnSaleOfTaxCredits" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <link:label xlink:type="resource" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xml:lang="en-US" id="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl">Represents information pertaining to stock options (including shares subject to repurchase).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xlink:title="label: StockOptionsIncludingSharesSubjectToRepurchaseMember to pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl1" xml:lang="en-US" id="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl1">Stock options (including shares subject to repurchase) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl1" xlink:title="label: StockOptionsIncludingSharesSubjectToRepurchaseMember to pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xml:lang="en-US" id="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember">Stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="label: StockOptionsIncludingSharesSubjectToRepurchaseMember to pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RightOfUseAssetsFairValueDisclosure" xlink:label="RightOfUseAssetsFairValueDisclosure" xlink:title="RightOfUseAssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="pasg_RightOfUseAssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RightOfUseAssetsFairValueDisclosure_lbl" xml:lang="en-US" id="pasg_RightOfUseAssetsFairValueDisclosure_lbl">Fair value portion of right of use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetsFairValueDisclosure" xlink:to="pasg_RightOfUseAssetsFairValueDisclosure_lbl" xlink:title="label: RightOfUseAssetsFairValueDisclosure to pasg_RightOfUseAssetsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RightOfUseAssetsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RightOfUseAssetsFairValueDisclosure_lbl1" xml:lang="en-US" id="pasg_RightOfUseAssetsFairValueDisclosure_lbl1">Right of use Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetsFairValueDisclosure" xlink:to="pasg_RightOfUseAssetsFairValueDisclosure_lbl1" xlink:title="label: RightOfUseAssetsFairValueDisclosure to pasg_RightOfUseAssetsFairValueDisclosure_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_RightOfUseAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_RightOfUseAssetsFairValueDisclosure" xml:lang="en-US" id="pasg_RightOfUseAssetsFairValueDisclosure">Right of use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetsFairValueDisclosure" xlink:to="pasg_RightOfUseAssetsFairValueDisclosure" xlink:title="label: RightOfUseAssetsFairValueDisclosure to pasg_RightOfUseAssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:label xlink:type="resource" xlink:label="pasg_ComputerHardwareAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" id="pasg_ComputerHardwareAndSoftwareMember_lbl">Represents the information pertaining to Computer Hardware and Software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerHardwareAndSoftwareMember" xlink:to="pasg_ComputerHardwareAndSoftwareMember_lbl" xlink:title="label: ComputerHardwareAndSoftwareMember to pasg_ComputerHardwareAndSoftwareMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ComputerHardwareAndSoftwareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ComputerHardwareAndSoftwareMember_lbl1" xml:lang="en-US" id="pasg_ComputerHardwareAndSoftwareMember_lbl1">Computer hardware and software. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerHardwareAndSoftwareMember" xlink:to="pasg_ComputerHardwareAndSoftwareMember_lbl1" xlink:title="label: ComputerHardwareAndSoftwareMember to pasg_ComputerHardwareAndSoftwareMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ComputerHardwareAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ComputerHardwareAndSoftwareMember" xml:lang="en-US" id="pasg_ComputerHardwareAndSoftwareMember">Computer hardware and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerHardwareAndSoftwareMember" xlink:to="pasg_ComputerHardwareAndSoftwareMember" xlink:title="label: ComputerHardwareAndSoftwareMember to pasg_ComputerHardwareAndSoftwareMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneticMedicinesSegmentMember" xlink:label="GeneticMedicinesSegmentMember" xlink:title="GeneticMedicinesSegmentMember" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneticMedicinesSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_GeneticMedicinesSegmentMember_lbl" xml:lang="en-US" id="pasg_GeneticMedicinesSegmentMember_lbl">Represents information pertaining to developing and advancing of genetic medicines.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneticMedicinesSegmentMember" xlink:to="pasg_GeneticMedicinesSegmentMember_lbl" xlink:title="label: GeneticMedicinesSegmentMember to pasg_GeneticMedicinesSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneticMedicinesSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_GeneticMedicinesSegmentMember_lbl1" xml:lang="en-US" id="pasg_GeneticMedicinesSegmentMember_lbl1">Genetic Medicines Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneticMedicinesSegmentMember" xlink:to="pasg_GeneticMedicinesSegmentMember_lbl1" xlink:title="label: GeneticMedicinesSegmentMember to pasg_GeneticMedicinesSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneticMedicinesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_GeneticMedicinesSegmentMember" xml:lang="en-US" id="pasg_GeneticMedicinesSegmentMember">Genetic Medicines Segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneticMedicinesSegmentMember" xlink:to="pasg_GeneticMedicinesSegmentMember" xlink:title="label: GeneticMedicinesSegmentMember to pasg_GeneticMedicinesSegmentMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:label="GeneralAndAdministrativeThirdPartyCosts" xlink:title="GeneralAndAdministrativeThirdPartyCosts" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl" xml:lang="en-US" id="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl">Amount of expenses in the period for usage of third party costs attributable to managing and administering the affairs of an entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeThirdPartyCosts" xlink:to="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl" xlink:title="label: GeneralAndAdministrativeThirdPartyCosts to pasg_GeneralAndAdministrativeThirdPartyCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl1" xml:lang="en-US" id="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl1">General and Administrative, Third Party Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeThirdPartyCosts" xlink:to="pasg_GeneralAndAdministrativeThirdPartyCosts_lbl1" xlink:title="label: GeneralAndAdministrativeThirdPartyCosts to pasg_GeneralAndAdministrativeThirdPartyCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_GeneralAndAdministrativeThirdPartyCosts" xml:lang="en-US" id="pasg_GeneralAndAdministrativeThirdPartyCosts">Third-party costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeThirdPartyCosts" xlink:to="pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:title="label: GeneralAndAdministrativeThirdPartyCosts to pasg_GeneralAndAdministrativeThirdPartyCosts" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:label="GeneralAndAdministrativeShareBasedCompensation" xlink:title="GeneralAndAdministrativeShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl" xml:lang="en-US" id="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl">Amount of expenses in the period for usage of share based compensation attributable to managing and administering the affairs of an entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeShareBasedCompensation" xlink:to="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl" xlink:title="label: GeneralAndAdministrativeShareBasedCompensation to pasg_GeneralAndAdministrativeShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl1" xml:lang="en-US" id="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl1">General and Administrative, Share Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeShareBasedCompensation" xlink:to="pasg_GeneralAndAdministrativeShareBasedCompensation_lbl1" xlink:title="label: GeneralAndAdministrativeShareBasedCompensation to pasg_GeneralAndAdministrativeShareBasedCompensation_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_GeneralAndAdministrativeShareBasedCompensation" xml:lang="en-US" id="pasg_GeneralAndAdministrativeShareBasedCompensation">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeShareBasedCompensation" xlink:to="pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:title="label: GeneralAndAdministrativeShareBasedCompensation to pasg_GeneralAndAdministrativeShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:label="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="GeneralAndAdministrativeLaborAndRelatedExpenses" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl" xml:lang="en-US" id="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl">Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit, excluding wages and other benefits incurred for employees in research and development phase of the medicines.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:to="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl" xlink:title="label: GeneralAndAdministrativeLaborAndRelatedExpenses to pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl1" xml:lang="en-US" id="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl1">General And Administrative, Labor And Related Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:to="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl1" xlink:title="label: GeneralAndAdministrativeLaborAndRelatedExpenses to pasg_GeneralAndAdministrativeLaborAndRelatedExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xml:lang="en-US" id="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses">Wages, benefits, and other payroll</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:to="pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="label: GeneralAndAdministrativeLaborAndRelatedExpenses to pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:label="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="ResearchAndDevelopmentDepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl" xml:lang="en-US" id="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl">Amount of expenses in the period for usage of depreciation and amortization attributable specifically to research and development division.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentDepreciationAndAmortization" xlink:to="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl" xlink:title="label: ResearchAndDevelopmentDepreciationAndAmortization to pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl1" xml:lang="en-US" id="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl1">Research and Development, Depreciation and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentDepreciationAndAmortization" xlink:to="pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl1" xlink:title="label: ResearchAndDevelopmentDepreciationAndAmortization to pasg_ResearchAndDevelopmentDepreciationAndAmortization_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ResearchAndDevelopmentDepreciationAndAmortization" xml:lang="en-US" id="pasg_ResearchAndDevelopmentDepreciationAndAmortization">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentDepreciationAndAmortization" xlink:to="pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="label: ResearchAndDevelopmentDepreciationAndAmortization to pasg_ResearchAndDevelopmentDepreciationAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:label="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="ResearchAndDevelopmentLaborAndRelatedExpenses" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl" xml:lang="en-US" id="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl">Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit directly attributable to research and development phase of the medicines.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:to="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl" xlink:title="label: ResearchAndDevelopmentLaborAndRelatedExpenses to pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl1" xml:lang="en-US" id="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl1">Research And Development, Labor And Related Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:to="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl1" xlink:title="label: ResearchAndDevelopmentLaborAndRelatedExpenses to pasg_ResearchAndDevelopmentLaborAndRelatedExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xml:lang="en-US" id="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses">Wages, benefits, and other payroll</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:to="pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="label: ResearchAndDevelopmentLaborAndRelatedExpenses to pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:label="ResearchAndDevelopmentShareBasedCompensation" xlink:title="ResearchAndDevelopmentShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl" xml:lang="en-US" id="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl">Amount of expenses in the period for usage of share based compensation attributable specifically to research and development division.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentShareBasedCompensation" xlink:to="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl" xlink:title="label: ResearchAndDevelopmentShareBasedCompensation to pasg_ResearchAndDevelopmentShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl1" xml:lang="en-US" id="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl1">Research and Development, Share Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentShareBasedCompensation" xlink:to="pasg_ResearchAndDevelopmentShareBasedCompensation_lbl1" xlink:title="label: ResearchAndDevelopmentShareBasedCompensation to pasg_ResearchAndDevelopmentShareBasedCompensation_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ResearchAndDevelopmentShareBasedCompensation" xml:lang="en-US" id="pasg_ResearchAndDevelopmentShareBasedCompensation">Share-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentShareBasedCompensation" xlink:to="pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:title="label: ResearchAndDevelopmentShareBasedCompensation to pasg_ResearchAndDevelopmentShareBasedCompensation" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:label="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="GeneralAndAdministrativeDepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl" xml:lang="en-US" id="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl">Amount of expenses in the period for usage of depreciation and amortization attributable to managing and administering the affairs of an entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeDepreciationAndAmortization" xlink:to="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl" xlink:title="label: GeneralAndAdministrativeDepreciationAndAmortization to pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl1" xml:lang="en-US" id="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl1">General and Administrative, Depreciation and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeDepreciationAndAmortization" xlink:to="pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl1" xlink:title="label: GeneralAndAdministrativeDepreciationAndAmortization to pasg_GeneralAndAdministrativeDepreciationAndAmortization_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_GeneralAndAdministrativeDepreciationAndAmortization" xml:lang="en-US" id="pasg_GeneralAndAdministrativeDepreciationAndAmortization">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeDepreciationAndAmortization" xlink:to="pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="label: GeneralAndAdministrativeDepreciationAndAmortization to pasg_GeneralAndAdministrativeDepreciationAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:label="ResearchAndDevelopmentThirdPartyCosts" xlink:title="ResearchAndDevelopmentThirdPartyCosts" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl" xml:lang="en-US" id="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl">Amount of expenses in the period for usage of third party costs attributable specifically to research and development division.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentThirdPartyCosts" xlink:to="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl" xlink:title="label: ResearchAndDevelopmentThirdPartyCosts to pasg_ResearchAndDevelopmentThirdPartyCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl1" xml:lang="en-US" id="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl1">Research and Development, Third Party Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentThirdPartyCosts" xlink:to="pasg_ResearchAndDevelopmentThirdPartyCosts_lbl1" xlink:title="label: ResearchAndDevelopmentThirdPartyCosts to pasg_ResearchAndDevelopmentThirdPartyCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ResearchAndDevelopmentThirdPartyCosts" xml:lang="en-US" id="pasg_ResearchAndDevelopmentThirdPartyCosts">Third-party costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentThirdPartyCosts" xlink:to="pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:title="label: ResearchAndDevelopmentThirdPartyCosts to pasg_ResearchAndDevelopmentThirdPartyCosts" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="pasg_StockholderSEquityAndShareBasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_StockholderSEquityAndShareBasedCompensationAbstract_lbl1" xml:lang="en-US" id="pasg_StockholderSEquityAndShareBasedCompensationAbstract_lbl1">Stockholder's Equity and Share-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="pasg_StockholderSEquityAndShareBasedCompensationAbstract_lbl1" xlink:title="label: StockholderSEquityAndShareBasedCompensationAbstract to pasg_StockholderSEquityAndShareBasedCompensationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl">Additional number of common shares reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: CommonStockAdditionalCapitalSharesReservedForFutureIssuance to pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl1">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: CommonStockAdditionalCapitalSharesReservedForFutureIssuance to pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">Additional number of common shares reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="label: CommonStockAdditionalCapitalSharesReservedForFutureIssuance to pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xml:lang="en-US" id="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl">Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xlink:title="label: ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease to pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl1" xml:lang="en-US" id="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl1">Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl1" xlink:title="label: ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease to pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xml:lang="en-US" id="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease">Percent of the total number of shares of the Company's common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="label: ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease to pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" id="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl">Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xlink:title="label: ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted to pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" xml:lang="en-US" id="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1">Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" xlink:title="label: ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted to pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xml:lang="en-US" id="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted">Period till which there is automatic increase in rights granted under the Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="label: ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted to pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xml:lang="en-US" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl">Duration from date of grant (issuance of an option) to when option auto expires.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm to pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl1" xml:lang="en-US" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl1">Share-based Compensation Arrangement By Share-based Payment Award Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm to pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xml:lang="en-US" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm">Term of award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm to pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl">Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xlink:title="label: EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage to pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl1" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl1">Employee Stock Purchase Plan, Maximum Employee Contribution Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl1" xlink:title="label: EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage to pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage">Percentage of maximum employee contribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="label: EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage to pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl">Threshold number of shares that can be purchased in any single offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl" xlink:title="label: EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased to pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl1" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl1">Employee Stock Purchase Plan, Threshold Number Of Shares That Can Be Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl1" xlink:title="label: EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased to pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased">Number of shares that can be purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="label: EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased to pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl">Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xlink:title="label: EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted to pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1">Employee Stock Purchase Plan, Period Till Which Automatic Increase In Rights Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" xlink:title="label: EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted to pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted">Period till which there is automatic increase in rights granted under ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="label: EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted to pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl">The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xlink:title="label: EmployeeStockPurchasePlanStockPurchasePricePercentage to pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl1" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl1">Employee Stock Purchase Plan, Stock Purchase Price Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl1" xlink:title="label: EmployeeStockPurchasePlanStockPurchasePricePercentage to pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage">Percentage of stock purchase price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="label: EmployeeStockPurchasePlanStockPurchasePricePercentage to pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:label xlink:type="resource" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" id="pasg_NumberOfEquityIncentivePlans_lbl">Represents the number of equity incentive plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityIncentivePlans" xlink:to="pasg_NumberOfEquityIncentivePlans_lbl" xlink:title="label: NumberOfEquityIncentivePlans to pasg_NumberOfEquityIncentivePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_NumberOfEquityIncentivePlans_lbl1" xml:lang="en-US" id="pasg_NumberOfEquityIncentivePlans_lbl1">Number Of Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityIncentivePlans" xlink:to="pasg_NumberOfEquityIncentivePlans_lbl1" xlink:title="label: NumberOfEquityIncentivePlans to pasg_NumberOfEquityIncentivePlans_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_NumberOfEquityIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_NumberOfEquityIncentivePlans" xml:lang="en-US" id="pasg_NumberOfEquityIncentivePlans">Number of equity incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEquityIncentivePlans" xlink:to="pasg_NumberOfEquityIncentivePlans" xlink:title="label: NumberOfEquityIncentivePlans to pasg_NumberOfEquityIncentivePlans" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl">The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xlink:title="label: EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased to pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl1" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl1">Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl1" xlink:title="label: EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased to pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased">Maximum amount of common stock that can be purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="label: EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased to pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl">Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xlink:title="label: EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding to pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl1" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl1">Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl1" xlink:title="label: EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding to pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding">Percentage of common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="label: EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding to pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMember_lbl">Represents information pertaining to Employee Stock Purchase Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMember" xlink:to="pasg_EmployeeStockPurchasePlanMember_lbl" xlink:title="label: EmployeeStockPurchasePlanMember to pasg_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EmployeeStockPurchasePlanMember_lbl1" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMember_lbl1">Employee Stock Purchase Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMember" xlink:to="pasg_EmployeeStockPurchasePlanMember_lbl1" xlink:title="label: EmployeeStockPurchasePlanMember to pasg_EmployeeStockPurchasePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EmployeeStockPurchasePlanMember" xml:lang="en-US" id="pasg_EmployeeStockPurchasePlanMember">Employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMember" xlink:to="pasg_EmployeeStockPurchasePlanMember" xlink:title="label: EmployeeStockPurchasePlanMember to pasg_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="pasg_EquityIncentivePlanMember_lbl">Represents information pertaining to Equity Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="pasg_EquityIncentivePlanMember_lbl" xlink:title="label: EquityIncentivePlanMember to pasg_EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="pasg_EquityIncentivePlanMember_lbl1">Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="pasg_EquityIncentivePlanMember_lbl1" xlink:title="label: EquityIncentivePlanMember to pasg_EquityIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EquityIncentivePlanMember" xml:lang="en-US" id="pasg_EquityIncentivePlanMember">Equity Incentive Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="pasg_EquityIncentivePlanMember" xlink:title="label: EquityIncentivePlanMember to pasg_EquityIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityInducementPlan2021Member" xlink:label="EquityInducementPlan2021Member" xlink:title="EquityInducementPlan2021Member" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityInducementPlan2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EquityInducementPlan2021Member_lbl" xml:lang="en-US" id="pasg_EquityInducementPlan2021Member_lbl">Represents information pertaining to 2021 Equity Inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInducementPlan2021Member" xlink:to="pasg_EquityInducementPlan2021Member_lbl" xlink:title="label: EquityInducementPlan2021Member to pasg_EquityInducementPlan2021Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityInducementPlan2021Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EquityInducementPlan2021Member_lbl1" xml:lang="en-US" id="pasg_EquityInducementPlan2021Member_lbl1">Equity Inducement Plan 2021 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInducementPlan2021Member" xlink:to="pasg_EquityInducementPlan2021Member_lbl1" xlink:title="label: EquityInducementPlan2021Member to pasg_EquityInducementPlan2021Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityInducementPlan2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EquityInducementPlan2021Member" xml:lang="en-US" id="pasg_EquityInducementPlan2021Member">Equity inducement plan 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityInducementPlan2021Member" xlink:to="pasg_EquityInducementPlan2021Member" xlink:title="label: EquityInducementPlan2021Member to pasg_EquityInducementPlan2021Member" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:label="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl" xml:lang="en-US" id="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl">Amount of upfront fees payable per product indication upon developmental milestone.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:to="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl" xlink:title="label: NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone to pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl1" xml:lang="en-US" id="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl1">Non - Refundable Fees Payable Per Product Indication Upon Developmental Milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:to="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl1" xlink:title="label: NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone to pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xml:lang="en-US" id="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone">Non - Refundable fees payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:to="pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="label: NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone to pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LossContingencySharesAgreedByDefendant" xlink:label="LossContingencySharesAgreedByDefendant" xlink:title="LossContingencySharesAgreedByDefendant" />
    <link:label xlink:type="resource" xlink:label="pasg_LossContingencySharesAgreedByDefendant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LossContingencySharesAgreedByDefendant_lbl" xml:lang="en-US" id="pasg_LossContingencySharesAgreedByDefendant_lbl">Number of shares agreed to be issued by defendant and subject to reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencySharesAgreedByDefendant" xlink:to="pasg_LossContingencySharesAgreedByDefendant_lbl" xlink:title="label: LossContingencySharesAgreedByDefendant to pasg_LossContingencySharesAgreedByDefendant_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LossContingencySharesAgreedByDefendant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LossContingencySharesAgreedByDefendant_lbl1" xml:lang="en-US" id="pasg_LossContingencySharesAgreedByDefendant_lbl1">Loss Contingency, Shares Agreed by Defendant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencySharesAgreedByDefendant" xlink:to="pasg_LossContingencySharesAgreedByDefendant_lbl1" xlink:title="label: LossContingencySharesAgreedByDefendant to pasg_LossContingencySharesAgreedByDefendant_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LossContingencySharesAgreedByDefendant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LossContingencySharesAgreedByDefendant" xml:lang="en-US" id="pasg_LossContingencySharesAgreedByDefendant">Loss contingency, shares agreed by defendant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencySharesAgreedByDefendant" xlink:to="pasg_LossContingencySharesAgreedByDefendant" xlink:title="label: LossContingencySharesAgreedByDefendant to pasg_LossContingencySharesAgreedByDefendant" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <link:label xlink:type="resource" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xml:lang="en-US" id="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl">Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xlink:title="label: AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember to pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl1" xml:lang="en-US" id="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl1">Amended and restated agreement with Penn [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl1" xlink:title="label: AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember to pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xml:lang="en-US" id="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember">Amended and restated agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="label: AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember to pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfTargetAnnualBonusAmounts" xlink:label="PercentageOfTargetAnnualBonusAmounts" xlink:title="PercentageOfTargetAnnualBonusAmounts" />
    <link:label xlink:type="resource" xlink:label="pasg_PercentageOfTargetAnnualBonusAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_PercentageOfTargetAnnualBonusAmounts_lbl" xml:lang="en-US" id="pasg_PercentageOfTargetAnnualBonusAmounts_lbl">Represents the percentage of target annual bonus amounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfTargetAnnualBonusAmounts" xlink:to="pasg_PercentageOfTargetAnnualBonusAmounts_lbl" xlink:title="label: PercentageOfTargetAnnualBonusAmounts to pasg_PercentageOfTargetAnnualBonusAmounts_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_PercentageOfTargetAnnualBonusAmounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_PercentageOfTargetAnnualBonusAmounts_lbl1" xml:lang="en-US" id="pasg_PercentageOfTargetAnnualBonusAmounts_lbl1">Percentage of Target Annual Bonus Amounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfTargetAnnualBonusAmounts" xlink:to="pasg_PercentageOfTargetAnnualBonusAmounts_lbl1" xlink:title="label: PercentageOfTargetAnnualBonusAmounts to pasg_PercentageOfTargetAnnualBonusAmounts_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_PercentageOfTargetAnnualBonusAmounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_PercentageOfTargetAnnualBonusAmounts" xml:lang="en-US" id="pasg_PercentageOfTargetAnnualBonusAmounts">Target annual bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfTargetAnnualBonusAmounts" xlink:to="pasg_PercentageOfTargetAnnualBonusAmounts" xlink:title="label: PercentageOfTargetAnnualBonusAmounts to pasg_PercentageOfTargetAnnualBonusAmounts" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl">The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" xlink:title="label: CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone to pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl1" xml:lang="en-US" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl1">Collaboration Agreement Amount Payable Per Product Candidate Upon Achievement Of Specific Development Milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl1" xlink:title="label: CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone to pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xml:lang="en-US" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone">Amount payable per product candidate upon achievement of specific development milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="label: CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone to pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableAggregateFeesPayablePerProductIndication" xlink:label="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="NonRefundableAggregateFeesPayablePerProductIndication" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl" xml:lang="en-US" id="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl">Amount of aggregate non-refundable fees payable per product indication.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableAggregateFeesPayablePerProductIndication" xlink:to="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl" xlink:title="label: NonRefundableAggregateFeesPayablePerProductIndication to pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl1" xml:lang="en-US" id="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl1">Non - Refundable Aggregate Fees Payable Per Product Indication</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableAggregateFeesPayablePerProductIndication" xlink:to="pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl1" xlink:title="label: NonRefundableAggregateFeesPayablePerProductIndication to pasg_NonRefundableAggregateFeesPayablePerProductIndication_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableAggregateFeesPayablePerProductIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_NonRefundableAggregateFeesPayablePerProductIndication" xml:lang="en-US" id="pasg_NonRefundableAggregateFeesPayablePerProductIndication">Non - Refundable aggregate fees payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableAggregateFeesPayablePerProductIndication" xlink:to="pasg_NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="label: NonRefundableAggregateFeesPayablePerProductIndication to pasg_NonRefundableAggregateFeesPayablePerProductIndication" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="CollaborationAgreementSalesMilestonePaymentsPayable" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xml:lang="en-US" id="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl">The amount of payable on sales milestone payment on collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xlink:title="label: CollaborationAgreementSalesMilestonePaymentsPayable to pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl1" xml:lang="en-US" id="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl1">Collaboration Agreement Sales Milestone Payments Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl1" xlink:title="label: CollaborationAgreementSalesMilestonePaymentsPayable to pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xml:lang="en-US" id="pasg_CollaborationAgreementSalesMilestonePaymentsPayable">Sales milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="label: CollaborationAgreementSalesMilestonePaymentsPayable to pasg_CollaborationAgreementSalesMilestonePaymentsPayable" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockIssuedDuringPeriodSettlementOfLitigation" xlink:label="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="StockIssuedDuringPeriodSettlementOfLitigation" />
    <link:label xlink:type="resource" xlink:label="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl" xml:lang="en-US" id="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl">The number of stock issued during period for settlement of litigation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSettlementOfLitigation" xlink:to="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl" xlink:title="label: StockIssuedDuringPeriodSettlementOfLitigation to pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl1" xml:lang="en-US" id="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl1">Stock Issued During Period, Settlement of Litigation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSettlementOfLitigation" xlink:to="pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl1" xlink:title="label: StockIssuedDuringPeriodSettlementOfLitigation to pasg_StockIssuedDuringPeriodSettlementOfLitigation_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_StockIssuedDuringPeriodSettlementOfLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_StockIssuedDuringPeriodSettlementOfLitigation" xml:lang="en-US" id="pasg_StockIssuedDuringPeriodSettlementOfLitigation">Common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSettlementOfLitigation" xlink:to="pasg_StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="label: StockIssuedDuringPeriodSettlementOfLitigation to pasg_StockIssuedDuringPeriodSettlementOfLitigation" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl">The amount of payable per product candidate for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xlink:title="label: CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone to pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl1" xml:lang="en-US" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl1">Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl1" xlink:title="label: CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone to pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xml:lang="en-US" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone">Amount payable per product candidate for rare, monogenic disorders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="label: CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone to pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xlink:label="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="NonRefundableUpfrontFeesPayablePerProductIndication" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl" xml:lang="en-US" id="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl">Amount of upfront fees payable per product indication.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:to="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl" xlink:title="label: NonRefundableUpfrontFeesPayablePerProductIndication to pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl1" xml:lang="en-US" id="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl1">Non - Refundable Upfront Fees Payable Per Product Indication</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:to="pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl1" xlink:title="label: NonRefundableUpfrontFeesPayablePerProductIndication to pasg_NonRefundableUpfrontFeesPayablePerProductIndication_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xml:lang="en-US" id="pasg_NonRefundableUpfrontFeesPayablePerProductIndication">Non - Refundable upfront fees payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:to="pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="label: NonRefundableUpfrontFeesPayablePerProductIndication to pasg_NonRefundableUpfrontFeesPayablePerProductIndication" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityIncentivePlan2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" id="pasg_EquityIncentivePlan2020Member_lbl">Represents information pertaining to 2020 Equity Incentive Plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="pasg_EquityIncentivePlan2020Member_lbl" xlink:title="label: EquityIncentivePlan2020Member to pasg_EquityIncentivePlan2020Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityIncentivePlan2020Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EquityIncentivePlan2020Member_lbl1" xml:lang="en-US" id="pasg_EquityIncentivePlan2020Member_lbl1">Equity Incentive Plan 2020 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="pasg_EquityIncentivePlan2020Member_lbl1" xlink:title="label: EquityIncentivePlan2020Member to pasg_EquityIncentivePlan2020Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EquityIncentivePlan2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EquityIncentivePlan2020Member" xml:lang="en-US" id="pasg_EquityIncentivePlan2020Member">Equity Incentive Plan 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2020Member" xlink:to="pasg_EquityIncentivePlan2020Member" xlink:title="label: EquityIncentivePlan2020Member to pasg_EquityIncentivePlan2020Member" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:label="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:title="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl" xml:lang="en-US" id="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl">The amount of deferred proceeds from sale of equipment in other current assets in non-cash investing or financing transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:to="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl" xlink:title="label: DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets to pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl1" xml:lang="en-US" id="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl1">Deferred Proceeds Receivable From Sale Of Equipment In Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:to="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl1" xlink:title="label: DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets to pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xml:lang="en-US" id="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets">Deferred proceeds from equipment sale in other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:to="pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:title="label: DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets to pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksLiquidityAndGoingConcernAbstract" xlink:label="RisksLiquidityAndGoingConcernAbstract" xlink:title="RisksLiquidityAndGoingConcernAbstract" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksLiquidityAndGoingConcernAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RisksLiquidityAndGoingConcernAbstract_lbl" xml:lang="en-US" id="pasg_RisksLiquidityAndGoingConcernAbstract_lbl">No definition available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksLiquidityAndGoingConcernAbstract" xlink:to="pasg_RisksLiquidityAndGoingConcernAbstract_lbl" xlink:title="label: RisksLiquidityAndGoingConcernAbstract to pasg_RisksLiquidityAndGoingConcernAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RisksLiquidityAndGoingConcernAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RisksLiquidityAndGoingConcernAbstract_lbl1" xml:lang="en-US" id="pasg_RisksLiquidityAndGoingConcernAbstract_lbl1">Risks, Liquidity, and Going Concern [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksLiquidityAndGoingConcernAbstract" xlink:to="pasg_RisksLiquidityAndGoingConcernAbstract_lbl1" xlink:title="label: RisksLiquidityAndGoingConcernAbstract to pasg_RisksLiquidityAndGoingConcernAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_InterimFinancialStatementsPolicyTextBlock" xlink:label="InterimFinancialStatementsPolicyTextBlock" xlink:title="InterimFinancialStatementsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="pasg_InterimFinancialStatementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_InterimFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US" id="pasg_InterimFinancialStatementsPolicyTextBlock_lbl">Disclosure of accounting policy for interim financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterimFinancialStatementsPolicyTextBlock" xlink:to="pasg_InterimFinancialStatementsPolicyTextBlock_lbl" xlink:title="label: InterimFinancialStatementsPolicyTextBlock to pasg_InterimFinancialStatementsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_InterimFinancialStatementsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_InterimFinancialStatementsPolicyTextBlock_lbl1" xml:lang="en-US" id="pasg_InterimFinancialStatementsPolicyTextBlock_lbl1">Interim Financial Statements [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterimFinancialStatementsPolicyTextBlock" xlink:to="pasg_InterimFinancialStatementsPolicyTextBlock_lbl1" xlink:title="label: InterimFinancialStatementsPolicyTextBlock to pasg_InterimFinancialStatementsPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_InterimFinancialStatementsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_InterimFinancialStatementsPolicyTextBlock" xml:lang="en-US" id="pasg_InterimFinancialStatementsPolicyTextBlock">Interim Financial Statements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterimFinancialStatementsPolicyTextBlock" xlink:to="pasg_InterimFinancialStatementsPolicyTextBlock" xlink:title="label: InterimFinancialStatementsPolicyTextBlock to pasg_InterimFinancialStatementsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:label="OperatingLossCarryforwardSubjectToExpiration" xlink:title="OperatingLossCarryforwardSubjectToExpiration" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" xml:lang="en-US" id="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl">Amount of operating loss carryforward subject to expiry, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardSubjectToExpiration" xlink:to="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" xlink:title="label: OperatingLossCarryforwardSubjectToExpiration to pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl1" xml:lang="en-US" id="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl1">Operating Loss Carryforward Subject to Expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardSubjectToExpiration" xlink:to="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl1" xlink:title="label: OperatingLossCarryforwardSubjectToExpiration to pasg_OperatingLossCarryforwardSubjectToExpiration_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="pasg_OperatingLossCarryforwardSubjectToExpiration" xml:lang="en-US" id="pasg_OperatingLossCarryforwardSubjectToExpiration">Net operating loss carryforwards subject to expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardSubjectToExpiration" xlink:to="pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:title="label: OperatingLossCarryforwardSubjectToExpiration to pasg_OperatingLossCarryforwardSubjectToExpiration" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="LocalTaxAuthoritiesMember" xlink:title="LocalTaxAuthoritiesMember" />
    <link:label xlink:type="resource" xlink:label="pasg_LocalTaxAuthoritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LocalTaxAuthoritiesMember_lbl" xml:lang="en-US" id="pasg_LocalTaxAuthoritiesMember_lbl">Represents the information pertaining to local tax authorities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalTaxAuthoritiesMember" xlink:to="pasg_LocalTaxAuthoritiesMember_lbl" xlink:title="label: LocalTaxAuthoritiesMember to pasg_LocalTaxAuthoritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LocalTaxAuthoritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LocalTaxAuthoritiesMember_lbl1" xml:lang="en-US" id="pasg_LocalTaxAuthoritiesMember_lbl1">Local [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalTaxAuthoritiesMember" xlink:to="pasg_LocalTaxAuthoritiesMember_lbl1" xlink:title="label: LocalTaxAuthoritiesMember to pasg_LocalTaxAuthoritiesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LocalTaxAuthoritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LocalTaxAuthoritiesMember" xml:lang="en-US" id="pasg_LocalTaxAuthoritiesMember">Local</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalTaxAuthoritiesMember" xlink:to="pasg_LocalTaxAuthoritiesMember" xlink:title="label: LocalTaxAuthoritiesMember to pasg_LocalTaxAuthoritiesMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StateTaxAuthorityMember" xlink:label="StateTaxAuthorityMember" xlink:title="StateTaxAuthorityMember" />
    <link:label xlink:type="resource" xlink:label="pasg_StateTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_StateTaxAuthorityMember_lbl" xml:lang="en-US" id="pasg_StateTaxAuthorityMember_lbl">Represents the information pertaining to state tax authorities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateTaxAuthorityMember" xlink:to="pasg_StateTaxAuthorityMember_lbl" xlink:title="label: StateTaxAuthorityMember to pasg_StateTaxAuthorityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_StateTaxAuthorityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_StateTaxAuthorityMember_lbl1" xml:lang="en-US" id="pasg_StateTaxAuthorityMember_lbl1">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateTaxAuthorityMember" xlink:to="pasg_StateTaxAuthorityMember_lbl1" xlink:title="label: StateTaxAuthorityMember to pasg_StateTaxAuthorityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_StateTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_StateTaxAuthorityMember" xml:lang="en-US" id="pasg_StateTaxAuthorityMember">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateTaxAuthorityMember" xlink:to="pasg_StateTaxAuthorityMember" xlink:title="label: StateTaxAuthorityMember to pasg_StateTaxAuthorityMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OrphanDrugMember" xlink:label="OrphanDrugMember" xlink:title="OrphanDrugMember" />
    <link:label xlink:type="resource" xlink:label="pasg_OrphanDrugMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_OrphanDrugMember_lbl" xml:lang="en-US" id="pasg_OrphanDrugMember_lbl">Represents the information pertaining to Orphan Drug.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrphanDrugMember" xlink:to="pasg_OrphanDrugMember_lbl" xlink:title="label: OrphanDrugMember to pasg_OrphanDrugMember_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_OrphanDrugMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_OrphanDrugMember_lbl1" xml:lang="en-US" id="pasg_OrphanDrugMember_lbl1">Orphan Drug [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrphanDrugMember" xlink:to="pasg_OrphanDrugMember_lbl1" xlink:title="label: OrphanDrugMember to pasg_OrphanDrugMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_OrphanDrugMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_OrphanDrugMember" xml:lang="en-US" id="pasg_OrphanDrugMember">Orphan drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrphanDrugMember" xlink:to="pasg_OrphanDrugMember" xlink:title="label: OrphanDrugMember to pasg_OrphanDrugMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:label="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:title="RemainingCapacityOfValueOfSharesAvailableToBeSold" />
    <link:label xlink:type="resource" xlink:label="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl" xml:lang="en-US" id="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl">The remaining capacity of value of shares available to be sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:to="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl" xlink:title="label: RemainingCapacityOfValueOfSharesAvailableToBeSold to pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl1" xml:lang="en-US" id="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl1">Remaining Capacity of Value of Shares Available to Be Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:to="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl1" xlink:title="label: RemainingCapacityOfValueOfSharesAvailableToBeSold to pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" xml:lang="en-US" id="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold">Remaining capacity available to be sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:to="pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:title="label: RemainingCapacityOfValueOfSharesAvailableToBeSold to pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EarlyLeaseTerminationFee" xlink:label="EarlyLeaseTerminationFee" xlink:title="EarlyLeaseTerminationFee" />
    <link:label xlink:type="resource" xlink:label="pasg_EarlyLeaseTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EarlyLeaseTerminationFee_lbl" xml:lang="en-US" id="pasg_EarlyLeaseTerminationFee_lbl">Amount of expense incurred during the period for early lease termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarlyLeaseTerminationFee" xlink:to="pasg_EarlyLeaseTerminationFee_lbl" xlink:title="label: EarlyLeaseTerminationFee to pasg_EarlyLeaseTerminationFee_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EarlyLeaseTerminationFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EarlyLeaseTerminationFee_lbl1" xml:lang="en-US" id="pasg_EarlyLeaseTerminationFee_lbl1">Early Lease Termination Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarlyLeaseTerminationFee" xlink:to="pasg_EarlyLeaseTerminationFee_lbl1" xlink:title="label: EarlyLeaseTerminationFee to pasg_EarlyLeaseTerminationFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EarlyLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EarlyLeaseTerminationFee" xml:lang="en-US" id="pasg_EarlyLeaseTerminationFee">Payment for early lease termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarlyLeaseTerminationFee" xlink:to="pasg_EarlyLeaseTerminationFee" xlink:title="label: EarlyLeaseTerminationFee to pasg_EarlyLeaseTerminationFee" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:label xlink:type="resource" xlink:label="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xml:lang="en-US" id="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl">Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour to pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" xml:lang="en-US" id="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour to pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xml:lang="en-US" id="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour to pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:label="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:title="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" />
    <link:label xlink:type="resource" xlink:label="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl" xml:lang="en-US" id="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl">Lease Liability for Operating Lease, Period Decrease due to Lease Termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:to="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl" xlink:title="label: LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination to pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl1" xml:lang="en-US" id="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl1">Lease Liability For Operating Lease, Period Decrease due to Lease Termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:to="pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl1" xlink:title="label: LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination to pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:label="RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:title="RightOfUsePeriodDecreaseDueToLeaseTermination" />
    <link:label xlink:type="resource" xlink:label="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl" xml:lang="en-US" id="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl">Right of Use period decrease due to lease termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:to="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl" xlink:title="label: RightOfUsePeriodDecreaseDueToLeaseTermination to pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl1" xml:lang="en-US" id="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl1">Right of Use Period Decrease due to Lease Termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:to="pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl1" xlink:title="label: RightOfUsePeriodDecreaseDueToLeaseTermination to pasg_RightOfUsePeriodDecreaseDueToLeaseTermination_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GainLossOnWriteOffOfOperatingLeases" xlink:label="GainLossOnWriteOffOfOperatingLeases" xlink:title="GainLossOnWriteOffOfOperatingLeases" />
    <link:label xlink:type="resource" xlink:label="pasg_GainLossOnWriteOffOfOperatingLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_GainLossOnWriteOffOfOperatingLeases_lbl" xml:lang="en-US" id="pasg_GainLossOnWriteOffOfOperatingLeases_lbl">Amount of gain (loss) on write-off of assets and liabilities for operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnWriteOffOfOperatingLeases" xlink:to="pasg_GainLossOnWriteOffOfOperatingLeases_lbl" xlink:title="label: GainLossOnWriteOffOfOperatingLeases to pasg_GainLossOnWriteOffOfOperatingLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_GainLossOnWriteOffOfOperatingLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_GainLossOnWriteOffOfOperatingLeases_lbl1" xml:lang="en-US" id="pasg_GainLossOnWriteOffOfOperatingLeases_lbl1">Gain (Loss) On Write Off Of Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnWriteOffOfOperatingLeases" xlink:to="pasg_GainLossOnWriteOffOfOperatingLeases_lbl1" xlink:title="label: GainLossOnWriteOffOfOperatingLeases to pasg_GainLossOnWriteOffOfOperatingLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_GainLossOnWriteOffOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_GainLossOnWriteOffOfOperatingLeases" xml:lang="en-US" id="pasg_GainLossOnWriteOffOfOperatingLeases">Gain (loss) on write-off of operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnWriteOffOfOperatingLeases" xlink:to="pasg_GainLossOnWriteOffOfOperatingLeases" xlink:title="label: GainLossOnWriteOffOfOperatingLeases to pasg_GainLossOnWriteOffOfOperatingLeases" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LicenseFeeDueAndReceivable" xlink:label="LicenseFeeDueAndReceivable" xlink:title="LicenseFeeDueAndReceivable" />
    <link:label xlink:type="resource" xlink:label="pasg_LicenseFeeDueAndReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_LicenseFeeDueAndReceivable_lbl" xml:lang="en-US" id="pasg_LicenseFeeDueAndReceivable_lbl">Amount of license fee due and receivable as of the balance sheet date under the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseFeeDueAndReceivable" xlink:to="pasg_LicenseFeeDueAndReceivable_lbl" xlink:title="label: LicenseFeeDueAndReceivable to pasg_LicenseFeeDueAndReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_LicenseFeeDueAndReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_LicenseFeeDueAndReceivable_lbl1" xml:lang="en-US" id="pasg_LicenseFeeDueAndReceivable_lbl1">License Fee Due And Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseFeeDueAndReceivable" xlink:to="pasg_LicenseFeeDueAndReceivable_lbl1" xlink:title="label: LicenseFeeDueAndReceivable to pasg_LicenseFeeDueAndReceivable_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_LicenseFeeDueAndReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_LicenseFeeDueAndReceivable" xml:lang="en-US" id="pasg_LicenseFeeDueAndReceivable">Amount of license fee due and receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseFeeDueAndReceivable" xlink:to="pasg_LicenseFeeDueAndReceivable" xlink:title="label: LicenseFeeDueAndReceivable to pasg_LicenseFeeDueAndReceivable" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromShortTermLicenseFee" xlink:label="ProceedsFromShortTermLicenseFee" xlink:title="ProceedsFromShortTermLicenseFee" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromShortTermLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_ProceedsFromShortTermLicenseFee_lbl" xml:lang="en-US" id="pasg_ProceedsFromShortTermLicenseFee_lbl">Amount of cash inflow from short term license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermLicenseFee" xlink:to="pasg_ProceedsFromShortTermLicenseFee_lbl" xlink:title="label: ProceedsFromShortTermLicenseFee to pasg_ProceedsFromShortTermLicenseFee_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromShortTermLicenseFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_ProceedsFromShortTermLicenseFee_lbl1" xml:lang="en-US" id="pasg_ProceedsFromShortTermLicenseFee_lbl1">Proceeds From Short Term License Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermLicenseFee" xlink:to="pasg_ProceedsFromShortTermLicenseFee_lbl1" xlink:title="label: ProceedsFromShortTermLicenseFee to pasg_ProceedsFromShortTermLicenseFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_ProceedsFromShortTermLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_ProceedsFromShortTermLicenseFee" xml:lang="en-US" id="pasg_ProceedsFromShortTermLicenseFee">Proceeds from short term license fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromShortTermLicenseFee" xlink:to="pasg_ProceedsFromShortTermLicenseFee" xlink:title="label: ProceedsFromShortTermLicenseFee to pasg_ProceedsFromShortTermLicenseFee" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EstimatedSeveranceAndRelatedCosts" xlink:label="EstimatedSeveranceAndRelatedCosts" xlink:title="EstimatedSeveranceAndRelatedCosts" />
    <link:label xlink:type="resource" xlink:label="pasg_EstimatedSeveranceAndRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EstimatedSeveranceAndRelatedCosts_lbl" xml:lang="en-US" id="pasg_EstimatedSeveranceAndRelatedCosts_lbl">Amount of aggregate estimated and severance costs to be incurred as a part of restructuring plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedSeveranceAndRelatedCosts" xlink:to="pasg_EstimatedSeveranceAndRelatedCosts_lbl" xlink:title="label: EstimatedSeveranceAndRelatedCosts to pasg_EstimatedSeveranceAndRelatedCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EstimatedSeveranceAndRelatedCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EstimatedSeveranceAndRelatedCosts_lbl1" xml:lang="en-US" id="pasg_EstimatedSeveranceAndRelatedCosts_lbl1">Estimated Severance And Related Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedSeveranceAndRelatedCosts" xlink:to="pasg_EstimatedSeveranceAndRelatedCosts_lbl1" xlink:title="label: EstimatedSeveranceAndRelatedCosts to pasg_EstimatedSeveranceAndRelatedCosts_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EstimatedSeveranceAndRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_EstimatedSeveranceAndRelatedCosts" xml:lang="en-US" id="pasg_EstimatedSeveranceAndRelatedCosts">Estimated severance and related costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EstimatedSeveranceAndRelatedCosts" xlink:to="pasg_EstimatedSeveranceAndRelatedCosts" xlink:title="label: EstimatedSeveranceAndRelatedCosts to pasg_EstimatedSeveranceAndRelatedCosts" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RestructuringPlanReductionInWorkforcePercentage" xlink:label="RestructuringPlanReductionInWorkforcePercentage" xlink:title="RestructuringPlanReductionInWorkforcePercentage" />
    <link:label xlink:type="resource" xlink:label="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl" xml:lang="en-US" id="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl">Percentage of reduction in workforce as a part of restructuring plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringPlanReductionInWorkforcePercentage" xlink:to="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl" xlink:title="label: RestructuringPlanReductionInWorkforcePercentage to pasg_RestructuringPlanReductionInWorkforcePercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl1" xml:lang="en-US" id="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl1">Restructuring Plan, Reduction In Workforce, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringPlanReductionInWorkforcePercentage" xlink:to="pasg_RestructuringPlanReductionInWorkforcePercentage_lbl1" xlink:title="label: RestructuringPlanReductionInWorkforcePercentage to pasg_RestructuringPlanReductionInWorkforcePercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_RestructuringPlanReductionInWorkforcePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_RestructuringPlanReductionInWorkforcePercentage" xml:lang="en-US" id="pasg_RestructuringPlanReductionInWorkforcePercentage">Reduction in workforce</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestructuringPlanReductionInWorkforcePercentage" xlink:to="pasg_RestructuringPlanReductionInWorkforcePercentage" xlink:title="label: RestructuringPlanReductionInWorkforcePercentage to pasg_RestructuringPlanReductionInWorkforcePercentage" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PaymentOfLeaseTerminationFee" xlink:label="PaymentOfLeaseTerminationFee" xlink:title="PaymentOfLeaseTerminationFee" />
    <link:label xlink:type="resource" xlink:label="pasg_PaymentOfLeaseTerminationFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_PaymentOfLeaseTerminationFee_lbl" xml:lang="en-US" id="pasg_PaymentOfLeaseTerminationFee_lbl">The cash outflow related to the payment of lease termination fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfLeaseTerminationFee" xlink:to="pasg_PaymentOfLeaseTerminationFee_lbl" xlink:title="label: PaymentOfLeaseTerminationFee to pasg_PaymentOfLeaseTerminationFee_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_PaymentOfLeaseTerminationFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_PaymentOfLeaseTerminationFee_lbl1" xml:lang="en-US" id="pasg_PaymentOfLeaseTerminationFee_lbl1">Payment of Lease Termination Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfLeaseTerminationFee" xlink:to="pasg_PaymentOfLeaseTerminationFee_lbl1" xlink:title="label: PaymentOfLeaseTerminationFee to pasg_PaymentOfLeaseTerminationFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_PaymentOfLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_PaymentOfLeaseTerminationFee" xml:lang="en-US" id="pasg_PaymentOfLeaseTerminationFee">Payment of lease termination fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfLeaseTerminationFee" xlink:to="pasg_PaymentOfLeaseTerminationFee" xlink:title="label: PaymentOfLeaseTerminationFee to pasg_PaymentOfLeaseTerminationFee" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MergerAgreementTerminationPaymentAmount" xlink:label="MergerAgreementTerminationPaymentAmount" xlink:title="MergerAgreementTerminationPaymentAmount" />
    <link:label xlink:type="resource" xlink:label="pasg_MergerAgreementTerminationPaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_MergerAgreementTerminationPaymentAmount_lbl" xml:lang="en-US" id="pasg_MergerAgreementTerminationPaymentAmount_lbl">Amount of cash payment required to be made by the registrant upon termination of a merger agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementTerminationPaymentAmount" xlink:to="pasg_MergerAgreementTerminationPaymentAmount_lbl" xlink:title="label: MergerAgreementTerminationPaymentAmount to pasg_MergerAgreementTerminationPaymentAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_MergerAgreementTerminationPaymentAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_MergerAgreementTerminationPaymentAmount_lbl1" xml:lang="en-US" id="pasg_MergerAgreementTerminationPaymentAmount_lbl1">Merger Agreement Termination Payment Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementTerminationPaymentAmount" xlink:to="pasg_MergerAgreementTerminationPaymentAmount_lbl1" xlink:title="label: MergerAgreementTerminationPaymentAmount to pasg_MergerAgreementTerminationPaymentAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_MergerAgreementTerminationPaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_MergerAgreementTerminationPaymentAmount" xml:lang="en-US" id="pasg_MergerAgreementTerminationPaymentAmount">Termination payment amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MergerAgreementTerminationPaymentAmount" xlink:to="pasg_MergerAgreementTerminationPaymentAmount" xlink:title="label: MergerAgreementTerminationPaymentAmount to pasg_MergerAgreementTerminationPaymentAmount" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MarketStreetLeaseAgreement2005Member" xlink:label="MarketStreetLeaseAgreement2005Member" xlink:title="MarketStreetLeaseAgreement2005Member" />
    <link:label xlink:type="resource" xlink:label="pasg_MarketStreetLeaseAgreement2005Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_MarketStreetLeaseAgreement2005Member_lbl" xml:lang="en-US" id="pasg_MarketStreetLeaseAgreement2005Member_lbl">Represents the member information pertaining to 2005 Market Street Lease Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketStreetLeaseAgreement2005Member" xlink:to="pasg_MarketStreetLeaseAgreement2005Member_lbl" xlink:title="label: MarketStreetLeaseAgreement2005Member to pasg_MarketStreetLeaseAgreement2005Member_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_MarketStreetLeaseAgreement2005Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_MarketStreetLeaseAgreement2005Member_lbl1" xml:lang="en-US" id="pasg_MarketStreetLeaseAgreement2005Member_lbl1">Market Street Lease Agreement 2005 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketStreetLeaseAgreement2005Member" xlink:to="pasg_MarketStreetLeaseAgreement2005Member_lbl1" xlink:title="label: MarketStreetLeaseAgreement2005Member to pasg_MarketStreetLeaseAgreement2005Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" />
    <link:label xlink:type="resource" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xml:lang="en-US" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent to pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl1" xml:lang="en-US" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent to pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xml:lang="en-US" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent">Orphan drug tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent to pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" />
    <link:label xlink:type="resource" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl" xml:lang="en-US" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount to pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl1" xml:lang="en-US" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount to pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xml:lang="en-US" id="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount">Orphan drug tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount to pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:title="DeferredTaxAssetsCollaborationAndLicenseAgreement" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xml:lang="en-US" id="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xlink:title="label: DeferredTaxAssetsCollaborationAndLicenseAgreement to pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl1" xml:lang="en-US" id="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl1">Deferred Tax Assets, Collaboration and License Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl1" xlink:title="label: DeferredTaxAssetsCollaborationAndLicenseAgreement to pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xml:lang="en-US" id="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement">Collaboration and license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:title="label: DeferredTaxAssetsCollaborationAndLicenseAgreement to pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="DeferredTaxAssetsDepreciationAndAmortization" xlink:title="DeferredTaxAssetsDepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" id="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from depreciation and amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsDepreciationAndAmortization" xlink:to="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl" xlink:title="label: DeferredTaxAssetsDepreciationAndAmortization to pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl1" xml:lang="en-US" id="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl1">Deferred Tax Assets, Depreciation and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsDepreciationAndAmortization" xlink:to="pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl1" xlink:title="label: DeferredTaxAssetsDepreciationAndAmortization to pasg_DeferredTaxAssetsDepreciationAndAmortization_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_DeferredTaxAssetsDepreciationAndAmortization" xml:lang="en-US" id="pasg_DeferredTaxAssetsDepreciationAndAmortization">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsDepreciationAndAmortization" xlink:to="pasg_DeferredTaxAssetsDepreciationAndAmortization" xlink:title="label: DeferredTaxAssetsDepreciationAndAmortization to pasg_DeferredTaxAssetsDepreciationAndAmortization" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:title="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US" id="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl">Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xlink:title="label: DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets to pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl1" xml:lang="en-US" id="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl1">Deferred Tax Liabilities, Operating Lease Right of Use Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl1" xlink:title="label: DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets to pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xml:lang="en-US" id="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">Right of use assets - operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:title="label: DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets to pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:title="DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" id="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:title="label: DeferredTaxAssetsOperatingLeaseLiabilities to pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl1" xml:lang="en-US" id="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl1">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLeaseLiabilities to pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US" id="pasg_DeferredTaxAssetsOperatingLeaseLiabilities">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:title="label: DeferredTaxAssetsOperatingLeaseLiabilities to pasg_DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:title="DeferredTaxAssetsCapitalizedResearchAndDevelopment" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" id="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:title="label: DeferredTaxAssetsCapitalizedResearchAndDevelopment to pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl1" xml:lang="en-US" id="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl1">Deferred Tax Assets, Capitalized Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl1" xlink:title="label: DeferredTaxAssetsCapitalizedResearchAndDevelopment to pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xml:lang="en-US" id="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment">Capitalized research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:title="label: DeferredTaxAssetsCapitalizedResearchAndDevelopment to pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" id="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther to pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl1" xml:lang="en-US" id="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl1">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities and Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther to pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl1" />
    <link:label xlink:type="resource" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xml:lang="en-US" id="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther">Accrued expenses and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther to pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>pasg-20260721_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 26.3.2.5342 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesCollaborationAgreementsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesSubleaseIncomeQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesSubleaseIncomeQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1DetailsCalc01" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1DetailsCalc01" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesOperatingLeaseCostQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetNarrativeQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksLiquidityAndGoingConcernQ1Details" />
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesNetOperatingLossesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationRestrictedStockUnitsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationStockOptionActivityFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationSharebasedCompensationExpenseFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationEquityIncentivePlanEsppFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CommonStockFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommonStockFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesCollaborationAgreementsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesSubleaseIncomeFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesSubleaseIncomeFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesOperatingLeaseCostFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyDetailsCalc01" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyDetailsCalc01" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetNarrativeFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksAndLiquidityFyDetails" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksAndLiquidityFyDetails" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1Tables" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFyTables" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1Policies" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFyPolicies" />
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StockholderSEquityAndSharebasedCompensationQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksLiquidityAndGoingConcernQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/NatureOfOperationsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#NatureOfOperationsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/SubsequentEventsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SubsequentEventsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SegmentReportingFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SegmentReportingFy" />
  <link:roleRef roleURI="http://passagebio.com/role/IncomeTaxesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#IncomeTaxesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SharebasedCompensationFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SharebasedCompensationFy" />
  <link:roleRef roleURI="http://passagebio.com/role/CommonStockFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommonStockFy" />
  <link:roleRef roleURI="http://passagebio.com/role/CommitmentsAndContingenciesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#CommitmentsAndContingenciesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/LeasesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#LeasesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SeveranceFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SeveranceFy" />
  <link:roleRef roleURI="http://passagebio.com/role/GemmaLicenseAgreementFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#GemmaLicenseAgreementFy" />
  <link:roleRef roleURI="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#AccruedExpensesAndOtherCurrentLiabilitiesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/PropertyAndEquipmentNetFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#PropertyAndEquipmentNetFy" />
  <link:roleRef roleURI="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#CashCashEquivalentsAndMarketableSecuritiesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#SummaryOfSignificantAccountingPoliciesFy" />
  <link:roleRef roleURI="http://passagebio.com/role/RisksAndLiquidityFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#RisksAndLiquidityFy" />
  <link:roleRef roleURI="http://passagebio.com/role/NatureOfOperationsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#NatureOfOperationsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfCashFlowsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfCashFlowsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfStockholdersEquityQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfStockholdersEquityQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfOperationsAndComprehensiveLossQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsQ1Parenthetical" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsQ1Parenthetical" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsQ1" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsQ1" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfCashFlowsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfCashFlowsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfStockholdersEquityFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfStockholdersEquityFy" />
  <link:roleRef roleURI="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#StatementsOfOperationsAndComprehensiveLossFy" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsFyParenthetical" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsFyParenthetical" />
  <link:roleRef roleURI="http://passagebio.com/role/BalanceSheetsFy" xlink:type="simple" xlink:href="pasg-20260721.xsd#BalanceSheetsFy" />
  <link:roleRef roleURI="http://passagebio.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="pasg-20260721.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="presentation: AssetsCurrentAbstract to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="PrepaidResearchAndDevelopmentAssetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidResearchAndDevelopmentAssetCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="AccruedExpensesAndOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedExpensesAndOtherCurrentLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsFyParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: OperatingExpensesAbstract to AssetImpairmentCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GainLossOnTerminationOfLease" xlink:title="presentation: OperatingExpensesAbstract to GainLossOnTerminationOfLease" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: IncomeStatementAbstract to OtherNonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTaxAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfStockholdersEquityFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="presentation: StatementEquityComponentsAxis to AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesShareBasedCompensation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfCashFlowsFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AssetImpairmentCharges" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense" xlink:label="OtherNoncashExpense" xlink:title="OtherNoncashExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OtherNoncashExpense" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OtherNoncashExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="IncreaseDecreaseInPrepaidResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInContractWithCustomerLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableTrade" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableTrade" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="PaymentsToAcquireMarketableSecurities" xlink:title="PaymentsToAcquireMarketableSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireMarketableSecurities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireMarketableSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="PaymentsToAcquireProductiveAssets" xlink:title="PaymentsToAcquireProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireProductiveAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireProductiveAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfProductiveAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfPropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfConvertiblePreferredStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="ProceedsFromStockPlans" xlink:title="ProceedsFromStockPlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockPlans" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockPlans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="MarketableSecuritiesUnrealizedGainLoss" xlink:title="MarketableSecuritiesUnrealizedGainLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="MarketableSecuritiesUnrealizedGainLoss" xlink:title="presentation: SupplementalCashFlowInformationAbstract to MarketableSecuritiesUnrealizedGainLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="presentation: SupplementalCashFlowInformationAbstract to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:label="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:title="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:title="presentation: SupplementalCashFlowInformationAbstract to OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="PrepaidResearchAndDevelopmentAssetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidResearchAndDevelopmentAssetCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidResearchAndDevelopmentAssetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="AccruedExpensesAndOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedExpensesAndOtherCurrentLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/BalanceSheetsQ1Parenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StatementOfFinancialPositionAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: OperatingExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: OperatingExpensesAbstract to GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: OperatingExpensesAbstract to AssetImpairmentCharges" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="GainLossOnTerminationOfLease" xlink:title="presentation: OperatingExpensesAbstract to GainLossOnTerminationOfLease" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingExpensesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: OperatingExpensesAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: IncomeStatementAbstract to OtherNonoperatingIncomeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="ComprehensiveIncomeNetOfTaxAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComprehensiveIncomeNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="presentation: ComprehensiveIncomeNetOfTaxAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTaxAbstract" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTaxAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: IncomeStatementAbstract to ComprehensiveIncomeNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfStockholdersEquityQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="presentation: StatementEquityComponentsAxis to AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StatementsOfCashFlowsQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnTerminationOfLease" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnTerminationOfLease" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AssetImpairmentCharges" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="IncreaseDecreaseInPrepaidResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInContractWithCustomerLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="IncreaseDecreaseInAccountsPayableTrade" xlink:title="IncreaseDecreaseInAccountsPayableTrade" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayableTrade" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayableTrade" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleAndMaturityOfMarketableSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="ProceedsFromSaleOfProductiveAssets" xlink:title="ProceedsFromSaleOfProductiveAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfProductiveAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfProductiveAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="MarketableSecuritiesUnrealizedGainLoss" xlink:title="MarketableSecuritiesUnrealizedGainLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="MarketableSecuritiesUnrealizedGainLoss" xlink:title="presentation: SupplementalCashFlowInformationAbstract to MarketableSecuritiesUnrealizedGainLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:label="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:title="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" xlink:title="presentation: SupplementalCashFlowInformationAbstract to DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/NatureOfOperationsFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfOperations" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksAndLiquidityFy">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="RisksAndLiquidityAbstract" xlink:title="RisksAndLiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTextBlock" xlink:label="RisksAndLiquidityTextBlock" xlink:title="RisksAndLiquidityTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityAbstract" xlink:to="RisksAndLiquidityTextBlock" xlink:title="presentation: RisksAndLiquidityAbstract to RisksAndLiquidityTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:title="CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:title="CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:title="presentation: CashCashEquivalentsAndMarketableSecuritiesAbstract to CashCashEquivalentsAndMarketableSecuritiesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:title="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementFy">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" xlink:title="CollaborativeArrangementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="CollaborativeArrangementDisclosureTextBlock" xlink:title="presentation: CollaborativeArrangementDisclosureAbstract to CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="presentation: RestructuringAndRelatedActivitiesAbstract to RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommonStockFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsFy">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/NatureOfOperationsQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureOfOperations" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksLiquidityAndGoingConcernAbstract" xlink:label="RisksLiquidityAndGoingConcernAbstract" xlink:title="RisksLiquidityAndGoingConcernAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTextBlock" xlink:label="RisksAndLiquidityTextBlock" xlink:title="RisksAndLiquidityTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksLiquidityAndGoingConcernAbstract" xlink:to="RisksAndLiquidityTextBlock" xlink:title="presentation: RisksLiquidityAndGoingConcernAbstract to RisksAndLiquidityTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="FairValueDisclosuresTextBlock" xlink:title="FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:title="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementQ1">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" xlink:title="CollaborativeArrangementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="CollaborativeArrangementDisclosureTextBlock" xlink:title="presentation: CollaborativeArrangementDisclosureAbstract to CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:title="presentation: RestructuringAndRelatedActivitiesAbstract to RestructuringAndRelatedActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsQ1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_BasisOfPresentationPolicyTextBlock" xlink:label="BasisOfPresentationPolicyTextBlock" xlink:title="BasisOfPresentationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfPresentationPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfPresentationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="MarketableSecuritiesPolicy" xlink:title="MarketableSecuritiesPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="MarketableSecuritiesPolicy" xlink:title="presentation: AccountingPoliciesAbstract to MarketableSecuritiesPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="LesseeLeasesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to LesseeLeasesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:label="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:title="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to OtherIncomeAndOtherExpensePolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueFromContractWithCustomerPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_BasisOfPresentationPolicyTextBlock" xlink:label="BasisOfPresentationPolicyTextBlock" xlink:title="BasisOfPresentationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfPresentationPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfPresentationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_InterimFinancialStatementsPolicyTextBlock" xlink:label="InterimFinancialStatementsPolicyTextBlock" xlink:title="InterimFinancialStatementsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InterimFinancialStatementsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InterimFinancialStatementsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskCreditRisk" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="MarketableSecuritiesPolicy" xlink:title="MarketableSecuritiesPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="MarketableSecuritiesPolicy" xlink:title="presentation: AccountingPoliciesAbstract to MarketableSecuritiesPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="LesseeLeasesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to LesseeLeasesPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:label="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:title="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OtherIncomeAndOtherExpensePolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to OtherIncomeAndOtherExpensePolicyPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueFromContractWithCustomerPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:title="CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:title="ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:title="presentation: CashCashEquivalentsAndMarketableSecuritiesAbstract to ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:title="ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:title="presentation: CashCashEquivalentsAndMarketableSecuritiesAbstract to ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:label="FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:title="FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="LeaseCostTableTextBlock" xlink:title="LeaseCostTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCostTableTextBlock" xlink:title="presentation: LeasesAbstract to LeaseCostTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to NonvestedRestrictedStockSharesActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to SummaryOfOperatingLossCarryforwardsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingFyTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:title="presentation: SegmentReportingAbstract to ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1Tables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="LeaseCostTableTextBlock" xlink:title="LeaseCostTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCostTableTextBlock" xlink:title="presentation: LeasesAbstract to LeaseCostTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to NonvestedRestrictedStockSharesActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingQ1Tables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:title="presentation: SegmentReportingAbstract to ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksAndLiquidityFyDetails">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="RisksAndLiquidityAbstract" xlink:title="RisksAndLiquidityAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTable" xlink:label="RisksAndLiquidityTable" xlink:title="RisksAndLiquidityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AttheMarketFacilityAgreementMember" xlink:label="AttheMarketFacilityAgreementMember" xlink:title="AttheMarketFacilityAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AttheMarketFacilityAgreementMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to AttheMarketFacilityAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: RisksAndLiquidityTable to SubsidiarySaleOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityTable" xlink:to="RangeAxis" xlink:title="presentation: RisksAndLiquidityTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="RisksAndLiquidityLineItems" xlink:title="RisksAndLiquidityLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: RisksAndLiquidityLineItems to RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: RisksAndLiquidityLineItems to StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: RisksAndLiquidityLineItems to StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: RisksAndLiquidityLineItems to ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: RisksAndLiquidityLineItems to PaymentsOfStockIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityTable" xlink:to="RisksAndLiquidityLineItems" xlink:title="presentation: RisksAndLiquidityTable to RisksAndLiquidityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityAbstract" xlink:to="RisksAndLiquidityTable" xlink:title="presentation: RisksAndLiquidityAbstract to RisksAndLiquidityTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="LeaseholdsAndLeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdsAndLeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="PropertyPlantAndEquipmentOtherTypesMember" xlink:title="PropertyPlantAndEquipmentOtherTypesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PropertyPlantAndEquipmentOtherTypesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to PropertyPlantAndEquipmentOtherTypesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:label="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:label="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:title="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PropertyPlantAndEquipmentAndCertainOtherAssetsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to PropertyPlantAndEquipmentAndCertainOtherAssetsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to StockOptionsIncludingSharesSubjectToRepurchaseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="LongLivedAssetsHeldForSaleByAssetTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="LongLivedAssetsHeldForSaleNameDomain" xlink:title="LongLivedAssetsHeldForSaleNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsHeldForSaleNameDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="presentation: LongLivedAssetsHeldForSaleNameDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="LongLivedAssetsHeldForSaleNameDomain" xlink:title="presentation: LongLivedAssetsHeldForSaleByAssetTypeAxis to LongLivedAssetsHeldForSaleNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to LongLivedAssetsHeldForSaleByAssetTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to GainLossOnSaleOfPropertyPlantEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OperatingLeaseImpairmentLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ProceedsFromSaleOfPropertyPlantAndEquipment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OtherNonoperatingIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="SubleaseIncome" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to SubleaseIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GainLossOnSaleOfTaxCredits" xlink:label="GainLossOnSaleOfTaxCredits" xlink:title="GainLossOnSaleOfTaxCredits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="GainLossOnSaleOfTaxCredits" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to GainLossOnSaleOfTaxCredits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockIssuedDuringPeriodSharesReverseStockSplits" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:title="CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="ScheduleOfCashAndCashEquivalentsTable" xlink:title="ScheduleOfCashAndCashEquivalentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DemandDepositsMember" xlink:label="DemandDepositsMember" xlink:title="DemandDepositsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="DemandDepositsMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to DemandDepositsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="MoneyMarketFundsMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="CommercialPaperMember" xlink:title="CommercialPaperMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="CommercialPaperMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to CommercialPaperMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="presentation: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsTable" xlink:to="CashAndCashEquivalentsAxis" xlink:title="presentation: ScheduleOfCashAndCashEquivalentsTable to CashAndCashEquivalentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="CashAndCashEquivalentsLineItems" xlink:title="CashAndCashEquivalentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="CashAndCashEquivalentsAtCarryingValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="presentation: CashAndCashEquivalentsAtCarryingValueAbstract to CashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: CashAndCashEquivalentsAtCarryingValueAbstract to CashAndCashEquivalentsFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValueAbstract" xlink:title="presentation: CashAndCashEquivalentsLineItems to CashAndCashEquivalentsAtCarryingValueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsTable" xlink:to="CashAndCashEquivalentsLineItems" xlink:title="presentation: ScheduleOfCashAndCashEquivalentsTable to CashAndCashEquivalentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ScheduleOfCashAndCashEquivalentsTable" xlink:title="presentation: CashCashEquivalentsAndMarketableSecuritiesAbstract to ScheduleOfCashAndCashEquivalentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:title="CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="ScheduleOfCashAndCashEquivalentsTable" xlink:title="ScheduleOfCashAndCashEquivalentsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="CertificatesOfDepositMember" xlink:title="CertificatesOfDepositMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CertificatesOfDepositMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CertificatesOfDepositMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="CommercialPaperMember" xlink:title="CommercialPaperMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CommercialPaperMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CommercialPaperMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CorporateDebtSecuritiesMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CorporateDebtSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="USGovernmentDebtSecuritiesMember" xlink:title="USGovernmentDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USGovernmentDebtSecuritiesMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USGovernmentDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: ScheduleOfCashAndCashEquivalentsTable to FinancialInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="CashAndCashEquivalentsLineItems" xlink:title="CashAndCashEquivalentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsLineItems" xlink:to="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="presentation: CashAndCashEquivalentsLineItems to AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsTable" xlink:to="CashAndCashEquivalentsLineItems" xlink:title="presentation: ScheduleOfCashAndCashEquivalentsTable to CashAndCashEquivalentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ScheduleOfCashAndCashEquivalentsTable" xlink:title="presentation: CashCashEquivalentsAndMarketableSecuritiesAbstract to ScheduleOfCashAndCashEquivalentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="MoneyMarketFundsMember" xlink:title="MoneyMarketFundsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="MoneyMarketFundsMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to MoneyMarketFundsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember" xlink:label="CommercialPaperMember" xlink:title="CommercialPaperMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="CommercialPaperMember" xlink:title="presentation: RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to CommercialPaperMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="presentation: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="CashAndCashEquivalentsAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to CashAndCashEquivalentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="CertificatesOfDepositMember" xlink:title="CertificatesOfDepositMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CertificatesOfDepositMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CertificatesOfDepositMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CommercialPaperMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CommercialPaperMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CorporateDebtSecuritiesMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CorporateDebtSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="USGovernmentDebtSecuritiesMember" xlink:title="USGovernmentDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USGovernmentDebtSecuritiesMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USGovernmentDebtSecuritiesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FinancialInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AvailableForSaleSecuritiesDebtSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentFairValueDisclosure" xlink:label="PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="PropertyPlantAndEquipmentFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="PropertyPlantAndEquipmentFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to PropertyPlantAndEquipmentFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RightOfUseAssetsFairValueDisclosure" xlink:label="RightOfUseAssetsFairValueDisclosure" xlink:title="RightOfUseAssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="RightOfUseAssetsFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to RightOfUseAssetsFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsFairValueDisclosure" xlink:label="OtherAssetsFairValueDisclosure" xlink:title="OtherAssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OtherAssetsFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OtherAssetsFairValueDisclosure" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ImpairmentOfLongLivedAssetsHeldForUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OperatingLeaseImpairmentLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="OtherAssetImpairmentCharges" xlink:title="OtherAssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="OtherAssetImpairmentCharges" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to OtherAssetImpairmentCharges" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetImpairmentCharges" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetImpairmentCharges" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerHardwareAndSoftwareMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerHardwareAndSoftwareMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="LeaseholdsAndLeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdsAndLeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="presentation: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="presentation: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RestructuringCostAndReserveAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:label="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="LongLivedAssetsHeldForSaleByAssetTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongLivedAssetsHeldForSaleNameDomain" xlink:label="LongLivedAssetsHeldForSaleNameDomain" xlink:title="LongLivedAssetsHeldForSaleNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsHeldForSaleNameDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="presentation: LongLivedAssetsHeldForSaleNameDomain to LaboratoryEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:label="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsHeldForSaleNameDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="presentation: LongLivedAssetsHeldForSaleNameDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:to="LongLivedAssetsHeldForSaleNameDomain" xlink:title="presentation: LongLivedAssetsHeldForSaleByAssetTypeAxis to LongLivedAssetsHeldForSaleNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="LongLivedAssetsHeldForSaleByAssetTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to LongLivedAssetsHeldForSaleByAssetTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="DisposalGroupClassificationAxis" xlink:title="DisposalGroupClassificationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="DisposalGroupClassificationDomain" xlink:title="DisposalGroupClassificationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:title="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupClassificationDomain" xlink:to="DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:title="presentation: DisposalGroupClassificationDomain to DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisposalGroupClassificationAxis" xlink:to="DisposalGroupClassificationDomain" xlink:title="presentation: DisposalGroupClassificationAxis to DisposalGroupClassificationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="DisposalGroupClassificationAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to DisposalGroupClassificationAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="Depreciation" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to Depreciation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to ProceedsFromSaleOfPropertyPlantAndEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="AccruedResearchAndDevelopmentExpense" xlink:title="AccruedResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedResearchAndDevelopmentExpense" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedDivestitureFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedDivestitureFeesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="AccruedExpensesAndOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedExpensesAndOtherCurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementFyDetails">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" xlink:title="CollaborativeArrangementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_UpfrontLicenseFeeReceivable" xlink:label="UpfrontLicenseFeeReceivable" xlink:title="UpfrontLicenseFeeReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontLicenseFeeReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontLicenseFeeReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableSublicensePayments" xlink:label="ProceedsFromNonRefundableSublicensePayments" xlink:title="ProceedsFromNonRefundableSublicensePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableSublicensePayments" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableSublicensePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShortTermLicenseFeeDueAndReceivable" xlink:label="ShortTermLicenseFeeDueAndReceivable" xlink:title="ShortTermLicenseFeeDueAndReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ShortTermLicenseFeeDueAndReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ShortTermLicenseFeeDueAndReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LongTermLicenseFeeDueAndReceivable" xlink:label="LongTermLicenseFeeDueAndReceivable" xlink:title="LongTermLicenseFeeDueAndReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LongTermLicenseFeeDueAndReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LongTermLicenseFeeDueAndReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:label="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:label="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableTransitionServicesPayments" xlink:label="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="ProceedsFromNonRefundableTransitionServicesPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableTransitionServicesPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:label="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PayableDecreaseFromAmountsReceivedTransitionServicesPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiabilityCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementDisclosureAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="presentation: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="presentation: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="presentation: RestructuringCostAndReserveLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="SeveranceCosts1" xlink:title="presentation: RestructuringCostAndReserveLineItems to SeveranceCosts1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="RestructuringReserve" xlink:title="RestructuringReserve" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringReserve" xlink:title="presentation: RestructuringCostAndReserveLineItems to RestructuringReserve" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveLineItems" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="presentation: RestructuringAndRelatedActivitiesAbstract to ScheduleOfRestructuringAndRelatedCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="OperatingLeasesForOfficeSpaceMember" xlink:title="OperatingLeasesForOfficeSpaceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForOfficeSpaceMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForOfficeSpaceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementaMember" xlink:label="SubleaseAgreementaMember" xlink:title="SubleaseAgreementaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementaMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementBMember" xlink:label="SubleaseAgreementBMember" xlink:title="SubleaseAgreementBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementBMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MarketStreetSubleaseAgreement1835Member" xlink:label="MarketStreetSubleaseAgreement1835Member" xlink:title="MarketStreetSubleaseAgreement1835Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="MarketStreetSubleaseAgreement1835Member" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to MarketStreetSubleaseAgreement1835Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="OperatingLeasesForLaboratorySpaceMember" xlink:title="OperatingLeasesForLaboratorySpaceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForLaboratorySpaceMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForLaboratorySpaceMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementCMember" xlink:label="SubleaseAgreementCMember" xlink:title="SubleaseAgreementCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementCMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementCMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="presentation: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="presentation: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RestructuringCostAndReserveAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaSubleased" xlink:label="AreaSubleased" xlink:title="AreaSubleased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaSubleased" xlink:title="presentation: LesseeLeaseDescriptionLineItems to AreaSubleased" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaOfLandSubleasedPercentage" xlink:label="AreaOfLandSubleasedPercentage" xlink:title="AreaOfLandSubleasedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLandSubleasedPercentage" xlink:title="presentation: LesseeLeaseDescriptionLineItems to AreaOfLandSubleasedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLand" xlink:title="presentation: LesseeLeaseDescriptionLineItems to AreaOfLand" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToExtend" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="presentation: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseNumberOfExtensions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseRemainingLeaseTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToTerminate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:label="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseNoticePeriodForTerminationOfLease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="SubleaseIncome" xlink:title="presentation: LesseeLeaseDescriptionLineItems to SubleaseIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfAnnualIncreaseInSubleaseRent" xlink:label="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="PercentageOfAnnualIncreaseInSubleaseRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="presentation: LesseeLeaseDescriptionLineItems to PercentageOfAnnualIncreaseInSubleaseRent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="presentation: LesseeLeaseDescriptionLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseTermOfContract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="presentation: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseRenewalTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AssetImpairmentCharges" xlink:title="presentation: LesseeLeaseDescriptionLineItems to AssetImpairmentCharges" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="presentation: LesseeLeaseDescriptionLineItems to OperatingLeaseImpairmentLoss" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: LesseeLeaseDescriptionLineItems to ImpairmentOfLongLivedAssetsHeldForUse" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="OtherAssetImpairmentCharges" xlink:title="OtherAssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OtherAssetImpairmentCharges" xlink:title="presentation: LesseeLeaseDescriptionLineItems to OtherAssetImpairmentCharges" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLeasehold" xlink:label="ImpairmentOfLeasehold" xlink:title="ImpairmentOfLeasehold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="ImpairmentOfLeasehold" xlink:title="presentation: LesseeLeaseDescriptionLineItems to ImpairmentOfLeasehold" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: LeasesAbstract to LesseeLeaseDescriptionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesFyDetailsCalc01" />
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: LeasesAbstract to OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="VariableLeaseCost" xlink:title="presentation: LeasesAbstract to VariableLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCost" xlink:title="presentation: LeasesAbstract to LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="OperatingLeasePaymentsUse" xlink:title="OperatingLeasePaymentsUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeasePaymentsUse" xlink:title="presentation: LeasesAbstract to OperatingLeasePaymentsUse" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesSubleaseIncomeFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="SubleaseIncome" xlink:title="presentation: LeasesAbstract to SubleaseIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="CollaborationAgreementSalesMilestonePaymentsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementSalesMilestonePaymentsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableAggregateFeesPayablePerProductIndication" xlink:label="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="NonRefundableAggregateFeesPayablePerProductIndication" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableAggregateFeesPayablePerProductIndication" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xlink:label="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="NonRefundableUpfrontFeesPayablePerProductIndication" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableUpfrontFeesPayablePerProductIndication" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:label="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AccruedDivestitureFeesCurrent" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to AccruedDivestitureFeesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="LossContingencyAccrualAtCarryingValue" xlink:title="LossContingencyAccrualAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencyAccrualAtCarryingValue" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencyAccrualAtCarryingValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockIssuedDuringPeriodSettlementOfLitigation" xlink:label="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="StockIssuedDuringPeriodSettlementOfLitigation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to StockIssuedDuringPeriodSettlementOfLitigation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LossContingencySharesAgreedByDefendant" xlink:label="LossContingencySharesAgreedByDefendant" xlink:title="LossContingencySharesAgreedByDefendant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencySharesAgreedByDefendant" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencySharesAgreedByDefendant" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfTargetAnnualBonusAmounts" xlink:label="PercentageOfTargetAnnualBonusAmounts" xlink:title="PercentageOfTargetAnnualBonusAmounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfTargetAnnualBonusAmounts" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PercentageOfTargetAnnualBonusAmounts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommonStockFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AttheMarketFacilityAgreementMember" xlink:label="AttheMarketFacilityAgreementMember" xlink:title="AttheMarketFacilityAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AttheMarketFacilityAgreementMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to AttheMarketFacilityAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfStockByClassTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: ClassOfStockLineItems to StockIssuedDuringPeriodValueNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: ClassOfStockLineItems to StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: ClassOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: ClassOfStockLineItems to PaymentsOfStockIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="EquityIncentivePlan2020Member" xlink:title="EquityIncentivePlan2020Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityIncentivePlanMember" xlink:to="EquityIncentivePlan2020Member" xlink:title="presentation: EquityIncentivePlanMember to EquityIncentivePlan2020Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityInducementPlan2021Member" xlink:label="EquityInducementPlan2021Member" xlink:title="EquityInducementPlan2021Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityIncentivePlanMember" xlink:to="EquityInducementPlan2021Member" xlink:title="presentation: EquityIncentivePlanMember to EquityInducementPlan2021Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EmployeeStockPurchasePlanMember" xlink:title="presentation: PlanNameDomain to EmployeeStockPurchasePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfEquityIncentivePlans" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfEquityIncentivePlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockAdditionalCapitalSharesReservedForFutureIssuance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanStockPurchasePricePercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsInProcessResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:title="DeferredTaxAssetsCollaborationAndLicenseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsCollaborationAndLicenseAgreement" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:title="DeferredTaxAssetsCapitalizedResearchAndDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsCapitalizedResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:title="DeferredTaxAssetsOperatingLeaseLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsOperatingLeaseLiabilities" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsOperatingLeaseLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="DeferredTaxAssetsDepreciationAndAmortization" xlink:title="DeferredTaxAssetsDepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsDepreciationAndAmortization" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsDepreciationAndAmortization" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: DeferredTaxAssetsGross to DeferredTaxAssetsValuationAllowance" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsGross" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsNet" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="DeferredTaxLiabilitiesAbstract" xlink:title="DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:title="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:title="presentation: DeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="DeferredIncomeTaxLiabilitiesNet" xlink:title="DeferredIncomeTaxLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="DeferredIncomeTaxLiabilitiesNet" xlink:title="presentation: DeferredTaxLiabilitiesAbstract to DeferredIncomeTaxLiabilitiesNet" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxLiabilitiesAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNet" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:title="presentation: IncomeTaxDisclosureAbstract to ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsAbstract" xlink:label="IncomeTaxReconciliationTaxCreditsAbstract" xlink:title="IncomeTaxReconciliationTaxCreditsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="IncomeTaxReconciliationTaxCreditsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="IncomeTaxReconciliationTaxCreditsResearch" xlink:title="presentation: IncomeTaxReconciliationTaxCreditsAbstract to IncomeTaxReconciliationTaxCreditsResearch" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxReconciliationTaxCreditsAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" xlink:title="presentation: IncomeTaxReconciliationTaxCreditsAbstract to EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationTaxCreditsAbstract" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationTaxCreditsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="IncomeTaxReconciliationNondeductibleExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationNondeductibleExpenseOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:title="presentation: EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract to EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" xlink:title="presentation: EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract to EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateContinuingOperations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesPaidNet" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxesPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="DomesticCountryMember" xlink:title="DomesticCountryMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DomesticCountryMember" xlink:to="US" xlink:title="presentation: DomesticCountryMember to US" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StateTaxAuthorityMember" xlink:label="StateTaxAuthorityMember" xlink:title="StateTaxAuthorityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StateAndLocalJurisdictionMember" xlink:to="StateTaxAuthorityMember" xlink:title="presentation: StateAndLocalJurisdictionMember to StateTaxAuthorityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="LocalTaxAuthoritiesMember" xlink:title="LocalTaxAuthoritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StateAndLocalJurisdictionMember" xlink:to="LocalTaxAuthoritiesMember" xlink:title="presentation: StateAndLocalJurisdictionMember to LocalTaxAuthoritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DomesticCountryMember" xlink:to="StateAndLocalJurisdictionMember" xlink:title="presentation: DomesticCountryMember to StateAndLocalJurisdictionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="DomesticCountryMember" xlink:title="presentation: IncomeTaxAuthorityDomain to DomesticCountryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="presentation: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="presentation: TaxCreditCarryforwardNameDomain to ResearchMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OrphanDrugMember" xlink:label="OrphanDrugMember" xlink:title="OrphanDrugMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="OrphanDrugMember" xlink:title="presentation: TaxCreditCarryforwardNameDomain to OrphanDrugMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="presentation: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to TaxCreditCarryforwardAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:label="OperatingLossCarryforwardSubjectToExpiration" xlink:title="OperatingLossCarryforwardSubjectToExpiration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardSubjectToExpiration" xlink:title="presentation: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardSubjectToExpiration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="presentation: OperatingLossCarryforwardsLineItems to TaxCreditCarryforwardAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:title="presentation: OperatingLossCarryforwardsLineItems to IncomeTaxExaminationPenaltiesAndInterestAccrued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:title="presentation: OperatingLossCarryforwardsLineItems to IncomeTaxExaminationPenaltiesAndInterestExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="IncomeTaxExaminationDescription" xlink:title="IncomeTaxExaminationDescription" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationYearUnderExamination" xlink:label="IncomeTaxExaminationYearUnderExamination" xlink:title="IncomeTaxExaminationYearUnderExamination" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExaminationDescription" xlink:to="IncomeTaxExaminationYearUnderExamination" xlink:title="presentation: IncomeTaxExaminationDescription to IncomeTaxExaminationYearUnderExamination" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="IncomeTaxExaminationDescription" xlink:title="presentation: OperatingLossCarryforwardsLineItems to IncomeTaxExaminationDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneticMedicinesSegmentMember" xlink:label="GeneticMedicinesSegmentMember" xlink:title="GeneticMedicinesSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="GeneticMedicinesSegmentMember" xlink:title="presentation: SegmentDomain to GeneticMedicinesSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable to StatementBusinessSegmentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NumberOfReportableSegments" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:label="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="ResearchAndDevelopmentLaborAndRelatedExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentLaborAndRelatedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:label="ResearchAndDevelopmentThirdPartyCosts" xlink:title="ResearchAndDevelopmentThirdPartyCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentThirdPartyCosts" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentThirdPartyCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:label="ResearchAndDevelopmentShareBasedCompensation" xlink:title="ResearchAndDevelopmentShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentShareBasedCompensation" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:label="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="ResearchAndDevelopmentDepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentDepreciationAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentExpenseAbstract" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="GeneralAndAdministrativeExpenseAbstract" xlink:title="GeneralAndAdministrativeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:label="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="GeneralAndAdministrativeLaborAndRelatedExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeLaborAndRelatedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:label="GeneralAndAdministrativeThirdPartyCosts" xlink:title="GeneralAndAdministrativeThirdPartyCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeThirdPartyCosts" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeThirdPartyCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:label="GeneralAndAdministrativeShareBasedCompensation" xlink:title="GeneralAndAdministrativeShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeShareBasedCompensation" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:label="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="GeneralAndAdministrativeDepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeDepreciationAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to AssetImpairmentCharges" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to OperatingIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeExpenseAbstract" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to OtherNonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="presentation: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable to SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="presentation: SegmentReportingAbstract to ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsFyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubleaseIncome" xlink:title="presentation: SubsequentEventsAbstract to SubleaseIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksLiquidityAndGoingConcernAbstract" xlink:label="RisksLiquidityAndGoingConcernAbstract" xlink:title="RisksLiquidityAndGoingConcernAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityTable" xlink:label="RisksAndLiquidityTable" xlink:title="RisksAndLiquidityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AttheMarketFacilityAgreementMember" xlink:label="AttheMarketFacilityAgreementMember" xlink:title="AttheMarketFacilityAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="AttheMarketFacilityAgreementMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to AttheMarketFacilityAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: RisksAndLiquidityTable to SubsidiarySaleOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityTable" xlink:to="RangeAxis" xlink:title="presentation: RisksAndLiquidityTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="RisksAndLiquidityLineItems" xlink:title="RisksAndLiquidityLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: RisksAndLiquidityLineItems to RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: RisksAndLiquidityLineItems to StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:label="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:title="RemainingCapacityOfValueOfSharesAvailableToBeSold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="RemainingCapacityOfValueOfSharesAvailableToBeSold" xlink:title="presentation: RisksAndLiquidityLineItems to RemainingCapacityOfValueOfSharesAvailableToBeSold" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: RisksAndLiquidityLineItems to NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: RisksAndLiquidityLineItems to CashAndCashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndLiquidityTable" xlink:to="RisksAndLiquidityLineItems" xlink:title="presentation: RisksAndLiquidityTable to RisksAndLiquidityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksLiquidityAndGoingConcernAbstract" xlink:to="RisksAndLiquidityTable" xlink:title="presentation: RisksLiquidityAndGoingConcernAbstract to RisksAndLiquidityTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentMember" xlink:label="LaboratoryEquipmentMember" xlink:title="LaboratoryEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:label="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="LaboratoryEquipmentAndCertainOtherAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LaboratoryEquipmentAndCertainOtherAssetsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LaboratoryEquipmentAndCertainOtherAssetsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to StockOptionsIncludingSharesSubjectToRepurchaseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockholdersEquityNoteStockSplitConversionRatio1" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockholdersEquityNoteStockSplitConversionRatio1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to StockIssuedDuringPeriodSharesReverseStockSplits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to CashAndCashEquivalentsAtCarryingValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to PropertyPlantAndEquipmentUsefulLife" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="OperatingLeaseImpairmentLoss" xlink:title="OperatingLeaseImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OperatingLeaseImpairmentLoss" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OperatingLeaseImpairmentLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to OtherNonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="SubleaseIncome" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to SubleaseIncome" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to GainLossOnSaleOfPropertyPlantEquipment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="FairValueDisclosuresAbstract" xlink:title="FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="FairValueMeasurementsNonrecurringMember" xlink:title="FairValueMeasurementsNonrecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsNonrecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsNonrecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to ImpairmentOfLongLivedAssetsToBeDisposedOf" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: FairValueDisclosuresAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="ComputerHardwareAndSoftwareMember" xlink:title="ComputerHardwareAndSoftwareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ComputerHardwareAndSoftwareMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ComputerHardwareAndSoftwareMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="LeaseholdsAndLeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdsAndLeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdsAndLeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EarlyLeaseTerminationFee" xlink:label="EarlyLeaseTerminationFee" xlink:title="EarlyLeaseTerminationFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="EarlyLeaseTerminationFee" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to EarlyLeaseTerminationFee" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="GainLossOnTerminationOfLease" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to GainLossOnTerminationOfLease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GainLossOnWriteOffOfOperatingLeases" xlink:label="GainLossOnWriteOffOfOperatingLeases" xlink:title="GainLossOnWriteOffOfOperatingLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="GainLossOnWriteOffOfOperatingLeases" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to GainLossOnWriteOffOfOperatingLeases" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to GainLossOnSaleOfPropertyPlantEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="AccruedResearchAndDevelopmentExpense" xlink:title="AccruedResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedResearchAndDevelopmentExpense" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedDivestitureFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedDivestitureFeesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="AccruedExpensesAndOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedExpensesAndOtherCurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/GemmaLicenseAgreementQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborativeArrangementDisclosureAbstract" xlink:label="CollaborativeArrangementDisclosureAbstract" xlink:title="CollaborativeArrangementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_UpfrontLicenseFeeReceivable" xlink:label="UpfrontLicenseFeeReceivable" xlink:title="UpfrontLicenseFeeReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontLicenseFeeReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontLicenseFeeReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableSublicensePayments" xlink:label="ProceedsFromNonRefundableSublicensePayments" xlink:title="ProceedsFromNonRefundableSublicensePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableSublicensePayments" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableSublicensePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LicenseFeeDueAndReceivable" xlink:label="LicenseFeeDueAndReceivable" xlink:title="LicenseFeeDueAndReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LicenseFeeDueAndReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LicenseFeeDueAndReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromShortTermLicenseFee" xlink:label="ProceedsFromShortTermLicenseFee" xlink:title="ProceedsFromShortTermLicenseFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromShortTermLicenseFee" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromShortTermLicenseFee" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LongTermLicenseFeeDueAndReceivable" xlink:label="LongTermLicenseFeeDueAndReceivable" xlink:title="LongTermLicenseFeeDueAndReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LongTermLicenseFeeDueAndReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LongTermLicenseFeeDueAndReceivable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:label="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContingentProceedsFromUponCompletionOfCertainBusinessMilestones" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:label="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ProceedsFromNonRefundableTransitionServicesPayments" xlink:label="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="ProceedsFromNonRefundableTransitionServicesPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromNonRefundableTransitionServicesPayments" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromNonRefundableTransitionServicesPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:label="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PayableDecreaseFromAmountsReceivedTransitionServicesPayments" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PayableDecreaseFromAmountsReceivedTransitionServicesPayments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiabilityCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementDisclosureAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementDisclosureAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SeveranceQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="RestructuringAndRelatedActivitiesAbstract" xlink:title="RestructuringAndRelatedActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="EmployeeSeveranceMember" xlink:title="EmployeeSeveranceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfRestructuringDomain" xlink:to="EmployeeSeveranceMember" xlink:title="presentation: TypeOfRestructuringDomain to EmployeeSeveranceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="presentation: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveAxis" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="RestructuringCostAndReserveLineItems" xlink:title="RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:title="presentation: RestructuringCostAndReserveLineItems to RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1" xlink:label="SeveranceCosts1" xlink:title="SeveranceCosts1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="SeveranceCosts1" xlink:title="presentation: RestructuringCostAndReserveLineItems to SeveranceCosts1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve" xlink:label="RestructuringReserve" xlink:title="RestructuringReserve" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringCostAndReserveLineItems" xlink:to="RestructuringReserve" xlink:title="presentation: RestructuringCostAndReserveLineItems to RestructuringReserve" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="RestructuringCostAndReserveLineItems" xlink:title="presentation: ScheduleOfRestructuringAndRelatedCostsTable to RestructuringCostAndReserveLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestructuringAndRelatedActivitiesAbstract" xlink:to="ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="presentation: RestructuringAndRelatedActivitiesAbstract to ScheduleOfRestructuringAndRelatedCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="RangeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to RangeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="OperatingLeasesForOfficeSpaceMember" xlink:title="OperatingLeasesForOfficeSpaceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForOfficeSpaceMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForOfficeSpaceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementaMember" xlink:label="SubleaseAgreementaMember" xlink:title="SubleaseAgreementaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementaMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementBMember" xlink:label="SubleaseAgreementBMember" xlink:title="SubleaseAgreementBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementBMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementBMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="OperatingLeasesForLaboratorySpaceMember" xlink:title="OperatingLeasesForLaboratorySpaceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OperatingLeasesForLaboratorySpaceMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OperatingLeasesForLaboratorySpaceMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_SubleaseAgreementCMember" xlink:label="SubleaseAgreementCMember" xlink:title="SubleaseAgreementCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="SubleaseAgreementCMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to SubleaseAgreementCMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaSubleased" xlink:label="AreaSubleased" xlink:title="AreaSubleased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaSubleased" xlink:title="presentation: LesseeLeaseDescriptionLineItems to AreaSubleased" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AreaOfLandSubleasedPercentage" xlink:label="AreaOfLandSubleasedPercentage" xlink:title="AreaOfLandSubleasedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLandSubleasedPercentage" xlink:title="presentation: LesseeLeaseDescriptionLineItems to AreaOfLandSubleasedPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfLand" xlink:label="AreaOfLand" xlink:title="AreaOfLand" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="AreaOfLand" xlink:title="presentation: LesseeLeaseDescriptionLineItems to AreaOfLand" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToExtend" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:title="presentation: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseNumberOfExtensions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="LesseeOperatingLeaseRemainingLeaseTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseRemainingLeaseTerm" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseRemainingLeaseTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="LesseeOperatingLeaseExistenceOfOptionToTerminate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseExistenceOfOptionToTerminate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:label="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseNoticePeriodForTerminationOfLease" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseNoticePeriodForTerminationOfLease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="SubleaseIncome" xlink:title="presentation: LesseeLeaseDescriptionLineItems to SubleaseIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfAnnualIncreaseInSubleaseRent" xlink:label="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="PercentageOfAnnualIncreaseInSubleaseRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="PercentageOfAnnualIncreaseInSubleaseRent" xlink:title="presentation: LesseeLeaseDescriptionLineItems to PercentageOfAnnualIncreaseInSubleaseRent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:title="presentation: LesseeLeaseDescriptionLineItems to NewLeaseAgreementOperatingLeaseRenewalTerm" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EarlyLeaseTerminationFee" xlink:label="EarlyLeaseTerminationFee" xlink:title="EarlyLeaseTerminationFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="EarlyLeaseTerminationFee" xlink:title="presentation: LesseeLeaseDescriptionLineItems to EarlyLeaseTerminationFee" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="GainLossOnTerminationOfLease" xlink:title="presentation: LesseeLeaseDescriptionLineItems to GainLossOnTerminationOfLease" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GainLossOnWriteOffOfOperatingLeases" xlink:label="GainLossOnWriteOffOfOperatingLeases" xlink:title="GainLossOnWriteOffOfOperatingLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="GainLossOnWriteOffOfOperatingLeases" xlink:title="presentation: LesseeLeaseDescriptionLineItems to GainLossOnWriteOffOfOperatingLeases" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="GainLossOnSaleOfPropertyPlantEquipment" xlink:title="presentation: LesseeLeaseDescriptionLineItems to GainLossOnSaleOfPropertyPlantEquipment" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:label="RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:title="RightOfUsePeriodDecreaseDueToLeaseTermination" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="RightOfUsePeriodDecreaseDueToLeaseTermination" xlink:title="presentation: LesseeLeaseDescriptionLineItems to RightOfUsePeriodDecreaseDueToLeaseTermination" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:label="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:title="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: LeasesAbstract to LesseeLeaseDescriptionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseCost" xlink:title="presentation: LeasesAbstract to OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="VariableLeaseCost" xlink:title="VariableLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="VariableLeaseCost" xlink:title="presentation: LeasesAbstract to VariableLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" xlink:title="LeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LeaseCost" xlink:title="presentation: LeasesAbstract to LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageDiscountRatePercent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="OperatingLeasePaymentsUse" xlink:title="OperatingLeasePaymentsUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeasePaymentsUse" xlink:title="presentation: LeasesAbstract to OperatingLeasePaymentsUse" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesQ1DetailsCalc01" />
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/LeasesSubleaseIncomeQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubleaseIncome" xlink:label="SubleaseIncome" xlink:title="SubleaseIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="SubleaseIncome" xlink:title="presentation: LeasesAbstract to SubleaseIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ArrangementWithGemmaBiotherapeuticsIncMember" xlink:label="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="ArrangementWithGemmaBiotherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ArrangementWithGemmaBiotherapeuticsIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to ArrangementWithGemmaBiotherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:label="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="CollaborationAgreementSalesMilestonePaymentsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborationAgreementSalesMilestonePaymentsPayable" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborationAgreementSalesMilestonePaymentsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableAggregateFeesPayablePerProductIndication" xlink:label="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="NonRefundableAggregateFeesPayablePerProductIndication" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableAggregateFeesPayablePerProductIndication" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableAggregateFeesPayablePerProductIndication" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableUpfrontFeesPayablePerProductIndication" xlink:label="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="NonRefundableUpfrontFeesPayablePerProductIndication" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableUpfrontFeesPayablePerProductIndication" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableUpfrontFeesPayablePerProductIndication" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:label="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_AccruedDivestitureFeesCurrent" xlink:label="AccruedDivestitureFeesCurrent" xlink:title="AccruedDivestitureFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AccruedDivestitureFeesCurrent" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to AccruedDivestitureFeesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="LossContingencyAccrualAtCarryingValue" xlink:title="LossContingencyAccrualAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencyAccrualAtCarryingValue" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencyAccrualAtCarryingValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockIssuedDuringPeriodSettlementOfLitigation" xlink:label="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="StockIssuedDuringPeriodSettlementOfLitigation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="StockIssuedDuringPeriodSettlementOfLitigation" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to StockIssuedDuringPeriodSettlementOfLitigation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_LossContingencySharesAgreedByDefendant" xlink:label="LossContingencySharesAgreedByDefendant" xlink:title="LossContingencySharesAgreedByDefendant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="LossContingencySharesAgreedByDefendant" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to LossContingencySharesAgreedByDefendant" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PercentageOfTargetAnnualBonusAmounts" xlink:label="PercentageOfTargetAnnualBonusAmounts" xlink:title="PercentageOfTargetAnnualBonusAmounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfTargetAnnualBonusAmounts" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PercentageOfTargetAnnualBonusAmounts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EquityInducementPlan2021Member" xlink:label="EquityInducementPlan2021Member" xlink:title="EquityInducementPlan2021Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityIncentivePlanMember" xlink:to="EquityInducementPlan2021Member" xlink:title="presentation: EquityIncentivePlanMember to EquityInducementPlan2021Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EmployeeStockPurchasePlanMember" xlink:title="presentation: PlanNameDomain to EmployeeStockPurchasePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="NumberOfEquityIncentivePlans" xlink:title="NumberOfEquityIncentivePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfEquityIncentivePlans" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfEquityIncentivePlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockAdditionalCapitalSharesReservedForFutureIssuance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanStockPurchasePricePercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:label="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="GeneralAndAdministrativeExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details">
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_StockholderSEquityAndShareBasedCompensationAbstract" xlink:label="StockholderSEquityAndShareBasedCompensationAbstract" xlink:title="StockholderSEquityAndShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholderSEquityAndShareBasedCompensationAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholderSEquityAndShareBasedCompensationAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SegmentReportingQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:label="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneticMedicinesSegmentMember" xlink:label="GeneticMedicinesSegmentMember" xlink:title="GeneticMedicinesSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="GeneticMedicinesSegmentMember" xlink:title="presentation: SegmentDomain to GeneticMedicinesSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable to StatementBusinessSegmentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:label="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NumberOfReportableSegments" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:label="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="ResearchAndDevelopmentLaborAndRelatedExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentLaborAndRelatedExpenses" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentLaborAndRelatedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentThirdPartyCosts" xlink:label="ResearchAndDevelopmentThirdPartyCosts" xlink:title="ResearchAndDevelopmentThirdPartyCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentThirdPartyCosts" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentThirdPartyCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentShareBasedCompensation" xlink:label="ResearchAndDevelopmentShareBasedCompensation" xlink:title="ResearchAndDevelopmentShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentShareBasedCompensation" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_ResearchAndDevelopmentDepreciationAndAmortization" xlink:label="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="ResearchAndDevelopmentDepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentDepreciationAndAmortization" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentDepreciationAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="ResearchAndDevelopmentExpenseAbstract" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to ResearchAndDevelopmentExpenseAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="GeneralAndAdministrativeExpenseAbstract" xlink:title="GeneralAndAdministrativeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:label="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="GeneralAndAdministrativeLaborAndRelatedExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeLaborAndRelatedExpenses" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeLaborAndRelatedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeThirdPartyCosts" xlink:label="GeneralAndAdministrativeThirdPartyCosts" xlink:title="GeneralAndAdministrativeThirdPartyCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeThirdPartyCosts" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeThirdPartyCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeShareBasedCompensation" xlink:label="GeneralAndAdministrativeShareBasedCompensation" xlink:title="GeneralAndAdministrativeShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeShareBasedCompensation" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_GeneralAndAdministrativeDepreciationAndAmortization" xlink:label="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="GeneralAndAdministrativeDepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeDepreciationAndAmortization" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeDepreciationAndAmortization" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to AssetImpairmentCharges" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="GainLossOnTerminationOfLease" xlink:title="GainLossOnTerminationOfLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="GainLossOnTerminationOfLease" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to GainLossOnTerminationOfLease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralAndAdministrativeExpenseAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: GeneralAndAdministrativeExpenseAbstract to OperatingIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="GeneralAndAdministrativeExpenseAbstract" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to GeneralAndAdministrativeExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to OtherNonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems to NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:title="presentation: ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable to SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:title="presentation: SegmentReportingAbstract to ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://passagebio.com/role/SubsequentEventsQ1Details">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MarketStreetLeaseAgreement2005Member" xlink:label="MarketStreetLeaseAgreement2005Member" xlink:title="MarketStreetLeaseAgreement2005Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="MarketStreetLeaseAgreement2005Member" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to MarketStreetLeaseAgreement2005Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: SubsequentEventTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_RestructuringPlanReductionInWorkforcePercentage" xlink:label="RestructuringPlanReductionInWorkforcePercentage" xlink:title="RestructuringPlanReductionInWorkforcePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="RestructuringPlanReductionInWorkforcePercentage" xlink:title="presentation: SubsequentEventLineItems to RestructuringPlanReductionInWorkforcePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_EstimatedSeveranceAndRelatedCosts" xlink:label="EstimatedSeveranceAndRelatedCosts" xlink:title="EstimatedSeveranceAndRelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="EstimatedSeveranceAndRelatedCosts" xlink:title="presentation: SubsequentEventLineItems to EstimatedSeveranceAndRelatedCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_PaymentOfLeaseTerminationFee" xlink:label="PaymentOfLeaseTerminationFee" xlink:title="PaymentOfLeaseTerminationFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="PaymentOfLeaseTerminationFee" xlink:title="presentation: SubsequentEventLineItems to PaymentOfLeaseTerminationFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pasg-20260721.xsd#pasg_MergerAgreementTerminationPaymentAmount" xlink:label="MergerAgreementTerminationPaymentAmount" xlink:title="MergerAgreementTerminationPaymentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="MergerAgreementTerminationPaymentAmount" xlink:title="presentation: SubsequentEventLineItems to MergerAgreementTerminationPaymentAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>logo_passagebio.jpg
<TEXT>
begin 644 logo_passagebio.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@!C Y#
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MA!5(IQUG'XHR-6BBBOH3^E HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$R*6 X)Z>G"^OMCGO4:&)XHY1G:Z;L< X/MU'7G/0=SC-6()5E5BHP%<I]2
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MK ]M]H*LI"G*QD[EP&!&W /%?CYK_P#P2P_8%_:$\4>"/C+\([CPM;:?X?\
M$^G>(;^X^&6MZ'XB\&>*;>VD>:2TNGTV\OHD69RCK(MX!&5.Z-\@+^Q;1PK"
M+=(Q';I$EOY.,)'$R[(XB.<!E C(!QSCG@5\WC*E*<HS4%3;?O*'NK2ST3O9
MN_?3RU/<PU.HH-2GS26D9-WT=K-N^NO9:^;/Y3?VPO\ @X)^)'@_XD>-?AW^
MSE\/_!L6F^%-?UWPE=^+_'NF:[J-U<:OH-]=:;J L;.QUC2;>+;=V<Z1_:X9
M02H#?-\M?FKJO_!<#]O[6+O[8GQ&T33A&P_T;0M&>#3C\Q;!AGU2XE<+NVML
MDP$7&!M-?T>^(?\ @CC^QQ9_''XH?M)_%W47O= \7:_K?B^Z\+>([W2_#?@C
MPS>:]<S:MK%Y=:K=W&T6T>H75Q(LDOD1A6 8=Z[;6/%__!''P3HDG@_6/'W[
M(]EI@M)+*73H/&7A34G*2H;=F-[97\VV4!<$ %E90<'(!]6AB,O]DI4\%7G.
MROS<LHII*UWR=V^OXWOPU</C5\6,II)I^Y%K2Z:7\2]U?HGW[(_ CX)_\' 7
M[7?@_P 3>'HOBM9_#SX@>")-;L8O$4%SH>JV7B4Z,+B(7]WH>HP>($A2^6W>
M3R)+NUN-.,JKNB?#J?[#O@#\9?"GQ_\ A/X2^+O@N_COO#GC73X]6T_9()9+
M))E7=8707F&ZMG!$L+!63<I*@,,_YZO_  4!\._ +PO^U#XZL_V9?$OA[QA\
M(M8>RUSP_J/ANZCO]&T?=)=R3Z!IMU"TJW%K&50R3,(S%YD8DB7<I;^I/_@W
M=\9ZCKG[&WB;PK?W$MU%X2^)5^U@79V%O9ZUI]LR6D!8D>1;2:8Y)0[0]P!@
M$\K,,#0IX*.+IJ4:E6:;@W'E49<KY8I1335[:RLK/M8TPN*JRQ#PT^1J%.+Y
MXJ7,Y))-MN36KNWI>]^^GZV?M3_M*?#W]E7X1:]\6OB+J"VFDZ2T=E96BG_2
M-8UB\AN);'2K5,,TDEP+2:1R@/EQ0R.S( 2/Y"_C=_P7V_;!\=^(+^#X5V7@
MOX:^$%N9X]"M](T76KSQ,+"!WD-[J=_=ZW-;.UTJO@VMI#%U@P'4U[K_ ,'&
M?[0.J:Y\7/AA^SC87Y@T+P;IL?C_ %_3EEVC5-;UO3Q#H*3*IPJ6FEW.LGYP
M2TEQ"%&&&?S*_P""57[).C?M??M:^%O _C+3;F^\!:'8:QXE\>H(I&2WTS3=
M/U"Z\.:=E<>6VHZU^Y9Y&0")2RJY&VM<+@J%+!4L763DIQ<];-:2VLT[VM;T
MZ]^>OBZT\1/#T;*I&2C9KJ^5JZNK))]]>J[?5?P5_P""^?[9/@;Q-IB>.[GP
M-\4?#$\R3ZGIM[I6I1>((+.*1DO%6YM]<B33KET4FW-W:G/#A&4YKM?'_P#P
M<-_M@ZEXGO9?ASX:^$?ACPD+FXBTK1KSPKK.N:_)9@H8;N]O#XF6.-G8R@(8
M(639G8-PW?T:>./^"5O[$OB3P'?^%1\#O#7A\-IURHUS18FBUV":* K;W NI
M R-( @9LJ%)Y(Y(/^?%XALX-+UW6K"!\6]KJ.J6B"(9G$%I>3PQ 3?ZIWV)\
MP3./7I6^$IX#,:E7V=)15*G[SCRIN5[QUM;6*UZKO<FI4QN'@G6<'*6L>6,D
MN6RO=-WNF]'?7MH?Z4O['/Q4\6_'+]F#X'?%WQC_ &8/%WQ"^&?@OQ;K[:3:
MS6.G)?:]X>L=2NDM;>>>ZECC2>X<*KSRL%P&9NM>0?MU_M_?"O\ 8:^&SZ_X
MHNH-;\?:K:7D7@[P+'<QC4]7U2.*5;:>\B5EN;;16O$$,E]+Y$#X,$5QY[(M
M7_\ @FQ<&+]@;]EZZN#L6#X(_#ZY=L?((8?".EL 6X 'E\YZ <^X_B=_X*A_
MM!ZE^T/^VG\:]>O=0-YHOA'QCKG@+PFOVG?8Z7IO@W49M!^S0(&,4@NGTV;6
M3-$0ANIFMQF1LUYF$PM/$8FM"I";I4G>U*RDVWHFW&2Y5J]K;I;G56K5*5"E
M.G*FIU+*7M4W!+E3:24X.]NJE:[U/JKXA_\ !>C]NOQ[<7,NAW/@7X?Z7+>2
M);6O@SPQK<=YIT+'?%!>:AJ.NWY>YCA9?MTK*D2W'G!!'&JJ(OAI_P %Z?VX
MO!%Y&_B&[\#_ !*T 2I/J%IXJ\/ZO/<:A8EECN+/3]6TW7;..UF,:.1/,&MH
M)'\R4D!A7Z;?\$@/AC^P-\-?V>O"?Q4^+/Q8_9]?XS>,KJ]UJ\B^(?Q'\ V6
MJ>%XHM3N[:PC'AW6M<T^]TN:\TZWMKJXCO8Y3YMR[E50JH\&_P""YG@;]D#Q
M;X)\#_&/X _$?X(ZQXTTR]FT/Q=X:^&?C[P+K>JZQH=^S)!?+H?AW6;V[FFL
M[B[N7FEAMMD=NJF0*%W#L<,+4G]4^KU:=WI6=KKEM))R]G97M;7NG?4Y)SQ-
M*'UF->E5GM[&TN1J3BFU'VE^9)IJR=NVCM^_G[ ?[>_PO_;I^&TOBGP?%_PC
M_BKP[%80>+?!5U,#?://?!PLUNCGSKG3VF@:(7:>;%&YC224/*@/WSO&2O<>
MH(![G!P1Q@\5_!S_ ,$-/C-K?PS_ &[/!GA-)672_C+HVM> =2L$,BVXGMK0
M>*=.OD)_=S,G_".3VWRC>#= !OFQ7]XJL&8@\%6;'N!\N?\ Q[^5>/C\+]6J
MJ%.3<6D[MIOEND[6MK=Z.WR/4PE=UJ:E4BHR>Z5TKV723D[/UUMO>Y_$5_P<
M*X/[:.F8&[=\.=!^4@G=FSL<@X]2<<<^G8U_3Y_P3-'E_L'_ +-J.(4<^!IV
M6$DHZC_A(-=QA&;<00,XP<\D<5_,!_P<,-M_;0T]B-P7X<:$=NW<6Q9V!(VE
ME!STQN7/3<,YK8_9S_X*$_\ !4KX=_!+X?\ @WX1?LP^/?%/PVT#0?L?A77[
M#X'?$S7;/6+)KZ]D:YL-8T?1[O3+RWCN)9H7FM;J6-9H9HRWF(ZCNK4*]?*Z
M,(R2@DFN6_/;IKM?5Z62];GG4\30H9C/VC:<FD^VG+O97UL^N^ME=,_L_P!4
MU+3M/TZ]U'6+NTLK&PM)KJ[N;N>*&.U@B0M(;B25UCBC9%(!D*ACT)/%?YVO
MP:TZY^,?_!070(?AII\Q@\5_'3^T=#L;*"1[B#3+/5+F22^MHHE)73MK;FO0
MIM!*6C\W<K*/I_\ :X_;S_X*;_$?P?=:#\9/!?Q4^$'@[4$:#4H)_AWXY^'N
MBZQ"<AHWN-:T<>>T09D=6:*-\C+#-???_!#K4/V!/ &H-K6L?%BP'[37BJUL
MM.MK'XA6&B^!H-+LA<7?EZ3X)N9O$>NC7[M[F037=V&TR0FXMX?L:D%Y'A*5
M7 X*K*3<^=*-IWDTD[^]:UK7>KOK^)B90QN*I)7I^R;E>%HM_!;36^BWT;UO
ML?U6:W>WEGH.JZA;R1>?I>G:A=J9-SQ2S6MG/+&LD:,&(5XTWHSJ1R,@YQ_-
MM^QG_P %E_CG\5/VT_\ AFKXO:!X"N_"WB#XB>(_ WAW7?#.@:CI.K:<UMXA
MU#3=(6]9]:O8;K<L5O!)*+1 &8S/M4$#^D7Q0KKX2\4!R21H>KXR^\[?[-N-
MI;]V@#E<%\%P7+?-7\#'[#C%?^"L7PZP< _M*ZJI]]WCV] 'XDX [D@#FN7!
M488B%><[Q<5S1Y;))Z:M-/MW6C.O$U9T)48PY7S246YW;M9-M6:UU>]_S9_H
M&-E5(7)/EQJO(!8@D 9Z MG&3@9//%?@;_P4@_X+2^'OV4O&NL_!?X1^&]"\
M>?%+P^5M_$M]XDDNSX0\,7TUK#>#3KU-/O\ 2[F;48+>XA-U&M]F"0FWD1)X
MI4'ZP_M??':']FW]F_XL?&4PQ75_X,\':QJ.AV4T\=NE]K\6GW,FD6!EDSAK
MJ]2&$*JM(=X"*S8!_C4_X).?LN2_MT?M>^)?''QB,WC3PKX3D@\=?$;4M3AG
ME3QKKNHW,]QIS2"0OL@U*_B^RW\322O##&P(+?*%@\-S*5>LOW$&TVM'S146
MXZWU::25NNW?3$59)*%-KVDDG9W>CLK[]+:/77SW]7MO^"SG_!4?QK9OXQ\,
M?#G2;KPC8SE[F_\ #GP8\87OAFUA;>RI=:M#JES8-& /E>]O%R 6R>37TS^R
MY_P<.^.I_&VD^&/VK? _@6Q\,W5RFG7/C'PA8ZSH6HZ3=2JRQ3:KIVI:UJ5K
MY?G!5E2"VB92<(0Q45_4]H?@3PEX?T>UT/2_"VAZ;I=I;)90:=:Z;9+:16\:
MB-%\L6ZK(0B@#<I.#USFOY;?^"]_[$G@KP)X+\/?M+?#'PZGA:\G\7:9HGQ
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MGC(:QKHUNYU&\@A@=),72E%2&W@0!EN%X ('E\8R<_?JG(!IKINQSC!S3@,
M#TJ:DY5)2G)WE+5OSM9?D5&*@E%*R0O6O(?CC\$OAY^T+\,_$WPG^)VAKKWA
M#Q79R6FHVGGW5K+$^UA#=6EW93VUY9W5M(WG6]Q:3Q2Q3*)4<. U>O#@ >E-
MVC&,G\R/Y8__ %\T1E*$E*+:DFFFNZ=U_P ,]!M*2:>ST/Y*?BC_ ,&WWBR/
MQ#>7?P@^,NE-X?N)+B*UTSQ2E[#>:=IURXD-F-1L8HKFZ6'RX4C>XGEF=0QE
MD=CS[I^S=_P;P^!O!WBG1_%W[07Q#/Q"M-*N;:\_X0;P_#+I.A7\ULI>-=0N
MH(;+4#!#.(I!':WD45QLVW2RJ<'^F(KDDAB#C'7(Z_W3D9]\9I=HR3CJ"#GG
M@]1ST!XX&.17;/,\7-1C)I\BM%[R:5ENV[-VNM%9]3EC@J$'*459S;E)+9MV
MOIMJ[]_-'\JGQU_X-V+[Q)\5/%/B;X-_$WP_X5\%>)=;U/6M.\-:K8/M\)V]
M[/<3VND:;<6UJUW>06TT\*QRWTUTYCMQYLSL6+_O_P#L=? ;Q'^SK^S?X!^!
MGC+Q+;^-KWP5IU[IG]J16P@@EL;V^N;Y;7F"'S%B>\N=LDN^4)(D8?;%&B?5
M"Q!2"K. &+%2Q93P0!AL[0IPRA<8( ''%2 8&,D]>3UZ_P!.E95L;7Q/+[9W
M<5%+7^6R3>NNEUM\^]4L+2H<WLTES/F>G5VO?NM/GWL?ST?ME_\ !!;X4?'3
MQGKOQ/\ @SXON_A=XK\1S7-_KF@W37&J>%=3U.?E9HDG%]<:4[NHWQ:?+:6Q
MW&1HPP+5^<\7_!N+^T,EZ0OQ2\!):,P5KF+[5%+)&,_+(L:*9%_V)-RY[<FO
M[+?+3((!4@YPK%5)/7*J0I)[D@D],XI0@''.,YP>GY=/?IUK:AF>)H4W3@XN
M+::YDW:R2LK-::$U,'1J3YY)WZVZZIZ][6T[(_";]A;_ ((B?!C]F3Q!:_$W
MXG:DOQ;^)-BD?]B6]VMQ#X-\,W*.&N)[;2(_LEOJ%X&5(X[C4X+XP1Q[;1HD
M8@_MEXA\+Z#XI\.:MX0U[3+74- UK2I]%U32Y4*VMUIUS 8);=5!54C5#B((
M4,:J@C*A$QTAB&<AB.23G#$Y()&YPS*/0*0!V'2E\L<X+<D'YF+CC'0/NQT[
M8KCJUZU62G)WDI75V[+;5*^FR\_TZ8PA&/*E96LN_3KZ?U<_F)_:$_X-V_"7
MB'Q3K'B3X!?%"[\%Z9J\\MW%X1\0_:+ZQL9[B:26:VLKUHKBZ:P+/NA%W=2S
M0AFA1UMXH$3Y)TW_ (-S?V@1?B+5?BCX"M=-6?"R6WVQX6A( +3VZIYDI')5
M0KY8D2 C%?V6&-3USZ  X '7H,#KDY(S33 """QQV[%?4JR[6!/<@@_E7=2S
MC&TDJ:Y'"UKM*Z5EVDKV:[._4XWE^'E4]K)/FWLF[=--]M_\EHS\AOV O^"0
MOP2_8FUT_$6ZU.Y^)?Q5FTZXL;?Q'J\20Z?X>6]N;6\NG\.Z5;16EE:W)FM(
MA#J$EH=1MXA(D%Q$LLH?]=+JRM;VVN+2YA2>UNK>6VN+:10T$]O-$T$L,L1^
M1XI(G:-D8;2I((J9(@F "2!V)+$^[,Q+-_P(GFGLH88R0,$?*2O!XZCD>Q&"
M.U<%6K5KU'.K)R=TT[Z:-/;I9I=/\SLC"%-)4TDO));O565NGF[G\V_[7O\
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M@@YSS7PFG_!M=X3C $?[0VOH1(\@9=)TX.6DV[M[C20[*=H.QBR YPH))/\
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D&P44458!1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>logo_redwood.jpg
<TEXT>
begin 644 logo_redwood.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M;P_J'P ^(>JRZ;INE1>+;^TU#X9^,]=U)WABTCX>_%2!++1]:U*65%%IX?\
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MM,N;KP=JW@FV;0O 'B35(!YMOH?C?PK9H^F166I8>S7Q'HMI8ZQI,T\=_/\
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M\1>%WN6.D^)=)O+=HO[,U[2[BVN-)\0Z=:75U!I^L6ES$EU=:?-9O<_V9_\
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MBWD_LG7? .N:QKGAJWU -OBEU3P3XLU/4;&ZLW/[N:TT>^\/RB,@V]W;2*)
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M)X-FO;IX[=#=:G!9:1KWB*/3]/FNB\=M;W^IF^P S0[/F;T/[?>'_ES\=_\
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M&O[5.GZ$TE[!X?\ V=_A?'J5Y-+*8]$G\=?&.XFEEE>$GRY-2\*> _!2[IY
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M:S6.*WU#49;6\\.^(=1\HG4KR3P_+<-]LFGFN/S@_P"" W[7FJ?LU_MV^"_
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M/A1\2];TO]K?X':SJFE> ?%]_I>DZ#X[T?6-9U34K70+^6PT[2M,TZ>>]O\
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M?#_B+PQ,8KE981;SC4I(U9_-0L[LA;+9/]&HL-18971_'.!\O_(]Q*/E^7(
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M-.<ZU51_WF7,W1A&].E&&CNZDH)S79\O+?139YE=?$;2X?%W_"$?LK^!(?\
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MH?";P;OD4+)MU;P-XL^&EV&R JO/%J;12(-I#-)"5) 2OZ)X^AXV_,2!TQD
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M)-TUQ+'$@5#EG&2!S7A#?MI_LM@$_P#"[/!Q'(XFON2"5(4BQ;/0G@D@ G&
M:C$XG!4KTL3B,-2<U=TZU:E3<EIK:I):67:S[E4J.(J/GHT:TU&27/3IU)VE
MI:_+%I;KJ?%?["/_  1B_9?_ ."?_P 7]7^-7PH\5?%3Q7XPU3P5J?@6,?$'
M5O"^I6.E:5J^IZ/J6H7.FQZ+X5T.Y@U"=]%M;5IWN9$-G)<0F(^:6'Z\
M=  !]!7F/PW^,GPQ^+T&K3_#;QGI'B^'0I+2#5Y-*FFD6PEODGDM$G\Z&'!N
M$MIVC*JRD12 D$$5Z>.@^G^?2M,,J"I1^K<CHRO*+IN,H2O97C*#<7M;1O\
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M^RB\VZN[AD5V$4,09Y"J,P X'6OGL?MJ?LLYY^-O@WO@>?>\XZG'V(' R.>
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MI*PWL.-N%P"17]"-C=VU_:6][9RK/:W<,=S;3(25E@G19(95R%.V2-E=00"
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M#Q%I/CVYU2QTK0+V2UO='N%L_$6BZ+;W]IIU_+/K5QJY@^W>J?L[?&CXB?\
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MY>FFT\3^*OM,BDQ0_:;EM)\+71!+I,OE*1/E1^TJJJ+L"@*H7:H   &   ,
M  XP, =!7JY8ECLXS/,&KT\,X93@Y/:U&T\;.*V]_$2BN9:SA&)Y^-:PN68'
M!I.-:M*6/Q2T5U44(X:-DM;4U.23VE+1=3YW_:L^*2?!_P" _P 0?&44IAU1
M=&FT+P\RR"*3_A(?$*MI6E2H226-G<W(U"0*K'R+20@8&1\3_P#!.2^^%GPS
M^#VJ^)_%7Q#\!Z1XR^(7B&XU"]@U7Q3H=GJ]OHFD*=.TBVOXKF_2XCDFNAJV
MIJ'53Y6H1;P6P:Y/_@HSXJU'XG_%7X+?LP>%Y/,NM4US1]8U@PL9A!J?B*[D
MT32/M4,9/[G2]*?4]7N1*"JVMS'<'88E8_2MM_P3:_99CM;>*Y\,>(;JXC@B
MCGN?^$PU^(W$J(HDF,<=V$C\QP7"( J;MJC %<E6>.QW$%6O@:6&KPR:@L$O
MK5:K3IK$XN-.I6G#V5&K>I&E&%.7,E92NG9V.BE#"87**=/%SQ%*IF-98E>P
MITYS^K4O=IQFJE6DE"=24IJS;O#78\@_X*+WGPI^*GP4AUSPS\0? FM>+OA]
MK5IK&G6.F>+?#]W?WVE:@R:=K=I!:QWSS7+(C6>IK% KSNVF[(T;?@\__P $
MI?BNM]X9\<_!S4;N+[3X?O1XR\.PR2,)I=,UAX[/7;>V1L@V]AJD-K=$!]X?
M5W8JP+./H*3_ ()M_LKF-UB\*>(HI&1A')_PF/B!_+<@[7VM=E6VM\VUL@E<
M$$9%?D#\(O$&J?LF_M=6MGKT[6VG^$_&6I^"?%<B@O'>>%=3NCIQU!B0"81:
MS:=KD+ !B;53@J#GR<;+,,KS_ 9SCJ6$H4L6XX#$/#5JM6$HM<OM*TJM*DU.
M,73]FK-25&[:>AZ.$6%S#*,9EN%J5ZT\.GBZ$:U.%.:DN1M04*E2ZLJB:NOX
MK=[;?T\$C!Y'0U^:/_!4O_DWC0_^RBZ'_P"FS7:_2D;63(.00IR.03UXZ<=,
M'I^M?FM_P5+_ .3>-#_[*+H?_ILUVOK<^=\CS7_L"J_C&+_4\#)O^1MEW_87
M1_\ 2T<7_P $F/\ DE7Q0_[*+:_^HYIM?K"I 49('7K]:_)[_@DQ_P DJ^*'
M_91;7_U'--K]7L A<] &)_/I6/#'_(@RS_L'_P#<E0>=_P#(VQ__ %^7_IJF
M29'J/SKX1_X*0\_LI>-,<_\ $]\#=/\ L;=+KZL\5_%+X>>!=2T+1?&7C+P[
MX9U3Q/<+:^'M.UC5+6QO-:N#<6]KY6GP3NLMP_VJ[MK?$:G][/&@Y8 _*W_!
M1Q#)^R=XYV MY>L^")7V@G:H\6Z0-[$$[5#$ GMGZ&M\[J0_LG-E&49RI8#%
MJI"#4I1;H3=FEL[*Z3M>^YGE<9K,,NDX.*J8NA[-R5HR_>P5[ZZ7=G;8^0O^
M"2/_ "$/CC_UP\#_ /HWQ37[3K]T?Y[U^)W_  21NHEUOXUV3$">73/!5XJ%
MAN\F*Y\11.< GA7GC!.>"<$>O[9+T'T'\JX>$)<W#^ ],1^&)J_YG7Q$K9SC
M/^X%O_":BOT$;[I_SWK\>OVD_P#E)-^S=_V#/ ?Z>(?&>:_88G&/<X_"OQM_
M:%NX-1_X*9?L_65JQ>XTFR\"07BXSLE;4O%>K;05S]VRGAF;=MPLH(SS6G$;
MMA,(MW+-\JY5?5\N*I3\_P"1W\KF>2_[SB'T678Z_E^Z6_8_9(=6^O\ 05^;
M?_!3/XK_ /"$? Q? MC=QQZQ\4-7BTF:%6/VI/#&D2PZMKEPBJ#LBGGBTW2I
M7D(1H+^9%60&3;^D9.,^AR2?0 #/\OSP.]?AY\6--@_;#_;ZMOAI*UQ>_#GX
M9V][HFO/I\SV[QV/AZ*:Y\3RB[1MT,][XKFMO#HDCVND<$<L7*;FKB3$5*>7
M/"X>_P!9S2K3RV@ENGB7RU)/M"--2YYV?LT^;I9F2TJ<L:L373>'P$)8VM9)
MW5%ITXJ^CE*HX\L=Y-6[L^Y/V5?$/P7^#GP$^'?@JY^*7PY@UB'1UUCQ$)/&
M'AN*<Z_KTDFL:G#<+'J+;GLIKP::F2SB&RA1B2BU\ ?\%-[7X=>*M6\ _$_P
M-XS\'>(=2FM[CP=XCLM UO2-4O$BMA-JVB:C<1:?>RW(@02:G:2S-&XC;[#&
M)$W!3]S#_@FU^RF,@^$?$).3S_PF?B$<< =+S&  !Z>GOQOQ'_X)M? .3P%X
MN7X?^'M=T_QJN@ZC-X7N9?%&L7\2ZU;P-<6$4EG=W$EM<1W-Q$ELZ2KC;,6!
M#*IKR\?EV=8G*9Y?]2RN%.EAZ<:2IXK$RG!X=0<?9QEA%!SE%<D;RBM5>5FT
M=N#QF64<PCC)8K'RG.K4=7FP^'4)1K27/SR^LN2CRRO)*+MT32/1/^"?/Q8;
MXF_LZ^'+&_N7N->^'L\O@C5WFF22>:WL56YT*Y)P&V'1KFQLBQ!S-93D,P!(
M^Z*_GB_X)I_%-_ /QTO?A_JLB66F?$S3Y-*>&YE:+[/XKT(SW&D1F)]J+<3Q
M#5=+"E5DEGD@0EF7;7]#M>GPSCOK^48:<I.56A%8:LY?&YT4DI271SIN#?12
MYDF['%GF"^I9A6@DE3JVKTN76*A57-RQ?7DES1]$GI<^,OV__P#DU+XI?]</
M#?\ ZE&E5\%_\$DO^1H^-?\ V+W@S_TZ:_7WI^W_ /\ )J7Q2_ZX>&__ %*-
M*KX+_P""27_(T?&O_L7O!G_ITU^O&S#_ )+C)O\ L"J_^FL:>A@_^28S/_L+
MI_\ I6"/W!HHHK[D^8/R2_X*T?\ )/OA)_V.NL_^F-*]A_X)B_\ )KUI_P!C
M]XT_]*+*O'O^"M'_ "3[X2?]CKK/_IC2O8?^"8O_ ":]:?\ 8_>-/_2BRKX;
M#_\ )<XG_L6?^XL ?45/^25H?]AE3_TY(S?^"H\US'^S591P[A#/\3?"L5X5
M!(\A--\0W$>_ ("_:X;?!) WA%YS7S-_P21CA&O_ !OD8+YPTOP,B\\A&O/%
M!90.ZY2,YYYQS@D5][?MW_#_ %#XB_LR?$#3M*B:?4/#T5EXU@@0;I)H?"T_
M]I:C'$O5Y3I27QCC7#RL!$N6<*?RY_X):^/+3P]\;O$G@Z[=8Q\0?"1&G,[J
M/,U/PW=/JL4* G#>;IEQJC1A"686ZD+C)$9A;#\:Y56K*U+$X>-*E.6D542Q
M%*2B^LN:M2T[S6CT+P;]KPQCZ5/6I2KSG*,=9<G^S5$VK[6I5&]-HZ'] ]%%
M%?>'RA!<*KQ2*X#(T4JN&^Z5:,A@?8@D'VK^27P@SV?[0/AO[ -C6_QATT6J
MQ$+M5?&< C6-AC:N,*I!P!P#CBOZG?BSXRT[X??#?QOXTU6?R++PYX7US5)'
M! =Y+?3YC;6\(.-T]U=-#;6Z9!DGEC1?F85_-I^Q?X"O/BC^TY\.K=[66YLM
M&UV;QOX@F'S1V]CX>6358I+AVR/*N=:&F61+ -(]X H(RU? <90^LX_A_"46
MWB9XBI*$8V;C%U,->;ZII0E-='&%1W]UGUO#?[K"9OB9Z4848Q;EHFXTZTK)
M]7>=.+7]_P!#^H@8R<]LYY!Z#/T'KU^O>OR&_97_ .4AW[4 _P"F/C;Z_P#(
MW>'Z_7I8_E&>#@\>F<'G_)Q_/\A/V5_^4B'[3_\ UP\;_P#J7^'J]W.W?'\.
M_P#8V?HW]2Q%W][?XZ+9>5E?^ZYQJ_\ D7Z+LO;T%^A]H?M??L[V/[0_PLU+
M0K:*./QIX?BGUSP-J+C#IK$$#%M(DF9XU6RUV)!87!F9HH9GMKYD9[2,5^0W
M["/[0^H_ +XJW_PL\?33:3X,\8:TVB:U!J),">$?&EI/)IL.H3))S;17-W&F
MC:RVYU@5;2[EF,-C.[?T3#C>3TYZG'K_ #]:_$;_ (*6_LQ_8+H?M">"]//V
M*_D@L/B5:6D;LEM?$K;:;XK,<99@MX6BTS5GC1$%PFG3OM,]U<#S^(L%7PU2
MAQ#ET?\ :\#R?6J:O_M.%7*Y<R2W@O=G)W:H72TII'7D^,IUJ%7)L:[X;$MN
MA)V_<UWM:]W9[PBM/:N]O>9^C'[9C$_LL?&KG=_Q15P,]^+RS /  [YZ#Y<&
MO/O^"=7_ ":A\/O^PEXP_P#4LU>OB7P)^TZ?B[^Q%\;OAMXQU(W'Q$\ ^ 9H
MHKF[F4WGB7PLM]9166I$[_\ 2+W26=-+U,HFYH_[/O)V\R]D\O[:_P""=7_)
MJ'P^_P"PEXP_]2S5ZUP>.P^99_@\7AI*5.KD6(?1.,ECJ,)0E'I*$HR36GZF
M6*PE7!97B,-6C:5+-8*^ZDO8*TD^L6K->K70^Y"JD $<#IUXKX*_;1^ /B/Q
MA!H7QN^$&C'5?C!\,K*XL+OPK;SP:>/BU\-;ZX2ZU[P!+=W$L%G;Z]IUPB^)
MO &IWK>59^(+>YT66:VTOQ1J\H^]Z:03GGTQD9P1WZ_G7U%>A2Q-*=&M'FIU
M%9K2ZUW5]+KI_D>'"<Z4XU(?%%WMT:ZQ?D_T/Y\? 'Q.'PPU\_M _##3M/\
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MAPS$UF_"']I7P-\;8=0M_!?CCXDKXHT$1+XJ^'^N>$-!T?Q_X2GF\SR8]?\
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MVLZ1%J5V/MWPQCDBO;CFX\$:I+>1R1SOCSYX_EDGC8?O)$.'DRZDX%? .O\
M["7P<\7?M.>,?CIXDU?P-?\ PM^)?@B]T#XH> #X?U@7.I?$#6C+<7?B?PO<
M#RI_#US+<Z9H_B$ZI%]JO!K"ZH%F*W9=?T?U>YU>'5-0BCU7XB+&MU-L&G^&
M-)N;%5=RRK:7+P.TT"A@L<C,20I!.0:SO[0UL<)JGQ/.6Z?\(CHAZXP=S6W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ny20077915x1_barchart01x2.jpg
<TEXT>
begin 644 ny20077915x1_barchart01x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M/O\ T/O[6/\ XF!^T7_\\.C_ (=D_L^_]#[^UC_XF!^T7_\ /#K]#Z*.>?\
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M\4O_  "/EY>2/SP_X=D_L^_]#[^UC_XF!^T7_P#/#H_X=D_L^_\ 0^_M8_\
MB8'[1?\ \\.OT/HHYY_S2^_^NWY]V'U3#?\ /BE_X!'R\O)'YX?\.R?V??\
MH??VL?\ Q,#]HO\ ^>'1_P .R?V??^A]_:Q_\3 _:+_^>'7Z'T4<\_YI??\
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M/EY>2/SP_P"'9/[/O_0^_M8_^)@?M%__ #PZ/^'9/[/O_0^_M8_^)@?M%_\
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M_P# (^7EY(_/#_AV3^S[_P!#[^UC_P")@?M%_P#SPZ/^'9/[/O\ T/O[6/\
MXF!^T7_\\.OT/HHYY_S2^_\ KM^?=A]4PW_/BE_X!'R\O)'YX?\ #LG]GW_H
M??VL?_$P/VB__GAT?\.R?V??^A]_:Q_\3 _:+_\ GAU^A]%'//\ FE]_]=OS
M[L/JF&_Y\4O_  "/EY>2/SP_X=D_L^_]#[^UC_XF!^T7_P#/#H_X=D_L^_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ+HFJQ+#;75Q# _GR1.7<;489(_IX_9U_P""JG_!/?\ :T^)%K\(?V=/VHO
M'Q4^)5[I>I:U:>$M M?%,&I7&EZ/$LVIWD3:OX?TVT9+.)UDE3[3YI0ED1@K
M8F/PKY_F-Z[:Z+\$K_=U/T$HHHJA!1110 4444 %%%% !1110 4444 %%%%
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M=4\&_"W5=9N/B%J6H?;? UKK.M,OB'2_#BV^JSK)'-<236D#(GZ[_MO?LY_
M?]J3X#ZA\+OVC?%%]X+^&Z>+?!GC$^*--\;V_P /+_1?$_@[7;?6O"U]:>*;
MJ2*"QG@U>"!X5=LS2!50>9M(^7_@]^P[^R-XA^)?@SQVW[3'Q6_:R\1?"'6;
M?QEX)\-?$K]IV7XR^&/!?B>!9+?3_%\7@ZRU&33AK5@'=-+U/4K:<V,A9[3R
MY26K1K7[OP>OYG,G97MM?IWMUTMZ].Q^6EK^TW^TS\1_B?K_ .R?8?'SXA>
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MDI0BY+M.UIKY237R"BBBI-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*^=/VH_V6_A3^UY\*[KX2_%RRU=]&&M:/XI\/Z]X9UB[\.^+O!GC'P[<F\\/
M^+O">OV++=:5KFD7)9[>=-\4L4D]K=0SVT\L3_1=%--IW6C1,X1J1E"<5*$D
MXRC)74D]&FGNF?F=\"_^"8'PQ^%?Q?\ #'QX^)?QF_:!_:G^*/P]L[VQ^%>O
M?M"^.XO%-G\,8=3MVM-2NO"6@Z7IFBZ-#K%]:;+>;6[ZSO-26.,>3/$Y+U^F
M-%%#DY.[=_R7HEHOD12HTJ,7&E!03?,[7;E)I+FE)MRD[)*\FW9);)(*^;_V
MK?V9?!W[7/P>OO@QX[UKQ%H'AZ_\4^!O%DNI>%I=/AU=;[P'XKTKQ=IENCZI
M8:E:?9;N^TF"VO0UJ96M9)1#)#+MD7Z0HH3:::T:::?FMBYPC4A*$TI0G%QE
M%[2C)6:?DUHR.&)888H5)*Q1I$I.,E8U" G&!D@<X &:DHHI%!1110 4444
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M#'OWIM=58?-'[:O_ "=_^T__ -EZ^*W_ *FNLUZ;^P3_ ,E!^)'_ &2;6?\
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M\0^#=)U/5]2DM[*&WM('O+VXFG:*V@BA0N5CC50 /K^O!OV6_@C%^S5^S?\
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MC_'6OVOBGQ!X5^+?P^F\;Q_\% _B%^V_X*T+XD?#RX\:?"74X/'?AZR\./\
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M(F>V%SIOB#P[>7FI/I&KV4T::A/'*BQY?[2W_!-RR\;^(_V;_BI^SOJ?PU\
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M*J>Z\XQ?_DJ.;"?PI>5?$I?^%%0****DZ0HHHH **** "BBB@ HHHH ****
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MRG]B7_HUS]J#_OY\+/\ YMZ/^(RG]B7_ *-<_:@_[^?"S_YMZGFCW7]?\/\
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MXRUC76TC0KTPPB\TK3#:65TL$"SPR+#&%_F(_P"(RG]B7_HUS]J#_OY\+/\
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M2_S\_P ^S/["J*_CU_XC*?V)?^C7/VH/^_GPL_\ FWH_XC*?V)?^C7/VH/\
MOY\+/_FWHYH]U_7_  _Y]F%UWC_X$O\ /S_/LS^PJBOX]?\ B,I_8E_Z-<_:
M@_[^?"S_ .;>C_B,I_8E_P"C7/VH/^_GPL_^;>CFCW7]?\/^?9A==X_^!+_/
MS_/LS^PJBOX]?^(RG]B7_HUS]J#_ +^?"S_YMZ/^(RG]B7_HUS]J#_OY\+/_
M )MZ.:/=?U_P_P"?9A==X_\ @2_S\_S[,_L*HK^/7_B,I_8E_P"C7/VH/^_G
MPL_^;>C_ (C*?V)?^C7/VH/^_GPL_P#FWHYH]U_7_#_GV877>/\ X$O\_/\
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M?^M)EI^A]?FY^W-_R4/X;?\ 9%/"?_J1>,J_2.OS<_;F_P"2A_#;_LBGA/\
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M\)ZY.EA)H7A7XAG77B\*^-HYB;C0Q<Z7JUKJLNZTEMEVJ63:6X[-[>?X:O\
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M^]]-/+SV*26E^KMH]M5Y;_IZGZ9 @C(.0>01T(]:*_EI^#O[/OQ)_:P_;/\
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M(]+LI[Y]/T32XF234=6O%@-OIUC&ZO=W<D,",&D!K^034?BK\=OV<%_X*0?
MWP#^U5\8?$FAW7_!0K]C']EO3?COXU\?7?C3Q9\!?A)\4? .EV_BAM(\0:]=
M75EHVMZ# J>#I/$0CM]0?698]9U*5]=#7@^L/VCO"'B'_@GS\6-;^"'P&_:
M_: \6?#O]H3]@O\ ;;\<>-/!GQ6^,_C3XKZ[\/O'7P<^%[:UX1^,/@OQ7XIU
M74_%W@R_\0ZEJ=WIMU'I^I66A/>V"3:7;6UU;QK 7_X.W>VWK_5KV:CK:ZUV
MW[)O\]/3I<_H[\!^+H?'O@SPOXUM]"\3^&(/%.B:?KD7A[QIHTOA[Q9HJ:C;
MI<KIOB+0YI)9=*U>T#^5?6,DLCVTZO&SL5S765_(S^S!X-\:?M??M$?\$_\
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MU::3<:F+F73[:XGFGAM6BCEE=U+'JZ9 4444 %%%% '^)G^VK_R=_P#M/_\
M9>OBM_ZFNLUZ;^P3_P E!^)'_9)M9_\ 4C\+UYE^VK_R=_\ M/\ _9>OBM_Z
MFNLUZ;^P3_R4'XD?]DFUG_U(_"]>!Q!_R(<[_P"Q1F7_ *A5C[WPB_Y.UX9?
M]G#X,_\ 6DRT_0^OS<_;F_Y*'\-O^R*>$_\ U(O&5?I'7YN?MS?\E#^&W_9%
M/"?_ *D7C*OP?P/_ .1IGW_8NPW_ *E'^QO[7#_DA/![_LK.)/\ U48 L?L*
M_P#(\_%G_LB&M?\ JPOAI7Z-U^<G["O_ "//Q9_[(AK7_JPOAI7Z-U/C?_R-
MLD_[%U?_ -26:?LD/^3?>+W_ &660?\ JDK'XM?&_P#Y*Y\0O^QGU'_T8*^X
M/^"2'[26L_L?_MEZ-^TWX>\-:;XQUOX+_"3X\>-=,\,:Q>W.G:9K-W8_"7Q7
M#%9WU[9Q375O;L;C>[P1M(0FQ2N[<OP_\;_^2N?$+_L9]2_]&"O3/V4_^1O^
M)_\ V;A^T+_ZJSQ%7[]DFF3Y1_V+,!_ZBTC_ !A\2/\ DY/'W_9<<4KY//L>
MF?U0?\1FW[2G_1FWP6_\+[QI_P#*^OT3^"?_  =3:S\1_AEX9\5:S^R'IR>(
M+N*]M]?CTSXH3V6D)J=GJ-U;N-)BNO"^HWC6)MDMB)+N=9FG,X\I8Q&6_P Z
MVOUC_9,_Y(QHO_85U_\ ].EQ7RWB1Q#FG#G#T<PRJO"ABGF.&P[G4HTJ\?95
M:>(E./)5A*-VZ<6I6NK:/5G](_0:\'N!_'7QMJ<#^(>!QF8</QX,S[.E0P&8
MXK*L0L?E^*RBEAJGUK!SA5<(PQ5=3I-N$W)-J\8M?WO_ +&__!>5_P!JW]I7
MX6_L^3_LW'P6OQ+U75-*3Q/#\1EULZ3)IWA[5]>6:32W\+Z9]JBE&E&U8)=Q
MO&TZR!7"LM?T35_DL^/?CS\6?V9]'M_C-\#_ !CJ'@#XF^%-1@C\.>+M)2V?
M4]&;6X;C0]0GL6NX+B*&YDTW4;N".X$9E@,OF1,LBJP\4_X?A?\ !63_ */J
M^.O_ (4%K_\ *^GX;<0YIQ%P]/,,WK0KXI9CB</&=.C2H)4:5+#2C%PI0A"Z
ME4J/FM=W2;T5J^G'X/\  7@9XV4^!_#S X_+\A7!V0YQ4H8_,<3FM=YAF&)S
M2&(J+%8N<ZOLY4L/04:5U"$H2<5>3/\ 81HK_+F^$W_!U?\ \%5_A;\/O#?@
M*]UGX)?%.?PY:260\=?%'X>:SK/CO7(3<330/XAU;0_&?ARPU*ZMHI$M([S^
MR8;J:W@B:\ENKKS;F7]?_P#@DC_P<O\ [3W[4/[6]M\//VUM:_9C^%?[/6G?
M#CQQXO\ %WCO3_"^M^"&T.[T2WL8M":Y\1:WX[UG3K2UO-7O[6Q>.:PD:YEN
M(H(GCD=6'Z"IIZ=_Z_KT/X[4DW9/5^3_ ,C^YJBOSD_X>]_\$P/^C[?V:/\
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ME6H*:IQDHU*<VI3HRDO=]Y)<T)-2Y6XQ:M:2V<L&BBBMCRPHHHH **** /\
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MVO:3::IHSQVP51;*=/NK?%OM7R/]5M79@==3$%%%% !1110!_B9_MJ_\G?\
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MHP/],S_@T3_Y1B>+/^SEOB)_ZCO@JOZG*_EC_P"#1/\ Y1B>+/\ LY;XB?\
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M)_@?\-EA26ZE6)'E*Z&S!%+ L54G . 37U7_ ,/Q/^"YO_1QGP2_\,GX#_\
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MCB)\KJ0A)1E**2>BDTFW;\&<WA]X+^*OBMALRQGASP'Q'QCA<GKX?#9I7R/
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MV#P?X4UOQ?JNV1O#!4SMIFA7:6T7!EN6BCR Q89'_#\3_@N;_P!'&?!+Z_\
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M-.DU2]BM4X5CND<_=CC4%G=CV55!+'T![XKK-7U&*40Z98!XK*S!1%  \YE
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M^IZMJ37_ (AU:":UBEU&Z?9IL:.8HU1YSMC6..,K&$"*'7&" !]I_P#!,/\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'COC3]G?\
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M#U^TY'_R0V4_]DK@?_532/\ +CQ7_P"4G_$?_L^_%O\ ZW^//X-*^!_V]O\
MC_\ @+W_ .+6^*/_ %=OQ3_ETK[XKX&_;V_X_P#X"_\ 9+?%'_J[?BGFOPKP
M2_Y*'-?^Q-+_ -3L&?ZV?M9_^3/>&O\ V<>?_K-9N<I^P#_R<2__ &0_]J'_
M -9M^*E?I)7YM_L _P#)Q+_]D/\ VH?_ %FWXJ5^DE>GXY?[QPW_ -><T_\
M2\ ?"_LB?^13XZ?]C'@'_P!1N+#I-9_Y ?@;_L7]5_\ 4U\4UXA\5/\ D :+
M_P!C[\/?_4QT>O;]9_Y ?@;_ +%_5?\ U-?%->(?%3_D :+_ -C[\/?_ %,=
M'K\VG_R5>4_]>N&O_51EA_;^&_Y1B\1_^QIXY_\ KTN-STNNP\5_\@?X5?\
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MW(\1#)YT+*Q4$,!RGB'X>:YX3B/]K:>RQ-^]CFC FCFC=25(<,6'R8Y7@]"
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MFGW<0#"-_F@?CS()(=WF0RH21(DB@\9!(^:OR4EN!*%BR1MP=DQP&? RRG@
MMQE25W=_=VG>+_$'@R^$FF:K?:-.Q#'[+,\<3AE!4R0@^7(K @\AL@Y[UU4L
M*^2%..DXJRYM>>*LHO6[O9VZ[+Y?-5.).3$XC%5HWPV*K.K.--*/L*]6SJ*.
MT'&<KM0ERRT;OO?]CBT<P.V2<R<;0K+$5&#]U@!@ CYMV>2"< U\_?'/XJ^'
M?#/AC5?#^J?8M6OM>TRZL(K"VO[:ZN[>22,HEQ?H@<6ZQ/MDB=B)'8?NQG)'
MP5KGQJ^(NN0/;WOBW4FM900\=K<?9$D'&%<6OEY'3 /OP>WDMQJAF9Y)YC(S
MDEF=FDD8\_>D<LQ/<Y)/4UU4<'+24G;5745H[)63;VZW/#S#B:E.,XX>GS2G
M%Q]I5Y4DY))M03DI>Z]+R6NMGLWS*LB,=V\EB4#/M8+GID#)'?/O4FIQ/)X:
MMIIN)+2_>%-Q9F,<R*^-Q. H;)"@=23GFL]+NR9AYDS*O?"@_3&#VZG]*@U7
M5DNX8;*V5EMH&+[G/S2R'@N1D@ #A1P0/K7H)2O%)62ES-]E;5?/:WW['Q3J
M4HTZSE)-SI.$8)ZRDY0:;7:*7-=]K==/]*[_ (-$_P#E&)XL_P"SEOB)_P"H
M[X*K^IROY8_^#1/_ )1B>+/^SEOB)_ZCO@JOZG*[8[+T7Y'!'9>B_(****8S
M\J?@#_REI_X*#?\ 9"?V0/\ TT^.:_5:ORI^ /\ REI_X*#?]D)_9 _]-/CF
MOU6JI;K_  P_](B<V%^"K_V$XG_T_,****DZ3\K?^"GOP7^+/C^/]E;XL_LX
M:A\-;S]I;]FOX\Q_%/X3?#'XH>)8O"^A_&:W?PEKOA_Q[\/K'4V=IK76KWP=
MJ>I7FFWT-M<+836OVBX\B%6GC_-;]L7]G/\ X*'_  PU']NG2?@3\(?@=XI^
M '_!2+P9X?UOXM^-?B/\6](\%:9^R'XZO/A]%X&^+OB7Q!;:RL%IXT\,3Z6T
MFK6FIZ6$N3>Z7:M<6X2-4N/5/VK_ /@B'\>_C]^TMX1^-W@__@J%^UQX#\-:
M9\5/&/CZQ\(2>)8-3D^"EGXF\/ZI8"T^!E],C/ILPGOFT61-79HHO#%U<6L<
MCR11K)!XN_X()?%/XF>'-6\!?%C_ (+"?\%$_B/\-?%-M_97C;P'K_B[PU)H
MOBWP[/(AU'0M25[.=?LNH0J8)6:"8*&W>4^-I7R>CNMM>G?MWZ>8T[6]==/-
M?Y+L?N?^S[X-@^'7P'^"_@"U\1V_C"V\$_"KP!X3@\5VDR7%IXDA\/\ A72M
M*CURSGCDFCEM-42U%[:NDTJ-;S1E9'&&/K]<9\.? ?A_X6?#[P/\,_"<4\'A
M?X?>$O#O@KP]#=3FYNH]%\,:3::+IBW5P54SW/V.RA\^;8GFR[WVJ&VCLZ8@
MHHHH **** /Y5?\ @V9_Y''_ (*Y_P#9\%Y_Z,\<5_557\JO_!LS_P CC_P5
MS_[/@O/_ $9XXK^JJIA\*^?YL;W^4?R044450@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *BFAAN(G@N(8IX9!MDAFC26)UR#AXW#(PR <,",@'
MM4M% 'R)^UA^Q)\#OVSO FA?"_XT6OB9_AUI?B_1O&&L^#O!VMIX2TCQY/H4
MIN-/T'QVVGV#:AKGA5;G%S<:%%?6%O=SQPR7+2&"'R_J/P]X>T+PEH6C^%_#
M&D:=X?\ #GA_3;/1]#T/2+2&PTO2=+T^!+6QT^PLK9(X+6TM;>..&&&)%1$4
M "MBB@ HHHH **** "BBB@ HHHH \K\6_ SX*>/=8D\1>.?A#\,?&6ORV]O:
M2ZYXJ\!^%_$&KR6MHK+:VTFI:KI=W>/!;*[K!"TQCA5F$:J&.?E;]J[]@OX4
M_&?]G'XP?"GX3?#3X*?#'X@>/O!M[X=\.>-X/AOX>TTZ'>74]M*9IKSP_I-M
MJ\5O+' \$YLI1(4D/RNH*-]^T5A6PV'KPJ4ZM*$XUH3IU/=2E*,XN$ESJTTW
M%M<RDI+=-,]# YKF.6XG!XO!8RO1K8#$T,7A6IN=.E7PU:->C/V-3FHS4*L(
MRY)PE"5K2C)-I_Q??\0UW[5G_1>?@1_X ^.O_E97\OW_  7"_92\6_L5?M%_
M";]GSQSXF\/^+O$WAOX(0:_?ZWX7@U"WT65/&?Q+^(OB.TMK5-32.]9K2VO8
MH)Y)8XU>97\M=@#-_K%^-/B9\.?AO_8'_"PO'O@WP+_PE>MV_AKPP?%_B71O
M#@\1>(KS_CTT+1#J]Y9C5-8NO^7?3;(S7DW_ "SA:OG+X[?\$^OV)/VG_&</
MQ%_:#_9?^#?QA\<P:-9^'X/%?CKP=IVNZTFB6$MS/8Z8M[<H9/L=K+>7,D$6
M2J&=\<&OG<CX,X=X<KUL5DV!>$KXBC]7JS>)Q5?FH^TA4Y.6O6J17OTX/F24
MM+7U9^T>+/TE_&GQQR?+<B\3N,9<297E&8O-<NP[R7(<M^KX]X:IA)5U5RG+
M<!5J7P]:K#V=6I.G>?-R*2C)?Y+'_!,O_D[KP5_V+GCW_P!1+5*_V:Z_.+3_
M /@D/_P3/T-KRX\,_L8? _P?J=YIFH:3_P )!X,\,?\ ")>)K*SU6UDLK[^R
M?$GAZYT[6]&N9K:62(7NEWUI>1*[&*="<U] ?\,E?#+_ *&S]H7_ ,2E_:-_
M^>?7U$8VT;_#T7?MJ?@R5HJ*U]YN^VZBK==N5_@?YJG_  <T?\I*/'O_ %TU
MO_T\R5^$GPB_Y*AX"_[&G1__ $LCK_3;_;W_ .#:']ES]NOXOZ?\7-3^.GQQ
M^%MY:^'QH][I.EZC;_$276=1?4+O4+WQ#JGBCXFW?B+Q3=ZC?/<K%+%/JDMK
M#%;PI:Q0H"E?D!^V5_P:Z_LX_L0_LV?$K]JOP=^TS\;/&GB7X,P^%_$>D>%_
M$OA[P+:Z'K%Q>^-O#?A][;4;C2[&&_BA2#6)9U:VD5_-AC!RA8'S,X365YG+
MHLOQC?HL-4O^OW>E_K. H2GQ[P5RV;EQ;PTDMM?[7P*MVW/Q6K\@OVF?^2S>
M+/\ ?L?_ $BAK]?:_(+]IG_DLWBS_?L?_2*&OYO\$_\ DI,R_P"Q+5_]3<$?
M[E?M8O\ DQW 7_9T<'_ZRW$QPOPG_P"2F>!/^QIT;_TMBK]MZ_$CX3_\E,\"
M?]C3HW_I;%7[;UW^./\ R,<@_P"P+&?^GZ1\9^R-_P"2-\:/^RFX2_\ 55FY
M_6-_P:U?\DV_;L_[.$^'_P#ZJ+0Z_07_ (.!_P#E%S\;/^QS^!?_ *NCP/7Y
M]?\ !K5_R3;]NS_LX3X?_P#JHM#K]!?^#@?_ )1<_&S_ +'/X%_^KH\#U^TY
M'_R0V4_]DK@?_532/\N/%?\ Y2?\1_\ L^_%O_K?X\_@TKX&_;V_X_\ X"_]
MDM\4?^KM^*>*^^:^!_V]O^/_ . O_9+?%'_J[?BGBOPKP2_Y*'-?^Q-+_P!3
ML&?ZV?M9_P#DSWAK_P!G'G_ZS6;G)_L _P#)Q+_]D/\ VH?_ %FWXJ5^DE?F
MW^P#_P G$O\ ]D/_ &H?_6;?BI7Z25Z?CE_O'#?_ %YS3_TO 'PO[(G_ )%/
MCI_V,> ?_4;BPZ36?^0'X&_[%_5?_4U\4UXA\5/^0!HO_8^_#W_U,='KV_6?
M^0'X&_[%_5?_ %-?%->(?%3_ ) &B_\ 8^_#W_U,='K\VG_R5>4_]>N&O_51
MEA_;^&_Y1B\1_P#L:>.?_KTN-STNNP\5_P#('^%7_9-=2_\ 5T_&*N/KL/%?
M_('^%7_9-=2_]73\8J\K*O\ D6\2_P#8IPG_ *O\F/T?Q._Y.+]'?_LY/%'_
M *YSQ*/#OB;_ ,BO%_V,_@G_ -3#0Z] 7H/H/Y5Y_P#$W_D5XO\ L9_!/_J8
M:'7H"]!]!_*L*_\ R)LM_P"P_-O_ $SE)[^1_P#)V_$3_LC?#+_U8>(QY[X0
M_P"1M^*G_8SZ#_Z@_ANIOB3_ ,BS'_V,?@__ -2O1ZA\(?\ (V_%3_L9]!_]
M0?PW_G_/$WQ)_P"19C_[&/P?_P"I7H]>M'_DJ<G].%__ %5Y4?DE7_E&;Q7_
M .OOTAO_ %X?B"=[72ZY_P @;P1_V+VI_P#J:^*JYJNEUS_D#>"/^Q>U/_U-
M?%5>=EG_ "+N(O\ L6X3_P!7>5GZ+X@_\G&\!/\ LLN+_P#UUG&IU/PC_P"1
MJUC_ +)7\>?_ %1'Q*KS&O3OA'_R-6L?]DK^//\ ZHCXE5YC58K_ ))W)O\
ML:9[_P"H^1'+PG_R?OQG_P"R'\%O_4KQ4.G\1?\ (.\$?]BE/_ZF?B^G>"?^
M1ITK_<U;_P!,6J4WQ%_R#O!'_8I3_P#J9^+Z=X)_Y&G2O]S5O_3%JE>LO^2N
MR;_NU_\ U696?EL_^43?%7_KW](/_P!>'X@'*)]Q?]U?Y"NZ\2_\B?\ "?\
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MPHHHKZ4_%0HHHH **** /SF^ O\ RD<_;\_[)M^R#_ZC_P 3Z_1FOSF^ O\
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M%PJ-]?:PFWTDMS^E-?CIX._:&^']AHMO:#1?C'X9EEO_  MK+K]E.J:J(O\
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MP/!&>*]$_P""OGPE_:\\=^'_ -E?XE?L/?"3PM\4/C]^SW^T)8?%'P_+XO\
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MA(1J5*?U;'8B+I2?*YRC/>"/P6^$_P#R4SP)_P!C3HW_ *6Q5^V]?B1\)_\
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M$8U=H9(&(2PO[I&6)7OKUZ^?FOU7W:;792V^)[Q[[;?Y'A/A?QMXO\%7@O\
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MN_FV?#YEG.<YU6EB,SQ^,QU6;YI3Q%:<[NR5TF^5:6TBDO(\.I0"2  220
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MB:[OHMKZE<L6,"?.M&VW5?U;\GZM>;;:BK1=VUJULNME^K[[;'^F9_P:)_\
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MBW]:_P"?E^?=BO\ /9:WZ?/2_P"&R/Y+_P#@UDC\6Q-_P5+B\?7&BW?CB/\
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M=/A[B5Y^\;6XCIYS'%1EEF,RYX5489/EKHM/%JK[5U9JU-QY+R37\%?[ /\
MR<2__9#_ -J'_P!9M^*E?I)7Z_WO_!L-X^_8$\$_&']K/6OVI_"'Q!TWX3?
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MK6/^R5_'G_U1'Q*KS&O3OA'_ ,C5K'_9*_CS_P"J(^)0_GQ7F-5BO^2>R?\
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MVC1>,+C2'UV'1FL-?TK6_.DTJ.\L'NEF&FFVVK=Q%#,),MLV-]KT4 ?P5_\
M$%[XI_Z/HT'_ ,,YJ'_S9T?\07OBG_H^C0?_  SFH?\ S9U_>I14\D>WXO\
MS%RQ_E7X^7GY?B^Y_!7_ ,07OBG_ */HT'_PSFH?_-G2K_P9?^*T8,G[=6A*
MRD,K+\'=05E8'(((\: @@\@@Y!Z5_>G11R1[?B_\PY8_RK\?+S\OQ?<_B?T'
M_@TP^(!TRU\,?$?]LWP7\4O"5MB.WM/$_P &M6_X2+2(2-I_X1_Q=:>.(-=T
M\QKS#:SW5YIJD -9%>*\V\8_\&8MK=:O)/X'_;6&DZ-(-R:?K_PKEU.[MG/)
MC2]M/%5FLT2\A&D@63 &\DY-?W4T4<L>WY_GO\AM)VNKV[Z]NN_3OW/X*_\
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MH_X@O?%/_1]&@_\ AG-0_P#FSK^]2BCDCV_%_P"8N6/\J_'R\_+\7W/X*_\
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MJ\C6_P#8YE:Y^T*'\_8(QY>YOU9HHJMAA1110!^4_P  _P#E+9_P4$_[(/\
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M&P^(4\0ZKHMWI-]>/'?_ &2WE1&D@WQ_TU4U_77^NXFK?A^*N%%%%,04444
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M-,;RB_T/2FO!?:K9-%%)(MU8P3PE(W8.0I- '<45YK!\9?A'=6WBZ]MOB?\
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M7FL@_'/X+CPK8>.O^%M?#;_A"M4U0:)IWBX^-_#8\-7VL,[1+I5GK?\ :/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RG^
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M7CA?".A#Q9KGA^>."*71=6\0+8+JNHZ5+':6D<NGW=W+:O';QQF,K&M>F44
M>&K^S'^SBG@:X^&*? ;X/K\.+O7!XFN_ B_#GPD/"-SXC#(RZ]/X>&D_V5+J
MX:-"-1>U:[!1<3#:*Z2?X+?"&Y\6>$_'=Q\+?A[/XU\!Z6FA^"/%LWA'0I/$
MGA#18DEACTKPUK+:>VH:+IZ0SSQI9Z=<6UNB2/&$VNQ'IU% 'C=I^SM\!+"T
M\>:?9?!?X6VEC\4Y$F^)EG;>!/#4%K\0)4EFG63QC!'IRQ>(V6:YN)@=76\)
MEFD<G<S$I=?L[? .]TWP)HUY\%?A5=Z1\+[G[7\-M+N? /AB:P\!77FQ3FY\
M'VLFF/!X<G\^&.?S=)CM',L:.3O4-7LM% ?U^GZ(\V@^#?PDM?&/B3XB6_PR
M\ P>/O&.E?V'XM\:0^$M"B\4^)M&^SQ6G]E:]KR6(U/5=.-K!#;_ &.^NIX/
M(BCBV;%"CE5_9B_9Q7P*WPP7X#?!X?#=M=_X2=O 0^'/A+_A#CXC+*QUT^'/
M[)_L@ZN656_M'[)]JW -YF17N=% ?U_7W'F#_!/X.R>,?#WQ#D^%GP]D\>>$
M=)BT'PMXSD\(:"_BCPWHD$4L$&D:%KK6!U+2M-AAGFBCLK&Y@MHXY'18@K$5
ME6G[/'P%L-*\=:%9?!?X66NB?$^\EU'XCZ1;^ _#,.G>/=0GE>:6\\86<>F"
MW\17,DTDLKSZM'>2EY';?R<^R44 >-W'[._P$O+'P%IEY\%OA9<Z?\+)(YOA
MI8S> _#,MGX EBFBN8Y?!MK)IC0^&GCN((IHVTA;5DDBC=6#*"->T^"WP?L/
M%?BKQY9?"WX>VGC;QSILFC>-/%MOX/T"'Q)XLTB5$CETOQ'K4>GKJ&LV$L<:
M))::A<7$$BHJNA &/3:* /"Y?V8?V<)_ D'PNF^ WP?E^&UKJ[Z_:^ I?ASX
M2D\'V^N2%B^L0^''TEM(CU1F=B;Y;07)W$&3!-=2_P &?A))XUT3XDO\,? +
M?$+PWI*:#X>\<-X3T,^+-"T2*WDM(M(T?7_L/]J:=IT=I++;1V5I=16T4#M$
MD0C8K7I=% 'B]G^SC^S_ *=X>\9^$[#X(_">S\+_ !%O/[0\?^';?X?^%HM$
M\:W_ )OG&\\5:7'I:V>OW/G?O?/U2&YD\TF3=N))M7W[/_P,U*#P#;:A\&_A
M??6_PJ:)OAE!=^!?#4\?P_-NUO) ?!BR::P\-&.6UMI$.D"UVO;PN!N12/7J
M* /+(_@;\&(O$7C+Q=%\*/AU'XJ^(NF3Z+X^\1IX-\/KK?C31[J 6USI?BG4
MUL!>:]87%NJPS6FIS7,$L2A'0J *P6_9E_9TD\$:;\-)?@1\('^'FC:T/$>D
M^!6^'7A-O".F^(%D>1=;L?#ITG^RK750\CL+^&U6Z#,29B>3[C10']?U_P
M\VF^#?PEN/'6G?$^;X9^ Y?B1I&D#P_I7CR3PGH;^+]-T(0RVW]CV'B)K$ZM
M::9]FGGM_L,%W';>3-)&8BC%:YN#]FO]GJU\->+_  9;? [X2V_A'X@:FFM>
M.?#$/P_\+)H'C#5X[E+N/5/$VD#2O[/UN_CN42X2YU*WN9A.B.'!4&O;:* /
M);GX"? ^\D^'\UW\'_AE=2_"@PGX827'@?PW*_P\-L8FMO\ A"VDTYF\,_9S
M#"8?['-GY;1(R!2JX?!\!_@E:Z[XU\3VWPB^&L'B/XDV$^E_$+78?!/AV/5_
M'&FW("W%AXLU%=.%UX@LIU 6:VU26ZAE  ="!7J]% 'AL_[,G[.=SX.T/X=W
M'P)^$4W@#PQK#^(O#?@J7X>>%'\*Z#X@E>5Y=;T?0&THZ7INJR--*TFH6EM%
M=2&1]TO)SUA^#_PI;QW!\43\-? A^)5IH_\ PCUIX_/A71&\96V@&W^R?V-!
MXD:Q_M:'2_LI-L+!+L6H@)B\KRR5KT:B@/TV^=O\D>)6W[-?[/-GX6\4>![/
MX&_".U\&>-]476_&7A2#X>>%(O#GBK5XY!,FJ>(-%32AIVKZ@DJK(MW?V\TZ
MN-ZR*X!K1NO@#\#;V^\!:G>?!_X9W6H_"RU2Q^&E]<>"/#<]YX LHFB:*U\&
MW,NFM/X;MXV@A9(='DLT5HT('RBO7** /*[7X&_!BQU3QYK=E\)OAO::Q\4K
M>2T^)6J6W@OP]#J/Q M9D>.6U\97D>GK/XD@D61Q)'J\EY&ZNX9"6).+-^S1
M^SO<>$/#OP_N/@7\(IO OA'59-=\*^#I/AWX4;PQX<UJ622635=$T(Z4=-TS
M49))9)'O;.VAN&=V8OD\>W44 >;K\'?A1'X\?XIQ?#3P$GQ+DTB/P\_Q 'A3
M1%\8MH,,1@BT=O$8L?[7;3(X"84L3>?9A'\@0+@#F8?V:/V=K;P=X@^'EM\"
MOA%;^ O%FKMX@\4^"X?AWX4C\+>(M<<H6UC6]!32ETS4]38Q1EKZ]MIKD^6N
M9,@$>W44 >3S_ ?X)76J^!M=NOA%\-;C6OAC96^G?#C5I_!7AV74? >GV85;
M2R\(7DFG-<>';6V5$%O!I4EK'"%41JH I+/X#?!/3KKQ]>V'PB^&EE>?%6*X
M@^)MW:>"/#EM<?$&"[#BZ@\9RPZ<LGB6*Y6647":P]XLOF/O5@Q%>LT4 >)W
M7[-?[/=]X2\+^ KWX'_":Z\#^"-2.L>#/"%Q\/\ PM/X:\*:JUPUV^I>']$F
MTM]-TF_>Z=[AKRPMK>=I7+E]Y+'HO^%-_"7_ (3JY^*'_"LO 7_"RKW2CH5[
MX^'A+0AXQN]%:V%FVDW/B,67]KSZ:UH!:M92W;V[6ZK"T;1J%KTJB@#PZ']F
M7]G2V\$:S\-+?X$?""#X=^(M5CUW7O L'PZ\)Q>$=9UJ&6.>'5=4\/)I0TJ^
MU&*>*.:.]N+22X21$D5PZ@UOW?P/^#-]KW@GQ5>?"CX<W?B;X:6,>F?#OQ!<
M^#/#TVM>!M/AB$$-CX2U233WO?#UI%"HBC@TJ:UC2,!54 8KU*B@#R*U_9_^
M!=B_CY[/X.?#"T?XJQS1?$V2V\"^&H)/B#'<M,]RGC22/35?Q,L[3RM*-8-W
MO:1V?<6-5+G]G+X WGAGP?X,NO@E\*+KPE\/M2&L^!/#%SX!\+S:!X.U99&E
M74_#&DR:4]AH-^LKM*MWIEM;S*[%E=6PU>T44!_7]?\  /,Q\%_A"OCG4_B<
MOPO\ +\1M:T>7P]K'CL>$=!'B_5-!FABMYM&U#Q&+$:M>:9+!!!!)8W%W+:O
M!#'$T110!S*_LQ_LY)X(OOAFGP'^$"?#K4];'B34O J_#KPFOA*^\0AE<:Y=
M^'AI/]E7.K!XXS]OFM6NOD7]Z=H%>Y44 >8W'P4^#]WXE\'^,[GX6?#VX\7?
M#S3HM(\!>)YO"&@R:_X,TJ*,Q1Z;X7U9M/-]H-C'$S1QVNF3VT(C8H$52169
M:_L]_ FQ3Q_%9?!KX7VD7Q6&/B=';^!?#4*?$$>9/*!XT2/35'B93+=7$I&L
M&[&^:1\;G8GV&B@#Q6Y_9O\ V?;W1/!?AJ\^"/PGNO#WPWO3J/P]T.?X?^%I
MM)\#WS31W#7GA33Y-+:UT"Y:>*.9I]*BM9#*B2EC(H>NA@^#GPGMO&FN_$>W
M^&?@*#X@>)](&@>)/&\7A/0T\6:_H8@BMO[(UC7UL1JNHZ;]G@BM_L5W=SP&
M&*.,IL4+7I-% 'P-^U'\._ /P-_9<\8VWP9_8-\$_M)V]EXBT3Q#9?LR>"_"
MG@#P]IWBS7KS5K&UO/$B6.KZ-+X<75-'M"VJ27UQ837<B6*1QN'V$?S+?\%+
MO^"BW[</@'P?\(OV@M'_ ."6_P 0?V,?B?\ "#QMX5T+P!\3O%E[\#O&>F>*
M-)OY3IR_!J;1[GPE+XPN-.UBWDFBTK3_  %JFE:K9%KF:#=")!'_ &Q5YQXZ
M^#_PK^)^I^#=9^(WP\\'>.=4^'FMGQ)X%OO%7A_3=<N/"?B HD8UK0'U&WN/
M[,U14CC"7MJ([B/8NR12*3NU:]O^#;_(/N_JWR?W=3^>3P3_ ,%B/^">.A?#
MCQ'X7_: _9-^)/P"^.WQ.T6WE_:1^%5I^Q=XY\9Z+<^.[NR%U=+XHU/P[X+F
MTKQ[9-<W@U&VEU*>YN##=F&\,=Z+FG_\$@/^"@OP#_X*'^+_ (@_LP_$K]G#
MX3_\)]^R)KNH^)?A%XF\._ '4?!_PX7P'-KD2:5K'A[PKXYT1]5^$7CFUNKF
MRDU/P_.VGSWDHFO].:5+64C^D35_#^G:Q8W]E+&;22_M;FV.HV,=M#J=HUS$
MT)N[*[D@F\B\A#"2"<QR>7(B-M;:!7PW\,?^"<'P#^!7P#^,WP-^!E_\0?AA
MJ'QVE\4ZGX]^-^E>++J_^.^I>*O%33-<^,)?B)?1OJ4FNZ:\Q;1I"JV^FA?]
M'MT=Y&=Z][K7IZ>>_=Z=--='IKH]7IN_^&^Y_+5OT;XY^)/V-OV4K;Q#^T5\
M<-+^%7PLC\;7.F> ?&GQ=U;P58QW>M)XA=+&PT7QIXIT[1;J];1;PVT<$LOB
M"Y31HUA1;J:-0@KH-._9=_9 \4^"-'TW2_V?_P!GOQ#\/;Z*#7]!M;3X9?#_
M %7PQ=0ZBS:I;:KI:+HL^GR17CW;7\-U;929[AKA68RLS?SS?MP?\$(OCQJ7
M[/7B_P *_ C]M3]O?]HKQYXV:Q\*P> _BY^TQIFF_"JWTO5+J)-3U_Q_;:O9
M;M;T'1[5&NGT32K>?4[^X$,=O&@W2)^Y_P#P3C_9#U;]A?\ 8^^$/[-.O?%#
MQ-\7-9\ Z-(FJ^*_$E[+=QIJ&HSO?WFC>&DN ;FP\):1<326>@6$\DLD%H@8
MF/S/)CG5W36EEYZ[V^3^YJ_5 FXV<6T]KIV:5K65M=KKLUIWMZMJ_P"Q]^R?
MX@GCNM<_9G^ FK7$.DRZ%#<7_P (_ =S-#HTUO):2:7%)+H+/'8M;330&!&2
M,1N5"YY'C2_\$M_^";JI=QK^PE^R:L5\_F7L2_ 7X;JEY)N+;[I1X?VSL&)8
M&1203UK[RHH<(/>$7LM8IZ)W2VZ/5=GKN:1Q%>/PUZT=)K2K-:5(N%1:2VG!
MN$EM*#Y7>.A^-'QH_P""#G_!._XT>,-/\7R_"^\^%_\ 97A[2O#>G>%O@Q=:
M+\.O!-A:Z1=:I>V][9>&-(\/&PM-4FFU>[^V7UN(Y+E!"L@/E+7P9^VE_P $
M!_V,?A?^RQ\?OB3\)_!'Q?\ '?Q6\._#S4M7\'Z!/XGO_%4VL>(]/DMI=-+:
M%HVBVVH^()[1E:>WTT&:*X=-LEM*HVU_422 "3T )/?@>PYKP+X/?M1_L_?'
M_P 1_$SP;\(_B=X?\9^+O@YXFF\(?$_PI;IJ6F>)/!?B"!W1K/6-#URPTS4T
M@E:-Q:ZG!:SZ5>[&^R7L^UL>3BL@R?%2K5JF6X%8NM&2^N_5,.\53FTN6K"M
M*FYQJ4Y1A4@[Z3A"6\4S[G)O%#Q R3#8++,'QCQ0L@P5:E4?#?\ K!F\,@Q-
M"'M(5<'B,LI8R&%GA<5AJ^)P>)I^S2JX7%XFA+W*TXO_ #9?^&3_ (]&T%DO
M[+_QK^PK)YZ67_"B?B"+99 2XF%L?"0A63^/>%5P><AJQOB3\.O$/@6;P+I_
MCKP+K/@SQ5%X1N;E--\7>&M0\.>)+;3;WQ?XJ:TF-CK5G::G;VEW&C/;LT,4
M<T8+IO1@Q_U+]J$8VK@^@&#GG]>M?PM?\'"G'_!08*.%_P"%&?#<X'3/]J>,
M.?\ /OZU^&<8< 8/A'AC-LQPF:YGBZM>.$P<Z>*G3Y%"OF&#JU9KV4(2<INA
M&,E)M.+?-S/EM_K']&OZ6W$'TD?I!^%G"'$OAYX?<.8'()\2Y_AL1PWE^,IU
MZM?*N".(L#EN%JQQ^*Q='ZM@/[1K8C!^SA">%KQC+#RIWE?\9?ACX5\-:IK^
MMZ=J/A[1+[3I_AU\:]2N;&[TNSN+6>_T_P""OQ!OK"^EMY(3%+>V5]:VUW:7
M$@:2WN+>&:-@\2;> ;2=-<V9?3[%S8,&L2]I YLF'1K0M&?LS#J&A"=N.*]?
M^$7_ "-6K_\ 9+/CO_ZHOXD5YA7Y%BJ]9Y!E$O;5>9YGGMY>TG=_[-DL=7>[
M]R3A_A;CLVC_ $<X3R/)?^([>,>&_LC+/JU'@7P65'#_ %#"^QI1>9^*&,<:
M=+V7LX1^N4:6+M&*7UFG"N_WL8R6KK>B:-;6WAB^M=)TZWOM7\*ROJ]W%9VZ
M7&INGBWQ;;QO?2I&LETR6T45N#.\A\J-%W;1MJ#PEX=\/W.M:3I-UH>D7.DA
M]3N/[,GTVSEL?.BT75)XYOLDD+VYFCF1)4D:(E9$5Q\P!K:\0_\ (-\$?]BG
M-_ZF?C"D\%_\C1I7^YJ__I@U6O4A5J_ZV9/'VM5+FX8T52:^'+<NC%JSWC%N
M,?Y8MI:-H_-:^4Y74^BMXJXJ>78">*6'^D1!8F>#PTZZA5\1..ZE2*JRI.?+
M4J8?#U*B;:J5*%&<U*5*#CQ2Z?8FXAOC9VAO(H1%'=FWA-U'%LV^5'/L\U(R
M"045PI!(Q@D5U6O^&_#MMX1^'36V@Z/!_;GASQ1<:UY6FV<?]K7-K\4/&UI!
M/J02$"]EAMK>&WBDN/,:.""&%2$C4#!3[B_[J_R%=QXD_P"1/^$W_8K^,/\
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M5_ *#XC7.@ZA\&_!?@Z[\6_$70OV8O'_ ,71\1O'7BRRNM9CLD\->!9]2LO
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MZ%;'PQV#E'"8^G6<\=@\-AYNE6HTJ\ZRC"7]# Y /K17Y!_%/X__ +7FE/\
MMH^*/!WCGX<:1X/_ &1KK0SIFE:O\/9]6U3XC7$?PI\'>/->T;5-1C\26D.@
MV=Q/K4Z6>HZ?;75W;-J"QNDD>GH9>RTC]HW]H?X:_$KX1-\9?$'@7QAX*^-G
MP3^(_P 4QX9\(^$[GPYJ/P^U/P%X3L/&ZZ/I^O7FMZB?%5A>Z7=R:6]QJ-KI
MMR+R!+M%6.4PKS/AK&^RC5AB,!5E*E*JJ$*]55K0P-',I0M4P\*7.L'7A5:]
MKR\UZ7-[5<AZ</$7)Y8J>'J8#.:%*EC(X.KCJV'P:PE.4\]Q?#5.M)T\?4Q#
MHU,YP=;"0<</*JX\N)]DL*Y5H_J517X2?"[_ (*&_'?Q<_PB\?)%X@\9Z=\4
M/&7A.PUOX+:%^S#\6](M/!?@SQCJ4=BFNZ7\;KW3SX>\0W/A6VO;+5=8NIHX
M=%U.TBO#ILH14=_2O$?[17[9%O\ #+]J']H#2O&WPLM/!7[/'Q9^(.@Z+X N
M? -U?ZCXY\'^!M1L(]0MM5\2KXD@_L34FM[F>VTR\T^QNEEDC%Q>PJI5!M4X
M2S.C5C2K5<'1G*K2P\55J5H.6(JXA8:-",7A^=R]K)+VBC["47STZTXIM<.'
M\5^&\9@WC<#ALVQU&&&KXZI]4H8&M[++\/@'F53&U:D<P^KP@L'&4Y825=9E
M3J*-"M@:=>K2IS_8"/5],EO[C2X[^SDU*TM[>[NM/2YA:]MK:[>6.UN)[57,
MT,-R\,JV\LB*DQCD",2C8AUO7M&\-V)U/7]4L-'TY9[6U:^U.[@LK475]<PV
M5C;&:X>-#/>7EQ#:VL0)DGN)8X8U:1T4_EU\ 8OB)XB_X*%?M)>,&\=V1\&:
ME\'?V=]?E\%OX4MTO&TKQ#H'B>\T#34U\:CYMI+H=Z;Z\N[I+69M5-ZEM)'"
MEHLLGKWQYN'\??MA?LL?!C5"9O!^C:1\0OC]J^ER,#;:_P"(/ 4>F>'_  9:
M7D+#9/;Z-K'B=O$D,<C;%U'2[&XVLT"LO)4R54L=2PDL2IP_LJEFN(G3A+FI
M0>7+,*U"U2,(NI%7I1E%RIN\9IM7BO7H<7U,1DU?,XY=.A5?$];AG T<16IN
MGB:G^L7]@87'2G0G5E##5&UBZM.<85X1A4I*FVZ<Y_9FA?$/P)XGU_Q#X4\/
M>,/#.M^)_";PQ^*/#VEZYIE_K?AY[G)MTUK2[6YEO=,:8 ^6+R"'>00N2*>?
M'_@<>+9? /\ PEWAL^.(=+_MN7P@-:T[_A)8]'WA/[4?1!<_VDFG[RJF\:V$
M +*"_(S^"_P'F;X5?\%&_P!H?XRR7KV?AGQ_^TUXD_9O\9YDE6RM)]8^'F@>
M.?A_J5RS8AC9-:T35M(2201KY^LHBLWF$U;^&UKK?CC]O*\^/FD7T$'B3X]?
ML]_M,7G@JXUFZ>ST?3O"7@CQ?H'P^^'%U<7+*_V72[R#1Y?$4]TD,S&#5D<Q
ML(P3[-3A.C3G5?UVHZ$<BH9E2JNA&\\?4PCQ57 S2J>Y"$*&+DJJO)PITVX)
MU$CX_#>*6,KT<+%Y-16.GQKC^'L5AHXJ;4,DPV:4\LH9UA_W3G5JUZV-RNE]
M7DHP5>MBDJCIX=R7[0:'^TG^S[XF\1V_@_P[\;/A5KOBR\O)-.M/#.D>/O"^
MHZ]<W\+2)-9P:5::I+?2W4+Q2K+!' TJ&-MR#!KU30_$.A^);-]0\/ZOINM6
M4=W>6$EWI=[;WUO'?:=</:7]G)+;22)'=6=U');W5NY6:"9'BE174BOQL^#V
MB_$W]A3PM^R?X6^+?P__ &=?%W@WQ%XI\'?!FY\>_#73]6'Q"T+QMXSCOO[$
M\776K:Q8&#Q/8ZUK;2)J]U8KI=S#_:)NXA+ CJ/J[X-W!^'_ .V[^T=\(-.5
M;;PEXT\ ^ /V@-.TR,*+;3?%6LZAK'@[QK+;QH2MNNM7&C:5J=S$5C$]])=7
M(#M)(U>;F&2X>B\5/!5YXC#4</5Q%#$NK1JT\7'#8VGA,0X*G"G*BX*O2J^R
MFI246WSSA*$W[^1\99CB?[*H9U@J6"S+&8_"Y?F67QPV+PU?**^8Y+6S? <[
MQ%2K3QE"I+"8G!O%T)PISK\L%3IU:&(HQ^_:***^;/T<**** "BBB@ HHHH
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MMTC=G8DD_P!:=3#X5\_S8/?Y1_)!1115""BBB@ HHHH **** "BBB@ HHHH
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M?LV^!OA&_C/]DK5+WQE\0?#.O:/JFN^!?C#\#OB]H&C^,/! G2/Q!I&@^+[
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M77HN4%6I4\10G.%[QC5@W\2.H\0_\@WP1_V*<W_J9^,*3P7_ ,C1I7^YJ_\
MZ8-5I?$/_(-\$?\ 8IS?^IGXPI/!?_(T:5_N:O\ ^F#5:VI_\E;DW^+AK_U7
M9:?/U/\ E$_Q6_Z]?2$_]>#X@'+)]Q?]U?Y"NX\2?\B?\)O^Q7\8?^K9\>UP
MZ?<7_=7^0KN/$G_(G_";_L5_&'_JV?'M>9EG_(OXE_[%F&_]7>5'Z5XD?\EO
M]'7_ +.+G7_KI/$$\/\ B'_R +7_ +&;PC_ZDNF5W5<+\0_^0!:_]C-X1_\
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M:VNH3V+2O+:B*8^97XL_\1:W_!*7U_:+_P##20?_ #4T?\1:W_!*7U_:+_\
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M.W>2>831M"0@_"#_ (BUO^"4OK^T7_X:2#_YJ:/^(M;_ ()2^O[1?_AI(/\
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MYDAC;\4?^(M;_@E+Z_M%_P#AI(/_ )J:0_\ !VK_ ,$I#CG]HOC_ *I);_\
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M@AV,BE59"*^WJK<84444 ?E/\ _^4MG_  4$_P"R#_L@_P#IJ\=U^K%?E/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)_PF_P"Q7\8?^K9\>UPZ?<7_ '5_D*[CQ)_R)_PF_P"Q7\8?^K9\>UX^6?\
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M K\7_P#@X4_Y0^?MH_\ 8B^'_P#U._"]?M!7XO\ _!PI_P H?/VT?^Q%\/\
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M^$W_ &*_C#_U;/CVOC,L_P"1?Q+_ -BS#?\ J[RH_J/Q(_Y+?Z.O_9Q<Z_\
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M'IY9E[KUKU%RP@TYMIVW5HN]E>^_9)M7W7KGPX^"]QK\5O=ZD/[.T@$>7%M
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MS;5KINVNKT3O9VZ/7Y$_S_GZ?_JHJ>>)TFD4CD,00/4]@.O&<8__ %U%L?\
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MODM;G9&_VU0(_E5_X-F/^1O_ ."N'_9[UW_Z,\<U_557\JO_  ;,_P#(X?\
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MWVC?:U[R>FBZ==7]30IX6MAZEJ?LZB:BI\MN9)[.]]M$]>7S/SU\??"'1?\
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MSJ)Q<E.=URPLGLM6T]'9)Z-'-Z%X(TS1-,M[6VMK.WB$4;0101*B(A VD)C
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M+*3+(NDZE/<V :0ESY&6).37'?M ?$/XK_#/P(/$?P<^!.L?M#>+CJUC9?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!C/(QT'UTTMVBC9E$X=L*JD,ORG.&.X>@!.,@>N"*OI:SQ1([LX#YVF0,#M
M'\.&/X^F!7@3E'FM**C>W=N]HZ;77X;L_8,)@)UJ:5"NJM*+YZCIR33CHVDK
M^[>Z3U=^7N>=>(/ 'A[4HV)TZ ;0RI'N=&R<[MNT@ !AA1C"KP/?S'5O"&E>
M%[:&:*UM'5I'5PX8SC<=Q0229+8QC<,#&<\5]%2R-AC(T.Q1A0JL)"<X7EL9
M &2?4]N>/'?B=XFT_2-$GN]4N-L,2OP8D:1@5.(XE/=CA 2W\6<@5Z."KRG*
ME2AM[JO97W25T];:Z6\[-GQ_%&2X+"4\1CIU5&HZ;G[]_9P5E>SDG9VON]+.
M[1\=_';Q#IUS8Z1HME(DDRW#W,\:L#]G"KM17.T?,Q)QWR/<$?-*VA +88Y!
M)(7(&<]^P!]>OY5T'B34?[<UJ^U/:R1SW#21(Q!*0E@40X[@ 9XXYX[#TVQ\
M?^'H_ 5SX3N?!.E2:A*W[OQ#!(\%\N/G1I]T4[/*LAP?+DA1H_D9,DD_7Q<Z
M%&DHP=24FN>UERWM=M7^RK*WE=M'\Y5*=#-,?C*F(Q4,+&G"3H2G"I-572LH
M4U[.,FG46TFK+3=I'BL<:HP/7D<GMZ_Y_/BF2Q[UX !YZ#DBK$A&21[G&,>I
M_7/^1543^J_D?\:ZT[K^NU_U/$FDER:.U[Z*[UWONMN^AUWPRM-/N/B'X&L]
M4D\K3+CQ;X?@U"5C@1V<NJVL=R[$= L3,2?2OT<_;U^'.D_#KXRG3/#01-"U
M#0M/U2RAAE\U56>!5+JB@$*Q0L <D+MZU^<O@C1)/$7B;1M-A<Q-<7D3O(HY
MBB@=999-PY4JJDANS8//0_5WQ%UWQ/\ $7XBZ5IEYJ3:G=VEE8:'%<W$DCM'
M!$@CCCEE(8[8D4*2<],C:#QPXNTJD%>\HQ<FK=VK._?KZ*^A]#D[=+!8B/(^
M6K5IJ#5F[Q5WOK:-]=>NSL?,_BN"1],L;H(1Y%U)#OYW?.49203G:K+QUYW<
MX-?>?P ^(2:YX5L+;489&DTF*&UEN2Y<M"CJC$H6( $0P6(X(X! P?FKXA>!
M;OPW'JNDWHBFD^S_ &B">$F2+]T=Y9'.,94$8Y]<Y%<W\'?&5YX?GO=/B.8+
MI-THP"0G"L4SC!4-OP2?NX[DCGJ.<L.G3TE2GY)\NB:UT[==EW/5R^-+#9LO
MK47[+%X?ELE>U2FERMVOT5K*U^:_<_H%_: ^%_Q;^*?@GX00_L[^+=/T'0M$
M%K?:@UMJTNG;OW-JZR^=:QDS"W/FM+;/\S.SJ=PQCBOVJ]0TJ^OO#&B>?9:M
MXGT7P[:V7BR[A3]U<7;00J5E88#2;UGD*'+()%5B>@^,O 'Q \>:?I0@TW5=
M;L-(OXFC;[%>-#$(]V"Q16*JQR.4V,!WP.-22ZE(D\[S[I[AI#)<22O).7<
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M*^/<Z6'A/%8JFZ>(JSI484W*M=RE.H^7WY2E.TKTX3J4J=.I/_3,_P"#1/\
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MD%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$9VSA%9CCKA02<>^!3J9*N^.2,8R\;J,YQ\RE>2.W/;G&<=*1TG\O,/[5?\
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M+_[..\7?^H/\/*_H.K]OX,_Y)/AS_L2Y9_ZAT3_)_P"DA_RD%XW_ /9U^/\
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MV?SN_=6F_KJW?<C!8K%13^LQ@YP:NW\;=^CT?>]^]UJ?@;X^\1?$OPKK.N^
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MV[/V&9O@CX+F_8__ &I?"_P,^/?Q \1S_M(V^B^--.TWX-:IKVC^"]3\ S>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_\ %;XE^&O@
MU\-O&_Q5\9#5F\*_#_PWJGBK7UT+2;S7M9.EZ1;/=78TS1M/CEO=2O/*1O)M
M+6-YIFPJBOYP?VJO^#E+]G+2/@EXMUW]E>#XECXQZ%;PZWH6F?&G]F+XOQ^
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M;@5_;(/^#+C0E=7C_P""@&M(Z-N1A^S]9!E96)1@R_%9=K#CD#A@2.M>@?\
M$'=X:U;29M,\8?MT:OXAN([5H](UQ/@+86.NZ?<+@0"XOS\3[EM4L4&Y6M+M
M=X!'E7$6W%8\DNR^]?Y_U\AZVU<;KU:Z:+2\;ZWMV]#^$9?A9<:NK2^#/$OA
MSQ6@&Y;&*_BTG72#G"C1M4:WN)I"5(V6KW!!QP-Z[N!U?P]KN@7#VNMZ1J.E
M7"'#17]I/;-]5\U%#KQ]Y"R^]?W:C_@RVT%6W+^W_K*X(*D?L^688$=\CXL=
M1Q@BNRL/^#/2^T^!;-?^"C7B6ZT\9#:?J'[/UCJ-BRD<I]EO?BQ/&JGH=NTX
MSC' !R2[?BO\R.2+W7+_ (6VNG1K3KM>_9'\ %%?Z '_ !!K> ;YB=:_;5OF
M8@XGT+X"6NBR[B<EGB/Q4O;23G) 6WCQTR>:Y2[_ .#+?PJ\SM9?M\:]!;G[
MD=Q\ M/N)5Y_BE3XHPAN,Y(1.>V!1R2[+[U_GY_GV9+IOI*+^_\ R_JQ_!51
M7]YG_$%IH'_1_P!K'_B/EE_\]BC_ (@M- _Z/^UC_P 1\LO_ )[%')+LOO7^
M?G^?9B]F^\?Q_P OZL_*_P#!G17]YG_$%IH'_1_VL?\ B/EE_P#/8H_X@M-
M_P"C_M8_\1\LO_GL4<DNR^]?Y^?Y]F'LWWC^/^7]6?E?^#.BO[S/^(+30/\
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MNVO97Z/M^;WL?P9T5_>9_P 06F@?]'_:Q_XCY9?_ #V*/^(+30/^C_\ 6/\
MQ'RR_P#GL4N279?>O\_/\^S,_9OO'\?\OZL_*_Z ?\&B?_*,3Q9_V<M\1/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO-_=YA]?PO\ S\?3[%3K;^[_ 'E^)^_=%?@)_P /GOB/_P!&P^"O_#[ZY_\
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M(T<DNR^_T\O-_=YA]?PO_/Q]/L5.MO[O]Y?B?OW17X"?\/GOB/\ ]&P^"O\
MP^^N?_.1H_X?/?$?_HV'P5_X??7/_G(T<DNR^_T\O-_=YA]?PO\ S\?3[%3K
M;^[_ 'E^)^_=%?@)_P /GOB/_P!&P^"O_#[ZY_\ .1H_X?/?$?\ Z-A\%?\
MA]]<_P#G(T<DNR^_T\O-_=YA]?PO_/Q]/L5.MO[O]Y?B?OW17X"?\/GOB/\
M]&P^"O\ P^^N?_.1H_X?/?$?_HV'P5_X??7/_G(T<DNR^_T\O-_=YA]?PO\
MS\?3[%3K;^[_ 'E^)^_=%?@)_P /GOB/_P!&P^"O_#[ZY_\ .1H_X?/?$?\
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)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ny20077915x1_barchart02x1.jpg
<TEXT>
begin 644 ny20077915x1_barchart02x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M?HC13]I/^9_>'U3"_P#0/1=N]*#[=UY(_.[_ (=9?L>?] /XV_\ B6/[5/\
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M+[_Z[?GW8?5,+_T#4/\ P5#R_N^2/SN_X=9?L>?] /XV_P#B6/[5/_SY*/\
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M^U3_ //DK]$:*.>?\TOO_KM^?=A]4PO_ $#4/_!4/+^[Y(_.[_AUE^QY_P!
M/XV_^)8_M4__ #Y*/^'67['G_0#^-O\ XEC^U3_\^2OT1HHYY_S2^_\ KM^?
M=A]4PO\ T#4/_!4/+^[Y(_.[_AUE^QY_T _C;_XEC^U3_P#/DH_X=9?L>?\
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M_L]?^'C^'_\ \T%'_#:7['__ $=+^SU_X>/X?_\ S04?V;F__0!F/_A)B?\
MY7Y?GW8?V]P=_P!#KAKI_P S++/*W_+_ ,E_3/!_^'67['G_ $ _C;_XEC^U
M3_\ /DH_X=9?L>?] /XV_P#B6/[5/_SY*]X_X;2_8_\ ^CI?V>O_  \?P_\
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M#ZIA?^@:A_X*AY?W?)'YW?\ #K+]CS_H!_&W_P 2Q_:I_P#GR4?\.LOV//\
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MZI>^+O"FC6=GXM\):7=6>MZMX1FG7Q+%H5]9:S'I<NFW<%S)ZW\%?VB_A/\
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M\.7?A7PUXA\7:-(FLZ-H/B36-*U:XTADU(VB6<D<S@6?9_<?5M%%% @HHHH
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M3_PZ7C;_ .6E?KU17@_ZX<5_]%'G?_ARQ?\ \M\OS[L^Z_XA'X6_]&ZX*_\
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MXM?$7Q;X2^&OPU^ /P\U[XAWTW[1%KXSCUG]H/4='\!:5<_LZ^-_A_X%U]?
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M/AW3/B'!X??P%>>(=$\+!-8UG0X?$C:GI4$]M'?6L%S/'"WTQ0*S6ZL%%%%
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M:QE@O],OX(+RSGAN(4<?$G[+_P 3?B%\"_BP_P"PI^T;XFO?%FMVV@7WB?\
M95^-NND)??';X2Z$T<.J^$?%%V0MO=?&CX1P3Z?:^*1$5N/%OABXTWQE';>:
M-:=/TEKY*_;._9YU#]H7X0-:>"M53PI\;_A?K^F_%K]GSQXJ_O\ PC\6_!PF
MNM!^T.I#R^&_%=M)?>"_&>G,7M]2\+>(-4AE@DE6W*5%_9>S_!]_\^Z\TK<]
M:G*ZK4E^]IK5*R]M3WE2ELFWJZ3;2A4L[\LIJ7UK17SG^R=^T!I_[3GP%\!_
M%VWTV3P_K>KV=UHWCSPA<D_;_ _Q)\+7L_A[X@>#-11PLL=UX=\4Z=J6GCS5
M1I[:.VNU!BN(V;Z,I--.ST:-H2C.,9Q=XSBI1?=25T_N84444B@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=N=#T[4-#UAM#UJ:VO"TNIZ=JMK&;-^Q_8=^"OQW^'$OQW^(W[1&M0:AX_\
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MQXQ_[*+\-/\ T^25^B?[*W_)K_[-_P#V07X/_P#JO?#M?G9_P7:_Y1\>,?\
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M*][\8H_$UMH?B:ZUK2KTZQXKGLX]>\,WEBWAS4=+M+FT%E VKZE+,1?\$T?
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M  5M_P"2+?LS?]I%OV!?_6D?!5?JA26\O7]$ 4444P/RH_X).?\ (E?MN?\
M:3?]MK_U8MK7ZKU^5'_!)S_D2OVW/^TF_P"VU_ZL6UK]5Z!O?Y1_)!1110(*
M*** "OPA_P""!7_)'?\ @H#_ -I:/VV__3GX#K]WJ_"'_@@5_P D=_X* _\
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M^_\ @I9X.\'_ !F_97^(_P !];\;_![PYJ7C%/ 'B6^TCXP>--"\*^';_P
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MW_\ 9!?@_P#^J]\.U]EBO^2"R?\ [*;.?_5?E1^099_R?3BW_LVW!_\ ZO\
MB@]ZHHHKXT_7PHHHH **** "BBB@ HHHH **** /Y3/C+_RL=? G_L:=&_\
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M+_\ X**_\E<_X)7?]I'O"W_K,'[45 X[KU7YGZ@4444""BBB@ HHHH ****
M"BBB@ HHHH _.3_@I[_R0OX1?]GJ_L2_^M+_  YK]&Z_.3_@I[_R0OX1?]GJ
M_L2_^M+_  YK]&ZI_!'_ !2_*!SP_P!YQ'_7O#_G6"BBBI.@***_BE_X*J?M
MC_M6?##]O#XZ^!_AW^T+\6?!?@_1+[PBFC^&O#GC+5M,T;34N_ GAJ^N5LK&
MWG6&!9[RYN+F4(HWS32.>6-?4<)\+8KBW,*^7X7$T,+4H8.>,E4Q$:DH2A"M
M0HN"5.,I<S==--JUHOK8_,?%7Q0RSPGR#!\09KEN/S3#XW-J.40H9?+#PK0K
M5L)C<7&K)XFI3A[-0P4X-*3ES3C96NU_:U17^<S_ ,/!OVXO^CKOCI_X<#7/
M_DBC_AX-^W%_T==\=/\ PX&N?_)%?H/_ !!3.?\ H<Y9_P""\5_\K/P#_B=+
M@S_HD.)__!V5?_-1_HS45_G,_P##P;]N+_HZ[XZ?^' US_Y(H_X>#?MQ?]'7
M?'3_ ,.!KG_R11_Q!3.?^ASEG_@O%?\ RL/^)TN#/^B0XG_\'95_\U'^C-17
M^<S_ ,/!OVXO^CKOCI_X<#7/_DBC_AX-^W%_T==\=/\ PX&N?_)%'_$%,Y_Z
M'.6?^"\5_P#*P_XG2X,_Z)#B?_P=E7_S4?Z,U%?YS/\ P\&_;B_Z.N^.G_AP
M-<_^2*/^'@W[<7_1UWQT_P##@:Y_\D4?\04SG_H<Y9_X+Q7_ ,K#_B=+@S_H
MD.)__!V5?_-1_HS45_G,_P##P;]N+_HZ[XZ?^' US_Y(H_X>#?MQ?]'7?'3_
M ,.!KG_R11_Q!3.?^ASEG_@O%?\ RL/^)TN#/^B0XG_\'95_\U'^C-17^<S_
M ,/!OVXO^CKOCI_X<#7/_DBC_AX-^W%_T==\=/\ PX&N?_)%'_$%,Y_Z'.6?
M^"\5_P#*P_XG2X,_Z)#B?_P=E7_S4?Z,U%?YS/\ P\&_;B_Z.N^.G_AP-<_^
M2*/^'@W[<7_1UWQT_P##@:Y_\D4?\04SG_H<Y9_X+Q7_ ,K#_B=+@S_HD.)_
M_!V5?_-1_HS45_G,_P##P;]N+_HZ[XZ?^' US_Y(H_X>#?MQ?]'7?'3_ ,.!
MKG_R11_Q!3.?^ASEG_@O%?\ RL/^)TN#/^B0XG_\'95_\U'^C-17^<S_ ,/!
MOVXO^CKOCI_X<#7/_DBC_AX-^W%_T==\=/\ PX&N?_)%'_$%,Y_Z'.6?^"\5
M_P#*P_XG2X,_Z)#B?_P=E7_S4?Z,U%?YS/\ P\&_;B_Z.N^.G_AP-<_^2*/^
M'@W[<7_1UWQT_P##@:Y_\D4?\04SG_H<Y9_X+Q7_ ,K#_B=+@S_HD.)__!V5
M?_-1_HS45_G,_P##P;]N+_HZ[XZ?^' US_Y(H_X>#?MQ?]'7?'3_ ,.!KG_R
M11_Q!3.?^ASEG_@O%?\ RL/^)TN#/^B0XG_\'95_\U'^C-17^<S_ ,/!OVXO
M^CKOCI_X<#7/_DBOL3X\?ML_M=Z)^S+^Q)XDT?\ :/\ C!IFO^,O"GQQN?%F
ML6?C;6(-0\17&B?%FXTK2)]7N4G$E[+IVFJMC9O,6,%L!%'A.*YJ_@[F]"K@
MJ,LVRZ3QN)GAH-4\3:$H83%8QRE>G?E<,+*"M=\THO9,]3 ?2^X1Q^$SO&4^
M%.(Z<,CRVAF=>,ZV6<]:E7SG*<EC3H\N):]HJ^;4:K<W&/LJ52SYW&+_ +HJ
M*_SF?^'@W[<7_1UWQT_\.!KG_P D4?\ #P;]N+_HZ[XZ?^' US_Y(KI_X@IG
M/_0YRS_P7BO_ )6>7_Q.EP9_T2'$_P#X.RK_ .:C_1FHK_.9_P"'@W[<7_1U
MWQT_\.!KG_R11_P\&_;B_P"CKOCI_P"' US_ .2*/^(*9S_T.<L_\%XK_P"5
MA_Q.EP9_T2'$_P#X.RK_ .:C_1FHK^&3]AC]M?\ :Y\:_&'Q=I'B[]H_XO\
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M/!OVXO\ HZ[XZ?\ AP-<_P#DBC_B"F<_]#G+/_!>*_\ E8?\3I<&?]$AQ/\
M^#LJ_P#FH_T9J*_SF?\ AX-^W%_T==\=/_#@:Y_\D4?\/!OVXO\ HZ[XZ?\
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M_P""\5_\K/,_XG2X,_Z)#B?_ ,'95_\ -1_HS45_G,_\/!OVXO\ HZ[XZ?\
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M6Y-0X5XCHULRQE#!TJM:MEGLJ<Z\U",ZG)B93Y8MW?+%NVR/[I**_P Y=?\
M@H-^W$54_P##5WQTY4'_ )*#KGI_U\4[_AX-^W%_T==\=/\ PX&N?_)%=/\
MQ!3.?^ASEG_@O%?_ "L\K_B=+@S_ *)#B?\ \'95_P#-1_HS45_G,_\ #P;]
MN+_HZ[XZ?^' US_Y(H_X>#?MQ?\ 1UWQT_\ #@:Y_P#)%'_$%,Y_Z'.6?^"\
M5_\ *P_XG2X,_P"B0XG_ /!V5?\ S4?Z,U%?YS/_  \&_;B_Z.N^.G_AP-<_
M^2*/^'@W[<7_ $==\=/_  X&N?\ R11_Q!3.?^ASEG_@O%?_ "L/^)TN#/\
MHD.)_P#P=E7_ ,U'^C-17^<S_P /!OVXO^CKOCI_X<#7/_DBC_AX-^W%_P!'
M7?'3_P .!KG_ ,D4?\04SG_H<Y9_X+Q7_P K#_B=+@S_ *)#B?\ \'95_P#-
M1_HS45_G,_\ #P;]N+_HZ[XZ?^' US_Y(H_X>#?MQ?\ 1UWQT_\ #@:Y_P#)
M%'_$%,Y_Z'.6?^"\5_\ *P_XG2X,_P"B0XG_ /!V5?\ S4?Z,U%?E7_P1H^)
M_P 1/B_^PUX1\:_%+QIXC\?^+KOQW\1K&Y\1^*M4N=7UB>ST_P 0R6]C;2WM
MT[S/#:0 101EML: *H K]5*_)LUR^IE.9X_+*M2%6I@,77PE2I34E"<Z%25.
M4H*24E&3BVN9)VW5S^K^%\^H<4\-Y%Q+A:%;#8;/LIP&;4,/B'!UZ%''X:GB
M:=*LZ<I4W4A"HHS<)2CS)V;1^=W[$W_)=_\ @IC_ -GHZ1_ZRK^SA7Z(U^=W
M[$W_ "7?_@IC_P!GHZ1_ZRK^SA7Z(UPRW7^&'_I$3U<)_ 7_ %]Q'_J15"BB
MBI.D^3/VZ_BK\,_@K^R-\=_B-\8OAQ/\7_AMH_@BYT[Q3\+H+/3[T^/;3Q1>
MV7A2V\+W":J\6F6UCJVH:W:6NH:EJ$D=II5D]QJ4S!;0U^2'[*W[*OQ@^&7Q
MY^%/C;4_^"4W_"):=X7UF"P\.>./B!_P4KO?V@K/]G[P_K$1TW6-;^&?PS\7
M:=JUA87UAH\TEK';: ]IJCVBO86&IV\<KE_TH_X*CZ%\0_%'_!/_ /:B\,_"
MO3/&6N^-_$?PWN-"TWP_\/O"C>-/&7B2PU;5M+L/$7AG0- 2VO))+WQ'X;GU
M;1!J45I=2Z%'?R:Y';ROIRH?RJ_9:\+?LJZ7\4_@?#X5_9._X+I?#_7]/\1>
M#H=$E^,OQ!_;5N_@WX1O[9[2.U3X@67B#]H;5_ -SX*TAT6+5K;4O#U]X;ET
M^%XY-*ELF%L9>Z^7;6[7D_TZ>JM7Y=$W=N^^VG;Y^I_2?7S_ /M)?%;XF?"+
MX?6VM_![X%>)OVA_B/KWBC0_"7AGX?Z!K6F^%--CNM9>=I_$GC?QKJ\-UI_@
MWP3H5I:SW&LZ_-8:C+'*]E96UA<7%[&%^@*^)_V^O%G[7?A?X!W</[%'PX;Q
M_P#&;Q/XDT7PR]_%JO@BQOOAUX.U'[2WBCXA:'IWQ"UC0_"OB3Q/HMG EMX9
MT+6-032Y=9U"UO\ 58;W3=/NM/O*>S_3?Y$K?I\]OF?+R_\ !3WQQ9^ O$_A
M[7/V5=;M/VQ]!_:8\*_LGZ?^S3IGQ2\+ZQX=\1_$SQM\/(_C#H&MZ?\ &>#3
M(]%M_A_!\)AJ'C+Q'KE]X<AU'P^=)O=(N]':Y>TFN/L']D3]I[5?VD?#GQ'L
M?'7PPOO@G\:/@E\2+_X5?&7X4WOB;2_&L'AGQ1!HNB^*=(OM!\8Z/;V=AXG\
M+^)_"?B/0]?T/6([#3Y9(;R:UN;*"XM)0?S \*_L]?M$>'O@7\$_&OP@_8]\
M;>!?C3^RY^UM%^T)X@\"?'CX\?#/QA\2/VOW\<?"WQY\,OC)XVUWXN>&-2UW
M0[/XEZKI7Q$N;[1)?$S:7HT%SX8TSPU86ND>&DTV'3OH[X(_L=_%'XN_"W]M
MK5/VC9O'G[,GC/\ ;J^+6G>-[GP]\"_BO'9?%/X+^"_!O@WP#X$\&Z;9_%CP
MU;3Z=%XXU2P\"-J?B:Z\.QWFE00:]<:);7-RD<LQ2OIK^'3UMO?TTZ(=EKLM
M>]^W2[TW?7M?37PG_@N%_P AW_@DI_VEI_9G_P#3'\0J_=^OX^_V^?\ @FAX
M-_8P^,'_  2T^(WAW]J;]N#XXWGB'_@IU^SCX.E\,?M,?M&Z[\7_  5IMO=1
M>*]8;6](\.ZII=E!8^)89-'CLK?5TE:6'3;W4[01E;QF7^P2F+HO5_E$****
M!'Y7_P#!6W_DBW[,W_:1;]@7_P!:1\%5^J%?E?\ \%;?^2+?LS?]I%OV!?\
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M0/\ ?+(?^56]?_LTG$?_ *TN:'^@O1117]4G^!@4444 %%%% !1110 4444
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MYKS<Q_WW(?\ L:5__5)FY]/PW_R(_$'_ +)3+O\ UO."SX:HHHKUCY ****
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MY/1-GD5%:_B#P_K?A37=8\,>)=+O=#\1>'M3O=&US1M2@:VU'2=6TZX>UO\
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MQ)DM++U5KU,3@JU-0<OU;'_!(+]FW1_$NE?L^ZI^S9XROO#<_@ +KW[:C?M
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MW.EZ6UKK%M<PPI&B^7'/+;VVVS:2^^S0W5>/_P#!-;_@HK:_L'^.OBIJ>N^
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M8?$]+?P;IOAE[:]BUBY\&>%7@%BFJW9O;B"U?5+>'[/97+Q27$LEO;R5X/\
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M,Q>&]ID'#$*+Q%=2GB*.&R3 X*.*]M+!TEAYTSX:HHK^C3_@F_\ \$YOV?\
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MC:_\3:_# +F;1/"FA1?VEKE];PO^[>\>WA6QT\3?N?[0O+3S@8MXKP<PQ5#
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M<IIFA:#80:9I5BMQ>>)[B\N!:V5M##Y]U<3W,NSS)YI)&9SZ%_P[*_X)U_\
M1C?[*7_AA_AM_P#,[7P]^TQ_P;Z?\$]/VC_'&C^-[;P,_P "&TGPM:^%W\,?
M ?PG\)?!GA35!:ZKJVJKKFIZ7>?#?67GU^4ZLUA/?K<QK+I]CIUN81]E#N\1
M+$4Z4I8:A2KUER\M*I6>'A+6*E>JJ5;EY8\S2]G*[26EVS/*Z.6XC'4:6<8_
M%9;E\_:.OC<'E\,TQ%)QIS=+DP,\=ET:W/54*<KXRE[.$Y5%SN/LY_8W_#UG
M_@F=_P!'\?LC_P#A_/AM_P#-#1_P]9_X)G?]'\?LC_\ A_/AM_\ -#7YI^#?
M^#93_@GUX2\8>$_%D^K?%3Q7%X5\3^'_ !,_A?Q1;?!Z_P##/B+^P-7L]770
M_$=A#\)[:6^T+56LQ8ZO91W%N]WI\]Q;K-$9-Z_R"?M7_"KX5^"OVI?VD_"=
MA\/O WA;3?#_ ,>_B]I>D^'8?#6B:/;:/HUKX_\ $$>CV-EI@LX$LM/@TP6J
MZ?!%#' EEY'D+Y)CS\?Q-QAB>%<NH8_,,FGB)XC&K"0P^ QGUB2BZ$ZWMISG
MA:5E>G*'(H/5Q?-T/Z*\#_H\Y;X]\:9KPEPKXD9;D-'*.%ZG$>(SGC/)?[%H
M5:M/-L!ECRS#8?#9UF?M:SAF%/%1K2Q-.\*5>'L4H*I+_0G_ .'K/_!,[_H_
MC]D?_P /Y\-O_FAH_P"'K/\ P3._Z/X_9'_\/Y\-O_FAK^#[]C3X(?!SQMX*
M_;JU76_A3\/?%*>!_P!BCQ[XAT+4=0\':#J\?A3Q8?B-\+;32-8TZ[FL)TT?
M7382:W!IUY"]O>M;-J26[F,7 'Q1_P (!X%_Z$WPO_X(=,_^1:^7S#Q=P>79
M;DN8ULCQMLYACIPH/$4H5,.L#B_JLE4YZ?O>U?[R#25HM)WW?[QP7^SPXKXW
MXZ\3^",J\4.#G/PRQ'"&'Q><4\!F6+R_.9<7</K/Z$L \-4DX+ 0YL'B55DW
M+$0ER62:7^DQ_P /6?\ @F=_T?Q^R/\ ^'\^&W_S0T?\/6?^"9W_ $?Q^R/_
M .'\^&W_ ,T-?PB>-O@=\&;/_@G5^SCX[M/A3\/+;QIKO[5'[2OA_6O%<'@_
M08O$&JZ'H7@[X27&C:1J&K)8B]N]-TN?4;^:PLYYGM[66\N)(8T:5R?AJ[\
M>!?LEU_Q1OA?_CWF_P"8%IG_ #S;_IVI9IXOX'+,1E^'GDV+JO,,MRS,H2CB
M:,53AF5&%:%*2<&W*DI.,I+236BL1P!^SOXSX_R+C?/,'XB<,9?2X(XVXXX)
MQ=#$Y7FM6ICL5P/C9X/%XW#RI2Y:>'QTH.>'IU?WE.+2J:G]L/\ P5\_;O\
MV+/C]^Q7XI^'7P/_ &K/@!\6_'MWXV\!ZI:^#?AY\5O!GBWQ+<:;I>KM/J5]
M#HVB:O>7\EI80LLMW.D!C@C(>1E4YK[ ^#__  4R_P"">'AO]EGX7>#/$'[;
MG[+>B^+= ^ '@GPQK?AO4_C=\/K+6M)\1:7\.M,TK4M#U#3I]>2ZM-4L-3@F
ML+NRFB2X@NXI()$61&4?!G_!23]CC]DWX0_\$RO"WQ0^%?[-?P.^'7Q'N+#X
M%1S>._!7PP\'>&O%DD>O6&G-K2-KVD:1::D5U4LQU!?M&+O<PG#AB#^E'[.?
M_!.?]@7Q1^SW\"?$WB3]C#]F+7?$7B+X-?##7=>US5O@E\/+_5=9UK5_!.AZ
MAJFJZG?7.@27-[J&HWUQ/=WMW<223W-S-)-*[2.S'^DL5=\ Y,]->)LX^[^S
M\JO^MOD?Y(Y:K>.O%R[>&W""?JN(.*%IY6/\Z*#XF_#GR8C_ ,)WX1YC4C_B
MH=*Z$ C_ )>O0U]R?!?]H_X.>&/V'?VV/"#_ !N\"^'O&GC/X@?LC7/AKP_%
M\0-)TGQ%XETOPWXE^*-QXDDTFRAU2WU#4['1UO\ 2YM8^S)+!:)=6CW859(R
M?[WO^'97_!.O_HQO]E+_ ,,/\-O_ )G:/^'97_!.O_HQO]E+_P ,/\-O_F=K
M^<\H\)L#E&88O,:&<XZ57%X/,\';V-&#HK,L/4H2K4YP:DJE#VKG2>EY1C>V
MI_K#XB?M ^,/$C@OAO@?-_#C@^CEG#O$/!.?J<,7FF)>8O@K,,'CZ& QN'Q,
MIX>6$S-X14,;'D;]C5FH+O\ YK7_  N_P[_T5ZS_ /"_/_RVK^Y;_@F!_P %
M/?V'O#/[!/[-7AWXS_MS_L\Z1\2M#\$W^E>)=*^(/QW\%P>+]--AXL\16VD6
M.L0:YXA_M2$VN@QZ7!8PW0!BTU+..("!8@/T/_X=E?\ !.O_ *,;_92_\,/\
M-O\ YG:_DV_X.!OV6?V:O@K^TE\#=$^$/P#^$'PRT?6/@?>:KJNE^!OAYX5\
M,6&HZDGCW7+1+^]M=(TNTAN;M;6**W6XE1I1#&D8;8H%50R:GX89;F_$5;-,
MVS^G&AA:,L)BJL8\OM,71I*=*4Y5(QE>I[UTKPC;<Y\T\1<Q^G-QQX;^#N5\
M ^&OA%CJV:9[C*&?</997C#$.AP_B\=.AF5/#TJ5:M0C3RV:H1@WRUJRDURI
MW_JN_P"'K/\ P3._Z/X_9'_\/Y\-O_FAH_X>L_\ !,[_ */X_9'_ /#^?#;_
M .:&OX"OV'_@[\)O&'[9W[*/A7Q5\,_ GB/PSXB_:$^%&C:_H&M>%-#U+2-9
MTG4/&&EVU]INIZ?=V4MK>V5W!(\-Q;7$;Q31NR.K*2*S_P!LSX0?"CPG^V!^
MU3X8\,?#7P+X?\.>'OVBOC-HNA:%H_A71-.TG1](TSX@Z_9Z?IFFV%K916UE
M8V5I#%;VMK;QQPP0QI'&BHH R_XBY@?]6UQ'_8^+]B\Z>3?5OK-'VGM%@HXU
MU_:<G+R<K<%&W-S6=['HQ_9Z<92\<)^!_P#Q$/AA9M#PPCXG///[+S7^SW@)
M<3KAG^RUA^;ZS];5=_6O;-^Q=+W+<Y_H"_\ #UG_ ()G?]'\?LC_ /A_/AM_
M\T-'_#UG_@F=_P!'\?LC_P#A_/AM_P#-#7\57_!._P#9Z^ _CKX.?\%,=4\9
M_!KX8^*M2\!_L2^+?%/@J_\ $'@?PYJMYX3\26TNI"#7O#UQ>Z=-+I.K0A4\
MJ_LFAN4V+MD&T5^78\ >!2 ?^$-\+\@?\P'3/_D:C,?%S Y=E.0YK/)\74AG
MM+'5:=&.)HQGAU@<5'#34Y.#4W4;<XN*7*M'=ZAP1^STXSXV\0_%OP]POB'P
MQ@<;X28_A3 9CF.(RO-:F%S>?%>35LYP]3!4J<O:T(X2E0E1K*OK.HXRA[M[
M?Z3/_#UG_@F=_P!'\?LC_P#A_/AM_P#-#1_P]9_X)G?]'\?LC_\ A_/AM_\
M-#7\4OQ@_9[^!&E?\$F/V,OB3IGP;^&-A\0?%'[27Q[T7Q)XVL_ _ARW\4Z[
MI&DW/BH:9IFK:Y%IRZC?V-@(XA:6MS<20VXBB$:*(TV_F ?A]X#<;6\&>%F5
MN&4Z#I9# \$$&UP01P0>".#6N;^*^"RC'97@JF48JM+-,NRO,85(8BC"-*&9
MPC.%.2E%N4J2;4I)I2=K(\WPV^@-Q?XD\)<?<6X'C_AO+</P#QAQOP?C,)B\
MLS.K6S#$\$*G+%8S#3HR]G3H8Y37U>G5_>4VOWE]S_29_P"'K/\ P3._Z/X_
M9'_\/Y\-O_FAH_X>L_\ !,[_ */X_9'_ /#^?#;_ .:&OXI_^"Q/[/OP*^%W
M[=_CCPA\-_@Y\,O GA6V^&OP9U"W\.^$O!'AS0-%@OM4\!Z?>:E=Q:;ING6U
MHES?73O<7<RQ"2>9C)(S,<U%_P $<?V?O@5\4O\ @H?\$?!7Q)^#OPR\>>#]
M4TCXK2ZEX8\6^"/#NOZ%?2Z?\+_%5]8RW6EZGI]S9SR6=[!#=VSR1,T-Q%'+
M&5= 1UOQ+PBXO_U0>5XGZQ_:"R_ZXJ]+V/.XJ7M/9\O/RZM<O-?;4\"'T)>*
M:GT<'](Y<;\/K)%PM4XI_P!6WE^8_P!J_5Z>/E@'A?K=_JGMG.+J*=N3ELM[
MV_2CXL_M7?LRZA_P7-^"W[2EC\?OA#=_L^:;XJTD:A\:K?X@>&9OAA9-%^S;
MX^\,R+=>-4U%M @9/$-S;Z(RR7RD:I/#9$?:)$0_=/\ P6;_ ."A_P"P?\7/
M^"?/Q;\"?"_]L3]FSX@>,]5\2?"6?3/"WA#XQ^!->UZ_ATSXJ>$-2U"2TTO3
MM;N+NX2RL+6YO+EHXF$-M!+-(5C1F'Q)\6OV8_V=+'_@NS\%/V>[+X%_":T^
M!.H>*M)-]\';?P#X9A^&MX9/V:?'WB&1KKP9'IJZ!.SZ];V^LLTM@S'4X(;W
M/VB-)%_I"_X=E?\ !.O_ *,;_92_\,/\-O\ YG:_<?$#"+,,)E6 G-TX8W@;
M*L).I%)RA'$X*M1E.">C<8S<HIZ-I)Z7/\Z/H\Y]7X5S_/\ BC#4*6*Q'#?C
MOQ%GV'PM>4XT<36R?.\MS"C0K2IM3C3K2P\*=65-J2C*3B[I'^:%_P +-^'7
M_0]^$?\ PH=*_P#DJO[U?^"=O_!2S_@GKX#_ &&?V5?!OC7]MG]E[PKXL\-_
M!/P/I/B#PYK_ ,;?A_I>M:+JEII4276G:IIUYKL5U97MM)E)[:XB26)P5=58
M$5]T?\.RO^"=?_1C?[*7_AA_AM_\SM?RM?\ !PC^RG^S)\$_C'^S=IOP?_9^
M^#?PQT_7/AGXZOM9L_ GPY\)^%[;5;RV\4Z+;VUSJ$.CZ5:1W<]O SQ02SJ[
MQ1NZH5#L#_/^7<-X#PGRK/N(*>)QF;PE0P4:V'G&A0DHQQ2I1=.<>97<L4V^
M96Y8JVK9_J)QOXV<;?M ^/\ PD\)\=DW"WA_C*&:<2K+<VPE7-LQPSJ9AD]'
M&XCZ]0K3E5Y*=/A]0H_5VI.>(;G>,4?U%?\ #UG_ ()G?]'\?LC_ /A_/AM_
M\T-'_#UG_@F=_P!'\?LC_P#A_/AM_P#-#7^?3^R5\(_A9XG_ &K/V8_#?B/X
M<>!]=\/Z_P#M"_!C1M<T75O"^BW^EZOI.I_$;PY9ZAINHV5S9R6]Y8WMI-+;
M75M/&\,\,CQ2(R,0>Y_;_P#@O\(?!'[<7[6'A'P?\,/ /ACPMX=^.7C72M!\
M.Z%X3T/2]&T;3+:[C6WL-,TZSL8K6RM(%)$5O;Q1Q("0JBDO%S OAR7$7]CX
MOV4<YCD[PWUBC[1U'@UC'653EY>11?)R\O-S6=[7-JO[/+C.EXVX7P2?B)PP
M\UQ7AI5\2XYVLKS7^SX8"EQ)/AMY8\/S?67BW7@\2JJ?L?8M0?OWM_>[_P /
M6?\ @F=_T?Q^R/\ ^'\^&W_S0T?\/6?^"9W_ $?Q^R/_ .'\^&W_ ,T-?Q0?
M\$T_V?/@3X_T[_@H'+XX^#GPR\72^"_^">WQS\8^$9/$?@CPYK#^&?%FE2:-
M_9GB30VOM.G.EZW8>8_V34[,Q7=OO;RI5R:_,5?A_P"!0JC_ (0WPOP /^0%
MIGI_U[48_P 7,#@,FR+.)Y/BZE//5F+I48XFBIX?^SL33PT_:2<.6?M7/FAR
MI<J5GJ+@_P#9Y\9\7^)GBSX9X;Q$X8P>.\)I\%0S',Z^5YK4PF;/C3),1G>&
M>"HTY*M0^HTL/*A7]NW[2I)2IVBF?Z2=Q_P57_X)GM;SJO[>_P"R06:&55 ^
M/?PV))*, !_Q4/4G@5^-7_!!#_@H#^PW\%?^"<O@[P'\7?VN?V=?AIXUM/C5
M^TMJUSX4\<?%WP1X:U^#2]?^.GCC5]$U"72M6UFUO$L]6TJ[M=1TZX:(17EE
M<0W,#/%(CGI?^"'7[#7[&7Q:_8/C\8_%#]E7]GSX@^+&^+'Q.T]O$GC'X2>!
M_$6M-8V+Z2;*T;4M4T6YNVMK3S9!;PF4QQ!V"* 36=_P0(_89_8Q^+__  3A
M\&^-OBK^RK^S[\1?&%S\;/VF=+N/%'C3X2^"/$FO3Z;HGQV\=:7HUA+JNJZ+
M=7DEII6FVMMI^GV[3&*TL[>&V@5(8D1?T[+,<LSR[+\QA3=*&/P.&QL*4FI2
MIPQ5&E74)25DY04^5M:-J^Q_#'&?#5?@SB_BOA#$XFCC<3PKQ%G7#N(QE"$Z
M=#%ULES/$9;5Q-&G4O4A2KU,,ZE.$WSQA)*7O)G[#_\ #UG_ ()G?]'\?LC_
M /A_/AM_\T-'_#UG_@F=_P!'\?LC_P#A_/AM_P#-#6W_ ,.RO^"=?_1C?[*7
M_AA_AM_\SM<9\1_^":O_  3TL/AYX\OK+]B+]E>UO++P9XHN[2Y@^!7PXCGM
MKFWT.^F@GAD7P\&CEAE1)(W4AE=0P((KO][R_'R_X/X>9\R;'_#UG_@F=_T?
MQ^R/_P"'\^&W_P T-'_#UG_@F=_T?Q^R/_X?SX;?_-#7^:]9?#_P+]CM/^*-
M\+_\>T'_ # =,_YY)_TZU]S_  O^!WP9U'_@GW^V!XWO_A3\/+SQCX9^/?[)
MVC^'?%%SX/T";7]#TKQ!;?%AM=T[2M5DL&O;"RU@Z?8G4K:VFCAO39VQN$D\
MF/;^097XO8'-,7CL)#)L72E@<!F>/E.>)HR52&68>=>=.*4+QE55.48MW46T
MVFKG^AW'O[/+C/@+AC@[B?&>(G#&/P_&/%O O"6&PN&RO-:5;!XCCK,,-E^$
MQ=>=67)4HX&>)53$PI_O*D(-4M6C^[K_ (>L_P#!,[_H_C]D?_P_GPV_^:&C
M_AZS_P $SO\ H_C]D?\ \/Y\-O\ YH:_S9_^$ \"_P#0F^%__!#IG_R+7VQ^
MUS\$/@UX6^&_[!E_X;^%7P\T&^\8?L<Z5XE\5W>D>#]!T^Y\2>(9/C-\7=,?
M6];FMK".34]5?3M.L+%K^\::Y-K9VT!D\N%%6,#XP8#'99G69QR;%TX9+2P-
M6I2>)HRE76-QE/!Q4)*"4'3G/GDY)WBK+4[.+?V<W&O"7'GA;P'B?$?A;%XS
MQ2S#BK 9?CZ&59M##95/A7ARMQ'B*F,IU)>UK1Q5&B\-15&SA5:G4]RZ/[P/
M^'K/_!,[_H_C]D?_ ,/Y\-O_ )H:_.O]N_\ X*/?L!>,_B?_ ,$W-1\)?MG?
MLR^)+#P#^WQX;\:>-KS1/C1X"U*W\)^$8/V=/VCM#G\3>();37)4TK0X=9US
M1M*EU.],-G'J&K:=:-*)KR!'_C9_9Z^%?PRUW]H'X#:'K7P]\%ZMHVL_&WX2
MZ5JVEZCX9T>[L-2TW4/B!X=M+ZPOK2>S>&YM+NUFEM[FWF1XIH9'CD5D8@_V
M>_MY_L ?L->$?BA_P37T_P +?L@_LW>'K'QQ^WYX;\(^,;31O@UX!TZW\4>%
M9_V<?VD=8F\.Z]%:Z%$FJ:++JVCZ1J<FFW@FM'O]+T^[:(SVD#I]AP7QC0XS
MP.+QV'P57!1PF+6$E3K58593E[&E6YTZ<4E&U3ELTW=7/YV^DO\ 1OSSZ,_%
MV0<)YYQ)E7$V)S[AZ'$5'%Y3A,7A*&'HRS/'Y:L-5AC&ZDJJJ8"=7GA[G)4B
MOB3/OW_AZS_P3._Z/X_9'_\ #^?#;_YH:/\ AZS_ ,$SO^C^/V1__#^?#;_Y
MH:^2/^"C/_!//]@_P1^PE^U?XN\'_L<?LT>&/%'A[X(>.M4T'Q#H7P6^'VF:
MSH^I6NDS/;7^FZC::#%=65Y;OAX;BWECEB<!D=6 -?P/?\(!X%_Z$WPO_P""
M'3/_ )%K@XV\0,-P55R^EB<NKXYYA3Q%2$J%:G25-8>5&,E)5(ROS>UO%K:V
MI]7]&#Z(G$?TG\'QCC,AXOR3A>/!V)R3#8J&;X''XR6,EG=+,ZM*5!X-I4U0
M665%45363JPY=%(_TF/^'K/_  3._P"C^/V1_P#P_GPV_P#FAH_X>L_\$SO^
MC^/V1_\ P_GPV_\ FAK^*GX\_L]? ?1?^"5'[ OQ'TCX-_#'3/'_ (Q^,_[1
M^E^+/&=CX'\.6OB?Q)IVB^)?$<.D6.MZU#IR:AJ=KID4,45C!=SRQVT<4:0J
MBHH'YAVWP\\!2W=G%+X+\*R1R7MG')&^@:6R.CW,2LCJ;4AE92592"&!(((-
M>5FWBK@LIS++,NJ93BJT\RP65XV-6&(I1C2CFD(3A3E&4&Y2I*7O--*3M:Q]
MWX>?0(XO\0N"./.-\%Q]PWEV$X$XFX[X9Q>!Q66YG5Q&/K\"2FL7BL-4I2]G
M3I8_D;P\*OOT[KVMS_22_P"'K/\ P3._Z/X_9'_\/Y\-O_FAH_X>L_\ !,[_
M */X_9'_ /#^?#;_ .:&OXEO^"O_ , /@9\,/^"@WQL\&?#GX/?#/P+X2TS2
M/A--IWAKPGX)\.Z!H=C+J/PG\':A?R6NEZ;I]M9P/>7US<7ERT4*F:YGEFD+
M.[$ZO_!'/]GOX$?%+]NSP5X1^)/P;^&7CSPM<?#GXQ7\_A[Q;X(\.Z]HTU[I
MO@+4[S3[N73M2T^XM7N+*ZCCN+69HB\$R+)&RL :ZH^)>$EQA_JA_9>)6(_M
M!Y?]=]O2]CSJ/-[3V7+S\NC5N:^S[H\*K]";BFE]'!?2/?&^0/)'PO2XH_U;
M67YC_:OL*N80R]87ZWS?5/;*<_:.=N3D5EJS^U3_ (>L_P#!,[_H_C]D?_P_
MGPV_^:&C_AZS_P $SO\ H_C]D?\ \/Y\-O\ YH:_S94^'W@1%"+X,\+*J_*J
MC0=+ 55.  /LO    'I7]4__  ;W_L:?LD_&KX+_ +1&K?%[]F?X%?$W5-&^
M+/A[3])U'QU\+?!OB>]TVPG\%65Q+965SJ^CW<UM:R7&9V@B=(C*6D*[V))P
MOXE83B?/:V1T<KQ.%JT:6*JO$5:]*I"2PM6G3DE"$5).;FW&[T228>.WT)>*
M? GPJR;Q5S;C?(,^R_.<QR'+J659=E^8X;&T9Y]EN,S*C4J5L3)T)0P]/!SI
M55'64YQ<?=O;^F3X(?M?_LK?M+ZEKVC?L\_M%?!GXVZMX7L;34_$>F_"[XB^
M%O&U]H6G7]Q):V5]JMMX?U*^FL;6ZN8I+>">X2..69&C1BP(KZ-KP'X-_LJ?
MLS?L[ZAK>K? ;X ?!_X-ZIXDL[73O$&H_#/X>>%O!=[K5A93R7-G9:I<^'],
ML)KZUMKB62>""X>2.*5VD10Q)KWZOTWU/XE"BBB@#\Y/^"GO_)"_A%_V>K^Q
M+_ZTO\.:_1NOSD_X*>_\D+^$7_9ZO[$O_K2_PYK]&ZI_!'_%+\H'/#_><1_U
M[P_YU@HHHJ3H"OX$?^"Q_P#RD9_:*_["'@G_ -5UX3K^^ZOX$?\ @L?_ ,I&
M?VBO^PAX)_\ 5=>$Z_7_  7_ .2ES#_L25__ %.P!_(WTR_^3:9#_P!EK@/_
M %29\?F+1117],G^: 4444 ;">(O$,>BR^&DU_6T\-SW2WTWAY-6U!="FO5*
M%;R71Q<#3I+M3'&5N7MC,"B$/E1C'HKT[X*'X;CXP?"X_&/[5_PJ<>/O"A^(
M_P!B6Z:Y_P"$+_MJS_X2+REL0;UO^)9]H\P68-T8O,%L#-L!RJ2C0I5JL:<I
M\D*E65.C!.I5E&+DU"*MSU9\JC%-WE*RN=>&IU,?B\%A*F*ITO;5L/@Z>(QM
M:4,-A*=6JJ<9UJDN;V.%HNHZE1QBXTX*<U%ZW\PR,D9&1U'<9Z9^M+_G_/Y&
MO[!?C9\ /A?\6OA!\;9?V8O@+^P?^T;\))_AU+/\,+7X+WUKX#^/_@&\T^T8
M#6;[7K.W\0)XIOK%X#=160NO"NHWU["-)NH+QYIED_)/XY_#3P!I7_!%[]D+
MXDZ7X%\*V'Q'\0_&OQWI.O\ CBR\.Z7;>+]:L;7Q)\6;>TT_5->AM$U6^MH8
M]/L(8;6YN9(T2RM(U0"VA"?&Y9QMALR^JQ6!JT*N)S;#95*C/$4'6P\\5@L3
MC(5<11]VO1</JM6A4I5:-.]1-T:E:$927[1Q/X'YAPV\RF\^PN/PV7\(YCQ7
M#&4,NQD,+CZ669SE.3U<-@,8Y3P&+A6_M?#XRCB<+B\0X8?ECC,-A*M6G!_F
ME^SS^SY\3?VH_BGHOP:^#^FZ;J_CO7[+6K_3;'5M8M-#L7MO#^EW.L:FTNI7
MI%O"T5C:3/'&WS2R!8U&6R/)-8TN\T+5]5T/442/4=%U*^TF_BCD29([W3KJ
M:RND25"4E1+B"14E0E) NY"5(-?UR_#[X;^ _AK_ ,%8OV!]/\!^"/#'@:WU
MG]B#4==UVR\,>']-\/QZGK]WX(\=)?:KJD&G6MJ+K59Q%&ES=W2O=.(D21R$
M 'S7\(Y_V?\ ]O73/V]?@3K/[*7PD^#K?!'POXU\9_"GXC^#?#\FG_$31K_P
M]JOB"TC?QSXDFE>^US6+W4=.34=1$TT5I>QW.HZ?/:.+>*Z/G4^/*DJT\5++
M:DLHCEF58ZK.%2C]9P7U[-,?EM2=52J1>)CS8>C.%*A34HQ59RFVX1?T>*\!
M,)3P5#*8<2T*7&%3B?BC),)3KX;%O+L[_L;AC(N(J&'H>RHS65U(T\=C*=;%
M8S$3IU*D\-"%%156I3_F=R.F>3T'KCK29& <C!. <C!/H/4U_3+\6+?]G?\
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MD8SD8YYSQQUY]N]+D=,\GH/7'6OZAOCO\"O@OI?_  6Z_99^&&E_"7X=:?\
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MU8XFBZ.&KTX5J\/XY20.I R<#/<^GUH) ZD#)P,]SZ?6OZB?V"/ O[)WB/\
M9K\!^%/@N/V*/&O[2.E^/O$4/QIT+]J?2(]1\0^/-(L_%5Y8:;!X U.2>ZFT
M33]3\/-ILVA:OH^B^)-&>>=(;BS>]^U.L/[-/[-_P]\-_P#!07]N7P]\9_V1
M? OACPMH/[-VJ_$OP]\%3-I_Q'\,16KZAH\AUGX?:S>:59K9Q^)#;ZG'I_\
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MHI?$_@GXD>&M%EE\D(NM7'AU]4MXU>5@5EN;32;VUA\C=-)+,L2J4DDQ^0F
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M$DGB&2]O?L^L0VES)=W=IINIRI+>:Q;SZG<G0;?3]&TZSF=[N\N+B&$?S$*
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M &.<P_\ 4FH?Z0^$'_)JO#K_ +(OAO\ ]56%/SN_8F_Y+O\ \%,?^ST=(_\
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M!'Y7_P#!6W_DBW[,W_:1;]@7_P!:1\%5^J%?E?\ \%;?^2+?LS?]I%OV!?\
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M7Z%_"/\ Y1I?MN?]G&?L;?\ I+\8Z_BGA'_D=9__ -D[Q5_ZKL2?]-7TC/\
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M?7,7_9N'QE18'Z[/%?5HWIT533NOTD^-'_!2SQU\4O@)??L]> O@K\%?V=/
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M8!:E7_L'K\(/^"X7_(=_X)*?]I:?V9__ $Q_$*OW?IBZ+U?Y1"BBB@1^5_\
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MM2_Y/4O^RDA_Z:B?G.'_ .57$O\ LT6*_P#6CK'ZE?&7_E8Z^!/_ &-.C?\
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M?V7D_%63X?ZMA\7B\=7I\V%P%&57GQ57FK2J2CR1E&$?[G?^#??_ )1UQ?\
M99/BQ_Z%HM9__!N%_P HN? W_9>OVK?_ %H7X@UH?\&^_P#RCKB_[+)\6/\
MT+1:S_\ @W"_Y1<^!O\ LO7[5O\ ZT+\0:_H7A3_ ))CAO\ [$.5?^H&&/\
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M,'CL'[!TIXC#*,9+'.?M.=M.FH\K4FU_F=_\*3^,O_1)?B9_X0GBC_Y54?\
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M^,O_ $27XF?^$)XH_P#E57^EY_;+_P#/!?\ OX?_ (FC^V7_ .>"_P#?P_\
MQ-'_ !&S&?\ 1.8?_P .4_\ YD]?Z6I_Q)3E'_1PLQ_\1[#_ /SU]?Z6O^:'
M_P *3^,O_1)?B9_X0GBC_P"55'_"D_C+_P!$E^)G_A">*/\ Y55_I>?VR_\
MSP7_ +^'_P")H_ME_P#G@O\ W\/_ ,31_P 1LQG_ $3F'_\ #E/_ .9/7^EJ
M?\24Y1_T<+,?_$>P_P#\]?7^EK_FA_\ "D_C+_T27XF?^$)XH_\ E51_PI/X
MR_\ 1)?B9_X0GBC_ .55?Z7G]LO_ ,\%_P"_A_\ B:/[9?\ YX+_ -_#_P#$
MT?\ $;,9_P!$YA__  Y3_P#F3U_I:G_$E.4?]'"S'_Q'L/\ _/7U_I:_YH?_
M  I/XR_]$E^)G_A">*/_ )54?\*3^,O_ $27XF?^$)XH_P#E57^EY_;+_P#/
M!?\ OX?_ (FC^V7_ .>"_P#?P_\ Q-'_ !&S&?\ 1.8?_P .4_\ YD]?Z6I_
MQ)3E'_1PLQ_\1[#_ /SU]?Z6O^:'_P *3^,O_1)?B9_X0GBC_P"55'_"D_C+
M_P!$E^)G_A">*/\ Y55_I>?VR_\ SP7_ +^'_P")H_ME_P#G@O\ W\/_ ,31
M_P 1LQG_ $3F'_\ #E/_ .9/7^EJ?\24Y1_T<+,?_$>P_P#\]?7^EK_FA_\
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MY1_T<+,?_$>P_P#\]?7^EK_FA_\ "D_C+_T27XF?^$)XH_\ E51_PI/XR_\
M1)?B9_X0GBC_ .55?Z7G]LO_ ,\%_P"_A_\ B:/[9?\ YX+_ -_#_P#$T?\
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MG[9W4>1<W^:'_P *3^,O_1)?B9_X0GBC_P"55'_"D_C+_P!$E^)G_A">*/\
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M#_\ $T?\1LQG_1.8?_PY3_\ F3U_I:G_ !)3E'_1PLQ_\1[#_P#SU]?Z6O\
MFA_\*3^,O_1)?B9_X0GBC_Y54?\ "D_C+_T27XF?^$)XH_\ E57^EY_;+_\
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MTRV$FI1W"WQ/&ZZ@MK$'!-Z <C_3 _X*!_\ )B?[9/\ V;!\=/\ U6GB2O\
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MZ3_T,UH5GZ7_ ,><?^])_P"AFM"L9_$_E^2-X[+T7Y'YW?L3?\EW_P""F/\
MV>CI'_K*O[.%?HC7YW?L3?\ )=_^"F/_ &>CI'_K*O[.%?HC1+=?X8?^D1.?
M"?P%_P!?<1_ZD50HHHJ3I.0\?^ ?!GQ3\$^*?AQ\1?#6D^,? OC;0]0\-^*_
M"^N6J7FDZYH>JV[VM_I][;OC=%-"[ .C)-#($F@DBFCCD7XM^%'_  31_9D^
M$GQ%\&_$NQF^-GQ!USX8R7,_PETGXT_M"?&/XQ^$/A1<W5A/I+ZCX$\)?$+Q
MCKNB:;K,.EW-UING>(;ZTU+7](L+FYM-)U.R@N)TD]3_ &E?'G[0/PJD\,_$
M#X4:5\*O'_@G3H[NQ\=_"7QIXIMOAGX\\4S7,T,FG7WPK^)&OZBG@9/$MK"E
MS;Q^#?&MGI&D>(7FC/\ PFOAYX<S_B%^SM\*OBA\>_VY]2^*7AWXA>'?"'CG
MPO\ 'W4?C%\0;[XA_&G]I+P7^UGX8^"NM:Q?:GI'[./BC]C'Q(@^"P\&6'AJ
M_P!+^&^F_%+PIJ^O_#G7M#TE/%OAJ\U#Q1<S7I7R^_\ X;RV*2=F[V5GWWTT
M?KIW/Z:Z_'G]J/XT_P#!2G6?A7XW\&^$?V)=?\+R^)_'NB^ H?'/P-_:$^&?
MC[XFV/P>U.?7O^$Z^('A31/&.G?#+1?#/C?^P=/TS2O":ZCK^I?V+K7BM=;E
M2X/AD6^H?L-13$G;\/P/XZOV5[_P%X<^"/PF\.?%[X+Z]\!_V5/A9_P7'^+%
MMXTT;XQ:QX.UCPAH\5W\._C'#\,M(^(FI6/B/Q382V_@+XSCP#IGB;6O%-ZV
M@7?C:ZT/4TUC56<7L'ZG?LG:[\1HO#W_  51\7?\$_\ 0/@WX]TV]_:PAO?V
M9-&US6[K0?V?/$_C%/A3\(;/XS7&G:[X/1X8]!F\:)XIGOM0\+EM-O\ QA;:
MAY<Y,MW/7["WWPD^%>I^%O%'@?4_AMX#U'P7XWU/5=:\9^$K_P ):#>>&O%F
ML:Y=)?:SJOB30[FPETS6]1U6]CCO-1O=1MKFYO+I$N)Y))D5QN>#O!?@[X>>
M&]+\'> ?"GASP1X2T2 VVC>%_"6B:;X=\/:3;EVE:#3M&TBVL]/LHFE=Y62W
MMXU:1WD8%V8F4K6]-7U>B2^7EWL-RO?Y:=-+:O;73[GTMK_(W^WKXX_X*O>)
MOC%_P2ULOV[O@=^R#\,OA=#_ ,%.?V<;GPSK?[/WQ&\>^+_%MYXY6+Q5%9Z9
MJFG>*2;"#0)=#EURYGO(1]J2_M=/A4B*:4'^PJOP@_X+A?\ (=_X)*?]I:?V
M9_\ TQ_$*OW?II6[OU_K^F+HO5_E$****8C\K_\ @K;_ ,D6_9F_[2+?L"_^
MM(^"J_5"ORO_ ."MO_)%OV9O^TBW[ O_ *TCX*K]4*2WEZ_H@"BBBF!^5'_!
M)S_D2OVW/^TF_P"VU_ZL6UK]5Z_*C_@DY_R)7[;G_:3?]MK_ -6+:U^J] WO
M\H_D@HHHH$?(7_!0/_DQ/]LG_LV#XZ?^JT\25_FJ5_I5_P#!0/\ Y,3_ &R?
M^S8/CI_ZK3Q)7^:I7\Y>/7\?AC_KUF__ *7EI_M!^R1_W3QW_P"PCPY_]-\;
M']W'_!OY_P HY/"'_95OB_\ ^I9+7(_\$"O^2._\% ?^TM'[;?\ Z<_ ===_
MP;^?\HY/"'_95OB__P"I9+7(_P#! K_DCO\ P4!_[2T?MM_^G/P'7[APO_R3
M7#W_ &),J_\ 4&@?Y7^-G_)Y?%S_ +.5QU_ZU&9G[O4445[I^7A1110 4444
M %%%% !1110!_+U_P<T?\D^_9%_['?XL?^H]X.K^12[_ ./2Z_Z]YO\ T6U?
MUU_\'-'_ "3[]D7_ +'?XL?^H]X.K^12[_X]+K_KWF_]%M7\E>+G_)??]RF5
M?DS_ *#_ -G7_P HB9K_ -E+Q_\ ^H&"/[DO^"M/_*(_PA_UY_LZ_P#IOTRO
MUD_96_Y-?_9O_P"R"_!__P!5[X=K\F_^"M/_ "B/\(?]>?[.O_IOTROUD_96
M_P"37_V;_P#L@OP?_P#5>^':_N;$_P#) Y-_V4N<_P#JNRH_YD\O_P"3[<8?
M]FXX1_\ 6@XH/>J***^./UT**** "H+FVMKVWGL[RW@N[2ZADM[FUN8HY[>X
M@F0QRP3P2J\4T,J,R21R*R.A*LI!(J>B@#(OTN]-T*]C\-:;I\U_8Z5=+H&C
MS3#2=+FO;:TD_LS3IKFWM;G^S;"6X2"VDG@L[C[) S21VTOEB)OYO?\ @HW^
MT?\ \%H/!GPB\$:[X*_9M^&/PR^)Z_&3X?Z?\+HO@'^T?XZ^,&L^/_%&H:KY
M+^ O&_PTN/V<=.\/>(/AWK6B#5)?%%UXD\3^"M/T&"TCU:W\6V%_;VMIJ']+
M-%'SM]WZH:=NG]?EZ^6A_+3_ ,'"=_X^U7]D3]BG4_BKH.A>%OB7?^.[F\\>
M^&_#.K3Z[X>T+Q=<?"^>77])T76;FUL[C4M-L-3:YMK2\EMHWFAC5SOSYC_R
M7+U'U'\Z_MC_ .#@CX"_&SX\?!7]GO3?@I\*?'OQ7U+PY\6M>U'7M-\ >&M2
M\4:CI&G7G@K4+2VU"^L-*@N;N*RENP+47/DF%)WBCD=&ECW?RR0_\$[_ -O*
M66*)?V.OVD TDB1J9/A%XSAC#.P4&2:;2HX8D!.7DE=(XURSLJ@D?S3XG9#G
M>/XYPF+P.3YGC,)'"Y7&6)PN Q6(H1E3Q%1U(RK4J4Z:<%*+FG).*:;LF?[8
M?06\6O"W@[Z*G&?#?%GB-P/PSQ!B^(>/:^%R//N*<ERG-L11QO#>3X?!U:&7
MX[&T,75IXJO2J4</.%*4:U6G.G3<I1:7U1_P7%_Y2)>/O^R5? K_ -5UIM0_
M\$-?^4FWP"_[ GQA_P#52>,*M?\ !<J*2#_@HO\ $."9&CFA^%WP-BEC;ADD
MC^'FG(Z,.S*RE3[BJO\ P0U_Y2;? +_L"?&'_P!5)XPKR9?\GJ7_ &4D/_34
M3]$P_P#RJXE_V:+%?^M'6/U*^,O_ "L=? G_ +&G1O\ UE'XB5_5G7\IGQE_
MY6.O@3_V-.C?^LH_$2OZLZ_MOC#^+P[_ -DED/\ Z8F?\V'A'_NWB%_V=CCG
M_P!2L(%%%%?('ZT%%%% !1110!!=?\>UQ_UPF_\ 1;5^%7_!N%_RBY\#?]EZ
M_:M_]:%^(-?NK=?\>UQ_UPF_]%M7X5?\&X7_ "BY\#?]EZ_:M_\ 6A?B#2ZK
MT?YQ&MI>GZH_=RBBBF(*\T^,'PD\$_'7X<^)OA3\1;;6[SP9XOM;>RURV\.>
M+?%?@769K>VO;;4(DL_%7@C6?#_B?2F-S:0^;)I6KV<D\'FVLS26T\T4GI=%
M 'X.?$__ ((%_LP^._CK^SCX\\/^)?B3X-^%7P/\8GXF^(_ =Q\8OVA_'OBW
MXB>/-&:-_!<,?C+Q_P#&CQ%I/@CPKHTRO=ZM'X:\(0^+]9=VLX/%NE6+R1-X
MI_P63_X)A?M6_MI_M%?#CXF? 72/ 6I>%?#7P8T[P)JC>*/'$7AK4H==LO&G
MC#776*SN-,NQ<63Z?KMB8[I;DNTZW$<D2>6CR_TG5RGB?QYX&\$BT/C/QGX3
M\(C4#*+ ^)_$6CZ +TP;//%H=5O+3[28?,C\WR=_E^8F_;N7/E9UDN S_+<1
ME.94YU,'BG1=:%*I*C-^PK4Z].U2%I1M4I0;MNKI[L^[\-?$CBOPEXUR;Q X
M)QF'P'$V0O'?V;B\5@L-F-"E_:66XO*<7SX/&4ZN'K<^"QV(IQ]I"7)*4:D+
M3A%K^+GX(_\ !"C_ (*"^"/C5\'?&OB'PW\)+;P_X-^*WPY\6Z[/;_%.UNKB
M'1?#/C+1=;U62VM8=#,EU<I86-PUO;)@SS!(MZ;]Z_T8_P#!17_DKG_!*[_M
M(]X6_P#68/VHJ]Y^!G[=O[//[0'QK^,?[.W@WQ++8?&+X*7-G/KW@S7I-&CN
M?%'@_5(HY='^)/P]U#1M9UK2?&7@/4FD^S'5M+OFO-)OE^P:_IND7<D,,O@W
M_!17_DKG_!*[_M(]X6_]9@_:BKBX<X7RCA7"U\)D]*K2HXFO]9JJM7J5Y.JJ
M<*5U*HVXKEIQ]U:7NSZ7QC\=/$7QZS_*N)/$G-,%FN;9/E,<DP-;!95@,HIT
M\OCC<5CU2G0R^C1I5)_6<97G[6<74M)0YN6,4OU HHHKZ(_'PHHHH *RM=_Y
M >L_]@K4?_22:M6LK7?^0'K/_8*U'_TDFIQW7JOS _RJQT_%OYFO[#?^#:'_
M )(/^TW_ -ED\,_^H)95_'D.GXM_,U_8;_P;0_\ )!_VF_\ LLGAG_U!+*OY
M4\)?^3@X[_L#S?\ ]2J!_OG^T._Y0[X&_P"RG\.?_66SL_I<HHHK^JC_  ,"
MBBB@#\Y/^"GO_)"_A%_V>K^Q+_ZTO\.:_1NOSD_X*>_\D+^$7_9ZO[$O_K2_
MPYK]&ZI_!'_%+\H'/#_><1_U[P_YU@HHHJ3H"N=OTMVNI#).Z-A,J(-X'R+C
MYO-7.1@]!CISUKHJY;4_^/V7Z1_^BTJX;OT_5&<^FG?OY>9%Y=I_S]2?^ W_
M -NH\NT_Y^I/_ ;_ .W55HK7YO\ #_+^KORMG\E^/^?]7?E:UY=I_P _4G_@
M-_\ ;J/+M/\ GZD_\!O_ +=56BCYO\/\OZN_*Q\E^/\ G_5WY6M>7:?\_4G_
M (#?_;J/+M/^?J3_ ,!O_MU9UU<1VEM<W<V[R;6WFN9=HW-Y<$;2R;5XW-L0
M[1D9.!GFOBWX>?MS^ O'>D_!SQ9J'PS^,'P\^'OQ_P!:TWPU\)OB-XVT_P"'
MLOA7Q+XDUV/4I/#>AWB^"?B/XR\0^%+[Q-_9-[#H1\7Z!H5K>WR0Z:;F+4;J
MVM92SWOM;M_71[>?E:95(0<5)I.5[:2V3BFVUHE>45=M*\DNUON/R[3_ )^I
M/_ ;_P"W4>7:?\_4G_@-_P#;J^4=#_:_^$6N_M6^,OV.(3XGL/B]X-\#:;X_
MEEU/18K7P?XATF^M],O;O3_#&OI?S/J6O:'8:UI.H:UI4^GV4EO8WT=U;R7<
M45PT5CX__M;?";]F_P 5_!#P1X^;Q)>^)_C]X_L?A_X'TKPMH\6L36MS>7VE
M:5+XF\2F:_L$T;PCI^KZ_P"'](OM7W7,PU'7--M;:QNGE?RRS\^_37\/ZU^2
M=:DHRFYP482Y)2<M(SYE'E;OH^9I6[OT/J;R[3_GZD_\!O\ [=1Y=I_S]2?^
M W_VZJ4DL4+1I++'&TLGDPJ[JAFE"/)Y408@R2>7'))L0%MD;OC:K$/H^;_#
M_+^KORM?R7X_Y_U=^5K7EVG_ #]2?^ W_P!NH\NT_P"?J3_P&_\ MU5RCCDH
MP!X!*D9)Z#IWKS_P#\3O!7Q/7QH_@K5I-77X>_$+Q3\*_%I?3M2T[^R_'/@R
M>WM_$>CC^TK2T^VK8RW4 34;'[3IMXL@>SNYU#$'S?X?Y?U=^5BZ32=KO97U
M=K7LKZ^=N_I;TCR[3_GZD_\  ;_[=1Y=I_S]2?\ @-_]NKQ/XC_%VX\!ZOI_
MA_1_A1\7/BGKE]I%WK\MG\./#>D36&FZ/93&WEFU'Q3XS\1^#/!R:G/.K)I_
MABV\0W7BS4PK3:?H5Q /-K4^%'QA\ _&CX9:!\7/ NKO<>"O$%CJ%Y%>ZM:7
M&AWFE2:->WNE^(--\0:?J:07.B:KX=U73=2TS7+*^6-]/O;"ZCD8I&)&+>?Y
M>7E_5W\I4XN7)IS)7MKJERWL]G:ZYK-\O,KVO$]8\NT_Y^I/_ ;_ .W4>7:?
M\_4G_@-_]NKY9_99_:U^%'[8/A;QUXS^#Z^*G\/> OB7K/PPOKSQ1H/]@MK6
MI:3HWA_Q';>(?#UNUW=SWOA/Q#X?\4:)K/AW5+I+&YU#3[V*>33[960/]/%'
M&,HPSP,J>3Z#CG\*+-;W_#R\OZOZ6<)QG%3@XRC)74D[IKNFGKM^+\K>/^//
MV<O@3\3?$*^+?&W@?3-6\4#38-&G\16QUC0=:U'1K66::UT;6=2\.:QI%WKN
MCVTMQ</;Z5K,M_I\!N+@16ZB>4-Z9X:\*>$?!F@:3X5\(Z7IGACPSH-E%IVB
MZ!H.C6VEZ/I5C#GRK2PT^S:&VMH%+,VR*-0SL\C;G=F.GM;.W:=W]W!SSTXZ
MTI1U&65E'3)4@9].11\W^'EY>7X^EA1BFY*$4WNTK-[7NUJ[VU_X:UCR[3_G
MZD_\!O\ [=1Y=I_S]2?^ W_VZJM%'S?X?Y?U=^5G\E^/^?\ 5WY6M>7:?\_4
MG_@-_P#;J/+M/^?J3_P&_P#MU5:*/F_P_P OZN_*Q\E^/^?]7?E:UY=I_P _
M4G_@-_\ ;JLS);&"U!N'"A)-I$&2P\PY)'FC;@]LG(YXZ5F5;G_X][/_ ')?
M_1AI6\W^'^0UUTZ>?>/F)Y=I_P _4G_@-_\ ;J/+M/\ GZD_\!O_ +=56O*_
MBU\0_%'PXT33]5\*?!OXB?&J]O=3%A<>'_AO=> [35=+MC;33_VM?2?$#QEX
M*TQK 21):;+*_N[[S[B(_9/($LT;MY_DOZ_X/I:7)13;6B[*4GTV4;M^B75^
M5O7O+M/^?J3_ ,!O_MU'EVG_ #]2?^ W_P!NKY"^!_[59^,7Q6^(?P:U?X'?
M%OX0>-/AIX0\)>,_$4/Q!E^'&H:>FG^-[_5[+P[8"_\ AYX^\;P6FMWT6AZC
MJ<>E:FUC=-I,*:@B-!/ TGUG19KK^7EV_K7TLH5(U(\T-5=K52B[Q=FFI6::
M::::6M_*VI:);B8E+AW/E3<&#;P8VR<^:>0.0,<GC(ZU5\NT_P"?J3_P&_\
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M_N\O+[_5]M)]M2M?FCO9WNFK*+;DG9Q24HMMI)*:;:3B?9WEVG_/U)_X#?\
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M_5>@;W^4?R04444"/D+_ (*!_P#)B?[9/_9L'QT_]5IXDK_-4K_2K_X*!_\
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MOZGXP_B\._\ 9)9#_P"F)G^)7A'_ +MXA?\ 9V..?_4K"!1117R!^M!1110
M4444 077_'M<?]<)O_1;5^%7_!N%_P HN? W_9>OVK?_ %H7X@U^ZMU_Q[7'
M_7";_P!%M7X5?\&X7_*+GP-_V7K]JW_UH7X@TNJ]'^<1K:7I^J/W<HHHIB"B
MBB@ KP#XX?LJ?LU?M+GP\?V@_@3\*_C0?"0U$>&#\2O!6A>+SH U;[(=4&DG
M6;.[-B-0-C9&[%N4$YM8#)N\I,>_T4 ?F?\ LI_\$H?V2_V0_P!HOXQ?M/\
MPQ\$:)9_$OXII%H6A)IGA+P=X/\ "_PC^'MO%!&O@3X<^'/!VB:+865O?R6\
M5QXB\2ZFNH^*/$4T<?\ :.J/&)8YL_\ X**_\E<_X)7?]I'O"W_K,'[45?J!
M7Y?_ /!17_DKG_!*[_M(]X6_]9@_:BHLELK#6Z]5^9^H%%%% @HHHH *RM=_
MY >L_P#8*U'_ -))JU:S=:C>71]6BB1I))--OXXXT4L[N]K*J(B@$LS,0JJ
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MQ_SPF_[]/_\ $T?9[C_GA-_WZ?\ ^)K4S(:*F^SW'_/";_OT_P#\31]GN/\
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M^]'WD[7LUU\CX\_X)UM<Z+\/OC?\,;V33O$6H_"3]IOXL>%=;^+6E3WDUO\
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MO&Q\82ZOXHUN#2?#%W8>-XM6M+J'5WNGO$_1ZS^&OA/3_'FN?$^U\,QIX_\
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M .G/P'76_P#!OV0W_!./P@001_PM;XP<@@CCQ9*#R/0\?6N2_P""!7_)'?\
M@H#_ -I:/VV__3GX#K]PX7_Y)KA[_L297_Z@T#_+'QL:?C+XMM--/Q*XY::U
M33XHS*S3ZIG[O4445[I^7A1110 4444 %%%% !1110!_+U_P<T?\D^_9%_['
M?XL?^H]X.K^12[_X]+K_ *]YO_1;5_77_P '-'_)/OV1?^QW^+'_ *CW@ZOY
M%+O_ (]+K_KWF_\ 1;5_)7BY_P E]_W*95^3/^@_]G7_ ,HB9K_V4O'_ /Z@
M8(_N2_X*T_\ *(_PA_UY_LZ_^F_3*_63]E;_ )-?_9O_ .R"_!__ -5[X=K\
MF_\ @K3_ ,HC_"'_ %Y_LZ_^F_3*_63]E;_DU_\ 9O\ ^R"_!_\ ]5[X=K^Y
ML3_R0.3?]E+G/_JNRH_YD\O_ .3[<8?]FXX1_P#6@XH/>J***^./UT**** "
MBBB@ HHHH **** /D?\ : _;T_8W_97\3:7X*_:(_:/^%'P>\7ZWHB^(]'\.
M^._%%KHFIZAH<EW=:?%JL%M*KRM827UE=VJW 0J9K:=%#-&PKY\_X)\?\%4/
M@!_P4&U[XV_#[X?W^BZ?\4?@-XIN-+\5>'=!\7:;X^\->(_!EY=21^$?B=X#
M\;:/:V6G^(?"GB6V5!-!-9Z=K?AW51+I&MZ9;3"WEN?TBU'P[X?UB5)]6T+1
MM4GCC\J.;4=+L;Z:.+<6$:274$KJ@9F;8"%W$G&2:\"_9T_9&^!/[+!^)5Y\
M(/"4VF^(OC'XZU3XC?%'QIK^L:GXI\;^./%.IR.RSZ]XIUVXO-6N=-T>W?[!
MX=T-+B+1O#^GC[)I-C:QO+YBUNNVM_T'I_7]?/KT6FY_/%\9?^5CKX$_]C3H
MW_K*/Q$K^K.OY3/C+_RL=? G_L:=&_\ 64?B)7]6=?8<8?Q>'?\ LDLA_P#3
M$S\D\(_]V\0O^SL<<_\ J5A HHHKY _6@HHHH **** (+K_CVN/^N$W_ *+:
MOPJ_X-PO^47/@;_LO7[5O_K0OQ!K]U;K_CVN/^N$W_HMJ_"K_@W"_P"47/@;
M_LO7[5O_ *T+\0:75>C_ #B-;2]/U1^[E%%%,04444 %%%% !7Y?_P#!17_D
MKG_!*[_M(]X6_P#68/VHJ_4"OR__ ."BO_)7/^"5W_:1[PM_ZS!^U%0..Z]5
M^9^H%%%% @HHHH ***CF1Y(I8XY6A=XW1)E56:)V4JLJJX9&:,D,%<%20 P(
MR* ,O6/$7A_PZM@_B#7=&T)-5U&VT?2VUC4[+3%U+5[TL+/2[!KV> 7FHW91
MQ;6-N9+F<HWE1/M.-BOYV/\ @H7_ ,$OOV^OCU^SMXP^&WA#]O;XF_'W5_&7
MB7PW%I'@7XF?#K]F7P%X+\';?$$%^GC^?Q=I'PS'C6PN/A_%#_:6DGP5=6GC
M&[O8K:#3K^V\VYG7]P_V>?AUXS^$?P-^%7PR^(GQ/USXT>.? W@?P_X:\4_%
M/Q):VEEK?CC6=*L(K6\UZ_M[*-(DENI$.UI6N+V6)$FU&\O;^2XNIE?R:_K^
MOUMI=M>:?]+O8]DHHHIB"BBB@#\Y/^"GO_)"_A%_V>K^Q+_ZTO\ #FOT;K\Y
M/^"GO_)"_A%_V>K^Q+_ZTO\ #FOT;JG\$?\ %+\H'/#_ 'G$?]>\/^=8****
MDZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP+_ZTCX*K]4*2WEZ_H@"BBBF!^5'_!)S_D2OVW/^TF_[;7_JQ;6OU7K\J/\
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M5DDM$DEHDELC)MR<Y2;E*5W*3;;;<DVVWJVWJV]6]3]WJ***9(4444 %%%%
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M&5<G:Z,,G%?JK^RM_P FO_LW_P#9!?@__P"J]\.U_9^)_P"2!R;_ +*7.?\
MU7Y4?\[.7:^.W%]M?^-<<(_^M!Q0>]4445\<?KH4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /SM_8F(_P"%\_\ !3)<_,/V
MT-&8KW"M^RK^SCM)'7#8.#T.#CI7Z)5^<O[*4XT/]M3_ (*5^!9E9+J[^)/[
M/_Q;MR5*QW&F>._@'X8\*Q319P9&CO\ X:ZA;W#J"JR1JF<K@?HU53W7^&'_
M *2CGPNE)KM6Q*U_["*H4445)T!1110 5^+'[8'_  3A\:ZO\'_$-E\*O&OQ
MT_:JMO$'QL^&WQ,^*O[,G[3G[3?C+7_AU\7_ (8^#-:U_6O$'P6\*WOB9[K1
M/ 5AKM_J^E:BEG?1-X<U<>%-%T+Q XTE6(_:>B@:=NWS7]?@?SD_##]AW]K3
MX4^"8?C3\'?V<?A]\%[KX8_MG^&?VE_@9_P3SL/BWH-WX8\,> IO@5XP^!OQ
MH\*:5\1M.L6^'W@[QE\4)/'>K_$+2-*T<2>!=$UG2;6&XNXI]>U26W^SO@M^
MQ3XR^-/PC_;4;]K_ $'5_@_K_P"WE\5;'QOXI^&_PE^*4Y\4_"KP5X1\'^!/
M W@GP[%\5?"JVT%SXPGL/ <.K^*-2\.[]&>75[C2+5[FR21I/UHHI6_K^OTT
ML[#YGY=->NEK+TT1^&_P]_X-\OV#OAU\4/A;\6[/Q)^U1XJ\3_!WX@^&?B=X
M(M/B!^T=XR\9^';/Q?X2OX]1T:_NM#UF*:UN5BF0QRH#$\MM+/!YJI,X/[D4
M44));";O_5OR"BBBF(^"_P#@H5\#OB1\>_AG\$/#GPQT6WUS5_!?[97[)/Q>
M\06]SJNFZ0MIX$^%?QJ\,>,/&VJQSZI<VL-S-I>@:=>7D6G6[R7]^\0MK&WN
M+ETB;[THHH_4 HHHH ^!O^"?WP+^)/P'\,?M0:;\3-%MM$N_B7^W%^T_\:?"
M$=MJNFZL-0^'GQ)\9P:MX0U>9],N;I+&XU&PC::73+MHM1LN([RW@E.P??-%
M% V[_P!=M HHHH$%%%% !7Y1_P#!)+]E[XS_ +*_PX_:\\/?&SPU9^&=5^*W
M_!0?]J#X\>!X+/7M&U]-5^&/Q)OO"DWA#79IM%O+V+3[C4H]+O6DTB_:WU2Q
M\M1>6L#2(#^KE% =_/\ S3_0**** "BBB@ HHHH **** "BBB@ KB]-^(_P_
MUGQIXB^'&D^-_"FI?$'PCI^F:MXI\$6.OZ7=>+/#NEZT)#H^I:UX?ANGU73;
M#5!%)]@O+NUBM[LQN()'*D#SG]HCX(ZO\>_ ]IX,T7XZ_&W]GVYMM>L];D\:
M? 77O"_AWQE>0VEM>V[:%=:AXL\(>--/.B7;W:75W#!ID%W)<65H4O8XEFBF
M_(?X?_\ !)'XZ^%_^"F?PP_:ZUK]L;XZ^,/A7\%/A=J/AJQOOB'\0?"WBOXO
M?&35_$US+-?> O&2>&/@[\.]&T#X-^'B4U*/2+_5O'6JZUKV+W2V\(DRRLG?
MM?\ K^OZV>FM_E^'_!_X.Q[+_P %VO\ E'QXQ_[*+\-/_3Y)7Z)_LK?\FO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFL;SQ5HEZZ^#?&^J:#=ZLFH6D]A>O;#Z"^#G_!0'XX^//V3?^"7_ ,:M;L_
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MKP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?@?UIT5_)9_P\3_;B_Z.+UO_ ,-O\"__ )U5'_#Q/]N+_HXO6_\ PV_P+_\
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M_P @_M.A_)5Z=(=>7^__ 'OP/ZTZ*_DL_P"'B?[<7_1Q>M_^&W^!?_SJJ/\
MAXG^W%_T<7K?_AM_@7_\ZJCD?=?C_D']IT/Y*O3I#KR_W_[WX']:=%?R6?\
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+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ny20077915x1_charts01x1.jpg
<TEXT>
begin 644 ny20077915x1_charts01x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M_+/)?<?G=_PPS\6/^DB_[;/_ (./@E_\YFC_ (89^+'_ $D7_;9_\''P2_\
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ME_=_\!C_ )>2^X/J]+_IY_X.K?\ RSR7W'YW?\,,_%C_ *2+_ML_^#CX)?\
MSF:/^&&?BQ_TD7_;9_\ !Q\$O_G,U^B-%'/+^[_X#'_+R7W!]7I?]//_  =6
M_P#EGDON/SN_X89^+'_21?\ ;9_\''P2_P#G,T?\,,_%C_I(O^VS_P"#CX)?
M_.9K]$:*.>7]W_P&/^7DON#ZO2_Z>?\ @ZM_\L\E]Q^=W_##/Q8_Z2+_ +;/
M_@X^"7_SF:/^&&?BQ_TD7_;9_P#!Q\$O_G,U^B-%'/+^[_X#'_+R7W!]7I?]
M//\ P=6_^6>2^X_.[_AAGXL?])%_VV?_  <?!+_YS-'_  PS\6/^DB_[;/\
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M_P"=U7Z%T4<R_DA_Y-_\EY?GW8?5Y?\ 03B?_ Z?_P J/ST_M[_@J=_T3?\
M8<_\.?\ &S_YW5']O?\ !4[_ *)O^PY_X<_XV?\ SNJ_0NBCF7\D/_)O_DO+
M\^[#ZO+_ *"<3_X'3_\ E1^>G]O?\%3O^B;_ +#G_AS_ (V?_.ZH_M[_ (*G
M?]$W_8<_\.?\;/\ YW5?H711S+^2'_DW_P EY?GW8?5Y?]!.)_\  Z?_ ,J/
MST_M[_@J=_T3?]AS_P .?\;/_G=4?V]_P5._Z)O^PY_X<_XV?_.ZK]"Z*.9?
MR0_\F_\ DO+\^[#ZO+_H)Q/_ ('3_P#E1^>G]O?\%3O^B;_L.?\ AS_C9_\
M.ZH_M[_@J=_T3?\ 8<_\.?\ &S_YW5?H711S+^2'_DW_ ,EY?GW8?5Y?]!.)
M_P# Z?\ \J/ST_M[_@J=_P!$W_8<_P##G_&S_P"=U1_;W_!4[_HF_P"PY_X<
M_P"-G_SNJ_0NBCF7\D/_ ";_ .2\OS[L/J\O^@G$_P#@=/\ ^5'YZ?V]_P %
M3O\ HF_[#G_AS_C9_P#.ZH_M[_@J=_T3?]AS_P .?\;/_G=5^A=%',OY(?\
MDW_R7E^?=A]7E_T$XG_P.G_\J/ST_M[_ (*G?]$W_8<_\.?\;/\ YW5']O?\
M%3O^B;_L.?\ AS_C9_\ .ZK]"Z*.9?R0_P#)O_DO+\^[#ZO+_H)Q/_@=/_Y4
M?GI_;W_!4[_HF_[#G_AS_C9_\[JC^WO^"IW_ $3?]AS_ ,.?\;/_ )W5?H71
M1S+^2'_DW_R7E^?=A]7E_P!!.)_\#I__ "H_/3^WO^"IW_1-_P!AS_PY_P ;
M/_G=4?V]_P %3O\ HF_[#G_AS_C9_P#.ZK]"Z*.9?R0_\F_^2\OS[L/J\O\
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M7Z%T4<R_DA_Y-_\ )>7Y]V'U>7_03B?_  .G_P#*C\]/[>_X*G?]$W_8<_\
M#G_&S_YW5']O?\%3O^B;_L.?^'/^-G_SNJ_0NBCF7\D/_)O_ )+R_/NP^KR_
MZ"<3_P"!T_\ Y4?GI_;W_!4[_HF_[#G_ (<_XV?_ #NJ/[>_X*G?]$W_ &'/
M_#G_ !L_^=U7Z%T4<R_DA_Y-_P#)>7Y]V'U>7_03B?\ P.G_ /*C\]/[>_X*
MG?\ 1-_V'/\ PY_QL_\ G=4?V]_P5._Z)O\ L.?^'/\ C9_\[JOT+HHYE_)#
M_P F_P#DO+\^[#ZO+_H)Q/\ X'3_ /E1^>G]O?\ !4[_ *)O^PY_X<_XV?\
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M)XF\1MH.IV,.LZYJ&F:=)<37LT4L]Q)*55BK!:]>_P""@_[?GQ9^,W_!*?\
M8#M/@'\0O%OASXZ?M.Z?IE]XIU_P5XBU?0_%T"_ ?P7JE[\7B=5T:ZM-60#Q
M+H%R^IB*9?M<<$T<@:*4Y/9-J#4KJ;:VV2ZO7[EHV.>;TZ=3&TIT9J>#A3FD
MI1?MG-4O<@[:24ZU.'6[DFM+']=M%?AM_P &\GQ&^(?Q3_X)Q^&O%?Q/\=>+
M_B)XJE^*OQ,L)O$GC?Q%J_BC7);.RU"QCM+5]4UN[O;XVULI86]NTWEPAF$:
M+DU^D_[9/[5OP\_8M_9X^(/[0'Q'N%?3?".F.F@Z!%*L>I^,O&%^&M_#7A#1
MHR&>;4-;U(Q0 QQR?9;47-]*H@M96&;BU)Q6KO966_R.ZCBH5<)3Q<K4J<Z*
MK2YI)J$7'F=Y+1V75+7H?45%?R1?\$/OVE_VP?CE_P %!/VX;C]IGQ)XZD\4
M2?"_3_&NG_!K7O$FK#PGX N_$&N:+JGA[0=$\+7=Z^D>&Y+/0;_3M,=DL[:^
MC1I3J+FZDNBW$_M'_LS_ /!2G1_@)^UO^WK^V!^W#\7?V8OB=\.?$FK:S\"_
M@YX ^)5@GPNN_#MA)9W'AS2#9^%->;39I]>N+PZ#I.G-:G56NK"6\UB&\CN\
MC3V5I<KFEI&VEVW*UDDG?KN<4<T]IAXXBEA:U2+>(YE>,%3AAW:4JDYVC&4O
MLTW[S=U]EL_L3HK^9S7M1_X*S?MZ?L(?\$\K?X4Z_J?PFN/C/96>I?M:_&GP
MUK&@^#/'6E^"TU6/3-!\1:-IUS?Z3JH7Q%X<#^,-0@\*"&ZO;E[6VB6WLYW@
MDX[]A76_VBOV6?\ @L)XS_8(TG]JCXG?M=? -?@W_P )WXVOOBCK4_B_7/A?
MXH;2A>VUG>:W<75Z=)U);XV,$UG;W,%K=6FO65O/9"_MBZKV>C]^/,K^ZNR:
M3;;M;?1=2UF2=2@OJU=4:\J$(5Y\L$YXBG[2,5!OFDHQ=JDHZ1E=:I-G]2E%
M?+7[:7[4WAW]BS]FKXE_M*^*_"VM>--!^&ECI5[?^&O#UU8V6KZFNK:[IF@Q
M):7.I,MG$8I]3CGE:8_ZF*0(&<J#^5UE_P %_?@XN@?#3XK>)OV5_P!J;P;^
MS)\0[S0M$D_:9U[P;9Q?#/0/$NKI''=:?(\=RU]JVEZ1J33Z=<:]8)Y%Z]G=
M3:9:W:HJ/*A.2O&-U\NGS_X?H=-;&X6A/V=:M&$^53::EI!R<5-M1:45)-2D
MVE'3F:35_P!]J*_F[_;7^.'CZ+_@MA_P2U\+^ /BMXQM/A'\3? <NO:MX8\-
M>,-;L_ OC>ROKKQG<Z=J>J:%87\6BZY'=6264D-Q>6EQYD$=OABL<>WZD_:
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M>'BVG52:JTZ+TE_%K1C*G#1;SC*+36FNK1^B]%?S^Z3_ ,%^_AUXJ^.GB_\
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MM6U7QCX^\7:D6CT7P9X)T"%A=Z[XCUBX AM+.W 2)/,NKR6WLX)IX_COP/\
MLR?$W]J?Q/X?^.7[=-M;0:!I5W;^(?A)^QO87G]I?#KX<SQS&YT;Q-\7YT(L
M_BC\5;2 Q2-;W,#^$/"5\T\&D6NH7$2:D-7]FGX(>-_C+X]TS]MC]JK2Y8OB
M'>Z?<#]GKX*ZDOFZ'^S9\/-8 DAN'TZ51#<_&;Q?8FWN?&OB>>-[W2+<P>&-
M*DM+6UNEG_2*KORZ*U^LNWE'M;9O?M;KS1B\0U4JIJCHZ5%Z<RW56LNK?V*3
M]V"M*:=1I4XX88;>**WMXHX((8TBAAAC6****-0J1Q1H%2.-% 5$10JJ
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MABFD\."X-CL.ERS#=+$8R[*S1;Q"3&?>/VH?BY_P4T_99^(7_!.W5- _;O\
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M!3UU3LFS]BJ***S/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\NF-HJZ#HJZ,S^8VDC2[$:8SEQ(7:P$'V4N9 )-QBSO ;.X9J?:_W?M1EO\
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ME%%%2=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEN%66SE^(OC#4&^&/PCM;UOF6*YTW27^(GB"UMY0))'6SO(OEMR3^C]?F_\
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M/F)N^F:&FK735]KJU_3N.,X3<E&<9.#Y9J,DW&7\LDF^5^3LPHHHI%!1110
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M)-U$G7I*;BDFW:#E?1KEO?2Y\H:O^W=_P6"^&?[>>G?\$^O$VH?LF^/?B?\
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M^5^VBW335[3Y;-Q9\*?$3X&>.?VO_P!F_P#;=_X+)V3ZG:_$GPS^UGX:\>?
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M?XF00K-:>*H+77[J"&*T@6>2RAL[VTCC42%Y_N#]K+_@IW^TSX,_:?\  _[
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M_A%?!'A:U@TV[UC6?&/Q)\<S6&HVOA?PSI-A9.D(^RW&HZWJD]GI&EV\MU<
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M "8+^U%_V32Z_P#3MI55#XX_XH_FC#%?[MB/^O%;_P!-R/M+PO\ \BSX=_[
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MNW=Z+7R5E]R5B(0A3CRPBH1O*5HJRO*3E)V[RDVWW;;"BBBD6%?-7Q$_9/\
MA#\5/C_\&?VD?'%CK.M^/_@%I_B2T^&5E/J\O_"):'?^*42+4O$;>'O+-O<^
M(XX(X[>QU223?:1HGEIO1'7Z5HIIM;-KTT)G"%1*,XJ24HR2DKKFA)3@[=XR
M2DNS2?0****104444 %%%% !1110 4444 %%%% !1110 5^;G_!1/_D+_L!_
M]I#_ -G[_P!-?CROTCK\W/\ @HG_ ,A?]@/_ +2'_L_?^FOQY50^)?/\F<^*
M_@2_Q4O_ $[ _2.BBBI.@_.W3O\ E*SXD_[,/T#_ -7KJ-?HE7YVZ=_RE9\2
M?]F'Z!_ZO74:_1*JENO\,/\ TB)A0VJ_]?ZOYH****DW"BBB@ HHHH *_/W_
M (*'_M*?&O\ 9W^%WA2+X _"7QM\1OB#\3O&5MX*_P"$I\,?#WQ'\3-)^#/A
MR:VEN/$'Q1\1>$?# 74_$DNA68"^'/"ZW>FP:_KLMK;WNI6EA%=LWZ!44?U_
M6X+3S]3^>#6/A<FH?LH?#;X@?L[?!K]IGQMXX_9Y_;<^&_[4GQIT_P",GPXU
M#P%\<OVA]9A:YB^*7B_0=#UJ33[;Q!KKZ'K*2>'M)LY;;3;:VT&V\/:?E[6!
M9>!^,_PG_:'_ &H-=_:/_;D\#?L\?%;0;/PE\8_V%/%OP9^"OQ!T.V\%?&#X
MO>#_ -DWQY>>+?BIJUIX5NM0:33;SQ!8^*==L_A]I6O7-O>:I<:#!*4C&HV]
MJO\ 2[11\W_77;_@#OI;^NG^1_-9\;OAC^T!^V5XJ_:>_;)\!?L[_%KP?IO@
MCP_^QKI'P6^$WQ5T*#X??%+XRWO[,_QE\3?'+XCW-GX?N+RYN=-M=0A\5_\
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MEU9S[&)BN;>6)P'1@'==_P"OZ:$>B4444 %%%% !1110 445\_\ [1OQRF^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:TZ=&:G5C4K5&HQI5)1J4Y1C",Y5)34KW@EJFTN?^%GP/\%_#G6O#NIZC?\
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M0 4444 ?GK_P5G_Y1C_M[?\ 9J/QM_\ 4$UFO3?^"?O_ "8M^QY_V;1\%/\
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MTRO^3N8+_LB,D_\ 5KQ"?N1_P0*_Y/ \9?\ 9%?$O_J1^$Z_17_@X1_Y-O\
M@G_V6M__ %!?$]?G5_P0*_Y/ \9?]D5\2_\ J1^$Z_17_@X1_P"3;_@G_P!E
MK?\ ]07Q/6M+_D7U?67YQ/T+@O\ Y0TXT_["\V_]7.4G\D5?TL_\&[G_ "&O
MVG?^P5\-O_2SQ97\TU?TL_\ !NY_R&OVG?\ L%?#;_TL\65S8+_>*?S_ "9^
M#_1D_P"3X<#_ /7W//\ UFLX+W_!Q)_K_P!E_P#ZX?$[_P!&^#J_F8K^F?\
MX.)/]?\ LO\ _7#XG?\ HWP=7\S%+&?[U6]8?^FJ9K]*#_D^'&G_ '0/_69R
M<_KE_P"#?3_DVCXP?]EE;_U$- K\^O\ @X$_Y.L^&7_9#](_]3+QC7Z"_P#!
MOI_R;1\8/^RRM_ZB&@5^?7_!P)_R=9\,O^R'Z1_ZF7C&NNI_R+X?]N_^EL_>
M>,O^4,>$_P#K[DO_ *T.-/P?K^OC_@W[_P"35/BA_P!EPU/_ -0KP=7\@]?U
M\?\ !OW_ ,FJ?%#_ ++AJ?\ ZA7@ZL,!_O'_ &Y+]#\A^B1_R>?+/^Q%G_\
MZB1/Q<_X+/\ _)_GQ1_[ G@7_P!133:_*JOU5_X+/_\ )_GQ1_[ G@7_ -13
M3:_*JL,1_'K?]?)_^E,_+?&#_DZGB)_V6/$'_JRQ!_<!_P $6/\ E'M\)O\
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M^Q?&3Q]I_BVVMI-56#5?#OBKPSIEYYIU&XTDR2_M!\*O^"??[%7P0O?$-_\
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M)M7N6O-7.BR3E[VSBU6Y=IM2MX[K[/?-M^U12A$"^[>%OA!\+O!&L66O>#O
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MKXE_]2/PG7Z*_P#!PC_R;?\ !/\ [+6__J"^)Z_.K_@@5_R>!XR_[(KXE_\
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MU66'QYX<A@MM-UNV_MB\&EK D!"!K&S"Z?/*I7S#;,\@W9+>4?M-?M6_#OX
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M?!C_ +-MTC_U87CFOYHZ_H;@G_DF,L_PXG_U,Q!_$OBU_P G X@_Q9=_ZJ<
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MU?V[-4TKX5_#?3=3L?V6?C3=V6HV'@;PQ9WUG=P^!]8DANK6[M]+CN+>YAD
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M6\44*W-XTTJQ(L:L$4*/TBK\O_V&_@7_ ,%!?V>='^&_PE^,GCW]D;Q1\#/
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M)O\ L8OB?_ZL/Q#7ZL5^4_\ P18_Y1[?";_L8OB?_P"K#\0U^K%>]1_A4O\
MKW#_ -)1_K/X-?\ )I/#+_L@^%/_ %28(****T/TH**** "BBB@ KX1_;WOH
M=,\+?LYZC<%A!9?M@? FYE*JSMLAO]<<[44%F8XPJJ"22!@U]W5^<_\ P4OT
M^UU;X3_!33+Z^OM+L[_]JWX(6MUJ6F2O#J-C!-?:VLMW931 R174"$R0N@+*
MZ@@9H<G%2DFDXPG).6R<82:;]&C*O%3IN$K\LYTXRMO:56"=K:WL]+=3$\06
M%U>?&;5_V@OB'XKN;#P_HG@H^&(_!>K:U/;>!M(\'G5I/$$VMZKH5Q<PZ,NN
MW;&VBN=<U5#-;6EM':6VU79:[JS\?_#/XL:/>)\,/&MG=6.I6DME)JGAFXCG
ML?L'VIK.\33)XE: W:NES:/<QOM 9_)!9 U;.I^"/#WBC3],\)W&A^&_%7P^
MU6QE3QJ?&\4VJZSJ]A864+>&1]FN8C:W!N[A4N-2;5&7RH8C)Y3.0U>4?#_X
M-V'PG\0^+=/^$O@;0/ WP<U*>?Q$=3DO[[4M2\1>-=?G2ZU:YT& 3W5GI_A*
MWC*K:0K/ KW[2BQLXH%+2>9A,%4EA776-JXC,94W6?M,13J1]E12AA:-+X)U
M*L:WM;T8PC35*I&5*+7.W]A5KT'4C2=!4*--QIT5&G[.*YFO:RJ1M)J37*XR
MO*I*49>U>J:^#?C%_P $XM#\/Z5%J_P.\(0>/KJZ^+]GXVU+PGXK\;0^%?L&
ME7MU<?VKH^C^(1I=Y>0>'],>Y?4;'P["\,-Y)<WD5Q,2Z*T__!/S]C;Q1\'O
M@S\<? WQ[F'PVT[XH^,/'&AQ^ O!WCC28=/T3P7/J<T&B:AX/\1Z/%97_AZ3
M5-)N'>YC$[ZG;RR27#O'.^P?I%HUIXA\$KXVU[XJ>(/!FG?#O2E&IZ3J@O+^
M2^@M8%FEO[SQ#<Z@MMIMI 5\J.VM[,.\;1C$TKR*M?E'\3OVY?\ @G/>_$>X
M\):?HK^-_%UWI]QXT\0_V;;>*=.T.QL8+"ZU2W\1:E;7C"V75-7-LD>FK9V+
M76I7%S##"7EEAC?#&5\%@:N6K.LYJ4J.54.?*Z=*5*K3H?69)UW0H2JT:MXU
MJT4U&I.C&K3:<811ZF%_M/,:6+HY?@)XKZW53Q>)5*JZD_814J4:U5WHQ7LZ
M;E=4HUFFI<\M#]?_  WX2LO#OAQI9+V_G%G<66G1:5JU[]MT_3]#TL"VL9]#
M1V"L[6:H+N>Y9WF"(S_-EFT8+;0?%%G=:3H#Z+8^'Y6N-2U9K;3H6M-8FF8B
M_L8/L\D<#W-^6+SW0\TN&961BQK\Y_"O[<OP]\4Q^&)KK2-;^'G@V_\ #^F:
MWI6K>-]=\,^']-\0:/=6-Q/=6D6FZKJXUR^_L-(!#+!#I0G>>:W01R+*!7W[
M\&/B1\ O&7P9L/%WP,BL=:\&:M->ZUIUY9A[8P:E!J!BUR*33KJ*WU'3S#/'
M/NMVL(0%)DCB\ME>NC X_"56W0KPG*KSXJ,'**KRA"K4C*K6PR:J491G^\A*
M<6G&K&K"7)*,WYV/P.-PB3K4*T;5(45-04J%.<X0E&G&L[P=XIQY4^9.$X2C
MS1DBCKFC:IX*7PQ!\-](TY?".@QW">(?!VF6D4$IT_<]Q+=Z/;QF)(KB!WEE
MGA41B0*TA,A)%<W\8OV<_A3^UOHFO>"-12Z\)7VG'P^=9\:Z-;"POM7T&ZNX
M=3N_#BZH%&\W*6R"^7>TUJ)(A'@2-7:?#'3-5T[3-3\2>(O%,.O?\)%XT\1W
M&F:C9Q31G3=%UB.WGT32IUE&99-%M[B6V$B?N9XE5@"2]4O"G@.V^$FGW6F+
MX^\4^+[SQ'K^O:Y<W/B75H;HG4M71(4TV&RA6"(:386KVK6EB@1H3B0@N23]
M#_:%G1Q5"5'VV%GS4,71C.;QDI555I5*LZB<).G)N2G4C&<W5@FY\B;\IT91
M<Z?M:D)R:]UIQ=)Q356/*FO=Y5R\MVHVDVD]%_.]_P %H]&B_8Z\:>!= ^#N
MF_"Z8?%7X<>(U\1:UJ^F3ZM\3?"/BNYU.QT7PM\1](\,:(D]S/96VKM81W&O
M6.E3W]K=HA>8QH0?T"^$W_!!S]E_QQ^P)\(O@'\<#J6O?$6;Q%X>^-OC?XV>
M'XK73_B'KGC74KH>)-4TDZYJ^G75^OA:?[;)I;Z/+#;Q&%1=&U@OR[U]_P '
MP8\,^.OC/X&_:"^*'PW\"^*OBA\)M"U_P5X&\8FSO/M^A^&=7;.HK,]R4AG:
MZ8,%@NK>Y%KYDMS:2*99B_VKX*\8S^*_[7=M%?3].L+F&#2]42ZM[JPUB!U=
M9#:O"VZ.6SGB:&XB==@W0M&[AF"<F(IX>HH-U,1B*K4ZE>.+E2E0I59<E"<,
M(HN2DIQA&=2HVZLG.2<5&',[Q>.QRH8>DIJFJ$>25:A.2E7]]SI^V7N-\G,H
MQ@X<J4=Y)I1_,S]OG]E[PC\//V'M2\+? CP_\/?AG\/_ (5ZUH7CGQ;X6E\"
MZ7KNC:YX'T.[>;Q/:Q6]PT,UAK)@N)-5M]8LYX[X75N0LJ&7</S2\+?M'_$S
MQG\9X=0^'[^ M:^!%AX6\):?\'_$-M:6UG\2_AG=:MI=K#=Z7J^AZRYU/7H=
M>543=8G>+9HY5N5<.1Z?_P '#/QZUK3_ (+^"/@UX3\;>'3X)\8>,=3T/XW>
M%-%\2ZWIGQ(U-M,\/KXG\,^$],30XIHOL>M&(SZMI^KFWAOK-851V4N*^&OV
M-/"7AGP)\)OA!\:]-$-CXR^)/PLO_#_P<^%'CBSO$T6]^(LES<3OXIO?$5FN
MIZEH.FZ2)X[6'3KJ*"+R%A2Q*NY ][AC'8&4L?DK<)3I8&?L:,:DI4L/]9E1
M]HU3IN*P$HT*,IU<8JD$L.JD,33GAHVGU1P.+_LVAFN)YY_6L75]G*I!RJUN
M6/O3E.:;Q"=1KD4E)<TO<FI-I?7NE_'C2OCWXV\9V?@C73\%_B78^(VT3X5?
M&+3=!M7\3P^'_!U]9W7Q2>_TGQ2K:-IL^H:K]JTNWOHGBD-I>2PB<'>K_,7C
M*U^)VJ:)\2O'WPZU#5+!=;\175G?WVOV]KH6N:GXBN9()=4\0Z1JEK<0Z3>Q
M0&YGNFBMXI9+D*R6\IPIKA?B9H]SIFEZ9\-/%OQ \->(?C#\/_&$>@_&GQQX
M0FC7PMX<OO&E_'J&EZ/HL#N9KNZANH[J/5S,;?4_MM@L5S812+&\O(^"/$/Q
M!^(WC:/X)^*TU!M TGQ2GAJ'^T($31KLZ?JGV3Q/)<*T:S^'81IT,&J6%]=S
M37-R]QE(QM1:^.XPXPG3XBS3A_$4N6&1*E5PN)E*GRTL#B*.'EA\5AZE;#83
M&8[#8G#QI8R-)5*E%57BL1AXTXSFJ7VN0<,T_P"RL%F^'J0<,>G&M0E"4Y5*
MN'J356G)TYU:=)JHI4HJ<:+4'24KN:YLF]\'^%M<^ FO77B7P7XDM_$W@T2Z
MI)XZO=;GMCJWBNTURVLX4M=%V&.YT6[FU-)+F508 #;J;DS[HZ_M_P!&_P"0
M/I7_ &#;'_TEBK^++]M7XB?L_P#A^YU+X._"#Q-X4\(Z:=?TO0]>M[SQF/&>
MK?$'Q#X,NM"N]%\.^#-5L9;BW\/VL.I7%W=Z_P"'[JW#:G<11">ZM+J% /[3
M=&_Y!&E?]@VQ_P#26*O0HXCZQ@:$EB'5@J^)5.DHU(TL-%2C%TZ7/&*:E4C4
MG)4Y5(0FW!5'*,DOSOB*$HYU*4J4J7M,LP-1>TE"56I&=;&2C.IR5*D4W&24
M;N,G!1DX132-*BBBD>0%?,G[5OP=_9P^-OPYL/"G[3]U96GP^M/$^G:S92WW
MQ,\0_"J$^([6UO[>P0>(O#7BCPG?SNUM=7NW3'U*2WN,>:]K(]O&\?TW7S-^
MU;\)Y?B[\,H]&M_@Y\$OCS<:'K]CXDB^&7QWT^.?PIXA^PV]Y;RPZ5J\^C^(
MK7PQXI$%W(-&UN\T'5+%7:6QO4M+6]EU"T!K==-5MH_OZ'X(?L4_L??\$UO'
M'C[]LRW^(?BNRU"#X:?ME^+_  1\($U+]KCXHV2V'P]TKP;\.M5T+3M)$7Q=
MM1K6FIK>I:M)#>W7]H2W4\L]O)=3)"(H_P"H&UB@AMK>&V(-M%!#%;D2-*#!
M'&J1$2LSM(/+"XD9V9_O%F)R?PBB\&?!:PO8M(7_ (('ZO#XZBDCEA73_A]^
MR!)X)%]%(!'<1_$8>.X+*.W62,2I>2:8ETL*HYLUEQ"/V(^#-]\8M5\*G4_C
M/X4\$> =>O;D2:5X&\$Z_?>+8O"VAK#&MIINN>*+G3=&LM7UY,$W_P#8FE1:
M+:2#[-87NIP(M[(:=%;Y6_K^MAO7\MT^B_/KH>N445^1GC/]J+_@H/X"_:T^
M#?P#U'X2_LE^)O#/QA\<^)[R >$OB9\4Y_B+X/\ @!X/N&F\0_%CQ;INI^ K
M'PW8/IUE=:'HZ:?%J\\>J^,-;L](TR6>W6YO+<)_K^OS]#]<Z^=OVO?^34/V
MF?\ L@7Q?_\ 4 \05^?G[(W_  45^(W[4O[16K>"M.UO]C:Q^%L'C#XN:)I7
MA'3?C#XNO?VH+K0/AMXCU[PG:Z]+\/I_"D'A=S?ZGHJ:EJ%K:>(9GT[0+V&]
M<;FC1_T#_:]_Y-1_:8_[(%\7O_4 \04#2M)7[H]8^'?_ "3_ ,"_]B=X8_\
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M?N);Z_N3&J^;=WDJB6YF;YYI!N<DUJT4 %%%% !1110 4444 %%%% !1110
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M=M=@@ULMI%B^AB:^_5O]DOQ%=?M+_M9?\%"?VG/V<-=&C?#+XC?"G]G?X/\
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M:_5BORG_ ."+'_*/;X3?]C%\3_\ U8?B&OU8KWJ/\*E_U[A_Z2C_ %G\&O\
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M4[6Q\<>*9M,M]9N?$R77A[7M7M=*#>*2MOXRT1$@BFN=$T&:?4K:\ALH'EC
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M]Y>6DL$\[$C-^)7B/X.^%_VP;[6_%7@OQ=X]\9WI\/Z!H_P_\26XT[X?Z?\
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MJ.(Q:IU:4:&-PM6E.KRY=2GB:%2-"G7K5EB'2JUZ]'2<XRJ2O[6%AA,5AJ&
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M_P#DG_@7_L3O#'_IDL:[&@D_@[_X.CO^3WO@Q_V;;I'_ *L+QS7\T=?TN?\
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M;K_##_TB)A0VJ_\ 7^K^:"BBBI-PHHHH ^7_ -M7XU^,/V<?V3?V@?CK\/\
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M@#\2O^#BG_E$!^UG_P!>WPJ_]7-\/Z^G/VVO^49?Q:_[-XTK_P!,VC5\Q_\
M!Q3_ ,H@/VL_^O;X5?\ JYOA_7TY^VU_RC+^+7_9O&E?^F;1JSJ?!4_Z]O\
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M(UGO-/N[:$R-XB\*,L8EFB2/>RJQ5-VXA6(! ./O_P#X.$?^3;_@G_V6M_\
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M_P B^'_;O_I;/WGC+_E#'A/_ *^Y+_ZT.-/P?K^OC_@W[_Y-4^*'_9<-3_\
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M #[I4L)AZF#P5:K..,3J8C%U:=*C-4:4H^SIN%&I64U-VJ-RDK.FDD]4=C\
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MH:EXZ\4ZEX<\+>&_&_QVTZU\ _ ;6XO%>N:)?^&[J_TG0O'UE8ZO9WFDR:U
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M[+W_ &#O'O\ ZLKQ=7YMXF?\BS+O^PVI_P"F4?OG@%_R.L^_[%=#_P!2XG[
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M_1(_Y//EG_8BS_\ ]1(GXN?\%G_^3_/BC_V!/ O_ *BFFU^55?JK_P %G_\
MD_SXH_\ 8$\"_P#J*:;7Y55AB/X];_KY/_TIGY;XP?\ )U/$3_LL>(/_ %98
M@_N _P""+'_*/;X3?]C%\3__ %8?B&OU8K\I_P#@BQ_RCV^$W_8Q?$__ -6'
MXAK]6*]ZC_"I?]>X?^DH_P!9_!K_ )-)X9?]D'PI_P"J3!!1116A^E!1110
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M!/$^G6L_B#P4]]?1'1[*TT2Y@N7N]#U&YL9+>&1O+N,2H@^G/$_PN^'WC_\
M: \1>$=-G^!'A[0]:\'Z:+>[T;QCX@TS6_&B^&H9]6\/:)J.AV&M6F@W>H^%
M=947<UK<1O>:IH]S="Z)WL(^,^ >O>)=9;7_ (9>)+/Q/HNB_#2_UB]GTU_A
M_H?ASP#XGT2+4Y)M9T2#6_%$]V]SH-U#,_F6UW(T#6[M(I$/EXWR_P .\[CA
ML?C\HSC"4\'CLDRW%\^<4ZM;&8.IC*$\/AX1I4.:D_J%*7L,/7IXRG4IU*>'
MJU*=.=.I24XCBK*JU;!+,,KJU:V!QN)A5PF$E3HX3$T74C6JWE.$I/ZQB>>K
M6I2PS@X5:M+FDG%OT_X;?M<?#3XK^./#=SHOP?\ &_C3X?\ QN^$DVL?%KXV
M1Z?=:1\!%UC1;:'3M1L-6;4+\R:3KMOKXFTMDT^!YR+BSN(I[I($GKRCQQ^T
M#J=]+IG[*?B_]F#P+XG^'&D>(-'\0^(_A_\ $+XNMJ6NZE\.[&_.J-XW\):C
MJ4TUKXC\,Z)>G2A;Z)?W-M?I"_ES6[VZ%X_"OB[XRF_8O\(?$+6? &H?#Y?A
M'^TI\2?#?@O5_A]%\1=1\2Q?"&V\1VMS#%K/@_P18ZGJ&D76HZEK=\9C;Z7;
MZ1IMM::8D2EI3 5_4CX@6W[/FE_"'P?\*/VK_#WA#QO=Z;I/@[0_B#>:)INL
MW<6F/K5HC:'KYU/3XU\1V/A_4IK>-II3>+;6ER?(N>57*I8#-\WP:R3,<]QF
M*SW+L;E]#.\IRZC'%X:OEL\)2A2E3EC,$W5G)4ZN'<INLX5)1P]6-6#I3?/7
MKY?EN*AF.#RJ#RO&TJ\\HQ.*KU:.+H8BC53G.4,+C(*G.DZU.*4?91G&-.O1
ME!\T#YC_ &D_^&7_ !1\#?B_\;M.^#FI?#']H/Q)\-/^$*U.+3]->YNVT2QU
M>UTS1X?$5XBQ:>=+MK?3+*.'4[*6Z"P"SBC=XS&I_I'T;_D#Z5_V#;'_ -)8
MJ_F8_:I_9L/[/G[+WC(?LY>,_BMXO\%>);>QB\;0?$?Q1+\1M&\._#>VU:#4
MY;#PY)KUW'J'AP8EMH].U&U2\FCT^U$#Y.'K^F?1O^0/I7_8-L?_ $EBKO\
M84*,:SPV6/*Z-;&8BLJ"K8>M"I.7)&==.A"G*,JG+'VD:]-5E)6E.K93?P&;
MU)5,RBY8VICN3+,%3A.JJRJT:<*V,Y<.U6E.T*=W[+DJ3AR-.*A\*TJ***DX
M0KEO&'A3P5XOTA['Q[X;\,^)M!LY/[3>S\5Z1IFL:5:RVD4I^WM;ZM;W%K#)
M;0O,?M)16BC:3YU4M74UXU\=/&_P[\)^"+G0?B'XO\,^$8OBB-2^&7A8^*=2
METNQU_Q5XET#5Q8Z!!<6X-TUS=VEK?3E+0?:A;6MQ)!^\C6@#\S&_P""@/\
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M>^#'_9MND?\ JPO'-?S1U_0W!/\ R3&6?X<3_P"IF(/XE\6O^3@<0?XLN_\
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M/I%I-?ZEJ%W*>([:SLX)KB9S]V.-C@XK^(3XI?\ !U5^S':_\%"_!GQ%\.?
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M_M;/^TAJWB+2_P#AFS]J'X'PZ!I=GJD>L_'OX;:7X(T7Q +RY:V%EX=O=/\
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MBROYIJ_I9_X-W/\ D-?M._\ 8*^&W_I9XLKR<%_O%/Y_DS_.KZ,G_)\.!_\
MK[GG_K-9P7O^#B3_ %_[+_\ UP^)W_HWP=7\S%?TS_\ !Q)_K_V7_P#KA\3O
M_1O@ZOYF*6,_WJMZP_\ 35,U^E!_R?#C3_N@?^LSDY_7+_P;Z?\ )M'Q@_[+
M*W_J(:!7Y]?\' G_ "=9\,O^R'Z1_P"IEXQK]!?^#?3_ )-H^,'_ &65O_40
MT"OSZ_X.!/\ DZSX9?\ 9#](_P#4R\8UUU/^1?#_ +=_]+9^\\9?\H8\)_\
M7W)?_6AQI^#]?U\?\&_?_)JGQ0_[+AJ?_J%>#J_D'K^OC_@W[_Y-4^*'_9<-
M3_\ 4*\'5A@/]X_[<E^A^0_1(_Y//EG_ &(L_P#_ %$B?BY_P6?_ .3_ #XH
M_P#8$\"_^HIIM?E57ZJ_\%G_ /D_SXH_]@3P+_ZBFFU^5588C^/6_P"OD_\
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M:A^TS_V0+XO_ /J >(*!QW7JOS/6/AW_ ,D_\"_]B=X8_P#3)8UV-<=\._\
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M].U']F;]G*>&:;4_VJ?BOHZ:9\0O%/AN!99;S5?@E\*M?BB;1-)OK./S-/\
MB1\4#I4-M93_ -K:;X0U%8[>9ODCP-=_L'?LK?MU_!*X\"?&;X5SW?C+X!_&
MFT\>_%?Q3\8/#OC3Q[\1_'^L>-_A:^EW7Q#^(6H:W>WU]JU_%9ZF=+MK^ZLM
M(TVVBNK;1K&PL8C LR2E:[M;_@=^_?O]PW%/=-M=MUM>[\^UF]'MUV/V#?\
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M,[M&;=2L4?:*JHJHBJB(H5$4!555&%55  55      & ,4ZB@04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\(?\
M!3K_ ),%_:B_[)I=?^G;2J^[Z^$/^"G7_)@O[47_ &32Z_\ 3MI55#XX_P"*
M/YHPQ7^[8C_KQ6_]-R/M+PO_ ,BSX=_[ 6D?^F^WK=K"\+_\BSX=_P"P%I'_
M *;[>MVI-H[+T7Y!1110,_/#_@ES_P FEV/_ &6O]IG_ -:$^)-?H?7YX?\
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M@)_P<(_\FW_!/_LM;_\ J"^)ZY\7_N]7_#^J/Q?Z1'_)EN/_ /L4T/\ U:8
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MH_\ 8$\"_P#J*:;7Y55AB/X];_KY/_TIGY;XP?\ )U/$3_LL>(/_ %98@_N
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M"NL^/O$FK^!? ^J:V6-]>^%O"MW=O8:;*2[-"I\Z*%MC)&#'&4]<^&G[%7P
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MAA^U[^T/_P %BKWXP?"S]J#]L'XT6FC?#GPQX6U;QS\)?"+>$_"UU\6M)O\
M6+JVN+N+XC^&?"^@>+/!G@]IOLFC>*/"?AZ\_MC6X;F(GQ396$EQ93+F5^7K
M\O+SZ??:_H&E[75[)M:MJ_332_S^9_3?X_\ VRM/EUO4O@U^R)X#?]I#XPZ+
MC1+VV\-W::-\$?A5=1+]FB;XJ?%A8)O#NC1:2%#W/@[PM_PD'CB6*'[);>'X
M7D25*O@+]CJ75==TGXQ?MG_$2W_:(^*FC746K:%HVHV$>@_L^_"747E5K=/A
MK\,+F6;39=1T^1HK:T\=>-7UWQG<O&EQ#>Z:TWV5/I;PKX>^'/P1\+:'\,/@
M]X#TC0],TZTU&S\->#?!^EC3-#@NM)LH[^XM-6U:UM)M.TB_NX9HYC>^(+A+
MW5+B4N9+NZE);JSX3N=:NIKGQA?1:M9[]3M[3PY;VQ@\.2Z3=W>FWNFC7=,O
M)]135M>TB;3\0ZM%+9VV)YC#I\18$.W]?=T_)_=U'>VVGGU^_I_6Y2O]0O\
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M<*D8SC>TDFFC[<_X(L?\H]OA-_V,7Q/_ /5A^(:_5BOF/]C_ /9HTO\ 9&^
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MX0[PSDDY)_XDMER2>2?<UV-<=\._^2?^!?\ L3O#'_IDL:[&@D_@[_X.CO\
MD][X,?\ 9MND?^K"\<U_-'7]+G_!T=_R>]\&/^S;=(_]6%XYK^:.OZ&X)_Y)
MC+/\.)_]3,0?Q+XM?\G X@_Q9=_ZJ< %%%%?5'YR%?Z3_P#P08_Y16_LO?\
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MX0_X*=?\F"_M1?\ 9-+K_P!.VE54/CC_ (H_FC#%?[MB/^O%;_TW(^TO"_\
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M2A1I1DMI1IPBUI;1I)K33TT/YCO^#B3_ %_[+_\ UP^)W_HWP=7\S%?UA_\
M!=3X"?&OXV3_ +.Y^$/PL\=_$D>'X?B$-;/@SPUJGB :4=0D\*FR%_\ V;;7
M'V8W0M;DP>;M\P0R;<[37\^7_#!7[:G_ $:U\=/_  VWBC_Y75X6+IS>)JM0
MDTW"S46T_P!U!;I=TT?Y2_25X:XCS#QHXQQ> X?SS'82K_87LL5@\HS#%8>K
MR<.913G[.O0P]2E/DJ1E3ERR?+.,H.TDTOZ+_P#@WT_Y-H^,'_996_\ 40T"
MOWNN+B"U@EN;J:*VMH(WFGN)Y$AAABC4M)+++(52.-%!9W=@JJ"20!7XM?\
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M=_\ 1T'P(_\ #H>#_P#Y;4?\-O?L=_\ 1T'P(_\ #H>#_P#Y;5_!-_9VG?\
M0/L?_ .W_P#C=']G:=_T#['_ , [?_XW7[[_ ,2]TO\ HJJG_AHCY?\ 4Q]?
MP\S^$_\ B?NM_P!&OI?^)=+_ .ASU_IZ?WL_\-O?L=_]'0? C_PZ'@__ .6U
M'_#;W['?_1T'P(_\.AX/_P#EM7\$W]G:=_T#['_P#M__ (W1_9VG?] ^Q_\
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M4KWMRJVI7YN?\%$_^0O^P'_VD/\ V?O_ $U^/*_2.OS<_P""B?\ R%_V _\
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MN2=&BJ_K^O4 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OA#_@IU_R8+^U%_V3
M2Z_].VE5]WU\(?\ !3K_ ),%_:B_[)I=?^G;2JJ'QQ_Q1_-&&*_W;$?]>*W_
M *;D?:7A?_D6?#O_ & M(_\ 3?;UNUA>%_\ D6?#O_8"TC_TWV];M2;1V7HO
MR"BBB@9^>'_!+G_DTNQ_[+7^TS_ZT)\2:_0^OSP_X)<_\FEV/_9:_P!IG_UH
M3XDU^A]5/XG\OR1SX3_=</\ ]>:?_I""BBBI.@**** "BBB@!"0H+,0JJ"68
MD   9))/  '))X KS)/C5\(I/A[K7Q:3XE>"C\,/#C^(8]>\?GQ%IB^$=)?P
MIJEYHGB1;W7FN!IT!T76-/O=,O\ =<8@OK6:V;]ZNVO (+KX@_M/Z=\9O@K\
M</V>OB;\#OAM+&='TWQQIWQ>\-P7WQ+T6/6V6>'1;OX;Z\?%WA6SU?3K*)M2
MBO9-.N;C1]3N-,>5)9)T'XF>$/#_ (#\"?\ !+;X >&]8L='T+]GGP;_ ,%.
MM1T?XE:=JI+>#M(^%.C_ +<_CZQM;?Q4]Z\MN/"-EJT7AU=;FUF233A9(TFK
MR-:F=B6?X7U]4EY=>K';\ULK[_KY?\$_H,\)?M._L\>//AAKGQJ\'_&GX;>(
M?A-X9%\?$GQ"T[Q9I$OA7P^=,CCEOTUS5FN4M])EM8I89)8;]K>58YH7"%9H
MRW1_"/XV_"+X]^%CXV^"_P 1_!_Q.\)K?3Z7+KW@S6[+7+"WU*U"-<:?=2V<
MLAM+V%)8I'M;E8IQ'+')L\N1&;^9_P#:\O?AK=_&O]I?6/AA=_#^Y_9.A_:P
M_P""5\O[4MYX8DT6?X4RV\'C;Q>?BA+XKN-.+^&KF&+1Y/A.OC-E:6-+9=.7
M6L!)-OZ!?L]>(4M/VV/^"IWBO]D?P_X.^(V@:;\)OV:[C1/"WA3Q#H^A?"WQ
MA^TGIW@GXAW&HZ"OB;1X[OP[I7B"_P! /@2P\8ZO;P7$]E%/I3ZH'F@5%5]4
MNK\_76W;3OU\M7RZ;]G^7^?X>>D/_!Q3_P H@/VL_P#KV^%7_JYOA_7Z^_#'
M_DFWP]_[$?PG_P"F'3Z_F=_X*"P?\%M?V]/V2?BM^RMJ?_!-7X0?#JR^)\7A
M>.7QA8_M=>"M=N=(/AGQCH'BU&CTJXT^PBNQ=OH8LF#7</EK<&8%C&$;ZT\-
M_M0_\%PO#OAW0/#Z?\$IO@M=)H6B:5HRW+?MG>$(VN%TRPM[(3F,:*PC,P@\
MPH&;;NV[CC-'5Z2V7V9>?EYK[Q:-)76_?OR_E=7_  N?O-17\['Q>_X*4_\
M!8#X&6/@34?B-_P2T^#VDVOQ(^*G@#X,^%'MOVO_  ]J;7OCWXF:TF@>$M-G
M2Q\.S-9VMYJ4BQ7&HW 2TLD/FW$B)S7K?_#77_!<7_I$_P#!7_Q-'PA_\HZ+
M^3_\!E_D%O-=.O>UOS_!G[F45^&?_#77_!<7_I$_\%?_ !-'PA_\HZ\<^(G_
M  4S_P""O7PK\?\ P1^&7C/_ ();_![3_%_[0OBWQ%X)^%UA!^U[X?O8=9\0
M>%?!FL^/=9MKR]M?#LEKI,5OX;T'4;J.XOY(8IYHDM8F:>5$)?R?_@,O+R\U
M]Z!*]K-:^?I_F?T7T5^&?_#77_!<7_I$_P#!7_Q-'PA_\HZ/^&NO^"XO_2)_
MX*_^)H^$/_E'1?RE_P" R_R\U]X:=X].O>W_ ,DOQ/W,HK^=G6_^"E/_  6!
M\/?&CP%\ =4_X):?!Z#XF_$KP7XX\?\ A+1T_:_\/36E[X:^'=[X;L/%%W/J
ML?AUK"SFM+GQ7HR06MS-'-=B>1H%802E?6O^&NO^"XO_ $B?^"O_ (FCX0_^
M4=%[[)_^ R\O+S7WH+;:I72:N]T[?Y_F?N917X9_\-=?\%Q?^D3_ ,%?_$T?
M"'_RCKR?3?\ @I+_ ,%A-6^-?BO]GVR_X)9?!Z3XG>"_AYX1^*.OZ0W[7_AV
M.SMO!_CC7/$WA[P]?1:J_AX6%S<76J>$-<BELH9FN;:.VCFF18YXBQ?R?_@,
MO\@2OLU]_>V_;<_HDHK\,_\ AKK_ (+B_P#2)_X*_P#B:/A#_P"4='_#77_!
M<7_I$_\ !7_Q-'PA_P#*.B_E+_P&7^7FOO#3O'IU[V_^27XG[F45_.SX"_X*
M4?\ !8+XE>._C%\-_"7_  2S^#U]XL^!'B/P]X4^)%C-^U_X=LX=)UGQ1X7L
M/&.C06MY<^'H[;4X[C0=3M+EY[&26."1S;RLLR,H]:_X:Z_X+B_](G_@K_XF
MCX0_^4=%[[)O_MV7^06\TO5V[?YH_<RBOPS_ .&NO^"XO_2)_P""O_B:/A#_
M .4=>1_!_P#X*5?\%@/CKIOC;5OAO_P2T^#VKV/P]^*7C[X-^*)+G]K_ ,/:
M8UGX\^&FLMH/BW384OO#L+7=M9:BIB@U"W#VEXG[VWD=.:+^3_\  9?Y!;S7
M3KWMOVW1_1117X9_\-=?\%Q?^D3_ ,%?_$T?"'_RCK]%?V/?B5^UI\3_  'X
MCUC]K_\ 9S\*?LU>.K'Q5)IWASPCX2^*FF_%BRUOPLNE:;<Q^(+G6M+L[.#3
M[E]4GU'3_P"S75Y1'9)<DJLR9?R?S37YKS%\T_1^C_5'UO1110 4444 %%%%
M !7PC^WM USX7_9Q@60Q&7]L/X"H) H<IG4=:RP4\,0,\5]W5\(?M\2&+PK^
MSG(&V%?VP?@. X&2A;4-;4,!W*DY'^15T_CC;>_3?Y>?8Y\7_N]2V_NV_P#
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M,U[?W5O:PK\TLJKS7S9_P43_ .0O^P'_ -I#_P!G[_TU^/*_2.OS<_X*)_\
M(7_8#_[2'_L_?^FOQY7F1^)?/\CW\5_ E_BI?^G8'Z1T445)T'YVZ=_RE9\2
M?]F'Z!_ZO74:_1*OSMT[_E*SXD_[,/T#_P!7KJ-?HE52W7^&'_I$3"AM5_Z_
MU?S04445)N%%%% !1110 4444 %%%% !1110!^>O_!6?_E&/^WM_V:C\;?\
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M.OM]: "BF))&Y(21'(ZA'5B/K@G'XT^@ HHHH **** "BBB@ HHHH *^$/\
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MA$B17;WUO.\\<<:2,RQH%Z'X2?!3X0_ 3PE'X#^"?PS\#_"GP9'>W.I+X8\
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M[A)=K7O_ ,!/[VO\K']&M%?AO_P2EUWXB^&OCS^UI\%?B'X>^-GP7L-)\*?
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MW)LYL9_NU7TC_P"EQ/*M?\%Z[\)W^+'Q%;S]4\?Z_J?C?5O">J:1]MU"ZM?
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MV?B!;R^L?$^@ZAXIET_5O$$LL<376FZ3#'=_\3>Z%NGF3A)QP7C+_A*/C/\
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M****S)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OS<_X*)_\A?\ 8#_[2'_L_?\ IK\>5^D=?FY_P43_ .0O^P'_
M -I#_P!G[_TU^/*J'Q+Y_DSGQ7\"7^*E_P"G8'Z1T445)T'YVZ=_RE9\2?\
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MA>%_^19\._\ 8"TC_P!-]O6[4FT=EZ+\@HHHH&?GA_P2Y_Y-+L?^RU_M,_\
MK0GQ)K]#Z_/#_@ES_P FEV/_ &6O]IG_ -:$^)-?H?53^)_+\D<^$_W7#_\
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M'PIJGB/0=0_:)^#WASQYXHA;[/IO@F]\.?$KX?ZQ:"]CG1&O)-7N+^TM(&M
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MQ%3\5&2_"2"BBBI.@**** "BBB@ HHHH **** /R_P#^"O*I=?L?)HVK>0?
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MYHPQ6F&Q'_7BK^,)(^W?"_\ R+/AW_L!:1_Z;[>MVL_2(#;:3IEL05-OIUE
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ME]^_9._9\\4_!?7OVH_&_CB]T:[\4?M$?M'^*_BRL&A2SS6>D^$8] \->#/
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M^,/ .H72*7>UM/%WA_4-!GN40,N]K>._:94W#<R!20#7Q#\.OV'=4USX5_\
M!.^V^.7B7[+\4_V$[C2-:MSX(N([SPQXR\1:%\/=5^%Z27D^HV%I=QZ9J6C7
M4.N&*"VM[BUOF-F6DBC:1_TEHH'=_J?&?[%O[.7B']GOPY\;[KQG=:3<^-/C
MK^TO\9?CYX@CT*ZN+S2M.C\>^(0OAS2K>XNK:TD>:Q\*Z7HJ:CB!8EU-[Q(7
MFB5)G@_:B_9S\7_%GXL_LB_%_P  :MI.E^(OV>?BUX@U?61JLDD9O/A[\1?
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M/&.'M%A<30Q'L^;EY_8U(U.3FM+EYN6U^5VO>S/.SC+_ .U<IS/*_:^P_M'
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M?B?R[_%'P%X5_9T^+OQ^_8TT_P")/Q.^&'[ ]Y^U_P#L5V7Q4MY/BMXV-O\
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ME;]*:?\ 7]6$[7TV"OQG_;=_:=_:]_9?^(FG>-T^*?[->D^!/$_Q4^'7PZ^
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MGPSM"=-[T:M2G;M%R<Z7WTITW^ 4445)T!1110 4444 %%%% !1110 4444
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M?\$\/^CQ_@)_X7NE?_%U_#A_PDNB_P#0QZ/_ .#NP_\ DJF2^)=&$<A'B/2
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M%K5--733[-:H****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<^N?%;X%VLC!4%SX,U_4;WQ7X4L49I&\'ZN]NBXTALVO>BUUC=KT?Q+RMO\
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MJ_C/Q/\ 'F""(:7'IEKH>D:MX3U*P"@R3W#VMO!J5M<V[RA80K1S2'!?:,'
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MI*3E-F"]M.O5KUE2BZD*-.,*3G))4G5DVY3L[R=5V2244DEY%%%%<IJ%%%%
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M,HSBI1:E&23C*+333V::T:84444#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#YP_;"^%/B7XZ_LI_M&?!?P;)I\7BSXJ?!?XC>
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M4 %%%% !1110 4444 %%%-=TB1Y)'6..-6=Y'8(B(H+,[LQ"JJ@$LQ(  ))
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M\$WTKPI#JFN:9J[PR/;6T6GMI]A>ZLYLH=5U6*U-]=:?:"Q:7RG^7]?/CE\
M/AG^T7X9T+PC\4])O-8T/PYXRT#Q[I5O9:G>:5)#XD\,R3R:3=//921RRPPM
M<S>;:NQAG5MLBD"JZ?LZ_"M/CY_PTNNC7@^+?_""+\./[<_M6]-G_P (HMR+
ML6/]DF3[#YWG@-]K\KS\#&[%9Y=Q-A\)E5#"556K8G#8//*=%U:-'$T*>)QT
MLOE@*JAB)2@_8?5JS<G3<J+E%TU*[MT<0>'&89KQ/CLUPL\%A<OS#..",3BU
MA\7C,OQN(RW(HY\L\PM2K@*5*K_MW]HX3EI+$JGBU3J1Q,Z<814_YX)?CM^W
M9\7?&OQX^*OPB\7?M!W/BSX._M"2_#3P%\+]$N_AO:? 63PIX3U.PTZ[\/\
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M?\/];M?%FOV.H0>&O#B1)H^D:W-9WL/]OVEFL* )J:S^<"ZSF1'=3-%^P?\
MLWP_"WPE\'$\*:J/ ?@CXI#XR>'=./B75S<VOCQ=9N->749;_P"T?:KBU74;
MJ9QI\SM:^41"4**!2AQCDT88)3PTJZH4LOP=2CB,JRZM3A@L&LUA5IT959U'
M)8A8G!2<7"G**IU8.;6M1U?"'BZI6SF=+,J>"EC:^?YMA\7@.*>(L'7K9UFW
M^J<\'B<92PM+#QA_9\LLSR$9*KB83>*PU:-&$GR8?\<O'_[1O[3_ .QO_P /
M$_AQ:_''QW\;KGX3^"?@OX@^'GC'XCQZ9JGB/PEK'Q4UO2-!UO5(FBMX;%+'
M38]8FNK#3S;_ -F6US!8$6T<8N6D[7X!>+OVU?!%_P"/Y-5\6?M">-?@QXH_
M9.\:^/-1\8?'#5OAW)XC\$?%:T\'ZMK.C:YX#D\*^*=5UB#PEJ<D$4>E VR0
M12R+D"6U,[?L;JO[)?P(U_QE\8_'/B#P9'KVL_'OPEH_@?XGV^KWUY>Z/K_A
MS085ATVS32I)?LMC) $CD%U:+%<>='',)%D16'EOPC_X)U?LI?!)_&$_@/P+
MJMO>>-_!VI_#_5K_ %GQAXF\07EKX-U>VFM+[P_HLVK:E=#1[&2WGDC1;)8W
MA!'E.H&#S/BG()X'$4Y9;36-Q$,$\15>58.<<36IY?EV'KSC*EB<,L%*CC,-
MB\51G2I58UGB&ZE&+<XOTH>&?'-#/,!B*7$.)>38&OG*P6%CQ3FU.IEV%KY_
MG^/PE*K2Q.6YC_;5/&Y1F.5Y7BZ&*Q>%J8*&7)87&5$J-2G^)7P.^*?[67@W
MP_\ \$V_CWXB_:L^*GC]/VD?BO<_#/QC\./$]W:7G@Y/"7]K2:?:-L\@7NH:
M\8?M4]SKFH3SZBUP;,07$,-KY<OUK_P3-^$VI:)^VO\ \%!O$5Q\8/B;KL?@
M_P",MQX<NO#6M:W:W&B^,I=?M]1O[?Q%XHLQ;++>:YX=C@>PT.XMWMX;6PEE
MA:)P$"?I)9_L,?LZ6'A#X"^!K;PMJJ^'OV;/%/\ PF7PGMF\1ZNTVC:\;I[P
MW%_<F?S=8B-Q(SF"_:6/H,8%=%X8_9 ^!'@W]H#Q/^TSX9\,7^D?%CQE;W,/
MB74K3Q#K2:)JTMY;1VES?77AK[8=&?49((U7[9]D\Q&+R)MDD=F68\695C,+
MF]##T)X2>883&8>$Z.6X"G&4(YV\;EU&K"E.FHQA@)/#SKQ4ZM*?*TJKC&:?
M#WA7Q+E69\)8[,,;1S6ED&;93F%6GC.(\]Q-6G4GP33R//\ %X2KBJ->52I5
MSZ"S&E@:KI87%4.=2GA'6JT9?3E%%%?G!_0P4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5\$?M;_M#^,K/6M)_94_
M9G,.M?M2_%72WFCU!(DOM#^ ?PZN)UL=:^-'Q#;/D6,&GQ230>"="N66^\6^
M)1!;V5M<65IJ#QQ?M!?M=:Y%XUF_9F_9-T?3/BQ^T_J,-NNM33">[^&/[/VC
M:B&0>.OC1K=@PALVM8=]YH?@*VND\3>*9XXK>&&SLYOMM>L?LO\ [+OA_P#9
MQT+Q'?7?B/5_B9\8_B7J</B7XS?&CQ6D!\5?$/Q,D)BB)C@40:'X5T2-Y++P
MIX2T[;I?A_32((%EN)+FZGI+EU>^\5W[-^77S]-3EG.59NC1;44^6M66T%M*
MG3DMZS6C:TI*[;YU&+[K]GSX%>#/V<?A1X7^%/@B.>6QT.WDN=:U_4&\_7O&
M?BS4Y#>^*/&WB>^8M+J/B/Q3K,MUJ^JWDSNS7%R8H]EO%#&GM5%%)MMW>K9T
MQC&$5&*48Q2C%+9)*R2]$%%%%(84444 %%%% 'PE\9OV'M#\1>,-0^-O[.GC
M?5/V8/VC;HQSWOQ \#Z?;7OA'X@20<QZ?\8_AI-);>'?B#ITX AEOK@67B6U
MC.^PUN%XT6N%L_VP_CC\ MNB_MN? 75M+TRU4HO[1'[.NG:]\4?@UJ<40&Z_
M\2>&(+-OB7\.)73,L\&H:'KNCV^U]NO,@4U^D](RJRE64,K AE8 JP/!!!R"
M"."#P:OFZ27-Z[KR3WMY=+G.\/:3G1FZ,F[R44I4IOO.D[*[ZR@X3EI>3LCR
M+X3?'[X*?';1H]?^#WQ2\$?$33&4&5_#'B#3]1N[)R 6@U/3(YAJ>E7<9.R:
MSU*SM;J"0-'+$DBLH]>KXT^+/_!/O]D3XR^('\:^*/@YHVA?$(NL\?Q*^&>I
MZ_\ "?XAQW2 B&\D\7?#?5?#&L7UQ 69H6U.XOD1R6$>XDUYU%^Q;\<O!D1M
M_@_^W]^TCX>L(<C3M%^*-C\./CCI]C&/N0OJGC7PH/%^HQ@?*7U/Q/>7! '[
M\')*2B_M6_Q)^757\]TMM;!SXB.DZ,:B_FHU$F_-TZS@H^BJS]3]$**_/D_"
MK_@I#IRA=._:V^ NO;!A9/%7[-M[;O+M& TX\-?$32T#MP7\E8UR3L5>*9_P
M@O\ P4^_Z.%_9 _\1Z^)?_SY:.5?SQ_\F\O[OG^#[![>?7"XA?\ @A_E7Z?(
M_0FBOSV_X07_ (*??]'"_L@?^(]?$O\ ^?+1_P (+_P4^_Z.%_9 _P#$>OB7
M_P#/EHY5_-'\?+R\_P 'V#V\_P#H&Q'_ )0\O^G_ )_@^Q^A-%?GM_P@O_!3
M[_HX7]D#_P 1Z^)?_P ^6C_A!?\ @I]_T<+^R!_XCU\2_P#Y\M'*OYH_CY>7
MG^#[![>?_0-B/_*'E_T_\_P?8_0FBOSV_P"$%_X*??\ 1PO[('_B/7Q+_P#G
MRT?\(+_P4^_Z.%_9 _\ $>OB7_\ /EHY5_-'\?+R\_P?8/;S_P"@;$?^4/+_
M *?^?X/L?H317Y[?\(+_ ,%/O^CA?V0/_$>OB7_\^6C_ (07_@I]_P!'"_L@
M?^(]?$O_ .?+1RK^:/X^7EY_@^P>WG_T#8C_ ,H>7_3_ ,_P?8_0FBOSV_X0
M7_@I]_T<+^R!_P"(]?$O_P"?+1_P@O\ P4^_Z.%_9 _\1Z^)?_SY:.5?S1_'
MR\O/\'V#V\_^@;$?^4/+_I_Y_@^Q^A-%?GM_P@O_  4^_P"CA?V0/_$>OB7_
M //EH_X07_@I]_T<+^R!_P"(]?$O_P"?+1RK^:/X^7EY_@^P>WG_ - V(_\
M*'E_T_\ /\'V/T)HK\]O^$%_X*??]'"_L@?^(]?$O_Y\M'_""_\ !3[_ *.%
M_9 _\1Z^)?\ \^6CE7\T?Q\O+S_!]@]O/_H&Q'_E#R_Z?^?X/L?H317Y[?\
M""_\%/O^CA?V0/\ Q'KXE_\ SY:/^$%_X*??]'"_L@?^(]?$O_Y\M'*OYH_C
MY>7G^#[![>?_ $#8C_RAY?\ 3_S_  ?8_0FBOSV_X07_ (*??]'"_L@?^(]?
M$O\ ^?+1_P (+_P4^_Z.%_9 _P#$>OB7_P#/EHY5_-'\?+R\_P 'V#V\_P#H
M&Q'_ )0\O^G_ )_@^Q^A-%?GM_P@O_!3[_HX7]D#_P 1Z^)?_P ^6C_A!?\
M@I]_T<+^R!_XCU\2_P#Y\M'*OYH_CY>7G^#[![>?_0-B/_*'E_T_\_P?8_0F
MBOSV_P"$%_X*??\ 1PO[('_B/7Q+_P#GRT?\(+_P4^_Z.%_9 _\ $>OB7_\
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M^46?E]Z_S#V\/Y:W_A/7_P#E?G^?9GW117PO_P -,_M5?](X/CI_X?3]CO\
M^?Y1_P -,_M5?](X/CI_X?3]CO\ ^?Y19^7WK_,/;P_EK?\ A/7_ /E?G^?9
MGW117PO_ ,-,_M5?](X/CI_X?3]CO_Y_E'_#3/[57_2.#XZ?^'T_8[_^?Y19
M^7WK_,/;P_EK?^$]?_Y7Y_GV9]T45\+_ /#3/[57_2.#XZ?^'T_8[_\ G^4?
M\-,_M5?](X/CI_X?3]CO_P"?Y19^7WK_ ##V\/Y:W_A/7_\ E?G^?9GW117P
MO_PTS^U5_P!(X/CI_P"'T_8[_P#G^4?\-,_M5?\ 2.#XZ?\ A]/V._\ Y_E%
MGY?>O\P]O#^6M_X3U_\ Y7Y_GV9]T45\+_\ #3/[57_2.#XZ?^'T_8[_ /G^
M4?\ #3/[57_2.#XZ?^'T_8[_ /G^46?E]Z_S#V\/Y:W_ (3U_P#Y7Y_GV9]T
M45\+_P##3/[57_2.#XZ?^'T_8[_^?Y1_PTS^U5_TC@^.G_A]/V.__G^46?E]
MZ_S#V\/Y:W_A/7_^5^?Y]F?=%%?"_P#PTS^U5_TC@^.G_A]/V.__ )_E'_#3
M/[57_2.#XZ?^'T_8[_\ G^46?E]Z_P P]O#^6M_X3U__ )7Y_GV9]T45\+_\
M-,_M5?\ 2.#XZ?\ A]/V._\ Y_E'_#3/[57_ $C@^.G_ (?3]CO_ .?Y19^7
MWK_,/;P_EK?^$]?_ .5^?Y]F?=%%?"__  TS^U5_TC@^.G_A]/V._P#Y_E'_
M  TS^U5_TC@^.G_A]/V._P#Y_E%GY?>O\P]O#^6M_P"$]?\ ^5^?Y]F?=%%?
M"_\ PTS^U5_TC@^.G_A]/V.__G^4?\-,_M5?](X/CI_X?3]CO_Y_E%GY?>O\
MP]O#^6M_X3U__E?G^?9GW117PO\ \-,_M5?](X/CI_X?3]CO_P"?Y1_PTS^U
M5_TC@^.G_A]/V.__ )_E%GY?>O\ ,/;P_EK?^$]?_P"5^?Y]F?=%%?"__#3/
M[57_ $C@^.G_ (?3]CO_ .?Y1_PTS^U5_P!(X/CI_P"'T_8[_P#G^46?E]Z_
MS#V\/Y:W_A/7_P#E?G^?9GW117PO_P -,_M5?](X/CI_X?3]CO\ ^?Y1_P -
M,_M5?](X/CI_X?3]CO\ ^?Y19^7WK_,/;P_EK?\ A/7_ /E?G^?9GW117PO_
M ,-,_M5?](X/CI_X?3]CO_Y_E'_#3/[57_2.#XZ?^'T_8[_^?Y19^7WK_,/;
MP_EK?^$]?_Y7Y_GV9]T45\+_ /#3/[57_2.#XZ?^'T_8[_\ G^4R3]I+]KF9
M2+'_ ()T?%6&3'!UO]H+]E>SCW>A.C_%?7WV_P"T$)_V::BWUC\Y17ZA[>'\
MM;_PGQ'_ ,J/NNBOSR?XJ?\ !27Q6\T'AO\ 90^!7PKC+;;?4OBQ^T#-XN?R
MR,>;+I'PO\+WBK(G40IK,B/@ S*"2*\G[-O[:7Q45D^-_P"VA<> ]!O4*:CX
M(_9:^'VC> 6-N[9EM(OB5XS/C'QQ"SQ$P/?Z2^BWBY\^S>SF"LIR]Y17SOVZ
M1OW_  9/UAO2G0KS?G#V27JZSIO_ ,!4GOH?1_QS_:L^ 7[.5E;3?%GXC:-H
M>KZDXAT'P9IXN/$7Q \3W;$+%9>&? N@0ZCXHUJYF=EC066F21*S#S98ERP^
M1[_4OVR_VSYH]/\ "]IXG_8?_9ON6']K>*M?M=.E_:H^)NE2H=]AX6T!)-2T
M3X*Z1>QMB7Q!J]UJOC9$*K9Z1I,K/+%])_ S]B;]F?\ 9WU.\\3_  X^&6GG
MX@:KO?7?BIXSU#5_B%\5=>FF(:XEU/XA>-K_ %WQ0RW$F99+.UU&UTX2,[16
M<>YL_5=.\8_"KOO)+3;:.J]+M[B=.M5_C34(=:5%R][RG6:C-I]8PC3ZIRDF
MSQSX'? /X5?LZ>![;P!\)?"UKX<T2.XFU#4[HO+?Z_XFUN[<RZAXC\6>(+QI
MM6\2>(=2F9IK[5]5NKF[F9@@=(4CC3V.BBH-XQC"*C"*C&*M&,4DDET26B04
*444%!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>ny20077915x1_charts02x2.jpg
<TEXT>
begin 644 ny20077915x1_charts02x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#.D^(--U31_$=U';)H4<FJ:AXBU73[X0:CJ>AVFIP-IEJ7M-2%]'+;E4@?\
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MNW"Z+I=AK^G>'-+^'FF:3<:C_9=MX?TS1$33+%5MOMUI<00M8RVZ(MK4/@3
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M33+76O#NKZ9KVCWRL]EJVCWUKJ>FWB([1.]K?6<LUM<(LB/&SPRNH=&0G<I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG\3?BU?)I&L>(X9-9UJ6+4]/T:[T/0+'5=4N9GT?0-,L8C!I\@AB\6W9GF2
MOCY_A/)%F7$M+!8C#SQ>&P+Q>+QU&C"=1UZ&7QG.5"$*:=23Q5:-+#0C!.3=
M9:(^_P#%3C3_ %>\.J^<8',*648_B!95D^1X_%UJ6&A@,;Q%5HX>ECZU>M.-
M"@LKPE;$9E5JU)JE3C@Y2E+E6OZ&?\$MOV_/B1^V%:?&CP7\=_#7ASP9\9/@
M]XHMK'5="\.:=JFCV_\ 8UZ;BP9;G2M7U36+VVU/1]=TW4-.U,->E%,EGF*)
MF.?U-\1>+_"GA&R_M+Q7XET'PSIWF>5]OU_5K#1[(2'.$-UJ$]O &.. 9.?Q
M%?R?_"+]KGX">'_^"S$/Q4^ GCI]>^#/[4-M:^%/&MP^@>(?"-O8>-/&=K'9
MJ+JP\4Z/HEY*Y\=Z-I&L->);R0D:U=D72LD\0]K\>^"-*_;\_P""R?Q#^ ?Q
MZU+7M0^"WP'\"2W7ASX>V>O:GH^G:K/ING>&[FXE;^S[FUNH)=4U3Q//>ZI?
MV+V^HSV5C8V0O%MX1L^DSC@^A4SBKBIT:V091/AVGQ'B<-'"U*F(P7LHT<)C
M<OH87$5*$Y5X8]N*56I3A&%6$Y24=3\XX.\7<=0X/P>60Q6"X[XMI>(>(\.<
M#F,LUI8;+LZE5J8O,,JS_&YG@L/F:IX*KD=.,ZE3"X;%U:N(H3IQ@ZDI*/[9
M?M9_MD^ ?V7OV?/$/Q\5]$^(=CIL>E/X>\/Z/XOT?3Y/&+:CKNEZ-,FA:J8]
M4BO!8)J:WUTUC9Z@T=M$7,81M]<3X1_:LU+]I?\ 8XU/XP? +7OA]X'^+GB+
MX5ZIXH\/>'/&GBO0]8L?A]K[1W\&G-XZG@\H6>GP7-F9IKN_TVS@$;*TT)C1
MU/YA?\%%O^">'[.7[.W[ 'QNU'P+I7B"^'@WQEIGCGX86?B'Q-K6I1_#J[\9
M:[X$\,>)M*T(FY4ZAI.I6=BLJVVOC5'CNI%<3><D<XB^!/[,WP4^&W_!'?XN
M?&_P=X0&E?%'XN_L7_$;_A/_ !(VMZ]?2:V+;3/%$D*QZ9J&IW.EZ4NZWB=E
MTBQL1(8EW[@HQST,DX:>1X#'X6OC*^+K<6T,LP^*Q&"A[.M3E3P]58;%X'^T
M72A0A2J>UJ3BZE2K753#QDL.E7EZF.XV\1:?'F=9#F6 R7 Y/@_"O$\2X_+L
MOSRO/%X3$PQ&886>899FRX=I8BIC:F*H0PV'P];ZMAZ&!<,Q;6/4\ OUL_9.
M^)GQ)L_@=X)G_:U^*GP9U/XL^(M9U^UM-8\%>*/#:^'?$5I#JQM]+L])N+.2
MRTS5M7M8);:WU)-%A:-+B6*(QB1B7^KO$?C'PEX/M(M0\6^)] \+V$]PEI#?
M>(=7L-%LYKN1&DCM8KG4;BVADN'1'=(4<R,JLP4A21_'5XD^#>H^+_\ @BO^
MS[\=O#4<B^+?V>OC+XU\1F_MA_I5KX8\3>-;C3M6DB8$.J6_B*T\)W\[+N\N
M*TDE8 (S#Z5_:D^+Z?\ !1GXU?\ !,/X":%)]NT/QCX8\*?&GXNV-NRO':?;
M\6_C"RNOW>V.;2=$\+^+(%+A06U6 0J#-$7WQG ]/$X^MB(8Z-/!4\TXCPV;
MU,-E\*-'*UDL)XM.AAEBI1=/$X7EE1HNK#V4W[-SE&*J2X,H\:\5@,@P6#K9
M'6Q&<8GA;PUS/A'#X_.ZN-QO%#XTEA<MJPQF82R^G-8O*\RE7CB\0J%5XJC3
M6)]G1<Y0I_LCX<\8_M7+^V[XXL?$GQ-^!,G[)UAX3N]3T;PA9ZYH?_"S]+:/
M1])N(-6U6Q1!K-I;Q7YOKF\OM0NAH_\ 95S#)$%=HF7E_@+_ ,%-OAE\:OVG
M?CC^SG/8:%X/M_A#?7EGH_Q#U/XB:!=:-\19+/7XM",>@6)L=.1))WG2YMDL
M]5UDS1JP!SR?SI^%WA?0_$?_  76_:;\$ZU9K=^%M>^ FN>&]4TKS'MX)]%O
MO GPWTN\LE>U:&6!9[&9[=I(94E50K1R(XW'YV_8:_8K_9N\<?\ !2_]LCX4
M^)_AZ=4\!?!#7-7U/X9Z*WB;Q;:KH%YHOCZQLM.=[VRUN"^U=+:V7R##J]Q?
MQSH"MPDIS6T^'\D>$S"MF4IQGAN#LES/"SR[ 4L.J4\74A!U:U/Z]&.+Q?-4
MC2JSJ-0JTW.MRJ=.$)>?#Q XVAF^18/AR%&IA\R\8>.N%<RH\19[7QCQ<<IP
M^)JT,+A\3_86*JY3E*C1JXO#T<)"I7PE6A0P2E7P^(KU:?\ 5EH7C;P;XIFU
M*W\,^*_#OB.?1I_LNL0Z%K.G:O+I5SEU^SZC'I]Q</93[HY%\FY$4FZ.1=N4
M8 TWQKX.UG6M4\.:1XI\/:KX@T/']M:'IVL6%[J^CY=8Q_:FG6UQ)>:>?,=4
MQ=PQ'>P7[QQ7\UW@+Q5IG_!-W_@K+\?O"GBR]3P]\$?VB/ 6K_$W0WE=(=/C
MNHK76?&&G"%GDC@AELO$&F^./#-K" &:34K&../;/&U>]_\ !#KP/K/CZT_:
M8_;5\;V\K>)_V@/B=JVGZ+<W3-+)'H.GZG=:[K2VDTF7^R2Z]JL.G!2!L/A]
M(T/EQJ!\_F/"-+ 9=B\W^OU*F7K+\EQ65UGAE!YAB<V4G/"->VE&E+!>PQGM
MG&55_P"SWY5SI+[_ (>\6<5GG$64\)O(:.'S^6?<997Q+A(YA.M#(LOX4C0=
M+-HS^IPGB:6</,<HC@HUJ6%A)XRHHU9J@G4_?VB@#  ]!BBOB#]K"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,G7]/.K:%K6E"3R3
MJ>E:CIPFVA_)^W6DUKYNPL@?R_-W[-Z[MNW<,YK\Q?V'/^"<$?[+?[/7QT^
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M29;RRN;6[A&MSQW4ZW=M/<6ML^JE+0:IK"0QP7FK-;^;#)[9^WG_ ,$Z=?\
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M'#9GG>#Q"A'.,7F5?ZSF.$S&CB,;E^*HXJ>%Q&!Q=2M3KI7JJ45%+X*_:0^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKSUX%Y>\:O8/"RP+J?5\+];^HSGSRP2QWL?K:PKDW>@JRIN+<''E]TYX^%G
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M[+ZYB/\ :*"IXF?.N>K+DAR^;_"#P/-\,?A3\.?AU/?QZO-X#\#>%?"#ZI#
M;6/4G\-Z%8Z.U[';222FV2Z:S,RPO-(8PX5I&QN/YY_ 3_@G*G@G]K7]H?\
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M5IHXHK(%/+\B^!?_  3?_: ^&G[.'QP_9K\>_M8GXA> /''P9\1?"7X6Z$/
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M5QE3IRA"4X1<9<TZ+J0]UR:M*<732NFY3@GY_IAXG_X*8_L?>$_"G@;QI?\
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M^R8,_P#!4#_@JKR<+IW[%W [EOA3XL;)!R,C@#& 0!N#'!'PUX>^!VL?'O\
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M2:Z\S=K6?ZS>+OCA\-? _P 3OA5\'O$WB Z=\0OC4/&3?#?01I6L77_"1?\
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MUE]&_P"%*:)J<^GW$,ACOK73M:M9[&YDMY-OVBVN(5??&PK[S_X)Y7-EX/\
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MTMQ:QB02-^>7AF&X_8E_8.\!_&_3HWM/V=/V[/V =?\ @_\ '*"!)3I'@/\
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M;F6_O7FDEN+J25BY]EHHN^[+]E3YI3]G#GDK2GR1YI+:TI6NU9)6;:/'M4^
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MG8W-IH]UXKN-# 9[F=F@?36MMTC,(=V"/:M4_9>^ >L^"/B]\-]4^&'AJ_\
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MT-*;-&*ER57 7:B[B!L_\,^P_P#19?C_ /\ ATM5_P#D>C_AGV'_ *++\?\
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MX_\ AE'I4%S'XYFNABQ=[]QNM/LVX@X60NJ_+Y;J&?RZV^ G[4D5C^U)!/\
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M1Y&"JHRQP!74U):=TGW2?WA1110,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ H/0YZ=Z*1NA^A_E0!^?OQ!)'_  4#^!?K_P *E\7D_A'XC_D3
MVK] ^E?GS\1&8?\ !0;X%@#.?A'XQ[$\[?$(%?H,.@SZ5]'GZ:P_#6VO#M!W
M_P"ZEFG]?,_.^ E;,/$5]^/\9_ZS?"Z_1_A\BBBBOG#]$"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^GI^B_\ $!?$_P#Z$6&_\/.4?_-O]6?E?]:Z*_)3_AY%K?\ T3#2/_!Y=_\
MR+1_P\BUO_HF&D?^#R[_ /D6C_BH/]%?_HO<T_\ $(XU_P#G#Z_T]#_B OB?
M_P!"+#?^'G*/_FW^K/RO^M=%?DI_P\BUS_HF.D?^#N[_ /D6OTC^$OC2?XB?
M#[PMXVN+&/3)O$>EC4)+"&=KB*V<W,\)C29XXGD \D$,R*2#]T&OU;PE^D[X
M-^.&=YCP]X;\28S.LURG*I9SCZ&(X?S_ ">-'+XXO"X%UHU\WRW!4:LOK.,H
M4_94JDZMIN?)R1DU\MQ5X;\7<%X/#X_B++J6"PN*Q*PE"=/'8'%N==TYUE!P
MPN(K3BN2G-\\DH75N:[2?I%%%0W,ABMYY0 QCBD<*> 2BE@"1D@$CJ <=:_?
MI248RD]HIR>E]$KO1:O3HCX9)R:2W;27JW9$U%?D_J'_  47UNPU"_LA\--)
MD%I>7%N)&UR[S((963>0+0!=V,[1G&<9/6JG_#R+6_\ HF&D?^#R[_\ D6OX
MNJ?M!/HLTYSISX\S-3IRE":_U)XT=I1?+)761-.S35TVG:Z;3N?L$? ?Q-G&
M,XY'AW&<5*+_ +8RA74DFG9XVZT?X/RO^M=%?DI_P\BUO_HF&D?^#R[_ /D6
MC_AY%K?_ $3#2/\ P>7?_P BU'_%0?Z*_P#T7N:?^(1QK_\ .'U_IZ5_Q 7Q
M/_Z$6&_\/.4?_-O]6?E?]:Z*_)3_ (>1:W_T3#2/_!Y=_P#R+7H7PE_;IUCX
ME?$KPCX&F\ :;I</B/5H=.DOXM8NIY+96CDE:5('M51V&U0 7 /() KU,D^G
M=]&?B+.LGX?RGC?,L1FN>YIE^399AY\&\84(U\PS3%T<#@J,J]?)*=&C&KB:
M].$JM:I"G33YYRC%-KFQG@AXCY?@\7C\5DM"GAL%AJ^+Q$UFV4U'"AAJ4JU:
M:A#&.<W&G"<E&"<I./+%-M7_ $IHHHK^P3\E"BOC+]OK]J35OV-_V:/%OQZT
M3PEIWC?4/#.K^%].B\.ZKJ=SI%E=KX@UNUTEY)+ZSM[J>(VRW/GHJP.)&0(V
M%)(_GK'_  <F?$\@$?LO> \$ \_$+Q#GGGG_ (D-=%'#5JZ<J<>9)\KUBK/3
M^9KH[GD8_/<LRRM'#XS$.E5E35515&M4O"4I14KTJ<TKN,DDVGIT5F?UPT5_
M(]_Q$E_%#_HU[P%_X<+Q#_\ *&C_ (B2_BA_T:]X"_\ #A>(?_E#6OU#%?\
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M%_Q 7Q/_ .A%AO\ P\Y1_P#-O]6?E?\ 6NBOR4_X>1:W_P!$PTC_ ,'EW_\
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MH48\U22I4L7.K4<8W?+3A*3MHNI]\T445_69^6!1110 4444 %%%% !1110
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M18!@ >@ _*OY]_\ @GQ^Q=\3_@/\>O#7BWQO^QG\8-&M;:3XDWVE?%'XX?\
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M.<<FMRBB@#Y U;_D_KX?_P#9H'Q?_P#5S_ ^OK^OD#5O^3^OA_\ ]F@?%_\
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M .3O^%/_ &<K@3_UJ<J/GN+O^24XG_[)[.O_ %6XD_HAHHHK_JX/\N#\B/\
M@N3_ ,HZOBI_V-/PU_\ 4STROX-$^XO^ZO\ (5_>7_P7)X_X)U?%3)  \4_#
M8DDX  \9:8223P  ,DGBOX-$^XA]44CZ%00?Q'(KW,KTHU&]$ZFC>B?NQV[[
MK[S\HXX_Y&]'_L H_C7Q*7WM/[AU%%%>GS1_FC]Z_KJOO/C;KNOZ_P"'7WA1
M111S1_FC]Z_KJOO"Z[K^O^'7WG]>W_!MO_R0[]H__LK'AG_U#A7])5?S;?\
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MX]<N- AT'3TOH8(;B&;C_C'IGB7]FBPM_&7P-\>>(/V?/@9XD\7>%="_:/\
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M@3_L3?"__IBL*[2N+^&__)/? G_8F^%__3%85VE(4/@C_AC^2"BBB@H****
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MCQ7\0? 7CRYTBWB7[/96WBQ/!OAW7+^QMQ#;_P!NC4]12(SZE=RGW*7X#_\
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M!'L2 >X[>XS7\I7QO\(^+YOVB_C7\(O''[9TO[-_@SQ]\7OBFF@Z)\<?@/\
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M_D%%%%(H**** /FWXI_\E]_9=_[#'Q=_]5G=U])5\V_%/_DOO[+O_88^+O\
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MWPMN](U;XJ>)] \-P?$4>$M'U_QIKNM^%OAMX.1?#ATNQE\0:K>6UD)=)@:
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M'B#_ )#VM_\ 85OO_2AZR*U_$'_(>UO_ +"M]_Z4/617_(9C?]\Q?_837_\
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M&*NFI2O;Z4_;8^$^M?'#]F;XD_#/P_H6I>)]6UY?"MY;>']&\6:'X&UC5O\
MA&?&GAWQ4]EI/BGQ-X:\7>'=*U*5-$863:WH-UI=S<".SO9]/@N'U&U_(OQA
M^QC^VAXS\+Z;;>*OACX8\:>(/B/\$_$OP.@U?7_&OP\L]<_9[T]_VE+WXF>
MO&'B^?0/#VEZ)XN\2Z#\.Y]'AUW5/A=IEI=:AXN\/IY:.+A-:3^AVBH4K*UE
MO?57;U3L_+3;8Z:N%IUI\\G)/E4;+EY6E+F3:<6VU=I._N\S:2EJ?$O[5?P_
M^)5[\,_B)K^E_'#Q+X<\*V/@HK>^ +/P?X!U#3-26RA07RR:[JV@W7B2#^UB
MH69H-11[9"?LQ1VW#W#XYY_X0[2/3_A-/!V/K_:L>?Z56_:9_P"2 _%G_L3-
M5_\ 0%JS\<_^1-T?_L=/!_\ Z=8J(_''_%'\U\AU(I*K:^L-FVTK6V3;MOT\
MNQXC1117<>>*O4?4?SKU3]GK_D&_$/\ [*'+_P"H7X+KRM>H^H_G7JG[/7_(
M-^(?_90Y?_4+\%UA7VCZO\C;#_Q5_A?_ *5 ^@Z***YCTCQWXZ?\B+8_]E*^
M#'_JX/ U>Q5X[\=/^1%L?^RE?!C_ -7!X&KV*GT7J_RB2OBE_P!N_D%%%%(H
M**** /FWXI_\E]_9=_[#'Q=_]5G=U])5\W_%&.5_CW^S Z12-'%J_P 7#+(J
M,4B#?#:[1#(P!5!(^50L0&;@$D8KZ0H)6\_\2_\ 28A11104%>:_&?\ Y(]\
M5_\ LFOCK_U%]5KTJO-?C/\ \D>^*_\ V37QU_ZB^JTX[KU7YBEL_1_D:WPW
M_P"2>^!/^Q-\+_\ IBL*[2N+^&__ "3WP)_V)OA?_P!,5A7:4A0^"/\ AC^2
M"BBB@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&Z'Z'^5+2'
MH?H: /SM^(I!_P""BOP$QU/P?\8 _P"Z5\3'O_\ KK]$Z_.OXAX'_!1CX"C_
M *H_XO"^Y,7BK('J<HH^N1WK]%!T&?2OI.('_L_#/_9-X=KOKF6:;GRG#,>7
M%<6_WN*<1+[\IR=7?W?<D%%%%?-GU85^>'[87C#X'_&3X@_#[]@'Q=X>^*GB
MWXA_%JPM_B\FL_"&:'1M9_9UT#X;>((-5\(?M :WXWGO;7_A"[C2?B-I&E:9
MX'DM+;6K[6_$BO92Z'?:-%JL;?H?7Y:_M%^ _C[\#/VR-(_;B^"?P;UK]I?P
MQXI^ -C^SI\9O@YX+\1^$/#GQ4T73_#7CO4_'W@?XB_#?_A/M8\+^$O$Z0WO
MB#7M$\7>%]2\5Z%>-93:=JVCRWMQ;7-C(/\ R_,:^[1M.]M=++YZV\].I\J?
MLK_LV_!7]ES]O+P[\$?BK\3?VO/B;\4=-L/C+\9?V5O$/Q['PWMO@3XFUCXH
M7;^)OVB==^%X^%_AKPO;ZC\7-+NO%^HP>*(O'-@FI:=X?U:ZN/"EM#HUR63]
M]1P /0>I/ZGD_4\FOR.\/:)^T?\ MD?M=?LW_'#Q_P#LX^,?V5_@/^R@?B=X
MLT"Q^,'B#X?W_P 9?BQ\4?B)X+N/AW916GA;X:^*/'FD^#_A_P"%_#FH:MJ-
M[=:[XICUCQ%K-WIMNF@V]MILEP/UQ^O^?Y4EUTMKI]R_KT!N]M>BO_7IJ_-L
M*^:+/]FC0+?]KO7/VO;KQ#JU_P"*M1^ 6B?L_P"D>%Y8+1=&\/\ AW3_ !UJ
MOCW5]4LK@#[7+J'B'5+S38;N.4K#!!HUN8RQGD"?2]%,1^9_Q_\ ^">/B'XO
M_$7XK^,? '[7?Q\^ /A;]HOPWHGA+]HCX<^!4\%ZYH?CC2M$T#_A$?[0\&:A
MXQT#6-5^$OBK5_")'AW7/$/A"42:A9PV]Y]D@U6""]C^^/AG\._"7PB^'O@C
MX6> M*70_!/P[\*Z#X,\)Z0DLDR:;X?\-Z9;:3I5F)I2TLQ@L[6)'FE)EF=7
MED)9B3W%% -W271;:+R_R7W'Q_JP'_#?7P_..?\ AC_XP#\/^%T? \_SK[ K
MY U;_D_KX?\ _9H'Q?\ _5S_  /KZ_I+=^OZ(!&Z'Z'^5?C+_P %&/\ DJ?@
M_P#[)]:_^I)K]?LTW0_0_P J_&7_ (*,?\E3\'_]D^M?_4DU^OX0_:.?\HSY
MM_V5W"7_ *GS/V[Z/G_)R,%_V*\V_P#4='Y]4445_P ]Y_?04444 %?T1_LO
M_P#)!?AA_P!BQ%_Z6WE?SN5_1'^R_P#\D%^&'_8L1?\ I;>5_IM^RW_Y/#X@
M?]FUJ_\ K4<.G\V?2;_Y)/(?^RAC_P"H&+/?:JWW_'G=?]>\W_HMJM54U A;
M&[8D "VF)). !L;))/  '<\#J>*_W&J_PJO_ %[G_P"DL_BVF[5(/M.+_%'\
MP/B#_D/:W_V%;[_TH>LBJ7B+QAX2'B#7!_PEGAE"-6OP5_M[1R1BYDZYOU(/
ML0,?K6-_PF'A+_H;O#/_ (/-&_\ EA7_ "78WA#BOZYBU_JQQ#_O5=?\B3,W
M_P O9+IA6NI_J/A^(<@5"@O[<RC^#2_YF.$?V(=JO]Y?B=-17,_\)AX2_P"A
MN\,_^#S1O_EA1_PF'A+_ *&[PS_X/-&_^6%<O^J/%?\ T3'$73_F29GUM_U"
M_P!Y?B;?ZQ</_P#0\RCI_P S#"];?]/?[R_$Z:O?_P!E;_DX;X5_]C/#_P"D
MTU?+7_"8>$O^AN\,_P#@\T;_ .6%?17[)GB;PS=_M%?">WM?$N@7=U/XI@2"
MWMM9TJ:>=VM[@!(8(KR265^,;(U9CC(!Y%?HO@_PKQ/1\6O"VM6X;S^E1H^(
MW ]:M5J9-F-.G2I4N)LJJ5*M2<\,HPITX)RG.348Q3E)I)L\#BK/LCJ\+\24
MZ6<Y54J5,@SB%.G#,,*YSG/+J\80A'VMYSG*48QA&\I2:239_1Y1117_ %-'
M^9Q\B?MQ_P#)N_B?_L*^'?\ TZPU^#*]!]!_*OWF_;C_ .3=_$__ &%?#O\
MZ=8:_!E>@^@_E7^"/[3?_E(7)/\ LUO#G_K1<8']S_1M_P"2!QG_ &4^9_\
MJNR46BBBO\[3^@0HHHH _7W_ ()P_P#(C^/O^QGLO_33%7Z1U^;G_!.'_D1_
M'W_8SV7_ *:8J_2.O^EGZ$W_ "BUX0?]B3-?_6GSP_SE\9O^3G<6_P#89@__
M %4Y>%?B)_P4$_Y+G8_]B)H/_I=K-?MW7XB?\%!/^2YV/_8B:#_Z7:S7Y1^T
MG_Y1O?\ V7W"W_J/G!]3]'7_ ).)_P!T+,__ $YA#X:HHHK_ )_3^\0HHHH
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M4UAKNEWDVGV?FRF33[AY;..9&B%W##N,?,B_U!QY@O$3%>(&4\49!E3KY#P
M\JY,-_:V+P6+S^.>UY4>-XX+)Z.7XC!Y\L)PW5P,<G6.S#+?JV?87$K#JM).
MWYGDE;(*>1XK+<?B8PQN>?6KU?JU*K3P#P-.%3)G6Q<ZT*N"]MF$:_UKV%&M
M[3!5:?.HJU^1^)WQ>\4ZIX'^)-[X6\&W]QX.T5-<\-3^+[;7K:SU==5LI!8W
MFI:7HZ0&632=-O3)#/>?;XKLO;RO;VK(A>NXN/B9XD6Y7PSX-\&S>+KSP[X:
MT35_&%Y/KUMHJ67]IZ>+FWT[3OM%C>'4];O+>)KI;:1[*VCBDB\V]A,B&N2U
MOX4?%*W\,>-?AWX2U'PC'X0\57FNZC9ZKJSZM_;^D+X@OI-2OM"6Q@LI-/N+
M9[R>[CM]2:]22"VNF,MG++&C/U$_@?XC>&M?U+6/ EQX8NE\7Z-H&G^)+7Q)
M)JMO%I>JZ'ID>DP:[I#Z;:71OE-B(4GTRZ^Q>;]EB9+N F7'Q&&EXOKB',<T
MQU7CZA1Q.7\)9=Q)B<!D7"=>KE-;#8OQ*Q6983@+!U<MKX3-LKAF.*X*P]7,
MLQP6;8Z618VO7GCWBJ&+GE?M58\*/ TL+AUD<Y4ZN98G+85<?F=-8N,Z?#]*
MA6SNJZ\983%O#T\WG##4*N%H+&T:</8>SG2^M^=?#/QM>7'A_P""7VG3M3UC
MQ'XKC^*,^G3ZAXAO[(6EQI<NL7<5KJL")/!J"O"MOI^;@3+IK#S;82%<FK\.
MOB#XHN_"'P=O/&VD2W^M>*/B%XITC1K^W\67N7DMM,\7Z@MWJ5O#96T5Q"B:
M9<:3%IDZSVL2FVOEQ)%'$G;>"O@_XK\.GX+'5-0TN[G^'9\?MKL]NUV1?OXK
M6\%M+IT;6HX5YUDG2X:(QY=8S+@,:GAKX1>-["'X6:5J,OAX6'PR^(^O>(X;
MNQNM2DGU70=6T?Q3:Q&:"YTV);;4H[W7X@UM'-+ ;> R_:=S",>%P_D?BW@X
M\'O%83B+#K Y7PUE-? 2R[)*^#K3_LCZ.4LSQF>PEA<9[?'X&IEOB0L/FN)Q
M<Z^#Q.5U<)@L9&"P="MWX_&<(U7F\:57+YNMB\QQ5*LJ^-A6A'ZWXA?5J6!D
MJE+V>'K0Q'#3J86E2C3K4\1"I6I.?MIP[BQ^,D>H^$O!VM6FDR-KGBWQ4O@Y
M/#SW2^;I^KV6IWNG>(TGN1"-\>AQ:5J5]+((U\Z.&-04\]''.S?'Z_6'4O$U
MGX.6]^'.C:I>Z9?>)/\ A([&WUN:'3;YM-U'6M/\*M:2W%WI%E=17&YFU"WO
MIX(7N(+1T7#:GA[X27VE?%K6_&,MY:S>%1+J6N>&-&$4HFTWQ5XGL],LO%%_
M('B$/E7,&E,]I)&6E635]27<BR$'RN']FZ]TF\OM'T[P1\'=:TJ\UN^U*U\;
M^)]#DOO%MA:7^IR:G-:76EMHUQ8:Q=67FRVNG7MQK-LOEF!I(#Y&U_J,ZS7Z
M0E++\%/"8?%T\11KYKP_4J83"91*KF&8\/87+\'DW$U?!QR#B'V>2<;9K4S[
M,,1A%_8U+"9;A,@A6SKAQ8G'2J^5A,-P%+$5XSJ0E"=+"XZ$:U3%1A0HXZKB
M*V,R^G5>88&^,R?"QP.&IU'];E6KU,?.G@\=R4%#[/M+F.[MXKF%P\,Z)+$X
M!&Z-U5E;D D,#N!P,JP^M6*JV4 M;6"V "K!%%"BJB1HJ11I&JHD8"(H"C"H
M-J_=7Y0 +5?U31Y_94_:I*HX1=11ORJ;BG)1O=\JE=*[O9*Y^9RLI246W%-\
MK>[5]&[:7:WL%%%%:""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K_=/...O'7MP<@G/
M08.3V/2OY=_VC=*\>0_\%*_ OPUOO^"EGBF/PGXE_:(\,^+;_P"'^A?'&;X=
M:M\$]-U;2;[^S?A&_AB;PIK7@OQ'?>([F^TA?"EKJ7BS2M9GTV_N;2X\%ZN+
MNRU&#^HD].F?8]/?/^?P/2OY=OC9\)DU#0?VT]7L/VP?B5X>_9LO/VX;=/B_
M9Z=^RGX(\2>%M"^(?B'Q-X,O=4U.+XE:CXWM?']]X7^&>KVOAGP[XH\::/:V
MI\,7\/E:)IUU9V5Z5TI]=;;?-M]^G4\W,5)QH\L>;EG*H_?4-*:4VG>M1C:2
M7*Y-SY+\R@VD?1G_  7#\?\ A?X:R?LZZMJ_QY\:?!#6?%.B?'CX:Z5=^$OA
M+J_Q/DUG3_&^A>#K/6[@SZ7\2?AK'X5UG18[:TE\/ZK=:A?+]JO9O*M 8F)^
MQ?\ @E#;W-W^SIXM\;W_ (H\6>+]2^*/QM^(7Q$U/6/%WPSOOA/.]]KD>AVT
MD.B^$]0\8^.YD\/*FFQRZ=?CQ)>)>&:9E2':5KK/V^_V1/C;^UUX>^'_ (8^
M%G[1[_ GP]H-]KUUX]T3_A$;CQ':_$6UU&RM+;1["]OM-\1>&=9TB#198[RX
MVZ?J"F[>['F,KV\3CT#]A+]DZ']C/X&1_!V&Z\'7[_\ "6^(O%=WJ'@G1/%F
M@Z9J%[XADM9KJ]O++QEXW\?ZM)JT\L!:\N4UR.RD'E+:Z=9JC*S<HNDE?WD]
MM/T2?EJWY=Q4Z5;^T:E5TW["5-<M1RDO?Y:<;*+KSC+9KF5&C:S5I_$?9M%0
M7-S!9V\UW=30VUM;1/-<7%Q+'!!!#$I>266:5ECCC106=Y&5$4%F95!(R4\4
M>&Y;;3KV/Q!HKV>KK$^DW:ZI9-;:FDQ41-I]P)S#>+(701FV>4.70*267.=G
MV9Z3:6[2]3RG]IG_ )(#\6?^Q,U7_P! 6K/QS_Y$W1_^QT\'_P#IUBJM^TP<
M_ 'XL_\ 8F:K_P"BT/\ 6K/QS_Y$W1_^QT\'_P#IUBIP^./^*/YHQJ;5?\#_
M "1XC1117<><*O4?4?SKU3]GK_D&_$/_ +*'+_ZA?@NO*UZCZC^=>J?L]?\
M(-^(?_90Y?\ U"_!=85]H^K_ "-L/_%7^%_^E0/H.BBBN8](\=^.G_(BV/\
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M!7_LX_"W_JSH'POB=_R;WC'_ +)_,?\ TQ(_<:BBBO\ J'/\T0HK\N/VO_\
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M$^)S?!KQC#;>.=,\"^(]1\6SZU\13%IGA/[#X4L$ETMGU?6FTQ(&@>3X<?\
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MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\YOB3Q_P4>^
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M?%7_ &,>N_\ IVO*Y:O[KI?PH?X4?X4XO_>\5_V$5O\ TY(****T.<*_0/\
MX)9?\I _V6?^RDZ;_P"DFL5^?E?H'_P2R_Y2!_LL_P#92=-_])-8KRL__P"2
M?S__ +$V8?\ IB1]?X>_\G X$_[+/A?_ -7>"/\ 0MHHHK^)#_;$^1/VX_\
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MXA+)I9'[3WOAKP[J5S+>:CH.CWUY-9/ILUW>:;9W-S-ITA#26$L\T+RR64C
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M?#6#QI>PW=C%XDL_#VI7ME<WYL;6RM-4CET[3M:;6XEM#2YKI>:2\GIIY?\
M#^9$ZF#@IRDX2:E.ZNG)RO-3BEN_>E44DDTI2G%VU1[:O['>GW'[=6C?M5W]
MEX9&@^!OV9].^"O@VT2?4KKQ/>>)+OQ-X@GUK7O$%K<V4>BK;:/X-O8/#GAW
M4(+R\U>XA\0>*;:]2WM!:K-T/@7]A;X)?#FQ\2^'O#&J_%NW\!^(?"OC'P99
M_"V\^+_CJ_\ ACX.\.^.H;FW\06'@?P3=:L^C^'4,-W<Q:4T$,IT".5TT3[
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M3;J_U#Q]XD\5VUW9V^EVNKZLEGX)\,:7<Z9<:A=S^'?"T45_<VX9;,:O@O\
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M1F^SZ?!=W<%O-?7 7<8+.*61'N9@GS&.%7=5^8KCF@+V_(\;_:9_Y(#\6?\
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MAI=P);BSLF5UOKVW@,D]E8E'%]=1PV;(ZSLI^(/AWKNDW7CVZT_X>?$7Q_\
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MUX>Y6A&JHU(7C-.+:/R'_P"&P_VCO^BE7W_@G\.?_*>C_AL/]H[_ **5??\
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M_P"&\?@!_P _OBS_ ,)M_P#Y-H_X;Q^ '_/[XL_\)M__ )-K^*/^)'_I>_\
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M,KN3F[KE?OR2MZ)V7RU\SX?_ .&>/VC/^C@/A3_XCMXC_P#H@Z/^&>/VC/\
MHX#X4_\ B.WB/_Z(.ON"BJ]I/N_Z_K\7Y6S^JT>T_P#P9/\ ^2\OS[L^'_\
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MY"/^&<O$_!=0[8Q^T0,#)Z$M]:]0^*_@=_B7\-_&O@&/4!I+^+O#NIZ"NI-
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MI2C24%+WHTUJG_/!%^S)^T#$1<Q?#KQ-%/#+&\3+$L<ZNNUUEB;S@8S&0"K
M?(5!!XKW?X$?LY_M*Z-X^T#Q7#9P^"9;&XU(KKGB[21XGLK!Y+&XA:6[\+VG
MBGPOJ&IQRN_E1^5K-DR22B<2.L1B?]J-J_W1SUX%&!G.!D]3@9/7O^)_,U/
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MT]CXF2ZL_%<-II5_$TLK0M_0P,X&<9P,XZ9]O;TK\//V5_V8K7Q[\?\ P?\
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M?QH?[)!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\*?%WX#_ !]A_:5MOVCOV??$?PF74O$?P:TWX'^/?#7Q
MBTCQ3>Z?9Z-X=\:Z_P"-?#?BOPA=^$[N"[;4H+SQ5KMGKGA[46M-.UVV&CRC
M5;";3F\[YWU#]@OXZ:C/XS^#\WQ"^%3_ +,_CW]JC3_VJ]:UD^&_$Z_'2SUB
MW^*6@_&:\^'NG2+J0\(/87'CCP_:6UGXWNY9-5L/"<TVDKH<M['::C;_ *YT
M57,U^'X=/3_@]SGEAJ<G)MS]YR;2F[>^K3C;I&?VEWU5F?FIX3_8A\7:%;_
MQ+OQ/X3FE^%/[;'QS_:BU22"RU '4_#GQ4NOC3+I'ARP,D),&N:6GQ*T4:A=
M2D64O]D78MV8&U%?+6L_LR_M,?!C]H+]ERW^$4GP^U_Q)'\0O^"D'Q4NM>\7
M>'/&=Y\,]'\._'+QUX0\9:#X5\0:MX?\B]\,^(Y;+5OLUEJ*)=VEYJ6D:E:V
MFG7=K-)/!^Z%(0",'U![=CGN"*.9Z[:VO\O4F6$I2C&*<H<LH-2C)\RY)TII
M7=]W1@K]DT?B=JO_  2>\1^)OA;#\,]?^+NDK_:O[,WQU^%_BG7M,\/ZC:AO
MBI\;?VA;#]HN^U_1]'CU2,0> -*\4KJ&C)X??58-6N/#_P!ELTU"UD:69=&P
M_P"":OC?5_A5\3/AGKFE?L_?#IOCO<?"_P $?&/Q/\-KOXR>+/%.K?!KP1J6
MO:]KMGH6N_%OQ'XI;2_%>JZIJLEKX/CATZVLO 46L:WK<6KZ[K":;]D_:&BC
MF:M91TTVO^=_/[WU#ZEA[W]FK\GLWM=QY>5)NU](W2LUHVC\_M&_8^\5WG[!
M7BC]B7QGXUT7RT^''B?X,>!O'_AG1FMIH? =F+G3/A=K/BC0)5M+.[\5Z=H,
M.AIXZAT^>'3/$.IVVJ75F]BFIE(/F[]KSX<_M=7?[(L^N>)C\-+G]I+X0_$;
MX/>)?V:)O@%X3\<ZS;IXYL-5LO!5Q<>*;77)/M2:!XHTGQ-K=CXAL[.WL](\
M,^&)KR6\U34T@$R_LE2%0<9['(]C_G^9'0XH4FNB>M_GW\G_ )A/"TY0Y(N<
M/W7LDU)Z16L7O?F@W>$KW4M=6D?F?I/[#WBSX:^*/V79?A'K_A)/!GPF_9O\
M6_LO_$S3_%ZZQ%XAUCPAXTO?!&LZOXY\(ZGH<+VI\<S:WX3O+R\AUJ)-,O;C
M6I;TS1S0;)/ESQM^P[^TGX9_9_\ #WA;Q=KOPY^('A/]C?X#?'K1?@/X?^%/
M@W7&^)GQCUKQ-\%/%GPP\)V?C72_$5Z_AS2I[70M:9-1T/P_<:K;^+_$1AN9
MKBPM#_9Q_=2D(!Z^F.@/\_\ ]5',_)^NME>]EKM?[M;!+"4G?XE=6LG[NT$O
M=VLG3A)+9..EKN_\O?[.W[+GQ)_:9\ _%WX&>)I?$_B&[U7X3_L[ZQ8?M%_$
M#PC\>_"&D:-KWP%\>V.N>#/V9M9\*_$FQ\#:WJOAF.*Y\2ZA?ZYX!OX-2TQ+
MVZNM2U&;63I$8_1?P/\ \$]/$VCZ7\/+N72?@G\.O$N@_M8?"/\ :"\8P?#R
M\^+'BBT\3:!\+?#^IZ)!I5]XF^)GB#6M=U7Q)*=2/]CSFQT32M(TNWM=,>&\
M>#[<_P"M@4 Y'4]>G/J?J>_KWIU)N_1?K]_]?E;.G@*,$N:\Y**CS-=(N3C:
M_-+F3E.\N9R?-*[>EOQ?^,'_  3&\8^.O$^H?$;3?$?@#7O$6F_M6?&/X[^'
M? _BZ\^(7A[P3K7@[XQ?#OP9X&U3P]X@U[X>ZGHWB_1/%FC7/A&#7=)UK1GU
M+3&>6ZT^_P!,O(;XR6GLO@O]B[XD_"CQ+^R5XO\ A8OP0\*R?!G3_C3X9^)W
M@73[7XCQ^$K_ $'X\>*_#?C#Q;K?@/5=8UWQ)XFNO%NGZOX<6Y\_Q?>26GB2
M]U74=1NO[%+0V</Z=T4<S\GLM5T5M/P7Z&OU2@I.2BU)N+NG=IQG":LW=J\H
M0;5[/E5UHC\@/A=^PQ^TG^SSK'PZ\=?!WQU\%=<\;Z5\._BM\)?'6G?$S1_&
M,GA:3PUXR^/_ (R^.'A+Q)X1N/#DD.L6VMZ%-XQO-)\2:'>&#3?$T<-EY6J:
M0=.MYG]L^&W[+/QG\)_M>Z_\=?\ A)/AY\/_ (::TGB^X\7>"OA?>_$%O^%V
MZ[KUGI=EH/B?XB^#?$NH7'@3POXJ\-+IYN[CQ-X+AEUKQ)<,MOJ5XMEOA;]$
MZ*+Z6LO^&T_J_GTT".$I04$N:T)*<5S.T9)*-T[W5TM5?6[O>[ ?Y_SDT444
MCI"BBB@ HHHH **** "BBB@ HHHH ***J7E_8Z>BRW][:6,;N(TDO+F&V1Y"
M"P17F=%9RJDA02V 3C - %NBLZZU?2;$6AO=4TZS%_(D5B;J]MK<7DLFTI%:
M&65/M$CAE*)#O9MRX!R*>^IZ;%)+#)J%C'- (S-$]W;I)")G$<1EC:0-&)9&
M5(RX =R%7+$"G9]F*Z[HO451@U33+J:6VM=1L;FXAW":""[MYIHBK%&$L4<C
M/'M<%&WJ,,"IYXIBZOI+B IJFG.+J5H+4K>VS"YG0@/# 1*1-*I90T<>YU)
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M,3/T[P6_Y.QX>_\ 9593_P"I,#^X"BBBOXT/]D@HHHH **** "BBB@ HHHH
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M[3D[MQ44]M2BBBI.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\$P?^3!/V6_^R86'_ISU2OQOQH_Y$>4_]C9?^HM<_L;Z&/\ R6_%?_9*Q_\
M5O@#[SJAJO\ R"]2_P"O"\_])Y*OU0U7_D%ZE_UX7G_I/)7\Z1W7JOS/]&)_
M!+_#+\F?Y@_CC_D<?%7_ &,>N_\ IVO*Y:NI\<?\CCXJ_P"QCUW_ -.UY7+5
M_==+^%#_  H_PIQ?^]XK_L(K?^G)!1116ASA7Z!_\$LO^4@?[+/_ &4G3?\
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M)/\ [*7)?_2,:?AS1117]0G^7@4444 2Q=?Q7^9K_38^"/\ R1[X3_\ 9,O
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M^Q1CO_3$S].\%O\ D['A[_V564_^I,#^X"BBBOXT/]D@HHHH **** "BBB@
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M_P!-CX(_\D>^$_\ V3+P)_ZC&EU_F3Q=?Q7^9K_38^"/_)'OA/\ ]DR\"?\
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M@?X<^&#KGB+QSXB%P&EETT:I=Z#X;LK:V5)+K4M:BVRK]G>.3\<O@E^SU?\
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M#:==:A<I8RW-['8IYD%O<N'C2#]BC]BCQ#KGA;]C/]HGX_?M!>-/C9J'P?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7S[]?O"BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MICTQVQTI:8GJ[O\ )?Y!1110!^'?QS^.W[;OQ1^)O[>NO?LV?&GP/\%_A_\
M\$\+71],L? ?B/X5Z9\0!^T/\1[3X(:#\?/&&F>.O$FH:QI^J>!_!;>'_%.@
M^#M#G\'(FL6^I3ZAXBO+F>*SCTBZ_43X&_M!>$/B_P# /X(_'6^OM*\&:?\
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MOV1O_##_  [_ *Z%_P#7K]1_XC94_P"B;C_X=WY?]2SR?W^1_+G_ !)/A_\
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MLX6Y^;G]WE?VQ_PLOX<?]% \$_\ A5:%_P#)]9^K?$OX<C2]2QX^\%,38W8
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M6U,AEALEPN3_ %.&21S)5%AL9C\7]8]O+-L#RNI]>]FZ7L7R^R4_:2<W&/\
MGL?:['_G_L__  )@_P#CM'VNQ_Y_[/\ \"8/_CM?Z$__  Z0_P""7W_2/_\
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M26]PZ!U5T;:6SM=3@9K^G'_AT?\ \$O?^D?W[(O_ (8?X=__ "BIQ_X)(_\
M!+\\G_@G_P#LCDX R?@1\/#P.@_Y 70=A7=PEQ)+A;-UFJP:QK^JUL,Z#Q#P
M^E:5*3G[3V-?6+IVM[-W3W3V\3Q9\.(>*7";X6GF\LDB\RP68_7H8%9C*^#5
M9>Q^KRQ>"5JGMG>I[?W.7X)7T_SU_M=C_P _]G_X$P?_ !VC[78_\_\ 9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC%QI94W9<V64Y:;:XC$J_K>+^04445X)Y84444 %%%% !1110 4444 %%%%
M!1110 4A(QDD  ]<X&0?7Z\$?@:QO$NM?\(WX=U[Q"=+UC7!H6CZEK!T7P]9
M#4M?U<:99S7ITS1-/,L OM6OQ#]ETZT,\(N+N6&$RQA]X_!/]JK]O_\ :O\
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MW_:!_P#5P^,J^@ZF2?,];[=%Y?\ !^_R-Z:GR1]_I_*N_K_7Y_)/_#7&G_\
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M_P!"=\0?_"3OO\:]%HH_LOBC_HJJ/_B/X;R_ZC?+\?6Y]8RW_H6U/_"ZI_\
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M.-UU3T=TNYT]%%%(U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*1NA^A_E2TC#*L/52/TH _+_ .)PS_P5#_9P'K\%?&O_ *3^+J_4$< #TK\O
M?B@?^-I'[.'M\$_&@/\ W[\8'^M?J%7N9U_ R!=LBH+_ ,OLP/;SB/+1R/\
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M@7Q]I?B'Q%#X;N]*T"Z\:OXO;5C>-<?8I)TWYV_3^M-]->NS:3WM?Y;ZI/\
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M42*B*JJ -.FDEM_5A-M_Y?)+TZ= HHHIB"BBB@ HHHH **** "BBB@ HHHH
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M;<:AI_PM^(7BK2)8]3\,:"UMISH/%,.MW6G:]<:?_:6JZ?<6;O>/9K:0Q?=
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MI-V3:5KVVOWL%%%%!04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_6M?\5:[=VVDZ;:Z>8?,GOKJSL[C^<3XQ>/?'7[3_P"TC\5/BAH?PK^/.M?
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M-YJ6FO<+^GP   '0# ^@H7KVM]RU>F_?[VKW$W>ZMY?=9JW3?7K;9.R$  &
M !Z 8'K_ #I:**8@HHHH *0G ))  !))Z#'<YXP.O-*3CD]*_'O]LW_@J1KG
M[.7B7XI6?PV_9SU/XY_#O]G34_AMX?\ VE?&=G\1]&\$ZQH'B;XMR::?"GPT
M^#W@Z^T;5=6^,'Q4DT;6M)UZZ\-:;/HD%M!JFE6":C/J%^Z62;2W&DWL>'_M
MU?&CX??'5/VC_ /[/B^./VQ[]/ A^%O[4O[,FG7'Q"/@)O@QX.U?6H/BYK/[
M-FMW_@R[^"=Y^U=X5O/$>G(+1?%%_JEW<>'K;08-,C\4:;8QP_"7P>^ 6M_%
M/X7_ +/_ ,+OV8-*\8?&WX Z3XJE\8?\$^/^"@7PIO?!/A[XY?L)ZE=ZN9/B
MK\(_VL='\37_ (=U+Q;IGAZ6[ND\1^';VRO-2^*MFEWX9\46"^((=)UBS]F_
M9I\1?M2^*_V$?$'[)?[)'PWD^+_P>^,-A\2],_97_;U^'WQ:\/?#RV^&_@_X
MJ^,O$FN7NH_M#^'+B\L?B9X1^./P'UCQ#JMGXFT;PCI&JS^.==\/QZ>@T.[O
M+VY']!_P5^ 'PR^!-EXJ;P#X0\/^'/$'Q(UZV\;_ !5UO0; :8?'_P 1#H6E
M:%JWC75;*)S:0ZKK$&D6L]\;.*WBGNFGNYHWO+FZN)UOKKM_D]^J\]=DTTT.
M_+M9K==>VNC5O^"T[ZEKX/?!'X>?!S0S%X5\ _"_PMXKU^QTF;XD>)/AO\-?
M"WPVB\?>*;2TVZCXCU73?#=I$7>^U&?4+ZVMKZ]U)]/6^EMX[N4;Y)/8J**H
MD**** "BBOE;]LS]J;1/V,/@1KO[1'B[P;XC\9> /!&N^%(_B,/"DNGG6_"G
M@?7-=L]$UOQS;Z;?RPMX@C\++?07]SX?TZ3^U]4@#PZ:DMR$B<#<^HKB<003
M3F.640QR/Y<*[YI#&I8QPQY#/*^"L:#!=L =5)_G2U[X\_%7]N7P'\<OVO?
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M_CG]H'QO8^+_ !QXZ^*WA;XL_&'Q=X>\->%];D\06/@/X?\ @.[T3X?Z=?\
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M\ W7_!)'X/?"GQM\9KOX,Z1X4\&?"3QOH/QA^+N@VG@BW\&^//"'Q T/XC>
M[SQ-X*\;:C;0Z9X43QG8Z1I-IX(UW4[>]?PO-9:(UU;ZDT<D?RS_ ,%8/'W[
M#:_M"'X:?M-^#_&'A#QKXB^%7PE\(:?\<?AI\5?$?PW\7WWPU^+_ ,1/'7A;
MQIH6M0:7:3:+X@\!?#JWT4>+/$ND^(K?6[._MM=$*Z9&4\R3ZEL?VJ+?P?\
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M_!/C&YAOO$OA>'2EDT;5[^"\GU&'4+BRN'FB348]2N9]22_@$5X-2E;4//\
MMF)A[W11=]WWWZ]QN$':\(NR<5>*=HO=*ZT3ZK9G'>#/A]X(^'?AN+PAX'\+
M:+X7\-1/=S#1]'LHK6SEN-0D>:_NKE5!>[N[Z61Y+R[NGFN;IV+3RR-S572/
MAA\.] ?P;+HG@KPUI4GP\T35/#?@5['2;2W;PEH&MKIR:OH^@&.)3IFGZDFD
M:6M[:VOEQ7"V%J)%80ICNZ*5WW'RQT7*K)))66B33279)I-6ZI=D?G;\3_\
M@G]X9\8Z]XJ;PA>_#'PIX,\:_#CPS\+[C0]?^">B^,_$7PQ\/>&H_$%O!<_
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MO_Y*H_X3+PA_T-7AO_P>:7_\E4 =)17-_P#"9>$/^AJ\-_\ @\TO_P"2J/\
MA,O"'_0U>&__  >:7_\ )5 '245S?_"9>$/^AJ\-_P#@\TO_ .2J/^$R\(?]
M#5X;_P#!YI?_ ,E4 =)17-_\)EX0_P"AJ\-_^#S2_P#Y*H_X3+PA_P!#5X;_
M /!YI?\ \E4 =)17-_\ "9>$/^AJ\-_^#S2__DJC_A,O"'_0U>&__!YI?_R5
M0!\Q>(_V+_AQJ'[5_@O]L;P;KOBOX6_%G2M$O?!_Q0C\"W.FV7AG]H+P0]C<
M1:%X<^+^AWNG7MMKD_@_4Y(M4\+>)K+^S_$^F*DNEC59=,>&VM?L&N;_ .$R
M\(?]#5X;_P#!YI?_ ,E4?\)EX0_Z&KPW_P"#S2__ )*H Z2BN;_X3+PA_P!#
M5X;_ /!YI?\ \E4?\)EX0_Z&KPW_ .#S2_\ Y*H Z2BN;_X3+PA_T-7AO_P>
M:7_\E4?\)EX0_P"AJ\-_^#S2_P#Y*H Z2BN;_P"$R\(?]#5X;_\ !YI?_P E
M4?\ "9>$/^AJ\-_^#S2__DJ@#I*@FM;6X:![BV@G>UE$]L\T,<K6\X4J)H&=
M6,4H5F421E7"DC.":PO^$R\(?]#5X;_\'FE__)5'_"9>$/\ H:O#?_@\TO\
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M&F>*-(\'ZK>SRV7B/7H]#>QT6QU4Z5,EM?\ B1X(\5^)?^".GP^\.>(_CO\
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M?&WX_P!I86KW-W>-!;I\9?&K*ANK^>YO)R&9CON+B60YP7P !],5\_?LW?\
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M_P#Y@J_KEHHY8]E_7_#?GW867;^M/\D?R-?\0@7[(_\ T>9^V?\ ^#WX9_\
MS!4?\0@7[(__ $>9^V?_ .#WX9__ #!5_7+11RQ[+^O^&_/NPLNW]:?Y(X3X
M6^ =/^%/PR^'7PNTC4-1U;2OAOX%\)> M,U36'@DU;4M/\(:!I_A^SO]4DM8
M+:U?4;RWT^.XO7M[:W@:YDE,,,495%_)?_@J%_P1-^"W_!4WX@?##XA_%#XY
M_';X3:C\+?!VJ^#-,T[X2ZCX3LM,U:RU;6SKDM[JR>(?#>MSO?0SL8(FMYH8
M?L^ T1<%S^T=%.RM;IV]![_UYW_,_D:_XA OV1_^CS/VS_\ P>_#/_Y@J/\
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ML8_&'BF+3]>D\*:7J2QW#6&MSZ)?65\+>0V NE21T[/XJ?MJ_LH? CQ-X/\
M _QM_:$^$?PN\;^.;'3]0\/>&/%WC;2-+U&^M-3F%K9WX2ZFA-MI-U>"2UM-
M7U%;&PNI8W6.;<CJARQ[+^K6_KK\V')Y/\>EO\D?S>?\0@7[(_\ T>9^V?\
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M\'3Z39>$_B!>Z/XQO=&N_!47Q.U:73;KXC_V*;^1KH_U?T4[+\N_2UG^&O\
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M69N?$ELUVSX]?!GQ]X)^)/[7'C^S^ /Q*UCX=>%O^"M7[#G[0"Z;X!^$VO\
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MOOU5_)?CY>>VB_0_ ']H3]DWQ[=?&O\ 9J\(?L[?#F?X<^?_ ,$M_P!K_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M57_Y#S_/LSZ!HKY1\3_''XU>$KWP98:I^SS8-/XY\6P^#-&^S?&30I$359M
M\0>(EDO"_A:,Q6@L?#=^AE02O]H>VC$161G3K?\ A/OV@?\ HWK1O_#TZ+_\
MR-%GY?>O\P56#;24[JU_W572Z35_<[-,^@:*^?O^$^_:!_Z-ZT;_ ,/3HO\
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M].B__,C1_P )]^T#_P!&]:-_X>G1?_F1HL_+[U_F'M(]JG_@JK_\AY_GV9]
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M_8JI?ABL6C]"X[CRX#PZ?\WA_@I?^;#Q*OT"BBBO(/ST**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^+G_ ,[^C_A^Q^R!_P!'$V/_ (;_ .+G_P [^CZA7_EE_P""Y^7EY_EWT/\
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M_P %S\O+S_+OH?ZRY=_S\CT_Y>0\O/S_ *NC^C:BOYR?^'['[('_ $<38_\
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M_P""Y^7EY_EWT/\ 67+O^?D>G_+R'EY^?]71_1M17\Y/_#]C]D#_ *.)L?\
MPW_Q<_\ G?T?\/V/V0/^CB;'_P -_P#%S_YW]'U"O_++_P %S\O+S_+OH?ZR
MY=_S\CT_Y>0\O/S_ *NC^C:BOYR?^'['[('_ $<38_\ AO\ XN?_ #OZ/^'[
M'[('_1Q-C_X;_P"+G_SOZ/J%?^67_@N?EY>?Y=]#_67+O^?D>G_+R'EY^?\
M5T?T;45_.3_P_8_9 _Z.)L?_  W_ ,7/_G?TH_X+L_L@ @_\-$V!P02#\/\
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M;OXK/Q!X@M[O1/"FCV<.G'4[BXU.,W$\=U%#9RF6"5)?<OVF/V5_V:I?V0O
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M$OA[PEJEYH]U):?\?2V-X8TCU#R&#1R-8FX59DD@SYT<D:_H-X8\4Z[\2?\
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MLVCEEW]9O6JTHQE&M1Q=.G3A53;6'Y8KG_0I^#/#\*N6O$8_.LOBJO&>!S[
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M%X[*,#FF&EQ9@,PQE66/QF(H2P6(CEO]EXJ%&EAL)AJF:N45&> ]E5D_YL_
MWP>^+/Q,MO$5Y\/?A]XP\:6_A*Z\/V7B5O#>C7VK2:->^+-8'A_PU9WMO:1R
M7*76MZV?[+TZW2%YKB\#0JFY6QZ&?V1/VI1\43\$Q\!OBD_Q:30[?Q-+\/XO
M"VHS^)8/#MT7%OKEU8PI)]ETJ9T:)+ZY>*W,P$'F><RQG]H_V;/CUIM[9?\
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M!Q-'!9'G,4H>T=3.Z]/,:]*U3V2PN'I2C%NKS*+>_P#>;_OH_P"-&]_[S?\
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M<5*C4R/ U8U\%E$Z;J\LLNPM:*J8?!M>PI35X0BV[^Q^-/CW\3_B!\+/A/\
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M^'WC?Q+X+LI,&.S\+^*?%?AO5M=TJVLR%.GPQWKI8*D<5H(H(88H_@RBN/\
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MCI&CSW4\]U-IMQ>P6.O3V4FMZ78:A-I-G)?V%A?06MVPG,L1^UW?G<7X7_:
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M^$_Q(^,OB*;PC\+/!VL^./$MMHNJ^(KC1M#ABFO(=#T. 76KZI(LTT$:VMA
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MO6QV*Q7US+L;A<2L37JU74DZM13_ &O_ &QOVQ/ 6L_LT^!O@^O[1=]^V?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[KJ?P\\;^&O%]J$(#3?V%JUK?3VI)5@%O+:&:T?*,-D[?*W2OZ3_ (]_M-_
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M*?&7AG4OV?\ X\VVNZO\0/!MMX!3PSXFN;J6QNM)M+2TO+^.X\/:79BRG35
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M"O/Q%\5W?Q.\)V/@GXI?LOZ%\'=,^+-C>:1XK\&>#/%^L^"O#USHVK:\]O\
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M&&9XXKN&.X2*>.*YC59XXYXXYD1PLJ(X91_1+^Q5;>.?!_@+X=>%_CI^T?\
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M_P!\_#C_ .8FC_B'LTK_ *+Q\?O^^?AQ_P#,37]>OEQ_\\T_[Y7_  H\N/\
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ME_U ^3_'OI_(5_Q#V:5_T7CX_?\ ?/PX_P#F)H_XA[-*_P"B\?'[_OGX<?\
MS$U_7KY<?_/-/^^5_P */+C_ .>:?]\K_A1_K;Q!_P!#O.NG_,VQWE_T_P#)
M_P!-A_Q"/P\_Z(SA#I_S2V1>7_4#Y/\ 'OI_(5_Q#V:5_P!%X^/W_?/PX_\
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M\G_38?\ $(_#S_HC.$.G_-+9%Y?]0/D_Q[Z?R%?\0]FE?]%X^/W_ 'S\./\
MYB:/^(>S2O\ HO'Q^_[Y^''_ ,Q-?UZ^7'_SS3_OE?\ "CRX_P#GFG_?*_X4
M?ZV\0?\ 0[SKI_S-L=Y?]/\ R?\ 38?\0C\//^B,X0Z?\TMD7E_U ^3_ ![Z
M?R%?\0]FE?\ 1>/C]_WS\./_ )B:/^(>S2O^B\?'[_OGX<?_ #$U_7KY<?\
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M>:?]\K_A1_K;Q!_T.\ZZ?\S;'>7_ $_\G_38?\0C\//^B,X0Z?\ -+9%Y?\
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M?]%X^/W_ 'S\./\ YB:/^(>S2O\ HO'Q^_[Y^''_ ,Q-?UZ^7'_SS3_OE?\
M"CRX_P#GFG_?*_X4?ZV\0?\ 0[SKI_S-L=Y?]/\ R?\ 38?\0C\//^B,X0Z?
M\TMD7E_U ^3_ ![Z?R%?\0]FE?\ 1>/C]_WS\./_ )B:0?\ !O5I(SCX[_'T
M9Y.$^&XR?4_\41S7]>WEQ_\ /-/^^5_PH\N/_GFG_?*_X4?ZV\0?]#O.NG_,
MVQWE_P!/_)_TV'_$(_#S_HC.$.G_ #2V1>7_ % ^3_'OI_(2/^#>K20,#X[_
M !] ] GPW _(>"*!_P &]6D@8'QW^/H'H$^&X'/7C_A",<U_7MY<?_/-/^^5
M_P */+C_ .>:?]\K_A1_K;Q!_P!#O.NG_,VQWE_T_P#)_P!-A_Q"/P\_Z(SA
M#I_S2V1>7_4#Y/\ 'OI_(1_Q#TZ/C'_"]OCYC.<>7\-L9]<?\(1U]Z4_\&]>
MDG&?CO\ 'TX.1E/AN<'U&?!'!K^O;RX_^>:?]\K_ (4>7'_SS3_OE?\ "C_6
MWB#_ *'>==/^9MCO+_I_Y/\ IL/^(1^'G_1&<(=/^:6R+R_Z@?)_CWT_D*_X
MA[-*_P"B\?'[_OGX;_\ S$TG_$/5I &T?';X^A?39\-\?E_PA&*_KV\N/_GF
MG_?*_P"%'EQ_\\T_[Y7_  H_UMX@_P"AWG73_F;8[R_Z?^3_ *;#_B$?AY_T
M1G"'3_FELB\O^H'R?X]]/Y"?^(>K2"-I^.WQ]*^FSX;X_+_A",4'_@WJTAAA
MOCM\?2!T!3X;D#\_!%?U[>7'_P \T_[Y7_"CRX_^>:?]\K_A1_K;Q!_T.\ZZ
M?\S;'>7_ $_\G_38?\0C\//^B,X0Z?\ -+9%Y?\ 4#Y/\>^G\A(_X-ZM(&<?
M'?X^C(P<)\-QD>A_XHCI0/\ @WJT@# ^._Q] ] GPW _+_A",5_7MY<?_/-/
M^^5_PH\N/_GFG_?*_P"%'^MO$'_0[SKI_P S;'>7_3_R?]-A_P 0C\//^B,X
M0Z?\TMD7E_U ^3_'OI_(1_Q#TZ.!@?';X^ 9SCR_AMC/KC_A".M?4\?_  27
MU:/]CNZ_8S_X67\4&\%W7QLB^-[>-#!X-_X39=:B\/)X>'AY7_X1O^PCX?:%
M!>L&T@ZG]LZ7XM\P'^E#RX_^>:?]\K_A1Y<?_/-/^^5_PK*IQ/G=;V?M<VS:
MK[*I"M3]IF>,G[.K3MR58<U9\M2'O<DU:46[IJ[.G#>%_!&"]N\'PMPSA?K6
M&JX+%?5^',FH_6<'B%%5\+7]G@X^UPU912JT9WIU++GB^G\A(_X-Z]) P/CO
M\?0/0)\-P/R_X0C% _X-ZM) P/CO\?0/0)\-P/R_X0C%?U[>7'_SS3_OE?\
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M7_1>/C]_WS\./_F)K^O7RX_^>:?]\K_A1Y<?_/-/^^5_PH_UMX@_Z'>==/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>ny20077915x1_charts03x2.jpg
<TEXT>
begin 644 ny20077915x1_charts03x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M&P]*I7Q&(KU(4J%"C2BYU:U:K4<84Z5.$93J5)RC&$4Y2:2;/0Z*X[P!X_\
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M2[Q;5I+I=75]"HU:<Y3C"I"<J;Y:D8SC*4);\LTFW%VUM))CJ***DL***.E
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MBEDCTOQ#ID=S:W,2K'.MI)$KR0RG=\W?\$X/V5?VLK/]IO\ :"TOX_\ P_\
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MB/2KNXGU6PT\+>O9O%=F-$NWDV6\L;LR!<Y<$?@9^Q9^S1X'?]J#X':MIO\
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M&A@,9XF^+.$HYCE>18G#\1K&XS#Y@LG6?YI^\J9CPIF%.>(C@X4Z&'HT<?\
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M-67PQJ#ZQXG\>7IU?PT=4TFVBA>?5(M)>[B\2ZK?Z<MU L:RW0:1GVU><8C
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M>EPE@\+AL/B\UP])Y>I\3YMC,7-5J5?#TXR]G#WA?^"Q?[8=Y\ ]"_:BTO\
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M/ZW93Z;J^ESMXEURXBAO[*Y5)[>5X9XI@DD:/Y4D;,B$E1\>? CX/?%+0/\
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M\0:3-.?[.=X-$T_5+*V@(+SK<[K?4&MKDPZC:VT\16OOWX^?LE?'GX:>$_\
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MNLFXQ7-5GRQNOTXHJO!-'(H\N02<L"RNKX));:2"3P#@<<#&>.:DDE2($N2
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M9@"#CY<9)SP.N.&S[/>WS[>I[=UWZ7^7?TUWV^YEBBOC#]LC]HGXQ?L_>&?
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M6V]M5\]-R:BJOVZTPC>?%MD.$;S$VN>^UMVTXXR,Y&1GJ*^-_P!JW]HOXR?
M[7/@SIGPH_9\U[XWV?Q$\:IX<\8:GI%]=6MO\/\ 26GTY/[9U!;+3-29ED@O
M+JXADN_L=@JZ?/'/>1R-&K=>#P6(QV(IX7#JG[:JIN'M:U'#T_W<)5)WK5YT
MZ46HQ=E*:<I6A%.32?G9KFV"R; 5LRQTJ_U6@Z$:CPN$Q6/K7Q%>GAZ7)AL%
M1Q&(J)U*L.>4*4HTX<U6HXTH3G'[2HJJ+F-%)FD1/FX+,%!Z#&2<%MV<XP 2
M.!4@GC/(8$8!!RI!!) (()&#CCFN3MY[?+=?+J>C=?U^'W]":BH4N()"5CE2
M0C[VQ@P7_>(.!]#S09XPI9CA1U)Q@?7!/3OZ9&<9&2SVMKV"Z>S3^:Z;_<34
M55%]:,55;B%F8X55D0DGG@ -R>"<#G@YZ5(]Q!&P1YHT=AE59U#,,XX7.3SQ
MP.>U.S6Z:]4UMO\ <":>J::[II[ZK\-2:BJYNH5*J[A"QPH<J"Q]%&[)(],9
M]J$NH9#MC<.<9(0ABO?#A22C?[+ -G  )XHL[7L[=^GW_AZZ!S13LVK]KJ_?
M\BQ14$MS##CS9$CW'"[W5<GT&YAZCKCJ/6O"?VB?VF/A%^RQ\/G^)_QFUV\\
M/^$EUC3-!6ZL-'U'7;R74]7:1;*"'3]*@N;MU<Q2;Y?+$4>W+-\R[M</AZ^+
MK4L-AJ-2O7KS5.C1I0<ZE6;=E"$(IN4F]+)-WT.3'YA@,KP>*S',L9AL!@,%
M1EB,9C,76IX?#86A!<TZV(K591ITJ48ZRG.48I:MV/?:*^+?VJ?VE_B)\)O@
MEX8^*_P!^">N_M%:EXFU7PZD'A?09[ZQN[/PWK^FS:FGB*[ALM/U'4O*@2.T
MMY+9+(R137T1N3#&KN/K?0]5GU#0M&U35+)]&OM0TK3KV^TNXD5Y=,O+JSBG
MNM/EE&U9)+.=Y+9W  =XRP !XUJX'$4<-1Q=2-.-&O6KX>FE6HRK>UPRI.LJ
MF'C-UZ45[:GR3J4XQJ-R]FY<DK88?.,#B\QQF5T)UIXK X3!8ZO+ZKBHX3ZM
MF#Q"PLZ&/E1C@L3*7U6LZE+#UZM6@E"5>%-5:3GMT57,ZLA:%E<E2R$$%6 (
M&<C(*Y(Z<X.1ZU^:L7[:'Q#D_P""F=Q^Q:?#WA1/AY;_  >B^()\0>3J;>*W
MU>73(]1-L+G^T_[*6P0%D:(Z7Y^"&6Z)RJ5@LOQ./^N?5HQE]1P.(S#$*4U%
MQPV%Y/;2BGK*4>>-H+5Z]F8YQGV6Y%_92S&K.F\ZSG Y#@/9TIU?:9EF/M?J
MM.?(G[.G+V4W*K.T()+F>J/TRHJN+NWS)F:,"(@2$NFU"<@!B&(4Y!4AL$-Q
MC-'VJW\Q8A*A=\;5#*68%0P(7.X@@@Y (KCL^S[[/:U[_<T_0]BZ[K[UUT_-
M->J:W18HJ%KB%%+O(J*#@LYVKSTR6P!GW(]Z1+B*49C8.O\ >4J5/ /#!L'&
M>2#C/>E_7Y?YK[PNKVNK[VOK;O8Y;Q_X"\*?%#P9XF^'WCG1K7Q#X0\8Z+?>
M'_$>BWH<VVI:3J4$EO=VTAC9)$+QR$QRQ.DL,BI-$ZR(I'Y3V/\ P0Z_8BM-
M2@EG@^+.J>&[>^6^B\ ZE\2M5F\&@K,9OLQL8K>'4/LSDF.5?[3,LT3,LDIW
M,3^P!NH!(83(OF@9,>Y=X')^[G)X&0!DD<CH<?F=\!/VU?B)\4?V^_VHOV4M
M<\.>%+'P1\#]$TW4O#FN6"ZJ/$NISW4'AJ29=6GN-2GTV2(MKDVR.TTZT=!#
M#F1\R5]%DN+XAP^'S.639CB\'0PF%CF&.A0Q<L.G2A5I8:-:,%)<]6,J\(Q<
M??C"[32BSX#C+*^ <?F/#5/C#(,KS?'YMF4\AR*KCLKI8^<<5/!XS-IX6565
M.;HX:=#+<16G&J_82J0A&47.<;_H_P"'/#NB>$= T7PMX:TJQT/P]X>TNRT;
M1='TV!+73],TS3K>.TLK&SMHE6.&VMK>)(HHU "HB@"MJJB7MO(A=9%95;:[
M*<JK=\MTP.YY K\U_P!J7]M'Q]\$/VQ/V/?V?O"V@^%=8\(_M":GJ-EXKU/5
M4U.36],BM=2L-/A?0)[/4[73HG'VIGD%_:7HD< ( JN*\S Y?B\UQ,Z&'2J5
MU0Q>+FZM3EO3PF'JXO$2E.;;E/V5*<DFW*<K+5L^CSO/<IX7RZAC<PE*A@GC
MLIRFC'#4)5>7$9OF.%RC+Z<:-)>Y2>+Q5"E*22A1@W)VC%GZ9T57DNH(@#+(
MD0)P/,9%SUP>6Z';P?<>^!KJ!%5FE14< J[.BJ<XQABP&6R-HZGM7"DW:R;O
MM9;^G<]RZUU6F_EM_FBQ14#7,"",O(J>:0$#LJEB<< $_,>1]W/48SD9:UW
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M[&1G5I4E3RS)L\PV-S"NG6E"-25'#TY3C1BW4JM<D(RD['\P7C'XQ:_^U/\
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M>Y^(,>@Z+IWQ-N->L[?Q&3$YU/6](M]0T=M4:%(K>*\:6.,E(HA\ ?"KQ?\
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MQ=:C@:W#&&IRC3IY$_[/PCECZ.)DL+A*=.,9OG_>3J2K5/YQO$?[-'B[4/\
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M)\YCG52/,^'*654>,\32C5Q5%<V(AA\5&O/&488G,:32BI\]GV_[?GQA\7?
M7]CKXZ_%?P',MKXR\+^#1_PCM^84N3IFJ:UJFFZ!;ZK'!(K13S:8VJ&^@CE1
MX7F@02QO'N4_R&^'_$WQ5C^'WPY^-7P9\.?\%%-6_:JN-9TKQ7KWQ3O-,UOQ
M'\'/%]I<SW,][;Z4EE'>ZQJ.CRYM3:R7\<]IJMN9X=0MEA\M(?[<_BM\,/!O
MQF^&_B[X5_$+24UWP9XXT2Z\/>(=,:66W:XL+U-C-!<P$3VMW;N([BTNH62:
MVNHHIXG22-2/Q[\.?\$@?'W@W3X/ _A;_@H-^TMX?^#&GWOF:=\.],NDL9-/
MTU+KSTTVWURRU:U@LX0A=#]CT:UMV9O,^R\E6X.".(,BRC+<70Q[H4L74S"G
M7E+$T,55HXS PP_(\'4>$HUYU(*JY3E0KJG1GSJ?.YJ\/=\9N .->+.(LJQV
M1_6\1E%'(*^ A2R_&Y?A\;E&=RQ\<3#-L,LTQ>!HT*E7#JC1AF&"G7QN'^K2
MA[!TZBC4^(O^"A'QC^(W[#/[3/PB_:T^&.O1VOB_]I3X&ZK;_$[X-:O?W\L6
MD^)/^$5TB"?Q))H-PTRV%K::P^C7T "Q-_:WA?4;4(8-0U&6O/?&^M_$7X'_
M +!'[(WA+X;?&G5U\9?M[?%J#Q%\8_C)I>NZM-JD$.OO96\GA;3]6,Z7>BQZ
M(-1@M?$'V*6PFEU#1]8LI#%%?SQ-^W%S_P $Y/!7C+]IWXD?M%?&GQI?_%I/
M%OPTO_A1X+\ ZQH-O::'\.O"FIZ<NC7QL+O[?>2ZEJ\FEOJD2Z@UO9RQW&N:
MK>LC7$EL]MX;HG_!'+X>M^S/K?[,7COXQ>,O&'A73/B+-\2O@WXAM-'LM%\2
M_"#6+J*6WU&TTJX6[U*WU73]7CE:34K2X@M(GO9[S4K)++4)8;FV]3!\3\,T
M\'DM#$5E/$8">72S&O\ V?4JK'48PQZPN'M.DG5CP_6Q&%DXUE&.-C0_=RJ.
ME2O\QF_AGXDXC-^-<;E^&E0R_/</Q#3X>P#S^CAYY)BZV*X<EFF82JTL1..'
MGX@X3+,RIWP2G/)9XKDJ_5:6-QDX?!?[17[/FJ?\$NOC;^QQ\1?@#\=_BWKB
M_$WXHZ;X ^(WA#Q[XFDUS2/%ME++I$6KW]SI\-O;P/;:C;ZI>PI;SVEU-I=^
MUA>Z=?6]S&"7^&OV>_$'[8/_  5 _;R^$GB3XV_%OP'\+="NM,\1Z]X:\!>*
M+S2IO$\L5GH6D^'K&:XG>YM[32]+GOY[Y[4V4L=P5B1$A4^:GZ _"'_@DEI>
MA_%GX>_%K]H/]I7XN?M.7_PD>WN/AKX>\>7$L'A_0;O3W6;3[B[MKC5-;N=1
M73[JVL;VWMTN;*&:\L+6;44U 0JH^H?@G^Q5IOP;_:V_:)_:GM?'U]K=_P#'
M^STVRO/!]UHMO:VOAHV4NF3&2VU>&_EEU$3MIL8CCELK4PI*R[IBH:N:OQ;@
M</A\2Z6:_P!H9U'(<1A(YS_9JH_6L96SO XG#THQK4%4YL+@J>(Y:^(IQY6^
M6G-OEMWX'PJSS'YC@%B^&99!P=7X\R_-JW!RXCAC8Y=E.#X,SC*\PQ56I@\8
MZ+IYOG6)P+JY?@<16=6C!SQ--TY5(KX(_P"")?C+Q[;)^UY\!/%'C;Q!XX\-
M_ WXR'0_!-[XDO[C4=0L=,GN_$>CW=I'+>2SS6]I<-X;M;]--BD6RM+RYOGM
MH(DN7#G_  5FU[7-)_:V_P""6MCI>M:MIMEJOQRU>+4[33]1O+.VU")/&GP6
MA6.]@MIHXKI!#=W4(29''DW-Q%C9-(K?=_['O[#^F_LE^.OVC/&>G^/K_P 9
M2?M >/!XVNK&^T.VT=/#<GV_Q!J/]GV\L.H7C:C&'UZ2/[3(ELQ2W4B$$L3-
M^UI^Q'I/[47Q9_9;^*M]X_O_  ?<_LS^.KSQI9:1;:);:K!XL>[UGP7K!TZY
MN9K^RDTP)+X.AB%Q#'=EH[V4F)6C0GRO[<R9<;5LX]I&.75<%B8RJ1PTHQ>*
MQ&05<+*7L(P4DY9A-N4E!+F;JW2O)?4O@GB]^"N$X/\ 8SEQ'A,XRZ=.A/,J
M,YPRS <>X?-*4/K\\0Z<HT>'Z,5"$J[FZ<(X:SJ6@_QRU/X'>)/VK?\ @KM^
MUU\$=9^-/Q3^'_PPL?!_AOQ7XIT3P'XGOM)NO$]CI&C_  _L].\.>>TDUI8Z
M8+[Q ]_<K]EF#^6\:P;KDS1^9_LX_M#?&/\ 93^!_P#P5;^&OASQ_P")O%L7
M[,WB"QT3X0Z]XKO3K.H^%KK6/&OB7P&^KQ"^2>&-A:V^DZQ)8HJ:;'JMJ\BV
M\*S3;_W6^&G[%.F_#S]M?XT?ME6_CV^U/4?C#X+M/"=WX$ET2VM[/0OLJ^$
MU[#K:Z@]Q>%QX3AQ;R:=#L-W,3*_E(&\U^&G_!,[X;^%/$O[:&H>,O&&H?$'
MPQ^V9?WD_BKPG/I4.B#PO;7VL>(=:>'3=5M-0N;B[N[>[\0+)8WK0VDEM+I]
MM*(W<.3ZO^MF25,,L)BZBQ> HY3P?&G@OJ>E3,,MQ.!_M:,9RI0DJDL)3KT'
M4G-4JL+4XR:L?+?\0JXUH9I/.,I4\JSS'<6^+53%9O+.&_8Y!Q#EF;T^$I2I
M0Q-6V&HYGB,!BXX;#T)5\'7YL1.BJL9-?'7[!?[!-YK'@+]FO]LRX_:?^-EQ
M\7O%\^@_$WQ['K'BVZUKPIXOT/7H97OO .H:;<7$=S)O@F6TGOKK4+Y1J"2.
M+!#':16GPU^SC?7FG?LC_P#!:6]L+NYL;RV^(&OR6UW9SR6US!*WB?Q$OF0S
MPLDL;[<J&5P0"0.IS^IWP&_X)*2?!/QEX$NI_P!K;XY^+_A!\+/%R>,_ /P1
MN[P:5X8M=9M;TW^G)K)M[^XL]1L;:[(NIK2QT7289[L><B6ZR2QR>O\ P(_X
M)G^ ?A5X-_:W\ ^(_'6K_$#PG^UGX@UW5_$EF^E6_AZY\-VFMOK4GV/3KVTO
M[][F\L9-7\^VU!X[8+/:02FU'S*3$\3Y7&KFDJF<?VM&OB\FQ&"A#+)X-4,)
M@\]ECYX%7I04I8?#/3GM2@Y*C1G-)DX'PTXFJX;A.EA>$8\+U<NRGC'+\ZK5
MN)*&:?7,VSG@>&24L[;HXBNX0QN:Z3E2Y\9.,7B\90I2:1^7WQZ\2Z_'_P $
M"O@MK,&OZLFM7'_"O5DU5=4O!J4N?B)XAB=)+[S_ +2RB**&-D:4JL42*0$0
M8I?M]>"/CIK"?LC?$3QGH7Q_^(G[%^C?LX^ ?^$_T#X">()+/Q1I/C!O#$US
MJOB36[,07S7LDD=QHEW!J&J6DEFUK97]F=3TEY9II/H*X_X(2Z3JOPTO?A1X
MB_:_^-OB'P3H]S<7GPN\)W]K!_PAG@2\O-52_O;^Y\,IJPLM=O;BU:[M!)%+
MHR1W%]=WRQ&5S&?JSXV?\$YOB-\2[[P;=_#O]LWXU?!*R\/_  @\(?"#7-"\
M(J[>'?$NE^$[.[L?[;.EQ:]IMOIVJZO!>2IJ$F+EG2*SB5PD!$G32X@X<P>+
MP\L+FF&KJ><\29E7Q&(RS,*2H4,YIX&%&C2J0IO$T\33C1J*&)I4I*C5<[0E
M!\YPU^ O$+-\LQU+->%\QP4J?"'AOP_@\)@.)L@Q4L=C^$L3G-7,,7CJ6)Q%
M/+\3EN)GB<-]9RW%U82QN$E3G[>&)INE1_'[]KCQY\.?^'=G['LW[.7QB^*/
MCSP5:_M+:GICZSXYUB\M?B%IETT.H:M/X.\32VLD2N_AY-0MH-/\LS6CZ<UC
M<VDLL4RRO]3?M"VOC7]N#_@ITO[%WC#XJ>.OAU\"?A7\([+QQ<^'O .MRZ#J
M/C+6C8>&=2NI;RY'F+>7#R>([2"*2^M+Q-+L=+FEL!%<W=Q.?I_QA_P1T^%.
MJ?LU?"?]G+P=\1_$WAC3?AQ\5Y?BWJ?BR_T?3=>U?QIXGOK*.PU&74(%N-*L
M].26UMK"ULFLTE%E:6,2F*><O._K'[67_!-+PM^T7\5?"GQ]\"?%WQY^SW\=
M?#&C0^'V^('@ Q2-KFE6BO%9IJ5F;NPG2[M(9;BU6XL=2M1=6<_V74H+V*VL
MA;Y1XEX<C*A&AC*M.M&/%,,)FF+P:K5\OQ&9XW!U\!CJT*6']^<J%+$4E.A"
M=2BZW/[.$KHZ9>'7B)4H8ZICLGP=?#55X42S'AG*\\^IX'.\OX:RG,L)Q'DF
M$KXC$RG0HPQ6)P%6-+'5Z>&QGU64/K-6+4I_F=\"U\??LD_MG_M;_L1^'/BQ
MXW^(?P5D_9A\?_$7PY:>,=9EUG5O!NMV_@JRU>Q^S70;&G75M%J]Q8WBVD>G
M1ZDLNFW4MJUW DU?&/P8_9A\4?%C_@F'\2?VM?$_[0GQJ'B?X,OXRN?A/X1T
MSQ9>VGA'PU;>$]6M[[5%N+8327MS>ZY?:G>R-?6MU87%G*EJP:5(CC]__P!F
MO_@F9X$_9_@^,OB;7OB7XW^+_P ;/CAX.UWP?XN^,/CLPW&M6^E:[926=S#I
M%C]HNI8][&SGNVO=0O[B<Z;8VD5Q;6<*VXN?";_@G=I'PR_86^(G[$T?Q-U'
M5M.^($/C>&X\>OX:MK&]TUO&EQ#=.T&@C5+B"9+ P1*B2:@GG*S9>/(*U/C'
M+,/6=7!XR,L3+'<*1QV/67JF\RI9?1Q=/.,;"DZ,O8QQ$9T*=124,17@IW@E
M4G$FCX0\38^C0HYOE,HY92R3Q3GD^1?ZPSQ$.'<7GN/R2OP;D\L1#&4_K;P,
M<+C,12JTW6R_ 5_9<M2,J5"H>M_\$Y_B)XL^*_[$7[.OCOQUJUUKOBO6O 4,
M.MZU>R>9?:M<:1JNHZ(NHWLV TUW>6^G13W,[?O)IG>5V+N6/XHZC\$/$'[5
MW_!7/]LKX'ZS\9OBIX!^&*>&_#?B3Q5H?@#Q-<Z3<^)X-(\(^ ;72M#:XE>>
M#3]/BU'6!J4PBM)4G-J;=D7S=Z_T!_LL? JU_9G_ &??AK\"[/Q%/XLMOAUH
MD^C1^(KFPCTR?5/-U2_U)[A]/AN+Q+7$EZ\2Q+<SX2-29&))KPGX8_L2:7\.
M?VV_C7^V3;>/K_5=0^,?A>R\.W'@:;1+>VLM#-I9^&;22ZM];2^EFOQ(?#,+
M+$UC!Y1NI5:638IKYK+\]P.79EQAC,)5C06/PF/IY)*.'<XJK5S7"XC#<E.=
M.:H\F&A4G3G4C'V4HPLXSY;?HW$7!.=\1<.>$N49EA:F.>2YQP_B>-*57,G2
ME4P>%X7S/ 9FJ^)HXFE4QT:F8XBC"O1H5:OUJ,Y.4*E!U+_SY?LC_LP>.OVC
MHOVT_@9\0/VFOCDGPW_9)U?QC;_#OPYH_BFZM;2]\3R7'BRSL=>UMKAI7N["
MQ'@VVN%T0&*&*YU*ZFL9M.D:1I\./]MK]H/P_P#\$CO 6F:;X]\8_P#"3>(?
MVD/$GP0N_&]C?7-YXZC^'NG>'K/Q2=&T;5'9[];R=-172[:Z%Y#>+9(EE#?0
M*P8?T(?LV?L#Z/\ L\>*_P!K'Q/:_$;4?$\O[5&M:IK-]9W&A6NF+X0CU*X\
M43_9;22/4+PZK)%)XHF7[1,+17%K$OD*79J\0\"?\$A/A+I/[(&N?LF^.?''
MB'QC8WWQ,U+XJ>'?B#I^EV7AKQ)X-\476F:?I5I<Z1:BZU>SD6VM+%X+F*]\
MV&_AO9TEMX\1-']=/C/A_$8VM/'2ABL#1S3AW&X&C#+Z4=:.7UZ>;U^1X>G&
M4WCJT:]=5G?$2BW%22IV_)</X.^(&7Y'A*&1.OE6>8SA3Q R3.<?4XAJ5'/Z
MQG^"Q'!^#E4^N8AP@LEPU7!8:KA(J.70JN-65)RG?\=?V:/$'Q.^$_[6_P"S
M?JO[-WPR_;_T/P5XB\3Z-X4^/ME^T-X;U6X\+>(],US5-/T^\\0(EC;-IVG"
MSM[G4-2DGU..-],N;:TELKT037HD^CO@Q\%/$'_!4']J#]M7Q!\;OCM\6O"F
MC_ KXBGX?_"OPA\.O$QT'3/"Z-JWBJQT_5HK)Q=6XDL;?PM;F[9+6WN=4O;F
MXGNK]ECAB'Z)? __ ()L_%7X:?$SX<^-?'7[=W[0_P 5O#7PTU--2T/X=:Q>
MWFG>'=0%M T-I8^(O,U[5QJUA'&562"2" N%78T>2:YKXL?\$CM,USXW>/OC
M-\"?VE_B_P#LVW'Q=ENKKXH^&_A_(@T[Q#=:C=R7NJ36%Q;ZCI%QIO\ :-W/
M=7DT=RNJQVMY<S36 M(Y7@:,5Q3D=;%XAX?,:&#QM3*:&&PG$$<!C<94HU89
MFL55IUXXC#0KRJU,*O8QQ%+#N$8MT>9Q49'1E?A?QM@\LRV&89#CLZR6AQ7B
MLRS/@.OGN3Y51Q6&K<-QR["XG!/+LPK9=3P^$S?EQM3 U\="5:M">/C15:KR
MGYU?ME_ GQCKG[>__!//]GR3XV^+X?%#?!#2O!.K?&_1IY+3QI?II[^*X=:\
M0V5XUW-+;:UKNF6=U:M>?;+AXYKZ29WD*$-Z5^S)I.J_L4?\%1OBS^S-I7Q;
M^(7B+X&ZE\!M5\>:K'X\\13:U<Z)<VOANR\5S:Z6*PVRZKIA@U6W34;:TMFN
MK&X>&[$\L4#U^CL?_!-7PAIOQW_9-^,FB?$_Q/%;?LK> [;P+I'AW7+*'7[_
M ,96]I!K42ZIK7B66\M+BWO[B;7+FYNFAT^>!W1(X4MHQBNNUO\ 8#\+>(_V
MV?$/[7VK^.+V]7Q3\)[_ .%FK_#231;<:;-IFH^'I?#E[=G7EOOM!%Q832$V
MPL1MD8LMU@!1P3XLRRI@8Y97QSK8)\+8_"U:;P"BZF=3S:KB<-**=)>RDJ,U
M5H.%3ZOAZDW'1N<9>YA_"SB/#9Y/B7"9/'!9Q_Q%#(,UHUEGLZRH\&TN%\NR
M[-</.H\5#ZU2>.HU:&)57#K,,PIT*5:<)1C2Y/Y5_BSJ-MX@^'?Q'^/OP"\.
M_MU^(;/P?XLWP?M4^,_B8MKX0@U&3Q/IUG(USH&FZ#YEM!.VI+8V@L_%,6H6
M.HW=DM]N9+G3#^B?[8_C;XL_&/3?^".$]K\3O%G@;QY\;=%T71M=\?>&KZYL
MM6M-2\9R?#;0M6\1I!:SV4,VIK'J5W= MY0\^1TCDA5MR_5-W_P0QTI_"OBC
MX6Z;^U_\;].^".JZIJ.O^'OA08+.?PUI7B&ZF673[_6X!J46G^(DL)HH9S&-
M,TNXOI[:WN+B\^T^9-+]6^)_^":>B>)C^P>K?%?4[4_L//X>?3 OANSF;XA_
MV!?>%K]?MQ;58?["^U3^&XD<VXU$0Q7,FW<42O=Q?&'"WM\KJTL5'$/ XC.)
M4ZU7 XZ>(CA,7DE7"X6GB'B:<X3F\:X^THX:,,%3E).%*T9U)_#Y7X2^)O\
M9_%&$Q>5RP"SO+N#J=?#X/.LJP^"KYGE?&^%S/-\5ET,NQ4:U"C'(_:QPV*S
M"K5SC$QIS5?$^TJTZ$/SS^&'PQU[]AO_ (*]?!/X"_#WXN?%#QA\-_C9\([S
MQ+XTTKXA^))M?;4-6-E\08Y;J;*0VTUS'JG@RQU2TO'M%O;62^O+47<L#.&Y
M+]DJ']HGXC?#/_@KUX<^"'BG7W^+<GQDNK#P-*WB">#4[>'_ (2'QP-2TSPU
MJ5]<^5HVJZAI%O=Z?I-U'-:+;W;6Q2XMBD<L?[)_$+]B72_'O[<7P=_;1F\?
M7^F:K\)/ ]UX)@\!IHMM<6.M0W'_  F16^FUEK^*XL98SXRF)A6RG1Q:0@.F
M]V/BO@;_ ()C6W@3P;^UIX5\/_'WQUH.I?M1?$.Q^(B>+?"VG0^'?$/P]O--
M\0ZKXAM;+2KRSU62748)YM3ELKR8R:=)/9*T:+"\I=/!GQ1E.(P=*5?$TI9G
M5RCAJAB:M? 3J0J8_+<_JXG$O$0I4Z4:\*>7NCSN,XNM2C[&$W-<J^XH^&?%
MF7YEB*&#P&+AP[AN*O$K&97A,OSZAA:^'R+B'@7"99E-++J^(Q%66!JUL[^N
M^P4X2>!KU'C*M-4Y.;_-S_@EE-\'O!'[1.D^!_'6J_M5_"?]K)?AKXHT_P 8
M_#'XUZM=7W@3XH:G/9PW.K>(_#HGL[34+>?3VTN[U'14U19()+4WT>FZEJ<E
MM<SM\A?LF_LQ^*?VE?V'?VF_C5XP_:"^,MA/\"]3\?ZC\,_!VC^*KZW\,Z?X
MAT+PS8^,M9UK6H9)I)]4EUGS(=-18'LY;(![M+B9W$</[M?L]?\ !+Z/X7_'
M;2_VC?C)^T?\4?VD?BEX8\/WWAKP3J/CF..UL_#>GW]G>6$\I0WVK:A?316F
MH7\5I"=3M;"-[VYN7M)KIXYXNQ_9I_X)U:5^SE^S!\=_V;+'XF:IXFL?C7<>
M-YY_%5[X>M+"]T!?&'A:U\+,L>F0:G<17YT^"V2Y5FNK<7,A*E8$9=O?B^,,
MHH5<RQ&7YA.>,Q57AF3JO"5)T(_5,9F-7-88%XC#QQ%/"K#XBC:-9*O)U*M&
ME*5&$(KQ\K\(N*<;AN&LNS[(*-#)\HPWB326&I9I0P^+KO-LKX9H\+XG/*.6
M9A/ U\TJ8_+<;5J2P%66!I5*&&QM:G2Q-:<G_/MKGPF^*'BS_@F7H7_!03Q/
M^TY\<M9^,7@_Q-H6B^"[2?Q?J$7A_P .>$_#WCY/AW!8PQ130W\^LW'EQ:O/
MKHNQ/-/$D%_;WC2W,\G]8'[*_C/6_B/^S;\"/B!XEG^T^(O&7PD\ ^(==N<
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M+SX>1Z%81^*KJ#PAX6\*:S+>)I'ASP[HR-&;8:,;.":4M.UEJ0N-0CFT_9<
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MNK?3K47UQ#"+FY66K'[(GC/XY>%_ _\ P4'^&EMX;_:>\,_LVP_LR_$7QO\
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MMIJU_%>>)].\'^./#F@Z/?ZY<1R1OJU[/I$"?:;V[%TUU,+B9WDEN9&DZ_\
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M,E;4;.*UOI%MM0M=%^QOI.E26SV)FNFNI)OT=_8.^)7[9GBS]KKX?>&_ 7Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117R5^VSXZ\6_#?\
M9^\4^+?!.LW7A_7[/4?#-M;:I9B![B!+[7K*UF6-+F*>'][%*Z2,T3'8<*0:
M[,OP53,<?@\OI3A"KC<31PM.=3F]G&=>I&G%S<5*7*G)-\L9.VR;/&XCSO#<
M-9!G7$.,I5J^$R/*\=FN)HX90>(JT,!AJF)JTZ"JSITW5G"FXP52I3@Y-<TX
MK4^M:*P_#L\UUHVDW,[F2>XTK3YYY#QYDT]K%*[[<D+N9F; X&[;T49W*Y))
MQDXNUXMIVUU1ZU.:J0A42:4X1FD]TI)25[76SZ-KLVM0HHHI%A1110 4444
M%%%% !28 )( R>IP,GZGJ:6B@ HHHH **** "BBB@ HHHH **** $ "C"@ >
M@  _(4M%% !1110 4A (P1D'M2T4 (JJHPH"C.< 8Y/?ZTM%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCPCH>C?$C0_ARL$_AZ9(_L9O==\/:W9W,UU$MW<,\\^F06R6RAI9#,-OTC\
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MQA0J+DJ.I%PKTU4@FW"%I1U4DDUM:36K?1114G>%%%% !1110 4444 %%%%
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MT/X??#7PYJ'BOQ=J]OIU_J\^GZ)I<7G7ES%INEP7-_>2(@^6"U@EE<G"H>E
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M9DGD5HBKLI]^HHN]=7KOKOZ_<@]E233]G"ZOROE5XWWL[72?5*R>J>YX9/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_'']E'X?_#?Q9\(? ^FZKH.O>.I]'^+/Q/UWP7XU^)'ASX+>"+7P]J6J_\
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M97G8^>?,KEO#W_!,#]BSPQX>^)7@S3?A7?2^!?BIX=\1^$_$?@#4_'WC_5_
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MUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%/$O_0O:]_X)M1_^1Z/^(@<0_P ^7?\ A,_+_J(\G]_D'_$E7@+_ ,^>)/\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%!_S_\
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M7_K<:5W:Z7KUU2_4_JT!!Z=\]CCCW_EZCD9%(40L'*J6 (#$ L V P!QD9
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MOG;!_P"&F_VD_P#HX+XX_P#AU_'?_P O:/\ AIO]I/\ Z."^./\ X=?QW_\
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MCXB?M+_M'0?$'QY!!\?_ (VQ00^-/%44,,7Q4\<QQQ11Z[?K''%&FN*J1QH
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M[:_#MUM_GI>^DM%%%4(_"?\ ;6_Y3B?\$8/^R>_\% /_ %3_ (>K]V*_"?\
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M:F!N&J:U-)J5YELY: 3EK:R4X#>3806L'3]TN !^(^&_CCP[XPXCB[">'5;
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M]N_X9;_:/_Z(=\4?_"+UW_Y#H_X9;_:/_P"B'?%'_P (O7?_ )#KQ'[???\
M/[=_^!,W_P 71]OOO^?V[_\  F;_ .+HYL/_ ,^\7_X/H?\ S)Y_GV8>QXB_
MZ&>4=/\ F1X[^[_U/_7[O-W]N_X9;_:/_P"B'?%'_P (O7?_ )#H_P"&6_VC
M_P#HAWQ1_P#"+UW_ .0Z\1^WWW_/[=_^!,W_ ,71]OOO^?V[_P# F;_XNCFP
M_P#S[Q?_ (/H?_,GG^?9A['B+_H9Y1T_YD>._N_]3_U^[S=_;O\ AEO]H_\
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MO_P)F_\ BZGFP_\ S[Q?_@^A_P#,GG^?9G7['B+_ *&>4=/^9'CO[O\ U/\
MU^[S=_;O^&6_VC_^B'?%'_PB]=_^0Z/^&6_VC_\ HAWQ1_\ "+UW_P"0Z\1^
MWWW_ #^W?_@3-_\ %T?;[[_G]N__  )F_P#BZ.;#_P#/O%_^#Z'_ ,R>?Y]F
M'L>(O^AGE'3_ )D>._N_]3_U^[S=_;O^&6_VC_\ HAWQ1_\ "+UW_P"0Z/\
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MBBB@ HHHH *I:A86VIV5Y87<8DM[VUFM)US@M#/&T;@'L<,2I_A;!ZBKM(Q
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M#C^+_A);#;^OX5]Y5\%?\%*#C]D[QOCK_;/@S'_A3:>/ZXKZ#A/_ )*?A_\
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M/[//_B37P"_^>)1R8S_H$?3_ )EU'R_ZAO-?>_D*?"&G_&08KI_S66=_W?\
MJ<^2_'NAO_"S?@1_T;/I?_AV?B+_ /'Z/^%F_ C_ *-GTO\ \.S\1?\ X_3O
M^&8?''_0\_L\_P#B37P"_P#GB4?\,P^./^AY_9Y_\2:^ 7_SQ*.3&?\ 0(^G
M_,NH^7_4-YK[W\A3X0T_XR#%=/\ FLL[_N_]3GR7X]T-_P"%F_ C_HV?2_\
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M^%SXFN/#FC-XKU;Q!X"/PZM]'TJWO?B#9M,VN^&K-K*ZCU*']S?$7CO_ (*
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M8P&NAKPJG\6K_C;^])GNT_X=/_!'_P!)04445!84444 %%%% !1110 4444
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MR<I2?5MW;_X"T6RT"BBBMR HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,G7;C5[71=8NM L(-5URVTK4+C1M,NKL6%KJ6K0
MVLDFG6%S?&*;['!>7:Q6\UUY,OV>.1IMC; #_'M^W?X;^+?QJ^*W@KQU^W+_
M ,$G/V!M/^*FLVEMX:\*ZEX]_P""FNF_"G7O'VC:?<!++0+VQMM%\-/XXT^R
MN[E(K>QOH-42U:\2T1]DBPG^Q/4=0L=(T^^U75+RVT_3-,L[K4-1O[R9+>TL
M;&R@>YN[RZGE98X+:VMXI)IYI&5(XD9W8*I-?S ?MN_L1?$W]IG]IOQ_^T-\
M OA%^P-^WE\.?VQO@3X%\,_#?5_VC/B#<1ZS\ ])\+Z-=:)J'CGX01Z38:_:
M^*? .L2ZI9^+=2F\(OI^M/XDEB0WL,2PRSI_?Y:-?-6=UTT[WZ#6CWM]ZOJM
M+]/7UMU/Z(/V;[#7=*^ ?P?TOQ-\,?"GP6UW3?A[X6T_4?A+X%UFU\0^#?AU
M+8Z3;6D?A#PSKEC9:;9ZIHFAP116.GWEM8VT$UO#&T<87!/KATK3#J*ZN=.L
M#JRVQLUU0V=N=16T+^8;5;TQ_:1;&3YS )1$7^;;NYKP3]D7X,Z_^SM^R[\
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MQ6JBXI/FC)M6;5K]7Y6_GBN_^"<_[4VI>'=4^$.I_#?X$7_C*^_:<G^-UO\
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M;A_.HK=Y7C5]^'J=KGVKX2.?#/A\]?\ B2:5CZ"RA _2NBKG/"/_ "+'A_\
M[ FE?^D4-='7@5/XM7_KY(]F'P1_PQ_)!1114E!1110 4444 %%%% !1110
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M_M)_\DKNO^QX^#__ *M_P+7O54_@C_BE^4#-?Q9_]>Z7_I58****DT"BBB@
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M?"7@7]N> P_M'_"*\^%$WB3^V/@WI\AF\)QWFJ:H=;ATL:8\>KO&85LI+W3
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MKHZYWPE_R+'A[WT+2#^=A :Z*O!J?Q:O_7R1ZD%:$%_<A_Z2@HHHJ2@HHHH
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MXJ1-_P )_A3*X6/7]010TDO@IY)&*@;GD=Y'(W.S,23R7_"^OB/_ ,]/ _\
MX:3X2_\ S$5U7C^Q_9K;QWXX>X^,GQ.BN)/&7BEYXHO@;I=Q%',=>U+S8XI_
M^%MQF:-)"RQRE$,B .43=M'(_P!G_LS?]%H^*7_AB-,_^>]7+4AFSJ3?UZ7Q
MR?\ R-:/65_^@KR_!=]'@*/"GU'!<_#=3F^J8;F_XPC-I7?L:=VI+(VG=MZI
MM-M6=F2?\+Z^(_\ ST\#_P#AI/A+_P#,11_POKXC_P#/3P/_ .&D^$O_ ,Q%
M1_V?^S-_T6CXI?\ AB-,_P#GO4?V?^S-_P!%H^*7_AB-,_\ GO5'L\V_Z#I]
M/^9K2\O^HOR_#S9U^QX2_P"B;J=/^:'S?R_ZD7F[>J)/^%]?$?\ YZ>!_P#P
MTGPE_P#F(H_X7U\1_P#GIX'_ /#2?"7_ .8BH_[/_9F_Z+1\4O\ PQ&F?_/>
MH_L_]F;_ *+1\4O_  Q&F?\ SWJ/9YM_T'3Z?\S6EY?]1?E^'FP]CPE_T3=3
MI_S0^;^7_4B\W;U1)_POKXC_ //3P/\ ^&D^$O\ \Q%'_"^OB/\ \]/ _P#X
M:3X2_P#S$5'_ &?^S-_T6CXI?^&(TS_Y[U']G_LS?]%H^*7_ (8C3/\ Y[M'
ML\V_Z#I?^'6EY?\ 47Y?AYL7L>$O^B;G_P"(/F_E_P!2+S?WH^F_V<OC=\0;
MK2_V@;B27PA'-IWP4CO;1[7X8_#.R*7 ^,GPJMMT@L_", N(S!=3)Y-P)80S
MB41B:.*1(C\?OB<23]O\+<DG_DF_PY[_ /<JU>_9DT/]G_4+/]H&ST;XN?$2
MY$WP13^T9+[X,:=9BRT\?%[X5S"YMHX_B=?M?7)O%LX%MO\ 1R(YY+@2E82C
M[7_"N?@*>?\ A<WCSG^Y\%;<+_P$#XE@!?3 '&.!6>8RS&$, I8]Q_V1_'FE
M&*;^O8W6TL59M+D7-J[+EOI8^/IKA*.;Y^I\-3TQN!4+<%9M)P7]B93>#4<D
ME*G[Z<N62CS7YTFI1;Y;_A?OQ._Z"'A;_P -O\.?_F5H_P"%^_$[_H(>%O\
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M/_\ JW_ M>]5X+^TG_R2NZ_['CX/_P#JW_ M>]53^"/^*7Y0,U_%G_U[I?\
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MG5E*2C""4:=.G%%%%%?MI\>%%%% !1110 4444 %%%% !1110 4444 %%%%
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M *!\BZ?\QF8>7_4%Y?U9%7_A"/&O_0F^+?\ PFM;_P#D&C_A"/&O_0F^+?\
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MM@LCM]3PK7-F&/4N5T*=K_\ "?O;>VEV[=+?%O\ PA'C?_H2O%__ (3.M?\
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M+ TG">*S"HKPR')YMQDL'3=G&I"Z:;4N97M9O[L_X0SQI_T*/BK_ ,$&K?\
MR+1_PAGC3_H4?%7_ ((-6_\ D6OA/_A?WQY_Z+C\9/\ PZ7CK_Y?4?\ "_OC
MS_T7'XR?^'2\=?\ R^KD_LK!?]!.*Z?\PM#R_P"HKU_'LK^O_97%/?AW_P '
MYEY?]0WK_6WW9_PAGC3_ *%'Q5_X(-6_^1:/^$,\:?\ 0H^*O_!!JW_R+7PG
M_P +^^//_1<?C)_X=+QU_P#+ZC_A?WQY_P"BX_&3_P .EXZ_^7U']E8+_H)Q
M73_F%H>7_45Z_CV5S^RN*>_#O_@_,O+_ *AO7^MONS_A#/&G_0H^*O\ P0:M
M_P#(M'_"&>-/^A1\5?\ @@U;_P"1:^$_^%_?'G_HN/QD_P##I>.O_E]1_P +
M^^//_1<?C)_X=+QU_P#+ZC^RL%_T$XKI_P PM#R_ZBO7\>RN?V5Q3WX=_P#!
M^9>7_4-Z_P!;?=G_  AGC3_H4?%7_@@U;_Y%K^IC_@CMI]_IG[)L]KJ6G7VF
M7/\ PLWQI+]FU"SGL9S'(^G;9!#<1Q2%'P=LFW8^#L9@#C^'O_A?WQY_Z+C\
M9/\ PZ7CK_Y?5_9?_P $%_%GBOQE^Q->ZMXQ\3^(O%FK#XO^.K4:IXGUS4_$
M&I"VBAT5X[87VK75W="WB:5_*A$OE1[R$50:_0O#'!8;#<41G2K8BI)Y;C%R
MSHTJ4/BPR;DX5:C=KMI65GKJD?RK],; 9W0\'O:9@\I]@N*\C7^PU<9.KSNA
MF*C=5Z5.GR?$V[\U[66KM^U]%%%?T6?Y3'@O[2?_ "2NZ_['CX/_ /JW_ M>
M]5X+^TG_ ,DKNO\ L>/@_P#^K?\  M>]53^"/^*7Y0,U_%G_ ->Z7_I58***
M*DT"BBB@#^4?1->U_P#9/^$7@_\ X*+>&?"FL^)O^%#_ +9_[<'PF^-?AG0;
M60ZWXJ^"'QD^//C.PTU%@++-=_\ "*?$Y/"&NV4>]DB^UWD\8C1KDM]0?LW?
M!KQ?\)_VJO\ @FQJ?Q%BDG^,7QA^&W[=GQ[^.6HR1.)F^)WQ:L_A)K][IUTY
M!P?#&B_V+X*LT>0^58>&+>VB"6\:*G]!;:?IYMY+5[.U-K*[/+;M!&8))))/
M.=WB*E'=Y<RNS*6>0EV)8DU.;>W:6*=H8FFA1TAF9%:6))-OF+'(0719-J^8
M%8!]HW9P*T<[JUNR;[I6M?[N_P V>;'+^6<9>U;C%T)*/*M*E*5)SJ+SJQHT
MX6VBE+1\[2_#WP%^SCX(LO\ @M7\5]9BMM8'A_PW\ -#_:9\/>#7E)\$:7\?
M?BQJUS\(_&_Q)T_2A&MI%XIU;P1X'T^QENSYD@N+S4[Z-Q<S.4YG]BG]J7X*
M?L(Z9^T9^S3^UMXE3X+_ !,\._M,_'#XC>'9O$>@>)I;;XU^ OB;XLF\8>%?
M&W@#4=/T:^A\9WU[;:BFAW>BZ3/?Z]:7^G06D]F'EA2OWG%M;BX:[$$0NGC6
M%K@(HF:%6WK$TH&]HU8E@A)4,20,FH+G2]-O)89[RPL[J:W.8)KBWBFEA(.0
M8Y)%9T(/.5(.0#VJ+IZ=-/OZNW7KY[:FJPG))5*,H0FJE:=Y4^:+5:SE%Q4X
MOW7"'+*,HV4;6M=/Y'L;G]I_XG>+O 7Q1^&/Q+^''A']GKQ-IOA3Q#=?#CXB
M? [QE#\7Y-(O;>WN]8M;G6IOB%H4'AO5-0@D)L;?4_",MQHKNL=]9W<D,B-]
MBJ"  3DXY/\ G_/K0 !C Z# ]AZ?3@?D*6D=4(<MVY2;E9RO*3C>R7N1;?)'
MM&-EWN]0HH) &3P!1G/\Z"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0$,,J0P/0@@@]NHXZ\5^>W_  5>\<?$_P"&_P#P3G_:\\:_!V\U?2_'^A?!
M[79M-UOP^T\>O>'='N9[*Q\8>)]$N+5TN[35_#7@VZU_7M.O[3==6%WIT5[;
MI)+ B-^</_!-WQ?XX\*^(?\ @H?X&_8FNM-_:)^$/P]U3]E;5_@)I'Q$^.GB
MG6?A^WQ$\>?!K0M6^.FDV?Q@U6W^)6LV>RZ%EXEUC0(1J5KI?B:\>T6QT:75
MKB0J^MOZZO\ 1_AO<=KIOL[>7V>KMW_#<]/_ &USC_@N'_P1@QR?^%>_\% .
M,XZ_!_P\!7ZT1_$#XOMX?TO4G^ ^H1ZW=_%Q_!6H^'3X_P#!K2:5\,AXJO-(
M3XQ-J:W1L;NQ?PY!:>*SX+MF;Q0L5\NDF$ZA;3+7\U/[5OQ)_P""AEW_ ,%=
MO^"5>L^+/V6OV?M%^+&D^!OVTX_A;X*TO]I76]4\+>,+2^^&>B1>,9_%'C!_
MA#977A670M,"7>C6\.@ZTFN7+R6S36!C,TG[#GXR?\%:0"?^&(OV4C@$X'[8
M_B7)QV&?@&!D^Y ]2!235WOOV?9>0[-]8K9;KI;S[?KZ'VIK_C[XM:;9_&:?
M1O@9J/B"Z\"VVF2_"JTC\=^#]//QLGN]!AU&_MK"6[NMO@<Z3K$DN@22^*_(
M6\D@.H6@>SD4UTJ^*?'9\<0>'S\-;H>$)/AW<>)YO'7_  D^@F"V\<Q:O:64
M/PV;01*=6ENI]-GNM6'B:-/["C6Q:T>3[1<0BOR9^%_[</\ P4O^+?C_ .._
MPW\+?L/_ +-J>(?V=_'&A?#_ ,?'5/VN/$-I8OKOB'P3H'CZP;0[F/X&W#:A
M9#0_$=@L\\D5JT=ZL\*QNB+*]+PG^WA_P4G\9_$_]H?X2Z/^Q!^S?_PD_P"S
M(_@"/XDR77[7&O0Z86^(_@&+XC^'O[!NA\$'EU(#0)52],MO9^1? P()8\3%
M\R\]^SZ;K;RUZAROJX].MK7Y5W>[_-I=#]2M"\?_ !=U'3O@M=:S\"K_ $"^
M\>2W\?Q7TV3QYX2U!_@E';^&M5U2RFOKFSG:#QPNH:]9Z=X:5/"QF>VDU:/4
MYPME:7)6*Z^(7QAB\-^*M4M_@'J%UKVC_%*R\(>'/#(^(7@V*7Q9\.I_$VAZ
M5=_%B'5)+C[!I%E9:!?ZUXG_ .$1U-XO$EQ'H+:7%!]NU*S%?C)X _X*I?M^
M?$>P_9!U'P]^P[\ E@_;9TKQOK'P<%_^U;KEO)':^ /!-[X]UX>*@OP5E&CR
M'0["<68@:_6>\,<#-&K>8/E?1/\ @X2_:AU^]T^QL/V&_A.)=3^%'@7XR6K3
M_M,:I'&WA#XA?M/Z1^R3H09A\)6VZFGQ4UJT>]LQE8?#0DU:*:>01V<AS+S?
MR?EY?U?T#E?9?>]-?^#;Y.VN_P#2SK'C7XH66H_%JVTKX.7>LV'@SP7I^N_#
M/45\:>&;$?%_Q9<:7KMW?>"+.UNI5F\&S:?J.GZ/I)U[Q,8=*N'UY;V(_9=.
MN6;E]'T62W^)'@C6$_9\TG2)?$_@?5=<\;_$:/5/![7W@7Q;:/X?;3_!-Y:V
MRG5_$-WJYU#6BWB+1B^EVKZ [74K?VC:E?QM_9+_ ."KG[>_[9VO?%/PY\(/
MV'/@+'J'P@NULO%9\4_M4Z]H\#3MX]^)WPYQIDL/P4OOM:CQ!\)_%#Y<0_Z
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MXZ#IQZ<4M?NI\0%%%% !1110 5^?W_!3?/\ PR)XX(SSKG@L'Z#Q-I_^37Z
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M*%-8KVE*W/**?LU.\^79VT_'+_A$?V6_^@)\>?\ PLOAS_\ ,%1_PB/[+?\
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MO_\ "]^'_P#\[VC_ (2?]F/_ *$GXW_^%[\/_P#YWM8__#,WQ_\ ^B3^+?\
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MAY_\[6G?\,D_M,?]$1^('_@F;_X[1_PR3^TQ_P!$1^('_@F;_P".T?[;_P!
M7;_F E_=_N>2^_S0?6>$_P#HMZ_3_FL9?W?^HOK?\?(;_:'[)W_0E_M#?^'!
M^'G_ ,[6O[#_ /@A/<>!+C]B^];X=Z;XLTKP^/BYX[0VOC'6-&US5C>QKHR3
M3"]T/0_#]F+6:/R7A@:Q,T3>8'FD!4C^/+_ADG]IC_HB/Q _\$S?_':_L/\
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MQBRU2YM3=WNMZ.@MKI[FR78/D:\_8;^"=E_P4=^%7[8GA?QEX/\  ?CSX?\
M[./C3X-K\#/#'AKPCHLWB[1O%.N6]^OCV_ET^]L=99]$MK&'0+5?[#N[/[%;
M6T U"W2U2W/\ZG_!02ST(:1X-A^+N@Z_J&N:[_P1/^!7A_\ 8#9-%\1ZI<I^
MVH?&EO+<VGPQN--MIX-/^+B/<?#*XNW0PZS_ ,(O;P^9(NE/>+-O3Z=XD/[>
M.@Z7XST77I/^"AY_X*G_ +-GB7P]JMSHWB";Q,O[#MK^S;I-AXONM+UFTM6T
M\?!J&^@\66GBJWAO3I*^))+LZRCW 8"6^ENJZ]=/+?5.W57*Y=+WO=--6WV?
MDK:6;MOHO/\ L4L/%/AK5+[6=+TWQ#H>H:GX=DCB\0:=8ZM8W=]H4DZ-+ FL
M6D$\EQICS0J9HUO8X"\0,B[HQNI^@^)/#OBK3DU?POKVC>)-)EEG@CU/0=4L
M=8T]Y[:4PW,*7FGSW%NTMO,K13QB0O#*K1R*K @?P+>'=#^).H?!7QAIW[.6
M@>.(?VN-$_8&_P""A6D_\%$%T/1?%MGX_O\ XA:K^T+I5UX0M/&%R]K!>ZE\
M0=3\/IXUN?AX[W$NJOX5VQZ.([>-(HOZ$_\ @C,/AM=_&7_@H%KG[,NGV^G?
ML<ZKX@_9>3X0QZ!I&HZ+X!G^(=C\#+>'XUS>#[*ZMK6SCN$UA_#MOXQ^S1?:
MF\2PW+:C(\Y! G>VGX_EIKV?9@XM)ZWM;7OM=Z;7O=;^9^^%%%%42%%%% !1
M110 4444 %%%% !7 2_"GX7S^/H/BK-\.? LOQ/M=+;1+;XBR>$]!?QQ;Z.Z
M-&^EP^*VL#KL5@T;O$;1+Y8#$[Q[-CLI[^B@#QZ]_9Z^ FI:5X6T/4O@I\)]
M1T7P-J]YK_@O2;_X>^$[S3?"6N:CJ$FK:AK'ANRN=)EM]$U*^U2634KR]TV.
MVN+F^=KN:1YSYE>B-XF\,P:Y;^%7U_0X/$MS8R:E:>&WU2PBUVXTV%Q'+?V^
MC-.NH264,A$<ES';&"-_D=U;BMVOX_OB[I\[_P#!3?Q987VD:I_PVY<_\%:?
MV7_$?P=U=M&UZ76D_8-L_@X8?&5SI6L):BS7X16ME;^*[7QK;V][%I"^*9+0
M:N'N8L*F[6TW=NPTM]=E?OU_2^^KMW/Z4OV<O@-X6_9"\&?%RQO?B!%J>E?$
MW]I#XW_M!ZEK?B2/3?#5GH6J?'OXBW_C%_"Z2R7\EM-;:3?ZM'HNG7LTT5SJ
MDGE-]EAFF$ ^F=<T+0_%&D7^@>)=&TKQ#H.JP&UU/1=<TZTU;2-2MF96-O?Z
M;J$-Q9WD#,BL8KB&2,LJL5R :_G,_P""U9^'O[77[#&A_M$_"CXM?$[6/"OP
M<_:$\">#[7P/X5N-?\*>!?%OCJ#]HGX?>!/$.I^.?#U]I&GZQXH?P*=+\06/
MAR-V_L".?5[S68AJ(CLKE/Z2%&% ] !^GN!_(?04)]/)/[[_ .0M>OX[KR9C
MWGASP]J.A3>%]0T+1K[PU<:=_9%QX=O-+L;K0I])\@6W]ES:1/ ^GRZ=]F5;
M?[$]NUMY"B+RO+ 6J-QX(\%W2>&([KPCX8N8_!$UO<>#([C0-*F3PC/:6?\
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M=K#+J(\)^(-5AT]O$-EI<ME>:K969THW26U[<B0!;K6VJUWL?0_[)/PAT'X
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MS\+]Q<Y^(G@H#YLX8^(]-&>6XR"5R.?F(Z$UH?\ "SOA=_T;OX:_\.%\1?\
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M5O$&CP6J72Z<T.IZAH&D7,TTUE)=HUC$D-Q%&TJ2>A[5_NCUZ#KZU^7WB?\
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M VE>*K+XF_#O3+'Q3HOB..PU"WUJ&YG\+WVN:G+)J5A+I!UJSCN!<P2_"/\
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M'\,/VQ?BG^R3XB\&>,;[QCH?[0=]9_"?2I9=8^)>A^(I=7D\*:EKVK:JL/\
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MT_YD,O+_ *F_D_O9]V_\*BO_ /HI?[/O_B0'PF_^:JC_ (5%?_\ 12_V??\
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M1O\ H8_@O_X?;X4?_-35C"_\\OTC_P#BJ,+_ ,\OTC_^*K/^T<+_ - F(_\
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ME'UC!_\ 0+B/_"NE_P#,/K_2U+<3?]#G*O\ PPU_+_J>>3^_R.F_X9D\>_\
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MCX>LM,@UF_M[:]\/6^F:DL,D,8N@MM"%Y[]K']AWP/\ M#_L*^.?V)?#,Z>
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MT+P;HWQ#6=/'&G_#7PGK7B+4/#'PRA\4QW$L.L'P'I6@275O(]L'CMW:(_H
M"#G!S@X/U]* 0> >:++LON7]=$)M_P S73?_ #_K4^./ '[ W[*WPPO_ -F3
M4?!'PR31[O\ 8]\(>-O G[/DW_"2>*;P^!?"_P 0[>UM/%VG;+W6+B/7CJMO
M9P)]J\0IJ=W:[&-I/ TC-7'?%/\ 8N;QQ^VQ\/\ ]JS2=<TFVT2]_9M^+'[+
M'Q_\$ZI'J?VCQ_\ #;QGJ>D>*/!UQH%]I\L2:9K/A?Q)9ZU;W4MP5%WHOB6\
M6*2.[L[-T^^:*?\ 7]?<OEH'S?7=WW=_SU\NA\(M_P $U?V-6TKX2:(WPD1]
M-^!OP%\<?LS?#*W;Q9XS#>'?@M\1_#@\*>,?"!F77Q+J2ZOH(-@=6U1KS6K,
M.T]CJ%M/\YYN^_X)3?L'7^D:_HD_P'TDV'B?]F_PM^R5KBIXB\717%[\!?!=
M[I^H^&_!9O(M=2ZBEL;S2-+=O$,<@\17,=C!#<ZI-%&$K]$J*5EV7]*WY:>@
M[ON_O9\&? W]C(_"O]K[X^?M/ZGKNDW]IXS^$?P._9Z^"GA33;:^6X^''P:^
M$FC2W>H:/J^I7\LCZKJ7B/QUJ%[J_FQ%EM]-LM-AFGN+GS63[SHH!SS3%>_Y
M?A_D%%%% !1110 4444 %%%% !7YZ?\ !44D?L=>.R"1C7_ _3K_ ,C/I]?H
M77YY_P#!4;'_  QSX[ST_M_P/GK_ -#1I_I7N<,NW$61OMFN _\ 4FF=&$CS
MXK#0_FKTHZ^=2*\S[M\*?\BOX<_[ 6D_^D%O6_7/>$B3X6\-9[Z!I!/U^P6W
M?\ZZ&O%GK4JO_IY.WFKVO\SG2LDNVGW!1114@%%%% !1110 4444 %%%% !7
M\>W_  7'^,>J^!OVT;#0[3P+\)?$47_"G/!=[]O\:_#[2_$^L![C5_%*-;C4
MKV42BSB\C,%L%"1&20J278G^PFOX^O\ @N+\-_"7BK]M'3]5UKXR^!? MZ/@
MUX*MCH?B'2/'M]J!BBUCQ6T=[YOAOPIKE@(+@R2+&INEG!A;S(T!3=\%XCN:
MX<O3E&#^OX2[G4ITDU^\T4JDH)N]FTG=Q4GLF?U/]#Q9<_&"/]IT*V(PW^JV
M=VIT<)C,;/VKK9=[.3H8&C7KN*M).2IN,6US-7N?C=_PTIKW_1)_V=__  SG
MA_\ ^.4?\-*:]_T2?]G?_P ,YX?_ /CE3?\ "DOAW_T<Q\*?_":^+O\ \[FC
M_A27P[_Z.8^%/_A-?%W_ .=S7X+[3$?\_J/3_F-PO]W_ *?_ -:^=O\ 5;EX
M-_Z%6/Z?\TWQ/_=M_P RS_#_ %<A_P"&E->_Z)/^SO\ ^&<\/_\ QRC_ (:4
MU[_HD_[._P#X9SP__P#'*F_X4E\._P#HYCX4_P#A-?%W_P"=S1_PI+X=_P#1
MS'PI_P#":^+O_P [FCVF(_Y_4>G_ #&X7^[_ -/_ .M?.QR\&_\ 0JQ_3_FF
M^)_[MO\ F6?X?ZN0_P##2FO?]$G_ &=__#.>'_\ XY1_PTIKW_1)_P!G?_PS
MGA__ ..5-_PI+X=_]',?"G_PFOB[_P#.YH_X4E\._P#HYCX4_P#A-?%W_P"=
MS1[3$?\ /ZCT_P"8W"_W?^G_ /6OG8Y>#?\ H58_I_S3?$_]VW_,L_P_U<A_
MX:4U[_HD_P"SO_X9SP__ /'*]%^#_P"T5KMY\6_A9:-\+/V?H([KXC^"+:2:
MU^$.AV]U%'/XDTV-Y+6XBGCD@N(T9FAE5LHX!P3@C@/^%)?#O_HYCX4_^$U\
M7?\ YW->B_!_X+^ (/BW\+)X?VD?A?=2P?$?P/.EK;^'/BLL]T\7B7366UA:
MY^'T,"RW# 11O-+%$I;,DL:_,-*,\2ZU%1K46_:T]L9A6])P;LO;-MV3M97O
M>ROMP9K'@[^R\RY<KQZ?]GXRS?#O$T4G]6G9\TLM45KRZR:2ZM*Y]G^-/C9J
M-MXQ\7P#X;_!.40>*O$</FS_  TTV2>01ZU?JKS2&[!DE90&DD."[EF(YKF?
M^%YZE_T3/X'_ /AL=-_^2ZZ#QKX"^&S^,O%TDWQ_^'MO+)XJ\2/-!)X9^)CR
MP2G6;PO#(T?A-XF>)RZ,T;/&S E&*;<\S_PK_P"&/_1POP[_ /"7^)W_ ,R%
M?,5Y9LJU5*M2M[2?_,9@OY^O[[SV^6[1\1@:7"CP6";RO,G+ZIAKM<.\2.\O
M94KNZRRSN[.ZNFMM&KS?\+SU+_HF?P/_ /#8Z;_\ET?\+SU+_HF?P/\ _#8Z
M;_\ )=0_\*_^&/\ T<+\._\ PE_B=_\ ,A1_PK_X8_\ 1POP[_\ "7^)W_S(
M5ESYO_S^I=/^8S _W?\ I]YO^FK=/LN$_P#H59ET_P":<XE_N_\ 4M]/N\U>
M;_A>>I?]$S^!_P#X;'3?_DNC_A>>I?\ 1,_@?_X;'3?_ )+J'_A7_P ,?^CA
M?AW_ .$O\3O_ )D*/^%?_#'_ *.%^'?_ (2_Q._^9"CGS?\ Y_4NG_,9@?[O
M_3[S?]-6/9<)_P#0JS+I_P TYQ+_ '?^I;Z?=YJ\W_"\]2_Z)G\#_P#PV.F_
M_)='_"\]2_Z)G\#_ /PV.F__ "74/_"O_AC_ -'"_#O_ ,)?XG?_ #(4?\*_
M^&/_ $<+\.__  E_B=_\R%'/F_\ S^I=/^8S _W?^GWF_P"FK'LN$_\ H59E
MT_YISB7^[_U+?3[O-7]G^%WQ<O=3\,?'47'PY^#")9?"BRN_*@^&NFQV]V1\
M4OAU:-;W\(NP+JUVW33BW9D4W4-M/N#0*#Y*/BNV!GX4? G.!G'POTT#/?@7
MAQ] 3CIDUZ[\(_ GP^.@?'&"S^.W@*]%U\)[6&[EA\/_ !%C33K<?%#X<W)O
M+E;CPG TD#30Q6FVV2>83W4+&,1+(Z^?#X5^ L#/Q^^'YXZCP[\1L'W'_%)#
M@_0?0=*[*[S54,!RXBE%?5JG-?&X-7?UW$ZINM9VB]>7;9NZ/$P3X9AF.?Q_
ML[,(1_M#!.,?[ XCO'_A%RSFO%9:Y0O/F;4[2E%Q:333,3_A:Y_Z)1\"?_#8
M:;_\ET?\+7/_ $2CX$_^&PTW_P"2ZV_^%5^ O^B^^ /_  G?B-_\R='_  JO
MP%_T7WP!_P"$[\1O_F3KEY\W_P"@JAT_YCL%Y?\ 3[U_'NK>GS\,?] .8]/^
M:?XE_N_]2W^KONKXG_"US_T2CX$_^&PTW_Y+H_X6N?\ HE'P)_\ #8:;_P#)
M=;?_  JOP%_T7WP!_P"$[\1O_F3H_P"%5^ O^B^^ /\ PG?B-_\ ,G1SYO\
M]!5#I_S'8+R_Z?>OX]U8Y^&/^@',>G_-/\2_W?\ J6_U=]U?$_X6N?\ HE'P
M)_\ #8:;_P#)='_"US_T2CX$_P#AL--_^2ZV_P#A5?@+_HOO@#_PG?B-_P#,
MG1_PJOP%_P!%]\ ?^$[\1O\ YDZ.?-_^@JAT_P"8[!>7_3[U_'NK'/PQ_P!
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M]FJ./4TZV.PE"C=WBU!3<Y6;BK)GZ:4445_2I_FP>"_M)_\ )*[K_L>/@_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK\7BS28/"/B+6;WQ[JNEZC)>>'?$B1G[)JNFV]OJ4 EKTC]G[]@32/A[XM^
M_C?QE?>'O$VE_!C]C/P+^S5X9^'NI^$K>\M]$\16FKZ5XB\=^-UO-2N;NW^U
M^(;C1M#TY+:#2[:YM8M.DE?4+C[3Y<=)+=_UK&ZZ:V;\O,\VI];J59TES0@Y
M0=_=4?9^VA:49PFJO-*G"JIJZDI3A9**;/C;X'_M8_M<?&+PY\'/V<O"OC]1
M\0_C1\0_VA_$_AG]J'Q7\.]-M=>7]B7X.>*K;P[X5^,R_#P6ND>&;SX@_%*\
MUOP[H_A"XFL++PVUE>7'BJ;0YX$MK2Y[']L?XA_%?]CCPE\#_ 7CG]N_Q[:Z
M5\>?VBM'T2_^-WB7X?\ PN@\>_"[X3>%/AOXM\5?$-8KC0O UQX8ULZIK&DZ
M!;:?J-Y\/Q-HR:JUO-)>*1./N#]H3]EGXB>-/C/\)?VC/V?_ (K^'/A+\7/A
MAX+\9_"ZYM?&_@"X^(GP\\:?#3QM?Z'K=_H.K>'M+\6>"M7TW4=(U_PWH^KZ
M+K&DZ]#Y)AN+*ZM+BVN%6,T?]E?XBZY\;?@#\;?C7\7?#OQ,UOX*?#SXU^'7
MT[2_AN/!VEZIXP^,6J^&$/B#1[,>*M>32M%\+>"]%OO!EEI6HOK>JZE#JLVI
M:AKQG:6&9II-/3;5)/>_XV5G?>ZMV)]AB%&=-NM.49T8PKNJU%TU['VC<(5H
M3;O[9OF3D[Q7/*R.+_X)N?$SXM_%?X9_$KQ7XW\=>(OBQ\*I?BSK=K^S1\7_
M !MX5TGP;XW^*/P:@TG2#;>+==T70M*T#2I-.N/%+^(+/PGK4'A_0Y=?\-VF
MGZK-IL)N%>7ZT^.GASQ1XF^'^J67ACXS:G\!VM&BU?7/B)HNC^%=6U?2?#>D
MK+>ZREE)XULM5\-:3YUM#FXUC4]'U..PM8YY$MQ(4F@^,OV:/@;^T+^S=XG^
M$_[.?A#6=-O?V<?AO?\ QU^(?C;QQJ?ARRLV\1Z7\3O'/B_6_A)\#O ]G_;N
MI:GI]Y\-O[>_M3Q7XIDBM=.OM/TS2-.L;6-]5GM+#I?VY_V5/CS^U/+\/?#W
M@?XS_#_P9\'M O)-7^)?PC\>_#CQ-XQ\/_&/4K2YBN= TSQG?>%OB-X#U&Y\
M#Z9/%'=ZAX-,KZ9XCND2+7O[0TO?IY3:<K[;-[K6RO;=Z[W]3>DZJPD4Z52I
M52490YU%N;2E)J<IKW(2DTI<[;C'W7+1R^:_V;?VS?C!HG[+$GB'QCJ&H?M!
M?%/XK_'SXG_#C]B%-5TK2/"'BS]H#X<Z=J-O9> _B)XPM/#VGV.FZ-X3TZ&/
M7?%/C+QM9Z%8V-IX!LK'6!8_;-0L;>\^8;3]JC]J6Q_8E^''B3QG\3_&7Q5^
M+'QS_P""CUM\(O VJ_"O1=(\,>)->^%?@KXKWT7B#PSX(TS3WTF&+2M?TGX6
M>,=*MKO6M4(@T;Q!'<:[JR64-S-7ZG^-_P!ACX;?'OP)X"7]I;PG\./'GQB^
M''@_7_"_A3QKX&TSQY\-?"7AI-8/[FV\.>%=%^(4FI6.APQ6FBQW>E77B*^2
MZ6P*1RV]O*MM!Y#^SS_P3)\+?L\V7[%6C>&O&%O<:+^RJOQ)\5>+;1M*U>6;
MXL_&#XA^ +'P)+\0Y)=4\2ZHOAL:=;OK]^FD1QZC')<:K 8;BTFMYKF\?N6?
MJK66^GY+JF[];LYI4<;+DC[27)&C[+G55<_-.5%3G4IR2BYQ7M7&]2JK125W
M)\_U'^RC^TU-^TMX>^)EQK'PUUWX2>-/@[\7?$OP7\?^"M=UW0?%!L/%?AS2
M?#VO23:7XD\-32Z1K.G76D>*=(E6XM@C6]XUW83();5F:M^U=^U;I_[+EG\(
M$/PY\8_%?Q1\:_BWI7P@\%>"/ C:6OB&]UO5/#/BGQ*=2']L75E8+I6FP>&6
M35;B>[MXK&"]6_GE2UM+AAX1\#?@E^T)\#/BMHWP^\,:OIVJ?#CQ5\4_V@?V
MF/VDOBMJGARTM(?&FN_%CQ)J0^'OPB\":?-K^IZS9ZCX7M_L=WXD\2W!6SAT
M3PUHMC:K)-K<EGI?TA\2/V?+GXB_M&_L[?&^]\40VVA?L_Z3\7);#P9_9<LT
MNM>,_B3HGA[POIGB-M4_M!+>SM_#7ARU\4V0LVTRZN+N?Q&DT5[9QV4L-XO=
MNGTTT>O17Z=[NWE8ZU+$.A97]NI4XN4E#:4H.<DDU!N-.4MO=E.#44TTG7_9
M4_:5;]I;P?X\UC4?AUKOPL\7_"[XK^-O@WX^\$:WK&C>)&TGQAX'GM5OQIGB
M30))-)UW3KFUO[&XAO+58O*FEGLI8_.M79N.TG]L'7]4^(%IX#;]CW]L#2[>
M[\4GPU_PG>J?#_P#;^ [:%=0>Q/B>YU6+XI7&I)X8,:#4EO4T9[TZ;)'+_9P
MN&-LO:_LN?L[/^S]\,/%7@C7?$UOXZUWQ]\6/C1\7/&GB.#2I=#@U76_C)\0
MO$7C:^M(K%]1U*XBMM(L]:M?#]J[7[L]KID4B+;HR6\7,> /V /V0/A;XXT7
MXD^ O@EX>\.^./#M]<ZEHOB&WU3Q3=75A?7<%S;S7$<.HZ]>V3NT-Y<HOFVL
M@C$N8A&54A:7T5UV^[KW>M]++I<<5BG&C=QB]76;<;O:R2C3G&3M=-J4%=7U
MNAG[;7Q+\._##X2V>N^+?VFM0_95\/W'B""#4OB%H/A#2O%_BB^@@TO4M1D\
M.>'+?6M#\4Z=IE_>+9F[EU*?POK;K96=S:PPVTUS%>0\]_P3C\?_ !D^*/[*
M/@GQ]\:O$4OC'6/$VM^-M1\$^,=0TS0=%\0^+_A(_BW5D^%WBCQ9H_A<+X?T
MOQ+KG@Y-,U#4K'3(X8XO.A^TV]K?-=6T7??'WX=?M4>,-2A;X!?'KX;_  P\
M/ZAX<N_#_B'0OB!\%+CXG/'?7,LH'BKP[J>G_$'P3):ZG!9RM9?V1KEOKNAS
M&*&:2U!,\<O4?LJ_L\>&_P!E+X _#CX!>$]6U/7](\ :9J,#Z]K"PQ:CKFL:
M]KNJ>*/$>LSVUL!:V(U3Q#K>J7T.G6O^BZ=;SQ6-L3#;H2[Z6O\ \/IKMTV_
M'9V!1JO%.;4HTE2E'62M*?/3<6HJI):*,M?9TY1;:YIJ5H_0=%%%2=04444
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M-%4_;Y;S2]O0P.8U.=/E48+#-2NVYQMK^&?VB+_GK'_W\_\ LZ/M$7_/6/\
M[^?_ &==A_PUU^TA_P!%2U+_ ,$7A+_Y04?\-=?M(?\ 14M2_P#!%X2_^4%?
MSY]1PO\ T%U__"*'E_U&^O\ 6_\ K0EQ/I_PE</=/^:DS/\ N_\ 5)>3^[[^
M/^T1?\]8_P#OY_\ 9T?:(O\ GK'_ -_/_LZ[#_AKK]I#_HJ6I?\ @B\)?_*"
MC_AKK]I#_HJ6I?\ @B\)?_*"CZCA?^@NO_X10\O^HWU_K<2XGT_X2N'NG_-2
M9G_=_P"J2\G]WW\?]HB_YZQ_]_/_ +.C[1%_SUC_ ._G_P!G78?\-=?M(?\
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M^\/^_C?_ !='F+_>'_?QO_BZ^U_^%W?$_P#Z&5?_  1^'/\ Y44?\+N^)_\
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M_P 4?_#&>&?_ )]-:?\ PKGXC_\ 0@>./_"1U_\ ^5U'_"N?B/\ ]"!XX_\
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MY]3?\(/XS_Z$KQ5_X2^L?_(%'_"#^,_^A*\5?^$OK'_R!1[6K_T*Z?3[&/\
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M(7XS_P"A1\6_^$]K?_R'1_PA?C/_ *%'Q;_X3VM__(=<?//_ *$M+[LT\O\
MJ-\OQ];]/U>/_14XSI_R\R/^[_U+O+\5V1V7]B_!C_HH?C__ ,-AH?\ \\>C
M^Q?@Q_T4/Q__ .&PT/\ ^>/7&_\ "%^,_P#H4?%O_A/:W_\ (='_  A?C/\
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M8KJ_B6QT^*\FU'2M#BNH[=K.6);R619U@^1?VGOV*?VJ?V?_ (Q_\$IOC?\
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ME&S3BDFK;O4****1U!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]_T,</\ ^#<;Y?\ 4/YH%/#:?\89F'3_ )@\@_N_]37T];>9S/\ PM/XI?\
M12OB'_X6OB?_ .6E=]\*?B;\39_BA\-X;CXB^/YH)O'O@^&:*;QEXDDBECD\
M0Z<K12(^I%721<HT; JZL58'MC_\)+^S=_T(7QC_ /#F>"?_ )WE=U\+O$7[
M/4GQ.^'"6'@7XMQ7I\>^$OLLES\2/"$T,<_]N67DR2P0> (9)H8Y-KR1)-')
M( %1UR2-L-[7ZQA[YE02]O1NU5QC=O:0O9.A%7L^LDM=3S\VEAGE69VX.QT+
M9?C)*4L'D'+%QPTI*3:S1M)63YDFXV4DF[)^/^.?BG\3HO'/C>*/XE?$&**/
MQAXF2.*/QQXICCBC37=12..-%U951$4!450 J@   8KEO^%K_%#_ **=\1/_
M  N_%?\ \MZ[;QUXU_9WC\;>-5N?AU\8Y+A?&'B5;B6'XF^%(H))QKFH^:\,
M3?#:5XHV?<R1L\C(K!6=B"3RG_"<_LX?]$W^,_\ X=#PG_\ .RK6K3J>UJ?\
M*F&7[R?_ "^Q6GO?]>+:?H_._H8"GAU@<$O]3,=*V$PRYOJW#_O6HT[M7S2]
MGJU?75770J?\+7^*'_13OB)_X7?BO_Y;T?\ "U_BA_T4[XB?^%WXK_\ EO5O
M_A.?V</^B;_&?_PZ'A/_ .=E1_PG/[.'_1-_C/\ ^'0\)_\ SLJS]G4_Z&F&
MZ?\ +[%>7_3C[_1^=^ODH?\ 1%8__P )N'__ )Z>O]+6I_PM?XH?]%.^(G_A
M=^*__EO1_P +7^*'_13OB)_X7?BO_P"6]6_^$Y_9P_Z)O\9__#H>$_\ YV5'
M_"<_LX?]$W^,_P#X=#PG_P#.RH]G4_Z&F&Z?\OL5Y?\ 3C[_ $?G<Y*'_1%8
M_P#\)N'_ /YZ>O\ 2UJ?\+7^*'_13OB)_P"%WXK_ /EO1_PM;XH_]%.^(G_A
M=^*__EO5O_A.?V</^B;_ !G_ /#H>$__ )V5'_"<_LX?]$W^,_\ X=#PG_\
M.RH]G4_Z&F&Z?\OL5Y?]./O]'YW.2A_T16/_ /";A_\ ^>GK_2U]G^#/Q+^)
M%QX;_: :X^(GCZXDM/@S;W-J\_C3Q--);7*_%_X6VJRV[R:HS02R6]Q-"SQ%
M)'BFD0,%D8'S,_%3XG9.?B5\02>Y/C?Q1DGN3_Q-NN>OO7NW[/FM?L_^(+'X
M[6%CX%^+FGPGX/6TVI/=_$7PM=R3V47Q4^&96&R,?P_LTM[H7QLY3/*)T^S1
M7,7D[I0ZO'AG]G-0%_X1;XR#;Q@?$'P>0,<8!'@'! Z#''I5XMN-' 7S3#I_
M597O4Q:4KXW%6:DJ.MN6S3BG=6VLW\IA\;@,-F_$$*_"F-4WC< U#ZGD<I02
MR3*U)2:S*T;R]Y1C=-3;;YFXG@W_  M3XF_]%*^('_A;^*/_ );4?\+4^)O_
M $4KX@?^%OXH_P#EM7O/_"-_LY_]"O\ &7_PX/A#_P"8&C_A&_V<_P#H5_C+
M_P"'!\(?_,#7#SO_ *&N%Z?\O\9_=_Z<>GX=STO[6RG_ *)3'=/^8+)/+_J9
M>GX]]?!O^%J?$W_HI7Q _P#"W\4?_+:C_A:GQ-_Z*5\0/_"W\4?_ "VKWG_A
M&_V<_P#H5_C+_P"'!\(?_,#1_P (W^SG_P!"O\9?_#@^$/\ Y@:.=_\ 0UPO
M3_E_C/[O_3CT_#N']K93_P!$ICNG_,%DGE_U,O3\>^O@W_"U/B;_ -%*^('_
M (6_BC_Y;4?\+4^)O_12OB!_X6_BC_Y;5[S_ ,(W^SG_ -"O\9?_  X/A#_Y
M@:/^$;_9S_Z%?XR_^'!\(?\ S T<[_Z&N%Z?\O\ &?W?^G'I^'</[6RG_HE,
M=T_Y@LD\O^IEZ?CWU\&_X6I\3?\ HI7Q _\ "W\4?_+:OZFO^".FMZSX@_9-
MN=0U[6M6UV_'Q.\:6XOM9U*\U6\$$3Z?LA^U7TT]P8X\_)&9"B9.U5R<_P [
MW_"-_LY_]"O\9?\ PX/A#_Y@:_I)_P""45GX0LOV8IHO!5AXBT_1F^(GBZ0P
M>)]7L-:U/[67L!</]LT[2=&M_L[';Y$8L]R '=(V>/TKPIDWQ4E]>HXA?V;C
M+TJ5;$2;UP]FXU:4(-12OS<R:TLGS:?S+]+/'8'$^%"IX;(<5E]3_6?)I?6J
MN%RVG!15#,+TG4PF+KU4ZETTN3DER-N2:C?]-****_I<_P R3P7]I/\ Y)7=
M?]CQ\'__ %;_ (%KWJO!?VD_^25W7_8\?!__ -6_X%KWJJ?P1_Q2_*!FOXL_
M^O=+_P!*K!1114F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4?6BB@#\Q/C_ .$OVC?@E^U:
M_P"UM\!O@Q!^TCX<\=_!7PU\&?BU\*M'\9^&?!/Q)T(>!O%_B;Q9X5\;>!-0
M\:76E^&M<LI(O&&KZ5KOABZU?3+J2:'3]0L))93<(G#?"Z7]H7]KS]KCX/?&
MCXE? N']FCX:?LK:%\2VTKPEXQ^(GP_\<_&#QM\0/BQX=TOPS-'J^C?#C6O$
M6F>"/"OAO1+2XN&M]:U,:KKFHWEM(EFL%LDT3_VL;+]LSX<?M(>-?B?^SA\$
MM0^-L_Q=_9J\._!#X=Z^OQ'\,>%O#/[/WQ$TOQCXUU6_\8>-O#GBC6+$ZGX5
MU"#Q/H&NW&I^&=/U37+F;PBV@7%N(I[2N"^"7[ H_90_:3_8MUGX/^&M?O=;
MD^''QLL_VT?CD-=U2ZLOBKJVH>'_  ]J&C7/CA-6U>9M9\1:M\2[W4=7\(21
M:<\^B:197]I]H@M!!$NBVO>-[:.ZTU7Q+?TOY>=_+DINORJ%9T5752I!I*'-
M[6#A.FY47*HG.U:I&%6,81BW)MOD/VM'  ] /\]3_,_6EI!C P,# P,8P.PQ
MV^G:EK,]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* # /49_SC^1(I,#T'IT'3TI:* "BBB@ HHHH ,#T]_Q]?T'Y5\^?'7]EKX'
M_M):G\(]7^,?@T^+-0^!GQ%TSXK?#*<:]XBT0>'O'.CE#8:N\6@ZKIL.K1Q&
M.,MIVLQW^FR% 9+1FY'T'133:=UHT3*$9Q<9Q4HNS:DKIV::NO)I->:$   &
M!P *4@'J ?K112*# ].O6BBB@ P/04444 %%%% !1110 4444 %%%% !1129
M'(],>W7@?F1Q0 M%)N'J.:,@]/Y''Y]* %HJM->V=NI:XNK>!5!+---'$J@=
M26=E 'N3C((Z@UYYKOQI^#GA8.?$WQ9^&GAP1MM<Z]X[\+Z.$;^ZQU#5;<*>
M.AP:+/L*Z[K[STRBODKQ)^WS^P]X/5V\3_M?_LTZ((R XO\ XV_#J%@3C V?
M\)$78\CA5)Y%>&^)?^"PO_!,?PHKOJ?[:'P6O%C&YO\ A&=;OO&;$9Q^[7PA
MINN-*?01!R<C .1EJ,GM%OT39#JTH_%4IQ]9Q7YL_2>BOQUUS_@O9_P2VT>-
MGM/VB-4\3,JEA%X5^#GQHU:5RO\ !&I\ 0*SMC"C=ACG!K]#OV9?VE/A3^US
M\&?"WQZ^"FJ:KK/PX\8S:Y!H6H:WH6J>&M3FD\/:YJ'A[5%NM%UJWM=2LFAU
M33+R%4N8$9T19%&QUIN,HZN,DGLVFOS0H5Z%64H4ZU*I.*NXPJ0E)+1-M1;:
M2;2NUOH>^4445)J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?F__ ,%7./V,/'Y_ZCW@3_U+-,K](*_-S_@K"<?L5_$$]#_;O@3!_P"Y
MLTS_ !'^<U[/#W_(]R?_ +&6#_\ 3\#W^%%S<3</Q>TLYRU.V^N+I(_0'PC_
M ,BKX;_[ .C_ /INMJZ*N=\($?\ "*^&O?0-'(^G]G6O^-=%7CR^.I_C9X4_
MBE_B?YL****1(4444 %%%% !1110 4444 %?RW?\%@_A)\1O&_[6%AK/A7PS
M<ZMI8^%'A&S-W'J&CVL8NK?5?$KS0[+[4;68O&L\+$B,HP<;7."!_4C7\8O_
M  7B*C]MW3P, ?\ "E/ @&0 !C6/%Y(^8<$JT?!P6 &,[3C\W\4U2EPQ%5HU
M)1_M+"-*G4C3ES*&(M[TJ=56M?3EN][JSO\ U3]#NAC,1XP1A@<3A<+77"^=
M253%X*KCZ3BJN7QE!4*./RZ?.^9.-3ZPU!1E>G.Z<?E;_AG3XU_]"-=_^#KP
MU_\ +JC_ (9T^-?_ $(UW_X.O#7_ ,NJ^ \^Z?FE&?=/S2OYP]E@_P#GUBO_
M  KH^7_4#Z_UM_JO_9?$O_0YR/I_S3./_N_]55]W_;I]^?\ #.GQK_Z$:[_\
M'7AK_P"75'_#.GQK_P"A&N__  =>&O\ Y=5\!Y]T_-*,^Z?FE'LL'_SZQ7_A
M71\O^H'U_K8_LOB7_H<Y'T_YIG'_ -W_ *JK[O\ MT^_/^&=/C7_ -"-=_\
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M_$T\$BWN@ 212:YJ+HX#:P#AD=6 (! ." >*Y?\ X9<_:"_Z)=KG_@=X?_\
MES7#?$$*/B!X\X&T>,_%(48Z?\3_ %+MUZ ?ES7(Y3V_+_ZU8UI8/VM3_9\8
M_P!Y)MK%TK?%T_V)_P##V['1EU#B9X# N.;9"HO"89I/AW,+V=&DTKKBA)V5
MU=):]#V?_AES]H+_ *)=KG_@=X?_ /ES1_PRY^T%_P!$NUS_ ,#O#_\ \N:\
M8RGM^7_UJ,I[?E_]:LN;!_\ 0-C>G_,72\O^H'R=O1'9]7XG_P"AMD'3_FG<
MQ\K_ /-4^OW_ '>S_P##+G[07_1+M<_\#O#_ /\ +FC_ (9<_:"_Z)=KG_@=
MX?\ _ES7C&4]OR_^M1E/;\O_ *U'-@_^@;&]/^8NEY?]0/D[>B#ZOQ/_ -#;
M(.G_ #3N8^5_^:I]?O\ N]G_ .&7/V@O^B7:Y_X'>'__ )<T?\,N?M _]$OU
MS_P.\/\ _P N:\8RGM^7_P!:C*>WY?\ UJ.;!_\ 0-C>G_,72\O^H'R=O1!]
M7XG_ .AMD'3_ )IW,?*__-4^OW_=^AO[+?[-_P <M-?XXV][\-M;BFU7X,Q6
M&G1BYT6:2ZO5^*OPQOFAB2#5)&W"RLKN<LP50D#KNWE5;U ?LU?'O'_)+_$H
M]B^E CV(_M/@CH1VKQW_ ()Z 'X@_& $!L_!"_(4+NR?^%F_#0Q_* 22!T.,
MYXZGG]&1N  &[&!C&<8[8]L5ICI8%T\ GA\=+_9).U/&T%9?7<9:_-E]1MZS
MUNDDXJSU;_#.)LZXBRKB?/,*\5D%>4JN7UY5)Y-F%)7EE.7Q48P7$;<;1@DT
MYS;DI-.*:C'Y(_X9J^/?_1+_ !)_WWI7_P LJ/\ AFKX]_\ 1+_$G_?>E?\
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M_P#2JP4445)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %!Z&B@]#_G^7/Y4 ?D-^W[_P39\0
M?M0_$W1OCWX&^,6JZ'XG\+^"[;PG=_"'QOXN^*GA_P""?B[3]-U#5-4BO;V_
M^#_CGP!XV\(^(';4I8)?$5CJ&LV7V>"U:\T*]2$H_P C_P#!/;Q!^R5H?[8
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M7"M/XV^)'B/6_%&H6[.+W2],O[&S-E%8V4$YXO\ ;0^$OC7PY^P!K'@;P_\
M#N#0/A)^SW^TGHFA^"M5%_X+?5/$W@NS^&\MOXH^*VOSZ/KFHW5YJ/CKXAZS
MJFJ)IP+WVF:3<:/IWV)8+&6Z(L3%N$>2-I5'"VC<4K6;2Z---6NE]XZV18F,
M<1*56M..'P=*O%NC4DZM>=W.BDVW&G!4YM5IVYN6*4/??)^    X"YQC<0&)
MR,$G=N!)'&<9'48(!']V/_! W'_#KGX!8 '_ !4'QJ''H/C5X]4?D !^%?PG
M*,  D$C@D$$9!YQM9QP<CACCH3FO[L?^"!O_ "BY^ 7_ &,'QK_]77X^KGS2
MWLJ+2M=S^ZU.WW7/9X$_WO'?]@\%]U1?+Y]3]D*P_$OB?PUX+T+4_%/C'Q#H
M?A/PSHML;S6?$?B75K#0M"TFT5UC-UJ>KZI<6NGV%L'=$,]U<11!W52V6 .Y
M7YL_\%?D23_@F]^U.DB+)&W@[PZ'C<;DD4_$'PAN1UR Z.,JZ-E74E6!!KQ#
M](K3=.E5J))NG3G-)[-QBY).VMFUJ?;7P_\ C3\'/BR+T_"OXL_#/XEC3=G]
MHGX?^//"WC(:?YF?+^V_\(YJNI?9?,P=GG^7NP=N<5)XG^,GP@\$>(='\(^,
M_BK\-_"/BOQ"\,>@>&/$_CGPQH'B'7'N9?(MTT?1=5U2TU+4WGF_<PK96TYE
ME_=H&?BOR>_;$^&GPW^"WQ>_X)Q?$SX'>$/"OP[^.?B3]J'P#\+)4\ :'IWA
MO4OB#\'/%G@_Q(_Q=T'Q-IF@VMNGB3PYHGA^V7Q+)<ZI:7</AN^L+34XKFRF
M,;G!_P"">OP&^ G[37PE_:9^+?[1WP\\#?%?XR_$7]IO]H_PG\9M1^(>DV&O
M:]X-TSP#\0];\(^#/ .FWVJ1R:CX(T;PQX"TGP[?Z'!H]QI,L OAK<<@N)8Y
MUM15N9O3I;=ZM7[=.YRK$U'55!1A[2_,Y>]R>S4*<F[6NIIU8IP;V]]M)I/]
MQ@0P#*0RD9!!!!'J"."/I2UXOX6^,GP(&NM\(O"OQ2^'=[XJ\':=#IUSX(L/
M'&C:KXDT*PTG1[*\BAU73AJ=WK%LUMH<]CJ,LVI()C87$%_-(\<PG?I/ 'Q<
M^%WQ6AU6X^&/Q$\$?$*#0[F*RUF;P7XHT;Q+%I=Y/%Y\%O?OI%Y="TDN(?WU
MKY_EBYAS-!OC!80=:J0=ES1;=U923UC;F2UU:;L[7MU/1"0,9(&3@9[GT'J>
M#5'4]4TS1=/O-6UG4;#2=*T^WEO+_4]3N[>PT^QM($,D]U>7MU)%;6UO#&K2
M2SS2I%&BEG8*":_&?XV_M^?%KX=_&#XA^!M)^,W[+.B:5X7\37FE66D>*_V:
M/VT?$WB:PM83%Y=KK'B+P4O_  AVKZA%O/FW^@.VF2NRF!  Z#]4/&?AZT^)
M?PCU;1M<\*^$/B,OB+PHLY\)>*K:>U\#^*M2%K#J.FV&KV^H6&L7=GH-YJL-
MI)*+S3M1N[.W ,]K<RQ/%([;7T3MU6QG"O&HZD8+6%]&XO5:)-0E)ZOY]+7T
M-GP'\5?A?\4["]U7X8_$CP%\1]+TVZ:QU'4O ?C#P]XOL+"]5=[6=[>>'M1U
M&WM;I4^9K>>2.4+\Q0#FJWA+XP_"3Q]K>M^&O GQ2^'/C7Q'X9D>+Q)H'A+Q
MOX9\1ZWX?ECG:U>/6]*T?4[R_P!)D2Y5K=TOX+=EG5H2!("H_FO^(.H?$CX%
M?$#_ (*>R^*/AGX._9O^-OBS_@GP/%OPP\&_L[WUKJGPFU#X:>";_4/#/B'X
MBW.N6&E>%=2/Q2TG6?%,6FPO?^#/#XLM MHVL)-35/.7[!UKX2_";X)_&7_@
MC3K/P \)^%_#&K>)M1\3^ =7U#PEH]GIU_X[^$.H_LP>(_$^M7OBJ^TD03>)
M;6'7-*\.^(SJ6MK?H-;NX]0,T5S.)&KE5[:ZI\NSV5];='Y;)'+'&SD[>S45
M"454YN:,K3Q+P\>6,K.+27M)*;NDU%*\KK]U-RGHP/3N._3\^U<KXR\>>!OA
MUHQ\1_$'QGX4\"^'EN[2P;7O&7B+2/#&C+?7\PM[&R.J:W>6-B+N]G98+2V,
M_G7,Q$<*.Y"U^<O[9?CCX]2_M??L0?L\_"'XU:K\%O"_QWT']IN?XD:WH/A;
MP;XEU^6R^&_A3P+XBT6;PZ_C'1M:T[2M?M9;W4K:PU*XLM0TZWCU&XGO-%U2
M6&U2+\R_CSK'BS]JG]D_1?V?_P!HWQ/)\4D\$?\ !8?P;^R%KWCF\TC1M#U[
MQY\/]/\ B'::)9ZQX@L/#=KIFA6_BA]%\3O8W5QHNFZ5:SW-I;7D5E!<N[D4
M5>-WH_O2:6O72[M\BJ^-]FJ\8TW*I24E'F:4)S4*<^6Z;DDHU8MMQ2T:3;/Z
M8M7\0Z!X?T2_\2Z]KFCZ)X<TK3YM6U37]7U.RTW1--TNVA-Q<:E?ZK>3PV%G
MI\%NK3S7EQ/';Q0J97D5 6HT#Q!H/BO1=,\2>%];TCQ)X=UNR@U'1M?T#4K+
M6-%U?3[E!);7^F:KITUS8W]E<1D/!=6D\L$J$-'(RG-?S@S_ !;\6?M(_L]_
M!_\ X)K^,-3N+[XN>$/'/Q*^'7[8?E3.=17X'?LC0:=J\VK:KO+W%OI_QXM-
M2^%>C6.HW $&LQ:]XGAM_/\ LES'%^H__!)@;?\ @FM^Q0@^ZO[/G@ *   !
M_9@P !P !@ #     I-)13UNV]/)):_.Y=#%JO54(QM3='VBDW[SFG3]I!K9
M.G[6$9:_'S1WC)+]#J***D[ HHHH **** "OS:_X*R$C]BKX@8[Z_P"!!^'_
M  ENE5^DM?FQ_P %9CM_8H^(+=<>(/ @Q]?%FEU['#[MGF4/_J8X3_T]!'TO
M!L>?BWAF&_-GN5)+35O&T;+73[S] _!__(K>&O\ L7]&Q^.G6V?Y"NDKFO!_
M_(K>&??P[HI_/3;4_P!:Z6O*J?Q*G^.7_I3/FY?'4_QL****@04444 %%%%
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M?XJ:MXG^*7P^_9E\'_%'X2^'_BAH7QJTSXL:AXI\8>%I/@9XN3Q+\ [KX;^
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M_K^O4****@S"BBB@ HHHH **** "BBB@ K^3C_@M"-W[7M@ IS_PJ/P<>!R
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M\;*<4O[/PJ5I2PD+NT4W[JY6TO7P?(]_R/\ A1D>_P"1_P *]X^W0?\ 0O\
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M'Y6_\.JQT_X>+_\ !4S/I_PUO'_\[ZD;_@E9P-O_  47_P""I?O_ ,9:(/\
MW16_D*_58R#H,[CC'^?\_CS3Z++M^?E_D@N^_P#6G^2/RE7_ ()6DG!_X*+?
M\%3/P_:T0=/]K_A!&_\ 0.?;M*/^"5*D<_\ !1G_ (*G ^G_  UJA_7_ (5^
M*_58'!S4RR+M (&XY&?J>.W]::BO2W>_2VFFO1?=YA=]_P"M/\D?E$W_  2K
MC!Q_P\:_X*G?^)9H?_=!%5F_X)9*I_Y2+?\ !4T ]/\ C+1&Z?\ <AI^>3GT
M%?K%)QSWP?T J!D08W<,O)&>/U^GY<Y%*R[=N_2W^2"[[]OPM_DC\HC_ ,$M
M4Z?\/%_^"I@/?_C+-5/XD^!7_+;^5+_PZS3 )_X*,?\ !4T _P#5VT>/U\ C
MTK]5#&C'..O/0=^>XS33%DD?P]NG'';&.]%EV_K3_)!=]_ZT_P D?E>O_!+)
M&;'_  \9_P""I>/?]K6,G//<>!5]OX3CN3G F_X=6)W_ ."C/_!4T>F/VM8V
MS^7@ 8_7/X5^I0BVL",G\O7_ .M5Q3QC##']['.<^A-%EV_/I;_)!=]_ZT_R
M1^5!_P""58 !_P"'B_\ P5-Y_P"KMD_E_P *_P"/S-,/_!*\#/\ QL7_ ."I
MN1V_X:V3/_J 5^J[ELD*>G/\O3'K_C55O-)XX)SUSV_'VY^M%EV_K3_)!=]_
MZT_R1^6?_#J]3C'_  47_P""IG3I_P -;(2?P_X0$?ED?AUH_P"'5P/3_@HK
M_P %31_W=HH_GX#?^GX]OU)VS EBQSCG&<?R//'K2*9FSDGCV/\ A19=OZT_
MR07??^M/\D?ENO\ P2MS@G_@HO\ \%3!SR/^&MD''_A >GZ\=:G_ .'5*'_G
M(S_P5.'T_:U0C\_^$ .?K7ZE12D\MP.F.??_  JZ), 9QC'7^7?%"273\^EO
M/R07??\ K3_)'Y3G_@E2@!/_  \9_P""IW )Y_:U0#\_^%?\?6H_^'59)&/^
M"BW_  5-((Z_\-;(1G/K_P *_']:_5QI%VY'.<C!Z?3CUJL7;UQ^5%EV[=^E
MO\D%WW_K3_)'Y6_\.JQC/_#Q?_@J9CU_X:WCQ_ZKZE'_  2K&?\ E(O_ ,%3
M#_W=LC?H/ *'_P >_ U^J@D 4+@X'TSTQZTGF$'/0 _C_A]>U%EV_/I;_)!=
M]_ZT_P D?E;_ ,.JN>?^"BW_  5-'M_PUJJ_F#X!;'_??O[5*O\ P2HC(+-_
MP48_X*G<<;5_:U1B>G.1X!/Y<_2OU5656Z]L>O\ AQ^N*E$BA21Z]_P^G^<T
MXQCUT27^7KV7W>H7??\ K3_)'Y0M_P $J5 )7_@HQ_P5-8_]G:H#^'_% <__
M *O6F?\ #JP#&?\ @HO_ ,%3,]P?VMD/;T_X0)#Z?Q<>AK]7F=0"1V]>?Z"J
M;3 L3QZ=#[?X4K+MV[]+?Y*_X!=]_P"M/\D?E=_PZL7_ *2+_P#!4O\ \2T0
M?K_P@S8_[Y/TH'_!*L'_ )R+_P#!4W'<_P##6Z''_F/J_5 S@<]?8 Y/TI5E
M##.&4 XP0/KGUQS19=NW?I;_ "07??\ K3_)'Y8_\.J4[?\ !1C_ (*FMGU_
M:V0?E_Q0 S_GUI[?\$J8=HV?\%&/^"IQ;C(/[6R #CG!/@ 9Y]Z_5=)$8* 3
MCG^@'YX_STH+H/7KZ_\ UA_.GRKRV7?=<OGY+?1V=@N^_P#6G^2/RB/_  2J
M )_XV,?\%2\>G_#6\>?_ % #_GTJ-O\ @E< <?\ #Q;_ (*G'W'[6J,/_4 7
M/Z?6OU8DD13G/!/^>GO^GX5'YZG[I&/H?Z4K+M_6G^2"[[_UI_DC\K%_X)7*
MQQ_P\6_X*FKGN?VM%4#\_ ;9_,8]ZD7_ ()5J2!_P\7_ ."IGO\ \9:HOIW_
M .$$?^0_I7ZG^</;\C4\<BXR3U'M^/4_Y[\T67;\_+_)!=]_ZT_R1^5Y_P""
M5$!7Y?\ @HS_ ,%3]_H/VM%(_#_B@.:A?_@E6%P!_P %%_\ @J;U&2W[6:=.
M>_\ P@J=O]D=,<]:_5Y77!;/3I_+G&:CFDS@XXX_F1_C3M&W9WV5]M+==/A]
M?D%WW_K3_)'Y1-_P2O53_P I%?\ @J8?I^UF#_+P,:8?^"6 /3_@HI_P5.'T
M_:S4?S\!M_2OU3:X() 0L!W&3CZ_Y]Z;]J'H/U_PI67;^M/\D%WW_K3_ "1^
M6(_X)6JV"/\ @HM_P5-7CD']K9 2?Q^'YQS_ #IX_P""5.<'_AXO_P %3<'O
M_P -;(1^?_"OO7BOU/68''3GZ]_K5Q)0%"X!7U//?/\ /\J:C'KIVW?5?Y?A
M]Y=]_P"M/\D?E-_PZH4#)_X*,_\ !4[\/VM4(_3X?]?:H_\ AU8G;_@HQ_P5
M-/U_:S0?^Z(G]:_5]IDZ< =>WOZX_E^-5V9 ,@D_4C^G\Z+)=$]M=?+S\D@N
M^^W_  /\D?E./^"5ZDD?\/%?^"I@QW/[6:C^?@;'ZFD_X=78;G_@HM_P5,(R
M>G[6B#CMS_P@K?R/IQU'ZI^:3]T GTY''XT>:W0 ;O3G^?3IS^E*R[?GY?Y(
M+OO_ %I_DC\KA_P2KS_SD7_X*F'Z?M;IQ_YC\_SIX_X)5#O_ ,%%O^"IG_B6
MZ?\ S "OU6BD4Y_#./;\_7\.XJ;>GO\ G_\ 8T**]/O\O\E]WWEWW_K3_)'Y
M1G_@E9'@X_X*+_\ !4P-CH/VMT*_4$^ >N<9'/7/ %1_\.K!C/\ P\7_ ."I
MF?\ L[9,_E_PK_\ K7ZL,RJ<#)_S^%0LY7+ %N>%Y/4XZ>V:++M_6G^2"[[_
M -:?Y(_*K_AU<!_SD7_X*F9]#^UJA_0> 5)^F1GUI%_X)7.V?^-BG_!4T '
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MO?B1_P#*"OB_S8O[Z_G1YL7]]?SK^;+87_H7X;I_R]Q_]W_J.\G][^?^I?\
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M_P#12?C)_P"&E\)__/3H_P"$;_9M_P"BD_&3_P -+X3_ /GITO\ B6_Z1/\
MT16>]/\ F=Y5_=_ZF_3_ -M^[;_B=OZ#/_1P>$>G_-$<2_W?^J9\_G_V\9__
M  TE\=/^BE>(O^_ME_\ (%'_  TE\=/^BE>(O^_ME_\ (%:'_"-_LV_]%)^,
MG_AI?"?_ ,].C_A&_P!FW_HI/QD_\-+X3_\ GIT?\2W_ $B?^B*SWI_S.\J_
MN_\ 4WZ?^V_<?\3M_09_Z.#PCT_YHCB7^[_U3/G\_P#MXS_^&DOCI_T4KQ%_
MW]LO_D"C_AI'XZ?]%*\1?]_;+_Y K0_X1O\ 9M_Z*3\9/_#2^$__ )Z='_"-
M_LV_]%)^,G_AI?"?_P ].C_B6_Z1/_1%9[T_YG>5?W?^IOT_]M^X_P")V_H,
M_P#1P>$>G_-$<2_W?^J9\_G_ -O'MWP/^/\ \9[[0OCO<77Q#\0O/I7PAM+[
M3YA/;"2SO&^+'PST]KB$I9IB1K.]N[<DDCRYWXS7.C]H_P"/./\ DJ?BL?2]
M@ _ ?9.!Z5Z[^RQ\+O@AXZN_C)X2\.?$CXG)<:O\(0E]<ZS\,_#MI#9V-E\2
M_AW?23VXLOB->27=T;JUM;=;=S;Q&*>:X,Y>!(9O9/\ AAKX<_\ 18O&?_AM
M=#/\_'N?SY]:_JSP4XGX5\$.$L1P;XV8G"\-\8U<YQ6<TLNSC!5\XQ3R;&X?
M!4,%B%C,!A,TPZI5,1A<8HT/K*J0E"4YTH^TBY?Y?_2_X>XA^DOXK4/$3Z,>
M'Q'%?AQ1X7RGAZMFG#]>GPU@(\19;B,=B,SPKRW.*^28N6(HT,?@)5<2L$Z5
M2%2G&%>;A*,/C[_AH_X\_P#14_%G_@;!_P#(E'_#1_QY_P"BI^+/_ V#_P"1
M*^P?^&&OAU_T6+QG_P"&TT+_ .;VC_AAKX=?]%B\9_\ AM-"_P#F]K]?_P")
MA_H[?]%1P_T_YIW,_+_J2>GW>E_Y7_XE:^E3_P!$CQ)T_P":HR;^[_U/OO\
M^WCX^_X:/^//_14_%G_@;!_\B4?\-'_'G_HJ?BS_ ,#8/_D2OL'_ (8:^'7_
M $6+QG_X;30O_F]H_P"&&OAU_P!%B\9_^&TT+_YO:/\ B8?Z.W_14</]/^:=
MS/R_ZDGI]WI<_P")6OI4_P#1(\2=/^:HR;^[_P!3[[_^WCX^_P"&C_CS_P!%
M3\6?^!L'_P B4?\ #1_QY_Z*GXL_\#8/_D2OL'_AAKX=?]%B\9_^&TT+_P";
MVC_AAKX=?]%B\9_^&TT+_P";VC_B8?Z.W_14</\ 3_FG<S\O^I)Z?=Z7/^)6
MOI4_]$CQ)T_YJC)O[O\ U/OO_P"WCX^_X:/^//\ T5/Q9_X&P?\ R)7]*_\
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M!0%21@YQ@C(QD$#%?BGK?[-O_!44:S+Y7BVZNS<RX:?<\2 DL<A!"Q '4@#
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M6%J7B.QM22TO3<3\R@<8Z@G'&3S[UQ\5IKD=J%+_ #$!3@ 9P!T"X&>2">F
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M8/\ Z%C\?I7Z=5^8G_!7XX_8:^(A[CQ'\/2!ZD>,M'.*]7(O^1SE?_8?A?\
MT] ^Y\,ES>(O L?YN+,@7R>9X9/\-S]%?!HQX5\->WA_1A_Y3[?_  KIJYGP
M8<^$_#+?WO#^C$_^ $ _I735YD_CG_CE^9\77_CUO^OM3_TN04445)D%4M14
MO87: D%[:= 1P07A=0P.01M)SD$8Q5VF2*'1U;&&5@<]!D$9I27,FM[K;N.+
MY91EVDG]S3\S\MM7^#UUJ]]-<ZI)-?7+LJ//=,TTQC0D)$S2 L4B#,J(6PB_
M*F!@5]E?L_Z'?Z#X8O[2^NKF\8WR>0]U(\ICMXK:...&,N25C0!@J#@#(Z5U
M<_A_2A.Y$T+$R-G   .[!R3CCKV%>;?M$?$'6O@+^R_\=OBSX(L;/6O$OPZ^
M%OC;QGH-C<PRW-A+K&A:#?7MB^HV]N\<T]C;SQ+=7T,+K)+:0RJKHS U\%P]
MP8LDS/\ M",91;IU83?-+WW4C9.:>DFM6KW:;;6Y^D<3<>UN(,F64SE"4(U,
M/.E!0BE35*49-0LDH*R5U&R=HZ;6TOV6_@?J7[/WPX\0>!]5UZR\1W>L_&;X
M\_%!=1L+&73X8K/XO_&+QK\3K'2W@FFG=[G1[3Q5%IEU<!Q'=7-K+<1(D<BJ
M/HZOS^_8I^*/Q,\3>-/VAOA;\0/B;%\:K+X53_!35O#?Q1&C>'-%NM3_ .%L
M_"ZS\;:_X;NX/"5EIWA^:/P_JK&]T9[:T%[!X<\0:/9ZE<7MQ;K>3_H#7WJ_
MKY'YL]/P_%7_ %"BBBF 5_/S_P %,/#/B/6/VB[*ZTGP]KNJ6P^'7AN(W.FZ
M1J-[;B2+4_$!:,SVMO+$)$$BED+[AO!( (K^@:OY<?\ @L%XL\5Z#^UA866B
M^*O$ND6/_"J?",WV/2]?U;3;3SY=5\3&2;[/97D$'FR!5#R;"[A%#,0H _7/
M!3#5\3QKR8>=*$UE&/E>LIRARJIA+JT&G=Z6=[;Z'XUXZXO#X/@9U\3"M4IK
M.,OART'"-3FE#%)-.HG&RUOI?L?/W_"!^-_^A,\6_P#A.ZU_\AT?\('XW_Z$
MSQ;_ .$[K7_R'7Q?_P +'^(/_0_>-?\ PKO$/_RRH_X6/\0?^A^\:_\ A7>(
M?_EE7]>?V1F?_/\ R_I_R[Q/2W_3SR_K6_\ &'^L.4?] N9=/^7V%\O^G?G_
M %='VA_P@?C?_H3/%O\ X3NM?_(='_"!^-_^A,\6_P#A.ZU_\AU\7_\ "Q_B
M#_T/WC7_ ,*[Q#_\LJ/^%C_$'_H?O&O_ (5WB'_Y94?V1F?_ #_R_I_R[Q/2
MW_3SR_K6Y_K#E'_0+F73_E]A?+_IWY_U='VA_P ('XW_ .A,\6_^$[K7_P A
MT?\ "!^-_P#H3/%O_A.ZU_\ (=?%_P#PL?X@_P#0_>-?_"N\0_\ RRH_X6/\
M0?\ H?O&O_A7>(?_ )94?V1F?_/_ "_I_P N\3TM_P!//+^M;G^L.4?] N9=
M/^7V%\O^G?G_ %='VA_P@?C?_H3/%O\ X3NM?_(==9X \$>-8?'W@:63PAXK
MBBC\7^&Y)9'\/:RL<<<>L63N\CM9[41$5F9F(  ))KX#_P"%C_$'_H?O&O\
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MXG_]$\\??^$CXB_^5U'_  K'XG_]$\\??^$CXB_^5U?GE_PM?XI_]%.^(_\
MX7?BC_Y:4?\ "U_BG_T4[XC_ /A=^*/_ ):5T?V;FW_/W+O_  3B/_EWDON,
M/[*R;_H(S/I]C#>7GY.WHC]#?^%8_$__ *)YX^_\)'Q%_P#*ZC_A6/Q/_P"B
M>>/O_"1\1?\ RNK\\O\ A:_Q3_Z*=\1__"[\4?\ RTH_X6O\4_\ HIWQ'_\
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M_+"C_B2.I_T<-?\ B,KR_P"I[YO[O,/^*@53_HUT/_$LJ>7_ %3GK_6_Z/\
M_"-^)/\ H7]:_P#!1>__ "/7ZC_L=6EW9?":2&]M;FSG_P"$FUIO)NH);>7:
MS0D-Y<R(^ULY!VX(/!Q7\S/_  FGC+_H</%O_A3Z]_\ +"OZ!?\ @F9J.HZI
M^SF]WJ>HWVIW/_"<>)8OM&HWES?7'EHUF4B\^ZEFE\N+)2./?M1> !7/B/HU
MR\*X+BN7%JSJS66?4O[&6!_WVTO;>W_M3%_PW0Y>3V7O<]^9):I_2NEXQ_\
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M HHHH **** "OY__ /@XV_Y,V_9W'K_P4)_9%&?3_BJM;-?T 5_/[_P<<_\
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MG!  &/H<_P#UZHS:-9REM\*$<8.W^?O[@UN$%LXZX//3'X^G2JY)Y!)/XYH
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MNIQ4<3>;H>SJ7Y=/>Y?=ONKGYB?\--? [_HB/Q(_\/+HG_SJ*/\ AIKX'?\
M1$?B1_X>71/_ )U%>7?\,4_M3?\ 1(-5_P#![X,_^:*C_ABG]J;_ *)!JO\
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M,/$.J":2*%_A!,T43R[F2)I96C4A#+(06/'_ /"5_LS?]$@^,O\ X?#PK_\
M.<KUCXB?L3?M57OQ!\>WEK\&M:FM;OQKXLN;:9-9\(!9H)O$.IR12J'\1JP5
MXW5@&"M@C*@\#CO^&'?VL?\ HBNN?^#GP=_\TM=^&QG#'U?#WXBHI^QI?\U/
MB%]B'19DONMIMU.O$4^(5B*_+D>+:]O5::X>DT[U+W3^H^]?>_6WF<Q_PE?[
M,W_1(/C+_P"'P\*__.<H_P"$K_9F_P"B0?&7_P /AX5_^<Y73_\ ##O[6/\
MT177/_!SX._^:6C_ (8=_:Q_Z(KKG_@Y\'?_ #2UM]<X7_Z*.CT_YJC$?W?^
MIEY_/_MXQ]GQ%_T(L7T_YIV7]W_J Z6_#S.8_P"$K_9F_P"B0?&7_P /AX5_
M^<Y1_P )7^S-_P!$@^,O_A\/"O\ \YRNG_X8=_:Q_P"B*ZY_X.?!W_S2T?\
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M_M-PZ'9?!.?X)-J[^'H_ WACP%I&GZ[I\0\(0/:2V=KXE_MJ/+N_UY^T_?\
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M]? YYKZZ_P"&!_V>>O\ PCWP?QZ_V7X#_P#C='_# _[/)Z>'O@^?^X7X#_\
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M2\7.?VR_AGSC_F!?$H_S\##'X=?PKZZ_X8'_ &>3T\/?!\_]POP'_P#&Z/\
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MZ6'QU"/L\4JM2;Q%)0A*=&R5'6*TA.ON[N*5Y2_#G]HKQOK?[3/C3]G'Q_\
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M]9Q7>233(/&L7_%9>,,Q+N_X2SQ*1^[4?*VN:@0?NXY[=\>U<QY)_P">2_\
M?"?X5F>-_P!JFRMO&WC.V;]GSX/7!M/%OB2U^TS:Y\:!+<>1K>H1>?*L'Q1@
M@664IYDJPQ11+(S+''&@5!S'_#5^G_\ 1N_P9_\ !Y\;/_GKT8:CFWU?#M97
M7UHT7_O&7V^"GM_MU[67WKT._%9=@98K$O\ MK+E^_JZ.CFUT_:.Z=LJ:NFU
M>S:NM&]+]UY)_P">2_\ ?"?X4>2?^>2_]\)_A7"_\-7Z?_T;O\&?_!Y\;/\
MYZ]'_#5^G_\ 1N_P9_\ !Y\;/_GKUM['-_\ H5U^G_,1E_\ =_ZCO7[D<_\
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M@AD0_*/M*H.[#N4J%"4FW)T:;DW>[DX1;;OK=O5WUON%%%%!L%%%% !1110
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M'PO?@<9QVQ24=/=CO>[7333;R[/?U#7I?^K?\#\#*;_@B'_P3&XV_LVW7O\
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M?\$0_P#@F*,D?LW77T_X77^T!].O_"TZ8/\ @B-_P3%!^;]FZZ*X^Z/C9^T
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MVAB-0>2 "0#DXZ].I^O^33TCC5R"5QSCY@.0>.=WUX)K^+T?\'&GQ[M !?\
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MQ'HVEV%^]M<Z;I'ADW[:)#([PZE<12&7T[]C3]F/XD:WX$^/MEX3U_\ :/\
MV&?@AXH_:*O/&W[.GPWT2S\%^&O'WACX=MX&\/:1X@L;GPA\3_!OQ&B\ >#O
M%?CN/7?%&C>"!I&BZKI#@3M'96UZ;)CE5KMV3=K_ '7:5KO73R3O;NHUZTL9
M45I2A&7LW2C)-QOAZ%:,IZ<B7/.<>?VJYKQCRV39^@/Q<_;3_93^ WB^S\!?
M&#X[_#WX?^+[RWT^\.AZ_K'DW6G6.JS-;Z;J.OO!#/;>&M-OYD=+34?$,^EV
M,_ER-'<,D;LNE\9OVN_V9_V>KKP[8?&?XT>!_ .H>+;674?#VG:OJ;2ZCJ>D
MP-&EQKD>GZ=#>WD/A^V>6)+G7[J&#1K=Y$2:^1V /XL?\%#?#W[7GB2]_:7^
M!(T_]KCQ7X U']G/POX6^!%Y^S_\&_AUXOMOVA?%5WX*U[3OB!-^TQ\2KSP'
MJ-IX=N;/7/LT,'AO08_ AN].OI+KPP/[1N;:V'K?PYM?BA^RO\?S\5OB#^S9
M\<_C'HGQ;_8A_9=^%_A*\^&/P]N_B#K?@OQY\*-(U^/QU\-/&]@\D,W@*'Q7
MJ7B'2M4.N:V^G^&Y;O3KL:Q=0W-@[(<JTLV[_+JE^+NE\NEV/ZY6]K.FZ3A&
M+BE4E3FU&[FGS*$Y\UW!<KO3TG&7*UO]J>%?^"DO[./C']JGQE^R9HWB>&3Q
MQX>\/>$-5\/Z[LU"Y\-^,]7\66>OZD_A_1KRSTV:%9-&TK1K75;C5KBZ32=1
ML]6MSI=S=212*-KP-^W;\&-,^"WPW^)G[07Q@^!G@*_^)%S\1X=!N/"OC34M
M:\#^(#\._$FL:3J]MX1UK6]$T35=:U'3K.QM(M5L#I,5U_;TMQI6EQ7Y%LT_
MAGAB#QUX"_X*)>/_ !AXA^"/Q3A\)?M&_LT_ OPOX7\2^$_"%UXL\">!?%WP
M_N/B+>^+?"OQ \4Z$TNC^#)M.AU^P@L+V]$%AK#,L>G33MB,?('[)_[./Q7T
MB;_@DO#X\^#GBZR@^$?C;]O?6?B GB;P=>A/A_-XOO/B-<?#W4O$?V^S9= E
M\02:AIUQX9N;SR);R2>UFL79C&]/ECYK1OHW9)=M-7HG:V_DQ+$8E2C&RE+V
ME2'\.I&,8_6\-2A*:>LFJ%:55-.*:CK:SD_W3^$OQB^%WQW\$:;\1_@_XY\/
M_$+P1JTU[:V7B+PW>K>637NFW4MCJ6GW*%8[FPU/3KR&6VO]-OX+:_LIT:.Y
MMXFP#Z57YY?L$_#WQA\/?$'[<*>)_".M>$M.\8?MO?%7QMX,75=(GTFS\0^%
M-:\*?#T6WB;0%EAAAO='U75+;5-FHV>^WN[VWO6,C3K,3^AM0TD]-59:^J3.
MZC.52G&4X\LM5)6:5XR<;I-MI.UUJ[)VNPHHHI&H4444 %%%% !1110 5^7?
M_!8AE'["GQ(4GYF\1_#HJ,$D@>--)!P!U.748')R.*_42O/?BA\*O 'QG\'Z
MCX!^)OANR\6^#]5DL9M0T+43,+2YETZ]@U"RD9K>2&=7@O+:"9#'*GS1@'*D
M@]>7XB&$QV$Q4XRE##XFC6E&%N:4:=2,VHW:5VEI=I>:W/K. \_PW"O&W"7$
MV-HU\1@^'^(\FSC%4,,J;Q-;#Y=CZ&+K4J"JSITG6G3I2C352I"'.US2C&[6
MSX);=X2\,'.0?#>A,".A!TRVR01[UU-5K2T@L;>&TMD$=O;Q)#!$  L4,2A(
MXD  PD:*JJ.P4?6K-<TGS2DUI>3=O5W/EZLU4JU:B7*JE2<TGNE.3DDVM&TF
MDVM[:!1114F84444 %%%% !1110 4444 %?.7Q2_9"_9A^-OB9/&?Q<^!?PW
M^(GBN/3;?2$\0>*_#=EJVJ+I=I)++:V NKE6D%M!)/.\46=J-+(5 +MGZ-HK
MJP>.QN7UOK& QF*P-?DE3]O@\15PU;DE9RA[2C.$^232<H\UG976B,,3A<+C
M*?L<7AJ&*H\RE[+$T:=>GS1O:7)5C*/,KNSM=7=GJ?%?_#N3]A'_ *-0^"/_
M (0^E?\ QNC_ (=R?L(_]&H?!'_PA]*_^-U]J45ZG^M7$_\ T4>??^'C,/\
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MY1=EJMNCZVOTULO/H[B_KI_7]=S]T*IR1;!][.<CIC''U-?A]_P]I_:K[?\
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M^U5W_P""2'[0C?[WQK^&>3]6_P"$8S_GFD/_  5B_:G.?^-1O[0@)&./C?\
M#4?E_P 4L2/\>:+IKM\I7Z7W6W7Y.V@;'ZR_\*+^#0F%PGPS\(B56W*QTF!B
M&[GH.2<'UXZYYKT+2O#'AS18TM])T32=,@4_*MI801X/M\I'8<@ C&<FOQ6'
M_!6#]JD=/^"2'[0P^OQN^&DGY;O"RX_#.:<O_!6+]JH'G_@DA^T+_P"'N^&C
M<_\  _"[ ?@ ?>A..J=W>UM)*WSY?/\ #T#I^E_3^O\ AC]RA:P_QQQ2+Q@-
M$I!7T()93D>V/05Q/BSX>>!_&-M+I_B;PIH6LVLBE6BO=.MW!5B6V\*HXW8R
M5Z=:_'$?\%:/VJP,?\.D/VA>./\ DM_PT'Z#PM@?A4;?\%9?VJF))_X)'_M#
M ^H^.'PU[=#_ ,BM0G&^NJ])>7DN_P"#[ ?HJG[&7[,=M<RW:_!OP:9I'=V\
MS358$GDG;O"C))X &.:T+K]D']F;4(0+GX,>") J[ #I,? QG ((],'U]J_-
M-O\ @J]^U4QR?^"2/[0QYS\WQO\ ALWZ?\(PH'Z]^:5?^"K_ .U4,Y_X)(_M
M!X(Q_P EJ^&?\O\ A%\?Y]ZF_K]S_P ORUW\QZ_T_3_@?TC]/?#'[*7[._A2
MZ6]T#X1^"]-NU*/'/!I,>^,KCD%V;J..-H'4#M7O.GZ)HVGHMO8Z586D(^5(
M[>U@B"*"2J@HBL0O09;_  K\21_P5?\ VJ@V1_P23_:& Y^[\;OAL#C\?#)
M^@ ]JF'_  5D_:J Q_PZ2_:()]3\;OAF&Z_WAX6W#'U]NE5%QU36_6STO;RM
MUOWT=Q?UT_K^NY^U^I>']#U!9(-0TG3[V&9&66*XM8G1E?Y77;M PP4 YW'
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MYK\]V_X*O_M5L<_\.DOVAOQ^-_PW)Z8Z_P#",C^5-_X>N_M5'K_P21_:$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*#_OE*/^&4/"G_/E!_WRE?8=%%UV73]/+R?WL+/N^GZ>?D_O9\>?\,H>%/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>ny20077915x1_charts04x2.jpg
<TEXT>
begin 644 ny20077915x1_charts04x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**^:-0_; _9VTK]I?1/V/M0^(UG;?M%>(O"4GCG2/ARVD^('N;KPS%:W]ZU^
M=<CTI_#4$QL]+U"ZCT^?6(]1F@M9)(K5TVEOI<<C/KZ]?QIM-6NK75UZ$1J0
MGS*$XSY).$^62ERS23<96;M))IM/5)K0****184444 %%%% !1110 445Y3\
M</C=\,?V<?A5XR^-GQE\3Q>#?AGX L+74O%?B6:QU/4TTRTO=3L=&M&73M%L
MM1U6]EN=4U*QLK>VL+&YN)9[F-$B.20"E*,(RG.2C&*<I2DU&,8Q5W*3=DDD
MFVVTDE=GJU%<#\+/B?X&^-7PZ\&_%CX9Z]%XG\ ?$#0+#Q/X2\006U[91:MH
MFI1":SO%L]2MK/4+4R(2'M[VTMKF%U:.:&-U*COJ 34DI1:::336J::NFGU3
M6J"BBOC_ /9=_;@^!_[7GBK]H#P=\(I_%,FM?LU_$3_A67Q(3Q'H#Z+;KXA,
M^MVT<VA3FYN4U33)IO#VJ+'<_P"CR@0QO);1I/$7+;^6Y,JE.,Z=.4XQG5YE
M3@VE*?)'FERK=\L=7;9:GV!11106%%?-4_[7W[.UM^TU:?L=S_$>RC_:,OO!
M;_$"U^')TGQ US+X51+F4WW]MKI3>&TN#;VES=)IDFKKJ;VL37"6AB*L?I6@
MF,XSYN649<DG"5FGRR5KQ=MI*ZNGKJ@HHHH*"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHK\Z_VC/^"KW[!G[)_P 5;_X)?'?X
MX+X-^)VEZ/I&O:AX8M_ /Q+\43VFEZ[;+>Z5<S7GA+P?KFGJ;JU>.X\K[698
MHI$:9(]R@M)O1*[,JU>CAX>TKU:=&%U'GJSC"/,[V7-)I7=G97N['Z*45\A>
M!?V]/V1OB;^S]XU_:C\ ?&[PKXM^!_PXTO5=7\>>,=&35+J;PC;:)8C4M2@U
M_P -?V>OBO3-3@LF2=-(NM$CU2Y62,6MI.9(PVC^SW^VY^S!^U1\)/%/QR^
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M3WVO>#;CPKJ?BI=$6\6%))I[J?5AI2:@L:,WV1;O:!*?D#]ES_@G!X#^ O[
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MZ_3>MUK7AG4M7U*QF\':Y=?:=0NHM4BLM5N]-U#4]0N=-EMHKN6V'3_M1?\
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M#\$=I/?R&'4&2.-!\7P_\$&?%VF_#C6_V7?#_P#P4$^-VB?L.>(/%MQXCO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $%US;3_ /7*3_T$U\"_\$V3_P 8\3#T^(/C$#Z"
MXM*^^KK_ (]I_P#KD_\ Z":^ _\ @FP2?V>+C/;XA^,Q^'VBSKZ7 _\ )*<0
M>6:\/?C2SO\ R/SW.5_QLO@1VVX9X^5_7$\%_P"3/T#HHHKYH_0@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** (6MK=YDN&@B:>,$1S-&C2QAAM8)(070,/O!2 >
M^:FHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@"&Y&;>?_KC(?R0G^E? 7_!-CG]GFX_[*'XQ_2>R%??ET,VUP/6&3_T!
MJ^ /^":A_P",=IQZ?$3QD/RN+/FOI<#_ ,DKQ!_V->'?_36>'P6;K_C8W!#[
M<.\=+[\1P?\ Y(_0:BBBOFC[T**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3_7]?U^E_P!RJ***8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YN_P#!5;X%_LV_%_\
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MZFTEO+U_1#>T/\$?R"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M?X/>!]7^R>!7\>:UJJZ+#I6N^/)O^$7\.QV.HN-L&L7>JZC;P:2>/].:$DJ
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M[.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+GFVN!_TPE_\
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MZ=[JW71ZVT33VOK]W^3:M9W\VM+N]U;NUKWTL]+']6=%%%,1^67QY_Y2U?\
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M3V->%6=*4*MY.G.\:D(K1117SY]\%%%% !1110 4444 %%%% !1110 4444
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M:[_:A^'?P$U+Q-X1^/?Q#\-? CP)X>TY_@KX>U7X?_";Q#XLN?A3I/A'1/\
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M&M-+^#?Q-\<6%U9ZKX1\'Z#J]O=0:WX1TT_)>FWFM7N()H9%D!'[O $  G)
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M,\?C:&.Q&)BJE2G@8JM1QF,4:6'P:I05-NDU4E5FU.=2<V4445\P?IH4444
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MQ!1110 4444 %%%% !7\YWQU_P"3P_VN_P#LJ/@/_P!9N^!=?T8U_.=\=?\
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M\:6=?Y'SF-5^)\A?;*\_U]<1D7YV_#[_ -$****^:/HPHHHH **** "BBB@
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MWOR _?"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWJV]V^[/Z7244HQ248I))*R22LDET26B04444#"BBB@ HHHH **** "BBB@
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MN))+J_N#R(C*RPVT6V"T@MK=(XEZ^.-(E5(T5$4!555"JJJ,*H"@ *HX4
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M_P#!1_XJ_$7]IS]G/]FN]_:U_8$^-GAI[/5O"LF@? W]EKX\^!_BAJ6E>#O
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M% @HHHH **** "BBB@ HHHH **** "BBB@""Z_X];G_KA-_Z+:OSQ_X)@?\
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M_!=S_LZSX'C_ ,Q!=U^^%?@?_P $J/\ E)!_P7=_[.L^!_\ ZJ"[I/XH_/\
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MR/\ U<'[+%?J?7Y8?%#_ )3)_LA?]F&?MD?^K@_98K]3Z "OYFV_Y+!^U?\
M]G:?'#_T^6=?TR5_,VW_ "6#]J__ +.T^.'_ *?+.EU7H_SB-;2]/U1N4444
MQ!1110!]:?\ !-#_ ).(_;!_[)?^R1_Z>OVHZ_92OQK_ .":'_)Q'[8/_9+_
M -DC_P!/7[4=?LI0-[_*/Y(****!!1110 4444 %%%% !1110 4444 %%%%
M$%T,VTX]89!_XZ:_._\ X)?'/[-5S_V4SQL/REL!7Z(W(S;S_P#7&0_DA/\
M2OSL_P""7A!_9IN><X^)GC8$^XEL,U]'@O\ DE\_7_4SR#_TWG)YU>-\RP4_
MY</C%_X%4P?R^S_6I^C-%%%?.'HA1110 4444 %%%% !1110 4444 %%%% !
M5#5M032=+U+59+:\O$TW3[S4'M-/@:ZO[I+.WDN6MK&V4JUQ>3B,Q6T"D--,
MR1@@MFK](>A[\'W_ $[T ?QE?M<_MA_\-(?&?5_B7X=U+_@Y&_9LTRXTK2M!
M'PQ_9]^"5EX9^&EO/HD4MK<:UIVE:AJ%]=1WNLEA<:C.]P?M$H615C!"+^_O
M_!(?PW\)_"G[$O@K1_@[X&_:9\#>&QXN^(&HZU#^U[H%QX<^/GBGQOK'B:\U
M7Q?XX\;6,TTZ2S>)]6O);VSO+5DM9[58]D2.DK/^37_!57XQ6&A_MZW_ (#_
M &TOVM/VS/V-?V1M-_9^\,^)?V9]=_90E\<>'-$^*7QBGU;7O^%F-XY\6^!O
M#NN7VH^+/!J0>%E\+^$=0":>+2^^VK+9OJ$PU#]9?^"/_P 1/CW\4OV#OA3X
MP_:'U#QOK_BF\U/QS:>#/&/Q.T1O#?Q-\>_"#3/&&L:?\*?&_P 0M#<"6P\6
M^)/!UMIM_J33@W.HH]OJT\D\FH&XEE;O_+;9:ZZ7MIY:W&]E;9J^[U34>_GV
M_1'Z<T4450@HHHH *_ __@E1_P I(/\ @N[_ -G6? __ -5!=U^^%?@?_P $
MJ/\ E)!_P7=_[.L^!_\ ZJ"[J7\4?^WOR _?"BBBJ **** "BBB@ HHHH **
M** "BBB@ HHI&. 3C..U "T5^<W[5_\ P5!_9K_8W\96W@+XNCQHWB>\L+75
MK73_  SH^GZR\FDW;B*/49LZQ:M96[7 EMX1?);2W4L$WV6.9$+5Z]\'/VW?
M@'\<OAQI?Q.\&>(;LZ%K]W?:?H.E7-HMQXPUB]TQO*U*TLO!^CSZIK[W-A<$
MP7<#62R0$&:0+;E9F]:>19S3P5#,99;C%@<3*,,/BE1G*C6E./-&-.<4U)N*
M<K+HFWLSY:AQOPAB<YQW#U#B/**F>9;&<LPRN.,I?7,'&G.G3J/$47)2I*,Z
MM*#YK6G5I1WJ04OKNJ.HZC9Z5:RWU_<V]G9P*7N+J[N(;6VMXE&7EGGG=(XH
MT4%F=F"@#)(KQ;_A(OBYXT9QX6\)V'P[T28NH\1?$+9J/B"6%F(,MAX'T:]5
M+9Y@5,!\0^(+"[B8D7FB#R_(EOVGP3\/WES!J?C_ %/6?BEJT$BSP2^-KB*\
MT*PN5)*SZ3X+LK>R\'Z;+'N98KN/17U0(Q2349%50./V%.GKB*RB_P#GW14:
MU3II)J4:4.SO4<X[^S>QZSQM>NU' X.I4BTF\3BG+!X9+KR*=.>+JRV<7'"J
MA-7MB$U8_.?_ (*J>-_&_P 6_P!BGXM>%?V:;'QKXRU"5=%NO%>N^!M+U)M'
MN/ =CJ<-SXML=/\ $:-9PZ[Y^GH!>:?X:?69K[3Q=V\MN]HUT5_F)_X)/^ /
MBUXE_;I^#$O@#1]8ET[PWXK@U/XBWD]C-/H&F^";&.:3Q!%XF$RR6>VZB@:V
MT.*[=I!X@.GW=E&E[;I/%_>=XG\&>&/&6B_\(]XHT+3-;T8RVT[:;?VR2V9E
MLR'MG$)!"^2X!CQ]T #D<'RGP=^RQ^SI\/=6&O>!?@I\-O!VN'48]7EU3PQX
M4TG1+V?5(F+IJ%S<:=:V\EW>*Y+_ &BZ,LK,26?))K[[A_CG#9'PWFV1QR^<
MZF/>)=*NU3J13Q>&AAIO$WG3=50C!3I*$*?LW=/VD6?@W'W@?F'&_B1PAQU5
MXBA0H\/O+EC,#!5Z#JT\LS"KF-".6I0Q*PDJM2M.GC*E6M7E7@TX>P<4CWN)
M=L:KUP,=_4^O/ZGZGJ7TU%V*%],_J2<=!TSCU]23S3J_-S^C HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /(?CK!\%]:^&'B[P)\?M6\%Z?\,/B;H&M_#WQ18^.
MO$&F>'-%\0Z/XHTF\TW5M"-[J=[81M+>Z7->*$MYUN417GB*F+>OY2?L>_\
M!/+]@/X'?'KP%\1O ?[67Q(_:+\??#G2]>T+]G_P%\6_VL;?XT:'\'=(UK1)
M-&U:T^%W@Q]3D:TF'AF&;2DNY(;ZZM-)CF6)T\GSD^H_^"I'[-/P3_:H_9%^
M)7PS^+D'P<3Q%/X9\83? O7/C=J]AHWA#PM\:[OP9X@TGP9XA^U:C?V-O]KT
MZXU"24!A>"*$2736-P+<)7\\_P#P32_9'T*/]MG]C[Q?X._8*_99_8SO?V;]
M+\<P_$[XC^%_VO? GQZ\3_'G4-8^&6K>$K:S\"^#/#WBS6M7#OKU_<>*_P#A
M)=42>[TS3;>:S:\,;_999>ZT3^^^ZOTZ>O;MK25TVKWUUTMI;3J]5Z=N[/[+
MJ***HD_+/X\*3_P5I_X)]D#A?V<?VVB3Z R_ Q1],E@.?7'7%?J*ES;NJ.LT
M121WCC82)B1XRP=4.[YF4H^5'(V,<8!-?ES\>0#_ ,%:?^"?0(!!_9Q_;;!!
M&007^!V1SZU]Q:7^SG\$-%T'P!X7TOX<>';+0/A9XYO/B5\/M+A@G%MX5\=Z
MA<>(+N\\3:6&G9H]2GN?%/B"9I)&D19-3G9$4B,HEN_7]$-_##_!$]E-Q H=
MFFB41L$D)D0"-V*!4<D_(Q,B *V"2Z\?,,N,L0+*9(PR()'4NH*QG=B1AG*H
M=K88X4[6YX./&M7_ &=?@CK^A_$CPUK'PX\.ZAH7Q?\ %EAXZ^)>F7$$SVWC
M'Q;I9\/FPUW5T\\&6]MCX5\/F-HC$F[2[=F0MYA?^<OXK?"+X9_%;]I3]KSQ
M-\2_!>A^.]?@^/WBOP+:ZMXI@DUF]LO!^@^&?"8T3PY837<CMI^DZ2-0O?[/
ML[01Q6QN9/*"@YI];>OX6_S!+1N^UNG>WGZ]NA^GO_!3']IS]I/X M\)+/X%
M)H7A[0?%S:]-XA^(NNZ4^MV@U[2[K05\,> +. ^&O%5FMYXMBU#49HK;^SH]
M;\0)I[:1X5OK7671FP?B'_P4'_:B^ G[-7A;X]_'+]D7P%I%WK7AG2+H^"=&
M_:&UT^.-7\6W7AJY\07WA?2O!H^ >IW&G:K;VNF:Q>W]CJ6L2VWARRTZ_?6M
M82+3[FY'Y$^+OV=OA/X;M=#O_ G[,'P\\;ZGIXGTM+![S0O"@T_3)[:,RW3W
M6KQ3P:F\CVMK;A'4W,+!I4F"LY/PK^U/\)_#MK\,+3PG!^QAX9\%>*?%^O:E
MI/PU\4^'?BAX1M;SP]XXN_#_ (AU)M3N[ZVT74I6TI-/&J'4-.F@N(M2@E.G
MP0I*]O)"M?3^EW7K_6U+ET5KZZW5K[=I72^_R/Z=I?\ @HC\;7_9RU#]I[3?
MV8?AWJOP^TR2WTZYTR#]I;5[+QE;^++OQ+9^"[?P)J7AW5OV>K"71_%:^+]2
MT[P]>V6JS6MK8W=R;F:[%@B7;_3W['7[6%Y^T_H'CP>+?AG/\&?B1\-?$&GZ
M/XO^'MQXPT_QY'9:9KVDQZWX5\06OBK2]*T;3[VVUVQ^VAK:.R2?3[G3KF"Y
M)8H3_(5\#OA%\/O&OPDN]+T_]A7PQKUE)KVO>'_&NH^)?BMX7F\0:MXT\/:C
M_9WB'55UR2PTZ]6635+%+BQO=+73(K>.*U-K!:2VRI']9?"O]D3X"Z5X>GFU
MC]FWP;X2US43/8ZI9:QKS_$G5;NQA>86EQ>>*[VXNY[US'=31VJ/.\MA;A;6
M-HX8H$471WNK?UT7]=.PU%75K/[W;3?WO7;7KHM_["!-"3&!+&3,"T.)$/F@
M*')CP<N A#DID!2&/!!IHN;=@I6>%@TC0@B6,@RHS(T0.[F175D9!EE=64@$
M''\W7[$/P:^%7PZ_;T_9_/@3P%X;\*&#X,_M%HDFBV*V<L@L8_A'869N70@W
M,EM9ZE?0123F1E6[G(.Z0M7[QVO[.WP2LM \.^%K7X<^'8?#_A+XES?&/PWI
M2P3_ &71_B=<:WJWB.;QE9J9RR:N^MZ[JVH>86:$3WTVV$)M57W\O\D_U):M
M;7=7VM^K[?<_+7V1KB!!(6FB40G$Q:1 (OE5_P!Z2P$?R,K?/CY64]&&?YT_
MCK_R>'^UW_V5'P)_ZS?\"Z_<W6_V>_@OXCTWXKZ/KGP\\/ZEIGQROM.U/XLV
M5S!*\/CF^TG3-*T?3KG6@)@97M--T/2K:$0F%56T1]OFO*[_ (7?&^&*W_:]
M_:VMX$6*&#XF^ (88T&$CBB_9L^!21HH[*B*%4=@!7X-]([_ )-KB/\ L<Y7
M_P"E5SQ\\_Y%\_\ K[0_].P_X/X/R.4HHHK_ #X/C@HHHH Z+X*?\G??L:=?
M^2O?$#L3S_PS7\>,#@'DX./6OZ-_M5OMW>?%M$I@+"1"//#;##P?]:'^0Q_?
M#_*1NXK^<?X*@']K[]C/(!Q\7_'[#/8C]FOX\8(_.OW5_P"&=/@E_8!\+GX<
M^'CH!^*I^.!TLPW!MO\ A;!\3GQG_P )P!]HWC6O^$G)U<2!O(%Q\@@\@"(?
MZ$?1R_Y-KA/^QMFO_IVE?]+?,^PR._\ 9\.WM:EONA<]D:X@42EI8U$',Q:1
M%$65WCS-Q&P%/G!; *G<"1S4H((!!!!&00<@CU!'!%>0ZU\ O@[XB7XNIK7@
M#0=17X]:=I>D_%\3Q3Y\>Z=HNAMX:TJTUQDG1Y(K'0W;3H/(:!D@9N=Y+'U6
MRLK73K*TT^QA2VLK"UM[*SMXQB.WM;6)(+>&,=DBB1$0=E4"OW@]C^OR^_KV
MZ%JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q_$6AZ?XG\/ZYX:
MU:-Y=+\0Z/J>A:E%'*\,DMAJ]E/I]Y''-&1)$[V]Q(J2(0Z,0RG<!7X3?"+_
M ()%?M+^$?$W[.7P[^*?[?.I_$[]B_\ 9$^)_@3XI_ OX&0_!GPAX8\<_P!I
M?":^GU'X5^'_ !K\4K&YEU35=$\&SFRB)MX1-K-E8+;7$=FD[^7^JW[8'[.^
MF?M2? 3QE\(-4\3_ !'\)C5EL-9T[5/A5\0=8^&'B^76O#=Y%K.C:7%XRT(_
MVCINE:KJ5I;6&LK&KI-83RJZG K^//\ 8_\ @=\4X_C1^PUX2T?P)_P67MOV
MKOAW^T?\*=<_:R_X7MXI^(-C^R-IO@?PEXGCU/XG7G_"7:G?C0-?\)QV^G//
MX"M+6]OYO&MNL&DWIU-]4$<R>ZW^7JEWU[V[)OH&MGJNG36RMW[^7W:']<O_
M  4'\<_$WX9?L+?M??$/X,OJ$/Q6\$_LX?&+Q/\ #ZYTBVDN]5LO%FC>!-;O
MM&U#3;>([Y;[3[N%+RT"ABMQ!'( =FUORO\ ^"2'QH\+:/\ $G]J'P)H/[3V
MO_&+]G#3?#G[&5[\//B'\5OC!=_$F,?M ?&7X8:AJ/Q-\#>'OB!XNUG4KBYU
MS7];M=#UJ[^']M?S2Z-KNK7%G9Z78S336:_T'R1QS1O%*B2Q2HT<D<BAXY(W
M!5T=&!5T=25=6!5E)5@02*\RTWX(?!G1M#M?#.C_  F^&VE>'+'Q7!X[LM!T
MWP/X:L=&M/&UM=_;[;Q?;:;;:;%9P>)[>] NX-=BA74XKD":.Z60!J?;^KZ,
M%I?S_P"!_E^+/Y6O ?Q<1_B[^WSX^_9D_;G^)?CGP)\'_P!EW]K/PU\2OB#\
M<?CYJGBBU^+W[16H2RZKH'C+X1_!7P[)KU]X2^&O[,M@)+!_B1\/? ^GZ9?1
M"#2-*BO["+4+T_4O_!*+X\?%/PI\)/VH?AW\*_AOI?[8?Q?^"H_9PU!_&7PZ
M_;#\;?$3X5_'27XH>$EN]4ET/XJ_M 3W^C^!/&O@S3;+4/$'CWPIID%AIDLV
MHZ3;6NFZ=<W=M!%^[_A']F3]G#P!KL_B?P+\ _@SX-\275CJ&F76O^%OAGX,
MT#6;G3=6C\K5-/N-3TO1K6\FLM2B_=W]K),T%W&2EPDBDBO0/!'P\\ _#31V
M\/?#GP3X3\!: ]Y<ZB^B>#/#VD^&-(?4+V0RWE\VG:+:65FUW=2DR7-RT)FG
M?YI'8XI6??OKZ]$M?+[O-E<RMJD]O32VZ5O^!TV1^)7P]^*7[17Q._X+ ?LV
M7/[0O[+,O[,.H:3^PU^UK;^&=.E^-OP^^,Y\76EU\6?V89=2O5NO =M;Q:$-
M)FAM(6@U%3)??VBCVV%MI]W[S5^6'Q0_Y3)?LA#_ *L,_;)/Y_&#]EC/\N/3
MMU-?J?0K_P!?J2%?S-M_R6#]J_\ [.T^.'_I\LZ_IDK^9MO^2P?M7_\ 9VGQ
MP_\ 3Y9T=5Z/\XC6TO3]4;E%%%,04444 ?6G_!-#_DXC]L'_ +)?^R1_Z>OV
MHZ_92OQK_P"":'_)Q'[8/_9+_P!DC_T]?M1U^RE WO\ */Y(****!!1110 4
M444 %%%% !1110 4444 %%%% $-Q_P >\_\ UQE_] :OSH_X)<?\FS3GU^)7
MC7\_.L<G\>*_1:Y_X]Y_^N4GZJ:_.?\ X):G/[,EP<Y_XN9XW ^GG6&*^CP7
M_),9_P#]C/(/_3><G)4_WS#NW_+G$*_36>'_ $/T?HHHKYPZPHHHH **** "
MBBB@ HHHH **** "BBB@ K/U>PBU72M3TN::YMH=2T^]L);BSG:VN[>*\MI;
M>2:UN4R]O<Q)(9()T&Z*55D7E16A6?J^EVFMZ5J>BWXE:QU?3[W2[P0S26\Q
MM+^VEM+@13Q,LL$IAE<1S1LLD;X=&#*#0!_(O^U/^TW\4?\ @D7?2:=\//\
M@JY\'/VR?#UEJ-S=:?\ L6_M>VU[\6_V@%EA"S6^C>%/B=\(;/Q'XYL]4+1W
M=GHDOC_1M)T&UDGAMW>5H=X_HD_X)]_M4>,OVSOV7/ /[0'C[X ^._V:?$WB
MXZG#>?"[XA6]_;ZS:Q:9=M;6VOZ>=4T?0=0N/#OB*+&HZ'=7.EV[36;AD:X0
M+<2^%?L@_L;_ /!+S]EKXP^-?@G^S1\)OA+I/[1GPZ\-^&?B!\0KJ]TR?QA\
M9-)T'Q]=:E%X=U_6?'OBJ+5=:AC\07FB:C(EIIVLP1I+$;B2PMDNX&G_ %(
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M,W[4OAOPYXU^)L?Q%UG6-%N_%CFUTOQ5%HGA6?PWJ>CQZ4VGQWJ13WSW#O\
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M<<42!1A(HE5(XU'\**J@!1A>O')S^"W_  2H_P"4C_\ P7<'8?M5_ Y0 ,
M?!^[   [ <"A_%'YVT\M=;_H1I;;7UT_(_?"BBBJ **** "BBB@ HHHH ***
M* "BN?\ %?B*Q\)>&=?\4:FZQZ=X>T;4];OG:6&W5;32K*>_N29[AXK>(""W
MD/F32)$N-SLJ@D?RWW'_  <:^(E^+ ^Q_L_Z7-\&!?BU-K+X@N5^(TFF[D1M
M3^U!?[ CU$#S)$T@6\ML1MC?5@Q::/Z'(N%L[XCCBY91A%B(X*$98B4JU&C%
M.:DZ=.#JSCSU)J$W&,5:T7S-75_S[CCQ1X)\.9Y73XNS=Y;/.*M6G@80P>,Q
M<IPH.E'$5ZGU2A65&A0=>BJDZCB[U%R1GK;^J\D*,DX' _,XKSGQ?\3_  MX
M3N(M&DGNM;\5WD7FZ=X-\-VK:UXIO8STN1I=LQ:QT_.%?6-5DL-'MV*_:;^(
M$9\T\*ZK\0OCIX7\.^+[;5#\-/AUXMT72O$.DVFAWFFZSX[UW1-:LK?4;*2[
M\00"[T3PO%/:W"9CT'^U]3",)(-:L+@;4]A\(^ O"?@>SFL_#>BVFG&[E^TZ
MC>CS+G5=7N\DF^UK5[IY]3UB_<DF2]U&[NKF1B2TK$DGRIT:>&E*.(ESUH-Q
ME0I--0G%V<:M;6&C5I1HJI?6/M*<MOK*>+Q./A3J8""HX6K3C4AC<5!\U2G-
M1E">'P=X5'&47I/%3P_*VIJA7AH_Y"?^"L7[$W[5OQ5_:K\1?&KP5\$_'GC'
M2?'>E>&4FTOPIH>L^*Y_"5UI.A:?HL>D:I?:?IITN_-S%:QW[7>@76IZ58S7
M%WITUU));K/+^QG_  13_9:\=?LV?LX>*H_BEX?U/PUX^\=^.7UW4?#NNZ'>
M:9J>@Z7:Z/I^F:;83W=_;Q2:BURMO+J%Q]E>6RMIKEK<,;E+@G]F2B$Y*@GC
MKG'!R..G! QQQCBE"@9P,9.3]?\ /I7U>9<=9CF?#>%X:J87#4<-A8X:FL12
ME5=:I1PB_<4I1G.4(QCIS."4IN,;NW,G^3\->!O#O#7B-FOB30S',\7FN:3S
M&M+!XMT'A,-B<UDI8S$T94J=.JZE1NI:,VZ--5JBITX)4U30*HZ*HXQP ./3
M@=*=117Q!^VA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^??_!3?
MX1_LR_$7]D/XL^-OVIO@'I_[1O@;]GWP7XU^.FE_#F]N-:M)]1U_P-X.UR]A
MCT^YT*_T^\@N;RS:[L&F:26"WANI;B2%O)!7^;?_ ()C?#CX.?!;]NC]D77-
M=_9@_P""9LFI_M*Z7X\U_P""'B#]B?XT_$[XC_%W]G:[T_X9:AXM>'XHZ-XJ
M\5:QHM_H][X9NM0\,7_B2TM%AL=;G"1W0>6&VF_HR_;_ /VJ+_\ 9G\0_L::
M9>ZM\/-!^&/Q\_:=L/@S\:M7^)?]G6_AZR^&^K?#GQYKFHLVK:SJ.G:/HLDV
MH:)I\$E[J;7%F]M+-:2P,+G(^*?^"1.H_P#!-3Q&/$_Q>^#'PM_8P^!O[2_C
M;XN_'OX?)X>^$GB7PDWCGQ#X0\!?$OQ7X=T35?#^AW>N7GB&QTWQ;X6\/67B
M>\L_#%A9:%>6\K7EG VEK RR[.6EK]=-=+>7RWZ^0U>SWMKL^NF_EK^A^^%%
M>7_&KXR_#C]GGX4>/?C;\7?$EMX1^&OPT\-ZAXJ\7^(;J&[NET_2-.CWRM#9
M6$%U?ZA>W#F.UT_3K"VN;[4+V>WL[2"6XFC1O)/V5/VQ?A%^U_X>\9:Q\-(/
M'7AS7/AQXGB\'?$?X<?%7P1K7PX^)G@'Q!=Z5::]I5IXI\(:]&EY91:[H&H6
M&N:)>0275EJ.FW220W+31W,$%"MHWT6C_K^NG<^7?CS_ ,I:O^"?7_9N7[;7
M_H?P.K]3:_+'X\$?\/:O^"?7(_Y-R_;:[CN_P-Q^?;UK]3J2WEZ_HAO:'^"(
M5_-3J_\ R7?]K_\ [.J^(7_J-^!J_I6K^:G5_P#DN_[7_P#V=5\0?_4;\#?X
M&CJO1_G$:^&7_;OYE[W[^N.GT]/J*Y7QIX'\(_$70+GPMXY\/:;XG\/W<D$T
MVF:I )HA<6K^9:W<$@*36M[:R$O:WEM+%<V[,QBE3<V>JH) ZD#Z_C_@?R/I
M3),/PSX8\.^"]"TWPQX2T73O#OA[2;?[-INCZ3;1VEC9PEWD=8XH@ 6EFDDG
MFE<M+/-+)-,[RR.[;E'^?R.#^1X^M% 'H_[*G_)^7P%_[(Y^TM_Z/^"M?T U
M_/[^RH1_PWE\!#D8/P<_:6 .1R3/\%, >N<C\QZU_0%26\O7]$5+[/\ A7ZA
M7\YWQU_Y/#_:[_[*CX#_ /6;O@77]&-?SF_'8C_AL/\ :[Y'/Q1\"XY'\/[-
M_P "L_EN7/IN&>HK\'^D=_R;7$/HLYRJ[[7E72^]Z'C9Y_R+Y_\ 7VA_Z=@<
MC129'J/S%&1ZC\Q7^?!\=9]G_7_#K[Q:*3(]1^=&1ZC\Q0%GV?\ 7_#K[SH_
M@I_R=]^QI_V5[X@?^LU_'>OZ/J_G!^"G_)WW[&GM\7OB 3[ _LU_'?!/U[5_
M1]7^A'T<O^3:X3_L;9M_Z=HGV.1_\B^'_7VK^4 HHH_IUK]X/7"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ^8/VQ/@=X6_:$^ 'C7X?>-?B3\7
M?A-X7BCL_%^L^-O@=XTU+P#\1--LO!=ROB2XBTSQ%I%O=7\=I=PZ?)!J5C!;
MRMJ%H\EJJAW4C^2#]DCP[XP\.?&_]C+]I/QYHO\ P49\.?L=?'3]H?X4>&OV
M>_BIXO\ ^"D&F?%1_%'B3Q/XK/\ PJ>/XO\ P"L=&@U%_!'Q'U.QL-,\2:+!
M>RS:'I.KWRZN\L-O,3_5/^WE^TQKG[*WPB\">/-"\.^'?$S^,_VD?V;/@=J]
MAXGN;FVTRU\-_''XR>$OAEXBU=7MGCW7ND:1XCNK^Q2Y;[$US!&+U'M?-4_E
MY^P/^PS_ ,$U];_:L_:*^,OP[^ R>!O'W[*G[67C'X7?#W2]1^,GB;Q=\.8O
M%5OX8\*^)'^(WP[^&6J7T?AGPA?W4_C">TTFPT^UU.+1Y[7[1H\]K(8$MD]U
MM_37D_T_ :=D]?33TOZ;)_+2W7^AJBJFH:A8:387VJZK?6>F:7IEG<ZAJ6I:
MA<PV5AI]A90O<WE]?7ER\=O:6=I;QR3W-S/)'#!#&\LKHB,P\H^"_P"T+\"_
MVC/#VI>+?@+\7?AY\8?#.CZO<:!JVN_#KQ9HWBS3-,UJT59)]+O[G1[NZ2TO
M%ADCG6*<H9;>2.XA\R%U<L1[%17@'A7]JW]F;QSXI^)W@CP=\??A#XF\7?!6
MVOKWXN>'=%^('AF_U;X;V6F/+'JE]XRLX-2>70;'2Y8)H-4O=06&UTVXAEM[
MZ:WG1HQT'P7_ &@/@A^T9X6N/&WP'^+'P_\ B]X2M-6N]#N_$/P\\5:/XKTJ
MTUBRV-<Z9=7>CW=U%;7L4<L,IMYBDC0S13QJT,L<C 'P?\4/^4R?[(7_ &89
M^V1_ZN#]EBOU/K\L/BA_RF2_9"_[,,_;(_\ 5P?LL?XC\Z_4^@ K^9MO^2P?
MM7_]G:?'#_T^6=?TR5_,VQ ^,'[5V2!_QEI\<.O_ &'+.EU7H_SB-;2]/U1N
M44F1ZC\Q1D>H_.F(6BDR!U(_.C(]1^8H ^M?^":'_)Q'[8/_ &2_]DC_ -/7
M[4=?LI7XU_\ !-#_ ).(_;!_[)?^R1_Z>OVHZ_92@;W^4?R04@(/0Y_S_AR/
M4$$<$4-]UN<<'GICCK7\V&@_M)_M@>+X]=UY_P!JWXF:&D_CSXFZ=::+HG@C
M]GS^R=+TWP_\2/%GAW2M/L&UCX,:QJLD-II>DV<'F:AJ5]=RR1M+/<2R.QKX
M[C3CG(N L!A<RS^6+CAL7BU@J+PF'^LS]LZ52M[\>>'+#DI2]Z[]ZRMJ<F*Q
M='!QC.LY*,Y<JY8N3O9O5=K)_P"1^[_Q2_:7^ 7P3U73M#^+7Q9\%?#_ %?5
M]/.JZ9I_B;5XM.N;[35N9K-KRV20'S(%NH)H"X/$D9!'3/B6K?\ !2+]A[1Y
M88)?VC/ NI3.GVFZC\-C6_%;Z)I:LR2^(?$Z^&=(U4^%/"EJZLM]XM\2?V5X
M:L6&+S58"17\^/Q4_;H_;@\%^+?%&GZ5^UGXQGA\&)X1^S^!M8\)_LWV_P 1
M/BW)XKDACQ\-EE^#-O8A-/><V43O8ZO%<:K8ZA'J,FCV<;7,7C_QJUO]LOXO
M^)+#Q5K!^.^M:U?:##\-O%M_XCN?V1+>;_A5MQ>ZKJ>I6V@Q^$K#PY;VWBJV
MU#4YWTC5-234+>TCO]05H&5D ^ S/QSX8AET,1E,N;&XF%&I@Z>=NGE6%E"7
MU:M4=2K.M*M)K"5U.F\/1JT_;RIT*E2$U6C3X*F=8;V;=!2E5LG%5$X0:YDG
M>]FK14K-NS:Z[']$OQ4_X*A?LZ^'8_#&D_!/Q#X?_:,\=>+!J-]I_A7P%XQT
M*RMK+PYHL5C+K'B+5_$.I.=.L[*,ZIIEKIT,*W=SJ=W?Q-''%IUO?ZA9_;'P
M6^*_ASXY?"SP3\6?"<.H6V@^-]%BU>SL]5A2WU+3Y1+-9ZAIE]'%)-;F[TS4
MK6\T^>6UGN+.>6V::SN;BUDBGD_D5^(7B/\ ::^(ND?"[X<_%7PU^T+\0_@?
M\/-,OK2W\*-KO[,OA_Q)H^IZ;H.G^'? MQX=\0?":X^'7BW^S[727UW3-?M+
MKQ3]DO8[O2[B]@OH[&5'^M_@[\2_VQ/!_P +O OA:X_:>^(W@[_A'O#]II5O
MX4T#P;^SM/I/A?2[0[-&\/VUU??!+4;F^DT71OL.FWU_+J.H/?ZA:W5Z;N<2
ML[>=/Q\X4P>:8JOC,?5GD=7!8&.74,)@,/B<;#'^UQO]H2KUL-FV(E*C&E#"
M-1J8/#QIJI3<:U256<(S_;6'5:;E*:H\L5!>S3?M$_?NXROK=6O%1TNK6?-_
M4%GG'/Y''Y]/\^XHK\Y?^"<GQ5^+'Q.\)?'FU^+7Q%UCXFZE\/OCI!X.\.^(
M=?T;P;HNJIX<OO@?\&/'9T^[A\#>&O"FB7/V?7_&6O2VUR='CO/LLT-M/<3B
MW1Q^C5?M^3YKA,\RK+LYP#J/!9I@L-C\*ZL/9U7A\71A7HNI3O+DFZ<XN4;O
ME=U>Z/8IS52G"I'X:D8SCWY9*ZNNCMN@HHHKTBPHHHH **** (;G_CWG_P"N
M,GZ(U?G'_P $LCG]F.XX(Q\3O' &?03V&/3M[5^CEQ_Q[S_]<9?_ $!J_.'_
M ()8DG]F2Z!'3XG>.,>X\^Q_SQ7T6"_Y)G/E_P!3+(7]T,X7ZF<HWG3E;6/,
MD^U^5O[^7\%VT_22BBBOG30**** "BBB@ HHHH **** "BBB@ HHHH ***#T
M/^&?T')^@H _DG_X*SZ#HGP]_P""B-Y\4?@_^V1^W_X&_:4\9? +PA8>-?@I
M^P=^S?IGQDU3PO\ !7PUJ^JII_C#XDWQU?1K0:7J&O2:C=:3;:TU_J]L8[D:
M7%!972>;^YW_  2Y\36'C7]C3X;^,=*_:M^(/[9FG^)[WQ-JL'QH^*GAJR\'
M?$%Y3K=U9WW@GQ5X7L\/H>L>!]0M+K0;S3[T?:H);=ANDMS;NWY!?\%5OB9\
M'?V2/VU[WXU_#?\ X*K>#/V"?VCOC7\%_!?@[XO_  Z\8?L^^)/VC])\9^ _
M!6I^(U\!>.3I/A7PUXANO _B'2WUK5]/TU]5^RVNMVUN6@4K#=>=^H__  1]
MTG]G;2/V'_!,?[-'QTU7]I?P;J?C'XC>(O%_QRUKPMXC\$ZA\1?BSXE\5WVN
M_$C7I?"WBC2-$U+18I?$&H2Q6EDMD;6.TB@,-S=EGN9)^T_3OZ=+_>[+H/7E
MW;MW6O3=K32R5UKWW/U HHHJA!1110 5^!__  2H_P"4D'_!=W_LZSX'_P#J
MH+NOWPK\#_\ @E1_RD@_X+N_]G6? _\ ]5!=U+^*/_;WY ?OA1115 %%%% !
M1110 45^6O\ P4]_X**S_L#>"?!=QX>\%Z9XW\=?$BXUNU\.V>L:G<6&DZ1%
MH4>GR7>K:I;V4$E]?VI;48+6&WMIK0O=2('N(T#9^4/^"=7_  6%^(W[87BW
M4_@WXH^"^@_\+7MM!U#Q)H^J>%?$']A>$-1TW3Y[2&\&L6^ORZEJ6E"Q^VQ2
MO-I+^(KBYA5EATSSE(/T^'X/S[%9'/B&CA(/*Z?/*5:6(H4Y*E2J>RJU_9SG
M%JE3J^Y*4K-MIQC*-VOS3,/%S@3*^-J'A]C,VJQXGKJBH8.EE^/Q%-8C$T88
MG"X.5?#X>I3^M8C#U(5:5./-'EE&,YPJ3A"7[[LZ+G<P& 2?7 &3P.<X[=>1
MQR*\K\0_&#PII6I3^'M$_M#QUXNM]T<WA3P3;)K6I64QQL37+P2PZ)X81@&(
ME\2ZKI,;J&\HRLH6L)?AQXO\9N9?BEXPG?3I1N;P/X#DU+PUX;",/^/?5=<$
MR^)_$:@A@ZM>:)ITX(,NB@K'M]4\/>%O#OA/38-'\,Z-IN@Z7:C%O8:596UC
M:Q<DDK#;Q1IN8DEW(+N22S%B2?!Y</3^.3Q$_P"2DW3I)]I591YY6>DHTX14
MOLUD]3[GVF88G^%3A@:+2_>XE>UQ4D]^3"PDJ5*Z:<9UJ]249)QJ81VL>(^(
M?!7Q3^+V@ZOH'C76+3X:^#_$FEZCH]_X<\'"UUOQA=:9JMI/97$.K>+-5LY=
M'TQY+:=UN+31-#O"DK%;;Q \:">7^?B3_@W*/_"UA/!^T$J?!E[XW)AD\,R-
M\1X[ R*XTN.19?\ A'3<B,/&-98*@^5SHS,6CK^I2BO;R?BS/,A6*AE&*IX*
MEBX1C6I4\/0J0;ASJG.+KPJU?:TU.:C4E4E/EDXRE)6M\7Q=X4\$<=SRZKQ;
ME=7.J^5U9U<+7KYACJ-1*JZ;K4)1P>(P]'ZM7=*G*KAH4H46X)QA%N5^;\'>
M&-,\%>$O#/@[1H_*TCPIH.D^'-+C\N*(II^BV$&G6:F."*&!"+>VCW+##%$#
MGRXT3"CI***^=E*4Y2G.3E.4G*4GJY2D[RDWU;;;?F?H=.G"E3A2IQ4*=.$:
M=.$5:,(0BHQC%=%&*22[(****DL**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#PGX_\ [,7[/O[5/A72_ _[1?PC\%?&+PCHNMQ>)-*\/^.=
M)CUC3;#78+2ZL8M4MX)&41W:6=[=6X<'F*=U((->%?"+_@F/_P $_O@)\0M
M^*_P:_9*^"_PX^)'A5[N3P[XR\+^%(+#7='DO[&XTR\>QO!([0/<:?=W-G(R
MC)@GE3@-7W7119=@N^Y\"?\ !4']G#X@_M9?L+_'GX&?"EM+?XD>)M'\-ZUX
M+L-:O1IFE:[X@\!>-?#?CW3_  S?:HP:+2H?$LWAI=".I7"M;6#:@MW<K]GA
ME(^3OV4?V4/V@OBCKG_!0'XT_'*Q^+G[$VN?MF^/_@?=^$/#/PS^*/@:?XT?
M#GPW\#OAEX5\#R:Q-XL\,6WCOP-I>I>--3T2]WP6$^MS/X9N6@O6L[R9?*_:
MRBC^O+KK^+^_T#[GKIIM\+_.*9^/6I_\$>?#VM>/O"?Q2U?_ (* _P#!2O4?
MB)X%TCQ-H'@_QA=_M ^ Y-;\.Z)XR_LK_A*M+TNZ_P"%, 6]IKQT/23J*A#)
M/]@MU,@5 *[C_AV+K_\ TDO_ ."HO_B1?@,?R^"U?J;12M_5WY?Y+^FQ\S[_
M )=[_HC\LO\ AV)KQZ_\%+_^"HO_ (D7X$_^<MT/3M7CK_\ !$'X7R:KX@UM
M_P!N#_@HPVK>*]=N_$WB._\ ^%^>!EN-9U^_M[2UO=6OG3X.+Y]]=0V%G'-,
MP^9+>(;<KNK]KZ^*?''[9.F?#C]MKX7?L@^,O!,VC:5\9/@;\1/BSX!^,$_B
M&)=%U+Q'\*]1LG\:_#JZT)])C^Q7^G>$;Y?&,>KOKKQRZ?;7D3Z="(5N)"R_
M3?T_.R]1J4NC_+II^7^9\5?\.1OAG_T?'_P4;_\ #_\ @G_YSU?)'[>W_!+C
M1?V9_P!BW]J#]H'X>_MN?\% +GQO\'O@KX[^('A6V\2?'+PCJ&@3ZYX:T6YU
M'3H]8LK+X5Z9=WE@UQ$@GMX-0M)'3A)XSS7W;\)?^"S/[)WB7X0?#[XO?''Q
M%8?L[:?\8_$OQ$/PDT'Q)>:OXOU?Q)\)O!7CR\\!Z9\:/$G_  BWAF>V\!>"
M?$E]:I/_ &MXDEA\/Z2+F*&;Q%<XDE2'Q7_P5?\ V+W_ &@/VCOV//VD[WPG
MX-TCP3XA^#_PZL+[QG#>^.? OQBTKX[> ]+\2V=UKMK8^$]0\-^$/"37FNZ?
MX3-[XUU4Z!KE[?6Z1WJ_:/LP5HZ=-K:M;I6Z]4D-.5]KV>MDMDTG;TTV[>1Y
MCX5_X(L_#O6O#'AW6;O]N'_@HJMUJ^A:1JERMM\>_!,5NMQJ&GVUU,L"'X02
M.L*R2L(EDEE=4P&D<C)WO^'(WPS_ .CX_P#@HW_X?_P3_P#.>KW:W_X*E?LL
M^!/!WQ'\3_&SQSX.^%6C?#_]I#XF_LT^']-\/WOBWXB:OXDU?X4:;I>J:W<6
MWAK0/ -EKUG/HVAWQU;Q/8Z5I.O>'_"6CVRWUWXJGM',D5(?\%7OV:K3XQ?$
MKPEKGB+0-)^!_@#]EWX4?M16G[1R>)5U/PCXK\.?%WQE=^"_#6@:)H&GZ3-J
M]UJM[J,=A%I4%A-J.IZSJ&I0Z3;:/'>@)([+\>KUOH^]^BMZ>HDY/IKOLO+R
MWV_X*5SR#0_^"*?P_P##7BK2O&^@_MU_\%'M*\6Z'I^M:5H^OVGQ]\"IJ6G:
M9XB_LS^W+&VN&^#;F.WU0Z-I9O$4 RFQMB2#$"?5/^'8NO\ _22__@J+^'[1
M7@,#\ /@L ![#@5]P_ ']HOX,_M0^ (OB=\#/'%AX[\'-JVI^'[N^MK/5=)O
M]'\0Z+*L&K^'_$&@:_8:5K_A_7--D>,7>E:UIEC?11RP3&#R9X9']LH273UW
M?EY^0KM?*RVVU7ZI7_$_++_AV)K_ /TDO_X*B_\ B1?@3_YRU>2ZG_P1+^&V
MLZ]X@\4:M^W%_P %&-1\1^*[ZUU/Q'K5U\>? DFH:SJ%EH^E>'K2[OYS\&QY
MTUOHFAZ3I<+!5V6=A;0\B,9^3_&__!PMJGP_^)'QBL=<_8KO;OX'? _]HGQ+
M^S_XR^*VD_M._!K_ (3-[OPUX]M/ =QXDT3X$ZVNB?$/6XI;O4;&^73M,BN4
M-N]RL&I7"6=Q.GU?\5/^"O\ <?"_]IG4/V+Y_P!ESQQKO[3WBGXH?#/0/V??
M UAXF:+PW\;/@Q\0=,U/6M8^/J>-9?"#67@WPS\,+#0-<@^(>B7]CJ>H:3JT
M-A86MS>QW=U=:=RXS X',*/U;'X3"X[#\\)NAC*%/$T>>#4H3=*O"<.:#5XR
MY;J7PN[U4X*<>6<(SB[/EG&,HOX;.TDUV_JY6_X<??"O_H]K_@HG_P"'X\"?
M_.;KQ/\ :6_X) ^"/A%^SE\?_BQX7_;6_P""@4_B;X8?!/XJ_$/P[#J_QQ\%
M76DS:[X*\":]XDTB+5+:V^$EE<7.G2:AIENE[!!>6DTUL98XKF!V65/5M*_X
M+-:IXK_;,\9_LQ?#W]C+XI_$3P+\,OCA'^S]\2/B[X4^(7P\OO%'A;Q@GV6+
M4_%;_ -KN/XF7'PGT:ZO(5O_ (AR06FE?9%GN(HWN(?L+>'Z=_P7\^$OCKX*
M?\%%?$7BK]F;77U#]CKQUI'PDMOA/J?BK3-;B_:1M/B'\2_$?P3T@:-+=^$X
M[*QT[5?$VB:CIWB+2[O3/$,%AIUP!>//'(Z'RO\ 57A;_HG,ATT_Y%&7]+?]
M0_2R,OJV'TOAL/;3_EQ1U3MM[GWOIK>VIO?LW_\ !'[P-\6?V=_@+\5/$W[:
MO_!0*#Q'\2_@Q\+?B!K\&C_'#P5:Z3#K7C+P-H/B+5(M,M;CX2WL]MI\=]J,
MZ6<$UW<R16XC22>5U:5_:/\ AQ]\*_\ H]K_ (*)_P#A^/ G_P YNOK7X(?M
MM_"S5O\ @GC\-/VXO$?@G4_A-\*M1^#7A[Q\_P .O"^EW/C35/!^D2^1HFE>
M#?#FD>%=(MIM;N(;D66CZ/9Z1HME"_FVT:6UK"CM'\S?"'_@JWX^_:-_9@\$
M_'S]GS]B/XK_ !!\5_$#X[_%#X,Z=\-=3\8:#X.T[P'I_P +;[5H=7\=_&CX
MB:II$^D?#C3IK?3$@32&TO7+U?$%VNAPS70@GOU%PKPMI_QCF0O2_P#R)\OV
M5M;?5_)?U<%AL/TPV'LO^G%&W3KR6?3;3\3+TS_@B1\,]%\0>'_%>D_MP?\
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M&NB?#KQK:ZC/)\1;7Q5H-CJ.HWVL:P+/2_#=WK!T[5+BTN]L4GZE_L+?L_\
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MM?[7U(2&XN*_?ZBE9:^>^_:P^9Z7=[6MWT:>MM]4?SM6W_!)[]JWX7?$F_\
MVB/@E\2_V=]1^,NE_M9?MH?%SPQX4^+NA>-]7^%6I_"C]KWP7X$\)W>G^('T
M.WCUZQ\?>$9_ UM>I'86=]H.L66H7FE75YY,C%N._: _X(E_'S]H(^,-7\6?
M&WX.6GBV]_9O_91\$Z!=^"/!?BGX5^$+SXO_ +-GQBN?BG<17?A+P)J-E/X+
M^&'B2SF_X1RPG\'Z^?$>@79M_$^F:=;7^F6EJ?Z5J*&D]U_6P<SMTVLW;I9)
MKR3_ #9^;W_!,S]BKQ'^Q;\(_B#HOCR?P3/\1_BW\6/$/Q3\:GX>^)/B_P"+
M_#D=WJ%AI6BZ;$WBCXW>*_%7CGQ)K*Z9H\$FKZ[>MH\=[<2K$FE 6HO+O](:
M**:T2783=]6?S-^)?^"!-K-=?$?]HKPE/\%K+]NFS_;L^(7[5OP=^)GB31M9
M\2> -<^'?BWQM#K%M\&OC1X<U32-0M]0L#X>N=82/5-&T&\U'PYXD&FZIH.I
M8CN)7]4^+7_!+/\ ;!^+?[3NO?\ !06Z_:#\!>%OVP/AI\4? $7[)_A?2;WQ
MC?? OP5^S5X=M=0TOXB?![Q\LVBV.L:IJ/QCM/$_B'4_$NN6.@7$FE:K8Z-'
MIDIMKN?^S_Z$,#IC@]1]>OYT4K+MU3[:KKIU[]^H[OO]]O+_ "7_  Q_,?\
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MKA^O^?:BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.2<FDEW:;M;:WXW[WZ+OY!\K?\,NEM.NFUK6)*_"/_@J_P#L$_ME_MT?&+X
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M Y'^T?SJ545<[5"YZX&,XZ?SIU%-)+9)7WLDK@%%%%, HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBCKTH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH @NN+:X/I#*?Q"-C]:_-'_@DXQ;]EN[)_Z*EXY X[>9IV
M/K]:_2V[_P"/6Y]H)3^4;&OS0_X)-D_\,M77&,?%+QR![@2Z< ?QKW\'_P D
M[GG=X[)/_2<SO;\#U</&^39E+^7&Y8O_  *GF'^1^F]%%%> >4%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?CU^TU_P5Y\'_ +.7QQ^*
M/PX3X%>.OB'\+?V;KOX):=^U=\==!\3>%M.T;X'7_P"T%>_9/AW!'X,U%_\
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M1_3K17\X?P2_8/\ "'C;]O;]N3X!>(/VF_\ @H3=_#7X&>!_V4]>^'FF0_\
M!07]K6UO]-U+XK^%_B!JGC22_P!7M_BLE_JR7EYX?TQK.*_FF334BDBM!&D\
M@;[T_P"'2GP'_P"CA?\ @HM_XL;_ &Q?_GN4!;S73OUMY>?X/RO^I%%?EO\
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MQM;CQ!XL\#Z%KNLSVME:_%F.VL[>;4;ZXDAM;=$A@1EBC4(B@>Z_\.E/@/\
M]'"_\%%O_%C?[8O_ ,]RA:I/N.WFOQ_R_JWI?]2**_+?_ATI\!_^CA?^"BW_
M (L;_;%_^>Y1_P .E/@/_P!'"_\ !1;_ ,6-_MB__/<H#YK\?\OZL_*_ZD45
M^6__  Z4^ __ $<+_P %%O\ Q8W^V+_\]RORH\$_L@:=K?\ P67^-?[&=_\
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M+R\_P9^\5%?EO_PZ4^ __1PO_!1;_P 6-_MB_P#SW*/^'2GP'_Z.%_X*+?\
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MD+*6%EEBNC;?9Y(F61)61@Q_)K_@O^6'_!*7]IDJ2"(_AR<CJ /B;X2.>""
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MRMI-KF2C?7K97[+8****1T!1110 4444 %%%% !1110 4444 %%%% !1110
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M D2UO+R>W_"'X1^ /AY^RM:_\$GOVLK?XOZQ\>?A#\+_ -J+]MCQI^W+\<?
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M3QOX4\.3^!?$NF>/?VQ_VPM*N;WPYH&M6=U9>&3INE_#_P *:Y+>03:Q?ZA
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MX[Y8C%<H[)/TNU?3Y:_IUOW':RZNVEWY6T[WU;_3>W[04444Q!1110 4444
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M*=/.&U\W!/Y,_42BBBO#/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M #7WC2;MV>SZ?>?T$4W8F_S-B[\;=^T;]N<[=V,XSSC.,\U\E?M-W_[:=O\
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MFC]99(89MOFQ1R[<E?,C5]I.,E=P.,X&<>@]*000+&T0AB$3'+1B-!&QXY9
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MV>7L3R]NW9M79M_N[<;=OMC%.554!5 50  %    P  .  . !T%+10 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** /P\_X*]_LW_MA_%7XL_\
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M-_X3;XA^-=>\27]O8>%?"?BRQ75I?#^D^%;JYT;PQI5E:3:TNF:G<W*GTO\
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MFBZ/.;R%[?\ JGHHLKW_ *Z?G9)^0<ST\G?7Y?<M.EC^03X(?\$IOV]O@5\
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M6@DFS\96-_X?S!IEIK+W,PM]&OG?4[6.V$EYY;SB&+](J*+:W_K6W^2!N_\
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MAG6(/$/Q+UP^,[^X@OH(]1TUU\?06XTBWCM;H-ILK_;&%P@C_.C;_P '$/\
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M\%K926-Q9-<R6LT9B^&-O_!Q#_?^"?\ YB3_ .-4;?\ @XA_O_!/_P Q)_\
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MU:2=)I+O3;R]MS(K3>8.S^*G[)_P#^+GP_\ %G@#Q%\,_ EI!XJ\!ZO\//\
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M%\4R_ESGA5?^!4N(?_D?TZGZGT445XA\D%%%% !1110 4444 %%%% !1110
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M_P!V_P#S">OWZ7LCXI_X7=^V[_T8MX;_ /$L_!7_ ,[FC_A=W[;O_1BWAO\
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M8MX;_P#$L_!7_P [FC_A=W[;O_1BWAO_ ,2S\%?_ #N:^U/M:_[/YFC[6O\
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MY2I<377SY5]R/U3HHHKQ3XH**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *^$OVAW$7[8_[ LAP!'J_[2KDGH GP3O&.?;
MK[MK\^?VJ9GMOVI_V(KB,[7@'[4\R-_=:/X$:DZM^! JZ?Q/_!4_]-R.7&?P
M8]?]JP/_ *FX<^@KOXN:!!=7$+:C;*T4TD;*9.0RN00<28R",57_ .%P^'_^
M@E:_]_/_ +97\A?Q#_:^^)EAX^\:V4/C&\2*T\4:U;Q('4;8XKZ957@ < 8S
MWKC_ /ALCXH?]#G>?]_!1S_W5_5O\OR[:[\B\_P_R\OS[L_LD_X7#X?_ .@E
M:_\ ?S_[91_PN'P__P!!*U_[^?\ VROXV_\ ALCXH?\ 0YWG_?P4?\-D?%#_
M *'.\_[^"CG_ +J_JW^7Y=M3D7G^'^7E^?=G]J?@OX@Z3XDU<Z?9WD$\OD/)
MLC<$@#O@LQ]>F.AZ\4FO^/=)TS5KNRGO(TDA?8R-*JE2,\8SU]?\FOYW/^"4
M_P"T/XW^)/[3D?A_7?$=SJ5B?#5[/]FD(93(CX#'N, _K[UY;^W)^U]\2O ?
M[3_Q.\*Z1XA%II^EZE%%;VZHA\M65SC))S^G3.,DDG-UY>R\M+._^6MU;KH'
M)>ROI?MZ+IZ=O^#_ $N_\+-T3_G^A_[_ *_XT?\ "S=$_P"?Z'_O^O\ C7\=
MW_#=OQ<_Z&H_]\14?\-V_%S_ *&H_P#?$5'/_=73MY?U\O)7/9K^;^M/+U_K
M?^Q'_A9NB?\ /]#_ -_U_P :TM'^(.D7VIV=I%>0O)-,J*HE#$DY_A!R:_C<
M_P"&[?BY_P!#4?\ OB*OH/\ 93_;*^)WBW]H7X6>'=2\2&XLM5\2VMK<0>7'
M^]1\_+N4A@.^1_/%'/>R<59V3VTV\_ZMY*Y[-=_ZT_X/];_U=^,?&6G>'[^&
MTO+B.)W@\Q5=PAP3V)9<YS[X]>PY#_A:.A?\_D/_ '_'_P 77X>_\%:_VD/&
MWPE^-_A30O#NN/IUM=>$TO)8@!\TC/& V6!]^,=,>V/RE_X;E^*__0V2?E'_
M /$4N9?RI[:OT7_!7_ 6KY>[\]/D^C\O7OJC^QS_ (6CH7_/Y#_W_'_Q='_"
MT="_Y_(?^_X_^+K^./\ X;E^*_\ T-DGY1__ !%'_#<OQ7_Z&R3\H_\ XBGS
M+^6/W?UY_P!+5<OF^G?R\_+^K(_L?C^*&AM)&HO(<LZJ 9@<EB% QN/4G XZ
MUV_B[Q9I_A_3-.O+N>.&*\">6S.%#;HU? )P3@>A[]*_B_T']N'XJS:[HD+^
M*W9)M7TV)U(CPRR7D*,#PO4$]#7[1_\ !4SXU^+/AS^SY\!=?T#6;C3;S7;7
M27NYX"@:<RZ9'*V=P/WF.3C\#2NGKRK36RZ[+\]?P'R>>]E]UM?SM_P-?U8_
MX6UX?_Z"$'_?X?\ Q5'_  MKP_\ ]!"#_O\ #_XJOXO?^&TOBU_T.>H_]]1_
M_$4?\-I?%K_H<]1_[ZC_ /B*?,OY8_=_7G_2U7(N\OO_ .!Y+[C^T+_A;7A_
M_H(0?]_A_P#%4?\ "VO#_P#T$(/^_P /_BJ_B]_X;2^+7_0YZC_WU'_\11_P
MVE\6O^ASU'_OJ/\ ^(HYE_+'[OZ\_P"EJ<B[R^__ ('DON/[6=<^)FBZ7\/-
M0\6RWL"V%I,(WN&D7RU8DGERV,G;C&>V,9)-?.G_  U=X*_Z#]E_W_B_^+K\
MC]"^,GB7QA_P2G^)'C+6=8N[[4[;Q,;87A?RY0GF7:JH:,# !X!&"<#/O^&0
M^,6N8&=4U#_P/N/_ (JDY-?#9+?IV7D_/MY^3Y5;5MVT7DM.S7W]?R_L]_X:
MN\%?]!^R_P"_\7_Q='_#5W@K_H/V7_?^+_XNOXPO^%QZW_T%-0_\#[C_ !H_
MX7'K?_04U#_P/N/\:.>?=?A_EZ_T]#DAV?X_Y^O]/3^SW_AJ[P5_T'[+_O\
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M>\M;^^TV_$@LK:XEMUCBEAE^5/\ @H)\0_\ @FAK]E\9OVJ?V=/VK8OV>O\
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M=OVQM>_;>UCP!X1G\5?!OX"I^RAXN^-ATFV\&GX8Z9X<U"W^*>A>!]:\4(=
MT_57\>O<7&MV-K+!J5X#<LWFPR2+*^6+;:YK7:LDKMIQ6G_@5[6=DNIA#&UH
M0I4JKHJ<UAK5I.7LX0K4JL^:KS24I3O0E!/F@JDZD/A=XO\ 8E_VF_V>D\$>
M OB6/C-\.IOA]\4?%.B>"?A[XSM?%&EWGAKQ=XN\1W,]GHGAS1=7M9YK*ZU?
M4;RUN+2&R$JS"Z@EMY%29&0=?>?%SX8Z?\3]'^"M]X\\+VGQ:\0^%[_QMH?P
M\GU:UC\6:KX2TR[-CJ'B&RT=I!=SZ7:7:O!-<HA17CEQD0RE/YH? /[/MM^T
MA^R!_P %<;O]GW2I=,_9_P!?_:-O?C=^Q"ND:;-INB77CSX0>'?#GB?Q-XK^
M&-C)%96]KX0\5_$/PY=Z7HDNDPVVF.7U!+8;$E4_/8_:,U?XK>+_  __ ,%U
M677(?!?P'^+?[-WP!U;3(8;V(6OP4U;X20:3^TNT>F(D?VR/3?C%\5+I;*1P
MT1FT.Y6&5TFC$0J:=[NS73K=J/*O5MM/S1,LSG!4W*E"TXQJ<RDW!T*<ZL<5
M6C*VL*<(4ZL&TE*-:"?=_P!9]M\=?@W=R?%..'XF^"A_PH^]BTWXORS:_I]M
M:_#>^FTF'7H[7Q?>7,T-KHDIT>X@U%EO)H_+MI4>0KG%<?\ !3]K;]F7]HZ^
MUS2_@3\=/AG\5=4\-J)-<TOP9XJTS5]2TV R"%;N?3X9OM?V%I2(EOXX7LFD
M*HLY9@#_ #5_%WX:_%#_ (<^:%\?=:2XTF^_:L_;1\*?ME?M1SW/AB_\96&G
M_!SXD?$R75]#D\1^#[74-/O/$'@+PMX,@^'=]JWAG^TK*"ZTNWEAGEMDDGD3
M[3_9_P##OPZ^+W[:W[-'Q<L_^"B?[)GQ@^(/PU\#_$O3O"GPU_9O^#&@_#[Q
M%XV\!>(O"B6U[H?BO4- ^*7BYXO#?A6:'3M?TO2=8TF :;=P3QV<=O)=3X.1
M6;N]+J_1-6WLGHVW;7:S[VN&/K3J48>QA%5(T*C4IPC)T\1.23CSU82YJ=/E
M<HQIU>>?-!<EDW^AG[5?[>'[/WPC\(_'3X?Z%^T7\)- _:6\)?!_XE>(_"'@
M.]\5^&KGQ3:>+M#\#:UKOA^"7P_J$L]M/J0O+2VN8=!U&%Y[Y L;6,\4NQ_3
M?V%?BEXS^-?[&?[,/Q?^(^IPZSX[^(_P/^'?C+QAJ\%A8Z5#J7B'7?#5A?ZK
M?IINF6]KIUBMS=RRS?9;&UM[2'>4@@BC"HO\XGPO^(?[$OA'_@G%^W1\(OVI
MX_AK+^V;?_$_]K>#XH>"O&F@6VL_&;QC\:=7\3>,KCX8^(_"FDSV5SXMU&SC
MLI_#5QX;UO1!_9FC):W=[]KM(_M4S_OU_P $O,'_ ()S_L2XY'_#,_PBQ]/^
M$/TS%*44HOOS)7[^ZV[?/_ARL+B:F(Q$'*4%&6%E4]C"4G*DW5@E"M%MKVL%
M>+E9:N<5%)7E[Y!^TW^S[<_"'7_C[!\8/ 4OP7\*R:U#XC^)::_9MX2T6?P[
MJKZ'KEOJ.JA_)MKC3-81M-NK>3$R7FV (7= W3Z[\:/A/X8B^&LVO_$+PII4
M/QCUK2O#OPKDN]7M43Q_K>NZ<^KZ/IOA5@[#5[G4=,C>_M5M=ZR6H$P;85)_
MET^+O@C4(_VN/C=_P1WET_4X_AA^U]^V5\._VK-/2SCN+2UC_9W\1:#JWQ2^
M/V@V%Y:"%-.L[;Q_X!MM%LUAE69HM1OD\Q9EY]%_X)N:SXV_:1_:<_9L^!'Q
M$M[Z[N?^"0_PH^,/@'Q_=:E;S_8[[XYR^-M<^!_PRN9)9<?;IK3X1^%4\207
M<3EFO+J9RN RHW!)7N[6O_V[96=[;MZ;>MF1',JDJL:/LH\[FJ%[NWUBG5BL
M1!)_9CAY>WIW=Y)23V/WS\:?MK_LC?#KXEV_P<\=?M'?![PG\4+FZM+%?!.N
M>.=#L-<@OK\(;*ROK>:[5--O+L2Q&WM=0DM9YA+&8XV$B9\"^./[0GQ3\&?\
M%&OV'_@!X;\0VUI\*?C1\.OVB]?^(/A]M&T:[FUK4_ 7AW2M1\*7<&MW%E+K
M.F#3[FXFD:'2[^UM[U9"E[%<(J!?YYOV?++3-9_9E_:=^ '[2G[</[)O[.WC
M3Q/\5OCYI?[27PZ_:!_9\TK6_C;/XCUSQ?KS#QLOC;7?BSX;UGQ;<W&GRV.L
M^!/$&B:'*-%6'3XM)!DL8Y9?U/U;P]%X2_X*#_\ !&+PM;^-IOB7!X;_ &3/
MCYH<'Q$G@FMI_'<&E?"7P=8P^,)K>>YO)X)/$<<"ZN\4UW=2QM=E)+B9@9&:
MA%.S=W:6COK:-^9.RT[+72SON3'&UJ].,G!4DZ^":<:E/GBJF,IPG1J1A5G.
M_)>,W*---\]-P33O]G?\$U_V@?BI^T1\//VAM=^+&OV_B'5/ '[8_P"T9\(_
M"]S;Z-H^B_8O G@'Q@NF>%=)FAT6RL8+R;3K%S;MJ5U%+J-X%62^N;F;=*WF
M7B_]NB+X-?\ !2+XP?"3XY_&3P3\-_V9_!O['O@#XHZ6GC)_#/A^UM/B1XA^
M)UUX<NKN+Q)<VT&O:E<7^CQF"+01?7=L/(:YMK!)4EE.)_P1J_Y)+^US_P!I
M$?VOO_4^CKY@^+GC?]E;X=?\%S/$/BG]JBX^'>B:2O[$OP_TOX;>+_BGIME+
MX0\.^/KOX@^(KDK_ &_K-M+X>\,ZYJ7AFRUR#2[W5+BRENHX[VST^X\^5HI)
MLG*2L]KV25^C_P"'+E6J1P>!FJJC*5:E&=2I.7*U*-1/VCNG)7MHY+F:2;6Z
M_<_P3\;O@]\2/ANGQA\!_$WP/XK^%;:??:JWQ!T7Q+I5YX2@T_3$>74[J\UQ
M+G[#8QZ;''(VH_;)H&L1&_VI8MIQP/P:_; _9;_:&UW6?"_P/^/GPM^*/B/P
M_"]SJ^A>#O%VE:OJUI:1RB"2^%A!/]IN=/CF9(GU"UCGLE=XU:<&1-W\MGQ(
MTG6?&'[&'_!5CQ_^S#97EE^R)XO_ &Z_A3XH\.?\(OX;O=2\(:]\*?#.O^#E
M_:%\5^#?">FS:4-:^'%QJ-O'JFLV&C76F:9K'AW3-5L!/9VZ7+Q??WP/T/X7
M?&C]K#]C'X@V?_!1C]D#XD^+?A0_C"Y^&GPT_9U^!.@_#KQKXO\ !^J_#G6+
M#6_ NLWFA_%7Q1>:1X4T[2%&LOHNKZ'!#976EB.&&"YD*E^S23;;Z^J=HM)K
MO=V>JMOWLH9A6G4I0C2IM25)RE[2"C453$5*$IT7.I"3@HT_:PM"K*HI1A:+
MM*7T=^S-_P %*/ FC^*/VQ-%_;$_:.^%W@8^ OVW_BQ\%_@Q8^,M1\)>"KN/
MP!X6L?"S:3I,,-G!I]SJ\.G7>JSI<>(=76YN&DN%2^U-ML:I^DOQ;_:7_9^^
M _@_1/B!\8_C'\/?ASX*\3306_ASQ-XH\3:;IVD^()KJR;4;>/1+EYF75C-8
M(U[']@%P&M1YX/ED,?Q,_8U^!OP;\;Z)_P %JO%?C'X8>!_%/B36_P!K']J?
MP7J>O^(/#FF:MJT_A73_  3I^IVF@QZA?6\]S9Z?;ZGJ-WJ"0V4EOB_>.\8F
MXM[:2+Q;X;?M1>(?AM^P!_P1_P# #VWP&T6^^-_AW7?#Y_:7_:F\-+XQ^&GP
M+MO NCZG)8BW@N-0T.!/&'BG3(XO#7A?[=XHT.Q-O9SVUQ++$Q:V'%.5EY76
MBTY4[K3I9]&WOZJEBZU*BO:N$N>%6=*;YY23CBH4%&IS3BI<SK0Y6I4XP2:D
MU%<R_?+1?VT/V3_$?PSC^,N@_M"?"G5_A8_BO1O S>.K#Q?I=QX>MO&'B'4+
M;2M$\.7]]',5T[5M3U"\M;:TL[];:21[B%L".17/K?C+XJ_#?X>:KX#T+QQX
MU\.^%]9^*'B>/P7\/-,UC48+2]\9>*I;"[U1-"T"W=O,U#4#I]C=W9AA4[8(
M6=F&5W?R]?LM_!W1OVQ_&W_!;#]G[3_BC\+OB[8?$7P1\!+CPY\1/@]X"M_A
M?\,K_P"+>E>$O$M[X?\ &'AKPW8ZUXALHKG1O'GAW2DU+Q'IVM:A:^(+[2[W
M4DGEBNY(S[9^P1\7?&O_  4@_:&^$7Q1\36-];7O_!/7]E6^\$>(HM7LI+:)
M/VW?B=!JW@+Q;>RV\D,4<TV@^#?"-]<-Y8!L+CQ%%Y:J92U#A%7U=E:^R^))
MJS;76Z*IYA5G[*+IPYZ\G"E9MJ3HXB=+%-N,IQ]RC&-6"4Y)MN',[*3_ &YU
MW]MC]D;PQ\5(?@AXA_:/^#VC?%J?4(-(7P%J'CG0[?7TUBZ*K;:/<6SW82TU
M:X=TCATRZEAOI9)(XTMVDD16[7XU_M'_  %_9PT33?$?QX^+O@+X3Z+K-Z=.
MT>^\;^(]/T-=6OE0226VF0W4JW.H20QLLEP+2&86\;*\YC1E)_D>_9UTGPQX
MR_85^(?[/'[0?[>7[)W[.WB'5?%7Q+T[]H+X:?&C]GK3;S]H?0_B;-XVU6[N
M_&%WXNUCXN:%XF\4^+&NUL-;\+>+=*\//)91+I]G91J+ PC],/B#JOP=^"G_
M  5$_9HUW]L'QGX6U3X0V?\ P3QM_!?P!^+?Q<AM+3X=WOQ=TKQ1I'_"?ZR;
MSQ$]UX?T;QUXM\'PP:D)[NY6_?3;R/3X[R:2:%)3V:3M=O?9:RMRVMI;6_GI
MYNQ-/,:M2FING3IJ<J"C*4X.-)UIRBU6C"K*?N624I>Q<ZDN1PARMGW+^Q1^
MU;XJ_:*_:L_X*!^$H_B%X>^(/P4^$/B#]G,? R\\,P>&[G2K70?B+\,=8\1^
M(YK7Q+H5LMQXD@U+6+&&X2?5+_49+%XY;2U>WBWP+]I?%3]H?X%_ Z:PM_C#
M\6/ GPTFU30O$OB?3D\9^(M/T'[;H'@]+"3Q-JELU_-"LUKHRZIIHO&0EE>^
MMHT5Y)D4_CC_ ,$@M8^!OB']KS_@K%X@_9NTO1M+^#.M?$[]G#4?!R^&M F\
M->&-12;P%X\76=;\,Z7):V4(T'6?$*:MJ&FWEA:PZ9J$$XOM.4VD\+'O/V]_
MASX$^*G_  5"_P""4WA+XC^%-#\;>%WL_P!JW6I_#GB2QAU71+S4?#O@'P]K
M>B3ZAI5TLEEJ*:=J]C9ZC!;7T-Q:_:[6"5X7:)<+E3G;5+E3VU^%/7UZ^>II
M2Q-58*-5.%6I/&3HJ3E*5-JKF,\/%J7Q.$(R7);[,4EI8_2#Q-^V7^REX,^%
M?A+XW^*_V@_A3X>^$WCZ+S_!'CS5?&&DV>@^+8P[QN?#L\LZR:PT+Q2)<1V,
M,\ELR.+A8BIQZ-\,_C=\'_C-X&7XF?"CXF>"/B#\/R+OS/&'A3Q'IFKZ!;-8
M1":_CO=0M;AX+":QA99KR"]:WFM8F62=(T96/XK_ !@OOV>?@1_P5Y\$:O\
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M_&ZFTOY9?=_7])^5^O3^9?C_ )>:/YD_[(UO_GC+^O\ \31_9&M_\\9?U_\
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M "2_$_G!^SZM_P \YOS;_P")H^SZM_SSF_-O_B:_H^_X='7W_0;;_P  (_\
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M':G#J]KI.@6'B,ZI'JU[-+;PWNC:\G]NV::A=V\$3?4_P6_8X\4?"_\ :/\
MAY\;M0\9Z!JND^"_V'O G[*5UH=EI^HPZC>^)/"7BVU\1W7BRWN9W-M'HEY!
M UO;V4@-_'*P:1B@-?H%14\\K6OI:UK+;1?HAQP>'C4=50?/*?M&^>37,IRG
M>S=OCG*7SMLDE^.&B_\ !.3XS> /@-^RYX9^'?Q0^&4GQJ_97_:9^)O[0'A?
M5/&/ASQ5>?#+Q59_$N?XLZ;?^%]>L=&U+3O$]G+:>'/B>SP:C87+;=8TE4\I
MK.Y,D?U#\/?V/#;?'[]J;XO?&5?AK\3/#7[2?AW]GNQNO -[X1.JZ%INM_!W
MPOJVD:O=7FE^*AK%A>6%_J^HQZCX?CD-S=V$,"?:IFND65ONZBES2UUW5NSM
M=/IYH<,)0IN/+%I1Y6HN4G&\*3H)N+;3?LO=>FMDW=I'Q5^UE^Q_HGQO_9AU
M/X%_")/"'P7\1>&_$'A'XB_!+7-&\,V>F>&OAO\ %'P#XNL?&GACQ#;Z!H%M
M:00VDNI6EU9:S%86RRW>FZSJJ%9'N7W>$:]_P3PUJZ_X)TZ'^Q9HWC_1AXX_
MMCP!XQ\:_$W5M-U"33_%?C[3OC-H'QD^)'B6>QMW-^)?%>MV>M+8([YM?MED
MDVV&!E7]3**%*4;6>SO\]/\ (<\+1G*<Y0]Z=!X>5I22]DVVXI)I1>OQ)*5D
ME>R2/@+3?V._$UC\1/\ @H%XT?QEH4EI^V/X ^'/@[PQ9+I^H"X\&7/@GX3^
M*OAW=WFO2%_+U""]OO$,.I6\>G[9([2WEAE_?,A/A?AW]@KX^_!;_AE'XB?L
M_?%+X3P?&GX%_LIZ5^R7\1[3XH^%O%VL?##XC>"M.ET#6K'7-*3PUK.C^*/#
MVN>'O%&CWE]I?[V:WU33M8N+#4UA:""8?KC11SRUUWWT79+JNR%+"4)6]UII
MRE&2G-2C*=7VSE%\UT_::^C</@;B?F'XQ_9+_:PM/C5\.?VDOAC\<_A%=_&H
M_L\W?[.WQIU7XE?#/7I/">L:5-XV_P"$^TSQQ\//#?A'Q)ILND:WX;UF\U:R
MLM US5+[2M6TJ2P34[X7<$]S/P_P;_X)P^/OACX&_81\)ZM\5/#7B;4/V2/V
MCOC%\;/%FN+H=_IS>/=/^)FE?%_3[6STNRA/V?2=8@G^(]C=ZBLH&F*;.^BL
M?W?V97_72BCGEMI]R6G:ZU[[?HK+ZG0Y^>TV[J6M2;7,ITJCE9RMS2G0IN3W
M;3O\3O\ DQX9_P""=?C?0M.^!EC-\1O"L[_"?_@H5\6?VS-2>/2M75=6\*_$
M.Z^)UQ8>#+$,V8?$&GCQU8K=W]Q_Q+G-E=^2&W0EOJ[X-_LXZY\,OVH?VOOC
MYJ'B32=3T;]I*Y^"4^A:!9VEY#J?AH?"OP#<>#]175KJ8FUNSJMS,MY9?8P/
M)@#1SYDQ7US10Y2=[N]]]%W3Z>:14,+1@X.,7>G*,HMRD[.-)T5N];4Y-6?5
MWW2L4445)T!1110 4444 %%%% !1110 4444 077_'M<?]<)O_1;5^5G_!'$
M[OV1;L\\_%_XB=1C_EOIE?JG=?\ 'M<?]<)O_1;5^57_  1O.?V0[L\9_P"%
MO_$3I_UWTS_)KV<+_P B3-O^PO*ORQQ]_DT4_#?CF76/$7 B7_;U#B]O_P!)
M/U<HHHKQCX **** "BBB@ HHHH **** "L*#POX9M?$-_P"+K;P[H5OXLU33
MK/1]3\3P:1I\/B'4=(T^66>PTN_UJ.W74KS3K&:>::SL;BYDMK:6:62&)'D<
MG=KX?_:C_;]^"G[+'BOPG\,=9T?XE_%OXV^.M.N=:\)_ WX%>";SXB_$_4]
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MD^D17CO=QZ:UR;-+EFG6$2L7/'WWP5^#>I^+4\?ZE\)?AGJ'CN.2&:/QK?>
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MA7XI']O_ .+*G#?M:_LV ^A_8A_:[!_(^*Z3_AX#\6/^CMOV:_\ Q"+]KO\
M^:RME0J_S+I]FIY?]._-?B<G]IX7SZ?\O\%Y?]1?7_V[T/VN_P"$?_Z81_G%
M_A1_PC__ $PC_.+_  K\4?\ AX#\6/\ H[;]FO\ \0B_:[_^:RC_ (> _%C_
M *.V_9K_ /$(OVN__FLI^PJ_S1Z?9J=;?]._[R_$/[3POGT_Y?X+R_ZB^O\
M[=Z'[>Z;I1L[CS?*1!L925*9Y''"@'UJO?>'X+NZEN'@1S(0=V$!/'?+*2<Y
MZCVR0*_$H?\ !0#XLG@?M:_LUD^@_8B_:[_^:NG']O[XMCK^UG^S:/K^Q#^U
MX/Y^*Z7U>K>_-&]DOAJ;.W_3O^\OQ'_:F%LM'I9W]O@_*_\ S%]=/2ZL?M/_
M ,(M;?\ /JG_ )#_ /BZ/^$6MO\ GU3_ ,A__%U^*_\ PW_\6?\ H[7]FS_Q
M"']KO_YJZ/\ AO\ ^+/_ $=K^S9_XA#^UW_\U=/V%7^:/3[-3K;_ *=_WE^(
M?VGAO/I_R_P?]W_J+\OQ79'[4?\ "+6W_/JG_D/_ .+JS:>';>VN(IEMT4HP
M.X;,CW&&)R.O0U^)W_#?_P 6?^CM?V;/_$(?VN__ )JZ/^&__BU_T=I^S9_X
MA#^UW_\ -72]A5?VEK_=J=;?]._[R#^T\+Y_^#\%_=_ZB_ZNNR/W%U#3DNY$
M<Q"3:N.2HQS_ +7M_GFL_P#L./\ Y]E_.+_&OQ+/[?WQ;'7]K/\ 9M'U_8A_
M:\'\_%=)_P -_P#Q9_Z.U_9L_P#$(?VN_P#YJZ%AZNEI+I]FK_=_Z=^:_'YG
M]J86]]=[_P ?!_W7_P!!?7]5V1^VO]AQ_P#/LOYQ?XT?V''_ ,^R_G%_C7XE
M?\-__%G_ *.U_9L_\0A_:[_^:NC_ (;_ /BS_P!':_LV?^(0_M=__-71["K_
M #+I]FI_=_Z=^:_'OJ?VGAO/I_R_P?\ =_ZB_+\5V1^VRZ(@((MU!!R#F+@C
MH>]7]2TX7UO%$55O+(.&..B@=1TQCL>:_#K_ (;_ /BS_P!':_LV?^(0_M=_
M_-72G]O[XMCK^UG^S:,],_L0?M>#/_EUT+#U;I\RNMKQJ]>7_IWYKSW\@6:8
M7SUM_P O\%TM_P!1?73[U;H?M1_PC*_\\H_^^S_C1_PC*_\ /*/_ +[/^-?B
MM_PW_P#%G_H[7]FS_P 0A_:[_P#FKH_X;_\ BS_T=K^S9_XA#^UW_P#-73]C
M5[QZ?9J?W?\ IWY_GY!_:F%_O=/^8C!>7_47Z??Z6_:G_A&5_P">4?\ WV?\
M:/\ A&5_YY1_]]G_ !K\5O\ AO\ ^+/_ $=K^S9_XA#^UW_\U='_  W_ /%G
M_H[7]FS_ ,0A_:[_ /FKH]C5[QZ?9J?W?^G?G^?D']J87^]T_P"8C!>7_47Z
M??Z6_<BRL!9VC6ZA?F.=HQ@'/KQGUYY]\G ?]FD]/_0?_BJ_#7_AO[XMXS_P
MUG^S;CU_X8@_:\Q^?_"5TG_#?_Q9_P"CM?V;/_$(?VN__FKH5"KWB[N^L:O7
ME_Z=^:_$'F>%=M'IVKX'7:U_]J]/O/W+^S2>G_H/_P 51]FD]/\ T'_XJOPT
M_P"&_P#XL_\ 1VO[-G_B$/[7?_S5T?\ #?\ \6?^CM?V;/\ Q"']KO\ ^:NG
M[&KWAT^S5ZV_N?WE^(O[3PG][_P?@?\ YJ\U]Y^Y?V:3T_\ 0?\ XJK$<16%
MXR/O!QCCG<N.Q(]J_"S_ (;_ /BS_P!':_LV?^(0_M=__-72_P##?WQ;QG_A
MK/\ 9MQZ_P##$'[7F/S_ .$KI.A4=M8=/LU?+O3?=7_J[69X5=]5;^/@NMNV
M*\U]Z\C]N/[)/_/'_P >C_QH_LG_ *8_^/1?XU^(W_#?_P 6?^CM?V;/_$(?
MVN__ )JZ/^&__BS_ -':_LV?^(0_M=__ #5TO85?YET^S4_N_P#3OS7X]]5_
M:>%\^G_+_!>7_47U_P#;O0_;G^R?^F/_ (]%_C1_9/\ TQ_\>B_QK\1O^&__
M (L_]':_LV?^(0_M=_\ S5T?\-__ !9_Z.U_9L_\0A_:[_\ FKH]A5_F73[-
M3^[_ -._-?CWU/[3POGT_P"7^"\O^HOK_P"W>A]U?M^V?V;]F]SY>S=\=?V4
M!G*DG_C*/X0<?*?IVK[QK\#=2_:"\6?M/ZK\/_@AXV_:W^ #:-XP^+7PEU"#
M3M#_ &4OVCO 6O:_K'@3XB^&OB)HWAW1/%'CKQ1+X8T_4=;U'PG;Z?&=1@G$
ML4\L4$9G:-E_?*HJQ<(4X2=Y<TY;27NR5.WQ1C?6+6FFAM@ZL:]?$5J:_=NE
MAJ2?M*,VYTY8F<T_8U:JC[M6#7,TWS:*R"BBBL#T0HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (;G_CWG_ZXR_^@-7Y2_\
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MJ&)CA<)"G)?6*'LN9SG+ENZ,J-1MJ[FH>T<XQ?Q.*U3LS\U/ ^I_M5^#]?\
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MB_:4^'OQQ_X)X>&?V:_VE?!?[9O[3OQLU_6/CW\&/A?\:OAU\:?B&WCWX?\
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MG(ZQNDOPI_9C\!?!_P",O[1/QP\,ZCXENO%?[3&N^"_$'CNSU>]L;C1=.O/
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M\$SO@5JWP?\ B[\(OB]XR^-W[0:_&Z\\+ZAXV^(/QE^)VJ^(_B%;WO@1YY_
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M;O/"^F7%O#+IWP\MKO3_  G_ &A=ZUJM[97=_J9FA\I\(?M>?M,_M&_LE?\
M!*;X5W7QG\2_#7QQ^V3\4/B5\.?C-\>O!CV.C?$2Y\)_ N_\4V-Y%X7U4VLE
MKX>\:?$*'0].6YURPMDN[>\^U/9(ANI%/[J?"/\ 9=^'WP9\=?M)_$'PMJ'B
M6ZUO]J/Q]8_$3X@1:Q?65S8Z=K.G^$M/\'06WAF&VTZTDLM._LW3XYWBOIM2
MN&O)97^TB'RX(_FQ_P#@EI^SA)^RK\+OV43JGQ-M=!^"7C'4OB'\(OBEI'BV
M+0/C)\//'.I>*->\5-XG\,^,-#TO3X+&_@N_$>HV*1'2I+.?33!#>6US- EP
M!3CI=;<MM$[6BD^VE[NW73L*6#Q"3=.5I36)]K^]FO:*6,HU:5/FNW"^'5>D
MI12]FJEMGI\O?M?6/QQ_X)\_LS^)-/\ A)^U3\9/'.H_M _'7X$_!;X<^+OV
M@==L_BCXD_9YN?B5KMWH/C'Q;IGC/7K4ZOKVG3Z?%'<Z3IWBEM0MO#NK1_:;
M)Y(IWMUYWXS^#/C!_P $[?C/^Q'XP\"_M8?M+?'+PQ\>OVB_"?[.?QF^%_[0
M'Q%G^*>G>*;3QYI.KW,7CWP9;:G;0R^!=8\-:AI;W]S;^&3:Z4;*:"T:T2UC
MEBN?M>Q_X)H? W4_A+\8_A/\8?&GQP_:*C^.J^&E\=^./C9\3M5\3>.(1X(E
MNKKP-_PB&H:?#HVF>"&\(:A>W>J:._AC2--D;4KB:[U![YY&!K?"'_@FK\,?
MAU\4/ 7Q=\?_ !G_ &DOVF/%WPCMKR#X.C]HOXHOX\T;X7W&H6?]G7NM>&=&
MM-(T2RF\2SZ<%L?^$DUV/5]8B@1#!=Q3*)0*44M7?5MKE^*Z22\K6OT[K6PY
M8:NY1Y*?LXVHJE;$2?U3DK2G5TVG[2FXI*-XNWL7:E%2?Y_Z+\._CQ^UC^UA
M_P %4/".H_MG?M.?"GX?_ #XB^#8/A+X,^$7Q!NO!\&A>)_$GP"\*ZV-1NM<
MBBNM:D\*:=J%@M[#\/["YT_PO=ZIJ>MZOJ-I=WU^9$^4)?&'[7MI_P $O/A;
M_P %/_$?[;7Q^UGX\Z'K7P\N+?P+INLZ7X<^ ^I^$--^,-M\)-0\,>*_A?I.
MF0Z/XQU+Q+IT%SKOB#Q=KQN-8NM8O&-J+.U@AA']&/PS_96^'?PK^(_[3OQ0
M\/:AXGN?$/[5_B?P_P"*OB+#JE_93Z;IU]X;\#V/@*P@\+V\&G6TMA:-I-BE
MS<+?3ZE-)?RR2+,D C@3QN^_X)S_  1O_P!A_2OV!Y=>^(*?!_2$TY+;6XM7
MT8>.F_LWXBGXFPF75'T!](8OKQ-M+MT-0=-)A0)/BY II.*Z+EOHMN5*72_Q
M*[[DSP%9JI)2E[24,<XOV]1)5IUU4P<FE)1_=0<U'3EIMM6OJ?._Q2\8>/\
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MYK_\734;J[4OE;]6#;3=K;]GVBNG]?@>DY/J?S-&3ZG\S7FW_"P=$_Y_K?\
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M#:ORA_X(S'=^R#>'&/\ B\'Q#'_D;2Z_5VZ_X]KC_KA-_P"BVK\H/^",F/\
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M=;;JUU:ZO>UU?^D1''X:45).I[RI.,72J*4XU^9TI1C**;C/DGROKRM;VO\
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MTO7?$&NW.OZV;:VLFTRRMQ&/T%\2?LY?MM_ +]KO]HWXY?LB:?\  ;Q_\/\
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M3J\7A^YM-%U6( -*56X3U+X'_L]_'#_A$?V@]/\ &'[*7[%7[,D_C[X.>)?
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M+A%V=TVK---I_DAX#_8[^(GQ4^#W[4'PG^,O[,W['O[*6@?''X1:M\+M$?\
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M #_KKT.23MM;3J^VM[]5K_5G_+'_ ,.S/%__ #]?^2+?X4?\.S/%_P#S]?\
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MV_S[5^C]?!7[<P @_8_P /\ C.3]G_H,?\O/B6OO6ID[P@_.?_MI%#^/B?\
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MH_&;XO\ PRU/XL?\$VH/C=JW@WP;<^#[?P_I#CQ]\'I-=^'NG1:YX,U74/\
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M *X3?^BVK\F_^"+QS^QY=>WQ?^(8_*72Z_62Y!-M< #),$H '4GRVXK\G_\
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MOXA^%?%]AHWB7P?JFG63)<RV&N:79W$D+H]NDP=<_D3^UA_P5/\ A'\8;_\
M8W\+_LM_&/XD^%O$OBS]M?X!VVIVM[X-^)GPD/Q6^#6K:AK^F>(;KPS=>+_#
M_AVU^(_PZOKUM,MM7ET2;5-,=Y; W:!)(6/D7C']GSPI\<OV!O\ @I-XH_9%
M^(?[4'[27Q'^.<OPHU?Q;XB^,WPZO? MY\4;CX0WNC:Q=:-\-=.;X<?#6/Q4
MVL^";*^\/ZA=Z=I5Z^HZA]AT]9I+R3;-'^U3^UO\)OVM])_X)P^%/@+\(?B_
M?W7PQ_;(_9GU+Q_J^I?!#QCX0\/? DV"W6B7'PXUO7/$.@:7;P^(9[DB&31_
M#$FI6-OIWAZ2_P!3N;:U&F-<5&,4XO5ZJ][6CHGJNS;W=K:==##$8NO.DHRG
M1IN5.G-."<Y5V\3*#5&4*KC!PIPC.HDZRC[2SERQYI?TC?$/QYX9^%G@'QM\
M3/&E[+IO@_X>^$_$/C;Q5J$%G=:A-8^'?"^E7>M:S=PV%C%/>WLMOIUE<3):
M6D$US<,@B@BDD=5/QY\)O^"F/[&?QKG\>2> /BNU]X=^&O@#_A9?C#Q_JOA3
MQ;X?^&>F^%H(-/FU62+XB:WHUCX0U'5/#S:G9VGB+1=.U>ZU/1[]I;"\MDNK
M>XBB],_;GM+N_P#V*_VN+*QMKB]O;S]FKXX6UI9V<$MS=W5S/\-O$D4%O;6\
M"O-//-*RQPPQ(\DDC*B*S$ _E/\ %']GGXD_$[_@@%\/O@_\'?"&K0>/V_9H
M^ WB!O ?A[2HM+\2>(/^$>NO!WC/QEX?LM(N+:-9_$.MVUCJTWV"ZM9)]6U:
M0P2V]U=7?E2Q%)I7OK)1W5DGUV_5'?B:^(IU)*C&$XT\+5Q#@X2E.K.#M&G!
MJ<5'F[\LW?11=]/T5^#?_!1_]E+XY>/_  U\-/"'BOQKHGB?QYI]]JWPP_X6
M7\)/BC\*=$^+>F:;%]IO;[X4^(_B)X2\.:)\08(+/%^1X9OK^:2P87L44EL&
MD'%?&_\ X*O?L9? '7_'V@>-/%?Q&UI?A5J]IX;^)WB7X;_!+XM_$OP'\/O%
M%]]G^S^%/%_C_P %^$-8\':)XG8WEI&^A7FM)J,,]S#;301W+>2/S-^!-_\
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M]EN+IK:_%S+)'MCN?,C'@'[<.A:U\$_^"FNI?M$_%/XN?M,?L_? 3XF?LO\
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M1!?VU[X>^#GA'2;[Q&VOZM!*MW=>'=(T:>32@ZQWC(Q#R?FQ^SM\</C!\1O
M7[;?P<\'?$_XH_M8?LC^#?V1O%$_PR_: ^*?P>UWX=>/M/\ B-=Z!XCTRY^#
M,FM:EH/AN;XMW.F>'X[+4;GQ##H$>HVET\=EJ$C3S(;CQSP&NN?L\^"_^"(/
M[7'Q3^'?CWQ#^S_\&?V3==^'GQ+N?#O@CQ%XPU3X+^,_B#\/_#L/AGXA>(?!
M^D:;?:W::6R6LVD7>M6^FRS:4%_>!))K5)CD5[6TNFE=7?NW2NTFFWTMI?1,
MA8VHXPJ+ENZ?+*HXS=*#>+I49U.2%:=.=.G"3FYJ>JB_WD(\R7[P?L[?MP_L
MX?M1GQS8_"GQCJQ\4_#.."?X@?#WQSX+\8?#7XE>$+2[BEGLK_6O /CO1= \
M46VFWT4+M9Z@NFR6<[ 1I-YK*A^;=._X++_\$]]6;PI<6'QDUBXT#Q5J&D:,
M_C>/X8?$Q_A[X/U[7KQ['2/#WQ%\>IX4;PGX"U^]F0,ND>)]6TZ]@@EAN;J&
M""19*^;_ (,>((/VO/\ @I)X]_;%^!OA7QI8_L[^!_V,M5^!6H_%/Q)X'\1^
M [+XU?$36O%\WB>STWPIIOBK3-'USQ'I'@O3(]EUKQTY+>#4F33H6D1HG?X]
MT7X?ZG;_ /!M%XX\.'P1J$'B.[\ ?$759=!/AJZBURYU,?'K5[VVU*32_L2Z
MA->B&&"\@O&@:;R(H;B.3RD1P*$=&VUK!6NM+VO?3=;]+7L.6-Q3BW3]C*,*
M.-K>T5*HX5XX:=!4W32JKD515)IOFJ)N#E"\;'[P_'W]N#]G[]G#Q9X>^'_C
MS5?&^O\ Q!\3>'[GQ?IW@+X3?"SXC_&7QE#X,L[O[#=>,M5\._#'PSXHU+1O
M"L-Z&M3KFJ06MB\Z21Q2R-&X7Z3\%^,/#_Q!\(^&?'7A.]?4?#'C#0M+\2:!
M?RV=[ITMWI&LV<-_87$NGZE;VFH6,LEM/&TMI?6MO=VSEH;B"*5'1?P'_;@\
M7_"KX7_$#X7_ !5LOBM^TS^RY^U]X=_9A\*:#X ^)'@SX*>*OBU\*?CWHUU#
M)K4/P9\1^'K'P_XBT;Q+K6G>*[6.2]TN\F\,ZWITFM6-[!=7B+$UM^S'[)GC
M;XN_$?\ 9I^"'CSX]>#!\/?C)XL^''AG7/B+X,%G/IAT'Q-?Z?%-?VDFDW4D
MUWHTSEEN9]%NY'N](FF?3;D^?:R 0XI13UUWOMLGII^K[.S.NAB95,16I2<;
M07-!05^6/NJU6?M&XU+M^Y*G!2C[T)32DU\H_#+]L'X1?"/X4?M._&'XQ?M4
M:]\4_A_\,OVK_&GPQ\0>)_$'PNE\'1?!O4[GQ;H7A33OA-:VVC::)_$OAOPA
MJNL6=N/']PLUM>6EU/J-U=QVEK(\?I'P3_X*2?LB?M!?%>T^"_PV^(6M7/CG
M6]&U3Q'X(B\3?#WQ_P""-"^)WA[1&D&JZ[\+?$WB_P .:+H7Q"TFSCBEN7O?
M"]]J,,EG%->0-+;0RRI^"7QA\%>*KS_@FU_P51T<^$?$-U=Z[_P5/\6W^G:6
M= U*:YUC2)OCY\,F:]LK+[(TNH:;+"DQ-U!%-:O$DA,A57Q^L?[=/AFXC_;C
M_P""1%]X>\/SK8^'_C7\<=.O+S1M)D%IHFAS?!:2*"RNI[&W\G3-*E>!(X;>
M9X+1VA"(I,>!<X1BVM;^]JK+:$9*ZMUN[VMW\CCHXK$N,;*$80C@W.,H593D
M\3C*U"=JDJC<>2$%-<RF[O6RLU^C_P <?C9\.OV<_A3XR^-7Q:UJ;P]\._ .
MG0ZKXHUJ#3=0U>73[&>^M--CF73]+M[J^N!]KO;='\B!_+1FFDV11NZ_$5M_
MP6$_X)[2^(;W0+[X\1^'K>/1M<U[0/%WBGP1X^\-?#_XA:?X<D\C5_\ A5OC
MG6/#5IX:^)=U!<D6EK9^"M0UJZU6[*6ND17T\D4;U?\ @L]I>IZU_P $P?VP
MM,T?3K_5M2N_AE'':Z?IEG<7]]<N/$V@.RP6EK'+/,RHKR,(XVVQHSMA58CQ
MO]KWX:Z7J'Q0_P""-%O'X#M;W3_!_P"T#IT3VT7AI;BP\,6%G\"]<NX$FMX[
M-[71[6SU32-,N(/-CMXK:]TZTDC*2VZ%92C97NVW+9KHDUI9WW?8Z<37Q,*L
MXT72480PKM.E.;D\1B)496<:L+*$8\UK-M[M+4^[_P!FO]MO]GC]K"?QYIWP
M?\4:[-XD^&4VGQ^.?!/CCP-XS^&GCOP[;:O;O=Z-JE[X-\>:'X?\0C1M8MXI
M)=-U6.P>RN@I5)MY52D/[;O[.EQ^RA=?MKQ>+]2;]GFS\.WOBF?Q:?"GB5=2
M71M/UN3P[=3CPL=,'B-I$U:)[=;<::9G4"=$,!$A^._!.@ZK%_P6J_:*U6'1
M[^WT?5OV ?A5;'5ET^X@TG4-8A^*>JPI#)J(A6RN=1@M$5!&9GN8K5-NT1)@
M?C3J7[1-IX/_ ."+OQ1_X)]:K\(_CU-^UA\._!OQ \#>/?AMI_P>\=7%KX0T
MK2_B7J'B6?XB:UXQDT:'P@O@6?0FAN]/U.SUF[N=6N;FWL=*L[V6:-VI0B^^
M\+JZ^&23;?W[Z?>8U,=5I0G[3V7-&&/49<DHQJ5L-.DJ,8QYY.\X3FW34I2F
MX-P:2:/V9^(7[0WB;0_^"HWPETRT\:^.+KX$W?\ P3P^+/QKU;P#X>B\0:QI
MWB#4-#\<Z+>:?XDL_ >E07-]KWBY- ,MCHUM9:7=:]<FX&E6$$D]U]GDYS]A
M3_@J5IO[9VC_ !P\+:[H/C[X=>-/#7C?X[Z5X.\5:7\!OBYI_@W1OASX$\Q?
M#6N^)?%'BO0[CPG9_$JTL9!?:OX'U/5-.U1M2@33WT"UEE%J<?PYH6N)_P %
M7_V/M5?1M672['_@F'XHTR]U)M.O%T^SU(^._!A_L^ZO&A%O;WV"#]DFD2X
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MU6PE^ _V/?VQ[']J'_@II^TS8?#3XJ>*O%7P.T#]E7X+ZCIGP_UJ+Q+X>M_
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M%O\ Y;5HR?&;X.^6JCXL_#0XQ_S/?A89 !&?^0K]/6O-?^&*_P!C_P#Z-=^
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M_P#HJ_PT_P#"\\+?_+6O/?\ ABO]C_\ Z-=^ '_AI/ O_P HZ/\ ABO]C_\
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MJ_PT_P#"\\+?_+6C_A<WP?\ ^BK_  T_\+SPM_\ +6O/?^&*_P!C_P#Z-=^
M'_AI/ O_ ,HZ/^&*_P!C_P#Z-=^ '_AI/ O_ ,HZ=Z?\]7_P&/\ \F'^U_\
M/O"_^#*GE_TY]?P\ST+_ (7-\'_^BK_#3_PO/"W_ ,M:/^%S?!__ **O\-/_
M  O/"W_RUKSW_ABO]C__ *-=^ '_ (:3P+_\HZ/^&*_V/_\ HUWX ?\ AI/
MO_RCHO3_ )ZO_@,?_DP_VO\ Y]X7_P &5/+_ *<^OX>9\[_ME_$/X?>*+C]D
M#3/#'CKP;XBU)?VW/@#=-I^@^)]$U>^%O%<^(A-<&TT^^N+CR8FD022^7LC+
MJ&89%?I'7@7AC]E/]F/P5KVF>*?!_P"SY\&/"_B71;E;S1]?T#X:>$-)UC2[
MM%95NM/U&QTB"[M+A59@LT$L<BACAAFO?:F;A:,8<UE>[E9-MVV2;TT[E4*=
M2,JLZO(I5'"T:;E))0@HZN48MMN[M:R5M6>1:3\#OAWHOQL\7_M":?IEY%\3
M_'/@3PM\-_$6K/JE]+8W7A7P=J>KZOH5I#I#RG3[6X@O=;OWFO8(4N+E&CCE
M=EB44NO? _X>>)/C-\/OCYJVF7DWQ*^&'A+QOX)\(:K'JE]#967A_P"(4VA3
M^)[:YTF.5;"^FNI/#NF&WNKF&2:T$<H@9?.>O7**F[_"WR->2%K<D;<_/:RM
MS\W/SV_FY_>OOS:[GPO\4O\ @G1^S!\7O'_C#XA>)]"\=:;>_$PZ6?BYX7\%
M_%+Q_P"!_A]\8SH]LME8-\4_ OAC7M-\.^,W6P1-/N9=4LGEO[!1:7[W,!*'
MTGXC?L@?!/XE>-_@_P#$6^TWQ1X1\8? W3WT#P%J_P ,_&WB?X<20>#9;K1[
MZY\ :U#X1U+2X->\!W5UH&CS7'A;4XY],D-C$HB6,R(_T_11S2TU>FVOHOT7
MW$?5Z'O?NJ?OR4I^Y'WI1ESIO35J?O)])>]OJ?$ _P"">W[.=K\2]5^)FAQ?
M%/PC+XA\;I\2?$O@#P5\9_B;X1^$?B7QZ+V'4IO%.N?#'0/$MAX3OM3O]1MK
M:_U138)9ZK=01RZC:W1W;NK\6_L2?L^>-['XR:=XA\-:O<VOQY^*?PT^,OQ)
M2'Q-K-L=5\=_"6]\':AX*O[)HKI3I5G8W/@3P\]WIUAY-KJ @N%ND<74E?6E
M%%WW?W^:>G;5(?L*%FO8T[2;;7)&S<HRC)M6UO&4HORDUU9Y"GP-^'2?'9_V
MCUTN\_X6J_PJC^#!U@ZI?&P'@&+Q4WC)=.&C^;_9XN_[><W!U+R3>&'%MYGD
MY4^O444C11C&_*DN9N4K)*\GNW;=NVKW84444#"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYQG.2G*LE/D4*U2HI\]&<J%:5H04:47%4IJ%*#4D]%\(^$_@9\+/VY_V^_\
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MX>=!OV5H8:G1JR4N>4I4Z4()4U*E&5-<T6W:JX25FZ2FW(]MHHHK,]0****
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MW%I>C+U%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW@?4]3UW_A#O"EY;32W>I0FVTT1.^%_[.G[1WQM^&GP \)?$:P^*?@WXA?\
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M*RQ=]J_P9_:'\0_MQ>.M:^(GB[XP^#O%-E^U#X(\1? WQ%X2^ /Q=^(&DR_
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M0^)GBC5OC//8ZQX#O_ADFI6>G>'DNG^TV6FR0V+<)X@^"O[5>G?!C3K?X?\
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MFXN*Y?=K2KOF5VI.4I.+E97A&$;7C=_@'X-_9G\<>*_$W[/GP0\>>$OC1/\
M 3P)^VO^VEI0T:^UKXD:;IT'P*M/ 7B2_P#A-I?B'Q-!J%IK.H_#F;Q%<6MM
MX3DU;6);+4V@T_3[6[NXXDB?Z8_X*:7'AC1]7_8,T/Q9HOQ2\1?#/4OVFM=T
M/QQX-^$3>-;WQ3XC\)6O[,_QSNQIMQI'@;4;/Q;XE\/V-YI^GZKX@T;3'O[Z
M_P!+TZY T_4L/:S?K)7%^)_AWX*\9Z[X"\3>)_#]GK&N_"_Q'>^+O .I7+W*
MS>&?$FH^&-=\&7NK6*PSQ1/<7'ACQ-KVCNMW'<0BWU*9TB6=8IHSF5T[:*^V
M]W_P1/!I4JE.$DY3G1?-.*=H4G2]QI?%&T)6CHKS:=DVS^?/PO\ #KQOIVA_
M!1?CY\*_VH=?_853XL?M=W_A3X4V.F_%?Q+\0_"7AO6M7\&/^S!_PMGP1X1N
M;GXM7'A.QTBV^*A\,:5JD=^_A.[UOPH/$UK92063V7.W7P^^-OA?PU^S)XF\
M2_#[X^_%CQEX4U[QX/A1^S+\1_"GQQUJR3X4>)?V@VU'X5ZIX@^-O@/7H_#_
M ,*/C=X%^'MMIRW$OQ<N_$6GKX)CMM!UJUL+R*[NV_IBHI\_E^/K^/=]?RS_
M +/5G^]E?EBDW%-KE5%+[23C'V*=.$E*$'.:<9Q?*?C'^S?^SWJ/@+]H']O+
M1OAGX?US]G_XU>./C2/B!X*^,?B/X3>,/B1\-]7^$/B/PI\,;V_T_2+^_P#$
MGA[P+K6J7?C.W\207>F0>([?Q+H]S!<SM9-ID,,=<+^TGX6^.G@_QK^V!KL_
MPI\0_'RX\4?!G]A#P1JGB#2?#WQ-\'^$_$TVD>-_C.GQ'\81>'_A-J%_XZ\0
M:-X*M]5T[7_%/PU\!ZYJ>LW6FZA:Z3<SO8WDDDG[K44N=W3:O9)?=;K:^RZM
MV>IK]3CR<D9N-I591:7NKVBJK6G?V;:]J[RY5*5DGIH?RO:+\/?C$/V8M4L/
MB'X7^,LZ^!/VKOBYXF^"WP,A^ W[5^I_";XJ^!;[X2^!)]#\*:GH&E^)[OXQ
M?"[PU/XMUCQ!?_#'Q%XO\4WNE^&?$LNMG4-&EAMWTS3?T/\ V?OA%H/AG_@H
M3X@^+'CS]G7QOX!\:_%W]E_]G/6?!NN6UCXX\9^$/!WCK0]%^)FE?&#P7XB^
M(=C+=^%++Q#H>G3>$-(_XJB2TDUV,6E[HBSWES>LW[)44W/?2UU;=]T[].Q%
M/ 1IRIRY^9TY0FN:%[N$)POK)M6A-J"BXJ%DVI.]_P"='_@HA\,_%'C+QW^W
M98_$/X.?M+_%;Q1XL^"W@+2OV(K[X1:/\2=:\':'IW_"%ZU:?$G2KBZ\'ZA9
M^#=#U27QQ)>7_C?3O&RC4O%GA.XTG3M'MM<5;735A^/7PY^)>K>(_P!I.QU_
MX8_M.:]^U1J=_P#"E?V"_'_@*W^)2?#;P+X7MO '@2UTY(?%&@7MK\-_A\?#
MWQ#M?'-]\6[3X@FRO-:TV>/9!K%I<:? O]&E%'M-+6[=>W+MVORZ][L)8",I
M5)>T?[QW=X1;LW6=V[^]./MW[.;^#DIZ/E?-_/CJ/@WX_:+\>_VLXO@7X5^)
M?Q'^*WQ%^$_[0EQI_P ;?&_@SXQ_#35O@K\0?^$;T.W\(?#WPEXK\9:K;_!?
MXM> ?$/B&S,'PLNO"6EZ9JW@Q+1;J_O;RPFN+]O6/^"6_P )_&'@[QYXF\4W
MWBSXNVUEJ'P>\)Z-X_\ A]XT_9Y^,/P>\.R?$VVU4W-SXHU+Q'\7_BCX\/C;
MXF6Z-J^E:_KG@6VC\.:SITEM?W&H3,NFJW[;44G.Z:M:Z2Z.UK>7ETLUO=CC
M@HQJQJ^TD^2<YJ/O**Y]7RVG>[=W-S]IS)J*48QBD4445!W!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ny20077915x1_ex10-33logo01.jpg
<TEXT>
begin 644 ny20077915x1_ex10-33logo01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !, 3@# 2(  A$! Q$!_\0
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MJJNKG&DWI_Z8/_Z":X^IZG0^*O@QX3TWQKX_N-+UL3FUV2S8AE*-N!/>O?\
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M3ZKK,WEV\8PJ@9:5CT11ZGI7S5J'QD^(7C359;/P18RVL(;Y8K2#SI0OJ\C
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M0 4444 %4-=AO;C1KV'2IX[>_>)A!+(NY4?'!(_S^-7Z0GC\10%CXOM_$GQ
M^$/B.YBU/SI8YY#)+'=EGM[DD\R(YZ'_ #BO4]._:7T*2V4ZEHFIP3=_**2(
M3Z@EEXKW&_TZSU2"2UU&U@NK<GF.:,.I_ YKB9_@S\/[F=I7\-VR.>OE22(/
MR#8JKIDZGA7Q/^-M_P"-K!_#WAK2KBUM[L['#D//<#/W54?=!QZGC->R?L^^
M KCP5X5>35%*:MJ#"6=#_P LE'"I]1U_&NR\-^"O#?A@EM!T:RLI&X,L<8,A
;'NYRQ_.NA_QI-@EU%HHHI%!1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>ny20077915x1_ex16-1img01.jpg
<TEXT>
begin 644 ny20077915x1_ex16-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  / #X# 2(  A$! Q$!_\0
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2<UO(Y\?Q+5Q=%T8QY;]4S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>ny20077915x1_ex16-1img02.jpg
<TEXT>
begin 644 ny20077915x1_ex16-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  D & # 2(  A$! Q$!_\0
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M)]GE*B3&<;EZ-C)Z@]:** /TVMF+V\3,<DH"3^%2444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ny20077915x1_ex99-4img01.jpg
<TEXT>
begin 644 ny20077915x1_ex99-4img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 2K!WT# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***KSW,5N4$C!3(=J9/4^GU_SFE)J,7)[)-_<"5]$6*1CM5F/102?P&:%.0#
MZ_Y_6J.IRO#8W$D>2ZQ/MQZ[&(_4"G#]YR6^WRVO_>M:_P!X'\P__!:'XJ:?
MJ/C#0/"HE5HQ:R13Q!LJ74\$@=#]>]?AKIGV:V9;!E7=/$98QZ+V[]>>,U^A
MO_!2SP]XR\5?%C6_$%YIMV-.T?4;F-)V1_*$>\A3NZ8P,?3!%?G=IR17+PWS
ML!+:1BV([CL<]<=*^@P<;7BM>5QIJVJT49/?_$]5Y:]O#QLHQG4;;O&?,]_A
MY86:?>[[;=78F\-64U]XP\.1P$AXO$&GM\O94O8B?T'.?\*_N\_9;O1/\*/"
M\3N'D32=/5OFR05M(ACOW%?PC:9J1T+Q9:7L9_=P>7=*WI*DB2 9S][<,#T]
MN:_JP_X)G_M!:EXS\&1_\)'(UMI]C;,B33OM3;;IM&"S$#Y0#T''6IS"E!TG
M*+DY<J<KZKGCNEVO?U-\N:_>-V2]WE;?KW]5>W5[(_9RCI7'>'?'/A[Q3)*F
MBZC;WOE!BPAD5R O!SMSW'7I75I-'(S1AAO .Y1U'O\ CU%?.RG9N*^+D<E?
M;1I6>EE>ZM<]4F!SR** ,#'I151ORQYOBY5?UMK^(!1113NG>W1V?K_3 ***
M*8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44T,I
M)4'D=1_G_/I3J "BBB@ JF\\33_9W(! +<XQ@>N>.WX=ZN5\>?M5_'_PW\$?
M!NM:[<:O:VNK6>GW4L,#SHDK,D+R)A2P/+ 8^N1Z4 FT]+WZ6W/'?V\/VX?
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MWM^I^E%]I4VH:3))8LOFL%="IY"XY&!R.GIZ#N:SM'U&'3$=-2PRQJRL&/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!FVZ3"\N&<G82-N>>Q_P Y!K2HHH **JWLK0V[R*,E<<>N:IWFK6FF:?\
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MZXFMV2(21J^"5;U!YSC_ #Q7"_L->!+GPC\*-(GNQ(MQ?6,9D64$,K?(<$,
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M3I+Y&F2.#SC+;A6E+@ !%Q@ ?7%?TIV]AIO@[2;?2= B6UBMH4@1(P%Q$B;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[2-[:KRV/H<+0Y8SYU[T&HTU:^G-?F?;3KOH-U.\N)93),Q+XVQ'GB/D 9]
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M#FN7-E$EY=P)(XDC D!*H_(*Y!&?4=,'I7'[14Y.>J3BGRZ\KF^5--=EK?\
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MIP3UZ5S*I>=&=VKU4X6>\(\J?-_3?J<&.IJ<;1=W&:C;2UY+5[+9[/:W7O\
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MM)]U5N823^ <GVHYH_S+[T!W5%95EK>F:A_QZ7<,V?\ GFZM_(UJT73V:?S
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MO(9"Q7 1U.03UX/(QVQ[GBMI'#\@@C .1R,]_P#/UJ95(Q<8MZR=EZVO_7_
M'RM).VCO;Y6U_%#Z***L04444 %%%% !114;L5*X[G\/\^OUS32N[$SDH1<G
MLK?BTOU)***XO4OB#X2TBX:VU#6;*VF1BK1R7$2L".H(+@C\:3=MRMSM**\]
M/Q3\"J 3XAT[D9'^E0=L_P"W['_.*:OQ5\"-DKXATX@=<74''_D2E=/9I_,=
MGV9Z)17GG_"U? F<?\)#IV<9_P"/J#I_W\IO_"UO ?\ T,6G?^!4'_QRCFCW
M6GF@L^S^X]%HKSE_BOX#3[WB+31GIF[@_HYI?^%K^ \;O^$BT['K]J@_^.?Y
MZ4<R>S7W_EW"S[/[CT6BO.5^+'@)\[?$6FG'7%U <?\ CX_E4T'Q1\#W,R6\
M/B#3GFD.$074)9C[ .3^G]:.9=U>]K=;^G]=PL^S/0**BAFCN(DFB8/'(H9&
M4Y#*>A![@]JEIB"BBB@ HHIK,J*68A5 R23@?K0 ZBN$OOB7X+TZYDL[S7;"
M"XC8J\3W,*L"."""X(-5/^%L> N?^*BT[CK_ *5!_P#'*5T^O].UOS06?8]&
MHKSG_A:_@+I_PD6G<\C_ $J#_P".5NZ)XS\-^(G,>D:I:7KC.5@FCD((ZY"L
M:.:/=?>OZZ@=31113 **** "BBN2UCQSX8T"=;?5M6L[.9QE4FGBC8^ORLP/
M'2DVEN[ =;17G'_"V? ."?\ A(]-P#@_Z5!U_P"_E+_PMCP$3M_X2/3<XSC[
M5!T_[^4<T>Z^\+/L>C45YW_PM7P)C/\ PD.G8]?M4'KC_GI2#XK^ B=H\1::
M2.H^U0<?^1*.:/=?>@/1:*\\_P"%J>!?^AAT[_P*@_\ CE-_X6OX#Y_XJ+3N
M.O\ I4''U_><4<T?YE]Z'9]G]QZ+17':/X]\*Z].+;2M8L[R8G'EP3Q2-GZ*
MQ-=C3$%%%% !1110 4444 %%(S!06)P ,D_2N#\2?$3PIX;BE.J:Q96C(I)$
MT\<9&!GD,P_SSVH;MN.*<FDE=MI+YNQWA95ZLH^I _G6=J&J6NGP-/-+&%4$
MGYUX Y[GO7XL_M?_ /!2GP_\'M2FM="UVRNTBLI)LP7,3_.JYP=K]<]OH><F
MOPL^(_\ P7W\3Q?;K&&25D22:-2K$@J"P!X;H<?S(QQ7)7Q4*7752<6GUM:_
M7S1T4,/*K*">D9<W6S]VU_S5NY_8[K/QO\,:/_K[J$?,4YD0<@]\_0^WOTSS
MT7[2'@Z68PB\@W X(\U,Y^G^?7I7^?SX[_X+A>.-6N)XXC>$(S.NUGY))( P
M>GJ,_P!">&TW_@LUXY!2\D:]5F)8@F3. ?US_ACWXH9M13Y9OWHJ7/I?52C&
M-K>NI4,)4FZBM9PLE_BNK_*U_P .FI_I'>'/B%HWB((;2XB;?C&'4YZ<_CGZ
M=?:N]$D9Z2(<^C+_ (U_GH?"W_@O=XTT"ZAMY?M(4,H!9G'=?4GL.G^/'ZJ_
M /\ X+?7GC_5+.TU2^6!)FC5C+(!U*@YR1V)[GI]:VHXZ+3=1Z*RT=^W3[V_
MFR)X:I"2B[7<7)>BM?77O;U/ZW 0>A!^AS2U\2_L]_M7^"_B;H\5U<^(M-$[
MJF(S=P[R6 /3?GOZ<GIFOL?3=8T[5XA/I]S%<Q'H\3JZG/NI(S7;2JQK1<H:
MI/EOYV3_ %1SM6W-.BBBM0"BBB@ HHHH **** "BBB@ HHHH **** "BB@G
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MXF:D9_&D$D>FVD5U(?,5X"JR +)N;@XS@CVYK^P'XH^ --^(7A'5/#U_:PW
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M]:ST:TE9X;?SKR\E\O:K-LR49.BC'KZ?T>&W5Q!;$_N8&2YWY^5BNT[,\@Y
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M^=_PEMWY6W8,74O#>G$GU]:_"H:1=1VDDAED!201 98'#$+GW&<G(Z<XI_\
MPC4X58O/D (\[(9AUPW7/K_CSTK.CB*N'BW.;E*";:W]VI\+=]WOOM^"THSB
M[QY$](1U6O)%N[UMKJOOOJ?NC<_\%4_B.=B+XMN]R2[S_I4N=F>A_>'_ #QT
MJ:;_ (*I_$>2WGDC\6W6/*(7_2I<;@.?^6G8XQCG\J_"C_A'KC!G\Z3,A$1^
M8\+D G/IGH?<YJ1/#]PD<]N)W.V,L/F8DDCIUZ^W)[>];2Q34/92G))WJ*5[
MO5QMK_V]JMM.Q;LH1BHQ_=\E]%JK<L]GT<DUW?H?N%8_\%5_B2;7+^+KS,8)
M?_2YO?K^\]OKGK5:'_@J;\4)X[PKXNO2)<&(?:YO0]/WOL3Q_.OQ(M?!\WV8
M!IY UQ\A!8Y&20<\]>>/S/K5Z/PS+8V\F)GS /E&XDG /0=3S[^_I63Q,N:$
M5)WYN6>K=O=YE;7NDNG3;2V<L+:K[-).'-&/-IU@I2[ZI7^9^TMO_P %1_BH
MD\3-XMO0B'Y_]*E'J<D^9_\ 6ZCBM2[_ ."J7Q)"B,>+;PNV&_X^YNG)_P">
MGI[?IG'XFG09&@5O.;,R[F(8Y!R.I[?GG@=ZH0^%[BY9[AIG_=%D'S'!!SS[
MC_)]:<<15BWRR;Y&E&[7O3T;3\G=?=TOI4J2]LWRZTH.4U96O'2/K?E3>^]_
M7]NU_P""JGQ*,J2#Q;=^6JA&_P!*E/S9'82<8_E]*^F_A#_P5IUS3Y+==>\5
M2D+(KOONW^YG/),ASGWQ[#CC^:6[\+3V\#)'.YRV\X8G').#SQU/'MQ64FCW
MTC@I=3(S8B #L,#D'C/&.?U]#79"LZE)RE)IPNIV?6GRN_\ Y.]NWH.5)2;I
MJRW2;Z\BBU]_/)779=C^]+X(?\%E?AFVI6B:SXCA="D2D/=#[P SP3GKQ_,5
M^M/PS_X*@_!/QPUI8V&L6DES-L4 7"$DN!C@#GJ?RSWS7^7+IVDZOHMVD\6J
MW8V,'^69P,G!X^;_ /7QZ<?4'PV_:?\ %7PFU2RU.'4+V7R)8WQYLC8">O)X
MZ?F0*Q>8PC5BHZ\BY(W6[O%7T79[VZ^IC5BG%T]I4I<L$E=RCRJ[>UW?KY?(
M_P!9;P5XVTOQII4&JZ;/')!.@="KJ>#@@CGD'/IZ5VH(/0@_3FOX/OV*O^"Z
M>O\ VJR\%:E/)'#;O#;^9,VT88*"=SD=/7/_ -?^OG]FK]J#P?\ %OP?I>J2
M^(-.-_>VL,OD&[A\PLX&5"[\YR>F/J*]6GC*<YPIMKVDHJ3VLME^;_K8Y9Q2
M:Y;M-1Z=6M5]]S[(HJ"&YAN(A- ZR1L 592""#T(([5.#D ^HS75SIS<.JBI
M?)MHC^OZ^\****H I"H;&>U+10)I-6:NGT(Y3B*4^D;G\E)K^%G_ (*>?\%(
M?%GPF_:1\3>#M+\27%G'8ZY>6P@CN'0*(WQM 5Q@ >WO7]T=R<03#UAE_P#0
M#7^6C_P69\%2:O\ MI_$:\:X="GBO4BBER.#(W;." !].GIFN#&5N6#A%V?/
M&,FG9]):?K^AI3@YRLNB<M>JCJ]SZ;NO^"K'Q FLTEA\6W7R1[7_ -+E^\?^
MVF1C^O'<U0L?^"JGQ&MXW6?Q9=;F)=<W4OW3@C&9/3Z<>U?A@?"T]L$LS</M
MG&YCO.."#C/05+J/A:=K=)5G?*!8P [9(Z9 S[?3C/:N*AB'!-SD[.4E+6]K
M**A9>;79_A8]>G"E"<*?+>;I1>V\8OF?S;=K-ZV6Q^Y?_#UCXAE_,'BR[V'Y
M0/M4N,D\<^9U_'_&FG_@JI\2!(4/BV\ROS'_ $N7[O/;S,8Q_+\_PN7PG<"
M#[0_&'^\>PST!_ST]JB/A^Y(\X32?O/W1&XDXSCIGU[@?RKSZ.(_B7G)\U2Z
MNW\+L[+YK;MU,)1IU7>*2M.5DDM6^3E7>UD]4K?B?N7??\%3_B9<(C6_BV[
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MK!,"._F1J_;ZU<KWXN\8OO%/\#SPHHHJ@&2'$;GT1C^0)K^.3_@M=^W'XP^
M?QU\-:!HVO7&GVUU;7+-''/)&I*D '"NHP"3V.,\U_8W*,Q2#UC<?FIK_/(_
MX.3O#1U+]JCP#&9C&LNGWCM\VWN#S_3_ /4:\[,*G)&+NUR\TG:^R2[-;?\
M#&E)1<TI_#=7]+I.U^MMCYYM_P#@J5\47MY<^+;PLTQ9?]*E(" _]=#QR,?_
M %JLG_@J=\3(IEE;Q;=[ @4G[7+]X8!Y\SCKS^/K7XD7>A3V49V2N1'((A@D
MY&0,\$'T-3R^%I9HHXVG8 @3 ECR3@XY^GOS@5Y-2M4A*G+F?++71]4DXKT;
M;OKM;L=U",)1<7:R=2+=NDU'DOM;9WT]-V?MS)_P5=^(:?NCXMN]_7_C[E!Q
M]?-YXSS5*'_@JM\28KF6XD\6WGDRKMC_ -*F(W#W\WU].<]>HK\09?!4LDGG
M_:7RQ";=YZ G!P#P,=/7'/%6I_!SRVZVPN&S!\QP_4XSU!SG^OZ9TL14G%\\
MFK7D[:6B[6\W?U[;(J%*'+";5JB48QCTLUHVWM[J;=^OG>_[@?\ #U_X@87_
M (JV[RG+?Z5+R#TSB4\=^^*B7_@JK\2&^T8\6W>)^8?]*EZ=\#S/\_2OPNF\
M%3J8<7#GSF"MAVX&3CD\CICO].<UKKX0EC"!KAA]G''SL,C'/UZ\]N*U6)Y(
MWYV^=1<5?=)J;V\D_P!+&B3I\C4(N$TVF[77LX>YH^Z6M]F?V,?\$8OV]O&/
MQU_:!@\+:SX@GOXEU0P-%)</(,?)P0SMWY[=>G6O[55.0#Z@']*_S8_^#>;P
M^_A_]L/1I/.9QJ.LM(P+9P=T>/?J/;G/X_Z3:?<7_=7^0KW,)-3I)Q=TW?76
MUTG;=]]KZ>1YU>4&X*'V8^]HE[S;;];7M\AU%%%=1@%%%% $$MPL3QHW60X'
M^?P]_P#&9F"@DD #J20/YU3NK;SI(9,X$+;OYGGGI7QA^V/^T]H'P$^'&N^(
M/[7M(M1L+221(&GB64LJL<!=^[.1TQGI4RG&"<I/1*[VO8NG"522A%7;-']H
M3]K[P!\#K2Z7Q%?V\#K#*1OF1#E4<]_3'/XCDBOXXO\ @HM_P5HO=>UW6+/X
M;^*)(T'VB)!;W38#<@?<=><D#I^9!KX?_P""AW_!33Q'\;-;OK"VO+E4\R>%
M3%(_(8E<_*1ZC@8K\6IM#O=>O6U>\O)IFNF-R1+(S<L=^,$GG/'^37E2Q:K-
M0<DH6;DUH[I^ZOGI?U=GT.^&'5/EA4TE5Y4K;\ZE>ROI;;736_8]9\3?M)_&
M[XAW-[>^)-=O;Q9;B01F665_]'9@0/FD;C;_ "Z9)K@Y[BXU*-Y;@F21P=Q)
M))<]3R>?;&?<^DT<PAL_(\K#(PB!P 2 =H/3)[=2>*T-*LUE9HVP %\S)XYP
M2>.1_4<5XN,JJH[J33]I/1/1W4-_2RW_ #V=5M-->[-*,(J+=G*+7/M:V\;W
MW?F8.F:-I+D&\B5G5B9"1U4'T(/8>^<5H3Z;X=DG:*WA01MD(  >3DY& /YU
M;GL%$DFU@#)F/ [9;&?R.?KBL2"P:UO"F\D1$,N2><YX/T]\C\ZY'3G2BW%<
MSC"TGO\ Q+2?GHTK?\ [8UY1E)5(PC&$82DU:[DU'3:_>_Y%?5-%M;5HY;5%
M5HSEB!SV(/0>QSW[\YIVE^._&/A6YCET6]G@D8YA*,ZD%<$<AAT(]>Y[<5T=
MY&)(<GGS 3],>X]?;]*9:Z1#=JLS!?\ 1>@QG.< GW_3]:FE*I3M"[?,D]7I
MS2BDNM]G=N_Y(Y,15=9J-DIJHN6VGN2BN57U6MU?7[C[1_9Q_P""@7QE^'6O
M:<-2\47T6G0S1B8-<3*NU2HP<R8QUR>O:O[*/^"?/_!5;X?>*/"VG:1XCUZ*
MXU:YFMX 9;I2Y:4A!G<2<DM^8_ _Y^VM>&X9T6.&4(TRA\JV""IXZ'C'YCK7
M4_![XP^(O@WKMKJ-I?7FS3KV&Y55DDVD0RB48&<=5]_J!7O8/$NE15).[=IP
M;OJXR7/?UMY;;=#&=.C3C[2#;FVZ33VYFH\[7I?3S/\ 8&\-^(++Q+I%CJ]E
M(DD%];Q7$3*P(*2H'7H3V8?7-;K,%4L>B@D_A7\L_P#P2+_X*QQ?'F#2?!OB
MW4XM/_LZVAL4-Y,D1;R%$2X\QESN*^X_+G^H'3-6T_7M/2YT^ZBNH9XE*R1.
M'4[ER#E21TYSGFO>B[QBW:[BF_U^[KV..I%0G**V5OR-2&59D#KC&2./K4M5
MK2#R(@GN3^9JS5$!1110 4444 %%%% !1110 444FY3G!''7VH 0YR#G"XY_
MS^7Z_C\O?'S]I_P1\"X+C_A);Z&W9+*2XP\J*<",MQD?U]N#BMC]H'XY^&?A
M-X%US7;O6+.VO+"TGFCADN8HW8QQ.XPK,">0,8!'XU_ 3_P49_X*J^(?C1XS
M\1Z#9W<ZP6DEYI4;PR-M:-':($%3@@@=>>O2N&K75+VB@[R<[ZO9-).VZMVM
MYW&HNZ5FK^7XGV[_ ,%'O^"O%OKVJZKIOPR\3O%*#-"BVUT?]9ED _=LO?M]
M./3^:7QY^U!\:_'^IW%QKVO7UW#/<.S;YIF!B9F('S.?X2 "<CIWQ7AEMX>O
M_$FM76L7M]/+YDLEUB21VY,AD(^8G/4]#VX]NN\N)E\K"Y'[O.!G & >OX_S
M(YS\_BL2INRD[Q<8M>2LY.VNO3HM+'HJI*%-8?E2;?).2M>RE#D>E_/6_3<Y
M[49]5U^YD-P[R+)@)G<0'(.?4]<_YY#8_"]L@@%S$"8R3/N],<]>@Z=>G'H:
MZB!%LY(S@$1-OSZXSU]O7'ZU)J5TDARI&;L8.#TZ\^O.,\8XZ>_-";G44HIJ
M$7*;79/5Z+J71YHUG%-\M)SYY7WCTO9V;VMY>>ASM_HNAQ6_R0H'8 PG XQG
MV'KVXXSZUG-8*R1BV4 *N&X[C\N!@<D?G6['I[7I(?(%L=JD]\]",_\ Z_YU
M?N+6/39;>)2#YZ[FP>F!T)]<_P"<<!-648O6<)NM"VJ<+J33\^U^G0VG.;@J
MLH*Z<O9QM=.'+%MM:Z\NM]=3E=-\0>-O#FYM(NIX72021>6S@@+R#\K =O\
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M2MLN7EB[]?FO5;W/W"G_ ."HWQ/N()%B\6W>\\J1=2G@9STDYZ$X_45:T?\
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M^'6LY]9N%MOM81MTH\LC!Z#@<<8]J /0Y;^*&#SV(V\Y.?3/3\>,]._T8E]
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MQ/&?@BP^('A34_!_B"!;JSDLIE6&10REI$(/# Y&<9/OD9XQU=]"QUV7Q%C
MCC:SCCYPR1DJ& R>"!G/?@U9TJ]\^[FN9!L/EG /?J ,GZ?4^E>!&2I5$HJR
M5_=M9-*RE>WFT['=&<:KI]5/WE_AO&+_ !/YIOA/XL\4_L+_ +?ZZ?<7$NC_
M  W\1^)-/L=-MPS0VS"65S*JJ"J'<.N%P?I7]V_@?QC9^/\ PQX?\3Z/,LME
MJ$$4JNK!@08P3RO'4CTYZGM7\B__  5A_9W?Q1X0T;XR:+;,NJ>!KF3Q ?LJ
M'SF:S^90=GS'(R?US7ZG?\$3OVO4^-_P0TKPQKMZD6K^'[&.!K6YD"W D&Q
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M-?FZ\=_7IU^N:V:*;;>^NWX*R^Y(=VMFU\^ZL_O6GH9S^1I5G+, %CAC9V[
M*JEC_(_YZ_ /Q%_;^^%/A*_U?0;O5+:*]TZ::WE4RH")(\J1CKG/Y?GC[^U>
MT-]IMY:@D&>"6/(Z_,C+_6OY-_\ @H?^R3XA\'ZQXK\;V-S?/'>WEU>XBDF*
MKYO[P#"MTX].E:T(N=5)6;4932>S<;63^_[[$MV5_3\SM_VHOV_[C6$OAX,U
MUD#)*J"&=N^X#[CCKQT-?COK'CC5/B'>WNM^*[AKO5'\[R)I6+,/G8QX+DG
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MB\EB9G>10I=_NEV<>G0<UYL\D>C7JVUF!':,VUD' V@#J.!QU%-T[0ETS2+
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M/M'IE2>._/MT^IK*\0Q0RZ/#+:C&I6MQYZ,,!@J8*XP <C Q@_CS5I8!)%+
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MVJK/]H'X#>'X9]0BEOM'T>QA>,RJTFXJN<KG=G)_K7Z\5])3FIP4NZU]5O\
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M].BXI.";=M;O^\D]_F8.J:]::9((IV"LV,9Z\X]?<U2_X2S3_,=-XRB;SR.
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M_P  SE'F5KM:IZ>3O;Y['4WOBJS:-$C<;G4..>WK_G\*YSQ+JN@>)="OM#U
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M_P#U?A7^<9JEQML;WY3^Y56!]<,#U_I],U_H\_\ !!,^9^R-X.FZ%]!L^/3
M7_/7M7NY6TYRNE94:?*W:[LHW?>_376QPU(22;MI%)OTE:S_ !1^[M%%%>V8
M!1110!S7BCPOI?BW39M*U6%)[:5&1T=0P*L,$88$?G[5_*#_ ,%CO^"9.G^,
MM%U[Q9X#\-HU_I\%Q?1S0VRLRNF6# HF>">QSVZ\'^N+')/J,?Y_(5YO\3/"
MFF^+?#>J:'>6<-Q_:UI-:DR1J^/,&W/()_E]1DUSNFZL9<ZY9<S2>SY4U;[U
MZ:ETY*,O*246^VJ;:WVM^I_CY:YHOB+1O$5WX$UM95U3P_.T-Q$X8,IW, ""
M21TQCW_&NEADAECA@AQYFG#R[GG[K8XSQD$GN03FOV8_X+3?L47?[*?QAO/B
M9H^F2RV?C/4)YI?(A9HH%C:0Y(0,JC SDX'/X5^)VFN(-/NM55@TFL@3.@.3
M&<<@@<J>/0'Z=_F,7248SBG9NIRQBM%?17Z:VUOWZZMG?.I%RI*DW*SA/7;F
MBDE]^[^9'>-)<F7R<E QW 9QD<KGIUY_#FKEC9_VII%U;7B[YP6$(89(0 XQ
M],# _P :;;#R-D;#BZ4N22/3/O\ Y^M+;WS6LCS*I(0M'C!QCCY@/KG\^:YJ
MBE%PI1;3A&+;3ZRDEJ^UU;?5;FM>G52IJ.D;[WL^>;5UZ+]#WK]A/]H+Q7^S
M7^T-X9URWU*;3M%DU>PMIRLCQH4EOHDD!PRC!1B#D>OUK_5(_9M^+^B_&CX4
M^%O%VA7*74-QI&FB62-U<&8V<9DR1GG?G.2>0<U_D:ZEI#ZI;+>PEH)M/F74
ME=,JVZV99AAN#G*\=?RYK^Y+_@W'_;0;XG_#!/A7K=^!>:,)PD=S(!(5MM\"
M$!R&Y" #&1]>*]C+J\JBJ4JGNIQ@HM7O=M-/YV_X<\^LGS\\DDYKG2Z6T25O
MDW;>V_<_JYHK/BNS)>R0#.U4#@]CG\/Z_0]:T*]V$E):='ROU6YA_7WA1115
M@%?QZ?\ !SSX"GF\&6WCL0$Q6=I8VAFVY"DM'@;NG;IV-?V%U_.]_P ''/@&
M/Q%^Q%X@U81AY[74;+#!?FV1D,1D<X^4^HX[#-8XCF=*2BKN7N^B>C9<$W.*
M6[:7K?I\S_/;TGSCI]L7R9#&K CGY"HQWZ<]_P!<4EXN)C(2?**G9Z;\>N3]
M,>IJM87Y%M&NT@P[;8KC^Z=IR.W(/Y<8-6;QC)MM^T8$N['KSSZ]>WMTKY&T
M8U)J5TI3FV[7<>64=O6_X];GL*2J1G/:"NN9+5.'*TUYM[_Y;26\DZ6\G)#N
MA#'/)&>!QZ^G?OUK[9_X)A^*)?!G[:/P:DFE\J/5/&FFH<G 8"09[@']>:^(
M$N6(B^7_ %K!"./<?@,#U_PKV/\ 9S\1GPS^TY\%M61C&-(\76%R6!V_=<=2
M.X]R!BNS#-1JQZ14JG-):RTE%Q7S2^[6VISQIMJI.M[L(RYN96^)2BN6^]G?
MKU[(_P!<SP_?)J.CV%W&=RRVT+ CT,:X_P#K^];->$?LU^)_^$P^#7@OQ!N#
M_;]*@EW Y!RB]_\ /IVKW>OIHN\8M;.*?WH\Z=N:5MFVUZ7"BBBJ)"BBB@!D
MC!8W8G 5&.?H#7^:5_P7J\;7/B[]M?7_  ^DYE@\-Z[(7C#$B,$N.F3@XS_]
M<YK_ $CO&^KC0?">NZNQVBPTZXG)]-B$Y_SBO\LG_@I?XW'CG]NKXVZH9!(A
MU<E"3N"X=QP <8[?_6->=CZL(0E&JO=<4XOS<E'\F[^7XZTY.-VHJ6VC=K6:
M?XVMZ7^?P^89)_M9/)0@0GTZ>_0]\?I53$EN8S_"4_>C/<GCU[YQ^.:GAU P
M_:"1]T@)G'S9ST[<>U-NG,HB0#F==YQ_#C)Q[=3[CGVKYYRB^7F:2M46G\JC
M>/;I9^OF>I*4YTX2LE*-XUK*RC"23TZNUU:^ET^]R#;,D3L,[G;<G;*G/3_/
M;@T7]NT]B3U*X;UPP&0?S&<BGRW>8.F3&5C]S@GIQC_)^M6?.)MF4KD,A?/3
MG:?PZ@<>GK7-.<(5&GLFN73XI2C%17II>_KU,IVC-MJ].$I2AT4IJ,-&NVJU
MM:]GTL_[.O\ @V=^)INO#EU\/YKG=+;0W5V(2V<*I=0VW)[ 8.!TK^P>OX#/
M^#9?QSL_:=U[P_+-LC7PS=.(RP49+R@84_GT'0CN:_OR!R 1T(!_/FOJ<KDG
MAHQO>2]YW_O)6O\ UT/-FO>?GM]PM%%%>D2%%%% #6^ZV.NT_P J_-C_ (*7
M>)_^$4_99\<WMW((A+INKPJ2<9WV4RXZ^_'MGUK]*:_#'_@OOXY/@?\ 8KUB
MZBDV/>WDMF54X)$T!0].3][Z<5CB/X-3_"5%VE%]I)_B?YN>H7$NK:_X@U-2
M6@F\5ZJ%;)(#-?S$?7GWZ9[=;'B9Y5M[J",G>MM\_/8@'G],#T'/:L[PI)YF
MCW0<9=]<N[W)[^;<M(.HSWST^M6M<E:2_A&TEM3:.U"XYRV%(&!U_#Z=>/FW
M:6(A0>JC*3IN_P 2T<$_*R?W+=7/1E6YFO9*]Y<S7^"-DUTO)-W\UU9_?K_P
M;@?#PZ%^S7I/BTV^PZ[IQ!E*@%]FS/S8YQG@9]Z_IDK\;O\ @AKX/3PW^P3\
M)93$(YI]/E+$C#'<(^O?W_QK]D:^@PBE&DE+9OFCYJ6O_ ^1YLG=M_UL%%%%
M=0@I H7I2TQG5 Q8@*JEBQ/  ZU,IJ%DW;F:BNU_/^K>@K)M.VJO9]D[7^_3
M\#\]/^"C7Q]TWX(? /Q9K%S>K9W$FE7\4#F3RV\SR"5[@^X K_+G^+_CO6OC
M;\<O%?C_ %.X>]M;[49S!.[LX;RIY ,,688 /'KS7]9O_!R;^V#+H=O_ ,*=
MTB]+O=WJV\J6\F6"7"JAW;#P  1^?2OX^/"0?1]$6TD!>8-)<%V!+L9CNY/S
M$]3U/ ]S7CXW$QC[1)NSLIW^SRI+2W?KY7WZ^MA(PC!5+)Q:O*35[5+J*BNU
M[W^Y=;&YK-Q<2/#;P$[8>' [#I[^F,8].,4W3$=V;S_O*?W>>HX)P!]<?A^5
M3VHWDW+X_P!)SUSQU[=L8.>._P"%4Y+Q[8SR!2! P"\?>'Z<8//'\N/F[PE*
MT;.G"I&IJM7&3C>.^UWV\[=%T5I.G*;@DH248U&M.2]DN7Y>];9-]&,TZ674
M;37([HEIK:8K;9)R$4]LC\B.OI7VE_P3?_9UUS]IC]H[PMHLU@^H^'+._CCO
M8C&9(P\$\9.X$,O&"<8Z=SG%?%'B=V\,6>G7MNOF/K0B9D09.92%P0,X/(P*
M_ME_X-V_V,XO#G@\?&;5=/ N+VX^W0FXB^8K<H7!3<!QZ8SSCO7N8>E3KUX)
M7M"_39M1E;_P%KO\['%4JJ4'>4E*,IN+6]N2$8_>X_?L?TW_ +-GP=\/?!3X
M7^'_  GX>LHK&"+3K,SQ1HJ#ST@56)"JHZD\8_\ K^_U0T^42Q. NU8W,:C&
M  O [>WX5?KWZ<%3CRK:]_P2_0X&VVVW=O=]R&:98MF?XCC_ #[U,.0#ZU3N
MK<SF,C^!L_RYJV!@ >@ _*M6H\L6G[SYN9=M=/P$+01D$'N,?G12$@#).!4@
M?@Y_P6?_ &+].^._P/\ $NK:3HR7GB.TLS+;2I"'D7:LCN5(4GC /!Z^G2O\
MZSQ5H.I>!/$^M^!=11X=2L+^>V\I@591 Y1AM;G@@C)]^>:_V"O&WAZS\3^&
MM5TJ[@BN([NRN(MLBJRG?"ZCALCC/X5_F;?\%D_V:+K]G[]JJ_UZ"QDBTO6I
M+O4&D6)A IN9PP!;&WC=@<^_(XKS<=033JVU6B]79/\ !==/DV=]"M!*#D[3
M4Z:;W;A%W;\[WL_)=3\LK2*=,J^=YSGJ"5Z'W[_IZ5!&C1W3$#" 9&/[V<GM
MWSU_KFIDU/S(UN0!\Y48[8;'L,^OJ?2F&8B1U(X";P?PSVSW/^17RU6F[RL]
M%*4FEM:#7I?>^W38UFI)U.36,Y5%;5)*].TEYZ[_ / ,WQ);3WEM:I:9\^25
M4<@'<0<=^_<GGICJ:_J>_P"#>/\ ;"D\%^-+CX,^+-7,<,AM+#2+.68JHFF*
MC"JS8YQV&3C@8&*_EXLK@A?MC*"+<F0*1_<Y].I^GIS7L7[+/QEU'X+_ +2G
MPY^(EK--;V\_B?3Y+@(S+&$ADQ\X'!!^@_*N[ XB4GR)7E'V>^EHWAK===+/
MY]!I1G&*Q%T[>SBTKWM*-V]]4].ME<_UVX)5FBCE4Y5T5@>N00#_ %_.I:^;
MOV4OBY9?&CX+>#O&]M=1W$FJZ9!-*$=7*DQI][:<C\0,U](U]8G=)]T>9.*C
M.45M&32]$PHHHIDA1110 5\7_MT?'32O@;\"/&OB&^O5LKE=#O)+20R"-O,2
M,X*G(.1[=.N?3[/)P"3V&:_D._X./_VKSX6\&:=\+M+O_P#2-:6\TZZBAE&]
M!(''SA"2.1T.,G@]L88BM[&FY)7DVE%=&WT-*47.I%)72:;]$[O\$S^0+]J[
MXN>(/C3\;M;\537DEY:WVJW,\,A=G!5G;H<],'KG Y[5Y,(I8V4*,#:1)C^]
M@G)_+WP<U@:7-)%!:M*&DDC!8NP)9B2W4G)P<Y[Y[UT\DY!C^7_7@O\ 3COQ
MQP?;FOF,;5E.4912O)RNEM\*<K_G_P #4]94_<=1+ENJCDE9>ZX6AIYM)_._
M4CA6<,<DEOX.>WKQCC&>3^-,<#SCYV#"$/7D>8#QQ]?Z4[[:=K2!?]4=F/7/
M'IV_R:J7DC2*(5^](-ZCN6(X7ZD]!WZ8/2N/#TFZ[G.*LX645LI1LU;3=II[
M:_>R'[E7VB?,KR4D]5R*G3N_5]?34^G_ -C#]GSQ+^TA\>/#?A'3+*2_M+/4
M=/OKJ)8VD7[+'<@R$C!7&Q>I]:_TZ/V0O@'X:^ _PN\-Z-I>G16$Z:;:1S*D
M:H?,-O&'SA5YW9]^N>I-?S"_\&WG[)B7"3_'K6M- DE2XTR);F$CA3(5<!U'
M7((..]?V, B74!IT:>7%;*C+@$#C P., ?T^M?38&BH7J2BESJ/*TMTEH[_A
M_P  YJU:56$H1=U_$G=[/6\5Y+2R_P""=2H 48],TZD P /0 ?E2UZAPA5.^
M#FW81_>R,?D?\Y_I5RD(!&",BG%\LE*U[-.W>SO8""./?!&L@!^49!YK\<?^
M"O7[(>E_'KX$Z[J&GZ0E[XCM+2Y:*18E>18H;9F!SM+<%<\$8YQ7[+5S_B?1
M[37]$U+2+R&.:*^LKFVVR ,H,\3QYP>!P>M88CDE%J=DYNRLMFWI;RUVN-2:
MM9Z)WMTNK:M?(_QW_&_A;7/A3XPUGP+K"26UU;ZK>JD3!E(47,B( #CICKQ]
M*6"SG$-T90?-\EG8GK@@D=>?0#GGW[?M!_P79_9(F^!OQYN?&VGV#QV%_?H[
M211$1 SW'FGE1M'W^YP#^./QB.M+/"+B,96[A2#(P0#LP3T/().>0 ,9KYW'
MT5.'+!VDY-U8[*-FKV\NW=_)+UHXF<U1E'7EE'G7:5MO-6N^I!$DT6DP2ID'
M+F,]\YP#^'_U^@JSK]K%?:'9S, US$C,['!(/49.>O\ @.]5?MF+461&/LR[
M@3QG))Z?H,?S.*9>7CK81)M)\Y< >G?T]O\ "N"DU2?+)M+GA[.>JDVVK*ZU
MLXM7Z=-M#2*E7G7YERQ<8.,TDFK<O*[[ZQU?W^9_0?\ \&_/[8=_\._B[_PK
M;Q1J[16.LZA#;Z?;2S%5,4;1KA59\$#H!CKVK_0FTK48=7TRTU&U8-#=P1S1
ML"#E7 (.1QR#Z_X5_C[_  5^)%]\#OC?\.OB#932PKI][%+,(V90=TJ [@/8
M$\]#W!K_ %/_ -@KXV6GQM_9_P# OB6&ZCN)I?#^GR3A9%9TD>(<.!T;@C!&
M1T^OT>$J2JPE2=DN1\LD[-ZKMUW_ $/.Q%!4Y/D?-RI.;?24K65G^5O7K;[;
M^M%%%>FE9);V25_0Y0HHHI@%-<95AZJ1^AIU(W0_0_RH _S^?^#EJ Z?\>?
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MC'Q4]Q-:S2><DLOF,"DFTKAG8CGU!P?0\U_0+$<HH/4#G\SC'M7\^G_!/_\
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M4ZC>_P 2E+3=Z.WG;9''CZ$Z=%.'O+VUY-](SLG;T>O9?*Y_=];R++&KJ>'
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MU/\ 8-^'?B*P\7^%M%\1V$BRQZAIMI*)%(.[S((W)W#/]X<9KNZ_)7_@C_\
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MJ3U[XJH8FM@LV"/L_P IZ\YX_P \=L^M?.TZC=2:?Q2BTMM)2?NM:M*^BO\
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M)_J>:%%%%6 4U_NM_NG^1IU(PRK#U4C]* /\_#_@Y;N&/[0?PZ,F"R)>B+U
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M =&_[!EE_P"D\=?Y9W_!+B+;^VMX1DR/^0CI"X!SS]H'/MGK_CUK_4Q\._\
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M!>[:#?DG3BV]^LGKUN<5:I.SC/>4(177W8\LD^VME?U['[Q4445] <@4444
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MBJLI=;0E).FMMF[:/KIY+^\[_@VO\=7'B+X&ZYH$DYDBT#3M/ACC+9V ^6,
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MF.H*V3% ?]"ZX497(7T'';G(^M:#K(LMH6SL*YFZ]>W![_A2Z3=J]JRD -&
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MUE%2;2Z_#OW_ !MWUL?.O@;X'_#;X,Z?:ZI:V5O:36MC"96"1H04C7<20H(
M.>..>:\6_:2_;3\ >"_!&K06FL01:B]E<16P$R*WG*I50/F!SGH.V>G2ORW_
M &M_^"FFL>'O'FN?#>UM+@,I>U39$X(W.8A@B/I]&P>F>]?DYXEU/Q]^T!XD
M&F&/5H[>*=9CQ<*CB4DD'('TZ]<^U:QA-U&XVE"G!-IOX93BG)?+YMV,U)1H
M)T8W;]UO9M)--Z]=OGN<_P#'+]H7Q?\ ';QE?>'I+^:]M[BX>*&,N[@B0L.
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ME/\ O%2]HRUO!*RBK:/YGEXB_-+F2B^972V6A_1E1117T1S!1110 44UG12
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MKM:WD?>7_!+O9_PVKX1V_P"L_M+2=V>N//&,8]NGX5_J9>'?^0#HW_8,LO\
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MY722:5]]'\_,N34_922UCRTU&VDY1E9I^BUOM?0_K*_X-DOC&MOJVJ_"6:[
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MVL/"D3/EXO#:HHR20NZ(8 Z=/Z\=J_T';^3RK2Y;^[!(QSV 4\_S_*O\Y?\
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M/]SGKSP._4<8Z"GW+/<!H4Y:U&Y!SE3C/;D<^G7N,U>M;M8))G(SYD80<<9
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MS/."1&2,_IZ'K[UYE^TK\,4^*_P*\3^!)4666WTG4=3C9@&*M;V<DBXSDY#
M=\Y.?0CPZ-2$:T82T<XRBK*[5K/F]=MSNK4FJ4I-\U.=2SN[\J2C>WHONNS[
M2_X)*_&>3XS?LL^&=9N;S[7<:=';Z2SE][*;*WCA*$Y.,%, <=*_4>OY9?\
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MB[TN68'_ %=TB8SP27X)&?7OQ^5?Z#O_  ;76WV?]C#65SG=XK=N>?O)(?\
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ME(6FV8Q_K8H6ST'7DY[U_F;?#713K/Q@^%>GJ-YN_&FB6S)UXDO(ER<?0_\
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M;T9<TY.S2:C.+N[JRC%KT5ON^\Z*=1-SER)J2C*FM7=R48<OFKV7W=S^U/\
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M%&/BAX\NF>^LO#'C>[:V:3,B1(\@P$+$@#!Z# K^@6XN?,U94(_<VX:,*>@
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MY/7/6O5;?PQ*N@6ZF(^<9G$@QSM)X]N1S_7ICV'3;*.PTNPL0@"6UI;VP4#
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M3GOTX_N>_9/^!V@?#+P;HE_86:6]W<Z19AR$"G#V\;'H.^3CD\9Y.:_F?_8
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M 4444 %%%% !7^?_ /\ !S-X?:P^/*>)6C*K.UE DA&!NW+\N3Q].?KTK_0
MK^&;_@Z4TQ(9-!U0)\\FOV$9? R06BXSUQ_G@XKSLR4704)/E52:@GYO5?DR
MZ?Q+Y+[Y)'\I=E/-)86LQSNRGFG_ &,#H3[=_8=#D5),[O*QR2N1Y!.>N?\
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M?3TJ)89F1Y,'?N)3TV<X/ [_ .)^DUS()RJ ?ZT!\C QCC&/\]#UJ9+P)%G
M_=J8L8ZD#'_Z_J.O?B2DYTGT4G"6^L)226_GIVT7H7!<RBY?$YTX)?\ 3IS:
M>OGU[6*]\RR:9,7^[&CD=2-ZJ<?B#T_+-?W"_P#! [XKQ:1^PSHUE=W022/Q
M#> *7YVC>!P3D# ''U^E?PU7DS'1;S@C(E8<D<%3Q^>/8#\Z_IL_X)$_$.;0
MOV5-.L1,T876KH[=Q7NXSC<*UDWATY4WS*4N63>CBULGWMT_ICE%4$Y)*JKJ
M#;UY6K-)=?ZTM<_OPHHHK[0\@*^ _P#@I1\4+?X7?LG?%36VNA;7D7AVZ>U;
M>$._:1P<Y[?SK[\/ )]*_G(_X."?BJ^A?!_0/AA:W+)<_$6VN]-2.-R'9B7&
M,*>1\I_2N/&5XTJ51/5N*5O*4HP7XR6NOH]C?#1C*M3YFU'F5WYW5E_7_ /@
M;_@D#X,?4M)^)?Q9UR'-SXJNX]3LKIQDRB1@2X<@$]CP2,<BOV-OY+4133Q$
M&9BV/7D?C^'Y<U\@?L*_#\?#7]E7X=:>T7E7=YX=M?/;&V21@NXESP6(]^_)
M-?6]CHKW3P OE9%5FR<\X]^AX^OUK\WQU>*Q,59+EJ.+C;X8RC%/\V_F]+:/
MZ"E44Z<Y/:+:EO;W=?/>-OR/#OVE?'UA\,?V??&/B"_N5M9YK2\MH'=@A+W%
MM+&@!)')8CC/Y]:\*_X-]OA;;7?@_P =_&O7K8?VU>^-M9@M;N11N-G<75PZ
M;789VE2",<8Z=J^>?^"QOC*;3?A'IWP\TZX=;W6=7T9%BA<B1HY[J.)N%.2&
M#D9QCG'2OV#_ .":/PQD^"?[*/AK3! 8IM7BL-:<A=K,US:K*2W ))+G.<_S
MQ];DV'5J-57M.-]K*\+-K;HK?+\/%QJ49R=U>4G*W:%HN+^>OW'[ G5+4DKO
M&0 WKZ\CD>G;WJ'^T+1/])W*/,R,YZX]OK^/%?/ \67!S)M?YU\L<'TV_P!.
M>O&:<WBNXDA2U"N#&=Y)!Z-D\^V<CTQBOHH.+Y9R2C[1Q2>[>G7M:_;TN]#S
M*=>^C=FU!:?:YES6_"]OS/HR/5+:178.,(,MST'^?\^C(]7M9'5 ZDL<  \Y
MKYO/C*YLF,1#G[6-@Z\8S[=?_P!='_"4W-EBZ;S&$1W8&?<9Z?XULU9M)W5]
M'W1L?2#ZO:H[(77*G!Y[_G3I=5MHMNYP-XW#)ZCCT^M?-O\ PD]U=9N1O439
M<+@\9]L=\4@\7W-^2 '3[-B(\,.@&>W^>:0'TF-5M3$90X*@X)!XSU'?N/>D
MCU:U<D!P<#/!'0=3R:^;?^$PN(S_ &;A]S_O-W/&!ZXYQ_GK4B>)[JV)8^8P
M8;.A.">G;U_+DTFTM9.R6[(J2<(2DMTD_P 4?1_]K6N =XY8#MZ_4_U_P7^U
M+4,REQE0">1QUZ_E7SA_PE5R%$963*-YAR#R.?;\_P .:=_PEEP^Z7;)B8>7
MT(Q@@>W8=..>U*[M9)<[=XQZ<FFK=[7L^_?U,'7M=V6G,NMKQG"+Z]I.WFK'
MT<-3MB(CO'[TX7GJ<'I^/U_.E&HVY,@##,?WN1QP.3[9KYWG\77$%O!)M<_9
M6W$8;GC/(Z=_3BJD'CF=I%!63_B8'CAN./\ /IDCVYN*YI1CM=I7[7=CL@N:
M48O[4DOO=CZ<AGCG7>AR!GG^9_SVJ>N*\(WK7EFY?(V@<M^?Y8 _ITQ70-K6
MEQN8GO8%=3M93(@(([$;LYK))JK-)>[:[?>5[?DA25FUV;7W,_-__@I?XATC
M0/@QJ\DDB1ZA+#-%']T-^\A*@#D=SQQW]:_C9\.>"/'?B;5M4&EVD\T5U?W3
MQE5=MWF3-@@A3G.[.*_M6_;0_9\?]H/04TJRO@(\Q$JDH .W&>C=?Z>G%?*O
MP9_X)[:=X":UFOX;>412I(S2K&0V&!;);UY/)YZ$YKV<%7C2BE.3]YK?[*33
M5M>OY=K,\W$8=U74J-VDM(1NM4K6^_7^M_Q/_9E_8A\>:]XGTZ[\2Z%<&SN)
MX?,>2%ROEL1DDM'C@'CGISZ&OHO_ (*1_ OP'\&? WP\AT"W@MM9FO!'?*BH
MK8*CAL$''7M7[Z_$WQ3X$^ '@*+5H[;2TGM8R/E2 /F.,>@SP>X_#GBOY=/V
MXOVE4_:)\6.ML^+71;LSQJI^3*LP.T X // SG\:ZHXFM6J^XG*G";DY/[5H
MV7,MM7;>YQ5:4:-&<>9N=2"4HNUHN26J]-5W]-3X;NY(8WA"]9"1+CN.O/?\
MNGY53PD/G2< AOW7;CO^G^(ZT26S2M;R!O\ 7L<>P [^G7@G-2S0;XY0#S;#
M:<#KD$_C^'Y]<]BJ3T;C\5W/5Z:)V_\  K:VL[^AYZI.U-;7C",U_AY6G;S2
MY>NE];"R1PNUO*/NF/,OIOZ]O\CCGD90;)[:09_>+( G.<(,].^".N.O2DMX
MLJML3\TX+Y/5>O'.?08YY],\B*!#"SR,>$;R\9/.3C/.>Y_/OW&RVLYM3@HN
M*W>K3=NFFEO7S=QR?OU$KVM3I)VU=TD^VMFM>WWV(C"9?(8CRO+Y&>/,Q]<#
MD#CW_&I+>U6."7C]^0Q(/78<D?Y/]*@^Q-]K"[L93SLY[8SCK[>^.?4&KXD!
M;[4,;7 M\#H",#ICCZ_Y,N*G.$82;<TN;?W7=.2^Y-.V_P"=^SBZ?))7NDV^
MO-H^;3JGI_PQ0M$W13"4#R\.(AC^(<<$_KCN*Y;6--DA-KJ%FI%U#())"N<C
M:1R2.!_/@^N*[@0@@6H(S$?-)YY#$'''\L]L?25+=&:X1\$3#: 0, ^O)P!G
ML,'T]^B=*#52:;4VN:*Z)<T>3:WV=>K]2)5(TZM%2TBGS_XI)J-I?XKW=U;\
M#Z)^ '[8OQ!^'-S::4FI3066Z*,#S64;5*C &0.Q./3WK^GS]E_]LSP#XP\-
M:)9:SK5O)K<MK$LB/+&7,F ",,^>N,Y&?;K7\8FI:8Z7<;PGRS V"RG&3R <
M]3CCZ^YKUOX:?$+Q%\,-9LO%']JW?V:SD67R?/EV8R,#8&QCCTYZ]J\FM@&H
MM23<ZKC-2Z\C:OJMM._S1Z4,5R<RY>92?-9]&K<J7I;1]-/-']M7Q(^!/@#X
MWZ=)?WMM!=K/&2K&-'R'4XZYSU]>OIBO@6#_ ()Q_#N/QU'(NB0_8V?S'/D(
M!NWY)^[]?;\ZS?V'_P!O'3_B)I5CHEY<Q"11% ?.?DX 7//7WZXS[\?L=INM
M^'KNW@O1<V9>6-'W;X\C(SZ\?SKS*D:V'7O-V;<8N^\8VM?3IOVOYLZ(QAB9
M1J1ER3<7SM:6>CU:TU\^W4\S^#_P%\)_"2QBM] LX8 44G9&JX)7VY_^OS7O
MO2N-UOQIHFE6RS-J-LI+  >;'T_[Z]__ *U1:)XWT75<!-0MF)Z8E0\XZ#!Z
MYX]^U<?O-7>J7]:+^MCLC4I4Y1I72;5]-FW;R2^?D=@8TC9YC@$CD_X^F/\
MZ]4O[7M?.\G>-V<8[Y]/S]NE76*W$#&)@RNIVLIR#WX(->)ZO-<:=JEQ)EML
M#;L#.",GT_#\_P *A12;:2N]V=+;=KN]DDO1;+Y'KCZS:+(\9D7<AP1GO^?K
M4YU*V!0;A^\&Y>1R/S'\C7SI=ZU=><;D>8!<?,.N.V>.<573QO<3M]U_]# C
M/#<Y!YQCG\NN/6J=H[O2R;?DTFSG55NC*I;6//9=^5M?C;_@'T@=6M0&.\?*
M<=L?S_SZ4O\ :EJ&"[ADKN'(Z<<]>F*^<?\ A*KDJR;9,RG>#@],YP./R]LT
MO_"6W+'SMLA"#R^A'8@GH,<GVR*B[L]/>EK36EI+37R6IF\0U=V^%2O?RA!]
M.[;]/O1]&_VI:[!)O&TOLSGOG_"@:I:EF7?RJ[B,\@<Y)_3\Z^=3XKN/*%MM
MDW!C-G#9QC//IWYZCJ.>2S_A+;D$R%7_ '@,0'S<< #_ .OZ9R.:.97NW[BN
MI-6TE=67YESK6TCJ^63?E*+AIMKI+T=SZ,_M6UPAWCYR /?UQS_GWI?[5M07
M!<93@\CCCOS_ (?7T^<3XIN5V(%D_<'=T([Y_H<].".E+_PEEPV]MLG[_&.#
MQ@?3CMGCKBB[U5O?O=)6UA=:^MGJ2Z[3>FB;6GE5C#[[/?H^VI]&G5+4;/G'
MSYQR.>.W/K]?K7X,?\%[OA):>,_V0O%_Q"TBU$_B;PM)IWV&5$#2(BREY,.H
M+#(7G!' '!K]6&\6W.%.V3_1^#P>3Q[#/ QGUR.:\(_:S\&M\7?V;_B!X0F@
M\_\ M6PEF",N\%HH)6'##J.WOCUXX\8H5J;I\UKJ#BU]J:DO=VVND;8;$N-6
M+TYDG)>?+/E:[;*_3RZL_)/_ ()Q_$.R^)'[+>B1&X6XU;PW;:=I5ZN\,T4U
MO$%EC;DL",$<@8P/>OM;6([?S[66T(,4:1+)C'$HQNS@=N>N,=Z_"O\ X)+^
M+KGX>^-OBY\%=4E=9)?'>K):6\[$,L,4LB+Y:,>% (QCCICK7[MW.EM8-+I[
MMN:4M=J<DD(26 !)SC'0#CVSU_.LTI3PU2G*=WRU)QBF[\T;KG5[]+_TS[&C
M*-6CS\UVXPY4GT>]MMNFFV^J/SD_X*C?#F/QU^S]9:YI]O\ :-5\*ZHNN%E4
M,\26"K-ORH) 78><#&/R_2;_ ((A_&M?BK^QWX46^O!<ZQI]W?64X+AV5+1A
M"!RQ88V'C ZUY/\ &3PC'XF^"'Q"MID6X^V>&M9M(4<!MLKVDJ*Z@@X.2,$<
M\=:^(/\ @WQ\:3^#O&?CGX!WURRR>'WU?45@E8C:MQ>3LN%8].../IU-?1\/
M5(Q=D[\_*HO^ZTM?*]MOUL>-C:5;>[=.G"-WTNK*[[-MW^=C^M.BBBOL#RPH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _E9_X.;E5_A#X$5_NE+[/_CY
MQ^//X9]*_A8T9HH=.@52/N_)^?/Z'GT'..AK^Z7_ (.</^20>!1G&4O^?3Y9
M!_6OX4M+MS)86L@8XC4Y]^QSZ],^HY_'Y?.4GB$FVHV6MK^]RQM'=:/3;N=F
M%D[."6W/47JH6T\UHU^'4U95M]IP0 2#)@C[QYZ'TZ<]/Y.58"@)(\S:0@S_
M  ]/7T_E^5 1,TIM]W^N8D'TP.F>?7VZ=*=<1M P?<?W8\LC/KQG^9_F*X;O
MELGI4O;S;IQBD^VJ9T-7E[1-OVJE&"M]KD@K^K=[Z:Z:[G;?"-$E^,7PW08\
MH>-?#9(&/OC5K4\D#'/7'Y@XK_7-^#H ^%'PW Z#P3X: ^@TFUK_ "2O@A8*
MWQ=^'2R.!N\9>')MQ/0?VK;$?3MVXZ9R:_UI/A!J^F+\*_AVGVR#*>"_#BD;
MUXVZ5:CL>E>UDM7FHN+>KE*R76R5V_56_P ]3CQ*M4Y;? E%ONTNOF>LT5E-
MK>E(-S7UN!TR9%'ZD@53D\5^'HL^9JMFI49(:>,8^OS<5[;:6K:7Z^G<YSH2
M< D]AG\J_-[]N']M#X?_  .^&/BY;W7+>QUFVM)HX%::-'\P(XP 9 <Y[#/.
M*X#]KW_@H;X9_9^AU#9J%I,ULDI 65&)*!N!@GT(/OS7\+?_  4I_;QUO]I_
MQ?=:-H^K7=O;:M=7&5AN)$3:6/!",!TX_P *X:^,I*%51E[T+*5[JUTF^VR=
M]S2$$TV]-%R^?O)-=]KGQ+^U1\;=>_:!^-_BK7]<NY+VP?6KU]-D9V=3;O(2
MA4G( X/3/U[UXZD<%M%Y+<0A3U/!(SC'J>!W^F*S[;2WM(X?-8RS6J!)9&.6
M=N[%CDDGJ3_/G+KS]_L@#%2Y#<<=R>.>O/O7R\\9.K5G9:Q46^ZC&7-=_P"+
MKY;Z[=D5.FZ<E)RO%56MKV=GI=WVM;]&:>GE)EE=_P#6@,!_USQZ<=?_ *W4
M5B6R+KNH/X<LQYES=DQ01#DM+*VQ0 .<EO;TQS5+6]3?0V0VZF9WC$0CC&XY
M<8R ,^O7&*_3C_@EY^PUX@_:5^+FC:S<6-TEI9W%O?NLL3A'2.;>00V%(.,
M>G2MX4'4JPJR6LX<KT^&2V^^_P#2.JIB'!0<KJ2IS<H+9N7*H]=]&]C]_/\
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MSA8TV,,@;F'4G& ?J<^GO5,7GBS2'>VT;6[ZPM&)F:*WN9HD+ DYQ&X&>?\
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M.7!TFXJ+=VDNB:BOQY;_ #/G<7SNO-S5F[65[V25DKG*#P+I04*(@ #GHO\
MGL/7\J4>!M+#E_*&2/1:[BBO0Y59*VD=5Y>G]:G'R05FHJZM;3;ET7W'!3>
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M$$ @DE&P/KCGG\!TX+K-@0D+C)FQ+GDD <D=/R_/ZMN_$4!U2*UVJ D6SVW
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M,[/OMCIG\_Z>]-6UN[::>O8B;DK<JO[R3[I7UM_7EUT^A/\ A/-"_P"?F/\
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MTCMQGYIF"SYQTST/X9)SCO6'.)K:Y="K$+M;=S@@\]?3G_/)#$=YIH1DXE8
M#/3_ "/3 Z_CY4I*E52>O.XI[>XM%IZRM?5;=MO1C2YJ?/LU>VVL+KF??26G
MK]YL.D<4EPZ] 08N<9SZ8S['W_.EB6!'AN92!&1F8\'#=<'/X8YS2R0>:LB
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M]N_^17\+&BQ13:9;N,$A#M[Y].>>P]CWK^Z?_@YS0S?!WP-$."T=\,_]_/\
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M,?C_ ,%R[O\ 4ZK S'U D7K_ ) '>O\ 55_X)PRB;]CSX-2#HWAFT(_&-?\
M#U->]E4I2YFU9M--=K.*?XK\3AQ=15)0=N6:4HU%YIV5_.WZ'W+1117M'(%%
M%% !1110 4444 %%%% !7\O/_!T(T0_9&\+*2-[>-;<,.^TB$'\LXZ<CBOZA
MJ_E>_P"#HVX$'[*GA+]X,OXVM4VGMDP=NO?Z<?6N#,7)8=\JYGS+3OJK_P"9
MI3E*,TXNST_]*6GS=EZ7/X1]/A2+2XP,8#%H^F-Q)/\ 3T'T-:,2Q^3O? =A
MB3VYZ'\\Y_GS4&F0F;2[>,G!B(=AZCJ,_GG_ /5BIU@+22@' D 4<\#@=CWK
MYBM&,I?$VW.\7U33BG%/717NE;I=;GI-J,91>];KNX2YX<T4_)_TD%HL;-)Y
MAX3_ %&>.,=NGMD_J>STCB=+B/\ A<-OX[X;WY_+GKU/,<\!@$9!_P!0N6Z<
M]O7O3[.$O<+&3Q>([ ]E^4X Y]OKGGD<5G-WE2:BI*#DFM]8/F>^_,KO3IZ"
ME&<X2E!N/LJ;A)+2_O):ZO5I\Q_0C_P;3V:R?M(&?'$&LWB+[#Y#Z^V/3CUK
M_0UK_/\ O^#9G21)\;];O,\VOB"[3W[9S_GGVK_0!KZS+]:+>R<DTELKPCLC
MS9MN6NNB6N^W6YQ?Q&7?X$\6(>=V@ZD/SM9:_P J7_@H58I;?MM?$$2C"%KL
MIGH6-U-Z_7_]?6O]6/QS'YO@_P 21?\ /31M03_OJVD'^?TK_+)_X*BZ6-._
M;9\=1#Y647$A P<@W$K8Z_7CU[5SYK)QC3:5T^92\HNVOY+YFN&:C44GT?GU
M3_-V_JY\.H(?/<$CG(?_ '<#OGG_ /7^+;I85C_=D9 _=]/O#L.?7K_G,$,+
M2*]SDCS04 ].V?Q_3VH@A,S^623]F(9O<'/OZ^G;/K7SM&3NTU=TYR;3[*#@
MON;2T?S6AV^SDOW=WS0Y*LM5I%4]E>VEW;6SL[];D^(!:*S$!CGSO;ICOD@?
MR]*J77E--I!/5=0L/*Z\J+F/'J/Y?D:CNHV DB4G]^1MQVQT_( C_&GWMJRS
MZ!S_ *K4-/#?^!,8S[]A^/TIP?\ M-*5^55.6VO\J5H?>K?D15O-5:B=H<M*
M<8K5/6,&_DUIUOWV/]3S_@EX!_PR-\)\=?\ A#]%SS_T[)7Z*U^>O_!,>V6W
M_9&^$14Y\SP9HC'IWMD]*_0JOK\+_ AK?3=GG2^)^O\ 7W[A11170(**** "
MBBB@ HHHH **** /YF_^#DD9_9_\/9^[MOL_]\M_]:OX%]#\O^RT!/ #;>Y^
M\3D=?\/YU_>[_P '*5QY7P!\,Q?\]OMJ ^F58=/\]/K7\#VB1$:9$-WW V<]
M_F+?_JS]<]C\SG$G'$)V33@HOSNE9?)ZZW5SKH7Y':"G[\M_.FT_N6O_  ;$
M@6+[0HR/+8DRGK@]AVX/XYY]*ENQ& #&<N.(\ =/;D\8_#WXP%:S*I(<G,OS
M#D<#)R/Z'^@%1P1&?,I/%N#'@@<GC!YYY'Y5PP7+%2M=04D_[UX)[?.SOOL=
M-KJ,=;T5SU&_M)P@TI:==FNWXWH_(C0,"-IB)?H/WG0Y''(.>#_@!^U__!O3
M$;O]N$S@9D70I@"!GY?,;!_3Z>U?AZ(F=GM0QRX:09/0'MZ8_P ,8K]Z?^#=
M?36C_;:,F-P'A^9<=>0SYZ>Y_P 3UKIP]I2M;6K+FI^B4+^B85XJ<%.-N>=5
M\BVYHN,?RMHFNNQ_HO6F?LMOGKY,>?KL&:L5#;\00C_IFG_H(J:OJELO1'EA
M2-T/T/\ *EI&Z'Z'^5,#^ ;_ (.8A&?VA/A<6/S>5?8_-NG'8<]^:_FVC6')
M!(VDC<?0YX]/I7](W_!S'"S?M#?"UP3@0WW';JW3GBOYM5MB0\>[EG!SCH >
MG7&>:^/QL;UIR;Y5%ZM=I3MS;=-[=]=3T*%OW/ON_-3T[OF7N^B5G\WTU+@"
M!@W_ "T P!T^3/7/?C&>?_K+.($MT"D;#*#T&-_7U]?;Z4L5N7E6;/RHGEMZ
M$XQD^_'7W^E4[BU80QVVYLBY$O;H#G'7]/ZUQPOR-<[6E*:]975K=M+_ (G?
M4:A1E-5&U.,81?\ >YE9^NMNFQ]Z?\$M,?\ #:7A%C_K#J6DY]<"<=^N!QZ\
M]^:_U./#O_(!T;_L&67_ *3QU_EE_P#!+F(Q_MK>$9>S:CI"@>XG'ITSC\!^
M-?ZFGAW_ ) .C?\ 8,LO_2>.OH,E5HXA7;:J:KMHK/U:U^X\G%1Y:BCS.=DE
MS/?X8Z:]MC9HHHKW#F"BBB@ HHHH **** /X]?\ @ZH5#X7^"!/WP^H;?7/[
M[I_GO7\6.GA/+M0<;&0><?<>O/MZ\XZFO[3/^#JF,'PQ\$)2P'EOJ#;>A.#,
M.,\=\U_%S96A&GQOG!F4%3CID X/.?;''3C%?.9E*,<0V]XRC+Y-1CKIIROS
M?DCT<.XQIQFYN7(US4WM%2E&S[=4_P"G>S>!%P8\%A@1_P"[WP/_ *_'M4TJ
MP>0F",%,OP!^\Y!S[YX[>E0P1>=^])R( 4YYR<\']<?YS4:Q,SFVS]\M(,GH
M!G@$?7G\,<5YJB[>SM[TVIIVVCS7MZ6U7F_NTC%N*I/XIN%5/JH<S=KVM9=-
M>I:MB&M9$;_6 L0,\[!GW[C^6>_'NWPUL?M/AY9(5#+YS@GJ,Y.<8]\UX-:*
M'>=R=H6&1-I/\0! /Y]\=/T^L?@+I+W/@D2!"^;R8;L'/5O3_P"MWP.YN-.+
MGS->[:TX[)35DO76^^U^VIO2IJ4HSLK<KA..R4XVLWYV?]6N?ZRM-RV3QQCC
MZ_Y_I^+J0D $GH*^NJ0<^6SM9W]=+'AG\OG_  <+?$2]:T^!GPYT:8N?$_BI
M=*U>W1N6MYF8%709)W8S@C''I7O7[,_A>+P/\ _AIX4@C\F*UT](VC VXRJE
MLCD ?H/RK\V/^"HOC+_A;/\ P4"^&_PL0FX7POXZTV1HL[@@D>0\J<@=/SK]
M?TLU\.0:9HBKM72HHT"@8'*#MG].^:^2S/%3A5=-P3CRI*??1)NWIML^^NWK
M9?34>:;?O25DK/6*<;^6CLOZ0:?"IO+_ $Z  P3R?Z0!R./;D\>_'\Z_#_\
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M-6EE4F56"J.^SGV&>Q^OUK:M2$@ER"3(=R\<@=>_^>W.*E%ZG^LV_*G[LC&
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M[>YC9^_SAP0/3CD\GG'<"O\ 0?\ ^#:DR-^Q;JXE7[GBIU3(_A"R8_E_.O\
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M+2=DU"_G_P -OV77H=6'V=]%S*]1;P]'_>V?>POF2B5E .U1E1VW9YX]>/\
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M/O=#D#Z_3 KYC&R=2N^9>[*23EVY>5*-_-_\!+IZ&'UY(R24)15Y=[5%9O\
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MQE8$84$$#(P1GZ=37V3^SK^V5JOP-U#3H=3OKJ2&*>)MDLKE<;@<8W8Z<8_
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MH?S_ /L:/^$WU+_GH?S_ /L:Z3_A6\WO^M'_  K>;W_6@#F_^$WU/^^?S_\
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MX$1_NF.^SGVWG_'_ "*_A8T8QP:; JGHN$Y'K@YZCH>OXU_=+_P<W\_"#P*
M<$I?X/8?+)_C7\*.EP.]A:2 \(I)YZ\8Y]?7_P#77R^<I.NE)M1LM=_>Y8VC
M;I>R^\[,+)O]W:]G.HM_B4+)]M-'Y>ANK' K>9D$<F0^C=>3G'4C\/H:J6Z)
M(9F)/F!CY?\ N<#/4^_0?04L4+-%/#D[I6++ST (/&>W'^ YJ6&V:*5)2<+&
MI0CGENF1UY]^<=^:XDX-:/XHN\NL>6$4U\VKVZ6N=Z=.2O?^*I*4[7<+4X7]
M/NOKZGH/[/L<+?'WX=(_^K_X2OP\QZ$;_P"U;;''^?09SQ_K>?"; ^&'P^ Z
M#P=X=Q]/[*M<?I7^2)\ ;-C\>OAY#N +>+?#\@)/./[5MB .!G%?ZW7PE&WX
M7_#U?3P;X='Y:5:BO;R:/[F4G>]1)N^]M4EWT7?Y'G8J/)-1YN?EBE?Y+0]"
M  X%-9$<$,JD'/4 ]>O44ZJT\_E-$O\ ST; _7_ZW'_UJ]A)0BDM%%)+R6RV
M.:,7)VBKO7\-6?@5_P %@?V _#'QF^&'BGQUIVCI>>*=.TZ\N[+R[<-*9]CL
M,%<\Y). #TK_ #O!I&H^$/%OCGP?XPB>TO\ 2]2DM+:"8%' C<J0%8*<CO@=
M*_V&?%OAW3_$^AW^EZA;QW,%W;R1-%*@=2KQL""K9!Y([<5_F3_\%H/V8+OX
M-_M7:IK]A;&QTSQ+KE_=I'%'Y<)3>Q'"X7''<=,5XN.A)NG)4[<S<9N_P\LK
MQ^;=O/S[]>&J4XU*3DDE!._]YW33TZK77?L?F+^Y6)TSDCA><<9&?3CG/J#5
M66.'RR01L+98\?>XXY[_ ->WK#"CSYEW<0#81V)/&>.N>#G]*G:T<0/!G+/)
MYB\_P\<=".F?UKP*T733FM)02;2ZWGO\M']QVQ@I7BWR.<8R4EO=SDX_-II?
MYW&/:0ZF#9-A@B&7'8*!P?U_I7VG_P $U/CS?_L]_M3>$-7TR\-G8Z[JVG:'
M<.)-BF.>[6-U)S@Y#'(^M?'%E ;)VU%R"LL3687_ &G&T'G'J#QTZ]^<30WN
MO#WC3PQ=02O%-H&NVFO/*I*MY<%PL^TL,'H.@/7J!S6^!3]M>[UC:$;/5Z.2
M\K:7Z'.X.=""AK.-2IHENGR)MZK;3MZVO;_8=^''B:S\7>"O#FNV,PGAOM)L
M)?,4@AG>UB=N03GEC7<5^8'_  22^-$?QK_8]^'WB?[0)YC:BU?<^Z3%K%%'
MSR3VSU[G%?I_7V%)N5.+>CLK^ME^6WXG!.$J<N62L]';U"BBBM"0HHHH ***
M* /F[]KS_DVSXOXZ_P#"&:M_Z(:O\H+XLB+_ (7EX^"D;O[1F# <\>>Y/;L/
MKZFO]7[]KSC]FWXOG_J3=5_]$-7^3Y\5[=D^.7Q!D)XDU*; ZX_?2#]<YKP\
MY7N0ETA'F:Z2]Y:,VHMJ5DK\SBG'I+6_*_)M=3EW6/S2W\:D^7GZ#/H?\]?5
MRQP[\CDMDR#T8<G/(]?7I48MVDN$8'B(Y;T/&.?7.>E1>4T-WY98XG)9<=AC
ML/PX_H:^?IVDY*%Y-QA+EZ+WTU'T??17;/549NA&25WS6]GK:\:EWIW3]W;9
M%+4$1M'N3(?WBW:+&./N;\'OG&/4X[YK_0@_X-KTB3]B[5_*(.?%+%L8Z[)<
M_P!,Y[]*_P ][4HVDTN>89 BN5C(YY)<<^^.WMDU_H._\&U=NT'[%VL!CG=X
MJ=A]"LI%>SE"7UBHW[LVK2A_*E%6\];WU_0\S$7YGS1Y'S?#VTV_+[S^C.BB
MBOHSG"HIQF"8>L4@_P#'&J6F2#,<@]4<?FI% '^8Q_P6LTN33?VV?$7FH4L]
M3\2:B\QQ@$!SSZ'\2.>:_)?4&,,=]Y6=L<FV+_KGC@CCOW]Q7[F?\'"6AKX?
M_:GT>0*$DUS5=0D#\#&&?)SC//4=<9Y]3^'6J11P:'=7;.I,"@'D?,3GGKSS
MS['U/-?+5I)3E>"E%5FJGE*35G]S2ZL]*2IS<%&7-*K[*#Z\EE"-UY:;/[MS
M^VW_ (-=EC'P-\:,F"S>*YV?M\Q\W/8=_P#/K_6]7\A__!K',)O@1XY;<#N\
M7SE1R>/WG'?^>/QK^O"O>P<4J*L[MMN2_E?;Y)+;3HMCSYZ2DNSM]W^84445
MUDA1110 4444 ?E=_P %@?\ DSWQGGH8;C/T^S2_Y[5_F$6R1#6/$P7[O]O:
MD3@9&?M,GN>>GKS^5?Z>_P#P6!Y_8]\:#N8;@#Z_9I:_S!K.W9=7\3H3_P Q
M_4VSSWN9..^.F,>^*^<SE.4^5;M0^5G=->;V^7FCJP__ ($U*-H/:?>_^%:H
MMK'!N#$_.20_'\.>_/O_ )ZTQ!&9I(S_ *F-<PGC!?';/(Z_XU$(7,[G<0'!
M4#/IW_\ K'_ZU3_9'$<<6?FA)=FY^8$],]P/KT':O)I-4T^5M\\DI/;E<H-N
MU]-&K?/YGH4:D6I/_IW""5M')0?N^>QF:HD)LKG<1E@N_D=-PSZ_R^E?Z.O_
M  0414_9)\(A/N#0;(*?^ I_3%?YPNJVS-979! $@4 \\$L/;U].G>O]'G_@
M@E\G[(W@^(G)CT*S!/\ P%,?U]OK7M93)1J5$]'.-**7G[.#_"VW^1YU5)IO
MG<G&,+7ZM\J:_P"W?TL?N_1117OG,%%%% !1110 4444 ?"'_!2+5FT;]DSX
MDWR-M*:>XSG'#12BO\KOQ!-!-\1?B/=97%SXIU&5B3U9IWP3]?YFO]0'_@KC
MJZ:+^Q#\5;UF"[;)5R2!]Z.4>HK_ "X9H9+KQ'XPF#9-UKMU.K9[-*6Z_3OT
M[>E?-YVTWI)\T(1<HKJI223UZI[=KKS.G#*]2":O^\6G?8TML)1GR-YX'3[F
M3_3/4_2JD"0FY9"1Y(!93G.9,]/3/T]L^\<H:%E<GY=OEX[!B< \XY_/IWZ5
M)):/%$HR,Y,N[.3@G."<<].Y]_:O.HMN"LK\ZIQ3Z\R6NENE_P >QV0:BU5^
MPN6EU2YG?IUMLO7LU<D1&N8E'_+20)(.WED_0_S'?D5]4?L)Z!;ZE^W'^S[:
M1J'BM_B#H[<#(&9#GZ>^?KTZ_+5M$9#]JYVM\H^HXSWQSV__ %5][?\ !*+P
MW+XM_;E^%[JI<:%XRT>ZD.,@ 2]2?Y__ *\[X2-L1"+M>$(MOJVYP:7I'9?<
MMS"I*5*/LVO>]FDY==>6:7RM9>O0_P!33PW9I8Z)IULB[5CM8%  P,"-0,5N
M57M%"VMLHX @A&/I&M6*^N.'?<**** "BBB@#_.8_P"#BGP?)H?[9?B#Q=-"
M8H-6O;*%)BI =AN/WCUY/>OP;)C%U')'C#[?-QV&!C/YGO[]^/ZP_P#@Z.^&
M36DO@[QQ%#M:^\1Q+)*J %E3L6 &1R?4=_:OY,[6(BP%R3GS8\ YY!"@9!XP
M/Z9]3GYC%M\TM/=C5UCT:E)12\[-MZ]KH[Z%-<JJ2U:LHQM\2;C%OMHWKY6-
M!8P\T\K'A"/).3T/I^A]Q5[5(K=[:#D8DA_>?[Q&<'M_^H57ME,EG&?XD7D]
M2Q_STJ"=7=HK?)S*O&3T R._ZCCOVKRN1SJ[*//*T;?RQLKK[K^=SHJQE5J1
MITX_NX6>FUG)1D^NSNKG[??\&\WBI-!_;<\):%--Y<=[->2*F[ 8$+@@9Y_G
M_3_1?\8W@MO!WB2^4\0:#J=P&![1V4S@@_AGM^%?Y??_  2,\8#P)^WY\+;]
MI3%$JR1/\VT,SM&OKCG/_P"LU_I:_$+Q/%#\!?$FOM(%2?P'K%PK$XR7TBX=
M3DD9SG/!KZ;*YOV#@]7%<U^_1>;VW\ON\V4/WB2UO*UO2R]'<_S"_P#@I3XV
MD\?_ +9_C#6)9O.6U?4K'?NW8$-Y*F,YXQM'&/SKXK"0M&5X\N,[QGGYAZ9_
M3GZ>E>A_'C7'\4?&KXC^(&D,F?&'B"S5B23@:I<@#/T[9YZ^]>:)$WEWUN6
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M)4$; 0R_[_X=\XQP>:;+!'L>8\LV?,))X4#C/X>XSQWJHL#F8VVXYB(E)'<
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M]NBT5FO7=_\  /*QCC*KS1DYII.[Z:+3Y&S1117MG(%%%% !1110 4A. 3Z
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M>WR/Z2J^ /\ @I1XT/@[]E;XH3I-Y3W?A/5X%.[&YFMFP/\ /M[5]_U^%_\
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M4O\ P38^"5Q\7?BS9ZQ-9L]G82PW<@DCRA2)RQ!+*00?K@\<@U_5 ?AAX2\
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M3:Y7&,^=;\MXNZ[WU7E?9]-+XY?%77?BIX\FU:\D:<374DJMN+Y#-U&1W_\
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MKCJ4L/-.2M%S3;[TTK>]?HG;3<^DP7LW&/*U%>]'F22;Y4K2VO=Z[WZGQ/\
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M7G_)MOQ?ST_X0W5?_1#5_D__ !9>1OCC\0%;.!J,VWIC/GO^OKZ=P,U_J_\
M[7G/[-GQ?'_4F:M_Z(:O\G_XKW"O\<_B @'^KU*7)QC_ );.3^>*\/.=8TU]
MEJTGT2<EJ_T-Z#2<D_M<JYNL?>3YEZ)/;4Y+S)4N8L#Y6/[SCIP/7CKQ^/>H
MM\CW;LX.4)\K/&5]L\'C_&IGF7S@F.9B=I[C(4_ATY/N*8K"6X$@X%L-C#L3
MC'./4^F>GY>%3<5&<6O9V2M45[R3DHK7\+_<>K!.5!14VHI.7M.JM.[^]+FO
MJ9NK-(NF2*@_=O=(7_W@PZ\''],\8%?Z$/\ P;6M(W[%VK>9GCQ2X _V0LN/
MZ_UYK_/@U*18])N(3@M-=HX)QE0KYQ^/]!GFO]!__@VMN%G_ &+M7*C&WQ4R
MG_@*2C_/;TKU,HB_K-22;<7&U[6YFEK]VU_Q[^;6DESQOS\S5I]=+?GLOF?T
M8T445]*<H4U_NL/52!^1IU-*Y(]CS_G\*BHY1BW%7=XZ>3DDW\DV_D!_ '_P
M<;?L^?$[QO\ '+P9K/A31;N\>*ZOWB:&*1LAFD*\JC<\^_Z5_.EJ'[+?[1EQ
MIC6K>&-3\N15,P,$Q 89ZYC /Z$'C'I_JH_M'?LP>'/C'XG\-ZQJ&CVE[_99
MD,AFMTDSOR>2RGUS^?6O")/V!_ S07T?_"+Z9F9CL/V.'@'.,?N_?U_ESXE;
M!5/;3:NXRJ>T\K\L5^%KI;_B=%&LJ<HS:NXZ6>VUKZ=NFJ/QU_X-B/AEXY^'
M/P:\7V'BO3KBQ>3Q5-(%F1U.T^9V95YY'/.:_K;KY2_9=^ ND?!#0-5TS3M.
MM[$7FH/=!8H5B^\6Y^51G&<?KUP:^K:]BC2]E%)/[*OYRZM^?]>N$GS-M]7<
M****V$%%%% !1110!^5W_!8'_DSSQICJ(;C'U^S2_P">]?Y@=G)+_:WB<L/F
M_M_4P/7 NI.V/<\=P?7FO]/S_@L#Q^Q[XT/80W!/T^RRU_F#6LZOJ_B=P!@:
M[J:$'U^U2<D>_P#]?-?.9RW&=XZ-*%O/7]-_SW1U8=73OHN97GUAVL_[VVO8
M 9OM#D*=NTE?=L]1P>XZ?AUSFP9I?)BQ_K2V)AW"]B<8[<9_QQ2K<(&$>!F(
M[V..N3T]^_ICKT.:C28"1KG!V7 *(N. >F1QP??UZ\8KRJ'NQGSK63O"_5N-
MX_@GH>C1A&TK+14H2OVER-.5^F]KF5JTDPLKW .%52F >3N&/\C/OZ5_H[_\
M$#BS?LC>#V<$.V@V6[/7[J8_K7^<9JEPBV5V,$F,*3] PS[X_GVK_1Y_X(*$
M/^R/X/E7A7T*SP/3"I_GWSVKV<H474JMV;4*5F][^SC>WG;SOZ[KS*RD]>7E
M48P;25MU%)_-O\3]W:***]\YPHHHH **** "BBB@#\2_^"]7BQ_#/[ OQ3E2
M7RPUO; \XY83#K^&#_G'^;%X>E>[M;S4.2]S<-*&!SN#DG/XCOQ_A_?5_P '
M*GQ+BT?]D#Q;X##A;G7K:VEC )#?(TF<<^XSZ^A[?P%>#9Q;>&K=G&6"1J<C
M)+8 )XP3UZ_F?7Y_,Z*=5N][P]Z[Z:63UUL]?5M]CT,'2YFW*\;QDZ;[NR3:
M?E_F:<B/)*0P)C"[NG\0Z?CD].G/3.:C:>61%0YW[MI!'.S.,X//3^7K6@95
M!,.WYG0R@X[#)Z_YX]:BTY!-+)<8^3:R $8&<GG\\>F#FO&C4A3<$Y<JY8S3
MZ\RNN]O>?FV=5.A4=J;A[G+&3M_/%6]-;J]^J;[E7S7@$D7\ 3*>A8^GX9XR
M?IS7[4?\$ / C>*OVM+O4Y8#(^DZCIMT3MR5"OG.<<8]O_KU^*]\0LCK_P \
M/WC'C!4'H2<#'IVS^5?T_?\ !L9X%_MWXU_$OQ"8<QV]C:3HQ7@%,<@X_4<^
MO-=F"@ZDU._OM1C9]8WC)2^:5_P.*NVFI3TGRI2CV<4DOO/[RH1B&(>D:#\E
M J2J5M<B222''^JPOY#_  %7:^M.(**** "BBB@#^5S_ (.>/!2:M^S_ .!]
M4BAWRVVM2SNP7)4+MYSU_+]3P?X2-+E>329U?I$A"=.H.#CH>#GIGIZ5_H^?
M\%[/AS)XX_94U.\2+S/^$?LK_4"0N=HCB+9Z''3KVZU_G :6=U@L(X,MQ<1$
M<<;9&';W]OU->#F5^?EA!?%'F:7>SN^UF]SLPU25XP45*ZE!*R^U*,K^J:37
MFMS4MGD2WL  =LO^M(Z#GCK_ $_^O5IB?M*$?>3(CYS[YY]LC')_K!+(MN]I
M9D<MD#(Z9/4#MQ].W7M8E&V1+C/RV_RN >#]>/P_3%?-PA)XB$74:?-4MM=J
MWSLN_P ST/XMZ4'R*GRQ51;RDE%S7?XDY/SZ7/5?V9_%UYX'_:?^''B&W<Q>
M5J5E"TF=N/-NH%()/<YP.3WK_2&_:M^)]SX3_P""?6G^*HKC9+J7P^B1I-X7
M/VO16!R>>N[ZGOTK_,JT2_\ [*\=^#=23Y&&N:3('&00OVZW)&1].QQ[=,?W
M??\ !13XTP:?_P $A_!NN), W_"/>'])9@V"6ETZ.(D\^Y_SP/HL#-4Z$H2?
M+-TY<OFHM-M>B?Y'FSIRC5A&+<IWULGI)NUNO1)^K[G\'E]=G5?$7C*\=MWV
MKQ9K%SG(^]+?329S[DY]Q^&,C6YIK6TNYHP0\L#1OS_ 5QV'Y<<=:--!BNK]
M')S>7,^HY.3D3.T@Y[]?PSU[&;5W6>WL5 S_ &K=IIZ*<$[I&"@@>O\ ^HC.
M<^5C7!U)<DKJ\>5=)-6YNVM[(Z8JI23E)N5.G5C3Y>DE]J[;V7KU5M3^[3_@
MVJ^'LND_L_:9XT-N576;&YC$^S&\J5.-W?!_$_G7]3*DD GK7XN_\$(? 2>"
M_P!@'X4Q/"J74L-T\CE0'99!&R[CC/&1]/7-?M'7T^!I2A1HRDVKTKN':4VI
M=OL[(Y,4Z;K2=.W+:*TT3:2OOJ%%%%=QSA7X^?\ !:_P9#XU_8[\1V$T7FBV
M>>[ P"08;9W! /H5Y_IG-?L'7QM^W7\-Y/B;^SSX]T6--[6WAS6[[&,_ZC3I
MWZ=3]WFN;%V="I%KF<E9+>[_ *_RZETTI3BI/EBVKOLNY_DZ16TJWFKQP@E[
M76KZV( Z1Q7$B8[D8Q^7IDFM6X240-*%)^7"\8^;TZ>IS^.!5S5"/#WC?QWI
M,Z?-!XKU^V4$8(*:C=1YXR.",@?E5*YU2-+=+;:,H^\DC((//7 __7R37RV)
M<I-TXPW49MKO%6?2[2O:[?J=TJ4ZDH*SEO:;UE*G>/O;NZBGI_P;$6G2S"W^
M8$,_#CT!P!D@<<8^AS7T_P#L!^*[CP7^V=\'M0CD,+2>*+5D;<5SB0=^_3/
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M3DX_/GBO[%O^#7_X?QQ^%M8\8R0D3?VO?P++MZIOE/7W'Y?7D_QPZW>*KM&
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M7:L-,N&8<MAI,] 1@Y[?7MUR<=:CNKI8KM>.(CAL _-V/KD?Y^FAJF!:1VX
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M_P"OQ7K7CKX!ZOX!^,T7P^N&D/GZFUHJG)!R[=.,=L>WIZ^D?M&_LO:Y\)-
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M8QG_ %T@R?S[^M?ZOW[7G'[-OQ?/_4FZK_Z(:O\ )_\ BQ$P^./Q ).0^HS
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MN1T+#.1_C^%?Z.O_  03(_X9)\)(F/+70K/9CZ)_A^IK_.&U:W=K*[((Q(H
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M>'!'))!SS[=/3KG.*RX8/)BN;A/]8KXB([J2><<$\8QC/>K23&"RN(,G=?\
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MD;H,#//?@#/M7VC>V\J7UE'&2#!.&DQQN&,GKU[C\N]?F%_P5VNY[OP?\/\
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MVM$6'NY' 'X^G3VS44R&2=5!_=B(*5'0N<#/)Z@_YXS5=K>6*/86R0P<Y/\
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M)-+:4XW+'\OKG@^O_P!<8SDUDP11Q%W!!W$E^W.!U/\ GI^;-#N3-92PAO\
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MP_#7]CWX77SVWV;4M>\)Z;<WZE-C^<47.X]2?<_XU_GD?L&?"R?X[?M3^!]
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M@ Y[5_3A7Z#@VWAZ;>]M?4^:Q$%3K5(+92T^:4OPO8****ZC$**** "BBB@
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M]]SNBK.$$DXR5.4VMKKF:^;2N^O6_=MO*T4HAZ1I@KP>3GKT_/KCU/?]5/\
M@BU\4KKX6_MH^'[2"8V\?C?Q%I>GRC?M$JF0#;[XQTX]>:_*:8^;,$4$%#N)
MQSR1^G'_ -?M7N_[*'Q#3X;_ +6?P&\2-(88+#QMIMQ=,3M!C23)W$$<8SG)
M[5TT*BC*,I.SCRU)?WE'EA%/OS73]=M=#*HIU.7KS*'/%]+6C&?S3TZK?LC_
M %P=/E:95<\J8XF![',8.<_C_D8K4KR7X(>.K/XD?#;PUXOLF5X=6T^WF5D.
M008DSR"<\\__ *Z]:KZRBDX*:M>HHS=G?=*ROY+0Y:]O:225E&T5Y\J2O\WJ
M%%%%:F04444 ?-_[7G_)MOQ?_P"Q-U7_ -$-7^3_ /%B20_'#X@*PX749BOH
M3YS]O\/ZU_J__M><_LV?%\?]29JW_HAJ_P H#XL3H_QS^(" ?ZO4IL_]_P"0
MG/'?'O[\8KP\YORTUM&2M)]HN2U_K\S>A))R3LN;E2EUB^:_,NNB3>FIR!ED
M2XC !PYQ(?3C)S^/:F*TDMTTC GRRPC'(R N._;D8'\JF>9/.\O&#*3LQCC@
M=#P.<?Y[R1R)(S$*/W&5?MDXY.<\_IP#T%?/PM'F:7)I"/,K^]%S2YNM^W78
M]-<\L/&,6[)\SJ+HN?WG;6UHIR_JYC:FS)IDT:#]V]RK.1C 8/D _4]CZ5_H
M.?\ !M3++)^Q=K'F @CQ4X&?0+*!^E?Y\NHR+%I%Q$V-TMXCJ3U"A\]<_P"!
MX]*_T'_^#:Z=)OV+M7*#&WQ4ZG'J%ER?U'U[\U[64?QZEO>5G:I_-[JNOEZ(
M\VO\3][G]Y>]WTW/Z,****^B.<**** "BBB@ K\$/^#AS6&T?]B"_F5]GF:N
ML0.<9+Q[<9]\_C^5?O?7\U/_  <Q>+XM-_8P32 ^V:3Q%9N0#R5)3^?3KR<?
M2N3&?P)/F<=5MUU-*3M4C[O,[Z1[_P">A_G^^'8Y9+*XE=3YCWEQ(1U.UI&.
M?QR#P..G0\&JNYL=20\(+9R/3.,?KZ^_;%:OAZ[A%NTNT!)8<*,8^9E^]]3Z
M\XSP<\'(U6X1K+4X0,,L$C$\9P<\=??D5\>FJ=27/&^NSO[MW%W[Z6O_ %<Z
MYU8SDY1@HJ5-1LNZMJM=G8_T%?\ @W)_Y-*\+'_IP<?AD?SP*_I%K^;K_@W)
M_P"32O"W_7@W]*_I%KZ_ ?[M3UYO[W?1:_/<XI_$_E^2"BBBNPD_*[_@L#_R
M9YXU/I!<$?7[-+7^8)9RR'5O$[,/F_M_4QC&, 7,@'Z$_P NM?Z??_!8'C]C
MWQH>PAN"?H+66O\ ,'MID?6/$[@# U[4E/KG[3(.F3_CZ^E?.9RW&=U>Z4&K
M===OEOVUU1U8=73^RN:-ZG\G;[]OT8BO,+AS@[0"5.>K9_(=.GI@>M63/*88
MF&?-=L2C_9ZC([]\YS^'0*L\88)@;HR78GT)!QUSG\/?.:8DRK(TY'[N<%(Q
MQ@'O@#/]?SXKRJ'NQGS+5N\$^MXW5OE?3KL>A2A%*5K:4J<D^TN3=6^?<R-6
MEE6RO-O\"@H .IW#'/4_T]J_T=_^"!Q9OV1O"#OP[:#9;@>N=J?XU_G&ZI<(
MME=#',84M] PSG_//ZC_ $>/^""A#_LD>$)5X5]"L]H^BI[GU'XYKVLH47.J
MW9M0I<K>]^2&J^5[]?N9YM92>O+RI1BVO)I)-^K?X[;V_=VBBBO>.<**** "
ML2^FF2*\* EDA+)C@[L9&/KR?Y=ZVZJW/E)'(\A54P=Y8@+@#)SGUXS_ /JK
M*K\%[7LXZ=_>2_"]RX-+F35^:/*GV;:=_P &OF?)7[37Q=L?@W\#/%_C/4;U
M+*^M]&N;B R/L)>-&'!)SV_SFO\ +S_:\^-NI?'GX]^/O%=_<M="'6[F6QD9
MRX=7<\J??VZYZ]*_K7_X. ?V[-.\.>%KCX*Z'J"6^H:E#>:81;S!7+-Y@ (5
M^O'IT_7^*'2_#UY#$VJ7LC233L99W;DN2S')XY///OSC%>/CL7!5XTV_=6C_
M +KLF[[VW_R-J5).+DY).\E;R2O^+TZ_(EAWH8CC'G*6DZ\, .OOW]NF*M02
MS%F9N"&*KU)P,COSTQ0\J*Z1A>7Y4^F!SSD]L^U3S7"0E' Z+@C&1GN>O\_3
MG%>)5<913^*3C[B_[?:LO5):>IU0DY6BWR2DZ:4M+RM)N]^G*M+=M^S:H.Y&
M/W?,3>>V,\YZ>_ZBO7?V7_AMJ7QE_:G\'^"=+LWOM+34-*GNEC4RJB&Y02,0
M,XP,]?R'6O%M6U&/3])FG/+2;@F.H9@<8Y'J.*_H^_X-SOV1;SQS\39OC7K6
MGM<V(MY(8'N(2P62*1V5U+*1G &.1VX]>G!TGSQ?+S<_(XOM[VNGRMZF7)&,
M95.>SC%.+VO-/6.E]NG6[\S^WK]E#X4:;\&_@KX0\&:9"L$%II=E(450F'DM
M8F<%1T.[K7TE5.PM4L[6VMXP%2&WBB50, !$50,=!@*.G_US<KZNG)RB[KEL
MVDO)6M]_S.)MMMMW;U;?=[A1116@@HHHH **** "OY@?^#EGP8WB'X#^&M72
M'S&T.&_N-P7.S:'.<\^OI^E?T_5^)/\ P7.\ GQ7^Q]X_P!8\D2CP_X9U2[)
M*YVA8R<YP<?7C^HXLP@IX6HGTY7?M:47<J#Y9PDMU)-?)W_X<_S2?#,LRV4<
MQ!"S[O,//0'U_ =^?QK?CGF032 $$$[/<9))'TYZ8Y[=JJ>'PC^'(" -\V\+
MQT(<_P 7KQ].ASUK1\^,0!<<PKM;CJ<]<9_IG^=?+5TG.G*F[\C5X^K4HW6N
M[=M?D>K*491]I9*I%P;I]KU%)-;?%?\ SU>D;O).R# *LN7.. PP1G\>W^/*
M_:I/+(Y#J1&O^[NQ^&/Q'X9IUK(L:O&P&Z4ED/0@=?;U]_UJN7'G";!V*^PC
M'5L@9^@/?CJ<XIMN\8W=HPA*.FB:E=+3SNO\[JR5XM1B[JT:E[O6IS72[IO;
M42V61=9L;,@[+NXA0#KEY75<>Y^;'^%?Z3?_  0G\"CPQ^QAX2N98?)N9Y96
M(*X)5PK G.#^./3'%?YP=E;"Z\:> +2-<M?>*M&M2/437D*E>,YZGJ/7WS_J
M=_\ !-_P4? O[+_@/2#$(=VEV5R5V[<F:TA?.,#U_P ]:]/*(M5JU[ZVU?5J
MU_\ +0XJZE"<XMW=^63>[V>_JM?D?>]%%%?1',%%%% !1111L!\=_MT^#H?&
M?[./Q)L)HQ((?"VM3JI7/S+92X/YCI7^4EXML)=!\=^,="V&-;77-89$((Q_
MITX "X!QG'3'/Z_Z[OQLTL:Y\)O'VF;-YO?#&K6ZJ1D[I;61!QZY(-?Y1O[7
MWA5_ '[5/Q%\,3Q>6UO?7UR58%<K+=3L.!CK].OZ^#FB4N6IS-PG3:C'HWS0
MU^6OX_/HHN3]W[,6N9/;E<H\R?S2N?/$;R0;)"#NE)63UQCJ<]S^H'KB@^87
M>7!Q$<Q'G/..G(/?.?PX%374Z2H"@P)?E7 Z'UP"<?A^7>G+,@MA$5^>#(?U
M;.,''3_Z_4CK7D-V4I+XJ<DH+NG*%]7NNEM7KV.YWM.?VZ4N6DNKC[6-[=;+
M;T?8LVUW(UO*@Z2C,G'0@8YZ?_KSQ6=;O(XN@W\(<)QU&,9]^"?\.E%O<K 6
MC89^U9*'/('IR?IQ[^W-B>>.UB,I  P(R,\DL",__7_.I4*;<H\WO3<$EU4G
M-<T?-J]OO.>I&*J05[J33F[KW&W=K;IW\KG]9'_!L3X#DO+G7_&/D$BS\17=
ML9MO"[B^1GW[] ?P-?V^U_*]_P &P/@I-/\ V;/&^MS0CSKCQC++'(R_,%?S
MC@'&<8SU[?C7]4-?3Y;'EPRTT;O'S5DOS7]7.?$<KK5.1WC=<K7:R"BBBO0,
M0HHHH **** "O OVF/A]:_$GX->._#=S")_M7AK6(XHRH8M+)92JH4'N3CC%
M>^U4N8XKI);.90\4T;1RKC(9'&&4\8QCKSZY]*BH[1=M6[12[MZ?\$3:5KNU
MVDO-O9'^1+^U#\--5^!GQP\7_#^^LGL84UW4[Q(I5,?RSWT[J=I['.0:\D>-
M)7MRWW2R[2> 3ZY'0@>G3/X5_1%_P<;?LR/X#^.-[\8=*T_[-I.JS6]J/)BV
M1^9]YV^50,Y8Y^;DU_./I%^-4TVVG0\VQ+OUR0O8^WK_ %KYK$T(J;Y4DU4;
ME)7N]KK375>:[GH86DJK3Y[.*BTE;5)QYK_E\[&W.!9W$3IPLIQ(>P !!S[>
M_'7WINH7;W%Y9D<I;[@OIC')(^A&?;BL^6^%XYC'#.=J^HX^OY?AQUIT$P$=
MP6&6M!@^IR.#^'7/UQCI7'4JSC[B7*X\RMW@HI*6CZ._X6UV[)SJOEC&FTXU
M)0@EIIR6BUZ?TKZ'Z _\$DOC[>_!K]L/PM)+=&STR^U=OM$C2;$RTD:C/\)&
M>GO[XK_43^''B*'Q7X)\.>(()1-'JFEVUVLBD,&$J @@CKGK7^//X=U.\\#^
M//#/B.SFDMIVO;>Z25&*,JB:-FP0<\@=<XZ\\\?Z@G_!)[]H_3/CY^S/X2>V
MNHYKOPUI&G:3=_O SM-% %8GYF.25YZ>O->OE6(<VXM6YDGKKHHQ2EW]YIK7
MJ>76BTH75FHV;MK)W=VWMOI_P=#]2Z***]TP"BBB@ I#P#]#2T'@$^E &;9R
MRLUQN!PKG;^?I].<_P!*_-'_ (*N_M%+^S[^RWXU\06M\MIJ<MA<VL0\S8["
MZMI8\*<@\[L<?4&OTR2XC43MP!'N+'C.5!)))/ ^O^-?Q@_\'(O[4<>HVR?
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M]AR'X/1,_B32XYI\)AIH!N!4KT)13U'^<DU^NFG:?;:; MM:1K%#&H54084
M 8QCCI_.MZ^+C[%4Z5DY1YI-=')KFZO5ZZ_\$RI890J*I*-_:-6CI^[VDMNO
M33;[F>$_M.^.F^'OPB\3:[!*(I[6T<1X.TX:-_R'3OGVQS7\+_QO\>7GBGXL
M:WK]S(6674+IVD)R 6D+#GGW_H<8K^WW]K/X8ZM\5/ACK?AC2FD6>]M]B[!G
M)"L.F#SS_,=*_D>_:(_8O\6?#[Q)-HUW%.;K4B]XDA0[@H;)&=@XY]#U[48+
MEA!23YI2E!27\K<K1?>_7] QR2@Y-ZNR@GW5N;2SZ:._0^/FDM=0T1K]V!N%
MG$8&>2GYYQ_ACK4D%M#]C(4@JB>9U_CP3P>_/]?6J6L>%+_PQ>#0+AGWXW[6
MXP1@'@CU]1[]LT^S#V^_3Y&^<HS<DC@CIU/3IVKW*,E.C%<MI/F?-_-=K3Y6
M];>B/F*]:4ITJG+[L+3>NSJ.UO+:^VMM7<JR+-+I<MS$I,Q5U8+UV @9X[8_
M'\<TFF6< T=;F8[9G#8#=2WX]?PZ8[9XV-+N8;(W-E.%83Q,B9[,^<$'Z]._
MMC-9MQ;2&(6L3%1:L9& /52<]B.![_I7+4E)SBW"_P"]<6G]E75Y_GK^/0[X
M2Y<-RJ/-9QY7UE!65UZWOJ[W5R#3Y?+=HV.(G.)3V"COG^?H*L1W$)ED\A@S
M0-MCP>#\Q_K_ )YJBBF:&>V7*R3+MC8CH?;CO['/M3=+T6ZTN4W%RQ:,$ELG
M@\D@GCI^/Y]^GV*CS3EJH7Y7IKS)<KVO\#YK7>QE-R::4=8U*?*_[KY7-_==
M/RU>VNJA1IUC<_+,"TI/3=SQCMSQV'?OQ755M_,?HPDV)T^YG'0^W4^G/4BG
MSVLCW2["1YY,B$'H.I ]._IW/6DN8B\1E4\1-L?W/3/0<@TX\MXI3M&:@IK3
MW=;:[;;]M;*P.%E&"UYI.4WW2L[/_$GROT6QU?@O1=.U?QUX8LKUE%I+JNFL
MS-C:9#<Q<9/'Z]J_MC^"/P=\.S?"71=/CAA>"ZT:T0G8O22T0'ISW';OVP17
M\/.G7<NF:IHMXDA62PU*SOG<$@B*WE64@GL %/IT]^/Z\?V%/VPO#OQ)\(:)
MX<BN81<V5E;6KYD&[=!$L1'WSW0_CTZ8'FYA.?LXTX7DW92?\JTM'79/[NEK
M69VX%TZM7EG:VJBK74D^7E:\FE9=K-[;?%'[;?[ >DS7UUK6@Z9Y]PTS3#R8
M<G.=W&T>I/./2OPQ^*7P7\5_"^>6XO=+N+2TG9D>1XF50B]\X QT_+ZU_>[J
M/AW0_$D*R7UK!=I(JMEE5P<C/XCGC\J_(K_@I[^SOHVI_!_6-8T'28(9M,TZ
MZN'>"$!OD&<\*?;G'0=>E<&%KJ-39*3Y$O6\8R^^]];ZKU/4Q5.,</4<8V<8
MQC>RU2E'3T2]/.]C^3A--M?$L"07##;$NV+IR?;'TP>G3/!KO?A'\<_$_P $
MO$T<>C33);Q2A25=E"A&^7O@C'Z9Q7GGA^">RC(E+*UFS"53PV0Q[=3Q_/WJ
M*_L%U-+NXB4>86R" -P/^?RZU[=646U/E4.51A?;I%*WK);^:?5GDTI-7@HN
M7.X>[WM)-:>>FO\ F?U.?L,_MN6OQ%M(](\::M"C3K]F2.>8'*.@' 8^_3\!
M[_.G_!2C]D31_'$-UX]\'627TI@:[,MM%N&<&4G*^F/7CKZU^"7P[\=^)? 7
MB'2[^RU&YM;>UE1I1'(RH=KAL9! ['O].17]5_[$7QJ\/?M _#^3PAJT$>I7
MLFGS6H><"4[_ +.R#[S'G<01_4<5Y<ZJA4YI4U&+23ATE[RM/[W=?Y:%\TJD
MHTFKN3D^?K#EY>6G^BOK>Y_)0M]J.BWL^C:NC6\]M,]J8Y!@A(V,>><>AX Z
MYXYJ_=0HCJ]OAH9-IW#D%CV^OICGU]:_2#_@H#^Q1K_PY\3ZOXSLK66+3IKN
MYE1(XV5 'E,@P H'W3C.3^7-?FYH.Z?3DM9PWGVTQ9]XP^V-N<YY[8S[8[UU
MT84N:<J33Y^6R7V6[:+U_0YG"47[_P 5Y:NUTGRWBNMKJ^I%-$NC/9Z]$Q2_
MMI5G0 X;>IRO([]*_:7]C/\ ;NUO1M(TGP[K&I&!%\N"-992-WW1CDCIC'IQ
MV)K\8-?MGN5M[A<B R*I4<@!0HZ>_P"%5;=-9T[6O#U]IES+;017<;N(V*J0
MI&1@<8YXSVYJ\?A=*4+^^XKGV7)S).VW?RWWON=6&=YQCL^=2Y^R@KM?<O->
M3/\ 0;^$WBF+QQX$T;65E$OVVT61F!W9W#KGGL?Q^G235/AOINHW#3R*"S,6
MY&>OY_YS7SC^P9?M=_L^^!KNZNUEEN-(@;YG!8?* <Y.><?XFOMT$$9'(-?.
MU(<DY0_E=CV:53VL%.VC;MZ)NQXZ/A+I(SA%Y.?NGK^5'_"IM)_N+_WS_P#6
MKV*BLTDDDMD:GCO_  J;2?[B_P#?/_UJ/^%3:3_<7_OG_P"M7L5%,#QW_A4V
MD_W%_P"^?_K4?\*FTG^XO_?/_P!:O8J* /'?^%3:3_<7_OG_ .M0?A+I)X*+
M_P!\G_"O8J*32::>ST8'CO\ PJ;2?[B_]\__ %JAF^$.D2A 47Y'5Q\OI^'_
M -?K7M%%.-XVY='&UO*VP'E%M\+]+M]0%\%&\1K'G'8 >N1SC\_QK^1W]OCP
MY#\/_P#@I;8^)"OD0Z]K>BV"RD "3,V-N>_!YSGZ5_9S7\B__!;W16\-_M%?
M [Q;$/);4OB5HMN\J@J747"\%L<CGUX].E>5FL8NDYR5W-\DG;I:ZV7EU^],
M[,NIKV].*?*J:YEV5I16B]7>Q^HM]%"#IK1$%9K6T+D<\-$AS_3W_"N5\8Z=
M'=^#_%>DXR+VQD2%.N_Y&S@'D\=!TK4T=VOM!T2[+9\[3[/83US]G3GT[CUK
M7NM,:_OM+LUP5E$PF7LV4/!'/Y$Y^G?X*ARPQ,HU*MW.HZD&T]E9I>CM][>K
M/IL5",*4:D:G.DI63Z)*[?\ X%\]?(_/7_@@U>P^'/CG^UCX=+".1_&?E^63
M@_*\?  ^N>>*_JLK^/C_ ()1ZVWA/_@H!^TOX;9RBZC\0IE2/. 0LD9X' /K
MW]<U_8,O0?0?RK]!RR4I89-]6K:WT<4_S;9\KBW>O*7\RA+[X1%HHHKT3G"B
MBB@ HHHH **** "BBB@ HHHH _E5_P"#G,!O@]X%5ONF._S],2<_ADFOX6]
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M[4U%R:EO%1I1?K>"M\M'WT3)<93]Z#M&-.C&4EI>7N+7K>^O5Z*^C9_IM_\
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M=>;T^[>VB^]/^"6@'_#:7A&3/SG4])!'<#[1_3T_QK_4X\._\@'1O^P99?\
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M7^%.UEIWNM$?(UXRFZCBFHQE"E&'2;2NWTVO_6IG0K-,LMRX(DCC+J.A+J.
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M;64FU9^37KU?R_EB?4+.Y62WCE5XXH]RD'(#\9 ^F#T^O7K6FU2*.TMRKC=
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M]LK&\N8$2.3>H5]_89&?3UXS[_S'6\<UI9V$6TC>A\P=^F<G/L.A[=:]7_:
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MWL\$*_OD^],ZH,_O?5AW_"O6HXR%2#DVEK9=+I.U_OO_ , XG%IVWTOI^/\
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M?IQ6G]IQY'*RYN9+E?6-KWNK=+_+[A?5MM7JDVK=>3GZ?=OU/],H_M7_  =
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M M-V!/L?AO38-@&-OEVZ+C'X5ZK7U%"#A"U]&U)+LG&.FG9W/+;N[O=[^O\
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M^"'7["D7PYAC^*OB#2$9-7T>#[))/!@I,$#!E+ $$;OSXX-?U$*H50JC"J
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M7L\@ D7EP01R,[>3G]<]SUZY-:NLM%<16_D@!MJ-D>F1CT]./Y]*SU"O<EB
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M>/H#VYZ=?Z5[WX3^"OV6OV7;K5_,MK+6[C18WCB<*DIDV$-P0"3].<\UX_\
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M!^-)O3^\OYBH6(K)-*;L]]7Y?Y?GW.B=*G-QE**;CMY:I_FD?G-J_P#P3_\
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M1^7]I=LY.00 >3_D_=G_  42^-]GXV3P%^R[X#D^S:G8:QIMOJ$-FV2\;K'
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MQJA2!<JWD.?KT].G]<8K8D^&GQ<N+:WN3X<U#SIEW2 0/G/OR,?I7^B9I_\
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M:XU:D74F[WNUJNONQUTT_P" ?YY7@;]CGXX:_JD+W_@O5U29D5BUI)C:3_(
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MBFXR:UC>WE??\@,;7+6.\L+BVDB219XI(FW*&XD4H>#[,?K^%?SE_P#!2/\
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M_"OY#_/U]>]8)UVW\J20.O[N3RSR.N<?Y]Q4HUJW\T1;USY?F=1TVY_^O_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%)D9QWQG_ #_GM2<E&U^K
M27J]$ M%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'ET348DW, V][60+@'GJ1_GFKY;SY4[JZU6FCZ^1-2<81<I.RVOV;V/Y/_\
M@H#^UCK/Q2\5ZGX"9VFM--U"9E^;=S',8\8!QQM[C /45^:T%I;+I\L\C!98
MPTDBYY4>I]!W['ZXK2^(^O\ G_%WQ;?WLAF0WNH,I//!NY6&.W3G)_E5+P1X
M<U7XD^(9M$TA)2=<9;*T"JQ'F2DJ-H QGUQWZ>E>]"4(R]FHIJC24>>]ES6C
M[CLEJVO7;Y^#.52JKR;EU2ZJ+:6R\VGV5]?+7^'GP^UGQ]K]@-.L9KJ 7"A6
MC0N"&/; ^O\ ^NO4OCQ\%]0T#Q%X T%;*5;S7)"C0A2')!QC;CG [^AYYZ_O
M;^P)^PG=^ M%T2Y\8Z6)YU\N5VGAY.54C)8=?\2*]*_:%_8Y?Q1^T;\*O$EG
MIR#0-$U"26ZC6+]UY?S$;N,=,'K6']H*DXWC=N2DX_R\C5UWU:U=OT:Z:&#G
M%JM+6\XVIO[*;4;[6T^)^OD[?7_[#7PJTKX-? +PO>7"1VLE_H-I<WC.H0I(
M(]QWG P<\?S]:_-W_@IW^V,-$TZ^\$^&]26XCN8&698)LE7 *D$*1@\\C'3Z
M8K["_:X_:E\,? [X:R^"(+F*TO$T[[-:+'(JLACC90 %QC![?TP:_D:^)7CC
MQ'\2O'NJ:GJ5]/>6D][/+")'+*(F?<%Y)_\ U?C6&'I?6*E:I-6DZD9*_G)2
M<4O1KT1V8FIR-4VO<<;MW7O<K7N?-::')PR3>*+R\U;42WGSW$W^L))PY)SD
MGI^/ITXJ=9ET</IT!W1N"V0,_,XP5SZC'X]LFK\"1F0"V 5%7RF"@#]X 0#^
M)_(FL2ZM)H=36WE),BA9B?\ 8.#CGV'4?CCFOIH8>+I2<:BC+V5VOYG)I->=
MDK>E^I\C5Q$*->7*TU6J0>GS7)UMOI?JC1BTR*YM0KG$DA;>#Q@-GKQGN3QV
MR/:GHD"0#1Y&58K?F Y!W,PY [Y'7VZ].MB%7DN+F:/_ %(@ 0#@!@N">V>>
MGX^@KF["TO/$?C3PGH5B6:XO=7AMY0@R6#R%<'';@<]>G6O(=U5YYQY8TYPL
MV_BCRWEOTND^QZV'H_6?:I2M:,^75:3BE%M?XE)W5^VR6GM7P]^!WB[Q3XD\
M,I:Z-=W&F:I=QK+,L+,@0L!DGZ8SZ=37]I'[(OPNL_AA\'=!L(X4AGFT=!(N
MW:P*Q'@\ ]0>WUKQ']CC]F?PEH_PA\*7>MZ';2ZK!9QOYTL*F02;4(.3CG/'
M_P"OC]!!I\>GZ?%;6BB*VM[2551<!0%5^GIC]>]<6,QD<2Y4HM05W*Z=^:,5
MIZZK]+G7EN$>'48SUFH.7FKS2_)_\/L?Q'?\%&BMS^T?XA@#$P?VY?>:V>%8
M29P?0]QQ7R)J2 /9(G(6)%&.A''/_P"KM^0^H_VYYSJ?Q\^(L 8/<1^)[T0M
MG)51+G [_P#U^?:OF*Y3R%LY9>B6ZQMD9^;'^.>Q[]P*]+ )1I4YQ7QP>N]I
M])6UU2M??3Y'%7JPIQJ)VYJ<YROI=IV2CNNJ;^?0BO D\\=JS 1I )<^CH,@
M<>X!XXQP37JWP=_:*\3?"37[*\L);@&*XBB&';&Q'Q_>&./SKQN6&9I0RD[B
M0_':,X(QSG&/RYI;JRA8Q7@4;%=02.FY>OUY[5>+PTIQIRYW&4XQE)]WI:[[
MI-^6NO<YL/)4\1>FO=M[7FC_ 'N5I=%I:5M^O16/[ OV(/VQ=.^*^D6EOXJU
M2&.\>VC189Y1EGVJH7#,>3]>?SKU_P#;[\.6GBC]GOQC+8P1RJF@WKH\:@YR
MG&"!Z'/'X>_\?/P9^-/B;P!\0]+NK'5;BUTO3[FWEN(DE*H848%P><8P/K]>
M*_JY^"OQX\.?M2_ WQ%X2L9HKG4#X?E@8&17<O)$JX&3SU]/QR*\JIAXX><:
MB?/R*,9+S<+J;^:O?ROH>_[58JG[.":;C*7>W)**7??I^1_&]I=BLFIZMIEQ
M\LEA,RK&W7[S<8Z=.,8S],&M:2$12)9C_5R9#GC@KSU].N,^W3K7J7[2OPOU
M;X'?&7Q#%J,4D5I>:A((@4*J5#,2.1TP#GZ5YGIH_MD3W$6#N.Z,^@*] .<_
MT^M>U@JUY4J<DO>]FY?WHOE;T_Q:;/6^A\[B,/4J3GR)Q?-"FU;XW>.O7X6]
M->GW_2W[%'Q#30OC/I&GZBZ16/VDP[I2 FQG1>=W'0Y]._3I_0)\6_V$? /Q
MW\*IXWT^2VN+D:9YI,"JQ\T0^9MRJ]2R_F#UQQ_*A!)?^%=:M_$-A*T$EE,I
M>1/E(;<#GCOQW]>PYK^G?_@FY^U[I&M^ AX/\1WRW5[+.L2B>4,=FPH5 8Y[
M]L_0XK#,:M3D35U[.J[Q=DY<UHI6Z>ZEMV>G0[LOIRP=>2JMR<TDVU\.R;L[
M;Z+;IKIM^=?@SQS\6/V2?&<WA[0=+U+^QXKZ2,S(L@B6)9BA.0R\;.>F"3[C
M']!?[.'[27ACXF^!;1?$FJVB:M>1>3+;SR(9 [Q@%2K$D'<2.2>?<UK_ !0^
M WP^^)O@W4K_ $S1[!]4N;><Q3)&KR>:\9*D$<D[CUQUP.U?A+XB^!'QL_9^
M\3GQ?/?ZA;^&+74GF$*^8L0B28O@#@8"8'O^0KY_EE.JE-\L[OFONI+:^^KT
M1[,*B@VXJ\)U%)2[1GU](O\ /OH?TG> OAGH.@^(M0\5:;' 6U.( O&B].6'
M( [-GK_.O;:_);]F[]O7PGXJAT#PG-<JVI7$L%BS._)D($9ZGKN!Z^YK]7;2
MZAN(8G25&\Q%8;64_>4'L?4FLZCE)\TVW+1.^^W]?GL;J:]HZ:W4>9^6J2_/
M\"Y136<*0/6G5%FK>>Q:DFVD]8M)^5U<**X?Q/XSL_#C!;@@93=SZ8//X>E<
M39_&/2+M)'5E^1RA&[I@XZ\?YQZT6?9Z;^0E.+Y;/XDVO.V_W7/;J*\=_P"%
MLZ3_ 'U_[Z_^O1_PMG2?[Z_]]?\ UZ11[%17CO\ PMG2?[Z_]]?_ %Z/^%LZ
M3_?7_OK_ .O0![%17CO_  MG2?[Z_P#?7_UZ/^%LZ3_?7_OK_P"O0![%17CO
M_"V=)_OK_P!]?_7H_P"%LZ5_>7_OK_Z] 'L5>'?M**S? KXG*@RQ\*:H /4F
M!O2K_P#PMG2?[Z_]]?\ UZ\S^-?Q%TW5/@[\244J5C\+:BSC.>/);/K_ )Y[
M5,]8R7E^'7\ /Y@?^"8T8C^-WQNC<XD:.42*?X1]H?ZC]1TK]<$C6>ZU5.H@
M;$7?=SR1T]?J>/>OR(_X)H3?VA^T)^T#=V_%M-;R>0 !@'S7Z=@>U?KU C6]
MVYDZ!\RGU /3 ].WOR:_.\8N7$SN[M-:Z:II-+MVM\O0^EP:G&BX.]1580E!
M?R-1BV_3ETOW/S7_ ."MUFB? "UD'+&&UWX_A/G#KZ>F/7%?T0?L"<?L>_ ,
M>GP_T8?^0 ?ZU_/1_P %9)5F^ =PG'SK:>6,XVXFYZ_3Z']*_H7_ &!05_8^
M^ @/7_A7^B_^DZBO<R)3A-QE%QYES)M;Q=K+?;5M:=>YY>8)NHI<EDHJ/-I[
MSLM?1;:]3[!HHHKZH\X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]C]A] ^('A?Q']G&G:G;7,CA<+'(')R >W!SG'\J[X$$9'(-?ST_"/QCXZ^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"RCJ0/J0*-R_P!X
M?F* %HI 0>A!^A!I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFO'OVX?A59_%7X%^*--O%5DTO3=0U)-PSAX+5G!Z'GY>/QKZQT:T73]*L;,
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M.M^MS.6XDA4VZJ2!+D#N0">H]3_D\5-HFKWGA3QIIWBZ)W@N-/E@N(U4E<M
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M,,S;@<'Y8F8<]N1G\*RKU51I3JRV@KO;NNYI2I^UJ0IWMSR4;]KNUST@^,=
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M_GW/[$+#5K'4XQ)9SI,AZ,C CIFM*OQT_9I_;2T&6"TT35[Y9+Q]B_O)1G+
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MY]L^_'PA]G\7&-7^T3[2^P?>Z],GGWR?_P!8J3[)XPWR)Y\^Y(\MRW0@>_\
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M89.>W?/-?S0Z5HT=YI.R];RY[20QE'^5@(>N01V(]ORK^\+]L/P=HOB'X/\
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M:UJ45O'IL21)YTP7[VT'J>O'IT["OYL+N%IBC#F*9MH'&"1CGZ9[<^@XKHO
M_P 2/%GP\UPC1M0GM(HG0L(W9>,G^Z1GI^7XY\O'0G4:2;:D[2C_ #2M%\VO
MXIKKY'5[25&-.HX.51U&X+K%R6W1:*ZWVWUO;^]3PW\7?#'B'6)--L-6M;B5
M9 @2.9'.3CC /H?0C\Z]1TZZ>YDN0P.$D(4GH0,8P?QS[U_(+^PI^TUXQO?C
MM8V^O:U<365[J<05)IFVE,J".6(_3W'K7]>'AR]MK_2[2]@="+J".7(8'.X>
MO?\ GDUXE2"CS-+2_*M-FK7U6A[>$JU*ZIW3CR*\V^KDD^7U5_\ .QO.P1&<
MD *I.3[#-<=<>)[2!VC,Z!Q+@@L,@ \GJ/T]\&NDU)'DLYEC^\4;:1SSC_ZU
M?&'CF+7]-UM[D2R"V<LH7Y@-S-A2/\^G%823::3L^C['?)-Q:3LVM'V?<^M3
MXITSS"INXL>7G[XZ[<^O]>OYTS_A*M-V(?M<62Y!^<=./?\ +IWKX7^S>,#,
MP%Q/DIYH^]C8<''7T_#'?-,%OXOV1O\ :)]K/L7.[[V3UY_SQ3*/NX^*=,#R
MC[7%A5ROSKUP#^7OUIH\4Z9B$_:X_F/S?,O'!/\ ];GZ=\U\*_9?&!>5?M$^
M8U+/]X9!4>_;K]>E(+7Q?B$^?/\ O6.SEO4>_P#CU]: /NL^*=,Q,?M<?RGY
M?F7G@'_ZW'T[9IP\4Z86B'VN+#+ELN.NW/Y9[]:^$C:^+\3'SY_W3#?RWJ>.
MO^'3\:7[+XPW1)]HGS(NY/O'C;]>AQGZ]: /NG_A*M-V.?M<60X ^<=.??\
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MNC<Y*45JW>R:7WNZU/6SF$*T*\90UC!V?5R<%9_=:U_O/Z](I%EC21"&5U#
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M^G2M"":16,KJQW)M!P>K<CG')SC_ /56C::#JNJBT6%9"3=(Q(0\H6'7O_\
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M*-*^R4(+FLU\2<8OMJ[M]3!GDM((XRDBEH0  #US@>WY\XS4C3VUU;%3*H+
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M@:]7D]I-N\8Q4+O5N*CMOJW[O7KYGH5<*H0C+F3<[)1ZMR2>ENJV?_#HP(-
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M5]X%U3P%X?O_ "]1>6*-TCEP248J_"GW_GTH<'BL4YI-TU))R2T]U+16[_\
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M\4[/6I[NW0M&<6X\Q3C^)>>#ZCT_/K5CPLFI^+O$JZ?#;22"698B%5FP&XX
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MH\L%9:?@DOR1XP44458'XS?\%8?&4VG^#_#^D6SY>XOFBE13R%8XYYX'3_\
M77XJ:'>M%HT=JPPVTX]6)]/4_P#U_7 _2;_@IEXL@U3XB?\ ",2R>8;*\C*1
MDYVDDC('/)QVQU]*_-66,6L]J "([=MTP P"O'4?C_AR:_&N,Y7QLJD]8WLD
M]I)I1CJ]FM7Y6?J?I'#T(2P]*"DN:%-SY?M-Z-/3K=IZ]"I]KDLIWB53_I9^
M?CIR<=#[9QZ^U1Z7X@N-,\;^'O$ # :1<Q1*_H#(G.<CZ]1^&15^[\F=Y;M
M-JG*'H /;\R> :R=2%O-H%TUN!]J$\3HP R"'4G!_#V[^]>!E\FIT'?1\DF]
M=91FDKO=6BEY::'H5:=6HG*:E+F=GO9NRC:VWD_)J^Y_7G^S]XB7Q)\+?"5^
MKAS)H]FS$'.&:)>_?OGW]:]KK\_?^">WC1/$_P 'M/MC*9)-*@MK)P3G!CC
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MKWCG3]&@16GO[N..%0 <G<">,=_;TK^I#X(?#;2?#OP^\.0-:)'=#3H!<':
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MMI$-Y\!OBM:E@3%X5ORB]W)3( SU/&/Y^E?%G_!"KQO_ &/K?QQTWS0K::(
MT9(^0>8G\)Z>V0.,GO7W/XFTR]U?X:^,--B))NM(NXIE /*,O (SSQ^'U[_E
MQ_P1GT#6(?VB_P!K;PU&646UU:QPQ#^$EDX"@\<Y]JZ<HE:5*<I7J<TH16MX
MPVU7^*S];LZ\SE",ZLY+FARTV^TE:*_%G]-]K\9;F9=1(8DV[ +\W!SQQSZ>
MGISUXL6GQBGEDC#/P5)8DXP>W?/3CKZGM7FFF?"SQ!$TOF(^V7)<;2,GD]^O
M^&.]1M\+O$J+<&-'!W_(<$97C/?WR.W;Z?H+5)1FM&U"DT_/W>97ZW5W:VQ\
M1)57.O).T934*:U]U2Y=5Y*Z\G9^IZ:_QBN%D==Q)$F ,CE<\]^_/-37/QAF
MC=,.=IC!)R#\Q]3G\QTKS*7X7>(C-"PC? A&[Y3]_ Y[G(_2HF^%_B5[7#1R
M&03<$J<[<CCJ>#]:Q4J=X-QVLI=FUN[>::7X[[VN?VB5[*%-WT7O2DDDNVC5
M]^NO0]2;XP3_ &19 ^'WX()' Y[9Y'OCO[#);?&&:3SLN1M0E>1R1_/KC'?F
MO,T^&'B+S95*/Y?DG:"I(W[<< G!Z#M@#CCFJ\?PO\2HD&$<$R?O.#RA/0\G
M_(P:+P2:LFTXM/1W2W7STOZ-]R/WCIK=2JSOM?D3::NUV2]'<]/A^,5PTL:,
M^,OALD<#)'^&#]#WI;CXQ3I+(H<D=$.0<G\^>PKS-_A=XC$URR(X!&8^",''
M3KQQ]/YT/\+O$;K9DH^X#]Y\I)]<GGOU^H/>GSTVXOD5N51:TNFHJ-[OS]Z_
M_!MI>?/-Z\L())?S2=I77R]V][_/4]1G^,$Z) P8_,N7&<XX!QR>/_K?FB?&
M"=K:5]Q# _+R.1Z@9_S@>M>8?\*P\2-#=*R/D-^[^4\#'&/S/8>]+%\,/$:S
M0J4<1E#O&TXSCC\<Y['U/:IO#E:25T]'IJFDOG9IOYD)5%&E&[O*2E)]HIJ7
M*[]UIZ_CZ=:_&&:27:SD*%.3G SZ9]>,XJL_QDN$+ L<AR!R.F!V_$?GBO-%
M^%_B5(W*I(&,W!P1\@;O@],< ]13;WX6^)&E5HT?:8UR #][ YZCD^O]*M.G
M*:7*E&:LM=(MI6U7:SW[]V7#F<ZC;:BG&*36[CO+TE>WET/2G^,UPFYMQ*A<
MCD<' /7N?;W]C5VW^,,TL5LV\G>^&&>@_,'W)KRB3X5^(VL$4(YEW\\'.#CO
MGMTZGL/JZP^%_B:-)U=)!A"8_E/#'TYYZ?3WR:YZGO7Y/<3DVM](M62?H]?^
M#=MRC-U*<E*T8I\ZVYKV^[N>R^'/BI=:OXANM.7+QPN@!!./F&?IU]/;OS7T
M/'%#=V\4T\,;MLW NN2I(!/7I_GWKY2^%G@'4]%U>ZU#5(SAF5LLI'((YY/Y
M_KR*^JI[N&UT][@D*B1,<G  PA//0=O:LZ-*K%0<I<VC@WWFVFNW2YL[7T5O
M+<_'?]O7]MFY^!&JP>';"<(;R*=/+5P"-H91QD'@9K^83XR_$R^^-?BZ[UN^
MFD=)+B23#L2OS-NP<L??OZY]#];_ /!6#Q9J7CCX_P!K:Z3<N]IIEW>6]PJ,
M2H.> >@''^>3C\[],LYM+M)DN1B>1PRDYSMS_G@'GIQ7UF#C3HX=4FKS]V4I
M;6>CE%^J:7?=>;^9QTY2Q%65.7,O=I12^R]+R]%S?=]RWK738KD*TA"^2/*4
M,<?*H7!]Q@?IUSS69J-S);3O80@F&!/.WKDC(Y([@^X//\JM7#S>6DT#$(0$
M;&<%R.H^O?H:L0)%':7"W8#74D3[6.,[6!QUY].I/XUTM0<IQA#11Y:<>U[-
M67=6?R>ISTVHQA%1<5)2E+3:2Y8N[UMS+IY6MH5],MDU>RDO7(!8/&P'50I(
MR1G']<_ID:AIZ(VE:5;L)&U*[6V*J<D[F&1@>Y''I^I9WC:#I4HN"0MX\D-O
MD_QNW &<YY_E7TW^S7^S!XZ^,/B_PCJ5C;33V%EJL%U<?NV9?)#ACGYAQ@X_
MEVIR<I4>6<K-24E%Z-1:UGKLO.Z+IQ5.I#DT2N^1=7S1=]7OT/ZJO^"9WPLM
M? '[._A;4?*6&;4M.1IB5"MD*IRV0.W()_\ KUY]_P %.OV@[3X?_"35M#TZ
M_C-SJ-E*C)'(/,##>,8##G'MU)_#ZST*_M/@?\!M,T[4"EJ=-TLC:2$*[4].
MWW3TX'XU_)-^W=^T9J/Q8^(>H:'9ZC+/86MY/"8O,++MWL ,9X]OR'2O!HT[
M575;O%5Y125M;1OS7>OI^I[%249M4HI0E5AJW]F]FX]KN[]-#Y!N9/[4U)]0
MD?<^K.]U*2<D-(2W/OGC\*JI&(#+)G!1S&/<$XSU]^OMG(YS4A@N8$M(R2'$
M8VCV&,XY] ?;\\U<N4=HUD7[J863W<]^.I]3Z8]L>W2;;>O(JCA?UTUM?IOY
MGCU;MQHN]HW3\H1EJM=?>=U^?GI:%8QIXO\ "RY&TZ[I<Y/8'[5$V"?\\<=,
M5_<[^S]96_B7X'>'K5]LD9T>SBP>>?L4*Y[YZ?EGK7\*MK<O9WNCW+MA[;4K
M*XSG&(XIT<X[8 4GKC]!7]C?_!/;X]^'_&OPUT?PW!<QR7MM9P!U\P%@(X50
MY!''*_X5Q9DYRHK5R<)1OY)+;2^^MO\ +4Z< X2FXV2IQA*&NB<4XZ_C;Y'U
M9X^\$P6OP'\<>&8HEV7&A:E&J*.,S1MCC'?^?/'2OX6_B_X>G\,_%;7O#-K&
M[.FI2K)$JG*B25ST&"/;@<9.37^@GX@L$U+0-1L=H=+NTDC*]0P=<8]P<^_7
MUK^2[QM^R1XC\:_MG_%-+>QDDTVUNHIH%$3%5!9SD=AU_#WS7C4915:%1_"Y
M\DH_W9?IIZ+T/9K*-.A)I74(^ZEYKE5ODS\FKF%A;3VTRE7L5P%.0<XXX//)
M/M^!->L_LT_%^^^!OQ,T/Q/;3NB?:1*X#$+G*\'D  <]_;..:C_:"\)3^ ?B
MAXG\,31^2]E=F&1,$8QD=.G8UX+K.E7U[9K]@)%RJ@Q,H.1R2>XZ\=#7T\(0
MJ8>HKI.5-VOT4:G+!]'M%235MT_-_)XNFW4HR<[0IS2G!_:;LG]VOX>I_<A^
MR-^TSI?QA\*17UYJ4!NRL0$;3)N.X#/&XGC^?:OPS_X+=:!X@\2?&_PK;:/8
M7-[:S:%:YD@B>1?F>(=5&#CMST/&:^&OV-?VI]=^#7B#3++7]5FAT^*YCCFC
M>5E0X=1G!)!'KQCGBOZ!Y?'7P>_:3\3^$+N^@L]1U#^S+-!)(8Y&'"'DE2>"
M/7G&.]>)3H1J54TU%.3;6NJIQ5Y==)2O\FOE[2G>$(R7-RN$H*WQ0E9)+RLM
M?)G\LOC7P3JWP[L].GOK*:V^UPP1GS8V3'G*H.=P'7=SG\N@KFELT\MK?/[O
MR_/#9X)8%L9]>>A_3FOZ O\ @JM^S)96'@/3?$7A338X;6V%JY>&-0 (T0MG
M8!T"D_XU_/;;ZFDT*V"G_2XW\F3GG"?*1^A[XKU,-4I\D6_?DZ7*K6NGSQ;^
M=DETWW.2O14)I35I1E)P;73W;I=K<VMD6'BC6RLHE8$F;#@<[5)QSQG^8Z^M
M5YE%I> QYVHPVGD ],_7_P"O^-.M].O([F[\[)C:(& 8. Y'4#)QR1W&<=JG
MAMGD$2R F2(YE)ZD=L\>OO\ I6U><75@U3<%*ZD]E%QM>[[VNWVMI=61R1E[
M*<Z48MP48R5OL>YS/7^\TK?KN6I[G[+%YP(W78W.!U!P?\G'I]*^T_V $T;1
M/C9H.NZK+;QHMV9,3E0""ZDG+?0D@5\+7+&>Z^S Y&<1]?ID ],9ZUT=KK_B
M#PGJFEZGHES);-9I^]:-BI#9!ZJ1C'Y=!G J$HOF:72*4K;+F5W\_P#A^B-U
M-\T)QERMI<T;6NN6-2"_[=>OZ]_[Z? GC/P??:/8/IU_8%W@CW+#)%PVT<84
MGGGIZUZM'(DJ*Z,&5AD$'((_SS7\='[,W[<6O>%FAA\4ZY,T:W<>!).P CW+
MQ@DYR,Y./\#_ $3_  7_ &SO ?CW1M+2UO89)W2WMW/G(3YK +T(Y)8CO^5?
M/5Z,E5G%/G:E96ZJRMUVU_/8]O#XKVLU#E:YDY-V6K22?9:=[>6Y]YUR&OZM
M<6$@$2L1D X!Z=<C']>^.]=-:745W;07,3JR3Q)*I# _*Z@@\'WJ&\L(+I',
MBACM.,C//K^'I^5<IW'SWJWQ1NM/U*\M7+((D)7)QDD=.Y)Z?_7S5 _%Z;9;
M-O.7/SC(^4<=?[N._P"?;(ROB/\ #_5-1U43:<C!7D'F%5/*\\<=?Q [?AP2
M_#+Q)B[!23 3]R"#Q_GBERM*;OK*RBNSLM?Z\CF:G*I[DO==Y7MHK+D<?6_O
M?+:QZD/B],5N3OY0X3D?-UZ<\_7]:CLOB_--<QQN^%(.XD@<_G]>/J>U>7Q?
M#'Q('MLI)M(_>_*W)]>O;G^?7%,;X8>)4-PT:2!O,!CP#T)R<8/N._3]-H*'
MLYJ37/&$+2[N\>;^O7T'"4U'FE>7/.*2M9I:0;U?5KF7KKIJ>ER_&.Y6=XPY
M.'('3[H)'KW]?:M _%R7SPN\[?)W$Y_B]SGUYX_05Y6?A=XA-S"YC<CR3N^4
M\OZ_7V/\Z8/AEXE^SL2D@D\T@';@["<8ZGM_6IIJ+DHRLDVM7;3_ (?;\RZL
M)R7N24;1FM5>[?+ROY6?WG>-\:+H _,>'.3GHN>,G/3KS]!7XX_\%J_B>^I?
M 'PK:O* -4U=K4+NQO:0*NT<\GGH._Y']3_^%5^("\Y,;X,!V?*<;MI^G0_I
MGCN?PK_X+?\ AS7= ^%7P$TZ<N'U'XD6EK*IR-Z23(H4YZC'7/?OWKES!1A2
M=FG%+GE:VJ:^'RM?9]3; TY.U6HU*2C2M3ZRDK7:M;?O_P !GO/[!>A?8/V3
M/ %JRF,O'<,5Q@@.5/(/YCOCTK['TR&.S01 @D [>A)Z],$Y /IS_3PK]G'3
M1X;^ '@[2\>68K%"%X&&>)">PZY_R:]CM1/-/I14G&7,F.XQWY'Z_ATK\PKW
MEBGB935G))0ZM>[%+Y+76^WJ?224535;D<:DTK-Z6<N6/1=+VV_1GXM^+]NK
M_P#!6+]F50PD%IK-^K@<A3O'!';KC\#GUK^SRV01P0H!@+&@ _X"*_BT^'R2
M^(_^"L/PZG),D>A>*+U!G+>6&=!CO@>W'\J_M.CXC0?["_R%??Y/:6']HE9M
M\OR27Z[=CQ\;)RE3;WY6GYN+Y6_FU?YCZ***]<X@HHHH **** "BBB@ I" >
M#ZYI:*4HJ2<7L]_S _,W_@IEX7?7?A+9R11%S:WIG<A2<!5!/0>W].:_G3MK
M5#;PX(/V>9R.3@E6Q[GM_+UK^LW]JCPO'XG^$7BF%XA*]KI-[/$"N<.L+$$=
MQ@X/&3_7^38036EU<Z?+D26=]<F8' ^42M@<GH/U]Z_+N*Z2HXM3Y;1Z::/G
MLY>>FB?ZGW7#4/:4Z:4TUS6G#JE!QE'[U?;\S29E:YM%)_US;6'IP.O/'O@
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MRE>*:5_)Z^GX_=<5U(5,IARR49<T7./\UVFONT^:T\_V>HHHK]D/R\*\4_:
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MK#PPHHHH *JW=I#=P2PRQHXDC9#N&>&!']35JBE)*2:ELUJ"=G=;K5'X6?\
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MN.0/7XQ_X+Y^'AI)^%?C)XPJO\1= MO-QCD7=MP&_F/YU]5> +^/5?AEX1U
M$-YND:;&S#!R!:1#!./S^OKS7Q6<4H2J5*D9I3BFW'K)WC:UN^MN_5GO994B
MG"-6-^5P;O\ :I[1]5'ROVT9Z%HP\SP[J$;)S?VLT+*P_P!D@<=<_I^E?E?_
M ,$D?$7]A_\ !0G]K7P[*HCBFUNPBB#8 ?+H#M!/)X[=_P J_5"RU&UL[>&V
M; \TLJC/<J> /Z=>/:OQJ_8^UJV\!_\ !33XJ@D0?\)/XHM(^NSS=KKCZ]#^
MOI7)D\N;$)VLV[6\U4CK\[=S?,]*5>ZT]U0T^RFN5)_X==>B6]S^RU8(< ^6
MG(SG /44OD0_\\T_(5D/K=K"EON9?WL:D'..J@]ZB'B*R)(W#@XZC_']*_0$
MFXJ2NX[*71M;Z_F?,<T>;EZWVTZ)2_)W_I&YY$/_ #S3_OD4>1#_ ,\T_(5B
M_P#"0V?]X?G_ /7H_P"$AL_[P_/_ .O1^A1M>1#_ ,\T_P"^11Y$/_/-/R_S
MG\:Q?^$AL_[P_/\ ^O1_PD-G_>'Y_P#UZ/Z_K[P-KR(?^>:?]\BCR(?^>:?D
M*Q?^$AL_[P_/_P"O1_PD-G_>'Y__ %Z/Z^\#:\B'_GFGY"CR(?\ GFG_ 'R*
MQ?\ A(;/^\/S_P#KT?\ "0V?]X?G_P#7H"R[;;>1M>1#_P \T_(4&"$_\LT_
M+'\JQ?\ A(;/^\/S_P#KTG_"0V7]X9QGK2<DK?WFDO-O;<#;\B'IY:?E_7K2
M"WA'2).?:JUEJ$-Z"8R"/8Y^O^?\BZ[!$9S_  C--*[LMWH@*L\$ @D&U$!'
M)P!Z=3_G^=?#/[8'[0^E_!_P/<M;ZC MV;28K$LR"3<JN.F[/; &/3I7UG\0
M_%5KX7\$ZWXBN7$<&GV<MP[$X 6,9SD_XU_&%^WU^T[K_P 5/B')I/A_59I=
M,M+N>*>))&9-I+@ X8#G/'7MVKT,)0E4<4W:,:JO%K9M**DN_+?\")S4+7:3
MD[1OW=M#Y>^)WQ2O?B+\0_$_B2Z#2&35+B9&;GACVZ\8'%>8-?SZK)(QC8>6
MQ51MZ@=\<=O?^E7+=+>.QE#@?:IN9#@!F8GG(Q[\\^E=#9I86,D/FJH$D.YL
M@<L0.Y'<]\]L#/6O=]FE.4%)=&WLFTE\K_AH?-UW["=1PCSOG5U'[3;CY;K:
M_6RM9ZF':3*;::T<X*+)*N3R7520/<DXX[_E6=]E\17?AH>))=.N4@_M!K(2
MF)PAB5B P)&,$<_UZ8?9VUQJ_C#2M%L0QDOM4M(=B@G='-<1QD$<X!#XYSGZ
M=?WJ^-_[,_ASX6_LB:1J^H:5%!>WBV]R)#$JL7FM$D!SMSDE\GO[ CG&%7DG
MRVY9I^X^KNMTDNGW*_<=.,ZJJ-1<8P5[M64F^6Z7X=7;RT/PR\/^&)/'FN^$
MO#D<9D,NL6BR*@W'$DB@@@9/MV[^]?V/_L,_LV:1\)O &EZU<VT,<DUE&\AE
MCPR8CC;))''7J<=L]*_F)_X)^^#T^('[0-C8^3]H@TW4X;DJ5W!42<D'!&,8
M /';IC%?V _'+QYHWP6^".L7KRI:)9^'I6@P^S:\<*\CC@\>OUQ7#B,34J1I
M*-_:SE."TO:G&T;-7Z[[7TT.[#X>G*I[6<>14X1A>6GO:.4MNZ5]/1W3/R'_
M ."IO[7K^";=?"&BW:R)="XM76!P<9WKC"L?3OGVZ8K^:.WMY]>\0S^([DL[
M7\[3R%^=I8[N<@\^O7ZU[O\ M(?%'4/C7XSNM;>Z>[T^.[EDCW,7 4LPXYQW
M]NOXCS+2FMK'3[BT8 3W:J+/.,@ 8X_^L?7TKLITX4XQBH_"DV^\G&*D_*]V
MGJ]?O.>JVINHI)MMOO;EFE'9_/T^\CN)69RX7!@!1!C^$\?C_GTJM;2F1'MV
M!VR,)#QTP"=N">ASD?\ U@:LM+$D]NK] A$PSP6.>OXXSG\.:K2;8 Y'#/)N
M3@C"$\@?AGN/;WZ:46E*,DWSN,J=MDE9.UN]OP?F<<TTY.]JE5J,=G9.UWO:
MT6^;SOZE.ZWS/T.Y.% [;>_\C]#FON/]B#]J75?@Y\2+#26GDCL[IH;<EG*H
M/-DVGDD=C_\ 7ZU\9EK<2&Y./*%O@]?OA#T_'_/05S4=Q(6AUC2"4N[*Y$QE
M3((2)BW48X&.N1VQ[354)0YFK1O3ISCK=MIWGTT5K/TN7"7LW&%/5R?(U'>U
MTYI_DU?Y'^@_\(O'-GX^\&Z9K,%S'<&YMHG;8ZM]Z-21P3R,\\#MFN*T+X*:
M9I/Q,\4^._L\+7&MJI=BHS\NX]<>O;OQSQ7Y4_\ !*;]IRV\4>$-/\)ZMJ'G
M:C;Q&+8\N6!X0##$D  <=<XYQTK]W%*N@=<$.F0?4$9_7-?,UH^SJRY?AYGR
M-;->7W_IY'T-*:Q%%-JR;LT^G*U^J/XB/^"GFAW'AS]J76)1;O':Z[K$^7V[
M4P&89R0!V_*OC>UN1:>?( #]G.(\\[E/?T(Z_P"0*_<K_@L]\'/L]]I7CJVM
M-LD3W5S+.J<\&3DL!^?\\8K\'--O([J'3>K>;%^^R<Y)S@]/7_/I[F%K^VIJ
M*3348P?>2LEIKIO;S;OYGC8JA"3G4E%\D*EG%V]W1/F^;5]NNNMFV:YX<@U'
M2[C5TG6&9)%EVH<,K!MWUSD=/8_6O:O@G^U/XB^%7B'2KQ)+AAIZPPKEFP4C
M( .<XZ#\,_E\_7K:C''>V@=A#)<!D7J/+#=.O_UO?@U-?6%DZP-&BB06Z[CC
MDR;1DYQD]?Q_#-;K#PC.#Y?9QE>"F^SMS;>NOW]-(55^Y*+NHI<K6RBK<OEI
M_P ,?U5Z3\9-%_:L_8YU[4]<N[<:CI]O?>7%-(GF$V]I(RX!)/)7C\NE?RH^
M)?#>N:']K\16-A<36I\27UGYJ1LT:QQW4BYW 8QMQSR!Z^OT5\$OC_XB\">$
M]5\#'4Y8;*]6Z'D"1E0K,CIR,X.0V,8[\=J_6WX"?LPZ)\7/V0;[74TR*ZU:
M2[U2[CE\M7D\QMSA\D9Z_B>N0#6<*<</*497B^?W6]+<UN5)?).WINC6K*6(
M5.<7SRC&<))*[C)<CDW_ (FT[=UZ'X4Z5K+:C*B.N"BKNX[@#(/X=1_B14IN
M1#JLT9("3$*3V'OGI[>W&:W?'7@/4_A3XKU+1]8B>&5+J6-=ZE>#(X48/L,?
MGZ5P=YYMZ97MLF0@["O)!SQP.>AZ>W6G3G-UG2K3Y[SB^9Z)\WQ+YJ[:?2YP
M4HSA*I&:YDU%^T:W225EYZI6Z]=-3;O+002M>QX;RLLO^U_G/_UJ8MZ;Q#"X
M/[X<G &WJ!^6.@QUYZU4M-;M_)BTVY/^E1C9,#U+9QT/.2#^-6Q:F"&:XQ@%
M@4..HSGVZC(_G7H*-)KEC&T'-4U+^51DI6U?56UZIF$85(5*ETW;E]F_.7+"
MZ_PQ:\K7=NW,:OI\\>GW%W!(Z2Q2JL:J3EL<@C&#VZ]?I7J?PA_:5\??"Z^M
M;:P@U":.*1+E2@D(S&P< 8]<>_' Q53PUHC^*M<TO2K==Z7,D4;KC.YW8#D>
MN6_')YK]L?A-_P $\6U+2=&U;4-#6474%K-N: $F.0*W4CD$9SU[^QKS*T*<
M)2E=1DFI<[VDD[-=F]/PZ['JX651UJ<(Q;24%*7=.U]?)K7;_+ZW_8#_ &VO
M'GQO2RL==TZ]@2%8[<&:-Q\L>$SSVP/IZYK]Q8'+PQ.>K1HQ^I4&OAC]G#]F
MKPK\(+&"6UTJ"SE5%+%8U3Y^"2<*/?CM7V)'XEL1*;8.N8QC (Z 8'^?:OGI
M-2DVE9-MI>70^@.B,$3.69%)[9'/_P"KV]Z7R(?^>:<^W^<?A6-_;]G@'<,'
MW^O^%)_PD-G_ 'A^?_UZF]_R)C&,;V5KMO[]S:\B'_GFG'M_G/XT>1#_ ,\T
M_(5B_P#"0V?]X?G_ /7IJ^([)LX8<''4?Y% VU=)[N]OEJ;GD0_\\T_[Y%'D
M0_\ /-/R%8O_  D-G_>'Y_\ UZ:WB*S49R.N.H%&X2:BFWLM_P"F;GD0_P#/
M-/R%?S _\'"/B)6;]F3P]:A7D?XMZ0DL: $A7N(^2!VX/X9^H_IIBURUF8JC
M D#/6OY+?^"P_B>W\=?M5?"#P27$W]B?$+0[P0[MP0F<<A>W2O*S:JJ>'2O;
MFERR\DXMJ_JT=F <?;Q?+S;)+^64K.-^EK7_ $ZGZ)>#(6L?A[I-D5*"TTJV
MD1>F2UO%D8]L=.U=[X?N"T6E.PQYBONST7Y6.?T'/6L^6S2'2;"SA7;Y.G6?
MG+C^'[.GU_F?3K4EO<Q6FCW=P/E^Q02,IR.,1MT[C_.>E? .*O>2YDYQE'^Y
M:-M5YM?CZ'ORES1IP:<DVX[?"DU+?M>V_IV/QU_8UMO^$N_X*<^*[X 2+X<\
M;742L.0OSQ_EGG^7O7]F*?<7_=7^0K^/K_@DEI<GC+]N7]HCQ"JF5-&\=R[I
M,9V;I$YR??&>O^/]@P& !Z "OO\ *(\N%2MU3OKK>*?Y61\_BURU$N?F6K6_
MNW=VOO\ ^"+1117JG*%%%% !1110 4444 %%%% '!_$NU^W^!O%%EM#&?2+N
M,#&22T1&!]<XQWK^0WXFV$N@_%KQ5HS1F/\ TB0;2"-N]WZ COQT'YU_9!J5
MJEY97-LZAEFB:-@>ZL,$5_*_^VUX37PK^T5XKN1%Y5M=RPK!Q@;B7)QZ]0??
M/)-?GW&E&:PCKM_P4[>?/*'+9]>5ZNZ>VMNOU7#6)5&NH6^*K&3U;]V,&I67
M2]T_EHSY/N9V@>&+_G@WRGUSD^W^3Z53\0*\XL)$!R[*21_#A@>?3N.G'&:U
M+SRI3&P&3&=TO3.#D#U[G&?7WJX4BG@R0"!CR_S_ !K\^P\YTE"JI)248=KM
MR44VF]=WMH?>8QQQ%'V3LG4@VI;<DK<R3OW7==KZ;?TY_L->,CXE^#OAZQ9M
MQT;2K2TY()&T8QU[<<]*^UZ_)#_@F%XPBO\ PKK>DM)F2UGC@5<]-O! &0!Z
M<<=.IZ?K?7[/P_BGBLMHRE?FA[C;ZVV_"Q^2X^DZ6*JQMI?3SLDG^*>O4***
M*]LXPHHHH **** "BBB@#!\4W1L?#FN7@.#;:7>S#ZQP.W]*_D;^./BB?QG\
M9_$.KS,S;9[JU4DY&(YY%_0+T]3]:_JQ^,>NV^@_#[Q+=7#;4;2-1C!R!RUK
M(!U]2<?_ *Z_D7UFZBU#Q!KM_'RSZSJ(#>H^U3$<^GMG\>Y^)XNJPE1]CO*,
M)-V>R?+H_6S\]>Q]3PY&TZDW&_,XI2_E2=FO^WK^6S[F9J<SW$FD:3&I/F7:
M)@=_,(XQU[?U]Z_J9_8KT<Z1\ _!T#Q^7(+4E@1M/S*G4$9[>W\Z_F+\ :5_
MPDOQ)\(:6B;S_;5F)E SE"Z@@@>I]?U-?UO?"70H_#G@71-*CC$:V]M&-HX
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MZ TM9FKZC%I=A<7DS!8X(GD8DX  ![]*F<U"$IR:2BFVWMH-)R:25VS\</\
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MEG?U-\_J4Z.%YDU&K!J<'?I3LU%+N[Z>?HS]J?AMX7A\&>$-(L((U5A:VH;
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MJ2E:TN:3MV=N7;RBDCP/_A8VK8SY<G7'0_X4#XC:L3CRY/R/^%>^?\*TL_\
MGV3\O_L:/^%:6?\ S[)^7_V-6I0YHOETC925_B:LV_G<9X%_PL?5O^>4GY-_
M\32GXC:L"1Y<G'^RW_Q->^?\*TL_^?9/R_\ L:/^%:6?_/LGY?\ V-+FCRN-
MO>;NI=DMU\[K[@/ S\1M6 !\N3G/\+=O^ T#XC:L03Y<G&.Q[_A7OG_"M+/_
M )]D_+_[&C_A6EG_ ,^R?E_]C3YH*2;C=<JBU?[7*H\W;XM; >!CXC:L2!Y<
MG/\ LM_\30?B/JP)'ER<''1O_B:]\_X5I9_\^R?E_P#8T?\ "M+/_GV3\O\
M[&INN5*WO7;YK]+*RMZIN_F!X&?B-JPQ^[DY&>A_PIO_  L?5@RGRI?F8*>&
MZ'G/W?\ /ZU[]_PK2S_Y]D_+_P"QIK_#.S(XMDR#D<#W'I[]N>U98BTH2E"+
M37+*"6ZDK6[^?W@O/YF]\+-7N-3M]\RLN8\_,#UX]>_S5Z]<LBP2F1@J[#DD
M@#'U-<MX3T6#1=."[ CJ6SP!QV_'KU-?+G[2W[4OA#X0Z/J5IJ=]%!=FWE2/
M]ZH(D*G;T^OZ#-:X>G4E)1U<I3NO):66G5+YF-:M&C%R>]KI=[63_P SRO\
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MTXHK\CC-6U=-6]=.566OQ;;W?H;TJ',O>:<XRBG>W\U_/X;W?W,_6B&XT?\
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M%I:ABZV<3VF <XVR*.1CW/0^O89KX:U:1K;5-&LXP2+R[L5)Q_STE0%<X/\
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MZ^E?3/[']PS_ +0W@M2,>3J*8/KAE[8]OZ5\Q6IB$Q+#Y6QY0/4'C/7/I_\
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M&9 <-R2JG_/I^M?=0\(:0$5! FU6W@;1U'([>N:?_P (EI.YW\A,NNT\#IC
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MMKGF6RQ C,A+MP%[]/3CCL1C]7XDE363?,3Y,VSRR1W [=CDYS].PYK\8_\
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M?C^<V6/K047%4WRI-6NN_G=WU%HHHKZ8\H*9)_JY/]QO_033Z9)_JY/]QO\
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MYJ:OVF+YHQDMI)-?-7/ST****8!1110!\C?MJ0EO@3XUF!P8])G/_CK#_/\
M^NOY7;2T$MC>G=@W!+'CI@G (R._TSDGBOZJ_P!L[CX#^-R?N_V1/GWX/;\O
M\:_E3T]9OLU\03L+'R^OW=W.#G\^3^/;\BXS:695W:[6&3;[I<ONK7=V7W>9
M]OPQ/]S5O!WA&K9]U[-NRZ?\.C](O^"8A_XN3%$3CRKN4#_:  P>W)_^N!S7
M]'5?S?\ _!,T$_%.VV=!<3"3'][C!Z\<_P">]?T@5]KP>H_V)AI1BX\RNT][
MZ*_X'@9TDL5%K3FIJ7+UC[TE9_GL@HHHKZ@\<CFC$L4D9&0ZE2#Z$5_%S\>=
M0?X:?\%C?B/JK)Y-OKFEZ98Q.051V>23Y4/ 8_,>!D]0>*_M*K^.K_@L)X>'
MPU_;2^%_Q)$?V8>*_'FA:1-<@;?-0SH"I;C=][&,D>@Y%>5G%)5<(XMV:=T^
MSMI^)U86HX3<4[.6L7M::V?S5UOUT/UBBO#/.CN"#>01?>[;T'Z?TKF_&FAK
MJ_@;QIH+KN6]T^6( C.[*'Z^F?Z=ZW3Y<T&CW=OCR;C3[%XR.>6MXR<?CG'I
MD]:T[HI);R6IY>:)UD'][A@,\>A''XU^;^RG]9I1I35W4BY6LTI*RE)^3OM;
M2_<^EHQYZ4)3:4K)/FZOD4KZ]VK;O6VQ^9__  0;\4#PA^T#^U1X&GD\L?\
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M+,P4<*W<G'8GGTS[U$4Y226[:2,YR4(N5K^7=O1?U\C\YO\ @H[^T%IWP?\
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M=-?B?0X&%Z5.,M&JDFV]$FK7[=._<S-?V:7X-UW7F<*-.L+BX+$[0NQ3SD\
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MZN;T^_S^?3ETU3QE&;VC)/\ %'\S5C;[Q;.2,QP^7C/L<\?Y^AJ"YCW&:R#
M[T:8'/?:3CK^'Y$U!;79CN7CSA;8O#*/20%AW]^O'4?DL,<WVHF3[[@E<_\
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M)P4FV[?#./\ 7D?//@6\(\=>%\K@378!]OF'M_GFOZX/@T,?#3PEW_XE5O\
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M !1110 4444 ?G__ ,%#Y?+^#<BXSODE&>./D/K_ )_K_,YIY\R"2'H()YI
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M@QX>TO\ Z]8__00:_DK^ CPQ?&OP&GKJ<8B[=Q@@9]O\]OZT_"?_ "+VE_\
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M:GIEA I^2.0LTH(0' )SV'.,^HK]M=4MA)>WSY'"HRCC@$ ^OISZ?KC\A?\
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M4)2\U)M-=_0X<7-N4N>7-?VB48M7236ZTW_7S(HX?[-F # ^21D]=W'<Y/\
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M5@@$A_Y8_N0/7^'/;/K_ %/6L^$2[86&?G!,6/[A) X''3(]?ZSW6\LFS)3
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M>4PZ;?R9 $=E<OGW6)S_ $Q[YK^33]K/Q5<^*_C!K#/*9;>RO+FT)+$A2LV
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M<C=X)*VKO?1>6A^D\,S<Z%+WE=-N2ZM)*Z[J^R^=NI!J^FBYC$F0&C3:.>>
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M"UTV/ON&G-X*J^9*,%>-^DHS4[_/9?=U-&6';$LP;)A0(/?<0/7^IZ5]Q_\
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MB@ KQ+]H(9^%OBP>NC7P_.%J]MKQ+]H//_"K?%F.O]BW_P#Z(:N3'?[GB/\
MKU(Z<';ZUA[[>UA?TOJ?R.ZE#C4=4(./*U&\<8/7_27..G8]NIZ=3@4Y8C(+
M6<G_ %SX(_N^_L.3_,U9OW:74=1C7[W]IWF_CHOVA_KZ'Z<<9X#)4>,,I! _
MY=^.C9[?IGZ<G%?AB4J4<8X^Z^6K)7UMS232:ZV5UWZH_7</-0<9):_%3CU4
M.:-EZ-VDK]%9'JGP#A:?XX>!%SQ;:I'@_P![Y@<#'^<'I7];_A/_ )%[2_\
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M_.W5?U;RL]FY8?$+HXQGY7<8?H?TD44@Z#/H*6OV-*R2[*Q^9A1113 ****
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MUXS\#ZIXJ;3/",T+"(".58FC(!0JK9"'V/4>@'OZ&&E'F]@USQNM4M.C>O\
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M<6LX+H&5AN0G[W&.>@R/YU^R_P#P5%NX-+_9D\7Z%:0I$E]IFS$:JJJ%4\<
M =.O'XU\N?\ !%/X<SZ'\-;G7-1MC'>7]I [NR$,Q4Q]R,G'7KCU%?3W_!4V
M2V@_9T\83W1 >.P;RMW^Z_3(Z?E[\UYE*4)8BG*"<73I\TENYR4;NVO5K5=F
M>W12IX-\L;M^[YZM1C=]DK/\#^.R&4I:0N0<VB+#[GD\].GK_7K5Q ,",C)F
M'FY]._OZX_+@8J.WEMI1:%<&*6,L_3ELG'U_+CM2L<%D!/F!_P!WT/R G'<C
M&/\ Z]>W1G)/F5V^95%OHG&-T^VVM]MNY\_6A.,^:4DHS<813=K23TZ=)7;U
M]"K.YEE7Y>FV,]N >O09X/6KOV!519%(RN"2.<G&<=NWTSW]*G=+<.\G&P0'
M/_74+_//O6797,RV2&9B";E@<X^X6P#GL=N?TY/0]+E%4[W_ .7<9<OVFZCO
M*VMM+1N[:)[!44U[*%*22YN22\G;[K:NWGY%J"[S<,I7F8>7T/&<C/3MZX]Z
MOZ2JPW&I6<@!$L6U21D?-G.#CD^O_P!:J_E11W1N!@1$+L(_O=\=NOKGI[4^
M2_MOM,#0D>;Y@\\CKC/<_3GG^G//;VL)3J--QC%):7:BXI:=^M];V-&TY1HI
M24(<LI/HXI*T5YJ23^2,*RTV;PM>WUU%<.AU%MRJK$8QP  #D=/\BEMKJZ%Z
M;NY>23<Y(+DG.>.,YS^'!S[4_7DO;R^M3%EH-_'7[K'GVQGO]..E;VIK9QII
M4<> ZQ8N.GWNV>_7\<@8[5FVVTMHMI+3I^O>QJVK2:5^1:I;[7U[WUVV5M2A
M<R%%*@?ZXB3(YQWYSG X/Y].M3+<Y"7>!F-!%C\,9QC.>_MCZ5&"D\$R\&17
M B'4A<GIUXZ=/H*=$\0F6)L>7Y?S<Y&\#]""<Y/\JWE+GUE%\Z>MTM(I12^[
M?YM[F,5)<L%;FF_:3>FBLF[OI=66O5>I5DB'V$W.?F\XC''=L]LDX^A]\D8K
M%NC=Z-/:>(+5Y(Y%F3"QD@C81SP<_3(]OIH.TB7 MVR(-_F=^F[/T QQC]3S
M6V8[2Y98I@#:!1M'&-^.<=LY''N..F:R>'A*56<5R0E%R]Y=K)Q2ZO6]NFQT
MQQ,FHI27NR48:;\FD6K;K5_J?JS^P[_P4&O?!$^G^%=2FDV*8K??.6(^;:.K
M#&>.>?3K7]-?P<^-^@_$#0+?4Y-3M5,L*N098P<D ^H]>_/T[_P.:FQT*2&_
M\.Y2[B=9&:/((VG()*_GG]>U?8'PG_;0^(W@+0K6SN=7N(4D01Q S2#H,?WA
M@\ >OL!7FXO"<RC*-O=C9-=4K6Z]M/R.S"54ZC4))1C#FJ1OO*,4Y)=;W5^N
MFC/[G;6^LM1C+6TT=Q&1R496&#]"1W_R*J2V%A8)->06L23 ,Y=44.6P23D#
M.3CUS7YX?\$\/B]JWQ8\ G4]2NGNI5M;=RS.7(+JISG)/?\ #@=J_226-98V
MC;E6!!![@@CG\Z\5IKY_BOSMZGK1DIQC+1W2?H]&?,&N?%VYTZ^NF:*0);3F
M+)4XP&(Z[?;_ /55A/C2)(T=3D%0QZ\' ...X/:MSXF?#^SFT:^ELH ;B4E\
MA>2QSWQR<X/'X'BOFGP_X'U^.UNENH)-_FR>5E6SL&<8_#H/3\:S5ZBG%Q=E
M+ET6Z7*[K7S^3Z%GOO\ PN@<8)/(![_R[_7BJ#?'+%Q-$,?NXBPZYZ\=OZX_
M2O$;+P3K_GS&2%]NUMN0>N3CG'I^/OGFJ$?@+7S="1H'PSE7.#C9D'_/_P!>
MKV ^@[3XVB:!9&)4DG@X'T]/\_C5G_A="?WOU'^-?/EWX$\00RD00N(2!MP#
MU[]0?7G]>*K?\(1XF;D0R87DG!XY'< #\\T ?1G_  NA/[WZC_&D_P"%T?>Y
MY ) ^F>OM[BOG3_A"?$K840R$MC'!]1Z+G^M;)\$ZX)[4&%]OEXDX/WMI_P(
MYSWZ]@#VF7XRK<^%/%.H2L(TT_2]3DWG@ Q6DS]3C!!4\?SK^0']G/69?VC_
M /@I/XH^*%RIN;3PX=8T-9'&^,&TNY0H!;C@QCH*_H:_:IURX^#W[.7Q!UN[
M<VD\UG?01N<IG[1;3( "<=<CD>HQQ7X4?\$=O"'F:5\3/B5J,6;V^\;Z\(;E
M@<F*XN;EUPQ&<$$'T/6OFLYK.,94JCO"HN>"ZK31/S33MKU/0PT'%R@DW)\C
MA):J+T:D^G=:ORL^G[<:_()+I+M1A( L0(''[O VC\!@#D#VSQS7C3Q,OAGX
M:^._%<F$2V\.WTBEN #'$3D9_P#UXQ^&[=3Q2Z @;_CY-\[-P-QC+''/7@=S
MP:^8OV[_ !E:>!_V3O&DD4P@O=7\/ZG9VGS!6::2'"J.<DY8_CT'I\?A8SG4
MIT9.R<;N3T6KBTF]KI7^_4]"E*4%%35HPIN5^C^%Q7JM4]=6_(^;_P#@A7HC
M>+_VK?VA/BY<P>=!XCMT%M<.H9-T,K#Y&(P2/;MP??\ K8 # ' Z?Y'X5_/W
M_P &_GPO31?V3/#7Q$OK;9KGB=K\7=P4 >5!/E=S$9(P<_G7] U?HF7TW"E"
M2TBZ:5N[7+9_^ JWJ>'5ES5)R_FDY??J%%%%>B9A1110 4444 %%%% !1110
M 4444 %%%% !7SW^U#X=_P"$G^#/B[20F][BQ=5&,G[K'@?X<U]"5S?BW3(]
M7T#4+"10Z3PNI4C.?D;Z_EW^N*PQ,7*A5C'XG"27K;3\36A)PK4I)VY:D'?M
M[R/XW[X'1-9\0Z2Z[6T^_DMMI&#D-C.,?B>3TI;*?[+FW;I=YFR?X>3Q_@?3
MV-=U\>-'7P_\;/%]BR>7;R:[=$J1@</QP,>OOT[<UP.I;?W?D_ZP!0F.NP]Q
MCL,\$?3O7X7FJ=/%3C-:*I&,>W,VGIMKS-O9>A^O94U4P<$XM*,U**>CNE&5
M_P#P*[Z[^A$EZ=,\3:!JR<-#K&GK\OHMU$2>!G''/X=*_KF^ WB9?%/PX\/7
MZD-MTRPB)!S@I:Q@@^_'-?R#WKHUQ9RD_NX)8)#SP)8W4]1T((./Y"OZ8_\
M@GSXP7Q'\&;%'F$LT,WE ;LX2--H[]L?SK['@^;O#GEK&-6FO-KD:MYM7_'M
MK\9Q1"<*[33FY*-24ULK;I^>R/OH'(!]:6@8[8Q[45^CT[^SA=W?*KM==#X\
M*:YPCGT5C^0)IU5KR016MQ(W 6&0_P#CC?Y_PJI-13DW9)7;\@6K1_.7_P %
M0_%W]L?$K0])C?<D,#1, <@$,!@]NW?K_+\[KV46NDH0!EXUB],^8-IQG\\=
M*^E_VR]:/B/XPZXC/YCV&IW,,63G:JR=!SZ<^G.,U\PW16\FTVP3DO=6L;#&
M3EI$7GOU;GUXYZU^(9G3ECLZY74BU#$247TU<>7U5[Z?):/3];R2DIY5%Q=G
M.C))O56C%-6^=];ZO1G] ?\ P2R\)+H_P=NKYXP);C5I90Q'S%7WMUQGN,=L
M8QCK7ZHX^;/J,5\<_L1^%I/"OP>T^UDB,37(@N0"N,AXMP[#^]_D5]CU^N97
MAU3P.'C+5Z5$U_-9*_X'Y?CDXXO$1O?EJ.-UL[?\$****]0Y HHHH \Y^*VO
M+X;\#ZYJ;$*(K&Y4$\<O"XZU_(GX\U ZWX[\6SG+^?KM]*&)R<&=CCWQTQGO
MBOZ?/VT?$L?AOX'^);HR>6_EA0<@??5AQD^N,]J_E@@NH[N\UB\<[I9[^XE4
M]RK.S#D]0?\ /O\ F_&=6FIT^6\U&,I3Y6WRR:25[;6LMS[+ABE\=7EM**J-
M-]=(J-O1M[]+_+J? 6BOJOQ \+QJI<#5].4J 3Q]I0$X&20,=Q]:_KT^'.E+
MI'@[0;15V@:98MC ')MH\GCW-?R^_LB^'D\6_&/383'YL-L\%QC&0KQ2@Y )
M."".^!CIBOZJ=(B$.EZ="!@16=O&!Z;(E7'X8KNX)HKZK5JR:E/FBDUT35^_
M6R^XY.(:\I2ITT[4W*5X]>:"CKH^O,:-%%%?=77?^OZ:/F J&XD\J)I!_#C_
M #_GZ5-3)$$BE3T/^?\ /H>:3]=7>PXV4HMJZ35UW5]5]Q^8O_!3+PL=:^"&
MJ:DL6Z2$P$,!E@ <D<<]%^O7K7\\ND7&^TVMC= C0[3U^1<9Y]QZ>O!K^JW]
MK_PRGB3X,>(-/\OS,0LX7 /W(W/ QT!_^N:_E5N;5M,\1:Q9L-L$-U=1;3Q\
MX=EQR.O0XYS^E?EO%U!_7N:I%R;49Q:ZIZ0BG9:J2?R>W;[7ARHY<D()J\^1
M-_9LT]>EW>R=^FVQ+9D&S(."3,<'&2?FZ?I^OY_9'[ GC<^$?CO<P,Q5-0@M
M[4+G _>$#@'J.3^5?&<8,<4, ^_]IWL/5-W&?P/;ISZUZG\%=9C\-?&WPYJ(
M?RX;C4;&(L. ?W@!!YQZ@?I[?*Y56]CF-'G;FZE6#BEO&,6G9]V[67?\_H,\
MHRG2<EK[E[;WLN5^J?-_6Q_7S;2>;;02#_EI#&W_ 'T@-3US'@W4XM7\.:7?
M0MO26T@(8<\^4F?RS[_T'3U^\4)^UHTJB37/",K/=729^5SCR3E'^5M?<%%%
M%:DA1110 4444 ?SO_\ !4 >5XSL5ZFYO-GT.6_S[X^HK\UA,(;6!<?-;@@X
MZGKR<CVZ>AK]+O\ @IOC_A-['S<X^VCROK\W]/TQBOS(9E+H&^Z#B3/XYSW[
M\_KWK\+XA@I9[C&[OE=Y7T4M5:W^'2^C6B[GZ5ELW#!8%2:G[U)P26J<K0M:
M_2+=_O*4_P X*GI=LK9P.,''?IG']:_H8_X)AS^;\-=8CQ@0W<: \\A<_P \
M=?3%?SOZ@VR.9E[./)./X<CICC'TYQCN:_H@_P""8)C/PPU-H\;S<0F3'/S8
MY]\=2?K7N\&N^:RLG[E.4?DXIIOROHB.)G)8"I%W:=2+<NDI<RVZ74;)K?0_
M4>BBBOU<_. HHHH **** "BBB@ HHHH **** /SC_P""CDNSX27ZXSNL+C\.
M&_QK^;O2KO.DQ<?ZE<9P>06^@],]?IUK^D+_ (*//&OPBU$,1O:PN-GKG#5_
M.!H_DC1;9CC 3]Z3USGOGWST_G7Y9Q;R/-)-)\WLZ:OT4K0:;TVMI;77L??<
M-RB\#4CR-V2E-[\R]JKI66GNJ_6R+,LQ:)80 /.3?]"I!]!_GTK[C_X)XW1/
M[0N@G:1Y5O-'P#V"KGOZYSTX[YKX=E,+6^1CS-J^7C'W<]OJ.?\ )K[H_P""
M=ZPO^T/X? V_\>LIDXS\V!G(^OZ_A7S.3M?VG@G%J,?;0LGO?VBN_2Z?2VO1
M'N9A;^R<0W9P]DWRK=*\M?2UEOTZG]-*-N16]0#3J10  !T  &*6OWB/PQ]%
M^1^2A1113 **** "BBB@ HHHH BG7=%(OJI'^>E?RK_ML'S?VD_&T>#BVNT)
M.#SRWY_I].Q_JGN,^3)CKM./\C]:_EC_ &U#&O[1GCEC]\7*F7./]KK_ )Z=
M>U?(<:*^4M='/9;MVTM_6Y]-PPY1Q<W%I/E25^[DE?Y)O[]#YN\)L7\?>&44
M8WW:#/7'S9..#Z_4^V:_KB^"R>7\,/!Z9SMTBW'_ (X#_6OY*_ S0-X[\-LV
MTDW:F/\ [ZX_ #CGG%?UK_!K/_"M/"6<Y_LJWZ]?NBO'\/Y/V%>&RC%-+M[Z
MT?\ PYU\4SG>C3DTU&4]4K7;:;?XGIU%%%?HY\<%%%% !56]F6WM9YG("I&Y
M)/0 *3WJU7F7Q<\0IX;\#:]J#2"-H;&9E;.,$*?_ -?7]*RKR<*-22=FH-I]
MGT_$TI4Y5:D*<=YR45\W:Y_,-^UIK!\2?'[Q=\VZ/2]8G12#D8)[?AZ=?TKY
MODTTW^J6>D*"WV^ZMWXYQB1#CV]?Z^OH'C_5QK?Q+\;:N[[_ +3J,DFXG(8[
MCSZ>W7GH,]T^%FD2Z[\0]$M63S'>[C,0QG*K(I_^OV]3P.?Q",'BL\J4Y24I
MS4DY;I3<VTTNC3:>F_0_5Y8>6&R>:;32IP=]KVIQ3O\ <G^-^_\ 4%^ROX=3
MPW\(_"]NJ!2VDV1;  )/EKS_ )S7TK7GOPKL%T[P!X8M=H5HM)M49<="L8'^
M!_R,>A5^RY?AYX;#T:4I7Y*,8OSE=^]N]UL?E%:;J5)S>\I-W\ME]R04F>2/
M09_S^8I::1R".N>?I756<HJ,HO:2YEW3Z&8ZOE/]L/PTOB'X+>+E*!VBTN8K
MQD]#P!^I_D:^K*\Z^*VDKKG@37],90XNK*6,J1G.5/&,&L,=#VN"Q$5UI2:\
MFE=/Y'3A*LZ.)HU(:24XKY2:3_!G\=%]_HEY-H^TJ8I&C((Y7:Q&/4<XX(]A
M[:EM="6ZMI&&?L<?DG('/!'0]>O'Y>U=5\3_  Q/X:^)GB^SNHS&BZI,MJI&
M %#'GGMC'O\ 6N0@:*.0MQM!8/\ 7G&1UZ8]Z_!<0I>TDIN_+)*7FY5.5]-6
MX]&]O(_3L'4G.BH<W-*;BN9;1<TD[V?;16_%G;?!36W\(_&/0M75C&LM[;KN
MR1CS9X@>F.QX!Z<5_7AX+NQ?>%= N\[OM&EV<I/N\"-_7KWK^-AYS9:KHU]
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M!'_#'\D?D$OBE_B?YA1115$A1110 4444 %%%% !7B7[09Q\+?%A_P"H+?\
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M110 4444 %%%% !1110 5\F?MK9_X9]\>X./^)1,<_0-7UG7R=^VHAD_9_\
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M\I<E"K-1V?OM+KS/E2^5K>7W'WM&,*]*,.5JIR\TY]$K*6MWVT_&U]3]/?\
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M2:ZK1:?@6GT2T9W80188 ?=4>OM[GCM_-IT&S( \B/@>B_X>U-/B.P"QL94
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M^CW*,\CGL,\<=0<9Z<9X_87_ (+8W_B?Q9\0?#/AC3S)-!9:C)%'&I=@H8L
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M4X26FG*XQ32\[IKS:]3^ACQK^TUIOBOP?K>GM/"WF6TZ!2RG)\I@,#&,\_\
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M1=U*E#7S45?\3\FQ</9XBI&]_>O]^NO];!1117<<X4444 %%%% '\[__  5
M/F^,[!NAMKPOP>IRW\_TS]37YI);>9;1R9P;I<].1^?M_6OTL_X*A*6\:Z6L
M/(:_Q*!UP2W7W]?P]J_-64R16T: D' ,0&??CGCC(&./7Z_A'$#D^(,9&+<5
M&22O>RVE)M]5+5+;[S]*RN-+ZGE[MR-3A*[^TG%0MKWD[_\ #HQKZ,M$Z?\
M/LRIUQG)S^./QZXXS7]#?_!,"#R/AEJQR#YES$<>@8?_ %_0?X?SU7*F)8GD
M& Y!ESZYZX/X$GGIS[_T)_\ !, R'X;ZV7^Y]KC\O//RX.WV],5]#P:VLUE9
M_%0DI^JM)>C(XFE%Y;*"V593BM&TN91:D^_,FUZ_?^I=%%%?JQ^<!1110 44
M44 %%%% !1110 4444 ?F]_P4?MO.^$]Y)G BL;@D>Q#_3_/'U_F^TF#=HWE
MY'[Y>.3D?-]?PY_E7](O_!1S?_PJ:^VYV_8+C=TZ8/7]*_FTT@S?V9@9S@^7
MR>/F/ [_ (=, XSS7Y9Q=%4\RE/FTJ1A%Q6]THM??*Q]_P .1DL"^6<5SNS]
M)3Y&M[:;OLKFBUN88%ESGR$5>><]LYSSU]/\*^Y_^"<\;)^T1H;$DB2"=L]E
MW%3].U?#+K*_E*=VPI^]^O!'^2,<5]X_\$]2J_'S1%7_ %OE2[1Q]WIGCMC&
M?Q[U\ME7+#-,#3<7-RK4TVMDI5%HVGT;T[,]3-)J.6SIZ>_1E!ROTYK1]=;O
M\K(_ID'0=^!2TR+/EIG.=HZ]:?7[W'2,5Y+\C\L"BBBF 4444 %%%% !1110
M U_NMQGY2<?A7\J_[<,!C_:5\<@-_P ?5TJ<<8^\<XS@=>O7I]1_52WW6_W3
M_*OY6OVV$ED_:7\=L^2J72&+Z@MT^N/Z]J^-XT=LOBD_>YKVZM>7W;GTO"[2
MQ\Y25XJEMW?M(6_,^;_!\1@\=^%P#GRKM3CIG+=.H_G[\XK^N7X+/YGPP\'O
MC&[2+<_^. ?TK^2#P<KS?$#PP%R0MXHE'7H?;UZ_IW%?UP_!E0OPS\(J.@TF
MW _[X%>?P)RJEB8V?/92EZ2DG;M=72_X8[>*91DJ'N<L^:;DVGJFU;R?3\#T
M^BBBOT(^-"BBB@ KX_\ VTM:&B?!GQ3=>;Y;KI5R4&[!)"\8'4]^GIS7V!7Y
M7_\ !3?Q5<:/X$T_389-D&IQ7$-PH)PR<]0",C.._I7GYG-0P59WLVDEZ\RM
M^.MCJP4^3$TIN+DHR3:7:Z7W=S^?J.Y:]F>\+$MJ;N[D\D'=T.<<]^1VZY/'
MJ_P1UV'1_BEH%U.%$5G-AMV "0R_4<X)ZGKZ5XOIH?[).PZ1[C;>P))X/;@?
M3Z#J7EU>V2PZCI987D*J69<[@^<GISP<>HX_/\-6-C@,S]JUS3=9RE+UG9[]
M+*_XVU/URI&>/RR-&E)1YX0=F[V5HIOT:NO2[U/Z44_:OT[0=,TBS2>'8MC"
M.&7 PN/?';OP<<<FK2?M@:>]BUS]HC!$@4#<N<9(]/I^/:OYRI?B5XTN-*0S
M7$QGB553+,2$')P>H&/0<5!9_$KQA) 4%Q-Y>1GYW(WC''7L>._;CU_0:'%$
MIQC.[2@DIW:]Z_+RVZ6T=M[^FWQ4,@_>*C42]II)RMIK)MORT2OU_3^CRU_;
M L)W=3<1 )&6.67L.W';C.,_XME_;!L([5)A<199R#AE)P,<X]/?ZFOYS8_B
M)XSA4E)Y=QRI^9_N')Z\>O\ 6FM\1?&4FZ,W$NP*2HW/PQQT_GT'YYI8KB:I
M*HI49VINK%\O504?>3_Q-IJUM$MS>/#4-+V3M%_-I7].6UGYOK>Q_2)#^UMI
M\EB;DW,6=I.-R_7&<9]O?M5>7]JS3=1MX;9[B$K=JZL"R?W3U].#[GT(K^<A
M/B9XV6%+?[3-M'##<_3 '.#GOG_Z]/7XF^-8^5N)?W8)B.]_3Z]_Z9SVJZG$
M\:F&J15U*<6TGI[KBDXM=];Z;^=[ETN'(0JPG*SBK.WGR*2TMOS+E:[NW8]1
M_:!\1V_BKXJ>)+JV"+'!J,^&0##!B0.1C//3D\$'L*\1>VVS" ' G/F<G.,8
M_'_(Z4^VFO=1N+S4+PLUU=,9)F;=N+DX!Y^N/PJND-XHG>4'S0^(3S]S)R02
M?Y=<FOSJK5A6K2BHM)SY^;HVE%Z==&NNSZ'T&"HK")4YQ<G4E%QEK;GNI)/_
M  K1^=[EVXAWW%L^<B H/^^&!S].![ GFOZ3/^"=FL_VK\%\O-YCPWQA +9(
M"*<#!Y&/3'K7\VHCE-L\Q[(P//&_;D#MR3G] /;]K?\ @ECXQN)/#-[X;N93
MYAOIYEC+$_)N;!'.?I[>]?8<(9DE75&.SDX6ZV?*D[;M)I^MV?/<1T95Z7MV
M_>@[2?>*?NK[K_/N?L_11]*1<X&>M?J//[\86>L7*_:UM/7R_P CX46BBBK
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MT#T_G7QW^PY^S;HGP@^'6D2I8):ZG);1^?\ NPC9>-2V>,]22._OWK]  ,
M=AC\J^=Q6+G7;BW[BD[*VMEHK_Y>FK/5P.%]BI5&E>>JTU3E9RUUZZ?>?E5^
MTW^Q.OQA^(VG^*98UD2*^$^& ( #$G@G]<$?T[FU_8RTB!_"K'3[;_B2!0_[
MJ++%>Y]?SX[^_P"BTD*2LC,.5/'3ZX_3/ZU-@>G3I[5C+$.2A&^M./*[_+EV
MMT2].AUU*%.H^:2U2M^*?EV?WLXO0_!>B:;I.GV+:=;$V<"1J3#'D!<$#[IZ
M'WKFOB]XUL/AWX%U3699(H([.UEV*Q5  (F(QG '..W3C->L%@" >IK\7O\
M@L!\5]8\ ?!S5;?2+EH;BY@C 5'*DB0,O8CKGKSW].)I4_:581T4IRBDWUNU
M_7R(KU%3H3<7K%*'H]+7^1_/3^VU\?KGXN?&*_M8[B22QMUG48<F+,4A '7;
MR!SUS^/'R[87 .CM,%_Y:-%CTQP#[<<<CG\S7/6<5UJ?AJ^\2ZJ&;6;J_8J[
M9+M%,Y/!P"0<_C^ KHM+,-II@@N2%+_,,_WR,]QZGGWQ7VT++"J*@U4=-IM+
M>4&K2TOIJTK[^I\W6=*550Y=*LW.U]8NT6VUK?5?@O(R=4NW?1Y8$0NZ*S
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M1BTD])[:_OHJZT[:W]/0:IN'(J=XP4FVNZ:7?5>]K]^FIYE#\0KN1(VS(#*
M><^OX'KQQ^M2ZI\39[#=K4KND.EZ?=EV8D*-L#$9)QZ=O\*](3X7%!M6V.%S
MM^3J,X]!V[8]:^9_VTFLOA!^RM\2_&UX1:2V-F8HIF(0@S1RH!N)'4\5.(E"
M%-/1\G.TTUI#F=HOSNKZ_B:14N:2>JDURVM_+%-/K=RO\C^9?P9XBN?VK?\
M@ILWB.0/=:=X2O=7TMG8%X5-K."H)/RC!3(S^%?T.M,MJ\<2C,=G +-0/NCR
MP$XYX Q@C';-?B#_ ,$:_AZNII\7_BYK,!;5[SQQJUQI=TX!=K2X>5T*.PR0
M1MQ@GH,=!7[6V,HN;*^G<@M]MD4$G/.\]/Q],\8QUS7YEF>)3Q4_==HRBG)_
MWGIUWMKN^Q]?@Z%J,(RDKQC&*7G+K:^MK:ZZ:%N2[6STC5+P\+I5I<:DSG@
M0JS^W0*>OY#M^-'[">E']I?_ (*J_%#Q)-']IT[P]IEK=6[."\*RV,TH)C)R
MH;*_P_GD5^J'QP\4VG@'X'?$77K^5;>23POK,-I(2$S-]CE\L*2.N2,#WXR:
M^2?^#>GX:WFJOXM^/>H6Y:X\3W&LV(OF4DRQQWDVP;R.>&X /Y=_6R6GSVE*
MW+3DXR?1^T:DFM-ERM6\_0\K,^5\LH.R3:4>MG;>S_0_JFMHO(MX(>GE0QQX
M]-B!<?AC%3T45]D>.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M^4?_  4[\#'4?AU<>+PFXZ1 B XR?G+ _P"<<=Z_G_NR8[.S(! >.-V..G )
M!Q^.<=J_JB_;:\/1^(/@)XMM6C\QO(5E&,GY0S<<$CH>G]:_EMO!$L&I6S_Z
MVQO3;J.,JJ/@XR./P_#K7Y1QRG#,,/H^6I"+;Z)J5HJ_JK_ATL_K^&76E5@H
MR7(JD$U;91:;OZK3\UW$NP;)9]N2/W0'<Y4#/KVP/I7T%^QOXW;P7\<;!2Q1
M;_R8-Q.,^=+C&>F!NY]#D]Z^?H%@DV0KCRR@8],;P!QZ ^F>O3CK72^!)?[&
M^(GA+4XCL<:YIZ2MG'[H7$><].W..GU[>%E=18?,,+4G)<MH\T>O+-Q:?3:S
M]-MS[?,XJG0<5%M583G?M.25K[Z:-M=>US^Q32I?/L+*;_GK9V\G_?42'^M:
M5<7X U>WUOPIH=];2"2-],LU+ YRPMXP?7N#^E=I7[7A&I4N=*RG)R7H[6_#
M]3\<J)QG*+5FG9I]&M&,<G@#^+C^5?G7_P %$O&J>'/A'JVG%@&O[0J%)QD*
M"IX]^/PR,U^BQ ZGMS]*_$C_ (*N^*/)3PQHD4N$NX95D3)YP6)R >G3MUXS
M7!FS=+!XRISJ,ITG"FV[+EY%S+_P+O??8[LJCSX_#07VJD4K]&Y*S_)?U8_%
MW2HF\J2Y;I=9E!/;.YN?3IC_ #S^A7_!-GP[_;?Q@M]>:/<EB\L&XC(.T]2<
M>H&.3VX[5\!EXK?PW(PP)41%3H#@@@>G'<X]^]?L/_P2L\*K+IU]XA6+=LU"
M1'?'0G.1_/UZ^M?G>0TX5JW+92G5J1A)JUK<R:>FMK\VO7?=6/K,[4HX=SC)
M1=&;WW:LHR2>C?P_AY'[A1J$14'10!^5/HHK];BK1BNR2^Y6/@MPHHHI@%07
M,GE02O\ W8I&SZ84FIZP_$=Y'8:-?W4C!5BMIB6/8>4Y_H!^-8UW*-.4HNSC
M:3](N[7G=*W<J"O.*[R2^]V/YFOV_?'A\4_&,6JMY@TTW%H5SG[K[1[<8[#-
M?&=J?LFG30/UDD,XSV'7K]"?IS7J'QMU>/Q!\<?%UU,_F6]OK5^@).0,/\N/
MQ'3_  KS"Z4W-V+&VRTTS[8E')*L<#&#T)(ZCWK\3S]+%5*BEK*<[/K=<]U#
M?=ZZ;Z^A^G491I8:$[/W(QU[I1A9?)JZ]?,@AU&*9-Y5?E)CP<=@>>G(].WM
MTI!?PF=H,+\@WYX'/) SCI]/3BNUC^"GC4(DJ6,WD3(LBD1O@LP!'.W'?(Q0
M/@AXZ'[S[!,')^8^4_W.,'[OU_6O/^K8U<W+1J.*7N)1EI9Q46[:/1M=K]Q/
M&M2J)S6SWZ.\.9Z-:2?+;;;2[L<3-J$$91MBYF)CZ#C]...A[?C4LEY$B,V%
M_= -_#SC\.?IS^7-=BWP3\;,V383;1CROW;?>&.F4_#C.?;BE/P5\<,H4V,Y
MQGS?W;\#/?Y>/T_$TOJV.M%>QJZ.TO=>J4HQ5O\ MW77LWOJ'UV7N7J0;C\>
MWO>]&[6M_BM+5-)+;OQD5[!)&K%5'G GG QS[CUZ>F:K-?PR1RN$7_1V"#@8
M/. 1ZXQ[_P!#WB?!7QP@VBPFP<>5A&''M\H'?G'Z'-6%^!_C4+_QX3;6.9?D
M<?,6&.-O4<>@[],X[,)EN*Q$Y.K"<80DI*+33?))6WO]F*U7SN2\8VYIR4U)
MQBDND93M;U<[R26B1P27L >*(JH\Q1)G XZ''3UZ<@>U7YM7CDB#*J_*1%CU
MP<9QVZ=\_ETZBZ^"'CL1@QV$WF @(=DF=G?^'/\ GZ5C:Q\-O$_AB--0U:UD
MAL510[NK!1+CJ<J #GIGGID]J[:N4RM>S4DK\VNC;7,__ >5:KN[ZV.G#8Q+
MEG:[5HI+I#FL[^;MVV^1EM+MB! R1A]V/8G'(]NN<]O<Y]W<&> G;CS,Q\]L
MD#M]#^=6;61)K7>>0)&4GKA><=>AYXYYX_!)EA,7RXP<[<8^]Z<?3MZ^QKYV
M="4:DZ+U2G%*6_NJ-_N32OMOY';RKDY9VJ)N"=M?=E%V77;RZ'[4_P#!+7QD
MMPFK>%FD&--M ZJ3P2QQP,?R].>,8_:<'(!]:_FL_P"";/BTZ)\5=2L))2C7
MQMX"I)^;<>G)[\?F*_I0CSM'H0I'IR,\9K]@X5J5/[-PT97<5%4K;V:2?,WV
M>KZ+4_-,[HQI8VIR*T&VD^DG#EBW'NK_ '(DHHHKZP\<**** "BBB@#^>/\
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M<Z+DGT35D]/.*1/%$::R^;IJS5:*E=[KW7?I=7>^NOW'ZBT445^KGYN%%%%
M!1110 4444 %%%% !1110W9-O9:L#\XO^"CDNSX37R8SYEC<#/IPU?S=Z-+G
M2E?;Q ,#T;+>_?Z=/KQ7])G_  46$)^$6I%\;OL%QLSCDX/KZ'\N]?S?:*(!
MI=O_ '2A\WIUW<$]N3C/3L:_*.+5SXZ<W=+FIV?3EC3A)6_[>ZVM;??7]&X9
MITW@X<T7)23;7>3J*&GDD[^NE^A;CF#0'(P7&1G'&!G'8=\<=.HSS7V[_P $
M[CYG[1NA.>BP3C'J<CG/7G'6OAB]!6V?RN#P4V\';[<?_6S@5]T?\$Z5Q^T!
MX>E/W1;2A^WS<#KCJ:^;R:-2.982:J*+E6A&SW5YW72^_P"?;?7-??PU>#?N
MPI5.575VU\%N]GOW1_38.@[<"EI%((!'0@$8I:_>H_#&^]E^1^:!1113 ***
M* "BBB@ HHHH :_W&_W6_D:_E>_;9O?^,D/'BA>8+E3[GALCGCOCV^O%?U0O
M]QO]UOY&OY7/VUEB;]I7QZ/E.;I=XXZ?-C\L<?CVKX7C6:AAJ;:<KZ:/IS0Z
M;=3Z3AIVQK3VE%)OLE.#O^!\Z> 9]GC[PZ[<FZNDQ[<X_GGGG\*_KB^#7'PT
M\)8.1_95N0?7* U_(YX3"IX\\,JO:[3R\=<[N@]0,_B<=217];WP4W?\*O\
M!^[[W]D6^>O]T>O/YUEP1RRIUYQT;CRR76ZE'7YI+OI8]#BM.3HU7)2YI322
MW2BTE?Y(]3HHHK[\^+"BBB@ )P"?09K\$_\ @JO\0%DN= \.1ON=+B:(J#G
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M WQL9HY9+";$R;G)B;ER/7;[^N<YZ5GS?!+QN)I"MA-Y@<@?NWSLR/\ 9/0
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MI3;FU^,5]>E<*\\(R1@/@'ZYZ_R_#\^I)P\*E5P;I2GH>"/;Z8]NGK7ZG_\
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M' [>M?HKI\$<SZM8WF#;:A87\*AL;6,T+HHQT.=P'OGG&*_GS^%.O7O[(_\
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MN<U;DKTTG%N3DHQ75<TE'F?DG]SWZG\3GPI^$VN_%KQ6= ^Q72I+>%%D\MP
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M!_/#_P %/8_M7C?3<8!@OPQZ\\M^%?FG<Q%8H4R?](&,^G'U]\CTX'T_2O\
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M]ZTMY=3^FQ%VHJGLH%.H&<#/7'/UHK]VC\,?\*_(_,]PHHHJ@"BBB@ HHHH
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M)2>S\[+4^&O)U5HT&Z?]P-Q^]Z<=^3]3W_&GQQ:J$F&Z?_2A@?>XRQ'J /\
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MO(9\Y?\ B)/ZCZ<@?2OM2/X4:(K*GD+L(WGY5QNX[_G[G\.-"R^&6C!FE:!
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MXB:WXEU^?4+F6+7M0DO(4>9R$1V) 4$G:!TX]_K6!93&WL!8,A\QP%W$9)X
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M9YKYJA6W/E9(&,[,X[X/'/X?7]/IC]D!8?\ AH3P.5ZG4D\W/^\N2>>O7/\
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M_FO)/;5)==]KG[OZ]8L-<"HV5M5:$8;KMP 1TZCZBFW5G%KWAOQ!X>N$$O\
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M&TVFUIHKO\#.56,>J>O*[/9VOK\KGW(MU S%1*GM@\]<?Y]*I7>I6UNX!D3
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MMY-M)6TO\6JMT,?409(/+Z_92J$?WO?^O4YZ5_0S_P $P(#!\,M6);/F7,3
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MYCN?!1L4,T"[9!YDP9CO4;API^N#7],T48B147HHKXH_X*"?"B#XP_LR^/\
MPE+:B[-SI\DZ1E Y+V\,LBD<$\$#UQ7)CJ<ZF&J1IZ3T<7YIIG1A:D:593DF
MU9JR\]#\E/V-OBG;_%']E#P^L<BRW^CVFFV<KALRAH(5#@M][.5QC/USP*^@
MX=<*/:2J#C,=JPP>I(4D^XSR<=3[ C\6O^"0_P 2I-"\2?%/X(>+[@V]W8^-
M-9MM*LIF(<VMM+-''MC?!X^4  8]3Z_MY_9%K:?:(KA=K"XDG@SU(#,4/KU
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MG_\ 87\1C6/@/X94OYCQ6[DDG)P%0<]>ASCI7\O@B#/J9 _=1VKO <<&3!.
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M<H:*RT?+?Y]F>H_L].&^-O@>4K_K]3CQWQR.<?7MCFOZV_"?_(O:7_UZQ_\
MH(K^2_X"^1;_ !J\!J2 %U./R\],[N<=#GCT.,]Z_K/\),&\.Z4PY!M8\?\
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MO=#64+)<6EQ"4#8+;P< C(S]#CV]*_GJ\,W3):*K@_OS_%GC!//T]L5^C_\
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M?VM#=A9 HW*3C?N[YZ"OUFT_QSI3:<IFN$\WRQE2P/.!GC.1CW'/&,]*\?\
MB+XYFL-*O)]*D'G2(6BV8!;D],<]A[_A0W.FHIII<RG%/OHD_P 5YE1ES)OS
ML>NVS:%X4BCMM.@M;8; "(E1 =H'7:!G&"!FM >+[8@$O'G']X_I_3GOS7P)
M9^/?$U\K/>&3=GY=Q;IGZ'M[8Q[UH#QGK(&-SYXQRW0?\!^O;^M+EE-N^DK.
M;O9.UDTOGM;ST)]Y3;;2@XI)?WKVV\T?=*>,;=@?WD?!_O'Z?T-2#Q=;DX$D
M?0G[QKX17QEK*Y^9\=^6[_\  0._X]Z?_P )GK8&=S GW;I_WSZ]_P JN%-/
MWVOW:NW\K:-^;>GDF.%U%*3O-+WOO9]U?\)?;G_EI'_WT:23QA;QJY,B<#(^
M; )SCO\ 7)Y/\Q7PO_PF.M@DY; &0<MU[<[?7^GXU=3\9:[Y-IY3.2\@$N">
M!D?[([9^GX<14BJ<;--SG-J+3NDDK7:[-VMO?H$I6Y4MY72=MG:Z;\NY^BFE
M:HFI6WG(0V4R0#ST/UXX_P \Y_DG_P""R-S]I^+?AM,@F"XNTP<^K\]\8)&:
M_IG^!VL:AJ=M?K>%BL40V;B<=/\ Z_\ ^JOY</\ @L%<2O\ &[0T3)1;R\#>
MWS2=1_D?RKJR^FYU4I:.,$VF[7=TT_.]K^:>FIQXY2]C"5U>#7-YMVB[?-W/
MS&2W*I' 3DW"AE/' Z]_3'&?3\17AC:!GD).U&$9!/4G(!/;.?\ #/I&9;@/
M"V#N50(QC^$G'Y8Z_P#UZENBY0,N=A(,A]'[<XSG(_STKZ>GI#D;5ZOL^1I_
M#:5FGU3ZO[UY>#-*_(O^7KO/?X5RWOVNEIKNFQEQ9$O)&>?W+39S_LDX_#FO
MZMO^",+-/^S[!-N.U=0N8PN3C*LP/' Y Z@?_7_E*EDF-K+( 3-Y+C&/^6>W
MK^ ]N!UK^IO_ ((K7$A_9]6(9V_;[MOQW,3T[^@]<^E>7CZLGAYQ>\6J>NET
MDK-:ZZ]?\[';@I_OX<FBOR/?5:7L^M[:=-S]DM1\2Q65V]LS*"H)Y/\ G\^G
MKUJ@WC&!2@,B?,3U;T[>GZ?CUKYG^)WB/4K'Q9-;PLP 8!@,_=)/^>*\UU#Q
M?K G<1,Q"X*<GKU]#WSW_,5X,+<T;IM75TMV>[4YN27+\25U\FFU\U='W"?&
M=N#(/,3Y/]K\#ZT]/&%NX7]Y'S_M'\_ZU\(+XQUEEY9MQ^]RW'/T/IW'KS4H
M\8ZXN "_.<<G/K_=]ZTJ1A3J.-G92BW?^5I-IWZZ]5?OV(I<[M*3O%Q>G6_-
MI]RT?FGJSZF^)NGV_P 4/AOXM\/E8YP]I=(%.&&5AEQP<C@].OI[5_#S\6/A
MQ<>"OBYXX\"3@QM>:IJVI0[LJ/+620C;G/')Z$?I7]E7P9\1ZG?:AJ.GWS'R
M;LSKALXPZ$' (&>I'7C!ZYK^8_\ X*N^"-3^'?[3-IKNFVS16FI:=)OD52H,
METZ#TQD[\#C)[]A77",E4<*;]R2O&_:2AS?DOGJO/DKJ6(E""23IRFI-I[QC
M&6K6GVM//[CV[_@B3K;VWQRU3P_)<'RXK6\_=%L*<-(I.TD@YSP0/K7[3_\
M!0;]E^V^,OPZU6ZL;*,7MC!/>//'&OF,$C!P6VANW<X/7OBOYY_^"6&E>-O
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M-5^(_P 9?B!^T;XLLWDNF\9:I)I-]*A;?9W4[LC*[+C# +R./>O[&P00".A
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M+_<?TS^#--73/"VBZ<5 %K8PQ;<8 VKTQQCZ>G%=2  ,#@"HH(UBBCC48"J
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M]$XM.[^_3YGO\/495,;S*UHQ<7?_ *>-)?C]V^I^9HL&^RW*$Y8J\@/HH5F
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MK0G)<W-TV=DM?P/T1_X)@PF/XE;">8[R53[D;?\ /_ZZ_HY QGG.3FOYO?\
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M".W/O^Q6FRVMC<:GKFLLL6FZ,DCQRR8"*@0L#DD#''\^!7\\?PVT35_VXO\
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M_./O+UL]N^N^]Y;B.RL[J1E&YDXR.XXX';'K_*OT]_X)7>&AKVO^)]>,(/\
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M***^U/G HHHH>SMOT _G:_X*AQ[/&NG=S-?E!CJ.3SGT./RXZFOS2<E$M6(
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MY1-;L+=[**2/!NHY8V4#KL4CG/M^F!7ZG_L!?M!)H.J1^%M:OE@LE@41I)(
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M\KZ).U^^MW^3/>XEQDI86EAWJO*WQ1:M]R7?\M?IFBBBOU ^&"BBB@ HHHH
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MGT5OY&G4R3_5R?[C?^@FC8:U:]3^7']O[4E/QUAMN3F]NNG7[W/7''TSTX/
MKXYN[I;?6=$=<$#4[%6 ][B/_P"MG_\ 57U]^WI;K)\=#)C+K?7>WC/<=/\
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MWQ7]7'_!%U!-^S[;7:\+]NND(]#EAZ#O_GK7\I%]%));3Y!\P(^!C)V $9]
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M)[<=\8_3%*NB>(EVD02[L_O.&^4 @9P.G'7TZ]JYZCGSQY?A46]M>9M*._\
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M^K+OXTV.GZ)K_B&XECB@TG2+R_+.P53]FA:3&2V/X<8[X_$?Q-?M(_%'5_\
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M;^&_B_K4#*46ZN;G"XP,RW#G./Q_SFOZ[9XEFAEA8966-XR/9E*G^=?S.?\
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ML^S"BD7.!GK_ /7I:4)<\8RVYDG;U ****H HHJG?7T&GP/<7#!8T!))(
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MXS7]/?CKX\^";/PQKDJ:K;ASIUZB_O4'SM;R #EL_>]N^.O%?RY^+M=N-?\
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MM\A1244D[J*2T?96U.9B\%VBV<T)MTW.PP2@SW]ORXZBDT_P=#:7 D$2@#V
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M2BO@<9S2ZIN6B?RU^?J.HHHK[@^8"OD+]LKQA)X.^%TNI12M$QD= RDJ1\H
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M_7JM9O:7T=^URXW0LODYQD@XSU_S_,:PSVO&,(-RO&,4U;>5HI_?9]M^Y/\
M9V'3U@^C^3Y;7MW7Y['-76H:[J%JDDM[<,L*B-PSL<DYYP<U=TZWV!(;H>8\
M@$NYADX !ZG/KQS]!U-=/-:6:V\<=NRLKH&DP1]['0]?<?4^]84WR*7QB5"%
M48P2F>#CTX]_PI2S7&U82=_=G)TU=>\DXQY;+MS7=^W1#67X91<K17LTF[V3
M:;2OT7;>Y/;I%)<BX555%'EX&, ],X/TST[YYK#U\.]S%8P[BRNKD+U(//\
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M]-C\YS3&?6:\U!OV::LGW25_75.WZZ6****]L\L**** "OC;]L?XE?\ "N/
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M_-[!VM927-?=ZV5OG^!\BR1%G* \W7SQ^P//'X'CVJE#&T#,S'Y4/EG)_B/
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M>+36MMC\-/VCOV(]3UJ/4M8TZ Q[99[G]VF/EW,^.%Z<9'J>37X_>*?!.K>
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M***H HHHH *_/3_@H;X7N?%7PM6PM0QD(FQM&3RI]!_^O\*_0NN$\>>"-/\
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MI*K)RD]=-MM-+^K"BBBNLS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 A&010. !Z 4M%1R)3<UNX\K^^]_70!, G..12T458!1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLO WP]T/X=^'-,T_2;""S%E;I'.(HPFXHF.<#WS_ /7K;FNU,5QGDSN&0GG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1R+N
M0KZ\?F"/0^OY5^;'_!0[]DO1_P!H3X,^)M,L-'@E\1/:,;6\6$-.C(CMN1L$
MCYL'J:_2NH+FWCN8)H)%#),CHP8 @AP0>M<^)I.O!4G_  Y<W/T>R2UZ=?\
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MQ+Q$B52<C(QQ(#U()_D*_EY^+G_!2S]I?Q]J]QHNDV6K7=A)(T4;QM*RLC9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+C#V;E:\Z3D[:VJ:)+KLF[K?\3K?V%OV./#'P/\  &CVVH:#:QZ[!9VXEN3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<X_/ Y/>N_"8:4'-:7Y9.3T_NJ*C;R;_ %[GBSKS7+)2;IOG;5W=0CRK6_\
M>>NG;:VEC7/%7Q!URS.H3:S>2PR,5(,C'..IS@_0XP>^,YS4TZ2?4-+C%PQD
MNH-S3R,<LWZ^O<]<Y]JLSWTD-NVE0*6B3<1CID_3@CK]?84Z&(V>GB1!F6<$
M2KW49&,^W?\ ^M7I.FX4Z,OL4M;[NT9P3N^[N]/+LT<V%JU)3C3?PZRDV[OE
M=K)/I_6@AMI2L&6XD)\OKQR!T_,Y%:85"T3'DV@Q-W))Z9].Q/X^U8ES>SI!
M&RH=T )BQWY/'7_$8Z],$M[JX\F2692@G"O(3V.2,YSWQ_\ 6K.3A5=+ENHN
MI*G)=??FI+3LT^^BL>AI\^_D:90R-)$#\TV6BYZ+R>.A'3MQCKUP:MLK1LQ<
M_(AV,,#E_7'U/7T_*HTN9$DBE )*J N.=RD^HQZGU^E2W)95&T?+(0[$=FZ@
M'\?7O^CM*,G"-N2I91=]K2:5[_C^/G@XM1Y'\=65Y-=(JU^UERVY?.]BQ;VY
M6\VR#.8S*N1QCJ!_7GGK]:KW+LT\<X/[M957 ]5;T]/\BGRW4@A%RH_>A1%C
MOM(Y/Y<CC'/I4-L6EC='X"@R#@8+<G\?\]LU$G.48P:2T:BUU<7UT75Z[$.5
M-3E4A>]'EA*^JY;+6/S71?AN[Q/ ^J6R);<3VP$C,.I &,Y[?C[=JQ](U;QE
MI:1+;ZE<Q12';"H=@ PQTQT__7Z5IV<TZRNSJ<2_(V<_=_,@<8X[=N<5$U[*
MMZT&W]U;'?&3T)YR1WP,#'%<[HNK3FI_9C'FL[.Z<4K6OWZ?>=%.KI3U?-.'
M,DNFUUMHWKI;I?I8Z_2_C9\1O"UT@.OWT:JWS 3.,@?GZ9Z]?K7U#\./VO\
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M&UL-NR.&."!T!_#Z^E/.EP*IE)&2 ".F!CKC'/KQ^AJG&5M+>\VEW3?*M/\
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MFGORK;3IY??8G10BJB\!0% ]@,4ZBBN0[PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2%4?Y2H4#T.,>GKZ>N.E037"R3H&/RJP3U&,D9]..?\ ]5:D<-D+O;O38$#
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M6SU$K)+LDON"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA+X!U\*( TAG67>QQSLSTSGIC\OI7VHL:'3AE1_K<=.WI7.&.,:Q-A1_J/\
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ML%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>ny20077915x1_ex99-4img02.jpg
<TEXT>
begin 644 ny20077915x1_ex99-4img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  F '4# 2(  A$! Q$!_\0
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M26,;W=JBG>H;&]58%<Y'(QCD5B_"F]\7>-O#E_J$GBZYMKNWNGMXU^QP-&0
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-.![<4444)6T0F[G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>ny20077915x1_flowchart0x2.jpg
<TEXT>
begin 644 ny20077915x1_flowchart0x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M?P>;X@:/J7B.V2XO+^U\G2+.^&CZ]K=MML6E6[BT.($,R[2(RY\P_P""C_\
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MQ:BV;Q FOQZMI5OX:S9:9?ZCJMZ-'>P@O86#_G$__!>G]JK7?A_JW[3OP_\
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M_$BGPW=V/VWPQXNTG5Y])T:YNM(U>:+4-(NPVF)+IFJZ9-',&@N]/EN?4/\
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MP\M/#^H6TUU:>(=:;1/VC_$7C"VTN58?*5+'PAJ.I>=+%'_9_P S,G-?%?\
MX*H_![X<>//C9X&\)?!#]J3]H2']FN&(_'_QQ\ ?AMX6\6^!/A1?&U:_O]$\
M0:MXE^(G@S4M5U[0].274?$&D^#]&\37>C64%U/?)$+.[$#Y7=JVJWU6FMM?
MFT1]9H\BJ<]H2=HMQG%R]WGO&+BI27+[SE%.*2;;LG;].:*\Q^"_QB^'O[0/
MPI\!?&GX4Z_!XG^'GQ*\-:=XJ\*ZU CPFZTW48@XBNK64">QU*QG$UAJNG7"
MI=:=J5K=6-RB3V\BCTZI-DU)*46G&2333NFFKII]4UJF%%%% PHHHH ****
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M^+'\9ZPGB_Q-/XHOWUM]+L-'+6]Y/;6I@M19Z=; 6ZQD>9OD+DM@>,?MP?\
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MT8RIU924'C\7*=I02YZ>,5)5:4D^:,J?LYPE%+WDW8_!'XS_ +:/[2G[?O\
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MFDZSHNGQ:UHQMBFKW\=CKM^KWLD\32R-%(Z$Q %^TCKOKSO;^94[=>CB[_\
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M?"WPJUG]C_0_^"(WQO\ AG\;OCYJWC7]I_XJ_ 'X6_'2T\<?%?Q7XI\$>./
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MPMX<\4?##Q!X/\1Z=X;LX"\5KH46J?V7 LLXBM%^T3^9V'P9_8S_ &8OV>O
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M%#*EY<06T\<4,J))!NFB0_H!;>*?VH_CW-\0?@;\9_V/A\&/@_\ $+P5\1O
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ME&5H5XT,1BX5Z*J1]Y4ZL8U([229^QM%?CE_PZW^.O\ TE/_ &Y__#@:Q_\
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MN?\ \.!K'_S34?V5D/\ T5.&_P##3FW_ ,H]?Z>A_K-QK_T;7'_^)1PSY?\
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M:C_AUO\ '7_I*?\ MS_^' UC_P"::C^RLA_Z*G#?^&G-O_E'K_3T/]9N-?\
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MW_AIS;_Y1Z_T]#_6;C7_ *-KC_\ Q*.&?+_J-\W]WF?L;17XY?\ #K?XZ_\
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MW/\ ^' UC_YIJ/[*R'_HJ<-_X:<V_P#E'K_3T/\ 6;C7_HVN/_\ $HX9\O\
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M?_*/7^GH?ZS<:_\ 1M<?_P")1PSY?]1OF_N\S]C:*_'+_AUO\=?^DI_[<_\
MX<#6/_FFH_X=;_'7_I*?^W/_ .' UC_YIJ/[*R'_ **G#?\ AIS;_P"4>O\
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M-\W]WF?L;17XY?\ #K?XZ_\ 24_]N?\ \.!K'_S34?\ #K?XZ_\ 24_]N?\
M\.!K'_S34?V5D/\ T5.&_P##3FW_ ,H]?Z>A_K-QK_T;7'_^)1PSY?\ 4;YO
M[O,_8VBOQR_X=;_'7_I*?^W/_P"' UC_ .::C_AUO\=?^DI_[<__ (<#6/\
MYIJ/[*R'_HJ<-_X:<V_^4>O]/0_UFXU_Z-KC_P#Q*.&?+_J-\W]WF?L;17XY
M?\.M_CK_ -)3_P!N?_PX&L?_ #34?\.M_CK_ -)3_P!N?_PX&L?_ #34?V5D
M/_14X;_PTYM_\H]?Z>A_K-QK_P!&UQ__ (E'#/E_U&^;^[S/V-HK\<O^'6_Q
MU_Z2G_MS_P#AP-8_^::C_AUO\=?^DI_[<_\ X<#6/_FFH_LK(?\ HJ<-_P"&
MG-O_ )1Z_P!/0_UFXU_Z-KC_ /Q*.&?+_J-\W]WF?L;17XY?\.M_CK_TE/\
MVY__  X&L?\ S34?\.M_CK_TE/\ VY__  X&L?\ S34?V5D/_14X;_PTYM_\
MH]?Z>A_K-QK_ -&UQ_\ XE'#/E_U&^;^[S/V-HK\<O\ AUO\=?\ I*?^W/\
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M]N?_ ,.!K'_S34?\.M_CK_TE/_;G_P##@:Q_\TU']E9#_P!%3AO_  TYM_\
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M=;_'7_I*?^W/_P"' UC_ .::C^RLA_Z*G#?^&G-O_E'K_3T/]9N-?^C:X_\
M\2CAGR_ZC?-_=YG[&T5^.7_#K?XZ_P#24_\ ;G_\.!K'_P TU'_#K?XZ_P#2
M4_\ ;G_\.!K'_P TU']E9#_T5.&_\-.;?_*/7^GH?ZS<:_\ 1M<?_P")1PSY
M?]1OF_N\S]C:*_'+_AUO\=?^DI_[<_\ X<#6/_FFH_X=;_'7_I*?^W/_ .'
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MT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***_-?\ X*9?\%'-!_X)M_#/X;?$36_A'XH^
M,DGQ+^(T/PWTCPUX3UVQT/4XM3N-'O\ 5;>=7O=-U3[:UP]DME!96]N)Y9[B
M/8QQL9I-M):M[&=6K3HTY5:LE"G!7E)INRNELDWNTM$S]***_GG\-?\ !?\
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M=SXCM?%POM,L-/CCTZ6+2O$-J\#VQEADT2>0R.LT:KY!_P $R?\ @MK\/?\
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M%J6KS?M&Z5JWA\ZYX:CT:^UC5O$FC?VMX8\-3W-CHPLA97,=I:WTDM[=6EK
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M_P#RH/\ 6SA7_HIN'_\ P\Y=_P#-)];45\D_\-\_L/?]'>_LU_\ AZOAY_\
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M[;M+=/5ZK9G'',,'-R4:ZO&-2;O&<;QI*]247**4U!)N7)S6L?M+17\UK_\
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M:?H&FRZPGB#49K>"Q9](U&PMM0BMY9+"UF75](UC2#"]S8EI>W_X)S?M[/\
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M)/\ P2-^"7Q'^-?[8WQX;XL?'#PEXT_;6^#%G\"_B1'X5U;P):Z9X:\'0O\
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M3PW$4B*P^LO^"AW_  3>^$G_  4A\&?#3P7\6/'OQ5^'UM\*_&UQX]\-ZO\
M";5?#.CZVVMSZ5)I*_:KOQ+X6\4QI%:QR"ZM9+"&RNX;N..47)5=E?!NC_\
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M "/1JTJTY)T\3.BDK.,:=*:;O>[=2$FM-+)I?/4_GJ_X?0?MF?\ 2#S]O/\
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M?%'@NRU.PN]?\,VVKVGPWL[S3KG6-&CNM,BU"VO;:YM)+A;B&YBDC61?C_\
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M.=2<9)\DU*$O:-3BK2]V+5]C^>?X#P>(%_X-Y/\ @HO>(EY#\,K[]L'X;O\
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M+?:?^$F\6VGB33&T3P^;2-9;A-:O'G1-,D2-T<1WODR2+)&8U?>F[YW^+O\
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MXB>.KKP;!;6]G#X2N?%VOS^&(;2U96M;6+09=0;2H[:V9%:W@2T$4+*IC52
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MZ)O/?_#3CO\ Y0'_ !%?PN_Z./P)_P");D/_ ,WGZPT5^3W_  ^Y_P"";?\
MT775_P#PT7Q@_P#F&H_X?<_\$V_^BZZO_P"&B^,'_P PU'^J7%7_ $3>>_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^+[#PH=7UC6=*TGQ)H6KZ;)X>EUIHOFRV^%WAOQC^SY\5KSQ_P#"VRU[X!_
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M\./CS\8_@II7Q]\,_"?Q9I&H_;D\ Z];WNJ:'YWB>WL1X7E\1:AX;LY/$O\
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MSW'ASPAXH\06]K.;6ZGT30-6U6&VN0BR&WGEL+2=(9PC*YBD99 C*VW!!/\
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M5[]17\)8>JJ%>C6=.G6]C4A4]E53=*HX24E"K&+BY4Y-)3BI1<HMQ4HWNO\
M=3&8=XO"XG"JO7PKQ-"K0^LX:488FA[6$H.KAYSC.,*]-2YJ4Y0FH5%&3A)+
ME?YI_P#!+G1/V@OA_P#LY^'_ (5_'V-=>?PYI>C>(OAC\2=/U&?5],\5_#GQ
ME9+K.GZ)?7-W'%?V7B;P9J$M]I5]9W\:&729M&FL9+J!)9Z_2RO'/V>/^2"_
M!G_LF'@?_P!1S3J]CKKS?$O&9GC\5*E2HSK8JM.I"A'DI>T<VJDX0NU#VDTZ
MDH1:A&4I*$8P48Q\SAK+H93D&3Y;2Q&*Q-'!9?A</0JXVL\1BO84Z,51IUL1
M)*=>5&ERT8UJO-6J0A&5>I5JN=291117G'MA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YS\,OA+\/O@WHNL^'/AKX>7PQH6O^-/&7Q"U'28=3UG4;$>
M+/'^OWGBCQ=?Z=!K&HZ@FBVFK>(-1OM4_L/1A8:#87-W<?V9IEE'*Z'3U'X=
M^"-7\=>&/B;JGAC2K_Q]X+T+Q-X:\)^*KJW\[5O#VA>,I]#N?%6G:5,[%;2+
M7I?#6A'47B033IIMO"91#OC?LZ*=WW8N6-DK*RM965E9W5ELK-)KLUH%5;^R
M@U*QO-.N3<+;7]I<65P;2\N].NQ!=0O!*;;4-/GM;^QN!'(QAO+*YM[NVDVS
M6T\,R)(MJBD,X/X8?#'P)\&/A[X0^%7PQ\.VOA/P!X#T2S\.^%/#MG/?7<.E
MZ38J5A@-[JEU?:I?W#LSSW>HZG?7NI:A=RSWM_=W-W/-,_>444"222222222
M2LDEHDDM$DMD%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (MUO1KR[L9/&5]:7/BNR2[NI--UFSGN)I7^)22223DGDD]2?4T45T87 8'
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M ?[C@O\ L$PW_IF 4445SG6%%%% !1110 4444 %%%% !1110 4444 %%%%
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M/$*K)03E!PCNM+I57)J2G'E?-[)6MJI-KX6X_7EQ_P %(OV;+;XG2_#J0_%
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M>IE:^FJTU^2O^-_T.BFZCBW424N>=DE9*"G)0ZN[<4I-Z;[+8****1H%%%%
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M[,/;0[5?_!%?_P"5GZ-T5^<G_#0W_!1[_I&_\/O_ !.OP?\ _..H_P"&AO\
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M?-NG9+S>BZGZ0T5\0?"S_@HK^R7\4_%-M\.Q\1KSX7?%6Y6,+\)OCWX1\5_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5_(9_P ''/BG6Y_CY\ ?!3W]P?#FF?""_P#%-KI@E<6H
MUO7?&>NZ3?7[0 ^6UPUAX=TZW24J72-'12%=@?Z\Z_CK_P"#C/\ Y.G^"/\
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M&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"BQXE_\)LK_P#E'K_2U_SC/^&!_P!N#_HT']I7_P ,G\1/_F>J>U_X)_\
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M2"AZMON94/X%'_KU3_\ 2(A1110:A1110 4444 %%%% !1110 4444 %%%%
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M?N>?6QKHUYP<8RA3]E>$;NM)5(U)2E!7LU34+M.*35WS)I)_U?5XW\:/C_\
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MJFBMI>F^+/"1TV_U'47TU+;7[V;7M-TJ-)Y+[PKKL4GV8?G)X"U;P7X=LO\
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MBK77LJ-2?->3LXJI*6CUC%I7DM?W)HHHJ#L"BBB@ HHHH **** "O&/VC_\
MDWCX\_\ 9&/BC_Z@^NU[/7C7[1JL_P"SW\=T16=W^#7Q05$4%F9F\$:X%55
M)9F)   ))( &:Z<'_OF%_P"PFA_Z=@<>8_\ (OQW_8'B?_3,S_,\HHHK^[S_
M  C"BBB@#>T?PKXH\0V>NZCH'AO7M<T_POIPUCQ-?:/H^H:G9^'=),R6XU37
M;JRMYX-(TXW$D< OM0>WMC,Z1>;O95-;4M!US1H=*N=8T;5=*M]>TY-8T.XU
M+3KRQAUG29+BXM$U32I;J&*/4=.>ZM;JV2^LVFMFN+:XA$IDAD5?OS]ACX[6
M'[/_ ()_:F\77;Z#J1U#P7\*- O_  )K=Y8Q'XE>"]8^,OA33/B5X*M;"ZE2
M;45UCP#>Z_;7WV2*=]/M)9-2F00VSL-K]O2?X.:-XP_93T;X6>/-'^(7PU\)
M? KPR+74M/73O$]_IN@:G\2O''BG3] \5Z -5TZ,>+=)\.:Q8V?B#PSJFHZ'
M/+J$<UO<R:7%<K+%X/\ :^)6<5,NE@I?5_:SA1Q<>>4:GLLNHXRLI)0<83C4
MQ%*E3NVJJ=3D]^C-'Z+_ *F95+@O#<30SZFLPEA:-?&9145"$\.\9Q/C\BP<
MZ<I55.M1GA<MQF+Q#48RPLX4/:OV6+HS/S4KHT\'>+I-,T36H_"OB.31_$VJ
MS:%X;U9-#U-],\0:W;/!%<:/HE^MJ;75M5@DNK:.;3["6XNXGN($>%6EC#>L
M?%SQ=\,O$6DZ7;^!HT2^M]0>:]*_!/PW\+R;4V[HH.IZ)\7?B+-J0\TC_09M
M/L(D/[\7CLHA;[=UCQ-\3M<_9'_9+GN/%O@?7?'7PV_:-U36/"GAOQ#\1OAW
MI]IX9\(G0/A79_#U=1T9?%6CIX:\+7VNZ=>MJL]Q_8X%X^NZYK]Y;7UUJ>JO
MIB<TJT:>!J>PI4OK6)GAYQQ=6IAY4[4*]2G**G1CS1E4IPC.4N10C-./.VK<
M^5\(8+'XK/L.LPQ6,CE&58;,J5?*,)0Q]&OSX[ T,32J5*&,KJ%2CAL17JTJ
M5+VLZTZ$^>5"-*7/^;/C'X<_$+X>36=MX_\  GC+P-<:BMRVGV_C'POK?AF:
M^6S>..[:SBUJQLI+I;5YH4N3 KB!Y8UE*F10>-K[8_:DTOP7?^$O!_Q-U73?
M!G@S]H;XB^/_ (G:Q\2O GPZ\;2^-O"DGARXO]/U30_&\ZS>*O'DOA'7-<\0
M:IXGTUO#S>+)+>YTK2-/U:RT73(+@RWGQ/79EV*EC,)3KSBHS<JL)\L4J;G2
MJSIR=*4:M>%2DW']W5C5DJD;3M!MTX^#Q/E$,CSG$9?2G*=&%/"UZ/M*DY8F
M%+%X6CB84\93JX/+ZV&QD(U4L3A*N$I3PU2]'FKQC'$52BBBNX\ *_T(_P#@
ME3_RCS_97_[)U)_ZDFO5_GN5_>U_P3)\<>*]%_8)_9ATZR^"OQ,\3VL'PY1H
M=;T/4_@]:Z7?)-KVM3B2UA\4?%?PYK:HHDV$WNCVA=E+PB6!HYI/QWQGA*ID
M651BX)_VM?WZE.DK+!XE:2J2A%O79._D?V-]#*K&EQKQ9*2J-/A:"_=4:U9W
M_M; O6-&%226F[272]VC]3J\=^"7_(M^+?\ LL7QM_\ 5K>+J/\ A9OC7_HW
M?XQ?^#O]G_\ ^?G4GP3L/$-AX2UA_$_AC5?!^I:M\1OBAXBBT/6KSPY?ZE;Z
M7XE\?>(-=TB6YG\*:]XET427.FZA;3-#;ZO</ [-%,$D4K7\ZNFZ6&K<TZ+<
MJE#EC"O0J2=E6N^6G4G*RNKNUDVDW=J_^B4:T:V,H<D,0E'#XKFE4PN*HP3E
M4PO+'GK4:<.:5I.,>;F:C)I-1;7KU%%%<9Z 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7R!_P4)_Y,%_;A_[- _:6_P#5,>-:^OZ^0/\ @H3_ ,F"_MP_]F@?
MM+?^J8\:TX[KU7YF=;^%5_Z]S_\ 26>T_ C_ )(?\&O^R4_#O_U$-'KU:O*?
M@1_R0_X-?]DI^'?_ *B&CUZM2+CLO1?D%%%% PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S?_ ."1O_*/+]G?_KW^
M)W_JY_B+7Z05^;__  2-_P"4>7[._P#U[_$[_P!7/\1:_2"@RH?P*/\ UZI_
M^D1"BBB@U"BBB@ HHHH **** "BBB@ HHHH Y[Q/X1\)^-=-&C>,O#'A[Q;H
MXN8KP:5XGT73=>TT7<"R)!="QU6VN[47,*RRK%.(O-C660(P#L"[P_X4\+>$
M]+&B>%?#6@>&=%5I&&D>']'T[1M+#2C$K#3].MK:T#2CB0B++C[V:WZ*!65[
MV5^_4X[1?AW\/_#EIK%AX>\#>#M!L?$7F?\ "06>B^&=%TNTUSSDEBE_MBWL
M;&"'4_-CFFCD^VI/O265&RLC@QVGPU^'5AI.GZ!8^ /!5EH6DZQ!XATO1;3P
MKH5OI.FZ_:NTEMKFGZ=#8)9V>L6[N[P:G;PQWL+LS1SJ6)/:T4!9=E]QR+_#
M_P !R6EYI\G@GPC)8:AKR^*=0LG\-Z,UI?>)TFBN$\1WELUD8;G7DN(89UU>
M9'U!9HHI1<!XU8?F;H/_  1R_9<T/QQH_B)_&O[0FN> ?#WQZU#]IC0/V?O$
M'Q,L-0^!^D_&?4+N6_;Q?%H:>$[?QA>2VU],]S:V.J^.-0L%<M'-;SP/)$_Z
MP44TVMFT1.C2J<KG3C+E=U=+39M>:;2;3NFTFUHC*TG0M#T%+V/0]&TK1H]3
MU&[UC44TG3K33DU#5[]E:^U2]6SAA6[U&\9$:[OIQ)<W#(IFE<J,9MAX)\&:
M5K^H^*],\)>&-.\4:PI35_$EAH.E6>OZJA96*:CK%O:1ZC?*61&*W-S*"R*<
M948Z>BD79=EIMY'*W?@7P3?^'W\)7W@[PK>^%9)7N)/#-WX>TBY\/R3RW;W\
MDSZ--9OIKRR7\LEZ\C6Q=[N1[EF,SLY?9>"?!FG'3CI_A+PQ8'2+^XU7239:
M#I5J=+U2[L6TR[U+3O(M(_L5_=::[Z?<7EMY5Q-8LUI)(T#&,]/10%EV7W&=
M+I&DSZI9ZY-I>G3:UI]I>:?8:Q+96TFJ6-AJ,EI-J%E9Z@\1N[:TOY;"QEO+
M:&9(;J2SM'G1VMX2G'ZS\)?A5XBMHK/Q!\,_A]KMI;ZCJNL06NL^#/#FIVT.
MK:[<"[UO5(H+W39XH]1UFZ N=5O45;G4+@":[EFD :O0:* LNR_K_AE]QS6D
M^"_!V@'3CH7A/PUHIT?2I]"TDZ3H6EZ:=+T2ZN8[VYT;3C9VL/V+2KB\ABNY
M].MO*M)KF*.>2%I45Q+:^$O"MC:Z'8V7AGP_9V7AB=KKPW9VNC:=;VOAZZ>"
MZM7N=#MX;9(=)G>UOKZV::P2WD:"\NH2QCN)E?H** LNR_K_ (9?<%</K'PQ
M^&WB'2;?0=?^'O@?7-#M-2N]9M=&UCPGH.IZ3;:O?RW,U]JMOIU[I\]G#J5[
M->WDUW?1PK=7,MW<R32N\\I?N**!V3W1YE)\%/@W-HMMX:F^$OPRE\.V5_<:
MK9Z!)X#\*R:+::I=Q1P76I6VE-I1L8+^Y@BBAN+R*!+B:*...21D15'7>&O"
M?A;P9IBZ)X/\-:!X4T9)YKE-(\-:-IVA:8MS<%3/<+8:7;6MJL\Y53-*(A)(
M54NS$"M^B@5EV1R^E^!_!>B:MJ^OZ+X0\+Z1KOB!F;7M:TO0-)L-6UMG<R.V
MKZE:6D5YJ3/(2[&]FF+.2QRQS5FT\*>%["/0H;'PWH%G#X7>XD\-16FCZ=;Q
M^'9+RUN;&[?0DAMD727NK*\O+.X:P%NT]K=7-O*6BGE1]^B@++LON_KLCE=-
M\"^"-%U'6M8T?P=X5TG5_$GF?\)%JNF^'M(L-1U[S69Y?[:OK6SBN=4\QF9I
M/MTL^]F9FR229/#/@OP=X+@N[7P=X3\,^$[:_N#=WUOX9T'2]!@O;H[LW-W%
MI=K:QW%P=[YFF5Y#O;YOF.>FHH"R[+[CDM3\ ^!-:U:37M9\%>$M6UR:Q72Y
M=9U/PYH]_JTNF),EPFG2:C=6<MX]BD\<<ZVC3&W6:-)1&'56"3_#[P%=:])X
MJN?!'A"X\42OI\DOB2?PUHTVO2R:3<6]WI4DFL263:@[Z9=6EK<Z>S7!:SN+
M:WFMC')#&R]=10%EV7?;KW.>@\(>$[:XL[NV\,>';>ZT_4M3UFPN8-%TV*XL
M=8UM94UG5K.:.V62VU+5TFF74[Z%DNK]995NY91(P/EWP,_9]\#?L_VGQ*B\
M'7/B#5=2^+GQ;\:_&KQ]XA\57UCJ.NZYXV\<7%JU\\MSIVF:1:QZ7I&F:?I7
MA[P]8)9@Z=H6DZ?9O/=2Q27,ON5%%WW_ *6P<L;IV5XWL[;723MVT5K]M-@H
MHHH&%%?GC_P46_X*!>#_ -@?X6Z/XEO-"3QM\1O'%]>:5\/? YU$:9#?R:=%
M#+JVN:S>1PW5S::%HR75H)V@MGFO+N[M;&!X6F>X@_FXO_\ @X/_ &X9[RXE
ML/#7P$L+.25VMK.3P1XHO9+>(L2D373>.X#.47"F0PQEL9*C.*^TR#@#B3B/
M!_VAE^'H0P;G.G3KXK$1H1K2IOEJ>QCRSJ3C"2<'-P4.=2A&3E&27XYQYX\>
M'/AUFRR+B#,\7/-U1I8BO@,LP%;'5<)2KQYZ#Q=2+IT*,ZU.U2%!UG7]E*G5
ME2C2JTIS_M5HK^)__B(*_;M_Z OP!_\ #?\ B;_YX%'_ !$%?MV_] 7X _\
MAO\ Q-_\\"O=_P"(0\7_ ,N6?^%K_P#E!\-_Q-OX0_\ 01Q%_P"&27_S2?VP
M45_$_P#\1!7[=O\ T!?@#_X;_P 3?_/ H_XB"OV[?^@+\ ?_  W_ (F_^>!1
M_P 0AXO_ )<L_P#"U_\ R@/^)M_"'_H(XB_\,DO_ )I/[8*IZCI]GJVGWVEZ
MC;17FGZE9W.GW]I.H>&ZL[R%[>ZMID/#Q3P2212*>&1B#P:_BK_XB"OV[?\
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M^(^51Q5:=;ZAE=#"T\!AY5).<H86EB\)C*U*DI-\E+ZQ*%.-H4U"$8Q7C/\
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M $,>-/\ P[95_P#.$_@Y_P"'(O\ P4D_Z(9H_P#X=WX0?_-Q1_PY%_X*2?\
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M1P\)SE4<*.'INK/EE6E4]G2Y"BBBOE#]3"BBB@ HHHH **** "BBB@ HHHH
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MY9J%KM)IS491BU?234HM1W=U;='J=%>9?%[XS_"?X!>!=5^)GQJ^(?A+X8>
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M%24JCC4DU%I\JINFI*=G>+O4C9-:Z]C]$****1L%%%% !1110 4444 %%%%
M!1110 4444 %%%% 'YO_ /!(W_E'E^SO_P!>_P 3O_5S_$6OT@K\W_\ @D;_
M ,H\OV=_^O?XG?\ JY_B+7Z04&5#^!1_Z]4__2(A1110:A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!_)%_P<@S2GXP?LT6YD<P)\-O&DRQ;CL66
M3Q18H\@7H'9(XU9NI"*#T%?S:5_2-_P<@_\ )9OV:O\ LF/C'_U*K2OYN:_L
M#PV_Y(G(O^O.*_\ 5ABS_(GZ2C;\;>.;MNV(R5*_1?ZMY-IZ!7WA^S[^RG\)
MOB)^SM\1_P!I#XR?&WQ7\*?"'P_^*G@OX626WA+X3VGQ,O+F]\::9<:A:ZU>
MI<?$/P1-9Z9IYMI%OH[&WU>_,(\RTM+F4K;M\'U]R_ ']K7P!\+_ ( _$+]G
M;XJ? 67XS^!_'_Q.\'_%"Z6U^*FJ?#2XM]2\&Z;/I]EI5Q+I/A37KZ[TR\%Q
M(UZ;/4-)O#&QCM[B&0+<+]#G2S)X.']E^W^L?6\&ZOU9X%8AX-8B#QBH/,;8
M157A^=0]HUK;E:=C\]X'EPU'.:SXI^H?4/[(SA8-YK#/)Y:LY>!J_P!CO'1X
M<C+-WA5CO9>V^JQ;Y+\ZY;GH_P"T+_P3EUO]GKX3?&7XGZU\3-/\11_#7XJ_
M"KP7X7@T?P[-'H_Q"\$_%SP%_P )_P"'/'UEK%SJRW&E21V,MOI]WH+:5?HF
MH1ZA&FLNEI&USF>-/^"?FH?#_P#8CB_:N\5?$:/3_&S:WX"2]^!Y\,[M2T+P
MG\3)]8/@G7?$'B-]=CETS5-?TC2#XEL_#[^''?\ L#4])O);Z)[P0Q]_XL_X
M*8:5\7O"7QH\#?'C]GZ/QKX5^*WQ$^'_ (XT?2/!7Q6U'X<0?#_3?A?X'MO
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M3I\_M+*33TY'>.KBW:324I+^PVBOY,/VLOB-^V?\2OVPO^"J6C_#O]M?XT?
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M^O?XG?\ JY_B+7Z05^;_ /P2-_Y1Y?L[_P#7O\3O_5S_ !%K](*#*A_ H_\
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MYMA(TIY7A%BTL/C9UH>RG4FZD8T:>$5-QG%<RK5G6G3=Y5J%"M"E:IRL_0^
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M]9N(HH)-3UOQ%XIU77?$NMW@MX8K>*;5M7O&MX(U@MS%$-E?-'Q0_P""1O\
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MQ2U-9WU;X<ZN)=,L=(\$_"GX8^'M"74U\:RK(NKW6IR"_E@GNKC48/J_3O\
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M#Q,3^0-3#_@OY^P<2 5^,J@]S\/[7 ^NWQ$Q_(&I_P!2>+O^B=S;_P (ZO\
MD4O&7PH?_-Q.$/GGN 7YUO/^K,_;FBOQ,7_@OO\ L%L<-+\8$']X_#U"!]0N
MN$\^P/Y<U,O_  7S_8') -[\7$']X_#MR!^"ZNQYZ=*/]2N+?^B=S;_PCK/\
MHE+QB\*7_P W%X.^?$&6KMWQ"[_GV=OVMHK\64_X+W?L!,<-JWQ7C&,[F^'%
MT1GTPFI,<_ACCK4R_P#!>K_@G\QPVO?%-!CJWPUU$CZ?+>L?TQQ4O@SBQ?\
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MKPIH0NY-3L%:\N8CJ'Q]^Q?\+OVE/B]^S%^V#XQUWX?_ /!+WQC:>)_C)^T
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M>&O#,VJRZ?IZ7D5I.ESKVIP)IFDVDUO!=S7E_:6@MDN)!")E&UK7=W:V[O\
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MCFDN:_Q6E>45+5V<0HHHI&X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^;_\ P2-_Y1Y?L[_]>_Q._P#5S_$6OT@K\W_^"1O_ "CR_9W_
M .O?XG?^KG^(M?I!094/X%'_ *]4_P#TB(4444&H4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^K_$+1OAS)!\*6\$W^D^!M9CU;3]7U/QIKWAT^)+*RBO/ B^(_M$0DVO#O\
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M+29\@?F#^SY_P6)^#7[3G[:?C+X)?"+7O _B#]FWP=^ROJ?[0.J_'/4!XO\
M!FKZ/K.@>+-)T3Q%H7B7P_X[TCPU-X=T?2-(U(ZS<WFKZ;8SBV$%ZKM83)*R
M3G)W6O*^;YW5WYMNU^K&X8'#Q>&E)1^L*-)TY59RJ2@XN$8J\G.%*,4XQMRP
MAK:S;/(_CS_P1T^-_BCXB?M8:C^S=^V?+\!/A#^W!X=L+?\ :+^%]W\*].\:
M3:SXHL_#4V@:CJ7A;Q+=:S9WWAVP\7&YU";Q'';(M^;?7=8LH;J6V_L^*SX;
MQ9_P0P\;6%G^S[XM^"G[1/PY\(?&3X9_LS>&_P!F3XEZQ\3/V=O!OQJ^'GQ
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M9DMV\F*1(P%'U%11=]W]X>SI\SG[.'.URN?)'F<;6LY6NU;2U[6T/@_X$_\
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MVG:-#+#'-:Z?!*H>OI>BE=]RG&+:;C%M)I-I-I25I)-K1-))I;I:GYV?"_\
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MKAXIY7KH]+.UG?7Y&GMJ3LU.$HOF3E&<'&+@KR3?-T6]KVZV1]]45\@_!O\
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M?O)33@Z<ZTN;EC%J:M5^'FAK&UU>Z_"[]G3X5>-?A%\ /^#?W0OB!I%WX?\
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MH/VEO^CA_CG_ .':\??_ #04?\-0?M+?]'#_ !S_ /#M>/O_ )H*K_B"6/\
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MH3_R8+^W#_V:!^TM_P"J8\:TX[KU7YF=;^%5_P"O<_\ TEGM/P(_Y(?\&O\
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M1117 >J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7R!_P %"?\ DP7]N'_LT#]I
M;_U3'C6OK^OD#_@H3_R8+^W#_P!F@?M+?^J8\:TX[KU7YF=;^%5_Z]S_ /26
M>T_ C_DA_P &O^R4_#O_ -1#1Z]6KRGX$?\ )#_@U_V2GX=_^HAH]>K4BX[+
MT7Y!1110,*B%Q TS6ZSPM.BAG@$B&9%.,,T8;>JG(P2H!R,&I:_GK_9Z_P""
M/G[0_P '_P#@K3\2OV_?$7[4%GXE^%GBS6?B%KEEX1AN/%3?$+Q#9>-["[M-
M+\!^-+>[LXO"T?A/P:]Y;R:5-I^KZCYP\/:*+;1=&)(M*23O>5K+31N[[:)V
M,*U2K3E15.A*LJE50J24XP]C!IWJM2^-)V7*FF[Z/H_Z%****DW/SS_X*L?M
M"?%']E;]@7X_?'KX+:KINA_$WP';_#?_ (1?5=7T6Q\0Z=9R^*/C!\/_  9J
M<ESHVI1RV5Z&T7Q%J442SHPBFDCN$Q)$A'YZ?M%_$O\ X*Q_L,_ 6Y_;!^('
M[5O[.7[1/PX\!OX%U;QS\'-1^ $7PNU?Q)X;\7>(_#_AZYLO"GC#PWKD]Q;^
M*+>3Q!"^FI<PFSFDC9WM[UE33KOZ;_X+T+&__!)S]K))6V1/:_!A97WF/;&W
M[1'PC#MY@(*;5).\$%<;LC&:_(S]M+]DO_@EK\)?V1O$7QN^%O[7E^GQ^^%G
MAS1/B'\&=,?]JVV^.1U+XOZ+'97_ (5\/K\)O$VM^-;+6XM3UM8M/G@BT-9=
M,BD-Z]U;6]G,3K%+E6BNYVU5[_#IY+5ZGE8R=55J_)-Q5/"4JD?]HE14).IB
M>::@ER57:$?=J.,9<JBVE)M?T-6_QQNM6_:[^$7P[B^,FA>'=+\=_LOZO\6#
M^S9J?PWUNX\=:O.?$NF6T/Q$'Q0CLSX>T73?#D-VWAO4/!ES?1:G?7[MJ,-K
M);QF2/SW5O\ @K9_P3GT/XI7/P<U3]J?P-;>-[+Q2O@F^8:3XWN/!5AXL-S]
MC.@7_P 4K;PM-\+['48[L-;3077C&'R)TDBF,;QN%_,7Q9KOQL^+'[7G[.?B
M6]TZ;0OVC?B5_P $'OB=KMWI-K;/IMQH_P ;/&5OI.H3Z=;6?F0R6$VG^.]1
M>VAMO.B>U>%8O,1H]P\U^%WQY_88T7_@WW\1?"GQ1XJ^&%AXJLOV:_B+\/?&
M'P=U74-%B^*,W[4]QINNV$$,_@FX6+Q5-XYO/BF=.UO2=7.E3RVB1V>J?;7L
MM-DN(URK3?[*:72][N_77_A[6+EBYJ4U&5*"BJM3FK*=I*G3P\E!+VD>24O:
MMR:YE"W\.3;/W6_: _X* ?L?_LM>*K+P1\>OC9HOP^\5ZIX(MOB)HVAW6@>-
M-;O=>\)WOB&;PM9WGAX>&/#6MQ^(-2N];M[BUMO#>C27WB6>"WGU&+2&TR&6
M\3P_4O\ @LC_ ,$S]*\&>&O'US^U=X/F\.>*Y=7CTT:9X6^)6M>(+$:#>16&
MKS^*_!FC>";_ ,9>!K*QNYX89=0\:Z#X?L3YB/'</&=]?G1^R7\/M;3_ (*(
M_P#!-B#XRZ/+=?$WX;_\$4/#%W.OB&%9]8\.>,E\<:5X:OI[DSQ^;!XBL='U
M75-#OKAC]J22[U*.6622621NR_8@\%^$4\1_\%]-17PUH@O=8_:;^-/AG5+@
MZ;:E[_P];_":ZU*+1KD&,I+IW]H>(-:O)+1E\J:XU*ZEG61I 0."6[;M'FNF
MDG[_ "Z:/UO^ +$XB<HJ*HP4ZDJ<5.$Y2@XT%7YI6JQ4GO3<$HV=I\[LX/\
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M_"5Z%I5[HVGW=SH#^"_#?B*/5+IKKQ!I"V.E6CRZMJD-TUUIEC>6EK>3V_\
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M-X>C\0?L!>/O#VA2:YJ=EI4>LZ_=?&6*2UT32Y+Z:!+_ %>Y1&:WTZU:6\G
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MHH **** "BBB@ HHHH **** "BBB@ HHHH *_FT_X.0O^2/_ +,W_92?&_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[!0@KVA%<S4I6BES25K2=EJU96;U5E;8*_(K]@W_ ()H_#CX5?!S0[;]J+X
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MUT_/NSU_^(+^$W_1O.$O_#-@_P#Y7Y?GW9^'7_$/O^PC_P!!;X]_^'!\._\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_+R7W'S+_P ,4_L;?]&E?LR_^&&^%G_S*4?\,4_L;?\ 1I7[,O\ X8;X6?\
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M_P#"A^('_P UU'_#I#_@G1_T:[X/_P#"A^('_P UU?HU11_K'Q#_ -#W.?\
MPZ8[_P"7A_J!P'_T1/"/_B-Y-_\ ,7DON/SE_P"'2'_!.C_HUWP?_P"%#\0/
M_FNH_P"'2'_!.C_HUWP?_P"%#\0/_FNK]&J*/]8^(?\ H>YS_P"'3'?_ "\/
M]0. _P#HB>$?_$;R;_YB\E]Q^<O_  Z0_P""='_1KO@__P *'X@?_-=1_P .
MD/\ @G1_T:[X/_\ "A^('_S75^C5%'^L?$/_ $/<Y_\ #ICO_EX?Z@<!_P#1
M$\(_^(WDW_S%Y+[CX-\'_P#!,']@7P)KUCXE\-_LP?#J+6=,GCN;&XU===\3
MV]M<1-NBN(].\3ZSK&F>=$^'BE:S9XW571E95(^[XXXX8TBB1(HHD6...-52
M..-%"HB(H"HB* JJH"JH   %/HKAQ>/QV/E&>.QN+QLX)QA+%XFMB)0B]6HR
MK3FXIO5I-)GMY9DF39)3J4<FRC+,HHU9*=6EEF PN IU9Q5E.I#"4J49R2T4
MI)M+1.P4445R'IA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX>>*]!\&_$;X-W'@*_U2^N;:3Q#XJ^(GAS0OAYK,,6L>'-,@C^'WC_6+#3M
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M7/A1+CP#%+#=QZ9/K'B"754U>WUD>)(?$H\72:LWC'_A,(O$BCQ&GC/^W_\
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M=<^/8?"VC7.JZGJ,VM7%II-AIEH^JI#>(D4\,<B%Z#O[LD]4G=V7\K?O-O\
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MV'\;_@Q_P43_ &F8?C%XOU+Q+^QAXO\ VA_!W[.&B7FK2RRV/[-GQ:U#X5^
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M'6OA[XGTE-*BDT'Q'I^J:GI]Y%J$5EJ<-A>-$?RQ^&VM?&'X(?LP_P#!0O\
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MPQ\5;B(W%Y>6.B:]&^JQZ3%:_P!DW]O^TU%4J\D]$DM;)-JU^7;7IRZ>K(>
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MM[=+6M:Q'U*FW&7/4O&G"G&TDDH4YQG%-))3UC:7,GS)M/9-?E;\"/@'\>O
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M^N^+/!7AR;Q?>MJ#Q:%=ZYJ\.IK/X/&F^&=1T?PU!X=O[N""R\+_ +*@
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MP3.U#Q/IGB_QSXV_:1\4:W^UCXC^,WPP^..C_M':7\//"^@V/@WQ-\%] O\
MPK\-?#FB?"%]1U;PY<^ M)\/:WXFL]8T#5];O[_7[CQ/J]_<:Y;7 TXV'ZIT
M4<S_ *2\O+;1:;$_5Z/\CZ_:G=MN3YF^:[G>4K3=YJ[M)'Y37_\ P3'N_$D/
MC'XC^-/VC_%&M?M<>(_B_P##/XU:#^T=I/P]\+>'M/\  GB7X/>'M0\(> M
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>ny20077915x1_flowchart0x3.jpg
<TEXT>
begin 644 ny20077915x1_flowchart0x3.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MB@&TMVE?:[M<]2HIDDD<4;S2R)'%&C222R.J1QQHI9Y'=B%5%4%F=B%5022
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MJJ***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY\^SY3GO^']/_!*__HY._P#_  R?Q[_^=E1_P_I_X)7_ /1R=_\ ^&3^/?\
M\[*NA_X<;_\ !+'_ *-3TW_PZ_QW_P#GHT?\.-_^"6/_ $:GIO\ X=?X[_\
MST:]._!'\G%/_@>5?_(GS7+XV_\ /WPM_P#!/%G_ ,N.>_X?T_\ !*__ *.3
MO_\ PR?Q[_\ G94?\/Z?^"5__1R=_P#^&3^/?_SLJZ'_ (<;_P#!+'_HU/3?
M_#K_ !W_ /GHT?\ #C?_ ()8_P#1J>F_^'7^._\ \]&B_!'\G%/_ ('E7_R(
M<OC;_P _?"W_ ,$\6?\ RXY[_A_3_P $K_\ HY.__P##)_'O_P"=E1_P_I_X
M)7_]')W_ /X9/X]__.RKH?\ AQO_ ,$L?^C4]-_\.O\ '?\ ^>C1_P .-_\
M@EC_ -&IZ;_X=?X[_P#ST:+\$?R<4_\ @>5?_(AR^-O_ #]\+?\ P3Q9_P#+
MCGO^']/_  2O_P"CD[__ ,,G\>__ )V5'_#^G_@E?_T<G?\ _AD_CW_\[*NA
M_P"'&_\ P2Q_Z-3TW_PZ_P =_P#YZ-'_  XW_P""6/\ T:GIO_AU_CO_ //1
MHOP1_)Q3_P"!Y5_\B'+XV_\ /WPM_P#!/%G_ ,N.>_X?T_\ !*__ *.3O_\
MPR?Q[_\ G94?\/Z?^"5__1R=_P#^&3^/?_SLJZ'_ (<;_P#!+'_HU/3?_#K_
M !W_ /GHT?\ #C?_ ()8_P#1J>F_^'7^._\ \]&B_!'\G%/_ ('E7_R(<OC;
M_P _?"W_ ,$\6?\ RXY[_A_3_P $K_\ HY.__P##)_'O_P"=E1_P_I_X)7_]
M')W_ /X9/X]__.RKH?\ AQO_ ,$L?^C4]-_\.O\ '?\ ^>C1_P .-_\ @EC_
M -&IZ;_X=?X[_P#ST:+\$?R<4_\ @>5?_(AR^-O_ #]\+?\ P3Q9_P#+CGO^
M']/_  2O_P"CD[__ ,,G\>__ )V5'_#^G_@E?_T<G?\ _AD_CW_\[*NA_P"'
M&_\ P2Q_Z-3TW_PZ_P =_P#YZ-'_  XW_P""6/\ T:GIO_AU_CO_ //1HOP1
M_)Q3_P"!Y5_\B'+XV_\ /WPM_P#!/%G_ ,N.>_X?T_\ !*__ *.3O_\ PR?Q
M[_\ G94?\/Z?^"5__1R=_P#^&3^/?_SLJZ'_ (<;_P#!+'_HU/3?_#K_ !W_
M /GHT?\ #C?_ ()8_P#1J>F_^'7^._\ \]&B_!'\G%/_ ('E7_R(<OC;_P _
M?"W_ ,$\6?\ RXY[_A_3_P $K_\ HY.__P##)_'O_P"=E1_P_I_X)7_]')W_
M /X9/X]__.RKH?\ AQO_ ,$L?^C4]-_\.O\ '?\ ^>C1_P .-_\ @EC_ -&I
MZ;_X=?X[_P#ST:+\$?R<4_\ @>5?_(AR^-O_ #]\+?\ P3Q9_P#+CGO^']/_
M  2O_P"CD[__ ,,G\>__ )V5'_#^G_@E?_T<G?\ _AD_CW_\[*NA_P"'&_\
MP2Q_Z-3TW_PZ_P =_P#YZ-'_  XW_P""6/\ T:GIO_AU_CO_ //1HOP1_)Q3
M_P"!Y5_\B'+XV_\ /WPM_P#!/%G_ ,N.>_X?T_\ !*__ *.3O_\ PR?Q[_\
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M\/Z?^"5__1R=_P#^&3^/?_SLJZ'_ (<;_P#!+'_HU/3?_#K_ !W_ /GHT?\
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M ()8_P#1J>F_^'7^._\ \]&B_!'\G%/_ ('E7_R(<OC;_P _?"W_ ,$\6?\
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M_A_3_P $K_\ HY.__P##)_'O_P"=E1_P_I_X)7_]')W_ /X9/X]__.RKH?\
MAQO_ ,$L?^C4]-_\.O\ '?\ ^>C1_P .-_\ @EC_ -&IZ;_X=?X[_P#ST:+\
M$?R<4_\ @>5?_(AR^-O_ #]\+?\ P3Q9_P#+CGO^']/_  2O_P"CD[__ ,,G
M\>__ )V5'_#^G_@E?_T<G?\ _AD_CW_\[*NA_P"'&_\ P2Q_Z-3TW_PZ_P =
M_P#YZ-'_  XW_P""6/\ T:GIO_AU_CO_ //1HOP1_)Q3_P"!Y5_\B'+XV_\
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M?^C4]-_\.O\ '?\ ^>C1_P .-_\ @EC_ -&IZ;_X=?X[_P#ST:+\$?R<4_\
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M._\ \]&B_!'\G%/_ ('E7_R(<OC;_P _?"W_ ,$\6?\ RXY[_A_3_P $K_\
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MJZ'_ (<;_P#!+'_HU/3?_#K_ !W_ /GHT?\ #C?_ ()8_P#1J>F_^'7^._\
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M)_'O_P"=E1_P_I_X)7_]')W_ /X9/X]__.RKH?\ AQO_ ,$L?^C4]-_\.O\
M'?\ ^>C1_P .-_\ @EC_ -&IZ;_X=?X[_P#ST:+\$?R<4_\ @>5?_(AR^-O_
M #]\+?\ P3Q9_P#+CGO^']/_  2O_P"CD[__ ,,G\>__ )V5'_#^G_@E?_T<
MG?\ _AD_CW_\[*NA_P"'&_\ P2Q_Z-3TW_PZ_P =_P#YZ-'_  XW_P""6/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJOB#PSXR\.:+I4NM7.JIXKTJUN=!T^UGTZ&2>Q:_O8#>%=D0+D _Q+>/-?\
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M5XIU"SACN+Z'0?#/ARQU+6+^.PBGMC?726HM+1[NSAGG2:\MHY=#]FS]L_\
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MAI?A[6O%%_-KGB&6>/2[*WTC0+.^U"8RBVN99)5@\J&&"1Y'7"AF?"_]K_\
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M/C+PWXH\5^'H3X=@\//J[Z5?Z/X-\0O_ &TEJ=.ANK$64\\=S<6T<M3X/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG^%VG_\ !/7Q9X4^+WQ5T[6_V6O@U^T)X&^)G[0>M?%[0OC%XQ^.7C+P5?\
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M4JZ, RLK AE92"&5@2"""""01BA$2-$CC18XXU5$1%"HB* JHBJ JJJ@!5
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MK*\U.:O&T_<A;^<_1_V7M+^,/C3]JC]C3X<_$71=?O/A]_P3O_9R_9LUCQW
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M?H_X2[]HK_HB?PZ_\/EJ/_SGZ?L)_P U'_PHH?\ RSS_ #[,7]MX/_GQF_\
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M&D7T$B);ZDJEJ_-'X11_M:_ ;3/^"E7P:\*?L6_'OQQ\0_VF/VB/C3KOP?\
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M3=2MTC75[74;VY\01Z/<10>'--O-9?3@8S:5^>W[7GQ,_:$^//[(G[%/P/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5Y=&UG6]$6!=(UOQ%X.74T\&>)-9TU+6V2SU;7_#^I:A EO B7 6&,+])?\
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MAT\)_P#A1Z/_ /)E8'_"E_@[_P!$G^&G_A">%O\ Y54?\*7^#O\ T2?X:?\
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M43EI_P#/JG_Y-Y?WO3^FQNIC(J[SC,;6<OXF&;:2NVDL*V]%?1.^O=GZ/?\
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M5W9-ZI7=MKO<****104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;Q%7VG7Q9\#/^29Z+_V%?&7_ *FWB*NK#_!4_P 5/\JA\KGO_(RRO_L!S?\
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M;\GL>F4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?"WQOK.@:;XST[1[)ETY+S4=(L4&L0:('T_^T].U2YM8;6W;[+;9/C'X#?\
M!/?Q]X&^%_PY\41?"&\\+?!;1O\ A'?A6EC\6;C0?$'@C0&L+33+C1=%\:>'
M_&VE^,X]+U"PL+*VU>QGU^>VUF.TMSJL=XT*,O9Z;X%_8?T6+X*6^B2? _1+
M7]G2_P!9U3X*V6C>-M#TFQ\!:AXATC4=#UV[TVQT_7[:TO)M6T_5M2%^VL0Z
ME]IO;R;59 VJ$7H2IU$DN26RZ2\O[OGI\NX1S'+TU_PHX)I)+_?*+6T%=1]I
MRK9[:NZU5V>!?\%A?"7A75/^"?O[1_B+4_#/A_4?$&D>$?#$&DZ[?Z-IUYK.
MEPR_$CP@)8=.U2XMI+VRBD$\XDCMIXD<32A@?,?/(>)[3XJ:C^W'\,?V8O@S
M\6[K]G#X/3?L?S?M ^,=*^%OP^^&)U7Q+XQTCXJZ)X&A\J[\2^$=;LM-&IZ=
MJ.GP:W=G3KR>YTW1X["T%E/<MJ$'W-\4]4_9@^-G@#Q)\+?BCXT^%OBWP%XO
MM;>R\1^';OXBZ18V^IVUI?VFJ6T4EWI/B'3]1@\J_L;2Y5[6\@DWPJ"Y0LK1
MQWW[+<7Q-LOC''XP^%2?$O3_ (>3?"BR\5CXA:-]L@^'MQK]GXHF\,K:_P#"
M0?V8;1]>T^SU'[0]DVH++"(UNUMWDA=^SG_)+_P%^7EZ?AY!+,<N;368X)>]
M!NV,HIM1;TNJE];K39[/1GY4? ;X]_\ !0/X[^*/"?QM\&:'X^U#X?ZI^T_X
MC\&>+/"FJ>(_V7M+^"&@?!#0?B;K'@/7M(MM+GUFV_: 3XF>%M$T]-8_M*\;
M[1K/B.WGM(O"QTJ]LH3?\0_M8_$:Q_:<^#-_\./CM\>_B3\,OB9^UIJG[//B
MNRUOX&^!O"G[-UII]]-XP\-SZ)\-?',GA^W\<:MXS^''B718(I->EU[7M$\2
MW6D:SOB2U=;2'[BM?@3_ ,$][#XM2?'&PMO@U8_$F;Q2WCJ;5;+XH?9-#F\<
MO*UP_C:7P-;^,8_ <GC"2Z9KN3Q0_AEM=DO&:\>_:Y9I33L_V>O^"=NG^/-/
M^)=E:?!^V\7Z/\07^*VAWD?Q9N1I7A[XB3WMQJ5]XL\.>%CXW/A7P]JFKZC=
M3WVO-HNB6$.OW<AN-:AOY55U/9U/Y)O7K%[:=DN_XW\B?[0P-DO[2P5[IM_7
M:.MG'ISV2EUCJM5;=GY<?#/Q;\:OV5_V//VF/B3X#^-/Q&\>>+_$7[<WC?X$
MZ+IGBJU^#ZZ1X-UOQE^TQ8>$-9^)]N;GPMX0TN/QSK>FZM-(B>,/$5KX M]=
MU/2[AM(L-,7[._O/C/XU_M\? +X,?M!ZIXY7Q5X;TG4/$7[-?@SX(?$CXYZM
M^SUXQ\>^ ]:^-'Q8TSX6?$/6_$%A\"=1D\)ZMX9\'6.O:=XO\-7'B/1]*9;B
MWO\ 3[V75K*!C!]S7'P8_P""?UW??&6^O+3X(7H_:""M\8=+OOB%8WOAOQI<
MB[L]0?4[GPI=>*9?#&E:W<:GIVGZK>:[H.D:5K-]J]A9:M>7T^HVL%S'3\*?
M G_@GQX+\ ?$/X7:-;_!RY\#_%>QT[3?B+H_B?XI-XXF\6:?HR7::)8ZIK7C
M7QEX@UYK70?M]Y)H$$&IPQZ%/<27.D+9W!$H/9U-+0G_ . ORM]E]UU6X+'Y
M>E99E@M(M+_;:-K^\DVG-O7FB]&K-)+3?YQ_9W\%>-OA_P#\%2/BMX7\<_';
M7OC_ *C9?L'_  NFL?%'BW1?!.C>+=$TZ[^/'Q%N!X;\0)X!TCP]H=[/'?/?
M:UIUV=!TR]71M:TZSG6\6UBU"[Z;]I[XY_'7P7\9/$?A[P3\:_BOX.\.V=MH
MSV>@>%_^":/Q<_:)T:T>XTJUGN7MOBOX6\4Z9HFOO<3R/--;VEG&VDRNVF3E
MY[:1S[_\%OA/^P?^SQK]_P"*O@[<?"/P;XHU;PW#X2UGQ&GQ3_MS7M;T"WU5
M]9MK+7-7\3>,=9U#6I;6^<&UU#5+B[U*VLXK;3(+R/3+6VLXOI/_ (7/\'O^
MBK_#7_PNO"__ ,M*/9U-?<GJT](R[+R_X=/S+699>HV_M# 7NW_O=*6CE=:^
MUC*]FNO6RZ'@O[0GQQ^('P>_9!O?BMX/\*^,/BG\4IO _A&T\.:?HWPL\7C6
M+SQEXOMM+TR'Q7XA^%NC6FN>+_#FC:'>:C+XH\5>&%M[_5]"L+&\T1S/?Q*7
M_-S_ ():ZS\,_"?[5O[6GPT\%6?Q@O+[6? 7[/7B77/%OQ)^#WQ0\!ZMXN\<
M1:%XSU/XF>,_&<OC/PKHG]@ZSXR\7^(KW6M(LM9^POK%G+,GAR&[T[29/L_[
M._\ "Y_@]_T5?X:_^%UX7_\ EI7":'K7[,OAOQWXY^)FB>-_A;8>.?B5:^%;
M+QQX@3XB:/+<:_:^";*]T[PM#/:S^()=/M5TFRU"\@B;3[2T>=9RUVUQ(L;H
M_9S_ ))_^ O_ "\U]XGF&7.4)?VC@?==[/%4&_AE%V?M?M<\;WOLM=6G]"UX
M[KLOC2+X[_#9_ =EX7O]=_X5M\5!Y'B[5-5TC2/L)\0?"O[5)]KT;2-;O/M:
M#9]GA^Q"&0E_,GBP"VL_QI^#Z(SCXI_#R7:"?+MO&7AZ[N'Q_#%;6NH37$SG
MM'%$[L>%4FM[X2:=J7CCX@7'Q8N-+U'1O"VC>&;OPEX$75["?3=2\0QZ]>Z;
MJGB'Q)]ANMEU::1*VCZ19:/]J@@N+U(+J\,26\ENT@[TX5)3BXITYQ7,K<TI
MQ<4DG:^KN[;13?0TA6H9AB<#AL%7I8FK_:& Q,UAZD*WLJ&#Q='&5JM5TW-4
MH>SHN$)3M&=:=*DFY3BG[--<?%0:IKBP:3\/VT5/#LLGAJ:;Q!XC35+GQ;]F
M@,-GKEJGAE[2Q\.F[-RDNI6%WJ&IK;+!(FE-*\D4?'>)M(^-OB;2_ NG17'@
M7PM,GBOP=K_Q"U+1/$?BJ:Z@TWPGX]T'Q1>>'_"BMX=T\ZO9>+] T:Z\,:V=
M:FT6.*TUJ]3[/J%NK07'N-%><I6^S'37;_@_UON?H3A=-.4K--/5;/SM==M&
MGOUU"BBBI+"BBB@ HHHH **** "BOC/]IW]JC4_V?OBW^QQ\-+#P=8>)K;]J
M3XXWOPCU/5KO5[C39_"%I:>#M7\3C6K"UAL;N/5KEYM.CM#9W$UE$(I'D$Y<
M*M<5\5/V[O#7P6_:_P!>^ /Q*L-%\*_"GPC^QI>?M9^+OC#?ZEJ<T^@VNG_%
M+5/A]>Z+<>'=/TF\>;38+/3EU9M0MIYKUII3:II[*HD9I-[+I?Y;&4JU.%^:
M5N6<:;;3LI2BI)-VM;EDFY7LM;M6/T!HKY:^#'[:O[+_ .T'XEL_"'PB^+.E
M>*_$6J^$KOQ]X=T^31/%GAP>,O NGZ[-X9U'QGX!O/%>@:'8?$#PIIWB&"71
MM0\0^"KK7M(L=15;:[O(9'C5O-[K]O3P#8?MQWO[$=YX'^)":]:?!?0/BO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK\*/^"PDNE^+/C?_ ,$S/@9\6]:NM'_9:^+_ .TOJUI\;+*;4KG1?"GC75/#
MOA^SO_AUX$\<ZDMS;V,WAW7]<N+J&71=180:DX,B,)K**2']UZ\B^-WP#^#/
M[27@2[^&7QV^&_A;XH^!;R\M=1?P]XKTY;VVMM4L?,^Q:MIEPC17^CZO9B:9
M;35M*N[+4;9)IXX;E$FE5VG9_P!75^J\S'$4W5I2IQY;MP=I7Y9*,XR<)6UY
M9J+A+1^[)W36C_G9_P""G/P>_8X_9<^&E_X0_9C\1^'?@-I?Q[_:J_9+^&W[
M<O@7X(>/DT+3O /[-_BG6_&D?B+Q/>?#3P]K=OIGPNT_Q*T%MH^H:O!I6AZ5
MKUJJZ/(&BGN%D[G]K/X ?LL_LD?M5_\ !*7Q%^P[X>\&?"'XP^/OVIOAW\-/
M%'ACX+3V=C_PM;]EW7M,O?\ A9GB3X@Z-H=SGQAIVEZ=;6%V_CS74U"ZFGOI
MKV]U&^N8K>XL_P!A?AY_P3Y_8I^%?P_^('PM\$?LU_"[3O OQ6M4LOB5HFI:
M$?%#^.+.$,+.T\3:OXJGUO6]6MM-=VN-)@N]2DCTB[)O=+6TN_WU1_ ?_@GO
M^Q?^S+XND\?_  ._9Z\">!?&[:?<:3!XLBCU?7_$&F:7=E/M6FZ%JOBG5-<O
M/#UC<JBQSVFARZ?!-"#!)&T+-&:YM+:];^=TM'KJDT_/;Y<;P<W-R4,/!/V/
M+R7O0]E5E4E['W(_Q+J^M-<UVU):'\Z7[./[%/[-?QW^#W_!;CXP_%SX:Z9X
M[^(?A#]I/]M'3? 7B#7YKF]F^'4GA/1KSQOINM> (9)#!X4\2S^(%M9M3\1:
M3'!JVHV5A9Z7<71TY9K:9/A;KMM^U%KO_!";X,_MB^)M0\4_L\_$+]E/XG^.
M]1\/^-M=OK;P5\:OCKX*M7TCPEX?^(5W>ZG;V?C&?P[X?L=*O='T/59+R2ZO
M=2-C+!>1>(IK>3^H#P;^S'\!OA_X:^+_ (/\'?#71-"\-_'SQ+XU\8?&#2K:
M;5)8/'?B3XBV/]F>--4U:2ZU"XN(I->L2;:Y@T^:RM849C9P6S,S'@_%7["?
M[(?CCX(^!OV<?%WP$\">(?@Q\,H+6W^'?@S5+6^N5\$+9EC#+X6\0-?_ /"4
MZ)=D,T<]]I^MP7MW"[074\T+-&3FU>]GMY:-::Z:OH0LOE&$(Q]DFHKVJLU&
MNXXFG62J6C[T90C.#E)2:YW[LHMI_AGXF\!_"S]GC_@HO^V+\%OV1(=*\'_!
M;Q;_ ,$NOC%X]_:#^$'PYDA@^%O@;XQ:6-7TCP7=Q>%=(F7P]X*\0ZCX6F-Q
M_9EK86,I@U.ZN(HEBU.9!Q/[&_[ '['U[_P0RU+X_:Y^SY\.O'/QO\2?L:_M
M#>.)_B1XY\-V'C3Q9;>)+#PIXXC\.2:+>:]!?#28?"A\,: _@^VTZ&#_ (1R
M]TZ+4=)-OJDMQ>3?T*?![]BO]E;X >"O'/P^^#OP0\%>!/"WQ-L+O3/B';:5
M;7LVJ^-=/O=/N]*GL_$WB;4KV]\3ZQ;KIU_>VMK'>ZQ,+&.[N38_9WGD9O3_
M (=?!3X5?";X3Z'\"_A]X'T7P[\(O#?AVZ\)Z/X"CCGU'0K;PW??:_MVCS1:
MO/J$]_97HOKP7D>H3W1NEN9EG:19&!.;M?[-_.U[WM;OIY;LN& 7-S5(T7%P
MQ*5-1YH4G6G2<534HI62IMR=HOFF^5).R_G&^$/["7PF_:'_ ."-'[*'A'X&
M7?[./P1^,WQ'\-?L[^._'FJ:II>C>#M,_:2USP<NMWLGPJ^.^M^!(M/\<>,=
M(\5W<6M/>Q7#:YJZZEHMQ<06<EQ9W4D'W]_P2Q\>? R'QO\ M8_ 'P9^RAX*
M_9(^/'P>\6^"4_:"\&_"+6[/Q%\%/$VI:GHM]'X6\3_#J]THV&F:99SV-O?"
M\T'_ (1?PYJ=BTT!U:*\U%KHVGOUK_P2<_X)U67A3Q%X'M?V4_AS!X6\4>(M
M(\6:II*3>*/+A\0Z!!K]KHFIZ%<GQ ;WPM+I5KXJ\1VUA%X8N='M[:WUG4((
MH5BN&2OI']GW]EG]GK]E;PYJWA3]GOX4>%?A=HVOZG_;7B!= M[F;4_$&J+"
MMO'>Z]K^JW6HZ]K<UO ODVAU34[M;2-Y4M5A664..2:>^KO\]//5:;._E;5N
MJ&$G2G0ERT(.E2C2FX7ES1A":7(I4HNFW.7-*49JZO&49Z27OU%%%0>@%%%%
M !1110 4444 %%%% !1110 5S_B+Q9X6\(68U'Q9XDT'PS8,VQ;W7]7L-'M&
M<8RBW&H7%O$S#<N5#DC(R.1705\,?#O3[+XEV\?QE\7VL&NZYXQ>XU/P];ZF
MGV_3_!_A>29[?0])\/65X9[?3)9]+@M;S6KNU1+C4=3N+EYI6B6)%VHTE4YI
M2;4(63Y;.3<K\J5]%I%MMWM;9MGBYMF=7 RPV'PU*G5Q>+C7J0=:4HT:5##.
MC&O6FH)SJRC/$T(0HQ=-S=1MU:<8-GT-_P -#? /_HMGPF_\.)X2_P#EO1_P
MT-\ _P#HMGPF_P##B>$O_EO7)_V%HG_0&TK_ ,%UI_\ &:/["T3_ * VE?\
M@NM/_C-;^QH=JO\ X'#R_P"G?K^'F>1_:N=_\_,J_P#"+%^7_4Q]?P\SK/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*IA<5-S2JQ2=7VE-N=3]W:K5FGR*/+-\LJ:2D[1<-'HF_P WOBY^T%_P4T^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUR;0IM?\,PS3P:EX1T>)))M9M$6&:>/<&E5E^BOV8?%5_P"-?A-I7B:^^/\
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MCU5--\5V>FZ_:%+>Q%C/*;B2V\]^'_[!'[=]Y^S1_P $L?@;XK_9R@\'ZO\
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M[&OQ#L/$/QJ_9J\,>"]6U+PG\2?A?\2O!.K>&I/&/C3PUH>G:AKG@#XG^&O
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MX;_$C4F\-IHNL:[H1^#]IXP^,]SK%AI7AZ^LI/$>A6UQ:P7G["?LE?!?PO\
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MTGC(>*XMII(I%.58T I1DVHRC)J]TFFU9V=[/2ST?GH;=%%%!04444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"C-?_ LI_P#GJ?6U%?)/E?'G_HM>D_\ AJ=%_P#E]1Y7QY_Z+7I/_AJ=%_\
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M'COQ[XYU_P -ZKKGB6QOH8HA>Z,8?L.D>&IF3S/^$9TK1TE:299)7L_LL?\
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M.]T35(S&3)$RPWEO.R*?-AD5D($B$5^67P3@^"O_  3/^)7QW_9X_P""O_\
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M3/AE;_$G76O;6UG91_PDWB/6;.RU:]MS:W^H>&]%T[37N+=4&S1_:^_X(_\
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MOJ#QBU5/K/XS?#WPU^UQ_P ''WP[_9P_:)TNS^)_PJ_9^_9[\.O8>!?%-O\
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M/J'PA\&_%5H=-T>S$6GVVG6'BI=2ET6QBMDATBTU22PL1#;IM?UC_@A!?/\
M!W]OK_@KE^R'IV8_!GA/XQR^-O">EQ2R'3]!?1?'WC;PIJT-A;HJ6L*ZCIVL
M^%K:39'&XA\/6<0\Q(\I[9_P3+_8=_;)\2_MV_'+_@J%^WWX3\,_"CXI_$+P
MO'X&^'GP=\.:I9:S+X=TO^R- \-R:A?W&GZIKEGI]CIGA7PSIVAZ9:G5[S4]
M5N[W5-5U 6*I E]XA_P06LI/C-^W9_P5J_;$L6,W@[QI\8Y/!?A#58HG6PU_
M^VO'?C7Q=J\]E*NV!UL--TOPE<L K/Y6OVS@QAF#R]IJZ=HP3?FFMN]M4WUL
M=.'IRIUL#:$J2J9AF%6E3E%P<,+.A4=G!I."<^22@TN64HII/0_JAHHHK(^A
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y[Q:[1^%/$TB,5>/P]K3HP."K)IMRRL#V((!!]17S!\&T
M5/A'\+PH W_#WP;*^ !NEG\/:=--(V.KR2R/([=6=F8\DU].^,?^11\4_P#8
MN:Y_Z;+JOF3X/?\ )(_A;_V3GP1_ZC.F5UX?^'/_ !P_])F?(YY_R-\!_P!B
MW'_^I67GHU%%%:G*5+^Y^Q6-[>;/,^R6EQ<^7G;O\B%Y=F[!QNV8S@XSG!K\
M$/ 7_!6+]J74/V;;K]M[QC^RU\+M3_95T#Q[KOA/QNOPU^*WBK4/C?X.T#P_
MXM/A34_&USX.\2> M*\(:KI-C<-%<26FG>-C>212J\ZZ=;+<7-M^]6K027.E
M:E;0KOFN-/O((ER!NDEMY(XUR2 ,LP&20!G).*_E\^#WP)_;QB_X)W>,_P#@
MG)IO[(OC?P5XR^*GCGX@Z9XH^.?Q$\6?"VS^$'A/X<^/?'CZQJNMV":!XX\1
M^.->UE-!+VT.EQ^$;,K)<O<6]Q<2P10RG];_ -?UZF51R37+S)<E5OEAS7FI
M4?9I^[+E33GUC?7733]C?@[^W&GQC_;9^(W[,.@>%]+D\!>%_P!FGX6?M"^%
MOB3!JMU)J7B6T^)DNDRVEC-HKVBVMG9)INM6EU;W$=Y+.[HZRQ@2+Y?BW[9'
M[?G[1'[%OBWP)XM^(W[._P .]1_9K\=?&_1/@MINN^'_ (N:CJ/QJ=M>^T-I
MOC-O!#^"K/PE;Z9>P6=]<6NB1^,K_65:W2WU(:9YZW"?.W@_X3_'S]C+_@H1
MXT^*'AS]E[XW?M"_!N\_8O\ @!^SSX6\5?"B[^$:WLVN?#2S\.V.H76L6'Q
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M>,*XH[O_  S_ /2)'VM3X5_CI_\ IR)[]1114EA1110 4444 %%%% !1110
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MG_PBP?\ \AY?GW9_*I_P_/\ V[_^C$+3_P )CXQ__(M'_#\_]N__ *,0M/\
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M_/"H_P"(GO\ 9#_Z('^TA_X"?#'_ .>%7[D_\,<_LB?]&K_LX?\ AC_AE_\
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M_P" GPQ_^>%1_P 1/?[(?_1 _P!I#_P$^&/_ ,\*OW)_X8Y_9$_Z-7_9P_\
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M^C5_V</_  Q_PR_^9>C_ (8Y_9$_Z-7_ &</_#'_  R_^9>A8_A%?\R',/\
MPZR\K_\ +OKK]_GI$^'_ !3J1Y:G'7#\XWC*TN$8M<T)1E%_\C#>,H\R>Z:3
M5M+?AM_Q$]_LA_\ 1 _VD/\ P$^&/_SPJ/\ B)[_ &0_^B!_M(?^ GPQ_P#G
MA5^Y/_#'/[(G_1J_[.'_ (8_X9?_ #+T?\,<_LB?]&K_ +.'_AC_ (9?_,O1
M]?X1_P"A#F'_ (=9>7_3OU_K:_[#\5O^B\R#_P 1*/E_U,/7^MOPV_XB>_V0
M_P#H@?[2'_@)\,?_ )X5'_$3W^R'_P!$#_:0_P# 3X8__/"K]R?^&.?V1/\
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M$.8?^'67E_T[]?ZVO^P_%;_HO,@_\1*/E_U,/7^MOPV_XB>_V0_^B!_M(?\
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M&?QBL?AH]\+C0-$\5>+-3T2\NK^"/RT\V_B@U&:Q-Z=LDUN%#*J[4653H/\
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MQ5.%50:A*K"<Z<*<)1I0****YSZ4**** "BBB@ HHHH **** "BBB@ HHHH
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M^EPZKX8TO6 \QO[_ %+Q);ZIX::P73A(JQ>([&Y<-!#=O#^(G_!*7X,_!/\
M:1_X)I?M\_LE_&#PSK>G_M!0_%+XJV?[74WB/6;C7/%&I_%:&6[USP7\4+%[
MA+9+$VNM^'GGLK6#>DNN>']7N;B]N[;55)]T_P"#9GX5Z':?L8>-?VC]3NM1
M\1?%OXY?$[4_#?C'Q9K<[WFI/X5^#<*>$? GAVVN)F>1-.TJTGU&=44IO:[B
M@D#PZ?9").*2D^SMO>[=FMM+)*75WT^6^'Q.+JU,)%SIRCB*/MYR4.5TU0?)
M7I.+VG.=6@G?6#59*UHGZC?MT?\ !1;X+?L(6/P\TSQKHOCCXE_%CXPZQ+H7
MPD^"?PLT8:_\0/'-[;36EO>3VEH\L%M8Z;:7%_96KW=S*9;F[NHK;3[2\D2Y
M^S^$_LR_\%=?A_\ &O\ :(TW]D_XS?L^_'C]C_X_>*-"G\2?#_P3\>/#]OIT
M/CW3+6"XNITT'5[)_*^WFVLK^>UM[FVBMKW^S[ZUMKV348!9/\(?\%0?&FF_
MLH_\%A_^"=?[;WQJT;5D_9BT#X4?$#X0^(?'EII&IZYI7@/QSJ\'Q/MK?5-5
MM].M[IK-HX/'^@:G _D275[8:/K$VGPSW.CCRO-?C7\=OAA_P4W_ ."O/_!.
M2;]BW6;SXH^$_P!E&?Q9\2_C7\9=!T'6K#PAH.A7-]I&H6WAHZYJVGZ6]U-=
M_P!B-IZP@FVN+WQ'#9V0NKA-32W%%-7MIRRES7ZKIM;RU5]=W97JKC*T:]2,
M:D%*GB\/0AA7%.=:C5]ASUDVU.Z52I*+@O9Q5)\]_>:^B=;_ .#A?P%H%]\7
M==NOV+?VG-2^"/P,^+^K_!WXE_';P]#X8UKP7X:U[2];;2$EU".*ZA>UDOXV
MMKZSTZYNX9Y(KRV@$AFE0-^@?[57_!2_X2_LO^'OV/?%UQX2\6?$7PS^V;X_
M\%^#/AYJGAQ[#2O[)T[QSIFC:QI'BG6;376MKHVAT_7M/G;38XDOQOECD$4D
M>QOXB=5L_@7JGPH_X*:Z?\0OVW_B7\'_ (F:;^UC\6/$WPS_ &0]'2_\0?#3
M]H37]!UI[WPY/XM\#6VG/;7]_J/B"$>&!KE_J:6NCVEG'>7.FWD%H\4WZB_M
MD_M(P?M1:%_P1)_9]O=.M=!_:Z\%_&K]GW6_BW\#=%\(Z_X?D\#Z;XA\+?#R
M^\.:M#I5QI4&GZ;H=_X=NM-U26PTVYN+?PR6U#2+A;8Z+<QPTX*ZLN]]]N5-
M=>FNNBZ=&<=',L1*%;GJ4W.U)TM*;?/+$RI2IV@]&X)<M.<?:.TIIM;?L]\5
M?^"Q^J>$_P!JCXW_ +*/P>_84_:7_:7\9_ 270U\;:K\(SX<U"SM[;7M,L;^
MSOWT^5WO[.R>:\:PCFNE7SKBWD*JH917J/[1?_!6;X?_ +.Z? 7P%>? 3XZ_
M$3]JC]H#P3IOCC0/V2_A_P"'[76/BMX4T^[LA=7UOXW<3#3M'GTR:+4[)TA^
MV7$LVCZE.UM;V-M)=+_/'\2=4^"ND_\ !93_ (*1/\:O^"@WQG_X)^:=,_PZ
M70_%?P:\8WG@[4?B)>C0=$:Y\/ZU/9Z%KCWMCI%N4U*UB:.W2*>X=P[E@H^M
MO&WQY^%G[(/_  6G\!?MF_'#Q-J.H_LF_M.?L:^#?"?P6_:<O=,UOQ!X:%]I
MOA/PU#<:AJNHZ?ILD]G>ZY)H[W.J^3IXDAC\:V.IW=K;6EW>3V\\JTW?NIV5
MTV[1>^J:;?37IYFZQM:U6]:,;8QX=SE[%QH4O;U*:J.$6JD7RPC#FKM0YIJ:
M4HZ/]#O$_P#P64\0:/\ "BY^)>B?\$[_ -LS7[WP/J/Q#T[X_>#+GPKIGA[6
M/@$/ /ASPIXO35_&EUJ,CV=QX=\2^%_$MSK.BZS:^5";;PYKC7$4:PPO+@?"
M7_@MO/\ $[X#_$G]IR]_80_:9\$? 3P)\'_%/Q9TCXJ^()_"K>"O'O\ PC'B
M73O"TOA+PSK<4Z6TFMWNI7.I+%(QD@A_L'5$F >( _2_Q._;%_9S_;'_ &"/
MV]?$W[-_Q%MOB;X;\#?L]_'[PGK^OZ=HOB+2])76Y_@CXEU=+?3;O7M)TM-7
MB%E=P/)=Z:+FUCE9H'E69&0?E+\)P?\ B%=O!@Y_X9L^+1QCM_POGQH<_3'.
M?3GI226EUKS)-.^S^?W?KN;3JUXU?<Q2J4_J=?$*4:=)PE*C*E!+F2EI+GE*
M5I?$O=Y8^Z?I[\(O^"LOPR^*'[0/[*?P#U#X5^.O EU^V'^S)X>_:4^$?C/7
M]3T"X\.WEKKNAWVN2> ;I+*=KI?$VFPZ3JEM/*@-M-<P6BPIY>I6;OUOQG_X
M*<?#CX1_M)?&S]FZT^'/C+QYK7[/7[(?C+]KOXL>*?#NH:';Z%X6\/\ A2RN
M]0MO MS#J-Q#>2>*M?M?[!FL&B5[2*/Q+ITL_P"ZM]1DM/PV_:H\#ZQ\._\
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M#75-,L-0%H)]2T#5H;L+%Y=K>Z7;17;P&]M?/\O^'7BS2OVS_P#@HG_P4_\
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MYV/<PU257#4*LG&4JE&G.3A=0<I03ERJ7O)7;LGJMFKA1112-PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\Y\8?%WX8^ +J.
MQ\9^.?#GAZ^FC6:.QU#484O3"S%4F:TC,EPD3LK!)'B5'*L%8[3AQC*3M&+D
M^T4V_N5V8U\3A\+3=;%5Z.&I)I.K7JPHTTV[).=248IMZ)-ZO8]&HKP;_AJ#
M]G[_ **OX2_\#9?_ (Q1_P -0?L_?]%7\)?^!LO_ ,8K3V-;_GU5_P#!<O\
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M*? ZS6MR()YK>;RI%CN;>1X+F.:([*U/#^I_L\^%=.\=Z1X?^'NO:9I/Q/\
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MU@6_OTL+3P'';0RW*VUNCB&..,)#&J(JJ!7?_P#"[? W_/M\0_\ PSGQ>_\
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MG^T/\0-0^&=AX4N?B9XF\<_'2QN=4T'PII6N>._#OC/1=#\&^&M(M9;B]=-
MNM7U34)4MGNHH$#IX9\?/VI_VDO@7\$?V]/@UK?QJUW5OB%^S'X\_9VG\!_M
M 6^@>&+3QY??"3XYZQX8NH[3Q-IUAH$GA>]\;>';!M;TZYUG3/"MK;:M#>6\
ML6C6]Q!LEKV;NXW2DK7B[W5[+5VMU6S?X'++-</&F\0J566&Y:WL\1'V2A4E
M0I5*TZ<%*I&I&\:-51E4C"FY4W>23C*7[6^'/V??@+X.UJQ\2>$?@C\(?"OB
M+2WEDTS7_#GPU\&:'K6G23P2VLSV.JZ9HMK?6CS6T\]O*UO/&TD$TL+DQR.I
M]>K\EOV!?C9XO^)GQ\^/_A7P3\<_B5^TM^S!X'\(>!DTOXH?&/PMI'AGQMH7
MQOU#4-6?Q3X TV32_ WPVGUOP_;>%%T;6KB?5/"%E/I>HW<5C;WE\CSR+]E?
MMI?'K4?V8?V6/C;\>-&TJUUS7?AWX+N-2\/:5?>9_9][XDU&]LM!\.QZCY4L
M$ITU=;U:PDU 1312&S2<1R(Y#"7%J2CU=EVUDEWM;?K;S.FCC*,\)/%J+IT:
M:KRG\$K1P[G&I.+I2G"I%JFW&4)24HVMKH?3]%?C9\=(/VKOV,_@IX<_:Q\0
M?M:>.?C-K/A+Q3\*S\=/A)XJ\,_#JS^$7B?P[\2/'?A;P%XCL?AC9>'?!/A_
MQCX/O?#5QXNAU+PS=ZGXLUD7<6E;-5@=KEH:J2?&OXD6O[<'C[P%^T%^TM\4
M/V8ROQ:\,V?[+_@>;P/X+M_V;_CI\*8],T5[C2CXZ\2^$[Z[\0_$GQ1J,NK:
M=JNFVWQ \-:KX?UB>QM]#TJ_"0V4C4&[M--6;NE+I:ZMRW^TNEO/>V,LRA3G
M&G5H5J524Z,>6I+#I*.(59TIRJ*NZ24I4*M-1<_:.I%14'SQ;_7'QAX \"?$
M*PBTKQ_X*\)>.-+@F^T0:;XP\-Z-XFL(9\;?/BL]:LKVWCFV_+YB1A\<;L5<
MTKPEX4T+P^/">B>&?#VC^%5M;BQ7PUI6BZ;I_A];*Z5TNK,:-:6T.G"UN4DD
M2XMQ;>3,LCK(C!F!Z&OR;^%EU^T7^VIKW[0/Q2\.?M,^./V?_!7PV^-_Q(^"
M/P,\$_#SPUX U+0]5/PBU4^'M3\=_%^'QGX8\0ZYXH'B?Q3#??\ %,Z'K7@U
M++PY;0017T5_=&[MTE>[;22M=N_7HDDVWN[>3.JM75&=.$:4ZU6KS\L*?LU+
MDII.<Y2J3IP48\T(ZRNY3BDG=M?I-)\*?A=+X-3X=2_#;P#)\/HV#Q^!)/!W
MAU_!J.MR;U73PPVG'1%87C-=AEL01<L9P?-)>M33/ G@C1->O?%6C>#?"ND>
M)]1TNPT34/$>F>'M(L->O]%TN*"#3-(O=8M;.+4+K2].AM;:&PT^>XDM+.*V
M@CMX8TAC"_SG?M3_ +8OQ'^&OQ@_;NLM:_;1^(/PP^(OP'T[X02?LY?";P]X
M:\&S_"[X@^*]6^'%EK&MZ;XSMM<^'VO7=EX;USQ6;:&_O[[XA>&8]!TW5;J^
MDOYXK$BO2/VN?VN?$'A#]HJXT3XC_M:_%3]G'P9:?L)_#[XQ^&K#X&Z!X9\;
MZ+XB^-/B'Q5XFL9X;JXOOAM\0(M3\/7T-K9VMB[ZKX:TW4((K;R-<@>Y\QK]
MD]-5K?N[?#Y7?Q+RWUT=O-EG.%BZR=*:="JJ4N:>%@KJIB:5W.5=0II2PM2R
MJRA)QE3<8OFT_>SPOX(\&>"(=1MO!?A'PQX1M]7U*XUG5H/"^@:5H$.J:O=X
M^U:KJ,6E6EHE[J5SM7[1?7*RW4V!YDK8%=/7S]^REXB^+GB[]F[X*>)_CSIU
MMI/Q@U[X>>'=4\?V%K;Q6<<6O7=DDLLDEE;L]O97=U T%U?65N1;V=[/<6T"
MI%$B+\,?M\_%SXE_#?XX?"&S\5_%WXQ?LX?LBZGX \33>*OCK\&?!7A_Q-_8
MOQF_MVRM?#FC?%C7O$7@KQ_9^"? !T!_MFFWS:'96^L:M+J%G>ZO!%:QM!"B
MW+END]?2Z[6WOY'?5Q=.AA8XJ5.HJ<E2?):-.<%6<4O:>TE"%)0<U[1SG&,+
M.[T/UHHKX%^+/[4_CWX$?##PIXK\+_#'5/VJO!^C_"6V^(7C/XY:!\0/A7\/
MO#?B31].T^ZN+N_\&:==:M>'QEXNU;3-*N_$R^&_#EG:Z,;&]TV/3M<FGO1:
M6WQ#\2OVF_B+\1OVV?@OXEMK?XI>'?V4/"_[(\/[6DD_@WX]+\.;#5O!\/B'
M0?$&K?$OXC>#]$B$GC;3/#VDPW7@^\^%&LW]]:ZM%)?:K!,L%QD-0;]->U]/
M*][^MNV^AG6S"C1M&TY5'.C'DY*B2C6FH^TYU"4)4X:\]2#E!-).2NF?NQ17
MY"^#/^"K.B_$VXM/#GA+X8Z.GBSXF?"SQ_X_^ NG6/QV^$WB_5=>O_!_AP^)
MX/"OQ5T'PQ?ZK??!GQ/J&AO_ &K;:?KL>NV"R66HZ/=ZC#JMJ]JUO]EW]O?X
MOZQ\%?V.O%W[27PACT5?VF/&&C?#*P^*VC^-?#=UH]YXC\0^&M:UGPIX@U3P
MEI&B6G_",6GBW6M%F\(V6D2W:2VNKSZ>_F3+?QQ*<DET5[VM=7_K04,SP4Y1
MC"K*2E%OG5*K[.-I4(I3FX)0<GB*37-9<LE)M1:;_6^BOGSX!?'ZP^/\GQ@O
M= \,WVD^%OAA\8_%OP=TGQ-=ZA!=V_CW4? B6%GXJU[1[:&WB-GI&G^);C4?
M#4327%V;F^T74&,D+Q/;Q?0=2TT[/1]CMIU(58*I3?-"5W&5FDTFU=72NG;1
M[25FFTTV4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH \Y^+OB^Z\
M _#'QQXQL8XY;_0/#NH7U@DREH?MXB\FR:9%(9XH[J6)Y45E+HK*&4G(\3\"
M^!=,\&Z:N$&H>(]0"WGB?Q/>*LVL^(-9F4/>W]]>N&F8/,SBVME=;:SMQ%;6
MT4<,:*.Y_:?_ .2 ?%/_ +%B;_TJM:6NVAI1NM.:I)2\U"--Q3\DY-V[Z]$?
M'9O^]SI1J)3CA<MPM7#J2NJ53%XG'PQ%2*>TZD,)0AS?$HQ<8M*<U(HHHJS
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M]G#0?V;/BAX!\&V'C'X,WOQ!\9>!OB1XG^(%AXCC?QA\,?#7AVZ/A3_A(?!
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MIZ;_ -!&Q_\  NW_ /CE(VJZ6JEFU*P55!+,UY;A5 Y)),@  '))X%.S[/\
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M**7/+NN^B2[]EYL<<OPL7=0FY6:YIUJM2;3EAY:RG.4G9X6A:[=E"RTE)/\
M'B3_ ()P_'2VT+PQ\&M'_:.\'VG[-OP\_:8T;]HKP/X4N/A;?3_$N2*Q^*:?
M$M_AYXI\<?\ "7_V-?>'M+NKO5X]%O\ 2?">E:S+=OITFJWMQ96TUE-E>*/^
M"7'C+Q-\6[KQW??$7X/:K;?\-5:#^TI:>/?$GP>U'Q!^T1_9>D^,++Q)#\(O
M^%K:EXSN8M(\":-8P2:+H-CX>T+38A:6^FQ7L#Q07"W/[.44U4DNWW+7;?[E
M]VID\IP,E:5*<DN5)2KUY*,87Y(Q3J/EA!2:C&-HI.R1\E?L[?LOVWP9\-?M
M$^%/%.L:9X]T7X^_'WXM_%^^T]](DLK.T\/_ !2L-#TVX\':E!/=W@U(P6FE
M3PWEXAMX;N.\*+:Q!"7^6/\ @D=^SAXM^!_P'\4^+?B-:^-++QO\5/%YMM,T
MWXD:/>:!X]\._!?X26\OPQ^!?AGQ1HNH0PWNDZA:^"=%'B"73YU5XY?$TUQ/
M''>W5X#^KE%+F=I+^9IOY?AV^XV6"H1JX:K%-/"0KPI1NVDZ[AS2;;NW&,9Q
MC>Z2JSM8_,+XB?L1?')_%/[35C\#OCWX,^'GPC_;!OY-9^+_ (>\4_##4/%G
MC;PMKVM>$-/\!^.-8^%'B;3_ !EX>TK3+GQ;X:TVW:2/Q5H/B*'2M9,FHV*J
MS,C<]J_[ OQN\ ?%3Q#X]_9=^.W@/X>Z%KO[-OPR_9E'A;XE?#+5/B ;+PK\
M.],U?2[/Q3;:EI'C#PC,OBVQBOK:XTAI4GT*28WR:SH]_"]JMO\ J]134Y+M
MM;5+RM?35JRLW>Q+RW"-N7+44O:2J1<<17@Z<I.HY^R<:B=*,W5J.<:?+&3E
MJG:-OP^^'G[&NGW/QQUO]F2'PG\6K;X">!O^"8WBW]CGQ9\8/$'@^_\ "NE^
M+_%WQ(^(6AZUK-]X'US4K*+1_$^H7^E3:]XAOKKP_'?Z/H^I.=-N9%D5(7^D
MOAS^Q5\6?^$%\1?!WXX>/_@-XF^%^J?!GQ+\&O[1^%_P"_X0#XK>)+'7=#B\
M,0^)O&GC34_&7B>PEUFVTA9[B]M_#N@:/I^K:Q</=7<7V=4M5_2^BCGEM?K?
MH]=V]=FWVMLNQ-/+<-3;;BV]8V4IPC[*RC"C*$9\M2$(JR]ISZRFU;G:/S<T
M#]DG]I#Q!^S[X\_9?^.'QZ^&WBOX5ZI^S]J7P(\&7O@;X2ZQX5\;1;]+LO#^
MA^-?'&K:MX]\1:;J^JZ7H-C]DN-,\.Z7X;TW4KJ\N;V<+(ENL71>#_V4?B]<
M_$S]C?XK?%[XG?#_ ,1>)/V6? WQ^\!:A!X%\"Z_X8TOQMIGQ:\/?#3PUX>O
M([?6_&'B>?3-2T*S\ 376O2FYEM-7N]44:=8Z3!;F.3] :*7,_);[)+=<KMI
MI=;V]=TC18##>[>-27(J*3G7K3;6'KPQ%#F<JC<O95H*4.:]DYQ^&<HO\C?A
M1_P2G\->#?"O[6O@'QG\2+WQ1X0^/7AK6_A9\*8--TI=,U'X%_!?4_%GC;XA
M6O@S2)KJYOK;49K/QSXXN]7>06]KIUQ;:/HUA]BCMX&2O9/A-^S1^T[X)\/:
MWHNO_%7]FF"_L?AA?>!? WBGX?\ [,2:#X@NM?9-,@T[Q?\ $J76_'FO6GB&
M(V>FRV^M>&M M?#FEZO)JM]=.\3P:?':_H=13YY.]W>^]TM=$NVFB2=K7%3R
M_"4>3V4)T_9QE&/)6K1O&4YU+2:J)R4)3FZ:E=4U)QI\L;)?"G[&_P"R5XE_
M9QU_XV>,_%?B3X<OJ_QHUWPSJ]SX!^!OP_U#X4_!7PK-X:T>32Y]:T#P-J'B
M?Q7)!XL\733M?>+M934(4U*6UL1]FW0M(W6_ _\ 94TWX4_&?]IKXP:U=^&_
M%>I_'?XJZ1\1/#LC^&((=9\#6>F>"=#\*2:.NLW<MY<7$D]SI,NH?:+'[!$J
M3K&8&D5I&^OJ*3DVV[ZM)/IM9JUMMD:4\'AZ4:,(0:CAZDZM).4I<M2HJBG)
MN3;DVJM325TN:Z2:C;Y:^&G[.]]X!_:A_::_:%G\3VFI6/Q_TCX,:98^&8M-
MFMKOPTWPK\*WWARZENM2>[EAU)=9DNUNH%AM;4V:(T4AG8AQX)\5_P!DG]HK
MX_>+/">@?&7XY?"W6/@1X(^-F@?&70[#PU\&;W0OC1-_PAOB!O$GA'P?=>.;
MCQQJ7A.PTZQNH[+3M5UO1/ ]AK>LZ1:O!<3I)=W<DOZ044<S3OI>R6R=K))6
MNG9Z;K44\'0G3=*49^S=2I5E!5:L8SE5J2JU%449KGA*<I-TY7@DVE%*R/G/
M]FB\^/FL^$_&/B?]H"&WT75O%'Q/\=:O\/O WV+1H-7^'OPF&L26'@/PSXGO
MM!:33]7\12:79?VYJ%XEU?2PKK$%A<7T]Q:3"/X<T;]A3]J?0/#'Q[^"WAW]
MI'X7^$_@7^T#\7/BY\0_%&HZ+\)/$MU\<=*T#XPZFT_B7POX>\6:C\16\%:=
M=2:2SZ3;Z[+X(O+JQ\^>]M4^TB!H?UOHH4FF[6UMI9-:;;K3Y!/!TJL:4:KJ
MS=*,XJ?MJL)R51)5%.5.4.93Y5>+]U;144E;\Y-7_8D\:?"SXC>"?BK^QK\1
MO!WPKUGP_P#!#PG^SWXF\$?%/P3JOQ"^'7C+P!\/G=_ 6I7%MX:\5>!?$FE^
M,O#*3W-E'JUEK9LM0T^5+:ZTT")FFX/Q5_P3D\3>.O@A\?/#GC3XQZ?XA^/W
M[2WQ-^&GQ&^)GQ5/@^;3O"]E:_##7O#5YX7\!>#?!T6MW-[I/A#P_H>@W.FZ
M-'?Z_J>J/?:K=ZCJ=_=YCAB_5>BFIR3O?736RN[=W:[V6[Z$/+\(^9>S?))5
M%[-5*JI1=6$J=25.DIJG3G.$IQ<X1C+WYM-.<F_SN^-?P,^,GPV^*/Q\_:?_
M &8[NWOO'/Q;^ .D?#6;X6KI6G^1JWQKT+7S8?#/XQW>HZMJ%OH45KX2T'7+
M^R\9PZCINHW.I^&M)M%MDNI["WL+CZ/^)/P+M_CY^S3KOP ^.&K-K<WQ ^&%
MGX+^(GB3P];VVDR7?B*32+--5\4:!:-;O::;-'XCMSKND6WV9K>SDCMHA#Y<
M>VOH*BES/3NMGI?1))?*VGJ:+"T5[:-I.E74U4HRDY46ZLIRK24&VDZKF^=+
MW7NDG*3E^8.H?L<_M1?%S0?A_P#"+]IS]I/P!\0/@)X&\1^#?$.OZ1X'^$VM
M>#_B3\:3\.=6T_Q!X-TOXI^*=6^('B;P]_9@\0:+HFL^)8?#'A;27\075@5>
M2U\U9(MSX^_LD?M%_M)W5S\-_B=\<_A7>?LY3_%3PQ\18=.TWX+WEE\<+#2?
M"'BS3_&.B>"].\=OXXG\'6445[IEMI4_BJV\!1^(Y]&\Y&G^UW$\\OZ144^>
M2=U9=K1CI?JM-]+7WL9O+\,XSA)5I*HHQJ.6)Q$I5(04E&E.4JKE*DE*?[MM
MPO.<K<TY-_.O[/5Y\>M87XN^(?C?!!HVG:U\8?%;?!CP>]GHL&N^$_@]I,6G
MZ#X=A\3W6AF:UOM7\1ZCI>L>,4::^U&\LM,\0:?IUS=B2T-O!\R6'[(G[1OP
M@\;?&=_V7OV@O /@#X5?'OXA>(/BIXC\*?$+X3:AXZ\1_#7Q[XV,3>-]=^$F
ML:9XW\+Z+:PZS=1?VS::)XOT#Q%H^G:RS3+:SVLES;W'Z2T4N9IMI*SLK-)J
MR\FM]-]]^YI+"TYQIJ<JLI4I2E&JJM2%6\[\Z]I3E"7)*]G335-)02BE"'+^
M3GBW]AG]I0>//VJ+_P"'?QS^#2>!?VMM!\!>'_B$/BG\&_$'C?QSIL7A+X<G
MX>:AJNBW&C_$#PKX,DU75K>ZU'5U75/"][IL&HRVQ6R%O T$OI7PY_X)Z^$_
M WCN2XU/Q(OC3X4R?L-^ ?V++GP=XBTW[5K>K:/X-UC5;N[\4:MJ\D\FGRMK
M&G:B+<:=!I<:6-VAFMI%@C@@C_1FBFYR:M?>U]$GI:VJMM;1F4<NPD9^T5.3
MDISG'GJU9QBZDZDZBC&<Y1C&<ZDY2BDHMM77NQM^>?[/'PS_ &J_@WKO[.GP
M&U+QE:^*O@I\$/@_XST[XD?$G4=$T^*Z^*^I7NM0Z)\#_"&A)>7VK>(])U7X
M:>$-(FNO&>K"XL=*UEK_ $VW@CG!6WL?6/V@?AS^U3XWO[^Q^#'Q=^#/ACP%
MXF\(7'A?Q+X3^+7P8U/XBR6=Y=M>0W?B'P[J&C>.O",4\]UI]VEO-HGBNQU_
M1#)9PR"V$<]U%+]:44N;6]E?S2:;ZNWKM;;8UCA:<:+H*=?V?NJ-J]6,H1A"
M%.$(SC)34%&"YDY-SDY3FY2G)O\ $_Q7_P $D;X>'? G@3P?\1OAMXM\$>$?
MV:K#]GFQLOVA_A/<_%>;P/=07&MW.J?%/X3Z3'XMT3PIX4\<Z[)K3&6[O=#U
M5M,?3M+-C<&"S2V;Z+\*?\$_H[&]\&6OBSQY!K/A;1_^"?5S^PSXGT[2M(GT
MS4]9AU2[LSJ_C/3+^:^NXM-BFTZ*YM[73)K:ZF@N)8YWNY%C,;?I+13YY/KW
MZ+J8PRS!4VW"BE>,(VYZCCRT[<D>5R:Y5RI6VMIM9'YU?LX?LC_&CX1V_AKP
M-X\\?_ 'Q3\,/ _@*_\ A]HNH^"_@ _@WXS^*M,&AKX:T/4/'/CZY\:ZWI0U
M2RTH>=JT_ACPSHS:[J0,UTT=O)/!+\^_%7]DWXP_"W_@FE\3O@#?:W'\8_$?
MPBT[0]3_ &4[GX._#+Q%;_$[3O$O@[Q=::_\+[G7=/D\3>)H=;U_3O$9TN#7
M-9T"Q\/Z;8>%(M9O+JU\M;BZC_9>BCG=[NSU3V2U7HEZ!++L.Z4J4?:QO0KT
M(R=:K.485X1C)>_.7,H\D)04K\LHIQLVV_G']D;X)G]GC]G#X2?"2ZN&O]>\
M-^%+2Y\::LY+RZW\0/$,DWB/Q]K<TC*LDKZKXOU;6;T2S SLDR><SR[G/T=1
M14MW;;ZG93IQI4Z=*"M"G"-."O>T8148J^[T2U>K"BBBD6%%%% !1110 444
M4 %%%% !1110 4444 %%%% '@W[3_P#R0#XI_P#8L3?^E5K2TG[3_P#R0#XI
M_P#8L3?^E5K2UVT?X$?^OM3_ -(HGQV:?\CS$?\ 8JRS_P!2\X"BN5\=ZM>:
M!X(\9:[IS1IJ&B^%?$.K6+RQB6);S3=(O+RU:2)OEDC6>%"\;<.H*G@U^!?P
MM_X*/?M*2_L*?%C5?BMKOA^P_:P\&_#SX&_'7P'XKL_"NBV>A^/_ (&?'CQ=
MX'L]%\46/AIK4:)/J/A2[UGQ/\.?%:6FGI:66J:=I-_M6[U%6JSFE)1M>^JD
MUII[EFU?NU+3O9_/]]_&O@SPQ\1?"'B?P%XUTBWU_P (>,M"U3PUXFT.ZDN(
MK;5M#UFSEL-3T^:6TFM[J*.ZM)Y86EMKB"XC#[X98Y%5Q\G_  9_X)S?L3_L
M_P#BG1_&_P *?V??"6@^+?#D3P^&/$&K:AXI\;:EX422(P2-X3G\=Z_XF/A:
M66 F"6?P^--GD@)A>1HR5/-?%;_@H%X*^%_BKXF>&--^#?QW^+]G\"=$T/6O
MCSXU^%/ACPIJOA/X50:WH,/BF.WUF7Q!XU\-:QKVJ67AB>/Q'JVD^"M'\2WV
ME:3(LMY#%,?(K[<\)>*O#_CKPMX;\:^$]4MM;\+^+]!TCQ/X<UBS8M:ZKH6N
MV%OJFDZC;LP5C#>6-U!<1[E5PL@#*K @&GW?@'NR;5DW&VZ\^C:ULUTV:L[-
M'R/?_P#!.G]C34?C)J7[0,_P7MHOB[K'C;3_ (CZMXMT_P <?$O21J?C;2[J
MUO;'7[_0-+\9V?AB[N8KJSMYI()]%DLKEU?[5;3+-,),C0?^"9O[$/AGXM6/
MQUT/X(I9?%G3O$47BNS\9_\ "Q/BS<WT>MPZM_;L4TEG>>.[C2KBR35O],&C
MW-A+HQ?]V=/,(\NN=UK]L/XJ:/\ \%!KG]E&W^ WB_Q!\,8?@/X6^([^.M%A
M\%K?66IZYX[U'P_?^-[V\U7XH:;(WPNTJTM1X?N-/M?"$WCH^+]/U2XM=-O?
M#SV%W<\_X,_X*A_"KQG\+=2^-47P:_: T+X9C7+;P3X,\3^(/#?@BRA^*/Q-
MO?&S^ +3X;?#VRB^(-QJ6K:]-X@25#J]]::9X,@MK/5)KGQ/ =(U)+9679;]
MNKM^.PKPVLDKR>L6E>/Q2U5M+KWMFWHVSUG]MS]E#5OVI?#?P6N?!GC#3?A_
M\4/V?_V@OAM\?OASXLU;2;K6=-AU;P/>W*ZGH.J6-C>6%Y/I/B+1[^[M+N&*
MZC22>*R>=7BB*U=\1_\ !/7]B_QC\4S\:?%?[/7@37OB++KZ>++K4M176;G0
M[[Q6LOVC_A)=0\$2:J? ^I:^;K_2GUG4/#=SJ4ET!=27+7 $@S_!/[</A7QS
MHGQ8&E?![XV'XG?!V]\)VGB7X'V6B>#?$GQ&U&V\=@'PAKGAVZ\)>.->\ ZG
MX;U8QWZW&O/XVM=/T$Z/JQ\13:4MH6?YH^.W_!3+Q%X6^!WC_P 9_##]GSXG
M6?Q?^%7QX^#_ ,'?B7\)_B;I'@E-:\$6_P 2]8\,W5CKNIIHGQ8M=#U33?&'
MAK6UTSP/JGA[Q=JT:^*M5TB;6["#0K;5;J![B;IJ\FKMIR?NMOW=+6MI)6:Y
M;*6CNO==OM_6OV0/V;?$5[^T#J.L_"K1KV]_:GT'P_X8^/UPVH^(87^(^A>%
M=(NM!\/Z=J7V?6(5TR+3-)O;JT@?P\ND3N)FFFEEN LJ^1?M!?\ !/GX(?&7
MP!J>B^%],3X7?$O3_P!G'5_V7_AC\5]$DU;4M8^&_P *M3L38'POI^E7NL#3
M-2TN2S,NFWDM_%)K4NFWE[!!K%O).913\<?M_>&? E[;>&KWX%_'#5OB+IWP
MYL?BG\1_AKHR_":7Q1\)?"FK7VL6.C+XQN;[XJ6'AK4O$&MCP_K=YH_AKP-K
MWB[6;^RTVXGBM,^6DC?%?_!0OX9)-X-T[X1?#OXS_M$7_C3X.:;\>)U^"OA3
M1=9?P1\*_$+O;>'O%/BN+Q-XF\+2K=ZS=0:A%I?A308]=\7WSZ/J8@T)_(3S
M33R_JW_ _ ;<+-/1=59J]W=M65VTW=M:IN[LSXF_9S_X)+_$KX'^-W^*EC\0
MOV?/AYXX\(?LW>,O@3\.]-_9V^"VM_"[PAXO\0^(_#\NCZ9\5OVA;>[\8Z]?
M_$CQ5IEX+;6+G[$^CB[U&WANX9;5H%CD_3+]BO\ 9ETK]CW]F/X3_L]:9JX\
M1W'@+094\1>*3;M:OXI\7ZWJ-YKWBOQ"8)'EFABU+7=2OI;*"XGN)[73Q:6D
MMQ.T!E;SG]@_XR^*_'7[ 7P.^./Q(U'Q1X_\5:G\(KOQIXFO=/T2YUSQEXGF
MTZ76;IXM,\.:)9?;M9\0WMI91VFG:-IE@]_J5^8+*UMY+J=$;T+X6_M:>&/B
MOXRL/!6F?!O]JGP=>:A;W]S'KWQ2_9E^+WPU\&VZZ?9RWLD5_P"+O%OAG3=#
ML;BY2%H;""ZNXY+Z\>*TMA)<2QHQ_7]6)IQII1E!<MXMQ3D[VGR7LG)ZOEA>
MW9=#ZIHK\]/V_P#]H_XD_"CP)+\//V=[S3(?V@O$_@[QM\0H-6U+2;?Q!I_P
MN^$GPRT>XUWQY\4-:TB\273KG$L6F^"?!]CJL<EEJOC/Q-IBS6]W8:=JB1_4
M7[-WC/7_ (C?L[? 3XA>*[J*]\4^//@M\+?&?B6]@M;>RAN]?\4>!M"UO6+J
M&RM(XK6TBN-1OKF6.UMHH[>W1Q%#&D:*H"^9.3CK=*[TTZ:7[ZK[SVFL[]G'
M_D#_ !/_ .RU^/\ _P!"TNM&O'/@[J_QKL_^%IP>!OA_\+?$6@#XR>.&CU/Q
M9\8/%G@O6'NF_LPW,+Z'H_P-\>V4<$+X6"Y7Q#+)<*2TEK:D!#-17I3VWANT
MNOG8UP4E'., W=_N<<O=C*3_ (=+I%-_.UC[;KP";_DZ;3?^R :W_P"K%\/U
M8_X2']IS_HD/P(_\2,^('_T+55O!WA?XJ:C\69?B5\1-!^'_ (5M[/X=W'@?
M3-)\%^/O$?CZ:^FOO$MEK]QJ-]=ZY\,?ALFF16R6"6T-O;P:L]T\[R/+:B$)
M/R)6YFVOA:W3WMT3;_I]F?8.:DXI*=^:+UIU(JR=W=RBDOFSZ HHHJ#4****
M "BBB@""YNK:SB:XN[B"U@3&^:YFC@B7/3=)*RHN>V6&:QO^$L\*_P#0S>'_
M /P<Z=_\DU^9/B[Q!=?&KQ#K7B3Q5+/J'A6#7-6TWP7X0N+B27P]8Z1I%]<:
M5%K%YI?RVE_KFL/;37EQ<7D=R+2">*RM=J1R/+SG_"N_A_\ ]"+X._\ "8T3
M_P"0:[HX.-ESU)1E9748*2B]+QNYJ[6STM=65UJ?F^(X\KNM/ZAE="MA%*2H
MU\3CJE"I7@G95E1IX*NJ=.HESTE*JYNFX.I&G-RIP_5G_A+/"O\ T,WA_P#\
M'.G?_)-'_"6>%?\ H9O#_P#X.=._^2:_*;_A7?P__P"A%\'?^$QHG_R#1_PK
MOX?_ /0B^#O_  F-$_\ D&J^J4O^?M3_ ,%Q_P#EGK_3TP_U[S/_ *$^ _\
M#GB/_G;Z_P!/3]6?^$L\*_\ 0S>'_P#P<Z=_\DT?\)9X5_Z&;P__ .#G3O\
MY)K\IO\ A7?P_P#^A%\'?^$QHG_R#1_PKOX?_P#0B^#O_"8T3_Y!H^J4O^?M
M3_P7'_Y9Z_T]#_7O,_\ H3X#_P .>(_^=OK_ $]/U9_X2SPK_P!#-X?_ /!S
MIW_R31_PEGA7_H9O#_\ X.=._P#DFORF_P"%=_#_ /Z$7P=_X3&B?_(-9<OA
M;X2P:M::!/X=^'4.NW]K<7UAHLND>&H]6O;*T94N[RTTY[=;RYM;5W1;BXAA
M>&%G59'4L 3ZI2_Y^U/_  7'_P"6>O\ 3T?^O>9_]"? _P#ASQ'E_P!2WU_#
MOI^MO_"6>%?^AF\/_P#@YT[_ .2:/^$L\*_]#-X?_P#!SIW_ ,DU^4W_  KO
MX?\ _0B^#O\ PF-$_P#D&C_A7?P__P"A%\'?^$QHG_R#1]4I?\_:G_@N/_RS
MU_IZ+_7O,_\ H3X#_P .>(_^=OK_ $]/U-U#7/ NK6<^GZIK'A/4K"Z0Q7-C
M?ZAH]Y:7$9ZQSVUQ-)#*A[JZ,/:O+'^%'[+DC,\GP[^!#NY+,[^%O 3,S'DL
MS-9$DD\DDDFO@7_A7?P__P"A%\'?^$QHG_R#1_PKOX?_ /0B^#O_  F-$_\
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M?E=^U_\ L$?$/]HO]IOPI\;]?^/&L_#+X@:#KEGX>_9 T/PCI7]L^%?!M[X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QO
M]H71M0\0?!+XF:3I5O+=ZA<^%-1>VM8$:6>X>T"7C0PQ+EY)I([=UCC0%W<J
MB@L0#RVAZSI_B+1M+UW2KB.[TW5[&VU"RN(F#)+;W42RQD$=" VUU.&1PRL
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M_&6\^(GA62RT>+5]2O8RGA$^$KOPI9!YK>WACU5=?D8QHE@% ]X_X4=\0O\
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M_P#(AA_V'YG_ .IU8\_\5W&HQ>+OA=#9^)=$T:SNO$FOQZMHNI&$:GXNM8_
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MIW_2^Z_;#_9RLOAG)\7;OXC+;^"8O&*_#MWE\)^.%\5CX@/*84\"_P#"N?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\15Q,L#G5&I7G*K5CAI8BA2E4G)2G4]C3Q:I0E.3<JGLXP4YN<Y)SE*3O_\
M#-GQR_Z'#X4?^"+Q?_\ +>C_ (9L^.7_ $.'PH_\$7B__P"6]4/^&A/VA?\
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M>([R^@4\,]O;ZAK4=I)(HY03MY98#<"N0?O>BCZW6_Z=_P#@N'_R/]7?E87
M^0JUX8]KJGF>-5]M&XUDU>VZ:>KLT>;?"[X7>'_A3X>ET/1);S4+F_O9-6U[
M7=4>.75=>U>>..*6^O7BCBA0+%#%!:VMO'';6=M%'!!&J+D^DT45S2DY-RDV
MVW=M]?Z_ ^HPV&H8.A2PN%I0HX>A!0I4H*T81736[;;;<I2;E*3<I-R;;***
M*1N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5A:^%_%/A'Q?!I=KJ=YX>OK.]%Y*;C0K:ZM3)812?-?$6_W9XI_:#\,?#_\
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M]DP^/O\ Z>O@;7O=82VA_A?_ *7(^HA\5;_KXO\ TU2"BBBI- HHHH ****
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M313H)(98YHR2 \3K(A*DA@&0E20001G@@@\U)0 44A( ))  !)).  .223P
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M;8C*3\@_L0_&K6OBC^SS\-=;^)GC+0]>\=ZYKWQ8\*Z1KF_3='NOB=I/PO\
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M+XD?%/\ 99_9L^*'[&OQ(_8V_:FO_C!\&KS]I[XBJ\GPMDL/@W\4+/3[^_\
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MI0TM[R?[)T445D>N%%%% !1110 4444 %%%% !1110 4444 %%%% !7YI?\
M!0C]K7XO_ W7_P!F'X ?LWZ%X0U+]H#]KGXIW7P_\'^(OB%!J-[X'^'7AKP[
MIL6L^-O'>MZ3IMQI]UXAFT?3;B!]/T&'5=/>\;[1(9)3#';7'Z6U^=G[?7[%
MOCC]IZY_9^^*OP0^)FC_  D_:-_99^)<GQ'^%'BCQ5H5WXE\$ZM%J=BFF>*/
M!?C+2+&YM[W^Q/$=E!:1S:C8K<WMDD$L<%LYNVE@:M?7Y=K]+^1AB%4=&7LN
M;GO#2#BIN'/'VB@Y62FZ?,HMM6E;5/4^4_CW^U-_P44_8=^&?B0?&>P_9[_:
M.\:?%CXP?!W]G_\ 8\\7> -$\3_"R+Q)\5OC'>Z_IUO8?%3X>W>L^+_['TGP
MW%HHU5'T7Q=<?VS),FE+J4#3-=6ESQ)^T=_P4%_8U^.?[(NA?M9>)_@%\>?@
MQ^UC\6_#'[/6H:S\(_AQXC^%WB?X._&+Q[!+)X1@A75?&7B^#QQX0GOK2\L9
M-9N+70+R6TM[B[N-.TJX^R6]U;^,/[ /[;?[8'PO\8Z1^U1^U;\+O#WCO0?B
M%\+OC!^S#I7P&^%-S#\/O@=\6/A)=:O>Z/XRU'5_%]W#X_\ '9\2#6;G2]8T
M?5[]=.T:U6._TB.>[5H'Z"W_ &)?VTOVA_C;^S=\1/V[/CA\"=5^'W[*GCO2
M_B_X#^&7[.W@GQAHR>/OC+X<M7M/"OCWX@:]XVOFN-.70&N;R_@\/>';5]+D
MN9Y(56WAD=A5UY=;V7DK6NM'>_EY7.-QQ/-[BQ*2]C['GJ0:BO:R=95[S;FG
M"R7-SR4+<MJG,?EI^R7XW_X*"^$?"G_!5SQQ^R]XH_9]\(?"_P"!'[:O[7?Q
M7U33OB?X,\0^-?%?Q6\6V)TK5_$'@^TN=-\3>';'P)H>F>$?"EM-9Z^\.MW>
MHZUJWV+[!#;127UK]ZW7_!3#]H']HK2/^">_PM_9/\)?#OP1\=/VW?@WK_QU
M\8^,/B=;:YXL\!? [X>^"+>*V\17MGX>TN?1+_QGJ6M^(H=3TOP]93ZMIJ6P
MM[.+4G!U1-1L?HG]G;]@+Q]\&_@S_P %$/AIK?CCPAJNJ?ME?&3]I+XC^#M0
MTJ#6A8>$M)^-7A:70-"LO$WVNR@N)=1TF>4SZNNEPW5MY*@6=Q<NQ5?G;0_^
M"5'QW^%GPT_X)^>,/@7\;OAOX3_:Y_8:^%WB/X2W.L^*?#'B'Q+\%OB]X'\:
MFX'B+PMKUI!)IOBG1[2R>[O+[1-8TZP.I+=W<WG00R1V%W8C:;Z;Z.S[/?NK
MV_X8BG1Q5*E3C'VMG%>UBJD6XVQ--M4KR2A)X=U$N1J]KW]I:1T>A?MH?M@_
M KX_?M!_LC?M02_";XB>-M#_ &0?B#^UA^SS\<?AKX.UCP+H?B?2/ EMJ&F:
MMH'CKX<:CXG\5C3+ZR\1PPE%L/%<@DM+656EN4U.VFL?D;PK\4O^"I_[8?\
MP2[^*_[4GQ ^-O[,'PV^&7Q#_93^.NNR?#_P_P# KQ+XH\9ZMX6\/>!?$=AJ
MMTOB9OBCH6F^'-7\=1Z1XEMK9([+5(_!<=[I6J+!KES%/I,7WAX+_P""?7[0
M/C?XH_M _M.?M8_&+X:^,?V@?B7^S3XQ_9?^$WAKX4>&/$/AWX/?!OP#XLL]
M2N-0\JY\17-]XO\ %%]JWB.]BU*^O-0BBFLH!>PP?;_M-JFG^\?LV_L3ZS\*
MO^":WAW]@[QYXPTG4M7C^ 'C[X)^)?&OA6UO9-)#>/K#Q7IUWJ^C6FJQZ??3
MQZ?;^)B\,=Y'9R7$EL=P@60;2Z6JM]F^GWV[=%^7<N-'$5)6G*NJ/L\2H1=5
MQEK*DJ*JRA+GD[>U<;R=H-*;<UI^0GP6^/G[:_[&/_!&C]G;XZZ!XV^''Q8T
M'Q'X&_9Z\+>";.X^!GBFPMOV8/AKXDAO8/$WQ-^)^I^'?B!XLUGXOZ7X2LH]
M+MKHZ=X=\#[);E;][>6+-@?VC_84\?\ QB^)O@#Q+XP^)'[1O[-?[47A+4]8
MTY_A?\3OV<O#>J>$;6XT@Z:)=:TWQQX;O/%/C.RT?7K2_EMOLEC9Z_=7,=F[
MMJ<=M/)';Q_(O[/'[+7_  5+_9P_9G\"_ +P9\>OV-[L_!0>"_"?PUNM:^&'
MQ.U"R\8_##PW9>+;35=)^(MU'K5E>:)X@U9[_P &M:W_ (5L[Z/3[?P]J-N\
MEW-J[WL?K7_!/K]A7XC_ +,'Q'_:C^.GQ>\8?"^]^(W[4OBWPWXAUSX>_ 7P
MIK'@[X+>"8_"]A>VL-QH&GZ]=2ZKJ.O:[/J5U=:[JEY:6<DTB([M=S7$TRC:
M=]5O=67X/2]_/UOT'AH5J;PRY:W)&C"G.%2I[M*482YIW]K+VO-.T5%Q;BDG
M"2@G$_42BBBH/2"BBB@ HHHH **XCQE\2O 'P]BMY?&_C#0/#"W>_P"RKJ^H
MV]K-<B/;YC06[OY\R1EE#O'&R(64,P)&?.O^&I/V>?\ HKG@W_P8G_XU6D:5
M62O&G4DN\82:^])H\_$9ME6$JNCBLSR_#5HV<J6(QN&HU8II--TZE6,E=--7
M6J::W/?**\#_ .&I/V>?^BN>#?\ P8G_ .-4?\-2?L\_]%<\&_\ @Q/_ ,:I
M^PK_ //FK_X+G_D8?V_D7_0[RC_PY8/_ .7>:^\]\HKP/_AJ3]GG_HKG@W_P
M8G_XU1_PU)^SS_T5SP;_ .#$_P#QJCV%?_GS5_\ !<_\@_M_(O\ H=Y1_P"'
M+!__ "[S7WGOE9FMZ3::]HVKZ%?J6L=:TR_TF\53AFM-1M9;.X53Q@F&9P#V
M)KQ;_AJ3]GG_ **YX-_\&)_^-4?\-2?L\_\ 17/!O_@Q/_QJA4*Z=U1JW6J_
M=S_R%+/<@G&4)9SE$HSBXRB\QP;4HR5FFO;:IIV:ZI^9\&:M;ZE\&V7P?\2X
MKG1UT<-8:+XMN;63_A'/%6CV9\C3]4M]2MOM-GI][+:K$+[2-0GM[RWN5E\N
M.2 I)6'_ ,+:^&G_ $/'AS_P90?_ !5?H?\ \-2?L\_]%<\&_P#@Q/\ \:H_
MX:D_9Y_Z*YX-_P#!B?\ XU7>JM5ZSPE=R>[BY13?5J+HR:N];<S\M#\XJ</Y
M1&;C@^-,DHX:.E&EBHX;%UZ=-6483Q%/.L(JO*K14W0C.4>7G<Y\TY?D_/IG
M[+=UX!\5_"VYM_AO<_#SQS>^*-1\6^#[AK6;1->O_&FK7>O>*+N_M)799+C6
M-9OKK4[B5"C)>2^?;F%TC*<GX^^&7[%?Q2T'P9X8^(/A;X2^*]#^'>F6VB>"
M++58[60^&=&M+*VTZ#2-*NHY(KRWTH65G:VTFG?:&L[B.WB%Q#*44C]C/^&I
M/V>?^BN>#?\ P8G_ .-4?\-2?L\_]%<\&_\ @Q/_ ,:H]I+_ * L1V^)[=O]
MW)_L/![_ .O7#U[WO]6I;NRO_P E'NTTOFC\JDB_9CBU3X;ZS!%\-;;4_@]I
M^M:5\+;JTCT^T;P'IOB+2K70]<L/#,=L(H=+M-3TBRM-/NX+>-8Y+:WBCVC8
M#5;XGZ?^R[\:;+0]/^*L/PX\=VGAK6(O$'A^/Q ]M=MH^L0H8UOK"8.D]O(\
M1,-PD<@ANH3Y-S'+'A:_5[_AJ3]GG_HKG@W_ ,&)_P#C5'_#4G[//_17/!O_
M (,3_P#&J/:2_P"@/$?^!/\ ^9Q?V%@]+<<\.Z;?[-2TOV_XR/K?YW\S\M](
MO?V<]!M/&VGZ3<?#ZSL/B1K>M>)/'MBK64MEXMUOQ':PV.O:CKMK/YL%_-J]
MG!%;:@LT;17,*[)8V5F#>7>"/A!^PU\-['QCIG@CP/\ !CP]I_Q T6]\-^,[
M.TL=/EM_$'AS4?,^W>';Z.[-PIT"Y\QS+HL0BTPL0PM0RJ1^S/\ PU)^SS_T
M5SP;_P"#$_\ QJM71OVBO@9XAU"VTK1_BGX-O-0O)8X+6U&L00R7$\KB.*&+
M[285>661E2.-6+N[*B@L0"G5DM7@ZZ2ZN3T^?U?0N&086I*,*?&^03G-J,80
MPE.4IR=E&,8QXB;DW=)))O5)=#\8/ ?PU_8N^&+ZS)X$\,_"?PY+XB\.77@_
MQ!-:);33:YX6O98YKG0-7FO9;J74M*D:*)/L=X\T,<$<=M&J6Z+$,.[^"'["
M%]\/=)^%-WX%^#L_P]T#6KSQ'H7AEXH/LFBZYJ 5;[4](N!.+_3;JZC2."=[
M.[A$EM'%;,#;Q1QK_1$"" 0001D$<@@]"#W!HK/ZW3_Y\3[?QH[=OX)ZG^HF
M97O_ *P82][W_L2O>ZV?_(]W1_/KXC^%W[$WB[X?>&/A3XB\(?!W4_AWX*N&
MN_"/A.2ST^'2_#=U)))-<7&C+;&">PFO)9IGU"2WF1M1::;[<;CS9-WI'@'4
M/V=?A9HMQX<^'%S\/O!.@76KZAKTVB^&VL=+TPZOJKI)J%ZEE;!+>&2Z:.,N
ML,<<0"(J1HJ@#B_VT?VT?VC_  =^W+\(KKX+_#OQ_P",/V=?V<]0UG3?CI<>
M%])O+W3?'NH>*-$M_P#A/K'3[>*(W/B:?X1>%I+?5MNB07XT3Q)'J"ZGL$+1
MK^\^E:IIVN:7IVM:/>V^I:3J]A::II>HV<JS6E_IU_;QW5E>6LR$I+;W5M+'
M/#(I*O&ZL#@UI.O"$82=&7OQNK5XMQU^&5J-T[6E9]'Y,Y:'!V-Q-3$T8Y]A
MU]6JJ#Y\BQ$85+Q3=2DWGEIP4^>DY+[=.71Q;_(/_A;7PT_Z'CPY_P"#*#_X
MJC_A;7PT_P"AX\.?^#*#_P"*K]BZ*S^N4_\ GS/_ ,'1_P#E)T_ZA9A_T/L'
M_P"&.O\ _/P_$KP5XB^ WPY\.VGA+P-K'@OPQX:L+C4;JST;2KR""QM[C5]2
MN]7U.:.+>V'O=3OKN]G.3NGN)&& 0!V$'Q.\#7TBV^DZ_;:]?R$+;Z7X?BN=
M;U2[E;A(K;3]-AN;F61SP,1A!]YW1 S#]A:*/KE/_GS/YUE_\I7YC7 6/O>6
M?81J^MLEK*3[VD\[DD_-Q?HSY@_9G^&_B'PGIWBKQGXPT^31?$OQ N]+8^'I
MG@EN=!\.^'([^VT"SOIK:>>W;4;HZCJ&JWD<3?Z(^H+9.6DMFQ]/T45QU*CJ
M3E.5DW;1;))*,4KW=E%)*[;TU;>I]YEF74,JP.'P&'<Y4J$9>_4<74JU*M2=
M:O6J.,8P]I6K5*E6:A"$%*;4(0@HQ11114'>%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117B7[1WQ=
MUSX#_!3Q[\6_#7PB^(_QXUSP9I]A>Z=\)?A)I$FO?$/QG-?:WIFCM9^&])AB
MGFO)K"'49-8OUA@N)HM)TZ_GB@GDB6)S<4I*,92EHHIR;LW9)7>B3;TZ)-OH
MCVVBN8\$^(KGQ?X,\(^++SP[KO@^[\4>&-!\177A+Q3:I8^)O"]SK>E6FI3^
M'?$5E')-'9Z[HDMRVF:O:QS2I;ZA:W$2R.J!C\/_ !2_;3UWX>_\%%?V8/V(
M;;P-I&I>'_C_ /"3XI_$?4_'<^K7D&L>';SX?V&NWUCIMAI,=N]E>VNH?V&\
M=U-<7$4L7VE7A!\HK(;_ -=B9U(0C&4G92G3A'1N\JDE""LE=7E)*[LEN[(_
M0>BBB@L**** "BBB@ HHHH **_/#_@H3^VQXJ_9!T+X&>'/A9\+;3XP?'+]I
M?XQZ/\%OA)X0UKQ%_P (EX337-1MWNKS6O%?B);:\GL])TY#:1O%;6YGE-XT
M_FQ0VDV_ZK^ ?B#XV^)OA?H.K?M#_#WPI\,/BS++J<'B7PCX(\7GQSX7M1:Z
MC<P:=?:1XA>SL)[BVU33TM[\6]S:QW5FTYMK@"6-@';2_P"J_+<S56$JDJ2;
M<X).7NRY8W2:3G;DYFFGRWO9WM8]DHHHI&@4444 %%?GWXK_ &T=<\.?\%+_
M (6_L&Q^!])NO#OQ"_9<\1_M 7'Q!?5KR/6M-U71?&?B#PS#X=AT=;9K&?3Y
MK;0&NI;R2Y2Y$]TJ(@CA/F_H)3::WZJ_R(A4A-S47?V<W3EHU::2;6J5])+5
M77F%%%?-,?[0/B1_VK)_V;3^S]\9T\*0_"B+XCI^TD?#O_%CIM9DU<Z<WPY3
MQ,6$1\81VP%^VGK(U[Y9!.GBS_T^E;\-1RE&/+S.W-)16C=Y/9:)V]79+JSZ
M6HHKYT_:I_:F^$/[&GP8U[X]_'+5-6T?X=>&]4\-:/J=[H>BW?B#4DO?%>O6
M'AW25ATNQ'VB:-M0U& W,BD""V668[B@1C?8)2C",ISDHPBG*4I-*,8I7;DW
MHDEJV]$CZ+HHHH*"BBB@ HHHH **^:_V9?VL?@]^UW\/?$_Q,^"&I:UKOACP
ME\0?&?PPU9]5T.\T*_'B_P "R6L>MV=M97X62XMF^VVDEC>(?)NH[A"-CK(B
M2?LK_'OQ)^T?\+#\1O%7P#^,/[-^JCQ5XE\-GX<_&_P^WAKQJUIH-XEO:>)$
MTUPDIT/78I!/IES)%%YWE7'DFXME@O+D(52$N7EDI*<7.#CK&45RW:DKQM[T
M;:ZWTO9V^D****"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "LO6]331=%U?6)$,J:3I=_J;Q@[3(EA:373(#S@N(BH.#C.:U*Y+Q__P B
M)XU_[%+Q'_Z9[VG%7E%/9M)_-F5><H4*TXNTH4JDXNU[2C"33L]]5L?EQX>:
MX\2#_A8?B)UU/Q;XRBBUR_U.<-)):VVHK]LL=&TT2M*;'2M*M)H;2UM(&5"(
MFFEWSRR2-UE<OX'_ .1+\(?]BOX?_P#33:5U%>S)WD^RT2Z)+1)=DEHD?S[A
MFW0I3DW*=6$:M6<G>=2K5BIU*M23UG4J3;E.<FY2DVVVV%(2%!9B%502S$@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M/?[6VM:OX;_97_:2\0^']4U#1->T/X$?%G5]%UG2;N?3]4TG5=.\":[=V&I:
M=?6LD5S97UE=117-I=6\L<]O/''+$Z2(K#^8WX:_!#]J3X@?\$?K3_@H9K__
M  4+_; @^/\ X)^!VM?%7X8Z/H'Q6U32?A9I>@_"N[U&"V\-^._"+QW5Q\2]
M:\36/AN_E\0^*O%6K7=W=:CJ5M)+!<VEE<6VH_U._'KX?:C\6?@=\8OA;H]]
M9:9JWQ'^%_CSP+IFHZD)SIUAJ'BOPOJFA6=Y?_98I[G[';7%]'-<_9X9I_)1
M_*BD?:A^!?AG^P;\2? __!)!_P#@GW?^+O ]Y\4&_9T^(/P?_P"$QLYM>_X0
M$>(?&#>)Y+/4//FT2/Q#_8MJ^N0)<S?V#]N*PS/%8.2D;7%I)=^9/Y?U^O1G
M!B:$ZM:]INFL)72Y9N*5=SI.F[*2O))2<6TU%JZ:=CXA^.G[5_[07[54?_!)
M']E?X??%#Q%^S]K?[?'PHN?C)^T#\6OAT\.D^-M)\+>!OA=IOC?7O#GPVU0Q
MW;^&]0\5ZO;:]%'J$433:="-(@:6:SDU*&6WXU\-?%K_ ()B?MU?L(>'O G[
M3W[2'QX_9\_;*^(?B#X%?$CX9?M+?$^_^+VI>&_%7]F:=)X5\;^"?%6MPP:E
MH^R_U5+K5-.BB,,L.G7-IYK0:G;Q:=[O\1_^"7OQ8U/X&_\ !/[4_A!\9O"G
MPO\ VS?^"?O@G2?#G@/XBW.B:EXD^%OC"&\\'Z/X3\?^$/%&FO!I^OS^$?$=
MKIDD-G?+8_VA9V=[J,;Z27U)S;;WP^_85_:\^-'[4_P3_:B_X*%?%_X'^*%_
M9@'B'4O@1\%?V<_#7B[3_ ECXY\5:?#IVI_$'QCXB\=1V7B'5]6L(['3;G1=
M+BLS96-]9VL\-S!'#>P:L-JUDTE9Z6>KZ='KMJWLNG7#V6(<[RA5=9U<+*G6
M4TH4J,8T/;PE[ZM>4:W/#DE[3GA\5KP^O_\ @HE^TIK/[(?[%7[0_P"T/X:L
M;?4/%7P[\ W=UX2M[V,S6*^*M:O++PYX=O+^#(^T6.FZOJ]IJ5W:ED%W!:26
MIDB$WF+_ "@ZW^UE)X+^ 7@_]H;X/_MQ?\%*OB5^WQIZ^!_B#XC\"^,_"?Q<
MU/\ 9?\ B!J^HWVFWOC;X<67PVG\%6O@K2_"26%Y?6NAZA:7JQRP6(>%U%]:
M_8_[(/VE?@'X,_:C^ OQ5_9]^()NH_"/Q7\':KX2U6[L#&-0TQKV,2:?K.G^
M:K1&_P!&U.&SU2S696ADN+2..96B=U/Y>?"K]G;_ (+/?!WP/X.^!/AK]IS]
MB77?AE\/]-TGP9X8^+?BOX6_%"[^,O\ P@FA10:;HXU3P9:7%OX"O?$5AHEO
M#:)<3^()H;J6WBDU">[GDGNI"+273?7S6FFSNO+RN:8RE7J5DX\_L_9<L'3C
MS2IUN=WFE[>CRRY>7DF^=+EDI<J;Y^5\-_'#XH?!3_@KC\+K#XB^,?'TGP)_
MX*)_LEZ'XA\$>!/%/B;6;SPC\)?VCOA[:6.J:_X9\,:%J]W/9>'8=4\)6TLF
MHV^FVVGSZCKWB* W:R+IA8_ _P 5?CU^T!\5/V.O^"UW[>OA?XW?%CPWX$G^
M(&C_  +_ &4K;PS\0?&.@Z1X8\&_!KX@^"_"OB'XC?#ZST[6+:R\/W7CV?4V
MM[KQ!H,-CJ6H/!K5M>7+DS(?V+_X*C_L(?$C]MOX+_"FS^#'Q!\+?#7]I+X$
M_%7PU\4?AA\3_$T6K66DV5Y:Z;?:-XKTRY?0=-UW4;.PU^UO+>_-K#INH027
MNC:;;7*&V\R5>/\ 'G_!-#5Y/^"0NH?\$X/AAXF\):7XVO?A'X7\*W/CCQ!_
M;$'A35?B%#XMT#QSXX\3:C)IVEZAKJ6'B'Q%9ZW-9N-*NKZW@O+*.:W(A<*7
M6CNKW2>^R>_;6R_R1E5H8EO$THJ;I1IXBM0DI).5:M1Y(TE[W,N2I*O/7W5S
MT[/W;+Y&_:#^*_QQ^/GQ,_X)2_L#>$_CE\3/@SHO[0W[.-A\=?VAOBQ\./$E
MSHGQ?\3>'_"GPVTV]MM T#QL5GU+1=0U_7-.U>;6]8CDFNKJ2_M[FX6=+26V
MO?(]+_9P\5?LQ_\ !>']A7P5J'[0/Q@^//@74?V>_P!H76_AY-\=O$A\=_$7
MP-92>"_'-OKWAN\\?3VUKJ?BG2+C6('U?1Y-5B-YID5Y-IQDG2%+B;] _P!H
M_P#X)S_&GQ59?L,_&+]FSXL^ _AU^UQ^Q%X$TOP!H^M^.M(US6?A/\2O"MUX
M*TGPGXO\*>*+;3(9-?L=)NWLM0NM)U"RTV:_ABU6[22""\-E?:;QOPQ_X)[?
MMI:K_P % OV>_P!O?]J#]H+X1>.]?^'/@CXO>"_$WPU^'&@>*/#G@SP3HOBO
MPI<^'O!6A_"F/6-/NM2\0))J6KZYXB\=>(_&6HZ+J$]S/966DZ7-:VJ%1-<N
M]K*5U;=O1?UV\KBG0JRJ)RI5936)P<X5>=<D:%/ZNZD;.?V9QJ2E'D?-)J>M
MDU^.^E_MQ_#_ /:^^(7[2?Q+_:<_;"_X*$? V71_BYXV^'W[.OPQ_8\L/BEH
MOP[\!^"O!THTW1O$?B^[\#>$]8T[QUXIU?4$6_UBQUB_#Q*ES$\4$%]91V'J
M/QB_;5_;$\6?\$3_ (.?%O4_B+\1/ /Q_P##7[;'@'X/I\5%M/$GPZ\1_$;P
MQX=\5ZNOAWQ-XIT:)M&O[W2_$^G'2(O%.CW4:Z?XC?3+Q-2MI6N;F*OTS\+_
M +"?[?O['WQ$^-@_8!^-/[,LOP"^.'Q*UWXP2_"K]ICPK\06U+X7>.?%8MV\
M3GP9XB^'<5XVMZ)J=S"L\=AK,6G_ &2&WLK5-T\=YJ%]W7[8O["G[6/[9/[$
M7PY^!7Q/^,GP;U?X_:'\>_ 'Q;\8>-]-\*^(_!/PUFT/PEXEUG46\->&]'LH
M?$^N-<Z=H>I6NGZ=>ZFD3:Q=633:E+IYN6E1MJZLU9.+5^EK75FOONVG;0CV
M&*]E74O:^VE0K1DX+E56<IQY)>T]O+FDDG[/EIPY82<6H6Y'\C?M!_!OX_?\
M$[OC1_P3T^-?AW]M;]J'XVWGQ]_;,^#7[*O[1WA#XR_$6;Q-\,/&4?QPDU(7
M7B+P7\-UM;30OAZFD2:#K,FD66DBX?38GTF.*Z9[:\DU#N=3L?BM_P %&O\
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MZ1#XHU*^DO;2-[K5;/3(9Q:Z?;I\7_\ @E)^V'XC_P""?/[#'[%7P_\ B?\
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M1W>H?:KM8HS,R+X=)\3OB.O_  7QC^$@\?>,A\*V_P"";MGXR;X;?\)+K/\
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M 4444 %%%% !1110 4444 %%%% !7)>/_P#D1/&O_8I>(_\ TSWM=;7)>/\
M_D1/&O\ V*7B/_TSWM5#XX_XH_FC#%?[MB/^O%;_ --R/R\\#_\ (E^$/^Q7
M\/\ _IIM*ZBN7\#_ /(E^$/^Q7\/_P#IIM*ZBO7EN_5_F?S_ (7_ ';#_P#7
MBC_Z;B%9VL:59:[I&J:)J4;2Z=K.G7VE7\2.T3R66HVTMI=1K*A#QL\$TBJZ
M$,A(92" :_(CX+_\%%OBAXQ^%'[4FK_$?PCX#\-?$OX<_#'X_?&GX!PZ99Z]
M%X3^(WP\^$.M_$;P0SZK:7WB.[U*[UGPWXX^'YL_&=OI>K::L^E:[I-U81Z:
M9W>+ZVU']MCX=>#?#WPV@\7Z9XY\4_$3Q7\(/"?Q=\4^$_@[\-O&'Q#N/!_A
M;7=+MYKSQ7K]GX?M=6E\.>%4U/[?:V,VJ7DMY<):2+ MZT,DIE-.WFK_ -?>
M=;IS3:M=IM::ZK6_HK[]]-S@OAW_ ,$O_P!ECX>#P38);?%'QQX3^&VLQ^(O
M 'PX^)?Q9\9^-?AAX1\00WDU_#K.B_#W4]1_X1:WOHKVYN+I6DTV6)IYYII(
MGED9SW/CC]@[X0>-/C7XN_: M?&/QW^'?Q*\>:?X8TKQAJ?PD^-7C;X:VGB'
M3O!^FV>DZ%9:I8^%KZQ2\M;6SL+=#;SN\+R"2;RUEED9OJOP+XX\*?$OP=X9
M^('@;6[/Q'X/\8:-8Z_X=URP9FM=1TO48%GMIT$BI-#)M;R[BVN(XKJTN$EM
M;J&&XAEB3Y6^*7[7K_#/]J7X9_L[M\*OB3XHL/'?@;7?%%WXL\*>"/$GB&.P
MO+/6]!TG3UM#IMI)976B6":G=7'C+56F5/#*OI)NAB^ HLK+:VEOT'SU92?O
M2YK-.[L[*S:?S2OUNE?8IW7_  3W_9VU;QWHGCCQ.OQ0\;6_ACQ;/X\\,?#W
MQS\7?B!XO^%?ASQE<7;W\GB+1O &O:Y?:'9WXOI'ND40M:)(VT6WDJD2Z'[>
M7[-'B7]J3X#CP9\/]8T/P[\4_!WC_P !?%3X6>(/$MQJ%IH&E^,_ NOV]_ V
MKW.DZ;J^J0V5YI$NKV#/8V%Q-'<75M/L986!N:+^W5\ -<N/B:]O?^-K7PY\
M')O&UC\2O'VH?#[Q5;?#SPIK/@+69=$UGPY?^,?[.DTB3Q+=31QW>B:#:3W&
MIZQ8WEA+:6S2WUM!)TOA3]KCX4>)U\;P7EE\1_!&N^ /"EKX\UKP?\0/AIXP
M\+>-+SP5?S7-I8>)_#?A>ZTR35O$^F7>H6LNEJ-#M[V\M]5,.FWMI:WES;PR
MED[Z;[A>JG&3YFX6M>[LNWIM==GKN<5\8?V$/@/^T%XK'Q&^)>C>)](\;:_X
M/TSP9\1U^'/Q%\7^$-$^(GANSDBO3X1\<6^B7.D+XS\-6UZICMH]6LX)Y[2*
MV6=$%O;0VW9V_P"QW\!K'Q]KOQ%TOPM<:/K>O_ 2']FFXL=)U.ZL/#]C\)+=
MT-OH6D:+ 5M=-N+>**"V@O[?$\5O;Q1IM(9F\7^(_P#P4)\">'/@Y\=_'GA/
MP%\5;GX@?!#PYI6O:O\ "KQU\,?&O@GQ6EEXF2\'ACQ)J6CZEID6I6_@:\DL
M+QK_ ,201RP:7%:R_;EMI&B63TN+]LSP!#X3\ :QJ7@;XTQ>,?B%I&JZYI'P
MGL/A)XQU#XG_ -B>'?L47B#Q//X/@L6U&R\(V=UJ%A!:Z_?FVM=3?4=/BT_[
M3<7*P@TOY[O_ (/]=P?M;)-RM\*5WHK1E]UN5]DK=#D]:_X)_P#P1'@?X+>&
MO"%KJNC:O^S1X-^(7AKX#:IJ^JW6NV/AR]\?>'+[0;K4/%.EW0-OXO@A:[%R
MUEJ2_9Y0)(FC:)S'7P;^R9_P31_:-^ GQ*^!?B2X\1_"CP!HGP>@\3CQQJ/P
MK^*?QN\0:I^T3_:-E=0:)I/C7P5XRT+3/ ?@C1+2ZF6YN(/#5OJGD,\DEE!Y
MT-H\'Z4:_P#ML? ?1_"OPR\5:3J7B[Q^?B_:ZM?^!/"WPT\!^*?''CO4M.\-
MJ?\ A++^[\&Z)IL^NZ1;^#[@&P\3C5+2TGTG5%?3)H3?)) M+]BCXZZS\?\
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M>^//A'X=O]"@U6&ZO-#UNQ\1>!-0BU)I=2T_2OL^KR7UM+/!!(DXD?\ ;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME#FM;GE.5Y/K?^%T?M$?]#O\.O\ PU^I?_/%H_X71^T1_P!#O\.O_#7ZE_\
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M\7^#O#.@W>@:OJ+V"V$G]LQ1ZW;3L^DR7>,T6I_R4==OW5+7_P E$L7FNO\
MPI9PDK7;S3,K).UF_P#:=-T?IM_PNC]HC_H=_AU_X:_4O_GBT?\ "Z/VB/\
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M-&-H*RY8QUN4445D=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\__ +5 )_9^^)V
M3_Q([8\<\#6--)/T !)/8 D\5] 5S7C+PKIGCCPIXB\'ZRLC:7XDTB^T>\,+
M!)XHKV!X1<6[D,([FV=EN+>0JWESQ1O@[<5=*2A4IS>T9PD_2,DW^1PYIAJF
M,RS,<)2Y?:XK XO#4^9VC[2OAZE*',[.T>:2N[.ROH?FY7D/[07_ "03XW?]
MDA^)7_J&:U7KNJ^#?BG\/ICH/B7P%XM\5"R40V/BSP#H.H^+-,URSB+1V]U=
M6>EPRZMI.J2Q1I)J%G<V MH[AV^R7<\3+C$EG\13Q203_"/XS30S1O%-#+\(
M?&\D4L4BE)(Y(WT4I)'(A*NC JRDJP()%>LE?6+C)='&2:?X^?77HU<_#9>T
MH5.3$8?$8>M"2]I1K4*L*D))ZQ:<+25TTIP<J<U[T)2BTW_-'XMT37/V<?V2
M?A-X6T_3=0N/@=^U]X!_8.\=Z"UE:7<^F?#W]HGPUXZ_9WU7Q]IMY*D;6>EZ
M?\6?"FG3^+[$RS(]UXF\.>(4@BVS';]6?&GXE:EJGB']M/7/'O[5'Q"^!'QJ
M^%?BC6='_96^".B_%F/P'%XGTCPSX&T;5O ^L:7\(Y)[>7XT+\7O%,]S:LU]
MI'B>"X-R=%T1;6>U95_:";3[RYT^UTFX^"'Q6GTNQ-D;+39O@IXOET^S.FF-
MM.-K9OH#6UN;!HHC9&&-/LIBC,'EE%Q#>:/+J.I66LZA\"?BA?ZQIH(T[5;S
MX(>++K4M/#'+"ROI_#[W5J&/)$$L>3R:2@UYZ)+5=/GU;_&VQI]:B[7A.ZE*
M3?LZCO?V:M;DM\,.67>]]&W?E_A7\2K/Q;H?A;0O$NK^'-/^,T?PW\#>,/B/
M\-(-5L8_%O@Z\\3Z+:W%PVL>$VNGU[1-/;6/[0L+*;4K.&*66TE@CEDEAD _
M-W4?#'@SPE_P49^/>N:]\6/'GA'Q9XA^ ?P^\5?#7PSJ/QE\2^'M+\>:Q"OQ
M-L-6T?0?"-UKEK8^--%\,FSM[ZT\+V%GJ.G^&]3N+K48;.UN+N:1OU91-8CO
M9]2C^#?Q?CU&Z@@M;F_3X-^-%O;BVMFE>VMY[I=#$\L%N\TSP122-'$TLK1J
MID8FM=6%[?7UGJE]\$?BM>:GIR3QZ?J-U\%?%]Q?6,=RNRYCL[N;0'N+5+A/
MDG2"1%E7Y9 PXJE%Z:)[;M:[>?I]YFJT4VTJB4E9VIU--4W;W-KJR6Z76Z/P
MQTK7?CAX/_8&_9S^,5K\<_BWXB\5_M ^+_@]HGQF\>_$OXR>*="\)_#CX;70
M\3S7NJ0>,(]&\3P?!G2KV;3O#GA;Q/\ %*+1[C5Y#K!U34M575KJWOK?T;1/
MBIJO@'X#_&'6_B5^T:_CWX5:[\5_AMX:^&=U^S#^U3#\9OB'X.U;Q!;1VVM^
M"O%_[1?Q$T;P/#X+\*ZMJL%KJJZUK_B"QU+PYI%W?00^(X_-LH+G]BUM-173
M!HB_!3XLKHPM?L0TA?@OXP&F"SV[/L@L!H(M!:[/D^S^5Y6WY=F.*H0^'H[?
M1I?#MO\  'XE0>'YPPGT*'X%^*(M&F#L&<2Z6GAU;*0.RJS;X&W, 3D@&DH/
M3R5EJM=O/^M/)JEB(:WA-WDW_"GM=-:\NC5K770_GD\1>(=0^*_[/GQ8M?&O
MQ-^+J?#[X&?MO?L_2:)XEU;]H5/&FJ^$OAYXQN_AS?Z[+XM^,?@3Q/JNA>(]
M(\'WFJ7NI^'O$^I>(]1D\'7LT$QU*SU*Q(B]F^-?Q%\;WOQ>\=_#_P -?M-^
M&OA]\+_!_P (OA4/V=OB!\2_VV/%GP0L_'MSXET+6-0UOXH:;XLM_"7C:R_:
M2FTSQ#:V>C:^^M>(-1T;1XK&WL;S37N?$,UV?VYCT1HK"\TN+X#?$Z+3-1BB
M@U#3H_@=XJ2POH(+:*SAAO+1?#PM[J*&S@AM8HYXW2.VAB@0"*-$$-YX<AU&
M#3+;4/@!\2+^VT4*-'M[SX$^)[J#20@14&F13^''CL BQQJHM5B"B- ,!5P*
M#2MITUO'5)JU^_3\&AO$0O\ !.V]G3J-7M#6W+WBV]?M;Z:_D+X]\8^(/%/Q
M*\6^"_VF?VLM2^!TW@W]E[X/ZI\*)_AE\5+?X:^!OCC\3/&>B>*I_B1XS\-Q
MZI#IMO\ &>RT_7-)T#1=-\+G3=3TD66NPP/X?BO=1C+?7?[)8U:#_@FK^SZ-
M)'CF+6HOV3OAZM@OPX@\,2_$2/4$^'>FB$>#;?QOCPD_BA)@!I$7B;&C&_$2
MZEBV\ROLN_TRZU6XL+O4_@=\5-2N]*D:72[J_P#@GXMO+C397"AI+":XT"22
MSD8*H9[=HV(5020!B]:'7;"UM[*Q^#WQBLK*TACM[6TM/@]XUMK6VMXE"106
M]O#HB10PQ( D<4:*B* JJ  *%!_GNT][>?I]Z^:=>+BDH35I1DTJ<[7BFG;W
M/M7NT[ZMVTT/@[]FFY^+,OQ-@7QA+_P4!?1O[$U8NO[1NC_LC6/PV^T!8/(,
MT_P;8^-?[:W9_LI(!_9S-YWV_P#=A:^;?^"D^I^/O$.I?$K3?%7P-^+_ (L^
M"/PK^ 'CGQ#X&\0>#-&\,:MX-U'XS>*_"'B#2I?&OCB?5O&&C7EGHOPI\.W$
MJZ+':Z/J=[%KVL:IK<<._2M*\_\ 8O[9XG_Z)1\:O_#2>.O_ )35!<OKU[;S
MV=Y\(/C'=VEU#);W-K<_!_QM/;W$$R&.6">"71'BFAE1F22.161T)5E()%'(
M[)>FMUTMKOZ?>MQ*O%3YN26R5E3J*VVOP6O:ZVZGDW[+_B&?Q1^SO\%]8N/#
M7B3PE++\-O"-H=#\6VMA9:W"NFZ+9Z:EW-;Z9J>KVBVFJ):+J>ENM\\LVF7=
MI-<0VMP\MM#[Q6)%<>(X8XX8?A)\9XH8D2***+X1>.(XXHXU"I'&BZ*%1$4!
M410%50    *T].TCXF>)[B/2O"_PK\>6VI71,<>H^-_#&K>"_#FFY#?Z7JE_
MK=O:W,EO%C<;?3+2^O)CMCCB7=YBEK:MQ2[N44EUNVWV)BY5)*%*E7JU).T*
M5'#UJM23;TC&$*;E)_*R5VVDFUZE^S?\"?@QX[\(>*_$7C7X5> ?%6NW'Q/\
M=P2ZSX@\*:-JNI36]MJ:16\3WM[:33R10(#'$I<K&HVJ !BOH/\ X98_9K_Z
M(/\ ";_P@_#G_P KZ[/X2_#RW^%W@/1?"$5VVHWEJ+J^UK57 5]6U_5;F74-
M9U#;M39'/?7$HMHRH:&T2WA))CR?2*\RM5<ZM2492Y7.3CJUI?32^ET?M&1X
M&6"R?+,+B:5..(H8+#PKQM"7)55./M(<R34G"5XN2;4G&Z;5CSSP3\)/A=\-
M9]0N?A]\/?!O@JYU6*"#4[CPQX=TK19[^"U>22VAO)M/M8)+B&"2:62&*5F2
M-Y'=5#,2?0Z**R;;=VVWW>K/848Q5HI179))?<M HHHI#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHKQ?]H;QCJ_@3X.^,O$>@3K:ZVD6BZ-I5XR"3[#?>*O$FC^%
M;>_"'(9[&36ENT4\%X5SQ50BYSA!;SE&*OM>325_FSEQN+I8#!8O'5E)T<%A
M<1BZJ@DYNEAJ4ZU113:3ER0?*FTF[7:W)_%WQ_\ @[X&U6;0O$OCO2K36K79
M]KTJR@U+6[^R,BAXUOK70K'4IK%G1@Z)=I"S(=R@KS7*_P##67P _P"A\?\
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M .5"_P!<^('TR=_]R&-\O^IMZ_AVU^V/^&LO@!_T/C_^$EXX_P#F:H_X:R^
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MVEEXAL+V&UNW-M?K-&KGY8\>?\$^/CIXM7]HGP?IG[1_@KP_\)/VSAX=U/\
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M^HZ3IOQ2\,>)/!MK NJ^&];\%2:M]HUFWU-(K>*RT[4;J*ZEC2T^U_,?Q?\
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MMA<2&Z7!U'_@DGXNUGX/_L__  V\3?%+X+>/[S]E'QIX]F^"D7Q%^ FH>*?
M6M?##X@V.H6FJ>$_B]X.E^)4#>)/%%A-=V5]HWC#PQJOA1+"ZTFW<Z-.T\S@
MM&]KZ=_)M+NM4KO;_@3SXQMOV:5G-1A>+37[EJ4GS735ZRBDVFXI/=2/L.Y_
MX*3_ +-C^%_AAXC\,I\5?B%??%6Q\;ZMI7@7X=_"CQAXN^(_AC1?AAK$/AWX
MG:QX]\%:98OK'A*P^'WB*YMM!\2'4(OM*ZK<6]KI=MJ;3Q,^=^R1^UPNO?\
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MG7K6;2;?4Y;Q/+/F6G?\%9?V7]9O= L=%\-?M%:U-XWU'QGX>^&3Z/\ L_\
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M:EKW>LI;K_##_P!(B>[2^%_]?*W_ *=F%%%%2:!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7RY^U9^TY:_LO^&OACJJ_#;QA\6/$7Q>^
M,_A'X&>!_!?@K4/"NE:KJ/C+QGI'B?6=+:XU/QGKGA[0;#3EM_"M_%/<W6I1
ME9YK8!=C221_4=?GG_P4/_9Z^)G[1NB?LH>'?AI<>*M'?P-^VA\)?B=XY\8^
M"-?\*>'?%O@#X?>'O"/Q-TO7/&OA^[\817FG7.IZ1>^(-(CMK&VT;Q!J,SWG
MFP:)>0P7+0AG6<U3DZ:;GHDHI-ZR2=DTU=)MZJRW>AS>C?\ !4;X)23>"-/\
M<>$_'?PJUS6/BO\ &GX-?$O2?'@\-68^"'B_X$_#JZ^*/C.3QSJVFZ]J6BZC
MH,OA&.SU+2-<\(W^O6-];ZE:S!XT$NS['_9^^,L7[0'PNT+XM:?X(\8>!/#O
MBZ74+[P=8^.K6RT[7]?\&"\E3PQXV;2+2\O+C1],\9:4MOX@T;3=8%GKD&EW
MMJVIZ?9SR>4/R*_:Z_X),Z7\3+;]F#X1_#:W\:ZEX*A^,?Q\^*WQZ^-'BGQI
MI>O?$&+XA>/?A9?6GAGXK>+WUN^TJ;QS?2^/=/\ #%O<^&M%T2?0Y=*L(='N
M]$L/#[3LGZ4?"32?C]\5/V:X_ W[0B>)/@'\:;-;CP1XD\;_  >\1^"6N-;E
M\)ZI;6UK\5?AC>&R\8:5X=T'XC65@FJVOASQ3X>BUWPY9ZK?Z'?:3;36MK?R
M4TK)JRWNKZ[Z&%*>(]I.%5-J,5R24;*;Y*;:<K**:;=FK*4G.UE"R^MJX"X^
M*_PMM/$EEX-NOB5X MO%^I:K=:%IWA2X\8^'8?$FH:W96MI?7NCV6AR:BNJ7
M6JVEE?V-W=:?!:R7=O:WMI<2PI%<PN_BWPH_9EU_X8>,;7Q;J'[5?[5'Q8MK
M:SO[1O!OQ7\7?#76/!UTU[ 84O+JQ\-?"?PEJS7E@Q\^PDBUJ&*.<!IX;B/,
M9_#+Q?\  CQ_^T!\:?\ @H9\.OAE^RUI7B7QIXD_;K^#6H:1^U[=>)?AGI4O
MP+M_ &E? OQIK<LD.LZK8?%1+O3M"T[4SH-KX"T[6+37;SQ-=66JR:=;0W0N
MTE>_DK_BEZ+?JTNF[1=6M.FH-4VY3DXJ-VV[0E-6Y%/XN7E5]$W=M):_N)\!
MOVM_ 7QJ\2_%3P1=W7ACP1XY^'?QY^+GP5T?P5J'CO1K_P 5^.;3X37EI:WW
MC?1O#TMOI&L+I^H)<2SSV%K9:K%I M9EFU>Z"M(GN^F?%#X9ZUXDU[P;HWQ$
M\"ZMXO\ "T#W/B?PIIGB[0+_ ,2>'+:,JLEQKVAVNH2ZII$$;,JO+J%K;QH6
M4,P)&?Q=N?V"/B+;S>+_ (BZ1\$?#MO\;-1_X*Y6O[16F?$""^\!6WC:7]G4
M>/=,DN?$?_"5KK2ZC!HDW@^?71/X(>_379K>ZNK=_#+WESY3^+?!?]DK]NF;
M]LOX>?%CXF?!'P_X%\*^%IOVO+#Q-<> ?#G[+7@CP!_9OQ0\$>,],^'_ /PC
MNL> _$MY\=?B0GB;6&\,7_B&]^+4=K<:;XDG&H_V/:Q176HV[23Z]=;]%IK]
M[M_EK;-5Z\>2,J,YN4HIRC&5E&4E%N7NI1<5>3W5K+NU^]2?'[X$26%UJJ?&
MOX2/I=C(\-]J2?$?P<UA9RQZ,?$<D5U>#63;V\B>'@=>=)I$9=&!U1@+$>?6
M]HOQ4^&'B36M/\.>'?B/X"U[Q#JWAZ#Q=I>@Z+XP\/:IK6I>$[HJMMXGT_2[
M'49[Z\\/7#,H@UJW@DTV8LHCN6)&?QL^&O\ P3NO-#^$_P#P29\"ZW^SGX"A
MA^!][:^)_P!JK0Y[7X=7MG:>+XOV?O$F@OK7BT)J%S;?$;5%^)>I01+>:7)X
MK(NI_P"T%<:7&]U'S?PF_P"">WC[X2>&_P!FW7/ O[/W@GPK\4O '[??[2_Q
M"\3:O;WG@:RO+/\ 9X\;^$OVE]%\!P:UKFDZR]]JO@K47UCX,:>/!>E7.I:Q
MH]E]@W^'K :1JALA13^TEJU_P5ZC]M7]V]#1J+E;GO'F]C=?!9N*J36K6M.3
M:6J7[=>'/BC\,_&-]XBTSPC\1? OBG4O"$C0^+-/\.>+O#^N7WA>96F1HO$5
MIIFH75QHDBO;SJR:E';,&@F4@&-PN98_&KX-ZIX4UCQYIOQ:^&6H^!O#US)9
M>(/&=CX\\*W?A30[R)XXY;36/$5OJLFCZ9<QR30I)!>WD$J/+&K(&=0?YCO#
MW[ '_!0_QQ<_%>3Q%\*=%^%6H^,?V*_BS\&[BT\/Z1^R[\)_A[=^--8\?_#?
MQ;8?#;PVOP'\2ZOXTU[P1XHTS0/$.A:9X\^*DUQXBLH[Z\O=7M]$EO);>]^\
MOB'\ OB%XY\/? 'QAX5_X)LZ7X"\._!CX]>%/&OQ3_9BE\5_LW6-[\>=!T[X
M-^-? >CZ]"OAKQC<?"S59_A1XI\0Z'KOAW3_ (A>);*ZUV#1 %M]-DBM4)96
MWZ-[K3LK7O\ \.O,4<35DFWAZD;6^*%1-W:3:2@[**=VKN4DFHIO0_3'QC^T
MYX6T'XB?LJ>#O"T.C_$'P[^U+XS^(OA31O'_ (;\7:==Z!H,'P^^#OQ ^+$N
MM6DNG6FJV/BFVU)O 4_ALQ6FK:8EC/?-J#7=R;%]/N.FT[]H#P3J7C#5-'AU
M#P]_P@EA\/-#^(%K\7D^(?PVN?!&JP:SXKUCP?\ V7:P6OBV;Q-";/5=(>!_
M$-]H5KX3O+Z8Z-IVN7>MV=]I]O\ @UXU_P"";7[4WQ7T32X?!OA4?LK:-X__
M &L?VCOC+I_@#0_%7@R^M?V>_ ?C#]E#Q5\+]'T'Q"G@SQ"FE2V/QK\?1)I_
MCS0_A'?ZQ)X=T+XC:G-8ZC;3VEUJ%EZ5\<_V2/VF/CAX!^)DNE?LM:=\*)_&
MG_!.SX(?L^V'P?TCQO\ "R3P_P"'_B-X _:I\4>*O$?@;0+S3O%D>E+X:C\!
MM9^*]"U:XDLK&?0]6L=+NIX?%D.IZ)9JR[KHN]MFWOTO;SL^I*KU_?;HSLGS
M0]V5I)4HMQ7N-I.=VG*T_>Y4FX3BOW5T7XI?#+Q)H.N>*O#OQ%\":]X8\,SW
M]MXD\1Z+XN\/ZIH/A^YTJ,3:G;ZYK%CJ$^GZ3/IT)$M_%?W%O)9QD27"QJ<U
MXE\4OVU?V9OA#X<^%_C'Q5\7/!%QX2^+_P 2]&^%7@OQ3H7BSPMJWARY\1:M
M++%-?W>N1ZY'I=MX<\/F)6\4:VEU/;Z"D]J;Y$-Q$&_)O]K+_@G9\8-?\0?M
M4Z3^S;\,-+\$?"3QE+^POXLT?P/\/[[X5^#=,^*K_ WQ=XPN_BKX1T;0/$27
MO@W1_$K>&I?"XL[SXB>&(?!_B6]T_3-,U>74],&I>1S=K^P-\2]&^#.E^)='
M_9N^)GC+Q-HO[>/P4_:+\0?!7XP^*/V23XG\7>#/!_A[3/#7Q!O/"&F?#-_#
M?P(\)S>(M.2Q@U/0=0\213^+O^$3AO=7FAGN+2*1\NFZZ65]=;?YO[MBI5\0
MFXJ@]$WSVG*#Y:DHNR4>9WC%2BEJU--7LE+]O-#^/W@J]3XH:KXEOO#_ (%\
M$_#77=%TO_A8/B/XA?#9_"7B/3->\-:)XDT[Q);W^D>+=1D\-:9=1:Y;VMG;
M^-8?#FJZ@!%J5A8W.D7UA?7/77/QA^$=F_@Z.[^*?PYM9/B(J-\/TN?&_AF!
M_'2R&,1MX.674U;Q.LAFB"'1!?!C+&%)+KG\1/B#^R)^T'=?'#Q)\;G_ &8H
M_B5\,;/]L7X<_&AOV;[GQ7\'[>X\;^!K?]D#3_A)#?:=:Z[XO@^';ZK\(OB%
M.YM?#?BC5-)T_4_[+N=2T"XFBM]&O+GJ/B3^SE\8;SXR? 3XL_ ']B2;X3>*
M[73?A]X8\8^'/&,W[)?CG]GKPI\.K#XQ:OXKUO1=4T67Q+/X]\">/?#>FZGK
M/C71_$_P L+JWN_$FKZ-I%[/K,&ESW%N.*OHU;:]^J2OU\^E]=/,?MZJYKTI
MZ2Y?AFY23E;F5H*-ELHMJ5ES7=U?]S[Z[CL+*\OI59HK*UN+N14P7:.VA>9U
M0,0-Q5"%R0,D9('-?E'\./\ @K/X#\7^#/#WCSQG\ /C/\*/#GQ(_9R^)O[3
M?P3U'Q-=?#K7+7XN^!OA+X._X3SQ=H^BR^#_ !EKK>&_%T'AAXM4M-'\9Q:"
MMU 9BESOMY(Z^V?@C\<]+_:9^&'C;QIX1\-:[HVA6WC?XK_#3PY>:U)IQ@\;
M1_#[Q!JO@J?QEX<GLKN>&3PQKFM:9J,6D7%T\$\B6<LDL21&.23\K/V??^"9
M7BGP)^P#IEE\07^*/C;]K?2?V!_B7\ _!/P[\?\ Q&\(ZWX.^#7B?XB?"R[T
M#7? GPRA\.1Z7X)TN'6]8M]'T2Z\3ZOK_B2X738$MV\51Z6;II"R2UWO;?9=
M_P!/ZL%6=9SIN@[PE2G4;Y4XOEE225VF[RA*;A%6;DDW>*:?VA\%/^"@^E_$
MGQ7\%O"OQ(^ ?Q=_9^7]I'PU_P )+\ _%/CV\^'OB'P=\2L>&T\8-X=MM<^'
M_C#Q/_PCGBZ3PNTFMV7A_P 4VND76HV=M=K9-+=0-;G]$*_%SX4?"']J/XP6
MW_!/+X;_ !._9VUO]GKP!^Q1J/@;XG^-O%WCGQ_\*/%>M^/_ (A_#KX*>)?A
M)X;\)> ]"^%?C?QQ]GT"[N?'&N:YKFN^)[[1WCM--L+>STZXNI74?>_Q3_9A
MU_XF>,]0\7V'[5_[5GPKMK^WT^!/!?PL\8?#/2/!FG&PLH;1[C3['Q)\)?%>
MKQW&H/$;W4'N-;N4DO9IG@CMX2D$:=M-+::ZW_S]=^MNFM49U7!N2G/6/+S1
M5.;3A%RO&2@O=FY13Y5=);ZM_2FM^(= \-6D>H>(]<T?P_837EGIT-[K>IV6
ME6DNH:A.MM86$=S?SP0O>7UPZ6]G:JYGN9V6*%'D8*?E[XQ_MA?#?X8^'?@G
MXR\.ZGX0^)7@OXO_ +0G@WX"W'C'P[\0=!_X1?P@_B>P\3WVH^*[S7K&+6])
MOXO#(\-NFI:.]YI9"W+23ZI9?9BDWQQ_P5#\#W7A?]B3X8> [J/Q+^T/=:?^
MTW^RWI<MA\3=:\-?\))\56G^-.@O_8/BG7(=#T'PJDNNK.-%>[ET.PTJ.V>(
MWL/E+/*WS4O["7Q7^)GBO6?%FL_LIZ!\*/@]\1_^"A'[*OQAOOV8M5USX1ZK
MIOA3X6?!WX0:]X*^)/Q#\3Z+X0\2:G\-Y9O&WB:YT^]NO"/A6^US5=0M(+6Z
MU#3[NZEO_++:7\[?EZ7WZ;=;)IDU:U53=*G!N7+"5[2?+S.>]HRC9.'*];^^
MFE:+O^YES\9?A!9>";3XE7GQ6^&UI\.=0D$5AX_N?'/AB#P3>RF>6U$5IXJE
MU1-"N9#<P3VX2&_=C/#+"!YD;J+.L?%GX5^'H- NM?\ B7\/]#MO%4%K=>%[
MC6/&7AS3(/$EK>W6GV-G<Z!+>ZE!'K$%W>ZMI=G:S:<UQ'<76I:?;Q,\MY;I
M)^#GQ._9"_:Y\'6GQ)\)_!;]G_P=/\+]>_;B^+WQ.T#3=.\)?LR?$'Q)X0^%
MOBOX4^$++0M?^$7@7X[^)[#X2>%;7Q'X]B\2V7BB'5H(/%&DZ=+=7FD^&Y4O
MF,_H/[%_[!WQ4\-:E_P3^?\ :3^"^@:K:?L\?LY_M=>%O$<?BJZ^&WBVP\#?
M$7Q]^T+X(\1_"N#3])T;4=0TF6]G^&VGZW)I.H>%M,FT;PQ:0MI/G:)=/9V#
M.RWNMK_/M^*_RW!5ZSGR>PDMDYM24+^TA!M/E]Y<LI36VD-7JW']CV^.?P26
MXU6S;XQ?"Q;O0]'U#Q#K=JWQ!\)"XT?0-(OI]+U77-5@.KB73]'TS4[:YT[4
M-3NUALK*^MY[2YGBN(I(UN:S\8_A%X<\-:%XS\0_%3X<:%X/\4&W'AGQ7K/C
MCPQI?AKQ$;N/SK0:%KM]JD&EZN;J'][;_P!GW5QYT?SQ[EYK\0OAW_P33U6.
M']C[4_'?[-?@.\\1^$?VX_VF?BS\<[_58_AOJ][<?"[QO<?&:^\!:GXFNEU6
M\_X3'3;Z]NOAA<VOAJ"37+S2IXM/DO\ 1[!M-U VOEGQ4_8M_;-TOX<Z?\)O
MAC^S[X1F^'=M\7_V]Y=%CT[PI^RO\0_&7A#P%\4?CCKFM? [1?#D?Q[\3?\
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M-WI]I?:A?VMAK\>J-I-Y<6-AIFI7MY#;W<DEM::??7,RI#:3O'^-OQY_8O\
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M?4=-BN;.)X)EDF4Q.%XGPK^T3X O_AKX7^)'Q&U?PO\ !:T\5ZMK6AZ?IGQ
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MK*T\4ZCX9\4^"?B'X]\,27GA&35-)D\3:)JVK:3K>E6NJ65Y+I[6LCS1^?\
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M[_3O"?AC]KW_ (*M?$?7=8DU/09(M/\ !?Q^\5_;?A!KDEO!JLMY+#XUM/\
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M78],U/5;NXGUF"^.G6FB:=#I<MOJ>LR7!L=/OKG3[.ZDBGO8%;\>/B#^Q_\
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M/P-J<'C#Q]X1/C71X-0M-5US2;!(+I>P_9H_9^\*?'OP5X9\!Z?\$= U+6?
M_P#P5?\ #?QI_:_^'=GX ^%'A#X3>$]$N_V>/'TVF:1X:T#P7\2?B?X0\1?#
M719]<\&QS^&AXQ\3:E)KGB36_P"V-#BL]2O(2.-DG?UMTV\_/^EJ3];J.HJ:
MI:M:-N:3O.459."E?ECSM-744W9I)O\ I+/Q \!#5-#T0^-_"(UKQ/90ZGX;
MT@^)=&&J>(=-N8S-;ZAH=A]M^UZM93Q RPW=A%<02Q@NDC+S3U\>>!GU?6=
M3QGX4?7O#MHVH>(-$7Q%H[:OH5@J*[7NLZ:+PWFF6BHRNUS>PP0A&5B^""?Y
MW_B)_P $]?B=J7[7WQ3U+7?AW\;[_P )>)?CU\(O'?P)\?\ P,TW]E#3O!GP
MU^&?@31_AS8^&/"4_C/XBZ8GQN^$MO\ #;4?"6L13>&_AGN\.ZEX;NH[30],
M\_4M3^W==J7[)_C>7XC_ +8GA6R_96^,.H?L^?&3PY\<[WQWXDU/PW^S'I?[
M26J>-O&_Q'T;5+"P_9T^,FF>.3X@\8?#[Q1,=3\53>#?CLMG8:#X<T;0]!$]
MSN/AD'+MKV_&WG?KV7RT*^LU;R3P\E:<HIWE9\M_>T@[1=D[ZM*2]UZL_;UO
MC5X5N_%'PRT#PK%)X]TGXG7/C.TM/'7@O7O ^K^#?#5QX+T5-9N8O$%U)XLM
M-9NY=6#-IVF1>$=$\4RV]_&[:]'HMAMOF['3?B#X!UB;7[?2/&_A#59_"J2R
M>*(--\2Z+?3>&XX%E:9]?BM;V5]'2%89FE;45MUC6*4N0(V(_!'P+^RW^V-X
METO]G2VC^$WA_P""5SX"\3?MVZ7X8\6:#X/^%7P?\1>&]$^)W[,MS\/O@]\3
MOBSX&^#NO:MX+TWX@ZGX]G6TO;KX?27_ )MAH^CZK>Z?I,KF)>+\$_L<_&/5
M_#'PSTWP!^Q=J'[+WB3X/?L._M-?!KXW:Y/J7PHLI_VF?B3\1O@K;^!_!V@Z
M5J?@7Q;K.I?$&VG^(MG=_$$^+_B<VBRZ3<7, B87FJ:EY*MOW5M-'KM_6_F-
M8BI=?N9VDU9-232<:5[6@UISS;YFOA:3;TC_ $5Z#XT\'>*I]1M?"_BSPSXD
MNM'>&+5K;0=>TO6)]+DN(_-@CU&'3KJXDL7GB_>0I<K$TD?SH&7FOD<_MM6>
MI?M%_$?]G#P-^SK^T'\2=9^$.N?#;0_B5\0/"=K\';?X=>$G^*&C0>(-$U"\
MN?%GQA\,>+[S3].T>2XO=:?2O!U_=0I87<=A::C-]FCN/F+]D[]CS6OV??VA
M/V:_%'A#X.:/\,/!\'_!/BQ^''QTO_"T'AO2+76?CIIWB;X>:I:P>,[?1[L7
M7BSQ=$&\;7/_  EEU!JS2+)>I)K;B:"-^C^%?['?BF]_;\_;&_:"\=7GQ@\%
M>%M=\8?LWZ[\)9/!GQ<\0^$O!/Q(C\#_  Y^P^)D\8^"_"OB"&S\4Z?I>N6U
MOI5Q8>,]*\FZM+F]M;>*XL+NXW"MKUT\][KM\QNI6DJ24'3DZJC4MJE'V;G=
M.4-KVB[Q3<DXIK<_26/XC_#R5]9CB\>>#))/#EI-J'B&./Q1H;OH5A;W=QI]
MQ>ZRBWQ;2[2"_M+JRFN;X00Q7=M<6SNLT,B++_PL#P'_ ,(O_P )O_PFWA'_
M (0O89/^$O\ ^$DT;_A%_+$QMS)_;_VW^R=@G!A+?:]HF!C)W@K7\^WC?_@G
M7\5;C]CGQ'8>%/@_'HGQ@US]OCQW\:?C#8>&K+X57?Q4^,'[/X_: \=^)]+\
M.VFJ>.4U;P/XLBET"]\(^,?#OP\^(=[_ ,(;?RZ-!IVKV%G=3RI7GWBG_@GS
M\:/^%)_#63P/X%_:5'@33?VO/%7Q@^)_P-\3Z-^QN/B!>Z3K/P<T_P ':/XS
M\"_!^QL9?V9H=,TSQA'+=77@C6R+V>>34?&EI%;:U)9@5RKI+K;UVVMZZ]GI
MYD?6:R_YAIM^SC/1NR<G;ENXJ[BM9*R:U\F_Z-O&OQ4\"^ ?A?XJ^,FO:_9O
M\._!W@[6O'FL>(M)DCUBT;PSH.EW&KWU_ISV#S1ZD&LK65K5;6207,A2.-B7
M!KR#X!?M/VGQR\)W'CO5?@]\6_@1X-GTWP)K/A/Q'\<1\,=#TSQ]I?Q$-POA
MZX\+R^#?B9XY>*8R#28+G3?$T?AW51=>)= L[2QN[NZN(+3PG]DCX):M\!/V
M(=<^']K\+/B%XTNKN;XO>(K#X%?&_5?@_I6N:K9^,-?UO4/^%>SQ?#NRN?A#
MX1\-^(X;J:73/"^GV]UH'A^TUQM(N_*@BEAM_P R=2_9*_::OOA/^TSX-^!/
MP.^-_P ,/V=(I?V2/'_P>_95^-_Q,\$^)-?A^*'P7_:?\%_&7XDZ;\$Y[?X@
M^.=+^'_@75O OA"32['P_K'C.RT;4/&-]9W&G66GZ?#,Z))._P K/U:UM>_7
M]-&BIUJL53FJ<G>E.<J44V^=0<DG-P:Y;KET<9J37NS3M'^BG4/&7A#23J*Z
MKXJ\-Z8VCS6%MJXU#7-,LSI=QJL9FTN#41<W49L9M2B5I;"*Y\I[R-2]NLB@
MFJEA\0? 6J:)?>)M,\;^$-1\.:88AJ7B"P\2Z->:)IYGMK2\@%]JMO>R6%H9
MK2_L;J(7%Q&9+:]M)TS%<0L_X)?$?]FO]H/]IWQ?^TEXQ\9?LM^+/"'@KXS_
M +5__!.WQ39^ /B#K_PYU'5]:^$WP6NKK3/BKJOB>P\-^+]:T>UM;+3@\VJ>
M'3JNH7-YIEXEM FH22W5K#ZO\;OV&OB4G[5ND_#7X*_#C1=$_8C_ &E=>^ _
MQ$_:2M_#Z^'/#WA/P)K'[+EYJE^/"=AX-M)=.,>F?&W2=+^%OA6\AT+2+NUE
MMO#6K)JWV.W-G*1*]NGKVLM?S?HANO5U:HR<;\J;YU)N4ZD(/E<+J+Y8.4G\
M,:G,URJ[_7;X??%31O']SXDTY=-U#POK7A[QAX\\+1Z!XCU/PC+K>NZ?X!\2
MMX7O?&VCV'AGQ-XCE'A#5[UK:?2YM6_LK7;6"_LK?Q%H.@ZI-_9R[+?$OX<I
M=:'8OX_\$I>^)Y)(O#=FWBK0ENO$,L5W+82Q:';F_$VK217T$]G(E@EPR7<,
MMNP$T;H/PA^(W[*O[7WP]\/>-_CY^SY\-;VZ_:2TS]L_]NNW\,Z"=?\ #>GC
MQ5^SG^U=JOB:#0_%EU=W&L0V+Z?X7\:VOPP^*EOI5[>VNJ1:?X?U94L$U9[6
M$?/W[7_[!O[5>GVGASX&_ C]G_P]X@\&?#+X%?L]^%_AK\8/"7PM^!>N_$+Q
M7XN\!ZH->\?W_C3XU?$GQ]H'Q'^$^I6_BB'4O$>B1?"_PS<'Q!?^(+VYO]1#
MZK?PP%DUH]>S7:U^OG?:Y#Q-6,6_83DU&+T4FY<T4UM"U[J:DM'%J.GOI']"
M/P5^/UC\9?&O[17@RU\-76@S?L]_%Y/A-?7]QJ4-_%XGN'\">#_&XUNU@CM+
M5],A$?BQ=.-C-)>/OL6N1=%;@00_0E?E+\(_%'B#]E;XU?&V#XI> O%UU>_M
ME_MU^'?#GP<C\/R>'-5NM6TFY_9_\$#7/B'J=J=>@NK/P;X6?P-XED\2W7DR
MZM9167VB/29X)8I'_5JDTEMM9??RIO[F_D=%&;G%\U^93FFFK-+GER)JR^QR
MOS33ZA1112-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6_AQ\"O$FD?%3P5^T]\+?@/\5/AWXNUSX?SW/AO_ (3'5O"-W!_9^M6WBO\
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M3QGX.UBYMS>6=CXJ\#>/]!\,>,?#\M_:*UWIK:MH=I%J-JK7%C)<0JSCX?\
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M:4I<ONVN[KE=K+5WT_07XC?M+^"_AU\9OA5\!'\-_$'QI\2/BOI^J^([#2_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0;76M2LK%I[BRTNYUO2(+ZXCCMI=2LDD:XC^2?B3K/P6\-_\%2M>U3]K._\
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MECUC5KZTDN;8ZE.)KA&D]/\ &O[1G[/?PVT_POJ_Q%^._P &O .E>.+26_\
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M2WU#2]6TJ\M]0TS4K"[B6:UO;"_M))K6\M+F%TFM[FWEDAFB=9(W9&!-^OS
M_P""?FIZKHG_  3,_9W7]FO0=/\ '_B?P]X"M]$_X1+XL^,9? B:?XUT_P 3
MZE9_$[PMXAU[P]X0\6-H,OA#Q7_PDNDZ7IUGX7N+9+/3=-L8##9-%=CZ@^$G
MB_\ :]UOQ9]B^-GP/^"7P_\ !?\ 9MY-_;_@'X]>*/B-KW]K(T(L;(>'=6^"
MO@.T^QW"M.;B^.NB2V,<82TN/,.Q6WVT\U?IMWO?2QU0JJ4:;:E>I",_=C*4
M5S).W.H\O7JUHKV5T6]9\3_LI_"?XWZKX@\5?$7X1^!?CW\6/#_A'PO/;>,O
MBAH>C^-O%/AKPS=:M_PB>B^'_"_B7Q)%<1:9!J.MZO-%:^&=(M8=4U2^GNKU
M;V_VRKWWA?XZ?!SQGJ,>C^&OB7X.U+69_&/CCX?V6BC7+*TUG4_&?PTVGX@>
M'='TF_DM=1UG4?!\;)/KZ:5;7B:=:NEW<2+:NLQ_(K]E;Q+^RCX;\??MW:5^
MV%JOP3T?]H'4_P!L;XCW>O6OQYN?!MOXJU_X2SOH/_#/C^#[;QL_]H:OX&A\
M&_V=:^%[?P['<64.NIJB6T27THW^(?!/XC>+/!7Q;\%:1X7O[&PT_P 5_MW_
M /!6J75FDT#P]J5XY\)_##5O$OA]],U35=*O=4T+[+K%G;7-Q_8=YIPU2*);
M'51>V&;4NU^^Z2;ZW7Y;>B9A'$6Y7:"4V[QCK.#=6$&IZI*3<VY::236MKO^
MBC6=9TCP[I&J^(/$&JZ;H6@Z%IM]K.MZWK-]:Z9I&CZ1IEK+>ZEJNJZE>RP6
M6GZ;I]E!-=WU]=S0VMI:PRW%Q+'%&[B73=2T[6=.L-8T>_LM5TG5;*UU+2]4
MTVZ@OM.U+3KZ".ZL;^POK626VO+*\MI8KBUNK>62"X@DCFAD>-U8_P Y7P_^
M._[5F@_!/X.^+OB)^T;XC^,P_:I_X)B_M8_';Q%H'C;P%\+;70? WQ%^$WP^
M^'&N>&+_ ,'6.@^#M.%SIM[;?$&]L/$FB^+Y/$VFZU)8Q7;V\$5U-8KZY^SC
M^T=XQ^)7Q1T_2/B[^V6/V=C\-/"?[&%O\-?@78Z3\(O#MI\?M+^)?P:\!>,?
M$VO76F>*?"MQXD\4Q>./&NNZ[\/-(L?A7?:!;>#I-!58+5+J>V6AQL[?CKZ>
M?732_P"8XXN$G'W91YK*TG!6<H*JFY<_+;DDGHV[^[N?NMJ^K:=H.E:GKFL7
M<6GZ1HVGWNK:I?W!(@LM.TZVEO+Z[F*AF$5M;0RS2%58A$8@$\5P,_QI^$=E
M\+='^-^K?$KP3X>^$&O>'?#?BW2_B5XH\1Z7X5\&3^'/&%OI]UX7U>77O$=S
MI=A9VNNPZKIO]G&]FMI+B6^MK=4^T2K$?YTOAQ^WM\3_ (M_M":OX'T;XH_$
MGQQ\%?C-\$OVU/M6A?%/6?V9Q>Z9>?#+PIJ=_P"'M5\._#+X11'XL_"*WL[G
M3M4T.#2_C#>7-UXAT>X6[1IM3LKF2+W#]JN62#_@@]^S'/%+HL$EO\(/^"=<
MR3^)69/#D#QZI\#V6;Q ZLC1Z+&P#:HX="MD)B&4X-"C=I7W5[_+MI_PVHOK
M:E"I.$;JG3JR][2\H*G)6:;O%JHG?KTTU?[I_#_XG?#;XLZ#_P )3\*_B%X'
M^)?AC[7/8?\ "1_#_P 6:#XRT'[=;!#<V7]K^'-0U+3_ +7;B2,SVWVCSH@Z
M&1%W+GN*_E+N_P!I+XS_  "B_;UU;X3ZK^S_ #^.OB!\<_V)YO$_QL_9EU[1
M8?V9/AIX&^)5EJ'PRU&>UUOQ1H?B;PYX)^(.A6W@R*X\>^(_%\'BG2+#_A//
M#?B6]TY$2&P;Z%\*_'3]M77/"'P?^'^H_M3>&H;CXC?MW^%?@YIWQ3^%_C7X
M)?'_ ,;Z=\+/$?P/\5>*_$'A7Q;XF\,?#;P[\,)_$^G^)--_M'PY?6/@^VO]
M.L)]'.M6^HFSF@U Y=+WZ7^5DW;[[:V%'&1=H\DY2U3Y4N6_M)4UK*2MS.-]
MVE=+F>Y_1?7C?Q5_:#^"_P #[_P/I7Q7^(GA_P $ZI\2==_X1OP+INJRW#ZA
MXDU=3;B>&PLK*WN[G[+9?:[4ZEJD\4.E:8MS;OJ%[;+-&6_G_P#B?^V-^V3X
M0T7PC\#K'XR!_P"S?VV?VK_V?O$O[1_B[Q'\)?@OKVK^%O@YX7\/^,/AKH'B
M'XA>+?ASXG^$/A'Q3XC_ .$IOK%[UO ,,GBB'PA!I.D166JZE/</I?#6']H'
MXJ?M;_\ !./QM\8?V@_[8\91? ']M2>ZUGX.>)/AAXX\ >+]'^&?Q'\%:9;>
M?X@T_P"'Z:%K%WXXT5K'P[\3[WPW!8V%S?>'!/X.;PR+B]6X%%/[2^2;[>G?
M7M^3>+3?+"G/GYJ47S)<J<YTXM7YDFXJHG=/E;3LW;7^B_PUXQ\(^,])TG7O
M!_BGPYXKT/7K!]5T/6O#6N:9KNDZUI<<RVTFI:3J.EW5U9ZC8)<,L#WEG--;
MK,RQ&0.0M<-\1OV@/@-\'=1TG1_BY\;?A%\+-7U^VEO-"TOXC?$GP;X(U'6K
M2"=+6>ZTFQ\3:UIESJ5M#<R1V\L]G%-%'/(D+LLCJI_G]_9"U?7?&G[2_P#P
M3H^*7Q'_ &C=?^'5]X\_8;^)\>G:%80_![P+X0\?>(]!_:;^$UD/A%HVDS>!
M+:"=/B#9-!J6L^'/"DUGXKNY/#\%UX9N])MTU5;KV?\ X*)^!_C7X^_;H_L3
MX"Z-\'/$7C@?\$MOVCKAM!^,_@?4?'6DZWI/_"\/A/:W>D^$+*QU;3;;2?'U
M_<75G;>'M:UFUU[18$EO;2_T2Y6^2>U%%/KT;U5OZ\^WF'UJ3I3J1A=QG2@E
MHW)5%2E=14D]JCM%M/1;['[WVEW:7]K;7UC<V][97MO#=6=Y:31W-K=VMQ&L
MMO<VUQ"SPSV\\3I+#-$[QRQLKHS*P)<ES;R336T<\,EQ;")KB!)4::W6<,T#
M31*Q>(3*CM$9%42!&*9"G'\H?QL_;FE^!/[*/[._AG]D?XV?&K1I/AQ^PKX$
M^*.@66H:_P#LO>%?"DYLWU/P_%%X\N/C';3>,?BMXFL_$?AG4_"OB+X8?!JW
MLKW18K/99W#W&I:<L'M'B3XK?$GX,?'W_@IW^T)X-^+_ (FN?C-%^RA^SW\:
MOAE\ M6D\ SZ1\19=4^"WQ"OY9M/\-/X3M_&_BKPY\$[F'4+[33X<U6)K6.W
MND\:7.L1N IR^?\ 3:W^3U_47UV%[<DG91<Y1:<5S4ZDWR/[=G3E&RLVVK:N
MQ_2U17XW?\$S/B]^TI\0?B%\1]-^*WQW^&?QM^'4OPT\$^*_#[Z'\;?@[\8O
M'7AWQ??ZMJ5KJ-S*WP;^&WPWT[PYX(\3:48IM/T;Q18ZAK>G:KI$\-K?S027
M2Q?LC4O_ "_%'32J*K!34913;5I6OH[7T;5GNFGLPHHHH- HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#*MJ)([_ %V"22'6;Q&6XU.)WCO9)T9E/2T4"LNRUWT.8'@GP8+73K(>$?#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>ny20077915x1_flowchart01.jpg
<TEXT>
begin 644 ny20077915x1_flowchart01.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ8&/I2U)^L?@%%%% !1110 4444 %%%% !1110 4444 %%%% !2$X!."< G
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M:/\ A*-$_P"@YI?_ (,],_\ CM')+R^_^OZ3\KGM8=W_ %\_/\^S.FHKF?\
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ME*ZI%!JGG:Q=//?3'4[:VU%VG$E];6UW)-:P?2%>8_"#X=>%/A#\-_!'PO\
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M*Z5*2NN[6BNNKL[+=G^=NJ*F\*H7$LZX"@85;B947  P%0*$'0(    *,/\
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M=_:VXC0Q/.:_T-?"ES+=Z#IES.0TT]I!-(025WR(&(0GJBDX7)8A0 S$BO\
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M^6WR,YU8_P"L^5)3]RI@Z[5G[LOW5/E:Z.\E9>KL?W?1_<'U;_T(T^OB*/\
MX*)_L@A%W?%#4U+#S K?"[XN!@LG[Q<C_A!.#M8$CJ#P>:?_ ,/%/V0.WQ1U
M+_PU_P 7/_F$KE^[[UY?Y_U9GU\:M*R]^.RZ^1]LD@$ D L<*"0"3@M@>IV@
MG YP">@-)O0]&4\9^\.AS@]>AVMST^4^AK\_O&O_  4S_8^\,>$?%'B(_$^\
M<^'O#FN^(!%=_#_XF:3;3+H6DWFKRQ3ZAJO@ZSTZVA:"RE,TEW<PPK")"7R
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M_M\_M1VEEXAOX;"R_:D^*T.GK;WJ1PVUI;_$;54L[>V<Q@0Q16ZI'"A<".(
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M\-M7G".%8QLT+FV:4*^QV2.7?A3E2A-?WB?\&^/P(^+G[/?_  3VT'P1\:O
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M_P"M/\D'LJ?\D?N_KLON/)_^%$?!7_HE/P]_\)#0?_D"C_A1'P5_Z)3\/?\
MPD-!_P#D"O6**+OO_6G^2#V5/^2/W?UV7W'D_P#PHCX*_P#1*?A[_P"$AH/_
M ,@4?\*(^"O_ $2GX>_^$AH/_P @5ZQ11=]_ZT_R0>RI_P D?N_KLON/)F^
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MTJ[NDC^[47:BKP-H XZ<?Y[<>@ XIL:!%5%4(J(J*BC"*JJ,!5 "@+]T!>
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MQDWUDOR78_/^*\NKXC%X>>'HRFO8--Q3LG[1NS\[.^W7[O@BOWC_ .#;,_\
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M_$VLW<*6\^H^(?'6O7&KW ,*2SE+?3+)K'1K$/<2LMGI\(7RHREO#[.L,2C
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M>DE)(\D9C+ #:7D"AM\: X"\%=SN<#S1@@@8_P @/6?V3?VF/AYJ-UX,\8?
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M&??CQ_T13XM?^&\\9?\ S.T?\,^_'C_HBGQ:_P##>>,O_F=HNNZ^]!]2QO\
MT!XC_P !C_\ )>?Y]F>0T5Z]_P ,^_'C_HBGQ:_\-YXR_P#F=H_X9]^/'_1%
M/BU_X;SQE_\ ,[1==U]Z#ZEC?^@/$?\ @,?_ )+S_/LSR&BO7O\ AGWX\?\
M1%/BU_X;SQE_\SM'_#/OQX_Z(I\6O_#>>,O_ )G:+KNOO0?4L;_T!XC_ ,!C
M_P#)>?Y]F>0T5Z]_PS[\>/\ HBGQ:_\ #>>,O_F=H_X9]^/'_1%/BU_X;SQE
M_P#,[1==U]Z#ZEC?^@/$?^ Q_P#DO/\ /LSR&BO7O^&??CQ_T13XM?\ AO/&
M7_S.T?\ #/OQX_Z(I\6O_#>>,O\ YG:+KNOO0?4L;_T!XC_P&/\ \EY_GV9Y
M#17KW_#/OQX_Z(I\6O\ PWGC+_YG:/\ AGWX\?\ 1%/BU_X;SQE_\SM%UW7W
MH/J6-_Z \1_X#'_Y+S_/LSR&BO7O^&??CQ_T13XM?^&\\9?_ #.T?\,^_'C_
M *(I\6O_  WGC+_YG:+KNOO0?4L;_P! >(_\!C_\EY_GV9Y(G4_3^HK_ $/?
M^#7./R_^";6I<YW?M%?%MNF,9M/!O'4YK^!]?V?/CT3Q\%?BT@[NWPX\9N%!
M )8H= BW!>N-Z!NF]0=P_P!"O_@W ^$'Q-^#W_!.C2]-^*'@W6_ VJ>+?B]\
M2_&^AZ+XCTZXTK6'\+ZH^@Z7I6HWFGW>VYM'U&;0[Z\2&:,,()H"N$*YY\54
MC5NX/2VM[?W--&][71]?PIA\3#&SK5*%6G3DN5.<4M;IJ]F[;/KON?OK1117
M ?I(4444 %%%% !1110 4444 (55AA@& (8 @$!E(93SW5@"#U! (Y%*  ,
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M^NW!_ D9_+VJ2BFKI6N[?GZBLKWLK][:B      #@ #  ] !TI:**!A1110
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M56,B-0A;+@Y8@;%%._\ 7E_7^>Y"A9WO^'_!_K5;,.G2BBBD6%%%% !1110
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M''3BI**CEEI>3=NFO^?D4HQ7PI+T27Y)!1115#"BBB@ HHHH **** "BBB@
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M<>%=/LK_ /MGS1::UXHTRRM=1NM+_L*]35;.U+SV4S6T,B[KB//0_!W]J_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK<*V/[I_D:=37^XW^ZW\C0)
M^E]5^>_RW/D3]GUB?CI^V0N[.WXG^!!C.=N?ACH)QC/&>O;/6OKVOCC]G=U/
MQ^_;44'YE^*/P]W#!XS\*O#Q'.,'H>GI7V,2!C/?I04VF]'?1+YV6@M%%% @
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *:Z)(-KJKC((# '!!R&&>C
M\AA@@\@@TZB@#XP^*G_!._\ 8=^-OCFQ^)?Q8_96^"/C_P <Z?)#-%XF\1^
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M;,W=K!(IVF"UEBA5 (E01J$'V!11=]WVW>W8:A%?9CT^REM;R[J_DSYMU/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $8
MD D?YYJ.0_N9#W\IC_XX:D8$@@?YYJ.4'R7]HWS_ -^V%"W74F7PO^NI\"_L
MLG/[3O\ P4&)Y(^.?PS0>R_\*&^'[8^FXDU]^+]P?4?^A5^?G[)[*/VGO^"A
MZDC*?'CX9AAZ%_@+\/MN?K^G?%?H&H^4?@?PSG^54M''7L_35_\ #F%!/EG?
M=UJCL][>U;OZ.^X^BBBI.D**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9*,QR =2CC\U(
MI]-?[C?[K?R--:M+NT!^>/[*#@_M2_\ !1N/G*?'GX4Y/&#O_9_^'L@QSGA3
M@Y YZ9'-?H;&<QH1T**?S4&OSO\ V2OWG[57_!2+/&WX_P#PGC&/1?V=/AQ)
MD^Y+D>F ._-?H?\ ZM44<A5"\]2% 'L,G\J;:M%=KW^;,X)J4FUI>5OF[K\_
MZ9)15.26YS^Z%N%["8R!L?1 P]>_I[XGB9V!\S9D8_U9)&><]0/;%9J5VU:2
MMU:LGZ/J:$M%%%4 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(8\[ WNUV=N_3K;1/RN]/QZJ-=U92BXJ+BD][MIVM^&^]M#T*BBBD=(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !112%E7[Q STR0,_3U_"@!:
M*3<N<;ESG&,C.?3'K2T %%(""2 <D'!]CC/\C2T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*(_]:]%:6VO=VVN]MMON7X]R*F"PU514Z::B[K[T]?)M*_<_'[]FC_@EG9?
MW]J;]H;XW>*/$'@;X@_#;XV?!G]FWX367PJU+PE]JL])3X"?#KX>^!6O-7CU
M1;O1M8M=4G\!PZW8POIXFM;N\(:11%$(OK?XX?L"?LE?M$?#33O@Y\4_@5X
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MNFN6&E^,YIKFYN@91#=VVN:):7MHL,BO;VL5XLMI%!<V]O)%_'%9_P#!<_\
M;KVEM1^*:R.X3<EMX ^#Z1J5B,3D(?AF<>9EB0C'@L.0>?U;_P""./\ P4S_
M &D_VP_VYO!WP!^*WBBS\1>!?$7@/XB>([D3>%?!^D:K9WO@_1?[4MC;7WA?
M0?#S1QW$TK*PF 1P6!RV6;"I@I1J7=27+=6?-42:=MM;*VS=E=Z];/\ #<)A
ML7F&:X;#RR_&N>*K5Y<]2.'5*G"4[1C.=/-*CA&G&*Y/94I<ZM*4+WB?V8_#
M&_N;KPQ9F^DV!+<^6'$:;0I8 ,RHH.%R"<G/J2!CNH$:^E2:52+.-C):Q'*L
M\D9*&:7')4;FV1LQ1@P+(S %<?3-+MEMH["T!AT^Q,<#LH+?:O*V2!TE+,)$
M9AMD=6;<0P+'&#UR[5554@*HV@$\X  '_P!?./6JEOHM;)-VZI)77F^KU=WW
M=W_0N!I3I86C0JR<ITHTXRFY-\SC&*:U:;BWLFK>7>G>6TC@S6KB&Z3!WA4)
MF5 2(7W!@0V2H8C<H)"LH)I8)!,&9W4NBJ98A@&%PH)S@9/3/)Q@],8 NY'J
M/S%8U[;O%*;^V4O,"JO&BY\V$@"0!0/G?@D<$YP.]2KO2W:S?K'\+6^_L=BC
MS2CRNS;MHTO-/MVWTU7D?%W[3'BF\L[/Q!+8F)Y]'T2]GLH;E+F9;C4([1YH
MH1%:S0-)YVV.$()%<[L1M'(=X^&]>T[4?[/TBYN/']_?7^K^./#<][ID14:?
M8037=S!)?0V5PUQ+;II]L!-L2=8'(#SQ2L2U>:?\%\?VJ/B;^QS^SK\./BM\
M%;^ST;Q+XU^*MKX*U&_N]$TC5;B#2/\ A'=3U0M;6FO:;>V8NX;S3ALDGLKN
M,,-DL,REXC_)PO\ P7+_ &VU21W^*-XURJ%D:/X??!UY \:^:/)W_#%XTD.S
M8CR@(H=@2"0:)QYI=;))6Y9=E_+>]D[*_GT1^"<;PS&CF]:G_9F:8WV_\*OE
M\\*HPYY-:NKFN FY*-HM.$HI7M*VC_NW^!>G7GA+76O8O%FJ^*8M>U6WD,VH
M7:7BVD<L/E1QVP/F&WANG9KP1C8@\Q4@"0HB)]\,K:?;VUXS#<+&:"?&!NG$
M6\%E7Y26&<9&>A'6OQZ_X(F_&/QI^UW^QKX(^/OQ8FMK[QM=^-?'WA^^N;&Q
MTZQM;F+P/XEU#P_I]S)::58Z=91WEU:PI+.8;:.&3;');QHI8']H+ZR2[L9+
M4QN,+N0[3DLHXX .2<8YR><#CBJ3Y5%-O>]G>Z3BM[Z[ZV[)'Z9PA@,7@<F4
M94IX;V]/GAA:U13J4G4M.<:DU5KKF<[M\M:I%.Z4Y*S7Y2_'GQ#J>IWL6DZ;
MK<&B3>)M:O\ 2[Z^#SM?V.G7%AJLK7-A<V\R'2[JWFBA5+BZ*LLL(:V9'(->
M43Z/:0^+M<M=1^*&MZ/IMSX,M-/BUVYU,1R-<1W&J.-.M;MI3/'*LMM!<RW$
M;K=R%%$EQ(I8'X'_ ."FG[9?QF_9]_:DUKX;_#[6[;1/#=EX<\-:HT+Z#I&L
M74^H>(8[J\OS*=<TS4TBBMI(([<[6@AM_M,:9B\Q<_(?@3_@H7X_^(FL0>'?
MC;K=QJ^C:A<6,&B36F@^&+2*R\17-TEJKSVOAW0H+HV<L4AB2X>Y%O \HFFR
M@8'SO%/*_$SA7PCXB\2.!.&\'Q7C\OA5Q>7</2IJKCLSEA*3J?4\/2C3E74,
M3*FZ2G0BWS3MRW;M^)</\1<$YYXP4?#_ (NS;,LAYLSPF"QV=582AE6$H8B4
M*56JZU#,%[10CB'6E"KAZ<II*+=G>7]5O[-NL'4_#3Z=9:]'XE@#::BZK$T4
MSW1C@D%W)-(B_,TBB!B1N'WF4@LQ;G/VB_%&IZ)=^(K>QFCSIWAV75-,MIK6
M6XM[C4&L[V9T=+5?/)@GL[2)(E8*YNP/+)V@/_8W^"WBOX6>$-8N/%$MNEYX
MDU6VU"TL+&Y2^BT^P2"8(#)$ D4\JW0\^  >48%4X(KZ!\>?#?2?$075Y#-;
MWUCMBE<12$W5KYN#$4#$'<^TC"YVE>HQ7QOA7Q#Q=Q7P'D&>\=<,RX-XHQV&
MJ3S#A^6(==X23K2C!5)7O%NFH25.?O07NRL]#^C.-.&,/E-#&<-\,9U3SW+L
MOK4WA\X@ITH8S#NE=**G+GG&FY77--IR@Y<S3U_('Q5;W]SX5N]8N?'^L/J&
MO7>FWUUX?$SPVNF2R>3&MI;0:BLD^GK80'[8UHCQ!A*8;M)(U"+XGX%AUV^^
M)D]E;_$RYL- 76=/\0;]/,L5[=3&'7-(N-+N=0\[+!9(K74G@M9(XKG[$MM<
MQ36DT\,WX+_M5_\ !8#]J_X;?M>_'+X0:-XJLW\&_#WXX>./AQIF@R^%?A[-
MI=QHWA7Q;=>&+5KG4;CPO)KC/+8V">;>-JAN3O:8W1E_>U^F'_!7C]H?XJ_\
M$^?AG^RCXJ^$FN0:3XA^/T'B37]6U*70_#^HSZ"-+T;PKKEQIEO:>*;#6='P
M]_XKFM9I+O3;F6VMEG>![>YC2XB^]<'S)VT7*FVK/=*]FW=ZW=F[+>Q_+F+X
M=SC,,4LPP^6YE5H9-5I3Q-)584JV(ESSC)T*;SF$$JL9SJUE5G0IVA"T=9'Z
MJ>"]"OM1U._?_A-]?LY;+Q[-?"" QQ1:Q::;$$CU&X"(?W>MQ,LDEI&([0!0
M88$))/ZU?"ZYENO#%BLQ=HXX@ K@!E&%< L &)RX(W-W 'RX%?S?_P#!!S]J
M3XK?\% _#?QZE^,VN+K-S\+=>\#PZ/?KHN@:/.;3Q3I.IW-W92Q>'-,TBU86
MEUIK*)#;@C>8_EVX']/.C:/:Z)80Z=:)MBB1$W8.3L55[DY!V^HSGIQ5Q7)%
MJR]Y=4T]UJD]4M-+[VO8_9?#W*\72PZS&K0Q&$IXJ#O1Q53FQ"E"HZ?+4C'%
M8NE&RA>].M*,XR5TFK+70 *H' "@ =< #CDY/3U)IU("  ,CCCJ.U&1ZC\Q2
ML^W]?TU]Y^GZ>7]?\.OO%HHR#G!!QU]OK10,**** "BBB@ HHHH **** "BB
MB@ HHHH *\>^-6N?%'1?A?X\U7X,Z7X=U[XG:7X7UC4?!&B>*[B6Q\/ZYXAL
M8)9=/TC4KN!HIK*/4IXTL_M!D2.!IA+(RHC$>PUYA\4?"FI^,O!?B'P]I.K7
M^@7NHV$D%OJ&GLL5Q'*(V*Q33.C*UI<.0ERT?S["VU@P%:4U&4TI:1=DWV3:
M3?XG+C*E2E0J5*5.=:<*=2<:$)<DJTHQYHTXSNN5S:Y$[JW-?H?F[^S]_P %
M6/ 'QT\+^'M1L/#&LZ+XMTC5;CPG\<_ WB!8K#Q#\(OB!IEY+IVO>$]2MC%;
M_;Q87L+7&GZO:+)INI:+-974-U/<O<)#^JNC:Q;:U90ZC972W%G=0PW-O-$8
M9(S%,F\ /'D$KT;+$@^G2OY'_P!KKX$?%+]GKXMW?[2_P6T%9OB!X/TY--^.
MGPN-O<C3?C5\/+$K+<7MC:*HG3QMH^EQH_AV[@A:353Y\%OY\Y2*3]5_V#/V
MQ_"OB[P;X7\2Z;XBCUGX<_$&VLY](N)9H$N_"^I1SRVEYINNVCNT^D7UG/+_
M &=JT-Z8!;7=HHVH\AS[V98' T<'0JX6;E4:BYWC>_-RIN5KI)-WO;ULE<_&
M>%O$/,:N?XW+L_Y%0J3ER0A"I2>1M5'3I8?%U:D*?UB5625&4U*?+5;FVHS4
M8_M$IR"=V?? XZ]<<?\ ZJ?^M4(+BWF@$\4\4D4T"RI(DB-&Z2*-KHRL597)
M^5E)#<;2:O#H/H*^>W5]-6UI:VENWJ?MR>UKM-)J5[WO9K[T[K\-!:***105
M5-U'Y@C#'.\*00N,Y ^N.>X_^M%>R-%&[J"VW!4;'*AU5R6? ):/!3[@."C#
M.=P'^61K7_!:?_@J'XSU2\\4M^V/\6/#A\075UXA.@^&+KP]I&AZ(FHSO=6V
MC:3;Q:1<2KI^G).MO;03NTXMHH_/9GW.:A2<]5*3UV3MV;7WNWY7L>7F>:T<
MLA&I5BY1D[.R3:O;9-K=7VUT[;_ZHU%?Y4?_  ^&_P""HO\ T?'\=O\ P=:+
M_P#*&C_A\-_P5%_Z/C^.W_@ZT7_Y0UT?59]_P]//S_+OIXG^N>5]JO\ X _+
M_@_AYG^JY17^5'_P^&_X*B_]'Q_';_P=:+_\H:/^'PW_  5%_P"CX_CM_P"#
MK1?_ )0T?59]_P /3S\_R[Z'^N>5]JO_ ( _+_@_AYG^JY17^5'_ ,/AO^"H
MO_1\?QV_\'6B_P#RAH_X?#?\%1?^CX_CM_X.M%_^4-'U6??\/3S\_P N^A_K
MGE?:K_X _+_@_AYG^JY17^5'_P /AO\ @J+_ -'Q_';_ ,'6B_\ RAH_X?#?
M\%1?^CX_CM_X.M%_^4-'U6??\/3S\_R[Z'^N>5]JO_@#\O\ @_AYG^JY17^5
M'_P^&_X*B_\ 1\?QV_\ !UHO_P H:/\ A\-_P5%_Z/C^.W_@ZT7_ .4-'U6?
M?\/3S\_R[Z'^N>5]JO\ X _+_@_AYG^JY17^5'_P^&_X*B_]'Q_';_P=:+_\
MH:/^'PW_  5%_P"CX_CM_P"#K1?_ )0T?59]_P /3S\_R[Z'^N>5]JO_ ( _
M+_@_AYG^JY17^5'_ ,/AO^"HO_1\?QV_\'6B_P#RAH_X?#?\%1?^CX_CM_X.
MM%_^4-'U6??\/3S\_P N^A_KGE?:K_X _+_@_AYG^IWK<K1%6%O)=*L:GRT5
MGVL6D <J@);J!AOE';!-?S&_MG?\$.+KXW_M9W?Q0\#?%NP\$^%_C;KC:]XE
M\/:UI=]J>KV&L6-D)_$]QI-P'^S1KK,<5N=&AO9FMK*<3QRF.!8D'\SOP%_X
M*P?\%)O%/Q#M-+\1?MI?&S5K"XTZ^=K2\US11$K6?DS"3']@L-S>:57",S8*
M\\8^XKW_ (*!_MO7%];7]U^U%\4IY-)6^?3I!J=B7@EOCL;?!'H*[TCC7:&8
M,BCCD5^@<(\)9]CJ<LSR7,,#AG1O&M&K&HYW:B[-.E.FWHM5*^UT]$<. ^F!
MF'@)Q'BL=PE_K=A<UQ>13I8G$Y/A<K5&M@ZU2TJ'-C,?0J58PG3C4CSTU&\6
MK\LI7_O"^$_@3PU\)_A]X)^&7A%9(/#/@3PSHWA/0;::8321:9H=HEE:>;+O
M>1Y9(416:5W9RA9B6+$^FK$BN75<,5VDY8\9!Q@DCL.>M?YN7[2'_!4+_@H1
MX.\):#?>%?VMOC#H=U<ZU-:2W6FZKI*/<QI )07$F@;@H4JPYVX8$<'-?&I_
MX+#_ /!44_\ -\7QU^O]M:+G\SH1KY;.N'\=DV85L#B_9QJQ7,U1E&4&G:ZY
M8-**OLFDDM$>?PWXIY#Q1E-#.L-3Q<:6)F[1Q%-*K&6CES).23L[W4M[IZ[_
M .JW17^5'_P^&_X*B_\ 1\?QV_\ !UHO_P H:/\ A\-_P5%_Z/C^.W_@ZT7_
M .4->1]5GW_#T\_/\N^GO?ZYY7VJ_P#@#\O^#^'F?ZKE%?Y4?_#X;_@J+_T?
M'\=O_!UHO_RAH_X?#?\ !47_ */C^.W_ (.M%_\ E#1]5GW_  ]//S_+OH?Z
MYY7VJ_\ @#\O^#^'F?ZKE%?Y4?\ P^&_X*B_]'Q_';_P=:+_ /*&C_A\-_P5
M%_Z/C^.W_@ZT7_Y0T?59]_P]//S_ "[Z'^N>5]JO_@#\O^#^'F?ZKE(<]CC\
M,U_E2?\ #X;_ (*B_P#1\?QV_P#!UHO_ ,H:4?\ !8?_ (*BC_F^/X[?^#K1
M?Z:$*/JL^]OEZ>?G^7?1QXRRN32M5UTT@_+T\^O8_P!59V*8RW7/8=OSIZ'<
MH.<YS_,BO\JF+_@L/_P5%2>"Y3]M_P".+S6L\,RBXUC1I[=AO:%4GLY=#6VN
MH&DF4S1RN/D4D#Y<C_23_P""?'Q9\9?';]B3]F#XP?$.]CU+QQ\0O@]X1\2>
M*=1BMH+-;_6KRQ O;UK6V)MX9+J6,SS)"%C$SOLCB!$:Q4HNG%2;O>5OO3?=
M[6?WGIY9G6%S.M.EAW-RA3E4?,M+1E3B]=5>\UIO:[V/L6BBBL#VPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *9(0J.6.%",68]  ,DG&3TR> >A]LOICJ6&%;:1DJ<9PV" 2,@,!G)
M4_>XY% /^OEL?F]^QL=O[6?_  4\9@0&_:(^$:+W+,O[-WPV<_*N6 VN,,P4
M,0=I.#7Z25^:OCO_ ()O6?B;XT_%GXV>"/VL_P!JKX(ZO\9]<\.^(_&WAKX3
M^+?!&D^%[O6/#'AC1?"&FW<5KKO@+Q!?*QT;188[E9+^59)97:(0Q(D(Q4_X
M)O>/D1$'_!2/]O[Y%5>/'_PLQ\H XW?"1FQQW9CZL3R0?;IHE9]+)+S\_P"M
M_P!1**_+W_AW!X__ .DD?[?W_A?_  K_ /G14?\ #N#Q_P#])(_V_O\ PO\
MX5__ #HJ ^:_'_+^K/RO^H5%?E[_ ,.X/'__ $DC_;^_\+_X5_\ SHJ/^'<'
MC_\ Z21_M_?^%_\ "O\ ^=%0'S7X_P"7]6?E?]0J*_+W_AW!X_\ ^DD?[?W_
M (7_ ,*__G14?\.X/'__ $DC_;^_\+_X5_\ SHJ ^:_'_+^K/RO^H.0.I _&
MD8KM;."-IR,]1CI^-?E]_P .W_'QZ_\ !2+]OT_]S_\ "K_YT5!_X)O^/<'_
M (V0_M^GCI_PG_PJY]O^20GK]#]*=EWU_P"&Z_-_<9.+;OZ:]MO/IKT_X'Z,
M:_H^E^(=-ETG5+"&^L+^#R9K>=&= CD$IP5Y!"E"2-K[74;@*_ /]O[]@^Q\
M7:2^FKJ&I>&]?T6Z;Q)\(/BOHMPFF^*/A_XLTZ[DNM):PU D(-,658[+6-+8
MW']IZ1<720*EX\,T?VZ/^"<WC\('/_!1G]OI7V.%C/C[X4LHW1D*Y7_A3ZEF
MC8[U7(!*J,@'CY!_:<_8]U7P_HZ^%F_X*"?ML>*-;U&XAG-EJ_Q"^&4EK9"V
MRWFA+'X8V$D&H2F)WM));N."V=?.G;8K-7F9KF:RW UJ]>2H0CR13E4BVY5*
MD*;A",>:4_B=XP3:5Y64>9GQG&629=F^ ^L8N"P^(P?O8?%M0YZ\I.*=-*-Y
MVDFY)3C%WC>+;T?SU^P5^V7XNB\1ZW\/_B/:6WA;]HOX4&&P^*G@IS'ING>-
M?#BXMH/'G@N&^FBA_P"$7U9(U'VB)3_9>J17-I("-K'^D[P!XZT7Q[X?T_7=
M%F$T%_;B1\,ID@GV*TEM.@QLEB)V,-H!P"IP0:_A\^$'P$\0?&?]L_2OBW\/
M_B]\:_'?PL_9]DU;PCJWQ;\=ZUHEP_Q,\2QJ][=_#;P+):>';1M;\':3-<1Z
MAXNU.Y;4K"[O[S4K/1[2*5I+I_Z_?V2OAEXB\)^%G\1:WJ$\,?B6WMKRRT(!
MS!:++$)'O%\U@T4EPS;C"85,8 &XX./G\LS253-999@W'%4'AUB\14A).&'C
M.48)JII"4Y2:C*C"3J;R<+1E(^?\/ZF98:O6RZ%Z^6P@JGM9-0]E.4E[\8RY
M6U-6<E"$DW)/>,[_ &&"H"C(YX'3K@D_CC.:=47E_<^;[C;NG7Y2N#S[Y[U+
M7V2T278_5]=;]]/N7ZW(WECC)#L!A=Q'<+SSCJ>01\H)]0*3SX_[Q_[Y8\=N
MBUR'CGP8OCCP_JV@-XA\2>%O[5L39#7O!^I-HWB;2B6=OM6CZKLN$LKH;L"0
MVDP./G5P%"_+@_8JM0%'_#3_ .U\=JJN3\98\MM4 LQ'A@ LV-S$ 98DX&:>
MFF[?7I;RV=_4RDZJE[L$X][I=5W?:_\ 5K?6_BCQ)I/A'PYX@\4Z_>0Z9H?A
MK1=3U[6M2N&$=MI^E:193:A?WMQ)(H2.&UM+>6>5W^541F8X!KQ'X(?M)^#/
MCKJ-]I_A+1_%-E)IGPW^$OQ&U*3Q!I5OIS:;!\8-$U'Q'H'A?48H+FZEM/%^
MFZ)8VFJ>(M(D7RM/M=;T22"[O/MD@M_A3]K#]B/QMKWPFD\#^ _C5^U'XVOO
MB3XN\#_#SQ9I'B/XLB_\,Q?#+Q9XGTS3?B=JWB6Q71;6>?1HO ;^(+$QP3)<
M+J%]9%@(PY/9?"/]C;7_ !;XB^-/Q9\9_$_]H3X0^(_BA\6/$>I6W@WP%XYL
M_".E:?X#\+BV\$?#5)].M]#NWCNG\(^';.[\D7ACMHKQ+9DD:%)V%;Y6W_X-
MG:STVZVN9JI5_P"@;5M6?M:6EDFWI*_EMU36BN_U%W$]OT8?S2FD@$L=WK@*
MYQCOD#G\J^+/^&*X1_S<_P#M<G_>^,>[\L^'N*7_ (8MM\'/[3_[7O'4+\94
M5#QGA?\ A&B1U_O'G/K@+OY?YI?J5&=5O6CR::/GB[O331Z72?EHNVOYV?\
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ME;*\Y7&<(QQD<<[1UKXL_P"&+(?^CGOVM_\ P\(_^9^E'[%=OU/[3_[7N?\
M8^,JJOUVGPVW;@Y)]>*!QG5;2E1Y%WYXOHM+)WZ>FB[:_A/_ ,'6$21_LA_
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ME4YM;.,-O))-6:6UGK^A]+D+JQRC!)0YDJ;UYHK[;>S?K_6J^U=WH..WWO\
MXFLG7];LO#FAZOX@U.00:=HFFWNK:A.SI&L-EI]O)=W4SO,8XTCB@BD>1F<8
M16*Y; /R!_PQ9!V_:=_:W [ _&$']?\ A'A_*OFC]K7]D'XB6OP1U_1OA'\;
M/VL_&OCCQSXB\ _#2UT^^^)MOK&BZ-X=^(GQ \+^"_'GC?Q%IESH,<5]X=\
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M117<?F@4444 %%%% !1110 4444 %%%% !1110![[^S5_P E4TW_ +!6K_\
MHNVK]+YO]9<_]<3_ .AO7YH?LU''Q3TX^FE:P?\ R';U^E\H_>3#^];D_3+M
MQ[]:_H'PNJ07#V:)NS51='TC!O9=M3^5/&^G)\5T&EH^'8VU76M5/E+]K'_D
M1/"O_8PW'_IKM:^ *^_?VLFQX%\*#'7Q#/\ KIEL*^ SP2/0FOS3CZG./%&8
M5)*T)TTHNZ=WS1>R=UIW2/U_P@:? N MTG/\5#_(2BBBOB3],"BBB@ HHHH
M****"Z?QQ]1Z]'_W(?\ TJCK_5M_X)*_\HU?V+/^R"^#/_2:6O\ *27H_P#N
M0_\ I5'7^K;_ ,$E?^4:O[%G_9!?!G_I-+7-BOX<?\:_])D?<<$?Q<5_@J?^
MG*!^B%%%%<!^BA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRNHTEK;I%?93O9=;MW6BBBOISO"BBB@",Q(V,@Y7<58$A@60H2&!SD@Y/^T
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M=IZ>:Z5^SW_P2'MKR#6=$U#]D>6ZTG4GV7$/Q2\&W4=KJ.DZC+:W,4N?'%Q
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M_P#AJ/"G_P @4?6H_P K^_\ X']6?E<_U(K_ /0?3_\ ">7_ ,M\_P ^S/\
M)AHK_6>_X=H_\$_?^C-OV<?_  U'A3_Y H_X=H_\$_?^C-OV<?\ PU'A3_Y
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M6?E?ZS_4BO\ ]!]/_P )Y?\ RWS_ #[,_P F&BO]9[_AVC_P3]_Z,V_9Q_\
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M%%%<Y].%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(0""#R"""/8T
MM% 'D5I\$/AA8^,O&OQ"LO OANT\;_$:QT+3?''BJ+3K<ZWXGT_PU;O::#8:
MOJ+(;J\MM'MY;B/3X6=+>T6X811%M[GOM"\/Z9X=LDT_1]/MM-M(_N0VRH@
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M J48 ,C*0596 PP8$$$CI7G'_"W/ W_/]JO_ (3'B;_Y4T?\+<\#?\_VJ_\
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MFG_"W/ W_/\ :K_X3'B;_P"5-'_"W/ W_/\ :K_X3'B;_P"5-%GV?]?\.OO
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M[4A&T<#336Q"!%_7Z?U?\QJ[ULUU5^UD[_<[Z7T/T1P/?\S_ (T8'O\ F?\
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MK;UMU9B\.I/GO:[O;Y)>?:^UO5:'X,_&;]F+Q]K>MZ%\1O@AX%\9>"_$_P
MOV6O@-XK_9WF\2Z?;FXC^)GPJ\4>)[J^^#?B1XYGNVU/QEX&UG5? /C."QEW
M2V/B6^G@DEN(XS7E'PW^&/[6/Q?T/]D7P)8_L]Z=X6\,_#GPA\?/CEX^TO\
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML]%%%!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4,;>Z0!61MI#+N #+AEZ@TOPM_Y'/]H'_LK>F?\ JF_A/2(3;LV[[?+WH_\
M _X<]GHHHH-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#D_'O_(C^,?\ L5]>_P#37=5\%?\
M!(XX_P""<W[*6/\ HFEN/SUO50?Y_G7WKX]_Y$?QC_V*^O?^FNZKX)_X)'\_
M\$YOV4EYRWPT@7@@$ ZSJV7!/0IP1WSC%4OA?S_.!A+^/#_!_P"WH_F=_P""
MU/PMUGQY_P %,/VC_'/A%+YOB'^S3_P3^^$_[37@2_L<K?Z=JGPG^.VAZCK-
M]:_9D21I;7PN^NWKHI#R8F2-D#A5^;O&WQ5TSXT_ /\ X.!OC3H@$6A_$]?V
M*O'>GN)&N)S9^)?%FF:K_9]S.7>41PK=/8W=K!)%;[DEC2-" 5_LR\4?L&?
MSQ9^TW\0OVJ=>3Q7J?Q ^)W[/%_^S+XITB35H#X/O/AIJ&H7&I7D,.D/ITQ3
M5[A[N2U%\UTT9MW1/LQ9-]?#'PM_X()?L9?"'X#?M%?LZ^&O$OQNO/ ?[3VF
M?"_2OB#+K7C/3KWQ!:V'PJ\17_B/0/\ A'-5/AM/[-DN&NQ:W8D@N<V]C:HJ
M*R[:N*IVUY;M.^CWM;5V\]5MKHV>9B<OJU:]2I"32F[M*VKLTGNMN9]_/8_F
MX^ >I6<'[+-Q_P $S[X017WQ/_X*(?L57KZ*\+A+WX3_ +0'PVT?XHWRJ%($
MD4T?PP\8QWEW#"(TED@2XW?;4#=WI?@CP?JW_!NZIU#0=-UFV\(?MO11^&5U
M2RMK@:.;CXNV7ARZ%G*;61[>34=#U34M.N;Q4DD-I?7,&5CE(']*FD_\$8/V
M1]%_:E^%O[6]O<_$V/X@_"#0?ACHWAS29O%EB?!4Z?"+P?#X'\)ZGJ^CIHL4
MM[K%MH5OY]U>?;(R]U)+(BPK//&^5XA_X(K_ ++WB+]D7PM^QA<>,_CAHWPJ
M\-?%?5OB_P"=X<\>C2?$6L^*-5&IO=6>K7G]E7$-SX>M-0U0:EI=@;56MKNT
ML+GSS)'NDJ48;+EYK-+31+1VTT3[[[JU];<U++*D:4G.4IM4W!<[6NL===[.
M[N^SLTV?F-^W?\!/@U^PE^W%_P $N_B9^Q7X;T;X-?&/XK?'#3?A/\0?AMX"
M3^QM&^(_PLU>72(=:NO$?AB-TCECT^TDU:!-4D6.$SE)[;RKF*=I/ZR;92D*
MJQS@N0, ;%:1F2(8X(A4B(,/O!-W>ORI_9E_X(_?LK?LW?&*R_:%;4_C%\:_
MC1HME+I_AGQ]\?/B/JGQ&U+PI!-!+;N?#EG>6UO9:;.;>YGB^U+$\JK-(J%"
M$*_JU$JQQI&HPJ*J*.#A4&U>F>P%8O=Z)7>B6MDDEH_/5M?B>UAH2A!)MVM9
M1?V=$MM>J=]=VWU'T444CI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$JC<X/?'&#SG-'DR?\^$_P#X#S?_ !JO[,/^'$W[#>YB-*^(R*2-H7Q_>DX
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M .5]'_#B?]AS_H&_$C_POKS_ .5]'_$6>%?Y,]Z?;I^7GY+[GYA_Q+#XB?\
M0PX>_P# J_E_T[\OQ?<_C.\F3_GPG_\  >;_ .-4>3)_SX3_ /@/-_\ &J_L
MQ_X<3_L.?] WXD?^%]>?_*^C_AQ/^PY_T#?B1_X7UY_\KZ/^(L\*_P F>]/M
MT_+S\E]S\P_XEA\1/^AAP]_X%7\O^G?E^+[G\9WDR?\ /A/_ . \W_QJCR9/
M^?"?_P !YO\ XU7]F/\ PXG_ &'/^@;\2/\ POKS_P"5]'_#B?\ 8<_Z!OQ(
M_P#"^O/_ )7T?\19X5_DSWI]NGY>?DON?F'_ !+#XB?]##A[_P "K^7_ $[\
MOQ?<_C-43+(@\B53O4*OE2Y'(P,!<@C@8P#["O[9?^",5RG_  [Y^$JDD,FI
M?$=02I4JY^)?BR%]RM@_*\9&TA3A<@'*YX63_@@_^PP[*YT;XA.5(;#^/K\!
MR#GYRFGA\$CG8RGDE2&P1^HGP:^"/@3X#?#;PW\*/AKHT&A>#?"]M+#IFFB>
M:Z8/=74U_>S3W,X,T\]U>W-Q/--(2S/,SE<X6O@?$'CC*N(\KHX+*X8Z\:RJ
MU%BW&]TFHN#B[))2E=.SO;;4_9?!7P<XGX XBQ^;YYC<NG1KY9/!TJ>!]I+F
MG4JTZCE4YX12Y>1)6ON]=#^>S]DWX<?%N3QE^Q_9_&.TN/#GP)\/?MC_ +?_
M ,2_A=:>'_ VIKXPL/CA;_M)_M+:)X=\,?%/Q+JTDUU9^ /$?@_QEXI\5Z!K
M=CIT,.JZWI6@07]W%:V=A//W/[*OB;Q1:_LT_M"?!W7/C/\ VQJ6I^%OVY+?
MPY^S^OP \1>%O$>CZCK/CSXOZG8,/B3)-<VVMVTZSD:0T%MY6JK=6MM'(UT%
M@/\ 17!:- !L6%3D;L X),S--+A5C'GS1R2N\F 3/(S-N5FRC6(9@VV$-A-\
MJJ5=]K-*R_*H=4:Z*W+9F?>X(9=Q+G\FC[L8Q3>D8IOTC%/2]OL][:G]+1PT
M(\MKZ)/_ +>T;WOU6MK;>;/Y)'^"'Q+O?A+HW[(5OX#\80?"&P^#5S^WGXCL
MD\.:]%9:AXE_X9A\/:!H?PLMY18I82ZC+^TKJEY\8KW24D?58?$6A1VLFG1V
M;M<+^_G@RQ_:MT[P:\GABV^$MSX+MOV?](D^%WAV[MO%.G?$AOB5;_#W1AI6
MG^*M5N[NU\*6^@?\)/;W=M*L>FP7]O926S7$Q,+AON<0'!#^7)OW;P4(5\ME
M%VEWVA5"JY);S2"S+DU(L>TY&  6VC)(PP3/4?*%((51D;0.1DX:;6WX^BLO
ME;\>V@+#QWVV6G5+OZWUUZ==U_/3\!?#/Q7^"_Q.^+#?M#?LP:WIW@O2OV#O
M$6K_ !MUF#Q-X=^+=W\2?%!\:_%;QY\19SIGA2PM8/%&H_$)_$]_8?\ "++?
M+J1LFTN&XN  LT'1_!#X@? W5OA?^U'^UK\6_#$'B]=?^"OA/PK=?LN>"_AO
MXFFM/ '[./@'5M=C^&GPF?0M5T'1;/QOX^UF^UVXN_&$JQ7EIH5[K*Z78Q6?
M@^Q@M7_?"6 2%&VH71CM8C##>IC=U8*2'6)Y HR58M@E<Y6 61R2SAF(D4MA
M]YCD.\Q>878JIE =L J5RNS.&HOMM9+MKTUTM?9V3TUU*5%1MR^F[6C:OO?S
MOU[>?Y=_\$Z)_#OCB]^-7QZUKQ+H>H?&SXQZKX+N?'OA;PQX7\1>&O#/PR\)
M^%]$&E?#KX;6!\2:+HI\1ZCH.C/>6^M^*+:-A?WU_($BACB4'[F^$_\ R./[
M0G_97]/_ /5.?">O7DL_+W"/RXPQW'"MM=FSO#)&T( 4<1'>Q R3W!\A^%/R
M^,_V@U/4_%_3\8Z?\D:^$[>W;]:6ME=W_KY_GO?17*BFKZ6UCZZ-7^77Y]CV
MVBBB@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHH/T)_+^I% !1110!R?CW_D1_&/_8KZ]_Z:[JO@S_@D
M9_RCF_93_P"R:6__ *>=7K[S\>_\B/XQ_P"Q7U[_ --=U7P9_P $C/\ E'-^
MRG_V32W_ /3SJ]4OA?S_ #@82_CP_P '_MZ/T?HHHJ3<**** "BBB@ HHHH
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M<_[*0]?AI!C\-8U<_P J^VO&>I07O@'Q-?6]PTMK<^%-<ECDA:.2WE5]+N0
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M^V=\/=)^%'Q8^-.N_':/Q[\+?'GQ&MM+^(GB/1/@Y\"?V;_"LT47BCPCX@\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)%7[^*D"J$6,*J]%50 >QS@_-GN&SD@$Y(!I5@A^\%8YZAI)&!^55&Y6<JP
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M;M;V%E(8M-@D7]V%MK;][LA1/-8O*4'EEI&.3+E"")B>3,,2[@&WY4$3B-%
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M,W[]+%&ARJ@'+$'J1NQOVYSM#E0SA<!GR[ NS,5**<_*.3EL<;CC:"V/O8&
M-V<87'*C!]VZ>W:W^6OS>^HHTX0?-&$8NS3:<NO35OS/S@_8R\ ^-?V;T\8?
M!"'X*:_H?POUW]H#]H;Q9\/=3T+4/"2^!?AI\/-1UO3_ !#X1L+C3+OQ/!KE
MGIGB>^U76&\*Z%X<T&Y@T&#3+F"]BLE\AI?TAJ'[-!MV^4@3+$H!A&9G+LS*
M/E9G<L79@6;>X8D.X::CT+WU>[W]?Z]/0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C\O.[+
M$Y.0"!@>W3D>F:DHI-)[] /*OB;\)?#7Q-T2?2]7C^SW& UCJ4$*O=V4ZR*Z
M/&2#OC)&R6-@5:)G!X/'+?"7X!>&/A9'YEO--K&MRQ2+=:Q>0+YF)",0V;9Q
M:P* &$,*A-P+$ \'WZC&/PX]ORKG>#PSQ$<5["G]8A#DC52M)13;2TLFU=VD
MTY).R=M#@GEF GBX8Z6%I2Q<(\L:SC>25[Z*_+?HI-.23:32;(((3"A3S&?+
M;@S!=P&U1C@8/3.<9R:G_'/Y?T HHKI.]ZMM[O[ONV7R04444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1149E49')(W<
M J"2-IQEF"@D," 6'&<XP:+-[*XFTMVEZDE%5TN8Y,% [ D@-MP, D$\D'&X
M;<8W$X8 I\])=7<=I"\\JR&*)&EE,:;VCB12SR&,'S'"@8*1))(20%1L\.S7
M3^M/\T/_ (<L$@8R0,\#)ZGT%+7X3ZI_P<,?\$];KXZ_#OX#?#_Q'X[^)&O>
M._B%HGP_/BK0_"K:1X*T"_UJ[FL(+[6-2\5SZ1J":?#>+!!=/;:5]HC>Y@ 1
MCYBQ_NC%*K0Q."&#QHP*?=;*@@KECP005RS<$98]:7?RW\O4RIUZ55SC3J1F
MX/EFHN[B^S)Z*A:=5&65QEE4 +N)+8P0J%F*@GYVQMC"M(Y6)2X1;A&R%!++
MPZ!XF:,XR%<)(P!(P1R1@CG/%!KY=R>BHQ(K$@!LJ,M\I(&<\9&06X^ZI+#(
M)&""8UN$<$@.HY ,B&++ ?=VR['![?,H'OUH(FF[65[7O^!*)(R0 ZDMG: P
MR< ,<>N 0?H:?7\]GAG_ (*](G_!:KXB?L)^)-9T:W^##>%?#_PX\!7#PV<5
MT/VA=-TA/%>N62:VL@CEC\20Z^OA"'2KU[;R?$'ARUM[<[IW:3^@V*990"H;
M:1PQ*$9#,K+\KL=R[06XQAEP2=P5M-='\^_7Y=C+#UZ5;VBIU(S=.;A-1=W&
M24;I]FKHFHJ)YEC)!#$[2V!C.U2H8\D#"[@3STIGVF/+*0X9>@8!0[$X6-9&
M81&1_P"&,N&Q@L%!!HL_Z^7^:U.CI?H^OH6**B6963S & )Q@@ Y^F<?K2K(
MK-M /3=DCC&<=<]?;THL]?+?[["NK)]'L^_4DHHII8#&0>3CL.>PY(Z]B./4
M@4ACJ*^/?VDOV^_V0?V2-(O-4^/?QW\ ^![FTVA?#$^O:?>^-KZ1@3Y.G>#;
M&XG\17<B@#>4T\1QY7?(H(KM?V3_ -J+X8_ME_ GP5^T7\&Y-;F^&_Q _P"$
MA;PU<>(M+_L;5YXO#7BK7/"%_+=:;]HNOLZR:IH%[+:XN)#)9/;2R"&61X(Z
M<91MS)JZNKZ75[7MVN[&2KT95/91J0=2W,X)^\HWM=KIUM?>Q]&T445)J%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %!('4@<@<^IZ#ZGM14<K;1G('^]
MC8,$'<YP2H&,!AP"V2.A  C2A205?_9(CE8$]]Q5"JC/<G!'-?GO_P %+/B/
M^TK\,?V-_C;XR_9)\&W?CKXV6'AN_C\.V.DM;7&JZ%8S/);:YXMT72)XI6\0
MZQX9M4EFM-)M8KBZFNTBDBM+D)]GE_&+_@NJW_!5G]FF^;]J#]E3]J?XG_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'3S/$8G&1A2II)4XJ3ET@KIRW7Q=/OZ_0 Z#Z"EJ)9HRA96#A54DQ_O#SD
M1[F+9&-H!)[ T]'#@, P!_OHZ'\5<*P_$#VK,^G'4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !377>,$\=>G.>Q![$>H_\ UNHH \[\=>"O OBJ"PN/'OAWP[XA
MTOPIJEAXPL3XFTRSU2WT/6] \^YTOQ'IJ7T$]O8ZKI1:ZFBU:&,7]I&76W=
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M;KOJ_P"NA]2KV2?1)?<DOT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(<X.T M@X!)
M)QP"0&(!/4A20.<'I2T4 0-.%4ML<X)&U5<O\H).4V[LMC$8 )DRI&%)8*9A
M@8V'<&;)D 544XW.2N5.3C&T@-D%N*_(KXL_M0?&WX:?\%+OAI\.)/$5A%^S
M#K7P_P#"OAOQUX:N-(TI)M%^(/Q(L_BWJ7@CQS)K[6ZWJVMWK/PQL?!C6(N%
M@EO_ !9IJB,R[,_-/P/_ &K/VU/C=;?MA^/?"'C>'7;+X:^,/A1\<?@A\-I/
M!_AS3CKOP$\1)X]O]0^%=W.;![V]N/&'@GP_9ZQI6O/,=1AU"XL+NVE(=H7.
MWFW^"NW]QG.I&#2?,[I23BN96NE;39OS\[/8_H)-Q@,?+<[?F"X".4!VLY$Q
MB"X8-P6.Y KH6W;1*'S@  L5!(!!"Y&1GHV#T!V_AVK\._&?[5'[1WQ!_8C^
M,W[9_A7QEKGP5\&>*O%OPQU7]G'2+?P+HOB7QMHWP4?Q=X8\%7_BJ^\/W?AG
MQ'<:EKWQ6DU74=?T?2$LM0%AH$NA369BFGN$KZ4_84^/7Q ^)OCK]I;P!XB^
M(VO?$WP[\+?$GP_@\'>(_B%\/'^%/Q,@_P"$G\'PZ[KVD^(_ ]SI'AV_.BP7
M41GT'Q3=:)I%OJ7V^XTVVMR=+8EV6EGOWT6U_NLKW[6ZNP1J*2O9][6=^G3Y
M[*_J?IG37<(I9B /<JN3Z L5&?J17Y-:]_P50L=%U;[/;_LO_'O6O#ES^TCX
MJ_9*T?QGIK?#%]$UKXY^'_$&H>&M)\/6<7_"?/J9TGQ7JNFW$-OXA^Q'3=$5
M)O[9DMGMI_+\>^.W_!1$Z]X:^!NLGXG>*/V+]$F_:.^+GP,_:(OO%7A_P5XD
M\1^!/$7PT^%GBCQ<OAU)6LO&V@WL-_K\'A*&/7M,MIK?[!J5PC%9Y8""WFOZ
MMWLNO5K\"?;P_EG_ . [^FNNFNG378_<,RX/3CMR0S9&0$!4*YSG(5SQM()+
M8#1.I\S&#Y>\D DNPCV[BB!<MMW;&QRLP,1Y&:_FLN?VW_V]-8^'_P"R-K_A
M'Q+;ZC?^*/B9^V-KAU6]^'>B>'+G]JW]GC]F^VT_Q=X,\20>';V"]E\ :C\2
MO <>O-H\MBNGRSSQ:3J4%JD&HPB;ZAU+_@H5K7A[PE_P4C^*#^)O[=\/?#'Q
M]^SEX"_9AT?3[/3[J]O/$_[17[+G[//B/X?>'+>VC2'[3-X@^,'Q@2X>6ZN'
M%K8M=W5V8+/3)<"6^RM:]_\ #S?@M_,/;172;TO\/GRVMWO?]+W1^V1FX#!"
M065<DE1@\DC<H+G&=@0,7; .Q26617#8P",KNY*Y!! 92N[<&4D!N, G&<\5
M^?'[ 7QW^(7Q0^&_C_X>_&'Q=:^-OCO^S=\6O$_P4^,/B6UTG2?#\'B;4;/3
M]#\9>#_&NF:3I(338-%\4_#_ ,8>&M4MY;...%=135[!%>>QF0>7ZS^W9J7P
MCM_VK?%GC/P=\1M>G^&_[0W@OX-^%/ >H77P[TG1+*3Q7X'\):MHFHP>-HM6
M33O#G@[6+K5K[4]4\1>/KFPCT0?9X[][2WW2A\NB=U9^O^7X=Q>WAH[2UNOA
M[6\]/35_K^K51M)M8+L8L0[8 S\J8YR,@%L@(&*[CGI@X^9OAQ^T_P"$O''[
M.C?M+:KIVH>#?!%GX9\1^+M8MM0U3P=XGN=-TGPHNH_VLT>L?#SQ/XP\*:PK
MC3)Y=.N=%\07T-XDD0)AE+0Q_#5]^W]XGNOB/\%/&WCGX<?%+]GSX"WGPT^/
MOQA\1:[XW_X1J^T7Q1\+_ /PZT;QM%XPU"+0;S4=2T)]$L99M1ATF]$=W)!<
MC=$SLJA6_3TUM^CN_+ST*E5BHJ3ND[6T5]]GKI^A^P5%?CEX5_X+/_ #5K+4
MM6\4>#?%_A'2+CP9JGCGP'-9Z]\-_B#K'C:RT^\L+6S\.R>&/A[XW\0ZWX+\
M7^(!K&BG0M(\=6_AV*ZO-2;2WNTU#3KZ&/TM?^"DMSH&M^._"_Q7_9=^-WPB
M\2>!/V;/'_[4-QI?BN]^&NH)K/@CP!JNAZ7>:'IFH^$_&GB"S?Q9?S:[ #I<
M@C71VMIX-6N8;I[>&6G"23>FGFO+_/\ !E\ZO;7I^-O\S]0J*_-6V_X*">(-
M4O/AQX5\._LL_&C7/B;\1?#&H_$FW^';7_P\T;5?#GP=L;VPTRV^)/B_5=8\
M566AZ*=;O;Y8]!\(I=W>O:K/#+;0Q(X4LW2?^"CFF>-/#GPDF^&'P!^,'CKX
MC_&'_A:NHZ)\)%;P+X=\2^'?"?P;\96_@;QGXJ\9ZIK?BVWT'0K$:Y?:=:Z3
M;F^N+J\N[Y+69('0L9L_Z^7;U6FXN=>>]NGEYZ+7=VV?E?\ 2@2 N%&"& (8
M')R06Y7'"E<%7!()RI .,K(^Q2VUG(Z(FTNW^Z&902!DD9S@'&3Q7X5_##_@
MJA9> ?A;ILWQ.TOQ;XO^+7Q*^-G[7:^"_ GB;6_A[\-M1\._#OX,?&?5/"CV
M7BSQ%X^\1>&O"ND3>&;>]T+P_::=#JU[?WEU(VR$H&:/Z.T'_@I5I'Q8TSP/
M#\ _@?\ %CXQ>*?$7AG7?%_C/PQX?;P;H%S\)M+\*>*]2\#:[_PD^N^)O$MC
MX<UK4H_&&C:MIVA:-X4O]8N_$5EIS:W: Z'>6U\Z5GLUKZWZ=+>:V)E5C'=2
MVOI&]MOU?];GZCJV[/&"#@X.1D=0#P3COD#GIFG5\6_\$]/BCXN^-/['WP9^
M)_CN_P!=U/Q5XMTKQ!?ZI>>)[.RL-?;R/&7B33K2WU:SL)I[6VO;.QLK:TFA
MAFD2-H=HD?!8_:5'^2?WJY<9*45)7LUU5G]W0****"@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MGTV?1=.DBF0;LT^Z35N^VNGEKVOKYJZULE^"NFHZ+2]]7;:_1,_3[P!^PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!TETS0O%C>*;.UM_#'B6U^'^B":'4- OKZUF%P8M3"/&4[ZQ_8Z^-?@SQO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>ny20077915x1_flowchart04.jpg
<TEXT>
begin 644 ny20077915x1_flowchart04.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /:M[O6-;333JM_:K?W#2,J>5;&1E=E5MI(%-U#XQ?#'2KR_T_4?'/A.RO\
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MGQ'J/_"+:?\ #^]UW5X8->NY;?P_)]"_##]B36O \W[-7B(>"_!NE>-_AO\
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M);)#HQMCC7"C:BC"*5084#"J2Q5?[JEB0, DXS3Z**184444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M%  1D$<\C'!P?P(Y!]Z^9O@Y&B_&K]I^55"O)XK\ JY'&[9X+C"D@<%ADY;&
M3GDU],U\T_!W_DLW[3G_ &-G@3_U#(J 6[_PO_TJ)]+4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX+\:"^EAU*?2+\)?1V]@(;>%[MG:*620((2Y5Y,7XC_\%QO &F? ?]EKXV?
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MFTZ4[53<I&K6NUKHMWTOT3Z==B7B:4=92LN[LDV[:+6[>O;SV/WAWKZ_H?\
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M#_G[^.G_ (:F+_YK*_SI]Q]%_P"^$_\ B:-Q]%_[X3_XFCV%+^4/]<<;_P!
M\?\ R?R_O>GW^>O^BQ_Q$[_\$T/^?OXZ?^&IB_\ FLH_XB=_^":'_/W\=/\
MPU,7_P UE?YT^X^B_P#?"?\ Q-&X^B_]\)_\31["E_*'^N.-_P"@>/\ Y/Y?
MWO3[_/7_ $6/^(G?_@FA_P _?QT_\-3%_P#-91_Q$[_\$T/^?OXZ?^&IB_\
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M2>2[JH')-?YUFX^B_P#?"?\ Q-*OSNB,!M:2-6  4E2ZY4E<':PRK+G#*2K
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M^>K_ ,'3TLR_\%&?AW&LTJQM^R9X"W1B1PC#_A;?QB1DV;MICECD=)X\>7.
MGGK((HRETTG*S5]M_P#$K_A?_ACS,WQT\OP<\1"'M)+W4F[6=F[[WTMLM_S_
M * 5_P"#GC_@FB0";OXZ'*@@#X4PG]1XL(/4<@E3G@D<T_\ XB=_^":'_/W\
M=/\ PU,7_P UE?YT^\]@@] (XU4>P4*% '0   #@#%&X^B_]\)_\37I2PU)1
M@U'5IW[:6VT\]?,^$I\8XYP3>'@[]N?R_O>GW^9_HL?\1.__  30_P"?OXZ?
M^&IB_P#FLH_XB=_^":'_ #]_'3_PU,7_ ,UE?YT^X^B_]\)_\31N/HO_ 'PG
M_P 34>PI?RE_ZXXW_H'C_P"3^7][T^_SU_T6/^(G?_@FA_S]_'3_ ,-3%_\
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MX3_XFCV%+^4/]<<;_P! \?\ R?R_O>GW^>O^BQ_Q$[_\$T/^?OXZ?^&IB_\
MFLH_XB=_^":'_/W\=/\ PU,7_P UE?YT^X^B_P#?"?\ Q-&X^B_]\)_\31["
ME_*'^N.-_P"@>/\ Y/Y?WO3[_/7_ $6/^(G?_@FA_P _?QT_\-3%_P#-91_Q
M$[_\$T/^?OXZ?^&IB_\ FLK_ #I]Q]%_[X3_ .)HW'T7_OA/_B:/84OY0_UQ
MQO\ T#Q_\G\O[WI]_GK_ *Z/[)'[9/P*_;=^%5M\9/V>/&EMXS\%OJUWH%_(
M;2XT[5]%U_35BEO]&US2+LK<Z9>1V]U:W,0EW)-!*DL+2HX-?5F>%]_\":_D
MW_X-/;B63]E_]I))I'EW?'C2)6,CM(SS2>!=+MY)9'?+R2R1P0B261FDD9!(
M[&0LY_K)KSNB>FO;;1VZZ^?SW>Y]YEV*6-P=+$+_ )>)/7R=G^3[^8C$J"0"
MQ&.!U//T/UZ51FU&SM[J&RGO;1+RXCGN(+1YX4NYK>!HUEE@M3)Y\T<+2QI-
M+&A2,NN\J64-;E5F1@C,C\%67&<@YQ\P*D'&"&!&#^(_#/X):[XI_:6_X+7?
MM.^.X]:NI/A5^P9^SK\/OV>O#FG:;/<6VA^(/C)\:M1U?QQ\1-7O!;^3;ZEJ
MOAS3M M_"MWI]Z;N#3(;?0=1L;>SO;ZYNKE?Y]TOS_I'<VTFUT5_Q2M\[V_K
M3]OWU2Q2[CL/MEM]NDBGN4L3-$MX]G:RI;7-TELTBS/;07,L,<MPB-&K2I&Q
M#.N;ZMN'N"5;&<;@<'&>WI7XF_LX:Q=_M%_\%=OVS_C);ZWJ^H?#C]DWX4>
M?V2O!EK%/J$?AJ7XA^(M1N?'WQ@FAMA<_P!F:EJ^FWT.A:%?W-Q!/=6'V""*
M%[99G\W]KH3N4GK\Q.3WW /GT'WL8'&!Q3^_=V=K7L1&3;U?2[MT;MI\EZ/5
MDU%%%(T"BBD5@PRIR/\ /XT +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG=O6]K:/?K;YK72YYT/@O_P7!&2/VU_V/ 6.6(_9L\2#<< 9./$W)P ,GG
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M?MFWY@E^R-)\([6*Z,3_ &>2>"R\2&XACGV^5)-#O3SHU8O'O3S%4L ?[0,
M'( !QC\*\^NTZO7356DU_G^!^G91A7#+L+'GE&T(Z*4ELDFK)JVVO=WNKZGX
MM?\ "F/^"X7_ $>S^Q[_ .(V^)?_ )IZ/^%,?\%PO^CV?V/?_$;?$O\ \T]?
MM-165UV?_@7IY>7]65O2^KO_ )^3Z?:E_=\_)_?YL_%G_A3'_!<+_H]G]CW_
M ,1M\2__ #3U_'1_P7Y\)_M.^%/VT/!5A^UE\3_AY\5OB9<?L\>#[O3_ !5\
M,_!&H^!]#A\-77C[XDPVFA2:-J&J:E#'-;7MCJ-P=2\H.\MV\HQ(79_]+VO\
M^+_@ZFMYX_\ @H;\,;J2"6.UNOV3? MO;7+QNL%S<67Q7^.,UY!!,RB.::TA
MNK66YCC9G@BN;=Y51)HRUP?O+=6<=W=;I>73^M%;QL]I.&7U'S2FV[6;<OLO
MH[]4[^39_,\2&8$# .T@9#8! P,@ 'CN  >N!TIM*67<"&7&5P01C''X8IN1
MZC\Q7KSE'DIKFC>SZK^Z?E,HU%3IVC-:RV4ETI^7?\1:*3(]1^8HR/4?F*RY
MH_S1^]?UU7WF=JO:I]TO+_@?AY"T4F1ZC\Q1D>H_,4<T?YH_>OZZK[PM5[5/
MNEY?\#\/(6BDR/4?F*,CU'YBCFC_ #1^]?UU7WA:KVJ?=+R_X'X>0M*%W$+\
MWS$+\IPW/'RG:V&]#M;!_A/2FY'J/S%.0@N@!!)=0 .222, #N31==U]Z/4C
M"3C%<LKN*6SOJE_FOO/ZK_\ @WF\"?M\>+/A7\?KO]CWX\? [X1Z+;^.O#4'
MC.S^)_PQU?X@WFK:V- DDM+G3);/5-/BL+9(99_M&V-=\TA)4DYK^BUO@O\
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M?I_E9&E.GR7O)ROR_$V[6MLV]+N]^^C>P4444C4**** "BBB@ HHHH ****
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M0O\ XU1_PZ4_X)M?]&6?LY?^&ST+_P"-5^B^Q?3]3_C1L7T_4_XT:?RP_P#
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MG_&C3^6'_@*_R_J[\K'U+"_\^*?_ ("O+R\OQ?<_.C_ATI_P3:_Z,L_9R_\
M#9Z%_P#&J/\ ATI_P3:_Z,L_9R_\-GH7_P :K]%]B^GZG_&C8OI^I_QHT_EA
M_P" K_+^KORL?4L+_P ^*?\ X"O+R\OQ?<_.=/\ @DO_ ,$WH;FWN8?V*?V<
MFN+=_-AE'PR\-!HF1D8%99;">1<L%8QQR0I-L_>B0(FS[N\(>#?#G@?P[IGA
M3PCH&C^%O#6AVT=CHV@Z#IUKI&D:;8Q*!%;V6G6:K;VT*<@1QI&!@X0#!/5@
M =!2TU)K9)>BM_7_  67##TZ>D(J"V22LDM+V]6FWYN_JU%VJ%],_J2:=114
M[FR5DEV5@J"YS]FN,=?(EQ]?+;'ZU/44Z,\,R(<.\3JIRHPS*0#EXY4&"?XX
MI%_O(PRI:T:?9K\QM<R:O:^E]K7TO\C_ #Z/V]D?_AL[]H\%'RWQ5UIE&U@Q
M#0A@RAN2I R#C:5S7R/)NCW-)N15CE!+?(/GAD1>6P"69PJ@<DD#GFO] ;QW
M^P7^RM\3O&E_X[\>_ CX<^)O$^KR27&JZYJV@6MW?W<[1^6'EG22V=Y"ORL[
MQ2$KD;QG-<VW_!-/]B43>8/V;?A6RLA3;_PC< \IR5*RC?*ZL4*@XV@G/4<Y
M_=,H\6,MRW+L%@9955DL$H-236LHQ2>C2??5?JD?Q?Q']&3B'.,ZSC-<'Q/A
M,(LRS6KC%"5.JY1IU)-\KY7:ZTL]D[J^FGX??\&^44R^/OCZS1N$7PMX4@WD
M'!D-SJ0$9?A2P(' /8\=*_JMA(P^/[Y/Y@8/Z8_"O!?@]^S3\&O@+%J\?PE^
M''A;P*-9E2346\/:;;:>]_Y+EH?M+Q M*J;F,:NPV%FPHS7O4*NI<,  2NWI
MTQ@]/?UY-?E7$^<T\^S?$9E1I.A"MRVIRT:48V[+6]F]._0_I;PVX5Q?!7!V
M5<.X[%PQ^)P2K*IB::E&,W4JRJ)J,O>22?*K]KK2Q-1117SY]T%?/WQN_9L^
M!W[2&@V?AGXY_"'P%\6-#L[U;ZRT[Q[X;TKQ-!87+!0\MK'J"9L'PB@MI]P@
MD(W21N20?H&FC/\ < ]<$?X4U\OG;7Y/<F2C)<LH\R=T]+Z=4_4_.4_\$D?^
M";^]2/V+?V<M@Z@_#+000.<\_9R<=NH_K3_^'2G_  3:_P"C+/V<O_#9Z%_\
M:K]&>M-V+Z?J?\:+K3W8Z?W5_7W?Y',L#A$VU0I:N[]R*[;V2N].O=GYT?\
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M=B^GZG_&C:H[?J?\:6G\L?\ P%?Y?U?TL+!85--4:::LT^57NK:[>7XL\O\
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M7_1EG[.7_AL]"_\ C5?HOL7T_4_XT;%]/U/^-&G\L/\ P%?Y?U=^5CZEA?\
MGQ3_ / 5Y>7E^+[GYT?\.E/^";7_ $99^SE_X;/0O_C5'_#I3_@FU_T99^SE
M_P"&ST+_ .-5^B^Q?3]3_C1L7T_4_P"-&G\L/_ 5_E_5WY6/J6%_Y\4__ 5Y
M>7E^+[GG'PU^$WPZ^#OA32O WPM\$>&_ 'A#1(5ATOP[X2TFST;2[,$1K(\5
MM:QQ1RW$OEJUS?7*O<W)R7<N[$^DT44CJ"BBB@ HHHH **** "BBB@ HHHH
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M&?K7P-^RY\??'_Q4_:L_X*&_"7Q3<V,GA']G'XK?!GPA\.H;6T2"\@TKQO\
M ?P=X\UL:C= F2[E;Q#J5]/ QV+%#<>3M*1IM^^6ZC_/\2U^37["?_)_/_!8
MG_LO_P"S3_ZRIX!I-NZUZ_HQ)+WG;I^J_K[^[/UGHHHI@%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5\)?M7?MIQ?LS?$#X"?"W3/@U
M\1/C=\0?V@[_ .(5AX!\,_#^X\/V=U)/\-/#UKXH\3-?2^)+W3K9#%H]S]JM
M?+G420Q7,F[RH]Y^[&!*L!U*D#ZD5^1G[8?/_!3?_@D-[>*/VUG/LK?LVA%/
MXN-N.OMCFFOUCY[RBOR;,ZD^3ET3O)1LVUNULUKIN>C_ /#<7[1W_2-C]IW_
M ,*+X1?_ #9T?\-Q?M'?](V/VG?_  HOA%_\V=?I;11?T^Y?UT_/NS7W?Y7_
M .!2_P _7^EK^:7_  W%^T=_TC8_:=_\*+X1?_-G1_PW%^T=_P!(V/VG?_"B
M^$7_ ,V=?I;11?T^Y?UT_/NP]W^5_P#@4O\ /U_I:_FE_P -Q?M'?](V/VG?
M_"B^$7_S9T?\-Q?M'?\ 2-C]IW_PHOA%_P#-G7Z6T47]/N7]=/S[L/=_E?\
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M #]?Z6OYI?\ #<7[1W_2-C]IW_PHOA%_\V='_#<7[1W_ $C8_:=_\*+X1?\
MS9U^EM%%_3[E_73\^[#W?Y7_ .!2_P _7^EK^:7_  W%^T=_TC8_:=_\*+X1
M?_-G1_PW%^T=_P!(V/VG?_"B^$7_ ,V=?I;11?T^Y?UT_/NP]W^5_P#@4O\
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M'?\ 2-C]IW_PHOA%_P#-G7Z6T47]/N7]=/S[L/=_E?\ X%+_ #]?Z6OYI?\
M#<7[1W_2-C]IW_PHOA%_\V='_#<7[1W_ $C8_:=_\*+X1?\ S9U^EM%%_3[E
M_73\^[#W?Y7_ .!2_P _7^EK^:7_  W%^T=_TC8_:=_\*+X1?_-G1_PW%^T=
M_P!(V/VG?_"B^$7_ ,V=?I;11?T^Y?UT_/NP]W^5_P#@4O\ /U_I:_FE_P -
MQ?M'?](V/VG?_"B^$7_S9T?\-Q?M'?\ 2-C]IW_PHOA%_P#-G7Z6T47]/N7]
M=/S[L/=_E?\ X%+_ #]?Z6OYI?\ #<7[1W_2-C]IW_PHOA%_\V='_#<7[1W_
M $C8_:=_\*+X1?\ S9U^EM%%_3[E_73\^[#W?Y7_ .!2_P _7^EK^:7_  W%
M^T=_TC8_:=_\*+X1?_-G1_PW%^T=_P!(V/VG?_"B^$7_ ,V=?I;11?T^Y?UT
M_/NP]W^5_P#@4O\ /U_I:_FE_P -Q?M'?](V/VG?_"B^$7_S9T?\-Q?M'?\
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MY8+OD#%T3.\HI<J 4WR&^M@GF-)M3&6=U,:*,9W,[A5V_P"T"1Z$CFOY8_\
M@DC\*/B;H'QN_P""G_B#3/VD?VE_C!KG[-7Q!^*'[,/P9\(_&+X[_$#XG>#D
ML+RR\(^+-'\0ZGI/BK6[NUG\::9K7A"VT*PUJTFLH8-(U37K:2UV36L]?"'[
M+?QI^+GP^_::_9_UC]H_]LO]N']G_P#::\1_'+5]*^,_@C]I*;QMX@_9'^*G
M@YM5N;>#P?\ #H/J-WH'AZ>Y,VBVF@3RVT%G')?6K-=6X969^[9-IZNVZ[I>
MFCW[:[B>,M9W6JNE9+JD^N]]/OVL[?W&I=PNI8,>%+%>&;;G (5"Y(/!!&1@
MC.,XIWVB/=M^;[KN/E(RL>W<0#AB/F ! ()/!K^77X:> /CY_P %;_VC/VN]
M:^(W[6W[0'[/GP"_9N^-.H_!CX5_"7]FSXAZW\.]6U'7?#VG3OJ'C'QAXJTJ
M_2^NS<;E>#27\RQDFP$:"-%+_+_Q+_:#_:G_ &</AA_P5L_X)^^/?VC?B1\8
MKO\ 9T_9<MOC#\#/CW=:W>:=\6O#V@ZU<>'K8Z'KOC/2YEU235[*+6;+=/-<
M-=SPQW;K<;GS'48*6OO*.NNCO97^7S_ 4L?&G%2E%N+;5UW2UZ/L_P#.VW]E
M2W$;!B-XVA2V48#YL  ,1L<Y.#L9@#P2#BFM=1*@DPY4D $+P=PSU) XZ'G(
M8A<9SC^!+P;^TW^TA\//V+9?@GXE^/?QK;XH^'?VQ/V#_B?H?CO4OBGX\N?'
M?B#X._M(Z39:S?>'+G7KGQ%-K>J>$)+R:1+[P[KE[J6@W\4<UI>VUS'-M;^E
M[_@N]XZ\:?#/_@E7^TSXN^'GC/QA\._%NBVGPLDT7Q?X!\6Z[X/\5Z0+_P",
M/P_TVY.F>(]!N]/U:QDN["ZN;2[6TNHC>PW$]C,9;:YE212BH]W9<SV6BOYM
M[KMU6V[N.-IU,/4K1NN27+9K73EN[/:][=E;5]#]CQ=P%2X<%=V 05(89Y=2
M"05 #$D'.$<@'::([N"5%>-BR/L*L !F-U#"4@D,L8R0Q<*596!7*U_*-_P2
MFT/]FW]HO4OB1X>^'7[4G_!5?Q9XIA_9_;PYXWT_X_\ Q8^,>A> [*/Q];VV
MAWWBOX;W6K>+;VU_X2/3M8BNKWPYKELB3Z7;SO,JA'E-?&7[*'QJ_:X_:"_:
ME^&/_!*OXD?M,>/Y/#_[%_QM^+'B+XD?&OPC\9?%5MX^_:1\%_#CQ(VI^%_!
M^K>+K/6$U;Q/+:+=C3/$&G^<[16&8-07S[4R5&FG]YVC9IZZ:/[[W\MM41/'
MPI\BE%R<XIKEU6U^E^E[OS5D?W!I?VDFT+,C%H_- 5ED/E[F4./++A@Q4A=A
M8DX! )Q3VNX5(7YR[+N5 C%CP#MSC:K8(X9ER2 "3G'\HW[(/PN_:#_X+%0?
M'7]JOXP?MM?M.? 3X<:9\:?&'PL^"GP2_9K^*OBKX9Z%X+T?P(]C)%J/BVQT
M/6H;/Q+KMS!J&F2N^K6=S-<R1W%Q'Y=K?0Q5\>_'K]J[]K;P1^R!_P %&/V+
M?B9\>O'?BSXJ?L7?'+X%^$/!O[2OAK6M4\'?$[Q+\/OB3KUOJ>G:3X@\6>&K
MS2-5GUZVTV\T\76HF]-[*//MKR>7[-"[/1)-IN][6:UM_GKY+S".-4HJ:5HR
M3:;WLM[KIL[-Z:]5JO[=FU&T4Q RJ!,<1,6C57.T, FYU+E\X38&W-TXYJZ#
MD CH0#^=?P__  A_::_:%T/0_P!CO]EGXA?'7XQWGQ>_9B_X*GQ_!?X@ZQJ/
MQ2^(T^N?$CX)>-/#UQX[^&TWCW57\3/J/C;0KZVEU_2=)M/%LVJI9Z5X=M--
ML[>UTR&QME_MZMD6.W@1.$6&-5&%7"A!@;45$&!V554=  .*5T]K_/T5UY6>
MG](Z:%5U8\VEFKJRUMI9O5[[DQ( )[#_ !Q7Y&_MAJ1_P4W_ ."1(./^1@_;
M0;\/^&> /Y\?_6K]<&^X?J?_ $*OR1_;&_Y2<?\ !(C_ +#O[:'_ *ST*:_6
M'_I<2<0VJ<)=?:4_QDKGZXT444CI"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\T_P#@K9_R9#\0
M_P#L>/@5_P"KK\#U^DEO]P_A_*OS;_X*V?\ )D/Q#_['CX%?^KK\#U^DEO\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!',A>-T5BI8#E2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+7,H3BE;E<4U=6Y7:VZ=VGT=M--!$0(JJN%7( R21R<@G<<D'@\D>G%/
MX Z4    #    ] . *6@Z4K))=%;[@HHHH&%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45"UQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(?C/\
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MI).=1I7G.5N:4I7;=]=C]1I4J=&G&E3BH0AI&"OIY]=7;5MW?4 ,$^Y_H/\
MZ_\ G%+117HI65BWK^'X*P4444P"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *3:OH.N[H/O>OU]^M+10 4444 %%%% !1110 4444
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M:YUD&:9;E>9I/ 9ABL+.GA,6I*,HNA5=U43C)-<O1JU[GV)1117&?/!1110
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MQ_C4<S_E?]?(/=ZO7T6^GFNZZ=B6BHMT/]]/^^Q_C1NA_OI_WV/\:.9_R/\
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MF>'Q^+SAT<+1H4YSPT,!AI8!PA352:A7Q*G*4FW&2;?V!14>Z(8.Y!Z'</\
M&E,D9X+I_P!]C_&O@'HM%?R/YUNN_P#6G^:^]#Z*BW0_WT_[['^-&Z'^^G_?
M8_QJ>9_R/\?\A^[W?W+_ .2\U]Y+146Z'^^G_?8_QHW0_P!]/^^Q_C1S/^1_
MC_D'N]W]R_\ DO-?>2T5%NA_OI_WV/\ &E_=^J_]]?\ UZ.9_P C_'_(/=[O
M[E_\EYK[R2BHQY1Z,IQG.&S]TX;H?X3P?0\&@&)AE64C .0X(PW*G(.,,.AZ
M'M1S/^1_C_D'N]W]R_\ DB2BH\Q?WE_[Z'^-)NA_OI_WV/\ &CF?\C_'_(/=
M[O[E_P#)>:^\EHJ+=#_?3_OL?XT;H?[Z?]]C_&CF?\C_ !_R#W>[^Y?_ "7F
MOO):*BW0_P!]/^^Q_C1NA_OI_P!]C_&CF?\ (_Q_R#W>[^Y?_)>:^\EHJ+=#
M_?3_ +['^-*3$.K+_P!]>O [^M-2;?PM+J]=%WV%>/?\%_GYK[R2BHP\2G&]
M03@X+ $@YP<$]\-C'7!]*#)$>#(AQ_MK_C5/1-I-V_KS%?O97\[_ )V)**BW
M0_WT_P"^Q_C1NA_OI_WV/\:CF?\ (_Q_R*]WN_N7_P EYK[R6BHMT/\ ?3_O
ML?XT;H?[Z?\ ?8_QHYG_ "/\?\@]WN_N7_R7FOO):*BW0_WT_P"^Q_C1NA_O
MI_WV/\:.9_R/\?\ (/=[O[E_\EYK[R6BHOW+<;D.>,!QDGL.#FD"PL2JE21U
M <DCDCD!LCD$<]P1VHYG_(_Q_P A:='?_@_-^1-14(, Z.G_ '\!Z?\  NU+
MNA_OI_WV/\:.:7\C_'_($X]_NL^WFNZ^]=R6BHMT/]]/^^Q_C1NA_OI_WV/\
M:.9_R/\ '_(?N]W]R_\ DO-?>2T5%NA_OI_WV/\ &C=#_?3_ +['^-',_P"1
M_C_D'N]W]R_^2\U]Y+146Z'^^G_?8_QI&:'!^9#TXWCGGZT*3;5XM:[]OP%>
M/1W?39=NMWW73JB:BFK@ 8&,] ?IVSUX'Y?C2AE;.UE;!(."#@@D$''0@@@C
MU!%6*_>U^U[_ .0M%%% PHHHH **** "BBB@ HHHH **** "BBB@ K\L?^"P
MW[8GQ(_83_88^)_[0WPITW0[SQYH_B#P#X1\-R^(K:2_TK39_'GB_2/#5SK,
MMG&Z&[N-.M;Z:XL[61Q$9D42!HB\;?J=7X!_\',?_*)OXJ_]E8^ /_JTO#M'
M?S5O3S7F<V,<HX:M.,G&48-IJV_S3/Y/1_P<5_\ !5C 4_&SP>Y 4%C\)_!Z
M[B.I >W+C)&<,2PS\QS2?\1%G_!5C_HM?A#_ ,--X,_^1*_#]NI^I_G25Z-.
MA%14G*4G)+=K31/MUOJ?D57.<PC4FUB:GO2>G/))<KLK6?;\4FK6L?N#_P 1
M%G_!5C_HM?A#_P --X,_^1*/^(BS_@JQ_P!%K\(?^&F\&?\ R)7X?45?LH=G
M_7R\OS[LS_MO,?\ H)J?^!S\O[WE^7;7]P?^(BS_ (*L?]%K\(?^&F\&?_(E
M'_$19_P58_Z+7X0_\--X,_\ D2OP^HH]E#L_Z^7E^?=A_;>8_P#034_\#GY?
MWO+\NVO[@_\ $19_P58_Z+7X0_\ #3>#/_D2GC_@XK_X*KD#/QL\'?C\)O!N
M?_28?RK\.Z*/916U^GZ?Y?UJ']MYC_T$U.FTY]+?WO+\NVO]:?\ P2W_ ."\
M'[=?QJ_;*^%OP6^/WB?P9\1OA[\2KS4M'O+:#P+H?A_7M%U*'1-7U"PU+1=5
MTHVL;6T;VMN+ZTO(YU41R1J-V9#\8_%;_@XU_P""FUU\2O'C^$?B'X#\$>$X
M/&/B&S\.>%+#X:>&[\:#I%G>M:6VG_VAJBW=WJ[*\3>;<7<LDV_S'5@3Q\2?
M\$@/^4CG[+P[KXMUEC[ ^%?$9_E7Y_>.@?\ A-O&';9XS\6;O;_BHKX=NOX5
M2Y;).*OU;M?:-OO;?W+R/<_M?'/ JM[:7,KQLF[?\NXK5.][.^^O8_9C_B(L
M_P""K'_1:_"'_AIO!G_R)1_Q$6?\%6/^BU^$/_#3>#/_ )$K\/J*GV4.S_KY
M>7Y]V>'_ &WF/_034_\  Y^7][R_+MK^X/\ Q$6?\%6/^BU^$/\ PTW@S_Y$
MH_XB+/\ @JQ_T6OPA_X:;P9_\B5^'U%'LH=G_7R\OS[L/[;S'_H)J?\ @<_+
M^]Y?EVU_<'_B(L_X*L?]%K\(?^&F\&?_ ")1_P 1%G_!5C_HM?A#_P --X,_
M^1*_#ZBCV4.S_KY>7Y]V']MYC_T$U/\ P.?E_>\OR[:_N#_Q$6?\%6/^BU^$
M/_#3>#/_ )$K5TC_ (../^"J5AJ5A=7?Q?\  >KV]M>Q37-AJ/PF\+):75M@
M9A+6$=O*O'RE@P=6Y#%L&OPIIR]?R_\ 0EJ948VTNMETZM+M_7WWZ*&>9C%J
M]>4N>K0I>]*;LJDN5R2YMU;2]UM=.Q_6Q_P44_X. /VX? 7CCX1:%\";WP3\
M)]%\2_ #X1_%7Q)%-X7LO&NH7GB3XE^"K3Q%=:5!=^(T+1:5ITMZL=HT<0F"
M(LCL[<5^<W_$19_P58_Z+7X0_P##3>#/_D2ODW_@I(/^+F? KW_8Z_95<?[J
M_";082?^_G&.N.>G-?GA35*-M;M[]%;1:6MY([,XS7,,/CJE"->HHTX4VGS-
M-\\(R=^5J.CVLE;1G[@_\1%G_!5C_HM?A#_PTW@S_P"1*/\ B(L_X*L?]%K\
M(?\ AIO!G_R)7X?44_90[/\ KY>7Y]V>7_;>8_\ 034_\#GY?WO+\NVO[@_\
M1%G_  58_P"BU^$/_#3>#/\ Y$H_XB+/^"K'_1:_"'_AIO!G_P B5^'U%'LH
M=G_7R\OS[L/[;S'_ *":G_@<_+^]Y?EVU_<'_B(L_P""K'_1:_"'_AIO!G_R
M)1_Q$6?\%6/^BU^$/_#3>#/_ )$K\/J*/90[/^OEY?GW8?VWF/\ T$U/_ Y^
M7][R_+MK^XR_\'%'_!53(_XO;X04,<-M^%/@U6VD\[3]E.U@,E3@\\XZ _IW
M%_P<(?MC?\.MY?C5)IOP_F_: B_:LTO]G(_$'_A'%31H]%U7X6^+/BE%X@_X
M1>2?[#-XCL+3PU'I;#8--GDO4E-L'1V;^/X'!!/0<G\*_1>-2?\ @D!?+W'_
M  5%\- _6/\ 9"^)<C?^.L,>I./6LY4DG%W;]Y/6S^U&/;?7?T1[F3YKC92Q
M=&5:<U'#8B<92E)S3A1DT]^CL]O);GU8W_!Q7_P5;WR,?C;X'*,<JL?PD\(A
MD&>@W6Y4>^0W&<8)S3?^(BS_ (*L?]%K\(?^&F\&?_(E?A]15^RAV_K3_+^M
M;^'_ &WF/_034_\  Y+MY^5_6W8_<'_B(L_X*L?]%K\(?^&F\&?_ ")1_P 1
M%G_!5C_HM?A#_P --X,_^1*_#ZBG[*'9_P!?+R_/NP_MO,?^@FI_X'/R_O>7
MY=M?W!_XB+/^"K'_ $6OPA_X:;P9_P#(E'_$19_P58_Z+7X0_P##3>#/_D2O
MP^HH]E#L_P"OEY?GW8?VWF/_ $$U/_ Y^7][R_+MK^X/_$19_P %6/\ HM?A
M#_PTW@S_ .1*F'_!Q/\ \%56X/QN\'!3PQ3X2>"Y&"G@E8Y+<([ 'A)"$8X5
MB 37X<5)%]\#Z?S%3*C'2S:V6C[M;^EOZUNWG.8\DIO$U?=<%;GG:TGK=7Z<
MJMY:>9_61_P3B_X+_?MM>/OBQX\\._M#WO@KXH^%-)^ WQK^,$?V+PMI_@O4
M[+5?A/\ #^\\96VGVO\ PCJ+;S6.I6^CO;W"2+NW7.Y) <JWP1J?_!QQ_P %
M3]1O[G4+/XL> ]&L+\QWEII%G\)_!]U%IL4_F3"V74+R*349FA$L=M(TK.':
MW/3DM\2_\$Z!_P 7@^*X[G]B+]LL#\?V>O$Q%? B<06H/7['%^COFMJ--<K;
M=]7:]MK4_=?=>\_^&LCOQ&98ZG1PLEB:K=:E*I*\NKF]$][:+=NUFE:[O^XC
M?\'%?_!58#CXU^#^O_1)_!I_]M:9_P 1%G_!5C_HM?A#_P --X,_^1*_#ZBI
MG2@Y/3MM;LO+R_/N<#SK,4[+$5-/[\O)]_ZT['[@_P#$19_P58_Z+7X0_P##
M3>#/_D2C_B(L_P""K'_1:_"'_AIO!G_R)7X?45/LH=G_ %\O+\^[%_;>8_\
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M]VS^/?!*U+Q.I.E[2#Q6$S:4[5JK2G2C.,913FU=I/397;BDTFO''_X.*O\
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M_K3_ "_J[/+J9UF*<6L145X1D_?GN][>]Y??;MK^X/\ Q$6?\%6/^BU^$/\
MPTW@S_Y$H_XB+/\ @JQ_T6OPA_X:;P9_\B5^'U%/V4.S_KY>7Y]V9_VWF/\
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M=?V8OB'3G\/&%FB_T1A?9^SDJ&'\AZ?>'X_R-?HUX)_Y18?M ?\ 9Y7P;_\
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M:U[)1MKZW_ _2>'*M:O@HSKU9UIK12FTW9J/9+_A[CZ***R/H@HHHH ****
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MV_Y^(?\ OL5+#-;RRQ0I<P--//';00H_F332.5($<,0>5N<#[@.>!FO]<O\
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M[[%'VFV_Y^(?^^Q7^NA_PP9^QC_T:_\  O\ \-CX0_\ E51_PP9^QC_T:_\
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M +[%'VFV_P"?B'_OL5_KH?\ #!G[&/\ T:_\"_\ PV/A#_Y54?\ #!G[&/\
MT:_\"_\ PV/A#_Y54>WJ_P#/R'_@M_Y^O]/2?]2G_P!!*Z?9]/[WK^/97_R+
M_M-M_P _$/\ WV*/M-M_S\0_]]BO]=#_ (8,_8Q_Z-?^!?\ X;'PA_\ *JC_
M (8,_8Q_Z-?^!?\ X;#PA_\ *FCV]7_GY#_P6_\ /U_IZ-<%-6_VE=/L^G][
MU_'LK_Y%PNK7/-S$!W)8X'N>.U;GAN*;4_$6A:=I4,^J7]]K&G6EE8Z=#)>7
M=W<W%W%%#!;VT"O-++)(RJJ(C')] 37^MN?V$OV+B"#^R[\"<'@_\6O\'_\
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M *-=^!/_ (:_P?\ _*>D/[!W[&+<C]E_X% =./AAX0'\M)'^>]'UBK_/%?\
M;GI_P?\ /OP/@J-M,3K=;KIUZG^1=]IMO^?B'_OL4?:;;_GXA_[[%?ZZ'_#!
MG[&/_1K_ ,"__#8^$/\ Y54?\,&?L8_]&O\ P+_\-CX0_P#E53]O5_Y^0_\
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M )%GVJV_Y^(O^^C_ (4OVFV_Y^(?^^Q7^NE_PPE^Q>>G[+WP)SV_XM=X/_\
ME/3?^&#/V,?^C7_@7_X;'PA_\JJGZQ5_GBO^W+]O^#^7F<E7@YU'&^)O:_V;
M;N/9KHO\M=_\B_[3;?\ /Q#_ -]BC[3;?\_$/_?8K_70_P"&#/V,?^C7_@7_
M .&Q\(?_ "JH_P"&#/V,?^C7_@7_ .&Q\(?_ "JI^WJ_\_(?^"W_ )^O]/3'
M_4I_]!*Z?9]/[WK^/97_ ,B_[3;?\_$/_?8H^TVW_/Q#_P!]BO\ 70_X8,_8
MQ_Z-?^!?_AL?"'_RJH_X8,_8Q_Z-?^!?_AL?"'_RJH]O5_Y^0_\ !;_S]?Z>
MA_J4_P#H)73[/I_>]?Q[*_\ D7F>V9<"XASG.=XP.1U(SCIZ5^^'_!$FRNY_
M!?\ P4@U&*VG;3%_8[\1V+ZJ(F.F1W4M[.P@FO@#;0SK&KS-!+(LQB0LD;<5
M_>XW["G[&2%U/[+OP)"H%.\_"_P?GYS@@_\ $HW$=NN!GMSEGCO]D'X-ZI\"
M?BY\#_AKX(\%_"72OBGX/\0^&K^[\$^%=(T:."?6=(NM/@U>>PTJ+25U*73Y
MKB.[2UGNX5G,(A\Z$/YB]. Q2HXO!RK6=.CBXXE6TM4YX2E*]]4K)\OJK=KK
M<(U*6#S-4ZWM\16RNI0HP24;3E0E""?1W;2NW;>[TN?Y[ZW,!A242+LECCE7
MKG:X#+D8_ND9]*^E/%FA:OJG_!)C]KN33K&YO)--^,OP-UO4$MH);B2UT6Q;
MQ7ISZG<1P)))!9/(HG^T3+&D-M(DMT8!O"_NA-_P;SFY^9?VE+K)R3N^',&[
M)Y(91XZC7=G.X( H_A&T8K]*?V&?^":OAS]DCP7\4?!/B;Q=;?&'1OBI>V4F
MLV7B'PK:6^G-IEM8W5C+H]]IUQJ^OV^JV5RMY<,RR&V5(Y&A\IPVZOV#B_C;
M*,WX?IX3#UHSQT7!.R:BE%13]UV5UK9IOI=6/YL\+/!_C;ASCMYMG>5TJ.74
M\/C88;$0QE*<HO%*=N:G"=W?F5U)6B]GH?Y97VBVQS<VX/9?.0L?H%)SCOCW
M/04GVFV_Y^(?^^Q7^NB?V$/V.'_UG[,?P);/4CX7^$QG\#I[C].E)_PP9^QC
M_P!&O_ O_P -CX0_^55?BWMZO_/R*_[<;[>GG^!_2SX1JR34L4FGHUR+;2^J
M:??^K)_Y%_VFV_Y^(?\ OL4?:;;_ )^(?^^Q7^NA_P ,&?L8_P#1K_P+_P##
M8^$/_E51_P ,&?L8_P#1K_P+_P##8^$/_E51[>K_ ,_(?^"W_GZ_T],?]2G_
M -!*Z?9]/[WK^/97_P B_P"TVW_/Q#_WV*/M-M_S\0_]]BO]=#_A@S]C'_HU
M_P"!?_AL?"'_ ,JJ/^&#/V,?^C7_ (%_^&Q\(?\ RJH]O5_Y^0_\%O\ S]?Z
M>A_J4_\ H)73[/I_>]?Q[*_^1?\ :;;_ )^(?^^Q2K=6@(_TB/\ /\.W7\J_
MUS_^&#/V,?\ HU_X%_\ AL?"'_RJI?\ AA']B_&#^R[\"3Q@Y^%W@_Z<_P#$
MHI>WJV^.+O\ W&M.OZ_\'8N/!?NRC+$Z2M>T>WS?5O[WOH?YJ/\ P2/T/5O$
M7_!2']E*VT*PN=8GTKXAW>LZC%IL,E[)8Z9!X&\6P2WEXENLC6T"2:A"K/,$
M5=KY(P,_$/Q5TV]\.?$WXF:/KMO-I&JZ=\0O%EM?Z=J,,UG?6=TOB+72+>ZM
M9HUG@=XG\Z-I(UC=%(#[RJ'_ %P/ ?[+?[._PLU&36?AC\&?AC\/]<DBDMVU
MGPAX)T3P]J?V6=XC-;+?:/:V5VJ21QF/B?\ B!8.JF-LGQ-^QU^RUXWUV^\3
M^-?V?/@YXI\1ZI*+C5-<UKX<^%[[4]0G42JLMY>76ES7%PX23;OEE:0D9+G<
M5I>WJ-.\HW;?V.GNVV?EKU^ZS[)<*^TP\,+5KWIP:Y;*S2]W1M.[LTW?6Z=M
M+:_Y")N+4=+F$_\  L4GVFV_Y^(?^^Q7^NFW[!W[&!&!^RY\"%]U^%_@\'Z?
M\@FF?\,&?L8_]&O_  +_ /#8^$/_ )54_;U?^?D%_P!N/_/U_K;DJ<&*4ERX
MBT5%))INUK:7NO/7_@7_ ,B_[3;?\_$/_?8H^TVW_/Q#_P!]BO\ 70_X8,_8
MQ_Z-?^!?_AL?"'_RJH_X8,_8Q_Z-?^!?_AL?"'_RJI^WJ_\ /R'_ (+?^?K_
M $],_P#4I_\ 02NGV?3^]Z_CV5_\B_[3;?\ /Q#_ -]BC[3;?\_$/_?8K_70
M_P"&#/V,?^C7_@7_ .&Q\(?_ "JH_P"&#/V,?^C7_@7_ .&Q\(?_ "JH]O5_
MY^0_\%O_ #]?Z>A_J4_^@E=/L^G][U_'LK_Y%WVFVSC[1%UQ]X_X4\NDG[N&
M1)YI"(X8(29)II9"$CBBC R\DCLJ(@Y9F ')K_70_P"&$OV+_P#HUWX$_P#A
MKO!__P IZEL_V&_V.].N[:_T[]FCX'V5_9SQW-G>6_PP\(1W%K<PN)(9X)!I
M&4EB=0\;C)5E#8.,4G7JM-.<=5;X>]K_ )OO_GM#@R,)PFL0[PE&236[BT_Y
MO(_SB_\ @KCX3\1>$?B9^R*WB?1[_0Q=_P#!.S]D/3H#J-K-;!K_ $+PUXJL
M=8LMTJ*GVS3;AH4O+4,9X/M$+21JK$K^3OVBUQ_Q\PG_ ('_ (@?R_&O]ASX
M@?L\_!+XM?V6GQ1^%7P]^(46B0&VTE/&'@_1->.G0N$\Q+,ZA8S+;J[11?NX
M$BB1(PJQ@Y:O-6_8._8P(P/V7/@2O.<K\,/!X)Z\<:3[TXXBK!2A"<5"6]X7
M=FTVOP_#[^K$\*K$\[E7LV[JR?3EWUZVU]+JU['^19]IMO\ GXA_[[%'VFV_
MY^(?^^Q7^NA_PP9^QC_T:_\  O\ \-CX0_\ E51_PP9^QC_T:_\  O\ \-CX
M0_\ E51[>K_S\A_X+?\ GZ_T]//_ -2G_P!!*Z?9]/[WK^/97_R+_M-M_P _
M$/\ WV*/M-M_S\0_]]BO]=#_ (8,_8Q_Z-?^!?\ X;'PA_\ *JC_ (8,_8Q_
MZ-?^!?\ X;'PA_\ *JCV]7_GY#_P6_\ /U_IZ'^I3_Z"5T^SZ?WO7\>RO_D7
M_:;;_GXA_P"^Q2?:K7_GXB_[Z/\ A7^NC_PP9^QC_P!&O_ O_P -CX0_^55.
M_P"&$OV+_P#HUWX$_P#AK_!__P IZ7UBK_/%_P#;ENW_  ?NOY%1X*7VL3VM
M9>6OVN_]6L?Y%RW5MN7_ $F 9(&7E2)!GC+22%$4#.268>@R2 ?U(\%^#/%(
M_P""1WQ[\71^']8F\+S?MC?"Z>/Q FF7HTA[?1OAG\0=/U2Z2]E@CADM+.^N
M(;2:YC9X%FEC3?\ .F?](D_L)?L8$,H_9>^!7SJZ''PO\'@E'4HXR-'R-R,P
MR.1G((/->H6_P!^#MOX)N/AE#\-/ 4/PUN_.%U\/XO!V@Q^#YHYRSS1/H/V#
M[ 1/<223SR&(W$CL )D4-O/K%7K..FUH=;?)=7U_S?;A>%(X5S<:[<I)J]MM
MFM&]=5WZ]>G^.Y]KM'9RMU;LOR'<LT;?>0$<!BV,<[L;#R Q((I?M-M_S\0_
M]]BO]= ?L&_L9\;OV7_@/G W%/A=X3&2. %W:=(4C5>%CR<=2QH_X8,_8Q_Z
M-?\ @7_X;'PA_P#*JA8BKUG%?]N?\'^ORY*O!OM)N:Q%N:S::OK[M];KSV^]
MV5_\B_[3;?\ /Q#_ -]BC[3;?\_$/_?8K_70_P"&#/V,?^C7_@7_ .&Q\(?_
M "JH_P"&#/V,?^C7_@7_ .&Q\(?_ "JI^WJ_\_(?^"W_ )^O]/3/_4I_]!*Z
M?9]/[WK^/97_ ,B_[3;?\_$/_?8H^TVW_/Q#_P!]BO\ 70_X8,_8Q_Z-?^!?
M_AL?"'_RJH_X8-_8Q'/_  R_\"^.?^28>$#^G]D\_2CV]7_GY#_P!_UW_IZ'
M^I3_ .@E=/L^G][U_'LK_P"1=]JM?^?B+_OH_P"%*+JUY)N8%55=F9Y BJJJ
M2S$M@8 [#+'HJL2 ?]=+_AA+]B__ *-=^!/_ (:_P?\ _*>@_L(_L8,"!^R[
M\">>#_Q:_P (=#P<$:2I!QT.>#@X/0KZQ66O-&ZU^'T_X/7_ (.G^I4/^@A_
M=_P3_/L_X-W;&]U7_@JC\"[W3;2YO[?1O#GQ*N]4FLH);J'3[2;P1K%K#<WM
MQ;I)!9Q2W5U;P(;J2%FDFC7;EL5_IAQ9"*",':F1Z?*!U&1U!Z$UXO\ #G]G
M'X%?!^^O]6^%7PB^''P[U;4X#;7^I>#/!N@^'KV[M\(!'<7>GV4-S(@" -&)
MEB<G<\995*^RPQNF[>P8D_*%7:H7<Q48W.2P! 9LC?@':.E92G*>LFF[MW2L
MM4NGR[^A]9EF7K+\.J*J<]NZUZ==O,GHHHJ3T0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH " >H!^M%%% !1110 4444 %%%% !1110*R?\ 7FG^B"BB
MB@84444 %%%% !1110']?<%%%% DDMOZZ?H%%%% PHHHH **** "BBN>N_$N
MBZ?J^BZ'J.L:5I^K^(Y+N'0M*N[^WM]3UBYTZT?4M0M]+LI2)[YK+38VO;L0
M!V@@!E;:BE@"T7S^?3_@?KW9T-%%% PHHHH **** "BBB@5D_P"O-/\ 1!11
M10"26W]=/T"BBB@84444 %%%% !1110 4444!_7]?<%%%% !1110 4444 !&
M?4?3K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T
MKG^)A],?U!IU%"=A-)Z,0#  R3CN>2?KP*6BB@>P4444 %%%% !2$9[D?0XI
M:*&K[@-V_P"TWYTZBBDDELOZ_I %%%%, HHHH **** *\]NLZE2[IG&2A4$X
M(/.Y6!''3&._7FE2W5-OS,VSIG;ZY[*/H?7VJ>BAZVOTO;RON)))N2W:LW=[
M=O+Y$?E+S@LI))RI (SUQ@<=_P S3!!@@F64X(.,J <'.#A>1P*GHH&U??\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YI_\ !6S_ ),A
M^(?_ &/'P*_]77X'K])+?[A_#^5?FW_P5L_Y,A^(?_8\? K_ -77X'K])+?[
MA_#^54^O^&/_ +:+K\Y?E3+%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"OUN;[A^I_\ 0J_)']L;_E)Q_P $B/\ L._MH?\ K/0IK]8?^EQ.7$_P8?\
M7RC_ .E(_7&BBBD=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?FG_P5L_Y,A^(?_8\? K_U=?@>
MOTDM_N'\/Y5^;?\ P5L_Y,A^(?\ V/'P*_\ 5U^!Z_22W^X?P_E5/K_AC_[:
M+K\Y?E3+%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **\E^,OQ*T[X,_#KQI\4M=TSQ3K>A^#-(FUW4=+\':;=:]XBN+
M*TC1+Q-+T2W<3:A<+$WGK!;QLR".288?+#YY\$_MS? WXIZ%X6\6_#/QI:>,
M?"GB:(*=<TB5<:'>I&LLVG:[ITTHNM,U*VWB*\LKM$N+>96BE ="*\C-<]RO
M),/3Q&:8RA@X5J[H4U6J1BYSYW!<J;UO;F\EJVEJ1*<8/WFEMKTUMOZ7UZ+J
MS[=;[A^I_P#0J_)']L;_ )2<?\$B/^P[^VA_ZST*_4W1]:L-7L(K^PNA>03H
MK+.DVZ(AMY!50Y7)*'C'!QR>:_+#]L/!_P""FO\ P2&D#$C_ (27]M4-GH%'
M[-RN%Z<KO;<H[$9ZUZ=&O0KTX5Z%:G6P]11E"O3DITYKF@TXRC=23;233MJG
ML98B$G1A:+^.D^FRDFW=.UK:[GZYT54N&"*9#*T8168G=A/NYR1WX]2,=:^:
M_$O[47PO\*^*F\.Z_KZZ;;P6MY/J'B&:ZM[70M+ELH9+EH-4O9W-O912V\%Q
MBXD*XD6-!\S@UTPHSJ_PUS6W2T=^RON_3S>R,<7F> R_V7U_%4L(JU14J,JT
ME%5*C5^6.O36[V5KMGT_17R[^S'^U?\ "O\ :OTGQIXE^$%[K>N>$?"'B^[\
M%1^+;S1[O3O#?BN_TVVAGO-4\%:A>JK^(="CEG-B=9MR;.XNK686_"EF^HJB
M<)0DXR3371G52JTZ\(U:4XU*<M8SBTXR7=-:-=FM'NKJS"BBBI- HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT]=M6V?T1E>$CE^!PV!C.=58:C"FJE1WG)122;MI>R7E9Z;!1116!Z 4444
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M@4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@)/48_'
M-+12?JU]WZIA\C@?&G@30O'.DW.D:_I,=W;SHRK(LB)<0R'[DL,F5V%"J, &
M4@KCG)%?D%\6?V!+35OC#X'U_P#X5GX<\<>(M$>[3P7X\U/3--;5?#5E+.S2
MP-J3R!?)C.V1YK\&ZB9F-BI^;/[=_3_/\Z: !C"@  X/<$G) XZ$\]>PXX%>
M7C<FP>.J0K3=6A5AHYX:4*;J1NO<J<U.IS1LFK:/5V:9XN;Y!E^=4H4\7"<)
MP:?UB@X4\0TM.2525.HG%K1KE37V7%NY\Y?!OX#:-\-M,26YL$O/$4\<1N[^
MXF2Z*.N\&*WDWL4B12%4*H7;P!UKZ%59%=0(L+LR7#KA6W8V!3\WW3GCY>".
MIYM45Z%"C##TXTJ::A%62;;MY]+OJV]6WJ=^#P6%P&'IX;"4HT:5-)+E24IV
MW=25O>;W;:O=MZ:609P,]>_^12+G!SU)]O0>E.HK:^C7<ZK*Z?5!1112&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9IOUBBBBLST@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ***8Y(7@A68A5+ D;CTX'X^WK0#T_K_ #/'
M_P!H'XJ:-\#/@O\ %+XT>(89;K1/A5\/O%OC_4[.W8+<7UKX6T:[UB2RMV/
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M"YM3)Y]M,B'_  P?U^GYL]JHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@$CV.1QGL>_:EID
M@++M'(8$$9QGCU[=#SD4":NOFOSV^>QR'CCQMX5^'OA?6/&GC'7M+\,^&M!L
M)M2U?7M;N8K+3-.L+=-\UQ<75PT44:J@RH9\L<!58D _Q_?MH_\ !S)>>'?C
MGX3T#]C_ ,-Z1XI^$/@SQ9$OQ&\8>*;.XAG^)6F6US/#J&D>"EDVRZ1I!CC>
M4:Y/;K=SWJV\4< MM[OZ7_P=3I\;+#X:?L]ZCX=\:^(;'X):QXCUW0/''@C3
M[BXM?#^J^*#:6EYX9U'Q,M@5NM1MK98+Z*UL9BU@TSEI4)6OXC7V*BHK,^\Q
MMYAC*R3,(8TFD:&,!8U%PDT,8AB2$11( #)YC5AB*TJ,&X:RNEI9MWY?N2O;
MUW?0_-.,.)L;EN-P^!PT'2YK5)59)VG%<K:B]K.[O&+YG9[I.W^L_P#L:_MD
M_!']MKX+>'/B]\%_%5KK-AJ-K&NO:#</%%XG\(:[OF2^T+Q3I<;&33]2AGBD
M9791;7\#0WUG)+:W,4C>C_'[X"?#/]IGX4^-/@I\8?#\?B3X?>.;%=-\1:,U
MQ+:/>VL;VMW;R0W-N5N()8+J%3'(ARKID=L_Y;W[%7[:?[0'[$7Q;TOXE_L^
MZ_=#5;M[;3O$_@>>UGU+0/'ND"X#R>'M8T.!76>W9<36VK10#7[.[D:*SN8[
M2*%:_P!&S_@G/^W5KG[;OPM_X2?Q-\ OBO\ !'Q!H]AIS:G_ ,)MX:NM.\':
M[<7L&5F\$^(KM8+C5849'>:VDLX[BQCDCCG:23<0L-B76YN:/++EUNO=DGR[
M6VOJFG\G9Z?39%G5/.J$:5:A-5(TXNJ^5^S:?+%OF>BNW9IO7HWK;\>_VYKG
M_@F=_P $0_#6AZM\ OV=_ 4O[7.M65[)\(;:Z_M+4M=TFYN+9[2X\:^)];OK
MN6:#1K5&V1Q6ZL+NXB-N$B1I94_&G_@C3^UU\8?B?_P6+\#_ !9^+7C74/&'
MC+XZZ%XZ\'^)=1N99?(FTF\T&XOM-\.V-H\AL]#T;3M<T;0]6M;>P5?/6WCW
MQ;_EK^LW_@JS_P $R/ '_!1GX-+H_P!GTKPY\:O T=S>?#/X@&SMA?V.HBT2
MY?PSKU[Y8O=0\-:D"NZR,XBL[J472J29EE_C"_X);? [XH? S_@L?^SQ\(/B
M;X:U'PKXX\$?%+6K;Q+I%U92QP+:Z)X>N+FUU.S11LDT[6+<":SNH6D@N(G6
M0,$(8QBHU/;89QBW%:^ZM$[T_BMIS:.W-JXVW1X6:T\=AL\RRE@<-*E@7BH5
M*M6G!*E+WH7E-QNKQU3<T]+1C9-./]&__!TR\*_L#_"LF<H[?M5>"+4%9YK*
M>Y1_AM\6KE(&:.:-;JV(>(NCQRKF3 "RL-O\?7[-?_!.;]LG]K.2W3X-_ CQ
M7J^@W[#R_$^NZ>?#G@B.(X4N-?\ $4,&GRQC(F C2Y$OE$1KYOED?Z0W[?#>
M ]+^$/A+QAX__9:NOVMM.\$?%;P9JMM\.++PE8>-]6T@W.H2:/?>.=)\.ZFK
M65_=^$M.U&YU14F1V6W@FDB!EC45<_: _:O^"O[*_P"R[K?[0OBN)O!_@_1/
M"]O=:)X8O; >'=;O-4N+1WTCP=:Z(AM!9ZQ,0\"V5G HM$MY;V5Q%:2&MJT%
M.2<FX\L$VK.]E*6M]+7V22?:UCTL\X?H9EC)8_'8N,,-1E"25XI/V<:;<KR=
MHJ[6NNB>ST/@+]A[_@GC\9_V7_\ @EC\</V2?$6N>%?%WQ<\=^#/C1'I]OX:
MU6_DT>SU?X@>$;VPT30)+W4BK64ZSS6N;VU@CLH5F$D4!1R[?E=X$\)_LC_\
M&\GPOM?&_P 4Q9?''_@H%\0/"4%WI/AVV6(MHEK?,PAM])O;FW=/#N@6EQ#=
M0:MXAM4DU#79H9;>.&*!SC]@?^"&/[1'Q _:H_9>^)OQX^(UW)>>*_B!^T)\
M1]<DB:5Y(=(TJYN=.&E>'K#>9"FFZ%I@MM/LHU;;'%&W&237\SG_  =!%+?_
M (*!> LVSE_^&<M 4R  MAO%7B993'*P9K=-H()0+DJ<')XAK]W&4(MO1*_O
M<MVW>UFN;2R^RF]F[,6=3I4LGH8_+Z<95<+#_9YM<UDI<O-%72YERW3U2;O9
MM'ZF_P#!*7]KC6O^"PGPF_;J_9L_:YU+3-?U?QHC:WH>FV]A%'9>$_!OBBWF
ML=+C\.6-WO=9?!^NVUG>65Z2\QO0)I)-SKG]YOV$?V&OAE^P7^S_ .&?@?\
M#16OCIHN+_Q+XUN+>!-?\7>(-0R;S6M3=4_TB>)8X;:RBF9DM8E8QX9Y0_\
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M5](@:'69=*DU--071;FTGU*USI6F211RRE83Y@1AY[@_R:?\%%?^"DGP$_9
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M#W@>WU"#49?%7Q:U&;P[+9VUFL5S-<:9I81O$UPS)AF5E@M$)*#:JX']=?\
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MG/\ V=>7%GXNT:30=7L->AAC2'7;>+3WC&D/>&673YFE-NT:GGX"UK_@A?\
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MM/P/MTH[I?UH^OHB2B@#  ]!BB@H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *0J#U)XP1@D8(SR",'D'!YQCMURM% .W7\2JUNK2
M!B[$!]YC9@X)V*@ +J[Q@;=X6%XP7)=LECG&U3PCX9UN-H=:T/3-8B=2K)JM
MC:ZDK*?X2+V*<%?]GI[5T!C5FW'.>.^.E."@=,_F?\:5ZB?NO3_AMUU_X?R)
M<82^)1?JDWTV^]?@>6CX+?")3\OPM^'Z')R5\&^'B2?J=.;ISC'K7<:?H6CZ
M7;1V6F:58Z=:1*(XK>RM(;2"*,=%CA@2.%% X"A .V.E;=%7SSM\4O/5_P!/
M;]25"GTC#[EY:^NVOGYE1K*W<J2I 7HJL47WR$V[@>X;([8Q7D7CW]G+X"_%
M**:+XC_![X;^-UG8M,WB;P=H&KRR$JZ_-->6$DI&)'_CSDYSFO:**5Y*S3=U
MMJ]/SL#A"6CA3:T6MGIIWCKTW\NY\/V__!-7]@FUOO[1@_9,^!J7H9'2?_A7
M_A\F)HRS(8E:R*1D%B3L4;N-V<"OJ3P;\,/A[\/-/&E>!/!GAKP?IVQ(S9^&
M]$TS1H72-0L:.-/M;=F$>U63+9!4<D#%=Y13=2H])2;7^)O]%_7J3&C0B[QI
MTXORBEV[=[K[R'R0/N\=^IS^/7/U.2<G)/6I5&  >U!4'K_,_P"-   P.@_'
M^=+3S^[_ ()JK]DEY._W:+3<6BBBD,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "HY 3MQV)R.?0XJ2D(!Z]O<C^5 &9J5N;
MBV:+YR65A(J8+/$Q =!N1U^=25) #[20K X(_A(_;-_X-H?VFO#7Q<U+6/V0
M-2TGXK?"OQ#<W>L6EC\0O$.E>&?&OA6^OIYYI].U+4?[*BTW6X4E"3QZM!96
MES.)S;M#"+56;^\HJ",$9&,8.2#GUSU]O3M436\3@ @X48 #,!@$G!&?F&2>
M&R*;LTD^CT:W6J?6Z_#L>3FF387.*+H8QU%3<E)^RDTW;H]5=-:/9ZW36J?\
M7_\ P1Y_X(V_MV_LA?MQ>!OCE\<?!'@S0_ F@^&?&6GZE?Z7\0++Q!?->ZWH
MGV.T\K3X+-9PIFGD0AYB&\O*.B!$;^T5<X&>3@9(& 3CGC)Q],GZU$MO&C;P
M#NP!RQ(P"2.">Q8_@ .@ $H&  ,X QR23QZD\G\:25E9=[]-VDGLDNG8VR[+
M<-E6'CA<(I*E'5*3;=]/-^>K;Z6ML?F#_P %>M+^+FK_ /!/G]I.?X)>)M?\
M*>/] \&3^(K:Y\.74EEJ]YI.C^1?^)-+MYX1YJ>=H'VQRT)61BA&[J*_RZ9+
MAKHM>--)-=2Q27DT]TSO)/=ZA<F.6ZC!601O( &O)O)DNIY/FEE?)%?[&'BS
MPMI/B_PYXA\-ZS;K<Z;XBT/5=#U&%R2DMEJMA<:?=HRG(_>6UP\;''*X!R !
M7\E'PJ_X-7?AP/&VO^(/CA^T9XC\0^&[G7-;O="\"_#7PE!X<AM-'U#6I+K3
MK+5_%VKZIJL]S=VNG/%;O;:=I&FH7+2+(6 =LJU*=5P<4K1CRN[MK=/^OR>Q
M\AQ;D..S>K@X8><51@JZKISE'FYG2Y%RJ,E)64UK:U]$W>W\8?@WQQXG^'/B
MO1_&'A'Q-JOA+Q?X=NX]4T37/#NHR:;K.F:A!EK>XTVZBBLW6:1@(A9W$DFG
MS;S'+9R!RK?WQ?\ !&+_ (*I?M/_ +3NC>'OA9^TM^S?\5M5UNWM(X]+_:3\
M,>#+^T\ >)K.'[-#;2>,4U&/34L==6-V>^U304O=&N"K*8+>6>+S/T/_ &>?
M^".O_!/7]F^6QN_!7[._A+6=?M!%(OBGQW%+XVULW4431M<";7IKZVM)7#ME
M;2VACR?E5<+7Z8Z;H.C:-9V^G:5IEEIUC:+LM;.RMXK:VMHP%'EV\$*I%#'A
M5'EQJJ?*/EX&*I0E233DG?=)W36FDGI9JVED][WNV='#O#6-RFK[2MB_W7)&
M'U:G.<H)I[^]&,=4[:)O2_,DK2\B^*W[//P5^/FE6>C_ !E^&7@OXE:78SM/
M;6/BW0=.UV*UGWAG:UGO+9Y;9)&CB9XK5H!E,.6!Q7E'A;_@GM^Q9X(\1Z)X
MN\(_LU_"3P]XE\.:E;:OH>MZ7X-T:TU+2]1L[F&[MKJSNH[02Q2PS01M&X;<
MN#@@[2/L@HIQQT.0 2!GZ @?I3JTOUOKYI=-O^'/KYX6A4<74H4IN#O"4H1<
MD]+M-JZN[ZIKR[G%^./"6B^-/"'B3P9X@L;?4_#WBK0]0\-:WIMVBO;ZAI&M
MVKZ;JEA<QJ )+>\L)9;>9,9,3L 0#Q_F"ZO_ ,$U?CGXM_X*">/?V%?AQX>N
M[OQ)H7Q*U*R;79K.631?#?P]N]1;5[+Q9KMPAA6#3H?"]U#Y$J^2EW?PF&&,
M I!7^I4\2."&!()!/)Z@8'?CCTQZ]:\HT;X$_"7P]\1/&/Q:T;P/HEA\1_'V
MF:5HWB[QA!;A=;UK3-%@>VTVSN;S/F""VBD8!$*!V".^YT0C&I3<^6[VEK_A
MT>FFZ:TN[:W=[6?F9ODU+-98=S44J+UYMW%[I>[*[OM=6LW>^B/GG]A?]B#X
M5_L+? +P?\%/AC9&7^S;"VO?&/B^XB@CU?QUXONK2%=<\1ZF8H(HT6]F5X=.
MM%1FTO2A;V:3R31-=R>L_M4?!+2OVBOV=?C7\#-4F\FW^*7PP\;^"H-0DACO
MGT?4_$/A[4M.TG6K>"Y)B>XT;4;JWU"V4L@\RV1=Z$[Q]#JH4!1P   /84QH
MHW!#+D,"IY/0]>];:62>UN6R_EM9_/?UOT.^&#I4\/\ 5:<8PH\BARI6LN7E
MTLOQ>I_E3?"+_@EI^W[\:/$6K>"?A]^S9XZO+GP[KNI^'M4\1:_I]SX6\)Q7
MFBZC<Z??2?VWXCMM*LG\^2 36\-G<7K)$6S+<-@5^V_[.W_!K%\<O%4EEJG[
M3OQZ\*_"[2'>"2\\(?"_2+GQOXKEMVPTMN/%&L2Z+H&F7PY0#_A'?$=JK\D2
M@#/]S4.GV<#%XH$5B923R1^^E,SX4DJ,R$D8 (' XXJ46\*G*IMY)X)ZGJ?K
M_D5C&A1@XM1NXVU>FJMT5^V]_P CY^AP?E=.<:E6$JDXM22;7+=6=FK72OKH
M_P!3\COV-_\ @BE^PQ^QCK>E>,_AYX+\5>*?B1I#F>'XD?$+Q==:OXFDG>,1
MNTUIHL>@^'%X!,2)H$?DJ?+#%1BOUR\E-H7))4 !CL+  8'&W8. .B#.!3U1
M4.5&,CG'?IR1T)XZ]>M.  SCOUZUM==$HVV45UZMZWOI_P ,?24,-2P\%3I0
MC&FE\*7H_GJEN]M!BQ*N2,DG)R<#J,?=4!2?<J3[X Q7GM1)'.I8_O$503M^
M4KN^90$X?Y@1P02B9'!W7*0@,"#T-%W>]W=.Z]?Z1MRJS5M))I^C];]4OZW_
M  ^\#_\ !%WX):-_P43^+W[=7C!K'Q+:>(WT'5OAA\-&L(QI/A;QM/"]]XX\
M=Z_YJ2)K&I7FL;9/#,%K]AATM);@7$-Y+]GE3[2_X*&67[2VH?L@?&/2_P!C
MXZ<OQTU#PCJ%GX6&H3_8;F&PF6*+6+OP[(X-G#XH@LF=?#TM_!=VL5W*!-:7
M!PM?=)MXF&U@2.P+-@$L&SUZY'![<XQFD:UA9=A#;<J<!V&-K;\ @\*Q WCH
MX #9 IJ5M+))WO;?5)7^5M%V^\XEEN%I4:]/#Q]C*OS<TX)1=W]KFB[W7333
M7NV?Y9'["W_!/SXR?MU_M;1? 2^TK7]!.A:VVJ_M!^(]8MY5O/ 7AJ+4IEUR
MYU!-1MI[>'Q#K&JQ3:7I=A+;7%SJ.K07&JRA]()L8O\ 3+^#?P2\%? ?X3^"
M?@U\,](AT;P5X&T&TT+1]/5I+QEM8($6:>66Y\UY;FYO-UU,UQYJEV=0@C;8
M.I\*?!OX6^!O%'C?QMX.\">&O#7B[XD7=A?>//$>C:7:V&K^*[O2[>2VT^XU
MJ^@C2>^DLXI9O(:9VV232RC][(SGT,VL)QPPPVXD.X+'!&'((W@=0&R 0"*F
M"4&I)M/OTZ=+KKOUT5CBR7(Z&3/%5(2EB:V*J*=3V[YH)**C:*=[72O+371)
M)(^:_#/[+/PF\'?&_4OCOX9\-)H/CK7="N-!UV]TZ1;:PUJWN+BPF,M]IRP?
M9Q>(UA&4GM#:YR_F+*6!7Z.>%),HQ#+M0%#@JQ3&PL"I)(*AATY&2.@JWY:X
M48.%Z<D_S)IA@C+[\'=QT9AT]@:TJUJM5PE*;<H*,5*3;=HI):ZO2VGW7/0P
M67X/+X5H83#4</#$5JN(K4Z5.-.$JU;E=6;C%*+G-Q3E)IMM7=VV?D;^TG_P
M2L^'O[0GQ[T3XI3>)KGPIX<U"S\KXF^%]*M+5+SQC<6TB?9KJVU&2TFATMYK
M5!;WS+;2RW!^>.6$]/T'^$OP*^%_P4\*V/A/X;^#]/\ #&BV%M#;;+.WACO;
MY88Q$)+^\2-)[]Y-H=VNF<_Q*J9"U[<T:/\ >&?7T/U'<?\ UZ3R8P" " >N
M&;]!G _ 5UXC-,?B:%+#5,35E1I)*%/G?*E>[TV?E=.UET1X>4<%<*Y%F^:Y
M]E>28+"YQG=:-?,LPC2B\16J0I4Z*<9-?NXN%.//&#@ISO.?-)MO^'#_ (+H
M_P#!+K]I+XR?M^Z'\1OV</A5X\^)=E\<_!VC)XCN+1C=^'?"NO>&HK3PY/;W
MM_=R+;>'M+NM&ALKD6V9(9+J-KE<DRQG5_9(_P"#6KX@^)Y=,\5?MH?&1/!F
MF2S17E[\-/A%!9:AXDF@:,2):ZGXVUFVU;1+58BPAEAM_#5XX*,OVIL[S_;L
M;6 @ IG:5(.3D;7$@YSG!8 D9Y P>*>D$49!1 &50H;OM P%SZ < = ,8KRW
M0I-N3C=M\SOLY/5O>ZN[O3[]S67#&6U,?4S&M&=;$5*E2I>I9I.I/GENV]9>
M:TLMCX%_9D_X)A?L2_LD6ML/@Q\"/"&CZS;QB-O%^MVJ^*?&5UR"9+GQ%KT=
M[>EV(#%86AB5@-D:C@?>,%G;VXCCA3RQ'G855$P/0(BK'MPH480<<5>HK:[V
M5DNRT7X;^=[GMT,)AL-%0H4:=.*Z0A&.NFNB6KLM=]-PHHHI'0'^?\_Y[_2O
MXX_^#KK2/B_IFE?LP^*]*\:^*(O@;K1\;>"_&G@BWOD@\+R?$)(H_$/A#7=1
ML[:UADO[JYT.U\2V,2:K=WEC!<:;I;V%G:S-J+ZC_8Y7YN?\%2OV$X_^"AO[
M+VM? &U\3:9X)\3R>(_#'B[PCXQU;2KG7+#0-;\.7ES(MQ>:59W=A=W=M/97
M=Y:/#;7D33"<I*?)#*TS@YQE%7O9-?)IV?D_OO8\K.<+5QF K4*%3V=2?*HR
M;:5[I6=E+2U^FCL^[/\ +!9GV(X#(5C5)7VK.26 V-MDP('"X&YV93DL% ^4
M?8W[%7[8W[2/[&?Q>TCQS^S9KNJ'6Y;FRBU_P"D5_KWASQ]9O(/,T+Q)X5TI
M3-?BX#;=,U&VOM/ET^=A+%*K8S_8O^SO_P &P/[(WP_CL-0^.OQ(^(?QTUF,
M1S:EI-O]G^'W@F2]1MS16NGZ5<W_ (A:S0CR]FH:]<R2*-SK%D(O[C_ ;]@_
M]D/]F^TM%^#G[/\ \-O!=];I'_Q.;3P_9:AX@D:(_NWE\0:E#<ZM(RD!@WVE
M,$# &!65*A.G*\G&VFSO*]T]ME:VK3UTWO<_/,LX(S&EBJ6(JXNG2]G555NE
M5JRE)>[IK3@]V[7EI;W4DCS3]@3]L+Q?^V1\'[/QMX^_9X^*O[/7B>VCL/[9
MT+Q_I$FGZ3K-_$()YKSPCJL[BZO--N+A"RV]]$)H[5EMY)YG#W#>L_$K]AO]
MDKXO^);KQE\3/V?OA7XW\57T2P7FO>(_!F@ZAJ5U"G^J2XN);!FG,/'E2S!Y
MEVC]X3S7U0+6!=V(U&X!6Z_, <@'GL22/3)Q4]=%[=;][K?;6UVK[^?GKI^G
MO"TJM-4\13IUHI1TJ1C--QZM25KW5]M-;6/G?X1_LG_LZ? 35M8U_P"#?P?\
M!_#76]?LX[#6=2\(^'M-T6XU"TBG-Q#!<-9V\:O%#.?,B0KM#@$AL5^=O_!=
M3]D\?M/?\$^_C"=&TYM1\>?!_3;OXQ>#/)M?MNHR3>$;*ZN_$FG:?!&JRR7=
M]X6.JQV*1.N+^"QDE6XCBE@F_9H@'@U4O+"SU&VGL[ZVBNK6ZBF@N+>=!)#/
M!<1/!/#+&V4>.:&62*1&!5XW96!!(J9KGA*/62:[+HULM+/7;]2:N"P]7#3P
MGLX1HR@XJ$8I13>C?*K16R>V_0_SA?\ @BI_P2F\1_MV?%[3?BU\4-&?3OV9
M_AMK6GW_ (D>XCV)X_U[3&AG@\-Z7=21SPW%@+ZVWZ^4MRCVSM;))!.5DK_1
MF\+^'-'\(Z%I?AOP_96VEZ'HMC::;H^E644=O8:7IEC;16EC86-O&B+!:6]O
M BQQ ':Q<@X( XWX3?!;X7_ SP;I'P_^$W@[2/ W@[0X7ATW0-"@^RV,(EGD
MN9Y7C!)FN;B>62:>YF+SRR.S.Y))KU   8'O^O\ G\JSH4W1I*FVF[MMK;63
M=EU:5]+[N[TT2XLGR?#Y50<:<(>VJ2DZM2"233DW"*=DVH1:CKO86BBBM3V
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MM=]^OSL>GOKD*,58@,,9'U ([>AIO]O6_P#>'^?PKQV:\F.2[OO/WOF;  X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT(YR/[Q(_3->F>5'_=_5O\:0QQCJI_#>?Y9I^T79_P!?T_Z>C49+K_6GG?\
MX;3<\W;PK'E,1N,'G"]>F,[1@?\  N.O3DUH0^'TCQ\I(X."#@9XQCID8[XZ
MC!].Z0*,[01TSD,/7'WOQZ?C3ZES?3MVZZ7#E;MKT77TVT=OO\]-CF(M,5&
M.<#\OT//H1QU]JV[>W5%''RCH,YSR3D\GCGIU)Z^]RBI<F^N_P#7I_3'&%G=
M_+7K]R_,****184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXW$PPF59H[<U;*\;B:MX8;%U&H+*ZTG"E5KU'AJ\H<\*J_=$WUN%1BQP\BQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLZ4XSM*,HM:II;WUW: 8&*6BBLS **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9.2&V[@2#2Z+?5)KT=^M]]-5YHTI55.3CU45+Y:?G?\ X;8]4HHHH-PHHHH
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M\4_##PUXKUBV\"_$WP^/%VEZ5\2;K5-)L[:?2-7T^_UO4=.TC5GEE;R;+6T
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MA@ @CC1?TVI>:V>W_#'3"7-&+TU2>COND^GKTT"BBB@H**** "BBB@ HHHH
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MD@$KD':2.1D<'!XR.#U%*,]\9]J*1T)6279)?<%%%% PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>ny20077915x1_graphic01.jpg
<TEXT>
begin 644 ny20077915x1_graphic01.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M_-_=YCZ*.O2F%L==PYQT&/PR/RH&/HIA;'7?S[#_  I0<YZ\8Z@#^5'S_/\
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MI^E+0 4444 %%%,+ 'DL.<#@8)YX!(YZ'WQ0+^OQ5_S'T4@/&3D?7 _/M02
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M3R_'WPZ"A6RK :\A*LPRI)9M^!DD.I'7%;/[2$PC_P"",'C %05?]CW0$C)
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MGA^2ZA/AZ'6M9DGO?MME8*MK)<0PV=HD;W5VKA_,"DLGA'_!*/\ 9F^.6O\
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M2<'0P=/VN=5\[QV#KY@WA\-2<9U:.&]G[&+CAUR2<**E=OY3_9=_;X_:[_;
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M-QJ3>(KR\CTO1-0:*X@:1[ 0.=6DC CBB<"%6\QCN4_!G_!('5M,\)?M=?\
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MWKVGV%Q>QW-UH]K'N>XOH89+:-59GF102/YA/VQ_V=M;^ '[1W[1/[3GQM^
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MJ++:V32_L_$4Y3E#V,J']J0P=16JSJ-J<YM12YZ7B/QQEN-R3.LSSO"8SA?
M^&?"&:<6K"4\%4P\,=Q6L_H8;B7"XJG2IU/987'Y=A*6.CI@XX=U:ZH4E&;?
MW5J'_!4_XIVW_!,?3?VX%^'?@M_'.H?$&U\'CPHEUKG_  C4-I-XL.@2W[2I
M/_:4DD5C'+=[!+%$]PH!VQY!\T'_  59_:Y^!]]\"/%O[6G[-W@+1/@E^T#<
M^'U\+^-_AEXQO-6U#2;3Q!:V=]:S:QI-Q)J"I?6]A=Q:A=:9))9/):^?]AN;
MN>UDB?\ /G7!%_Q#W>&5ED3R[?XW:<]SM(D/E+\2[P2E&RT;%DW!6+"-L?>
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M7E.0#Z@'\Q6?9:?%96UM9PHJ0V<,4%N 2<1PQ^4H)(SPJH!]#UZ5H*,*H/4
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MA9:\/A(YM3PM*6%I.G0IY[*<LXITX<JBHYC.I4EBU:U9SDYJ3;;_ !I\#_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]Q'=ZKICVD]G+83/:):C#F3:'V>E_P#!-?4+SX@>%?CY\?M3TI](O/CA\?\
MQIX@L[&X,;7EEH6AFVT/2;"X,8*A[-;>>VF7>_\ ID5W\Q R4'3\GWU7I^OI
MU/TJHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9V5IXGT^XTV^6]M;>9HQ*\4$X4J?H[_@G=X[_:2'@GP!\#/C3^QQX@^ -O\
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M1FQ\':%K%_X=N-(:\TR\U*VDBDD\+VOV<HWER@IY4O\ //'H7A'3+&-'\!6
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MR6NVOIKU2V5WU6W<[HX[!S@ZD,5AIPBN:4XUZ;C&._,WS62MK=M'WY17\_\
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M#T\IP/U><ZD*V&I8E3G+G;=:,925VE9)Z*RM96LG<=1117Q9[ 4444 %%%%
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MH3I6YDI24?=G*-M[-2=K']7D<@<@;P3MS@8((^7YL@=L\8."#TR :FK^;/\
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M[N0FT<X '38WR_\ /0_D*/E/)!)/4[V&3W.!QS[<5_3L^".%IVY\AR&=G?\
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MS[]:_/+3_P#@J+^R/+,EIXAU[X@>!K]F99+/Q=\,O&%A);E,;UG>/398@RY
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M)B*L&O9NDY<MIIJ3BI1;71M-V9L>3%)NGDC5YRH=I'&79Y"6<LQY;+?PMD*
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MEW #.,'/\Q_6OA[]L_\ 8-^'W[;NF^"M+\>_%7X_?#6#P->ZE?6 ^"/Q+G\
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M_B+Q?'!&MM'XBM5FMPT_FV3KI=C/?/\ W _"[X?Z-\)_AOX%^&7AV?5;K0?
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M.#SUY.3UP<5V4BD$-_?!89/0;F&!Z@8SUSSTZ@9D\& "&)&X<>G7)QW.,_\
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MTT[[-GYG^$M'3PQX4\*>&(U)3PYX7\.:"A1<IY>CZ-8Z<F" HX6W4$   @@
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M/VG@C0_$^G:?J?AC3-1A\,C6-(MM;U*:&^UNQO+JT=KFZ9KN^>],L[1I+<N
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MK)L<L-^8/A#-\7+.W^('A3P1H'@<Z9X;^)?C6REU+Q-J^H17<5Q>W\VIB/\
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MU:]U+Q%:Z=;1JMYI+6J6QAN6OKA3'9,\?QO_ ,%;_CC_ ,$W?CQ\-?V?)/\
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MX0UV6,*!<>*/$'C+6IG92#O=I]="G)^\@0(V2I7;P?T:^"?[/GP4_9Q\'P^
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M=4\5>!S;2.,"6UMO"^OZ;81.G'EC[&R*W(7G%?+WB+_@V]_8B:1KSX9_$?\
M:?\ A!J*DF"7PG\8]6N[.V7.Y5AL=5@G/R, 59KDO@ %N]?T&T8'3''I4M)]
M%]R_ILX<1DN4XM<N)R_"5E:SYZ,6^FETD[/KWT/YI-4_X()?'GPU(;GX.?\
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M[4;9YE22XL=3M(EO+*[P?/@E#L=XD"^;.H7N",9/&#_M9';'IDXZCBOZ>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M/7W_ ,\4444 %-V_[3?G3J*7*NR^>OEU ****8K*]_ZZ?Y(****!A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF"K^VW_!-7]IV/\ :I_9)^$WQ*N[N.?Q=:60\$_$"*-Q+);^,O#,<.G:J]T
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M&#CAJ&(]E%XJJE.=# 1Y\5-<JJ0I2J*)_6/1117VQ_-04444 %%%% !1110
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M%% !110>G')[#W_SW[4 9]\L+12I-MVM&2P?!1D".KAE/!0H[(V> 6&?2O\
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M:* "C_/^?R%%% !_G_/^?YFBBB@ HHHH **** "BBB@ HHHH **** "C_/\
MG\S110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+VT?D]4^ZZ,=1112+"BBB@ HHHH **** "BCIUKC_'GC[P;\,?!_B/X@>/\
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MY_?SRQP@,SA3_'!_P:6^"=<\0?%W]MKX^7%J]OH%WHWA3P6DD:M%!<^(-?\
M$NM>+KRT2-5$1-GIMA:R+G]XL-TDBG;(6,OXH^=T_31E*_*^W_!5_P!/OZ]/
M[AJ***HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F,@8,IP0V,
MC /3USG/3KU!Y'/1]% 6_K_/O\SS+XM:)\0-9^&_C?1_A#XETGP1\2=1\-ZE
M;^#/%6M:9_:^E:%XBD@D73M2U#3MLGVNWMY69GC,,X!;S##,5$;? ?[&G[:G
MQ/\ %'Q(U/\ 9(_:W^'-]\._VH_"&AWFMQZUI5C-/\.?BWX4TV>&%O&GA+58
M8VALC,+B.6ZTV54M?,9_LLD5T+G2[+]2:H/I]D;M+\6=J+]()+6._%O#]L2V
MED2:6VCN-GFK#+-%%,\6\1/+%&[J612'?>]W_7X/L_E9IF%2E-RIRISY%!WG
M!)-3C9Z;-IK1IQMYWZ7<G(P,C."?3J#Q['OT]#TIU?E!\3_V[?B3^RC^TIJ?
MA/\ :R^'^G^&OV7_ !_K5A8?!O\ :!\&_P!HZMHGANZ:T@AE\/\ Q;1@TND7
M^H7Z2R6=W!;+;Q)/&B?:8/.DM_U1L-2L=5L+/5--N8;[3M0MH+VQO;5UFMKN
MSNHEGMKJWF0M'-!/"Z2Q21LRNCJPZT-6_K^ODUNATJT*KG&+?-3ERSBU9IV3
M5]%NG=-:/IUM>HH'(!]:*1L%%%% !7.^+/%GAWP+X:UWQCXOUG3O#OA;PQI&
MHZ]XAU[5KJ.RTS1]'TJUDO-0U&^NIB(H;:TMHI)YG=AB-&*AFPIZ$\ GT!K^
M.O\ X.DOVU/&UE8?!G_@GI\)KO4$UOXS+:^,?BA#I$RK=ZYHEYK,&A?#SP"3
M%(9Q'XA\2P76HZC R1_:%M=%5"\+W*%-V3?8:BY.R5^]NB[V_K_+S+]M7_@Y
M(^/OQL^*MS^SI_P2H^%^KZY>76K77AK3/BC=^"_^$V\:^-=0WK:QZA\// Y6
M\TW1](69)GMM6\40W-U/ T=VVE6(5S'\E^)_^"6'_!Q%^W)H<C_M$_$?7[/P
MOXHU"PO;WP;\7_C/;:/I<*2R++]LN?A]X0L-0T_3XM/_ -9_93:=I]Q'+\@L
MV&#7]3G_  2"_P""7/PO_P""<_[/'A>V&AZ;JG[0GCSP[H^M?&3XA75I%-K!
MUF^M(KV7P7HMU('DTWPQX8EG;38;6T9!J=U;2:E>-(\D4</Z]4N5OXF_1;>G
MGZ_CU'&3B[QMIUMY+OKWZV\D]%^97_!,/_@F)\%?^":GP0L_ O@BSM/$7Q4\
M1VUI??%KXLW5HHUKQAKRH&:TLW8"73?"VE.QMM'TB Q(88Q=WBR7LTLE?IK1
M4$\\,$4LUQ(L,,*-+-+*RI%#''EVEDE<B*-$5?,9G8!4&6P.*I*VB$VY-MN[
M?4F)P"?0$X]<=?\ /O7E7Q1^.7P@^"?AK4/&'Q=^)/@KX<^&M,M;B\O=7\7>
M(M-T2UA@M(S)<,/ML\4T[( 5$5M#-,[85(V8@5_'?_P69_X+7?$OX^?$?_AW
MG_P37U'Q%K>J>(/$,7@WQ[\4_ATUU+XA\:^)#>BVF\ ?"^_TZ6&X31;.2WG'
MBCQ3;!H;Z*&:TL[F+3$NKV?R[X2_\&IG[3GQ&B\,:Y^TM^UKH'AJUU&SL-9U
M[PUHEIXG^('B[0[Z_@BN]2T8W7B&^LO#2:O87$C6\^I6LVI6 O(S)!'<( 6G
MFU:2;MYI*^G7^M2XP7VWR^3T;VO:_9-=':ZO8P/^"P__  6"\0_\%,?$_A__
M ()[?\$^-"\3>,_ /C3Q9I&F>)/%.G:?<0ZC\9M5BOH!8:3H=CM-YI7P\TC4
M"+_5=9U2&V75!%%<31VEE:XN/ZI/^"37[ FC?\$[/V.? GP0==-OOB5J+W/C
M'XR>)[!99(M?\?:VS2W,-O//'!-+IGAS3VL_#FE,8XDDM=.:Y2*/[4PI/V /
M^"37[(/_  3HTF:?X*^#KG6OB5JUBEEXH^,/CFXBUOQ[KB EIH+>Y$%OI_A[
M3979B=.T*QL4>-8HKJ:Z\E7/Z9T):W>[TTV2\B9.+TBFE>^_GI^2[7ZK0***
M*HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBUHTTTTUHUL+1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX\? )/#7[%WP=M=:^'^C_%_X?W?B7X@?%J!KFRO-=\/7EW>:/+X"\'7\4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A&?R(_/'^%+
M10']?<?S/?\ !PGJ]K\/O'G_  2^^-'BA;FQ^&GPM_;)\,:SXY\4) TUEX>L
MK:ZT+5_-OV4J(5EL=)U&6-F;YFMS&H9W"CQ[_@NY\;?@_P#M1>(O^"<7P.^
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M['?[-?PH^ =[^R]X$^$'A;1_@%J%OK5M?_#&X2^UOP[?0>(IWN=9BO8]>O\
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MYK2>W))B=H+F#)GMY0% 9"P#DE54;4;<P4+SD"OZ#R_P:QO"U..<\/<45_\
M6C 3]O@VJ,:&%QD5!JIEV)3E[*5#$I\LO:*45R1O'1-?'YHLNXDPV(RK/<+1
MQ&3XNBZ=?#5*'MIX?WX3IYAAJW*ZL<;AVE[)4I*:YI.*6M_WT^$]SX6^(OA/
M1O&'A'4;37/#FO6D=SINHV<GF*=W^NMYDX:&ZM9/W%S"^&CF5D.Y<,U7XF:-
M#X=^(_P/U6<+!IPU7QS8R7$F42*\G\*M=QS2-R @AM[I.>"T+,2$R1_/;^SS
M^TY\7/V&_',^D7%LGB;X?:K<)<ZQX4OI72QOX<;1K'AZ\";M)U,1H4F&&MVE
MW+=V\JXV_N7\5OC+\*/VG_V>?"/B_P"'7B!I+RZ^('AK2QIQD-KK_A^?4K'5
MH]=T[5K9)R5@ET*;4(EN(M\5PX3:^& KV<%XC+,:$Z6.P[RWB?)L7@:F,R?$
MS=!5JN KT\3&.$]JH.M1KNE&4)THR3C4CRMQY4_YEXW\-*O#.7Y]B*U2>)X;
MQ/#_ ! Z>;4XRK3H818#$UJE7&<O,J4\+1<JE:%24>6-.<IVC&5J/B/XC>)_
MC"9+/0]4U'0?A4RBQLK*TF^PZUXZC0M#_:6K:C&R7MAHMP8EELM-LWA^U6NR
M>>4),BI=\/?"RR2%#9:/;VT2')C^S1L[J1P9;G;%)/*3C,KD,<'IS7:_#OPW
M9-#;QP1K%%$D:Q6PC4*D4,:QVR)A"@2*%8U R2K;@/EP!].>'_#2B)!LPN,
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M7>@K>[XKB VFGZM(]O!=R; 8-K_L)L'3^'!^4].<Y&.G?K_^ND\J/&/+7 &
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYAD"$E&P6_S_ *_K;78E5*;DXJ<.9/EY>97O:]K7O>VNVVNQ]!44W>OK_/\
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M)I(XS;>'?%,2E(;F*]DCMM1E(N;*67>\47]&\!<94<PP.$X?S:O3H8G"R5+
MU*K7[VG5E:2G7GI%4N6FHQE.T5*3C:[1^7^+'AOG.39KB?$+@K#5,=0QCGBN
M*,HPL*E?$_64G7QF>4J48-1P^(4I2K*BDZ%6G*=5?[0I/]"=-\5*ZJ XP1P"
MPX'.<GKWZ'IUQQBKM[XA1H3O(8<\9P/K]<<<\9Z8ZU\/Z+\39HT3SI&*A0R/
MY@,9C.W:WGAMC;U8,'0[3P1QQ72ZA\2HQ%&8Y&+.F?EE1@#D\'.[L.G/8X]/
MT9Y8L/4=9^]3<I*-9-U,/)R:M)5(J47%Z.,ENN5Z(_,</XH8.O@ZL/K'[ZE%
M<U#WG6C%N*]Z,%)*2TYHOE<=FKIV]$\<>(HQ;S&0A-P(#,P!;*MQ@ X! R6S
MCCC!KX1^*ES'<>%_%99E4W.B:M!$0KSDR264RIMA56:5P#MC2)6>4X5<N5SZ
MCK_BF;42ZL[2(VTD&3YCT09#8PH!.<\9 ZCKYYX5\.3?%/XA:;H,$=S+X:\+
MSQZIXKOK=2;)KF&*:72="-T%V/=W-Y]CN+B"*0RQ68,LF(B5;PN/^)\L\/\
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MM*+/N^BBBM#K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_7M 8:7X8\#:Q:_&C6?!OA?6TUS1/#EYJ5_H*:; MO<6UL\ ;7;J.TF2/?\
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MU*,YMJK*'LVTH>Q6'J3B^6UN?V\:<5*_5K2[/@OQ!_P50_X*X_"7]GWX=?\
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M]URJE+,)I49^U5.,M)J:DY6FK>U>O,N76Z>KZ']6F@_\@32.I_XEMER1C/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWPGJJ)*EEJ6L74+:CJUEJ$.HZ5?SRAKZSGFB@FA_$FZ_X(]?\%.[6]N4\(?
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M<J<XJG6K4%6C[.;M&K!<M6FYP;7M*4X]$G_2)11170>Z%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $#=3]3_ #H#$=#_ "I6'S,/0 _F>E-IV=KVT_SM_FCG)5;.
M<D=L9P/6GU7J56S@8[8SGT'TI#3::U=KCZ***"Y>];EUMOTW];=@HHHH+6B7
MH@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%'/X?7^F/ZT4 %%%% !1
M1S_D_P#UJ* NN_\ 7]-?>%%'/?\ GG^@HH **** "BBB@ HHY[_SS_044 %%
M%% !111S^'U_IC^M !112$GL,_B!0 M%(">XQ^(--9\,JXSN[YZ?ABFDWL)M
M+?J[?,?113=W(QR#QG/IUX]J0QU%(#G\R/R)%+0&X44P.2VW;QSSGN/; I]
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MI#K-]NL9;6&Y^K;WP5KO_!+FTU[]DG]L?]E[XJ?M3?\ !.;3_'^N_$+]F/\
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M1(_SR D< 8YYX/3\!461ZC\Q6_+>*3OJEM\G^J^\YKKNB<,#TS^-2*0""?\
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MW'PZO'\,V'@&TT>VLYKVY\9/%#%I&G:@=.C;2E@#Z?J::A8M92S+<2E/>?\
M@N9I>H7W[1O_  2'FM-/OK^.S_;0TF6]DM+.ZNX[>W:;PNC2W<D$4L5K$RM*
M%EF,<?!(8;6Q#23LO[J?31RBK:6Z???7K?HI8FO4R^EB))3K2J4U*,83@DW6
M4)1Y9.4ERK1MW5[NUM#[._;)_P""N_[#_P"SQJ_Q/_9\\5?M!6?A7X[V?@/Q
M5;6EII>C^(-4M_"'BZZ\,:E/X;M->\1:5IEYI?A_6I+_ .PFUM;^Y26.:YLF
MN(XHYLU\P_\ !)K]NW1/ '_!)WPE^TW^V_\ 'V^>UL_'?Q$TC4OB+\2=9O\
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M1TGXG:?JEXD<?A#4++3X;F)/B7X0GN7LHM7\.S7$<>IV[?OC8WFH6L'[=_\
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M- USX-R_!'4_BGXMUBRMH+YM7?5KU=-\*C3]2XELXX[GF:$QQS,ZSQ3HA0@
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M.0=H!Y8$L&(I1"BJ$ !7+$AE4@ASE@<!>IY.<@\Y!XQ-10*R_KY?>]%KN0I
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MX/#6K7EW>W&C:SXAU:ZN_$=C"]W--Y5G#K2WBVL-L4LDA5#:110LJ#C/$'[
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M%U:R0^7+;36T4UNT<L:O3K34<>6<]1ZG]>._'X=*OW%['(FW!). ,?/\Q.$
M .27<JGMG)XKY:A45&2Q"2YZ4H2IJ+49.3^"W+NUYW73NCW72G4O"4W"+B[W
MVE%<JE>]ULD]?EKH_P"2O]B676_V'/\ @J#\0/V6+S5+Y_ OC77-6\ 117Q,
M2ZC%<6I\0?#'Q#Y/S9NY[>8:>DP"F5-6=BJ(^U?WS_:'TM;_ .%OQ&@65K=X
M?!WB.^@N(V\JXM;O3-.EU2PN[:7K#<VU]8P/;3*-\4ZHRD&OP8^,]_#\2/\
M@NIH<_A1Y)E\-?$[X86^JW%MB4M)X \'Z0_B*-RI*)!;C2KN">0,1Y2*#AF
MK]X_C+::EXXTV#X8Z#ND\1?&'7]%^$WAV.+YYQJ7CC58M-N+F-$#.4TKP_+K
MFL3/M\J%=.$DK(,$>SQE;$9SP/6C1_X5,RR_*IXFDM*[J0Q&$Q4*TY*T7*5*
M$Y<RDWRW3W//X:JK#Y=Q,ZE11P>&K9I0HR>M*G&]2E"$%9N*M*,4K:=#^J3X
M4>()_%WPS^'7BJY22.X\1>"/#.MW*2DF1;C4M%L+N3>6)8L7F=CN8MDC))R3
MZ%6)X=TJVT#0M#T"S4"TT72-/TFVVJJ)Y&G6D-I$0B_*H*0@@+P,D#@5MU_2
ML4U%<WQ67,^\DDG^5C\+;3;:VN^7IHVVOP844450@HHHH **** "BBB@ HHH
MH **** "D(!ZC/0\\C(.0<=,@\@]12T4 (!C)[G&2?88_ =\#C))[FEHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH,ZG3Y_H%%%%!<=EZ+\CB;]U^VW(SSYC<=.@CQ_-OUJID=B/SI=08_V
ME<CC!FE_\=$6/Y\U7'!!]*]6%*\(--OW5=:;V7EVU_K7PIU;5*G^.22ULM=?
MO>OZ7-."7!;S&XXQGUY]!5Y) =N&!!Z=/3\ZQ%8D$'';^M6X)&+HF!CGUSPI
M/KC]*SDDFTO+?Y?TC>G-M)::O7?^MK&TC* >>_U]/2K@D Z']#_A6:G0_7^@
MJPK$G!QT_P *AQ3M?IV_IG0I.-[6U[FG&P.UL\8Z_A_C4X(/2J,;G:HP,=/U
MQ5Q.A^O]!7'--2:?=_F=--ZKS7Z7'T445)L%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUXSM]O:M"WFD9FW/QM]%'.?8"N246K:K7_@>AZ-.:=_.VNENOX>9OP'"*?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(W0_
M0_RI:0@,"#T(Q0*6S]'^1!6;(?E<^HS^H/\ 2M3R$]6_,?X51,28;C^$^GJ.
MO%:4W9NSZ+HNC3_/^NARS3:OVN7;;_41_0_H2**?"H6- .@'\R3142W?J_S.
)F.D8K^ZOR/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>ny20077915x1_graphic02.jpg
<TEXT>
begin 644 ny20077915x1_graphic02.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)_$E^\_B3Q9!ILUO+'<:I/;AO[/TR35Y-#T]H;.U6$6LFJ7URTUY<3O+X/\
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M-:GX4N-#^(FIL]]:I%X<\2,-%GACOM*D%]:N[7HB:YA*&W2196>-$=E^5SK
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M<CEGF4XW+L/FV'E7JYSC<^QF'Q659O\ 5\RQ&6YY*=3%8_+HNAB9X7&\[A+
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M=XAL[.8J\UC<R1FUU*PEDCPD[V.J6MY:-* -_D_=C(*#\%/%GQ;_ &T?CO\
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M8I-0BU#20LUZ5+13P6]C?R11W&H2M/YC_P $V?V<_AKH'_!5?]N=;71Q%8?
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M#2<;-$*6MNJ!/(BVC^$QQ^N>0%VY]<#&>G%3JJK]U57I]T =!@=/0<#T'%*
M!P**S.A)+96TM\ET_!!1110,**** "BBB@ HI-R^HZ[>H^]Z?7VZTO7I0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS9)Y"\@D8;5(1>_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8NVJ:KX#M-4@\':C?O(S2275YHLTSNQ+.1@#ZVSSC!ZXZ'TSU],=^F>"<\4
MY[8'/)X/&.Q&?7KCIGH10%_/R_R7Y'E^H_!GX<ZK\0/ _P 3[SP^A\8_#C1=
M7\/>#+Z&\OK>RT32=<A%OJ-M;Z/!<)I#F2 +%#--9236T:B.WDB3*FQ'\(_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4A(4$DX ZD]![GT'J>@ZGBEKF?&?ABS\:>$O$OA*_EG@
ML_$FAZGHEQ<6TLD%S!%J5I+:M-#-$\<L<D7F"1621&R@PPZT!_7]?UH?F'>>
M%OC1^QS\5_C)\2?#GP4L/VA?@_\ %WQO>_$36]3\*>0/C/X&N=2LK:#4]._L
MG4(!!XB\-VD6GK-I]M9W<-PKS2J8<;6)KWQ4_9WM?V=/VEOVQ?V<;"\\)_$/
MQ)X/3P;XI>*._P##VO:/XYLIH]+\/6&K^$7E?3-)\1:?JVO6[2WEMIWFW[.F
M;FX"N4K^#?#/_!3CX$>%M/\ A%X1T/X#?&+PKX8LH=!\(?$/Q3XCU[1O$4.B
M6JO%I\FM:>55M1U"SMA'!)O:9I!#&6N)AOW_ #Q\7_V<OB%\-/@QX>^$GBSQ
MAH^H_'#]M']JSPWK_BS5M#MI4\):%=::!XGN;6QTZ2.&YNM/TI-,2>XD2!3+
M((F7"J&("UM;77R\O\^NAZ_\3M._:C^ '[.7@/\ :7\1?M(>-M>^('A.#X<W
M/C7X=7EKH<GP]U_0]6O=*L-1\/O8QZ8^HW6OF"^5)?$TVHI=7M\CSB&W>8HW
MK/BK6H_'/_!03P=>7,DAT?\ 9W_9I\0_$'48F<)!8:Y\0I8HK8L[,0\G]E:?
MGY^D3'D?-G1\3?"/]IO]I"_^'/P]^-OASP%\.O@W\.O$V@>)?&S>%O%=WXHU
M3XP:EX/N;>Z\.V-C9R:?8-X9\,RZA:6VJ:C!J;SZ@X!M!D1K(^7JW[//QRFN
MO^"@/C73]$T1_&7QST'2O 'P5@D\0P1-%X2T?PA>Z#;3W]XL8CT9WU'4[J[6
MV=96C%O:[D+K+YIV#RTO_P -\O-[;ZZG@GPD^/GQ_P#'OPW^!'P\\+^.[[3_
M (F_M7>//BQ\0)/'^J6EAKEW\-O@=X;\4:E81_V!87=JMA+JLFF65C!HR7]O
M-!;//<R^8TA05]M^#?A3\?\ X+?%"'5V^./B+XL_ F\\'ZY<>,M.^*FHZ9<>
M+_#_ (LT^);C2M1\+7^F>';-I-*OHX[E-1L+J]CAM2ZM"D@B0'R?5OV8OBU\
M*G_92^(GP6TCPKXL\5? 'X87'PL\3^ =?UMO#=AXD\/Z[IUI)K%QI&O0V%[;
MVFJV6LP-<0275KY%YO=Y  VVM'4OA5^UQXR\!_M'>/?&&IZ99_$GXD?#/5?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6XO-/U+POXYT70->M)4M[VUG1Y; 0S13(\4C#=M][R#T.:#9.ZNMGJ@HHHH
M**** "BBB@ HHHH **** "BBB@ HZ=:*XGXE>*[;P+\/O&WC*[E6"W\,>%M=
MUR25E+*G]G:;<7,98 CCS40'VSTZ@ \COOVQ?V5=-OKO3-0_:%^$=GJ-A<RV
M=[97/CC0H;FTNH93#+!<PO>!X98Y@8W1PK*X((X./=_#OB7P_P"+M'LO$'A;
M6]+\0Z'J,*3V.K:-?6VHZ?=PNH=7@NK626&0%64_*Y(!&0,U^6'[!'[(_P #
MO&G[*_P^\;?%KX._#WQKXV^(<.O>--4\0>)/"FF:KK;0>*M9U#4+.)=7O+:6
M^816,T!A>.93'E60[OF/%?!GQ=X*_8E^.7[<_@NRFU"V^ WPP\$^!_B]I/AR
M*>:^A\/:_P"*%EM[SPWH22,QB?5;NXM;6TM5#32SE#*9)-S$#^ORW/V?HK\H
M]6_:&_;1\+_"$_M1^);3X*6WP^MK*V\9:I\"K;3]8D\?6'PYNVCN1=#QP=>^
MPR>++729HKR;1_\ A'3")?,MP[R JGM?CO\ :-^)?C_XE>%?@E^S-:^%(?%&
MI_#[1/BAXX^('CRSO]4\/> ?"'B18)O#T$6@:=>Z5<ZYXEUR"1Y[*T-[!:VT
M">9=E5E1@6_K]0/O&BOB/P1\3/VJO!]A\<-*^,?PTL_B#JOPVTK3=:^'/BWX
M8Z8WA_2/BZFJZ?)*V@Z=I&M:S>MI6L:+J"+!J;S:A]G6"42)N8 -\X>,OVG/
MVIO@WI'@CXF?$?QA^SKKVF^)/%7A30O$OP'\,V]U;^.O#%KXMU2WT]3IWBE?
M%>J#6]1T%;E'U&+^P4MI3'(8Y54' !^M=%?)&D_&GQE#^V1XW^!/B)]$7P/#
M\$?#?Q/\&W,%D]OJ<=X_B+4]$\2Q:I?R7;)<00BVM9H(X[:(0I+N>4D@&O\
MLW_&KQY\>_&WQB\7VXT:U^ GASQ,W@3X6RP6$AUKQ9J?AX>3XM\5S:JURT,N
MBR:D38Z1!!:A7CAEG,S[U"@?AZ^9]?T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ]J]]7OUVWZ[)(_/(QY5:]_PZ)?H%%%%!04444 %%%% !1110 4444 %%%%
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MCU&SAN5CXS&SHIDC;'1HI-R,,Y!!! (K^5G_ ()=^ /BMX:U[XY>//%OA5O
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M8AL 5<TC]D+Q]X+MW@^#_P"W'^VM\-&7<;?;\9+SQ796;.V<1:?JEM:^=%M
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M+M\,OV4/VMO'DQ.+4:EX0\+^$K6Y''S?:/\ A*->EA7)P2]HQ[A3T'B.O_\
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M[1;R212F;XT_#V" /'G<([N?6X;6;!4C=#-*K?PD\&OX&/VB_P!NG]K#Q/\
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MZ>8<^F%_PHW#@;SD\#@<GV^7]*_SL]*_X*@?\%.] 1#IO[:_Q%O9(@ O]O>
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MXQA5]^/J.,"O)? _AG3/#&G1V>F6QB3;&99I #<74FQ,2W#J #*6!!4<+@
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MP980I!8_*[J<MG)RI4Y).2<C/?--GG\["M$708!5YI6&.^ 7(/&,$C)[]JB
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MH]EOVUN<L\)2G-SO**E_$A&3C"I:UN=)KFMK:_=]-#SKX2?"?P!\#?AQX/\
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M\)_LT_&GQK=:;X=N9+'PQ(R7T6E"TUP7MS?6L-I-%<(F1>":7S&F#)O8,?\
M9K]/,0N T:EE(^\4)Y^I'3&/;K7YX?\ !3Q]5O\ ]EX^ O#<,<WB7XK?%/X5
M?#[0+60B..^U+Q#XG@BM;*4[X2R74B)')&)8G,1<ET4%AZ.#Q^/P[5/"8VOA
M5/1PI2M&HM&U5C?WK6=O.US7 95A<;FF A6PU"O-XJBH5/9\\X/FBU*DTOB=
MK.25^5O>[/Z+OV5/@;\2KS]FK]G>77[G3Y-6N?@A\*KC5KJ^OY'NI-0D\%:-
M+=_:E6*9S*9Y'WL&<AP>H)-?7&@?L^6T,L5QXAUF2Z5>6L--0V\+_P"Q+=2
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M)?Z!XLL)$.UHKSPGXAAD##/RM_Q+V13TSF08!Y.>*@7XT> U;9=3W-JP^_\
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M$OA)X!UVX@:UGUKP9\.?"'AC59K9RA:WEU#1='LKMX&,:%HFF*,44E3M%>P
M < 8'H*^"XJXGQ?%>/I8[&4J5&=&C["E3HIJ$:?-SM:MW;E=M^B/V[PH\*\J
M\*<HQ^599B\1CEF&-6-K8G%\GMG-4848P_=PA%1481LE%:W;NV%,=58 -C&>
M^/KW^G([XYI]& >HS7S)^IM)[_U_5CEM:\%>#?$4<D6O^%O#FMI*2TBZMHNE
MZEYA(Q\PO+6<'C Y!XQ7SSXO_8:_8W\?_:!XV_9:^ OB<71#7!UCX4^"KR29
M_P"_)++HK2%\_P 2E#V)-?5V!Z#\A2T[O_A]>W?T7Y$2HTIVYZ<)VVYHJ5OO
MN?SJZS^Q)^V9_P $\?VF?B]\7O\ @EY\&_@'\0_@9^T=9>$QXR_9Y\6Z[;_#
M.+X9^,/"FERZ9:^)/"&HR7NE:=)X<N1/>W-QH5I=2R)/J=XD.EH1#>0_-_P:
M^#/_  5;_P""=G[0GQ>_;"\0?LV>%/VV-9_;*L;75/C7X#^!_BO3?"WB'X1>
M-M+UB_G\/Z3H-[XJFF_M_P )VNC7,-K=W=G:7"2SI;"6:.2S2XNOZN-JYSM7
M.<YP,YQC/3KCC/7'%)Y<?]Q..1\J]1T/3M5^TT2M>R\K=/PWT=UKLMWQ?V=3
M4X2A5JTH4I<]*C"25*$GO+EMJVFUJ[)-VWT_CW^$%[^VC^PQ^W)\6_\ @H[^
MUU^PYXR\0>&/VP_#NIZ;<:%^S[;:;\6/'G[/E_INL:8GA_2/$NF:1+)=7$NN
M^&]#L(M8U>QF$-P]Q*XODF\_2[?R?P+\7[#X&_\ !2SQY_P5#_;)_8<^)/P>
M_9?_ &A]!UOPM\+?$^N?#=?%>O?#;7-#M=#T2#QW\0?!6D6^H:UX9UOQ_;V]
M_$+^[TQ;QXM0"V4EY;&>[F_MAVK_ '5XZ<#C]*KW-C97L+VUY9VMW;R B2WN
M;>&>&0$Y(>*5'C8$\D,I&>:?M/[OX_UY]M]S*66U7*#CC9J%.M[>%.5&C->T
M<U4ES5)1]IRRFY2]UJ4>9<KT/YW_ /@EG GQP_;\_;7_ &W/@9X \3?"O]C_
M .*W@[X<^"?"46N^%;WP'9_&;XD>'I&N/$/Q4TWPEJ,%A>VMO;PB[L_M\^GV
MSWO]J[W+W N%']%55[>TM+.&.VM+6WM;>)0D4%O#'!#$B_=6.*)51%7LJJ .
MPJQ4SDI.]O6_7;];Z'=AJ"P]/V::LY2GHK+FFW*5ET3DVTN@4445!T!1110
M5X%^T_X$^+WQ,^!/Q$\!_ ;XE6'P?^*GB?0Y-(\+?$C4=%D\01>$Y;R6.&_U
M.WTZ*ZLY&U!-,:\33;I+A'LK][>[3<T(4^^T4"E%2BXO5-6?3\>A\1_L*?L*
M?"/]@_X0P_#OX=+=Z_XKU^Z_X2+XL?%;Q'Y=WXY^*OCBZ>2?4O$OB75%5))%
M,\\\6E:<O^CZ;9,(OW]S)=W5S]N4  #   ]!P**!1BH1C"*M&$8QBNT8I1BO
MDDD%%%%!05$T:-D$C!R&!(.0>V/NX]<J2?7(S4M)@>@_(4":3W5SS_Q1\+/A
MMXUCGA\7^ ?!OBF"YC:*>/7O#&B:NLJ.NUTE%_8W*NKKPP*C(ZYKY"\=_P#!
M++_@G=\2XYD\7?L=? >[FG;=)>V'@#1-#U%FYR1?Z):Z==)GOLE4],$5]_8
MZ#%%'K9^J3[=_0REAZ$M94:<GM[T(O3YI_\ !Z[GX;^+_P#@W=_X)B>(RTF@
M_"[QS\,IF+,;CX:_%'Q?H<R,S[BT*:G>ZY:1GJ@ M2JQ$JBJ=K+XGJW_  ;M
M?#K1-TGP5_;D_;1^%4L*YT^UG\=Z/XKT^!T+&%9XY]'TBZN;=%(1H_M,;LJ@
M^9VK^C2BE9/HO1*W;M;LMCR\1P[D>*4EB,KP=7F=VYT8-MZ:[;Z;[[VL?R\Z
MM_P1>_X*,>#8L_"G_@I7IGBZ"W93;:3\7?A'#<F<9Z7>MZ?>:G=%3_&$@&5)
M(8,!7F^K_L2_\%R/ .3:6'[&7QVMHPP3^R=5UOP/?3(APJSMKK:);)),,,S1
MSLH (W<C/]9H  P  /0# _*C:O\ ='Y"ER1[?<]?QN>'B?#WA3$IK^RZ5"_7
M#MTW\[:6\K=$[G\=6IQ_\%8OA_YI^(G_  3%U/Q5%;@^?>?!OXL>$]=MPJ?>
MN+6W.JZW+-$5!9;=@LS/D848)\ROOVR?B'X:9[7XA_L'?MK>#-=(*)9V_P (
M-3\06DSR@I'!#?V,*H)I68>6PA"C;@NH(-?VQ8&<X&>.<#/'3\NU(40XRBG!
MR,J#@^HXX/TI>RHOXH7[NZN]5KMH]]?P/!Q'A%PQ6^"6+H?$U[.HFU)[27,F
MERNUE9W5TWM;^&_Q!_P2L_;!^/G[+7Q]_;'O_A#J'A;]H/Q=^T)\,/C/\)O@
M#K-[:VWC.7X1?#+0M>\/7&CZC#+)Y=EXIURP\4W^HVNBWMY:W-P-(M8Q!'<R
MVEM-\0V/BCXWW]V^BV7['/[6-[XH@Q#J&AP?!OQ9&=/OXT59[*:[O+*UC"0R
M!P)U1XI%PT)=2,?Z-IBC(P8T(X."BD9' .,=@2!Z4GE1<_NX^>OR+SCIGCG\
M:[*&+K8>+A3DU&ZLO)66WW^5M/,^J_U4P4,/@L-1JU:5/!X6CAH\K:=14HI*
M<[/63M=G^?7H7P(_X*->,S'_ ,(=_P $YOCQ/#<$+'>^)M0\.^$+5 ^ K3KK
MVI6CA/F!8##8R<#!%>TZ-_P37_X+$^*O)>W_ &3_ (7^#;.1E/F^,_C-X-,U
MNK,59Y['2O$<]RWE\O(H@<NH^6-RP4_W7%5.,JIQTR <?3THVJ>J@]N@Z>E;
M?VCB=/?V]-ODENC7_5;+VDISKS2[U&M;))[M)JW];G\7>B_\$1_^"L/B=HI/
M$'Q,_9)^'=LV0Z0W'C?Q+J=FK8.U(8=#&FR,BYSLOF5LCYL BO9-"_X-W_VM
M]5:)_'?[?_A_1XY$/VVQ\"_!M90C$\);7NL:W "5&"':T5L8X'WJ_K@  Z #
M/7 Q2X'I[_CZUB\77DVW-ZVV;Z):[^1TT^'<KIJ*6'4N7K/WI/6][]^G:UM-
M#^8W0?\ @VI\$7#QR?$;]NC]J/Q2A1?M-CH#^$_"5E++P)74?V=JTRJW.Q=Q
M"\$[QQ7MF@_\&U__  3TL94N/%&N_M*?$&8QA)X_%/QDE2RG;(+N;70M T9H
MS(0NX+.0 !MVG)/] U%0\16?VW]_I;>^W3^K=4<HRV.JPE%NUKN*;_'OU/Q^
M\+?\$&/^"5?A607$7[+&@Z]=XB#W/BSQ7XY\2F4Q  ,]OJGB.>R.\C<Z+:K&
M3T0  #ZC\)?\$U_V!? K0OX5_8\_9UTN:WVF*['PJ\)7=Z"H !-Y?:9=7+-P
M#N:4MNRQRQ)/VYM4]57\A_A2[5_NC\A67--OWI77ETV_R_J^G5'"8:'P8>BG
M9+2G%:*UNG2WS.=\,>$?"_@O3(M%\(^'-"\+Z1  (=+\/Z58Z/81XX&RSTZW
MMK9<#"@K$#@8S71$9QR1@Y!&/0CN".AI< = !12-XI1222271;(3:#UY]<]#
M]1T]^G6L6^\.Z'JBA=3T?3-14?PW]G!>J.".%N8I0.O7&<$C/-;=)@>@_(4T
MVNK5^W_#H4HQE;FC&5NZOU7D_P"M.K/-KKX0?"N\=GN_AMX&N68DLT_A+P],
M6)ZY:33&+9]R3ZUYEX@_8V_9/\6R23>)?V;_ ((ZS++_ *Q]0^%_@RYDD[DN
M\NBLQ)))R".??FOI>DP#U /X4XSE%WBVFM$UH]K;^G]:LSEAZ$U:=&G)=I14
ME^*/AF__ ."9?_!/;4BS7W[%O[--VS @F7X.>!=PR.65X]%1U;K\RL&&3@BO
M'/$'_!%O_@E_XE=VOOV.OA/9F0DLFA:=J/AU1N&"$71-2L$A!Z_N8XR&)8?,
M23^I. .@ _"EJ_;UO^?DOF[V]+[/S6IC4R_ U8J%3"8><(NZC*E"44^]FFNG
M4_&F_P#^" '_  2@O_-+?LL:9:O(#B2Q\?\ Q,M6B)_BB6+Q<L2,.V8R!Z$<
M5Y)J_P#P;<?\$O-7+O9^!OBOX=4L0(]"^*^N1HI!8$*-4M]59E&2 LC,-H&5
M) (_?&DVKZ#CIP.*N.+Q,+\E>K%NU[3>MN][W]>ASU,DR>JE&KE>7U(+7EJ8
M2A-)Z6:4H-+K?OH?*'[(G[%/[-_[$/P\E^''[./P^L_!6A:A>)J.OZA+--J?
MB7Q3JD$9MTU+Q)KUX7O=2N8XP5@C+16=FK.EE:VT;LA^L*/\_GUHK&4I3E*<
MFY2DW*4I.[;;NVWU;>[/1ITX4J<*=.,80IPC"$(1480C"*C&,(JRC"*248Q2
M2222"BBBI+"BBB@ HHHH ^&_^"@$W[9=U\#!X2_8<T3PQ/\ &#X@^*M(\$W_
M (Y\5:S8:78?"'P5K%OJ(U_XF6UI?2(VMZKH/E6L>F:=:QWLZ7-TMXFGWA@\
MJL_]@K]@KX6?L*_"VY\,^%[F_P#&?Q.\:7TOB3XR_&?Q*1=>.?BAXROV:YU+
M5-8U*7?=KI\5S/,-*TQ[B5;*([Y99[R2:X?[SP/0?E]?\3^9HVKZ#UZ#KZT?
M\'\=_OMJ9NG%S4VKR4>57];W[7>VVVFPM%%%!H%%%% !1110 5^=7_!376+W
M3?V:M;T^S73)(_$.O^'])U!+]B9ELWNTF#:=&)(Q)>_:;> D,VU;;S7P2HK]
M%:XOQO\ #SP1\1M*71?'/A?1_%6EI=VU\ECK%G%=P)=VKAH)T64$"2(YP<X(
M+*<JQ!:E*+O%\LEL^J[M>=CP>*<IKY]PYG>28?$1PE;-\LQ67QQ,E*2H?6J4
MJ7M&H^\U'FNTM;7LT]3\_/\ @E[IGQ8LOA'XENOB+=^))/#][JFC1_#NQU^2
M-H+'0K*QN8;HZ+#DW-IILTS6\:6TZQ(IM0\$2B1RWZ;U5L[*TT^"*ULK:WM+
M>&-(8H;:)((8XHP1'&D: *B("=JCC)8XR3F:4X3.2,%2<;NFX9^Z"3QVZ$\'
MC(JIR=2?,W=OE5VDKVBHW:6BO:[L9\*9"N%N',HR#Z[BLQ_LO!PPSQN+DZF(
MKRYI3DVW*34(RFZ=&FY/V=&-.GS/ENY**^;?CK^TO\*_V<M$M]=^(NNWL+ZI
M</;Z7HVG13:GK6H/"I>9K/3HY$V0P@*)9Y&CB4NB,^7 .A\"OVD/A=^T5X8N
M?$_PSU]K\6%P;+5]+OH9['5]'O/+658=0TV8%X1)"RR13+YD,@;,<K'-:_5<
M1[+V_L:CHW2]KR2Y+O3>U[735[:V9K'B?AZ6>/AE9UE;XBC0>*EDD<=AY9FL
M/9/VKPD:CK<O+)2^#X6G>SN?05?"W_!1_4O$.C_L>_&;5/#'BN\\&:O8Z#8S
MPZU83R6EX\"ZM:B\TJUNX")[>?6(&;3HI8V1HY;B,A@"QK[CMW+P1.Q!+1JQ
M*G<I)&20>X]#Z5PWQ$\$>&OB1X:UOP/XQT6R\0^&O$>G&PU?2=1B6:UN;24R
M[E*2<;PP5EDC*2Q,JNC9 (WRO$PP>98'%U4Y4L-BZ%>K%0IU6Z=.I&4TH54Z
M<M%=*7NMJS=FS/BW*L9GO"W$629=B(X/,,XR/-<MP.*JU*U"&&Q>-P%?#X>M
M.I0:KP5*K4C*3I?O$D^5<UC^)'X;?M8?M6> /$NDGX=?%_XAWVN2ZGH6FZ;X
M8O-5N_$]GX@EMKTP:5X=?2-2CU%I;:[:ZDLB;94G*W,EQ-.!#$T/]O?@2\UK
M5O!WA/4_$]E%IWB.[T'2;W6;" GR[+5;G3X)+^T3.24M[MIHE)P2J G))KY/
M^!?[!G[._P ";5H=)\$Z+XEU2U\97_C+1-?\6:-I&M>(?#<UU-OL]-T;7)--
M34(--TM24L(Y9Y9XD=P\SL23]K(NQHA'M1,D,NT@M@$  8PH[K@\ G\?L>/N
M*,FXEQ6#EDV6PP<,-"K&OB%AZ&%GBY3<7%N&'2A:"37O7E)M]'=_AGT<?"GQ
M \,<CS2GX@<9XGB;&9I_9LL+ECQF-Q^"R-X6C*GB88?$8V3G.5>I).3I4Z5-
M0ITI.'/S%RBBBOS\_I0***^&OV]/VX/!G["?PKTKXE>+?#6L^,;CQ#XAM_"_
MA[PWHMU#87%_J,EI>:C<S3ZA=+);65I9:?8W%Q-(\4DDK"."!))I$0W3ISK5
M(TZ<7*<VHQBMVV<V+Q>'P&&K8O%U8T</0@YU:LK\L(K2[LF[:]C[=NE=H66-
MRCG(4C;G+*R9&X%25#;UW KN5<@C@_PBW?[9_P"VW\+/^"D_BFXTGQ]XZ\6^
M.K3XS7OPG7P)XEN&UFU\1^!$^(,T>F^#Y?#T'DV:6L]I<P/97]E%:75B;G[5
M#<KNX_JY_96_X*1_LO\ [5GAGPA-H?Q#\-^#/B-XHMG,_P (O%GB33+7QII6
MJ0R26\^FBW>:&+5'\Q2]G)I[2&]A*2PJ58J/H_PS^S9\ O"GQ$\4_%W0/A%X
M#L/B?XTUA-;\1^.U\-Z9-XHO]5^RV^GO=IK%S#/>V3RVUM"+A;">U2Y9/-G2
M69F8^YE>.IY-/'TL7@(8FIB*$L/&%9*U*;TY[M.]KIJVEU>[NCRZR_MBG@,;
ME>80]A"I"NZE*?/3K4I-/E:BU:346DG9ZM6NCW&SDDEMH))4$<KPQ/+$,_NI
M&C5GCR2<E"0IY/(//8?"_P#P4E_9Q^)/[5/[(OQ'^#GPG\06N@^-=:?1-1TR
M._O)--TSQ NB:K;:A<>&=4U",G['8ZQ%"T$T\JO KK%YR^7N-?>  '0 ?08[
MD_S)/U)H(!Z@'G/(!YZ9^N.,UY&#Q5; 8W#X_#N*KX6M3KTN>/-!3I2C*/,G
M\4;QU6CMLT]3W)1C).,DG%Z--7NOZZ'\IG[%/_!OTNH^&]9U_P#;5EUKP[XD
M/B"R?PSX-^'?B_1I F@V42"]C\1:OIUGJ5H_]J3LZQVVGW22VUK'&YE6>3;%
M_45X(\&^'_A[X2\.>!_">FP:/X8\)Z'I?AWP_I5L&\G3M'T>TCLM/LHRY9V2
MWMHHXU9R6(&6)8DUU.U<YP,GJ<#)QTYI:]SB3B[/^+,4L3G.-E6A3;>'P=.\
M,'A;QC!RH46Y<DI1BN=N4I.\O>L[$TZ=.E%QIQY8MWLMNFR]5J^OEL%%%%?-
MEA1110 4444 %%%% !1110 4444 %%%% !1110 F!C&./2D**01TR,''!('3
M)Z]O6G44":3W(O)7(.6X.0"0W/\ P($C/?!%4;[1M*U2"2UU/3K'4;:4%9;>
M^L[:[@D5NJO#/$\;*>X92#WK3HHN^X<JLDTFEHDU?\SYR\:?L??LI?$4./'?
M[-WP.\6M(KH\FO?"WP5J$S+)GS T\^BM,V_)R6D)&>"*^-_'7_!$C_@ESX_G
MFNM3_9"^&V@W$_+2> DU;X>A'[2Q1>#-1T2".0'G<L0RP!8$U^JM%5SRM;F=
MO/7\SGJ8+"5K^UPN'J7WYZ-.5[;7O%[=.VMMS\#/$/\ P;I?L.2RFZ^'/CS]
MJ3X/7JF1[4^"/CAK<FGV\IP4=[/7+/5))1$/DC4WD>5X9F(!'C.L?\$$/C=H
M#S/\'_\ @J%^T5H<229L--^(?AS3O']A;1(K"')D\2:>\VSY00;:-& ! R *
M_I9INU3V_4_XUFXQ>DHIKL]O72QY5?A?(,3%0JY5@G%=%0@NVFBVTTO>S=T?
MRO:S_P $KO\ @L!X)F/_  @_[8O[-OQFMXE553XD?"R^\"W$PR03.V@6_B+=
M.$"EI3>(79R#&@7<_8_ +_@D]^VQ\6OCU\'?B9^WUX[^#NB_##X!^.=&^)WA
M;X2_!>+5-7_X3SQ]X>N&FT'4O%NM:K;:?'9:9IMQ^_6UA^WS3HPMXXK=V:>O
MZ<=H'3(_$_XT8QZ_F3_,T*$(M.,5%K:VFNFO?OUZGGX7@;AK!8ZEF&'RZE3Q
M-&HZE-ZN$9N+C=0;Y59/W5;W6DUJKG@7[07PT\?_ !$\$6\/PE^*VM?!_P"(
MWAK6K/Q1X4\1V=K'K'AS4=0TZ"6(>&?'WA>=X8O$G@C6H9C;:QI\%Q9:A;8C
MU'2]0L[^UCE.IX6^)NG0ZGX/^%WQ'\0^!-*^/>L> H_&6I^ ]%UB6X%]96,]
MOI/B#6O"UOK$-AJNHZ!9ZU)]G^T2VD=Q;B:!;R-%<2M[57COQ9^!/PV^-#^$
M;OQQH*W>L^ /$FG^+?!/B73KV_T/Q1X5U[3I=Z76B>(=(N+35+."\B+V6JZ>
M+AM/U?3YI['4K6YMI6C.E]M;6O9ZZ;=OGW[>GU4HV;FES:)./\SZ-]&U9=-E
MZ'H>I^%O#>M0_9]8T+2-6MSUM]2TZSOH".>#%=0RQE>3QMQ^%>-:]^R7^R[X
MH#?\)%^SK\$=9+L[.^H?"SP/<R2-(<R,\DFAM(S2'.]BV6R<FL70_CYKUO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*\7^'+R:T\))#JFAF."V\9SM9Z?);:K/J=DTDFLMY:7DEQ:1J#.MP[+^OO\
MP3?^ _QM_9R_9A\(?"[XY>++?Q)XDT"ZO[;2=.LUM[FS\(>&XKN5-,\/6NNQ
M$7/B"U2,->V][J$4-S:Q7::8$,5DC-YV?5\NQU.CC,+-0Q$DO;4I*7M;ZJSD
MH\C25I*SZGTOAED_$G#.8YMD.;X6M6P-"GAHX+-E:.&Q$84859-0E-S4U4KU
M:+]U.]!:.-I'WY1117RQ^T!1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !114<C%<X./EST'7GUH(E)+3NOP(B0!DUF73@!CSRW\O
MQJS)+VW#C.1Q_A6!J$\BGAR 2Q(P.@/&,CC]*[J4'*2VUT\]6EV..M44(MZZ
M=K;_ ']-;^9GS7)"N%.U2Q)SU[ ]#[?YS7/W%V=YRPP/P[^@(Z]3TINH7I56
MB )D)R&'9<XZ=.H)[GU&,5QFIZI!8PR7=W>);Q0(\TTDKQQQK$BLS&1G "(@
M&YB2NU06)P#7NX7!N;A:#E*Z6EFW=Q6E]7ILK7>UFSY7'8^--2]]1C%<SE)M
M)*.NK>BLM7TM=KHCJGO5VG#'..,@_P!3BH!>D#D@_E_C7YC_ !I_;]\-^'M0
MN/!?PBL5^(GCJ-661K$R-X9TPES&KWNIKLBOI/,! @LKB.),$SW,2!W7G?@[
M_P %";*ZU*T\&?'[14^'/BV5DBAUM$FF\':G-*V$C%PCS2:9* 0#+/<S::9
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M#9^OZ(****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'&C+$8W+X581E65.&(P\W2ER5E'$49.ERSNOW!-VOF1PKM\QT+C.[;M#LG#
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MD-0>R;3C;M<&,8G$8>8+%<+-;DREI(795Q^P6I(?.4<9503] S#C\C7XS?\
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M>EMKN^Z=N]M/4I8FKS>]3M3=G&2;N[NWO)Q5GHGV2:W5[_O!8^._!^IZW?\
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MN81HPFIN%1XK%XNAA\*XV]I[>G%.[N>^_LD?\% O@/\ MLS^/(O@7J>JW_\
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M-^,/@W=:D]JTD,ESHVIF]L+;5-#U-4?;!J&DZD)K.ZB;;N,(GB#02PO)]/\
M[&_B;2/A]_P3X_9W\9^)+J"ST;PM^R_\/O$6JWTDB+%;:5I/P]TV_O9I&<H%
M2&"WFDDR<!%!!;<:\.KE=6AA7.O"5+&1S2>5U,+-6G"M"*:CRNSYYRO'?5IV
M/T##<4T\3Q#++*+PU7*H\*X;B:&9TZM_:4L5CL10ULW36'C0P\IQJ)I\_-&5
MK:_2</Q\^$-S\4YO@E;_ !)\#R?%NULO[4N_APOB+3G\9P:7Y*70OY= 6?\
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MO)LUK1FDZ57%O#8N,Z22C35*&OO7?8T445\\?HH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?#7_!3)=_\
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M,V^JYO@\[RCA_*<3A:^%C*BZ>2Y1_9=1U(5'4YZ>+_CQA+^%)12<FFS\-/\
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M)[NVQOQ]GN)4>6# D<#RG3 ; X  V:**0));)+IHDM.P4444#"BBB@ HHHH
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M4Z<:6%A/EJ2J5&U^!?Q;^#/QFUO]G#Q7KGQ+_P""NO@G4/@%XE\#SQZY?2?
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M&F*--'IGB+PWJ6C:[90R/&LCQ0Z@L32CS-@8YKQG3_\ @EG^PYH^@V.B:?\
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M=_VK-(T32?CG\.M+\;Q^'I9I_#^I3S:CI/B+0Y)FA:9])\1Z%J&FZYI@F-O
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MOX&^(/B-X#\*ZKH6A^*M#^'JV5O<?#_X=V\1@O/$EGI!B,E_9:%;0PA=.M4
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M>EHI@( !T &.F !BD*(<Y13GDY4')]3D<TZB@! JCHH';@#IZ4;5]!^0I:*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=/\ 'OA[3/CM_P %(O'7CC6O'?CL1>*;[X,>'];G@O[%]4MQ>H?B9X]FFO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M -*J3D@$_P"?Y]_6OS1_;0_8A\5_$_QAHG[3?[,OQ U'X0_M:^ -+MM+\/\
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MN_A=\-7T\W#W?B>^,;Z7XAUVUC\O1_M+Z?8L=09[BW^]O^"!_P#P2/\ %/\
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M>O/48!Q4M>!L?2Z/5:I[/N@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI8]%!)^@Y)_ <TI('4@?6HY,&-AG&1@'..2<#!'(YZ$<CJ.0*1O==T?S7_\
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MRXU75K^>]U#3/#5UK,T&FV]U>0216,45NSH"&'TIX8\)_';PG_P4*_8%TO\
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M5_#?B_P*=NB7L.K:7<V][/;/;EK+4[&>5[;5+.26WO4E20X^B:*+OO\ UO\
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M<5:UTI2C.5M-VXZOK9::7/YE/&/[.O\ P4?_ &.O^"CG[57[0'[)7[/7@O\
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M$H5/#?@[7-?CT33M.TZVN(;R\O;Q(+V+3; S6=K%=2O;R?NGXY_8H_:=U?\
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MK4E3@N=<7H'Q-^./AR\MWTOQSJEPENW^IU)EO[61<X*E+@2F?:!R65@1@9/
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MB/Z9I\LGT?Y?F'/'O^#_ ,B2B@'(!]1FBI&FGL%%%% PHHHH **** "BBB@
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MF'3M9@CMQ#+:?VC:W#0R+MVP2(=OY(?!;XG?$7]CC]B+]K/_ ()E_%G]@_\
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M(/A31_%.KZSXI^)OQQ\9>"?$J:9J5Q=VTEKID&@Z596NCZ=HGV&Z@U&U%_\
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M#+Q_>^)-+B\/VMHNJ^)/">J:!%I_A>ZBO?#>CS>']2672)]#T"\AAN-(TN:
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MJ\6Z';W.K^$]%M?#DMF;>[T.5%N[MM0O'9K;4+9%BC9&>7\@/V*OV!/VO_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+X@:;K6@>&K'18_"4]IIU\]AIWR:5I9U2UU2*VU*PO(+FWNK4M$2_P"C>'7
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M>_ 33[>S?7[Z^\<Z?9I<3RZ?LM[&:\^'7B>/[:6:&%8K=[@Q+<QD_1G[!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKZ'-=13-I6IW5E!<:AIBW"[5NO[-NI9;,SHBB4P[PB*ZBOX$/%WQ9^*&J?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(/K,F@:$^J:KK;63Z]K-_KVIEM2UN\OM2N?/U/4KN?-Q=2;!((T"1JJ+\O\
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M;[1K&2:QUO1?@_I6KE+HPZ;>*)XM3\<7\.PZSXB2YG.GAYM+TV1D\^ZF_I>
M"C &!DG'UK5)WN]T]$M4O->>FXI32C[.*V=IOO)6OU?5:_=L+102!U[G ^M?
M,UE^V1^R[J7[05W^RM8?'+P!=_M!V.F/JUU\*X-7W>)8K6*%[N:+;Y)T^748
M+..2\N=(BU!M7M[)3=S:>EO^^-&7IK;>W0^F:_EL_P""\?\ P1(U']K$ZO\
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M.E*O4C2HKFJU)6A22LY.W>R@GUU<;[KL?VD45_/[KG_!0S]N'Q'/+-X?\,_
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MFUC5_ASXQ\+ZC;6M_I1\2>)M+TR^O--URPN)-16VN!</%-&[V]TUJJ11<C\
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M +,\(WBZUIMG?VL*/>:C:76M6]@U]9VZ-(]I#/&FR5T=0.O]?F8_PM_X*%^
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M:I??_6^Q<5MQQC'&>O\ ]:I$^\/Q_D:J!@V<9X]:LQG&TGT_GG%83BTV_O\
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M<$L,J*R\_E7KFFJ>2A8$%=H# L"1E&Q@[&X#Y(4*278)G'X-_MI_\%:/$O\
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M@CPCX5T+P[X3TJ(0V'A[2]/MX-*MD$AERMJ(A&\CR_OI)9%:62<M*[M(2Y[
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M"RG_  4"\3_L/? '0S\-;2%?BS\8]4USPIX/U^Z6*YM/!5EI=C!<:OXH^R2
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M<:=9X>M5J7Y(*4E%[:6MS/=/OH[=-=5_1HJJH 50H  "@!0     .  ,# [
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M3LU?H]T?C]K:)WMI<****8!1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 444$@=2!]:#.4E9K6_^3(I6&QAWX_0BJ98+WYZU8D(PQSQGK^-4W()
MX.>/ZFMZ45)._=_^V_\  _ QD[+I?I<:23U)/UJJ[ %AWYX^M*TCKC!'.>H'
MM51Y&+]N67/'J1G^==&UE_6EO\S"4DM[_P##&]8','T<C\E6BH],8M:Y/4R/
M_P"RBBN.I\<K[W.VEK3@^\4<-J<Y74[L!>5GE&<]<^6.F/;]:@2?<!E>2?7W
MQZ#^51:M(@U6^RWW;B4$8;J=A';GC/-5%E7(PQQD=-WKZ8KV:</W<&XOX(O9
MK>*/FI57[:JDU95)I6L_M)-_>G^1MQ-N+#&. >O_ -:M*WE :-<'(R.OL:P8
M).6^8]!Z^M:=O-&)$RW0'/#'G:?;UK&<8IN]KV[];=KG32J?#[R7O+>W??T_
MR.A1MI#8STXZ>A]ZTD')/MC\_P#]58D<T97ALX..C>@]16C')Q@L<X'KVZ_S
MKEG'F23UTU\]5V^_Y'IPDM=5;3JNSU_ TD;HN/7G\S4E5XV'RMVQU_#%3@@]
M*Y'HWZLZ82;=KZ6TV\OT%HHHI&@4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1^G^?>BB@#S;XI
M?!_X7_&WPK>>!OBYX \'?$GP;J 4WOAKQMX>TWQ)I$[HZ212_9-4@N(HY89$
M26&6%8YHI41XY%901^5OB/\ X-^O^"3GB363K<W[*NAZ3-)<R7-Q8>'O%?C;
M1M'N'ED:5T?3+7Q!Y$4&]L+;VWD1)&!$JA %K]FZ*?,[<MVX]GJON>B^0TW%
MMQ;5U9V;5UYJ]C\_/A5_P2K_ ."=WP7TV+2_ /['WP'LXH98KB.^UOP!H_BW
M6Q/#GRY?[=\50ZQJP9,DA4NU0,2X0,68_8_@_P"%_P ._A[ ]KX$\#>$/!EM
M*<RP>%?#>D^'XY>G,BZ7;6HD;@ L^[(XQWKO**FRT\KV\D[72[)V5[;A=VM=
MV>ZN[,:JD=\CTQ3J**8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWCZ?H+1112-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ /((]:9L'J?T_PHHH,);OU?YE*XC4HPR?O>WK]*H- F#RW0]QZ?2BBMH[
M?=_Z2C&>_P O\S.%G"YP2_ /1A[>H-,-E#DC+\'^\.Q_W:**Z7^J_-'')+LO
LL]%UM<Z#28EAM3&F=HE;&<9Y5#S@ ?I1117%/XG_ %T1ZE#^#2_P1_(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>ny20077915x1_graphic03.jpg
<TEXT>
begin 644 ny20077915x1_graphic03.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M;_XFH_.]W_[[?_XNEJO7%[3$])Q6W672WEY:=ON9IRI?\._+S\E]Q/YWN_\
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M&+Q-],7B-NMNZ\V2XIKX5^7XI?UON3_;+O\ YZ2_]_7_ /B:/MEW_P ])?\
MOZ__ ,35;>WK^@_PHWMZ_H/\*OZUBO\ H*K].WEY^7]60N1?RQ^]_P"7DON+
M#7EWM;]Y+]T_\M7]/I53[=<_WY_^_P!)3F=L'GL>P]/I5?)]OR'^%7'$8EJ_
MUNOO;IT2\_+^K&<X)6M&/WOI;R)OMUS_ ,])Q_VT=OT)'YT?;KG_ )Z3G_MH
MZ_H"?SJ')]OR'^%&3[?D/\*T5;$O18NMWZ>5NO3I_P ,9NR6L5OW?^7E_5V6
MH[ZYY^>?M_RVD]Z62^N2I'F3C..?.D]157<1TP/P'^%!8G@G]!6T*^)BDGBJ
MSL]].Z??R(NOY5^/E_E_6MW?;+O_ )[7'_?Z3_&C[9=_\]KC_O\ 2?XU'16G
MUG$?]!=?[H^7][R?W^1-EV73J^EO/^ZOQ(7O[L,P\VXX)'^ND[?C^?O3?[0N
M_P#GK<?]_I*K2NPD< CAC_"I_4C-"L2.<=?[J^WM25?$R?\ O5?OO;MV?K]_
MD8>[?X?Q]/\ +^K(G?4;L ?O)SST,TA_'K_G-1_VE=_WYO\ O[)_C44A. ..
MYZ ?R'O45=-/%8B,5%XFNVNNCOJGU?D8S:YOA6ENE_Y7^FQ:_M*[_OS?]_9/
M\:J?VG=_\][G_O\ /_\ ':1MV?EZ8]NOXU#6D<5B7>V*K*UK:1OLEU;[&;5[
M625K=+?R]O\ #]_D3_VA='GS;DY[^?*/Y,1^IJ-]5NHB!YUQR,_\?$O]6%,I
MC(CXW*#CI^/TKHAB<5)J/UNMMU2MI;L_+M^M\IQ48N7*KJVJE+JTGI\O^''-
MK%V1CSKCK_S\2#^IIG]K7?\ SVN/_ F2HI8HU4%5 .X#UXP?6J^!Z#\A6RJX
MI6OBZRM;9+96_O+M^+[G,Y-OX4]MW(NG6;M<9GNN?^GJ7_&J+>(-1#,!)<X!
M('^D2],\?Q4;5/;^G\JKC<&.>G..GK[5T+$8EWMBJ^C6]MM-K/R?7M\L975N
MGHWT27EVT_J]M=;OV&YI;C=VS-(>G3G<34<NO:BNW]_<\YZ32'T_O$_I4).
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MCJZD]$M%ZKK?NOGI\[7]M:C_ ,_-Y_X$W'_QVJ4FOZHKL!>70 / ^U7'H/\
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MWT_I4]02=6^G]*NA\;_PO\T<LMGZ/\BB_4?3^IJM/]P?[P_D:LOU'T_J:KS
MLH _O#K]#71)-II?UJ<T_A?R_-%-NA^A_E5<J&QG/%67& P]C_*J]:4/A?\
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MKIC]K_$_T.<KU!)U;Z?TJ>H7^\?P_D**'QO_  O\T<[U37<HR @C((X[_4U
MX)' SS_C5V5=Q4YQP1T_^O4#+M&<YYQT_P#KUU'/*.\;_P!;E)T^5CM.=I]?
M2J6#Z'\C6J_W&_W6_D:HUK3V?K^B.><%=*_3^OR_'RUHL#D\'J>WO3:L.,[A
M[G^=0$8)'I6T-WZ?JCDGLO7]&)6?*K ,2"!GJ0<=?7I6A5>Y_P!5_P "']:V
MCNO5?F8RV?I^6IFO]QO]UOY&ID $ME@?P/\ R:H7^XW^ZW\C4Z_ZVQ_W'_DU
M=2^"3ZW_ ,CE?QQ]8?\ IR)^HN@?\@+1?^P3IW_I'#11H'_("T7_ +!.G?\
MI'#17JG[M0_@4?\ KU3_ /2(FM11103=]W]_]=E]P4444%J:22=]/Z[A1110
M/G79_A_F%%%%!:U2?<**** "BBB@ HHHK.4E9K6]_P GZ@%%%%9@%%%% !TJ
M)F#8QGC/7\*D;H?H?Y5!2G\#?=V^YQ_S ****P-8;/U_1$<G;\?Z5'4DG;\?
MZ5'6=3I\_P!"PHP#U&:**S 8P&T\#\O>HJF?[I_#^8J&LYI::=_T KTC=#]#
M_*EHZUQ/5-=TP*]-?[I_#^8J5P!C ]?Z5$_W3^'\Q7---)I^7YH")>H^H_G3
MY.WX_P!*CZ4I)/4UB7&22L^_^17;J?J?YTE3;5/;]3_C4;  \>E<M2,EO:RU
M_3^O^&+4D]KC:<OWA^/\C3:<GWA^/\C62W7JOS*)"!@\#H>PJED^I_,U>;H?
MH?Y50J:Z2Y;)+XMOD 444N">@)_"N)Q:5VU]Y<-WZ?JA**:Q(&1Z_P"--5R2
M!Q_D?6LW))VUOI^);DD[:WT_$DHHHK&O]C_M[_VTH***AE=D(QCD=Q7. LW"
M<>HJCN;S -QP64$9.,'&1CWJ9I&88.,?2H/^6J_[R_TH)E]G_$BW@>@_(4+T
M'T'\J6CI7)*+E:UM+[_(TBTG=]O\@HI!W]C_ $%+6;5G8V6J3[E)R=S#)QN/
M&?>F4Y_OM_O-_,TVD<X4444K+LON0!1117-4IM.4M.6_YV6UN[_/YMV_!?@E
M^844C$@$C_/-1;V]?T'^%8B&8'H/R%3*!M' _(>M15,GW1^/\S0 N!Z#\A3'
M  X '/I]:DI" 1@U+5TTK?U;_(""BI&0 $\_Y/TJ.LG%QWZ@0E2!DXIM3D ]
M::57!P.<''6LG#72UO.YHI]]^_3YZD5%2*N<Y![8SD>M,(()X.,\&HLTD^C_
M *U]>A::;:[:B4444AA1114RC=625^GX?H@"BBBHY'W7X_Y %%%%'(^Z_'_(
M HHHHY'W7X_Y %%%%2TT[=?\P"BHI&<$; 3QSP34M)IIV87W\O\ APJ"8D;<
M$C[W0D>GI4]5Y_X/^!?^RT$R^%_+\T0[W_O-_P!]'_&G*S%ERS?>'<^OUJ.G
M)]]?]Y?YB@R3=UKU7YK_ "7W%ZBBJK2N&8#& 2!QZ&@V;2W"?[X_W1_,U#3F
M8N<GKC'^?SIM!C)W;?\ 6P4444""BBB@ HHHH **** "H7^\?P_D*FJ%_O'\
M/Y"KAN_3]4 VBBG* 3SZ5JM6EW$W97?08W0_0_RJ"KCJNUN/X3W/H?>J==5&
M+BG>VKZ>AS5FI.+79[A1116QB%%%% !111730VEZK\@(7^\?P_D*;3G^\?P_
MD*;6T=EZ+\CG&/T'U_H:IMU/U/\ .M$('!![8_K4<D$81V .0">IZU2BY<K5
MM))OY;F<VMNJ=_Z^\HT445N9B'D$>H-0LN#@X/Z_S^E3TA4'J/YUNMEZ+]#"
M6[]7^97"J#D  ^H !I'^XW^ZW\C4SJ .!W]_>H7^XW^ZW\C3.=IK<HU W4_4
M_P ZGJ!NI^I_G6]#>7HOS,JG3Y_H)11177#XE\_R9C/X7\OS1%-]P_453;H?
MH?Y5H,H88/2HFA3!Z]#W]JZ822TUU?\ D<THMNZMM_F93]!]?\:BJU(@P!TZ
M_P"><^M5CP2/0FMZ4'!RO;HM/D^WF<LWK;M^MBI/]\?[H_F:JN2,8..O]*T6
MC5SDYSC'7_/K5<QHW4=/<U3BW-6=G+;?L<\XN[?3_AD9L@;#$G(YXR:J5L20
MIL;KT]:I>2GH?SK>G>":EO>^FJM9+\+?Y=#GFM4^Z_K]"G@>@_(5"RC<>!U]
M*GJ)@=QX/Y>U=$-WZ?JCGFDK-+U_"Q7< '@8X_J:A?H/K_0U.X.1P>GH?4U
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MQ5GN2X&>,R3-*U:6$RS,:^#H^VK4L[H1J8A4Z495Y1I0BZDI*,(Q7*OZO?\
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M<8Z_B:94LWWS]!3%1FSM&<=>0.OU(]*V@KS2O;?5^C.>:TDEW_4;2-T/T/\
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M5J=Y+Y/)?$W@K)Z_B/A%E.;5N&.*YXN61Y!0I4L%.DJE3&U,MEBLZH9I0Q>
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M_P 14W[>'_1&OV;?_!)X_P#_ )O*_F1HJ?J-#^7^OO\ )?<']N9M_P!!DO\
MP"'EY>2/Z;O^(J;]O#_HC7[-O_@D\?\ _P WE0M_P=1?MULY+?!G]FW<<9_X
MDGQ QP .G_">8Z?YS7\R]%)Y?AGI*%U]VO\ PV@?VYFO_09+R]R.FWEY(_IG
M/_!U#^W1_P!$8_9L;ZZ%\0./_+\IO_$4]^W'_P!$9_9P4]]OA_Q_Q[ _\)]R
M/PK^9JBE_9N$_P"?;_\  G_73\^[&L\S3_H+F_E%=O+R^7XG],O_ !%/?MR_
M]$;_ &<?Q\/^/P/Q/_">\#U-'_$4]^W+W^#?[-X_W=!^(#?GGQZ,>WXU_,U1
M2_LW"?\ /M_^!,/[<S3_ *"Y_='R\O+\K6L?TR_\13W[<G_1&_V<O_"?\??_
M #>TO_$4Y^W&>3\&_P!G'_PGO'O/Y^/Q]/PK^9FBIGE>$FK<C6J>[Z=-T)YY
MFO3%S7RB^WEY+^K6_IF_XBF_VXO^B-_LX_\ A/>//_F_I&_X.F_VXL?\D;_9
MQ/M_PCWCW^8\?D_I7\S5%9K)\$FKP;757:OMUOY/[_O%G>:_]!D__ 8^7EY+
M[C^E\_\ !TQ^W$3D_!G]G'_P0>/_ /YO*3_B*7_;A_Z(S^SC_P""#Q__ /-Y
M7\T-%7_9&7?] _\ Y._\A_VYFG_07/\ \!AY?W?)'], _P"#I7]N \_\*;_9
MQ'M_8/C\?^[[1_Q%*?MO_P#1'/V<?_!#X_\ _F]K^9^BLO[#RZ]_8];[O^[_
M /(_B']NYOTQL_+W8]+6Z>2^X_IA_P"(I7]M_P#Z(U^SA_X(OB#_ /-_1_Q%
M*_MO_P#1&OV</_!%\0?_ )OZ_F>HI?V%EW_/GMU?3E_^1_$/[>S?_H-G_P"
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M^OCW.?K4?_$4-^VQ_P!$7_9V_P#!%\0?_F^K^:RBC_5S)O\ H6X'_P $5/\
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M*\+]U7R_Z>^7]65C^W\Y_P"@ZI_X#'_+R7W']*7_ !%!_ML_]$9_9W_\$GQ
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MUTLNOM83B?*,4X1]M.C*>L?;148VTWE>W7NK]+NZ/ZC2@R3@XR>>>?Z4  #
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MZ#_"C>WK^@_PKH7BIQ^K6XAQ:M:W[C :6M;_ )A^EE]WW^-_Q*A]'W_HW_\
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MH7LR5^&#+N3RVQXJQE,@[3_Q3?0E03ZD<T1?\%"O);=%\+V1L[LKXJP<^O\
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MU6NE_56DN\6GU"BDR/44OOVQG/MUS],<T#"BBDR/44 +1110 44F1ZC\Z6@
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MM[U)14@,5<9R!VQG!]:?110 5 5(ZBIZ0@$8- $%*%)Z#^52;!ZG]/\ "G
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MF33[._APY^F/&?[9W[%VA_"']M_P;\#_ (7_ +08\6?MHZGX)\5:I=_%#7_
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M@#X?Z_XFOKGX3?!_POX9N-3TO0XK;2?$<MIIVOP:98V>H_V/X<MK_P (V/\
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M\+>$_C+^R5\*OV3O@/X7BU6TUNY\"^$/@]XW^&&L>&)_&^MS3:7)?W5QX>\
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M3H)]/>[[_P %?M9?LB>+?"/[)>J?M(?#?X\7WQ7_ &-_#-GX$\*6_P *M?\
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ME^%?BSX,Z_K7B7QWXBA>U_MO^V+7X=:K)+KEK9G4]0UB^MIIM(L4$DD'HO\
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M2NUS/=:)W]/FCP[IN236DI:7O97=OPMZ[A1115@%%%% !1110 4444 %%%%
M!1110 T*,<\\=.WZ8/ZYY/K7M'P)_:(^.'[,GC>Q^(GP%^)OBSX8^+;.5&DU
M'PSJUQ9P:E;(RLUAK>EY?2O$&FRD,DVG:_9:I:2PDQ-&<AU\9HK*M0IXB#IU
MU[:GTIU'S0CM?EB]KV5[=EU2-*=65*2G2M3J+_EY!<L]+6O):NUNOF?VJ_L
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MPHV'U'Z_X5+12Y(]OQ?^8$6P^H_7_"C8?4?K_A4M%')'M^+_ ,P(MA]1^O\
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M .,G@XZ?_7-7ZBDC!4[5&XGV'UZ\5K3CS<WDK]?T,YWLDMGOIZ6*#(22>/\
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M[:&?/;LZR'<H'EL._P#=-5]A1[+)!R%QCVD7K^=:<G^K?_<;^1JE*"'L,C'
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MUUL_M)M\4/BQ\(_V?[/]E?QUX:^&OQ2U3XH77C:XTZ'QCXHUCQ/HFG:;H[^
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MZYI6G?#=/!&M2:6UOI5[XBNI1+J<MJT_8H_91O?BSXT^,-SX9\,^#?A'I?\
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M&WA:P^#WCKQ#\2/A/XP\*^(].:;2OB%\.?%GBKQ)XLURX\+^+WAN]2M=-O\
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M]KRZ.+M]Z/OK0R3HFCD]3I>GD_7[)#FBC0_^0+H__8+T_P#])(:*] _6Z/\
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M::T[[!\7+_X>:M+-XID\8W^M>'?@M\(? 'BG4=>N(;^"\O\ 5/%?@3P9X?\
M$NM?;!JEY<W5MJFLS6UW=-'/=12S11RK\LT4U2C%IIRTMN^VU]/ZOZ62Q%?E
MG!UJDH5%9PD[Q2TLHJVB5E9)B*"J@$YP .YX'09(!) P"<<D9'%+116AD%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M -(SQCC!_/C!]N_3-?H5_P $X_\ @HC\6?\ @G?\;K'Q_P"#Y+CQ%\-?$<UI
MIGQ=^&-Q=RQ:3XP\/+.K"\M%\PP:;XMT<-+<Z!X@:"<VSM<:=<PSZ;J=]$WY
M[TUO0$ G&#G!YR#TYQT]N_;C*O1H8FC/#XE0EAZJ=.4*D>>G&51J,:G*M5.,
MW&<9)VC)*332:>^&Q%;"5J=:A-PE"5[?9=]'S)6;T;6]M=4S_6I_9W_:%^%/
M[4'P@\&_&7X->)+?Q1X'\;Z;'J.FWD1C%UI\\>(]1T36[99'?3=<T>ZW6>IV
M$N7AF4,C2V\L4TGM1&,=.>>*_P W3_@D#_P5&\4?\$]_C+'HOC"\U36_V9?B
M1JEM;?$KPC'+/<MX8U"95MH/B9X7L6=XHM8TF%8+;7;. HWB#1(7C+F]@M"G
M^C-X)\6>'O'OA?0?&GA/6=-\1^$_%>C6'B#PUXBTBZCO=)US1M5M$O=-U+3+
MR(F*ZMKRUD6>&2,XVY0J&1Q7XIGV0U<EQ2IN:J8:I-QHU%%J,8IZ<T[**O>U
MG:ST5U9GZGD^:T\UH)I)5Z?NU8Z)-J*]Y)O9W=K:*S5[HZ2BEP?0_D:,'T/Y
M&O L^S^YGK"44N#Z'\C1@^A_(TK/L_Z_X=?> E%+@^A_(T8/H?R-%GV?]?\
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MYT?]X?FO^-=!XU2I4J3E.<DT[<JMJN[;ZWTZ+;H2T5%YT?\ >'YK_C1YT?\
M>'YK_C022T5%YT?]X?FO^-'G1_WA^:_XT 2T5%YT?]X?FO\ C1YT?]X?FO\
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MUT>TO=5D@CMS/;Z9IVJ065DBPQHBQVT4:A1@Y!Q7D_\ Q#A_\$I?^B,^./\
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M*?\ B'#_ ."4O_1&?''_ (>/XC?_ "\H_P"(</\ X)2_]$9\<?\ AX_B-_\
M+ROW6HI>VJ_\_)_>_P"NB^X/[+R[_H"PO_@F'^7E^?=GX4_\0X?_  2E_P"B
M,^./_#Q_$;_Y>4?\0X?_  2E_P"B,^./_#Q_$;_Y>5^ZU%'MJO\ S\G][_KH
MON#^R\N_Z L+_P""8?Y>7Y]V?A3_ ,0X?_!*7_HC/CC_ ,/'\1O_ )>4?\0X
M?_!*7_HC/CC_ ,/'\1O_ )>5^ZU%'MJO_/R?WO\ KHON#^R\N_Z L+_X)A_E
MY?GW9^%/_$.'_P $I?\ HC/CC_P\?Q&_^7E'_$.'_P $I?\ HC/CC_P\?Q&_
M^7E?NM11[:K_ ,_)_>_ZZ+[@_LO+O^@+"_\ @F'^7E^?=GX4_P#$.'_P2E'7
MX,^.!_W6/XB__+RHS_P;C_\ !*3)4?!GQQN_[+'\1L?G_;GI7[KOT'U_H:BI
M^VJ_\_)_^!/R_P OR[!_9>7?] 6%_P#!,/\ +R_/NS\+/^(<;_@E/_T1CQO_
M .'C^(W_ ,O:/^(<;_@E/_T1CQO_ .'C^(W_ ,O:_=.BE[:K_P _)_>_ZZ+[
M@_LO+O\ H"PO_@F'^7E^?=GX6?\ $.-_P2G_ .B,>-__  \?Q&_^7M'_ !#C
M?\$I_P#HC'C?_P /'\1O_E[7[IT5$Z]96M4FOF^EO\D']EY=_P! 6%_\$P_R
M\OS[L_"L_P#!N/\ \$IAU^#/C?\ \/'\1O\ Y>4G_$.3_P $I?\ HC/C?_P\
M7Q'_ /EY7[JTQESDY[9QCT'UJ/K-?_G[/[_3_)?</^S,N_Z <+\Z,/\ +^KG
MX5/_ ,&Y?_!*=<;?@MXX?.<X^,?Q&&/SUSO3/^(<W_@E3V^"GCH?3XR?$7_Y
M>5^Z=-=MB[L9Y QG'7\#1]9K_P#/V?W_ -=E]P?V9EV_U+"_^":?_P B?A:?
M^#<W_@E3@G_A2OCG.#\Q^,GQ%X]#_P ASM4/_$.C_P $J^_P7\;M]?C'\1>/
MRUX5^Z)FR"-O4$?>]1CTJ"G]9K]:L_O_ . )Y7E_3!89?]P:;[=X^7X^M_PR
M/_!NE_P2LY"_!KQN<=A\8OB-Q_Y7.U/7_@W1_P""51&6^#/CG/I_PN/XB@$>
MA_XG>>>]?N52>;MRNW/OG'4#MBL/K6)_Y_U/_ F/^S<N2UP6&LM-:-/R6ON^
M2/PX_P"(<_\ X)5M]SX,>-4QUS\9OB,,^G76SFHV_P"#='_@E:,_\69\;\'&
M?^%R?$4CTXQK8K]R/,]OU_\ K4A?((QU]_\ ZU)XK$VLJ]3;2TFO3K^HEE^6
M:?[%A5KJ_80\NG);IV[;V/PU_P"(=3_@E;_T1KQO_P"'C^(W_P O*3_B'4_X
M)7?]$9\;?^'D^(W_ ,NJ_<BH_,]OU_\ K5G]:QG_ #_J_P#@?_!+6798UI@\
M,VK?\P]-=N\/+_A^OX:M_P &['_!*\$C_A3'C7@_]%E^(O\ 77!_*D_XAV?^
M"5__ $1CQK_X>7XB_P#R]K]P7.68^YIM3]<Q7_015_\  V3_ &9E_P#T!8;_
M ,$T_+^[Y?U96_#]O^#=K_@E>!_R1GQIU[_&7XC?TURH#_P;N_\ !++)Q\&?
M&F/^RQ_$?_Y=U^XS#<,9QSFHRF 3GI[?_7K"IC,?S-QQ%;ETM:?DK]>X?V9E
M_P#T!8;_ ,$T^ENT?)?<?AY_Q#N_\$L>_P %_&9^OQB^(_\ \O*/^(=W_@EG
M_P!$9\:?^'C^(_\ \NZ_<"BL?[0QO_056_\  V']F9<O^8+#?^"8=+>7D?A_
M_P 0[O\ P2R[_!CQH?8_&/XC_P#R[IZ?\&[?_!+$Y_XLOXS'T^,?Q''_ +G/
M\_C7[>T]6VC&,\YZ_P#UJ/[0QO\ T%5O_ V"RS+D[_4L+I_TYATMY>1^()_X
M-VO^"66./@QXUS[?&/XC_P!=<IO_ !#M?\$L_P#HC/C7_P /%\1?_E[7[@^9
M[?K_ /6H\SV_7_ZU9RQ^8-NV*KV\JC\C2.6Y;;7!86__ %XAY?W?)?<?A]_Q
M#M?\$L_^B,^-?_#Q?$7_ .7M)_Q#N?\ !++_ *(UXT_\/'\1?_E[7[A>9[?K
M_P#6H*9R<]3GI4/'YDML57??][VM^>OW^@_[-RO_ * L+_X(AY?W?)'X>_\
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M^2/Q#_XAW?\ @EG_ -$9\:?^'C^(_P#\NZ/^(=W_ ()9_P#1&?&G_AX_B/\
M_+NOV_4[AG&.<4M2\TS-;XO$*W>I+R\_ZOZ6I97ENEL#A>EOW,/*WV?)'X=G
M_@W>_P""6H)Q\&?&N.W_ !>+XC?_ "[I/^(=[_@EM_T1GQK_ .'A^(W_ ,NJ
M_<6BI_M7,O\ H-Q'_@R7^?E_5V']EY;_ - .%_\ !-/R_N^2/PZ_XAWO^"6W
M_1&?&O\ X>'XC?\ RZH_XAWO^"6W_1&?&O\ X>'XC?\ RZK]Q:*7]JYE_P!!
MN)_\&R_S\OS[L/[+RW_H!PO_ ()I^7]WR1^'7_$.]_P2V_Z(SXU_\/#\1O\
MY=5G7_\ P;G_ /!+J[B=+?X7_$;3&;($MC\7?&N],@Y*"]O+^('H<O$<$#D#
M(/[K44?VKF/_ $&XG_P;+_/R_/J']E9;_P! .%_\$P\O+R1_.9XF_P"#8O\
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M*=UK=-:/Y_>1T4H&2!ZU($P0<]#GI_\ 7I1I.VL>O=;:>?\ 6OF+FB^OX/\
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MS:D G>./8_XUT62V5C&46WHM+>2[E,J&Z]J@,8R?E)Y/K5R2/8 <YS[8_J:
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M@ HHHH **** "BBBL);OU?Y@%%%%( HHHH **** "BBB@!K@D<>O^-0]*L5
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M2O?X?2VOJ?,]$[J[WC]J.WQ>NOW!1116@!1110 4444 %%%% !1110 4444
M%?0O[*W[3WQ2_8]^._@+X^_"'56T_P 5^"]2\R>PFDQH_BC0+L+!KGA+7X"K
MQW.DZ_9%K.42(QMYV@O(##=V]O<0_/5(5##!&000?<,"&!]B#@CH?P%8UXQG
M1G"<(SC))2C+9IM*_JOBCVDD5"K*C.-6#M.G)2@^TD]'TV>NY_K%_L>_M9?#
M']M3X ^!?C[\*+^.?0?%>GK%K.C/-')JO@WQ;9QQKX@\&Z]$F'MM7T.\;9(L
ML<7VJQFL=2MT:TO[=Z^GJ_S;/^",7_!3'5/V /C_ !:#XXU+4)OV:_B]J-EI
M'Q3TF/=/'X9U-5-OX>^).D6H;S$O-#FN38^(X+0QMJOA?SE6.;4]/TW9_I!:
M+J^F>(=&TKQ!H>HV.L:+K>GV&KZ1JVF7$=YINIZ7JEM!>:=?V-Y"7AN;2]M9
MXKBUGC=HYX)4FC.QQC\JSG*98'$Q]E>5"L[PT=J/-*2Y&^RMS:;<W;4_5,DS
M>.:X7GEIB**4*T;IWDDGS1U;47?1RMJFNFFC1117D>PEWC^/^7K_ $]/:"BB
MBCV$N\?Q_P O7^GH!13E ) /^>*DV+Z?J?\ &CV$N\?Q_P O7^GH$-%%%'L)
M=X_C_EZ_T] *4=&^G]12454:,E)-M:-/KTL^WK_6P%%%%= !1110 4444 %%
M*%)&0*2@!0,G%.V'U'Z_X4]0, X&<=>].JHQ<W967J)NRO\ UN1)U/T_J*=)
M]QOI3L = !^%! (P>0:V4''1]7T7IMW,6[MOO_D5$C+@D$#G'/X?XT_R#_>'
MY&K 4*, 8'6EK51BTM.BZO\ S(4(V5UKUU96\@_WA^1H\@_WA^1JS13Y(]OQ
M?^8<D>WXO_,8XPH'H0/T-158P#U&:3 ]!^0K6,;V=]G^5B90;;>G]+T(**GP
M/0?D*,#T'Y"NGVB[/^OZ?]/1<C[K\?\ (J,A))!'--*E<9QS5EP >../\:$
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M'YBC(]1^8KS<_$[X>C[WCKP)[8\4:,?K]Z^^E-_X6?\ #K_H>O W_A3Z)_\
M)M3_ *SY!_T.\E_\.V!_^7/^E][Y).VC6V\7?[/IW9Z5D>H_,49'J/S%>:_\
M+/\ AU_T/7@;_P *?1/_ )-H_P"%G_#K_H>O W_A3Z)_\FT?ZSY!_P!#O)?_
M  [8'_Y;_5GY7%"6F_3[+Z\OG_>9Z5D>H_,49'J/S%>:_P#"S_AU_P!#UX&_
M\*?1/_DVG#XG?#T_=\=>!/?/BC1A^BWO\_Z4?ZSY!_T.LF_\.V!_^7?U^8H2
MTNF]MHN_V?7N^AZ1D>H_,49'J/S%>;GXG?#T#YO'7@3'MXHT8G/XWV/6F_\
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M-"]1]1_.IZF4N6VF_P#P"XQNKWZV_(KT4K=3]3_.DIIW2?=7("BBBF 4444
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MCG.:;6\+<J:_K7_AB6HNZZZ7TU^\S6BDR<(V/8>U-\J7^XWY5J459/LUW?\
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M\4?+;7;5?>>G45Y;_P +P^"G_18_A;_X<#PG_P#+2D/QP^"F#CXR?"U3Z_\
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MC_PNGX,_]%B^%_\ X<#PA_\ +2C_ (73\&?^BQ?"_P#\.!X0_P#EI2^K5_\
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M)*=U?>23:=TG=;?D?G#]HI2C57+.#</E'1-/JNSZ^6P4445H(**** "BBB@
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M)>*P:_YC,)M?_>*76S_F\SI\#T'Y"C ]!^0KFO\ A.? Q&1XMT$_[NKZ>?\
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MO/PR/E/F*-,\4X+,/F/_ "+_ #EN221GN*_8<?Q5](W'X^GF$O"[B*C5HXC
M8FG3AX?\8XN$98+-LRSNI2]IFL<QQ,\-C\9FV/AB<)5KSPM'"588/+Z6!H4X
MP4NK2OI5IVMM[6#V2W>E^;1;75[-O8X#Q#\-/V@?VB/&OP?/Q7\$^$OA?X%^
M%7C*R^(6IV^B>+F\5ZSXQ\3:2J)IL.G"#3K&WT?3(Y//=S>.UR!<-&-X SF?
M#CX>_'GX=?$'X^:-+\)]"\2_#SXU_%76_$1\4+\1='TF]TCPUKUI'I=_.N@M
MI][=7<\%E-/.(5N(I7EC$:H V\>H?\-Z_L@N 7^.?AD,"I^72_%/5#E#SX?_
M (>J]<'IT%/_ .&]_P!D'&/^%Z>&P"03_P 2SQ3RPS@X_P"$?QQGKU[UY"Q7
MC;#+*V00\%\YAPW+*UE>%X?I\"<?T\#ELO[<I<1SS+!8FGB5FCS&KF]&CB)U
M\5F&)IRA1IX54EA4J*/:4+M^UI7>MU5C\5N5._6T9-+?XEH^6-O"_!_PR_:Y
M^%?P>U?]FSPQX2^'WB/0Y4\1Z%X7^+MYXOETY=(\->(Y[N>9]4\&3:7-?7>I
M6,&H7>S[/<K"3)& LGEJ3KS?LE^//A)!\!_%GP5N?#GB[Q3\(OAWJGPU\6>&
MO&-Y/I&E?$#P]XCO=0U/57@U-8IFTFY;6-8U.6U%RI5UGCS'(Z/$WKH_;W_9
M!4$#XY^&<8 YTSQ2, 8P!CP_P!@8'08'H*0?M[?L@@Y'QS\,@\X/]F>*>-QR
M<?\ %/\ <X)]2 3S776SOQ^J8FMB*'A!FV"68YAF&:\28?"^&7$U/"\6YAFV
M58O)LQKYW2EAJDJ<:^7X_&TH8;)YY5A,+7Q5;'8/#T,:XUXKVM%[U:>R3_?1
MM)J491=G>S3MJU>UDK7=_.OV7/V?_&'@+XP?%/XE:_\ #3PE\)?"OC3PGX?\
M.Z/\._#GB.W\3165QI]TLVHWUQ=6]G;6DBW:1.\K*BS.9]LN[: >_P#V./@5
MK_P+\/\ Q:L/$.C:9HTOC'XR>+?%6C)IMQ976[PE.EC%X=BFDLVVPJB"\DAL
M&&ZR,DBM@R F<?M[?L@9RWQR\,L?4Z9XJ)^N?^$?Z\4A_;U_9 +;C\=/#1;
M'_(,\4]!G"Y&@9PN3M';/&,UY?$=?Q^XFPW$V!QOAGQ?A\'Q5A.#\%F6'PG
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M<64#M9W$']CSV6H-+"8&:1')&D/V]_V00#CXZ>&LM][_ (EGBGD8QS_Q3_/
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M6_\ !U7_ .3\E]Q"(5!)XY_V5_IS^M+Y0]O^^1_C4M%#IP>\5]W:W^2#WO\
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MP]RO_?M#_P"A!C^N/:I**.2'\L?_  %?Y![W\]3_ ,&U/_DB/8>Y7_OVA_\
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M[&W)P >.Y/3WKG[0<";@H  <,K.""-R,BDO'(N/FBE"2+N4E,,I._9G* ^K
M_K5*$+*\(7MK[D>R\O)'B8RO4BZ,54LZL(UX)->_0J**A4C;3DDU*S6FAOJO
MS*P/=3\P#>G?@XKI+/<Y4;MN%)^4#GYL#.1VP?SKG4_A_P" _P!*Z.P^\/\
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M&".3[CMR 345#YO&2N!U)W+C' RO/S#) SQS4@8' Z,?X<,>O/4#;TYZ_K0
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M)_S._+]W,I*_EW):***!!1110 4444 %%%% !1110 4444 %%%% !113'D"
MEN%56=SR=JJ"Q. ">$61B3M4!,%LL*"X1YY*-[?UHOF.R/4?G2U]>:;_ ,$_
MOVUM6\#Q_$C3?V8?C!=>$9M&E\1V=^/"EW!>ZAX>AMUO)M<T[P_<F'Q%J&EI
M9.ER+^RTF>TEC+-'.RJ7KX^:4 ,0,A<_-D[&VG!V.H96!(.T@\C&<9P"_P#7
MK_7RZA.E6I.U:'(Y>]#6ZE![2O9;ZDM%1"92/<;=P&3MW_<Y .=V&[#[IQFG
MDE0"0 <@$$D8).".A.1Z8'OB@@7('4@?C1D'H0?QK<T3PGXJ\3V7B?4_#OAC
M7]>T[P3H1\4>,K_2-)U'4+3PIX9&HZ?I!\0>(+FTMI8-(T8:GJ=EIYU+4);:
MS%]>65H9A-=Q+73ZW\*_&?AOX>>"/BIJUGI4/@KXAZAXGTOPO=VOBCPOJ6L7
M-[X/NK6RUU=3\*Z?K-UXG\.0V]S=PI9W'B32-(CU5&DFTHWD$4LJG]?E_G_6
M@<E;XG!>SWYKO9V2=K=VD^QY[14>_.0,<'E@RLHP>^#D9Z#CDGCUKV+X&_ [
MQ]^T-XZF^'?PYMM,N/$4/@[QYXY=-6U#^S;0Z#\./!^L^.?$S)<>1,6O(_#^
M@:F]A:[ ;V_2VLA)$UR)$'\OG_7:XX+VE14H:U6N;E=DN6]KWOO=/2QY#17J
MGCSX->./AOX#^"_Q&\3V^FP^&_CUX5\1>,? #V>H+=WD^C>%O&&K^!=7;5;;
MR8_[-NH_$&B7T<%K)(\L]HL=UA%D"UY.');;M(]B1N XY*YSM.>&Z&A.^P--
M:--.R>JMHTFGZ---/JFFM"2BBB@04444 %%%% !115W3-+U+7-4TO1-'LKC4
MM6UK4K#2-+T^T3S+J^U+4[J*RL+*V3<@>YN[N>&VMXRRB2>6.,LH;< :3;22
M<FVDHQ5Y/R2ZOL4J*^J/C#^PW^U[^S_X9N_&GQD_9\^(_@3PEINJQ:'JWB'4
M])2[TO1M8G9DMM.URXTJ[U :'/=R1RQ6G]LK8)=31-# TDI2-_E4,K;<'EC@
M*00V3]U0"!N=L,51<NP5BJM@X"IPG!VJ4JE)]JBY6]MEY?U8=17KFA? GXKZ
MY\13\)G\(7/AKXAKH=YXBE\-^/K_ $CX=3V^DVGA1_' N;FY\>:AX=L[?[?X
M3^SZQHR23JVM1WEG;Z4+NZN[6*;QX2%@&", P)4,&#,H)&Y1M.5.-V<@A2-P
M5LJ"_7^M2;-;KR^ZW^:):*A\WK@ X]&)QS_%A3M)_A!^\<@=,UTEGX3\5ZCX
M7UOQM8>&-?O/"'AK5=%T3Q#XHM=(U";P]H6K>(X]2D\/Z;K&LBW&GZ=J&MII
M&JOI5G=7$<]\FG7LENCI$ID!6N8-%-4Y![$'!&<X(Z@^XIU !5NWZ?\  _Z+
M52K=OT_X'_1:#*M\#]4:D'5OH/YUI0=4^I_F:S8.K?0?SK2@ZI]3_,T'BU_X
MJ]5^4303[_X#_P!FK=@^^?\ =/\ ,5A)]_\  ?\ LU;L'WS_ +I_F*#DJ[1^
M?_I,#1MOOM]5_P#9:V8 /F8[?E!(R1G) Q@'KSC'O]*QK;[[?5?_ &6M$=3_
M +I_]"2FG9W/%KRC&O3E*"J*-93C%NT>>#G.#DK-2C&<8MP>DDK/<]^N-0D^
M$VE:/IWAY8[;Q_KVCV&O>(?$3+$=3\/V.M6ZWNBZ'X<E=2=)O!I4EMJ.MW\;
M#4#-J%G9V<\"VU\DF#H_Q!\<:;=M>V7BCQ)'>ON,DSZ]J%REP7.YQ=PSW4L-
M[&Q.9(KJ.=)$^0H8\I3_ (R9/Q"U/)S_ *%X9 ]%5/"7A]$11GA$3"JO1<$\
MD\<79'!4^B*?TJJ:4H0F[-M<UTK/WE]]UM??2^Y^-9)D>5XK+<#B\?@Z&/Q^
M:8?#XS'XW&X7+\57K/,J=/$SIPGB<'7JT(4(5_84%2K)4U352G&$I-+V77+;
M3_$OARU^(.EZ99:7J4&JP>'?&.E:5$8-)?4;JVNKO1M?TZTB"QV%IK26ES;7
M]C D5M;ZC;RW5C'!:WB6L'*6Q5LLF=A?*9QG:6)7..,XQG''I75^%'*?"_X@
M]2K:KX!E*[L &.37XQC@C<1+P_4 $8.<CE;8;=RCHLA'IT8CIVJXR<G)-WY9
M<J]%&+M\KM>>YX&04WAZ6:8*-:=7#X#.WA\-&K>4Z-*ME659BJ2J2;;A3>/=
M.,5:-H*5E*4DMI&._;V"*P^HQ_//^&*Z>P^\/]P_^AM7++_K?^V8_P#9:ZFP
M^\/]P_\ H;5J_M>LOSB+%?QJW^/\YQ-^V!W$X.,8SCC//&>F:Z:RZ#_=3_T%
MJY^V_P!4/^NG_LK5U>BV%[J=W8Z=IMM)>:CJ-U::?86<(!FNKV[D2WM;>+)
M,D\\T<2 D#<PR>>!/23[<K_\!_X"/*JQ<ZBC&,I2E9*,5>4G)Q=HK2[;=DNK
ML;-B"KIN!7D]01UZ=:WK4'<_'\1_F_\ B/S%?1?C/]A[]K7X8>&-5\8>._@3
MX]T+PQH47VG5]:ETZ*[M=-LC(8X[V_33KB\N;.T.89)II[=%@B=I9#LC+';\
M,?L3?M5>)O!FC?$30/@QXOU3P7XBT2/Q-H^O0QZ6EGJ.AS0"YAU"T:?4XI)K
M>XMV\RW<1JKQ,DCM$&.W.G7YY.Z4=%;7=W_X/X>9QXGA#B>&*6$7#>>.JJ$<
M4J7U*HZ\,.YJ"K5J:3<(<S46U>TG;H?/T;*LB%B%&T<D@#\S70V?(C(Y!D!!
M[$#))![X'/%>CM^SY\9[/X36WQYN?AUKS_!VZF-M;>/$BADT*68ZB^D1_O$G
M:X2-M03[)),]L(HIP\3/E23T'@[X ?&GQ;\-=;^,.@?#7Q#J7PL\,K?MK7C*
MU@MCHVG+I)C;5F<S74%U,NG02-)=O;VTL<;QF+<3EEV4XV6JZ)M--7=K+O>V
MK\O0^9Q7#6>RQT\%+*\R5>K@O[1IX:&5X^KB/J,5&3S"7)2=-X!J'+'$0E*/
M/**ZNWG]F07=006+<+D9/#=!U-=3IZ[25.0QVD@\'.3VZ]!^0S7I'AS]FGX]
M:SJ=II^F?"WQ%?:C?^ X?BG9V%LME+?7?P^N2(X?%%I;F[62ZL9'/EI'"#=,
M\<R?9P$5Y8K;X9?$)/  ^+5SX1U.'X?CQ#)X3C\5RK!%I<WB"-'9M+A$TT=[
M--O1HR\=DT",&$DR-&X6*DE>]U;3JGW^>O3OY['F_P!@YS1C3K8C*LUP]/V&
M*Q3JU\HS&E3IY?@(TYX[$S<Z$7%T(UZ3DVE!>T@FTY1OCV75O>4$>XP>:Z:S
MZM]/Z1US%CV_WO\ &NGL^K?3^D=915H_]O1?W\K/GY_8_P 3_P#;#KM-_P!<
MG^Y_4UVUK_JX_P#KK'_Z"]<3IO\ KD_W/ZFNVM?]7'_UUC_]!>LY[1](?FBZ
M.\_\<ORIG36O4_7^AKI[7K'_ ,!_]"%<Q:]3]?Z&NIL_X/P_K6$_B?R_)'T6
M6O6*\K_=;_,Z2T^[_P "'\ZWK=CYA7MD&L&T^[_P(?SK>MUPY?/3''_U_P#Z
MU2?886_+&W97]+NYT$72'_@?_H(K9M.A^J_S:L.W?=Y8QC;N[YSE?I6Y:=#]
M5_FU-:M+NT?0X7X5\OPA$Z>U^Z?]U/T!S^7>MBP^_:?[J?\ I0M8D+[=W&?W
M?KCJ"/2MNP^_:?[J?^E"T2ARRCKNT_QIGT6$ES.'DMOG _I"\#_\B7X0_P"Q
M7\/_ /IIM**/ _\ R)?A#_L5_#__ *:;2BN&I_$J?XY?^E,_T!P7^YX3_L&H
M?^FH'^73_P %E_\ E*3^VK_V635/_33HM?F4G0_7^@K]-?\ @LO_ ,I2?VU?
M^RR:I_Z:=%K\RDZ'Z_T%>G#X(_X8_DC\PS+_ )&=?_KYB/\ TZQ]%%%4<X44
M44 ?27[.1*V?[284D _LP>/<@$@'/B?P$3D#KDDDY[D^IKYF5U0<YR6DZ#TF
ME4?D  /0 #H!7UE^R?X=U[Q=J'[07ASPSHNK^(]>U;]F?Q_;:7H>@:9>ZQJ^
MI7"^(? 4WD66FZ=;W=[=2"..:21+>WD=8HY)=H2-B/TL_9X_X)!Z;\4O@MX*
M\?>/T^.'@_QCKMOJ\FM^&1X1&F_V3-::_JME!$;36M'34D\ZSMH;D?:(XRXE
M#HI0J3\;/.\IR?,LZ>/Q=&C5GFF44H1UE5?MN'Z:A':_*ZF!Q$VKVNX22<IN
MT9KF*RS+<#B*U'&U:,JN(I2GA:,Z_+*"4GSQ@^?E7/&-U&5GO9)M?F1^Q+*#
M^U?\#-C,#_PFL><9&1_9.J'''49 ./7%?+O5B3R=TO)Y/^L-?T[_  $_X)5?
M"/X8_&[X?^+HO'_Q)?4_"_B$7L6F:I8Z%"D\ZV=W;?9[@Q6RRQ$?:-P"*[EE
M5&158R+^*W[;W[-WA+]F+XD>%O!G@_Q#K7B2PUSP3;^*+J^UR*SAN4N[KQ!K
MVF?9[>.R58%M_(TR"8^9(\X:5EVD@XZ<!CL-B^(LRJ45.:ED7#\X3Y+:2Q7&
M,96;=TVX0NM+J,-U%6\7+N,\FSGZEEV$KXAXG%8O,Z5*->DZ253+,)A,;BHS
M4Y\\&J.)I<GN>]-N+Y4N8^,Z***^I/="BBB@ HHHH **** "M?0- UGQ5K>E
M^'/#^GW.K:UK-Y!I^F:99Q&:[OKRYE2&WM;:(?ZR>61U5(P=S') (5L8S'&[
M)V_*2#VR,9SPQX']U6/7 )XK](OV"?"_[,VK>(_!^M_$;QMXCT3XQ6'Q0TI?
M _AVRBF;1=9@A.CW&F"[EAT:_CB:YOYKJ%WDU2R?:BKY<9SGX[Q!XJ7!'"6=
M<1O+\RS*6"PM>&&H95E>(SBH\=4RW$8S"2Q&%PK5:.!I3IQ^OXM+DP5)5*U3
MW*;8UOKLM7JEIZO;\^R>Q^?_ (K\(>)O GB+4O"GC'0[_P .>(M'D2'4=(U2
MW-M?6DDL23QI/$W*L\,BR*!]Y22. <<_C/'KQ7ZR_P#!1KPI^S3%XH^)/BC1
M?'/B67]H0>(- 75_!DL<O_"/QV\\-E!=O&QT2*)A%I/D7D3+K4["5L%,/MK\
ME49F1B?O<@<>PQQWY[=^E>=X7<;/Q!X+R;B>>5XS)\3CL)A'C<%B\JQ>54XX
MQX#"5L15RZ.,;GCLMJRK<^%S&FW1Q"<XP;=*3%U:::2:6MMFD[JU[K6W1W3T
M1U>C>"/&WB.U-[X>\'^*M?LE<Q&\T/PWK.KVOGJ(R]O]HTZTN81<1>;$)8"X
MEB,L0=5\Q<\W-'+;326]Q%+%/#))%-$\;^;#-&Q22*6,!GB>-PR,L@4AE9>J
MMC][O@+\0;;P#_P2T^!K3?MK?%#]C635?VO/VF+:.]^%GA;QSXDN/'IM? GP
M+9=*U*'P+XF\,S6<>@/.9[=;Y[S=/J]U+;I&R2LWQWJ7[.?PNU/X7?\ !-_X
MA3IKNO>)/VKOV@/CMX3^+OB.ZUK6DD\7:/X4^._A/P;H5YI]A<7<O_".:G>^
M']>OKC49;(K?WE]>"YU&:YN(E>OO%5AK:]M]5MHEO=W_ .'UVOZ57 Q4:;HR
M3<J<:KO+[$O9Q6FK3O-;K75IL_-'<, ]003D8/ SD]>0"I4E<X(.>C$-=@,9
M)')&1\R\!"274E%4;U!9F W';G<,5^YGC_\ 9K_8@_9V\(_MR?$KXC?!KX@_
M%6/X'_\ !023]EWX0^"M,^-&O> M/D\)77A+Q7KT9\:^)(;'7=8O!IMMX2O+
MF"]TZS&J7VJ"UM)IX]'74+>2/Q_^Q5^RG\"O'O[:WQ;\5^$_B%\4?@+^S_X/
M_9B\4?"[X-0^.-1\)^(-9U3]K+3]*U7POI/CGXEZ+IUQKMKH/P\L[O6([B[T
M6RAU3Q%>P:+;M-;Q7MU'3=6*]?\ +?\ )V[]NY_959QBYSHPA.[;YY.44DY7
MM&#?V9;)M;-IV:_#A%+ N&.Q=NYF(5%WF39O9F"HLGDR&-G(64*?+9CQ72:]
MX1\6^%K#PWJGB?PKXE\.:9XRT8>(_"&HZ]H6J:/8^*O#QNIK(:]X:O-1M;:V
MU[1C>6US:#4]*EN[(W5K<VXG,L$J+^R_P<\=_LGM^PY_P4K\0>#?V5KJ\\)6
M7B3]C"^M="^(7QB\6:AXBL&\4^*]?M6T&Q\4^&AH\YT?PGXBL=4U/PYK-O:6
M&L^*],U2UL/&4%U'98%3P?\ LH?"+QZ/V9/$7Q+U#XI:U\-?!7_!-/XJ_MC?
M$GPAI_CC6=0U3Q#_ ,*K^(/Q'L#\//AY?Z[+JUM\-/#7B!M+TJ6[CT:S-KI4
M#ZSJ=I9R7UPR4>VCI^>W6VS_ !U^^Q"RWW8NA6IU(SCS7;G&UI*#?OPC*VG2
M/5=-3\4 P*E@&(4!FPK$JIZ,5 +!3V;&#D#J0";@>!D\L ?X6*'#%7.$8 C[
MP8KCG-?M)\-_V9/V1_VF+3]B[XQ?#WX6^-/@YX/^*'_!0#X>_L;?&?X47?Q4
MU[X@:7K&D>+XM \3Q^,O!?CK4[&R\3Z)=3>';S4]$UVTFFNXK/5/L=_I-S$1
M' >.^*WP+_9)^(/P,^-GBK]F_P""OQ9\#^./V=_VJ/A7\#DM->^+%Y\0K_XY
M>%OB5/\ $/0[:6\T:7PW#8>$/&$>O>"H9-*7PK;W.D/#J=M;LUY)'+>S'MH^
M:_X9;6OWUO8N65XB*3YJ+3VM-ZJR>SBNEWUVM8_(S))X#C)"C*, Y.<>7D+Y
MF3A<Q[AN9%)!89[#Q]X \:_"SQ;J?@/XC>&=6\'>,M%%A_:_AO7K1K'5M-.J
M:?8:KIZWEK(2\+W6GZE9742/AVBF! ^5@/V-_:*_8E^#GA_]EG]I+XD67PQ\
M$? ;XQ_LV^/?@_IUYX \&?M<Q_M(^)VT3XA^(+OPKJ_AKXO:! 7M/!/C+P_J
M\=G=17.G)I-M-?6^K:!?Z!:&))1\Q_\ !5RQGU3_ (*(_''3=/B%Q=:E?_"^
MPLK>,*!<SWGPL\ 6]K;18VA!/)*D<10+_K%+87E8E4BTUK=K?;73[MOEIO<=
M7+U2P_/.4?:R<8Q:D^6\N9=4K.\+:K>^FFOS5_PR#^U"/A4WQR_X4#\5/^%2
MIX<3QDWCK_A$-5_L5?!TEP+6/Q@3Y/VM?"4DY"1^)VM1H;YW+?E02OSFKJ^=
MN>, Y!'WE5QUZ_*RG(X[=0:_KH\2^ Y/$UCJWP:_9VDTSXC_ /!1[PE^SY\%
M?^">?[7UA9:AJL7ACX9_!G5?#VD?#SQ?\2_@U\.[Y;1/B-<^%]!ETWP=\7-?
MCO;73/"=QI-SXPTKPX+/6Y/$3?S3M\#_  S'^UU!^S=HWCB7Q?X2_P"&A;3X
M*P?$/1=)2%]:T-OB1#X$E\7:1I"7VK*5N;8W&L:?:QW5_!+A8?MCJQ\I4ZB@
MFI.3U];6T[[]7:^G5O0K&98L-]75*2DZJC&;E+3VDK6M[ND;;O6SOZOYOW#<
M% 8L02%"L6( +$A0"3P.P.>@I X8X 8G<J@;&));'0 <X)"L.J-\K -Q7]!_
M[0_["_[-/A#POKOPRTOX"I\#_C+XN_;6\ ?LO_ 'QMXO_:/UOXA:A\0_A5K,
MFJ67B?X[)X*L+^/2/+TW4=/T.*]:/1X_"XF\8#2M.BCOM#N8SY5^UE^R1^Q-
M\-/"/[3_ (6\,>(_A=X&^)7P"UNUTOX0ZKI_[6>D?&#XA_':Z\/^-;/P;XR\
M-?$3X/0V4=GX"U^ZTJ?4O&EDOAN&TMO#,NDS>&-1BU*_C:[.GMH^?X^7E_6G
M<F658B*<G.C96UYVFVU>UG'=*[\^E^GXC*P?[H9OE5SA6.U7!(9\ [!\K#Y]
MOS K]X$! X+!%5W9G$:K&C2%Y&(58U"!LN[$!5ZL2 .37[[?&/\ 9&_85L?B
M?^U3^RW\/?A3\5/#/Q*^#?[)^M_M(^'OC/K'Q;U/Q#8)XK\)_"?PO\5-<\$K
M\.[C2TL+KP=J5A?7VF6>M7VL7GB*WOYS<>8-/MK:RC31OV$?V./A[X0_9Z\)
M_'OQ=\)]#UGXZ?LV^$OC;XT^.GB?]KC1?AYXR^$^K_%?PEJ'BKP%8^%?V?7M
M6MO&OA/PY-!IFDZW)K']HWGC6YN-3GT.^T5+>%2>VCY^>C_KOI;6W0%E6(=_
M?H:<UW[39QLFOAZ-[WMJC\$X+>XN9HK:V@FN;BXDCBMK>WB>>XN99MGD16\$
M2M-+)<-)$D"*A::26.- TCJIU/%'AKQ+X(U_5/"GC/PUXB\)>*=$NFL=:\->
M)="U70]?TB]6,3-::GH^IVEMJ%E<K"T<S0W%O'(L4L,A4)-&S?KQ\=-:^#4_
M[ /_  3?T;2_@9X=TKQ!XD\9?M'>';/XE:1\1/'9UC2KKPO\=/ VD>(O%%A9
MG45T[6)?&G[[4H['5%N;7P8;D:9X=CM8+=9'[KXX_LZ_LS_!?Q9^WW^T#\8O
M!/Q,_:"\,?";]LS1?V6?AK\.=2^,WB[PUJE]J&N^$_%_C&^\=_$'XKQ6?B/Q
MQKUQI6E>"&TK2[)YA)J=Q>K+?7+6MA#9%>VCV>U_P3[>M_3JK LLJRNHU*3:
MY+OF:2YU?;E;=E?M?30_#($$ CD$ CZ'FEKL?B'<^!+OQSXINOA?I'B70/AY
M=ZS>W7@W0_%^IV.N>)M'\/3LLVG:?K>M:9;6=AJ=[:PR+$=2@M+5+] ES]G@
M:41CCJV332:V:NO1GFRCRRE%M-QDXNVVCM=:+1]/R"BBB@04444 %%%% !11
M10 5]/\ [-7Q#^!7P]UG7Y/CE\*;CXE6VJ66F0>&H8Y!!_9=ZE[>M/?,TDL;
M!9HI((D"B8%HU.5"+M^8*<SL[([,=T841GCY-A8H4.,JRLQ964A@V"#7C<0Y
M!@N*,EQF0YCB,PPF#QWLW4Q649GC\GS6A4I\_LIX7,,NJTJ]*G><EBJ49QE7
MI6I1G!.3;3LGW=K:1:TDGM)/M\^NA^[_ /P43^)'[/NB3GPMXP^#UUXD^)'B
M'X56<W@SQPERB1>&+2\NM1AT>VDC^TQYDTN6WN9&9%F+I<(00!@_@WQ\Y!.2
M.[%F &=N223ZXYQZ=\];XK\<^,?'5Y;ZAXR\3:UXGO;2UCL;6ZUO4+G4IK:R
MADGEBM(7NI)#'!&UQ((XQPB[57 45RI ))P!D ' QG&>OY_X8KX/P>\,H>%7
M!^!X=6;9AFF*E2ISS&I5S7,\9@(XJC"G3Y,!@\SG667X.KRSK?5,#*E0IUE"
M7))\TF)][7Y6M%%7=I)7Y8J_35J[ZO1,_6_]A;4OA-I?[ __  4@N/C;H_Q$
MUOP/_P )C^Q-#/8_"SQ!H7A;Q;/J4_B[XUMI,D>L^(M'U[2X;*W9 ;R%M-N)
MIHHQ&GE.?,7$\%V/P;TK]C_XZ?'SX8_#73;Z^\$_M\?LK>'_ (9ZE\;- \'?
M$WQGIG@C6?A5\:=7\0^$/%3W&BCPSKFB:WKOA_3-4U72CHT>A7ZV&F->6DLV
MEH8?S5TOQ[XQT'PCXJ\ :/XGUG3/!GCR]\/:AXQ\+V>H7%OHOBB]\)3W]QX8
MN=8TR)UM;^?0;G5-1FTV66%I+:6\N)%8NY-,M_'/B^T\$ZS\-K;Q+K,'@#Q!
MXCT?Q=KG@Y+ZY7PYJOBKP_I^J:3H>OZAI0;[)<ZKI.F:SK.GV%W-&TMM:ZE?
M1QD>:Q'Z?4C-R3CM96L[:WZ_?]WS/3I8U4J6'@J;DH4HPJ24$_?YFFT]+JW*
M]6NJ2T/TL_X+1>*_$OB+_@H3^T3INN>#_"/AC3?#/Q,UNPT#4?#?PV\.^"M4
M\3Z9/IF@7T.H^)_$.C:9977Q!U,VS6?EZ[KESJ=TL%^!;WL%G)'&WZ->'HO#
M7[3VK_\ !*7X4?%/X7_";Q#X1E_8-^+_ ,9[;P+X7^&'A#PCKWQ!\:?"+7/V
ME]<\&_"[2_$_AO2-'\3:=X4\7:SX2TZ[UWP1H%U:P^*KR37[W[-/JVI3W]?S
MT_%+X[?&?XW#PK_PN#XI>.?B8/!.EC0_"3>-O$>I>(I-"TD1VL9T_3[C4Y[B
M=('6SM3)OEDDD,499R%4#,'Q?^*D5]\.=03XB^,;?5?@YID.C?"K4(/$&H6V
MH_#G2;?6+WQ#!IWA"YAFCGT.UAUW5=2U>-+-HRE]J-U,&!FP(5*=^GEK>WO)
M_H73S"G2K8FI&,G&M4347%+W$TU!K56M=+TO;H?LEX.T?P!^TS\"_A9\8?BQ
M^RQ\&?@5X\\+_P#!03]G#X.>%V^&OPOC^%?A/XR_#[XF7M[??$GX?^(?!(D6
MQ\4W/PXMM(TF:^U]X'U**R\11Z;K\J*9S+\1_P#!2/QEX-O/VH?BQ\)OAW\$
M/@[\$O /P)^+OQ9\ ^$--^&7A)="UW6]'T_Q;>:2+WQUX@N+N[U3Q?=BX\.R
MZAI4UTT=OX?CUB]T338+;2H=.A'@'Q(_:E_:2^+VL>#_ !)\4OCC\4/'FM?#
M[48];\"ZIXJ\8:SJTWA+5XKN"_&KZ!]KN7@T[47OK*UNI[V",3W#V<$<[R6\
M0AKQSQ-XCUWQIXBUKQ9XJUF^UWQ/XGUF^U_Q!K^K7,M[J6M:SK%XUSJ6IZE=
M2N9+R^OKJ[EN+B[G9YY)9'=Y#DT>SJ6W2[N[N_N]?5VUZ(RQ.,CB%3ITZ<8K
MFAS2Y(Q<E&2D](K2]K6NTTM==_Z0?@_\,?ACJ'Q2_P"";O[.>H_L/?!WQ#\*
M?VLOV7/AQJ_QQ^,^H_#?5#X[N9M5L/%EGXM^)'A?XE_:(]-\$ZA\,[#2M.\1
MZW?:!%9W.HS>=-XMN[A;NV,'R?9?LX^ O$OP=_X)/7'P_P#A1I7CC5?B'^TU
M\;_ ?Q7UO0?"#:[J'CS2_#_Q\\%V6BZ3X\NM-MK@ZG!:>!KFZ:VL;R2:WMM&
MNY[B%%TYIY*^6/B__P %#?C5XL^'OPA^$OPL^(GQ<^%_PX\%_LX^!?@EX\\$
M:7XXU;2_#7C/4?#EMJUOK^L_8-$NX(HK+Q%I>IZ797J2M;7US9VD<-Q*T!6.
MOG;X8_M4?M(_!7PMJ/@KX2_'?XI_#?P?J^JG7-1\.>#/&^N>'='NM96&&&;5
M/L>EWEK#!J$T%K#'>75J()KJ*"-+IY$C50>SJ-=/F[/ITZ-6W>Z=^IVU,9@H
M3DIX?VE[.,N6,7%>Y916_*W!MNZ?O.R>S_7GXH6OP9_9S^!7[=/Q'\/?LR_
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MLZ/XU\0>/O#OA+P;9Z!XGT/3O$EV-%\/77V_4="$QT*/4-,\*WMKK6H(TO\
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M@ HHHH **** "OHC]D/_ (5P?VJ_V<5^+XTUOA8?C7\-?^%@+K)@_L=O"_\
MPEVDC5/[8^U?Z,FDBV\T:F]P?);3VNX)08II ?G>D.T@JRAU8?,C+N4C< "P
MQ\P^8Q['S&PE8%"VPK,TW%I;Z6^]%0=ITY6;4:E.325[J,XMZ==$?T!'X!^)
MOCI_P4J^/_PT_:E\3?M<_#[]H/Q/\5/BKJGPR^(WPZ73X_!&F^!O#OA/Q'XN
M\,S-K.I;=0MO"UWX?T/0-,\)3>";V/18O#FIV5O'(1/Y34_@9X0_9+^!O[*W
M[#OQ"^)OA_X;ZWI_[0]]\2O$'QKE\9_LK>)?V@_$?C#3?#GQ"U+P*?AK\/\
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M/WNLW M$N+^59&?'_P"$WP_\,_LU_M<ZSK/A']F77_CG^QS\:/@*MK>_!O\
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M@P<* V2ZDW+C=E>@+-D '^%20"$7@*GRA0Y7>VZ5I'<!!Q@@Y!(P>H!*DCU
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MY\8=:^"GQ(\5:Y\$? OPV^(OQRM_!_@[PE\7/B;9^#M<^,EMX3\2Z0?'>B^
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M9KJ_N_@.L7[,;_LB2_L/6/P2TGQ[<Z;XOT_X&033:YIU[%\3&\/WMM)\0/\
MA-;N\\3WNK7'@^YT:X^U75A'I-O'*)$=/_P4:\ >%?B%^PGXA^#/[.]YX(\#
M_L177Q 73/!GB/XGWOB_4OB#I?Q"\2'6M:EUCQ2/#NEO8>([Z"[U%+R^M-*&
MF0ZA);7=AID5K;_89#FJK92Z7]QZZJ_3M>U^VNNIC3GET9?6(0Y5&=*,*3E.
M4FWB*4:DN6;NX>Q<W:2:2]ZR:3/SX\:>$_AW+\5QX2^%/BOQ'XE\#ZCXAT#1
M-%\3>+_!ECX*UEWU2>VM-0EN/"EAXM\:V=O%I&H2W%I83IXEO3JT%HFHW26\
METUNGZH^*_\ @E'\'?"NN_M'>$)OV]/ O_"5?LBBS\2?M +<?!WXB6N@:'\/
MK[5[?0_-\%ZQIESJ$GCGXEV=UJOAO2-0\$P:+I.@KKFMII8\;W$-M<7Z_EYX
M_P#&7PSN?C"/&_PA\#>*/!'P_M==T+7=(\%^+_&MOX[\26;Z6]M=ZG;W?B^W
M\,^%K2\;4]4AO)M.== B72M-N;.UD^TW%O-._P!:^/OV\K3QOX\_X*#>-U^&
MESIK_MT>'K+08K(>)TED^'+6'Q$\%>/$N[JY71T7Q#'(OA3^SA#;Q:>ZM=2.
M6,8)D%*KVE_X"_T2O=]]EWU,,.\$EB'B*?/*>*J0H6J32A2YVXOW7K%Z6<KJ
MS6KUMT>J?\$Y=-?Q_I&F>!_CCIGC+X6^-OV+?B;^V=\,OB,O@:[T/4O$7A;X
M8Z7XH;6?!?B+P?<>(+N3POX@B\4^#];\,W4MOKVLV$+0+=(D\9,->@_L#?LQ
M0>'OBI_P3)_:1U+7M.US2OCI^V3JOPQG\ W>AJ]II"_#/5?!S7-_=3W5W=:=
MJUMKB>*9D%F^D6SV;0^8T\[,AB\P^&G_  4$T[P'JW[,@U7X0?\ "5^$?@M^
MRS\7OV4/B%X<E\7OI=W\1O 7QD\8?$CQ)XBO_#^LVVB&3P5K-G8_$1M/TZ:>
M#7HEN=*EGD@:VOWM1Z%;?\%'/A)X*E_8CT/X0?LUZ[X+\ ?L8?'[QG\;;#2=
M<^+7_"9>*/B*WBX>$KB>VU[Q'<>"]%L;37$OO#UWF^L-!M-*%A)I-M;Z3;75
MG<WUTU*III+I]A[>[?IZ_P!6.VC]0I3CBJ;IQY&E*G*HY2;;A+FC"4G=6<EI
MHK=7J9OQ#^!O[)]M_P $_C\>;GQ/\0-,^.^J?M>?&OX=M<Z?\.4OM"U>?0/
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M.7\NN+%<L&7(>0X(&Y2Q)V[6ZDMW.<8[8Y/KGB/5+&ZM[+1M%MYK70M+:66
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M/^TIGDBAWS17,>G3W=JI5_(/C%^U=X.^.'[1NB?&CQ7\)AJ7ABQ\&6/@[4O
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M?K_[? ^BP=O<[VU^^)_2%X'_ .1+\(?]BOX?_P#33:44>!_^1+\(?]BOX?\
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MPF!I5<1C897.CF//CH8:A3JU:E.G7S"-*I&,;0A2=>4TFX0_1_X(:MYOQ?\
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M:Z9] ^+Z^'U\*)X<234[=-7OHTTNY6_LE^Q1V!\M3-,H9VJ?#K]IW]D'Q?\
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M#>(O"?BSPEK7B?P;+/97^FS?;M"U:RUN"XLM4M9+>ZLI+=PM?GC12]A_?_\
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M]HC]C'X%_#_XA_#7PA\3?BKX4U>7XW>&?&UE^T)8_LO_  D\7_$CXE?![3_
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M*WETUNVU  H"DE1G:3S\N3M[G^''<TZBBMDK)+LDON. ****8!1110 4444
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M>2^X7+'^5?<A  "",C;C')X 5% '/W0(H\+]W*@XSS2X Z */[B@*G4-_JU
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MP#Z]S]3S_G%?='_#L7_@HI_T93^TE_X:?Q9_\KZ7_AV)_P %%?\ HRC]I/\
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MJF+_ .@;$?\ @FI_\B?#%%?<_P#P[$_X**_]&4?M)_\ AIO%G_ROH_X=B?\
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MB/\ T97^TC_X:?Q9_P#*^C_AV3_P41_Z,K_:1_\ #3^+/_E?1SP_FC_X$O\
M,/JN)_Z!Z_\ X)J?_(GPY17W'_P[)_X*(_\ 1E?[2/\ X:?Q9_\ *^C_ (=D
M_P#!1'_HRO\ :1_\-/XL_P#E?1SP_FC_ .!+_,/JN)_Z!Z__ ()J?_(GPY17
MW'_P[)_X*(_]&5_M(_\ AI_%G_ROH_X=D_\ !1'_ *,K_:1_\-/XL_\ E?1S
MP_FC_P"!+_,/JN)_Z!Z__@FI_P#(GPY17W'_ ,.R?^"B/_1E?[2/_AI_%G_R
MOI?^'9'_  42_P"C*OVDO_#3^+?_ )7T<\/YH_\ @2_S#ZKB?^@>O_X)J?\
MR)\-T5]R?\.R/^"B7_1E7[27_AI_%O\ \KZ/^'9'_!1+_HRK]I+_ ,-/XM_^
M5]'/#^:/_@2_S#ZKB?\ H'K_ /@FI_\ (GPW17W)_P .R/\ @HE_T95^TE_X
M:?Q;_P#*^D_X=D_\%$?^C*_VD?\ PT_BS_Y7T<\/YX_^!+_,/JN)_P"@>O\
M^":G_P B?#E%?<G_  [(_P""B7_1E7[27_AI_%G_ ,KZ0_\ !,C_ (*(CK^Q
M5^TD/K\)_%G_ ,KZ.>'\\?\ P)?YA]5Q/_0/7_\ !-3_ .1/ARBON/\ X=D_
M\%$?^C*_VD?_  T_BS_Y7T?\.R?^"B/_ $97^TC_ .&G\6?_ "OH]I#^>'_@
M2_S\U]X?5<3_ - ]?_P34_\ D3X<HK[C_P"'9/\ P41_Z,K_ &D?_#3^+/\
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MU?3[H_'^9K[0A_X)E_\ !1$$_P#&%W[2 X[?"?Q7Z_[5C_*M&/\ X)F_\%#
M%W?L7?M'GCD?\*J\5 _I8_UI^UI?\_*?_@<?+S\U_5CR,1E^.E.ZP>*>VV'K
M=HK^3N?%5K]YOP_DU= GWA^/\C7V%;_\$T?^"@RL=_[%W[2"_3X5>*]OMDFR
MZ\G/M]:V(O\ @FS_ ,% 2_S_ +&/[2"@=S\*_$XSR!U^Q>GKVH]I3_Y^0_\
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M_:K3609VY<Z<;97CGHZD&VDJ&JM?HSY;MO\ 5#_KI_[*U=!9\*#V(4?CM_\
MLA^M?4%O_P $_?VW0"K?LK?'%5W$@-\/M:'0D9R4SR/<]2>N*Z"V_8"_;7
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M (NC:?\ 8_[X/_Q=/HH 9M/^Q_WP?_BZ-I_V/^^#_P#%T^B@!FT_['_?!_\
MBZ-I_P!C_O@__%T^B@!FT_['_?!_^+HV>NW\ 1^FZGT4 U?<9L'M^1_^*I""
M 3\G'^P?Y[JDHH%9+;1]R#<?1/\ OD__ !5*HR<$+TST;_XJI<#T'Y"EP!T
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M 'PW_P <IN!Z#\A2TOZ^X!=SGJ4_!#_5C_*C<XZ%/Q0_T8?RI** %WR>J?\
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M^_\ F6_.3W_*E$J$X&?RJG3E^\/Q_D:7(N[_  _R!3;:6FK7?_,M[QZ']/\
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M*M=>>GIH!#L;T_44A!!P:GJ%_O'\/Y"JV,I125U??_,;11100%%%% !1110
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M;WOAOX)>"YMEQ]LUQ8E&H^+]5ME<S#PSX+M;H:KJ#",C4+]-.T./<^HLT/\
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M]&IIM*V__ _X/]/2[14&3ZG\S1D^I_,T>S?=?U_3_IZ66 <$'T.:?YGM^O\
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M_P"BUC_X:\R\O^H'S_/L@_L'-?\ H$?_ (''_P"3\_S[,^@][_\ /(_]]?\
MUJ-[_P#/(_\ ?7_UJ^>O^%X/_P! /_R:3_Y'H_X7@_\ T __ ":3_P"1Z/\
MB9CP9_Z+2/\ X:\Q\O\ J"_J[[:']@YK_P! C_\  X__ "?G^?9GT+O?_GD?
M^^O_ *U&]_\ GD?^^O\ ZU?/7_"\'_Z ?_DTG_R/1_PO!_\ H!_^32?_ "/1
M_P 3,>#/_1:1_P##7F/E_P!07]7?;0_L'-?^@1_^!Q_^3\_S[,^@R6/6)O\
MOK_[&@%@<^6W_?0_^)KY\_X7@_\ T __ ":3_P"1Z/\ A>#_ /0#_P#)I/\
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M-JNFPQQ3/;R/+>VT:K<1L%> L\BCST9@'ASYB$_,HK\@_P!C*XUJQ_X*=_\
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M_AZ+3_YW='_$6AX9_P"C*-9_\/1:?_.[K^TO8U?Y>W3OR^?G_5M?BO[3R_\
MZ"Z/WR_^1_JS\K_V'[U]?T/^%&]?7]#_ (5_'A_Q%H>&?^C*-9_\/1:?_.[H
M_P"(M#PS_P!&4:S_ .'HM/\ YW='L:O\O;IWY?/S_JVI_:>7_P#071^^7_R/
M]6?E?^P_>OK^A_PHWKZ_H?\ "OX\/^(M#PS_ -&4:S_X>BT_^=W1_P 1:'AG
M_HRC6?\ P]%I_P#.[H]C5_E[=._+Y^?]6U/[3R__ *"Z/WR_^1_JS\K_ -A^
M]?7]#_A1O7U_0_X5_'A_Q%H>&?\ HRC6?_#T6G_SNZ/^(M#PS_T91K/_ (>B
MT_\ G=T>QJ_R]NG?E\_/^K:G]IY?_P!!='[Y?_(_U9^5_P"PQV!'!SSZ'W]J
MCR/?\C_A7\>__$6AX9_Z,HUG_P /1:?_ #NZ/^(M#PS_ -&4:S_X>BT_^=W4
MO#S;NT[NW_MOKW7XE+-L E98NC\W+R\OZL_*_P#81D>_Y'_"DW+Z_H?\*_CX
M_P"(M#PS_P!&4:S_ .'HM/\ YW=)_P 19WA@_P#-E6N#Z?&BSQ_ZKNHG0G%)
MV>O>[Z)]%YC_ +8R]?%BZ/R<K].Z\_Z1_81O7U_0_P"%21L"3CGCT/J/:OX\
M_P#B+.\+_P#1E6N?^'GL_P#YWE*/^#M#PPA_Y,KUOD=_C/9>WK\//\_E6;I2
M:M9Z^4O+R_K7LP_MK*UJ\922ZMMZ;>7G_6I_8AD>_P"1_P *,CW_ "/^%?QX
M_P#$6IX8_P"C*]9_\//9?_.\H_XBU/#'_1E>L_\ AY[+_P"=Y6?U>?\ 2EY>
M7G^'K:?[=RC_ *#J/3OY>7F_N9_8=D>_Y'_"C(]_R/\ A7\>/_$6IX8_Z,KU
MG_P\]E_\[RC_ (BU/#'_ $97K/\ X>>R_P#G>4?5Y_TI>7EY_AZV/[=RC_H.
MH]._EY>;^YG]AV1[_D?\*,CW_(_X5_'C_P 1:GAC_HRO6?\ P\]E_P#.\JG=
M_P#!VKI.PFQ_8FOV8H2IN?C5;\,#C+Q6WPYE;9ZGS !QE@3@'U>?Y=)=;>7G
M_6MC^W<HT_VZE^/EY>;V[?=_8UD?3Z@@?F< 4_:1Z9QNQD;MOKMSNQ[XQ7\0
MWBS_ (.SOC%<121^!_V0?AAI;$$1S>*?B-XLUIE)'!,&C:)H.2K?PFXB#*,;
MU))'QO\ $;_@YQ_X*/\ C**:#PC;? OX6QR%_+F\*> ;O7;VW!!"!;KQUXB\
M46\KH#G>^G1@L.$*Y%:0PLY7T>C2T7IM>W==M]E9F<^(,KC\.(56Z^PMG=*S
MO;^K'^A^/F) ()&>,C/')(]1[C(KYK^-_P"V7^RI^S597%U\=OV@/A=\,7AB
MDF&G>)/%FF0>(+@(BL4T_P -P276O:E<'<@CMK'2[J>5W2-(7=U4_P"9O\8?
M^"I__!0WX\)=V_Q)_:R^+]]I=]&\-SH/AO7U\ Z!);RC][;OI/@.'PU;2PN?
MO+.LK$  MC(KX+O[V_U6\FU'4KZ\OM0N9&DN+Z]N)+N]N'<Y=I[JY::>5G;)
MD9Y6>4G,K.22=J6%E&;<DU%Q:3NKWO%[<O;6U_*_4\^OQ+'E_P!GPTN>ZLZW
MP<MKOX)7;OMK:U]=#^]+]IS_ (.COV2_AU#J&C_LS?#WQ]^T)XFC$D5MX@UJ
MWC^&_P -$D"R(ES%J-^U[XUU5!/M+6J^$-+AFAC81:G"74G^9S]L#_@N)_P4
M%_;!34_#VN?%1OA+\-=3\Y'^'/P9MI/!VEM:2H\+6FK>*A++XZ\0)-&<3VE_
MKBZ22Q=+'<%*_D*J!2<$X., \X SP#U(R20"3CMBGUTJA!6;O)IWUMKZV6JT
M6GD>/BLZQV*4HNHJ5.6CIT5RQM9)KFES3U:;?O:-Z6L@D>661I))'DD=G=I7
M)>3?)@2/O=BP>3'SLIW29;<3DY3 'Y ?@.E+16J45\,5&^]KZ]-=7V/)TW2=
MWK)N3;;^;=OEW"BBBF 4444 %%%% !1110 4444 %%%% !1110 444AX!^E#
MV=NP/1-]@+ 8SWSC )Z D] <  =3QD@9RP!_HY_X-_O^"5LO[7GQ?M_VF_C3
MX?\ M/[./P7\16MQHVE:G;,UA\5?B3I4B7MCHD<;1^3J/A7PK=Q17OBOSI98
M;F]DTS06@DBN+];;\K/^">7["WQ%_P""@O[2GA#X&^"4GT[P_P":FO\ Q0\;
M&%Y+'P+\/K*9$UG69"J,LFLW,<G]F^%[)FC%_KUS:1/)#;+<W$'^I'\!O@=\
M.?V<?A%\/_@K\*- MO#7@/X=^';'0-!TRV4%F2",M=ZE?SD>9>ZOJUY+<:EJ
MNH3EKB]O[JYN96+S.3Q5*\W&W+&TM'OY-=;:-7Z]/4^CX?RYUJBQE?6E!)T8
M)I1G*^KJ)IMJ*LXV<6F];H]5CA2W188D2.)%1(XXU"(B(BH%5!A54;<*J@*%
MV@ 4^GOU'T_J:97(?>1V7H@HHHH&%%%% !2@$]*2GIU/T_J*3=DWV 38WI^H
M_P :-C>GZC_&IJ*S]H^R_K^G_2U"'8WI^H_QJ500 #_GFEHI.3:M;^OZO_6X
M%%%%2 4444 %%%% $B '.0#TZ_C2%6R<#C)QTI8^_P"']:DH @((ZT $]!4I
M4$Y.:4*%SC//K0!$H^8 ^^?R-2X'H/R%(% .><\_K3J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHIIM.Z ****V6J3[I %%
M%%, HHHH **** "BBB@ HHHH ^'/B7_R.NL_]A.Z_E#7#IU?_?/\EK^:;_@H
M5_P7;_:%_9P_;3_:-^!7AKX-?![Q#X?^%_Q'U+PYH^M:_+XS_MN^LDM+"Y6?
M4%T_Q'IU@LOF7#QK]EMN(Q'O7AI&^,A_P<E?M0)Q_P *!^!')R<R^/\ .>G_
M $-W3BO\T^-/HP>*_$'%?$.;Y=A.'YX3-,ZS#,<-[7B7*Z558?$U5*DJT)5?
MW=3E2<H-MQO9ZIH^AH<>\,X6$,-7QE:%7#P5"JOJ6*:52F^224E2:DE)-)IV
M=KJZL?V4UQ7Q-^'^@_%KX=^-/A?XH^W#PUX_\,ZMX0\0'3+F*SU$:+KUG+IV
MIFPNYK>\BMKS[%/-]FGEM+B.*;8[PR*"A_D,_P"(DS]J'_H@/P'_ ._OC_\
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ML]RBOO7\"O\ B),_:@_Z(#\!_P#O[X__ /FMH_XB3/VH?^B _ ?_ +^^/_\
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MTE8_I=T']@K]GWPE#^R$-#LO%-C'^Q7/K]U\&H(-<L]IN_%FCQZ-K]SXV/\
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MT9TUV"\UCXU>*[CXB^*M=LO$;2?;=+U[7-2@@DU'3%@N)["WL9+=88[&;[.
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MTOO\@&G@D>E*O4?4?SJ4*" 2.2,GD]31M4=OU/\ C66G]+_@^O\ 3T!U%%%
M!1110 4444 %%%% !111347*]K:=P"BBBFX-*^G]?( HHHJ0"BBB@ HHHJG%
MI7TMI^(!1114@%%%% !1110 4444 %%%%-)MV0!1116RT279( HHHI@%%%%
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MW_,_XT8'O^9_QI:*.:I_S^Q'_A17\O\ IYY(/>_GJ?\ @RI_\D)@>_YG_&C
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M1ZKH$GB35+&YL-&CO)0F^#PQ^P/\:?%GQP_9Y^ 6EZOX#3QK^TK\&_"/QQ\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9CJ?P_D.^<GMU_6OF."L-A.+^'Z7$O$?"N#H9IQ!-9C7P^;X&GB<;@\/AE'
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M5<\>>"OV@M-\6VO[1W[+_P )_B%\%O$&J^/+36/&TWB7Q/\ ';X!^/Y_AO\
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M?\$0OV=_"_B6PL/@O\8O@_\ #G1?C7X'?2-%ELOB;HGQ(_:9^,GP_P!?\/\
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M4'! + !B"%R00/U(_85_X) _MG_MZWVGZK\/OA]=>!?A'-<I'J/QH^)%G?\
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M^WS_ (A6/V9FX7]J+X];CTSH/PV(]3TT7/2E_P"(53]FO_HZ+X\?^"#X<?\
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M_P ,^1[_ )'_  HR/?\ (_X5_<N?^#4']F0]/VJ/CV![^'_AL3_Z9!_*G_\
M$)[^S/\ ]'5?'G_PG?AO_P#*BCV\.TON7^8_[!Q_:C_X,_\ M3^&7(]_R/\
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M^1_PHR/?\C_A7]U"_P#!IK^S$1S^U7\?,Y[>'_AN/T&A/_/\*=_Q":?LP?\
M1U?Q]_\ !!\-_P#YGZ7UFE_>^[_@C_U=S'M1_P#!OI_=\_ZTO_"KD>_Y'_"C
M(]_R/^%?W5?\0FG[,'_1U?Q]_P#!!\-__F?H_P"(33]F#_HZOX^_^"#X;_\
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M*T>PM=-T^PMHHQ'%;6EG910VUO#%&!&D<,:(J#:H XK5\N,=$7.<YQSGGO\
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MBB@ HHHH%==T%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6L9K5OO_ )(H****D HHIRJ3SQ@'F@!T??\ #^M2444 %%%% !1110 4444
M%%%% !1110 4444%PW?I^J"BBB@U"BBB@ HHHH **** "BBB@ HHHH)4KMJV
MU_P=@HHHH*"BBB@ HHHH ****"'&\N:_5.UNWS"BBB@L**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#S+5?^/^]_Z^9O_0HZS*T]5_X_[W_KYF_]"CK,KH/
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MHJ6HDZGZ?U%2T&L-GZ_H@J=>@^@_E42KNSSC%3 8 'H,5E-ZI=O^ 6%%%%0
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MW/[,M_[TO_?2_P#Q%']F6_\ >E_[Z7_XBC3S^_\ X'K_ $M3DG_<^]_Y>O\
M2UP]A_O)_P!]BC8?[R?]]BMS^S+?^]+_ -]+_P#$4?V9;_WI?^^E_P#B*-//
M[_\ @>O]+4Y)_P!S[W_EZ_TM</8?[R?]]BC8?[R?]]BMS^S+?^]+_P!]+_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>ny20077915x1_graphic04x1.jpg
<TEXT>
begin 644 ny20077915x1_graphic04x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /CW]MG]J>7]DOX3Z#XWT_PO
MIWBKQ%XV^)W@+X2^%+7Q'XAB\'>"-,\0^/\ 5UTNRUWQ_P",[BWNK?PMX0TE
M%FN=2U26WE9I1;6$"&YO(:QOA1^TI\0;#PUXA\3_ +5&C?!SX<^'5\7>"?"7
M@#QU\*?B=-\3/!OCS4/'%Y'H^G6:L-%L-4T/4TU^YL-(6"^A>WNI;R.:&=(E
M<CTO]J7PA\3_ !Q\,6\/?##P/\$_B9=7>M:?_P )3\/OCU_:\7@CQ;X13SFU
M/2X[_2-(\0/I>N>>+2YTN^N]#U.RCD@=)X )!(OY6Z-_P3:^.EEX&_:%U[PQ
MHOP3^#'B;XB>/_V=OB/\-/V<O!/B?Q;J_P %?#>M_ 'Q1#XFO[W5/$=WH%A/
MIFM_$PJNFZK<>&_"<-EI=O8:?*T>I2^9Y1_7]?TAV3TO9]'UM=7]/FM?)H_4
M;XD_MD?LW_"2?Q?8^._B58:9K'@?Q)X/\':]X>LM*U[7O$Q\6^/]*N-;\'>&
MM'\.:#I>I:WXBUO7])M;G4++3M!L=1N#:P2RR)&J,1\_ZC_P4S^ ]M\?O@'\
M$["V\;:A!\?? 7C7QEH/B4_#KXCV<VDWOA3Q'H_AFV\/ZUX>N_!\6L:5=ZCJ
M%]J"74^JP6$.BC3-^JM;0WEI++\K>,/V&?VE/BB/VA/'OQC^&'[.WCKQ;\9_
MBC\%?'>@> M#^+?Q1\%GX<VWPM^'^J>$X]7\+_%?3?!T6NV/Q M+K4&-KJ%K
MHEGI=[8S7<$_E1LD4G8_"_\ 8S_:]^%OB;]DKXE7GC;P7\5O&'PF\/\ QV^&
M_CZS\?\ C?Q1?:KHWP]^,7BCPYKOAQ]!\>2^%KJ_\>:]\.-/\.P:.TGB+2=#
M_P"$B5EE-Y8B,4G?^NUU^-ONV!<NMWT>FU]%MIT;U>VWF?:^B_MR?LY^)_B7
MK/P8T/QI>6OQ1L+7Q?+I>@>+O!GCOP38>)Y_!$5P_B-/"NO^*/#6E:+XKAT<
MP/+J$OAJ^U3RK)6O(A+ -]>5M_P4P_9A\%^"OA]JWQ>^).AZ-XO\:?"K3/C#
M)H'P]T+XA?$>QA\!7^H2Z9)XSM+K0?!T]^O@^SO(95O-;U6PTV*QCBEGO5MX
MD+U\*_"/_@FQ^T_I/Q[^$/Q-^*-Y\)-9U'X5>(_V@;SQ7\9I/B'\2?%GQ+^,
MEM\5?#GB'1O#%Z?"VM:/:^%? %GH\.JV%M?^'--O+ZVM4L2FEW'D*F_W?X&?
M\$]/B=\,X2FO^(_ ^HL/^"=FG_L@J]H-1G8^-X==\2:G<ZX?M-E%_P 4R]OK
M%M'CS!>O)"X:W9=I#^[_ #V\[]^WEM9GN]WLOOOYIZ-7Z?B?6OBO]MSX*_#_
M %/QEXA\=_$7X?:%\&_"WPH^&7Q3/CF+5M9U+4AHWQ/\32>&O#>K7^DZ?HMS
M!'X:UF]ETV#1M2L[R[N+FYNI([NSM(8Q,UCPY^W[^R;XG\ _$OXF6'Q7M[/P
MG\(=4TO1O'\NO^&?&'AK6]%U#7T67PS#%X5U[0-/\4:L/%4;!O"SZ1I%\OB+
ME=(^UNKJOP#XN_X)C_%[Q%\,I?!,/C#P"M]-^SG^QE\'9)KIM7DL7UO]G+XR
M:5\0O%MZP73O-?2=9T2QDL-%#(LSWK(MY!;0;W;>_;+_ &5?%FCW?[3/[1R>
M+?#FAVEQXB_9!^)_@2S?POXP\76K>(_V;KWQ,E[I?CGP]X-TO4->N_#VOMXG
M@A2YT&TU"]L5MUO9[5HK%8Y#^OZU_KY.PDGI=WNE^*\NJ;]#])_@1^U!\%OV
MDXO%Q^$GB?4=8O? .HZ9I'C70]>\(^,/ WB3POJ6LZ7%K6EVFL^'/&^A>']:
MM'OM*GAOK9VL3#+!*K)(QW!?H"OR+_X)AZO\6?BCX^_;._:/^)F@:3HEA\9/
MB5\-;/P7/H7AWQUX9T35])^'?PJT'PS?WFC6/Q'TG0/%EYIT&J-<V0UN_P!#
MTF'5;NWNY+*Q2WB$LOZZ4 U9_=OTT5UTV84444""BBB@ KYG_:O_ &HO!_[(
MWPMM?BCXQ\+^-O&MOJGCKP-\.-!\*?#W3+#5O%>O>+?B)XAM/#'AG3=-L]3U
M/2+$FYU6]@CEEN+^".&,M(S$+BOIBOS,_P""L'P$\<?M&?LQ^'/ O@7X?:I\
M4;G2?VA/@%X]\2^"-$UZS\-:UKG@?P1\1=(U[Q?;:3K%]?Z9#:ZBVC6UR+5E
MU"SE\T@Q7$; , :W5]KJY],_!+]I,_%A+F/Q?\'/BK^SWJDFJQ:1X<T+XWP>
M#-"UCQK<M83ZE='PI:^'?&'B8:F-.M;>1[Z,R17$2@R)#)$DCIWWB_X^_!#X
M?)YGCOXN?#?P<@U>?0"_B7QGX?T95URUAMKBZTAC?ZA $U&V@O+6:XM&Q-%'
M<0NZA9%)_)75/V8]>E_9]\0^)?V;/V6?B5\$?CG\$_BMX"^.GPI\)?%?XDV6
MO3?$KQ)X+$T&L^%+37CXR\81:'IGC#P=J>O>$KQKFYLK5KC4;26ZC,,!9?$O
MBE^R?^UM;^!?@1X=U3X=Z_XKT'XDZ3\>_B5^T\/@\?A;=?%72OVAOBS>Z+J'
MAGPXOBGXFV]U::9\,M(T0ZCX6UO6O"Z?VI.^AZ4TB?8O+C)^>FU[=.ZZ:M_@
MMKJR=]=+VO976E]K_CJKO7L?N/\ %+]HCX-?![P8/&_CGXD^!]"TF^T/4M;\
M,MJOBS0=,7Q='I^F2ZH+?PW/?7\$&K2W4,:+ UG)+&S30DN ZD^;_!S]L'X>
M?%KP7X4\?W%G=> /"GBCX)?#_P".(\0^,]9\,:=H>EZ#\0_,&F:3?WIUD36^
MI6A1%N;FXLX-)F>:.*SO[B821I^+?PO_ &2?VE/@[\/O@;#\3/V7M6_:(OD_
M84\1?LY6OAB7Q)X'U^[^#WQ2G\=>.-:BU#6+CQ3?V>AG2?$_AS7?#FGWWBK0
M5N[BR.A_9/(-J+=7U]4_8#_:3UC]F_4_AS??#S3Y]6U3]@+]D/X&7.AS^(-)
MEM9O'OPU^)!\0>//#CMYRPO:Z7HS23"^^2SO0?)MWSA2??M]VV_WV]=KCLEI
MS7UW=EU2TL]M=S][-"^.GP6\4>'/$WB_PY\6?AQKGA7P7<7%KXO\1Z5XT\/7
MVB>&+BT027$.OZI;:A)9:1)%&1(POIX?W9#@E3FM7X?_ !7^&'Q8L+O5/AA\
M0O!GQ"TVPEB@OK[P9XETCQ):V<\\9FAANI])N[N.WEEB!ECCF9'>/YU!7FOQ
M$_:N_9 \1^$/$G[2/Q!\'>!?ASX:^!]Q;_L/^,KWP;J'B'PS\.? OQ57X'>/
MM=U'XF>!M:GOA:>'])GUO09]'TV"]U](M)U>5+/3[^Y%J7>/VK_@F!XGT_XB
M_&_]O3XC^&_AGHGPQ\(:_P"/?@]I.C:1X:U?PIXAT.2^\.?#N2#5VBUOP+-<
M^%+N_BFN;<:E!I%[>):S$0W$YFW"C^OU_'^N@6T;33M:^V[M=;WO9O[ON_3G
MQ/\ 'CX*>"_%5GX%\7_%KX;^&/&FHK:-I_A3Q!XU\.Z1XAO3?W"6EBMOI%_J
M,%_(U[=216]HJP%KJ65%@$A85;G^-/P@M=:NO#=S\4/A_;^(;&/5IK_0I_&&
M@1:O8P:#"MQK<UYISWXN[6+28'2;47GBC6RB=7N3$IR/Y=/VN/"NL?#KQS^T
MS\&-9\ ?#OXK_%/X]_\ !0KX%_%7P'\4='^('@?5?B;H7@?5/%/PWO\ 2_A_
M?^ [R:3XEZ3>>#--T#55M8-)T]O#LGAZ^N-6%[;B2Y23]$O&/[ /C'7O@=^W
M6=,^&/@Z/XX_%W]H_P 8_$/P/K=TVFIX@\9_#1M;\#:JOA*3Q2$:[T6R\9:/
MH&L^'YK&2:*U1;PK?1-&99& MM=V3T\NGY7:]5]WZY>%OCE\&?'&DQZ]X-^*
MOP\\5:)+K=KX:CU;P]XPT'6-.?Q%>L$L]"%W87T\/]K7;,HM; L+FYW#R8GS
M5K6/C'\+="TC5]<U#Q]X1CT[0[[7-)U&9/$&E2&'6_#>G76K:YH6Q+HL=;TS
M3K.YN[S2^+RW@ADDEB1(V(_$3QK^RK\=?BO#^U'\9?A1^SJ/V>M23X;_   F
M^!/P9UR^\*Z/?>-_CK^S[XPO_B#:^*]7M/"=]>>'?#]G?0/8_#?3]4NKS^T=
M2TI);F[6"S2V00? W_@G'\<O"7[0'@J\\7V.D77PJOOAO\2/VA?B)<W6M0ZC
M#<?ML?&7P/??#WQKI?\ 9;M*\VA6UEX@U/6+34$3[(3:"-54N$)_7Y?EU#3O
M;1/2S:T3L]?EI?KMN?HE;_\ !23]E_4]#^ /C#0O'N@ZCX#^/FL:QH]CXRF\
M0Z#IVC^!IM(\(:EXQ;_A.9+O4%&B3W5CISVUO9W+QW!N9X04*L,_:_A+QAX4
M\?>'M,\6^"/$FA>+O"^LP?:=)\0^&M5LM:T74H [1F6QU+3YI[2Y19$>-FBE
M;:ZLC892!^(OP/\ V0O&.L>%OV"/ GCG]ES2_!>F?LP_$/Q4GQ;M]?M/ MYX
M>\6S1?#+Q'X=T;QWH]OI$UY'KUA=:S>6'V:?5;.#58]X>6W58B]?H)^PK\%O
M%/P(^'GQ6\&>(O#UGX5T[4/VC_C5XP\"Z'ITMN^FV?@#Q5XD34_#?V"VM/\
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M;_GS3^[^NWY]V'^L&=_]#/%?^!KR_N^7XON?N#_Q$"_MY_\ /#X-?^$/>_\
MR^H_XB!?V\_^>'P:_P#"'O?_ )?5^'U%'U3#?\^:?W?UV_/NP_U@SO\ Z&>*
M_P# UY?W?+\7W/W!_P"(@7]O/_GA\&O_  A[W_Y?4?\ $0+^WG_SP^#7_A#W
MO_R^K\/J*/JF&_Y\T_N_KM^?=A_K!G?_ $,\5_X&O+^[Y?B^Y^X/_$0+^WG_
M ,\/@U_X0][_ /+ZOJFU_P""TG[8DO[%FJ_'EX/A9_PG5I^T7:_"V(#PA=C2
M/^$9F\!6OB0EK+^V]QU :C*P%SYP!@.SR\\U_,K7WY8?\HQ-?_[/2T__ -5'
M8UG4PN'CR6HP5ZD$]-TW9I_U^;OVX'/,WJ2Q*GF.)DH8*O4C>:?+.+I<LU[O
MQ+6SZ7?<^Q!_P<"_MYD?ZCX-=2/^1&O>Q(_Z#]+_ ,1 O[>?_/#X-?\ A#WO
M_P OJ_#T=/Q;^9I:M83#67[FGLNGI_7W]V<7^L&=_P#0SQ7_ (&O+^[Y?B^Y
M^X/_ !$"_MY_\\/@U_X0][_\OJ/^(@7]O/\ YX?!K_PA[W_Y?5^'U%/ZIAO^
M?-/[OZ[?GW8?ZP9W_P!#/%?^!KR_N^7XON?N#_Q$"_MY_P#/#X-?^$/>_P#R
M^H_XB!?V\_\ GA\&O_"'O?\ Y?5^'U%'U3#?\^:?W?UV_/NP_P!8,[_Z&>*_
M\#7E_=\OQ?<_<'_B(%_;S_YX?!K_ ,(>]_\ E]1_Q$"_MY_\\/@U_P"$/>__
M "^KX8_8:_9J^$/[5_Q7TOX+^.?BYXW^%_CGQ??26O@3_A'?AI9^.-"U)++2
M;_5=4D\0:C>>,/#CZ(8(K(I9FWL]0%PSL7,6PFM[4?V'-1^(WQ)\?>$OV3M>
M\0_%3PG\)\:9\2OB!\6M)\,?!'0O#GB9]9O-&M]*6\U/QEK6DW,6H36Q.DR2
M:C:WMXS2YLT2.-GQ]E@U.4'1BN6/,W*-E:Z2M?>[O]SON=]/'<35:%/$4L?B
M:L*LY4X0IU:<ZTIP4922I04JGNPM*3<5:+E)^[9O[)_XB!?V\_\ GA\&O_"'
MO?\ Y?4?\1 O[>?_ #P^#7_A#WO_ ,OJ^7]$_P""77[1=YX'^/\ XH\4W?@+
MX>:]^S]JGAO2]=\&>-/%NB:/=ZX/$8M[BWU33-;N;]=&M=*DL+J*ZTF_O9EM
M]?E62PTII[U#%7EH_8,_:'L?!%I\4M8\.>'7\"6I\(:EXI&A^/O"&L^+?#'A
MCQCJ5G8:;K>L^%=-U6[UG2[6]2[!LKF\M%0D^:@D4@-7L<#_ "4MTKVTNTFE
M?;5-/?KW;"6,XJ@HN6(S%)P=1NS]V$9^SE*?N>[RSA)23U5I:'WE_P 1 O[>
M?_/#X-?^$/>__+ZC_B(%_;S_ .>'P:_\(>]_^7U?!O[?_P"SAX/_ &4/VG_&
M7P4\":MX@UKPSX?T?PAJ5C?^*)[*YUEY/$'AVPU>ZCN)].LM.M'2*YN94A\N
MSB*Q! Q<\U\854,-A9QC.-&%I)25XZV:35_U^?=G-B,YS["UZV&JYGB/:4*D
MJ4^6HI1YH.SL^573:WLKW?<_<'_B(%_;S_YX?!K_ ,(>]_\ E]1_Q$"_MY_\
M\/@U_P"$/>__ "^K\/J*KZIAO^?-/[OZ[?GW9C_K!G?_ $,\5_X&O+^[Y?B^
MY^X/_$0+^WG_ ,\/@U_X0][_ /+ZC_B(%_;S_P">'P:_\(>]_P#E]7X?44?5
M,-_SYI_=_7;\^[#_ %@SO_H9XK_P->7]WR_%]S]P?^(@7]O/_GA\&O\ PA[W
M_P"7U?47Q_\ ^"U/[8WPW^&G[*/BKPW!\*_[5^,?P7N_'GB_[=X0N[BW&N0>
M-_$7AZ,:9&NM1FTM#8Z3;LT#/+^_>1@^" /YG*^\?VO?^2(?\$^_^S8M0_\
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M*ZMWN4B>2-)98U:*.21(W<.ZJ?QB_P""?/[&WC_X1_$GX'O\5_@[\==$\>_
M[P?\0/"][\0K_P"(/PON_@SJ,NOBWM+_ %72(/#&CZ;XR\71^-FM8-7MK+Q)
M-+<Z!<M+)J$EQ>!+@>F?\%(_V=/BE\1/B_H?Q0^!GPD^(FN_&+3?@W??#_PC
MXZL6^$GC/X-:G%?>*&UUO ?Q?^&WQ7T_5(K/0_[0BM]3F\6^%[>VUEK.>>Q6
MZ9X8$4U_S"RO9/3OT_"^C_(_2I_VD_ACH\?Q9U7QSX@T'X>^#_A%K6B:/K'C
MCQ7XL\+6GAR^37_#VE>(=/OXYX=8GGTN*:#5K>VM[?7(;"^O7 GL[::UN(9)
M$'[6/[,;>";;XDCX^_",^ +O4[K1;7QC_P )[X;_ .$=GUFQL9-3O-(BU4ZA
M]D;5+73XY+R?3Q+]LB@1G:$ 5^*7QU^ WQ9^%5QXX^/OQ=\%_"O7O#%A^UW^
MSG\7]<^&GB3QCX5\%?#_ .)VG:!^S/X3^%FO6FC77BB1/#%C+X7^(4-[J7@_
M1_$LB6=[_9-MO9)/L\C<=^RC\#]4_:MO? ?Q47X$>!K#X1Z3_P %-/C-\8=:
M\'0W?AGQ3X%L?!A^$NH^$=(US1I;73[;PYXHA_X2N:V5Y]$M;BP^W>=/;2W,
M,+RL??Y?>M_E\QJ*M>^V_P!R]7>[MU\_/]XM7_:K_9JT'X?^'/BMK/QU^%FG
M?#7Q?=/9>%O'-UXTT./PQX@O(_.$MKI&K_;#9W]Q#]GG\^&WE>2$0RF54"-C
M@=3_ &R/A5;?'CX6_!*TN;+6M)^*_P "_B1\?-'^*-AK6CW'@"U\&_#76O"&
MCZHUSJ"SM%-'>_\ "76]W;WT,IL88+*X^T2 LN/R2U/]DC]ICX?^&1\/[;X0
M>(=6^!&I_MA?M6_$#4? _P &YOAI;>.K#P5X\NX=0^$$GAN^\96EUIG@_P %
MW=TVJIXDL?#PL-3LH[NW5V>U:X@;B_A9_P $^?CSI7AKX":7\2?@MXDU/P?X
M._8Q_;0^$'CCP-I7Q(T%?&$&H_%SXT^#/%?@/P?I7BU98K"36+CPOI=[<P:K
M%$FD6MW9"VG$<<L5N#TMTW]4G^K^74+1ZN^UMNNWW/SU=M4M3^@CX6?'#X-?
M&NRU2^^#WQ,\#_$BQT*Z2PU>?P3XBTO7X-+NY%+Q6]Z=-N)UMI)8U+PB3:)H
MP7B+H":]6K\M?^"<'PJ^.'PPN_BU9^/O#>MZ%\*Y;3P#IWPHD^)OA3X4:!\;
M)'T?2KVT\1Z?XNU/X2:;I>D^(O#>E'^S+;POJ6N6\OB"0G4C<7,MN;<G]2J"
M7_E^04444 %%%% !44T\%O&TMQ+'!"@+/+,ZQ1(JD L\DA5% )')(ZBI:_-S
M_@J)X'N/'W[/OAW2;;Q[XS\ R6/Q8\$ZZUQX;^'OB[XH>&/$<>DMJ%R_A+XK
M>$/ =_I7BV]^&FNA?(UR;1]4L;BUNX].F$C!3'(?UV&E=I=W8_1V*YMYUC>"
M>&9)4\R)XI4D66/CYXV1F#IR/F4E>1S4<U_8V\8FN+RT@B(!$LUQ#%&06V A
MW=5P7(0'."QVCGBOY\_@?\3OBE\)Y_V0/B9\2_@9\1_AY\/[;P+^U)\,K_PO
M\)O#?Q4\8^';W7M1\9>'=0^''BS_ (0[7YM:\:^%]-\?Z=IFJ:CX:T_Q5<3R
M^'S=KIIN8('C$?Q[H\FFW'C;]FSPA^UOX/\ VB/$D&H_L(?'?7[?X7V=O\4;
MSQ3#X[O?VA[U/">H^)_#WA.^34+76[?2KNQMM'U365:VTJ:2W43P1PQ!3JM[
M-7[=M/G?3\AJ-^VFO1_\#31O72ZZG]9L]_8VJJUU>6MLKE%1I[B&(,TA*QJI
MD=02[ J@!.YAA<GBI#<VZML:6-6)4!6958LX9E 4D,68 E1C+=LYK^4G6-&E
MMO$O@OX8_MI^'/CK\4OBCIO_  3.\-3^&?"7@4_$G6]5L/BA??$OXB67AJ[U
M*+P9J,5I:>/+/3#X7TAO%.M@*M_87$L]V"LI;Z]^!?[,7[0OBSQIX]\0_&FV
M^(6H?&SX<?L5_LS0?"G6==\7^*;/P1:_M#Z=\./$46O:J]CINJ6OAOQ#XGTO
MQ,NEQ>(;_4+._C>X!>=72;%'W_A]VCW^_P"75<K[_AI:ZUWU6N]NJLGJ?N]K
M6E^$_&.E:KX8\1:?X?\ %.BW<1L]<\/ZQ:Z=K6F7$+$,;75=+O4N;66)BH/D
MW4#*2 =O&1G^$= \ >"- 32/ FC>$?"?A>Q:1DTWPK8:/HFA6CLW[UA;:3%;
M6$,C-S(VQ79@2Q)!K^7WX"?!#XB7O@SQ3)XR^-O[0/PU^*5Q^S/\3_"WQFT[
MX??LS_%#1O&)\7:U8V]K>^*?$/B_7_'GB+0?'WB;P]KPEU'P]+X5M;#4-?L7
MN(M,N;""3RX[5C\/_'FM_L^^+? ^HQZI\+_#/@[XY_"3Q%H/Q=^&WP'_ &A[
MGX:?M$/8^$?$2ZQX3^-WP+UOQC=?$/1_#-G<-9KXCUKPAXBL=,O/$<^F7"1,
M]NT;GK^#]-/Z73770+:VNMU96?6VNK7X;Z=%=_T?7.D_!!?C!HM[-X&\*7'Q
M<USP]J6N:7XXB\!VEUK#Z+HLMGI]UYGCZ/2)!;R1_;K>&VL9M82YFMC(;:%K
M>.0K[#%?6-PDDD%Y:3QPR&.:2*XAE2*5#AHY&1V5)$. 58AE/4 U_-;J^B?M
MK^,/@)X$N?@W\*_%OP5^((_8M_:D\/:/X5\+W?C:#P[#XG_X6QX)3PYJ.B+X
MXU#4==T'7_'/@:SU[6O >D^(;N;6_#HU1+**XB%NK#@?$OPZ\=>(]"^/]G^R
M'\/_ -H?P1\!]7_9%^%7AOQKX>UU/B-X>\0:S^TJWQ:T.36;OPRGB*Z77V\7
M:?\ #^/5;;QSKV@3I8W[20M))-(JRD^_9/56_JU@23W>MTOQ2[NW2R3=[']2
M=M=6EV)&M+B"Y$<C12M!+',(Y4 #Q2%&;9(O =&PRGA@#4^U1T ';H.F ,?D
M /H!Z5^9O[*_P,?X _MA?M#^&/ ?AKQ;X9^!_B/X)_ ;Q3I]MJ.L>)=<\,7?
MQ4.I>/\ 2_&5]IEYXBU#4WBUVXT>R\.'Q!%;72^>RVMU<P^=,9)/TSH$TO7;
M_/\  **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _)G
M_@MS_P HY_C1_P!A#P-_ZENF5_!(O0?0?RK^]O\ X+<_\HY_C1_V$/ W_J6Z
M97\$B]!]!_*O>RO^!+_KX_\ TF)^4\;_ /(UH_\ 8'3_ /3E46BBBO2/C0HH
MHH ***]Z\,_LV?%+QC\$]5^//AG38=:\(Z7\3M#^$G]D:89[WQ=J/C'Q#8)J
M>G6FE:%:V\]SJ$<ELP7-NK2F1U14<Y8*4HQMS.UW9>KV1I3I5*SDJ<'-QC*<
MDND8J\I>B6KM=^1X+17:Z]\,OB5X5726\4_#[QQX:&OSO:Z%_;_A76M(&M7<
M;JDMII OK*$ZC<12L(6AM?.E5RH9<L,_:GP]_P""<OQ=\7?#/P#\3/%>L6OP
MHL_'WQMB^"=KX?\ 'GA7Q?8>(]+OI]#DUVV\57.F1:2]S<Z%=1I]EM_LD$L\
MSGS(U:,,ZQ*K3BDW.-GHK--MKLE>_GVZF]' XO$3G"C1G*4$G--<G)%N*3DY
M\J2]Y/75J[29^>U%>HZS\&_B#8:EX_BT+PQXF\:>'/ASXBUKP]KWC;PSX5\0
MWOA>!M&OY[%[V[U#[ J:5#/Y(G$.J?9KFW25$N(TDRM+;? SXU7DOA)(/A/\
M1D3QWJFFZ/X.N[GP7XAM]/\ $NHZO/';Z?:Z-?2Z?';7[W#R!D-M++B%)9MK
MQH2*YX63YHV?FELKO>VJ6_8R^KUKV]G-]K0DU*\N1.,DN62<_=33:<M$V>6T
M5]E:O^P[\8?!,GQ]TSXM0CX4>)/@'X(M_'&H:)XDTC6KI?&EE=:A]@2V\)ZS
MI=C>:'.$<KYFJ7.H1Z8DI:%IO,20)\VWOPN^)^F^'M-\7:C\./'FG>%M8FM;
M?2?$E]X0UZTT#4[B]=([2VT_6)[%;"\FNGD1+>."9WG9U6-2S*"E4A*]I+1I
M;Z.\5)-/9IIK9EU,)B:5O:49Q;4I<K5Y149RIR<XJ[IVG&4;5%%^ZW:UF^'H
MKO/$GPJ^*7@W2SKGC#X:^/\ PIHHOO[+.K^(O!WB#1=*&I;9'&G_ -HZC8P6
MOVPI%(5M_,\YMAPG%<'_ )_/I5W3V=S"4)P?+.,HM;J2:>ODTNS^[0****"0
MHHHH *^_+#_E&)K_ /V>EI__ *J.QKX#K[\L/^48FO\ _9Z6G_\ JH[&LJNU
M/_K[3_,]#+OCQ?\ V+\3^=(^ AT_%OYFEI!T_%OYFEK2.R]%^1YX4444P"BB
MO=_A)^SI\1?C7X.^-'CCP6NC-HOP)\%)X]\;G4M0%I=_V$]R;4#2K<QN+V\$
MNXM"9(1Y2?*WF'YIE.,%>3LKVOI:[VW[FE*C4KS]G2@YSY92Y5ORPBY2?I&*
M<GY)L[+]B3X\^'?V8_VH?A9\<O%ND:KKWAWP-J&KW.IZ7H7V5=7NHM2\/:IH
M\?V,WDL%LSPSWL,I6:9%\M) "20I^AOA#^UY\#3X!_:L^!GQT\+?$Y?A9^T1
M\6=$^+NF>)/AA>Z%%X[T#6/#VM7EY::3J5IK<L6D7^FWVGSQ1W#1W"O;7:/)
M'%*&W+Y?\,_^">W[1GQ<\/?!'Q/X*T[PW>Z1\>&\=2>%KFYUN&S31M-^',/V
MCQ5K?BJ2:,1:/I-G '>*9I)Y)RJQHAEDC1_ OC?\%]7^!OB?3_#.I^,OAWXZ
M&JZ1!K6GZ]\,_%MAXOT":VEGN;22UEO[((UGJ4%U:SQS65W;0RQ*L4I#QOEL
M)+#U7*[3E97M=./)-R3[7YD]7>]M+V/5I3S+ X:#='EPO/5FG6HPE3J_6\-2
MIU(RY_>G3J8:4'9>ZN=.ZF['Z@?$#_@HW\!OC=-^U1X.^)WP]^*.B_"_XS>"
M/@CX/\ W'A+5/#VH^--)C^ ["?PW-XK?6#!IEPVO7443ZS+8>9)!')+% LNU
M9#ZS_P /1_V4M#_9[\5?";P)\%/%_A"]\5?"/P;X"ETC2_"WPWM-&L_$'A:[
MM9KW7[[QE Z>-_%*ZXT<MR8M=EEATV=5%I;*979?A;Q3_P $P/VH?!_Q@^#W
MP6U>S\'MXE^./AG5?$_@;5+?Q )/#4T&B:++K^J:7J.J"W_T#6;/38TF>SDB
M<LMS:LFX3 U\3)\,/B//H^O>);'P)XQU/PGX9OK_ $_7?%VG>&M8OO"VF7&G
M7#VMR+W7[>Q;3;54DC()N)XB&8;B Z*,XT<--)J3MS*:3G:[2C';=I\FO6][
M-*R.VIF6=8>I-U:$8U9QJT9SGA(.HDW]8J1;<7*,8+%.:T4%"I!.ZY3Z1_;Y
M_:1\*?M8_M-^,?C7X*T77- \/>(-'\(Z;::;XC^Q#5DDT#P[8Z3<R7"Z?/<V
MJI)<6LCPB.9B8V!<!C7QK79W7PU^(]A+K4%_X \;V,_AO1+;Q+XCAO/"^L6T
MGA_P[>1B6SU[6DFLD;3-'NHSYEOJ5X(;29/GCE9>:Q-9\.>(?#<ME!XCT'6]
M GU+3;76--AUO2[O2Y=0TB^#&RU6R2\AA>YT^[5&:UO(0]O.H+12,!FNJ"A"
M,81:222BKW=DK]]=-?GI9'AXIXBO5JXJO%J=:;J5)<G)%SD_>LDE%>]=>J=[
MO?'HHHJSE"BBB@ K[Q_:]_Y(A_P3[_[-BU#_ -6IXVKX.K[Q_:]_Y(A_P3[_
M .S8M0_]6IXVK*?\2CZS_P#2&=N&_P!VS#_KQ1_]3,.?!J]!]!_*EI%Z#Z#^
M5+6IQ!17UQ^R;^Q3\9_VS]7\:Z)\&SX7%]X$T6SUO61XHUI-%BEAU"Z:SL;2
MQD>&47%Y=7*"**,[%9Y%C#;R*WO@#^P%^T-^T;IOQMUCP/I>B:9IWP 74%^(
M-QXKU,Z*MO?Z5::O>:AH^FE[:9;[5;6WT:YFFMU,8B5XF=@DL6<I5J<6U*23
MC;FO?3FVOUUZ.UGW.RGE^,K*BZ6'J36(]I[%QBVJGLE>JHO;]VOBNTEWW/BF
MBOOV3_@FW^T3%K:6+S>!E\-O\#)?VAS\1O\ A(U_X5_'\.XQ&K2G7_LYB.KI
M>'^S_P"R@#<-<2HN?XAC#_@G]\9;'X;:!\1_%WBOX/?#Q_&'A+4?'7@KP)X\
M^(FE>'/'_BWPI8QR7"ZWH_A^^"2/:7EO&S:8+J:UDU+Y3;AMVT'MZ/\ .M[;
M2_R_JSOLR_[+S#6^$K1M%R?-'EM%-)N[LFKM)--\S=H\S32^&Z*[#P=\/O'/
MQ"OIM/\  _A#Q3XMN;(13:G'X9\/ZKK[Z79O)Y;7VI)I-K=M:6<>"TD\NQ-B
ML4<\$^Y_M-?LE?%#]F3XJZQ\,-?L;[Q6NF:EHFAV7C'PYX=UU?#.O>(-=T>S
MUJW\/Z3=WEFJW6MP0WBP3:=$S7)EC.V(@@FG4BIJ%_>:O;2Z5TM5>ZW['/'#
M5Y4I5U2G[&,HP=3E?+S3Y^5)V][^'._+?EM[UKJ_RY17?77PF^*MCINO:S>_
M#/XA6FD>%KW^SO$VJ7/@W7X=/\.7X* V.MWKZ>MMI=V#)&'M[V2*5#+&&5=Z
M9GO?@[\7M,GT:VU'X6?$>PN/$=XVG>'8;SP5X@MI=>U!(%NGL=&BFTZ.34[M
M+=TF>WLQ+*L3!RH4@U7-'3WHZ[:K72^GRU]-1?5Z_P#SZJ/1/2$GI)VB]MFT
MTN[C)+9GG5%>@Q_"+XLS^*KCP+!\+_B)/XXM+=;RZ\&Q>"_$#^*K:S9#(MW<
M>'Q8MJD-HR#>MQ+;)$RX*OR,Q:Y\*OBEX96_E\2_#;Q]X?BTJ[TVPU676O"&
MNZ7#IE]K,?FZ/9:A)>V40M+K58_WFG0SM')>IAK=9 <E*<&[*46WLE)-O6VU
M[[M+U=A.A62<G2J1C&7+*3IS48R2;<9-QLG%)MIM-)-]#@Z*^H[?]DOXEGX
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MGLTTT_FM#&490?+).+TNFFFKI-732>S3]&@K]4/^"*W_ "D=^!O_ %[^./\
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M^0HHH 0*!T _PX X]. !@>E+110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!^3/_  6Y_P"4<_QH_P"PAX&_]2W3*_@D7H/H/Y5_
M>W_P6Y_Y1S_&C_L(>!O_ %+=,K^"1>@^@_E7O97_  )?]?'_ .DQ/RGC?_D:
MT?\ L#I_^G*HM%%%>D?&A1110 5^S_\ P3^_:.^"'PF^!O@+PQ\1?B/H'A37
M-,_X* _"#XJ:CIFI_;_M%I\/-!\.1V.M^*9C!9S0KINGSYBDVR-<;\LL!4(Y
M_&"@\C&3] >.W4=#TK.K356/*VTKWNK;J]M^WD=F!QD\#75>$(SDE;EG>UFU
M?9IWMU3_ ,U_1]#_ ,% ?@QKNL:1K?Q:^-$7Q!L_!O\ P5"U+XE>%[35_P"T
MM?N=#_9^/A7QYHV@>(_#]C=6(CM/"6F7NH:'/'I]L(94=(9FLVD.3[=X>_;7
M_9^\,V_P5T/XC?MN>&/CAJ_AC]MK5_BS>^*)?^$NGM_"?PM\1:+XF.C:<NHZ
MSI,<UQ8^'Y[B.WOK> -#I=SJ265O!]DBC9?Y4L>A/   ))'&.O0X]L@#\*,<
MYRV<]=QZ?W><G';KTXKG>#@[+F:235DDOYK6:U5N9[;Z7V1[,.)L5%.]&C*3
MM>4Y5F]%%7FE42J:0@H\_-*"BTG[S/Z%OBI^T_\ !WXE?!C3='^$'[9>G?LV
MS>"/C)^T7X@^)WA:TA\7VVK?'#1/'GB?4=1\/:WH-EI&G/IOBDZSHTZZ;#;>
M(9;:'2_->1XX6BC+^\_&O]L?]DC0_P!F?QUI/P\_:>G\>>,I/%O[/GC;P(UY
M\0_B=XJ^)B'P=J7AC_A*9H]+UG3;#P]\/=9LM/AU>P_L'P3<6=E<64:O<.\L
MA9OY<>OKGL<G@^HP>I[GK2$9[D#^Z"<'W.<G/OFCZG#1<\K*2DDM+V45[S6K
MVW?>SN2N),5&-5*C0YZM"-"4^;$OE4:;IQE3@Z[A3M>,G&$8\TX<SDN9I_TH
M_%;]KG]G2\^)7_!1'QY>_M.>'/BMX0^/_P #?!T'P@\$"_\ &%U<Z;)IFOV]
M[JGPUM[/5M.6RT;5)8X[BZN--TYH;%1>9DG,QFV:_P 5?VTOV>[B;]H7QTW[
M4VB_$SX4_&KP3\%?"GP?_9=BM/%,EU\)->\/:GX5EU'7]2T34-+M] \(Q^$%
MTO4=0:ZT.Z:XU1Y665FG2'=_,OCC&3C). 3@Y]02?Q/&:!D8Y.1GD$@G/'//
M0#CZ<4+!P5KRDTG"Z:6L8J*Y?+F4=6K/5^0WQ)B??<:%%.4JDE[^(=IU)8F3
M<G[9>TBOK511IS4HQ<8-)<J/Z&/VQ/VY/AC\8_!W_!3'P3#\>K?QQX8\:7G[
M.C_LT^&[B^U2ZTF]3PW?:%=^.F\#65S8I;::\!34'U:7-E)<YFW23G+5_/.,
M8XP>3R HR<G+84!06/) '4GDGDH5SU)_/^G0?E_3"@8&*WITE25HZ+31*RNH
MQBW9=9.+DWU;^_R\PS"KF%2%2JDG!54K.;NJM>K7M><I-*'M?9Q2=E&"LEL+
M1116IYX4444 %??EA_RC$U__ +/2T_\ ]5'8U\!U]^6'_*,37_\ L]+3_P#U
M4=C657:G_P!?:?YGH9=\>+_[%^)_.D? 0Z?BW\S2T@Z?BW\S2UI'9>B_(\\*
M**,CUI@%?I9_P3S^,'PG\'Z'^U=\&?BSX[T[X6V'[1GP1N? 7AOXAZ]9ZA>^
M&M \26]Z+RSC\0II5M=WUO87H:5/MD-O*+=E7S4^:ODG2?V7OVC=>^'<WQ<T
M;X)_$;4?AC;V5UJ<GCBV\-WK^'SI=B";S4TNRJO)I]NH+2WEO#<6T: N\JJI
M->#+)&WW9%;@DX900,9)(5V P.2-S #N1S64XPK0<.;31WCK9IW6NU_+<[</
M5K9?7HXB5%J\96C6A5A"K1JTY4YV=H-IQGI*,KIV:/W[TW]H/X8_"WP]^QC\
M"?@I^V?\-O#'CG]G?0?BQXG\0_'>;PWXJU7X*:MKGCEE1?ACJ,4^D#4M2T?6
M+![FWO\ 4)M'DM()(K90%NGCV?#G_!2?QQ^SM\0/BI\/-?\ @/\ \*YOO$C_
M  [L/^%\>(?@]HFI>&_A;XE^*<M_))=:CX0TS4K2QGCM%T_$6HSPV-I#<3RH
M[H7CN'/YS%D*L=Z!1]XY&T$'&2P(P<J0>1TQV(I0R*H.]0I. P? ).> Q)YX
M/<G@^E9PPT8SC4YG*R?-HDI.4KMZ;1=[6VT76YV8C.*N(P\\-[&E"$YX=P<9
M5I.E'#4Z-*G&FJE248R=.DJ=2<4I5(>[)\K1_5IX4_X*&?LEZW^UGJ=KX^^+
M?A^+X8> ?"7@7XA?!CXF^3J3:/IOQ ;X3?\ "O?B7X$:8Z>]]"NN6EU97"QB
MW6U.K:.Q$ID(9_/_ (<_MT?LOZ1^RK\,](T;XD_#;0=7\%_"3XO>!O'WPO\
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MG^!XV-QE7'58UJS;G&G"FY.4I.2@VTW*3;;?,%?JA_P16_Y2._ W_KW\<?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ'MJ7_/VG_X''_,^1^H8[_H#Q7_A/5\O[GFCXMHK[2_X=S_MT?\ 1K?Q>_\
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M[940:IJ()OKVU$LTLC,:_$Y>!CZ]\X&3@9QV''<^I)Y/Z?:5^S+_ ,%*-$^
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M/$W_ $!]&_.[_P#CM?C#<?\ !3KX-V'PI\%_$S5? /Q6TR^^)GB__A#OAMX
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M@)/!7Q7U33/@7X5TOQS\3?B+I7ARPN? OAGP?K?P_L/B%I.MWM^=:BU!EO\
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M0'B;_H#Z-^=W_P#':\&HHY8]E_7_  WY]V&O\TOO?E_E^+[GO/\ PT!XF_Z
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M "3B;_L;T_\ 32*X:NY3_DG$W_8WI_Z:136_RE^3"6\/7]4<-1112+"BBB@
MHHHH ^2?VD?VF=;^ NO_  KTC3_A/XB\8:5\0/B#X*\$ZUXT:^L]'\)^%?\
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M\0H]/M/%>GZUHVKPF6SG2'3K5[07&?@S5?C[^UI\6_V6?BSXN\=_%GP[XO\
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M#Q!^QG\&_$=[]NO+'5(IOLMI:9MM2FC4)9PBWB.W:1GRE4$C&2,D' KBK_\
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M?_M+ZOK?]J:+:W5LD+7,VEZ;&-:99 Z:?')>LI$BAJ^X_B#_ ,$Z_'EQXO\
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MRLVZD-).-D[MGZJT@(/0@_0Y_E7Y4:;^VW\4M2\ _!CX@>(+'PO\-O!&OO\
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M_P#29Z4MGZ/\CHZQ_P 4?_2D?<5%%%8'0%%%% !1110 4444 %%%% !1110
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MM,GTGQ%HUAK%E/&R-;WT"2J RE28V92T;XZ.A!! .<@5^;GQ8_8;%AJO]O\
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M>*].AM[B\T+544EK6_A@NK>8PR $QRJRY'0"\;V35];+3I:_W>[^!VU;:_\
M(O2?]A4?^DT=8E;:_P#(O2?]A4?^DT=)[?./YHHQ****8K+LOZ_X9?<%%%%
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M3:WH-K%>67C6-;N34O&^E6F^X32-6U*[U+4ISY,\YMTO)(%F?:&%*RM=+?\
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M]5S2C=J*<()J[2NW*,I/W4ES):N["BBB@W"BBB@ HHHH *\T^+?_ !\^&/\
ML!'_ -+[FO2Z\T^+?_'SX8_[ 1_]+[F@75>C_.)Y%1110,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KT[X/?\E T?_KG>_P#I,]>8UZ=\'O\
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MHTZ_,H+5Q'[*OQAD^%WQ)LK6]N3#X7\430:7K2R.PAAF9BEK?  %0T4C(CY
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M22C%)))6225DK)"U]0?L??%%_AC\;/#TMS.5T/Q6Q\,ZO%N"HOVV:,V%TP)
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MC?\ 07TG_P &=E_\>H_MW1O^@OI/_@SLO_CU?CA_P[%_8V_Z)QJ__A<^+?\
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M^#.R_P#CU?CA_P .Q?V-O^B<:O\ ^%SXM_\ EI1_P[%_8V_Z)QJ__A<^+?\
MY:4?N^\NGV?3^]Z_CV5SVN:?] >#Z?\ ,PJ>5_\ F7^OW_=^Q_\ ;NC?]!?2
M?_!G9?\ QZMQ==T3_A'I!_;.D;CJ@.W^U+'./L\8S_K^@/?W X-?BI_P[%_8
MV_Z)QJ__ (7/BW_Y:5U8_P""6G[%3>"9=5/PQU7[>OB-;$7'_"=^,<BV.GI,
M8S'_ &OY1^=0=Q3<222>!0E3>\I=_A[6;^UZO3K\@]MF:LG@\'K;_F85?[J>
MV7>K^[T/UD_MW1O^@OI/_@SLO_CU']NZ-_T%])_\&=E_\>K\;Q_P3%_8V Q_
MPKC5_P#PN/%H_3^U*7_AV+^QM_T3C5__  N?%O\ \M*+4^[_ / ?3^]Z_P!)
M7/:YI_T!X/I_S,*GE?\ YE_K]_W?L?\ V[HW_07TG_P9V7_QZC^W=&_Z"^D_
M^#.R_P#CU?CA_P .Q?V-O^B<:O\ ^%SXM_\ EI1_P[%_8V_Z)QJ__A<^+?\
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M_=]Y[7-/^@+!?^'"MY?]2[U_K?[N_MC2/^@MIG_@PM/_ (]1_;&D?]!;3/\
MP86G_P >KX1_X=A?L9?]$SU'_P +/Q3_ /+*C_AV%^QE_P!$SU'_ ,+/Q3_\
MLJ+4_P":?3["\K_:]?N^\]KFG_0%@O\ PX5O+_J7>O\ 6_W=_;&D?]!;3/\
MP86G_P >KT_X.ZOI!^(.B@:KIA++>(JB_M"S,UK)L55$Q+,S!5"@$DL .2,_
MF%_P["_8R_Z)GJ/_ (6?BG_Y95ZS\#?^":'['>E?%/PAK-C\-M0BU#0]237-
M-E;QCXH=8=3THB]L)VC.I!95@NHHY3$^8Y-NQP5)%)JG9^_+9_879?WO7^MW
M&KF3E#FP>#C'FA=QQ]632YHWM%X"*;WLG**_O+=_NM12*H554=% 4?0# _04
M5R'KBT444 %%%% !1110 4444 %%%% !6!XJUA/#_AK7=;D8(NF:5>W@8D >
M9% YB&20.9=BCGDG'6M^OG7]J'7O[%^%6HVZ/LFUV^L=)C (!:.20S3\'DKY
M<6&QG&X<<BM*,.>K3AI:4XIWVM?6]O(BI+EA*79:>KT1\<^&?VEOBAX?GD$^
MJ0>(K%YS)]EUJ!)9%1WWE8KJ$131X#%5!+*%"Y!ZCZ2\+?M<>$-2,,'BK1[[
M0IV*H]S;J]_8#D_,Q1%E2,$@\B0+DG/0G\[!P /\YP!_2G$ # 8D<<'.!CIU
M)Z=O2OH:N"PU6-G2C%K[4%RMZIZVT>UE=:79YE/%5(IMR;:M9-V7];OU_#]0
M/%'PY_9P_:*TN>S\2>'O /CNTO(]KB>TLEU:$CG='<P?9=8M94+$AX[A""W(
M8&OSM^+'_!&'X+^(#<ZA\*/&'B;X=WK"5X-)O9/^$DT%9"IV*HN]FHP(3A23
M=7&U?NC/-<O;S36<\=U9W,]K<Q,'BGMY98)XV'(*21.K @^X'>O:?"?[0_Q0
M\+&.-M;DURR0C_0M:Q> H,#RQ=-MNEW*.29'P>GOMA*V<9;+_A.S*M3IWNJ%
M6HYT7HEK3J\]*^EKJ"=OP^IR;C//LD:66YIBL+!:RH1J^UPLM4M<+5]I1=^K
M]G>VB??\=OC#_P $P/VI/A9#<:AI/ARV^)>AVVYFN_!<K7.HQQ*&P\NC3>7>
M*=H 9(?//5@".GS'\$_@CXG^(OQY^'WP?UC0=7TC4=>\265MJUAJMA=Z==VN
MEVTXN-3>:"[ACG5!:0SHSB,H"0I8;@:_JY\+_M=>%[_9;^+?#M[HKMM+7MBP
MU&RW#)),>%NHPN-V%28 9/ R1]$>%[OX;>.I8/&GARV\.ZUJ%DTEK%KT>G6;
MZM8O/&AEMOMCP"]MFDC*;XQ(H<  @XKWH<>9KAZ%2EC\!1G5=.I"CBJ$I4N6
MKR6A*=-JI"2C-J5HRI\UG9+4_4,'XUYM+!U\/C<!A<1BI4*M/#XW#SEA9TJT
MH6IU:M!QK4ZJIR?,U3=&]K:.\EJZ;9Z+X$\(VFGP06^EZ%X7T6&U@BC40VMG
MINEV2I&%&<!8X(0I/=P<#%?@9\7?'=Y\2/B%XG\6W<S217.HW,&GJ7#"/3K2
M1HK18QG"J8P'7UR?2OU\_:Y\2:QHOPDU?3/#=I>WNK^(]FD^5IRO+<PZ?)N-
M[.L$1\UT\E3%(T2N45QN4*<U^/'PO\!ZCX^\?^'?!,-LZR:AJ*1:A%+F&2TL
MK5EDO99HR4EC5(58$$ Y(5@,DC^6?$C%8G&X_*\DH1J3E5JQQ,VXSY:N)Q$W
M2H1<[-2<%SSEO95$VM+G\D^(6,Q6+QN7Y52C5FZS59R:G;$XG$5?8TXJ7_+Q
MP]YR:<K2J.^J:/U"_8@^$:^%/ K^/-4MI(M<\8_O;=9PRR0:/&P-F0A4%/M1
M'GD _=89]!]U* JJHZ* !] ,5EZ/IEOH]A9:99Q+#9Z?96]E;1JH15AMHTAB
M544!5"QQCA>!D@ 5JU^EY1EU+*,MPF745[F%I0IN7_/RI:]2H^[G-R?X'Z%E
M.7TLKR_"X&DE:A32G*UG4K2]ZM5:[U*EY/RLEHD%%%%>D>B%%%% !1110 44
M44 %%(S*H+,0JCDEB  /4D\"LFXU_1+5BEQJVGQ,.JO=0[A^ 8GL?Q!'44 :
M]%8D/B30+AMD.L:?(QZ*+J($_P#?3#UK7CFBF&Z*6.5?[T;JX_-213::W37J
M*Z>S3)*Q/$>KQZ%HNH:I*P46T#LF[H92"(QZG+8Z9/'2MNO&?C7?-!X>L[-"
M1]MO<2 $@&.%"Y!QURQ''3O0M_Q^[4'M\U^+2/F>]NYM0N[F\G8O-=222N3R
M27).!GT' ],#I7T1\'-,T*?2[VXVK<:H7,5R9L,T4+KA4B0Y"JV"68<DXZ<U
M\Y0P37#F."-I9"'DV1J68JH+N0H[*!^&0.]=1X)\33>&=;MKU68VLK>1>Q98
M!HBRKN8#J8B&(!!VD9 [$7YZ7^:_I^H_T_0U?B-X2;PQK+- F=-OR\ULZKA4
M8G+PL<;0<DXYYP>VW/H_P>\7F2,^&;^;+Q(SZ<SX!9 Q9XMQ8#**<@8R0.,G
M->G>)]"LO&?AXQ(RL9H1<V%PH!VNRAD*G&<-P#CO^-?'0;4?#^J*49[>_P!.
MN,9)92)(9"#D#'#@#/(^4D<YIZ/Y[^O?\?S2T%_2?1K1VTV[;7MMU/O:BN9\
M(^(H/$VB6FHQ%1,4$5W$&#-%<Q@"13R3R>03US735(PKP7]HOX6VWQ3^&.NZ
M-Y._5+&%]6T.1 3+'J-G&S1JF%)(F7=&Z_Q @8KWJF."RX !Y&0>A'?U^OUK
MFQ>%HXS#8C"5X*='$TIT:L6D[QJ)Q;5T]8WYHO[,DFK-'/B\+2QN%KX2O'FH
MXBE.E47]V::;7FMT^C2:U/YGI[>>TN&MY$>WN[*:2":-P8Y8+FWF9&5ACY9(
MW3D_WAFOW._99^*"_$SX4:/<W<HEUO0X5T75U9@9I);.,)%<2+D$&XBVL?4@
M^YK\T/VOOAPOP]^+>H7=M&D6D>,D.O62J(PD=S*0E_:@ * XN%$H)&761B"<
MD5ZU^PIK&O\ AOQEJNCZI87EEX9\5Z<7L+N[7[+;W&M69$D4=J+@QFXFN+<2
M(BPJ[,"6X&37XGP?/%Y!Q?7R:<:M2E5J5<#74(N<8JFO:8+$U.16@I15E*>D
M8U7KKK^0\*?7,GXIKY4Z=6HJDJN%Q"I4YU-*?[RCB7&*ERPT4N=KEC3JR;:C
M=KB?^"AWPJ;PWXUTGXH:? ?L'BZ)=-UE8HW*+K-BC&VF.V,HAOK;(.Y@6FB(
M P,U\1^"_A=\1?B%<PV_@[P=KNMB:80FZMM/N!8PDXRTU[(J6R*N06_>D@9P
M#TK^E7Q5X?\ "OB#37B\6Z3I6KZ7IS_VHT6L6T-W:6SV:,_VPQSI(@:W0,V[
M;P,U\5>-?VY_@GX$A?2?!.E3^*KBVWK#'H=E%I6@I(AVE?M4T,*2(#C+VL,@
M[*V>G]69%B<WS&A# Y7E-?,L30C&$ZL':C3@W:DZM22C3IVC[OOU(<RBVFVF
ME_8&!\<5PKPQ@,MQ>$P];%X.G/#T<;C<3*-&6&@U]7C]7HP=>O5HQE&D^6K"
M+C&FM7)GRSX#_P""=?CK6C;W'C[Q/8>&('"NUAIN_4KX)C&Q\J+19 <X)#%2
M.">:^O?#G[)G[-7P8M%USQ0+/4[BTQ(^J^.-74VJNH#,\5A++;V:\EG5/*DZ
M* "W-?#/C[]NWXR>+?,M_#KZ?X&L'1XPNEQF[U (Q."U]=K\KA3QY4:@'D$$
M"ODGQ!XH\2>++I[WQ-KNJZ]=.V]IM5O[F^(;&,HMQ(ZQ@ D!8U55!*J M?=X
M/P\XES"TLXS6AE=&5G+#8!/$5E%V;@YJ4*<79=*M6*>G+NS\?XG^D+Q%FJE1
MH8[%.A+FC['!/^R<.EH^63HKZU7CLDZE1W5U=ZH_8KQ7^VS\!_AY;RZ1X(L?
M^$CEM4$,,7ANQMK+2=X)"1F[,<:8SR2L;DK\PW=3\?>/?V^?BWXE66U\(6>C
M^![*0E3-;Q+JNKLC#! NKI3!;2'.?EMG.0. ",?"Y4'DG.,X4YP,]>,8YZGG
MK2]\]\YSWSZY]:^URSP[X8RYQJ3P3S+$1LW7S&?UB\E;WO86CA]7K[U.36UW
MI;\6Q_&.>X^4W+%/#QF[RCAKPE+6_O5I.55O9?'9[M7N?K5^P-\8_%GC#4_'
M'@[QIX@O]>O42V\0Z5<:G</<7,:R226VHPQO*S-Y1S;R)$@$<9W[50;<_IM7
MX ?L=^*W\+?'SP>[RO';:ZUWX?N<N DBWT):$-SNS'<11$<%6WGNHK]_P<\B
MOQOQ-RNEEO$LIX>E"CA\?@\/B84Z4(TZ49P4L/54(02C&\J2FTDKN=[:GZ!P
M5CJN,R91K3E4JX6O4H2G-N4I0:C5IMREJ])RCK_*%%%%?GA]>%%%% !1110
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MHH **** "O3O@]_R4#1_^N=[_P"DSUYC7IWP>_Y*!H__ %SO?_29Z4MGZ/\
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M[:*V'%S<VX)ZA@]SN.1WW!L8X]>:_LY\"VZ6G@OPE;( $@\-:'$H'&%33;8
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MG\>--THW'BBVDAT#7H+9+6-M1 4P1,&<K::BK2?Z%<V[H9I(9(Y,$A6_9O\
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M667<1X[ SDI2IX6M%33NIP56A*$T^TXI22?O)-75VF?#'['?_!6'4?V@M/\
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M  KGP)Z^)?\ P(MO_D>NGHHOZ?<OZZ?GW8<L>R_K_AOS[LYC_A7/@3U\2_\
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M:>;AK2WT!EA:Z=)+AE-_=',CH=I.3V ^E>IUYI\6_P#CY\,?]@(_^E]S2O\
MU_7H%DFK+H]?2R_K_@L\BHHHH*"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *].^#W_ "4#1_\ KG>_^DSUYC7IWP>_Y*!H_P#USO?_ $F>E+9^
MC_(.L?\ %'_TI'W%1116!T ?\_U['MV[]*_!3]G[]F_]IGXO:/I/@KQ9X:\
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M%]H#ZCI-\LXM[RSU8V+WUBD)DE6U<&8*0V +O\[OU^_?7K^;/DNU_P"">?Q
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M_@K\1_'/BOP)H6D^-M(^(%IK7@V/3;C4DU;2].U+3OL-S!J4<MNUM)%J<Q<
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M,L+==H(P%60R# [D],U:_P""DETK6GPPT\[@S77B"\V\?<%M90+D$_WY,=
M ^#G K[SPRBY<39 EU^LS>ETHO"5Y-679Z7\]EL_YI^EGB:>)\2_$ZJGI'-,
M%@W_ (\)@\KP56/RG0FK];:6N<[^W#I5QJ7PJ^ WBBQ!FTBSTF.QGN$.88I+
M_2-->T:1AD 2FV>,-DD,<8)!%?)'[.?PA\3_ !:^(^BVNB&\L=*T.^LM7UOQ
M';AXHM*MK6:&X413G8WV^8@);PJI;!$C@1DX^U/V8?CC\-_'7PU_X4G\9WTM
MFTE%MM(DUUECL-7TAB6MX4NI&C2&_P!,D=H59I$8P"/:=RL:U?C3^T%\+/@C
MX+O/AI\ (-'&OZHDD%SJ&A1AM/T&.9'62\GU!"XO=4*!4M8%D(C0*[.JH$;]
M6P&99]E6'Q'!>#R;$5,T6*QL,'F<J=\KIY?C,14K_7JM1Z2E2C6F_9KW7-1C
M)N494G_,.*P>5XRM0XCQ.84X8%X?"RQ."4VL9+$X>C3I4\+3BES)3E!7=E)Q
MYG=74H^O?M5^#Y_C1\']6LOA[X@_MS4? ^K/<:II&EW<=P=0N=+A9+W3KR*/
M8S7\"EKF./Y@\H.S>2!7XF:=87-_?VFEP6\S:C<7]K8Q6GE3+<FZGF6!(?(:
M,2^:)3L*%%*L) Q4*6/T-^SC^T+JGP1\;27VH2W6J>%?$5Q'_P )7:;W>65W
M?C641P[27UNSO)(0R^?&-A(  'Z<"7]D-+^/X[)=>"UU"VB;4X[Z*X2.;[68
M]PE_L3[QU=AN11]F63S3G&6$E7@\5F/AW"KDM7+L9G.7XF3KY-C<%0CSO&5:
M<8U<'BX0NH\U=*5.:YI*F_=A):0SQ%#!<75*>8T\9A\OQ%.U''X7%5))?5X3
M;I8C#RE9W5-6E#9N23E%K7XZ_;T9;)_@MX;FD!U/2/ MP=00L"T/G/IT*&3T
MS)9SJH/4(<<5]=?L;ZRF@_LM1Z\Z)+'HLGC'4WCEN(K2)UT^2>Z99;J<K#;1
MD1;7GE(CA4EY"%5B/R;^._Q0N_B_\2O$'C*16BL+B06.BVLKEFM='LV=+6)E
M!98Y)"7N9%&<--@YV@U^J7[,?AF_U_\ 8VO_  YIJQ'4O%.@^/M.TX3R&&!K
MK5K:^L;4S2%6,<)N)%$CA'*J2V&QBO.XPP%;*O#K)L%BM,5'&T*E:"6D*V)C
MC,54IK5_PY590\^6_4[>'<53QW%V8UZ&M#ZO5A2FI*2G2H2H8>,W;^=13>[3
M=O-;-Q_P4 _9>\'^#_AYKWQD^,'PX^%6O?$'P/HGC^Q\+:GXOT_6KF+PYKMU
M-86VM07NBK=07_AU;ZWN+9_$<*II*&"22:XAB4L.T\*?ML?LG>.!\1'\)?'[
MX::[!\*-!F\5?$"[L?$-NUCX<\+6QD%QXGN-0D6.QN_#D#1.LVNZ;<WNE0L-
MLMVC$+7YO>!O^">GQBTSPIK>F>)-)^'NH:G=?\$M=)_9!TZ6?4(]0,/Q5MKO
MQO<7<:75QI&^'PJZZYI1.J1JLDKQONL?W";G?$#_ ()Y_&#6/AMX>\(^&-(^
M'MC?6'_!,/Q-^R5J,45^FGV4WQ3U1?"36<1,&F(LWA?S-(U1GU22+S8VF4BQ
M8W#X_#C]/2C;>ST]$M-[]E?KTW/MMO\ @IC^P.EG?7[?M5_"(6VFW]A87C?\
M)%F6(ZHGF6&HBV%N;F70+B/,@\2PPR>'TC5WEU-%1B/5OB%^V!^S'\*?$'AC
MPO\ $+XV> O"VN>,=.T[6/#]GJ&L(RW6CZO/':Z1K5W=VT=Q9Z3HNK7,T=OI
MFL:M<66FW\S&.UN961@/SP\7_P#!/SX@:S\5/BEXLT[PO\-H]$\5?\$O_P#A
MD?00WV.WGB^+"W6IL ]NFD$6GAE;>YME75XY&E*IY8L\(JGR%?V*_P!K3X<^
M /'OPO\ #WPH^&7Q;3]I']EOX"_ [Q7XUU_X@6VC+\$/%'PQ^'LO@77[R>QU
M#P_?W_C'PFS7S>(]!70)K:^_MBP\N>T@\U+NC^OZ_I#TOUMIU7E?5I;:OSM9
M:GZ9_'#]OW]D_P" =I\0[?QK\9_ Q\:?#CPYJ?B+6OAOI^OV5UXYDCL/#+>+
M+>SAT*%Y+N.;5-'\JXT^>X2*TG$T>)\Y S]!_P""B/[(VJ_![X=_&W4OB_H/
MASP;\2;"UN-&EU2#59+FVU%M)L-6U71[^&QTZ[>"ZT"+4(8M7N&7[!;.';[4
M8P7'R_\ #?\ X)^>,?#>E?M_Z+KR>"-0U;]HKX>_#_X??#+Q]=Q1ZCKDUKX5
M_9MT?X3W-YXD>2R_M'2K=_%5E>WZV4%Y>%[>X>YWF9RM>$^./V?/V^/&?PJ_
M9E\#WOPAMM,\*?#KX1ZQ\&_B/\*/A_\ M*V?P\77?%6F^'=(\+>%OBIJWCS2
MO"$FHZOX!O+/3;RXN? ]C#9ZW;F\MFOH[XH\$1_7SNOPW_X"$DGUOM=W2Z)]
MN^WZ+4^_/''[=O@WPWX_U[PGX:TS1O&/AO3?V7[3]IK1O'UKXUT'3/"?B#0+
M[QQ;^#+/3;76KV0:9;17'VF/4HM6GN19M$R0;A-(HJ?PS_P49_9;UKXI_&_X
M0ZU\0](\&^*?@+?>'K+QF_B*X>UTG&N:5I=_+>6NK>1]A6QTJ]U>RTB]N;J:
MWC-[*&A,EN1-7YE>&?\ @F=^TUI?P'L?AY>)X"BU^V_X)SZ=^R^\$?BN]NK"
M'XEVOQEC\<O"NH3:5'/<>&XO#RB!-9DC,\ES$L3V*AB]?8T?[-7CK3OB;^V=
MX>^)GP]\*ZQ^SE^T[\,=%O=8^)EKXIM4UOPAJ'A3X5V_@G5_#]_X+FT@ZC?R
M336C:_IFN:?JWV>'[)$9H5N5C5CIM;:ZWZ:]>_DUZ!:*5D[V:M;JKQ6E[WW=
MNK/THLOB/X#U+QO?_#;3_%NA7WCW2_#6F>,M3\)VFH07&MZ?X6UJ[NK'2-=O
M;*)FDMM.U.[LKN"PN)MBW3VTQAWK&S#M:_)+_@D3\&/&?AWX):S^T/\ &6_/
MB+XV?M!3Z-%?>)+BUNK6\'P?^%UI/X*^"VB&WOB;FT \,VUQXFOXG"--K'B:
M^FE!8*1^MM GOZ6^^RO;ROH%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <_P"*/^0'>?\ ;'_T?'7B]>T>*/\ D!WG
M_;'_ -'QUXO6L-GZ_HC&?Q/Y?D@HHHJR0HHHH X_XA>---^''@/QE\0=9@N[
MK2?!/AG6O%.IVU@D<E]<6.AZ?<:C<PVB2O%$]S)%;LD*R21HTK(I89KY"_9R
M_;FTSX]^!!\8-=^"7Q-^ OP.N?!*^/=)^,WQCU+X>:+X)U70GE18YEFTOQ;J
M>I:?O@9KO?JME9QK#&<N79 WTA^T!X8USQK\#/C!X/\ #%G_ &AXC\4?#7QI
MH&@V/G6]N+S6-6\/W]EIUJ;BZEAM8?/NYHD$EQ-%"&(\QU3+#^??X ?L5?$/
M1/V(O'O[.'C?_@G9\7=#\9ZS\+?!ND>./$+_ +4'@AK/XIZYX:\46&H2+X L
MIO&'BC1_!6LVFV76M*AO=(L?#MX]DNG:C+#!<-M:5VEYZ[[>6C_KMUX<15Q$
M*T%3BY4_93DTHR:E5BX\D)2C2JM1DF[6Y'>+][H?O/=?M6_LQV7PWLOC%>?M
M!_!NU^%.I:@^D:?\1;CXA^&8O!][JT>?-TNUUPZ@;*>_@Q_I%I%(\\ !,L:_
M*&L:[^U%^S7X8\->&_&7B/X^?"+0?"7C+2]2UOPEXFU;Q]X;L]"\2Z/HWV4:
MOJ6AZI)J'V/5+73'OK.*\DLII_(EN$20+AROX#^%?V,/VX/#I_93^-OQ(_9J
M\&_'2T^!GCWXZ)?_ ++USK7PE\.^+M6\(?$+PU#H7@7QIXMN+*&U^$.O>/M
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MV9-6\9^/K/2'^+4>@^(?B!\1]5U+5/[-O!XI2'2;ZZO-2OK2V2*SMI/O_P"
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M1.HR.AR0:_GLCADGDABC!+3SQ0(  27E8(B@=22S# %?TS_#?11X=\ ^#M#
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M?^#NQHL^S_K_ (=?>%_7[G_77\^S*U>:?%O_ (^?#'_8"/\ Z7W->J>1:?\
M0;T#_P '=C7EWQ>"+=^&1'+#.@T)@);>99X7(O[GF.5 %9>>PZ\9I6?;^OZ:
M^\.J]'^-OZ9X_1110,KW=S%96EU>3EE@M+:>ZF95W,L5O$\LA5!R[!$)"#!<
M_*""<CP+X-_M1_!KX[?"[7_C%X \1S3^!?"UUXBM/$5_J]A/H]UH\GA:(SZL
M]Y87;-<Q0K:J+RV=\_:;>1'BRK+GV_7X9+G0M:MX8VEFN-)U&"&)%+O)+-9S
M1Q(B %G9G90JJ"S$@*"Q%?@W\,?V>_V@O"&B?![X2^'_  )XFTOX9_M8^$/"
M5K^T/=WEC<60^%&N_##Q!)<Z_>:W"\:G3S\4? +V_AL1SJ)+N_M(]WR)\S23
M2UZ^6VFO?^GMJ<>)K5:52GR0<X.G5Y]).TVX*C:VB3FVIM_#&TUI&2?ZE_"3
M]M+X"_&E?"4G@O7]8CA\<:9XZU+PU/K^A7FB6U_'\-KZ*Q\86RSWAVIJ6DF>
M&[DLI&$\FGO]M6,1)(5TK']K3X2ZYI?@O4/##^+/%M_\0K37M7\'>%_#7AJX
MO_%&L^&O#FJ2:1J7BU=(>2W:W\,F^C,-CK%]=VEM?Y06<4TF^OS/\4_LU>/-
M1_8G\1^'](\">-_#_P 2O#/[9/Q*UGP/;^'])N;;Q7:?#SXA?%>Y\*>)KW3X
M!;&ZD\,:Y\,];U)[F>.(VMQ8;+\R 6B2I]AR^#I/V=/VJ=/^(EOX"\2ZK\%/
M$O[-W@[X,:)J/@+PIJOBV[^&>K?#;7M2O[31M4T'P[9ZCXC@T7Q3I6IVTUOJ
MMEI]U:_VII!BU-X)#;SR#M:ZN];6TOIRZM=M7UZ'-3Q&)<8>TA&,;4>>I&$_
M=E5;3T;^&$H<K?-=>T@VE&#O]S>'/$VG>(_#=AXI@CU#2].OK&6^:+Q%9SZ#
MJ-A#;/<+>#5;#4EMWT][-X)Q.9 (Q#$)P[0E9#:A\2>';G3X]7MO$&A7.DRR
M&*'5+?6--GTV:4;LQPWT5R]K+( I+1I*74#+*N#CY\^.WC37-1_9O\2>,?"O
MP<UGX@W^IV%C+;?"[Q9H]Y::I<V%SKMO97%]K?A2RDDU:]MM-TX+XBF\-0'^
MU]6TR*/3GMA=320I^7FF?!?QSXRNO$VE7_PCU-/AQJ?[<_P(\8Z7X?TOX5Z_
M\-/!D_@33?"=O#XL\1:7X U)ENM%\+OJ\<O]LBYMK6"XN,_;;.(S-"!)::K?
M77T\O77;]=ZN*G3E3A"FZKG%7=IQLY*;BY*TN6/N2BU=R4G#FMS1;_<6V\3>
M&[U].BLO$.A7LFL1S2Z/'9ZQIUU)JT5N2+B72T@N9&U&*W(87$EF)D@*D2LF
M#3D\1^'Y;Z/2H=>T2;5)HYY8=-AU?39=1FBM6D2XEBL$NFNY8X&BD6:1(3'$
MZ,DK(ZL%_%X_LW^(?"4OQ%\0>"_@]JFB>(M#_P""B_@GQ)\.K[1O#-Q:7F@_
M"2XU'1/^$ENO!?D6^-$\!75MJ&O-K%KHB6F@W:37;WD#[ \?,?!_PA;>+EFT
MWP)\)_%$'QBL/V^O%7BAOBS#X;O4T_3O &@^,-6G\5WJ?$80M8Z9X=FT=+SP
MY>>"TU.&XU2_U%'_ +#N"QO!2C'35:K:^M_DETT]?D9/&U4U&5)1D^9W;FKQ
MB[/E7)=SOLKI6:<FC].O!7[6'@?QMX7L_'5OH?B/2/ LNE_%;4=2\5ZV=&L-
M,T,?"/Q)J'AC7+;4 VI"]^T:G=Z7=W.D>1!<I)"T4=S+!--$IU/@Q^TCIOQJ
M3PM?Z)X&\3:1X9\9>"+OQ[H?BG4M3\)7FDMI45Y:6]G9WD6D:S=:E9:I?VMR
M-16RN+=/L5NDD6H2VERK0U^9?PP^!/Q$?0? .E>)OA5X@N+2U^$/[?\ I6HZ
M;KGA2>ZMH]4\:?%36-9\"65]9W]I+ UYX@M)+;4- CFB+7B-'<6@9B'.=J'[
M/?Q>L/"WPETOX;?#/6_#&IV?_!,Y?!NLQ:%HI\)D>/9?&7@_5_$O@V[O;&WL
M8[/QQK^D6^J!K>Z=-2NYI':4EG:0))/=[->2>U]=MM[:_<9K%8FT)2BVN2FY
M1C%\TI25.6B:T@HR<9]5*]G=7/VV3QAX1DTZ?6(_%?AF32+2?[)=ZK'K^DOI
MEK=[BGV6XOUO#:0W.\;1!),LI;@(:X+Q+\=?A9X2\??#;X;Z[XMTRR\3_%>V
M\07W@F/[;9M8ZC:>&K.VO]0FEOOM0M;>.Y@NHETMI=ZZC,&@M'>3<H^)?&-_
MX$L_!G@B'X3?LH"W\-:OXDT33?'U_P",?V>/%-UHGA,Z?X3U&\M=5OOA78:/
M9:UXTU..Y@;P[-KBZ/=Z=;WU[%>3ZK=1*EY%\U?!/X+>)]$U/]A+QO\ %'X)
MZG+I7@'QE^TOX:\20ZG\+KK6-4\&V'BAY;CX4)?>'GL=>US2/"]O>02MHMTY
MGTSPP[Q7/VBP<K*HDM-GJNNN_;JG_74UGBZO/"$8)IN'/-*HHQ3JT8RU:7V)
MMQELFG>]F?L-X4^).EZ]X8N?%6O64_P_L;;7M9T%X_&>I:'8;I-,U.ZTZWO4
MO(-4N=.%MJQLYI].C:]^TM  )[:"?Y*ZZ]\2>'--@BN]1\0:%I]I/;I=PW5]
MK&G6=O-:220Q17<4US<Q)+:RRSPQ17*%K>2218TD9R%K\:?A/\+O$GA$?"#5
M?C=\'O&'BKX1:/X\_:U?5_!4WP^U3QK#I?BCQ;\2;[5/ 7B[7/AY;:7JMYJF
MGZOX;&I6OAW6G\/W]MILMXLZRP+="X1?A;^S'XCU?XM_!ZY^)WP@U74?A]I7
MP+_:N_X17P_XRTB37-,\"V7C/XE:/J7PQ\%ZU;W?VW3K?Q#!X<ENIM%T2]\Z
M[TF*3R;2.WN;/]T[1T2O>RW?>UNFMK^01Q=:T4J.LE3WY]')4.9R]VRBO:O9
MW3IS5K+F7[61R1RQI+$ZR1R*'CD1@R.C#*NCC*NCC#(ZDHZD,K%2#3Z^9_V-
M='\6>'OV6?@7H7CFQUG3/%FC_#_2=-UO3?$4=S%K=A<VAGBCM-1BO?\ 2XI[
M>U6WC6.X^>.!8D "! /IBH>GX?BKG?"3G"$VG%RC&3B]X\R3Y7MJKV>BU6RV
M"O3O@]_R4#1_^N=[_P"DSUYC7IWP>_Y*!H__ %SO?_29Z4MGZ/\ (OK'_%'_
M -*1]Q4445@= 4444 %%%% !1110 4444 %%%% !7QU^V)H)NO"OAOQ"B@MI
M&KO9S-MR1!J,+!<GLOFPJ,'C+9[5]BUY%\=?#S>)/A=XKLHT\R>WL?[2MUP"
M?,TYQ<DKD<'RED&1SVKHPLU3Q%*3T7.D[[6>EWZ7N95E>E--)Z=?Z7]=]C\C
M,@]#FBF*0!R&4YR01R,@<' X.<UN:/X=U_Q%<):Z#HNHZK/(<*EG;23Y.,@%
MU011@@'+2R1@=MW('U#<5KS*SLU)Z)IVL_1W5N]UW/'Y7)OE6FFWHM-.W7L8
MWMWZ8]_2COCN<X'?CKQ[8.?3%?3GA3]E7XB:[Y5QK;Z;X8M)"&>.[G-YJ07.
M2!:6R-$C$<@/=#ISP<'Z%TC]G'X2^!K#^U_&-W'J:VB^=<WWB"^@T_28E1<N
M7C>:&,0I@G$DA7;D-NQ7)/&T(24(N56HW90I+G<G=)1CRWO)MV2L[NR6IM'#
M2<>9ODC:_-/1)63N^RM=[^7K^>&FZ1JVM2K:Z-IE_JER_"Q:?;2W4G/JL:E5
M7&<LQ4  G-?IO^S;X<\7>%O <^C^+-,DTJ1=5FNM-BEFC>Y:UNXXI9/-C1W\
M@QS;E6,D-C.5!S7RC\6O^"FO["G[.%G/IEMX]T/Q+K-N6B7PI\*-,C\17[20
MAD\NXO+'[/H]L05*LUUJ@*[6S@C!^(/AK_P7/T3XH?M"_#GX>6?PHD\'?#/Q
M=XFA\.WOBCQ'K<=SX@C?4LVVD7!T[34ETVS0WS0I<HU_=,$DY<,*^DP_ 7'>
M>X"OC<+POCZ.7X>A4Q;Q..C'!2J4Z--U)_5J>*=&KB92C%J$</3J*I+EBFY6
M/'J<5<,9?7IX:KG6#J8FI4A1]EA9/%.,ZLXP7M7AXU8TX)M<\JCCR+FE)Q2;
M/K;_ (*1_L^:?X^/@7XBS^(+;PW;Z!'=Z#K=]+I]SJ5S<6=W,;NSAMK>V15:
M<3>='$;B:*,;R W) ^:/V._^%:? _P"+>BWNC/XEU.[\30GPQJFO:Y?6^GV"
M6][+%)"]KH5C!.C,]RD>UKS4"\0Q@9=L?LO\:?!$7Q-^&/BCPSY4<LE]I4T^
MGL_&S4;:,W%E*IYQB4#!XR#7\_DD-[I%[+"^^UU'2KV2!]I(>WO+&<J64\,K
MQRIO!SCIQWK^8^-L\S;(LURVOA)4J>"KQIU9MT8RJU*F'JQ=>BYS4N15*+IK
M1*5I2DFG[Q]EQEX[^+.3\+97X=8+B)X;@2.%JT7EE# X15<;2ECI8O$X'&YA
M4HU,74PZJ5HNE1IUJ-.-.2BU+EN?TP!E8 JP8$ @@@@@@$$8[$$$'N"#2UX/
M^SE\2K;XH?##0-<68R:I9VL>DZ[&S!GBU.Q1892V"3MG55F0D\ACTQBO>*_2
M\+B:6,PU#%4)*=+$4J=:G).Z<:D5)+U5[2722:>QQX3%4L;A:&+H-2HXBE3K
M4VG>\:D5))]G%MQDGJFFF%%%%=!TF=JVEVNLZ==Z9>()+>[A>)P0#M)'R2+D
M'#(V&4^HKXBUW1+SPWK%SIESE9K.5?)E7<OF1*3Y$Z' /[Q,$E3C)(ZBONZO
M)?BMX/&NZ4-6LH5;5-*1W./E>>S(/G1Y ^9T'SINZ $#H!36NGW>O_!_!V\Q
M._3Y_P"?R[&A\-O%R>)M&6VN2IU'3XU@N48J3+$!L27!)+!@-K$C![\Y%6[;
M0M'\"Q^)/$"R!4NS)=%61%6 !6=8(B!R'E.3GVXX)/RYX3\1W/A;6K?4HMYA
MC/EWMNA/[V$@B1".A;<1LSC!!/!.#T'CGXA7OBR3[- LEGI$>"EL6422R*1B
M28J3D#G"YVD'!'%._7ONK[M6_/>_35>I;IY-)]EIY;]M[VU>YQ.J:A-JNHWN
MH3$M)>7$TYR<;=Y)123G:  J_7ZU]6?"G17TGPO#+,FR?47-VX(Y",,1C) .
MW'*]>/;%?/O@/P==>*M5C#1$:5:/%)>3-PK -GR%/.6<#C'H0>M?94,4<$4<
M$2A(HD6.-%  5$ 50 .. *7YO?[T[_/\O5!N_3?UMI^#_K4DHHHI#"BBB@ H
MHHH **** "BBB@ HHHH *0D#J<4M<WXO\0V'A/PUK/B/4I%CL]&L+B^F+$*"
M(8V*ID_Q2-A$]6(J9SC3C*<VHPA&4YR>T8Q3<F[VT23;(J3C3A.I-J,(1<YR
M>BC"*YI2;[**;^1^9?[?GBSP#XHUKP_\,O%'AO\ X2JTTF&36KR6TUJZTB_T
M2_NXY+>W:TF@2:U>8VQD:2&\MYP04_=X8!OBG]G+]E?X>>./CCX.N?#OBKQ
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M X;V64U\2XV>*Q4FG;>G1A&G'Y<W.^UVUNF%%%%?E1]T%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'F/QA_Y)]K?UL!U(ZW]L.H(/&<CWZYKX=K[B^,7_)/M;_WM/_\
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M["WK][_KI^?=A1111?T^Y?UT_/NPMZ_>_P"NGY]V%=OXJ&-%\"@<#_A''X
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M(M4:1-(NI&"JI-HS.%08_K&^/'PKMOB_\/-3\.NJKJ$2'4=#NP%/E:A;H[Q
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M^GZ'8PZ?IMM';6\2@!4'S.W=Y&ZN['))/K@ #BM.BBD,**** "BBB@ HHHH
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M3](A\4JOAK6]/UVQL8M6OM,O)19376GQ0W,)#%K9Y(X6A)5A^2%O\6?BG<?
M)_V&I_''BA/CQIOB+4/#6I_$(:WJ*>-IOV<M'\,CXGVOQ.C\0QN=374]7\-B
MT\"C5FNENWU/SFC=KE&%4[6X_:!\/?#/]EN3X>>.O%FJ6/[;/PJ\#_!'Q1J&
MO>+]4U'5/AS\0=&LKK4(OB?X>NM5O;FZM;O7/A[!KVF:W_9[6TMQK>FZ-K$E
MP;^1I$I1U>K325M._K;S5].^ASO%T9\T70E-.FE.]D^>4H0=/2[;4Y0BY*UK
MWUY6S]P9O!?A>[U%]9NO"WA^\UIDLDEU6YT+3I]2/]G,KV&^_DMI+PM9&.,V
MKM<%[<PQ&)U,8-//A3PR-:;Q&/#F@'Q"P*-KQT>Q_MDJ4\D_\37R!?DF',1+
M3[BAVY"@(/@'X7>"--^+_P :?VB/ /Q%U?QO?^&?V>;SX:_"_P"&7AF#X@^-
M_#LNGZ$?AUH^KS>/KZ]T37].UCQ!KWB+4;BY5-<U^YU)"VF!%65H[EY/T2L+
M2*QLK&QCGN+J*TMK:TCN+V=[ZZFCBC6!)KVZE\Q[F>949IIY27G<N[D[B2G&
MSMZ:_<F_O[V.JE*-6[=.,5SM)RDG)S4E"5XJ*>DD]7=O1Z7*T'A_1[4:8EOH
MFF6RZ0TLNDQP:99P+IKSI*EQ+IBQ0H+%KE)I8YGM!"TD<LJ.SA^,ZW\$^#;:
M6_DM_"7AJ&;5I8IM5DAT#2(9M2N;>?[1;RWKQ62-=/;W&9X&N/,>.X/GQNDA
M)/\ ._J'QC^+'P@^&'[:6L^)OB)XVU#P#\<_B-^U5X-^'VN:CXEUN:Y^%?Q9
M^'GC/5E\/Z#X?UJ2]^U:!H_B_P +Q21:39V5U;VL.KZ5]FLX8?-.?T^^/_Q@
MT:7]DCXG^&-(\1>++#X@:=\ 8]4EU6QTCQOI-S:SR>'-/GN;ZR\>#2K+2&U+
M;.)A>6.O/?BX9G5C.CE3EVUWMTUN_+K\KO9VLS&GC*52,W[)1=."GRR<4_>Y
MTE=K[2I*2>S4MKJ1]TR>%/#<VM1>(9?#>@R>)((DABUU]'LFUN*- Z11)JAA
M-^B1J\B(JW&45V"%02#)IOACP_H5Q?76BZ!HFCW.JR^?J5QI>D66FRZC<_,3
M+>RVEO!-=OND+$W$DI#L74AV+'\/-%^+GQ1N/V>!^PWJ'CKQ3'\>K'6Y/"MQ
M\0?[8OAXSG_9Q7P7!\5++XG1^(O/;5'U67PO<)X%_MHW<=U_;EG.OVE[L/*M
M.POOV@_#'PJ_9:U#X?>-O%6K6/[:'PP\#? +Q1J?B#Q=K&K7?PZ^(=K#<76G
M?$_0YM7U"YNK2]U+P)9>(['5IK":&:ZU32]-U2ZD>]9IG:@_1=[/5^GX7=B%
MC:>DHT&DHPYVK<T:DN6+IN/>,Y0A*5WI)2U5S]Z/*(W(B$_?)41YPS'+,P08
M.<G<2 TA.YV+9)Y&W^'O@&SU/^V[7P-X/MM:%V]\-6M_#.C0:F+V1Q))=_;X
M[-;PW3N"SW#3F9G=V+[MA3X3^&'@K2OBW\<OVB_AQ\0=:\<:CX7_ &=!\*OA
MK\,?#<?C[QIH,\>CZA\/--\17_Q$U"\T/Q#IFK>(]>US5+B:R&LZU/J%O$=.
M:(0LWF"OT,TRQBT^QL-/@N;JZ@L[6VLXKG4;B2_OYXXHTA@GNKRX#27=PPP]
MQ/,KO*0&F)^9S+6MO/UUTV5M[Z>>FQUPG[364(NTG&/-*+?-&7++3E37O+1W
M=TT]+ZTK'PQX:TS4;[6-,\/Z)IVKZIN_M/5;'2K&TU'4/,D,DQO+R"".XNFE
MDVNQN9)B9%\QMTA+4EYX7\-:AIL>BW_A[0KW1HI5G32;K2-/GTU)DF-PLJ6,
MENUJDBSLTPE$1E\UY)"Y9B:_.WP_^U3\8=3\(?#[XZS#P:_PW^(O[1,GP7L_
MAE::3<'Q)I?AV_\ &NM?#[2_$)\2MJ#?:O$T&H:+)K&I:,-,BTZ/3;GRXBK6
MS2S>[_L?_$OXL?&7P-K'Q&^)6H^%DL[OQCXV\-^&_#WAG1+BQ.GV'A'QAJ^A
M0ZCJ6H75[<27%]J-M9HLUI'!!;6C(&@+F5U4MMKH^O3I?KY[F<*]"<HPC3UF
MG+5+E<+0?,VFVXRC)635V]&DG<^MDB2%5BCC6*-%58XT01HD:J%C1$4!51$"
MJ@4!0H   &*=7P?^QSXYNX?AQ^T-XF\::WKVJ6/AO]JG]H*R6ZO/[<\3WVF:
M#IWC(Q6.F:=8VD6J:HUE8Q&.&RTS3+-TBC!^SVRLSY^R_"?B[0O&^B6WB+PY
M/>W.E7;2K!+J&C:UH-TQA<QR>9IFOZ?I>J08=2!]HLXMP^9<J02-6_'3K\_7
MRN;T:T:D(/2+E&ZBVKZ:/16V?8Z6O3O@]_R4#1_^N=[_ .DSUYC7IWP>_P"2
M@:/_ -<[W_TF>IEL_1_D;=8_XH_^E(^XJ***P.@**** "BBB@ HHHH ****
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MDTXQDJI(^)_AHGAB7QWX9C\<0RS^%;G48K?75@=HIA9W"FW1XI8P-C0R.DI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/=6/>[_@O+S]?Q\CY'\M_P"Z:/+?^Z:^N/[:U+^_!_X!67_QJC^VM2_OP?\
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MC6] ^,V@W7Q0'PP^&]_<S^);O4])\*65Q'K&J6UMI^K7AM3=>7<,D=W+]@^
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MYIOP]\/^(K/084;;-8Z[<:C:WN8-/1E74]2O;NUMX&69I98 OE+]U_"G4_\
M@F/^SO\ #SQ7%H?[:3:I\6/&6GKI7B7XXP)?>(/B7!HPC%NVC>$$ETC5#X;M
M3:JMO%)91-=1JJ?O<QQ;(OA!^TW^Q?\ !CX6?%V\_9D_9P^*7Q*\&0Z1J4WQ
M9^,_C6[M/"=OXFCG$]O-:7?CKQ?J-IK&JZKJI=S::'HT(O+B2>1S:QNYKY?
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MUX;U;3==T>Z:X2UU32;RWO["X>SN9K*Z2&ZMGDAD:VNX)[:8*Y\N:.2-L.C
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MPW"G%&(<LHE)4LJS.JV_[,E-VCA,5+7_ &"4FO9UFO\ 9&W&7^S.]#\BX]X
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M3>$KXB#JPH4*4HRQV?XN;MRX3 TY2=)^[*M62A&TY04OSQ_X*9_MH_\ "_\
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M4ORQ244VI7E9)?%?SZ'Z!@/I(>,659)E>097Q;#+\LR?+<%E. IT,ER'VU+
MY?AJ6#PM/ZQ6RVI7G*GAZ4(NM*;JRDN>4W*[/Z8_"?\ P2I_9WT&:"XUS4/&
M?B]XB&:+4]5AL;64Y!_>0:=;PDC( QYI&,]\$?5W@O\ 98^ _P /A%_PC'PP
M\)64\;(RWUQIT>HW9=<!29KX3.)#M!+@_>.:_@.^)G_!X?\ MS>(HKRW^&?P
M*^ 'P[682):7VHVGBOQCJ%H&_P!7+B[UW3K":6,<X>S,3,!N0J2M?E)\=/\
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M# U$GS8]I<E?$0DEA$W&DWB+RI26MK!:6\-M#%%%#!&L,44:*L<<2 *B(H
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MOYI?U_PXFW>*[WZ=DOZ^\XBBBB@84444 %%%% !1110 4444 %%%% !1110
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M429' Q7T#\/?^"CW[8/P]U*VO1\6=4\8VB.C3Z/XW2'6K.\BYRKRR10W,/\
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MIK7XB?%CQ?:Z3JGB>?*O%<ZIH]WK;&WDN ^R73+.)EV0I&/X:?@[_P %8O\
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M2 ;\#=^B^ 0<^GY\@?RS7XM>(?\ @GA??'_]N']J[QK\<8_B5HG[/_CO1_A
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M:3IOP\\%_M$?"SQCX)U_P'H_P7T.PN_AWX9N-,LI]5U;QG?ZK:_%:Y\2:;:
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M^-'QNUKPYX*T;6?$VEZIJGP$_9[\>:M;+JUYK&IW>MW*L= TB+7)+#0-*O\
M6KC39-:L[*V,L-NPB_2CP9X2T3P%X2\,^"?#=JMGH'A'0-)\-:+:J-H@TS1;
M&#3[-" <;C% )'; 9I)'9N3PEL[[]#"A4K3J>\Y<GL[M3C"ZFVK)2BELE=KJ
MIQV::72T444'8%%%% !1110 5V_BK_D"^!?^Q<?_ -.5Y7$5V_BK_D"^!?\
ML7'_ /3E>4UM+T_5$OXH_P#;WY'$4444B@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O3O@]_R4#1_^N=[_P"DSUYC7IWP>_Y*!H__ %SO?_29
MZ4MGZ/\ (.L?\4?_ $I'W%1116!T!1110 4444 %%%% !1110 4444 %%%%
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MW_R[%I6V5N^M[Z+?;2][+0****H84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!YC\8O^2?:W_O:?\ ^G"VKX=KZ8_:[^(ES\+?@3XK
M\8VG@/QS\29["YT6%/"7PZT677_%5\+K5;6)I;+2X5>2>*U!,]TRJ?*A5G/
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M_P __P#RC7\O^G7I]WEI^A-%?GM_PWCXB_Z,E_;1_P##/ZM_\CT?\-X^(O\
MHR7]M'_PS^K?_(]'L:G\J_\  H_Y^?Y]F']JX#_G_P#^4:_E_P!.O3^D?H31
M7Y[?\-X^(O\ HR7]M'_PS^K?_(]'_#>/B+_HR7]M'_PS^K?_ "/1[*I_*O\
MP*/6WGZ?CV8?VIE__/\ _P#*-?R_Z=>GW>3/T)HK\]O^&\?$7_1DO[:/_AG]
M6_\ D>C_ (;Q\1?]&2_MH_\ AG]6_P#D>CV-3^5?^!1_S\_S[,/[5R__ )__
M /E&OY?].O3[O+3]":*_/;_AO'Q%_P!&2_MH_P#AG]6_^1Z/^&\?$7_1DO[:
M/_AG]6_^1Z/8U/Y5_P"!1_S\_P ^S#^U<!_S_?\ X)K_ /RKS_/LS]":*_/;
M_AO'Q%_T9+^VC_X9_5O_ )'H_P"&\?$7_1DO[:/_ (9_5O\ Y'H]C4_E7_@4
M?\_/\^S#^U<!_P _W_X)K_\ RKS_ #[,_0FNY3_DG$W_ &-Z?^FD5^7O_#>/
MB+_HR7]M'_PS^K?_ "/74)_P4$UP>#Y-(_X8?_;6\Z37EU!9_P#A3NK"W")9
M"V:)G-ON\W=A@NS:5)VL0.6J-35\O1I>]'=Z?S>?R$\TP+<;5V[-?\N:^S:_
MZ=^G])GW#17Y[?\ #>/B(?\ -DO[:'X?!_5B/S^S"C_AO'Q%_P!&2_MH_P#A
MG]6_^1Z7L:G\J_\  H_Y^?Y]F/\ M7 ?\_W_ .":_P#\J\_S[,_0FBOSV_X;
MQ\1?]&2_MH_^&?U;_P"1Z/\ AO'Q%_T9+^VC_P"&?U;_ .1Z/8U/Y5_X%'_/
MS_/LP_M7 ?\ /]_^":__ ,J\_P ^S/T)HK\]O^&\?$7_ $9+^VC_ .&?U;_Y
M'H_X;Q\1?]&2_MH_^&?U;_Y'H]C4_E7_ (%'_/S_ #[,/[5P'_/]_P#@FO\
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MFO\ _*O/\^S/T)HK\]O^&\?$7_1DO[:/_AG]6_\ D>C_ (;Q\1?]&2_MH_\
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M'Y23D'Y?S[^(?[ G[6GPP\V37/A)K>L648)74O"03Q)9NHR=P;33),J@#G?
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MU^/VNP%CV^U>"KHX(]28/PQZXK_.RK_8[_X*;_\ !,+X/_\ !4CX1>"O@_\
M&/QAXU\%Z-X&\:GQSI>I^!FTM=1GU-M*N]):VNO[6M+R!K1H+II&"1K)YL:'
M=C(K\;?#W_!H%_P3GTV6.37OB=^T;XD1""\)\4>&=(CEQG()L_#4DB \?=DS
MZ8K]8G&4I-Z:V^6R_K?1=S_.;D;2UV23O>_Y>??H[V/\U:E )Z?ED9K_ %._
M!O\ P:T?\$B_"IB?4/A7\2?&<L9RS>*/BQXHECFY!Q)!I4FEPXX/"*AP< U]
M\?"7_@C9_P $P/@D+=O ?[%GP.CN[<QLNI^)O"=OXWU-GBP4E>]\8-K<WF9
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M?,XH"ZTUWV\_3N=714:2QR)'(CJT<JJT;@\.KKO0@^C+R/4$8ZBE>1$4LS
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M9)_ST?\ [Z;_ !IE%62/\R3_ )Z/_P!]-_C1YDG_ #T?_OIO\:910 _S)/\
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M_P ]'_[Z;_&F44#'^9)_ST?_ +Z;_&CS)/\ GH__ 'TW^-,HH ?YDG_/1_\
MOIO\:/,D_P">C_\ ?3?XTRB@!_F2?\]'_P"^F_QH\R3_ )Z/_P!]-_C3** '
M^9)_ST?_ +Z;_&CS)/\ GH__ 'TW^-,HH ?YDG_/1_\ OIO\:/,D_P">C_\
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MG3/@-K7A#]IK4=.NY?\ A;&G:I=?%B?]HCQ*/"UI\0SX2A/BVWN+?X92:<?
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M&&E$:"5AQPT@&\C@<$XX%'^7EW_7Y_Y#;[+MOTTMTW5M$K+\B6BBB@04444
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M]8U;P!X0U+5/"/B2_.J>(/#&H7N@V-Q>:!K>I'YK_5=(G=[&_O7 >YN89)G
M=V ]#>VMY=GF6\,GEMOCWQ(VQP<AUW*=K \[A@YYSFIO\^O\Z/\ @?@DOQW!
MN_2VK:^=O+H%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_%'_(#O/\ MC_Z/CKQ>O:/
M%'_(#O/^V/\ Z/CKQ>M8;/U_1&,_B?R_)!1115DA1110 5^#'[2-A\)_B?\
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M'_D.V_\ URG_ /012EL_1_D:1W7JOS/8Z***P-PHHHH **** "BBB@ HHHH
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M\KZ]XD&F#59UFD,B02_V18Z=9^5;@^7"%M$8)PSN?FKTKPC_ ,AVW_ZY3_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7^7E^?=AR1[/[W_GY?GW8?\ "B_!/_44_P# T_\ QNC_ (47X)_ZBG_@:?\
MXW111SR[K[E_EY?GW8<D>S^]_P"?E^?=A_PHOP3_ -13_P #3_\ &Z/^%%^"
M?^HI_P"!I_\ C=%%'/+NON7^7E^?=AR1[/[W_GY?GW8?\*+\$_\ 44_\#3_\
M;H_X47X)_P"HI_X&G_XW111SR[K[E_EY?GW8<D>S^]_Y^7Y]V'_"B_!/_44_
M\#3_ /&Z/^%%^"?^HI_X&G_XW111SR[K[E_EY?GW8<D>S^]_Y^7Y]V'_  HO
MP3_U%/\ P-/_ ,;H_P"%%^"?^HI_X&G_ .-T44<\NZ^Y?Y>7Y]V')'L_O?\
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MV/AS3-/N4N[9)A*BNJF24R+AQ@\,.#@<$$>^:**7,^[_ *_K\^[#EBNGXO\
)S-ZBBBD4?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>ny20077915x1_linechart0x1.jpg
<TEXT>
begin 644 ny20077915x1_linechart0x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M05KBPU*QN%BO=-U.WW!9]/OH8+J!SAHP#EN'^*_[)/[/OQ3^#^K?"3Q%\*/
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MN'XX2>%I95@\8L%+,*4LPK..%ISQM:CA92E7=*%6<E%/351C)R:1\[X;>/>
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M5A,\PN!HSG6Q.35<?1I+'4Z"Y*TER1YZ,XSC&4.9Q]P_X)Z_\% M)_;T\/\
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M"UL!SJ-/6K"%=U7-QA)3BHJ3DTY71?&N1>*&:^*/"?%^4\(9+B\HX*_U@PN
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M7RHUBCCM$*+G<SYKX_\ VJ_^"/G[,_[5WQ;O_C#XFU;Q]X*\5:S9:?:>)8?
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M$FOVQO[,R0S'2M&*S7\\;R+;/'+#(RM RK_7[ ^\2<8"R8!_O QQN&SWSO\
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MDI3G)WE*<G*4GWE*3;;\VV=%.$*4(TZ4(TX05H0IQ4(12V48Q244NR208 Z
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M'%&[G )PO S7Y@77_!8__@GM;R21?\+^!>.1XF*?#OXF2Q%XW:,^7,GA$Q3
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MUO'.R1QM,(I6C&7$;D;6_#+PK_P7=\3>/_ .FVGPS_96\9?$CX\37.MW.O\
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MZI#K<NM2:W#;LS3V-U(]VGEB(6]JHD+;P!]5G^ X-P%*M&C#+I9CEN:X2C'
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M=3?2'CD@U"\,=O9PW2/ 6^0.>6_8M_X)??M*? 3]K*3]IKXO_'KP+\0==N]
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M]2O_ !!=>)9]*O-*7Q1XUO?")BL["/2;N"Z:V2REOBTMU;AG APH96K\@/\
M@J->>!KC_@K#^SS%X,?P_+??VM\$;?QL=":T:9?$4?Q!E*Q:X]F<_P!L+HKZ
M29#<'[8EJ]H'PAC%=9_P6F,5K_P40_9)O[F=+&Q@\-_"LS3W+"*%;>T^+GB&
M:[<RRE0$M(V62X96Q%&RR2%48-7K8;A;AO'XWA25+*7@\/G/#F>YI7P<L5B:
MLI8G"?670HN=2U2$HNG:'*N5PY&VK._SV:>)OB%D^2^)M+%<50Q^8\(>(?!W
M#F"S?"Y;EN&H3RS'UX4\;#ZM[+$TH3Q,(36(J5*]25.HY*E*BDHG[E_\%#_V
MU-8_8?\ @5I'Q@TKP1:>/;K5?&6B>%/['O\ 6Y-$M+==6L=2O&O&NX=/OY6>
M'^SUB6$0X=I<M(@4FM#PK^W9X(@_8F\-_MG_ !8MQX&\-ZKX3M]=O= L;I]8
MN6U6ZO);"Q\/Z&TD5I/JNHZK>K';V">3 S^9OE6.*-W'YX_\' 'B70H?V//A
M_H#ZMIQUC5_BKX9O-)TIKH"]U&ST[0];:YN[>W(222TMDN;8SW2AHHS+&K2C
M<!7P;^V1+KP_X(O_ +#:6+7 \/S^)]-'B#[/O-NTW]B^,)=$6Y*[L(MRDOD[
MVV_:(T(S(L>/G\FX5RS,LAX9JXBA5PN(S+BFI@,1C'.I'VV!5*=14J4)-^\G
M3=-2Y+>T=F]&C[CC3Q1XEX5XT\2Z.$Q%/'Y=POX88'/\OR>I1H.G0SK$8REA
MGC*U:E3CB9T:=/$0K5Z,ZO)*G%."@Y*2^MO^'Y?QLU'1;[XI^&/V'/&^J? B
MPN6\_P =W.IZ^L:Z=#)Y=Q=2:E9>$+SPY;NK8Y&I7%DC$H]YM(EK]*?#7_!0
MWP'\2OV)?'W[8GPGTV?7[3P/X9U[5M5\$ZW=I8:EI7B/0;47-[X9U2YMH[M+
M<8DMY+>\MXYXY[.XANXPRR;5_%K]FS]BO_@HQ\</V4_A[+\,_P!N7P5:?!7Q
MO\/++3;+P/\ :]:N+/2M N=.:QO_  GJL-GX>FCM[[3LW.EZK!%+E)X98Q-(
M(TD;Z5\'_L0^.OV'/^":O[<?A3QSX^\*^-[GQGX6UK6+2+P=%J<>D:0NG>&8
M]*F#MJ45N[WEUY$33+% L<<,<*$L5!KKSO*.#Z#>$P4L!',,/G>#PE/#8/&Y
MCBG7P3KPP]>ECOK6$HQHXF]ZDI4'.$;.$)M6OY'"7%OC!*EB,RSBCQ%6X>QG
M V=9Q7SC/LKX4R^GE.<T,N^NY?5R&.2XS$8C&9?5:Y5',Z$ZJ3C*="*4[9?A
MG_@N]XM^(?@72(_A7^RAXS^)'QA\K6M6\8>%?#%WJ^I>&O"/AVPNGBTS4I]8
MT_P]>:E?2ZG:J+IX/[+M(;8,L9N))'5!]P?\$YO^"HGA7]NN;QAX2U+P7=?#
M;XG^";8:GJ'AR34AJFGZIHDLJV[:EI%W+:V%\QL+J2*UU.TN]/@EM)IK?#2)
M*-OR3_P;Y:3I+?LO?%;6?[-LAJM]\8;ZPN]0%M$+RYL;+P5X1FM+*:X">8]I
M;2WM[-#;,QACEN[B1$#S.S?,O_!,G3-/T?\ X*\_MBZ9IEG%8V-E'\?[6SM;
M<&."V@A^*&E>3!$@)"1JH5508'R@D';6V<9-PW+_ %URS Y(\%B^':='%X?'
M/'XBK.<9UJ,:M&5&:]FXJ-;W97O'DMK>YR\)<:^)-.?@IQ'GG%U/.,O\2,7B
M,JS+(5DN P>&PD8X.I5P^+H8NA3>+J8V3H\]=RG##NI.<*6'IT^51^^_VOO^
M"PFF?!;XU2_L[_ /X1ZW^T!\5=-O4TS7;#2+RXMM.M-7:(2RZ!ID>EZ5K6K:
MUKEHNUKZ*TLDM;/+Q37(FBDAKV/]AW_@H]J7[3>L?%'P+\7?@YXD_9_^(WPF
MT2U\4^)M)\2RSKIB^';NYN;>.[+ZKI^CZG8SVXM)9;N&\T_R1#MFBNWW/''^
M,W_!'JZT-_\ @I=^TJWCQH8?'=Q9_%HZ VL)NU.755^(4$VOM;"[W8U/[,C#
M;&HN#;K=[!Y?F"OWP_;IN]%C_9@_:E@\'-HA^+!^!?BB[N+;3/L)\8MX4CAF
M226X6(#64TX6]Q>B 2!;5;EY#;[6?GR\_P LR/*:V&X<H90Z^)Q.%RJM'B*6
M)KQJPGC/8.O6IX6+>%J89N=6G3]K*,XJ4+J,XV?TO ?%/'/$^69UXFXWBQ4<
MFR[-^*<-3X H91@)8>6!R3#5XX7!/,)-9H\ZKUJ-'$\ZQ"I5(NK3^JQA5C.C
M^>7C'_@MOXG\5_$'Q7X7_9'_ &5_&O[0/AOP;-/!J_BVW;75@N4MSM74;'3?
M#WAW79K;2[HI(]M<:E-!<7, CN([4(XK[-_8!_X*8> _VWKCQ7X,D\*ZG\,O
MB[X$@2[\3> ]8NA=LUGYYLKJ_P!(N7M[*ZFM[#4@MCJ%O?6%E>V,TUN)H2L\
M3M_.I_P2]^!G[9_QF^'OQ(D_98_:Q\-_!'3=(\7O;^)?!MS<:L-:NIKG3+$V
M.OS0Z;HNIL]E=V9%C9W(E \W3W8$#:3^N?[ ?_!,;]H+]G']J[5OVC/C!\<O
M WQ U/7-!\7VOB6V\.IJY\1>)-5\4W%C,^H:Q]LL=/M8[6*>SCN\JCNT\,*>
M3'@,/6XGR#@W*<-G& 5;!87,<OH4/J'L\9F6)S+$8F$(O$0QU&6#6!IQK2:=
M-TL3)4FTI.UV?->&G''C-Q1F7"'$%;"9UC^'.(,;BEGT,1EG"V#X8RW+93J1
MH5LBQ^$Q]3/JV(PLHPC4HYE2C4FE54859+G7[SW$2NLC'>WR*63C8X56RIZ\
M'=R,>@P<U^%/_!.K]JOX6?&7]KS]H#X>^"OV4?A;\&/$'A^V\77>J_$/P<UH
MOB#Q:FB^.FT:Y36Q;Z%8.C:A>O\ VE,$O+A1/N4^8,N/W<E 6)\$G*.3GU"\
M9 X! XK^3K_@BY&I_P""B'[6YYR=)^)\F0S@[F^,*(Q&&& 5XVC"]P,G-?)\
M,86AB>'N-<15EB8U,)EN!E0C2Q%6E2J3J8KD<<32IU(PK4[6E%5(U%%KW8IN
MZ_5/$O.\PRKCGP;P>$JT(X;..*<UPN/4\%@\15G1I92YQ6&Q&)H5:V!GS2?/
M4PDZ-6JKPJ5'"\7]/2_\%V9--^)/QF^%UY^S]XA\0^,O"/CK6_ GPO\ #7@3
M5KG6]2\=:OH'BS7?#=T^IH-&$VD0+!ID5_)'86VL32-*+>&,A1(?3OV6O^"R
MVH?%;]H?2_V</V@/@7J/P%\8^)-270= >YU>\NY(O$<T4LUEH^OZ7J^B:+?Z
M>^I(L<>GW42R03W$B(0L<L<C_GG_ ,$IM&TF_P#^"LO[5,U]IUG>2Z/=_'Z]
MTJ2Z@CG?3KR7XQ+;/=V;2AC;W36UW<P?:(BLPBGEC#A7(/3_ /!2O3K&Q_X+
M%?LQ7%G;1VT][<_ Z6\FA!CDNI8_&4D:23NI#2R+'%&@=R7VQHN<*,?=8KA_
MA6>;/AS#Y,Z5;$<+T<WAF<L97=2ABE@8XAQA04G2=.4DTU*[LW:VB/PO >(?
MBE2X8PW'N(XRABL%@?%2?!M;AJIDF60H8_*JV9JC*>)S*G1CBH8F$*\*5"=&
MG!4Z5*+DJE5RG+^KN+?MSYS,  ,L!DD C/3'.,G'.>2:_&/]KG_@K?IG[(W[
M6>D_ ;QG\.WU#X?GPAIOB77_ !SI^KS2^(+9M5MM:DM[;3?#B:<+>Z8WFF6U
MDCS:G;@_;#*YC6'YOV15V6,H"0HC0@=<''7)R?UK^1C_ (*@3^&(?^"OOP&?
MQJNCGP@LOP$N/%$FOBW.C+HT7C"\-[_:OVL&V_L\P[OM0G!A*#$ORGGX/@;*
M,!G&:8W#YEAJF,H4<FS'&PHTJCI5)5:$*4H\LE*+YU&<G3BF[SM&UFV_W7QR
MXIS_ (2X2RK'\-9G1RG,,7Q=P]E,L9BL-1Q>&IX;'5ZT*WUBE6<5/#\M*]?D
MG2JRII\E:C)^TA]::U_P7>\?^"O$_AS5?B/^QUXZ\#?![QC=M)X7\3:[J>HV
M.OZSX>C=0VL:/9:AX;LM$UBX%NZ7+V%EJSKY1#)>L)(R_P"A?[;W_!1*S_9A
M_9C^&O[2_P -_#&F_%GP[\3M<\,Z?H,<VMRZ-:OIGBC0]0URSU$7$%A?R&6.
M"P:WDM6A4I.Y65XVC93\@?\ !>^]\#K^R%\/+/SM&AUFX^*WAB;P3'"MKYPL
MH]&U:;5YM(58E06,>DE%FDM\P&&2)'8L\*'\]?VJ;/7+7_@AI^QJ?$+SR7G_
M  L&PN--^T8W1Z)-%\49M$ 7RXPJC3OLAAB=/W,2QJH4=?KLLR#AO.:7">:0
MRF67T\7Q-3R3'Y:\7B9QQN%Y*TXUE4J)3A*]*,:DJ;OSN:LTT?E6?\=^(/!F
M.\5N&<7Q6^(Z^2>'F"XQR;//[*RW U\GS#$8RAA*F#=##T9X>IA*DJ[Q&'I8
MJ-7$1PWLJ<JE1MXA_H%\'/\ @MVWQS_:"^$_PD\#_ G5G\*>.=7\)^%O$WC2
M_P!<F1] \0Z]:I)J9L=/@T:2"XTW2KTS6D5Q>7]I+?10B[CAA1TCKOOVCO\
M@LA'X'^-^M_L]_LR_ CQ/^TI\0/"MS-8^*+C19M031K#4K-PNI6%A#H>DZWJ
MNHG326M[V^%K;Z=!>Q26HF>2*39[W_P30^'_ (1\.?\ !/KX.W_A7PIH>FZ]
MKGPTN?%-W>VFFVJ7VJ>*KE-2D&K7=V4:XGU!YA"(IG=GB5$BA\N-%0?S/?\
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MVR+3]J+XV?'GP'X_U>:P\3/XF31$UP^(O$=WK.BKI,4MW]NT_3K-(4?R)9I
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-U;48-)L+C4+A
ME6*VC>0Y/+%48JBC()9SA0!DY.<'&*T2<#/^?7^6:^<_CAXHD2WM?#]K)Y3F
M5;NY9&(=T\MUBA(Q@ ,Q=SGJ$&,$D:4H.I.UKI+FETT32\MVTM._D>=FN/AE
MV!K8J5N:,>6G%_:J2T@OOU=]$D[Z'@7BGQ'=^*-?O-1N795!>**#<62- X\O
M!.#E8U53QRVYL L<X-1)#L=FR<D$$?B#USR1C&<#/6I@,G ZG@=LD]!GH,^_
M?CJ17HPCRIJUM;[WZ(_%:U6IB*M2M4DYU*DG.<GJVY/^DODA*X'XH>%[KQCX
M$\0:%I]Q%:ZFT5GJND3W"&6T75_#^HVFO:6E]#@B:PFOM.@@OHRK VLLIP2
M*X>'XL^+=2@N_$WAWX6ZIXB^'MIJ-[8QZQIVMV(\6:Q:Z9<265_KF@>#9X8F
MU'2EO(+@6<1U>#5]1M8OM-GILH=$.Q=_&;P<UA=,EA\0'=K.XV1#X9>.O-9V
M@?;'Y9T/<)"Y"%>JL<'H2+.5U:$HM2J*,9JWOJ5-2A)6<H2FH\\;/2<+K5-/
M5'*:-XBN/BQXU^%FI&TBT?3O#'@6U^*EY;,5EO;C7_&MGJWA>PTBWE4%8M.T
MFW&MW5U*&WW\DEA$1Y=M+7T3Z^Y)_,Y_/U/<\U\A?#?6O^%?7WA:7Q1H'C.T
MAO?@;X!TR&2Q\&>(]8$.HZ=JVO7%[IU^-*T^[^P:A;P7EK++9W)2=$F4NJD$
M5ZY/\69M4FATSP!X%\8^*-:FW22G7-"U?P)X<TJT1HU>\U;7_$FG0 Y:0"VL
M-(LM6U.Z9)"EH(XI9$"*5:/LTZDE[:;4IQ6M1R48P5J45SM\BBTHPO:[2U9Z
M^S.@#QL4=&1E920058'@CD$@8R.F:^Y?AEXC7Q!X:M"SAKFRC2VN#N)9BJC8
M[$]691SU^O'/YO>"?&=UXFEU[1M>T&7POXL\+W%I#KFBF^AU6R>VU*W:ZTK5
M]&U>WC@BU+2M2BBN!%(]O:75M<6MU;75K#+#AOJ7X#:Q);:W<:;))B*] 5$8
M@9D7>\;!>N?ED0#_ &\Y^4 X5Z?/"ZC>2N[WM:,5?:]G]KS_  /J^%,Q^KYE
M2IJ3]CC&Z,U9IJ<7:/-&24HRC47))-)I\T7:Q]@T445YQ^NA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4@.<]./0Y_/TI:_F&_X.5_VJOVC_P!F7X:_LP_\,^?&'QK\
M(;SQOX]\=6_B+4O NKSZ#J.J6VCZ+H9TVSO+ZTV3R6<,NIW4WV<RK%).8G=7
MDBB*N*<G9*[=M.NK2TU2Z]?S.;%XF.#P]3$3A*<::3<8<MW>2BOB:6[1_3P3
MCGCWR<?T-&>,\=NIP/SQ_2OX6OVGK/\ X+/_ /!.OX"_##]LK6_^"BVH?%;P
MAXKN?!@F\&ZMXBUS6'MI/&6EG6-+L[[PUXVL9--UVW%N3;W_ -@:.Y@;-QA8
MD,M?K9^W5\2M2_;#_P""-OP(^-7Q!_:.T_\ 8AU7XFO\)/&7B/Q?=P^,AH>I
MZUJ.G:O:OX/%OX+M[CQ4-,\0W8/B/2(K.UO(XTTRREN0UO ;A:=*4=W=]8Z)
MIVVO:V^E[V\F<5/-54IU&\+5I5847B/95*E&\J5X^][2%2=..DD[2DGK9J^B
M_HY!R,\?@<C\Z6OB']B_5_"7PK_81^ 6K>)OCUI'Q1\'>%/@WX>O=2_: \0:
ME=Z1HOBK1X+$SCQ9>ZAXKGCOK*RDMV55?6IHKM(HD%RD4I,*>+Z;_P %I/\
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MI;BYOKZ\N(;*UM0YS*DCHLDTD*@2S2J%_I>^ ?\ P4Q_88_:>^(-S\*_@?\
MM&^ O'7Q MQ=-#X9M)]1TV_U5+(2M=2>'QK>GZ;%XACA2&:9FT22_ MXI+@D
M1*6HY96O;\G^7]=SDPV84J]3$4YN%*5'$U,/&,JD>:KR-)3C%M2M+IIT^_[L
MHKY[_:%_:M_9W_92\+6_C/\ :%^+/A#X6:!>3R6VG3^)=1$-[JUQ$ADF@T?2
M;=+C5=6FAC&^6.PL[AHT^=]HQGSC]FC_ (*"_L=_M@W>IZ9^SG\=O!?Q)UO1
MXC<ZCX<L;B\TKQ+!: @->IX>UZSTO6;BP0O&LE];V4MI&\B(\RLP!7*VKVT_
MK7T\]CL=:DJBI.K3527PP<XJ3ZZ1;NS[+HKXM\4?\%#OV-O!/Q@\>_ ;QC\>
MO!'A7XH_#'PO+XS\<^'O$=S?:+#X>\.6]EI^HSW]YKFH6,&@N\=GJEC-]BMM
M2GOF%PBK;F3<B\K\%_\ @J/^P)^T#J?BC1_A7^TY\-]=U/P;I&H>(/$%IJ5_
M=^%7M- TE9)-5UN!_%=GHL>H:5ID,1GU"_T][FWL[=HY[F2**6-V?++^5_=Z
M:>NJT(>)PR=G7HI\SA9U()J4=6FF[II:NZ1]]DX('KG]*,\XXZ9Z\]^@[]*^
M!_@U_P %/_V#OV@OBFWP9^$/[2?P^\9?$?S+N&Q\.V=SJ5F^N3V9F%S!X=U#
M5--L=+\0S1K;RR"+1KV^DDA0RQJT>&/Y3_M[?#[2=;_X*_\ ['_B&[_X*#P?
M!C6;=OAHVC_LQ&V^(T^I>,7@\4:@3#I!\/1MX+AC\?7&-$O'\3W-F2B3Y^U1
MK'&@HR_E>R?:RNKO6U[7V)GB(>S52BX5DYJ*Y*D.65VDTIWY;I.]K]+*[=C^
ME&BOFC]H_P#;"_9J_9&\/67B?]HSXP^#?A;I6J&1-(3Q!J#'6-;D@:-9UT7P
M_80WFN:MY!EC\]K#3YT@#*963=BN=^!/[>'[(W[2W@GQ9\1/@K\=O ?C/PCX
M"L;C4_'&I1ZE)I$W@_3;6">ZGU+Q-INNP:;J6BZ<MM;7$ZWU_:P6TD4,K1R-
ML8!<LGLG]QI[>BI^R=6FJMN9TW4CSI;ZQO=::ZK;7;4^N:SM5U?2]"L9]4UG
M4+'2=,M$,EWJ.IWEM86-I$.LMS=W<D-O!$/XGDD4#MD\5^7]_P#\%LO^"7>F
M^)#X5N/VN_A\^J+>16!GM;/Q3>Z*+F:18T'_  D%IH$^B^3N8;KG[=]G1<L\
MJJ"1Y!_P6^\;^&O'W_!(/]HCQIX"\3:9XD\+^(_#OP]U30/$_AK4X=1TG5M,
MO?B'X3$5WI^I6,K07-O,DA!:.1AC<C!6! ?++^5M]MG?MUM\S&IBZ,:5>I2J
M4ZLJ%.52=.$XN245>TDFW&]K7:1^S>CZWI/B"PM]5T+4].UG2KM&DM-3TF^M
MM1T^Z17,;-;WEI)+;S*'5D+12.H964D$$5JU^+G_  ;ZS/-_P2C_ &:FD9G8
M2_%0;F8LV!\6O&J@98DD *,9)('%?IM\>/VD/@9^S'X+_P"%A?'OXG>%?A=X
M0:]73;?6/%.H+91WVI-#/.FFZ9;JLMYJ=^\-M<3+9V%O<7!BADD$>Q":5G>U
MM=-%KJU>VF]C3#UU6PU'$->S56E3JN,FO<YXJ5F[VTO:]['MM%?F_P#![_@K
MG_P3J^/'CG3/AO\ #+]J+P%K'C'6YXK31=(U*/7O##ZQ>SR>7;V.EW7B;1])
MLKZ]N'XM[6WN7FG)41(Y90?I']HS]KK]F_\ 9+\.6?BO]HCXN^#_ (6Z-J<D
MT6E'Q#J##4M8EME5[E-&T2RBN]9U4VRR1M<?8+&<0+)&TI4.I+<9+H_S7WK3
MU[=2E7H2BYJM3<(MJ4N>/+%K=2E>R:\V?1]%?(O[,_[=W[)_[8D/B*7]F_XS
M^%OB?+X2CMIO$UAI?]I:=JVB6UZTZ6=Y?Z3KEAIFHP65VUM,MO>/;"VE="JR
MDBO#_''_  6"_P"";GPZ\>W'PT\5_M7_  WM/%UEJ!TN^M+&75]:TRPOUG:V
MDM;[Q%HVEWWA^UEAG1H;A9M2002CRIFC?(!RR[>>MD2\5AE&,G7I*,GRQDZD
M5&4M/=BV[2>JT5WY'Z545\M_'+]M7]EK]FWP)X8^)7QJ^-O@/P)X-\;V<.H^
M"M7U/6%F7Q?I\]E;:E%>^&K2PCN]0UNU;3[VTO#-IMI<QK;W-O([*L\6[Q_X
M!_\ !4[]@;]IWQI;_#KX*_M)>!/%GCJ^#'3/"MP=9\-:QK#+&96BT6T\3Z5H
M[:O.(E9S;Z=]IGVJQ$9VMA*+:NE_6^V_7Y@\3AXU/9.M252R?(YQ4K2V=K]>
MA^@E%?(7PO\ V\/V5/C+\=_'O[,_PY^+FA>(OC=\,CKB^-O 45IK=EJFCOX:
MU.'1]?19M2TJST_4#I6HSPP77]G7ET0)4F4- 6E6]\6OVW_V7O@;\9OAK^SW
M\4?BQHGA;XQ?%Z32XOA[X(N+36;S4M??6]8;0=((ETW3;RST^/4-626TMY=3
MN;2)VAGDW^5#(ZOEE>UM;7^7]/[]-RO;T;-^UIV51T6^96552Y'3;O924FE;
M>Y]7T5\K:+^VS^R_X@_:/UG]DC2/B[X;O?VA= L9]0U7X;P_V@=4MH+6RAU*
MZC^V-8KI$UY:V$\-W<Z?;ZA+>V\#[YK= K[?JANA^A_E4[_U_7_ *A4A43<)
M1DDW%\K3M);IVV:["]STX]^?Q]*0G ]?\_CS7\F__!(3]L/]IWXT?\%:/VXO
MA'\4_C7X[\<_#3P@OQ=G\+>"?$&L27GAWPY)H?Q?M=%TC^P]-8>5IL=CI=P]
ME#';E4%OB,@A0:^JO^#C[]I#XZ_LT_LE_"OQ1\!?BGXQ^$_B/7_C5IVA:KKW
M@G59=%U>ZT@>&]>OFT]K^ >>EL]U;V\LD2,JRF)5D#* !:IR;44M6FTKK6U_
M-+=/_@Z7X5F5)X.KC%"7LZ52<&KZM0J*GS+163NGJKKSZ_T.Y//R]@>OKU'3
MM_D=*<>/3\3BOQ=\9_M;_M4?#3_@F1^RK\4/@A\(/$W[4/[2_P 8?A_\)= L
M8&BO=1AM_$_BOP2=1O?'WC:6R$3-IEM>6^Z\EN[S3;.:ZNT^TZC;KN$GXL?\
M$GOVO_\ @H5XW_X+!>,_@%^U[\;O%VO7&D>'OBNGC;X4QZW;W'P\\/\ B?1=
M/L[JVM-#T736.CV<>B2*8+4V.0IWN99C*\CCA)?9]=5;MO?KKMV=NPJF8PI5
M<+2=*K+ZU4IPC./*HT_:QO#FYFG+L^12\]#^TFBBOF;]H_\ ;'_9F_9&T*P\
M1?M&?&'P?\+;#5FE71X->OG?6=:^SLJW#Z-X?T^&\US5(K<NHGFL=/GB@W()
MGC+ 5*3>B5SOJ5*=*+G5G&G".\YR48KIJVTD?3-%?'OP$_;Y_9%_:>\)>-O'
M'P+^-WA/Q_X=^'%A/JGCFXL/[2L;WPQIMO:W%[)?:KI.K6%AJL%I]FM+F1+A
M;-XI/)=(V:0;:\;D_P""O?\ P3DA^%UO\9)_VI_AW!X!O/$5]X4LKZ5M:36;
MW7=-CL9KZTM/"CZ0OBBXAMH-2LII+^+2&T\1W",;G.X*^679[V_K[R/K.'48
MR=>BHSBYPDZD%&<5:[@[VDE=7Y;VNKGZ345\W?!_]J?X&_M,_"C6OBK^SM\3
MO"OQ/\*V>GZHIU;PY?>>VFZI:Z>]VEAK&FW,5OJ6D7P1HIOL>IV=M.T3JXC9
M&#5_$S^P)>?\%<O^"F7C[]H?3_A=_P %'/B/\,F^$&JVE]<6WBKQEXU^P7Z>
M)]:\10:?8Z3;^'8YH+*VL1HSQO%)#'#%#+"MK"\<;!:A3YK\TN1+JU?56;6^
MFCO?Y;G)B<QA0EAX4J4\5/%<[I0HRAK&"C*4N:3C&UI+[5_(_OV)QZ?B<?XT
M9XSQT]>/SQT]\5_(S_P2(_X*$_MPZ%_P4%^)7_!-K]LOQXOQJO\ PN?'6C6/
MC&YEMM6UK0/%?P];[3>O'XG@M;2]UWPUK^FDO'_;?GWUI=);B.2V$EQ;'\R_
M^"@?_!2W_@HA\)O^"E7[5$OPM^/OQ+A^&/[.WQAA>/X9VNLW'_" V?@W2=3T
M;2H--U+PW&@LKG2-3N+F.UU::Y'[R2]+O,CN'52A*+Y;7>KT:U5DT]^J=U\[
MV.2>>X:GAHXITJ_*\3'"U(<J4J4VUS-W^)13O>+DGLG?1?Z#0.1V_ Y'YX'\
MJ3</7GVR?UQS7X?_ +>/[;&J>//^",7C7]L7]FOQUK'@G6O%7P[\!>(?#OBC
MPKJ7V+7_  MJ^I^,?#VC^)='AOH%,EGJ.DWKZIH=^4"2+Y<RH5\Q6K\_?'_[
M8O[3VB?\&Y'P[_:2T[XT>-XOCSKT^FZ1JGQ<.KS?\)[-:R_&CQ!HCSKKW%RM
MY)HVFVVFR72@3/:>8NX,^X)0DVE;5[;:NZ5M]]4=E;,:-%U+J<XT\'/&N4;/
MFHP<5*R=O>M--)V;Z(_K"W#OD>Q!S3@0>17\(OPX\"_\%M=?_81T_P#X*-^
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MMO"_AG3#I&F:@\8,=SIT=YK#:C/8SD03RVD,DJE8:^__ -LC_@C;^P)\,O\
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M."<XZ.3O[LN9W_('XD_#+PC_ ,%!/^#CCQM\$?VFWO\ Q9\)OAKIFI:?X=\
MR:M?Z?I-WIW@;P+INLV?AV,03V\T-GK&LZC?:MKD&FM;W&IYN$-P(S(4_;;X
MJ_L*?\$\/^"=OPE_;"_:4L?A[KG@[X8>.?V?+_P#\6/A1X4UZ[7P_KNA3W"6
M%O!X6@NY)M5T7Q!KUY?6FD"X@UF*Q@:9;D6L<F]CX3_P4D_X(G_%?X]?M2Z)
M^W)^Q+\=[#X"?M%6T&D'Q"-8DUK3=,U/6M#M&TNR\4Z3K^@6^HW>F:A<:,MM
MI6LZ7=Z'J>E:O#;>?.B37%R);OP4_P"".O[4'Q \!_M0I_P40_;"U/XY>/\
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M'!IVF7ET]P<^#/&?B#PWHUW+]V(WHTFXDM[B=8PTH"Y)&17Y;_\ !+WX"?\
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M=K7ABXT+QQID$:F./;XA/F>:9POW-\5AG_@U:^$0#==<T?IC!W?'WQ> #R<
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M^E>/?&'XNZ!\'/"TWB'7I!/<R.\.EZ; 0+F_N""5C12&(BB!WW$VTK%&&8]
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M\9->U"2?1-3L_#NE^:S6MC9V<$S)#N8QF2XN8YGED9"H<E44G)"C->H?"/\
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MTH)P,_RI?UW'=?TGY?YK^DSY<_:G_8U_9Y_;0\)Z!X&_:-\ 0?$7PIX:U_\
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MRI/:WEE>0I/;7-O-&622*:)T=&4D%6%7\#.<#.<YQSG&,_7''TXH[>3O^?\
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MH"0N5X/6^!_A)X"^'<,J>$_"VD:/+,3YMU!&T]],H&U!-?W*R7#D#@MD;<G
M.:_R4X=_97>(3XKA2XG\0.$*/!=+&QE4QV3K.<5Q#C\NA5C*5*.6XO*\!@<O
MQE>DG!SEFF,I8>;=2*Q"AR2_K+&_2KR6.5-Y9PYFKSJ6'Y(4\=6PG]G4Z[27
MM*M>C-XFK"F_?C&G1INI\,I0^)8GP.^&A^%_PV\.>%B\+W]M;-=ZI-&6VRZI
M>-YUR5..8XR[0QDY^1$'(YKV*%&CB1&()4')7..I/&>>].C!5$5@ 0H! .X
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MCPK\,M+\0Z=>^*(;W7M5U>[F:5!83M;ZM;C^SH(8;9+5BSU^?/\ P08G\_\
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M8S7FK:OIGB[PS#<16L[1P:C?66@II]G=,UO-<^;'*$_;;_@CI^V=^U;^W1\
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M22BTTTVWBK0VN)3&#Y,1O=;L;=I9"J*9PH)D:-&^<?@_^T/\&?VM/^"'>O\
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M2Q+P=)X6MB(U8N*E5J4Y12A>2LHQNY-7O+LEJ?5OPG_X*?\ @W_@IA_P2_\
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M4PSP>([34+33=*;6H[:[FT2X?PU>:;<1Q_N+O40JO+^?_P#P4I^%GC/X-?\
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M\6/AKX!T/X7_  XM[R6RCU&:R\(^'8=0UG5KNVMKRYBTRRN+ZSM(K:TMWO\
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MQ/HNJ^'=?T^VU71-;T^[TO5=.O(DFM;VPO8'M[JVGBD#(\<L,CHP((P:UJ*
M/SJ_93U75?@'\5/&7[%GB^^N;K1M%M+GQ_\ L[:WJ,DDDFL?"Z^O&_M#P>+E
MQMN+_P !:C,]G'%N\U-':URA2-7K]%:^$/V[_!VL6?@CPI^T3X&M2_Q$_9I\
M1P_$.Q\B,FXUCP2ICMOB%X:D,;+)+;W_ (;:ZO!$0Z>;8#Y"SU]C>!_%^C^/
M_!_AGQOX>N8[O0O%F@Z3XATFYC=9%EL=7L8+Z [U.TLJ3B-P.5DC=3R" !_7
M]?U^3.IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O/?BO\*_ 7QN^'7B_X3_%#PY:>+?A_X[T:Y\/^
M*_#E[->6]MJ^DW>WS[22XT^XL[Z#>55EFM+NVN(W4/',C &O0J*!2BI1<9*\
M9)II[-/=,_,KQ%_P1T_X)L^*_!?@;P!KW[)_P_N_#GPXMKNR\(""_P#%VG:W
M86E[J$VJW-K=^*=-\1V?B?6K1[^XGN4M=>U?58(7D;R(XU.VOL3PK^S9\"O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB^*HM/CN8=(ET2[O6,WVV4&=5@M9(%AW0$B1ESXQXKTG]F[]E>/X/?##Q/\
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M[N3X"%"KC:2Q5:..Q.%K?5*494*E/DJ8>2CFU1U(X&+<I0CAJR;KS<(K\O\
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M=1+("""8?^"C#?\ #17_  4 _P""<'[&L2&\T#1?&FO_ +6'Q2LP))(5\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT7_@CQ_P3,T#RQ8?L<?!UQ'C:-1T&YU<G V_.VJWEXSY7@[RV<D]>:]:T?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^4OP<$O_ $IATOIHTMNC3_R7],_9&BBB@04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%+4O^0=?_P#7E=?^B)*_'O\ X(%_\HM_@)_V-?Q__P#6@_B=7[":E_R#K_\
MZ\KK_P!$25^/?_! O_E%O\!/^QK^/_\ ZT'\3J?3Y2_.F/H_5?E(_9&BBBD(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCU1G\4KX6L+5=.\!ZA>Z?&FKW-S;Q6>=12V81(X$NTAE)D;/8?L<6]S\-_\
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M<6ECI]YX?U$*A^T75N+RSO;NP2X@FNX[B,?E_7]?/T8+=>NNES^>'X<> _\
M@HYX/UK_ (*V_!+P]_P4;^*GCSXX?LFR_LI_'?P9\4_B7']I\-Z@[_#[Q_\
M$[QU\-X_",E_>Z!X6\$>,$:#1[N"QMX[>:+3-,FN[%(X]L7]*G["G[0NH_M7
M_L>_LZ_M%:SI4.B:Y\6OA=X<\4Z_I=JLB6=IX@E@:RUU;!97DE&G2:O9WDVG
M"5WD^PR6_F,SY)_C/^/?P,\??LY_&/7-._;*_P""Z/PY\-?#'_@H=X4^&5[X
MW\1_"SX3:[>?%OXU_!CP9I$GA'P3J^N:IX=\/7.@>"O"NM^'-5O-'U#Q)'XF
M:SUP7$U[<Q:XEK>2P?W$? ;P#\-_A9\%/A3\.?@^+/\ X59X*\ >%O#OP^DL
M+N/4+2Y\):;H]I;Z)>Q:A$S1:A]OL5BO7OXV9;V2=[H$B6I7STOHW?=W75]/
MO^13M9::Z:^7*OEKOWVN>LT4451(4444 %%4=0U/3=(M+C4-5U"QTRPM(_.N
M[[4+N"RM+6')'FW%S<R10P1Y!'F2NJY!&<U5T3Q#H'B6QCU/PYKFCZ_ILK,D
M6H:+J=EJMC(Z8WHEW8SSP,Z;EW*LA9<C(&10!L45SLOC#PE!K</AF?Q1X=A\
M27"A[?P_+K>FQZW.I4,&ATI[D7\BE65@4@8%2&'!S71 @]#GZ4 4M2_Y!U__
M ->5U_Z(DK\>_P#@@7_RBW^ G_8U_'__ -:#^)U?L)J7_(.O_P#KRNO_ $1)
M7X]_\$"_^46_P$_[&OX__P#K0?Q.I]/E+\Z8^C]5^4C]D:***0@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MPYURRLJ=.#NKNWO1>EWH%%%%>T>:%%%% !1110 4444 %%%% !1110 4444
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M@>,]/\26VB7FFZS#&46SM]4TZX$EGJ%Q;O\ IS7XF_\ !>7QSXL\-?L=> ?
MNC?$G5O@SX(_:"_:G^ _[/\ \;_BUH=ZVDZIX"^"GQ$UK4(O'.K0Z^)85\/P
M75OIUMI-]J4[K:FPO[RPN]]KJ,T;G]=O\OS0>A\,^$O#?_!>.^U"S^'F@_\
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M*6B@!-HSG SZ]^,C^1QGTXI:** *6I?\@Z__ .O*Z_\ 1$E?CW_P0+_Y1;_
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M;#^^O-1O;>)!M,CQ_C9_P1Y_;=_:A^.7A[_@I1\0?VU7E\.ZU\!?C]J\5O\
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MK5(TZ=-+364Y);K?=;F]JVIVFE6=U?7\L%M9V=K-=SW,\JQQ0PP1O)+([,
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M'!X2D[N=6KS6<82:_'N6"2P$<5Y!-9R=6CGC=),.Q82%" P5@<J2/G4!E)#
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M(!@ >@ _*EK_ $2C%1BHQ248I1BELHK2*^221_&EV]9.\GK)]V]6_O"BBBF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]S>3!9SR6UM"@RQCCB@155.-N2< GCRF*5HXII$'ERJ %W#RV.%( ))&XGH
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M&\>E:HSW%YJ<\>G:5X;TN(ZK>2,9AM4PQW'+?LB_M\_$?XA_&KXT_LG?M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)QBTU3<8\W]%OG1?\]8^.3\Z]!U/7M7\LND^/;3XDVM]XXLM3&JQ:S-?S37
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MDM;7G=V35[K3LM3^B?<N"=RX'4Y&!QGDY].?IS3J_#/]@?Q]\5_!W[8_QO\
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M4L## 83!_6J4L/7Q-:G.KBOK-:KAISHQ2=.-.,YR]Y22C]GXB_2 SKCC(_[
MPV34,AP6)E"693CCJF,Q&,C"S^K4YPIX94*/-[U1N-252T4I1L^;\KO^(N[_
M ()_?]$0_:M_\(WP-_\ -_7C/Q6_X.??^"8'Q=M[./QA^S-^U=JFHZ8[2Z/X
M@TWPUX/T7Q)H%P4"B?2?$&E_$>TU.P9P/F6WNDAD*J)HI % _K@_X5=\,_\
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M +*4>J:8VK^"/@=X<\">"_A'XLNK1F%O#^T!XE^&]R?B#;>$YYTA?5K<0_\
M")RRR>;?7^EC$\?JPRK%3A[2$.6,H1J48UYTZ5>K&5I0]G1G*-:LIPNU5HTI
M4Y;Q:<E$_.\=Q+PK0Q>)I_VO]7P^&K.&)JU,)F%>AEW,Y)T<;F6!RR63X>M1
MTC55?$X)4VXRG1HP:2_"K1O^"S'[>GP+^(G[4D/[#TGPJTO]GWXR_M1?&KXW
M^"9O'7@*+5]<2W\>^(VEM[^TCGU&&"SL;^RL;#4K:Q-O)%%+<39W-))7LWP
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MV-?Q_P#_ %H/XG5^PFI?\@Z__P"O*Z_]$25^/?\ P0+_ .46_P !/^QK^/\
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M?"5O?/\ M&? CQ+L\O69?V>[CPYXZTWX;WUM;N]R?"MAX^-W<W%G>,HCL_\
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M+M]3T_Q!::[9,8_&OA'QKITBZSX6\=1JH\060<2I#<6<\"?I77Y(:6=+N_\
M@MGXGE^'_E/-I/[ &B67[0TNEDFVBU^^^,=Y>?!:S\2M%_HY\1+X=7QA=:7#
M.3J,6@3QRE4LKFW:;];ZXZM6I7J3JUJDZM6I)RG4F^:4I-W;;W;;U?G?T7-"
ME2H0C2HTH4:4(I0ITURPBGK:*;;W>KE*3;NVW<****S+&L-RE<9R,?\ U_PZ
MU^7G_!6W6M&\'?L:^,O%_GZHOQ%\.>,OA?J?[/MGH-I%?ZWJW[0\?C?28OA'
MH5A9SNB7$6M^)Y+;3=;0 F+PW<ZS<J"8L']1:_+S_@K9X+\9:W^S+X2^)_@?
MPQJ/CC5/V6OVB_@3^U5JG@C1XDN-9\5^#_@UXN&J^-]-T:U=A]JU2V\)WVLZ
MU8VL:RW%Y<:0EG;0274]NKU"I.E)5*<G&<7>,DD[;7]UIIWLMTUT:DM'UX#&
MXG+L;A,?@ZKHXG"5Z=>A42C+EJ0>G-"<90J0DG*$Z<XRA4C)PG%Q;B_)OA9_
MP3*\2_%S3HOBW^WW\=OB[\6/CSXMTZ.75O"OP\^(OBWX2?!7X3Q75O&6\&?#
MGPEX$U;1)+R+23*UK<>*/$-]JFJZY>PMJ<C1/*=WQ[^UC^S3\3?V+;OX,>'_
M /AH'XD?$;_@FG\3/VE?@[HOQQ\$_$V<^.OB)\#;Z\\<Z9=>!;CPK\2;Z9/$
M-Y\'?%7Q"@\,^&?&VE^(&U2Y\.V]]'?V-W(M_>RQ?T*?!_XM?#WXZ_#3P;\6
MOA5XITGQEX!\=:%8:]X<\0:-=QW=I>65[;I*(Y"AWVU]:NS6NH:?<I%>:?>P
MSV=Y!!<PRQ)^:'_!7'QAIWQ"^%W@#]A'P2+;Q+\?/VO_ (G_  U\.^&/"EE-
M'-J/A3X<^!_B!X;^('Q1^+WB*.+S+G0_"G@KPKX9O=FL30^7>:]>Z9I%J3-=
M/)#Q8? 9=A,?6S7"Y?E^'S/$14:N84<#A*>+JQNG:I75!SGS-7;;O=MJSU.[
M"\09Y@ZN!J4,TQ:67XF&+P="=657!X7%4W4=*O0P51SPE&5*56<X<E%.,G>,
MHM)K]<8(42&-% VJB*N"2-B_= Z=N!Z# '2K'7K5:S@^RVMO:@EA;006X=CN
M9Q#$B!F/7)QSD D\XYJS76>-Y]6VWTNWJV518V8F>Y6UMUN' 5KA8(O.('0&
M0H6(]LXZGK5JBB@ K\X_VB?V^=1\%?%JY_9D_9<^!WBC]J[]IK3=.TW5_&7A
M/P_K%CX.^''P=T;7+=[G0]6^,/Q1UFWN-%\,SZO$JW.D^&+.'4?$VJ69-U!I
MZ0M"TWZ-L2%)4;F )"DX!.. 3@XR>,X..N#7Y%_\$4]-TS6/V,D^-VHE-4^,
M'[0OQ@^-WQ(^.WBRZC8:]KGQ#B^*WB_PP^FZLTY:YM8?!^CZ'IOA;2-')BM=
M+T[38A9VEM'<,K+R\OU6RZ[_ "ZC7??I]]_\NZ,S5O\ @H-^UQ^S:;7Q3^WG
M^Q$OPW^!\\ZPZ]\<?V>/B<OQ[\/?#"%SM76/B;X4M_#FA>,-*\,(V6O_ !)I
M.G:I8:3#B:^1$)(_6WPWXCT+Q?H&B^*O#&JV&O>&_$>EV&MZ#K>E74-[INK:
M1JEK%>Z=J-A=P.\5S:7EI-%<V\T;%)(94=3SQ/K>B:3XDT?5/#^O:?::OHFM
MZ?>:3J^E7\"7-CJ6F:C;R6E]8WEM*K17%K=VLLMO/#(K))%(Z,"K$'\M_P#@
MCI(^F_LM>/?AYIFJW6M_#OX,_M8_M2_!_P"#FHW5Q/=JOPJ\$_%O7;/PSHEC
M>7#2276E>$)YM3\':3(LLD<5AH$%FKM]DS1Y?Y=+?U_2%T5DDUVO:WS>GEZ^
M6O6?\%8/AUX^\9?LK6WC;X8^&I_&WC']G7XQ_"']I:T\#V:F34/&.C_!OQ=:
M>)O%7A_2;?[MWK-SX8CU>?1[-E<W>I6UM;0HUQ+$*^S?@)\>_A9^TQ\*_!_Q
ME^#GBO3/%_@7QII%MJFFZCI]Q')-9RRQHUYHVL6@;[1I.NZ1<,]AJ^D7T<%]
MI]]!-;W,$;J-WL+J'4JP5@1@AE#*0>H(/!!'!K\S_B!_P2H_9U\1>/\ Q/\
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MI_"MA\?)M%*F00OX;7PU-X/L_$DL>)$T:Y\2JL;N+66Z$P+5L^*=)TOXB_\
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MC?J=7SQ^T)^S)\'_ -I71-'T3XJ>#[?7FT&^DU'P[KUE=ZCH7B[PMJ+1"/\
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MT?0/ Z:U;L"+'5]1\,Z#8:O?Z?E9+2;4&BF19E<#3\+_ /!./]F[P]XI\/\
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MKD+%):WZW^G1V$KLUQ810,#]G?'K4?'/[+W_  4&\&_M5_$CX?ZWK_PV\6^
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M_L:^&?"/B;26U>S%AK_AZ]U72?'0EU;P?XELPMOX@\+ZDMSH^IK;VDEQ;--
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M/^&7/^"T_P#TE2^"/_B"/@?_ .;BOV<HHMZ_>_ZZ?GW87]/N7]=/S[L_&/\
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M_&/_ (9<_P""T_\ TE2^"/\ X@CX'_\ FXH_X9<_X+3_ /25+X(_^((^!_\
MYN*_9RBBWK][_KI^?=A?T^Y?UT_/NS\8_P#AES_@M/\ ])4O@C_X@CX'_P#F
MXH_X9<_X+3_])4O@C_X@CX'_ /FXK]G**+>OWO\ KI^?=A?T^Y?UT_/NS\8_
M^&7/^"T__25+X(_^((^!_P#YN*/^&7/^"T__ $E2^"/_ (@CX'_^;BOV<HHM
MZ_>_ZZ?GW87]/N7]=/S[L_&/_AES_@M/_P!)4O@C_P"((^!__FXK0TG]F'_@
MLI!JNF3ZS_P5%^"FI:1!J%E-JFG1?L->"K.:_P!/BN8I+RRBNXO''F6LEW;K
M);K<)\\!D\U"'1:_8RBBWK][_KI^?=BO_5E_EY?U=C4!5$5B"RJH8@;02  2
M%R< GD#)P.,TZBBF C8(.>G'\^/UK\V?VX/V-_'G[2_Q)_9]\:^$/$7AC1=.
M^$WB$:IKUOKS:D+J]M6UO0=4 TM;&QO(99@FDR1>3<O;(6E1O. P*_2>BFO2
M_P#2V[>OF95:4:T>2?PW4K6^U%\T7\FD[=2I;6T$0$B001RNH\R2.)$=SC!+
M,H#-DC/S$\8&.*GDBBF7;+''*O7;(BNN?7# C]*DHI7>]]>YHE9)=DD1Q0Q0
MKLABCB3.=L2+&N?7:H S^%(L$".\B0Q+(_WY%C17?_?8*&;\2:EHH&5TL[2*
M0S1VMM'*WWI4@B20_5U4,?Q-2R11RKLEC25"02DB*ZDCH=K C([<4^B@++L1
MQPQ0@K#%'$I.2(T5 3ZD* "?>D6"%9&F6&)97X>58T$C#T9P S?B34M% K+[
MMOZ^1$L$"2-,L,2RO]^58T$C?[SA0S?B34M%% RJ;*R,GG&TM3+_ ,]3;Q&3
MU^_LW=?>I?(@\WSS#$9@ HE\M/, '&!)MWXQQC=C'0=:EHH%9?UY?\,B(P0&
M43&&(S 8$QC0R@8Q@2%=X&..#TXIDEI:2N)9;6WDD'222&-W'T=E+#\#5BBB
M[[CLNW]?TE]PQXXY$,<D:/&1@HZJR$>A5@5(]L4WR(/*$'DQ>0%"B'RT\H*.
M HCQL"@= !@>E2T4 0FVMS$L!MX3"F D)BC,2@= L>W8N.V ,=J='#%"NV&*
M.)2<E8T6-<^N% &??%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %6[6\:/%E);12\_-<PR3(/3Y(
MIH3ZYRWX<<\5J-G\3SN.DZ]X(0_PIJ'AG6Y!W^]+;^*(SZ#(B]3CM7?T4 >&
MWD?[2,;YL;OX,W,0'(GLO&5M*Y'H%O9HX\]1EY,=#GK7(:CK'[7%HS?8O"7P
MDU51D@V^I:M;LW)P +W5+89P!@L5'(SCG'U#10!\4:G\1OVR=-7(^#'A&^(P
M6_L_4([D8QD[0GBK>2.PV\],YKAK_P#:"_:ZTU2UU\ 80!DXAT7Q!=G ZD?8
M]5N%8#N59AZ$Y%?HA1@#H.O)]SZT ?EQ>_MC_M&::2-0^"L-DJYS)=>'/%4"
M<>\M^A'XJ,]NU<M/^W]\6[9F6X^'WAN%E.&$FG^(%((]0=3X_&OUN*JWWE5N
MHY /!ZCD=^]4+G1])O%9;O2].NE;[RW-C;3JW^\)8F!_$&@%YZGY*?\ #P[X
MF<#_ (0KPAN.<)]GUK?QG.5_M;*XP3\V,CD9J,_\%$_B0I ;P;X/4G@9@UD
MG." ?[7QP<YR0/TK]0[[X6?#34\_;_ '@ZZ)_BE\.:2S@]RLGV0.A/<JP)YS
MG)KB=1_9I^!.J'-W\,_#8;LUK!/8.#[/8W%NX_!AP2.G%'3S&FENK_.WR_KS
MUV/SQ/\ P45^(PSGP?X-R.WE:N3^FL8_6F?\/&/B-_T)O@__ +\ZO_\ +BOM
MC4_V+?V?]21D'A6_L<Y_X\=?U:,<G/*S7,ZD#L&4CVKB+_\ 8!^"=T#]CN?%
M>G$\?N]2L[D#KT\_3BV?JS=.<YH&G'JG]][[>GG^/E;Y>_X>,?$;_H3?!_\
MWYU?_P"7%'_#QCXC?]";X/\ ^_.K_P#RXKVF_P#^"<W@AU?^S/'OB&W8Y*"]
MTW3;I5]%+0?9&('&3]X\\C.:X2__ .";^HC>VF_$K3Y#R8X[S0KB#UPK/#>W
M&,G@MM8<YV'&& O#JI?GV_K[WZ<C_P /&/B-_P!";X/_ ._.K_\ RXH_X>,?
M$;_H3?!__?G5_P#Y<57O?^"=_P 48-WV'Q-X-O4YV[I=0MY>>.?-T]H\@=@X
M!/\ $,DUPFH_L)?'FR9A;:5HNJ(IX:SUJPC+CCD)>RVQ'T!!]!FC^OZ_K4:Y
M/-?TNW?7\=M#T/\ X>,?$;_H3?!__?G5_P#Y<4?\/&/B-_T)O@__ +\ZO_\
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M/[_Z_IORM^BG_#QCXC?]";X/_P"_.K__ "XH_P"'C'Q&_P"A-\'_ /?G5_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M")3X6^(I+^;5?#MUK&M7TEQ+J4UO/=2#5+K4)]3BD\ZUMY8'AO(_LTD,9A
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *88T889$8>A4$?D13Z* ,:[\.^'[\$7VAZ1>!OO"ZTVSGSZY\
MV%LYSSGK7):A\(/A9JJLNH?#WPA<!OO9T'3HV.<YRT4$;<Y.>>:]&HH Y;PE
MX(\)>!+"?2_!^@:=X>TZYNWOI[/38?(@DNY$CC><IN8!V2*-?EPH"C '.>IH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>ny20077915x1_linechart0x2.jpg
<TEXT>
begin 644 ny20077915x1_linechart0x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*B2+')_:6L1[T#@[7"#:&&& Z$5]]?\ !R.JCX<?LS/M7S5\;>/$#[1O"_\
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M ,'%0>W\<_LYQS+F?_A -?BG)^9A,9M,$IW9.2) 03DY);'6OZ"O#%E9P_\
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M!S+%8.A.LH)1E6]C1C[2=KSE>4FVVPHHHKXP_9PHHHH **** "BBB@ HHHH
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M:2"]UZ]U'46^VZWJ+":2*T,\,26BHLD:>9M,?[VF-&QD=/0D?G@C/XT[:O'
M^7IQT^E>OC?$#B/'4<93G5P="IF%*-#'8G"8.AA<7BJ<;<RK8FE!5:CK6_?.
M3O4^TWU^:RCP'\/\GS'+<?3P^;XZCDN(>+R7*,USO'YCDF48CG]I"KE^5XBI
M+#X>5*6M)>^H.S2NC\)/^"N7_!-7XX?MO>*/A;XA^#NN>![ >$-(UW2-7MO&
ME[J-D@CU*2VEMYK%].TZ_,KQO"=Z3"-0/NL<MG]3-$^$6OZ=^RWIOP5N[VRD
M\2V7P;M? #WT;R#3%U:#PK%H?GQR&-)?L*W",X<Q+*(&.4# 5]($9XI,#&.W
M3J?\_P"/>O&J\19E7R_*<LFZ'U7):U3$8)*DN>-2I-5)>T;TG!R2]VR32LU8
M^PP/ '#F79_Q1Q-A*&(IYKQAAZ&&SNK]:J.G6I8:C["DZ5)OEI5%3TYX^\GJ
MFC\#?^"2?_!-/X^?L0?%3XN^,?BYK7@+4=+\;^$M$\/:.GA#4]1O[C[5IVO3
M:G-=7:ZAIUEY*2P&*()'),<[N1A37[YTW8N<X&<@Y''(Z=/_ -1[TZN?.<YQ
MV?8^IF683A/%584J<I4Z:IPY:,%3@E".BM&*6AV<&<'9+P'D&&X:X?IUZ658
M.KBJU"&)KO$58SQF(J8JLG5E&+E'VM63BFKI.U^K****\H^I"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?7FIZE:1-9^383B0A_*:%_-5XOL7]F7P+X0^//\ P6Z_;YUSXW^&]'\<:_\
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MDE,DD<(8A5'Z@_!S_@F=^VY\</VB/A-^T#_P5&_:=\&?&/0_V>/$0\:_!;X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!DZ]H
M>E>)M$U;P[KME#J6BZ[IUYI&K:?<+N@O=.U"WDM;RUF7C=%/;RR1.,C*L>:Y
M#X4?"?X>_ _X?^&_A;\+/#&G>#O 7A&T>Q\.^&]*C,5AIEM+/-<R10(Q9@'N
M+B:5B6)+R,2>:]%HH **** "BBB@ HHHH **** "BBB@ KYX\4?LG?LZ>-?C
MEX2_:3\6?"3P=X@^-_@33#I'A'XAZKI<5YKN@V>Z1HQI\TP=()X/.F%O<J@G
M@$L@B==[9^AZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5+RZ6!<C=*8A&,C+#(KU6OX9_P#@ES^R!\-?V$?^#BWXW_LR_"/4_$^K> O
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MR["/5H;VUO=+N[>[FM[VTN(I(W#L\:(+/LS])**^!O@A_P %"_AC\9_C39_
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M.*\L?$9\'1R+#I<?B32;>9=0TJU9%^U,D]O&K2SJ*_3RBC^NX7_3\$E_6Q^
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MD$YPN3CC&>@SS1UM_P ,&Z3UL_+T_P T2457DN!&Q! V@?>)(&<]S@J!^/\
M(U@:SXR\,^'X?M.M:]HVEP!PADO]3L[-0S XRUS-$H!P>Y/&<54(3J-*$93;
MV48N3Z=$F^J,ZE6E1BYUJM.E!*[G5G"G"*75RFXI+S;L?-W[=?QA\8? 3]E7
MXO\ Q7\!264/BWPCX;DO]$GU"V%Y:079ECB6:6U9E6<1ARPC=MC$ ,"N0?Y"
MK3_@N3^WU]IM!-XL\#3V[RVTTR-X'TY?-&])&BXE_=JYRI9 ' .Y2&&X?U0?
MM>^./V>/V@?@5\2_@3/^T#\.?#>H>,]&DTA[VV\2:-K-YI4Q99(WN--M+J:4
M@O&$*,$<@D(=^*_F@;_@D]\)]-O[)1^U#XB\0A)X(3#X0^!OCO6I9@FT,\%S
M;:5/:I&W/EW,D@MSC)<<L/V'@!\+X?+,72XBP%*IC98JI.@\1E>)Q-1T'A&H
M*%2GAZG*OK"BXQYDU*\DDN9G\>^/F(\2\?Q5D53PYXCE1RBAEL89C2RWBO)\
MOIK&_7IRG*OA:^94*M?_ &7E3:HU8N*<$G.Z/[./A[K5WXC\"^"_$%^8S>ZY
MX8T'5KOREVQ?:=0TJ&ZG\M<G;'YDC;!DX7 R<9KM*^&/!W[4>AZ)X5\.>&_#
M_P +/C3XE3PWH>DZ&+P> ]3TLW,NG6,-A$Q754M&+7!0,7C#Q(6PSK@@:=U^
MU'\7%<-IG[&OQQU2S*,WVH:K\.=.)(.%1;?4_%EM<$MP06C48/3<0*_,L1E6
M-C6JR^K^RA*K4=-5*E&DN1R]VRJ5(V7*UV2UO9G].X;BC)UAL.I8NOB:JPU%
MU7A,!F./;J*E"-1R>#PE>\G44G;=Z-*SC?[38X!/IZU$9& X4$YP0<KQ[9ZF
MOCB/]H;X[WB*8_V2/'UI'.F]4O\ Q?X%2>$;2P%R+?6IHU=<?,L;R#L&.<U_
M*_\ M;?\%7?V\O O[2/QM\&:3X]'@72O"/C6^T33_!\.EZ1?_P!B6<,%NUO9
MR7XBG%U-Y<BS2W",REY"JY !/M\/\$9OQ)B*V&P=7!4I4*<*M2<L32KVC.<8
M1M2PTZM65Y-1;4&HW5VM&_B>/_&KA7P\RW YIFV#S_%4,?C*F!HPP^48K"5%
M5A0^L.4WFT,OIJ/)>W+*3EK9/EER_P!M!D/' ';G/7/<CH/PXI0S=S'CV8_X
M5_/O_P $L_VO?VZ?VC?@[XL\3:II_@+XIG1_&-SIMMK?BC6I_"FI1H((I'LA
M;:7IEY#-! ^?)E<1N2[#8P Q^E\OBC]O21V>U^&?[.,-NQ/EQ7WQ \<M=(O3
M$QM?"DD!;WC8K7GYGPWB\JQ^(R_%8O+H5\+-0J*6/PE)R;49)\E:K"I"\7K&
M45)=>B/H.&?$3*>*LBRWB#+LLXC6"S2@L3AU4R+,:DE3<Y0_B8:A7P]1<T)-
M2IU9QDK.+::/MLM@$_+P/[W_ -:HQ+GTZXSAL5\2'Q'^WW@_\6W_ &9AQU_X
M3[Q_Q[\^$0./<@5\E_M5_MV_M _L=Z)X<UOXY:+\ /#EIXMU&72]"70?$/CW
M7KZ\N+>(S3$V[>&[>..WA3!DF,A(9E 4'D9X3A['9AB:.#P57 8K$UY<E*C0
MQ^%JU)RM=Q4856[VO9NRZNR.S-^.LER++\5FN;4<ZP&78*G[7%8O$Y'FE*A1
MAS1CS5*E7#02NW96NW?:[2/V3!./FP/0Y&#^M.K\D/V5?^"NG[-_[1'B[X>_
M!V'6-0C^+GC2*>WCM;30]5B\,W.LV5C=ZC=VNF:E?012-$+*RN)8S<)'N,94
M') /ZWUQ9CE689376'S'"5\)6E%RC"O!P<XQG*FY1W4HJ<)1NFU==K'I<-<5
M</<7Y<LTX;S;!9Q@>=4IXC UXUH4JSIPJNA5Y7>G6C"I"4Z4TIPYES)!TKXA
M_;7_ &V/#O[%?@'PAXY\1> _$WQ!?QO\0-/^'NA>'O"4UA%JEQJNI6%YJ%L2
M^I3009=+,PI&I=WF=55#UK[>K\(O^"Y^J:?X=^#W[,.MZO<K9Z3HO[67@/7=
M3OG5W%O9Z7I>N7=W<F*-6=E@A@>=D4$N/W9Q]ZN[AC X;,\_RS 8R%2IAL36
MJ0JTZ4E"I.,</6J)1FY047S0B[\T>U[-GC^)>>X[AK@;B+/,MQ-+!X[+L'2K
M8?%5J-+$4Z,YXW"T'.5"M.E2JKEK.+C.I%*_,KM(]ALO^"MN@>'/%?@W0/C]
M^S+\=?V<M%\>:K;Z%X?\<?$33M*E\*2ZO>%!96MU?Z3=W!M//,L8WSHB1[LN
MRK\U?K?:WT%Y:VUY:S13VUU#%/%-&V4ECE0.DD;#(9&5@5;)!4@\CFOYN?\
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MUMJ=SX4T=([..<^!K.YC>WM->U.YN_WE]<$QPHF54N *]:_9I\5?M&_L[_\
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MJVG&TE$-S,MHDBRWUI;RE4FOM/%U9Q,Z*\X++GZAK^+GX!?"C]FOX)_MJ_\
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M "C^R#^RE\5_BK^Q1^V/\*;OP_XV^'_PK^+E]XB3]F7P/\5[FZN/$?A;1+B
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M' 90-RYR1DL1GTR#Q4E-"@%B  6P6/<D<<_AT]*=7S>G3^F]_P 3]%NWOO\
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MMM)))MMNUEHNMT)M)-MI**;;>B26K;>R26K;T18EG\M@@7>S*6502"<=OND
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJFGQ7,%A8P7L_P!JO(;.VBN[K:%^TW,<*)//M& OG2AY-H  W8JW3)"BBB@
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M\1B%;ZQ5J*,5#.72=.S\VGV)"G*$6D *].F(@1R >&Y/)K1554!5   P !@
M#@ #T X'MQ2T5S.4I?%*3MM=M[[[GK*$(MN,(Q;T?+&,;I;+1(****DH****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5GO%7E;ZGOO^"A7QTA30AIO_  3N_:>U ZIYJ3-CPO;FPEMXA*ZW0DNR520
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^1?V]/A9\7?C;^Q[^T)\*?@-XH'@_P"+?CCX;:_H7@K6_MDFG&+5;NV(%F-3
MB*S:6VIPB;3EU*$B2S:Y$ZD%"1_$]\%/V$?V_9=4\0_L[>#_ /@GI\4?V>[7
MQ9\:OV8/B1;_ !V\4?&&ZO- ^$?B[X(6]_IGQ!^)C^(!?_:O%R_$.WU'4;N+
M3D"0Q+/%"B7'EH5_=#]OW2?VEOVS_P#@IEI_[$'PX_:H^)?[+7PH^%7[*5W^
MT)K&H_"DQV_B'Q=XXN/$,ND:&-0OE:*4Z5ITC6ZS6,UPMO<0K,JQ"XD5A^;G
M[$6M?\%9_P#@M1X7^'7A'QS\:=2^!/['?[/'B8^"/BQ\8/"]P--^)7[3?CGX
M=>((VO;93IQL[BU5H(K6#4)+62TTJV)9KU-2OI,&7OL^R=O2]NV^KT^](I.V
M[LG9V];6ON]>VCMIUU_M@TN.6'3-.BGN_P"T)XK"TCFO\ ?;94MXUDN\#('V
MEPTV!Q\_'%7JHZ780Z5IFG:7;M*\&FV-I80O.YDF>*S@CMXWFD;F25DC#2.>
M7<ECR:O51(4444 %%%% '\BGP1_Y6N?VI/\ LW[P[_ZK[PE7]==?R*?!'_E:
MY_:D_P"S?O#O_JOO"5?UUU,?M?XG^@WM'T_5A1115""BBB@ HHHH **** "B
MBB@ HHHH 1E5@590RL""K $$'J"#D$'N#7$R?#/X<S/+)+X"\&RR3/(\SR>&
M=%=Y7E),CR,UD6=I"27+$EB23DFNWHH I:?IVGZ3:16&EV-GIMC;@K!9V%M#
M:6L*DY(BM[=(XHP3R0B 9J6[M+6_MIK.^MH+RTN(VBN+6ZACGMYXF&&CFAE5
MHY$8<,CJ5(X(JQ10!\Z>(?V9?A_=7\_B'P1)K'PK\6RA#_;_ ( O3I!E$1W1
MV]UI3+-H\]HS#;-"+*)GC9D$J @C^9C_ (*[?##]H'4/VB/#,>N:!KOQ,>T\
M!V4%CXK\$^!-9FM;RP6_N_*BU6'38;ZVM=4A9@DZ+.?-7;/A/,VK_7E32B,<
MLJL1P"5!('IR*F<5-6;:5T]/+U)E'G5FW;3MI;U3^X_EK_X(.Z#KVC?M ?'B
M'6M"U;1KBS^&VA6MW!JFEW>G7%I<MXBD9;:YBNHDDMYV0%A!+MD*C?LQS7]2
MW].M>*^/?@3X.\:7H\06#ZCX'\;PL\MGXW\&7']C:VER45%EU%85^PZ[&BJH
M6VUNUOX !A44G-<#'\1_BA\'W2S^,VE?\)=X+0B.#XL>#M-F+:="/N/XV\,1
M/<75@L<"-)>:Y8;M/,I/^B0C II6279)>MM!K1)=K+IZ>2_K1'U116/H7B#1
M/$^EVFM>'M4LM9TJ^C66UO\ 3KB.ZMID8 C$D18*P##<C[70Y#JI!QL4QA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?B?^V_\ \$A?$W[5G[45O^U7\+_VT?C5^ROX];X7VOPHU8?"NTTS
M.L>&K6^EO_L]W>W,\$[037$I>2U821%XXY 0RU\@_L^?\&]OQ>_9CM-)\/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JI?W]EI=E=ZEJ5W;6&GV-O+=7M[>3Q6UI:6T"&2:XN;B9DBAABC5
MGDDD=4102Q %<S\0O%X\ > _&7CDZ%KGBC_A#_#&N^)?^$:\,VGV_P 1Z_\
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MJ(&IV]I'?PF6S@4Q7";%P,G^[BE'9OHY.WX?Y@^GI^K"BBBJ$%%%% !1110
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M;VCZ?JPHHHJA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?S'?\%W_!/C+Q-\6?@3>>&_"?B3Q!;6W@
MGQ!;W-QHNB:CJD%O,VLPR)%/-9V\D<4KKEEC=P[*"P7 S7SE_P $>?A3XG7]
MKF+_ (3?X;ZRGA]O .O"Y/BGPI=C2C)^\,(?^T[3[()M^#&6RV-P09-?U[7%
MG:78475K;7(0DH+B"*8*3U*B16VD]\8IL%C96KF2VL[6W=EV,\%O#$Y3(.PM
M&BDKE5.TG&5!QP*S=-.?/?JGRVT=DEO=?E^>D<GO*3>R2V[)+]$>!:_^RI\"
M/$-]_:D_@6UTS4UW&&]\/W^J:!) [$G?%#I5[:V@(;! :W91@#;@ 5S,G[+M
MQ97"S>%OCQ\<O"]O$I\C1[7Q597^BH^<AGM=2TJYN'' 5E%XJE<C:"<U]6T5
MH6?DC_P4 ^'OQT\/?LC_ !DEO_CA8>(_"-OX8E75M(UWP-:2:OJ5B\\0>"/6
MK6]B6UN"3E+AK)U4+M(7=N'\;5M#9A[(I;KD36;HSHA/#QNNYR@QP &D&2O+
M*#@9_P!'S7M T3Q1I%]H'B/2K#6]$U.!K;4-*U.UBO+&\MWQNBN+:=7CE0X!
MPRGD CFO&T_99_9PC*LOP0^&09&#*3X0T8D%3N7K:G[IQC.<  5G*GS3C/FM
M;ETM>]GYM6T'=I6M?YVZK7;6UG^2/&?AKXW_ &M;;P)X)63X(?#.ZTQ/"/AV
M.RFL/BI?/>S0C1[,6\MQ;W7A6VBA+QE'E6.:<(V]06VY/>-\9?C=IO&L?LX>
M([QE^1SX8\0Z-J:-)QDQM=RV ,.#Q(3DX/R \5]06\$-K!#;6\44%O;Q1P00
M0HL4,,,2".***-<+''&BJB(H"JH    %2UK?^M/+R\OZUNCY.N/VCOB%8[5N
MOV5?CG<L^2IT>W\(WZ*!GB5I/$EJ48D<#!'()(&2/XP/VV/$]YX@_:Y_:%UJ
M]TG7/#-UJOQ(UBYF\.^(9XX]<T-IK2W?[#JD-K=W-I#/#NP5M;B: (RE'(8@
M?WX5\W>*_P!D']FCQQX@U;Q5XK^#/@?6_$6NW+7NKZO>Z/"]Y?W;JJ-<W,@Q
MYDS*BAG8%FVC<32#^OZUZ'XO_P#!&'XV:/\ #OX">.M*U/0?&VOO/XZFO$F\
M.Z+=:S90*T"0^4TB2E8YW8;W0 $H$9CP /V,_P"&KO"G_0@_%?\ \(J\'ZF4
M ?B0/4U[%\./A-\./A%HT_A_X:^#]#\':/<WLNHW%AHEE':0S7LP427$@09>
M0A54%B<  "O0Z/E</P_I>7K\O,^6#^V!\)XF$5[:>/;"Z&!-:7'@+Q,9H')^
MY(8;"6(G&"#'(ZD$$$U^%W_!;CXT^!/BAX+^#<'APZ\C:9XBU22YEUOPYK6A
M6X$MIM1(IM2L[>.64D$E$8L ,D8K^GBN6\4^!_!GCBVM[/QGX3\.>*[6TE,]
MK;^(M%T[68;:8J5,L$>H6]PD4A4E2Z!6(X)Q3ONK+56?X?Y?BP]?\_\ +S_I
MZ?Q&?\$M'M9?V]OV>_)99637];<^6=^W'A;6XP6.  !YN[)Y^7CJ:_N<KS;0
M?@W\)/"VJ0:WX:^&/@'0-9M=PM=5T?PEH6FZC;;U*OY%[:6,5Q#N4E6\N1<@
MD'(->DUE3AR)J][N^UOU9,8\J:O>[O\ @EW?8*_&W_@N]_RCT^(7_8S>#?\
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M^;]7K2K_ -G^R<<''DQTZJLZ=[W6'CI[W[R/-)JUE:T7>YY__P $2["SUO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ[K^O^'7WG545RO_  G7@C_H<?"O_A0Z1_\ )E'_  G7@C_H<?"O_A0Z1_\
M)E 77=?U_P .OO.JHKE?^$Z\$?\ 0X^%?_"ATC_Y,H_X3KP1_P!#CX5_\*'2
M/_DR@+KNOZ_X=?>=517*_P#"=>"/^AQ\*_\ A0Z1_P#)E'_"=>"/^AQ\*_\
MA0Z1_P#)E 77=?U_PZ^\ZJBN5_X3KP1_T./A7_PH=(_^3*/^$Z\$?]#CX5_\
M*'2/_DR@+KNOZ_X=?>=517*_\)UX(_Z''PK_ .%#I'_R91_PG7@C_H<?"O\
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M-4M5E>!KG3KRWO;<31$"2(S6TDL8DC) =-VY21N J_0,**** "BBB@ HHHH
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MTMX0_;"_:0\3^(_A?H-OK&G:)KFOM%I6H--J%I8F&Z>UNQ.JA;EWW1G)V@<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)V=M+V:V;.IHHHK(ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***8Y507=]B@9+%@J@#N2
M< ?B: 'T5R6I^// ^AASK/C/PKI2Q@L[:GXBT>P"*.I<W=Y#M [D\#UKYJ\>
M?\% OV(_AB)V\>_M3?!/PW]E+B=;SQ]HDLD9CW;P8K&ZN9"5V/D!2?E( /%-
M1DW9)M]DFW]R(<XQ^*48KNY)=N[]?N\S["HK\=/'G_!>S_@E=X%25E_:D\-^
M,I(6*M!X"TO7?$LK,,Y$36]A%%(PQC EVDX]0:^.O%O_  =%?L ::;BW\!^#
M/VB/B'>0NZ0_9OALVBV%R5Z-%>WVHLWEMU#M;@ <G&"*KV=3^5_KKY&,\7AJ
M:;G7IKE=FN>+:V6J3;2UW:2/Z4**_D)\5?\ !U%<SS3V_P -/V"OB-JT1WK:
M:QXJ^(.C:-:GC*22Z?!HEQ<$9SN5;L8XZYKY=\7_ /!RA_P40\022CX;_LW_
M +/W@NUD?$;>--2\4:[>6T9X +6.J:9;R2@YY>!4X&%/-:QPU>2NJ<K=-'KK
M:RLGJ<=3.\LI)N>+I*UK^]&^MK:7OU[=S^YB@D#DG ]37^>+XS_X+5_\%?/'
MTDAM/C?\-?A3'*3\G@?P'H^HK"&PV(GUVTU25=IR@+F0L.1C&:^8/&7[9?\
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MQA_P<U?MF^($9?A_^Q_\// )92L,WBWQG?>)&4EOEEE2VM],!"J0658QD]&
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M\ZKFN8U7[^,K3TM>4W%I=DHNUE=M-ZW;^?!Z=\,? &E-_H/A+1;=>/NVBL<
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MN]S^\/QS_P '$/\ P2R\#R2P-\<=<\57"%@D?@[P%XDUV.5E.W;'<PV<=O\
M,?NLT@4^OK\C>-O^#I3]D+2A*/AS\#OC]\3&7=Y)@T.R\-I.<_*JG5)'9"PX
M4,@Y&#]X$_R16?A_0M/399:-I=LF -L=C; 848'6(] *U41(P!''%'CIY<4:
M$8Z8**"".Q'/ ]*U_LN/_/SMM?ROK]_^9Y]3CJM+2G@X0]Z_,ZCDW%;)Q:LK
MK>SW[IG]$7C#_@Z4^).J"9?A5^P[JFGD\6[_ !%\8QJ5W$[6GCT>&$],%E3
M4L "0"3\O>+?^#B__@IOXI5H?#OPC_9\^&L3[Q'=P/K7B&[2-P?+>1-3O)H=
MZ*0Y41J"W&".#^/VU222,DDDG)R2>23SU)Y-+M'3''ID_P"3]:V66T$DG*;=
MDF[1U?5]_/IVVN<%7C/,YW]G&E2]ZZ?*YOEZ*S:6UM==>FK/MSQ3_P %>?\
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M>@ 7C^M.HJ^6/\L?N7^7DCE=2<GS2G.3[N3;^]NX#C[I*YZ[3LS[G;C)]S2
M8).22>I8ELXZ?>)]:6BJ3:5D[+LMN_YDW;=VW?O=W[?D-"A<XSSZDG^9-/!(
MZ4E%.[[O[PYI+:4E\V*6)ZFDHHI">KN]7W>K[;[[:!1110 4444 %%%% !11
M10 4444 %*O4?4?SI*5>H^H_G05#XX_XH_FCQ[XY_P#(D)_V-G@__P!/MO7^
MK/\ #'_DG'@'_L3/"_\ Z8["O\ICXY_\B0G_ &-G@_\ ]/MO7^K/\,?^2<>
M?^Q,\+_^F.PKP<S_ (M/_KVC]0X)_P"1=+_L(K?FCN:***\T^V"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBM73_AQ?Z7C^S_V,OCQ;8QC9\#_%C'(8,.9-)?N!]1D'()!_UF/(@_YXQ?\
M?M/\*;]EM_\ GA%_WPO^%:1Q=6.RI_*FO)?S+I>V_;O?AGPSAJEKXO&V73ZS
M5:^S_>79V_X+/\I*"R^(-KCR/V5OVB;?: JFV^!7B6-L#.,E=*4GZG)/<\"M
M#[1\4\;?^&:OVGMO]T?!CQ>%'T4:> /PXYZ5_JN_9;?_ )X1?]\+_A1]EM_^
M>$7_ 'PO^%5]>Q&FL5M]B/3E_O:]?N\]>5\&Y<]ZE=[;U)/:W=^7]7T_RH?M
M'Q2[_LT_M.'Z_!7Q8?YZ::03?%$=/V:?VG?_  R_BW_Y75_JO_9;?_GA%_WP
MO^%'V6W_ .>$7_?"_P"%4LQQ>G[Q].G^'^_Z_=YN\K@K*EUJ:VOKOM_E_73_
M "HOM'Q2_P"C:?VG/_#+^+O_ )7TOVKXJ=OV:OVG?_#+>+/_ )75_JN?9;?_
M )X1?]\+_A1]EM_^>$7_ 'PO^%2L=B%M)*]KV@O[M_M:]?N\W=K@S+([3K*]
MKVFUV[-=G_3T_P J$W'Q3//_  S5^T[_ .&6\6__ "NH\_XI_P#1M7[3O_AE
M_%O_ ,KJ_P!5[[+;_P#/"+_OA?\ "C[+;_\ /"+_ +X7_"G]?Q7\_;[*_N_W
M_7[O-W/]2\L_FJ_^!/R_X/\ 6W^5#Y_Q3_Z-J_:=_P##+^+?_E=1Y_Q3_P"C
M:OVG?_#+^+?_ )75_JO?9;?_ )X1?]\+_A1]EM_^>$7_ 'PO^%'U_%?S]OLK
M^[_?]?N\W<_U+RS^:K_X%Z?\'^MO\J'S_BG_ -&U?M._^&7\6_\ RNH\_P"*
M?_1M7[3O_AE_%O\ \KJ_U7OLMO\ \\(O^^%_PH^RV_\ SPB_[X7_  H^OXK^
M?M]E?W?[_K]WF[G^I>6?S5?_  +T_P"#_6W^5#Y_Q3_Z-J_:=_\ #+^+?_E=
M1Y_Q3_Z-J_:=_P##+^+?_E=7^J]]EM_^>$7_ 'PO^%'V6W_YX1?]\+_A1]?Q
M7\_;[*_N_P!_U^[S=S_4O+/YJO\ X%Z?\'^MO\J'S_BG_P!&U?M._P#AE_%O
M_P KJ//^*?\ T;5^T[_X9?Q;_P#*ZO\ 5>^RV_\ SPB_[X7_  H^RV__ #PB
M_P"^%_PH^OXK^?M]E?W?[_K]WF[G^I>6?S5?_ O3_@_UM_E0^?\ %/\ Z-J_
M:=_\,OXM_P#E=1Y_Q3_Z-J_:=_\ #+^+?_E=7^J]]EM_^>$7_?"_X4?9;?\
MYX1?]\+_ (4?7\5_/V^RO[O]_P!?N\W<_P!2\L_FJ_\ @7I_P?ZV_P J'S_B
MG_T;5^T[_P"&7\6__*ZCS_BG_P!&U?M._P#AE_%O_P KJ_U7OLMO_P \(O\
MOA?\*/LMO_SPB_[X7_"CZ_BOY^WV5_=_O^OW>;N?ZEY9_-5_\"]/^#_6W^5#
MY_Q3_P"C:OVG?_#+^+?_ )74>?\ %/\ Z-J_:=_\,OXM_P#E=7^J]]EM_P#G
MA%_WPO\ A1]EM_\ GA%_WPO^%'U_%?S]OLK^[_?]?N\W<_U+RS^:K_X%Z?\
M!_K;_*A\_P"*?_1M7[3O_AE_%O\ \KJ//^*?_1M7[3O_ (9?Q;_\KJ_U7OLM
MO_SPB_[X7_"C[+;_ //"+_OA?\*/K^*_G[?97]W^_P"OW>;N?ZEY9_-5_P#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>ny20077915x1_linechart0x4.jpg
<TEXT>
begin 644 ny20077915x1_linechart0x4.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M5_M._P#SVZ_0ZBCGG_-+[_Z[?GW8?5,+_P! U#_P5#R_N^2/SQ_X=<?LB_\
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MB_\ 0,^.'_B5?[3O_P ]NC_AUQ^R+_T#/CA_XE7^T[_\]NOT.HHYY_S2^_\
MKM^?=A]4PO\ T#4/_!4/+^[Y(_/'_AUQ^R+_ - SXX?^)5_M._\ SVZ/^'7'
M[(O_ $#/CA_XE7^T[_\ /;K]#J*.>?\ -+[_ .NWY]V'U3"_] U#_P %0\O[
MODC\\?\ AUQ^R+_T#/CA_P")5_M._P#SVZ/^'7'[(O\ T#/CA_XE7^T[_P#/
M;K]#J*.>?\TOO_KM^?=A]4PO_0-0_P#!4/+^[Y(_/'_AUQ^R+_T#/CA_XE7^
MT[_\]NE'_!+_ /9:MR'TF[_:)T&X'2ZT;]K7]IFVGSQ@DS?%2XB8KCY=T3 >
ME?H;11SS_F?WW_K8/JF%6V'H+TI07;^[Y(_.B;]@3Q7X9;[5\&?VY_VT/AQ>
M0*18:?XH^)>E?'+PC; $LL$OASXP^'/%,LUJ2=KK'J]O=;,B*\A<*ZT3J_\
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M-_Q$D>,/^C5_#7_ASM4_^9&C_B)(\8?]&K^&O_#G:I_\R-;?\0MXW_Z%-/\
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M)'C#_HU?PU_X<[5/_F1H_P"(DCQA_P!&K^&O_#G:I_\ ,C1_Q"WC?_H4T_\
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M_P#F1H_XB2/&'_1J_AK_ ,.=JG_S(T?\0MXW_P"A33_\..7>7_45Y_@^P?\
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MO^(DCQA_T:OX:_\ #G:I_P#,C1_Q$D>,/^C5_#7_ (<[5/\ YD:/^(6\;_\
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M*-_Q$D>,/^C5_#7_ (<[5/\ YD:/^(DCQA_T:OX:_P##G:I_\R-'_$+>-_\
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MBO6/CPHHHH **** "BBB@ HHHH **** "BBB@!&Z'Z'^5?='_!0__DX32O\
ML@G[-/\ ZHCP#7PNW0_0_P J^Z/^"A__ "<)I7_9!/V:?_5$> :\G$?\CO+/
M^Q?F_P#Z>R@^QRS_ )(?BW_L>\'?^H_%1\,4445ZQ\<%%%% !1110 4444 %
M%%% !37^XW^ZW\C3J:_W&_W6_D: /NC_ (*.?\G8>+O^Q%^"O_JG/ ]?#-?<
MW_!1S_D[#Q=_V(OP5_\ 5.>!Z^&:\G(?^1'DW_8KP'_J+2/KN/\ _DNN,O\
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MV$9EVWYD:*5V5'=50]=KW[$FE^/+7X">*OV4/B#JGQ5\#_'SXDR?!BRB\?\
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MO^34O^"@7_9._@'_ .M!>$J^(Z\S+O\ >\]_[&M'_P!4>3'U7$G_ ")> /\
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M;:^%?V=/ VCZ1=6UN2<".X\>^*O&M]*8PJN\J!]SQEJ_1ROR"71=HK[VKO\
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MQL*?.6_JC55151%5$10J(H"JJJ,*JJ  JJ      , 8K\P_CQ_P3ITWX]_\
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M)K-[X<F^(S^&-7ETGPQH%Q80:I%!K>N:;X@U&TB\)230V_O7_!5O]J;_ (*
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M'WQ0U_4-!\8V&K:M?W'A:?XBZ+X?C%NT6D:1+>W<>I+I\T%A'I3ZQ))]@?\
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M%DRW&O>./%20F?7-;NY5BA)@EU">>'34E0W$6EPV45U+-<I+-)Z9XN\6^&_
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MW*6=W<:?)<6RW$<<ZPR()420,H_=+]J;]HKX?ZUX<U^P\$R?"/6O@OXL\;_
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MX+SOB;/*66TISR[#YA/#XS*5EU.G''4OJE7$4J>*K2G=O\."Z* S,H4XP2P
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M=*=HTE8]C$>##P_+#_6-XO$2KY_0C3P&0XO$X>I+),3F&&CR9G/%T,JHNI+
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M#;XD_L<?M)>"/C'\3];^"_PFU[X2>+8/B5\4?#C:6NM>#/ UKI[W_BC5=/\
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M.QL+*V2*VM+.TMXXX+:VMXXX8(8TBB1455"4;/R_'I?5^G;KT!OMW^_1:O\
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M#CYY^[NFK.SOI;6VM^SW/F+/5/1KH][W2MZW?WZ']9=%?PV_#W_@H#_P4)^
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M0>(7M+=?^)#J3V]K>WI18$DEF0;M_7<2U:7<_I^HK^$O2?V^?VV/V;/V,_\
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MK_,PPO\ NV'_ .O%+_TW$_SOO^"F?_)_O[6'_97]=_\ 2:QKX8K[G_X*9_\
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M1115&04444 ?<O[0G_)GO[ 7_8O?M'_^KIN*^&J^Y?VA/^3/?V O^Q>_:/\
M_5TW%?#5>3DO^Y5?^QIGG_J[S ^PXY_Y'F&_[)7@/_UAN' HHHKUCX\****
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MG$I95/,L1'*J7$7L:&$PN8X/#XJ."Y,90Q.'KQPM#]^OA4+7_A[U^PRTV?\
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MAQ\6/"WCKXO>/]3^&.M^"G\5?$W4_'&C6FB:&NC_  WM]7U%_#?A>6+2+W6
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M/B)_T('C?_PD]?\ _E?7^D5_PL6/_H7+#_O\O_R)1_PL6/\ Z%RP_P"_R_\
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MF5K/_-B_X5Q\1/\ H0/&_P#X2>O_ /ROH_X5Q\1/^A \;_\ A)Z__P#*^O\
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M_P!(K_A8L?\ T+EA_P!_E_\ D2C_ (6+'_T+EA_W^7_Y$H_XC97_ .B;I_\
MAT?_ ,PA_P 25Y=_T<7%]/\ FF:7E?\ YG7K]WW_ .;K_P *X^(G_0@>-_\
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M<L/^_P O_P B5U_\1LK_ /1-T_\ PZ/_ .83R/\ B2O+O^CBXOI_S3-+RO\
M\SKU^[[_ /-U_P"%<?$3_H0/&_\ X2>O_P#ROH_X5Q\1/^A \;_^$GK_ /\
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M3U__ .5]'_"N/B)_T('C?_PD]?\ _E?7^D5_PL6/_H7+#_O\O_R)1_PL6/\
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MV"2C/VEX_P";%_PKCXB?]"!XW_\ "3U__P"5]'_"N/B)_P!"!XW_ /"3U_\
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M$W3_ /#H_P#YA#_B2O+O^CBXOI_S3-+RO_S.O7[OO_S=?^%<?$3_ *$#QO\
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M3QVSAK^Y<_Z!_P#PL6/_ *%RP_[_ "__ ")1_P +%C_Z%RP_[_+_ /(E8?\
M$6<.HU(KA'"I5JU"O54<R<>>KAJE*K0<FL$FXTJE"E*-._LER\K@XRDGW_\
M$JF8N>%J2\6\VE/!8+'9?A7/AVC45#"YGA\3A,?&G&><2BJV*P^-Q=.KBK/%
M/VBFJRG"G*/^;K_PKCXB?]"!XW_\)/7_ /Y7U]*_L:> /'EI^UK^S5=7?@?Q
MA:VMM\</AE/<7-SX8UNWM[>&+Q=I3RS3SRV*1111HI=Y)'5$4$L0!FO[]?\
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M7]LKFY>>2O97LG97L?YNO_"N/B)_T('C?_PD]?\ _E?1_P *X^(G_0@>-_\
MPD]?_P#E?7^D5_PL6/\ Z%RP_P"_R_\ R)1_PL6/_H7+#_O\O_R)6G_$;*__
M $3=/_PZ/_YA.;_B2O+O^CBXOI_S3-+RO_S.O7[OO_S=?^%<?$3_ *$#QO\
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MV9]545\J_P##1?Q%_P"C/OVCO_ CX&?_ #YZ/^&B_B+_ -&??M'?^!'P,_\
MGST7]?N?]=?S[,+>GWK^NOY]F?55%?*O_#1?Q%_Z,^_:._\  CX&?_/GH_X:
M+^(O_1GW[1W_ ($? S_Y\]%_7[G_ %U_/LPMZ?>OZZ_GV9]545\J_P##1?Q%
M_P"C/OVCO_ CX&?_ #YZ/^&B_B+_ -&??M'?^!'P,_\ GST7]?N?]=?S[,+>
MGWK^NOY]F?55%?*O_#1?Q%_Z,^_:._\  CX&?_/GH_X:+^(O_1GW[1W_ ($?
M S_Y\]%_7[G_ %U_/LPMZ?>OZZ_GV9]545\J_P##1?Q%_P"C/OVCO_ CX&?_
M #YZ/^&B_B+_ -&??M'?^!'P,_\ GST7]?N?]=?S[,+>GWK^NOY]F?55%?+=
MM^T-\0Y[FW@D_9%_:)M4GGAA>ZGN/@AY%LDLBHUQ/Y/QCEF\F!6,LOE12R^6
MK>7'(^$/U&#D D%20#@XR,CH<$C(Z'!(ST)%,0M%%% !5#5?^07J7_7A>?\
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MV2Z;?R:8AI_6O:WZW_(M+$*$%JVJ=%2:<&W).U9MRWERZP>L6[MW=CQ35_\
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MO%5YXO\ #EQK%H8)]=M-(\1:QJ5QI]\NIPZC+IEE966ES-/-;7#7+I\OTO\
MJ0_KD8.3:<E!OEBH.\N6K\"M=^\J5DV]Y7TV]&@_;0T.XUC_ (5VOPO\=#X[
M'XG7?PK7X,_;O"3:I_:]EX&M_B;<^('\7KKI\&)X-A\!7,6N/KQU7<9V71UL
MFU-E@/-P_MZ^'M7U71O"G@_X-?%+Q9X]O/#WQFUGQ#X,MIO!6DWO@K4?@)XE
MTGPM\0_#?B#4]8\3VNE/JL>I:O:_\(Y)I-SJ-AXBCGLGMKJ&.]22/HX_V,=(
MAUR'XD0?%7QO%\=XOB?J?Q3?XQC2O"+WUQJ.L> [;X87WA:;P8^C'PC_ ,(2
M_@.SL]'BT1+%9[>\M8];BU :FTTTNMX"_8W\"^ ?%VC^.K/Q3XNU?Q1;>#OC
M'X;\2:IJK:*9?&FN?'/Q?H/C;QSXVUE+/2[6*UUE]8T"WATG3]*CL]$TS2GC
MTV&P,%G:[%II_6O^7]:7+7UIZ-I+F6ON-\G-#5Z/]YR^TYK>Y\/*>5^*_P#@
MI=\ /#FG:7KEG]OUK0G^%_PV^,?B:Z?7?!7AO5_#G@/XIQO>>&[FP\*^)_$F
ME>(O'&O6^C6][KVL^'/!=AK&H6&EVJE/M-]>6-E<=K;?MP>%+KQO>>&U^&?Q
M"B\*Z?\ M%)^RY<?$FXD\*1>&I?BOJ&D6VJ^'+6RT_\ M]_$EQX?UV2^T_2C
MK[:1%;:1J>H6D>IQ16YFN(#X>_L3Z-\(O^$6/PN^*OC3PG)I?PI^%OPC\6RS
M>'_ /B5_'.B_"#3[K2/!^OW"^(_#6HP^&_%L&CW]_IESJ>@Q165S:RVOFZ4\
MMA!(>FN/V/\ P3<)J:-XI\5J-4_:XTC]L*4C^Q\Q^-]'.AM!X7C_ .)=C_A%
M)3H5OYH8'5QYTVS45&P*>[V?K]W3RU];KL2EC+)MP3T;2C'ETOHGS-M.\5*Z
MBU)2Y7RM,3]C7XY_$G]H#X9:[XQ^)7@.S\$ZCIOQ)^)?A#3GTW5-*OM/U;3_
M  =\0/%'A:%4M;'6-8N[2_TFWT6TL]7N;R6&UU;47GO]'B33W1(_K>O%/@C\
M%K+X&Z3XL\-:#XHUG6_"NO>.O%OCK1-$UFSTE9/"-UXX\1:KXK\1:79:K86E
MK?ZOI\^N:Q=W-F^M/=7ME!Y=HES)&N3[72>[MMT.BDIJG!3;<U%*3?*VY):N
M\='=[=;6OK<*Z#Q-_P A)/\ L&Z1_P"FRUKGZZ#Q-_R$D_[!ND?^FRUH-#GZ
M*** "O*/CK\5-+^"'P=^)/Q9UA5EM/ ?A'5]>ALSDOJFJP6[1:'HL"*R/+=:
MWK4VGZ3:0Q,)9KF]BBB_>.HKU>O#OC[\!/"?[1GA+0O /CV^U9?!.G^/?!_C
MCQ%X;TZ2"&R\<P^"]3&N:9X3\2221/<GPW<ZY;Z7JE_#I\UI>33Z39HEU$GF
M!CU(GS\DO9VY^5\M]N;I?R3U>_H]CXQ\*?ME_%Z/X/6GASQSX;\$VO[62?M0
MZ!^R3K.DV]KJVG_#O3/&WC2"W\9^&/'4FDRZS>>()/"S?"74K3Q3#I:ZVMYK
M>IVTEC;:A8VMY'<V_M'Q!^)?QR^'/BOX._!5?%?P[\5_$7X^>-/$EAX7\<3^
M -8\/Z-X*\$^ O!S^+/'6JZQX1A\>ZH_B?78R+/3_#-I9^(-#LI9=46?56,6
MGR+=9>K?\$^_@Q/XH\>>*?"NJ>,/A_=>-Y/A3XDC@\,ZE;W(\,?%GX,:IJM[
MX&^,.AW7B2VUVZ?Q?!I>J#PGK-IJDE_H&O>$[.#1-2TR:U+"O1_%'[-NK>-U
M\(ZYXK^-'C.^^)WPX\9/XR^&OQ)TWPS\/]#O/!LUYH5SX:US08O#=GX<;0M<
M\-^*=%OKRU\2Z;K\>H&]D:SN[*?3+O2]/F@;MIT[_<N_2]]-_/56YXQQ"BU)
MRDX\L8R4UK",VI<UW&]6I27QM64Y:<EKOVGPROC+0O#ES;^/O$WAGQ/XDMI-
M4GM-6T'P_=>$K6_T]5:;3DN- O?$7B22*_A :"\DM-5DM;D)'+##;,SQCXH_
M90_:O^)'QP\4_!O1/%VF^$K2T^('['.A_'[6GT+3=3M)X?&FI?$:X\)7%EI[
MWFM:@D/AY=-B66*RGCN;Y;PM(VI/$1"/K+3/@UX>NETO5OB5'H'Q<^(&BS7L
MFB_$GQ?\/OA_!XI\.Q7,SS6]EX5N=*\.VS^'+/3G<S6HLIVNS=R3W<]Y+)*!
M'YA\#_V1_!?P)UKX?ZYX>\3>*=9N/AY\ =,_9ZTR+6O[)$-]X9TSQ9+XOBUN
M_%CI]J_]NR7TIMI/L[PZ>+10%M!-F4FEGWTM]^OX%R59SI./NTU?G3E>35Z;
M7->]VK36DI:/?4^KZ***1T!1110!T/BG_D-7'_7"Q_\ 2&WKGJZ'Q3_R&KC_
M *X6/_I#;USU*.R]%^0Y;OU?YA1113$?-_[4'Q@\0?!_P3X+?P?!H\GC3XI_
M&3X7_!'PA>>(K:\OO#^B:W\2M?\ [.;Q#K.GZ?=Z?>ZE::)I%IJNH1Z;;ZA8
M-?WT-G:R7EO#++(,_P#9W^+/C3QIXH_:!^%WQ%F\/:IXP^ 7Q/TSP=+XH\+Z
M1?>'M*\6>'/%G@'PK\1/#&JR^'K_ %77GT;6+2R\33Z'J]M!K5_9SW.DC4+8
MV\5Z+:+T+XV_!S1/C?X.LO"VK:OK'AO4- \8>$/B'X-\6^'S9G6O"/CGP)K5
MOKOAKQ#I\&I6UYIEZ;:Z@DM;S3]2L[FRU#3+V^LIHU\]9HHOA#\'-/\ A1_P
MGNJ2>(M8\:>-/BEXTD\>?$#QEKMOI=C>ZYK::%HOA;2[>UTK1+2QTG1M&T+P
MUX=T;1M*TRRM\10VDEQ<3W-W=3S,]++OK^EO7K_6^+53VR:?[O2^NEN6=UR_
MS.;@^;;E35^C]CHHHI&P5KZ!_P AS2/^PC9_^CTK(K7T#_D.:1_V$;/_ -'I
M0..Z]5^91O?^/V\_Z^[G_P!'R56JS>_\?MY_U]W/_H^2JU @KXX\6?%?XL^!
M/VGO@E\+;G7? /C+PU\;+_XJ2W/A#2?"6L:1XP^''@KP/X3NM=T?QU>>(6\6
MZO;:UILVOIHO@W6S>>'=%MI]7\3V;:/-&;1[63['KY/\&?LR:QX-^-WQ(^-\
M?QI\5:]K7Q/U.#^VK'Q!X0\"W]QH_@S3('A\.?#3PEXB.D+JWAOP3X=FDEU.
MUT^PVS:GK=Q>:UK\VJZE=27 :MU_K^OF9U%-\G(G\<7)II6BFG*Z;7-S)<EN
MBDY6;BD_-_A?^TQXCE_:"^)'PN\<_$7X4^*_ '@7X3V7C[Q/\0]+T'4/A;9_
M#_Q=)XVU#PU<^#+^3Q7XOURU\2:.=.A2]?Q%;O8KHMY9_8]5E>;6+*"#Z#^!
M/[1?PN_:'T/6-:^'7B71-4?0O$_C'PUJ>D6GB+P[J^KV@\(^,-<\'+K=S::'
MJFI-;:)XCN-"FU7PY>7'E#4-)NK6X50SLB\]X1_9UFT[XIZ5\8OB/\4/%'Q>
M\;>&OAWK/PN\*W/B#P_X+\-6&C^%_$NM:+KWB5KO3O!VAZ1:ZWJ^MW_AO06F
MO=03[+91V#II>G61O;MI/4/AC\*_"'PB\/WOAKP99S6VG7_BGQIXON6NY(KB
M[?5O'GBW6?&FMI]HC@@/V*/6==OETVU*L+*Q$%J'D\KS&6G]?U_7RUBDJR:Y
MG[EYZ2UGJX<BNI22M[]_>G?1W5^6'HU%%%!N=!I?_(&\2_\ 7KIW_ISMZY^N
M@TO_ ) WB7_KUT[_ -.=O7/T %?,7[87Q-^+GP=_9\^(WQ*^"_AWP3KWBSP9
MX:U_Q/=2_$#4=3M?#FAZ%X=T#5==U+5Y-+T98M4\37Q_LZ#3--T"UU/1%N+S
M4HKR[U>UL;*Y67Z=KQ[X]?"BY^./PJ\8?"A/&VK> ],\=Z'J_A?Q)K&B:-H.
MLZG<>'->TJ]TG5M.M(_$5I>V5E/<07F^+48H#=6LD*&([7D4M;J_<BJI.G-0
M;4W%\KBTFI=+.6BUWOTVU/EOXN_M!_%[PGJGP9U=)QX$^#GB+X$Z_P#$KXI?
M%>V^!7Q ^,>D>%O%UE)X#GTG1-0/A#6K.'P=H-QHFL^+=:NM5UXW$,=KH@D>
M]@BMKAY?9O$?[7?P'\'>.?A-\.M:^)_@6XU?XJZ3K.IZ?K47C/P?8:1IMII'
MAG2_$UAJ6M0WWB!+S3K/QG8ZI;MX2*1W2ZD\BI%*\929X=:_9Y\;ZW\.M*^%
M\O[1'CFQ\,KX!G^''BI=-\$_#&"]\4^'IQ-8-<0WDWAFXG\,ZX?#4[>&WU'2
M)/):".'5([&'5UDNY>WL_P!GCX6:=J'P4U"PT-[0_ #P[JOA7X<VL<ZR6EIH
MNK^%],\'S6VK)<0S3:L]MHND6<=C-<3K);W"R7):1Y#1I9=];_H_\_0RM7YI
M.+23=-^_K97@IQBHS:MR*3NU%\[W:=X^VJRNJNC!E8!E92&5E89#*1D$$$$$
M$@@Y%+1TZ44CH.I\%?\ (T:3_P!=9_\ TDN*^CZ^</!7_(T:3_UUG_\ 22XK
MZ/K.IT^?Z'50^!_XG^2/S*_X)!_\F*> O^RG_M)_^M'?%2OTUK\RO^"0?_)B
MG@+_ +*?^TG_ .M'?%2OTUJ9_$_E^2)PG^Z87_L'H_\ IN(4445)T'YF_P#!
M4[X__MP_LY?LY:KX^_8<_9YTKX_^.((;R/6X9M4EGUWP1")],_LWQ!HWP]M[
M&>]^),=RSWVG7NBZ7>6FHZ>TMKJOE75C;WWD_/W[./[5O_!6+X[_ !V^"OA_
MQS^QQ\"_@)\"=+O_ !'+^T9XQ;]H;P=\6O&4UM:>#';1O#_A7PSX3O;2_P#"
MWB-/&&H:%/K%IJ^GZF]KIEVMO<MIQ7SKG[\_;T^&WQC^,/[&G[2?PP_9^UV3
MP[\9/''PG\4^'_ >H0ZLV@7$^K7MGB;1+7Q LL#>'KOQ-IRWOANUU\3P?V'<
M:K%JIFB%H9%_F0_X)<?LG?M+:+^VA\-;WPM^P+\;/V(/A#\&/VC/C+\8=?\
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M72?);;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 50U7_D%ZE_UX7G_I/)5^J&J_\@O4O^O"\_\ 2>2G'=>J_,#X!_X)0?\
M*/#]EO\ [$34?_4Q\2U^AM?GE_P2@_Y1X?LM_P#8B:C_ .ICXEK]#:);OU?Y
MF&%_W;#_ /7BC_Z;B>;:MX9T.\U*\N;B.],\TQ>4QW*(A8JN=JF)B!C'!)K.
M_P"$0\._\\]0_P# M/\ XQ767W_'Y<_]=/\ V1*JULEHO1=7Y?Y?U=D\JWTU
M=]E_E_5SG?\ A$/#O_//4/\ P+3_ .,4?\(AX=_YYZA_X%I_\8KHJ^7?B;^T
M=JGPD^(_P^\,^,?A+XAM_AY\2_B?X6^#WAOXI67B;PM?Q-XU\9:7>7F@O>>"
M;:[?Q';>&[C5;.3P]-J[M]MM;\_;9]&31E_M$NWK][\O\OZNR9.$%>5DKI7Y
M597LM6EHN[=DKZM:'T!_PB'AW_GGJ'_@6G_QBC_A$/#O_//4/_ M/_C%=%11
M;U^]_P!=/S[L?*NR^Y?Y?U=^5L.V\)^'XKFWE2._WQW$,B9ND(WI*C+D>2,C
M<!D9&1FGWOA30)KRZFDCO_,EN)I7VW2!=\DC,VT&$D+DG )) ZFMR/\ UL7_
M %UB_P#1BT^X_P!?-_UT?_T(TK:KT?5]XCY5V7W+R\NMM?\ ACE_^$0\._\
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M5\W^/_V@+S0_BG%\$OAK\.=6^+'Q-M? \'Q)\4:9:^(-&\'^'_!O@S4=5O\
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M@CCO?+NHK=9PURA8K%<QRIL/E *=Z@L2&RH( YS6?_PB'AW_ )YZA_X%I_\
M&*ZR#_47?_7./_T:M5:2Z[Z/N^R_K[^['RKLON7^1SO_  B'AW_GGJ'_ (%I
M_P#&*/\ A$/#O_//4/\ P+3_ .,5T5%.WK][_KI^?=BY5V7W+_+^KORMSO\
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M* "BBB@ HHHH ***9++'#&\TTB111J7DEE=8XXT499W=R%55')9B !R31MN
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M (S1?U^Y_P!=?S[,JZ[Q_P# E_GY_GV9N1_ZV+_KK%_Z,6GW'^OF_P"NC_\
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M+Q?X6\::'I>E6RMH2J_C2WN?$.G/>6LCQ:3#;V\YM];G>*&.7]&O^$F\-_\
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M*$8P6KD]DEHE%:MM-IM;-%8W_"3>&_\ H+'_ , +[_XS1_PDWAO_ *"Q_P#
M"^_^,T7]?N?]=?S[,WNN\?\ P)?Y^?Y]F;-6S_QXI_U\O_Z+6N;_ .$F\-_]
M!8_^ %]_\9J^VOZ!_9D=P=2/V<WLD(E^Q7G^N$*N8RGE;QA"&W;=ISC.:+^O
MW/\ KK^?9C36NJU7==UOKI\RU16-_P )-X;_ .@L?_ "^_\ C-'_  DWAO\
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M-X;_ .@L?_ "^_\ C-'_  DWAO\ Z"Q_\ +[_P",T[^OW/\ KK^?9BNN\?\
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MT#PAK=_X?GO+G1+J_P!)MS#+)I4^H66G7LECC:L#7-A:2[% :!  *^B:QO\
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MY/NG_E^/9VUY(W@W+FE!W4G*-VW%QN[67PR:V7=ZILV:*QO^$F\-_P#06/\
MX 7W_P 9H_X2;PW_ -!8_P#@!??_ !FB_K]S_KK^?9EW7>/_ ($O\_/\^S-F
MBL;_ (2;PW_T%C_X 7W_ ,9H_P"$F\-_]!8_^ %]_P#&:+^OW/\ KK^?9A==
MX_\ @2_S\_S[,Z2^_P"/AO\ <B_]%I52JNIZ_H-O>/%<:D8I5C@+)]BO'P'A
MC=#N2(J=R,K8!XS@\@U0_P"$F\-_]!8_^ %]_P#&:2>B]%T?E_G_ %9CNNZ[
M;K_/^OD;-%8W_"3>&_\ H+'_ , +[_XS1_PDWAO_ *"Q_P# "^_^,T[^OW/^
MNOY]F*Z[Q_\  E_GY_GV9\1?'WX/_M!?%7]H'X;:S/X>^%_C+]FWX4OH?C?P
M_P##W5?B7XD\&:UXE^-=E?S267C7Q_:6OPM\7Z=K6@?#FU6&]\ >%;;58+6\
M\4W,OB+7Y/.TG1+>W[.R_9#\.VO[4M_^TB?%?CMA>?#G2O"R>%V^*?Q;EAB\
M2V/C?6_%EQJ4L,GC@Z'<^$I;?58[&W\#2Z1_PC=K<P2WD.F1F=UKZJ_X2;PW
M_P!!8_\ @!??_&:/^$F\-_\ 06/_ ( 7W_QFCF]5I;9^7YZ7^?9F7LJ3DY2:
MFW-5%S.+Y9)67*]&DD]$VTM7O=FS16-_PDWAO_H+'_P OO\ XS1_PDWAO_H+
M'_P OO\ XS1?U^Y_UU_/LS6Z[Q_\"7^?G^?9FS5BT_X^8/\ KHO\ZY[_ (2;
MPW_T%C_X 7W_ ,9JW8>(?#\U[:PPZF9)99XXXT^Q7B;W=@JKN:(*N6(&6( Z
MD@47]?N?]=?S[,::NM5NNJ\O/S_JS-*;_6R_]='_ /0C4=9<_B3PXLTRMJI5
MEED5E^PWIVLKL&&1#@X((R.#U'%1?\)-X;_Z"Q_\ +[_ .,T7]?N?]=?S[,5
MUWC_ .!+_/S_ #[,V:^!_%OP-^-'C3]KO7OB=JWAKX<0_!GQ#^S5XI_9FOY[
M?XD^(&\>G1_$WC-/%D_C&+PVWPP718[A(/-TL: ?%S!9'6]&L,JFW;[?_P"$
MF\-_]!8_^ %]_P#&:/\ A)O#?_06/_@!??\ QFB_K]S_ *Z_GV9$X1J**<E9
M2C*RE'5III.]].]K/?71GYN_!W]C3XI)J'[.&G?'+4_!UOX9_91^ WBKX(^#
M=4^%'C7Q[IGBKXC7GB?3?"WA.3QSJ-[:Z9X.U+X9BW\'^$(,:#H'B'Q)>'6M
M=O"GB-+'381?_2?[*?[,&E_LR>$?$'A^V\3^)O%&H:_XZ^)/BF>\U?QI\0/$
M&F0:;XS^(_BKQMH]C::+XP\4>(+&PU73;#Q#!IVN:YIT%I?>)=0M9M5U2:YG
MN68?1_\ PDWAO_H+'_P OO\ XS1_PDWAO_H+'_P OO\ XS1S-]]7?9[_ '>?
M]6TBG0HTW%JSE%-*4I1<DFJ<;7TVC3A%/>T7=W<F]FBL;_A)O#?_ $%C_P"
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MFK:;\.(_"NK>#[RU@M+33(+7PGI^I:*+.&ZT_4HKN6]FN_O_ .#/P?\ A_\
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MITJGN_5IXO"588[!8O$8?$5<+COPQB^,W[0G_!.B\L?@!^VGX.T_]HG]DSQ
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MZ>.0EB?J6'3=.MXHH(+"RA@@C2&&&*U@CBBBC4)'%'&D81(XT4(B* JJ J@
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M'[+?_8B:C_ZF/B6OT-HEN_5_F887_=L/_P!>*/\ Z;B?-/BW_D9-8_Z_'_\
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M6+B8W]QK'Q/T;Q/%K-S)!J5D]O9PPZ7.N@1V4?VK2;.">YGO7_77X:?M1_\
M!9CXDZ%X*;3OVY_^"-.DZMI[WMYX@_M75O'&HW_B5=5=);+2]9TN!= AL3X>
MB'DQ#P_<Z3<7SS;;VZEDC)KTL7PSG>7TZ6(Q.4XB%'%Q=6G6I1IXBG5C#EAS
MSJ86=91]WEY'4<7.FHSI\U/E9Z>.X7XCR^CAZ^+RK&0P]>$IX>M3BL31E!25
MY*IAI5H4XR<E.+G*"J1E&I#FA*,G_25XL^!?P6\=I/'XR^$WPY\3?:1B>36O
M!OA^_GE SP]S/I[W!'S'CS>I)KYTUO\ X)S?L@:M</?:=\*V\$ZF5*Q:E\._
M%OC'P-<VV3NW6\7A[7;*QC(8 C_1"HP %QD5^<OAOX.?\%S?B%IZ2W/_  5(
M_8;\++<ZA)J"WOPK_99C^(2QPW0WMHUK<>(O'6GVT^EZ:R1I82R6YU2XCN)G
MOM1D:.)3Z/#^PS_P5RUN+R_%_P#P6:>Q60*9#\/OV)/@YH#)D"1A;S:AXDU2
M=5$P"(7E=C:YC=G=BY^,Q_#.09A)O,^'LIQ=3?GQN5X*M5B[WNIUJ,JD9)ZW
MBU)/5:G%A\VSC -T\/F>8X-+1PI8O$TH]+Q=.%11?9Q:LUH]-#Y__;)_X)<:
MGJ_QB^$4O@/]J;3O#>@ZE]DT72-(_:!^+>IW_CO2=2MM5$]Q)\,WU)GOO$@=
M+FWD@T>UDM+R#4Q$CWDB7B2P?I;;?\$Y_AE>Q6A\<?&/]I_XA74,$4=T^O\
MQU\7VMG>2)&J2.;+19].,,<A#8A%P^Q&V;V(W'^9?_@HU_P;D_\ !0S]I_\
M:&^"'Q)C_P""B0^/WV*UT_PWKGC[XZ00?#;Q?\++33M<NM82[^'7A7P#:7FB
MZS:(UV;V"VL9](UIM9(^UW,EL(KN']I$_8F_X+,_#_3;*P^&7_!7CP3XYM-)
MTI;"ST[XZ_L9>"M3NKUX;9;>"74?%7A;QE9ZU+/'L60WES%?RRRYENDN26#_
M #&!\+^"L!CLTQ]/)8U99M5H5:]#%5ZV)P4'AX.$(X?"5:CH0A>4FXN-11O[
M.G[.E&-->QB>->)<5A<#A:F8RIPR^%6GAZU"G2HXB:JSC.<JN(A%5923C%*7
M-&]G*?--RD_NK3?^"<7[&VGW O+CX.V_B"\X\R[\6>+/''BF6<@\&9=<\27L
M,F.F/*"XR-N&;/KOA_\ 9-_9C\*L'T#X!?"33I 0?-C\">'9I2RD$,\MS832
M.P(!W.S'(ZU^0TVC_P#!R!X"O?"E\OB?_@G!\?-+\.QZC#KVAV=O\3/A7JWC
M]+@2"QN]4U&_TG4;#0;^PW(T2Z";2QF>-1=V\J,Y;D]/_:@_X+F_#W3/!%E\
M6_\ @G]JWQ"N_#'C*\UWQWXL^ WQP_9YUJ'X@>$I;I)K?P5;>#_$FAZ'J.A0
MV5NKVL6NZ5J3:S<JXEF02H6/T.&X5X7P3YL)PWD6%DW?FP^3X"E.[M=N5/#J
M5^[;NV>35SO.\2K5\XS.LFTN6KF&*FNEO=E5:LM-E\C]B?B?^Q?^RW\8KKPQ
M>?$'X*^"M7N/!\YFT%K.P?0$@1ITN7L[J'P]-I<.IZ=).@DDT_4H[JS9C)^Y
M'FR[_2-5^ _P1UR!;;6/A!\,M2@6..%4O/ OAF?;%%&(HHU9],+A(XP$10P"
MH H %?QD_P#!0?\ X.,OVWOV1/%OA'X8P_LW?%KX1>*_&7C-_B%J<O[4WP[\
M$>%-3TOX6_VO)IL7P^^&MMX+O]?T7Q;I:M!=QW'Q,UB\?4Q=0K:IHJ&.6>7K
MOV^_^"X?[?/PHU_X7_$7X0_#[XX? OP/\6K/4]0T#P/^T?\  ;P':>']2TJ;
M3O#%U8-\//$NGWMYK_C"6W-W-=OJ6HQZ>([?6+)6L)TF2.'LI9#DOML55IY/
ME4:V,]D\95C@,)&IB_84W"A]8FJ7/7]C3;ITG5<O9Q;C&T6SS,;Q!B\'0H+$
M9CF#I89M8>E&OB9QPZK5(.HZ45+DI*4I1J34'%S<6[2FDC^J+6OV!OV.->5U
MO/V>_AY:&0L6DT+39_#4I+9W,)?#UUICJQ))W!@<X(/ K@KC_@FO^S+$!_PB
MR?%KX?%<&/\ X0;XU_$O2$B(.08X;KQ#J-N,$ X,17@#& !7F7[#?QZ_:+_;
M4^$FI_&;Q%H_Q>_9?'B+P#I_AGPYX%^)GPM\%R6EEXT;3X&G^+G@K6I[BQ\0
M^+="O)UDGBT3Q/X;\/Z8K7'D6JW<$(N6^U-/^'_QEMM4\(7=]\?+C4M-T7P+
M=^'_ !1I)^&GA.T'C+QG-9W<%KX^DO8)_M&A26=U-;7H\,Z:#I,YLQ;RR>7/
M(5\ZMP7PC6FYU>%\@=7K6CE. A67I7IT(U5_V[-=ST\/Q-GCI0E1SO-?8RBI
M0C+&XQP::5OW52;6UE:4+'X^_MH_\$C_ (L?%6Y\"W?P6^/'B[Q59>'_ +;!
M=:!^T!\1/$.OG1&GDCGBU'PMK%MI%^T/FF)(;VSFLXY=T4-Q%>. 8$_1+]B_
MXYQ^(O"&F_ 'XCP:SX1_:(^"WAO2/#/C[P;XPOHKO6]=M]&M(--M_'WA[552
M&'Q3X:U](8[M-5LD9K:6<07@!:&XN?9= ^'/QOTZ/X9KK?[1%QXA?PK?Z[<?
M$*1_A;X.TL_%&RU"<R:-I\JV<Y7P<-!@(MUN="WRZECS;L!\BOF?XY_L3_%#
MXN:5X5\4:?\ M*77A?\ :#^&WCS4O%_P]^-6F?"WPKI^JV?ABXMYUMOA1K5A
MI]Y%!J?@^XG>,:M>7)N;V[A$F;5C)*DWSE+@;#\+YQC>)^$:4HXO,(T*><Y-
MB<34GA,RP=",(QC@*M;VD\!F.&4'4PCG.6"K.57"5H4(5Z>+PGMU.)JN=Y?A
MLDS^I!X?"2JSR[,:-",<1@\15<G)XJ%-0CBL)6NHXA**Q--1IUZ4JLJ4Z%?]
M%J*_+3X%?%3]H3XBWWQ0^ OQ<^-W_"G/VH])UW2];TO2!\+?!][X?3P)8RR)
M=ZE\+I-0NA#X_P##7B.,(]U?:K(VO>&IM\3PLH,B_:VM_#[XSW][\2)](^/T
M^A6GBC1=&L? %DOPR\):B/AEJUB;7^UM;BN+J<2>+FUL0W(;3]<"6NG_ &O-
MJ3Y$>?M\KS7!9S@X8W U'.DY3I5:=2$J.)PN)I2Y*^#QF'J*-7"XO#U$Z=?#
MU8QJ4YJS5G%OYK'8'$9=B)8;$QC&:C&<)PDJE&M1J)2I8C#U87A6P]:#YZ=6
MG)QG'9WNE[K17AJ^ /C(-6%XWQZG;3!\,QX4.D#X:>%%4_$(0&,_%+[;YYN1
M,9B)_P#A#A_Q(A@1>85R2W1OA_\ &:QNOAW+JWQ]N-;MO#.B:U8>.[1OAGX2
MT_\ X63K%^LXTG799[6<OX3;0VDA9=.T0/:ZAY&+I@)6 ]$Y/FOQ[>GR]?+4
M]THKY]TKX;_'*TT_P%;:E^T9<ZM?>'?%NI:SXUU$_"KP;9'X@^&+JYCET_P=
M):V\Y@\+IIENLEJ-=TC?J5X)?.G421C,$WPS^/$FC:M8Q?M*7,&K7GQ)7Q1I
MFMCX2^"I&TCP $8'X8C3GN/LM]$S$.?%]P1K@VA1& 2: ^:_'OZ?/T\]#Z)H
MKP36_AW\;+]/B6ND?M"W&A-XJO\ 1KCX>NOPN\'ZB?A=96+(=5T^$74X'C$:
MVJNK7.N^7-I^_=:@E5 M:CX ^,=UJ7BNZL/CS/IEAK'@;3_#_AG3!\-?"EV/
M"/C&VA@2_P#'J7<\XGUR7498YIO^$;U$+I-I]H\N%RL2E@/FOQ_R_JS\K^XT
M5X99?#_XR0:KX8N[OX]SWVFZ3\/+CPUXBTD_#3PG;CQ5X[DMKF*#XD27L4YN
M-&DMKB6WNAX4T\'193:B%Y!',^*^A?#OXV:>GPO76?VA)]??PG+K;_$:1OA=
MX0TS_A:T5_<-)H\4JV<Y'@O^PK<K;!] ,AU+;YUT%<E:!?/\_P#+^K^MO>Z*
M^>;;X:_'6+2M#L[C]I"YNM3T_P"(-QXDUG5S\*/!D#:]X&DE5X/ARUC'<&VT
MV*WB#0_\)5:EM:EW;W4,HR[5OAM\=+S2_&]IIG[1UQH^I:_XSM=<\'ZJ/A1X
M,OCX$\)PLQN?!$=E<W M_$<=VI53XAU8KJD.W,:98@ ?/\_\OZMZ'T)17A.N
M_#WXT:C>?$R?1OV@)_#]KXJT_1K;X>V2?#'PCJ8^%U]8FV.K:C#<7DXE\8G6
MA%<*;77@D.GBZS:EC"F96\ ?&,ZK<7:_'J==-D^&B^%8-)_X5KX386WQ!%IY
M+?%'[:9_M$TS76;S_A#WQH0XMQ)Y8W4!\_S_ ,OZMZ7]QHKP[2/ 'QCLK[P!
M<:I\>I]9L_#GAO4]+\;Z>WPT\)V"_$3Q!=PW$>G>)Y;FVG,WA9]*ED@F72-&
MWV-X;;R[A@LS[<[2/AO\<K*T^'D.J?M&7&LW7AKQ-J6J^.[P_"KP;8'XD>'[
MJ[2;3_"TD%M<&/PG'IEJKV8UC1O,O[P2>?.!(@!!_-?C_E_5_6WT%17SNWPT
M^.YTBYLE_:2N5U27XE)XIM]8_P"%3>"R;7X?JKAOAA]@-Q]GFA=BK'Q>[#71
MLVA,,:N:U\.OC;?P?$F/2/VAKC0YO%.JZ1>?#^X7X7>#]1/PPTVRG235-)BC
MNIPGB]=9A#P-?:X([BPW^;; NHP"^?Y_Y'OE%>-?\(/\6?\ A(_$FI_\+MF_
ML'5/#6C:5X?\-?\ "O/#&WPQX@L9+)M6\4+J_G_;=8?6XX+N)M'OE2PT_P"W
M;[8EK:/=[(,@ $Y( R<8R>YQVSZ4 +1110 50U7_ )!>I?\ 7A>?^D\E7ZH:
MK_R"]2_Z\+S_ -)Y*<=UZK\P/@'_ ()0?\H\/V6_^Q$U'_U,?$M?H;7YY?\
M!*#_ )1X?LM_]B)J/_J8^):_0VB6[]7^9AA?]VP__7BC_P"FXGA/B/PMKE[K
MFIW5M9>9!-=,\3^?;KN4JHSM:4,.0>& /M6+_P (9XC_ .@?_P"3-K_\>KV*
M^_X_+G_KI_[(E5:VCLO1?D9N";;N]7?I_E_5_2WD_P#PAGB/_H'_ /DS:_\
MQZC_ (0SQ'_T#_\ R9M?_CU>L5&\T,3Q1R311R3LR01R2(CS.JEV6%&8-*RH
M"S*@8JH+$ <TQ>S7>7X?Y?U=^5O*_P#A#/$?_0/_ /)FU_\ CU'_  AGB/\
MZ!__ ),VO_QZO6** ]FN\OP_R_J[\K>8V/A#Q#%?64KV&$CO+61S]HMCA$GC
M9C@3$G"@G !)["I-4\(^()]2U":*QW1RWMU)&WVBV&Y'F=E.&F!&00<$ CN*
M]-C_ -;%_P!=8O\ T8M/N/\ 7S?]='_]"-+JO1_FA\BM:[WOT\O+R_%GD/\
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MWMK>%$A@@A1(HHD6.-510![#10)48)MJZ<MW:-W:RU?+KM^+\CR?_A#/$?\
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MQ'_T#_\ R9M?_CU'_"&>(_\ H'_^3-K_ /'J]8HH#V:[R_#_ "_J[\K>3_\
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M'_T#_P#R9M?_ (]1_P (9XC_ .@?_P"3-K_\>KUBB@/9KO+\/\OZN_*WD_\
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M!?/MCO:*_AED&1*0NV-2Q+$ ] 2>*QO^$,\1_P#0/_\ )FU_^/5[%!_J+O\
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M^?7/ NHI<//>7]XABDF@U>^M;@7]I%-_;#VA@LK+ZJU#X%_\%%?#$RW?@/\
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MJ8*O3IJEB9Y)1:@X3:5+$8+#XJG-V56,)1<S]VU*XPF % & ,!0!P ,#&!C
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M8\,ZYX@O_!-DXBO-%^(]F=5MS)XL\.6R!8;VVW7/B*&,.\;W#/<U\5?M<?\
M!RQ\#?A%K7P2U?\ 9W\)ZM\:O!OB#4O$UM\7M#\5^#O'OPM\1:9ID-OHC^';
M[P3K_B;1[71+_4%GFUA-0LWL]4M)5AMT-U8B2*Y?[SA+CCAWC18VCDF8X3%9
MEE*PL<[RRAB:&*Q&4UL7"I/#PKU,-.IAZM+$1HU*F$Q.'JU,/BJ"C7HS<)H^
M+XIX?S7@ZC@L7GN$Q&"P&:.N\IQU>A5H4LRAAJE*EB)8:G6C"NIX:I6IT\50
MJ4XUL-5;IU8*46C^H*BOB;]AC]O7X(_\% ?A2WQ6^"D/C.QT^QN8-.U_1O&O
MA35?#]]HVKR0B:2QBU*2"3P]KZQ)@F[\.ZMJ<"@I]H-M)(L0^V:^P::=FK-=
M#P:=6G6A&I2G&=.:4HSBTXR3U336FOX;.S304444BPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *SM7)&E:B1_SXWG_I-+6C6;K'_(*U'_KQO/\ TFEI
MQW7JOS$_U7YH^ _^"3_/_!.[]ED]SX"OR?J?%_B0G]:_0ZOSQ_X)/?\ *.[]
MEC_L0;[_ -2[Q)7Z'42W?J_S,<+_ +MA_P#KQ1_]-Q.1OO\ C\N?^NG_ +(E
M5:T+RWN'NKAD@D=3)PP1B#\B]"%(/YU6^R7?_/M+_P!\/_\ $5JFK+5;+JA?
M)]MGY+MYH@K\3OVA?"'[2>J_MH?LT?%+QG\(_$'B;1/"/[8@\/?!F\\*^-/#
ML_A?PC\%;CX-?$"RU_5M<T:WFM+^T\1>.=>M[?Q3XDUKQ?9W,6C6VD>'_!/A
M[4+>2>4:M^W'V2[_ .?:7_OA_P#XB@6EV#D6TH]?D?YOF##/R\@$ XZ?D*?,
MNZ^_[^IE5I>UC&+<E:49JRZQE&4;IJSULT_LRLUJM(/QS[],^_4_S/UHJ?[)
M=_\ /M+_ -\/_P#$T?9+O_GVE_[X?_XBBZ[K[S75]']SZV\O-#(N9H?^NT7_
M *,6GW/%Q./^FK_^A&I(K6Z$L3-;R*JRQLS%'P KJ23E0  !R<TZXMKEIYF6
M"1@9'((1\8+$C!VG/&#GOFE=76JV?5=T&O9].CZV_P T4J*G^R7?_/M+_P!\
M/_\ $4?9+O\ Y]I?^^'_ /B*=UW7WH/D_N?EY>:(*_*3_@I9JWPW\10>!_@/
MJOACP_;?$7XOZ=J.FV_QS\8>$-1U32/V>_AII^K:3=^+_'6@>)+;3KB33OB7
M<70L=.^'>C:#?:;KEUK_ -F\0WMS!HOANX-U^L7V2[_Y]I?^^'_^(H%K> Y6
MWF7D,<+( 2%"@D;<$A5502,[5V_=+*Q==));=49U*?M8.#NDVK^ZW=7BVK:6
M;32333C>Z::/PK_:W\)?M!^)_C'^SK\0)?AKXE^(_P ,/AO^U+^S%;_LZZCX
M:\;:-);6_@Z72VE^(?Q&\<Z5)+9Z[+XM\<W,\>C7>K^+[>ZT+P;X:\-12:/+
MIEYXU\4S:E[+HGQ0_:CU'6_ QU#Q+\1(+?6_^"F/Q.^$6O6R>#M!@M8_V9]'
M\)^-K[P]H?\ R)B_8?#+ZQHVD/%\18)8_%<LLRVEKXW2WN$MS^MYM;P@@V\Q
MSR<HY)/<DE,MGC.XGH,8!;)]DN^/]&EX 'W'Z J>FS'.T9.,G'-"DE?6+OM?
M6WIKWU_#H9?5WS<T9U(\TE*=KIR=X-)VZ):13YN6+4%:,4E_/SXM_:]_:_T&
MZE\&)=>/=5UB_P#!W[=,=IJ$'@+RIOA^/ G[0%EX)^!'QD\7Q^%?AUX@UW4O
M"7@CP6U['(ESI<>B^--/2+5]3_X2O6!+=0_N5\-]:M?$?P\\">(+'Q+9>-+/
M6_!OA?5[;QCIA)TWQ7#J6AV%ZGB/3B?^7'6Q/_:-JO 2&X6,<*">!^*/[+GP
MK^,7B.#Q?XTT#Q5%XFB\'ZG\/+K6O!OCSX@?#K4-;\!:Q>QZC?\ @WQ-<> O
M$GAMO$_AB2^62ZBT775U"RM);O4&LXH/[0OO/]B\/>$].\):!HGA7PQH%KH'
MAOPWI&G:#X?T/2K-;/3='T72+.'3]+TNPM88UBM[.PLK>"UM8(U5(H(HXU 5
M13<D[:Q3\K)=//U'1I5H3FYSE4C)+DNY-K2*V>UW=NZ;7-:]K&C14_V2[_Y]
MI?\ OA__ (BC[)=_\^TO_?#_ /Q%*Z[K[T='R?W/R\O-$%6F_P"/*/\ Z^)/
M_1:?XTS[)=_\^TO_ 'P__P 15DVUP;14$4A=9V8IL;<%:-!DC&<9!&<8SQQ@
MT<R[K[T%F]KVMKNKWY;:=>GWF?14_P!DN_\ GVE_[X?_ .(H^R7?_/M+_P!\
M/_\ $477=?>@^3^Y^7EYH@KYF_;"\5?%'P3^SSXY\5_!W^W5\;:#>^!M2DG\
M+:!IGBGQ-9^"(/B%X5/Q2U#P[X=U?3=8L=8UO3OAB?%]_IEDVDZG<R7=M$;"
MQNK];:%_J#[)=_\ /M+_ -\/_P#$4TV5T>MM+V_@<$$9P0=F01N.""".W4Y.
M9=U]Z)DG*,HIRBY)I22::YDE=/HUS)KSL?CU^T5I-K^TW\?_ -CR;X2Z?X5^
M)'@JWA_:=L-4UCXS_#'Q;X]^%^FW$OPY\'BV>]LM630);VY-Q/+#H5_<ZK)"
MFMC4=.L[EKBT:RM_DGX[_L;_ !%\,:S\1_ 7A&2_^*MO\"_^"=_P=L+;Q-XS
M\!?\)'X[\>MX8^+7Q4UOQ7H7P9^(-Y-<'X5_%K_A&8)H? NKZ3;^*-1\.WDO
M@^.YMKN*PMKJ;^CXVMZ228)R3W*N<#.<#Y.@.2 <X)R,'!#39W1S_HLO..-C
MXR&W9 VX!X R.0%7;@HI5\RONOOU^SU36W+IIHGI;6_-+"1GSN3;E4LV^3;]
MW&FDE=Z)\LM6^JT39QG@+6-/\0^!O!>O:1_:_P#96M>$O#NJZ8-?CO8M=%AJ
M&D6=W9C6XM35=235Q;S1#4EOE6[6\$PN5$^\5UM3_9+O_GVE[X^23C.,CE>G
MRC\:/LEW_P ^TO\ WP__ ,12NNZ^]?YG4E9)6>R6S\O+S1!1V/LK'\0"14_V
M2[_Y]I?^^'_^(I1:7><&VEP>#\C]#P?X1V/K1==U]Z'\G]S\O+S0^8#[-9GU
M$^?PEJI6C-;3F"U58G8HLVY0C%E+29 8 $C/;(!Y_.K]DN_^?:7_ +X?_P"(
MI)KNMWU7=C?H]ET?9+]5]Y!14_V2[_Y]I?\ OA__ (BC[)=_\^TO_?#_ /Q%
M.Z[K[T+Y/[GY>7FB"OA7]N2RUJUMOV7OB'::7K>I^%O@_P#M8_#CXA_$J?0=
M+O\ 6;[0? 4/ASQ[X6U/Q)+I.DQ7.I7NDZ+?>)])NM::TM;N2QTL7FJ2P>19
MR-']X_9+O_GVE_[X?_XBE%K>#I;RC_@#_I\G!]".1VIJ44[W3\FT3.'/%QU5
M^6SY6[-2C).VG5+JM&U==/Q3U?Q7\7;GX]?%KXU_!*Y\9:=\.?C/^UI^P5\)
M+?QCIGA%[@>+?AOX?T2[T7XUWFC67BOPY?RVWA"VEUJ#P]?^-[/3+2.VOK74
MWTG6[:XL)+V'Q#]HWQ%^VEXI^)7A+5/AE8^)];\<?!;]LS]L/1?A=J-]X*TY
MM1L/@W8?LZ6EU;:5X9U+5?#D_AC5/$>IVFH>)]!^%WBKXA6?B/2-3\5RZ5:^
M(Y_$5M;SP5_0T+6\SN^SS9[G8X).,$DA 22."2<D$Y/)H^R76"/LTO.!PC@X
M  Q\JCL/R)'0D5-U?XE;U7E?ROIOY[::\TL*Y1M[6K'FG[3W;JTO:*KHG=).
M<E=:Z16O-:2_&+QO^T7^T)XB\%_MB?$3X0:W\6[70/!O[/'[.'CO]G+3];^&
M]K%K\7B_Q18:[>^.TU'0-6\&'4?$GBF2XL;32_%WA76EUBQT"Z-S!8:/I,[6
M]XG87_QU_:'&I>./APFM^.K;]H5_VV?#&E?#[PHOP^LCX;D_9*N_'_@Z\OM1
M^TCPO)X8O?!$WP>3QE=ZYX^U+47\:Z+XO,^D0>(-/U.STG3U_6W[+>]?(GSD
MD-L9B">I&Y& ^@ '/3IA/L=UC M9@#U $P!]B/ND8 !4@JP&&!!(+NN\?Z^?
M]>?2_83:?[VK[R<;:I+F;:E%*]I1511@VWR^S@[65E^"/BC]I/\ ;M\#WGQ
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M_?#_ /Q%%UW7WH/D_N?EY>:*YX!^AJ[??Z\?]<8/_12U$;2[((^S2\_[#_\
MQ-6KRWN))0T<+N/*A&55B 1$H(R 1G.0>F,8Q2NKK5;/KYQ#7L^G1];?YHSJ
M*G^R7?\ S[2_]\/_ /$4?9+O_GVE_P"^'_\ B*=UW7WH/D_N?EY>:(*X/XI>
M.K;X8_#;Q]\1;O3=4UFW\"^$-?\ %<NCZ)8W.I:QJHT33+G4$TS2["TBGN;R
M_OY($M+6W@B=Y)YD4;02R^A_9+O_ )]I?^^'_P#B*0V=V1@VTV,CH)1^&54'
M![COSG@FCF7=?>A--II73:T?*W9NUG9K6UUH?SA^"O#G[<?P;?5=1LOAKXQ\
M'?%+]MS]G+XJW/CKQ7;ZUX>\46G_  VC8V'B/XE^ /$JV6F-J,7PVMY?!^M:
MQ\'M+BU:#1M*@D\(^!;">&XU.Q^TCZ5\5VOPTUW]E#Q%I?[(7PZU[PY^T1;?
M#/PG#\0M*\.> _&'ACXX2^&8O%_@^;XX>"?%WC34=+M?$5W\4O$FA1>+K#3-
M3UWQ+>^-M4\02WVL^%]5.I.-7K]J/LEWS_HTO)R?W;^@&.$^[P#M^Z&RP&XY
MH^R7?_/O/G&,D2DD\G)RI!()W#C&<G')HYM$N9:>>K5DM=?):_@<RPJBN6,F
MX\KBN:%Y1YU'FE"22492DW-MQE>3NSX<^%VL_!Z/2[V__8H^%/PRN=:BT?PW
M8^)K*[T_Q9\$-(AT.-+^XTRR\0ZW:?"O7VU#QK8%PUUI&L:8_B2""XDFU2^B
M 1+AG[(NF^(['XF_MUW7B'2;_2SK7[5UOJFF&YAO5T^_LS^SQ\"+*XN=!O;R
MULQJND0ZK9ZC8)J%K D$MW:7:.L5Q'-!%]S&UO#C,%P0!M4'SL*-V["C&!T
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M2-3M"4&N1W:DX27O7Z-:*WVGYD%%3_9+O_GVE_[X?_XBC[)=_P#/M+_WP_\
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M/O%O=<U(WEQX;N](7P]-=ZM+(FO1ZG$#:#] /LU]S^YG /4!74'DGYMB+O\
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MC$B+-"9+:>&9_>00>0<CU%?R,_M?_#G]M#]E7_@IK8_%OX53:[\)?V:?BO\
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M+QF(Q&$RRC7FJM:E@</5J2I86G5J)3G&C&"E*,6T[*S%C"D$$\ A1P %..
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M^V9^U/#\=]0DL;*'PWX-33Y-?D^',<8WR6+_ !6U<V_B7Q:5B9;46=W9G3K
M1 6%U/!L-?JK7A-)-I-/S6QX-&I*K2A4G2G1E**;I5.7GA=;2Y)25_G?ND[I
M%%%%(U"BBB@ HHHH **** "LW6/^05J/_7C>?^DTM:59NL?\@K4?^O&\_P#2
M:6G'=>J_,3V^<?S1\!_\$GO^4=W[+'_8@WW_ *EWB2OT.K\\?^"3W_*.[]EC
M_L0;[_U+O$E?H=1+=^K_ #,<+_NV'_Z\4?\ TW$^:_%=Y<Q^)-919YU5;U@
MLT@ &R,X #8 &<   8 XSDGG_M]W_P _%Q_W_D_^*K7\7_\ (SZU_P!?K?\
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M\M]FV[?B8?6X\THN-16DHK6]TG%-ZRC9)N,5_-9R2Y;.7ZY?;KL]+BX/!/\
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MY^2+GV^[_P"?BX_[_P G_P 56_)<W/\ PBT+BXG#_P!M2@MYK%B#9QM@L><
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M]/MV?68A#F%8M3<F]C6,[0DXV#:*VJ1TIMI/5:)[O3;S\E]Q<^WW?_/Q<?\
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M9Y""3T ^8Y.>.,\@BC[;>9 \^YR2 !YTN23T &>2>P'6OR(_9Z^,GB;X/?\
M!*_X*_$?1I- O_%5W9Z#X7TO6-:DO;GPII>J?$?X]7O@2#Q5J;+=?;;KPYX;
M'B,:VMO)?PM?6ME;V+W\4=PUY']%>(_&7Q\TSXT?#_\ 9JM_BOX+@USQ+X(^
M)WQ/U;XM7_PPM8;YM(\&W_@S1M+\%6/@O_A*6T-]52]\62ZWXFU=;R$VGANU
MTN&WTM+N[GU6C6VUWI[JWN_6R_%?<5'$)PC)*;;A1G:]K>VMR1NY+5N+OT5M
M6KGW;]NN_P#GXN>F?]?+T]>O2C[;> X,]R#UQYTN<>N,^QK\0+W]NO\ ::\2
M?#7Q]\2/#5S\,?"0^$W[$5A^T[K6C77@[4_$EKX[\9Z/\0_B[X4U72-'U6;Q
M%I[Z-\/O&^G?#>/5M+OUCO\ 7;"UU;3YK:_OBUQ))Z=\4?VL/VBOA=JGQ'\
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M&C>*[JRU>6ZFU5F;3[?2+[LX_P!J+]H&+QIK.NZCJW@6#P!I?_!0'3OV/HO
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M/D_PO\:/C;;_ !T\4?#CP'XUTZPTSXN?M_?'+X>_\)/XOT>\\=Q>'O!GP_\
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M5&GS?WOR\_)'5>*;JY36I@EQ.BBWL#M61@,FR@)Z="3R2 ,GD\DFL'[?=_\
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M:LJ=7+,90PT:6&QF#G&$J6(P]:NIQG2KQJ4WRWG4I3G[*JZ5:,Z4?B8_%?\
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M?NETU*W,HNS35XWL]-5=:/TMMZV^>C@DG(Y.>7BS^.)!S^ ^E)@>H_[[B_\
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M47]KJ5]!=:P!]IFBNIXW)61L_8FRW_Y\;#_P#M/_ )&HV6__ #XV'_@':?\
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M*45:4K7=F^W?Y:;:=-;?/.!ZC_ON+_XY1@>H_P"^XO\ XY7T-LM_^?&P_P#
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MFWO?Z MQK.K3?V7<%K8OJ=_E6^U/CZTV6_\ SXV'_@':?_(U&RW_ .?&P_\
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M?1]-D$WQ.M3:-:^/I@2HD\5V[6-HT6M82[5K>-D=" 1]B;+?_GQL/_ .T_\
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M:=NKVTTV[7_K8<'??LMGY+^O3UM\\X'J/^^XO_CE&!ZC_ON+_P".5]#;+?\
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M#Q^!KT\5A,51G]FK0Q%*G5IRL[2@G9GP%_P3R^.GBCXF?!S4?AK\6I!'\?\
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MX(89!S^GY@\BEK\E5_9B_P""J7A/S1X0_P""CW@?QM:P,'LK'XJ?LO>#TGG
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M']Y?^^E_QK:.R]%^1-UW05^7]Y^V/?W?[1?Q,\/>)/&_B#X6?!SX1?'#X??
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MJKQ_>7_OI?\ &K1_X\X^1C[1)SD8_P!6G?ISV]: ZKT?_MI5HHX_O+_WTO\
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MO@/_ +1>7G_J=^,Z_IQK^8[Q%_RM>^ _^T7EY_ZG?C.OZ<:2WEZ_H@"BBBF
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M^R#^V]\0'(_T:6S^ >I>'+"Y!SLD2_\ %.J:.JQ/U#R0H,8/K7Z86.CZ7I<
MMM,T^RTVV4!4M["U@LX$4 +A(K:.)%PH"@A<@8]!5SR$R3R<@ D_,W P/F;)
MZ<?Y.?3^H\3U/XW$& H;^[@<@<&K[6GC<VQR=EU=.*;WC8^%_P!9?!G"6>!\
M*N+,PFOM<3>*=+%4)M---X;AO@+A:M"+M:4%CY2L[1JQ>I_+)^W-_P %7_\
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ML5Q87T#LLT<MQ:WL;I]EEMON_P#9*_9P\,_LF?L]_#'X!>%-0GUC3?A]X?\
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MQ$'M5IZ2Y;/EB[II/XFMFFGU32OLK_=@^(-N.FA@?34I0/\ OD6@7]/K2?\
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MQ>1WK>6;MT\D07(B*[C:_/OP6!P. 3@@9K*_X6!;?] )/_!@_P#\A5R^J?\
M($\._P#7+5/_ $L>N:HLO/Y-KK?_ #&Y2ONMET3Z)_UYV['IO_"P+;_H!)_X
M,'_^0J/^%@6W_0"3_P &#_\ R%7F5%.R_O?^!/\ KO\ TM5S2[K_ ,!7E_E^
M7;7TW_A8%M_T D_\&#__ "%1_P + MO^@$G_ (,'_P#D*O,J4 $X)QP>20!G
M'&2> ">"20!U)P*++^]_X$_Z[_TM3FEW7_@*\O\ +\NVOIG_  L"V_Z 2?\
M@P?_ .0J/^%@6W_0"3_P/?\ ^0J_/[QE\?\ XI^&/C]X*^!FG?!7PUKC?$/0
M?'?BSPOXIE^,-QI,1\-_#^Y\,6^LSZQHW_"K=2FT_59_^$HM&T_3K:_U&VG:
M&5)=3M\%E]'D_:'^$DNB:-J^D^,=.U(^+/$WQ'\">#(DMM7CC\2>/?A2?%L'
MC;PO:O)IJ/%/HE]X(\2VMW=W*V]DQTN=K6XN4D@>0<4K7;U_O-=N]N^^J5U\
MX59-M<R3C+E:<.75*#TYDKV4HNZNE>-^E_KK_A8%O_T DYZ?Z>__ ,A4?\+
MM_\ H!)_X'O_ /(5?FK\$_V\_@7\3?@AX8^+/B;Q9I?@R_F^ ^E_'?QSI#Z?
MXI?2-!\.PZ)I][XZN?"^MWFA6]OX\TKP'K5X_A[Q!>>$GUF;2]21+35+6RO9
M$M'[WXY?M.^%_A4L.CZ VF^*_'5OX^_9L\.Z]X3N)M1L)M&\)_M$_%W2OAAH
MOBQ[M;%[>5HUFUK4-/L(Y'GFN-)-O>):I*LC#BEO?H_B?E_P?Z6L+$TW!352
M'+R*>UFHN/.M._+&6F]XM?99]V_\+ MO^@$G_@P?_P"0J/\ A8%M_P! )/\
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ME5Y.7FDES24%[M_>>RT3ML]7HM-=-?NC_A8%M_T D_\ !@__ ,A4?\+ MO\
MH!)_X,'_ /D*OA/]GG]I!/VBXG\2^%_#WAFP^'U]I#:YX:OY/B7I>J_$74-(
MN+J*+0=7\1?#+3=!9O!6E^)K(W&K:2VK>*I]46Q%BMYI4-U>R067O7A+QCX8
M\=Z1<:[X1U>#6])MM=\2>&9KVVCN8XH]=\'Z[J/AGQ)IY%U!;R-)I>NZ3J&G
M2R)&89);61H9)8BKDLO/O\3\K_JO^&U4:O,HRC)6E\+Y5[UK7MZ?AIV/<O\
MA8%M_P! )/\ P8/_ /(5'_"P+;_H!)_X,'_^0J\RHHLO[W_@3_KO_2UOFEW7
M_@*\O\OR[:^Q67C6*:PU:Y32$3['#:N4%Z3YOG7<<*@N;91&$9U8Y!W %<=2
M,K_A8%L/^8$GXZ@V?QQ9D?D37*Z3_P @;Q-_U[:9_P"G2WKG*22UWT?1M7T7
MZ:?B-R?NK39O9=)+^O74]-_X6!;?] )/_!@__P A4?\ "P+;_H!)_P"#!_\
MY"KS*E !/)P.3R<#@$\G!Q]<''I3LO[W_@3_ *[_ -+5<TNZ_P# 5Y?Y?EVU
M],_X6!;?] )/_!@__P A4?\ "P+;_H!)_P"#!_\ Y"KX>?\ :-B'[4>D?LTG
MX:>.+*/5OA]XX\;6OQ2UF*VTGP?JM[X%D^&AU;0?"UO.'U3Q)%!:_$_1WO\
MQ%;Q6NBV>I6UYH=O-J.HVFI)IWM^E^,O"^M>*/%G@K2M8M[SQ5X%@\-7'B[1
MD2X2ZT.+Q?:7M_X<:Z:6".W<:I9Z=?3VX@GD<):R&5(]R;E:/G_X$^R?^?\
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MOBE^W'^RM\1=9^%OQV^)G[3G@7P1^SY\+/BUX:M?C+\6X?V?M)_9JU:;P?\
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MTG^"?_!2G]F3QM^R1^S;^U9\:?BS\(OV:]$_:*\$V^O:%I?Q:^*?@_P=9?\
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MPZ^\^ZJ*^%?^'H/_  39_P"C_?V,_P#Q)?X.?_-C1_P]!_X)L_\ 1_O[&?\
MXDO\'/\ YL: L^S_ *_X=?>?=5%?"O\ P]!_X)L_]'^_L9_^)+_!S_YL:/\
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M .;&C_AZ#_P39_Z/]_8S_P#$E_@Y_P#-C0%GV?\ 7_#K[S[JHKX5_P"'H/\
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M9&_L;5!H;V<OV6-IS'?"Y4M):QP8D/ZA_P#"OT_Z#?\ Y(7'_P 71_PK]/\
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M7] *7*M=$]>RT\@N_/\ JVOSLG_GN?CM_P 0_P#_ ,$=?^C$_A=_X/OB9_\
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M-CNTNN^_K:R=ETOIZI]3Y1_XA_\ _@CK_P!&)_"[_P 'WQ,_^;FC_B'_ /\
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M"@*!7L_P1_X*F_LX_M(?%?P3\%-2^$_Q\^&+_&'0/''B[X&^*/V@OA+9>"?
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M[^U9\!?$^FZOKVG^,KNR\*Z+X9U3QK<>./$W@OQWX,^']]X.T639J?BOP_\
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M!;VVO2P1)Y7](%%%'?S_ ,DOT'?;R_K^OF%(1D$ XSWZ''?!'(.,X/8\TM%
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M3V$^G^*8O%WC7QIJ\6@:/JL%Y&E_;0:!X)T_P[86&GW+R+:*;AXB%N6!_6?
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M3UN+(_6\@/8#_GKZ #\*^>>>?E7Y?O<=,>O/'2DW?[*]SG QP<'G/J,46?\
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MM--TVTMK#3["V@L[&QLX(K:TL[2VB6&VM;6VA5(8+>"%$BAAB18XHU5$554
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MZ[?6?'OCG5I6_>RW&M:W<3"RCE+'3M%M=+TB$K:V$$:4M$WU>BTZ=7?\/O\
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M%'V:7_GC/_WZD_\ B*+/L_Z_X=?>:J*225DE;LNW_ _I,FTK_D*:;_U_V?\
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M%4T;LG[5U7:+E;5M*^^E[[V_$[QU^T-\6;?0_P!IKX@?##]J#Q1XR\$_ #X
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MZ]NW]UZ6;>O4/JU2[O6;NVTDW&UX\MG9I-:PDDTTI0;TNR4X!( P < << <
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M 'ZD_P#B*'=O9_U9+\+?TS6C2G34E*HYW<6N:3;5DEO)MJ_76VFVC*U'9O\
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M;2W=[+(?OO\ 8\^(GQN^(W@'Q)J7QF\+V&D7EC\4?C'HVCZM#XDM=3O;S3=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ?\ RTH^S_\ !43_ *"G[!O_ (*?V@/_ ):444!=_P T_P#P.7^?DON#[/\
M\%1/^@I^P;_X*?V@/_EI1]G_ ."HG_04_8-_\%/[0'_RTHHH"[_FG_X'+_/R
M7W!]G_X*B?\ 04_8-_\ !3^T!_\ +2C[/_P5$_Z"G[!O_@I_: _^6E%% 7?\
MT_\ P.7^?DON#[/_ ,%1/^@I^P;_ ."G]H#_ .6E'V?_ (*B?]!3]@W_ ,%/
M[0'_ ,M*** N_P":?_@<O\_)?<'V?_@J)_T%/V#?_!3^T!_\M*/L_P#P5$_Z
M"G[!O_@I_: _^6E%% 7?\T__  .7^?DON#[/_P %1/\ H*?L&_\ @I_: _\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>ny20077915x1_linechart0x5.jpg
<TEXT>
begin 644 ny20077915x1_linechart0x5.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( CH$S ,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG !QQQGK@8_'K3J* LNRWO\ /OZA1110,**** "BBB@ HHHH **** "BBB@
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M9)KF6A/;3?5>FFOX[>N^EQJRO\OFNG^35_.Q_4VW0_0_RKXT_P"">G_)F'P
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M^57@Y<K_ - N./I-<:YEX85:N!X&P64XW/\ A]3JYF^(:>/E3RW$82$\US'
MY/1RZI.G2C@JZFIXW'Q6">)I4V\3BY8>C6_N[\%Z/J_[<GC?0OC'XYL[O2?V
M3_ >LQ:Q\#_A[J\,ML?C5XCTB</IGQL\;:==1Q.?"%A.AO?AIX<U"(B]=;;Q
M;J$2G[!;U^@%YXU\':2NS4_%?AK3C&,,+[7=+L]FW@[OM%VA4#Y<[B,!AG%?
MYQFN?$KXX?M[ZGJWQZ^-WQP^)EIIOB36=6B\"_#+P/XKO?#/@KX?^$K.\DL]
M,\/Z/HED18VMM:6D$-H%@LX))5M_M%Y+/=7$CCF_^&3OA=._F:KJ'C[77SDO
MJOC;69V/3.?+FB';^Z.0.1BOLUE]:K&$DX0BXIQA?X4U'OWWNV[[Z6:/\Z8<
M2TZ#FJ>$G7E)WG7G5C!U9)64HP49\E-+2G3YO=CNW)R;_P!$O6_VH_V:?#1=
M?$/[0GP2T1T4NT>J?%/P/8R!0"V[9<ZY&V-JENG !)X!->.Z[_P4D_X)_P#A
MIG36_P!LS]FNRDC#%XC\8/!,\H*9W+Y=KK$SE@01M"EB> ,U_!);_LG? 2W)
M+>"3>9QD7^M:S<[L C#%KU3@Y(.,\'IUSTMI^SK\#+(YA^&/AASQC[7:/>G&
M=V&-U-+OYR?G#9/X8:RN?6:^6O;R]=?3S"7%=>_NX*G;2UZK;N_1)6U7X^J_
MM'\1_P#!:G_@EOX6+C4OVR_A5<M'G<-!?Q%XGZ ,2I\.:%J@88(Y4D$Y )(-
M>*:]_P '#'_!*?1/,^S_ +0>J^(S'GY?#?PM^)=\TF,_ZK[5X8L0^<<$$*<C
MGKC^4BU^$OPLLF5K3X>>#+8IC9Y/AK2T*D'(;/DG<PX.2 21]X=:ZBW\,^&;
M156U\.:% %^[Y&D6%N!^$4"C\26/;.*T65IK^(TWY;?C]^ASRXJQ[^##X>/^
M)5)=NU2-O/Y[6T_HNUG_ (.8/^"<]ID>'K']H7QBXSM71OA#>VV_&,8_MC5=
M.*[ADKO5?NG/;/F.I?\ !SI^S4R,/"O[*O[6OB&?!,2W'A#PYI,,G!"YD'B&
M_=<N8E($38$@;G&#^&4=O;Q "*WMXP.@C@B0#Z!4&/PJPKN@"JS*HZ!6( Z=
M "!V'Y#TK19722UG)O35*WKU_K\L7Q+FDMGAZ>VU%RZ*_P 4O7[_ "/V U'_
M (.8-3N1*/"7_!/'XY:AS^XFUGQ/9:9&ZGE3(L'AF\5-P5QM$[$$*!G<#7,6
M'_!RQ\3=#U2UUGXG?\$_?%OAOX86]S ?$NO:'\0H=6\0Z'ICS)#-J*:3<>'K
M&VNOLHD61X+BZL8V */=0Y5A^4VYO[S?F>W3OVK&\0V::AX>\06+J'2\T'6+
M5E8!@PN-.N8L$$$'EQ3_ +,HV?O3O9VV6NFKWOMMINS*7$&:N2D\1%1BTW&-
M&E:25FT[Q=KV?33=:G]2O[4G_!<']FKX(>"_@GJ/P@\->,/VH/B1^T1X0LO'
MOPN^%_PTA6/5W\)7CO$NM>++JYM[D^'$CO;:^TXV+V=UJ"WVGWJS06UO:SW4
M7R-9_P#!PQX[TUD'CC_@F1^U)HT:KFXGT2>VUQ4QRSQ)+H.FB2,@,4;S?FQC
M/>OYJ/\ @CF;OQ)\:/B3JVK[[M_ GPGTKPMH,MR3.VE6MSXID=K6R:0M]D69
M5N&D6 H""PVD2,:_HC#-C&XXY&,G&"2<?3GITK^%O&_Z4F;>%?B#BN#,JX5R
MK-\-EV799B,7B\PQN,HXBKBLRPM/'.%%89*G1I4:%:C!<\:TIU'.;<4E!_V+
MX1>!E'Q+X)PO%V/XFQ^35L=C,=A\-@L#@<%7P]*C@:\L)*=66*YJU6I5K4JL
MUR3HPA#DARRLYR]CLO\ @Y*_9PMRB^,?V3_VTO!Y&!<S7?PLTV\M;=OX@94\
M0V\T@!XRMODD$8R*]"TG_@Y'_P"":MVZ1:]K'QP\&3LY1H_$?P6\5 1,.TDF
MEKJ2 <J 5+ E@,U\L."^-V&"] ZJ^,G)P6!QD\\=^>M9UWH^DWZ[+[2=,O4S
MDK=V-I< ].OF0'CY1D8YP#G@5^?87Z=M=)+'>&5"H].:>#XKJT%TNU"OD.*Z
M7T=3?KV^YK_1-Q*;>$\0]+:1Q?"U.>O2\J&=T/O4.FR/T<T'_@OO_P $H==6
M/=^U/I>AR2 ?N/$7@+XF:5*C'.%D:3P?)#&QP>))EZ<$U[SX=_X*W_\ !-/Q
M2D;Z5^VG\!(Q)@*-9\;6?AQ\GL8]?7374^H<+CC/45^'FI?"7X5:PK+JOPT\
M!:@K9#K=^$?#]QO!QP3)IIVC@< '/&>@KS;5/V1_V7]:#?VE\ ?A/<.V=TL?
M@O1;.9L^LMG:0R\<8VR+W]37TN$^G1PI4M]>X X@PK^W]5SG+<;'_MSVN%P4
MI:=XK6_1+F\6O]%;BZG?ZMQAP]B4MGB,HS'!.7_@K'8Y1^=_)O7E_IYT']N7
M]C#Q0L;^'OVK_P!G35UE V&S^,O@"1FSC&$_MX-@Y')'4@=Q7L6C?&'X2^(X
MTE\/_%'X=:['(%,<FC>-O#>IQNK#*LCV6I3*X8<@J2""#GFOXX-1_P"">O[&
MVIEVE^!/A6U=P?WFF7&M:<X)SG8+;4TA3DG!$.X8&"!D5P]W_P $POV1)R7L
M_!_BG0Y,DHVB>/O%-EY>><JK7\T>1V(B7V '%?283Z;7A36M]:R3CC!MVO;+
MLFQ*3ZZQSRG)I=U"]ME?1^)6^C)XFTF_98[@W%+6ULRS;#R>UM)Y+55WU]ZR
M[V6O]R5K?V5\@ELKRUO(V&1):SQ7"$>H>)W7!['-6@<^GX'/]!7\*7_#M+X2
M6+!O#'Q8_:.\),I!1=%^+>K1QQX P5CEMW.X,#A@RX4E<=QT5G^Q]\:?#D)B
M\!?\%"OVT/".T'[/#;_%+6KBVC<DA"R1:G9NR+O=S&I&XX1<9#+]+A/I?^".
M)M[7-L_R^]E_MG#F.J--VW67/'MK?X4Y7LN74\3$?1Z\7,/=K)<FQD8IN^#X
MAPJ;LNBQU' ZO5ZV7:6Q_<917\/?AS_@NO\ M>_L.:!\6OV3_B\MC^U#\>=!
MUKPROP%^+7BK_0;.X\'Z[9S7=_=?$A+&XMM2UFYTNU^QRZ7&L\-Z\\]]!J>J
M3PVMMOQ_#_\ P<=?\%&M).?$'P=_9K\71AL'[';>+-#E;@$X>+Q+<19SE<F(
M#N><U^]1XQX3>"RG,7Q%E5/!9[EV&S;*:]?$K#QQN78RE"MA\53C7C3J0IU(
M5(V]K"G)24X-*<)J/YK@>%>+LSK9MA\MX1XDS&OD685LISJGEV4XG,/[-S/#
MSG"K@L1/!QK0=:+IRE:DZD73<*E^2<6_[G**_C-T'_@YY_:,LXXU\7?L1^#-
M6=2OFS>%_B?J=@&!)#F.*^TC5 &QC8"Q&<Y//'M?A_\ X.E/"B&)/&_[#_Q=
MTUB5^U3^&O&WA[6XHUZN\45UH^GO-CJ%:2//]ZNRCQ%P[B4GA^(,BKWM:-+-
M\OJ3=^T(XAR\MMTUN98KASBC W^O<)\68&VK>,X9SS#))6NW*K@(PLN_-8_K
M'HK^;+P__P '/_[#]V(5\5?!_P#:B\'NY DDN/ /AS5;.+@?-Y]GXOBN)!UP
ML5B[L 2%&,5[[X<_X.,O^"6.N^4E_P#%_P ;^$YY"H>+Q/\ "3Q[:K 6 )$M
MS8:1J-KE,X?9.X7!Y->K2J4ZZ3HU*=9-77L9PJZ;W]QRMHT]3P:N)HT&XXB?
MU:2WCB8SPTDUNN6O&G+1[Z:=3]T**_+7PS_P6L_X)<^+'CBTW]L3X8VDLJJR
MQ^(!XB\-;0V1B237M#T^)""""&DXXYY%?0OAO_@H7^PIXN*KX=_:_P#V<-19
M@I"#XQ> [60!L8W17NN6TBDYZ%01W%;.G43:<)IK1WB]':]GIH[.]B8XS"32
M<,5AY)[.-:F[^EI:_(^Q:*\\\)_%SX4^/72/P+\3/A_XUDE4O&GA+QEX=\1N
MZJJLS*NCZC>,5575F., ,I[BO0ZBS6Z:]59_<SH34E=--/9IIK[T%%%% PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _E!^'_P"S_/\ $;XP_MGZ[X=_
M8!_84_: T^']LOXYV<_C_P#:V^,5EHG[0$VIQ>)P^J6WB70D\!^-FT?PC:74
MDL?PKM[J]TJ\O/AROAO4Y=.E2^BU"]_J8\%6;:=X.\)Z>^D:/X?>Q\,Z%9MH
M'AZX%UH&B-:Z7:PMI.AW0M[07.D:<4^QZ;.+6V$UG#!(+>'=Y:_RN?$3X3?#
MKXS_ !]_:7UZZ_9B_P"".GPIUOP]\??'_A/5M)_:R\<>+M!_:"\6-I&JQFR^
M*/C72=+?3+:UM/B;87,/B_PC+;B[MM0\-ZII=_!?72S+G^EG6/B-X#^ /[/A
M^)OQ$U'0O#/P\^%_PQT[Q!XKU7P=9ZKKGA70O#OA_0;5[^Z\.6NF6VH:M?>&
M]/M86;2F@M;BX;28H)'#%6-)==M_+LM_^#]_:F[VWV2MKV7GU\DCW"BOROTG
M_@L]_P $_P#7]*L==T+XB_$_6]#U2W2\TO6='_9J_:/U32M2LY 3%=V&H6'P
MLN+2\MI0"8IK>62.0*Q1F"L1^F7A;Q)I/C+PSX=\7Z#+<S:'XIT/2O$6CS7E
MA?:5>2Z7K5C!J5A)=:9J=O::EIUR]K<Q-/8ZA:VU[:2EH+JWAGC>-7\U]_\
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MK0 ZBBFLRK@L<9.!UZX)[>P/_P"N@!U%("" 000>E+0 4444 %%%% !1110
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M#\(9K0P%;-8XS"9%@N(</5Q57#3PRP^,GATL%5ITL-"I4JPA5;>)C.G!R?\
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M\/?!&@+$J+$NC>%-!TL1J@P@06-A!M"C[H7 ';M7;K#%'CRXTC [(JH#[$*
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M_A33U49)PHM=)B Y)/'J:]?HKFN^[^]E>SIWOR0OM?EC>RV5[=#%L?#?A[3
M%TW0M&TY0,*+'3+*S"@;>%%O!& /E7@>@[5L!$'1%'?A0/Y"G44KON4DELDO
M16_K9?<)@>@_*EP/0444#"BBB@ HHHH **** "BBB@!" >HH*@C! (Y'//7K
M^?>EHH K365G<(8[BUMYXR,&.>&.5"/0K(K*1P.,8X'I7'ZI\+_AKK:21:S\
M/?!&K1R@B1-2\*:%?*X(P0PN;"4$$<$'MQVKN:*!-)[K^MSY?U[]B7]CSQ0)
M?^$A_9=^ 6KM,'$KWOPF\#S2OOW;LRMHGF@G<WS!PPR<'->/7_\ P2J_X)R:
ME=QWUU^QG\ S<QS+<*UOX#TNR3S58,&:"S2"!UR!F-XVC(X*$9%?H#13N^[T
M5EKLNWIY&,L-AI-N6'H2;W<J5-M^K<?)?<?F[^VA_P $K/V2_P!MOX8>!?AG
MXZ\)W/P^B^%7F)\*_$OPG_L[PAK?@"SN%@2\TC0X8M/GTC^PKX6ML;K2;C39
M;8R6\5Q!Y%RHFK\<?$7_  :U?#5W9_!'[:GQKT%5!\F#Q#X1\->)QDC"A[B'
M4]$8!3DGRX &[H,BOZL**YL3@\'C$HXS!X3&1C=*.+PU#$I)ZM+VU.=DWJTK
M*^NYU8>KB,'.53 XS'Y?4DXN53+\?C,!.3@E&+E+"5Z+DXQ2BG*[44E>R/XW
M?$'_  :__'2R9V\%_MS:!J"H"8(O%?PLN[1V(VX66?3]<U(+NYW%(6P ,#U\
M1UW_ (-N_P#@H;I(E?P]\<_V;O%01=T<=^?&6C3W!R3M);PK<PPD^IE(]?4_
MW(45XU;A'A/$7=;AG().6[CE6"IOY2ITH27JG=7=FGJ?18;C;CK!6^I\=\:X
M>UK*/%&<U(Z*RO#$8RM"2\I1:Z6Y=#^ 3Q!_P0;_ ."L?AV-GL/ 7P-\<%=W
MR>'OBGINGRRC)("?\)&NCHI(4?>C ^8#Y>WB?B7_ ()._P#!6'P@K'4OV,-5
MUY4!._P=\0O 'B)W'4F.#3_$,\C;1Q@*S=\&O]&>BO(K>&O >(NZG#6$BW_S
MXQ.8X9)VM=1H8RFN^FVODCZ'"^,/BQ@VG1\0,]FE;W<91R?,$TK;RQV5XBH]
MM6YMN]F[:'^9#XD_9 _;[\&[O^$G_81_:;MQ&2)&T7X<:YXG P<$AM"L;U64
M'JR!E !8G )KQ#Q!HOQ9\'2&+QM^S_\ 'SP9*K%&3Q+\*?%^F,'4992+K2(.
M0.2!R!CL:_U2]HSGI],#/3J<9[>N>34<EO!*"LL,<@/7S$5L^N<@YKR*W@]P
M)534<%F&&;V>&S/$-QVT2Q2Q*:W>J;OUL?0X7Z0_C#AG[_$F6X])KW<?PWE6
MJ5M'++X8"5N_5ZW>J:_RL/AW\-_B-^U1\1/!?P#^#_P^\:^)?&WC;Q7H.GS6
M9\-:G:V^A:7'J<$VI:WKMQ/;"/3M)TZWCDGO;ZZV6MO!',TSJWDK)_J5>!/#
MO_"(>"?"'A/>D@\,>%] \/!XEV1O_8NDVFFEXU_A1S;%T!Z*P'.,UJVF@:%8
M7,M[8Z-I5E>3JJ3W=II]I;7,Z*Q=4FN(8DFE169F".[*&9FQDDUK5]?PUPSE
M?">6SRO*?K+P]3%U<;4GBZL:U:=>K3HTG>4*=*"C&G0IQBHTUM=MMMO\]XOX
MPX@X\SU\1<2UL%5S'^S\)E=*&78.6!P='!X.>(JTXPHSQ&*JRJ5*^*Q%:K4J
M5Y7E-1A&$(J(4445] ?-!1110 4444 %%%% !1110 4444 %%%% !1110!_)
M?^TI\)/&OPT_:'^*?PNTGXQ_\$TX?!GC>+]LO1-<\9?'7]HWPQX#^*OAO2_V
MW?&'@CQOKM[\5_A-J%K=:KXN\5?"(:#J&C_#^2#6+2S\0>'XO"$5X_AS^RY@
M?W0_:E\4?#G]G7_@G'X_U[Q3X9\/_M&_#_X7_L]:'IMOX<\9)IWB'PO\7(M,
MT/1?#_A9O$\L\.I:5J&C>(]4.DZCJVI&&\@CLIY]2B6;RT9OPJ\ 6S2_&/\
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MO-_+RL;$H8Q2!?O&-PO7[Q4@=.>N.G-?QG_LX-XF^"L/P%^"6A_'K]I35/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4>-[SXO>%_#OQ/T.3Q-\/-9UC7/%-EI_C+P_%)'%)J_A^ZGU!(=1L4>6(/-
M[*HFA;E94)\__P"%B_$;_HH?CK_PK_$7_P LJ_6"Y_8)3XP3_P#!+?X?>%/B
M#XT&I_M2_"KQ7XB\67OC77V\1:!\.]&\(ZM=7_B*Z\#://'9II&EZ?X5T_4=
M0B\/Q7,BZAJ-K%$)XVG(%GX9_LW?\$\/VK?B!XR_9E_9PNOVC?"_QJ@\.^,[
MOX.?$SXB^(O!.J> ?BSXB\":-J.M3Z5JGA;3-#T[5O"5GXML='O+K1+F/4[R
M6TMQF^CCN8TM;CD6%S^K4IPIX_$4IXB>'H82C7S.HZV+Q5;"87%_5\/R\L95
M.3%X=_O%2IPE7I4'5E5FN?VZ?''AQA<!7Q6/X7PF/66T\XS#B#'9/P?AO[.X
M<R++>*,^X;AF^<JO6K5J.$6(X=S95)X26.Q%>CE>8YG3P-# TW[/\EO^%B_$
M;_HH?CK_ ,*_Q%_\LJ/^%B_$;_HH?CK_ ,*_Q%_\LJ_1KX-?LZ?LBZ%^Q-%^
MUI^TJ_QKU758/VB_$/P4L? 'PKU3PQI8\4/%X*TOQ%I<-WK/B+3+V+PO%I<G
M]MWNIZO'%J\]\D=GIMEID<KM=#W[XD_LN_\ !,;X,>*_@!?>)=;_ &IO&_A?
M]K?P5\//B!\//".AW?@C0-6^#O@_QO-'I+ZMXV\4WNEZC;>-M3@UP7PM=#T'
M2=,:"STVY>\O+MY;![R*>'SR="GB'G*I0G2H5VJN:U8SIT,1-TJ-:I#F<N6=
M9*DXP4ZD')5:D(X=RK+IQG&_AOA<TQ.4T^ ,RS#$T,QSG**-7+N"L%B<)C\U
MX>I0Q.;X'!XF4J4)3PF!;QLL1B/JV!K4X5<-A\56S&/U$_&?_A8OQ&_Z*'XZ
M_P#"O\1?_+*C_A8OQ&_Z*'XZ_P#"O\1?_+*OT)NOV3/AA\%_VYOC;^R[\2OA
MY^T)^T?9>"+O4M+^'?AS]G;^R;;QWXEN9WTO5_#^H^(A>:-X@-EIL7A:]9M;
M&DZ7>36VK>7C-NKUW/[:/["?@3X2?!_]G[X]^!OAS\??@AI7Q1^)FK_"GQI\
M'_VA?L$OC?0-:TZ.._TS7]$U*ST'P^U[H.NZ5'J1BDN]+CD@NK:(!3N>)9>'
MXA5'&UGC<8GEM2I3QM'ZWBO:4'2K4\/-RF[8=VJU(+DC7=5Q;J*G[-2D=L>+
MO"N6;<+Y6N'\M5/C/!8+'<.9I+)LDA@<RIYAE&(SO!PA0G7CG--U\#@Z[5>K
ME,,%'$Q6#EBEBJD*,OS"@\?_ !+N)H;>'X@^.GFGECAB0^,=?0-)*X1%+R:H
MJ(&9@-SLJ+G+, "1Z5\9/#_[1OP ^(NO_"?XL^(O'7A;Q[X7&F'6]#'Q#N=:
M6S&L:38ZYIS+J?A_Q'JFDW*W&F:C9W(-K?3>7YIBEV31R1K]^_M\?L^?L*_L
MD^/_ !G\ _AP_P ?_%OQYTC6_ >MZ5XDUK4_"D?PP\):3KK>'M:O/">JVJ:=
M;^(?%&I+X8N;V\77[)-/LXM5U'3K%;.6*SO'/V=_P5$_9E^%O@CX^?M&?M9_
MM5W'BN/PGX[MO"/@_P#9D^&/@34;2P\2_%7Q[I/PI\%V^L>(]=U^32]<T_P?
MX \&7#C^T?ML":[K]XDEMI-IMB0WW=+ 9S2HYI&IFM=XG*L7A:&+E3S&I/"8
M2G.GF7UGZS53:52%?!4:-*,)2=2K6CAX0JXBK"FOE*/B+P)B\UX#GAN"L-2R
M+CSA_B',,APV-X2PM'B3B#,L%C. UDL<BP+JI3R_%9=Q+FN-QM7&4:*HX7+:
MN:5Z^"RG!XC%5OYY?^%B_$;_ **'XZ_\*_Q%_P#+*C_A8OQ&_P"BA^.O_"O\
M1?\ RRK]H/!7_!-CPAX(^$_P"\2_$K]FO]LG]H_Q-\<O!FC_ !,\1:S^SI#:
MV?@GX/\ @KQ/*[>'].6[D\$^+AXY\<MI"Q:YJ6C-?:%9VT-Q#8M=QSS1N_.^
M#_\ @F?\(="_:M_;.^!7QD^(GC6S\ _LX_ #5/CSH/C?PWIM@?$[^';23P5X
MD@BUSPO=*T4^O)X/UO4=*N-$%WIB)XF$%Q)-':Q-9R8?V?Q1:@_K6,7MYTZ<
M54QF(I*%2KA:F-I0G4K.G1;GAZ-2;E3J5(4G"4*\J4U*)Z</$SP7G+.%3R?+
MJ]/)\+CL<ZF%X?RK'2S#!Y7GF!X=S&O@,+@9XG'/ZMFN/P=*-'&X7!8G'T:Z
MQ>5T<=A7[4_( _$;XC#G_A8?CK_PKO$7_P LJ^TO$'[+W[5ME9?LTZ9X3\9_
M$#XC_%#]IGX=:Q\5/#/PA\':YXQO?&?A[P78W=Y'I.IZY#-J44!/B#2].U'7
M+**V!:'3K.1YCD@' T;X3? K]IK]KOX-_!K]DSPW\6/#/@/XC^(O"OAK4+3X
MM:SH&N>*[2;[?=W'C+Q"+[PK9QV,&C:?X7MWUG8UO++9&QOFF9K5%D'ZO?LO
M?&'3?CU_P6\N]1\$/!!X#\'^"/B[\&?A%;131PZ?8> _AE\'O%'@SPTUE-'(
M]I::?>2V5QKB3I-'!G4I+C*+S5Y7#&8JM2H5\VQLOKF;8'*,)6P^+Q$HRE6K
MTWB\31YY0=18>BZ$.6I!)O&TY.-T<7'^?8'(\%7S+)>#<CPDN'?#SBSQ%X@R
MS/,ARR->G3R_ 5<)PUDF8K#QK_5'FF:_7L=4J8/%>V=+AS%8>%;V=>:G^/GQ
M<^ _[<_P%T2W\3?&/P5^T-\//#5U>#3X/$7B*?QC:Z&;]L".RFU9+Z2QMKJ<
MD"U@GGCDNCD0!R"!\XCXC?$8@'_A8?CKD _\C?XB[C/_ $$J_;?P]HOC']D#
M]D7]MWPY^U7\8O WB3_A?O@S3O 7P7^ NA_&70?B_KM_\08O%MMJR?$DZ9X2
MUOQ-IOA"Q\+6,+SS:K?7.GW-W=1PZ<\9N6L8I_&_''[._P"P1^R1?_"SX0_M
M46_[1GQ ^,OC7P)X)^('Q+U[X4:]X0\,>#_A-:?$'3DU/1]"TK1]>T34]3\:
M:MHFFSPWFN%[O3()F<16?[[%H#$X;-(JC4IYGCL%!X:E4Q5/,L?5C/!5ZV(K
MT*%"K*BN9SQ4<.\12C*A3G"DYSJJ-&*K3?#_ !EPS6^NX3,.#\AXHQG]KXS!
M\.X[@'AC#U\!Q5E>6Y+D^;9OFN7T,RQ52E3P^18G-89-F-6GG..H5LR]EA<%
M5JX^K5P&&_.[X>:9^TC\6;CQ-:_#2[^+WC>Y\&>%-6\=>*H/#>M^*M4ET'P=
MH7V<:QXDU)+;4':WTG3FN[=;JY<!8S*G7->>CXC?$8Y_XN'XZR"01_PE_B+@
MCL?^)E^(]B#WK]>_!O\ P3\T[X;?M4?MM_ /7/B3X]_L3X2_L=_$WXT>!O%O
M@769O!MWXXT1M%\)>(O"%CXMM8K6Y34O#VH:?KHM?$_AV-_LE]J&G$0W2);I
M7'>!?V0O@'HG['7PI_:0\6_"O]H[]HN+XB/XX/Q/\3? 'Q7X8TW1_P!G!O#F
MI_V;I>C^*?#<_A3Q5J=]K-_9?\5#+=>(KSPKHILI8X8K]#+#+)G]4X@Y9J6-
MQE&IAUCI8IU,?6J1IK 8FAA*UH8?VM1^SK5H1G*/M(*#E7E*G0C4J+N7'?AC
M[2&(HY%D^9Y?FCX4CP]# \,X#"XG%RXHR',>(,+[?%9OBL#@4ZV RRO.A0JK
M 8GZPHY93I8[,\5AL/+\MO\ A8OQ&_Z*'XZ_\*_Q%_\ +*C_ (6+\1O^BA^.
MO_"O\1?_ "RK[U^#'[._[-?A#]EVX_; _:EF^*GB/PGXM^+6K_!_X._";X5:
MCH'AKQ#XCU/P]I$.M>)/%7BWQ9KNGZU9:/HFEPW$&G0VUAIMQ<WE_,'C>2#"
MQ]G\3OV-O@/J<7[%OQR^ FJ_$9?V=?VJOBU!\(_$'A3X@7>BW'Q#^&GC/2O%
MFC:+XAT-_$.C6B:/J=MJNF:A>ZIX<U,Z<DZ16;O>VT@:*)<(T<^EAU769UG+
MV-#%2PW]H5_K-/"8FM3P]#%5(.7(J4ZM6BN55'64*L*LJ2I2<SVJO$_AG0S6
MIEM7A6E"A#,\UR*EG<N%\"LCQ?$&29=B\US/(\)C&O;5,=AL'EN8IU:F&I9?
M5QF"Q.74,=5Q\)89?FO_ ,+%^(W_ $4/QU_X5_B+_P"65'_"Q?B-_P!%#\=?
M^%?XB_\ EE7[BK^PK^P)XB_:R^*W[ G@S5/VDG^-^D#XEQ^$?B]K&I>#(/A[
MI?BOPGH.H^+M-\(:AX/32I-<U?0[;1]/.CWWBLZKIMUJNK)+=6FE:?8S13P_
M@G>6LEC=W5E, )K2YGM90IW*)+>5HI &YW ,AP<\CFLLP_MO+>3V^9UJBE7Q
M6&<J&85JJAB<$Z*Q-";YU>=)5Z$G*'/2E&K'DJ2?.H]W!N;^'G&\L1#+.$J.
M"K4,JR+/J=#.>&,#@*V+R+B6&-GDF;X:'+6;PN.>5YA35/$?5\;1J86HL1A:
M49TIU.G_ .%B_$;_ **'XZ_\*_Q%_P#+*C_A8OQ&[_$+QT0>"/\ A+_$70\'
M_F)=<9Q[UQ]%>;_:F9_]##'?^%=?_P"6>7]79]S_ *J\+_\ 1-Y#_P"&C >7
M_3CR_%]S_3 _X)NWE[J/[!'[(E_J-[=ZC?7GP"^&]Q=WU_<37=[=3R>'+(O-
M<W5P\D]Q,YY>65V=C]YB>:^V*^'O^":/_*/W]CO_ +-\^&G_ *CEG7W#7]G4
MKNE3;;;=.%VVVV^5:MN[;?5O5]3_ )N^*8QAQ/Q'"*48QS[-XQBE91C',,0D
MDEHDDDDNB"BBBM#P0HHHH **** "BBB@ HHHH *0G';/XX[''YG _&EHP#U&
M: /,O _QG^$_Q+USQ7X:^'_Q&\&>,O$'@:[%AXQT;PUXATW6-2\,7IN;NS%K
MK=G93RS:=/\ :K&\M_+N51O/MIXL;XG ]-K^5_\ X):_'WX)? G]LS_@I1=?
M&7XJ> _AA;^(?BYJ%OH$WC?Q+I?AV/5I=.^)OQ2DOX=.;4KBW^TO9QW5J]PL
M6?*2XA9L"1"?W:_X>%_L-?\ 1V7P#_\ #F^%O_EC6]:A*G4<8QG*/+!I\K=W
M*$9.S2LTI2LK>1Y&7YM0Q>%C7K5</0J.K7@Z3K03BJ->I13M-J7O*"EJNNC:
ML?8U%?'/_#PO]AK_ *.R^ ?_ (<WPM_\L:/^'A?[#7_1V7P#_P##F^%O_EC6
M?LY_R3_\!?\ EYK[SN^NX/\ Z"\-_P"#Z7_R9]C45\<_\/"_V&O^CLO@'_X<
MWPM_\L:/^'A?[#7_ $=E\ __  YOA;_Y8T>SG_)/_P !?^7FOO#Z[@_^@O#?
M^#Z7_P F?8U%?'/_  \+_8:_Z.R^ ?\ X<WPM_\ +&C_ (>%_L-?]'9? /\
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M-5=?#8>M))2K4*5626R=2G&;2OK9-V7D%%%%2;A1110 4444 %%%% !1110
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MOAOJC^ =/U6VM9DCUI?&WCA_!O@;Q5%I,F-2M]"\,>(=;UGQ(($L]$TS4GN
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M,C+<&_DM&NO/0QQLDOF>8K1HP<%5(ZNB@04444 %%%% !1110 4444 %%%%
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M_P#PY/C/_P"6E?KK167UK$_\_P"K_P"!OR_R_%]SN_L?*O\ H78/_P )Z?\
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MNC7ECK4^C6]OXHU[3KV:S6^O[ 0M,?-BM(=@'[;?LE?">T^''[.G[/FA>(?
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MU*JJ/A3XG 50 !\2?&>  , #.J$X'3DD^YI?^'''_!.K_HE7B?\ \.3XS_\
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MIX>\0^*/$.B_$+X#Z;H%W:Z='8_'?2O#G@KQ;XBU2[GO8[?3?"_P^L?%.O\
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MM-,O[F\UZ:%?#ND6]N\FM:IIP:,M^Z'A_P#9@_;*\*?\%9[_ /:H\3C6-!^
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MQO&8Y;#PO+JMS#(T<<L:--#N_=+]HZY\$?"?X1?M#?\ !4#P7>:19:U^WO\
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M^Q_G'_JQQ(4445H> %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVF+Y)5I?T'JRL 58,"2 0002,Y ]Q@Y^AI<CZ\XX!//OC.,=R>!WK\N_@O\
M#CQI'^R*WPB^('Q<_:)T?Q!XJU;5_$>H?'+X?^*=(\7^+O#CZEXQ7Q0^A^#O
M%/AW0=<.D:!IL<)\,Q:=J7AJ\>QT2:_L5U&Y41:A4>K_ +8GP!U3]JWX;);_
M !J^*-IH_@_PAXI\,W-CI.H0P?!;QCXD\2R:;;VI\<:)-H#^(-4\3:$-/?\
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MV@_ B]T26YA-M<R:1\>/@WICW%NQR8)Y++XF0230D]8I'://)4U4D_X(A?\
M!5.:QBTN?]GUIM,M[B>[M]/E^-_P5DLX+JZ6-+JXAMG^)3013W"11)-,D:R2
M+&BNS!%Q_H144?\ $+.%;6Y<QLME]==E>U[+V>E[)Z==2G]/CQN<W4>7>'WM
M&XN53_5O&J<G"+A"\EG?,^6,IQC=OEC)I:-W_P ^*?\ X(D_\%6;K3K72+GX
M!W$^DV,DLUCI<OQT^#,FFV<TQ8S36MA)\3&M+>69G8S2PPH\N3O8Y.;FB_\
M!%G_ (*T>&_/_P"$=^"&I:#]J 6Z_L;X]_!_2OM2KG"W)T_XGVQG5<G:)2P7
M)QUK_01HH_XA9PJFFHYBFK6?UUW5E96?L[Z+1>6@I?3W\;9TY4IY;X>SI3;E
M.E+AK&RISE*:J2E.#SMQDY3O-N2;<WS.\KM_Y[%Q_P $.O\ @J7>7$UW>?L[
M1W=U<R--<7-U\:O@C/<3ROR\DTTGQ':261CRSR,SL?O,34/_  XR_P""H7_1
MMUI_X>3X'?\ SQJ_T+:*7_$*^%/Y,P_\+7_\J+7T_/')))8+@)))))</Y@DD
MDDDE_;MDDE9+9+3O?_/2_P"'&7_!4+_HVZT_\/)\#O\ YXU'_#C+_@J%_P!&
MW6G_ (>3X'?_ #QJ_P!"VBC_ (A7PI_)F'_A8_\ Y4/_ (G]\<_^@/@/_P 1
M_,/+_J>^7X^M_P#/2_X<9?\ !4+_ *-NM/\ P\GP._\ GC4?\.,_^"H(Y;]F
MZUQD9V_&/X',W)QP/^%C<DGCD@#J2!DU_H6T4?\ $*^%/Y,P_P#"W_[DP7T_
M?'-6_P!CX"=K:/A_,;/;>V>IV=NC3UWWO\K?L._#?QE\'OV/_P!F_P"%GQ#T
MI-#\<?#_ .$'@GPGXJT>.^L-333=<T;1K:SU"S74=*NKW3;X07$3H+JPN[BT
ME #032(0[?5-%%?H\8J,8Q6T4HKT2LOP/XMQ^,JYCCL;F%=05?'XO$XRLJ:E
M&FJN*K3KU%3C*4Y1@ISDH*4Y24;)RD]64444SD"BBB@ HHHH **** "BJDE_
M8PNT4UY:12+@M')<PHX!&061G##/;(Y'(J6"YM[E2UO/#.H."T,J2@'K@E&8
M ^QP: )J*** "BBB@ HHHH **** "BBB@ HHHH **/\ /K_*FJZ.-R,KKDC*
ML&&0<$9!(R#P1V/!H =1110 4444 %%(20"0,D#IG'ZX/\C7&>#/B+X&^(:>
M(I? _BO0O%4?A'Q9KO@7Q.^AZC!J"Z%XQ\,7?V'Q#X:U0P,PM-9T:[_T?4+&
M7$UO,=C@&@5TFDVDW>ROJ[;V76W6QVE%%% PHHHH **** "BN*\:?$;P+\.8
MO#L_COQ9H/A.'Q;XKT3P+X8EUW4;?3TUWQEXDG>UT#PSIAG9?M>LZQ<1O%86
M,6Z:X9'"*=IKLRZ*I=F54'5F(51SCDG '/'/?B@2:;:33:W2=VO7M?I?<=11
M10,**** "BN*\*?$;P)XZU'QCI'@[Q;H'B;4_A]XDE\'^.+'1=2MM0N?"OBF
M"RL]1F\/ZY% [/I^JQ6%_97;V<X658+J&0J XHUGXC>!/#OC'P;\/M=\6Z#I
M/C?XAQ^()O WA:_U&WMM;\5Q^%+*'4O$CZ%82.)]0&B6$\-YJ7D*WV6WE223
M 84"4HM74DTW9--6;O:U]KWTMO?3<[6BFJZ.,HRN 2I*D$!E)#*<9PRD$,#R
M""" :"Z!E0NH=\[%+ ,VT9;:I.6VCDX!P.30,=1110 445F:SK&F>'M)U37M
M:OK32]&T73KW5]7U._N$M;'3=+TVVDO+^_O+F4B*"UM+6*6XN)I&5(HHW=F
M4T :=%<YX/\ %_ACQ_X6T#QMX+UW2_$_A+Q3I5GKGASQ%HMY#J&D:UH^H0K<
M6.I:;?6[/#=65W Z2V\\3%)(V#*<&MT7$#3& 30F=1N,(EC,H'<F,-O '<E0
M.1S0)-/9IWVL3445&)8C(T(DC,J*':(.ID5&X5F0'<%)Z,0 >QH&245'+-%
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M\KS_ -[OK5HH"_IIY!1110(1@&!4YPP(.#@X(QP1R#Z$=*_-7X??\$F_V/\
MX6^.+;X@>!;+XTZ!K<'Q#U#XJ26=K^T3\:AX:U'QOJ_B"7Q1K&L:QX6;QH=
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MQ4\.\5A9J2Y*G+M4I\\WA\1#DQ.&E.<L/6IN<W+Y4^-NK?$SX*?"_P 7>,O
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MOP[;?LX?M&Z+\;]9L]1L+N]E\3Z;I'A7Q/H)T'3GMI(X[*]GNM<MKC[7=+)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7V=11;U^]_UT_/NQ\S_N_P#@,?\ +R_/NSXQ_P"%'_M=_P#1\=U_XC=\)_\
MY)H_X4?^UW_T?'=?^(W?"?\ ^2:^SJ"0 2> !DGT HMZ_>_ZZ?GW8<S_ +O_
M (#'_+R_/NS\OOVC=&_;-^"?PIO_ (A:1^V;%K=]9^+_ (6>&DT_4OV<_AC#
M:-!\0/BEX-^']Y=.]G>1S&73K/Q1/J-K&&2.6ZM(HKAO(=\>Y_\ "C_VN_\
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MHNH3QP^*O$]RAT(27%[;R2S79DBL$:'Z8\(^,/"GC_PQH7C7P-XDT/QAX/\
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MV?7?@O5;K7?!_A37+XQF]UKPUH6JWGDH8X?M6H:7:W<YBC+.8XS+,VQ"[;5
M!).2>FKYG^'G[3?[+>J_$:?]F'P+\?OA5XG^,7P]T=--U7X6Z9X]\.:KX_TN
MU\-V=G9WL>H:'9WAO3>Z7"UL^LP);"XTXSH][;VJNHKZ8IDA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5A^)-+EUO0M8T>*9;>35-(U334G="Z0/?V4UHDS(""ZQ--O9 P+*"!@\C<H
MI2BI1E&2O&2<9*[5TU9JZLUH]TT^Q4)RISA4@[3ISC4@[)VG"2E%V=T[22=F
MFGLTT?B-IO\ P3K_ &L_$?[-/@S]BOXF?'SX*VO[./AZT\.Z)XANO /PK\6C
MXJ^+/"_AO7H?$$&B'7?$GC2Y\/:+/J%U;0Q7FL66@&YABC5;:V"R2*?IKQ?^
MP%I7Q%\<?MB7OC#Q,!\/_P!JCX.?"3X30:+I=K-%XB\(_P#"M="U72TULZC/
M++97LZWMUI^I:<B0QB.6R,=UYZOE_P!'Z*^>I<+9-3A&$J%;$*%.C0C]9Q6(
MKVPV'P>-P-#"I3J.*PU+#9CC(1HJ*BW7E.7--0E']2Q_C/Q_CL57QD,RP&6U
ML1C,;F=5Y-D>3Y4IYOF.>\/\28[.)?4\%2E+-,5F_"N08BIC)RE5C#+J>'IN
M&'J5J53\I]-_8J_:>^(E[\#/"?[4'[0'PY^('P<_9\\8>%?'6A:+X"^%^K^$
M?&GQ.\3?#Z-X? E_\1];U3Q;KNF6=OI$@BU+4+#PWID,>L:@&,\T<>&'L/AO
M]D/Q'H4/[>L+^,])E_X; \3:SKN@%-)NT_X0V/5?A)I'PX2'5LW!&IR0WFG-
MJ4DEH+=7MW2( 2!MOWO16]'A[+*,;*&(J3O)NMB,7B<17DI8.K@%!UJU6=3D
MAA:]6G3@I*,)3E52]K*4WYN-\4.+\:I4WBLMP>%=*C2C@,KR+)LJRZ#I9[@.
M)95X8'+\#A\-'%8G.<MP6)Q6)5/VU>EAZ6#G/ZE2I8>'YYWW[&7B2Z^#_P"P
M3\-%\::0M[^Q]XM^"7B/7]3.F7_V?QBGPH^'%]X(O8=(MQ</+ITFL7-REY:-
M>RW$=K;[HYD>0*!\C_%G_@EU\:/%5A^U5X'\#_%WX*Z;X'_:?\>^+?B/JWC'
MQQ\%+_Q?\<=$O/%0MYI? 5IXT/BNUTZ+P=87-HEII.I1Z8VKZ-H]S/;:;;)/
MY4Z?N)166*X7R;&1<*^'J-.,*;<,3B*<O90PBP/LE*%2+C3EAHJG-1:YM974
MFV_0R?QEX_R+$O%9?FF"51XFKC>7%9+E&-H_7:G$$N*%BO88O!5J/M:.=REC
M*-X.%/F]BH.C&--?''A_]FG7-%_:MT#]H9O$VFW&CZ)^RS8_L^OX<&FW,>H7
M&K6?C:P\5-XC6^:=H$L'@LVLUL?(-P)7\QIGC(Q\X_%/_@G#-\2?B)^TE\5[
M?XAIX/\ B3\0?&GPE^)GP!^('A_2ID\4_!CQQ\+/ ,?@];J\G>YB3Q!HGB61
M'@U_05:"SU/0IY;2X'VI;>XM_P!5:*WK\/Y5B:7L:^&=2G]=K9@HNM636+K8
M6K@YUHRC-3C*-&M/V3C).E5Y*U-QJPA./E9;XF\9Y1C?[1R[-HX7&/(\OX;E
M5A@L#)5,ERW-\!GE# 5:53#SHUJ-3'9=AEC(U:<UC\&Z^ QBK8/$UZ%3\N_B
M;^Q;\;/$/Q7\&?M+^ _''P2LOCO=_"#P_P#"OXTZ'\2OA1?^-_A#X]_L6>34
MK?7]!L(=?TWQ5X4U'3-5NK[^SBNJ7GVC2I+:PO7!@9I^R\1_LC?%3QW\//V>
M=!\<>/\ X;3>,/A%^U#X$_:#\0ZAX%^&3> /!^J:7X.UK4-4'A#P_P"&;76]
M3GL[@6ES;Z?!KNJ:A>W-[)!]KU"*-GVI^B5%9KAS*E+$R]G7:QC4\13>+Q3I
M5*OM*565=T_:\JK5*E"G.I.*7-)3E92JUG4W?BEQ@Z63TUB<KC/(>2&5XN.1
M9-''X;"T:.+PV%R_Z^L%]:JY?@\/C:^'PN$JU9TZ5!8:@OW."P<*$2@K$ <Y
M  .>O!^G3WYXY)/6OYTOV8/V9_VI_CO^SG\?/A9X=^/7A?X?? 7XP_M&?M,^
M'_&^@:U\*K[4?B7X<\/7/QA\46'BBU^'7BF/Q/INDR6OC33A*TMQXCT*\FT:
MZN[R339)X62,?T8D C!_S@YJ**WA@4K%&L:EVD(50H+NQ9F.T#)9B22>2>N>
M*TS/):&:U\+4Q-6O&CAJ.-HRHT*U?#2KQQJP\9QG6P]:E/V7)1G"=)\T:GM%
M*\)TXLSX.\0\TX(RW.,+E&#RVKCLTS/AO-*&/S/+\MS>GEU?AR6;5<-5P^ S
M7 8W#_6_K.94<10QL'1K8:6#=+]]0Q5>F_S6\5?L7?%?X>?%W0_C7^Q]\2_!
M'P[U[_A3GA#X'>-_!7Q7\':QXU\$^*O"?P\A>#P)K$4_A[Q!X;US3/$WARVF
MEL1<)<7-KJ=HL<-TD(,K/'X-_8W^.OPG^$WBNP\ ?%[X:>)_CG\7/BYJ_P 7
MOCWXO^+'PHGUWX=?$R\U_3I=,O/"=MX,TKQ%8:CX8\/Z7:PZ1'H<MOK5_=Q)
MI)2\CF349@GZ9T5E_JWE:J5*E.GB*2FZTJ=*EB\33H86KB5&.(K82C&JJ6'J
MUXIQJRA&THSJQLHUJZJ;/Q5XQGA<+A,1B<KQL</'+J5;$8WA_(\7CLTPF3RG
M/*L!G6/KX">,S; Y?.:GA,-CJU:%*>'P,H^]EN7/"?C[X6_X)H>+M ^!^@_#
M:?XF>$8_$#?MF^ ?VMO$%OX7\%7OAGX9>'8_"WB[2/$>H?#GX8^$O[:U"X\/
M:"\&E>5ITES=S@W]S<WES:IYQ ^E9/V<?C-X8_;'\1_M%_#/XD>"M.\!_%OP
MU\-O#/QC\">+?!.K:QXADM?AG)J\>FW7@+Q%IOB+3K'2KS5;+6KFWO7US3-2
MAMF7SX()VV+']VT55'AW*J$,/"A1JT?JM3"UJ,Z>)Q$9PJ82&(I4Y<WM&VIT
M<7B:-:,FXU:=:49+2+B\?XK\:YI5S*KF./P6-6;X?.L+CZ&)R?*JF&KT,]Q&
M3XO&P^KO"*E"5/&9!DV+P52G&-7!8G 4:N'J0;J<_P":%C^P"U[^RW^U7^SE
MXN\6Z?J'_#0_Q7^.'Q3T3Q#IVFW4'_"&:K\2/%4WB[P9=""6[\^YU+P;K$>E
MWTDT,UO'<SV++%L5P3B^#O\ @G)%>_L6?%']FCXS_$.;QA\1/CEXG\3_ !&^
M*/QAT/2%M+N^^)FKZ[:Z]H/B?3](U"1T,/A>70_#5O::;<2);W-OI<EJD=G;
MW2B']2:*3X;R9SA.6#4W#+JV5VG4JR4L%7<W4I37/[TDJM>,*C_>4X5ZT82B
MJDKB\6>/HTZM.EGLJ'M.+,#QNJF'P>!I5J/$>70PL,-C*%:.'52C2YL!EU:O
M@826!Q-?+<OKXC#U*N$HRC^?GP"_9_\ VG_!'CCPSJ?Q8\>?LT:OX1\*Z9J%
MA-_PJ_\ 9[F\%^//&MW-ITFG66K:UXDOO%FK67AIHBYO;VS\-Z;Y=]*TEIYL
M-G(5KT+]M[]FCQ%^U-\$;?X?^"_'%C\._'?A?XE?"_XN^!/%&KZ*_B+0[7QE
M\)_&>E>,]!MO$&CQ7-G<7FAZA=:9]AU)+6YBN4MYS+"QD0*?L&BO1P& H9=1
M=##NO*#FZC>)Q%?%5')QA"WM*\ZDU%1A%<J:3:<W><YRE\GQ-G^-XLQKQV:4
M<NI57AHX7V>597@,GPWLU4JUF_JV6X?#474E5KU).JX.HHN%&,HT*-&E3^!K
M/]E_XQ>)_P!H?]D_]I#XL_$7X?ZOXQ^!/PQ^-W@SQWI_@OPEKF@:+XKUGXK-
MH*:=?>%K;5=;UJYT73-!M-&%O<PZI>ZC=Z@Y$Z20F1DB\K^.W["7Q.O_ -IS
MQ3^U-^SEXS^"FF^*/BAX(\+>"?BQ\/\ ]H;X03_%'P+KS>"/M\7A3Q?X>O='
MUW0/$7AOQ)IUCJ$^EW=M!<3:9JMGL>["RQ1LGZFT5W<SNWIJK-6T:TTMM;3I
M\CYR6%I24DU*\JD:KDIS4U4C3C24HSC)23<(*+L[/6Z=W?\ );XU_P#!/_XR
M?%3PC^ROK<GQ/^".J_&3]FCQMXQ\;2Z'XC^!S6G[-GQ!N/&VG7FE2V>J_";0
M?%$5SIMWX1MKBVF\(^(5UK4=1M[^VGOKN-YK^<IG?##_ ()J^--*^#7[?7PQ
M^*GQ;\'ZOJO[<0N9[K6_AI\-1X$\/_#RXO\ X<)X)-MHWA!M;U&"73=(N8H;
MBQB;4TN[^SM@VHW3:A=33+^O5%',[6TMIT[6Z[]%OT^9#P6'<W-QDY-6=YSL
M[TG1;:O\3IOEO_V\K2U/R1\=_L"?'CXV?LZ?!CP1\7_C3\*S\?OV:/B'X9\>
M? [XC^$_A)>W/P_B7P?X8'A&VT3XB^ /%WB;5'\46?BO1[C4H/%ALM2TJ-?M
MD3:5#&UFHG[K1?V+OBU\2?A)^T+\)?VH/%7[/C>&_CI\,-2^&$.E?LW? Z3X
M:+X9AU:TOX+OQ/=:_K_B/7]8\0ZDMQ<65Y9Z7<)9Z78W&GQS(LDCNZ_II10I
M-*VGS2?9]O+J4L)13O:;O%0DG4G)32BX+G3D^=\C<?>OWW2:_&:U_8)_;3\8
MZG^R5:?&[]J[X8^*_ _[(GQ>^'GCSPWH/A+X/:MX<UCXDV'@/1]8T"WUKQ_X
M@U+Q?K3Q^,!HVHK:65GH%I8>'A<W&I7^H_;)FLXX?U%^.'PG\/?';X-_%+X,
M^*XT;P]\4O ?BCP-JKM$)FMK?Q)H]WI:W\4;8!N=.EN([ZU.04N+:)PP90P]
M4HI.3;3VMM9)6UOT\WZE4\/2IJ:2E)5-)\\Y3<DH*"3YF[+DBHV5EUW;;_G:
MU'_@B3\1]0_8OT/X*C]I6UM_VG;'XVZ[\4=3_:1C\.:C]IO="\4?#V[^"&O^
M$8[(7\6J+;7WP:GAT##W36_]H0F8JL;"5?TN\4?L517'C']@+4O!/B'2_#G@
M[]B34?$&SP]<Z;<3W?B;1=0^#FI_"S2[+3;FWEBM].N+22[@U2[FNXKE)XUF
MBC*R,CG[WHIN4G:[V_X&OKITL94\!AJ5^2#5U13]^;;]A)3IMMR;YN9)RE?F
MJ-)S<FDU^=WP:_9,^-?P4_:(_:/\7>'?BOX#U+]GO]I#QUKWQ;\0^!=5\#ZN
MWQ-T+XA:[X-T[PM-:Z/XR@\1QZ$WA5)=(T_4FANO#TVI,8WM(IH5DDF;Q^Z_
MX)M^*[C_ ()N_"#]AA/B;H$?B+X9^)/A9K5YX^?0M1;1=4C^'WQ<L/B3>0VV
MD+>"_A?4;.UDTNVDDNBL-V4N94,(*C]<:*5WMT[='M_D:?5:/*X\KY7&K"W-
M+2-:49U$M=%*4(O2W+KRVNSQ#]I3X4WWQT_9V^./P3TW5;70=1^+?PC^(7PU
MLM<O;:6\LM&N_&OA+5O#EOJEW:0/'-=6UC+J*7$]O$Z2S1QLD;!V%?'?CK]@
MSQ-J?P\_8,B\"?$+0_#7QJ_8C\0?#>73?B%=Z%?3Z;XO\%:9X3@\#?%?P3/9
M6E[%?VFE^/\ P^A>%9+BYCM+^ST]YXW >1/TSHHN[6Z7O;OMO]Q52A2JMRG&
M[<8P;NT[0FJD;--6<9I2C):Q:NFC\G+S]DS]M;X;?M5_M0_M ?LY?%C]FS3_
M  ]^TOJ'PNU'5/#?Q@^'?Q'\1ZQH4_PT\"P^$+86>H>$/&?ANS>*^<W5VXFA
ME<QO!#OA\IV?Z"O?V8_'WBS]J+]FS]IKQQXP\(3ZK\(?@#\5/A9XY\-Z#H.K
M6NG>)_%7Q0NO %[>ZWX;.HZA?2:5X=LI_">HI%IFK2ZAJ!@OK19;N1HIF;[A
MHIN4GJWK9*^STLEJK=%8B.%I1YK.HXRJ*JX2J3E!5%4]K>,6[1O4]YI*SVT2
ML?D9^R+_ ,$M]/\ V7/'_P"U3XQ7XAGQ98_%K3?%/@;X":'=Z?<"V^ 7PE\7
MZ[XE\<:WX#TPSW,AN+2]\=^*+G59OL/V:%[73K)3NFEE"?6G[+?[*6@_!3]F
M'X$_ +XD6/@KXI:K\&O MCX07Q%?>%;.ZL+J6WDD>XN]*L]=AO[C3X;D>0)$
M\TR2&%&D)V1[?K^BDVW:_3_)+]!TL+0H\OLX**C&<4KMJU24)3T>CNZ<+7O9
M*RLM#\U_VAO^"5/['7QTM?C#XCD^$&AZ3\7OBKX=UFSF\?0^(?B#I\$/B>?P
MNWAOP_K^H^'M \7Z1HE[%HD4.FA;'[ D$EI9+;"+:Q!\"\??\$S/BQI'[!GP
M<_8J_9K^*_@?X8Z=I$_AI_VA;_7]+^(&JZ3\:K/3M'T^'Q=HD$]AXL7Q-X5\
M/^.];TZWEU_3-)U:S\S06GTBQN-.AFN5N/VEHH4FK:[=]?P9,L%AI.I+V482
MJTW3J2IKV<I0<U-IRI\LKN2U=[O9W6A^>OPT^$7[<'A?X,?$+X77?C_]E'P'
M=VWPU7P?^S]>_!?X2^/M T3X;Z[%:SV5GJ6N:%XF\9:Y;:KI&F6[6SZ?I^G1
MVCK=PO-<R7:N83XK^P]^R#^VG^R7;^'_  ;JGQ!_9/\ $W@?5/$U]XK^-/B_
M3?AU\6_^%W_%GQ'JRS2:OXMUWQEKOQ O=+N_%%]=M JSWNE2Z;8:<ALM.TVU
MMTAA3]=**?,]=M=W97Z>7E?_ (=@L)24J<N:JY4DU%^UJ;-IM-<WO7LEK?33
M;0****DZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH _++_@KC+X<M_V>_A!=_$9H$^"=E^V1^RA>?'>34C&/
M#</PKM_B_H,FKS^,C,5M!X-@U8:)+XD:_)TU=,29M04VBRXX[]CFY^'E_P#\
M%*/^"@=Y\!YO"5S\(?\ A5?[)]KXINOAR=,E\"3_ !LBT_XCRZPL-UH!;P]/
MXKM_ D_@^/Q%]@=KQ+9M%35/WZQU^L/B?POX:\:^']8\)^,= T;Q5X7\06%Q
MI>N^'?$6F66LZ'K.FW2&.YL-3TK48;BQOK2="5EM[F"6*0<,AKD/A1\&/A)\
M"?"L?@;X,?#7P1\+/!T5W<:@OAKP%X9TCPMHS:A=[?M5])8:/:6EO+>7'EQB
M:ZE1YI%CC1G*H@56UZ6]-?D_O_'OH[Z-=_\ -/\ 3Y_(],HHHIB"C]*** /P
M7\*_ W2O@5^WI_P4%T+X$V_B1_'?C3_@G7X/^(!U[6O$VL^+/&7B?XK^(?B-
M^T,EAJ]_KWB*]O[V6ZCNX='TS1K)9(-,T?3-.TS3=,L[:SM(XQ\V?LVZC^SC
MJ%U_P0-LOV:)O 5Q\2M-\/>,E^*$'@0:0_CW3/ MI^RQXLT_XNP_%:/2RVM6
M-N?B_P#V);:W%XP5'E\=BV7_ )"V2?Z4X?!/A&V\7ZE\0+?PWHL'CG5_#^F^
M%-4\71:=;)XAO_#6CWVH:GI6A76JB/[7-I6G:CJNI7UG8R2M;V]U?W4\<:R3
MR,WG_@3]G+X _"[QKXM^)'PW^"_PP\!^/_'CR2>,_&7A'P/X<\/^)?$SS3_:
MISK.L:7IUM?7XN+H+=7*3S.EQ=*MS,LDX\RDU_7S3_&WZ][U??>]K;^5G?NN
MOD_/4]HHHHIDA7R?^VOXK_9A\!?L^>*/'G[7FFZ%KGP9\#ZOX2\7W6@Z[IKZ
M\NN^,O#_ (ETS4?A[I&C^&(W4^*O$U]XR@T:#PYX=DBN(-3U=K6*Y@:V$SI]
M85YC\6_@K\)/CWX0F\ ?&OX<>#?BIX(GU&PU:;PIX[T#3_$F@R:GI;M)IU^V
MFZG!<6IN[&1VDM9_+\R%V+QLK'- =M]UMN?S4?%WP;HVO_#+XG?M=?%S0?A9
M\+?AM\?_ -K_ /X)VQ?%C]GSP)XA\%:U:?"W]F#X4?&S3+6T\1?M*7GA2\N/
M"TGB?Q5=:Y%J'Q.LXVNO#OA;PIIUGX:NM8U:/2M2F3]*?V1+OX8ZA_P4K_;I
MO/V?I_!EU\*U^"7[*MMXVN?AFVFR^!YOC)')\3RR+/H"MX<D\3P> '\.KKBV
M$S7T5@VA+J@#?9*^Y/AU^QC^R7\(]'\;>'OAC^S?\%O N@_$C28]"\?Z+X9^
M'7A?2]*\9Z+"+E8M*\3:=;Z:MGK=A&+RZ"VNHPW$/[^7*'<:]+^%'P7^$?P)
M\+CP3\%OAIX&^%7A#[=<ZF?#?@#PQH_A71GU&\*FZOY;#1[2TMY;RX"(DMS*
MCS-''''OV1HJI+;;S[W]?F^GYZ-OM?:VNV\=;:ZKETU^?4]-HHHIB"O@C]LE
M_P!G2?Q'\--*\=^+/@-X#_:9U7PY\4++]EKQE^T'X7/BOPCH6IS:;HH^(%Q9
MZ/J>L>&_#>JZ@=#2Q\W2I_$.EZW=V2SG3)7LH]5C?[WKRWXM?!#X._'KPRO@
MSXU_"_P'\5O"<=]#JD7A[X@>%M&\5Z3!J5N'$&H6]EK-G>0VU]$LLJI=P+'.
MJ2RQB39(ZL#6C_R_K_AS^7?]@S6OA#I7Q2_8+T'XY7'PU?X2_#71O^"D_P *
M?!?Q&UW5M F^ OQ/_:1L/C#\.]6U?XB_"FXUK3M(\.:1X?\ &?@&]^),G@;P
M]!;?8-%TRTUSP_H%[J4>G&_O/U\_X(YO!+^S%\49_#;:<_PCN?VROVO+G]G]
M]!%N/"C_  0F^-?B1_!;>#A:?Z*/"C2'56T7[*!:FV(:US;M$Q^[_%W[,_[.
M_C[X:Z/\&_&OP/\ A3XH^$_AW[$?#WPXUOP'X:O_  9H#:<K+8/HGAZ?36TW
M29;1'D2"73[>WDC269 VV60-ZKX<\-^'O!^@Z1X6\)Z'I/AKPSH&GVVE:%X?
MT'3[32=&T?3+*)8;33],TVQB@L[&SMH56*"VMH8X8D4*B*!BDE;_ (;R2_3\
MNPY-/_+IWOZO\//IM4444R0K^3+_ (+8>+_VA/%6I?%K5OBE^RA^T3K7P0^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ+\*[WQ!/X9U=]/N;J[&H+XB\':JEK%XQT6YTR!]%34].9[B5K@HGXB_$?\
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M_&3QM8/>1P>'O ?CRYO9+BXN-??3[]/"5UK6B:+I_BF2TFBT:[N9C#'+\&_
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MZ_EW!I:V\K7:;ZWM;[NO?L?&WP*_X+66\'@;X]^._P!IOX*?''0+'PW_ ,%
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MTEVAXI"&P.[JB=OZN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5XSXD_9X^"?C#XP>!_C[XH^&WAC7OC'\--)U/0_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT,+3Q<I2P.$K8R5*4*F+P:@JE.A.*J*I-QFXWIN+;7O(.1D4M(JA5"J,*H
MR3@#H,G)X[4M>PKV5][:^IYH4444P"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7F6L?\ )7/ G_8E?$;_ -.GP\KTVO,M8_Y*YX$_[$KXC?\ IT^'E?/<3?[A
MA/\ L?\ "O\ ZU&3'KY)_O>(_P"Q1GW_ *H\P/3:***^A/("BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OBK]I_\
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MG4I;KPL?#$GF1>'M3GT\ZLP\20R1:;>I>K"Y\N%^@_;N_P""CVA?L>Z]\(/
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MD\%:3,FY3T+X5N-Q.*Y"?_@KI_P6$UQI/^$>_8(^ 'AJ"3;Y,GBGXEZE>3P
MX#-*MOXGTL2?,'P%@5MI4LBX->J@8]>H/))Y!R.M  '0+_WR">@')(R>!SZG
M)/))-K!45O&_S_X%K&$N(\YE_P Q2C_AITT[:=H))[Z_\.>$7/\ P4)_X+J:
M\9A:?#O]BCP2DF!&;MO%.IS6X;()!7Q/J4<K*&!YB )0\<@US5Q^TI_P7<\0
MO(9_VB_V5O!,<A)$6C_#8ZB8%;^"-KO0-2D?8% 4M*3\[%CQ7TX!CH6 ] S
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MK?=7?W?>65M$^W;3^97Z::K;7=']4#=#]#_*OC3_ ()Z?\F8? #_ +$^Y_\
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MAWHW[.?[/?PLU/\ M"Q^'-MJ2:GK>K6C7EO=:EI\<,-]=75]K'B&.UMM.O\
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MHF>N_IT.#P>1D<'U'('4]J!R< $_0$_A]?;K7%6O_!&C_@I[K40;Q3_P4O\
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M=6^.J#06\=^$M(\4-HHU(VE@=0_LLZH;'[<;&S^U>1Y_V:#S/*45N]^[[O\
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M=+@LM;O-0M[^2XN[:YU"W@WM<>7J4%JT7W_IVEW_ (GOX-=\36TEI96\HN-
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MT:[>_2&XU73(X7M$(TVYM+J4RES#Y:RDY8&,!\[NM\7>%_!GB;X$>(?B)/\
M">W^#7BGP_XIT31]!CLKK7C8>,[?5'"7]JEAXAFN+II-.@,ER;B!MD#Q"4LT
M:LI+>?Y>7E_6OD2U9VO^'DGM?S.O_P"'H7QI_P"C4?AO_P")2Z][_P#5L?L?
MR-'_  ]"^-7_ $:C\-__ !*77O\ Z&.OG3QKX3U9]"^#\6G_  UMM O_ !7H
M#KI-[H^L7.M:G\0IYKJWM(]0NM*>5H]*U!I9#;I9QH5Q<N6F4%-M_6_V9_C'
MH&C:EK=[X:MIK?1K47VLV6FZUI&J:QI-H%5Y9M1TBPO)]1MA;H2UPIMV:$*V
M]?0MY_EY>7]7=N@))[RM]W^?]??;WS_AZ%\:O^C4?AO_ .)2Z]_]#'1_P]"^
M-7_1J/PW_P#$I=>_^ACKYC\%? _XD_$'0QXD\+Z'!=Z%]OO--FU6ZU33M,LK
M&YL;6VO)_P"T)[^X@6UA,5W D4TH1)97\M"S*P'70_LK?&^75+K29/",=G-;
M26T4=UJ.MZ-8:7JDEY&LMO#HFI7-XEOJ\\D;;C'8B;R\@,=V5!9[ZV[Z>7E_
M5_2Q:/\ -^'_  ?+^KH]N_X>A?&K_HU'X;_^)2Z]_P#0QT?\/0OC5_T:C\-_
M_$I=>_\ H8Z^4_#?PC\=^*?$VO>#]-TJ"V\0>&$G?7K/6M3T[1(],%K<+:W"
MW-SJ-S#!N2>6)0(GE+HYD4%1FI/'/P?\>_#J30QXHTNVM[;Q)(T&BZG8ZKI^
MK:3?3I(L;P1:CIL]Q:B6)F!FCDDC,:'>#)M*TK/S_#R\NOZOR'RQ_F7]?,^J
M/^'H7QJ_Z-1^&_\ XE+KW_T,='_#T+XT_P#1J/PW_P#$I=>_^ACKY\\1_L]_
M%/P)IT_B+Q;X=M-,TC2=6TRSOA<ZOI<LMPEY?V5I'-9V23M<ZA823720/=6\
M1@^9R70Q.M>B_'#X0ZKKWQQ^)FF?#WPWI6F^'_"6E:)K&J-$]CX=\.:%8'PY
MI4T\D]S,MOIUM)<RO))#;QL9KB3SG\K/S2.WF_\ /\/+\?N7*N^EKWML]-+7
M\^GF=]_P]"^-7_1J/PW_ /$I=>_^ACH_X>A?&K_HU'X;_P#B4NO?_0QU\U^%
MO@1\2/&&C:=KVDZ5IMOI>L74EEHEQKOB'1- ;7[E#L\G0[?5+V"?4W\T% ;9
M7C=@5BD=ABLK0?@[\1_$NO\ B7PKI'A>^F\2>$89)]>T65X+?4+58[VVL2JV
M\TB&60S7<#JL;,&MW%P2D="3TWUMNEY>7]7] Y8_S?A_P3ZI_P"'H7QJ_P"C
M4?AO_P")2Z]_]#'4S_\ !3GXY1PQ7$G[)'@&.WN-WV>XE_:<\216]QL.'^SS
MO^S"(Y]AX<Q,X4_>(/%?(WBSX6^,O!7BG3/!NO6-I'K^L"P.GVMAJ5EJD4QU
M.Z>QLH_M%A+/"LKWBA)(V<,B@YY88^VX="\'^)/VAO 7P*UG2[3Q!X-^$GPX
MU;1+K3)I+N"TOO%-KH,FMZU>2O:3PSL3J+1QY617_=R LXXH2;ZO=+IY>7]7
M]+)I*VN^OR^_7KIY=CE_^'H/QJ_Z-1^&_P#XE+KW_P!#'1_P]"^-/_1J/PW_
M /$I=>_^ACKD['3/AA\7OA]\8[O3?AAI'PS\1?"[0T\3:?K_ (>UC7+G2=61
M;V6S;1]6M=;GN2LDT<9-H8+I29VW!!Y127R?PS^SC\7/%NB:9K^E>'[2&PUM
M2^BC6]:T?0K[68MI9)M,T_4;N"ZNXY%4^4T<7[]N%P 7*^_\/+?3K^K\@23O
M=V:\O^#OY'T)_P /0OC5_P!&H_#?_P 2EU[_ .ACH_X>A?&G_HU'X;_^)2Z]
M_P#0QU\]_#;P9KB:_P#$3P_J/PRL_%VK^'/!OB"YU71O$&LW7AV;PE)IWV5;
MCQ#$8&C?4+O3EN4$%D"8IUN"XDVX<9?AGX%?$CQ7H%CXETW3-,@TO6)+N/1)
M-;\1Z+H=SKC68;[2=#LM3NX+G55C='C/V5"AD!6-W96 %\_N]-]-+_K]SY5?
MXE;OIOZ7_$^F/^'H7QJ_Z-1^&_\ XE+KW_T,='_#T+XU?]&H_#?_ ,2EU[_Z
M&.OE?P-\'_B!\13JTGAC0TELM#E$&K:KJ6I6&D:18W!_Y=9M4U&:WL_M9&2M
MNDC/@$OL0AZ3Q/\ "#Q_X/\ $NA>%-?T,V6J>)IK.+0)$O;.[TW5Q>SQ6T$M
MCJMI++8S1?:)HXY'68B$NIEV@J7/F_P_R_J[\K/E5[.5GYKT\_/T/JG_ (>A
M?&K_ *-1^&__ (E+KW_T,='_  ]"^-7_ $:C\-__ !*77O\ Z&.O"[K]EWXU
M65EJM[<^$T0Z+'?W%YIZZQH[ZU)9Z;++%=7]GHWVT:A=6#-$\EM=1PE+B!?/
MC#*R@?/H^H/KCCGZ'D?0\BG9^?S6^WE^7=_(4$]I?AW^9][?\/0OC5_T:C\-
M_P#Q*77O_H8Z<G_!4#XU.Z)_PRC\-QO=5S_PU)KQQN8#./\ AF0>OK7P/4D/
M^NA_Z[1?^C%I?-_A_E_5WY6;A9-WV5]O^"?T2?LZ_%X?'[X&?"SXT#P\?"9^
M)7@W2/%C>&CJPUW^PWU.#S9-.&LKIVD#4UMG#(E[_9>G_:$"R&T@+>6OM%?&
M'_!.S_DQO]EW_LD'A;_TF:OL^A.Z3[JYF%%%%, HHHH **** "BBB@ HHHH
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M8@HHHH 1NA^A_E7QI_P3T_Y,P^ '_8GW/_J1:W7V6W0_0_RKXT_X)Z?\F8?
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M_P#AO^'$J]!RC!5J3E-7A'VD>:2>SBKW::U5KW6JNCZ[HHHI&H4444 %%%%
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M_M/L7PR_:+O='\1^+/@U\4O VC']F'QG\)_ /_"TO"6FZ!I'[/7BS2K?X?\
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MB']B;_H2/V@/_"0\'?\ S?4?\1$/[$W_ $)'[0'_ (2'@[_YOJ_8[_AG_P"
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M$/[$W_0D?M ?^$AX._\ F^K]CO\ AG_X#_\ 1$_A'_X;?P;_ /*:C_AG_P"
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M_P#*:C_AG_X#_P#1$_A'_P"&W\&__*:CGP?_ $#U_P#PHC_\H]?Z6I]5S_\
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M6JSG4E*3D-5$10B*J(H"JJJ%554!54*   %   &   .!3L#THHKWSQ@HHHH
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M2^G][U_K;3VDNR_'^N_]/3\*L'V_,?XT8/M^8_QK]U?^& ?V&O\ HT#]FO\
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MD;Q3QSI<L)+>YAFWQD.K&19,K^OO_# /[#7_ $:!^S7_ .&6^'O_ ,H*/^&
M?V&O^C0/V:__  RWP]_^4%%G_-KWY=>G]ZW?IV[Z%WV6R6[Z6_R_X:^GY#>.
M/B1X9\4Z(FC>'_A)X(\!$W\>H7.J:++J]_JUPT"RF*S2YU34)DM+%GE9Y(88
M7,K+"KD1H37D>#[?F/\ &OW5_P"& ?V&O^C0/V:__#+?#W_Y04?\, _L-?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MR;^V_P#LUM^UW^S7XZ_9^_M71](MO'&I>!)=2N=?TI];T>ZT?PO\0/#'BW6=
M'O\ 2TDB%Y;Z[I6AWFC/%*Q@Q?;IXY85DC;ZRHH#]-?N/@\_\$N?^";V0?\
MAA3]E $<@K\"?ARI!R"""OA\$$$ @CD=B*^X-)TG3-!TO3=$T6PM-*T;1K"S
MTK2=+T^WCM;#3M-T^WCM+&QLK6%4AMK6TMHHK>W@B18XH8TC10JJ!H44 %%%
M% !1110 4444 ?,/[8/AWQWXI^!FMZ/\/=*\7Z]J\GB;X?7>KZ!X!\4S>"_&
M.O\ @O3?'GAS4/'6B>'_ !-!XA\+OIM]JGA&VUFT ;6K2.^ADFTU_,^V"-OS
M0^'O@_X)7VJ7/[1/PA_9$^-7C']F#P_X3^%=A\)?@KH^FZA#X6U[XK:O\3M=
MT'Q9\5?!7[/GB#QI:^$;-O!.@W>DWGB#QGK7A>UGN;?3;G7/#DLD]C<ZE?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_75?>?9M%?&7_#P;]D3_ **O/_X;KXJ__,/1_P /!OV1/^BKS_\ ANOBK_\
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M]0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^%M8T30WL;(V.@:O9WNAE+6**YTZXA#1LG>]_)_BT-=-;6=]4WV_R\O5]/R
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MIGVQ-/\ !GQ;T[P)K>DVGC?0[.TU'4M-MQJ,8U&'2M0N]+CU!;&18$L?MO\
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MO9?BA\'_ !)^W[JG@S_@DMXEUC_@H7\:9=>_X*/VWB'X=_%RUG\(_"O5=$\
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ML4M=-NVLI8KF_BN[>Y@NC"A9]^W5_P!V_P"3^_S!2U\NG3;:]DV[??\ C?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3Q!;S:QXF_9\U4ZW\'=4FCLM6MK>&3P3JC&ZL8;:*&VO#F/58;^(E#P&N?\
M!.']B/Q)\?K?]I_6_P!G?P+??&N#7['Q<_BF1-573[WQGI@7^S?&VJ>#H]2C
M\$ZQXUT^6."YLO%VJ>'+OQ#;7=K:7D6HI=6MO-'^:7_!+W_@I]\4?B1^P_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&^$]:OK>T$@N-0FMDL;-);JXAAD\KN_V7_C'+^VY^WO\:(M#TT> /CM^Q?\
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M,^H>0^L:KJ.I7AGAL]WZO44K?\-Y]_P"_P#P_6U[V[>6U[-ZZGYI?M2? _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>ny20077915x1_table01.jpg
<TEXT>
begin 644 ny20077915x1_table01.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN/\=^/_!7PO\ ".O>
M/_B-XL\.>!O!'A>SDU'Q%XK\5ZO8Z%H&BV$3*KW6I:MJ4]O8V<(9E3S+B:-2
M[*H.6%5?AU\3?A[\7?!^D?$'X6^-_"OQ#\#>($FET+Q?X,UW3?$OAS5XK>XE
MM+A]/UG1[FZT^[$%W!/:S&WN)1'/!+$Y#HRJ$N4>;ENG*U^6ZO;O9M:;?>=U
M130P/&X$^@X^O4__ *JS[K6-)L+BQM+[5-.L[O5)WMM,M;J\M[:XU"XC0R20
M64$TJRW4T<:M(\<"NZH"S*%&:!W[Z>MM/Q-*BO*]1^.'P?TGXKZ'\"]2^)?@
MRQ^,GB;P[<>+O#_PQNM>L(?&NL^%[26[AN=?T[0&F&H76EQ26%]&UW%"T/F6
M5TH8FWFV>G,[*%&Y W0G!VDD=AG)Q][@]L=,FC^OU_KU"Z>VOGTZ?YDU%>*>
M _VB/@E\3O'7CWX8_#[XK^ O&7Q$^%EV+/XC>#/#?B/3=6\1>#;E[B2U2#Q#
MI5I<2W>ER"XBDMF2[BC99D96PW%>S;V;(4KD@X)!(# G.<'G&.V.>OI3MK:Z
M];Z?>*,XR7-%\RU3LT[..CB]?B33371JS):*8I;A7*EL$DJ,#KQ@$D]CGZ?4
M53OM4TW2XDN-3U"RTZWDN(+2.>^N8+2&2ZNI!%;6R2SR(C3W$K+%#$&WS2,$
MC5F.*0[[.S6E];:>NOY7+]%-W#=C<N#T&.3^.<?I3278@HR  D'<"=PZ\$$=
MOKGKVIVUW7KT"^E[/TTO^9)17S=^TC^UE\"_V2_#_A3Q1\>/&L?@G1?''C'3
MO 7A>[DTC6=7&I>*M5@NKBQTPQ:+8W\UOYT5I*_VFX2*U3RV\R9!EA]$VT_V
MB&.9<%)8TD1@&7(<L1E6^8?*%//<FE_7]>NMO1]B5.+FX)IRBKM)K1:;]5>Y
M8HHHH+"BBO%_V@?B#X\^%?P@\=^/_AI\*]8^-GC?PQHYU'P_\+M!U*WTG5_&
M%T+JTA;3M/O[F"[CAF2VDGNMGV6>6586C@BDE=$8_K^K"D^5-ZNR;]U.4OE%
M)MOR2;?1,]D#MG&P8]=Z_AQ[U)7\Q>@?\%WOVM_$_P 8/%GP"\/_ /!)_P"+
MNK?&?P)I%CKWC'X<6?Q(CD\3^'-(U*"PNK&_U6R/P_ M[:X@U/3Y(G:3YQ=(
MH&Y6"_O5X'_:5^&6M6'@C2O&WC3P%\._BSXF\.>%K[7O@[KWCWPQ_P )QX2\
M6:]HUEJ.H^";S26OX-1N-6T2^NY-+F"6*M<30.8H@%(#M?9/Y*7ZKR>U];^1
MQX;'8?$\_LY5$HR<&ZM&I03G%)RC%U80YI13NU&]ENNI]%45Q?B'XC_#_P )
M7$]KXI\;>%/#ES:Z+>^([JWUS7]+TJ:V\/:;)##J&NSQWUS \.D64UQ;Q76I
M2!;."6:*.297D53SVM_'7X*>&M.T'5_$?Q;^&^@Z5XJM#?\ AC4M9\:^'=,L
M?$5@%@<WNA75YJ,,&K6FRZMF^TV#W$.)X3O_ 'B9.63V3?R9URG"-^:<8V5W
MS22LN[N]%YO0]5HKS?2OC'\)-=\*ZGXYT7XG> =5\%:+YO\ ;'B[3_%NA7?A
MK2?)1))AJ6N07SZ98F))(VD%S<Q;%=2V-PSF+\=_@Y=^"O%?Q"T?XF>!?$'@
M_P %V]Y-XD\0:#XM\/ZGH^DO9VGVQ[6_U:VU(Z98W,D31>3'>WML&:XM\NHF
M1B<LOY7]S$JD&DU.#4DY1:DFI16K:=[-);M:(];I"2.@S^.*^(?V&OV^_@9^
MWU\++?XH_"&\O=(\V\UBUN_ ?BV\\.0?$#2(=&ODL)=2U7P]HFN:W+9Z7=SR
MQBQO)9%2X+9&-Z+7QSXY_:T^-7Q!_P""P7PT_9$^#WC2'1/@G\%/@KXC^+/[
M4B1:?I-^FIZCJUM?VWA7PS+JEQ;W\]A/#/=>%KQ[5)-)N8+>;4[F-[A8FA)M
MOO=*W5M]+;_<92Q5&,:,U-3IUYPIPJ4VJD??DH\RE'FBXQNVVFUH]S]I1],4
M5^ =W_P69^,7Q<^)/Q7\+?L)?L&_$K]JWX>_!75M1T#QG\5XO&&E^"] U3Q#
MHMU>6^HZ3X-@FTO5SK4UQ%;0W&CQ--;:A?)+(TFF6T8MY;G]9_@_^TGX=\<_
ML^> _CS\4-)NOV>H?%.B6EWXB\+?%W4-.\,7_@K7GN)=.OM U>\U*6RM!+;Z
MG;3P65P3 M_;-;W,<8,X53E;=DG?LE+2ZO;5:Z>OJ%+$T:RDX3<H1L_:.+C3
MDI7LZ=1I0J)<KNX.2B[)M71]*T5Q'ACXE_#OQKH-UXI\'^.?"7BKPS8M,M[X
MA\/>(-+UG1+1K: 7-PMSJNGW5Q8PM!;LL\HDG4QPNDCX1U)RD^-'PAEU+PYH
MT7Q/\ R:QXPL;?4_">E1^+=#?4O$VG7A<6E_H%BM\;K5[2Z,4HMKBPBN(I_)
MF\IW\J3:<LOY7]SZ[?FOO-N>'*I<T>5ZJ7,N5KNG>SW74],HKA-"^*7PU\4>
M(-7\)^&OB!X,\0^*?#XF.O>&]#\2Z/JVNZ(+>9+:?^U])L+R>_TTPW$B02"\
M@A*2L(V ?BL?6?CE\&/#EM)>>(/BO\.]#M(M;NO#,EUJ_C'0--MU\1V,:37N
M@&:\OX8_[:M(I(Y;G2PWVV".2-Y(%5U).67\K^Y@YPCI*<8N]K.26NCMJ][-
M/YKNCU.BN?U?Q9X7T#0KCQ/KOB+1=%\-VEHM_=>(-6U.ST[1;:Q<QA;NXU2[
MFALH;9C+$%FEG6-C+& Q+KG!\&_%7X9?$6"^N?A_\0?!GCFUTR3R=2NO"'B3
M2/$EMI\QC,PAO;C1[N\AM9C$#((IWCD* D+@'!9]GIOH]+;_ '!S132<HIR:
M45=7DW>R7=NSM;>S.^HKA8OB?\-Y_#&H>-H/'O@^?P;I,MQ!JGBN'Q'I,OAS
M3IK2X2TNHK[6H[MM.M7M[F1()EFN4,<KK&^&8 V[KX@>!+(Z,+SQEX7M#XBT
MN_UOP^+G7=,@_MO1M*L8]3U35])\RY7^T=,T[3IHKZ_OK3S;6TM)$GN)8XF#
M$L^S^YAS1_FCLGNMI.R>^S;27=NR.OH_#/\ GK7#^#?B9\._B-97&I?#_P <
M>%/'&G6ER+.[OO"6O:9XAL[:Z9!(+>XN=)N;N&&8QL)!'(ZL4(;&"#7Y??\
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MB,N]5=25 895GV??9[=RN>%^7FC=MI+F5[JUU:][KFC=>:[HZVBBBD4%%%%
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MPO:^&=:DTZ'1_$-QKFFPZ+JLVKSI:Z5%IVIR7*V5[+J=S(D%A';S2/=S,L<
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MW6K/6/'J7VA> ==U;4%O=-\&7G]FH6TO4;&:Z/V_4RMS"ERL2>-?LN?M4?\
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MTM?<<Z<I-PIJ*D]U+[.#^V5_P48_:Y_8T\+?LG?LZ_$?XG_LZ>%OVAOCY?\
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M+HEV&!M;%;&6:U6((VR"5T0C//X,_M1?\$V/VI-5_;;_ &A_VC+/]G+]F?\
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MAC2F\27AUR2RM);6WU#P_JFE7LMG/,UNVF12:@(1?6DDV3^V_P"._@'^V?\
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M];E\1ZS9VUUXAU&+[5X3EU&&%-2T[3;!5@_#3Q5IK^$_B-_P22^./@C]E?\
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M+:MKFBZ?*'&@0:7>2VEA=V5Q+Y<T,]H4DE:%S"WW#^UQ^QI\(?B)_P %<_\
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MK<\:L8Z1]UT[^\G9?B!^VO;_ +%G@KQA^P9^QS^S=^S)\(/VC=2U[7?B]??
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MX/\ _"FT;_Y,HY*G_/N?_@+\O\_ZNKEZ?>G_ .!1_P _/\^S.TVJ>WZG_&E
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MC?\ R91R5/\ GW/_ ,!?E_G_ %=7+T^]/_P*/^?G^?9G;4W8OI^I_P :XO\
MX63\/O\ H>/!_P#X4VC?_)E'_"R?A]_T/'@__P *;1O_ ),HY*G_ #[G_P"
MOR_S_JZNU*"VE!?]O17Z^?Y]F=MTHKB?^%D_#[_H>/!__A3:-_\ )E'_  LG
MX??]#QX/_P#"FT;_ .3*.2I_S[G_ . OR_S_ *NKB<%M*"_[>BNWG_7R9VU%
M<3_PLGX??]#QX/\ _"FT;_Y,H_X63\/O^AX\'_\ A3:-_P#)E')4_P"?<_\
MP%^7^?\ 5U<YH_SP_P# H_Y^?Y]F=M17$_\ "R?A]_T/'@__ ,*;1O\ Y,H_
MX63\/O\ H>/!_P#X4VC?_)E')4_Y]S_\!?E_G_5U<YH_SP_\"C_GY_GV9VU%
M<3_PLGX??]#QX/\ _"FT;_Y,H_X63\/O^AX\'_\ A3:-_P#)E')4_P"?<_\
MP%^7^?\ 5U<YH_SP_P# H_Y^?Y]F=M17$_\ "R?A]_T/'@__ ,*;1O\ Y,H_
MX63\/O\ H>/!_P#X4VC?_)E')4_Y]S_\!?E_G_5U<YH_SP_\"C_GY_GV9VU%
M<3_PLGX??]#QX/\ _"FT;_Y,H_X63\/O^AX\'_\ A3:-_P#)E')4_P"?<_\
MP%^7^?\ 5U<YH_SP_P# H_Y^?Y]F=MCG/?I2  $D#DUQ7_"R?A]_T/'@_P#\
M*;1O_DRC_A9/P^_Z'CP?_P"%-HW_ ,F4<E3_ )]SZ?9?E_FOZM<YH?S0_P#
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M_P"?G^?9G;45Q/\ PLGX??\ 0\>#_P#PIM&_^3*/^%D_#[_H>/!__A3:-_\
M)E')4_Y]S_\  7Y?Y_U=7$X+:4%_V]%=O/\ KY,[0(H.X#!QC//3KBG5Q/\
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M-_\ )E')4_DG_P" OR_S_JZN^:&_-"_?FCY>?I_29VU%<3_PLGX??]#QX/\
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M)5X@_P##I?$S_P":BC_AR]^P%_T2KQ!SU_XNE\3.?_+HK]6**/K.(_Y_5/\
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M8"_Z)5X@XZ?\72^)G'_ET5^K%%'UG$?\_JG_ ($_+_)!_8V5?]"_"_\ @O\
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ML;*O^A?A?_!?_!_J[\K?E/\ \.7OV O^B5>(.>O_ !=+XF<_^711_P .7OV
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M]//^K^A^5/\ PY>_8"_Z)5K_ !T_XNE\3./_ "Z*7_AR]^P%_P!$J\0<=/\
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M_P "?E_D@_L;*O\ H7X;_P %^GGY?CZ6_*?_ (<O_L!_]$K\0?\ ATOB9_\
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MET_YE*\O^H_R_JR#_BI97_Z,Y1Z?\UQ+R_ZI+SU^?9']ZG_";>%/^AH\)?\
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M0>@-?S%0R7J31NEQ,C(=P*SR*<J5*GY6SD, 5(Y!Y&.M?I]^Q%\==;U?7/\
MA5OB2^N-5\^RN[O0+N[G>XN[5-+MC-=64LDCEW@$"H]LQW%%+1L21N'ZOX/_
M $U<E\2>,<HX.SOA.IPMB<]Q+P63XO\ M9YC1K9BU2]CA*D7@\-.,L1.K&G2
MDVTIZ25GS+2$E)2W4E%7O9IZKR5M-K=>U]/T\HHHK^Z1!1110 4444 %%%%
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M5*UUVN[/L>A+-ZD:N(H^PO4P[J)Q::YXTZ;G[1.]N23C9+6U_BO9']<'A_\
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M40ZKKHGN+X7$<ULGW[^Q/\*6_9 _;M_:,_9_U<^,_B2GQT\ ^'_V@OAU\?\
MXA7E_P",/B%J>A>'KVT\$>+?A-XV\>3P_P"DQ^#-6EL-<\*6=TUO-+I_B6=D
MAD,4D@_:':O7:N>O0=<YST]>?K1L3.=BY'(.T9R.ASCM4SFI6TM9+7Y)-?\
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M?ZW/^*<_BW_T5O ?3_F)SKR_ZDOD_O9_'QY<W_/HW_?8_P#BJ/+F_P"?1O\
MOL?_ !5?V#_\.MOV+?\ HE2?^#K5_P#Y+H_X=;?L6_\ 1*D_\'6K_P#R71_Q
M'OA/_H!S_P#\%8+R_P"HKU_K<_XIS^+?_16\!]/^8G.O+_J2^3^]G\>1M[DD
MD6Q )_O=LYQ][Z5FW,$R2!/(*[@"023R6/<%CCI^1'4<_P!CA_X):?L6DG_B
MU<?_ (.-6_\ DNE_X=9_L4G[_P *%8C&,:[K*C'NJWF#UZ\5SX[QWX8Q%!PH
MX//%5;BN:=# ?"E9J_MF^UKZ62] ?[./Q6FXJ7%7 ,$FGS?6,]GII=6650:O
MW3T:VZG\=L<,R/S"S Q@,(SD@X R23TPN,#DD9'&<=)81L;&9=C<.,G!XP5Y
M/I@$ Y&.<U_7D/\ @EO^Q6N?+^%"QY^\5U_706&<X.+\9Y)/UY&*L)_P3!_8
MPC0HOPLD"MC<%\3>(E!P<]%U$#],5^5<1^(.7YLF\+AL3"=_BKJ-+6R][DP\
MY0236RLVOBUV^GR/]G]XGY7->VXIX)JP46G[.MG4KJ6C2=3+D[:ZMJZU4;73
M/Y-K9&6&T##"^8,9XS@<<X&!TP>YX&<UV=FZF88*@@'^+/ 9,'V&>W7'KCG^
MIP?\$R?V-@% ^%\I"$%0?$_B0],<$_VF"1QT]_I5A?\ @FG^Q\ARGPSF4YSD
M>*/$V<<\9&JCCGMCI7XMGU#$YLW*E4PU&7OW<H5+SYW!J]D[<O++>][^EOV3
M(?HC<=Y3RJIG'"M2*]EI'%9K[OLXV=F\MZWTM:UM;O4_E^A(#L<G& "0#C&
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M.O:ORS.OH/\ BIF$I.AGG D5*?-SSQW$E*JES)^\J&%5/F:6JA[JUMH['V>
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MY_\ "GB?R_ZA?7\/,.3S?W0_^0]?Z>GX6^9:_P!]_P#OD_\ Q-'F6O\ ??\
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M6WSOTF%&M%:N@[.+3]G9W@ER/1Z<C7N[\O1GYR>(?B5^S_X4TK1K?Q;^S_\
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M#QAJMU#I/A__ $F76Y?%=CH/B7Q#<VV@:#XBU'PK:Z1>ZC-'(;J.Q)N*\?\
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M]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\
MD1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_
M !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\
M VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\
M!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T
M[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\
M!_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=
M_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_V
MQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC
M^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_
M^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_
M (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-
MMO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S
M#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^
M%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_
M $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=.
M_P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?
MVQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1
MIY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\
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M]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\
MD1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_
M !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\
M VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\
M!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T
M[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\
M!_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=
M_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_V
MQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC
M^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_
M^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_
M (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-
MMO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S
M#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^
M%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_
M $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=.
M_P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?
MVQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1
MIY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\
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M]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\
MD1_VQI/_ $%-._\  VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_
M !NC^S=._P"?"R_\!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\
M VV_^.T?VQI/_04T[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\
M!8/_ (W1IY_AY?\ !_#S#7LOO?\ D1_VQI/_ $%-._\  VV_^.T?VQI/_04T
M[_P-MO\ X[4G]FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1IY_AY?\
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MSX67_@+!_P#&Z/[-T[_GPLO_  %@_P#C=&GG^'E_P?P\PU[+[W_D1_VQI/\
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MC[J5@PR.GY=@>AY[]\>O3!I:_G@\+>+OVYO -U^P?^RQX8^/WA_P!\2/CO\
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MU""UN8-*$0M[R+5]6%C?6>H&TT>2]1+*XAO'D\AP]3L[%JK3E:TD[V=KJ_\
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ME=;7/MNBOB7_ (>$_L;?]'%>!_RU?_Y54?\ #PG]C;_HXKP/^6K_ /RJK?\
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M*M7Q=:M*<L1&I)\E:C6O&>'G2;I.ER*FHQBHQI8A_P">"?\ ?VZ_^2*,0_\
M/!/^_MU_\D5;^P7/I'_W^A_^+H^P7/I'_P!_H?\ XNO;]K+_ *"/_+E>7_3S
MT_#R/C.6IIIVMK'^[;K_ (?ZN5,0_P#/!/\ O[=?_)%&(?\ G@G_ ']NO_DB
MK?V"Y](_^_T/_P 71]@N?2/_ +_0_P#Q='M9?]!'_ERO+_IYZ?AY HU.B[=8
M_P!WS_P_U<J8A_YX)_W]NO\ Y(HQ#_SP3_O[=?\ R15O[!<^D?\ W^A_^+H^
MP7/I'_W^A_\ BZ/:R_Z"/_+E>7_3ST_#R#EGV[=8_P!WS]/ZN5,0_P#/!/\
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MGPL_Z'70_P#P+'_Q-'*_+[U_GYK[P]M2_F7]6_S_  ?8]4HKRO\ X79\+/\
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M (FC_A=GPL_Z'70__ L?_$UI]<S#_H.QW_A;B/\ Y=YK[S'^RL@_Z%.4=/\
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MI]-'[/\ \$B3_P 6=^&PSSD^#O#_ ">G?33[?YZZ?_"[/A9_T.NA_P#@6/\
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M(487_DITX=M^6*VO\K,T%^$_PUC&U/A[X+QU_P"1:T;@_C9?C3O^%6_#D=/
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M (5G\/O^A$\)?^$_I?\ \AT?\*S^'W_0B>$O_"?TO_Y#K*_X79\+/^AUT/\
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M_75+323:VSQM<D?3'_"[/A9_T.NA_P#@6/\ XFC_ (79\+/^AUT/_P "Q_\
M$TK.UK+[UKMY][??VL2UAY*493YHS<9.,G&R<7%IZ)/5VNFVG9JV]_4PJKG
M SC./88'Y#@4M>5_\+L^%G_0ZZ'_ .!8_P#B:/\ A=GPL_Z'70__  +'_P 3
M1ROR^]?Y^:^\W]M2_F7]6_S_  ?8]4I"0.IKRS_A=GPL_P"AUT/_ ,"Q_P#$
MTO\ PNOX5GKXUT+VS<Y_]EI<K_II]NS\U]XU5IMI*2N_^!_G^#['J08$X!_0
MTM<AX;\>>#O%\US!X9U_3M9FLU5KI+*7>]N'^Z9 P4X;L5# ^M=?2+34M4TU
MY!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF!_#FA6,>H1P1Q37GBW3/[3^W&$S64G7:S\;OVI/@#\9O^"F7Q6^''A;X/\
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MM4_LTWNM>%/V@O!'P.UOQAXC_9<^-WQZ^&%Q\+)/&MKH&F>+_@3X:;Q)XJ\
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MA1Y$'_/&+_OVG^%?FI_P]B_8Y_Z'W6/_  B_%/\ \J*/^'L7['/_ $/NL?\
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M1Y$'_/&+_OVG^%2T47?=_P!?\,ON"R[+^O\ AE]Q%Y$'_/&+_OVG^%'D0?\
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M.@. ,XI]%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS1=1TJ+5YC8#4+#PQX@U.^TXW0M)PLL;R/\ 3G[*7QUMOVD_V>?A/\:8M/\
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M #UE_P"^S_C1]F'_ #UE_P"^S_C4GG)[_E1YR>_Y5[/MZW_05B.G_,56\O\
MIYY+[GYGR7LUVJ_^!5O\R/[,/^>LO_?9_P :/LP_YZR_]]G_ !J3SD]_RH\Y
M/?\ *CV];_H*Q'3_ )BJWE_T\\E]S\P]FNU7_P "K?YD?V8?\]9?^^S_ (T?
M9A_SUE_[[/\ C4GG)[_E1YR>_P"5'MZW_05B.G_,56\O^GGDON?F'LUVJ_\
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MQ4&[15&E5NE"SLN6T$FM$F?UKD"DL(VHQUC3=W".MTKZM;MO\0!!R)%5UQT
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MG973Z.RNODPHHHKZ$04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $-RNZ"5<D;D(R.2!WX[Y''?KTK\QOC4WB36?$EY-XIM9
M(S%9:]I&F&XCCCWZ&GQ/^'VH6,B;%&Y6&GK$F1N979F)9%!_3\C/O7CGQ?\
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M?$_QM\2ZU)H7A;XYO\/!I?P]M+>6+X;'PG/>&XTKPMHNGWTT6H>,_"&G%?\
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M/AY_X5&D_P#R319]G_7_  Z^\/:TOYX_>>[T5X1_PT_^SU_T63X>?^%1I/\
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M_P#R31_PT_\ L]?]%D^'G_A4:3_\DT6?9_U_PZ^\/:TOYX_>>[T5X1_PT_\
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M[P]K2_GC]Y[O17A'_#3_ .SU_P!%D^'G_A4:3_\ )-'_  T_^SU_T63X>?\
MA4:3_P#)-%GV?]?\.OO#VM+^>/WGN]%>$?\ #3_[/7_19/AY_P"%1I/_ ,DT
M?\-/_L]?]%D^'G_A4:3_ /)-%GV?]?\ #K[P]K2_GC]Y[O7PI_P4!^"GQ-^,
M7PJ^'&J?![3],\0_$+X%_'_X4_M!Z%X(U>[MM*M?B&/AGJ-_<:CX&AU^]CN+
M#PUJ6OZ9J5W#I>OW]G>V=C?1PB>U*2^?![I_PT_^SU_T63X>?^%1I/\ \DT?
M\-/_ +/7_19/AY_X5&D__)-"3[/Y?+_-?>B9SI3BXNI%)^:[WZGYX?M#>,_V
MA_VQ_P!E/]H#X9Z=^QO\9OA2-7\'V.EZ6_Q*UWP5I7B;Q+XIM/B%X,^T:)X<
MT#PMXDUG4?[).A?V]K8\6W&I:;;B3288;..:2\6XA\P^(/[!OC?2O%G[7_P'
M^%OA;5)?A=^U5^SSHWBCP?\ %+Q5J^N>++KP%\<OA[J<&GP?#WQ3XU\0:SJ'
MCBX\$>(8(]!U_0O#S7>H:5826_BO88AJ+P2?J]_PT_\ L]?]%D^'G_A4:3_\
MDT?\-/\ [/7_ $63X>?^%1I/_P DU49.+NE?Y6[=EUO\[KR.:5'#S2=2I&=1
M?\O'9/ELURJ*T6C:O]][(^9_@O\ M1?'S5VL_"?QF_8_^(OP9?P-X1>]^+GQ
M.\4>+OAW'\(M+GT3PN]_?W?@'6].US4+_P :Z7<ZA:&WW#2M'32;&5[R_N U
MF;>6S_P3#L]6?]COX<>+=7TO4=!D^*.O_$WXPZ?X?U-/+GT;0?BM\1?$_CCP
M[9*/NO;KH>L:?/9RQQP(]O=&01J)0&]U\1?'O]EWQ?H>K>&?$_Q0^%FN>'M>
MTZ\TC6]%U;7M&OM,U;2]0@>UOM/U"RFGD@NK2[MI)(+B"9&CFADDB<-&[JUS
M2_VBOV:=#TS3M&TCXL?"_3=)TBQM-,TS3-.U_1[.QT_3[&".UL[*RM8ITAMK
M2UMXHX+>")5CAAC2-%"J %)N3O;[O/E71>7X^AI%TXN#=:$G34HJ[2;4FG=Z
M[I:*RLUKW/H6BO"/^&G_ -GK_HLGP\_\*C2?_DFC_AI_]GK_ *+)\//_  J-
M)_\ DFE9]G_7_#K[S?VM+^>/WGN]%>$?\-/_ +/7_19/AY_X5&D__)-'_#3_
M .SU_P!%D^'G_A4:3_\ )-%GV?\ 7_#K[P]K2_GC]Y[O17A'_#3_ .SU_P!%
MD^'G_A4:3_\ )-'_  T_^SU_T63X>?\ A4:3_P#)-%GV?]?\.OO#VM+^>/WG
MN]%>$?\ #3_[/7_19/AY_P"%1I/_ ,DT?\-/_L]?]%D^'G_A4:3_ /)-%GV?
M]?\ #K[P]K2_GC]Y[O17A'_#3_[/7_19/AY_X5&D_P#R31_PT_\ L]?]%D^'
MG_A4:3_\DT6?9_U_PZ^\/:TOYX_>>[T5X1_PT_\ L]?]%D^'G_A4:3_\DT?\
M-/\ [/7_ $63X>?^%1I/_P DT6?9_P!?\.OO#VM+^>/WGN]59$3=(Q1V)7&0
MK$%=RG: !SR.>O3/&./$O^&G_P!GK_HLGP\_\*C2?_DFC_AI_P#9Z_Z+)\//
M_"HTG_Y)H5^SZ;775/=:KIM^H>UI;\\;K5.^S[VV=C\__P!M_P#X)D>&?VAM
M5OOB+\-KVS\$?$F]CADU<7&DM<Z'XJFC9H_.U VX%SI^IBU\J'^T(%=95MX$
MN8)0&<?DG+_P21_;&MI)EM?"&BW#)<31I=1^+]!@@N+8,/)ECM[FY$D)E #O
M$\9:,C:)""0?Z;/^&G_V>O\ HLGP\_\ "HTG_P"2:/\ AI_]GK_HLGP\_P#"
MHTG_ .2:_2N'_%?C#AW+UEF&K8'%X2G%0H0Q^!IXB=*DK-4U5<E.<4_A51R4
M4U&*22/Y7\1_H>^!WB9G^(XFS3+,QR3.,=.=;,L3PSF,,NAF.)JN,JF*Q6&K
MX7&X5XB<DY5*M&A1G5G*4ZLJDWS'\Q__  Z;_;4_Z$S1O_"S\,?_ !^C_ATW
M^VI_T)FC?^%GX8_^/U_3A_PT_P#L]?\ 19/AY_X5&D__ "31_P -/_L]?]%D
M^'G_ (5&D_\ R37L?\1OXQ_Z!LA_\-%+R_O>GW^>OYW_ ,4^/ /_ *&7'G_A
M_P L\O\ J0^7XON?S'_\.F_VU/\ H3-&_P#"S\,?_'Z/^'3?[:G_ $)FC?\
MA9^&/_C]?TX?\-/_ +/7_19/AY_X5&D__)-'_#3_ .SU_P!%D^'G_A4:3_\
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MBO"/^&G_ -GK_HLGP\_\*C2?_DFC_AI_]GK_ *+)\//_  J-)_\ DFBS[/\
MK_AU]X>UI?SQ^\]WHKPC_AI_]GK_ *+)\//_  J-)_\ DFC_ (:?_9Z_Z+)\
M//\ PJ-)_P#DFBS[/^O^'7WA[6E_/'[SW>BO"/\ AI_]GK_HLGP\_P#"HTG_
M .2:/^&G_P!GK_HLGP\_\*C2?_DFBS[/^O\ AU]X>UI?SQ^\]WHKPC_AI_\
M9Z_Z+)\//_"HTG_Y)H_X:?\ V>O^BR?#S_PJ-)_^2:+/L_Z_X=?>'M:7\\?O
M/=Z*\(_X:?\ V>O^BR?#S_PJ-)_^2:/^&G_V>O\ HLGP\_\ "HTG_P"2:+/L
M_P"O^'7WA[6E_/'[SW>BO"/^&G_V>O\ HLGP\_\ "HTG_P"2:/\ AI_]GK_H
MLGP\_P#"HTG_ .2:+/L_Z_X=?>'M:7\\?O/=Z*\(_P"&G_V>O^BR?#S_ ,*C
M2?\ Y)H_X:?_ &>O^BR?#S_PJ-)_^2:+/L_Z_P"'7WA[6E_/'[SW>BO"/^&G
M_P!GK_HLGP\_\*C2?_DFC_AI_P#9Z_Z+)\//_"HTG_Y)HL^S_K_AU]X>UI?S
MQ^\]VP"<D GCG SQG'Y9./3)]:" <>QR#W'_ .OH?4<5X3_PT_\ L]?]%D^'
MG_A4:3_\DT?\-/\ [/7_ $63X>?^%1I/_P DT6?9_P!?\.OO#VM+^>/WGN?E
M1Y!V@X)(SR 3GH.@Z^E/P/3V_#GCZ<GBO"?^&G_V>O\ HLGP\_\ "HTG_P"2
M:/\ AI_]GK_HLGP\_P#"HTG_ .2:+/L_Z_X=?>'M:7\\?O\ 3_)'NVT<# X.
M1CC!Y'&.G!(XZ@D=":, = .F.G;T^GM7A/\ PT_^SU_T63X>?^%1I/\ \DT?
M\-/_ +/7_19/AY_X5&D__)-%GV?]?\.OO#VM+^>/WGN]%>$?\-/_ +/7_19/
MAY_X5&D__)-'_#3_ .SU_P!%D^'G_A4:3_\ )-%GV?\ 7_#K[P]K2_GC]Y[O
M17A'_#3_ .SU_P!%D^'G_A4:3_\ )-'_  T_^SU_T63X>?\ A4:3_P#)-%GV
M?]?\.OO#VM+^>/WGN]%>$?\ #3_[/7_19/AY_P"%1I/_ ,DT?\-/_L]?]%D^
M'G_A4:3_ /)-%GV?]?\ #K[P]K2_GC]Y[O17A'_#3_[/7_19/AY_X5&D_P#R
M31_PT_\ L]?]%D^'G_A4:3_\DT6?9_U_PZ^\/:TOYX_>>[T5X1_PT_\ L]?]
M%D^'G_A4:3_\DT?\-/\ [/7_ $63X>?^%1I/_P DT6?9_P!?\.OO#VM+^>/W
MGN]%>$?\-/\ [/7_ $63X>?^%1I/_P DT?\ #3_[/7_19/AY_P"%1I/_ ,DT
M6?9_U_PZ^\/:TOYX_>>[T5X1_P -/_L]?]%D^'G_ (5&D_\ R31_PT_^SU_T
M63X>?^%1I/\ \DT6?9_U_P .OO#VM+^>/WGN]%>$?\-/_L]?]%D^'G_A4:3_
M /)-'_#3_P"SU_T63X>?^%1I/_R319]G_7_#K[P]K2_GC]Y[O17A'_#3_P"S
MU_T63X>?^%1I/_R31_PT_P#L]?\ 19/AY_X5&D__ "319]G_ %_PZ^\/:TOY
MX_>>[T5YWX,^+/PV^(ES=VG@;QMX9\5W%@D<M[#H6L6FHS6L4V_RI)X[=W,:
M2&,A6/RD\ ],^B4--;]5?Y%1E&2O%IJ]KKO_ $RJ;&R+%C9VI9B2S&WAW$DY
M))V9))Y.>IH^PV7_ #YVO_@/%_\ $5:HHN^[_K_AE]P[+LON_KLBK]ALO^?.
MU_\  >+_ .(H^PV7_/G:_P#@/%_\15JBB[[O^O\ AE]P679?U_PR^XJ_8;+_
M )\[7_P'B_\ B*/L-E_SYVO_ (#Q?_$5:HHN^[_K_AE]P679?U_PR^XJ_8;+
M_GSM?_ >+_XBC[#9?\^=K_X#Q?\ Q%6J*+ON_P"O^&7W!9=E_7_#+[BK]ALO
M^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 15JBB[[O^O^&7W!9=E_7_  R^XJ_8
M;+_GSM?_  'B_P#B*/L-E_SYVO\ X#Q?_$5:HHN^[_K_ (9?<%EV7]?\,ON*
MOV&R_P"?.U_\!XO_ (BC[#9?\^=K_P" \7_Q%6J*+ON_Z_X9?<%EV7]?\,ON
M*OV&R_Y\[7_P'B_^(H^PV7_/G:_^ \7_ ,15JBB[[O\ K_AE]P679?U_PR^X
MJ_8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $5:HHN^[_K_AE]P679?U_P ,
MON*OV&R_Y\[7_P !XO\ XBC[#9?\^=K_ . \7_Q%6J*+ON_Z_P"&7W!9=E_7
M_#+[BK]ALO\ GSM?_ >+_P"(H^PV7_/G:_\ @/%_\15JBB[[O^O^&7W!9=E_
M7_#+[BK]ALO^?.U_\!XO_B*/L-E_SYVO_@/%_P#$5:HHN^[_ *_X9?<%EV7]
M?\,ON*OV&R_Y\[7_ ,!XO_B*/L-E_P ^=K_X#Q?_ !%6J*+ON_Z_X9?<%EV7
M]?\ #+[BK]ALO^?.U_\  >+_ .(H^PV7_/G:_P#@/%_\15JBB[[O^O\ AE]P
M679?U_PR^XJ_8;+_ )\[7_P'B_\ B*/L-E_SYVO_ (#Q?_$5:HHN^[_K_AE]
MP679?U_PR^XJ_8;+_GSM?_ >+_XBC[#9?\^=K_X#Q?\ Q%6J*+ON_P"O^&7W
M!9=E_7_#+[BK]ALO^?.U_P# >+_XBC[#9?\ /G:_^ \7_P 15JBB[[O^O^&7
MW!9=E_7_  R^XJ_8;+_GSM?_  'B_P#B*/L-E_SYVO\ X#Q?_$5:HHN^[_K_
M (9?<%EV7]?\,ON*OV&R_P"?.U_\!XO_ (BC[#9?\^=K_P" \7_Q%6J*+ON_
MZ_X9?<%EV7]?\,ON*OV&R_Y\[7_P'B_^(H^PV7_/G:_^ \7_ ,15JBB[[O\
MK_AE]P679?U_PR^XJ_8;+_GSM?\ P'B_^(H^PV7_ #YVO_@/%_\ $5:HHN^[
M_K_AE]P679?U_P ,ON*OV&R_Y\[7_P !XO\ XBC[#9?\^=K_ . \7_Q%6J*+
MON_Z_P"&7W!9=E_7_#+[BK]ALO\ GSM?_ >+_P"(H^PV7_/G:_\ @/%_\15J
MO)/C[XUUCX;? SXR?$/P\ML^O^!?A9\0?&.B)>0M<6CZOX9\):OK>G)=0*\;
M36[7=C"LT8=#)&63<N<@N^[_ *M_DON0I.,(N36D5=V71?\ #+[CU'[#9?\
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MDR(-23L]'IUV^[:UOE;R!8B@U)JI#W>G5ZV]U6N]5;3JK'W;]ALO^?.U_P#
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M?<^P?7L#_P!!>$Z?\Q%#R_O^GW>E^U^PV7_/G:_^ \7_ ,11]ALO^?.U_P#
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M3(C1JS*K,&8 _A)_P3N^#OP%^,/@;PS^UY\===U#5_VP=5_:)^(H\1^*M?\
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MF(W*0LVU)7M\B18F8%?-P8]PVJS&I)=0M;=H8[B>""2XD\F!)9HT,TVTN(H
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MKJ0Q3M(QB7]32B,0S*I(Q@D D8.1@D<<\\4QS#&07V*>Q*C.%QSP. ORC)P
M2JYRR@VY-QY?1='M;I;R7GYG+#"4Z<^9?"I\ZBW)J+Y>72[ZIM-/1NS=V?F3
M^SK^S'XF^'/[=?\ P4'^,>K_  _TW0_ 7QX/P)E\%^(HGT=T\82Z'X#O-/\
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M^BP6_C:_L?V?=0\&W\<;B_DDTJ*V\27$>GM-K4=@)'?S5!B5F7]'_P!E2_\
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M<:[G%P:7):UE:RT=^MD[*]E97LKZ=-;A1117T @HHHH **** "BBB@ HHHH
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MA"I[M:?+:+48M)*,G&5E;F^%JVA^N"DL-WJ 0/3\>].HHK$]T**** "BBB@
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MW^&/@*'0] UZZF\6C07T^[O=>US[)H.DS:E:P3076YVK\Z?VH?VE/%7[;?\
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MKWSY9=7^+[KS7G]WHUY?_P +?\&_\]=?_P#"1\3_ /RHH_X6_P"#?^>NO_\
MA(^)_P#Y45ZAL'J?T_PHV#U/Z?X47\OR\O+R_'UN<K_+O_=\_)_=Z6\O_P"%
MO^#?^>NO_P#A(^)__E11_P +?\&_\]=?_P#"1\3_ /RHKU#8/4_I_A1L'J?T
M_P *+^7Y>7EY?CZW.5_EW_N^?D_N]+>7_P#"W_!O_/77_P#PD?$__P J*/\
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MW_GKK_\ X2/B?_Y44?\ "W_!O_/77_\ PD?$_P#\J*]0V#U/Z?X4;!ZG]/\
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M3_\ RHKU#8/4_I_A1L'J?T_PHOY?EY>7E^/K<Y7^7?\ N^?D_N]+>7_\+?\
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MUN<K_+O_ '?/IK]VG2WE_P#PM_P;_P ]=?\ _"1\3_\ RHH_X6_X-_YZZ_\
M^$CXG_\ E17J&P>I_3_"C8/4_I_A1?R_+R\O+\?6YRO\N_\ =\_)_=Z6\O\
M^%O^#?\ GKK_ /X2/B?_ .5%'_"W_!O_ #UU_P#\)'Q/_P#*BO4-@]3^G^%&
MP>I_3_"B_E^7EY>7X^MSE?Y=_P"[Y^3^[TMY?_PM_P &_P#/77__  D?$_\
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MI_PM_P &_P#/77__  D?$_\ \J*/^%O^#?\ GKK_ /X2/B?_ .5%3_\ "T?
MO_0Y^"__  J='_\ DJC_ (6CX%_Z'/P7_P"%3H__ ,E5I]5Q/_0/6Z?\NWY?
MW?ZOZWS^N8/_ *"\/T_Y>KR_O>7_  VEH/\ A;_@W_GKK_\ X2/B?_Y44?\
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M^_\ 7BG;!ZG]/\*SOY?EY>7E^/K?;E?Y=_[OGY/[O2WE_P#PM_P;_P ]=?\
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MUN<K_+O_ '?/R?W>EO+_ /A;_@W_ )ZZ_P#^$CXG_P#E11_PM_P;_P ]=?\
M_"1\3_\ RHKU#8/4_I_A1L'J?T_PHOY?EY>7E^/K<Y7^7?\ N^?D_N]+>7_\
M+?\ !O\ SUU__P )'Q/_ /*BC_A;_@W_ )ZZ_P#^$CXG_P#E17J&P>I_3_"C
M8/4_I_A1?R_+R\O+\?6YRO\ +O\ W?/R?W>EO+_^%O\ @W_GKK__ (2/B?\
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M -WS\G]WI;R__A;_ (-_YZZ__P"$CXG_ /E11_PM_P &_P#/77__  D?$_\
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M.STO1M)M9+W4+ZY<](;>VADD<+EV"[4!<J#^4%W_ ,%8=1LO!<'QZU#]B/\
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MT7?\E+_PGH?_ "KS7WAS5/\ G[4_\"?E_DBW]NNO^>P_[\1?X4?;KK_GL/\
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M?"SP5XC^('CKPOX-\,64M_J_BS7-+TBQMX6=6D)NT:\E\R/B&*RMBUU<2/\
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M*]Q^FG[9/[!>@_MF^+/@O^UI\!?VAO$_[-G[0?@+P^EAX+^,'A2RLM4MM?\
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M\]ORIU   P. **P/<"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8WF1R@>0J0TCEO7:^9_^&BM:_P"C</VBO_"6\%__ #P:/^&BM:_Z-P_:*_\
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M1 FH7-Y'-+>)M2X9PHKQ;_AHG6NG_#-_[16#U'_"*^"^_7_FH/>C_AHK6O\
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M#P)X,MI?%,\/A7PU'-XW9'\92IHVG+)XK>/3TTF-O$3"VSK132HX]-7^T/M
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M?U9^5SVT/[W_ (!/R\O/^KJ_TQ17S/\ \-%:U_T;A^T5_P"$MX+_ /G@T?\
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M?EY>?]75_IBJ4D;N&51&-TIR0$!"G<#DCDL>,_Q=0:^=/^&BM:_Z-P_:*_\
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MO_YX-=W_ !$[C_\ Z*O-O_!_I_<]?Q\CYY?1:^CMI_QJGAGI_P N,?\ W/\
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M\2M_1WTOX4\,]/\ EQF']S_J*]?P\C\YO^')WP4_Z*E\0_\ P&T7_P"-T?\
M#D[X*?\ 14OB'_X#:+_\;K]&?^&BM:_Z-P_:*_\ "6\%_P#SP:/^&BM:_P"C
M</VBO_"6\%__ #P:/^(G<?\ _15YM_X/]/[GW_/R!?1;^COI_P :IX9Z?\N,
MP_N_]17F_O7D?FE)_P $2_@BTC[OBK\0V4NVX1:;H$DH!8A@K_V;,%8=-S;B
MIRVXL,U]P_LW?L%?L]_LSW<NN>"/#TVH^*YU,!\5^*)8[[6H8&C@62WT]I%6
M/3[>=HO-FCM(HVE=B'8JJJ/2_P#AHG61T_9O_:)'_<J^"_\ YX-'_#1.L_\
M1MW[1/\ X2O@K_YX-<6:<>\89UAY8/-.(<QQ6$J**J4)U5&%11M;G]G"'.D[
MNTKIN_>[^AX5\!?!;@G-:>><,>'?#V69M1DI8;'K!XC%8G"R:2<\+/&5L3]6
MFU)KGH*G.UES62O]*H,8!QG;SCUSUSZ8QQG\*DKYG_X:*UK_ *-O_:*_\)7P
M7_\ /!H_X:*UK_HW#]HK_P );P7_ //!KY'YK\?+R_JS\K_L7MH?WO\ P"?E
MY>?]75_IBBOF?_AHK6O^C</VBO\ PEO!?_SP:/\ AHK6O^C</VBO_"6\%_\
MSP:/FOQ_R_JS\KGMH?WO_ )^7EY_U=7^F**^9_\ AHK6O^C</VBO_"6\%_\
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M[_P"?EY>?]75_IBBOF?_ (:*UK_HW#]HK_PEO!?_ ,\&C_AHK6O^C</VBO\
MPEO!?_SP:/FOQ_R_JS\KGMH?WO\ P"?EY>?]75_IBBOF?_AHK6O^C</VBO\
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MW#]HK_PEO!?_ ,\&C_AHK6O^C</VBO\ PEO!?_SP:/FOQ_R_JS\KGMH?WO\
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M_P#PT5K7_1N'[17_ (2W@O\ ^>#1_P -%:U_T;A^T5_X2W@O_P">#1\U^/\
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M%==?^U91]DO5S;:A;L6XR6ZZ7[Z/O:]OF$*M.:O&5UM>S6NFFOK^9]#X'O\
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MJ/Q.F^).@^&+J0OH=OXV'A^&'2+7Q%/8>3=ZA8VB$6,MQ]ED(FB=$Z;^U?\
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MU+_0[NWMVMH?,\W$X*AFV7SSK+<+' 8K!1A3X@R*E[>4<)*32IYUET:Z]O\
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M.:*3#97?B!TN!H]WT,7N?P73X(>-_B!\%OBO\//VI/V?_&?B[X<_LZ_&;2/
M?P7_ &>_A'8_#GQWXH\&ZGX TV\N_"WC.2X^(&OG1KCPC)IFF76EV'BBPT<Z
M=XBGN%DFCDFNFK^A98(HT$2*J1JNQ8UC"H%P5"A% 3:%X "[>G' KS#QA\%?
MASXQ\$?$7P)=>&].TC2/BAX6\2^$_%USX<LK30M5U#3?%6D7NBZK(U_8V\4Y
MO6L[Z;R+F8RO#,(Y4PR*:MR;LFK=K)J[NG??KVUZ?$<GU-J4ZCJ^TE))\C]V
M$9*3DG%*3Y;N33NW=):[H_EG_P"">GC'X/\ Q+\=_P#!/KP7XY\:?LJ>#KWX
M$V>OZOX _P"$<\&_$NQ^*OQJ\;^._"NI02^%]6U3Q?\ #G0/ &EZWH.MZGJ)
M\3+HWC7Q=/XM\6Z1)?>&KF&UD61OM3]E;PMX*^'OP=_X*W?'^Y^!'AGXG>/]
M#_:P_:[O8M)USPU;W&L>/-&\-Z!#=Z5X2&I/I]]J0T.]BU+5=,$6FP21S66I
MWR^3=-,0?M;P/_P3>FT>U_9V\(^.?VDOBC\2_A3^RWXC\$>*?A;\/-6\*?#7
MPY&^K?#C3)]+\"/XI\6>&O"MAXAU^W\,Q2));V\=W8+>S6\<NK_VA))O'Z=)
M;01*R10K$LC-))L0*'D=0&=P%!=V &7;YR>IQQ4[)+=^FGPQ2ZOMIO?=ZA0P
M\K-S]G&<?@E&+5FDHIM.3O9*U^;T6MS^73]G+XHW'Q-_;X_X)V>++/QO^S[X
MFUK7_@3\=]2\8>'_ -F/X:WO@CPY\/Y->^'.G:OI/@;QMKBZ[K5OK>HZ1?07
M$%OH&J'1M6T:\MC?S:5:17<3O\I>,-6_9I_X=:Z3\-O%&F^#KW]NC1OVK-&U
M/Q_HUSX<&J?&_2/BA;?M5Z?=^,_$GBV_MM/O-5L;63P++':77B?4+A?#5[93
MV6F:?/<7;V4+?V2:5X9\/:%&T6BZ)I6DQO/<W+IINF6UDKW-Y*TUU.RV\48:
M:XE=Y)9&R[NS$G+'*)X8\/1:G=ZS'HFE)K%_##;WVJIIEJFI7D$#M)##=7RP
MBZN(HG=VCCFE=(]S!%4,P+BW&Z2^)J^C[1VU\EZWZ#6$DFF\0I<O/93CS1:F
MX7NG.]URMKWK>\U9(_FH_P""C7QWCU/Q?_P4/^$NJV'[-?P7TOP?\ =*B\-W
M_CWX4W7C+X[_ +2GB+QQ\.M5-A>?#O4CJFB.EKX:G2U\,6TVDZ;XIN-!UF+^
MU+F2TMX9H1ZYIM[\%/!WQ:_X(W^-/CE9^ M&A\2_L<>+-!U#Q3\1-(TD1ZGX
MQL_A1\$9?"]GK>O^(+!$DUV&Y:_C\/C59X;Y;Z6ZBTR))Y95;]_KKPYH-]J5
MGK-[H^F7>KZ<D\6GZI<Z;;3ZC817(Q<Q65[+$US:Q7  $\<$L:2@8D5@3E]_
MX>T/5H+>WU72=.U."SN(;JTAO[*"ZBM;BW*M;S6T<\;K!+ RJT,D01XF52C*
M5&!2L[ZZJVNO5-=5TLKZ-JS;=[%QPTU-S]LI-N+2::2<7>*MS/1+1))7LF?S
M _M-Z+K.I0?\%I&CT'7=:\&2?M'?L5:Q\2=.T+3M7NM5UCX+Z3X1^'^I_$@Z
M/'I:BXO+>/PM:ZA)J A2ZMWTN'489875L'Z3U#Q#^S?\4_VY?V/-2_8:?P'J
M=MX#^!OQSN/CAXD^%6BV8\':5\&-<\%Z78^"?!7BZXT&VL]-M_$>I>+XK:7P
MYINI,=6TK^RM2%Q:6QG;=^_?V.V E AC G)\X&-6$P*[2)5*D2 J I+@DJ I
M) %9>D>&?#V@)<1:'HFE:-%>7,M[>1Z5IMKIR75W,Q>6YN!:Q1+-<2.2S32!
MI"2<,,FE?5.STY=;:^ZT]'\[/U\]">%4W)RG!.4HR>COI/G2C)27*I;-<KNK
M][K^4OP5\&_!/AK_ ((F?LK_ !+T7X<Z7HGQ<TCX]_"3QE;^-=,\/6]KX]MO
M$#_M53Z)>:TVMP6IU6.>XT&YFLK@2RRVJ6%U,JP!"C#^L^(DQ1D\DQH2<YY*
MC//?GO5?[!9^4L'V>+R$(*0[%\I"K;U98\;597RRL!E6.Y2&P:MTG:RM?1):
MI+96O_7WFU&BJ5[<BO&*]W2_+>U_3FLNMGJPHHHI&]UW7]?\.OO"BBB@+KNO
MZ_X=?>?CW_P42\)VGC7]L_\ X)6^&M7TJ75?#FO?$O\ :CT'Q) ()9+631];
M_9WU33[NUO)(T=;>*\CF:+?)M21%D@+?O-K?#G[-N@_&OX@?&GPE^P=\2O#_
M (B@^&O_  3(\3_$3Q]KOC'4K>7^Q/B;ITT=PO[%UI8W5Q<7EQJ3:!X5U;6=
M=UC[=#"1J'A#2[ZUEA80QU_3%)!#*\;R1H[PEFA=@"\3,NUFC;[R,R$H64@E
M2RD[6(,0M85DDD1 CRX$C*K O@;5+$=64#"O]Y>=K#)S<).+;WVZ:V]U)?\
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M  C5C#XI@\*VMKXC\56MU/XF,FF:UKMQ::Q+:_VGYC""*>28GE?VZ;.ZF_;
M_P""6LL-M-+%;_M#?%&6XECB=TMX_P#A3?B&/S9W52L,;2,JJ\A57=E5"S$
M_J1I6D:5H=E%IVBZ;8:3I\&?)L=-M(+*TB! '[NVMHXH4X 'RH.  >@JY)!#
M*T;RQ1R/"Q>%W4,\+LA0O$Q!:-BA*ED*D@D9Y.93L[KNO/9I]6^JVUML;RH1
MG1C2;2LXR7*[*\9QJ+=-VYDF^]_-'X^_%/X8^!?B-_P6&^$D_CWP-H/C.R\,
M?L&>/=3T)O$V@VNMZ=IFO3_&G1K!KFSBO[:>S&H'3+VZA^=7E2WN'DC";6)_
M*J_TW7?"_P"R[\%[*6XT'PA^S?\ "3_@J9\>(/'Y\5>!=2\=_#SP!X0B\6?$
M _#?5/%/@W3-2T*YU;P%HOQ$U:QU"66?48M%TR6[L9;\/9VZ(O\ 6F;.V,WV
MCRE\[8T?F@8<(Q#,FX8)4L Q4Y&X;L9YJ&;2].N;:>SN+*VGM+I9%NK6>&.:
MWN5EW>8)X95>.82%F+^8K;R26S5.46DM;)6V7=/777;RT,OJKYIM5.7GJ3J.
MS>LIJ"?G;W597NF]WH?S#?M$^#/AW??LG_\ !5?XH?#S]I'X1?'CQ/\ $[]G
M#P)!XQ\'? +P'%X6\#Z#/X>N]3TCP[XB)TKQ?XVT[4/$FN67VVTU*.WOX;M[
M33K9[N!0+=C]H?M1^(O!'[*WPU_8M^%_@#X<_L^_#WP?\2?%.FZ1JGQE^./@
M>+Q#\+/A'_PC'PX.JIJWB4QW.D27GCWQA8PW'A[PQKNOZ]:1S:@]RU[?R.RY
M_9G2?"GAG0+'^R]"\/Z/HVFD8.GZ5IUII]B1GD&UM(HH&SR"6C)P2,X)%6=3
MT'1=;LY=.UK2[#5]/G $UCJ=K#?VDP48'FV]TDL4N.#^\5L$!A@C-2FEKJM+
M;7Z\U[MWO=OK?K=,%A4M4XJ6GO1;O;G4WJ[VN]7K=WOO8_DK\57>G'_@ES_P
M5AUJWU31O$'AS5OVU='\1Z=XC\"^$-6^'WA3Q5H%[?\ [,U_?>(O!'AA[R]G
MT[0]66/5'TIM,U*>UO+OSKFRN/-<FOJS5=1^$'Q-_:W_ &;KS_@G7:>$KB]\
M"?L7_M*P?$GQ#\)](LM)TW1]%\3_  T@T[]G_P (>.+NUMDMXO$4'Q0MX-3T
M[PQK:+X@TZZCNK[4(%CB;/[6?M0_LS^$OVHO@7XM^ WB+5=7\)^&_%T_A2>[
MU/PK'IT>JVA\(>*M!\5V$=DNH6UU8QK//X?MK"5FMR\=HX6!XC%&1[CHOA70
M/#T4L>CZ38:<]U(MQ?S6-E:V4NH78B2%KR^-K%$MS=R+&-\\H=SE@&VL01M6
M2[*/356=]&V[?>_42PFMVX2VU;DWH^96=UUEIIUU>Q_+;^RCX1^%'C'X.?L-
M^#/&W[6G[/WPM^)_P>^+WPF\4:W\+='^"QT+]I"[^/>CZTNC>-_ 7C/6;OQ]
M=>);V[\7>+[_ %33/%OB63PG!9ZX)EU>Z,&FLD<';7'[0GPO_9_^'_\ P6T^
M$WQ.UB]T3XK_ !*^,_Q\U'X??"Z'0]6OO'OCG2?BW\$;;2/!'B#PGX?M;.6Z
MUS0-2N+._GN]<TY;C3-(L[2XNM7N;-1&)/Z64\'>$X]9G\1Q>&]$B\07*HES
MKD6F6<6L3I&X=$FU*.%;V5%< ['F9.N1@MFQ+X=T*;5(]<FTC39=9AMVM(M6
M?3[=M2CM78,]NEZ8OM*PN1EXQ)M;+9'S-E+I;IY/T36KL]MMGW!86U^6I&G=
M6T5[IQLFTY+9/3[G=:G\\^GVWP<\$_';_@C[X^^,>D^ =#\->(OV,O$/@@>*
M/'.BZ''8:EX\3P)\(KOP;H5YJ&JVKK_;20I>CPTE_)'(DLLD&F,LTKQGR3]L
M#1]<N_'W_!5G5DTCQ!JOPPL/VH/^";WB+XZ:3X?T^]N-1\0_L^>&_A9X2F^*
M5E96]O&'U&S@LX4NM4ALWXT^SO?.<PLT;_T[WWA_0M5AM;?5-(TW48+*>&ZL
MX;ZQM[J*UN;=@UO/;13QNEO- P!ADB5'B^ZA5>*NFQM#YN;>/]\,3?*/WP\L
M18D_O_N@(\G+;%5,[0!5<RM;5:6NO1>??\-.H?5.CE&2=15-;V<O8QH:V>SC
M9VUNW\2T1\??LQ_%#]B_XF^)_&M]^RO??#+7=<T[PQX*7QOKGPRT&TM+*30]
M0CU&^\'Z=J.MZ3IMII&H7=HCZFXTM+NYU'1VGDAOH;0R1QGX(\=Z1\?/VF_^
M"@OQK\6?![2?A3K'P]_9?^$*_LRR:?\ &N]\?^'='OO'?Q@T^U\;?$W6?"S^
M$M'UO^TKJV\*/X2\,MJ[1V0AAEU33T9]PD/[6Z1H.B>'[=K/0M(TW1K1II;A
M[72[*WL+=[B=B\\[P6L<4;S3.=TLS*9)&P79B,UHI!#&9#'&D9F<R2E%">9(
M< R/M W2$  R'+D*H+$ "IOJGVM^']?\-L='LDZ3IOEC>[O3?*KMWO;6[=];
MI[W/Y0=5MM:O_P!A[X9?L,?&W0;77_%O[*'_  4=_9Y_9_\ %^A_9M3O= \3
M?""]\:QZ[X!UBS;4K6#4M4\&:CX'U$^'+;5=3C&HW]QH$T]XD,A!;ZQ_;(\+
MV_PJ_P""A'[-^M7VO?!GX"_L_:;^S7\1/#_P\\3_ !=^%NG^)_@;H'QMU#QC
M:7.OZ9I^EVOB7P3HGA+QSK7@&!6AUZ_O(QJ6E:?-I-F9;FX85_0+_9UB69S:
MPL[F)G8QKN=H!B)F.,L8_P" G.T\K@U2UCPYH/B&PFTK7]'TW6],N,?:-/U:
MRMM1LI]K!U\ZUNXI89-K#<NY#M8EEPV"*E.ZMV=U96V:T?O7=[:NZUUM;0P^
MJN5N:49-1A&+;=TH[7:L[ZWNM+]KZ_SFWOC/P7^R_P#!+X=>$/AQ\3/V?/C;
MX,_:*_;@^)_B'4?CY\0?ALQ_9<_9IU'5](_X2G6=(T3PMI^O7FGV-J]T-2TC
MX?-_PEMKHRZWK=V9M4P6=>!^#GACX(^//@K_ ,%&/#7Q5^-G@WX>_#CQM^UQ
M\)?$7@KXT>%? =WX*^$DWCF;PQX0UKPGXLL? FLW>L^&]0\"Z_XIT2.?61JV
MI7'@;Q;:K<WMQ>0Z9>0W=?TTS>%O#D^CGP[/H>D7&@F%;<Z+/I=G-I1@7&V+
M[ T!M!&N%VQB$*H5=H  JP_A_0Y].ET>?2=.GTB:V6SETN:R@DTZ2S6/REM7
ML9(VMGMA%^[%N8C#L^4H5XI?*Z6V_9)K?YW;OLKV$L-+F@_:I*"<5"-TN5P<
M%&_/TNW>U[I6=M#\TO\ @F?\=_$WQ@L?V@/#GB/0/@G?GX3?$O2/"%C\</V>
M]!N-!^%_QYAO?".G:Z/$NDV\JW$+ZGX<@O;?PYKWV+6M8LK?4X9K6U>V@ACB
M'ZC5F:7HNDZ'9V^G:-IUEI6GVB%+6QT^VAL[.W1F9BL-O;I'%&I9F.$4 EB2
M"3FM.I_K^OZUW.JE%P@HRES-65V[MJR^_?RW\]2LW5QG2]1X&!I][UP!_P >
MTF.N .>_;KD5I4$9!'KQP2#^8Y'U'--.S3[.YH[-6OO^O_#K[T?RJ?!GP+XO
M^#'[%/[,'[?GPUTC6[OQ!\#(OC1\/_V@_"&B6%U<:W\1?V7?%7Q9^($NOV-I
MI<=K-/J&J_#;Q)J,?Q&T&&&.)Y%@U=4NHXYSYFE\&=7\$> 5_P""07C+]JVS
MT2P_9AM?V4O&FB>#-;\;Z-*?"?@_]I#6UTJ^L+_XB2:FO]A:-#JO@.WN=,\%
M7&OP 6>OIJ+QFUFE29/ZC_L5KL,0@C6(J4,2H@C96+%PR;<$.78R9'SD_-GF
MJ.I^']$UC3WTK5=*L-1TV5!%)87MG;W=G)'C:8Y+6>.2!T*Y!5HR,$XQFFFE
M;?117=:<NNZM>WG;\#@>$<5:E-<L>7EC4]^+LX_&ERW;79K6SUNT_P"7[Q3X
M&\&^//V>O^"VWCKX,^#M+UC]FGQ+?^&/%'P9N]'\/6W_  @FL^-O OPZB7XR
M>,OAGIKVT5MMM-8MWBO-<T.S2+4M0MI&T:>[A7G]^_V4O$OPH\7?LX_#K6/@
M/>^"+WPA-X+TB&VNO <>DP:"GB&+1+*+5(9X-%CBM8=5M;]!'J]O-&E[#<J\
M-ZB3*ZCZ,ATC2[:Q33;:PM+;3XX!:I96]O%#:I;*C1BW6WC185@V.Z>2J"+8
MQ39M.*32=&TG0K--/T73K+2K&-G=+/3[6"RM4>1B\CK;VT<42O([,\C! S,2
M2<FEYO=7MHM-;_=OIY*YM"CR5%*/)&,J,83C%/XU)RYH^\[)\VUGJT]3^0GX
M@^)/V7+;_@FI^T;\*OC/X=T75?V\8OCE\9+GQ=X;O/#<FK?&.7XQWGQ0U?5-
M.^(-E]FAFUZP^':^!SIEZ-?29/",/AZ*XL3)(UZEE<_>OCC0/!&N?MK?M*Z1
M\5-;UCP7\*_%'_!(/P+X3\<>-=.M;UKCP_X>U/QCX@TS6-5M9H=,U+==Z98:
MI)>(18W9A6-YI;8PJX/[\-X=T)M3GUHZ/IG]L7-N+.XU4:=;?VE/9KNVVDU^
M(OM4MLH=U$#RF+:[+LVG%7WT^RE+M+;0R-+'Y,I>-3YL.3^ZD# [X^3\KY')
M(')RXOE:?96VO>UG=ZJ[?7Y&/U*-[J5.[A1IMQCRMPHJ48)OFDY*TW=::VM;
M8_DW\6_$7XBZC^R'^V1^R;\/=0^$/Q[\'_!+X+?!;7+W]H_]E[PB?#]QXX^"
M6G>+-,TSQ;\)/&UIH[WMC>_%RW^'NE:YJMNOA6_U#2KG2);Z.\AT[4'FM9OT
M(^/_ ,6?V'/BC^Q#^UY9_LGW?PNUKQ=8_L<:F^JR_#'PHMMJ&F^";VPF7PSH
M7B'5-+T:WMH=2MM1CF<^$]1NWU_3V#W%]I]O#+YC?MCI'AGP[H%F=.T+0])T
M;3V>21K'2M/M=/LV>61I96:WM(HHB9)'D=\J0S2.6!W&F:9X5\-:+!<VVCZ#
MI&E6][/+=7D&GZ=:6<-U<SG,T]Q%;Q1QS2RG[[R*S-D\XH;3;?>W2]K7VU6]
M];WO9;:6UIT9TXJ*G&4=K3O):V>B^:6KN_*]S\&;?QE\#?AG^W]XRUG]M^X\
M :5X8\1_L>_!.S_97\5?$S2[:X\$VWA#0TUR;XO>&H=1U^WN="@^(5WXFU!+
M^YM+<#5M1\--IUM;^<1Y+_+?PK\#?#?2?V9/A]XFU+XP^!/V9]4T+]LS]K#X
MX_L*V_Q_\/7&H?!'Q7\(-5NKG3])T;7O#6M7&FV=EX1UCPYK\UYX2F:XT7Q?
MHUK>0WOABW6Z>[C?^HW5_#/A[Q!;Q6NNZ)I>LVT$J7$-OJUA::E#%<1LK1W$
M<=[#.JS1L@*2@;U/(/ PW5?"WAS7K)=-US0]*UG3E:-EL=5L+;4+16A*F$K;
MW<<L2F%D1HF"AD9%*D$4O=N]UO9I:W=K]4U:WNV>GG:Q#PK:2DX2LV[RO?WG
M&6C3Z.UNJLK>?\Q?CCXX^(_BEX=_X)>?'WXH:#\)?V=?A9/XI_:"T>^OM8^%
MFL>,OV?_  [\6)8SH'P^^(5[X>77? <&C>$_B!IEMXEO_!GB'Q)>7-IINI:Y
M]L>":5DU<,_:,^'W@K1?V3OCGXY\!?&WX>_'CX6>-?VW?V4O'W[1FD?!+P.?
M#GP@\'>#]*\5>$5^+EQ+HFC>(O&9O]/\3Z"='\0?$6WT_5;FT,T=S-_9]LS7
MD<G]/UWH.BW^G2Z1?Z787VE31>1+IMY:07-A)!C;Y#V<T;V[Q;25\MHRNTD8
MQQ45EX<T#2]-_L73=&TRPT?RVB_LJST^V@T[RF&&C^Q11+;>6P'S)Y6UB69@
M2[$FC?5WMTUVBMD[=.WDM[J7A')-2J+6^DFVM8J.R:NK;W?7SN?A!\#_ !+^
MR]XU_P""PWA+Q/\ LMV7@F^T$?L.?$#3/&GC#X:^'HM/\(:WK4/Q'^'9T/3(
M==TVTM?#^NZGH>ARQ6]U'ITD]UIBRC3[]EN;<P1?OP 0$]EP?R K+TK0=%T2
MVAL]'TK3M+M+99%MK;3K&WL+>W66033+##;111QB:4+),$51*ZJTFYE!&N!@
M8]*75Z)7UTTW.FA2C1@XQ<=9.3Y5RQNW?17?=7=]7KI>P4444&UUW7]?\.OO
M"BBB@+KNOZ_X=?>%%%% 77=?U_PZ^\**** NNZ_K_AU]X4444!==U_7_  Z^
M\**** NNZ_K_ (=?>%%%% 77=?U_PZ^\**** NNZ_K_AU]X4444!==U_7_#K
M[PHHHH"Z[K^O^'7WA1110%UW7]?\.OO"BBB@+KNOZ_X=?>%%%% 77=?U_P .
MOO"BBB@+KNOZ_P"'7WA1110%UW7]?\.OO"BBB@+KNOZ_X=?>%,D!,;A?O%&
M^NTX_6GTAZ'/H:-.NW7TZA=/K]S_ *[K[T?E)_P5*^$?Q2^(?PJ\ ^(/#.B7
MGQ0^%7PN\>:?X\^//[.VE7%SIFM?&OP#HT7VF31M)U2T=;B\N]"O%C\0+X3E
MDM].\5C3SI]U/YI@M[C[A^$'Q-^&?Q>^$/@_X@_"*_L-3\ >(?"4$OAQM+@B
MMX;*S2 6YTU[)1&-.N]*EA;3K[394CFT^[@:UFB1UVCW*1(Y  P!!7!#)NR
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MI6MI=^KU;]6VVV]6VV]3ZIN[;>[;>K[N]O35)>5@HHHJB;KNOZ_X=?>%%%%
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M/0?D*+KM^/I_D_O\@]F_YE_X#_P?7^EKYC_PGGB?_HEGBO\ \&W@W_YHJ/\
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M_P#-%1_PGGB?_HEGBO\ \&W@W_YHJ].P/0?D*,#T'Y"BZ[?CZ?Y/[_(/9O\
MF7_@/_!]?Z6OF/\ PGGB?_HEGBO_ ,&W@W_YHJ/^$\\3_P#1+/%?_@V\&_\
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M_(/9O^9?^ _\'U_I:^8_\)YXG_Z)9XK_ /!MX-_^:*C_ (3SQ/\ ]$L\5_\
M@V\&_P#S15Z=@>@_(48'H/R%%UV_'T_R?W^0>S?\R_\  ?\ @^O]+7S'_A//
M$_\ T2SQ7_X-O!O_ ,T5'_">>)_^B6>*_P#P;>#?_FBKT[ ]!^0HP/0?D*+K
MM^/I_D_O\@]F_P"9?^ _\'U_I:^8_P#">>)_^B6>*_\ P;>#?_FBH_X3SQ/_
M -$L\5_^#;P;_P#-%7IV!Z#\A1@>@_(477;\?3_)_?Y![-_S+_P'_@^O]+7S
M'_A//$__ $2SQ7_X-O!O_P T5'_">>)_^B6>*_\ P;>#?_FBKT[ ]!^0HP/0
M?D*+KM^/I_D_O\@]F_YE_P" _P#!]?Z6OF/_  GGB?\ Z)9XK_\ !MX-_P#F
MBH_X3SQ/_P!$L\5_^#;P;_\ -%7IV!Z#\A1@>@_(477;\?3_ "?W^0>S?\R_
M\!_X/K_2U\Q_X3SQ/_T2SQ7_ .#;P;_\T5'_  GGB?\ Z)9XK_\ !MX-_P#F
MBKT[ ]!^0HP/0?D*+KM^/I_D_O\ (/9O^9?^ _\ !]?Z6OF/_">>)_\ HEGB
MO_P;>#?_ )HJ/^$\\3_]$L\5_P#@V\&__-%7IV!Z#\A1@>@_(477;\?3_)_?
MY![-_P R_P# ?^#Z_P!+7S'_ (3SQ/\ ]$L\5_\ @V\&_P#S14?\)YXG_P"B
M6>*__!MX-_\ FBKT[ ]!^0HP/0?D*+KM^/I_D_O\@]F_YE_X#_P?7^EKYC_P
MGGB?_HEGBO\ \&W@W_YHJ/\ A//$_P#T2SQ7_P"#;P;_ /-%7IV!Z#\A1@>@
M_(477;\?3_)_?Y![-_S+_P !_P"#Z_TM?,?^$\\3_P#1+/%?_@V\&_\ S14?
M\)YXG_Z)9XK_ /!MX-_^:*O3L#T'Y"C ]!^0HNNWX^G^3^_R#V;_ )E_X#_P
M?7^EKYC_ ,)YXG_Z)9XK_P#!MX-_^:*C_A//$_\ T2SQ7_X-O!O_ ,T5>G8'
MH/R%&!Z#\A1==OQ]/\G]_D'LW_,O_ ?^#Z_TM?,?^$\\3_\ 1+/%?_@V\&__
M #14?\)YXG_Z)9XK_P#!MX-_^:*O3L#T'Y"C ]!^0HNNWX^G^3^_R#V;_F7_
M (#_ ,'U_I:^8_\ ">>)_P#HEGBO_P &W@W_ .:*C_A//$__ $2SQ7_X-O!O
M_P T5>G8'H/R%&!Z#\A1==OQ]/\ )_?Y![-_S+_P'_@^O]+7S'_A//$__1+/
M%?\ X-O!O_S14?\ ">>)_P#HEGBO_P &W@W_ .:*O3L#T'Y"C ]!^0HNNWX^
MG^3^_P @]F_YE_X#_P 'U_I:^8_\)YXG_P"B6>*__!MX-_\ FBH_X3SQ/_T2
MSQ7_ .#;P;_\T5>G8'H/R%&!Z#\A1==OQ]/\G]_D'LW_ #+_ ,!_X/K_ $M?
M,?\ A//$_P#T2SQ7_P"#;P;_ /-%1_PGGB?_ *)9XK_\&W@W_P":*O3L#T'Y
M"C ]!^0HNNWX^G^3^_R#V;_F7_@/_!]?Z6OF/_">>)_^B6>*_P#P;>#?_FBH
M_P"$\\3_ /1+/%?_ (-O!O\ \T5>G8'H/R%&!Z#\A1==OQ]/\G]_D'LW_,O_
M  '_ (/K_2U\Q_X3SQ/_ -$L\5_^#;P;_P#-%1_PGGB?_HEGBO\ \&W@W_YH
MJ].P/0?D*,#T'Y"BZ[?CZ?Y/[_(/9O\ F7_@/_!]?Z6OF/\ PGGB?_HEGBO_
M ,&W@W_YHJ/^$\\3_P#1+/%?_@V\&_\ S15Z=@>@_(48'H/R%%UV_'T_R?W^
M0>S?\R_\!_X/K_2U\Q_X3SQ/_P!$L\5_^#;P;_\ -%1_PGGB?_HEGBO_ ,&W
M@W_YHJ].P/0?D*,#T'Y"BZ[?CZ?Y/[_(/9O^9?\ @/\ P?7^EKYC_P )YXG_
M .B6>*__  ;>#?\ YHJ/^$\\3_\ 1+/%?_@V\&__ #15Z=@>@_(48'H/R%%U
MV_'T_P G]_D'LW_,O_ ?^#Z_TM?,?^$\\3_]$L\5_P#@V\&__-%1_P )YXG_
M .B6>*__  ;>#?\ YHJ].P/0?D*,#T'Y"BZ[?CZ?Y/[_ "#V;_F7_@/_  ?7
M^EKYC_PGGB?_ *)9XK_\&W@W_P":*C_A//$__1+/%?\ X-O!O_S15Z=@>@_(
M48'H/R%%UV_'T_R?W^0>S?\ ,O\ P'_@^O\ 2U\Q_P"$\\3_ /1+/%?_ (-O
M!O\ \T5'_">>)_\ HEGBO_P;>#?_ )HJ].P/0?D*,#T'Y"BZ[?CZ?Y/[_(/9
MO^9?^ _\'U_I:^8_\)YXG_Z)9XK_ /!MX-_^:*C_ (3SQ/\ ]$L\5_\ @V\&
M_P#S15Z=@>@_(48'H/R%%UV_'T_R?W^0>S?\R_\  ?\ @^O]+7S'_A//$_\
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MQWXH/3X6>*S_ -Q;P=_\T5>FX'H/R%+@#H *+KM^/I_D_O\ (:@TT[IV\O\
M@^O]+7E?#VOZMK,EPFH^$=:\-I"J&.75+G1ITN6;[R0C2]2OG&P=7E5$;^!F
(S75444C0_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>ny20077915x1_table02x1.jpg
<TEXT>
begin 644 ny20077915x1_table02x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
M+0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0":
M )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0T!
M$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0&I
M ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F<"
M<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P-:
M V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'$$
M?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M07%
M!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!ST'
M3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC[
M"1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*
M\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\PT-
M#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/
M>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('
M$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,X4
M\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA?W
M&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;
M8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA[I
M'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J\B
MW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR;H
M)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S8K
M:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR_^
M,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--@U
M$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3HV
M.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_
MXD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:
M1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+
MXDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q
M4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9
M&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %
M8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUG
MDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>
M;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW
M5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$
M?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(
M:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_
MD:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:
MU9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16
MI,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVN
MH:\6KXNP +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1
MN4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#
MU,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZV
MSS?/N- YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':
M=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-
MYI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_R
MC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<
M_VW__V1E<V,         +DE%0R V,3DV-BTR+3$@1&5F875L="!21T(@0V]L
M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
M                                                          !8
M65H@        ]M8  0    #3+71E>'0     0V]P>7)I9VAT($AE=VQE='0@
M4&%C:V%R9"P@,C P- !S9C,R       !#$0   7?___S)@  !Y0  /V/___[
MH?___:(   /;  # =?_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( C@$R@,!(@ "$0$#$0'_Q  ?   !!0$!
M 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T!
M @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F
M)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MZ;HVF!TP3:,^KM&P8?:CD ?+H_X+V_M\KG_B=_#!LL6RWP[L.,_PJ%N5PHZ
M,7;KF1J_1L-X3<78BA"M.GE^$<TI*AB<7)5XI_SQH4*\(R[Q=3F6G,E<_G3,
MOI7^$67XNMA:6,SS-(T9N#Q>6Y-.6$J2CI)T9XRO@ZM2"=TJBH^SG;FIRG!J
M3_N&HK^'K_A_=^WS_P!!GX7?^&ZLO_DRC_A_=^WS_P!!GX7?^&ZLO_DRM_\
MB$/%?_/S*/\ PLQ'E_U!>?X>MN#_ (F\\)O^?7%?_AEP_P#\\C^X6BOX>O\
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MBN?3;B^?CKG.#TP3U$O_  _N_;Y.?^)U\+AQP3\.K+@^I'VS]*7_ !"#BO\
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MN(HK^'EO^"]W[?1!VZU\+@>Q_P"%=6./_2LU&/\ @O9_P4 W#.N_"D+CYO\
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M?#;3Y<CT*O?Q@?4$_3O2Q_\ !>S]OL*!)KOPN=L8W#X<6*Y..I479 )YR 6
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M+F&P -_PKBP1B_=BHNV4 _W0QQZFA/\ @O;^W\"=^N?"QE[!?AU9 _CFZ'Y
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M,@_X+V_M^[5SKGPLW#.[_BW-ESSQMQ=G QQS^E/_ (A!Q9_S]R?_ ,+,1_\
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M,1Y?]07G^'K8_P")O/";_GUQ7_X9</\ _/(_N%HK^'K_ (?W?M\_]!GX7?\
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M_P $X/'3?#G]J;PUXG7XW^!OV>OL_AGQ7:+\3/B+X23QMX5T]KW1Y8?[*O-
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M2?VG?VK/C/\ M=_$!/B-\:/$<6LZO9V"Z/HFEZ;91:3X<\-:-'-)<)IFA:1
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M.[^Q1_T4+]H__P +'X>__.MH_P"(M<'?\_LR_P##?+R_Z>^?X>MC_B4WQ?\
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MBO[1?^(=W]BC_HH7[1__ (6/P]_^=;1_Q#N_L4?]%"_:/_\ "Q^'O_SK:/\
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M%K@[_G]F7_AOEY?]/?/\/6Q_Q*;XO_\ 0'D'_A\H^7_3GS?W>9_%U17]HO\
MQ#N_L4?]%"_:/_\ "Q^'O_SK:/\ B'=_8H_Z*%^T?_X6/P]_^=;1_P 1:X._
MY_9E_P"&^7E_T]\_P];'_$IOB_\ ] >0?^'RCY?].?-_=YG\75%?VB_\0[O[
M%'_10OVC_P#PL?A[_P#.MH_XAW?V*/\ HH7[1_\ X6/P]_\ G6T?\1:X._Y_
M9E_X;Y>7_3WS_#UL?\2F^+__ $!Y!_X?*/E_TY\W]WF?Q=45_:+_ ,0[O[%'
M_10OVC__  L?A[_\ZVC_ (AW?V*/^BA?M'_^%C\/?_G6T?\ $6N#O^?V9?\
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M'MD-WKUQ#%I:II]S86D#SB46K,"K?9W@7]HOQMH'[$W_  4&^,7PE_X*WO\
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M+^.ZF-Y?:W/<O?S1!E,,,,<95%^S_P#@D+^W)\=?BO\ #_\ ;3UW]H3XJ?\
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M;S4[36]3L-?O=3T_7;&;3;&X6]M9?$%LBO/'<%?TI_X+F^-_ '[2/@__ ()
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%!( ))P!R2>@'J:S7UC2XY&BDU"S21"RO&]Q"KJ5.U@4+A^#P>.#P<
M'BFDWLF[;V3=ON$VHZMI+NVEY]?)-GS9^VR/CC/^RC\>=-_9K\*S>,OCIKOP
M[U[PW\-M$AUS0/#C_P#"1>)+8Z)#JAUGQ-J^AZ-9+H4%]/K3/=ZG:M)]A$5L
M9KJ2*&3^<#5O^#>GXPQ_\$]=/^'.E_M9?M&ZA\5M#\#6'Q,TG]EZ]\:^#A\
M[+]H);3_ (2:]T:RC^RK9V\J>*KO4;&V\5'7O^/^9M4DU0V4LI/]:/\ ;6D?
M]!*R_P# B+_XJC^V=(_Z"-C_ .!$7_Q57'GBK*$MTV^65WM9;66^]KK7:S.#
M$X7"8N3E6J7_ '4J48QJ\BBI24I27*TW)N,=VXVCL?SN?$K]CS_@H+?^(?V$
M_P#@HQ\+/!'@U/VY?@9\"+3X*?M$?L\?$;QIX>@T/XF: MMK.G:Q_8_Q!\/Z
MOJ_A:SU>]N=6UC6]/D.L"TC36-.E:]CN],NK"?S_ /9Z_8!_:O\ BG_P4B^#
M?[;GQ._8I_9O_8'\(?"2Y^(6N^*_#O@'QMX6\?\ Q(^-?B_Q[IMQ!>^(/%&L
M> TGT*^NXK^ZEN(=1U%]-O;>*XU$2QW\ES&\?],?]LZ1_P!!*R_\"(O_ (JC
M^V=(_P"@C8\=/](BX_\ 'J?-4M;DDM+*T9))-I[6U^>VO9D?4L+S1E[>5E5I
M5Y0<Z3C.M24+5&W'GC*7)%S4)QC)K6.KO_)U^S5^S;_P4$_93U7]H[0M3_X)
M _!C]JO3?B;^TA\3?BOX7^(?Q!^-_P"S1IFJP^&?%%_&NF:1;V/B0^)]6MK(
MPV7]J1V]Y/9213:A-')8QRAPW[,>%/VL?CYX&\:?L'_!+Q_^Q]X8^$-Y^T;;
M?$G0O'/A?P[\7_!.O1_ &?X<^'];\0:'I^C:'X1L)+;Q;X=U/0=&MWN=9T9-
M,\/>&[C4=/T:XNAJ5U965Q^EO]LZ1_T$K+_P(B_^*K,D'A&;5K37I4\/R:Y8
MV=UIUGK,D%A)JUIIU[)#->6%KJ+(;RWL[J>VMYKFUBF6">2")Y8W>.-D+R>C
MI2?RG>]DD];[?ULRJ&&AAX\M/&2Y4TE&:PO*H\\9R5X483;:4HWE.5E)NS=F
MOR7_ ."T/[*'QS_:Z^"W[/\ X)^ W@^+QCKO@[]JOX0_$7Q3;S^(?#7AV+2/
M!/AN^O7U[7'N/$NKZ3#>"PBFC?\ L_3VN]3NLE;2SG<%:_+#QQ_P1]_:@E^.
M?_!5GQ/I/@JW\1?#7XF_!?XN:=^QOH4WBWP9#I^I_$']H?4?#?B;XA0:597?
MB*WN?!L]GJ7A=+&^OO%$&B66I&[MY;2XNHX9#%_65_;.D?\ 02LO_ B+_P"*
MH_MG2/\ H)67_@1%_P#%4XRJ122A+K]F5W=Q?:WX?DQ5L%@Z]5UIU/?<HRTJ
M12O&E.DDUU5I*5NDHQDK-._\G7C#]@_]N[X=^,/^"6OQ-\-?L0^$?VG_ /AE
MS]C+4O@_\8/A'XV^*WP2T'P]:^.]72:S-A<7OB_6M8TG6SHZW U.WO\ 1M-U
MK3WF@18KY)L,OVQJO@G]M3X^?LE_ML_ C6?^"7WPN_8YUCXC_ 76](^'<OP[
M^,GP*U]/B;XZOG-A9>&M3C\%QZ!8Z,MM933WMOK'B:\MK"(%K<2Q/)FOWM_M
MK2/^@E9?^!$7_P 51_;6D?\ 02LO_ B+_P"*HYIZ7IR;3NO=GWB[;=TOZ3)A
M@</#VBCB9\E2"A.FY4&FE0A0NI^S]JFX0B[>TY>97MT/Y5-6^ /_  5[_:&_
M84^%/_!,CQ-^QK\/?V<OAE;>"/A;\)_B7^T7XD_:(^'7Q!N'\#> GT,:I>Z1
MX!\#ZCJ&IP:KJ@T>*06C2ZE;[7>T^T1I(]Y#]&>//V)_VM_@G^VK\3?C;^S#
M\*)O%?A#P?\ \$N]._9F^!VN'QS\/="N]6^,.@SZ?IGA[29['Q!XHTR^L/L=
MI;Q:W/K&IVUEH+26TD::@UQ)'$W]#_\ ;6D?]!*R_P# B+_XJC^V=(_Z"5E_
MX$1?_%4<TUM3DE:S2C+6]K[IV^5K:W;LP6!P]ES8JI.<514:CJ4E**H1G&"B
MH1C%:U)2;Y;N5KNRL?R5>'_^#>CXP3_\$^I_AOK7[67[1>E?%;7/ MU\2=<_
M9BMO&O@Z?X 3_M!260\01:3>Q1V<]G>N?$EI965SXI37'+WL7]HIJ(ME4CZJ
MT3]D/]M?XQ?''_@CC\5?VA/@C;VR_L[_  =^,_PU_:UBU?QS\-O$-OI]UK?P
MU\2_#C1KJ]M],\6:G)XQM?B#9MIVH7T7AZ/6&MFUF6'7H[7R[N%?Z*_[:TC_
M *"5E_X$1?\ Q5']M:1_T$K+_P "(O\ XJES5&K.,V[[N,M-O+^M>JNE#+L#
M3Y?9S5-*-",E&I&T_J]:%:FY<U_M1:<5:-IRLDW=?S,?\$^_^"4'[0?[$W_!
M6/XB?$>RT:36?V,;'X4^//"_P3\8W/C'P[=S>$])\:>)H/&5I\,T\)W&O-XM
MLH] U[4_$R"]@T'^R+OSS?F\6>^F4?2__!8?0;WPE^T7_P $GOVG;Q&/@'X,
M_M@P>#?'EZ=PMM#@^,MIH^B:!KFH2\16>EVVI:#):W=Y.RQI->V4)/[^OW0_
MMG2/^@E9?^!$7_Q5>??$_P "_"7XT>#-5^'GQ4T'PIX\\$:VUC)JOAGQ)#;:
MAI5[+IM]!J>GS2V\K%?/L=0M+6\M)EVR03PK)&RL :2<^92<).R2:Y9*ZTZV
MT^6WR8_J6&IX6KAJ-2,8SK+$14IQ:A.-2G5C&.MU34J:2C?2-U>VWXVM_P $
MW]3^,G_!3_\ ;N^*W[17P1\+^+/V7OCU^S9\._AKX"\5Z_/X*UV]E\4:=IOA
M_3?$$F@:4UY>^+O".MZ7';7LMCK[Z;I)6:VBDL[R9C&1\/1?L>_\%8_A#^PA
M^UQ_P37\'_#2Y^+/@75_&FD^#?V8?CHOQ4^%NAR)^S[XT\1I<_$#0]=L-=\<
M:3XJTV31_#R7%K;6EY8/*UQKNJ:=IJ7.CV6G1R?U76^IZ);0Q00W]BD4,4<4
M:"YC*JD:A449;.%  &>P%3?VSI'_ $$;'_P(B[=/XNU-.>ON2:NG9P>ZMY?A
MTZWLQ2P&$ES-573J3>(YZE.I!3E#%<SJ4Y2L[QC)J5-VYH2BG%J[O_*E^TE_
MP0C_ &@_AS\ ?A%XC_9A_:K_ &C?CW\9_P!ESQ1\.?&/P)^!_P 3O&_@73/A
MAX?U#1=9TIM=B\%G58_#VF>%6L[.%[BS#ZU9P75C:/87#7-Q<))7U_J7[ 'Q
M2_:/_P""A_[1GQ7_ &B/@NFC?LW_ +1__!/3P;\$]?EN_%?@?6[S2/B?-JGA
M36=:\-0Z=I.O:IJ\>J^#=1T^:^TSQ);6$NA/J.D6UYI^IW6Z!C^]W]M:1_T$
MK+_P(B_^*H_MK2/^@E9?^!$7_P 51S5-?<D[WWC+2]O+T?RUV:']0P7->,^6
M+E2E*G[12A)THS@KJ;DTI4YNFXII<JC:SBFOY0OV"_\ @B[^TAX9^$W_  4]
M_9<_:J=]/\'_ +0VC?#[P'\'_C*GBCPYXKF\3:9\+=2UZZ\"^+I=#TSQ!?\
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MC.-&4ZG-*4/:2J2A*GS2<>52;52<I2DFY2LV^_H=%9G]M:1_T$K+_P "(O\
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M]OT'Q%IT^EZG;+/"R2PO+:7,JI+&P>-R'4@J*_!&3_@AG\7M0^&MM^RGKO\
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MW_#MK]A?_HV3X9?^"JX_^3Z/^';7["__ $;)\,O_  57'_R?7W#11_;><?\
M0US+I_S'8KI;_I[_ '5^(?ZG<(_]$MPY_P"&/*__ )E_J[\K?#W_  [:_87_
M .C9/AE_X*KC_P"3Z/\ AVU^PO\ ]&R?#+_P57'_ ,GU]PT4?VWG'_0US+I_
MS'8KI;_I[_=7XA_J=PC_ -$MPY_X8\K_ /F7^KORM\/?\.VOV%_^C9/AE_X*
MKC_Y/H_X=M?L+_\ 1LGPR_\ !5<?_)]?<-%']MYQ_P!#7,NG_,=BNEO^GO\
M=7XA_J=PC_T2W#G_ (8\K_\ F7^KORM\/?\ #MK]A?\ Z-D^&7_@JN/_ )/H
M_P"';7["_P#T;)\,O_!5<?\ R?7W#11_;><?]#7,NG_,=BNEO^GO]U?B'^IW
M"/\ T2W#G_ACRO\ ^9?ZN_*WP]_P[:_87_Z-D^&7_@JN/_D^C_AVU^PO_P!&
MR?#+_P %5Q_\GU]PT4?VWG'_ $-<RZ?\QV*Z6_Z>_P!U?B'^IW"/_1+<.?\
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MIDQM-?TW1OV>?B9XDTNRU%'O,O!9:YIFGZI;JI!6[LH&9BH96_:2O@[]I?\
MY.H_X)W_ /9:?C3_ .LN_%NO0RK.,UJ8R49YGF$XK+LZFE+&XF2YJ>38V4'9
MU6KJ4(R3W35U9V/G>*.$N%:668>5/AGA^G)\0\(PYH9+EL9<E7BO):52-XX5
M.TZ<I0DMI1E*+T=B^/\ @FW^PR0"W[,OPQ+'DD:3<*,GDX O@!U[ #TXI?\
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M9=/^8[%=+?\ 3W^ZOQ#_ %.X1_Z);AS_ ,,>5_\ S+_5WY6^'O\ AVU^PO\
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MO^9?38G^#G[,WA;]O/1M/N[K5/V-/^"CG[<FL?$--,@FN+_5_P!G;XH?M/\
MQ5\"?%_2X;>W5Y;L::FH>&_'4$.UFCG\*%M\$,DSG(\>R:1\//V4_P!G'XJ?
M'?X5?#'Q%\1?VZ/VM?$O[3GB;QC^T?XG\5^'OV=/@YJ_BKPYK6K?"5?C5!H-
ME<CQ/I_AWX46WA/P/X,\'^)(;/1)/%4$,MU=V5[;+++_ %!'1M(-E<Z:=,T\
MZ=>M=/>6!L[?[%=M?2/+>M<VOE^1.;N6222Y,L;&XD=WE+LS$E]I.D:A8'3=
M2TW3[[3-B1M87MG;W-EY<:A8T-M-&\&V-0!&NS"  *!@5*G:*5K/F3YD];*V
MFO5O\++TIX!^]RU4G*ER6E#FAS_NXRFX<UFW2IQIZZKXE:\D_P")KQK?Z+XG
M^'__  5>\-Z'KGP?UCP7XHL/V#]4S^SEX"UKX7?!?5M1U'XK/X=UW6/A[HNJ
MZOK0UM&B@CTG5/'^D/9V'B34[!VM[5)+,S2_MO\ MZ^$?A[^P%/^S=^W=\&_
MAGHOA'P?^SWK/BCX7_&SPI\./#>FZ#%K_P %_C?I-E9RWUS8:3:VT6HWN@_$
M[P[X U.WFF22X9]1O)Y;J)&N';]H/["\+S1M_P 2?0YHOLUM8,#I]C)&;.QF
M,]I9D&$J;:TG<S6]OCRH)F+QHK\U\O?M/_LO7'[4M]\._#OB'XN:]X>^"GAG
MQ'IOB/XH_!G1/#WAJ[T_XS3^&]>T3Q-X2TCQ-XIO[>;Q#H'A_2]8T19=6T?1
M'CMO$UG</9:GLCAC>JYU)QNN5+XMW=:6V7?77J^NQDL"Z5*IR5%4K2C!4I)*
M+IRC7JUXSO*;?)&52/.N9N5.FTE)R2.:_P""=7P=\1?"+]EWP?=_$"W$?Q?^
M,VI^(/VA?C7,T;1W#?%+XU:I/XY\1Z;<&0+,P\,1ZI8^$K42HC1V.@VT9&Y6
MQ]S5'^ZA3DK&B@GG"JJC)/H%5<^P IX(8 @@@C((Y!!Z$'H01R".".16;=VW
MT;9Z=."IPA36T(J*\[))OYO5^;%HHHI%A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_P"/2Y_ZX2_^@-5FJUY_
MQZ7/_7"7_P! :G'=>J_,F?POY?FCXE_X)R_\F>_!_P#W/''_ *L/Q57W'7PY
M_P $Y?\ DSWX/_[GCC_U8?BJON.O1SG_ )&^:?\ 8PQG_J14/#X5_P"28X<_
M[$.3_P#JOPX4445YI[P44PR1J0K.BEB54,P4LP#,0H)&X@*Q(&2 I/0&E:1%
M +.J@D*"6 RQ(4*,GEBQ  '))  R10 ZBDW#!.1@=3Z8ZY],>E,,T2ABTB*$
M 9\LHVALE2V3P"%8C.. 3V- $E%0I<6\A(CGB<J 6"2(Q )P"0"2 3T)ZTY)
MHI-WER(^QMK;65MK?W6P>&]CS[4"NGLTR2BHTEB<LJ2([(=KA6!*-_=8 Y5O
M]DX..<8H\Z+8TGF(47=N<,I5=AP^2#@;3PV>G?% [K:^O8DHI 01D$$'N*6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \A^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ5;WGB'PYH&Z>]GN(EA?5]BI]J0#TGX^?\$PO&?QBE_:ZO-+^*GA#2_^%_\
MQY_9X^-GAGPOX@\+:QK7@>[M/@;X,L_#-[\-/C!HMCK&E7'BOP/XVEA:XU*Q
MT>_T]D@BL2_FO"R/JY0=]O>;>BM:VW3S>BT7Y^)2PV,A#"IQE?#1:CRU(7?M
ML/5=2Z;E%^SJ2ITH74DTFTFG=><>(O\ @H9X@\;Z?^U_^S9\<O!GP(\3^(/"
M7[&7Q2^.UKJ/[,?[0FJ^-O"6N^%-)M[GPUXA\ >)?$=OH7ASQ=\//&R27UM<
M0WMI Y_LVY&HZ=*L\48/K_@W]L?XX>,-0\(? #]CCX$>!/&6J_";]F[X"_$+
MXJZU\9/BQXD\->%_"O\ PL[P'::UX$^&'A[6;+PSXM\4>,?&5SX>LFU&]\0:
MS:V6FP6KVMQJ]Y]ONWC/P_\ M'_L@>(/V6?"?Q__ &HOC%X^_9P\)67C/]BG
MXP_LF^$O@E^SQ\$]:^&OA8^.OB++#JW@C3_!=O\ VSXHUGQ9XB\3:A8:C;:C
M-KJPW+2O8PZ;!:6%JZI]J?#O]C[]ISX=7?@SX]_LO_$CX9?#WQM\6?V8OV??
MAS\>/AQ\>OA_XK\6>'4\4?"GX?V7A_PWXU\.OX1\5^$]<T;Q=HFFW-QX?UC1
M=3DN]%U6"PM//6VNH#,4U"T;._Q7>ME)J-K[O37\;W:-:<L8YN-134ER\TX^
MP]NJ-ZO*TY?NI-3WO&ZI\S4;N\N;M?\ @J1\7OBEK/[+7@']G_\ 9V\-WWQ4
M_:!/[27AKQIX5^*OQ!OO#FF_!7XB?LSZIH6D>.-(\1:QX9\.^(9=:T2*[O[M
M;?4=+TX7%_%=Z!<6]O'#=W+0_LKH$NMSZ'I$WB6UTZQ\0RZ98R:Y9Z/=W%_I
M-KJ[VT3:C;Z9?75M9W-Y80W9ECM+J>TMIIX%CEEMX79HU_+?X#?\$V-1^!?Q
M9_90^)$'Q5M_&-U\%=,_:QU?XLZOK&A-IVN_%7XH_M3ZEX9U[Q!XKTNWL+E]
M,\/:9INJZ)=1P:/,;UX=)_LZUBNI9K>:>3]7ZAVT2717>NKZV\OE_P 'NPJK
M\KEB'+G?(E%N%HVI4^;X$ES.I[3FMI>ZC[MKE%%%2=04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:\_X]+G_KA+_Z U6:
MK7G_ !Z7/_7"7_T!J<=UZK\R9_"_E^:/B7_@G+_R9[\'_P#<\<?^K#\55]QU
M\.?\$Y?^3/?@_P#[GCC_ -6'XJK[CKT<Y_Y&^:?]C#&?^I%0\/A7_DF.'/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6(W8KYU9>(OC=^T=^V-_P3*T/Q-^T!^S1\>_^%4Z[\0?BG?K^R];>(-1L_\
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ML_9$^$5]\:_"WAOQ-X-N+GP6GBU[R*.XUG7+3PG8:Y<:9=^(X[NS"VLGZO\
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M$+?&^7XKQ_#?3?#@\3MH<5N+34-&N;/XC+??V"6B\)SF7[-))'N=.+WWVO\
M-)K[[Z=6$<5AYQ?-RQTE)QDD_@?O72NKIJ\4]6E=;.WZ)#P/X+&K>'=>'A'P
MQ_;OA#3M0TCPGK/]@Z7_ &KX8TG5HK2#5-+\/:A]E^UZ+IVI06%C#?V.FS6U
MM>16=JEQ%(MO$$ZFORP_:%_X*%_&+X%67QA^("_L6>,M8^!/P'OM0M_'/Q)\
M5_%;PC\,?$7B2P\/Z99ZMXHU_P"$'PV\2Z/-JGQ&\.Z;;WGD:3JIUCP\GB>^
ML]0M=(AD:U#2Z,__  4'^(/C']HCQ-^S_P#L_?LOWWQAF\)?"KX0?&;6O'6H
M_%O0?AYX;MO!'Q@L-3O-'VQZCX7UNZNO$$+:?BVT6R^T_P!I6L6I737E@UG;
MVVH'+)]/^&T5^[6JVN7]:H1:A>7,VE&$:51RE?F^&,8-M+DE>5N56U:1^GU%
M?FGX:_X*/:!XR^ _[+_Q3\,_"[5K[X@_M,_&C2?@18_!F;Q)#;ZWX(\<Z;K7
MB#3_ (OQZ[K?]A/Y]C\(=+\'>+]=U><Z'8/JEMI-I;^7I<^JP"+]+*35OZ_'
MT[,VA4A45Z<E-6B[QU5IQYHZ^<6I>C3ZA1112+"BBB@ HHHH **** "BBB@
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M ,T-']GX7_H=Y7_X*SC_ .=/G^?9A_;>8_\ 1(\1?^%'"O\ ]$Q]T45\+_\
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MRQ5 6/)R:^)_^%$?MK_]'X6__B+WPS_^:&C_ (41^VO_ -'X6_\ XB]\,_\
MYH:/J&%_Z'>6?^"LX\O^I3Z?TF']M9C_ -$AQ%_X4<*^2_Z*;LD?=%%?"_\
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M%$?MK_\ 1^%O_P"(O?#/_P":&C_A1'[:_P#T?A;_ /B+WPS_ /FAH_L_"_\
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M.C6.M+H,0GLM.M9*\?\ ^%$?MK_]'X6__B+WPS_^:&C_ (41^VO_ -'X6_\
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M%$?MK_\ 1^%O_P"(O?#/_P":&C_A1'[:_P#T?A;_ /B+WPS_ /FAH_L_"_\
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M!7Q9XBMO$/Q+^&.FZ[XG\%Z0LVO6>B^)1K^G7NFIIOB6]BTBPLA;R-!:^_\
M[,&E_L_^*_V;/@O^VW^T/^T;\7O!W[67BO\ :"LM-\:>,/#?Q5\<WWB2U^*%
MU\<=0\&6O[,Z_ Z&]UOPC!X16TCM? ^J>#4^')O;#PTE]XKGNK::&775_9#P
M+^PG^QS\,=0T75_A]^S9\(/!^K^'/$UOXQT#5M \%:-I^J:+XEM+*_TZUU32
M]1AMEO+*2VL=4O[6&WMYX[2.*ZE5;<%LUT<'[(7[+MI\76^/EM\!/A7!\9GO
M9=2;XD1>#-$3Q4VJ3V_V2;5CJ2V@D&KS6_[J35@!J3J6#71W-FO:1[/S:LFU
M>^O?MKT]-<:>"JPUG*E43E=0E'W(-QHKGC&$(PYX.E)QM"+_ 'DKSO>4OYRM
M?^!>@^&OV"/VZOVP]'\6?%32/CU\*_VM/VGO%OPA\3:+\4OB!H.E?#IO#/[0
M,UNNEZ'X)TGQ%9>";W3M?F75;KQ+%J^@:G-K3:K<03W!CM[*.V['XI77QD_:
M6_:W_;6LOB!X?\)^+-/^!.G?#JW^%]CXR_;.^)7[)R?!3P)J_P -+/Q/+\7/
M"?AGP/H%Y9>)F\0Z[=ZAJE_X^\17NI6FG3:%:Z$(+:Q1K>3^BV\_9\^".H_#
MOQ?\);SX8>#+CX9^/]4\0ZWXU\$2:)9MX<\3ZOXMU>37_$FI:QIWE^3>7FMZ
MS*^IZA/("]Q>'SV.\ URGQ9_8_\ V7/COJFAZY\9/@)\+OB3K7ANTBT_1-7\
M6^$-(U74K'3H#NATQ+R>W,\NF1M\R:=.\MDK$L( 223VB]YV=W9)W5U'32]G
MV_X84LODN50E%12@YPUC&I.*K+FG[LTV_:Q:;A)WI0OK&+C^$%[X^UKXU^&?
MV*_@S\5U\8?MH?&6/]EG7/B;XF\.?#3]IZ+X%?LS^+O"_P#PER^$]!^.'C#X
MGK-X"\8_$;Q:+'3K:R@LM'@N-+BEU37/$LFAHLD-U7*_LA_$#Q1\=_@=\.OV
M2=9U_P#X2?1?%?\ P4W^)/AJWL/^%C:Q\8=*T/\ 9S_9EO\ 0_CGKG@S3/B=
MKT/]I>.?"-IJVGZ#X*TS6-61AJNCZU% K-'+;[OZ#?BE^R+^S%\;+?P?:_%C
MX$?##Q[;_#ZU&G^!XO$7A#1[U?"NFB&*W.E:&#:K]@TIH(((GTN'%@Z0Q*UN
M1&N-?P'^S+^SY\+=?3Q3\.?@]\/O ^OPS>(KFWU/PQX:TS1IK2;Q9:^&K'Q-
M)9)900P61URT\'>%[;4_LL4(NX=$L(Y@RP@%.:Y6K/I:]K:.^J_*WY-H?U&K
M[2+=2#I\BIU%KS5*;C3@X-\O/*\8R5ZE6>LE**B[\WX8?!+P3^TYXE_;%_X*
MHR_ ;]L+X?\ [-&B6G[3OA^'5](\7?!7PK\3[C6M5?X+>"&@UVSU?7O&7AV3
M2(+&TVVKV8L[R S1&XD<NS0CYG^%D$/Q+^ W["7P#.N:YI>CZ5_P5:^-GP9^
M+7Q(^%/CWQ5I.C_M,?8?!WQA\2^/OB)IWB31]4TW4DT/XIZI?W46JV6E:E)9
MZ/=-?6F@W$$=E9BW_H(^(G_!.;]A?XM>.-?^)7Q+_99^#?C;Q]XJO8]2\2>+
M/$'@^POM;UN_BMX+2.[U&\=0]S.EM:V\*R/D^7$J]!BO<K+]GSX'Z9I7PRT+
M3/A1X#TS1?@SKJ^)_A1I.F^&M+L-.^'WB%=,U+1O[8\*V5G;PV^D:@^EZQJM
ME)=6L:2RP:A=K(SF9R4IVZ+35.VMULV]_P ?07U"I)VG*#AS5&[U*DW*%3$P
MKN'LY+DIIQCRR<7*[27PMV_%SPO\#/@9\4/VN_VQO@+\?O&GCGPE\,/V3/ W
MP7T?]F3X:_\ "_OBGX%L?!WPR\1_#%/%GBSXV6NL6?CS2=<\8ZZ/'5UK.E3>
M+?%>J>)%\/IH%KIAEB$.)/G+]F:R\6_ME>,O^"=OACX]?$7XJ>+O 5Y\'/VW
M8[R]L_'OC/P5<_'WP!\.?B_X?\(?"3Q+XXU7P=K'AS5=8CUCPS;Z-X@GN8KZ
M*XUZ2%+J[EGM;R[6]_H-^,G[)W[-/[0NIZ+K7QN^!WPT^*&L>'8FM]$U;QEX
M3TK6=2T^U=S*UG#?75N]RU@TA:1["622R=V9G@8L<^@6GPD^&6G^(?!_BNP\
M">%K#Q%\/O#.I^"_ VK6.BV%G=^$_"6LG3SJGAS0&MH(DTO2+XZ3IGVBRM$C
MA<6-LNT*F"U/K=\R5D_DK?<U_6B5_49.:<O9.";;5I7J1=:G5C&HOAM3C!TX
M+WDHR:2C&\7_ #2:1XM\4:58']DG7?BK\1O#?[+-K_P6 ^(O[,/B'Q)=_$7Q
M5!XET?X*:?\ "+1_B-X%^#%W\6KS4V\8Z-X;\4?$#43H$6J2^)+?6'TT6OAF
M#6,ZC'O]+_:X^$_[.OAOPSKW[,W[/_QQ^+TL$7[:G[ I\8_#VU^(/B_QAI/[
M/]UXV\>06T4OPT^(WB-];U_0?$7B_2+>?7-1T)?'.J2^'M073]:L=,T2.XQ<
M_O-J7[-GP#UGPW\1_!VK_"'P!JOA7XO^*+OQO\4/#^I>&M,OM)\=>,+^VTRT
MN_$WB.RNH)8-0UR:WT;2H_[2D3[5']@M7BD1X49</PE^R-^S)X#\%Z5\._!G
MP-^&OAGP3HOC71OB/IWAO1_"NEV>G0>/?#U[#J.A^,&2. 2S^(M*OK:WN;+5
M;B26\@>"-4E$:[*:J)6^+16T=NVKWUT_(7U&?*X2=*:E?WY*3G"+5E2@KI<E
MK-WE9-:4WHU^(7[0?A"W_97^*O\ P4%^!?P5\1_$3P]\+/$'_!)CQM\>CX3U
M?XF_$#QH-(^+MGXI^(W@Z;QKX9U;QEXE\0:[X?UC4=$L+*/43IFIVUO=7L,=
M^+<740<\K\3M<\(?'#QQKOAV;X??$_X\WOP1_9>_9T7X@ZK\0_VQ)OV4O@'\
M KWQ3\-9/%<7BC1!X?UG2?&?BSQ+XBTR]37/%/C/4]*\2P:;_9-CI-E>P2BX
MLY?Z%O%GP&^#GCO7/$OB7QC\.?"GB/Q!XR^&UW\'O%.L:MI-M>7^O?"Z^OKS
M4KOP)J<TJ,;GPU<7^HWUW+IC@P//=SR%29#7GGB_]BO]DSX@>*O#7C?QO^SQ
M\)/%?BWPAH^E>'O#FO:[X(T+4-0TS0M"5%T31TDGLV6YTW2$1$TVSO%N8+)%
M"V\<8)S*DE;1W3;OW;M>Z=[K33UVOJ$\#4;E[.=/D<[J$EI&/-.24>:%6'NN
M2:3IVLFDTVFOYY_V8_VD]=LX?^"7O[2?QA\3W_BO4_!G_!.G]OWQ/XB\5ZWJ
M,NH:OKEGX%UWX4QZ?/J.L7FR?5-2O+#1[*U:^N5CN;V:1;JX1)I'Q[]+X"OO
MA!X\_P""#]IXY=-/\8^(OC!^T#\5_BE>ZHT=HP^)?QB_9Q^*GQ)\>M?R3LD4
M,\?BWQ;J%@JEOD,$4$9"B)*_:-OV./V66T;0O#K? 7X8G0?#&@>,?"OA[1CX
M6TXZ9HWAGXA:YIWB7QMH&GV1B-O;:1XGU[2=-U35M/CC%M<W5E QC"IL.S\<
M?V6OV=_VE])\/:%\??@[X$^+.D>$KZ;4O#.G^-=#M=8M]"OKBU-E/<Z8DZ_Z
M+++:$VTC1D%X"8FS&2I;G%M-*UM.FUT_7NMWI9=[BP5502=2,Y15&SES*\H/
M#N;G*TVW)X>.J6E^^I\4_P#!5#QY;Z3\!/@]XD\.^-8]+T_0/VV?V-KGQAKF
MB>)A86FE>$9?CIX8@UR7Q!J%A?0Q6OA^:UE:'5?M\JZ?+;.T=V&BR*^2_P!O
M'XM1ZA^T%^V_H/@?XC7%Q+X(_P"".WQ:UO4=.\,^++@V_ASQ7?>)O$]WH^I/
M#IFI"#3/$RZ7%!=07BQP:M#IUUI\J3);75LTGZH^!?V#?V-/AGX7\?>"/ ?[
M-/P@\->$/BGI]EI7Q&\-6'@W2CHOC/3=-:=["SU_3[B&>VOX;.2YGEMA)'NA
MFD,R,)0K#4\*?L4?LF>!M"U[PSX._9[^%?AK0O%/@K7OASXET[1O"6F6,6O^
M!?$[QR>(/"^L/!"DVHZ3JS11?;+>ZEE+K'&@94CC55%Q5M&VM>EF[II/RT?^
M1M4H5ZLTW*G"+4.91E.4DX*I=0=HW4O:)W:BTX6M*Z:_'^^^%MQ^R;\0_P#@
MF7\1/@_XJ^*>L_$SX^:3XQ\(?'"Y\7?%3X@^,['XV7'_  S/KWQ"TAO$GAWQ
M1XCUGP]8ZE9^--"L;K1+CP[I>CKI4<LEA$GV.1;9OD#Q7H/PYU#_ ()S_L_?
MMBWW[0GQ-A_;"^+WQZ_9V7XIZNGQU\>07GC+QUXG_:.\)Z9\2/@5J'PR_P"$
ML'A?2M"^'D*ZQIMCX>T3POIEWX<LO!D%Y=/Y(U(W7]2VM?!_X:Z]-\/KS4/!
MGA^?4?A)<2WOPLU*72[2>[^'NHRZ!=>%_P"T/"SS1R+IMRF@7ESI0:)=K6,K
M6[JT> /Q@F_X)/?$_P >_$737^,%S^R'>^%[?XO>$_BAXU^.7@'X'W?A7]J+
MXP6?@#Q_8?$;PMX9\430W47PY\)7FI:UH7AZQ\<^*_"E@;_Q-H^G7L*6-F^M
M7A6HRT^+E?6VC;>E[Z[?)+R6_)7PE2*E&G!3C-25..BC1J.%""FFYJT^:G*2
MFE=<\FY)Z2_>6(DQ1$DDF-"23DD[1DD]R>N>_6I*:H 50!@!0 /0 <#CC\J=
M61["T278**** "BBB@ HHHH *K7G_'I<_P#7"7_T!JLU6O/^/2Y_ZX2_^@-3
MCNO5?F3/X7\OS1\2_P#!.7_DSWX/_P"YXX_]6'XJK[CKX<_X)R_\F>_!_P#W
M/''_ *L/Q57W'7HYS_R-\T_[&&,_]2*AX?"O_),<.?\ 8AR?_P!5^'"BBBO-
M/>/R,_X*Z$>(? W[+7PFNM3L/A[I_P 6_P!KKX6Z ?VA+N1K:_\ V>M7\/P:
MSXS\.^.O"E])=V>F:?XXUC5]"M_!/A*\UYKO0DU/Q"(]2TK5(I1:/P_[%FB7
MWPB_X*0_M9?"34/BCJ7[3VM^+?@3\&OBEXI^/WBI]$G^(O@Z:QUOQ+X4\._
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MU\,7-Y'\,? X@35)X;V7Q)K+1P2Z?:']+=3_ &;/@'K/@OXE_#G5/A/X(OO
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MIJ%-2UA>3?)%4U"-V_>TC.-I645**BG[.-_C7_@FI)-I_BK_ (*'>"],=Y/
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M)*-FTU>[ZZGY\?LI?\$N?V+/V*/'NL?$O]G/X7ZEX*\8Z]X9N/".I:G>>/\
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MJ[$#ZSJ7H;PG&I",XZQG%25U9V:NKKH^Z"BBB@H**** "BBB@ HHHH ****
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ML;O[%<NGBFA_ S]M?]EWXI?&SQ]^SU\+?AG\8=,_:D\)?!R_UK3_ !E\3(O
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M%%%9GJA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8HO@&_[0?PY'Q:N/$ \)1^$O[7D+/XN^ZOA!=;%L?#A\6LY2(>%SK UTSND
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M7_T!JLU6O/\ CTN?^N$O_H#4X[KU7YDS^%_+\T?$O_!.7_DSWX/_ .YXX_\
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M.;4I>\E:%M;V/QLT?]LW]J?]H;_@G-^R]\5?@M9?$R7XB:;\0K/X6?MGZ?\
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MA4!8UKVFH=KNVW3^GJ=]%3C2I1J-.I&G!3:=TYJ*4G>RW=WL@HHHI&@4444
M%%%% !1110 4444 %%%% !1110 4444 %?!W[2__ "=1_P $[_\ LM/QI_\
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M?B5\,_$W[2NH?'?P[X/EM/&.F? OX\?M2_"OX.^)-3\0^&;+X9?!FPTOX3_
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M[^OP*IUH5744'S*G*,7)6<6Y4X54XM;KEJ1U[W"BBBD:A1110 4444 %%%%
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M=?\  K_PX>@?_)='_#P[]AC_ *.O^!7_ (</0/\ Y+H_LC-O^A9F/_A%B?\
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MMXTU70[ZTO%M9)EO+591#=V\$RO&O;?\/#OV&/\ H[#X%?\ AP] _P#DO_\
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MA%125K-Z*RO]ET5\;?\ #P[]AC_HZ_X%?^'#T#_Y+H_X>'?L,?\ 1U_P*_\
M#AZ!_P#)=+^R,V_Z%F8_^$6)_P#E7FOO.G_6SA7_ **;A_\ \/.7?_-)]DT5
M\;?\/#OV&/\ HZ_X%?\ AP] _P#DNC_AX=^PQ_T=?\"O_#AZ!_\ )=']D9M_
MT+,Q_P#"+$__ "KS7WA_K9PK_P!%-P__ .'G+O\ YI/LFBOC;_AX=^PQ_P!'
M7_ K_P .'H'_ ,ET?\/#OV&/^CK_ (%?^'#T#_Y+H_LC-O\ H69C_P"$6)_^
M5>:^\/\ 6SA7_HIN'_\ P\Y=_P#-)]DT5\;?\/#OV&/^CK_@5_X</0/_ )+H
M_P"'AW[#'_1U_P "O_#AZ!_\ET?V1FW_ $+,Q_\ "+$__*O-?>'^MG"O_13<
M/_\ AYR[_P":3[)HKXV_X>'?L,?]'7_ K_PX>@?_ "71_P /#OV&/^CK_@5_
MX</0/_DNC^R,V_Z%F8_^$6)_^5>:^\/];.%?^BFX?_\ #SEW_P TGV317QM_
MP\._88_Z.O\ @5_X</0/_DNC_AX=^PQ_T=?\"O\ PX>@?_)=']D9M_T+,Q_\
M(L3_ /*O-?>'^MG"O_13</\ _AYR[_YI/LFBOC;_ (>'?L,?]'7_  *_\.'H
M'_R71_P\._88_P"CK_@5_P"'#T#_ .2Z/[(S;_H69C_X18G_ .5>:^\/];.%
M?^BFX?\ _#SEW_S2?9-%?&W_  \._88_Z.O^!7_AP] _^2Z/^'AW[#'_ $=?
M\"O_  X>@?\ R71_9&;?]"S,?_"+$_\ RKS7WA_K9PK_ -%-P_\ ^'G+O_FD
M^R:*^5?"_P"W+^QYXV\0Z/X2\(_M*_!SQ'XF\0WT.F:'H6C^.=$OM3U74+AM
ML%G8VD%R\MQ<2MPD4:EF/05]3QRI*B21MOCD171U!*LC@,K*<<AE((/<&N6O
MA<3A9*.)P]?#2DN:,:]&I1E*-[72J1BVKIJZ5KH]+ YGEN9PG4RW,,#F%.G-
M4ZE3 XO#XN%.;2DH3G0J5(QFXM-1DT[-.UFA]%%%8'<%("#P""?0$?7^7--D
M02(\;%@KJR$JQ5@&!4[64@J<$X(.0<$<BOCGQ=^Q!\,O&?BC7O%NI?$G]IW3
M]0\0ZG=:I=V/AO\ :?\ C?X9T"TFNY/-DM]'T#1/&EEI6CZ>CY,%A86L%K;@
ME(8XT)4].&AA)RDL7B*V'BDN65'"QQ3D[ZJ498G#<J2UNI2;VL>=F-;-*-.F
M\KP&%Q]24VJD,5F,\NC3@HMJ4:D,!CW4DY6CR.G!):\^EG]DT5\*_P##OOX2
M_P#15?VN/_$O/VA?_F_H_P"'??PE_P"BJ_M<?^)>?M"__-_79]7R;_H9X[_P
MTTO+_J:>;^[S/(^O\7?]$WD__B45_P#Z'#[JHKX5_P"'??PE_P"BJ_M<?^)>
M?M"__-_1_P .^_A+_P!%5_:X_P#$O/VA?_F_H^KY-_T,\=_X::7E_P!33S?W
M>8?7^+O^B;R?_P 2BO\ _0X?=5%?"O\ P[[^$O\ T57]KC_Q+S]H7_YOZ/\
MAWW\)?\ HJO[7'_B7G[0O_S?T?5\F_Z&>._\--+R_P"IIYO[O,/K_%W_ $3>
M3_\ B45__H</NJC&/\]?>OA7_AWW\)?^BJ_M<?\ B7G[0O\ \W]'_#OOX2_]
M%5_:X_\ $O/VA?\ YOZ/J^3?]#/'?^&FEY?]33S?W>8?7^+O^B:R?_Q**_\
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MDYM^..>>U(GA/P=(-T?AOPVZ],II&F,,^F5MR.X_.OP+_P""H_BGXG?M!_\
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MNCHH]I4_Y^5/_!D_+S\D'U?#_P#/BC_X*A_\B<Y_PA_A+_H5_#W_ ()M._\
MD:C_ (0_PE_T*_A[_P $VG?_ "-71T4>TJ?\_*G_ (,GY>?D@^KX?_GQ1_\
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M+*&VZ<&VW@,.V_AZMMG.?\(?X2_Z%?P]_P"";3O_ )&H_P"$/\)?]"OX>_\
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M?^#)^7GY(/J^'_Y\4?\ P5#_ .1.<_X0_P )?]"OX>_\$VG?_(U'_"'^$O\
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M^3J/^"=__9:?C3_ZR[\6Z]/)_P#?I?\ 8LSW_P!4N//FN+/^15AO^RCX._\
M6OR,^\%Z#Z#^5+2+T'T'\J6O+CLO1?D?2A1113 **** "BBB@ HHHH ****
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MQ/XRU_Q);P7GB/Q3I,]VUKX@U2VCOM4GLI]8BOO)OM1N=2AVW\,5RG]!6L_
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M^MGN-+U#6-:$(AG9VK^@CQ1\$/@UXW\3Z-XW\:_";X:>,/&GAT1_V!XN\4^
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M_@G!^R5-XM,[:HGPPAM;5KGS/.;PW9:]K=GX..)%!$7_  B5OH@M0ADB^R"
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MNM^#_@_IOBGXA_LN_$OPO\<?%?QQT_\ 9X^&GP&M/$7A_7(?BQ\0=<T^#6-
MU?X>?%=;?3O"6N?#.\T>2ZU#4/'QL[>VT9='UFVN]-:[L1!/\A?MQ?MV?$Z^
M_92_;<^#'C[X6>,?V2_VGO /[.VG_&#P?'H/Q/T_QGI_B3P#J'C;2?#5UXL^
M'WQ-\(6GAJY34M"UDC1/$.E7&F:3J&G-J-I+%)>6=T\L<7P^_P""4OQO\">
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M)$R8VE'CRK*1@@D'@U\9? O]C_PO\.?@KXT_9E^(FF^"?BO\ 1XW\6WOPO\
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M*3(]1^8I<@]"#_G_ .L?RH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF:PFCMIUR+E?9/ /QR\+_&GX"7/QK\,^"?&.N>"-:T3Q;JOA[PYJFC:0-?\
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M?]?UIU.NA-U*4)NUW'6VBNFTVEK9-JZ\@HHHI&H4444 %%%% !1110 4444
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MB^HY;?HOJ-+RVT\E]R&LAH--K/<^:2NVLXFTDFE=OET2:2;?4^>_)_X*3_\
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M ,(:/^7DON#_ %=A_P!#GB'_ ,.M3R_N>2/A+R?^"D__ $$_V+/_  0_'/\
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M10 4444 %%%% 'S7^V7_ ,FC?M/'GCX _%T_*<-QX#UT\'U],<YZ$'%?Q3_
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M[/;IY_H>=B\"\77@YRY:*PU:E/EC3E*3J3I.R]I"?+:,)/FC:2=K-6U_E?\
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M:/UKX!_\$\O@%\ ?AG^T=\(=-B\3>/O /[4?Q'^)7Q*^*.A_$.]TG5H+J_\
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M#\2_ /XB_L[ZQK/Q;OO!_P 3/VG9?VKM8UB;Q#X8/BC3OB%/;+97.D:/??\
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M&6_#OV91<7?9W3U3/L/_ (7)^W7_ -&8^ __ !*#0_\ YWU'_"Y/VZ_^C,?
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M#GEU:DVJG&F>0<9<KYH<+JTHQA-I_P#&.Z-1Y9-.UE)-Z6O]H?\ "Y/VZ_\
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M\N>&>G+_ -4Y_=_$^%/^%R?MU_\ 1F/@/_Q*#0__ )WU'_"Y/VZ_^C,? ?\
MXE!H?_SOJ^Z\#T'Y"C ]!^0H_M##_P#0HRWI]O,_+_J8^7]60?V%F'_16<0]
M/^7/#/3E_P"J<_N_B?"G_"Y/VZ_^C,? ?_B4&A__ #OJ/^%R?MU_]&8^ _\
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MT^WF?E_U,?+^K(]S^PLP_P"BLXAZ?\N>&>G+_P!4Y_=_$^%/^%R?MU_]&8^
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MRWX8\1^#O@3X&L_ 7ASQ9XV\0?$3Q!IMGJ&L:C'J'C#Q1)#+KFL-+K.H:C/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGQS6Z,LD\3W"O$I5Y%4$&JW@;XL_"OXG_P!J_P#"M/B7\/\ XAC0K@6>M_\
M"#>,O#GBW^QKLEU%KJO]@:EJ']G7!,<@$%WY,I*. N5;'XJ_LV_L^^ ?VO\
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M?U3_ &)?C?\  KXM_#C3/V2]&^"OCGX:^#[7]G/PMXQ\#>%?BE:>&KN'XO\
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MM'A6T22UTJ&9;.WGFNIXXQ)<RLWLZ(D:JB*J(@"JB*%55 P%50 % '    '
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MA1112-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KA_$OPX\&^+_%'P]\9^(='34/$GPKUG6M?\"ZBUU>PMH>
MK>(?#&K>#M7NT@MKB&VNS=^'=;U/3S'?PW4,2W)GACCN8XIH^XHJX5)TY.5.
M<H2<9P<H2<6X5(2IU(-II\M2G.4)QVE"4HM--HRK4*.(@J=>E3K0C5HUE"K"
M-2*K8:M3Q&'JJ,DTJE#$4J5:E.W-3JTX5(M2BFBBBBH-0HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\.?V?O
MB=\;_P!@/2OC?^SUXP_8Y_:<^,_F_'[XX?$[X(?$/X$>!M.\>> _'_A'XO>.
MM8\>Z!8^)]>37+"+X=Z]I%_KMQH^OIXE@M[2W6 7\,LUIMED_<:BJ4K735T[
M75VMMMC&I2<Y0G&<J<X*:4DHR3C-+F3C)-/6,9)JS3BMTVG^ 'P1_8[^.7PS
MT?\ X)1Z5\1/ %WJ?B3PC^U9^U-\?_CA;Z';KXA\/_"2\^,W@7XZ^,M!LM<U
MFR26PA_L+Q#XP\/^&H]7$AL[GQ.BK83,LMKNX;]KS]EWXY?$CQI_P4XT_P -
M_#KXIVVE_&?XO?\ !..X\$>*O!FB7T6HZUI?@K4]#M_B)XK\$ZE':SQ7-WX!
MM(I+K5M5ACN!HCV:370"0 #^CBBJ522ES65_R]Y2_2R_4YY8"E*FJ7--1771
MMKZJ\+J[;N#YKJWO>6A_-OXR_9N^/7P;_8__ &X?^"<VB_!WXA?%'P+8W'AG
MXH?LR?%C1?"=WK]S\4/ GCGXV>$O$/B[X>?$+7M.M!%KOQC\!7G]JRZE>WRK
MJWBSPBBZ])"(]/G=OL/]L[]G/XG?%W]J7]FNS\ ^'=>TGPXW[(_[:/PEU?XB
MZ;I=R/#OP^UWXC?#'1O#G@>UUS5;:/R=,-SJA+:7:R.&EDLI3;1F2+C]A:*%
M4:UMKK>_5M)7:^5[=V^F@_J-/D<.:?):C&*T3C3H5I5H4T[7:7,Z=[WY$M>:
M[?\ .;+X<^/?QF_95_8__8%M/V._C1\*/B=\&/B)^S6/B5\5/$GA:PTCX(_#
M30_V?/%OAW7/$/Q$^&WQ.CU:XL/&VI^*++P[(OA/2_#WG:M)/KTT>LI EO=L
M_F'[1/[ /QV^*?QQ_:>^"VG_  [\51? KX5^$?VBOVJ_V7_&]O:3?V+JO[1'
M[0-O\-=7T7P5X5NRGV*+7? OC/PC\3KJ&QAC+V5GX_T^14B*I+<_U T4*HUL
MDMWN]V]7J^VEMM7NR)9=3J14:E2<K*G"Z4(WI4DU&FTHZKF:G)JS<HQM:*27
M\ZWA?]G'X^>.?@1^R5\7?BA\&O%MO\</CK_P5$^%W[6G[0W@>YT&[N=5^%G@
MVVMO%V@^'-.\56<D"W.E:)\.O!.D^#--NWU1$.EW4_V>X*L56OT2\#_#GQSI
M_P#P5,^/GQ1N/!^OV?PY\1_L>?!'PGIGCB32[B'PSK7B[0?B3\0[[4M!MM6*
M"UO=:TG2]0LKFZM%=[BTL[R!V"1S)N_1>BDYMWT6J:]+M/\ ))>AK#"0@J:4
MI-PE3DY-1O.5.$HN4K+5S<Y3E;[3=K(****@ZPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&X_X]Y_\ KC+_ .@-
M4U0W'_'O/_UQE_\ 0&IQW7JOS%+9^C_(^)?^"</_ "9G\'/^N?CC_P!61XOK
M[@KX?_X)P_\ )F?P<_ZY^./_ %9'B^ON"O3SS_D<YM_V,L=_ZDU3P.$_^26X
M;_[$.4?^J_#A1117EGT!^;W[0'PX\?>(/^"D'_!/CXCZ'X/\0ZKX!^'W@+]K
MNP\<>,+#3+FX\/>$[WQ=X/\  EGX7M=>U.-#;:=/K]U87EOI4=PZ->S6TZ0A
MC$^VO\5?ACX]^+'_  4V_9KUG7O!OB";X$_LV_ +XG?%#0_%DVG77_"'7GQ_
M^(7B#3O &F:8VH%38W'B+PWX"L]7U>PMBPN]/CU:6Y0!+D$_I315<[T\DTGZ
MZ7^[0PE0C)SO)VG7IUY*RM>E&E&,?2]&,GUO=;:&#XITN?6_#'B/1;68V]SJ
M^@ZQI=O< E3!/?Z?<6D,P8 D&*257! )!7.#7X*_!7]H3X\_L[_\$A/A#H_[
M/'P&\<?%?]H_P!XAUO\ 9=USP?X4\$ZSX]G^%GCKP/XU\5>%_'OQ \;^&/#W
MEZCJ.G>&H]%N-?33(KBU/B#6-7T.P-W%;:C+<+_017FW@KX2>!/AYXI^)GB_
MP?I#Z+JWQ=\1:?XO\=QV]]>MI6J^*=/T6TT ^((-'DG?3=,U;4],L+"+6[S3
MK:VEUJ:QM;O4C<740F)&22::OJI).^K6EM^S8JU&<YQG";@_95:3DOBC&HZ<
MN>&ZYDZ223TM)RO>*3_'3]F.UO\ 0_@A^T?H7PC_ &7/VDO'_P"UKX]\"ZG\
M0OB/\3_V_P#X$ZI\/O"7[37Q M8X+.'P/JVJWFK?V7I_A\6<TNA>!_A[8&P\
M/>&=#2#SWG$6JZA=ZXMOB-^U[^U!^PKXO\*?LD_%S]F&S_97UOQ7XW^,?COX
MJ> ]-^'%K:66L> KCPF?@=\-)()[F3XAZ)K^M74<VI:IHRKX6LM&T:VO8YS?
M7%K$G[>T4^=WO9-ZZZ]4D]FE:RT73;96(^J+EA#G:A!TVX*$4I.E456+YFG)
M2<U><^9N>^DO>/R4^)'[&_A3Q=^TQ!X4^$WP*T#X3?#GP]IDG[0/Q9^).F^$
M(=$TGXS_ !R2ZU>/X'_#\7RQ10Z[X<\#>*9=9^+_ (\TG3P=-7Q/8>!?[0B2
MYO)Q<>&_\$RO@E\5/AY\:=!UK4_@W\3_ (-6'AO]DJ'X>?M1ZU\1+"]T[3_C
MC^U;'\3+75YOB'H-]=:O>P?$&2#1X/%M[-\3[)+BSO\ 2O$VG:0EVQ4067[N
MUA^)_#VG^+O#>O\ A75FODTKQ+HVIZ#J;:9J%YI.HBPU:SFL+S[#JFG36]_I
MUW]GGD%O?65Q!=VLNV:WECE1'!SNS3ZI*[N_ST?EVTL'U.FJL:L=)1E*222C
M'7DLE9>ZER*]OBYJG,GSR/S5_P""6UK-K/AK]L/XPV2-'X(^/'[=?Q\\?_#=
MD!%EJ7A#13X8^&)\16 9G=K37_$/@'7KZWN!(T%[;&WO+4""=,_J-7(^ ? G
MA+X7^"?"OPZ\!Z+:>'/!O@K0M-\-^&M#L0_V;3-'TFVCM+*V1I&DFE98HPTU
MQ/)+<7,S27%Q++/+)(W74I/FDWMV7DE9?@C:C3=.E"$FG*,?>:5DY/65ETCS
M-V6]K7"BBBI-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ***^=_C!\#O&/Q/U?2]3\._M(_&[X,VVGV,UG/HWPR
MD^'*:9JLLMRTZW^H#QCX \6WANX4(M8OLMW;0>0J[X7EW2-M0ITJM10JXB&&
M@TVZM2%6I%-+1.-&%2H[[)J+2ZV.3&U\1AJ$JN&P5;,*JE%+#4*N&HU)*4DI
M253%UL/02@FY-2J)M)J*;LG]$45\-?\ #(/Q2_Z/T_:Y_P"__P "O_G*4?\
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M[R_ZFWF_N\S[EHKX:_X9!^*7_1^G[7/_ '_^!/\ \Y2C_AD'XI?]'Z_M<_\
M?_X%?_.4H^HX'_H<X3I_S"YEY7_Y@^FOW>8?VSG?_1(YI_X<N'O+_J;>;^[S
M/N6BOAK_ (9!^*7_ $?I^US_ -__ (%?_.4H_P"&0?BE_P!'Z?M<_P#?_P"!
M7_SE*/J6!_Z'.$_\)<R\O^H/S?W>8?VSG?\ T2.:?^'+A[R_ZFWF_N\S[EHK
MX:_X9!^*7_1^G[7/_?\ ^!7_ ,Y2C_AD'XI?]'Z?M<_]_P#X%?\ SE*/J6!_
MZ'.$_P#"7,O+_J#\W]WF']LYW_T2.:?^'+A[R_ZFWF_N\S[EHKX:_P"&0?BE
M_P!'Z?M<_P#?_P"!7_SE*/\ AD'XI?\ 1^G[7/\ W_\ @5_\Y2CZE@?^ASA/
M_"7,O+_J#\W]WF']LYW_ -$CFG_ARX>\O^IMYO[O,^Y:*^&O^&0?BE_T?I^U
MS_W_ /@5_P#.4H_X9!^*7_1^G[7/_?\ ^!7_ ,Y2CZC@/^ASA/\ PES+R_Z@
M_7[@_MG._P#HD<T_\.7#WE_U-O-_=YGW+17PU_PR#\4O^C]/VN?^_P#\"O\
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M?]'Z?M<_]_\ X%?_ #E*/^&0?BE_T?I^US_W_P#@3_\ .4H^I8'_ *'.$_\
M"7,O+_J#\W]WF']LYW_T2.:?^'+A[R_ZFWF_N\S[EJ&X_P"/>?\ ZXR_^@-7
MQ!_PR#\4O^C]?VN?^_\ \"O_ )RE13_LA?%)89F_X;S_ &N&Q%(<&;X%$'"$
MX(_X4IR#T/M36"P-U_PLX3=?\PV9>7_4'Z_=YB><YW9_\8CFFS_YF7#W9?\
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M_AD'XI?]'Z?M<_\ ?_X%?_.4KS/J.!_Z'.$_\)<R\O\ J#\W]WF>]_;.=_\
M1(YI_P"'+A[R_P"IMYO[O,^Y:*^&O^&0?BE_T?I^US_W_P#@5_\ .4H_X9!^
M*7_1^G[7/_?_ .!7_P Y2CZC@/\ H<X3_P )<R\K_P#,'T_3T#^V<[_Z)'-/
M_#EP]Y?]3;S?W>9]RT5\-?\ #(/Q2_Z/T_:Y_P"__P "O_G*4?\ #(/Q2_Z/
MT_:Y_P"__P "O_G*4?4<!_T.<)_X2YEY?]0?K]WF']LYW_T2.:?^'+A[R_ZF
MWF_N\S[EHKX:_P"&0?BE_P!'Z?M<_P#?_P"!7_SE*/\ AD'XI?\ 1^O[7/\
MW_\ @5_\Y2CZC@/^ASA/_"7,O+_J#]?N#^V<[_Z)'-/_  Y</>7_ %-O-_=Y
MGW+17PU_PR#\4O\ H_3]KG_O_P# K_YRE'_#(/Q2_P"C]/VN?^__ ,"?_G*4
M?4L#_P!#G"?^$N9>7_4'YO[O,/[9SO\ Z)'-/_#EP]Y?]3;S?W>9]RT5\-?\
M,@_%+_H_7]KG_O\ _ K_ .<I1_PR#\4O^C]/VN?^_P#\"O\ YRE'U' _]#G"
M?^$N9>7_ %!^;^[S#^V<[_Z)'-/_  Y</>7_ %-O-_=YGW+17PU_PR#\4O\
MH_3]KG_O_P# K_YRE'_#(/Q2_P"C]/VN?^__ ,"O_G*4?4L#_P!#G"?^$N9>
M7_4'YO[O,/[9SO\ Z)'-/_#EP]Y?]3;S?W>9]RT5\-?\,@_%+_H_3]KG_O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?!'_!3?]J[QQ^Q)^Q3\8?VEOASX>\*>*?&'
MP[7P>=)T/QM%J\WAJ]/B+QOX>\,77]HQZ%JFC:HP@L]8GGM_LVI6Y%S'"9#)
M$'B?\H_%'_!4?_@I?^S=;?LZ?$_]J?X%?L7>(_@E\>?B%\-O <&F_L\?$/Q]
M??&6R?XFQ07.E7VG^&?$VM:K%J$VGVDYFOK&VT^[7[3''83WMBUY;W1^U?\
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MDWD:;.UW;IJZI;2M/$&+?GWH7Q#_ &GM)_X)F?\ !1+_ ()A?M$_#WXD:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)%.(O*D:*14=BC ?S^_MU_LR^'_V3M.^#_C;P9\%/+\">&?VG?AS\<OV@?\
M@HM=:YX:\5?M0^#[CQ#\8'U'7[:\LXK#0?&?B/PAJ!U;2O ^L7$>O7>A>'?
M.IM#'X0U*+1B'[[XW?LO?M 2?M)?MF_M8>(OV+_V*/VL?AOJEO\ #R]^'.G_
M +0&KZ;K_P 1IOA;\+OAI;R:IH/POL-2^&OC3PYX5U'6];N_$FJ^7XGUC1(M
M1U*YM1<1)9K#>-HH)V][1[;;IQ5M^M[VW2W1Y[Q=6,IPE0:E"4.;E]K4483A
M4ES-1I<TE%PY.>"=.4G:,VXR2_?^RO;+4K.UU'3KNUU#3[ZWAN[*^LKB*ZL[
MRTN(UEM[JUN8'D@N+>>)UEAFA=XY8V5T9E8$X^I^,/"6B6^N7>L^*?#FD6OA
MB"UN?$MSJ>MZ986_AZVOE+V-QKDUU=11Z3!>("UK+?M;QW"@M"S@9KQCX _&
MCX:?$[]E[X9?'7X7:*GAWX5^(OA+I'C;PGX9MM+L=&7PYX:@T 74'AN+2-,"
MZ9IQT*&U?1Q8Z<!86[6?E69-NL9K\8=*^"?QP_:]_P""65QXO\!^&/!GCGXS
M?MV?'CP7\?/B]8>/?$JZ!X8U/X7/\9-+\0:;X'U#5I[/4[O_ (17PU\)O"7A
MGP5I^B6=C?7,&F_;196%Y>2RQW*4;WN^6S4=>C;UOY))]=[)&]3$.*C[.'M9
M3H5*\5%NTHP4+*-HR;<Y5():?#=[I)_O9X1^*7PR^(%S>6?@/XC>!/&UWIT$
M=SJ%KX1\7^'_ !)<V-M-(8HKB\@T;4+V6V@EE!CCEF5(WD!16+ BNMBU33)]
M0O-(@U&QFU73K>SN]0TR*[MY-0L;746N5T^YO+))&N;6WOFLKQ;.:>)([IK2
MY$#.8)=GY#?LI:E:?!S]H_XA_LHZ_P#LB?LD?LJ_M#>+/@1<_%?X;_$[]EOP
MKHTOP]^(G@C3M>_X1J[L/$@7P3\./&8U3P-XMO-+O;_P_JL3:9JUG="[TV_M
MY/G;E/\ @GQ\-/&/PR_;W_X*9>%?&_Q;\6?&;QW=>"_V.-:\1?$;Q=':6%Q?
M:YKWAGXSWDUOH.@:8JZ9X3\):0\B6?ASPQIGF6^E6$"AI[J[EN;J<Y='KLHM
M=;W:5]+Z:]+_ .<QQ+DZ*4+^TJ3I3EK%4I0A*7*XS2J.3Y5;W5'E?-S6M?\
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M/Q'-XK\2^#-5UR:TO3K7AR?6Y([VSBU2WNM3L;BUM[JWU1;T374WU5KOQ(\
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MB,LL<8=V WNJYR14[[%MI)MM))-MMV22U;;>B26[-VBCKTHH&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7\RGP2^ 7Q!U']E"P_;$_9SL6;]J?]DW]KC]M7Q'X;T2,- OQI^$.H?M$
M^/W^*OP%UQU5GGM?%F@+=ZIX1=H;IM-\;V&DW%G'%)=S3I_374%LEJD96T6!
M(O,E+"V6-8_.:1C,2(@%\PREC*3\QD+%_FS5QERIJU[M/Y*]TUU33LSGKX>-
M>47*37+3J15OBC*4J4HU(N^DJ<J::T=VU?2Z?\8O@:^\2^._V/\ _@GI\8=1
MUC2_AC^S@W[9/[;GCKXF^(/BU\(=0^,WPT^'7BGQE\4/B!>_![6/C/\ #6R\
M3^$(Y]*TG4;[6-+CUS5=770_"GB2ZM-4OHW2.-U]3UCP1IVK?##]J/XB>!OB
MK#^T7^S7JG[4W[%GB#]J32_@-^S)K/P3_9\UOX8>!M7UV?XW:E\,M/T_XC?$
MA?B5+?:+=^!I?C"_AK3],TV&Q\,6SROK#7-Z]K_7%%;:>]J]M#;V;V4C2K)!
M%% UJ[-(QG5XD4Q,S2[S*&4DR;M_S9KQ?X^_!2S^-7PLU#X=6GC_ ,<_!VZ;
M4M%UKP[X\^%FMCPQXF\,:_H.I0ZEI5U:,(WTW4["6YB%MJOA_5[2\T?6[">X
ML;ZUD24,EJJM%:RNK]?=O?>U[KR\OGP/+6HMJK[22HQBKJ<>:<<,L/HO;*DJ
M<TN9PE"6LI+FLTX_S\^(/BQ^QQJ'[?7Q'^)/['OP^T#XL>']'_X)5_M%WOCC
M0?@/9W/A+P_\4[[2?&_PZ.D>#O#&L>%]-M(9/%0T42:-J6J>'(;C5-)COM,M
M)0;^V@MT^7_AW\0_!OB3XV_\$IKSP#K/['UA:Z/^T!X1T.3X>?LL_!SQHFL?
M"?PIXJ^&/C70[GP7\9OCWXMUMI]2US4&N(/#^J>$->\.6>K^)_$-KJ.LR,CZ
M<WVS^C[]GS]C:X^$OQ6U[X]_%#XV>-?VA/C3JO@&/X5:3XL\3^'?!O@?0_!O
MPX.O6WBC4/#GA3P/X"TK2?#^GRZ_XAL=-U7Q%K,T=SJ6J3Z98(98((#$_P!G
MQZ9IL((AT^QB!G%T1':0(#<J<K<$+&,SJ22)C^\!Z-0ZB6BN[123OZ[WCYVO
MIU2T=QK 5:EISE3I-U74<(TDK6G2DK>SK:-^S]Y.=2-VI6YD?RO?"0_#W1/A
MAH'PVT>S\-:+\3O!'_!<S3IO'WA'3]+L]*\4:#X>USX]>-+[X=3:[806MM>1
MZ+?Z()[CPK-,K6+:?YATYEAR*]3\5?#;Q-9_M:^(?^"45EH&I#X*?&']J/P]
M^WBU\EH[^';7]F95NO'7Q4^&F\1_9K2TN/VC?#FAZ+!8B0*VD^+'MQ:FV\Z1
M_P"E#[!8^:\_V*T\^62*62;[-#YLDL&1!*\FS>\D()$3L2T>3L(S4Q@A,PN#
M#$;A8S$LYC3SA$S!FC$N-XC9E#% VTL 2,@&E[3LOO?7W;/1=&G;U^_7ZAM>
MHE9TXOEIVYJ,4XSI.\G958\JFU]J-TK.R_C_ /BOH.C:-\0_^"D_A/\ :D^/
M/P3^$GCKXA_''XE7NA>$OBU^QKJWQT^.'Q&^#VKV=K:?!*__ &<O',7Q?\&7
M6LQ:?H@L-.\'^&_"&D0W'@_Q-IX?4[A)C+<0_P!2W[,^C:UX=_9V^!N@>(M?
M\4^*=<T;X3> --U3Q'XYT%O"WC36[NS\,:9!)J7BWPV^K:])H7B2ZV"76]*E
MUO59K'46N;>;4+J6-YG]EFL;*XFAN+BSM9Y[<YMYYK>*6: ^L,KHSQ'W1E-6
MJF4^9)6V=^G9+HD^G5O2RN:X;"+#U*DU/FY[I?Q+VE.4WS<U6<6[R>L(05^9
MV]YI%%%%0=@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5#<?\>\__ %QE_P#0&J:H;C_CWG_ZXR_^@-3CNO5?F*6S
M]'^1\2_\$X?^3,_@Y_US\<?^K(\7U]P5\/\ _!.'_DS/X.?]<_''_JR/%]?<
M%>GGG_(YS;_L98[_ -2:IX'"?_)+<-_]B'*/_5?APIDK,D<CI&TK(CLL2E0T
MC*I(C4L0H9R H+$*"1D@9-/HKRSZ _F>_;9^._[.7[4>E>"/B)\+M.^)_@W_
M (*C?"7XQ^#O"/P5_9\U:;Q+<?$3PKXS\,_%2/2]4?QG\+5N=1^'=S\.M5\'
MW&O:_J/Q'ELFL5\*WUI?6?B2.]MK>T7U'P]^T5\.OV)1_P %/O@M\?+Z?0?B
MM\5/C9\3_CQ\$O"4FB:K>ZO\?M#^-OPA\%:)X;T7X80VMI<?\)EJMIXV\/ZI
MX.O])TYY;G2KI8S>+#;.9E_H$:VL([M;QK>S2^E'D)=-%"MW(H4GR5G*B9P$
M4GRPQ&U2<8%/FL[2XEAGGM;::>V8M;S30122V['JT,CJSQ,<#)C*DXK3G5K6
M=M]7JG=.RTTCHU;7=OR.#ZI4YI5%6@JLK)R5&T9)0G!RG!5%S59<Z<IJ44_9
MPCR\JL?&G['/PH\=?!O]@7X"?"'7HIK#XD>"OV<O#'AO4[-Y5DFTKQA%X.3S
MM-\V,[6.DZM,;!&1MN+5=K8 -?E1\$_A;\?/CC_P2-_8[^$7[/7AWPAK^B7N
MJW&E?M5^$O%OQ&U3X2:SXKT/PCXS\4R?$SX<VOBFQ\%>.;K1IO&_Q&LIM/\
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MK-:45**J*6'I0J4K7NZ<L11IU5"3:<:<(RO9I_SX^-=$\?:K^SE^W6R?%O\
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M6_!?P1_9J^,?[2O@3QG^R+\ /&GP\\4:!H^@_"W4]!^-OQ-T3X/ZQ9:Y\,?
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MBBBLSO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ=I7]H7,FIV^E:9I^FP66G6)WO,*?Q>_8/A_:#?]L.Z^+?C>*\U+]HOX6P?
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M  .^*5W\./!C^,[RS\:>$%T7PGJR:WH'V*#5=&N/$&B7!\B>_L(-<N'D*O\
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MWXJ^$^G>.-3&H/H5OX4O#X0OUU31].\0ZAJME8744CV5RUS[A^Q_H?CWP_\
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MYH6M%RJ1_=33G!N4::G"W-%2DK>Z_P WOAA^SEI&H>+OB!\&?VH8='^)VK?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[X4444 %(%4,6"J&8 ,P W$+G:">I R< GC)QUI:* "BBB@!&57&&56&0<,
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M'PW\*^&OB!>Z1I/A;QUXL^,?B+QK#HT^DZ'XALO#.J:YIWA^[T^#5FU"UO\
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>ny20077915x1_table03x2.jpg
<TEXT>
begin 644 ny20077915x1_table03x2.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MR_/NS\U/^'6OP0_Z+/\ MG_^)>_'#_YJJ/\ AUK\$/\ HL_[9_\ XE[\</\
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M:JC_ (=:_!#_ *+/^V?_ .)>_'#_ .:JOTKHHYY?S/[_ $_R0?4\+_T#T?\
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M#T?_  "/^7E^?=GYJ?\ #K7X(?\ 19_VS_\ Q+WXX?\ S54?\.M?@A_T6?\
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M "\OS[L_-3_AUK\$/^BS_MG_ /B7OQP_^:JC_AUK\$/^BS_MG_\ B7OQP_\
MFJK]*Z*.>7\S^_T_R0?4\+_T#T?_  "/^7E^?=GYJ?\ #K7X(?\ 19_VS_\
MQ+WXX?\ S54?\.M?@A_T6?\ ;/\ _$O?CA_\U5?I711SR_F?W^G^2#ZGA?\
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MC^HJBBBL3US\R/\ @JA_R27]FS_L_P!_8I_]7=H%?IO7YD?\%4/^22_LV?\
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M?[SBO2A_Z1(*BEG@@"&>:*$22+%&99$C#RN<)&A<J&D<\*@RS'H#4M?RK_\
M!9S1OVQY/VC_ -CKQK\1?B!X+\/_ ++UI^WI\ O!OP;^$W@DZK)XE\37EQJN
MGZEJ7Q&^)^J3+!9I?VTMIJ&CZ!H=E)=P6UE=W$\L=M-(\EVX1YY6NEUU\NB\
M_P#AQ8O$_5:/M?93J^]&-HM)+FDH\TY.ZC%7[-MVBDVS^J&XNK:T0275Q!;1
ME@@>XFCA0N>BAI&52Q[*#D]A4P(8!E(96 *L"""",@@C@@CD$<$5^"W_  55
M_9.^ /B;QCJ_[77[>G[1WB2T_9.^&/P@O_"_@K]G#0-3UOPC<7_Q;O?/FT_Q
M)H6J:+XD@G\5^,]4FE>VT?1(]!,BRPZ?)J%[_8FG7R/^=7P-_:Y_X*0?L<?L
M;?\ !,CX7Z'HWAKQ7\2OVL_C=\1?!'@OP_\ M%KX@EUK2?AAJ=UX?C^$5IKV
MNP:G::MHT-HNLW.L3-<6M_>KX=DTZSMK6#RX[>J5+F2<9:MVU5EM?1]6MGI9
M76ISU<Q]A6J4ZU"4:<(\T9TYJK4:=2E2BYT8KW(U9U7[+WY3DJ<[P35C^O\
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M5W%VTO%W3MHVM-#^=?\ X.3O^32?V?\ _LZ[PA_ZKOXEU_'_ %_8!_P<G?\
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MGA3PK;W2QZ!HWAW2= NUTC5]1N;V[&NZMIU_J-[:3ZS!#IT-\D,<JV$&2*^
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M'61?Z$*_,OXT_P#!4WX#_ +]NWX1_L(_$G1/%&B>+/C)H&C:KX;^)DLNBIX
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M)3<9RI3CS04HJ2BVTI*Z5S\B_%?_  25_;$\4?!#_@G)I7A[X_? 'X5_'?\
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MGJ7D7<4DX-KJ5]9W=A>*UE+8?HOX#^)OPN^)%M?2_#'X@^ ?'MGH\D$&IR>
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M4_$JTO;;7;'Q')X0\+_$;5]3N);+P_)J.EZ8MO,ZQ"WCLK6:YTK4;B*<WO\
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MXMII(G*.KA7.UE."/P"_:C_X-Z_V0?BCXC_9_P!2^ 'PW^&OP/T;P#\5]/\
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M=#CU*[6/?!)<W$L]N_D31@?JY_P5"_8'^-G[8'CKX8>(OA7\*_V$_']AX/\
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MEV,=O"NL:IX5T^_UCPQXKGMX@C1C4=.BN9K*?85>WNWTW=C1E"_QV^ _B/\
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M0GQ3_P#F&H_X>Y_\$[_^CCM*_P#"$^*?_P PU')+^5_=Z?YH/KF$?_,5A_\
MP=3\O[WFC](:*_-[_A[G_P $[_\ HX[2O_"$^*?_ ,PU'_#W/_@G?_T<=I7_
M (0GQ3_^8:CDE_*_N]/\T'US"?\ 05A]?^GU/R_O>:_JY^D-%?F]_P /<_\
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M%OC#X7UK7M0,NH>$+2!UT_2[2XNV@CD>ZG6(Q6L$\[)$WW[_ ,/<_P#@G?\
M]'':5_X0GQ3_ /F&JN67*E9WYI/;NH6_,YX8O"K$UV\302=+#I/VM.S:E6NK
M\VZNKKI<_2&BOS>_X>Y_\$[_ /HX[2O_  A/BG_\PU'_  ]S_P""=_\ T<=I
M7_A"?%/_ .8:IY)?RO[O3_-'1]<PG_05A_\ P=3\O[WFC](:*_-[_A[G_P $
M[_\ HX[2O_"$^*?_ ,PU'_#W/_@G?_T<=I7_ (0GQ3_^8:CDE_*_N]/\T'US
M"?\ 05A__!U/R_O>:/TAHK\WO^'N?_!._P#Z..TK_P (3XI__,-1_P /<_\
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M_E?W>G^:#ZYA/^@K#_\ @ZGY?WO-'Z0T5^;W_#W/_@G?_P!'':5_X0GQ3_\
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M(:*_-[_A[G_P3O\ ^CCM*_\ "$^*?_S#4?\ #W/_ ()W_P#1QVE?^$)\4_\
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M)\4__F&H_P"'N?\ P3O_ .CCM*_\(3XI_P#S#4<DG]E_U;_-!]<PG_05A_\
MP=3\O[WFC](:*_-[_A[G_P $[_\ HX[2O_"$^*?_ ,PU'_#W/_@G?_T<=I7_
M (0GQ3_^8:CDE_*^GXVM^:#ZYA/^@K#_ /@ZGY?WO-'Y\?\ !R=_R:3^S_\
M]G7>$/\ U7?Q+K^/^OZ0/^"\_P"WO^R5^T+^S3\%O"WP>^+]AXRU[0OVD/#'
MB?5;"#PQXWTEK30K7P1X^T^XOVGU[PSI=M*L=WJ-G"88)I+EC.'6%HTD9/YB
M/^%D>"/^@_!_X":C_P#(=?T-X09EEV!R+,:>-Q^"P=2>:RG"&*Q5##SG!X3#
M14XQJU(2E'F3CS)-735[JQ_GG]+C(\[SSCO(<3DN3YIF^'I\,4:52OE>7XO'
MT:=7^TL?/V4ZN%HU80J<DXR<)24E&2DU9IG;T5Q'_"R/!'_0?@_\!-1_^0Z/
M^%D>"/\ H/P?^ FH_P#R'7ZU_;^1?]#O*/\ PY8/_P"7>:^\_E/_ %(XS_Z)
M'B?_ ,,.:_\ S+Y_GV9V]%<1_P +(\$?]!^#_P !-1_^0Z/^%D>"/^@_!_X"
M:C_\AT?V_D7_ $.\H_\ #E@__EWFOO#_ %(XS_Z)'B?_ ,,.:_\ S+Y_GV9V
M]%<1_P +(\$?]!^#_P !-1_^0Z/^%D>"/^@_!_X":C_\AT?V_D7_ $.\H_\
M#E@__EWFOO#_ %(XS_Z)'B?_ ,,.:_\ S+Y_GV9V]%<1_P +(\$?]!^#_P !
M-1_^0Z/^%D>"/^@_!_X":C_\AT?V_D7_ $.\H_\ #E@__EWFOO#_ %(XS_Z)
M'B?_ ,,.:_\ S+Y_GV9V]%<1_P +(\$?]!^#_P !-1_^0Z/^%D>"/^@_!_X"
M:C_\AT?V_D7_ $.\H_\ #E@__EWFOO#_ %(XS_Z)'B?_ ,,.:_\ S+Y_GV9V
M]%<1_P +(\$?]!^#_P !-1_^0Z/^%D>"/^@_!_X":C_\AT?V_D7_ $.\H_\
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M_P (3XI__,-7YUR2_E?W>G^:/Z,^N83_ *"L/K_T^I^7][S7]7/TAHK\WO\
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MZ"L/_P"#J?E_>\T?I#17YO?\/<_^"=__ $<=I7_A"?%/_P"8:C_A[G_P3O\
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M(:*_-[_A[G_P3O\ ^CCM*_\ "$^*?_S#4?\ #W/_ ()W_P#1QVE?^$)\4_\
MYAJ.679_\/;_ #0?7,)_T%8?I_R^I];6^UYH_2&BOS>_X>Y_\$[_ /HX[2O_
M  A/BG_\PU'_  ]S_P""=_\ T<=I7_A"?%/_ .8:CDE_*_N]/\T'US"?]!6'
M_P#!U/R_O>:,W]IG_E)!_P $R_\ KT_;#_\ 5*6]?IG7X8ZY^V1^S9^U#_P4
ML_X)UV'P)^)MGX^O/"VG_M:3Z]!;>'_%VC'3XM4^"KK8NS^)- T>.<7#6-T
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MJUY1YXI87$N7(G!<W*J7,HWE&TFK/HW8_9S[):?\^UO_ -^8_P#XFC[):?\
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M8Z_:E^4#GII?6L1I_P NL-^=<K_9+3_GVM_^_,?_ ,31]DM/^?:W_P"_,?\
M\35BBE=]W_7_  R^XZ++LOZ_X9?<5_LEI_S[6_\ WYC_ /B:/LEI_P ^UO\
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M[*Z2_&R7R)E.G!PC*48RJ2Y*:>\I*+E9+RC!M]$EZ'UW]DM/^?:W_P"_,?\
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M?M6^$ VR-%R/^%>?$O@X49'L>*_D!\N/_GFG_?"_X5_8'_P<G?\ )I/[/_\
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M_!+G_L>_VJ__ %G#6Z_26FV^6.O?\T<U!+VN,T7^\P_]0\(5_LEI_P ^UO\
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M<"ZE^+?&L/[3'[%'@G_@G[\:M5_86\5? SP1^P'JVD^#/C%\5A\;/AA\0/\
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MZTI5)J=XU*SO[6G*+YDZ>BC%V;C&$54ARIGY^?M!Z]XOU+XZ_P#!&SXA:MI
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M\;2ZQ&6TXZ-HGQ!\8^$O#NJ:QYIL;75;*2WEN=UK+Y?]*?Q2^#'PD^-_A)O
M7QB^&O@GXG>"VN;6]_X1?QSX;TKQ+HB7MB&6SO(M/U6UN;>&[M5=T@N8D2:)
M))$1PKL"W3/@K\']&^&/_"E=)^%_@+3OA#_9$^@GX96?A31(/ KZ-=%VNM,D
M\+QV2Z/)9W+R/+<0O:,LTKM+)ND8N:51)+1WY>1[6Y>:]UOK;3IW\C.K@JE2
M4DIP4/:_6(-IN7M51C2C&:^%T[Q<FT^:2:A96<I?G9INK:9\0O\ @L>NL^ M
M5L/$&D?"G]@:3PW\3M7T*\AU/3=,USXA?&>/7O GA;5KRSDEM;?5[K2=$UCQ
M)9V4DIN7TUA=&-87B=]W_@F!)):V7[='AK3G:3P1X3_X*&?M$Z9X$ ?_ $:S
ML-3MO!/BGQ+IFGVX9TM["U\<Z_XGN!Y;^7)?7M^0D;HZ#[+\&? +X=? 7X;^
M+O!_[+?PP^%7P<N]6LM8U#1M.\.^%+'POX3E\93Z=+;Z3J_B2T\-64%U?6\%
MV+7[8Z)+>&RB>"W924 S/V4?V?--_9B^!OA'X3VNK2>)=;LY=<\4>/?&-Q&8
MKKQO\2_'&MW_ (L^(/B^YC8L\7]N^*=7U*ZM+=V=K+3S9V.]EME)3E>+7E&*
M771W<GVU;2UV=M=673H5(UJ<Y63YL16J.+?+S5%"$*4;V<H\L5*4G%7G34N5
M<UE]&4445F=Q^9/_  4B_P"0W_P3]_[2$? O_P!,_CFOTVK\R?\ @I%_R&_^
M"?O_ &D(^!?_ *9_'-?IM5/X8_\ ;WYG-2_WC%>M'_TV%%%%2=)S_BSPIX<\
M=>&=?\&>+]'L?$/A7Q3I-_H/B+0M3B$^G:QHVIV\EIJ.FWT!($]G>VLLEO<P
ML=LL,CQN"K$'\A/V0=)\&^ ?VB/^"PNC:?H\GA?P'X4\8?!FTAT3X?Z&L-QH
M?AK2_P!F/3U>S\'^'M%LW O++3XG71M+TVPD=[E(+>VM979(F_9NN.\/_#WP
M+X4\0>-/%?AGPCX>T'Q-\1M0TW5O'NO:5I5G8ZMXPU/1],CT;2K_ ,1WUO$E
MQJUUIVDPQ:=9S7CRO;V:+!&5C&VJ3LFM;-6_%/\ )6,*M+GJ49KE3I3G)MK5
MQE1JTU%-:VYJBDU=*R?4_G''AOX(?LN?L[?L7_&W_@GU^U%\>_&NO^-/C7\&
M/A]X ^%GC/XW>)O&^@_&/P7\0/&L.F_$GP-KWP1U"ZD\+^$-2\*^&[CQ%XBU
M&]\/^$O#FH^"]3\/3O?2Q3/,)/TY_P""O^I:KIO_  3Q^/ATZYN+&WU4_##P
MYXHNK9V5[?P+XH^+O@+P_P"/FDD096V_X0[4M;CO'X46K3%R$R1]7^$OV3_V
M8_ /Q)U+XQ^"?V?_ (/^$_BKJ[7LFI?$/P]\/O#&D^+KN34N-1EDURRTV&_6
M6_!(O98YDDN@S"=I S ]]\6_AAX4^-7PP\?_  C\=67]H>$/B/X2UWP;XAM1
MM$C:9KVGSZ?<2V[L&$5Y:B875E/@M!=PPS+\T8JG-.47J^62;;M>UT[:=%9V
M]7HCFAA)QP^(I)TZ?M:/LH0I<ZI1DJ<H>T2D[QE4;7-&+=E&*<IRO-_F=^T[
MX;U;X>?M9_LM?%O]GGXB_ ?1/CG-\!?B'\(;+X)_';6]<\&^%_BO\%;+4_!G
MBB^NO!OB_0='UI]!\3_#_6K;2=0^QIIM[_:VBW]Q$UM';6<L\?Y:> &_:\\<
MZ3^W#-X,\'^)OC=X-_:I_;@MO#7QO^)7[+$FBV]CIGPP^'OPC\&:5\4-!^#4
M_CWQ=X6&KIX@U)[?X,P^/%U%2T/A_P 7:T(8]073[2+]_P#PS^R?X2\<?L]?
M"[X+?M?^$/A7^TCJ/PTTRUT>+6O%G@ZS\0Z;JQT!9-'T#Q1]@\36EW+IOB;4
M?#=OIK>)'M)&BEUAK_[//-9M#7TYX0\'>$_A]X:T;P9X%\-:%X.\(^';*+3=
M!\,^&=*LM$T+1["'/E6FFZ7IT-O9V=NA+,(X(44LS,069B6II)*UVE:[VLG?
M2UGOMVZWZ3+!3JSYW.5&$G[5PA+W^>=&-*<91DI03<>:,I1;NG[L82YYS_$O
M_@D3XQD/QF_X*#?#O2_V=/B7\'/!]I^T98WNF6OB6P\$6.@> X-$^"GP?\+Z
M9\,=2@\.^+];EB\3QZ59PZS!%I=OJ6AG198)9=;%_(]H/H__ ().275O\&OV
MB/#5LA3P3X*_;H_:W\,?#)$54M(?!<'Q0O=3>STY$+)'IVF^+-4\4Z;:11NT
M4<=GLB\N-5BC^YM<^&,/AKPK\8KGX%:!X#\"?%/XHIK'B&Z\37.BBTTW6OB5
M=>'K?P_I/C'QL='MC?Z[<V%KI^DPS32+/=SV.F6UD'$2+MQ_V8/@%X<_9A^!
M/P\^"/AF[GU2V\&Z3-_;'B&\!&H>+/%^N:A>>(?&OB_4LL[?;_%/BO5=8URX
M1I)! U\+9',4,>%*2:D[6YN56[<JU[Z7T6JOU5RZ&&G2G03ES1I1Q3<THQ3]
MO5C*%-126B2<I622E&*6C2/>Z***S.\_G7_X.3O^32?V?_\ LZ[PA_ZKOXEU
M_'_7]@'_  <G?\FD_L__ /9UWA#_ -5W\2Z_C_K^E?!;_DG\S_[&\O\ U#PI
M_FM],S_DX7#W_9*4?_5IF(4445^QG\@'ZM_L.?$;QWXE^!/[='@;7O%NNZKX
M-\ _L*?%"#P7X6N]0G?0?#2ZOXU\.ZEJLFE:6&6SM[G4;VXEGO+P1-=W'[N*
M6=H88(X\GX5_%3]JWX3?L;?#F/P7\&/@I\2?@;XH^.WBJ\TR_P#$WPL\/?&_
MQ WQ(CTS3=)O?#OB+0-?A\06GA%]6TM((O#\MOH^D:]J=E]I;3]2:"=Q-^<G
MAOQSXS\&VGBBP\)^*M?\-V7C;P_<>$_&%IHFJ7>G6_B?PQ>30W%UX?UV*UEC
M34]'N9[>":>PNA);2R0QL\9*BNS^&'Q_^.7P4358OA!\7OB/\,H=<\HZS#X'
M\7ZWX;@U1H%987OH-+O+>&YEA5V6*61&E16*JX4XKYC$Y"ZE7'U:='+JT,5C
M\)C8X7%4ZD:+=#"2H57*=%7IUYUIRKJLJ=9-\RG!RJ>TA^J95Q_3P^%R'#8G
M%\1X.OE609MDE7-,KQ.%J8N,<;F]''X6-.EC6XXG!4<)0A@)X.6(P3A'V<Z-
M?V>'5"M],_\ !2;X<_#_ .&/[3^JZ)\/?#VE>"5U?P!\.?%_C3X=Z(-FD?#O
MXC>*?"]IJOB_P?86_FR_V=;V%_,EPND?N_[)^V&R6*..)%'7?MW7]]X4M_V#
MX/"+2:=X7\,?L<?"#Q/X#U:W@2W:;Q#JNN^(?$'BC6%C\ORCJ">*HQ-=,Z,7
MG13,K \_G7JNK:IKNIW^M:WJ-]K&L:K=SW^IZKJ=W/?ZCJ%]=2--<WE[>74D
MMQ=7,\KM)-/-(\DCL69B3FOH'QK\<M-^(?[.GPG^$_BC1]3F\>_!'Q%XEL?
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M\&Y?C1\3I/A,ENMHGPX?QKK[>#%LTF^T)9#P^U\=.^Q)/^^6S\C[,K@$1#
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M $>5\"?_  M+/_XFC_AZS_P3C_Z/*^!/_A:6?_Q-?:W_  K_ ,!_]"3X1_\
M";T;_P"0J/\ A7_@/_H2?"/_ (3>C?\ R%1[G:7WKR\O7\/,.7&?\_<-_P""
M*OE_U$>OX>9\4_\ #UG_ ()Q_P#1Y7P)_P#"TL__ (FC_AZS_P $X_\ H\KX
M$_\ A:6?_P 37VM_PK_P'_T)/A'_ ,)O1O\ Y"H_X5_X#_Z$GPC_ .$WHW_R
M%1[G:7WKR\O7\/,.7&?\_<-_X(J^7_41Z_AYGQ3_ ,/6?^"<?_1Y7P)_\+2S
M_P#B:/\ AZS_ ,$X_P#H\KX$_P#A:6?_ ,37VM_PK_P'_P!"3X1_\)O1O_D*
MC_A7_@/_ *$GPC_X3>C?_(5'N=I?>O+R]?P\PY<9_P _<-_X(J^7_41Z_AYG
MQ3_P]9_X)Q_]'E? G_PM+/\ ^)H_X>L_\$X_^CRO@3_X6EG_ /$U]K?\*_\
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MX>L_\$X_^CRO@3_X6EG_ /$U]K?\*_\  ?\ T)/A'_PF]&_^0J/^%?\ @/\
MZ$GPC_X3>C?_ "%1[G:7WKR\O7\/,.7&?\_<-_X(J^7_ %$>OX>9\4_\/6?^
M"<?_ $>5\"?_  M+/_XFC_AZS_P3C_Z/*^!/_A:6?_Q-?:W_  K_ ,!_]"3X
M1_\ ";T;_P"0J/\ A7_@/_H2?"/_ (3>C?\ R%1[G:7WKR\O7\/,.7&?\_<-
M_P""*OE_U$>OX>9\4_\ #UG_ ()Q_P#1Y7P)_P#"TL__ (FC_AZS_P $X_\
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MN=I?>O+R]?P\PY<9_P _<-_X(J^7_41Z_AYGQ3_P]9_X)Q_]'E? G_PM+/\
M^)H_X>L_\$X_^CRO@3_X6EG_ /$U]K?\*_\  ?\ T)/A'_PF]&_^0J/^%?\
M@/\ Z$GPC_X3>C?_ "%1[G:7WKR\O7\/,.7&?\_<-_X(J^7_ %$>OX>9^$W_
M  4F_P""C/["_P 2/@-X'T+P'^U)\(/%>L6/[3?[,GB:\T[1?%-O>W=OH'AG
MXQ>%]9U_5Y88E++9:3I5I<WU[-C;#;PNYSP#^@?_  ]9_P""<8_YO*^!/_A:
M6?\ \37E?_!5/P9X/L?V=/A]-9>$_#5G*_[67[)L#RVN@Z7;R-!/\<O"$<\+
M/%:(S131LT<L9)22-F1PRD@_I5_PK_P'_P!"3X1_\)O1O_D*J]WECI*W-+JM
M[0OTVML<\%BOK-?]YA^;V6&N_8U+-7K[+ZQ=/?J[Z:+6_P 4_P##UG_@G'_T
M>5\"?_"TL_\ XFC_ (>L_P#!./\ Z/*^!/\ X6EG_P#$U]K?\*_\!_\ 0D^$
M?_";T;_Y"H_X5_X#_P"A)\(_^$WHW_R%4^YVE]Z\O+U_#S.CEQG_ #]PW_@B
MKY?]1'K^'F?%/_#UG_@G'_T>5\"?_"TL_P#XFC_AZS_P3C_Z/*^!/_A:6?\
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M_P!'E? G_P +2S_^)K[6_P"%?^ _^A)\(_\ A-Z-_P#(5'_"O_ ?_0D^$?\
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M*?\ AZS_ ,$X_P#H\KX$_P#A:6?_ ,31_P /6?\ @G'_ -'E? G_ ,+2S_\
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M$5?+_J(]?P\SXI_X>L_\$X_^CRO@3_X6EG_\31_P]9_X)Q_]'E? G_PM+/\
M^)K[6_X5_P" _P#H2?"/_A-Z-_\ (5'_  K_ ,!_]"3X1_\ ";T;_P"0J/<[
M2^]>7EZ_AYARXS_G[AO_  15\O\ J(]?P\SXI_X>L_\ !./_ */*^!/_ (6E
MG_\ $T?\/6?^"<?_ $>5\"?_  M+/_XFOM;_ (5_X#_Z$GPC_P"$WHW_ ,A4
M?\*_\!_]"3X1_P#";T;_ .0J/<[2^]>7EZ_AYARXS_G[AO\ P15\O^HCU_#S
M/BG_ (>L_P#!./\ Z/*^!/\ X6EG_P#$T?\ #UG_ ()Q_P#1Y7P)_P#"TL__
M (FOM;_A7_@/_H2?"/\ X3>C?_(5'_"O_ ?_ $)/A'_PF]&_^0J/<[2^]>7E
MZ_AYARXS_G[AO_!%7R_ZB/7\/,^*?^'K/_!./_H\KX$_^%I9_P#Q-'_#UG_@
MG'_T>5\"?_"TL_\ XFOM;_A7_@/_ *$GPC_X3>C?_(5'_"O_  '_ -"3X1_\
M)O1O_D*CW.TOO7EY>OX>8<N,_P"?N&_\$5?+_J(]?P\S\)_VL/\ @HS^POXL
M_:D_X)T^*/#?[4GP?UKP]\._C7\5]:\<:Q8>*;:>Q\+Z5JWP-\7:#IM_K$Z*
M5M+:]UB^M-/@DDPKW,Z)ZD?H%_P]9_X)Q_\ 1Y7P)_\ "TL__B:\L_;+\&>#
M[;]KW_@E_;V_A/PU!!>_'KXRQ7D,.@Z5%%=Q1_L]>-Y8X[F-+14G1)465$E#
M*LBJZ@,H(_2G_A7_ (#_ .A)\(_^$WHW_P A53Y;1TEUZKNK]/6WR,*4<7[7
M$VJ8>_MH<W[BK9OZO0V7UA65K[MZZ^1\4_\ #UG_ ()Q_P#1Y7P)_P#"TL__
M (FC_AZS_P $X_\ H\KX$_\ A:6?_P 37VM_PK_P'_T)/A'_ ,)O1O\ Y"H_
MX5_X#_Z$GPC_ .$WHW_R%4^YVE]Z\O+U_#S-^7&?\_<-_P""*OE_U$>OX>9\
M4_\ #UG_ ()Q_P#1Y7P)_P#"TL__ (FC_AZS_P $X_\ H\KX$_\ A:6?_P 3
M7VM_PK_P'_T)/A'_ ,)O1O\ Y"H_X5_X#_Z$GPC_ .$WHW_R%1[G:7WKR\O7
M\/,.7&?\_<-_X(J^7_41Z_AYGQ3_ ,/6?^"<?_1Y7P)_\+2S_P#B:/\ AZS_
M ,$X_P#H\KX$_P#A:6?_ ,37VM_PK_P'_P!"3X1_\)O1O_D*C_A7_@/_ *$G
MPC_X3>C?_(5'N=I?>O+R]?P\PY<9_P _<-_X(J^7_41Z_AYGQ3_P]9_X)Q_]
M'E? G_PM+/\ ^)H_X>L_\$X_^CRO@3_X6EG_ /$U]K?\*_\  ?\ T)/A'_PF
M]&_^0J/^%?\ @/\ Z$GPC_X3>C?_ "%1[G:7WKR\O7\/,.7&?\_<-_X(J^7_
M %$>OX>9\4_\/6?^"<?_ $>5\"?_  M+/_XFC_AZS_P3C_Z/*^!/_A:6?_Q-
M?:W_  K_ ,!_]"3X1_\ ";T;_P"0J/\ A7_@/_H2?"/_ (3>C?\ R%1[G:7W
MKR\O7\/,.7&?\_<-_P""*OE_U$>OX>9\4_\ #UG_ ()Q_P#1Y7P)_P#"TL__
M (FC_AZS_P $X_\ H\KX$_\ A:6?_P 37VM_PK_P'_T)/A'_ ,)O1O\ Y"H_
MX5_X#_Z$GPC_ .$WHW_R%1[G:7WKR\O7\/,.7&?\_<-_X(J^7_41Z_AYGX9_
MM)?\%&_V%?$O[9/_  3L\9:#^U-\'M5\+?#OQE^TC>>.->L_%5K+IOA>U\1_
M ;5]"T*?6+@+MM(]5UB:+3;)GXFNG6)>>GWM_P /6?\ @G'_ -'E? G_ ,+2
MS_\ B:\Y_:I\%^#H/VZ/^"85M!X3\,PVU[XY_:G2\MXM!TN."[2']G36I85N
M8DM5CG6*4"6-95<1R .H##-?HY_PK_P'_P!"3X1_\)O1O_D*J?)RQTEUZK>Z
MOT];'/1CB_:8NU3#W^L0YKT:CO+ZKA?A7UA67+96;;OK>SLOBG_AZS_P3C_Z
M/*^!/_A:6?\ \31_P]9_X)Q_]'E? G_PM+/_ .)K[6_X5_X#_P"A)\(_^$WH
MW_R%1_PK_P !_P#0D^$?_";T;_Y"J?<[2^]>7EZ_AYG1RXS_ )^X;_P15\O^
MHCU_#S/BG_AZS_P3C_Z/*^!/_A:6?_Q-'_#UG_@G'_T>5\"?_"TL_P#XFOM;
M_A7_ (#_ .A)\(_^$WHW_P A4?\ "O\ P'_T)/A'_P )O1O_ )"H]SM+[UY>
M7K^'F'+C/^?N&_\ !%7R_P"HCU_#S/BG_AZS_P $X_\ H\KX$_\ A:6?_P 3
M1_P]9_X)Q_\ 1Y7P)_\ "TL__B:^UO\ A7_@/_H2?"/_ (3>C?\ R%1_PK_P
M'_T)/A'_ ,)O1O\ Y"H]SM+[UY>7K^'F'+C/^?N&_P#!%7R_ZB/7\/,^*?\
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M?_Q-'_#UG_@G'_T>5\"?_"TL_P#XFOM;_A7_ (#_ .A)\(_^$WHW_P A4?\
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MI_\ 5W:!7Z;U3^"/^*7Y0.>'^\XC_KWA_P ZP4445)T!1110 5X=^T)^T/\
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M$-I=O=V N)OM,TUM;_.-K_P5$_9DO/&<VB0VOQ;/PWB^(8^$G_#29^&&O?\
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M_P#4!\55_HFU_G9?\$Q/^4E7[$__ &576/\ U ?%5?Z)M?RIXM_\ECB/^P+
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M\-_!_C3]E3]NSX?:C\6/'6B_#GP1=>.?V>5T#3M6\4ZY-LMK.*>?QC)/*EM
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MM;:PL=/TZXN[FVB'VO[-I]K;2,S!+=$.RO#O^'DO[ /_ $>/^SI_X=;PE_\
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MMX2_^6='_#R7]@'_ */'_9T_\.MX2_\ EG2?M)6NI.VWNVWMKHMWIKOL72>
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M9PW_ $$4/_!M/_Y+S7WGVS17Q-_P\E_8!_Z/'_9T_P##K>$O_EG1_P /)?V
M?^CQ_P!G3_PZWA+_ .6='++^67W/^NJ^\/K.&_Z"*'_@VG_\EYK[S[9HKXF_
MX>2_L _]'C_LZ?\ AUO"7_RSH_X>2_L _P#1X_[.G_AUO"7_ ,LZ.67\LON?
M]=5]X?6<-_T$4/\ P;3_ /DO-?>?;-%?$W_#R7]@'_H\?]G3_P .MX2_^6='
M_#R7]@'_ */'_9T_\.MX2_\ EG1RR_EE]S_KJOO#ZSAO^@BA_P"#:?\ \EYK
M[S[9HKXF_P"'DO[ /_1X_P"SI_X=;PE_\LZ/^'DO[ /_ $>/^SI_X=;PE_\
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M7UZ/JU;\U]YST\1A_K&)?MZ-FJ%G[6%G:,KV?-K:ZV[H^V:*^)O^'DO[ /\
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M2BI*2BG02YDDE)+;F2LD]]M36O?V??%'C7]M'1?VC/'UWHC>!O@I\*=1\"?
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M;2*)2&E*F:221['_  \E_8!_Z/'_ &=/_#K>$O\ Y9T?\/)?V ?^CQ_V=/\
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M.TR2>8X;T'_AY+^P#_T>/^SI_P"'6\)?_+.C_AY+^P#_ -'C_LZ?^'6\)?\
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M+EC[KZ]'W1A2Q&']KBOW]'6M!K][#5?5Z"NO>U5]-.NA]LT5\3?\/)?V ?\
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MM]]G]P1J8*"BH5,+%1;<5&5**BY*S<4FK.2=FU:Z>NYK^ _V?/$S?M>_%_\
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MX_\ $/Q1\;FRFOIF\0^/O%9MF\0^);QKZ[NS'>:D;.V\V&U-O91"%1;VL(+
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MISHTH59U4K/%UH)^SE4DY2JOEBHPC*3;:Z(^W_\ A07P)_Z(K\)?_#<>#O\
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M"7_PW'@[_P"4U'_"@O@3_P!$5^$O_AN/!W_RFKUJBB[[O^O^&7W![.'\D/\
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M ,-QX._^4U'_  H+X$_]$5^$O_AN/!W_ ,IJ]:HHN^[_ *_X9?<'LX?R0_\
M 5_EY+[C\@O^"I7P9^#^B_L[^ +K1_A1\-=)N9?VK?V4K&6YTWP+X7L)Y;*^
M^-WA*UO;.2:UTN*1[6\MI9;:ZMV8Q7$$DD,R/&[*?TC_ .%!? G_ *(K\)?_
M  W'@[_Y35\3?\%7?^3</AY_V=O^R1_ZO7P?7Z9T[OECK]J7Y0.>G"'UK$>Y
M'2EAK>ZM-:_EY+[D>2_\*"^!/_1%?A+_ .&X\'?_ "FH_P"%!? G_HBOPE_\
M-QX._P#E-7K5%*[[O^O^&7W'1[.'\D/_  %?Y>2^X\E_X4%\"?\ HBOPE_\
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M221V"(BLS$ $T:JVZZK?;NON_#R$E2=^54WROEE91?+))-IVV:5KK=:'E?\
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M]6PW_0/0_P#!5/\ ^1\E]QR_VAC_ /H.QG_A36_^3\E]QF_V-H__ $"M-_\
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MP/3Y&?M<):,E4P_+*7+%J5.SE[ONIWW5XZ;J\>Z/I/\ X4%\"?\ HBOPE_\
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M?\T8480]KBO<C_&A]E?] ]#R/)?^%!? G_HBOPE_\-QX._\ E-1_PH+X$_\
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M$J$5.E"I%*O&%/VTJ7LY5'2=.M+V;Y8N/+43]ARN"DG2CS2G;YR^$?PKU?\
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MK3U\*7GA[QSJFFZMJMWJ5I)ITFI2ZI!<:7 EG+;ZG;VR1,XEMI6.ZOD33_\
M@DM\%],\ ^-OA-;?%OX\2?"GQ3\>O!O[0^@_#Z^\3^'-1T#X<>-?"7C_ %/X
MCW-EX&-YX4EO[+0O%6OZE_Q4=KJ-YJ5S/;6=H+.[LYUFGG%46EWK[K;L]6KW
MV6]N77K;R05<#5YYNG3@E;%TZ-I)>RC6AAG!QNWRQYZ==-1LXNI=*S;7RKX?
M^ &I_M@?\%&O^"D7@'XE_'_]H_P[\)?A7+^S?+X5^&OPL^,OC+X;:/!XE\8_
M"2ZDG\0O>^&=0M-4C33!827%GH-G=VN@7>J7UQJ>LZ;J=RD!B^//#7Q^^.6O
M?L6?L;6>N_%[XF>(/$'P[_X+"6/[-NI>.KOQ/J]KXJ\:?#CP;XV\66.C:1XX
MUK3+RVN/%$%QH\MA8ZDNM&6/5#8Q+=P3^2CM_1K\,OV9O!'PK^.W[1/[0.@Z
MKXCN_%W[2LWPVG\;:=J=S82Z%I;_  O\-77A?0AX=M[?3[:]MA=V%W)+J7V^
M^U#S;E4:W^SH&C;Y@7_@EC^SM+^S7XX_9CU#6OB7>>%?&'Q[\2?M*:;XO@\2
M6FC_ !!\!?%G7M>7Q%:>(O!&OZ+I-A%I<OAV^$D>C_:+&]D%K<7,%[)=B8D2
MIQ6^J7L[*W:-I=/O[[(<\#7M)PY54F\:Y2]HUS*>)C6PT6]=.2+BM&J?,]-7
M?D_V@?'FMZ#_ ,%5?V(O#4?C/5M&\)7_ .SG^UEXA\4^'4U_4+3PS?'0['PI
M+IFN>(=!AO(=,U!M((O9+&^O[:22SVW/V6:(^8:_"WXL^(_B9\0_V?/CY^U3
M\,K_ /X*,?';QAHUW\3_ ![X8_;,T[XUS?LQ?LW^&M*\(ZOJKZ8_PP^#-S\0
M+N+Q)\/O"D.F?V))9GPA?7?BNYM+\0WMF]S"EG^_OPH_X)A?"KX<_'#PA^T;
MXI^,/[0?QT^,'A;P;X\^'TWBOXV^/K;QD^N^"_'>FVNER^&KNP71-/T_2](T
M."*^N-,M/#MOI"W.H:UJM_K3:I<7"/%X])_P16^ 4W@?Q-\%YOCO^UH_[-VN
M?\)/)I'[-J?&6XM_A+X1G\2W%WJ(&CZ;;:1#K-YINB:W>2Z]HV@:_K.KZ%'J
MRQ7%]I]\JE&:E!6UU2BKV>MF[VLT^JW:36Z=K$U\+C*_.W3C'VDZLXQ]M%RI
M2E1PU.E)N494TDZ=64G"$JD)->RE[TI/X/O?A/HOQ\_X*8_\$K/BG\1/$7Q)
MN/%_Q9_85D^+GC+4- ^)7C?PM9W/C3PCX6\%ZI:OI6G:%K5E9:%HVKWLSW'B
MKPYI$5IHOB9I9#K5E>&60MQVE_'3X]:O\+]=^!GA_P"-WC_P'-^TO_P6F^/7
M[-^N_%N#Q)J%YXS^'_PEM]>N=3G\*?#O7=9GOO\ A$[[4K:P30_#7V!8X=(2
M:Y73;>%Y"1^SNO\ _!.+X=:I+^R#K.A_%OXV>!_&_P"QGX,MOAW\/_'GA#Q%
MH&GZ]XL\##3O#VF:KX9\?P7/AF\T?5].UZU\-6$>J+I^FZ6\B27<<311S!4B
MNO\ @F%^S?K'P8^+OP0\2OXWU_P]\6?VAO&7[3X\1/K\.C>-_AW\7/%VMQZ_
M'X@^&WB;P]I^E7GAR?PWJ$?_ !(9R+N[2WEGM=0N+^WGDC9JI"UG=V225KVM
M)NZ\K6=O*P?4<3>IRJ,'4<YRDJG*ZCG0PT91DXWDFYTZT7-)V4^:-[V/CC7/
MAKK?_!.[]M?]AWPS\&_C=\=O'/PM_:Q\7>.?A#\4_A%\:?BKXK^,%J+SP_X(
MF\3Z/\4?"VH>,[W5-8\-ZM87]NJ>(!I]U#I=Y;3K"MK;QRNH^(_AG\!/&_Q;
M_P""?7[7'[67B[]J[]K*U^*WP?\ &O[7FL_!%O"OQV\;^&O#7PYA^$OC7QCK
M&AV7_".Z=J,=CXL&I:E821:M+XL&KM'HSVNCZ1_9EM8PU^UGP'_X)R?#?X/_
M !?TCX^>-OB_\?\ ]ICXN^$O#U_X5^'?B_\ :(^(">-9/AMH>K0"TUF/P7I=
MAI.B:1INI:U:#[+JVNRV5SK%[;M+%)>!990W>>!?V&_A=\/_ -F'XN?LIZ1X
M@\;7/@'XR7/QHNO$>L:A?:/)XHL7^.-]K5_XH72+J#1H--A73Y=<NET7[5IE
MV84CA%V;PARZ4TK:MM.-Y6=VE)M[Z[-+7?5;;W]1J3<^:FJ=-QQ#I4%4;C2G
M.GAHTWHU%7J4ZM1**<82DI)\S=OQS_:"\0_M2_'OP-^P1\:-9\/?M$?'K]GO
MQ#^R;X>\:_'+X0?LC_%X_"#XUW?Q<\1:/X=NX_B7JN@^&-9\/^)_&WA*-)KZ
MWT[P_P"']2LK2TU>?S+@*A^SW7Z"?\$EOB;HWC3X-_%'P=IOQI^-?Q3D^&'Q
M?UW08_"?[2?A+6O#'Q]^".A:E96.I:#\+?B/>>(+_4-3\8WFC1F\DTWQ=/,I
MU"RD%MY41LO+7IO%O_!+?X/:SHW[/K>"/BI\>/@O\2OV;_A1IOP3\$_&?X2>
M-[+PO\0=8^&NG6UI"?"_C,MH=[X<\2:=<W%G%J+0W.@HMOJ!:>S%OD*/H[]E
MC]D?X;_LF^'?&&F^#=9\=>-_%GQ*\52>-_BC\4OBCXFG\7_$7XB>*WM8K"+5
M?$FMRPVL)2QL(8K'3=/T^RL=.L+92EO;(7D9E*4'"RWOHK;:[OY=G=[-:7+P
M^&Q,,5&K4V=-*I*53GN_94XVARJ,OXD;N%55*:UG3FI2LOSK^,7ASQ%^VC_P
M4U\>?LI^//BY\7_AO\!?V>?V;/ _Q2MO ?P?^(WB/X4:K\4?'GQ(\0ZAIC>)
M/$7B;PA>:9XCO] \'65K%:66G6NHP6D6LRPRS!EFN(9_RP\4>%_&_P"S+^R_
M_P %W/#?A?XU?$OQ;XH\!?'K]G6#1?BU?^,=4D^*']EWI\#"SM-=\9:7/9:I
M<ZWI&A7R^'=5U#SHI[V"W?[8"9Y4/]%'[2_[!_PY_:-^('@_XRV/Q!^+_P !
M?CCX*T*_\(:;\8?@-XPC\&>,]1\#ZG<"\O?!7B0W6FZOI'B+PZU^JZA:6NJZ
M9<2:=? W%C-"S.&\Q^$W_!*K]FOX7?"K]I_X-WNJ?%#XH>#?VNKG3M2^,4GQ
M0\9/XE\2ZMKEEI)L+CQ#;^*$L;+65US4-2/_  DLU_=75V]KK<<$NGK:6MO%
M:J1G%):Z+D]RVEU*+;OUND_RTTOG6P5>I4JVC'FF\4UB75=W"MAZE*E3<+7C
M[-RC%VNE&/-&[G-+S#]NCQMXJ\/7?_!**#1O&'B/0I?&7[9WP.T7Q-#I7B'5
M-+D\6:+=?#WQ-=:GI.OI9WD#:]I5S.D$^H:?J0N[.XE6.2YA=PIK\G]/\9?M
M'?ML?$[]JGXF^)?A%^W_ /$BT\$?'_XG_!/X/2_LP_M+^%/@9\.O@SH_PUOK
M73=/:/P?+XT\,WGB+Q]<7#+KGB#5?&6G:OIE_!=V5O;0&W$BK^OGA/\ X)&_
M"?1O%_P/\=>,OV@_VJOC%XA_9R\>>%O&GP<?XK_%*V\4:9X+L_"T5Q#%X3T[
M1AX?M-+.DZM&UA%K.J36LGBFYMM'TZS@UVVM(YH9^F^*'_!+3X5^-/B5\3?B
M7\-OCA^TQ^S3=_'"=;WXU^%_V?\ XG+X,\'_ !,U9H3:76OZOHMWHVL)I/B+
M4;)Y+74M:\-RZ/>WJS3332-<RO,SC*$4E=72^*TOYKO:SU3MZK7057"XNLW.
M47&#J*3H1JTY2DEAXTE)RG3G3?+-2?*ULU4C+GBHGJG_  3@\6?M$>+_ -D'
MX7WO[5&GS6GQJTG_ (2+PSXDO;O5O"^MZAXBL/#OB#4=,\.>)-7O_!VIZMH$
MFN:MH$&G2ZX+.\).KI>RRQQR2$'\;=!\!>'_ (!?\%$/^"Q7[1GA.X^(VJ>-
MOV?/@3X%^,'@C2M3^)GCW4O#VI^*/&/PK\>:UJ=OXG\/S:XVG>*?#VG7R(WA
MO0=8M[O3?"=K$(/#L&FK%$8_Z'?@1\#?AI^S9\)?!7P2^$'AY/#'P]\ Z5_9
M6@:6+B>]N"LEQ->WVH:CJ%T\EWJ6JZKJ%S=:CJ>H74CSW=[<S3.1N"KX-JO[
M#?P[O_VJO$W[5=IXV^)6CZQ\1? .G?#GXO\ PKL]9TJX^$/Q=T#1=%US0-$'
MCCPQJ6BWMY<SZ5IVO7,=N-.U;3[=GBB>:"3S;P74QFDY]%);=[23:MK:Z36]
ME?>QTUL+5G2P,5:53#3BYSG)3FG]7J4G44W&"G*%24*C?+%RY.914K(_&S7_
M -G+X@>$O^"<-M_P4>L/VUOVEI_VM;/X*:)^U'>>-]0^,WB.\^$>LZGJ>D:?
MXQN?A7-\'9+C_A72>!9;6Z;PA8Z/;Z)%.E[Y1-RT+-9U_0W\%?&]_P#$SX.?
M"CXC:K8+I6J>/OAOX(\9ZCIBJZII]_XG\-:9K5W9HLG[Q8[:XO9(HP^7"(H8
MDY-?FE!_P1F_9\CM;+P#=_&/]J/5/V9]-\2IXFT_]D?4OC%?W'P$MY8=476[
M;0&T7^SU\1W/@ZUU91?6_A6Z\23:2DW_ "Q*C%?KE:6EK86EK86-O#:65E;P
MVEG:6T:0V]K:VT:PV]O!#&%2*&&)$CBC10B(JJH  %%22:5G?63VMRIVM'SM
M;T73=CP="K2E)S@J<?8TJ<H*HZGM*T'+GKMM+6:DES2_>3M>HERQ/QP_:#_Y
M37_L _\ 9L7[3G_H6GUYY_P56T[XK:M^VU_P2:T_X(^)_"'@[XGW/Q(_:17P
MOXC\>>';_P 5^%=-G7X7Z ]Y)JN@Z9J>CWM_'+IRW<$"0:C;-'<RPS,Q2-E;
M]0/&/[*_@+QM^U)\'_VLM4U?Q/!\0/@MX#\=_#[PSHUG=:='X6OM(^(!A.KW
M6L6DNFS:E/?VWDK]ADM=3M((\GSH)N[OB_\ LL^!/C/\;?V:OCMXDUCQ/8>*
MOV7=>\=^(/ NG:/=:=#H>KW?Q \.6_AC5X_$T%WIMW>74%M8VR2V"Z=>Z:\=
MRSM-).A$8:G%<N^D&GIU?J%3#5)PQ,-O;8W#UHM2<7[.G+".;4EK&25&?+;6
MZ33U1^%?QWTS]JOXB_MF_LZ_L<?\%-/C9X(TW]G/XA^+/#WQ'^#NL? ?X:'P
MAX/^/'Q7^&^JPZ[IWPB^(OB;Q1X@UK7/!U]%>06UW8Z-IGG1>)FN+"&UOX;U
MX&A]\_X*,_&+Q-XS_;O_ &1?@-X)^"7Q3_:+\*_LSS?\-??&OX??"*#P]=ZN
M/$=L+_PS\!H-;_X237-!TN.RTSQ+)=^*KBSN+R26[BCL'CM)8UE9?U"_;$_8
M\^%G[:_PIMOA;\3[GQ'H/]B>+?#GCWP5XZ\$7UII/COP!XS\+7\=]I?B/PEK
M%Y8ZC#IVH!!-8W#O:3+-97<\>U9/*EC/@1^R1X-^!?Q6^/'QM@\7^-OB!\3?
MVAKWP1/XX\3>.+C0I;BUT[X?^'5\.>'=!T&WT#0]#M-.T>" SWLML89FEO[F
M:?S "% IQLGHG%-**5E=N-VFEI=7?>ZTM<R>#K<U6DI2=*K6HU)8B<_:UO94
MU*?L&JG.I1C5C!15N5TZM3F3DI.?Y4_\$NOBYXA\ ?M/?MF_LD>-_A%\2O@#
MHGQ!U;6/VP?V>OAI\5[;0[+7=,\)^.K\:9\5]%TF/P]J^MZ,='TWQV\.HZ9:
M6%_F"VOKV:6U@<S ?.G_  2@\'_\%--6_8^TB^_9S^-'[*OA#X42_%;XW+H6
M@_$WX5^./$WC"UN8_B?XD75GU'6-%\3Z9I]Q%<:B+B:S6*T1H;9HXI&9E)K]
MX?BU^R%\/?BW^T1^S]^TY?:[XM\+_$W]GFW\;Z3X>NO"]WI=K8>*O"_C_2UT
MO7_"?C*&_P!*OY]0T-H_,N;2*QN=/GMKN>:=)RY0I\)>!?\ @C;I'PKT2;PI
M\*OV\OV\_AKX.;6]>U^T\(>#/BOX4T?P]IM_XDU6ZUK56L+"'P'LA6XU"\GG
M?EF9W+.S.S,6IP:=VHM\K:<7)72L[+7??5WN9/"8F$Z22J5:=!XJ%.5*O&A4
M=.O+#5(*5N5*,)1JT^1*W+"#25U:]^W!X._;_P!2_8K^'7ABQ\:Z+XP^.+?&
M#PS-\<-)_9T\32_ /Q+\6OA!#JVM76M> /@SXE\4ZM=:CX9\87VD#13=RVVH
MC4;^WT_5TL,1S&UF\8_X)B?$?PWI'[47Q*^#>G^*OVS?A-+K7PALO&4/['?[
M;-GXR\5^)-%UCP_XG@TC7?BA\*/C!XN\1^()-:\*74&HV>EZOX=M9W26]N(=
M7CD\FW%O9_:>M?\ !-3P!XZ^ </P-^+WQW_:4^,%]H?Q/L/C!\/?C5XU^(\/
M_"Z_A9XYT>TBL]%U/P#XRT71=*72H]+C^W&WMKBPO8I/[6U%)Q)'+$L/:_LZ
M?L$^!_@+\5-6^.OB'XM?'/\ :'^-.H>#7^'.F?$?X]^-X?%FK>$_ ,^I6>LW
MWA;PGI^EZ5H6AZ/9ZKJVGV5_JMU%IKZC?36T2RW8BWQNN:/+)-KK:T;7NTUI
MM:ZW:326AK]7Q#Q5"LH.*C&FI^TK>T<8Q4HS5URSYY)ZI3J4:CM*<5):_=E%
M%%8GJA1110!^9G_!5W_DW#X>?]G;_LD?^KU\'U^F=?F9_P %7?\ DW#X>?\
M9V_[)'_J]?!]?IG5/X(_XI?E YJ?^]8C_KUAOSKA1114G2%%%% !7Y7_ /!2
M)%G^*?\ P3.M=</_ !04_P"WGX.;Q&L^W^SY/$-M\,OB5=?#B.]67,#EO&45
MB;-95.;Q83$5F$9K]4*\B^.7P*^&/[1OPZU7X6_%OP]_PD7A/5+K3-31+>_O
M]&UG1==T.^AU30/$OAKQ!I%Q9ZQX=\2:%J=M!?Z1K6DWEK?65Q$#'+Y;R1O4
M7RR3]=O--?K_ ,%;F.(IRJTI0C;FO"4>:_*W"<9J,FDVHR<>5NSLFW9[/X4\
M.B.+_@LI\1$T+*VMW_P3V\)7'Q!6U $$GB*V^/$\'P_DU8181M17P_-XP33&
MNLS_ &'[6MN1 ) ?U(KYI_9Y_9-^#_[,S^--1^'UOXOUGQ?\1[W2[WQ]\1OB
M9XY\4?$WXD>+SH5K+8Z!9ZWXU\8ZEJFMW.EZ#9SSVVC:6EQ%8:>D\[06ZR3R
MN_TM1)IM6Z1BO6R2N+#TY4XSY^52J5:E5QBW*,>>5U%-QC=VUD^5+F;M=:A1
M114FX4444 ?F1_P50_Y)+^S9_P!G^_L4_P#J[M K]-Z_,C_@JA_R27]FS_L_
MW]BG_P!7=H%?IO5/X(_XI?E YX?[SB/^O>'_ #K!1114G0%%%% !7Y;_ /!0
ME()_CU_P2^M?$#'_ (067]M5IM82;:=,D\76?P3^*-S\-%OEF!MVF7Q3'&^E
M>8IE&IK;&U*W&PU^I%>.?'?X"?"[]I+X>7OPQ^+?A^37O#-SJ6DZ[92V.IZE
MH.O^'?$OA^]CU'P_XJ\*^)-%NK'6_#?B70[^-+K2]:TB]M;VV<R1B1H)IXI*
MB[23]4_1II_=<QQ%.56E*$&E+FISCS:1;IU(U%&32=E+EY6[.R;=GL_A;P0)
M(?\ @L=\=$\/JJZ3=_L'?""Y^(PM0HB;Q=!\8O&-O\/Y-2\K"MJ3>&#XNCMG
MNMUQ]@B"Q,(%"G]3*^;_ -GK]E3X1?LS0^,IOAW:^*]5\3_$75+#5_B!\0_B
M/XU\2_$GXD^-+O2+-M/T2/Q%XW\7ZAJFNW]CH5@\EGHNFFZ2PTR":<6MM&]Q
M.\GTA1)IM6V48I:6>B6ZN^OF*A3E3A+GLI3JU:KC%N48^TFY**;4;V35W97D
MW;0****DW"BBB@#\R/\ @IY_R+/['/\ VD%_92_]32XK]-Z_,C_@IY_R+/['
M/_:07]E+_P!32XK]-ZI_#'_M[\SFI?[SBO2A_P"D2"BBBI.D**** "ORY_;Q
M2.?]JG_@EC:^(_+/@&3]JCQW<:@ET4^P/X^LOV?_ (D7'PP%PLV86NDUM;R3
M2RZF5=06%K5DN1&3^HU>+_'K]G_X6_M*^ )?AQ\6M"N-9T%-9TCQ-H][I>KZ
MIX<\3>%?%GA^Y^UZ!XM\'^*="NK'7/#/B?1;DO)IVLZ1>VUW"LL\!=[>XGAD
MJ+49)O;5:>::_4QQ%.56DX1MS*5*:4FU&3I585.632;2GR<K=G9.]GL?#OPQ
M!B_X*_?M41>'%MUT:Y_8Q_9ON_B(+38$/CI/B)\5[?PA)J(BPIU:3P@NHH7N
M ;MM,AT\9%LL.?U*KYU_9Z_9:^$G[,UCXNC^'-GXFU#Q!\0=9M=?^('C_P"(
M/C'Q'\1?B1XYU33[)=-TJ;Q3XX\7:AJ>O:K#HVFK]@T:RENEL=+MFE2SMHC/
M.TOT51)IO39**UZV26VMMNXL/3E3A)3LI3JU:KC%N48^TJ2GRJ34;VOJ^57E
M?3J%%%%2;A1110!^9/\ P4B_Y#?_  3]_P"TA'P+_P#3/XYK]-J_,G_@I%_R
M&_\ @G[_ -I"/@7_ .F?QS7Z;53^&/\ V]^9S4O]XQ7K1_\ 384445)TA111
M0!^(?PM^ /PZ^ G_  62TVU\#6NM7&J^/OV%/BKXX\>^+O%GB+6/%OC'QGXH
MU#X_?#V)M2U_Q#KMW>7UQ'8645OI>C:; UMI.B:5;6^G:58V=K&(S]3?\%8O
M&GB/P-^P'\?+WPKJ$^D:KXFM/ OPSEU>V=XI]*T7XL?$OP=\-/$FH13(RO ]
MKX>\5:G*)U8&#'FY&S(^LKCX#?#FY^/FF_M+2Z=J!^*^D_"S5?@W9:J-6OET
MM/ NL^)M,\77UB^AB7^SI+U]:TBRF34FB-W'"CVZOY4C"J7[2WP-\/?M*_ 3
MXK_ GQ1)]FTGXF>#=6\-C45C$LNC:I-$+C0=?MD/6ZT#7;?3M9M<%3]HL8\,
MIY&CDG*#=WRJ*E?6]I-OUT9PK#3AA\;2I\L76E6E2Y=%'VE*,8WT7++F3;:O
MO>[9^1/QV^&_Q+G_ ."F7[&_P4^"WQ#T3X$^%_"_["'Q,T_P1XO_ .$(\.^,
MM4\)V^C^,_ NE>((/A-H/BR*[\)6_C*\\/Z9X8T>^U+5=(U=-.\'RZJL=A))
M<QR1]C\-IM;^,?[._P#P5+_9A^.DG@CQCXJ^$'B'QWX%\4_'#POX'\._#]OB
MV^M_!30/'7A+QUXWTOPO:6VC)\4?!T-QI&FZ[J%E$L<3:#H5Q!!:JL<*_7R?
MLI6?[3/P)^ UG^UWX5U?PQ\??A!8+'9^/OA?\0]4\)^-_"_BVQM1X8USQ7X#
M^(O@#5;#5]+TCXB:;IMMK%[HK72(]E?VVG:WIJWVFJL&#\5OV0YOAW^Q]X\_
M9B_8_P##;:'JGQLU>X\,^-O'OB+Q3/JWB2PL?B?>1:;\6OC/XT\4^*-3F\3>
M//&-OX3.H"UWWM_K>H:H^C6D"P:=:,UH^9>ZF]597Z*TKN7->[NNEO._?!8:
MI&56JHMTZD9U'3<ZG/*,\-"FJ#P_+[.$E./\1-R45R.R<K>O?L#_ !$\2?%G
M]BG]ECXC^,)9KGQ3XN^!GPYU77[VY,AGU'5&\-V,%WJDSRN\DDFJ2PMJ#3.Q
M>8W)E;!? ^N*XKX;> ?#OPJ^'G@;X9>$;467A?X?>$O#W@OP]:X7,.C^&M)M
M-'T]7*A0TOV6SC::3 ,DI=SRQKM:S;NVUI=MV]6>E2C*-.G&;YI1A",I=Y**
M4G\VFPHHHI%G\Z__  <G?\FD_L__ /9UWA#_ -5W\2Z_C_K^P#_@Y._Y-)_9
M_P#^SKO"'_JN_B77\?\ 7]*^"W_)/YG_ -C>7_J'A3_-;Z9G_)PN'O\ LE*/
M_JTS$****_8S^0 HHHH *_1[]F+S8_V"O^"D$NF+$-7:U_9@M;Z6,?\ $P3P
M;<?$;Q*VOI$T9$XL)=3B\/+J*#=:NHM_M*-MC*_G#7LOP1^/GQ+_ &?/$FK>
M)?AOJ>F6\GB+P]?^$O%6@^(]!TGQ9X0\7^&-3,3WF@^*O"FO6M[HNNZ8\\$%
MRD%]:R>3<PQS0LC!MWFYMA*V,P7LJ'LW6IXK+\7"%63A3JO 9AAL=[&4XPJ.
M"K+#NES^SFH.:DX22:/I^#\VP62YVL7F#Q$<'B,JX@RBO6PE.%;$86&?9#F6
M2+&4J$ZM"->6#EF$<2Z'MZ+K1I.G&K3E)27UY^T28)?^"=O_  3VFU1B_B5/
M$_[4EIICW+,UZ/ L/C/PT=.BC,N9AI,6LMJ*6*(1:1MY@MU&7K\WJ]J^-_[0
M/Q-_:$U[0]=^(^IZ5)'X4\/6GA+P?X;\,>'](\(>#/!WAJR=YHM%\*^$O#]K
M8Z+HED]Q+)<W"6=JDEU</YD\DGEQ"/Q6EE&$K8+!NEB.15JN+S#&3A2G*I3I
M/'X_$XU483E"FYJBJZIN?LX*<HN2BDTA\89O@LZSI8G+O;2P>%RCAW)J%?$T
M8X?$8N.0Y!EN2RQM:A"MB(T98N> EB(T?;U72IU(4Y5)SA*3****],^7"BBB
M@#[;_P""8G_*2K]B?_LJNL?^H#XJK_1-K_.R_P""8G_*2K]B?_LJNL?^H#XJ
MK_1-K^5/%O\ Y+'$?]@6!_\ 3*/]3?HD_P#)H<+_ -C_ #O_ -/4@HHHK\R/
MZ;"OSI_:C^.OPU_9I\?76G_!;X2Z1\4?V\/VF]#T_0O!W@3PS96T7B;Q;I/@
MV&]LM%\8?%KQ$H_XICX0_#U]3O);_7M8EAA*RW6F:,ESJ$T@A_1:OSU^*O\
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ME^^-'_K.WCFOTRK\S?VT?^3P_P#@EM_V7[XT?^L[>.:_3*J?PQ_[>_,YZ/\
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M,?\ #?\ ^9RCW?[WW+_/U_I:G^U]L/\ ?4\O+U_#S.M_X:]_9-_Z.@_9W_\
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M#7_YIJY+_A@?]AW_ *,^_9F_\,?\-_\ YG*/^&!_V'?^C/OV9O\ PQ_PW_\
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M )G*/=_O?<O\_7^EJ?[7VP_WU/+R]?P\SK?^&O?V3?\ HZ#]G?\ \/7\-?\
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MM_&GPGI^LZ3-<V.A032Z=JMA--8ZC9NYM[VTFEMKB.2&1T/Z(?\ # _[#O\
MT9]^S-_X8_X;_P#S.4WR\L=_BET6]H7ZG/#ZU]:KZ4+^RP]]:EMZVVE_YM_+
MS.M_X:]_9-_Z.@_9W_\ #U_#7_YIJ/\ AKW]DW_HZ#]G?_P]?PU_^::N2_X8
M'_8=_P"C/OV9O_#'_#?_ .9RC_A@?]AW_HS[]F;_ ,,?\-__ )G*7N_WON7^
M?K_2UZ/]K[8?[ZGEY>OX>9UO_#7O[)O_ $=!^SO_ .'K^&O_ ,TU'_#7O[)O
M_1T'[.__ (>OX:__ #35R7_# _[#O_1GW[,W_AC_ (;_ /S.4?\ # _[#O\
MT9]^S-_X8_X;_P#S.4>[_>^Y?Y^O]+4_VOMA_OJ>7EZ_AYG6_P##7O[)O_1T
M'[.__AZ_AK_\TU'_  U[^R;_ -'0?L[_ /AZ_AK_ /--7)?\,#_L._\ 1GW[
M,W_AC_AO_P#,Y1_PP/\ L._]&??LS?\ AC_AO_\ ,Y1[O][[E_GZ_P!+4_VO
MMA_OJ>7EZ_AYG6_\->_LF_\ 1T'[._\ X>OX:_\ S34?\->_LF_]'0?L[_\
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MU_\ FFH_X:]_9-_Z.@_9W_\ #U_#7_YIJY+_ (8'_8=_Z,^_9F_\,?\ #?\
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M_P"::N2_X8'_ &'?^C/OV9O_  Q_PW_^9RC_ (8'_8=_Z,^_9F_\,?\ #?\
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MC_AKW]DW_HZ#]G?_ ,/7\-?_ )IJY+_A@?\ 8=_Z,^_9F_\ #'_#?_YG*/\
MA@?]AW_HS[]F;_PQ_P -_P#YG*/=_O?<O\_7^EJ?[7VP_P!]3R\O7\/,_#+_
M (.'?C[\"OB)^RQ\"M*^'_QJ^$OCK4[#]J#PGJE]IO@[XC^#O$]_9:;%X!^(
MMO+J-W9Z)K-]<6]C'/<6\$EW-&ENDT\,32!Y8U;^4'_A(O#_ /T'M%_\&MA_
M\D5_5#_P<&_LM_LU?"7]EWX':W\+?V?_ (,_#K6=4_:;\*Z+J6J^"/AIX/\
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M%X?_ .@]HO\ X-;#_P"2*J_\(AX4_P"A:T'_ ,%-A_\ &*/^$0\*?]"UH/\
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MQ1?/OY<H_P# L;Y?W/7\/,+<%_\ /SBC_P $Y3Y?]/\ U_#S/M+_ ()O^._
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MLF_]'0?L[_\ AZ_AK_\ --1_PU[^R;_T=!^SO_X>OX:__--7)?\ # _[#O\
MT9]^S-_X8_X;_P#S.4?\,#_L._\ 1GW[,W_AC_AO_P#,Y1[O][[E_GZ_TM3_
M &OMA_OJ>7EZ_AYGPI^V!^TS^S?K'[67_!-'5](_:"^"&J:5X9^.?Q?O_$FI
MZ=\5_ =[I_A^QO/@%XTT^TO-;O;;7Y;;2K6ZOYX;&VN+^6"*>\FBMHG>:1$/
MZ,?\->_LF_\ 1T'[._\ X>OX:_\ S35^8?[7/[&W[)'A_P#:M_X)MZ#H7[,7
MP"T?1/&?QP^+NF>+M(TSX1^ [+3?$^G:?\!?&>J6-AKUE;Z%';:M:66IV\&H
M6MO?1SQ6][!#=1*D\2.OZ'_\,#_L._\ 1GW[,W_AC_AO_P#,Y3?+RQWZ]%O?
M7J<]'ZU[7%:8>_MH7UJ;_5Z&VFUN_7R.M_X:]_9-_P"CH/V=_P#P]?PU_P#F
MFH_X:]_9-_Z.@_9W_P##U_#7_P"::N2_X8'_ &'?^C/OV9O_  Q_PW_^9RC_
M (8'_8=_Z,^_9F_\,?\ #?\ ^9RE[O\ >^Y?Y^O]+7H_VOMA_OJ>7EZ_AYG6
M_P##7O[)O_1T'[.__AZ_AK_\TU'_  U[^R;_ -'0?L[_ /AZ_AK_ /--7)?\
M,#_L._\ 1GW[,W_AC_AO_P#,Y1_PP/\ L._]&??LS?\ AC_AO_\ ,Y1[O][[
ME_GZ_P!+4_VOMA_OJ>7EZ_AYG6_\->_LF_\ 1T'[._\ X>OX:_\ S34?\->_
MLF_]'0?L[_\ AZ_AK_\ --7)?\,#_L._]&??LS?^&/\ AO\ _,Y1_P ,#_L.
M_P#1GW[,W_AC_AO_ /,Y1[O][[E_GZ_TM3_:^V'^^IY>7K^'F=;_ ,->_LF_
M]'0?L[_^'K^&O_S34?\ #7O[)O\ T=!^SO\ ^'K^&O\ \TU<E_PP/^P[_P!&
M??LS?^&/^&__ ,SE'_# _P"P[_T9]^S-_P"&/^&__P SE'N_WON7^?K_ $M3
M_:^V'^^IY>7K^'F=;_PU[^R;_P!'0?L[_P#AZ_AK_P#--1_PU[^R;_T=!^SO
M_P"'K^&O_P TU<E_PP/^P[_T9]^S-_X8_P"&_P#\SE'_  P/^P[_ -&??LS?
M^&/^&_\ \SE'N_WON7^?K_2U/]K[8?[ZGEY>OX>9UO\ PU[^R;_T=!^SO_X>
MOX:__--1_P ->_LF_P#1T'[._P#X>OX:_P#S35R7_# _[#O_ $9]^S-_X8_X
M;_\ S.4?\,#_ +#O_1GW[,W_ (8_X;__ #.4>[_>^Y?Y^O\ 2U/]K[8?[ZGE
MY>OX>9\0?M/_ +37[-VJ?MM?\$U-<TS]H/X'ZCHOAGQM^T[/XCU>Q^+'@*[T
MOP_#J?[/>LZ?ILVMZA;Z_)::5%J%^Z6-C)?RP)=WCI:VYDG94/Z&?\->_LF_
M]'0?L[_^'K^&O_S35^9W[37[&G[(VB?MI_\ !-[PUH_[,/P!TOP]XR\:_M,6
MWBW0]/\ A%X#M-)\36^B_L_ZSJNCP:]I\&A):ZM%I6J(FHZ?'?13K9WR)=6X
MCG57'Z"?\,#_ +#O_1GW[,W_ (8_X;__ #.4WRVCOUZ+OKU^[_@:\]#ZU[7%
MV5#_ 'B'-K4^+ZKA=O=VY;;Z\U^AUO\ PU[^R;_T=!^SO_X>OX:__--1_P -
M>_LF_P#1T'[._P#X>OX:_P#S35R7_# _[#O_ $9]^S-_X8_X;_\ S.4?\,#_
M +#O_1GW[,W_ (8_X;__ #.4O=_O?<O\_7^EKT?[7VP_WU/+R]?P\SK?^&O?
MV3?^CH/V=_\ P]?PU_\ FFH_X:]_9-_Z.@_9W_\ #U_#7_YIJY+_ (8'_8=_
MZ,^_9F_\,?\ #?\ ^9RC_A@?]AW_ *,^_9F_\,?\-_\ YG*/=_O?<O\ /U_I
M:G^U]L/]]3R\O7\/,ZW_ (:]_9-_Z.@_9W_\/7\-?_FFH_X:]_9-_P"CH/V=
M_P#P]?PU_P#FFKDO^&!_V'?^C/OV9O\ PQ_PW_\ F<H_X8'_ &'?^C/OV9O_
M  Q_PW_^9RCW?[WW+_/U_I:G^U]L/]]3R\O7\/,ZW_AKW]DW_HZ#]G?_ ,/7
M\-?_ )IJ/^&O?V3?^CH/V=__  ]?PU_^::N2_P"&!_V'?^C/OV9O_#'_  W_
M /F<H_X8'_8=_P"C/OV9O_#'_#?_ .9RCW?[WW+_ #]?Z6I_M?;#_?4\O+U_
M#S.M_P"&O?V3?^CH/V=__#U_#7_YIJ/^&O?V3?\ HZ#]G?\ \/7\-?\ YIJY
M+_A@?]AW_HS[]F;_ ,,?\-__ )G*/^&!_P!AW_HS[]F;_P ,?\-__F<H]W^]
M]R_S]?Z6I_M?;#_?4\O+U_#S.M_X:]_9-_Z.@_9W_P##U_#7_P"::C_AKW]D
MW_HZ#]G?_P /7\-?_FFKDO\ A@?]AW_HS[]F;_PQ_P -_P#YG*/^&!_V'?\
MHS[]F;_PQ_PW_P#F<H]W^]]R_P _7^EJ?[7VP_WU/+R]?P\SXY^+OQE^$'Q2
M_P""DO\ P3:@^&7Q6^&WQ%GTFQ_:\DU2'P)XZ\+^+IM-2Z^"J"U>_B\/ZIJ#
MV:7)@G$#7"QK,891&6\M]OZ]U^-GQ*_9[^ WP4_X*3?\$W[GX._!?X6?"RXU
MRR_:Y36;CX>^ O"_@Z?54LO@H#9QZC-H&F6$E[':FYN3;I<-(L)GF,84R/G]
MDZ)?9_PK]2,+S\^,]IR\_P!9C?D;<?\ =,+:W,D]K7OU/S0\-_\ *7CXI_\
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M?7M2T*.YU2RC&BWLLNVUCDD2^C2WE4KYBU]^?!/Q=_P50U'XF^&+/]H#X/\
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M\MK=_P#!/CPE<?$-;0 6[>)+;X[S0_#^35O*^0ZE_P (]+XO33FNLW!L%N1
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M,\L<4LSQ)\;?L)Z-\/\ XW?!O]NWXD?M!:9X<U_2?B_^US\?],^*EMXT,/\
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M?"7C;P#KNI0@HCS:3?\ C#Q'I5KJ$IFFB@U:XLXE2.9R?U&J)*UO.*>OW/\
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MMKS2==T[[7I%^R7MM;7DEUI]]!;^D5^6WC:_G\#_ /!7#X S^'9)(K7]H?\
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M\F*XN#;W5O\ H;_PLSX;_P#10?!'_A5Z#_\ )]'_  LSX;_]%!\$?^%7H/\
M\GT<\N_5O9;M6?3MTVZ[EO#89J,7!6A"G3C:<DXPI3C4II-237).,9)WYKK>
MUT?F-XB_X)B^/_#/C#XNWO[*W[;'Q=_9=^&/Q_\ %>M^.?BM\*/#O@SP)XXT
MN'Q=XK8#Q?XA^%>O^*+0:O\ #'4?$:&2:[>Q_M>.WOW6\M(X5@@MX_:=+_X)
MZ^ O"OB/]AG4O!OC?Q58:%^P^_Q#?0=,\1O)XNUSXBR_$/P5>>$]3OO%'BK4
M+Z"[M]3%U?7&NS7-O9SV\]Q*UC;6=A9) D/VA_PLSX;_ /10?!'_ (5>@_\
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MMT&KZIIT]_;WEZL=\UBLD4:#]'O^%F?#?_HH/@C_ ,*O0?\ Y/H_X69\-_\
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M&_Q!^%-R^H^%/%7AZQMK*P%L\EY9Z@-2M1JPNA<RR*?TN_X69\-_^B@^"/\
MPJ]!_P#D^C_A9GPW_P"B@^"/_"KT'_Y/H4I)63LKWV771[KJMUL74H4*LN:H
MKR<8PNJDXNT9^TBURRC:4)^]":M.#;Y9*[O\E_LF_L1V_P"SMXV^)_QN^(WQ
M@\:?M&_M)?&2TT/1O'?QC\<:;H?AXP^$_#!F?0/!/@KP?X:MX-%\(>%+&>=[
MR73[:2\GOKX1W-W>2&&)$^U=?TI==T+6M$>9K=-9TG4=*:X5!(T"ZA9S6C3+
M&2H=HA,7"%E#%0I(!S7/?\+,^&__ $4'P1_X5>@__)]'_"S/AO\ ]%!\$?\
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M"[?_ ..5^P^VI?\ /VG_ .!Q_P S^0_JV)_Z!Z__ (*J?_(^:^\O5]0?!_\
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M7XIZL]U>76H6EO:VR-X$\4(KSW$LR10JSLJ*TCJ&=@H)) K_ $*O^%F?#?\
MZ*#X(_\ "KT'_P"3Z_E?Q9E&7&&(<9*2^I8+6+37\%=5H?ZD?1,C*GX186-2
M+A+^WLZ?+-.+LZM*SM*SL^CZG;T5Q'_"S/AO_P!%!\$?^%7H/_R?1_PLSX;_
M /10?!'_ (5>@_\ R?7YF?TS==U]Z.WK\_OBA_P39^ 'Q5^./BW]HO4O%7[0
M?@_XK>-]#T3PQX@U_P"&'Q_^)7PXCN/#GAZ"*'2M"@LO"NM:?!:Z3!)%]N:P
MA"VLNI37&H21-=3R2M]E?\+,^&__ $4'P1_X5>@__)]'_"S/AO\ ]%!\$?\
MA5Z#_P#)]--QU3:?D9U*=&LE&K"G42DI)349)25TFD[V=FU?LVC+^$?PMT;X
M->!-*^'^@>(/'OB?3-(DOI8-9^)?CCQ%\1?%]TU_=RWDJZCXK\57VH:S?1PR
M3-%9Q3W+1VELD=M J11JH^$;']AZWU/7?VU_V?/'&D:K>?LB?M9:WIOQJMKO
MPGXOG\*:_P"'?B)XF;3M/^,GP_FDTN\MM>M]'\57_AC0/&-A>Z>C:?<VVM>*
M] U)XXQ:Q77Z!?\ "S/AO_T4'P1_X5>@_P#R?1_PLSX;_P#10?!'_A5Z#_\
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MEQR6^G:#\2].\$>(-'L?%UE:6<T^GPRZC;MJ":;/+IXO?L9$*_4?_"S/AO\
M]%!\$?\ A5Z#_P#)]'_"S/AO_P!%!\$?^%7H/_R?33:V;7H[?D1.%*HN6I&$
MXIW2DE))JZNK];-KT;6S9=\#>!_"/PT\'>&OA_X!\/:7X3\%^#M&L/#WACPW
MHMLMII>BZ-ID"6UE864"YV10Q(HW,SR2.6EE>25W=OA/X4_L?67AN^_;"_9W
M^(G@31O&_P"R3\>?'-Y\:/!UK?WMN\>G:S\4XTE^+7PVO=+AN+;5M-31_&^A
MQ_$#PEKVFB)8/^$N>*VO+;5=$\^;[?\ ^%F?#?\ Z*#X(_\ "KT'_P"3Z/\
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M74(X]0FNHHOMVN(_X69\-_\ HH/@C_PJ]!_^3Z/^%F?#?_HH/@C_ ,*O0?\
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MRTV-_P#X=;?\$Z_^C,_V?_\ PWVC_P#QJC_AUM_P3K_Z,S_9_P#_  WVC_\
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MBYF2..,D\%Y/9O[V)X;"13E*AAXQBKMRITTDENVVK)*VK?G?=GRK_P .MO\
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MS_\ ^&^T?_XU7WM11=]W][#ZKAO^@>A_X*A_\CY?GW9^ /\ P4>_X)Z?L/\
MP\^&7P"U+P/^RU\%_"U_KW[:_P"R3X,UF[T7P5I=E/J7A7Q7\7=%TGQ)H%Y)
M%&#-I>M:;/+9:C:MF.XMY&C<$&OT(_X=;?\ !.O_ *,S_9__ /#?:/\ _&J\
M^_X*H?\ ))?V;/\ L_W]BG_U=V@5^F]4V^5:OXI=7V@80PN&^L5U]7HV5.A9
M>RA97=6_V>ME?N?!/_#K;_@G7_T9G^S_ /\ AOM'_P#C5'_#K;_@G7_T9G^S
M_P#^&^T?_P"-5][45-WW?WLW^JX;_H'H?^"H?_(^7Y]V?!/_  ZV_P""=?\
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MUJ<>((8;VL*CHRI^WDE2]I&K3E2E#GYE4A.#7-&27R-_PKOP+_T*>B_^ O\
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M^'6W_!.O_HS/]G__ ,-]H_\ \:H_X=;?\$Z_^C,_V?\ _P -]H__ ,:K[VK
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MIT[-NR26FMW:W>_F?&W_  ZV_P""=?\ T9G^S_\ ^&^T?_XU1_PZV_X)U_\
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M /#?:/\ _&J/^'6W_!.O_HS/]G__ ,-]H_\ \:K[VHHN^[^]A]5PW_0/0_\
M!4/_ )'R_/NS\!/VLO\ @GG^P[X6_:F_X)S>&/#G[+/P7T;P]\0?C9\6-&\;
MZ/I_@K3+:P\4:5I7P+\7ZYIMAK5O'&$OK6RU>SM=1MX9@R1W4$<H&17Z"_\
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MPA_8Q\*?#C]H7QM\)_C1^PYX87PI\)_COH'A30=8GU#2-0\,Z;X5\6Z?XF\
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MKP//K5O:I?3Z3#XHT2]T6348;*6:WCNY;-+PW"6[W$*3-&(VEC#%AP7[/WP
MLO@)^S'\+_V:[/Q-=>);#X9_"G1OA;!XMN=,BTR\U>WT?0ET-=9FTF*\O(;.
M>=%^T-9I?3QQL?+%PP^:H37*E?53O\K+7\#KE3F\4JB7N?5IT^:Z^-U(22M>
M^J3=[6TWN?S??L(?'G_@IW\ ?^"2WPG^)OP+^ 7[,_Q7^#O@3P;X]US2;>[\
M8?$E_C)-X:LOB)XSN?$.M7?@^QTVST/4KC1;D:G>C1]%UJ;4+_2;2/[)!-?R
M&W/Z(?L-:[\.OV6?V OC]^WKK_QG\._&N7X\7WQ#_;%^)'B[PGHLWA3PE_PE
M>KZ6 OP[\+^'=0GDU339](U6QC\)/9:RT.M3>('FM[RWMY@D*_H7^Q5^RYIO
M[&W[+WPO_9EL/%UU\0M-^&FFZ_IL?BK4]%M]"N=;BU[Q3KOB:5KC1K>_U6WM
M1 VN/8B-;ZY$L5NLKE6E:-?@:]_X(YZ%%X)^,?P,\+_M">)O#'[+_P 8_P!I
M3P7^T+J'P)A\#6%Y8>&+/1-?3Q1XR^%OACQ)_P )1:2V'@WQYK=KI=S*HT8G
M0HM.CBM[6_>>>9M)3A*4MDG--NSO*-]4][-;JR2W\CSZ6%Q6'IX5Q4J]2G@O
M9*G4J04<-B%1C%2A;DC*G)ITYW<Y12@Z;2<[_A]H_P ;XO@+\"OV2_VHI/@S
M^U98_M1_";]I3Q5^TY^TUXZ\1_LX?$3P]X$\3>"?VC=3E@^/6@S^/-0TZ'2F
MTG3?"%WH,&AZA>/#IT[Z!'-;-#]HMV3]7/\ @H1XO^+VI?\ !1?_ ()>>,OV
M3])^&/Q$\=Z[\+_VE=:\#V_Q'\0ZQH7P_P!;\/ZQX+T"\GU*XUOP];7FI*DF
M@W$E[I9M[>1+F<VZR%8G9A^Y?Q,^&OA7XK_#+QS\)?%EA'<^#OB!X,U_P+KN
MGQHBHVA>(M(N=%O(H%V[(GBM+IC;,H'DR)&\>UD4C\C;S_@DI\3K'PQ^Q=#X
M#_;E\8^"/B7^Q5X%\?\ PX\%?%-?@SX5\2:GXB\*^-DMM.MK/4]"USQ;-IMI
M+H'AFUA\.P7'FZ@]Y;QQW;"UN$P6JD9-2?NOWE9WDK26]XI.R?2S>N[L1+ X
MFC3=*FY5H2>#J-TO9TJD:F%KT>9KVM1QE4JT8)\[:3E2M)7DK_6/P!\7?\%,
M-6^)>E6/[2WP>_9.\(?"62QU=M9UWX4?$KXA>(_&EMJ$>GSOHD5AI/B'0[/3
M+BVN=3%O!J#RW,;P6CRS0[Y$5&_#+XR?M)?M1_#KXF_&S4OVG?VIOVM?V-?C
M)HOQ=\3/\!;^^^%EUXD_X)UZI\-M.UQ#X'L/$FK>#?!?BW4M8L->\.EHO$>N
M:JD6IZ;?3B6>-+FSD@C_ &E^%/[)/[;O@KXB^$/%?Q _X*7>,_BOX,T+6(+_
M ,1?#F__ &<OA=X7L_&&FQJXFT:Y\0:1K4^IZ3'<%E8WEE#)/&4&U3DUXUXL
M_P""5/C[4=/^+'PM\$?MU_&KP/\ LO?&KQ'XGUSQM\";KP9X)\<W]A8>.;N:
MZ\:>&/ WQ2\5-=>(_">@ZS]IN(+>U.FZJ^F0S2>2\LC-(9BX)N[BE9?"I:6W
M^)/?KIKH[IFE>EBZM&"A'%*<9STK5</S.\(J#E]7KTDX)W:DJJJ4Y7DH33CR
M_K)X'UQ?$_@OPEXC35M!UY=?\-:'K(USPM=&]\,ZQ_:6F6UX=3\/7C?-=:)?
M&8W.EW#?-+92P.WS,:ZBN-^'7@+PW\+/ /@KX:>#;22P\)_#_P *Z#X-\-64
ML\EU-:Z'X;TRVTC2X9KF4F6XFCL[2%99Y"7ED#2-RQKLJQ]#UXWY8\UN:RO9
MW5[:V>EU?K97"BBB@84444 ?F9_P5=_Y-P^'G_9V_P"R1_ZO7P?7Z9U^9G_!
M5W_DW#X>?]G;_LD?^KU\'U^F=4_@C_BE^4#FI_[UB/\ KUAOSKA1114G2%%%
M% !7Y6?\%*K:+Q%\0_\ @G#X \0QI<_#GQE^W/X.;QMI]W&LVDZS=>$_AW\0
MO%W@;1]7MY T-Y:7?C/2-)FBL[A)()[VUM6>-GBCQ^J=>!_M(?LY^ /VH/AQ
M_P *Z\?3:_I2Z=XC\/\ C?P=XQ\'ZI_8?C7X?>/O"5\-1\+^-O!VM>3<KINO
MZ+=A_)DFM;JTN;2XO+"^M;FRNYX7J+Y9)_TKZ7]5NO,PQ%.56C*$;<S<))-V
M4N2<9N#:V4U%P;ULI'Q7X.L;'PK_ ,%B_BCI7A2WMM,TSX@?L#^$?&7Q&L=,
MMXK6TU#QEX2^-K>%_!.M:I% B1S:N?"^L>(=.@O) ;B73[18&=HK:()^J%?)
MG[./[(OA7]GOQ)\1/B)=_$'XF?&GXP?%6/P]8>-OBW\7M8TC5O%M]X>\)17D
M7A?PIIMOX>T/PWX>T'PWHK:A?W4.FZ/HMHMU?WMQ?7TES<NLB_6=$FFU;I&*
MOWLDO+T7D@P\)0A/G7*YU:E1033Y%.3:C=:7?Q2M=<\I6;5FRBBBI-PHHHH
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M17W:.W0P6#<522C%>RQLZT?>;M2G*;NKWO-II-OWM9:ZRO\ ''@O5;GX9?\
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M5#C[.?B7\$_'4/@K3?%4EO'D0WFJ^!=?L_#]_?RHAOHO#^BVPDD:Q"K^HU?
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M (7_ ,6/_F\H_P"'/G_!.3_HVS2O_"_^+'_S>4>YWG_X"O\ Y+U_I:G-B_\
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M1L?_  +M_P#XY1_:>F_]!&Q_\"[?_P".5^<'_#GS_@G)_P!&V:5_X7_Q8_\
MF\H_X<^?\$Y/^C;-*_\ "_\ BQ_\WE'N=Y_^ K_Y+U_I:G-B_P#GSA^G_,14
M\K_\PWK]WW_H_P#VGIO_ $$;'_P+M_\ XY1_:>F_]!&Q_P# NW_^.5^<'_#G
MS_@G)_T;9I7_ (7_ ,6/_F\H_P"'/G_!.3_HVS2O_"_^+'_S>4>YWG_X"O\
MY+U_I:G-B_\ GSA^G_,14\K_ /,-Z_=]_P"C_P#:>F_]!&Q_\"[?_P".4?VG
MIO\ T$;'_P "[?\ ^.5^<'_#GS_@G)_T;9I7_A?_ !8_^;RC_ASY_P $Y/\
MHVS2O_"_^+'_ ,WE'N=Y_P#@*_\ DO7^EJ<V+_Y\X?I_S$5/*_\ S#>OW??^
MC_\ :>F_]!&Q_P# NW_^.4?VGIO_ $$;'_P+M_\ XY7YP?\ #GS_ ()R?]&V
M:5_X7_Q8_P#F\H_X<^?\$Y/^C;-*_P#"_P#BQ_\ -Y1[G>?_ ("O_DO7^EJ<
MV+_Y\X?I_P Q%3RO_P PWK]WW_H__:>F_P#01L?_  +M_P#XY1_:>F_]!&Q_
M\"[?_P".5^<'_#GS_@G)_P!&V:5_X7_Q8_\ F\H_X<^?\$Y/^C;-*_\ "_\
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M_P#GSA^G_,14\K_\PWK]WW_H_P#VGIO_ $$;'_P+M_\ XY1_:>F_]!&Q_P#
MNW_^.5^<'_#GS_@G)_T;9I7_ (7_ ,6/_F\H_P"'/G_!.3_HVS2O_"_^+'_S
M>4>YWG_X"O\ Y+U_I:G-B_\ GSA^G_,14\K_ /,-Z_=]_P"C_P#:>F_]!&Q_
M\"[?_P".4?VGIO\ T$;'_P "[?\ ^.5^<'_#GS_@G)_T;9I7_A?_ !8_^;RC
M_ASY_P $Y/\ HVS2O_"_^+'_ ,WE'N=Y_P#@*_\ DO7^EJ<V+_Y\X?I_S$5/
M*_\ S#>OW??G_P#!5F^L9OV<?AZL5Y:RL/VM?V26*QW$+L%7XZ^#]S$*Y(4=
MSC [FOTO_M/3?^@C8_\ @7;_ /QROYYO^"CO_!,7]AGX6_ GP3XA\!_ ?3M
MUC4/VEOV:?"EY>Q^,OB/?--H'BOXO^&=#U_3C%J?C"]MT34-+O+BU>>.)+J
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MG_:>F_\ 01L?_ NW_P#CE?SQ_P#!1'_@F/\ L-?"_P"&OP(U7P+\!]-T&_\
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M&Q_\"[?_ ..5^<'_  Y\_P""<G_1MFE?^%_\6/\ YO*/^'/G_!.3_HVS2O\
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M^ K_ .2]?Z6IS8O_ )\X?I_S$5/*_P#S#>OW??\ H_\ VGIO_01L?_ NW_\
MCE']IZ;_ -!&Q_\  NW_ /CE?G!_PY\_X)R?]&V:5_X7_P 6/_F\H_X<^?\
M!.3_ *-LTK_PO_BQ_P#-Y1[G>?\ X"O_ )+U_I:G-B_^?.'Z?\Q%3RO_ ,PW
MK]WWY?\ P4XOK*7PS^QWY5Y:R;/^"@?[*;OY=Q"^U!XSN,LVUSM4=V. .YK]
M,_[3TW_H(V/_ (%V_P#\<K^>/_@H#_P3'_8:^&>@?LNW/@CX#Z=H<_B[]M;]
MG'P%XBDC\9?$>\.I>$O%'BJ:SU[1W&H^,+Q8(]0ME$37-H(+Z ?-;74+_-7W
M[_PY\_X)R?\ 1MFE?^%_\6/_ )O*;Y+1NY6UM[JONKW][3K;<YZ<L5]8Q'[F
MA>U#F7UBI9>Z]G]6UTN]M'IKU_1_^T]-_P"@C8_^!=O_ /'*/[3TW_H(V/\
MX%V__P <K\X/^'/G_!.3_HVS2O\ PO\ XL?_ #>4?\.?/^"<G_1MFE?^%_\
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M^T]-_P"@C8_^!=O_ /'*_.#_ (<^?\$Y/^C;-*_\+_XL?_-Y1_PY\_X)R?\
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M;_\ QRC^T]-_Z"-C_P"!=O\ _'*_.#_ASY_P3D_Z-LTK_P +_P"+'_S>4?\
M#GS_ ()R?]&V:5_X7_Q8_P#F\H]SO/\ \!7_ ,EZ_P!+4YL7_P ^</T_YB*G
ME?\ YAO7[OO_ $?_ +3TW_H(V/\ X%V__P <H_M/3?\ H(V/_@7;_P#QROS@
M_P"'/G_!.3_HVS2O_"_^+'_S>4?\.?/^"<G_ $;9I7_A?_%C_P";RCW.\_\
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MU\%_] 9?_ R__P#DJC_A6O@O_H#+_P"!E_\ _)5'M\^_Z%N4=/\ F=8SRO\
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MS_@G)_T;9I7_ (7_ ,6/_F\H_P"'/G_!.3_HVS2O_"_^+'_S>5^=^YWG_P"
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M-C_X%V__ ,<K\X/^'/G_  3D_P"C;-*_\+_XL?\ S>4?\.?/^"<G_1MFE?\
MA?\ Q8_^;RCW.\__  %?_)>O]+4YL7_SYP_3_F(J>5_^8;U^[[_T?_M/3?\
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M_@G)_P!&V:5_X7_Q8_\ F\H]SO/_ ,!7_P EZ_TM3FQ?_/G#]/\ F(J>5_\
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M (7_ ,6/_F\H_P"'/G_!.3_HVS2O_"_^+'_S>4O<[S_\!7_R7K_2UZ.;%_\
M/G#]/^8BIY7_ .8;U^[[_P!'_P"T]-_Z"-C_ .!=O_\ '*/[3TW_ *"-C_X%
MV_\ \<K\X/\ ASY_P3D_Z-LTK_PO_BQ_\WE'_#GS_@G)_P!&V:5_X7_Q8_\
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M7_A?_%C_ .;RCW.\_P#P%?\ R7K_ $M3FQ?_ #YP_3_F(J>5_P#F&]?N^_\
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M\$95ZCI4I323E>$8J3M'FJ3C3BY/^5.2<K:V3MJ?=OP4_:&^!_[1OAV]\6?
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M6KK1W5S\@?%G_!/K]ICXN_LR_MA_#SX]_M:2?$KXS?M7^%[+PQ930:)K6@?
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MVMG"SM UTWU+^WU^R&/VQ_V<=>^$OASQ#IWP\^(EAXF\&_$+X5?$2?3IKM?
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M@ITU3BXJ[O*<Y-[N523G)Z:;MV71670****1H?FU^U=_R?=_P2Y_['O]JO\
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M)7_M"_\ SPJ/^'3O[*/_ $%/VDO_ !*_]H7_ .>%111SR_F?W^G^2#ZGA?\
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MR"*9 [ [O_#IW]E'_H*?M)?^)7_M"_\ SPJ**.>7\ST\_3_)!]3PBVPU!?\
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M[#_5CAK_ *)_)/\ PUX'_P"4>2^X/^' W_!,;_HCGC+_ ,//\5O_ )JZ/^'
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M+_\ /"HHHYY?S/[_ $_R0?4\+_T#4/\ P5#_ "\E]P?\.G?V4?\ H*?M)?\
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M;#4%?5VI05WIJ_=\E]R[!_PZ=_91_P"@I^TE_P")7_M"_P#SPJ/^'3O[*/\
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DVWNV]+:]D:TZ5*DG&E3A3BWS-0BHIRLE=I)7=HI7WLDNA__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>ny20077915x1_table04x1.jpg
<TEXT>
begin 644 ny20077915x1_table04x1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M&($V9W-C\@O^(DWXS_\ 1L/PP_\ "[\5_P#RHKUC_@Y6_P"/+]DK_K]^+?\
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M#\,/_"[\5_\ RHH_XB3?C/\ ]&P_##_PN_%?_P J*_FNHJ_J.$_Y\K_P*?\
M\D8?ZS9[_P!#"?\ X)POE_TX\OQ?<_I1_P"(DWXS_P#1L/PP_P#"[\5__*BC
M_B)-^,__ $;#\,/_  N_%?\ \J*_FNHH^HX3_GRO_ I__)!_K-GO_0PG_P""
M<+Y?]./+\7W/Z4?^(DWXS_\ 1L/PP_\ "[\5_P#RHH_XB3?C/_T;#\,/_"[\
M5_\ RHK^:ZBCZCA/^?*_\"G_ /)!_K-GO_0PG_X)POE_TX\OQ?<_I1_XB3?C
M/_T;#\,/_"[\5_\ RHKWCXU?\%\?BK\+=!^ &L:?^SU\/M6D^,?P,T7XM:E!
M>>,O$=NFB:AJGC?QYX4DT>Q>#2W:ZLXH/!]O>)<SB.=I;V:)D"1(S?R;5]J?
MM=_\B1^P[_V9CX1_]7%\;:B6"PJG!*DK/FO[T];*Z^T=-+B/.I4,5.6.FY4X
MT7!^QPWNN56$9;4;.\;IW3W=K,_7W_B)-^,__1L/PP_\+OQ7_P#*BC_B)-^,
M_P#T;#\,/_"[\5__ "HK^:ZBK^HX3_GRO_ I_P#R1S?ZS9[_ -#"?_@G"^7_
M $X\OQ?<_I1_XB3?C/\ ]&P_##_PN_%?_P J*/\ B)-^,_\ T;#\,/\ PN_%
M?_RHK^:ZBCZCA/\ GRO_  *?_P D'^LV>_\ 0PG_ ."<+Y?]./+\7W/Z4?\
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M_P#0PG_X)POE_P!./+\7W/ZS](_X+V?%34OV8/'/Q\?]GOX?1:OX2^-GP_\
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MH_XB3?C/_P!&P_##_P +OQ7_ /*BOYKJ*/J.$_Y\K_P*?_R0?ZS9[_T,)_\
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MG"^7_3CR_%]S^E'_ (B3?C/_ -&P_##_ ,+OQ7_\J*/^(DWXS_\ 1L/PP_\
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M9L\_Z&$__!.%\O\ IQY?B^Y_2C_Q$F_&?_HV'X8?^%WXK_\ E11_Q$F_&?\
MZ-A^&'_A=^*__E17\UU%/ZCA/^?*_P# I_\ R0?ZS9[_ -#"?_@G"^7_ $X\
MOQ?<_I1_XB3?C/\ ]&P_##_PN_%?_P J*/\ B)-^,_\ T;#\,/\ PN_%?_RH
MK^:ZBCZCA/\ GRO_  *?_P D'^LV>_\ 0PG_ ."<+Y?]./+\7W/Z4?\ B)-^
M,_\ T;#\,/\ PN_%?_RHH_XB3?C/_P!&P_##_P +OQ7_ /*BOYKJ*/J.$_Y\
MK_P*?_R0?ZS9[_T,)_\ @G"^7_3CR_%]S^E'_B)-^,__ $;#\,/_  N_%?\
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MDWXS_P#1L/PP_P#"[\5__*BOYKJ*/J.$_P"?*_\  I__ "0?ZS9[_P!#"?\
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M_P#U2'BVOARON/\ 8 _Y*]\3O^S3OVK_ /U2'BVLJ_\ "GZ+\T=F7_[]A?\
MK]#\SX:3[B_[J_R%.IJ?<7_=7^0IU:1V7HOR.,****8!1110 4444 %%%% !
M1110 445^B7[)G_!,3]I']LSX8:_\7?A/J'PLTOP7X;\8WW@;4KOQ_XSO/#-
MR-<T_2M#UBY,45OX>U: V0M?$6F(ES-<PM)</+$L7[L,T3J0IKFG)15TKON]
M$;X?#8C%U%1PU*=:JTY*$%>7+'XG;LNKZ'YVT5]\?M:?\$U_VIOV,?#>@^./
MBWX>\,ZEX!\17\&DV7CGP!XEC\4^'(-8NH;BYL],U&1[/3-2T^>]MK:>>QGN
M--73[Q8WCMKR6=)(E^!Z<)PJ1YH24HNZNG?5;KR:[,5?#U\+4='$4JE&JDFX
M5(N,K25TTGNFMFKI]PHHHJC$**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /[J/^"#'_*/#P7_ -E&^*'_ *DDE?LQ7XS_ /!!C_E'
MAX+_ .RC?%#_ -222OV8KY;%?[S7_P"OL_\ TIG[=DW_ "*<M_[ <+_Z9@?R
MT?\ !RM_QY?LE?\ 7[\6_P#TF\#U_*M7]5/_  <K?\>7[)7_ %^_%O\ ])O
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M**LP"BBB@ HHHH **** "BBB@#[?\+_\HY/C-_V>'\"__52_&.OB"OM_PO\
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MR.&^UZWJ/@K2C,(I$4-?1EE6*[4?D/\ LS?'"#X)_M._"/\ :"\76&K>+(?
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M9;>)=#7Q3J&N"33;AKBZL]+O(K_0M92PU2:TU*SN;:[T^TNK">0+@7/VA?\
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MUGPFMG=:C!;HM_9:M%J5U#>SV^BZAJ_]EZSJ6G6]K:7<L-M%>374GYZ^/_\
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M0IO!PE_:M.5+#4*7.ZM*>+J2:Q#K82%2'LZ3BH2C7<:D5&,J,'HM#]F#0O\
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M %C\3M2\+:!=:OIECJWQ#?PY>ZQIEE_9\>DV6M2Z$([!IHK$VLAB2XGM)I
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M)4O;SK1IT(*5-QA'EC2459?A*IRJD]2H/Z4ZBBO9/SH*^U/VN_\ D2/V'?\
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M\833MJ7A:Z\2C6!XHBT&-%B%KK&E&T-F=&8N7\\3"X4#9Y9W?DI_Q#6>-_\
MHZ[PM_X:W5?_ )L*_H\_:$FFBA\+F*:6(F75<^5*\>["6.-VQESC)QG.,G'6
MOF?[;>_\_EW_ .!,_P#\<K:EB:].G&,*G+%7LN2+M[U]WJ_GZ;,XL;DN58O$
MU,1B<)[6M/DYY^WKPORPA&/NPJ1BK1BEHM=WK>_XM_\ $-9XW_Z.N\+?^&MU
M7_YL*/\ B&L\;_\ 1UWA;_PUNJ__ #85^TGVV]_Y_+O_ ,"9_P#XY1]MO?\
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MM4>&+E-$UW1]8>V3X8:K&UPNEZC;7[0+(?%S"-IA;F,.58*6W$'&*]!^/?\
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MSQO_ -'7>%O_  UNJ_\ S85^TGVV]_Y_+O\ \"9__CE'VV]_Y_+O_P "9_\
MXY1]<Q7_ #^_\IP\OZ_X=A_JYD?_ $ /I_S%8KR_Z>^3^]GXM_\ $-9XW_Z.
MN\+?^&MU7_YL*0?\&U7C8$D?M6^%03U(^%FJY/U/_"89-?M+]MO?^?R[_P#
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M]?\ #L/]7,C_ .@!]/\ F*Q7E_T]\G][/Q;_ .(:SQO_ -'7>%O_  UNJ_\
MS84?\0UGC?\ Z.N\+?\ AK=5_P#FPK]I/MM[_P _EW_X$S__ !RC[;>_\_EW
M_P"!,_\ \<H^N8K_ )_?^4X>7]?\.P_U<R/_ * 'T_YBL5Y?]/?)_>S\6_\
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MUGC?_HZ[PM_X:W5?_FPH_P"(:SQO_P!'7>%O_#6ZK_\ -A7[2?;;W_G\N_\
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M7SQF:9\E(8@\J^9*P!*QIEVP< X-'US%?\_O_*</+^O^'8?ZN9'_ - #Z?\
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M_P"&MU7_ .;"OVD^VWO_ #^7?_@3/_\ '*/MM[_S^7?_ ($S_P#QRCZYBO\
MG]_Y3AY?U_P[#_5S(_\ H ?3_F*Q7E_T]\G][/Q;_P"(:SQO_P!'7>%O_#6Z
MK_\ -A1_Q#6>-_\ HZ[PM_X:W5?_ )L*_:3[;>_\_EW_ .!,_P#\<H^VWO\
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M7_/[_P IP\OZ_P"'8?ZN9'_T /I_S%8KR_Z>^3^]GXM_\0UGC?\ Z.N\+?\
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MSQO_ -'7>%O_  UNJ_\ S85^TGVV]_Y_+O\ \"9__CE'VV]_Y_+O_P "9_\
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MWA;@ ?\ )+=6[?\ <X4O_$-9XW_Z.N\+?^&MU7_YL*_:3[;>?\_EW_X$S_\
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M?_XY1]<Q7_/[_P IP\OZ_P"'8?ZN9'_T /I_S%8KR_Z>^3^]GXM_\0UGC?\
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MW_Q#6>-_^CKO"W_AK=5_^;"C_B&L\;_]'7>%O_#6ZK_\V%?M)]MO?^?R[_\
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M&U^+P_/-/:Q:S?P>%-$U&WL+*6YL[N.-KRZAFD-O*RQ%0K-H>'?VSO@)XT^
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MJ:.#J<RO&3DDU)W=SZ!^,W_!0K]E[X%^.=5^&_B[Q7XHUOQEX:LH-3\9Z/\
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M*E+X8N24GZ)N[^2/?:***"BYIW_(1T__ *_K/_THCK<\;?\ (X>)O^PYJ?\
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M0Z*BBBD:$"VMLLQN%MX%G;.Z=88Q,<]<R!0YSWRU/$40D,PCC$S*$:4(HD9
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MACP[?>'M UCPO8:)J-KJ>GQ6WA^?6= NK.[L5NWMYA')-S7[._@#]J#]N?X
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M"EU#;I%K]O;P7%W,LT\A 2V2/ZD\;?LI?M,_"[]I'XJ_M&_L:_$#X060^/\
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M-?+[O^#Z_P!+4Y(^?W_U_3?E;QW_ (59XL_N:3_X.]-_^2*/^%6>+/[FD_\
M@[TW_P"2*]BHHU\ON_X/K_2U.2/G]_\ 7]-^5O'?^%6>+/[FD_\ @[TW_P"2
M*/\ A5GBS^YI/_@[TW_Y(KV*BC7R^[_@^O\ 2U.2/G]_]?TWY6\=_P"%6>+/
M[FD_^#O3?_DBC_A5GBS^YI/_ (.]-_\ DBO8J*-?+[O^#Z_TM3DCY_?_ %_3
M?E;QW_A5GBS^YI/_ (.]-_\ DBC_ (59XL_N:3_X.]-_^2*]BHHU\ON_X/K_
M $M3DCY_?_7]-^5O)K+X7^*XKVSE:/2ML=W;2-C6M-)VI.C-@"X))V@X &2>
M!R:UO%7PW\3W_B77;VW33#!=ZK?7$)DU?3XG,<MQ(Z%XWG#HVUAE6 93P0#7
MI$'^O@_Z[P_^C4J[K'_(5U'_ *_+C_T8U+JMMG_[;?KU_KS?)&UM=^_IY>7?
MJSPO_A5GBS^YI/\ X.]-_P#DBC_A5GBS^YI/_@[TW_Y(KV*BGKY?=_P?7^EJ
MN2/G]_\ 7]-^5O'?^%6>+/[FD_\ @[TW_P"2*/\ A5GBS^YI/_@[TW_Y(KV*
MBC7R^[_@^O\ 2U.2/G]_]?TWY6\=_P"%6>+/[FD_^#O3?_DBC_A5GBS^YI/_
M (.]-_\ DBO8J*-?+[O^#Z_TM3DCY_?_ %_3?E;QW_A5GBS^YI/_ (.]-_\
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M/[FD_P#@[TW_ .2*]BHHU\ON_P"#Z_TM3DCY_?\ U_3?E;QW_A5GBS^YI/\
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ML_N:3_X.]-_^2*/^%6>+/[FD_P#@[TW_ .2*]BHHU\ON_P"#Z_TM3DCY_?\
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M?_!WIO\ \D5[%11KY?=_P?7^EJ<D?/[_ .OZ;\K>._\ "K/%G]S2?_!WIO\
M\D4?\*L\6?W-)_\ !WIO_P D5[%11KY?=_P?7^EJ<D?/[_Z_IORMX[_PJSQ9
M_<TG_P '>F__ "11_P *L\6?W-)_\'>F_P#R17L5%&OE]W_!]?Z6IR1\_O\
MZ_IORMX[_P *L\6?W-)_\'>F_P#R11_PJSQ9_<TG_P '>F__ "17L5%&OE]W
M_!]?Z6IR1\_O_K^F_*WCO_"K/%G]S2?_  =Z;_\ )%'_  JSQ9_<TG_P=Z;_
M /)%>Q44:^7W?\'U_I:G)'S^_P#K^F_*WCO_  JSQ9_<TG_P=Z;_ /)%'_"K
M/%G]S2?_  =Z;_\ )%>Q44:^7W?\'U_I:G)'S^_^OZ;\K>._\*L\6?W-)_\
M!WIO_P D4?\ "K/%G]S2?_!WIO\ \D5[%11KY?=_P?7^EJ<D?/[_ .OZ;\K>
M._\ "K/%G]S2?_!WIO\ \D4?\*L\6?W-)_\ !WIO_P D5[%11KY?=_P?7^EJ
M<D?/[_Z_IORMX[_PJSQ9_<TG_P '>F__ "11_P *L\6?W-)_\'>F_P#R17L5
M%&OE]W_!]?Z6IR1\_O\ Z_IORMX[_P *L\6?W-)_\'>F_P#R11_PJSQ9_<TG
M_P '>F__ "17L5%&OE]W_!]?Z6IR1\_O_K^F_*WCO_"K/%G]S2?_  =Z;_\
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M=V;LN[LF[=DSM:*7!&"00#T..OT]:2@84444 %%%&#UQQZT %%%% !16/?\
MB'P_I.H:/I.JZ[HNF:KXBGN+7P]I>HZK86.HZ]=6EN;N[MM%L;JXBNM5N+6U
M5KFY@L(KB6"W!FE5(P6K8H#]-PHHHH **** "BBB@ HHHH **** -F+_ ) -
MW_V$[7_TGN*QJV8O^0#=_P#83M?_ $GN*QJ'N_\ MW_TB(!12@$\@$@=2 32
MA6(R%8CU )% #:*4JPY*D#U((HP1C((ST]_I0 E%%*01U!'U!% "44H!/0$_
M09I* "BBG;'_ +K?]\G_  H ;12[6! *D$]!@Y/T%+M;^ZWY'_"@!M%.V/\
MW6_[Y/\ A2$$'!!!]""#0 E%*01P00?0C%)0 444I!'!!!]",4 )12[6 R5(
M'K@XI* "BE((Z@CZ\4NQ_P"ZW_?)_P * &T4H!/0$_09I* "BB@ G@#)]!0
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M^!Z&#5L-17M(U;1?OPG[2/Q-\D:EWS*G_#4F[M15[/0****1TA6OJG^IT?\
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M"&J:Q=>'++5].2/P[);37\2:='8BXU$W<-PR_H-^V;XD^'W[*7_!07_@E_\
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M9^!OV0/VJ_$G[-/BOQE;^#?#W[3&E^$-'O/".IFZU\>&(O%\/@N#59/'G_"
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MBY^T7\,OVK/@KXE_:0^(WC?Q)X+_ ."I_P &OB#\6_ ?ASQ9XAU;5?#OPO\
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M_P $S?C'^TW\:? NK>'?'_QQ^.OQ4^+_ ,*_@AK%O/;^,=1\4_&GQ$MM\)/
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M=HP, 8%2T4 5K6RLK&,PV-G:64);<8K.VAM8BW3<8X$C0MR>2,\GGDU9HHH
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M-/L-/1X["QLK%)&#NEE:6]HCL!@,ZV\<:NP' 9@2!QG%=-H/_'W<?]@S4_\
MTCEK$K;T'_C[N/\ L&:G_P"D<M &)1110 4444 %?CS_ ,%0[O\ X3KXW?\
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MC#POXY\&7OBZ_P!-T+4C:ZE#%9ZII\M[#*MK; HCB_-S8\=^RY\*/VOO$O\
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MSUZBO(?^%K^*O^>>@_\ @BLO_B:/^%K^*O\ GGH/_@BLO_B:-?+[_P#@>O\
M3T.>/=_=Z>?F_N\SUZBO(?\ A:_BK_GGH/\ X(K+_P")H_X6OXJ_YYZ#_P""
M*R_^)HU\OO\ ^!Z_T]#GCW?W>GGYO[O,]>K7U3_4Z/\ ]@J+_P!*KNO"O^%K
M^*O^>>@_^"*R_P#B:Z7Q#\2?$EG:^%Y(4T8M?^&K>^G\W1[20"=]2U2 B(,N
M(HO+MX\1+\H;>PY8TM>R^_\ X U..N^ROIMK'S]?N.YHKR'_ (6OXJ_YYZ#_
M ."*R_\ B:/^%K^*O^>>@_\ @BLO_B:>OE]__ ]?Z>BYX]W]WIY^;^[S/7J*
M\A_X6OXJ_P">>@_^"*R_^)H_X6OXJ_YYZ#_X(K+_ .)HU\OO_P"!Z_T]#GCW
M?W>GGYO[O,]>HKR'_A:_BK_GGH/_ ((K+_XFC_A:_BK_ )YZ#_X(K+_XFC7R
M^_\ X'K_ $]#GCW?W>GGYO[O,]>HKR'_ (6OXJ_YYZ#_ ."*R_\ B:/^%K^*
MO^>>@_\ @BLO_B:-?+[_ /@>O]/0YX]W]WIY^;^[S/7J*\A_X6OXJ_YYZ#_X
M(K+_ .)H_P"%K^*O^>>@_P#@BLO_ (FC7R^__@>O]/0YX]W]WIY^;^[S/7J*
M\A_X6OXJ_P">>@_^"*R_^)H_X6OXJ_YYZ#_X(K+_ .)HU\OO_P"!Z_T]#GCW
M?W>GGYO[O,]>HKR'_A:_BK_GGH/_ ((K+_XFC_A:_BK_ )YZ#_X(K+_XFC7R
M^_\ X'K_ $]#GCW?W>GGYO[O,]>HKR'_ (6OXJ_YYZ#_ ."*R_\ B:/^%K^*
MO^>>@_\ @BLO_B:-?+[_ /@>O]/0YX]W]WIY^;^[S/7J*\A_X6OXJ_YYZ#_X
M(K+_ .)H_P"%K^*O^>>@_P#@BLO_ (FC7R^__@>O]/0YX]W]WIY^;^[S/7J*
M\A_X6OXJ_P">>@_^"*R_^)H_X6OXJ_YYZ#_X(K+_ .)HU\OO_P"!Z_T]#GCW
M?W>GGYO[O,]>HKR'_A:_BK_GGH/_ ((K+_XFC_A:_BK_ )YZ#_X(K+_XFC7R
M^_\ X'K_ $]#GCW?W>GGYO[O,]>HKR'_ (6OXJ_YYZ#_ ."*R_\ B:/^%K^*
MO^>>@_\ @BLO_B:-?+[_ /@>O]/0YX]W]WIY^;^[S/7J*\A_X6OXJ_YYZ#_X
M(K+_ .)H_P"%K^*O^>>@_P#@BLO_ (FC7R^__@>O]/0YX]W]WIY^;^[S/7J*
M\A_X6OXJ_P">>@_^"*R_^)H_X6OXJ_YYZ#_X(K+_ .)HU\OO_P"!Z_T]#GCW
M?W>GGYO[O,]>HKR'_A:_BK_GGH/_ ((K+_XFC_A:_BK_ )YZ#_X(K+_XFC7R
M^_\ X'K_ $]#GCW?W>GGYO[O,]>HKR'_ (6OXJ_YYZ#_ ."*R_\ B:/^%K^*
MO^>>@_\ @BLO_B:-?+[_ /@>O]/0YX]W]WIY^;^[S/7J*\A_X6OXJ_YYZ#_X
M(K+_ .)H_P"%K^*O^>>@_P#@BLO_ (FC7R^__@>O]/0YX]W]WIY^;^[S/7J*
M\A_X6OXJ_P">>@_^"*R_^)H_X6OXJ_YYZ#_X(K+_ .)HU\OO_P"!Z_T]#GCW
M?W>GGYO[O,]>HKR'_A:_BK_GGH/_ ((K+_XFC_A:_BK_ )YZ#_X(K+_XFC7R
M^_\ X'K_ $]#GCW?W>GGYO[O,]>HKR'_ (6OXJ_YYZ#_ ."*R_\ B:/^%K^*
MO^>>@_\ @BLO_B:-?+[_ /@>O]/0YX]W]WIY^;^[S/7J*\A_X6OXJ_YYZ#_X
M(K+_ .)H_P"%K^*O^>>@_P#@BLO_ (FC7R^__@>O]/0YX]W]WIY^;^[S/=XO
M^0#=_P#83M?_ $GN*QJX>'XD^)&\&ZCJ131OM,/B/2[) -'M! 89]/U":0M#
MMV-+OA39*?F12RC 8US/_"U_%7_//0?_  167_Q-&M[Z:VZ]DEV\F'-'N^G3
MO;S\W]WF>O45Y#_PM?Q5_P \]!_\$5E_\31_PM?Q5_SST'_P167_ ,31KY??
M_P #U_IZ'/'N_N]//S?W>9Z]17D/_"U_%7_//0?_  167_Q-'_"U_%7_ #ST
M'_P167_Q-&OE]_\ P/7^GH<\>[^[T\_-_=YGKU%>0_\ "U_%7_//0?\ P167
M_P 31_PM?Q5_SST'_P $5E_\31KY??\ \#U_IZ'/'N_N]//S?W>9Z]17D/\
MPM?Q5_SST'_P167_ ,31_P +7\5?\\]!_P#!%9?_ !-&OE]__ ]?Z>ASQ[O[
MO3S\W]WF>O45Y#_PM?Q5_P \]!_\$5E_\31_PM?Q5_SST'_P167_ ,31KY??
M_P #U_IZ'/'N_N]//S?W>9Z]17D/_"U_%7_//0?_  167_Q-'_"U_%7_ #ST
M'_P167_Q-&OE]_\ P/7^GH<\>[^[T\_-_=YGKU%>0_\ "U_%7_//0?\ P167
M_P 31_PM?Q5_SST'_P $5E_\31KY??\ \#U_IZ'/'N_N]//S?W>9Z]17D/\
MPM?Q5_SST'_P167_ ,31_P +7\5?\\]!_P#!%9?_ !-&OE]__ ]?Z>ASQ[O[
MO3S\W]WF>O45Y#_PM?Q5_P \]!_\$5E_\31_PM?Q5_SST'_P167_ ,31KY??
M_P #U_IZ'/'N_N]//S?W>9Z]17D/_"U_%7_//0?_  167_Q-'_"U_%7_ #ST
M'_P167_Q-&OE]_\ P/7^GH<\>[^[T\_-_=YGKU%>0_\ "U_%7_//0?\ P167
M_P 31_PM?Q5_SST'_P $5E_\31KY??\ \#U_IZ'/'N_N]//S?W>9Z]17D/\
MPM?Q5_SST'_P167_ ,31_P +7\5?\\]!_P#!%9?_ !-&OE]__ ]?Z>ASQ[O[
MO3S\W]WF>O45Y#_PM?Q5_P \]!_\$5E_\31_PM?Q5_SST'_P167_ ,31KY??
M_P #U_IZ'/'N_N]//S?W>9Z]17D/_"U_%7_//0?_  167_Q-'_"U_%7_ #ST
M'_P167_Q-&OE]_\ P/7^GH<\>[^[T\_-_=YGKU%>0_\ "U_%7_//0?\ P167
M_P 31_PM?Q5_SST'_P $5E_\31KY??\ \#U_IZ'/'N_N]//S?W>9Z]17D/\
MPM?Q5_SST'_P167_ ,31_P +7\5?\\]!_P#!%9?_ !-&OE]__ ]?Z>ASQ[O[
MO3S\W]WF>O45Y#_PM?Q5_P \]!_\$5E_\31_PM?Q5_SST'_P167_ ,31KY??
M_P #U_IZ'/'N_N]//S?W>9Z]17D/_"U_%7_//0?_  167_Q-'_"U_%7_ #ST
M'_P167_Q-&OE]_\ P/7^GH<\>[^[T\_-_=YGKU%>0_\ "U_%7_//0?\ P167
M_P 31_PM?Q5_SST'_P $5E_\31KY??\ \#U_IZ'/'N_N]//S?W>9Z]6WH/\
MQ]W'_8,U/_TCEKP;_A:_BK_GGH/_ ((K+_XFNG\)?$CQ)J&HWT-PFC*D7A_Q
M!>+Y.CVD+^=9Z7<3P[F09:/S$ DC/RR(2C<$TM>R^_\ X'K_ $]!2B[*[U\O
M3S\W]WF=O17D/_"UO%7_ #ST'_P167_Q-'_"U_%7_//0?_!%9?\ Q-/7R^__
M ('K_3T.>/=_=Z>?F_N\SUZBO(?^%K^*O^>>@_\ @BLO_B:/^%K^*O\ GGH/
M_@BLO_B:-?+[_P#@>O\ 3T.>/=_=Z>?F_N\SUZO,/C-\&OAQ^T%\,_%?P?\
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MYHMWCITDF_)?@?\ M&?#K]H*X^+%M\/_ .W_ #?@Q\5/$GP=\9#7=+CTP?\
M"7>%6B34VT@QWEY]OTAFE M+Y_LTLVUR]I"-A>IX0_::^%WC3XN?'3X+Z;=:
MO8>*_P!G>Q\+:E\2;[6["#3?#-I8>+=%;7]/N]-UE[Z074%IIJ-)JLMS;6,=
MFRMAIHU:0?BY^Q?\3?VPO!7Q#_;TT[]GK]EOPE\<?"ES^V]\9KO5O$FO_'+P
MS\,;K3-<.IB)](BT;6K.XN+V%;-+:Z&H1.(F>=X<;HS7?_L7:5X^^-W[7?\
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M_D$,35<80<HK$5*E.G*$Z,H>P<J=2I)N+G^]A:E-4IQERRDK.<K-+Z'\/?\
M!3/X%^)-,\9BU^'7[3-AX\\$:!9>*KWX,ZU\ _%^E?%O7/#=YKNE>'GUKPEX
M:N0NG^)+/3KW6;.;5?[/UQKBPT_S[Z:#R('(\UB_X*]? ^?Q9=> X?V>OVVY
M?&]CHT/B*]\(1_LXZB_B:TT"YN!:6^M7.AKXD.I0Z5/=$6\-_);+:R3'RDE+
M\5^JC6EJ]U%?/:V[WL$4L$%XT$37<,$Y1IX8K@J9HXIFBC:6-'5)&CC+JQ1<
M?EIX4)_X?)?%@Y.?^&'_  /SGG_DI2T*VN^B[^:7;S-:KQ,/96K4_?JQIO\
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M\27R_P#24%%%%49A1110!\!_M\?MTV?[$?A'P3JMC\,M5^,?C'QQJ?B-M/\
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M\/>!/"L=LNM^,=6U*71]=:.T74+^QTO3K;[ HU"]DGBCN4DMS&_Y5?LQR?\
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M5.2C)1IJE%RBG:4E32C=K51C>[C%K\ROC)^P[\2/%WP5_8QL?AC\2/"O@_\
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M --6JUQM=E;_ /)/M6_[&[1?_35JM<;0-[_*/Y(****!!1110 4444 %%%%
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M3H4G4]JX+GNG>[LY17+&3C?D<XK2,W%R2LDTD@HHHH-0HHHH **** "BBB@
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M5%K_ -#A:?\ @EU#_P".T7]?N?\ 77\^S#DEV_%?YGCE%>Q_\*HM?^APM/\
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MP;=M)OI6A,T[N8S(D@5RF[:64 $C(%*^J]'T?>(^65EIU?5>7GY'@-%>Q_\
M"J+7_H<+3_P2ZA_\=H_X51:_]#A:?^"74/\ X[3OZ_<_ZZ_GV8N27;\5_F>.
M45['_P *HM?^APM/_!+J'_QVC_A5%K_T.%I_X)=0_P#CM%_7[G_77\^S#DEV
M_%?YGCE%>Q_\*HM?^APM/_!+J'_QVC_A5%K_ -#A:?\ @EU#_P".T7]?N?\
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M_P#':+^OW/\ KK^?9AR2[?BO\SQRBO8_^%46O_0X6G_@EU#_ ..T?\*HM?\
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MK]S_ *Z_GV8<DNWXK_,\<HKV/_A5%K_T.%I_X)=0_P#CM'_"J+7_ *'"T_\
M!+J'_P =HOZ_<_ZZ_GV8<DNWXK_,\<HKV/\ X51:_P#0X6G_ ()=0_\ CM'_
M  JBU_Z'"T_\$NH?_':+^OW/^NOY]F')+M^*_P SQRBO8_\ A5%K_P!#A:?^
M"74/_CM'_"J+7_H<+3_P2ZA_\=HOZ_<_ZZ_GV8<DNWXK_,\<HKV/_A5%K_T.
M%I_X)=0_^.T?\*HM?^APM/\ P2ZA_P#':+^OW/\ KK^?9AR2[?BO\SQRBO8_
M^%46O_0X6G_@EU#_ ..T?\*HM?\ H<+3_P $NH?_ !VB_K]S_KK^?9AR2[?B
MO\SQRBO8_P#A5%K_ -#A:?\ @EU#_P".T?\ "J+7_H<+3_P2ZA_\=HOZ_<_Z
MZ_GV8<DNWXK_ #/'*[3P)_R%M3_[%7Q5_P"F6ZKK_P#A5%K_ -#A:?\ @EU#
M_P".UTGA;X:P:??WDR>)[:Z,NAZY9F-=*O82BWFFSP-.6>4@B /YAC W2!2J
MD$BB_K]S_KK^?9C4976G5=5W]3YXHKV/_A5%K_T.%I_X)=0_^.T?\*HM?^AP
MM/\ P2ZA_P#':+^OW/\ KK^?9BY)=OQ7^9XY17L?_"J+7_H<+3_P2ZA_\=H_
MX51:_P#0X6G_ ()=0_\ CM%_7[G_ %U_/LPY)=OQ7^9XY17L?_"J+7_H<+3_
M ,$NH?\ QVC_ (51:_\ 0X6G_@EU#_X[1?U^Y_UU_/LPY)=OQ7^9XY17L?\
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MUU_/LPY)=OQ7^9XY17L?_"J+7_H<+3_P2ZA_\=H_X51:_P#0X6G_ ()=0_\
MCM%_7[G_ %U_/LPY)=OQ7^9XY17L?_"J+7_H<+3_ ,$NH?\ QVC_ (51:_\
M0X6G_@EU#_X[1?U^Y_UU_/LPY)=OQ7^9XY17L?\ PJBU_P"APM/_  2ZA_\
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M9^'W\-Z[8GQ9I5Q?:#X<NH],GUAH?$!2[U3RUGN(8[>*1F2WBQ^3?['-U:?
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MJJ$*5*A?._W_ *H='$.K)0E3=-SI1KPO)2YJ<G;WK?#.-X\T?>7O*TY:V^D
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M'NM0U/4)K>RLK9"RAI[F>*)2R@N"1G4K\T?^"QXS_P $P/VSAC.?A/$,>O\
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M$^,O"GC'PZDUS;/K_A3Q'H_B+1$N+,*UW;MJVCWMY8+/:JZ-<Q&X$D"NIE5
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M"TU32KB[L;DP7$4L$WDSOY4\<D4FV1&4;=?C[_P0;55_X)>?L]*H 5;[XH@
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MHGB/3/AMI6FZCHFIZ?,$GM-3LK^*2SNK29%EAN8WBD4.I _%;2_V9_VA(O\
M@WJUK]G^7X+_ !'3XWR^(/%=U%\)F\*ZH/'LMO=?M7:AXJMY8_#1@_M)TG\-
M.FN18@/F:6ZWB@PLK'^G"BFG;[T_N.:>$A4A&#G)*.%K81-6NX5E13D]+<R]
MC&VEM6?BW^WS^SIX^\(>&?V3?VQOV8_A3?ZQ^T=^RQXJ^'8\4>#?AWX?">,/
MBC\'/$.GZ=X>^)OP^O\ 3]#MDO/$7V2-Q>06DZW+V,/]KSVRK(1)']E>-?\
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MK4=2\3:KJ%O&UC%9>')Y+:[@;S8TFG-I+;>^?$WPS\:_V-/^"B'Q _:[\,?
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M,HT?K-:E4JOD<9JC0KRJ**3=1<M2G9-17-R25[./-_2O17\>-Y_P4$\2V/P
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MP/\ $7X(^$-#^(GA'QS#J&C:?>W2W+P:WI=]X+O-+UFYOM#N[?7K9K<KI_\
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MHHH **** "BBB@ HHHH **** "BBB@#V#P?_ ,@.#_KM<_\ HUJZBN7\'_\
M(#@_Z[7/_HUJZBL);OU?YF\=EZ+\CS_Q[_JM,_ZZ77_H,%>;UZ7XZCDDBTT1
MH[D27.=BLV,K!C. <5YU]GN/^>$W_?I__B:UA\*^?YLRG\3^7Y(AHJ;[/<?\
M\)O^_3__ !-'V>X_YX3?]^G_ /B:HDAHJ;[/<?\ /";_ +]/_P#$T?9[C_GA
M-_WZ?_XF@"&BIOL]Q_SPF_[]/_\ $T?9[C_GA-_WZ?\ ^)H AHJ;[/<?\\)O
M^_3_ /Q-'V>X_P">$W_?I_\ XF@"&BIOL]Q_SPF_[]/_ /$T?9[C_GA-_P!^
MG_\ B: (:*F^SW'_ #PF_P"_3_\ Q-'V>X_YX3?]^G_^)H AHJ;[/<?\\)O^
M_3__ !-'V>X_YX3?]^G_ /B: $@_U\'_ %WA_P#1J5=UC_D*ZC_U^7'_ *,:
MH(+>X$\&8)A^_A_Y9/\ \]%_V:N:O!.=4U B&4@WDY!$;D$&1L$$+@BEU7H_
MSB!D45-]GN/^>$W_ 'Z?_P")H^SW'_/";_OT_P#\33 AHJ;[/<?\\)O^_3__
M !-'V>X_YX3?]^G_ /B: (:*F^SW'_/";_OT_P#\31]GN/\ GA-_WZ?_ .)H
M AHJ;[/<?\\)O^_3_P#Q-'V>X_YX3?\ ?I__ (F@"&BIOL]Q_P \)O\ OT__
M ,31]GN/^>$W_?I__B: (:U]4_U.C_\ 8*B_]*KNL[[/<?\ /";_ +]/_P#$
MUK:I!.8M( AE)&EQ @1N<'[5='!P.#@@X/K0-;2]/U1AT5-]GN/^>$W_ 'Z?
M_P")H^SW'_/";_OT_P#\30(AHJ;[/<?\\)O^_3__ !-'V>X_YX3?]^G_ /B:
M (:*F^SW'_/";_OT_P#\31]GN/\ GA-_WZ?_ .)H _*OXU_LD?M/^$OVOM:_
M;(_8K\<?!K3_ !/\5/AEH?PN^.7PQ^/=GXR?P7XDB\(7,DW@[QQH6K>"$N-8
MLO$6CV\BZ=/820PVEW:0D&[!NI5CXW]GK_@G)\4M#\=?MZ>(/VI_BQX:^,ME
M^W'\.?A_X3\6:CX6TBX\+7FG7UAX8\5:%XNL-,T![$Z?HOAK0X]?L-+\!C^U
M=;U.YT_2([W7Y%OI94D_8;[/<?\ /";_ +]/_P#$T?9[C_GA-_WZ?_XFG>W]
M:]/\CE>#HNHJC4W:<ZB@YR]DIU(2A.7L[\MYQG*^EKR;5FW?\>/A!\#?^"L'
M[/OP^\)_L]^ ?BW^QEXS^%_PZT^R\(>!/BQ\1?"?Q<B^*=GX#TK9:Z)::[X*
M\.7UKX.UG7-&TE([""[77K2VNQ;P/>I,PD>7T?\ :4_9$_:&OOVEOAA^VK^R
MC\0?A=HOQ[\+_"6Z^!GQ-\(_&#2/$0^%WQ8^'MSJK^)+8SW?A#[5XE\.:SHW
MB2>YU#3YK=;U9(AIUM-*(M/>.[_4#[/<?\\)O^_3_P#Q-'V>X_YX3?\ ?I__
M (FB[7;_ #Z:][V&L+34%3YJKC%P<+U9N5-TW[G)*]U;:[;<EI)M:'X\_M,_
ML:_MH_M;_L;>-O@[\9OBQ\#+OXP^+?C5\-_B%H<7@_P_XH\-?"KX?>"/!6L^
M'[^Y\&:=J%U::UXR\3ZC,VG:MJHUW6[1);N_U)+'98:?!#Y/IW[9G[)OQ^^(
M7[17[,O[6O[+_B?X2Z=\6OV?=#^)/@JY\+?&V#Q8? OB?PG\2+.VANIA?>#(
M;G6K+5M(N()9H8TA$5XLT:-=6XA=9_TX^SW'_/";_OT__P 31]GN/^>$W_?I
M_P#XFB^MPEA:4E*[J-R5).;J2<[T)NI3DI-W4E-M]MDDDDC\</%G['O[;?@C
M]J_Q5^U]^S[XR_97UCXA_&_X+?"[X>_&+2_C/X9^(3Z1X(\9> =&M]-OO$GP
M8O?#DE[KD7A;5+E)+W_A$]=U&UDN"%&HZE<2F.:#S3PS_P $P?V@-,_8%_;Q
M_9;\4_%7X;^+?BO^UA\=?&GQ=T?X@PV6M>'O"Y;Q?)\,KV]F\0Z1:Z/=W.@7
MD^I>#]<F&EZ+!KEE8V]YIT45]<D3F+]VOL]Q_P \)O\ OT__ ,31]GN/^>$W
M_?I__B:+O\OPM;\B'@:#<F_:-359.+J2Y5]85JS4;Z2G=MRW3;M:]C\-/'?[
M!'[>?QO^&O@+]COXV_M!? W5/V0O".L>"!XH\;^%/"7BO2/VC/BCX ^'MYI^
MH>&OA_XCL7 ^'FCS*=,L-/U7Q5HDD4^J)IUIJ%QI9FEOK:[^QW_9)\6Q?\%(
MO#/[86GZOX5M/A?X>_8Z'[.4/A))-37Q7%XAA^(^J^*[2]MK<:>='7PY!HM_
M!9K(VJB_6[@,8L3"1/7Z"?9[C_GA-_WZ?_XFC[/<?\\)O^_3_P#Q-%W_ ,,K
M=O\ +^D7'"48M/WY24J<E*<Y2DO8\WLXWDV^6'-)I=6VY-MW/SQ_8%_9'\=?
MLH_!SXZ_#KQOX@\+:_JWQ1_:1^/?QCT6\\,2ZI)I]EX=^*5SI[Z#8:DVIZ=I
M]PFKV<-D6U6*VAN;2%Y!':WEX%,A^5O#'_!+;XB6G[ O[.'[/TOQ4\,^"_VE
MOV5_BSJ?QR^$?Q7\.Z?J'B7P7I7CQ/B%XM\5Z59:II>K66CZCJWAS4M'\11:
M9KMNUG!(EY D\,=Y!;*EQ^V_V>X_YX3?]^G_ /B:/L]Q_P \)O\ OT__ ,31
M=K[T_FM@>$H.$(.+Y:=*=&/O--0J2IR=FFFI*5*#C)-.+5TT?G]\*)O^"DEI
MXQTK6_VF_%/[&?A[X-^%].US4O'$7P?TCXNZKXQ\4P6>B7S6MQ:W_C>^T_1?
M!]E:WPM]7OT2VUZ=K>TDL8K@)*9:\&_X)2:7J/Q7LOVE_P!OCQ597,&N_MF?
M&C6]2\ +?QNEUI?[/?PKN;OP!\)-+B60 QPW5GIFH:M(T86.\,]M=E2S;V_7
MEK69E96MI65@596A<JRD8*L"I!!!(((P1P:CAL&MHHX+>R,$$2A(H8;<Q11(
MO"I'&B*B*!P%4 #L*&_1#6'M.E)U)SC2]I)*HW.3J3C&$9<S>BA#VD5%+5S<
MKWO?\D_$W[(?[7_P/_:A^.W[07[$/CKX!2>&OVHY_#_B'XM_"K]H73/'":7H
M7Q'\/Z;_ &1_PGO@O6O "2:A<R:Q:E[G5]%U/[-!/=2S*MT$%FUGK?&G]BO]
MIWXC:/\ LL?&_2/CW\/%_;L_9@OO&FH0_$+5?A_=6'P:^(>D_$6>[7Q/\.]8
M\(:/=G6M&\*V^D2Z?HNCZK87,VM)%IKZA=!]1OC<6WZM_9[C_GA-_P!^G_\
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M?^(+"XUWQ9J6H:SJ%]K'C+7?%6H:3Y<4-A9:'I8@A\M?V&^SW'_/";_OT_\
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M /Q-'V>X_P">$W_?I_\ XF@"&BIOL]Q_SPF_[]/_ /$T?9[C_GA-_P!^G_\
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M/<?\\)O^_3__ !-'V>X_YX3?]^G_ /B: (:*F^SW'_/";_OT_P#\31]GN/\
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M .)H AHJ;[/<?\\)O^_3_P#Q-'V>X_YX3?\ ?I__ (F@"&BIOL]Q_P \)O\
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M/&W_ ".'B;_L.:G_ .E<M*RNM.C_ #B.[LM7N^O:UON%_P"$X\9_]#9XC_\
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M679?U_PR^X+ON_Z_X9?<=3_PG'C/_H;/$?\ X.M1_P#DBC_A./&?_0V>(_\
MP=:C_P#)%<M119=E_7_#+[@N^[_K_AE]QU/_  G'C/\ Z&SQ'_X.M1_^2*/^
M$X\9_P#0V>(__!UJ/_R17+44679?U_PR^X+ON_Z_X9?<=3_PG'C/_H;/$?\
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M,ON"[[O^O^&7W'4_\)QXS_Z&SQ'_ .#K4?\ Y(H_X3CQG_T-GB/_ ,'6H_\
MR17+44679?U_PR^X+ON_Z_X9?<=3_P )QXS_ .AL\1_^#K4?_DBC_A./&?\
MT-GB/_P=:C_\D5RU%%EV7]?\,ON"[[O^O^&7W'4_\)QXS_Z&SQ'_ .#K4?\
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M,ON"[[O^O^&7W'4_\)QXS_Z&SQ'_ .#K4?\ Y(H_X3CQG_T-GB/_ ,'6H_\
MR17+44679?U_PR^X+ON_Z_X9?<=3_P )QXS_ .AL\1_^#K4?_DBC_A./&?\
MT-GB/_P=:C_\D5RU%%EV7]?\,ON"[[O^O^&7W'4_\)QXS_Z&SQ'_ .#K4?\
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M3K3_ -/&MT#6TO3]4<=1110(**** "BBB@ KX._X*?\ _*/W]K#_ +)%KO\
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M)+*TBMGOKR5V9Y+J[:(W%Q([,SRR.S,223IU)Z@4444 %%%% !1110!V5O\
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MOLG.:C>,/;2E"GS6?-9RBTVHM1WDTM3]<:*_'N#XO_\ !0;XZ_M2?M@?"SX
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M $GHK\G?B?\ \%"M0^(_@+]DO1?V-7\-^(/C5^V%=Z;JGAJV\36DNNZ7\+O
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M@3_D+:G_ -BKXJ_],MU0..Z]5^9Q=%%% @HHHH **** "BBB@ HHHH ****
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M****"PHHHH **** "BBB@ HHHH **** .RM_^2?:M_V-VB_^FK5:XVNRM_\
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M<1[5U81H4I\L^9QJ57&M)T^6"JT_9QC[DK2]I><VH*"Y5)V_#_\ 80\.:_\
ML:?M1?"[X[_'/X?>'/ W@/\ X*,:-XKB^'36MO=0P?LZ>*/%OC74/'G@WX32
M/<S2VVD6'CCP_J&C7#QA;5EU2X2TF,;:7J2M^C=J"?\ @MCJ0 )(_8-LL@ Y
M'_%S;GM7Z!_'?]GSX2_M*?#Z3X8?&'PLOB7P@VJZ/KEM:6^H:EH6H:7K.@7
MNM(U31=9T2ZL-5T>^LI 5BN-/N[>0P236[%H)9(V\,^.G_!//]EK]H[QSI?Q
M)^*WA#Q3JOC;2/">G>"+7Q!HOQ,^(7A.]D\-Z7<75W9V5Z?#/B/2DOI%N+RX
MFFN[I9;JX=PT\LA1-KNG>]]5;OU5NO96_&[(C@ZM&G"E2=.<*=>E6ASRE"3=
MG[92<832O/\ >0LG;FE"RC&-_MS:V<;3GTP<_EUK\D_^"2X/]C?MS\'C_@H7
M^TL#QW_X2*VX^M?3=G^P'^S;I_P8?X!6.C_$"S^&\GC+_A/'L[;XP_%*'7SX
MC-L+,S?\)='XK7Q,-/,"J#HXU3^RFD G:T,X$E8/P4_X)N_LI?L]>/-.^(_P
MJ\,>.]!\3Z9J6K:S&]W\8/BEKFD7FK:Y97-AJNHZOX?UGQ7>Z+K-[>6]W-YU
MQJEC=2M,4N"WG11NJ[^:M^*?Z'1*%>5;#U.2DE34U47M9-KVBBGR?N5S<MFU
M=QYMK1MK]W4444CJ"BBB@ HHHH **** "BBB@ HHHH *[3P)_P A;4_^Q5\5
M?^F6ZKBZ[3P)_P A;4_^Q5\5?^F6ZH''=>J_,XNBBB@04444 %%%% !1110
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M[#FI_P#I7+2ZKT?YQ'T7J_RB<O1113$%%%% !1110 4444 %%%% !78^*_\
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MJ^*O_3+=4#CNO5?F<71110(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M\^[/"_\ A0/A/_H):Y_W^L__ )#H_P"% ^$_^@EKG_?ZS_\ D.O=**.>7?\
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M_P#(='_"@?"?_02US_O]9_\ R'7NE%'/+O\ @O\ (/90_E7WO_/R_/NSPO\
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MY?GW9X7_ ,*!\)_]!+7/^_UG_P#(='_"@?"?_02US_O]9_\ R'7NE%'/+O\
M@O\ (/90_E7WO_/R_/NSPO\ X4#X3_Z"6N?]_K/_ .0Z/^% ^$_^@EKG_?ZS
M_P#D.O=**.>7?\%_D'LH?RK[W_GY?GW9X7_PH'PG_P!!+7/^_P!9_P#R'1_P
MH'PG_P!!+7/^_P!9_P#R'7NE%'/+O^"_R#V4/Y5][_S\OS[L\+_X4#X3_P"@
MEKG_ '^L_P#Y#H_X4#X3_P"@EKG_ '^L_P#Y#KW2BCGEW_!?Y![*'\J^]_Y^
M7Y]V>%_\*!\)_P#02US_ +_6?_R'1_PH'PG_ -!+7/\ O]9__(=>Z44<\N_X
M+_(/90_E7WO_ #\OS[L\+_X4#X3_ .@EKG_?ZS_^0Z/^% ^$_P#H):Y_W^L_
M_D.O=**.>7?\%_D'LH?RK[W_ )^7Y]V>%_\ "@?"?_02US_O]9__ "'1_P *
M!\)_]!+7/^_UG_\ (=>Z44<\N_X+_(/90_E7WO\ S\OS[L\?3X+>&H]&N-$%
M]JYMKG4K74WD,UKYPGM+>XMHT4BU"",I<N6!0L65<$#(.7_PH'PG_P!!+7/^
M_P!9_P#R'7NE%'-+O^0_9P_E7X_Y^1X7_P *!\)_]!+7/^_UG_\ (='_  H'
MPG_T$M<_[_6?_P AU[I11SR[_@O\A>RA_*OO?^?E^?=GA?\ PH'PG_T$M<_[
M_6?_ ,AT?\*!\)_]!+7/^_UG_P#(=>Z44<\N_P""_P @]E#^5?>_\_+\^[/"
M_P#A0/A/_H):Y_W^L_\ Y#H_X4#X3_Z"6N?]_K/_ .0Z]THHYY=_P7^0>RA_
M*OO?^?E^?=GA?_"@?"?_ $$M<_[_ %G_ /(='_"@?"?_ $$M<_[_ %G_ /(=
M>Z44<\N_X+_(/90_E7WO_/R_/NSPO_A0/A/_ *"6N?\ ?ZS_ /D.C_A0/A/_
M *"6N?\ ?ZS_ /D.O=**.>7?\%_D'LH?RK[W_GY?GW9X7_PH'PG_ -!+7/\
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MA/\ Z"6N?]_K/_Y#H_X4#X3_ .@EKG_?ZS_^0Z]THHYY=_P7^0>RA_*OO?\
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MG_?ZS_\ D.O=**.>7?\ !?Y![*'\J^]_Y^7Y]V>%_P#"@?"?_02US_O]9_\
MR'1_PH'PG_T$M<_[_6?_ ,AU[I11SR[_ (+_ "#V4/Y5][_S\OS[L\+_ .%
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MV4/Y5][_ ,_+\^[/"_\ A0/A/_H):Y_W^L__ )#H_P"% ^$_^@EKG_?ZS_\
MD.O=**.>7?\ !?Y![*'\J^]_Y^7Y]V<YX5\,V7A+1XM%T^6XFMH9IYEDNFC:
?8M<2&1P3''&F 3A<(#CJ371T45+=]6:)65ELM$?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2026</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PASSAGE BIO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (FY)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">39,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent', window );">Prepaid research and development</a></td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">78,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">9,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets - operating leases</a></td>
<td class="nump">13,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">102,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Non-refundable sublicense and transition services payments</a></td>
<td class="nump">8,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="nump">21,788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">41,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 11)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2025 and December 31, 2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paidin capital</a></td>
<td class="nump">720,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(659,235)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">61,261<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 102,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PrepaidResearchAndDevelopmentAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (FY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,207,810<span></span>
</td>
<td class="nump">3,182,810<span></span>
</td>
<td class="nump">3,161,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,207,810<span></span>
</td>
<td class="nump">3,182,810<span></span>
</td>
<td class="nump">3,161,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss (FY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 7,737<span></span>
</td>
<td class="nump">$ 23,276<span></span>
</td>
<td class="nump">$ 40,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="nump">24,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net gain on lease termination</a></td>
<td class="num">$ (600)<span></span>
</td>
<td class="num">(633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,247)<span></span>
</td>
<td class="num">(16,459)<span></span>
</td>
<td class="num">(49,296)<span></span>
</td>
<td class="num">(70,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">5,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,405)<span></span>
</td>
<td class="num">$ (45,522)<span></span>
</td>
<td class="num">$ (64,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (4.87)<span></span>
</td>
<td class="num">$ (14.35)<span></span>
</td>
<td class="num">$ (21.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (4.87)<span></span>
</td>
<td class="num">$ (14.35)<span></span>
</td>
<td class="num">$ (21.04)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,205,866<span></span>
</td>
<td class="nump">3,163,914<span></span>
</td>
<td class="nump">3,172,870<span></span>
</td>
<td class="nump">3,078,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,205,866<span></span>
</td>
<td class="nump">3,163,914<span></span>
</td>
<td class="nump">3,172,870<span></span>
</td>
<td class="nump">3,078,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,405)<span></span>
</td>
<td class="num">$ (45,522)<span></span>
</td>
<td class="num">$ (64,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,413)<span></span>
</td>
<td class="num">$ (45,530)<span></span>
</td>
<td class="num">$ (64,716)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (FY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paidin capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning of period at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705,794<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
<td class="num">$ (594,468)<span></span>
</td>
<td class="nump">$ 111,283<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">2,805,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under the ATM Facility, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under the ATM Facility, net of offering costs (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">45,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares in connection with employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares in connection with employee stock purchase plan (in shares)</a></td>
<td class="nump">10,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,767)<span></span>
</td>
<td class="num">(64,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,488<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(659,235)<span></span>
</td>
<td class="nump">61,261<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">3,161,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">4,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,405)<span></span>
</td>
<td class="num">(15,405)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(674,640)<span></span>
</td>
<td class="nump">46,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2025</a></td>
<td class="nump">3,165,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning of period at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,488<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(659,235)<span></span>
</td>
<td class="nump">61,261<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">3,161,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">16,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares in connection with employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares in connection with employee stock purchase plan (in shares)</a></td>
<td class="nump">4,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,522)<span></span>
</td>
<td class="num">(45,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(704,757)<span></span>
</td>
<td class="nump">18,755<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2025</a></td>
<td class="nump">3,182,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 724,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (712,316)<span></span>
</td>
<td class="nump">$ 11,752<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2026</a></td>
<td class="nump">3,207,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (FY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (45,522)<span></span>
</td>
<td class="num">$ (64,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Sharebased compensation</a></td>
<td class="nump">3,001<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium and discount on marketable securities, net</a></td>
<td class="nump">129<span></span>
</td>
<td class="num">(1,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Other non-cash items</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, and other assets</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">1,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Non-refundable sublicense and transition services payments received</a></td>
<td class="nump">4,015<span></span>
</td>
<td class="nump">8,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Right of use assets and operating lease liabilities</a></td>
<td class="num">(464)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,880<span></span>
</td>
<td class="num">(556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(2,054)<span></span>
</td>
<td class="num">(4,963)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(31,509)<span></span>
</td>
<td class="num">(47,956)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,170)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable securities</a></td>
<td class="nump">39,046<span></span>
</td>
<td class="nump">143,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchases of property and equipment and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Sales of property and equipment and other assets</a></td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">40,216<span></span>
</td>
<td class="nump">54,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of common stock under the ATM Facility, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">8,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">8,730<span></span>
</td>
<td class="nump">15,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning</a></td>
<td class="nump">37,573<span></span>
</td>
<td class="nump">21,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end</a></td>
<td class="nump">46,303<span></span>
</td>
<td class="nump">37,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets recognized upon the commencement of sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard', window );">Operating lease liabilities recognized upon the commencement of sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease liabilities recognized upon adoption of standard.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Q1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,336<span></span>
</td>
<td class="nump">$ 46,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">682<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent', window );">Prepaid research and development</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">34,741<span></span>
</td>
<td class="nump">47,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">4,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets - operating leases</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">10,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,462<span></span>
</td>
<td class="nump">62,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,895<span></span>
</td>
<td class="nump">4,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Non-refundable sublicense and transition services payments</a></td>
<td class="nump">13,750<span></span>
</td>
<td class="nump">13,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="nump">3,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,104<span></span>
</td>
<td class="nump">23,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="nump">4,606<span></span>
</td>
<td class="nump">20,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">24,710<span></span>
</td>
<td class="nump">43,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both March 31, 2026 and December 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paidin capital</a></td>
<td class="nump">724,068<span></span>
</td>
<td class="nump">723,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(712,316)<span></span>
</td>
<td class="num">(704,757)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(659,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">11,752<span></span>
</td>
<td class="nump">18,755<span></span>
</td>
<td class="nump">$ 46,706<span></span>
</td>
<td class="nump">61,261<span></span>
</td>
<td class="nump">$ 111,283<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 36,462<span></span>
</td>
<td class="nump">$ 62,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PrepaidResearchAndDevelopmentAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Q1) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,207,810<span></span>
</td>
<td class="nump">3,182,810<span></span>
</td>
<td class="nump">3,161,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">3,207,810<span></span>
</td>
<td class="nump">3,182,810<span></span>
</td>
<td class="nump">3,161,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss (Q1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 7,737<span></span>
</td>
<td class="nump">$ 23,276<span></span>
</td>
<td class="nump">$ 40,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="nump">24,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net gain on lease termination</a></td>
<td class="num">$ (600)<span></span>
</td>
<td class="num">(633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,247)<span></span>
</td>
<td class="num">(16,459)<span></span>
</td>
<td class="num">(49,296)<span></span>
</td>
<td class="num">(70,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">5,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,405)<span></span>
</td>
<td class="num">$ (45,522)<span></span>
</td>
<td class="num">$ (64,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (4.87)<span></span>
</td>
<td class="num">$ (14.35)<span></span>
</td>
<td class="num">$ (21.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.36)<span></span>
</td>
<td class="num">$ (4.87)<span></span>
</td>
<td class="num">$ (14.35)<span></span>
</td>
<td class="num">$ (21.04)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,205,866<span></span>
</td>
<td class="nump">3,163,914<span></span>
</td>
<td class="nump">3,172,870<span></span>
</td>
<td class="nump">3,078,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,205,866<span></span>
</td>
<td class="nump">3,163,914<span></span>
</td>
<td class="nump">3,172,870<span></span>
</td>
<td class="nump">3,078,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,405)<span></span>
</td>
<td class="num">$ (45,522)<span></span>
</td>
<td class="num">$ (64,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,413)<span></span>
</td>
<td class="num">$ (45,530)<span></span>
</td>
<td class="num">$ (64,716)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Q1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paidin capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning of period at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705,794<span></span>
</td>
<td class="num">$ (43)<span></span>
</td>
<td class="num">$ (594,468)<span></span>
</td>
<td class="nump">$ 111,283<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">2,805,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">45,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64,767)<span></span>
</td>
<td class="num">(64,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,488<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(659,235)<span></span>
</td>
<td class="nump">61,261<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">3,161,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">4,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,405)<span></span>
</td>
<td class="num">(15,405)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(674,640)<span></span>
</td>
<td class="nump">46,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2025</a></td>
<td class="nump">3,165,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning of period at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720,488<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(659,235)<span></span>
</td>
<td class="nump">61,261<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">3,161,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">16,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,522)<span></span>
</td>
<td class="num">(45,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(704,757)<span></span>
</td>
<td class="nump">18,755<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2025</a></td>
<td class="nump">3,182,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 724,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (712,316)<span></span>
</td>
<td class="nump">$ 11,752<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2026</a></td>
<td class="nump">3,207,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Q1)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (15,405)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Sharebased compensation</a></td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium and discount on marketable securities, net</a></td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">2,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, and other assets</a></td>
<td class="num">(709)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Non-refundable sublicense and transition services payments received</a></td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Right of use assets and operating lease liabilities</a></td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(2,713)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(13,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable securities</a></td>
<td class="nump">39,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Sales of property and equipment and other assets</a></td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">39,631<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">25,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning</a></td>
<td class="nump">37,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end</a></td>
<td class="nump">63,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets', window );">Deferred proceeds from equipment sale in other current assets</a></td>
<td class="num">$ (585)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred proceeds from sale of equipment in other current assets in non-cash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">1. Nature of Operations </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#8217;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#8217;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-<span style="font-style: italic;">GRN</span>,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">1. Nature of Operations </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#8217;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#8217;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-<span style="font-style: italic;">GRN</span>,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityAbstract', window );"><strong>Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">2. Risks, Liquidity, and Going Concern </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $712.3 million as of March 31, 2026. The Company anticipates incurring
            additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its
            product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on March&#160;4, 2024. As of March 31, 2026, $15.8 million of capacity remains available to be sold under the ATM Facility. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These financial statements have been prepared in accordance with U.S.
            generally accepted accounting principles, or GAAP, assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In
            accordance with the Financial Accounting Standards Board&#8217;s, or FASB, Accounting Standards Codification, or ASC, Subtopic 205-40, <span style="font-style: italic;">Presentation of Financial Statements - Going Concern</span>, the Company has
            evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
            issued. The Company incurred net losses of approximately $7.6 million and $15.4 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, the Company had cash and cash equivalents totaling $33.3 million, which the Company does not expect to be sufficient to meet the Company&#8217;s capital requirements over the next 12 months. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result, there is substantial doubt about the Company&#8217;s ability to
            continue as a going concern within one year after the date that these financial statements are issued. The financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported
            expenses that may be necessary if the Company were unable to continue as a going concern. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April&#160;20, 2026, the Company announced that it has initiated a review of
            strategic alternatives to maximize shareholder value (see Note&#160;13). These strategic alternatives may include, but are not limited to, merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships,
            licensing opportunities, or other potential paths. The Company does not intend to provide updates on the strategic review until the board of directors approves a specific action or otherwise determines that disclosure is appropriate or
            required. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">or other arrangements on favorable terms, or at all. The terms of any
            financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, or prospects of funding are unfavorable, the Company could be required to further delay, reduce or eliminate
            research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">2. Risks and Liquidity </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $704.8 million as of December 31, 2025. The Company anticipates
            incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop
            its product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            issued 300,000 shares of its common stock under the ATM Facility, resulting in net proceeds of $8.7 million, after deducting offering costs of $0.3
            million in March&#160;2024. The Company is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on
            March&#160;5, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company plans to seek additional funding through public or private equity
            offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances
            or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding or prospects of funding are unfavorable,
            the Company could be required to further delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the Financial Accounting Standards Board&#8217;s, or FASB,
            Accounting Standards Codification, or ASC, Topic 205-40, <span style="font-style: italic;">Presentation of Financial Statements &#8211; Going Concern</span>, the Company has evaluated whether there are certain conditions and events, considered in
            the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company
            expects that its cash and cash equivalents will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these financial statements. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to risk and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">3. Summary of Significant Accounting Policies </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s complete summary of significant accounting policies can be found
            in &#8220;Note&#160;3. Summary of Significant Accounting Policies&#8221; in the audited financial statements included in the Company&#8217;s Annual Report filed on Form&#160;10-K for the year ended December 31, 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited financial statements have been prepared in
            accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_9c4ae5c452f740698340777ae9877470">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of
            shares of common stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity,
            have been adjusted retroactively to reflect the Reverse Stock Split for all periods presented. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Interim Financial Statements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited interim financial statements have been prepared
            from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the SEC, which permits reduced disclosures for interim periods. All adjustments, consisting only
            of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets, statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows have been made. Although these interim financial
            statements do not include all of the information and notes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of
            operations and cash flows are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and notes should be read in conjunction with the audited financial statements and notes
            included in the Company&#8217;s 2025 Annual Report filed on Form&#160;10-K. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">dictates the allocation of funds within its portfolio of money market
            funds. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money
            market funds.
          </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2026 consisted of money market funds. Cash consists of cash deposits at banking institutions. As of March&#160;31, 2025, all of the Company&#8217;s marketable
            securities matured and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#8217;s balance sheet. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company had cash and cash equivalents of $33.3 million and $46.3 million as of
            March 31, 2026 and December 31, 2025, respectively. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity.
            Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable securities sold are recognized as a component of other
            income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all
            marketable securities as current assets within the balance sheet. As of March 31, 2026, the Company had no marketable securities. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years
            for office equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company did not recognize any impairment expenses for long-lived assets for the three months ended March 31, 2026. The
            Company recognized impairment expenses for laboratory equipment and certain other assets of $2.6 million for the three months ended
            March 31, 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of March 31, 2026, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When assets and liabilities for operating leases are written off, the balances
            are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company did not
            recognize any impairment expenses for ROU assets for the three months ended March 31, 2026 or 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relate to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, and income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $0.7 million to other income (expense), net for the three months ended March 31, 2026, which consisted of $0.3 million attributable to interest income and $0.4 million
            related to income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $1.1 million to other income (expense), net for the three months ended March&#160;31, 2025, which consisted of $0.7 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $0.4 million related to income from subleases. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to 2026, the Company estimated the expected term of the stock options
            using the &#8220;simplified method,&#8221; as the Company had limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The
            Company now has sufficient historical exercise data and has determined it is no longer appropriate to use the &#8220;simplified method&#8221;. Additionally, the Company no longer uses comparable public company data to estimate expected volatility and
            instead bases its expected volatility assumption on the historical volatility of its own stock price. The Company will apply this methodology prospectively and the change in estimates did not have a material impact for the three months ended
            March 31, 2026. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur.
          </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;7) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue





































              from Contracts with Customer</span>s, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">704,699</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">25,000</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">62,500</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,593</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">848</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">872,700 </span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">768,047 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim periods. ASU 2025-11 is effective for the Company for interim periods within annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be
            applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement disclosures. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">3. Summary of Significant Accounting Policies </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying financial statements have been prepared in accordance with
            generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP&#160;as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_87ff84423c1d4358a1dd1652b1ad4132">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of shares of Common
            Stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity, have been adjusted
            retroactively to reflect the Reverse Stock Split for all periods presented. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which dictates the allocation of funds within its portfolio of money market funds. The Company has
            not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money market funds. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of December 31, 2025 consisted of money market funds. Cash consists of cash deposits at banking institutions. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. The Company held no marketable securities as of December 31, 2025. Marketable
            securities as of December 31, 2024 consisted of various securities as described in Note&#160;4. Marketable securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other
            comprehensive income (loss) within stockholders&#8217; equity. Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable
            securities sold are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund
            operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years for office
            equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. The Company recognized de minimis losses on disposals of property and equipment for the year ended
            December 31, 2025. The Company did not recognize any losses on disposals of property and equipment for the year ended December 31,
            2024. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company recognized impairment expenses for property and equipment of $3.5 million for the year ended December 31, 2025, $2.5
            million of which was for lab equipment, $0.9 of which was for leasehold improvements, and $0.1 million of which was for certain other assets. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result of the Company&#8217;s January&#160;2025 announcement to reduce its overall
            workforce and cease its lab operations, the Company reassessed asset groups at its lab in Hopewell, New Jersey, and evaluated such asset groups for impairment under FASB ASC Topic 360, <span style="font-style: italic;">Long-lived assets:
              Impairment or disposal of long-lived assets</span>. The Company determined the laboratory equipment was a separate asset group based on management&#8217;s implemented plans to sell the laboratory equipment and estimated the fair value of the
            laboratory equipment based on the estimated future cash flows from the sale of such equipment, resulting in impairment of laboratory equipment and certain other assets of $2.6 million. Subsequent to recording the impairment, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement and an estimated market participant subtenant borrowing rate and compared that to the carrying value of the asset group, resulting in impairment to leasehold improvements of $0.9 million. The impairment expense for the leasehold improvements relate to the proportional allocation of total impairment recognized for the asset group subject to
            impairment testing. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognized impairment expenses for property and equipment and
            certain other assets of $2.7 million for the year ended December&#160;31, 2024, which primarily relates to the proportional allocation of
            total impairments recognized for asset groups subject to impairment testing as further described in Note&#160;10. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of December 31, 2025, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company recognized impairment expenses for ROU assets of $2.6 million and $2.5 million in the years ended December 31, 2025 and 2024,
            respectively. These impairment expenses include the proportional allocation of total impairments recognized for the asset groups subject to impairment testing as further described in Note&#160;10. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, income from subleases, and the sale of certain tax credits. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $3.8 million to other income (expense), net for the year ended December 31, 2025, which consisted of $2.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $1.5 million from sublease income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $5.6 million to other income (expense), net for the year ended December 31, 2024, which consisted of $4.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities, $1.0 million from sublease income, and $0.3 million related to the sale of
            certain tax credits. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The expected term of the stock options is estimated using the &#8220;simplified
            method,&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the
            midpoint between the vesting period and the contractual term of the option. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For stock price volatility, the Company uses a composite of comparable public
            company data as a basis for its expected volatility and considers the historic volatility of its common stock from its initial public offering to date to calculate the fair value of option grants. The selection of comparable public company data
            requires the application of management&#8217;s judgement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;8) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue







              from Contracts with Customers</span>, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Income Taxes </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Income taxes are accounted for under the asset-and-liability method as
            required by FASB ASC Topic 740, <span style="font-style: italic;">Income Taxes</span>, or ASC 740. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
            carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
            the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">corresponding to the enactment date. Under ASC 740, a valuation allowance is
            required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">FASB ASC Subtopic 740-10, <span style="font-style: italic;">Accounting for
              Uncertainty of Income Taxes</span>, or ASC 740-10, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The
            Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax
            position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.
            In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income,
            net, within other income (expense), net. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">577,581</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">50,000</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,093</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">696</span></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,636</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">709,669</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">587,310</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
            Not Yet Adopted </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income&#160;&#8211;&#160;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed, and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">periods. ASU 2025-11 is effective for the Company for interim periods within
            annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement
            disclosures. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Pronouncements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2023, the FASB issued ASU No. 2023-09, <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>, or ASU 2023-09, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and
            income taxes paid. The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU&#160;are effective for annual periods beginning after December&#160;15, 2024 with
            early adoption permitted. The Company adopted this new accounting pronouncement retrospectively during the year ended December&#160;31, 2025. Refer to Note&#160;14 for additional disclosures. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Marketable Securities (FY)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">4. Cash, Cash Equivalents, and Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">The following table provides details regarding the Company&#8217;s portfolio of cash
            and cash equivalents: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost or </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized cost</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized gains</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized losses</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash accounts in banking institutions</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 5pt;">2,500</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 5pt;">2,500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">43,803 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">43,803 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$46,303</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$46,303 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash accounts in banking institutions</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 5pt;">3,527</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 5pt;">3,527 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 5pt;">29,058 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 5pt;">29,058 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988 </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$37,573</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$37,573</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 56.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following table provides details regarding the Company&#8217;s portfolio of
            marketable securities: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized cost</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized gains</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized losses</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 5pt;">5,970</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$<span style="padding-left: 5pt;">1</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 5pt;">5,971 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 5pt;">25,433 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 10pt;">6 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 5pt;">25,439</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 10pt;">1,864 </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 10pt;">1 </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 10pt;">1,865 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,908 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1) </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,908 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$39,175</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 1.67pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(1)</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$39,183</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, all of the Company&#8217;s marketable securities matured
            and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#8217;s balance sheet. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Non-Financial Instruments (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments and Non-Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments and Non-Financial Instruments</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">4. Fair Value of Financial Instruments and Non-Financial
            Instruments </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expenses and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <span style="font-style: italic;">Fair Value Measurement</span>, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: </div>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 1: </span>Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 2: </span>Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 3: </span>Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents include money market funds that are carried at cost, which approximates their fair value. The fair values are based on quoted market prices in active markets for
            identical assets and therefore are classified within Level&#160;1 of the fair value hierarchy. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Non-Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 inputs is determined by estimating the amount and timing of net future cash flows (which
            are unobservable inputs) and </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">discounting them using a risk-adjusted rate of interest. Significant
            increases or decreases in actual cash flows may result in valuation changes. There were no assets remeasured in the three months ended March 31, 2026. Assets remeasured in the three months ended March 31, 2025 included laboratory equipment and
            certain other assets which were sold prior to March&#160;31, 2025 and were not included in the balance sheet as of March&#160;31, 2025. The impairment related to the remeasurement of $2.6 million is included in the statement of operations for the three months ended March&#160;31, 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">5. Fair Value of Financial Instruments and Non-Financial
            Instruments </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <span style="font-style: italic;">Fair Value Measurement</span>, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: </div>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;1:</span> Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;2:</span> Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;3:</span> Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following fair value hierarchy table presents information about the
            Company&#8217;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 147.47pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.26pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 147.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement at </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reporting date using </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets for </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">identical </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$43,803</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">43,803</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$43,803</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;">$29,058</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;">$&#8212; </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29,058</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Marketable securities: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;">5,971</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt;">25,439</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;">1,865</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,908</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total marketable securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">39,183</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$29,058</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$44,171</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.89pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Non-Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">inputs is determined by estimating the amount and timing of net future cash
            flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest. Significant increases or decreases in actual cash flows may result in valuation changes. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following long-lived assets were measured at fair value, on a nonrecurring
            basis, during the years ended December 31, 2025 and 2024. Assets remeasured in 2024 or sold in 2025 are not included in the fair value presented as of December&#160;31, 2025. The significant assumptions utilized are further described in Notes 3 and
            10: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 189.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2025 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2025</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;">$<span style="padding-left: 5pt;">3,155</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$3,373 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 10pt;">9,489</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;">2,633 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">139 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$12,644</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,145</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 61.43pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 189.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.54pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2024 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2024</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;">$1,668</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$2,279 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 5pt;">1,642</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;">2,516 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">200</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">438 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,510</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,233</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">5. Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Property and equipment, net, consists of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;">$<span style="padding-left: 15.83pt;">55</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 10.83pt;">107 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">959 </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">306</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,564</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt;">2,884 </span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,058) </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917) </span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">826</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;4, 2026, the Company entered into the Hopewell Lease Termination
            Agreement. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $4.8
            million as well as accrued rent through February&#160;14, 2026. As a result of the Hopewell Lease Termination Agreement, the Company recognized a net gain of $0.6 million on the lease termination for the three months ended March 31, 2026. The net gain is comprised of a $3.8
            million gain on the write-off of assets and liabilities for operating leases offset by a $3.2 million net loss on disposal of
            property and equipment. The assets disposed of as part of the termination included office equipment, leasehold improvements, furniture and fixtures, and computer hardware and software. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Depreciation and amortization expense was $0.1 million and $0.2 million for the
            three months ended March 31, 2026 and 2025, respectively. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">6. Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Property and equipment, net, consists of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 15.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;">$10,020 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.87pt;">119</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10.74pt;">1,111</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.5pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,386</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 5pt;">19,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917)</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,724)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9,331</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the Company&#8217;s January&#160;2025 announcement to reduce its
            overall workforce by 55% and cease its lab operations in Hopewell, New Jersey, management implemented plans to sell substantially
            all the laboratory equipment and certain other assets and estimated the fair value of the assets based on the estimated future cash flows from the sale of such assets. Subsequent to recording the impairment of $2.6 million, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. As a result, the Company did not record any
            depreciation on the impaired and disposed laboratory equipment during the year ended December&#160;31, 2025 as the equipment was considered held-for-sale in January&#160;2025. Neither laboratory equipment nor accumulated depreciation related to such
            equipment are recorded on the balance sheet as of December&#160;31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Depreciation and amortization expense was $0.7 million and $3.1 million for the
            years ended December 31, 2025 and 2024, respectively. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">6. Accrued Expenses and Other Current Liabilities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses and other current liabilities consisted of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;">$<span style="padding-left: 7.5pt;">500</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,297</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,174</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,895</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">7. Accrued Expenses and Other Current Liabilities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses and other current liabilities consisted of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">406 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">4,405</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">1,896</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,707</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Gemma License Agreement (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborativeArrangementDisclosureAbstract', window );"><strong>Gemma License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Gemma License Agreement</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">7. Gemma License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $15.0 million in
            initial payments for licenses and clinical product supply, of which $5.0 million was previously received, $5.0 million of which was due in May&#160;2025, of which $2.5
            million has been received, and $5.0 million of which was due in March&#160;2026, and has not yet been received; (ii) an additional $5.0 million contingent on Gemma completing certain business milestones; (iii) up to an additional $114.0 million in development and commercial milestone payments; and (iv) single digit royalties as a percentage of annual worldwide net sales, in exchange for sublicenses
            to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will be responsible for all payments due to the Trustees of </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">the University of Pennsylvania&#8217;s, or Penn, under the Company&#8217;s research,
            collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs. On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services
            Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which, the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for
            transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of March 31, 2026, the Company has received initial payments of $7.5 million associated with the aggregate $15.0 million of initial payments
            to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $4.8 million associated with the
            Transition Services Agreement and applied $1.5 million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts
            due to the Company for transition services under these agreements. The Company recorded these amounts ($13.8 million) as
            non-refundable sublicense and transition services payments on the balance sheet as of March 31, 2026, as the criteria set forth above have not yet been met. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">8. Gemma License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $15.0 million in
            initial payments for licenses and clinical product supply, of which $7.5 million was previously received, $2.5 million of which was due in May&#160;2025, and $5.0
            million of which is due in March&#160;2026; (ii) an additional $5.0 million contingent on Gemma completing certain business milestones;
            (iii) up to an additional $114.0 million in development and commercial milestone payments; and (iv) single digit royalties as a
            percentage of annual worldwide net sales, in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will
            be responsible for all payments due to the Trustees of the University of Pennsylvania&#8217;s, or Penn, under the Company&#8217;s research, collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs.
            On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which,
            the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. As of
            December 31, 2025, the Company has collected $7.5 million in initial payments, $4.8 million in transition services payments, and applied $1.5
            million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts due to the Company for transition services under these agreements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of December 31, 2025, the Company has received initial payments of $7.5 million associated with the aggregate $15.0 million of
            initial payments to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $4.8 million associated
            with the Transition Services Agreement and applied $1.5 million in amounts owed to Gemma for the Huntington&#8217;s disease program against
            amounts due to the Company for transition services under these agreements. The Company recorded these amounts ($13.8 million) as
            non-refundable sublicense and transition services payments on the balance sheet as of December 31, 2025, as the criteria set forth above have not yet been met. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Severance (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Severance</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">8. Severance </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the three months ended March 31, 2026, the Company did not record any severance and termination-related costs (see Note&#160;13). </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately 55%.





            In accordance with ASC 420, <span style="font-style: italic;">Exit and Disposal Activities</span>, the Company recorded severance and termination-related costs of $0.4 million in general and administrative expenses and $1.3 million in
            research and development expenses for the three months ended March 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">As of March 31, 2026, there were no unpaid severance and termination-related costs. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">9. Severance </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately 55%.
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with ASC 420, <span style="font-style: italic;">Exit and
              Disposal Activities</span>, the Company recorded severance and termination-related costs of $0.4 million in general and
            administrative expenses and $1.3 million in research and development expenses for the year ended December 31, 2025. During the year
            ended December 31, 2024, the Company recorded no severance and termination-related costs. As of December 31, 2025, there were no unpaid severance and termination-related costs. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">9. Leases </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2005 Market Street Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately 37,000
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to extend the term of the 2005 Market Street Lease Agreement by two
            additional terms of five years each. The Company has an option to early terminate the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than fifteen months prior to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#8217;s measurement of the ROU asset and operating lease liability
            as of March 31, 2026. During 2023, the Company subleased all of the space at 2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement A </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately 8,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to extend the sublease agreement through November&#160;30, 2031. The base sublease rent is $0.1 million per year and increases by 2.75% annually through the
            expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC Topic 842, <span style="font-style: italic;">Leases</span>,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Sublease Agreement B </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately 29,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024 and Sublessee B has elected the option to extend the term of the sublease
            agreement through March&#160;31, 2029. The base sublease rent is $0.9 million per year for the entire term of the sublease. Additionally,
            Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005 Market Street Lease
            Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Laboratory Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company was also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and was expected to expire in March&#160;2036 with an option to extend the term of the Laboratory Lease Agreement by up to&#160;two five-year terms. On March&#160;4,
            2026, the Company entered into the Hopewell Lease Termination Agreement with the Landlord. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $4.8 million as well as accrued rent through February&#160;14, 2026. The Company has no further obligations under the Laboratory Lease Agreement
            subsequent to the effective date of the Hopewell Lease Termination Agreement. As of March&#160;4, 2026, the Company recognized a net gain of $0.6
            million on the lease termination comprised of a $3.8 million gain on the write-off of assets and liabilities for operating leases
            offset by a $3.2 million net loss on disposal of property and equipment, which was primarily leasehold improvements. As a result of
            the Hopewell Lease Termination Agreement, ROU assets decreased $9.4 million and lease liabilities for operating leases decreased $18.0 million during the three months ended March 31, 2026. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Hopewell Sublease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately 3,200 square feet, or 5% of its approximately 62,000 square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and was scheduled to expire on December&#160;31, 2029, with an option for Sublessee C to extend the term of the
            sublease through December&#160;2032. The base sublease rent was $0.1 million per year and increased by 2.5% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C was required to pay the portion of the common
            area maintenance expenses, operating expenses, and use and occupancy taxes that the Company was required to pay under the Laboratory Lease Agreement. In connection with the Hopewell Lease Termination Agreement on March&#160;4, 2026, the Hopewell
            Sublease Agreement was concurrently terminated. The Company has no ongoing sublease arrangements related to the Hopewell, New Jersey laboratory space. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes future minimum lease payments for the Company&#8217;s
            lessee operating lease, which comprises of the 2005 Market Street Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A and Sublease Agreement B, as the Company was not relieved of its primary
            obligation under the 2005 Market Street Lease Agreement: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 420pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 30.83pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 420pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 8.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 10.83pt;">900 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,270</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,308</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,348</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,388</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">7,447</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,692)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">5,755</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 420pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The following table summarizes lease expense by lease type that was
            recognized during the three months ended March&#160;31, 2026 and 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease expense</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$476</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;">$<span style="padding-left: 7.5pt;">880 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease expense</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 1.5pt;">326 </span></td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">538 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$802</span></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,418</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">9.0% </div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">5.8 </div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;">10.0 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The cash paid for amounts included in the measurement of the Company&#8217;s
            operating lease liabilities for the three months ended March 31, 2026 and 2025 were $0.6 million and $1.0 million, respectively, recorded in operating cash flows. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes sublease income that was recognized in other
            income (expense), net during the three months ended March 31, 2026 and 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$356</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$367</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">10. Leases </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2005 Market Street Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately 37,000
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to extend the term of the 2005 Market Street Lease Agreement by two additional terms of five years each. The Company has an option to early terminate
            the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than fifteen months prior
            to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#8217;s measurement of the ROU asset and operating lease liability as of December 31, 2025. During 2023 the Company subleased all of the space at
            2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement A </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately 8,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to extend the sublease agreement through November&#160;30, 2031. The base sublease rent is $0.1 million per year and increases by 2.75% annually through
            the expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses, and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC Topic 842, <span style="font-style: italic;">Leases</span>,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement B </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately 29,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024, and continues through August&#160;2026. Sublessee B has an option to extend the
            term of the sublease agreement through March&#160;31, 2029. The base sublease rent is $0.9 million per year for the entire term of the
            sublease. Additionally, Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005
            Market Street Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1835 Market Street Sublease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February&#160;20, 2024, the Company entered into a sublease agreement with a
            counterparty, or the 1835 Market Street Sublease Agreement. Under the 1835 Market Street Sublease Agreement, the Company subleased approximately 16,000
            square feet of office space in Philadelphia, Pennsylvania. The sublease term began on March&#160;26, 2024 and expired on September&#160;30, 2025. The Company had the option but did not elect to extend the term of the sublease agreement through February&#160;28, 2029. The base sublease rent was $0.3 million per year for the original 18-month term of the
            sublease. Additionally, the Company was required to pay utility costs associated with the subleased premises. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Laboratory Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and is expected to expire in March&#160;2036. The </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">Company has an option to early terminate the Laboratory Lease Agreement as of March&#160;2032 given notice is provided to the landlord no less than twelve months prior to March&#160;2032. The Company has an option to extend the term of the Laboratory Lease Agreement by up to&#160;two five-year terms. These options were not recognized as
            part of the Company&#8217;s measurement of the ROU asset and operating lease liability as of December 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company implemented a restructuring plan which included
            ceasing lab operations. As a result, the Company is no longer using any of the space covered by the Laboratory Lease Agreement and is actively pursuing opportunities to sublease all remaining space in the Laboratory Lease Agreement as well as
            discussing with the landlord potential alternatives. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Hopewell Sublease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately 3,200 square feet, or 5% of its approximately 62,000 square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and expires on December&#160;31, 2029. Sublessee C has the option to extend the term of the sublease through
            December&#160;2032. The base sublease rent is $0.1 million per year and increases by 2.5% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C is required to pay the portion of the common area maintenance expenses,
            operating expenses, and use and occupancy taxes that the Company is required to pay under the Laboratory Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the Laboratory Lease Agreement. The Company continues to account for the Laboratory Lease Agreement as a lessee and in the same manner as prior to the execution of the Hopewell
            Sublease Agreement. The Company accounted for the Hopewell Sublease Agreement as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2024, the Company determined triggering events were present and reassessed
            the asset groups related to its laboratory space under the Laboratory Lease Agreement, which resulted in changes to the Company&#8217;s identified asset groups. The Company determined whether an impairment indicator was present for each of the new
            asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying values, which includes ROU assets, leasehold improvements, and other property and equipment allocable to the
            laboratory space for those asset groups. The Company concluded the carrying values of certain asset groups were not recoverable as they exceeded the estimated undiscounted cash flows. The Company calculated the amount of impairment on those
            asset groups using a discounted cash flow model to calculate the fair value of the asset group which incorporated the net identifiable cash flows for the term of the Hopewell Sublease Agreement, including an estimate for cash flows in the
            residual period, and an estimated borrowing rate of a market participant subtenant. As a result, certain asset groups were impaired and the Company recognized impairment expense of $5.2 million, including $2.5 million for the ROU assets, $2.3 million for the property and equipment, net, and $0.4
            million for certain other assets during the year ended December&#160;31, 2024. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the January&#160;2025 announcement to reduce its overall
            workforce by 55% and cease its lab operations in Hopewell, New Jersey, the Company determined triggering events were present and
            reassessed its asset groups related to its laboratory space under the Laboratory Lease Agreement. Laboratory equipment was separated from the ROU assets and leasehold improvements allocable to the laboratory space as the equipment was no longer
            being used in operations and the Company had implemented a plan to sell those assets. For the ROU assets and allocable leasehold improvements, the Company compared the estimated undiscounted cash flows from subleasing to the carrying value and
            determined there was no impairment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement based upon sublease market activity and an estimated market </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">participant subtenant borrowing rate and compared that to the carrying value
            of the asset group. As a result, the Company recognized impairment expense of $3.5 million, including $2.6 million for the ROU assets and $0.9
            million for the leasehold improvements during the year ended December 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes future minimum lease payments for the Company&#8217;s
            lessee operating leases, which comprises of the 2005 Market Street Lease Agreement and the Laboratory Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A, Sublease Agreement B, and the
            Hopewell Sublease Agreement as the Company was not relieved of its primary obligation under the 2005 Market Street Lease Agreement and Laboratory Lease Agreement: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,757 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,863</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,973</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,085</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,200</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,421</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">37,299</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(13,289)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">24,010</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes lease expense by lease type that was recognized
            during the years ended December&#160;31, 2025 and 2024: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease cost</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,419</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,505 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease cost</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,103</span></div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,127</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,522</span></div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,632</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.7% </div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.3 </div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;">10.2 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The cash paid for amounts included in the measurement of the Company&#8217;s
            operating lease liabilities for the years ended December&#160;31, 2025 and 2024 were $3.9 million and $3.8 million, respectively, recorded in operating cash flows. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes sublease income that was recognized in other
            income (expense), net during the years ended December 31, 2025 and 2024: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$1,467</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.25pt; text-align: left;">$987</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">10. Commitments and Contingencies </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Amended and Restated Research, Collaboration
            and License Arrangement with Penn </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company (i)&#160;terminated the funding of discovery research programs; (ii) terminated the research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS,
            indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe and MLD and certain platform
            technologies resulting from the discovery programs that it funded. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the Company&#8217;s licensed programs in FTD, GM1, Krabbe and MLD, the Penn
            License Agreement requires that it make payments of up to $16.5 million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $55.0 million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Gemma - Research, Collaboration and
            License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New Drug,
            or IND, enabling work for the Company&#8217;s active research program in Huntington&#8217;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and
            (ii)&#160;Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $16.5 million per product candidate in the aggregate for Huntington&#8217;s disease and any future CNS indications available to the
            Company under its four options and (ii) $39.0 million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $1.0 million per product indication, with $0.5 million due upfront and another $0.5
            million fee owed upon a further developmental milestone. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;7. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Catalent Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#8217;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $0.9 million to Catalent which is accrued as of March 31, 2026. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Litigation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of March 31, 2026. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#8217;s initial
            public offering in February&#160;2020, he was promised 150,000 shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to 33,836 shares (1,692 shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it agreed with the
            Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the initial public
            offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#8217;s favor, finding that no binding agreement was reached and that the plaintiff was not entitled
            to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate co<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">urt affirmed the entry of judgment in favor of the Company and on October&#160;7, 2025, the plaintiff filed an Application for Reargument to the
              Superior Court of Pennsylvania. In December&#160;2025, the plaintiff petitioned for review of their appeal to the Pennsylvania Supreme Court. The Company intends to continue to defend against this claim. </span></div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other than the above, the Company is not presently a party to any legal
            proceedings that, in the opinion of management, would, if decided against the Company, have a material adverse effect on the Company&#8217;s business. Regardless of outcome, litigation can have an adverse impact on the Company due to defense and
            settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Employment Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to 150% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">11. Commitments and Contingencies </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Amended and Restated Research, Collaboration
            and License Arrangement with Penn </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">(i)&#160;terminated the funding of discovery research programs; (ii) terminated the
            research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS, indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate
            transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe, and MLD and certain platform technologies resulting from the discovery programs that it funded. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the Company&#8217;s licensed programs in FTD, GM1, Krabbe, and MLD, the Penn
            License Agreement requires that it make payments of up to $16.5 million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications, and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $55.0 million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Gemma - Research, Collaboration and
            License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New
            Drug-enabling work for the Company&#8217;s active research program in Huntington&#8217;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and (ii)
            Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $16.5 million per product candidate in the aggregate for Huntington&#8217;s disease and any future CNS indications available to the
            Company under its four options and (ii) $39.0 million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $1.0 million per product indication, with $0.5 million due upfront and another $0.5
            million fee owed upon a further developmental milestone. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;8. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Catalent Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#8217;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements, is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $0.9 million to Catalent which has been accrued as of and during the year ended December&#160;31, 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Litigation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of December 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#8217;s initial
            public offering in February&#160;2020, he was promised 150,000 shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to 33,836 shares (1,692 shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it
            agreed with the Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the
            initial public offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#8217;s favor, finding that no binding agreement was reached and that the plaintiff
            was not entitled to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate court affirmed the entry of judgment in favor of the Company and on
            October&#160;7, 2025, the plaintiff filed an Application for Reargument to the Superior Court <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">of Pennsylvania. In December 2025, the Superior Court of Pennsylvania denied the Application for Reargument. In December 2025,</span> the plaintiff petitioned for review of their appeal to the Pennsylvania
            Supreme Court which is currently pending. The Company intends to continue to defend against this claim. </div>

<div class="BRDSX_h3" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Other than the above, we are not presently a party to any legal proceedings
              that, in the opinion of management, would, if decided against us, have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management
              resources, negative publicity and reputational harm, and other factors. </span></div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Employment Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to 150% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (FY)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">12. Common Stock </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            issued 300,000 shares of common stock under the ATM Facility, resulting in net proceeds of $8.7 million, after deducting offering costs of $0.3 million
            in March&#160;2024. The Company is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on March&#160;5,
            2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected the Reverse Stock Split. The Reverse
            Stock Split did not reduce the number of authorized shares of the common stock and did not change the par value of the common stock. In addition, proportionate adjustments were made to the number of shares of common stock available for issuance
            under the Company&#8217;s equity inducement and incentive plans; the number of shares underlying, and the exercise prices of outstanding equity awards under such plans. All share information in these financial statements has been adjusted for this
            Reverse Stock Split. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">11. Stockholder&#8217;s Equity and Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected the Reverse Stock Split. The Reverse
            Stock Split did not reduce the number of authorized shares of the common stock and did not change the par value of the common stock. In addition, proportionate adjustments were made to the number of shares of common stock available for issuance
            under the Company&#8217;s equity inducement and incentive plans; the number of shares underlying, and the exercise prices of outstanding equity awards under such plans. All share information in these financial statements has been adjusted for this
            Reverse Stock Split. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The total number of shares authorized under the Incentive Plan as of March 31,
            2026 was 1,106,739. Additionally, 204,732
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of March 31, 2026, 405,163
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January&#160;1st of each
            year, commencing on January&#160;1, 2021 and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 159,141 and 155,155 shares in January&#160;2026 and 2025,
            respectively. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Inducement Plan was approved by the Company&#8217;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of March 31, 2026 was 125,000. Of this amount, 87,634 shares were available for future grants as of March 31, 2026. The Inducement Plan provides for the granting of nonqualified stock options and
            restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest based on requisite service period and have a term of ten years. The Company&#8217;s restricted stock units awarded to date under the Inducement Plan vest based on requisite service period and have a term
            based on each award agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at their grant-date fair value and
            records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations and
            comprehensive loss for the period presented:</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> <br/></div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$142</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$244 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">614</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$556</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$858</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The following table summarizes stock option activity for the three months ended
            March 31, 2026: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.14pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$44.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">191,510</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 10pt;">7.64</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,376)</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 5pt;">10.99</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">846,107</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">387,675</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$74.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The weighted average grant date fair value of options granted was $5.81 and $6.20 for the three months
            ended March&#160;31, 2026 and 2025, respectively. As of March 31, 2026, the total unrecognized compensation expense related to unvested stock option awards was $3.6 million, which the Company expects to recognize over a weighted average period of 2.6
            years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The aggregate intrinsic value of options outstanding was $0.1 million at March 31, 2026 and was de minimis at March&#160;31, 2025. The aggregate intrinsic value of options exercised and options exercisable were
            each de minimis during the three months ended March 31, 2026 and 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">92.4%</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.8%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.9%</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.8 years</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Restricted Stock Units </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company issues RSUs to employees that vest over periods of time as
            determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant. Compensation expense is
            recognized on a straight-line basis over the vesting period of the RSUs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes activity related to RSU awards during the three
            months ended March 31, 2026: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">50,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(25,000)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">25,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$11.70</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2026, the total unrecognized expense related to all RSUs was $0.2 million, which the Company expects to recognize over a weighted-average period of 0.8 years. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Employee Stock Purchase Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to 99,088 shares of the Company&#8217;s common stock. Of this amount, 59,103 were available for future grants as of March 31, 2026. The number of shares of the Company&#8217;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for ten years, in an amount
            equal to one percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP were not increased. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock
            through accumulated payroll deductions at such times as are established by the board of directors&#8217; Compensation Committee. Eligible employees may purchase the Company&#8217;s common stock at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000
            worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than 200 shares of
            the Company&#8217;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from 200 shares to 2,000 shares in any single offering period, not to exceed $25,000 in any calendar year. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the guidance in ASC Topic 718-50,<span style="font-style: italic;"> Compensation &#8211; Stock Compensation</span>, the ability to purchase shares of the Company&#8217;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the
            purchase date) represents an option and<span style="font-weight: bold;">, </span>therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair
            value as estimated by applying the Black-Scholes option-pricing model and is recognized over the withholding period. No
            share-based compensation expense related to the ESPP was recorded during the three months ended March&#160;31, 2026 and 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">13. Share-Based Compensation </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020&#160;Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The total number of shares authorized under the Incentive Plan as of December
            31, 2025 was 947,598. Additionally, 204,732
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of December 31, 2025, 433,624
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January 1st of each
            year, commencing on January 1, 2021 and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 159,141 and 155,155 shares in January&#160;2026 and 2025,
            respectively. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Inducement Plan was approved by the Company&#8217;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of December 31, 2025 was 125,000. Of this amount, 87,166 shares were </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> available for future grants as of December 31, 2025. The Inducement Plan
            provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest
            based on requisite service period and have a term of ten years. The Company&#8217;s restricted stock units awarded to date under the
            Inducement Plan vest based on requisite service period and have a term based on each award agreement. </div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 7.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$2,529 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,001</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,820</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The following table summarizes stock option activity for the year ended
            December 31, 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">577,581</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">77.56</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">248,208</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 15pt;">7.78</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;">(125,526)</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">82.56</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(41,290)</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt;">175.24</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">658,973<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">357,766<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">78.82</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">658,973</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The weighted-average grant date fair value of options granted was $6.07 and $20.20 for the years ended
            December 31, 2025 and 2024, respectively. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The aggregate intrinsic value of options outstanding was $0.9 million at December 31, 2025 and was de minimis at December 31, 2024. The aggregate intrinsic value of options exercisable was $0.2 million at December 31, 2025 and was de minimis at December 31, 2024. There were no options exercised during the year ended December 31, 2025 and the aggregate intrinsic value of options exercised during the year ended December 31, 2024 was de minimis.
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the total unrecognized compensation expense related
            to unvested stock option awards was $3.0 million, which the Company expects to recognize over a weighted-average period of 2.2 years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.7%</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">88.4%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.2%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.9 years</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Restricted Stock Units </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company issues restricted stock units, or RSUs, to employees that vest
              over periods of time as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant.
              Compensation expense is recognized on a straight-line basis over the vesting period of the RSUs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following table summarizes activity related to RSU awards during the year
            ended December 31, 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 8.33pt;">7,093</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$44.80 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">60,000</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(16,825)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">27.92</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(268)</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">90.40</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">50,000<br/>
                    </span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the total unrecognized expense related to all RSUs
            was $0.3 million, which the Company expects to recognize over a weighted-average period of 1.0 years. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employee Stock Purchase Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to 99,088 shares of the Company&#8217;s common stock. Of this amount, 59,103 were available for future grants as of December 31, 2025. The number of shares of the Company&#8217;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January&#160;1st of each year and continuing for ten years, in an amount
            equal to one percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP was not increased. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock
            through accumulated payroll deductions at such times as are established by the board of director&#8217;s Compensation Committee. Eligible employees may purchase the Company&#8217;s common stock at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000
            worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than 200 shares of
            the Company&#8217;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from 200 shares to 2,000 shares in any single offering period, not to exceed $25,000 in any calendar year. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the guidance in ASC Topic 718-50,<span style="font-style: italic;"> Compensation &#8211; Stock Compensation</span>, the ability to purchase shares of the Company&#8217;s common stock at 85% of the
            lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and<span style="font-weight: bold;">, </span>therefore, the ESPP is a compensatory plan under this
            guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. No share-based compensation expense related to the ESPP was recorded during the years ended December 31, 2025 and 2024. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (FY)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">14. Income Taxes </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The tax effects of temporary differences that gave rise to significant
            portions of the deferred tax assets and liabilities were as follows: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets:<br/>
                  </div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net operating loss carryforwards</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$105,425</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$94,923 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development credits</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">55,020</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">50,842</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration and license agreement</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 15pt;">2,832</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">3,422</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="margin-top: 11.25pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Capitalized research and development</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 13.33pt;">46,041</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 13.33pt;">59,803</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;">4,329</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;">5,863</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses and other</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;">4,581</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;">1,404</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liabilities</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;">6,520</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;">7,560</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,048</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">461</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total gross deferred tax assets before valuation allowance</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 8.33pt;">225,796</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"><span style="padding-left: 8.33pt;">224,278</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valuation allowance</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(222,752)</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(219,833)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Net deferred tax assets</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,044</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,445</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax liabilities:<br/>
                  </div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right of use assets - operating leases</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,044)</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(4,445)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total deferred tax liabilities</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,044)</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(4,445)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Net deferred taxes</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In assessing the need for a valuation allowance, management must determine
            that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined the deferred tax assets do not meet the more-likely-than-not
            threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December 31, 2025 and 2024. The valuation allowance increased by $2.9 million and $19.1 million during
            the years ended December 31, 2025 and 2024, respectively. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the year ended December&#160;31, 2025, the Company adopted ASU No. 2023-09,
            <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span> retrospectively. A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="height: 6pt; width: 165.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 165.09pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 73.44pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 76.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">US federal statutory tax rate</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 1.67pt;">(9,560)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 3.33pt;">21.0%<br/>
                    </span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(13,601)</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 3.33pt;">21.0%</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Federal:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Tax credits:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Research and development tax credits</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt;">(175)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;">0.4</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(626)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;">1.0</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Orphan drug tax credits</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,003)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;">8.8</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(4,896)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;">7.6</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in valuation allowances</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">12,334</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;">(27.2)</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">17,422</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;">(27.0)</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Nontaxable or nondeductible items:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Share-based payment awards</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">241</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 5pt;">(0.5)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">459</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 5pt;">(0.7)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Expiration of share-based payment awards</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">1,159</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 5pt;">(2.5)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">1,233</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 5pt;">(1.9)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Other</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt;">4</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;">0.0</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt;">9</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;">0.0</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State and local income taxes, net of federal income tax effect<sup>1</sup></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective tax rate</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 26.06pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 26.06pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"> <br/></div>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic;">1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; text-align: justify;">In 2025 and 2024, state and local income taxes in Pennsylvania and Philadelphia comprise the majority of
                    the state and local income taxes, net of federal income tax effect category.<span style="font-style: normal;"> </span></div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the years ended December&#160;31, 2025 and 2024, the Company made no income tax payments. Additionally, the Company generated no foreign pre-tax income or losses during these periods, as all operations were conducted within the United States. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The following table summarizes carryforwards of federal, state and local net
            operating losses, or NOL, and research and development and orphan drug tax credits: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 91.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 91.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Federal</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$398,039</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$339,055 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">398,035</span></div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">339,051</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Local</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">277,828</span></div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">218,844</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research tax credits</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">55,020</span></div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">50,842</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For federal income tax purposes, $0.3 million of NOL carryforwards expire in 2037. The remaining federal NOL carryforwards were generated subsequent to January&#160;1, 2018, and therefore, are able to be carried
            forward indefinitely. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">For state income tax purposes, NOL carryforwards begin expiring in 2037, and
            expire through 2045. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For local income tax purposes related to the city of Philadelphia, NOL
            carryforwards begin expiring in 2042, and expire through 2045. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the Company also had $11.6 million of federal research and development and $43.4
            million orphan drug tax credit carryforwards that will begin to expire in 2038 and 2040, respectively, unless previously utilized. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The NOL and tax credit carryforwards are subject to review and possible
            adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders
            over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually
            to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in
            future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOL carryforwards may also be limited, including Pennsylvania, which limits NOL utilization as a
            percentage of apportioned taxable income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"><span style="-sec-ix-hidden:Fact_bf46da9b45834552bfbf43a7fff05a75">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net.</span> As of December 31, 2025, the Company had no accrued interest or penalties related to uncertain tax positions and no
            amounts have been recognized in the Company&#8217;s statement of operations. <span style="-sec-ix-hidden:Fact_76a8a6c10938470cb53d52e197480e2e">Tax years from 2022</span> and after remain subject to examination
            by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">12. Segment Reporting </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a <span style="-sec-ix-hidden:Fact_54f55c66f3b44146b30493895e843cea">single</span> reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies in the Company&#8217;s 2025 Annual Report filed on Form&#160;10-K. The Company&#8217;s CODM is its chief executive officer. The measure of segment assets is reported on the balance sheet as total assets. All
            assets are located within the United States. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The CODM uses net loss as reported on the Company&#8217;s statement of operations to
            assess the Company&#8217;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses exclude
            certain non-cash items such as share-based compensation and depreciation and amortization expenses. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes significant segment expenses: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 3.33pt;">1,458</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,589 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,432</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">3,794 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">142</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">244 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">61</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">110 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,093</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,737 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">1,891</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,790 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,415</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,603 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">614 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">67</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">78 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,787</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,085 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,637 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8,247)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(16,459)</span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">688</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,054 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(7,559)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(15,405)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 54.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The components of Other (income) expense, net are further described in Note&#160;3 to
            the financial statements. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">15. Segment Reporting </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a <span style="-sec-ix-hidden:Fact_6fcb045ac6ef441986cb7c4046a9cae6">single</span> reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies. The Company&#8217;s CODM is its chief executive officer. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The measure of segment assets is reported on the balance sheet as total
            assets. All assets are located within the United&#160;States. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> The CODM uses net loss as reported on the Company&#8217;s statement of operations
            to assess the Company&#8217;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses
            exclude certain non-cash items such as share-based compensation and depreciation and amortization expenses. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following table summarizes significant segment expenses: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$<span style="padding-left: 5pt;">7,462</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$12,265 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">14,532</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">22,691</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,529</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">440</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,694</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,276</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">40,179</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,784</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,255</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,644</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">12,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">288</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">387</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,875</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,988</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,145</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,296</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,400</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (income) expense, net</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,774)</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,633)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$45,522</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$64,767</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The components of Other (income) expense, net are further described in note 3
            to the financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (FY)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">13. Subsequent Events </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April&#160;20, 2026, the Company announced it has initiated a review of
            strategic alternatives to maximize shareholder value. These strategic alternatives may include merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships, licensing opportunities, or other
            potential paths. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April&#160;28, 2026, in connection with the Company&#8217;s review of strategic
            alternatives, the Company announced a restructuring of its workforce, or the Restructuring Plan, to decrease operating expenses by reducing the workforce by approximately 75%. The implementation of the Restructuring Plan should be substantially complete in the second and third quarters of 2026. The Company estimates the aggregate severance and related
            costs for the Restructuring Plan will be approximately $3.3 million, which will be recorded primarily in the second quarter of 2026.
            These estimates are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with,
            the Restructuring Plan as well as the Company&#8217;s review of strategic alternatives. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">On May 21, 2026, the Company provided written notice to Gemma to terminate
            the Gemma Collaboration Agreement, which termination will become effective in accordance with the terms of the Gemma Collaboration Agreement. Following the effectiveness of the termination, the Company will no longer have any rights to the
            research programs or the options for new CNS indications previously available to it under the Gemma Collaboration Agreement.</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On May 22, 2026, the Company and the landlord entered into a lease termination
            agreement pursuant to which the 2005 Market Street Lease Agreement was terminated and the Company paid a termination fee of $2.3
            million.</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On June 23, 2026, the Company delivered written notice to Penn to terminate
            the Penn License Agreement, pursuant to Section 10.2 thereof, solely with respect to the Company&#8217;s product candidate referred to as PBFT02 for all indications licensed to the Company thereunder for such product candidate, including
            frontotemporal dementia with granulin mutations, or the <span style="font-style: italic; font-weight: bold;">PBFT02 Termination</span>. The PBFT02 Termination will become effective on the date that is 90 days following Penn&#8217;s receipt of the
            notice, after which the Company will no longer have any rights under the Penn License Agreement to develop or commercialize PBFT02. The Penn License Agreement will remain in effect with respect to all non-terminated licensed products.</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On June 23, 2026, the Company delivered written notice to Catalent to
            terminate, pursuant to Section 20.1(b)(ii) thereof, the amended and restated development services and clinical supply agreement, dated November 9, 2023 (one of the Amended Catalent Agreements), in its entirety, effective as of June 23, 2026.
            The Company determined to terminate this agreement in connection with the wind-down of our gene therapy programs and the proposed Merger (as defined below), and the Company was not obligated to pay Catalent any termination fee in connection <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">with the termination.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 24, 2026, the Company entered into
              an Agreement and Plan of Merger and Reorganization, or the Merger Agreement, with Remix Therapeutics, Inc., a Delaware corporation, or Remix, and Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, or Merger
              Sub. Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Remix, with Remix continuing as a wholly-owned subsidiary of the Company and the surviving
              corporation of the merger. Upon termination of the Merger Agreement under specified circumstances the Company will be required to make a payment to Remix equal to $1.5 million in cash.</div>

<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
            </div>

<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> In July 2026, the Pennsylvania Supreme
              Court denied the petition for review with respect to the plaintiff&#8217;s challenge to the post-trial rulings in favor of Passage Bio, but it agreed to hear the question of whether certain communications between lawyers and the mediator were
              appropriately excluded from evidence at trial under Pennsylvania&#8217;s mediation privilege. The Pennsylvania Supreme Court timing for this hearing is currently pending.<br/>
            </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">16. Subsequent Events </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">None. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">1. Nature of Operations </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#8217;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#8217;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-<span style="font-style: italic;">GRN</span>,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">1. Nature of Operations </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#8217;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#8217;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-<span style="font-style: italic;">GRN</span>,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks, Liquidity, and Going Concern (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksLiquidityAndGoingConcernAbstract', window );"><strong>Risks, Liquidity, and Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityTextBlock', window );">Risks, Liquidity, and Going Concern</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">2. Risks, Liquidity, and Going Concern </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $712.3 million as of March 31, 2026. The Company anticipates incurring
            additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its
            product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on March&#160;4, 2024. As of March 31, 2026, $15.8 million of capacity remains available to be sold under the ATM Facility. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">These financial statements have been prepared in accordance with U.S.
            generally accepted accounting principles, or GAAP, assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In
            accordance with the Financial Accounting Standards Board&#8217;s, or FASB, Accounting Standards Codification, or ASC, Subtopic 205-40, <span style="font-style: italic;">Presentation of Financial Statements - Going Concern</span>, the Company has
            evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are
            issued. The Company incurred net losses of approximately $7.6 million and $15.4 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, the Company had cash and cash equivalents totaling $33.3 million, which the Company does not expect to be sufficient to meet the Company&#8217;s capital requirements over the next 12 months. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result, there is substantial doubt about the Company&#8217;s ability to
            continue as a going concern within one year after the date that these financial statements are issued. The financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported
            expenses that may be necessary if the Company were unable to continue as a going concern. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April&#160;20, 2026, the Company announced that it has initiated a review of
            strategic alternatives to maximize shareholder value (see Note&#160;13). These strategic alternatives may include, but are not limited to, merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships,
            licensing opportunities, or other potential paths. The Company does not intend to provide updates on the strategic review until the board of directors approves a specific action or otherwise determines that disclosure is appropriate or
            required. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">or other arrangements on favorable terms, or at all. The terms of any
            financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, or prospects of funding are unfavorable, the Company could be required to further delay, reduce or eliminate
            research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">2. Risks and Liquidity </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $704.8 million as of December 31, 2025. The Company anticipates
            incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop
            its product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            issued 300,000 shares of its common stock under the ATM Facility, resulting in net proceeds of $8.7 million, after deducting offering costs of $0.3
            million in March&#160;2024. The Company is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on
            March&#160;5, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company plans to seek additional funding through public or private equity
            offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances
            or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding or prospects of funding are unfavorable,
            the Company could be required to further delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the Financial Accounting Standards Board&#8217;s, or FASB,
            Accounting Standards Codification, or ASC, Topic 205-40, <span style="font-style: italic;">Presentation of Financial Statements &#8211; Going Concern</span>, the Company has evaluated whether there are certain conditions and events, considered in
            the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company
            expects that its cash and cash equivalents will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these financial statements. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to risk and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksLiquidityAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksLiquidityAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">3. Summary of Significant Accounting Policies </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s complete summary of significant accounting policies can be found
            in &#8220;Note&#160;3. Summary of Significant Accounting Policies&#8221; in the audited financial statements included in the Company&#8217;s Annual Report filed on Form&#160;10-K for the year ended December 31, 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited financial statements have been prepared in
            accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_9c4ae5c452f740698340777ae9877470">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of
            shares of common stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity,
            have been adjusted retroactively to reflect the Reverse Stock Split for all periods presented. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Interim Financial Statements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited interim financial statements have been prepared
            from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the SEC, which permits reduced disclosures for interim periods. All adjustments, consisting only
            of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets, statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows have been made. Although these interim financial
            statements do not include all of the information and notes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of
            operations and cash flows are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and notes should be read in conjunction with the audited financial statements and notes
            included in the Company&#8217;s 2025 Annual Report filed on Form&#160;10-K. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">dictates the allocation of funds within its portfolio of money market
            funds. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money
            market funds.
          </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2026 consisted of money market funds. Cash consists of cash deposits at banking institutions. As of March&#160;31, 2025, all of the Company&#8217;s marketable
            securities matured and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#8217;s balance sheet. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company had cash and cash equivalents of $33.3 million and $46.3 million as of
            March 31, 2026 and December 31, 2025, respectively. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity.
            Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable securities sold are recognized as a component of other
            income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all
            marketable securities as current assets within the balance sheet. As of March 31, 2026, the Company had no marketable securities. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years
            for office equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company did not recognize any impairment expenses for long-lived assets for the three months ended March 31, 2026. The
            Company recognized impairment expenses for laboratory equipment and certain other assets of $2.6 million for the three months ended
            March 31, 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of March 31, 2026, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When assets and liabilities for operating leases are written off, the balances
            are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company did not
            recognize any impairment expenses for ROU assets for the three months ended March 31, 2026 or 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relate to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, and income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $0.7 million to other income (expense), net for the three months ended March 31, 2026, which consisted of $0.3 million attributable to interest income and $0.4 million
            related to income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $1.1 million to other income (expense), net for the three months ended March&#160;31, 2025, which consisted of $0.7 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $0.4 million related to income from subleases. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to 2026, the Company estimated the expected term of the stock options
            using the &#8220;simplified method,&#8221; as the Company had limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The
            Company now has sufficient historical exercise data and has determined it is no longer appropriate to use the &#8220;simplified method&#8221;. Additionally, the Company no longer uses comparable public company data to estimate expected volatility and
            instead bases its expected volatility assumption on the historical volatility of its own stock price. The Company will apply this methodology prospectively and the change in estimates did not have a material impact for the three months ended
            March 31, 2026. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur.
          </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;7) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue





































              from Contracts with Customer</span>s, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">704,699</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">25,000</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">62,500</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,593</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">848</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">872,700 </span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">768,047 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim periods. ASU 2025-11 is effective for the Company for interim periods within annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be
            applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement disclosures. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">3. Summary of Significant Accounting Policies </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying financial statements have been prepared in accordance with
            generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP&#160;as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_87ff84423c1d4358a1dd1652b1ad4132">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of shares of Common
            Stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity, have been adjusted
            retroactively to reflect the Reverse Stock Split for all periods presented. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which dictates the allocation of funds within its portfolio of money market funds. The Company has
            not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money market funds. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of December 31, 2025 consisted of money market funds. Cash consists of cash deposits at banking institutions. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. The Company held no marketable securities as of December 31, 2025. Marketable
            securities as of December 31, 2024 consisted of various securities as described in Note&#160;4. Marketable securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other
            comprehensive income (loss) within stockholders&#8217; equity. Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable
            securities sold are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund
            operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years for office
            equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. The Company recognized de minimis losses on disposals of property and equipment for the year ended
            December 31, 2025. The Company did not recognize any losses on disposals of property and equipment for the year ended December 31,
            2024. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company recognized impairment expenses for property and equipment of $3.5 million for the year ended December 31, 2025, $2.5
            million of which was for lab equipment, $0.9 of which was for leasehold improvements, and $0.1 million of which was for certain other assets. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result of the Company&#8217;s January&#160;2025 announcement to reduce its overall
            workforce and cease its lab operations, the Company reassessed asset groups at its lab in Hopewell, New Jersey, and evaluated such asset groups for impairment under FASB ASC Topic 360, <span style="font-style: italic;">Long-lived assets:
              Impairment or disposal of long-lived assets</span>. The Company determined the laboratory equipment was a separate asset group based on management&#8217;s implemented plans to sell the laboratory equipment and estimated the fair value of the
            laboratory equipment based on the estimated future cash flows from the sale of such equipment, resulting in impairment of laboratory equipment and certain other assets of $2.6 million. Subsequent to recording the impairment, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement and an estimated market participant subtenant borrowing rate and compared that to the carrying value of the asset group, resulting in impairment to leasehold improvements of $0.9 million. The impairment expense for the leasehold improvements relate to the proportional allocation of total impairment recognized for the asset group subject to
            impairment testing. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognized impairment expenses for property and equipment and
            certain other assets of $2.7 million for the year ended December&#160;31, 2024, which primarily relates to the proportional allocation of
            total impairments recognized for asset groups subject to impairment testing as further described in Note&#160;10. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of December 31, 2025, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company recognized impairment expenses for ROU assets of $2.6 million and $2.5 million in the years ended December 31, 2025 and 2024,
            respectively. These impairment expenses include the proportional allocation of total impairments recognized for the asset groups subject to impairment testing as further described in Note&#160;10. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, income from subleases, and the sale of certain tax credits. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $3.8 million to other income (expense), net for the year ended December 31, 2025, which consisted of $2.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $1.5 million from sublease income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $5.6 million to other income (expense), net for the year ended December 31, 2024, which consisted of $4.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities, $1.0 million from sublease income, and $0.3 million related to the sale of
            certain tax credits. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The expected term of the stock options is estimated using the &#8220;simplified
            method,&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the
            midpoint between the vesting period and the contractual term of the option. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For stock price volatility, the Company uses a composite of comparable public
            company data as a basis for its expected volatility and considers the historic volatility of its common stock from its initial public offering to date to calculate the fair value of option grants. The selection of comparable public company data
            requires the application of management&#8217;s judgement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;8) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue







              from Contracts with Customers</span>, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Income Taxes </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Income taxes are accounted for under the asset-and-liability method as
            required by FASB ASC Topic 740, <span style="font-style: italic;">Income Taxes</span>, or ASC 740. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
            carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
            the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">corresponding to the enactment date. Under ASC 740, a valuation allowance is
            required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">FASB ASC Subtopic 740-10, <span style="font-style: italic;">Accounting for
              Uncertainty of Income Taxes</span>, or ASC 740-10, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The
            Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax
            position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.
            In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income,
            net, within other income (expense), net. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">577,581</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">50,000</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,093</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">696</span></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,636</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">709,669</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">587,310</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
            Not Yet Adopted </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income&#160;&#8211;&#160;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed, and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">periods. ASU 2025-11 is effective for the Company for interim periods within
            annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement
            disclosures. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Pronouncements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2023, the FASB issued ASU No. 2023-09, <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>, or ASU 2023-09, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and
            income taxes paid. The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU&#160;are effective for annual periods beginning after December&#160;15, 2024 with
            early adoption permitted. The Company adopted this new accounting pronouncement retrospectively during the year ended December&#160;31, 2025. Refer to Note&#160;14 for additional disclosures. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Non-Financial Instruments (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments and Non-Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments and Non-Financial Instruments</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">4. Fair Value of Financial Instruments and Non-Financial
            Instruments </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expenses and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <span style="font-style: italic;">Fair Value Measurement</span>, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: </div>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 1: </span>Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 2: </span>Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level 3: </span>Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents include money market funds that are carried at cost, which approximates their fair value. The fair values are based on quoted market prices in active markets for
            identical assets and therefore are classified within Level&#160;1 of the fair value hierarchy. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">Non-Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 inputs is determined by estimating the amount and timing of net future cash flows (which
            are unobservable inputs) and </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">discounting them using a risk-adjusted rate of interest. Significant
            increases or decreases in actual cash flows may result in valuation changes. There were no assets remeasured in the three months ended March 31, 2026. Assets remeasured in the three months ended March 31, 2025 included laboratory equipment and
            certain other assets which were sold prior to March&#160;31, 2025 and were not included in the balance sheet as of March&#160;31, 2025. The impairment related to the remeasurement of $2.6 million is included in the statement of operations for the three months ended March&#160;31, 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">5. Fair Value of Financial Instruments and Non-Financial
            Instruments </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <span style="font-style: italic;">Fair Value Measurement</span>, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: </div>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;1:</span> Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;2:</span> Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. </div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"><span style="font-style: italic;">Level&#160;3:</span> Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following fair value hierarchy table presents information about the
            Company&#8217;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 147.47pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.26pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 147.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement at </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reporting date using </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets for </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">identical </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$43,803</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">43,803</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$43,803</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;">$29,058</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;">$&#8212; </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29,058</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Marketable securities: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;">5,971</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt;">25,439</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;">1,865</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,908</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total marketable securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">39,183</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$29,058</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$44,171</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.89pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Non-Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">inputs is determined by estimating the amount and timing of net future cash
            flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest. Significant increases or decreases in actual cash flows may result in valuation changes. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following long-lived assets were measured at fair value, on a nonrecurring
            basis, during the years ended December 31, 2025 and 2024. Assets remeasured in 2024 or sold in 2025 are not included in the fair value presented as of December&#160;31, 2025. The significant assumptions utilized are further described in Notes 3 and
            10: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 189.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2025 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2025</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;">$<span style="padding-left: 5pt;">3,155</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$3,373 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 10pt;">9,489</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;">2,633 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">139 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$12,644</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,145</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 61.43pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 189.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.54pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2024 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2024</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;">$1,668</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$2,279 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 5pt;">1,642</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;">2,516 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">200</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">438 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,510</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,233</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;">5. Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Property and equipment, net, consists of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;">$<span style="padding-left: 15.83pt;">55</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 10.83pt;">107 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">959 </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">306</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,564</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt;">2,884 </span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,058) </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917) </span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">826</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On March&#160;4, 2026, the Company entered into the Hopewell Lease Termination
            Agreement. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $4.8
            million as well as accrued rent through February&#160;14, 2026. As a result of the Hopewell Lease Termination Agreement, the Company recognized a net gain of $0.6 million on the lease termination for the three months ended March 31, 2026. The net gain is comprised of a $3.8
            million gain on the write-off of assets and liabilities for operating leases offset by a $3.2 million net loss on disposal of
            property and equipment. The assets disposed of as part of the termination included office equipment, leasehold improvements, furniture and fixtures, and computer hardware and software. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Depreciation and amortization expense was $0.1 million and $0.2 million for the
            three months ended March 31, 2026 and 2025, respectively. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">6. Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Property and equipment, net, consists of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 15.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;">$10,020 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.87pt;">119</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10.74pt;">1,111</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.5pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,386</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 5pt;">19,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917)</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,724)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9,331</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the Company&#8217;s January&#160;2025 announcement to reduce its
            overall workforce by 55% and cease its lab operations in Hopewell, New Jersey, management implemented plans to sell substantially
            all the laboratory equipment and certain other assets and estimated the fair value of the assets based on the estimated future cash flows from the sale of such assets. Subsequent to recording the impairment of $2.6 million, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. As a result, the Company did not record any
            depreciation on the impaired and disposed laboratory equipment during the year ended December&#160;31, 2025 as the equipment was considered held-for-sale in January&#160;2025. Neither laboratory equipment nor accumulated depreciation related to such
            equipment are recorded on the balance sheet as of December&#160;31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Depreciation and amortization expense was $0.7 million and $3.1 million for the
            years ended December 31, 2025 and 2024, respectively. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">6. Accrued Expenses and Other Current Liabilities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses and other current liabilities consisted of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;">$<span style="padding-left: 7.5pt;">500</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,297</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,174</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,895</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">7. Accrued Expenses and Other Current Liabilities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Accrued expenses and other current liabilities consisted of the following: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">406 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">4,405</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">1,896</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,707</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Gemma License Agreement (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborativeArrangementDisclosureAbstract', window );"><strong>Gemma License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Gemma License Agreement</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">7. Gemma License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $15.0 million in
            initial payments for licenses and clinical product supply, of which $5.0 million was previously received, $5.0 million of which was due in May&#160;2025, of which $2.5
            million has been received, and $5.0 million of which was due in March&#160;2026, and has not yet been received; (ii) an additional $5.0 million contingent on Gemma completing certain business milestones; (iii) up to an additional $114.0 million in development and commercial milestone payments; and (iv) single digit royalties as a percentage of annual worldwide net sales, in exchange for sublicenses
            to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will be responsible for all payments due to the Trustees of </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">the University of Pennsylvania&#8217;s, or Penn, under the Company&#8217;s research,
            collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs. On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services
            Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which, the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for
            transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of March 31, 2026, the Company has received initial payments of $7.5 million associated with the aggregate $15.0 million of initial payments
            to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $4.8 million associated with the
            Transition Services Agreement and applied $1.5 million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts
            due to the Company for transition services under these agreements. The Company recorded these amounts ($13.8 million) as
            non-refundable sublicense and transition services payments on the balance sheet as of March 31, 2026, as the criteria set forth above have not yet been met. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">8. Gemma License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $15.0 million in
            initial payments for licenses and clinical product supply, of which $7.5 million was previously received, $2.5 million of which was due in May&#160;2025, and $5.0
            million of which is due in March&#160;2026; (ii) an additional $5.0 million contingent on Gemma completing certain business milestones;
            (iii) up to an additional $114.0 million in development and commercial milestone payments; and (iv) single digit royalties as a
            percentage of annual worldwide net sales, in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will
            be responsible for all payments due to the Trustees of the University of Pennsylvania&#8217;s, or Penn, under the Company&#8217;s research, collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs.
            On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which,
            the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. As of
            December 31, 2025, the Company has collected $7.5 million in initial payments, $4.8 million in transition services payments, and applied $1.5
            million in amounts owed to Gemma for the Huntington&#8217;s disease program against amounts due to the Company for transition services under these agreements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of December 31, 2025, the Company has received initial payments of $7.5 million associated with the aggregate $15.0 million of
            initial payments to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $4.8 million associated
            with the Transition Services Agreement and applied $1.5 million in amounts owed to Gemma for the Huntington&#8217;s disease program against
            amounts due to the Company for transition services under these agreements. The Company recorded these amounts ($13.8 million) as
            non-refundable sublicense and transition services payments on the balance sheet as of December 31, 2025, as the criteria set forth above have not yet been met. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Severance (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Severance</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">8. Severance </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">During the three months ended March 31, 2026, the Company did not record any severance and termination-related costs (see Note&#160;13). </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately 55%.





            In accordance with ASC 420, <span style="font-style: italic;">Exit and Disposal Activities</span>, the Company recorded severance and termination-related costs of $0.4 million in general and administrative expenses and $1.3 million in
            research and development expenses for the three months ended March 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">As of March 31, 2026, there were no unpaid severance and termination-related costs. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">9. Severance </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately 55%.
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with ASC 420, <span style="font-style: italic;">Exit and
              Disposal Activities</span>, the Company recorded severance and termination-related costs of $0.4 million in general and
            administrative expenses and $1.3 million in research and development expenses for the year ended December 31, 2025. During the year
            ended December 31, 2024, the Company recorded no severance and termination-related costs. As of December 31, 2025, there were no unpaid severance and termination-related costs. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">9. Leases </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2005 Market Street Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately 37,000
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to extend the term of the 2005 Market Street Lease Agreement by two
            additional terms of five years each. The Company has an option to early terminate the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than fifteen months prior to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#8217;s measurement of the ROU asset and operating lease liability
            as of March 31, 2026. During 2023, the Company subleased all of the space at 2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement A </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately 8,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to extend the sublease agreement through November&#160;30, 2031. The base sublease rent is $0.1 million per year and increases by 2.75% annually through the
            expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC Topic 842, <span style="font-style: italic;">Leases</span>,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Sublease Agreement B </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately 29,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024 and Sublessee B has elected the option to extend the term of the sublease
            agreement through March&#160;31, 2029. The base sublease rent is $0.9 million per year for the entire term of the sublease. Additionally,
            Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005 Market Street Lease
            Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Laboratory Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company was also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and was expected to expire in March&#160;2036 with an option to extend the term of the Laboratory Lease Agreement by up to&#160;two five-year terms. On March&#160;4,
            2026, the Company entered into the Hopewell Lease Termination Agreement with the Landlord. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $4.8 million as well as accrued rent through February&#160;14, 2026. The Company has no further obligations under the Laboratory Lease Agreement
            subsequent to the effective date of the Hopewell Lease Termination Agreement. As of March&#160;4, 2026, the Company recognized a net gain of $0.6
            million on the lease termination comprised of a $3.8 million gain on the write-off of assets and liabilities for operating leases
            offset by a $3.2 million net loss on disposal of property and equipment, which was primarily leasehold improvements. As a result of
            the Hopewell Lease Termination Agreement, ROU assets decreased $9.4 million and lease liabilities for operating leases decreased $18.0 million during the three months ended March 31, 2026. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Hopewell Sublease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately 3,200 square feet, or 5% of its approximately 62,000 square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and was scheduled to expire on December&#160;31, 2029, with an option for Sublessee C to extend the term of the
            sublease through December&#160;2032. The base sublease rent was $0.1 million per year and increased by 2.5% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C was required to pay the portion of the common
            area maintenance expenses, operating expenses, and use and occupancy taxes that the Company was required to pay under the Laboratory Lease Agreement. In connection with the Hopewell Lease Termination Agreement on March&#160;4, 2026, the Hopewell
            Sublease Agreement was concurrently terminated. The Company has no ongoing sublease arrangements related to the Hopewell, New Jersey laboratory space. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes future minimum lease payments for the Company&#8217;s
            lessee operating lease, which comprises of the 2005 Market Street Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A and Sublease Agreement B, as the Company was not relieved of its primary
            obligation under the 2005 Market Street Lease Agreement: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 420pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 30.83pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 420pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 8.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 10.83pt;">900 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,270</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,308</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,348</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,388</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">7,447</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,692)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">5,755</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 420pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The following table summarizes lease expense by lease type that was
            recognized during the three months ended March&#160;31, 2026 and 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease expense</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$476</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;">$<span style="padding-left: 7.5pt;">880 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease expense</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 1.5pt;">326 </span></td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">538 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$802</span></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,418</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">9.0% </div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">5.8 </div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;">10.0 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The cash paid for amounts included in the measurement of the Company&#8217;s
            operating lease liabilities for the three months ended March 31, 2026 and 2025 were $0.6 million and $1.0 million, respectively, recorded in operating cash flows. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes sublease income that was recognized in other
            income (expense), net during the three months ended March 31, 2026 and 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$356</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$367</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">10. Leases </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">2005 Market Street Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately 37,000
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to extend the term of the 2005 Market Street Lease Agreement by two additional terms of five years each. The Company has an option to early terminate
            the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than fifteen months prior
            to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#8217;s measurement of the ROU asset and operating lease liability as of December 31, 2025. During 2023 the Company subleased all of the space at
            2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement A </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately 8,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to extend the sublease agreement through November&#160;30, 2031. The base sublease rent is $0.1 million per year and increases by 2.75% annually through
            the expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses, and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC Topic 842, <span style="font-style: italic;">Leases</span>,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Sublease Agreement B </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately 29,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024, and continues through August&#160;2026. Sublessee B has an option to extend the
            term of the sublease agreement through March&#160;31, 2029. The base sublease rent is $0.9 million per year for the entire term of the
            sublease. Additionally, Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005
            Market Street Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">1835 Market Street Sublease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On February&#160;20, 2024, the Company entered into a sublease agreement with a
            counterparty, or the 1835 Market Street Sublease Agreement. Under the 1835 Market Street Sublease Agreement, the Company subleased approximately 16,000
            square feet of office space in Philadelphia, Pennsylvania. The sublease term began on March&#160;26, 2024 and expired on September&#160;30, 2025. The Company had the option but did not elect to extend the term of the sublease agreement through February&#160;28, 2029. The base sublease rent was $0.3 million per year for the original 18-month term of the
            sublease. Additionally, the Company was required to pay utility costs associated with the subleased premises. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Laboratory Lease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and is expected to expire in March&#160;2036. The </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">Company has an option to early terminate the Laboratory Lease Agreement as of March&#160;2032 given notice is provided to the landlord no less than twelve months prior to March&#160;2032. The Company has an option to extend the term of the Laboratory Lease Agreement by up to&#160;two five-year terms. These options were not recognized as
            part of the Company&#8217;s measurement of the ROU asset and operating lease liability as of December 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In January&#160;2025, the Company implemented a restructuring plan which included
            ceasing lab operations. As a result, the Company is no longer using any of the space covered by the Laboratory Lease Agreement and is actively pursuing opportunities to sublease all remaining space in the Laboratory Lease Agreement as well as
            discussing with the landlord potential alternatives. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Hopewell Sublease Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately 3,200 square feet, or 5% of its approximately 62,000 square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and expires on December&#160;31, 2029. Sublessee C has the option to extend the term of the sublease through
            December&#160;2032. The base sublease rent is $0.1 million per year and increases by 2.5% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C is required to pay the portion of the common area maintenance expenses,
            operating expenses, and use and occupancy taxes that the Company is required to pay under the Laboratory Lease Agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the Laboratory Lease Agreement. The Company continues to account for the Laboratory Lease Agreement as a lessee and in the same manner as prior to the execution of the Hopewell
            Sublease Agreement. The Company accounted for the Hopewell Sublease Agreement as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In 2024, the Company determined triggering events were present and reassessed
            the asset groups related to its laboratory space under the Laboratory Lease Agreement, which resulted in changes to the Company&#8217;s identified asset groups. The Company determined whether an impairment indicator was present for each of the new
            asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying values, which includes ROU assets, leasehold improvements, and other property and equipment allocable to the
            laboratory space for those asset groups. The Company concluded the carrying values of certain asset groups were not recoverable as they exceeded the estimated undiscounted cash flows. The Company calculated the amount of impairment on those
            asset groups using a discounted cash flow model to calculate the fair value of the asset group which incorporated the net identifiable cash flows for the term of the Hopewell Sublease Agreement, including an estimate for cash flows in the
            residual period, and an estimated borrowing rate of a market participant subtenant. As a result, certain asset groups were impaired and the Company recognized impairment expense of $5.2 million, including $2.5 million for the ROU assets, $2.3 million for the property and equipment, net, and $0.4
            million for certain other assets during the year ended December&#160;31, 2024. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the January&#160;2025 announcement to reduce its overall
            workforce by 55% and cease its lab operations in Hopewell, New Jersey, the Company determined triggering events were present and
            reassessed its asset groups related to its laboratory space under the Laboratory Lease Agreement. Laboratory equipment was separated from the ROU assets and leasehold improvements allocable to the laboratory space as the equipment was no longer
            being used in operations and the Company had implemented a plan to sell those assets. For the ROU assets and allocable leasehold improvements, the Company compared the estimated undiscounted cash flows from subleasing to the carrying value and
            determined there was no impairment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement based upon sublease market activity and an estimated market </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">participant subtenant borrowing rate and compared that to the carrying value
            of the asset group. As a result, the Company recognized impairment expense of $3.5 million, including $2.6 million for the ROU assets and $0.9
            million for the leasehold improvements during the year ended December 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes future minimum lease payments for the Company&#8217;s
            lessee operating leases, which comprises of the 2005 Market Street Lease Agreement and the Laboratory Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A, Sublease Agreement B, and the
            Hopewell Sublease Agreement as the Company was not relieved of its primary obligation under the 2005 Market Street Lease Agreement and Laboratory Lease Agreement: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,757 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,863</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,973</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,085</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,200</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,421</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">37,299</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(13,289)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">24,010</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes lease expense by lease type that was recognized
            during the years ended December&#160;31, 2025 and 2024: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease cost</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,419</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,505 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease cost</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,103</span></div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,127</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,522</span></div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,632</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.7% </div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.3 </div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;">10.2 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The cash paid for amounts included in the measurement of the Company&#8217;s
            operating lease liabilities for the years ended December&#160;31, 2025 and 2024 were $3.9 million and $3.8 million, respectively, recorded in operating cash flows. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following table summarizes sublease income that was recognized in other
            income (expense), net during the years ended December 31, 2025 and 2024: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$1,467</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.25pt; text-align: left;">$987</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">10. Commitments and Contingencies </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Amended and Restated Research, Collaboration
            and License Arrangement with Penn </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company (i)&#160;terminated the funding of discovery research programs; (ii) terminated the research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS,
            indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe and MLD and certain platform
            technologies resulting from the discovery programs that it funded. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the Company&#8217;s licensed programs in FTD, GM1, Krabbe and MLD, the Penn
            License Agreement requires that it make payments of up to $16.5 million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $55.0 million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Gemma - Research, Collaboration and
            License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New Drug,
            or IND, enabling work for the Company&#8217;s active research program in Huntington&#8217;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and
            (ii)&#160;Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $16.5 million per product candidate in the aggregate for Huntington&#8217;s disease and any future CNS indications available to the
            Company under its four options and (ii) $39.0 million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $1.0 million per product indication, with $0.5 million due upfront and another $0.5
            million fee owed upon a further developmental milestone. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;7. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Catalent Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#8217;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $0.9 million to Catalent which is accrued as of March 31, 2026. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Litigation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of March 31, 2026. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#8217;s initial
            public offering in February&#160;2020, he was promised 150,000 shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to 33,836 shares (1,692 shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it agreed with the
            Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the initial public
            offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#8217;s favor, finding that no binding agreement was reached and that the plaintiff was not entitled
            to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate co<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">urt affirmed the entry of judgment in favor of the Company and on October&#160;7, 2025, the plaintiff filed an Application for Reargument to the
              Superior Court of Pennsylvania. In December&#160;2025, the plaintiff petitioned for review of their appeal to the Pennsylvania Supreme Court. The Company intends to continue to defend against this claim. </span></div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other than the above, the Company is not presently a party to any legal
            proceedings that, in the opinion of management, would, if decided against the Company, have a material adverse effect on the Company&#8217;s business. Regardless of outcome, litigation can have an adverse impact on the Company due to defense and
            settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Employment Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to 150% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">11. Commitments and Contingencies </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Amended and Restated Research, Collaboration
            and License Arrangement with Penn </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">(i)&#160;terminated the funding of discovery research programs; (ii) terminated the
            research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS, indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate
            transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe, and MLD and certain platform technologies resulting from the discovery programs that it funded. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For the Company&#8217;s licensed programs in FTD, GM1, Krabbe, and MLD, the Penn
            License Agreement requires that it make payments of up to $16.5 million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications, and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $55.0 million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Gemma - Research, Collaboration and
            License Agreement </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New
            Drug-enabling work for the Company&#8217;s active research program in Huntington&#8217;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and (ii)
            Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $16.5 million per product candidate in the aggregate for Huntington&#8217;s disease and any future CNS indications available to the
            Company under its four options and (ii) $39.0 million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $1.0 million per product indication, with $0.5 million due upfront and another $0.5
            million fee owed upon a further developmental milestone. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;8. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Catalent Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#8217;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements, is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $0.9 million to Catalent which has been accrued as of and during the year ended December&#160;31, 2025. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Litigation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of December 31, 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#8217;s initial
            public offering in February&#160;2020, he was promised 150,000 shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to 33,836 shares (1,692 shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it
            agreed with the Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the
            initial public offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#8217;s favor, finding that no binding agreement was reached and that the plaintiff
            was not entitled to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate court affirmed the entry of judgment in favor of the Company and on
            October&#160;7, 2025, the plaintiff filed an Application for Reargument to the Superior Court <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">of Pennsylvania. In December 2025, the Superior Court of Pennsylvania denied the Application for Reargument. In December 2025,</span> the plaintiff petitioned for review of their appeal to the Pennsylvania
            Supreme Court which is currently pending. The Company intends to continue to defend against this claim. </div>

<div class="BRDSX_h3" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: justify;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Other than the above, we are not presently a party to any legal proceedings
              that, in the opinion of management, would, if decided against us, have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management
              resources, negative publicity and reputational harm, and other factors. </span></div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Employment Agreements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to 150% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity and Share-Based Compensation (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_StockholderSEquityAndShareBasedCompensationAbstract', window );"><strong>Stockholder's Equity and Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholder's Equity and Share-Based Compensation</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">11. Stockholder&#8217;s Equity and Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected the Reverse Stock Split. The Reverse
            Stock Split did not reduce the number of authorized shares of the common stock and did not change the par value of the common stock. In addition, proportionate adjustments were made to the number of shares of common stock available for issuance
            under the Company&#8217;s equity inducement and incentive plans; the number of shares underlying, and the exercise prices of outstanding equity awards under such plans. All share information in these financial statements has been adjusted for this
            Reverse Stock Split. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The total number of shares authorized under the Incentive Plan as of March 31,
            2026 was 1,106,739. Additionally, 204,732
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of March 31, 2026, 405,163
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January&#160;1st of each
            year, commencing on January&#160;1, 2021 and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 159,141 and 155,155 shares in January&#160;2026 and 2025,
            respectively. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Inducement Plan was approved by the Company&#8217;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of March 31, 2026 was 125,000. Of this amount, 87,634 shares were available for future grants as of March 31, 2026. The Inducement Plan provides for the granting of nonqualified stock options and
            restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest based on requisite service period and have a term of ten years. The Company&#8217;s restricted stock units awarded to date under the Inducement Plan vest based on requisite service period and have a term
            based on each award agreement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at their grant-date fair value and
            records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations and
            comprehensive loss for the period presented:</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> <br/></div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$142</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$244 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">614</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$556</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$858</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The following table summarizes stock option activity for the three months ended
            March 31, 2026: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.14pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$44.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">191,510</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 10pt;">7.64</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,376)</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 5pt;">10.99</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">846,107</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">387,675</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$74.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The weighted average grant date fair value of options granted was $5.81 and $6.20 for the three months
            ended March&#160;31, 2026 and 2025, respectively. As of March 31, 2026, the total unrecognized compensation expense related to unvested stock option awards was $3.6 million, which the Company expects to recognize over a weighted average period of 2.6
            years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The aggregate intrinsic value of options outstanding was $0.1 million at March 31, 2026 and was de minimis at March&#160;31, 2025. The aggregate intrinsic value of options exercised and options exercisable were
            each de minimis during the three months ended March 31, 2026 and 2025. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">92.4%</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.8%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.9%</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.8 years</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Restricted Stock Units </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company issues RSUs to employees that vest over periods of time as
            determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant. Compensation expense is
            recognized on a straight-line basis over the vesting period of the RSUs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes activity related to RSU awards during the three
            months ended March 31, 2026: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">50,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(25,000)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">25,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$11.70</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of March 31, 2026, the total unrecognized expense related to all RSUs was $0.2 million, which the Company expects to recognize over a weighted-average period of 0.8 years. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Employee Stock Purchase Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to 99,088 shares of the Company&#8217;s common stock. Of this amount, 59,103 were available for future grants as of March 31, 2026. The number of shares of the Company&#8217;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for ten years, in an amount
            equal to one percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP were not increased. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock
            through accumulated payroll deductions at such times as are established by the board of directors&#8217; Compensation Committee. Eligible employees may purchase the Company&#8217;s common stock at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000
            worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than 200 shares of
            the Company&#8217;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from 200 shares to 2,000 shares in any single offering period, not to exceed $25,000 in any calendar year. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the guidance in ASC Topic 718-50,<span style="font-style: italic;"> Compensation &#8211; Stock Compensation</span>, the ability to purchase shares of the Company&#8217;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the
            purchase date) represents an option and<span style="font-weight: bold;">, </span>therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair
            value as estimated by applying the Black-Scholes option-pricing model and is recognized over the withholding period. No
            share-based compensation expense related to the ESPP was recorded during the three months ended March&#160;31, 2026 and 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;">13. Share-Based Compensation </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Equity Incentive Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020&#160;Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The total number of shares authorized under the Incentive Plan as of December
            31, 2025 was 947,598. Additionally, 204,732
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of December 31, 2025, 433,624
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January 1st of each
            year, commencing on January 1, 2021 and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 159,141 and 155,155 shares in January&#160;2026 and 2025,
            respectively. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Inducement Plan was approved by the Company&#8217;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of December 31, 2025 was 125,000. Of this amount, 87,166 shares were </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> available for future grants as of December 31, 2025. The Inducement Plan
            provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest
            based on requisite service period and have a term of ten years. The Company&#8217;s restricted stock units awarded to date under the
            Inducement Plan vest based on requisite service period and have a term based on each award agreement. </div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 7.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$2,529 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,001</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,820</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The following table summarizes stock option activity for the year ended
            December 31, 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">577,581</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">77.56</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">248,208</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 15pt;">7.78</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;">(125,526)</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">82.56</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(41,290)</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt;">175.24</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">658,973<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">357,766<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">78.82</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">658,973</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The weighted-average grant date fair value of options granted was $6.07 and $20.20 for the years ended
            December 31, 2025 and 2024, respectively. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The aggregate intrinsic value of options outstanding was $0.9 million at December 31, 2025 and was de minimis at December 31, 2024. The aggregate intrinsic value of options exercisable was $0.2 million at December 31, 2025 and was de minimis at December 31, 2024. There were no options exercised during the year ended December 31, 2025 and the aggregate intrinsic value of options exercised during the year ended December 31, 2024 was de minimis.
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the total unrecognized compensation expense related
            to unvested stock option awards was $3.0 million, which the Company expects to recognize over a weighted-average period of 2.2 years. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.7%</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">88.4%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.2%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.9 years</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Restricted Stock Units </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company issues restricted stock units, or RSUs, to employees that vest
              over periods of time as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant.
              Compensation expense is recognized on a straight-line basis over the vesting period of the RSUs. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following table summarizes activity related to RSU awards during the year
            ended December 31, 2025: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 8.33pt;">7,093</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$44.80 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">60,000</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(16,825)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">27.92</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(268)</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">90.40</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">50,000<br/>
                    </span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As of December 31, 2025, the total unrecognized expense related to all RSUs
            was $0.3 million, which the Company expects to recognize over a weighted-average period of 1.0 years. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Employee Stock Purchase Plan </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to 99,088 shares of the Company&#8217;s common stock. Of this amount, 59,103 were available for future grants as of December 31, 2025. The number of shares of the Company&#8217;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January&#160;1st of each year and continuing for ten years, in an amount
            equal to one percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP was not increased. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock
            through accumulated payroll deductions at such times as are established by the board of director&#8217;s Compensation Committee. Eligible employees may purchase the Company&#8217;s common stock at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000
            worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than 200 shares of
            the Company&#8217;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from 200 shares to 2,000 shares in any single offering period, not to exceed $25,000 in any calendar year. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In accordance with the guidance in ASC Topic 718-50,<span style="font-style: italic;"> Compensation &#8211; Stock Compensation</span>, the ability to purchase shares of the Company&#8217;s common stock at 85% of the
            lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and<span style="font-weight: bold;">, </span>therefore, the ESPP is a compensatory plan under this
            guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. No share-based compensation expense related to the ESPP was recorded during the years ended December 31, 2025 and 2024. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockholderSEquityAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockholderSEquityAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">12. Segment Reporting </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a <span style="-sec-ix-hidden:Fact_54f55c66f3b44146b30493895e843cea">single</span> reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies in the Company&#8217;s 2025 Annual Report filed on Form&#160;10-K. The Company&#8217;s CODM is its chief executive officer. The measure of segment assets is reported on the balance sheet as total assets. All
            assets are located within the United States. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The CODM uses net loss as reported on the Company&#8217;s statement of operations to
            assess the Company&#8217;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses exclude
            certain non-cash items such as share-based compensation and depreciation and amortization expenses. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The following table summarizes significant segment expenses: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 3.33pt;">1,458</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,589 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,432</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">3,794 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">142</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">244 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">61</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">110 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,093</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,737 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">1,891</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,790 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,415</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,603 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">614 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">67</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">78 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,787</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,085 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,637 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8,247)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(16,459)</span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">688</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,054 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(7,559)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(15,405)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 54.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The components of Other (income) expense, net are further described in Note&#160;3 to
            the financial statements. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">15. Segment Reporting </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a <span style="-sec-ix-hidden:Fact_6fcb045ac6ef441986cb7c4046a9cae6">single</span> reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies. The Company&#8217;s CODM is its chief executive officer. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The measure of segment assets is reported on the balance sheet as total
            assets. All assets are located within the United&#160;States. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> The CODM uses net loss as reported on the Company&#8217;s statement of operations
            to assess the Company&#8217;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses
            exclude certain non-cash items such as share-based compensation and depreciation and amortization expenses. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">The following table summarizes significant segment expenses: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$<span style="padding-left: 5pt;">7,462</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$12,265 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">14,532</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">22,691</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,529</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">440</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,694</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,276</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">40,179</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,784</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,255</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,644</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">12,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">288</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">387</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,875</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,988</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,145</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,296</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,400</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (income) expense, net</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,774)</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,633)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$45,522</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$64,767</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;">The components of Other (income) expense, net are further described in note 3
            to the financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Q1)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">13. Subsequent Events </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April&#160;20, 2026, the Company announced it has initiated a review of
            strategic alternatives to maximize shareholder value. These strategic alternatives may include merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships, licensing opportunities, or other
            potential paths. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On April&#160;28, 2026, in connection with the Company&#8217;s review of strategic
            alternatives, the Company announced a restructuring of its workforce, or the Restructuring Plan, to decrease operating expenses by reducing the workforce by approximately 75%. The implementation of the Restructuring Plan should be substantially complete in the second and third quarters of 2026. The Company estimates the aggregate severance and related
            costs for the Restructuring Plan will be approximately $3.3 million, which will be recorded primarily in the second quarter of 2026.
            These estimates are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with,
            the Restructuring Plan as well as the Company&#8217;s review of strategic alternatives. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">On May 21, 2026, the Company provided written notice to Gemma to terminate
            the Gemma Collaboration Agreement, which termination will become effective in accordance with the terms of the Gemma Collaboration Agreement. Following the effectiveness of the termination, the Company will no longer have any rights to the
            research programs or the options for new CNS indications previously available to it under the Gemma Collaboration Agreement.</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On May 22, 2026, the Company and the landlord entered into a lease termination
            agreement pursuant to which the 2005 Market Street Lease Agreement was terminated and the Company paid a termination fee of $2.3
            million.</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On June 23, 2026, the Company delivered written notice to Penn to terminate
            the Penn License Agreement, pursuant to Section 10.2 thereof, solely with respect to the Company&#8217;s product candidate referred to as PBFT02 for all indications licensed to the Company thereunder for such product candidate, including
            frontotemporal dementia with granulin mutations, or the <span style="font-style: italic; font-weight: bold;">PBFT02 Termination</span>. The PBFT02 Termination will become effective on the date that is 90 days following Penn&#8217;s receipt of the
            notice, after which the Company will no longer have any rights under the Penn License Agreement to develop or commercialize PBFT02. The Penn License Agreement will remain in effect with respect to all non-terminated licensed products.</div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On June 23, 2026, the Company delivered written notice to Catalent to
            terminate, pursuant to Section 20.1(b)(ii) thereof, the amended and restated development services and clinical supply agreement, dated November 9, 2023 (one of the Amended Catalent Agreements), in its entirety, effective as of June 23, 2026.
            The Company determined to terminate this agreement in connection with the wind-down of our gene therapy programs and the proposed Merger (as defined below), and the Company was not obligated to pay Catalent any termination fee in connection <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">with the termination.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 24, 2026, the Company entered into
              an Agreement and Plan of Merger and Reorganization, or the Merger Agreement, with Remix Therapeutics, Inc., a Delaware corporation, or Remix, and Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, or Merger
              Sub. Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Remix, with Remix continuing as a wholly-owned subsidiary of the Company and the surviving
              corporation of the merger. Upon termination of the Merger Agreement under specified circumstances the Company will be required to make a payment to Remix equal to $1.5 million in cash.</div>

<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
            </div>

<div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> In July 2026, the Pennsylvania Supreme
              Court denied the petition for review with respect to the plaintiff&#8217;s challenge to the post-trial rulings in favor of Passage Bio, but it agreed to hear the question of whether certain communications between lawyers and the mediator were
              appropriately excluded from evidence at trial under Pennsylvania&#8217;s mediation privilege. The Pennsylvania Supreme Court timing for this hearing is currently pending.<br/>
            </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">16. Subsequent Events </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">None. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (FY) (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_BasisOfPresentationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited financial statements have been prepared in
            accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_9c4ae5c452f740698340777ae9877470">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of
            shares of common stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity,
            have been adjusted retroactively to reflect the Reverse Stock Split for all periods presented. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying financial statements have been prepared in accordance with
            generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP&#160;as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_87ff84423c1d4358a1dd1652b1ad4132">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of shares of Common
            Stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity, have been adjusted
            retroactively to reflect the Reverse Stock Split for all periods presented. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">dictates the allocation of funds within its portfolio of money market
            funds. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money
            market funds.
          </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which dictates the allocation of funds within its portfolio of money market funds. The Company has
            not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money market funds. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2026 consisted of money market funds. Cash consists of cash deposits at banking institutions. As of March&#160;31, 2025, all of the Company&#8217;s marketable
            securities matured and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#8217;s balance sheet. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company had cash and cash equivalents of $33.3 million and $46.3 million as of
            March 31, 2026 and December 31, 2025, respectively. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of December 31, 2025 consisted of money market funds. Cash consists of cash deposits at banking institutions. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity.
            Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable securities sold are recognized as a component of other
            income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all
            marketable securities as current assets within the balance sheet. As of March 31, 2026, the Company had no marketable securities. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. The Company held no marketable securities as of December 31, 2025. Marketable
            securities as of December 31, 2024 consisted of various securities as described in Note&#160;4. Marketable securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other
            comprehensive income (loss) within stockholders&#8217; equity. Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable
            securities sold are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund
            operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years
            for office equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company did not recognize any impairment expenses for long-lived assets for the three months ended March 31, 2026. The
            Company recognized impairment expenses for laboratory equipment and certain other assets of $2.6 million for the three months ended
            March 31, 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years for office
            equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. The Company recognized de minimis losses on disposals of property and equipment for the year ended
            December 31, 2025. The Company did not recognize any losses on disposals of property and equipment for the year ended December 31,
            2024. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company recognized impairment expenses for property and equipment of $3.5 million for the year ended December 31, 2025, $2.5
            million of which was for lab equipment, $0.9 of which was for leasehold improvements, and $0.1 million of which was for certain other assets. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result of the Company&#8217;s January&#160;2025 announcement to reduce its overall
            workforce and cease its lab operations, the Company reassessed asset groups at its lab in Hopewell, New Jersey, and evaluated such asset groups for impairment under FASB ASC Topic 360, <span style="font-style: italic;">Long-lived assets:
              Impairment or disposal of long-lived assets</span>. The Company determined the laboratory equipment was a separate asset group based on management&#8217;s implemented plans to sell the laboratory equipment and estimated the fair value of the
            laboratory equipment based on the estimated future cash flows from the sale of such equipment, resulting in impairment of laboratory equipment and certain other assets of $2.6 million. Subsequent to recording the impairment, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement and an estimated market participant subtenant borrowing rate and compared that to the carrying value of the asset group, resulting in impairment to leasehold improvements of $0.9 million. The impairment expense for the leasehold improvements relate to the proportional allocation of total impairment recognized for the asset group subject to
            impairment testing. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognized impairment expenses for property and equipment and
            certain other assets of $2.7 million for the year ended December&#160;31, 2024, which primarily relates to the proportional allocation of
            total impairments recognized for asset groups subject to impairment testing as further described in Note&#160;10. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leasing</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of March 31, 2026, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When assets and liabilities for operating leases are written off, the balances
            are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company did not
            recognize any impairment expenses for ROU assets for the three months ended March 31, 2026 or 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of December 31, 2025, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company recognized impairment expenses for ROU assets of $2.6 million and $2.5 million in the years ended December 31, 2025 and 2024,
            respectively. These impairment expenses include the proportional allocation of total impairments recognized for the asset groups subject to impairment testing as further described in Note&#160;10. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relate to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock', window );">Other Income (Expense), Net</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, and income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $0.7 million to other income (expense), net for the three months ended March 31, 2026, which consisted of $0.3 million attributable to interest income and $0.4 million
            related to income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $1.1 million to other income (expense), net for the three months ended March&#160;31, 2025, which consisted of $0.7 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $0.4 million related to income from subleases. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, income from subleases, and the sale of certain tax credits. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $3.8 million to other income (expense), net for the year ended December 31, 2025, which consisted of $2.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $1.5 million from sublease income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $5.6 million to other income (expense), net for the year ended December 31, 2024, which consisted of $4.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities, $1.0 million from sublease income, and $0.3 million related to the sale of
            certain tax credits. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to 2026, the Company estimated the expected term of the stock options
            using the &#8220;simplified method,&#8221; as the Company had limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The
            Company now has sufficient historical exercise data and has determined it is no longer appropriate to use the &#8220;simplified method&#8221;. Additionally, the Company no longer uses comparable public company data to estimate expected volatility and
            instead bases its expected volatility assumption on the historical volatility of its own stock price. The Company will apply this methodology prospectively and the change in estimates did not have a material impact for the three months ended
            March 31, 2026. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur.
          </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The expected term of the stock options is estimated using the &#8220;simplified
            method,&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the
            midpoint between the vesting period and the contractual term of the option. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For stock price volatility, the Company uses a composite of comparable public
            company data as a basis for its expected volatility and considers the historic volatility of its common stock from its initial public offering to date to calculate the fair value of option grants. The selection of comparable public company data
            requires the application of management&#8217;s judgement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">License and Other Revenue</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;7) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue





































              from Contracts with Customer</span>s, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;8) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue







              from Contracts with Customers</span>, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Income Taxes </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Income taxes are accounted for under the asset-and-liability method as
            required by FASB ASC Topic 740, <span style="font-style: italic;">Income Taxes</span>, or ASC 740. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
            carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
            the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">corresponding to the enactment date. Under ASC 740, a valuation allowance is
            required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">FASB ASC Subtopic 740-10, <span style="font-style: italic;">Accounting for
              Uncertainty of Income Taxes</span>, or ASC 740-10, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The
            Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax
            position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.
            In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income,
            net, within other income (expense), net. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">704,699</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">25,000</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">62,500</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,593</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">848</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">872,700 </span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">768,047 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">577,581</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">50,000</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,093</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">696</span></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,636</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">709,669</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">587,310</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim periods. ASU 2025-11 is effective for the Company for interim periods within annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be
            applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement disclosures. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
            Not Yet Adopted </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income&#160;&#8211;&#160;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed, and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">periods. ASU 2025-11 is effective for the Company for interim periods within
            annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement
            disclosures. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Pronouncements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2023, the FASB issued ASU No. 2023-09, <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>, or ASU 2023-09, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and
            income taxes paid. The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU&#160;are effective for annual periods beginning after December&#160;15, 2024 with
            early adoption permitted. The Company adopted this new accounting pronouncement retrospectively during the year ended December&#160;31, 2025. Refer to Note&#160;14 for additional disclosures. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_BasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_BasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other income or other expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Q1) (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_BasisOfPresentationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited financial statements have been prepared in
            accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_9c4ae5c452f740698340777ae9877470">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of
            shares of common stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity,
            have been adjusted retroactively to reflect the Reverse Stock Split for all periods presented. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;">Basis of Presentation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying financial statements have been prepared in accordance with
            generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP&#160;as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">On July&#160;14, 2025, the Company effected a <span style="-sec-ix-hidden:Fact_87ff84423c1d4358a1dd1652b1ad4132">1</span>-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of shares of Common
            Stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity, have been adjusted
            retroactively to reflect the Reverse Stock Split for all periods presented. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_InterimFinancialStatementsPolicyTextBlock', window );">Interim Financial Statements</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Interim Financial Statements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The accompanying unaudited interim financial statements have been prepared
            from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the SEC, which permits reduced disclosures for interim periods. All adjustments, consisting only
            of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets, statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows have been made. Although these interim financial
            statements do not include all of the information and notes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of
            operations and cash flows are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and notes should be read in conjunction with the audited financial statements and notes
            included in the Company&#8217;s 2025 Annual Report filed on Form&#160;10-K. </div>
<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Use of Estimates </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Fair Value of Financial Instruments </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Management believes that the carrying amounts of the Company&#8217;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">dictates the allocation of funds within its portfolio of money market
            funds. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money
            market funds.
          </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Concentration of Credit Risk </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which dictates the allocation of funds within its portfolio of money market funds. The Company has
            not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money market funds. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2026 consisted of money market funds. Cash consists of cash deposits at banking institutions. As of March&#160;31, 2025, all of the Company&#8217;s marketable
            securities matured and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#8217;s balance sheet. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company had cash and cash equivalents of $33.3 million and $46.3 million as of
            March 31, 2026 and December 31, 2025, respectively. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Cash and Cash Equivalents </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of December 31, 2025 consisted of money market funds. Cash consists of cash deposits at banking institutions. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity.
            Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable securities sold are recognized as a component of other
            income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all
            marketable securities as current assets within the balance sheet. As of March 31, 2026, the Company had no marketable securities. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Marketable Securities </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. The Company held no marketable securities as of December 31, 2025. Marketable
            securities as of December 31, 2024 consisted of various securities as described in Note&#160;4. Marketable securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other
            comprehensive income (loss) within stockholders&#8217; equity. Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable
            securities sold are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund
            operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years
            for office equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company did not recognize any impairment expenses for long-lived assets for the three months ended March 31, 2026. The
            Company recognized impairment expenses for laboratory equipment and certain other assets of $2.6 million for the three months ended
            March 31, 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;">Property and Equipment, Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years for office
            equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. The Company recognized de minimis losses on disposals of property and equipment for the year ended
            December 31, 2025. The Company did not recognize any losses on disposals of property and equipment for the year ended December 31,
            2024. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company recognized impairment expenses for property and equipment of $3.5 million for the year ended December 31, 2025, $2.5
            million of which was for lab equipment, $0.9 of which was for leasehold improvements, and $0.1 million of which was for certain other assets. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">As a result of the Company&#8217;s January&#160;2025 announcement to reduce its overall
            workforce and cease its lab operations, the Company reassessed asset groups at its lab in Hopewell, New Jersey, and evaluated such asset groups for impairment under FASB ASC Topic 360, <span style="font-style: italic;">Long-lived assets:
              Impairment or disposal of long-lived assets</span>. The Company determined the laboratory equipment was a separate asset group based on management&#8217;s implemented plans to sell the laboratory equipment and estimated the fair value of the
            laboratory equipment based on the estimated future cash flows from the sale of such equipment, resulting in impairment of laboratory equipment and certain other assets of $2.6 million. Subsequent to recording the impairment, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement and an estimated market participant subtenant borrowing rate and compared that to the carrying value of the asset group, resulting in impairment to leasehold improvements of $0.9 million. The impairment expense for the leasehold improvements relate to the proportional allocation of total impairment recognized for the asset group subject to
            impairment testing. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognized impairment expenses for property and equipment and
            certain other assets of $2.7 million for the year ended December&#160;31, 2024, which primarily relates to the proportional allocation of
            total impairments recognized for asset groups subject to impairment testing as further described in Note&#160;10. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leasing</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of March 31, 2026, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">When assets and liabilities for operating leases are written off, the balances
            are removed from the respective accounts, with any resulting gain or loss recognized concurrently. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company did not
            recognize any impairment expenses for ROU assets for the three months ended March 31, 2026 or 2025. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Leasing </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of December 31, 2025, the Company has classified all leases with terms greater than one year, as operating leases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company recognized impairment expenses for ROU assets of $2.6 million and $2.5 million in the years ended December 31, 2025 and 2024,
            respectively. These impairment expenses include the proportional allocation of total impairments recognized for the asset groups subject to impairment testing as further described in Note&#160;10. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relate to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Research and Development </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#8217;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#8217;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock', window );">Other Income (Expense), Net</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, and income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $0.7 million to other income (expense), net for the three months ended March 31, 2026, which consisted of $0.3 million attributable to interest income and $0.4 million
            related to income from subleases. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $1.1 million to other income (expense), net for the three months ended March&#160;31, 2025, which consisted of $0.7 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $0.4 million related to income from subleases. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Other Income (Expense), Net </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, income from subleases, and the sale of certain tax credits. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $3.8 million to other income (expense), net for the year ended December 31, 2025, which consisted of $2.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities and $1.5 million from sublease income. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company recorded $5.6 million to other income (expense), net for the year ended December 31, 2024, which consisted of $4.3 million attributable to interest income and the amortization of premium and discount on the Company&#8217;s marketable securities, $1.0 million from sublease income, and $0.3 million related to the sale of
            certain tax credits. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Prior to 2026, the Company estimated the expected term of the stock options
            using the &#8220;simplified method,&#8221; as the Company had limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The
            Company now has sufficient historical exercise data and has determined it is no longer appropriate to use the &#8220;simplified method&#8221;. Additionally, the Company no longer uses comparable public company data to estimate expected volatility and
            instead bases its expected volatility assumption on the historical volatility of its own stock price. The Company will apply this methodology prospectively and the change in estimates did not have a material impact for the three months ended
            March 31, 2026. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur.
          </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Share-Based Compensation </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company uses the Black-Scholes option pricing model to value its stock option
            awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application
            of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The expected term of the stock options is estimated using the &#8220;simplified
            method,&#8221; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the
            midpoint between the vesting period and the contractual term of the option. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For stock price volatility, the Company uses a composite of comparable public
            company data as a basis for its expected volatility and considers the historic volatility of its common stock from its initial public offering to date to calculate the fair value of option grants. The selection of comparable public company data
            requires the application of management&#8217;s judgement. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">The Company accounts for forfeitures of RSUs and stock option awards as they
            occur. </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">License and Other Revenue</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;7) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue





































              from Contracts with Customer</span>s, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">License and Other Revenue </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company may enter into license agreements and transition services
            agreements (see Note&#160;8) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The Company applies FASB ASC Topic 606, <span style="font-style: italic;">Revenue







              from Contracts with Customers</span>, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#8217;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#8217;s balance sheet when the Company&#8217;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#8217;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">704,699</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">25,000</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">62,500</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,593</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">848</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">872,700 </span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">768,047 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Net Loss Per Share </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">577,581</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">50,000</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,093</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">696</span></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,636</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">709,669</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">587,310</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
          </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim periods. ASU 2025-11 is effective for the Company for interim periods within annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be
            applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement disclosures. </div>
<span></span>
</td>
<td class="text">
<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Recently Issued Accounting Pronouncements
            Not Yet Adopted </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In November&#160;2024, the FASB issued ASU No. 2024-03, <span style="font-style: italic;">Income Statement &#8211; Reporting Comprehensive Income&#160;&#8211;&#160;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses</span>, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#8217;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In September&#160;2025, the FASB issued ASU No. 2025-06, <span style="font-style: italic;">Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software</span>, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed, and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#8217;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2025, the FASB issued ASU No. 2025-11, <span style="font-style: italic;">Interim Reporting (Topic 270): Narrow-Scope Improvements</span>, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;">periods. ASU 2025-11 is effective for the Company for interim periods within
            annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement
            disclosures. </div>

<div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Recently Adopted Accounting Pronouncements </div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">In December&#160;2023, the FASB issued ASU No. 2023-09, <span style="font-style: italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>, or ASU 2023-09, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and
            income taxes paid. The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU&#160;are effective for annual periods beginning after December&#160;15, 2024 with
            early adoption permitted. The Company adopted this new accounting pronouncement retrospectively during the year ended December&#160;31, 2025. Refer to Note&#160;14 for additional disclosures. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_BasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_BasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_InterimFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interim financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_InterimFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other income or other expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">704,699</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">25,000</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">62,500</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,593</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">848</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">872,700 </span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">768,047 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">577,581</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">50,000</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,093</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">696</span></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,636</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">709,669</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">587,310</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Marketable Securities (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, Cash Equivalents, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of details regarding the Company's portfolio of cash and cash equivalents</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Cost or </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized cost</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized gains</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized losses</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash accounts in banking institutions</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 5pt;">2,500</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 5pt;">2,500 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">43,803 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">43,803 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$46,303</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$46,303 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Cash accounts in banking institutions</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 5pt;">3,527</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 5pt;">3,527 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 5pt;">29,058 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 5pt;">29,058 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988 </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$37,573</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$37,573</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 56.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.74pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of details regarding the Company's portfolio of marketable securities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amortized cost</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized gains</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Unrealized losses</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;">$<span style="padding-left: 5pt;">5,970</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;">$<span style="padding-left: 5pt;">1</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;">$<span style="padding-left: 5pt;">5,971 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 5pt;">25,433 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 10pt;">6 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 5pt;">25,439</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 10pt;">1,864 </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 10pt;">1 </span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 10pt;">1,865 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,908 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1 </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1) </span></div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,908 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$39,175</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 1.67pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">(1)</span></div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$39,183</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 240pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 56.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 34.74pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Non-Financial Instruments (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments and Non-Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of assets measured at fair value on a recurring basis</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 147.47pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 4.26pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 147.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair value measurement at </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">reporting date using </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Quoted prices </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">in active </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">markets for </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">identical </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;1)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">other </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">observable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;2)</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Significant </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">unobservable </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Inputs </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">(Level&#160;3) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2025: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$43,803</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">43,803</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$43,803</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">December&#160;31, 2024: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;">Assets </div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Cash equivalents: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Money market funds</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;">$29,058</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;">$<span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;">$&#8212; </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total cash equivalents</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">29,058</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,988</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Marketable securities: </div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Certificates of deposit</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;">5,971</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Commercial paper</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt;">25,439</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">Corporate debt securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt;">1,865</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;">U.S. government securities</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,908</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total marketable securities</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">39,183</span></div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total financial assets</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 47.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$29,058</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.89pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$44,171</span></div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 45.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 47.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.89pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 45.77pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Summary of non-financial instruments measured at fair value, on a nonrecurring basis</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 189.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2025 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2025</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;">$<span style="padding-left: 5pt;">3,155</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$3,373 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 10pt;">9,489</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;">2,633 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">139 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 61.43pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$12,644</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,145</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 53.59pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 61.43pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="height: 6pt; width: 189.54pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.23pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="7" style="width: 189.54pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Fair Value Measurements as of December&#160;31, 2024 of </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">assets remeasured during 2024</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;1</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;2</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Level&#160;3</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Impairment Losses </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Property and equipment, net</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;">$&#8212;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;">$1,668</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;">$2,279 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Right of use assets</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 5pt;">1,642</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 5pt;">2,516 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other assets</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">200</span></div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">438 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$&#8212;</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 58.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,510</span></div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,233</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 192pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 55.26pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 58.1pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.23pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 65.53pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;">$<span style="padding-left: 15.83pt;">55</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 10.83pt;">107 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">959 </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">306</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,564</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt;">2,884 </span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,058) </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917) </span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">826</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 15.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;">$10,020 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.87pt;">119</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10.74pt;">1,111</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.5pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,386</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 5pt;">19,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917)</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,724)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9,331</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities and other current liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;">$<span style="padding-left: 7.5pt;">500</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,297</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,174</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,895</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">406 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">4,405</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">1,896</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,707</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum rental payments for operating leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 420pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 30.83pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 420pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 8.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 10.83pt;">900 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,270</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,308</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,348</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,388</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">7,447</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,692)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">5,755</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 420pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,757 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,863</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,973</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,085</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,200</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,421</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">37,299</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(13,289)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">24,010</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of operating leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease expense</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$476</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;">$<span style="padding-left: 7.5pt;">880 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease expense</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 1.5pt;">326 </span></td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">538 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$802</span></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,418</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">9.0% </div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">5.8 </div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;">10.0 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$356</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$367</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease cost</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,419</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,505 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease cost</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,103</span></div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,127</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,522</span></div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,632</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.7% </div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.3 </div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;">10.2 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$1,467</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.25pt; text-align: left;">$987</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense category</a></td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> <br/></div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$142</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$244 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">614</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$556</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$858</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">The
            Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense
            categories in its accompanying statements of operations and comprehensive loss for the period presented:</div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 7.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$2,529 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,001</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,820</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity plan</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.14pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$44.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">191,510</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 10pt;">7.64</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,376)</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 5pt;">10.99</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">846,107</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">387,675</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$74.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">577,581</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">77.56</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">248,208</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 15pt;">7.78</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;">(125,526)</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">82.56</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(41,290)</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt;">175.24</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">658,973<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">357,766<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">78.82</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">658,973</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions applied to options</a></td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">92.4%</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.8%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.9%</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.8 years</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.7%</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">88.4%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.2%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.9 years</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of activity related to restricted stock unit</a></td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">50,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(25,000)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">25,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$11.70</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 8.33pt;">7,093</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$44.80 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">60,000</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(16,825)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">27.92</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(268)</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">90.40</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">50,000<br/>
                    </span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax assets:<br/>
                  </div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Net operating loss carryforwards</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$105,425</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$94,923 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Research and development credits</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">55,020</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">50,842</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Collaboration and license agreement</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 15pt;">2,832</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">3,422</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="margin-top: 11.25pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 89pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Capitalized research and development</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 13.33pt;">46,041</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 13.33pt;">59,803</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;">4,329</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;">5,863</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Accrued expenses and other</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;">4,581</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;">1,404</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Operating lease liabilities</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt;">6,520</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt;">7,560</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,048</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">461</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total gross deferred tax assets before valuation allowance</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 8.33pt;">225,796</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"><span style="padding-left: 8.33pt;">224,278</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Valuation allowance</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(222,752)</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(219,833)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Net deferred tax assets</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,044</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,445</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Deferred tax liabilities:<br/>
                  </div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Right of use assets - operating leases</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,044)</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(4,445)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Total deferred tax liabilities</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,044)</span></div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(4,445)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Net deferred taxes</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 9.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="height: 6pt; width: 165.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="10" style="width: 165.09pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 73.44pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 76.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Amount</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Percent </div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">US federal statutory tax rate</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 1.67pt;">(9,560)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 3.33pt;">21.0%<br/>
                    </span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$(13,601)</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 3.33pt;">21.0%</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Federal:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Tax credits:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Research and development tax credits</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 14.17pt;">(175)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;">0.4</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">(626)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;">1.0</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Orphan drug tax credits</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,003)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;">8.8</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">(4,896)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;">7.6</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Changes in valuation allowances</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt;">12,334</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;">(27.2)</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">17,422</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;">(27.0)</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Nontaxable or nondeductible items:<br/>
                  </div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Share-based payment awards</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 17.5pt;">241</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 5pt;">(0.5)</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 20.83pt;">459</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 5pt;">(0.7)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Expiration of share-based payment awards</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 10pt;">1,159</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 5pt;">(2.5)</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">1,233</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 5pt;">(1.9)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;">Other</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 27.5pt;">4</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 8.33pt;">0.0</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 30.83pt;">9</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 8.33pt;">0.0</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State and local income taxes, net of federal income tax effect<sup>1</sup></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Effective tax rate</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">&#8212;</span><span style="padding-bottom: 0.5pt;">%</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 288pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 32.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 26.06pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.44pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 26.06pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;">


  <tr>

    <td style="width: 20pt; text-align: left; vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic;">1<br/>
                  </div>
                </td>

    <td style="vertical-align: top;">
                  <div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; text-align: justify;">In 2025 and 2024, state and local income taxes in Pennsylvania and Philadelphia comprise the majority of
                    the state and local income taxes, net of federal income tax effect category.<span style="font-style: normal;"> </span></div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of net operating loss carryforwards</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 91.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 91.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Federal</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$398,039</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$339,055 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">State</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">398,035</span></div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">339,051</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Local</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">277,828</span></div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 5pt;">218,844</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research tax credits</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">55,020</span></div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><span style="padding-left: 10pt;">50,842</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.25pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 37.5pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (FY) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of reconciliation of reported segment net loss to the statement of operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 3.33pt;">1,458</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,589 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,432</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">3,794 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">142</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">244 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">61</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">110 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,093</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,737 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">1,891</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,790 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,415</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,603 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">614 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">67</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">78 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,787</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,085 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,637 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8,247)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(16,459)</span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">688</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,054 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(7,559)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(15,405)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 54.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$<span style="padding-left: 5pt;">7,462</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$12,265 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">14,532</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">22,691</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,529</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">440</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,694</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,276</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">40,179</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,784</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,255</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,644</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">12,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">288</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">387</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,875</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,988</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,145</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,296</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,400</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (income) expense, net</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,774)</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,633)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$45,522</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$64,767</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Q1) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;">704,699</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">25,000</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 5pt;">62,500</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,593</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">848</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">872,700 </span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">768,047 </span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Stock options</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">577,581</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested restricted stock units</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">50,000</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,093</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Employee stock purchase plan</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">696</span></div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,636</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">709,669</span></div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">587,310</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Q1) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;">$<span style="padding-left: 15.83pt;">55</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 10.83pt;">107 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">959 </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 15.83pt;">306</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,564</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 8.33pt;">2,884 </span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(2,058) </span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917) </span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">826</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Laboratory equipment</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;">$<span style="padding-left: 15.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;">$10,020 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Office equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.87pt;">119</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Computer hardware and software</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">988</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10.74pt;">1,111</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Furniture and fixtures</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 15.83pt;">419</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 17.5pt;">419</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Leasehold improvements</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,510</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,386</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total property and equipment</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 8.33pt;">8,024</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 5pt;">19,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Accumulated depreciation and amortization</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,917)</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(9,724)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">4,107</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">9,331</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Q1) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities and other current liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;">$<span style="padding-left: 7.5pt;">500</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,297</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 5pt;">1,174</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,895</span></div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 324pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Professional fees</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">347</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$<span style="padding-left: 7.5pt;">406 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Compensation and related benefits</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">2,740</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">4,405</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt;">642</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt;">1,896</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Divestiture fee due to Catalent</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">924</span></div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$4,653</span></div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$6,707</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Q1) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum rental payments for operating leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 420pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 30.83pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 420pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 8.59pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 10.83pt;">900 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,270</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,308</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">1,348</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,388</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">7,447</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(1,692)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 420pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">5,755</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 420pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 30.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 408pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 35.83pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.09pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2026</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,757 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2027</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,863</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2028</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">3,973</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2029</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,085</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">2030</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 13.33pt;">4,200</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Thereafter</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">17,421</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total undiscounted lease payments</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 8.33pt;">37,299</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Less: imputed interest</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(13,289)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total lease liabilities</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$</span><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">24,010</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of operating leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"></div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March 31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease expense</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$476</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;">$<span style="padding-left: 7.5pt;">880 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease expense</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 1.5pt;">326 </span></td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">538 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$802</span></div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$1,418</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">9.0% </div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;">5.8 </div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;">10.0 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.52pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 118.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.52pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2026</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">March&#160;31, 2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$356</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;">$367</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Operating lease cost</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,419</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$3,505 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Variable lease cost</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,103</span></div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,127</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,522</span></div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,632</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average discount rate</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.7% </div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"><span style="padding-left: 5pt;">9.7% </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Weighted-average remaining lease term (years)</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;">9.3 </div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;">10.2 </div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.75pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 142.48pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 6.75pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2025</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">December&#160;31, 2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Sublease rental income</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;">$1,467</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.25pt; text-align: left;">$987</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity and Share-Based Compensation (Q1) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_StockholderSEquityAndShareBasedCompensationAbstract', window );"><strong>Stockholder's Equity and Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense category</a></td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"> <br/></div>

<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$142</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;">$244 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">614</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$556</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$858</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;">The
            Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense
            categories in its accompanying statements of operations and comprehensive loss for the period presented:</div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 7.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$2,529 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$3,001</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$5,820</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity plan</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 5.14pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">658,973</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$44.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">191,510</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 10pt;">7.64</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 6.67pt;">(4,376)</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 5pt;">10.99</span></div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">846,107</span></div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">387,675</span></div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$74.20</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at March&#160;31, 2026</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;">846,107</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;">$40.13</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 5.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">shares</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">exercise price<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">per share</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">average<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">remaining<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">contractual<br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">term (years) </div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at January&#160;1, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">577,581</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">77.56</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.5</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">248,208</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 15pt;">7.78</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Exercised</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 25.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;">(125,526)</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 10pt;">82.56</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Expired</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(41,290)</span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"><span style="padding-left: 5pt;">175.24</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Outstanding at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">658,973<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested and exercisable at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">357,766<br/>
                    </span></div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">78.82</span></div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">5.6</div>
                </td>

  </tr>

  <tr>

    <td style="width: 300pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested or expected to vest at December&#160;31, 2025</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"><span style="padding-left: 3.33pt;">658,973</span></div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;">$<span style="padding-left: 5pt;">44.20</span></div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;">7.1</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 300pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 36.95pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.14pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 46.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.13pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.96pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions applied to options</a></td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">92.4%</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.8%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">3.9%</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.8 years</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 51.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 95.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected volatility</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">93.7%</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">88.4%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Risk-free interest rate</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.1%</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">4.2%</div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected term</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">5.9 years</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">6.0 years </div>
                </td>

  </tr>

  <tr>

    <td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Expected dividend yield</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">&#8212;</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 360pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of activity related to restricted stock unit</a></td>
<td class="text">
<div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> <br/></div>

<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average <br/>
                  </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">50,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(25,000)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212;</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 17.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at March&#160;31, 2026</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">25,000</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$11.70</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 312pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 60.58pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 69.84pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Number of shares</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; border-bottom: none;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Weighted average </div>
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">grant date fair value </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at January&#160;1, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 8.33pt;">7,093</span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$44.80 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Granted</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt;">60,000</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5.37pt;">11.70</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Vested</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;">(16,825)</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">27.92</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Forfeited</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(268)</span></div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"><span style="padding-left: 5pt;">90.40</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Unvested balance at December&#160;31, 2025</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"><span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">50,000<br/>
                    </span></div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;">$10.52</div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockholderSEquityAndShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockholderSEquityAndShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Q1) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of reconciliation of reported segment net loss to the statement of operations</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 117.85pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 7.08pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Three Months Ended March&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2026</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 3.33pt;">1,458</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;">$<span style="padding-left: 8.33pt;">3,589 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,432</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">3,794 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">142</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">244 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">61</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">110 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,093</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">7,737 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative </div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">1,891</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,790 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt;">2,415</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,603 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt;">414</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">614 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">67</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">78 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">4,787</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,085 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 20.83pt;">&#8212;</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt;">2,637 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net gain on lease termination</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(633)</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">&#8212; </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(8,247)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(16,459)</span><span style="padding-bottom: 1.5pt;"> </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other income (expense), net</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">688</span></div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">1,054 </span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 49.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(7,559)</span></div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 54.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$(15,405)</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 49.35pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 54.34pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;">


  <tr class="BRDSX_boxspacer">

    <td style="height: 6pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 6pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="height: 6pt; width: 107.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div>
                </td>

    <td style="width: 12.36pt; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Year Ended December&#160;31, </div>
                </td>

  </tr>

  <tr class="BRDSX_header">

    <td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;">(in thousands)</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2025</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; border-bottom: none; white-space: nowrap;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">2024 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Research and development<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$<span style="padding-left: 5pt;">7,462</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;">$12,265 </div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">14,532</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">22,691</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt;">842</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,529</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">440</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">2,694</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total research and development expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">23,276</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">40,179</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">General and administrative<br/>
                  </div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Wages, benefits, and other payroll</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">7,784</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,255</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Third-party costs</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">9,644</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt;">12,055</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Share-based compensation</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">2,159</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt;">3,291</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Depreciation and amortization</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">288</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">387</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Total general and administrative expenses</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">19,875</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">24,988</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Impairment of long-lived assets</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">6,145</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">5,233</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Loss from operations</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">49,296</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">70,400</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Other (income) expense, net</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(3,774)</span></div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt; background-color: #CCEEFF;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;">(5,633)</span></div>
                </td>

  </tr>

  <tr>

    <td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Net loss</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$45,522</span></div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;">
                  <div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"><span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;">$64,767</span></div>
                </td>

  </tr>

  <tr class="BRDSX_boxspacer">

    <td style="height: 2.75pt; width: 336pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 12.36pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

    <td style="height: 2.75pt; width: 41.28pt;">
                  <div style="font-size: 1pt;">&#8194;</div>
                </td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (704,757)<span></span>
</td>
<td class="num">$ (659,235)<span></span>
</td>
<td class="num">$ (712,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember', window );">ATM Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (FY) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 14, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expenses for right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,633<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">5,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GainLossOnSaleOfTaxCredits', window );">Gain (loss) on sale of tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872,700<span></span>
</td>
<td class="nump">768,047<span></span>
</td>
<td class="nump">709,669<span></span>
</td>
<td class="nump">587,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock issued during period, Reverse stock splits | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember', window );">Laboratory equipment and certain other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember', window );">Laboratory equipment and certain other assets | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from Sale of Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,107<span></span>
</td>
<td class="nump">704,699<span></span>
</td>
<td class="nump">658,973<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">7,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember', window );">Laboratory equipment and certain other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember', window );">Property and equipment and certain other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GainLossOnSaleOfTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gain (loss) on sale of tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GainLossOnSaleOfTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Marketable Securities - Portfolio of Cash and Cash Equivalents (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="nump">$ 46,303<span></span>
</td>
<td class="nump">$ 37,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">46,303<span></span>
</td>
<td class="nump">37,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember', window );">Cash accounts in banking institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">3,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="nump">43,803<span></span>
</td>
<td class="nump">29,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">$ 43,803<span></span>
</td>
<td class="nump">29,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, and Marketable Securities - Portfolio of Marketable Securities (FY) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 39,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">39,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">5,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">5,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">25,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">25,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">1,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">1,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">5,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 5,908<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Non-Financial Instruments (Recurring basis) (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 46,303<span></span>
</td>
<td class="nump">$ 37,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">43,803<span></span>
</td>
<td class="nump">29,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">43,803<span></span>
</td>
<td class="nump">29,058<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">43,803<span></span>
</td>
<td class="nump">29,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 43,803<span></span>
</td>
<td class="nump">29,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,183<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Non-Financial Instruments (Nonrecurring Basis) (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">$ 2,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Right of use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,633<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Total impairment losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Nonrecurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
<td class="nump">1,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RightOfUseAssetsFairValueDisclosure', window );">Right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,489<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,644<span></span>
</td>
<td class="nump">$ 3,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RightOfUseAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RightOfUseAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
<td class="nump">$ 19,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(2,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,917)<span></span>
</td>
<td class="num">(9,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total, property plant and equipment net</a></td>
<td class="nump">826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,107<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,510<span></span>
</td>
<td class="nump">$ 7,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (FY) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2026</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment | Disposal group classified as held for sale or to be disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation on equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember', window );">Laboratory equipment and certain other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember', window );">Laboratory equipment and certain other assets | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from Sale of Property, Plant, and Equipment</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="nump">4,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedDivestitureFeesCurrent', window );">Divestiture fee due to Catalent</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="nump">$ 4,653<span></span>
</td>
<td class="nump">$ 6,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedDivestitureFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedDivestitureFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Gemma License Agreement (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_UpfrontLicenseFeeReceivable', window );">Upfront license fee receivable</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Non-refundable sublicense payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,750<span></span>
</td>
<td class="nump">$ 13,750<span></span>
</td>
<td class="nump">$ 8,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember', window );">Gemma License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_UpfrontLicenseFeeReceivable', window );">Upfront license fee receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ProceedsFromNonRefundableSublicensePayments', window );">Payment received</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShortTermLicenseFeeDueAndReceivable', window );">Short-term license fee due and receivables</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LongTermLicenseFeeDueAndReceivable', window );">Long-term license fee due and receivables</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones', window );">Contingent proceeds upon completing certain business milestones</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable', window );">Maximum additional amount in development and commercial milestone payments receivable</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ProceedsFromNonRefundableTransitionServicesPayments', window );">Amount of transition services payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments', window );">Transition service payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Non-refundable sublicense payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent proceeds upon completing certain business milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LongTermLicenseFeeDueAndReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license fee due and receivable in long-term as of the balance sheet date under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LongTermLicenseFeeDueAndReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum additional amount in development and commercial milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in payable due to amounts received under transition service payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ProceedsFromNonRefundableSublicensePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-refundable sublicense payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ProceedsFromNonRefundableSublicensePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ProceedsFromNonRefundableTransitionServicesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-refundable transition service payments received by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ProceedsFromNonRefundableTransitionServicesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShortTermLicenseFeeDueAndReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license fee due and receivable in short-term as of the balance sheet date under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShortTermLicenseFeeDueAndReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_UpfrontLicenseFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront license fee that is receivable under the license arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_UpfrontLicenseFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Severance (FY) (Details) - Workforce reduction - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Unpaid severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (FY) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 04, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 20, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expenses for right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,633<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment expenses for property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,373<span></span>
</td>
<td class="nump">2,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of certain other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, period percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember', window );">Operating leases for office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions', window );">Number of extension terms | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Renewal term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Option to terminate lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease', window );">Notice Period for termination lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementaMember', window );">Sublease Agreement A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PercentageOfAnnualIncreaseInSubleaseRent', window );">Annual increase in sublease rent (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementBMember', window );">Sublease Agreement B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_MarketStreetSubleaseAgreement1835Member', window );">1835 market street sublease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember', window );">Operating leases for laboratory space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Option to terminate lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease', window );">Notice Period for termination lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementCMember', window );">Sublease Agreement C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AreaSubleased', window );">Area Subleased | ft&#178;</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AreaOfLandSubleasedPercentage', window );">Subleased area of land</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PercentageOfAnnualIncreaseInSubleaseRent', window );">Annual increase in sublease rent (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expenses for right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment expenses for property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of certain other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment of leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Operating leases for laboratory space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions', window );">Number of extension terms | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm', window );">Extended term of new lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AreaOfLandSubleasedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents are of land sub leased of the total area under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AreaOfLandSubleasedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AreaSubleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area subleased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AreaSubleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the notice period for termination of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of extensions available under the new lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the renewal term under new lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PercentageOfAnnualIncreaseInSubleaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual increase in sublease rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PercentageOfAnnualIncreaseInSubleaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_MarketStreetSubleaseAgreement1835Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_MarketStreetSubleaseAgreement1835Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Operating lease cost (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 3,419<span></span>
</td>
<td class="nump">$ 3,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease expense</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 1,418<span></span>
</td>
<td class="nump">$ 5,522<span></span>
</td>
<td class="nump">$ 5,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">10 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Operating lease payments</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Sublease income (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaboration Agreements (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NonRefundableAggregateFeesPayablePerProductIndication', window );">Non - Refundable aggregate fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NonRefundableUpfrontFeesPayablePerProductIndication', window );">Non - Refundable upfront fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone', window );">Non - Refundable fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedDivestitureFeesCurrent', window );">Divestiture fee due to Catalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Amount of loss contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodSettlementOfLitigation', window );">Common stock</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LossContingencySharesAgreedByDefendant', window );">Loss contingency, shares agreed by defendant</a></td>
<td class="nump">33,836<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PercentageOfTargetAnnualBonusAmounts', window );">Target annual bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate for rare, monogenic disorders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember', window );">Gemma License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate for rare, monogenic disorders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate upon achievement of specific development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedDivestitureFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedDivestitureFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable on sales milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementSalesMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LossContingencySharesAgreedByDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares agreed to be issued by defendant and subject to reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LossContingencySharesAgreedByDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NonRefundableAggregateFeesPayablePerProductIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate non-refundable fees payable per product indication.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NonRefundableAggregateFeesPayablePerProductIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront fees payable per product indication upon developmental milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NonRefundableUpfrontFeesPayablePerProductIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront fees payable per product indication.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NonRefundableUpfrontFeesPayablePerProductIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PercentageOfTargetAnnualBonusAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of target annual bonus amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PercentageOfTargetAnnualBonusAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuedDuringPeriodSettlementOfLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of stock issued during period for settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuedDuringPeriodSettlementOfLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember', window );">ATM Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Common Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Equity Incentive Plan &amp; ESPP (FY) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 556,000<span></span>
</td>
<td class="nump">$ 858,000<span></span>
</td>
<td class="nump">$ 3,001,000<span></span>
</td>
<td class="nump">$ 5,820,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlanMember', window );">Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease', window );">Percent of the total number of shares of the Company's common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,141<span></span>
</td>
<td class="nump">155,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member', window );">Equity Incentive Plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">947,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease', window );">Percent of the total number of shares of the Company's common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member', window );">Equity inducement plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">99,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under ESPP</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding', window );">Percentage of common stock outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage', window );">Percentage of stock purchase price</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage', window );">Percentage of maximum employee contribution</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased', window );">Maximum amount of common stock that can be purchased | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased', window );">Number of shares that can be purchased</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased', window );">Maximum amount of common stock that can be purchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased', window );">Number of shares that can be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of shares that can be purchased in any single offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration from date of grant (issuance of an option) to when option auto expires.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-based compensation expense (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">$ 3,001<span></span>
</td>
<td class="nump">$ 5,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 414<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="nump">$ 2,159<span></span>
</td>
<td class="nump">$ 3,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (FY) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning of period</a></td>
<td class="nump">658,973<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">191,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(4,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending of period</a></td>
<td class="nump">846,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,973<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable at December 31, 2025</a></td>
<td class="nump">387,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at December 31, 2025</a></td>
<td class="nump">846,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning of period</a></td>
<td class="nump">$ 44.2<span></span>
</td>
<td class="nump">$ 77.56<span></span>
</td>
<td class="nump">$ 77.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">10.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending of period</a></td>
<td class="nump">40.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">$ 77.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at December 31, 2025</a></td>
<td class="nump">74.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at December 31, 2025</a></td>
<td class="nump">$ 40.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at December 31, 2025</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at December 31, 2025</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (FY) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">93.70%<span></span>
</td>
<td class="nump">88.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Units (FY) (Details) - Unvested restricted stock units - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, Beginning</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">7,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(16,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, Ending</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, Weighted average grant date fair value, Beginning</a></td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="nump">$ 44.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">27.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, Weighted average grant date fair value, Ending</a></td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets and liabilities (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 105,425<span></span>
</td>
<td class="nump">$ 94,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">55,020<span></span>
</td>
<td class="nump">50,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement', window );">Collaboration and license agreement</a></td>
<td class="nump">2,832<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">46,041<span></span>
</td>
<td class="nump">59,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">4,329<span></span>
</td>
<td class="nump">5,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">4,581<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">6,520<span></span>
</td>
<td class="nump">7,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets before valuation allowance</a></td>
<td class="nump">225,796<span></span>
</td>
<td class="nump">224,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(222,752)<span></span>
</td>
<td class="num">(219,833)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">4,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Right of use assets - operating leases</a></td>
<td class="num">(3,044)<span></span>
</td>
<td class="num">(4,445)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Total deferred tax liabilities</a></td>
<td class="num">(3,044)<span></span>
</td>
<td class="num">(4,445)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the federal income tax rate to the effective tax rate (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">US federal statutory tax rate</a></td>
<td class="num">$ (9,560)<span></span>
</td>
<td class="num">$ (13,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract', window );"><strong>Tax credits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(175)<span></span>
</td>
<td class="num">(626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount', window );">Orphan drug tax credits</a></td>
<td class="num">(4,003)<span></span>
</td>
<td class="num">(4,896)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="nump">12,334<span></span>
</td>
<td class="nump">17,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based payment awards</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Expiration of share-based payment awards</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract', window );"><strong>Tax credits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent', window );">Orphan drug tax credits</a></td>
<td class="nump">8.80%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowances</a></td>
<td class="num">(27.20%)<span></span>
</td>
<td class="num">(27.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based payment awards</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Expiration of share-based payment awards</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income tax payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign pre-tax income or losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net operating losses (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination, penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income Tax Examination, Description</a></td>
<td class="text">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December 31, 2025, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations. Tax years from 2022 and after remain subject to examination by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationYearUnderExamination', window );">Income Tax Examination, Year under Examination</a></td>
<td class="text">2021 2022 2023 2024 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research tax credits</a></td>
<td class="nump">$ 55,020<span></span>
</td>
<td class="nump">$ 50,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_OperatingLossCarryforwardSubjectToExpiration', window );">Net operating loss carryforwards subject to expiration</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">398,039<span></span>
</td>
<td class="nump">339,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">Federal | Research tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research tax credits</a></td>
<td class="nump">11,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_US', window );">Federal | Orphan drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research tax credits</a></td>
<td class="nump">43,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">398,035<span></span>
</td>
<td class="nump">339,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 277,828<span></span>
</td>
<td class="nump">$ 218,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_OperatingLossCarryforwardSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward subject to expiry, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_OperatingLossCarryforwardSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationYearUnderExamination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year being audited in the income tax examination, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationYearUnderExamination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=pasg_OrphanDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=pasg_OrphanDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (FY) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 7,737<span></span>
</td>
<td class="nump">$ 23,276<span></span>
</td>
<td class="nump">$ 40,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">4,787<span></span>
</td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="nump">24,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">8,247<span></span>
</td>
<td class="nump">16,459<span></span>
</td>
<td class="nump">49,296<span></span>
</td>
<td class="nump">70,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(688)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(3,774)<span></span>
</td>
<td class="num">(5,633)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">7,559<span></span>
</td>
<td class="nump">15,405<span></span>
</td>
<td class="nump">45,522<span></span>
</td>
<td class="nump">64,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pasg_GeneticMedicinesSegmentMember', window );">Genetic Medicines Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentLaborAndRelatedExpenses', window );">Wages, benefits, and other payroll</a></td>
<td class="nump">1,458<span></span>
</td>
<td class="nump">3,589<span></span>
</td>
<td class="nump">7,462<span></span>
</td>
<td class="nump">12,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentThirdPartyCosts', window );">Third-party costs</a></td>
<td class="nump">2,432<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
<td class="nump">14,532<span></span>
</td>
<td class="nump">22,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="nump">4,093<span></span>
</td>
<td class="nump">7,737<span></span>
</td>
<td class="nump">23,276<span></span>
</td>
<td class="nump">40,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeLaborAndRelatedExpenses', window );">Wages, benefits, and other payroll</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">7,784<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeThirdPartyCosts', window );">Third-party costs</a></td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">9,644<span></span>
</td>
<td class="nump">12,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="nump">4,787<span></span>
</td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="nump">24,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,247)<span></span>
</td>
<td class="num">(16,459)<span></span>
</td>
<td class="nump">49,296<span></span>
</td>
<td class="nump">70,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="num">(3,774)<span></span>
</td>
<td class="num">(5,633)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,405)<span></span>
</td>
<td class="nump">$ 45,522<span></span>
</td>
<td class="nump">$ 64,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of depreciation and amortization attributable to managing and administering the affairs of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeLaborAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit, excluding wages and other benefits incurred for employees in research and development phase of the medicines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeLaborAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of share based compensation attributable to managing and administering the affairs of an entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeThirdPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of third party costs attributable to managing and administering the affairs of an entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeThirdPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of depreciation and amortization attributable specifically to research and development division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentLaborAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit directly attributable to research and development phase of the medicines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentLaborAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of share based compensation attributable specifically to research and development division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentThirdPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of third party costs attributable specifically to research and development division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentThirdPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pasg_GeneticMedicinesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pasg_GeneticMedicinesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (FY) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks, Liquidity, and Going Concern (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks, Liquidity, and Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (712,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (704,757)<span></span>
</td>
<td class="num">$ (659,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,559)<span></span>
</td>
<td class="num">$ (15,405)<span></span>
</td>
<td class="num">(45,522)<span></span>
</td>
<td class="num">(64,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,303<span></span>
</td>
<td class="nump">$ 37,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember', window );">ATM Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks, Liquidity, and Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold', window );">Remaining capacity available to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember', window );">ATM Facility [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks, Liquidity, and Going Concern</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining capacity of value of shares available to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=pasg_AttheMarketFacilityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Q1) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 14, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Stock issued during period, Reverse stock splits | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,303<span></span>
</td>
<td class="nump">$ 37,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment expenses for right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,633<span></span>
</td>
<td class="nump">2,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">5,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium and discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872,700<span></span>
</td>
<td class="nump">768,047<span></span>
</td>
<td class="nump">709,669<span></span>
</td>
<td class="nump">587,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,107<span></span>
</td>
<td class="nump">704,699<span></span>
</td>
<td class="nump">658,973<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">7,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember', window );">Laboratory equipment and certain other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentAndCertainOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments and Non-Financial Instruments (Q1) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Instruments and Non-Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Nonrecurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value of Financial Instruments and Non-Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 2,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,024<span></span>
</td>
<td class="nump">$ 19,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(2,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,917)<span></span>
</td>
<td class="num">(9,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total, property plant and equipment net</a></td>
<td class="nump">826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,107<span></span>
</td>
<td class="nump">9,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="nump">3,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,510<span></span>
</td>
<td class="nump">$ 7,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Narrative (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2026</div></th>
<th class="th"><div>Feb. 14, 2026</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EarlyLeaseTerminationFee', window );">Payment for early lease termination</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net gain on lease termination</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GainLossOnWriteOffOfOperatingLeases', window );">Gain (loss) on write-off of operating leases</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EarlyLeaseTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense incurred during the period for early lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EarlyLeaseTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GainLossOnWriteOffOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on write-off of assets and liabilities for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GainLossOnWriteOffOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="nump">4,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,174<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedDivestitureFeesCurrent', window );">Divestiture fee due to Catalent</a></td>
<td class="nump">924<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="nump">$ 4,653<span></span>
</td>
<td class="nump">$ 6,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedDivestitureFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedDivestitureFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Gemma License Agreement (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_UpfrontLicenseFeeReceivable', window );">Upfront license fee receivable</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Non-refundable sublicense payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,750<span></span>
</td>
<td class="nump">$ 13,750<span></span>
</td>
<td class="nump">$ 8,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember', window );">Gemma License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_UpfrontLicenseFeeReceivable', window );">Upfront license fee receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ProceedsFromNonRefundableSublicensePayments', window );">Payment received</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LicenseFeeDueAndReceivable', window );">Amount of license fee due and receivables</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ProceedsFromShortTermLicenseFee', window );">Proceeds from short term license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LongTermLicenseFeeDueAndReceivable', window );">Long-term license fee due and receivables</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones', window );">Contingent proceeds upon completing certain business milestones</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable', window );">Maximum additional amount in development and commercial milestone payments receivable</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ProceedsFromNonRefundableTransitionServicesPayments', window );">Amount of transition services payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments', window );">Transition service payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Non-refundable sublicense payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent proceeds upon completing certain business milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LicenseFeeDueAndReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license fee due and receivable as of the balance sheet date under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LicenseFeeDueAndReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LongTermLicenseFeeDueAndReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license fee due and receivable in long-term as of the balance sheet date under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LongTermLicenseFeeDueAndReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum additional amount in development and commercial milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of decrease in payable due to amounts received under transition service payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ProceedsFromNonRefundableSublicensePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-refundable sublicense payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ProceedsFromNonRefundableSublicensePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ProceedsFromNonRefundableTransitionServicesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from non-refundable transition service payments received by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ProceedsFromNonRefundableTransitionServicesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ProceedsFromShortTermLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short term license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ProceedsFromShortTermLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_UpfrontLicenseFeeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront license fee that is receivable under the license arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_UpfrontLicenseFeeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Severance (Q1) (Details) - Workforce reduction - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Unpaid severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Q1) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 14, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 04, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 29, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 07, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EarlyLeaseTerminationFee', window );">Payment for early lease termination</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net gain on lease termination</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GainLossOnWriteOffOfOperatingLeases', window );">Gain (loss) on write-off of operating leases</a></td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,289)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember', window );">Operating leases for office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions', window );">Number of extension terms | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Renewal term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Option to terminate lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease', window );">Notice Period for termination lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementaMember', window );">Sublease Agreement A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PercentageOfAnnualIncreaseInSubleaseRent', window );">Annual increase in sublease rent (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementBMember', window );">Sublease Agreement B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Option to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember', window );">Operating leases for laboratory space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Option to terminate lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease', window );">Notice Period for termination lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RightOfUsePeriodDecreaseDueToLeaseTermination', window );">Right of Use Period Decrease due to Lease Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination', window );">Lease Liability For Operating Lease, Period Decrease due to Lease Termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementCMember', window );">Sublease Agreement C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AreaSubleased', window );">Area Subleased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AreaOfLandSubleasedPercentage', window );">Subleased area of land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PercentageOfAnnualIncreaseInSubleaseRent', window );">Annual increase in sublease rent (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Operating leases for laboratory space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions', window );">Number of extension terms | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm', window );">Extended term of new lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AreaOfLandSubleasedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents are of land sub leased of the total area under lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AreaOfLandSubleasedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AreaSubleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area subleased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AreaSubleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EarlyLeaseTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense incurred during the period for early lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EarlyLeaseTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GainLossOnWriteOffOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on write-off of assets and liabilities for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GainLossOnWriteOffOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Liability for Operating Lease, Period Decrease due to Lease Termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the notice period for termination of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of extensions available under the new lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the renewal term under new lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PercentageOfAnnualIncreaseInSubleaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual increase in sublease rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PercentageOfAnnualIncreaseInSubleaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RightOfUsePeriodDecreaseDueToLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Use period decrease due to lease termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RightOfUsePeriodDecreaseDueToLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_SubleaseAgreementCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Operating lease cost (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 3,419<span></span>
</td>
<td class="nump">$ 3,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease expense</a></td>
<td class="nump">$ 802<span></span>
</td>
<td class="nump">$ 1,418<span></span>
</td>
<td class="nump">$ 5,522<span></span>
</td>
<td class="nump">$ 5,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">9.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">10 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Operating lease payments</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Sublease income (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaboration Agreements (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NonRefundableAggregateFeesPayablePerProductIndication', window );">Non - Refundable aggregate fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NonRefundableUpfrontFeesPayablePerProductIndication', window );">Non - Refundable upfront fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone', window );">Non - Refundable fees payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedDivestitureFeesCurrent', window );">Divestiture fee due to Catalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Amount of loss contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodSettlementOfLitigation', window );">Common stock</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LossContingencySharesAgreedByDefendant', window );">Loss contingency, shares agreed by defendant</a></td>
<td class="nump">33,836<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
<td class="nump">1,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PercentageOfTargetAnnualBonusAmounts', window );">Target annual bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate for rare, monogenic disorders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember', window );">Gemma License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate for rare, monogenic disorders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate upon achievement of specific development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedDivestitureFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedDivestitureFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable on sales milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementSalesMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LossContingencySharesAgreedByDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares agreed to be issued by defendant and subject to reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LossContingencySharesAgreedByDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NonRefundableAggregateFeesPayablePerProductIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate non-refundable fees payable per product indication.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NonRefundableAggregateFeesPayablePerProductIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront fees payable per product indication upon developmental milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NonRefundableUpfrontFeesPayablePerProductIndication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront fees payable per product indication.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NonRefundableUpfrontFeesPayablePerProductIndication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PercentageOfTargetAnnualBonusAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of target annual bonus amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PercentageOfTargetAnnualBonusAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuedDuringPeriodSettlementOfLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of stock issued during period for settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuedDuringPeriodSettlementOfLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_ArrangementWithGemmaBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity and Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Q1) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2026 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 556,000<span></span>
</td>
<td class="nump">$ 858,000<span></span>
</td>
<td class="nump">$ 3,001,000<span></span>
</td>
<td class="nump">$ 5,820,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlanMember', window );">Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease', window );">Percent of the total number of shares of the Company's common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,141<span></span>
</td>
<td class="nump">155,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member', window );">Equity inducement plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">99,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under ESPP</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding', window );">Percentage of common stock outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage', window );">Percentage of stock purchase price</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage', window );">Percentage of maximum employee contribution</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased', window );">Maximum amount of common stock that can be purchased | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased', window );">Number of shares that can be purchased</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased', window );">Maximum amount of common stock that can be purchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased', window );">Number of shares that can be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of shares that can be purchased in any single offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration from date of grant (issuance of an option) to when option auto expires.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity and Share-Based Compensation - Share-based compensation expense (Q1) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 858<span></span>
</td>
<td class="nump">$ 3,001<span></span>
</td>
<td class="nump">$ 5,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 414<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="nump">$ 2,159<span></span>
</td>
<td class="nump">$ 3,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity and Share-Based Compensation - Stock Option Activity (Q1) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning of period</a></td>
<td class="nump">658,973<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">191,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(4,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending of period</a></td>
<td class="nump">846,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,973<span></span>
</td>
<td class="nump">577,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable at March 31, 2026</a></td>
<td class="nump">387,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at March 31, 2026</a></td>
<td class="nump">846,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">658,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning of period</a></td>
<td class="nump">$ 44.2<span></span>
</td>
<td class="nump">$ 77.56<span></span>
</td>
<td class="nump">$ 77.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">7.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">10.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending of period</a></td>
<td class="nump">40.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.2<span></span>
</td>
<td class="nump">$ 77.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at March 31, 2026</a></td>
<td class="nump">74.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at March 31, 2026</a></td>
<td class="nump">$ 40.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at March 31, 2026</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at March 31, 2026</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 6.07<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity and Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Q1) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.70%<span></span>
</td>
<td class="nump">88.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.40%<span></span>
</td>
<td class="nump">93.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity and Share-Based Compensation - Restricted Stock Units (Q1) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, Beginning</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">7,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(16,825)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, Ending</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, Weighted average grant date fair value, Beginning</a></td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="nump">$ 44.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value</a></td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">27.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, Weighted average grant date fair value, Ending</a></td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 10.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Q1) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 04, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2026 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,093<span></span>
</td>
<td class="nump">$ 7,737<span></span>
</td>
<td class="nump">$ 23,276<span></span>
</td>
<td class="nump">$ 40,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="nump">24,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net gain on lease termination</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,247<span></span>
</td>
<td class="nump">16,459<span></span>
</td>
<td class="nump">49,296<span></span>
</td>
<td class="nump">70,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(688)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
<td class="num">(3,774)<span></span>
</td>
<td class="num">(5,633)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,559<span></span>
</td>
<td class="nump">15,405<span></span>
</td>
<td class="nump">45,522<span></span>
</td>
<td class="nump">64,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pasg_GeneticMedicinesSegmentMember', window );">Genetic Medicines Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentLaborAndRelatedExpenses', window );">Wages, benefits, and other payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458<span></span>
</td>
<td class="nump">3,589<span></span>
</td>
<td class="nump">7,462<span></span>
</td>
<td class="nump">12,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentThirdPartyCosts', window );">Third-party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,432<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
<td class="nump">14,532<span></span>
</td>
<td class="nump">22,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ResearchAndDevelopmentDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">440<span></span>
</td>
<td class="nump">2,694<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,093<span></span>
</td>
<td class="nump">7,737<span></span>
</td>
<td class="nump">23,276<span></span>
</td>
<td class="nump">40,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeLaborAndRelatedExpenses', window );">Wages, benefits, and other payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
<td class="nump">7,784<span></span>
</td>
<td class="nump">9,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeThirdPartyCosts', window );">Third-party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">2,603<span></span>
</td>
<td class="nump">9,644<span></span>
</td>
<td class="nump">12,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_GeneralAndAdministrativeDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,787<span></span>
</td>
<td class="nump">6,085<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="nump">24,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">6,145<span></span>
</td>
<td class="nump">5,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net gain on lease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,247)<span></span>
</td>
<td class="num">(16,459)<span></span>
</td>
<td class="nump">49,296<span></span>
</td>
<td class="nump">70,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">1,054<span></span>
</td>
<td class="num">(3,774)<span></span>
</td>
<td class="num">(5,633)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,559)<span></span>
</td>
<td class="num">$ (15,405)<span></span>
</td>
<td class="nump">$ 45,522<span></span>
</td>
<td class="nump">$ 64,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of depreciation and amortization attributable to managing and administering the affairs of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeLaborAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit, excluding wages and other benefits incurred for employees in research and development phase of the medicines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeLaborAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of share based compensation attributable to managing and administering the affairs of an entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_GeneralAndAdministrativeThirdPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of third party costs attributable to managing and administering the affairs of an entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_GeneralAndAdministrativeThirdPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of depreciation and amortization attributable specifically to research and development division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentLaborAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit directly attributable to research and development phase of the medicines.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentLaborAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of share based compensation attributable specifically to research and development division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ResearchAndDevelopmentThirdPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses in the period for usage of third party costs attributable specifically to research and development division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ResearchAndDevelopmentThirdPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pasg_GeneticMedicinesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pasg_GeneticMedicinesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Q1) (Details) - Subsequent event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 24, 2026</div></th>
<th class="th"><div>May 22, 2026</div></th>
<th class="th"><div>Apr. 28, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RestructuringPlanReductionInWorkforcePercentage', window );">Reduction in workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EstimatedSeveranceAndRelatedCosts', window );">Estimated severance and related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_MergerAgreementTerminationPaymentAmount', window );">Termination payment amount</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Market Street Lease Agreement 2005 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PaymentOfLeaseTerminationFee', window );">Payment of lease termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EstimatedSeveranceAndRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate estimated and severance costs to be incurred as a part of restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EstimatedSeveranceAndRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_MergerAgreementTerminationPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payment required to be made by the registrant upon termination of a merger agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_MergerAgreementTerminationPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PaymentOfLeaseTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow related to the payment of lease termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PaymentOfLeaseTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RestructuringPlanReductionInWorkforcePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reduction in workforce as a part of restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RestructuringPlanReductionInWorkforcePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_MarketStreetLeaseAgreement2005Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_MarketStreetLeaseAgreement2005Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Jul. 21, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001787297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">PASSAGE BIO, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Jul. 21, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">42,605,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 8,190.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"><table style="font-size: 12pt; width:100%;"><tr style="height: 0px; font-size: 0px;"><td style="width: 1%; vertical-align: top; font-size: 10pt;">(1)</td><td style="width: 1%; vertical-align: top; font-size: 10pt;">(a)</td><td style="width: 98%; font-size: 10pt; text-align: left;">Represents the maximum
number of shares of Common Stock, par value $0.0001 per share (&#8220;Passage Bio
Common Stock&#8221;), of Passage Bio, Inc. (&#8220;Passage Bio&#8221;), that are expected to be
issued (or become issuable) to securityholders of Remix Therapeutics, Inc. (&#8220;Remix&#8221;)
pursuant to the merger and related transactions contemplated by the Agreement
and Plan of Merger, dated as of June&#160;24, 2026 (&#8220;Merger Agreement&#8221;), by and
among Passage Bio, Merger Sub, Inc., and Remix, with Remix continuing as a
wholly-owned subsidiary of Passage Bio and the surviving corporation of the
merger. The number of shares of Passage Bio Common Stock to be registered on
this registration statement (&#8220;Registration Statement&#8221;) consists of (i) the
estimated number of shares of Passage Bio Common Stock that are expected to be
issued in exchange for shares of Remix Common Stock (the &#8220;Remix Common Stock&#8221;)
outstanding immediately prior to the Effective Time (as defined in the Merger
Agreement), including the shares of Remix Common Stock to be issued in the PIPE
Financing, after giving effect to (A) the conversion of all outstanding shares
of Remix preferred stock into shares of Remix Common Stock, (B) the conversion
of the 2025 Convertible Notes (as defined in the Registration Statement) and
the associated warrants into shares of Remix Common Stock, and (C) the
conversion of the 2026 Convertible Notes into shares of Remix Common Stock,
each without taking into account the effect of a reverse stock split of Passage
Bio Common Stock and assuming a maximum pre-split exchange ratio of
approximately 0.1734 shares of Passage Bio Common Stock for each outstanding
share of Remix Common Stock (which is subject to adjustment prior to the
closing of the Merger), and (ii) shares of Passage Bio Common Stock issuable
upon exercise of warrants issued in the merger in exchange for Remix warrants,
without taking into account the effect of a reverse stock split of Passage Bio
Common Stock and assuming a maximum pre-split exchange ratio of approximately
0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix
Common Stock (which is subject to adjustment prior to the closing of the
Merger), and (iii) options to purchase shares of Passage Bio Common Stock in
exchange for options to purchase shares of Remix Common Stock outstanding under
the Remix 2019 Plan, without taking into account the effect of a reverse stock
split of Passage Bio Common Stock and assuming a maximum pre-split exchange
ratio of approximately 0.1734 shares of Passage Bio Common Stock for each
outstanding share of Remix Common Stock (which is subject to adjustment prior
to the closing of the Merger).</td></tr><tr><td>&#160;</td><td style="font-size: 10pt; vertical-align: top;">(b)</td><td style="text-align: left;"><span style="font-size: 10pt;">Estimated solely for the
purpose of calculating the registration fee under Rule 457(f)(2) under the
Securities Act of 1933, as amended. Remix is a private company, no market
exists for its securities, and Remix has an accumulated capital deficit.
Therefore, the proposed maximum aggregate offering price is calculated based on
an aggregate offering amount equal to one-third of the aggregate par value of
the Remix Common Stock that will be exchanged in the merger.</span></td></tr><tr><td>&#160;</td><td style="font-size: 10pt; vertical-align: top;">(c)</td><td style="text-align: left;"><span style="font-size: 10pt;">In accordance with Rule 416
under the Securities Act of 1933, as amended, this registration statement shall
be deemed to cover any securities that may from time to time be offered or
issued resulting from forward or reverse stock splits, stock dividends or
similar transactions.</span></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants to purchase Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">24,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt; font-size: 10pt;"> <div style="margin-bottom: 4pt;"> (2) </div> </td> <td style="padding: 0px 5.4pt; font-size: 10pt; text-align: left;"> <div style="margin-bottom: 4pt;"> Consists of Passage Bio warrants issued in the merger in exchange for Remix warrants, without taking into account the effect of a reverse stock split of Passage Bio Common Stock and assuming a maximum pre-split exchange ratio of approximately 0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix Common Stock (which is subject to adjustment prior to the closing of the Merger). The registration fee with respect to the warrants has been allocated to the underlying shares of Passage Bio Common Stock issuable upon exercise of such Passage Bio warrants, as described in footnote (1). </div> </td> </tr> </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesOthrRuleFlg', window );">Other Rule</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Options to purchase Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">3,058,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text"><table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;">&#160;</td><td style="width: 99%;">&#160;</td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt; font-size: 10pt;"> <div style="margin-bottom: 4pt;"> (3) </div> </td> <td style="padding: 0px 5.4pt; font-size: 10pt; text-align: left;"> <div style="margin-bottom: 4pt;"> Consists of Passage Bio stock options to purchase shares of Passage Bio Common Stock issued in exchange for Remix stock options to purchase shares of Remix Common Stock, without taking into account the effect of a reverse stock split of Passage Bio Common Stock and assuming a maximum pre-split exchange ratio of approximately 0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix Common Stock (which is subject to adjustment prior to the closing of the Merger). The registration fee with respect to the options to purchase shares of Passage Bio Common Stock has been allocated to the underlying shares of Passage Bio Common Stock issuable upon exercise of such options, as described in footnote (1). </div> </td> </tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesOthrRuleFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesOthrRuleFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Jul. 21, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 8,190.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">1.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>204</ContextCount>
  <ElementCount>348</ElementCount>
  <EntityCount>2</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - Balance Sheets (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/BalanceSheetsFy</Role>
      <ShortName>Balance Sheets (FY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - Balance Sheets (FY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/BalanceSheetsFyParenthetical</Role>
      <ShortName>Balance Sheets (FY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - Statements of Operations and Comprehensive Loss (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy</Role>
      <ShortName>Statements of Operations and Comprehensive Loss (FY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - Statements of Stockholders' Equity (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StatementsOfStockholdersEquityFy</Role>
      <ShortName>Statements of Stockholders' Equity (FY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - Statements of Cash Flows (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StatementsOfCashFlowsFy</Role>
      <ShortName>Statements of Cash Flows (FY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>050000 - Statement - Balance Sheets (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/BalanceSheetsQ1</Role>
      <ShortName>Balance Sheets (Q1)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>050100 - Statement - Balance Sheets (Q1) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/BalanceSheetsQ1Parenthetical</Role>
      <ShortName>Balance Sheets (Q1) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060000 - Statement - Statements of Operations and Comprehensive Loss (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1</Role>
      <ShortName>Statements of Operations and Comprehensive Loss (Q1)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>070000 - Statement - Statements of Stockholders' Equity (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StatementsOfStockholdersEquityQ1</Role>
      <ShortName>Statements of Stockholders' Equity (Q1)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>080000 - Statement - Statements of Cash Flows (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StatementsOfCashFlowsQ1</Role>
      <ShortName>Statements of Cash Flows (Q1)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Nature of Operations (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/NatureOfOperationsFy</Role>
      <ShortName>Nature of Operations (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Risks and Liquidity (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/RisksAndLiquidityFy</Role>
      <ShortName>Risks and Liquidity (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Summary of Significant Accounting Policies (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy</Role>
      <ShortName>Summary of Significant Accounting Policies (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy</Role>
      <ShortName>Cash, Cash Equivalents, and Marketable Securities (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy</Role>
      <ShortName>Fair Value of Financial Instruments and Non-Financial Instruments (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Property and Equipment, Net (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetFy</Role>
      <ShortName>Property and Equipment, Net (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Gemma License Agreement (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/GemmaLicenseAgreementFy</Role>
      <ShortName>Gemma License Agreement (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>090900 - Disclosure - Severance (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SeveranceFy</Role>
      <ShortName>Severance (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Leases (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesFy</Role>
      <ShortName>Leases (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>091100 - Disclosure - Commitments and Contingencies (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CommitmentsAndContingenciesFy</Role>
      <ShortName>Commitments and Contingencies (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>091200 - Disclosure - Common Stock (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CommonStockFy</Role>
      <ShortName>Common Stock (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>091300 - Disclosure - Share-Based Compensation (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SharebasedCompensationFy</Role>
      <ShortName>Share-Based Compensation (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>091400 - Disclosure - Income Taxes (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/IncomeTaxesFy</Role>
      <ShortName>Income Taxes (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>091500 - Disclosure - Segment Reporting (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SegmentReportingFy</Role>
      <ShortName>Segment Reporting (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>091600 - Disclosure - Subsequent Events (FY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SubsequentEventsFy</Role>
      <ShortName>Subsequent Events (FY)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>091700 - Disclosure - Nature of Operations (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/NatureOfOperationsQ1</Role>
      <ShortName>Nature of Operations (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>091800 - Disclosure - Risks, Liquidity, and Going Concern (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1</Role>
      <ShortName>Risks, Liquidity, and Going Concern (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>091900 - Disclosure - Summary of Significant Accounting Policies (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1</Role>
      <ShortName>Summary of Significant Accounting Policies (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>092000 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1</Role>
      <ShortName>Fair Value of Financial Instruments and Non-Financial Instruments (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>092100 - Disclosure - Property and Equipment, Net (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetQ1</Role>
      <ShortName>Property and Equipment, Net (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>092200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>092300 - Disclosure - Gemma License Agreement (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/GemmaLicenseAgreementQ1</Role>
      <ShortName>Gemma License Agreement (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>092400 - Disclosure - Severance (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SeveranceQ1</Role>
      <ShortName>Severance (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>092500 - Disclosure - Leases (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesQ1</Role>
      <ShortName>Leases (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>092600 - Disclosure - Commitments and Contingencies (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CommitmentsAndContingenciesQ1</Role>
      <ShortName>Commitments and Contingencies (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>092700 - Disclosure - Stockholder's Equity and Share-Based Compensation (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1</Role>
      <ShortName>Stockholder's Equity and Share-Based Compensation (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>092800 - Disclosure - Segment Reporting (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SegmentReportingQ1</Role>
      <ShortName>Segment Reporting (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>092900 - Disclosure - Subsequent Events (Q1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SubsequentEventsQ1</Role>
      <ShortName>Subsequent Events (Q1)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Summary of Significant Accounting Policies (FY) (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (FY) (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>101900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies</Role>
      <ShortName>Summary of Significant Accounting Policies (Q1) (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>110300 - Disclosure - Summary of Significant Accounting Policies (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables</Role>
      <ShortName>Summary of Significant Accounting Policies (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>110400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables</Role>
      <ShortName>Cash, Cash Equivalents, and Marketable Securities (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>110500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables</Role>
      <ShortName>Fair Value of Financial Instruments and Non-Financial Instruments (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>110600 - Disclosure - Property and Equipment, Net (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetFyTables</Role>
      <ShortName>Property and Equipment, Net (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/PropertyAndEquipmentNetFy</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>110700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>111000 - Disclosure - Leases (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesFyTables</Role>
      <ShortName>Leases (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/LeasesFy</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>111300 - Disclosure - Share-Based Compensation (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SharebasedCompensationFyTables</Role>
      <ShortName>Share-Based Compensation (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/SharebasedCompensationFy</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>111400 - Disclosure - Income Taxes (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/IncomeTaxesFyTables</Role>
      <ShortName>Income Taxes (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/IncomeTaxesFy</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>111500 - Disclosure - Segment Reporting (FY) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SegmentReportingFyTables</Role>
      <ShortName>Segment Reporting (FY) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/SegmentReportingFy</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>111900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables</Role>
      <ShortName>Summary of Significant Accounting Policies (Q1) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>112100 - Disclosure - Property and Equipment, Net (Q1) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables</Role>
      <ShortName>Property and Equipment, Net (Q1) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/PropertyAndEquipmentNetFy</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>112200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Q1) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>112500 - Disclosure - Leases (Q1) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesQ1Tables</Role>
      <ShortName>Leases (Q1) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/LeasesFy</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>112700 - Disclosure - Stockholder's Equity and Share-Based Compensation (Q1) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables</Role>
      <ShortName>Stockholder's Equity and Share-Based Compensation (Q1) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>112800 - Disclosure - Segment Reporting (Q1) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SegmentReportingQ1Tables</Role>
      <ShortName>Segment Reporting (Q1) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://passagebio.com/role/SegmentReportingFy</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>120200 - Disclosure - Risks and Liquidity (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/RisksAndLiquidityFyDetails</Role>
      <ShortName>Risks and Liquidity (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/RisksAndLiquidityFy</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>120300 - Disclosure - Summary of Significant Accounting Policies (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>120400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities - Portfolio of Cash and Cash Equivalents (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails</Role>
      <ShortName>Cash, Cash Equivalents, and Marketable Securities - Portfolio of Cash and Cash Equivalents (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>120402 - Disclosure - Cash, Cash Equivalents, and Marketable Securities - Portfolio of Marketable Securities (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails</Role>
      <ShortName>Cash, Cash Equivalents, and Marketable Securities - Portfolio of Marketable Securities (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>120500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Recurring basis) (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails</Role>
      <ShortName>Fair Value of Financial Instruments and Non-Financial Instruments (Recurring basis) (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>120502 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Nonrecurring Basis) (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails</Role>
      <ShortName>Fair Value of Financial Instruments and Non-Financial Instruments (Nonrecurring Basis) (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>120600 - Disclosure - Property and Equipment, Net (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetFyDetails</Role>
      <ShortName>Property and Equipment, Net (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/PropertyAndEquipmentNetFyTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>120602 - Disclosure - Property and Equipment, Net - Narrative (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails</Role>
      <ShortName>Property and Equipment, Net - Narrative (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>120700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>120800 - Disclosure - Gemma License Agreement (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/GemmaLicenseAgreementFyDetails</Role>
      <ShortName>Gemma License Agreement (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/GemmaLicenseAgreementFy</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>120900 - Disclosure - Severance (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SeveranceFyDetails</Role>
      <ShortName>Severance (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SeveranceFy</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>121000 - Disclosure - Leases (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesFyDetails</Role>
      <ShortName>Leases (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/LeasesFyTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>121002 - Disclosure - Leases - Operating lease cost (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails</Role>
      <ShortName>Leases - Operating lease cost (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>121004 - Disclosure - Leases - Sublease income (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesSubleaseIncomeFyDetails</Role>
      <ShortName>Leases - Sublease income (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>121100 - Disclosure - Commitments and Contingencies - Collaboration Agreements (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails</Role>
      <ShortName>Commitments and Contingencies - Collaboration Agreements (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>121200 - Disclosure - Common Stock (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CommonStockFyDetails</Role>
      <ShortName>Common Stock (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/CommonStockFy</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>121300 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails</Role>
      <ShortName>Share-Based Compensation - Equity Incentive Plan &amp; ESPP (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>121302 - Disclosure - Share-Based Compensation - Share-based compensation expense (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails</Role>
      <ShortName>Share-Based Compensation - Share-based compensation expense (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>121304 - Disclosure - Share-Based Compensation - Stock Option Activity (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>121306 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails</Role>
      <ShortName>Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>121308 - Disclosure - Share-Based Compensation - Restricted Stock Units (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Units (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>121400 - Disclosure - Income Taxes - Deferred tax assets and liabilities (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets and liabilities (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>121402 - Disclosure - Income Taxes - Reconciliation of the federal income tax rate to the effective tax rate (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the federal income tax rate to the effective tax rate (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>121404 - Disclosure - Income Taxes (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/IncomeTaxesFyDetails</Role>
      <ShortName>Income Taxes (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/IncomeTaxesFyTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>121406 - Disclosure - Income Taxes - Net operating losses (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails</Role>
      <ShortName>Income Taxes - Net operating losses (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>121500 - Disclosure - Segment Reporting (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SegmentReportingFyDetails</Role>
      <ShortName>Segment Reporting (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SegmentReportingFyTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>121600 - Disclosure - Subsequent Events (FY) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SubsequentEventsFyDetails</Role>
      <ShortName>Subsequent Events (FY) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SubsequentEventsFy</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>121800 - Disclosure - Risks, Liquidity, and Going Concern (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details</Role>
      <ShortName>Risks, Liquidity, and Going Concern (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>121900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details</Role>
      <ShortName>Summary of Significant Accounting Policies (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>122000 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details</Role>
      <ShortName>Fair Value of Financial Instruments and Non-Financial Instruments (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>122100 - Disclosure - Property and Equipment, Net (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetQ1Details</Role>
      <ShortName>Property and Equipment, Net (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/PropertyAndEquipmentNetFyTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>122102 - Disclosure - Property and Equipment, Net - Narrative (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details</Role>
      <ShortName>Property and Equipment, Net - Narrative (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>122200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>122300 - Disclosure - Gemma License Agreement (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/GemmaLicenseAgreementQ1Details</Role>
      <ShortName>Gemma License Agreement (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/GemmaLicenseAgreementFy</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>122400 - Disclosure - Severance (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SeveranceQ1Details</Role>
      <ShortName>Severance (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SeveranceFy</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>122500 - Disclosure - Leases (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesQ1Details</Role>
      <ShortName>Leases (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/LeasesFyTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>122502 - Disclosure - Leases - Operating lease cost (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details</Role>
      <ShortName>Leases - Operating lease cost (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>122504 - Disclosure - Leases - Sublease income (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/LeasesSubleaseIncomeQ1Details</Role>
      <ShortName>Leases - Sublease income (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>122600 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details</Role>
      <ShortName>Commitments and Contingencies - Collaboration Agreements (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>122700 - Disclosure - Stockholder's Equity and Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details</Role>
      <ShortName>Stockholder's Equity and Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>122702 - Disclosure - Stockholder's Equity and Share-Based Compensation - Share-based compensation expense (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details</Role>
      <ShortName>Stockholder's Equity and Share-Based Compensation - Share-based compensation expense (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>122704 - Disclosure - Stockholder's Equity and Share-Based Compensation - Stock Option Activity (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details</Role>
      <ShortName>Stockholder's Equity and Share-Based Compensation - Stock Option Activity (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>122706 - Disclosure - Stockholder's Equity and Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details</Role>
      <ShortName>Stockholder's Equity and Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>122708 - Disclosure - Stockholder's Equity and Share-Based Compensation - Restricted Stock Units (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details</Role>
      <ShortName>Stockholder's Equity and Share-Based Compensation - Restricted Stock Units (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>122800 - Disclosure - Segment Reporting (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SegmentReportingQ1Details</Role>
      <ShortName>Segment Reporting (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SegmentReportingFyTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="ny20077915x1_s4.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>122900 - Disclosure - Subsequent Events (Q1) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://passagebio.com/role/SubsequentEventsQ1Details</Role>
      <ShortName>Subsequent Events (Q1) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://passagebio.com/role/SubsequentEventsFy</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="ny20077915x1_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="ny20077915x1_ex107.htm">
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="ny20077915x1_ex107.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-4" isDefinitelyFs="true" isUsgaap="true" original="ny20077915x1_s4.htm">ny20077915x1_s4.htm</File>
    <File>pasg-20260721.xsd</File>
    <File>pasg-20260721_cal.xml</File>
    <File>pasg-20260721_def.xml</File>
    <File>pasg-20260721_lab.xml</File>
    <File>pasg-20260721_pre.xml</File>
    <File doctype="EX-FILING FEES" original="ny20077915x1_ex107.htm">ny20077915x1_ex107.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo_passagebio.jpg</File>
    <File>logo_redwood.jpg</File>
    <File>ny20077915x1_barchart01x2.jpg</File>
    <File>ny20077915x1_barchart02x1.jpg</File>
    <File>ny20077915x1_charts01x1.jpg</File>
    <File>ny20077915x1_charts02x2.jpg</File>
    <File>ny20077915x1_charts03x2.jpg</File>
    <File>ny20077915x1_charts04x2.jpg</File>
    <File>ny20077915x1_flowchart01.jpg</File>
    <File>ny20077915x1_flowchart04.jpg</File>
    <File>ny20077915x1_flowchart0x2.jpg</File>
    <File>ny20077915x1_flowchart0x3.jpg</File>
    <File>ny20077915x1_graphic01.jpg</File>
    <File>ny20077915x1_graphic02.jpg</File>
    <File>ny20077915x1_graphic03.jpg</File>
    <File>ny20077915x1_graphic04x1.jpg</File>
    <File>ny20077915x1_linechart0x1.jpg</File>
    <File>ny20077915x1_linechart0x2.jpg</File>
    <File>ny20077915x1_linechart0x4.jpg</File>
    <File>ny20077915x1_linechart0x5.jpg</File>
    <File>ny20077915x1_table01.jpg</File>
    <File>ny20077915x1_table02x1.jpg</File>
    <File>ny20077915x1_table03x2.jpg</File>
    <File>ny20077915x1_table04x1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="862">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>170
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ny20077915x1_s4.htm": {
   "nsprefix": "pasg",
   "nsuri": "http://passagebio.com/20260721",
   "dts": {
    "inline": {
     "local": [
      "ny20077915x1_s4.htm"
     ]
    },
    "schema": {
     "local": [
      "pasg-20260721.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/exch/2025/exch-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "pasg-20260721_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pasg-20260721_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pasg-20260721_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pasg-20260721_pre.xml"
     ]
    }
   },
   "keyStandard": 248,
   "keyCustom": 79,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 23,
   "hidden": {
    "total": 17,
    "http://fasb.org/us-gaap/2025": 14,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 200,
   "entityCount": 1,
   "segmentCount": 59,
   "elementCount": 506,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 862,
    "http://xbrl.sec.gov/dei/2025": 7
   },
   "report": {
    "R1": {
     "role": "http://passagebio.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://passagebio.com/role/BalanceSheetsFy",
     "longName": "010000 - Statement - Balance Sheets (FY)",
     "shortName": "Balance Sheets (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://passagebio.com/role/BalanceSheetsFyParenthetical",
     "longName": "010100 - Statement - Balance Sheets (FY) (Parenthetical)",
     "shortName": "Balance Sheets (FY) (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
     "longName": "020000 - Statement - Statements of Operations and Comprehensive Loss (FY)",
     "shortName": "Statements of Operations and Comprehensive Loss (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
     "longName": "030000 - Statement - Statements of Stockholders' Equity (FY)",
     "shortName": "Statements of Stockholders' Equity (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://passagebio.com/role/StatementsOfCashFlowsFy",
     "longName": "040000 - Statement - Statements of Cash Flows (FY)",
     "shortName": "Statements of Cash Flows (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://passagebio.com/role/BalanceSheetsQ1",
     "longName": "050000 - Statement - Balance Sheets (Q1)",
     "shortName": "Balance Sheets (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://passagebio.com/role/BalanceSheetsQ1Parenthetical",
     "longName": "050100 - Statement - Balance Sheets (Q1) (Parenthetical)",
     "shortName": "Balance Sheets (Q1) (Parenthetical)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1",
     "longName": "060000 - Statement - Statements of Operations and Comprehensive Loss (Q1)",
     "shortName": "Statements of Operations and Comprehensive Loss (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R10": {
     "role": "http://passagebio.com/role/StatementsOfStockholdersEquityQ1",
     "longName": "070000 - Statement - Statements of Stockholders' Equity (Q1)",
     "shortName": "Statements of Stockholders' Equity (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R11": {
     "role": "http://passagebio.com/role/StatementsOfCashFlowsQ1",
     "longName": "080000 - Statement - Statements of Cash Flows (Q1)",
     "shortName": "Statements of Cash Flows (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20250331",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R12": {
     "role": "http://passagebio.com/role/NatureOfOperationsFy",
     "longName": "090100 - Disclosure - Nature of Operations (FY)",
     "shortName": "Nature of Operations (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R13": {
     "role": "http://passagebio.com/role/RisksAndLiquidityFy",
     "longName": "090200 - Disclosure - Risks and Liquidity (FY)",
     "shortName": "Risks and Liquidity (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:RisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy",
     "longName": "090300 - Disclosure - Summary of Significant Accounting Policies (FY)",
     "shortName": "Summary of Significant Accounting Policies (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy",
     "longName": "090400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities (FY)",
     "shortName": "Cash, Cash Equivalents, and Marketable Securities (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy",
     "longName": "090500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (FY)",
     "shortName": "Fair Value of Financial Instruments and Non-Financial Instruments (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetFy",
     "longName": "090600 - Disclosure - Property and Equipment, Net (FY)",
     "shortName": "Property and Equipment, Net (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy",
     "longName": "090700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY)",
     "shortName": "Accrued Expenses and Other Current Liabilities (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://passagebio.com/role/GemmaLicenseAgreementFy",
     "longName": "090800 - Disclosure - Gemma License Agreement (FY)",
     "shortName": "Gemma License Agreement (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://passagebio.com/role/SeveranceFy",
     "longName": "090900 - Disclosure - Severance (FY)",
     "shortName": "Severance (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R21": {
     "role": "http://passagebio.com/role/LeasesFy",
     "longName": "091000 - Disclosure - Leases (FY)",
     "shortName": "Leases (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://passagebio.com/role/CommitmentsAndContingenciesFy",
     "longName": "091100 - Disclosure - Commitments and Contingencies (FY)",
     "shortName": "Commitments and Contingencies (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://passagebio.com/role/CommonStockFy",
     "longName": "091200 - Disclosure - Common Stock (FY)",
     "shortName": "Common Stock (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://passagebio.com/role/SharebasedCompensationFy",
     "longName": "091300 - Disclosure - Share-Based Compensation (FY)",
     "shortName": "Share-Based Compensation (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://passagebio.com/role/IncomeTaxesFy",
     "longName": "091400 - Disclosure - Income Taxes (FY)",
     "shortName": "Income Taxes (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://passagebio.com/role/SegmentReportingFy",
     "longName": "091500 - Disclosure - Segment Reporting (FY)",
     "shortName": "Segment Reporting (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://passagebio.com/role/SubsequentEventsFy",
     "longName": "091600 - Disclosure - Subsequent Events (FY)",
     "shortName": "Subsequent Events (FY)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://passagebio.com/role/NatureOfOperationsQ1",
     "longName": "091700 - Disclosure - Nature of Operations (Q1)",
     "shortName": "Nature of Operations (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1",
     "longName": "091800 - Disclosure - Risks, Liquidity, and Going Concern (Q1)",
     "shortName": "Risks, Liquidity, and Going Concern (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:RisksAndLiquidityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1",
     "longName": "091900 - Disclosure - Summary of Significant Accounting Policies (Q1)",
     "shortName": "Summary of Significant Accounting Policies (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1",
     "longName": "092000 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Q1)",
     "shortName": "Fair Value of Financial Instruments and Non-Financial Instruments (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetQ1",
     "longName": "092100 - Disclosure - Property and Equipment, Net (Q1)",
     "shortName": "Property and Equipment, Net (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1",
     "longName": "092200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://passagebio.com/role/GemmaLicenseAgreementQ1",
     "longName": "092300 - Disclosure - Gemma License Agreement (Q1)",
     "shortName": "Gemma License Agreement (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://passagebio.com/role/SeveranceQ1",
     "longName": "092400 - Disclosure - Severance (Q1)",
     "shortName": "Severance (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://passagebio.com/role/LeasesQ1",
     "longName": "092500 - Disclosure - Leases (Q1)",
     "shortName": "Leases (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://passagebio.com/role/CommitmentsAndContingenciesQ1",
     "longName": "092600 - Disclosure - Commitments and Contingencies (Q1)",
     "shortName": "Commitments and Contingencies (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1",
     "longName": "092700 - Disclosure - Stockholder's Equity and Share-Based Compensation (Q1)",
     "shortName": "Stockholder's Equity and Share-Based Compensation (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://passagebio.com/role/SegmentReportingQ1",
     "longName": "092800 - Disclosure - Segment Reporting (Q1)",
     "shortName": "Segment Reporting (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://passagebio.com/role/SubsequentEventsQ1",
     "longName": "092900 - Disclosure - Subsequent Events (Q1)",
     "shortName": "Subsequent Events (Q1)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
     "longName": "100300 - Disclosure - Summary of Significant Accounting Policies (FY) (Policies)",
     "shortName": "Summary of Significant Accounting Policies (FY) (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:BasisOfPresentationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:IncomeTaxPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies",
     "longName": "101900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Q1) (Policies)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:BasisOfPresentationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:InterimFinancialStatementsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables",
     "longName": "110300 - Disclosure - Summary of Significant Accounting Policies (FY) (Tables)",
     "shortName": "Summary of Significant Accounting Policies (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables",
     "longName": "110400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities (FY) (Tables)",
     "shortName": "Cash, Cash Equivalents, and Marketable Securities (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables",
     "longName": "110500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (FY) (Tables)",
     "shortName": "Fair Value of Financial Instruments and Non-Financial Instruments (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetFyTables",
     "longName": "110600 - Disclosure - Property and Equipment, Net (FY) (Tables)",
     "shortName": "Property and Equipment, Net (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables",
     "longName": "110700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY) (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://passagebio.com/role/LeasesFyTables",
     "longName": "111000 - Disclosure - Leases (FY) (Tables)",
     "shortName": "Leases (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://passagebio.com/role/SharebasedCompensationFyTables",
     "longName": "111300 - Disclosure - Share-Based Compensation (FY) (Tables)",
     "shortName": "Share-Based Compensation (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://passagebio.com/role/IncomeTaxesFyTables",
     "longName": "111400 - Disclosure - Income Taxes (FY) (Tables)",
     "shortName": "Income Taxes (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://passagebio.com/role/SegmentReportingFyTables",
     "longName": "111500 - Disclosure - Segment Reporting (FY) (Tables)",
     "shortName": "Segment Reporting (FY) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables",
     "longName": "111900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Q1) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables",
     "longName": "112100 - Disclosure - Property and Equipment, Net (Q1) (Tables)",
     "shortName": "Property and Equipment, Net (Q1) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables",
     "longName": "112200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1) (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Q1) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://passagebio.com/role/LeasesQ1Tables",
     "longName": "112500 - Disclosure - Leases (Q1) (Tables)",
     "shortName": "Leases (Q1) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables",
     "longName": "112700 - Disclosure - Stockholder's Equity and Share-Based Compensation (Q1) (Tables)",
     "shortName": "Stockholder's Equity and Share-Based Compensation (Q1) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://passagebio.com/role/SegmentReportingQ1Tables",
     "longName": "112800 - Disclosure - Segment Reporting (Q1) (Tables)",
     "shortName": "Segment Reporting (Q1) (Tables)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R58": {
     "role": "http://passagebio.com/role/RisksAndLiquidityFyDetails",
     "longName": "120200 - Disclosure - Risks and Liquidity (FY) (Details)",
     "shortName": "Risks and Liquidity (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
     "longName": "120300 - Disclosure - Summary of Significant Accounting Policies (FY) (Details)",
     "shortName": "Summary of Significant Accounting Policies (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "pasg:GainLossOnSaleOfTaxCredits",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
     "longName": "120400 - Disclosure - Cash, Cash Equivalents, and Marketable Securities - Portfolio of Cash and Cash Equivalents (FY) (Details)",
     "shortName": "Cash, Cash Equivalents, and Marketable Securities - Portfolio of Cash and Cash Equivalents (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
     "longName": "120402 - Disclosure - Cash, Cash Equivalents, and Marketable Securities - Portfolio of Marketable Securities (FY) (Details)",
     "shortName": "Cash, Cash Equivalents, and Marketable Securities - Portfolio of Marketable Securities (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails",
     "longName": "120500 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Recurring basis) (FY) (Details)",
     "shortName": "Fair Value of Financial Instruments and Non-Financial Instruments (Recurring basis) (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
     "longName": "120502 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Nonrecurring Basis) (FY) (Details)",
     "shortName": "Fair Value of Financial Instruments and Non-Financial Instruments (Nonrecurring Basis) (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember",
      "name": "us-gaap:PropertyPlantAndEquipmentFairValueDisclosure",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
     "longName": "120600 - Disclosure - Property and Equipment, Net (FY) (Details)",
     "shortName": "Property and Equipment, Net (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
     "longName": "120602 - Disclosure - Property and Equipment, Net - Narrative (FY) (Details)",
     "shortName": "Property and Equipment, Net - Narrative (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231_DisposalGroupClassificationAxis_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentMember",
      "name": "us-gaap:Depreciation",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails",
     "longName": "120700 - Disclosure - Accrued Expenses and Other Current Liabilities (FY) (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
     "longName": "120800 - Disclosure - Gemma License Agreement (FY) (Details)",
     "shortName": "Gemma License Agreement (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c20240731",
      "name": "pasg:UpfrontLicenseFeeReceivable",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember",
      "name": "pasg:ShortTermLicenseFeeDueAndReceivable",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://passagebio.com/role/SeveranceFyDetails",
     "longName": "120900 - Disclosure - Severance (FY) (Details)",
     "shortName": "Severance (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://passagebio.com/role/LeasesFyDetails",
     "longName": "121000 - Disclosure - Leases (FY) (Details)",
     "shortName": "Leases (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SubleaseIncome",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails",
     "longName": "121002 - Disclosure - Leases - Operating lease cost (FY) (Details)",
     "shortName": "Leases - Operating lease cost (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://passagebio.com/role/LeasesSubleaseIncomeFyDetails",
     "longName": "121004 - Disclosure - Leases - Sublease income (FY) (Details)",
     "shortName": "Leases - Sublease income (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SubleaseIncome",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
     "longName": "121100 - Disclosure - Commitments and Contingencies - Collaboration Agreements (FY) (Details)",
     "shortName": "Commitments and Contingencies - Collaboration Agreements (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "pasg:NonRefundableAggregateFeesPayablePerProductIndication",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://passagebio.com/role/CommonStockFyDetails",
     "longName": "121200 - Disclosure - Common Stock (FY) (Details)",
     "shortName": "Common Stock (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R74": {
     "role": "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
     "longName": "121300 - Disclosure - Share-Based Compensation - Equity Incentive Plan & ESPP (FY) (Details)",
     "shortName": "Share-Based Compensation - Equity Incentive Plan & ESPP (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:NumberOfEquityIncentivePlans",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251231_PlanNameAxis_EquityIncentivePlan2020Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
     "longName": "121302 - Disclosure - Share-Based Compensation - Share-based compensation expense (FY) (Details)",
     "shortName": "Share-Based Compensation - Share-based compensation expense (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R76": {
     "role": "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
     "longName": "121304 - Disclosure - Share-Based Compensation - Stock Option Activity (FY) (Details)",
     "shortName": "Share-Based Compensation - Stock Option Activity (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails",
     "longName": "121306 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (FY) (Details)",
     "shortName": "Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
     "longName": "121308 - Disclosure - Share-Based Compensation - Restricted Stock Units (FY) (Details)",
     "shortName": "Share-Based Compensation - Restricted Stock Units (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails",
     "longName": "121400 - Disclosure - Income Taxes - Deferred tax assets and liabilities (FY) (Details)",
     "shortName": "Income Taxes - Deferred tax assets and liabilities (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails",
     "longName": "121402 - Disclosure - Income Taxes - Reconciliation of the federal income tax rate to the effective tax rate (FY) (Details)",
     "shortName": "Income Taxes - Reconciliation of the federal income tax rate to the effective tax rate (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://passagebio.com/role/IncomeTaxesFyDetails",
     "longName": "121404 - Disclosure - Income Taxes (FY) (Details)",
     "shortName": "Income Taxes (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:IncomeTaxesPaidNet",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:IncomeTaxesPaidNet",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails",
     "longName": "121406 - Disclosure - Income Taxes - Net operating losses (FY) (Details)",
     "shortName": "Income Taxes - Net operating losses (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://passagebio.com/role/SegmentReportingFyDetails",
     "longName": "121500 - Disclosure - Segment Reporting (FY) (Details)",
     "shortName": "Segment Reporting (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R84": {
     "role": "http://passagebio.com/role/SubsequentEventsFyDetails",
     "longName": "121600 - Disclosure - Subsequent Events (FY) (Details)",
     "shortName": "Subsequent Events (FY) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SubleaseIncome",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R85": {
     "role": "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details",
     "longName": "121800 - Disclosure - Risks, Liquidity, and Going Concern (Q1) (Details)",
     "shortName": "Risks, Liquidity, and Going Concern (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember",
      "name": "pasg:RemainingCapacityOfValueOfSharesAvailableToBeSold",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details",
     "longName": "121900 - Disclosure - Summary of Significant Accounting Policies (Q1) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c20250714to20250714",
      "name": "us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R87": {
     "role": "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
     "longName": "122000 - Disclosure - Fair Value of Financial Instruments and Non-Financial Instruments (Q1) (Details)",
     "shortName": "Fair Value of Financial Instruments and Non-Financial Instruments (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260101to20260331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details",
     "longName": "122100 - Disclosure - Property and Equipment, Net (Q1) (Details)",
     "shortName": "Property and Equipment, Net (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details",
     "longName": "122102 - Disclosure - Property and Equipment, Net - Narrative (Q1) (Details)",
     "shortName": "Property and Equipment, Net - Narrative (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c20260304to20260304",
      "name": "pasg:EarlyLeaseTerminationFee",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R90": {
     "role": "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details",
     "longName": "122200 - Disclosure - Accrued Expenses and Other Current Liabilities (Q1) (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R91": {
     "role": "http://passagebio.com/role/GemmaLicenseAgreementQ1Details",
     "longName": "122300 - Disclosure - Gemma License Agreement (Q1) (Details)",
     "shortName": "Gemma License Agreement (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c20240731",
      "name": "pasg:UpfrontLicenseFeeReceivable",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember",
      "name": "pasg:LicenseFeeDueAndReceivable",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R92": {
     "role": "http://passagebio.com/role/SeveranceQ1Details",
     "longName": "122400 - Disclosure - Severance (Q1) (Details)",
     "shortName": "Severance (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R93": {
     "role": "http://passagebio.com/role/LeasesQ1Details",
     "longName": "122500 - Disclosure - Leases (Q1) (Details)",
     "shortName": "Leases (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SubleaseIncome",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260331",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details",
     "longName": "122502 - Disclosure - Leases - Operating lease cost (Q1) (Details)",
     "shortName": "Leases - Operating lease cost (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://passagebio.com/role/LeasesSubleaseIncomeQ1Details",
     "longName": "122504 - Disclosure - Leases - Sublease income (Q1) (Details)",
     "shortName": "Leases - Sublease income (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:SubleaseIncome",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R96": {
     "role": "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details",
     "longName": "122600 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Q1) (Details)",
     "shortName": "Commitments and Contingencies - Collaboration Agreements (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c20260331",
      "name": "pasg:NonRefundableAggregateFeesPayablePerProductIndication",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R97": {
     "role": "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details",
     "longName": "122700 - Disclosure - Stockholder's Equity and Share-Based Compensation - Equity Incentive Plan & ESPP (Q1) (Details)",
     "shortName": "Stockholder's Equity and Share-Based Compensation - Equity Incentive Plan & ESPP (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "pasg:NumberOfEquityIncentivePlans",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R98": {
     "role": "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details",
     "longName": "122702 - Disclosure - Stockholder's Equity and Share-Based Compensation - Share-based compensation expense (Q1) (Details)",
     "shortName": "Stockholder's Equity and Share-Based Compensation - Share-based compensation expense (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R99": {
     "role": "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details",
     "longName": "122704 - Disclosure - Stockholder's Equity and Share-Based Compensation - Stock Option Activity (Q1) (Details)",
     "shortName": "Stockholder's Equity and Share-Based Compensation - Stock Option Activity (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c20251231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R100": {
     "role": "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details",
     "longName": "122706 - Disclosure - Stockholder's Equity and Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (Q1) (Details)",
     "shortName": "Stockholder's Equity and Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c20250101to20251231",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details",
     "longName": "122708 - Disclosure - Stockholder's Equity and Share-Based Compensation - Restricted Stock Units (Q1) (Details)",
     "shortName": "Stockholder's Equity and Share-Based Compensation - Restricted Stock Units (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://passagebio.com/role/SegmentReportingQ1Details",
     "longName": "122800 - Disclosure - Segment Reporting (Q1) (Details)",
     "shortName": "Segment Reporting (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c20260101to20260331",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember",
      "name": "us-gaap:GainLossOnTerminationOfLease",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://passagebio.com/role/SubsequentEventsQ1Details",
     "longName": "122900 - Disclosure - Subsequent Events (Q1) (Details)",
     "shortName": "Subsequent Events (Q1) (Details)",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c20260428to20260428_SubsequentEventTypeAxis_SubsequentEventMember",
      "name": "pasg:RestructuringPlanReductionInWorkforcePercentage",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20260428to20260428_SubsequentEventTypeAxis_SubsequentEventMember",
      "name": "pasg:RestructuringPlanReductionInWorkforcePercentage",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_s4.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r764"
     ]
    },
    "pasg_AccruedDivestitureFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AccruedDivestitureFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails": {
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails",
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for divestiture fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Divestiture Fees, Current",
        "terseLabel": "Divestiture fee due to Catalent"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_AccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails",
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details",
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying balance as of the balance sheet of accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities.",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFy",
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails": {
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails",
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "pasg_AccruedResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AccruedResearchAndDevelopmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails": {
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails",
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying balance as of the balance sheet of accrued research and development expense.",
        "label": "Accrued Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r111",
      "r592"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r57",
      "r117",
      "r588",
      "r620",
      "r621",
      "r888"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10",
      "r19",
      "r462",
      "r465",
      "r535",
      "r616",
      "r617",
      "r808",
      "r809",
      "r810",
      "r820",
      "r821",
      "r822",
      "r823"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paidin capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r764",
      "r956"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paidin capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r632",
      "r820",
      "r821",
      "r822",
      "r823",
      "r889",
      "r958"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sharebased compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r393",
      "r402"
     ]
    },
    "pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn.",
        "label": "Amended and restated agreement with Penn [Member]",
        "terseLabel": "Amended and restated agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://passagebio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of premium and discount on marketable securities, net",
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r61",
      "r301",
      "r906"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of antidilutive securities excluded from computation of earnings per share",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfLand",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area leased",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "pasg_AreaOfLandSubleasedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AreaOfLandSubleasedPercentage",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents are of land sub leased of the total area under lease.",
        "label": "Area of Land subleased, Percentage",
        "terseLabel": "Subleased area of land"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_AreaSubleased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AreaSubleased",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area subleased.",
        "label": "Area Subleased"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ArrangementWithGemmaBiotherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ArrangementWithGemmaBiotherapeuticsIncMember",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details",
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the arrangement with Gemma Biotherapeutics Inc.",
        "label": "Arrangement With Gemma Biotherapeutics Inc [Member]",
        "terseLabel": "Gemma License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details",
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      },
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details",
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of long-lived assets",
        "totalLabel": "Total impairment losses",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r766",
      "r767"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r89",
      "r113",
      "r141",
      "r142",
      "r143",
      "r173",
      "r185",
      "r203",
      "r207",
      "r246",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r452",
      "r454",
      "r503",
      "r577",
      "r578",
      "r584",
      "r657",
      "r722",
      "r723",
      "r732",
      "r764",
      "r770",
      "r771",
      "r783",
      "r842",
      "r843",
      "r912"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r118",
      "r141",
      "r142",
      "r143",
      "r246",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r452",
      "r454",
      "r503",
      "r764",
      "r842",
      "r843",
      "r912"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r750"
     ]
    },
    "pasg_AttheMarketFacilityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "AttheMarketFacilityAgreementMember",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to at-the-market (ATM) facility.",
        "label": "ATM Facility [Member]",
        "terseLabel": "ATM Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r254",
      "r583"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value",
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r254",
      "r477",
      "r496",
      "r497",
      "r498",
      "r499",
      "r574",
      "r703",
      "r750",
      "r755",
      "r762",
      "r831",
      "r893",
      "r894",
      "r895"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r254"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "pasg_BasisOfPresentationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "BasisOfPresentationPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of presentation.",
        "label": "Basis Of Presentation [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r109",
      "r704"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value",
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r891",
      "r892"
     ]
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsLineItems",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash and Cash Equivalents [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash, Cash Equivalents, and Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, Cash Equivalents, and Marketable Securities",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning",
        "periodEndLabel": "Cash and cash equivalents at end",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r64",
      "r138"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r64"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost or Amortized cost",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r923"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of deposit",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r777",
      "r778",
      "r779",
      "r780"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r175",
      "r308",
      "r314",
      "r315",
      "r316",
      "r318",
      "r321",
      "r326",
      "r328",
      "r460",
      "r626",
      "r627",
      "r628",
      "r629",
      "r733",
      "r797",
      "r813",
      "r815"
     ]
    },
    "pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable per product candidate for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone",
        "terseLabel": "Amount payable per product candidate for rare, monogenic disorders"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable per product candidate upon achievement of specific development milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement Amount Payable Per Product Candidate Upon Achievement Of Specific Development Milestone",
        "terseLabel": "Amount payable per product candidate upon achievement of specific development milestone"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_CollaborationAgreementSalesMilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "CollaborationAgreementSalesMilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable on sales milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement Sales Milestone Payments Payable",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_CollaborativeArrangementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Gemma License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFy",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gemma License Agreement",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r449",
      "r450"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details",
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r290",
      "r777",
      "r778",
      "r779",
      "r780"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (note 11)",
        "terseLabel": "Commitments and contingencies (note 10)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r83",
      "r586",
      "r644"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesFy",
      "http://passagebio.com/role/CommitmentsAndContingenciesQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r283",
      "r284",
      "r698",
      "r839",
      "r841"
     ]
    },
    "pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of common shares reserved for future issuance.",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Additional number of common shares reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r774",
      "r775",
      "r777",
      "r778",
      "r779",
      "r780",
      "r820",
      "r821",
      "r823",
      "r889",
      "r955",
      "r958"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r645"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r51",
      "r645",
      "r663",
      "r958",
      "r959"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r122",
      "r124",
      "r129",
      "r575",
      "r597",
      "r598"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer hardware",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ComputerHardwareAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ComputerHardwareAndSoftwareMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Computer Hardware and Software.",
        "label": "Computer hardware and software. [Member]",
        "terseLabel": "Computer hardware and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501"
     ]
    },
    "pasg_ContingentProceedsFromUponCompletionOfCertainBusinessMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ContingentProceedsFromUponCompletionOfCertainBusinessMilestones",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent proceeds upon completing certain business milestones.",
        "label": "Contingent Proceeds From Upon Completion of certain business milestones",
        "terseLabel": "Contingent proceeds upon completing certain business milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1",
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable sublicense and transition services payments",
        "verboseLabel": "Non-refundable sublicense payments received",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r341"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r736",
      "r738",
      "r750",
      "r765",
      "r772",
      "r952"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410",
      "r585"
     ]
    },
    "pasg_DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred proceeds from sale of equipment in other current assets in non-cash investing or financing transactions.",
        "label": "Deferred Proceeds Receivable From Sale Of Equipment In Other Current Assets",
        "terseLabel": "Deferred proceeds from equipment sale in other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "DeferredTaxAssetsCollaborationAndLicenseAgreement",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.",
        "label": "Deferred Tax Assets, Collaboration and License Agreement",
        "terseLabel": "Collaboration and license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_DeferredTaxAssetsDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from depreciation and amortization.",
        "label": "Deferred Tax Assets, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets before valuation allowance",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development credits",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "pasg_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities and Other",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use assets.",
        "label": "Deferred Tax Liabilities, Operating Lease Right of Use Assets",
        "negatedLabel": "Right of use assets - operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DemandDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DemandDepositsMember",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash accounts in banking institutions",
        "label": "Demand Deposits [Member]",
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation on equipment",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30",
      "r134",
      "r705",
      "r706",
      "r708",
      "r710"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details",
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r135",
      "r173",
      "r190",
      "r207",
      "r705",
      "r722",
      "r723"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationFy",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholder's Equity and Share-Based Compensation",
        "verboseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r357",
      "r388",
      "r389",
      "r391",
      "r740"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal group classified as held for sale or to be disposed of by sale",
        "label": "Disposal Group, Held-for-Sale or Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r6",
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://passagebio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "pasg_EarlyLeaseTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EarlyLeaseTerminationFee",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense incurred during the period for early lease termination.",
        "label": "Early Lease Termination Fee",
        "terseLabel": "Payment for early lease termination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share information:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r130",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r163",
      "r165",
      "r167",
      "r168",
      "r169",
      "r172",
      "r304",
      "r392",
      "r443",
      "r448",
      "r474",
      "r475",
      "r576",
      "r599",
      "r712"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r130",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r165",
      "r167",
      "r168",
      "r169",
      "r172",
      "r304",
      "r392",
      "r443",
      "r448",
      "r474",
      "r475",
      "r576",
      "r599",
      "r712"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r171"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r742"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r145",
      "r413",
      "r434",
      "r742"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r742",
      "r813",
      "r818",
      "r875"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r813",
      "r818",
      "r875",
      "r877"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration of share-based payment awards",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r813",
      "r818",
      "r875",
      "r877"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment awards",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment awards",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876"
     ]
    },
    "pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Amount",
        "negatedLabel": "Orphan drug tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Orphan Drug, Percent",
        "negatedLabel": "Orphan drug tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsAbstract",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r813",
      "r818",
      "r875",
      "r877"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails": {
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyDetails",
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and related benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to unvested stock option awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Workforce reduction",
        "terseLabel": "Employee Severance",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding",
        "terseLabel": "Percentage of common stock outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.",
        "label": "Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased",
        "terseLabel": "Maximum amount of common stock that can be purchased"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan, Maximum Employee Contribution Percentage",
        "terseLabel": "Percentage of maximum employee contribution"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan, Period Till Which Automatic Increase In Rights Granted",
        "terseLabel": "Period till which there is automatic increase in rights granted under ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EmployeeStockPurchasePlanStockPurchasePricePercentage",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.",
        "label": "Employee Stock Purchase Plan, Stock Purchase Price Percentage",
        "terseLabel": "Percentage of stock purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of shares that can be purchased in any single offering period.",
        "label": "Employee Stock Purchase Plan, Threshold Number Of Shares That Can Be Purchased",
        "terseLabel": "Number of shares that can be purchased"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://passagebio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://passagebio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://passagebio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://passagebio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://passagebio.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r101",
      "r102",
      "r103",
      "r126",
      "r127",
      "r128",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r174",
      "r247",
      "r248",
      "r268",
      "r303",
      "r329",
      "r392",
      "r432",
      "r433",
      "r440",
      "r441",
      "r442",
      "r444",
      "r447",
      "r448",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r516",
      "r535",
      "r595",
      "r616",
      "r617",
      "r618",
      "r632",
      "r682"
     ]
    },
    "pasg_EquityIncentivePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EquityIncentivePlan2020Member",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2020 [Member]",
        "terseLabel": "Equity Incentive Plan 2020"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Equity Incentive Plan.",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EquityInducementPlan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EquityInducementPlan2021Member",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2021 Equity Inducement plan.",
        "label": "Equity Inducement Plan 2021 [Member]",
        "terseLabel": "Equity inducement plan 2021"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_EstimatedSeveranceAndRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "EstimatedSeveranceAndRelatedCosts",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate estimated and severance costs to be incurred as a part of restructuring plan.",
        "label": "Estimated Severance And Related Costs",
        "terseLabel": "Estimated severance and related costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value of Financial Instruments and Non-Financial Instruments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r488",
      "r750"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r488",
      "r750"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of assets measured at fair value on a recurring basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r891",
      "r892",
      "r897"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of non-financial instruments measured at fair value, on a nonrecurring basis",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r892"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r487",
      "r488",
      "r490",
      "r497",
      "r542",
      "r543",
      "r544",
      "r703",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r750",
      "r755",
      "r762"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r750",
      "r894",
      "r898"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments and Non-Financial Instruments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsFy",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments and Non-Financial Instruments",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r483",
      "r485",
      "r486",
      "r487",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r573",
      "r750",
      "r756"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r343",
      "r348",
      "r349",
      "r478",
      "r488",
      "r497",
      "r542",
      "r703",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r750",
      "r762"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r343",
      "r348",
      "r349",
      "r351",
      "r478",
      "r479",
      "r488",
      "r497",
      "r543",
      "r703",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r750",
      "r762"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r478",
      "r479",
      "r480",
      "r481",
      "r488",
      "r497",
      "r544",
      "r703",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r750",
      "r755",
      "r762"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r750",
      "r894",
      "r898"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r476",
      "r478",
      "r479",
      "r480",
      "r481",
      "r487",
      "r488",
      "r490",
      "r497",
      "r542",
      "r543",
      "r544",
      "r703",
      "r730",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r750",
      "r755",
      "r762"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrecurring basis",
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r478",
      "r479",
      "r481",
      "r750",
      "r894"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r898"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r302",
      "r326",
      "r460",
      "r471",
      "r495",
      "r502",
      "r505",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r582",
      "r596",
      "r728",
      "r750",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r765",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r833",
      "r834",
      "r835",
      "r836",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r898",
      "r900",
      "r901"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "pasg_GainLossOnSaleOfTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "GainLossOnSaleOfTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain (loss) on sale of tax credits.",
        "label": "Gain (Loss) on Sale of Tax Credits",
        "terseLabel": "Gain (loss) on sale of tax credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnTerminationOfLease",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details",
      "http://passagebio.com/role/SegmentReportingQ1Details",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net gain on lease termination",
        "terseLabel": "Net gain on lease termination",
        "label": "Gain (Loss) on Termination of Lease",
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "pasg_GainLossOnWriteOffOfOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "GainLossOnWriteOffOfOperatingLeases",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on write-off of assets and liabilities for operating leases.",
        "label": "Gain (Loss) On Write Off Of Operating Leases",
        "terseLabel": "Gain (loss) on write-off of operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_GeneralAndAdministrativeDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "GeneralAndAdministrativeDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses in the period for usage of depreciation and amortization attributable to managing and administering the affairs of an entity",
        "label": "General and Administrative, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "totalLabel": "Total general and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r666"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details",
      "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "verboseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "pasg_GeneralAndAdministrativeLaborAndRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "GeneralAndAdministrativeLaborAndRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit, excluding wages and other benefits incurred for employees in research and development phase of the medicines.",
        "label": "General And Administrative, Labor And Related Expenses",
        "verboseLabel": "Wages, benefits, and other payroll"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_GeneralAndAdministrativeShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "GeneralAndAdministrativeShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses in the period for usage of share based compensation attributable to managing and administering the affairs of an entity.",
        "label": "General and Administrative, Share Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_GeneralAndAdministrativeThirdPartyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "GeneralAndAdministrativeThirdPartyCosts",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses in the period for usage of third party costs attributable to managing and administering the affairs of an entity.",
        "label": "General and Administrative, Third Party Costs",
        "terseLabel": "Third-party costs"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_GeneticMedicinesSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "GeneticMedicinesSegmentMember",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to developing and advancing of genetic medicines.",
        "label": "Genetic Medicines Segment [Member]",
        "terseLabel": "Genetic Medicines Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLeasehold",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of leasehold improvements",
        "label": "Impairment of Leasehold",
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/LeasesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "terseLabel": "Impairment expenses for property and equipment",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r29",
      "r71",
      "r131",
      "r706",
      "r751"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsQ1Details",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of property and equipment",
        "verboseLabel": "Impairment of long-lived assets",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r69",
      "r752"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign pre-tax income or losses",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r144",
      "r412"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details",
      "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r271",
      "r276",
      "r456",
      "r457",
      "r458",
      "r459",
      "r482",
      "r484",
      "r489",
      "r504",
      "r505",
      "r506",
      "r613",
      "r615",
      "r667",
      "r701",
      "r703",
      "r743",
      "r744",
      "r748",
      "r749",
      "r754",
      "r762",
      "r883",
      "r884",
      "r925"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details",
      "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r276",
      "r456",
      "r457",
      "r458",
      "r459",
      "r482",
      "r484",
      "r489",
      "r504",
      "r505",
      "r506",
      "r613",
      "r615",
      "r667",
      "r701",
      "r703",
      "r743",
      "r744",
      "r748",
      "r749",
      "r754",
      "r762",
      "r883",
      "r884",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r413",
      "r414",
      "r420",
      "r429",
      "r742",
      "r881"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r413",
      "r414",
      "r420",
      "r429",
      "r742",
      "r881"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r145",
      "r406",
      "r413",
      "r417",
      "r418",
      "r419",
      "r421",
      "r427",
      "r435",
      "r437",
      "r438",
      "r439",
      "r581",
      "r623",
      "r631",
      "r742"
     ]
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationDescription",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Description",
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings."
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax examination, penalties and interest expense",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "us-gaap_IncomeTaxExaminationYearUnderExamination": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationYearUnderExamination",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Year under Examination",
        "documentation": "Tax year being audited in the income tax examination, in YYYY format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r98",
      "r141",
      "r161",
      "r162",
      "r173",
      "r193",
      "r207",
      "r411",
      "r413",
      "r436",
      "r600",
      "r707",
      "r709",
      "r711",
      "r742"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r407",
      "r408",
      "r421",
      "r422",
      "r426",
      "r431",
      "r625"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r742",
      "r875"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r742"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r875",
      "r877"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration of share-based payment awards",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r875",
      "r877"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsAbstract",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesReconciliationOfFederalIncomeTaxRateToEffectiveTaxRateFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and development tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r875",
      "r877"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payments",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r137",
      "r428",
      "r429"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable sublicense and transition services payments received",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r811"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets, and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in prepaid research and development.",
        "label": "Increase (Decrease) In Prepaid Research and Development",
        "negatedLabel": "Prepaid research and development"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities.",
        "label": "Increase (Decrease) in Right of Use Assets and Operating Lease Liabilities",
        "negatedLabel": "Right of use assets and operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "pasg_InterimFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "InterimFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interim financial statements.",
        "label": "Interim Financial Statements [Policy Text Block]",
        "terseLabel": "Interim Financial Statements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of premium and discount",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "pasg_LaboratoryEquipmentAndCertainOtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LaboratoryEquipmentAndCertainOtherAssetsMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to laboratory equipment and certain other assets.",
        "label": "Laboratory Equipment And Certain Other Assets [Member]",
        "terseLabel": "Laboratory equipment and certain other assets"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Laboratory equipment.",
        "label": "Laboratory equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails",
      "http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Lease expense",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r763"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/LeasesFyTables",
      "http://passagebio.com/role/LeasesQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of operating leases",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "pasg_LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Liability for Operating Lease, Period Decrease due to Lease Termination.",
        "label": "Lease Liability For Operating Lease, Period Decrease due to Lease Termination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r534"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r534"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasing",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r521"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to extend lease",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Option to terminate lease",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease."
       }
      }
     },
     "auth_ref": [
      "r523"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/LeasesFyTables",
      "http://passagebio.com/role/LeasesQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of future minimum rental payments for operating leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://passagebio.com/role/LeasesFyDetailsCalc01": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://passagebio.com/role/LeasesQ1DetailsCalc01": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r814",
      "r819",
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r814",
      "r819",
      "r921"
     ]
    },
    "pasg_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesQ1DetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://passagebio.com/role/LeasesQ1DetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r814",
      "r819",
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2030",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r814",
      "r819",
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      },
      "http://passagebio.com/role/LeasesQ1DetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "verboseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r814",
      "r819",
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      },
      "http://passagebio.com/role/LeasesQ1DetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "verboseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r814",
      "r819",
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://passagebio.com/role/LeasesQ1DetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r814",
      "r819",
      "r921"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesQ1DetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "pasg_LesseeOperatingLeaseNoticePeriodForTerminationOfLease": {
     "xbrltype": "durationItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LesseeOperatingLeaseNoticePeriodForTerminationOfLease",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the notice period for termination of lease.",
        "label": "Lessee, Operating Lease, Notice Period for Termination of Lease",
        "terseLabel": "Notice Period for termination lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term of lease",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r908"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of Contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://passagebio.com/role/LeasesFy",
      "http://passagebio.com/role/LeasesQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r515"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r141",
      "r142",
      "r143",
      "r246",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r453",
      "r454",
      "r455",
      "r503",
      "r643",
      "r716",
      "r732",
      "r783",
      "r842",
      "r912",
      "r913"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r84",
      "r590",
      "r764",
      "r770",
      "r771",
      "r813",
      "r817",
      "r837",
      "r905"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r108",
      "r141",
      "r142",
      "r143",
      "r246",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r453",
      "r454",
      "r455",
      "r503",
      "r764",
      "r842",
      "r912",
      "r913"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_LicenseFeeDueAndReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LicenseFeeDueAndReceivable",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license fee due and receivable as of the balance sheet date under the license agreement.",
        "label": "License Fee Due And Receivable",
        "terseLabel": "Amount of license fee due and receivables"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_LocalTaxAuthoritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LocalTaxAuthoritiesMember",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to local tax authorities.",
        "label": "Local [Member]",
        "terseLabel": "Local"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Asset, Held-for-Sale, Type [Axis]",
        "documentation": "Information by long-lived asset held for sale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_LongLivedAssetsHeldForSaleNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongLivedAssetsHeldForSaleNameDomain",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Assets Held-for-Sale, Name [Domain]",
        "documentation": "A name of the assets to be disposed."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "pasg_LongTermLicenseFeeDueAndReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LongTermLicenseFeeDueAndReceivable",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license fee due and receivable in long-term as of the balance sheet date under the license agreement.",
        "label": "Long-Term License Fee Due And Receivable",
        "terseLabel": "Long-term license fee due and receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of loss contingency",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r798"
     ]
    },
    "pasg_LossContingencySharesAgreedByDefendant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "LossContingencySharesAgreedByDefendant",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares agreed to be issued by defendant and subject to reverse stock split.",
        "label": "Loss Contingency, Shares Agreed by Defendant",
        "terseLabel": "Loss contingency, shares agreed by defendant"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_MarketStreetLeaseAgreement2005Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "MarketStreetLeaseAgreement2005Member",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to 2005 Market Street Lease Agreement.",
        "label": "Market Street Lease Agreement 2005 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_MarketStreetSubleaseAgreement1835Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "MarketStreetSubleaseAgreement1835Member",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to 1835 Market Street Sublease Agreement.",
        "label": "1835 Market Street Sublease Agreement [Member]",
        "terseLabel": "1835 market street sublease agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "Marketable Security, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "pasg_MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum additional amount in development and commercial milestone payments receivable.",
        "label": "Maximum Additional Amount in Development And Commercial Milestone Payments Receivable",
        "terseLabel": "Maximum additional amount in development and commercial milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r286",
      "r287",
      "r288",
      "r289",
      "r352",
      "r383",
      "r384",
      "r385",
      "r403",
      "r481",
      "r570",
      "r612",
      "r614",
      "r622",
      "r635",
      "r636",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697",
      "r699",
      "r700",
      "r727",
      "r733",
      "r739",
      "r743",
      "r745",
      "r746",
      "r755",
      "r756",
      "r760",
      "r761",
      "r768",
      "r844",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "pasg_MergerAgreementTerminationPaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "MergerAgreementTerminationPaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payment required to be made by the registrant upon termination of a merger agreement.",
        "label": "Merger Agreement Termination Payment Amount",
        "terseLabel": "Termination payment amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://passagebio.com/role/NatureOfOperationsFy",
      "http://passagebio.com/role/NatureOfOperationsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Operations",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r177",
      "r713",
      "r714"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows provided by (used in) financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows provided by (used in) investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows used in operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details",
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details",
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1",
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "negatedTotalLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r66",
      "r85",
      "r103",
      "r106",
      "r121",
      "r123",
      "r128",
      "r141",
      "r142",
      "r143",
      "r146",
      "r150",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r166",
      "r246",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r304",
      "r307",
      "r309",
      "r312",
      "r392",
      "r443",
      "r448",
      "r475",
      "r503",
      "r594",
      "r664",
      "r680",
      "r681",
      "r707",
      "r709",
      "r711",
      "r781",
      "r842"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted and Recently Adopted Accounting Pronouncements",
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "NewLeaseAgreementOperatingLeaseNumberOfExtensions",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of extensions available under the new lease arrangement.",
        "label": "New Lease Agreement, Operating Lease, Number Of Extensions",
        "terseLabel": "Number of extension terms"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_NewLeaseAgreementOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "NewLeaseAgreementOperatingLeaseRenewalTerm",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the renewal term under new lease agreement.",
        "label": "New Lease Agreement, Operating Lease, Renewal Term",
        "terseLabel": "Extended term of new lease agreement"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_NonRefundableAggregateFeesPayablePerProductIndication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "NonRefundableAggregateFeesPayablePerProductIndication",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate non-refundable fees payable per product indication.",
        "label": "Non - Refundable Aggregate Fees Payable Per Product Indication",
        "terseLabel": "Non - Refundable aggregate fees payable"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront fees payable per product indication upon developmental milestone.",
        "label": "Non - Refundable Fees Payable Per Product Indication Upon Developmental Milestone",
        "terseLabel": "Non - Refundable fees payable"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_NonRefundableUpfrontFeesPayablePerProductIndication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "NonRefundableUpfrontFeesPayablePerProductIndication",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront fees payable per product indication.",
        "label": "Non - Refundable Upfront Fees Payable Per Product Indication",
        "terseLabel": "Non - Refundable upfront fees payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationFyTables",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of activity related to restricted stock unit",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "pasg_NumberOfEquityIncentivePlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "NumberOfEquityIncentivePlans",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equity incentive plans.",
        "label": "Number Of Equity Incentive Plans",
        "terseLabel": "Number of equity incentive plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r726",
      "r825"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "negatedTotalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r707",
      "r711",
      "r717",
      "r824",
      "r826",
      "r827",
      "r828",
      "r829"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails",
      "http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "terseLabel": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r763"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment expenses for right of use assets",
        "verboseLabel": "Right of use assets",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/LeasesFyDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities - noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease liabilities recognized upon adoption of standard.",
        "label": "Operating Lease Liability Recognized Upon Adoption of Standard",
        "terseLabel": "Operating lease liabilities recognized upon the commencement of sublease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePaymentsUse",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails",
      "http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments, Use",
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r528"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right of use assets - operating leases",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails",
      "http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r531",
      "r763"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails",
      "http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r530",
      "r763"
     ]
    },
    "pasg_OperatingLeasesForLaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "OperatingLeasesForLaboratorySpaceMember",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease agreement for laboratory space.",
        "label": "Operating Leases For Laboratory Space [Member]",
        "terseLabel": "Operating leases for laboratory space"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_OperatingLeasesForOfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "OperatingLeasesForOfficeSpaceMember",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease agreement for office space.",
        "label": "Operating Leases For Office Space [Member]",
        "terseLabel": "Operating leases for office space"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_OperatingLossCarryforwardSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "OperatingLossCarryforwardSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward subject to expiry, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforward Subject to Expiration",
        "verboseLabel": "Net operating loss carryforwards subject to expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_OrphanDrugMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "OrphanDrugMember",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Orphan Drug.",
        "label": "Orphan Drug [Member]",
        "terseLabel": "Orphan drug"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetImpairmentCharges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails",
      "http://passagebio.com/role/LeasesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "verboseLabel": "Impairment of certain other assets",
        "label": "Other Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r838"
     ]
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of other assets."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r892",
      "r896",
      "r900",
      "r901",
      "r902",
      "r904"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1",
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r245"
     ]
    },
    "pasg_OtherIncomeAndOtherExpensePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "OtherIncomeAndOtherExpensePolicyPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for other income or other expense items.",
        "label": "Other Income and Other Expense Policy [Policy Text Block]",
        "terseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-cash items",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "negatedLabel": "Other (income) expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r747"
     ]
    },
    "pasg_PayableDecreaseFromAmountsReceivedTransitionServicesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "PayableDecreaseFromAmountsReceivedTransitionServicesPayments",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of decrease in payable due to amounts received under transition service payments.",
        "label": "Payable, Decrease from Amounts Received Transition Services Payments",
        "terseLabel": "Transition service payments"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_PaymentOfLeaseTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "PaymentOfLeaseTerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow related to the payment of lease termination fee.",
        "label": "Payment of Lease Termination Fee",
        "terseLabel": "Payment of lease termination fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance cost",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment and other assets",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r885",
      "r886",
      "r887"
     ]
    },
    "pasg_PercentageOfAnnualIncreaseInSubleaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "PercentageOfAnnualIncreaseInSubleaseRent",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual increase in sublease rent.",
        "label": "Percentage of Annual Increase in Sublease Rent",
        "terseLabel": "Annual increase in sublease rent (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_PercentageOfTargetAnnualBonusAmounts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "PercentageOfTargetAnnualBonusAmounts",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of target annual bonus amounts.",
        "label": "Percentage of Target Annual Bonus Amounts",
        "terseLabel": "Target annual bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r314"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r645"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r314"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFyParenthetical",
      "http://passagebio.com/role/BalanceSheetsQ1Parenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r645",
      "r663",
      "r958",
      "r959"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both December 31, 2025 and December 31, 2024",
        "terseLabel": "Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding at both March 31, 2026 and December 31, 2025",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r306",
      "r311",
      "r587",
      "r764"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "pasg_PrepaidResearchAndDevelopmentAssetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "PrepaidResearchAndDevelopmentAssetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research And Development Asset, Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock under the ATM Facility, net of offering costs",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "pasg_ProceedsFromNonRefundableSublicensePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ProceedsFromNonRefundableSublicensePayments",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from non-refundable sublicense payments received.",
        "label": "Proceeds From Non-Refundable Sublicense Payments",
        "terseLabel": "Payment received"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ProceedsFromNonRefundableTransitionServicesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ProceedsFromNonRefundableTransitionServicesPayments",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from non-refundable transition service payments received by the company.",
        "label": "Proceeds From Non Refundable Transition Services Payments",
        "terseLabel": "Amount of transition services payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales or maturities of marketable securities",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of property and equipment and other assets",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of property and equipment and other assets",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "pasg_ProceedsFromShortTermLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ProceedsFromShortTermLicenseFee",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from short term license.",
        "label": "Proceeds From Short Term License Fee",
        "terseLabel": "Proceeds from short term license fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r14"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock under employee stock purchase plan",
        "label": "Proceeds from Stock Plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_PropertyPlantAndEquipmentAndCertainOtherAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "PropertyPlantAndEquipmentAndCertainOtherAssetsMember",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to property, plant and equipment and certain other assets.",
        "label": "Property Plant And Equipment And Certain Other Assets [Member]",
        "terseLabel": "Property and equipment and certain other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details",
      "http://passagebio.com/role/SubsequentEventsQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r533"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFy",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r95",
      "r96",
      "r97"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant, and Equipment, Fair Value Disclosure",
        "documentation": "Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r891",
      "r892",
      "r896",
      "r903"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r110",
      "r593"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1",
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total, property plant and equipment net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r533",
      "r580",
      "r593",
      "r764"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r95",
      "r96",
      "r591"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyTables",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property and equipment, net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details",
      "http://passagebio.com/role/SubsequentEventsQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r533"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r286",
      "r287",
      "r288",
      "r289",
      "r342",
      "r352",
      "r383",
      "r384",
      "r385",
      "r391",
      "r403",
      "r481",
      "r545",
      "r554",
      "r570",
      "r612",
      "r614",
      "r622",
      "r635",
      "r636",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697",
      "r699",
      "r700",
      "r727",
      "r733",
      "r739",
      "r743",
      "r745",
      "r746",
      "r755",
      "r756",
      "r760",
      "r761",
      "r768",
      "r775",
      "r840",
      "r844",
      "r894",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r180",
      "r286",
      "r287",
      "r288",
      "r289",
      "r342",
      "r352",
      "r383",
      "r384",
      "r385",
      "r391",
      "r403",
      "r481",
      "r545",
      "r554",
      "r570",
      "r612",
      "r614",
      "r622",
      "r635",
      "r636",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697",
      "r699",
      "r700",
      "r727",
      "r733",
      "r739",
      "r743",
      "r745",
      "r746",
      "r755",
      "r756",
      "r760",
      "r761",
      "r768",
      "r775",
      "r840",
      "r844",
      "r894",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyTables",
      "http://passagebio.com/role/SegmentReportingQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of reconciliation of reported segment net loss to the statement of operations",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28"
     ]
    },
    "pasg_RemainingCapacityOfValueOfSharesAvailableToBeSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RemainingCapacityOfValueOfSharesAvailableToBeSold",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining capacity of value of shares available to be sold.",
        "label": "Remaining Capacity of Value of Shares Available to Be Sold",
        "terseLabel": "Remaining capacity available to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ResearchAndDevelopmentDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ResearchAndDevelopmentDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses in the period for usage of depreciation and amortization attributable specifically to research and development division.",
        "label": "Research and Development, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r701",
      "r707",
      "r708",
      "r722",
      "r920"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details",
      "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "pasg_ResearchAndDevelopmentLaborAndRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ResearchAndDevelopmentLaborAndRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit directly attributable to research and development phase of the medicines.",
        "label": "Research And Development, Labor And Related Expenses",
        "verboseLabel": "Wages, benefits, and other payroll"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ResearchAndDevelopmentShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ResearchAndDevelopmentShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses in the period for usage of share based compensation attributable specifically to research and development division.",
        "label": "Research and Development, Share Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ResearchAndDevelopmentThirdPartyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ResearchAndDevelopmentThirdPartyCosts",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/SegmentReportingFyDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses in the period for usage of third party costs attributable specifically to research and development division.",
        "label": "Research and Development, Third Party Costs",
        "terseLabel": "Third-party costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credits",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/SeveranceFy",
      "http://passagebio.com/role/SeveranceQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r275",
      "r278",
      "r282"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Workforce reduction",
        "terseLabel": "Number of positions eliminated, period percent",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r274",
      "r275",
      "r279",
      "r280",
      "r708"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281"
     ]
    },
    "pasg_RestructuringPlanReductionInWorkforcePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RestructuringPlanReductionInWorkforcePercentage",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reduction in workforce as a part of restructuring plan.",
        "label": "Restructuring Plan, Reduction In Workforce, Percentage",
        "terseLabel": "Reduction in workforce"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid severance",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r280"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r77",
      "r589",
      "r619",
      "r621",
      "r630",
      "r646",
      "r764"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r247",
      "r248",
      "r268",
      "r303",
      "r392",
      "r432",
      "r433",
      "r440",
      "r441",
      "r442",
      "r444",
      "r447",
      "r448",
      "r461",
      "r463",
      "r464",
      "r466",
      "r473",
      "r514",
      "r516",
      "r616",
      "r618",
      "r632",
      "r958"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "License and Other Revenue",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r702"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use assets recognized upon the commencement of sublease",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r763"
     ]
    },
    "pasg_RightOfUseAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RightOfUseAssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsNonrecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of right of use assets.",
        "label": "Right of use Assets, Fair Value Disclosure",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_RightOfUsePeriodDecreaseDueToLeaseTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RightOfUsePeriodDecreaseDueToLeaseTermination",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Use period decrease due to lease termination.",
        "label": "Right of Use Period Decrease due to Lease Termination"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_RisksAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RisksAndLiquidityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Risks and Liquidity"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_RisksAndLiquidityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RisksAndLiquidityLineItems",
     "presentation": [
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Risks And Liquidity [Line Items]",
        "terseLabel": "Risks, Liquidity, and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_RisksAndLiquidityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RisksAndLiquidityTable",
     "presentation": [
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to risk and liquidity.",
        "label": "Risks And Liquidity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_RisksAndLiquidityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RisksAndLiquidityTextBlock",
     "presentation": [
      "http://passagebio.com/role/RisksAndLiquidityFy",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to risk and liquidity.",
        "label": "Risks And Liquidity [Text Block]",
        "verboseLabel": "Risks and Liquidity",
        "terseLabel": "Risks, Liquidity, and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_RisksLiquidityAndGoingConcernAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "RisksLiquidityAndGoingConcernAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Risks, Liquidity, and Going Concern [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesFyTables",
      "http://passagebio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyTables",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of details regarding the Company's portfolio of marketable securities",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsFyDetails",
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalent [Table]",
        "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesFyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of details regarding the Company's portfolio of cash and cash equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details",
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesFyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesFyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of effective income tax rate reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r742",
      "r875"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationFyTables",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share-based compensation expense category",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r533"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r356",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationFyTables",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock option activity plan",
        "label": "Schedule of stock option activity plan",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r79"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationFyTables",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationQ1Tables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted average assumptions applied to options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r35",
      "r36",
      "r37",
      "r75",
      "r76",
      "r77",
      "r114",
      "r115",
      "r116",
      "r175",
      "r314",
      "r315",
      "r316",
      "r318",
      "r321",
      "r326",
      "r328",
      "r460",
      "r626",
      "r627",
      "r628",
      "r629",
      "r733",
      "r797",
      "r813",
      "r815"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r173",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r277",
      "r281",
      "r445",
      "r446",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r719",
      "r722",
      "r723",
      "r729",
      "r769",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r953",
      "r954"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFy",
      "http://passagebio.com/role/SegmentReportingQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r173",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r197",
      "r199",
      "r200",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r718",
      "r720",
      "r721",
      "r722",
      "r724",
      "r725",
      "r726"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance and termination-related expenses",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/StatementsOfCashFlowsFy": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      },
      "http://passagebio.com/role/StatementsOfCashFlowsQ1": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sharebased compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unvested balance, Ending",
        "periodStartLabel": "Unvested balance, Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested balance, Weighted average grant date fair value, Beginning",
        "periodEndLabel": "Unvested balance, Weighted average grant date fair value, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested, Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/SharebasedCompensationSharebasedCompensationExpenseFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationSharebasedCompensationExpenseQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r356",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and exercisable at December 31, 2025",
        "terseLabel": "Vested and exercisable at March 31, 2026",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and exercisable at December 31, 2025",
        "terseLabel": "Vested and exercisable at March 31, 2026",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding, Ending of period",
        "periodStartLabel": "Outstanding, Beginning of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding, Ending of period",
        "periodStartLabel": "Outstanding, Beginning of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested or expected to vest at December 31, 2025",
        "terseLabel": "Vested or expected to vest at March 31, 2026",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested or expected to vest at December 31, 2025",
        "terseLabel": "Vested or expected to vest at March 31, 2026",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration from date of grant (issuance of an option) to when option auto expires.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Term",
        "terseLabel": "Term of award"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r361",
      "r380",
      "r381",
      "r382",
      "r383",
      "r386",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ]
    },
    "pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement",
        "label": "Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase",
        "terseLabel": "Percent of the total number of shares of the Company's common stock outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.",
        "label": "Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted",
        "terseLabel": "Period till which there is automatic increase in rights granted under the Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and exercisable at December 31, 2025",
        "terseLabel": "Vested and exercisable at March 31, 2026",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationRestrictedStockUnitsFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationRestrictedStockUnitsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationStockOptionActivityQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested or expected to vest at December 31, 2025",
        "terseLabel": "Vested or expected to vest at March 31, 2026",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at Beginning of period (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "pasg_ShortTermLicenseFeeDueAndReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "ShortTermLicenseFeeDueAndReceivable",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license fee due and receivable in short-term as of the balance sheet date under the license agreement.",
        "label": "Short-Term License Fee Due And Receivable",
        "terseLabel": "Short-term license fee due and receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFy",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "pasg_StateTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "StateTaxAuthorityMember",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to state tax authorities.",
        "label": "State [Member]",
        "terseLabel": "State"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://passagebio.com/role/SegmentReportingFyDetails",
      "http://passagebio.com/role/SegmentReportingQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r89",
      "r104",
      "r173",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r212",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r277",
      "r281",
      "r445",
      "r446",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r719",
      "r722",
      "r723",
      "r729",
      "r769",
      "r924",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r953",
      "r954"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r51",
      "r54",
      "r55",
      "r101",
      "r102",
      "r103",
      "r126",
      "r127",
      "r128",
      "r147",
      "r148",
      "r149",
      "r151",
      "r158",
      "r160",
      "r162",
      "r174",
      "r247",
      "r248",
      "r268",
      "r303",
      "r329",
      "r392",
      "r432",
      "r433",
      "r440",
      "r441",
      "r442",
      "r444",
      "r447",
      "r448",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r514",
      "r516",
      "r535",
      "r595",
      "r616",
      "r617",
      "r618",
      "r632",
      "r682"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r174",
      "r305",
      "r306",
      "r308",
      "r310",
      "r516",
      "r572",
      "r624",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r709",
      "r711",
      "r776",
      "r957"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r174",
      "r213",
      "r305",
      "r306",
      "r308",
      "r310",
      "r516",
      "r572",
      "r624",
      "r633",
      "r634",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r682",
      "r709",
      "r711",
      "r776",
      "r957"
     ]
    },
    "pasg_StockIssuedDuringPeriodSettlementOfLitigation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "StockIssuedDuringPeriodSettlementOfLitigation",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of stock issued during period for settlement of litigation.",
        "label": "Stock Issued During Period, Settlement of Litigation",
        "terseLabel": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares in connection with employee stock purchase plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued",
        "verboseLabel": "Issuance of common stock under the ATM Facility, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r77",
      "r626",
      "r682",
      "r692"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during period, Reverse stock splits",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and vesting of restricted stock units (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://passagebio.com/role/SharebasedCompensationStockOptionActivityFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "verboseLabel": "Exercise of stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r77",
      "r367"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares in connection with employee stock purchase plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r77"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details",
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock, net of issuance costs",
        "verboseLabel": "Issuance of common stock under the ATM Facility, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r50",
      "r51",
      "r77",
      "r632",
      "r682",
      "r692",
      "r782"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options and vesting of restricted stock units",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r50",
      "r51",
      "r77"
     ]
    },
    "pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "StockOptionsIncludingSharesSubjectToRepurchaseMember",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock options (including shares subject to repurchase).",
        "label": "Stock options (including shares subject to repurchase) [Member]",
        "verboseLabel": "Stock options"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_StockholderSEquityAndShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "StockholderSEquityAndShareBasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholder's Equity and Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://passagebio.com/role/BalanceSheetsFy": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1",
      "http://passagebio.com/role/StatementsOfStockholdersEquityFy",
      "http://passagebio.com/role/StatementsOfStockholdersEquityQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance at Beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r67",
      "r647",
      "r663",
      "r683",
      "r684",
      "r764",
      "r783",
      "r813",
      "r816",
      "r817",
      "r837",
      "r905",
      "r958"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://passagebio.com/role/BalanceSheetsFy",
      "http://passagebio.com/role/BalanceSheetsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://passagebio.com/role/CommonStockFy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r313",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r329",
      "r460",
      "r472",
      "r685",
      "r686",
      "r693"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "pasg_SubleaseAgreementBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "SubleaseAgreementBMember",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Sublease Agreement B.",
        "label": "Sublease Agreement B [Member]",
        "terseLabel": "Sublease Agreement B"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_SubleaseAgreementCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "SubleaseAgreementCMember",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Sublease Agreement C.",
        "label": "Sublease Agreement C [Member]",
        "terseLabel": "Sublease Agreement C"
       }
      }
     },
     "auth_ref": []
    },
    "pasg_SubleaseAgreementaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "SubleaseAgreementaMember",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Sublease Agreement A.",
        "label": "Sublease Agreement A [Member]",
        "terseLabel": "Sublease Agreement A"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/LeasesQ1Details",
      "http://passagebio.com/role/LeasesSubleaseIncomeFyDetails",
      "http://passagebio.com/role/LeasesSubleaseIncomeQ1Details",
      "http://passagebio.com/role/SubsequentEventsFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Income",
        "verboseLabel": "Sublease rental income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r763"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details",
      "http://passagebio.com/role/SubsequentEventsQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details",
      "http://passagebio.com/role/SubsequentEventsQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SharebasedCompensationEquityIncentivePlanEsppFyDetails",
      "http://passagebio.com/role/StockholderSEquityAndSharebasedCompensationEquityIncentivePlanEsppQ1Details",
      "http://passagebio.com/role/SubsequentEventsQ1Details",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r537"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://passagebio.com/role/SubsequentEventsFy",
      "http://passagebio.com/role/SubsequentEventsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r538"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://passagebio.com/role/CommonStockFyDetails",
      "http://passagebio.com/role/RisksAndLiquidityFyDetails",
      "http://passagebio.com/role/RisksLiquidityAndGoingConcernQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesFyTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of net operating loss carryforwards",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://passagebio.com/role/StatementsOfCashFlowsFy",
      "http://passagebio.com/role/StatementsOfCashFlowsQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r302",
      "r326",
      "r460",
      "r471",
      "r495",
      "r502",
      "r505",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r582",
      "r596",
      "r750",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r765",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r833",
      "r834",
      "r835",
      "r836",
      "r890",
      "r893",
      "r894",
      "r895",
      "r896",
      "r898",
      "r900",
      "r901"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsFyDetails",
      "http://passagebio.com/role/CommitmentsAndContingenciesCollaborationAgreementsQ1Details",
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r451"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://passagebio.com/role/LeasesFyDetails",
      "http://passagebio.com/role/PropertyAndEquipmentNetNarrativeFyDetails",
      "http://passagebio.com/role/SeveranceFyDetails",
      "http://passagebio.com/role/SeveranceQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r133",
      "r274",
      "r275",
      "r279",
      "r280",
      "r708"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesNetOperatingLossesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://passagebio.com/role/CashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesFyDetails",
      "http://passagebio.com/role/FairValueOfFinancialInstrumentsAndNonfinancialInstrumentsRecurringBasisFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "pasg_UpfrontLicenseFeeReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://passagebio.com/20260721",
     "localname": "UpfrontLicenseFeeReceivable",
     "crdr": "debit",
     "presentation": [
      "http://passagebio.com/role/GemmaLicenseAgreementFyDetails",
      "http://passagebio.com/role/GemmaLicenseAgreementQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront license fee that is receivable under the license arrangement.",
        "label": "Upfront License Fee Receivable",
        "terseLabel": "Upfront license fee receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesFyPolicies",
      "http://passagebio.com/role/SummaryOfSignificantAccountingPoliciesQ1Policies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r176",
      "r178",
      "r179",
      "r180",
      "r577",
      "r579",
      "r715"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://passagebio.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesFyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance increased",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://passagebio.com/role/LeasesOperatingLeaseCostFyDetails",
      "http://passagebio.com/role/LeasesOperatingLeaseCostQ1Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "terseLabel": "Variable lease expense",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r763"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r169"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossFy",
      "http://passagebio.com/role/StatementsOfOperationsAndComprehensiveLossQ1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r169"
     ]
    }
   }
  },
  "ny20077915x1_ex107.htm": {
   "dts": {
    "inline": {
     "local": [
      "ny20077915x1_ex107.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2025": 1,
    "http://xbrl.sec.gov/ffd/2025": 3
   },
   "contextCount": 4,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 33,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R104": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_ex107.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_ex107.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20077915x1_ex107.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r792"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>171
<FILENAME>0001140361-26-029162-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-26-029162-xbrl.zip
M4$L#!!0    ( ,6J]5QS$]TCGV,  /EF   3    ;&]G;U]P87-S86=E8FEO
M+FIP9[2Y!52;7_,N^N)>W-TI[EXH4"10W(J7X@1W3PLM+@4*M&A;W(L&*6[%
M'8I[<9JT2( 0+K_O.W^Y:YVU[CWWG#M9;S*9S.R]G]GSOON9E?N?]YL B:8:
M2 U 0T,#NA]>P/TI(*GG[.GGZ>OLZ<4B)B@,2"N#M#%.\0T<?#W=_/U</#V
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M?BS]&/PX[_$4+SJO!*\S;P[O)!\ZGR2?"U\>WS0_%K\,OP?_5_Y% 4(!)8$
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MDZ81&L<6^UYO"/UKE6MY#S./?J+WFU1S.#E;)D9D2(A79^?/_0ZU:.YX&;6
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M&\&8K37'RS.7JC/!,VL7V^8EQK;R]SQ6?75]! 80HYL.\\ 0DX"VO<8TG\L
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MP57Z'0."+N %B.=(<8MET?NMXZH2AG3/)(>WS1@.DD%X!>).]"1VE7IK\&W
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M*JOS?M$0N$KYZFKNGUSU*[2Z.',A%/<5F:3V%/%;5)""9$1?5Y/0R;%@H=0
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MD@ULR('KBX9<Z'-D<A$[O6P@RBYJO>_AP0/IW;PPZ#FUYG+61T0X6K.NS<D
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MAMBS3U+\#>-JIAD_%ETQ?H.?Z+],N#O$KF^^VL?J+>*"WOC=<DJ>.?B77Q]
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M@32MJTV?=T:2$Z.U5"6Q-_=KTHLS=UJT<>J,S?D%P.EGGYXRC1)-\E_V.YH
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M'5_]\BUSIT&2Y]AHHFHH6DZB=N&#P_?_%*C#74E-E!N\9]2!T:YO1LD/<1<
MFLS8>J'DE22VQ:YLY1=6?KDASS]^_:MX_Z7R-4Z1JD*;2OY4-R-Q<R<AQ)Q3
MW5+8D)-^3K9WZ?4]E@#FA?8EZ6VC'OO_/>6['HX^I>^:AZK0Q*O9OH@H_Q[8
MW3/U>1E.A2Z"*MS5BREG%-CX]K,WO"B4Y3R'<BO\=P<W#Q-)<OD>0V?PC>Z&
M]/0,V;8# /-P0%B85T"9G:H((#NNW.M]O/=-;:8:&X-T<Z')]$3C"LNCV6NB
M9C9EVO)0.<3?_/40/V83V\&5C-(3KLO06ES19G[^_VHT%[/_!U!+ P04
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M9>%FD6)18=%C,6>YQ^+%$LZ2P)+#4L;2P-++,L6RPG+ RLHJPJK(JLMJQNK
MZL,:Q?J,M8 5Q=K!.L:ZS+K/QL8FSJ;"9L!FS>;&%L*6P/::K8H-S3;.ML)&
M.L%Y0O;$A1/73SB>"#@1>R+GQ(<3[2?&3ZR=.&;G8S_-KL=NS>[!'L&>P5["
MWLP^RK["?LS!SZ'(8<!QA\.'XPG'*XX:CEZ.>8Y=3D[.4YR7.&]S0C@?<[[B
M_,CYE1/'^8=+@$N9RYC+F2N4*YVKG*N#:Y9KEYN;^PSW%6Y'[A#N=.X*[F[N
M16X2CR"/.H\YCP</@B>?IY%GG.<7+SOO:5XC7E?>2-X<WCK>4=XM/G:^,WS&
M?&Y\,7SY?%_X9OCV^07YS_-;\_OS/^/_P#_ _U. 3>",@(F A\!3@6*!;H%E
M029!>4%C07?!.,$2P5[!%2%6(44A<R$?H52A:J$1(8*P@+"6L)TP3#A?N$UX
M281)Y(R(N8B?2(9(K<BTR)&HM*B1J*=HLFB-Z+CHH9BDV!4Q3[$4,938E-B1
MN)RXB;BO^ OQ)O$%"68)98G;$N$2A1*]$EN20I*7)=TE4R1K)3%2C%+*4C92
M45+%4G])[4O+2)M*/Y)^+=TMO24C(G-%QD?FI4R[S+JLH*RA+$3VI2Q:=D-.
M6,Y(SD_NE5R/'.&DU$FSDZ$GBTZ.G#P^I7CJ[JG84ZA3"_(<\A?E'\J_E.^2
M)RC(*E@JP!4J%3"GV4]?/.U].O=T_^G#,XIG[,\DGFDZ\U-13-%<,5*Q4G'^
M+/=9T-G L^_.3BJQ*EU4\E4J4/JFS*BLK>RMG*\\JL*HHJ,"42E0&5-E4;VD
M&J#Z3G5&C4O-2"U,K5(-IRZB?E,]5KU)_9>&@H:CQ@N-?@WJ.>US?N=*SLV=
M%SA_XWSL^>;SOR\H7W"_D']A4I-;\[HF0O.S)E%+1<M3JU#KN[:@MJ5VHG:7
M-D5'5R=(IT9G75=!][[N&]V9BT(7;UU\=O'K)99+5R\A+K5>^J.GHQ>B5ZNW
M<UGMLN_E#Y=_ZBOJ>^J7Z"\;G#)P,R@R6#*4,[QO^-9P"702Y 9Z!\)?D;_B
M<:7LRIJ1DI&/4971KZOGK@9=;;AZ:*QG'&W<<8WIFNFUE&LC)@(F=TWR3!:O
MG[KN=;WR.L%4VS3*M,.,Q<S"[(79C+FTN;MYA3GAANZ-Z!L]%EP6MA9Y%OB;
MRC>#;C9;,EK>L,RRG+<Z;15@U60-6)M;9UDOW%*\%7BKY3;K[5NW\V^OVIRW
M@=OTVPK:@FT_V![<N7HGX\[<W;-W0^]VV?':.=M5V!W:7[//M%^ZIW$O^MZ0
M@X0#Q.&S(YNCG6.9X[Z3B5.VTXJSMG."\[2+H@O,9<!5PM7/M0W,"W8#U]UG
MN6]__\-]LINUVSNW_0?F#]X\(+@;N^>Z;WI<\7CIL>YIX)GIN?;0X&'FPY]>
M!EY97NO>(.\<[RV(,20/0O0Q\T'Z'/I:^Y;[TOSL_5#^)_SO^W\)$ CP#>B!
MRD!AT+%'*H\2'BT%Z@5F!Q*"+(+*@AF"78(_APC1#Y:_0L^&QH?BP@S#\L-(
MX7;A=3!^6 #LKPCEB.2(M<CKD:51S%'N45WPD_ G<%RT4711#$/,@Y@NA#SB
M*6+EL>GC]T\XGO@^&8X]%YL9NQ=G']?\5/KIXZ?+\:;QE0D\"4$),XF7$Y%)
MS$F0I)%DS>37R=04CY3!U'.I.:GD9^[/!M/.I[U*HZ4_3!_)T,DH?,[Z/.#Y
M] O0B_>9_)F1F<M9EEF-+^5>IKS<RP9G#^1HY2!S.7)#<Y=>W7SU^;7"Z^>O
MR7G>>5/Y5_-1;Z3>)+\Y+/ H&"^\4EB#E$:F(H_>0MY^+S(M:GQWYEU.,6MQ
M6/%JB5U)?^G%THHRB;+4,DIY0/G2>YOW/16Z%14?I#YD5#)6AE:N5SE7?:N^
M5OVY1JVF""6"2OT(? S]N/'I_J?I6HO:KKJ+=37UI^O?- @VI#0R-$8T$IJ\
MFY8^.WP>^W+C2U?SY>:&%O66\M:3K?EMPFT9[1SM3]MIZ$CT?L>CCJU.K\[E
M+G#77/>][LF>VSTCO1:]7_NN]W7W&_6COQI\;1W0&_@R>'&P:4AGJ/$O[;\:
MAK6'&T9T1AI'=4<_?[OTK7E,?ZQ]'#3>.7%MHF_2?')HRFIJ;/KN]/<9YYFE
M[Q[??\[ZS1(Q89CCN<?S+/,I"WP+.8M2B^^P2EC4DLY2&^X:[B^\+7YNV7UY
M\T?P#_+*TU7NU9PUV;6*GQ=^MJY?7_^VX;2QLOEH\W@K89M_^\VOL[_J=Z[L
M_$6X1U@A!A%IOY_MBN^6[VGM=>W?VE\\\#\X/DPAB9/>_[GXI__(_FCM.)S,
M1GY%4:(T4RVH\S1_&NW?.(GZWYSM7WSDFN=#MU"_$+F_B8HQU \:&B1G^\C-
MW5-.[3^)W?\_/.7!:P!HB@< ,<R_;'2Y]<^/?_*U?P@#\-\+X[_&,8G0+TVZ
MJ>1?-N@[ +BX3[<_#X9X_<-F;'-'[M_BH&;C^= SR#. #M4.XAD."?"BXP_P
M@/S-EN4@ 7+_6YC^/P'_;_*O]_P75P[QA(7\XSVACR*"(%[>(7)FGN%^GB$A
M<K?<W'W=@CQ4Y2Z<.Z<%!#_4O/"/H0Q<=([,@J71=L\  -M+ *!DT&C'130:
MA8Z=:0X .D)I<X#QWWW"_Y7\/<G_[1P,M Z _P3PG&&)B>$4P,C/P,3/0.L!
M9.DH6/[I\)^A86!D8F9A93O!SL%)=VC@ Q@9F)@8F9E86)CI/)8AFOX[P,S/
M(G#RO!&KX&TWME.!0A>>O"@Z(7_U4Z>PS1A!0?-!4"P[AXBHF+C$Z3.*9Y64
MM;1U="]>TC.^9G+=U,S\ANV=NW;V] 5P]_!\Z.4-\0D."0T+AT5$QCV-3TA,
M2D[)S'J9G9/[ZG7>N^*2TK+R]Q4?:NOJ&QJ;/G]I[NKNZ>WK_SHP.#XQ.34]
M\WT6@\,O_UA97?NYOD'\O;NW?W!(^G/T-RX&@.F_H/^WN/CIN!B9F9F8V?[&
MQ< 8_K<#/S/+R?.L D:WV=P"!4]=>')"Z.J+HD^=[/*:-@3A!T%C'"(*6KC3
MQ+^A_0/9_SM@L?]'R/X+V+]P80 N)@;ZXC'Q R" 2CW[+@4X6_9)CNFSQL6U
M\K6XE/+H]P[K8>&1"<51_N[N[E#MA97]+0)F=A8SUS<^[[S@_->ZD CA>K7"
MQ(TA*;.J7U=CO2-5]G;^4!:,PSTKMV=^:=Q1B#5;NR3/P/ C*@XKG_7DZXC*
M;E0_B' KBOOAZN8URFLX#PT0\TA>2FM7WFQ.)5DOW;EZM6M]3T-H#K-!E2.E
M!9?[G=PF"^*.%WA\WQZ(&JI/J)_,'R*-XG/[4"GV@=\WP+(TP+<%F2!RB$&1
M+?0O$1)O?2*)XK[@7X^=FK#YY30J2+8C2A'K4TY_^4CL_=P\V*IW.E_3V-5.
M_E+GK:QR\<&VN]"%;\ZC=M7A(54+*-^"$,+=#Z:%-[3P#5:E$U$& I:4 U!4
MW%MFP;E -O%^^;>*S2]& \%/==&$V_EIIE2.4!PJ@2H^Y2>YU-S]'LY-Y-RT
M9BEX4ZCJ8GN[M97HFA4M4W80] 2U?J237.YR\U/JMA[^]XEJ.SP>X[XW_07G
MA/A. Y9D>VA LJ-Z 9YBCY=-&H[=--2N(U73 ';=)&TC#YG#;IL%7[2H-HAO
M7D]W3KUJN9$Z0.0^5EMNAH@^,OO42RZ'%??ET@#1=BV?13U2 ;Z2PG/8%Z.1
M?YL(3MG:RKT]&1+R^8N'[U TR"K?NBF[2O[><P?(J*>G@&*V.X=32=C:S]_-
M((=2Y:FWZ\'C@2N1@Q>RMT/&VW)0%N7OVM<R7MG=4;8I9=]UK7+R]6*>T486
M;!7F-C;.(J(;#\^-"@QQ]FO9\)Y72.Y)VHC95"GR5([ &"EW2)<\N_NQ(Y,U
M2//(_<_:XX@#5/\HSW>R(.F8H$T#O,%LW@A10Z$-JO3X'O:$-5$6EX#"[S!N
M&"K4$L)2M%ZM?FHDC*:H:@]!F2&R7F?[P1,A0R$V 0&JT&VC9H0NR8VX<Q#W
M32M:TYYD<&S\$RQ#%BO#>4[$:)W)74YH[^24+LLF.N%FR/*+<F,!-M#Y =WD
MO8RDVO<V9=\O!NESV;F9,B1E<]WTM-295S8)[BW95E1QZ,.X*,SX?M]?=RM/
M+M]6NJ%A5BZN4S)W8\#!W+#)OW+]1\SJ&)B%?);2IL^.]P??((#ZH+P;LH#A
MR8W:]>: ;-%4Z+8V;T*,YDRH(NS!N*$,^<X3U?IH7YN<.[<A.!K OT[E)4;C
M!\NPW39)*YF@UNPX(+B0S?#+SYC$1KT9%RX3J9O"-X3E;7BK7"LM,.:SO7^T
MD"_B;P27*DJ\>)0Y/ARV=1!34:^7<K8ZB>/LN\?_Y]?7?:%;#";_>3$_F7RR
M_]^X7;WZ[ U5R"/T:W^-[U#[.;(SP;Z#!B123Y%RERE7HT#<L+#%^6'N^,H-
MQS[4>Q_=6^O-NHFMH)*NF*DJ6$:/1-M43D811"1E1O0H>Z6>\_'6U_S;5C:0
MZTI?=+:JLA>PUW*J]SAOV-TFY9L[N.S,5:02)Y9'N[&/93B@XK CZCK+P@]'
MC7BR9HF382E^5!I6<R3^8[Q5?HDBP"HJT=Y2D1\!?_\D961D6J7:VJYE8B_?
MHN4G0L)0%VY.5.S%JO3)-K!6R":VLNB@W*%+UK.H[AG[=KEO[E->DR>IG75$
M%U3B]D@1<0YOLK)2(BJ2)UWS.AIG*;#](['[B*=&]2$QOL\KE>R_#!:$=4TL
M:_062"SW(*7T$8_@O 2GI<:X:&A%[U*4FM=0:Q,I<.F/Q_-[.L7AONZ\2>T7
MX.;/"RX:%6^(_C:'XGAYUG5"C\2/+\8,/H)?;FLB51/#=CN1?(8&/G:9E3Y]
MOR/@&H1*J\EW#UL(IEV5ERL?3.O!E3?+-]O/YXCI6RY7R.D>U>?H1<UZZT%'
M;\!:%^M*KUHE< CXA&9.5^?9.(&OO[EC:V$QL#B][\YQ\:QRED_HFF2?$OC%
M^D:;TXUC4^..=DGJ(%(Z1LO)<8.>A1K:B-DZ7%O/254R)Z[QFP95UQ=S9WJL
M7F SYK37I+XN 7Y6 ZJ8" >5P^IZ/K[=E2>"$[1/4/O9,(:<E$+$0]!LN<54
MJVT9S+B+RI!NOE5.U.A!BVYBH429TJC@0/_R>\-XC:08C:E06;Z%X<#P<*B_
M3V[>YZ;CNX,F4 &+"RI1WV._!ZF1E5K>]A6=-3#_J=:Y$;%6F/VGGP:P"!$>
M;"XRB;IJ41H\*'E4*=]IW7:)*7VID&J0,P&;MA)EFK?8)_+)4J.W3MR]L=7%
MPBIE\T[]EV2AZBK5^#,'YQP>BO(L<]S!;]RP"UT3UJO-GL%,U:Q?'Z3P@OA3
MJV];!>4VYW;*!JE,J2@6MZQ.A8RM_Z8!V[,$9)?A15+E!]A$9R8YC !-;K5\
MMXYQ;<+3@(0C?W2OQE-9OE9-+[<#C\E]"F<W=]6BZZ8=)M*X=.%GNWS3>-6.
M?U55><(J= $\1#Z (:R^5<4H&9<-Z;14_\R1.=.:,/U[Y-"$9(WG_/&Q<*4J
M '/<DU;Y,X;I2\2[6*<7[]O?:O6D^X;FF#->V(L$=Q;8][LJSX2@8F^3ROMC
MA @YR.BJS4+]-D+:3J)6&J_I-US4L%//4;V>_TZR5=J[V7Z_0QW.X+"CD2*Q
MA$6L>8;M:S^V5Y!VQ:F]#'Y3_/N'M9,-2>KE7YQ&^=8C$2EJY5^^I)A)K.Y8
M$X7+BCW?W[1[F,,4#0%E/QJ;5U;X(!:=+A)7>N/._)2)1\Y@^/@P.MD@N[ "
M_N(WZ<-@J=G='X'^)4C-ER$0%Y??+1&0M4\4<VH7DE]5.T/(:;-0D52Y--?V
M\*AOL]L1V@WE):'Z9.O!/>[E+A:>*XND%GQ!8U$H3DUBS#.%O6R<++^$YET_
MK^QD'?&^?&<I=YL&I" _@;8H1&N;9N+IF5AU\LGE/_ZGZ^/P&=W2/LL=KJ G
M#Y6/UZ9#'*K?S10GF'#+(/'5(-?QB]XEGS*5Q'E_-QP;4#$@$;(PWJ(2+$8=
MIP&2<(:E2HK([Q[T8RU>'M*VGV*A+T+U'NQR#Z8Q'C?,GGWJ34UET:F%[^8K
M_;Z^*_-F1(0# J!JPL^2I@C8;GLP-_4D*1@OW9>%6Q!PB3&P[L7HU.$IZA:I
M8C/;](-Z/!3%/P_16_@QUN(RM[AH]LF9O=HNW#>H$O_PXKTO*%\KP6?8>TIJ
MJCG5T+::G=6H>ZI.@8?*%ZU$K,97LC:C%#]L^MN@W7?CEA4[K)^AV;3:7/0C
MWID>F\$Y6V*WM;'"$!G1"3SI"8Y;!M>C(9H1(PI!0B=:(XH<'5J;])I28V0P
MZYCL$G95%&'!OWIM,O?R$J(?*TX=/;)+KH3)WYTV-(@9.HJ/K_]&4L;>R>JA
M$P1HT5! &FL#(;='--,9"QOJ:HZNNGV-3C?V6\HFM]YFVA%<VR2_.\(4;U&R
MSG68GY+E8)J0Q5Q8?G[]8IS8Y220*ZPW)I#ZC0;4-I;B7$P=27/'VNL20A(+
MPU-];43CI;#D]R:>;\EVHJ*\P56DXLZ#W7Y6) [Z+%\A<^?8B,O1OH<MR9NJ
MF.1CN[YX:J(=+)@SU35RK[4QZ-GX:J'$3)PUOC;RQCI9_2#L9?3/DJ@[@8]J
MLJ7NN ]NBTU-;PSJUVQ6Y9D/.![.5!R9$ [QLK%4)=CE;JH!*1HO?;G7D(=H
M\#0R(;YF/5C<'UI]K]Z/P^S3/&9^SEIJ.G=:]WEG5/GBW+P#V&ENP4C5'#.S
M%-Z)3N<D:-ZU3D=P>[3-Q#"15H^<=M(1O*I5Y>F'1LTI/[[[8D7@EW&S=I>'
M>?O;.5L:/]>3&I8FI.P+Y2;V%FP<MA"XBX2]<[ZR+1*LZ&)2_K5QN.E;GT:]
MD3C4.OV>7+D^<\YE_:@LNV+.-*)\0T?WUF7C8*\(7RU[D8F^&Q9"*1L]Y_K#
MF"2E_&5B[*VJ9$_[6,,L%1::/]=/6$^Y8';R!8V^O5^.\39P4]]LF,YU\?^Q
M-^LW9B(\'QP/-SCVIP&=5Q%>4)+B3@*9#8_&2.SVV45:]_@C; G8A(PXLE(P
M/O^UMK2\I:7-\?;'N?FYZ$SFADR0NGW8KJ>;1(V1_"\)(C0-5%?>@<"HW!C;
M Z?3@!.M#$2H.6%_OZ_\[7?88;<>-%FMWO_Z!G:K2;?9Q^><Y8%*?BITWE*+
M53=38Z%%&%_W_L-%2YN7[KH!IJ=#"G.;-R<#&V9T%OR_D%9!2S^PI#.!HV0K
MJNYCG1\TH.OMI!GSFLJ+#R^R^_]BC;YNQ(PD"D#)@EI\/%^(GST$OI",*@2^
MR\$_-%=J!HYR7-T+JKH"ZATE"\7ARI]0>6,6P0U>W;()1RS(>#C[TN@SF5/C
M< U<]<6O6MN<-WYOJR]/^ DXR)CY51=NF%7[_W9O;#1[^_3/[3ZV?5X:P RB
M ;&A,3W8^E&RX%H7EK_]<LR((4#*6!ZVP(OV+$@<]N9-.K9&+O3EE\ >.Z[G
ME!W>G/([_<2O.OM!DS=74%4$R\BA&L[MTVR"/+\MK[C;G0KPZP:#"+^"3,LV
M<KO+Y8U;159Y%:=MQGT&-9RTRZCI.V5'Q3M@%D1G-Y9@@1;=.+<^@Q75ARZ9
M?GYQ*F&GCUYW^N%>9;EA&*[FA+A26 )F_)P9UF KAW"=9UWAEEC&%#:6!M2+
M=EIC5+J>DY:7H#T[;' ;0M5X6XNO#,^,:JAWM7KQK1W/"J=NC;F0RA]V7 >.
MV0W5XTIVL+LNG A%!,$^@R0WVCD:!V:$0XYO4?O#%D\22L"<6P'Z?_-ND=(J
MG\*SWW[I"_KA]A'\)-/;4S(TH$<O&AM??;B1EY/]?D,O(3^TJ!<1RCW\]"BR
M^SWB(@WX9+W]F@@^$"<1<> T-&?HL-4X]N:D*HZX]O1M"VP/FN3**?AATU5\
M1E7&R#/J(%56Q_+4ZJINEOG4\J?);1FEZMOQHQ=ZW52Z<M1?GF8W\+%M=FYR
M_=V^KO@!XCJW=;5[HM)RY.7J&]N "_93*O48JYGVG!8,9H=:.45"$J.HG(?T
MI221Y(GV>-U.M+2OK-@I8GD75IR4VA&CDFA.<GB_$>D7>1B_KY*F<M?%D*IF
M(G(PIKY=>B] 1&NWF//LE6<EU $8N,<1FMJJ2Z?FPMX3!GUI>!=><R)K5K!"
MC.UHV::.R%':LU%QQ2&(?\"#%\4*+Q^J9#WV)512.6\?\\0,L!]SQDRC9:L0
M7G2.X&C:5Z!AUD2*9^OE%NRV<]1]5D8,74NKE]U6<[>9#OG1V#+E.<5:%$6I
M$'E[R _.?^UZ=_>O8,7RY +/J[;=@V\\Q7:;;NO*W*D9K_4YV/D1/'XK^%9>
MS.YM1\QX &8?^TL"\8\J\MZL@0>(RRK1@'CC"K[A3,8:;1OSAQUL#!$KB:<R
M2,FZ5/;\.6?2? SR1 ,3#?@2L$^^3.UU%2",9H#\P+.F'8OGQ[1H@ #,H@]<
M']ZIP0DK[CZJ4@DL]UV4FFF7)P5;3(?XVRS$4M[UWYJHJ5&M60JNO7<FV^G^
MBQSTV%OZ3G,:O93WF!'Q8/3Q_?MOZ*4LZCOP8_GU^0YF9-%JZ[R,ANRSI^56
M]^Z];Q#]J^S70I.%_S'J]9ACMH1 2E[6JGUM9&EY6(,C9:U[F<IC22]$+]D_
M:61_IG3TB09^+'V^GAG.AIB@>_$J8ZF>INN'6Y!C/S@OI84JO($6HS*XD H/
M.R-UTQJ@ '@(/\KC3'*WS>AQU,EZNQG^2;T@6.NWP?N/1)E7Q 6V684,K2ML
M3SK(]"C$;B,ZM4">H*?HC^T5Q,2#($H!59:L041U(Y-E6-MFM-&,WMLESHLP
M>=>69D+?)[>*;NCY!.J8MC^X^W!,\M7KK97Z"+D7=N;+N8OHI>_7Z-%G/B(E
M2%WX3*EH/[EDN'05F0@Z$?B[Z59DK-%&Q(\92^7O7_'MJ*20'P6&L)&"2[T&
M34'-8=-DU,P'S0H)PZ'"/,B"BFYX[7JX[\ZN:0O9C ;$/44L%: YVD_"EG&Y
MJ=H9SP))2-Q.JK[Q$II?'4FH.3KH,@CNUJM>3*OH]X)IF_4N?&RM16X=LDLD
M%W&J3W*Q!"*( N'T/7198JT/;]Y/SI0V37_L46 O>_[DE<U"*R$1J7"R*.^!
M..5%/>B[Z4$Z:1>'G3W$(1,,SZ^+4J6(H4T]""Y2T(01T:4_2=]HF<(SZMP^
MI6V@N56[4>R0Z#")J'\PR3(I:NL2_<YL>E6LS!KO=7"=@$XD^Q[;4H>I?$37
M#'<\+R>I?#FC"\M+2KTZB1/5D6A/K2+-F$XT6%XXFG]>YPAVL-:N[O%PP^5<
MN\CEFRN:UN_F>S4K1\9UVN+%\4"ITN\:?ZW=L(;%H[RQHAM54N.9M]$7H-6Y
MKACLFK\(=GX>1 BR)PNJ.[BGD8V)'Q9U[Z,"09V4^]T<F4SFRIT(@X$[BMD)
MBPYFQR_JX W[&5T:)%4L6=!VV64A/1^G@<GMC+3Z]-Y:N$K"NL< U(/E^M4^
MI>F7S@1*W[-DLWSXL"LQY<C,X@+#R7GE_A3$4AJ6<!,JLD[O[1.W @G%5@YV
M=T5C1!JFR;(5/>-GNE7U<A.T"\X0/:^$RVN-?+@>QO<(@822E,K)DM6EY'.D
M"#PH'?216H0?Y7. F5HC[Q$1'6C!15!2PT"(BE@Y\O:4H90O^F&&S>2OO>.[
M3A5DM:K4EI86)X?5\0:G?*)(5NB$343IB2A3*>U0:?H&T6=7VU;ON'BLN%[V
M2?@ILB7RY8^YNK FZTN1(:[AH#HGZ>M#M@U-[1,UU3M;-7A!S*+#J/!4]5^J
M#.;W/S]95'KWR,B<?_"<7%Q<'BY&C6Q+0'5:)\B 2"W+%1K;9&G"3)?C3AK<
M6B??\TSI>],B4K@UTF9R<;#K5*VKR^GJU@1)[^_ZJ 8&FUG4;@Z]J'P0G4[M
M(&J'S"4"]85.2PWY&N6-1H.%$T(2+C.U+YEV==1BO*:&^'X3RYUSM&+?;:A8
MG[;:FC*-<?*7=2Z0KYM^JW8*C*$![Q1CX6!"W$$52?(=J<4XF@T/[D2FQ; E
M_#ZKS>D4;6%"5(R'6Y:_;!X/3=-#Z*@MWIR Y(UDA94Y.7W^M:6.=WCWXCK)
MV>_\R[6M;8Z/UGF"X2L^B[]]YL<L2_;L-L?_W"U6ON \\%DGT[<FMS&Y=*:"
MM/4?>RE0$+P,4R19=W%;R*-L*95U+V*!!X\B@!^W_L.!!=U(U5WB0I+J]3*8
MF&.#*X%P("Q>X4T0JVTX;I0L97$,P'DH+^&F!"9\^=8:H>X&R6EI)_D\;*YK
M47=,7X.G6#1>M/=(<-VQ+SG:URLP--BK>-$GSY**XEP_>C#K,-];G/K>7W^R
M^<5G#9(N&#>ZU4)L.GA&&B#X'B213A..\2,5U63-CT1DMR]6YJ?(XLE$$V27
M!!Y#*K?Z5#NI/R16.E6E;U*&S7\"/3V-Y1U,N//TU$R^?H">6&]<MK/>F\S,
M7!6?826%^CI_K>K*EKI?H5$<ZK&58J-W%@_G3%>*K8[7L<;'0P31M!!0L@P;
M(;P'Q-4VV2Y)G(EO!2U+,SK-0511"F-PRY+934?G7+L@ZN]IW!;T+:3ZQVG<
M\WJ_<"54-L@?03K+MK5V#)",.Q>U*$7[&0(0##1#WR(4!^6:A=EVU\&0#NA)
MU9#94*?CC*W-J-3P#*M/C69VO_:1'KJBC>>$-8*R#V22BR$R$N-::%YO"?^<
MU+<_'3W3,XHA>J&M89%AN:60L$\.ZT>A\27*SQUG[\UV"S<TM)Y]8<Q\NR_E
M?0H; 4(#V,[#$> D&M X\[2=$Q(^H^F-K3OL-C"<L6G:M?Y^BHCN@103K:J^
MR06+%^AKRL:]_9S%\-?0Z2_BC6ZN.9K\^NK"DV-3M3<&M%8Q8XKMN=]6BRSF
M[MZ:R;4[GBMK$VA&KP4??:<D@Y;*0;7E9"&.W?XCZ-8N"E:S8T?R]R\"P[+,
MB;GQ-7#%]]*@G@L;Y^YM2#B+VHLRV=2EK-W,PQS=DPU].>&@UB77VN1U#,:+
MIH?()K@R$7-[H$)MDZX2!-GX4!H@1HJU4'G8VI9A0IC.#:WRR8!X/T.%!C7:
M!8NIC667O51U>W+?E[R/6,(B,"?(?/0J? 9CZG9,*/+WQ&5D%$H1>;NDO;;3
M7_1@>LG\I-3.ZZ)A)A:S9/NWZT?:'_V2[9URF*_GW!ND%QUODI:!:*^$3#4.
MS0_)D< F[E/4:8#)C):_#49R6//N>*B%@VJ#M.ZMNL_VL1N#1^.0ZAK_LNOI
M, ]8@<.]E#=H8557\3NY&O56@=E3N1=\L^L+DW?5FAKC4.8V[[,+\BP/HB4L
MCPP/FD$G^LE2!?03<\33SM)W.>[7K4&V+FEC53$/_@)G[I9'<W5US/!9?-OA
M@2<=S@*U&]30U(=EC1FE-R':X)1P$!\9ICU*,L419;NCC8W&?AC*$'Y5XJ.O
MN6S4@2V%RQ8T3-O.B:;E^#X18GCY50QQ$4P(+-_"'LO$_-6N3GE#UCZ^3#Y)
M"._*2"K4'">'XK$RLR09E0)-JW9"=?9B8BGL012*M_1'GL&;71\BZ8E?@&K]
MYB5UEH*MX)OK A&(,46R )+*CCJ^2!U&UXUNS1%==Y<0<5LT $(QQ9DFD)V6
M-9*;#IJ:D<^VX);+*"X*RGEB;W/!<77I)^/0S1DOPL)462HK,H!@&BPUH&*I
M7[L[CDHO5(>%V_),B8K:#6R*.P[J6BS6'4^H/RJ2N(U4_5)64'/@6XT*J/@U
M53CJ%-.?./@+$T7L@XV"!]MO4BI  <A9IX,+WZKW1S$:^,-$.,N9(FAH\#N2
M7^IP<%^A7/HWQ5<AUFP_=3"Y21K+:@J!E I5D3XE*;7>267I+#R:I&I-%IH>
MI;(O$]0'-5C4"RICOB%%9NZ.M0M[8U+4IG(3M_V6KLT8GMK,D7PYO[XH&34G
MMC=\J2/UWHQZM9J'AAO/NP=4'D,!N ZE!+%4BFPHC%OJ(<I\(<HO6_=I\%D$
MXS6D2%V_:8!-HLFXO_"O4+00+'9#+,#)BC":4-_P^EU=72RGA>>Q3'*I8\>A
M2$X?,2+CT_N/>Z<J'RB,UZ%5(PIS&VN&[ -R/+YU']]9TQVPTFOY>>04]6LA
M8Q/1CR2$>&W%%;N^TF<B@):;,M28[OM(/">$QQ:]"#^'%6X;^5+MNJW, #9<
MG*?@3J8]KPX#<X"6UGB_>_7I'CB&]R 9X7XD?8TSL4JA^10V<V+?D_*J$M5<
MW0F8A5WS3&_U%_GA*#"/RU?!X*J;P@<4Q/$Y1"<_: E) ^J:GH2,\FZ"F>G,
M<:[/VI^7K(#D;[_@G;.H-A6:=N6: -X%='4R;2V1K%96]\M;:UAFS,%V\-C_
MH#B0[XNA]'$4HI,9Y('&:.!6F]Y31T&\9$UZ:H:.UP_EH]A\%MD;_3D[9!2F
MY&3\VQ.7$1RSQ>LO''SN16D395(A[E4036MI,@W '$Q7EXX$K1)CD?5=(S=^
M9ZO;93E&?;BAUU SK)[<)F[?I3M8?'EQ_A "MLI%Y*+<#^COOLU"<#I()[AD
M]%@_00OHJQ!U.YNV%6YOQHA,%K>E+ZZ>4='.*?7N4J$HWDK:54=^<)S%GLH.
M:SHQV/_]R>B#2_)(]YF?D1D!GR\)4^W!=<AMW6,K>B>@B_".MG8E(2HVJ,S$
MG2=DTW <*!G+HYVE1#A,88VKL/"L(NGV882")2__%%F5?*56LVP;7>8<H9>>
M&@4->M&&*$%L&1W?AU^D?*8!7AJ,,=]D><Y8^"+X9NE?24W= O/=AL5+".GU
MYYVR*7#YB@C_UO;7T2>C#3>\E_SM33Y/A+Z,/:M]8BRD8Y6O=_%-[FD8_-'/
M;=_/^^-'Y1\<%S:]48DA>9!%7J^HAG?8:8K^GIUA$TJ;5$E,Q"$Z=EA]L'Q4
M#=A.%PW@@?,7]67ZQ)PA!J @Q>MAJ_;WBN*]FD..3:9Z:EXX.<RISH1?:#9A
M%C ;+$^GE-$ ;W0"MC:C YL$EJ$J;_*OQ_"2$$4N/DW\JM_4BU$^;A)JHET8
M+LT!"5=87$]>I>//(Y.R%8%%EY/9^">G\T"[%I1F&@!%9F )MQ#/=&,NDXJJ
M?%1P<_Y6&U@<HLM%8N,WF!/&9M;VVKUV(B3Z_ E+TY[P;Z8^>3-)#Q]O8%8V
ME%_X>G*GYSYP_T3H+*G>5IX<%YK.B98J/(@6.?+6$PMW6%AG:8ETJ=1!-2Y$
MRGZ']O&2+D4=L!)$BM^O@WGV0,_ $J6?\BQ@^QD\,+N)KD+121GM@<S^V\2:
MXA+?"W.B@^S8[L#BMQ#\KMSO'UE?X:+TP]4\9E"OIN@ (4$=14NWRI>+K-T>
M_]4JB#],/]^:[%%K";Z2RQ80UJ\0;Q\,S%EM0TEG3,F2-( @CT-T@SG@MRGU
M^FP0HN]R1M+>9O2#31PJ1?Q7C#3Y?.S!^=.%<<%%5X@8$JIG^F!8<#.\^5O+
MA)\V6Y;U1/TV)G *BC!OUZ0GG#1HJ4!64E_T/<G8AO+*4(;$B(>)AV#%X$K?
MJF)D8-U&7^[\4=^CV!LUQ7(6I.UJYZ @']9S]=5Z7_;R9YVHPI<8E#=TVP;=
MN/5N.4I-Z^4;)TML>]Z9";565<>XIR43Y@/FI8W'V^MK_JI1HEOT$XM%BI*!
M\(^Z@/#:>::GF*QOPI(TJ0T"?&_/DVSQ(B]\9(=R?$?9-XD./KHZT[^%S/>Y
M3X8:G.?Z)MN8G7<*"]U9DI*2H;[Q"-U$[F)E5Y:/?6,&T%*@I5QL0TDA*UB8
M%&<YI7\IW&MY-!8L1M8YI$JT$T7C%U?2L_ N9WXOO*/^-5/?DNJ;IMBC%UHZ
M-2D1\PD2+.#B MEU:!L]\*(?J#?IYV7E\'$47'NR703NWCJA!H*@GD::O%P\
MF3GO]+V7:-R9?!"MA\5+QS\-DDN\UXB&J<*A;E[^(DC(>_!Z9%JF(V;S_'<'
M2-Q?T=7@2CSDP]T)GX$F<:<0U(?H!LB>AWWW;]/"K-4X\[(M3+/5H<7=:OH.
M.G\\>K! ?W)*S(@LP7I8OD,/N\T=M6QQ62-9+Z>IE.1! G79&RKE6*!X,0ZN
M&Z  BZA\-R^)3D2 6YC7[KW/ +,:N!!+%/ B"UZFQB$D2<QT>BWQ>F\NMKG(
MMO6'NJ1<,1M'6 (EGC1UK$T&*,5[%-$;I%U"%.ZP=QC47;?HXBW2KD^8+L"+
M[?D67#^QC2J?X"9?:'C9]-Q$R)XW8*R^0LAMX/>$[&HT?0G52/9+H%A0$VK;
MG-"$RWG"%@]G6:(!*9%MN?&MNKX*F?=^1OHO9.=4-0>\J1M2_;C>F(4=$$'Z
MW4N]K!T[P) BUF7EF=Q['_]A(EO1<B@WQ]>IOOIA-F;<-2^RN6N\_.[% </0
MAY@PJQT/]%+TVD$8O7$8)9UY1 ->S?3SPN&RDP,V@8]-#\JB#IB?!:F,M;+1
M2XE^=:J3H>'2:=B^#"$2ZRKDVBT:T!5-J,3SY'K_Z9M5F-)*XW0=]Y=_\$CB
MX&CNS2].,$ ?PXZ^;_V]_R"%\G@/D8200CS$QB,%X<'!1&-\0"(HI?4N[NO.
M?OEXR-S<6555P_G3Z7<2QI6D[W^_6ZSZEV3@0Y K=0Q-"$"3!7?QU,0/R/A"
M$:+HULJR;VH$J#84"VSF]7W!549?T2&53ND+XH>M;W]JK@L^_E*M%;7#.R@O
M-[<P9_;NBDW%:ZLT/>)1@\E%I??JWHT%55FU]MAMI[<W+GJ/W%G9?C!9/5RN
M8=I8V]C83C7=TNC,P%Q>,MT6Q.V0;L2PDAT(BKT&[+)#GUL)T*3Z;;<MSQ']
MM!N#F(?M$XKR:WP^(M/CKP:_\O5MK&&88@/C9J2;J1%BR]I4)[1D#"]U&DVX
M(8NI7>N"XA?"<<A>!%MTA@L!T0,&?/0*$M*6$>R+%JN0YL7D<"T18V?":@G!
M&9*WF%P)V76L*7;[\#.O!BG7!-4\?D#/7RU$IWT58NDMFI=>T^3;U/YO( @Z
M_LC_)57EXP0\55H3KQB?\<*=K0?$LSZLE+?H.>G@K^]6XFAR.B'Q_2*D#F.E
MJEUIX>O8]5"Y >)6:32.DLF & [5+0XYE1:W)]_M#C+&3.0:&&@W?CAHQ("Z
MH^M;*.UALX]%Y=;D0G]:VT17$ID.DDG]I60/TB<\6,HWK[3Q-8'SP&VR]78)
MR6IC_T>&Q8SA&5*H1@@X&2D$G?;U$-6)8?N]#P)($O=<5R^I9Z2%1MUYLZ$G
M57'$>>P/=YBBBI"Y)M7TY>%^AO)D^^GZG3@:P(WJK6]"?&]7)):V[86[JN8L
M\GED8CL*Q3X1>=-*;6N5K!.7FW+,>CL"_Y03LG"LJ41>/*K;^C$F(!X110A?
M\DJ$:Q/9\%:Y$):$8LB',VF7U]$LK6Q5_1]N>GRA3A+5,Z*);/9YUO627\DL
M[OX?..? @M;RP:L-BHYELNJE2HK)"'0!Z)/U;JW/[UG,=,#6',N)+NU VW&M
MK%L+NKI>PZ*-,^EMGG6&GRCI5(Z-1G_0MBCQZOC:-5+!<K7LE@P7P2L)KO%^
M$0R7)($C],.G727.90DXP.;ZN+ESDZBGYQ5?K7\HR\=YK^4,=1&'0@_1F%]7
MF(X=.Y881F/W#1^!-C>?_+SPZ.) GT]@%*R$!A21=E"R/S$,>P;&7JAVD-0X
MI?V0"B>'TX#'&%X:(.S:)\O+I2T1HH0*RENQMAA8<+6V=,YOB8FN07+?R*R\
M="?G=WA#8:J%.D8=;?@,== 2]VQCVEF*N#1L092:EYE=:RI"]8+F=@\F"*;=
M&:GE.'2_['>O;AH@U*I4#MD1C85'+W,>7_9%\GGG]5;7YPWOQ"DV$P***<\K
MP[CC]TL;Z[C)@IB$EF/E(7Y0HW5EMW=&<.4B*=7H8[R$^;Y:&)07TAS"47PI
M;_7Z]SAQT+D.(//*)OD7HO,:"$K1[07S:VL\B1$E'';N8&R7LLH3:^)C1Y=)
M#1DDRWJ+@>+)D&,D'TF^QU4BZ];=R?OIL/MCEJO("*B6V6\SXRL&7%(1E1H+
M'Y)5T(O*_JZ#&XZ^T\.'NUXRZE9:"I3R.LSH[&[97KVSWT+^(F9N AQGJ$K%
M''D]:]7TIV^JK"11V[%6)0@\8!O.4K$1\_=_E*+UA%OR5L>[0/%8]E;04BJO
MH,'+H+YB6V)?"YX_6L]@:N1E+.0^(G4/*N:\3M5M(KXD0"K.3:U.0OVVX+JX
MBI *N=8(NZ/!F:[F]-?!.-9:D4/-?FB9R[H Y/:IMR(=[Q6_Q8",EN>@8I!I
M5T-2( [TM.D;"6&=:TJ0?4J^7 (+D!8U;BO<V.A2L^L:="H(;$B^63ND5:C9
MVDRTG7O%O5GZL2$%Q-7A3#Z&#7SMP 1="+J"B0P :1A$"._=61]_ZI+]9J;U
MS9O\N8A*[$!UFS5K]8W,@I(_;05?G"&_JX7 '>,-C2L( K9"AIWTB5!WB] -
MZ^^5K<MR(&G^U3)13.S%;OTA&./!L1.W)W)TVQN(S$A>N#C!UN4;_'VIPT.8
MOJ7:_*T+PP)Z&?K4M]1N= -HJQ/G@,:)?B-?/KY,0O1C^3UKQ_35/(^U28IX
ME[5G9(C^U:,C"[ (#-KCROZQY9O_WJ:';JI,Z;+T]:]6S6^2E8T>S@31@,L8
M%AK03\]J04?8S!5984,AA&^2>R-18GWQ-*']->JJD+.QSTQX3LZ1=9+J#RZ.
MV1O0ZA6>C0?W?Y7OH&+1C>#MB*A0?SPV'L2)\$()PRTG U;JIUO=B\AZ!"Z$
MF#9:#_:V[?/TGK_HW3%M<.W&A3]G:(!STYBJ'Y2IZM#^6WPX&"2<:/,L+[!N
M[K!VX?3#/Z@H7Q*D.IVL<VJ$8WPU+2NF3YTX=CFHX>&XM<MQ0Q'E7G[E2U4T
M!A-S][65OBSB+/-Y9O93S><;><6OFK8I8M9 47:?^@WT)3\H]3M[;2MP/==\
M#F.QYK)\A.32#U]&29*N#H&)J&Y0$IIK/P?F[TDX*%>,>]C6#-O^MN#SR $B
M<9A4/+'WIR:UWQ^*J,C? H9Y1E^W\6X?)E*=_ZW^I?/"(#H%!=4/)RPL=:!0
MQ4V$ZZ%YM7J6ZZ\Y)Y-W3;C?7BO0;7M"KR$':63S((%0*4^^1%RM*(-@95L-
MRG^&8_P3$^%&$0<NHD:D94_(*1<C9C:]\ 2J<M+BR.*R6;1N7WC5;UB4TS'"
MZ%B4; 9B,U1 ;TU5.?]!\,3(ZZ#QV,<7;LYF=+N>;4I?!I/B"$'?5,XE6NCX
M(HB<'=/Y:MM^]3];W7%SVNG=5\:W*_? /8X/D7@T[V:A*%'F"9[BWDU5&-M7
M8W(9#^74X!UV_^!]U/OF**:TW+5GA'FZ*2=<<\Y:4$K?IADAPHO3J28<]BT*
M)O:#&?#MDZI41>HH]<PWN#5!M[>9+'^CI9VP\&P4K_&8>JH-_3',]WWUUMX:
MR8G(^ON2A]XF++PWM4+>I+I> 'Y@*# 4^.BO"L4MY1M"1*T]A%#V2JT=I)RJ
MH1/Y*J)?.#%'),SV:43%\$) 9HHC>"'ZZ'*(UYYSN7))B)SL!!8YDM.:L63=
MVR:XW-1E#9 =";^UV_.7,W@=-VHAOV^<05Z;*K[PW9<JT_+<1&1SA]=W.C(G
M&7'\^6O[Q\\V;\_>WKP?]R;L(BKLPK-B<9-R<07\]+!VR$QVAG:YZ."AH];A
M1"!$LNA(=L7";('W&PU0?@L:.J1RT/M,)0U* V*KB91( \Q"FJD#-&!I/N//
M=8TG-&"K$NY* R:S?4DS=+;02 ,&+6B O_6QNLS)42H "3V8V;I$)YC:]!]?
MQ'P%UZHCEQ"SAP>>]41D!P74XWI^NJI=;8.^NDJD]D&LW90VN-Z7:(D'\6SJ
M%(J<A]B;*UPP,?C05L$0H!#FR?3CG'918O]TA?:9+Y6]9TT&%D8N8P[LK,$O
MMNQ+E>O/]NFTY[= WH'JD"0E;*\L.UR.\I@&^$)%8(-XL9!-[&.T(%RTW,FR
MG@;XD'+[%X4FR9*X AFMAW8O]KF#G6J3#_C<FP2M'KW0Y-UE(%@_;K4G7NXS
M%"7Y+T6?6083D>FA"YI=,1)CV_R%T:9.,^KO)JK\GV\S&,];23CD^]VZDNE\
M\^<+B[I?2(PUE8/[V#0&&Z-#",L^]B _FMY#)#2SUGIEF!),'X>LZX.6*EY9
M<QVM(+O3-.T)Y62%O#T^:X,WX9B=),6II?K,* N+KV\+WN8?[=$CIX+H!"&6
M"A$\<,%BZ@2Z;K1G"($IQIO\L&\V)KO,;-D:HTE1P=$>Q7<((Z\)WQ86FKK;
M0JMJ8D8K+*L&$'B+ L-?9MNAUEL6N](COW,/VM4S2W_=+I:TP%SL*[9W'K[Z
MR^H@;$&A9BM/,^ZH0%SI>/Q-5GV876V=OTHD90#3_RNW:Y3=?(DWG@;PZK-I
M=[D,+64PP2RZ+BQ<'QF;'\ -,UF-R^ DKDB5C'J/Q'<\*!$!?O".HDAJ9_O)
M C,' S)(KBU3JBM5&#5YY<-%X/YQ9 AJ"$U2TR6_FSN@)U,MQ)T&5*#C?7_Z
MEGS<SQR+NN00=D.$PJO#LU_1U)*)^*-OO;M&#P,B@S3*^_W+GR[J%+:.\#,0
M27)<%%3PDGK.<T5\N4*8^J&Z_NWH ^O;Z9IO=CMD2@+3+Z%^FY DB^ F1-,^
MU-,8,9(!PC";&-P#%B1S%I$UIM1"W=XZKV/Y&L""ZV&NW)-J^ZN9YXM'O?"7
M0F:7)S%FRQ.+6BW^78K"%!6+8U9$YT"O9'@_.LF*0V\+C,'>9.FTX8@]ZF+(
M5FNH;7'R#7#V@/^R3ZI(++<[WWVWIMSNPFKYPV*/FH*CG]LT@ M;GE(ND147
M>I+SM*1%S2(B_&=,6\P@DF"W;7'01D>7"/>DQ.VCGE#9&TG12THQYYTPI 6R
M401>$BE@3$#UBD@(U^=2I='C(\_EI_*\FD,MDL=GBY-Z?@>M'3I=)6 3R>>]
MSB!Q;:*FW_P\"WZ5U(V%#$DK3_WR,%O.Q&UOR<6>R;N6<CK"@;.V+\7)YZQL
MIRQ9$EU"RK_Z=W^\V2R;5MT@:2WN30/8#?4@A:J-4ZM1:7:\ M\WJ6*-,Z<F
MRS,A/PK_A%X,Z)U$Z6\KX!9*GW\*HU((;%?8<*XC+G:P/)X&<"IFTEP+)596
M+0YI)E<%/G"3"'66;U(%N[@T39*3Z0_:(-([\D;*^W[*57UZ@U>IT3E%9H[I
M1O^.0-?F4M[8=Z(H]R*%$0A9@@OTCPEZVYP&W$<R(C:&"*$(>G/W<8=<"-TJ
MI0%>P@1?&F G$^]J!Z4>TA,3=8<&[)]2=.6E8)JJ:,#>*]F-&;+[!F)/N&A9
M@$OG1"<S_YM8^GV93>&<W ^I0%-B1@4-^&:'!-^(")R-U/A* S1&22JR'9:2
M!S[T%WT:,R'+"5>['S)ZPG19!2P.LQJX9L%=F$H4[3X"IQ5_;+A'LC X<PQ&
MCV_A&3@<9Z\]%9#&'GG0@#A7D+=_>!^8,48O9D1O^Z_<' 2KOMM;V$QGEO/\
ML/Z!H0P)R5HA4OIVKE?)(^[F1Z)H_$ZHA<?C=Z6C22CCLUQ/J;J(SOZQV7*R
M4$M/FA^?I48G#8C7>"\TE],L\?#MB]<ZN^BMU  T:'2EZC[\B>_&#DD[TF*?
M4@;R.5O,%?(EAA5F9S$?@-%8)N[70AXOKPPY#52^>-%RHH=/$ZR2$-.ONU)6
MS6[?8^N#"1I0TK#0EL$4SU1]^7AG;L'V6<UQ"5H:H7FH2^5A(4G1 ''Z3I\O
M*]3@='&L 1%K>(K0U-?"Z&:NH!,C4;AK3%16?5:*2]-7P?O[''A=OV(W ._[
M?@+4:T\6*%[^2GE#;QN1=:(]0\.WUEVE$4G3KNS$[.X6M3J8-5Z[H3\V]&&K
M^%V8ZO4OD$KNN=AA-Z[M.'YZZ&]:IR)Y]U I-( S1H&L,>-?U#)F* ]CZZ6R
M3%67 YT&B:E:W*976])OS_@:P?]X_LF5?,+%@/K]@#CS5-^4T(27?09GJ>D.
M+":UX$:?M1KAU!ZP]6-"T/PDD%/S./2Y"+/6M&-AX5:)^LS9JCCW:O_\"IO>
M^\3S$V:]]?4V<7&6Y.JZ]GSOO%'FR?6I=[]VHM3S2O]HUQR@7U._./YJ*H>%
M7YMJ-:J:/YV>5;0>F=#PP740$0PIA^1DN2[.FT5NQXZSE_EQ/2ZX1,_7PL,M
M6T*0+$G%BRQL>Q!'#'_6?Y#[!&[M>7P=?A?M\I !IAK"'=GO0.#M4@%K"/9R
MS\1KD%V66K;UE?Y2[ [,]U)CZ-_+/GY$Q;(N4T]$:VRKE6_JZ-D_0T,TGE!Y
M25$EY@^(?Z4N0U.:883^]*V]=RF,B]Y'<$/=S\].)4ZLC+M>9S_=)*M, SI1
MH+IQDOU!%&GAV&RC^5;#)%45?J6!(!N_K]0I*BK#10KVJ,4.>]_3.!+&IFIO
M'E^29GW8_.V$>](ISKFDS-X'A#O";^1EJR:GU_NSWY?-A&TU;*ZZ6Q2FZ4T)
MKF3ZY 4<79ZMKZ[YM8A$$)MPV[9]V#I$OQJGT[GV;*+LDD9OFJ:=KSN:PML'
MXFH%LRP[?;*1,9MQ'-,O!YY<8!UAZ$54YG99)V%,>['QLMR&RC]YN9HU>D89
M8)?[FRTZ=0OX)LC@MQ#,?I["9Q><W*0P)Y_8EJ>G_1^V/\N(3AC("TVZ!2+<
MI@&I,XYAZ5J($V1(_9BA%NG>26BMLS4^7[B.6/5<!#B)D%DW//,E\\3(5Y;!
MI]?2BMF.HNFESDB=BF1[1L_TUWW]O9BW'Q&S&G>(R*>M#E'A)V';^OSECA9$
MSJO3[(\X'# PQ-W6"0'MDZ=HP-.8:U>%SKKJ5U/ PLG=EK..ZR&KI>J%5NKK
M!]C2IEZ4[XVT>YL!=]=VSN[0 *CC]*\8 43G;:@"I0F]U.S*1RGLV:)*?#,\
M!>>BO*&.E6?46_N_31U6Z<'R0XN=:U/3E#=[8]32KPJIM7Q'O6%/L58Y'O\T
ML1W2(JEVH>]TPI!57=.G^L>!4CJ-'_NA4#ZFQY]Z!7@ M2??'ON2KM%1<9*\
M["D5Z*5*A  -@(SR&9U>0<7M(5/1XJ&2!58@0QCY-M'4.=>(L&5%8M!PJR?J
MM(1*:O UYHTI\RZ\I!)K=7X\*Y@/^?'D3=#Y=,-L;(YZ:'+/@.-=HK#J<1>(
MT]6I=-V_.L#/=B6D8I'\$5V<G>6R\PYAF+[V!X7H?&0(\@7)@I9*0+)I*]@"
M'/:IQ#"ZTYK5L60XD*4F=^ER:,-T2<;I,8])N'L$WFG]*<=KAW'%"ZV^IV-&
M$)U5"&!O]BVE' 2)MC9OR+>-/>RBM\VMLI6C,L=IA@M^- "G1FQKR!>>XYMD
M&8V3;PF!:N<,G#Q]ZZL"U8T&^*&W94F^* SBV-F"0C\KN!F(<'!RTJYE!_&@
M^0SV6="]'X>7_B1?TJ:\IQ?&QP$.^MU0'^;>\9PZB> CD]TO)SXV%$S:Q5*L
M<U@1//LK]T%1>2.5D14/%+(;FSY/N!@:B%I$RE?R'[>JRDN7B_TO-L[]D<G_
M___KU3E)R5E9A22GDO-IG1!"D?-AE<2L67(:9BM"SN583JN<DE/8R&G+.>1\
M6.8PF^3,%N9B,Y^]OS]__X!MUW4]'H_[_7Z[GL_GY!:SG$C)GMRXEVU"]Z%6
M01[; +;I)_4_/U($N&89?$K-GE93M?N1*XX*[*A+)33((P51A2UVHIC]H[-\
M)Q_ 5)[Y*0G<__XAW$Q]=O)7;V!MX!85T!!EI0[KG64;H^UVWQ-"'=T9Y>W@
M_>8S.#Z8ZLG^-A[D6#EA/2V?\5UN42Z>+NZY/IEB]51*:FA&V]ZN>P,+Z!"'
M[H*%2&ZQOV/B79'[.,Z$AL3 OMT/"#KX0/?#-DB$ 3GPRQ?M/W\>^N)^08!S
M;A-R'&$SEO?)X\5C:"<GW/O$C0  ,A/P&$2KN'SS^?-]QU#E*7:?LK6&AG"G
M194G"-+"LHUL)TZB[2)*+:.QJ',EU.U)^>B6:_4RAF=834-@O%&N!Y*MB>G6
MT2@,1#XJ;BE'PYGMV0<*=.'S&^Q"1OI+P^F;$M@JE\(X[]+/+]QBZ'PAU48?
ME/XD,F]QC\0SKMT$MGGD(+N+0T/H<+<06M]^ZA)59%-7)$;[$?$[X/^YK]13
M9$OA<L/3GH8'&6=J[C]34&I0>09:KRD<)S%\J3A>Z1<8Y%\=29"GR*-\KK5'
M>=EFJ]57!;KCY50HWH=^U8=MJESPQDY_(DH'I4FK8GI))QW[?XH&=Z$MIV7>
M-N6@^ZI,GI=6_?V7<9=37T1.*LULSKY-V6E3/TL4:U/+6*\*]J\Z(QAY+* :
M/US";L3J$V<K=G>^KO1I]QJ$2V7AR'(3@]\F\H.?G,K1ZO/)4=6)&QR /@B2
M6]?? QW611_H;WC$!J.U@=T3[Y\PTYNP,12CL)VL^_(^T]!HD2W'@ IW/_;=
MR D4SIP1QW"/,3R?M7PQ\!$GB?=\M4B>*QZL^SPN\R#%92!:F?_;2^)7S@^T
M=RE$(Z9']01F'(PCT/?=T=+^#KGA%B/Y(PB1YTS#HM_VDT(JAR&3B1S1RJG1
M&>Y1!-N8[_V,[VFT9L9X<+&JBTKK'NC(D1RE'_1[XLVI<P?HI)X1F1PY!T0L
MWQL7V6K*B=D<3;O7GS>/R_#A]V4QH0J9O0]\-A9OF?RS+L9J==Y0<5%96"<5
MOW8&O+Z%N+1!ZTV69H."";Z[KZ4?MHCW+6W.?6J:V>@\1]Z.Q38]ALS*@:LA
MNZDAN%UCO 3/_=>.&WQ2B=R0W_0[M3CD6?>D+@,D=/$CZZ0Z_:"KD&SGN^MG
M^ G<IQ"&?>*V2<=*XA[(W97'!O=7#M7[5D])\9+@W#_V;JH1E9Z %F#B"A>Q
M4"H#L<7)-;O! XT^)G(/9&$KS*906[@,+@&0Y0D+%=NEA@>S%?= (KS@./L(
MVMBQD_A78:![#S3QG+3Y%_PN4AH8@;3M2&\G\/)=#LEC\G0[N!+7 J%<'IV:
M4A'E2  ?"E%6+"9B6E23> 1(1?JX^;NKC_;A&X*QT1LD@4G*]=[^SY.+5I<5
M:GTY\9@F*"&@F"W$PYBC$,_8B\-/!SCBI=V'XS<0&H^$B#(,*8*'03H]GG]@
M76A%/[Z/LIR;>O;"R#,\FW!?MN09I+8/T+K_$ G(]K6':]]K::,>B3OX4J:/
M%YC UX^=/L=A'\_6'J_7.PV=TU<M-F+O@48B=$F6"[@6]?7MKZEGFM5A]>8W
M4]9VYZ>N!HRX7"I?G/OTV@OE[:#0UF6W =-%?JWBID7M6')'IA0M);@C.IC7
M@ZY-M#W0&)6&#D[],]CE-B#')+?K1N>GV;W&*9N;->?L9UBMYEP_'@ ^^33L
M@DA0>#!I67QZ(WQZLJ^M&U!SBD>R7C,U/C&]SEIR!<UZ3ELAHW;R G:PS?RJ
M7#&EVY_P:Y'54E*U*"F[!"4SVY%"4$_@-<VY]':EP-;@]@]L%]2268:^92M4
M!*,&S/V8 DU6:Y4V>^UH+O=-JQD[USN5[H&B2@DONTZN-J3@/G2;L!&T4)5F
M*2'&Z"L:XC(4=*, !3<<Y$ *K^LI7+%75',24QO7>L"7_*\-B1"\M"P$ H'L
MO!U$W_RJ^%WX:T0^Y'*@!3-NPF_([,L@8<T/]T&LNNC1\^''9-+!R]$.D\7J
M(8MEL_Y/D@F$BG$$='NND L^27@)45%8W\KEVP/IX=<3GF/.P\_,9/GL@WPJ
M01)06"ZF83\O,^#W0)QW=[P;=",G Z?]MYT/1[6<J)1.-7!^\^3#,!X1>6R)
M\*9)[$^HH,62B69!M.D:;9V*K1^<LDUC*YBOA2#*BEUQ+]8*<S@89N+R+@T;
M]6**.\0B_I=)^S3\Z79L6W4@]*3?!_\;0CWBH=H;9V_GO;OM/O:"J?I#+"I)
ML*MC>Q(H+:.B;S&C$M$(M@YJG741.,J(;2:GU0E$-?C0Q/&X0V@C1E_$+"RO
M\LKD.$I0)3JMKH!TJ2%I10],JRAR-O8W2/ N+T'HC9&,N-KH@[NU7%WT]2&,
M9.&*]?3D_FG%]?&)12D9!C*RD&$<1SBR>KJ3.*@./N'Y;[*[U+D]GH<.'M%J
MNR>P5URG*+G-2C@FDGL,PM9#V;'\@9D"P.Q'AG=B 4I'Y2#J13OE#AI9@,IL
MY9X?74;,6IY$E;<Y7JI/=F!,Y9>ZWHF@-U2:J\YUF6PLU/3YN,/F:?(W3"[U
MZ%2.%,L;7:T;LLE+GM0EC&1IU0[[U#NG?-Y$]RHCS=3V0.E]DXL^1/%A@P.>
MP1%E$=,"$5(JNV4&UQ872;!ASA.TF<>T ^>VU-**-6#\0THH@]PQI3DH=XT2
ME 2,6P\6$M/ZS?P+G1RG]!LP4$9B2X;<FSV0YZ1H"U@8(P(,N1!&.;!23\QY
MP))1W374;' EW(6$N'ED WQB0>=[3?5 9DM=ZT^+1*QZRCT8Q2\#744Y&$HQ
MV+_[A:B(UF$(8?DQ LJQC%6$^Y0^MMW@^( TC__RZ>QXBX=6@Y9G?I$Q%X8V
M]D"7'!P<YJ<$DXWPC[R2\*<G)YR[-=^C^/$(.!WS"M**DP*2?U L<NF/@NBD
M: G_R'RZI;#GZ3X?I9Z^-S-5-8V$4?6SYNHBHIK6MP+JDJKZ0B0FIFZGK>\T
M)+N.F/CAGV2RTDT<FOF,-@>OQJ[!<YR_&EGE#>/_)JKZ)%955>(+%>IE&PI6
MDUT$JN48A>V)K\&G5C#'.$),5N%,L1+<H2X,.M8W\_25>\&BCG<A AY8LN!H
M&<\5 CB3P&&'X;6-[L<4XVB.>&C1C:^N>CYC7CHNO9^\:G0-= <:Q!EV;1B1
M$9(G[C>93EUFTL=CQ_61W-.DL"GM<)/^:2)JU!<[33H&C%]G8L,0RK<7G]0S
MO@():A50U2;7=K6$B=!]S,OK,]0F:I2C1M6,O $/99MND-P3SW1*Y0LDEN!W
M;04D['\#QXGU>8FG.(:#C]([,/R-@XH00AD-X?2 >3;RG>?.;!K[CDR(0Y6?
MY1G,$.D4\<P259AG-Q Q(',&W"QPY-?"C.58[DP1([UM[11*<+]WS0(K5+,U
M:7&+J\](?17]L7]SGC:H9W/:<2(OV(8\)L=C@R!3)5>]2B]EKQ>O,QT=K:SN
MO<Y8L!) J#6RL\[EBZ24BZU?TC+Z'+/E_]I=W,*''.QK2_PZMRSP S<>PK)B
M'HJEK1WM9ML[ ^NM&9/9I2P<@GF-+=?$E?N6H:^[8B=A5/059=R,.=7/_\?R
MKR+=I#QNRZ=3.&7KR7GD=R6DVJ019?S>8$$%<0A96KJFB!1(5(_U\87["_8<
M[SZM&%=\X8J?[@<7<6>I.^ WI&^6*\5L/0!GQ>T%:AARTWT_!&*[GU4NX(3]
MJ%$Z@5%Z<O2EVM4#4C8-3,^WI CU4R<&?(5V=A:VXN)86U=-VYL@WM-AW=9#
MZ:TB50"?]> JS>DW 6Z^SU_2Z;M[DRA/7:"]Z?)R![HE?TJ&UPO_M2M<7M3Z
MUZNS.*LU;(5HFU(M2/+:"J6&Y 7VX_!AZ/ZTF(EO*8HE>)],Y =_1Z]JIR15
M>2L->P$L8*_3M+4PZ[NQ-DC2AB"@1^4B]4(9QC.8;%BNDW%0T13Z./"N"-M\
M/^AKCUPDVC-ID7IB-DGA>^K=NL#674WS?OS8!Z:W7M#7]E.4[3'L=2Z91K_&
M(H&FMZ1$,O= 2<;KPO_65HIR/0TN[J89:-[PYIZL&T;K3V?VO0D^KF,7I:Q$
MN,A4:6;'(M],26A8=_C^-0S<K:7%ZUV_]R1I@+,D?7Z=B;=!2UW,^CRY8%*\
MCKYGTO*WD$ ,M#4K%]"T:)0O%$I)<2>4*BCYC01OC,#A/J1OHC&1L702+]WL
M+U/Y@\)C3WJ2)!I.Y__\]'"H09KI[J\+/34&:Q1(/MRF<A08<FV(#E04!.K&
MMM+J?^RJ6N"LN?MW['BCLS)SL'*WQ&#_TLX9!<U(XA6T$I YW;G6="K=?8"C
MS?1H<M^2AX4M3(DP?66PEXR'95(T7#A4BKLVN(^S!\*9TCN+=7X?,[7S_3Q[
M$[&9HKAK(*Y4/LH*5JK #U\5A,&TVDVFMLS]@N<I"&QJ1)YWU#PV5<E'2@OX
MP)BAI;Z6*&Q-!*.NT;@? F7Z*8L&ZDR#6!I<LNAC;%^.)+SQ!:M]*NA3^-9@
MFU#B!</URHB_C9J7VC3E+^77(V0:G0;.%&E^M@M]QWV*9=CV;9M@5XIYXT=J
MA>S<RB>S+'G);>XC%KBH\G)?!R=E+7;F70Z$II2<^&E.?WOZY4&L,)5A#3V#
M,J;;<83X6-^9<R_1MPI0-4U$.:";[K0F@$J__=UI4MJQ,D%7X5I(P62[7GV]
MQO?J#Q?J7N-/?SWZ*.E.CK;DSCHO\07RY!W[DJ+".;T'XJ'O)BD.RN\'?D.!
MM*E$'_V" KLRT\(_HPJDRX%(A953] %UIR4S]D^"$_R[1'O()>7SWU,SIK3Y
M?UFUXI12.XVO?IU(>DVL@&FDN <UM15LH,>+]6W)^L\>/&4,)\65E?Y*"DP8
M'T=@3T]# .U;W*/K-)7]MZ;7QL-IHA&*#?K@-QQ#\$NNKCT*>S>L[VX=V1\U
M5\=(;#4;AZLG*(3>NI\VNMY"/#^,_NROT*D'46H)K83]_<Z9W@.%[<>0,PJ7
MR>P 0.6'1'4=!=O<1[DC$,%5KJC+\,TWI-=.U]8"L++2[]E*CX:'VB#N#+SC
MZW=W'@VAS4./CDE6J6S=8OMB>D7 !/)R-K.;A:Y[ZS2%OLE0+G*G%;-^1Q>B
MR.;_-LL/+@KBQZV71S'R0WX?UNQ>!%4K^(JEZ7,?\YSW8FX!V@38SWRZ='=$
M25U@/\<.T)T90@;" T^*<L69?:\VF]DN^SP+$!#[(70K*L/,Z?L[]T@31*$)
M^&X[W^'8%CI-4MY",#NU;"@FQ3M]W,PFI";D5.1L:521A<5Z_+!_O4D^S)$M
M-S)?6@PA7]%XD.6W\E-_G_8!'H+=.(,A;(?PD+)@#Y3BA!F#L,P5L9N:C%)/
M;AN4\8"7;S59=0"$IB(VCGX,^$XCWPQY!ARFBS:OB:%J[C!JHM&R]-=O;A4[
MWG*G\W4?'L'#O&>2YHQ&U6H:JVH'Y_#7S/GIDXY.G%W>3Y3^[\6#1S$2D .O
M&$[O9U;10OL2&MRF=Z^U8,083S-G7/;;,BVJ2OOHU!,N'6ZPC[! <L8G!?B!
MFFN62B4!U?U&3[_G7&)T3!3;IC (<A)OT<.S<%-E<D*?4V$@7-_/X\!Y=<>C
MS69I,$T/9(S.U&A--J>/!N7R$+=O998MDKA3MS8&S"TPH<VX7M*(V\/GJA9:
M6EO6'=Z_SX*TY]2Y]TD5HF\VP(<Q8SPL@L:AK8L7N&!&>20$9OF*>X$I^L;?
MZ7T)/EOTY@!7!N5Q;\0?8<IZ:J^DJ*B(\$8JE[G[)TAZ/OGPVRB_>%=&E'L,
M]K]CAJ#][">8/@7N5FL??SG6.G@?1Z&CT^MFM@ZS2.NF5:F4C?:EZ@R[62L8
MX6^U[M7^%REGW.1E)6N$*,1,P@Y.C=L+9MR!1D*KC%>&F):L!<9:&U5BB9>C
M/D#:%.I)41D%4;1QR^/S4?3(1CC]K/FS32=UB1(F+%VD0,%22\'L=.3WQ_,.
MW"G C WC=H&E]&!%'"W@*OLF^B* F^D1:;D_HHX\BE)I=[2H+[.'40Q7JC.+
MIB;L?_<I#HS;+XJF5:>K?N<[7G-%8:;'<7N(OL415F$=[#<00IN-;I HU.F
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M\9>+0Y2VU:@/=C7[N2\X2%YB^(*^VE 71 1CR#E: Z520<<U7#4!**U/I.<
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M@>^%HY!13=46O^'Y( 'ZJ3*&QB!_0"X@!1#B(ZU>\T# *I*;*CZ44#=S=^W
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M0R$4_DZ>J=\;GUFK&S6)A&<9@SB89\9+CU>=^C0(8NGUN)GTK+4#A?M'X!-
M)YC2N4+J[4%%'8()1YOG.K)Z([6Y$'KC?C,0$'6[ZV9(S;91A#+,JXY(:^AJ
MMLJ_,),;11:TE6@(!96Q>IA/&K_O]>+=:#MR0!@?I]%!/B5P?9#(%;BJPQW"
M B0R5S(&)W()7C]R^X'6>!BS=F_9=&E>W83<@JK9Q_S85:!<=WKE4=*1(:I#
M7O/< BI26X32T"$/Z42Q*Z.BFM'=*$XHT:GL5$2.3@#\<_#T+G!65U>8I5O5
MF.]>2( >KJ'>/@]U,34KH0-7G^Z5C,_2 H/'E#QT34?\8((YJD]&O+9V!RW
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M.:Q/N18^0 )'V=FF$-K%H8B/GC=K:W]^SO$S#@ E>L4@>>A7:J@G@'AM8>2
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MIA/ [S2FG!/ MVF1$P D@Y%5;/AA34>=9L!@T1W:*%IX[',"X)H[YWL"J&X
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MMTCK]_MBV5==07L%\@S/P?LX;L)FIK8O8;7*VMJ6D?'(J7CP1C6U+&>.JN?
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M[=K<QP'\>1V>"M7DF\&+A8K!S<&+8>0Y/A$%'>.BG2K949F&*?\0D%)=EU_
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M;SA)QRVB_-;%].C:FG>UK]LIAQP!D.J/.L\>"UJI<IHBVK=N$],6VJ?@S)E
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M[_C[_/_6M/_$9J,H2):[]EE:FNPVV;4Q&AT9?.2D[7\Q*/]O[<\:_5TR> @
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M!4=N= B*OA@4&;GQY-G T+-7SN_8N'OG3G,@XL*>W7^[5&R-""-+,83"GUL
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M\_"P 2BYP3MPF.@H)C]$AR WX8+9H:7B R5YNFR_=J9HO9MQ8_"TO5@RBY*
M5\:63$;SU'4$<M2I)3I&(-?"S(0,EJCS9IG]OFB"NHT< ZKJK&0CNO)<T13P
M%LZ:?4M0-G4PI.=0OUEX_Z/F5PYVU-GFW,<&\7.2@1B3T=_!C7'(6*\X$H.8
M=_X7;>:W$" $2$-+8"@+<PMOP-L+Q;'WM)%WL6?:QMVZCT)E3#/E^=R8W)9)
M$U_WIM J17@'1_.'-?WT\'BS];/.2T\^/)[$O7D=TTN D4V%0'PQSXG_ET!?
M"+1%" R"*<IDC?D 8\B1>XBW!O($0QC'H6@F4LX_5,\$RJGX_&WU6 4;T6FS
MX=F@M>U45=R6,[3RF8[\PFFZO=:GZN]A#Q\DKNJT$QJZ>1K&G'7\I_!SR"1"
M$[&3$4^H3VYGC"UY#Y'4RFJIF6)&\=:.H#/+G&YWNZ+<>]3?EXI23K6V"HRM
M0H]8Y5EE^1T<3O='R"9]E3W^88ZSW- P/AK'%ZO"Z[7"^Z9I(A!0\<X8LLP3
MR \+ :GL3 X<ZN5&HXD;!#((L(43SG_> +N1P[,8P:O-9D-5K(::*I9OJ+.S
M;J#W(+.IOC]269D>LC^\(&05\RFJ9WPE+V=.U5E]"V((,\K@_!3%Y3;.0O1^
M%R?++Z1<1*8( 0E2%#C/><._\XM"MVW#:X-6"5_ I+O@,4'W<9I% 5S.A97^
MW/3Y$^_9D57SW-6)AJ<(@M3[W?P:"<G&[R_D*L:#\W^WF,3@A(#)D8G"%9H_
MI98B<N/Q_O/9!JZD%\VB C'@\/W(DTW;4%>-KC]YF(T Q$.A?K863U."\Q**
M8%,X;FS30JXO;S>_U!QVF] PG?>Z-HTA9Z/&DQFB<="@\DV>'<O!O-"4RJ0L
MFCR!8H\,\R*F7#8CFF\M3:?]6!UQ_E1V_UQ^KUS! CP97F_/4Q_D5(J<?"3X
MC*SKIF;2K9C=[4NCF9RCT-W)0ON @5^81!^C5!**A90.C7&()2;[:!:?3:Q6
M.YTT=KKE%5NIY++%8F'?:.XH[]G9\D+N]]S<V+&^OM7/)D) IH>V2BOK^^8^
MN=)-3(#7:]YX"E5-)G<PI'GNX$PRR;4*:^0WPE.K'IUOOIK'&I?T+411:4T>
M;HX;]I<_,%W,GQN^#8U@[]VJ*5T=)A01>*K*G&5H7+FC&B:0R^'N@U;L^$2<
M'3N0L\1_2-Z*.P']8O$5[-F25C9*39EVEA1Y@?9LS*_JB<S8*89*&W/1Z1 F
M*\AE-<8G[/T$YIO68HLH;6[SZY8(%^%TVF3M0B][C#GS&B$KZ-SI'9P/3R:Y
M@PK=\'4D3ZX+SV&PGM@T7[2A98BWC6FFXH7=,B $3C82'0:^&^W7K7^!0&_Z
M;![AYS?JE(VV:?'M:Z30'OL6BQ*32D!N(00-T2)OZ3GJ!MZV0&7;GTE)N5YW
MH&[MDR</<\\= E0=Q"E_8=+@X*E::)O6HB+;2"!G!_9Q0FG6AEPS:(DS"^UB
M*Q%2F[4ZEI+ZJM$"6?;,S=H&YX.^'8UT9$HDQ'/(Y5B28:):I31[8E[J$[G^
M-GOII!QB.8)MQJS(_(7\%-$-E[/9P8OL-R%OF4<"N,.32&W!QSUC7E@)*AM+
M]0++1C()4[GUM[_2NZD^)X>^WWK7GN<:ETL#' R_YD>/K393YC3I?/_&Z-G!
MK\XB0C(F!#B;V,C.:WAI;"BG!I*KP04D_:YOA.+*>2Y@ RT5=LKCU/Z@UCLQ
MJ5R/8H.H] 7+/I/^.[^/J&W<;E/XBHU*7"#9E6./+'7XZ#:E_:HR[K5W (=6
MR^[X<,HJT&-X!B&PU)HE^/KN?;-)[]!.Z[5UQ6\WU0&$OM@CD.-CP6NB#$D*
M[!;(IPH!R5)0JX,QFODZP 04-#")T%;,0LZUL^@I2)_8$1;%I&A#%2S/^-K\
MI0X/K14M3K;O+6=/<'%\>8]71WOL8Y-ABB/)]:%@$+86/CG5=]/&3%3Y3D">
M+J!'$U</,F+-)-1:$,5-*U3XN64C$RN^D*?UZLUL$:^2,TJ;;!HV^\(>;[O]
MXV/(<_.7L;MTC04FQMY52!&L/EB@@ Q/6\*8S8--[ER=&H) M4^!J"8$VM6M
M[8IAZQ0WSL^T4T^]L-GHO\:OFLBA?F,%XO//MD0U^L[<""NZ<LY;(5Z&S617
M">2% ->;I\=>HIJE"G3XM61-P4=-/6-^G3GFALU>2!$D3!ZKJ,+WXA6A"%:8
MYZGG@SN>$D(4W:FKEH^J>>XOZ@?[ER[N:-#I08?3.:'8+PV#Y=XQ"&EH#^=#
M@D#)B%]G[<SLH[NW^P3E)5!02 F>/3O@?C1(I_.@],DU/_V0D//DQ+V?3O.E
MH?F*C-$R$CMR1V;EFVR$@='[;,UHS\:6L8JBEL62GX-GZ@;[:"XDT@B-8LM5
M**9D1(IJ"TDP[B):)NMF?IURIR),H"T&#P\EQO=#+R'1.7$>IIS3?775";WY
MD."]H&M/3:$QG4]9(%S<:DW==>]:PRRA:8:G[BF0MQ!11DX3.X]ZA_^0I,@5
MQTF 33<$L'FBC& ;SH5?0/)GVS-IW;V^OJ"@\#&4Y!++NIK.)*K.VB@TU0V'
M!]6W7.\,,6\).KO)_+F+R88>E]7(T8/-JPR,_V%C^@AMN4$(P-M^(U<7B\DX
M_EWKV&H>@E\H4(66.BBJ>$U< %LKA:=?@0PEJ-K(D?I 2F?S?67=B4JFRN6H
M:Y<UB0;/[TW(5?S4;[[-VJQ([I<D'!Y<ZVJG#HBZV"2E'K9  _,X^2"&)SIG
MU7$V&+UVPJ*9'-1DWUQPE-UW'6>[MC<OE:3":I%.]P Y#8%;'0.+/ER6>E<Q
MNE3]O=H@5^:W&A/>O91&K#/KP,@+>BB-)YZ0]0=)OGAK.'>_8+CHZ%5MLTZ4
M76 %[R!4N<8AUT8#>HL)A>5)#9AKF]V>RO"?K<14%E1Y\BUJMT)C($)T0"B"
M@QT4.;(Q]BJM@ZS(MGL8_V/@W,?Q3Q.'6'$'?/NC9)W\9[6_9V*SD+/:K3>?
M!7P*L-T .CVM,"_C!#TE:'RE]-30 V8..IGTT/M#-+(=F\#A-"&0%^4V3C#X
M56CU%*.U%3'\K?:#\BAJ2CF3K($[.40X2Z$C_)I'> 1FJ]Y4!ZR.UCE^)F6,
M<Q/:5]'\^E;<U0[;RVQ?YO(Q7;/N7%F[D8HP47TXE[BX9+H%V;_JXCWVE1C9
MN^WTZ;/O<])=NB[E=<IULVY6E]&.U=_QN>.;[G+'U6[SH>*TK<#_T,F6_!+"
MY$/X"_N%^RR&,J0UM=0Y;O6ZR)1](MTJ)5)7VE^KHWGDT>/@QA4SE.6C#7JP
M_E_'O#:_NNUPO_33E8S+UUVN+5&5H>W="V)L0K<VC$J0$@S8*!&TH?SI':1]
MC["W!SOTUA#]R7?C;<^6]K(6-]LU4"A%1YX?1F&L\]3>O55W)=U^$IKK@KP[
MUEK8;#;4QGK63WR1NRGM<7YZ^5S;B>\C?C5^-%R/<Q3\R+?BM)Q+Q2^%0(K>
M03"OO4\"JF/99T85$)0@X]>KTA4L@OI\DZ-Y+OU88@G];6QEB%H9*>($VV?,
MSJ#F6:=!AI9L1H?$5TM"@];K K[SY(DL-%O!J<!51!UON?M#^A>?(;^SO]\M
M"=Z)+7!O&5Q'E[QA$NF<@OF,;*BJO[)]4_TK)[35"TR_30&_PZETT^*V+I,Q
M>P-BJZ'LM_%?.:[^7P8^K\QM+<XZ:Z=^4NQO76/:1@=B@"V=#'6!/DX=7$J_
M: %/9<C7,Q1#)FS TEWC)BO)YD) :^S@3')X^)=LR8:LJ /!=*]$TL_=6_5"
M'FUT#>,U$.(HEC>GU5D/LJ]<30LS,D(9VQT<S[GJ,VKU E7EZJ?<:9:F)PD9
M@S\[*1KX+5 \K;U(##3-LFEEU:H$=%\VJ<DI\ZU'FWSN][$]^#ZM=D>PJFQ0
MUOWATW(6_=C CGRC#-*^AU 3U9,=0M9EVV26SZ]J5@"7I1^5AG N,69ISU(U
M#%0^TQ'J;W0UXE]^?OC%O:YA-8#V4W OPKX@>_Z^*4JG)DB3[E(]$&9>U%N>
M^_YS<=H/3!IA UF#IT%D3C=U,+2\(#="&F6MN5DB6>PVQ_@5(H44S?+,,D<J
MT_G9$Y/V$;A^!U7?',474EN\_XHXXM)B,+;0<';;L6WOW%S3QM^6WAV_._;"
M,R:FJ$[$R-?]MPKR/W3/-EB35>?2NEDZ_(80N "/W]\R2ZFW6CQ<.0Y9M>>W
MWMO]F6<.Q:%4^]BV4XJLKG9G+VL8L^)E^N'"ZUH!)I3^L'.?)RXP6@VR-MGG
MVGM-W=)VU'US^N@A[_%[D]N?Q'L5 9+YO#?\E,@NB,N.F,I;7&+)EA:-L31+
MHD D)RIM_FOF44@,9/B0ZN,B3MC[M9EU*J^WK<06_3C?]G(P+-+A[;:UO5WT
MMXL:^/R6V9)QI.<7,H*HLLW&:6V84UV(F\]>M[033P>_+4R=, E=/Y31#,/P
MY"&C2;/1,:9]@HT2SV* Y@3FQ=??JY_?.=-+'JI==_^72[17R^;>(8O6B)/9
M,^[##7(]+M&Q$>8UGZ\?#$_;KM,2]OW7!7;&68UU9>LZMW9M\S:XF^U<[/ ?
M?/<:LFLI0P@H$U#$FP)K:)CM'M $SEPGZV)C5CKP^D,S/?"LD!MA]5R%J/=-
M=')MK&'CW1)TX]R*3V[5-71@F$Z?=0AA'TY9!!K/@LD9A,DB(: D!,+O0 >F
M5)[@ MD91$6!"D]BL,%E_WR7P!S*? () 1]0*\%Z8W/9@G9X0=GXO)6V;4C,
M\/B0"X8Y)OM+;@/2(KNZ^SZA[9B9$ @FJN('X9(D&T+@4@:RWG/A+IAS^!7T
MMLH;9S)L+:=+S+2Q\>Z-#IK4W=.U2D@G(1[^%JA!*-F<KMQ5PMU8I2I65W^X
MT8WB@;567Y +U"G^%01D2..IK;!HMP7:4!VSE@H?%;&EL')L3_?$5O;%YJ/-
M%K3K%IFI1(V%*&6]L<(M*R>S!ZED)38\H]KZ0,WGD%Q.UZ#K(,:4U7O]]H()
M9AHUV-"P/#+1]&,[W8C<@JS ($W[WHZM;N;?A8?5;N#Y06U3Q%$B)Y-?%(48
MC>9D@H0;R\AT[>@;Y= -)B,-K\7N;B^,=<L[DMY9I,;N3EJ,Y/I652MWG'1^
M"!'MF@?#:LS'NAKR)T+'0K-!09(G*^#N%$Q1T \#O>,V=S+$13YCJ52"&.4,
M11T;RI+I@,L'^$ Y[71"AF 'SKYAR%IA<M'Y],!W@\'O#;YQ>QR:V3ZS</0U
M3\3=LK,*CODS-? @(0"9&7_^P!$"H#MQ-%<'5>01OX>[8?9V_Z&!7:D*,%75
M]UEWW9Q5':8S?2P6&.,KR])YQW)36QC18PC$W,SW:@T>E] F)5IY!'V0T_V,
MWX3;Q_6!YMN1:W&N7"O\1TVD'.] +>3\>A5YH]KT8O5%WF&EJLM;B&6%V673
MG"R-X2:ZE9^O_>:.@3>R8WS)CX6_U#P$+7.B'-TEI>YZZ/]TA^4QP%-+T!;\
M+5&F[X,08 ^SJ()=T@63,!/!(/=!LG&PWF[P1%905:AC-3K&7T \_U=<#?=$
MJ%Q84*OS?"C7]^[+>!9]=X+!;@&!MTD()%R[N$RY#9<5[!(,"8$F(;!XFGMA
MEB%I?1H]50O@]D%MU?[^V(#NSA$UV\NHRL^Z]J+M>/?A[5A?;U1]_>V/XP7!
M@457;YIC^"I00F? .O#N4\^);6S-1&;5MAG-CQ.A](:DK% +JO'>^&V_Y!99
MV>?2/FSV-&OP?G[=Y0H,;!8H$?J]H# AD-B=1/B-<OOL/ERZ/#[F/%L2UW\Y
MT=&X2S6;SDZ(62W]Q<OL.8@4R%9RX=",EPBYIKQE>W8%&+,9B4)@\A'>!"1D
M\!#,Z1>#R\;$Q-6E^#"#S"-#)-T:G[<1ER,>?YI;DY]8/?SKA>Q[9XS!GJX?
M>5]%M0;:U)4#SD_5MA,SX?68Q6OL%<Y;&@7ELIOKR"^(5$Y?+*%#$4SS: _[
MXTW# X/']SBRX*IHCKCLHD7A$8<+6I8CM"NE+\;&4BAA%S%/&PX<\+=W:6D8
MVF%V)FWNP^H[;$VUZ6+Y80,K3=K. U1KU1+C[ATGWLS9&J\]7'5JH7XPC!PC
M.#\^3[ GT 88FW\+D-#&:&HD_R9^'YYJS#V"G80(4YC%W93ZLI7,@G9ML9%(
MD],6U<:>R#4^LPKX1L]\ L\I6Y.<RU*('S2/-SRE JO ;Q4";48V.CP??B4!
MA:1[=C#4K-WK)K467K&(HVB>1%CI;+\7EM8^L0.<2;'>\W@^FL[R,Q1D5L8E
M=WB&/_O49A!J?G*WXSHEV&(M/8=3 >WC;L 9DJ%1-LUW:!DFYA4ZL0&DC@?3
MI:M8<6XS_NP+%9J9#]&-^TW3,5&/)_Q"M#/ZQSK^.C03L>;7>A">@ 3=:T=M
MIY =F<H\@P&+VI0)";80R+ 9(,M])._&Z4/IX!UHXNL[F>;609Z1R%_E69_P
MAB<^/EVTW;.YM N_'TH[G+E[^ETN,F]RF6>_%-X<M=PT74;^-4R\UXSDZ?25
MH_'2(BZ@KCP6/64XTXX9-9MJ+&13.'&@(NTZ23*?D%AKPCM%WCID7JO*\%$(
M%0+K/_N_T7[7YS44=*/^):H9N^.\E936,HWSAP_AL2C.-7XE)0Q!3SX.I==B
M<SSY=5$(^;F8I42SY;C]/2= 9RS2A30X8&)TLJG(N?JD/[]A^@(IZ7.[2J"X
M;5[M"YP$VXS*4/G"?A C14P-TWE-MACA23TEJD H;Y#^>=Y'HBNO:;]:J&9N
MB?_'H-V5SVC+??7HZ+GUU>'G93\M;T?[AIG4(O.833UO/&,)_O"WL+[R+"$@
MS>?I?X1?N$^6"R;JXD)+>/8?A<!%15].!^3//3R+5__X%'<-'.N*:?V01@O0
M&YQL:KUMXGPTM\=>L^[WRLA7=%#:E]>4"U[( ?P^48JLJR%%< _A#O%+*:BE
ML4#.#7Z6S29>E(C&)=4CZ!9DY;%OM@[0\VO,WOT,%X2:75 ,V'239'MMP^[C
M*_13@Q:MG1T#8]=<=@BBOVNH/VVYRK-4:+5N_"%XBG?'9@KD4,PE-<$0\1EQ
MT;X:%PL160AU 54@RS9+,/]&"I+.89F@6&WL+5F/9Z.U5V[A3MHE=NQ_&>;D
M6UGZ8G#<5-O\R-J\+,I1FUVX+2"\FY!(7&NCB',:\/0#M3KZY$-M%-D7[IS'
M^ORTH^V8?D%RJ,A(-?FN8O SK&;S)@?3S6GG#_SE64J[!<U,,:BP9+@Z7HFG
MP[[PRI(X)00RM?1V-4"HTBV%L5%Z35;7Z[TLA(#:#MJSHYQF[(N![^<*M7\X
M)%)WW5;](%NQFD0FT'A6DW@M0H=-78A LE\(H& ;1/&S(X1B= 0= MBP>57A
M'H[_L!'X>?^!;S%Z9=)5I9"]&_N!PVKG2O+3\$E;S/F+K"2IVQ(8]=UMZJF_
MB-T,R,#HAF '?I@B!0_)3(;KVACB)(;)FKB- Q14K2H6]IKC<W EB;R)MV9P
M2ZLW'H9TJ0QK[3=I.&CF2NJ/4N!N>?DJU#+>]VS8M?"<I@4-]6QG#*WBUS-_
M(8 T^P$O<"9"5J$.<%F2"M=Z5@@T"H&N=+/K1!GR02_!1Y@4>3WEAK74P8J;
M.&],#;G:'+]Y9/CL,"\\B_YY;O_5'--'%G\-BJJA*:F@XDZ'S0*;QE.E=W?
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MJ]-RS_K0Q+Y6D)%7,2O0*%JGT9"4YIM:DFC0A"DE67#WX*XD=!-!.X7YI:0
M_00G?I% '7?BH\U>/PJ'D ?.N-)L9- VZP>?1OTP2[]&RQ_:,_L\+A'COJCR
M[.HI_5NF+M<>A,7DUMU^)V>/:ODY(@0NK^74E!HIUSCA>Z2T!ZJU>U8RU]O1
M,ORR_4BW3X04<)SV=[U;0+4STD7>N J!,1[/#Z)Q+7 HZ##7G"<-9G9@='A6
MD#YS29-G0DBUV0C570:7/%Y]C")H8,>\\MQ?Z*T#O]?6C/I]\MZ2+,5?5K&+
MT&\,Q.@$1/2)>*P/-%XCZ"Y2(AZ%PIAA,,X7=M,B(IJK9,_4X=[_;J,73-0V
M=SF"M7:=2A[5IS2#25F/?!UK3=+R[GWNQ9SO,UB?5<53R>$LB"*,'L6=X.?S
M=+GKL16<1@A1B7.%$D4'[>@8RY-*T,4B#S7T+Q-35OFT5$8;0[U^2<59L2^Y
MY&-#J],RN;:B\_*:D0&'CVT;/TV]Q=ESQ7!8R)6[A;<=RF(A-7&FF1SF "&\
MU9;S<1"G4H6MZ3X,(F[9&$"<K] \0\S:C'70R1F+&HXB*,B9U!?<RW6-J$*7
M;9(>IC.#MB(# @*"WMPENEQKNMH?((B&V6S?N:)G/,;5SES?IWU[%_&@R:4Y
MM/N,:Y2&U!'V';>O;GG&^!OLGU/V/ TUSFZHE:N.W<-"=9O=I.C@M07]C'I"
MO$ 7HG:MPMI#"1)0 G6/O_><6JB>N(LQ%^'^O+D?9QN\6!E<9)CF95&UC[0O
M*BQ"WOYJ.>(82.F"0UNM%C=S8_!T(B#*G<O099 PR5B@3A$3652/$;R:#S33
MX=-)2<=IE,Q[VLB[FU:7^7:B#MSR/?EJY$*NR['U1@U-#9EOCAFS:Q<KN(<$
MPY1ZU**4:)^T#>"-\.\"]/FY),4* 9VL_"K3#KHU!5.:)^]C]]VN'Y=QRY];
MH=*MDB:89T#[Q/IK%EYE(TO^AD.U%BU +F=6_;J@&M]%E+;9AH/S7U(F*V J
MO*#)5B1U0@;J9)M--M:"W1U-[8-<>)</)EF@.?9M=?AKSI?//?N278;51_WB
MGNA<^-GF1;WNI=2?=C79:C.]UZI/X: YQ3A&4.;^M<I_H,)]'<CN'$0485-.
MF O*/,+V(7+KT<V?;_]$OS+/07<)+-B^W:),/TE8QSL!C49=YMKQ)/G7R6MP
M5K0Q*E+.$*ID9LI"C$[X^NJ+.S85+;$TGV^I9?&WTZA%:D.8\VMG.5<=5HN[
M9TJ?&32.5?Q^9P9MUUK<PT) !DL9A!"XLOVDC@B0P)A-BU+%O+4%[F!G/@.2
M8%ESD!JX?<QMOUSD1Q8?C'["=CL-'[7\&>]2Y:?0<QHQ7@SU)B\TL:FOD?5Y
MBT:$/W5NSR_EL2D6JJ,O8\)0A'@Q=.5.N KOX#4PP1Z*?4(B@,E8]XY\6/I2
M^7/P0@%S;\EI4OP8M8GF=NQ\0]/A#2<=C;*P+9/1B\I<"T*;#@5MEDQ4QVN+
M.(,">=L8?CQ E8VX>7%'+XF@_$N?!;\%4XZ"*\X5*>7V3B"@(YN&$)]VO&\<
M:5*A>[_@W]U97+F5?/I[4^^)$:</WZU&FT(/8L+"O@3N_W2O^:<00)?GZFSX
M^F6^2:[K0_K*["!U,#\#67?*3+.Z;Y]EJ1 XBM_.PXIV<+: ^HRG^>>I4#0A
ME2!-WH53@E+9.FT!$M X6-N&5)H!<RM :YQ]J[.NVFG0,P/FUM+"+DQ._B7'
M&K1 1U6%;@N?5G'$2-A'!C7\B#VHS*EC,_X\HL$!B0NM;*/72.GE<003L3!;
M!?UDY:7CM(PZ=)''D\;:6'"E;V1UL)Z>E%?6%U6%B(@XR.=41FZNJZO;M*ZL
MZ*C/$ME\EM"$XJFC$**RL(/GQ,]J@(T2F;5)-H8\.)NVJ,7.["C:#S)2K2U8
MBP>8765*==()8,#@,5%-\+(^_<379YQ:&7+9VR8O1)/^3=,Q*&<!/BIBZAT,
M&4*;DPB9"8%T[:7XAKC-S.@.3#*CKB83Y'99'?LX&V!$ C.3PB]&<5WV=D<9
MCN8Y/"C5NO"5+D9*T'&0W:+S(NQ'1-F+Z3J_CXV%(\WAN54N39R(:H_L]$[2
M_HZ!.R@X1OLY<?CY]M8*\R==!:U;?P9L.^&>85#OS&I!CE$YY8/P<YG0MN]9
M[ LS3$$3UQ[?MEI4QE1 IFJ;)593F'+0C=#'7O20H@ULQ:4;#5;-=8TMFHB=
M0^9OCX_L&/!E>I?<L:K 3G':^96"';QC_&QX(&8TPA>4N6YCPG/AYXD.+4?<
M%8C&ZI.O35E&)I/7M#P?J.>&PN2PJA-S[SZL^-$LWM;<U%R)5D%S+&O/I[7Y
M7$COQ.L+WC+JPZM JD"ANF26(8=#1%4*!HJ,^\W(4MY=YHP#+/^RVIN+.VJ,
M0##LD+1#C>LC>)CEQ?-2&MX)6[^3SG(/X(<8=<A.QJ@59P;2!P-^3N'KF)F?
MN.WP.K/%]5R;T=!F1#)9WZY\-K?9IK8"2FCSS'_06Q+BTWCK:>?!I*K2@^\O
M'*V[.>:\W<_%L&[%9& EW-@YXLKAJN6&L1^OMGN13Y6R;3Y8/ZO<6LE%!*X)
M\K+2TOCP]=L3W$#BW/ZPM_ZC1)S@K7;>8@^3F(K4M%'"CV1A4:SHF[A=%1"A
M RY'0=?*!%O:R#UG3S<^_[KE.5-9!:NMBSB9X\@V2IHY?:&ESJ1\PD>WQ^S>
M:82NZ*1<#W'9"I,7ZKA*/I"\O_16LBE^#"ECHX[MYD905Z\V_\#:=ZQX9LT]
MGS4C;$BV'_8.1-2%<'S-3/ 8PZ'G%H^X&[$)G%&(RLYA979CZ&IMJ]T+;!#N
M#C8F3(KX#+P.EA)EIC@_858W]-1T8JD#J8:[7!E\R<E\W-?C0.3X@</IIU[&
M*R@.N&CE/^^S,A;-:!=DQD9,23=Q)3_C]H >M5/K;-;CQPE2>$,LQ]]XH0QG
M-HE4]@]PK,86N'%=>EL(*/2;;RA+UK4N9J/FXS2G8K?I,5^+\[^CAM%DSL#J
MYL83!%?BB]6>$&1SU*G6EN1&CZM-]=/3%*-ZIY(*U,%P1L\JIDL(0%N)BT;<
M,/PXHP[1!L\@K+%1Q%GP"RV6DB.^P=9:VX'MRKK8M &$&G1XJ9JD@2IM+"OW
MFO"9BP8G0N@UK94N%HN)K?6:,7$M_$>CUKZ32XO[1,YX\BO@090,@IXUG!TZ
M*=,VSQA%>4 5DW&>B&1F(2/#OGM)"Z<=VD)1#[7Z.>=S]PY<&0>O'+.5SBNG
MHSWH=^>1W==B=S4U!9^M_6CV:6RRMA.1+ 2:S'CJ/UGV&225IUC":\8Z7A2(
M<(/.LGR9:#YQZ@!,"9(Y/6C14FCTYE5^A%XAP=IRD%^N<_6G@9C$]8YK,@NV
MW .X,"B**XVG(]>0,.!, ,C(Q.OS_/C/+!A2V,"3EA*N;,VLJ;Y%L4GN/&P3
M)_2R$NE\AE=!*C.PU>?T+8>0JJZ1$.WM'OT')HSS5QAU"]Q@VHYMG@7IA7X^
M[M?2\T6DV:<P]FQ8:*QY\9*,GJ=Y=OCEC_,6RO0I3ALTPU47=",UX1=JQ;#&
M5,I: KK0J(TF!-3)1M! [(',)&0=+;G6/.H5&WG++#)]''F"3'/])9D+4T*C
M=Y2@.[E5V[78B 1&H]'B>C"!PX7V<8U$4W^"EQ1\(DM"LY.9*?06;":3DF2N
M+ WU,(U2\;#@;"C]'4T$RM>$TCEY426AEE<'Q^CI52FU]TEOX[?6;9J9IJ12
MGE<LHLP6K$2@HQ[\6@NJ=2'7DV&"/AM8':P!L8 IQ8[C%%A"0-O/,D>W,6D0
M@7[BXQU* =,#Y*:)MF&N$J2I\&_3+[,GA !5>90PI=&WN,A5PUT%D3RU0&?^
M7Q24F>P8+P!$IBZWRB^U-3'43!A=>,DA\S>D(';,0?&3C3[:O8;D^R6VEF4U
M(9==#)?K2)?[M.O2TD]\M\1Q#6/Y=\9PX]7OJI\,C]YWJC'YD##=\23-2VK+
M.-[Q"+Y[[.V10HO#ARM/G=9%ORM%K8]]YGI#Y'$[\38<=,.,95-9#%&&6^ 0
MD 6(G$3%\PA3!$F< G1Z"IGLCNUQ@\:4J6''XHP]:3S,U-9?QLX,&?2$P8B)
MF7FK&5>I:S74(K7&(-Z!Z6A*0K6)T(P'@2YQ2'2^8B")*62' B:Y@E,"37-/
M0O.<"-#<QAB+,P;[7ON08&LM6C6BX.L#CO0G,)>28TQN)KLVHVY/N7$W7#G!
M++U_F[+0,Z4\ILS1!^T[8:.9D]$+_4%</YZ()"56L)$^D!CW",\:JI[L44[&
MJSUG!U#BJN;(ZA#-9/I]TX3V$!F&39IW]_?S[HRP_F@T.I5DJ?(.[\8O$ *!
MF6G$A@J>*G(R.95G]8AG ^6Q<T0[,Y6-X20,6DM-)<;/,&N[T":";=@:1E>
M(J7 +=Y9OPQJI\<=-J_J@?1H$;X%":I. \>& B_0D[<_4+WJ68=@S5?G6>WY
M;?C(9E#M^Q/W3NM3S^[='\D81J(62]S7E'[;9I_M]_S.L-G97CU/F:?YF/E>
M8\XR](N[DQ?*+USNRR T(A9:N6B<@8AJL[7LH,.L,<S-&&2RM;Z(5R20S=FG
M]B@K89.=!^O-5.<3.B8DXSS,%GJ/S+LZ^W*#<N76G'-<NPX7P;V,'Z!H$D(1
M=-0D,5$(7(2-<CFP9DAM:BMI/5C+].S*3&[,9Z0(]MKIY>DN!%A1V%:I%M4*
MB#JP-J56[T#<=KCBP45^:T;/Y<NR=T^Y:%%A"7 U\A[<)<@01A451(/DUYF?
M$MH"Q-AWD]-M+'%N4!,X,]F=VL#WZ#YV:Z8);&JK,E/X5+80<W>B=H.6)MD\
MNB%NGWX:4S_U3C?\,-<+LN7<H D,>$$@;'&/:%.] RD\=65F4VI43U7?*(55
M2U4@2&!].XKDP6K^$WOT9%_*_O+JV"!6M;0(O;7*#F"K'(?NAC.5S:]^N'$N
MU=2WRC V]*F.3W48R*LI;'SN]XF(BG)?.[N=/7UBW7#DXWD95T+C,7G<BXS?
M1AJN3HI.BH9<$;>%$J;LT_#2N ,T>'"83)M@ _0VML3)&E.!E?!/Z"A2S#O9
M.&1F$A9%4)H;6=KACJ9S[BOF-FDT]^QZ9K5XYJ<3I^O82@CO#Q?TPG\@KOM_
MB'GSH*:RKVTTM@,B8E0F 2$J(BI#5"9%2!P:F00$! 2$M*(R"6D%)$#(:45F
M(2VH*"B1R8@,D5D@)$(86A$1 D2"DJE%1CE1"$<RW?C6'>O^OKKOK;IUOS].
MI2J5G+WWVFL]S[/V7GNC+Y,^,GF*N,)DKY#9MF'!55 O)HWA,5N/*QGG]:;9
MNO*/2H,9]$VFM@Y_GFX=#M)@1EULR%TVA;.#<*:!\Q=2QA?=:N^W/*F.F(ZD
M^=/?B5Y^NUY\RMO@L.M0\N-PB\GRMS7/AC*OT[M^!E=+/\YE[BTI^U7%#X,<
M9!O00J/N(ICTO@3S5'*XQ8JN@;*:16E)281MYPVV6)+NH Y&6$VH)OO^M=-/
MQW7UZ6%+NYCU8Y<08VUW[]4X#,MA2K)M4!RWN9.>!BCC#6&*"660E'")'>P3
M@.[8E,[EIL?Y:E:K<OE3KUG6AYH'3+Z_,<A]YXK'B$_O%"[/-XJ5)?ON*3<0
M-P1)_*4EL6U7E=R;<4J,!T';P//UQ>_7V"QDU6 C+_6^B257K'6D#"8TEUUL
MFW#_CKD>N-)8W.\:?=%X&+APXK9M;F:E%;UGQMZ%7D^,W+"WY.GT!N/OL[(-
M$>*3A$&T2A7]"O(FJ8Y0P>5LD,1)JV5VY_"&X%>B)*G\3344\AJE-RBQJ\2-
M]] ,"IU^OQNK>@(-GXJS8L?6,U _GP5O-SV<D2\<%^5(2P$LZ0Y'D\XMPS08
MO<:R65Z0->@K4W9_.J6#3),AI@F;F5BJJOBDQ LDIH0(XWKTS'L/33@/F!7:
M3+-L#%\$N-JR3\ZT.MS?&%77?PC;5".2(-N8%\H!Y#10('&?M<G\3KR)V%(.
M=8 ./*7NK&RT>(^ CV$@?X.^"UQT,Z=9^B;@^T<U Y=29#=R1B.^IEH!CTKM
MKW3L]JUD;F;9W_73.UE::5 )\[Y_<V,5?,V!W9MQ.[@LY6<2$RBL%-HEX!7E
M@W)81Q-B4PUW>+Z&JA+!:]^%6/]I?-;76JN5JJ6O'W"\W'43.3XN-A;8_J J
MWU=+S>5 W-V'RPUGE HEAZ C8#ZWB1C+6[B-WBA1!ADG:-2D4\M.H%:*A?N&
ML.7\[WM]J&V-@R95)2VM>W]3_NK[]X[U5>JK@N[:JZ^2O% T78_^?ECQ<5X.
MFX.0Z,60'..5%Q0^7+8^22%PMDHSZ1>)&23P+%%5-LQI0"035"-HUM+ZV/:0
MSE9L1C75WG9E-/]9$-3S7B8:GFK=4[F5$1E[;2/\ZQNU_&N-VRX1IP6B6$5P
MO0 Z['ZM(&9HTM<#(>[LK-<(#91AT'3"@\8PGNEOK.X#X;XZ0<2M_143O[/I
M:8OCIUP./[ET'\6<O&=X=YOQQ6"00IJTKF%/T==0EF/1QQ4A4_P_N[CBOPHL
M^BF2[0T*0]9CYK[7O)A5I,+O)?-_;+N$6]UU^/"..W<>ZY?NH6>;K]F&;LDJ
MEL,>A,EA7:R5BS(6O1;[FCX.O/8W8E!R5MS:GD\5Z0JW!^W_4$.UYJMP5&=6
MHFH>^/K'Y)X$+K^B:EE9YXU_"NC??O?5I3\U'0=[ORIF+3D!X#Y1"/%_D((C
M(K1FXV,">JH1HNA#\22A%;[>MEGW%H/W0$4U+6:6U<6LF-_[OHILYG]V_XE^
M-RL\Z\:(@?38RLXD"]L=H%KG>???KO6N%5H!3T;Y55^/IJ+WO7T%:-_.43G0
M\>4<W@X>^6CRX6GW1K+76O_H6Z5S?+*6LE,SMDT.XQ:BOQ/EL(_CLOY>W@']
MUSBT"PS^QV']$='(GPI%)M/#N?#@C($U$A-0_W$,<:W$#J1E<!=4PK*O63(_
M3@4A7B:[,B/+6E^%%$TZSD<*MKJ;-]0[M3I<?!?QBC(6>IQ9>NIQP76R\^/=
MHQ6OCMLW)D7&E@_\,$8$;7M\PUS-U=E"N(UJGW MU]E9(\*M3/W>^9*RTMT%
MGF%'R]C#DA,*(]T$FN0PWBT+=^B46X&M@QRF>D%L)(?]H1<6A7'084G,3%>+
M368J+@DG4(^1^+R$ICI#1D#\+2T_J[L\H+&$,$Y 0 SQ*HF]M+E0=&V$'H)9
M(V,A-AFDCHNB:H4]^<+?^OA?[T3&NJ^3F([$%A+3_1\4BSBK_6=MF,CT& 53
MT"IMWFQG;74-6[V+T"8;Y]237@/L/"ZJ&&P390OMEV_)=,E9>&V!&C_;ND<D
MA\&1BQ@UZ&A@\RC5-"F,7UBQZU8/SA*W ^<];NZH<2:^T/$GP%V>.RHVP*7Q
M,<FV-S@-O=U8=E\79GUL(:"-,V)@MM+#Q@B'H. .@M'-2\U,"48KN:I1VX)7
M?4XI9FC)SID=';PSI.'[%\/*4XUBNA)E,MKH<F(DX<D\RR5A<8[@[R]C @T#
M74#&B@(72!>$/_A:?UVEAV(AXZ_SKJ".F/^>F!1FG4W8+MD".7 _XF,1#&QJ
M0@TE,CZ2%[&PY2'P<C'[A$H8UB(Q/NHR$_;J#P</L3/^M+28'IQM)-O@)S:!
MK$4/H1:AVDG0=^X(;X =S8WK0F:@=J=UT;50&W&%?E R@B'UZA3T[@N+K(Q8
ML?\W>Q.]S(6BW:BRQFG^8L$YPQ#*:.1)F?*@&"$Y 8;T(-;8ZS=6((E &':K
M;,AF(4."%&X0C?>B5>FA@<Z3R@N2DURB^E3^OA<X^/FAW=F[TMQN.4Z,*I<W
MM=YR)%]"*G#XUZDQT>5!FJ8$@$)>H+LX>A,$)MN2F":SQ'M :4*M(&%:-UUK
MBNV$^-@: (W[Y ;THT\/'C,XS8R!(N<BF_^9.'GT03$G$,_ZB4;^^'X\]EEA
M !C&^2%KDM33(838%<**JJ3IJ'5P:"]Z_D(<;V#<0 1 >0(2V^V;H!NEG^])
M&Z5I3M'6L';F<9?ZH&MI'7=K/D.OI_V3<2>,XPT^5/U^8ZCW^7FGQ/.I&6)[
MO!M(GGLCC.,BB?0(.#O92ZATD\XMQZC)89=)*3;T3OK&,,QF!>[2LSF;;+7#
MR% .DW?E)O^(:16?V3CRLKW5IKEKO.]:4EFH3^F[UIR3VY-7E(<5])S")G=3
M;I)THN9CDP78,<'K"7,H$9R\-$)V17$8M*.UX.@3RI[*BTKY%9_;FU-BRIM:
M'J8U7SCZW'2?P>2"KH)0S.2P*_#MH4$F3"/W#'UMEJV+V!$BBB@OA0I_WS$;
MM$WXJWK&'*KI89T>75I8@RMTVQ=7?&YB>C0C&$74Z0\V;<CMW7UU@[JE)($3
MB>9*.BS+Q0&7.=_K:B5B>[$W812A9*M((M9&0BX7!$@V_;6.0R<PMII'Z:7?
M\@^9=Q5@5'%?!<V=) THORO98?C;'\*@E&L5GWI+9K=LJ^%^:&SWE,UT/]VQ
MC3!X.&^0?I4.83"UY P%H#W$:!&T Q5R_A4Z%-@R16KH[;H_1-@-U=E=X7_M
M0>V4DFR1L37A-GN>J.LDD5,E:WE?(MIC(/-CCEU_L_<4DK?$WJCSG0LD2;;\
M$-DW9PGJ)UR$0)?.P+PI> N>C-;%>_$IF;3=0F2F;3Q/')C ZK)*>$^NFOD>
M>-XHX^JWZET-#<.1U(>1BY]'/?Q-3D?,<#1D_9S52Z0,>MURMJU]M%USMAP6
MH@+?-HU94W59>&BLL V[!;)A=!)VY\PZ/CANE#$!AY_SK^?MMG)MG19E*!L^
MJ8ZCR6%'?U;;F9*/M<XSJ^D/^@(1%$X+9"1,%N5#_3S$1Z)(N1FR5$BT#X .
M/D!AV?70^Q5BMQR6@U99K%8[#PU>)O?SJMV[)VR@2-"\TV;N)83AM<ORDI[U
M<4T1)U(/+^"-PDIF\M=&Q=YOO?L3O@5_7=I(6(]75<QTUC1!CRF'11$WXI5
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M5.%G:U;03[6BL[5$?UN5XD9OT$-;[EYD?[8C2M1\17&#U$!0JT>VG085\Y(
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M8>KBQHDK#_<9%?%#=Q_X_6UN$@8[)(<E-?]8,UJ0,!W[A?QU,N_33P.9,D9
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MK==]\H(2$NQ\9+^?*:PX=6\B]]ZN?]O<1@M^.EE^W_"_K6O]CQ[CK^YLHB@
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M\>TA2G_7IP]/TH&LR,!E.<Q DN!J4>#SDT,I41#>\__C!/7__X_2CYN*.#Y
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M/LS3S$,3+#_%Z1"3&R-7>X&^W:1-8:,1-_)]SN $'0G]WQX^\_N2H_NP.J3
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MJ??^H=BIH9@7SHW.9W_N=V_2-[U\+=OF517)NO-"L*_V2;T[U<>9C O7MME
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MQSPR6OUK#71!\<*]TES"'HD1Q!%FR=3: WB]J?0K;>)L<\'[/&%:A\P0NB!
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M9^!"X[;5,ZW&D**!]+? 1<R*Y0 [62;#*V3WY 01ND,6&<IA"M7['+WPM7-
M%CD37_H9P"A@FG3%N$;A_J_S?_Z4)3V2IGA@>BF24U[BK7+88 UA&+'\@Z<
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MU[UQ;JA#K$EXY\/9N$#8<APL/$GLT,G/B)2$ 5>;"_YAF4F"0W9?]\<U 5I
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M>]F9K  >,);'34LV!*LF=$#3FD?(6UC9SO"B;;@ET_#@<H[D;&LK5?BEZZ+
MX]YIMK1__EV]Z3^/3.^4^9G6I:S^&?7?A87P*RTI5SZ?[]7V?KM_:^Q![\E/
M\>'=]BVN32W7- 0AY97> 6YQ5>A-H&CK@1RMW6]>#I(]1L@ZVC<VW+G@/:#D
M/7R+?&J_>>R!;<HMQBZDM2GW%U++>-(S[F);O"*9@?]%T.KG]OF"UIW2B$[9
M3M L623UN_ A%E@7*&UC^/[]J1IJ;XDTFU(.SA%-3NYS5/DS#ZG1B>.(3*2/
M:+N@YG-"2A9-:WHEIYD?4*@[H&&/K<(1G142(N[9SXOOO_;H:PW%)B)5H1<X
MS[W\'['SQF?B=]JGGL+=,P3,,?]--%"O/YVDW3+8RY]V<RLKM\$5?,B[']99
M[O-%^]EG_[_)-MEM[_^\4QZG2T[GR1#=S.SM/BYY_-#.P[@3]_'TM?Z/+]PN
M]TS5W)+B['DG.+78OUIGB]/^LR]&R&NWN2FR]3]N-#6-6HV*?&Z [+&Q#M7J
MZFIJF&I[8R,U0ET3/+GM'#]UV]W@3 OOW^V]SZBO\F+]M\&4I74H*6[AJ\)M
M%/CWLL73Z7!9KI.1>JZ/DV'B[OL-T]__WX&B6>@RAB5!?QU+82F0BNLBD?S"
M6%GG<XJ )3/8)\T IECH<+CX)U@OAQ4FH/F'2!_S9=G1HJ=R&)VD@O[97%I@
MQUKZK^Y<B)U 0PJT0:,'ZM$O7_SW66IJDA@K!1BRI(>!<439&OK P(^Y@;G]
MF3([X#^T]Q^Z=>1_9SFM0($<=A/YXX=$;"[>4$(G8OY#<_^I6SG_0T.\YT![
M0B3J<;Q\B<9J4=(P/11(T5\K'& LJ$X7H5@H1'\)_IB-\FC9<(.QZ?X5OLB
M-^_K4V?E95]Y[.^%5T[+O7MQ]V^8RS*\HP[\VD+[3N;")>5DV095.>R2D>B8
M',9TSXE8\J?O)\#DL+?^ /<I1W0"N 276D"3=.\7Y:URV$;T8OKCCYA;%.EM
M/K HZ<QI#RTIFT;KT;GEK;)'H&\G8I5,63: KD?,C0M7"X#Y"+'#<2X'IABJ
MID2E&,U05>K*+]!;3J?MD/@*?9Z$/,N(-0UV Q^DQ>W.]PCQHL=D7$[L3KDZ
M*;DJ+96X"O.ZZ=IT[*^BG;H%!N8CL0-=_U6RM:^3  <R2'")@]A4@A):TN=W
M"K>R&/4X.I^3DM?=K+-;YW]A[SV#FFZC?=%845"*-$$@*DU$1'HG-D! 1$%Z
MB8A(>P&1%C&05WI'J4J+4J5&Z3410D!!16JDAB0B'1*!\(>T&_>9<^?N.WO?
M.1_NG/OE?LA,YDGFJ6O]UF\]92U4S%JCBZCEQ*5&IV_G>C^L\)34SH (%D$!
M]+_7"ZR!:Y3=/N0!AA8U'X=L[$*NA9 V)SW[0\'BAJ*LX?W8HLSJ9?0AJD59
MZD:L05HM\=N#9$OA9=>+(SOFA4<WL1?J9U>/KNB9FS]/?"3RAR7!D*?TKTES
M7*;#D&.-;!"@D)NBGGXT<IC08ORN./(G5*K),EX<B:UUHKT%*LA=(%BF'6#L
M295Z<XBA06E);'RM?JLVQ+NT:32O;\Y"84'-)]WGSW17XV97EP@3ZM(><M%
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MRM&] 15]!S;(4XG*P8-[A"-V.SI._1Y+&&G86I?HK[]9+Y'9$!!B00E"N1M
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M):'+N$K'E2D#!Z;TMCCE^0M&"+6YXA 0_Z+OL01$ZL100]F- Z])]377^Q>
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M0X*(][FUY_:VN-_[T*DED-@_]O="Q7PN!XSZN_W I)Q<(B2>=79<&:W",)Q
M"P($W)P>D$A&)1CJY1.+.BI<O,/01X;UW4E,#C#!M8A9#9UO_!IG>3?Z+LCP
M?]>R.'P'^3;K7D!A>U?/9@>=[L?TAR=3,FGBS +#8[!58D4O(MZ5;ZPQ780A
MS40J_<V7?@@Z Y3TBA<X!G0/2OIC>S7GP*WU&$S1"&M'PT5W(JC.]<;EFL^I
M/"ZGG<O@OG071+=^<<"_X@0L=#)L/K<'FJAKEX;QEH32$@ L98@LG]H90ERW
MQ+F>HUYI[YS@B%XF"9U;:5$%EP:2/>I.&G)4=1_7:%$ZZ22[GM%].$SU.,+M
M0C$A.VJ?$!K)L9G=JHAY9)$&LP"MRO!BEK#.P74H_=TN3B1/[.8!^.4?D2)>
M2&&&.76Z=[D,T+/!AS#M^B%":&6@6'L3[DD..+4RM3AY#@9?C5##MMMF5]1\
MZEZ07S<2LC;[-#O;\W^CM_\I8,JBUB?HWJW%]3T.NYZF<4SR&((4$9F"_V_*
MQX?^IIL"9^A\0/;D,A$<M%G>?V$D=%_R/_;WH,D$RI,6QKM-VC!G<<]@,?M%
M,$>,ER_U.8M7A./J&;"F(#1I&(?-6 _QW.7:D[AG)/P]*%;H'KX,)&0;(^ZR
MT[.9-ML3N(7YW%D0\H]-9HE9M*KEP2*8W>SG%=6W;-"=K+:2V0@V"#GG\][6
MA_7=-"QCP?://YY0]M4G;V[.M[*XY86XZ>.0-/5[&5_7A*_N9W"-D>K,RRTD
M_%3K3<4?M#DO7-,6._PHA7+KM"1POAT3_Z,GI"3D@JUF:&XN?W74_1DC7^F>
MJZ",0;D)4$K@E\J",3>%C>+\5<R..USN%"S%%7Q29K[Z?HK3NJA,F>SP) 1C
ML:UQ/@YRXI"G^V$[\9\N+;D;IZR]>OEIM/P&\7H5[ S(Z6S-/R69HS [XE J
MZZR+]H]M/Q.'S*=[^$=[FII[8CC<#E:&VW+W<'[KO/@VX@7A1"U+!OAPN;A>
M,[U<82PD14)]29;GY"L/[*$0E8L;?(/BIFGVXLQ+']/O4,:CO,,-8G.0GC[%
M%VK/WHSC?QMV5TLM^$BIN_13<W=4H1U_9=>IK-FV7Z.KOM/U+B)?MC=W=?Q-
MK"6%ORZ8'RYEIEYP',HU_U)M]&UJI"#3KZ(IPU"6LKN67/U%B(^$$ICT=DO7
MS'-^O.\AV=OP9:$GYD5Z+FS^95 2+4)KWJY'^:A3+:W:UQN6@X6WQR>B/K5P
MT>=NZ&OV2CSRMSM4X-G,U3LTQ65,"<:'A[L8U?F\.^%;OFR5Y>1@/'^T['W4
MLN!ENV"1+S(_3WOSD] 'J-!T^ W2]*1_D\OUT"13L7?U6H)=M>TB _U"3P?E
MCX\&G>K]8ZFADAI.VRT[IO&\ZTQ'N$SA+-ZI;M6%MQTH0,H_C7IG+IP4O? K
M)2OK4HGW_4K9"WW0V=BRR.2*6</S )/RO$=OK5.MS&G5^BK+$>&^K)FC"_/X
MA2AW[LDP$VW ':K\;O,9]^1>Y'B[Q;<O28AXVS#-&G)\1^RO*<MO69I.3CK:
M2XHD_0WZUZ B5CR*O,=-MZ8)<7!XB,S53S@*DR:U)*YW*A)/^C"FH2N[:C@_
MB=O#.E'2@7HR=_>V_HFY]>OP0[6^H$5/V(PHWZ_)G*#DBH3:^,$K(1^S*XGS
M*W:5W/Q!65XCJ6U5YKFS=HZ;,G5C'L_2?(M^OW9&I][6/*7Q>S029V%<J&U6
M9HQ7,FMZ1#S^=+2\K<KL1\RS0N0['U=IP)1L<1#![PJ<,1\E16GXIM>[3BU/
M?6OY>A>2^<_PU_57V4<U[:"O#_(JEG4PD_4-R,B#,/>^(E$J*FY[%2ELCRXK
M Q X_-;R;L9R$;QY^'M[_T_TIXS$X@>TW3"QF]S?EU1<[>@AC+]1L'UI<=1^
M[%"LE+R4 B4L/N1(P^A.@O_95D'P>1VYV#HEOE=Z3K<=13(N50L-U3Z-/,S\
MP+H"<&'%H=%*"Y2A!(9*J5'0T<(R (5UC*Q7\JLKL-!HU"I[,.;^HDSJ86^N
M3U5O40Q>Q":EU_.9G%.AAW^P^VOBDON%$1QNI/9.+,RXU,U6X8MQL4608NLZ
M55%MS2V5Z"P2DCRHW:)<G?!IN*<G*U!;W-LVY[Q/]JV)0O&TK&79XQH7U9YF
M7TSL<ZR^C,/,%V).UXEYC,2_:'HO99>"\(";4BQF2HT_W;X)F589F+MUKG0J
MY6Z(I.\,7(<-.HRC'ERV6M&M^TAD&GO5^"N7?QAA6!/W-HA.%XI\2YU@J%\9
M82TWY6Z-RB:M.Q<<F@^,G&8I-\/RE&,Q1TNNZ'^/4S[A&RC\[+.:IFCOBN'3
MH\:S7==CC[;X(>;?@06WWXX [I\(W R]\&$+,70CY7=EF';&(X\<+_)8$[WC
MD>=A#_'CTD.R3J]<:$,%1+%VJ>^K4Z8V/J:*OD+%A2R$WGH5,EK(ZZ'/CXJ"
M(='/<^)Q\B<J+*<<J5/.2?H3OQ<GE4-I9Z,YANN9<*^A5GMSE"C,PRAJ[IO(
M+=XO-H_?7%E+.?:4Y\$N64-C\1-?S,@Y7ZBDN5J62Y5&[7GO&ZJ_KB3PWY(O
M7C#MT^E3)",%.!8 )Z70WM4VKCS#1/\AL4AS4]KKEW#?!ALS.C6;5R54%/4$
MZS7NB\T?P 7^]AYD9)BV/CT6^AT!&=Q&72^2JK<K]#7;?SJ[[%'BARK:W8!+
M*1H,%&0]V3/2&6FY2,LI\PR>CCE?X:=YQU%KU).F64F_[#PDD-\SIQ"W5F1U
MTDRD^6*I8%.=GRL,Z_[N0E7$<WP2K(*8VVMY:#W"R7S\?/WAM3'U/2E:=Q:U
M8^C?SZ_B3N]Y"&A"XMJ@)^%7J0$Q3<>:)$6=.J.\/A-.9.K36@2BOW*H7TZ2
M_4\/L_HBOM-GQ>FY1-0Z^!WPT<Z4*H?DS:XR2^9Q^M1C ;$.ZE,J:=6._;G(
M%+?+NO+91'[A\&SXQ3]-7HIS*W_L-B>?5=<MN+EG/$ZU*EM7_?HHX^Z=ZFSQ
MU*>3UYHS\EE.H_A;6P;HD[I99;?#FG/RLCRC I3&/0^5GR*!+]O(/#&5.7B@
M>TB];+@34EG=*.<GOHQ<<# MZE5P55-_,!!M8'Z=S)4CB;'L=*#8$2O2ULLS
M3D)8 NN/[XZ:O/?^$%&D_K3MZ.]/KTX,+!ZUO&1,Z*T[$TU)[T7%S,D"@9&O
M?)[D%U[^;>*B9]MHYZO8Y!JJ)O#:\\ +F"SV1$9^[HF+V>%!H<G!9>ATX^UE
M?]O&AG;+S;8TCU>D#U=L5(26R5?6.[[?L\JRKG<>M9RV#@O7N-='ZYK^.!^.
MB=^1%/O4ENHJ<J:D+7;"2^9&@:KY&?U_CDD0$ZU??N(W<L-7WU!I4/8-UZ>?
MR>8Q:(P^)]Q _VR?@E6-^!6(%8@[42&,!:)-60-=*N\(AZOJ/Y%+L!<(@FD$
M5:DGL+-I;_%^NFFV*7E^U7WF1NHM]1T-+C8,O!,\3NN0^+UL'VZ?@D<E5@53
M64L#YK.[&<X_,JT6_%5\)C(F!X\F7:A-O_0_GT&R0;>' '5+UKU$TA!=)R !
MN9\&7,14#K#L.61T&+)G+)\,65M GT>LZ,U7L2H4_V,S+T RMY@1E72A7.W_
MC<M!21<J=2V_HE*@%#LV")!?[ 8GL;@  S+?E!JQC6J7U!E @AZ I=9TNA%+
M/"C5]A1T^ON5L"WX'=\NVXE%K"U'9U!OI_6<G&_OS^*:JJ\G#%WT@+MQ"-D/
M1+<&FI]QA=K?V\>L09]D<+H7HXC%3_V!R1,7TQE**(",4W4H7VJTY%GJMVFV
MN&&/>5FC^=(\*.!XZ.PEJG$->0$#7$2N;=*Y&-IHP(8:OL@Z3J<DT[*9'PRO
M,/RE> $%RA_P<9@BEDRVQ&'$E\*SNUCOJ+FNZ)'4NA:.MW%R:3""U!7*!O66
M4R\]'B6."<^W6C9/L[Q@@DZ4W'\AGIM3@K1_@7<<+/T;:A'A.Z?*3(+XM@ A
M=&.8^SP>"SUHHOP"S0-#=.?))\%-J#S=XFE-[][HVY$01WWROA7B>OG/8T/*
M'5UFN@^6*H6(=^!MRCNTRCG<++=$$L4&\79BAO8;('66<5*0D4A%N":%JY=Y
M=-3ZP[#A>9@:UE!K>"VDVJ-A?%U]2-AK(GPVMKG")^-KSNZ/*8*1Y-B];^K>
MJJVFCZY*[&I\9D"HGG&=S^<MCP#D[DR30"+?:< :.W>!TOGCDU)Q)G:*ENE=
MY34D^<%&9""87@UW6H=*,VW')U_@K?G__PV^_Z<-/LSV ]1M9A:G]0  R08]
M)M*OLT$K-53A9\C_E7]%,C,XW<I7X,S#8\X0[GF#R7R)X#]/8;NLP31.Z3A-
M>R\*PU'H1T-[TN+*S-@0SJ3J.MO]6HC\R/J"_&.L#J5SK[)!^\&MJ.^,1VQ0
MQG4P3:L;L5S@P,31+R,6Y%;8H,D6$H9YY_,A6@/G=[4:Q$\[3NNC61I[.M :
M1!.2\:K0G=73+LHJ>(?Z,J!_YF\E")H6I_O+!>? 37PLJT#$9"?1DGGK^W5T
M%K,(\^L W0PQV0[$<]P>-BA>>,LE0H%N@. TP!EA0PB5CU7!D5[%G82-+KO?
MB,)@EO8^4@._]HM L=D$+@2L55/R:=Z %MTP<BP2 D I@S> (\1"$S-*?/PZ
M0W7*KW"CA11P>L6QMD?SW=NYV<[<EM'!0$7S(#DQFMS/<0'$Z=5EOBEYECX;
MQ)$XNA;T *>G9%S6932RZEASB6:CMPD;9&:RS5&APZ8<S9QE31I>878RE+C6
M.^CN *$7VN":2,&34 GP" ]2AZ1(Q"FQ&GV%0+XX_\7XJY2Q\,X&'"FYZ[R>
M>L.ES1#U>^WZEN>1:Z,LL 6GP@DVJ"1S!$+)H!+8(#4;E@/D X21A4F$T&YV
MNG!$CR^Z>OL.1HEZJ%<"&_WQ3:3H\7^[R=(I6!N4#JG,Q8RWT,;"V'#@B7.M
M2\?L+'()^J-C*: '8\HZ0_YG,Z&U/P'VN(5[T>&Q75Q)IIOJFH6^S:70H\T7
M0WP[@V6UQRHNFO'?)R@F=]@YLD'EZ?]B_""3-TB6T7 (F<##^@'F'HKKO.=M
M0$L,K ,&;U*ZF+.U3<RY-^K?2H",+?/QVN& ?_S?'OT]H+3.H^KOK+*-.0D/
M 63)!H_Q6#0?T$W!X%S/H@6;<N*)0U* G=/XQL24:%NKKY^6Q;A_@#R_$TYF
MZ_0[-R&5SO0FX00V2&)S^MMK^&T*_XE/B)YB"N8Z!Z1?MB0PV:#LYUH, 2PM
MLXGY$N*_>8@UFI<>NZD?X$$Q(::O'R+O,60]*W$EL[ 7ZI8OY@RSO%^NY(K@
M7_[4P%ZQ?DK+/2@[TR/&*\1ZE>/NF398SWA$/&TI%M7SL.*8UN!QT@7KZ@M]
MN_XJ65.ILU-F&[N0>.U!V1*LOCO.62V^UD[P1CR0J?^9 N0-\-<FE&3_AA6<
M%!]W._Q.O,GMVIWB^-8*^<&-$F;\$HJXRY(V CC.M_$YLC+#((^#)5="Z!Q]
M9X.Z/Q$^@-<%*'S=8!'T>;C92.0A -];XFB!(!HV<*7H0RL!XT5SO(:DZM3<
M9J\N5U2N&2;BAF53PX3@V@#ZIFY,Z!_.T%PTJ#!G)8AO8N\/K%5[>F.O32PW
M?,AK:_Q)NEI#HW5'@[>#\];3FA+-H4"HU1?5SG[MOJJ@VAW]ZB.)7U5<^_*3
M*NU6 #.;ZN<7=(SN5,C+.!>7CF9@-D*$]W8H9!8W1\D.,X$&LA+XD]1A9KF^
M:!50[:H5;3:Z&;PI @N?F_]I/^-C]WPGX!3LN>GP^DU-VQ;!G [,"X>'#V*1
MW)'%;%!<(A.)66J'2[!!V,)Y),ME%$OZ\+/=OTY4X(:@J6GW&':BPC$OS[2U
M;32KY&M69F#7B'=3E91WIJ>8E,*#AIIJU2_4M"S%&CGO%S@/H,*XM$P\) <L
M:I9J9_8TALR=))&1)5,\G6S^<ZG&0+&7=08?O&K@?I/*&U^SK!O#$^16Y>W8
M%/>N NID&.KL,#?E;.$7=&A^/4?,5;,;*V$;3TOC8"5D @$(<K%!HBXB$<@=
M#JZ@M[ZU;S(1%A$+ Q>1__DOMJ]&C.Q2)VZZ90<_6,&6VV2]-'X>?8OK/YV6
MNYI31\DFT1C/]!B6!O"->I!/< : ?'*\-Z'Q65^,Z!+4-R>7\</YAE^+*043
M?VESI]"1_+7P>%3?A(/(.9GO(MJS\5L?Z3Z([C[P,0:88F)%Q:R5E3$>QI.T
MHILLU%PQ/PRU(S\CI1K!AV#8GIS1&#Q<1SFEG,+*]YZOM=J8N[KOF1!R''JG
MI37%*+1:HL?(HJQC2YQC:K2*(>_%%1<L?^;2/E#2U[OH5Q@7F.4,0>*0,,SD
M.E!(7-JY1L2<7M9RO--0LG)%S]&G^:HS[I1/>+ 6Y7O[XS;WW][[N(2X_6&:
MV3W#ZHK6__'T77&1D()H,OD$GMS"07@Z):DEI#O)E$4'8(AT'*Y F;,\A7L_
MZ84^3[WT\%0>/U7^)Q*[[UKQU#/Q'[^05'/+Y\L2)MZ+IG]^@"?RD-?NW3IV
MEO_:X8/'= Y+73O\Y)I$E.[(C_^MX9#_O][=\U\6%^Y[[VAEU)4E';QKQ?A8
MM7\P<DN%://TV_?A?HF1C*3./-,01)3+]*1L=;BT[OTJV[P*L\M!.5^"79R>
M7ZB=*<QP;/;\N;PK'H.^S_/IMZE3 NG>%T__)-".!M[^IQ,V4#@GWV>_KD3M
M6(91:IF[&K^PTCM03K?V;,K'[M,2(UTS'H*F(TJ]]T2Y-X0:=S,\#R"]+MU'
MMO&?NZ:CEXB+S&%]0QP_1TE+]B1)^IJXD6H?7/I@,/[V67"'0OP&,4Y!^KS8
M[_3=^L$7YZ5CM$%)OU .H^GJF7: =T5U$U*]$.4QZ3WBM+RC(V>Q,V/V[KKI
M@&(>6@E;)-3<>*%\Y&G.0,GX"MFK[P\E@#MR4+P/(YSIRSJ7,6T]]B[-"<+G
MK1OR_5UE[LL >QGN8O6L@X=B;>_+' W\%FZPNR9 SI<TQFV>GPA&\#K';05H
M1)RWUSC2:L-'>PZ+O%6A>LYS3L9:O#K@1AK"3 MNU@*HD <M)ZNF=-#:_57+
MR.E3&MFM5*66%^6),9DP'92 6\;O,S5*??U;$ZJCQK5G;]PO8H/(ES,I9XCI
MT0@OJ& C4C"@TZ$.EKRVWU?& U3?IC2&]A LQ+%&"G+$BKR'^<FJ-]T37[=+
MHI_WCOW*VB.?@<0-&I5W^'6UM-15S/;'/UURKWRP$-W[\)QV$--[P.Q4]:,]
MH;:ZV=VD$7Q3H_GOH2@DQ10#CAP57TS0/T"1=QS5X ,ONXJV486+7I -PHPI
M \ 'I\&3'5ZNDGDL<R^4QN0<5'4*)^OIE6$,N2C.F 7>T"$,;^9KEH(K7 ,@
M4K!]4!Z&F]MS@YI]T91&@QM&123UK$];]H,A)^ZN:-Z6=-0;%*MHSA:3E#DW
M@;'?J?Y-60M:3219/1I6*AL3V3>X8W^Y-F=*Y(VXSH,LU<9'_#49I6\4T_IJ
MX7]#_.+@L GUUK_IMEG<%*WU:;KN%+.*!CD*C_C@8M?O*CBZ3LQQ(?"AE=X'
MB &>]QJ;#TIJAF(ZS&_7!+Z-V0NQA]^7YQXH+<5+^P?8*]F@A.IJPZJ>^LEN
MS!"'6L/M)1X[[/A<*7,,(7+#O*R#5P=OF6T$O2=J& @)QLJ*3&>;RF^P[.!J
MU/X$EB0098XY*=NTZO/ .]/[J8ET+59_\-=[@0]!VEE\%RH?FKM+Y.VWT"K3
M70!SRM"G<$1BY]TOU&B2C*B4/!ZN57IZOH42$%,G))==,?<YE999Y</K4J!V
M(>ET4FIO#FH]>3Z7<0K!.IY.XOL9W3.G1@F(T]>A9)*44Y6#45.>GZ:@?>"D
M.9X)N!ME$]>.C*46PS4F&'<OK^/P47)IL,-Y$135?@-<<TEPXONI9]X,07@
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M+SWY DJ)-(S[^BK1SE1T*?=>]>5?)Z4O-&WQ<0\N9J1GASH+NNK5,72HR/@
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M'.4XW@\=-;[^GG3JECHUD]-G>Z7:'X!_RTYXK_<F7SK'/<,Z=(E0C)Y#3J2
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MJ[]8A&7,V.2#/ZW/'EA 8"-J$PO1;S?YA*^&Q6NFO7R]=4_MC,!KA@'B/%4
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M;<"@P[KKL)"FM+[A91G6;A/G'WJ$D\ 5M?-$FYB#]#N0OZ6/\G (1DA@VA)
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M_)'2P%LH^3GU+!W4UV_3_)?(@>F^\B'[6,6@ $'T:B,P\]GXZ?J0;R[P\FX
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M_+2.8V#V1E".\7=!QG30^S,Q0(2WL?/'CWT"]H^=:/="S@!10I@ DQKOD">
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M0^W\*2,3#GM=ZB%)K3U=J(EDN=@.9O"91,GU:]HFW"<69#(=F"F_23+?*+]
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MLQYD  7*M604K?K#R.!'W.M':25Q[P1<?2(>#@<4#L.WBOY5SE?\/);.QLF
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M:Z**,U_Y, VG"'BYT60B"*[+9)$9&/5=SU_ K_X,X(_+ XJ;-5V% >EH%V9
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M6M CLVM.F<Z)JVS1T5D3XVN@%=+1OBH^-<RPA,]P3J:!SZ13L]:L_W'N(]*
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MM0:1L_W[IJ>WJ]WA2K/$,Y:6#5D+7[\FJ0@'LYHE.%F(1&O[^$!>#'<P(.7
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M'#L#LFWHZ+W/I!(K4X=_NX)1 GXMDF09$#/M5\N;RW0V9V8?KA0?8*0)#6-
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MUB3P&EH>L;^;X6S9<86  K'ZSZJ#UGMK<!+T::(0-6*]R\Y"5&I]<<?;7[G
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MTTKT^+%$GRJV(SUK86!H?"[YCRF#@=\<;=7XSF?%B!6,QF)NJ"\D+%G+;6%
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M;DP)!$VV7?!K)CLO*:HA;4A>LB'+8WIE:67[_/RD>#4,O,3V9W3S@0&FO;<
M3E$.&$.[4<.2VQ19; B(J0YV6#-.-3*TJQC0*5*+=:SV._*^(\UX^PZW'._G
MU85-$%N.4 Y]OO^B@ZL!.U4<6;I/;YC"PT3EO&I?B0,]>9;*1X^7_C;V2GNT
M-8^K"MXV- H8_;SNKG:G"56G6^N[P2;-A"1PNHE5'BVX _@^^F1->PIPD:V]
MDTO%)!S J]N#GX.9LMM='NWI;C?F#/!U@#B]:^#70$2\!V/X!0J-H<B$7N[3
MJC&\&N2W=TU%"S94\QF$VK/TZJ>R!; N.L!&71@978+W,^TGV#"P1DZ3+C7
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M2S^S^"G@W6P>SD$U6ID-2D&EG[R?*DQ6I8A26/SNON7._\-5C@8?\--(7/I
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MQAUUO0:H%:LK$P-#\ADFG-7''<._=,\&@,%Y_IIUAC-@#2)!Y?,##^9LU*E
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M1TA7E_7^;VW27$#!UNKO><V[WM<F\JL36U-C-;*:6#,,=O#V[9!.&*_N^;M
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MST%-<51 A";09;O86J.\O7;<LU6T<D$+5L[M<L"[@H)I^G_;Q9)_D +(Z53
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M9U8:_9RP"TBBG$&-C.QMC:PO_M?N+_KOMS_Q6P01:>0>!!JI!Y6]DCZ*_J^
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MN3N *W.7*4[E<8KRK&;JA]>:7N0\T#//V1&"[J@"FIDR F*29XT\AL4J*!_
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M;4&Y*T<:N3Y,B6H77>/5OL6:]<NJQ@Z[^"33 9<N:L.4\!6KO)?DS6-KS]?
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M;1+)>R'HZ+B;Q/<$F?%:!R:;07)5TL*#_\-">L,TL_QZ6>\ WQ^@&LVP\&L
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MT@6DPCDN70-N>0*UXG60.$48653:O9R<#TJW38I#WLSKE998Y6<H/(OMUN(
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M+=-5U& 5IM.X.1?8BV>PUE(#4H]<%\9*"LME$)\GLZ._4PL-P1D!S"$PLZ>
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M1ZZW%1H,UE<>L1[P;6C(XYP:7O_(Y=QVBRY_R>7B&XY$,%@:^&6U7,BN>CR
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MY=0# *B* X!5 W^7P>WP7S[^@M?^:&+ GS?QOU\GH0'WK;#HR=]EN#P V+8
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MG+V90>!C:)8ZO*;W"H7-)3\-YF:J>+:%6.9,K31H>G58^5,$&&[7F&PZAST
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MG8P$9C'EQ@#_%N$,AUO(9C'HL7P_QJP$WA)'V,S9ZLM1OZZRBY$CQ\<]_NJ
M/]W-]XG1N=>33(PMF^X27IS_*I#,J]_,IO/55+D'.>YW2D,N8YH&R[O+$<IM
MS.@'ECB O[?#J.=L*,$?QV:YO6(/Y;YEV*'FFGW7=0C7^?3S41R9.(*U=!'3
M6:%EL9*HV1M1XWQJ0L%Q$7E-!.@05PL[4*M[^=[L*N\>RYQU5.$F6JT,^2F9
MD:X&[3C6 6\UJBJE":73R[=CZ6COHD4(G/9G3:S"Z5=WY\N96@1__)V!@<Z5
M30E9M,"\9$DU%P?@C^YNG5CQA/W]ZHO)GT$#]2^SK!Y$%U7>8?#D+'VBW'CJ
MM9GB5,?N4Z>CIP^P6\RF2F);C-[<MKCDM[O+?+0U"08A V>NPNAY S0*LN.1
M4E\)ASF:K3[KA"JD%!&@;H%(N(RYG@_)@<PWEM/()EW;BHY:SSRPL9ESE!P7
MIMK@*]L]73I=41(X/!["#"PI?U_AZ30(3AZA8&FG6^Y$@]XBX [ZF DY_O0?
M-;BM4G5\V?<M$[TF<-BXUGG+Y['&!(9F<VB(9S?!^QG?JJ-^$YI:-$CU5>XK
M'VQ/O Q2/Q%IS1Y"E2[R AP16MT>%*=+9A$Q![S#OF,&P[G^NJ9L\]A0X;K*
M@N=\Q[=L#1+#>PC9Z&O51]B*(G,<,<Y8QDQL,9[JQ!ZEQQ$LF4C-P"ZCLOQ
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M:^RF@+%N>_GV^F\+&\9JG;7NY"L>W?"J8'O+YANCD@_ONH8^(<)<E9H*CN3
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MMI9"J:^^;1JR8X<3_EON]PGFL9%KJX8]?50\$]I%@*((.(OLQ[(LLA2Q\NA
M['7TBM,<CT3^4092GAQ'N,28/HXO;!J6Z8I(!9N7C>.]^I9H3=9"G8X%@:9G
M[\G.3^,570NF3HMH_[M.QZWY:@H,L]96S)<Y5GIC-F8U'O.N*G<3^WM.2$ )
MM.AJ@[X:-C-EZY07S*U7YY3FO6XV)%_GGT>1D+&VN]D/C&W<ZR)>#@S_WA:
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ME4IQ&\UO']9@ /2X"!B!?M]'PM18-B_H^R>)P)DR5FD9W0<,%M!N1181TR4
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M"_OV.P7%E,Y"_;!AIX[_=\U!:8<TT'M27]& &NB[_83_L?0_EOX_;0E39VB
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M1\I?VBY6661I?5A@S=K ES3^T24S@$B=]1X.Q-2=MK\[[' ;2$-$QOXAZ?^
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M Q$$7;-:(CYW86/:'#X=0;X+&%']Z5<R;,$P(4F>2FQ:QEZ*H$PCS,H*3O=
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MP-X(K(U<Z$/*-N=<?_@]>+M-C''QCDV5WY3ZQ8'/DC5&MMD4SX#LR3JE,#5
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MDJ2L*AOV*('A9/?L6:K_>)S96)&MQ4Q/I%KWB0!120WVY)_^7EE5/CPXPX*
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MC?6=-U[-(QB#,I=/?I%#I?KRK<6>A]IT;8WX[RUN9[)EFSB+&>(L!F0]V8<
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MBP=R2L]=8O4\11WPQV^>>D99N^4_U3-:[$NVZU>RRQ"3N,-HJ;5K,IW>WH>
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M8V4?7:[:A\3I=C,AR"^'*R*Q4RWB^Q"Q\WK\A:>'%+)IJW;##K=6;#+.II1
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M[?NSIN#V7LGSLI57OBN!Y:M3D^Q0V]4'0ETQ\YY0>)MVBQ6RU"J-#CM')J@
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M4SR#F!W8T9,PY0RD&FV@732Y[W;^5Y';^6$6[>HDAT$]_\1780WY"1[Z/^*
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M._N6D;L5^L;9T77SO_;2J2=WJ5HLQ.J5'\C)J[4GF$/*#^D^"2V!A\#*'K8
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M.)QYI';]W8?\V9O+A:F>>O.[=$]TN#\H6/ UW'E0_IAUDK']3X/@8D-)_;Z
MEX6>QTPL0AD_W$Y,5*AG1LYT3X#7]$@1=RZO'*5#1TC$:P[BNRN_N/G&E"04
M/>[YW)BFO#\ZRC^FX)P.:R6O4\;^F9SY?BBQ7HU.B:0P[;"@\M(\G8F^  XR
M:73EA;.<(]0BW!W47CRZ?U=\ 4AJ3!EVG,'>JJB/M6R?J7M-+ #=?EF:6O:&
MO*CZA#'_U$N:WQ'J4%L!"K20AH+8EWC)_GS$#<W?IF$-ITY0AP9#4?*0@B]6
M8HV/V &^5B-%N1U@W@$I5N\Y&@N/8D-V)GXY/AQ.?J%>%T4L&FO855#J<SK
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M)K[.#P73P6] @SHP023N,?2C8V/(.WC/\8+T)5E0T:67:TFWO"],DW(=G<Z
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M?$3_73O@2PZ\CLHC":CYT8!DJ.K@E;!^6#L<)-3]73- 7O\]N^%D^)IM)].
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MD5S3MWP$=VT-2J/\BO['B]L!C2E;!]0NI#,\H7TYQ^!$L <*IMCP2UVP5:#
M_R4VCP/CU12<&338T33!$+B_$BZX"[^0?,1>6S[B%QH[X_/O\?X]WK_'^_=X
M_P!>;,J"(#.3D3TU7\(1N.J$UV'Q^MFI=-'DHJ(A9_!,DY;K#"F4%<?XU:VY
M,-F;X:O[H?;WL)#WEX:]+J6=^.L\9KV#5\%'K#0 2[ S8?AXZYA<RDUIL_'
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MY)=>%F5HTE _VS0J[T'Q''66&R+J@2JGGS0_.96ENF)C-]5EOO]7\$\;<6B
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MM^89O1FC=K25B%V'KKVP6B8?DY--7 PL[0?C T-RX?KIK?]>4C TT;#]&?A
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MUCW&>I$F,%F60;IP]SC:,@@Z%Y9&42][;S&QQ1/HI'6W4\=B><1GMZ2JHX;
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M;4[F:TZW&E?O& /Y1I):"X26V%:23;/N2UTG+W0"U@+<PEU$]V-:R0!1UWD
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MB!DELP%EMX#/A;=2S[Z;M6=GX(*+BRHG7](R4LIZ+0T^XE0BAB[:[B^?,V>
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MM3X4&/1Y5>6BW^PW_/=:[A^?#>*7I+9>V#*2<0TETI$>(LV=XLY);4UE$,'
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MJ1OXPN#P9%U6+>.TL._>^M[['8JI#ZEW=)(1O#&P8 _WO3HH]AB.NI*?/S/
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MBGUP<%UWB=1F]E#CZ6+7O-+-6:GW"OU.!%ZZ](?E]U*7PZ9%>#V<!A0A+.0
M*Z18D5^ID(T>PIGZ:-=VU>I!4XT8-7O_0"O9_I[#R1*C)II:9QE#@[34:]PH
M;NP3L4Y<;?;RQ4L>.61S,%0GTH67>0T25L.=F!??&UWMA+/C*B0P77Q)Y-C<
M:+&74[M5EHO#4]T@NH"=:'.XOG;ULX\L)R'9<"3+C#.YM$Y5!9M8PK(KH.M
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M/5XN1Q7I=+./C?Y3=%PA4IH[MQ!]TOBA*]5&PS\3Q&\1*O$+A'"Y)QT-M^'
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M?OKSI+&@>3P:04&^J(0) @TVQ.6L(%&'^$F%2*FI-8ZGA=L$_\$H^SYN*[0
M^#V-<E0<3K6[7!;4@%%DF4<*_*O:[!5/EO!&YCT>9D2TV<9;A_!==?>(%%),
MCM.Y5S;H71J?(O8, COQJOB3/&X'GW#M)-0!1HA#H"C0;Y1/'V?P&5SBH+]4
MZP-',! 3P:>K4I:3H_VV0/JBW/HLSX;@78V(R;=K(FH;BQ JI'*@O2S$+#K,
MU=^Y/$XPL7%F_+ /4%JK0FO$;5NH,2_N)'/EJ-U=,'I4CJK,;/3!Z$.%?'8]
M,>D(0UNZ"?2\3L4,$A0H9ISGU&/@D[[=H4+E,7LE=:8@Q853/>V?Z?FRW<+O
MVUMC$MY[0SYY=%YF5?ILCI'I>F4X".NJ 9'!65CMAPP!"^HAR$=TH;6!4>Z4
MQ"* $0)T',V,LKY#H#1N(,2NABZU-L*:;+I[&W.BS.'<QN(+'AM_:]ZDH-42
MO!F\_"1]!_Z5MOL>Y_.FDS*?'PM[(/1KB$X\("K4&E,C(7]P+X>A&N83%>H)
M$L=O2XRE?B+%F@]%!<,JI$%"+*#'VBI$ZP<^;WUR@LL)M<F\3^K)O$GJGC21
M21HLG@9/6/JN)]=L>$CO_-,_CF8/,GB+86.I$M@\OKM ^G-;<)D+.Q&HU!W'
MBPKK-?H"JRX\M4;',S2I_DN+^6I^_AV6%]*:A.[/4@HR?ZX.*->W-&)57COR
M+&K*45L-8=F^9<@;1_^;DB,06&?,/CMY [$Z; Z=.\7AZ=M;^_/O>0HJI=H8
M\7U(-$C9/#.N3W3UY-,;LB>7N_+5+I'*?%H^E4E2#CI8SN2U8[F\H\]_=/IY
MOVY?BR^Z=<A *D>]QW_\.YTQ3^Z@&4GQW522 !NO1TB1;GQ,W0VF,@H"!S:"
MCJGL_'Y**:?*K\QX%RZ_F$+3+^P*ZU,[Y&CV"6LY?JJR>NO+:TZ;?IIB<(T&
M4YFBR=?B'-4VVBYIL(QQ(;A\U.$"08^JV,/"\GFK_?:2@B,O<%=V/Q"T+J-T
M$':9]/7G=WW>0OK-]VW(V8##XAT9 072> A M.<F-,H'H(T,#IH[ZBU[7KL+
MXO")=818+CWNZ4+-O-U@91*,I9[IDKJ&;NX96"Q*HYP>G.34Z/\$V?(%1P[3
M#["[6.%/1KW%V+ *,'';N[<\A+4S1^=[AXMA8KP4 ]D9MB!& A'M6U1*,_P.
MRR'(<,[$A\#?)1U\]Y?J!L'N(B%&LH&MAI^>,Z$EPG^3QN"?A."2BAFR;MG_
MADLT? ;P=EK D]A\QLA11?"_%<Q*P1.7;]I0&'?Q_9*VGY_\<:/M0)IB./]F
MDJ;"1OZMP51!/H(EIYS7%-7:.J_(6'3S=N?M4T]M-QIM>EVD^F7+VL%K&YR-
M?MN:TE9?O;]Q]7'S!YS<8#/UPK@CUPJO*:)P21M5-@E#%(PWO%78[(9:/>(\
MJ)XW?5]QX6 Y,A3FKH@FHZ5.0@RTHY+_[<%]K\;PH$'M=BE9$)$VP?W42_D5
MW5O= *_)^&'\,LV6=3.<K#FL(^CN.OO*_->.!%:"61I^1(?-P"C+4>_J@!7X
ML9AF!)2_U\_(E#P_A225N^E/\=<DLJ5:QVCQ7V@:=A]%&@ V><V%6JF;!LR^
MBIA)T??1:$?M0XN0L>1(KKW6^ANEC>LW?-CVQPW4V^&WH\3;1-!QLA<0VHY%
M290I/H/T9K8:ET(0V-P1^0MGD\A601:1CB)CC8 %H1#(43J4P*' +,6)!P75
MO( KQ2E]?<UA4URKIH'A=2]3#Z3/!";MXO6(*N?4)7-R%&>!R?T+K1?7ZLA>
MT)2ECE"U""U6[I$JY?:-5!%?3_8Y[8;J1*:79USM7(-U7]O@%]?:09N^>U3&
MS0N4P[TZ&F@VX->DX:K $[PJGL/'F+&*RB..LZ[:B]L*/_TC-'U!L";GIARU
M?#M_\??,!2?RE*-[_^]P.T\]X9#=W<47[12(N>%S=8A4&I+'H[:+=T*1FJO)
M5$!RF?;^9E_3TL%G%"5B)VW3B*?F?<4;-F)#I7O]K_OT?[^3L'(>?Q1>-?<*
MGUG%MH*%.3DO;^SUV? Q68[2/&;< ROL8/_^/_'I_X*Q:*Y:<.<('R-=J<!G
M)Y@!SZ%(<:4LB^H(UI)6>P67T#; K32SS.:<5;'Y_5^399ZO#1U$6?MN*+0H
MQ=TV^GPH2;:>&8O8]OMRE K51\B(]F"O@'4_W=LKQ(^U"1EJ<!M/>2QWP*Q[
M9C)>+1R?8+^*KF.B+.0M)E**ZM[KK7CQ_JE/?'W)UWGR(+N1H4R]!!' 6:%N
M-%9Q]GJM$41P$IU+MMR=I1_EW6Z7N!F[(G1I;O[G.]/];EWU+:1'WB?Z#B9N
M=GN8\YQ0607[T/2H%9/O73X7>Z>W'?0;8/BOSGMB\EWOW9',LQX&K:X/DS:Y
M_?;ORO=_,A1$+; *(C,;(!%==HL8QYBGIK'WR5%GR7/6"#=FPV^PB.3(/&L-
MF!]:(<L>::ZP"2]VI^D!PS\.RK3^;G^XMF4AMTR'@#S$!B&S3Z2/I#&;Y:CT
MX4:V./@EPK4]I0B-IB*\5]$,Q#<P$GDOL WH>/PR*BF7LE>@FV)-7A(P;Y+Z
M7*0&:]LV1!X5Q:4\@I+YZC=%R_O;)?7<V4:TZJ<@0_7V<H<=UI]M]>YCJBM)
MWY(GYN=FQ?=D631]6C>P+)P9P]!>RB;E!NIEQ A<T0VUZ.X2>ULA>3'45^]=
M7%&#&&$#R*S!X\G44,XFL.*5?]#C8=OZC7S-AH^^?;Y>K2'!6,0G\J5_TDG!
M_2$])J.'D:.)"O@@>EPMIHU]EL?UAY5S19&-/#1MP]"4=(T(5TP6F8F#9<48
M3HY!>4^^KYW ,E[(Q%#<1IL!E:RFJ49ODU%F#)7\),#VRHM G?1/?C7/YE4&
MOTNUE81T.OX,#S*1HYJ*+[2^?BM$]ZF($\#)>G92FU= Q$>2#JS?A>=?4'E,
MW7AN_H\7P]X,Z:%Y.Z?0\/#'^V(G@;:$.TOPSE)CQ!;0>!2B4"D:9T.](GM2
MBZ-UX\RAW?E0X0$(6TCUQ*"GT2I4>^)JD@J?MX(278:)@]'@+<,M(H0RQJM]
MN 9;BLYGY8^0N''WGW%6-KY]2=2%2 AR1H.V'((653FK5?R[["%K-U@J]H.Z
M0D79XDA(7Z#F6=<NQ4'DT,<8+>?'T.GW'5*+DP+L2M(>HC:O\8$OQ#S>%8Y6
M)8U;IZ9L7BH6"TB>'A7]9?"D4&1G@3M?U%A#K9[C^1"?\,J9I7@<^PR9NUW<
M*[N#R-#D(BI-I#A;A]>DO:%++DH](/,G5.LH3),NWL 4S&P$^D(%:(X^/FE8
MI"-LP(-TT\H\Z5Z1:YD.#XWGZV:[ 0I>/OUO!0?"$PO*RH981Q"YPXHR7[.7
MG:#BP*7)X!0_/I5F!=3M95_ QPV+EF-B>+JX+5!$'6T9M*[D<^# >A%<"&;S
M[WTK%=(-I'M$OOT3B?D)8Y9A9%7'1X&>NSX\LKJW[7TN4&YOCDS4;=",LRHL
M80;@HL5WH'P0P__>A%U-Z[)AO"C_.AE3PE(48%)LV2NHKJ)0 BO5'*OF!54?
M:@OC:8]JC%S!<K8+$EA&@%#%G*#ARXVJ^C%C,H7O+12KBIR:,5=G\1JX=<ZB
M(K$#-*D[7BXY0NODE<I1R6$>8/<=43K?+UI4V.A=G+?+Z0;+NL@;*JWW%..V
M@=?KT;J0EE]%Y]B%L8&WEH;Z"=%[6AU[3>;\6EM]SLLB"/W]O35V>;!O9 WN
M9R%LL+ ]*T<%3B9CEDL5P(XZG 9H#)15-K"YO".R.RQ=$;.9J QOD6Z%S 78
M10& ZE>H[BF5V@%K2'<3U:C.NC:&VG& FNO@ZO#PTLQFCX@@?X'Y/;73=^;(
M?<N N@,6L!'R$UNI)B*\H/(U4P5ZBES$LLP+*3W\V6OV7J%\;#)M%:&W5#"9
MQ-HJX&E3EDXV>U325C'<.J9;#:'37J J=Z+Z9*A@H_U&H>]V8F7,P2C3[]-&
MGH@"!%'(#< R*V IE"F^(<NUWRMB<AAZ2N,K$0>&X2&Z=/NRB(AXQZLR?\[>
M[>O#\=[,-9+N^,C2M+<.">%[0+X%$(Y7ITFY(A!P?;=.%D0=^#+" '^&RGE*
ME-54)XDGK<UP(_1UD, ]PN&5&]Z1[($>3M5=^9[X0/0M=E!VFM]' ?:#%CT(
MDO"]*2[\\<FKK+TET&6I"9^L.NSQO.)QZ!.K#IZST9LQB;CG0D_OQ(RTQK]_
MF-=3F=$W3:Z*Z/C"O@J [JWTG"VREQ=J%:014":H,KBRJZ<)DY"#:D-T HT0
M0J5:+-4.*A(0%@U%5-7$<YCZTG70;'%@FG0;5"<@K.GK"X"-B6I#5<=J\C^D
M U'!>7_TZ '99I/%-#\G1$X;VYBUFR';1MA*5L@.8"+N[3*</O4BD6O+;QT;
M%]XCUN^:O&YO)/+K\^RTWYWGVP?]F*R?%"&FO@[6[[$V1]RPG*5L41[7\'>1
MM_>+S\/BE@#>HS#LZ#Q[[K*Y<I_+)4^8S9==69^TH<!H3@0RI$]U10KP&WM@
MOH2*)7X,!W X+3GJ]C5X+="K1)>CCK7&CLZK,Y\+,8*+/;*TU;IPUE.:(Q\-
MVN]'^' I8HSG;\8@[DSM#EG8WS$A*%W\&EG^&W 3\=F^G"7QXC*H+Y^Z-EW@
M'?2#LBX<KT[I\(/["2H5MZI&]U%-^.^C@FFON0,9JXCZ1VRYT96:"=^VPL;4
M8#DJAL$^S8QCE]'K@NT07QJ++.4:X"S&\ ^JM<BI@:;Y$6<Q!.C5JE&NA:Y]
M(4H9B!4PEP\;KA)%<#Z7/^\\V6:)YYN5[JL-&+O@NSFW!KX[TZH,^33\"9/7
M,SG>2@FTYF^R=$GH_HYR\HNY/OO)TJA:KO#-%/6EE&=.OO.U8&S\!.TR=:$>
MN@_<RBYCC*\#3PL9C>(JD6XTK+ ]B+9$=M>"BN<[8 :_\AJV3'2S->R#3A8&
M@",#UMUE']M*,@M&,Z>&/$X-6/LZ"+-@N\[)=IZ5'&4'QW3,P^R63MGJ-NM[
MY@U7;-(%!LMAWM$VZ_YM'*^V&3NG*8MP ^R1\J190FU%ND)437^>B* R>"'5
M<<=J)@=A!!WB\^T(1\J=-VO$<]/%MZ#G(O$W\@HI&>H=1%_CJ2,R% S%@D ]
M<1%K$1@O<$JH744)&]9#<XHC=[OP$G?=:XW%4MT%>&W*@_+D.R7A09$ND78^
M*L<'@?ZUBZ\^6?SDZLJ?4*BE*-1%U!K4CL7L+?:[)8NE9T$G>NT&J%"\4U;*
M.BG90G$2 C?*"0EL39K.@-0,NBQBU'5C-.SW_X9-MK\,UE #,V;A13WVQQQ>
M=H7W6WT.RM&MZ3G[LBLN7GMJUTT9[ O#O.XW02455X)*^B]5CW<\ '6O Q=:
M^]"#S.NLG9+MT$;J:LD!Z2E0CI)J,P7HA7KA'+86SFYTON3:P#K0-!,LD0@8
MT=)0H<R__I)6_P"46U]U;"(]#ZJ=:#GXDB4Z&*#[PZ=O]]/ T1#RY$6@S@D?
M&*7%&;!"X))^';,T'.B+=Y&54BTD:Z!M/1R<F>ALX9A,8,[4IQIVU.*'>3HS
M+C5N'XAKAOW6@*WUK\I3]C;4KHHS?W\NZK1S/*'#LA\K[2/G3N,A4P*'L2P
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MX B@"1P'#  CX#1@#E@#$, )< .\ !_ 'P@";@%10!QP!T@"TH"'0 Z0#Z"
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MZ>11/.%(D+AZ:XQ74DD7ITS\X]I?GOWW'$OXO^79?SCV3[^P #\;"S-Y;"(
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M"YMPHWDLSKG$+9!4<(<_>XY6K9H[N"W%:A,[=^I@:U..RR65#',7$.<&M,X
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M8P!7C""WD<)M'KC1#%3]-JH<"J^ $ESO-\0+]7[2?H_DV,C#2*5,A<-J;-T
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M+U8VMV2M-8E1+.@?&0#!L1"TI(H/H<30/X.:A'H79].6H[I1HH'8T?>8NT4
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M=M;$])FABE$ZZ,6$AUSB"["?>[VWJ;-^?N[#6Z$7@\S+))0F2[$.$T]+IQA
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M#:3'?5ICX^!?/(OH Q.<D)\72;O3QF:XD%D&L'R MI,>IW.EI:-V*42*C&
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MSA&5PG-?FJ=JY6J,YMU0GW,DJ-.(88P\DPUB9E%T/JD:1"<#D 0'8 X@)A@
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M+7784/@HHL>(YF*?JAB+[XK6>:X]ZE"&U*(MO1"Z0N@9D)VB] Q/Q;-MT-L
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M5Z5[^@Z+A+HT?KFNT>'L-2*GWY(E8/7_MW2GH?@X=AG[&2ZYCG\(;_@[B9.
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M%J/69E,3-4P+#,+&S ]<&IY_I2*SN'CW56WU."DBU7T-<0[ZAK^$:[>@(B&
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M>2^LK[_"Z)2/=V\9+2B['W43B40E,8R=)F-$0<C> G$]OFR!Z"4%1O6"'-+
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MI'>B@1S. %=.A/FT!1^K8>$> ,]](DB-5:U*23\(V#@-6\2P-9G"A)"8D+)
MX8GA5O.J_ OV(\2\E]5^7OU6\P-#*])SGS LUH:#GUAR[!71@ZJPH_AM5/I+
M'/OR%B@=O&>-D&"&3J58\ATX8@D6H0Q+,&,\R<*</@6W&UIO<U2R%.]LEGN)
MWI5#7V&9)I^N11/S;F><*<U8 -U[+T@J$7Z8(8ZGBO!9,$,V3#"F?HWA>@A>
M8D_R@]D:!(93 EQ\"Q2 ,N^@@9.-\_=-Y=48V@*9S#SH.PO=R'+:J6,3'W>5
M263:DCU<K/V'NT$ ;A;'ES'D3G#0?!FD< ^2K?GW;I-?:*&V< "G$$XX&'N=
M_8Z#?G DLR-:>?P1@8!:*1D)MK"1RZK0:WS;:YA5#(<[YG6TVM/+59<G[7X7
MSS57(7=/3^GW+^:$C @'W2:?<$[A1_05GY6X2,]C%B,<]>&T2OEF+/]-E'&5
MU?M,[M_#=$]%H"2/+V>RE;@?VP0%K2'L%NX0D@>76,#OYIM7+\#P'2R8PG*-
M$E3Q<SD'CCR),*5]?KSSQW0AF9M;4M,]TNB$U&\:6)/@F/>XSTABE6+/ ?'1
MIIZ ?+N*#B=UB+/J!02<IXZ5^MB"C2(NGSD2^O$?JJ@8I!>!ZU=8!SB]PKT[
MMT [W@+#[$[&&D4#0/,L,%5=9NG=,P<TFAA39RPT ^)J <5?TPB]< ?W/I>1
MSDF$XL/[1BG0/V(3GTXF83J%'_E(-E0D1DTY 8PADU[.2B?\,'#B,$X<P'<J
MEB:G]A;YQ'M"LW@F3<'CE.S'R-(\?5/+ZSI=YV8K/ETM.^26/OH#QB+I&6O;
M74(9!%;60B^->,^65.,,9NK2<J)FT<"Q#?[!7BZ)$]OI#N3S//IX#L!DMQE_
MV8^29\O>2 Q>,Y3ZV7]*NJ/7KDEQN=&$KZ9=?MK:34=L?H!E>'<,SPYVXLLL
M+AS)_E%#11PJ\PJ\Y/\N,!R>XK+[EO+WY[5=RA,)V$)<NVZKZBSX,9Y]$4(;
MYSJS"^ZK;_2D;T-226+O/[8JZ_>7YL>9/B&E6H;K:W0@PNV667=2O^7^AI5T
M?^=RW]"?$JO>.E!N<JJ$>RIX"$R5<#>9IX#]1)-JKTK9 J7-B%N930+47A\Q
MN!Q&1R',2;*W(O;".[-XI+S*T93SK2KNI%+3B>5P\[QGW-?[/-.NY)4^ST49
M3@?F01TOYC#\0COR%;/NAOVPS[=/BS(JTCXOG9E]#--J:?]L@NS\T2U'=R,_
MK[Y'E*[LJ/2*+9 ,]@RN'6)EP%?\NS+Y2B2<9CHDP%T%$NS&ER$<5Z98DES?
M^\U_K@5MROX7G5@1*<C;#86.$[UB;FEX#TV=/VG73L<%.RE@>GOA]3C^_GFN
MVG"K4Q7@RAA@63)F$K+A!\L&?_F1\)Y#>J_9<@EE"SD2VXN<$$B1PI)\4YYW
M!NKE$*/\9*AG;NPD=="0+RM#U^S&T<2%>SHY>?2 #HBX'9.:;*7-=GI(S)?J
M/+ 8[?AB@[P93&+PJG[N*JJ:N88(.:2_7'M;WW(9H9G5:!)QVQV0^A]WAE_A
M^PJ*(/0"<!TAD:]=>2U62]" \X7LP,BXL6^,H6O\AS*[-AU3W]2V,/2AL"'\
M%>(#Z]$PY9,K#J.HXM:ZY-__%;>P@HNS3S]Y$QA8V#1?LN(_JP3USG&<1KJ'
M,>M>?'3KUM1YD:,GJ:P=<WK(]4F(?7B@=;O6IWNE9461&QD1[I:SLUL@_GY7
MKB@SLHLZ?'8#Y^@ID(F\WNE_QBQ,*P&G67BGEQV$845"R?VF>76/H8/#=X.[
M/,QJ6EVVX2J_0<-OEA,5$XKBQ;W^-_+>,ZK)KEL7CA40,=(1A*B - &E*B)Y
M%.D"TJ7F :0+40$)$!*E5U&J@A 5,%)"1 @H+0(!!$2D5X$$4>F)0+PA[<1]
MQGG'/N-]SAA[CW'.CV]\/^[\N).LN<I<<U[7*G/V;\*8XN9]'JQ\U!%4.X1
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MDZ)*60+6E3_G>)H%%C(N=D=%=+(N+LS61I(A\4X&?#27@-W(!G?O[@*/6K)
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MML5MVN/_HV6&%6*H-M =?O8']!]0.LG@6DN4/GY([U]@ /:_P,#<;A!MT=Y
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MKE?6N;P,FUCQT^=[Y?'4XWMTW.N=1_WG4H*_.H5'PDE$X,R!'VT^?VZ]2W!
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MUZ3"_/9H=P<'!%BT\J'&[W% Q_6]:(BLG:URY#'QU/ ,SVS3%CW)OFB<E 4
MJBD8&Q-6;O9=/> $3X0&8D17H+4)W&DC(C4_T+Z1"=N?_0$CHW^9 A9&E'PP
MT!C2#PJFC5O0T"E:B_6C2-GY(AZ&CK2*^UN:;J$ #I-B,!F.G9YHG&E/T[*-
MG'M!I.Z4HE,@P@9B4^P^C_.M-(6V'3'UY 9'U"4JLI$GZ73TZ1'9Q!B?V,MW
MY.I[^X6FY*8GW91V)#*A0!P7J<5288D&$$/:2C?LS5RZ+W5G9/S:H'9E$]=<
M[N)3">^#I[\W4>MSJ)8453_KFN"7T6LZ?'\3_#)#%6]EOBXCO>]R'RB@'73$
MYEE5=.M"/6/;FXV],UX4DI<_5ZOEG>8S#QN]!E&0&[W@;EXEWP=]V*\OUE>S
M@Y)2(A_V#<[]'D:]<>UEL48US_E/YVSZ--8A).IPQV#BWGKGT\L^0%[-YZI*
M.YR>>:"(\A51S]U:!AAP<J::<*&A#L*)Y*CKXMOTDBE%E:^N?#7;/O:[(&;I
M2_#IXL_+/#OD=_4!US2-Y_5,TZLK/KS>+29JLR'L:8R,@1P"9DP+>< 0 68'
MKHUMN:MX$ @T,&ECST^]3D)B3<"!Q8)E/<M-U3$,XN3[9#=G-^6!8*5SUU*7
MC<(K&?:H(?"9+^JK,(JZCD#A E0");TASUZNV.C3?0V)*#\1"L.,E^MW"R=W
M=4_JIN%=14;UWN0(XQT=)-.^CRGUE^Z6_69WYOU-SO9Y>L]&$K%DJ/+A[U\_
MK:KY125K$_G!%@)\(ZDE_I]M8G.R'"V; KPW&E4V*X;I'P'&7;8]!U2#3]YZ
M.N> ,2(TC*'.,L\/5VOS,R(FY:+"-#YYT!!^3O%G;QK?^77?2NP!(P+Y-TV?
M?:KA"P=TTSUJFZE"<=W@#3I#%$=!ND5D3@S?-,57G<IR-'H7'7E<MLXU_^0;
MT_U#-\Y8_""<9F'4ZP(Z7X<VF3Q]-?0]H"RB,LU\3;JB&:9:[M7R;08]08L(
M<%E3][Z7RW7:B<2E7-&=I86-:9X%8OO<'D0<)2D3[3TGZ,_FH187-W8G$R["
MT]!@@M2T]$GYQ(N%[[3Z(H1G]?ETMAM2XBSJ*MY\U-[E"[K=X#CVV_10V:>C
M,Z?J=97[)3^^J'G\2&)?7/J84/S+['NUP:?+C@5F!?M_+6B<"5L9KE1JUU^^
M;9-38IOK8FN.[%4;/<G_:D$^/,9K\)*(S?5;_]VK]:([[[FS09@#>D1<Y>&
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MWV;SDH3_YX)G__+U5YJ%9&9ZOXZ[SW<?,Z4$VPPO2-?^?/6T\\H" ;&>J".
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M-<P)C&F!O=-?NBL87$8 =/$7T+*Y,$FD0F,$_$MLSU'G1("G"T8MO(/9P4@
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MGR*J_+].%OA?['0!^&"+4 7.?RU*7L8A-D"[Q6\I,H"10)LN'M\?&4\QQT[
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M+=V!/)Y'-V-WNV$U<-U53FA)%CV>0*SCER;G%S#[($5EZ!/.^2?=)>;LG3O
MRW[:3 ]MC*M</!AU%#'^H:CLZB]X C>HBNUR])WVUH'NDB.N&@O>V,T\*!ZK
M ]CV/(B@:+TX'. +0.TF,,:H*$=(%W-X^\*4;D0'=[8^9_%2G5WOLZO65D9W
MJL,&5?M]W]IOOX=T>Y?O'.0;@<[:KKN%8W^H_: U1_&@>XT@(\8WP57.X\%D
MBNS:OJ7$?WY:20#"(>UPI!+W88CF=';%5UHO>\+DX'&G.Y&GWIC^2''TS)+<
M=^SBF!/1M9AR%#L$E;6Q!*=2#"-:J9(W7%NXV:*PR?I++U5CF U6%O[)K2,@
MPI"/T3&].MOJ7[8]M#N9,DF<+JY=BC9>09;Y5:2T/Y6+Y#L"Z0@NS ](#R['
MN-,H>Q?CW"VSVD-XZLR^EKLHHJT=<'%>>]/8?$]K?AD3K+2_/*H&H HVO>OF
M"()/CU^Y<NYG07Y.E\W2V2$@CPU-IJB+GB/)5%4TN&_N)*]X@2M.*A-">08O
MQBFZ"Y*<\,+MR<Q"XUM.2)E"4'<\>4?P=D(5W3$FTCC.QWOLM1Z!B&,6%."V
M+%/V"0-YNLG"BSPM]O9',>SB4S>@.L!P]V&TSY]<?M$S]'W$#N'V491J:^I\
M;PYP8^$[_>NF;_T&:8Z9FE?<3K\KO_9EN]>K%V5)/YZ-]M#N1<\9:4G?2E5K
M/MYW"'C53[2\FP*O[:_.JL]K^'#RN)='SN<[%645CH6BF+07:=+^:!+?Z8CO
M3;:JD^<_Y;)H+)JL00K6_X 8V&%P*+K0\U>50"(#=&505FOX-/_]I"<][")G
MAY?MXV96V#T(XF-.0C6]ICHRKM6@5TV2E\88[[8U^BU/W;P9<G=PEW>/264O
M0S&2HC\IU)GBTRC'N :S):7LDQ9C._3OBUKI7N2<@[>V+HQNWGI/=ZU*LX4+
M,D:3>DKV\I!XH=;\0UYS6<4"159G?[(WU^E7*"TPUSVG/U"[[NIT0X&+K\Z!
MNPZ1SZ)#?/:>[L"$L20:H+M!5&]S[2G0_6:\1T>WK?UYXPBR#JSL0Q/>A&8:
MTWS&4#>?L9/VCZ["Y1FGZK[&C@[I]UL1Q:/'JAW5CI1H_>$A=_>>;':<]8WG
M&R"OSK&'GY^OSEEGR]ZO7CP-WOGU(IMC>/H?[(')W!1K+SU*;#+)O2%?[\:G
MX[8[_,LC[4V]+CIYN-U.R?$R--A:U!AE]-(<.4I5"O(??@S?&EGDLHG30]-$
M_3I32+O0^&"IQ ]9=_IPGL/[L!][7]Q-GSKVTG'/,A#'=P<8U1AYWE2;P$+H
M:3F.CG'-&.^E;FN/.S!U<02%WQ[I_M;X"MC&MF;0)/MSS>Z&Q!)TRL=<\4*T
M_IWHH<28K=3*2&_-1^I09$9BA-'#PLWZF<;0]R-.M\>XTGY_91E.SSZ]4#M]
MY]F'E[]BYBDI"%;1S94=0A2^TWI@:288589.Z[X^K%-!L>8BLSY2,_H'[<>S
MVW$7IU8'!7Q',PXJ?TK\P=6@S.&HL8G;G3O7[I<HTH^_<^.OEJKDV67T3&3M
M/:0R<Z'7LT8S+_Q-<K&A^[&B2C>O2I>#%U*LK'S*!S4;/#_^>AF"<"BQR"O*
M>K)L#DTP<<AW&LL3&P LB7S]QG5=UA($8$X!T[P9]DIW>KLCZZ0UQZN1J]M=
M4],6Y?X])GI=/?42D!E2MYA04:2?[Z_<LS.B-3$_MRJQ.B[8"&:W"5\@5D$'
M][3:9SX3'J9!=J/+^)>YJ1V\D^U@)E0F*)*R9\+&W+A$AYH;R(WK'99#%[F(
M1UH%NG>1"FU =W_B:6W3C_13EQ[TWUMDE 4=%N53Y,-'L*,X=<P^MO,&*'6=
MFFESO"X(X\AK3D:CBCVZ"U/FBO5'(_+I^Y]^+W*Q=9K33SX/"=CD<.%T?#!R
M8(<0E ^_*WF': /X9%T-&P_>$W :81O&C9D=U@G?A?%!,6&$G9P&P,$7WTTY
MDMDS+HD=83P+$HE3X!]5JWES>&O.%!?V <9XU?<H,"#ZXD-:?ZB?J4_19RL-
MMS?/V$<BBOW=2K.[)\NMVU^B#K+#/;-E41QOWS0G8L+JC7_F#^50R2FIRJJI
MI;<&0M'GS!/<^FP@VOW_G)R^F'O'^U#0<-Y4E5.>^?ER+\WK&9^\$;I%4"VQ
M#M#8F8O!\"Q[./!,Z@XL%!T*EXID*$.T @ MN];<WI9"T_IK%8H9/K36TT/;
M)FWLRH8-TVU.E-=>CXB=.OPZ[D3 L4;#O=P6=N5=3 @S,:X?I]'N_GMGZ<GY
M#M=>2^5PL1[7OHG^!ZT)J3C;D0RT];L%T3GU"N<7Q^2,BCHLPJ_,MSZDOWGB
M[08OA?\A/0#/T,SKW0"179/:I5E4NBVSI=<$W E5,B,>9?^PYRKVZ6[".&5,
M1ZT.*[F4UK9AX"QM4\36M!B#H>&'<]%21:R/ D.^2)0A5A8&MP%0P0D$9"=M
MU06BFSIG.1Y":_+]%KVUBL795H>\,2Q/!][$?TYJ=T#6'.QHM2Y_2%./;53]
MT;/3J/+XX'>D$K3^&"/,N$7+0R'(MS;0Z6B)WJZ DIV5-LW;90G/2VUW.!.D
MW?-DV'MEZY]4VU^HLN(S8VJ1<IY]ER<)4\]>GG)+L6[JR#[TXF^/VOIK[BD.
M?I/EAS!OKGN:)&0[O7;^)<TKP(M5@ *V3V>VU)+9\+;%9K$);_N3YB"-Q@ES
MY+9(\>$7'<\)YZ:6R#7D7+>6"8PC:DNVF4]+P0Z8OO<;O]Z<,!%T]7>I6T(<
MC__K-!CXYT_<%;',X/P&* FJ*$R<!]^E%4+3EC"*O)O=_"#M,6/R=+L=NPV_
M<YK3_-JTH [A,S455;9@&:3UZ-L&J,DXVG23X\X/VPS(?[=N@)Y&2_!K3[:1
MN*L9NNZL>AU7 WS3K72_!]62C[IB?TP91A_O<U:6%D(0!H8>[]^<#UHS3._S
M#*CVBHQYW:UKV/NK0LO\W4'OGHOSJ7>.9LEK&SCG7(B@F!]P(K766[BUUNR&
M:,HX3_=GERX;EMNI>(?=465!FW2SQ<?1<ET6A<.=BK>MPP:H&H-UT].!@*47
M\*@,<ZBY:>132WO.#QA\!Z<PB!AFDU^@1(?5%38/FG%BQXVKFY=(WR8'@;EW
MV@Y=6-/Q;ZAX&R@2Q\I.>)>8H/[]T^C>UK$Z9H%/^O<V_7$W.F_7T>7P4Z_Z
MP\74FB2@F#4,&%D.#"NCAWM+MHQ#0_'3&3]Z(=*\L!2,ZGS'"0DZW$X7JE':
MN(3T]K"JV06=W5QQU>Z@73L<V IA%\;)1MK'[(YE<H9.][/[K5+>F 7_=-^:
MQTSY<O?4B3XMEVWWG?;FW=?0V_E,;D_VZU-[0%9:MT!LZ@/J'5PC=/D$+\DF
MBHMC*7;K3OOT0:4A>WZ?&KZ)&GIBA1[&8@Q( !7([;(V)W4Q,G5WVD158V(:
MN&JY3SZ@>6)##CTN*\KT]SB@Q6O3'Q:P5L_;VRD\E[XG _MP,'IBZ?/G]?7'
M!J]?65HF*KS]<BQ "^VN;#/0WK#T0__D;'I9$#5GJ<T QR&^R7&.Q%""D,/?
M3&@#)9L!Q7DY\(P</U7T1!AFFHZJ ,I8+=W4.P0I87KA#[<1C.YC.R(Z<Z *
M%VE\I/Q.X<][YC#'3QDRGP)/C]N-EP1KG:Z!7QP]=5(X2579 -GR\#V$!NEE
MYWD<'M[87,H+9C&6*KD]K)6E+AZA'Z<NN?\,ZA_$-6TYMF)?ZL0-JNI7B@[W
M;8F*ID$Y]?9J1^Q,[VB$KLKR-YM31!B0[#;&%NS\=3T-/T>]XCJMS"P?7MH
M"<X#GWW%)@0E%RY^7CI#_XAX#-Z40DD7U<U)R/6H1W?^!DA-CUOK'T;_I2EO
M;9P@.X-[7%=HC!NM6<V@Q/Y7C1V*(/RNL4L(%<23DMH_@W^-/;!&2$N#@+A'
MK%YSXU(=.T$Q3Z9O@$#2ST';;_T1F'*-L5U"O01 7=R[(H];R.EOTY3YWQ,.
M_C]/./BT 9KQF8=G0<-TIRWY20"'*P%<:URF,(S;R$I+;Y<XD.+B> <E-_[9
M@H6+L4<$2?[Y!\<*Q!NX!Y5,+C0:''0^3C31=W[$OO@KF>O.X-_AI9!N0TP1
M$E-Y,-Z[PQAW_9%IYLL1T,WB(:IT_KP_>2JXJ;V=NTQ(9[ OZQBT.R@[EW=!
MRA7YA6?_>-GD3$8[-..Z/*@1#$F>_Z-I. 6G(#PAT/N '6<HBBTC?>:4@0=A
MM0O/.13IQ$V!6H$OJ6/D0.6SB<C^ O?P"XAZ- WF<JQ3YR"YG=M<4.4+NVON
MMSP'?BP\*%%$+-&MJ"7,B3I?<3^\T;N@RH"25SOC7([1YW84^BY" M1YPY?V
MCQ*CF8<#+\%B2^;F%C2\*C(.)A^JB?RT2/.BSX*I;V8>UN9WP'-'82[(.E$+
MC'#=U]<7$7O?%Y'O78A*J8Z/G?)6&Z'[PP9R8D]%13_HV7DYM]G,Z[6AQG[B
MZ/_=^JDX#/^/3]Z(+Q"J$L1N>,%-W/0S8=0&:$+9C^0B"938#=#K3.P @1^E
M*P5="T)CDU:Q-=\?K"VKN/UY^S\I0->;#^\$8GK4>$'H@EY-PS2B8=$2-S"R
MD)B:BS03:+KJ'5SYTI+AV-X4]WTT<\D[ZH6[_6Q\6A_T-FX;Q.KK.BY-?$1X
MC OM4U!TFK G5B @UMRY/'84I,=3[8>_PNDQFG=S:^H<%Q;@BN3?';W\/23G
MY$Q@$FCZ.?"(.^_5T3Q^@WI79]L$6>NUFI:SG*+J5\N"%H_#!I>:R2W4G/B/
M?\EX9EA<^J.3W18AO"-YWNO8U]3&[<4LQETQ=%P,$NHU\JBW)8&)7MW3'632
MS-5-T^-)IRZUF_-Z^OU]THAF@5[&4I^+MZ97V&XGE/=$&B."PU1B^9S=9ZNA
M?JA$I,L(,S7*_K.5_S>F'X+_:5[=NN0)=\A&,YJ@<H^ H+8ZQ]N1&RQ^^9W=
MU;5GL_^+2*J::Y5K8CGZD-;),/<&@N<X<DTK,T53.FUMUO3DH8]?UP4S9^E/
M+0OR"Y^X1N1[^SBI642FI?A#C^HW36&"-5VKB>_26#<YNSX&;GD49;[LX3HE
MA)I02LO1=<=V#C]F( IHE\Y"GY-MKS;,_&$RIO0*#<^BZE(4Q&_G5)Y/0O2
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MPF?L*<SA>E$Q>26;(8T]*/250'.$\,C$JBO=EH7LA.[ZJF,!#(7,NVZ*P.E
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M\/5DSAKS@OBD[KI  @#.Z>(3@+,$#QQZJ (3*\D5O0';WS7,VQ]PKV\##/$
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MK)4K5\WGST[<*0430TGYUZ[%QK_S"D/H+PD(KU5QSE!N]!=A*A7!$$AA+#9
M8\-J/C]<_K4I>>CV!@A=^4/X" "/YHI=TS;_GL7]8P/D5\N4 )?T3ASI]Y%C
MG+3>%9$6<U$<:K0>]F]SQ57J"2M>'1<EY%15*#H _0A<JQ2-0-<>O1[F%(@5
M) B<&_Z[M!F21UU3&C'ZP1%OEY@GMQ;XW8T-/2MYO,%^\W6Y_W#0.$<"?7H
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M!DC%1H[=X8Z4^S #9';[\'_>S^?VQF8:M]ZA9P1$C)/X65/-UV$]^\1OA#>
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MKTNS"Z94+LZ$$FGOV1J[L" A2>FX7QSL_Y[O_O_OZB<3"1S +^-8*].6_*M
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MI5"%Q(^D0=2$T4 9NXRGR]HF*@X>_?1[K#K[RRT4<AOF O=#T(&FC)6NZS/
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M[/)W>'Z,>1ZE:OM+];M1<UK%IGZ7ZJ_%OB)*1/"2[3SU-GP'E/F4H6'C)3B
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M9U,N^+)1G$]'2(K(CFD#^Q;@3]M99;K?!>--<0V/,3XD=G\MJV7X=@#U8FN
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MU9 ._(87]:=;6Y-.YO)L)]=QB;<9J=SU/[*0_MNZ[?H2>0M^F@Y"B&R+ !&
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MI&+.H7/&AB:?21R\[;M&DHO\F27MO*4/JKD'M0SBQU*L2C4\0KH6_A21^5V
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M_;2OI:)6]=@:\5^LMUP3))C,^KV]97#M'DO@]\=NNX4@>A5Y^AUY5>1M#\E
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M'ZP\_AY_?J]YJ&,@WU73*5GO1,G5 U< *.#HB\]?PS!PVV/,9^4+/REQJ[
MY!]0VN6^>K3W.(^JDIG5MJ@1R1RJ$9TD^?0$)]VMT+QJ5X+'LA[,+388=<&/
M>O%&/;@M+./7I3]QQ_Z/2IPGK04X]+_+(*XI$RJA3']"% 3_KE0AAT[S?J33
M%"G#<=\0*PTA&A)%QG]7]>PT2HE%K)PYOY_@*F4-BGL<SRKOX__6V?O?QN8I
MAEB9)G6DBB(HPR_$A%78@)([X_>N*'D5]BZ)W$$3$A ;T4M>1')]IW1;]RIL
M?X>D@34W0#[VN[M[.:=H%=:,IGQI8WEWBXY1']!6&!;H/U?0EWZ=6Q&^I2I
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M]R5)Y/9[LYD2Q.-J"O\!PSK46?Z(Q#'8&R9(9J#O6>B-(]2(<2UD-8CR?"1
MJ2/_&U<[SCN,L$W&?/_XPQF!="N#4;&A1G5A[P\;6Z>O-5]_)50QPYCSS%58
MF2&%W[V$DSQ#WT#$LM:%R"#78_VENE #V-VJ,HN,0L%(>OW]K:LP)8O3U[VU
M&J3/KZ5V%!,-6DKV&[Z ^MLSN7JQB[-^DUEVPUZ'UT/!B->KL'8:]_'(+*T&
MD3 7S(NKM).34.?N S37ABC^^X.W[PHS>.KB2/@GL248NO+I%RZPIYSV)W37
M9.",W?/98[,[Z3^"Q)KO)NJ0#Q&  R*64K6)-4XP/P>U34B"VLU\VZCQ_9H2
M3!M%M=Z2CY$?\S>88"@0,R^_87%,S',<1G5LYK^R(H^TKXP)Y0X,?7QWM3I)
MF(8%+X?>H?A\RV#CP W]GFYMWGC]8]C 0I64$#K64K#V@!F:[(P:P&,+O6+!
M$->5)> >SWM4G'P46R!*#REL"%KV<*#1OKC5U !Q;):LNYO[R#=M68 2=W N
MN,'L?9^,E@Q[Q3":(!=+N^*+7^?A]@F;;Z%270UT[+#%'I]P_-M@WPGQ6<&3
MZ_*ZR]&+QXUT4O:]K8Y%*GJ-39O-@;B6H;##N&D>D#Q;ZU._[_V*OK-3QMAW
M&T=#S?>W4$_X-MD7W@Z1[$KL&%[O0B*,TO 6QX1"+T0?4\V8C8SKTS2NJ1ZZ
M6M7P,J*,X'J1F>G4Q=[U2&&'*]YZZ65R@^K9?@OS0K=O62:EP_[A-V3P/@&O
M[?<_V'#0Y;!A:YK#N,I5V=2ZVW?IMO_W0>W_Q[$79K,+=L1F'&:6&O''GQMW
MW(O]XW&LTY$MNQZ</+538;' ]^S&)X,7=ZI<AZWOWY!V[T[[_C\&G"_UMG_Q
M"?EXI%S-MW_7HZQ0:XN'9J)(/UC>/ZE67Z(?[7SX7,N-6K&U8P+SGU_9*+_F
M77(H[QY(!W!">R/6XGRAZ^@2$"?>,2L]KRK,6X6]]@]9A143#I0B=JZA<I?:
M5=;H*\22H$::_4B8&;/F0]V!!<F]*JK$=&1H_@H1)SU+V[X*^R1S;A76']D0
M.)!M[?.-];M'E/K_7 HH!M9^Q>4U'U?X:14VC)<449:>H_9ROD5>E.K]$#_J
MCEZ%A;!789PLRLKIW^(0W]8N]_YK_'0$\/S]P/8ZX(7X&'"&)F?A(-7);"7_
M06-CSTL5.'M!<G$$G5BXA(-WX_<](7.EC!+<3/BKM]5_C_$\/WMB&OW5NPM=
MOX;-BUZ0+H*J\^JB/\0; '@[+YZV@60(CG2@M8,I";7=;!DZ$@.ZO.(O;!9K
M#) N72GRYQ:5%0<\\EM&<UU>],P,"6^/N7V_2PCM>C4@P>(B7@XQ(D)8^(!(
M]AH%#F<+B1 %J'.#=,=I#Q R%H9 5.OA&4=B%#\W89RR_1-1S]/^JDG<)0U.
MW*Z7GD<OF46?>^39L%2_8'&K/?7H03_5YY -X,R'-V&V6H^C'U!DQ7"@N/G1
MV.<9.SX51L3; -6)W)1IYS"*;NPC/'X#IT97J;ONB=?=TWOJ8QS_E :3-XNM
M)>7U.UFOT>UH)2F'HDXV&)NEU"RW83YEMVK#0 ORCJBFW,.0S7@)&>F7I5+"
M^%;K%4<(N0N>]N#],9U5.)4R,7#U3>V;)W3LOQXEBE=()R3/R$=F:HO%2I2)
M](YYWD17F  W'R2Z4AQ#-I.^OSW;*)O=TJ@.?*W.!HTF+D(4/FW#-/<&:A_@
M26NI2U$]WR.V-UP:_) UUV[0X)\*</\MG<6D5P^/2#<O77WK,9/#_;[4D"ZN
MX7Q'EY3NSWNRN8-2[3HW):!R+4]!FPN)'I=[%O6E2N0A="6O8_ZJ?4A0EJ$=
MF[*E/H@@( 19]:<D*[V>-4MYBMG^3Z#RP:ZF2V^SU#Z]9UUU_8D3X4F6(*^M
M>R1)F _YOH \A-U@]SVT#^X!;TL(1>X;[C6NU0,>.R3=.-"X&PIR [L34";X
MGUY0'#NN W6R)W6H&P-8WQ]F9IN/G$0X'O4OK'AJ(^H2F4)L*^@^L'F<DT(Z
M.1'I*W!)$@3%-FX?7%Q 0%0,LX]T=D(F@KZ]JR/>XE3A)S;!MQA?F_;]S=!!
M H'_@.,8\<^>%(5UT?1E'M#[N-^&XE*+H9CP:KRY90(:%R/T!7%K40 A5(;8
MSV9KMV?FD3O1JM*]I--@[)/2I(5YM+P_V1@RF$#'5A\C:Q^K_ND16<MQ!95S
MYGL&=)EQ<PJ7C9WJ9W<>B3P%[ND6;'H^CE%V$Q\8(IGPN^-KLDYVU42;K,+4
M_%5KUZBNRO/Z39V:09-(N .K;\$D B_??=OX6X@!@MFY\Z9-B"Q&A]HD T]
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MFM90GW7ZEA&O#GG8+,UZO'$2ON>=8\:/3"\[^,2G_Y.VY!+%&'6#3-DKU0E
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M'RCM]GQ\@M">P4;23YL=,/V.(5V<;2'>>5_C1_+Q/:'H6'Y"[>U1-KO;;<F
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MP=_S](,CM?(-WA=Z%Q@W95-;N"R L/L[P:=Q(+BQ$"7A?E<0UD_LSQ26=J.
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M^I"\M;2#LK6R?FZC)\.9+>89S.\3G\7M!!7$2!_<)A C5'PMVRW4ZJ#M>"N
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MN_5'#X]T+]M4GZHOW;6G'<QKE]8TWN=75#LK?2VE%^O*26%2W@)?&K%3S6'
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M!2]-T'0EF)&(.#4WZB#N!$_Y*%T9@[;^NJ%\.7$)J=JGOIPW,E>]:)ZB=O%
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M AS(%2$KCQWV9?:5KUM./OX9C7X5NZ$.[+M<[C;SG"R^1=[#[LW6'MNRC.!
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MD4BN]^HD2S#18"D0WTFN.3$0KW>4/9C,5 =$VU@"ZY3FHD^..@H478MVBT:
MN[TXXP3 >-,QE(X]E0]:^_T+YIY_=MB75.4*-Q/1%:D$1@!VF"PXU\PJ;$(
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MH)L8IWAD5JQ-\6S<\SOE8ITRR:X"3C)"5@;[_\>!'\[$_P%02P,$%     @
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ML*&6H6U0!J@O=#),+"PQ;"]<)[PR@C3"-6(8=A/V$H9\?N]Y6211I$OD<)1
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M%:VFP-:5;+<:<7]1AO"%_0Q+^0QM2FS)0)5(-ND9?VGUE1C_GI1[WA?XR%V
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M;=.(-ZT?I_D(/T /)/.9(N_Y6!)11\MK_QGS5U<STNCD9_\Q/V0VI9Q.5[@
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MV%)(\G2+]5%KL+=;=^W>2M%P8Q#G*JS&S/J.V=B0\]M*:I,4#P7IL6M RC4
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M%G/%X\5,L\L[F<TK8<*5TOP)C WSRHE3\%I#!.FFW496'B\JN(-_:) 8,E#
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M2R=+7\!D_'T\_>5FE+5+TL1/E.0D(>!\:2_WO],VT-]1/ 3&>8D(L0^!;;>
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M$LD24K_'B;^1!F:B1GC'!<LH+V'[NJJ1ZR$:V1E.B)TE:F 5V9=*V9Y#KO)
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M$X<)IY$3=@S!PMW+/!AWQ*$&X[?W^"2XPMROC[(;LD@*G->D R#\G\"$63E
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M^JK586(+C@73UP<\^C<)5]:LKR9_,M?((UE2;B2U*@C^M;#)]U'+,6P#H%A
M2!Y3>B^:A.AK[]V\'1IX>-]0;-$#EMN.5 ,\ZOX0L08*7 WX4O.;P5L89:G
MN>=XWH56YIEWK(E8S15$(_).R%G+8OW'3^*>Q+\Y\_/-VY\#&;ZZ6T^#&YM'
M9GG2@"ECNH4' V*8%A2,6+\V+AHB:=M:P3%EFA;5R^!B^UMD K_A:)>+=U,,
MA=A2-QJSOO5_BCQ^)BG-Y/3A%M)>X#)CDA8QC",:[J6)*%"D8.)H9!G:G,D9
M?7(#TFY\:9A6\]*)J5D\9W'A2Q&\W0-Q<D6F74Q1+?J%4%"^S;7R:^HNYQV>
M^'0]^+FFW/1S;'8M*'2$/KF/#_)"AF&KTF+HUB*<8X ?C1S9 (EK@I>A=MI<
MX)&$_-KJ04-7XD%'^R$O<\_793OJR'UW55W4$:CL1/4'IV.N"/-$  E&.FTM
MC./*V&G!'.BK!A\ UER9=3&&<!I;L5[2^-0P1N&VFQLP>6O <.3G/ZN&9G[/
M_#78BD5::L?*'I3D#A6]N_[F3'+\F==VR>;J2LIODM=3S$E<*RAMF$(^@%9F
M0".,9= &O><X&E/PO?,N09%H-5KWQ:\/ RR%S&LM+ TLJ_4N]%P*HTYHQVII
M5UZSOQQTO^L2^0CI.%H?T,OUX<D#GC0CK1:69C-]\CBPY-B_F7TQC-V>]?O
MO<$FBW++[9@";*T/*[[2[?:*W[&G;>8RH-R^HG<^HK=K8V_'I>E:C"?&]BV7
M)5<NXRXQ(:WP*'<-YAIE+8:GP,A**47MT)R8^AQCING D[?6K:73&DH"ER)R
M/LT^!ENKG6>A3M:_9'*E]+T"B*+^QZ]84>0/,W&4!+&/69!J!K1-#MXQNI:
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M>F2GQ51BO6?E!?L*@ER%;0V%MF>),"SQ;=;1QGI +H,X-4S!'UP<W4 Y_C&
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MZ-+.\C@#*P@6;MF9+<?18TRV30JC%9G#E+7GL"-H+:8,6)JCW@B4:DQ4Y*/
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M=)0<AH%Z;X\Z1FX-U/2/7@BT%*(?B/ N6-([WLKLS@>BK@[HY9H1VA0VB;*
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M\R%* HF<RD,S<[3Q7WK*1A^@;S?6)*I8#H 7#4*/ EIF2&+C2(6Q#5V#&:P
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MT0$5 D3;W+J',J]4;EA<$ENI:!-O'6_]P+?OM%VA<5,)SWKJ8G]:?;R@=*C
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M^Q:.- ;2^%[OO=,+%$?9H</W;)Z4?;+HXAUYT^C8WJS;GYL%O1$^9/&DU9/
MG1+O"P#B-O("D()%)$N]EZHV,=YVXK,;8EG[',X6R-,XW3A2U$ZD"/D>__;!
M=^8"NRSP0&\481>2@-"BAG>[:"4(O]6&"[FI4X_TOS,!=(8Y'QG:IA=[/-YF
MBDNLT0#)5WYQ N!L2D @-K)K/MC_I<J]O]\&*8?,TG)E;1=H)3"UG.J$SP$V
ME4K N-TS5!-%?+3\[WL55G1$V-<N_^'RJ!*32RO67==*O,U1D_[K*J@+1F\
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M22*63KVY2ML02];**-0#N[N?Q8,([V+4. 4H :RR<]$R-"_LG]MH1$44+?-
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M'G']S#=>-:9;6TRSCY'\M?,R['N#KO <KPF_;M\O=6[7GY9Z6'VT'&\)J&7
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M"0M:-/@P7RAH0'0RJI9151G)@KWH%Z!JN"G+U&;BUIM^$5[/"P3GXVXTC4J
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MQRSH:[+HCA^"1$\*4;6995C%0&7G*OF7#-CR7-1T0/>SD#3ER6\_-W5BL,J
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MU=.B)!CK*4_Q[4][1I4O9HB.^$-JZ%V(70".9\LU[>A[AML?(B'%4%S\$P]
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M3FUK );F+T<DI>+J'W!WYOUC*M TM0YYT_B,9>M"E $L.#,")!,/:+G&8DT
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MCK[@V[[P.&!K=Y=[(/_HM12[AYX;M',W:'=F=]CL3_=&#C%VG$CP,7__R;#
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M//^<Y2M*8F@8WE1-E'%44H-?,4K'XG%0"H_%)JS2B3$+,V9KMY>VWAW4@O+
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MY8B\]2GK_L(B:[L,9Y/C'K.DCU*,@$A4]!:1ZELJ;]+#@375UL^0;MR*Q>H
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MI]4DK-(UF3G7;CCA/6TD[V#[MO1)SLFK#(.BHJ+<6Y61'EFW['>HV2%%CC$
M=WGFK8*QD.O]Y<_SSYTK^M%,]NU)2Q46W@C8^/F:ZY/A(X9?#Y[,^3%YT-'P
MM9A<@0[<Q44TWS\]2LI^E4"T,;[\T5=%&]KN<6G7D/B<_8<(=?*^KZN<?BU[
MN6KFZ0VG.[+/6]OO1/X?OV5!CW\5R,WW^5>GRL.XIP2%)OA*CI V2XY@&K16
MKN2U#F/&2#GU]_'AK ,T;1158[=+LA9P?RRH?P-8W8:G$MU9RDW<$9(Y'?AP
MK4>2\IC\86(AC1L*_P[@;LXQ\V=V[[U.*X[2I(6C3&\F[V^G9E;Y2 .@!"M(
MGE(#P"UU[ONA@X)?4LRQM"/A,XTDS<4^7AD?T_<_>CV1JJ;/U[EK)F?$B#7S
MXQ5V "J90YSE8VGER90,=D_(Y?L==P+?,M\Q_F% .TE-T]\SS 57XP2N/,+4
MT@L"4WYB)"\IDEY*K-.= KC&#<08IH*6-N3*GP 4H7.4NJ:/-(5N?R.LW(0+
M/8I1:D.VC3M;VG-ELA@HF]PH=JR)?IJ%TA?2SX6$JZ7,JK$P['W@;^Q=SEML
M+,$7B&*52J:;6C? 1R3%3&V*'W\9LN)=*;1%=3),T'$^@KN80X5;0CW77L14
MH)#J7%8C.T"OB+)[!IL[9QEQ[OM!3L*L9(>>T9.IU+[VGM-QHGV,G\>0E1_X
M-4MY%5,[!-9U+%37OMC;[EO2N,&-27TY_.DZ<I04LY2I@G2\]<LZ"*6)CPY2
MC_; 1X)YTYK4OR&'(7WU>KR2P#BR^@;/])!B?6KX+_[Y&FO3&@_'6\_?EA"Z
M**-[,0=&#R[MU5A#6#*;;5*DWT$V#QV?8\Y[I$J"2/K"-MH1<^4A=QU) >LR
M($.U:T-60"SA;>@@-RD>O]'OY"PQ2FV:35XY1C/M_,E:UFONPXT;.*OI[LSH
MO-RXSGM;]7KQWI;W#EOG^W1_ ?'T<O+D$[$IE-I4R]("?'#A=-EJU_Q1 11G
M(^"PR?<&501196'/S@^Z^PA%#<491>-!:3?&2DAC/<( ]Q?NQ]/V!^\NW+#I
M@=-HD8%#1UF1,;';,&["AFC9]=H_4'^?W=LLTPQ3"5ZTK*JDIK0R)DLWSK70
MYV+6H/>3G-0="L<O.SD<QNG\%S6C*V!Z#QK-Q(;8."E&5(G(]O3,IOZ9DZQ=
M,8#])L7L1 X0AGC3"R;3*&<5DDTLD-?8&$=)4L6Q6<(G5B(6.O !L?VP^-%P
MQB*W*US*<Z1E<G7@5 I1_-=GPFS7OH62L0LH&P[=*\6\'3PFQ>2_0D)'44*?
M0VCY5TOY?[^EL<!U$FE),;6[@>%:@B=+K*V"$]WHT@59:H1ABX=23.]W8%S_
MAEA]%.73VU@HL_^NBY.X#F&KQZ-0\K"QQAJI-B#,9EFQ_D//UID7P>Z%,X2V
MF/_G/U)8V";%R* \^F$0?&ZQ42RW"7F9;@/(%G5*B#.,:;G_9BND@[8&5>>.
MV$6-ZTHQIP4Z"VFS;"DF)?\1JBA%]#3.QRO$;F=T$7_N7BRVOYBC'!' &KY+
M^X83GIG%2LQ5_KO]CB-23'++?[??L>GK&I,A?I[[P$G<DZ6#K%0.A YC*AR_
M'.FJ L)_"C: &U*X3G?+'G42N)M,+G?5=,*6V._(5\/0-G%YJ0?KZ];HX=5.
M<SHD-@->S%O7Z7B!#EQ>H(/0J5XDK&LM834<EB2*Y#6MP>_@6DLQ_BC;:SK0
M>MU8DI=:1I2])YI>\^N6[07?TPT\Q9PYU@6'K#D?F[HUAP;W0B5-@ZNO77G?
M6D\%K\TKZ'4L?:17YWS9(</@E<>C6Q=?A3F8?/RU7GO<[)!*0;5IX1K2P%>-
M=E8$4-]\48K)/@D(WA'@+VWH<]L6A\1LDF+J_I%B9HQ)J6><#&#[D5$C*>;$
MV3Q$+TD99HU7_H%)-Q8,D)V:L]523$XA.M"U9/31B)3^D )$&?]1B 5LEFH@
MVAHMQ<AMD6(^#]"<[2S^K<QK4DQL=)@!872\78IAJ]>SD$BSM!^T5SJP4N)F
M"]C%8J*_\1BKI]X+GA,BHS05WV/.D+]@_NR?>-DS N.[<[B-;X M4U7*D4V/
MJF4X)9_[<+Z_5ZECRG5A-F\"8LP8(1FX9<!P$E4'M5W/(:+DA&'58'0;\2,Y
MYT:J06V6;)HLCU)F(<]6]F3_<&-C<<>TKQ:[K7'7:2UY?"$L\E3+!AT]C6M_
MBJ:*W+K.C.T$6!!V-A%,:GIJH<BM/L/K!8VT-N0^[&G>I!$=O9>4W_G%,RDO
M*6W_L8>>R>Q0RM^[8WOSG.V%I,HS/\9OB#(#  7"<!9E!F%S%-%EE"I<;#"Q
M%6@V T<D,4QTB!WZ4T%MB+Z!: $KV8'[UILT'X(ROE\,Y,$6F&UDL+"" _1\
MIG]VW/DA'_CGA!AA7D(NYCO->YU<[#DNLB+4G?Z7'^K'0AO),/UEIA1SB<'#
M(3'M?B">=84P=(?UAY8>+$EFW0-$.I:,=+[!PK8#T4C#^FG)GGVSTS*LX4E*
M*&J 9QU0[[:;\'[5]FQ6 E:XN!F*^?_KT 7[$3E306BC%+,!64&5_U:]5%#2
MR%$*U%<4)@N,8^8FB,LH._ ;W;V9*SL, 04+7L:41=T[2E+=6[^0L(&BSR:A
M/HI^^^W&G11KKUXM<E7,F[11ZO!Y6>&*ZO+C'K;=N=A].3L.Y+_(L-S_NJ-]
MK#BUWZ8K\PE,]R:\JVBDRU,/"6R?B,\AC1R<%..33P8ND5?!^R19I0P92JS;
M62EF2*=!WJ !6%=L]!"\^X#2UTV(8FX$3ZGEU7,4&D#5*5&U.[:CM)"\PB+_
M'G5_3, _\$4)&I&&GH58)%RA>IMM !5Y20E4IQ>T!N OYIX)%ZVB;5/%'W(I
M^^HY*Y@;H5:>35Q&[]G?G#J" E-Q7$WG7F!F>8^J'50E.ON R[Q)Z E3SBM/
M\Q:Y?N+HSI6E>"W[4^ 0&U?H8.V<NVPRV<;RE7C>R?+3[U4V1P< &?3&3^C+
MD"WP+DFV%+/8[2"&M:S:GQMVHY%V .*\'B6L*YN^VW2\HXPN/T%8/U?C=Z2D
M GJ_6.7,"<SV,U%&DH"<L2T?:1IJYH^2[AM<;6_SK(1?0/O$ZY'!+ SH-?G<
MOY@J!]4;AQ.\R/%X9<GSG^)#DVD*OJ*FA@3CC]>I5H*!@1+?K_.J6O*=3-R$
MG_Z+N*UKZ:KF6[WQ@_% J<F.G0G[%SR\VCD]GM]N?!K]E+D^U"JNM_)]\_7!
M\S.1)W)O_GZ8WU#<[.J7!R?[X-Y%PTJV/5S5*6LN00.6[UZ3*[Y"/2A@-!#6
MMKR@=,\WC;VDDLLEV:_-B 6]E ]'@A9?1&]:A48\,Y_E=_(I%D>[MKZM>@OY
M4,O3/QL'GU#BT3:B<<\,N!)&Y)+J.:M].*OA8]J5 L!14C@]UW)(APABVN&#
M*A_ PJ%0R!.X%)71!/[P5E7%86]. 8WT5:H-+GGW>'%GRD%:-."C_*5O+W#1
MT&YJV\_Y6]OG)Y,5/WE;[5J3ZZ3EI"S8Y=J=$-3U++7$*<3MY5Q-.G()=A4;
M4GVKH#Q^IG:_\"HT5H#TXC=*&-4$T)B+G6H*?FUM4-\J2VM-91H)A(4O>_V8
MNN1U]>3L6N[TW527D=MFQP3AY-6?LS9U7_VMT>LN89JR%W2:6&]Q4WUF-N!2
MZV_,==0S=&L!)Y9Z0;R>\A?2Y/QG5F(AO (-@.I\IR3X"$AKJQ[;'*93K^*^
M6[ _(?"5VZV^LM?IA!3RK;4/GL>)-V??ZPH8T^SOZR\5!95G5FB@YB;%I)5=
M[)@_?\O!JKLK=]I65)78\2C[Q4"QEX]:6'E*[EB?8_ID:8?>E5GQF9&?Y27E
ML8,R+2HZ5^R>;4V^CC7*,5=^,K[-\VH?SHS6S5I-9NY#/@-:B(J/MET1-,$U
M3H1-N<**![Q,,_,P[@27N[ I>>^[K6_]+"_L5/+<=%_STW*+F74"EI @^6!F
MPR>M@E)XN#I<K,NABB9_773AX@W*<U[].#&X!LH3>-1R2BU0C!(Q*%/EV/TS
M5(ZA,E8U4J_O0"Q+/LBK?GKX4OH>GW*#"5%LN^)/F^MY-,D:O1.KUJ>7CG_*
M/6D2U"[O<O8AJ3H]Y,],K='E1Y:$&'/&S^1I(8H<PN\F1:?;)"6FL#DJAH5
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MT:+&2M" *UL?YLJ;CYD]4&W!I8?CE: 4$%?/E >-&Z8 B\I4>?R?EEJ3$XR
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MBGN!R^H["*?QZY!V0(6VC=9"+S% Y2Q%OJHB>[N8>ZE;!5Z)L,70@&(3?HW
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MR)F(O/B(#*&/#C$D?-_X/VBX^?_RL73&CV?9!"O5"\/.9]%60__P*T0L52W
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MA?2AL## DFQ :L,D_#=1I%?\K_:6$!IX(N)8PQ-,U.]\KQ[#B=[@MSF-#2H
MS5YWI9@W>BCSL'$@9.!3<7^\2@S$FL,$47K2"#-V.V-\'_QN,:5NE11SC -I
M8^''.I,5J/NH0W]B&Y(+9"D#SZ=A15GDE*+058IY=^$"&@4.V;/4P1SD^"VB
M)"$-R>XAO&5&$?ZX@B1)\ELIIHN)^3\630),+ +_%WMO&M5$VVV+QA8%$>F5
M+B@@(DUL:)0F>=47Z82H" @(40'IA-B ! @I10$!(2^@H"!$!43:J'0*2*17
M$9 V D)($)%.*@JA($GEEM^WSSGW/?O;^^Y[Q_UUQLX8!6.0A'JRUEQSSI5Z
MZGFF&?N%6VD-&+#]I^_R36@<MD++(W1=AI#"T,_7 =-DA-0UJ F,62\FL# 7
M?J82".V!Y7"-5+! $5Y"R/MY FOE"A):Y[@#_W)OR:X/_W)&YH2O"/43/XDH
M^\Z/N(5F*AU<@AW$5@.#OHALK-0VH+^[(]S*W0Y_IJ420/?Y92MB"Y6_%58!
MIOWSF&#$"+Y/A#*%0<98->MG,BL1S=LK.(!(0*\-?6RQAE8(API-QN8%J??I
M?%4.8U%J-?  .(9?-GU $*8<),!E^]D(/PE/P8Z_XXZC _]22B:584G$HZ5*
M\_\ !AT_X1;EW.#DP&6Q9O2R7OD\?P.2GNG-6Y!PPE3@YX57LG#+?;K0[=NJ
M?WWI8-CI7PE/9+TTPJR(AH>4A,$/&VE2"TCFTVQP?)TK!*&&$D7E]]S<PT#&
M#4NYXVM?_(<R CPP]P#DX0N,7J\QJB!E'D$<[U@=(MK/6C,(L1 3GF]B+/+W
M(\*_QVI)^U.N4(1J)O#7L:E"L^R<@C.$9NJR=HXY8B=,FI'X^[PIZWG%B$?_
MQ)N'BU#GB?$BU$)[)"'Z?WW3/?I_W#?=OUB)!-DZ'="=3:76&Y"FIR,QZP7&
M8#ICG" [XC9L,=%GJAV[T)[M<CS0W?I=9%8:,6"*N/KE<OF^G5\E7Y$+^ <I
M3)P"UM08H8<TWA]0 1C'CKM#7F/23(O[O<.YW3@QAK*C-Y0AU1Y4$."F2KT=
M@A&'GB+"#,;=KK/,G3X^G7DM*]3WF;O5)I-+HP%;SKC?9TT!R9F,)E6)L:7F
M*)?Q4\Y7!9J58'(%0_I17TC4$4+O)!@U<K?*[:O)$/:>/_",,/C>Y_)N#\L@
MW\L[AA]H#A4E[: H4][7FX&T:""0$<LHI\]*\FV1\64*J>:^8"^'DLLU8P^4
M%MMQ]S<"+R/]5M94-X6"M):L1)/^"@FT-'3C$5A*;V1)!V:6_J %5"M6#8!Y
M!Q,X:2Y1:BN#I09E-<6L@IPXA1T5A<Z/7L^)4],&FU+Z[T[L:M5O/''EWJZ1
MUS7!^^+:=!ML624XQ!@%=DF1W81)'.&+B^;H,G\UE0SV/!6K3ET_.CK5.U/L
M.V9'E1X>]1>A@JN]"I2S>.#7N4"#/ZT-SO_Z8S>GGL2E"N3BG"O!R5FKJV Q
MC\CU;:$IPU\HJ_IA=9+8V[_(?X#X:!_P6_8C ;:'HA%0%<&Z3<;O]OLUZOX]
MXF&]=;4?YW5FJY.5<ZHA+H>&V!U,-'H-8^R!VCXA%;N+%#W?R*BD(F6]1G %
MVHZ;G0S/G9[G7FWQ-.'NK!R/!#905T.FNFN*2;5_<H]YJO?00QA;_ :63-4K
M,L/+*C=H5&0/3#:C!_F<39Z_+RQ+"U!]=:'<-6-4JD 7U/@]+TUP9!P3>Q4*
M)Q/84M(D1]XYL,ZM-<L_E*,JU6*Z*FD^R*#"P[HKW\% 7VWB8MG<1*KNK0")
M.;]A.\]$^XOTI[6##]-:F'=W\0^V99YZ_J%ZQ\V0F8%F]I0M=G%\V\\/17<N
M5/A7E5#K@AACA:.;J\&UH_NX0 ,^7@W53Y;@.Y+,>(["1P(M3O:1QL:E,6*\
M($CRYA36I-\H2<.QWQ G3\;Y(P#='>BF/WO2GEC2$A+T9(N-;%0H=YQWOYNR
M 1KGA4+!YIAB$K.544%M.0&.-];L3(P\YVN<DC^5HS10YS&.4YN>)S?@X\RW
M/?I.OUHH<8EIHF@R%'6OZ,&/7,EE'?YN2N<*KID^F N+FR"]_"_H$362?\B/
M)DL.E&JF)M14?GL1R2'>R6!L6=#%* C6"1\O)I8>A;EC_1/EO2%V.GJ&X4&&
M^AK'P<#!0?^!XVD!3&#L >*7!;[\R^3P'L"/EJ!D0']*H""VH3J.X3.3*$G$
MUSQ':"@ +=,A)T)5$&Y?/%=C[5H6,F?6"*-![EE:3373X-Q!K=.;]PXP*X)R
M9YXL5([,]7MX^)^?XA17'Y8)2]=(L7Q5W'JJR"CAUIQ?86NJS<]\*?]0R1[@
MS!0!=*2O98V0;"/G8V#='G-M#FX8:$,_;RW@\+.]CJ8Y@-7-4I)'02BPN29O
M@X(76X12F1&O,<Y6>GEFBGFEF9FTHWVUW:)B"V[(UPH*Y,[PK@IS2@7ZQ:3R
M5EJ%UA+5X'&&74UE=3EH<@-6@<[.Y.S@=MV.>>OOTWNT,.P1%/QA:/"D7:F=
M6^+%8EY8,KX-$TTH[Q>AYK3X:Y&.QI:RU:^[PV><!1&!H=I6AGCE%LW*VAZ*
M#DFL)4>)"S2-N'7ZG/Y:?9>4=O1%I<G><EKY%X>8D6WC1@Q?J:%9\FF0.8?X
MC747N54Q0/X43@RX0%@/([V*>(7^242L'?SJP@O\3*V2ZHVG,J]EA^P@FGA"
M,\4DE[?.S$M_>%YFWY_3R)@(_6O"I=NOM(,2/]05LA1D,?<J-[&4GZ^C.7-4
M_M2$O)]CWE=NP(=N_\/2$Q&O/A2-N(E03W$2N+%'(M1F6 ?^#,@RO"TPC12-
MY_6@?O7M<R"S16)PX=<8(SY'&Q0G'2<[@M08F8/8+Z'4.$7LWIZYT(9+JS^<
MKT\?=-.-ZIJ#UPGS0@@JE%Z<*N-"('%S0+K;Y%OZ>K(F-[V8X_^C%&W##*K7
M=R>E3S>V-G;OC0S"IJ#C3GO:7-ETM7(H_,#/X;!?M<5D36$MX$V]SGAI,G>0
M:_665=ZLA)Z]QW4#J"P%LN,87HE\C(D]"*4U A5QMW^TS:&#.$D2SJ!]W*VG
MZ8%HM=& F@_N,SM5U4DG/TTY+E^3EEW"Q""P[!JL'<,)Y'5Y0\QZ8S(1\@%S
M;:$84)EG^@JT7Z(*/'))GL,M>]S]L-B:UVF',YQKJSRLW8:G3<G,"\.D*KMA
MHHG_@U4'@RMLZIV>#-B=GO$>9GIF!=:*DX823HV[%I'[.1-S&K.9C]VEW"XE
M?KOV+2;B2MY$?X-K9-MTQIP==\;A]];GOJP$!KJ2*#GMB>FM5R2YS30O>2KU
M8/06A':N=N&/;N@%84*E%LQ<+Z2R<< EI5U_[7]^H(4\ 8;Q)KA6"113DATO
M#.+RC4GCO"M0'-?D+78GE 0^B7)OK5\-I; Q:M^Q$ADV>(4AMQE8K&\RS8H9
M<CIT;@?/WL2Y=RR9TSG_,7;VPQ/%2<98L5+5/0X>VHF;LZ?[1>0IQ<:5D>73
M7'I"WQB0@H."%TIM)ZWJG_?/!D>?<;?WUW_833ATQ2OS2T/5A?5ZF8(NR(33
MM=9$(*?(PW%QLTS^&0BAFE7%I+BW, XB<A^1:I"J8,G,,GP),6E^SI0=1/GO
M:D90$!LO#EUEUS\N@>CVO8;Z=G8#.^KZ!5Y!DMG74W)[QW5T=F9%X3P1YUU6
MC9&.+\1O$[^<]?5RX]!&QP#/H3>VH6A=X>P7KZU&L]F/LA[VYS!R@;4 $4@F
M5.RL+O(4[!?&FQ,0"'77[X?FQ^!\KMO,>%ACT#ZS\'H5TOP)4#M!\&?]QC>U
MB<T]0ZZ>_F$NSS]K A?KJIWLHGZ:!L^:(]9MW3;(OY0RBMO"./LFL!&[$RQ(
M,M?)]V=B9;APL7XB29=SM%8[NN[@^-S5AA65V]P15U+&89 5/UNYWRM$*^AH
MZ_#QU]4_6ZK>XW8!8XB+E %\Y\5(-UN&B$F,L2=N2XTL=/7<:[[#\!#EW1)!
M!M[B1Y'GKFNE<YFMQJ;K\KMN&3'6GA$<22%[!L^%RB4P6YQ?LD;MUM:$#<[E
MG59FUJM3.B@:PB=84R2^QW]@E3PLV:PAV;'Y-MQ@V#A^EL59?O(3<9BP+FD_
M[Q)8VIE58'_UX):J. X?4T6R:TXO<^OQ,#GU*SCW5^FYD/K3HRZ,I9# :R55
M5=D#--VM;?*W0_P<'O:[I98&5 SG8OV.QMBF%DCYE!YT.&XKGC^ID'GOQ^"2
M23,!TE&,J1,#W7D,J G=V"4W<QE^)T*INHQAB]G/0CMD6I?:W 1#U.L+M5$N
MEGT&YNWZNO;I,VU5VYDG)<UU?*YT9CV0BT#',@)PR3SL&HC!U1C/F(WC8*(I
M\I K6-[,DM4W^ 8U@>T<^:X[4C$5@2/7EIK2C2G2K\,KLMXO\$U21T4H1PFO
MU^D'MZG$X+K,6?+!\ &@00<8*V1M#<V6\H"\PL;GAWV;ZC6Y"HDEEL+L$DC*
M#9"E=*;#>KUE:G"G=;= OW1HNNK)CQ]#[M?LC#+]FBG>7HMVAY"*DFUFO*3-
MY;*!&!QXW#Z0U\U%"_:Q6B0)QS^1K;C*;'32(F;55!5#RMS1>VDEE-:$7P\=
M_=G9>Z*>45U>E^7$)U_@]+0J>P5NSYB32-&L&)B>\9 ]P7*8&_8L_C!A'F2;
M9M]?02DJ/H3QV=KQ@71/@7V ?^&+O^7/7LK,R9-V<U&'^(;P($$9MH (3319
M@25?E93+=FF@*9(Q:1QJ'+Q]FK -NY7TTFYNW[AE(N%3";K1$_T*9I6_'JA8
M/N1J<-ZI]YN:TZS?%:LX4@$LGCC.1P^:-3*J,J)Q7D1ETN38T4(PG<]A)!IU
M<R/9U-A*XMJA*;>!\OR 3/G.FR4.H1;75@8D=^HNU'2/I0]-A&XH??SQ4T<"
M .*)U]5T0<*L'8CG.!?PK04 =R"CC-*VLN$F6S$I%!UWE6P$#@<2-AL.%X=\
MFJT@Q+DI)CP1H6Y%[0A4E2- 3Y=3!\);1*CAISIZ@!84H),!2S[KWT'R=HV;
MC1\?.[\+/ML53_[3ZGW%W@]_C4],.%BI]%Y.FF5D6Y7V1!G9G>IUF0!2 JHT
M!EML\ZUMQF8X*J6'WCMD]'\)\K.E:?!2>XY?+7=)X2/Q$_A"[=S<(_U&(E0"
M4'[M!1]WNC(C=A&_OKZ4N_\M("UVIV(DHO/'2N!]J^@?6AF6IMXZ!>&?IKN/
M:'7Q4J/NRP9=KFZAJ ,-A\C:8UMQQ ?!]6JDK!/$S]I-:I((&:<.G^SQ0F\)
M$OB,Z;)4A]Q(E_/T0MH3K?5\>B>#3EI0S:ST"-MW8YLA7 J8Q2:I1R-@D<N3
MCA:'B/8J-]^97Y':P: !0SMT,EGP9KWF?2G:C<0;6)M3>CN]H57T=.NW[69K
MKK_%M/^%=[N?-Y+9_8J.#]?OKW;Y)>@(["\^G"2FE.P00#?\]F3X<J-+L<*R
MG$8>&QV[UYG?U2.!AG2J&^>\>*IIO"_==;*<]FRT+=,0(P8UL9WF6A_D0[\:
ML"9]Y,C'9-R N0Y'VOSEZ:$ "KK/:#C*P<?W!)!GE#]R?QA81:_ 6@C<GT.2
MH!F'U2;I8EW'K&#<HDD*O+@:)SXM+#^N9O27D%79?!%JBX=_59@B[CLXXM%T
ME@?:[=FKF5PR]LQ(T($0E1V,)K7Q/$!)9GR=Y.-I1 C+E^:F\N$.'EK6T&+W
M0& Q)HY1:7)=X %..G7#ZC:K)_0,NQ(]5W43S2TX.B<TDL>;<Y1Z,73TG&**
M'N.-" 6>\ G_O?Y^5<2.C#!A.O9@S)]'- [B-M4=-7ZRZWSSPJI#V.L+&K;<
MZB;]ZOD+]8L3KPTO&WU]<6J2Z!_;U'CF2]7)0BTWVX"Y@FV-AOE!X=X3"L,U
MGMM!=UC<HIC4V\9892[)K>9Y0S?YYBV(I8\8]Q32R#[(4V_1TN:JXP]*R?O%
M[OB /W*?D?8[1EDU>FIF-(7MG;YV36DT]:^1HO=!JI]K[[PEJ4K!XDE<67>0
MV8Q/C !F]W-SFPGE3,31W<;)D#=RNN)A,2ZK<5Z.E-"-58 2^$VCN[@J.''O
M@05 P7-*0;+ (T!1QTN_8_::SK=#Q"OL<6O<>>KGW&;3R1B&%VY(>WQI;MTX
M/BDSK@%IA2AR?=BUY(.O0$(T@E5%=A SB:+JKV0/YU_V90>N[1?X<NS0FS_6
M2,:6<_2M2RMKVB_57*J[_X&F#;< U<39-CZ.\I%0X=O4I42V_&3T>S/27A&J
M<HFG/<MGQV:U %O-ST5RT/&C6GA)OTQ\T\AFR2/-+C@PQ<:HLD+QRM1409OJ
MNU>UKV._&-YX5A#I43'>PZ_L>3]5OM ]^* (NEVD-KSE^]&\W0[[:?U?)MH=
MJ+LSCW\E]VMKR]NW!IL7.:?Y4_*&8(38-P7#>HC.25;V_OA!4:0,L"3GD4;:
M9/Q+V(#_&" +%7WX%$@ 2S%Z!5NF([3CY^OVS)3Y T/8DX1VU=$D%;O"H??R
M$839UWR\'S)^YWBN5.OH)C"G.E]@!+8U,V3(%B"::F0S.WP,JO5G*\;AF>:7
MV1*!UR)O@3>XJ#Y#CQTP^*.?=:RVMMJI>F,M:-6,+F^CPMLI+83G#(&,?<D<
M69MO/?/[:_W86U#V^-JJFE=]@/=\7(3+'7,[#M\CHN=;S\_.23MN63Y]9D"$
MVDBV6&OR[,+I.NL[T1\^OZ.5T4 [5H(S5E?XH()Z,Y-V*X01RY '?'3'^6:"
M<Y!_OB4O$+>95/YVH-O-=2;SV.8N0UB)^^V.OKG[XX DS2F*D<17OE-_2_['
MNYDV)D'$JIJCO-HP_ZH?)?1JN_W'#':^L>U.<M_U(3-K*2B@\Y[.J29";FZX
M _^]78:+0ZX^9 6+ZXQ)R5!&"5MPYU2/O,W1 R?CR5IG.]BL>,4E)>_1S=RN
M>#VR/!NX;<JZN?!./8-OV^366Z?-N5UY7^&G,?5X94]E&/4#W_Q\(*XB0R"'
M>0N45\_I\@_"'_>3E%O4S+@9;0Q9DOO1OD6\%$(-*[C&4G2;F@ZU@2+%12?:
MS^@M[8&HS7NG!X8N9)]_,AT9)>;\6K)JG97@*;0XAI?OX@;"XE'\PP+C7@,,
M19_2BN01/?N&;T]2&!W8J>CV(VF,.-C5T$UV!J_(.^5,#R.2(F$@<'UJYQ.D
M$]C>7=#V_-WMTJ2@S71NKHTPAT$$Y+^OY&30X<\X\!1CT,017'^O9!!/+((<
M>8&05Q%$:V2)"7"7 W=\6+F86=S.H:E,FZGJE^5SO1V_&MM5;GT3ZF;4+IP(
MU!VN9!65?VD\/33ED,VLX"UJ;?R)=8HMB+^G0!N\*\S3L'5_?[3D0BXQG%)#
M/B:LJ7272L+N14;@BQ\<YFC/'>&:L9.S'T\#"NZ-]1J@R77R1I )R]A)S=E+
M'&+671[O\,6_K./&ECZ=[2LE&ST9G';9\ME.M4/8\NC#9@, TIEOJB4, KQL
M2(0J).^!XM@T9?B=?>0Y;CLODAO'4Z!RT8TKPLKLY,=>9S$70U5]FVIBJ1Q)
ML^,W'9$<+_!GLC$NSV7L-MCL2-5:SATCMG7%H)]7SX7R 4B9]X(;_ !TEDHF
MJ)8"?IA;:-GZ[5JM<6.8>+4-7*GH$/W=XX<^":Y&R7ROQFX'CQ;DC?A7YRAF
M'*>>N!&\-EUAG_L+(Z[OG%P&"RF,"P3( #V7QJ9*S=18->"IZ$WP-DA[[%MN
MF5]$^LUP+N88=' ,,L1(DZU[%H(<1GM/$24"3:OR5H"X4+O:7=X#^A4S6;4^
M_%W1-F?.9R7<=:NUG;\P7TH/\N QOSH=\SA].&_<S8#.=S%:_YA_O[O [=2W
M'L]NLB%1ISW5L]O5P+N+J8^P[S8.09S4Q0[[W0/2!MTYOK/O'Y,#F0L,,8$A
M1'L&M;-9OW>NC(A+"OV>E]54OX6+N6V^L00?/B8,;"Z4BW^LZF7M8<R;H'Q8
MB:EKUL4DB%#!(E3B$JXBK T8'![#SX9Q&,EN<;,\FJ15,MDID)O(CFL:.7"&
MC =I JTA.073L#L_].<-G,WD:J+]V>F6O^:2O\9[VT+#O&9A+BP!?R&LITC
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M"AXFJ(E0_KC!R7',G#VXQ N!5-F8P5C@-E8=_'$/#./$W:G'D%@<S!WSJ+%
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M&]=Q3Q+0]0\*F@R5<'=F+1\Z7Z7D]9P]NVG3IK-GSWH]M=@[K*KC'S_] [$
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M-;&$"KT%1&568"QNC$V5(UT](RRBR)SQ6^$E%@T? =?85J:.'^NOX$,GV>8
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M(KC@XF;XPM]-Q6VTNC2@VS^=XE1A&EOZ[$N>C?["-WPW"PJ)$\CP8>1C\#4
M=AP4+D)]V(W[=V/_"VA.0Z3F^U<7$:K9@98A/.7) %+@2'3 WR.%M$@-^^K5
M(9EVGJ3P?A"&',A6-LL"8J_M;2>&<H)D)&X_##!-6YNY#7./\U=NL=RY>YOV
M#U3BV#UHT&Y^!4'%;)((%:O!GA2A=A6ZPQNUD,_,(!.%UW'>U]KL6:NQ:L;8
M!Y^2=<=?M5,G6B"5G>*N)]_J&>C.>'9[>>IT\'5ZCD^L/$7?B_SA\BV]RME:
M>+.!@=(A669?>-V!W5U(J^O5=?5JZM)*/OTL/[&)\^9EL4JOZIQRR$$+6GG,
MZ^77PE$77IM CQ&'7CANCJ0]QAG)YOM%6C'9#KIB^,9.#0LZRGI=0ZGM_O1>
MLT$=M8ILHYG36&_T+XLH'PW:2$%:W]6ID/;2[)T-WZW> G'7J8^5Y"G7LNS-
MM"]DEPF0[KV@8.'8O5Z7REZ7N=! VJ1PW&X.2U"$\GN/O_3&:@Q\>%Y;M?UF
M0!@^I<KK3O#0H8:U:GNCPVE_ TR@4%Q*(&,%;Z1$P&_1+P^.JP@V0"22JIBI
MHBW^7Z98V(DU<MB+(-AEQVRI"*5QH:(7SJ=WT0D:4 #]4[&4<ZD;@RL]TS9T
M*MN!L'@RJ]K\=2FP&./)#."YO)FMPG5YS5W#_1*A?$6H&WL [A"6Z25"X7@
M)"LF0JG29ZMA<:2U7-N.E >)O!?Y2:;TCUI X7Q9^"-%G%L=4R\W'4&/%;BP
MJ3<]Q;H7A5(G$_@.UO,5;QR:+!-^='XS3+7\]2C=^%28D"-U/ZJ)W05I,@2R
MFR>;AB0_BE#/T;-IADM*QAGF/>]!;?:,C=[+SPV:J6:J&]+#KNDUI]K)V'2X
M"(Z^'V5-?XD /B*5]*O\O1 ^"G U/T<B[:+TCGJ>")5Z,L,2O?*L9D0(6RU#
MPK(V&)A%V&>G%&Q&B/R=SL5L97MA/> S/#SG95U>'L?QS-GYNK9?KY03H]#F
M?"W5-]W'^B_BFI"2!)NMFG_I\A$&B+,&&C",*;0(]=+D-PYH_\0!!M*".G%G
MI095O.4/0-(@Z&.M7M@:\T[]+ZO#&\4*RXX!=YSV?MYT34Q(2#)*;N#L22T4
M/OLV5;20;73"BF]J_B4U@%S7_L#3)*DO@]Z$6*Z/V".TKZ[3W/7U.E\?M+IF
ME>QG)X0X[W -WA>[]W@H4#W-UW+J_AIJD>U@B0VVN3(H?/'O)0(-OH15@.X_
M0#PL[Z8H0FDSFQG@=Q$*TIH4:O!YB*5LD@+G1:B[IX"F7(2,,F@+U/E!Q7_P
M'P,^X<+)7$9:#M "@3#OP:\V@0*CC2+6CQO+$:'D9BM8VR '^"=16G#PYUR)
MP"KWS,<&LD_^_NH,R9GZYN.N+/\-Z]W7: *;UO]H3H-I/GTW$XNOK!+;M$]+
M?>RKM\SF?0?H"]K_K*"?DT0!4HR\HV?NJ) 18._;MWFSH<'1/PXLKD9H9^T_
M.%@-_\^7:/<AT/\GQ/??%!RE;9QPNM)RUTJER"M@W**:F:,T.I"LEE'^=25G
MAZ"^H5+K "M[U%07,"(U+(3F<MKDSI'2R>Z.V].5M1J_BE".L38J[T^=OG@!
MI[A()>H-K_DP'14Y6./9\I.OA?/7-MDJ0N6T#<T"D[\GY*T^*T*-5T3]#4;?
M\8@H_/5O(B%"_5,EI'#+EH2']3J_ER8%&K#ZP%@)30PK[PZW,,K-T9)&U,\2
MXY/)B\35+2"Q82,[Z$AKA'8;ZWKFYD1.UAM50\+S+OI4A/'KDBDWRE-N5%E/
MFU-]5:QW\EP/ODB$NCWH",>_0E(\L@ST_0:]U02!JPE% >/>+MT$V,8T8I;Q
M_<D,G?454"/\3>BZ_ZZ"P&.<P/0(O!%)L;4()4QA@$T"Q#9/R*/!*20I2T*-
MW_'^!T9^_0,CS1<+1:@_OP#@#P%CVO4K+$*IBU#QV@A:N]_1D8%EXS KS^IH
MK*^4TTAQU6+W@<F)(&Y\5JDM@6R2;X-ID5QMG7:269&EHW6(??;.E&H+9[_Z
M)<=+\WUK6H _D8C^.[1._E,AWNI6_(/V/+&."!FP/4TO"V.2S1P!=C?R)KNN
M%:NEV41$5M!L%B(KQ3\-U#M&(Q^.EX?%G79)*G3(?514\X%6_M@VZ9Z5>'#8
MJ=?T]\J$],XO72OC3; T=?6E:Y:-)SYJ95II-CDUE9"?%Z_E[B[3E4[X1O(A
MR!5>X5/LHLZ7+H>7O7[MQ>N&,L!),5@7&13M'*=40GL8QLU %4BBETEQ32M=
M<TWY'E-NO,1GPU+1:NOB"WH7W24^.SL-",YWR=H0+WU7=>JN2N]D.M[(A!_^
MV_!9?Q]^81N\4>.W*IK3((3(9I,=4.]_\PEH*K6\*D0U)NQ2AHQ=3'EH9HE2
M*Z-HH,E4:@NXXGQ/YR ?[T4X77.MNCP,'\+CFKN"'#6=2UEL_V\_W^_XI:?@
MM?C]K+.7[EB_SRR%KN>YT:V@*JQP3MA)B';I%2S"?Z/WW+]SOPAU&/B7(O-/
M32*O:A/(\I'*%*/^_G)V\[)@01VW#_N$@?]78/VE*+#!HN%D2T#PY]0RT&_Y
M&T<: A[V/QL!S&'XH"&M:H%L6(NG&)06Q<%]]N*Y,@T6YH?">*5@?TQG,6CW
M-BQM\+N:HO )5N,[5J4[Z.NK;@].KZ&^+/Y%3TCQ@0_#GZ<&K@U<X[:ME6YE
M./R'GD_Z98%0]C+R=.U/$:K0-XTON EKTJ1$**L=#'A'"(+])[_='ASI'WFV
M8.=*[[.IJ\1A>(BYXD*6@Y+ %?0MM/AX5AME4^SI>F62FLZ.C!8E)1OE@MB*
M?I\4)4@NU,?'^^PV:W5F)^-?%QH:TD2"#5V7^B?CJ8>((?:Y4>P3<.XR0;KU
MX56#/049CNFG7XI0S_"R1EIW2/3 Q=N?$NVC7*3>OY]UYY_Y,K 4'C7_Q5P!
M-,VXV0\E5&*U"INE</GI)P/"CUUA("1RH5W9P'O\_KBPNFIEHC3 LVMP'AMI
M-4>#7('-N.^/2 CRQ$LE1*BTF42(RM5E#Y/-N4-MXUWK[31(9LT?4MHXV1MS
MK$SUOY^R5%S6:T.M>K^SWO4_,TD__T*LPMK?-'-#3)UZ'>'(56M#U),DU*DG
M"&(;#SC(O"2_O%,:Z=EAYCGZ!C=&F3^IUI-M&S8Q>>MQI.>7[LMO:H:67L!D
MEZ4A<@:SI"8F9?WT6=N1/XX>V?('<<^:WH<A!ST'BQC_FZ^70R))%<@('M(^
MK^%9:2YJCUDU-0+['Y\$_E7J77X 7.7=0+>)&NV7<:2N'X-M5.MJ6#;,=!YZ
M+=C[-VMO^]O:1\Q,OGR!6.3_E&,OTRKI AD6O/$-&Q,#;^TWW\_?1/DPI) ;
MRC\$MZNIY2P=@[3&=,T>5!#D*3T$<8$11W6WC?JGYM3/,Q$*Q<^^KR0]53*;
MD9C).IC"R>X3FOR/GN2W'B)%)_8*O0I6Y2[[[:!"2?=PW[.HL"HK0VAGCM P
M^G^:H=^X77%#3-*)B-]6:/;O&E;. @]+29. H\+:BIE2%\]NPV$"Y$3;<FHD
M0*D^VP<5EF@G'O/#X*_5+9=>OSUO;=]"("[*_@>RYX"D&P?M1"E;S:[A:ZZ;
MG$"OIJC=>-<PSI=0299Z-N-YX2IGY!AK]\=]7;-;V0.XC>[B,R*4?TU9:JE]
M0X<CW%70.7ZM+YR3U5VK,?5J__=[1VX=H,=!CR]/7&QTW>P?\W% _(S)IMTM
M=A)&)TZ08G)<0DX-#00DN6N#^^> ?X=>Q.O$9(#C<()8-  6?6(L8^NU_G4_
M#*LBCFYMG0B5!U#>,:!SL*H(]3.!H<)L1_S1C1FA!>Z%5*TA?1OIB$>ML1(Z
M06!2PMJ0<]4W/[#&,S=$_<ZS\*0W^7V]&U*RY;\.OK![IADLW^/RGK >=Y;V
M.9<7PDTE'X$D^3J"U9#%^*N%]I%MY@1PDAUVBZS%T>P)W2XSK100,&2<X1]1
MY?)D@V7_J_N6!Q)P>]W/C\^XG?VO;L?]7SM2IG4VKBE<P]#<+*8)HV2AXZN[
M;5*F#W8>7)A9#GN4LW'K5$K:#>BABA09G8_2E_^&WEAW]1G2T__!7 RR[>SY
M$*3-P36SUA]2?7"W39\:;1Y&)SDW3I_;O[^TO_]IFMR2[09J5]C>W:U.5@6?
M^JME_(M+[_^/K=3^'X]<C;ZKO:-_;;D:O?G  0NIQX_6_7^^JUB#$RLFD./S
M0ML<0??6N)_XK>@"%!#G)C2A?P02UN$%\FMX(>NNH\%\\\!D*\TVSA?AI:T+
M@@B7J9;(P>$WFV["S8:X1;,] GVH*N+!G3/^/O:#5WWN3CP=XNS=#5<G+J^3
M.^&Y<>(_O-R_76.;)DKJS)@WFD!?2UG_HLZN%&@T88]$-FO;#1@U//9;27\>
M0I!RE;0C]+<^\#6:ZC6T-V]'U??3FW$^O:6;P,3$U^=NM6^-&@?QO"(A0X0*
M0!SH#+RU$N23KK(9LU/\$Z0E1"_#V?BA?4N--1=9TKBS>&G!']4@3:"'64WI
M9T@N=FTA^&6:)&,JWIRKQ,1EPO3+FV\\)J6=*>^N<\\[,S0X^&7:OQ8@,#F&
M97/"8 9;*(L+(Q\<HZZ'#B^UN%%CS/792*$'J!W@2D"UK6&9.].\GGJ0BEOV
M364&)VK?KCMB\7#+^^*9D_Y*QFGY]07DWI'*V =>?A?V#!V.[V-.,&:97%G>
M76@_W\43;F54$%K>F/'N@TM4RF:DZM&45>1K:DH@,[I^^_!WK 37*J9.:WP>
M178%VVZ.E8.5PT,LTGB3$OV&>>"CJ:&@^MJ"]R6? Q1LHIX6NTQ;[K5 CT#%
M_RL!+A]9E9@6AAQ9!UR5UGC-T5^)FJ!/]L@K:+7PQ7\*E;HE0J$*>LG2'(RT
M/]+ 8$T,7G!8&T?<R<:]B_H[F []!H;Q1/JZCL42J;4V>]*O6S!;1J5 6K.4
M9"!6DML69XC;2K)K-C[I7[,42[9YZCKCMKG\G*Y.>KMCS^*&8#UZ:7:*7</E
M3;=M[Y19ADA;RDE;KMV;=[Q)R5+NQ+-3R;OZ-"\_N;/N3TOQ(A0*);::D4U#
M]*("/[?(ORS 0W2PK'U\,@XX!R33REV:&'&F.0] A@V(OD'!D,V%^4;SLFX!
MS"6T:DB7')0V9\J(9US *R@'*70U<J'5D[;,BL"@"_/\JXY!%X8&D';X#.X<
M=4B[&:C4GNT8PR52C,&!##8&C7]&8KT5H;8L8*2F[4I(%X;;D*Z1?)6#B87W
MO@;+GJF.BE"-0T\9[,@YEZ9J69,AX"5&7Z-6A+))/GG27\#[505'10Q_&/>G
M-TV$1@&JU+)G_[;=CCA2O)K>WJ&JK1&^,W^LN])+TFBHQNY_ 27B8NIP)M0*
MQN8 S\V]=?X[T[Q'=9Z#3^F%_C6=Q>Q:^\N/X)[J3XNJ[E8]E;HC^W1CRFO>
M]):4Y<=,5,<SWU',*9]&%2$S'W2<80?^]TTO\YP.W9-98ZRW20"''HU5@FHY
MO-=GKY?%L>/K",^.?%.\\B?S^6?/EHO2U7_.W\+=8:W!C3UA*6$5X,^,*@ )
MNC_^,^*K.KLUN'\"*(HNY-B@MKZ';,2W=1=H@*V/QS;":E LNZT)HQ3 =(8E
MN&)WS#>&%WX/8A.E/-J-)EI?&)2?>\K:IS=)Q,V<R!L=B/"KG69(AEY[(=QR
MPM5-K73SFUQ_M_XW9?E>Z^D%K@&7!@.50@=2BMV.1 5G['4/B/"8O>PQQ03S
MHLUJ=>^/OZK,]MR6HFI=ZK;V?Y*TBM=#+U:!W*WK^ZQ1OIH/-YO"'C,_%6'Q
MR_R $8%8.;2*C1,7!%5"RF-=29X&$.T1-,R[#3)O&<XG4C3 [+8FO)C4%G^6
M!$6%Y! 8Y'6DKWX/^1338 <X?RLH-,GLU&F?WM#3ZCT8(]>+YS;6!AB6S5)>
M?A_:',<>CBRV7V/=&Q+H/N=^FDG77Z@UB]QJ4,G8,AWF-O"F^(QED(J_<6[)
M]!(S,Z> Q"YXPZAY5?,JU28_+"A D(?X@3"X!XVNC'+&#X;QWJ:Y]P-^<SCV
M9>&3"J$SOS%'$?Q1G$]>SP6HBX3U @S(:L5#1Q9MR/N#^']L,(PLQ;<I6=U:
M<$>+#UH:;OGL2?!P'WT'.$^5 J5O#A6;_2[S?VX!ML\B"N<I]HTDGUT4J'0T
M+I W1W3J#8G$F$H 50$9 S51]"$#G]/ZC_B67YZW3)XY-K5)FLC2*WO16C*[
M"A7G]JD")^W:<HXCJ>TP<%&]KR+[O+*]<Z?$L%]ET)I3%0,5]K8'@D]:]RS9
M#.CIA5J83IRR]P?\@T*#IPSWULPL3!$ZZ$DBU$5@^,AXV]P-KC(;,]O"?2&0
MYYJ-S<]IAX/3D[S@/JP<1#@).;&E!EEO>3G2#*[OW#K^28$ML]2]I2:JH'G&
MGNA,O%FCV%3J;MMG=,</=#UR*8AL5>P/U-#*,6WS&^$^QJKZ;? GS_6]Y$-Y
M)"M.QN\--S4^&<[+N[KYCZI7/S=AIDMGVW8V'>^_^#C]VLO(^S$Y!<_<;8(,
M]S6$7Y;-*TEC+$[! 3.A_=LK>@@ "P9R9R,K_VT2TJK_/P^""CS*4%RDW4"7
MBS5+)6!5N+'Y8\0M4,!D(_'QS IP*X2J[/ZT.(HSHHPO1S[-X\#,G/@"M'A@
MZI<DY>:ANT,_8@RHN03/@&NFE3F/ _UW"),(BD##(4/"5BB.YPBEY9-D.8S8
M^DTSO?BQY3PN+;$N@"49HE.ABU?R4Z1H@DG,Y@-S/WZ82VLGAVPP0F\8(CWY
MT/.#;UTS</YU974XJN7HEP\KQ3-3S!56Y9W+FVUC7"1^[;YR^26C+NUR#[>^
MJN:;R]#D1\9S=#-]*)(#M#+N4'2$3T+QVT@.4C*0+'LRD2P+7IEOS/!E9Q?$
M51;K7O8?Q\?FX%(WG*][49>N^[D2LV'ZTA3%_%-PI;3_>)0IA]-DVQ=,21,^
MH6 $KM Y[B3/YA/9H@C:3E$@GX=2.$ <]L"G17MQ>+PU+*P*V$C1%!SJ6525
M(,"#5;T5M;KN]'6N@UV!.Q.!R'!]GLSTNA/R78UHT*[#JKF8.SSN$!/.[6H8
MU0(Y9%UP9ZD_Z-[(J*Q. H+6/ E(0_19P04M8T#9"34U#1EZRBB5*'23@LRE
M\[M"-2?ME$86%-KUT[I6VKEBO"A(ETMHP8ISJYNIL90M7'HB5L53\LA;BCIW
M?4K0LX!ZF7KW^\$MHS%A^RIJR)QOH]MN_;5ORSO3Z$-/>[*_5BR%5%:\G'H*
M^QIL<RB3,9!-RRH,T^FTRTJMGI<E9]A>/IF0$)U@;^ 4A)-9($"[7.;<@7-C
M[PS,7<!\.D+$P&;R7JY)T\P"*/G^)H]"O U4&A+*)UKO%0Y1Y8L$A^ /G\K6
M5_H8UV*I%FUW]#&S/\P[="_0Q*;B9IE\*ZBW!;V:UH*66;#P;8,Q8%>+"'4'
MO;XRRIV-B\:4/>'JT23,HSB F!OT$;HP($(=AYNJF:6&6X/G@]A]!GI!1F9/
MJRM]JKRMWQQ%?Y[DN54_AU+RFT!9-MD-:%E.)\9?2X'PQZS)'IH1MVKJ] N+
MWN[E19T/7RP.K31^'U1J;TP/?A&P[TUO).:Z8-48/69T2W>=&/BK20ESDZS*
M'G:NZ"8?9,]L,!S1=;@QD<IQJJZL=OKCUQD[_9;FKOK(Q'B?'([-A92OWE_"
M+Z;7=8SD1UZKIT<**@R25([M]LRGD':3JZ[<?<,OZ/#7-2M>[!$43>O0Q 3B
MPH+9$,QFTD!#_3I*;TTQT#@+384$+^"BL9I]"R+40E<BUN#U%OTO!M)E^K=R
M++^<'EGWP4["^RF^$F@Z@UB?!2*NL@#>BI$3H;@?D"[P FM9EOQ[E6T6[X8(
MU=\TOGME\U.;7Q;$:LL)$4IL_J?)TX+W:*#@9QG,8$[^Q N,6FDBU-%??#>
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M"XX),'>+*38C_MY=-8JF-BJ2Y*:U5>-"5ZK.?'*^,[W:Z%VS1U!4\%T^)G^
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M!6D+$^ &_A4:7Y#2Q<U&F"*Q! DV#;U$9_.VK%..MH;2@Q"G0/OI+B66RT_
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M($5N1.UH=5.%:EO)"%(8H!? A'0='*J1NZ[%%S33%'!I3W8/(K-D#20'$"=
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M>[ZL='Y];ZNGZ-Y.SS'%LTKQVTG][[';_;\U!JI5S=H*U$:-*>B:YLY8UOW
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M[2%\%8?'-A>L#]IUF4D^L7_'OTUWCS0WD@;S;F+?/$]J1N5]:$U:E?Q/*J7
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M1:V)$= ;]<K,6K,?,!!Q[*'<+Z*V803<(!U[G-JEQ$N75PQ^!$UMM_+/]V\
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M*C&?'T>6-KHMM-M97!@@8_O'AI+:E[Z1,]#I-.BNFMA> 2M\*ZM1,F,DP%7
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MI8<J#L469>><*K"8SG(G2B[4YCM>(?M VP![0?C4&,!IXJN@U FGE&D$MS7
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MNV]B3UF;6;#>]M2>^Z%AN]XX;(ZYQ$RU/5<@M0:,DVV#GC::D0P!Q-V%6>U
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M$N+:L8FV2GY=H0(<4VJ0"$2,' ;Q[0%X,U9;N@:3D&_9&Y:G>[)7J@?BQ;7
M5/YN )49-8)[4&GE<A5>8^^+2&&\5),X1^E,GJWVLC[5M\7YFYG\K:R$?%6F
M(BZ$HDJ(!T#C5&+(2)XQ!J3$U?LOHE2HG/RKM$B!<VM/:,.VY@BW9.)!(4T=
M2N8$E9I7/HK\8]+#:(8:&7;Y2O#EK)]2\*)LQ#/D[3!XTK ^1*L@ND U%=@
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MCTC._HVJ.M''BX0JT?")_3?[3GL%Y!^(:3;<E"_T[>QXRZ^06P%O"-V-PZ8
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ML9>5L:]!MEN DT0_62%J'\&[OX5-Q[094'0GK:F:>-):1GPL QZ#KBEIQJR
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MJOSSOD*NZ-5FFE[<CUUN%2<J'[Y80P'OZG!YBG 0DGGK[%),H3E8;ST=K="
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MF^SF=$ZY9WMM%>I?LLIPO>#Y"6Z*)E;EPX!??_\(\4I)Q/ "#Y!"-I8RZ&H
MQ(@X-J33-,%Z'QSE&XP3MD,&WC76MFP8_YX\M1X*,P[S*7-8SVSZE?EG<?J;
MR/3:QB2MX<-7='D*CA2RQ02Q9@X? A/4Z+$5=G"3,9;METEEOPU4GBHD,4'2
M1!["%C%/=\5AK,,XA SG7Q>5;!G?+#K07!/J[4J="U^N:[O-(='VQ>#<GD_
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M:7%8S[9$W^.,M,JU3(6__QQ[4SR-?S)O0J$;]B O54P.B5V'6%+T(NF:!]I
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MYJ;<SCH7&1!S#Z>L\],A5Z^]U ]FSBG[3*-XJWRD0Z<4G2/QMW;.U;A9B"(
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MJ9$9IZ&E>',^!>PWDN#?+FLQ7X,=OY,I;UD:G GB1(2GY*2]AKT)$5BO>T(
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M&[\#'+*\4X<=1[8=LNY;*K0U +M4Z/,H=P5 ]UC5]Y2%#?H8G=UQRB+"O!&
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MC0I&+?A0AW.8 DAC>F&.LLQ<'-OV'.SKX(G$75IA(D-SC<!Z]IR/KU?=7[V
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M-^$R8OQWUIT=NSZKJPA-V+0J0S/F:C^^MV 6U289P-=5Q"X;?_E1UL;)OZA
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MX'@<O.4F,[>'L[KH>Z1<4%VG8:X@O<N( K$4> 5?]\/X_-%/_[7UZ*:WTJA
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MT2>%0F98C%;FM[2;]H5EBR2'I>B8O7)\"U,<P?[C%NT_[D"HDL.P4BL9TGI
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MN[ZFAB&=)Y68$;@2H)'A->X< FK+%EG$ K*(!*@R11<R\P!-Z,H2P0VT[I_
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M7Y2J/,8:4))^.HWE1V(*?/A^>5BMLI]0'GVCT#*506-J'W!V\ F1'^Z7,E5
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M'G";AZBO+[*N#"YS04<-?>?_N?YQWF#^@Y#_V4%<D#,ZDA,3.H'8S?9H(QZ
ME<K)!@-1$=+8(;%.*?A2^KLVXAK/>X[>-N<Z\;^J'8W_*E/\][[_9\GSG]CR
MKS8&IPH H5S0;]Y'#P(RR_G<P?42B!RP,[++^T]R9^C_1(@K_I/8,?IGH4*L
M1OZ[:^<_U [D;YC^ANEOF/Z&Z6^8_H;I;YC^;\/$SP7].W!:UF*:<D%/9%E2
M (26I$4]O$B,Y\@ 6S<>A@MV$T]K*IKY(8ZW98*#*94G2.8C4+T"/T,MGY[J
M(UE[A99UR@VSYXQMB5@,WT(Y^+#OR55F[./.GV1*Q.02$W>6]_8F[@K9?RUQ
M^?[V$#Q-&3U9\5!.S"HX2,AOO-R28%7IEUIN5V"L.%!D)-]??B'TRI=GL#[Y
M=_<^I()-^3+<U0"HWM%O%B2*CV4G9:6C28[7X=%)@N'ST.RTO*/EC1OEO!?S
M7P_>OI@?#_I[_'L'=^I_ %!+ P04    " #%JO5<9F8,_#"C P##Z@, &P
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ML <X J !YX!+PH:D(*(C8B;B(.(C$B*2()(C4B;2)-(E>D!D3F1'](C(BRB
M*)PHFN@Y41I1-E$A43D1G*B9J)MHB.@#T3S1&A&2Z(#H!]%O8A)B6F(68AYB
M86(98F5B+6(C8DMB)V(OXF#B*.)XXDSB5\05Q W$'<1#Q%/$R\0[Q$?$9R0
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MQ&&MMJIXL&1<8P(>"S50_J \81I9W6;?Z%S8M&^&T/:1R_ Q3]\_&#:#D]<
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MQ6 (B]:[W7_?O%P[0[1[N=&^4?^F!<R$,??0LKCRIJZ*0561!GWJ;A_1[C6
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MD(WS^]@2Y/:&G]/6%HYK>="[C"MV=IO3?S<;]>3M G!*0\FA9;F=^ <+I+S
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M:9MG1"V]?5%ORFCE6JXM!Q$O/A,7G<-.C:UC)>M5WZW.ACC6I&#ZO H?\3Q
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MQ=RTM[.ROZD^1?/,5O)<Q?^!'GV_WS:')%>&G_I7CZ78EUA":2;3NJKJD\!
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M7! 7+8 \<7A72HT-BG;%V$PPST&O.M\<L:LJ+_V\$C&Y+Z3JKK?HJ\G8^3H
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M^(*K.I!B&KG":@GPXWL*Z7 !V=C69X'$EP[Y)4.N]QY>(;L8E+(X2LF5?"X
MA'56G1J21 /VS0ZRHC I)/X50+/B:L6JQ-VYQG;2.4ZW_HL:RAEJFE_X%=!:
MF9_$W5(*+ V)WP-"=MZ<.S E@Q?C\-+*1_@RBIB2-@"*:5:_<* 3\/NTY\&7
M1G'+*K07KIC'OS/'X/*T]3O"G5VN^>B18A7RM1[\*^<O(>>PH;W/;C0I,=P
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M785DK 5<&ZNL\L6ZZR;?K(KBKW<]@)-$R31@0(!RYY)JIT_J,.6G/H$S#?<
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MH6A1LGI+K4GE=>1IQ%QE!_?"#OA_ Y6BD)2859#0@ CK(X@'(0JW?]NCW),
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M1T==";@?&9CC2"@D2<]IB)2!Y!X0WX*(J/C00M+03"=RLR!,&TN,""QYUU+
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M4P786@&EE(SBU7B78$YXX8'+M-3,70-Y*^V?2\;Q?M'UG&[YV:^+'R3:#F3
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MDE\OA(2H'K*1-:;(IB^@G9EQ-0'/327C'*2AD>]FUG]])'YYSY<=ZRRZ)JA
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MX!]\,+:_%>)F_LG-XA7&=\XELNXVUZ!XA<T-;*%7FOS@D]TK\O>33*NSZ19
M#P;^\B@?=Q[^F.96^J$$EDXV>!V"$EC/]4ZE9XYM83789)Z&_ KT:<4Q5'7Y
M+N1"$T$*8@Y7-;[O;MH,.D#[I2OTGM4=@&%[1]X7KR:\=[N]=Z/2-GFU$0O;
M_D!6NC(HS3<2:V^&G]O?=79B5K2JV1G40SU\LL<K),S=!^S=9?*+?E7H)@D5
MM#B#WQ3]!TUX$_!RYG._SQ^[T_E>.?]R>;S./WS]]N^6V+B54"\Y2/@;6S]J
M'^(ER>K\USMTMC1Q\"($W-<<&N$&B7!S7^C_5;GTK&E+5>J4C>B]Y\8F6<&)
MJ@:?K<I<[5)5;PQZ<@=<RP0I/7^8\3<(>5@?_7H-5]B*=,&V"UC2?><C;L]/
M9"5%R>=XLQ$W;CC,+3KQ@X(*S83<"_:^!DW%M\1IVK^=%,VIC/.R(7ILQUU]
MOMKTM+X#@PWH. 9=^IF*'<(LKL_/[XU/WPV78V])4FF9N43)\@1YOE$U]\@2
M-S& Q6[TR'V_^ZNZ3OZJ9QR;_Z6_K(8+VD\5-H3@S>>.E.>.F%'K=%Q31]/+
M<9= ?\<1B_[R2GQ 0[<62FB6AZ^=.+>*FUIHH*2D_/#T*<>F'H/\EN:4*;*=
M6\'+7S]0B^GP:9S6+/,?6B4LN%>L\&UD*#20>@PR]=W_P9J=$!J\/_$AZYZR
M4O7EC)W-EYRM<-K(*XE4L69WWC,)?4]NDIZOHYHJ2TE;4&O"^-'WZS9A&/>0
M-:/RGEDSWP&'&-MWIG]FJ_VC^FL$ZQ5"T$<.T1_%TKEB>CPV('SNA5+9,N)G
M3/@2R@O,:E;?WS13)PT[%*?>L QBF"55*GD8R?CR@0.X;CT(Y_;,%UK(IX#X
MM04O%:I]>61\BEWN#MN;<Y?>1J?I5%LN1L";(4IEQ:%'"&GD73^YBY^C[CKH
MV-P%TWNYA8_(/.S?]NX4WBK)(9G8!+T^Z-*_?>CI(RJJ0&_JB%K;'/]3G7=$
MG+"WCGS:8Q]PV=LCUOXMAVPAZ'S_<CX/3&?-1I_(5V.2J_Y2U-[GP9!:FK".
M'JUSM?&V1BMT4J/I&/1<IK"BM*VT\!!+L/&3:VF--4-_OMO'*5&N$'DQH/_J
MN"C]H]+'-UNIA'S/F,M)OPFQUXJ1=9V:ST&R20I;$;?#UGZSI%K9U6WK_8ZJ
ML4N["M8/S(.YM?<\[_V64/IMW[\OGA.>]GE=']J-?(J:\R );]92_[!DF=[3
M@7H&I.M3ZL-G JK4(TW<VK-M)^>,ZJ(D#<RB?FY-#MD$9@_RF30K+*EN3_/&
M8Y,QYB>P9=,1OF?W:[2$73?3>^']Y7.E*S+[=19+AN^D<QZIMDO)JPS5YCP[
M>_J,\<,4;S5AYT+I\[$?SPSKSB1->HF%5!CK#@2_?Y*%F?D])T]>FBNC9P.)
MU+SE[#BP//,4(%O-&G7.3FR$\'R2$O[F@ZMMJZ<NXDN'*\H2JDEUXP>2Y@.O
MKS8T9\PJI+RUB.1KN=5;3=F(Y+5'/?C6X&]K5Q<IQG@PUK QOZ5$-GH5,CB(
MUBYK'5]Y[^]TK;[@1U,8B!TV"#I%<?XL822A(>%V;SQ5[ !-6BMQ3D%'N*I^
MVI#+@0U/EPAN5>Q:EFCW%K^@![AF-(G *:>3AX(^N'%,%<J?CNGR0 ^N?RXG
M@3$Y>G>[O\:![3RBB ,0^ZIU&\(TVB'J02;,UMY79VO4?FC]B[.0XW7SRVR"
MC\Z)?ODBGZ$;'/UV Y);BYB3OO#C1)I\^([H*2,L7K2*_]\AER(@"G[GQ[H_
MN7ER9?SJA$5-"VN<->#"=N9MD2X$%24:D#A0\JB.:6FP@7)(\3J0X+EZBWC3
MPJCO?.P/^EA2^(#U:NI_C>%T;YW>R*P?D%ES%;1NH.[7YSH\IV?'"B"^'[S!
MT^L-JU]0]67*7EIR]0V7,GZ&%^\/)%4K;>W)>*><2^#G7VOD^'(JX<G%'X*7
M:PR#4D;I:*3*$_Z/8;V3W"4Y@MSG7+<O1?'\?>7S)@/,T,=$' T;&,ZT;N,.
MIJV&-=9S%X1NE#N3+]KL7"F*COKZ$JNOZ@+R^9X>_L_G).N<&=UCT"NS3+W3
MA+-=O:\N4?37D)#L/]AV)2P4O0/="*#K!$H#7-VHBWJBY,#X19U1#-R0Q"OR
MJWE1FB:5'"XQ[^=L6<*6]?OEF,CLM;NT+_=?$-<45.4L!*H2/B%L9XY!73SX
M)_(69AP^T>2O%:2VB!5<<J=N-A'C$'@VJEX4-_3L27/\ X9:AD<FLF&H_I^A
M.K,P%8.:L^NG+L=\P3T55=EV6WZ!V'X!$P5YOOWR*^A/ 56 /@DDTDSHC*-R
MO)=B,*'P8BW5I/-(P&*B7:?ZH5*EGGG%2"A[W*</H;[;&C?W9Z\H5EO4W;;0
M'?UFR.,)[X<899"!>-[XH95WWMKMDMPR0CIQNA=57A#*S 1]'Q<[W[)Q/?"0
MHZ:X1@+=6^I%(_]2%+#_!OU)/V]+X8Z6'Z;]:?+2B[^"3AM8\UB5L*/"AN9@
M3O:9.JW:OM\&@P3+Q+ S9I\NBQI]#<+_^E]GU]M%,)._1^&*)(Q<GR'U=WQ#
MFZ*XT>C^#/^TU;CZL.[B;7-Y\=M/,SWBYN86KR7=F "5)X$PE>793;N70]\Z
MV3>UW1Q APV&=&Z_^@NO<8+PD'F3OB6V__WC^DU'4)NB26X>W08-,F7ELS"L
M[:2M[3N7\2N-$U7J .3OPA';QO&B('KIJS-');_>=I[["YVT=TL'H:Q!_!HG
M*9<YR>VN%("Q=!GO?KQ.IO&__SG__BCS9K_,]S)Y11=P^NV1%X7"@^4>P1QF
M<1R4NOS2E.<3UQVS^?)^:KL6*Y>)J6>WF))I=C?-3&]81[]XF>)TZ&/DF+%^
M[E_5+V__>J[7:S3B*N7R<;[KMQ0@MLYF[YTI*/%7]=>D,NU>D1K19ZG%%5NN
M-[6@,CN-6:R"D1<;;@YY?_Q93VN-_IZ^=2FE/:G0]]3INHHG09ULS+ZWOX,G
M/'1$H6Z=50EC-WP6:L-N>,_=>W2QR51$AY+&?,/A,WLT'#LU/=V\@/>?2JDW
MLM=J^FC^A[9YOAZQ/_/0YQ)XZU,U^'%^&D7#Z^&M+P;EE)GE@V/0574GS/@&
M$/@[E&U\MNS7#@Z]XYQL=-'F_UZN_;^/I"XK;XG,(Y?;4+4;P;M,]FE>2=@8
M0E5*6X_%%IYT=(B-QEU&$%L=TPT"#&(@33$X _QXJ%4L^%P'U0[,EOY/T^?:
MJ:NX1II7):2_JF,_3.B%L9[+[02';M(U3>O4=4G:/EPMAZ3ZW=C75M1Z/$X^
M?J_]C-!'G3UR;8[8^^?[<U$!<J%BR>\:/"*:WOZ93M0SR T2@G3OJU;R81T5
M::>C@C<]?1PRKULI]-</:6K=JB[PO:MQW837TC95I-D&[?HFY=,F\I:["M"#
M94T<@\3POBAAN.>H08!T@C,^'@[% BXD'A1#W8D+Q097:A[7T+>9-FZ>PCQ1
M0+\*R&KRO^;0/>=OQ,]:_TG;#KC0MX'3ISENN92RB$MU!EL1-!7<C36(@($7
M?HY_K[/P2J#8/"R;<+B3@!!;6@]W;R8-FQ.S=$=F D*-S =%X%*AR3D!GR8N
M37!G"SN>;S4\/ ;1>%D<"B8]^ 2\(-+[&#2'I2AO$I1[_&TH;K2EV':^H.NK
M\8$'>;/;RAI<&R)/)AN@R0:-[FZN"R9G)J:I,X/!+UI?S,T/7+(J9=_4*O+#
MUT*2##QV))@/:$O$-HB0;_B^<W8/KY3Y41N%?5H#R6=*'E1\JK#7G)-[MLF_
M=$S!><=3T^'YG#[!6#)O'PX1??[=]P>:G5.-8-WCE<P752C.MU7S*F)P?5G-
M51_\3._6:,R:8T;^4X=*FL9C2[R"CR2R<'>$'7X7#59TJKXJ::Y&7)$P4A *
MYNY3@DFLZJ>%O?[ZV4<TX;W*^-"ZW<?$+MN0=0H59I_]N 3"P:%K;^>X DG#
M::X;-,0S+T;; A^6)7T>3+ $$#W2=;@R6NAF5:A\0L/YL%Y=U+\RM,)T7R3=
MZ;X6?X%CC]A]8<TQ21)<*PQZ:TF\!_(VG#<=?(D9"B I!JGA4__K6\)&6]VR
MP@#%MI-, 9H\*3+V:*<K]:_=WD,.]6$I];&%'8P"9M:GL;UY-*N_(0;ZM.K9
MO2@^Y8/+##9DER:<G2$ ,R&GQW^BA2[UN)F0)[*:$%>G&CO.SALID]HD=;=[
MI7FNYXO%E>%ZC2<T;FZ+;C<-!7@87N"[JC6\<0QB"YUJ9R\'4*9'A<<@?^P<
M[W)@-Y9_0SB<> SBANL'*VYEQK1&9[6<I)QV:(?JO>5[/QCJPL)"PEK=(B1A
MQVR;3AD/)?*B<*<C<?F7O1UU1D+3*GJ@GG/&>5T[19-? TTAN:O?.JA59]6G
M$<T^59AEUQ/'4VY.50A:%DQ? )S(WF&O!X/A+\5*7/MTASX3M,@I\6=RO1I]
M,KV=T)V/@)?59YL,)*,'H0IEUP=]'_L^*9^&I>#Y'*KE.<R",2[99&0:0A-X
M1^,E(YD75GN61-0[?$R #Q7 B&5ZKT/AI;'J$+<7%AX6P%OJ;_/L!Q,-;>@(
MI\T=C8>;11,KB1CRJ>K=A(N8Y])-.]'MT.6E>5X*>QH^X#+CH6RG](5U!U.J
M,GFI$W+A]3(^SMES+.=2I*WY[K;BL]4&?F<CS4+OT8-7C?+F;5_\->(FMIQY
MY[")!E3+87FR=/(QZ$F@X"(<0@MI-JC%3*5'^ 1A?>FL2].(Z^:?E@"?!\+@
MZU.K'?6Y\P]P+=0ABX@(0<S\0*!LY.M)"UA?'R]P72L9H04;)%]K'=G"T%;-
M 7V:5L\84$]$G;T<@OOVGTOR3".'>N25B 4'<RY],%=.448OQ[[\9TR*M9JA
M"ENA:UO2"SE[U4D%>PE)3M&7T-B>&X]H:3@QD>I+/1YK-H/RMB5:QLV3<K8_
M['U'>&WR#CM>W='1/A0]!L5)!"42@L3CG%*^J@!#>['U"DWVP?""Y3VQ/X[Q
MLX&\Y%H)\YB>)^4FDC$5N;;$WK+)C6]]WXAW1;/.:N@\*COTI9(A',#.,C+*
M@"1$\_J=TBY.MHK7%<2E4C0+C2:8IA_]P!)14].0PE=%_#+%%4X#RB6OGC@)
M;3NH&E>+RO])/U&!+Q%$:2ZF+2,2,54H-J%G3M.=&J0_ CY^\G,_VS;>[MX4
M'M<LDTE1O'>'/;7Z4<U2=5=(KGZ;*Q'EL9CQO;?K?B7[@2R50&J.1? Q]:A6
M!&FVN>'')&40X&%,S8[;DBVH+FT>;;@MHJ!0G$M^X%GH<:95?=Q@Y%K)TLJ7
MTWL0IY,IN,_-LJ9S?V]94?OH\4 >M0JVT>.LE82XQM2GM@N]]7570UE,/-.X
MO7!EQRYM>\I^5".O3;!P]RN=8 -;W&:ZN!E*?DDRR")M[O!FCY'S)8)U_X3J
M39^C_$O\FK+>/UF<DNH<1#0\;QD@""5Y.:?K\9=P?#6S2?',1SXX(8QZGDN]
M,+?\P?CG.O2KL<&)]E]WOWC<>+S6QY7>CWX,G>B:'O*SM7_ZJ/[AHR _@3SB
M9%E<=(J7C9+RKCS=Z^C-DZ-J_+,=X*9)G)XA+9@,(>#/ A'DI12EG7W>>-WY
M7R]@*+<VVE+Z?]2#I81KGH5<&"U"ZIG)'V*>-77?W5W9U>X^AR93LWN6DG3[
MF'Q]]%;J2*+>*[+;BXWEG2VNY24VF!6D;;+Q*L89> $1!\"_?*'E_=HX?_#M
MQ(#"J2FG$O-[2JGOG_F3$P4.>8]RD(^WE.F^P"S#&NXUWHXL!RHI]"S:?99\
MVS?ED-O^FLJ<^KUMV(U4'_]R0^1SC7\$-O8Z,_0[WN[^EYCB-9CU!VM\LB#&
M0)CI41;R:>!L)EAM(TP()06^>:+R!,IHUM3,F#"$6-Z]J89(AWFS9'/6[*WU
MYP.M9@2-\<59L+?WO3>EA(-=BD*>0#I4.#'V&8^T>!<L'X\Z!0XW5[*[G-_O
M'-_X@NX7LA[A9#J=XL$)'[4VWPV7X@EZZ48837/,LN(J_.FDG/(*$2GG-*G!
M[4(6^]R:+VE6E*6VOC@\42!&M?,XMXS^6O+,I ZM6Y?]<S4!+ 4//$I"/L+S
ML[Z+A6V)TP3Z#$0-GJ;'HCB9LFI0@>^F)3"QOC[=M-?ZI<4?%UP7AO7"FY))
MT&#2$1CH"I2L+GY%G[^Q13>ZT'U4;. 9":4;'Z6#!1#?43Q(7U3J'AP&1<6R
MKM&$*JI@W:LVW]K-7U&.034+P[Z!C^:WW24U7?Y+A9:[KF>%XU"2/QRIS7.B
MV8=B-/;-U]2]OF-0G7$VXPK3)&./B.,<9TG"?#IM-AP6W3.KDM,Y9AYV%0'%
M%I<6>LJ@0EI30G,E6":\2Y+X1)3_J=2]^;UTPC&(^L^1W*[5:<"$O+,%I?6=
M@.12?&LCKH*$BCILJ/5E23>G]1I'N*FN__ 3_E:@793G:Q3WKO1K%E:_*2^X
MS$13&*5 D<#99L)?>DA<-W/Z>94OK42BM "YU9Y6P*TOP>-H-3N>*L=79EG@
M9R9XE'^ELC+-TF_5AP\P(JJ7$TZ]I1ZYCL5=?4W5"3!-0O?DI%P#E%/7/8)$
MVBF):#UOU5!:IHI]K8BK72U,E!RD5O'Z,/^I":^]6E_#3F+A#=HT4XB=KC,=
M"F4PSC&#&9<!2,_A=#REO37=C#4QU<Y'&;9A>!=*^L][3?2_N:S(*.?^<.NC
M"X0;[D,QYP7DM9@7'=S8B0BWG7@$:",7%>OH/JD)^)A.JR^<[GSG.[Z V:=8
M-M0UM7EF'/S<Q6R1?!<=K#1MED(1TWCJ_1$NQ)@!/UB(Z04@:1Z]D/J^GL!8
ML3/8F!!E(>#LU,TPF'NWRX>0-K:&-,:]C-Y54_,-QNW;;= N@;7FC)F%V05B
M%ED:I;X#R%@Q59O>,AXPH<!C\I(XZQM+'XAG: 'CG7LP+O)%#[M)9AAYRWV.
M"V-KAZ,)5G_T>A6AV1CDD]"0<"GJ4;U&@UC,.Y$<#T-=TI Q3V[:]0>]CJ1*
M/7WNUFH>RXLTOJ\59'N_G-XI49M",>ND]^NV+^WMG493A+40\C%Z_PS6)U67
MNC@*OUMA7?TI=<F!K* 99#A'KIMKEW913.-)L^6!]SZL?!6=:391;&RF1K?I
MLNEM:;;Z,U'['O$-P@.7E(YCWF&X,XV/FL&7F1:YBG#SB,A@ZJ MM8=543Z?
M?*1LD_BC(]4:]^6=6SSC[ <YB!YM;LVAQG'M&+0ERE!UA2"[+)$>D%ED-U(
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M-@OW8OB)PPQG!#'<:LN(YD-W ="1%,8QB/T[:XBEVTXKR7KK7^3B5P.KW3Y
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M"UX,>!=[6I#V^"3-?7X5LSAHQR!N$;"\7YFE.7W"BA@(&&V=IQ6P+B&[PQ_
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MH'\(GP9U!*^LF_H)A3=L.;3 Y:4K'F9X#?\<]G1(NV/27KRP_/EKX+<F3;K
M\L4^536&8#R/#8<JQY9'I2#LR]O=7I59FP>=B;_[X7IV0'%>6OF)C1[EJ8#4
M0ZS#$6V&4FG,7Z)HI=1>O2R5;T9OM4Z"/1UB+KY^&O9*XJECQ8TY"UE;352V
M6+*,:'E/>E%T8/2)VYQ@EO+SNO\&&$ABU-$!3%(G50QM 62P*-!8^:M ,DL2
M>1RA'BJ<<!9(S&\K!:P&SS9M!(TPYU:WBTI\;]VP]=7]/3TUE5K3A_#C&X#5
M*7S&*7#[]T'5W;Q@HA;V07597?N@XYP 5DP),_W.R,,QM$O$/NC(7%8LQV5V
MHMFD $#>'!ZZF2?K)]1M53WDG_9[[=> \W/"@4 O'#Q!9^_)T#YH]F6V=VSK
M >X@J?9F)/L?X/WX['JWL-C"C"HS-1IOJ.)9N@]J_] ZR+& 5YVHRVG8RLAQ
M?;';:_5Q2//&/!1NWR]G_+5)]*OR)^YW"--J59G1O1+&=-@V;P+>E +^O;,K
M,$%:+:M"7JY^1(.0SYQOKT6YB0476)0Y=_H&NX3-_()J['76?9% CWR!6,?0
M.06"">_S'E;KN3I(/+C4D.'\)J3V2_75$-$,0W5G&[+!=4&] >&5\^'E/VX^
MMBFFJ6 \7P/0SH9ZVX17G\+9NE=ZF]5ZGQC&I,C&*2X.,BJ(<5JNEJ[#PG$I
M[GT7/E&"%[WN5O])7C;Q*+_3<7>7W ';R&%LK:=B_7' >>ISB =)DG.'123#
MGG-/ LHT?'SV]G,>^KCX"5NSBFO+49I6K.@?GQKO+0<HXRJ=?UPCANR8E2Q2
M/*>V0^(##:8UCS*'.ZDBD-D\2#ULU9I]%9"EAR:UGD.?9@ZL-##6DV>DF=0.
M=<^MR50A5#H9?'@?%(4WO77NL;TD^X;M#ZJL2[AC,+]*95]?^;W)SDM[NGLE
MO 2];A4#=OX;L@V10HNPPKNI?W'UT)>9K:DT?H7XU@,/V5;5!3XA2'>O8,NK
M&BMGI5X:JW?63#LMA;RWO+)V#\QQ<S85"%C!].R#F+=),3!0,#:>"V;M@U(-
MX>P;'&> ],X7+,(:Z!".MWFCW,1L+1<(V<U,+)DX6O7KA:#YF"H"L=R4:W&G
M,7-L;&9,A4:(OG_R$OWV"VFUB^LBJQ=3SQ8]QPFIU0]E^IU\> &JL\MY7U;E
MZVOGH6.[+%)WD?.VL7NRC$:5=Z!_LP*?N.I>"V?EJ1J1@5B-4_/)\A+EK_1/
M6$DYG?6-<*\ *UJ3H0+,7LVLVCS=2:O"#-T_$>Q#W"[PN3T\AM\'5D_Z[X[%
M]>1L:#=5A&,V$MPD& IEN:8!B!O#Z#/TU)H!VN3JH7.)_1_'#E4.MQ3EY;N7
M_%C<3:[,J(RO3G[7\(=O&[?W'JR*Z2,1%3CBI$Z%HT&YQH1UT45Y,>;- D:O
MTH8' "]"C.4=J&]DW?ZH9O-E/%!4._<<-LW R(I+H?WX\I&WX2IGCN^#7EQ<
M!(/&-8(@?-PQF#SG*MOH'JIKLDN7]+=VY3^.BU([DEG6;N=R@BO:,)G#/RQ_
M&L-#UM_E+/?J*;(MI\8#3%$XBP4JTW(]-I5]C3L*D>' Z6$</QJ54M"6/$L2
M0^N,!!D@_""WAO.&C>O3Z./.%A-55?Y9;"'9Q*O1E6_'="^?97WQBE&&7=_S
M^^+C]2=&4R0E)3#3H=VNY'F/9\;(Y^%V=\_7<QF+GBF%]S/,; NNU?Y\ZR9B
M_DIQWEXOX5\W669YRJ6WZF2G*P>4R]I/FF5Y;:K.OW40.I/_UJXOX#L-K-I3
M;6AAE6N^=<$&]18#C[(IE[#0S3#T-+N9*Y7I7H[OQE("R99,[VWDWG.L)^X9
MY&2S11A-<_(,7<!YIV,?E!*2ISC*T^X<1$#IUUDYN4*G/&"@!!6<S[+P^"?&
MY_B55&_)JO2IB):U'!9L^Q8/B1YB 1481XS4-B,-5+*4Z<I1P>N26%^?1LT.
M/SCZ>MCL5[^M$^HZT<,:/ZY]A&?O343>N3+H=/VDU)7VXT/XK%22*4>DI#T;
MMS+ISC9"%3#64W1^H ^QA#:Z20<-D<C\'_!61<!QM\X@&"=\*M'F%:)1OBQ4
MHKY,6]'OLHN?S8S!M$Y%H71EZG]_-IRN0!NQRF=#>9U)&L,3^Q*MZF@;P)+^
MQ="X?+D5$H6XWM'HA1.XN("1'3[]:;0(R0^G!$9\H!4Z;3E5>;=^@C3>OK!H
MFE!SVTAF,";BJK)IO'MB\>\/'XI#$_M4Z,J9#%][Q^"3^OG'7CTFN$OQF0P'
M+70Y/DTKK>E$P;I0G!#1%O\C!685L!B]BN(*5(D DR.7];A+60-MD6[=;B%M
MXY3017_\H[D_UWM5\D*>AEZ2)7+5T-"GEYX:O0\Z2A@ +CBL!K.]%7A:2P:C
MBG+XC ,9!FJ2UV/V04(8.:"LCM](0V?<T([&5O>LS!NCCR8]1CFMX34$WS6.
MZ,C9WUKSMY%U](!<6;R$]N1!Q0JOK1R2V,O1Q)P#:KM_<\E4B2"\!$>55;36
M5+8/0A)C.:H\A!)?R#L_G%(F\-MU:A'+3/3)+JYV+^D+#98H6M9I^4#VJ:\V
M90NS\-RC6L6H$D9L"L80_==>(5<=\PVL#A2>2Z<;93U+F/*946QL5=HR*+51
MM[C96I-S]Y-P1*AT<_,+V3\ES=4)_68_4HOV09[4'[*S/,^(3-MNR!%#(S"1
M(8VY8%Q.ZA26136BUM'7&1;33]J7K1K"W_W;[>?MX><7\213\M+A'\,#@<$Z
MTZN=HU/-!%33>;([W*[]P=@Y;=)HSQLO\]_CL=PN?"944*VGKEH(5U.Y56I;
M:=R?X5S;T2TRX'S\IUDH#7V6OM)]N3*J[\F?N8T.6Y:8<,>4M_PIQZ^L&+&X
M!0;\\?01S[IEPYNB3B9H*SYIJQ/9)YY>1?_^8LI_M<?:XD_37@T) 4U0J%..
MQ'JD2J.5QH*O5NV#O$D39&. Q?)9V&WA=336X2S&M"IMNURC]/1K_JR/H^BK
M?L':@9'GJT<U?E$\O 86D.3UN"Q2/8XC@6SG7F;V$TJA3-PV:B^K69/>E'@/
M8M.2>.L3"YF"OKB[]6&J3?RK8.=L ^NG=4^:_S\S,G9!&^J.FH/4FG6.R#*M
M9&69!J% VF52.R(\Z!+$U:/,96O@X4XH5[YZJ(09&H/OJE2++_8;"?XK#"NW
MNE>T\ E9<V-C,>2;WX[TB7!-CAB;>W20!OD!,0$*X$7 NC5/R4+CB?K0[=AX
MG7N'J3<RR:;?*]96Z_KD9RB"4%O1PE#]Z*V?-7L?=!XSVQ7C_I'.\^Y JUC\
ME9+_JI?B\-D]X W&PG8IHZS"1&"[7D'D]5CIDFU46>^!OB3RH)UHH&UD],B#
MR!A#?9:M2(>TI'MGPO'/\TYYEKB W"->GYXR>P.F!*._772%1+4-%3ADMIS<
MME#I9MA)V63(O'[Z:EE9Q;R0!(+PV'%H![:.5T>V[#L<#Q9I]1"K^#-'8)2K
M-,/19OI'TYN:L$*. .X:,Q/'\(.ZC;W/@WN.GAN37@TJ,58OW!YC3EG*T<+L
M%+G/L+/_\OA= ,MC6P PHF/CGN[Q-*"A!5PYH5GK'.G#E&58V9(S-J;9H@SN
M[-H8/=>&2&SZ5'$_9L:E;,9L_K>]V<.T:]\>87IQ3*B<V+;O7C;8 -,?@A/3
M@4HX<I CAH'AH70$7I@"#\W^&T5MOS(CAE+?! C\7Y PJQ>#_D-._J==RASQ
M60(H/&HO >NE"OFQLXUE=G]V49!R!>B3[934.,(AEMQ,NGRB$0.5Z-(RYG9E
MF-9,2I&HUW6[)A*T>@IZZ87_,<.4"W17DEZ;UP]?NWP7KM1'O;?O(;9W(U)@
M O6$DP]*=&[FO"B/SU!VEE P<KHF8?0K!US2CA/<X KWH6PO=LTNT;P ?KU>
MO=:"OKEDQ[Q3:.-,>HVW<U)UQN)8AD"U1]GW#O?91?<%0O2O%S^+(SQ,Q!U^
MS6_>_S^Y]/%_9]_CA&8_R(Z<Y]OH@H]8_W-(G&>G02^.')1_EQ2Y=3@S ?3/
MW\] ("&>[?[UW.+_@@?_:T-GL!\!RYTDP?^.D<4!8IM^WWCL%MO(E'QEC%+T
M^OG:*8O5ISUCGLD:#_(49CI5"Y,&+_UX7"BSTLNTTSJ)$=8LTKM6I2MFRF\5
M?+7EK;=;(;RSK]/<M>RK;J^TP:,<0_\S_<PIG7^]7:\G%3FWBIWI84U4G4N1
M-J9?^/[9_<,#W^%W'_IS=>T?%S,.V13I7=7ITZN$5OI40(0&=,:2"Z?Z?YFM
M:5>"PWX:AJ5#$>)5["?7UKR\/L_Z3P[>#%5-,^NRTAA/A$_>LUZVS2X[<M>L
M2.\FW&@HS<:!,#90@*A%W'F?H"(I;FT"^O_L-2@-]'7I\65,25G1_WKBVW%0
MP3&0_#,0Y/3_FP:;XT?:I/D(ZN*@A \%Q_Y.F@=YI%.7_R\GZ:\!5%/'<91%
M>]XYEMW(9==)E#=YMSO.7SW_H5G5_<&@Y61S%U0N6?&K84B?J-;?!_2,RO^,
M,94Y)Q4^^.Z#^)L5V.9HD[U(L"H@M6W.@G9H,6?F&6O1+(-VKE$M<_N3CHIV
M3(1WNV2KU'="HHOC>L'%NG37?VI[\'[%K05!BB^P5&JRM\+A5G7LA!;KQ^8R
MS>]N\)>M+0D.@L=*U'EJ $>JR^*(\W&/4IEX6FKB/L@'>P#%MWVR%EBG4Z6
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MK!3@*X?73]#3GZP;K9L9<3?5*@OF<I <;7ZW29Z<,(,>!C?OX&H\;L'(LJJ
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MVH.VHYEGL@ZX1I#'(I1\\(&,:'U>,J7VQ1?DK59UMP+(QZNK*_%DOYY'5M+
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M]=:B'$,IT$T_&8R*,%*2RN;ZY@V%2[,-*]VL%]!%\ B*.!ZDH!3!#JYV]Q"
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MC D*0!2ENEV>5!Z8??EBB"BY,67PRZN=#N^_7K5[L#<_F1)ZO'3YQK95%<P
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M':YS[+&MQI7M(D^L),#RY/8&7;*$5Y<0T/=#P.-H2?C^@($@)9.JH/I/Y _
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M5.Z4DP D=9C?@EO3X?>2@;. IP"4\Y6O J7+L@QX8F,;_#VU$+YM 5\*)BT
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MR'B:$^I'1GYON*EI_M3^HL[(7\Y+=L@I&')OKQA;;>K7SD^T^>\7+[R$[1&
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M %IFH-&8:4IAFT$?Z:TEJWI'PJ3K:J.P06/+3>_J2A!B7K:^U_UO'UU27);
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MPWQ%3Z</V9YVP_>Q)M2NO_U_BUY]D7J=\)SLV_/8E"J*4;7?RB3(%SV8=AE
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MH[$B(J(B15I4>A.E*@*Q@H@8 >DE*M*%2).>V.@E2E5:%*2#4:K4B+27WD%
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M)SGB ;FN-.E[.>_:.:Y.Y_4F-6GS5W"A#QLN'1HP\+=VC!Z2/)&K=_@K3Z*
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M7+UYTNC8_[PL[?^Z[C\R:SVM>IORE+U^+H:-+69CO8?)]01, Q.VM^D&@8&
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M_%Q1#6+:Q74O]M"29V-#:[]*01[\0D$$/;]&AQ8UC-$ 7*8FH\J((TG?,1Q
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M4^W\R;$TA>.M5&B[E+P02),O%=9\O<?'].@TOJ+%0\5A)B;#UD'4*_1KQL-
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M1<*"K>O4!C!W84QY,"&G9@+WZL)F62@/EA'$:D+ ) CM'NKGP;*[X;1W"!^
MJ4D4(=):1X&5$4)30Z,:]SZYG^L]8$R<5^OF?.7!'&I +6Y\1S_7]_QL%[>(
M!T/6];$+_S;&9@6F!)# @YW2V@F0WX(./-A7MQ#@7X?(Y8K%+4*J,!NF&' E
M,Y'<"-T(K!.'OZ60W?TF#!APRF0]OTU#<?8G%[*_O^A)AV(I/C1_ PGZ$A)X
ML-5]M#BN-"$&Q6[;3#D2HZ.X4>Y[(4#O0(.F^+QV'N*%EW#?H!^ZX10 <GP%
M1 S++=AJPB,D;B*A%<W6UL>S&;X,D, 4CD-N9%[89(($@_4CLY-$IC(<N?%:
M!V)9A1R39:L_>%HO2HP'^Z5$%F;KH02(&XD$,_ $ZQ3;K@ZLH97V15HTQPH2
M'DSLK,ZZ"GK2VD?-8ZFMM5[U;\O'0!.5' W94KZV@V?C=C]ZM^4="G2$EQ,Y
M$J@')/!J(&)C<3@'>P ,8"&:Z&CR=08@8PR$A@JW(K=W!6SO:!(T\BVH26X-
M#SBU+9V?\JY]7/GQSHR;NPOVCC$>'QGM)22&O!F#BW-*-,0#S*J7F^<.4US1
M3A\:\:'XC)[[\DXO7..D@1&PVXG/9^_T)IAJZ%&/5150[;L]<_FM<>>XVHH[
M ERB[X/+@Q3)*9K-9[87)<^:!]O%%?U"]AQ>VW:ASVJR,,5<=<?LDPD+A=OE
MVHI_4+3&1@4>K ?)!ZUP'F@%*=<LQ!U1QLD8Z\ =BTA^B-^?\_%IN[M*&"5Q
M,BC]INAMN0B[%<\$ '2]^2+74E#]UC/3@[#I_7=Z/_-@/MROI%47$Q6 _* ?
ML;'LI''6^UL>:3B?WLF#?1Y*=H:46D_<3K*XF]N,MVVZ31NW0;_UJ"%2=W;G
MAR[ZC1>I)Q7>F2BJ&'.\<PW_#W+!_Z'-@H-GZ0"]OF ^9*8*YS=+/UDP@,5N
MR!!S(=XNF001]>PUB_)NXB_#2,1,@%47-X=-%-8/8<GOVTP.*81,8P7B8D_"
MZL)SD" *)0)U47B/!Z/U8:%(,G,P^1_:<KD]G!?$7Q6;]+U%I !8F<AE(1C>
M4'^]=$BJW>8O("G#DWTR@>_!3.#K4'HZQVP#)W_]1/(NH-? 'MH &\1TSMGZ
M\09;9;86X0$/MM+_B0<#_4P@F59$+/ZAS?9OJVO[MYG7_?LT46!(/F0>MCA4
M7*9$&5F+>6B6!WM@@H;:[+0,UG/GB"-=U-!6F1(MQKV/*:B=%OI9-#NC,8M*
MR-B_?<[_!';2WHX%1_4T'Q%\\%7"7OGI#:5HG?@S5WTI3PXBX(W*^Y!C;(U.
M9:XEL26;!UM7'5P>>6K*P:\)(D9W])B#-?1]4]8T,T3%M490N] Y4<,8ZPXZ
M':FI>H2('UZ*O(46_[:]B@>S.'A\ZN.^U.C<):"Y!A0(@QQ9-_4;4$-S_*G%
MWB8<?V7[ZB=9SWO.,T>_>NS>FG:B@_.$'98O6<!M2!KJ:W.NJ)'0+^U*8UX"
MF0'1N9FS\UB]$]H?Q01O. 8J;^?$/YL0LE!\5L2:ZTH[9SP\:UEDUNC*E5AN
M76;NQ+A"#H;8@N=Z^4)CLNA&W"AY<4B/:!JT3"]<Y@'R9?9V2)7=U&7VT2$>
MC+UR&/K=;9H$-]$@F4CK@OZ^\I6@X=CA!\4V74B]8T*<,>"K4^%/;F3UY#+S
MT/SF._4*AMQESMD&DV4]W/_HP*__:5POT(@;7YN%F'GP;Z^0VFDAZ[I1:?\T
M"(*,8T-0Z55<#)$VQCX.&;-C+1YT0FP!?I5C6)#I5A)Y,.,OB+^+XE V"C0G
MF>!7]%N .Z05L;EUQ O<GO_80CDZA,V2@8G]OU><IHE_'X-8E PJ5">L$22Y
MG>7SS-6AVR3A^.RCE<*>>;Y,Q:V2,DB1-Q^^+^J.'6BY^17OLX)*^J._'3@*
MIY7BMD*QS9N^SI4* +AAJ9P3FV=?Z.(%?8D?\ACNPG3Y(DJ2(M:2_I XZD*,
M<VJ1P/L]J5C153[OYGEYZ['/6WPD%I6F'O2_Y":1 \]?_)AO7GI4;/+/3\\;
MEYC'XG);G%F''=^,9R8W=/UN" *T.1K X"S9D/NUL_!>:ZER)W$4OGM&RNXB
M)]:C&[GP_%WY+NOCK*J\MS47IP-/O1G'%?::B7$. L\+_^FNQB2Q L].J2.P
MY$V$>;!Y$DTC8M >5."JX"[HH-KPG AHX^8[0E ][]\3F0E0>/NQP!50GM0:
M7:<4=A"B#7WNUMO3EMM0V]B6I3\N)>]WGTNOPHNPE2&R+HM))[>_IJ(%.PNS
M>G^,@"W-&=E/W_RX7(ST5*P-"\L+R'ER"D)L5LT2I&HH9"]JDQ%Q\H?H!O$5
M/5M!/*H1?)A1^L)C\J-Q*!G8/8<[4@]>+5:WG[!^UP)U+H)Q9-D-7.!D6@(B
MSJ=N\M5^+/S""D9.,8#XJ-;O-QX.FG49)CR3RU^^>&O*]MQP75JBU8GE0&1O
MN-J*83]7P(^V<I'S @?'WNDS@6,*5B#F+X+3\2.5/TIEG>@L\G,D[;V.,T8D
MYM/P#TSDYT./[O?TTXJ)2<NGG'"ZF*98C=P]4O#F:E+0ZX>CPYOEQ[(5AQL/
M8JUH6HO]+!6V,Z>P8OE>XU_IS7!)=L@D#[8/:T(+C5Y%2(VXM(658.!-!KAC
MP\$UN(.8CA::E?2"BWNJ6%)JZD]&FO5;W77)A],18Y&$?,;R?"/=V$'0C&6U
M<OCCF_9;3V>LB\VU;P5UUJBYJSDKXI[V7B;<8SM)/#+^BYPL:9H#QK7<!/&G
M^O4&:! G"J[118KZWK>KB%V<<S_0IQB&LA[273$8"9'14<\1?#.5I/1"]&SX
M6U>Y7>.HQM?_A6/?^/_GDKR(JO4*K "V,YV_?0S%5W6/7*1K;=^:@KG5?_Z(
MVZC;6&!#@%GM4SO;$)54_>+S2?Y?1IY;"&QXQ%$;U3!SGTR$/#$*6]HK5_PO
M)>_5J9DR1L@25 D9MSU5D'SGWM%M7PV>N_B7T]$F^\K#3JT#J>B?Y'GS+&?3
M!8QG5/F$YNNLJT?#,<Y]GX]8P9];[4\HC)G.57*QO9AEK6P@>\+/^>-I57DV
M%4-:LWU^6/'E%G<=>OG%(>1=8Z<<4.MB!$INOE9CO#HV<#$O=>VXEO?)NZ,=
M0?)6/BH-GL0GCA/?S%WCKYF='AS@P3S!%D=;3B5EYRK+3R"MGZV-9OB,WCI_
M:\&I.6!6BMI=5M7G+?CYKP=ZQ0&3'($OS;^_?1D*.-1@[EK,LJK[J!<?KQB7
M?FF_W#G+.+,,J[0;NYI@E,9R1,NLL<.362E-8:'XS[211H?G7N7=VI(];[T'
M/!XU.[1$8-\^VAHR3]8^)U;S'OSIK2R(XGMP<:&>*%IT[F']2Z'SFJY)S9ZJ
M%PN3BJ+;/.C:+:?3*YN[OQ<+O)5\,73!0:7&O#__7-99Q\)N,?=,?ZL5-$,-
M#*%'"86V?<">3$15TO:53#FY:#W0]/'50TE<FG_?,<N)O>-I?,?=C$FJ$7%U
M<]OI@JH\JI*\IN%Y!G;P( RVY>)A& PFR7<7!@N&P=12:+-1JX3=73<U,V^6
M'JM)^1WV>J!RR>EB=4 BJ["AKF8ORLUZ'U+O:[+"N3>2$EYVHD_<(K$6$.1N
M-C01 &^FTLYUS!RO4N9WE4#M?S[SXN'M\^>G$UHOMK[3EQ&1W8-:PU8+&0XZ
M"F^1-8SAMVOPGG7=[WZ+@9E-\&J7-4WXAB/$-=N7"!PIC&OQX);8J*8>L[_]
M4NZZ:9;?'XM1ARSG<^>.1-D6VKR$&+;34F''?_U([W^^_AN'D_YGF4O_<>F$
M9$9TE2C85_:7.G[ASC3_%I1I/W5PU*V;KP-]JS=;[LJ+%+N&LZ?YCQ&^P$>&
M)WTZX''$BNW9-90-S0HW>=>&JR>LG#\.VOT9;G</MC]7);(S7RM,;RI%\[5L
M->V3[9*R;\MEU?O,2?, F4N]ZFN)NQ8+]SQ<DJ7]/-,6I!&T-.Y565O].%9%
MK[XW[\E+D<<.J4_&76E$<>/=G[&V%$ (0Y)[0=\C?(*&-RINE36*^E*.7F27
MZT$JFG[^]J/ZA$ESB6]?Z9_:B^+*VUT%W74#G/(?8-[I3L<! <WL@$?D=]4/
M/OA+7M]^64+T"O5>QU K.;)13=#F".&<WOL4QN/$FX\.%:>J?B_>L>&UW>;=
MQ>Z[M[-WS@UX$C:6K2X7W'MWN5.I_4G)]CC7]Y=:\S1_A!C=N'.HZ&IXQ7YQ
ME,D>EV;RZ'@G2M/2L)Y;SX/AOQ']FRASGN]IK;8SYR[W9AD^N5%RND(FZ?*)
M<+2+PZ\!NT+'S*&CB>7^W>P0%[M<@UTCE=[Y$AB;HTX/R1KYN]J*S*W,,SP@
M6[%]_D\5\?Z/A^N? )K]/O[%)]27$&7V:<(SGUYR(J72A-FB_7P,<WH31 =)
M]Q%K2N\[U@BOR,@-E0_;>V<V(CDFE9;<.'Q&!UZ]HV/C/>8!9S4ON8H-H?R#
M/7&(Q2UYP%SC:*WA+%91F*U@(LN#O=_Q^,0'=8U[,__/_8E?&KE<21YL;O/6
MQ.._GY1Y IBL,9&ARQ>S_"Y=]C.1'PXQLJ4%-(EP<JU[UV18'@<#3#3'X5E^
M@;JGSPX^O17T\^W<DR@UE@"!NL(53*2;4H#[/-AUEI!R,T*$#9#=E!J%P(-S
M%3U[,#VMX7LR&44AR1+OJA%7^];4K% 5Y^,ET]"'NPXD\96)O(%G85Y+VY$3
M'5+/=K L=OF<TWY94Q/@2U4Y=>SC2J#B<E ZHM@DMD>ZWA.Y9;?Z0JG8M[%+
M7U*+;*<<_@P?*H2<.LOJSYM2UV,UXR7"[7CPM'$ #W8:G0C0,B!,N+$C^6\M
M)4 S$UR"N%<Y99DK2Y(&_OS9Y$]RQ%]56#<(A692D5QWIY7T,D@?/3]1W/V]
M_\;3$?,0OU\0KJ"@F?R?:X&OWAZ;Y;C<48-/G+A[DZ4AC6922.Q#E43NJ=Q_
M;2C>9+!&0._US6-4X@S:\>SZ7*[$< >:J8&7 &@S8#\/EOXL0A;.YK1!M/$$
M7(N9L,(M+8VP.01A5&QB(;O=6QZUMGV:XRP&D'?2"9Q=C1J0/PR X/:4-.)O
M+9N'TRQ0JSGB/8E$\#86 N-=$%R.Q-Z!H/ ('?(W>]!)B(TPB[]/<?:_,C^"
M!6@T290RH]\F7_X FK9IF\%;\5LKDI7C])Z9G:&;O%!(\R[;XF K]:-,0,QJ
M_[W+$A!9?$1:=371A&;732_DP;34>AOWL&^!8Z%0)UXEL^WHA'7]?K8%[8R]
MZ\]-J/S=6K;Q4/_!%)6<IZZ^TX_.3EW#3#E:./[U+&%8V()_Z1=N190'B[1<
MB,M)2STP1'2^,^X\LO"'B,^TBO=*];8-/JJ;S2?UMHTZYMCRK5LYJBH)Y::_
MF)QM<A"CW%Y"Y^L@P.\;N]")CXS=>VLQ <Z'/T_\-7!.S,,K*N^6=OL>"Q<J
M$5I5(F>7NQ:TJCXNT*JJLE8Z &FNSABXT$X[18^@/-.G83K:1$Z)HO9B79Z8
M[0L833"3/9OQZ4R2B(/MWNT.,-B.[;>(M'J<'D0/KH+%FS5RVN'LFI*W5]^;
M]!6D<H\#7T_(\V",_3/<99WS.WQ: _BBJ@05J@=H);>])=<TG4YG$7BP7:RQ
M"+\[2WTDB"(UBU !YKYZ% \6_0U2\N>+P+^V.##2V5KP)&#U4J,JM-BM]#@>
M3'.3RU'I!&ZB1!N*?2S[" \VW6TQ]![1!?UMUZ_-K(%,5OTWXI*) F1NZM _
M]D"^@@O9B1/.$:R&U"\#J3^5 G&L0R$$[NG<O[40*HAD#!O:9SEM="?H[\H/
M$1NW+?Y!$.80_T; ?YAX_ H0^ASPH\,Y6ZXAP!L0 %\A,NO^5+<1:=$8$C>:
M( ']4*<$^",&_]>&2(B6"'9041QQK00B>-/8 [+P#,0_B/"ODVQA(1_P8+\$
M_X(V>BS$@K)XL$%2:C&N R=,#Q9FF99T1&.1?$B:["G^+/*2P^[RZG94]%-%
M6SZ_]*>=L7Y;#VA,MRELJ91,MC#932^P,?Z+\LXG&2Q<\V#*7+#XOEK@BY=N
MU#5H3AYU66K49-M%-!A-_DX.+?R):-62L#R1-,S6)$4/%5"^.0U)6X6-]LU$
M.&:(6TI/4##.#V]]+J$1V%JD9(5[] [J ;Z["+(ON'#74'A#V,E<02BJO>_3
M$.-C O:CL[VEQQLKLZ2V3A[LJTU&Y\2X^GJM":#5<E,?H4LQ/O_7X[[-,H5"
MRKLHY0()M,^WPJJEU.4,?*0?U_I5:GI%.!/K$.3=]$*.@ FDF:8=$&K_7 $T
M2U&13%$L1,.BA" G\B2 C !1)'G@UT?V-6BQ\JD$+LH66G46M8<C 7^(!X/K
M0Z!5GY_B?FD"OMNH%;*;O_^;%T%U?" 2.*EM)T#(@/AGW%%K0@N<P'4?]E_9
MNCS8:XLV%'A@D+@AG@R:&D.>Z71R I%VJACXH[%Y>OW?ND>0 6P8I%0J_2FD
MU/1'Q(U("X:C(#?JIAMB1CPNG6,6SCV1VK-8JK+<0@011S=%0*,6T/^34T1\
M>(]:W9^PF156L7EG>IB^6 IXW43B-E^;W4A/YYB&\V"ND2,\V$Z?),0O6[H3
M=Z<>FFM&F/?D[EPJ),WA/UQGU*9E119<AK9P-SV/Z#V@/EOVLD-A;NS:WI\6
MHC%P_NN9=TSVM%_9@X@C_DTF)P9DPMLDZ#X);"_6?O?Y"6TZXD&]<[%P(M>P
M4KHP?JT;V2K]N"I!3HQ:)3%:.3C^O3H^'U 5T4J5_R-R49HCV"(K+B/4)I*E
M^B,A)2Q(^]:W)-4+X/O.FF,.;\9+1QT=P^>?L(M7VS_Y!!O+,U[<_Q(91:E/
M MX/MML0C%X_?S/NE&^#5VX=(^HM>157+T6*VJ)Z?3;.8[0VC]]5+%W@=B1#
MX9]9S19T7W/_YY0*!T04@I(^S:?'=N;!AFM13(<K.0FJUIM)D<+3\#/#D.L:
M09 EH&XF<R:D: 7E%#1X@0>K I:::)E45&RPC/.>:@HA"BYE8@Q^:[$VN_NA
M&S*OG86M4[38.B]YQMG&X3#CJ[H!*:0+N&[2CGH4#<]X"RGZNC\@<C4%>(B2
MQ,G@QO'RW./^1\]0O,$LNG\/^1 QHM#M.#]_B[060ROJ7>^4B4-<K,92SBZT
MM"IP*K!P;F;"RJF\4O]#G7'5TC;O78HIR./C%%7;\>FOI5_SLT^[Q5^UM@E<
M&KU4Z'O5[[7%6>]KCFF*3]'/RSZ?"G;6)SP7NQN9>^>&FH51L>L'=*UC)?<W
M#Z8?5M:UX2,5X4B5.'W.N/C<LWS+;SDKQ=*ZY,"<9Q78):T6TA;<-Y.=FP\,
M!]E.0U>KAOCCV 8T/E-. ?;$Y/ S_#8_ (Y3]Q]&[&2CZ<K(ON@ /XF$$/0V
M#!Q9EK:XD2*8V&W#-)#0.6[CPU#A%.$$<,V&/DM2+%WNT(02,HH'VV]LQ#K/
MO@$FD4?J+5YA,ES12;BM8":EL]Z#C)+!\-GVKP;\POI$1@2^*8@+S9G3(2T,
MI3.#Q9^.Q*6)$B9N!@9I2B^>VEN+&1+_N#/'.\8UO+7O7D.NHU+4OHO:BKLS
MHF:M^M%*L1%=@D9%)=^N9% F5/*C[S_V3#'S.2U\W&[/R1-O-;.S=%G,NI"%
MV:J"XEV=2G8/7^]ZFUH89C^3Z/!N6D+L&#&D6?;#PUPO&9=AY%2$#'X4H(0F
MUF^G6Y"36XEQ\B*<['KK M"^U0"UQ^0@=@_]&4)BJD\K<.GW6J)KEC_Z@8NH
MO,R@WD[%0^TD>]K#:FFUVHY(GU#%HPJ1":_N;CE^; K"_BL+)V&>?*\^,>3Q
M-OQ3*GYR%^(TQIYEIKXDJ!R;Z(QX$OC'HL+3:V+Y0D[422GC+>:WV;_4_[,7
MFU2V[#Z:=^3$S@/WQ]Y0"6(;$,C<[D[O:.7!8GDPF@TPNM).Y$?K16IU,"6:
MENX$&KC26$CY!O*X_$R$&EP2@S_SL3*XKF*0K3<Y5@*X]Q.6#-PNN<WUNH_E
MI7QZ0'J)H%F3)$!J<R,4O:+B0!G&H=I^P!<?C1 .08ZX.H&[\K!GP#E*E@^9
MA3U#GVTJ$70$Y_)&V%<& [E* ?H1FC'I\2%)6T6*7.9PA^HCS,IZ\P=+%569
M8TP(VEJ Z)NC<XW?)E ^Q=5 RVT(D@;>3@8UX6R1^[)XT(E(N[!'YQ&1GVV\
M'5=A0>>CL#" U0!^TN2U?'4H_29;[ T8#$+^L.10*NTSYNW*6>1#ZZ*2WK*Z
M,F#/*3]*^62=-UI4W:DK[[G-Z\"CPROV+$<VY"FB8B',W>1&G$P-[TE$>!%&
M6&9@61XTM_YD,CJJ@CCJY#IHK$$5M%J.#5=TU\:WR1\!HO6=W,723_=O=?LU
M1/MEV!>0KJ54;GW%4\>2M0=W%&AR.:G,E4QDV!W;-HG[P57J[/# W[URC?7X
MQ%G1ITX1RR,,=]/RR*M5KJ5I*TM,)MP_@&L"5A:,L+WQYJ#4&S!JX5/5Z#6B
M0(D"G71_=87^(:)AAYPY=[39M:ZDD=_0IDRQ=EL*2/CLVGG ,.95Q''1X7.-
M*O01>JL\'"$4%!>M"(;>I(1MAHY=)E%7JNA?71KRGR&$,D_MRW)Q+5H=^5WI
M0?'M9PGHE058/%V2V)O ?@&B6#>@9;#B:D!+2"6V (*X%AZLW!\3QPBEM\?0
M>+".CHN<4F-3OZO,Y0?8_:\PS*8*H^?<'3_U7U_318C\4%_I%"NV""]O+JL]
M^&6U7AE23I,EVX>.8,2!5KG<5G@YP%:$>E0 MR+BC[KAAJ57#3W0#[A;$BE0
MQ'D?%-?$GV['=S+5;K4+[3.%XMNZR[.U;47K!,LDLZ2^<EZ64)QL4U6YX11:
MQQYU$QXH$830FD2(G-%DY5 Y#0JQ)QOI4]5TME/_-?IL="4_J"1'C*UTL_L2
ML)!Y?%185O,UP7EN0OHBK>S%4MY@[L"LH)??+4<UP@.4Y%4:*:'2"K@;'C/4
MD,NV^T"+BS,^:O(71E\%ZTR;!_;[ACN0VAZ$6&J:-.4Y._M*,(?C(10H,C"A
MM>^RQ:NJ=%%XT,"[-MQ1#!]7()^%PUJ\YSP.@0OC6HBP-.$QGW/TQC+:#11W
ML':Z_LDHR-=DT'AB."XABBWVS/>/W)[FF]X' M:R:1U\NOX35S909WBP^]%$
M?SG<.K+L/2>6NS\^!!$COQWL]._G]DOGW:R.-OD+U\^T6'SZ>H<'+;5JWH]N
M[U(1,::=&M=RVMI%I?"QA<]?7^M)G1MA@-/J'J>1R&5K8')L:JF4!^O[5D9%
M)8B[)+<5!ZI-3D^4>TSV;)]C+K><,,/ZD3-%Z$!;NK1[76CD9**1:Y$C>D=W
MX;PA+CDO*Z*U74Z5O#;=\("3;E/C/;T:*6X%Q,OO'-K/P/8%QV.1DY%.E^G$
M5M\U)'_E^CVLJR\7'HAH,DBK^A("[!V?G[TPE(A)--?*'VV\NQ2B!OB.IK(#
M.2E0K"W&5Q.7L@A8>]ILL_"/VY/JX7'-@I4?Z,YTY)(]P9>FNT0EQ9/VW"RP
M$FZR6JY\0^=O!D1-+IMR[S*]ONG<Z35E),VVDT UC=2*]=NX5L2'HH0)*9_T
M+DY9_;E+%KL#U:-W@#MSH\V-W_-+\BOR-3WL.EK_[9+EC-0=P2/9?/MW>V_%
M?)63O?C^TI=P^S8/)9>7$_#]0J_=$V,N1;Y0"'>@'PMQU-46NS'?@/!RURV^
MF%=LEZX67'SXG&J^0=[+0R]=AWI,EZS5*!)M+*(P]MA B/#=C+2GI9C<CFJ<
M#'TV3A&,F<SLQ$EA-'=AS=-(>TO7U*QJU(WM R/VI),WAEMP\+#*KIN4!Y[9
M2I%J%P26/#=[TN"G9.?FL[<-K&7Y-''5*GH;Y<!(DP,8S794HKQ,AM!6JV2)
M2_,&3E:>9$F-0P.5SUTMZ I-;ZT@-,(FR)[Q%S_%@RGQ8)[+X&$"6Q3%^,G!
M&PNQK+ RG#BBCR].E@U]'QW'VH5U93D',/7K\;2'8.8E6D$^8TE?.$HZRG7V
MXO=EZ\:Q(NP8^I#=WL^V.!0:U/19>D!\7_T0F'SMPY "CYELQ<#;I0GWUIX3
MR84A!-#:U:67J^R*/53+DK_'@PF$?L[NK4>&BI99<_(>!K\?1N\[ME=^M<\J
MLJ)WJ: NK.2\!E>>M53=4U+2R!CJ6'6[32'"6R Z)^J;QH/MUBQE:^=A!'I:
MW>7HC^E.<>2X-IQ>]JQCP@)YU441,AR_7RLC8\YSZ1:MX0^D%4FCE)W3*^J%
M&LDYF%E*]FNMIHI!K@#)UQ9<:![.(+:IX#OD10?XFY B+62.@5T%+?NU6![7
MY]&AAJ'?E<+"0I[-49'Z$]9'YG5J1\8_=="4*42V.)XQ"!K0%:BSS3T2W!;4
M=N%XH@\\&BZ TV>?,D0M6;QS]UN>['GH?K2O7HA\ZK6;0=,/5]M!A:&U8N$E
M*\N#E8_Z^BP^6L6W7D^=QLL DY/HT=Q)X8>5:#YPF2$-(CF5N=ASX!*M8/$7
M#U9150;X8NU9QFQ]&JE-2W[#WJ!9YDZD(5((+#R?;%JG78R:1_A6I\F<I>RO
MG7$C_61BB<51B96KD;K+.2-NO]F,!8B0YE: ,?3(>AW/8L0GMW,G<%3*U\;=
M];0R.N13I ,1Y+>8OMG3R,0__EUW@EF)4EBUW29Z*'Y7*6.; [76(I-N-BH.
M@0N-QF!QH2O6)]T"5 8H@LE;?SC_Q"I7QG68[._O:5\88>OL*0DK_-$5>5,6
MMST2T;K/FAR';_/>&72M.M!E)+MI(/FS\ B<*V &88^]G(I&.$BD()N6?P",
ML.06[BZPABXQ6561K<8I9IOFHI(EV4<&GYK3%5S&6FBGN49)*K_SS/O19^:'
M+Z0L;]O][GXOX*LUAN0*!+#TV.+@$SJ5HKQXBJ5+C#(1![U7VG"'W/@9M73Q
MW'?ZZ=?HBBW(LO1)A[Q0 YD"Z[*&KZKFE,M;D"_0)740-7I<@PHIJ6C 6Y!*
MB]9=@]%KWG!1<(Y]NQ 3CHI-M\6<7O@D1+%:A@/-2/)Z93_67^^L.A6\PX5+
M\+G4U$4:.NNAP;.3\15Z9Z5[N@V.FJN]^&X,T-%VO=R]J #4UDJXL'^V?D-C
M-8C/Z:*2^/V/8J4KJOOT,L>,%EAC,D4:QO[5S*Q'J7D:Q!@72H#WD..?&QJ+
M03<W7M,!QG<(AV1B]X%B=!U&+#U]T92E@X=A54 4A9B(.R3MM!1"41OW1@I@
MC)K7)S0&B>77928OJ]Q^DZ79'%)9$?'\S/"A8U_?/+PFBT\@3KY"T.RT^!=(
MY:BX$-2/VXS@2%/&V^&@^A.TED5\96F=[B[ C[;@!&:IT$63:.8Z^<W8X[EN
M;^L#0K-.O:XZH/#B6>T*"[_!K[8L,Q>)XS;@R>O<=RCL:; :329)^M_!;]53
MX]PV!3/YH]DZY KZ\OU7F>T(X:FA5===.)531<@[:=(:SPS-N,50S&G6>&L)
M?^!^8H_KEIUU#97\G@YT?&OB"4]*4EHF#4*E3GWU"I-9:B@PHL2"*BPXJMR&
M%A\?Q41%(C\-.1H8J(62U9(.S5I_7W1UHZNZSDFD8&(.53UN*7!_SY:B\[/%
M%1@4VL1#YN]<EA![C[XV=PB^G^AI%\B#^0?Z.P-D-%N)5IUL[$8IV(D3.@#Y
MO<MSP)ZUJ?[*I(G \;%+K=>O6L6F:27_)D[.()*'L@7! &HGT0.(0_Q B;(-
M)K5$P>N%2S)O]7Z&HUM=$8^&1P7F]:ED&XU2SSA&&'U^7L1\)=$/=>:A<0'7
MWK\F'3B1/<Y806$VW)8*& MUTVO#[MGAOLGSQ5;TN-:(A@CR1.8;ME)]WRJP
M'^2SI<,?&9_&HLAU'TUDP*%!K/YU'-S-CV;-@!C297_KMP&?&Q6^YSX]4[59
M1]8\PT[/2I;\@WT*K+M))O'YI^.WA%@)W6Y%B&AAM:G"0M7)]6(W#>YBA784
M402MD/$&+JD-"S\P47TK-OW!UDY<D22AWWJ@1*OV2/V.6>MZL0T6C<3 0X97
MP+8'0R>UXB<D.0\ +S*9^&!B-ZWC4;U);?(20+&R/NF;K=%[O9*CB'(A?/)+
MFUA9E&#,S&S/<$BX2H^'!U')D/_R88L"7 $EEA:FF(&FQ;42?T0P,('VC#R0
MG(/KX<&$4!"<K(Q[H&=TMCZ$,)>15G*5>S #%27N<[ZWL2O_9SS:PZHSS5Y:
MJ3C6V^)K/3,8F!YP7$FV:<Q<F"T=JB8QYTJQ)\&:PCF$A%9P\EUF&K$(5&LU
M=,^D]9C'=4P(]4^!;:\G_.2E&@:,S3PB(D/D\/?M+0<J47O]]OEEJT1$+%33
MZM/OO&4P2^Z=,)Y0I8]B^MV^7P6](A QNLLP9\Q3"_H'$-_2N:.!ZKQ<Z1I!
MC+OY"WE++]!D_DM[C_6 <+Q6BH; S>+\=_9A0Z$[B-)0" + PT2VJ"O#C@>+
M@?-@@J8,>4[6%**"OX,0!R'=PGO\D'T'P/?ZYYL<P%I^K*NBK2QX0U.V*OQE
MJ?2,A!ZP+;U6[1:CX=W9@=^LQ!_U'C=!$FHTPOIPLHTM6'NPVR&]LR:=%M.+
M<2,3N@'PT>++-;V*(")G/KPT%9MA\@HG:+Z>K>):<I#ZI7>FJC+A[%3L*>R6
MIUU:"^N(/W*$?&HAOG!C(8BHP*">H?>T6=%I-Q;@VPD5<-!&-])QG?+\Z69<
M%&X*=.PY5340O'DF]J+3GD:#0)1S"O6DU;* 7EMEYIB0^52B97H0!HRC1W!%
M!@=Z/EF?#XBCS-'L,6CN_LW";+ED/%OIO@5<LKV0T?->SA@,D%>'9#_RD7[A
M(01$.,_F^?@WZ"A0D["$(^T.-(&^;!'"RLJ+-7!>F@AR!VX [38+&D7P6*)<
MH]I/M@SMHK4OD?^%4ZLMV-R'7HK4^79D9"Y!ZV!]S=6_"N;P-#=@=-T!K)X4
MCAHBO9]M:J)JQ<-%*E$Q7/D5A%^W#TL%:Y6'#1K&P7Y6<E8!_CS]T0C,0LOP
MDEA?BYK^PRN-VNHIG!=.NA%<8?;]U V]@MIU*\>*\;&"T5#@^U -E93 Q +2
M< M0 2BMOKOJ=A3"^^>4'V%5"B%_MC08M"I8<HX',RL+*")28B/5G!-()U-8
M;59B)0/IJ%'Q_*6_;H5+UCM0V^E53U]9T[[-PW=-8(WJZ?J%U">4R!VN@0H=
M%_S#K?.K6^Y\3T$M)79E=ANNV \ZM3)ZY03$^EQZIPT,;AP&E;D2<+98(?=A
MXJ:%M7;0#7BP8ZIT<<Y'8#)_@671PM*$0U$U +YO%E0.H_\YCB"78B%HMY-.
MTTM_M(B3/U=H!^<[W^)LR&&;J>/:ICGQBA\#4@.?&/UO]RZ?=6>L9YC>[[FZ
M<@:\3P^]T-LHC)HG;M63$[Y(;ZR)*&3;]GK1U^\OYX%Z>:=R,+'<?O>&QO*/
M*3WM921_IG=<CB:>')KQAX]R;+E $%W@ON2UWJKU\ @FHD,Z*_V3]6G698@X
MMG8;-6?OI9'8ZL+\KEW4'MCE!7?I]XW@:_1;*\0/74%K(\O!$$XPZ'K)=XWU
MG*VM^;]8>^^@)M?N;316%(2H- 4A5E!I*DUIL2$B8JQ4(2I28\Q&6I"0;$6(
M@(""@,*6J)2 E @$D!KI6Q$0 D1"25-Z>4()CZ2=^/[.^?[XWC/GCW/.#,PP
MP]SU6?>ZKNN>=:_U1N7.RHV/UW['?I ,$X"KLS!!+("9:0T70B6=)*#,*@1(
M:B=I4%WWR?3HZ5%M;44PA-N]!C1'JF>\!G>4-7ZHI/"53YN9G>XZ^ZDB4>*4
MI1-S<!P0HR3R7X3A$YYR8 =_[:) "Y1?A7[N9D8U2B%E=@EJ4-GI0@W:' 89
M7+EFHY@:!S\ WNC7N]@<""9QVZ,[YR@FE13%QP'I#OZ'REW&#.L$D;#?!.?%
M4U^7\;,UTY6%Q6)GSWHG6K4&^9ED'Q,%WSX3S'H2MEJ9RD&LGV1*(7]7_"M"
M<B)<&@YB*Z>Z;V:M?!XP,U>_L]BT.,DPT[#.GI;L=8C4X53T98QDZ2F02Z:;
M5A-+"T',R7[<F;<.',>(JSW4#C&J67E*S8TJT>J_/\/)DD+.9EZG>SI:7DEW
MJ$EV/V14M#^Y:Y)M[&[9--'^VQ%,E4+DU"2],CX^9[/;'9LIV '>[!69@=U"
M>Y$\?P==YL4<G0*ED,V4&0J0@@"[^:8S%UF;T:U=+XR>F.IAZ\RQ%Z].U;1-
M[S0H5D8W1U2)E.TD"K^YM"&&8#1)8,)WGJE]+])IP#PQIZD.M5G8M3I0=K94
M-C=K;^6'IN0I6A V^JW)J>NU0OH8_C(/N%?"25NSB^-PY1N5\74@8O+7.!C'
M#*9'(#OZ412>;ZE8O^?_K&K_7[^9Z:$CS:'FZ']'JHZ/)'[ZLNYX&S:7\C.H
ME: L<I="H/OK^=Z,5M@.%WR_6YA([0RG?8;_#J<?SS6/-9BUFU'/QVVBTAH<
M"$_T"JN(1G4;"OT?#(-#+OQ88&2HD>N065@Y,&/(WG8RLZI[59)^)3=""KDD
M-A$_#.V3?(I=MW/W7?;=1\E!?QOW =A=@#_JM^PP/F[ X<%POC&W/:ZB3_P^
MQ& ?1TXF?=BO8%2C-MJ@>RMAB\1H&J_4LRR%#!DWPM7S )RZIUHU0'Q*C<#
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MOQ/J$KZG"\\0.(V@S.=T#?RINYXBO$CHV0;*IO%8)EQX5$+S?@D=MG06OYO
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MWG"MK_'0;UC-H: 7%[/EC/#"&?XY6!Q>9<"';XE-\N1GU;[UB(]$G(PZ6SE
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M>*2,="7^&E_N[[IK'+1F>]J >65H>I@&NA<;<#[D_&R>19#'CAP%]2;H4+?
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MT:(+J-\[Q#G%=S(E\A@9B:[KL3IC/EOP)^;D N&6 4K@WL?K$=G9U)%*!0E
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M_5;G\P7>YVCY3!9KB#4-43PWIS#TJ<3P;N*8-R'3YCA.3IQI<TC235,5;3A
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M,^R"XKE&6T3Z Q5KWH'ES3),7$8[M[IMR8#TB&QSL:%2R.4_Q;+=7Q0ZO$^
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M;_]$,*^/S.2)LU(X2>KN.'A-*3 6S^T& TZ8UINA#L1(%(]QD3'Q?)98(_Q
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MU?R%2LJR\MHC_*ZV '^E\Y:K#SB<W+C;X53<JP.!K0\<E#>C\EZM.W\(E?]
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M.P83NDPS.27"&GX2^Q"N8>3HIFC4,Z@.K+UWS9Z@]8"<S_G5_5@^!:<1B+9
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M.%7NQVKT\O7$5 MU-PFJP<3,#TR]"!G3B*?%3^JE_22H-2* 18M3HR24T39
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MG0H.LV]369FXV#L33/G:G1S,L"VKDQLEO##THYWFYTINJ?-B>43=082XX>6
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M4A4^ )UR WFKNI -W]DED4]JL$U%1>I[GP-^/]P3AU%F7GLDG<N9:ATZ\G&
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MH!C]JBAEQ+O5T/>F*+0E55O::V+.,&XG<WPEW&^I*DR18.Z1@E%XM-2A1O5
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MU(\D;=5]A=C?OX/D_3(#<2:,%'! -QUQ#N!-U#"='$+A\A)R&ZF68!*]-H!
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MFU(1*UTP+\T5G"S NC71+XMU'[,U@]LAG"^L.&B;F-TEC.FQ//8^_X[71NB
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M5/'G;^9U0%Q;&^GGAJG)165<&<KL91Y @@7 A9P,^  "(NK$+.A)7E]AF?&
M-,,;^6XM] ]);;BRE7(P?4VZJ)70\CJN[5 6MR4UC9IX/P1-H6''<;9(Y^%@
MS3F-I00-<"!V.>SI;U=ILL\ID'O=.Z!NZT'<3@AK%J<PV93.B8JZ7AEHP\T
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M_"F(_9%=I+E#;\W]Q%7;@Y9OB_#%V^_A,+ H:EYO^,](V_OZ_I1+1U;MB)=
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MT>:G7.8#./HLVH.EX>ES>&'^?E3OKA23B#T9@>=VFN]RWIK2[!R#!"]]!$/
M(W/Q87?J2/M@=<.K7*[J%PH3N1ZKL< [_]/KO8;QNAGXX-,;#IUH%,#BQ@_9
M_^$9.,P39:EBK"M/K]\1 !=]Z,TISM=^?/A](.EL34OA;[V[NN9O*UQD@[O-
MC^I.8.0#: M$)1WN;3+[;\H:=KV3RNPKW"9#Y5-74I9OS#5N2=24S'Q,W^&K
M8W)J_Z5W:D;YSLA6-);U(W&B%NA)N'/1=/#)TZ4IK@AKY>5]NM@(%8XC:2BB
M?"XA["P<'&2'&4&)AH'-+&[0OC-"I#.'2!,'W8\BRXJT0[19:3ZA;;+ZMD4
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M  PS-/6:YF3^EVMJOUW;=(TE;N@]RKAUF_X1YO8GCU:5("C@/!KF%BP%'!8
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M;%_B7I625/V$T[=RC1S5=W?V-=,<CXZ]RT.IA_;_3NZ$^HT&J7^D3QIP-PN
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M>8-\Y2T168/"Y\D'%$V&NH<?I'8LX%=7G."P:_<=C9<(H#P;N),O=='0^5Y
M!5VC?N2GWS/6VXCD3>1.[0L:(:"[WO?\P7-GAD-CRBA*+F #'G)GQ/?/V:[H
M/=X_) #@:%/XP"A]FJ=FJ"H OKP $6,J2G8B;JU\I\&8P/)"Y.+%!<#LCTQ$
M]O- "E\2?$2#;F!Q:-YN34,3\H?"[%'^UHO]^*4T%T/"_*&YY4JME6):$L_G
M=J.Y>7\XR%W+(FCQ5AXW!BFA4"NFSUU&HN(?H2BP&S7DA!7ABS2(CTYF6B<
M( DO ?"U:*J?T]*_AO8G![84 +5G_Y'L>P+6'B9N1<>D<M%YQ4Q7=#E67@C8
M+$YG\%0*JLBS>DU$VKCGV&+0)0'PZ!M/ OSN54.#0KE:*7QKE")4BF_Y-W,5
M@K561!(Z;"8+A$5*!,"0_<(T='TZE#!W#D&7,)C]3W4'@U.XP1=5(N!WNQ7%
MNHC,E3(7\WO^[?KW@74C(2*T/R6#!-@H(*49>0>.]T4^1!?RWR>:)DF2VG&*
M7E6JL'[A9RB=Y9Z73_0?E/=X:!]\W3PO'VM$J<7BRYE_CQR2696L*+N?X2P
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MB)?;OVWZ=W.OP+P]SQ9=H')=.FXDN_$?XYVF(7V&AN@@\= L.@B^G@S)"PN
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MS%!0S*I^F97OX1T@$7*0W%K\&%4+PK6[3F8D<6MKF>TJMW]'>#:]D7V\>OW
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M9,/!9:> DH;^K7 @)ZRV7Z+">+ _$E.XNXCSHA8L8(:C63I.(6"Z!K<%WC*
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M?ZNLCF<5?8JV44K99)F1H'/%Q^FJ*-OZ(C]K=J>/0=BK507C7BI)FS^U1[Q
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MBTP1/HMRKXLBD0&>^ 7OU 6P/:=M<I;JQ/KT2#@OL'"M$@M9#T3HG:M0063
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M/JQ4PSW)7HZ=%7E+[/B">;#<L;:"'X\X2=W.GBO5?S3J->ZMOVRJO. \H2+
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M2%O/#R=X'IEX[^Y]:M-$C);V%B_YLWV->[RI>NP<QV@!I7#5MB!\"Z3-=>U
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M6(BU7NZA[:R5T8:AUY!1YF7T]-YVA9Q1T4UZRX@@A%(K9+E^'-=FH&Z*HBN
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M4'W%FX_XBSC9.R(XAUQWF5Y+)#V![%AI*Q?]?Q;]WIKJ9U>GWFR:DB5XD$7
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MG?Z%+'M]#]!.#)&$JZ!^^1_$RNSE(WKBC\(#?*8/#[!V8X";^8B\/D'NMD4
M.GV'O&K\<AV/1]%IF$(%KN1*/1&2TZ!NG&;[/X9^C(^PT7['BSFQ F=S-9J/
MT!!<JWD._,+#.6Q\(,1'O I4*0>7_GLH,"!JR??0:YH+$1C0R(4  Z(1!D3Z
M4_)4&A5@+OR+A__7L.SY"&8+7:$1%6$@8[ 'M!P!=H6@F"T8.U?WCR#&/,*L
MT_9JS3&/!9O^047-UOJXG47/;_V(35Z^I/1._/WDS364->7!:M;I: VG.=4
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M!#A,"F$4%2VXUG5!6K2"\_T[Q$3M@#86TA;QNN_?)8^\X"-*#B YMCC8<*B
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M*PWZ_NY&B7'$>ZC-2B0@XL'O,(SJ,?F/CZPZR[I/0 R_I0(G&U3H;B*:A;\
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MU;4_T^>HW"H#32IAM1U CY6&.">(H6U\,R^%SQN1?OUAQ2<)H@F=R(5:@(Z
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M?FI5O#\[F1O3]KH<-W)YT,4C"1\6>>FN6*Y;(2''NN5*1N"S\Q7[!K[XC=Q
M?JQ?+3[.#/>\XJH&(N7>>PH\KY)H(*DT-C2M&F<"UDD2ZXHF(\K?![F'"SU;
MY!O"<RF1]FFLV^KMG^V(163:L2@%]KBS+L;O+#PF\@VUI"!+- $25K<Q8B9_
MI<%TT?LMH>;=NSQ"S8=<P:.1*6%LOU*@RJ:=AZ6(JG!I2B_)L$@HXJ&-#27K
MJRK = EEU [<J^CAM\,,8KH]>M2B8PP>SI" ZI4T%Y%]GU\1M*#,7N0.NO7.
MC^PW,SU>62FX1+>:01JL:)%]FALWJ3*4FT9= ?.J0FJG!F*,# 2RK1L$UU\Q
MP2RIW*B89UKJS-ABL;;HL652<N/N:93%[Q$KRN'QF[ +L[^MS*4XB'#@(:+H
M*K?,\?[6>UM24B?2OIYBV@X=;"O,B(XB1:<00H2D;Z_LWQKYNT.^X_\&:)JA
M?P)02P,$%     @ Q:KU7%0"5:6WK ( &=T" !L   !N>3(P,#<W.3$U>#%?
M8VAA<G1S,#1X,BYJ<&>TN@=8DUNW+AIZ$T-O"D%ITL1"44JR% $!,10! 2$B
M( 2$B("@A$110/H2*4HQ4B-2(ET0$NE+$9$N"2U!D2J)2OB6*9SX_WOO?]][
MSW//WN?<.WEF,C*8<WYS]'<\R>ZGW460E(.MO2V(CX\/](;W!]K=!)DZAZ"B
M45$AJ.OJQP\? 9TX;>\DL"GN&A2%NA83C41%@'A#ZO=:$!^([]_?=VD2B_;6
MU@AG5[BM_3D;WH$@D,3'"%1$$#]O07A$] U7N]/J%[V\U44F0"(@>9 L2 )T
MP#\@ZCKHWX:]C;5Z%&_1/\[[C\&<^N>G<<.SSNKJH/_>D H,B@K@'7>&1T=?
MX3V<1[_BT7)7+KA:\^CW()#HGL#PP$ 02.P3C_\@^!]KQ"__7A/\G]9<BPE'
M\OC1O_GA0?Y1//H!C]:\$G:=QQ.O_<V_\<^];_Y!_Z>]T4$!(3S^!(^_YV9,
M$.]9XHL\.B4V^O=>B9#?ZP.NW_A-HWGTH8 0?]X:B0H>;?#/^_]CJ/S6C3I/
M2:9'3YJ:&AXS/*H>BXP..>UL_=]4RO]J_+;1/RG-9R 0^#X(U#H2$'/CYC]Y
M@K]?A$#B(#!(#J0,4@-I@ Z!#$''0&8@"] ?(!N0 P@.N@#R OF! D AH'#0
M#5 L" VZ"TH&I8/^!.6!"D$X4 6H&E0/:@2U@3I!W: !T!#H(V@21 $M@KZ
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MWP@T4#]VY(@Q*.KJ\6/_V,JWAX>1A19V=W]H@T BN2 0)WMWEU6ZN\OAR2Y
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M*_OFH%;FCHFMNZ JG#1V\2%,JI3S#*.-&<,V$C8;& ),5^ NX\>9AD9@%Q1
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MG1E7#+'HI,.<H\,WD<@EUC0])1$62,'.F(XL5FXE+W6VD>AUK>G/@5!##];
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M:SK!FOEZQ96Z"8]/5A1?BB#MY^4(,!D#FS'C2E;P2E9Z&*85:LA0Q?<O)"'
M34<3EQ%*:%N@;@DL><JJ*$<YPMA*.P'55]J8?*+YI*:,7;,)VI$%0;MQ"K#^
M.$HY5^P1#76'I,)5B]NQ!<;I G#.4VR8!5PD#!D%36=8#ZCTA*[6Q;TP2]:4
MA&2@X=2ALR8"FM^M2/=1U*MGI+[N>(.! \N9L TJ"XP9>GJ04[H-DT;K<W(P
MQ]=Q*I;!9;-LT\8T<-;M^DI:6+84\A>T.H)K]"J]YU?$$U3U^B_CN[L@JH[B
M5.'$F.-^E(+F+QASAV?K<VA^3B-1?!4KB9:NB)-@AC,(*9;Q5!PD+IB&[UVX
M/R_/I8P;65JV?7Q;-8*L&*9:I&]:.+>1'A9JU/:T[DQ-*;[(,7GI.KL4._WD
MW=:D)B&ZH^9OU(JC0-;U4A>WJA>77P(GG.]7%*]=J'SKT7A_R40%/>8W<#[6
M-</'07\>>Q,S-F\T381P/^#4+&]1'4>K@*)NK#!1.ZZIMS U4:(TH#XNOMM[
MBE QO\^G(H?\V0?A[?/A<GO666W1@#QEI6KNM5W0%3@EGBN.>H$9?'J8)](3
M[BA$@:@2-\U$ 2BZ(ZVRJH@>=8X^F5^P1(*@3]&KRGX%)[,C_]&_M-15%<@/
MIGY^Y#!1^W/8>VK26.)L?=EH/\6X">OPU!1PPRYMS>STPP1;=D'R0U#\$OB^
MRF /!S4H5GGF$3R!$&>ZU-.!2RLXX].?I%D87[WM7ZG]K*'<;$9A*T0&]R<L
M: 30$;G#Y>>^>81YXW>2X?ZU?P$4I@+I,Y($\'WPLOY%UASB''#OQ1HY;Z9Y
MO&[;-XIU>,M1)><P[F9'WFQU+%)H>=*_)<I),[]@>:T^IW'B)\,XTB12[HM#
MC&[/B=!A[XIR<.T/-Z9>K5S=B9JWQ)"WWH9^PW@VA:W!4T43+X"=M\-]%ML&
M,D]RH>B(!N#>$AP,RX;R4;@].UQ50!^/MIC>^IP8/Y*"4S66Z I#3$5<,U29
MW&BQ&#8=>^>EE;_LU2(1=E415GF[;=.0E]?W<%I(*!Q%8!&^@6.,4W<V%N@D
MIM88VR@@L@)HHWXH66KG&@$+?JVOBI%/]3MX"26U*H6Z3AG6\1JOW_HID1Y6
MHM(C86^X$6-X^M<M0\Q=@%>\!2LX5:3@(JP VYB'%.76E_)(&T/TG7X%[\$4
MS-Y^^D*W!_<@?.^G=9=U_<5JXJ%6?&2M'76]L7$&\6D&:=IZ@WQISDZH6.*0
M1!LCGBNF2%A?:$'T8\E89A3G)5>/.V2&;3Z?&O ,\_&I'-TNV1@LI9.Y61>^
MV%3D3)]OJ0U5V%R<NT&;D@F8DCTW23"F4-(IPT<WDSY_-&FW>V(R%)A'N)E/
MMC)JV0K<;(PO'\&GO \X+XY2-ET;CUED'+E?D:<\X%KJK?3$P7C.4\SA6(F9
M9A<Y<F?)Z WD4SHS Z"P='F6D"1=@V201"R]P(D8@Q!LVW[O2Y@#S>/&)5?G
M9UI&Z6WG&((>K= ##1,;@6DTL7KUS'I#M9!2/8;Q#;XF9CJ3S.$Y(=+H/DZ1
MEQ+3,4ITQ>R!I#+N)%&_89QK.;,+ZK%ZAM#)V QZ"1P<HZ1NJ^HMAZN9%0P4
M+GT;U1G_FDFX<M#IY6G%CU EWEVD,?+ /J8,IPSF+QE+6TBW]%PD9<$48K!I
M'7:9>S/#JN**WL1^!KSA$CZY"6ZN]_JF"S6Y\JU%%R8B L=E_7R&_NK/*OS0
M2,"%0.AGX&H(]!E>)M)%AW Z,3KL,(;91LH23#04 KYFL@M**51X2/6!ISR5
M##M99RE?M7(;FUJ1,^@[B1_[F32%CGV^9CY?FH"LO$@9JLIOS7+^^QDE8L1C
M>_U;O\_GJ8*YD))O-@:F00Y)>KKNB([N_E=3:4RWRO3<]79HR+OSE<*/<F^U
M3^78LVJ21G=!(6#@4"Q;3H<YRFDBRF/>[8*:\?=(@81[V(:4-&-<BL((EHX_
M!3RA@5.)YAVOINMT7DTC?)X$C1LK$SKUZQ]&5K[+#,*;YC>LDI,^[R1/\\H0
M!;Y(V+Q;B^V^AO4?V9--7H?3\?U;^S C;05^XD!J*5N5ODRH8&L6G:$'IQF/
M0)#F=LG;%J\#&1%/EE#R2+4C#/G*>>)4K+ED6UKYRS1=C;$#)K^Z&$9<,3"M
ME.7 #N(9(0A.@=':-@IT-@^]A WR6O@XQQZH*N,JCK;^<[[->SHYQA#AVE#4
M3?XR38Z1>-YRMK;%I\O,>6);HL34)Z3^2ZLJ;-.&%T;/)J#'@2VF,]!/1S&K
M@&RZXE+*!F[Q 'V\%R;WK=.JDNTVA7:C8E]:933%Y5/Z5*H>22X\B,A<)IC,
MUUG,V<3%I'='7?ER.?!IW)S781_OX5#<ZYN4!%]RV]?6ENN/.YHK7ISN7!M4
M=*C)Z=,2;_9/#;?-2*@-.._\;'S*>,'2K;/B$4)M#=9"ZL,E8ND7X=E<8<;D
M3K*E_R(BD42''V4<[U/)+.A%":P0S1D>I,41(2"@K[#E1]R'(5N4HG58[5JP
MRU/(7GN";XC*[;E^^9;$HHM/B:'CI% LH#_8A_WDV(^C>X#W<B=@XIVJB^':
M6WU0DX^PP%P 1N7 >YO0Q^@CZ<OTRNVJ2@8_TYKF,7VJF?A:8;&VX"9S_=#$
MQN&K/IJ<Y$9>:D2LQ.+:%#-W0==P:FAW(F,#)HV]*H&::1J 2;; 1+V][ @4
M>^J<;.]M'NC<0CLB">%>,2Q?[;#4YG@4N%NU8N>[4HSPV:53##2,?@JGB"3M
M-2'-Q/* "=T9GDG6V3A) RO,QF7M@IB1V=U0^5>3!4Z=DTM3!$NC,,9I7S?6
MZ84S[<2LDU^:U53#=.M[%V:1/WR'-#/&D_)?K.GMG!^^N17[M\^+QB?^3<)K
MFC7?':J.7<@]"OUPO<3>[6+HH\)J1;W(Q*+KG7\'?EN<RS[ >09;+,>UXOI&
M,GE=/T$,,T0\2<_ND6;=Y(Z,Q17UJ\ S+76":0M[ %1_X?>#EX DC[/8MJVB
MGLC>YW#JYF%#VW=#;J_21F-B0O!%P9,0NM,NB)<]7R,H-<QWG#NDT*VT#I'!
M3>M%Q91.^262"-MOW%*Q(D[$C3ANZ1E>YDM\5+VB(N>R6J/<R%!X8A"BLAPO
M,11^&K*Y#]!NRX&5LF_QO+.9;O8 BQSY9+TTDM@9%4EG]2!>XA(KZ#KWN/+D
MN*N&?@M]9/FNXGQSX^-QA>&W/R0<=%3R<IH8*5_[OG:8&/9V#T$#=Q:P9@GZ
MH/5X)KR#&8>T>:,=VZ?J>8%/$HP[WAV%/H&5Z/5'42_0\W'4(NGG.JD%OJ\?
M70P;I39'7B-K%QKV4_!%)S,O%G_\TMC6LUG5=L/;K+[+:97*8/2=KEUSS_DU
M(3=6IV-[,>;^_:N3VG^[,UR6/=)P[B'MD#(Y%YLK\:?^K:T3BO]@& &O.(9=
M$2:*\"X3L<157CMW'4:]#/!\P,Y[>D$1RUB/W 5="MP%?91$2_+DI[SEE,SN
M@B;_8"1CMSC/"17=V+?Z..PG2@IWR[]D"X 4!SMR3;-!Q%E#FCB+@9;9!5G_
M%$X[1"B"V?UW?\L LR(MUL*^9Q(HCMR_%+/,?^R"#A\D/<X&= ;[(7MY%< 8
M:HKYB[3/,N@V<3\'AXU8 '2V\RN7+%9;R4@%DA)4>(7\:%!7_5:PZX0Q 8PT
M;?BBX#,TLD\!K#]T +7.<^M:0%IQTXIU AW,P>DP#(A[4V@[=V(6!-[2'D?W
M305]3&Y"?9:T-\9WCA<XF_:)L/019#';"Q]*PKXW,7-X&CL0I\C,XMPG!1$^
M37L"0]AG8;C&Q?%%^M<!?12?-\)O74$ 3AQG6^.'J'8,]Q>K4[^^C_A??VUI
M@[Z&'ZM[TK]X2RA,S,8ZK^OK%C9)Z^^-UZ&_U$S]D_HF^GKE4Q+SSIE""I,^
MEU7Z4+H[(C:]SM^K$=$I<YWEQG&5@.-]?AJ<,NQB :Z5U.>H2P6*6+$\E9S&
MZ+$#.I\R5"/"H1#D4QTZ*@6CMA*B9-&+)U.ZZWR1[Y(.%#AUC7>29@<E("VP
MQ18B'S#$$N5.D0LV+5@&2C\IO/(SV+,EA7D/DXE^I:. 1#+</-K&FL/@<F1-
M-4?K%Z&W-?,]?\4 ,2$F0U8WOM&B?<9R,#2V#T\?/G$P&C@-NUABCD\B'IR+
MD^A%T.&^=F=QO6I*Z3TW._YB?"@I0\[+CF\:1&Q+UZUBZ=DC>H"O=D=GXI"[
MK-,M?<X3!WX.B2T'XXIM!K$2/G%'/%12^O6WDA^R18'A2K2/S S "[%AFC]>
MJP.:.&3:7E:5.Y9^/6""N2;,OX'IUWT1(T^;:CV_,U-G4+<+BMA@_5V,F\FC
MIO2?/HJAD/UK_-=L(UWS+H[BSW=.E$S<*JK%F=8Y.!EF?WW$!#BYG2=9A^,L
MN**E/%??F-:Z &C0MK*\KU:RSLSW:N:3[?H@#SKP:99\X S4=MC]BU/+\[IH
M'YI^@KKOT#)YI<WTSPQ.L>=V)@V2O L"60I4A""D3;*3YX5':[D@(-YGNE.'
M<#'N8/<V),5;N( ZM.X;WJE="'UB6A,D1E_L:BYP^DB[913^F#P89IF]/YP*
M:9O>X*/?XXJ#Z=E. ))Q>L>/3FRC&DF=XA5UWB-DT%K&IEP#NF):7?G% I>Q
MSWGHHB*+5Y,:$]$S&<@;+RE.<JW3^3<+I.*R-WC^+LCE5&)4T4Y S!*)K,@5
MUV4T,?/H.STA)H?8BG3:UY[;X%ZL1*BB2G)J G6%0-1X6[9&_E#*4%@_/T[X
MDC.\_?;/^K*#I*M(#;W1>/+WEI;X]2:/ULWP];K-:HJ=I)O$@_K24Q?*O?P#
M;)'=!I:'7)-@P28G=1V.Y%K5GKQ0_WG\R^V\::YX*<N0R\,Y8J0046P0@FS7
MBP$#2?1IZN&FI53H 78@X,-PZX'LY:KY_,TD.Q6D==KK9%I"J$-.5]_U7B"U
M>(XV#Z7/.:QY9)VHK;*]C)7%"/$<WY-H%1?/_,S)(<J&(.C.X+V8><0>4@CD
MP1&T)?"D$C(3[P$HABU:='E_'SG_<M)2D=<\68]2^IA7:)QOM81KV_O^"DPY
M%V?4#(QQI[Z0\$;DKTQ7.G@SGG62[<HI1OM'8JFXO6SGCZ5C1B8+>ZR#A!LJ
M9C^%>MR>>O2<7,'8%U8>Q(OO6*/@ZT2;69>W*(V#0UU8S4Y>7A6$ JD5;"=.
M-O$@VYGSFAW,N#+-/,J(3=XV2N**MP,F5)@8<'6AFZADCIVQ--I_6R?5CV9U
ME1%=<EC5NI^<43@\-]R2>Z0K-63L,HVZA2QWM)W_M1F<L'U[=6P@KL.K^,7'
MZ-F@=ZOMDV5K+IF3(>V\U(\7DK>W:+>6UIWK/Q0R@KO"J8 MXB'-@YO=O/;G
M$.<)5P@SX2<&'%_,GBEP?M0/E9TR&4G"0!@I#S:N17.@WQ;LZ8?OC\]8(]7R
M:))GK*8?=)XBJ(:YC^>,32!O?J]H,QU#9X+9<G"N^#2-!&CWI[#EWL'(1E2=
M)+0A_?5@H4XO!7??VZZ;H_UKB[;8S$A(23+9DH_[ZC=141+MF%YBYYPH^A,N
MYK.:/[[Z<7;!.J;2K]-TDR..%N9ED4@D3VFPT"U*+/-9"JUEYT$$]EJ-8[P]
M^X#._;J?*Y;\#95O2Y:FW!"O"_JNVG_S*I7$AY2=^-.6&\#]3@P=)2VFW[Z9
MQSNB;9K7912&L_Y8D_4.PYPL&%BBT=@6K8[I7A6,;R5+_I?12O-'XNH/(#:V
MQ[U1@+U_K)?WHL&UQ(-_ET<WD\UNHML:23YU1.^;QY[*0@Y-A%;IGG=^KR77
MX):1@&^[]^;Y\PD'_8?#,S/ZWO6I&E_!Y"+F.J>-[<X*QW;#,(*8(9@T6I7>
MYLAI( 518&IK^1@S>F9V>C1$;)VH,VZ"DIH#6C1\XK;KX![TJB3\)54!6^YD
MZVB,JH-$W':@Z?C[]66,'*<6&T;QC>+IF2?0.J<>J@U@EZ;:Z)Y,*%#)./YF
M0>DG2A0)%29-H&'/X\3?[CLW^=-IKT4"U*QP:(!L\NYT=50D?L%KS92'A;PS
MFU^>?QK/NHEY-W]B@J>;&AC=8>L. LS59I\&HIX#8*8W="]]9Q KN'*TM8;*
M": ^35_2J K[<?%20IMMCL3J3XM3]7$WF4S'L#D-U]=CR^U'YL1&UA!OC !-
M!1S]]1E. ]N18<U,9> &4608<Q2(I^&2YV' )@TFONHM_9%M13-4V'), X,!
MO5[/KN8L"Y_4:X>_MH:'ZB-+1W_.07L,]:;X&SW;Y25F5FIKOW6M_[!J#ILD
M4J1% VJNZ-_H8.+3JL4;\["S+)W[22L#Z47GS]=23PS-?-=Z4=B<S7/N%(@:
M]\!OI)+X^ZLLQ>P[\/NG&(.;CVJ ,#^H'AUR#QW1ZX!-A^KL,49:^I:M'XM#
MN1Z,/;M- I<<]V[;HT)QN3.@/\^6IL<S"[IV0?>R,(8AO[";\,,E-,/CU*R'
M#!$OAAU;+UMB;A<4CI8+1W6;=["%??7";<*C5\KHFY.XY(+!_/>_9JO>A#:2
M.?6W;#!_^OYN5J.+"#.Q3&5.8?:F1+4!K $[J(PY/DC; CQ-$^$/;L!I7=9]
M/P",DRQ75@&Q1]]D9^;@1('[=,;IH\=GS@U_(7S"\'K>1/3,[Y]RNRSM@H!#
M=P!<?&S\4O8]#Y@8C.H!D:#T(ZLX.49[_R#OL+7N^=RJ/_<02/ RIC[SV0C#
M&]ZFF=@5F"!]:KU)%[94_P<U;Q[5U/:M"^;8(2*@H+1"5%1$A-B *$UBAQQ$
MS0$.?1,5$4*$' 4D2D@4E59 0< #0A2D$R$*A"A-(H2 RD&$ !$0TJE(O[=
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M!#V?, B6B9-+ R952QV>3>@&_SJH$\\D#7(QFO8;)4AY*V7M-'$OP!7F3OL
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M6 1JG:(WE;/115('* #H%NQ(&-6#E"3G#7-MD]5BKD$J%"-8O!VEN2KT='G
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M74P]"5(U(3OA0*$RM#2:P12C.'L3@87+[U#%6K)FG05"KC.64AW5M8-S!KR
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MW5^: 4_9WE?"N4AC]F_R\_,[$IV@U9#PTU2,_=7JA[@",@$[C\B>,\RDSI!
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MHT[JP]10.I3T? EQ)SP(:BZ3GN'4&7D*Q9(WHSN!L01[E9( I9H)RCW#S53
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MI?QMH#8#<A+-#N4*,?%/072:9S>;7+\[<'NBZ$Z_$'>E2E;]@F'.B:KZ\_M
MY"V->%Z0'_ZE^DN[FLYDM&=S%*<3TU')!?[LS[P>-3$\&".G.8UU2#<5 &O&
MA&2I-D<(9YO/IBA@ZXF'!-2;ME?SA7#H3\;&OB>]1'T0P99OA=( T6% 3@=U
MCJ<MJ%_L>+,4-21M@"<.>$?]I 5<"HNYU#M>_U8!@Y-;CC^!R'$2U[!Z'EP
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M7X<T[C-U\5._[C,__+"X!Q]QP2M]E/-GC([-_H9]CFMG3<QWW2.G,R%3^)N
M#?+/R'681 6,KCM5)='"R=>#X84TD29DJOQID"Z,:8^%)XM87O5TA@E@FK&
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M< ,YR_!X<5^L#\$$*T[[M/]J=Q\F]6UU&_.DPV3_HJCO#!B<'_VS_B_86@^
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MGK26+^* K^'N$S",;\'8+43).+?WG\6R8%5R0E#9#GX5=)(=Q;G1M\@DU3O
M2I=UA"!8Z8'_Z@'U8 _L4MS(X#+?_OT_EVTWK93P%"P$=NJ<5B&H"L;5P$S/
M<@H(HY=Y\+^I)'5V0@@Z)+@DH@&QOZN]8'%?"%+[QX(79GDKX2L6T.SF91M,
MDAG.21B(2;<VFT&TK/A'YN%/[9EBXFDAB)91 JG6;/V*8?Q"?I<MR;F5L&ZF
MQ$O;*P3QGRW*\HU?ODR'4(_]IBY.RA%(+B*,LEA&)QPBO#1I^SLW5KT2OJW6
M7<=A\%?6+XJJ#;3Y;0;C:TA=8WW"(L7MD5;M^RO-S5^L#Z1*]@<D.+HHI>_.
M<UEOR?3#3[OF;G0!5H5!FP<7Q$Y:!QZO(=9E#-(LS:Y4M1Z.<9;O53F:TJ*Z
MYT346?!'XCR4:[O1\2C2DFI=@A)A6F0%:A^_"G7&Z_7W<3\1C0;.AR/"V8&<
MQRZWI Q;DNC0>.JVNSPK9O:9JS6A(6$:+9"!FIRM(];T^M#TO E(/A30IL[;
M,_7'3#DW6;+SFY@+C\U-^5DH6P:SM/T1JY&QNYG?4@U7?!$R,D(1Y ;;@L\-
MZ9F9,@Y5OIX*=39Q;[3UIJ=4R.EVM.SF[M_H^<ZRZ1N%,V63T)*"7K!DR\YI
M2(U/.T$:\&%(=.B4C9_ [$'=&0P"@]W][9&AL!%4..-UK;O_'MZY1_G^)S2+
M<\I;E6WDWZ6VC>K11..Y!E*-,0U:UEZ?7-)NUL YER#FE\*(LV^IQ>,(?$T]
M[<]:8*,5Z#U@@>O ,P66N.;(</H#-&5"EI]E=IR%899T]E$\&;%S&!:YU4-O
M! &ITF#A,R,-^#8P(*70WUR1A$<9>GDQH0KP,/<"\^;@8J@OQR28?KR9L%"$
M#D6/4M\*01T$2J)[]0AZGV 4HBP$>9?9.M!+GJ&E438LS-/R(,@^E!D0S5KH
M%JNHF?P@T'L^E;L7B)>N_NZW#NW Z^TUG#]I^\XHI5OC4D+4&'06EMGG6-2O
MHTV8'3?/).?/5L32^^;U1:.0YN?QW!^QR1W$*I]Y.&-,]BGN[0)/H9J#XN/-
M=!AN"Y)()8<AB#],D6<S'+U<#]GSM8B^1Y%LU<1R>F&>C<D#KO6U[QQ#5MLW
M-8W?O>O4>0)MAFF%0N X)2CW%GH()V6N/X.1,I/B;D7"!9*K9:/HOHP)159%
M&0WW["1ZJ$6%-9F$UNIF*[F,&+@1%4_7#O(<%>/I+CSCTBGVM&U)=U@*%+4J
M(P058G83:3&8;2CG6Z+8D$)I $SV21JT?=R&XP\\Y!Y !;/03PJ0;IVV[![1
M;=4'TICV!N^\"F3,V/S$#G;:37Z+B-BZ7'<\[ TNG D-0Y+48US,OI8Q0WGR
ML71,)RY>36^8=YJ=U@W;+MB&\JKDXY87*!:<<%9?;)/.:R"<J4J8^Z2*KV]#
MWF(GEP8(M%F[0AH0R;@"(,5  L<-MZN.EZQ^I_6CS :V1/HTAT<H_$X;6"ED
MS,VEUXR8\+.IMN.Y/;]]R#!5(JU %#8+<ZT$)*P- C;7Z:')[@;J6\.LL#5)
MNP!9!BQ^(E :[NS,471.]0 L6M<%.#%L1)&_4:_?_=#=<]Y#/9I5%D?UM7_B
M>/)6#,)CP2GT&(SE)IL(V6%(8L! R$G."P!<#L#<3;P)!:HV=B)-:5\Z^N+K
M"\(WO[#.%V[9;G%7G-<C:D:?O7W6]7&>O[L;(7:\>\?]@Z*K<Z?XGDOYCI>8
M]KQ#;UZ)[_%H>O 0T/WGPBU6"&H-E;C%=>3)7 5] *' C2"0Z:8/>3S[M3&H
M;C!QZF+&&,P=HKXJ JTW_RKTWF\TX4KH;O/82^;9ES9TER##+PZM-$[ZW:IW
MK!DL+R&^UPJ/39C8O[_^S[6T2REZQJ9'(JT6J2*LE5 6B=2CLI6"OO6;U*WB
M0*U1%1#Y$ZUN7?S[ @(Z?P[S5GWH[)*&[7ZWGKL7OU&==KCZ"F(/TN\NQ#$3
M,^R?WHBCY>V]K7EDR+?S=*E)$&WFJ]F*5I[QGD[7 52O.VSI]RFV523J=*XS
M-+$Z-*/O5)E3[E:Y5N;Q!R\/F=AW.)>N7-Z=KKQ+->Q(X<RIQJ&;*;EU@K)/
MVT_826Q9.D4XS<9T;/1SL6/H*EO_KB7NGK#\-3TAS1HO@WL<;GZV_%[9O5JQ
MDK04'>'IF-IN57^;Z$>,D\<9B** +<4LB>:9,KB(JSP#()@QKG29+9/FES?A
MU]"7O#*NX%I5/W2WL)$MMGGA JO)@?)=R[,?4[MR[)E&E.O;=RH.WU#J-'U)
M0.TK'"(]59=UOS%SWB1I:DDOV-UC02-['N[<\&CES&W^)RV;\8N_9WY=U*@I
MM];^G*.,]+M\*O[A2-3]].VVAI*=HUUXQ*T"I^>^;S)'S =?UJU_1C;9F>^:
M^6/_:[H_*>F2Y_VKJ.'#O1>OYH(ED-?O/_=(ZX3*?J9DY7DH0WYH"[9W<A70
MP\3=&'^B/,J?Y=P*44-V6[,GTNG/LVU8Q;'E0 5&TMW/1!&7WUWHGTE!9P4U
M+CW<71XZ'_K*W3_,\1E9*2R(?,TZH+J'*^)#,0=^1E,PUPC]5>T(EI$9NP*1
M1G*[T:<C0NU9OQM%[R8K-ZJ(,K6.?E'\#1J*"=R5E7@3W]00W3WJX:;C5^'Z
M_?A[FTB,]^4#IX](,BONMWYDEHCMN-]UJFC[UGO'T])61-XN?>51IJKW:9PT
M'>E?K"1M)1V=K)S5<2W=V;5HWT%^Y^&+#Y^K[YG^0GM>S%1I?*B])GH"E?8F
M0X81G&&[H_MDYZ_WA4O*@ZV,<8FG[;<?NASV/&[@=3G'I*+HXHSKR8 D0]?\
M$CM)A^O]1Y(3"I[= S%)3P9S+'>S)>;S_I]+G_W])3%)Y>VBTL%S/6PEC@50
MS0RD9-/4<-R+@ HG@@5+0IOX860" PS+K%=4,1\F9,CZM[#0]_V$9>Y'O<"C
ME-^MQ7Z:D1,JI0$:T4U_.J_5_Z.A[2G@-,N-,\5/">X-Y?PANN7]J50PV ##
M&HH^J^WGQPL,-M8_V:&<D$:28*^_FBX2?6AJX@C;J3*?.K7:LK=AR.PXAF%C
M8QG3[?92(_3<SQA*X%0/1R1SWH@8QQLC)^C*\OJ-9RV= SS92YR<M\!)=IDS
MD,G/":3/ZL>LU[?CU.!9B4;X\AF3$&S^)Z.\?#^6=7AI;6?VF(UAX=MC[S\"
M)0))!1$<M1J:732#LL-IW6W4;^VTP'E]9F B44T UHYMV8G,;+-EXN0 BP^P
MG3QG^KB"(TL0&UKA@8SIMF4'1C>=\6*$]T!VW'#Q=<Y8K/WY4KJH?$?5W,\B
M MDVJ#ZS!]UBX5P]09E;GR9F$/.X=,M'F"[",Z(,Q <7K78&&&.'=F1,R -P
M%JD]+#:A"<90>1WP.Q,Z:#"U^KE_],:Y8,QKC^^GD\E04KEN16"MU.C\W/S^
M#(;O0%,:YSJ_$BV/)@O4V!F5K$%95>3#F\!]!K))E0VF=W?"Q. P&7,MI$2'
M4IAC<7.1*[*D37G9[Y&78N,K?T7E7_&/Q#*=7).S@U(M'I"L'HKMTO&E6A8(
MB!4Y?9GH?Y<]#%_L9K:"69R-T_OJ ML>#N6W*?'#=W1$,WS%)'7"@YBO0@'3
MXIR7'$3J^E,HGR#2V#,M!S SQC1_07K96NFP$/2C44 6@CC!,#G,B@K+&% V
M^4<B*#V3W[B6V<Q=9Y:02#,ZZ>R2)SQUMM+9]ZSZ9-298@#7OOK@G '%NQ24
M=>"^O\ +_WWGYC37"<I'&\J$F\WNWL:3>XIL>W/?1)Z=.;LN@- PZM-7TF3;
MS?>P%B*7=8W;U78.!"W( .'6]5RC[()IHP'*C=$V]Q_!R8<>BQ=E66MG.>L>
M7;+1()GVJ#<&V LPZE%K:N8U5R4*!)]QBVC8)LQ<,GJ0N@ZAX3%G#7D"P>>G
MF/9'*+'3>R 2$+\_9*PT^E@.H+!)]26U6OZF:VX]Y&5+FSD16Z+S8%]#NV%K
M9A#*@N S]K$0M)+=(DY>]H1]#>R^#:&+%!J\Q0JR"R65;,42] I!FZO7 FZN
M!^R=T6%A_I&%8#%5_?+-0NU/=_WF*>3H)"]Q\G]F(GS;E[3KA5K!TJX[8=@O
MSFLL5##.AX]I)S2Y'CYQQFKRHM5K7N<FGU'1'[-F%TP@_ZY@U*0$K827LSKG
M-\\.9VPR_R 0W6=!R;48JV'!TXA]Q!\4.F0.D8V9IFA_^X%9U(_E1Y2MG3V4
MCYT>^:_D*OR2'5.@A483?:&/U0R!""8L'J*$5D!Z')KCP<J!,5IHDJ$^B'>!
M=+=)Z4&+QKO$*VS%E,!@C&K1=Q/4G_Y.Q]P^4Z(+/OF_41W"_HCB7&(M/#,[
MS29R3O +>8_R14%[$76:JXH*XN<)=B'AG'"@E"$$ 8>WOF#;\^P94 6@7 AJ
M*_D?K+UY.)1M_#<\)4F6"5E"IEUEF19+(=.&)$T((29)C(FYA8R,F1O9PQVA
M%)-DRS+9BV&RWR7).ADQ6]F7:XIQ9;9G^CWO[WC>YWB?W_,>[W.\?YQ_S/7'
M->=Y7N?WLUS7>7Z_Z9*+[_5V:BI8"92X,*?J-T,6MB_;(O7I.IGE#,.JGQW8
MHX@1Q.(/_B4,J::Q';X1]^LLL)R OR0Z+GQ%O-T?36])2%H*"JSK12E(O/T'
M%CS>:\_(R&+^*5J3]2.V>3E_^SMLM?$GI93A2)0Q\L?T I0O_P=15JGT6EXR
MV LL,X_AM'H8-26+OAQ8' ,:VF+#T4VB> )3<%4/T*>]=1\QD:$H0<"< ="O
M77W-"6R/M#_0@:P?9@],U_.MTT]5Q&]J0(8UKM RA8@-);=65X8&1<]T?PY.
M$ M>'RXN*+V&-E&G5Y5'^16C[_OF?2XH"W"/^V3BHAD5]Q@>$A$5%7&7.TYW
MHWOT[%LS/?Y!^\@YK5Z]EWN/_$S_DWX9_IY*EUCXG!3"1H$G&,%-Z#"S) >_
M"* O=Y#5_"?UAXSZ @9<;%>:^7DZ2[,&<+4=>_-N/B_(GKRPM/O7[K"[G9&J
MJDP=56$Y\396&RQAA\=8[.2NL:!_1NA"7U]C3R>$HA)U=E!'6K7&T.GZ]XO6
M'E8PA_,]-_?89<N^&(&'2<?3[-_&>T3.5DY;/PR%28LA_M 86)U?7)5%( !C
M]_S)[32I7#=2M6).W2:PX+JDLUL.#UVK^4HS\QV93 \/4ZU?<.B5+YZ\F6%T
MW,HBX$NO]L,- /%/X4#2_Z-PX'^OODS]GXHOB_;^^M^DU-YF>80P,K:+V.V.
M_VM>#/'^G[?*V#Z:0QS]$VRSB9+ DW%$F$FB;^J@U#SJ_VR?N^-&Z#G2+Y%V
M^I4SVDKGHD:GM77N^Z35"[[Z(^I(B]%L<'4B0@P)8"3E:B(Y_4E-8<4I+W%[
M>7C1A\$5!E1P@>N7$%IIV5:?'JO97;[/)-<KTT_F:6F *^WN!RV[4YTUYIK@
MDA'G><K?;S2N]R*R#4_<\3*X44HY )L_SON<=7%2$,'J5;SHN%8EG-<+N'NS
M.O2OX(?S)P]^OEZ>;7B9AW6F?Q!#'O&I7#M>#B@-()V'ZA I*#6\*B"9RI&5
M7Z]G<XE)];BZ^6>+QD&W:S&]M_Z!'9-NBO&7B^U\](_-)3"[4N(6]P@3ZB*\
M8U#TX^^;'G\FH9O2.WP\N!XSN>ZU^UIW<\U OPLCR#B+0P%SO5%LAC+1%Q?0
M%0\WOB:K*@ %5X5-B""H--C8I4G(XKN!W3B\1KX2'Q%=GR[Q[;P_.U4,/K#?
M[4Z'*62C8DUXNXW6GH^=7_8I[PI^_75.:>Z8/R^X_I,7@EON(:P1P<&,CB[W
M-G"Y$N-*ET<H4#R(;'/2F/(D%G1N5&^J*BGS\#\*7NSHR.9-'FX8-C[)N#!B
MO&_88'$O=5CUA>\M*>9QA#9X<T?HT1V7WE6_?>)0%EN2UQ3AHG8E9Z3\:MCA
MSW7EMA7[P\RP4.M*!/9PZ.&K#T;\AYAE>=XMST*W%[E\Z+IZ>1OFJ6[D6+G5
MQ;YFDZ8%XGFJ*H)9BJHE)_@ W9D LM,2)BRT"&.WE3+0(E5 _6&HGAX&KNA?
M?:VW I?BRE5\-7VYMN;A7*YO59Z\7GA(V02C<Z!'+0]++'435@,>;&J"Y4F\
M/H#L(LEVE'KX6YH.W!Q96%B]YLAP'/JAW.=7BLX9Z-HW.K5\:;@2:_3[1WT^
M^W-$8"[&_%F*VYY\Y'=7MGJB&((F)S;9M"\G(%3QQORS@G,@#/AUJ;6N$2C$
M4&OA"0+;PKG[0;$E8/C[1IV=7)EV3'J"EX&HOWX0Y3EDS+<C;Q=F\,Q;#-D\
MN9D%7YMU!G.YDSJNTB8Q/!0Y%B:='LDVC:6R= !A<1:692_51JVM6T?&K32?
MJ[4&A/4C:VT&UE/K]NK6?,5G443#PM)3H@),V/V@:>7:QCP$[(233.[-<L[1
M5;]'(VTW?'*NM-\X CZ_<U1$TQ(6'%Y],]:PQ[%0\TJ[L>83"POTZ\??,%>S
MW-J/"^L3G(M_''IM47W%J\]T465MB:,W'X;ILK$K=_M%O.(VK2VR@9&0OY8.
MDC^C0%W=+E0*3(6RGSM%8],Z/7W8044 G_-*1Q%83@P3:K4U&;[.UVZ5S(Q/
MCQ^R.>']I"90G!3"BY* QTH#3=<F[=="[;G 4YWL"6U"JNOB;TO,@_YC%<TG
MWYNE2^?>>/-5H%<.]7-F<4.]O5+*+O_\_JSDQ#OKY:P)KQG>H;ZK)5L?@0'6
MQ],);GKE56GC+UXFZPWJ_^<AF/AIT2F)-*@Z1D@<^=TCP9B:D\(G2R?V2KK[
MU^:H33R-E<5%5&$.C+N,$ ;GB"&G P0LB1*_ED&\;??"!IDT>:+G[:\%8K_J
MRC7X[P,A/\00)_TXX9?/ZG-^!R=#?P3Z?,I<)+B(1*BV>T,K&<D'R7E&_W6V
MBQ<K"!;IRUU"S-^(#"*H9QG[$G_JST?=2;P#B.#?(C!$FX5%%KZ 7+N:1!H<
MXLL0^M;]NNV=VB7@@#<NGRLK 3O8]MR1%<R9HCG-E=S4T<S 2F,1^8[/.\WK
M5]P\=9_Q\R1#?,<U3D@E^B#C14<'J0&,1$3#;1([DJ$2\ ;O#Y:QRN$R^#,1
MEQO#_**8)%6<5S^T8%Y'9MC L$ZKSW(EZK5LX->@C&_CS80SQ#;GU@/XG<(,
M1& D(Y6H((8P7T_*"V.(_LNI1&F!.G,Y10Q1I'CS+<%,7OH@WH^)D X@[$5M
MP'V?M50%:(E!%"A[I\%J)0HYA'+F&U0U!@:Y2^LIT/+6TR7]C!HD^@7NY<&
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M5@R1P];[AQ%W"OS!I-=HE5F8HM%LY4IGM%'\X&KO"%>:/O-77^BN?*%5.\5
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M#@?'O&>Y1=;;8AY//,]-_4&I0F\YC+9^OG?+1+W&&2LO;G.=HVN3ZY+HMJ[
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M"X1P3'NL0&>^[0P)VJJ"UVD&5PLQ$D?5D:=#[^7(M(_#U:&;KF,8\JOF4/6
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M%LV=:]75YR.GQ]J(O!/"1I$L8<)R!UC)0?U-<Y\J9XHA<; = @_ FM_I7O]
M39.8;'&&.6^@MOYGJ\[3^)]+$CTJR^BH<F]->>VY_^'ZPZU!V1_-(VYD($L[
MO-]\M3@E?T Y3M]07>'B]B-?[UCLM8[;NOUFV5"A=:JQ9FB9XP.?+4Z29G6P
M:U^&V<W'-PLUNH\FVUI9'[(R4+;5V]=@YUO]"R$X*H$]&5'&*C=6#%&28!Z,
M7TZ;78Y;Z7.R F@)=5$AJ'=<K_HB_UR7O I<,>]CSR4*]T"9KX]T0P%Y8I9^
M_0HZ6]VLZUM(@,H8&CCG@S'H.(/>_M>^ %/_RLH@,<2$,66R/+YD]U,BXY_$
M)!]\L24(\3^J)W5(D.+-2>'3H)9671R3X/25-K/:(XCL%T.N^XHA7S2IID1F
M5BRL=N>T, NF3?H<J8(Z]R?C!]92#*E..U<B?/=,1"RP]3H6]=QULDAD,VNU
MW0%E<>&_3%*S(H8@/B>?>ZX=UM9SN:4I!G'$IOH%](<'KW^T%0$215MGN73B
M6"U'1J!"Y6%HAD1?V)@0'U8NFM"L,$NE=H'_<7+K<VH9J(YLB#:&*C!PAW>M
MJR?>H3G7V[M\7.Z@%TWFW8]IGZ*MA?.VCA#@&$1M570$MX.-76CAAO3T>''U
MPPE&PO0''&;6U//<% 6SH0O\\[6PQ6<:C6>J'O@BZ_^^)W/[]G\4VLDFMAD1
MS A#I+K61BZ&M;;PYP7Q._#=RV^@:?OZ)9V#PM<5K7!JU_QXGV8WKF2(O$2!
M69C)#@3N'-VI=EDW;>*5NL'/*LL6R:UVS]U;3UB O:"GQR&D6F4#)K7 9FYM
M&^$0Z,L_Y39O0E*T.,XF2PM.C^#A51WH XVE\RH!9G$_IA[3:.Z5V651Q:BV
M$#_CQZ5Q+Y+"^ R4WJS$A8Q6!/7I>9QO6+%;FJ$R257##JAL(N! I:OSQH5Y
M^)-L<C)J0RA\C'0:5 )BF>EI(D/\9? I_S1&M/\MA49Q8^'[6&)([.0V@!Q'
M7M%+/<;O<AG0J*1XE,V9Q;W*;2CP>34^._#Y&5EC?WC0])ROJN +WDDRFD&!
MU7#K/M&_HFU 8XI$[O:/P3M(VA)- Y<2#;4BN#:+"!8L<=*D >A);MT'YD.A
M.%=67Z-@%[TQ?K$NQ>U%X_"J-YNTW?,:^BZZ9K91??-'S(/&S#IA,9591:I3
M;Y<8^;JI(F"HG2J%]^5;B-XK$S[0X8OGPE[;L_]MW2VX/"H1OP?JWXW4PV)H
M[O<*X/%&._7:UG4*BN?<PZA):6236HN?IX/.;S[D[!DNJB3VKK]UFRT6KLSE
M8!'S(>MZ9(E7!??;"%[%BN2:)0-P Q!BB+/T!*$%9/#RA<\M-;S0]_VZ8.DD
M:9'&G,2S^K(#]6S )*[=^U;9D64!HO1#L'1V+:88E^,Y!/<;"@K2)QL44)-E
MZB)3S$O5? PHI:2'1,"&H8YSZB$U+@O4M;IU9+B(!(J?Q-CP7H*PR *PL#UW
M]!D;KCAO0@3*X"Q3=Y?&PF^3Z-S4M[F'O(^/3=AORSZTE_%.8]-_3PY(>,;[
M;4G=NZ[TIUC5?VPLM,^P2M*T\3U_VFUB/&!/=/;MFUNNO%"V?0^Y]<]),JM$
MM#65'T88G-PKK+8\#-J<!=^QR;(X*,LU)4@ 9]JKL]:25N&*L]B2KW7Z]-$"
MD^BR\V%YR"OO;)Z2@VYA:[MWUT;OO:9K2RA_\-9)M>OM^E=]DP/QRB?P%M6J
MY2Y.>3E&WEO./M>?/G0Y^/+/Y =8W7!_:B_^&M?U,/!L=]NT6S[J8=_^)[>-
M?GX[ )4Q,_(]7%/DJN18Y+Y*UKPZ^Z70H?SLJ]?.?Q47:GQTWBW\:&=TQ7KP
MXZRV?U'>Q(C2]HUVM=5;7T/V59^0RC@]1;FYS/XUGZ.NZ=I.@MISH5?B71O>
MT1QG9L00:%W*@]M)0X[<A]EKP0''N@Z;(7U86C"5 +6T9OAB1:SU\N\/DJBM
MYKIV0NE\W@4@O)-(/][9M)Q6=<>XA=ANXNY2R(M"=+3N'<(;W\T>;5I.T@\%
M%Y<L/%Y;#")]P@T;@PVS#KU)';K(/_VV^9TPJJ:F?JAR5W5-8\S@X*AQ_"1]
M5&-Q\442X?N5,]NNL9)D/CYZ&6<%V1#MY>(3G89,[_9=_2'OHB>55!GW>O:=
M_IXRZ\('SWV71BHKO$COKH0_?$>_MYZFTW\X.-XJD[O94W/,RS7/%[S4J[":
M&UJ4>S'>\*'>D&-QD8?L@WL9S9G=9O\$?2G4W0'+HC:J"U3<L>.-;?3M1"7+
MHP$$F,2K/S"$2S HI #$(B4_Y,YKOAXCHMV0!?8GN(:5VKV^V)1QDDK7,5MY
MQQZ?K4\K?WQ',)\C -MT**%]4I]&T)VGJ@19[A5<& WUH,J/?_!YT?8"Q%I_
MP=Y^T]R4/#@Y%^7D\FZXRO#.S5]D$0,=--IF,/C^IFVQT%FBI-,W@@H50]V6
M>E\$)NM_/ZK(N3:\JP93].#%TQ<J1PRK=VP[NO/KA@R,>0=,G; #[+^J:1IG
M@661MP7$RQI:Q>>\'O><>++G\/['9[1VR <'>2ZGEK^]17N$4'NCX4786-;]
M[51\)ZU2^SCKZ>T( _E1YV!"OQ)2%KEA<?>3DB3G0R,E9[?_+K>N\%,].$QY
MQX@1'$UD6R"2CK/DO70MVMJ-#W%W6CT;?5F44+)Z[>;\9>>BO\M1T,N6[1K)
M;QZ7=A\MV6$UE  O'+!2M1G[?\V_^?]7(S@0V]R(-[#)L$;3=FR" Z&?J"PP
M!3"\.-">8X]U!&PZR2KN :8N9L18PCZ<5B=1WE(?%_'L8EUK:](J0P:7:_?,
M(+OF;%@J["(Z?VS[Q+GU9BM(7OH4]<^QR!@U7 [;JP7PFN;AN.D=4<?;1$K"
M?_#F?'60]IZZ76#%'6H7Z: VX<(=/<91.V:/"+9Q20^6\.AP? []D^5ND,C!
MO,4;D_OW5TY\+E"=_)TIP7R)S-MEN1O#4$ P7U 5!5H<;#P=#ZNW+.3+G0->
MKSFCU.S@#RS,^0?&\$>J1Q<HKA8\^N3K6Z,%P'Z._R%TV?R06G.]B#;\()[-
MIA)+BWS)^7S>F]_Y.>'UE0SK_ ;&5:*Y"P.P7:8WLL([GXDA]+W,G$[J&,,!
M["T2C:(:$KKZY7%.[*4X3A2*Y5("%/): %2TA6YX"1B]8HY;G8?!<-9$*0^O
M5_?4PNF*U;ZE7FA7U_Q+#SW2A"\0S"0B#.&_EZ. ZB)I$13=<0UK/*SP,5[E
MA2>X]P\;N[+D^B6,5NO7K4=*#E?R!.W>YZ8^%LF!WFR[DU26]AM2V_IOKD[T
MO4 !LA@]2EOW+2H39946O%I#C;9]6AS"F 9EVY(ETV1"P!+;CB-NDI5$7=0M
MHETSK1:DMN,"&["1Z].)V"X((.B F6PQ)$5P<N=D@7>1?],=>W9ZZJ0>US4-
M;UM1];2P[0"Y:K(A?>=B9[DR^K1[2B]U4/-@<9WM/97P$=(G1A*1&6U2ZXFW
M$;ZD[$>T8>#CQ?V\!3".[R+8"3YEVVNY<77_-NY/(!APZ\RZ&MO(J3K:(T:I
M9QE7WECJO!M5/N4DB6MCF"+N'W13<6S93?,DE$1<$]OTQ9 [L!1BW9)$MDA+
M-PE?"*19V'$I5DD7#&+%UP51MBW<U+7W5&E"G]?.^F$C:B))AH*O]6\PZRXK
M%?C4<1&)80CE^6PSZ<Y<EW*?0IOBBX%5TZ)^T8,C9CZQPU'W1:&.-8LCEO2J
MIK!E1ND27\C[*8;L%T/DB4?_XXVU4B:O4_A"T@M/!,>ZGIO LQX0[/#C-K<C
M5%?24UMUP.-LY&;16+X\T)-@/ Y7(K97U7#3_\92#K&@.Z^]STYHXTT>XG:&
MWR^:CO_J.>G>@WOD5B+]DMC6RE#U!IL!#MNPD1O)^I1[^RF7PVL""[CGS@P]
MZRK#<(A025#L7^[$CN5<S*5[[MS5-$S0$EP8,=Z)Z>H-W]]2,6JZK:T8^?JW
M[ Y1N?_L8(J!8(A/-:A7]!M8]/U]GR>J(MB*WA,!NQG$K3XXTS5%$,@ELQDI
MK0?Q1D)2*"Q&9P](?(6W&?$3/JEZ9AL_JLO531"I!S3M?S8^G\:[XFE8'6)D
M"@O,6&+2"_MZNIK6!,I#O'6@<4$6OH &]#CDMG39;_C3PC*"*?X:^(-]:)6:
MY*5)ZB))$_;BEAVX@>GM)$7P64>^YEN:P#R,K8=97J#N#,ANN/+-QD?KZPQ=
M0I(YJ?"5*"NUL5 48+8\$$8K]5Q;C)R///Z;*BQ ,./ITXMR?!-_NG-C>AUC
MC,&+ VAM<%E"OXXF 'O/T,8]('QH0G9 M^+=AD2[;%X1?7#-[YM(G1[-?4$&
MED/7N=)B""^N<O0=)PIN-5R/QNZJ5A2.] BV38N48/1>GH^PL%5#-(*JVR]
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M)O>"9&XQ-EG'Y!U7>EB]>+P37>$Q$: 9UI^R;/P6;RO,BY2)7_!^,U"7>K1
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M4N7!P:#6 W':%HS:'T$.Y(.];,>,<,O_QMR;!C6UA7N?.:*B(B*S@A"424#
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M>]*\ZLJOVKQ:H4LH+?+%@3DZ3Y-=..S6 9<.)T@'P<5((2@Z.<[8C?9'V$2
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M='+[A/2T?/(&IT*WTF\XK$74D0FIUT.1G#%/A=:[.A"NXQ)[Q*^6U"SC-2\
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M=:+AU7*!O-:]MCOYBO?B;R>W[CM^/^3Q)4">+KK<R*): WG_]N<;YNXG!NY
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M5:+K0+WH0B\. 7=M]F*)W5VMVUQ?_PV]=I+8C0?"2C[C=TS@P,D&_BDTNU,
MFFNTY9HY3T%YQ_2Y,EX"D)PQYY8 ]/M7,?A_9/*V&TO6>!/\;O(- 6@?9IS-
MYC5"_L!$LW.%IG@VP34$CD[A1V&^P,-BJW^_#^)5H- ;$PX,<@Q?)2C?(%TH
M;1N \NR=:E]?#/XRTH0X^\I@,/%2Q6Z$Q9/6#0$HSAXKC/2"&.'=DO",+@'H
M+IP?^7(/:>0*#S4S!T!U^(5.\"P!Z#]=W[3_S!I_8D>F^? A0J8 ]%]:#'X
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MQB!]1K!@>F<<):(ZD":-#6%80O8;='U*GQWY4N^3'9B][^*+6'"_H\[:/RN
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M0YFBPCR=ML"!8J_S7H<)0)+$Q[H0%2#;YF,U_@ R1Y@NN:8,F-0H]P+K2.W
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M@ 9 1S796KP2 Y@BX$S) .0[F@+2\'?QXV+VC2W,V2<5'A,>F-L+37"* '0
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M$1%B0R-MMKH5 2&B0J3-1E0(B$C?A2Q% 6FS!0%%(2H@G1"13FD2@0 J(DV
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MJ00]AJ<O(@HKS4I$%O @8Y,V647\FT!#O(W%4YR>$%E @SPV/P#=2MTV23]
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M@1+3G"_>0^@WBIDI!QIM9*D#V$KKVWM^$U(/ZLL]N*9PCF*2H^K9]&@PTZ>
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M@RR'= >?AR]E^1=?=U6Q?%E8]$#+(/9)H8Z#QLGT2>UJ;+BE>,Z^)M:>)RD
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M>9PN-5,+O^@&! :6CG26(8Q5C8:RBA&:&A0C]TT6N8VWB3 L6K97I(SV%59
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MDK6T'5T%5>8NW73=4&_SZ,CW :,M)3]'1U_=<:S?Z3H<XQSV9X6O)]#H(S_
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M']Y:M)'5^5&9DZEGFFS^/C&QSL\QLRX-C5^NY?5(W)F#-JWCX)OGL#]9O P
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MHPE;,O2I":L8#:6\W'IW]86L<3%(RK=ZKG=Z3)FSD":;0-!E^[1QX=E'L^Z
MXXVB'!0:!@@>X7K^=SV\;@P<2#@F2<5-@2%AN^$:;36'=)Y;7&1 6]CNS?6X
M/018S-BF 1'8Q0:IF/+8: ,IEIKKK[M=OD](IK0JFP9G'R&&]J?I-5Z\F[C[
M&?&.2YK'BL*.$_X(7;>A&D+>["C.*Y5#?X26&I]9""!JC>.E4$Z32]#^X)RN
M%!D@R*9WJK%_>;]W0^_R2%9=EYFK-F49$3[YU+8V/7O$(09^MS99X<5 ]\;+
M&F>:>RIM&;([ :^6&E2:TP>JX))(K=>P4F:%';HHLB14PNNZ[)P&C1"X-=0
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M:6[A>HF21W@(,:CMD+!*#%JKJ$S?1?[>&)6=!UM>[,9H:_/RE'M*!.3F<.P
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MKNJ3VA%BV<MSC4&; "LV7H=H#VZ>\GI/+PBL73#:-.LWDJ.6.O[@2D-,P-V
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M8 ):L3$.<!,LS2T*YL<X CR;3*%NNHE81PP$G;O)JR"1@,/NI:@33P%)*;*
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M0P;Y)=3\3;QU":= 9S$8:IL3>JB 8+ W9_896 _&K#N6ED@K2K[J;Q#;]AC
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M_0>]MHO(SE]&2-SW6'E)?U!/_KS.@!C>(Z']%Q%.X*C%%[]]@K6%6/RV1SO
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M,\_B<LXH+V[1FMQFAQP?NN'Q]\WW)'&]3H:='VOQ1V3<:C.;DG02,^OQS*7
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MBN3LG'$R;V?%P)=I^]LNHO!LQ*?/@>&^KNL=V%ZCQ6>1M]%?V,"1N-(BO-A
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M[6IM3'0M0MO*5+Q-<G,(/_6,VA"]4!\-CR=TL@DZ<&E%/7U#JP6?!D3=I)S
MY%\9:=4Q+7"OZ\SI\ ^]JR!Z>?#)OV\>/]W07_?X,V(!+?Q+$OYS$Z7DMYV
MVS=$#:D#_HBB +1NKD&,_SG:ZB70I>&5ZTH%54V,CGDSE.#O8$_;KW>G&9-[
M5-7_31C[X+!.LO&T(N-1DJ=Z:RNV"->B('CLYRN8GLG91/)>&\M9\M*!II8J
M$X19ZR;Q$:P+@!3'X8;P6E9*\,0B:0$BA!#OMZ=5N/AP_5E#\]<L\07,@;M8
M1"F02#OOH-^0;R\T?[!4G='TJN1S-+3\K$KAI$M-[^1Q02JH2*Z:0P@<-DH3
M**<GOWE'$WX#[E<%48X*2B3K)8WW);'10O-.]@[K/9B>WT=TACJ$45!EMM^W
M-4]DV/:=_\A3K,F7Q]RG8W*:=:AD8"$G973$*&Y"\PME:KT %C/[MO?4/V_-
M%[]S2Q1'4SP&[2.'<YK-#8,6J(5P.800."'&?Y?#=SUV#;L3I2*QI K9W706
M=Z9;+I>4&DE6G8Q+G)]")6/#_'E0[:M!MPMV*M9#53$OZ@P=%.L\'@R8U8TL
M>81^/%]#?(X/80.ZZ(5:+O$>[AA#!OE3!KD'4Z HX8:TH!+=PJ. H5#WXE ^
MC=D,S9!H<K4-.F-^:QJMTOC*9='=?4^$'5B/0)^Z2)Z,3D_[@S#6>WBY=[;"
MT'*V1,1N'@SZO4_PN7#@<I1F3<*6WB*79X?;[2YDAD78>N9G94;?KJ6D3)ZN
M!%0]@%K!!E<@6'A]CY&E'T 0I"RW(U2N?5S$U]5)$5Y"5/R702MW:?K=,VW4
M\;#*)3(YWZDIAP6S/O7B"8=PZRQPEB?/U-'@5B(/\<EL#53D,HEO6)@-[\"]
M@Y+]S[%_HG=B*/A=$D\!,K[U+"G$;[M@F**>?S;50:!<?G1%;(C?@4GY*H-X
MNFY^]G=P _S,Y\;X]=]?9F9EC$Z<B:T8 P\R.URKVWZXI4:2;%T>_@BPB)B^
MG590L,C-"^FW+.8?-@"JQ$[@.X1:/8QER6'R48)<#GJ!+OX]5$,&@9A [Q$U
MK!7 H1ALX&_#_-;C<BIZ$Q/= X-*O&YQB&KM+S&I3H7SEX>6_%L'A[;U'RYR
M#\R\JP%[2D6C-F-_^UER>^/B:*NBT&"*NE D1F!J>51^@,"PW4\3N"8P'N4Y
M 99<7PMQ)VO3:FF2<*E[QE&@ZG4EY!RM>4P(3S6Y8K+T.EBCV99(^C?\1C9Q
M=NM;>C)"&;M!Z-_AW7B/8H Y28/ML%(GG_][WEI=F/B(!"3]-ER48I.W_V[)
MW)TULRR3DP<<-]397@PXGZ-_P?V/X05>5&3>ZIO@]4C?[>53UPYQU4_;[R0K
MEA8\.UUN8WL;N,L\T1)L1WO:=-L,IX![CQ^GUGCRBP2Y4X$$W":PWR(I#1\*
M5P3(%Q@40^Q6@"G,YRYU$K< H9R,9"N[P!* PN1EO.(25(.H6XLMC4QNO0PU
M\]XZ)ZQ[P I^[H9J0?P)^R3F,MNI8ZJB!X *EZT6C-LI9'814HCUT!0)G$O?
M/.=ID2O1U4)W&T5[-0L2ZQJ-0DETG9K2L[%A95?'?VNING%6S=/HR!*J'*<(
M]L@@;^@+$V4A>8WOD&-B#KS#T<?[GG=(<^-]*Y4705I5J\\#\#7T5U[>%V)&
M P:UJ\YS)PIT[Z2]V0^[P,AFC(4L?)GD5[>TX(IHG#-Y4I[?4GWZ*=<WZ191
M[M:895NU9].'&5&G/Q]@Y&<T7 +_,$$!!U'\JU0H_D]ZPM\@G5JC27M%O4'/
M0&S!1LLM.:-09=3TC"M/H2<5N@%#XC=3DS-J[DX9(3P$TNZ*/QBAA7I#J^P=
MH8T68$-8567^I3>-*H2/J)VX 50#^QV<M21*!Z;%!^0L])=6O$ &$;VM!?#E
M&#H-M:O5@4O<XB<Q!(A3*"5R/+-;*UCP-;6"J &@O89T'\@@;H,[?1&N>: N
M&AT1N-5(SL/(;BXSL5X^OEH4OC6Y^>QV2KI)]D&/$VDO#CG:'[D<.3N0YA:V
M:4_LX=Z=3O \"9V]1IBQZ ,5_<6>Q$_X'M1&*U<N^>&D&?"B#&2S9! ^NAH3
M>KEM= 7Y$ _#:MZMF&6US<B3Y)YSI5[(.,X$O,OS8S]V_6C#>E=BH2@/JTF.
MBK="_(;KQ=<8]- W@.SCN!'*"<! ;/AS0_MVE,A_%%2:E4&VRB"!H:4Y2_9,
M?>'7)UQ#WPM=G@W@-@$NEYONXUS_ .BK_!0L^DMNLUJVCZ<G'-%&#/#3X+EG
M>:&.:$8;&=VR_*WC-$[G1(G>G%_NFVDGNXFAVW_=SDK-;SS9[.*<%7WKMATQ
M%5^+7$@5H[ J@*G8%?PW9B!=$.@!&/".BY'S; 7<D2L8>J<BK\#?$V!7SK'8
MB5@$E[T%R1DD!>6L6U'VC_PQNIH:Y[)VZT'GE;$!2N32!P.)JEP_+X P02RH
M6"'7_0,6M6,,'X+^Y,"QE)P4PA^TAE6$.DN. _) IXF!VPN8!"O3,&Z5H6.N
M\Q Z;-%D^.W'5>I"UO:T >;QEWK!!HN^:A&4/GI<>.52]"=RV>!T&MJYS/98
MZ8_,)Z<ZBH\PG$,,@0B2@J;QC:&ZIJS :>([^EB^Z(EPC7\K6GP39'JPM[6J
M<ZE;L;N'*0I8#<!20.K48J;54;<%4?:/XANM?+A+ZABZUU#=\7),O$^!+H-_
MM*[?V'"/T5%N8&SV1B W7DZY\-HK4$ 7U4GXY"3";VSL7E('''BVCTOM-K?=
M!J&:E#-  1>M^2WX5K79/UGGX^U'PER^GR6=:(_^>MZJ$WD,_#QXP=*70G=L
MNB.#Q,=UOW:+:GE6<@23$O&LY*[C]3AB?7:>782IO4IZ9MJ!)G^URMQ"[$D!
MA<1!),"@K>KECMN]Z8D4'8QKQWIZ5UJZ:6M,83JG14E_,?1TP8'@:PXMP3J3
MMAEFD5L^)-LY2]X#/: B5/Q'".+-4IH<J?'-I]@+GM68@7FN/HGGZR :%%K7
M5(8@=*R-O:]*'%![O?<TM@GTUID/6[TB0@:#+1:K8KE\I*.%8W9S6,*S=$QX
MQ3KY9?8-7JR/!W&B<65Q5YKZWDO^6L]F?R^PM^OJ!@=>/LA;*]++%_VU]C)[
M),_%W@6Y#/:( H%4!8D:U4U:^2671N,$,!?P11+H@X/#)&L#M-:8Q)$B_'.!
MA?R4T!PT7]ROXK/$WZ#[N>:A#Z1DGD=7P[<?Q^EC+P-V<G)V&D#)HR?&IR.:
M79_$-Z%JXS8#A;US\SY)9]\*%G"J(Q+87>Z\>DU#3C\A&6O6P"IY\I22IVT=
M3&K,##Y_409Y&^D\L%B8IT=Q#B9W[<O9^G"XZ.!A6Y<J_6=U;1B+*(V<.]/A
MK(DSX3AUR04YBIHB$>L5,A#7)_"\ZESQ,6!;!['6@ \7%'&9:2MP"*:Q"Z?+
MQ!VPXZBWQ:.$;:6O*C!X9*U@M4XC6K4Z=2KY>DL+I7ED)M=Y](]49'TZ*)4[
M0B:^%X$(0XC-X.FH]7NA]:*V"(JQ(#?1*HZ#5L'H=C=KY'()6S"-ML-82RY:
M.?3.8]2LUF)"!:O/OSS8HB![[N/$)_98OU%]?VOY^Z,G+([MR\,N"IL]4IOM
M?,K1W[4ZNH]UVIY\-I,<GT;RN-I?[\A('=3+]'#4(X>R^(T2H<18FH] $\8W
MB$Y)TQ"!B)3;.'KA'NF3,(F1V QK(T1WH;?,^QW)XN()UKLQ!K8"0IK$0/ 5
M#O&;18SY:0OUZ &D8+\#P@.A:]Z17SM#8N):];V.EDBM !_Q">PY 5JBYB J
MD);5VV$1\O!%E^<SZ ,BU$I7J;K$9/* +_K=B;FPZ@92:7WV7V-C1^B0V@)X
MN-8,?OVMJ,'ZFX"=9 )3 &)_%Q 3ZM(1-'"W8. Q*4A'YV-=?E!E7=N>\X,+
M',9*FZ%3;8+''A]MZ][);3X.F"?^B5LR32Z7;PISN1T^>W.)5.%(]>RE<(.F
M7C'<I@\[E=CCZ.QLLN1(!&G+P8!%&_>RH>@G7SX73]"[XS1%=Z44ZI_X-%0=
M7P99R'V.H^,U0660@5*KIZ:OAQ.%L=V%1P0&CR@[))>$44^*=0[[$!:0T'F/
MR6."L($7-_.>5*57CEK4W;)M2(U0K<OL[P7(H&*H\  "T$>FRAT/I2PY)VA,
MI@:1-25>#'PP2A7@^30,FQ W $6\2WB-%7BJ=W?^=+O2UU>E@/=<G 9":99I
MA#[8Z].CM-I5M]GK6M+:UA3LDF-U7O3<C[#0]2O61;\S4J/V&FP=YBD@[F0?
M5UYU-\D,?5H2'FA\ONE:WQX2T")V!'OP]5"^#P<]ELNCIN'VXCZ8X>N6%B9X
MB+URB/]2@HXKQSI*B:"NQ%I8FE$(&Y88DN=9Q(1145^GJ@_KRKR%$UDS:3',
MQ-=CWP9[]W!5>>0$Z?B]"(Z*]/F*#+(+UXNJ\5QXCR!0E#&Y[W2V-4B)T7Z8
M1@]F%-_ M>YO@-V5XZ<@R"'"$C9UCIX8GQW-,6\\]KD[_&OPU@/0D:V'(\Z8
M,<)6/)W&^9$N[0QW;;_@)OO)(0F!97_,;?C+C]/933N1CSN,W[_]ACN -?N/
MNBS1 M)]ZA1!9^^(L=6.G_N?J3L @CLP.MJ\.OS:#ETN.2X,3.![=ABSKH95
M7S2-NS%P^/Q[TL.'K7.^.YC,=<V%,:&FDUS24V!>5/<V#B(Q%&HNW.50[S?'
M7'AE/WE0QVP(/(+O\(\,-\FZ\;JG&/_GH>]+.3\F%I,?CM_/A>&<S^7C(U#Z
M#"FB=$>'\X,4@FF1RQ.;NW'E)B]L-1GA%VWG*UKFL+^(HW ?9! 5?%!;K.C$
ML-4O\"1N R /Q9*3 (^710XY&?S=_$'K01+P0,DY\L_$WF7^.LVA;-RH*BUQ
M]'2CI>FP_4-FOISJRB#745K@(,Y,F@]:8PT^4K9CEKB!"V,5P*PJ!\'?5J3M
MST%TP3=([ :/KA!5,;$>CR/;@NO"[G3S'(96T4JACB43M !\>,!C]\P#>)=#
M+^PJ?$ID$.U%BW^\W<\TGLA=*K&_'<P_8FS\K*@TPUCE3K1CA0DC&+R(@8HL
M@4="UZDU_ED!D0=?Z!?K@+W>"CVPA]Z-'7P5&>1&_ME*X".]^M-<SIHW-6WU
M&U9[JNV(V&$(_N=0U!E-V[KZ)_T3K?2H4P>W_%#ESBS<DL=O-V!>K(^UEOZ-
M#6*_Z4[BH..;F>V#MWA\S2YK^(B5@[#G N#(75+^'*0K_KF6<C0/3T,;V@ZI
M^C))=T;14;[^3@U#=9^.'D57?T%]*T\)"?-^'\3P^39DOTZ%4P=]3O\1[&15
M'>4^VYO].6"71?:T<;C=]W;;7L_0)S9CO49O>^U =]Q'& 1Q$ZH LM;1_$=B
M@UGV9LI^>"H^,!0]QN8B:/C420.APH/K0[F_"ZO6TEN->&T*?A\C'6\MY;"6
M79MK1E:"PS@YH<?D?GVC$$.J_1%-0PD<R*R3W>PW:_P)02X/WXE,LHCNAK',
M1?FOI<44;>Q9@79UV224@?7EK C@R2N'X9(SN"071EVD$)%H''EZ8?KM,)E:
MXQOE<<+O5#V,LG*YE(FNK:(^*6VM>Z/XQR$GU]M1!W>+/1<^LVN=6D\?>5N<
MG949-F_0I__Y=/B20/.='&UM4A&BDJ=>2\LDI\7F6"O@5C&PP5,@JE+H(.[$
MM/3H' 4>\?*':][4",_4=S<6!\7@'V"/7PO6*(E<-\2'SC5&YPHZUYQ]6%\I
MIM)"JC]JW))#6C@HE,.X3<*<5('M3/LH>PON-* ZA>J4;N@&#V3Y";LKA"<]
MA1XEG"7 T>IT+.?M38EN ,D'R'0(<YF;7'-[4JU[;WS<RLYD",<;='@ZEVEG
M5I Y1X7U#'6UZL$,G]@/95_S(%J5:!YVK7Q.4E@\-+[FQII.\^7=89LT455-
MD9_0HC+ X:YX&_B16%O/[DB/E6/)!8;XF!?8)X-H6N_&_LXT;3-XA]\I48@E
M8<)%ZS!EH,]AB!R^XAA(FS0:/#ALTC=?L&=A_9EJI_'#6^-[?,C.P%GQ07 0
M/ ZTBVW 47;]=NKV.K@<(*GA ]_C;[ ?LK?A=L]KC;9QH(EXY9=97LQ <$*8
M4U,ZV^BW3PA]U.KSZAR^[+/7-Y%(*Z"D,?=FX^:(O;!*M\M?)T0CWK.AH9/L
MI(GG10^*=MO:#4^G%9DZOH]%A&J%9%:$^RR7'7P9LG=2!C&P)LE!F)P _P"$
M$?)__@+/!>V-X!9TAI9"@I5B,=M^73J$.3;Y#:8IC[3:(8>5VZ293*A6T$?[
MO_^-[-HY6?80DJ9?314M2__!AQ!8NDXC%+5@U"]4?T(&8FL]]=?9&/-[K=>$
ML>Y"9 )%'_NKL#/O]UGOM92Z%K[A[Z-?F=<>B"S1.X). *&7!=VOM/LK[YA_
MY>[B/?DY<5-4,+D>/KU\IRV/^;QP<VK2P;E#S29!EJ<H(9%JP[H'#]D;@T-.
MCE4_O&M3 C-P=(2RU04!?@K9 4W '1,6+'4BU>7V%\&1Y_&D'HO4JZ9+*?7I
M&\[7,M"KKPH7O:H_3W[V>7_DS&>&;ZN-UIR7P0G+6&TUM\6H[B/'TSP&[8_P
M&_^LK)XDV[2,)*@Y_];Q?]&7ZO]U4-2ESZE?OLL@?\#$2K@AU'I)^/QB^?]A
M7WD%28@0N,D@C-NG;Q';DZ0)?^!7S95Q<?(83/57PO.2>A*%.05_^=_[YI$3
M:_TA8,]+PZRW@>32S<<G*3MDD*0;&"J(HWZWH790*\X$GGL];/QP;8?A^]?&
MW*9_(?X,"G[OZ 7)@6:D9)TLE?L4LS@[EI)O*))!$//D<YE.XSY.Y(9&JCMY
M-5!2(P]\M58H^5>H'P?8G L2RY-=,LCRJ@R2:02J2YWP'8;%,@B]7 9APZ0Q
M"([Z$'YF!+]$ -LL+[0V1\K-!0'$&3<Q\30&G;G._E$/'/PYT2*\\)!B)$$(
M3;M&KPU:.9#F=D)KW@3\<4,O7'>#9(T\ A]'BLX.4H.@&H#/U>&JZ3Q'W?.A
MF_Z\<?F7XSNW7%U#+F<1/VY#;I_]ZW/[$9]#D4^\G ;2H KDJJC<OR\8ZEI4
M[-BEU+MGPSXAL6HKLZ'YVS@CUI3=R*->_CHT'T"9CT6MS/')=,$&4#N>@_RQ
M3 1!.U -3WN-/2R#6,L]@/T>T4'%@CT*DF4""*C%94!_S,"D@B--FD2V#+*!
MN1Z#K(O+794B9D.!W3*(<KN )/E!ET'P>G*0^?EGQ0Z'CO4+R75&'I:G:;/-
M#40LL35BV>=JSR&>3L7<R2%JU'_*GJZ-OPTN(EH1]V(&_Z62_IMTZ^@Q.*(%
MA*Y2O\+Y8K&>.5_QFJ";9?FJRK,C+_I33W;RE[)[-LM_JG9#> SJ*<FP7.GN
M<DYR-I8M%A E-GA'K8*2MMZNF0,%#_G_;OPEXY[.IC_Q 5?DFCHE@RQER^\R
M.\NN#G0Z'$SRQ*..-WF-.QI-1/HAUU'X95_Y Y5G@0_6J&L<!)""X(RXX#_Z
MK8$2 SF(0 T11.Z$G[?^ RDH$A_I >_VR"!8$N ZC9H4\T!<Z)(F(E/,_H'W
MP'F"80LRR-23[^W1P0A1_>SW\#]R=>RAJ[>+H@YG3,ROR9/4]N(VP&<*NFV_
M\22,82(^\6F:TA^LYK5O>^#TS(:T+[?\UDTJ=IS]7G1*-_T5O=%^O*4AX\H!
MVZWNQR SZ(EWNKMX&PA5AGJCZ>P65 *Q8/5[[=G^N#O.M8R68)&/%Y@T0Y <
MJB N-DH%>" /P;&Y*H-$49?B99!.)ILZ]A%_"R%<$A:)+:"+!N 9T.0'OAE<
MG99!%-8_B0@MLS)(@]PQ)9;! LW_*S&WY5]+Y_ODZJOAPZ(9C6OX]Z!V79^
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MN G--;IM.1ZK4N7K>)?DK8<,,UT0]=88/+Z9^0>1X2T)$(A2*PF 832_O[Q
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M=<?=Z?)>K_,2_IXXFXU7A!#]"11GI@,UO@GAI;S9R(?[4S\ON0-+G005G.>
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ML/]$O;D$'D/U3MFSIW,XP6+6&U466X5_3\N#!TB!^"W<C&1#J!Q8WYE/3VF
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MR@8..=2>GQAOS@U&.)TBN[>P]@CW"WP!8K+?1B&!R7Y7#- 3-?*Z""JL/-J
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M\>S W?23^SY]<SA/U7^=T/)^^(^17]<'8T8+VB8%-S?*-B$W,3%P0(0:R3
ML91$J(NC)^'4N*9LU.(UH(5)36V0U$\4'N9ZX7 @@I-HI"2(JL .V8P9U?A
M9;V_CSI?()&3KY.35F9_;.\K5%N0,D%)6&P5P<\;>! &/ ++@*/A<MC7""4\
MG:#.8'ETVBM9B 1/.Q&@$R5Q^BQSX\N_3S+=+@U##NF:P2O LMDE,WOC),R!
M(FTB(K-LA[)><?9*"]-:(.O!,]AX9A96AK,#D4#& OX4P"L,>X%%7.4B4G&A
MG%^MLF4^)99AOLQ$LU"V+GZH\S@]9!&MS=NFL->H1-5;Q+:T3,C<#*%$!U]9
M@ ,KC'LRDN$[#*<BV;M+_$MGI[6&%W]O!$ #A29##:X[!ZLM]H,$6O./O+_
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M@^]E>SG-)^RNUN_E%# _IE[QTLP]?6V[0^"9N++XY19%]A1FVX9RQ]D$Y)D
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M:?/,&M68:AL(ZZ&GE&Z#]$">^ .CG&R=)4%EQ+:VVJU3VH,6N<IPD-]%U5Y
M_NPE1NE#:QJ>@JC?<L.;QDT\ANP:RV]H*4Z+OE?I3*C&X4]$/2A-R@#=2.;R
MG=WS@0P>#&F",[,"B#TVP8%0 N@Q(*4E-?%2\L@> A;+P6XK9,(_<):N-Q7Q
M+8U6WC DLS]Y-_YQ(QKMC".\-;92^+$_#TWZ(@3!E:LEJ8]_]K*]/#_S(L;M
M7L_ICYHAMC%WRGT_SVP)[[/RJK'_ZO_!6AX$[5*$GH/K0)G^QLH(8$5&P -Z
M\NQARJX(8>]S3&;ICD$7+$@( 7*;L>(LFB&9!%9UY\1(++(+O4#%IY 5_LU+
M$E$JOG!^,"NX:<C>HYV3-K6F<4&4*O0K5H127H59 Q8=,"'A>9 3;!X'7N)3
M=RB#P3K^FH:^_2(,0XX=<_$!C*?/<MC-4 :5Q#'[>60AUC=^,72\\01^";9M
M4CCS^9,P]6F1ZX1@38-27?$Q809O(W@O>%#S'JB:EYWBA5N^_.SG^\S[?OW]
MCQ::_A.,,YTOB;S]<;PO PH/LCTT+O$7PN4O1E1F,_2FDL)>5E88$MHVC9FP
M[A+]:*O$K6G\>"A0-0#0;G'A]9-*_Y9A*355;DQ-(9 1+%1.K"AS7(M E%A#
MDYUW#\XB; 6J1,I;^@8[Y.%9WN/QY#C69BB_2V7P=)49*R-(DTA^TUTA%[%A
MANS5$E2$ELGD:C@:&.TO9921U*J#&;&GPF;UVE9+FI3Q;YRV=;UJ8=U&?&+H
M'PD37F7R5DY3M3"C#>Y)B6<""Z:#HHNS,M^OX+Q;/P1'^@7D9Q442+9[C.>(
MQ/ DZN_4'216EZCA8P?,C.0S?7Q-XSL7305.)0PY.<1J8F481Y5L?%[G_QTI
M;TU#XE@HA>L=K0[!.='X][CNT3B\Y(@#_B+:QO>!8$F!;GTF/4&?H4%6C-Y4
M^YL8^>9!Y;DR90!HR'?UD1>-QZ)VD! 2/=+82C=R-U# FA\ 7\UC.<:>MYI,
M4 90(5^.**+0:Z$D#X&9ZMN:AH^@_A?!\G[71Z)'!=T072)*Y(;70UI=4Q;
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MB/,?5%N\XY'!_4IH%JD-K98I$U8?22%#"2:#NE5E37:'_!7'SF/7-$S(!/%
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M_:^53<$6'<\HR8KKC:]_37_[=7@Z')PQU<G6!+#:2YSRK"Q@ZQ/@-R5]7T5
M('AT<(_G(*6)6O R5[3/9G]H[J&LV1XQ7,M:40#L!!#'O,SMZ/0V9)_FI^9)
M> E=LB+*\5;/\[J2P=V^6<*J0/#6.&9]22/3C>21%EP9(IUOM-O R6 2=AO,
M2F"%N,U)8Z>J.:S'VPJ0K0%\,2V D]%A/ #9'!W_!HH.KN;=\>G07X]A.G@[
M\#PF<!^+Z^K'KS^KMJAN",FM#1'-?.,_[_^_]2UPP_?Q*A"C)$8C;]T(!A7H
MJL*8TYSWC5F-HUJZ/DV6PIN(6F[LAOZ:!_UR>]DMW;J//>V=*:N5/P;/MF!"
MP>;L$_Z?KY1V+V!K\Q6MP'#^)4YM, 'E.@6+0IV9$2W(TX'-7:=P0F52S8"%
MXQ7%FWH"#*3(0_J;I(5\0I(Q3DOX*<@NN*(HR_A?**7RNBPR&!(DB?PC0^;)
MOZP<:YL3[P+Y"@J-^27/@WB!>7N:C[-YC!2"WQ7S.LC2*<@STFIP:A=)#EI0
M1D(:_@I!Z.;1!3XP3="4"($?3L J*W$"/%'X WBD]QKX" >[@CV>H^K$,C.8
MP"Q!7%[C]TC<T03(.D@^I7 T.*7+%!6CUDH5ZVI,3VW &OZ$IHA7H4R*R3H]
MY4\?Y01-#VX.') (+%!*Z'<LI\?"6W'$JB[&'R_A['G!S1?@)H;MI0=L^)F?
M^[NS&O=Q^]'<Q[=%5,9]=U$+2_QBZ^4;4#+P"3P50[\KPB-W'L^9H*\EJ:I@
M/[KI/9HHN$Z2CW&$>EQ4!Z,H_P@?PB4O9@FK,2,S3,HZV0<0:< 3SH!??5T%
M9ODS>_YHSFSOW<&'L]ON$<B*&A0V$!;O@!W#!,!.ODJJFACGZI[2B\=U2L\.
M@*&-<9.=KZ#GBHE1@[>)Q>M:NAZ ?0]2MDS^-0<&&(?FX$ @@WR*T \3)ZAP
MICDK!F);:;L<!9H3OOR6T-D>\EK0?:;11U#PT4A.QR3'XV2<1>)'04U*=)&
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MIKTA;=Q7G2ASP.I/G?:06HEYR"4\R=;3R'"EEV\BXI64RE_X,69RL/=3GEV
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M[_%?I[\=P!S/3P='9_ @/CG\W[WAR7EP\N'T[,/@Z#PX/U8X,4?!$%ZP=WX
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M&CH\:LQI'QNT//NT;M#HW$*CA,MWRSEG<D[2>(ZPBZ@3H*=.>5[#CNP6>:/
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MB?-])"D=:><E86^'8&TY=VLTF2#'C[W;&2HLS_F44+FN..!%=F0F.MC5JB0
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MG>!/?QL5\0W]<5E/,_CC_P=02P,$%     @ Q:KU7'RI6M6D.P  0$,! !@
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ME#AB)[OJ69@[W?3*D+#-<FZW] CYP08$\( '-,!<87<'S%6^-L;Z@T'L6[Q
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M"[!S1WP+Z/FAP  Q#G6B$U'<4N:_.VW6ZJQ<JF3U).1I*+7!: RBBP*C=/!
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M/$G0&(. B""PQ/N1-#NY#MB*X*TAO,*OWN,LQF 6 H9P25 7@UJ<"V%QT]-
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MI647U@JR#:[W)K8U*>](TH%F9TGNLMYQ[>#\S^P/!F-*EV0[^6BH0!(=ICK
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MOOIO@ML/@<^<"2+5+<AW@J$)_!,0(FK:4=5<K6N1P>1G2,6#?'Q4'MO2$V)
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M4<,OX<]X;] S7YG'.QD-\L,.#[+=A6U_^OZK:5ULZ(=%MUK"#_\?4$L#!!0
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M.Y&@:;"]TP+5@-E5YX4*VY=K7&]\#:.OR9D+[;-@F(N>X'(A/;*UXIB3XNB
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M:A:8]'@2/O8U'.11"WLI>A7V/P(7:)@52P#&E8X?6#M'N8AB8R@.0%.0047
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M+COF<MC\LU"A8)"FV1U,Y0!#7GHYK$I.I(OT0^'^LT=CNNSP/+F&\9^B;;Q
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M92/#*#&8?W$/YDLA=-K!C8S#JVX %&ESA+"+\68%LI>N*"O73);,*.\(KVP
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MNK?; L%NXJ8(SYN;!.C*,<9I4-M&#61RUZ&+0S/O:_HW& ^K%H^A,1%*+J;
MG\H[6HC@#>P76Q$$Q6!O=3&$>ZS8)V^+E9FR'C#D $-0I@#>5(= 7-H"9"U0
M62R7>ZS1S66@55NK/WJ=1KN_EF6KZ1@=6\DJ5=.4]>5?AED/\Y:T CK)ABM
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M3G5R+S2$G'-!W*01!<_D#""=*77/-$X+\>BG_.@><==S#49!A,J*H4:^N.K
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M%XX"4\[5 @A#U81NH!DW#>K]Y/2!C7#A*.P*TE4)UF;Y6ZK:1(Z\R@QP82F
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MT73OT@&0 >G+9ELVH&YXV"3OL@X"KE="E /__<T)=<\W6?D:,NG<.II93_*
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M&UKUT63*78!9F V87'@VVLY;KQ5 Y4C3^]J14V)54Y']GB(<LK?X-S(#5C@
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M&HU/3LFGQM7_L\3-TT<US,%XO5'S%5IG#P!TAI5##'H:KQPC$E-O&4!B#CF
M$&OF+;P?L*JO?%)$_T1VM]YK&&.K]!"@BM;*? ==)'+O'G3TKB/K,VR/QG]Z
M12#2V2*V5E"T@+"40V\+_^!T1X08"7<<;,"$U?I+%3TKHAZD_L/HKCD'4XHB
M2+=;[\LO%"C"J@$>I2#0Z-<@QP A+9?Q0:9^(X,<79:LDE^W,5#IR :5AFWS
MIEU>P5MA"K<P<P;5BND_C))NF\@MQLXM'/H J"C:+ %6NM'E =!X$7E_Z=&V
M4'=6IX;WRGJUF33D3W"\A0\V^YKO?LH]7JCWP!<Q7@TMRDBRD* (;O73 .<H
MN?]21CT-O+Q\]U=-<< DT7ERX8$[(DQ4J9/GB></(@V .>2TK=PH J+W-@.E
MPM2Z2%OEEAGFK)>0"_B>^+!6/R1_NWR=_/I3\O[#ZW=O+E]?_AF.F=5CLV(Y
MF5*=C_V&0]/#EI<-3AJ%_A&)7]?)G5&:T&Y*AN9?E9MP1PH:0XNVSBFY9:?M
M,&L'&P>^N&W\D)>VTP'H,-YL54J0RC>*_D)18'$R)O1.:_#D$_*%Z=&/X<[D
MOCY FI*",6EM\$V=PE8&F99]!N9 AUI%5OW/_VL\F;Q(Y=*1OBF8B69G9*2P
M/_!NH#Y^+=>:'!3I5B-6I8(X ]\R=OXJ> PA%[RJ(^*%P4Y"#3&"JG"H7.0'
MMPRCETX'T( VS9X=$F\4X$7U0/RB451OZTHDE](I!TL(4^ME5'7!5U\*'9"=
M2FEE.SC+6DAR)5U6B3VB>>7QOD6=19MCU!\$NW*$WRGP3=YB>\P'NS @GUC[
M?\Y?(J630H4$5KUDUR!*"3%(UUF[D4Y9DM5R$N4;=40STY2,ABZ:YA/7.CB<
M:1N(PL#WTK]K\K_3D4-RJO1=ZWH85(*+OQ<Z\/=?7PUH[!T41M)YB^S ."*,
M0Z6K1+TZZ)B!5I]N!-%7[DUD/6<'OS@[.'[.#GZ3(S!_G"/0X&, N $T8!GM
M-N(_\-(1<ENKO9E)I]S.T:LZD[7_4O0T0[/'W]!^IX4RR.MF!Q9*1HN'O5L$
M($XQ*RIRF2:NX011S-)[02UCTIZ9FH,,)."<M7XA_ZNSO%SK+]V&8NK-!HL<
MX F<P5V8%>,>;\MVK"YPG#H]>4BC,?CO_\W]'W>(7+4I+.S \*:68Z&,\Z$%
M&4>2FQ(Q-Y WL/0GY $CGTS!G_F!TA.^<MW<0EI7?X,9,'POA-=1CDM&KJ;&
M%MP*3F0*DV!L_+=WJ"WX!2.%IIT>XGO/SXJ&1S^#[<M)1TQO 3C*\6;RV>'S
MYAD#BII@@A.QE1$:D:KR?>H-5++D;Y#M4A2B)-T"V&C42![0RB96>1(1/32T
MU-; B"#"WM@85,AG<LK9.%(*0DU_BJ!N#ENK6 OK"[A6S_E]] RD"$=>8YH]
M>.G4;&(S'=T!O0.= 5*-\I13PI03;\\(:5MH'4SQ#S*9^[8N]L3S7IM&?G2"
MCRX!33A[!:P9'3A\B)K%/ZB"XP[0QC50MD/:)D,@>%:J)9":&H1"U+'W>PN=
M9;!ZX$$5@3QC=P'@I]^%JJF02J^ 5MA_>2_;U,LQ_,<-0S% 6P,.7BK_17$1
MO;1BI-D>ZLXC]--+(>(&)C?U3=;6APWG3,K!/:/ .7SK'*#]9C<02_\"-,A-
M.7LGY G"V)XRD0,@]KRCY4!N_]Y0ZT1^Y^<WC.:Y3G:H I2+!,*_U:WJM,2&
M K1LI6;5#3LG&"=3J@8E._+Q1Z%H=@R8PR_CD+*<%(0<-S $NCZBPU3UCMJ*
MJ+=0HZY;0"&PX3<);1GCP#--<0&&L, :6/AA-/6>;0^RTE3NB;X% ^TBQX"'
MNSN2K_;&FBDI*V GA8($N!0(>Z?!KP0/ A_G;YC!TA++!%YN^4',S;E)MA4G
MV1*R 0,%,2P=?E6=X$VI^)=R]C/5=4G<V%%XJ3\2?6C3MD8L'2"'R1:AX6'6
MS(>M!@","JO%,#;+](ZY BH;+X]YGEU!#4!R:@YR1$M+*TG1J<YP;L65](X%
M(\X F"<7@O_VP/]E>N:XX$LI?CUK7S72>_RDWKV8RR],Y_&(8#.(7<A7'GYG
MNHK6!G9C;UN_H!_TY-@T?DXQQE/!8X4)Y<G<PF8!B\?T\\I%\J&5;PEZID !
MO(E8RER[^XT\@OV_(>F..7*C:_+!J\]=>T?*F5C%A %AUA[>X:I_B7(G_J)-
M7G_A0S[N<Z71I-WIAO4X*2+X3UL!=]ZW<G/A_8A]J:BE31+D4[:"B/_E3QL!
MJ0SX!Y2,\5]0;,/_QD1CB\S3TK^F%S*$ :EJ_N=F_S0<CA3?:"=P8SL#X[[]
M*2UE-D #R%/0$BMHNMA(9XJA)C*&E>-W:BAIS8P71*9?_^BY[ZSQ19=OK\%'
M;5JN >%)E!**5J.NM3O<4"43G0DY$E<$*6&_0K&)PS-BEK?:NV @EFONJ%]1
M%U_E(;/6F&UEREZHFN)CW"E$_=CU,+L0'<F)#+S=K@96N\=9P7ZHSJ5:*%6S
MO'!FD8P=P#&D6H)9 %QO"ERJH$,1;]7L'6LSJ/T!>G89_LO:$A'P[0TNRR]=
MV?Q6[PEAXRWN%W8Y-9A#S?X3&V.M/-%G6#-K>B$ VM^%@H%XL\1ZQ+M><D5S
MO"(20&-AK,,6X=3:)0KQX012;DNQ)5V.1CJ6+PAW?C/0;2O.2C"',ST>)>?D
M7-ZIHC9K;!C96 TD8J,?K3!C@(D(J (^2@N*B#IHE<$C>7Y"+ET"A8Y7:K=.
MDVH?"MT%G4<PYW]P,?+CM3"#UNE1B[G_3!IP:&_JF[!EMM6T#""84V\M]ULS
MXC_7);YB76+R7)?XZKOABP.<QT4MOS1IK]_ TO7DN3[6>WE>OY,>C33V?WIL
M0_*[P W8]TRE5#=V-V!!!_K0]J:^4L8NX5GJNX.)VVIW4S=K9K5V4O3K[!8\
MBQ(I=J#-!0$05X#O4O1^K;@ZK!D"40K+AN)7H+N-7B?5B23M[.!)[EQ,)<&)
M634[V4$)%I;GH^AC&%::/Q*T\#1TW3V)>\]>'.W,2\[K!*<!'JNT* <=!/X
M5,>Y.$^#8H5V/JV<YKV]C4%Z-.7@42[X_0&GU21_0SEC3(I;,%6(S $!OS=4
M65L4;*OX\&2:1V?;6E W.73W3I@\IU]_OJYSN6Q?P2'-\P51C9QY42H4-_:
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M5#TY$C+IT2A(W*F3F,-]-(BI.@7C$!V&5!ETY.1PKZ+<-6$*.FL@>&G!ZMY
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M4:]U0E]W8K]K:IN(>S9,JH)PVDC>UR"H:;?.M@QHKH'0$P\5E',SK7_/ZSR
M<"R+\6P^*Y<C44[S\6RUR%;38BEFH^%\-E\MGT.7/T'H\JLF]+L4VZYI44%
M)2E.C6/,13J^2.#-52KGK4ZVJ'_W':>4XU/T(XDT8TG1T@2*-:*3/5D#BU%Y
M*J(Y-=WPI!8 +2NA6 "9M]Z>E8CXB.8IZ@XY:\LZVB3N<!I&?&J5<,0B#!^#
M;HMI!=,Y6N&MW2=ST'^&<4C&P^%*M[7 0@$J+NBX1ZE-\NF[L+GF/'D-7*,U
MHN^H^58.YPY%/5U(=TTLE\B%)$I/@+A??=H=!)Q#:*^&6957Y5GLGSRDGE+
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M3[Y#(H[.H;F+\: 0OP,3A[KSZLHUZ6[<8\I-P9ZRI:^!E*Q?XPKXG4 7B1]
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M$V!>=NO<'X'3(VL2U#%KRTI9*5\LPX@2-958(F;3E$Y)U2"=<ICK4A-AX,L
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M4J<980=\)*]0NT;\H[3_B/C0)[$'7B([@E_.VG6-29P6U06]JPQ0H$8QW<L
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M  DR+1#)SDR08OWZ><]^WB4!4)OE:M:]T19)(/-=S_J<YU1,PT?249J-*C6
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MYH9?*/8RX[^'=4)09=XM]D!7.7&3D>K4L>4F]+A^$9C#IK=#8]V+FHBM'%
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M0<-<4(#0@_QZY,K+B7==>,J->R1^R7QQ^+AH\YW%B+A<(A]P=2]M>0BS2+;
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MF)(2*K' Z"+<A]2[ ??L2NH\>?*RN@DJL00HAEB) :F+V.+IC%)J1$G3QRL
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M%$VO"$F@LG5FQ4.NQ*?WXOER$&(K!!R83908"@NQ%_F?A3F8(Q8+$!IIT*;
M;L* 7M868*+.&MH:P]I*6(.W0B=LZA) K'IAS>KI&&YZ,X'=O[BHU_Y4)5PW
M;,HEIKI;9 )[\F*6YI^OK]O7/>9*)JL24\5T2V*F[(F ?#7*YWZ]?+)X]/C^
M-]\\>?!@<7?^9![4T(-O5G<>WJF6]^_<^>=2/L]^!^5S@#)9-5 ^-[ELUT'F
M08#UHAZHV*8!ULK-NVY[,1"?I65'EK]MEWAA(!@O'Z)BU;Y=@^7^U+Y ;]BX
M)R,0L+\"R[^NWTERI:O;[K3:,'HB"+FN@S8/A'R#$AJ0F?@7XI^GC^6W;MGT
M2$');^J;<+BKCN+D*P>LA"@W!Q=66Z0I6-4 VES/N.+<H@[(R0-XIB#M45V<
M"D3"@]=MM6:Z$+1R]!@> ?87K^?0&<:M$JS$3,A^"-I/&8A%F&L0O,KL5UU<
M0%J1(R?Y](DL/!P/J(AA#%M']-RT:JWC$'<#4(OBM-[ *GA(0H%G9A%T5B-S
M^&\ION[=6<X?/EH^_.;^ZOZ#U=T'\[JN[S]Y=/_.:G%GN7SRZ)]+?#W_:L07
M=GMNM]U ],&8?$6O;A8>NSP5?-&R7F!&#^LLR%I3 00B"=+!%5@W&J/Y:%GT
M :(GO[^_ERR:"8%^+F0P#4J"Q(5$Q]<\0H=L-Y<5J0J@1(8&7]?<HZ+:%*37
MZ2D8E11/VP3#%<I7GW#YZG];43.__[AZ4CUZLGCX^)L'\X=U]<W#>_.[JP?S
MZN$WX9?_9&[ZBZ]*U 3?D&ZK^C!7* V&Z[3>CIVB!D R6):IZ60J?5.D+4;S
MX<O_;0_T-W<7\_KAG?FC)W>6#Q;S)]6\NO?HSMU'C^X^?+*\._\G.] __'/$
MG9+T'95S$[BER[ NFQ(IJ*_SEG(E9#SW7(0^ZC1HAZ[AK,4X@34YRY'Q\C]K
MH:KLE2?*7OEB.IK6X_P,5U+72^_J+T I<_C$.K'[0(H+9V!\!%0< JZ:%;#.
M^P>$#^;/<-FH$7H=#D TG"^;?:YDX$=D^#[YF#CK^-%)1\I ^;K<><0KC=#+
M" <OM1@;;:5UW@9[!'QD.3;XY$6UD8.#K#!1-7"\D<;08QTG&4*^;,(-X$)]
MK 8'W#J67319)R3YGPPCC,!>;^G \+O38/LQ<AR.WP%#XQY/PL@JPZ)SVF/\
MT3^1,^%4](+X1*2Z@ JNI[]#;.LV[Q;EW>[?YMUN@GWZTW<@@6=2*:78[P6B
M2QQ,EMKX5*>HOH(CMMH"L/N\0F=K4C%Z18+90.6^;'SC,B70@W4'=D=/)-QV
M4=[>749)@2^#9[59,N8?-$+%) 1HG?*'+H VJ(\AL=@"CIKN8%9BK&N*"$&
MY\G?E)#N'))(Z.Q1TJ%R  9/*.;9VA*2M^42=!^I\;AI)O_)%"NWJ/91]$?'
M=QY.((S.V1$566B*&S\?O=MF3SV5N#(Z*2'L/<S5<!10]]1!J@!PFEAXL,S0
MW8;G#@+WNF50-)-NN0UR!D"_HV'KYN BTQ0BD?9M%:11A;BCJ,>)L8P;N]Q_
M;1OF\8)_X>B1&<V=!B%S%93*8BOYLW D+SA48OK'X^WQO&4+G)T7 W,EM28)
M;J:3RM[P2ZJ.=27O8\PGA."EB@!'$U@8K9YIC\&&DK-3B1!%EN.LR([67A!I
M%8&JF79/8$+\1U>')Q%UKAG#&I3>7:2K\.Q>#D>\;5*J*+I=:1<]IF9TTX%C
MTU;#EV8P>S[V<+T0D4;5O$B3YVZ^K(>A>JA89>2=U(GRM(.6-7(GHCL?]2OL
MME@V@<6,:(LH\WWV?'Z8GGXYJG'MAQG\-G$L!]*^B-SX.ZC !HL%^WK@$]>N
M5J8=SA'ZC[*6)'JK*')NKD[%]"5&3RS#$-O2@2%?:Q<#<GU V%<X1S^H_K-W
M>/K3=[_"I:6J4KQF+/V51<J(.)7BD7IG4J8:ALPBQ-'J"Q.H<_E\B0'2$'M]
MN+"R;/T05)Y#H>LZ?2KU(^@GN$1AG+:]="C=QX/L;XD!LNFXBJ!7[4E9E+J'
M#EZJ7DFMUIC\JLO:/1S0JNMM%SGCS8K^J9>.(I?7:W>*B_(7G%TP-+3"U?'@
M[1'1-O^2K&[049\F)+L;R+SWQE=6H@F F;OR*:%YBX-A[,5'081PJ\_GVZY/
M,O(P?M\MB$0*G/PRM8,$JGT_\KHV6CP=O)/STJZQ 5I1.L.57#170[1L,1#0
M;[O+YM(Z:(]1CTJW>ORTLWC"F:JZ=0.7>$S)?8$;_&976P:!E2KHY+YGQ=8F
MQ&$?-N$%3A%RX@3+JMO>CKLK\0(.AYER4\SH<XA5J<[Q>,6<NG"AL5I=<*I7
MVF',-M ZNVC72U)N1"$SK]9165=-!Y*.B&<<+&X&'JF4MR,%H>JI/M;3I,T_
MX>F<.U6 2VVQJ/WW  4("L^<T*.@GZN.B#28PX"[T.GLHBI6A-=2J20_$N\T
M48[ !YB3"'"YGO$ZQ=A'DL>N7I':<,:O#&,+"R+E9FRLAU^]JZ=/1^<;\8L:
MA8G7UO!6E&24\8)"O2&VZD'Z5LBL)U6@;DF6&&CME29 6$N0IH^:6@.U.NL+
M89OPLPJJ(#P>0=5 /#W+YB::#F\$SC)(,2!RC<W*>!]11 ,)/_Q.(.8V;[?#
M5"VH!XDR]6[SK&XRKGHH"UQZ%7J<+?TW*M\M%HR2K;Q1S@F \L^!(5!V<J9Z
MDZ!B5"]7LVU3CY!5(!LE^L$")R_._U,)T]M(T7>/'MQ&BCY1E=S^ND>HWB@V
M.7WM34EUZK_8N":?V/:( ACEV/Q1-=6H1;H<N__OY("G!],&^#8&%*7*P/:<
M#!!L!35Y&9D C44DV W=8Q"(4O<GW2>Y,)Y3F?&ZV)YO&>GJ2K!)S.4*' SK
MZGK4/A;1S.' )%11#&C%M,0)]5%$?+%/NS/G,'Y+.A4/K5^'9.DD0,#!U;+Q
M88TBR@1GF1_2R?[ZL6O_WN5VP3G&L)2;^HK_,J[N<6;4*!<Z<4*"LT&E7QF_
M?:+[(XLC:4'C1A=W-@VGXF09-KH!-B@\#L^0$P%.3%\CX&XX2^.>(#:.ZBD"
MB(]NT"4ON0 )+6.X UB2A0&2M-4%F.50;C!N7.5&%I73#5'H=8+L"QA^PQ<0
M<YRVXINYUB+@.!DMI&]I0?V&;^X$T.[!*T\[M(NL7[,_(_X$K0#&1+R=GGR$
MN^A@VX-ETR\ZS'0IWV</5F73PZ&=I81]6'^!&$OR3X%O@*,?[)OY8/2'OA$2
MS1%!,6P;,?X+<TAG/9$H?"'G@\Q%@-=C^!R^#6N3WF.EN3A&BM0+]2V9O*8Y
M)\KBN"K"A<0Q"5'JQ1'&[H3BJ$GO.4OYS%EK^](#;$0(FL, 4\R4!T<\EY5P
MC[2M4WNA,IEHSY@6A$!YOO7VKYO&*%_\&F!Z'SJ(TQ]Q''TKLR E0'7*TU+;
M;D>KN5.NXZPPM(0Q%&Q>#OL+L]#R":R+#2+GO-T 8Z%27J!P<NVYSYOWS'HG
MDG.+[KRQ@J*3) T*Q/L9Y[3XU &.0XR,^6<V,MXZG^336A=X9+8;E(Z)0 DJ
MLUEG38F Y0ZKY 676EO$)6ODM0GK"<([B/[JXDP#%#L,F-E."T83IB4KYF*[
M60Q;9,#R-%3<[0?&3$=(.T:0"8-WST+%?@5<JF&P>G]T7=G(T%_R\08O,]J2
MX DPZ@?*SW5SPLYMC&M/.W8+L[#V82)!0E#XVA6J 1<2YP1Z04-UQ,L!# 6R
M#IYAUJ) X&%7EN 2\=QF,!!'@(I0#1#7@X1[-!Y7L(!1F[+(Y3'A B#5@*/L
M+#9[Y\P)TN)D23F<3R2A6^D.F$Q'EF>&C"4,<J'-<NJ?@^A-\!=QQ8*)6#P!
M7Y>\67QF>?,C7/(WX9+_:)?\=_1J/D(HH)U[Q=S$)A,*R53IJ*B@VR0PY2$3
M'#;R[ZOZ@D0$4G,(O8%1(G)3\G#:)3JY=,133DU(,>Y_SK1N$F2C\L&D;:"?
MFA8.*O>T-HN\6 =5C!J>6'ICZY-$_ Q[29+!99VK:ZTIN*S6VY1N[#7U\6&V
M-<N=!!MR&\?+CW SDG2+GS]SL"'^<M'A^?I__O5?__7_U7:@0#%<A5E=UU5'
MC+>6Y,3*B2TQ?"'S[=2H;[/Q(QQ$RP%^J)IN\E/5@;.JLBWEB9$ 9T[<JK+2
MTV ("PC98]D;'$P0#.%(^\ZC#BY!F/U&>XC; 04/FT7#3G*!R+@DE$T[8YER
M8E6SH [F?XO!4135$0$Z-_2$FTGUR_X$R[%-SX0E;/ @PVF0D+_0#2<<T8E!
M:YN/N-:H'[J G#**E"R&_0,5NX0Q48<H\'1P#NB*@,D,.=%P,L*8I[8O6\ZL
M9YHZ.DO"6>F:E88;]-$:XS9J_-VCA[=1XR]B4"P_U*#P__?0@"G'H)^I3O\V
M2)EP#7\QA#]9&91]XH\K$6(4.PKW,&CXG*HK"@U$:3+&,S! @Y[M(IDS;/CD
M[(TC;D4&"#Z-#,6P_!)1>197FT^-(F)J\02@I +4"\A<"5HQ+FJ9N1U(8XFL
ME7$Y  DL3!2GY@3U'DTH-I&^G&0S,G,B8D@A1A2@C$NS78G?B (XK]XWY]MS
MRF22RV'X*0*&;->X-! C 26.B!AOL"0=Z:IUWSIT  P7P2F.V*L[1\^5=X&<
M,#][W:=ZW==72*@K152K-$3$#&[8K8Z,0&)ZN!8@CD*U&'A%G54T.&C0%(4O
MP/YJ/PSJB<W+XGZ=E(G*I^ ][CF$.U+8$;:B$)0_UCT:^.AI%!:<3W$[0:DO
MUFW/Z!VDSF^X&F0=#F5'V"LN)%MM.V K(3N,RS83<E6&M>"PGB+?B5V/O1EG
MAJ]AY!#X97A%#<15?@O3E$1]:<,6#W".=O5R4"+N#&Z 82IWU.T6N,Y'#GW'
MZXR=V>_>%5,'(G+0T7Q XIAG[;(F)^8<*SZ^+M^Q_MR^8VJ*/D.#6/U&@4UJ
M-VIMX'FM/J"OBW*!75_A=-2L8AE_/>5HEG>%'+ 4,PT"%@!HG)9BDX3L2!U<
ME_S7X&#\FZL_FX[AYV4N@V-@MI)G<QBT54:I7R7XG(ZY]LF[GU[^[>%__L?P
M^/G)H\<G1%[KTW1^&48)D03JIF".$NKM./\^=BRY 29G2DTT9"7*F:DJSDP1
M6[?3)A I8F<O3/1_3-6NI]$<FIF*$V#C_).4&4N;B966I]0M(8'W4>^T#LFN
M/2!_%MLM^"<B%E2 KBMP'#TS/I4[UK]=8)>SM!&I\[VBR$O3!7NG1\IRC%\N
MR(6->SF_OVBZJ.YBY&)&G4]344WDP1# AU@;!DG2[-3,<AR\"-H[O*6V<PV\
MLMG\MN6G$B)WQFFH,7V0=F,H!3K=NR79("__/$+\(ZFL'R54U@^^G;QY\>S7
MUR_?_N?D^8M??G[S\NT7PG!S"<)B6ZJT2(I\B>4L[N1<<4,E^.HS#'?#X4T2
M"D:V3S4/APJ"]-')59]14IRXT^Q86'L@RBND%<@8A,*T_67=72>,]R/P1HS[
M;UHFT69D>XD#SIH14(^DB@ !,81_H]PZ#=<54](669/.P_O8V,L#DU\ &/P6
M SS)GAK#T\8UHP#&@+"0D#[5+U#.H]A+G9(O?;]E+\/U/493;KS',B>[G4"T
ME+=$Z73,=A*BP0O?FQ1ZL-,&1'T;0C2&MWP?%!4\\J<J"+_%V;8/#^W9L \#
M0]Z6&F.\6JO1:0G'S!C]8F:(%8:3P5H);UL-J!W.+ZI-HPOAF.:@AD9^[RDF
M+NO8W>TY3DB(D$'I"6WZ$+3SJYA!GKDKM5;F[VI5DE ^-K0$O\>\!^:R@7T$
M5PYUZOCN7U&;G* %'4-?4D6O=HJ-QWIDR@(P[3;+0;RKV$R(JJBR*R,1AA9Q
M)N1XIQ< 3WW"]>C%I6L7[LN4BHWGI)V)+< /&-QX75]L@XA;3+['*^8N,C<\
M0:T,@]*^*>E<J,!1I!C=&)^9])'A9!4\[::+L[K<!,>"-0:C(SRKUPEV#>K&
M%E5_EHO=@VW+9_[KJ>F8MK$;+^XX3JQ"@(IAN@A,P^@=L;ZT$D"T/E=AY7K%
MYZBA$^&S"<G"\? 1P<R,2B!SM^MUI JYQI2#-BDM?45PE?"<YCW<B$=R([A@
MM6Q!0D+HN&P=H%CAM&P^VL1VV$@(YUU=7Y3/#T_)S02Q?N?!A-W1O-ZAPCWW
M!D9=A"J<)A$<V_CRN78NGF\44G# JCI3@\/U5=:  Y&2$O,L0LJL6ZX8QN/F
M[< 1+FC06:-EO@JKN%EP4CSK7)]X)L3*%Z]B)@SY8$,XCI89Q=X'3_(66O\Q
M29)'MTF2C[96XRN@/<<R!3&T5Q542?L*[;0/FS3OV"/]]A;Q>W@,T_W$8?\C
M+J],L* "Q^K#A(,XKPO:C\*Q@FY$KP0'J;U]7'"\14W="Z$#LP]P86D"EU1U
M;-"DDCA&VR\\>/^3(AV8>))IBVY'Q% HZ#3+%MY,Q5+)TARI/Z74$QL*XI[7
MILT+N@5Q"I*)CMF]LT^S=K"A9'90SH+N*;8C9#X?'.IN4BSBZUO:SZACV%$?
M5VT^+%%Y^]IYR9H@I0285\MIGCZ)H%I(7+YLQ2="$Q84L $N]JP3E.A#MD>_
MF1P%/$'G"*^?"S:2S[,3@5$<]=]?9G%4+*67H2 &HO7PL#U,[=P'7'G.M<[5
M4GW8T-RA^\1?9,C'&)-$:C("JAET^U4+^W(.?2@7$)(0;&6IW'8LXGGWP92B
M\:,]\4""D>1(:,?B7GFSJ$J[]8U<A?L>$STT<?:0QVW\MK-KJ:UO<B/84Z,3
M[AZAE]%>1+$B/)^NL-.7_N]N"6, 4,T<$/HRZ0[C"G"$L()C1^#_G]:%S\'P
MJ<,EWYHH0>O':#>IN&J8\Z H";U7\JJ.SL#QLK"=CUE?X1Y2Y"DIA^R8'^#/
MJ*.9EH9"80$B4?L+B$X)X)P6Q]IS:?UP6+!VT52*=M76D3-LHH#\C'BG-+(,
M>1_N4='AYXAIC0ZTF[KTHQ Y7?(1QDE=\HF:"M<HA5-CCO2H8$2DI02M-60:
M#QXZ$L'@)G6@'/3,\ &+( Z^5$BA#I&A Q#=F0LCDIQRD_+:,:)ZX0:I[N]H
M1,@!GTG8HI8K546%M<19PA9%?N_&UT";IC(<SM0'+%!R4&WZN3@51-CWEONE
MO&VI< 3!C!B &MI=UN%15N.,N1@[JE0G<XGT6-KD'M6B*AJQW@PY-U8[[V-R
M":@.(RW.'N(GJ,FUW$4K9'#1>:V?)X0+G]SM!N&!(UUWN?H$P!8PY"B-M")R
M%[$3E2\;>4PP<0,_VFQ&MND+Q*^3<^#<XK'['$Y?6(+>XE_@JSOVL*0M75R8
M)#1"*BBITZ]8_L<33+-(7QN/YVD=!#H=@AT!R6/-DJ0S)\FY]!#(!Z1 *PZR
MA/ML77Q3L[CM6#C7OM]B'K:)\5O2KQK,/ S=L:E*AA?9 4!!5U_ECPJ+0O4H
MJ(\=BQQ\.NC*P@K ;MP&&CXFT/#X-M#PT6+E[\R0FL1)K:^A#Q3LH/B1RM-$
MG#0;QE%'&74K"T5C4CVRD@E.ZFVW1VY[IK*PZLVSX3CHT!K,(8^5F&U-V@''
MJ"9AA*^W@,9J52?T+2A?9TR!K 32+%F,.3%;*&"ILL9@XZ'F(YX8RFD ,#1(
M16LK@(5-Y-N0P43SFU+=,AD*2<UPXLER,UDD!*8UG!F8XPMHNM0-Y'13D54H
M*\C""MX#PAXCQK7UPS(3[=N;3?FKX9R_=^?1@V\>W7_TL/KFWH/'J^63>?AA
M_N#^D_L/ZWM/GCS\HW/.>Q3AW2_(./]=7"9X]%YSJ0!HK07+C:6!?19_!'^V
M \_G>Y<'R<(^1@^ ]2:<M;V>,G'KD%:8P)O1$[T)#D42J5A&B:6\0P8[ TP
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MZ/[XH#:%?_KN5R39&R(L=:5 ZA2Z-.'>6IA2QGR)M21J$QXB*U^CGC/MRG,
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M;!B?1K0_XF[D3.R1EX<6>!Q24*=1?92:DS!,T;%/)-C1T7;(%#'@Y$<$=;#
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M2%OHN0H+2 \CP!-B*9ABBN*I)!IMS&&?KDKY9U>E+)!>U2!*"*; 9,?3&$[
M:=,/%/E\#AU%N6PJF=.,U<\H>\8*L=3AB2#W$+DWB]M@V?3?Q@_1U:"!"C_S
M.3[2S@&.'HE-LR'?"H8/%@R/2X+A6=N%"PNGXV0;+A;QCQXF'5X /M!!RGR:
MAU&%:2#;0=2\XJ!^B-74*R=@B]BN@6OTM +RP6"=H49;.R9,(L68G+8M-&SD
M6VS\->OJ2E7-;\& Z9>--K_ABX/%8<!_ S'TWE[VE&Q7&\X94Z56LDI(N7%%
MA*G* \WV\"+,_AHLG03E*=A@N/,0MH!X!I:&I)Y,>/TB>STN!]_1I:^XJ9?1
M5]'R7DX9F<M4J3,S!!$OZO*M\VO_IOBJ@P$.R0E-BD*7CBLFAK-O<=-$JYV!
ML48BD9;M'VQ0H\T1'+H@NVN6TM(2$9B#4=<087V=!*F P["Z4N[\3GH78-IJ
MVQ%@X+1F_/8IFK#GF#7AKQBQE-8@&A^P09CCDUC)XF#$6+OFR2A6\2F W"'X
M_[-H!:2*42=HU$:PK,A*T_BD:S#\B2R+6@.PRHS672-D\FXMY61K?[Q- =Y>
MFI6+_$\@F$+7.M*&<J$;;5#-%YG=<U;70VH-EE+<1IA8NT1@YLROM&('<ZNF
MY#8MIF@1-@E1_D-&UF^#@\,YR9A#U'('7>1QC:H_:?EB_-EQQ+\(^X^YTARC
MR<*X6B@QNEC7W;L9E"]"Y)K(EFE!W1T2K+J+,L--=;5Q+%^K97NA9RJ<RJJ#
M%>K;M5)_T[-9!EZV@XJX?^1TR[%LP!T,LUSY86@$A!"WBE2(+$3*MKCY.(-J
M]PMNU?\'J_]O2NK_W\/E)M7]!JRYX'\I=]W!"9-54O=-0@6*ZOJRUVI(Y!G5
M7.K5_@V&PWG G@:TOO:-/-#!C7O$_.$/QFVP_[O']V^#_5^KW'A2+)C$XN6?
MJM]JU,0'2XHHX(6$<.OJFBJESV Z7"(39U6A_3GQ4%!]9!DO")R(6F93:GLR
MUZ^1%>I,O+E4YV*@%6+)0]>\PRJK=O$..([1?EQ7<XBH-OW%=F!NH>#-=\U\
MJS4B:#4Q#P);%_0*ARV(03JT!MC&*7R?<ZBXOGX->*DE5QI;GCX%>L3+$0RB
M;NK!8.&]35= 4.+:&9$ZS5&>2+.^XJKW8 \QKZGQ#=+GH3,(LZS24KF0HC4;
MYMJH,!RI<:?4\FKRUU9JT\UDKR*^,?$2\'IBR@CV:*%TG]Q?O'^*Y>.+YK)9
M8PZII:^%L77!V.C/PS>;=L ,,O+3ZF/!D(0O@QW5AI4YE\81  YKJ-T;IZ:J
M?ENMAVO\-&0H*OAXL[!/<#G-61T^%AS,\[HCE\0W9%_$B2V!HHS.WSN>X2A#
MM>HFA;-(?4\.P.;#;@,=&>*4)@4IK"#6N \?;352WFQK@*2#!1\6OP&'XZK"
MQG)]?07_0<J#\&>?O9,4">?GL9ZMI[O<!Y]M(3^HM7\-/F>4Z>NIVQ@-!%,W
MEHB0&P:P]R[X3 NK?^(I.% BEIF.QKN)WW,=)@2;?UG+^)Y29NC]U-#WTD*E
M#[=Z77$W-N 5I40B<7?6F^!6=NCBNR8&<6T:G-I(5!2(A6,4[U$0]6N*Z*_#
M!AP*NXAD=H(K9F*41*Q22?+",^:\7^ *:N=*0L!*+2%(,DU7RA_=9U.977K!
M0'5L:.TE7@,\#:[+9;5V,20; SX.!U$.[J;>\%B+=6'D]Z6-+-1G0>5OWG7;
MBV$19KH.ZA\>M0JBE%"D^OE(5BH@5R/I"")%H1B)_%3.4_DEUCU'=G3BD;Y)
MJOFR>2*/R%BC <3G8E.I5#V;YJ5,(NIJ(DMBD+.@814NWIS#VVLNE3VG=JC4
M>_JB:K!>&>Z7\33'7\"&8]VFZ<_D>TYX),<!EC3N;"H06QSN5F6EJ?V$-'G,
M!,!P$C9N<&AWOL&%Z O?8KY$FT+C5<'9CO5>G?FA1(T;#'2KH95H&? ;HE;!
MHN:OLRJ *T7\WM8>;R[EVZBGE[9WKSF#S@LQ2/[&G@ICZ*OSF@BENX:;X)!U
M \<H0:>MJLNV\\EB-HWL^/>2R28=SF<)^YZW _T:RX&Q%.J2 [AP!-,2$FTW
M <@V"@Q"*!8'=KC-E5S V4[]PGCV,/"F6VS/8<?#$\ZW/46SL=#A>BQ!FM,K
M2SF!%3O0, 7^WANJ HYFTDS9/0UCPW)!G88##.HY-/)!8;VU()A[F0AO2AI'
MDMU@">$4GW;<NS,3 -!TWMK.797*[/#@N_:KQ6[%1.V= -4CJN^D9D3OD@+9
MPW"B714T2C!O2)/MHJD'N1TF/<*R!&<GSMA''/EH+X?+1\XA<74X<M2Y1K:-
M742(\;*FL..O2F1BPN0_2JUO='],3[ /EG-(@E)!37<]C[*($$76\+KO+.WB
ME<\^<P( $;(?R*1X<U&%'WY95QNP3OU2V$>OSC ?D2YAU/[W#QP]NN' ]M<J
M!Y__[IV"SV](@K]KQ/WIY,<@4 ;+[VKP\ L.>/([4"]^*8+3<*^B!8>K=5Q$
M)MC%Y7P^,Y*"0\.<C#Z#$JPN8!5QV9/$O Q^"Z"C!MY0Z/(P;^RG?NM^"&H5
MTYIHLY.Z7FS!*=+&]IJD(\$6C,(P^& ^(/QG.Z3&D%;4X=C#<%V2A[Q$\A/,
MJVHCV=776)P4'-L(4_C1E(RWH=KO'C^X#=5^W>RN-Q<Q(T*<A$W<YC?FX$U[
MK2/V$*0 I9&INTT"@K R2"H;P^SR60.1)F2F::\V,8?]MP7S@T]E&/6Z681)
MB+%B'6;% )&BYG&./7@I@)-KC=C2,4F=4W-:TH:K[/AE]HI&)B+9"O,+[NV%
MGV.)?A8:O]"*XASX8;145A,<="#3(6%S)*S*%=Y*3E6C%\UL?\&(WO2K>('5
MYF>Z(P:%($R7/UZ[5_(WDS0<11G22N6\VZ%(_02_3H1..P8YB\;C*".BH*KK
MCEE//2[.&E,1M$*",ZT/B4]<%;>,TZE8>MRZ;=]AB^3UM5;^%58)2)$ /@$P
MM@BW#[ZT])[T[M?8F&HCXF*L1!^%?95[BD.>O'1'$7ZBN'#28>L<X_AX@Z?'
M'LZ%4!#)UB\&0U<E,J%-%R6]"7X!E%25@2]X DNK@G$3=-_36FYL>(;W: ;,
MI/T 7;G)OU\TP4F<H0V"?SZO00]"(&H3S@0$J DZ,9M0R3+PHF)Y&;HH4F &
MK^=8F!TS,V*L;Q*[:^M:VIF518>?_QJKTZ86KJ?XBBM#C9::TSP#,",RRQF7
M8UMA!)&N!$74++<^8UY 9Z?N8['\U9JS<1VL8^-EXAK*^;0;X>^3I1$XC^_Q
M%AU_:V+F22DX;E#L$C>3\OSB"ZMS^BE.;7GN/5!'D) @1UKG5DB2Q"OC@TI/
M70R,@%^8II"M"'?KJJ8N\) P:Y@C+X5&&[^ UN([Q@*<X1(?Z/H=#QS'H/1=
MZ?+@;5CBV0]F8'4!2C%=);H&$DQC!9NK\;@!L1=)TAXZ?PX<(2!1KB,N:2IW
M 0A;G,[@V T ?C;"@'T-RW'*_=<3UH:L#S$Z,KXK;AM=R:PI.HJ7([[,06Z&
M8U8#HJ@#"2UQX#!5B+1T4:\T0M1-=U(C'/$-HN@M7J-^FA F1%$JJPNC;P)@
MIE1V7@17"=^"LBP8\8*R*W 85;D7A&XA8I8"[M<PP55#A;T8Y=]"Z)19'U,.
M5!QAKSI1N9^$*^O^\1UB?X+=L=_'Q#9/CN\\.#HEAGP)"S79TK)J.61AX^J\
M&ZRG?>G_;^]:F]K&LNU?4>7+0)>*QH1'"-.I<A+/A)X$N$"Z;]>M6[=D6P9-
M;(N19&CZU]^SGV>?(YE7GIWF$V LZ>@\]V/MM3Y3CX9Q6>K<E#8$-\7=J7F&
M\3_:N@HZXRF:^C\__/##_R:ORZF;D'5K'*"#>"PTY&]M 5D^<CX'XX4#;4N\
M/YE;_)4A*KW>DI*7EU7Y 8@5[DV%X6T^CU@W9+FX?66A@(5!LDO* *(50/O7
M7?:9L7HB6OA2X3ZD%F/BD?2W*W/N8O@#I@2RHL;P<,CDPW_DW(OS/I!&*%@9
ML@*VN!N4S>/S;RW:D4.';@9\<S"C6QX0C4 7&P[_QP9ELZ0&%F%<&HK2'N;-
M56Z<*SX W*OKZ-Y8J%,@E /R,/!?=(^\372>53.L2V5OA U. ,L[@Q&4^TJ2
M#M"3T"SZ9<F7QAF5\_SZ)EX^+*9M/.B#T>4RA>9WG$+##'+QF)6!T7=M8E<,
MW$7--5&B6[H!B9:I=O&T&R >2J?>B)RV77 _$/5?)N#^R3>[3NH^#!)#><=>
MTD=Z:<+T&H_J'A+?PKT8@HO"L;8R?XP3$WH0FG\^I40*Q '8OX-+BQR"6<%7
M*JZF13[BS%T+4S"I9O4LZCS_ )GM2H+25$O".Q]N"L"O[?.9!"7K0JA(M(J<
MM"8F:J82XZ"C.)&'*\\+Y/#M?'F%OW%L?6<Z ("RJXC<JU(3G&Z!1G_[;H;^
M@ /\HF.$93EX*Q4=Q]N1(@TS):0(VZ9]R2>^.7,N41O; RSQ>^EC!J8FJ:-<
M&H7*;9#)]EM&83@(!LW\-HB]"9Y;MY=B-LW0.?3[$+I+4.<^%?D<;#;<V/IU
M,#[.CR^K6M$1GNF>PVBC\WST(3CV*_;S7-N1'A%:,+O(2$I,+R&/Z9I/-!UI
M(8.G0\VLUKVPG Y.=.HW[O'XGE(5ZXP5="WSKBB,)P@4[C_$1633 .\5=!4?
MT+G)W=!-8AO7O0Z?*#>,[YRSZ<N$NVP P5WW8QF>($&9.\-C=,U$JX3+R,/0
M':D7 2N4"(#C;,DK"C.AH>__KDEUWDW&&2-WC*<>@@]X%\2B)CR3L;4B&6%T
MF_#U19X@%,_ ZJMKW,;80D<I;BTHPKJQHG+N1#E"/-(47J(1DD7<C-&LX"DB
MB)R((I%/@V_EF'LLEWA(#F[K,0?WK9IGG=R,?8^O?YM=X=[^RL"F[LS'X/TS
M\?&D'#@F^,9M# [=.NVRMB [X<RD;(J72OFKU1@![!)"T4F;5 7"VH6E%,O!
M2_F?MO :CU  X;"[:[6G(?%6CA#>+ <8A$8J)GE5-1@P<,Y+IA3@\E]@)7%]
M2N4#[K.UP#Y=WE' NH+P]7)>C-#<R1K$]494"JC!0@4IT%E@.19N'8!RAURC
M%6F"T#7=IPRXB):,%5>I_YVAN;#W6W.=X_5"P R\B.NQAVZ1D&'AVQ-AP#I>
MCLZ5$9K4G IB:SJUWP?Z'#@Q )-&\GQ,5IF0V(OR6U^,)QXX/G;-:()NJ<M)
M<X6@$YKV1#--6.\:&3!/W'=7M22;2U!-0W+70CRI$0J.DR$''#!'3.3-SZKL
MPHT:5;07D,PIHJ*)BPO786K/ZPNE=)J&@^2'YN+\N@;.D4"_A>QAT%O3;M'1
MD*$LJ\[^)\/()+XGW3&+D 4X]:$.?VGW6F;#+:R7::L4RKH\15+2V:R<7U'Y
MA_OLG3L2G#.QJ)T96Z.,>JOPOAT>L@/,:&'5?J><4@R.+6J-N3+*^#R?BBU?
MS)'B(>4J"<A+CB4+'$A,MOX?R\EJNU=]<KN[K>R>4(0Y;FX=&IL9SI"<L4E#
M9_ >>N^#"1U*-]WR<E&;;;5>QMH 6<9+0"<B31OI]*3V71GL2BQ-/ >-?%$<
M&XOY!C2&R5%?]E2<%2#&IS+ITE2#;LC'S I%B67S.&H\QYGDV9"8Q/GMP5K(
MXW1#,SO;=DOXL;VCL^00\UT%>39#Z&!8 )<,@ML;EPD[+0V1!8S@A?74['*F
MB5=4%@[MZ4D)_(#BH[4]>(LY1S$BT'KP"$@SA+<*QI[N2JCE@* %>2J4D&Q9
M8PRQ<4O@@_H$(\LU#OB$#F,WCPLJ+IE+ ;==.O8XU;2;+6%I,:V;"VF?PRIS
MBM1@Q)Q2'5IQ'H+!,=%"W_!!B%E>L0ES653-0O$^X'0S4(BRQD:-7(3MW&IP
MEG!!EX-]5>=3RDI[[6&.V*9PFV%.,EJC\FQ.' ?HX"V9:?1$!+E#-2F.S1#V
M($@X<7]*@:7'G5#C)+S:C8;'K=SK?IU!_B(GGG_T/"4?0#U$;!$I[\>>.(X<
M5><8%TBSZ5HC!'"TDQJLS6*NU7'@P."LTQ:@I<35"%Z7+KB[ $4O3+SN$AQP
MF+O$L<W[&(E?,/@J"LWQY?*ZVKK+LE#!!FD-6KC\=$,?JF_O)B?#Q"2LY/QL
M6T?%K :"F/%\,+QOT)J18D !_1 IZ,@].YN)F9N)6J(Y>9<L!S0AIQ:Y%U?$
MM&[E2_,L7[,F-*3H;!D6+?Y^JE:[;P;?8RWIUU1K&0!P'T 6;2DB(\)H:B<V
M#2-'69!"R2#\O7 FD#M23YS'"3]#4QDO$"HH++*I1J27.?^ D^QE63?0:X%M
M1'!JP\52!36\+*[ J*H1!&G&-/YN16O^#48:P2\MLXJ2WA1RXHE$D[ZS=A#\
M@,DD#[/ "C+80V6.S",#@]!MP!8Y<M:8G(TV^81$1E1#8=I9+#5I;CA-Z8Q!
M,2<?8896Y2U@E2PT-4_<]BCA0A_MHEL%>]U!255#K*O1MI;#8Y)>6^^<4Y(
MP9DW&2VN=>R=@J&#%'I"*#418 S:DLAGD@"ZP9WI]!%9ON9!9LI.[;,:-4&"
M'08A )0?J%//H"PB6;5^2>2VB&%,?)90=5;$2=VUX\4HSD?R'RW'C$ 'ZE"F
MSE\JFY*=L329%2, 0DQG^NOHW%3/R]-PT\*@:NTUZ\6UT\JD,93YE]? R.81
MB2W6*JXOU?L:/PFVR3&N.\)D!;XR8(;1*YD+#(E063!.8ZB6<P^G0G"K+%.'
M7B@CBE;<(J$S%%6BHN_4!/- 55<.!43?#_KE"FNSQLH<6>5G6% !'&=T1@J7
MW*ILZMP-DT75[N8.#RGX/R-;BP\Y9NR@V[3/O"_(86QN$CO[L$<)*$U+QB:4
M%FG9RA#YYIK]6?9[,5O,S,5JEA)<A8MJ,1CN-E4DTG;?RX;3HCZGJ3K!OE7P
M& =-7 >P3<!N,3V@O?>!=9AGE)IL@D;YMFCS");0:@(^0EKP&%7_4T?5MQ^C
MZE^TRC!4;6$  SJL%9IAU\G/"Y"F>ML_>/WV\/AUXGXFIX.#_L%I\F9P/'CY
M6_)K?_^707)ZO-]_F[@_?WY__%NR?^"^^%O2?W6Z?WB0G!XFO[[9?_4F.7TS
M<!\>#Y(C$%P=G+C?]T_V#_Z9'+X_30[_D1P>)\>#M_U3^,A==/IF_\2/W=M!
M_V20PCV2H^/!N_V3P0G]]?Y@_Y1^>_E^_^UKO-\Q_OUZ\,O@[>'1N\'!Z9^W
M&O*SI4F62$@DQQ%]HSM(]D&&1J2R[RSB@WL(!;V"T%('C,4M'\%IL#WA_64Z
MF:>8S6<,0,0PF9I0%PF=5249K0'2M%2I-'D9LMSI&&G;[FC;?4Q)XS=_Y'SM
M*;B,*/T$:*' !+D'9(HA4.1\C"$D9 >UA?")(_4"F$ +II;GQUX067KSTJ C
MFS+ A?A+?<"#(NH,^3'A4(_T"<IJ; F,I98J.^18";5J,UY$:7!%W!O<,GB%
M#_EU';].&*_G(B:)#RRA7CTE+@I-RN!].>/PX);#0@.P/UMX6;L!N?'/EX]/
M).II=Q(VSK'<T+DT*)K*R*Q.8E@T@:=Y*-=B2"3\BQ#@*0W>>-GK1I$+ @+E
M$M^C,5*V60P-N\82^0X6:"'@6'*=70H9"*,ULJZ4T87P \PX48T4K&V[D##@
M_&J)!MIP*>E><EU?W8(9^<H5:/BT)' ]E- A=E^FC ;'M:<HZ%<OI5"3@8$E
M]+CW/GCO[>2B[U?#HJGNI5 !*E+*QVA24AJ_DBAKK!]4Y7#V$I</SC&K_ X-
M1("U*2"MR^DEA3/;F=5EES/0"^AFNK2H.:F'A#G00T)@#91DD%QI!.L H0,H
M';N^64C74T%W/S".#VLDC:D<W;JN\[HVNY[N/!P*<NV9+*8<!O(HOHS%9I9N
MW,H+#92/@)7S(^U>8$1Q;K/@;QX,KAS3(KMH/ (RRZN.,CPFBI]PC5>@#?#]
MK^EOCN!D'^JLG+]G$5'):U[4E'+<9Q8J^A#L\KATA<3)ZY:(Y<O(Y)>2?6+_
M0>^"GLX'"WY\9QWW6YK>IEC45Y (5,$)OB'G!QK!*%DF/GX77=+62;K,-7C*
MKQ#]EZ15A/(]@DGETH3 J[G,U5C3?=3$4VGAURDKUXDXPAE>=YM 5"$^%K$]
MN,=.,]R%81L,F_[\H75I/&FC?Q"FB4>3(RS I)E=U&[1R6\:B=F"0$SG(IYD
MLV)Z_3SY&Z0%Z^0@OTJ.RUDV_UNXR/$ M(MRFD\@:E:,?WKRQWAWN#D<;TYV
M>Y.GF]OKO=W>UG8VVAB/=I^N]\;/1D\2O,@M&W1DGW!(Z*<GZT^243Z=7F1C
MF,;Z=WV!O0A_FSTC"#XU51",@D_&TAW\SAM;[ITO047 '9C2[*:\V'L271KN
M/!U;V^+.Q7;+QGS1BL/18#?C;^DU.M?<O5_"?1 .SF<8K!?O,K>U]0%D6(]
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MH1M-$S-%[C(W[C4I< [(<-T^)$)<%I[66/ &RG)8/2V053Q'M9\!.Q) W\D
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MO_\X+,?7^,MY,YNZ7_X?4$L#!!0    ( ,6J]5RH*H/Y$P(! -Q_!@ 8
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ML3#\<?D8^JO310JN*1"@[2W&]EF0?2W$CVV6(,G+Q@7\*2(-JYWZ1:V82G6
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MT$#RL6H8-]?H/&0M(>BI*[99V 0[,7DI?A6YOY*2I3KBB^2J-@E)0W(P:9V
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MF')=>'\M#TW#YH;L8@DF'$S-KDHO8LZ4BX"98 ^/+N(D'<W&!)VYPJ2M1Z/
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MD01^$'K:HY$:F%Q@RJDJD!(,*"(]%Y)V@<6@P8-,)4OT?+F5CZ>#PCX&%"I
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MS_1JAD)A-U OP:TIVKB4UUET ^M;J95I2, TJ-PFW*-W#&[%$U;@?R$J<0E
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M&58["+RR*L^K;%9S Q@QO>CU^+A9\6_F[&ZF#I<P*P./+WR:^("!%(=M.UZ
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MF7(*"QK ]N6PL'ZXK@9_QWJ?+;IS)I8E*:U4()K:1Q3CT2NQ0!D*I($7PA!
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MO>^5< @KBFX@?&D(Z[Y$#; M3C*]A9:>#,0PJ[GFY']7L"(3+K>;9)=EQ24
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MI#,8]-X==>$GD^7LXS^Z1WNG']["E_:3XSX\AQ[WH7-TU.TG^[W!R?$ _W(
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M#P_?=X;\4.^EO0'-'^\&=8]ZU7@TLJ3S%G81+G,8@/> 8]ZQSF^=WF'G;8_
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M7H0X3A+>?):ON??;W9]H3$TF%%@IY-9D?D&#63M_EN)C:V0#%K"X#D^*#H+
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MPQ:;5'8/>D>]X>-GJM/7U08W7%A';ZB%.7*!P"V1#UU)_P6"3-O 5-YRJ9H
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M<8$(?$SSDA&C@$E"V8J0=EYHH> -+X@([6?:+<!0%,,C:/X%0TU%"ZH'+R]
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MO(3U;:U?JC<N4=*]2$#?8+C+[T 2:#3:E"6:_O/L',7!BFY>>6!#I?.2'7R
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MPQVCR<(2.0FY7IGJQZ8" KNI6KN^,K52O=4NN0GT8%V'7;J).C;VE8VW."8
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M77O^J<W!54Y#VA'[[@#CMJ&G17*-%6LPX4> )_5F"^QF'.56K:--+0LV'DZ
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M[4D#/6=M#2QET7CEI&2,D:MY%MFW#$P9M%4[N_)EZ0FE8M#O3'C[RAK26N_
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MGN.N\[YM(/S ^>_GCGS_CU+3(6UU^B/U#94SQM= /*9,C^^%*R_WOD04/2B
M#[_(UK]#H;YT'FG>&D0IN2C03E7MBYKW5,4CI=$_C+XLU+G, 0WKQOJM>-^<
M@M; L,M%?QPW_LK'C?=XF_K.E\>'#VEJ'[JI/^-Z!,+B#P_\K3WPCC]QX-?C
MAV6IBE3?BN$#WH?_95YW.?IX*7X87E^?75[]VNYW!S9V/K3^QS.?:\U?\8]G
M.C'"IY-=^J,C_M#\:=7_ %!+ P04    " #%JO5<_=ACR)<>  "*GP  &
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MX/<):B3XF!:(1V:$GL(>FP4L#-KM+E7-1#GF8T$0P5(4/*@CEC"@Q35YC=P
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ML$PD)1):!D\#'B8R1]A;7HRL6?7Q9,!^.X=_@-IG EFML:1$_ CI%_\7N1'
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M>VI7G%%P9B%>-"/0%5$T,(];)*W=[H#3$MU"[:\I.FE0C038^QX]V!)TL(+
M0N]V/G<L7!>X:U.9]M]8 B%[)WB*PF*9Q;/XC*4G&3DB040!V9'S,I95^T/G
M42'+@0CG7%1<\SBOP)V7C,O<*GW+T "X=SIOO02@ 7XO,Y<[,%67G<<6#Q@>
MA$\[9.O,<D??!,MMY>"I=>O;Y*!?WYR=W),-,^NCU\(F^_3L&D=%]:**&C(F
MR*DZMU3^!JGSW(:ID F5>&HV#[;Z]E-['MK3M.G.9K18H:5*VU0X7+2C=Z!Q
MN[0 "$$P$3P'Q@3<K+%#)&@Y8X#*9J<0RF)-KWLX5ZT65RCKH"9CLA7ASBG9
MWF2OM"AD4W3F I1+F^$$2F4N70X4"J!>7.5@FP:*Y ^M_SIP20A9R5))S3M0
M.<S8#Y?B ;;(BI[ ;F>>98Q$HHJ%J%V7WZ(E.D4MOKX&ZQ)G+DO'34AHE&+6
MR5U$4S[/MGOAR18-Y'ZR5-59DPMQ&4^1!?R6!/&120VX]K%86MT"(AW/==CW
M8C:(#UQRAQ7R+>_E 2.,>+OJT$J@CQ*ML+P7!^YI*]+.O#_<!GGA=WL9'VYQ
M05 8F,VP>J:Z9I2)R/=!\.7L2B/0J;=@LK6X[)+>@JL)Y9*/6]#ZOL<1OJTX
MPF;R34CHDR31J&V?X:?!2KTA!N<]?5WO V49U+&(SF*&:?,GYLX1=$BBA+O9
M;1HF90?$LKB> &F,)RV;QW.Z<@*?1N(''35U2\Y-V:!SQH<.CZP$PL=M9@$^
M[4&P60";RQ(0MM!6<MQB"41'3B[IC@?-K[PI(S=1ST-VY$RJZ99-A @QXC:<
M"WR7HL28MN:3$<@:BO?'"LJ.213Q-:\>5#FRXNNW;)T5Z)=?EROIH8ZK+Q6S
M,0*_F:?.WE^1[NAS75$W0/?[I1 5'MB^=\"G98,T8#;37&-$1"%&,3Z3^ND'
M+EE+EN2YM:H:UUH*E.:)JFQJ-"@<*K/ZKWU^K%1J;/H.GX()232YF&8>6?!H
MX 7KW?B\]$U9)GF#Z6<#.K=H(N:RD#:E<X")V*G$1'N= C2%&F&F.NH-32E]
MZH"@7/4!(&-N.@L#2R(=*74)/V:A> _..A_80X,YGV]@CV1R&24;+T<$L"(\
MX@0(82'G%8AQA*5JX-R!;2"N$E'5G0R+B.N0SZ-V-0UMWJ?/4%KF.5^6T!IG
M>B#+FX9L:Z0/2I&VG%V";I4BKO,Y(<(&\(@?I1W2NV8[W2:Y-#-1II9AQIG>
MB#?B/:8QR/TB]3_B6IAD+^(\[%9\K#-K.E@OUO2HZ@-R'J!ULLX_1$< 200L
M=Q1*Z( +&]^+('6HHAM)M9EVY'*+=/2[S@AT6',T9%!ROVJ.?1WER:NGS?$Z
MD]'.\,O3T:/2SOM6=3O#^BG<MXFL%D@D>JKGNY66+93*NUL3;XPBL723R3I)
MF[V1O);K7#DNZW;@7#BL$+P,>9A"VCQEX'$+90.HBH4P_F*F:,38:N)D% 5'
MLNVR-I<,"Y_Y&J:$@^X:IZG:TA>-;U0@GV'PN, EN,='F U,S-FS9/*NH5=<
M!#\SX# 7-3H%>#^=PLH=4O,;C/I3G@RL2* 3_-K$XR##2SL'HJ7G(#G)<8%C
MEU3[;S5RS'Y@:PL'-)G/G*>A.ZF-ON9BF2O#NOY+D=OHKW19%: *)2)M-,Y!
M!536;]C+2K"E5UUJ\,3@RC6\O(W("D=4I:WILR/;J#'FI.-& <A: J[+"'DV
M!!-5&\X#'CF@ _,:&\"2AO.6NH*4$*0)$0(KC<F)#R]W A<T$RU+PSBXC6'5
M-A\%:*<!;"#V"4,^;1ZELR+EAU0"=H/.];,L+T7Z <CW)YX(5*!HN(L9+E@/
M;-P#U A05DH+*];84/8^^A+H@Q8+<:%7UFBG8DU5[G+D^V$<\K'6G5@/U7R#
ML #E]@:[;=EFNG0:A:[@'><*#L^MMD)[97[K+&+6H*IYJ8CY],C[!;]B'SF2
MW/>0^Y<7\;^WA4*+Z?# NE%Y<ZF $9O7(A.4;X/F2+E<0BW&B>!Q6\9L?\DH
MR!)Y/:*")5>'8KW%-;\2L3V3^G$P7^F/1FHK)7,^6VMB^E:"B7:+]X8'O>@A
M"1(LM2Y1L2'A$J(&WB'6,360V$PV#QD.8ZK=IA@_&=[H$Y&4Z&"M<2PIHV(R
MTA3:6(&7 #%PK7@&U6O3NR51T&*X?89?&Y"<5 A"51!;G=0-&\6Q4%^@3MB
MIG=&E2,TA9]JYPE.MKT#V[^YM_4(]'G+[B";E#[B="4#JDJ]C>(1#A,>9)XO
MYBC\M%"/MU@$3K5HO%!-6;MR+ULVIKWVYS]UJ!JTJ@G 8<  L.-&B<B!& 9!
MT\>:P=HZGPV]1L%)P:B'!65N^$UQ[_;J".,M?YC&-=_#0M_#0NO!:U&-.DG1
M1;JJA+Y,0 _FSFVH1C7WWF0U*U&N4IN(! .I8Z[3$+ONB/K 3!?<E)'=,G%N
MQ% 0J80AV\,F@*'!.$<(4LIE(PN@,T6P_BA[-S(^HB1Y60(W_E,8I]H#[&!
M4)\7LD4['6MPZ@([QI!['%/:XBRT1=>U+;^-N\-T!P=42NKU1ICH(6B=E8Z=
M-6@R\:A'X(.U'D7M4E9.0 BD(=#X'EV/R4J?9E]AA7<6O8]6!LD:4PHIJ>9.
MKA5JE4/'#K,KG<IAZYE66+/QVY$WBHK\G5.(R-KVRPE P!%8]#.A^Q[U$\J[
MQRX ;4,>Y^' '#\L'X%S $!(C)Q>LY;K<8=N%9<%R NKX2E,7DI)3(<0RFA^
M&T\+/H;R"<'H(N&V[I8XUS+@>X69$HJKC.O^2-FPR,>DP0B0(?^554&=DW'@
ME,)!-[JCV93G,L5&.RNGHR8EEJ&@WQ!#;RWOL5F7;7S/Y3?%OB<DDL'RL0<W
M4A1S7DQK2>G(HWNM@]#K8V.,-)7!WHI+#@M5SFRF%GSV$7@'*(B- 0 -[;U3
M_>@E.RUZ:E7HPD3DFDR4M$$R-.8B<HN\D7$< NDM,C"!AZ!-B?&H$:@U<.I(
MVP3UMAS;0[+6O'H-NJ\\L)_G'1@"2"V8$OJ9<'_;;HG.$KI%;Q@@XI!P8WW+
MMJ (.<$C=W[L-$S=&;[\=(58KHM"?'^= ,1'4T;\OS'$>(%78[XK.OV==WYE
M.7296?N1YYV, (P3:0S$&)& 1H%F*.7O]">@6 ^&U('[XB@3WFN%=O38U/[@
M%+(V)'(OXF@W!8L?(FH@^5!@J<[* D6OC01S!'9=-WDHTQX)E"?!^>,?!RGD
MBQF?V>(,-R)3%29S-Z6TYD\"X'R%=+$&A'$?DO#IZF#H.MV.E"QL>XLLP@F"
M<2/SVC?&Q>_=YZZ'H3"U_PZ5-,X2C8%(&^U"JBA(DZX;78&ID&(6%J9?@D8&
M;&.B2GB?=*],\\:Y/B?<6$:2+N,?7E$+D;(%=O;UT='T+T!&8ZT,IGB-,1?+
M:?RH&V<-Z ,@'U2)H8FE70INN:].YC@)@X3QU>WT&FST VVWWUK7>L35/'K!
M@LWV.D4KSA3L1/I'/F.$NHE)XUH3;W4*Z&VI(O6&DJW7R?<;1MU#8)]4JMPD
M261SNY'OQ$(HBT(=%,;WD 877MM/MRNI6OOJKR"RIE^YQ+(5J+7-DN.V.;2E
M'B=)6NE"\F30ESXM,QHPC!:XQH$:"V21 Z'!'4V!'I7(0=JFU*JHK[-ODKS8
M:,AI6"15B:J=PAQE+&.@)[>M?E/=C(TK_HF<&KXK+,K>KX_>OBC!W8?4R*7E
M-69'**WY1/+*N2GC%LTV[!GZ7=^87_: ZO,#D\?W8-[G">8]PI'[0F?NWDI%
MI#XD"DM"7#$DINGCEZ ZVNX+SMN*I\LYZ9$!E^2UF (?=L=QD1N[J%;JKV,8
M> \YV;.^8,F$ E'_'MHCF$\#(XO4A[DL?)\CRG6GNTYN[;U;K#CO>O+<CK;^
MO+9T&KOJ%T5 ,';>T&.,,M@["JAOY3+L^[1@V"NLC'=7)V#9USPJJ#8\1\7?
M'W**#2V60$<!(R!7T1.[ Y_C[/(?:\U+PQ/ORHJ3+$)\H7W$+-1G2^.#'P.6
MRS^:L#S4@BE\A(V35\=8L(_$6.%CL&9$@H\Z#6[$G<>"1Z'=#O3M1Z&WD+O2
MVU)OEP,YQX4Q5N;8;-85TZ.SZ-]*AVB-8%-%<8E*S=J 4L(KO.")4?_$\*&U
M!MP-#J;14ZN.^YUV5IX]A)8>W,\5UR@N$Z4KI3OJNL?#36/[8(R:E6T?$M]%
M9391;"9<3X]^!RY8 J;8(3.(D66#B6307(.OI5U1#"\HR\>U+3 NUUM2C@',
M@Z&E:[#;\\Y:;'M<6*3?&=2'OZ+J4=G4BO89"V$'9%#&'WJLU"<>';?;^-W5
M(E#0@@[XR#UU1ID7/+1:_P<*FS-?I?4UX>J:E2S%%X]:6M@L,K!AFKR]+$A'
M [IT<FPM@O?7' RWXF8[R&5[[=S:EJ2>9LFQI\@["&0JKN@6(-<8#W?'.R0Q
M5/_8=X=U-:Z]O;],!"G^]QX:V4F4E>QSHSI7.93I4]5>#&#O$&C-DB_B&KG7
M+J[9-MY'F_Y]P<MJ3[/"*S',=7>;M09O*H%U-IW-]Y4U Y]B8OWV/>_<+5R\
M(*"P%%AIZW'!3/56C'\I/\?]B&=MJ.>^=!/X<.?:L0%)AUPEW7HC>*;$MOYY
MZZ:BNSULZS2P&C*9H;C8!W%12(H78NY.\+J& =M^$*2BX6A4XK],O;$92:Z\
MH05JO>RPD^L4BTYG.'L]$BZ,<D)5XOJU1GT3Q[Y;2;"ENAZB5O6V M=+ZX-.
M1[SN(RB'S8(@#E:72QEU>;'NEK++4LUR@3='>2]Z&&W0<VRA+6]L.0NL;KX<
MOF<=^%K7O0TQ=-;XE>EBK6:U0O7R]0:M!D:'PK<2]X]31W&;*N2Z0NE02>&]
MC:MJ-[XRE*U4U^^LO/*;:B,7.E3.XMF^ET)\3=[3^V05KL%-/X_;&TN/9-UA
M0KTB?'2C&E++7"U )_WVFJQ@BEV4:=P9-\Y=O3'9-MQG 8/GUE>#H34;4!XY
MMQIO%Q [U**/X]Q?JH>\%*Y)N@PM E>GWZX8- #'4ZRM,+70K3?II  %&:_
MC;#+3@R5FM//EB>CG_D7[J*49Y0IY7O:G'62J:/^$.]<3G6\2Z N:8IS9PXG
M4?U7R-6+ZDZZ*>&=2),OI'=A)K+9O1O6Z>RNQ;WPC7^P,*73-@>>PX"GK4=9
M[##9SQ1W_E-<5>B'P>F2-%VW-! L"-?ODJZNG)78^43I4K11KTSX>I8ZVC',
MI7<9]H2MN%'%D@&\7L6IHA$=J*YM,[;>IYLS\=:7T)'#.IQ]3J6Q>@_>_S:+
M[A*FO/]0U[C75OG8#M@8S[!G!)>'NBV<.@]3I]PG= 6F"H7H +4]/OTCJ^:F
MJRUZ +1(<9# BL'F*_U%<\$C.0AY^EB7F*%=YA+H"VGH6@W0PUU)29OW2=\Z
MSYJPI24NG<,'2U?EEN)UCU2Q2O>;4.^MN?NQX.:2L#6PV:<@A2Z[6?IQ4JH/
M U&B.UUQZ+N(3T0>$04ZCK%I!VD!JWNAA((0:M!2!\X8VM/=O9//-7'@S]3L
M^;8JV^^"30!Y++0L=S=Q4YT*A;RS3) M!NRT*:QM0OX%V.W;W:3>:4Z.;7Z!
MO26A[4PK;#QG,?%E1PX2$D\6E%&H"/)W,^-SJ1-(U,>+>O["9XTM?$9:E6.2
M.5[2=46<;5-+5BCY,=IV/!=A7@H5$GD01%C-0ZBBWJQT4\?^X7#(3C^R]Q?8
MD>2D&;.= 5T;VNGM ZQ(UZX5L..*2QX]Z97UKRYK60P=V6M&$1WX%#4O<Q8\
M2@,J0*$D%/A=94%GMB>V=K+><4'N.Q50JS8G:'\KJ97*.5:)FY4Z]*>3)%M!
M[S7)J_B49+R0^?R0_7@AT<+]1<S8F2IX^6-G6%*S.VJL4X*Q5 8O5#ID_J<C
M>\.)N^T$O44K5#) U^N-/_>>9\/=T<O=@Q?9WMXH$YSO'3P?IMG++!'["3\
M]1&85(77#)7CUQM#^[O!6\CM[T%'CW3U6D>:._Z.:7?X4OEZ8V<#SMXL_.QP
MX=:VCTOKW=B"E[4LL]2LS[A.5T^VNW2R6TX0CWISK?[&\?\*[**JL:P-R=$,
MXJUW@W2AA5]C3/U%\+9T@K_F4N]*(F>BD%>HP6M>"5 \$P/"-WGRT(3R*!CK
M#OKL$<;<>W'/03\3FIACA\'C@;Z$Q\#=BHGN2G5OYH<W4MC=]L-)GP@L1D'[
M&P7C74%_:IZR_Q%3$-MOJ+59T:W5>XC#\A=E-=^Q]BE8^QCN9;(I]O##.Y^
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M<(=WTMOG+6/"YGX.N+ ,N57(M5FEY:H:L\1[IK6AZ)0 ++'@[<W[:QA,F8/
ML'H6]7K.P4) R6.%BXPZ&H[8U? --CIB-TV."^M,7IEM;V)[OE^QO:U,\EF\
MG3-D61'9V]9J$?]=/$<9FFUQ<5?,)A9H71%F%X;GX]VN;3*E^.W9Z=/!R<G0
M;6K WBM6MID*W[&CPA$?FW:WD";?&Z!EL#8P6XA^U!=E$XTYZ4&_]%@FF]]A
M]Q*.2EI1:Q]IUA6BAC9ZZHL0ICZ0\0_K,O CGGEEY+*[ 9R)CD.(Q!1.G\N.
M2S&>O\T4HN8,9=^FC8;'%YZ/[W+L3,Q,NM"FSHLDK]DIA0R0N%,EZ0>K>ZK*
MQ.HQYO*PG4<C?^9%)U 7S>57>QW2B7'>EEE $]!X(Q?L1^QSX6[PSR0N$4]
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MO"["'H1T##/2<\/SM0E9V()'-CFZ=7\&=_=&TX>MXFM$0;29E(O:'V0^.8^
MFCM=P8OJG AQJURG.#XPTK>$T"A,H:T7VM".<=]8!U>4_H)HD\+OJW_C>/AL
M]V!A_6_8T;J(+&)=LD3">E&K$ 61/M[;D-?G_DZBB)J%=914HF2#I;"^5 F\
M,9R;2R&M3Y 0>TOR&]18E@,_K?6+KO'IV[%O.WC:$7W9TII)G4=,8E,$&[K<
M7 X+WJJ!?V"&K7,5$K)C13;-M\"DS>WPBCIQ>.+$=:#X$8694X&X+K2#FPG(
MV2.[DEU"4P\9B[O&A+)SHBY[DB>O7I-:YU5H :7?_77?%:S**OS&;=G4@CBC
M?/6=R>^(5S-"0**J[1Q()E4#(.Y$:;@TR-C4%'B>G5=F99TZ@#V%3V:I2_N$
M+7@Z"7  -%RI_GK3'IF<_BJ59JXC] ,T*M0$$RH/+,C=9C7,$G3/%!1=K_6F
M;<&&-AG)^NRUE_BX1XZHG<4N+-;#7*K'4*>MUU?*E]=C@M7^2(+'8)U,U;CM
MA,A(F%Q@M'S<:25W")]+O[H-G$H/0<G2*6I=Y]HF*[@EZ63!];H=Y(I4''!4
M!K11UM3SZPENXE(7P7UW.Y#]2J]#-:3*51P(3"65Y[%7V%:)66T'ZTK>"O%
M4(H%O"+YM'1NB20W8>353$&X/PJ+L^;$JXG.3M#]V,MJM;O3F_<&L!OK1,#[
MLCE4#8_[;8/<\5&%U-:3ID]Q8>QGC@+WN"63772$XY'@Q3S_6D_/ZN_+3_&1
M"U<J;EHR'HP0OZ%+ Z/_2/O]#M)^C3A.=S;9D7%.C.'39%R7GAC#EKN:AIX-
M%RF2^#D-9L4M&(%RW\%$QB';2@XL;3M0?/S/("PJS^KN<P07* 7M*MMQ1260
MN9=LF MMOF4<LUKIWRFF\3O51C8"H8=/&Q5E/9LU/ <^5G9":15&?R60;AIO
M2*L$;5W3%1.QCQ3Q^I-OU'D&3P"([A),,F<,0O.[0RF1_^:+;MN@F6K-A ]"
M(12KAXL1?/!5)B%4D=2HH5UK41-\M[>P@ #[\HCP4B'9,Q"Y_KEN5D>H@_-T
MU%JV,:?4+I_ZS2:&[L>2B0<ASS=XD(=M$H/W@Y)F43)/B@>VG$1<SV8J)6"7
M!T/-B&/3O!3U?$*4&!)32MP9SK_,S:)-H25R3N\ @!A1/TNXZ/"7/["(H.^.
M 5#+B+#5'G(Z#74"X3_/I>673Q@[-[8+D3:,W@P:BN9F$75AN1P/M5X9 ?+5
MALX)+()*5F0B8G8U/:_W<@Q<[PJID^(9GQWBKEYNSBI;/N &S>4*3$B9M7L8
MO1:(=QB_,[%[.V?"5JPQ05ND[WN[F)IV;R>]9'[*H-%DAMA_Q%U/'^.V!-;>
ML;_K/==C?+4'/_R=O,M[QOE[LN';K_X>VGHY(,6M@F9X!75-Q'0TN %O-AK0
M-X)=^ ,L3N7)%H;,9M.E'K4.<JAL.-ZF%LDO&CX0X61S7,:S.43Z5+O8TW'X
M;I+/,_979K^NHZ)U*!;&YTYAC8_8)A74!NB/%K7@]-N#^7M6NDNBBL5_[<P9
MS#]YQ]U/\;>10JJA876'7^%@_2 45ERZ92TF[DDUK)Z3\.8?=BH!8<:Z0(YJ
M_ZT]WR40^!9LWR7AM?[WQU@_G"'V6C+HGFH+"HM["NHMS]N0D5S6S+"+ N@Z
M&R+TY70A%7>:M$ S4'-VU;DU&H7;U/L<0K0%38M%2]/>K.'U?3:XK6IS]S1B
M3"Z#<%'=) @%+;<LYR2YM,H)56PZ::EN>-E"$-]6V6L&N[>0P2M7+%Y3=7>-
M!<T1 ??*@O:\7H1*0LON:E1,<4[IFF2PNF4_?2<=^MJDD4MN==;XW=U6ZX0V
M>"D_4-DZ*Q;<T!P=;N<>:5<U\GD3=R8F3C[<^CK:Z?#B.FSNFQ#^O:>#3S5Q
M.N6=.+YX=N[Z:ETU^;MS:B-$V=F]RZ9W<T.O\,IA[6Z?YJ_@@W^ET,'5?PK_
MOWV5)3\J,45\W9QC<Z9!)MP#P*DI?D</%.F3T45?M$557^HIH# B:;I<V]Q5
MJ-*4T?F), '7R=T,X_95)W1#ZOPC]Q9PY;C@8_5T6IV;W;BHJR=\IMO7\#=V
M/ 3;T(RQ:Y.V3T!7M?4]OXKK&?%!JK .3FR0974KI(8*YJCZ,H?I#\?YFU<$
M-&E1S/Y/_\>]#BHZMK;2FO=P'T'@A"Y]X#:AN]ICE2Y-R%5^3J/B.V@)\NU*
MC97K7@EE2QF:#LG9!<OQ/P!H(.N62O3EI@9KZF?/2]-/2?.V%!YVO1^" WY_
M:"R\,.O8,^B/5.7O(%7IS<R;K'T3$6TL)_K<.S#=^\!$XE)>I"'_C/]LN\WM
MAE3<"?NU+[5<95/,_ /HQLN#7T;C42)/CI-,'F>G:G0REN,L3>39L^Q,):,+
M=> WZ>7!\ "F/,_G=+2HF#3?R[E,_/=(!-I/M A[%7^G*VE8DR?I;/B$B;IJ
M7[78W'Q4I3W/8VV8NGAY,#JX^E\%XU=9:M8B32P':\_@0G?<_1.UQ4/?@:KN
MKYLUP+T#=>/+$_M>G,?OS8M%^5]IW?O;#=@QKQ.-627SM0.=W1%/-@YXL[S\
MRC%/G[;6-AI3<#YO]64[1^51_)Z]?<NQL&;AMNFX?<%E[YJB&SM[VWDIX,J;
M_V[?/D1M8VN/V-AN\!)7N[T#MGV+Y1OG*. RTS6T&+\ID@#7MIFPW] _J+/L
M-,U.TJ?#H3H]/[^X>)J.QZ/1R2@;79P]/3_^S?S#C@+LWQLJ/E)UAWIE0QOB
MURG0/6K>9U%[]FWC=+_.&-YGSSOYJ8MYM7[W[O=_S1-?]\Q#3]UR1L@?6UO;
M[C[6MQS?]-NF7_JO;[6].^_>]Y6=76;_%U[::ZK(7@:=K\,+BL_"ZXGKJ^^Z
MFF_F<_IR1M=\XMH=6=G.G30'4@+'=C_*OMU$][Q)O?5IZR_4WS4<_ U?J!^M
M(WQZ<43_)0+^X/]["_\/4$L#!!0    ( ,6J]5SZ5G_,$#\  &YA 0 8
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M1:C4.?[ZR^JU[./_R6K>H"13@:IGJ9-&D1='T<B?C)+8\R;1Q!UCJ;F8^^.
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MI0?B%;+BHD)339JNOBDK,M-6QZ0:M9QYB($)"C">Z=8V-7"%1Q&]EK IV@3
M&HK*-&ZA1:<GX>]MG<HA"7Q=IS(UDXEN"R%@PSQ>]SPK$_KD*>OL5<41".-K
M$S]H!2+6Y8Z,]!LF 1=[5'&*<7Z>(M3A/AM/>.2.$M]SW(C%R9B//#^9.#&/
MO"<-6OOY\8O0O7Q%*7-PS#8&]*NB[&K;XXT/SD5&SFBZ]1F-#"R%QRJ%*^+Q
M(9(ZWEISN >GF8RRES9A:06&>W%6!\;C?:U**6:MP<*^7TA KU/^OV]A"R3/
M&G(J](T#<\ 0/47:_^DXGW\@/C7B$D8_XA*^<H_6_.%V<"V88%+HL*M2[]J0
MPWYMI_XVL5T:>"Q_>CB%7"RL^\.6)3RC_KJ59))H52,$I_*]<,R\T= )X7\L
M#IQX-(GY,+HWW [H'5[*_O'">=$2 IZ_ZW@_;2HLNYGC]^V WM3&$[Y(OY 2
MS99\!7V4UD$6W<Q.^R26LQM,-HY5,;2>5C9/W[=W@_%#3E]>9 Y9"-OJ5A-O
MR)';J!3![FCT-51IMN*.=OW@VYOYVB5ZB"EY[JYCWZV96Q#_Z\Z2XA9*9 )#
MQW(N<.4+Y\#&[[S97KS^N?S9.D;X ^L4+G$73^! /0P-3M:@W[T!#3"?KZ(H
M_7&^GOCYNL-([[I=T'/V\JL.RG6K=__;^L\ZUH^2]-?MLOLG_0]N\H.;W'*K
MG*75_&FPDX*7%+1+UH^]V8>_"E/YAA7XOEQE;WHSS7]PDF?+2="V\108B>WO
M3%?G.\[0<?\J+.3K2?]].8@]NCWIO]D2O=&0^RWFX2=@!!YO-@+WFGAO-@WW
M&X%;9EZR[78INLE(_)4VX3N;@?N,X#V+HE8;[9PPF=VAWR&ZM(7I& ET3KXG
M7)/:7-RE><-)MMDNWVN*HR]3"F,")NGO3GQC7XJ12D^<,%KKD6TIV_--.&GU
M*W+3;*/!>P%D-6S==7(QVKW+JFONOGMWPA!.72I;>+W)5#!%U^HJK(^W[[!1
M45+C;1IQV-,#U21F7W',#,.<:*HMV[%Z;M^^XT;Q;=FQ3$#+J7JQP/.B;!$%
MC6LZ#6YJOQD!I\J?405F@I"\4T/K/@)1R((LO*B"[=O;O2_L95 #;-2.$[6%
M@/O#YK;LT<!"(=!TE-RX>^I3UACN[KV<N@V,P-[$!TYF>P=GT\/3K^Z\T9'O
MT3G^A%67IJ=M<*+R@B(A<$5:,2F8 4%A%")2PH#IAXG08E$PQOV0Z"L8T]&'
M3UBQZ&2&U9T&,E<*[W$%,V.N!2 ;9<"G6.X3HY72;-#<5P*S@Z*\<P*[PH1-
M!,5#03&@=T*)>(W'5\"[E"_O-O5'&N?!1ZX71]R=#.W8\R=)Z$P\%MAL$MJC
MQ/7N4!'&]+)U[PA].N*&:(\>_7+CV[<'$9UV@S[Z6MT<]M'62N62-T*$155"
MY&PB\"NK9##_M*J ?=+)FM*&0GB84F\M^K5..C;2"A A\$K'.DUUG%=_VV^^
MH>TW/<ZW/E6_>1>L=[NI0C_9XQ#9(7/=)(DBAWM\Z$S\8#QT1YX=3:)HXD5_
MF>/PYH&.@RK_:7?#'.L]&7,!NR\+GXK@W&HM\V:7< GD<0^<EJXM:O?<21]N
MJ]XDM!KBR1W1(MY6]7C'$2-KOJO4Y/TFZ(O.4H0;B8%#+EM7"46FEB9_:E3H
M5K_WU+V9UKCOB".[Q:A,:TJ1GJB";ULUQD =<%G3='/D97^&I)%TR>9E+@K<
M*DP$S%>B4N,$JB950SFA1A%R796WT*10U<HU+;#U5@W:3&+Y4*"<&3_*VO.0
MK=;3V57MGHEDRO0R50"W&.TM8&&;-YN:2#W98H7*$ O%>"A'4W%J.;*M<MN$
MY@FYR-VB%CJ1N++J"%8 P5GC?VM<"R-B7 ,SE;6<>B_#ELN^]9==4] M$ AQ
MV"6<IKBJ-;)/964IA,.KIZ_+?#2+#% XO(:J$V=_-5<HNU(;P^%=P$^$A(&/
MR RU@N?);D^O=6<&G"AMX+ION=O.5RFB?62BAKK &:74 ,0YKHLS$VI4#!,E
M9$^F-ZL\BV6#S%,3U"/.H]5"Q?H/FC@<.*0P!<%TCGQU8,&Z+_"O&A1QH1=%
MHJ'.Q9JKLT)I$$4&*GRC3DHK0DPOK1D<-B "(:;=)<-;%&U;_>1 1X'6>(.D
M(M/U4FK3" >P5LG19I2].&\2V[FFA7X%>A(SH 2 -BWU@N(B LLQ!F6NM4I3
MK#=NF<^I@'1IQ'CWX">@M#%A6-N9F3H=H_=TZ.K3<!XJ8%PEXOD)0,PX103:
M<"71H2D$'I,A# H0T%DC0U+DC*A<2$HW*%6XOR327^*.P3S'"5C $\Y<CS&;
MV8X3>VP$=P[F^<%COF.,Y17TUGK5W@/K5>Y#ZE7N7T:OFJYBH, K5=NX7[OJ
M"F;@?6BA-H6'K#12<UX#=\'D20R)J9Y1V+4*"J;.^@)N:Y3YDQA_PL1>XXX"
MAY#H-,"#FB6W1/J2.+I5_M*ZD1)$@1K9$<NB(&T$P$RYE"MO%E*17\&?!!@K
M.%J.[!)1?:D@H^)B @2;_.8UK)564W7UL3L-LL46ZUIE*N5LTQPB5A0ILN-5
M=3,0< N2HX%>65ZC/"QS^"O5"TOX8BK54.?G*_+4@+OUDI>@8A98M,!\61IP
MLT2@AS$LJH-DK&312"H;1Z+UDK8@RB:Y^20L,S9A$L.L1<<:]9V*NM(4<*&+
MG 9#+8H\J/E:UCF@K+UK:JYIH_5!W:T 7JL5#>.$W'FO*DVGH[,*.)+6DM7H
M++)\PS+/I"RV.@.44S4U)Y5"5U-V@19EHZ&*JH*V6GJE"3/ NEBP/H74$[]R
MME+[0%1IH83R7IT6=P\OJ[*9T]90@GOFO7NW4<EU_$LH(='8G3C<#=C$MCT6
MC4.;1Q,GB&S'9?'8O0/D\.-70O8?6 GQ[JR$W%H%\?XR*@@:*JS?<&,#=<6M
M[X0C0)ID-2<<33&E5DX:EAZ\2Y'Y Q@W7)V*5("[R>./1(9?\4:HQ&0A6E-(
M;S7;%K>=!@9F3;=Z_1IL).8+3/0CYM-BL\1ATDT&)*FTE 98U4;^= T*EK5E
M.C,'ZCXK*::]B01Q0_*4,M"922 I/!5RLZ@+ ETFXNH,E\VJ6(ERSS4Y>O5#
MWD+Y(>0;I=F8%99OQUK5<E>Z7C:J,;*(")59D)BE*NE<SEK#E1:X]#(56YEU
M8%C"MWX)NT)EN$N)4C\FD/ O4^"_=Q1.ITWP,FB(4QW:I@HL1J8'?*.Y40P\
MK61]2/0M-M2KVO2RVY#)2K_<I"AJJT(J$,T0@D'".)FV2]H#^5I8EM9ZV(8V
MB[8O*6C5 !!5%70GM#\@X)%Z253;KDO!R"U!=CAM,]*'",UH60G3^BH!^_")
MJ,U.OB&UTWKDR9U]M'V"NDTR=N-XXB9V,O*\X3 )1O%HY <CQMS$Y\E?RL R
M>V#=QG\XW<;_R^@V9K5B 4_=T6/:1@%#-K=N-GC%DL(EAOO3/%\J8S]=AJ0G
M "0]*23GHH0LR  F0H"PLLLJDSJ6L!W7Q.NY[*:\C>MWW1VWSXW5=7F@%80J
MS!21@'\Q;FJJRB :C@EI4&/$P&Q)KR,-A5P0>HK\"T+[7 =?8JI2N!<I:,7P
M.=5@I02'CL]IX*-K9+A6/+%BVT+46R3W@[4E-SV:VDFD@KB'YK<M++'6CDDP
MZ-Y:GYKT2J13Y8PY40,78:NVHZ39)8A>.0\FR$Q5VN2S(J ,%!X$/X:^3-E.
M&PF7DE/=MK,&)56$C[*Y$Y;0-]@J_A)2)!YS[MB)Y]D3YD7QD-EAXC(^]H+8
MCX.1^XBER-UB']X^D B9B4/;N/YHEJ+1K52HJO#"B1N0-/^)$#OD0["_\U6)
M]0AYA4<5#WEV#;@5XEM14"1Y,3>^(\N$-V)Z5411TSL-AQ#CZ1#O5$:0ZI&V
MYV[50%7&74ZWOQ''2:KXC3>YR65U4<9KV& )O*&4-6TD"FG/(+YK:%-;\'Y-
M/*/IV:?X4;PBY6W2@D92ATP+^J6%$G3_XAW/@_#I/Q9N=0\((7[(^=".0.,-
MAUXR&4ULQH:Q'3OAR&' R!Z490UWO<W8(!OR=:P;  *<8-=U;YF^(Y?NUA B
MMV2FWJ[C?-VTFNU,'H \WOBZ1OOC,YOQ^%_#"!Y\/[3V@+=KWS%![V%7\L_?
M$:VTOOLBD.U>=]HVI=S=_^;HW;AOUK>[+MYU"]TU^TX.YT9 E>_,7K[+IKSW
MA;ENZW[#PMR(RW!;1?HQ'X@-(!E_WI'X<1R^?5D>X$ \B\.P"=SA3SP--^-H
M/)LS\8VK\P"'HA=CXZ]P$#9 %/QYY\ .=O9YM &+X-F<@&];E@<X />Q+/=Q
M$.[!JO3#Z_M]O;XW)';WQA\;^9X/WMGLG[\>O#DXLZ9W3$G^BJX.#_9F1Z>S
M?6M_>C:UID?[UNR?QX<?3F;6\<F'=R?3]];6]&AZ^/O9P=[TT#J=G?P&+YQN
M/_BXI#?FQXGY*YR8-]_MQ+RYWQ-S6XB'L]G)^U/KPUOKX^G,>OOAQ#J;O3_^
M>&J=?GA[]FEZ,ONSCLL/^?/GG:9^*MRXRUQ[U]VTS:RF.[6M]MQ;/]/WLZ-]
M^/^9]3?'.OM@O9^>P@ZWIN].9C/\NJ_CUU\WMKL@A3B37;\/Q @&>7=@H3:2
MS7=!,VKJHSW01G\*HE'R\^>?61?$Z >&T?UB& UP;\GZ3BK9N][$^%+#$P^7
M&TZ%7^S@ 3&0ONGPWIFQ]$,AW7D,C?Z\L>0*]PF)M,14ZF@M,9&LNX$3&8$?
M,B1"8!5A&(?,94.__WT20;/&9AB(R#P_S_.8/EZR^8J<_XW1JZ)K$4^7E2R%
MEV"E-ZQ<65<.PB 2(W5+M$B[7P:JY)D(IR?<@@;_;$;)F,MS P;3[8CR2,.O
M'.[&$\XFL6M/O& 43%PW&@=1$@YMQTZB.T'/-*,9^FQOO=8B=32Z85B]!I)>
M$\G&4*P7K^V^N*N^1KZQ]I;>"#W83/U'N\QQ4R%N4A;E!19OK'3F)SY]BK@<
M*]@U=@M/J1E)A<7D$%*)91G_T@.XA* /<,8,;H.)PS&54*1,Q;B3(=/($H73
M88PDS73YU^[\+=E]6H@TBK*D](?$.B8< F [E)^DPENOK^6U8?T[)E[ST#6M
M6T_Z9-H.EAYRDM!WN.>'=N#:X20)PG XFOA.<(=RLDTBB3D_AI/I?.^3V4AG
MQIPU76Y1)'7KX,-HW="C6@ECFX,8!^W'3>5)H2EQ3)>ZSS!#JR<$M.]L/K*H
MT!\GOGWB[7CBA&'([5'LC2(WC"/;#[S1:,1";^+SIW_BW>\OBQL'5AS!D(.V
M"6W+=$:YX3$U4\)TM?('<=N*%U":S=F542.WH2ZWQ2XF^,5IN<3*E;U=DP8J
M'RAXF<]7I*GK%,2-S?\X/.W#,_$8&]F3<#)*/,^/Q\'8&T:NX\6^SQEG[.D?
M'N]//CP]E5^;M5X;-5S%?C=*M^89UP*S9(04AT=.'Y98@ ="PY<ILQ(6E2EL
M*UYCDW$TTA1YED8"!TOB5OV)1^&N%@>Q/>Y4-Q8-TNKBV5<W]BN&^F"&]'LT
MI3]^8WH_C;_9-')P9'TZ.#N:G9[".2+ P88I0@+M7C!,0408I+BMDPHP:;BL
M&<"2>5;;AS<4>?U6BUO_;$X/WAW-]JTWOS](ZQ0#:/W*&;&'3["G."+L/4A?
M)SD>T+TW'W[>^]"):;H?6JD%>6G]LJ+XVL[,1*Q']]\6XBS>W/\W#_$MX@UD
MM)]"#OP]@8UTUU:^I2#MD]F3-P2#WN>.[$;8/=!N;,UITUZ\_M]/?J?>D-AS
MQ\'?H#X+[5DJS]]>@QXE,LJ'MGOQAT+QEU H;JV"]F[LT[U?9_L?#V>6_1V&
ML7$4J.=8TY>$[T#HP^3W.A:V9+P)U  ##S#,AGM_QW-VN^[]L;-IZ#W1+0_<
MXQTB+7X<T2=S1)WK#\>;E];LHW6J(,/IH#"!D+TWQQO!0QR,VX_QJT[![9N_
MQ99O;LYZ1WWM%KEQP,+<(K\J1"?B.[%-L9A=QF%[42-P%JF1NX5KU7^KOW[Y
M.<SC-?UQ42WF\,?_!U!+ P04    " #%JO5<AXI(<^$1  "!<P  %@   &YY
M,C P-S<Y,35X,5]E>#$P-RYH=&WM76MWVCK6_NY?H6'FS$E6N-B&A$L29B4T
M26ES)VW:SIH/QA:@QK=8=H#^^G=OV08#AA!R>9,V7>N< )*VMO9-CV1Y:^<_
M \LD=]3CS+%W_U;R\M^$VKIC,+N[^_=>J]%L_OV?NK3SCUR.'%&;>II/#=(>
MDGW/T0R/&5U*KCS-YAW'L\B:;ZV3'.GYOELK%/K]?KX]JI;7'8OD<A&MAD>1
M4HU<!91\"DRB*D2IU-1*35'(EZL&465U:Z8Z=MQP++>E,W))N1-X.N59<GS<
M((Y-3N"_,]TG2I$HU5IQLZ868U*;(:F>#X.% =N\!MRX7&>[F8C9Z+L74T5V
M,U%=@X[K#=J>F>=4SW>=NP(4%)!Z7+'3,=(K0L%$1<:=DJJ41Y515**!XW6A
MHEPL1#5&#0;SZBI0US:93;_M7QZ/J_OI]<=5"WZL-LT'W2-[<DY6<XJ:()*#
M 4P0B@>TB(ZRF9,KN:(2TX&:-PM&BL5MC=.X>L!S_M"E?-2DH_&VJ!Z73(@2
MB1E3^HEH;Q7"PF15MDCF-O<U6Q]Q,C 75/YV#'R/:TZ/L5\4595JM5H0I:.J
M/*T>D%0*WTZ.6WJ/6EINAA/.'MYJ/C_H!YFZ1'9Z5#/@+]GQF6_2.MDIA!\D
M(NU8U->([M@^M<&8?#KP"Z*=<.\<O0W8W6ZF$9;GKD OF0*X6"$BN=-VC&%]
MQV!WA/M#D^YF.E UU]$L9@[![9E%.3FE?7+I6)J]340I9[]HC2BJZV]G1-NZ
MA,P5\--.SXLIM1W/H%[.=]P:*;D#PAV306PP-?UFFT2%;<?W':M&;,>FHQ]-
MVO&G?O)8MS?ZK4?#;ZH[V":6YG6972,5Z$$+?&>;])GA]X _6?YK&P:;'!R*
M)Z>9K L-!,FX?=R!G"]OBF'!@,@.=S5[0B[1R.6\#)5 ZJ;CU<@_9?$O$DX_
M8J[MF ;0.1CT6)M!M)/+.P6D5Q^+:DIR"3XCIF+I***[Z$<AS_"7Y'!TT"_U
MEN0\C=.==KVAF7I@B@!!G XY9. 177)(8?+0VB;E.X5V/7T4:8-(Y6X!:PL8
M.\1I:X<-:F  IX%%/::'-C_P+VEG-Z/+&6)K%E+L&+56T+88Y_:5FR$,0CT;
MW.64ZB906I8"]C?9>BM3;^5*.X4)"O79[R,!+2N0%0PM4U\3 D%O7G^4/LBT
M C+U?_]3V9*WES'2.?I=1L8P(]<.; ABPTO:91SG)O\42L825U%=JYC*^5ZK
MM7=T0/:;9UG2/&WD$SJ95M?SZNA@H ',P6&A,XT'2C1.6B[568<!5F(V83XG
MC9[F06>/5&=J,%M6R4OK^&EB8QB]#*H[GH@X-1+8$.H1L$ ?(N 0I8:3CSF,
MI$<]$%B+ZH''?(;A*#6@3OT;E?J"Y.3D! 1TB'$@*YQ+HA^!=U-S.8PF_C22
M;#@UY>2\*B2;G&I2Q P3]F@VC"<MT5&B*GX'P_6-N&)$4_UKI">8[HV4&M4G
MJ*&4[J^BO/$J 'WK"47 *LIGNF;&9@WS::@J8\HV8H*HZ-A<L$(M1#))<T%3
MCX#--/EP#I_+M:L91FR 9#-?2G3V?/T_V6!'W ,6)(IP"OA3%G_0SN<PDPY<
M4F+*5'B/7'\H9K[Q//O<(U*?>S@-4^,<P#9@^K<_*H2+$T#2@Z^>-R2 6?J:
M9Y#+X"6'^8SFN&<Y 4SGX[GIMQC5N>>X#H>)]D0;,"NPR%FG V@)%@+G@)DH
M.:<>^6(S_[<8;#S&O6[7HUW-IU.C??6#)/T>\ZG ,137QWU/<Y=VTTL8\-P1
MOM3,]$CO2T!K$6Y@7%-#POF?+ < @&%LNIM18*GR7')8<;SW ^&'#'BTB:*$
MW -G70\$:L3,>MWVFBJ7LD0M5N!_FYOK+X"2TF6SIJS/A4VS'O2<ICHA-!0'
M+BP6+GF5# DW77%9Z]<Z;$"-7$<S<2-UO-]P[M$[;@[/C4.SF]QU* L_Y: Q
ML@^15V/&G"7L*PY0,S);+*VQ4.)(W-+]X>1F3"53/[@- #FE2..-B$&:W>Z#
M",-2MEA)VZ/:34[K )D:T>X<)G8Z5I(B(,RQ',OEQ5LLF7K#L2P(J2W?T6^R
M( V/W&EF0,F_8)$ORPIQ 0KPGN;1.?LKT<+[K>CDX8[L>\&$'Z.SGOD]#R'N
ME"M7,W4HH=[;-=E8/(>>IHNI=EH^!M69!:%M-],\/9P4EQU8.<,1VSU8)2FS
M/<L'VX19#*8V V9=8 Y*8/X- &0*VL+$>&)O4)8S]9*:W9(WL[*JQ!*-^7I#
M!G=:V'M#^O_7\Q@ 8'" WWX<J!!WIYI!P(VD#2B9>B6K5.6\HKYA"W@>D4(<
M0FR?*D8W\)+[[+*:J8?AO%B9=:7?TSK5AP@2XM,RYEC,U)6\4IIGBDML0L[:
MQO\+V%;?+MA6'P&V8:WSAX%M=1FPK<J;[V![-2E.@.VJ>A_8OM8\?#HH[ ]B
MM-[3."5)!/X'@.Q4!UX:9*ORUIL'V0LG,?4E,3:L#M52ME)]Q]<OYAG)^&!2
MWT\^H+91T^;,4_.<WV/ZC4TYKQ$&RF1I=:)QS2V/AC@J[YB.-CIM93#NFMH0
MB_'9//D'LUS'\R%4X:9D82\.2SQPT<_PS]L1^2M_*/I D*L^-\BMA&N%)P.Y
MKWS?N?AVH7#Q45"X^H=!X>)24%B1WZ'P:E*<@,(*FM=B+'SF8ECYHZ%PJ@,O
M#X45Y<U#X<5[8\47Q,(*+-Z*67FSDBV5M][A\#L<?H?#KX/?Q7"X^,QP6"G>
M#X>7/'CR!()^J1.FLR=)1Z=F2K.'9M08&3\E3$YYC6?NL=?[#]9<.;YFCL]]
MA>>*IL_4S)%G9,_B8^($^=.B_YG3XK^7F\JKSN17OAEK;4F'+3WDF>&[HI]3
MT<O'8U#S\B%Y\_['</<>C7OA38GWP/VHP"TV*G C@SD!-X?1;L5K"=YS??B=
MDS<4UY8/:W+:LOT7]9RIB#;:>5LRKFVAT"JP$MV>>T;CX<=^WUX,F^;_-4:T
MR1WNIXAO"$XY?<V8]#Z]O//Y+'S^00$S=($EHV7Y.:+E[XH+_ZB8>DI]$5$_
M!$N^^?2*O?^=SS\DFC[+LAH\8?EE=669975!9%BX[]44"KVYT-OTLZQX*^?4
M\1/GDY5-3 0RD;IAYD%EJ+ PWT_]$2D7E+]FU22F@=G,#BFOI*U 1)M'I%I)
MR2<Q82J8B )(7%+7HYR*8X,]2JSP=58)U-ZF'KX;&3[+PD]+O\Q#UG#N5.7M
M<XUSK4O)/G.D9&M1K&RO9Y%LHE*6-&T]G]9\W,+O:3[!3NC I3HFB_,=TJ82
MXSR +VN.!]]TQZ($?T&UKV,-'KTJWX,H3CT>OO5IL0&YZE$/S"D >?.I_D6%
MN&?)#3R@9_M(38B*>ET8L68;Q*.F2%LG4J2%ALU#L[5<,TYHAVWVNAZE%DA;
MPF;GIB;2))T(2EEBB*J:8.Y38-,PRJB(#C!+7LQ66'U,:RP;Z 7H2AH(NCLI
MUZA-*VB'8\P*OL4 LV#^?B^2!C+-[ "WL8$/3>J#O,QASNG;P!D/VIP93/.&
M4WH3Q'!\//#NV!VVUAW/C1Z'864HE$*!Y5'B),V^D@23UA(J&(0\>G'5L26_
MQWCT4]0+]T%\*(^$_A+%K;@X%A>.E4.YZ'N-K0L>*?<AS*$:'L;A8J-D-A3H
M/<V&MA!<$Q1#J4_06D-!)BV0I+F.Y 0^9H'#*8,PRZ*@%Y^:0^)Z#'J(;/0
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MYLBH,*45L6E-88W&ZSMX1TR-BXM<H"LB[HRI]3SL%2]<X?.N%,(/F&QI,S_
M)ZMA.[PF9S<#JR#7Q&M91,>)SJ+.HZN.4FZ+F7,O3GU'7*%3BT02-PR'#K(1
M&?/#*E2H663TCW_"Y9F/=Q. 3^$X:>K-0HWFYTD#F&X<IN6?[B7JPP5).\9$
MM\"[YW^ N%;'C?.<7,YA9K?ILF0+6$7.J1^7)%B(>XR_1[)9+"KEY40UE@/M
MXJ03_A;]:C!A*L8)%0^U#%B3V^(FL G<N#=@/!.W@Y;HQOB*VJE3!\DDOL6D
M"[.T(U8*,[R\=56JOXLJU3]>E<7?197%)U>EN(7OO]<G7\O_^Z_39GQP5=8V
M?E6[E0WGJ']U=>&=[7N&?'Q>+.R?'IJMPM7%J;UQT+ZNM+Z>-8^5K4+WHG3<
MW-/\N].3C6]'SIEW^_GNJQ+T;\^;'[_KUP>5?3XHWEX=7C2+O0_NT?$%5T]O
MO(W3RT/U\GA#5YWAWMW/+QW5_%4].[)NKAN?-CO#']^"$^=KYVS_ZN+8KP;M
MSSV]>D0'&XZ\\>78_W';.[^UOW*U].G[]]*'XKE]_$.[;&B#PD63[ET5C$Y1
MN?A8O3!^E#\<W7QNR,?M,T>Y"1KLNZ%=?;QK[JOZ?O'VJ-GL-ZOZR4W SRM?
M/[<'E>M/&]<?^_M.9V/8['_^=D('6_U.\VJCO.=\N;[V/[IGI1\_/[2LV\;>
M1V8XSN6/5N^V,I"_'UX,M:IR-OCQK7^\W[R[5C[\^AG(@[YFM>7AUOFO;J]Y
M9169/!SLW5:/K@O-W?^11NL2[RY\O;Z$)[LF'2EZS3W!M$4U'GBT'O$DRF-R
M<=F(/A*<3QS/CZ50CNY+K'UI?5B1L$A?.9=G++V'<"$)JL*O(S@>Y8\(_Q]>
MC2=NTZO_'U!+ P04    " #%JO5<V?6U%@P(  "N%P  %P   &YY,C P-S<Y
M,35X,5]E>#$V+3$N:'1MS5CO;]O($?U>H/_#5$%S-B#)^F4[LF0#B9, UZ9W
M1AST/A9+<BGNA>+R=I>6=']]W^R2$JU*%QGMM?6'A%QR=V;>O)DWU#QSR_SN
MCW\@FF=2)/X*UTZY7-[-+\+_]>*?>CWZI&)96)F0TS?TSFB1&)4L)'U4A2AB
M)7)ZU'GEE"YLE[XOXG[8Z__>Z[A:RL)1;*1P.*.RJEBT3WGX_&.J<DFCJ_ZX
M/^I?CB>CUOY[76Z,6F2.AM/I)?5H-!A=M;?W>B&2BSJ4>:23#5FWR>5M)]6%
MZZ5BJ?+-#7WW12VEI1_DBC[KI2B^ZY)?Z9*51J4S\F];]:N\H>&@=#-R<NUZ
M(E>+XH9RF6(EUKDV-_1JX/]F'8H6?NFV\RKU?YW@3:*>&A_:A_A(:D,KR3<W
M%.D\F74:O#/3[,OJYY-R_2]V*1+QUX7159'T]A^U[2%O3IH9+859J*+',=R0
MJ)S>+IE@)*Q%VB029Q6ZD(C-'W+;"8=TL&HSD<"S^J)S]V&=J4@A-5?]X?P"
M,6^#OYM'IL[+=MF)"&G^SV1FI1*7\<W@SXW;#$0N2HMWFJN3,JB2V\ZO S$8
MI(/K41HGT21)IM-D>CD4;Z:CT>3RZO+-M ,H\[P420+VWG8&X=Z6(J[OZ_PU
MS)T[<[=C\=PE3=R-X]/^9 C7GZ1Q*A9YXZ/3Y<$,=N[F:KD@:V+ OQD-!M?7
MT^'E>O@/N1Y>]89X-ACV?RX7':[?Y#=-3Z[[HZLCICMWKU\-KP:S;QXR'O?'
MXY<<@IL=(O\..IW6SH9KWX)FU$#3<''KT_\Y5*&"?.'\9FGQQ5^J?$.C8==W
MR&]7(U\\RK@RRBG4GB@2^K".,U&@I][KY5)9BX;.%48?Z=$9*5V7?NA_Z.^=
M\9.P&6K Z:)+[^]A_'(R/<WZSHHT]N:T/3])RL23)(@)Y"CC=@)588&QZ&B)
MI&A#G^52K>E+)HTH)60IKE6)SF*("0GG1)S)Y+Q+JTS%&:TDH8_"!\<@K%2>
M4R2)-8GO7.;M?!NJ+I65L96 UCE-W\,K&@\F9^+\;'A..H5;BRH7K)+TV/MK
MEX2E4AC'C]@ 'BOK3/U"$Q7AYJ,VRT"'Q]XDG'0DP,0K[#,B] F0B072MXNE
MA5FLBUB:@B595P:*;I:\YH0JI ?82%7LI_Q(;OXNS8:<8>L;'&:[IVV[L!?T
M8#!BK."5R71EY;W6)?)!GSX][+W\3EO/M+\):Y%%O.N</<E.4Y5Q+H5AU779
M5@11BHVPU"MX[/2R7D2SSV'OMO/N\\/'![&0[T"_KV_QSU:V6P9*O-"+^(V>
M2!W+J<A78F./'+/K9RWM#UYX[:<!Z_\AO:O7(/G-J#!ZX:C0QN*0OK<0? G$
MA\:;>U\NEE3AZ^>]LIZ4@86>F6_C&$ZB!K$ UM>WS$S>L)LUL37.M:V,/(U?
M/Q9@BT&=CT-%=.OZ293ER@7-C[./SEZ_>C,:#68/JWM_-9R=<^$JQY$DLI3X
M!U4J=K[WR1O<T'#/GBP6R#E"E[E6SDEZ+980^R^Z0C?RQ@X<;'Q70!4FZ"Y1
MKN+&%..2<K6FVOBB3@$+T-D@HS#%8PHLQ7(921,(-@X=X=+#B8O)B67MO>?@
MA]<SBW0*DW 32I21L=/ 292ET4^A75 B8^6% SVP;I'/#WA1=/LNHN=A4ZD-
M<R0E9(6I\MQ NF5*J\\=0<FG(X#4X#-I\!DCQ 1%X9J&B <D$LBXE:1+57"4
M.%8PDU#9&%@-.]4\\F*"V/P1OU10_53!'G8L=1*ND7# 5'$+9@-N U6H$@S4
M%DHEN_[T+2 ABZ51"*[,>3B6ZUB6;AN;7)>Y* 1RLF%E07V),B,1Z<J%ME]%
M+'&.H4ET%;G6,\A8*8K-%D01J5RYC<^B9O.59&\%+33GII:-$QGT'LJ)37OX
MVV\G@"\:S^4O%5,&E:DTKZ*C+;+]RO:"U:#.>=DU&2^XB4R]L"&9SP7Z3#T=
M%.E(NI64-<6\/S7G !:T F7L<]ZB[2Y!(6%(3FE$#)7FE!T@9Z"/;V@AX\P
M/LF3(.S7L4S\\S"Q[ 6F4L\Q(ZW.?1UJJON5SZ5%/#9E%U@Y5[K*DS!$Q:+R
M[0\18<M2?.7B2@$>DLLK-?0_H\Y;L?HJ?]:^@28(44AO(31S[F-UH=8PG%RF
M%OWP&4_V6?:_HE.(QW_$RJ<6I6QL5'205(<X]9*NRYE_4DF=(P^L(#_$UGD
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M.$=E>,?^P?$/S"^I?.<"\/_?"^!H )_E1@K:Y>U:"?4_Y"]02P,$%     @
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MX(5,[T&*H\GT#J!<6:NJQP"EXVB:/)H2=@^U/EVY5?4".IO#EGT&"5YQP0W
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M"HG=.L-NY!1OCA9DZ30@#EI52F+,K'W8X]$]+7KF=FL?VCO\OU!+ P04
M" #%JO5<IT0+E=T#  "*#   %P   &YY,C P-S<Y,35X,5]E>#DY+34N:'1M
MS5?;;MLX$'U?8/]A5L'V O@J7VK+%V"3M$ 7B[9P^@,425O$4J1 4K7=K]\A
M)<6.G339M$ K!# Y)&?..9P9*?/,Y7+Y^V\ \XP3%D8X=L))OIQWJ]_:^$>[
M#?\(RI7E#)Q.X-)HPHQ@&P[OA"**"B+A1LO2":UL"]XKVJG.AN=:TS+GR@$U
MG#CT45JA-L=>/JT^KH7D$(\[@T[<&0V&\='Y*UWLC=AD#OK3Z0C:$/?B\?'Q
M=KMBTJVIS%/-]F#=7O)%M-;*M=<D%W*?P,O/(N<6/O MK'1.U,L6!$L++#=B
M/8.PVXJO/(%^KW S<'SGVD2*C4I \C5:J);:)'#1"\\L@G033(OH8AV>J$+#
MQ)=&P<PT:#+NB20P+'9GGB E]-^-T:5B[=.E8QAX$XZ;&>3$;(1J>U0)D-+I
M6Y.I@E2V5!O&T9?2BB/:X&0154XBM-J,,$16#Z(&\P%^-6D8'",)<<YY!!&W
M-=-42S:+EF]WF4B%@^FT,YIW3YTOYZDY&,Z6[XO=J/"4X%>8ECX!G8:4PP>2
M8Q(2"P2NA>'4:?-]B(1BZ#V!P;BX)S^6[Q7:E,) 6!ZP%2X#EW' C/=ED.[A
M$[&68!Y?"ET5#^AUV++B&V&=(>'@C</B"76$DW?:Y'#3'A[<W7!:&N$$IC=1
M#-[N:$84.KW2>2ZL]1XPL;@YW?P7=3Y<?SH8M((H&(*A/J_\OA<7DSCNS0[;
M#V6)Y\)J?_8:04/&#4<JM%*Z!45I;$DJS5<EUO9P,&EHW8W>JJ[%:Z'"S0CU
M+?*>'%'[ZE?*"J]?J7C;LB@DK^;.@T+GX:ISGJ?(OH:0:F*8G[ Z ZR?G%_$
M6DNIMQX;GCJ0]S3+/*^PU2YS;C88(%S(BN=B!Y\Q/BDXMD5:=\46;#-!,]R$
MR#$5#:\H/[0?A272ZD96K]11ZH3 PMZN>IX*>%UIN->6-'M4QX-^M5Z=9U?#
M6>I?^WZ?P-^EW&/7;H7.?7+<D12SX\<TZZU@+O.3WI]-W_.=5)+"XIYF]*2F
M+M@B^DJF(SJA9!#3:3H<TC>3Z7K26]-^W.O'@SY[$V$7DK(@C.%U+*)>-;<%
MH?5\>4B9HQ<:DC;+X[FWL$:#FL1HW.D/D,87;C ?B&SPYH(QB8U\^>*B/^[-
M\%W-'O4U''0F_6?X0L-=H-\#W.EB%IV<?NS5$BTO]\G=A+E%]GS:'DF3'JEV
M3N<)Q,4.K):"@=FDKS!5_=_K!P ON[:+GT2*$;CJP"41ZDD8?P$Y_;OOQPM:
MB?B06#]9J)]8,(>.&;K<_VFI1U[N^7R,?]W/QV,JAW$SFG?]MWD8U/^!_ =0
M2P,$%     @ Q:KU7'.6$0\%!   ^@T  !<   !N>3(P,#<W.3$U>#%?97@Y
M.2TV+FAT;=U7;6_;-A#^/F#_X:9@?0$LO]NU9<? DK1 M[4+G/X!2J0M8A0I
MD%1M]]?O2$FQ8CM+TF1 ,<& R1-Y]SS/'8_V/+696/S\$\ \983Z$8XMMX(M
MYIWRNS+^$H;P)T^8-(R"51%<:$6HYG3-X .71":<"+A1HK!<2=."CS)IEWO]
M<Z62(F/20J(9L>BC,%RNFUZNEW^MN&#0'[<'[7Y[-!CV&_LO5;[3?)U:Z$VG
M(PBAW^V/F]O#L&32J:C,8T5W8.Q.L/-@I:0-5R3C8A?!ZR\\8P8^LPTL54;D
MZQ9X2PL,TWPU [_:\&\L@EXWMS.P;&M#(OA:1B#8"BV)$DI'<-;USRR >.U-
MY\'9RC]!B8;RK[6"J:[1I,P1B6"8;X\\04R2O]=:%9*&AZ^:,# 3END99$2O
MN0P=J@A(8=6M29=!2ENL-&7H2RK)$*UW<AZ43@*TFI101%8-@AKS'GXYJ1DT
MD?@XQSR\B)N*::P$G06+]]N4Q]S"=-H>SSN'SA?S6.\-1Z]/Q:Y5>$SP2RQ+
M5X!60<S@,\FP"(D! E=<L\0J_3Q$7%+T'L%@G)^HC\5'B38I,1 >#]APFX)-
M&6#%NV,0[^":&$.PCB^X*@\/J)5?LF1K;JPF?N.-Q</CSQ%./BB=P4TXW+N[
M84FAN>58WD12>+]-4B+1Z:7*,FZ,\X"%Q?3AXM\2Z\+UIH-!RXN"(2CJ\\:M
M>W4VZ?>[L_WR_;'$??YM;_8604/*-$,J2:ET"_)"FX*4FB\+/-O#P:2F=3=Z
MJTR+TT+ZS'#Y;^0=.2)WY;<0)5[WIN1MBCP7K)Q;!PJ=^U1G+(N1?04A5D13
M-Z%5!1@W.4[$2@FA-@X;[MJ3=S2++"NQ52XSIM<8P"=DR3*^A2\8G^0,VV)2
M=<46;%*>I+@(D6,I:E92OF\]"DN$4;6L3JE&Z?C W-R^=3PEL.JDX5I3).F#
M.N[UJ_1J?_=I."K]*]?O(_B]$#OH35J^<Q]LMR3&ZGB99KWAU*9NTOVU[GNN
MDPJ2&UQ3CQ[5U#D]#[[UQMW1B"1LTAN-AN\FXVFO2Y,Q(]-WDTF\&JT"[$)"
MY(123,=YT"WG)B=)-5_L2Z9QH2%IO6C.G876&E0D1J/V9( TOC*-]4!$C3?C
ME ILY(M79PAOAG<U?=!7MST:GW 5*VM5]C17PT%[W/\.6&BXR_DY&EB5SZ"2
M/2Q91-#'*S4X</G0U14L+G;1W8*\A?M<6>\!^ ):>_I5>3><@U&"4]#K^$VW
M!>[S]AY!%AW3@4]$<P)_*)8*IEOPJ7V%[>DZQ:]'"?+B"7UZ[MQ%_E]E[T42
M=>OK9!)^I 3\/[K*_H;RM\I3KK"&EQ,_U_L_[L_U)I7]N![-.^Z_D!]4__C^
M 5!+ P04    " #%JO5<17J",P $  #N#0  %P   &YY,C P-S<Y,35X,5]E
M>#DY+3<N:'1MW5=M;]LV$/X^8/_AIF!] 2Q;EFS7EAT#2]("';:N2/H'*)&V
MB%&D0%)UW%^_(R7%RMN2-!E03#!@\D3>/<_#NZ.]*FPIUC__!+ J&*%^A&/+
MK6#KU:CY;HV_A"'\P7,F#:-@50HG6A&J.=TR^, ED3DG BZ4J"U7T@S@H\R'
MS5[_G*F\+IFTD&M&+/JH#9?;OI?/YW]MN& 0SX;),!Y.DTG<VW^JJKWFV\+"
M>+&80@AQ%,_ZV\.P83)JJ:PR1?=@[%ZPXV"CI TWI.1BG\+K+[QD!CZQ'9RK
MDLC7 _"6 1BF^68)?K7AWU@*XZBR2[#LTH9$\*U,0; -6G(EE$[A*/+/,H!L
MZTW'P='&/T&#AO*OG8*%[M 4S!%)85)=WO($&<G_WFI52QK>?-6'@2=AF5Y"
M2?26R]"A2H'45EV9=!.DL65*4X:^I)(,T7HGQT'C)$"K*0A%9.T@Z# ?X#>3
MCD$?B8]SFX<7<=<RS92@RV#]_K+@&;>P6 S?K48WG:]7F3X8;KV^*W:GPF."
MGV):N@2T"C(&GTB)24@,$#CCFN56Z><AXI*B]Q22675'?JP_2K1)B8&P/&#'
M;0&V8( 9[\H@V\-G8@S!/#[AJBD>4!N_Y)QMN;&:^(T7%HO'UQ%./BA=PD4X
M.;B[8'FMN>68WD12>'^9%T2BTU-5EMP8YP$3B^F;BW_+K0LW7B3)P(N"(2CJ
M\\:M>W4TC^-H>5A^*$O<Y]^.EV\1-!1,,Z22-TH/H*JUJ4FC^7F-M3U)YAVM
MZ]$'S;$X+:0_&2[_C;PC1^2^^1:BP>O>-+Q-756"-7/K0*%S?]0E*S-DWT+(
M%-'436B; <9-;A_$1@FA=@X;[CJ0=S3KLFRPM2Y+IK<8P!_(.2OY)7S!^*1B
MV!;SMBL.8%?PO,!%B!Q34;.&\GWK45@BC.ID=4KU4L<'YN;JK>,I@;65AFM-
MG1</ZGC0K]5K^-W5<"OUSUR_3^'W6NPQPP:^<]_8;DF&V?$RS7K'J2W<)/JU
MZWNNDPI2&5S3C1[5U#D]#KY-Q\D\(5&6TVDVB:-W9+X9TV@^BS<3&BV228!=
M2(B*4(K'<1Q$S=Q4)&_GZT/*]"XT)*W7_;FST$Z#EL1T.IPG2.,KTY@/1'1X
M2TZIP$:^?G4TGD5+O*OI@[ZBX71VAZM,6:O*I[F:),-9_!VPT'"=\W,TL*I:
M0BM[V+!((<8K-;CA\J&K*UB?[-/K"7D%][FRW@/P!;3V]-OT[CD'HP2GH+?9
MFV@ [O/V'D'6(S."/XG%@L?:&F+?LWB7&B4?)<6+'^733\U=X?_5N;W($5WY
MNE/^'T/Z_T<G.=Q*_B9YRK75\W+'3_3XQ_V)WJ=R&'>CU<C]__&#]E_>/U!+
M P04    " #%JO5<!6U^]O0#  !\#0  %P   &YY,C P-S<Y,35X,5]E>#DY
M+3@N:'1MU5=K;]LV%/T^8/_A5L'Z "P_)-F-9<? DK1 AZ(+G/X!2J0M8A0I
MD%1M]]?ODI)BNTF;1S-L$Q*8I,C#<\Z]O+3GA2W%XM=? .8%(]2WL&VY%6PQ
M'S2?[>"+,(2//&?2, I6I7"N%:&:TS6#]UP2F7,BX%J)VG(E30\^R+S?K/7/
MI<KKDDD+N6;$(D9MN%P?HEPM_UQQP2":].-^U!_'272P_D)5.\W7A871=#J&
M$*)A-#E<'H:-DD$K99XIN@-C=X*=!2LE;;@B)1>[%%Y]YB4S\(EM8*E*(E_U
MP(_TP##-5S/PLPW_RE(8#2L[ \NV-B2"KV4*@JUP)%="Z11.AOZ9!9"M_=!9
M<++R3]"PH?Q+YR V.SJ'>%[4+<"&PX:YERED2M!9L.CLF!>Z0RK:&4FUO8V1
MD?ROM5:UI.&WKPX98% MTS,HB5YS&3J!*9#:JILAW6S2C&5*4X984DF&PCW(
M6=" !#AJ"D*16=L(%N^V!<^XA>FT?SH?'!NRF&>ZZP[N]ZIC^A"S+C +7;Y9
M!1F#3Z3$G",&"%QRS7*K]%.Y<$D1-X5X4MV1"(L/$L>DQ"WP',"&VP)LP0!3
MV^5[MH,K8@S!A#WGJCDEH%9^RI*MN;&:^(77%D^)/S#8>:]T"==ALH>[9GFM
MN>68QT32_3EYM\T+(A']0I4E-\9!8?R9_G;5[[EU^XZF<=SSON!>%"UZ[>:]
M/#F-HN'L>+H?',W>(&DHF&8H)6\\[D%5:U.3QNUEC8<XB4\[6<<HO28@S@OI
M8\+EC\2C./S?-9]"-#3=&Z\;3%U5@C5]ZTA9M??"1[MD98;J6RZ9(IJZ#FV3
MP+C.[8BLE!!JXTBZ54YF798-MQ:I9'J-N#X@2U;R+7S&_4G%L/[E;?GKP:;@
M>8&3D#DFH6:-Y._-1V.),*JSU3EUD#I^8VYNWCIY$EA[NG"NJ?-BK_X^0_=&
MML;UGW @;F7_I:OM*?Q1BQU6Z)ZOTD>++<DP/9ZG+&\XM87K#'_KRI(K=()4
M!N=TK0>5;T[/@J^C84:2.$DR%D^3?#R9CI*W+(GHV]$J9LDP"[  "5$12C$>
M9\&PZ9N*Y&W_ID+OPS"W>G%PC6&?=NI;^N-Q_S1& 5^8QE0@HF-:<DH%5MC%
MRY/19#C#^YC>@S3LCR=W &7*6E4^!BB)^Y/HT92P>ZCUZ<JMJF;0VAPV[%.(
M\(8+C@#ONU.#Q?DN/4R^&YH_9^1WJ/VTNUYVF\8'T&"4X!3T.GN-!\K]O;G3
MB,7 #."*X06)Q5^0K%92W:O^66/VV/"X2_F?"- SQ.(&Z0Z?_S6/_]\5H;M)
M_ WPL&OF1]]XH__N-]Z]C*XU'[A?([[1_N;Z&U!+ P04    " #%JO5<EIU8
M%OL#  "(#0  %P   &YY,C P-S<Y,35X,5]E>#DY+3DN:'1MU5=K;]LV%/T^
M8/_A5L'Z "Q9EA^)9<? DK1#AZ(+DOX!2J0L8A0ID%0=]]?WDI)BITF;1S-L
M$Q*8I,C#<\Z]O+27I:W$ZM=? )8E(]2WL&VY%6RU'+:?W>"+,(0//&?2, I6
MI7"B%:&:TS6#=UP2F7,BX%*)QG(ES0#>RSQJU_KG3.5-Q:2%7#-B$:,Q7*[W
M4<XO_BJX8)#,HG&41-/Q)-E;?ZKJK>;KTL)H/I]""$F<S/:7AV&K9-A)66:*
M;L'8K6#'0:&D#0M2<;%-X=4G7C$#']D&+E1%Y*L!^)$!&*9YL0 _V_ O+(51
M7-L%6'9E0R+X6J8@6($CN1)*IW 0^V<10+;V0\?!0>&?H&5#^>?>06SV=/;Q
MO*A;@"V'#7,O4\B4H(M@U=NQ+'6/5'8S)O75;8R,Y'^OM6HD#;]]M<\ @VJ9
M7D!%])K+T E,@31670_I=I-V+%.:,L222C(4[D&.@Q8DP%%3$HK,ND:P>GM5
M\HQ;F,^C^7)XTY#5,M-]=WB_5SW3AYAUBEGH\LTJR!A\)!7F'#% X(QKEENE
MG\J%2XJX*8QG]1V)L'HO<4Q*W +/ 6RX+<&6##"U7;YG6S@GQA!,V!.NVE,"
MJO!3+MB:&ZN)7WAI\93X X.==TI7<!E.=G"7+&\TMQSSF$BZ.R=OK_*22$0_
M557%C7%0&'^FOUWU>V[=OJ/Y>#SPON!>%"UZ[>:]/#A*DGAQ<[H?'"W>(&DH
MF68H)6\]'D#=:-.0UNV+!@_Q9'S4R[J),F@#XKR0/B9<_D@\BL/_;?LI1$O3
MO?&ZP31U+5C;MXZ453LO?+0K5F6HON.2*:*IZ] N"8SKW(Y(H810&T?2K7(R
MFZIJN75(%=-KQ/4!N6 5OX)/N#^I&=:_O"M_ ]B4/"]Q$C+')-2LE?R]^6@L
M$4;UMCJG]E+';\S-]5LG3P+K3A?.-4U>[M3?9^C.R,ZXZ D'XE;VG[G:GL*?
MC=ABA1[X*GUCL249IL?SE.4-I[9TG?BWOBRY0B=(;7!.WWI0^>;T./@R+XK#
M$1O/C_)B.IG-CDA,V>'H,*:'27(8CZ8!%B A:D(IQN,XB-N^J4G>]:\K]"X,
M2ZM7>]<8]FFOOJ,_G49'8Q3PF6E,!2)ZIA6G5&"%7;T\&,WB!=[']!ZD.)K.
M[@#*E+6J>@S09!S-DD=3PNZ^UJ<KMZI>0&=SV+)/(<$;+K@!>-^=&JQ.MNE^
M\EW3_#DCOT/MI]WULKLTWH,&HP2GH-?9:SQ0[N_-G4:LAF8(YPPO2/@C@LL*
M*], SLOH++K7@V>-W&.#Y*[F?R),SQ"1:Z0[W/Z7G?Y_5X?^5O&WP<.NG!]]
M^TW^N]]^=S+ZUG+H?IGX1O?[ZRM02P,$%     @ Q:KU7.H9U1]KFP$ #<\!
M !P   !N>3(P,#<W.3$U>#%?9FQO=V-H87)T,#$N:G!G[+MW5)/MTC=ZTWLO
M M*D]R9-6D0$!*3W+E(#!)1> E%4>A%$4! B34": J%#Z(@HO0B(-*4C"0H$
M",F)^SG[W?O=[S[K?'5]_WQ7UD4FPUQERCWSFZP5_!?\"L!HJ&>@!Q 1$0'=
MA!> WP>4S7P"0P*#?0+O\5^5D0-4;Q@8D^Q36W@&!_J'AH # P#"8/PC"Q !
M1']_QZ_1K!CHZ+B:69CJ&=S6)6P( #3C 8$!GL0$ 4A 2)"%_@U^.WL'?HII
M@ )@ U@ &N"*FWOP/>#_'0:Z.OS!!*&_[?<?XWCVKT]3TK?,^/F!_[[!Z.$9
M[$[8[B:!#KE+.)Q MQ!HUKM6%CH$^A, 4-)Z0#P\ (#J"X&?Z/TW&>H[?V2\
M_TG&/Q0")O!#_O AGF[!!#J10 O=];M'X%%7_^$'_;6V^V_T/ZT-\73W(?"G
M"7S:L%!/PEG4*P0Z(3SDSUH:GS_R[O>"_M!0 BWF[N-&D*$I)=!2?]W_;X/K
MCVWX"492EK^FK"RM("W/'PX.\;EAIO/?:93_O_''1W]10J\!@.$Q #2-N8<&
MA?W%(_WSAPR@!A@ 5H 3X 4$ 3% &E  5 !UX#J@"Q@"IH 58 ^X .Z #P !
M@H!P  H\!.*!%. I\!S( ^! *5 )U +U0#/0 ?0 @\ (, [, (O "O #V 50
MP#%P3@A("B(Z(A8B3B(^(F$B22(%(E4B+2)=HMM$%D3V1'>(O(D"B$*)H$2/
MB%*(LHCRB(J(*HG>$[42]1 -$TT0S1.M$FT3'1*=$9,0TQ*S$O,0BQ#+$JL2
M:Q,;$5L1.Q-[$]\GCB)^3)Q._(*XF+B:N(FXAWB$>(9XA7B7^(@$(*$A82>Y
M0B)-HDJB0V)*XD#B11)$$DN23))#4DQ22])&,D0R1;)"LD=R2DI.RD+*3RI-
MJDYZB]2:U)WT/FDL:2II'FD%:1-I/^D4Z2HIBA1'1D?&329)ID9F0&9'YDT6
M3A9/ED/VA@Q!-D V0_:#[)B<G)R=7)1<A?P6N3VY+WDT>2IY 7D=>3?Y!/DZ
M^1$%!04GA22%)H4IA1M%"$4\Q4N*:@HDQ23%#PH,)0TE'Z4"I1ZE V4 91QE
M#N5;RB[*2<I-RG,J1BIA*C4J4RH/JDBJ#*I2JC:J,:H?5.?43-2BU)K45M2^
MU ^I7U#74@]0?Z7^14-#(T!SC<:<!DSS@.8%S3N:#S2K-*>TS+02M#JT3K2A
MM.FTY;3=M/.TO^CHZ$3HKM,YT(70I=-5TO71?:/#T+/0R] ;T'O0P^CSZ9OH
M)^E_,E Q"#-H,[@P1#'D,#0PC#'L,5(QBC#J,+HQQC+F,[8RSC$>,;$PR3.9
M,D&84IG>,@TS;3%3,(LPZS)[,#]F+F'N8UYG(6$19-%A<6=YQ%+*,L#R@Y6<
M5935@-67-86UAG64%<7&S*;(9L,6P9;/ULFVPD["+L)NP.[/GL%>SS[+?G:)
MYY+V)<]+29=J+TU>.N&XS'&=PY,CF:..8X;CC).?4Y?3CS.3LYESB8N42X++
MG"N<JY!K@&OO,NME]<ONEY,OUU]>X";FEN"VX([F+N'^Q'W$P\NCSW./YR5/
M'\\>+SOO=5Y?WFS>+MYM/A8^+3XP7S8?DF^'GXU?F]^?_P5_/S_J"O>56U="
MKQ1=&;UR+B J8"T0)U GL"1(+:@JZ"68+=@KB!+B$S(6@@I5"2T(4PFK"OL(
MYPH/"9^(B(K8BB2(-(MLB7*(&HA&B5:)?A6C$P.)W1<K%IL6)Q=7%?<3+Q ?
MER"64)+PD<B7&),DEE26!$L62$Y(D4E=DPJ0*I::DZ:5UI8.DZZ27I5AE[DM
M$R?3+/-35DC60393=D@6)Z<DYR]7*K<HSRQO*!\GWR9_J""AX*Z0KS!]E>ZJ
MWE78U9:K:$5)14_%0L4O2BQ*QDH)2KU*%\HJRD'*M<K;*D(J=U1>J<RILJJ:
MJ::J?KA&=NW&-=BUCFNG:LIJ(6KU:@?JTNI^ZF_5MS1$-3PU2C76-04TW32+
M-%>T^+7N:+W66@%= ;F!BD%KUP6O>UQ_<WU36US;5[M:^^<-N1M!-Q W3G34
M=&)TNF^2W-2_F7QS5)=9UUHW3_>;GH">MUZ5'DI?23]:O_L6V2VC6YFWY@QX
M#-P-*@U0ABJ&,8;]1K1&ED9Y1FNW)6X'W6XS)C8V-'YF_-5$V"3 I-D4,#4P
M?6:Z9"9J=M^LW9S<W,P\WWS#0MX":C%DR6+I:OG6\MCJAE6&U:*UF'6H=:\-
M@XV33:7-B>U-VRS;%3M9NQB[$7LN>[!]BP.%@XW#&X<C1UW'YXX_G)2<XIUF
MG46=(YR'7;A<_%TZ71E<W5P;[I#=L;WS]@[6S=2MV.WHKL'=5W=1[CKNN>Z[
M'M<]LCVV/34]LSPWO32]LKRVO#6]GWEO^X!\<GSVP#K@/##:]Y8OW/?$S]2O
MW _O;^M?!Z&$W(&T!C '^ 7T!_(&1@1.W).\%W]OY;[:_>?W44%&06^"B8*=
M@UM"6 F%Y5.H6.B3T-4PK;#\,$RX37A#!%-$0,2G2(G(I,C-*+VHLFC2:/?H
M7N@5Z$/H:HQV3%$L4>S=V%Z8(.PQ[,<#_0<5#ZD?^CW\'"<7EQ7W^Y'MH[;'
M/(\?/%Y_HO^D*IX^/BA^+D$] 9Y(F@A.'$VZFO0R"9?LD?PQ12XE)P6;ZI[Z
M,4T^[44:/MTK?31#.:/P*?G3@*>SF:#,BBRFK*BL]6?&SYJR^;.3LW\_=WT^
MG*.8 \^ES@W-77EQ^T7+2Z&73U]B\WSR9O)OY->]XGZ5].JDP*-@LO!Z82V<
M!YX"/WL-?OVE2+^HJ5BD.*>$O"2L9*/4IG2H3+6L\@W7FY0W%^4!Y2L5%A7]
ME2J5E6^YWV94$5>%5FU7.U6/U]RL::F5KBVJ8Z]+>0>\"WVW\_[.^]EZH_K>
M!M6&VD;AQE<(%D1R$U%39!.JV:=YI<6^9:+5L+6W3;T-T2[37MYQI2._DZTS
MHXNZZW$7'AF%/.J^U[W7X]VSWNO:N]AGUS?=;]X_.F T\&%0;[!O2'L(^4'S
M0\>PVG#K1]6/S2/*(TV?E#XA/BM]1HPJCS:-J8RUC%\;;YO0F.B:!$WV3-V<
M&IPVF!Z9,9F9F+6>_3+G-+?RQ>/+UKS_/'HA;.%\\<%7LJ_)2XQ+.=^XOQ4O
MBR_7K2BO=*[>7/VT9KFVN.Z^OOL]^#OVQ^,-NHV<3;[-RBV%K8YMO>WQ'<>=
M'[OW=L_WXO>9]E_]%/O9>'#]X!/*#O4#'83&'Z;^XOQ5_EOQ=^^1V=&W8\CQ
M^4DRAA-3<:IZ.G1F>[9Y'HZEP+ZX$+]HPQGAON(A>/P_81*9/YCM'WCDIJ>7
M6ZA_"/\?H*(3Z!\8&L1O><_-W9-?^N_ [G\/3KG[$@":GP  Q\(_>(1A]M?;
M7WCM;X,(^/>#^!_K2-@)\RJ!5?H/7F Q *@>$?A/@\'>?^/I6%CQ_Y,=I"T\
MO3R#/ ,(JMJ /</! =X$_0,\P'_0,C\X@/\_F>E_B?+_-/YQSW]@Y1#/B)"_
MW3/P7F00V-LGA/^69[B_9T@(OYF;NY];D(<4OX*<G"(0['55X6]+B6@)&)EL
M&8__)0( %-D <)&!QY\7X?$7!-U)%@&@.Q2_".C\Z1/^I\:?3?YG]R#"=P-,
ME,3^I,4D1 ( ,1,1"1,1OA_@(VA!]I? WTU#1$Q"2D9.04E%34,00# "Q$0D
M),2D)&1DI 0<2Q1#^#] RD3&?$5>FYS%W(U"X#ZKPL/,(DK!&^][V"PF4$)7
M[P;%45&S7^+@Y!(6$143EU!44E91O::F<U-73_^6@:&EE;6-+<$![AZ>7MX^
M8-_@D-"P\(C(J$>/G\0G)"8E9SW+?IZ3^^)E7G%):=F;\HK*M_4-C8BFYI;6
MMMZ^_H'!H0_#'R>GIF=FY[[,+ZRNK7__L;&YM;V#/OSU^^CX!'-Z]D<O(H#D
M/U3_MWHQ$?0B)B4E(:7XHQ<1<?@? 292LBORY,S:YA1N]UD$%!Y2LM[(+'K?
M0R5XU0+%=C=H@II=2'%5&/U'M;]I]M^F6-S_D&;_H=@_]%H :$F(",XC80)
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M02-FLZ$TFA*3,8']E][TW9@L:9FNK;F;;SX3L"!)HZX>K-1_4LLDN& R-L#
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M04]GK M =]'(XXP+>"RU09D/C!,;6101]&L@; $QF+&Z6"-KCM9JJ-E>D%B
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MBN/B2O3#SH>;T5I+"B78Y*R6.DZH-LJU;XE_%Z>!AL5K7"I*2=Q/1ZQ]CC9
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M SG>5K>SY/0,+EQ1Z4UYW]+ X1QN&X[]*X99_:=,;^7DC5D5,EY>)GU-&J1
MJ73*@FJ:TYG]>>27)O-K=2RE9@.=4U9S4=?G4%A0-USRU??3V9.TU\I,9,UY
ME!M^B4E?NT<7*6_;[L!Z%VFJ3.G NR%.MS)#[WT8L(-V,*J_WQVZ7[AH">FI
M5(&L[9U,.;;76,Y'UGZX2.E;P#3MW+!FBV)YE"T:E?5\RC:HTJ+&6B720)3>
M*LL<1I=ASD,10,&;W?B(@V/[84:9M,'9T H!-0'_G_/Q"DO</:IN3E&>!S]C
MR*0]_,X<=J-XZTH02_O).U&0_8>=4][1CN>F",=AB@7_GXQ5?<'D>$"9BC4N
M2^+==VI@QH;N5:B%=8L@K?Q3!7)]#::>/?#,81T!2?!&Y/:ZB 8^1+(?I"TG
M[=5XMF!BUOTR9"[#DGB9XVYK*_9+R>FL=<K)-<W\_JV;%\KDHI=>.QI;R8GK
M./I>J,JQOF-:5TGR\^ 0E]?2^!]7MGN&>:3;G.?C.=M8\>;!:;"V3)D[Z_C(
M")%4D"&/BH@J2/G;#6\AHNC+(;;*4/.B=9Q.% A+8?5N#*<I(HY$9?O ?W-/
MX@&4]QL8>J&,H$J=Z2\L)QR1 !O!CN8E;\!6Q29 6]?*")5T[#8>6&^$]9H7
MP\:#"96DIY#0%0^!#XU&#G#(4FQM9[4Z<G=S\_38VU@W&/0O6X/^=9^@OR^+
MM@N'S8V-_=K[;SK.YWMN[O(%S.#4Z?C=3\)MX?#-^0(EMD]XX%\%\<#CDIMX
MX/5&+AYXI'D5#Z1/#,O*(L]PSPY;]]V6\( K"#36H.8K^?+?2.(!*KTD/*#]
M618/D$=YXP&>DBP75]C1A>B/X(6^=EQ7+ SN%3)M>_7?".*8TUAPC_)<<;2_
MQW#J^D(=77A@]\STXR8B(?P"BL4#6I^V*VJ]_T4,*\PE>D&AB,1R;L.Q8>D&
MD3%X8.XW_/F8'_W!V>DI+N;EE+G3V'^6RL 8*IJ>T8-AF*M3(,P^=];A.<$D
MVR#)PEF>Y:-?O[#G5]\4M\+_LQ3?OWCFFO"/$X(Q)F-M-?\/.C 1:O":3'5.
M$;J>NI/#0]!]4I^W!60XU52H_F(RPCM]C>IA%E5QEOC='!'^*CTTNZWN"H7-
MG>[O6::,/@4XV-S1EEUQLAC'?_E>[98C3]+W>W*W*#0R"U_!"L'QNF8<\4#J
M8>F=^R=)W2Z=')6:\3[$AEA"Q8\;-;I/@66>.EXKG/F1[@=[$"O=:ANOGVSM
M:.YW7U J\^ENXMK=?J;'7PVZE<X"[&_DBE(3"35_!'A&]]S1=3D@B.G\=.P<
M'JA'#A[,$Z)@6XN/(;60 HERZE+4XC%E;8Y_9AX-_H[D(LT;?<A>L<LJPE??
MA+A3[;T11*3O>Z$.ZGR3&]#D6"(QW!;4= Q[YCJWW8J5QW*A;1I0[3BJ^7,;
M7&]E9!!.%'.$[CLF@Q'K7[R_=Q9?Y'9N[L-+B[9-E)72+PQP69@R085\EII]
M6"SOY&1T-=+P>^PC6(\R\FX%S!^)$=0?,GW,Y?7^[38?"XX7-^/*VA&(DAVT
MF7LV4!EANP;J@]@:=J**XD^_+UR9^3Y9"U6OZ#]46+3?V3@8L95KO6#)P%&*
MEBW%SL#JR_<%8. D9#W(:XP\]G,7-QK4IXICM&O#VJ O[6T6&9?X=(EWH/WA
M3,Y0A= *;_)U8UZ6.=%W\420P+?&&Q?%H'$\@!$YV*,3Q;*LKY2G=M'S)0NN
M=:,#!^IXL!:F3'#R##*1%QI@Z>Q'-XQY",V??;E:E"/']^G26:II&=K<B?GM
M)+7MV5X;B)&?H?JRWE37W,[)PC+LI0Z-^5@A]+PJ>A+1ZA3NX&SDDGY1$XQN
MP%$IPCE!*V7PQMCR\XC8:1LYNVU0O>LC@8NL+N8(=O56&<4DG"P8Q] 4F 9G
M/$HAS2'-=>QH12OU'S\L29UWW#GS9Y_4B2QJ',9B,"/=2/H.6=0YCEJR<GNY
M07]PWW80SH '_&-L^T"T!/0-(\64#S3!":0WG$%_K8Y:AR(!&PJC2 S5U/5H
MCSM;NV8(/EPN=1&>"KA3(.RG!#_/(\1@-*Z[>?D=J.<@!495C9,J'V##O$0W
MKX$&_1@8,TB,5J+AM&/KYQ"NB1#EAMS!6$6NOJV44EW%J)*O7V ^U^:EGU=0
MZW_7>D9(1GM0G\A8B8BK ZXH2P+RB<KMAF4@V0)B):$A&,M5T(,HV.. +D'?
M\*C!S KGH?#UR\A47M')ZE#[=10NS4VK!4H7FN^G&_$[6^IC:)!%6L[Q_.(:
M6%KV#1Y0]S] 6/>NG<K-OBW?V_E6;/+3? )25H.$[#7.G=%>/*T[HK,]OG-1
M>&1L.CB!->B<UJ+$2K6U8!Y2+TNY*.8%DOE,.D5DUU:R<I475#MKG$SQF"PL
MFH>],HB!0,*%9M_%7'%Q1SU:G7NBQ8A50>GWX@&2GF"_5;Z$0I9Q#:;51:/\
M9S!%+OT$?X'ZJ2<#)YDLSM^47B?L/UN]&YE]>E\G@6(RQPKR191:P97"B^A:
M/_S>.J>J_X/((=7A@T-'2'V[2WF9L1)K849,^'PX-EJ32NS-3](5[SEUQ\#;
MJ"\+,%! XX[>0UVV44S5@ -?'*%-CJCKSPUT>QT1;=(V$YIRU-3:SAZF?#_)
M.W=OUMS)Q:2'WD;2+[(,RECA"#P(L4K]6")UXV%J#C_1LX?#ZUG7>8_00C"4
M><:78RL#04QEA4:00$> %@?4<6%K1>&=^\IUY?JGVD*TW)ML_5 30@CDX8:[
MF#"1ZR#6;22C$EVP)>HD(=38U6C<LAO.]+LR],)B=-8@Y#,YG;XERL)NWLDO
M?&W9J*FUS3->_.=Z^)W74T=@V=S<TWW<[8_6E0,JG]DGHYQ%0Z><,\:G6YJ?
M6Z\5<C+-\/ (Z]L8L"KZ5U?K2%;2IE+1EK()<>7S;Y)R<_.Y;\4P""!Y8VEC
M%^NQU] A>( 6YF>:$I:P1O$@E@)*@<#D\CY"3?4?@J/@0R"6"!<\T(\'F!$\
M\EC1E?,*Q7TUCB,&>GM[GQ.6NQ\7*%^ZIT?^3#HKEL6(Y>X]KDK E%5L:NKW
M,:3<OM7-*:Q!K7V-8OS<$NP8$ZTNNMC*V*]G7*DZ.#?1&=)\>@8/M%T/Q%X:
MC"PB&,8<-TLN7I;8'(^EK'7/G I2(9Q*1F$CH6>>>Z5G)?7[W:X6/)"0'/N!
M[[<50A:KA <N4>Q *8&S++)8,U@/A/!P'LPCU\*Q+%>/7Z+TXV+YG7:^B<XU
MRE(N@J-"OE%B'I4*]S=I@5"%96%\9K,=DN7@G-[+EQV3AMLZ'GTZ3)4[S65@
ME;6JV1>,]HNM<@W]?8H';+RUW%4[D.SKDF6&AKOM#I*UM:,C8;""MN(WJ+>7
MF$=;J,G9 D2LG  Y-N+'/']^\T,M1\ J5@PQK1?:9?19D>EIK2YKFV!@9:_E
M)8.96F;FSK7B3AEKCSS#8?]<(UA.^5IMS:U1FU>_LQLW<G_YE6$SYI$8E4_U
ML!X'D.>19:,I!.TF2AE6/<S7B^1U$C"\1'S3*+&X@.VA=9[J=S,>UHS?/^H.
M":U/' ]6%Y70FX$1']I;73_@]<THQICJN"9-^$:51H555FDV$M /K8:?IS^H
MH=%/6L<J6W-@C]KELCB3MI<TPJ#N-XA@VQ3<4/\#+?&=:\/K.#;8P)C.%$[,
M=&C;Z46505_69^&:ZJS8_8.IN8W8RMXCJ_H9<:.7E>U-!WYBVS5+;=B.C&:?
MNB38ZAJ\GN*"39J ".@(6^#<Q/[5::#3Q[6.43&[9[L$*#(1[> ZQM=Q[HO,
M'<.H%>IE''-@G+G4!8S.=2+ 'FEV;S]4K;IRLME>OWZOS.Q!]P/K6]S4%Y7_
M9LNZS:LX>NN+2AP9UO_BJ187QG2U+K7V" \PVD%#QI6JJJBP/.L%9)9&&7V%
M<DTJ8-@:'QW8P?_#%&/%4Q<#2>++(P-6TI]9%V:J)&MBMIK+2Z8/&RH'[;W$
M!PT6\FU-O1;N&YQ :Y<<3(;0'!7QMX:MU3W2'DK03];2KV8.RK\Z'O2[(!2?
M>:JR9SBJE%(JX2S=1^O> R_NT._U7@Z=_CV;+J;#+/@D7/[6%*4*<\DS^*]7
M7RMHTV\4,W(FK887I Q9V'\P8V6V2Y?_#(M<1@5L[@>>@[!<!,>&;W=18]+6
M\PM(^M]C73&Y,)D"AD<:T;6)^X$RO^>:P;(:ZJMI#CT>H7J?R#='KY-H^-:F
M+GTI?:[DD=N6#Q:>5;\8&K[7B =6;X!'; W%14YR\J*0G? 94"1L]^WZ]ONK
MF*@Y]'/"HS8170F"J+K+"NI?ZJVCJ'G[<73\YI3K[N#6S6K#*SG"J5])23YI
M\[U\3N,ZQ4BX5WSLA_92P;6T4]I3"AQ;^<#][IL4\2A5MSC*[?U9Y',81G)N
M4#8!Q@WR=0SDQ,K-+?9_N^R:T,7^/L;H7-)AHM>I<M9UQ"\FW&1*IL?3LC&1
MWI1C-Z,>U3<_DI2?[6[#U&.;79R5BVU/:YR=#(-V.G[!!);&A#/0OL]\XFW2
M@?X2T:-7\D1O7?E-\93%2>Q,TP[4\5P=1P"T;#!/TZ2F9=98]AWEB=VJLJ\^
M9UWPBNZY-I5$Q<OM5>J+%Z+6\9>K[/LAFFF(_>K9+*7OX<=-:XKR&AO(\;G>
M7(6E+37/3]\5IQ:T%1\SVT(3.1Z+OA57=<JY<IVV/QD/*%9^U;_\\92*U=+H
MBG4DY]TX*N',N,&Z*U2L =\%<KI5R=XQG'2NPC!BIGL9;J^WP\)!K#]Q$W[>
M@8%JBU@U3%E4DH:YQ A?@?=*Y8J7GJJZD-NKE:=778W6<"0RO;;#.RN5%58#
MYJ]VYQTFDU/,<_V"C:)#YD*@H(E@M8'U=UCKN($U2<-XI\.AA!*'JFSP><1,
MFOW4(X@,S-O N,JY+#;W? ,Y;(2CEE:<(J#R&TC_\\J-++\7>,#7-%6^[%.]
MXK/2L&\JT\7-:5Y!'E;-2<RJ9G)V);HWJ=\">, 8A(DHWWN(!W2-+/! GRLZ
M& ^\,,0#<F.+??U1LBDP0II=6![HXNMRQ ,,F(SC9YC.:I^%A\WMB$MMH<OI
M"!V>7L=OBXM+(CV?WAM1WWXA.")T%\G]IC%G<:C9"P^,;&[ =-">CN/=;ZTU
M#VHM [.,E<C4H/OS=:&B!R%&P6<$;/,HHYP0CRMY?"CC;'"I9SO:M&];9OK#
MIV93OKU?U6J=O5DW1[,,!"4-.:H^[%%ZW;V'7)E4#IDEY/]%R.A3.O55TMW
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M+K\1[(3Y*^]8>U'/<.]HWL^ZK$_BUD4YK^BW:E*L:]^8<('40=T)Q0=R8],
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M.CY[+AEU-OE[<K[EC'EH=*$WR-;&:(7O-3Q1YJU<;(:#V<55,UFY_._;-9+
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MH6 N2-+W.HR(H@NE] 6Q6N06%1+[JX#F\+=N8%J(I3:M,[<XW^]H"./N#X_
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M7^>- \5E-7\_=)19/RKCU/O8LF1HPXFX33W27&8IT@XY[%L[0# PW':#$KR
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MVE/"JYY*GV[4OS:ZZ'E!:.JR[W$G2USVY-1ZR1)N>8\9V@U7GJC3U>@:+K]
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M^Q83DG4"]H@^DA3(Y6O(1TG+BV\EY!UN\#\?H?E9G3"A6NKG$]?3^E5#0D!
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M;;).J"*[ZZEP:<4XD^7S3AD];+N3JN!NG0RFW,#.-.-WU]<H?3MOJ9C$ABQ
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M7DI&>VBNS2-,DY%$ ]0;0U'QZ8)S!)\$($1._"[T#(V- B%.8+>BO!S6)X8
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M _U"!ZV-<7ESW]T9C0 %G4/U9+@-.90C,JZ'N9EYN ;:+V]B(*OO32W^I*Y
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M[/\<S%J+X]F$,P?PXLLC(6[@XW_A5XF83H5IE<YI3/Q3(B3:,V<\F.7H+J"
MI3&/!X.Y/QRBL7:_[?[R>Y;FZ]]RE<N+LP@C*_%:22*I[D-V]NZS,^[--3.;
M4*2W]*/O8Q86JP4YFRV[>]L>,OL0,.8Y$A#/2ON!F\X@1P*S"\CS 0(+[%A8
M NH4XCGN[3CT#%J!)>3;H+[)&Q1;BS# 7:X<L*?=.(2.<S!#',.63K8=!J2/
M;Q(CD^Z9GFZI!?!'Q^'=T&I=K)':_$H')-01-$:[Z I7J0*27.>I8&-4&[]!
MP'*7]EBPAL?"+5'BVT.N-%[2W\/-\B?""_K>\I?J) @\J8/@*0M+Z$BY<3D"
MFD7;T</_;;O^UK4KU=_;:NZ(X#'8QJ!3,[33441K\F-J.5R.-@QAN41<>4NY
M54:1H8/>RLRCWI9(D/('RHD9':I;$644Q44<=PVZR'T?5HKDL)\=^&4WI\XH
MI.)AMU T^CW?%; JO!-,U*6# $GKC6>+(6=IW/N$;J*],6#^C?+P%_Q2\(LA
MI:VIB;9]# =-,< ;+##C3I,FUF!(6NT-5RH6 )P#L<]?F"OL4,.%577Z3Z\S
M=U/<,GC5,]9Z)C\#$5+6K&3G,>)QSI&)_0C-+:F3['G^[6\GO_0QA3C=G->.
MLTF4\8!DVNF#HY  &!E+_0QQ-YE:(>, ?>)..THPV,C?GTP'"02?&8%+!31B
M'=E\Q/R$+PSMX02F@=!=-4,9I8HJ%\K50_'2/K^7/8]B+7T4=C6(.%V2<Q3#
M:0)W2%LQ<A2GQ5*!-DVA$777A74C^9%[:))UG"R#BC D0.*,SO?(Z5[]</NQ
MQ:;1A1&/2[%SW?(1U9)%_+$$E]R>S8GF\GSRS!\/XPA5HSH)_]E:X$480Q9/
M_K<305(L74_@X4K"QP[YPP+O20[T<7#KRTZ>_2$;J,[^@;.;*;%Z>*9TMG0?
M\3'#8-^OTJ@E%4-AWQ;>D3Y_\>%Q%=Y++TPS@U<@"@]W.Z5B?+E"XYT#C!O/
MU.C<NG1* D349\KTNU6>#)>B6#378VA]O^3/\=0L=J<'W+O6E'S]W)+AUNU;
MVC(IGM?4)CX$7P$(05\'OSV,1KL'&5UW;/Q5_GGL27A0]S.IB$U"WW.7Q1H_
M'=_?1_'.\M\Z4EQU5)8\=EZ[H!S*IAT<TW<KM@,2%7J_.JW.0Y4^9.824C+=
M;HJMW93_M1R;[.'K959Q>$'^01FU[-1\W25GB9N+_B8?]HM&-T'S\61UX;J2
M?LTU@?6;GKF7<SZ)I/ )1LIF? S/?"28J''=.OMIXHV0GB\ZWEUA(<RWQ';Y
M5C0:+= >RLUT$/NZT]J'#Z4WT1M_DI&#SO!_CN(X2C:U("@\:;2>+A=,RM0_
ME_OB*\NC^-[,C7=2DK-=^39)->?V*9#R@W7]8I>>YK%?@:BK#N^]==7@ILGQ
MR=G,/@2CP$4M="++7Y8')B-R@]"=I&R93K@<FEB6XA7T<IV,DG9R%Z@\>?UT
MK\[3WN/G%<U^7["6*(2&MHA17,9?Z>]2X9L>S^U#=!TKACSPPX]M4Z>7#RWU
MEE)%E]IKAC:NZ-_/>'?>TN:"MM)[8SO'<4<[]_(@PFQ9U(#S0_VWW2)4]+J!
MXDH1GYUF3];&DDII8WYO.1Q7</;2BT=7)00YU@$Z2'8BDV)#XFG&LT?-72-!
M(@D>,'0_IU;]J%*<6D=CZK#[)+=VP\/6%[VR%5NN=O="\8$<IK:)UYI@;;#H
M9"#LHE+</K-I!<],>R2[8BXJ,.$/QW6"/$>=>E@S^Y7F"'D"6H%PVH#E2;Q<
M$['G2VZZK)[>F?DBZPN/!VZ>.;9JDE*L,3(U$V*VGK]Y2!ET8DK,_?@X-_:+
M/[.PJT1NG$FJ:;*)KX)O^:\=] A-Z2LK@R/J8G_E>JH$.+4_B[XY;;S%6:,/
MGA/,W!0J,IM8%-#C:+(D BLWF=H.?TF ,DD+\K>[+C<D3G4\#C8!WKVR@1J.
MB+-\-:B,>79*\-ZI,7';F:5;$@+1H,QL'?<__;R+5J7N)&$H:WBYQE)-C$*T
M>-,GCS^_RA[3AN+NWRCV7;XN/F+HQ6%AH_=,;).OL"=9?RO'/0CBK[,U34LO
MBPK_2+*"ICTIPN?SFID7\9MERKD8&U!JQC<5C;H=Y,#FFZB3<T#?6HOHL+J3
M;RZTOU W][<-SB7=8_.3A^SK*')AQKEW<VYVD0>7>%XN+2@B2@ZP%QHUV%^O
M"-%>L*W 'B),[/!-X(5&(X2V@\U)<_*K]XN2Q=*!7O4N?Z:/.2>$@YJY;LS?
M?G$J -EYX[5\Q(V2#>Z\VBNG]4TETBD@+>&C2!T6H:B+^9)*A(;**A.C9 ;B
MRV7V#MG+'J3RKG]S?3RFX+(45%!OWA R5S8P6^*WO*!\23 L\"+HJ?#;ISN4
M5;N D:VL)J;P^'DB^PFB$=PS^#8P5/JWB-KL>Z5<HX2WPJ[[6=[9P+GK7JHE
M]N?U!90>%+'?\JIWLKJIYF7M 5=;UQ1)W;];C4F1&/YS8^>W[(.MK.2-I=(Q
MFN6=BPT1X3+'39]*".B=^;5^I<7^T+T@O9$ZR_XN3?B95ZFZ>M&HI;5(X:F%
M?/,L U-7-<F"+S?*9NL=]BH1.<4^9T/&NW<%%S6NZ3)!H&YI_B?>Z6CH:C13
MUW?H(#RDL_GNHNGX!<OQU!&3\41D($_1";6G02\=#8MEWJ::*K&N2(&]PLKO
M_ K!%^#$"1_\W=9(#:+%N3(R,CKQ-[Z?.2U0,<#FD\YOM6R\7J[3 %<H6"_:
M>CJUR:F:LX;?8A;8N6M,$)?@&K$O=!Y2&DN?/M1ZQU[*%>LO_?WO#W#?\]0\
M\OX9R9PW_U^9-'I8[A=:L;^N[<JUMZ=.FFV$VNY[LJ<,W' Z"7^1:='BG1W[
MQ^G2FZN!G<P:0;NK_<_7:I_T7%>,*1"_>WID*S-5](VUZ*4_GD*JPNX,&4L'
M4;AGR/+4=+@\CL(*9"S"SML'3.@829N<5XEJ$B\.B-,F[I-;G6#"I:6NO<KY
MI7\XWJ;OF/S>3_W5S]E](8KO[Y>(\MCWB<+QQ?H%]8^V9#H'C&?^9G>5OG]Z
M$<>QL#Y_3;!**-/I)>"Z^ WO39&[KZWW:'7*."_7F* CE[<TU#QTF,XG_(8:
M9%XLJC?^PK=70,[:H!D]^JK?8'INNXTV8+-2W5S=&"I1VU!=%Y,M$WU%]]Q[
MG8U\8V\O._=+SI*J$8,8&#R3#MI;/ZL1C'% 7IZ3T]'':;O;4B:,R&(YL5+_
M[EXP_W^:5/F^ '7\OUVO2=A!+B/[!_^11#C:F3 U!%8K& R)H69H\H<?'CNP
M7E6PH_RF)B#^$"#SA1CR2\QIS%ZFIB#[$C3O%==>U68.';1MH?,D_IV>6-'/
M@XSPW=GPD6:U)RM^MPY12YGF7W-Z"#/6C6M4QXV[C\X=[:T;#L=*5MK+_,LW
M53/%'Q+9Q]2] R[.^R2OMN;GP1IP6G_57F<S+W8<\\4=TM*/!GL5$A@)[T&"
M"8//%;]H8:>\)HXGX9'A8.XF&>ZMC0.27^>F?723%HE7"_W>A#=8FI3'AF2/
M4N[]\'[&E)B=[^U137ARNNS5QZ=IUJESXD<"\[5=S3(+'5F_S;1YD.6N&PM;
M]UUS/QAR7G61?W6@]60-+/7^5I9WQ6^6\^^LF79R:6<4CN17<1>K%3A<:2HU
MS22)L&"'<^?S*O/B%,+1T9^<AM .PIM<S/?KJL=2.S<''^B+6#2=CXL,\DN"
M;B^2-1EB59IR'L@MA/>#+^Y=? )4X#T4?<$1"(X!D5\T]6!%\?&Y;>VZ=BN:
MPDANK8-">X/Z"P6Y,KF%YKK0<Z5B&!,J*DV](1-OJ6YHW>AV:-NX'E*?W:SD
M5PDYUT^Y-U!I+)_-Q!N6WOVW3CHAG^#,WW_W0G[.BILW4L3:>#C.V_,A9GR[
MJN?;^J4'V- (B;#7Q, ]IGSC^A_=W5T2B2' 0I,SGKG#B',!&N&A;*@6%X 6
MNS)C/IS0=V6SARP6-Q#SF77YXWX%RY4?)6WW3E1[\DZ)/GO&)UHH*BJZ=NUE
MB/MRH8"QD;Z!5%TA3Z9#H_<J'*F]G/R+6L@<]R4!:]J.7Y/^4&R>H-=]8_>]
MB?U:>G.F0[J_?8%F[#4-ER+5L'^90KF/-#U@7.LN2U9MR)2M'])!4=" :K.G
MKY%]IDEK$,7;F_]RA/-MXV.:X>H3J.![X\G&Q+F<'OVDSRZ_1#\_V<X].4W8
M+@)EFUSD:YV?6&&F\"#)7X".HTN(5@A<EN(!L"[(P$Y33$;0@U'3S%'J1D%?
M7%HNT;!03@"C-[*G=A0";K?B;XGR\>?Y,-(*XZG/P]ED?.+M1_LI+@)NC(04
MQF DK;;*RD>:%4>6K<53/W,'*AN BT>W9D3GP[?["R@B(RL)Y"6FP'Z^<^V=
M4*="HS,/"3U;LWZ5=K/3 _L[%/6-8')0AM9)G0(A*=6][V/B1KK)C9$[F1=<
M<0B9/5UR[4*_[H.))IAF##A.ODGFRU]]YS)]Y3"'5O]2Z,GL:2-5#ZV^.]*V
M/[M+U:T&+G]PI8.>U^O+Y:7S+JL+X8]*G[C_[$IHTBH8+ B@@QS&+DQY)C2X
MI_)#XY?3EY?_7KRGXC>]'.,:Y/+]9SG,G7NAUY6+]P9Y6YOB9<MHEP\=Y-F<
MCP;'NHO6&75[S+.'K_*G1+?_N0P\]UI^%G.Z*PS[+I!JS^B%FXR[[]-!KI 9
M=O(RT?\'.'9.LHK$&QJL/0^)SA:MYPRP;CW4*78.FJ?R'IE-SD #H'>(.[I"
M[<.5WS^>>&DC6&/[O2CL@YO#:)K<&$KY7KK?C+W,B]F4N>87=!!KV^.*P$CW
M2&RO0F?]0K%UFH8>?DSZY0<"W\"K'8-$CD*^,I-G!@_7AC\H!*"FD%B!HXSR
M<[89JS=.U&K:>/%[G+$!]7W]C/=FZ1XLNN34$,I_:)%N*3)PXYI=NW?)MH[!
MQ?PN<9WE*0%%G7-G1:^>]-KMEY_RR/U>?4I(L[V+J3(,Y[9=HR<D+MMV[[G
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MJ=64(RW6+ #/.>?[3%EX*]W4\[V$QG&Z;JX%7>'PU%1#*B_)YHN;>;!Z2=3
MZ9X*^;,A$P5A12/#[I8;?@/"Z;9.Q3N,QTB9YZ5"5J 'EGUP X/UBC'O]/&B
MC8%(PX#A[4FZN$4[0HWFK^)C05'H*+Z?PJ&6FB24\Z!/F%/RA6^O6+M^]6K$
M3ULWQB'0=R?R$KO$,/33X,1\$4;%3Y20B29=WYVG"\A;<(<I2.T#'>O])-$,
M%F[,<'36J;PYJW-8UQ69"U)M&<B87P,O_V%V.Y96KQG2W+_L()/2V 8Q!0XY
M"CI!._#QL,NR";Q/XFU)MW8NKL_'?-ANY"F7+.3,-$@OV9E/H 6NXJIW/M&<
MPMZ3T+-L((4J@"=66PP^+#//C/T]!<&>>QM1'B!06P3ES4;!Y&?&!K=$21;$
M:"5I,S]1TWN-]SDVN>A:WE(8" [[Y^0WNB<76_$_AR.5]PMWZQFOHLZZT/DG
MMV'/D1(@*$B<2NHU.4OFZ[1R-Z$1 ]N^%"S.2E'C*1P=3![*0C+=M,1M4:L[
MDH #P'G<*7HI(8DRNBV3V+"X*K7 H#5UW]AY21'<GYW&%3V8I^]!4^;VM/L!
M,B<P:H7J2K. \Q'G6_GBC%08'QEE.&XZ!R5J<]*N5CA]*4J(FA-)=.4[;H[(
M]WJMRWO%]MC*2&7CB3;3C.NU%\_71QZ:EUD,WN9DON<'9Z(X0)ZM5UTHP!Y4
M4KXJ-8>R0%"(CU*D7V'V#QNID#=Z[:BW;(:9O C@:"'5G>QED=U!NCRF+KO5
M8OPA0%HK7>9Q&M(?/LC$3ZN._E!%F8)67>__%:#91$V: TY&:94\. [J)!1)
M,;0WD@#;RVWKB38K.[@']E5MW>L;E*O6+0<KM;2FR/<^E_/#.>3-507S@K F
M]\/P LO:W98>YF0409FN, S3L6B305A2G^8\>=X4MYO:A>-WI:*<&B OSTU@
MF5+:-]("18#-"9[:2BQ =FSKH[A 50:B87/R8X4D=H_41W,'=6N6&%;<%9&Y
MG2?LZV"WHVKND><]NA)#S<$GHE[F'Z,HQ%30(22^.+3'F9%UG=]&/GB5%5Z]
M[EE@NH^R+B_;9]J/UD,-77]OI<DU",347^))&E%=-UJD-2EM^]U(M4DRETT;
MNCK()]CFC=P:!FVP]98XO1=,51!)%K)C>V;774:'N;@W_3KU@96@J?U/VXX"
M*X,CK]/#%3(LV35.H* 8<F F]R$V3^@1>MEN.-=DH[>_?W*^S6L4LU-*%]H$
MV2"^LP +!4B<%5,G/(T%&+K& K3ET*%;$DRI3A+HP )#%^1@]P7K3&6&Z+#]
M+L*/[7?9)CGZ*9(P0'W(=KPEV6U@))T/O+28.HHZ#]I?1.V-L(VL]+\9<P][
M! ^H0\QT#;9$ K"EQ%LRVTR_LP:2UX%B+,"(*9N=W@.IP5&2R*V/A6 -#).K
M>GN;[W]B=^9R7\)AM.]#?7_"7Q[7-WK4"7P7Y?,?3^\]C'IN(RE3F'W1Q"A<
MR^%@-M[I$19!;Q$:/EQ_/@"VZK9+T$[#D+#RFJ;6=.MFE6:7=6S JFZU:VAD
M"],5=2/J%YCC,28>>RL ^_B!0D+=:P_H.4:_U!7!YV^V:4]]C\W#27:"-4JG
M+(2O'+.OI+<@',BQK;23"$>*^=H1//#D,AI4.YF@VQ"WFT;U(M"2]Z).4BX4
M!O,6]_8,<2T5F#6.SHGPPO@2ZZ9Y+I?V^_CO?3G6%6N%G''W8QYG8U'DX8X]
M^S$DO@");L*Z3+<,3B(%323#U65M-:M$"&YRM?>Q)^EA,G%]R!,L0"#XL#^2
M>QMUFCK4!6X KJ42K5+YP:71+4+X<*-@?*55-T:0;EWN,E2\R!2K1==2O>Y/
M"C^9&?]>@WFGR@88G1]^-&_*_G ?QJ#+>6/7QT4T +YX\>OS?7\#?:71:)M'
MD&YEQ*O6S#_NYOX=6\/,JT2%DSY5C[<D+]Y!!%I=[,NM[;V=JE!3KMCYQG*D
MK-"NI[BU(-H*EW2+<<!(0098:_=>-(_;CF@-'77]53^@W'N;[)0@DRU;LISK
M^P'05!\K4<)=H^+:U'_XC3,AU-7 (<@S6Y>AFCQQS?R*L[M#YD'Y8P-]*0-C
M1J,8TQF$?PVL,>^V?0$ZVJ)&[G>GG*S^2,UG6\BQ%G PM.SG7JY>IU5DJ,6<
M[8FECQ*%;ZWY'4I\G-4^Y'3GB+_[J=4-F^M"ED5R]U@;7ANY+]^8O6EE;#(R
M:U7^ZL96BV9/B7,\:$4T^DY^6'"/EL.K>9A6J4.[ >&CHEF*S$?3VQGS"]&W
MDKS'+^2T0G7EZNN'"O&JOI"7?:VQ/D/.A#Q/<R$3[^7VQ8_8 .VH;OD-2_<>
M.]O9&Y,%"2J+MDU*;([I;<'M#&"VCZO0/>I ^YQ+N-V3=>S<]X<R/L"0I%G8
MP3SN@#.+J>$"I$<_WJ!QN2"7='3'8ZEM+, /H% /<OTQ"["RBI3S'S85^A/E
M_]_[>"]B8W6<!9"_Q6;YSX[5+$#!6OEV&VPG![33Q=;#,' NL-:NM]M8_P#B
MTLX"? _=.0 K,OYVTB;^,LZO]6)<F,_(344B?+[QS;IVCR-EC^ZZUX.RC&"E
M"MV/Q5U,I)+KW:$.)O:,"N3?:^1J1I(>\ !:7_U490.'_?$%#^8^$4)A9V75
MF_LJ>.UVV5^Y]-'4CX-&=J]OI]<I6"LVEX8-B-2$N819,) =1U&'\6HCP?3;
MH._7%0O:Y!B:_^:?8YY22N_8DVWDG@S['I6M,%R1^'3,9C+X=RWSNT8,:#O7
MA050DE]D =;9=JG8;O+@GR7UY9%SXI@O?HQ7X*/LFU<_D,"41/9@MM\ '[8#
MN[N1T:7,O/=1+^U,A;Y%)?RO^\#2.OAY\"1WK^@@W+A&>_O[0<(%C@5D"E)\
M>^,%$_B5O^8/-?K@0HS9%^>SR;E+?XH.1WZ?"^Q7DI_TZFM,4#KM: ;\J;<F
M2PDC\JW94L >C)PH7GA?I/; !0C-&N$^,E4E\JU->HR4.[] J,IZDC#Q!;[0
MG0M[ PWS@\B\-7U9! OF+-GJIVDPN7TH0*(.2*R @0+Y#=@A_&B7$#?)%?D*
M7U_M-Z7DT(P0\FW-<:9OB>8I@6M#&47M(8]U#8$<5T&93=4O3>-!D&<^R8R,
MW1.,ET9*>-@Q?^S)1%A(!(&A#M$%"E%SF?(H1VH\26+">0=\>GFO//OKU['Y
ML' OB,*%AN'I.S]_>F%!Z?!R(Y+J1G* ]YT\H1L7SMV9NOK\D:FB+7:.FS\Y
M2*7WGA+Z^IWKK[("[B#D[RA]JMLP@8]F7<2IO;O[Q:#A7+8X;\<+>3&'LJP/
M@]B =Q4;Y[(6Y-9$FU4:1G<QOU&[YN2A:+H" 6IMV/EE$<>'D/&#0O"5I^^<
MN.=0<RYD3-WM\[NYW$UBQ-LW5;/.ZB$&.TJOZ\(4^59XBUL<&WY-=WRX%ZLE
M&5 8\*GZ$@!_Z->AGHN.H<G%T_Z[FE/3KMTP3JU>P8>FXF>+'A:8Q=>;:7XX
MRJ6_YLH3?4CT;^@2>)BNU/DZ2K3OXUW(]>* '1 RJ6LBXZ-CP]D ]<(0N3^-
M@GF-,@/^E>O3&;N?195%E94%/P@9RML7>?4MZV0W+ GMWFK-<46'L/%C:?"?
MS0(.:Y^^</ZDTT-'SM@CKS[(/!NT, "M 7!PCNNRE[J_[:>L/[+%_785TV]7
M+)V6]#J'8F?:*-O. AF<M\I*(^GC&$$6X+(K3 '97CU&9W-C3.IW(/DZ+HGS
MW7LX"<^T7&,!A&;CA@C@^9'N\X?U[U=9 .- "Q.8WS$DOV]#+\!UX,Y**,&V
M)Y5C$7.J#0B/6[4/8(I1.$];E<[\*/TC/_-\^K1%:0)Q@BB7JW3:WS?6VSS%
MU.=H&P>8>A9)%P#D([TU8@M3FNE7XLI(#R:+%"8E+ND/PMMGD\&^N35A81/6
MZHE%X)W14$35PS2B%K7,L=B1/Z'H_5A&8/VYC4+L4+_[!3:P9>,WR6%MH[^E
MZ4[K&W2)![?99>_(%#EBF,$4LNVA \'4P@R%_=2E7.8PF'GL'=OX?^-$]@ 1
MNCDX9+Q<^T'R$]4H\V65J;9_%MS6^6=A@*F<7C+"CBI$,Z!*$'I3UQXW,X1'
MNUUTGGP9J]1IM;OQ)*NR&;R\M\3C838@N-DN:*MSY&YF2X#2>/F:H$-!I6(?
M?6]89W?.9<DKXTCG./EKG^A'A^>M&4[1SS-@;PRW//J6IZL:%B.76[E^(95=
M+FD"_N(/94P^PQG-9S>F-KBJY[O_\_*UX_0/'!FZ \K"42]. \F]8$Z>4,;[
M^[&1@G 5,.Q7LR3MX% J_EE?8&1E-G]_CSF=DK$$7J'13)G]X$.@ !: RYG*
MM_N<ZD?8B)\5' WQ#UGA!8(3",3:\;6T@NB#":C!FOJ'MWV^T?<RSF1CG>^F
M):DOXP12_R4X'&>0G3(('8?]&&]X8I:W]]T+\)>:<GJ<?M)ONA_;5WPLJ7BW
M.C.3'Z^F$[;B$X$"YCU@RFKVW.H:J3S6(UG989>U(>W4NE9=/)2-Q$^U(?%9
M*+ZA8$HP*8Y9>O"&6<\XY)1$YZ(>)Z-VH=3P$H0B50&?S$/8Z%P3=FU^I]WI
M(8U.Q]E&;]@U9F_8-<-,B//S$?TK\2?VPIS._S#NZOJAFC*7_!@IA'!^B ?%
MS6I1DNOL_EB_]Q?)3>\&O3XS[2?QO1NK>OY=E>69% %CP8E;B*W D!KZZ56,
M[/*#NCDK/K,\IN(5K8CUNE'KYJ@X2B-;A:*U@=/-W=?+^4_#>=H3PDQ."A^+
M)A_;6?@P" +V#9WX"..'!REEG6>>_5406/7(WMVEST 0 )^1T.0RC WC>,6+
M? @21DBPTZN7ND;\0$(E>*@P<HR\B"7U5A<F0V )LSP12_<+AS*"-IWA50-^
M"4?TT5N=KW..A.;G0XNCAI!DBPCH=]UW C<9:7--(R$*4P_YNC6.SIA#RY8N
M)C6@M:Q0DFZ7U!\S;/J($_.S\/[+$1#CEL6,RW)0VCDG8I#KT^^/?A;C'PI!
M\9JODT!U#A]$'=X%0?6K+/5[U"$!TZ%-5E[[M@EMJ5/KD3V-&$'[H?-8?;=>
M8%QWA='BQ$>7Y(LVR22E*P7/2\8OK&8Z8">PF''P<4-+0NMI,P._D;I>KR2?
M_,&C7L^^_9##/S!T[,8^$TPQ(6_L/,R_B#S,])AOP1"JNS!'Z-=0X!@""Y#0
M(D/B.[G([Y]-@4KS4(2SB-87#=]FC64'7HRH%-[<[9N-L%B]"_+3CH_^>>)E
MH:=)Q;V3+UR-'QW_L?0=ORL&JHPRL+_NX*/K(^;P42?'U!XQ,=J #1I:_J2)
M="RU7E&T*[9L6\\4=*M?Q#:UE5>5[FM&X6XILTN8S?[0[W'7&)^8:D>D%XBM
MOXP6C"/A7%+)R.M <HA8;SN(JJ"Y-H=P4)CDZ@!RQSS954 +,22I_<SCNNSH
M;5+C*!)=("$ZA*9$OS#)/ ,O[1:1/D_A>[FN5G\'YT21']A:UA.OW,ET:0D5
MT<9Y-+9B4E<[>,I+SEN?.J.X9XN5V-5BY"(#<'QPJPY4G4@'WW&$S2\$7[#Q
MPO-*79KAKUG@U\8OB=:-XO=WG;+ULD,SIJ:GNX,A0J2KCR<:;EU/F?AU'J+<
M9V>5/1$X2SM8*@UJ#C6Z86+EF*0MVO3)5LK4/O$F=$I/N&I#X7'5V_J&=:06
MF P1Z%5X@0R\D.1IGF B5/8W/UM:\_L"#M6+OL[L+9\'3I7N7F2\17H;:W<=
M@%97R!D=+ #W*L*SS&4Y_UQ,YZL9%J!K]F!02:8^FSC/G%]?MJ@LR+X,"_+3
M<GU3HO6IKLIU:;G#9IT%F&>N%._+3O8_J&F_6^;I(Z]G9L3.L(\!,ZL[*S/[
MS2^TTES%1#M5$$55UQ\U3B<]?1":KR_&^="V(.V/UBF%*PM/3?Q\:8T+\PH9
M>0)C3[5_W5K\/_EZ+7KY#KXA'_+.*T$QWU(NE/OER^(W;U( W(?D,I*X<U!O
MM^G-4;I$('!=[7Z4,)QT>XQ^-__H\&-;WF67P5:B:WEF[>CV.Y'KM;E[]OD'
M\V;@6F>).PHB>M>OFI]ZE'0GT"3*+ZDZNI\";S$Y?>>G*;>#CSF/6$_>%R%9
MX:51![E&SR&Y@ND1O<VC=:&A 49]TS-RJRT'4?[T*08:=-^6&Z[1R3P_H5M]
M2CV>3&N_<,[ZT8'E=&AMJ-'+]R-UB8:^T2OVF#'Y<!V:A(2YAO'.0$NZRF7)
MHBBWJ'X,!U.1.8P3K@!!8,DN4MV8A/JO16@J#SD!ZOS.A)\J</-:RA!X<L+/
M_S["DRBE<!_[>3.=.#*3?L9+Q)K[H0<'%4FLGBXD5KV@E/<RA297D;X;/. [
M?YB#0#Y=FL'V?IOR<NJ#$5/*$'A$0^WG7I-T29JM0O39+*/XQ\W]B:^O#0>^
MPY3"IG#X2E1GY4GK6[<:$E:ZFMK4@X+DT,E10_,YCK'G+WLUZ,3JW;-:2Q:,
M/IS+M"=4\ E04*=)-2T3=W+A&U6W!_1S-.<R-1M]N6O*C?CX\.\7PAV26I^K
M.);\<8NL\Q%^=Z>?N.Q3'_RS>[)'W4U(^(-9ANW;W+<3]I-92BIEETLVPH?,
M,E:8?'2%8:;DHN/N<$=&P-ZIBMQB^ONZ/8&@\,.UVIIW/!WO$$T=S&YOB8I)
M3;76/9:Z>/(=B"\@H*",(R!:4*/O_<FCF@!)OLN_3BKM,'R>M=_L)V=JOH8K
MVG^PT2'F>-S.R(A *X1.CS=,!S;@)H<+K?AL!,NNZ"Q=4=:*MG29P<Z@V3\V
M-ZQW)"A6U=Y2N9G6I8?J%'1D 503KNKE#;N)."5]D#.+G?DE,R-[W0FH+D'W
MOG]_851U355716+&A#DXK*:A"CN3/<@<6<8*)?C#UM2S?!K@\\DDK<SDO8_V
MASB=:)>%' F9FMMGI/%[>P#&I>ID(RLVT&RS5;(/4<JIF\T3&2"_&627R\[X
MP&Y]90"0!Z%DO%X<8;3IUCKS=^1W[1_W@8>R \;],7(US19=;-E7['!KO'QC
MNK*)CC%9B,GW$1CX:):I8I:JFEFM:# [,=)G!Y[\S@+(#5#R10S6)NF12BH,
M7W.Z@/GNX2'Z&\SJO#$+0+A%O<8"J)Q"NKQ"MNL@[YX,B^IA 6KCMUF 1%O"
MY1T6($=V;<FUPGY%9.\ &8)TVC1Q95AV7<!,0RI%Z)W]VV4Y[A'0O\@,(2%F
M+8Z\!J0J;##$T*O_K'5<V(&B/S.G&YHSC]-8 +- FC[[>F7D4A;@S*V#,606
M@P4@@\I!*JAE4^0!'[OY^28+,->&1/DB,WC_A[JSVREC3X+=BD<Z1CF!QA)8
M@&V@+0MP?(X%Z$>P "8_68!SXBH,/PP!"R+;X@ZT85.]+ "O^0O0_N%4:F@J
M76"/F32]^Y %Z+0CV#(O%:[8,9WV6(!OS IZ%?*C$-LBFZ"8 OULH;G/C'S#
MO*'C=#"$[*Q#XE&8;5]<;2I3/)4;N7D$^!\->:*07KW! CQC..^[L0#V*BS
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ML^1G,EQ=[P@U^E ?52W5-NI5^=WG01&G9GEMS);HD/#E!=T?((5V469T^#'
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MKQ'Q=HZ"Z-7J[*#1$NNW#Q<NO3+TI"C439AFHVV&G,#D+&H& XW5GH8YT7D
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MOGU;2#Q66&[TM*3U5]:/+S?R,7M6!K] )39]'YB3Z%I^Q&$4]1U;U$[.B>J
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M9%F@S\$X8$SR/U1906,#&8J?V8G>X0)2V+1D=XD%DO_]K_/^H4V=3&E4%_1
MY-D>\RBLCYF['Z[41'?]OW16P7^L%_D80B8A?_@Q7^#X(&1L*PNT$ ;^YQR*
M$-QF__HL^BDZ"YU*0[]&=GT V.:]Q2W)+J=B'SF"4^K^[YNH@'D>?Y(%D@D=
M61_9VMZ"^6WS )E@7LCO!YT$0!"I=!"T &"7*+F_V);3X6<#IQ:![I'\'^NT
M8KS^5P-O!_FO\KKLB+!?^)"PYG"G<..-\ <L$%\G299Q2BV4!?H#\V^+$CCA
MG\SKEG=KSFY)6[3=Q&0H&EPX?,CW^)PSB':2.8F<2["YR )Q[P-&A:^^EB$,
M[AEE7%HBP>+/A7W[ 9'OT1\6(/H>^K84E<8\#J&=TI3/%2?Q9YS[P-3!'?JB
MOO_-G4B^L^1\\1<[RV!%MAT3H7,$X")/=R)/ZHC]'G1SXB*WU7U8SG;+\RSF
M"0A08:R-_!PX-8(/"/7ST1JY8WS]^X"-FCT /@V?OT32JD[BE(_6H%26C]HV
MBL_(Y,^1UE+-,T9JVQI&&5GM, XU]'.U>'#.TNN?S?Z>"VGMPR4OJ*F+N49U
M*^J62R_-%WX9VM/:_"%Y^$E58F]WDY8+#3Q)=Z[[1%[ZC.8)_\'F/BQ0%RYJ
M/ ],OE&,O?(!('K3#)G#4[(HQ%4*M*NY+LW1#CC<%<Y#R8I#V+SS#-3PO[+2
M/)OQ3A<9)%B5^W)[#U*#B6TU\Z0I,P?1' 'X!!9H6BRSA.@]G4KH1-<>T$$4
MX:A6@X(5#7RRCM)*X"D=J:\J_0V-7AH#^J\&'8+MRV?LIPTN.!Y]S@+I/;-7
M!CVQM?SU]+.:U/=^Y4]6"<';!E+56W_Q:R7T-]G5)#X4C?1Z>8,?45[D2*TU
MZMLJ#=!OEO>=?+/WZ5R6CR)2)KE%I%NU\&'.3H+%,)6FO5[&4#BC?*'/\W<:
MNZ5UWJ&[]E/3P;7[4L@(,-]F.-]O0HT@[CG] 4>'.$^D#:01';.6UIF]8VV/
MBD427R.TW[DA.146A"X^4"Q06I<O=T(\;!LV-QA[0!&*DJC,]@]\.L%)VY_K
M T\UFI(]OQ+CO5\VZG V,- [L3K"\,"-Z6Z-H*YH(,.;O*<O9HTF55EO;$QT
M9!YPT*6H>X'#E2%/A*E4<P>5KJX.(G;I])G3S/LY>]Y'C]OTN0B[!TT)WJQ(
M=>@_6ZMH<N?CNKH(2&CJVIW.(WBSK:BS468I==SZIF)>7L"!O%(&3G+JC\[>
ML ;[ &-<U>Y$B>/$]@A9N!,BR.2DFP(?"'6J:^U5R[.<P[B_-GD]6"#Q@-=:
M)D1"?!"2#W$/X4EQZ$7SNFJX1EU6^(NB7T Y08<BV7YSO(:@6/@DQSB:- >J
MU1VBGP9>D%6M 1C-C#F.$Z)?Y8B?@ 'R1,C)F?"^/$[ F^1>I76(I@9P6$\X
M ^[D-SL*-KI#3^C>\^N/:8Z?6B@O*P07BJ-"*ZNSG 71D6M_U2,))_[B$_ J
M=119?WBE,^3US%A$JL3#X#\2,A[^D/;+>&YW)G5 -";%^,'>ZU^:WYT>!%XJ
MOB?QX63&M[4!L?CU^M1UC(E_/340:A)PT<RL4:EXW6T*N[>-<YI%9B')IK%T
MS?EX0B),LA[#]SL$U8-/",%$;"!"B=ZGX+ N)S$ROE/I! "[+6;3B8D>Y^C*
M5HQ#&)3^UK@^Z[ :+M>0&,78I;\X'ZV6#F["LL/2EWG:3>0D;(0%VC5%R&*<
MC"%*SY+[$J[^?%95/UG;>DU_\+F #^]LUZFTG^!S@,46@*=&6HS282.4)/26
M/I:_L=%[/+/!)HB)1>;M#=TO+<84U2=7)\(6)I9^4*?84NG/_QI7X1E$]QVD
M_-O)-6?0_Z"!\("4*[T@AVK!9K3NWFPDS'7";O^3J!)E$TZVVZ:S-162:J+
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M'VGLZ=T&2)O5R[[PAH:^RQ\OF#;Y)LI081,[7_WB KUD6J@0:>1<,5-^!*%
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MC\#F'!2%%6?DMVI#/O-P.=%U#+%"!/HMH"B I!0-.[WK'9TG3RE$<^Z">5?
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M_DOJ_^- :5K.W"NU<I8KS5&*TG1$:FIND\H<2$KE0D4H3<U):6IJ:N7*'.1
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M;/TJ7%J-;'*'&$SQ)-V&\Z1=9:=JIN11T?)C"U)^9ZZ'AA>8*\38Q>X!9C]
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M]\\89<[5-V 6FG(Z:#$J_^8?[S_PV?J?(S42AL;YK?8P1"ZSO*F0Q,(#H7N
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M$8''F>-C62[^SMW4_M&"::<AGX=_#[L)E!N>5BG2V!AN*-=D_QRWV%5876L
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M5V.M,+/H?,_QRC"R.-*4WMA9*#)+#W_./8D$HN- XB?V ,\*V^DKS<P,*NC
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M7@CKUYIW:>/>I#W/ S>RW^5<.G'_Y9O9X_<9D#BT(&CVHY37/I9':3_#%,R
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M1W.9$.;4D;(=X'<0$W@&\?2J#T<O/Q-"!;Z@E@;!<:1J]VU67QQ<^,D8:?\
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M04'J!-CH*>>HBZ@HS@.4;!14;!2D7@!$MH+F;P/^[AH*2BIJ&EHZ>@9&)O*
MQK, )045%24U%0T--5G'4L20?PY0L]&PGU/4I>4P=Z8['\AYZ6%&(;WHU=HN
M+HL1C)B22U L R,W#R\?O[B$Y 4I:645535UC<MZU_0-#*\;W;"TLK:Q)5^
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M%^IY^,HGCHCTNQ\)VLA].!GFN26AOR,RHF^\21/*B 6Q/GLE<V+BCA[PO/F
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M&R]^S22\$W?@ZU^X'U@PEXU]@5/WX8$W0/!<,T?#V(\!U;].$WK2I]06#1_
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MG:+1189'NA[EXW\^EU]#WB5J]6)?"?/V_PH"./Y%8$R'2RPBZL#LA7JI,QX
MMRXL+' 1MQ=S^"K:PG9%$6JV?;Q71.;@;P37%P/>*>#*^O$3*]G! @C)^RW
M>L]3'"!@"P40)2/]@FF@)0F>!@.W"B#ZT_-MK3\^$!?I6/[ZNKHZHN(P][<
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MG18A(7!5QCMN^AH??:DW&2@U[4)N:+W6+-'Z#)>+K)Y/FX9WLG31MNC/P (
M9U[$<O0%D$H[?D7! Z31''YF[8!Z_:\ ['L^@3_+\\Z.UW[P7[T3Y7_GP]$8
MQIJ'\X+2!9"COAEO/PH@F'L"R$PB<6V#0_),+_H*^CS0""5.*B'6 [-(WEOX
M<@Y_7_^,</[_]K3>TS_Y7WI^)("'^&E8@UGDV@BA\@'+Q79R%;3X0CTZ2Q9
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MD&W]C-W]_/(K>L9DKS\Z?2J<:'@=N(4$D)I=E6H*F(YUEZY;>/P\/]ZNM^V
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M2..M#2>;'W9>*YC<!Y6(:CQNXFG(E4(W$_$ 0Y1)8I>#K87<\[PW_/UA)!K
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M#Y8P]'14?Z=V>%S+IT%M\NSLV8FY@:*/KZIL5;#>(3/O>:>?[X+'[W5U<Q9
MU&?Y )/Z%%M=QI45<>+EH;50AWCOB-X(S*@:+U4 \2N+6K-=B>'JL*Q(HZK=
M=39"2I<*LUS[Z?:U[L X9NLTN]_9M3E7QF;OU(K+K6FI02NS<HO44.GXPR@'
M-B DL NHNV3^X5,<#S0%P(^^Y3CS?UB(,8T?H[29LO8?F8HQ=;N8I+%E_J<"
M*Z1^W$TNC%:O=K*B%Q\4+NX"(*-.=Q]OZ91O<DEYK*?&H_&S]AIM$;UVY,JZ
MG>)9N?)?I^^^&O/>\2JJV70FM(02P*#,E%01L^K/JHI)CO0:Y-V9[S!?<KOM
MYC5$# 4:H .!?-%PCCMW(QC'<1SE=U%Q*P\(^U &O-([6!B80"]-8JXT_&KD
MZWX"2?3\+@-__5;*C<K;;T\:D#QII@CI*>J@$NJK3TWR!T,%65OD]H^L7<(,
MZO%R+7:/H@Z#.AQK-)7RJP4V$#JVTF1^J-5#!+31(D5L. 5B[QJ(?.)_Z5Z>
MC^]32"/LC>\S->7P]D[?8.E5JG1D#9-)G@7N)PJ,,CE_=G+:Q<LW\^*H\%L
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M=UV5LI [HQG4HQ?/2+NP_6SJ->"5WN]_5B(UZCE##HOS+53F"6!;6&<CP+S
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MK(<S\/1 "I46V%1K"T5$MGY6 N+*0GR6 ;'1XJ#.]\/MA5.NSV^-1KPV>H!
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MH_S'<FGA0B2?H>I!Y%HX[#UJP>$LE-0)9UDY^YVN1 J?CY:&%NW1>6R5R_T
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M.&PKP"H]%%443C_NO.#(A.CA2& R<\8^AFU:&,*V];U!';8-N[?<XO3C)#_
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M<6C;_ GO[X Y+3^$:U2)!_X?YMXSK,FHVQ:-C2HBO8,*2 >E]RA*%Y N($1
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M]FYE1R9O\E_/V%R<T1I?K8DT3 VS:,L>;OM@-M?I&Q=#A]%.H!Y:GGD@.H+
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M2\7-2S6NFS9+?VA+#G?DDGFE?["H^+ABBR)$@A*01&<"]O$9G"EM->=&01G
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M^U!\,$D(QTI4Y!/]##[=GISK$W5-_K37=:QJQUYNN*GF-)6DZ3S:KBM7*UW
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MY5455:8U3WFOY]A[V<,5YPSJ91H,TRT2\J_VK^=6FY#8B;W AF(2&SLX?#J
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MWL40DRX'Q7&%;)\UK)&;O3:LQ\U7\ILWG>RWBO+Z#T=5%!,N A#+\5H]^!1
MU]=]PACO& [IZPQ4RN&?K-@[G .S_NB1?A]2M,EA93[,O+ Q4Y37A@QDT;),
MO6_> U<5J-'ME/E13J$QPJWW+/$!O61B%J\TD4LTQ4-: J**R+F/\3[IA9M*
M,Z]2LY=' 02'[PY>BDQ>-Q6:9UI-7C8[)/KY7@[87[@OV$V.U1>%BBF5^_2K
M?:YOWT6#0U0%3*SJ'(>M+*\;9SF/K(O9*C;7FGGKHE+2ELB&06]8J23MW/L7
MQJKE<F:I-?Q&;8=;IY_)?W,.,::@AWG#]:ND\UX;##T_GUSW- E /Z+7IXQ8
M5CM>.P6$1</=06AKFS/@\R+*#9;!1E&T_@QF##(/\<+9 XAN%(N-/B04J :*
MR,!V*1YH75#U<+49^(;K][VA*'&81KEB@YHL($<!G9MNM+8@ PEQ*Q,:\THL
M@LAT7,&C-UVLCVOU);^JYT!G+ 34WCR>\OJ:]?0H5]QX8*O"J5FQ77J U!Z/
MQW;_X/[QN(\I=+UBO\=PSD-:OYE$*F,0"1$=?+JP4Y2!.M(XXV,PSC/0#U.W
MQ!Q/[PB/MPKG><*N3>T^:7GK4EL]MB,T"19.'I0,Z/,&"_)6*U]<0XTN46C_
MUF"3;R48G?VIX=<3U/TQ2M4$?:(35'_Z)8C-4(H\[H%61&%&V>9S:2 1*[(?
MV7DTK,CRQ>GYKI&+!^XN=^Z<K%,87DRLX]VZ$7,<#_"2'+:_(X^6(A;I<$=#
MKZ+0/G6#A*IZ>QCZ]X.T5T',:<@F6K\K&/R]6X$/*T<Q:20VI6/Q*;@C:(X%
M8_W5\O7&$J-"W!DYY(<*37=K/I# $6U:4KW9IU4*J)[":1[K^N:-"A>G2UIE
M@),Z'_Q0";:Q"A?7D18S,!@@5MD[Q!)!>WO./<-^T%X(;XO:U^++,G7'EK^*
MA37=S%0'%,T\T&+!S?:?JR9 FWZN.Y*N9G/A'QT/;J^?,P3HTR76OCK7RS.C
M\ (E=@I8CD=QMTM" \FO*9<(6UC-L/(-?FD0?>=*BSW(X9UB*19TA>">('(7
M[S]7S?)XL/3'W">O/_W)YCD\"0:RWQ=U!6'ENP^?/[JP\3YWH-EIC[/-7W^K
MO8R<MN0=J+E%&_U6@N$>$RNF;"*\R:'2O0HQO3"=",L?>W# $C"\@>)IV.5I
M^,DPYY?U]$V6L]"5SUE<)EJ,W\,F$*L6+^G_=WQ'*D0L]#LXW\2G8W$ ZDDD
M\27B"LQ23P''#H1A5C.&&S10NV6UK0\1L]?;9.V\%&\]-CY'YX/QBGFB2QR\
M.-2T/X\XSA25S-0UNR-0"?.'=YH!G=H$CO?("92;))HF0_=6%^D<Z!FMM,V2
M)G-@W")V=L'JMY4^#FBA/9,4^J+J'X2B9C/:)@!">NDOB_">.\6;.:B9]/6U
M#^R"EVRSCWP#K+R1!5;(HL3]#!?' ]D:]E[33JM[JWW7+E^A\4ZZ[J)>SAQ_
MH5S4^Z6F#"XM&GH.L\1"X.FU5?@=V6J_PN=F_AUJF.]9[LN?]]F+6_J; @_/
M5-.YGN&LSLJ?:?1\A]'@/"FV<:;1%[07KW9<%]>AV]-^?Y>_B,\$ZY!8'UXQ
MB9DP&*'H^Y-@(8F]$HYEYI5F&<4B R?2&QI2$_84LE:L:+GQYI9;F0K:HVXJ
MPUO^MY'[Q.'?8^7_<1?!Z.9"DO<?!NU^M!C2:^.'Q.\T"L,2N:35$J=+H6-<
M9@SO+U\0B!*HJ^!88H#:K#0T-JL^R[D>.[)E@4M%>GGSYJL9.=!'WZQ+)3,)
M9?3N8A0_A.3<!H7%QO\4?_TH\AK[_?FK+M7V*9!OO.]3KUTQ@M]#X7QTM^%8
M1(( 4B0"[LZ3>\6^^*O)[,B,!?XLH,:BIU"U"B8"_6Z^^0105X"2-)N,3*54
M?;:Y=1-[@OA<G)J)RIN,ZX\?E4K<O=GT80+I#610S3D%,(PAK&\5J\JO*VN-
MEXI^QG*6]BC=;+ M__W*?X+,D:QF'6@?DU4UD<6[>E<MB,*;];*_U^-PZJ*S
M;S_ZTYD7NXGPU<ZP;F*!3_Y1:I3_7Z9U3O#'3]^</I2G[=/7-3N\D1>9LMP2
M'18855AIRQ$9I.,_VR_XE?'("!@_ ?0(7QSOOR/3I<G]_=G-R?J08+NFV,$'
M$Q52$] 9#@YK!E;3LD\#D= O'99.=X!]OW<*3@'4L@Z00&QN^"'CC[.X^4HW
M%G:5(-?S7J8;S GY/(+AH@A[I,[(=95X\-/9* X6>E I+YI6F?@@_18K6TT[
MI) M)R 2GW$NCZ0F-VST56(4U O#(Q!JVQ=]M'"ACY]F8E=:"@HL(WQ"VSI
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M%QQ^]NQD>(S4GZJA1?)2_-R>5;!@Q;35G)5]\C;_KUO)^OW?COX<A:%>5$9
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M5<W!A)N9V9\UNTN^?7X5]UE"M% UJZ;&!GH0>W@1U?(5C4-U&@KJ52+',:8
M)YF@,9XD+R4^;5HSTGP]6$O/AT6D.?PUVBVQS=J.?$^*7N*:MF*<'B-V,43S
MZ VPS*"OCT>AZL14)6GLX57D3\%SNRR<0!EQ= .S$&_X/9?/$- ,ELA#%#S]
M%J3J2F=CX?1@4IVK*I>?T5.H#(([!OD&"94&:+P]MPI?,V0<C.4H&^5Y##JQ
M/"<%J"]*!,@'Q<H I6I7H>-I"BA6%:' Y6I]6;-!V-C-I">7)V1>.C;$;/&R
M06K/]5C\94B=!OW2/G#J$ IL_65P[]M&&\6U8Q#%M3TSOA]+.=7.IQXQW7X@
MFE I@U&T4#SHBI21QZK80/MD>P;*IN9:1=ROSEC.-'=&NIGX_,X.@,C/R];X
MU?6,Z_9)8 72 @OF$.*6+YM(]U^SMI.@)0\<!"7%K0T4W<?-AOV&4RLCWSCD
MH]0)+.K$KR@\9CW]T(/>G\LYI@)U),,7[+$43*L".TT1T,<T9UVN*9R'&N5/
M L/MUK\S*["D*Q2N"-*H*?C+76%9C1=7MP:$T>.B-(Y#ZC\*PVZN4NWKCSZI
MR)*3X;'I24 ZF%Q>;SPV_WA(1>5@I9<S,:KVZ#&_Q'3A( S.U3\4!%.;XTX+
M E*+']H_H1D?Y1*($T'HM\>@J\T<-$?4%*715+0-PO=/X&Z*)BK<Q'T(JJTQ
MHK^U/&3?MI@6\:N/1P^%ET^=[BQAF?S]S*SR7Q>UXPCM YE"45\  V3V=K\O
M?:Z4<]^5.F,]G,Y"A,ST+.H'*QW,$;2&6"F8I$O"DV3%5Y^9;VM8W!Y(FMJ
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MCPO>L^.O1?_X^XM46'A=H*GI!]WL1$:I35:L2^Q?D=2PF(^2E+LG?GEJ0W+
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MT66SO'.H*4G*,&-L,SA;76=F =8&K!M,33<UU7Z6G= 8"V9CD]0T&;HB-G@
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M2[2=7C)"TO/ $!(O#!N@1E64W*0M#'(R?P)1<NW0XZ=!'@$V7WK3+&8C@Q=
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M$/K<4T./F&Q53W5*+SE?^-[=D)+WV,"8?2S"3^#G%<7+8-!KR<]R1"!YM9=
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M<P1()IRGVQP?KC&0!DHDC@5@KV'4$:!'0H5J2798T -;CH(%EMP>+AX&@KI
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MC9$\ G0X++ZK1W++W;4&2(]RF_8;CZV@<AZU-:4SF>H7":+2-K#U<VM6!T>
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MA<7$)*[H&)K(#X)]\,EF-^PMPBUB_D'-R__A]2/_/P3KT=3_ %!+ P04
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M; &12^Z+VQF#>_Y%ZK<\W5WB8/I;UZ@Q274?E/)UE2R-NHZ>,V7<1\VN>]+
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M0NM$5R@%<F#T^+N8N<GB72[.P7GO@[[*E6SM/2,/@O<NLH^XKT/ZB9^%&;>
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MXJ/:F^!2<4:EDPZ_.?>)=V/O'F013<;'L22F.*-Q:TYV*+ 7)L-RH,\,LI6
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M+.09"MY() 2,H'<BHUBG.>93?,W/V>R>&J"]K?N\RHUV9$UF[T.N"-2@<VE
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M@S4!N85YW&30V?\7A.WD@D6?X@1V2ANH\0\+,H7RB]D/7C!$( TX&LQ&)$9
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MXAX"=-A+C%WYLA,U!R8!7A=-8IG*L QLSY:OQ>>4P6:.#JZZA>Z /3SPXK&
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MI%5!1Q KR\6\9JWI]=&I6HK>AM/=;*M.<>##B_E?ZWU($%T=IJ'&,8C%S*:
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MEY:><8(ZXKP'H9HB4#M*V$Y?CZ34084:^'@<?\!5;.P_>+*8P1EA'P9X1-;
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M<2BSR,1<$>+CW'G\?:%#[ACZO)NWXTI8<0'^Z.>Z-#K[O6=(FH+#D-WXX_:
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M'IHOUAO".1\HK5I0IA9KCD79!PXX#D<IO'I58%?^*C+_##*5]8+P=B4#U9A
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M(V%)GG<G7'K<JZ&H'##QY8??H\B6 ]86(^%^YP1[EXW2)(G-Y]\/E@EN][?
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M3T3'T7 U'NTM60V(%M#&C/K!@DPUV"NXXK (- L!:5S$Z_O@SC4"?:%\"T?
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M,A#^$C^JK7*@=;HC1Q5]9:L3*O<Q9V9KN_.'3SZB.[VOO7:L(Y(-"Q)8!5F
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MOB:/CXQKQV[IKLU8&05?+ILT>Y_@]:/(T_? P:JJ6#-[XS=EU1U/6X9K+!8
MC#HGS+0VLZ])V.-:>>_MY9X!2>)_)T.,9AU[V#<-J_W0/\82;#\%90I6J]Z=
MVY3 )K/?5&BYO%BCP>!&^,%MD#3<#(<<$IW$IK2P#N N,"E&T_U_$F0 C04O
MM?):%/;HA9:/ABN*\XJ/,>8)'&R'J*=GL-7'SN'5B[:"[[L*1GO^RW7[&8M(
M04E'+AWU_&BX#8)@1WO/\0_W3\XD1]HAY#%M'59OHO$U[6->'PIW;7C.YYG4
M)+??9EG VG53M8(D0&NQX =27&0Z20X/ 5QQ%J%^TV)V SI4]K8@=P(3'*-5
M+S<BI]K0V[2ACG*X'&->=U(#^N>[&M3YW/I39:>0@L(GKIND!ZQF_:1T6@A)
M$K>'WU9)1A=HM,&/\:$I4*BAOC][^>4&^ %5%7C,\:T.V$7,C"R,73HPX\*D
MG(XH_QS24?S8J/[U9&^U?NLWRC4SOVNW<%K*+B/'SN?N@'H,^*W=M?LT_6)U
M)/B8F243_UX_UOQFU1>5%J>VPKYCW"MC)RM3<W7K;S@0&(_?P:G-YH;45T7?
M#U7>JS=?K1Y-U#W9[1J?>53>?=]>UP<.967?Y*$%6L!];E^R07T#+)0SMT1N
M.6M"-VG[B7WLF2LY(#4[=+P#D=3P/'8TDVLQ5.[ZV'XHP/U%XR/7I5#.U;V;
M[=,0H=PV2)"\1:)(AT]/RMKS3#)FF#"_6F#E')_(4 0RJK&O+_*UFME]4$F[
MVQ%1;''=*58>@OF@ \KF1A^AO5#$U7"%N0YTHE%KZ\5KB<>HH<#6M"P[@;<G
M;35<"G=Z" X16G]<*W)_VS'0-4G@P%\]QSX8.\^7%]VO,ZB@R4>9"?TJ%S;4
MRD,B^ZVF%B[P1I[.O_#YC!Y0_1[R:[RE^L'[YCI5!>U=5JW[')P$KGZ[S*/0
M9I>K]W6<QK7^Q=8UJO[Y^M;[#-?E]Y*YN7>[OT@5C7G>B<WH_"Y7-?2@FXVY
MIFDM_;";64FDN]/K0@^9/XE9Y<OQ7\(L2M2PHXEZ4@9>CVJA>&!LTQJ[SJ6F
M\$ATZO$6WG+^<Z$J3TSK#X702B#LO:AG:FZM/F:30=7@&S<>%E17UTUI\+7(
M,6%&F P8NL//SMOT>,MKTV=[IW98RL^R>:LG6DK%)4TNN/N#8^6NX&K7:MU6
MS;"?U68?[!=T;-IKX9B3_S7^HIZJ0)SN=NOA8LXGF#\I^#%3:^IW<_7%2ZQ)
MP/(@_7+I^:=.MH9S73J>?Y'GF2*I)C%.N0M>;8,:XZ=[1854S;$?>:B12J%*
MP#9(G;QT>QODOZ>3N&6"LR/'\Y&BB^D3(FH ;:.Y"T*)4R!\7;LYL'6?#Q95
MG9;=B'R>JO=+8QOD\2#UV+,__T]9E!E.=!<R":$4*4F0Q#GP6HGIL#.AU>,8
MR=(09Y1U97_<=8V#*A.Q>J]=AD.-^]21E:BM2H?75B<GQQV>.,X.NS*KG;*Y
M3MDSMF400UWG[!)3FQO<8ZW':(;,T_56N>K9LV/E#F^4&V_66K4<=<JY:&>]
MCUF0K:W0$I&%7KL082DG;;U3NG?_B9Y'%OLO-G;+.59=Y&8:_B%C^+>\]-^N
ME^7_!DEDI>I*&7_2^X _C-, HG@%8&EO(9SWIC+).HUR+HI#EOUB>;LJ1#GQ
M#4?EWZMMA2XC46>]?FR#'-\4A8;6U^N/QE8F?O@P)6EW<;HMU31OL*HVP_;1
MP[F>VQGF3ZE#TMG9NK>,V0-ROP+^G8CXCLQI&\E_6C549.L:9/MT?G!&8*2Y
M]WTY%*WF5?P^U,Q9\&@]Z-\QP\B<T?N6<B[*_]/\I<"Y#N-'I9+L,G3,G5RC
ML[8_/88320'A@="UN'.,]HWRE<]<XI)7PN*]LR-?-Y<-#NW.M?K++4=N>0AM
M_+AU9/7.^$)]QQ5[+2;:F!PXU$$5Q-:NM;$MY9P._4\CU"WE_O@N@@,6O E.
MQGK\&C@9+L/$N4=,ZT? [-@7UX)>Y_9=&CN2-8Z)LUS]M.S/;-6I#SM>M[PX
MYMI"3?T@&!T7C)HVL#,#5E./U>;89CW4>5_VS2'/I/EAN;8$;J4 ]RBT1W5H
MO?Q]WNF1R?R>C$,NM6YRU5WU>&2HVXGT$#=!Q-?*I<"L'&00Y([JTH_>R8S<
M__6._(_E/L/J00*ZJ$5-'J0[;VH/D,!?L"1VFU]9P=2B?>4_4MRYO4/AZIJ!
M3</+.,62A;8[)B].Z)PM[V9$'[RX_U9/EMZQQ<X 0/B^MB1ONA$[_]X@+%<6
M["[K:!FN+7'B:39NO/'KC)+ FO[)-7/@Y]-:C4ZS&CO%PN^'+K7OG[=C5]1R
M]1S+OH_62#C8:RU=QS]P1#UF\39)@!9K2]$'M0V24NP!B_RJQ$KXRS:HTW@;
M--LQOPT"@JDG"#^E?,D;Y=VH5?L9&H#N)?R(_T;CZ $^VR!KR'T$7_]?PB_*
MEM]SFC:-O8[@V=,V##IH(F5H.D1(=]P&@<6IY4'H-F@P:F0;Q!O$7=T&?5<F
MKMFETF8+!P@\9N8VZ-L?XBJ/ZEK9,!7NVP:EA(GYK7]F04K^U]G_M]N!N &A
M;+@HK4%,>8EIW#W;H!/#A)HK8DB\,!4KOO0T>AMT# RDBA0)@[W32*'=+8@H
M'%$8#N@C%V?X.]C:2^5\",>M]CGJ'6^=Z[-5F4[1Y+RL__;X8O$/>SUDTUBD
MSHJ\ETJHM]UP?8!^P.FRID\#Z&@)BM-)Y+_*HMG?4\%WB1/Y U?LNK4XN9L#
MC_VX2/"D_Y*78AK\3^$EOAKQ=F8Q/K\.!Z,T%1ZF_*LB/QTD^"R^8Z>,#1"Z
M:2[C8(-H//Q.H[B,!#C#'J->75<-8N3?<7[0]_/ 3H[YV@O3&-.+G!.?5%V.
M>.7LM<K1<1!S-=O1.=T?[NEP*NO6E;QO* ;\+ZP)FR83$1C-\-R36:SZ#;BR
M?J+[>^L/8=_9][K#7?XG1\I3NGLRM:4*;XV6P"QM6W5T!LO-3V2C;5V?QI71
M,@KT-C7%N_5)_+UVB+?8:*L(P=^[3/CUGQB[I!JW03O%&_L<LVE.X$B+O>)G
M/CEHB]!/FV7Q@T32;F)#^',1'!"O<@NR(K8;;_W>-F@F7QCJ/@3?N54G,L,9
M\B&=8'G@=/?EX(VQQ;4R3,<>NEWR:JA!<%TD2F;!2_"F8:Z@OT4P=(ZC9V^[
MR>AX^S+-(W,.WW_S'^O&T.F3VR G$F\"PON;L*%%:ZX4'3D\L TR*]@@"NX,
MTZ:)B%;?DMO/A6# >A,"D!EN;3^F;-BQK,]C8IQ(H#AJ/E7!;?:AP-C:M^;&
M];&8W6LFLI_'/_SSI_*UU',-^_L8$O_0'1I"W\+.[=<XZNA2G=EERF8K#U>>
MKWE:ZS=BVE.NG*.#S"\_YN 88U.YJFHRO<L\/^<X8A]V_:U\<\Q0B;GA*=4I
M^6:)YDX.#Q#"JITZ T\S'#QP@8I2J65LA;G1$MNRT&-:M(?]L5[#,)L&#%Q]
MY)OGF@_!=3BJWB$RU=0IU,*54K A<$G4]'CN:1"4,WILQ#_]Q(7+S_[X*#0%
M4C@K#T4FO'4&XL^0)"N^>R)4[:<==?/LFR^FQ:.QD@MZ$WHOO[?0F%'VQLL_
M[48,-U\&M-*89(.ZY:/8H"C$;,DV:/_937FQ79_A^VC 5;BLV(2:UL(3ZXMB
MU61U?]-@&\2^!R"W0?_EW#W%)VD7Z5PF@;F:5I&3.DXY.+U*72>B1O7[ ["&
M U+=W;6FLR/$JO)58ZZ$:0=V T;(=NIU8M"5[!21._(MI)'R#C7U^R_I6=4\
MQ9QO<O5WM'$PDLF*=D<,R'*@W40%H0-JOQ=FQOK%1Z%LV95@_$$>+3$2 SX
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M2A,I@0W]JVX!%5 :G? K^#ZEHN"HB0]6RHZ+W+7\8"EHRSB307]1[J<]>GP
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M[JM.TF,]E.3;UQDFG3X27O4N9GPCX$_ZW/XZ@9V/2;>EP>MA?=\^1).E!&X
M_X>8?.T603KU 4.61SQ..>CF2^'' OKDV;TAJ(V.6[GV(H@,F,5$LF&RP7DR
M+9]\@HO^&M[0/SW/F@GZ[FNM[SMK)3WKD.>_^?/7 VUK^).9:-4-S0"#?!O[
MTZ;P6]H&]>$7?N_J_T]?/%5%<P*8Q$Y8IJI<$V#3@T\LV@D^9]D_XZTCE,%(
M>X[T8^=S"=(#68O'?[PE^1;_D!8\R!U[?<3C/F;:C?#&A%:[NF+&DP_GF"S'
ML&E[A1^(6]:!PV-X/WQZD6'+*-:A>.%(N2%E>81#Z1K+#FY7::EK2(&+QY.
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MS=N)F_:H;1OXNIS#<YS^]+;A76,S:,@YS(X]_M)J5J]YR[]33FX>D0>T)(]
MY 22? 41)#ZU58J-5PRZ#>NAW441Z'BIQ9A<KC/8TEEDC%:J2N8FRQ_$5P29
M"%6!;OI"_7+'JOKKHOGO^[?TRY7V/TN@O?!1]AIJM2I9\/WK U7*Q^/LF-&4
M"MIF1,_?:YFJ#W>N3UGK% Y%:1RN;Z'FZR9I.+N?>^$NL;T]P(RCG(:Y2=X?
M<$#_;D=?Z[5OPYL#=L.OUM;BK"3!VR-!3=:<KP3$,4?I"B_:4*/AMX7?9YDQ
MY]W5'I@[#?[(/Z'T^'E:R0%YV,XDNETPZ74.=C=B2T*W"\E)9S'!ZX+K_(@G
MHR#B9>:/9^AQ72[;V@,Y >7FV5CORJ!MPQVJT-7NJWD- #I]?_]U?X?:7_-5
MP;#7LRM?*\XW*%&62WE.BS&2]S6(%T $Y]B:?[KM9:7^R.?G6%L,]]R[?[_K
M7E:(0#$D!\C+,%>;ZW?PY77,_,4PMPIZ!N:A@5NUEGDW\[3+Q(YB\T&S+ZW8
M-W1>67!L\W B6P'"[-613_2<;K6:LXY07]1+-<@B!?85EZ<$'^!IZE)5<1Y7
M)^?K\[X$3.*[G@!8Q(0(,H;3R*S_*2#4],VMW$FG( *6VT00_Q6%MCX!L0Y5
M%8I_/R7<#^.*.Z?DE* 4#[SEGQ5!YF]G@I?P4_'"= FN&.7HFAP9$>3)H@AB
M8ZHE[L6) A'D0YZ^"-(Q3A':CVVB*&#6>Z@(4MR;C <*Q-#P194V-,:?0_P'
MVW\5AP;%"FSE;4R$=!VZ!K9R(,N1;11"B9\QJVEP#TL,:9G>-S,Z;>%?%#B'
M9D>@OTU8:<[Y1@1<+]!WG#3QD!WACYDVKS5O', E/%6)'N@Y<'XN^ET)H8\]
MV=SLC(G5JJ=<FU,O<""%(#J)X"$1A"]3PH8O)Q=C?K!_]O#.&<%28#)1_3#I
MH':IQ$6II4Q)S+&^[](H%_+TI'ENO/<H-3#T<W[GJ/<_RWKK4V<T^B].(\-#
M>60KN5^^,4_G(OF#,OGS^^*[V/ZJ@8Q,#9T;I!V,4KNGWMD72(Y'4^8?OUC^
MHFWGT"! =CP]F'T#)OWEJ?Y#EPJD7M_"<+KV%1V=QOR-D-'RI"YVA+&?9$0A
MUOH0V8YZ0)M!4C"P<UU@I!W<EZ)%4=^\6YRB!?GO%,I3VG6$S Q&C6LC*&\-
M(CEP[YSI1-3F]8@@,N.?\(-2 UM8Q.0-;Z^FOW"+<6=Q)=\W*"4AGZ&@%I+_
M#WQ%[%>NW>/9XQ?_X9!/?&_SF+=R'S%-#WM^O,W5VP;-.X#QG>V U9@L4YE+
MYUH+\%*X][1M6,0!#!VZ3$P4*E=?R[Z+"E+=GA6K#%=_OW;2X!UR2.X+XD_$
M9P)?202I<0%611 G:=4VU$/F8S_9.CMMC0GU+#'MN'\_1?=7!O@[6,P]CL(;
MRF2M4')"<R6>D^CCQX0OM\R1#>D(B%#9"PQX8^J1]-WXCDV7I58- RO-DFI3
M._WA=Q"0 #?J$%L:GKQ!]HI:L>SYZ=7>W%!7V]8DM[_)=UIN968M+>K7OU\I
MR:6$J!QW]JN^"!?LJSV?2TUK'D\%?_Q"THAZL>H?XD-9Z$GA'Q5[EPO@3Z&D
M/<]ST5)-4(</IB7WLO#+LYQ]/F(RQ[TCR#;"_XFUH&IV-O0EOP!I73/'VX%C
M6.MPZ)F@)ZU&%/;+#9CLC**Y52P7)EUHZ# BN+DJE,H40;;.UH(E<+JBI7$P
M<ALM=>R-!UJ6"6BFEH&:(6QN]EMA-Y&=$D2@I_3#I5\F%]CL@36DGUUX,_-'
M]W3IJG'(A$G ",*&%/;NGRO?^A[K# A\C;VY]GM8=FYJ0W8&#J4:059V0U^"
M^HZV98[IZ,Z%2PMG8+6#*8B0P7U".M=T-DD?9P&&=,C/[MV=4P[>7.NGBQU(
M@L&Z0,T]W@F@)$]/.8[1%YH'VIC>QT[=G[H0?8TG.TX#7+@SH#3O%#9.\ P?
M $_8)"9'#R8A:E5+0XNQWLUYG9L)>0_J[MR<WUP]KZ21F5S6G4%Z984G!><R
M4']O*5E )3LO7%]VRY\V+N4NS'Z8<'\Q:?=".3)'_7'Q5/G63\R<[U]D"QZ[
M5]LV7'VR,2+'%^ [8G\'49DD<MT9>#]I-:X/R/('8*[@'*?!$XR9@RDL%NT!
M8]D#AV;M&AL :A7QY>);CE2G\' =HVYZ^YQ'T_!J512']([[5JNQ*?#1G[$-
MG7 HON,"%9I"DUXQS@0-&I;C.(BSV;V6\G?B6(,)[:JX]\<PF;VHK4HC.3TM
M+(N]4>CM-A55),K"7M^@W*R%&JNXK6.ZQJT?[97^K7_^O?QDCTE;]GQ+K?T+
M%!\O-96+^:+T@TZ73JK0\1V<=(1"]]M,EHK!4F&O8]C;^E^75D(-\+;#'C\Z
M "27+7C!_QT:Z++8S'*$ S,GP,$8?QZ"_R>H2 %[6>]30\4TB+6Q+"9YT;HJ
ML#=Y2':<?0MRER=8TMV@Y+RD1.6;PI/-3Y6/+^X[49>K?U]&X:-8R0;P9668
MWW^?G1*,X4.0F;#Z,BKG*VLVT1S/'H"Z@BL<!68  ?='R$^/>I)MJB.@F@-0
MWISF3KD-_Y7_V:9DH,PJ^E5(EN\[AO7#\9;.ITH_AJ!GA9/-WBBAQUCI!I71
M\_'EI,=]YZ[NOA?E5O!7P^FF6;7E[UBQA\N*Y^3" YE?9$60JUJ47AI!! %\
MH*#F6!?M %85#&(-*O+/$7IG#[3_!?JQ>N]AM2E\30Z!$.T5C59:S ][Q+((
M<?+Q'1J=F>V\O?&]_$]/,'&4S65<C6Q[<U?O"A+!0(0(<%^YC\0=]@RSI9-6
M'YXN?A61BP$E.)H]18H"(A4_T?+&=S?0\$8?_S?PI92;787!L_E'?4-@\NJU
MPZ7U20OMNM6YG:[#U^)2XQJ7<[QNMI>3X:_N#/T*WJ#YF'R@D%FS\-H*R59&
ME @2X_R8K.'H=IV1'[IFO7C$N9!H C_TN(27;(4WF 4<9T$XI2,5-@%G993R
M;F,C.1XIEB>6?'4X/H0,\_ 2K,J35CA+Q7*NVS2'<G_%/.0.T-\QB8A?EVI)
MWS=BL'*=?%UCY+L12_YYS);DN5SD1_QD/Y?Z :O-<Q'[5(M6?19RRKX++=5J
MR#L+%MC>D6#EW1/^":K-*<0C@NXH>W$T$RXQ]#80J:BZ7C?0Y\7BK>8Z5&@[
MC15I3@ZHM'Q5X%^3D'HC*]1HG6:]&AI5PU_Y>D5[[O5&8 _U9/</'0-70:G6
M,&GER_X.5^>7)8J^[E_F6_,C"$:5Q*4<.?X,7T[0B@]"R(GK<@K/?$W<AE/#
MWA[&(@ 3\30\R)'J%D$DRQCM^_FFHZOMT@///1>R84I!];?:%1G&@TD>,TIU
MC6TCH5@3MB#._?7HUWMZ!HD3.7,<BAC] *_,_<+W:. \[($((B^4P49P$"O^
M'-(<.H,?P K?B?L VT>[QH,^F+0FEF#"NUS&P=P?'@ L7K%5[O<MI^0(4I O
ME$$U*S_$.<'SK8T,PN6'OB<>7?X\:4_1:&AHST9-3OJ@5ST.SI^(=HSV']CA
MXID1%N!@+\AO>$W4-W9Z;^<"*J6F/W7]Y*\ALTDJIHG92@ <U$4NMW$:V-!E
M 2"U,BMK!$V'J>"4IS&]'5S\'IQ\R,P6!M\1:QC$]FRU5U?(?R&?6__3<!:C
MUO4C:#0U?%?,!_KUZWFA*\4(VH1P%EU;5<)SY*,$C]8' KHFB=VK]V:EOX D
MSC%]1&=S^EA"ZTG6/U%M, \,B6-^=OQM98%%C(-4J?6NGGF/.CV#R[D:!9:#
M(<O<U87YJ-Z]IVU/C);]*BNO<#38.! [; )^4B(:\-NYD\3 CV@#7*\(4@_K
M0$YE,Y?%5?XC&,6M8$H1]X44R68L=17!6H'1,N/,W=17BT['G]P>.))@.?%'
MXHUNC5VWF!5_;*A(&RTS',**TK'I:EKOCS[54.R,<$XK'B[1>NMCI^]CQ&@.
MFGA6G*(M^WLE_+]:Y 8Q+=8-'(4$<R2+UY@;YQ-#GQQ-C]RB%9T_Z\H(NUZ6
M_/"^XM6,6Z=?['GS\-1 E-$%92)$;&NZ&U-DO'#G'$_#XG-/;!3TP6V;NR6/
MFB("@*$?%\!84N]!]=Q<9:C4U!G=:H,UZW=?(XQ_;N#"Q4^JX;^HHFMI@CB^
MHP@R,LB1IYW3NEW/>W)!N VVN8$40<XE.5G)_H]O3_V_)1;>.WWZARTHPZEP
M8Y#B?,Z<!^TYL O53<DI;\-C_9DKU^8G,>-[W%A%ZH_V[SFC]==\6W"K'U<\
M'[(QX \Q9OJQ,X7/-E>B+@UA6G6"%]A:AXL&3*N; PY;-#(C:E*#G3JOH((F
MREX.E!&MB\J)\UA;]:R;2/6B%YOY6L6T5BB0M-BZDSD=SC9)YRL#/^E'IP;8
M2!6P@CXC#?!-8G8&A1@TL--]!\\.^36U/-R_$CHCW)R^UGC#>7__N3<)QEQX
M&H+Y=+8N\T'XNO<))A@YIV6,2,LW>:/B[0;B.6ITWR,,<VE.@"]'UE*68:[&
MV;;>DM<"I"]O+E-(K?F%^:>DNUN!@4..AU+0!;2 0<5OQ-TX"_X>,($=9' %
M^'K/$HXUYA"3-&H;0EH:UY%2X*#5Z(:7?NB%BD^?2A/2Z:?"*LE&S_V<I;:@
MJXX*)_ U 9WAJMB+'#B=HH2U K,C>!>$4[3M^$!XTL])(GT4P"4#M:R\3MKD
M[M6YX 4EX_3W3>7!,WJ<A.%\:D^!\7"$U_C%22^3'.FT(?48&+S([T>K@4&Z
M.45:[ZS&:<.(S?3;ZXNNF']<JD@II!,NG7V)>X>[AM*M9PZ5GOCP0%,G&3X"
MRA! V/&WG/$,[7<OOX IF,TZ/Y274,*@BP4 _0%);_H279)('C+YC'>&@1_[
M.&XW@+2;RY:'RBRIP4; T$W^)& C9A@>/4)C\ LS:@1W ./XDQO=.ER)TUDJ
MLN#,9[)@.P-=%G!'P__X%(M3&^[S]+'13':[3G[A;M6XKUL]=I]6)?$^HM::
MQJGEI@SA ]K4NMMEZAL;1S9X=T+8V_->6K&)VQ9\58"B@I=+OAJ<Z(SGI>\>
MA6Q:Y6:6^OJ.M^5T.06?_3LU,EQV($+AFT(B/A ZP7B#J%OM64TMDA"0S4-*
M,"YSE$PJ6@6L/=,J>&P$5_QVNR&1&IZB1,B@0A-Q&A_YX6Q]IZJP70K'81.^
MZA^7EUD*[F.9MW*O>E6,"'*$VOS#H%@?;K/F$)+;%3$WQUCA8@61GA_3B]^*
M-00^OT8%'0G:I'0A$W!: "WQ<NY0GPVC+GECY?9WW4>70TW&ERG1&C7WW:44
MPR2;WD<?L Q'+XX$#=$_._>P=)%_I-#C=OF;ZRN@<@+] IVY5/F#;!U&@@(J
MO\0^EU:;3:C?U(-O!?1^J$KUS_@_Z+KR8[=YANU3)L _\W@^Y,C;",4JPT7/
M-'DU]7><U)V$(M^:3ZJ'JH[MWW6^>OPM<IL.)\'_ 3AX7I",.P+FL6!IPN/@
M,1YK-16KS$1+^V)6NTRM'W$D.O,0>Z.(A-%-*C<'FK9!A*""&_)[,LLN2NVD
MM!;T*CSRBE<[/?Y5$RWXG:,2)LW?"OKQK!<M]]@ $CW0_5X8V!OYXPH5+\$I
M[S%C[U#<#VM/OG+ @>8^U%)NN_)P6)37.PVJ64QU8UV*9_C*U>REU>U8-\$_
M0DEAK^]1T%8LS)-5U8&Q%0G.(>7/@A=Z5$K"[7F29EHE5AL?8YG)0X#VW5S5
MOQC76V68*V%KTZ'F:'9RU K:I:VQ*;;SU.4_%_K71W\/TCE!8:O_<[[6B'D(
M0/$6D^=!2=RGV3^%Q]'?\B62-E;E,9&=(HBT4 Z$V0(QW+'$0WF.0RN'A.\!
M[F-SM3*^*;7^_CL;,_"AKVVYHOS%D("+R)TCN0JZ%1F=0^^67-Q4MY?)MYV7
M,]WCNN)(QO#L,&EGR,ZY)E('SKI)'G'3LBX[?+1T(IZ)EUSZT,D8 "NV/9P?
MKU+L\,B55Q3"C#L^O*\^L3G4;8=I-=A7>:.QL@6>(0--?FL8]&6M"*&0E+/+
MY_QQ+W?J[\7'W5B?AA2OKZ '1W7'7Q^]N[(=3.[Q'60O@-%2NDMK_VZB7MS6
M.7:L_N5GSW+W[3=<YR([$%O-H]EQF3L7)V<3L0$L1*+EH;$Z%=T+8&TL$[_'
M%Z-)WPQKJ$(%.E"F@X56N=D1E_VC;Q7_W5PGI9<2FG793(<XA2;, FYH,3/-
M8UXL.@$^YT2ZBTV:%@2=[.\1,X:IE]05QUDO$,DQ/,71)W3>V;W8YV-5,A8:
M-=7F>ZA(A7B'1(BO>U@<:]^P")W\RAI,:_7GR6(0K)]T_+Z@21]2,A8N_A[@
M3$ /F]M-2G29=6S/?O8-IPS:Q)4N96$MFML9Q@,1T;,J5BP1!'K.?VC=+_+.
MP9;JC,A$M=3:ZX<U)>+?'<N/C1GC['F.5#3-^>*X!],'HAAIP9>+2]US3ESH
M/F49''8B?^_+QX<7;8;ZL4K,Y2G]]X9%JNQ%OKW@7JYK+_OF10N]MBL1)XC+
M3VG&':Q7KIW7W#3MI9,I23U?W#ZIZ-F1<^?WT5USL*;T86%@NP56A0-;YG$*
MV!X=:'E[Z?<T8*Q[LB&!0@EEY<^,N?A8WM2CQIT($*QYA<A#0\HGDJ5D0F)V
MSC )EK9HC-AQ(\TO/P.7N%Q!V>],0?]&JZA@XR0(SVD-.A]\?3 F=)1"/-4^
MR<=K]%SI2)3R6(;;+:^'R:XK$6@)CTG_$RGCK15ZW5<\#-1D\IC5^Y/6UFZ.
MDA-)SJ\^,W)'-#3Z_?L;S@!%!OW 2:1\A*5;KCU1O_\$P;1_[1?/QH.X)?Y=
M]8GKZFT5H</SSQT+N.D-9C^.K]Z@K,/%(N-BL$(^D2^SQ'5K:B^R3YX#??PO
M99WK_@<5A*JJ*!T_DV4[$>H7$!JZ7[B?[7;@#_37Y^AO-F+A52Z"/(X5]HD@
M7,<7(LAPMB^EKS78GB>E?<O#JRU[,;N#'4:9F$"WY?EM5GQ#S6ZN=%>W?,'J
M.U#O*&>$WK>E3FO;:@ZMME@.@#DA<ZF_DT[7.H(A,2\6VLV'U^U7##N;VUL#
M3"T3*H./4 NK:"_/!&==G/'^YH#@5C/(G?;E%OGC>MS90).CN.OXCN-B9A&>
M!*NY,]8MA;'4\\$Z@1&<+3U%IGB9*4SNAR#AP0]"'1#>TSR;&,;W*A;\,Q 0
M6PS^/%\72UWR3KXR;#3M@AQ"R0]?:FPM&MO M<8P\_BI.'T1I*:;TR""N#>D
M5@!BNII,_Q*;L;W@Q6NPK]$C.>TEX^FB*6[4%1^GU?R0:^@[1*Q];+%@3RPZ
M%H&?Q? SX;T1VVV?L@_Z>B4Z);[+]7'?7^E@BHE.V:3JH3#!T7Z)5=6N5\O=
M-[MUR-:%VL[<:.V>D/&7Q2EKR.+_D;,BO[8()65$D,-2O!LBR,0SW-#L9IEY
M"!H]]B\,N$#\=00]11 .;.'FBIGDT3E4Q/1MRKOW#< K$62L2019T.,2[\'6
MS@BE\1/:8(P(\C(QTY?LZP*H"<_A.R@\#<1N$61CS\>ED7(%E;QB_OT4K6>7
MT?2Q3B1X.*83#VK]Y,N-"25[7V#]./#D*.)N+)SS->/KASK*;KOZ@<@YM,KL
MTJ0$ 8M\>3%/6K_A_K7Z N^&H;U^#F@G;]TX7N9RXVIE-/2[?.. !*N7/B@)
M$KK:]0':7;XBBR8'OH]J%COB.IC4M]N()*Q7I/);]1A5C=$ZGO(=>Y^BDQJY
M9_-<FYH?J7JI>!I6FR@V1AJ71-3<:?O6(I3_-?N\-[6#T6,/77'U=TSW<'?]
M7."&B#FAOCQ"UBX/SL>VDKVF\3IXX#Q\$CY'(@AEA!.S@!4R'57Q;9:*[T D
M(I3--7E&(3$-F7]B**<;@8R*\#),@-4(/']G%:(FS-@,(8?1=>JK!14\O/3G
M$J<Z%V%K$MRX1M#A%;[#W!@_0?J]U'R?B"%Q;P!\O/PJ7^UWM$+<+/<,$- %
M39*W-*CGM&74DL#<7C>9()@,_&&PNWQ,<QEY>TE 9,D@R1>#.J/N$%Z&%D&>
M=8_]#B;4,&-&!4OC@!;6R&S7DERZ7KN:CQCJ/53-:L^1U1EL>[1"?QDB27]4
M=V=93?J5X3T:+VJ\M?:T'$SA,7L[5I ]K[%VP^TR?.-A2S54G73('&_U3XSO
M:D_]0/!]LVOQW2X+SB&OJ:V7U+>;;1QY)J7HQB:[V:WFOG<PN=9@[TY1: F=
M*OT9]_1FWU<MYP<5Y:^.D D$T\K'KT?\'2\D(/U]'Y-,@_/CPQSEU,("IP_C
M]<3ZV&5P6P@-<)RV%^[\O4*D!@;=84.3(G'O??\ B,MO.2[H43XBA@7?B_GY
M)@8/#5]NU7V)R::;EAC/Q)>'Y#N2YW@J9^Q'#X<,0-UH'\GJQRY.YJ6N2PFE
M 5"1@M'DZH_B T60I(=O3;HI4]YL0BHB$"H?HA \&][^P3C4>G&J\] U_(RY
MPL28N5>HV@\CG.Z//P+?.<9E@CJ$97V>&%5.*Y\2$,4:((2+!0-X"L$HTCVL
M$^>0 _(<1["ZLJT<C*>;5I7$XLN"^D.#8IBZJU(ZZ0JN'Y]E_:1OOAS3+S5-
M7Y[$[NE +#70*7^ X:P ,6/<PC\&1#]G\#6 'YV6!P";1#VOG$G&WT#5HX#G
M"_+OOSTJ:3TN?YS34AE1<2QWQ]T$29<VHX+6@K$^7==ZU'3[XFSBXR-9&9=1
M#7HEA <*-6GDH"LZUK)+KH0V[9L\':.<+]>^F!:T-/"[Q3YG4.T-22P)[T=F
MIEBB^;J&//L0/S8\/]HJ5;C'1>)>;VHK_?DC<I((PH()/\Q$W33^N\DT5@'G
M< 6[FQ/#5^H'&',*=(0J5F[4W.0YWQOH3<=:E&-/C)0@&JX]XZH>\['>4;=S
M:+![[RSF%BOQN9YD.7D26?:EP8>4M3]S44*LUW<*Y;$>5$8E3AMK))97.OWG
M&O-7;6LY(D@\]N2<LH_!XKQQ(ONK8P-'ON EW3_"7.N1@W&-E7IU<4FMSEUS
M-H-[5I!=:4"F5.*O02?8?=P^MG*+63_R/DV:7$4V(+_P(G\/K3H(##ELZY(Y
M9+_KHZFM;%)56N6S!Z_B7EFN-9C0S31C[GCH\GM=MIR\LGCERNO(:!7Y]NK$
MZ&"7J.+B0M.4RI-A8\=3;;7:"3^,@:M^0BEOL2V219!:.S!^R@)[$/B\OBH(
M67,Y#\2D1E/ OZ!OT,KCW_*)24)EOI:X;S,PJ3V(_4;DX]K?Y^([G3&XJ7,$
MKQ&]8A?EA=RQO%Z;W,6;^T:_HJEGDKY?S4*L*U)!%Z"YOZM=@U-*I(=#)C&]
M/;>@I1AZ=V[[;F"%EHSU*.T_<*2_#,SS275T</%YG:6,.11GX;RX.#UW7S:P
MK^L>#B4@B2#7,E.4!I>78H%:KAR'0H=-F/4<P>3#]DSV*G2&;P_&2YE[E'T*
MVBPK9".W808[JL$PGF.F%<<Y6+X!540F!3:8OFSZN.R79=:B':ZO6>H1JL\W
MCEN_'Q$>UD#+>Y)PL<91#E87&79"!+FU)],0T[P>TJUQL@?^Z/>*NTYQW!MA
M*(WY#%^OL)S.\\)WV(H@S)081(T(DMIJP9%$;A-^A.W(ZQ:S^?8GT=L(A'7B
M7KXWB(QFH?]85$H8*'SB$V#K+>V^MD2?\D5#4\EYVJ$1<7K&-."\W_^=DE5B
MN]AAD;!7$40"_WC(=_06?(>."'(=G3);U[N<P\%SWW \ENV9\$1B-2V5R+:Y
M:ZDH[$;LQ@8Q06PH9[>%#7WSG>4ASE.<[L>Z4$/'IM91[-'GLXN#S[M&:WHO
MC;HK^61.J7Z'SL2A'] D*Z-7Y<&R?E8>?0DA V[VA,)[<6I4(("@O[&JM)"W
M]X6'DGCL,77#P^8V?N9.O0=&\[N[O[16%ZOU]+WZ0[M;O83,"JB:X0>TY:U-
MA6S@_ ]HW![Q]Z66&Z>F7RVTM#%Z#9=<V>8<MM,NE*1M8F#SO=O6F']4V$^L
M)RZ',F=!DU5NBB /*]:?4@Z"9WQG$62?T<H65OI\ZLT9;? >.U-Q*7<?WX(S
M2!BY_DZIO8#U:SFTI&4T=[F>8/+ O^X?&[.%6S]G2&P$ ;&W?=_OY^.OXF!8
MK^KA.HKJ-Z6JN]&%,,^,0*K/[BEW<)JE'_GW!ZIRR,/:25\QYQZN2S\\W^?F
M49T[0+8K)P0*^RII 92[J!",T_KJO5F)9=B;+"3\WDP_BW1_Q;NC9AKM4/[I
M+<LZWBH-O&6?;L>^<SIF2+K _H[YV$WYQD>?PRI^A^@\ +:@@<$4OA<3NA4D
M=EM*-?'"XUOMV3#);ZA1&LMLT%292 4#O(8K#:)5MG]=D>?^5,7E18; "[<>
M6_UQR-IEDAPJ7_5Y>7HCRS[.MQ^-?MNK^_*YHR%E^[>/G1?*6+8=)RY7,*H^
M,<IUWX<1]5 U*:$3TZ7\!WPC,2M-%T-?+X(;0(-9B"#SKK4K,^UFG-*<+X._
M-^8 ][6947:<CS*WQP?I7K3_:JZ^F:,E'$PM2YWJM;H<?CU:VKKS7X?#PR8>
MN1^VS#NFS$Y?A>W R7B'6![ER#6(92/AEO O,)GT*0BQQWC<7([UDDH\L.#Q
M:(?!^N#^Q8B%U#AVJ.7BGH.--:.D]OJBO]1RCY]*R78$'0"*#6#52[?09)'H
M CBK[5/,A6FL):-5F=4/VWJQ.PXQ2;G2")36%\C'&\7$J'_R4<_=U2!#-+VP
MAAW.\38N>U\P*[SSLFHZ%*]/_43*>=OSXD[-Q?7J]=5_IXM,9 Z<OC7OX;K2
M-S)FN=#K]RM%#$WD$.$>3N9R.6\KOL,#[X^7#43O,T!<02;#H$P.+!E[\-;8
M\6;*?0H5MNN;I<8'>%76B6GV1_/(T@GPYMJ?_U[WZ+[],?IJ[%7")SSS@5"%
MV(N&XL,0H'9#MT"]K()WE>\O-LX0>[,IXV$8$C1D2LWNF;%YX3EU_G# 4,&%
MD0TBM*QPOE]EA?C J#3O?;K^)X&816Y3%X@=3@ATTH/931.#Q\&EV9K,-]")
M\-[;%KD%G)19%)"9NHZ'+<SW=W.+#L6%)Z+0]Z*2L1*JZ14= 6'-TT45?J6+
M'AY'^U7J:P.V?5Z#?R,L3_ L,7!NH* 0MT_X7G5?HID(LH.O"\8\QTB>I(1>
MDF8?9JP/-XP9#Z ^2-3'#<H%9P6;CE)VN-^W'W!<./WKK/YN^XD7163J_/.2
M6L:OW")[_]%R5G!K]VA6\&.M3H<)+=>>$W$*[D]C2]5+SGP*G5C,"BU7%1O7
M5A%$\ SO'S[IQXVK PMX!\#3]#<BR/;2W]Q4RTC%C#6:#31/(F2"X%>-IXB@
M593G7]4V32;',WY^2[1_MT5-/G/+RJO/K7),Z)]8XP\,.FPW5HX%AV#"S"I2
MQ_D63(KTMQFY#T-KRQ4^TV79S[T\/?5'&(>,NSNGDJ_IE-E<*5$)O;9RQR#O
M[/3LK#^^237'6*M3,LP@^*CSC=0'![)L&[N;3G2W3!HX]MNW=:9HO?#\7[P[
M^\<OFKB5Z;^E'NZ]F.ZO<L1=ZX'H0@G^H@R((*!Z.+^DGRL>5@H^>7:S27AH
M;&';=E?$/1MAFXL(,G1(ULEJ^_/_E.8QC1\M*+;<(7S7OJL>)'!^LM&)EG+@
MX1]H!E\WB(V0][4H(D:S+=QGA*N.'\DS)TA9(;Q^'_B%QOL[YJX%5GZ'):3E
M#X(*/$?A(+YN]%%%" V".X*!LGL*GOF<"J @XJE+/G9+9YJ:;:_6I:(89VS*
M%QPP#QVYUL*AZ7#YG9,3I7O^]5BK$$HQ7BW<5GB#'&?XC!GK2BN?_8AGEA)K
M;I$KEY3(7]H+2X-,W9_.6+8,&UL@+[1D*=M+6_:,:H>%P\/*4B9'9TX>+CJ;
MKDCH(-;E]0S8N CJ:>'02;IP9X<&(>,OT$W<=[V<PP2.(;NAL\([?!\H@0(Y
MD7,%TBZ=^>D9%26G- G8F#GT=NQ)Z@BU/W;Y>^NISX7;GC7QSKHSQI733N:L
M!MS*"ZGR1E-_D7%?B=Y*W\:>'O#3<N%Z/ A;LG5-M[6[X%'K.FS 2''P^7$X
M"S^R@9GMR<P4\RY\0)O)FTU:]ZSL ,L'P;;IHDGR8<!5  SOQAT.]6-KIN<Y
MA>_Z)AW.TH?Z-C'4ACULAQ4WR+[*4.@">]:TJ")@GCZ/AZMN!W]P=D_U;D(?
MB"#^8E%'ZII-MMP'BBUB:Q^8PS'C9H 5' J;V\(A=<!J;7K1H WY!1">N6IL
M]G,$S[H0O,">6ETNM.\P]:\TQ$0ZVK1FTVO[MX9"_PE$U"OT+"$F^EFS\>N(
M='3=7I (_!!*QO-D^5H@F>/A**BB4B8-6>'=9&COS%;.3#EE'*L--EP*#?_.
MW\:N+?8*)NX1R@2;SB:M(W8OY<F;1EI=47*00>(&%JI6HD8.#[6T3RW0GA][
M=RG;3MI6VVO:-3XBS3^P\6UD7$U,RWWGM.*G3Z_F<:.M\$J3>3W(R4@; +VR
MD^<TB1LEUBUA*E@2?'E[.[$"@ '"5;8(D@*WW"."=!:/\J-+4(O"W:/ML.F+
M]J209I\NU8,\_<*B<HV!1()_F1<J4!YUQ1X[%H$U%93BX/Q;8C#.LP&6>A!4
M0B^,< $,%TI*<TS.<@X%(ZA5%""&!4UNE\#HEWWD;P,T.XFUN=EL%9BWZO$1
MK MI_'E["P.&Y%BD3[]3(@O)&OQZ;OB$"!)[9\8)SXN9_?(2'W0:\.VS<WDL
MZUHJVQ2@?>8)-<ZKTZ&L+KWP^S+>?]BC _%Z+(FO3,:8<7.:P1B>/=].4(ZO
M001GIJ/"JLOYCO4<8_)L)TUAG,[Z!1=NP[ABBMZ_#^)#F2[Z3SZ$1;EFTQDJ
MUX"%8SOHW;#/B.4)SE+WY,K8LC1'ZHR +(1C;035.&/AQY]".0$9X;_BQWY?
MS<Z4Q!B^B='F;!/J!]TF+O^P&!]JEUX@;ENI(Q_D'V7;AT/!VW'ERRM7LT00
M+P>?RUDG?=M1UU=_N#?S,O*24US;IGA6=S059!^SH+?L.$\+7N:GQ 39OZH5
M%E2\:PWE9+,:Z,3]6!U (8UOEP]/M3P.YGD!^$Z!QGI;& B6=-V62-A *RY.
M!L\L-(?.%[Y01DH'YA<5&U"7!G3ZF%-2NMY/-J12O6UIA>@'^+W1L-VX3CQ4
M> (;"(H@/'_P!]MD185G!8ZQ5)](4U8B7V%5@=P<:()0D^]*H#?+_>P*EUT\
M\HVXG:\BG\URS_;A9"18$#,W%LAU-"GO):7$'#W4%C_AP*P\-IP3TD,$Q"0T
M9$XZO/<,2P3AR_[@CH-!3!%D#X; /@GV5C;<-3\)2+'E5A^L3]%2TT."X%W?
MZD*D+RW<QF>0" .<PWE!_N5&6<D/TB_F+XH@%5%\W!R\ZG#Y6L_0RW+;P[_(
MBL.E\H65E+?.BP,39!=WVOH6SABW19"/O^9SIG/3HY>2AH."E\LQ0X.H8:R^
M']N[XF55="&"GA7T>JEAM!J%\CDVL>"\I'3%=_K\H?ORK82HI_6?T$FT>A%D
M.1L@TO'2K9?G1)!,VNYUJ!3_"B-:.H!UJT50-5E5.->F:TMP:!PQADE_"GP8
M;/]R8H$3HN3GBU3XOC+)W?_%_U$*=! Y56LM>&8\"VH1EZE^/$-,BWC>6^HU
M+'OQ0MX^7T3(FD/+,3\[?W9@D3S+5X'DTH5V/> 1(WQ#Q6I]N'YL]=I8W;2.
M49']JN12M2WW\J^W3'WO#IR*6''</Y*9B*^SR%S.4?B]5C,SH\HA=!%31_%0
MXQ[ HSM5Q88U0.J!;0EQMSR91U>5OK\8GJS-+E2PJ5^KF] W^OQ:Z<Z#,/F_
M;NIJWAFZQ>,W3]E0?,S><:(/.E?*J@6Z/E#3#'4M372^/6SG:#E=3ZRU^SA"
MTH0M2-@*JL0R[$YD%UJ"KU;*#P0L>I.%B&]*Q!3+7=^@Y=2J"H[,WQ_3Z,[#
MK6;^,;MD/M&#0ZODLEP3@Y1FHA.UE13_Y+;K@2M W!OB/IP*]G>MT5)@')O0
M75W90$?_N6B:<H:-4-0DD!WFJ8?327>'D/+$ZV3U(5J>XOB"LGG2(H*(F")V
MH$00,7C1F,3,=AF,"'(&[.?$,!%\&6(WOJZA@Y:,DQ5VYUF!F1PD$[&B %1T
M.=N_Z&;9MTS_H=^NX>D)DCH:3,,>Q4:4GH&F5*T/^=?:'KH^NQ/S?HY;(ZB@
M75D%M>*#;A>2$G"&PK$@()5[X^/&<)S#&5M0$XCG7A$\+^9L6[+2"7^-5\6&
M#6/OE%]4?Q0O(#[_IE_OFAP6ABHKK)RNG,+=:K8?0>-!M5R#B*?E:]UOW8J+
M-VI+$5=?.52T7=9),;4M'71<F9[=#!Z.5I960[:/4+VG'$SL&7K?HZ7MG6B-
M*4,]G9WO%1I;VEJ;"^?N3XZ*G:]F8^.3(:TK-EG6KLXV[QBX*7R-?T/''2EN
M,G%NE?Y/^TZ0B&H!OB8*#UG653S'Q'?)FYB22^>3B[,5IJ(=W&="H9X_KNN1
M-9L\H_J7B/#ET:$^VE[<2'[FRA*'P;J6 %2X")*K*OG2<\ADE".1P[ !;7A(
M_B&.28JY+0"S>]TRTFK%4E:Q9YMA=S"B L!'9'HQB/#*[7<:_7X)\.]-F<N:
MT&BO\5LC+"?P D#=WQ%R[\<NSEB"M4!"JPQY C<R6X>^+X($$/_$%'0C),G(
M+E@R3@?LY9C\"_0F4@?@W4KUJ4P5LX[DZ"I,9$^[/D=CD+"NKWMZR'@:>;YM
M)$JJT-+'43:,=G8LE]?>O%!*_32$*4(]K?]<5NX85FH7O6\^-3%E4?M%:0@Z
MWSE89R"$!V?#IDRXK@"I,UP2&STFM.0;O@:MYIK2:?'F&*Q]0&0QIFQ!?H%4
M^P'U[M/%Q9CZ$/\XP?. H'#]T:>A!@E\]_F9"T4C3&B2Z@ZPG#D+Q9X!P]EM
M4KVJVSG7"N7)+)H<)L"Y?J3.(0#Y3XW^0+K@1=:98Y7)ZH:'6?IM7<Y3[Q\-
MRCZBL$ETA)A%_$%C/A5!7FO>,_:>349O:4=@KW)FNU:3')A3: +N!'"(?W)4
M! F"I2E-BR!IYEY,FA2&'>J(WH79(L;1>WK\LQ7LS+TAS3U/MA<PIT^NKM;/
MA(BM.7+CY[(F4]J$J;"\EX3Q8VEV(0E$&-^;-2#%SDL-YY\"*+X?J;.$_*\]
MB'V+JG]QOC>QT)*?0-S\9E__J=<<Q_K\W3F7+OJ>*NL-,9YN-7S_H=Q_B#>!
M#B WWV*@G<M''W_9WV[/DW-^<46P>#-8VJK]&M%X?CDKPLFA_D6!0*68]H0X
MT3"72WVY2 208C]U7%!C>80?*7@F-%N8,6L1U%GN!+/9WVOGT-*@4J]0EI;:
MZC+7/XUD?OH9<%Y0I ':<!P9-L#7>!?D4*O6V/N'@1KFI[@-QWIYFIA:;CQ
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MII/F*NBY9SNOOR@83TWTLTRQCP\8^35YP<8W;_C8>%UCVN1KOLP@+ [#\H
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M/G?!!7>D^W!*?.+YX3<%PW?R-:W%UP*/_<JC3DYPH^+8>J\@-1F?(,D8R5F
MQ ICKCXC_HG2KY'? ='0IP=,S&[KIN9:%9IQLAW&V_$/=)H%1UHH@8\GZ=^
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MS6I6NYRA_*%%H]XWC;T]:4,510W>]TAYV\F=],BGT$XI2=XN$CL]6ZH3+ =
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M.G,E:>D[G64#I24S(2N)7!4 .E/7<9N1#%P+I8-1=UG+*PS),Q$:ER,T/NV
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MI3XAC7)1J.;%;EN?XP7.9-6NQ'QQ()D+*K[3GHI$,+BF@FZ,&/$HNH]^2 A
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MY'QN (1])J+,QYF*"+YAA2L&]#@NP%NN: !=5"#I2:,E[T882:V<+J@@XHJ
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MSLTF*+:<&W_Q&BC; >TA\'&DZ;>FN_C/B(< C9GYY=A2E"_0X>,W4XPR*UZ
M?.C+98=?9]_-C$XTL31-Q=W@74G]E-$85!?*3WOD@[N\ADR\0_F>>,^+^8V6
MEKPAP=DE3$)0P Y("7.[5YJ!6S%DT.-@(@(I\#BN"U:SU889>]F>R+%YS5*8
M7#"$'##=QW,9,"BN-)"0VE]9$5P.O."VZ7*V+#QZ$%EI5D4^T,%@X!ALF<'V
MYM@(URC*VPO0<[\!CYBP%]&).R#&T<&-E6 KMFQA[BCO"=,V#'IH<5MEY.?;
MQSZ44"4K[#+U3$PV[8CXYZ1\"8$XB8$=KV-J?)($,V#+.@S\BLHCIE2<M#70
MQK2%, U?$161^+\!Q^!=OQ_0+<F6C]>]$WV-B@JX&WAPJ58N,W(N&J>S435>
M3CUUM:)[/4!'JYO7NY*_1HF($#';O\ XX82'9@^1+; C"P,/2C1.#,U%0I\Z
M%%->V)U+"$U]XUE.-&#!HHABP+I 0H<5Q^7( 8\84ON0:ISK )2=00;7KK;K
MO=S>^YH!B21JC)H\88P,F1Y"*9!@XF/? $2[J2%++TZ[D@?%*-M/>"T,6G#D
M'UGJ10EZI8R%F;S!?TORDTH 5U-7SC+!\9#J'5 K)%;P9RJ'Q2_9L*02_T)I
ML0P3"-7YK14_;/>F\2N8.A(.PWNS=T]Y-LLA'NHPPK.BXPS@!3J;ECSII6O\
M"K0(-AI<74'E2=LPZ,MUW/,+Z9EC;-%V/2G!B-<^H(2I%>@E=6!1OC93T)('
MWS8Q/<8FQ9IX,STNGK4=W>SIO6Q3GX0[CC.)ZOOD(96"\0[>*UR2*^EVLA@J
M (!.T[^!&=2.7HDN2 VI$Y] 5&5/X;ENJ/,LIT <RGRTXN[0[6;6]\=&/W-E
MY$:?^E3,=OK9<#Q*='K?.))WXZKCX&[DJ;41W:"Z2<,U3_V3A^Q+K,L7G-[X
ML@^7*# 0]922\XQ\!7)685_N%UN<X1Z<P06W"^?Q[K^Q$HFPXJ>1IHO!==3E
M2ZQ"77WL& T:1=]'@I- *%-#5^D?6 F>XXP(89 7G =8B\UF<"%F;%E.B5R>
M_H_N\3&SPH7:]*J\OU?T5G70,,$GTD>-SOXHS&'A0/@M>CCUHSRI<O0(A"#D
MOZ]T"'0IGF&J?1-+GJP7A091P-=8?FW0_8N-[\YEN+>/<E;W$(^-W*TY1(<M
MU#J8AV*.3BP:THME#Q,VJ%?+?A47")MI:7B%?(F<^,Y3?]'EC6:+LF9?^:R=
M3D36I:X)+GCONUKA0"U8^/_2\[1?;YDM+,):?BU:3ICEFZ;'!>-H WYQN8D-
M2ZK#O:Y=Q6Z<S$9F=!IZZ;(MGC.;))J")5#&;/E7P?H_FC4*?JCNS9F'9MC5
M5XT2]AT51BW8+O#LM2I$E ?T1T!<H882;6JMNA&Z?JHB&N?EY&.*&"@M<YQ]
ME]? S+SYQ:!7)31^<'-1QM[<JN'7'T):N^PI9(16R;0QLS-R'P']W#>,#$@-
MA'RIP6K/WIO?#Q_8I^PZ#UYIXTJ@AV'[2=[T RA_5O+*:ZX/>@BR#Z7.")9
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M DO<8ZID$O;XS9!CL=5;HA)^M^BY4+:2,.0NO#TH))I2.5/.IX875E"[\/M
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M ,E2(4OU%LSCY#X,UFQ$2!@3]S+1:<UWCXZ9'7H\=N835D<01;N#?,+<Q8\
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M.SF4Y6;M[U]C>?W0<_2FD/ @?:SG:82:&E*RHK)XU-)D.W*WN;24:0[9RU\
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M3[L&1EQNI#W<@NS=&,SR)R(N?]9(?&,U;^MH7:*7ECB;?/SB@\ :RD!@U<,
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M1NIR0V9%G1?(=H_8?XW6P<5:9\//V=((FJLGZM*XTQVC3'3T+\(,.7OIMDA
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M#Z E]_:H<M@^G#R,X X,C6!,1VIR-;U;)+]@E&:A$I@K@P9R .5C*#QN>=7
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M"?E3QD'J4H8: W@?JEM^.^-"N2W*[/7"15J&AZOMAWF.X*S(83NW9YKRHC)
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M*=,B+2>XD_#JDH_]AQ="M[I<)%D5X%%F"2N(1\_$V6KF".M#Q1CZV5+R$V8
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M8__]@9FD/](2'5:^E-3@$8/QT6G--6ES,BI8M$&%/&K7K%/*=@;I9(09.$'
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MN8NH>=JV)\_2VW^X_H \1'!R[OYH>%L'>93[+P5J*(@1YD3@9BHH0H8:[%N
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MIZ$^QO*LYS]R'91#+\@]/5\J6L7'0 Z@QMTNVB,)T;$O0-(5L"F?1=@L]!;
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MM=^N+^4F7_:_YX#%5%C!HVDV]76"C]LF3P;V#)L*I=>?FGE?7U,!26T;D)K
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M?X8%6T=U!2XE'B+MHZH$KYEW<S8@\BPWEGC Q"BQ%IW4:#-SI\9_=5[C-'4
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M;4#@FBLPR97]%^/V$@N.:VJDWN+(CW3P.DV)]$,;;6O_>_@9TF&D0%'L9;.
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M5H7%4)I]A$/"MZ2B<K3KD=+#Z6F327<>1GK\6HNPP-GDH6I'OA9CU/?#BL,
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M,O$TZ>Q82?N";5E6:ZJ(7U;KJI"UFW-D'LE;,&]\L/@A?A JB28R-#E"D[L
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MIPB2.*A7P=F */@+O>XD*I46X>[(SV07UXSZ]\VL#/:$7M?/F%SX-,OZKGB
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M7[L@<@'@(BT3U\'Y):TA:L -N@(<FKST)I2\@T7P-TJ\,7B\"OFR)V;P3$#
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M<06Z9QM=MZ)1K.T#U4ZA-T?(9/?FWZ)/7VP']Z]UY+'=JCB%N0%]MV*<%VL
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M,NC;+UKG5K04WLB<:V':0,FX,DROZNT^H"Q7*ROV#,&_$$F6T'#ZF(06>JD
M$O=PK-<L!<E]S">Z%;GK?^V\;+EJDGA!7KNA9OUTB<\;&VT97_[?LZR@X0K&
M\L2;BL45F:L$$9VTYZ;KR<\=4U^?DH!+13W (/2/8BM?FWU(5,5A/1R8@!E#
M)$F5J*I3:N0,;*CU%'R-%(X^*P-MAZFQQ<Y=1*-LL;@_9 #^^>60PE'4<>&]
M^[%U4S:LI3)K"OZP2;$/D-[KFVZL<0(M^%V!?X'!%>/)_#3BWBLND<]G2RP9
M'Y:S<#\#[MWUYOGU,>7^G50\A>LK",NC2],)QT1S5H:)/BOWY<<)FQ#[<=M@
MWVVH<>V%.PF)P%]S&VK 8WP_154SM!G.8>+^_1&P*-7(9TI8X%EP*R6\FA2U
M7B7'N?]+["V/\M7S<KNA:'DFWT^ M=BT]?\A4: FX?O'/BI0J,WX6A24"KIY
M-D,Q]81@]_,H@P6E%A#73[X*M&3%/)]/>"@8YE;F7JT,1#S_<^*@D_W)?Y)G
MS\J;4)>+QPO^;95:;Z@Q"BXL4J_>"LU%"7A/_9IO!1X[&R2H%F2$K':\N5WW
M#1=VD^@ R<6(3-!1%@EA)DF[/^+/PS,GCD#)E1 EH( M"SG20:<!!>P.-V[^
MI;G?Y[TZPPW=JT</VVCW;7XH>]=EF?[/5?&&VF96E%8Z\]1ZF?8D*B.('=^B
MU'RY7FIO*F;MF@O\)5]3/!XNNE /W$9KX/.[QN2N,H?-$_A$<9"JG/V<'?3Q
M$*A9//-QYA[O*'9P$9Z&WL(T5G@R =_:*0W8KMY:Q5GFL!5\*P:Q'Y22&9KU
M$?%M(X\L[C_OTVN<Q&E#,=YM^FL_?PVXXD2*B]?H.<3*-PDU^3U=?H2PO;4-
M>%]6"<5P#792169H_<!( Y6P(,P45X#6=!,4+$I [%"99"*G9#\X4M  -7N"
M%LT5<VOY]<^AVDLC]+.U[=?RI#:GESSSK Q=S9D!9M4]+F<%?M/NHT'.:P=G
M4'OF;<_?])2]R/$H'YZK<'(MRJB<TOMBD#.=&3_M>=N+P'(>\*FK/_BBF=YX
M=^E:RGN!AG^(3/;5BX&OG_(OP]0[>I;,*]>^Y'U7\N_:M'AI^OS@E?X3[Y=&
M,-IU_S\G0QVE=FIM4GXD&2IWD#I_WE"+_(MX$L_R N&+_XV. -8I;$Y)OU/K
M=J(%V1S.K7<4H?]0N !+DY^02[%"-<5OPP34<PCE>6>[8(YXB@9(WI%O%-('
M/]VB;&9%: G,IF2Y\H/*=Y<(OX/"NU35JA?*/H,L;G]6H.5:L)3K"X4#^E/A
MZ00K$2G5>!/?_ESE@B]S;_OPX6'+8&LI)[VR]WD$<>^'*=J'ZRVO7IYVNM+
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MH;9U0SWT+]8PU[_R,;CX3*QL*0H:[*@M<:GJS=;E:)]@,;OE[KM94S0)-SF
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MR22KAM"*:5%-[G5^-=]5":PW? OR1<(2.,/5?-#\6/I*AP"CQU6$YF'<.FU
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M]0U9%.7D;W-'VMH2)+;HJCC[>=UN%&CO0BJQ/2"_F33T49":9JL'B778;F<
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M-B<09^346_"&(Y$]$W*?=M57&=/AG9;!'5G)W(E-1P$/2TX- \%6O<-\#E'
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M2[%!G3I&KYLU#%]PAX?A52T'SQ-,<TJ\&LL"M7+3-MLO#[X/2/H27*JP1FQ
MKE!8![C=!/&6 XS>V9Z4=6TY6D]*U)0<)5]GU$Q.>FD:3CP]8N-4,KUD9>6S
M,*U=0V[=[;?0'-?W;LK,6/!980Y5+Y3Z;HZM#*,G)+(N$MH/D\.JA+PX?_(
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M&YNEV9&:<.&%W,">I+%30^LF:NXU(U5?A]SJERHQV[\49T[NHB:17U01.WG
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M;[KF9YP3F=&31*8)9[9S=5Z]PLC+X$VNAQF?;'P]N.+A8VU8,AP>F'+L]K=
MSCN^<5RA'SUOJ"^(R_M UUFG3H3$/*J>#]"%)[$I'61)MCM]2O,85$+"RDXO
M>0Z;:3LY@R<JXL+H>:AC@S9:S9@)S&6SWL?64M:7CULY"66Y)WLV+)?T5C?5
MCA7^*CJFNK<JR-DS2]WJD_?9APN.ISF/RV=57$+/&/F][=VXVN+[ZN*K2*<A
M6"-B999EB6]O4P.#4A$A<BIH_):!MJW8;(($]O2\CAP#GKK:8')U$IEY.G?X
M+#;HQ'!XP9GZU!?9P0,ZCD?_J&N<^(D97^5*%K 4N$-<)>@5G1I/5"T>O@"I
MS7 "^&6^4LM!$H3LLE5F$!-QZ@4A8\VE)71S,.>>V6,9S.DADY7+!G*V6>C8
MKY\/5M57:FV,1O3_XI=,8HHP30GRS*,RVC/(C[LM?1)-Z7GS=O;:,](=GZ["
M[D[H!N[TA!K[1&+B_4JFVW-M ^Z.[6\^7.8!@S;-$)$9A=2&2$Q^\7R;BAUB
MOLNA^(MSFG$(EBK[!)BV2I%+R(4S+3MD4+1XLJ2I7\N-F10.ZO1PRQEZU*/(
M?G&KJ="2<$6*;S*3N?C]^W>?X^KE!LJKU6UQI\9COD\UK&VOMFC9\^'VR<C,
MU*@RDZ^)>4$QTP-.CW-W.A+KOCV\0=Q;%[22WHZ$3#W92IC9L4ZX*'LOB.JN
M"CC&0'1J>XS9@3[8)1HY'2=3@$WQ:VN^WX,<J.<!"E"Z7>V IAN9G&VL::C?
MFK*B5ML5FAJ4O7^R&/K]4U4!7Q\L&X#(U6P%J(!!=/_(#J&A%.'Q.*^#9 KQ
MGD;9W18X?>MBYD+N6(H9/XI\#KX^Y)4C@PUXG6<R?. 29W*%>PUQ ?&)ROS]
M8TX"OIM?B:,2O',H\'B8)"& -+Y*QS<PT$C.TR#&9ZN>KG[80BZABZ3IBTTY
M_+%E6VG)R$9"M6A91/6":F-N0T/6W971Q\7H)HU">XQ,0\\T'QT@4[@RG&9;
M0R]^1;X#$20$SB%'OD*)-&H2JH':0Y+W#XY1N\65GL2&<@.;![Z.Z*.#UTG)
M>]]::3N.!.:R+7-HSUNG1ILL$WNV3+]CLKS+>E?U8TN"\%-3K[=0M-.RE2;-
MG4_G%H*+IXTH2TJ5SL<'[AX8=7?9=YWY_82LY)D#-RZ,;\ZRW/C2SQ(N8#ZQ
M.LER;'W&8[HI6;6&X?2&252TD6X3!\52\=N\EJ:ER+G!E\U[7?E5R8)&59'W
M]"_%XZ&XP2'ONZ_<OC1;Q\*6'[&B?_]%K9&96+U$J(ON\H/W[,5ZH+&X,[3>
M%&UW2OX>D.+W2/6#W[4._+:ZH:A>3=>>A. 5^$3?\_ =M[&ZKT)F<LW8QE!K
M*<X:@O/WD+_/MT]B?5P9^/NVFFP+3E)4NM"\#GQD?<KHH.E/"E<5S/EOS+U9
M5%-9US::*EM$1'H!(66+]#8T2I.46H! 002D%_(J(@3$J'010F))WZ8$(24(
M$2$@3:!H @(A$4)3BHCT$IJ04(+T>ZN$K6DX\1OCG''&_]U\%_\9Y\\8^V9?
M[#777&L^\WG66EFS"R7[*7K38NZJ#=5A<VS,C+6HX'SHY4OR_H486@2ZX5T%
MP.[E G?5NM</$%Y'(PZ,$50_4>JO6&!7%?BDQ,^+FQ3Y2&RJ9W-^S(=C/33>
ML'ERI%;T6Q+[/?KUWE433@^IRJ#,Z:+3J/H^]]O-'^_%Q48TI7O2-LV]WMJ-
M';SQR8)X-4O%S26[<N1OH'+)]G:)V[^/*29Q^>(9QFL:L>S[B><-UI?_#]AI
M_=_\B'K$9<@04L:,LKA2I"(\([( DU^A'^Z'"GA^7!(#"<H*4M];N=4$4U1$
M5XL.:9P6&0-J GB&E5Q 8-6B:F5^37LXHIP6\G#\<F,8DKWYL]F9*]?_7:'1
M-U8_MPG)O/"]MH</!.OVVU<X*\\=^#SC5F'DU?/E\2'-=J6G_()&MWN/KV_!
MG(-K_R0<DWPH^AG2>8&1R( "TASQ@.CW(8+VXA9L/_/X)^(VQD]\;JH%ELW=
MU^H8]@+7@&ZI_SLI[DAG3HB'QH#@2(A"33NQ;)%L7G)I8GOU&:MP88QH&Q W
M\+ ZXCP(YPNH<[5)'&*/TQE'" Z,=Z.5([7,>4:5?$-SOG'*JM6Y )-6M23L
M/%?NZ68Q]O;'ASS#:NI)1[JW@'B'FL:^6%#4?N)E8RGU;+GJ=#:F;>:[:6N,
M-:J4H">=Y$20Q1M/ERB*W(%^2@93"Q+:O 0VTQG&+YQBL4&TX,U C5C=-9/)
M*L,+.VYFF7M7KZW6'([P3+L1N==(9 '=GQU(8&X#DMGP9)\=M8F,7;-P>8R_
M,I"<;!#8FC_\&R!(Q:ADD<LF^^/N1L>:>.3]V:O8%QUY-_SX]!>GHQGO" Z0
M5 KND!<7,=5QZ5()7XX%T5UYDI\'K9!\XS2)+F#<B=+$-71LP78V4I0P@\L6
M5[=@*OCS98NT,)YN4JI!S%AQP)T&[J)/0%R):Q.=\T8??UD:KYF$=T19/*8:
M^GD)F:9M"6K_ 8Q+R=F!C4L$9=%)*:8[ZJ,2F?I-(^NW1-&($MYR:+HC=I^W
M-R8SNF))[=YD[UZUIN.3JUB#BFTN.?7VRY4>!!^)/OKTL8P.6]?'=0<B3[""
M="W^G'?^@L^<$;1;Y(?A4-6!6%=@8 4M-,99LK=@V@Q]WD!\D?JPR%*(6HY9
M3V%:!Z\BZ'&!X!$?T+!]NJ8YKMKN10B9>"/V$[:F(]W6(JR=D<,0/#J/F-AE
M/LO]("M 0G%5HI_&18> B[\.;E FL(Z@1RH@?]DOJ'N\&;[/I%;3+X3,/%XW
M-.D"RO&7]H>86[RK.)QY/_+FW\(;J67TIZ$:QXDD%K9V8OE5+2#0=!S0QCN\
MA!X!:^-S.TD8()XWD(XX.K.(E#'>41'/1Z?=8IPKGYK&$3MOWQXR;64DK]8[
MJ;P]Y65OR'C!0DCZN<TKV81>= -%*L(XQMVD-&D&9.KCSO3X&TO5.\]!I#8N
M"CP=7*0"1E50_:$<SV&&6NG%8AS6L>%OBRN_7K4/LEYYZ-G0T)IM66:'6<=@
M%V(GMF"Y#($M5HE<F9:3I_7&A.I.7YG"=*J<,(VBI^<ZC)1OSWW:OEQ60GSQ
M3)Q(O%&%349K2A2[@8N=7*"&B)%7"V%:01,\[]N1W[Y*G8YC^V3WA%WT9V;'
M77?L-Q/8?^V367V7&$ZUN69=[?;!)DR/?(9+8'/KDZ@\XL1<AR=QAY7!C(KX
ML96]-,$>( SX&"@MY^51]HJ<>/=7;W]U"G40:M.VMV:NTE=SZ:)UOHQIY$CD
M[GY)&9F<;6\)^.M*9ULJX9V_=L$LM2C3O N=ZD-950#6YOBD#K$F#\W&*D$+
MOB IX=::R8M:(YI)IMZX\ *'_X;K+AEB-+<_G/+QPGQ_3%:T,SDY.14YQFU:
M?]5'2>H'SQF)/+7_HFC1MF W7UN=,T\RXH.M^!NM($/[I_B.=5X4>;4J]C@]
M7&7@[:N:+%^W0"^7SBI49=[WX,UVIK JIDJU:O;8N]S?]?]-G,\I^X;AJ+0O
MAVE>2?2U-CP[L'I<?&:6LC(-7!2$Q_<">!7H?BEN+]X-BJ_!7X$2$92[E5PN
MKJ%WYNA^XBTHW7TDLOVB&RL[M.1V1I[+U>XR[[:IUP&!MS:CP\P?+,.!WUD?
M4.@FL+N()K3 .:_U\>VZ5Y%SW,Q;1+HH<$=6,QCK2/;,[^M9#PKC>X551RKG
M^(]R0L-.ZQL:K: =FJ.4*GLJOL)[6%E,#4B3&NSY?2&1J8/CNH!FY8B<9SA/
MGC&[5@EO#_I3[V("C4IB3R\B#M:WJ'J8>?SYQ,AXPS)=_]=U986^HY]+[18R
M R1[K(5G%A$_0Z? /?I;L!0-02&XC@:C$Q '@[4U("R_$-O#(6<RY 0I5O:S
M50.[O"?,VJ[Q8^6<Q^+4ORZ&:6H\=I4YGO5.%WM$L6!4UW+#,UK(#*CPW.'4
M&AF4E-R0^4TOUO2U^IO]8;:^N@[4LVV&?I=TP![)(E]^(GQ6+8U@A4>*RTVY
M2?F&Z[V41"9\%*\[BT[5#Z_V7HXQ3C:MDD/_/A*1_+#7M6F('GON%GW:_X#;
MU>&-(S>PU+QN6IG"/V2K<T(S_#Z W(M-038.)$MSB0^Z%YU6I/E>= C<QC<P
MC^G*;T[%F_/:P@X/_#94LVIDJML8BKL5UBBGH9+-=FI\^<1D&=O8?^H"*K56
MI*PIB"+&CU$.9"_W#F")(&)]-I?,_@V*YGM" ^%@6N>_;"+PQC@I-#ARCC^I
M?R?2L>JX>W.R0_>7Z929DQ"ZCKQJ5R491BINP6[=M*=_P/\$L/E<-FNGR$*:
M+*R4[LZBU' .G/59.S9I/S3'EN@,;EA;HL9[:$&@CBL83!;>NNJTYW$\ZF6.
M?=:KP3Y]L[7''LVMRRJ!7T(O$.@/(X/=$A:O5*12K)%!KW7Z5_2NN%.#(@KU
M7!\6U7KU\F+BZOC<W3BWWAF-,8;Z'&7O)^W30'*J@<X0XSR/J+RHJK$%2Z;W
MG_X8=17SO8E4Z3N-^9[XM*\K;SSJ<Q>D?N'7VB2"BI1?GMB"S18B=R .3^"]
MH"#A$=$Q8)W4V,:K#.:LM-ZDUM8F;_R6&]0\(C(OQ9'=QDR0^T(\W/3ZRM&?
M8FY2HLO^J10H^9[<'DW0$3,(/^,<>V-8\::>T(/OJ"1\'%6D#Y*Z0^63BXXQ
M(=-95JI%=P\E,'!V0!EODS3RZ7M436L6C;I(_FQ,*5O4*"K&!E2A/TQ]J^N-
MOBAND4[5]*X8XX<F_1>[Y<%=/M!'/G8"$EF3V6J/<,-V8&]\XV(D2S'$1Y!R
MX_1BD<S0UQV-XQ_!A"R.5:LSK63*M^_,TOY.1P>.KG?51H,':J$$?9CJN^U<
M;Q$.,Y+0\I_YQ3=W"\AZE^^UN89ONF;5V%.C"EO6.9X2F6;A?LD'_W-#S&.2
M(73#%BR)J0LMVP!T\L.( 840SD*F254?6A;#J6F@??C$-Y;#%=@TYLU,NH/[
MZ/</YDPZWCDZHN-V*L,VE<)'0\?E14J;W=P]>'7@HI\X1Z(P +3Q!.WW^:3=
MD&OO18I-N@.H2@W#!%6%&E8&D_.C6BI"-*9K*.63R^,63>5QQUOV%9:7U6 ]
M>MY?S)PE0;J]*]USZ_MQ=I<&4=V^?FH]+,6;D'F)R':,J8QK<X!\**IJ'JS!
M:HDV&O<]%KFB251:&L_;VQI6>=4):\ZA'<Y?FIFW-^1_J7U(;'ZJH<8F92 ,
MQ<\V: %=,=.453:X+@B'K'G&R9(=%']P(+V:H5[;BD-U2#0 2H*4]3?AXCV&
M&_5#A6W3SA]5/1H:\M:OC.S]P]^N#S$T6*5#:*8SUQ_%=WW,+ASN')B\<*_"
M7>]T?(9UCGCE^Y?PX3OM(_G#5TC%" 2QPYH8(,\ALI&R#'6P3T $L)D,'0#E
M/&I"2M36LJ=OP60QVMN'(@N<?NYU'3;1--X9BM!.XJ)>-@#-R;3NG.JF]W94
MG_1@'IM,YA%%2LN"DY Y$-NS!6O89/_8KWBE$=U!3+4H"/4_!]VE^8;XFP #
MJ9%NH4$WR=\S*9D;<(53+<W)J+K0<X?RC@2$8["Q0?_Z_Y:3A?K!E?XDO,TW
M[HP+XF^F1!IKX\+M@>9N:_G9WDS\D5J\)6CT!#3N@"M8V:HZP7\%D0_*Z1H;
M3\F"^O-Q&,-&M;H9SH"L5T'%@:[CX ^@X<'9++E%IAY(8J,Y01>'N.Q[.'8/
M/%1<1#@B(U&&_$S;W2XZA?*?^1ET\#1C4TUB5YUG9():F7$RA\;DGD]<G7Q]
MV"%JT&&\GAL'YU82+?,MOD6;5%K\Y8R]0=6CM,X+7-M-/AI^@Q])+* 7'_V:
M0 L71$L[$49@(^N)F36$HY(!8@/V 4$3)YB7,CZI4$QH0$FF1C?ZG"RO?$XJ
M":"B<62O,>I@&-;U +\E^9*9O8DF;>K T6QS 2L)W8!\Q8I'[R<8B]RA0&#Y
M$D#J@I-B-II3)490?N>Z5]&7'LY&@7\[L^3%^1<AGGEF]TKS,U>2K(^/HQ[:
MWP[,\RJZ< #?5RJ9&8LI7R77$MX*N+*$0R'^,O60&R#DJSX"HW\#;K:_P(6X
M@PU+T>5=/CU__XRQ"&*?:(R-/1MF]9^%U^0NEY#OOZ5H=Z0L,;5^'$5B!:%3
MF69 4/S7XQ"Y;)&BM$'S9+-D$,>A*AXQ770*R.'/M)7VWC?A>+('X"%CJM^=
MV^]'AY6'F/O\'B9PJ?+],,4L&M^K<.-@4$WFIX+EDE'TE^9O.ZQL_6D:X6QV
M7KO#Y<QBU.;[;*J+FY/M>KY+V4>MHPL'RK[-$>] ^E)=M4=<6 KE&'=@DWWL
M'I1"K+E^-!_;E31L1(\=@!P8X35MB*K:F4RTZX@-H_GVYU,-PXE%!3+9J(:)
M[O:&7L*[+5B=^0I-J!.*WB^R$5J(U(#FSO90/GVCIGAN>0LFWT=S.LZZ&QA=
MP?7N>5VUU/K8(BR7.M-0X80M"P8QWV\91G1:VESB>8E^K.<]+)3T^ZS6ID2V
MF['G?JP,D+-^D>9T4FJ]Z 1XK)9M+=LSC+<=8JK;\Z3?UKQ:ZF,LR"RBTS#Y
MU-7VQDW%2=R]CW3/JY-^D^<WFA+!VE?,H]#K.>X?,:8]U-@Y2A)!$0C*P =^
M7!PB7EM4U484^)#8%A'YTF [[!0EF+S &.$Z_G9Z<O&>M_^;3LM_MLG9^R_Y
M3:\/37[WB_%3<V[:4]X@<#_YY2.Q]=^(Z4(;%\G:Y+F>0L\UD8-2S(LW7"61
MK;0/YX@=)@1#:+.;I<0\3'B#D .-LT21M2':.F!0B@YHWA6KOE$8ZUY80Y=S
M"'72[XFRB%#RF[+LU^-X3W;>N!F8H1C^_6+)HD74'Z6+,:JD4*VLG.>+8S[.
MY "%<)6BPK))FZ" 4/5'11>UVAM/74BRB]9[T'#F!B55<I38\1LKR#AQY@Q8
MGFAU7J>+=M$!0M,6$1I0,VC)ALN*_/C(!*(,XWPUK30OWZX+GF(1F9!OEAJ]
M/28Q?NFZ&2/93GCU5$@VQ_E8&K)P79I2GS=Q=V_!0E&3=KS>[I>20U #C]QI
MJ#FKELJ0E^]<3XAISCH,R"=8V0-SET%X%TL=FNO25ADJC47)E94C2!'-'$F)
MU9^^AKT"TRJ.;\A.G3[SP4^-SF*^%()?D7,S_(V-V.\&B[05J[R'JO0(;_1,
MCSBW^XYG8ZC"M$&G+\A@JI9& 6DY4P4\(:;AMP6"H7S#L0HPMG-NMO?A%BR0
MNQU/*#HKTJKXI0Y83Z5S%5/P.-9^-Z^6>+^_QZ0L0]-2?I<7Y*/EJOG7LY=I
MGP5S+HXJ0T#TZCAPI&NN9[F6D@*7,;+:!C1MSB75!H$4J4Y(81Z<0>,/#I=^
M-F8>"SX9JBJDD_9.3/U5O3;S80N&\9Z9XG#\%M]?]3M_,.>-T#I'.$3,L7/H
MOO9]M%QU:FB^0N[^P>?_YN=X, )#&\5C^4XF=!:F]H.OX)*X'I7$%3R!-'GR
MZ>:(_5F?Y?<N64PN6T35EOBB7RN/-T7%#"1'^FFZ.VI6%*=AJOW!5>T;WK\C
M@OJ].)XBI0'!B?>-ZP]C;!.%9_%GWW^E3$SV>!(5$/L68XPH]TL79Q3!C]\7
M0^_/R1@T"I=#L8I0UIQ0R?Z^*5&UN];_R2W#,B49M_O?%N8\12J[V(@]D Q_
M( ,N3]A%>&_1+TBNP.MJ6">3$+M%YW_LOT%H/C&]^JNU94^>!?5CQN$Y-CGF
M#HMTB9'8-0QE;W9^MYFFL@0;#<UA<Z3)MDZ6O.AN %]>?0JWV>$/JQ?_A<>
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M!0UG!1%)9 3\?9@HL(HP/*,S0F\SM(F4.\/FP#,9X5(QIHE#=9/BE$\UJLW
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M,8W%.]1L(_6="TWF*T<2*O2&'*AZCS^:KSLZ>_5^;N:3V,1)2T&V.)NI)U(
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MY:\MN3,-=0#VP18L )WI#Q<_9<T6LO;2-9'[C-.0-UD<RPM0(8@X08<"Z^D
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MR*^S4/XNQVA:K=),+K";\UPQ!Q=<Q'G(V6H$'"A? ?DRC%CPQW]ZG^-M(?-
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MM;[>]&(CT\$ Z6:>R)7$)J]%J$X@US)V@D/')72Q^NBT-PXF+ 7=!"Q>?SQ
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M^C0^=ZO8NU)2$2K1%$;6 TNTU&I:HO8FD(YLZL!3+$EE<K]VXAVSI@=?KQD
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MQ[2  CO=-X-MN%+CY1.I'3_PP2E#]N/4&9%H.UCG"#J(CHKUP7:1CMBA%V%
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MJMZ\>5,5.V<R#S>9TSYBC,/]E>HP9V+P8$_<C@C=4+NKL,/>TB_<-^C[Y7X
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M[J^\<MOL,EM@+]0%UPN,VFN=EENA@YFCRZW<A,A^"A^5:'FR1+"1EWE'NH=
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MWK(D47N'7"DHQ6)D$!/FG(&4$T%=.$H6'D"OINO0?W%SC\*^%[?_.S:$*YA
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MY'F-G<EY$V&E;%P>1IZ,@N939C<\PR@]/0".W;)7R&A7-U!%VP+M<?4'UW%
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MEF>O\IZOK=UW7'G\T8 %W- %]_(KK>0[9N+%8FU=9)T1,H=]\'&QVQ\$:^.
MN S#7<5+P=M2CO:E'-!]_3JDR/!UD?/A$FL?"\.*>U\Q/46[[,X_#72=)O.L
M)'G(B37 V2@M<OL)"DWLNDAN#A>=)']>-UHHA=:'RB#_2$(7/>R-D2M+*!E$
M7P;Y5L]$S C@J?+T7^,O@]SA,5>R.Q;F/ME*59B<P]+;L/5(('J,)@V8D -]
M7GA?!GF^L0DEAA&F99 GJRM0X8*D8HG\I:.)O'E)!ME*U(T?,TB4^[1K *4)
MO16\/,W_C:QTO6R)NLOVU3/DN0;![ARHX+7CM;G27'H&;"94T\1K].OSF([,
M?XBJ,LAZY8$RTCZQ [A&=)+T:;6P$4Y!; &-^7@* @I4TUO*-/GX.](#!)7F
M&@NZ914#"B;F@WA6V<Y\_UM^QOE2:C'!G</ONES[[OQ;QZOV1^6SDUU,7K&0
M0?2^KRQ?J7W;LN*+?^+C)5U2-)I*R^S#A>-4YT:R&\C'F?_U[%QED(TCEC+(
M#Q(%=)9!KK%7(<0=<A6^G,I<H=+62"C,0"<+88GD$6(7J7>9H8:*T_!H@2MB
M2?N90-]\0EK+WZ 7^]A Z+"&:%9;5]H&_$0/O8S<P8D9?J:)VLXR:8L_J [[
MP?Z"DBJX%4J_(G<RK(DV75*E*2J4: $4HH#V1/'V,9QKFV+91>(Y )82JA4(
MVTQ@2K??XMELQ6\Z1IO@^!0FE![P[[?^LQO#J2Z)+KSF</5BU8"XMK!GI9[9
M(,$.WRVYOXSD^1V4\.MMQ,CZ1Q',"34GU24Z;G!5SOJ;N;/J,LB?T+M4$"$8
MD$$._V]00HSATS@]+?TR")U]E^E'60^B[/M#HN"#TZVP*HLV\HZ+-86(=[S.
M]=9_6NN,XM18YNXW6?Z(HC(P]L*('<GD"G;S\Z@+E_P/.321/J*!LYVVPC1)
MK@R"0=_.T9,\LPX'-!:$!(!^V]I/C]V"W(89\(4+=B8*-C1/7^B^VD?<F#=Y
M#AY3KGDBM=TMKAFU8YJ3W/2J'4\.R.?:FKWZC\"^(G\;08](J^>+9@]FND@'
M_BG_-MH@1E0X.)1(W(=,ZNK*?-@,.8W_6X%]#[U+!BY@&"9@N_!:SH+0O[?>
M&#@L? ?FC5'O,=>3]G'$?D![,A$3S$>N^^H[Z.M#X(Z.I/&2H^V;5L\,N"<$
ME3-YQGW?NF9,RJJ-G3>5!1EGD>O*D*//T6]4Y^H*P:M<81&H$2IQJ3^>X761
MN:U*$5M(5O!!>Q)B];RSW[KW+7:4F4O5'\X^QRB5ED'2U8*-4=)HUY6%B/#,
M0NZ/9K/@FQZIP8^K7]3E: 7EZ6%Y;G-/?83A"P'=2."9M(NZ"/FU,"9F7HN\
M@+07&Y"K B00A )Y5-2.%K,'*"!6V"3)J/<#6*UDC7JX0,1SIP/41GKEY,A!
M\([?F-9>U!8"]BS]I\4@5N/!VPNEY2]%3O3!Y]G7Z7'\-=<JG_@-_X2VSX/[
MQYMM+(18L$XP+CPN6&Z&<US/@INDB@+[5IC"-:E.+2,:R6.4\;U]C%JR[AV:
M5&:9993A\QN6I.G!M[2&DVJH-P;,P_?EN/R/N9FYW( L:)ORVUN^<+^M_Z94
M7[WF81WF@!'>+EJ%T3"X:O/O ?8B$)X40MD-VC>/F -B&23P,]&/UPEMM=1C
MHZHPVGMZC$-QYL0M=\8]?6T-Q JUEL0J>8+N0XJS99"'/\6B-UPM&<3V>KL,
MLN%2/7-*LV.U[NCV,1F$HP\?<>"18\*O40][>X&9;6'+*FL^G"IX!TPW:;[F
M>;GMV[S^+<T-Q B.L_D[O*I3/E&B>7@U0J"W(UF%X''^X>:YD.6&V(+*AHJ&
M&OTA]Z[JWU+=7_<9U[PLV'\IRRCJU54ZY7&YRDD9Q$Z2)][1/WJ"PVZF)'0%
MVOVY8=84OEV,R'3T3&B30=XPJHMVA0<$</*'4MH*SA=]4JG2V7Q2.>O1149S
MG9-YC_/^P1(S(ZOJ$*RM5FK3Y1MI1:DMEX&E-Q>N:P7N2C^.GD_/C<MW3SD=
MLK\W]K3;5/>C1_F&M_)F+_-FM2S_7OW$U$..%I-K[%O1@SW-3*7Z-2(+ ME'
MD-E.4R=D.PLZVV)Y#1L66C)K/9I1\;7/Y"'N1+GVS.#@5REG!$J2AOA8_ZQ3
M)Y0Q UY3526Z!U\RRT+'F#NJT(J3PAN$XF@[:_7R0)(5J)[K W:<Z<Z9]^TS
MO@1VCO9^KM]\*QQ3(2:06[-J7DI5&A(+I!T].*)'22 ];'XS8^$=YO3!(O73
MUI/(V)'.&1KN.KVBCS.,*F]S+?%0<G]FR(8>/3G"V7^T)_7GC1^!AL[[6T\[
M?V::U[S!CGJT017%T> Q8'E,+:;@T#5?)-#VA,;"Z[M/.S2\N^/A_CETUR<-
M+=<_^\XMG^SE'?U)*PUP"_BS?.3-A55X?!5\JVT$[CE&(RP9]RHP?+5OMN8)
M1BF]X1.M^)^@4)O3IXR[CZ3\R OQG5N]<=>Q[IU^[;.7;[,\89=S.7,#I^<^
M3'5/9$\'K:*CC%-&7^:IFN>;[<C?5[+?P=C+(\QI*GVXIN[KOA=)=O]?K[S[
M?VT%WX>!&?DL7;]!4H" 2;GH72%P#IH?D&0=+3(0DR1E)#/2/S+(EE":ZM2M
MJ0SD;PQ3(K+?U1V Q9;F7/AFJ18G)N=B)WD=BIKA,4[1I]OZ>?Q8TY(GW$4C
MX1%)V1)\B_C7'H!VD"E\!':4M -HX37)RYDR:YM;8\:^HK.?2>H$Y:'FVMC.
M3Q1>F8T['^OM7?(*ES%TLAN77]N[=/3WN]W]_-7ORJC',H@_^XN]JZ1 _@8J
M9[1&6))418!B/4.W<^GX-EH";"/1A4]6FM:&,;J(WB^=7@8RE:3Z!"^GT_W-
M_.73,5XUI[+=NJ]@HQWMW_9=_[WNVEP^[39C':D#3?>851)MD6<57^N# @N>
MP7U3"@?=CM:2;@&[QXX)])-?@6&P9,Y\\^& 5R!7NFW6_CR]9Y&]G99$B9^;
M.V 2DIW<8"(ZVUMV?39(S\+]>Q7&9[$Z;=!KUI.6/B>5+ $8MHK=I6ZWP(7H
MRPVF7[^MY!VGVVQN\*94WWBVKX;+X.U(/Y(ODHRBP0-J,TU\[DZB_F=KQU$\
MQV.4'2>UP6;AXQB;Q1?  <#6&S!HQB=RYNKVMO/*K%@C!Z(D)QV/$L]H7>WR
M%^@_>3[$7J/\U>GZRZO,%AIX #G3 XR/(=N0@](!'G/60H#D4QN3WY%YE\%P
M'K2I7=#5341B<@>Q'$J*T_?"A-FROX"<[ VYN(!;$44?"@,/<2M;+^6/L+;0
M-P/P6;*@L(4*G./>05<.S-P!K(07)"^)Z@(#-/@.L&I%JRQ1DV'KZO$ BS<_
M,_R<:-Y7MH14"W0%AUK#-((2^4KV9Y(XN,,LX<A69M^GLL*+3KLM-I---:[+
M(!>EC3"H-9;'!?=1Q*KL5E\#P#YQ$;Z%\*N&;@1Q#]\XG!59_B079#1W-')*
M+>^-:/:%*AXY$"JR<L@_A=?K,:B[N_G*A1_^80H>QND<[,G9J%#WR4'Q\I?I
MU+WUXYN.OS38W'LONO;E2FB>5^COF3;O<BUO+)?WNCD[&!RI(3V5LJDPQDYI
M+W*C6$4P,,I,8/+V@;?&)&9+QNO./VQ;.%/GB@L/+@ST"LLO"-S6%%$86'NR
M"!-1$.A^JVV+6D:EH?6;B%L. K98-5X8+Z W0@<56\*H&T,=&RR$]\!I/GN]
M_ H0[S-OS3E5Z.V(?5AA%ESXB7KS></3D5U UX#85@E4J!FHC7ZH?ODAX2E1
M30;YK5225.\M@$HW-P&*+)@R0H_TA5K!_24SYSG'O2E;B 9@(I]ZV^M3&9:/
M3Y$+V9XYHM^+K]>8^%Y^:MO(R#0K[>)0TV[WR/1>8<$%?$PO5Y/L3TU!5J%G
M%T3FTD\C*F")Z-2O$A\S:X 8=[ =*SH+LDYU(_3!RC:F-DD_T%R..UQ\LM2$
M8($&#"A$6QY*L?4 ?[+*YS)Y:W+*\2-C/=5&49ZSR7H&Y<D^)/?YOL&)\R4#
M13&%>LXN)0GY)P]^PSYQKKH\=:3-:5^M2ZC^NV_IO*M+[Q:I8N5V82KX)EID
M(_U,WH"\UN#71I;?,P;^Q9Y/::'&P93GG\<Y1?'M6VU44-$>;3 EL6WAY')F
ML&,)UO<P,,2(YSTNZ/4T2PS)=EK-Z[#NH>42;*4*30#Z(CC+@P^.MR/7D;'0
MVPQK 26F/D"PM7ELK+W91ZV1!.NIWSRJI>8Z8(T:4PI;L@XO14^2-%_7=..-
M4RM-,H0;)'8ESO<KJM *L#BJM@PRFDT%7!S9E*SV1/(U^-!A7OLL5F0I/DX'
M._G9T-B<G>0=DUQ59 !<@9Z(4!N<BK1H0J\E8)N!#CYZRP7Z;3&,'/W"TV=X
MJC9_N/I3WHT'Q=2GB#4CA;-V %W8WR\U)$2-S<G%S/J=<IJ\2]P/O@':FSGA
M24C_>8Y5,W>K]#=0 :V [6=N(:VY(#XG@+*B-7G2E.=':]Y0V[0-L]'5/:%.
M7L+]04&AZK,:CL+<?^886N8]Q:CHTJ7IP0C_W4Y>P?DGY\PPGV[<*.4/GPY9
M\7>*<L;<ZB]Q#GG^U!\^<OIF^%F,]$6K? BO)7\[I3X9BZ(ID+I7T3.2,D(K
M<?M+4E]682->Y8+T4U9<F<G+K#-JP82/WI39+Z96R0/;V\M\"<[]K></=^J>
MOF]O$2 X*61+%=/&L)HR"(P[)-[[6GY?IS!(Y:L]043'L!Q(Y;L88;8B,M7;
M^2%P[0]?>UY_QE'BL6_&[[L=6P;0_A\'&J6'0<D8.8D*G$Y1E&ZNXS&_,(7/
MJR2EU92[C/62]"7X&BQU'?%2KM@8B*/SHF!;"9=%_.CQ-BU;9SJ(E4$VN15U
M7Q&8I$5A^9K/3AM]N\WU;/)7">Q>EAI+*"13++*&THJ,L410RD_!F:-<F\-"
MSVZ$H>/+0&$.I!=AXDUT3#X68XO>Y03I&NN;:WW3K]>CZ8([S3WU]]3A)J';
MH;1T/9-,G]">+"6S%\,6;P[1O K?5+I%!%Z:LG!6+@RL2,%CCGNDT>$'0C(;
MMF+/][</9^'%.V.$=DPJ:W5&JBEYL8B2VV'!"\)&%K(:F8#81$@^)<E>HFU#
MO9)!_ :S\=H7OZ8X<QT8?<&7,.6!"/6*;B_7<8=PU>?86$F@NX>;_Y[TV_Y_
MW?RU4G+YMVW'%FEC,3QXD_Q!C^A(,AC:I(_<:G>*/*"5=8(?SPI #QZUA3R8
MUNR.W%%_#/!<0BE,]:_M.0>D+TJ5DT<Y8LNJWL4&9(NE(?/^P^G3J2.;C9_G
M>)\R*9"VSLR.55555]\[O:>FYN[('FN**?_(Y0N?G4Q+?W;L<].^\M"JCN$Y
M^/CA50=CVL)@V8&!*!GDP4!,F5=%VJM)LPXG4:9KK(-=[=]/@U8BT'!#_#,+
M/9NTL&LODM*J_G,[]O^Y&?'9=Z@_SRRB10I@APSBBM_NP0D5!#2R5_0CX9+8
M7UL+B^@))250X+P,HHK\F/OSW;SX?@53M*93!EG2T;<)2C*B?);N =>U+!"*
MN2S?HP Y(0 P*;SU@C"B!6WAF)19Q(1F'R%UA;\D%%LI#L4#PD(L7B3*5O*Y
M/O<\?KFBI6C!O7WSBOQ"Z^^!X0);N9J'DOU3PGF4YGF8V#.;%S!+!O+X^&3K
MH\# GVDM(_MBFA%J%,\Z>6IRVKO_.3:%6D>G$#^SA-D).ED$=Z>Q]V:T.&H5
M?)8B\@3CA65,<*, .NK13+X'>\-M8\? %(AF@JL]K%6+5GDFW<8PNN;5VB!>
M(%@X]IMAN5NN95T,#[XP6$XG( 8C_[YXX2&=WH$547*G:PT2%Z,/M_AJ](?0
M?M41J:#W5N'";7N-S7 P]Y[R,<\R_&*G<S,VV4AD]/B)/[VV.N>"?DKZV(-'
M=T.OB9GE!3<+7@[AIOB<[LYVWF2T=JV-EQ=G4@8QAU6B[B QW"0DX$A6DLLC
MBQ!8#%6+>966\C?QC[Y?%1"2R+M)NP)'U$"#4)Z<Q1('O.CWK;7DQE3'I5=\
M:I6>7*_*URS;V7_$^O!O#W6FIJXF;4)\ELK-X&^@)(=\'17#!,Y".;=\Y;0W
MS[.X)]T1B-X@W4#0[FF!;:WB)F1(-_5?!LD\(]S&IBQDLZ,,LO/4@J\=;]:R
M=Y P&?KC(0&_\PLFUHV*E-/,=O(UV&WFQB5-+1W^0-O\/;1B-<ZY92HR*%.@
MQD?%6*N\FM*X]C;C\]1.<U^]_JJ.[+KMH5OZV^8VO:2+3IQC_8AX4)N:S)MO
MA<>A=RYBJ=O%^\&4450B0[NB-[^+9L:-9\ !&23%%.ODJXAU'%PL>>;*BHS+
M]]N0K_1,DO*UYM"G3)<A7XZSX(#''W4EZ/"?7KB &F;/>F>C!SXC64E>4[U^
M^XS*:K*#/IC/AE]YL'*4=XX+98Z^8VIP6_9.IHVA9K:/-D3Q%M8[R',T;X R
M6T55)@0XG/OHWYM^?7Q XY]#ZS8_C-BD? *51.I$&(+#%N(=8T(..( 7&9!Z
M$>L YJPM,#8J@]Q#;"?4\<G-1TVA"G*#QMS,4/M0X.M+1#4DH]\ELZ2:C('%
MQ[,A'0V6T;[1Q_#&VT<K'M[Z3OJ.)2M(=Q/2VDE*8"Z-8,#*HK>@XFNROL??
MM<9$%WBS^7#%04+&L+'9M).FZQ61D]Q.XC5LH[8$Z3S9H'[3P4:BL4SO** "
MI#.GLVK#(\^'JI6FN9,<L]SIF5CD-R/A"4FR/,>SUY*ZN!7L5CB4] FF35*7
M]F?9M]$2O<9GJP7X]E44:P@Y6-("VU(?3"Y2N@F-.S@9^71$&_OKF*T/&Y[E
MVP)#)WI"=S3TEG-^1.32[XXY#P*T&77!6VDK5=%:CP\;S&YQ):S*I71.O,"U
M3<-,3HNS<Z&3I+4R"$XN::C)H>"(>D!VH]/EXU\[(]F7]*E[3W55EWYD2["L
MX/7-==Z=.Z8>.BA6'=(M3CO1JI?X\?#ZAP;K=>___;ZQ!'+2T$NCH9[9B>Q"
M+^H?(=@[?ICHKV\XKX(?[D<-%@SUT?7G0_%C"\)ET$6 YF6VT(86W-#QG/C8
M*CA'43@A'PN!,LA9<.E>G#9>Q[=(J4?F3BW7OAS9TE/]P71^'5CQL^-<W(K9
M,ZLVKYK8T97O&3^=HCSIM7'#_O-5["2OC7>1EV#@@?:["&.*^B"ISW(ZL':\
M':OEP2)O-45N<1BCI6JK]""TP'4G 25*,QI&= (B6<+DJ @SQPM$=''@;'"H
MS?!,1;UK!+([H%4)*@P'9XNFN)7VK</01J1** RT,Z4D<FC--/5KPBR TDS/
MZG_#2]%LVXCJ-?:GQ^GW5PUC':J8] ?P/3F:;Q^U[W[YX=,$]0UY)IM'BX_A
MF=\161-UNZ0:U)W71BPSF[S(=Q>Q>.A7D,6J9-W*!5.%S5:7M(0E^4[X=5^&
M?2/F(8DN?\3@M!Y.%GY?);,.6L*?O/U@U.;H77<KROZ%N\>YG(>3O_%P%U-0
M@]!F+_9M\I7YP9A&AHZG1PM"4?),JD!P]/%L4BFOY+'C1C2ZENP>[[RIIU9S
M*W%-^)YE8F>O!/HG9,N:VT<@(>NZWQEO;!_Y3>!>S:<H@7YM#&4!+*$>&H4K
M)/3\^9EHGS>M,7#/3/%+#O\3JU7#G1H1',T3#;W5>8C%^G@I.HPG:I_*"W'_
MJ[/;06]0E_8MM>:MDY74V8I'ESQD)U-7R:"KS_"-K'#QTW 67J1'54,NRB!
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M(YX^YA["G%<C!HBG5(61=)'G#]DN-:*Y8Y%8N5/%XMC![<-+65TSWP ):)
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M!U8A5MM*SK5NKEU([?UB5IJNDU*<=N(RW"F_%IAMZ[+)WR4XV5+#1GFN"?Y
M1D<"Q>OQ.59ZV'/RU;#U?EV5AB9F>YJ>$C*B".;'1Y[<//1OT>+GBS86??KX
M*[\O2=;8_HN8.8(2O18KE>^X0+K!%S7""X7GO9]E_-^L.J[#H#.J>S^[DV+
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M^28O ,2D<E!CV<.[:@LL<+TX'1W4^/:T4/?HH;JO0W6S576DO(-DPS#?#Z6
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MC9+R!#3W1HI3N$FD?OHVHIWHMOB1M &I(GGGI%$Z@CRAG@\3U+D*_@2(@CO
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M$Z(03.R7X^=L^/W5J;(-?FBJ 7>66]VB24T;0+:^&@EN-50V"!T[GV5%$UP
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MSPN&X^G:@_WXH>JS->Y.Q,MATG0Z3@LE@%I& \/,8$X][2'MN@%,<%#<(35
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MZ_=-E2ZW?IPNYT:JHX]Q%R[<V^_C)T/L@WM%^:0N? #YBNR)6P>E!PC72+]
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M/FJ@Q;L<5Z9^+%^39&<!'V'V(4/$7$%+SW4MS/5\=90B*:)P&:(WP17@'!7
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MVV6(O*VK6WJO1@#]=.R,ETBA';^".J8@/E_P;S5I9_ ,/'1_7GA.ALC?(+H
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MY_F[/_[]4$OY-YPG?7WSV@ S-,0K%:^3//%9G4,D?6!O;=X)M)@ OM2DE8O
MYE"Z/(1IQVYKM.>6RI4K71+8%7+U?2V&J(=-U<&5_C/5U0T@O]&9%3A6_/QT
M!TU;.'9>:Y[R:8/P#R;I"*F+LE:,$01WY&H.2G4('=@$UOJTLNHLG^A(@0^#
M0T\U=>24XG?[F6D@K^.*AAJ/YUTAI#EYJ+PMNRYR9\5L=YWJ;]GM?VJD&[NR
MJ/8P: AGL513\]6.Q;;4IEF+^#[23_5#BVX:&.M>/"WJ<,\59NR/CXO9Y;_V
ML1V'+#)_]@CPM7Z9=:-^P"(G4#M<58;P2L2_>C-EV)FIKJ=A+8Z3U#0KH<C
M^%,9 K2S*H0H@O W]@$K+ORS!644!:*/Z5'-G% .'3$YIE6;9A5<Y%E>5,)M
M;\@^+SB7IH=KWMU7%C*0^/FJZ?Q"^D1[#TN/0=F"'G^.I+DCD6;[9TPHL[6"
M>1Z]E1Z-WORM_F,VAQR_F'.JE:YPV+$M=W]?A2D:B.22(7-,B@Q1:Y#D)OK;
MH'P[T5C+X-A(0-;+1\U2._8]X/F3OJ;^2KR3;WYB6B3[W5 S"]DT]@LX'R]V
MRYMNWBGPC"V * S7I92.S I"9)N)=P8M;\;$^XN/>M,II[[0_8=O&JJK/W^<
M_[JZL39KC/#IV:O*AP<W[@%K[YH>E:=5FVR()JIS-%1.Z//'R7;@<ISI4<ZH
MRGO+'4?:=U;U57NH6O7S![525%@=K1\0+_;>VZ,JH')ZDN PW7-W!=V.2D1J
MD/81NMZPJP*D[SWW"H2O>!@UH@\4+K(DGOO8>*NP.4V?TJX06V\1/:ZAO =<
M$CYX\3FJM#73E50^#H5F@-!+6G7B-"Z2G&:F!=%YFE6<GI$189  #_\&+D?O
MS9U,L5*/B^29@1R6M:$#*V>(2KKC3.?,[PBH#\O/"BH$.R9< Y7>:*+[?JM]
M*4#?;;34S(P,],:7?G*=NN-=E">LD^-'H7XT7(V8A];D9+;.5V3I1AI1AZV[
M]ZV(^9(C;NXC8VXMX?ZFQLZ9E]J#<:&!!S'X8+S)H9<]:WN/6QH<M^C2=NAX
M_U!+KT!YS^.K3H,/!CUV65>^W%)6=N3=N]N;_[RPY][&$Z8NXUL;2L6W05=I
M*U#9V<+6% <()N*DATD]I*,0LS2@3QP%,AGS]S4/#"QJ*'&(:KKW&O4%OEC0
MLTJ2PT%NN@*1[9GY8'P\?^^@H;RI6P2S^]E4;<DM]I1TCZ3<U(-+^21#".VA
M>0$;"YU] ?$N2HH:[7F8!/1&\;7Q!LI]39,:"%TQ&8;<TK@A6+"^BZ'/Z<(J
MNT% FR,.NVV$P9(O8PTR8^8+7M?4I.*^K!/G2*.H3<UG/]"6;Y2_RTUDIMVS
M7F:S/6JBTF4(2](F2$Z('C0]QZ,G #^;*8EW](FQ'+8F-,$!R(W^X^P83W4P
M/-%+P(Q9,NXCAG(DCIY)K:S#52^Z<"41?V(]+4,CBP)N=N!P(Y_<NLV6QMEK
M(#U.3_RL6 =<;I&J@+JQ(3\.?WT)]D03T<\@+$-XC#UJ&Q6EGYN2[WIEJJ;/
M<^PS)B(,'-%R]\ 8MK5_?3!*/R%#C#_Z*7-\@J](YE4)SN9+ZN@!G]2YQP^G
M/B1\:>%Q%,0ZC@H*[>OO!1DV45BJJ *WD:G;[ABM3VYNK.I+Q7^)]: \T95I
M]"ZQ4B$ALP-VNI2)F IQ1.'PC(K9<4D<VE>&V$#8'*5B>U6KKE:@0#:P]<1N
M\]/<'>E>.)]0_0GI6%TY&K'6Y_?\.+XDHG!%>CV&NM$FXX.57UEY9#@ID]8S
M0$_$[B0I$[>#;P69'0H)N5LA?PZVYFSQOB:>!V +"A\?S@M]/?+I;'")^YE,
MU:J8!_FTZ/<Y?<:AR2^.JM$5I'LA.2X]IIJB23PN(,>)(\>;PDX6]HH=.?K7
M.ST^TK1K7V<,3<QF9>08""N;: /'W=PM*B/^=#?7/O;B0G+!@IMT\X$-"31Z
M*OJE;YR9@A4'1DO^;TE:8D\!MJ5*L,_@-02#FXWS<<V[SQ6)?T-OO^E56S^$
MJL#$B!U]D='7P&HK[A7#.LV5/NZ(7?5@D6>!=%.@M@IR8[,!X9QK+[=7>@1R
M%.9 S93J@Y/,+!A"_D%32";]TMQ/M*H(0&\IZM.?G3TDEC-**O';-N7Z2U7U
MP.+)\KE9P[^?#6DU-=0!S*\28ES1Y\^!^</+84F#;,MYHM$=/;8;JM]:0-Y(
M](#\029/H2,)K4GH.0_2ADI\P7<3F&CG.C_MAGOR2E<3_:_)J<]=^!)JH;OS
M^KK(T\'L]>@O9<1P&:("*V?)-9#':TT?.[Z4[RQTHH;5:5552?7-:H 'E_&2
MDK3;U13F*[5JE@SQP,(_2HF,.:U9/QL(,"ZOKK ONA U9(B[\S)$!^[>@-E^
ML1E4(J",[T9N;70J(K1BY'%CZ"'3,P866;-^*QX]#+3BE,KR2E*"DWY@\2!J
MMFQOAK-39,/S/0Z>YAMFWNG=/U'*.M:4-60UER5U8M<)*XZ'.3PY],2M6@V?
M8>U6G\K$5?7^"+ W5UY_=W5*^;\_&U*(+M (AQ*KA7G94#70:,YM"MA588#9
M-'FKC97RM;RQ1+XC+S0T5-M(S3D3?R@A#8O%J&6^#^O]_+[H(!@LN@*-/W0<
M)ZIC1A?,]E_1_HO?Y-CJD%]C!E[5.#M^:BOF 33'];#AD3MP7;7^%09- *-Y
MUZN(G:]J^O1-E3CE :<N!$M?:#W'U<<R\L=-'\[??+DSS_/1D<6"C<$M=@[)
M^SX7&@HZCMM;*R96VK%&:\-#\[$/OKG;YSAW>FG%='3]%,?@';UB<ODY!PSU
MUHENN\RP*P_XZ_WA?0XYKH^*#4I>7(H]^>OF8X^\G4DP>)>'8=;*+T(Z%%)&
M_Y%:(%7K[$0OGN,#X-158$'#4\\<^RI/AC"#0?5=F-9\I0^RTU\#0X=AF)_W
M30\VXN]X:1C@0G(64B'<:A'<7@4:S#X+5U%O*!(<,CL) VTD#H;DUC ?_6M:
M:BO=1N@75@P XQ32:4G#(HHUPC-DMP-QI"-0^@L/@E+'"C5>[ 1&MHTI@98I
M7_J#B*?0L33]S:>:C+@S9Y4*FPMPY8]_:4S]R5>Y])B5ZB@6@?;')K!58?PP
M5&\@_66H6H:('=.7Q))VB:^_@OR66WEG>DV=N-V8\XWU]'MH?=,1Z.F SROC
MXIMI;K%;7C38>SO"R.-K6RBM::5^"O@A^B*5(6QN+GS0MK;U?9V1%R)#?*H,
MG3=O-_1-7VJ>L15^E(S!C..5H$>R3805FSACQ9WV_UZ0U*\B+L OB. "+*PP
M%[W#[)AT  YK9NNDW=CMQ%-@[:^O)4^(V]=-1"^>=MB7JK"=,,'+3*YH/%[V
MH]ZG@/JZWZ!'_OGCE$<^-I%!Q-%SBQNDF]T$G5<@#]%FL;F@F(%5[+I&A41V
M(/FNJ3)/X]@4?ZZLITWB8MNKU.;JQ*]RZPHDUFOF1486LET;E5P]#6E?&\RU
M]Y^=!87X3PS,_"!3ACA86(KI6L2.-%[(,5AX[]+,%+?<$+I\O0-C=M>&JD%]
MVG?T;VA.&1'&Z.?-X/>WIL/<Z^@ P+@"34@3HJA2#3V4U*L4E)-NWE0,]0A#
M)7^6F^V# .%KJ <<::/+27<2C4'=UOG-?EG-L;=P B0W/?JL3Y#I5;.2O #I
M8<%<%4_N"% =>)CVRM=[:WIXN<U:KNT%VS;I$*6:S=]#KS)NH<9(-06'B\$%
M(46 FOT*B,S%40),_)XDFZ%F=3B7==[+]!S<&+?6+^2T+U>5[&@+QAQQ6^NF
M'!BV9H?SS&X[2;K<C,5IL]% /&R1Z! FIGG,UK?18L"UY];AP[;&2[OS#&]D
MATF[JA:J[C2$6B[Z_L\\ GO/4T'29+:?<+P5^9+2&J4W/D<5G2?>D#R#Z9TJ
M='?]JP@!Z@)XW!W7K C.I97,8+CJ$B]&??G+VJ9^MM/@_%+A:]QK[TH;-P]5
MISKZ67D@'@"=]6TZPNAKQ%>II*Y<'1#3N@KMU'Z3Y.")H5$"F]:5\HDXLR,]
M$;>*4_;VM&;<T789TP+?N[Q4CVC$&,['WUA0N;4^!?TH-V+VY7+M*[)TG5N7
M-#=":I:!'7EBVV_21@O+%.VS"?<98@_7,M-';$-KSRTS_]W +,6&Y%1@,IZU
MNI%B]<H6$_IZ6&;W\J%:%RAG?%Z.H"#TBF[#;A5'B"[BV/ ;<=*].,KN:K(<
MSL7S*/ADG)#F4@?A56'ROPVG1DK!W<A4K8_TG :;)FT(*'7KR!$?_%E)@CB4
M6XX2YDKHL+PPVZ%L-X'S YA!\?:1!99OC#7W#!F>OBTZ S([]+>'EO9L&!X+
M2!O%K+_[-, YT<#64'>;OV#,PQ*O>/[=B\B#R(5OJ.).ETI@8=FM8I2='I\K
M.'3]<U6C=:4MJN1+.8U0'%(YU&];6I0QC],29OZ[$5O3:>24%DW?-]"OOM^^
M-^M.?;=*%2EB-K4FCR7V=2B$*7,?V<_Z 3U_P8@G%/CANP38^$I?W4)*M@K0
MD&5:!#!0M=+PO784N]GL..3%;6\NV)J-+_'SU/F8\0F*;[WSY2BCU-^*T*^?
MT]>%UQXRR<B)$$;8UN05NW]V>^6XNV@7X_SI.W0#TL[/-L72C^A-.K2P^TO5
M F8\;6_R98\I__%NMS9[MP\;% ^I%=WWO;5^[CI@D/?SU36D3!?-?8_\;6^/
M6OSN:-7P6M27Y#)=E\]JKO$_10M?T97S@9+9J')3K/:K$Z8W0*> _OBJE/#=
M9NK*FYN[C7?:]K4[QCJMSSOX\LE4ZQ,=M4O[\Q,GS![]S\IZ_*\\8CAUW(N6
M(5HL%S&?=)TE.>*#,L0:TCXB4=#)1ZV6SB+H<2:B23O=_7IQ+J[S\2ZMTS4'
MUI?O;5J:HX9S1X_UV%15I5KY//8=^_L\3O<NM$8JYPMB.M#K !PEP15NF)),
MV4+2([6/J9/;D3#%],4FJ)&R\XF_DFT:&I-L7U*L&Q^.3P5;[BO84]5D_.M0
MU,EGM"RWB#W-50_Q#^CC37?"V[K=A,5P-XW\*>M#X6 '.7+;90C^25X#)MYL
MGR#LL5D5)W!#A^,TL";MS"#Q;*&;=MJTB7E&_F^OFZON:UKQ>0^4=^84]P!^
M5$C7N T]'"S<#C='E0[0J_$=W<=YM7QSD:T8>0^I#D6W-BMC-Q!T&2R5^(K)
M_I8"0OC%SVD>445^LQ>7@S]-E:ZK2"]FM?AX!,T?GCMX^.U2+?"MBFX##_1X
M9VE"QR$[?8>A5 V;QZ_[O\20GI6:EV!9UM3:1U%C5\\-UT8:!L_2_V"#[G#2
M92N1]I%ZQGZ"ZD0'I+WT*N=XD6,WWAM4X )M@7HV V9(\9D!ZL.!J; 54FG!
MVV^23 ?*I?Y#3P<"GS;5UM0/ABP/F*?'5+);^%098ET0Y*(2"__587Z%W'B#
M-:LE'PD/V0PSL_OXQ?797,/1H3QNSL%=XE^D?ZK:1?.;E>L5))5>H?>^C?U6
MUGK!Y0<#0HU3[J/7DE! RS:S@Z01&4*51B4#E3#D,BPD#T^_F5)S^<, .5S*
M'90F/:7'+.(5KQ+"QAQY&F;]3L"&KD JC(J:YAJ\B\=&1_-JP"5I>M2TRQLX
M8\&=B7Y!,!5?[7W5 F,3-N\GZ7ED7K=C,OX[QH(OZ#A]<]YG+J<\+]:4I/<@
M^%W?1.G<AQV#YLJ9-LH;=&SKB94OJ';VX;^[PUCYH309/9Z+!1W1T6SP$CT&
MO9UTD&#)(&E#;NA6_';;/.*O($ .JJXS!+:.:"B;GBO&+7CX/VRJFJS/?832
MJ:WS3BAC^13('1 9_R4UE"'6BE=K@1!AJ[P73XR BL%3G$R&0@)),8W#C U%
MJ4^1C@H\.A)7C%,:4=>X(^A-[253SG>(?9Z?DJ9H<C8BOSEQBS L2_=/6SD]
MX"AR9Y#46-KFZMLJ0OYA8I87#B>>%BS<80K"3&%D9.K*O5/(E+"5\#^DNV=J
M__PUX7Q64\\]6M*S5&^CA=-L<@5*$3 :FCLGI,QV(N^AQ_^B@_;H$4'XU>(X
M&>)&#Z3#_F/GL0,P((&H#$]UR'1ZVY%UU,90WG!-P075G@%:=_^.L=F">]:8
MICK28FY6+9WSW6D+8SO_R.+$_G:'DEG!P]^M,"S'$N>DN'?&!;:7<ZKMK ]\
MDE1\I(]7HA%+\]#^*!E"K#2FL [J4]CF2FCPA (#!?<BRW<3S0;,= EXQGWJ
MC.:ZFAA;25&HVU5QM_R'G2D>7K'C%R92K1M$-^#!.E^7I ,!R(VDMW J?D0Z
M(>U'*Q.]P&=$]Y=]4H6W>9BP9DVRDV!?=I3:E,L'5LI _4W/70WTIJR=C7^5
M>R?<>U\9*+5?HL=AP4O8=:068!,:I\?^U%2-AUPHU1]A+65@1#=J._'QK,R4
M1FO2?LQ3S\]&Q>"=S]34FP;R 2SFF_KT]VD]AH-/7 \,H0[ISU)I*N3%<&'&
M .F0E$4!78!/[$[L*V:G0'0*6N IB)4.H^Y[KH%R5&,,T!KFU_!E[0)+SSHP
MH^#9#-VONC_N&5.!,^IV)4Z.[\)P[ P.]?<.C?33__PE,;)4>VX^)(LV\C5\
M2 2TZ/CL?.SXL'KPZA##^I&3LET!@ZO->[ON_N6I#Y<_NWLX_]!F^5.*]&$/
MG5T]X\WYE7!*&(_<8';,%3HN59TF?6!KS(9&VFI9,>F^J%T]NX.'QR!N:V2F
M6DU29%!]4ONM_ O](Y^GPEV#\O#>)0;.9.%<YFK93% AD8ZWE$2+?QJG;X=F
MVK(VM"8!25C%YOU^=U*3I6LA?&' BKL)-<Z@Z3?3#A@].PATFDLX12\]3EPH
M54V8#7(WV#;:B$Z@@-;8:/1:F PCH7V9_ 61CO@W\$,MG/PNB1V@4E^1ARWW
MM _/76!1+'#=%;34LTY\Z55D3(V-$JX<BIBHI$7?L:D@ "YUKYL::@8O4V!D
M'NU#4IX,H[R*3P'\)'8S]@+5=GHJ5HF&EH<ZV[,^ST>4H&-)\JVYVT'=^,"*
M?;X/#/@'^Z(L0LT/-%5P[YT!IX2_:G,?ILWRF^9&LT9LM L'V9@,B&AWN/RB
MMOO4NQ.)9F.W+WT-&=SPUC,MB16<X[J)?<7PJIZK[K0QOW>U^!.D+]IX16S:
M;XK+AWA<;#LYV:2M7K45<P^0,[A&%9\1=/.KAS*6TUBNIB_=KDS59*H*G:GA
MP0<ROLU-ZP6:]7T_7R="QTC?TT$7;#P,^F0(OQ1C(0;J%IF)"1*R%$TH^)72
M1H&-2,!C"%="S$[WZ__VNC['0,/SK9A:FXW3^\$/G O,KVF2]C33:IK2[/^X
MBFY%@I>1:O[T2K)8!2G=Q!3AB0&]M!N2OZH58I';S+9!\9T961;%%?Z>:P0?
MJ!O:1+@H1Z?:_O*YK.Z"Z,Z5]<5K?BAZ>'[R6VEC$8]_GN2]6\"F !JK$]*V
MJY=CHT$[*_KU49\%+CE&AO#>);XJ0/&P'1X;S@Z5F?[R=-+%F&61%\@IJ A@
MD3*6'3UDB.M&N2_O!5:@B);R.7_6O[:UU6_?,<@O/E3832HM&OH^B/4839^N
M.%:-&T@..&N=BU+X=:?+C@G7%.RUGJM& W/IU@^3[@EO7::<EGQKO@^#B7$.
M\).?*ELU=(3ZJ5;X9*!YHW@+1"\5:T"9@A'&1\C+%<3&T?@HM\!?= :T$J=5
M:0^E1C7-5?T509S<"U3]IXJ["L^PGP(T%_$..@<U2^?,?UIN9VHJ"GS;L%ND
MP\UH$!MMIAF0NSM27D^D:R?X\+@ IV:9&)IM&UI>D9+7O\0W"^OWNH_J^.'U
MI[EVI#IT?_"F=-TT93-ZO*@>:$.- %PLG(?N9^'Y7@*O-O86.+B>UD")SX+]
MPACFHH;_//$D.HDH'UA\FB:1%G W6L:MKP-*"BO(_KX:7S]D1ZPK:#>>1O'3
M1!=:1/9^6/ \95BX;$?["."HZ\0!$DHH/0E8$X+=."-%IKU9P2<0]<'O(D96
MM8E31_IZ2M%DN%2COC_4ZJ;!2'82L"5CP" IML9$__WO_??J*^>CA%]M0Z<J
MZ@_G[.JT/-9FK5PW[1A,T[6Q#ESH4CKH4.QW6OV>>_4$TH]_H&B(7<56!L9?
MK13#N@X@I\@0E>26^4^.PDQ)H=@75/20)P:^$&N9[1XXQ.?3^,<ZI!\DBS\\
MYF=G<W$=+U-QA5@3[MBO+_(>N3R7]L)4!P];>54]<1VH//$&DTK?C@X@L]:T
MF.!3#12&41P8L_!#R8EC._KG9F,'E^@IGR\:\#6CCOG13NE>( W?.L0R*SSE
MYO9IQ"J$WH-LRW$<KTB#W? 1'+4?H#NHT'[C#@#2_99S7&SBH= .K&_TBACG
M6W)U)C^&6-2!4MKIW-B*T_S4!T&.#K3[!;47BE^';_UZCUS>&"B8X/C^:Q&P
M&%3E9PL8;:S4 M$^:3_E%36:J NZ"9\T]1O2MQ'\L/[-2N" L5I<Z?.IE9MI
MPV,S#_WF@U_\,"$\W"G&>96,LD9</<8P>--26W9]3GI_4&_D=%;@(K/X<7W'
M$,UM*#DPF1!^,E)5;4=3DW5 08QKB6K71D96PZ5O65D.J>3%4ZOW.EW%;/.3
M(38?)NE,4D [&6+D.+8)-"L0*-A!DO$NRN:I7,TALY\4$%!P:R[*%MN1Z9I,
M]KW%82M"V+9:DP])9:P?E[+Q6W$IMW;@MJ .;VC%0OJ-,H12\QJQE:08!5Q3
M8/FV('\RW00"[6B5$')B\QY*:_DX51.&4D>Y'J=:^R ;ALEGQ\+JK-&YPN"2
M0PY''VX$7H:>_VM#PII%>MO\B*HP6/)*AOB-/,)L8U<!;6[X^\WJH/'LLD#4
M>D=*+_9KWMNWF#XT 6EQ/3ST%T>:(JWZ^ET2KGJ\^>XQE?]MZ.35IQ'.-VX@
M']$WP8Z2X()?OQ7@9)OI[_:J%:,H:KLE1S]$G9RRTBD<:GQK,%_U0\*N^-9?
MZFD8]=ZA!#,=*MAL7VS5ZE!P\)+-XP/^AR.LG3/;FL:NB(JGYEM1D!Z*@4I$
M5BO,%H,*ER 7'O5G#](GH$HWGNZ/B2$=9RZ=_IG'J,VHGXN/JK :5W]6F5.1
MV<:Z:6)7$FCZ7+Z:><3UT(&OT\Y!$CQL3@<Z&>08H#JSHV>XOI_3D]P844[J
MP58BD^DX>I+F 7 N+V]DTE,%)K&QARJ6Y/ _?V8\_WPN0C>1)L+.[BI3TXF\
M4" XG'-(AJBO';A1+3:2O#!5*".>@FWV,@QGU(#QO-QUE5F\3O3+^7C &U":
MZ74K_66 I 1#,$W%6H%M[)=>8Y;9WRM#V1R^"2$_96"*):0>BCU_SBQ6I#ME
MC-6D7U> ]/'B'=2V>N^EC'+1-<A%6-37K.(Z[9\]JCNNP,#&CNWK)ZKZ5![L
M*%L8[;E5B(VYKWA5K+N.M7![W"TYB&7W]O42^[&^Q%!B\IBQ*^%1@?D[LZ%+
M<7J/S8'Z1F/3G!KZD$ME4T6!]O* 9+\D!1@OTSPMJ21BP&<$G'037^0(Z8[/
MMP-\J^H>EFK;4<*=!8YG9K%_ALD G9597Y$[G/5NPKF7PA"<;E!1*VRS5]:Y
MBA-:TQ^0H3V9J8"/1.&<),/ 'PZ>6+5&*T&V!^B;0CRM,*M<#HVMS' VQ"\E
M/6YT(MU<Q&^"#=0H(XSIZI/DA4H^]*H"B;I4]_JOO^?X0>Q>)A\'XH3)T.!X
MC_PDNLJ7CRN1_NUYH*_QHF%@9$<]MH6]5NR3W<9"],W/POA(->V<H".O^(J_
M/9QUW8>GZ:R:X-/?9M95'_TK2-O[OG9A8&:DS43D/%ZK>$U"B=O&TK?U2VK)
M3WXYA#;\O.>S4DR>G4G-0("5K;Y..;G4C]J.AW[#0P?IDGT+,'.$[B&KYF4(
M0Z=EE]G[(%J8!>GD03V8U4NO;Z:X"1F#2WPWFR:PINZ%6 E4;?$![7)\?8/7
MYSUK*894+PWD,2W*@P^I/O0,.*Y=$S>XIR99N^KXOOR,APU\'SIZYEQ^3D#5
MPV0P?;*].&(@=U?[5<]NA[;+.2.]KOK8L(SB#VA:CUC9C4.>[174GI=DBG\"
M 9XNWT5D,\W:#+U8/9V7\K.&KS/8&:^=;!OXG$!QK$_7#QG&ZP\'\6?SX^;\
M9I_5UM.-CF+].[[#5 &.BS<A/9'E)%#MF1,.\KBU+9149.7$/5,KP1IN+>SU
M+N>CST%W_3ET^:GC >%J<>0]?TVMQ%97:JOAJOE>IPM'I13]]N<OZ56-E._<
M+MXR PWI4L6J;L)/T'T1=O0S$04%BBX1M:#@4-"7*ZTMP&5*57*16_T\U_8O
M><B'VAYC7%*Y%V5S9C"O04XU$Q=9.&(>!JJ/8-%=4@U"E;6D"H8%^0#H" ?+
MS'&-HKI@T1'(5[J)(T"/QP!*WA]#]17.03F\95 U/GYXL7V 7SV3)"+HBXV?
M3UM<U?_V.F[$ZN-<4%Z-K7/[BSJO0;?1I&_-F6'U_$%JV\+0L5J:#>ML-W?F
M4H;2@^#^ @SK^U"0>(JVT>GV0^'MF(&]C[+21&A.K7BW,<AHJ\>W4A*0BC*$
MUSP+/SXQ^T, =&1($2"=O[W"GZ6;0%(C*[JSW?U;QR*[U9QR_<H/E\W;Y=<@
M<0/Z_%F\=VW_O':M'Z:>U+N:"4X!]Y T=/O\L,L;["LJ7UYD"96.D^^*]03J
MG5G+K4I/ YQ-?*,;,1R\/%0JBEBL4[-U.&UL4RNPR/8*#ST40":.N9\I:.L1
M5X@-H7"![QOVRWBQ$IZW6GY'X-8&J-+'L[V$1=])OT@_U%ND%$+Z)$6<T9BA
MX#2-G$0EVN>/C.*D)WN7MF](F/\F'<IJ*?.MP\M?M;W!ZLXH1DY.\.7 6F$!
MM'J)$$PA[STY)]HN_6B,76\:ZBM2%.L*;/,G/7=\;+Q .DIPP,92UGC50OAB
M7-;32/+:M]P-C:\:^XA.>6>-"I1'"\NSU"-Q;RN>%F\L[AL*DBXU[R\-K\?0
M*OI'@JP)XIO/^P.[!TI,C5^7< ;#-[]V'2P\Z-_SJ=XAW7#V<U:)WT#,PRPK
M&<(>>)7)!\ "X3?H)PZ&I34^@KL$8>"L6),6_HSPL"5D?ALAN(V$;(I"NW\T
MC/3[^KK&V-GX(%6C.Z>[O?#K$V'M[]8.@25+YB0].#HC&C&@%Q8>%XYXL)^T
M;3*<I#)@JL5%J4'!/(6X)0]GGLO0+.EH2[E5.+=+8C<]/=9W)DO2-)1>/N4L
M&"E3"WL0Z?UL0P;/MBY \KSL61F+:;$\-HJ:\/K,N)SN;KBY\M:C%_;%)T]X
MG'UWR<[]A>=WEZ"WTS4!'/,=#L;_^0/)U)."^'9VG!FB/K6S@W02G(BG%J7X
MI'9>&KAFTR]W]/+C<JUC[MIV[UJT">F[2]=Y57,ZCJ557_\B,C>2?@WSPBK%
MM_:'OG*:Y)3L2ROU+-O?;]N@/>%@GQ@XF7:GB6R1WZ@N58L6DF2(?"H')9:'
M66'RZI+'61$:Z'4!,Z7KNV2(#CV,EYLTR@D6VFT9 F6XG L(A98RQ+DGQ3+$
MUA-HJ<>WYH4Q/^IZ&2+NJ81"GRR%;&2(-=XR!&\'P+A$ZF$O.HEU9(B[E3*$
M(/%T"O['TFKQ]2YQ(W,,.3*,E&R]31&?&)<A?H1GB7HB_G-]VB\TI$\,8L6J
MJ.\+6 * OP$LGGP'@#P8Z'T=P\V?_O!M3+TA,LDF1O%LZ)::A8[;:Q@&@;L3
M+GQ9;^%]8B(+*GI+@W6_#4XZN[CTK5"V,^B3IBT<VR2@QX6<MFF_U<492#/Q
M3.)J(!D9+JRAQV5^PHJLB#JUD"&UG*9JEUN8W3V&C:3._]BO_R@$Y7(=5\JQ
MD(/6QVB\MP9S-8^P>E76M@%9_M.Y\>F/N96[6SZ68Q*.-1JAMKRP2/%.;7$N
M/AB:8^R<<@>U?8/SHT*[1\RJ4HLRW8W?G9-U')1-,Z6J^+OTB1$N4KJK)XDM
M9K@\M/$5'?E,-!*XM,R08UGM/:TRA/HH5"%J;UY?!RD)?'B,>LE\JF'#O"*A
M<L;^9?:;GMW],UG"PJC2,>O-])$Y-:[2CL18$NT_I<&1+.RB7((,\88B0^Q?
MP$9\@7&_#-'KP<!(OW*&V$N70B4N/1QD K")?AV59*+PA_BH0&M\,Z'S'(0M
M=)M$*Y2%TH>7N;2_P=Q8'"[06R7^F;O"FL(!M:.T*MJ]P /%D7*/:I/X1@L[
M'$ZK6:%]A@WI<20M&(3YEG:6$W>]'%BDQQH+5_=\'W1]"X.SBT,AA&IY# :L
M#AM;DZAQ\-V">9R&D0W.+T.Y^O[>E&W[.P>1X "R:EFB#&P"QF_2Q=?)4(#"
ML$B:2(^A@T98Z5$;>$B;X&#P,\E9ALC4I/SQD '  S)A"1G]0T.UX@%D.(Y*
M>4M7*9<A?+"I*T%WGQ&O05[EQ//]C?I<.:PRX?8(C.Y_;M;'IBBU&=VR6:M6
MD7T -.G&W=Z3BXMH+%$YE1VA*??7MX39<HS"-%#5$QLRKS&EB80BJ?Y9&/BK
MBKA<%!1?= [4Y59-28\)4/>KN]$6@O54KMS)QDWZS06A9?ZNSCG%TYK$0(WN
M\F='WNZZ='8E\C_C*=\R)3^[,$4]GNSOO.XHWK\J;><WQ-%JQ0R&!WWZZ4+_
M(%&Z 8H"?87*D),_SP893ZDJC(\M:][KE^FY2T"KH(A.BC%^II:<[&'3$;K\
M]-%1PE8.EL%4Y&=X*/ZBF='W[+:ZA\"BJQB<X%!FKX*I49XSG,XWF6 .,\%4
M+VH\D#1C!ZT17)NCL3<$.+;<BN24!W 76E2/!]0;]. "D9]08]R-Y>6<JEBM
MZI0]R*=C:M ,&-EA\L3$.*Y9B^#B/!ATI;""LKYX1[B+W8ZZ5)8Z66=.YU/9
MF/LO7UAEOX[OOM-^_D6'_(%+):JXPH.)AT?[0IRS2!N"U/7:>+_P?X^8PR06
M[SHANFATU:%:2V\?K\?F]*/+97.#\S[9'C($<H[TL_3-,GU+"#7:!5L5]4R&
MV!*B3UIN-]&-T990S YIG+(0J.1OQ]-2]F&A7TFC16.CYKN=%[I\P[>*+ERK
MUII]V:Z()V3"--.*AXSSW $9<K'#4K8SY#'NQBF!C%N.2S^P=VCUFAY_/E?O
MCZ^^HB_>L"5#U24PBL!<:#EH]9PVV$+'I1EDTZ^4"CSGI9O3_/%P@#Q3+<FH
M.0#M6(F CAHGK7MJ!(!]+FK)QJ!%/7LXV1:G9(!5T.Y3F0UD5J0L'#V:%/;<
MSC"BSJ_[NWGW6%F8\\CR*:%'X)=#%D[)K9%(?/;7C\*E$L[4*LS6NMK#P4A5
M%A.K&G,?U-,I?6SY)?+P\K@T.IB#CVU&"#;\86H<7H:=69@T4X;CAYMEG]N5
M@:%U=+J-'.:GSL MM7J!0:F_I)YH/:>6?_"Y,AMNE \:BT7$<S($XZ0@4H;X
M*T!DET@N@T$;!7Y:8$+Y51<CW.I'_X:#S91#V;ZZ;9>.9=30']-W&;"'@X6Q
M'V^:'A54<3S+!:CS?:'K!JNST3O$&Z$J$LNBJ.2KA&[5($/$J)T:/<;G2@:J
M/GT>>7L(6Y^>B\ZH5XAS[9F5@%XM*W@&'"<T$4PIDJ!W(?*Q >P-!)=QRW8/
M79O:7&%X76.=D7!L#<9D[CMG#%?ZEN66_5B=V-?P&[GWX/Z5=O2/);18'2EU
M0'[:E3,O*<EDXV"H=QT5:$ 7,I>* TGZ<.N,?"Q00,#!(5:QT:;,^GR8ZT7D
MEL:(O.S'G_DIVH.FCAR^@D5ES"O-P.YO>3LN6:A9GKH\P6K>0E#U "LH7/0V
MB#$[Q<-HSMA4S&08A6\*]\YS=74U+YKT5*]N3-%RFUQ,,5FGJMJ":!@XC/=)
MWJBF@_7+SR\D^;VVV'V?]OYSW3/^"Y>OB?;US0\:_#V&K_#?W$AC<*\E=7AI
M)95;'+]"L&>8[E-[],*\/\?7[DJRTU5FR%<3^R>EHA..)?86#Q\]:4W<7Q',
M_O=8 XT27Y4A="B\6@F9A9:68GYRNO.*V_,#9K<:]-E5Q+KD2MA<RJP4QDON
M%,@014])Z]PD"\=DB%?-MV2(THNKM7 3T+M6ET/6ED&4/.*V1DF&Z3G1M>9"
MD<%,[I$A4WLN>RT!,V[V&,[UNPGY/6Z"7PD5RPP7NB)-X7[ND8PN*\JEQ(US
MZM9@=\I@>W5@T/>DB,*[3?WM])>U;5$H83I9F"S)(9E!-N/5O<0=8.>;OTVW
M<U%W%8F.?8>(!SBXY[Z5)E&34-VXE?Y(5]7+VM23-RL\=_(IH>\[@K\N MO0
M-_')S6NAGO'Y>U["4X*X6B[J/DYP$+;'''YM!R;&*,SS\$<S%>"W;JZ'?_-@
M631GR0VYP\\E@T5JT,D1<Y?&XP[XTNHN2*O B0YTW(KX3W_=3L^?:8)D$^5O
M=53H,+NS66G(D+W5//^S_*EVF^=G"Z=KUY43]2IT/L263S_0%886%>(.*6%V
M_V7M[(8K?B$F1:UDGW1R'=.WGGOK^# \@-^^K^*S<[GG5,7$A'$;%=J'2FB,
MK!"'TOK1_C;4C>)#DA>AP$^$3)@+AWN#V1<'YHE7N=B-.O>'#)%K",UPN,\-
M9XS@53VN1E5(.VQ5VS$W^@Y=&K/=L>WN+ 6\A!VF.T&O1%N@><Z&UASE>;'-
M.*! P+0AMQ"--QJKJJ46@!4+%P=#\ I7XT..!ZAE/'[6_<Q_A+U<NVS4>B[^
MNMD[D-F.BO,\WDO#;H?0L.Q-73C\315*;DRB(7=>8:;>*%7X,CNI<##4%G6I
M_E4_BX7P?>U6QSG2NN7ANC.NC;5<5;ZO""T^!7]Y/M4%4&I4YY+CI5N"_4NF
M/3<(\#'B"TS7#XY=X-CC0VJ+)H',^[HN[/7)*\FJ#RVH>\XDM,GK$P>SOROF
MV+0/-UOI'7;3FWSHKQ,VX,!T3J\QVP\5B':*<9(2Z2_2;AFB>H"^VZ G-A.Y
MU6PWP<85K'V#302JEIAM'GIOT(I+'IICHC;2WJ% -"=0?%J5=*2?ZA-O%W<:
M8Y5U6HUGF5*>7*%X?I&21 ?MD'%TI-B8ZQ')%=*!$FF?ISZ$U64$!O,H=T.Q
MB7"^6%2?+/<:2&,L9P+KB8:"9(*+0U]U!&HHHM&X;+H^)Y=ZR"%IAGIX7!M]
M38&,7NO24J_;=HJ<Q-YRLU&>>[*Y*P^J$76.*=' L1)BV911SK6*KM*4?0N7
M:K(./*VKHC5F$7SO^>6L:1L/(>V#TL&)%E>[3"K4U2G=!&;$EO<$X@IPGOL$
MSK%/ITR:NF>ONYV*0MD/XOF'YB<:$N[KYU=G7=5-CK_O8>=7>6<>:!AB/16F
M!SUL#)QKW_]L-N='T$-\@?^8!'.7M'K/H?$B.@;81O>B[)ZD[Z#93*)OK)[/
M4&Q<<ZL@X,YAV@L;@8(3E)G?711 THZ_RA1'5GA ^UK??9^>EG:U.O\YPW)Z
MIK ^O1!3>-5MCZD=#!+7-JKA6X!H8-.&CJ%Z? RZ9@>6EH6+YKP; 5HMA-)?
M!DS/4!0^9!%#3_2VI41H9!.H_)6B7B5W!7F*P3G541A>XCMHDJ=2Q4]$![6U
MI)VIL)EC51KW9UV^\WJ(=Z5Y)]%-T,G8N&0X$$<I.I1483D^R"3>]5-AB"QG
MY6[=J<D7\ECY ]537Z[DT2NSG#E>B=.;M*^OOW#92D[SY+CF_LH[8IC7?#\S
M[92<,_;JSF1.UNWO\P=P0](+4L_53:O#7<)&"">Z,-F,!GO>S">8X#MLO81/
M!!:E K49+K95(;J>W:JA,)Z9*/: S5A[:!'%<IBJD&K-C!T,U)S4>91U6H9@
M%:?.?6/U?4P7F;(KD*]\6ZD)*NQJ8SY39$X\#^:^&J^!:(+<GA;LUI 4P"[J
MN.. 5$VLVQ<7^XSPT>WOTCU]8NRMD&571^O[!B^O-,YJ[GKZ0"+B3?#5J6(M
M ;,5&^>Y"3I-)7H)F.V3C;>"\R;KT4F-.N-_W[S9N*;(GU53%1SY FJ=Z[+3
M*0]=9P26S6BG*+V(NYX8-?.&Q;Q/-.><5G45Q$<'-6M"&5*652A^_=C,'=3]
MP]7JL759VK1L-Y#?/I;TW.!/2^6/6:W<*^E!*KI[KWQQLM+)GYQGVBJR\=#M
M%Y<?I7_VTO1[/FH8EH:Y,9?.+0\=X]<&E^4G'DR61\>SOV-)&X!/OIW 2IFI
M![:(]B,=%$EMYM_,KX8D&<(I/JET<>BU@*Z,7%F0(>I*D?F@@B@.!D->=<!T
M@2Z<IU[W-/P_O=KK?\"R.]##QWF8-D!1VKLLW2HII/MC$[%R,H1?-C8!O:,@
M6V@MR+Q'5.;T1*.WD7:=O<7%X1%CXDW,(+$.CHM1[;SVU)(SK^()95I!=\NG
M78Y_FC%RS8S7GWWV<+KO4="SN:;!R( 1]HVT_H8PZY4G@X)+>8X*=K?2"/=?
M6[@4J]UZ>,OYT;3=I@_NS-@3P8//"\PNV#R@5#UR^;JA=1[20[6B$Y';FW="
MD1APZ+$_N,QS(=.0<7#4$?L&"B(Y&71>9,Z=SP%=^=.>AM"!@@"FF3%H'&N*
MO94_RN"4!WVWM0AS:]*,PMOT_C*X]\8B>0V)S209?FP\)WA*ZAD[W@O<.*UJ
M!Y66NI'ZU.)33!5J[?O,E*Y"*4L>1/$140CI( U<OA^*EPMP58BF9DS/+5^A
M_S?6WCNJJ>UK&\VQH2@@TJ1&14! B(6B@.18 "$" E(,0GZ*2(F0@X!$"8F*
M@#0Y@L 1A*@T*2$B)0(A$4)1$2.$(D%($Y6^(Q"VD(0OYXYQ[[CW?;_QCOO'
M]\?.'SM[)W.M.><SGV>--=9L'KCZ9F!I3:82[?_H0,3^CHTPF&;?QCQ_>E1'
M[4R1S708QZ^CQ,78*Z?2]/1X:8E/86Q9N+.;&=-K*3!-_%.63/$S$WN%E ZH
MHOBBI "_!Z<(<.8TGJ/9/]X2=H.)731%H07^0,X98!'L@"F"S-. ^/L*[T=:
M8Y:\XRHMORR 23IIZF2647 _[O"C2]!V(FA<MM!U%%#J7/TQRQ!J\!;:Z6PC
M?L!*.^8/L<^0W67N^)4)3)J5H"LSJ+R/9V;O1SU%4QDBMM]>3LK/,'@X#F^L
MJ:A/V.-?X\MZFCT'DJW+6V9%M';)\T2J_ASR\>2'%U,^&3EMFY[RIRJ]TK$%
MZD\'KPSY6<S.X_-G\ I 2FHL5&E:J@^0D\4GJ[$NDF64_'3!1$K9=$M6<JRU
MLMP@#AY/0)_XE(GG;]TX$38P=NE0\IZK]L@KTN;GH<5& Y9*2F".XP#U]+/I
M869(U<^"[T5AU6%:1:7_+)K%*EA)M=-M>\,.6;='[WADOV7R&+DSBVTM6@2)
MPJ,,N&(C(9&^37H0U.<V5:RA<7M!UQ)\?XO3PR5=<T[W(Q C\"GDH;2^A.LI
M]"\?L[M8(3XF3!^=T3)\4C6!((3P_5ZLJ9-*OOA/W+%G@2EKU[%9//=NI:W@
MT1X9]%+2<=9 13='PPX.^)X"Z;>$<KRO%!:VI"O.M0Q$=QX5P^J'(JGNLKCT
M'<Z]?EGH,#ZK$>5PT#=.2]71@6*TOZ:A;>%%_6U_2F$CQ?#X0W7/ESD%][TU
M;6IS YU-YL./T.L'BIX1FP@M46&5HU:TCD&I)LYZN,%5CH'L82QL"I_0 1I$
MUO:[/UO"Y4.M5XU2S&,Z?S6,9<JYM+S*ZSE+=,]:N7ED"O!_'THT:'6D>KDS
ME)(S-3+V8%**MX3:[_U@)!0;=2#_2.\Y>O> "K;C:,6LT.*9ZZ%=:,1M+N*
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MF^_E@,'LP!P<V&=ZZ!<AA=A GOTAC//./PFZ"]>X%9V2&UN1WR.T>3^ZW#>
M(][)XR?-[%KBDI?GW'X=N[ !Z7M_#R2[@TH72=<A.7LD->N065G](DQK5_LN
M#@FCW])WV"FL0S;UR52NC]@/#.$M*(((40OA :K^!+V#L!/4/SNP1$ZU-VL>
M@>DG=K,C9E<O^+3T/(A!M*ENBZU/$*U=/O*%$>,!N]02R?S&&<<L#GXH_0J[
M6N!Q UW=\**&.CO>VFH&BUXM!1:RJ-OY$J\N)/2^.(P'5T7C-P_EG!32LG@<
MY9^KPY7<N1M^FP=O6Z<U2*Q^?5]@L!OR.B\9%E4S0K" LDE'T.^JHJS.A60V
M\:$E+-D&TPG;. W=%1-A$"M!\>:RTBVTZ3IA2)6OI\-;ALMXQRRW6<[H&M36
MFLWER]S&KT>G\NZ?NYJK1M<G</.)O^(X@!]FS<Y5?QWB,1=)'>-:MY.3B9L(
MW!:XFM@:H'<,TS0&&CE?3N!":DM];^>5Q)- <B=!RP)1A$')V.N5Q?.#R[HN
MTC.I5XNGYU$F$]OC$;%IPQ-;@ZZ(R'F[)@.7?5UG7GL]-F\8FHH/Q0_B?,$>
MH(<;DJ31+1/NU) 24*/C-5I&%WA#R_E/3T>3P6RIV=%3_7-[&I._S\M^?*'\
MK%E$1,1D[J??\C4>[Z:</,'? ,Q1.)[5,1XD<.I(,.+?+ ><*OYM7[D//.TN
MG!/G[[&DWL0KM@[O%:I]S*G<LIO'*OJVZ;H7*I\.7&A]OTQG6TNW'04H7DD5
M@'4Z/*)521-,T]RZIO"]%6 PA-.!.U@+@BO[FM/X*Y<&0_R=<P5%->\.UYND
M@1SI]HM<;:9BJ$U<YQKS'JI^)7D=$J(K)\H&'02$U'6(KE0U/,\+/[+ZL$ZM
MJZR\59>>@K'3YTG48M6'R^*W&;@_P.\=PEBLF=G/S[B^&HW2K>/T2J&_=*:/
M53UD>S6NC#@87R>:.(O='4)^$L[%^"ZJK3G@6:@FMQ*AEU2^IU)\2%))]0=Z
MWA)?K4,8F#L<-:DZ:.0.6#/:KIP(7^B&*^J/D)=D656\#Y@HJR*G1.:?'C:/
MW;[;2"MC]5,C^D8+J>UAWFKP\I#D#1R]<!>E0K6;. 1.!0NO] HXXET+7:BF
M/.)S4-"AIPS0$^W5Q1=8=O J,,NAW\Y@';)U*+FH6DF.@4'K/;',>M"8&7]^
M*/+C#<3+#E8E!<9:G9)>G@NZ65#@_*;94CO E24-,;M6$+@0$AR'F8)V39@"
M*W?$IGR4-DCQ2G< R(E+NOZ=TOW#1FE\K$61W*DZHM?0LC&_(9D_Q:U[U?2F
MY4D$MP!E;FBL_?<?9"Y!&T3P?1.I1X4;W]Z6%O')FT'F&1;5F8?9%:8B*3DW
MO'0B<-BVS];S=:%\X,0TVV_2]</#UJ:S#Z8_P(L70$-F%Y2=(WH&=EE1! L/
M40V$3M3H5WRO50N]LTA.H,102J8KB/=6X6X*Y]H^$6M!VPZ?IL!-+$NF&NYX
M?XSV\+ =G!2Z6IK'_"NO/]SF$RG8:+166B\##'5T2ZT,)3>M >5)>(J^*Y@@
M]!>XW\$9CL#V9TRH?I;N":=H>9X^> ?3U)C@./U!(>G%0]O+.X)]#FMMS'2+
MTW8H._ )R98*RIO<7/KZ1CFS]2*]M ///O_ N?+@2EC&N<*S0KU\=.7HN2.;
MWJ?.E7EJF5:;EHY%!]_"[+D8,3\7G(8U.)-M[7,>724AXD[6S 1N()X3*BP5
MU-9QLU2Q.6_CD)T,#2VJO3;MT%1!$F>_Y1+[W/ &Z<FDXF6C-]XG#SB0+W+J
ML\1WI4;KD%&T<!TB32H;]!G.R!G)\T#WQLRQIZK'XDUG2;=N7%BD'N3-?Z"I
M:+I0S--JC->T&MI>(%W["_)?/ZZ=JFHLV9*+3$.=.9+LX_7TD,G->M/_9.@<
M^?O#7]C@O7>_[71$"XRE\F(#N'8-38N84JR"V< $C@8.E@.]H2)2!:(:WJ6D
M- TCO2O;P21;E62>F2$9#ZU#&B!M&O3P#1ZB6.PFSJ\8-D;RMP)F'>(#2YG)
M,ZM%6[4-2]$ATRW0(,_#V9E\8IM:E;OCT'";;NZ(OVGQ:IJR]Q]7E+U/QMW2
M28)L^#3[:>[NHFV]K4[>%6>+Z0,O+?ZG&ON_V_4T13L>&@=7E![$YG?>IF*4
M[ML;])6AK?#[0B>UKCWAVRKHNP*3\ZDU$_]TU1:9S=7F5P2&>5[Z^"AP8ZP\
MO4CQ S^YNOS0CI;<NYY_; KT__NDYB9EPZWZ?SMM\GU-M##^8!T5(YMM1+=R
M>F"5<S7T7M!_@-\/PU)(X;$E3[Y;!ARW*)L5'IMUW)>$L U4"QVZSS,H\>P?
MMR#W7R T+'%6MWY9AW #Z.L0G9(U=]=UR+/,+.GFL76(\,/!-?B,5#?ANPX@
M#94]@Q S4VF6V*#.@OPYSMH.;(D;(&TD\,@[<"<D=1$X9[[V"?/5'V< "?-!
M#/S>^9]6[(GJ'4I!94Q2;T6X\M1.CONF@O0O$V8%'R-"M@$')/^(@Q+6U/!?
M^GB8^^QRHC"GF]C [ JX-GT!()7E=V*T<0?K0-8+-++IT3,$WW:C85TIF-6.
M]*G02R]Y9)7(=\R][(_NQW40QN%S)ZRE]ZS@H(;,R3T'I"P6X:=^T#KD[LUU
MB/A&;G%+Y (E&S52&=[@Z>QB<T-21BHS3F 6</2%IT\!PSDOL-:B3+ 7H+3#
M=?$GP(X9[H]$G-)+W!%P=,W"3ZP/QO*WN]IV=:]VA8"$?\\6I2LV0A^P97EL
M!K,T.[4ZXO)ZL+SM\QR+L8JOW5_PV1_;R=DJW0/*\'8= IP_VT!,T2C6?R6D
MS+X'JB\ V'["-?@N*5.J)R0\Q!E58R7S<W:Z7*CJQ PRN83?=Q1!23E+&;S8
MT!?B";N\=<",F\TZ/TA_COD?1YE^PN(V>G@DOO76>,)DPA7U1@$K,#9!BW6&
M0D%@2+,D&<2@'2E"I2[R/92&&=52V/,66K_\8W:&#&X\O0ZYKR^ZE-6]2DG$
MZ],S^%2AVQ,^(3'P$.C!'X_NN#EQI)]_=Z\P@'@_PK%FU67T_<OW%1-'G4/<
M0!17-@W%%I)<2Z8NS@C\(:P7_?69<(V9IO<'$)&2@=\Q(3XIS+]+VX\E\C>G
M/! 0=N,. R,ID5E)<-Y>X$_"MM"CB.?(BU/LV++BW)?V_[PZV[L6):DH7X=\
M=NQ9AVR86X> DU#V;8QDTW4"8,Y9ASSTZ,5GQ8B6Q$MBN^0Z9>?]@GKW"=^F
M5MN $W&M,^-$>4*[C5BY!O02F0)9B99$R#1<$9/3Q6E(&\/9"XL?62:-I,1D
MQHM2P+9*,,YY:.GY@6NO;!3+RFT2LK\CT!+ST,B8M=$Y\XCYTD79V AUONE2
M;9P'D)6Y#$M"O7)+"N:M_8[\,413$ZN#,@8&'96K;[X;#,@8*NZT3&+9+S5\
MR+(<+HHA7@OK#YKXP%@B_Y>\@O]_TZZLMVD5R;E->+$F?B>:7@R/NC375%L\
M-S<5S>.,&3E(BI83@GA]S!Y,TCI$#X>Z]6**=OB-C(9(Y7^BM&.-J;"$RO*L
MH*HP2IRLHL!XP]<M R+'(TH'!",U99_G][VBJESJVO<@9 Y^N5 I?35N]@?/
MGY!Y!&RFGF&/9$3:'9;KM,VE@IF7@8X?G:M/.3N6%AY8!UY]W2<PA6^AY:B_
MB9R,!VN='KU4:TN+0573_V?,N)E _#W! <RFC7P43>S>_VZN0,>DK9D&Q#7?
M3BOYKW[5#V]!5EX;K%&[L.OC2![O@J+S_G<0R UGKE?][#J$#,:NY#"5?F1)
M-]$__J1!">\30-UUR&6B[&/ZE3 67S#RPUWVW/, [ J_.T40<<08VLY1F&L<
M=7JPP[-65H]S.FU<?Z1<8378UD-'EX_%D&QFO I]FAMS>93F@@]C'\/./:"_
M&&)DH-E>67X#'MFSXRXY];._@S4BAI;A+ER3Z(>^6;5\21[,JA*E!*]'9AS2
MO*DVF+AV7@2&?_;TS6C6>?$5>?U%FNG?:W=>I!V _)^\R'UKS%$C43I8)@SA
MAJ2M0T*9#U';[<*XY-$1_@6.FIW2O^<G)5K3MH"/^%F[D%,MQ4^>G11@5#B@
MH+- H3@G2*_LQ_2PG@+PZ:Y>FT%#U*5;RFJ_Z&</E!?Z^\^[S[?<_+U[^+D;
MW:CA1_BNC$%OE[_OEVDZ1HG^SG@<?N"#<K:7IW-%6:'[(E04+GE@;RKM6RF6
M ^-+<*=!#3*>N0Y1M"RZ1MCQO@JW:9$06DC<'O U?(0-NQ^;E18AT.<-!\@+
M/.]]@"E_P>X;\2>>99%(U"_E84;7%R#X]G6(!M4((*,DV9:$S,"-P_0@,Z<S
M8"LOT[9#M [9WJ@-RP2P*/[50%/J0(PV^8$G^&FAPQYU%^?$OS^T1'+I?6O%
M3A+;F!,K M^9%7/ATZYJEWZUS3?&C6(X$>*5XX+\R_J[3YYZD7GLPU/]N9E1
MSX+R,@=R6)A'=IFKC6>;K4-\*_&); 2$(*6'(S*,4ZK"]Q/T[-2$VAWTU]_O
MUH9QMEI@(.(C@^)M56C:WD&Q@=&=&KLPH;O'H#B,G^Z*NM!/-;+\:-42E[2T
M#E$(>ST]XCFM4M)M_^$75ELD-TR% AM%AT!3H\Y,\]4%T05):8P,ME;S:,6Z
MK<F<;A\?)*5K_"QXH[N]T7G_@'DI*K4)R#S%_[ZJ%F$88E5C7N)'0!PH8YK/
MT%+-)?F%.C?$!P,&#2>O-5<@2<X-DREYKY].&H4D/4=3@K>;&>R7H8+LNO>7
M.*;I,_4P@':2E%"A86M68CM)N06&;?I6JOH&]$^ =S;OJP/+B;LXO!]IN*AU
MR#:"R'(EI:&UNBWPA/HZQ!DHSJWIO;D:4T":Z\IM&/8*QI9(MT4)8"HX_Q;A
M^$HG*I%-HH@M?1+77)#8E4ZB7"-T)[X?.GK;/>,@U5FI P8BV?D9\U<&[+:5
M^+4;IC_[ L:?8EU1SUN][OO*[OPE,^;LI.J0LSGGQDB$='(E_.JOISMRRUQN
M('(-3):_E>Q&91]V*YF\KUJ0$11:.OOHE^_LW!IL#*<)C,RI\-Q59[1"LF)0
M670HWDR,HK$X9[,_?&+)4D"UQN*$E:"=_5AE?$+A;'M8F;O")%\;&RF@'FBJ
MVV0@]9/-C1/^DYX9" 6@7?9F8"9:@(!IBR\(;S6Q+#BI6B>^WQ5P%,4:H#,&
MQH#>Q6L*'=-?GE:8SWF)!(T<]/;DNQ=Y"_([69?<=>(HOG>DM1Z()VS$[P+,
M)'AS+3-/_GXXKZK+ OB;+._1&F8SKS,0T4K9W1V5.9]=;>LG[@!3UY1Q-PBJ
M4I8/?"/M!'B4]Z,#/K9%ZAK"7X>D4+T QGEA2";5C(P.W,D2RPDR@WA.J0WK
M$$ULO O+'.?/(UF-EV9U(94>/!]HS#$LN5+U\=U7$7EM@S@2D.MRWPFNB +
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MEC_PXM'E_]?Y^/_UDDO$L]8AO_ZT-UZ'?*FSEN8B!P;^VYV1""C724J3S<S
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MN42Y+]-U[X.K0&8G^TH?)NYR17@J=!!5'Y<AJV /./64M^X/ DU;TE:Z[.U
M,X#2C3=HNS<\\4&[C="EM^5S8]N5:6W3L_S&AC2!!ZTYS]8_M(1"<5(^K>68
M]@SVY/BQF9C:)59Y_D+5&C.L9F&T1_JGC""N0V8;P77(.N34P(PC-9H[3Q;6
M,J7J3_6V@ 2 THF$@.\%R5E>PI!N)74LS"^^7/K1^A MI42L()Q[_-<IT,_<
MM_/(^[]*&_*:2C<=]0A\+)K0;FCY_65DLX&. #+.F8_J'<\HE=$U1*D7P=9O
M+9*Z ?/;)L):^FX+91U2K<%8#I+N@K*CI:E*;[/$9YD/H)+MWO[M$QI@Y4OQ
MQ7R^;Z?KOP(Q*6)6JOL5"STW@-,0+"B#J^@I,A413/X:;CUR^P<#FOR^W.%Z
MWK8(A3:J5OVXW8)^;_C>;?!]/M\CR$DDUL2X"F8UX8E(,=S-V)A3 $/&[JLI
M&O_Z(OMW_4\957HV^']W/;CW?9K]R?!-ZYM[PYNZ?]=>>[@U_X2ULZF)>7QP
M,EI;NHLIOP[YW">S1ZPSQ1'GH)[8FPLWCW23=\X$[A=>J)_64TN\--3 V0R>
MXO.=<2>"2L,T1K0N(+N^Y_]BHV8*&&.NMZ*B;NF^:[B'K2'=++UA1_TA-J6G
MK$.6]H&VZY!MF3)__(UN.79L-'KP<7!P[&[C VTP[>;JQOJ!$1]?)+&0?^Q7
M*PG^,CC&]+)JZ<N13D'5^<K ;:,^%\*XU54QTP9,9Y?JPG+NM./3KY6,Y9#_
M9K&3V*!8%N+/"QGK$/ XB_[;D&Y,YP6(X;)[&NT<\%PH49SH]-]M"J=5(J3_
M;F]NCUJ'3!;362REY86CLI?L-ZY#%+%9TINKZQ!W]R$BB+"3D?/3UK+W@>@*
MPB]7*)"']94F8Y36(=P?;NN0;P7B<ID_XX!UB/0^2H[ ._R"\$L!"M1*H3)+
MT[D+8D,+=^G)DNG']!]S[F(-J/3BC.3$_]E_"^[E8>Z_"A\NV"35!6,56PGH
MJ(3++WI+L>$GD*(/_;GF"V86/RC^O87^OC'^Z0\N8R^'>#\:?+5IM0SV>\UK
M';*Y9QV2=UMF@I.T[3MAR>CM.H3'_/?<(T\.BD$CDNC_S0HX[R! ENR8D(VQ
M_5/1.N2]Y6]767E9D#E&LI6FN [I"#HC>TX+_M]\,61,8+*)H#E<7#^R>AOV
MOYN'P?'3EP!S4H@]L0JMIS)88_YW5W00X67H2EZ^<G$=,R+*XN\/*2TMAT3D
M@X0DZ.MO&4PC!OVNXCSB*#V)NNGCQUL'/PZ?R7;?G^U,ODOX_Q,,)2GGP<-J
M)0F_KY0DM'K+).8=VJ4W#\U(Z5'86NWW=>8F_=B,2]7'2-H>L4<J+<BU>:,X
MF@QDDES7#JY#^H^!"NN0^^0[A-];LL +G-=,B4K6'0[H LK]&_R+K L I2-"
M^>"W8>IQ8.%LUGEZXT -],* G65%F:CR=M?!AC&K5DI2)&;^JVIC_?VV+L:&
M.L=ORDC"?PVA*I&[]%X=-/K?KK83J'N_H]<A-18R5IOAE$('KN*:9$8\S!-K
M]"[\=RO"0^T594#G6:I.WX'?<JEOK_S?[3RE#:ZF=3]W'9O5_%+\=@.:"P5]
M"3(/_W0 XJ0J6D;KD#TL?][(G0^/-!*IUB%[-QE\(I:$K<9^V_]0;T+4O3V^
M^I9&U?L=[Z;?JOWGSY)1Q/]C&TUFFV7GA4ARAQT\ A;^JJV!_=LI+^M]V-@2
M6JKY@PN5*,/O<\#(?\_I^Y &YQ7C_Y#-H@HH"Z#DA0Z4^"597_*/73Q_^QA9
M37Q$:%493W;G(5R- H&)YLJO;1/54;S,:^BQ TOC/O/G]U-;!BQUK;YOA96%
M%'__@(YMCBN6RT.1T0]K9@8*$TD>[#Y+SYMAI?R5EI:FK(@6Z*W'G]]%XS;O
M2- APBJT: ,J97:*RI\RPRT-'!N-CPU$Y1L@;W@\31CM<HQ:N9J50PV2A?27
MF;?V-N!E8*2+J"C='J9G ?94HMGNC#Y%@>S;^P[#]%L\DE9 G*^?[YK12M38
MZ)F7KYV3"N;Y[($3K'/5@<_7(3L6 27I V('1FR-WR6#' >\+WYD'?+*J1/.
MAHD*@8IN"4'070_T\K<DUEX$XT5_?A;KEQ&N@[[M%!ID8#GK 05O!!*C[9KR
MF='\M3E%27DZPU'SH)E;YN6HZ$H+V";":ZE6/JJ0T:)#,VFHJQ/:3MG<$JJ5
MY]]8:0F@441^R=5Z^;?V6[$"PEZ ;M?-C9H:W^1][EA1;ZIO^-OQAV=4IK6.
MPT7G_T7>FP8UE;;MHK'55D1D%!2$.("("&EE4H:D'0 1(8+***1M10@QIA&1
M "%I4>8A"@(M-*212800990ID;F%1F0,!$A(XL 4DBB$!9E._/;9I\ZI]ZU]
MWMJUZ_PX^\?S@ZI5*VO=PW5?U\.S[KN7=>W;M1IJ3N28KR%#[,&[A3EKVO_2
MJZNCVC%GN-R]Q,N@?/15^ECY.X/@DR_1':'(OJ,N@4_GI2\&G-\3_M65Q?_J
M<)&N*0SM+_L^^:T]4PZ"&:WI(R::8-(==P<E^SL4FIUBM&;@\&\L!A8,PA2%
M?2Y9<E@.ZHQD0V17O%\-.3>0%3<)52#3.P(I4_Q0K*.(W")W7X5?]B!D5S]2
MN;VT?WVN\EXQ5+(M>?P\51EGDG'.[@D7B&%;1ES_4&F>N??\ZA;=U063F%#6
M-U&Y;&?N^CKD#6%BTG;*I/^J(LNN=\RC_&4!49"FW;>K;M=-^1R[M^CJKVSJ
MT^4U?O^2(PJ%43-,FFU\H''DL<;Y\T-7--Q/55[Q\"U,N6#B9'*D)-/%,//"
M.\,Z%S,-/T,M#\?-_^N[Q/Q_O^PQHOBA>E4UG ;PK&3>Z^O,@@Y4:S20,;X%
M&?PFYN?<])W'S0-=2C)FQD]^T(D\FJ*LIFI6M&A+2*I#0P*&JP^UC$3$Z*'/
M]'$.[\R<FCE7TW-:?[M*_2C[2:<IZ.V#%20H;OL6]3C5_0]'U:=UUZ<\I84\
M=(3R%#\1;R=T[CQO99>,P:PX')PZ2\>=I-,U+.DV>7@B!VUW.=$Y9\$9:?[K
MB %CV,7E#_]CE$,T-]W'EW[+_U3W9[&IC=X[1Q?7[%-F!_.0T(K2IF^^5$1:
MSHF3$GTPV81=P0[;@QTMO5!SY>AX96+E:7JVK05]=Z!5D6>]<?_2)W>WGDLY
MP6DK_D0-+*P;KU^7L\>\7@Y2036;U:UM[6ZUT:W.C;BQL_:/3)<MQ]_9MI:=
MG.GX<2)MXC(P(^3+E) *K9E"J $O%0LH'5![@?,C0HCJY.); Q#@R\'L.;\Q
M+X 39?M\C!/ O3(E:FO#!P3BS7#P. Y2#-1V: ;.A8[[B9YLRJ'# YR^<L"3
M!,"#I4:;FVW]'ON03KCLUIRB1ND+E649RMTDX(S$4@[Z?*?A2ZDB7ZXK:IPB
M 3\1QDC9DHKKM2Z5KH:]C %"Z\=%O#\O;QW2,HCXAVB ?P>NQS_@JC)RX=+"
MUG#!P7YV)._W\>;<]#NR(S[ 9X2!Y*C02I&-4@LV+2V"N&4"N-OWY;1PH)I2
M//]DH=D]F^-PN:.B>&'I4$S+U/YY8P7D;9/MP;D#IUY([(& HE#9UC:%8-'%
M;1;D=DIWF"ZBL9*@5B"9[7NL#EL?>T%THE =JM$B*'T<1>:QB5<#\$['G_ML
MW<R$L9UQ9^2@XCAAL$R-I@);SR^6:45V039.0K0);&6!0OX^:[ZV0ONR0A#H
M4A$K_ WZW]I@2_^;;Z0!<A#S;JSY.DDR$-W GP]Z[ORW0H!L$_Z.9T 5L(K7
M#67M,K<W>XE31DR*.8,)DK PCK_^_?Y.+[ :'[H?66@,$,SC2T+OV^8TTW6I
MY64S\_@#34,KJ\G'EF^T9;?.F7[V(<S^66C1+ ?%Q4J,I=GU- W<3V-X(\D^
MH"5"6'RZ2?CC0P(7_+#0A'Z,:HW]PKF5S8;HS=DV/+M1L5"H1F\]Q5G''>?<
M"[#@:=<.A$5>5]GP>]N(J 0+BJD'"$/MV%HY:#LB0?$"0PK29<?1D>[3284)
MX@&D'/3/S+X5"@&E*OF1XD\8H4':UY78X38Q'_\0E<:4)[WC\>^R9+<*O5?=
M9U3[\UD3O=SWY0(+#O@1SHR-F>"+@H0*'1LD:+P::R?R'<)A!/1.F;W )LYJ
MJ!)H>0O3@![!!G?B58$'F"#NHI(Y#K:KG$U0Z7R!=79KH:%<ZI%6>[W AA\4
M</P,O.<V7D<VT;RU@2:(;(>: JM<TF0G!]'! W=NK'7#=;$6[<S]P";"\T7U
MD,#C0E4B^@X.536?)UU^N)4\WG++Z,WF2RVC:'N'LK,HU%^-/%7)$7X28N6W
M0 7KZM!AE\M!%O<('1E O!SDO)4S*#F UR5\LW&VTH?%Z,-:O&L0W_A?>;&\
M\(6F0I(@E<A@\??:7*%?''$S%-6,H-773PMAHGW %!>6?D(VU$A2H5W'I!;:
M UF"XK?,+4#M]Y& :X\D;ESP#P"DBPIJ$QKF.:= 5; O^6^C^<D&O9=&<.<W
M"$DK#J@S F <<6$$LW4UJ^=@ZH<(^"1<] <0)KS0SXE<&B3C_Y'I?!\S7,OZ
MG;I5<E60F]1Z@,-7P>JUTVF[(!%B_D[LX.Q@O$2W\8F^!1QZ7&CV7 *E0^I<
M]YH]'T[%)H/?J\N(_^9-_XT]PH?E(-+0O"AT7>%\VI>/8*]_-FZ^6>''5+F[
MYZ%G6JI&*N](;1HV)(/BH[+W?K1VA=/9Y4O]PLU=ZBA=2CQ5+Q2L*G'CP'\(
MW5A+'. LH"O/1E1@4=?JW)2[HG>O35I!K/LOC[S/KYBW66BTC>BRF&K_S5QB
M)B7BM24'A-F)&3@(AT9D5+\N]U_0_N"+71,]!7A"<.<)YPK?_AN_T0LUA;W$
M5?XNA-L^"[O)P:@R-[/TON[($,%TIU;%"N(_<C&\,%<B391M5C#U;#G("^^-
M4GE6NEN:F%'GZ4$]=/C^A?%:V>@(FHYQE;B)+^/?$G;20OKYR6 USKC,".O-
MA:3*E%F2@R.K_)V26T#1+$1Y>M[Z S:3WVD+3ZE3_1&5P[A?R>['J&$S17*0
M]VN2"XUX*27F05@PMLN).2\VD:AGB>Y*"ZAJ..VF\56X>F@@2 !.J-/'>(W9
M>W!@.D;O:<$EOIW5A%\7J$>S5Y-:(08O<SV &RZ9IG9HG3/^*N;][B,\]*]U
MB9.$_Q3(EOX[D-6NIZH\JP@_1MQ7,I;OD_8LD.> SD/)09O6]=+Z4MXOO4@J
M+9B(OWIU2ZV%Q@\O?W<Q_!UD^.=5\.1?5O0XG!OGY%A//A><7&@KM$ZT*'86
M#6A_N>RJ; J,O;V!QEE.FI.->OI377YYDU3G66RE+K9CHG8V4!V UUR$;LC6
M!RT"S@00W'%?][F"41DTDP?C[Q787&Y^%?[0(8_9N;N/>)AP8EN."33M]>O:
MD6-D2Y[MN+*ILG((^E@5K]@'S4.CN3Y_Q6U_O"7C2+'C.4?0T=^W!ON5G#IU
MP#S26)N1ZF)86/C5K8$QE^D:&>NPCP+IM8^POP/9);CW:L5TN/1,Z87=8;M1
MWO>R*F"55REG"G2OS/<=OU!_(3O8H\DI+82"#DTY4GUYX4S*D;]^^#^7ZM_?
MV_F93!#HGUL4ZD3JV7*!(P,3_BY7U$!$'E]&6KW ,V60>B%"UV_!WZB:TA%E
M.>B7%<+*]!F: 6RV:L,@G\.[(5(5."==SU%$)?6$M%IBI.#]6B'/OXK>T_V&
MZI7WHN\L070[../W$T*,\^Q+WAU4VM,SUQN![Z3WRT%U_*6"655&I3L0%<Q%
M:.+.">X7"1I[1"RU5AT./"%:EL]FJ2,##]?6YXR/\R!6 =NZK#_]HI',F0S>
M)YP^J_7D_4M] ]UF?D/!$A_SC.Y^P2(M'WEXU9^LVP2L"2FG%6C#I?"08AO)
M;KK$)4@ XT DFGJBWX'^6$$?OTM1AI(L20EXJ$"4R*&H^BP::&5YMXV:M]J@
MJR88Q?U(E04EOOD_GZX>&,G&QX] -25NTB+";"IM.W6OQ"(]@I(4: ZH"Q!B
M:Y8GO2>I^?%(!&%G*..ICA]O] 'Z47-0_/"SPX_Y("<;BZ.DUZT'Q)MQJH+J
MA\*:/K$GD,UE[9%]P(/HT#T2=Z!)J->3B:WEY%3.SD2>;A+P>HCE*+HMSC8P
M$84*NO?-ES'OIT)^W);"X"R,\Y>$!]DX:^GO.%-!R]N[.$O!&F^OV']@MA^Q
M<SY01U!(C!02X#6I[%5JX@OD1L*3%]BC\%U8N]-9[J/':+7#;XW$H7E7QY^%
MQ]R(+9UQ_.U^992OY<@%1B#KTUI>\Q.DE?' 7B?O,&#Z:O62'&1SOW50XWMC
M(6PYV_D1W@P7)LVSY$_>14S&<!-_QSG,DK2P8J=:X"&D6W47MK\S[Y&R03Q'
MW[3[MJ"GQG3AN4O=Z@CZXHU+'E^F7;=VW6^2@Y3)GX%V.6BKA[3QSJH;_/)(
M$* O=I#H :=F]<0Z*6:NG3])O(<IDB .3#W$:9FY,$[W<?,<]D#&F+5UV!_<
M=,SB[>!VL;.(('TBVR,;U)6#B/:8OQ:H4.%:%S]Y&,D2%$B\@-><<B&1*#D;
M5-S[*63CXD:>+S(Z-N=)F;'VN&U@U@V]W4G3SP;:&K,^WJ?5PKL@N_!,Q&ZH
M/39T61D6#ZL#+ZT5 YH<\Z*RQ4OSU)\$@UV4S>Z6@]L!XIGZO+YY<W^9>C#*
M#O6\QBA^A1!2:**NL?=1G9]1<,WZ5!!ZB>7^_$MJ@5.)= %I8F/ZS=S9^/YT
MWOU,E\9[HX%?NA&OUA)_ 5R$O;(=O-DYV1&@8<1%8,3JZ&D 2$)(5R/S)WK=
MMEPVL<O!4]S3+"*_.&&UQ$!/4ZJN57GX^Z];A_GY^[>C=ZKUKO/$6X#*@"%"
M"'%B*E!X.)T+>613:"+@]R+Y,@?@X?>F]%8SRJ+5T;3HIX':C0$V7;_:H4W0
MV[(J_<'J1FUC0_Y[+=^0[U3?>\QJ_MXL<_9/\ [97@7O0F0@.'R>CG 7)MTV
M0/1$2.PD:-@3V#,8A0[50M^1'*_$.LU(@H-* +V?1ZU,"\ NXQ3"Z^H#8V8W
M7S6'+&LU>:;AS!5!@\1M!A <3&+@?KB6)%3(2VRO1 =.S=+B9(82IZPNIA)P
MT:K%]S;&6' K5?M)V87<XY-]O]3D7VL;'TC*4$*?B]06_),R4+_,&$2;-<?:
M+3;0#H[YF$=$&A_I#GS__H-'-**J/M+-%\D_0BJ$J<)FG],:,:E4L*R?I<ER
MDC[[- 1#(M(-#D@+5]+55U23[NLF)'+^6'6X#!_"1;Q<4 =>;H"74$@S0S$A
MX5C5E^:61#<-1[*_:^5Z-*((!19X#F8PMP)7A?T7A6/E[2^@9KA]TMI6L/A8
M*$V3.VSO6X[;/X2#<*^'6]&Z*6I8)S>\'-3U>;#S S(Z/S3O< ''Y5:VW_CY
M+U<2;I&6B3L([7:R'P"[MS 0?M^\CARD-G5:^B?TIVG<'<%..O[ \*U1OOWU
M\!>A>:E30 [;_I26;D*"\5C9N9I7=</5CR[YFR)JDS^2/JLR%"*I*8J#5N[2
MI;_50^+@%(FCM!JG*89+;@@2TZ 'IH%=_"Z"(&6NT&BX1$'7.L%)>(,/8$\
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ML/2O@*RDNU0QQKD^:*W> ZY)T])-YW\VU-BT_Z/&J6U;;D;OTSBY=)[O>FV
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MAOQ*&>(+$&'[R<7L2D'U,J.-?%/DMR#[G ^[B8)RO89YD!7IT47/$5Z]FT]
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MM;B<(AD"U 7%[3!UJ"GN>I/P:EE3N'4!&_;HB9^^<4^AE:#FZ+5 G#ORW ?
MN\OVF,W%B\>78MY\P?Y^77-_YL\L;SFH\SA.7P[Z"Y$F!PGXN%_DH,]?WPAQ
M5*;W77AFQI ;X4=28- ZN%QPEK31%/\IS6]C.;RJC",'?8SX ^&H9*;/JVZ
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M27Q[>#),1:J22).-W,0E+'! 8"ZN(DN.X#6IX@K:_IHW_&8':"Q1Q6A%*-R
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MWV%S5O/2EA%&Q*[-(7P5_/DQV+EV(#1@3<"45HYZH>+J[I7F5,8.B-"&MJI
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MGQC71$KW5LO[\T,MU5'0KF^B.QKVY,OQA<4R1GC0YTJU"'63'K>Y(*A$]A+
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MEXDU36^YTL^ENF^[0^0%'-Z39B,?C]%)A,&<OL4$D1I!'G#U\/@JC-S+>$M
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MCH"H$@%C&W$ZG].072E_V%]^/AZ6R(X11H-V,ZU$;E^TG-3 F!QEPKX@G2/
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ML4:*T Q,-#HTQ,?[R!5X$8L6=,PW=G!L8F'*4M#UVFCO\.9LIZ E<78 Q/+
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MKY/H[ 8;DP'\B9O\Y6HKV-7 LCFIUO"2,77/37Z(\9?'#$\7T\3EP.%"T%Q
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M^&>:";4%A7(D,:G7Z!H3]#IJ AL-9,D_F!CW+\/PPHVTQ-Q%6KJ0QT? R;9
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M5:'7*8:DIH]I]*RR)-,:Q?^.:%^&06:41Z#^11"1,:TDBK0Q_C3Y/>J]P#5
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MN:HMVY"7;DD+X+P),3[2:)AJ]2NHA6?IQQSHY_DE-?\C+X^\FGOZH]YI@3"
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MW6ETX PBGJ[Y KEIS!K@=IJ!N$RD=CG9(U^<4P#<;&<)==C:@,*U7^C6KPP
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M$4QJ&WW87X1]C4V/QL'8>%&5 (&%IAA#I%AQ2++R5AFT(%J&)5,,_(9""PU
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M)7>;!N5)*%&QB_(Q&K<=Z0XVJ&'54F5./E"[5$W9KKQ&'.*,MU,U9#-(HHA
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M':1G1W:'M&D,]BF49WH(Y\.C'P8-N[,SS1(+(DO%Y\],D54K R4&ZDU0ZCE
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MRM(R(H467GH\9$/R.OC/B=+1@G_7CZ_=]4.0JE@'-1:K^WT=0+8 S6"BIJ^
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M%TU)XDL]FU6>4O7CLJ JVJ^B^8:C:KU)D.KPI@8Z*D-I0P^,B@NZL>BB@<%
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M&EG+;D:NI5I!!F7P$9"87+_ZE79,RX+:!NH%S5M^GH&\N_B8E[2CI][YQ7&
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M610Q%CZQ=V;R?[G!/K9_I@\1CJ?NI_3&V7<_VOO^'*>7DQ:Z]]#N 1=AO]E
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M?,8NM6'KWL'C+NRA'.213NR!?-+BZOBY$ N^>$/Z_ZGNO(.:SOY^'QL6FH"
M@A!%092V*D5I674!,0M1D!9*UD6$ #'+TB*$9*47(2MU 2'2I80H!**T**&L
M(B)=@I2$16F!;Q3"5Q*2)SYS[Q^_^]QGYIG?S/WC9N9D)IE,OM]SON>\/Z_W
MG/()SHUR32E9Y!<X/JQDV9$-QQ'#P<?IC8W-I%.W5=[W*O[#O5$P2OTGCQ_
M -D<1CQQAZ6W0)G(O#DC#&O=CK>V0@@<P$).S$"/!?4 2.)H##"+]EA#8$DF
MT#2Z&4QN@WS8[ %A(AS@++-#^_Q5DTY,4*\U4W?;#:\9HQ0'@*^<[MZ5T'+1
MARUL$NK[J2*5 _Q4Z*'CVZ64IB(W?OZ+9L 3?RZK,X*AXBEP%4/F=JONYQUO
MZEM+B.A_3'G0''#RGL[PS0-F$>U%0Y$3J%9&<=&4P.NO.>?8S'+6O(/N&^'K
M'L.1[=&!U_V!K='6;G<QI"7#5!'.,@8PZT(=N$NX(#P/?.XBL3S9J$Y2"O3I
MYQ7NG!AR"&27;)=T6/U-## %7W,H>MV<Z!@EIS'KXRQO<+*S6>U."@]F"]ZK
M W\7,9GFV:Q_S@;,:[50_VJ[M[>7=!14Y=\>WB#MP5_:)L/\N+"?MTO#+%YA
MV=3)O#FC1$LW'AS.^YR$(4"%5UJ \7AA^"R517HEX?>!.!A;;[Q#;7%&$;NZ
MCCWPT6 Z7R=/?S/*M3KX1<17,>2D&.(9-1%NZ%ZE7@5WP1P:6RVMBGY>:Z-3
M/F_H;9@9$2%ZLC$@AXON&AMK)IQ\3\,>]/BP5'"'[A=4+P&WIJ;BIM)IFR<!
M6^UUJH"7#;8&;08P8RH#%<YX?_"Q4>ZO&W10NS!!36+X#J28$Y,L]P!0_ATP
MC@?O1BG" BQ@$^^8G,JR&EPO>^V!I0*'>%!H,8R'HV?[C)1Q50C>SB4$FQNR
MNF$ A1=>YEEWB$Q&?-3;?42O_W%P]"0^1YO<&??WK5%T2LUTQ>C55G)6R/H%
M&&^? 93#SE3=\NO_^_@^5YTX-E4.AQSZQ&2J2:6P^]3[$4YC]2LTC3.]5VDM
M8^&%K\-E?5U?- _/TA-C$*Z,XB#N-='-H-KEUQ4O6G(]RB,MPJY#QS<VC_VO
MN85=1I[OUU&*BVJ)]SE64#A/*J&6U>=;L] R34;7+*H592\W1UM=<6 D1EM,
M>N3-YTY_.G+K(2[L1.JPRTV7GZ[7/#Y3\T=-3=F.FS*0_WS)'$#^M_,8.W,K
M*A=9/47$\D"^"K(^JV;"&]U2G%^-?!53%8@,7U=$3G] 37C;&33-Y\S3&B:G
MD!]M3JH>M#_IU,-K/7WG83G:!SI$Z]][:=AX6^G*H+' X(3M("U-#V-V;<B8
M8LK2L[+X>=AX^4))X]/A%7UVXMB;-V.'*11,:>H^K0S=0:F$?ST*\4'-TM]+
M1]R5_7XYXN'^2^VN/R_MCMUW+"[.7:0IX?NV$Z6+T^I 94*9Q(FTV#QO&@J3
MEY=T%,.T"E82>D]S4<7B4T_W"<^DR!!9FH*MQD3S?(J%\;^T[7^V;RZ/?+]-
MF0=ETD4'P:19,40:][43^20E'"$-#C"W$*F6%M7ZBN5 VK:2%ZUCV&CW>2V'
M@\^;_[0[<S(EZ;H-#"(T 4.!JA\1!_"&P-[8#G4<TB*?Z@O,_('7*\%9_ CO
M^S.6PS4FRGU LW[_^$[K@8/YY'X_A<>1OZ1EC*7N\8N>\!EK;VKF=_ [F@_H
MEMY/^&^<]6%ZASJP6E&W4*PU$B:K>IVW-]'Y)HD9Q5W-\PVO V-,GA]O&LOZ
M:>1S+'SJM$ET4%!TS(W@4W15P),I^R'W0ID+JS05HOMOEM-'7+)K(6]>UNI!
M7+(?'+PT&WOA&& GE9L*^0;WV<ZT5(Y\XC6-@W5+0DY(T#T]A'42&QUF4;3'
M$"KE$6P\H+#0\M'</7\3KJ\6TMQ\KK7A<O[++C$D\4>2* W;+2^$@%@QY*U)
MS$.;,'V7, K7Z+-N)Z+R2[97<5_D^V]O'FDS1T^=(1G>_%B8E0%5>M YY$";
MT98QU<HY[%W;="#$81GCP6,(S^TFKGL2=(FS>YE$T:TG_]?_AU'&1=]7EK:@
MA$F9@F0QQ!F,%OT1*(:P>\]_$4.>#)S$2WXJ<Q^ZK3*3"@5W #-BR%^!,/:?
M)R3P.\F[\CV=H;H8\E46=?N&W=BR&&))!+R-1%=>Q[P250&;VQ ))#,S_.?%
MD!O%5\$9T9&=L"T#QB$8L(O-$$-^&"$RC]F)(39T3I((@C<30SZI=?Q=2OJ7
MFXK;1K#7MG;4BB%)1P?Z1&66#_^'=8-Z4H7?5SB',;[):V_NW2(S9]9WN8DA
M<A?)>=NV]T[,$<';^\20A6;A=3'DI7RBQ"PP;_S7R@JT4JWIJ&^24!*[2/RB
M"5^5WX E,1:DJ**CH3"CK0=?['HD9N%O!3%D$ .62,P[5$)<WQ++_L^ZCO)M
M#L7<97SME7"WA+__L<S["%TBRA/?RZ*$%SX14!M'_B&E2QK^OS0M4@V[$L<^
M&RZ-:^PE6//>Y1Q-.SD-';MK:56Q:,:^JB5KCS=Z'! 9V?R .(YT"/NEB&!_
MXWT.S.L&?-E%#"F>#DFXT-3\[JQ#<)-#\,T+5Y)NZ?8)+%B_T[[I<7@?4IV:
M:$5J8$%VH)T-;B2^=*O2I:&A<3B8&\:U9DGKJ:OC,/HKW+*K&"X&,^?^F!Y[
M\L##[D-7J]5T#]0\WG'?]4GIBX$R>QO=;NU#F?8G,^T]3N:F:)?"?XI-U7U\
MR^;0]1W_D^+>H<4[E80_7AKHH\V[TUX*HI@%)HW32Z)C/)5JW]*  I='N*^&
M&P9N3L6LSAZ69?K7*<0A^,,7/4&!C#.2CE*57G*)*%#R$2+AIMMY*\0@A*P7
MX3VV_C%V-Y(E+P6VP!+&Q1!%M=^-G^#W^O.LA%:FM2$<14L+J5+C>^%:1PR2
MT=X?WM5-7;B&UAG-K7_M<\TLJY'F2T!;H ]-;.V?'?A^B&O'"5R0!T_2B=)F
MI(61$F&4D\[B0%5PYWM%AWAVB30%_^#QO"2/\3 'I  ^U$TIM1I]W='RQZ5@
MBF7KKTZ=:TQR&F._Z(=%^M9 )^+[2G#KTP%;WIO\.U4UPHL\:J(0*PDV>=E9
M8HC_S S.WWF$&[S6EJ*(;?"":_1F+Y[*>Q8'?84E::IOYXC,",,H6D<Z(. D
MW1>IB=X23F_'8D1JA&&BNK6B%Q@FU'M/,,"1YAR3"?OZ.1A_YMOI_:.6SF4!
M#."A1H3LM?D#.!V1U?DN9$)QFO4RBO8],_N,.MZ%\YH1((;$*4G>&ND9&P-_
MJ&KN&0XCDAB-+I2\1)$L/I2H@+.>N_&>$EX^>&PL;$8._R,PWYZ30\X(ZY>^
MSM/,*ZFDW GKB\99%NZ7HC$&[A82B ED[[,)D6=2%6\T_I[Z"'7N46DAOF8S
M=1[A6OXH^W%%V N&:]  04OH!3H#Q&O-XP0#O",8#;3^U-XBD"UNY*GV%*L#
MCCF1T73B!VX35"D0Z5>^Z;F#V-A]OH]V=R(CZ#-B/^XK_VL[#Y$4+,0(S$3O
M"% @9JRITA,L\WX/0\\< 4E>@^O[J<<=/)V'C*49$S.7FL::]/14BCE]\!=C
MZ\E&]2<R6-[77I\,2A;9@UEU0A5@1JBLYS,*"[(00W8L3,L7\G\$'!@KK^N$
M=YZ_#[;6F 138<G%YC#HBM"D&O?N:MOYO21#V@1!]76T;'EU?3_[KSLRZ@C]
M(U_6(FCV"\,=U9[P9>IL7]'M;"]GK^$'1D[GXWW?%K9^NH%!OZ&T??0-CR93
M?#1YT*0V[U)TL390V5J&(S,+1NLB6;!D2ZL:]V6D#L7/$%_;?]YEV/_%4T93
MUMZ^YTW%[JB]08_4)JB?/-DDK@*5T(N$IDG,/7GW4E0B60S9/8Z:)/*S "XC
MWMA![B7XJX#]N4M^Q\(/.'6.&?-3\3 7B;J/8:")^Y<+Y!,+;3J> >^J5;N\
MG=SU/]];_T3*!O,%$G5\9;=N%?22<<#2@<?H).[%$ZM$;Z950)XI8^Z[%]Q-
MD$);ZX(/>8AN'Q/>'E%"S6L>C!V9%BR,9$/C5.*81%EJV_'9:OP)CO*SX4FG
ML?#\#>\;AMQW/O2AR;4O#9%#RUM-O*T5Q<T2,^V66"<'XQ=^JN&K-S?;"]&A
MO]M[7MG*KC_/D>]"[!:> 8I+YLC)Q2>&A:?8&F>6;1I&PKDN%7!U.%5AN<4_
M,>SJ'9QO@0W&SF?,N/_<SA-Z_+2_Z0UV+\9YT_(9,,UZZY,$%D/)6D<TJ&D"
MH)CD"1@_ #S!TR(FSNP1:@!?>S2A[3Q4%VQBH,O:B-?QHG(*5]4Y!,9UJT5D
M<62A N*K%DO6ISC?D(A!ZQ?5-F5',*7"Y1%B$#2-J"[:36#!9(5^<VLJPDN
M3@K;Z(,GAQJ[9GT,-\X/!9/FOB]Y&^=ZL_OU7(97A9<$YSTG<6;7FCJ&C36D
M;UKOY2E"C^!<^=%_;4",!5Q3S_LV'A9\AF.-&!*^>93W,"-5\5,@W8#KOY*]
MD5.!ZW%\E-F"<" M83NA"GB%N46\W]ZX-ONJH"]"*UYQ-;#94_WK%R7V@-I"
MLYIK=0T8>>-<[T&X0 /F-73WLT*^E@+JLJNK=BP;5)HCOL*F(IO;'^//@>T
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M8N<GCH.Z5RS3:9A:.12NW,Q(?2=Z,\\=4W^BZ1C+@%AZ"ISP7MOY^" ><X[
MF$M+=YLU>LD =0_@CX!K)5?8\GL6JUQ ?YXZ'PD>:Y'H2*3S^[:+58%9001%
MD%&+;LGY5*N][!!2!39L#8D\UM-/.#QM^I;&+]END8@6-HXH)91^$@15$YU9
M@-)<:P7Z@<1FVS*VAKF [PY& KU,<_\NZE'<5W?PWJQ5J$A5,U^59*V/PAG]
M/$1;2S*G,F$)8\P>6?\*#80 =7TL?-O:#U_=KEEPM[565%O3Q&5]U<=<L+U[
MHX@]$)9Y=S#O#!KEX_^V##-U<2$;L5AV&4R9)2OA6GM]=K['VU4%$LZ"_J<2
MV1*#SRUP)K)3+%%E8@@6]#/1QF6:F+^34(&2]/E#F8E_*,X?5:[$V_+\F0PI
MG(7G&.$,2.\D[ ?TD/:5RRPQ)+T-7HFS8SY%+J4&JTE/1;LQAO57TC^SK/N5
M3%84:0TUG1RGG&]4@1[>'OB4+_ @S%A? .,X6!G0?*9;3["[AT5*#B\R8[)^
M%NGP2"O?_%7R2SV\E\9=F[\$FG=0G]A4!6P%7MO,VPQ]Y8\^-*Y8:@*;;/GZ
MLL".*P'2W5_&80%HO!E:8(S^2AA\'5X-<NM*0-]R/.$%0(S?VQF]EFP6Q4-)
M3[P504D<9?H?=S>J,B[@[4U8DW^W/&@)W6_?3D=N3[7U:R-''@VE$88G)MH5
MP]LSL^F#1O<V&Y$&;F,B67!0< B_ Y0H!K/C,/A5 ,/MFNVN3YR6!Z^$5@NQ
M0  P5EN&.Z-N9;U\#6"DMMES!%6\F\6:&9S.&9=<*U_7#EKFIP]+SBGU"N7K
M8HB::)#<.,/$P#JW&%VH##%$JFU7!8XSY"DAL4"""5@R2Y)&BXR>QEK8^[<#
M[:LOZMT]<;%#AZDKMW,_V^>N'IYKIT7^1C^8)X1M-PG=@(@Y?N5VK EY(J\;
M]LR@*J&>AIH<DH![%TR)2MLEN.# F:3NQ^]/\O&.D(2[O-PHA\U4/[>&!!DW
MBGY+JG;[7'YI&"*]0RF K(R/9L^ .G;W17L"R/M6\40)"D[010?,9KTU),,[
MU G, N)ZS^.N]!"DANJ%=K.X=3V2M#IU'U@IC*EB%U.U*U9SRA>&D!-3Z*CY
MINK<^<F8J%.4K4FA&$+!Q'5?4RRZT"G_<#C^HK5J_\;M;RY##?RU')_3NA61
MD=AEXK71L/;(GY^.T1RN,3T&-SSA,5?@H[3:OI@K/X_4&7(\*-A@(^[)@K$O
M0Y]4[2FKF/G,(Z7AF6:W?W'8$KZ4>!A"8%3]]UTX;[>+QOE![\/$$"A(9D[O
MI _"V(I@X]P1_+X"8KKD:Z4E5Z)2FP%'(YHY?9#G&W .O-)-!#(7S7V*_-G1
M:;<;A\,F#\N8.BA_V(ICGY) 1] 4MIO\*S@!P&;SF)+')-'K:8=MQBR4Y*,+
MIE.)02<NZP<G)85C8SMVT00:G;1/''"Y%.Y[]):!H27SF6<,[:O;(CUZ!JYQ
MO:9"#5/M4WX"%G$NV^V<X\<ER_:HIM+VG$&L!P^V4@60YPBU''EEO UH-XLB
M$54L86RH] !FSBA539,TAST$!C'-D'2A5I11DM"(@U*T"5')ERJC+'VU"6(7
M:8UI.-_L*%[:P&+Y;]HW$T3F^*.\XC)-$IN:0I ;:<H7^LZ1DOA(W7%]BDD1
MHH<H:TI.UM087"_\9A"NX7\#P =G+2]6>/KH% 4N1H9HL5K>$K48?EA%T1MK
M==XF=ZJ"\ %)?64%Y=\?$4."L<F;41O4WD*RU"18BP+A%@LP8( T*\"JP_B)
MU-D O/IV41 [FBC7&^(GUU)0ZOE3WE#Z]U1('+,T2V4>]A72+F%M)=A8#%$6
M37U/9E,=?B?K1X!?@?O<290QP2J",>O]SBY#U' 'Z966[J*F_EZ^QJ=')E=+
M/35N^GRX,]**ZEC4V9HB>$;IW#IJ\\+[<?9DFV_=[)3[I>JES*S0NTCTR;'F
M5E&J29'_56#U80T8UZ567U@28*Y2&%.W'#7=&!-4B5:S?EB)[(NN#FRIKXC6
M5T$2"JLF+IE,;6Q\?,]B(9D&W5W/NM6?YSF,T+C^CD_'C*,%!F[VH\&4< .C
MF\-W'W<,-QF8;^U;K<.N&%%NY[*^O/G"<J\WN$N9SY1./ID1<!LWY2Z&7$3)
MBRQ$HP7RKV!Q'89@BL 6),W]L%U#G/V+T43JQ2H$:)H"JIV3WGM?SB@0E/#6
M8$@][E?)>!TSEX^CL4,KIR?QE]J?\G32.-\L'2J7G=R[(_B 3;A)ZM;GE3F!
M':Z7X]:M ;L*M@K\2!,?A,:2 'P+"XS/>F=D 6G,9C*4QD@A2K7MF8,J!8TC
M_5/Q>B$<Q*'N.9+:<LL:LU^KE^W-OX^97316=C=P6HKV*^EY-Y/141P3)C'T
M?\VEQ3^*F; K>#/TF^OOL36%>3"#%R>+TUL%K>065@>EZON&J/H@U1#TEFUZ
MU?02JV+[E9:T@85C<^Z7K=5?2_ZRP6!D&J^ZN,?;'E/J_NV\$ W:^0%T.W"F
M%G\-0"1U' R:U@!FTL(8*3ZZ$J?%1DDAV .'/1<W?51'Y\?;[$(K/GBPEI\N
MM6#Y(>T%+'@*ED(9M1X\TT4L,DJ"TNE=8D@:D:9#G8U1_Y[(_2A>&>R7X-6(
MP#6!A_#8SN]>S;\']'46%(DA24TH.>$YT$8!; 12I]]]=APUOF#,>&"69^9S
M?'!5A:N&<7SSZ6H[DU^;>Q4V&S?3>)0'+WVES>B4!T]YO8:E>&0Q_[2,JGK)
M]VC[<>GOP85G3V5K+H3IW=8YGCW[OBPB9].-T==,!EAIRX'7JR_8+A69-VS2
MVAY7O_:H7%.I.45H-QX5+0IA8!$PR7D7]WU[:2<CV6<OF,<F-0W<DGR&2@1&
M)<#ZW'O"5/#!CQ/$(##T^HC$QC9-IIPX/QE3]B[9_(A"I&%TJLAI54*41@_$
M$$CI=GLX-GZ+NB*&P#(ZCN%#MU,^\6 ] Q-Y/H.WMO.MU22>R"6W!.B[43SN
MR;--XF#E<*<X<@F8V;_K+:,Y,-57G"(MIDAI0!;,W73\Z6JP^@+J@#!LNRE\
M8!\>"A*?B$:FU1+G.&;<&38JKB"R&Y8@,@&U>6)(SU9DYX""4)[GEBJ\Q$:I
M@(5,J&R;!=!)5%H4G1PFTO 78WQG!4';YITQ1Y==MU(:"V1_G!_:7"3F9$4(
MN)2$H[>]RUY?A-_\YC3/H.68U)53WL[%L-S@^:M$FXTYHC(Q !8KANQ:$\I7
MX-W %+9$WY?(BN$SH*U0NG*IX:-U"<?!V^%YL;JTGEYT*[EA(J9^9 E9SKM2
M@4X+O;N5P&WH/X+]+(9PB-QTP6WPB@U >KD,?7!?#&DD8L@L!I_ ,^)".6L*
M0FW0B!HH4@$OLHGR()-=?Y\#3?8Q $,YQ'AK!1XB60QAG^YX%CT&R)S#E4+W
M72I?5/ (;,G>E*\ QJ"LO9PJ+E9R<W,\>@^4)2_P[;F!W['==*IEC""'RV(G
M95CNX&Q#V>0NXAYT[C0Q62)Z28LE0:J$"X/(7B9#:0UOMB<]H7\S:;=(#BN3
MEC;Z_)"S /Y/(7=QQF<F"T>;T3\]0"[(1IWSJGX7QAG]EGGW3&DD(H>V,M4D
M2A.:S$'W@0/V0^%K>\$J9K'>^XWEO:-A5D%,Y*?\^D7SL;RC?1B=BO(E<^_1
MT>*R7_)DGEK-/QKVK'O[[,BN/YN8>-OMQ]:[\!HC8450SN>>F7B4M$D,@>79
M+PT'TWFG7G7L&PFOO7H*[K%**Y3H!]+O705&]NW#R3ZK1\XV1[^<-.P[44/^
MO,F_/+HQHT:0* ;@2$I%*8@A 5-$]N@F"7:+D<);9"G'P_:V2;/EH3C2I>U*
MD9*'?#S2-,OLOL'C(NMC$\9JN8WL@0,._IS6%Y:P/>.)=]<+PT9=ER66:;:4
ML!<<GUN;+!,HS1JF Z%=/A>@ !S+,F?3H ]$>T?PX>7+40BAD7P\GQZ%B->O
M"\>83MKS-K:[1XOH24V4.^,^@[_88S%&Z_"<#GNNS:&M=:P+=GF _E=,H&/V
MDJUJ2)&N=MGO+LJGO6WLK6HL;&CKGBN$398W"\6:1+E_G)R>\)EDAOO?0QM'
MFM(CZ IUS9NFXP<;F59M/'.XS*!%KWYP_8,W+_.T^]NR'#!'@=<AP5I!R8HW
MT92QW_IW.2@^P\6_R1@\HOS3_<.5EQ\1=8GJL+MHPF[1&U@C(Y%XFYA.5J.A
MK8\2.CMV@V6//0+5Q)"5=C;J@&/PC#,@O('[,C>G09L^"U(X03 %T-\9H"9W
M',:KT1O:!W]MG/#_;5,M]]'3:+L4:PEG@V=YFZ(#D8++N.\+9%+J">=M!+J$
M :):QQ'\SM%R0&;+KLLC'!$[<Y Z7X@ AD''F1[1&>#S*XN_PJ6YQF"H2PK%
ME]Z"4/-:5GA^X/=O8H@#181 C:"\$[BO3_FI7K2I4NYW+)\Y(8@(FU?7,V4U
MU_>N-]D0S(BOSEL;$8;(!PG'\7;#!#U\I,0PT=DC#%E+)0Y#OB.)1Y]=ZS'2
MP$5V;VXU5P0]^?AF1DJDCC<;;KLX2U)"VYZF;:MWJY@GTJL"6WX"6#/]N_/@
MJBOI<#'$J%O#N.;,4^<;V<X8I&M'QOA@DW\+>J4S5??Q^W]WJN/_IW(FL;H"
M73!-CBQ?1F(2J16H3OXXZTZU/Y98-3WY]P^ ]\14KT'36\,+N,KTP:0]#JC2
M/R[*JK(W_V@S8R]3]^,B7VD>?(\_C3?,W62J&272,$;,\;2H8A?.5$"SZ74T
M?><J;&IJ/^61UZG7AAL<*LZWT^<0X)A; (W#GV6O[0^H-J:?+@-];8;#- P,
M#?>=?U= R,&@ QI_=OFY(?G*WS=5[QQSNV*ST]X@T]75U=LB:L_OT_J 62P^
MVE<E;XZ\%_3LB;JME/:7\9H*CFC/4WY@=@RCJH ,4LG+Y;U3O7_&MF''RV W
M9YM=%[E7)%<>;8.)(?N*:]DD^4""\I<ZB0^)#[H^&#8Y(/_-/+Q+%8F'?1@W
M'4)/NZ2/4IKZ'Q'O3 2%8'>_WYUY>"(05_C21XI75^ U?0Y Q0L]39-^&R_0
M[] !/I&H]F53+QZTC^5N48HFT9LRM^)I_,0C[MU']*\9FK_15<Z[?;O^?LG)
MK?:A@(++WKA8Z6A,U'S8I G9L[FQ.?/-T(S;7Y=/CCQN:LSUA..HR(#9YLRK
M6BXI$_(&E7A=T+/4W6L1:<9$0=!JWDM(NWN5B\5R #<A@>4>Z%#WH:*_J+)(
MN6W1K\YBJ3E-_ZY!TZF@A<O>9[,WUZ^K>.?Y%&T*MC;/!],P)WX6#8KZAVA3
M,,&OHA@W-X%R.J6*7UD=+F.Z:9Y;]H\-=)*Z>JR9GAC=1S;E!&#8&?9'M-+=
M=OT(1@)B2&=N2SLI02@]NR8[@8NUUQE?69>7"2BPJJ?K/^'!#:G8*O=)FVK[
MD[_;'R5%99TOSWAPK7'7A\$?5UHQ](<O%\D'K%466O!;CNG ^$LUQYQPR;-"
MWLF?79/[@-[\83$JF_4N_Q#?M27,==BF*G!358WRX'?;/G0UPF3C><:26TX+
MY@J3)44AEBVUU">5+461D^K]VP!1Q1-TKAM]2V-JM!7I-16PF?<#/*32ZR.R
M=1)AE?TGW*"5=NZ\;;=C]Z$#?0T7:]?V@!;.S\;#^N&=A",CQC.'?'1*.!AK
MP:6AU16\#?&HJ2MO)J@Y3Z7!<VGSX:O*Q??:[THTNOID$[(#V0:_N"^ 2>Q>
MYH#*1S2=H = XRP1X667K.H?AG*@T@M1HSTY0:%'$C]-.A0Z/7N1V2.=G)**
MPR!UYQ]D/_3 U;]+W=G78+F7T[LR"8S/*<\PO^$1O@;%Y%E4JJ8,V!A>NA#!
MLB57@FM=*+DP@0"[PP,'%!E*'.(5(+<B_!9U42TL,O=7*\2E04ZN1]AS_^'Z
MF*PN375@+2VLD+*W&RF7QL$< +6F%SJ.#:V$4W1XON&99\.K J][37S<_=#U
M)\5.MK=+GLP.]9O7M0]7LNPO(D41$U%Z[98SH6^;C&(94AM%4%N 3P7RV+FU
MCW&_39'E Z+R_A#JQ90MZ&R71<^5H?.0-YN1'FT!MX(:?7=# P+*T/1L)W,!
M5AKWZ[L8E:5A9H$L92!Q?3G]!).N(JG,[BVY+%QS=63%0J/-W09T5/B0^X1V
M=T[:)8SY!*ONV0_T9)V-0W)]#8('4WHV@^MZ:'V:U:F?!^OFV]I'M&E#=09A
MRVCLAGJ^D8GTXK'&U,/%7T1?T/74NQXRXV[G7ENN?FF].%2:*A72,LZD)DV?
M'#=F*(%I+XMEQX7PTMW>JEWFXXG&#FY>0RH7D0'C\%%JG3_CJ<);[AEI>'+L
MFWXM=HK."D$:"#O/#%6-%YHH][>+&FLNA6@F5)0#@02ME%F>5)E,;>#)##'$
M.];^^!A6(7?..67:8N*4K9^5P?<>-1XC]PONU*O8<<<&307@9>.0L22DR*)-
MXWX<2JC/8_>[JGMB$,RM<,:$9:V!DA/]68.$.:\U7ZTS.M[8E,K9KSBM?2T2
M)F>MZ;/$DFJ_-PN3\EXN5FZ*[>O<ZA](6+^X@96=0/(PZ,>!YSZT?R(%W;T0
M.^-8,*U+G"\PB C[/KJGMB-0(4QWX0\@NC*P(/%%I= 2,"53 K^BO );NDGQ
M-&D'9V>R,SUSV(E\?<1@'5Q=NS-BX)?+VH+G5T2WWCN9&)%IYF=>D!<KU*@#
M_?#*=3@$TYP:Y_2NUQ&Q/Q IEQ?#SAE>'S@A,.T.4Z_U"*MH'!;U8?CJMP*.
MT026FI?MYNWH%:5_-*QTS*4-6:L++;YGA,*V'7^,DWX5!8W?./N;B9'THJ;*
M^_49N:6=B[LC+PM^:G@6Y]"J>O:/O)T<UJ5SD(:[U_?8EPNM +G[50M;M@FS
MQ+T++8BDIE-CQK+G[8%W:57H+4WJ2>>76_4D/W\_V>;\:DM5MQ_:-[*O>QN[
M*?7XG=:_WWI 5UJ[ 17R=R!#OFU/_2*R,HX"GNA4ZTFB+&4&18VEUX!!MB/&
M%!0RI^Q>>(RS8VM#P<#U4>V 4K2)]/,[K1&IIN@4&RUN59Q0NZJ#I)V4(+3P
M.Y44-MFNSOR"#"CP:UQ 6HDA$QU3Y0M<V1K3_,KI[8QA;H2IK;0GJ6'RWB#L
MH<ITZO<A+LBP$FGB=MH ;QCWVXXNS[8^O#<[3Y19J.M0:I5Q]\;=5M<R5O^S
MZRD9+M O2;%H"+I'PV@T);==9KD6L(1JP5O&YG/NK*)?-327EJ:W/E]+<SZK
M_F%],FW2 OYZQ2DDR&24TM[UT/CI3\L5-KL:5N[-;W8:Q6\]0MY4RV/*)Q7$
MJRD&*@3\.8/38T:&! PN#1BWU$7=#%W,U"DN>)2G]/J)=FDGG6HY\+LV^FCS
M,FCT:BBHV?HT<3_H)W2H1&<&%&"3R9>&)KV'U]$YF=Y:O6ZF5==IP]JV?IF=
MTLE<;X^<TF-_1@5*0IK?9L3DZD7$ 5#^I6A/ZI;\;MSYSF*YN)LO5 L>62L#
MJP_9"TWJ3P]+URZLIUD8M[[8\7'_JHK]CQ$[GO9:>1^Z_L._LTOZ_U'9)9[X
M#U!+ P04    " #%JO5<CJ"77PEI @#;A0( &@   &YY,C P-S<Y,35X,5]G
M<F%P:&EC,#$N:G!GQ+H'5%-OTR^ZZ=)[%0A([[V7* @(B A(;R(=I(,$",1"
MKXH"TJ6+E*!TI(<BHO2.E"0JTB11B1%"./'_WN][O[O66>O><[YSUYVLG4PF
M\SQ[VI[Y[23G*^?; (N9L:DQ0$9&!@R2'L#Y(:!^TR\D,B3"+R142$5>$= T
M,+6@.*2S]HX(N1L5Z1\2#)"(Y:\N0 :0_<?K.8I^V]30T/VFM:6QZ74CTH8
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M^4ZQ#@"#4>?K@.'?^X3_%OW=Y+^[!]GY(,!Z@9R!LIJ"[!) SDI&P4IV/@*
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M^H\$VRA^=9U(4TT$>T5,&[;NT=#IZ6EQ*@D;FP),U8]I4!#!!7A3XUELY#D
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M65[<5R?*=!!G9P[:W5D<U_SLHA75EE>\>G\<Y'%^'!;__4Q)6CMG)1K7<C8
M]H_$!V%U4#2#1P\V><Y*"-$U 47UV.AD@G?C)#K03\ZSN[U%9'AYF=N -[@=
M0M7;8JIB2BGHE92'7MLP.7SD&8&<QHLNC_2Q6]N=WL@YE8/ S+IS)GYT;*Q
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M@SJBS@%FO AR_.$Q39\B/L-YR==1_$'E_*;.A!NCG+Q/MLP]9K&A!\SO/CJ
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M'V^JX^O4R^OP-C=[YN'H&<*5NE%/E*D<W5@MT7G_&N?<M;EK_4EX-9HA[#E
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MO-6Q&VSU3I(6'DRZW*]!6;!UHW !@B7I31X4VNG?+TR(&%B0[>?T7QON+D>
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MT$EL(0>T"L/8':4(JN(]24VEM@^CD)4@&4 "KKVV%?A]Y(]]$!O!I';EV]I
M&I\[5_NP:72=@ZN;D],?UD\F?D_&=1ZFUGR6'=>R>_\#=EC&,>F1.(EZW3*A
MWVU\JY4'%1@?D"T8U6 _$N>;$CIB^M[J%H<$E;ZSR8;R8)@[WR(2S G)K?48
M>=+P&,SRS:OK)$_3R9%:X//*A/6DU,W)"@.M_5&DE$V10^.=,CJK.JM%VYJ#
M^:8&TL5L>@YL5[C3)/#B#7'I^"^GP@2MQ7/ =P-FB?G>_1*?@TS)A@>K]=$;
M8'G>Y"-L%V45Q!;^!WOO%=74&OV+XK8@(+V'$ND=1.DB;$6Z@-)[-B(E=*0%
M"(DBO2I5J9O>"2UT$B$!! 2D-RD)TD$2E1 EA,,>XS[<.^[+?;GCG(?_PWQ:
M8ZSQK;7FK\RYOH+Z#+A_YL;RH+F#^^^'@=4.]7NR\$[X#9@\67\3<5GK78,Z
M$A@I$<4QFI&XHWO8"+GI+3>N[NR625)D=>*J?Z3G5H._W(N_C+VKW>/^%KPK
M\V-ETP:+B!>\<IG).I^TA [L]8K/6\]D(?X8#>74N;D>1Z]E$A+'>,]LJNV,
MSWS=L[O'>RPA>=B7O^%6P/C+Q3C:MQ'K%-89#. T%KY1#/Q+EF+H$5*UM@_P
MZT+8VZV)OG,<+/->)E75[FX;N#_.8)<O#KM5JOHL-D3]=C24_X#N==V[N<_@
MK<#10)XG^W:^VBXGL3I\#V<*OI8W6WD;KSP+QO%JF-[Q,M]. @-+ OS 1?_\
M][>K$R4Z&*C%?&_#D9L-+^ARJ_6@2\N5W^J6[%[DDSJZF*H3'ZC,1'#-0I74
MD*V=AA6_F"CTF&A&I;]RYNH%;Y\<3%^Z1W(C*Q#RA]DI:E,^(?UAF\7L^RA!
M5%];E,QC%.I=9=H?&29Y9*>OSS^2J<(#QT(,/P7_6T%"X;39/!UD7IHA91&U
MX[3^@D0:G)=HN_FZTY(3-QB.'"SF*<IU9+^U XN.!;]??.<J#MXK3C9/J)]Z
MW6>V(P=#8K^EEB?V@U(HA@3OX75!^$8K$*GZALI#@1/3#P\0#S<<^ XN:+@@
M.CHS)STKX])C#PDI0;NGUKD+)%:&J$?>G1+LX5.CT6**_K3IMI??S%0@;&/]
MR.G,"89!B20/:'.PFW&OJ1"9AQYHS(?.4VQ"PN33_8,J(<L_O N=Y$7S%@8=
MY X;$7Z"R]\%_)1S I+9SL6@N1*8;P><)YHW)#AC/OW@_X[BV__=".@E9!^,
MYLB7'\QBS\W+O1_.F$RG*S4<@8<8LH'OMPI PY )!<@MO:B"K26ML&$MD8!0
M=N4</C'L/Y+/FPH(.*BX10[FNNP,8\)8@: PRC5O%'655R_;8/2>>4K9B=F@
M-EFF,#=>^Y_)6""2&W-\RQ,F22XAQEM-0YEQZ7$M9I&:H9?<G+$/H5B4K_6#
MI>8$9XPZD'>7:S4<OZ+*RH8[^PXOW;H=BL-[G26D.$Z+89XJN1NA'4^][:7%
M.XUDYMJ-X#]E!]M;=X2X"@Q2"UV5O[9\-6,L'$.VC$[?-]S*G6#R_NUUGH%^
M84)_.18/+'II_LRI>Q9UBSH&("&)D_W.-[K9QLK%T7B()IUXHK= S^B7_O-8
M[B0EG4"(B,>L!&$\N2V0<H9ND'HIYS8:_=CAE?F]KK>IM3>?K=-X%*E]0F3C
M*5P6.9I,S#+EA8Z.8@7&[%*6VW',=Y_6O1K+R/H*7PKXKLS_-:K\O#0H,\SX
MQ(SN)TH1'Q$^[S_(*1);D6.33O]TM/K<OD)Z:>BAU 8Y^4&AEV6V7O-2A?1L
M4_"#TC)]9ATC4PLKL=^)9]=A:RCU\WJJ#'4.=H5H$WWI8?.97ZVIFS%"(DYU
MN] Y.[;-49&#W7=RK=-^A#\.$])4%^@_4S,P=KI;*_FW"?P*;!VE1@11.(KQ
M'8=V\ T$XQ*$[Z,@HY90,S%8%9 )2?KQXX'"XUF 3 ) OXE%?:X\Y28^\6.L
MPV?7+K/^8H*!@,,30NY1R*69!Q+<T6$W"O&)*&F3(-_258WE?6[K=I0J.?K4
MAFO^U/EQ:[]77FJFHS& (^E^M=ASX3R)<+B[J]NF/UF^X\@$#V?\NG+0S1Q/
M%?AJO[Z_[%WQ_<.-?__HQP3#FTPBKT!$NI,M6E&M.>RW0SI;>V*NBLJ7K0V]
M4+>2'4X6,KO*@[OCJ*@/S*7^Z!#3M-+/5K;/VK)8+YCS,4H1W>$>%RWYW@A*
M^-1YG$0LN(<+\?HPV3[^<Y*CM1$XR5&]X0)BS=P(DI=)&K#&/(IQXG%I@LBV
MYC4 +.M>/BJHLCH#=Q<A-K7)LMII;N<-6@P49G(40?P'!J>/A:>H7-#0QP\"
M$]KSYA.#\"OY0'8[LL?@ NKZ="+2II5PM'52#X:'GC:OC0>4KRS7_G5!TZ?X
M::(D@89S=:%KY&I!8%J\,N42^OT6N%CMC7^!!"/MYI5A7UYR![3AFE?SO^_)
MQSB+WRX65S^/>/SS][6ZD<[8(-"77VS';^AYGBL[UZJZ7;FEKF;^\HJ:IJ B
M2!6KYMA=9(?AZ65B=9%('R/>'2P_&)]%Z/#91]<H>$N)[ABQ9#[=BO8;"0:5
M$[C 1?C.=&QOG?JXEWM6BZ#H6,"28U7\  X7-[#9&2DS+A93=A*AM&H4?+ I
M+3G1>V =8#A1GRY!K#JB)7C@YIO!N&-^BC79%R<7\;OT3#X9#P)X IBJ7F:R
MO4,VY-14.S@Z<O\3*AN8^\Y:7U>&_5V0+7F!L(E9+LQ);R3__-BMU5RSIYI'
M_5#J!9.9JD<66OS=_%!LK:]JT=%Y."BD;'FXZ[M"29RQYYQ=T8NG!E07;1_X
MTHH#^<J9/FQ*NVUG:/U5,?.EFSM>6L?+5U3*-]0Y0J;WQX:UKQV)]C0W1<K=
M_9(_ELQW9@=8,&W+-7LS^H,Q3^G/WS^M31&D8H+- '#9G[1U2:8N$*.A2=OT
MC6+L^JONR.7=O6IG6Z\%+=;V-F):7>6N?>%B]C& -_/O&1]E'R>NV0;4E]3;
M-GSG $>)Z,Q^P\U:,T:0W. V)]&RQ#1X;Y(A)D>ZD4O1PL*JM$12S2I%;&(F
M>0M<+)).A&L.6$TTF0F-[GFH/3F+;RGH$!W:#)(5OXMBUL;+.C^,&3_ Y_R%
M^LM6TW)78U8LMB9A*U4CZ^ 1^[,@:B:%F]B#Z\#V/'C^$X=(AS(2;PAP\OI7
M$?R3@N'L#DNK/J%I:W]\V4B_Y7A:8F7NB13G>Z56HF^@^.'_-8\V2K0%Y+0T
MR*T;Z,-U@@4614^^CO<%&1-](M)3E0NYL:FN+D&-AG[=3ME;OV1JUTPJ/+>_
M;Y0'Z/)GU/;S8\,?Q1^.$]#]%S2M" K7_<V._N,WW<\A(KBBNC.M]KZ0C7'1
MM@CA_62W2M,6'??/>_0K3WZ,^XRUQ7>_C[42\OXQ20J>OJ#QY2)+71+%5:+V
MX2"1[Q%A/9JBNBD0194G\^^R.)$Q@QIRO2@I[Y7CFP<OEYS&RU?!:WSI3]-L
M70KEOY>F]*603I]+"%+M!GX_H+?+^AJPN.:C?6OS#F=0^!S&O$Q'M4CN.=@R
MC:M7O9GQ68KGV7?6/),Z"?@[_#&[6ATO*-XE-LX_:S8N"!]G7/"/FE&EW7N\
MXOLBCGZ)G.=W?HPW*0/GP'@.F86M*OJDNP$9>1DI:(@RG"QC0OUO0=!V]WD;
ME)FP:=9.#"W<[+MWF?P;_JS[W!T TP\(XP9=CYJOC15NC 6GI$<#$&4&[KB;
M8J&=:4OH2+[F$_1B/)7^?BUL#MUJ-CB9V#WYILV?GN)(EJ--R!RDWD!V]66,
M5,[\DD*N<OV9=<2?*XV;WI;C07\050UP>FRZ40=*!W'YP)@N:#!Q4'6%C[-S
M<K^.;(;7V&9[_2]HZ!@I8<ZWS1(Z!*5RF-EU:XT]%7=$"2L7-.XQ:<J^W&=:
MP7^GU*]Z#/;=V"$QD[,)8Z2$*6?\\(;'4>Z9>C^A"G_>D"4N<$^/?&D&E/H(
M%S0)VQV)SE_-ZL<K?T\9N$;;='8NE(,_?+]FAO3CQ1TZ\;LST\76Q Y?T-2'
MD[AE+0KUDZI;EI>4T*U$CBUUG<71>%+YG1#.VHDRKZ#\9\9%N0F4P)S-ET\.
M[DT0WD]P?R1[#/!6<=6+:7(^T53\:MWZA\=/; !?,UUEL>02^#N4+4=#XY_-
M^!#O6HXL]_55^W@*IS:^L(/"#C0Y[^3&K4>O#VO$8_E M.GT8O-=%S0W9U4R
M(4V[;.MM-=JDK Q=5_Z.R&O-CT_IKZP(/OSY7UO/[KP11KL.O4GT/P*?J4(8
M'I/%SO[^2HZ"*FS"XYP5>^>0C.(S6*[VL/E6;X )-B^ZXJ0O]JM][/P'T1PS
M,40QB2^_Z^A%X@6-5D@_-T5G%9>=\_C'$545/!G4ELB<A68[OE;!)\?'9=)O
MVY3:?/K*%W, N@+# -N'CX9Q9DLLU"F4 EEQXX)F*1,G&+MAQDX&88J911>4
M%7C):$/D5-OI##>6N4;$;G$_]X\CEWW(S^7U$0^76]UOENS'-3\1?^%?^G'V
M&]^I2>G?(CMV:UI@(72S-2"NYMD 'C,WV>O\W?0]J7;ZRWH_ZDS+*VX4E$](
M$M,3?D^H"@^\^(!@=0WR6N,G>Q>;8[9^AYI92&&W/[3[)\:SN*HE(1T9((X/
M?% QN?)L*"X64A")-=74X;^9T6'$M96'8736T?N2V^V![[;UA;EM=EJES&F?
M\G@T.%N\9:ZF_<E9[%8UZ.;KZT$OK>-QZZG#*T-LP/"6I&@*H?95%+-S]K]E
M]/^>T%PETU.LK;=S%3"??_M'_E@W_KU([4]7E0T_&A\3]'/JZG(=]T-SGL[:
M2Y:^>ZC+\=^6"/];X@:LQ(VIPBW<-8@U@Z$G_$@\<>%;AM04[BWKNRRWEP8[
MMXN8#! 3ZTOI5+JR,PWJ)S@'Q9<8CW/.Q_^&/MLT9K0P[4QWF-^:5SH"/IE'
M5BLWF&(>-JD$\*E]]]MH<S14QISG3;$T+WY>+[>T<0<"DP>FL"Z[-G5&<=**
M:>)9XIN J>3NE.E5_QE=\>XBO?M"(S]E0^T^;//Z,?.^?X'T6A@-A!0\T)AK
MH>AZ^14<N!3,D*SX?8_U)E?M=S_\1N"TR>*@PQE<\?*PU7G3KU7F(5;HDUFD
MB1D6M'2:][6%;+2 S1MOM??2&*R,DU.M&,?Z*V$-X:+/OJZN&O(;.?KLP[V/
MR1+PCQ<T*]KV!.XDF.0J^=2 ",1 0G@T5>L@[-@92"A)$BEUY.?8F^P=GIP@
M[RM<-+%_Q3_06]+.^N]/*6CXE,.P^KA0 N9Y22I6G_5-V>$=I)5AT)<R][Y"
M=7^>GIZ*LJ[ML6B(D9V[2Z:6P"B75=YFQ8=M'IZ-:@QS\O!$6R#[X$+,\ZZ#
M;D*JE=49L< BILS-_Y,,,UGD@N;PW'4#D:C-W*@E!)ON7H^#28 !XJGX.@56
MJ-W<20470"'!!VKBD_?2:>E!9\[.LQG?LKX,2?%PV=XQ?9EKTS*P-(@$CCM&
M2P"J1D /:#-X#C!?)=OTSQ?13A_*.X=_<_IKTBC=T$#^A>O6UTGE:O^V<6G_
M(IMP.[L)_:8I,^Z"[?>[%E7)P\^]9RJL%F*DK;)*ZXSNI-16!'<M1YLZK!@?
MPPI:8]7"Q!ML6+._D?F9A-NY(  DX5>X]R2MIHF/8U-&G;IE/J9[;M\RFZ_:
MR-?(L*WAMQF0PG:/Y)R\ 4J'>T"^HR01&+,$('LP.NETV9,8@_:=ZC4KHW-M
M=?J+^&N3Q*A<VNG9*+N5ME=E*Y<_D6:@4VQU_N^ELA==BO+QD<@&*/:"AHGB
M7TYN->D@J_N6Z1#.!F'<<_*__'D\WWJ2WNZ]=8 /Z) B<XK4\6TM75UV0C^O
M;U6@*O@P@;<L%'8%.*H*W6<*O(SO8,\,K$-J1DRJZ#,J .R9R*X*C:<IHNO8
MG#[_3YU\;W*84$[4^F_I5Y+Z75X>FG+9A0I:UOT3H+R/;[+UX+Y19D:;@+!O
MYU*T+C$O*]2RA@G QH&MPT/%@$N3^T1+@SH- L" $ R&>H5L<ZDWAF3C,ZU]
ME-(KWEX=QEZ5B)#CQ%]=8?>_-LRR>.=VV-0WC<CF_9+::AV42>]#HA<[<-J)
M<*]T>NK"'S+1O8H(ZA=DSQP0Y$[:L<T T>T!?+$:;>9?'3SU5E(-*CNJ91P9
M*FDGOT[Q/D_-//PC4R90O,TS^NM@J&I.0+:65UG2927&Y?73@#K#$.=5H[+:
M&5/3<N3BF-A&0;YTO]7 <R'9-:M6BAG;+-9=L<J\;KS.QLK3QE#WD<+5F],E
MES)NE WP^PX>H42=V<&&M&G1/NCKNS Z<I<OWJ"A5Q'O8,;EJ3$9&P)6>A!I
M,G<DG/<U/TJWX7OZDM_1=[%H_->!_K=E=:)-_:)P!8K'I1$UI$X4\Z/$X0-X
MHGZBENJNH)8_(R1R(%?C\AHE*A!WL'*@P+@W5F'OY&CH73D2T9%K'3B4^T-'
M2>54C*.7GQ54KV3-XWBLTF^>>DO0-1EC'JLQ6P90KN+383WLZ_6/[)P-!G?I
MF0PB(QUWQR$R,3^[%PM,_3%+UBY)@Y/7+=@3L"Y"TG.U6Z-M 9RUELDI%39T
MMW0]GQ;D9ZO-9B0;MOYT-;\<B2^%<_:_+1K,2/IS2'1RWBG&>YU=%]\54@@?
MZHB83%VQZNB+M^ZPA>I'NKX<>=XZR ]TY1IG&ZI_SWZO)TIN$[C4@]M)17L4
MZI-<YX]"$&1K^]Q7M\F^2EP=,X,-"O%']7)M8V"1N2F!>=)]!Y?\PM@/[WL3
M,ZQ1[TI+*WW?6P5F$:T<2Y**-)@_G'6.IMTM$@HF961QE/_JZ9K3CU.#1==7
M?_L-U6K->OI)D7G_2U;=MT6/)))ZB-UD7LB=V7GY[E3U4<-(PP>.^=J\%*%+
M<V=Q_H%""\<=H!DH>N>5OU:T&??G[0MSDGV)F0[M4X_;;3!/TT0JEFU7EOG4
M_1CR$UA=V1)%UY9\BIM^32["-R82SVSV+VC:E<N=9?R3NQ=BAF.^/\[[O*#%
MS253V5\>OE<6]2'4&9G:^ZPU'RV4U%9#FW<X?&0OXZ@75?A\Q[I20A%A';([
MR>QL\RS;BS/<R=X*,/\L/X;/O/O4')FFR7V5$.=@S*AS!;/DS!7'P!?_N<D2
MC .?R8K?IZ.SP#QO^K6\56&=(J$VG<41SK$NUP@%5L#[M;6N>1:WJ6(O:)8M
MGB0/M@LJDS$X1IT!P?M3AR%=OA2QNKT_A;&-Q=5.6@DYU2-U9@(%]^0V>F3E
M>\?> ?-%6J%A%9=X98*[I3(QO.^5(UXE_4LH+)S[?-IJ"PG:9*KZ=YFA)D?M
M6[9/V]'=.;?\L22U>=Q4Y3M7\Q_M=NE'%1QE11XLYC%!]/O91L%@J\JM<4 3
MIM^BA'=MWRB%6Y0C<RN]N\U0-E +2+"^MW3N$?<RJ3%-!)A2)A'[-)O?&6QG
M\UF1H\+(<LL4,CIBB7W98U7<=[^G.!<-U-[(U;[D.V D8<R>N-9,S,%@X3<I
M E40]@&4,&$A#?&KT"]*^.,0J2.OL4*Y86MU#7'K[8B(5^"X?\"TX^B/GK;D
MM%S2I7..=H*-KK>&I<)Q[I P#$J46(RM?E.1FXZ2A%19$3L2V^8R%#F*ESH
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M_;1VZ]G(;%E<ED=\E;S[,>!>C!O3=%(44X2F&$8-,I5Z*UVVZL0GU.6#R]>
M+)NF8?<V+Y>?_%;BI04RKI+6"'U6<SFC"HW6E'R3LBW$TCV2%=G[3( B]09'
M._#^A$3H0W4TD-],$,7+_Z#J J,:'/D2U[Q;_7UZ'J8I&[AV)#X+?/O9MJ.8
MNGA!TY3;CU[Q4KAF1P'!^9;2XR.RO]?AHHS[-7Y_030T(M5\<;UV3D<*>#<+
M-W#@M9IK[/V:-Y\7,PNCO[993H\' 7@6/CP=>BZYS621/V1>(VFS72-HB#17
M^!#4/WIW?N)NH-?GZ8Y; 20)X?1;S^]"46AF#+,.PZW21D&%JP U^ZQ]%QR
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MQ['QEK<9.^E-.+C>:B#Y9AC>3LSUSOO=OK8RM,Y\0?,<L<)N\P5Z!5\<!V1
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MZS"85[B:!)X/?;<W;U^!RI0K/RU>#G):-O0S>E+O(QM*93NO0<E#HF\J.&!
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M-:\UYI'P*X;W06@YV96 <W/Q0S8U:OWU<G**O5KX,:+2^Q+E#/ =<TN>$VI
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M<PW0\><8Z!<HKQ4Q+-\?4^F30=YMH?VAAWYD?G0&>,&\&;J896X-<FEL7,3
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MA'<J<O3PBYSFP]UJ8E1D=.& )3XY[.HI*L?=<=2?R1?;$]:O/X6:^!@7TA%
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M86!RIWFT*]3;GN!N101CNV65E85;W#(Z?GITG1S(?P\U49FK.\_C*6T\7=6
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M,[-H;3>[H)5J;:-QOR*)>Q1VA5*S[-*)8:&(DM^0A%JCHNU1J69$-C3A,EY
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MC-.N.9+^GLMJ3.,0N/<,0$=CMX3>(?(7^Z'Y<AAQ2M%J!G@&S\KJB'1D-<3
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M5CJNCO'W+=J8:Z/D2EX\U)XHF6I0M14UGI#^.B$<<:!;T1.H8_S48!8>=09
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MGP&<#W7:0!K'D]WP<]KC8]VD64L EPO@1$O0E7ZOUOY.^$P]/E@P/ @8 37
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M@>V.^3KB(@=H/3]U9$0^KM:WX-K'[J&_AB7&)7)N#6GS;LJJCV"V\OO226<
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MV9\G"C[0Y2)2Q9 "!$[T>0,3.VBFOKN%&9 4EI3'CXUB:['GM9VR<ZIK++\
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M^M1^$I5XN$5^P4I(N@*\A81!:O@ZQ6CPMW# KU8[-O1_;(Z)QU< PW17Z2O
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M7>&:JJK!5T83G+3*;A^!O^6QLC]7B09XMG?#*\BYO!7EF+*$WKJ18K((7JE
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M@#?(#P@Y"0!>LLFX0AK#MO))<U/);W[!\2,:F>H@!AW+*3M]M93\B>ILIO
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M5_5OI4+W4\-UU,,9[\TW1=I"P_L,DEL#F/*&\MUQJZK8>U,?:QZK),M%VU?
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MW_*V;B=I/X"&_BFOQ&*-2A?:[OQUWN]1\LS+RQT'>_YZKE)U$W"[SX5;2>?
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M)(WUXZWD-<.P/+V.G/3+EQNCK@-O/XMD^::Z(Y_JIRAN48JK-"L 0-IPN)/
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MNL1A*GA*$R[MGT6HO/8LV0#[%_;PF2B!/P]_T-]" P[!+K+B'?2R.7(X./^
MJVWM/*,/KB-_&"<6X9^,78.^(;*"?K[!BB8(DD(^SH.@WA0FCFU;&$48A9IJ
M]&'MQD'<K&8^16T_3C^GLB"(P&_V'@<#W:T_A65;M+B_$Q2 -4@QVN3/6N_,
MGIIA"$J@Q%ZM'[T27+9<'M,<$LA]^WR7"O,"6=<'<J8(<94A0F)D7!?O:&M1
MS.>,8:@5$WK<D7,C1"[:\YEJ@[UW6/2PYQI)0PX]HK^"/\(#,$%^HV]2/#(S
MRO9-_?Z@,/MH-=D=U#G5E3I"?P5>&:UF'-V$9"1?'0_D%6!V#W6H:6XJ ^=V
M\B@5(3V&J^T&&/XL/<X)\."T\E$'8HZ78SC]!N1@)J>RX.5&V5B4RW)<$9V&
M\,7K6O"RO;)Q2Q)XCH)RCZX[,UVR,)7"?9R$)P;R9;T8%]8=?'DY*<5]83C@
MGP5[W8#G=6@/Y/66I\#BE# L4RS9#9]ZO+*1ZE5-UL4Z>'8;K!0QVSRIU_6I
MV*S?E"Q=OJW5AC-X']S^:H=09RH@V4JQ(?E0:."GEF0!_.$Y%1W0#442$TW1
M8,#K,#5B2,X]$6*DR(_0@3X W8]].%@F$,A ZEJW TOO2I,W^PN$1XN"I#OT
MU^^]'($1'7)_A(0_D0X=AR=EN]*[U'$E/%\0U6$P>">E,>&39R/>_R>YM&*(
MU?8,R.H;ZTE_(/O=_SN'$T@BC?;AK9"7#UHM,S]SE<\2CR2&&7JA8"=*3=(G
M;$R-E-"B=3OS!MR4X3&_]"G?)@AO@IKC):H87X*&$4$37;>@8X:D59Q>)R?^
MN'>9H]'.SH<&QC4-43BSTXV:[/V\:*\5<I92*[V><:UH/:0'8^-*Q^?)!MZ.
M9(NX2YD#LJ&<F>:]EXD59Q_(LGA&M [I-G(0RYO&"'O80%@H%&MK'R??#QJV
M*Z\1DBY+D>,-O[>2_H0N>XI/QK!#[(S^+ ?H&LD8,;1,VXB,*60G !,[[>@Y
MCVV)7W H7D]EV]D$#4.<H3XNQVSZB&:MEUEQ<J!)VLNYN:DE_HXN]9+S/&4\
M\KHH:1<OB6OI_A:4%,ED2!#MYK^-A]G^FJD']<$+ HP\F9J'7?EFD"]O6[V\
M2Q??$L4963HSZMLD_S@KHNI5OFNN6:^N@#$#B,%2P<DQ<SY&U-8WF4]0]J5O
M_O0:4O'#CI.*NGP/OH^/06I>'2[!=R]^:!-_YF5D$O\U3-_UZ#,IE/T>EU<'
MDZV%^%2^X)@!R^,TA5NK BY%RJL^.X0+@,Y;?^%P1$$.RJ]@\B$5I"JB*2F&
M<+F7![[WSCFD8BM"\H)8VO7:5ML6]%=(43\%>WG?25"8,<A44B+B=3V>_[P7
M2:$YQC.MG&V061^,'EO@J6.#:@P&(JDI8IX4Z:FC&HE)\ZFF11V:SB?9Z8X@
MQX?2:)D/#$WPYMR$.W0JSU*<:+_6G7&10DX%ETF\1.Z&L[1?A)38DG(,F99
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MM% Y5#V[FK/+4$[V(ASO4)=&?%.S(M\P)F;A8Y!H)!W4"/0/:?WDM'OVZ6^
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M?^N79Q RQ1UFJU>B/T5=7T,[TAQ_>5!^E\'F@B=R:=W-=#)M#M@] *'L<4=
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M.EXF4V]R*W=HZ5A0H,3.&E39V%MU<6'HBI,+-  Y3).?IL,.@NB<C 8?*JW
M']3/$WN$XK CXR?+XT.E.G]_Z4'4#<HT(&H*KGCB2&TO'>W-Y964<S)$SM6%
MWQ#7A^*C:=>GH;Z(9$*CSL"!E<@J4S2:=A<HJZ0;=TTJA^057+<2NOIN-:PS
M&*[]Y]8BOOREI%;59X1T'' VK(;]RKV=E=ROP1_)YGSVJOW?=3<DU#HLU;(4
M'%/PM1Q#^CIR=U4G4G+A>+5W?^]._EGY /R)(U<U?%9-5O^",B6.'H 'OC@^
M:D_\(1(9R%WFWF-@F?F 6GQ592P7V]$?1FN,U;L]<'#(DH]NG(U&J5%'F.RU
M!U% &]DP-3[%P(YBV"L,"!$EHDEBYH\/H)Q(*X?WTUM:8"LCW-:,XYVLU;WU
M")L=N0S'[^WMI^;$[12B9I>X*-L?Z@'Y83K?[A"!=6\,VB>A#8R1H"+TRT"Q
M)_&R?Z2VBC @?8="][2>J?&8]P_9U\&_KEUXGD,;/!;V_,/K Q M[<AVH6N$
ML[UZ5PZLH[X0Q%J*YH;)&W@#B#C5LJ?B5Y:[ B4[7?,&Y_6EV<%"P=X#?7=7
M?$W439VO2\9Z,6\QJD-]12S0Y8+<V1B(KNPF], <A9A!PU72]MW3(XB'+*?]
M9O%:V3$H <K!C2F(^1XE/2;D=WO:%]H.2X,KS-5MX>9\>:C<3D-MY4^D;D42
M<JWNV:>R[&&EO%J%PLE6-N*:D<%LB2AD^G,UO%)F5M+*D:Q\=MP[+H+O4Z4)
M/\ (TD1V"H^JYXUX#H3L-J^X+(Z6I!4>YY$N.&-+X^'2ZYL)D5K%)*&7CW+N
M&8@8LIJV<K3>?.3!T5(FNTU(Z1Q17X7PK/&AAF&3\W;Z,ME5B^LZ#JNE5R/X
M9V@/8=T/&%4_Y09'J9+#2F-GOUT&S:7W2X@!X4?1XL?H[E99'E/ ]3/%IJ$^
MZ?%,\)0!M,0HRUF)>:&KNS%MW5H4909^T_[:U=)I<Y+7V2GA;\4KS!*HL6C#
M+?) F^[$J.F57@!^#@_>8N) _&(DZ=X7B+<6I9^(<LE^EKDWVQ"12"V;^%L*
MRC:*$('70TY4>X-S!V)^[KR,IJC+4=,XY,\O3!Q9MM^*BZX1WY=<,LXUE B-
M7VG*7]OUYWI$61P.IOF O).M6N7<K%X_F$^:FU9XG3)=$V!G5&<:UT>4-YW*
MA#P21O%?O*Y9NT&6,WLUF9?4%(W"+VX_6^X>Y\FFY#K9\_"\]EZZX..TY&V?
MHAI4T[@0ZB[[HXK*O_&S&C?HG53JJ>(O]UFMFG7$6F7%I,]=A2H; UU.0;<
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M3A"'",#=]68-G*B7: F3W?<.6?AZ-8!A[T.61 -C$D800-_Z.NO:'3=Y6>J
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MW;5[/ZET#W[I?=J.22Y:4OAKR;</1*SQ2R*&@VY=3]<X9(E^C'(@IQ^3QQG
MPCU( :=W!SH#NL_YAXE">JB=(*YU(9S?&<F.7<F)4+$1QY_P#T\#ET/E/):*
M6@F-Z V^9?2<3Q\$^C4 94$")4IH IB@R*HCIEE,-I_NH,)26VK-ABP@$5N<
M]F^7/G_&LWG[<]R(3O!N+RB#EWK*4PASX4RV%C+HZ2$+>Y0T<_20A1>B"8>)
M0+T)PKY+DA,&&A2<#>6F**2-F&!@4F=1O;C@BJR;6<VSS3DUNF0CDP<_K[/D
M]KOA*=EQV'5WE,O4KG)S1=I$C;CA6NPTM3*,5<9>3]/>24(/YKOVT/)2\#-F
M*^.X96ZI$,K9_3(#[DNJ1!7^'<=I[$S_.,.A?DBOET/[XSL#"SVCP"PW\Z(3
M(LN>-L+H*B/-5_!W-P'/99XXJ*\X!\V.8M4/EF6R^5-6AHJX?F_'/W)V\W^(
M\@""@T+)KW^/<9]NI[J7@/LAI5J&3H%<9(VEYE:$)/;\F_^ZHAX"FY0*\K\G
MYH#D>'*4  I-&:=+=J;'8GP1IU2>AD1TFU8@J]8M*:<.608B.:PG-&>F]_(.
M/GK%FW5T].+NI/FXQ#Z;D<0&SD#?19T_BD!$U R:LUM6IV\\&D.YA3Z/O+I\
MT]IUM5""PFQ8!O$@LX=[>2D_1C)%):+)_M'W[R9-3C&RAB+V5BVJ..>'V3/3
M(/.D;3HOP9B*WKC,L^&S;)6XO_2ZB)(#^ SM9P^@$\#O@'G8;&C!I4%!IO2,
M<LL5 =HKDL4]Q]+$BPVYDR-6)C>66W8FVK9CQU5O4[_Y) QYN/-&;-FEO5OB
MXTM^@)VLMR/)VDW7BMB$O)L.RI?OKZX?G9Z50J0I/FFJ<;?.)?[ZH;=HX*U\
M<AR)8#/ BO>_>M">;ZG#%5=FSA./_=YNYI@?RM[R?JU,X>^0+#MEOI_;,>5J
M_""Z)1N+/HUR.]+ $:7H4Z2+DWLD>,X"YG: )]E_S/S*E+4W[K>(@1KQ%54P
M\W1)H$/ 9L9:J_:.JY-;1&NVW#.]MR&D'EDF>R)E]D/4&0![R')RA;H2@U(I
M ?P'UP\<D+!^PGSGJ=BZ]"C4Y<@*/\EMLPPW;46$^F=;OX0[S]7/M T)W6]B
M@Y"IVQO0*N0(K8;Q' .7,X@HA[<2FGB>T1V(8MOLXKP[<)0SRIRXNG<ETK^2
MR_3B)/.35&+0]S'/L*.\C;\[Z!IRR-+R9^,Q^N#6.JCI7BV<[ \]@^Y_!LP7
MT]T*Q5(E(QV1&6"9I7TVS1NHKGEIW(^BS=@,IEVW8^MS<.+E]9'BO%MIBM(/
M!\<\*N]0U0;[/K<UQCZ:;J@SN]V2NF)Y6_Q-OB=2:EMP'"'P8:YTYPB@31O4
MGS 8UB5]$1M31QG[.>I-USX=:2SD*G$/61O['!(9)WLBWZA /Z-"=RIEQ<R@
M1?X++,#E^V=R$(=HXTE0>):-(S6_3K4[1?X2Z[LN.V)L"5PDJ> @Z)D5=##_
MZ13Y?-&C!MC%L,E>VFP $Y9S\,A^Y_](YUTN=.<P_/[QL#13&MT_A;K]A"Y-
M5>Q;ND1A3=/DL.(%K@[B[7XFDPRY&4X;O]V4J6&+3FY2 6+-MN_8PSI;]577
MW6H%K%]&VR3[6?M99P1H':FBYD_RM+J";:RC9<&-ZV7ZSS/U7_U\5:P?//G@
ME7M&"GGKT^7R9M]E@U.4@_XB#@,>(B$>PT.'^A"+6 $K\^:)[LMOX)62<W!G
MMXR$VIK-&9,,*P7AS%M"+[[KCNCI:2W5/=#HD\J E!:M6[Y-M+0-//J\*I.W
M6)?7<][$W":,)14HA'B*AI2(AE3V\Z]./K.NL#SKVI B6?,VPU2JV=SXC;6Q
M@,S3_\]>1Y+(?_B8![U+:&'Q(2B!^2NU%VM%E$"G1([KMWL;\,MMI!8>\R@R
M.V2!0 &P[ ?H$]BQ0Y;[*OQPS'&47?F2,5D1!EA +M!U<6]YY^@JU+@FN:X.
MW(7>-FLXO^A>L'@4F!7J]W409[26U80W!NW)'S'11D8;-! T)S-LV@A(+Q^R
M</_"L'5'O"VXR-1S=EI[M))(ER55=O<%%X_X?M:TXCFB[\>"WZP[O-U2S&BS
M[G^^.'_\D&649T/^X.S_1&\R\RMZK@YER103W= _9!F&)G6^Z,:X:5BU=PJ%
M;RHW(2>5*\@JY]B<E,!1./!&G"FB3AL_WY4^:& \!O<1[CPO^^QS]=U@Y-U5
M2]W$R>;5H:"4V>D(KRJS@AO::S.YM+,Q$04_1G319="KA2=&4?J?@C$@(#MU
MISO[B?N5M'[2PQ09[_BZ)I.3^(K\3T-EG!)05G?5.%:9:*<AY18'8?T0P]KS
ME@YT/L2'0Y8FV0$>_"XQ.Q[C#Q6X2DR/&0\R_!XV^]T9"!Z,4FP[L\\39^!0
MJ^TYT6QHMOLGVX&OV9KPB1>>&GP,H\&S]Y"RF!ZOI+FH:$F9;LWV((Y!+9L;
M)N_O?21'6[3A:C=)YC="?FUZ"0;-F?A=O''RG)21X5,V5P=JQ9'2+QQI2@CY
MARB^.3M8].V/T4RO)$H]8\&BBBZ]ZV('/%W^>])"8'HI%J$U@$]/:78RZA[W
M09S?G\GI6'!9^F:L-25>1#^'P!91; CGZ+<G0E*O#J-%F2#FYT,6+F61[H!B
MNNUD"WRO /:Q[852E 1PZ09U+"9['_5RP;!Y_]4^?UAKKD6*M!.YO:,U=9;5
M?A2 JF=S_3ROE5"?-$C**\M=OJB04<OV<+A@YETQ^VMG:]>%M3*HMZRU9;9^
MP3XSXQLWV_X52AIHJ.XL-5ZN[X>KUHNIXI3E0/D! TT*\O6GVQ56'%E$]TL"
M3\:#6A09[F5L=QK.#5H7/RTX[]-0H'&@_O;YV>!GW-S<9W0A\>(\#67U\SR[
M2O_O>H$K] PNUN9KN+HM7/%'(,3&# <'*CG/&O-F9SF5/:\),A:5CY *NVTL
M]OIIM&6A[^;;#%+$W6=+9[[GDB(*/).$[\+43;U?S-GHDE/="K[%_J>CQBZ*
MB;8"Y*WH_$VTFB-+-$9--:'[#-#+^;M #$J"^6W*0*MV78)_2GGO<GV2CK[T
MU"H)(0"T#;2.B?K"V#13WSC-NUF)US71KO5V"%6_P\-G/C77=G4UFH?_TJWS
M\2^KLNC-9CSZQLP]9/'E 919Z7R7: ]GZKI5R A\-%9T.ZFF+)>CYP0Q*Z<6
M9=;97(B/ %<\VSH"IH_"*HI=7$T,$)Q936L-B]<^<PPD2]UG7J6,,+GECN[4
MFFX^71." 'S]MX_#_&PY'GM2^8A_4@WTRDTNZ3KF;CN*@G]F>W!4JHM5'QSX
M7TMU^IZKJ@N8TTR/D*$]U M]#!F(M6?4&"#(B/2BLPAP<9[#I(%>]0*2A[@8
M.Y4UD0.N>8,+1U8[^KO$O2B>5M%:OZAYER77[7UJ"N8:ZHB\1'M@EG,P9^F&
MH=Z4]?^ '(K.P-*UVG(@N1\"F3$POI]-TA;<7>M422V=)4T%3,QK7 F(*%NX
MD9<A-A)VL?_/@8H%XL_&[6DM;R'9Q?7% *_ZV9*#= +L&-V8 AKDX8!#M(%0
ML@HGL-[O_*/3#0Z1IA2V5*SC98I//E$W]7\'SQ:RG^14WSKN]M%REGW!X9ZP
MSM47:_I1K,5T1?I::,$1 ! _9#D]R\052G3&#[1!!:#>L(3<;ZEW6[*M87%0
M_F87L7<_IT(Z]A2K\]Y%B=/M<1LR8'\TQ]_)O^E(Y99(U1%>]..B)M9-$<HL
MK0G@H<S38@#3:IGZ95ABE$3;K&8'VWQ$Q<+6XP"7:],>"ND!U;\>E0KENI><
M3*AI$ZS[P!]R#TZPR%T\.UV[PD##*+0_G?^O#Z) *SNKQOPL-G=\=$7$N?7H
MJ[[_,Z$.??'H)+KHZ$?.VR0YEO^=E/R;0#PZ\?]E([\C$;#?P8MU18 #)7??
MM-OR-Q3:E3RPPW*OW7X>U>*7!&_&68YIXES*6ZR^R[RT,"Q,#7=S&-WAB48?
M9_+162B#*]%,'J28*44H[C?/63]WN9Z)/=\?:?@5]YF;EVY/_=C]D8/_N;M!
M::Z(ZOM1-^CN/_OK;?Z*_LM7*[)Z(TYF%AV0W+9JC6*C--%4 XA$ICZ_W*!1
MIJAJJO[MY=:4BR=+A.L2I9[_*Y;_V^XZ_S\4UHND;5; ?]C9OH28+O++624)
MI58]SQ%@_M]L<Q<8=K,W88M'?#&N!!'L$RQB$V5:'%04>!J*A<6"N)AG?VT3
MZV.7CE/06 )7#M>'"90(<5$6Z^SI^M$T(_S]Q*92+><XW29".MWB&PO/-2][
M/>F^U9U/DNF?'$_\OJ2Y?#R%DV$JQ93*L"+Y1<CO/K:\H9_U8^5[4J[;JZS6
M59^RO+40$Y'4-$'D&1)5[<-43?7XF08!2*U-H^GUTE^PN8Y!J1*9_&R%ID9[
MHX0;TOPO\GG?O'@1'9VFSL8J;N*,R.2-FQ=5OO)ERCK_]Q=68.I5:)7>P=_M
ME?4%^CUJ/59E'DJ[S'C3PI-$.+9-]SBP88[#Q*(NF$12=98125K8(#(H3K\B
M24O118]N2UEWG_K>GHK2*V?#K^V:9G"X*(IK3RH^+M.>H;KCF<-S'[U:8TL3
MYC_^$EF^9^^;7U3 <='K;IU9EHW=1Z68.B[';Z6GAD]4N*87K_&TZ]6/8^;C
M/V!:I4<E3@,=!R"461QV$'1F2\O-W!D0J9]SAD8SM> .+_K_.(.9I53#Q?(F
MFK^ITI[-I,EQ-W<14C<N\$E!\\.5'ZD9CQ3_/'YT!$;<N)6MWN'J[:&.M69K
M_EP61H%"87D5XW*FBUWM';W=59O7&*??]OHQ7D$,_4'-X7UC?"1H0I0(,$MD
M393JG=8$G0/$AA]YKN+KLNM_"3V$XRL;U4MY8;]PKOT[<'RTBXM80N)I ;4M
M1.FP[>Z)M(6@P@)#$[.XFHU]\5OY?D9:%[9%!LU4 D OIR'K)>+&_#;_SR6N
MI,*93(\@;Y^FJU'0"<P+R".*V&D2<^0PXC*[[E25A-_SWY0T"T W<$3XUK:*
M\HI7FO#;E./FVC^5*H5]0FU.'X!>8RBN,#R?,R,/O9R#;LY.1:F\<UN5 %.5
MH\OHJI3>:D_YN&W+Z2C)=<$HL<??I&YYV;?AE'\++0IM\Q__?#L5N\O!Y')C
M9- U*-LT$RIZTQ9=?@6:SC1$KKA]W8MT_RE<T87K%0$DB9I=8.VAS>3/+_QZ
M+\;;8'J\/&@OX'>E3O:K_64[ C0<C&XH7 50X=G4></$HAM \5KAC"+-(E[P
M9K4%Z]PRU>U+?)!TV>P@(>'/Q+5)X''?HPN=F7MB;#(C4L_'E?C\_F2]<#YD
M\3]D>0_;R"EE#D ;X_OJY_),9Z%$&1 G79>F7Y]XJN(;'XQZN@+]SE^?5BV0
MD(%H=%E8<T[IQR]\1+5+)NL^O))94S^A*+M27%,D=5[T3YY#FX\/9GDSM'?E
M6XBUL?6+?V_XOZ194=";!0<B]%! FM2C/KGVQX:BDA Z?MS/UJ5F%B(.Q+_Q
MG<V-CPE=EV6QX&_%YYL&A)Y7+M^V[.AJ>MX<W A:.<'D4@0.2(\/6=B84X3&
MUB[#A4X8MO8Q%L:'4@D(?B#E)L3D]9FBZY$V%986,>0EG>F]@LNV"+#=29PN
M<L8D[.5^/Z,$(NL+.L4\1O<!&DB/O]W75(E'<QH@2 PSDD^LW9VO],OO8&>^
M6H[POW0U9W>9[U_YLSMR_H*&KBW] ;JOK)=MUN *-9R&!_X&^='V3RVE$JU.
ME;ZH-CXUGJ!UR,*[[J[<W7QC^MJUN=56P49E-/+]HE12V$?'$:!D)82AZ:VX
MTTN@V!VR6&'JK;9$D^2JI/[/'N'R?S613WD:+=_'E9)R C>K-V[9<^5[\,3>
M+4$F9APSNJN2["P[P.5#Q*3NH6,@TI.H<U19:\I2&6)Y7,#?V8?6FUF,3+HA
MY7;99DISLS&R;FG)_AYR5..)RZCJZ.WKA&/,H:+6BH%#%G[4C:E#%J]T/($X
M]@>+P:?WBXK_;)-H*7,<@V*+DJ/X<3YQ@M2*F!9'3]_[*?TDO<#F.3LP:@C=
M^$G@:\?D!L;&+WJ5=GU39;#@'>:&5$L:W05+&VC-NI;KXKNE'5'-V63,/RY(
MY1OA#UQSXH^/W YG1/$T_74J][!YM5#Y.?\OO_C*R9>VJ85YVKD3%6(1A+*%
M_!3.E.4BRS?4C<=[>X;RTW^O4*&T3>#E@1QS,K<HYB@H5>+WT7$8[T,6T+J]
M(.CT$:C]G\,:7C9N*W?RC#?ED&6P^<[DJM!^[+ZY=,&"X B"UTI4%G]GM[2-
M8?U^JB;4A</0UJ(C[L!R"ORFIZ&G)307O_5E3;H0O[;D!3[_U8JCM,%43+U3
M__WZ57LFIOZE2_%D+7M=4#)JZHCKM=PK>.DP$5B <X84!#Q*8KT <I87^Q\H
M%=RK1/6)1W$0:\.'("HS(=O<@ M6]'I)/3+>?;JNI!&G&0DR:\G8O36%J"N7
ME NH!;_-B"CX=E?S;G$>^R.^#[)?19E')'5Y567>=FC&'G0:O5Q8Q%;W^^0,
M4P-<GQ(E=[7T9G5XG6]V[JBH$':<Y25_7! H 65^:J;DW8=/(+S@K/%M%8Z%
M8HLYG6]^RI:?8#V=RC0F9F04$P #]"Z1MX?&D]J@315TWA)B5'V=NYO?K+LH
M#B*W"*@P^1"BP.RMI=:&-1"/ ;?]KL7$7FR.S!&N'#R[L&AUPB0,;Y?@H$;/
M)OW;$D$_;WSPT/<A=)./"H(U43!)6AP<\X33=!@P'E"R^J"T40ESOP.()')P
M7;7"D7"'+#-H;^V"B@43E8]*W^[,_M8[9#GY[-]\7+K*T3&8.2XAU"HJD5<5
M];70@+*57HOR F)#X?SXOAE$K61/=M\C\-33[SB4&C'1)T!;S.7ZE<I%%]-*
M=\UT*6OL_F_S3$PBQKBMHJB>/!7T,KD[H,(E0GG_SSI":@^6 Z/<A (RLGTP
M0*:BCP-Z')#\@AN "1B8!, CJ?ZDL>FWJ?Y#HCMO[C4WA1UWT^G'VS:T3NPE
M<-[P2'%;4LIN,I>.RIVX966@:JPTRZNDVI^J-/GY\XNKYR/"LDQ=$TJNV>V*
M%#RY+7*?6R&C-<&B0WN^*](T\<B2?.FNH8<LD-\_8/Q1>J@+@"RQ]NH02"A*
M"E DCL<UC[@DCRS"!I<D<2'FCG>:4SX]P&XV#6IN/!$XYW)5\\NWVZFOG\*&
MT71!'R:'&U6%O#* !L*+Z'PP:ZI@6Q4R>D -J3.,X6>*:TWU7J36)W+]:LW[
M .+8WEOU:+<0_&(>,9QD8'M?5.Q7<>[DEY]@->5ZGYWM& S%SV=3CRJJPNE?
MU-RVZ?\&Z3=KW?1^)G2;RS>K4!9X2MKDWF>>J?L-%EY$QNV/8$VKO[G>F-E=
MLV_RLS^^HR%U;N'"J8H\^XS );CBZNS^5'M?9-O(]SV$/Y[QTDV\KM[S!).#
MYZC^/J/RT/F'!YB@(_,^1O=!-%7XD.,?()K4>R_*D2\']<.*@KA+J'EV2?O'
M/$I_A5VV^)E)V;TQ=08S'5I@(^8]?=+:U4*\++-.&5IE!4C-;K"5H/LN0SV+
MCJ/.AN(0O=)^*L%D4$JA['LGKV08E=8Z!A[5WAT_SV=>C@RV\H=RPV]Z)DJU
MX')_2*9OWI2'WN'Y=Y'H(Z_[-7FO:+D^NBZT/M&Y)<D)64+F20N4G*$_KKL@
M7?YLZ?L51 7PV")S+A'7K"C&CYR1JROOW+$;7RU@\P_OPEED[,A8JMPHS]S&
M%!9E;$95__<V22&17>[MD_];WC[1@PH#?'V8LR'F!$Y@!:NODHPR?/>:BY9(
MXM*>M9O<PL\@MP)R'U_^6/YTB8V<YNOV,N2A0J?Z^Y.HL@,OYF24'N,%78C(
MD^#.!YRK1[D \(KU9_.D/29W1YL;@CC[E-@2=P9E7(8,42FH-0[0D.]\QB,S
M;HG;6,GX^=A#ZB2CZ=:"2U_XR9FV6U># X+XG[NZ+%Q_><5 O=)4,E=>H"1#
M_ER206!-76GU<3;^;8(;K_M1;N>3QW6B,F@/T7[R.F@K[->=HF=0<8A@U 24
M1],J"70&Y5&&'.D7W6"3$MH/(?0T=NY,K."TS.6-W.&/RO*T1WH@^\*!;U#Q
M_ZGZSZKS&'&AMI<)T1@VC#?F-,IR&L).EVV<(,[4=YM2==PIV4_V?@74TV$D
MK(<T=A[>6JO@7/;CD&7. ]?<)3S6$EMB]L+H^7]FZ5J,%]! :$Q1R\^GE6VQ
MW,5$4$(O;W>D(DFG'R1\89(>N0SVD$6ZXVY/_KCAOC;Z"M&T-F/=DSIT_&^B
M-O#<&N$?$?&GK:( HR[@S>/-_D6MVOJR7"OI>VVHB&;=QG; 8IYIZ1PMD]_Z
MQB\]%0GD2O\1H!4G68& (\#_R.H?X =+[KI291.UYC_6:-:"S!IBRSJZN[M>
MQR3I3@5AN]/LY<@9)M>@*\/0H0 Q)GO9(0LK-UT"J*"$]T==HA;U6W&C;(!P
MKK+%G]G!!O*4[672>% 0.=7]$VF^^)<#OK8:!O^Z=GJ)+"1H="-WQ[X-]@ZS
M_+ZH665SXBAU:#!ZM.H!::N-'\MH0:05<1@[+FA2ABS$!5:4KB[I=>#(+5/*
M3&F4T4R*M=,\2ONK)[(N1,QF$K\F9+2$S/ICW=GZC&<5PV2+/0IW#/"OS=$D
M(!^PG'X"[X+,)A4E;C8?'+(DPP01(0<ND>&#^ WMSZ)#@V]M93*)%@H^[<G7
M)N[FE"3I2;5W1-3523\?^9/;.O$(HS6!AE%"8GH*6Z?+,,8ENWN(WF3SHO+U
M@NK"KNM1[?L\WR'/LI(44OHQ.>F OABM_(@T&AS!+"ZZ."5Y.-O]5!%Y>*#6
MY$.A?L=$F;\5KU_4*1Q=_MVZ:%9.N9^U0#NN1D5Y\LN\2]8B*7?KBS=NH-=N
M;. A^J:0PRVG*UK34U_GG>>'=EU=%\S/G[W"Z1D\HCG9:'S>M\/GR!+7.$<_
ML!\5FWI L6+X:'& 4A%=X,2RSX;W@1JL2 2E @37FU(.K*C<&=OA;]8A%WN[
MA3""S(M8A012 $=_KT1#W!#.>E>4(R&D>OZ=E-J:=K+FI]7R[6NW(5+[)FZ;
M58\4Y[;&%Q" #I;)!J,DT_P9!4PQYC>(;%/R$+I99;CH^&HON'&V19$EB\")
M$B/ER6V#42K$R_X)'/BU\)G)')1%70YD(@RGG><GV9C*G&4H'.])&)Y-.ZV[
MPA+T]8Z/;*76 $J?8A]-Z2(>LD1#Q)$/!9HIA"<HQ3?(J\;)9Y)/9Q(797"F
MC0X<L3876HPV.L1&FCPKB09N!R;,<0S/MO<D/93:132)^:V(BBRQI((&K-C@
M^BDBNJ?].<8L.;[U&7@7L_!%CPN$K'YYF*H?].H[<U3^2^GWK:PDMMXNP[W6
MH=!J(_FI:EW;I*50!:-7DLUA@0&*S@>ASFN/"W\8"H,&;&8S 5FR2=]V0ETU
MY8 4CQT7^_CY_##12A3Y>(!7P><87ER=^=/+_<HI\I4,?MZ@(EM6O=6^2]%%
MXP3ACYO;,XG7;[U,>4N6:RT3D14QKKA76I ++\^%:^(L9&+9GU<*R%EJ))M6
M&IE9PTMQR<Y'I[5*7#C^%Y+^_]?R/#_J&M/QC411/&D#+/ W^P"%[OOOM\JW
M-I+#1L R!R@NRQUBA:\FUZ52'NY:=U*5F"#$Z7F_V4Z+;-KO;C7?_;=KNU=E
MWH$.(*;WHTMAZW$D6T4F._PH*0A.898+ET",PM\C5G&"4#Z>89[4?=G^R\G^
M! %SHA5@$J!U/<:\KD_ID4RSUN6$+**HH5[&F!3^JMN0F*(9>'Z\KM59MJX@
M%\](D4XH$W"V"5#@5BC/TW/^%+Z(QA95:CK(AY)A[/!=OPD_=P7*4H%,=,"I
MK0XN6DOYW-C;N86/7^?=UBJ#0L6^.2_>2 $'!LX(5T@IW1_ZG]X]L<P%?="&
M]8$XRH)1OH?LUB"GVF+WC:L 5NPN$#<Y>Y-Z#U.U-O/(L.AE!$*S$;:ZCY[G
MKGYG4BZ4Z\)AFJ%7.Y)(-@-W1<S]?91ITZ)_>\7^X1]Y7(&3B\/(F5VS3WYX
M-R'W"D*SPPJ(SD>@I3'>0I298ZT@H4.6^^NP)VB>%@SO$GQ_/&:+*0A,7L:P
MCRS7AE^=;(E4AYX=J?:;'2D&&H?\YY/!+J8O;^<L9X&6I*2=K!;'R8235TM=
M@#B$*-(,RK.T "[+:F=*3N!N='8])((#6K2[!6T7]-+^>V]\^;.9*KM9Z^E<
MPNP^O<?$LD:A7R.YV5M >JRD.<-OO:1I6CQ4(+D2^1+;J8D/;6VH]^VT&VH(
M:=6_*9I5Z>FI7?EHT&AN=<+-BF]I4<V; W&_\;.YW!E3@>M_AIB<N'^-R/P@
MRI2Q.$QX,_Y7>"<MV[]Z85O$JFFUR4UZ8SY>\4?_?/PER1?A;K-+:6^3/DS1
MK8D]HB1%L,N ODQVI&'!4LFIPN(JQ[G%,0\/D2S:OJ)+<L)*QI<OTNINBPJ:
M@A//=O7E/G[I J*7+73,<"T]YD-+YW![D6Z"%HKVO53!='CYFN_*CT@(C;2C
MZ#]X_TDYWNF8U)W"Y6!%_.IE]UD'\_'MR^R*.]E,]NF#,/HU1BS:>YP#%0RH
ME0*@H4=?,-1TXLJ3FQ#YY%M3>ZQ?4?:YH[-_9AI]'[467'*K<;Z/OOMZT;!)
MA'MYSIEQ@8))V^/ANR+0DH8A'FR?=5EMU<F=22Y?._I*2P>/O1+B$6#$"*DO
M.GELG95<E+)HR9;ZSN>:T1A&V)_=QU6F!/&7V=?R;^NK5NAM!CIW+^37[1,R
M*^96.Q:M81D@BCEFGD"*WVP(.K@C.[#- VA@GS/'_[4638'P #<!^WG;ULBK
M_4N@+-]-Q.^AJ1;SZ>S;00&*KJ[.)O[P:9N+/QJ@E8]DD^GRI/#N9*R[+(6&
M42ZZF,0$BSGA6DSO>W-37]=-?OX9UOK<]/R+5Z\OL9K8G) _IMN^#0B8M>A_
M35G>R]PH*\TL4NSL<MFL[IBTAK&B^ZY$J3.G"*<@IQV1P[3K0"1EG60RT 8\
M)8+%;":BI)%)P]A'7&TQ+9?_@G_W7.>H-1^ "+7D[K-<3)(C.*623;TZDF:H
M9,'-WT,YY$@)<8519),K92B69 [C@G=N)VG&S>XM=XHNS%^?S59O_G/ND\0+
M 6+N&2WYR<OP+-5^&],RG\=.A*\"OGI?BGJ$SN!>OLI\.WUM(<*-L>*U'2 4
MW/&VUY51?A1-T*>'+(WH#[!SS",@PH>Z@8"( H%?.(8[*!$XNG'E>G)PD$#W
M+<!OTO Z7CSP>\[-,:[:.4F\?+D2KXS6+RAKE#Y=%UBE8/N+A.C'2(IBVZ>1
M35A1V:3:BO;.QJ0_9N]GFY,- R?G!U2-PPT>*5><BBOV^S,C%%S3FB'D\/G)
MSPYI_[E#%LMYA/_O;X8]LCI6>),"DX*A_9T_K;1(D.VW=W7A)E2?6+J)1U 5
M,GQ@"30;,G(]I',J),#3<EHI(%=NH!$\N)@Y2J,T!YU3K$E+:7C^/>#"ZY!#
M%C% PRYC2%QCD"DT53ZM)#,=\K%&:U-AR\W$O W.&VDVI*O\_?$81##)+FMG
MP31 S$2R^TG),9ELMYDNOQ;]),7L"7K0,N8LP0V>RY/<K5&[IGVY=]ZCU+_3
MO2S"I^69#KZV9JL\E\!M5*3%QVGT6[?$GEH1LV=H-GY]QL#J#5R_]VU7\Z:&
MS?3>NB+#Y.=<LMCEO-=;@5]V^ 2I-\(;ZVV3X#J-"-S^KM'#I"7SUA5K8Y0<
M@6+-,U<'PA_<8B36=;N BX:X=#Y8TXTZ>[N2;[91I/2#%Y/YBC%)/V9XI:FW
M@^/4?6V<P),7 K[YSOD+T4*!V0-W)('6Q*ABBJ'N 9Z4X7Y,TR$+-F]3D+#L
MD$)7)(V(>PZYR\?]EHS(&^R4[NUY!X.G&K9W=K):3Z#T \H2P6#RU OF5'V&
M\]^HSOG9CY]U<S7"8CH(+9DB#]<_Z5XM=-U:^V1<,1M:O,]A'"P(T:*$552[
M^8HBDKO5WOFW6DBZ_VK5W\H.KW8VN-!<&5H^OV0:$3BAT'2CL3_V>,8'%C@"
MY4T$@W\[ME@)(!%6V4;/EE9<DOZXX,#>$YMUNS3S5#O9SM3F7\JM[]NR-CW2
M[H/ \Z<SBWS^B+DA0@/_F%@8W\+]5N1R_C)O/=G"(6YNU9OJW=C3T!FW-;DF
M<RK+W#\O/$/DZSNI_P=U;QX-]1__CTZEA"PA0DR%5+;*FFT^+0@A9%^FDBP3
MDFUDS%2R;R&4M;)E&4MF3-D&8PDA>\8RBY!E,A/&&S/CZOO7/>=W[CF_>\\]
MYY[[Q^N_.>\S[]?K_7HLK_?[^7CJ6>N\YN$^E$".S W19GD?]%[&<JJW_QU8
M_>^T:N4B-O$7@GX=$Q"\G8(05IQ/\F3J "+EG*$6<7;Y67K%[X*33<KWRY:&
M81RIIIP;,1W,AHS$$!"\BV!YZ1K5L_:Y]N<(X^]!RA(9I<XP+^K.Q]3G'A>?
M73I-%^1R_\ %_L E0XX7WT8*L/T\K7//%?:?[&DW?=)@F6E%-%TQJN+8&_?$
M[7HBN".9Z6-[( ]76 >NY02 ]?SX>V<AU9W:;[!(V%%-.CTNB@G)/SJA(7(X
M)DZ#S_4;3JS^V%_U)#DQZH*9,R9R1=[C]/VZUJLKKXVN#=Y.'1S)S_BK2O/=
M/8$09]?J27E3!N,D@V>SJ/H'R3YN1X ,RKLC.7.#!V&7<>_$"BELG],JU\6X
M7+WK="=G/DC-"1ORE0X;'*%_G^6GAT:Q+@16K[@I?J'/1I5XU<&S.D(50ZMA
MG[W'4Z<,*BI=SQKA=))6C#P;<KRNF*ZN.L8]F&E N4%''EHS62.V+O*B$W*%
M0<3/B,\)3DXT5ZV@S 1W-V41PTB;+^/D8?4OP3E?A(DK]O'MP_H6"T2EL) M
M\26AANRC=$U#.;3D/5\KI[>G&!/I?P(2"UH/;.Q;NNGHL(\O)1YEWXT^[Y[F
M*)]F&*]=&'<L12[MVTVOV'A7XO7C5HXY\W:RVY?_Y=;M@=H&9*39!1S]%?!A
M_$/2JUD)]L=*O9,X'<]$Y)D9>)\=ADX;C%>>R]=%B[?;$<6R(MA8WP\N4>;V
M#O$,\I=LQ;?*SV\9$IZ2Z(%0EBA^KKM5CCZQZDH/F7 "4(4L*( *I4)CP6+O
M83F*_:&$B:S0;+V6@_1@EM4>J%#<H0AU NIL@5OR#?9U/X9T'7UIN4A@^@"Z
ME)08(E<@7*2#Z)_ ND:E'>IEE';T'QY?&%\8<38LL*%KO0B6Z'@6G5[D?.TL
M$:AVC5=6=!K?=%#=R!'QIWQQ<R85451.],-'#-I_2>A=6A-QM<#Z_*S8/:8B
MG'BW@OHHW7Q7G9I1'6:NJ#B#((DQ[*S:',44(0/+X]&2D:6F24HZ;E/BB=4:
MQS2%T](" BNW\]%RA>>(N M+8*P62ZR PVO^3Y76I5-$=6;CZ'P4RWB%:((K
M?8O@A<7S+VW9W3,[10<(W1,/UCM&O.KD$H.E-;GC>U?/RF7Z73_,)N_/_45
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M#3Y?:O7TJ^5QZS?E3V?U.'L@U5<S"%YZI5;-LHY%MIY&U91:GT<UW)JZWM[
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MOJ)\15SI[&?L2WV#WXXNESFU>O:[YSB#'#4 3T^9P\6VB,-1=X!2NIH%?MA
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M4-:$TUA5=9D;0;*/N8*[%=0QXDO-]LP^*>RB_R3_7S>;1YSVV4.  G5M<HH
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MIC_#'VE7F6Y(FTQT6%><E+_6;IJ6H8,K^9AC^IMEW&%Y8KU%L;1#[P0A8TQ
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MY2<MB)\:YC)A0<U&,W^?'K//5#O/S64\_U+K5$%CTP5UZXL7'KQ_,W!TL/=
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MH8*_'!NBZ^(5PYH6-NY.^BNK;4Q?A"T9-WQY)?BMK_="4['?);?P,<9-"7J
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M>?V;I6@5L95JFE?H6_64$4\I[( "2I $C"P*3])(IS_!S$VVJ0&A2-G5I*W
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MOJ;KED'QYH7"\VJ3A5#E=.\SW;&"I@W<HA:RVF]Y^:[AKGQ>@,D<R_I70;K
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M/*^DGJKS_LWM7X_+&TK)V'$[_"_SM12+UX-K(=/IG0=>6[+T.VN.7G%0/[B
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M1P6>SP]6^TDVXQ$^:CN#VX4_FU02CG^Z^7"V0R)\_M@EQDM-(X=,U83CP2=
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M1!Q+LL3,>+Q ^+2=K$9L:N!B=2W./+ZCQ920\H&2AG$4FR$H>00S\V_2ET9
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M2QP:HH(X6U,^/=13CEA'U-&*,@-V@B'ODGFS%0B9?>FM"7B5H*49ABD,Y W
MM]S?PG($?:H$TT<1/ZW?6V%J*7_BU ECJ%"IY(6[]I]+XPU=A.*M1>E8KL#*
M_SQ8%)Z%2;'/ G<+T:C!%I7YPE2(Q!(9>]#\[,HP[,O.HZ438R8<+,N*V_Y-
MP<QE;&P VEA?7Y=HG2)Y7P\VC&4K3?!Q0)M8MI0[EA$/F5/\#OG-QZ/XV<^]
MNZ"7KI<>HDKF?)\EJ=8^< X(#WAC>>ZC_O(2:]QAD?FHE$B8_X^U\B'U1?[)
MRZ;?LP(<$&=[#.X5RKE/^Y>%^6%U*?\4HPI'OP2.DMV.8MO/V@O.6T56 $;M
M9(P@O7,+]T4[GFJOUKX]Y&G_L$"XGO\T-=73YLY&L%CXX]30)/R>7RDXU6&N
M &^6]BO5 &UJW7#L0;1G O5&5D5_2W ^"X+V#K<DKR.DVC=@R9?@UH-*8VNK
M@XA*@^N?//_>EO-^5."ZN0OZ_Y^H-GE#19UBF<%\F2%<+>_S>:)QHO+R!=6T
M>T-XX]HL.V]RVDB&A?61Z!X5TWS1Q ]TX-O1^S,'DS1$YOF-9>)12%_9D1O^
MPPG%^G.]_-89@]9_=D$,"ZY -Z_A(0"Q#$6^/FA^B#OXK_B>&MOJNSY2>-E<
MA([[ HX[ Y^!1))F0GCS<*R)B*_#?T(5Y% ]>UWK<2*F/<H_/A J>38:S/T/
M5VO=!9YXW4&A.U(F!><VB0<->@AR$VQ93AK$5X-5/U*'C,3QR72K,.NHC459
MM@A3.+7-'ZE:Z*M_AG(^\+3'>J_H@8^P)OKO)K/F.*W:"L,9AR$;3:T3KVXN
MQKA=D!][L[,X-;\#@EQN&"H^VE_@/YQX.6E+3<9*-WMF(W6[:#TDU*BR^=WC
M,VZ:!AY;]!]7S!4)ISJI<,="@>"'(KJE9YN&7_BH5URM\Y\)A.96V"+/&3I8
M'LD;^K^-+BZO7L'XY+4WBOA 0C]Q&^N7DC>^'I+?DQ0ZN\D^8)FR#-'Q_#-S
MRF0Y@Z*V4]6RT+061]HW#$FT*=A[:!=D>EWLE6T;7Q+%P7',T04!O\NU8Y-G
MHJ_RFYT*.-PA)'1]5#5MATV\QJ,:_?\'1@[M^Z-&5_ KPF.W/7>NJ17/$*52
M #F>K>$YQ5@X^!E7A1-%.(KY!I'-G(V)A?AK)P^BU<CLZUP!.C;I>/RDM^S5
MMT4WIOR]M0>#_3PH=H01\K5T38]O:W.W#:F_CL2!35!X9AG/"K+^IRZK7]7X
M_'E.H[D>:A^SD9.)]8,IC*/UD/&R?*16M3G\2PP857XMV,Z:1]$&Q>[^0^FI
MX>X'<DC+8@%-X=.F(2[XC!>V/EP11897)@D9BZ-?T8[?V8K&!\V!>>%+76#V
M?++4U&\/2V9-N&\>$+A(RB*\'V,^N?:-+(WTO_N@OK[_>]Q/N4L)S^%?( '$
M"6TG7L/FT$&<5YB]W![8(?/3EG2].:.N5KUY<!<QB7B8+5B"4B-EF>&CGX3*
M7GVW34"O/QY;L)"':2WDEU+\7:H]K'T/,/.D7B5.UF:-^O?=I;?1[N$#N;#D
MA/BRZ8#-^5-==4:VMT9N-"I7'+7+-0P(K]U*'O> 8R?7XWBZX@;^(3B[V F3
M08L#,8P/7H+4Y&?LH#E<3!;E!302?2NT%!)GZJQ0VQ3F_[S7*M?,R;XN:6VZ
M+L*E[V?UT(MJ3J4?^^LVBT):G\QF(H"\>=R$TQPYL@4>CJ42QY6?,;YU886
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M#NE!V1>K0AFJA@_\48EM9<!C)14:_()[XV7U-4//[M;DDCF,7"GN>D>C2XZ
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MUSI=I.3<]L=^;&AZPTY("KIO>!J>==0KX'.T= [[<%'CT%7[LQ.3'BP-SJA
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M==F&Y<>/FMFI2][Z81Y:S%.?A[PI)]48Y#D-.L+"=6R4(2 O/D(FQL#M[L?
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M 19X-Q3Z[30HI>R^MXM2N%7<UX.Q_P502P,$%     @ Q:KU7(#ZWF:?=0(
M+9," !H   !N>3(P,#<W.3$U>#%?9W)A<&AI8S R+FIP9^RX!U337]<N&'J7
MWI$B3>F]25&1+H0BO4DG]"H]493>% 24*B!->D<ZA")=>H<D"$I/1#"2$";_
M]YWO?M^L==>:N7-GUJR[UFS6238[^YS\GG/VV?O9N5F]@0'H]+7UM $$! 2
M ?P?X.8$H&#LZ1_B'^SI'\ K*R$%4'JD9TAT0FGJ%NSO$QH"\O<#X(7N'U\
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M^ 98 FP 8( ]P!$ ";@$8/ !249 0\!(P$[ 0R!(($H@0Z!$H$Z@1?"$P)3
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M(B8A)2.GH*3".[31 0@)B(@(B8E(2(CQ/)8@!O\Y@)B>A(%/^B$IHXD3V9U
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M7I6?M$_F^\J>=&7::*>ISFOZ.(0^MH^UMJNIU5\58'+,Y8J,UC&!>4&Y&ZW
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M?N,#>/L&T/SCA/$&0(SK1 .180BMA R<8+1M,=PB']Y/&.ZGN-AC[A%3BNZ
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MZ@NU]IBH&=1SYC=0R_8!DQ$E%"][(D0090)[1K]TKWNN"_ID/8M;A0=YXF\
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MX(\YM1\2;>"I?[N059F"YBY'\1.U1K7K!EN\7K;&"Z..(3^(V&)K?^V(#6U
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M%UUX_H>2G^*U5W**RE=TAA)LT!Y3E=C=P!W5L%X2^8(WV(4M"" "YTP^[CS
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M6 J6]7@+Q&W_O(*6^1!U9$+/;XC<%^1[*>X0<E11FT=M%TN;>@\^AB%UX(Y
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MN-3%^Q^$3]FFW]%I'"]1AB!BY4/TM-W=\P?P17X.X6&],T1\Z\Q$\J>G;",
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M!7[&1>,PDOO;KK0A<"MMD2\-$\S22(3KI4M16MHE"=-;\F4'5AJ7);]N\&8
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M>FY@GO?<](IC*-]52:K(>T1?SI5F#[L.2D[@0>T%X+8P:3B0!\Z#7([TX)\
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M#LB[Z:_B(?>Q_)N!UG=V^6V0PT(KVRC4DSQU < :TT=>"A.\7Q#*"J?VM%/
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MY^OJ#/.E]J)BFN+/_ @ZM/U >I*BF-S-$(',:Q*.]])W@S\$HZZ[^.;<8 ,
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MS$. &#&40-#=I]0L4+]&SGM&ZAY?NRJ#?OG<YR>[)^-(QC?%B^#%]49+A!<
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M9:@C=>'49TD>$W8PLYM?S;5)0'\VVRU\9E:"#5EYICG%/R_,V;L4?-O-*J%
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M0;@C^"MG)TUS-@1:UQZ<U]39)1/H_JA$?1&)FE.@[?*T/7MS>U*1-"(NCIM
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M(7W=CYL:]Q]E&?G[#A.,L;7+R'C'/!X6/%D[2CA\71X:='Q Y9K5U)_0;"?
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MT/$0[W1B J!&M.#GE\EA7+/RF@4*W HXB6+GB@C$_6A-]C=QL3F[**<WB=D
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M1HE_F^5=R;J_^&!A'EOOGY.,D^!-X]98@NJS1N3R9V;/(<!:)8=- Z"?6U]
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M F0V#;?@<@G:"HT[]RXM_*D=92;H&5$QM+:X\:H9.^ W'&Z7WDB)<1Z/$^.
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M6SD!N@YNB>$65>Q06&H@/'ME@$.CA:6>FQDU<:\IJZ_'Q.E9ET>0L$G5X^H
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MX]Z!^8S6F.K/'>.!WL+_! M&36N_O5WBCK_?^D(/698X*Q@;62[^J&: <5Z
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MB=Y2^7Y^L*.'8\;3!UY*,KQQ9A:":="?9F@M0:2;H?*UR9.FF5'A%4EA>K<
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M2SDJAW*![)[))(&4R?#+9,V)0_"<&;&*E+A:0^W.3KF'IXZF",",4828&.G
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M3V )N4AF;50<C4S $'>KE+U@4_3VR'5<\\5@5:G53!%K/L439VA$O>B-=Z(
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MP"N#Z 3_(4?_&:=ZE*0^.X4FLM*NY%/=6;Q"U2"'TGP)ONK6I\410?J1GQ&
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M]*IQ\FAU@"S?M_ZWRV5FX%G_^D?) _Z<'EED@1L&K>*TY&B:7IRN-B1=FH
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MD]H&'B(72"TZ.IEGSMLMVR3E9T<]MJX\U&<A\?"G:V;R_&+)2@+;G*.R6V(
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M_[=.QH(=3*<,M*%/<YXM,,#=, $VM'H<%<5R"H#5$6<T&9J=TSHKG<=BH4<
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MN330ROD:I7XL;4 4GJZ-?\&TMSC5<KS:7S! OYX8JVP?/T7V3P/.0E>]6&#
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M#%SLO;H6<[.&#]&JCD-JSLZ,P\<SX9%7_W;BZ:0/(]G3]:HY%TU5P4OFS"H
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M],Y+36B/XZ6E?MM#\Z50E/,$5X8A=G _91FQ)T/(18_OQ'S<X2(^/LG6S]I
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M\3'[QM VP^L(<450\DUF],*W@NP+:T'E"X_D&F]C--B76;!E"?W84ARX;4,
M[D )B-0@R"9FM,LV2@M5>U4J$;<,(SZZ_*A)I3@E^J%=;J8,-$)*/;48?>FU
M+1]'%6MM=+Y+56EH*Z>HGSKJ?3!]/;$C.>^J%^2<E]BMH'1Q\@F2(7JX:1>4
M9!A0CI($A*F"8"ED<W>#!%DP;*&:WE+:4B%%##B[U%3L*3J4V[5NP7:LH!C
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MO*U])FBFF'1T1F2<.<41CV;E I'330*T'5",D0B0!#D,/&K] 9SM@PCW,G9
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M0H\MZFW%UZ(/41#A>EM.I('AUFXZVLIQ>'\4Y)1L$5X&2&.JL,B ,=]#39\
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MR%T?D_V[]_*WBQ<_^]FWD!@PC3'(%]XQ[MO&$_D<R  &J\:V"R[< 74BC@5
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M!AY5G4E9GS.+MT%[3'ZS^DD-=>4!_1F%Q,D)<"'J[WT^'C+YSA#5@E#;%W=
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M=P R8__(-+$GAX=Y)YN9 91-8PYX$\ ,9YIU-^PX/-:%X8@NL& ]K/F)E '
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MO<?IGSD5S3(,.4IE._C4$AF$8_N&5<++J.HO*A$PHB$X6!N=8 ??;Y$JF%!
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MI2_0DVQ7HT,>N&? 3L*]Q1[E#MM'.EJ)[!V:!7A!]^E!E!"4[H0&9/$ID(/
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MW)9FX&.!.>*%/V%H+MN^3[&)@'!^E)[ZY> P->21PRVM&A_=,=G+?#E?]@6
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M1"Y8?61 -&B:*P@<9+FP!7]RY=BR@&890O$+X$4=$H+7=TOS,\CQ?[::4**
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MKF@W[QQ+E_U*F,#7@"G)!VMKR.]W0?^8L$_5=^>>;@&"6$^YA.-D;Z16(S!
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MDW:$E0KL7A\I+$^)^Y<(]R",Y[_KV]KQYVT\2]@*/5M1Y,>'X8_P0V3N,5/
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ML7_Q-0[0DI& RB-C *  @2"0&P7\A^O<D]PH 2DC[:L5D;Y$X#IX(R(U_,M
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M'[NQ=7AT<8:^##0J>D^M7Z ;G"^J14G)VL>19F^9_@=25/*65=N\!O\8%'G
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M8H83S-90H:] TRM:#!E=()QPP!'7@(-_/TF*XX^MX] G8"DBM36*^RI0E.]
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M!/M;W90L1C]8J#PHOQ!CM;@BUVF]OV'RPW%*$^9E/#\YG)E1._.Q3ZZQ;I#
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M4<CP.6%W+2STP8U96V7*P!#!_'+[F0,ANL:I(_S-*(&B:QJ*&AY9'C?D <S
M+%>>E(D&0\J7X:GCQC5W27GMP@'X\TUF RTM3J?>--^JILIA=$"L1-.?4=W[
M/?4U'/';G7(=00X5RIT%BIY91""'"%#[/'B/+EL0OG<0ZCM4.'_@&K)$>EWK
M0.X]QWG0WN-_*B_8]W#8JC07YA4YE5]R.G+N8+^@1 2.H+O;A(XX?OC/1O;F
MQ[:% 9W6@96F(\;4[^LNWU#B>A\B>"%;\KB\-F6PSH5E2N:\9$;T0:>G,JQ
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MH'ZVAX7C'N=^]&6YSO?*^W@A:2)@;GO@CB?5^<B/^0R==,>3#P$,5V-#V(G
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M,CV3B4%YDP0A# 25V 1-#(EJF0-?D#W07$A\FZW+L=J!69KS!ZI(<4?,NBC
MNY3*[0#Z0V.7<P<?G*RH]GJQGS"$[L%4K3Q!\X"N=($?&RL<3[7!T&V9E7KN
M.W!DK]D)C0\">!)4N(F:/BPH #YP6OQ<4?M+G0$;&GL\E)!YRV@RK7;MX4NU
M&"SE! D W3%C; A)Z'[(ZA(;4F'1D?@<(:*G64!NV5$S[&=)>T*/JFW ^?U%
M(RD;RG3:'PQ]C^O1#_<H7H&$/B_9*WVK&1M'5O"C59WW*U96UV'.6.8[A2O6
M,7,/HQ@-?N7QVN>*L^M2,\8F)ND33+<=3IYMTD()YJ#'$2)X=\QHW;1\A*\>
M+[6O)3VQ5>V%!#Z!#,;>1^\!N5H:#U-]BDN\\(<K*?"O]#)DY08_HO5'1XX]
MXWP9[5Z1OT%QGL?)-M^\FT6M4QS,Z8>Z.,QPIP*F5%@;(L+E'.A*PS;#CM;[
MOV<\KD9(S\OP<FKFJ$:N>8?$%P;JL%@-Z%'PK"$8F[.(YNY_3/OHM"#;5"U:
M6UF5DV<0D\:&^+PP'J[&4*VA3T-@%'\:E/Z>*AH%W&=#>'^A"6S(W@W\<T0%
M?U44.7$_Z-4.Y?/1#.,FQ<=C8O#N.-'[A/H1AZH79+6HH[73</+@0'N>:Y!?
M+AN2'8SQ-,C<.<KZ<8XHPH8\$#SH)0,%"3N.Z %1#.]NM\<8UHKP&#;FV-9X
M:*C>FYPH@JPCI1:1,F%-"$@]UZ<EA!!*.I3L?&^2_FLQ72LFEZ::1E:&*^\4
MU*L_K,HQJW$9R";TH9V/U*X.!?O.>DOHN#DJY%'DHZ^;:F95C,?ZIO34:5>'
M>HE[Y'>T'450K\7#VUPTF$D,<6HW/0N4I9T$QJ$LH0*6N%>(2SS-MV7L7 H6
M96#FR1]TG8::/ ,"I+KB8\;%\UIC1\:,/?37K;.)?7M#'#M"Y9,31WE)PBYG
M:*+/ ]3&\72_%WH&&LH7R?S*S?@*XYC'\>Y.@R4;H2J^IOU1D8V'%ZLW;1L/
M8> 1E7V'NSU\29W% 6%*:\:#E<J.'TXSKX)]M'^)=!^P9H>7-0H3>X ^@Y1@
M0R[4@YU3=YEQ*&^.SL,1@O7NU):O@5E'\9\)>MY3:GM1RM3J9M_]]PT.T( 8
MO8"0:AC'N 48)XH6MQN3BQ<1'D/C/!@,&U):37E%79D2;09B\0*,BP&T.E)B
M;'TP38BT$E_1%X\O#QB)J,#%!,D<H=IDU0@447VOT[BC?36ZB7R@=6NR)Q5A
M5((,7-VHF##O/-%([8A6\3ZE$HVU;%"EN*%M-RMQWN.$U3 C:\&T_N+E.4DC
MLK#/HNEDIQ56>:+23:=&N3J@''XC!!&!G\IP^8<:% [XQHO2$T 2R2(2+X)W
MX\#6Y[7H\(_C"W@1/?C4_&,B%)ESY=EXAV@_4OYK+67N1;W.=)B0?15!3\W=
MS>UHN0?RWN!&IFK[-S-_%Q,JCG40-XU_48MHXJC+GW&2BFB%C9UIL1T&W($(
M Y4J,+I1 2SXX.!96_+BO2>E:-[EX! #.L6+D%JL/9GG1MH+QN/ >RO6R+WE
MAL)GVO0:MVB"+![>'3V&#[BU\]B+#1&N%Z$U=D]54^*GB,^VG;0,)(;J%0M1
M-ZF^+]!\\D]+*I;&6X?_O*?V17MOQ!+Y%NFBFP/.#I-O5"F:&N6O9M('2N:A
M5*L>;D?0>,< J=P*Y>C6A_ADC+B\-L4-V@B\W3G#,.I?1^QC6%!3XS]YCD4]
M"VAPX"4*(6\@>3ML'7SR/#X@$^U+?]1[N16TY(Q/CHV.ZF'<(G9,,ZT=]65G
MZTJ(^1]T@^TJ9RQ->8Z4TP?*7]_-*GOD+#U=Z'V_9$3Q-U"6N+P/(#M;T/U!
M#"V-S(9\Y0ABUZ:6<*Y1%/2@XJ>5D5G3K5 Q63!X.E[0E-90V5 505(31GI=
M[#\Q+ ,<N!@ZG6EL2*@,<[M;&N.KF&JW*C@N.<7LB(9-<1R]PO=K8KC,8<*G
M/YJ8L3FR?(M@9-8^*B6S)#[7P:P =:V!.A*YK@(UKSY\<R$DK.K!K5&)-B\W
M=^%-5=G(DUR3C9*L,7RY03FU@WZ3$VT\$J/8$.EZ1YH\78>&?5&)CQH!!/3L
MIBCG#<$"$G"$<=$BIO\^_D@E1FBA6F(D2K-8OKTG..BC5Q:4H-F=>'CLN[=,
MF*YCZN#M+4([K'+0D,4C3T:,QWZ5D:IWU(%YAMG1(ZD=$7KF=/KF@ >!<0'3
M;CL)'<XG$&TKG\W^:2>;*<W.=E.@[J]2'[^@^^1DY:S4CJ0TCBQX2U=5X<R^
MTP0/2FD<-VDB9/V;IG=CJW!54T2SYU-*YE!JNNH"'K^.^)E,PC>I_2QB\?@7
M+&*. NZP,5$RHD5%;<KB^0F+J%HTO@A9-P4D4!JUFG*09;PJ\';602JCK*7(
MD!,F(V=I6D]6*J4EK=-,ZP?&F,^:UU#*?CO\"[5IS0@9E#V5FZ)/=22[89OU
M>9M<E,%J#C@3 $.G93 %2-EF&76::M343G&@-)Q3>:/T27VBQB2+PV"L22GM
M*&:*Z6X_Y'KFK<;.>?#AW$*B.&N46!H818VB$ZF^7]F0"(XNQ6CNE)P"4+[-
M(8_8Q@]\/0NZ?AU!2X(UHJW=."X/NH'DP8(E![EGFTY/D'CK&HE*PL4/8_BH
MXCWU]8CK((>9?0;@69KL%)ZB,P7E4Z-HYC?1=J;F6OJB&O>!T +/R?T$_#W\
MZ.Q:$UH>]"<K+UGL1;H:UL1,.U0.YE$3/J;**'ZATE^0^<\-LQR]QJ5]YFQK
M\82$D$RA\2W'NJW-_NV&2MW"^K)/Q["=.Y_T:G24-,8?->+,[Q5+RU2E3BY5
M]Q K@Y8==\XQ%,%,JO)7%H19Q-B3;X\R E6HKNVLT_4T;$2CCB8N4IZ&:0[U
M%5N$'G(;1) >]020$D47&XUPSU'2[YL*D!U7=&=2(JNS[4W5LM0LF4ELR&VF
M6A-0%<40FG8:0KE2,?1$)B>\WL?%RLA2Z6^+%QIE:'=EQ <U??>,>1YU4:,&
MQ>L)T>R:&\5H(G'#@H5@D,W% C!HY\QV%QMB@2^KJ7$F*2!#Z7^8J0\,SJ"[
M\!4G<=1Q\FP>391D\97(S> &7WWHAK8TP)O'E)"\4[TX*JZ9#1$U.-Q3-(:8
M<$)=[-=4)^$EYNGHDP2-=_SGKP],#O [NYU>/+A  )JN-PJ-HRXRGU3V&%YG
M%C1J7MR11=WE^+]DQ^1Y<)JLQNL%/80^OL R^,'0PC;E(V^K:/9<Z6YV\'E[
M+O%A%?IHFG,=X=,QQV!*97>!G*.8D6YBZ()OV4H]JM(6'SA._!!W.T5GZ)&G
M7J7BCERACK-&A<>$QL1@1854D%TY&$O>7)8%IJ"1M<1V8#\J#.2EO6MJ/ +F
M?4 I@@WRS1/6;4$'J5YMC:JI&^O'R>?CO9IU]Z4VD!SKBLP0%F4T]Z?&T17G
ML?U_XO.&OHVFR^@RHWPT$I]OK[1;/.<8*7>SQ1A7<^-A\!UUAV07E]RD:]<&
MY75!!K4B1,P+!)^LW(8)U^^;0FH2!;R":L\5W:D=?KY)=31S/5YS-0<I8^$-
MC O1;4 X-0<!WM[10_T+EI-5N,DKE#U4_VE$>QC7]$JTWHD"#W40/C5;!Y#-
MA*8Z(GWT-+%P?[+^69NA#7LVI!KE2E;6_Y>^8U;V3/['OUGD ,"-^1$_E4O<
MS])B"(%SU,@^.^8G/;M\Q@-PDYI(;G^;S3 >UMN7#\I.^3XQ@"ZQ3C;6@&94
MH)DE_F5PO4% V5N^]=&8QQA#PBT^*X>92.KF9)\#/SF54F<8,M0T=90RK(5
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MJLZ8[DB>'WCZ%"%'8\P0I25ZOF A@34K_5=$"Z+:'),3#40RBZ4BC#A$E?L
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M;,'/O.^TP-]<Y'VW)N7&#CR+$4\]F)X$PB.J@W2&7A +V84@W/\I:L82KC]
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M>D\]>6S/!A13RM*6S;.W!"_HI.!]SNT>ST?Y%_[Y^XXAO/2#+GZO#^7&^T<
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MFEFJ"]IU2!)^T'=7\SAO+Z^#*SHK86K-6=7F6DPK_X>:TZ>#^$@8YG[XYMU
M'E+8XT NTM+4:LVY>%*#D -IR3"QR6;O8*#YI "'OHNU.[&)5S2R GEPS+>M
MN3%Q/?:[3IZO$=Y&?^\:WVB*7@J/<_(-.ZHWR&K5I7$:+8YW\+:HHFFJJ'2X
M87PJVO4%9=@E*)N$9N[GV;Q)Y^M75<J@GIBR2;GG/($_X1O6+LC>,,B$!2J2
MM9ZKLD_!3BP<**#6S'Y*%R$CGGIU.35ZCXMA7MS#>>(YQF[,T]ZDSXU9?4#(
MUWV7?L:"/("-0)N8>ZGU)+P!.?YI^@'J[)2U4QMPV-/:JDGP "XSKDU0J'Q
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MD8K[E<9U#&UA.7BFP34;\X5MS<::!;ET TD_!EU>IF^6D8K 3E:S("3=V^"
MP?;_4AU1^M6X?W$/H*LBC[ @6^PK;[LY/5OI%GV9DD?K C8VX1@L/?$[_.=7
M<$8>8I2WQKLP.PGJ0^-'D(M>;?B0<<7 645J.YG;=@6G@@6'C*>*(%Q#TI5A
MB C4$6"K4D^<\\M:GNF#]@+ +JTA)W!ZAADL".[>.MN:G35F8&NFP6CZ=/!Q
M%%5!@<EN' ),ZE)G%>$RU"_D$]%769!3W8-0^M5,L,.%2R1DVR(%;.]$=*<-
MUV:&W6<AU^M:XQ3NU3QQAAW&L@P$@PGV&3_@VG$>X#NO:Y7O1K!Z%5T63G))
MI!\M>X796^?B]BWP#C6RG6FN8HQC'@(Y&V)Z)(%Z@9!* YH(U/ =@F%,4;_9
M^N 9([]:]UJ/I52O7962T.([P"P#06>/WE0XIW?S.&^G_GWLLN5F@S8=%.7G
M'F"S\<[KZ@=]!V5P<)X&H8,TKZ%NQXN@?^H)3,1GPLEV@:Z-;<"D>Z"&$#;"
MZ0[&7;7'%<>"%&LC3T9XK6\] ?$MTB\J'!C5TT$;8/(2D D.S-90RP7&4]4:
M=ZM<E]%O]*T5TE[PB7A0K>M<_Z76XO I 015Q(=Q!,4'3$YOBUD!XW,>_7?]
M%@PGT,^$+X =!$AZ%MXWAMZH7G#$KT#UO9>@TM1@S+-B%F3O3Z!1LE&(R=D>
MZ0M?M0@^S8)8/P0D$-0P>R8[$C0$MFT8JM\6>7D-\_#FS)O-9&<$3@:Y>L0<
M-*-W61"[>RS(ZIYGH&#(T3&U,PP+*Q(#,S&&IHKXPI8U QUPF#;D<SSV9AZ4
MSE<+3N2'+^V-*%Y;9B>L!6!:XWY=.-3,TZZ4UW'K6'HZGN'?E',!]O6[&]='
MSXK<:32N&OA;_32K\L#$[\&"0(L*AJ0GR(+LH=L%8[@;A,#.;9DN'R:[_9;I
M:D-MF2Z0^ OS4*P(*)?!K')9@;V]S4A*E-X(:08FWGA6)<90 5"U?H$5GZVE
M<Y/?K<&Y?Q=*1Y%<\/2C+;/,LYB(=BP!U@(BZ<>>%2IN<5'-ZG[;A6Y_%H22
MQ^QM8T%Z35WIAT(Z9:>7*&?/H59_"$C-3 >?!,79B<E^+PH4"IPZ?KM::_<4
ML+5%H/'LEB)3P?F!GFA!;BDR-&EQ:S%5WHH:!LFLL#\;?&NT4J*^K@ NI#WS
MT;FB\38XX3:G9AAXD758&)[,@:,?[0&M821 (@=J@"J]"*KTQRW&@BHM3T!L
M 2*P$8"LMK&O CV=H;<Y[AX#L]E7VW_H/3#UP:_7%V\0UVG0307)W^BS+RQQ
M/3"&&K#%"[!WF+E(7^PVRB!_8\__AXA;W.!6S$DX$#&;W+.)D*EOJ+"A.2S"
M$NDPO0WHY@4IT!$R;!I%;+A!)8-0PL&GP-E"D?2D:4(V<MO(#UJQQ/)_(E9L
M^M3YP[#T^^-JT'FF'.!@!U_E>@[.3W0G$SJ^>>"_=CGTK^G;YNCO_H$BU??/
M9-SB['\P^AXC$XQ0>LW N=F+D88O+%6&K;F8_P;1(U#I7QM"9"CSU-A6FA(+
MTL=#SF4*PL'.T&LS_Y&*'J6H/'.+<M,S6KG6Y?JR1=(G7QJLE9F0'3]38[4K
M=-[U>W,'WOX+#-2K0Z"Y"[$,<2/9MU4OLB G7FYI\[EY4)N7J")5H#;S@E9C
M\D]U;LW(W327!0?^78MY,'%C S"_S4A, 'O.L>4.8)>92[%P#LP_%?WOZDM<
M*P%UZG(UBLXGO0(:B_>@L03FV+:,I<,&X -V$4GF6*<?'?TM9:1MPS%HC]S"
M?M"0Z!56ITDQ3] UL3P?=E?"3P0ZU<MRZ!X8[:0^GG,G\Q]6VG62"?IG:R6V
M?VN$%K9F!JK@)<4M"R4M+0PHI9\!$?(.B$WIR5^=&:%3B!&^)H-AOG(0Z?SW
MYAP+V0M4U4$+51X%WZ[14#SE ]FK?I4*VOV]6=2=-W[9474VK:A8G6H[[PHL
M4SA0O4]^\_KC&UG&CNE\@W05V5?^W<F>8<PT)!?#!_L0#_*[7>/FA0<="I7G
M,H?6\XTRG>YE(ESFYX?:C+ZXYX]0E1W'3G%Q80/D?9:!6'@/?@H/=AO$EYVD
MLS[F>(ZZJR0]@G[$Y>EGV,MDL]Q)Q&$$MZ*)ODJ;I69DUHOG)R<#M1Z&-E@3
MHX#3#2K,)F2E],^OZU!R^YHG-9/$@NA7Q6JGM/ F/I.6ESZ@?0=2]\JW\+*S
M5G,/NQ'/7>7'UV!UK58P$*9-<R/M+&[''[V1_>)=K#BGG+O&Z1AAH\RP*.WI
MW87Y!B;QPD^LRWU1Y[/E%C0CYH?%Q=O3:JUN_!Q(UK\X.M90J2CQL,1:7MI>
M@IQ>HK[IH)YH@+,>["$/'%3<>+)3>[?MC]NI!1/+W_FC,AUZ/CS;'<$?<B&F
M-XA#B0[0!IGI\/)V^A$"DYVR:7(FVX^ ?A0L0(I^60%7PD^Q-9D@P@3/12T\
M**U-UN<0Z9/W&^Y).8];M;8\\&+OQFV[.UHK5ILV0.-[/%_@?GDD5_!G)*<<
M)F+DX"'Y%AA4_;1:]!/UDQH[WYT>19!EBP0/XF:[_4!;\-3)#7(ZB:\3_;:)
M?,;Z1:PI)RF>5V\]RB-;W('S[3L>"1^=B],#QC]<S)Q1*I&3J9T'3BBK]QS;
MXR/"Q26_IW#FI</'481/$O[NZ /FC3GT-6HM"3DU^PG.;>/+1D T ]R!,N30
MB ]:ZD\(4D?7-6K=>"3L2IW>).!-*@+W1K$@>LGK!C'[[M;=N8(ZSZ&.0JT*
M5OQJ*E:.F<V5-X(Z7!U'AO:DQ$VGYG?I'GM9%C&IJ++AH2&Z[ S->/R9;2B\
M]_9?*4__];@\;4O;13M\F798*R\C'+(&#./6'E/C-L\&VI/8VA%/_;_33D2I
MPXB5M+84Y40G-5W<F4/(9EH=>]>/EU,"YYR*A<Q*^6Q^M"W<WM7L_DH?1O,+
M;@(J%9JC1PO7O$F(]N@P;.N#D?J,^?&+I$P$?PWJ<:!;[N@G58W)($,AH?OE
MU4DNY86+A<=S,[Y_0PJ[E2]R C/ZR$* I(VFBK,]AT^D ^7Z.84E-C8+,(BZ
MZ/?Y=#YJW^2;R*_SMCGL7Y5=6PZ=[N"! $=]SUJ/&Q25?J9%O? KO,^\%OO=
MXHTZ\H7[O:3;! GVL];G'"Y+:GK=YOP8EUK,=UEX4;PP-\/Y!DU=H M31I:(
M=!AEM](1]=GOQ6>6'&'L$W QOG8>=-&O2;U<:A2*1AO0HUX/7:]N\^M!-I76
MB4Q%0ZFSS<K0B$#)8@?F25)[N%R*%- \LA;O(? CJ6B.5ER#=*!%AK9<,])S
MJO4C),ARG' S_&ARP5EGE#Q;$6RM.-8AP?\!$=_V16X07?*BF&+0X]F#/7:S
M-!YK(#[FY#D4/;L>TZ>[5UNPXN2UPQZ]LULKV%\[J#@)U@^-^+$@EALODZ71
M$RS(Y^C=7KN#.>.=,W;?DB$R\.A-4_:7NR/'U# T"DJX-EB2WNG=$,4,.&(2
M]9:##0#\_9NK[;V5VA',>NV^G>>Y*<PE'*/ 4;:FIG]A<V<%*DAJ?<$,40>'
M33LZFH;M%L!3EZHV!T43X'7 4@P+TFK\VGK5\D;U%Y%"XNRT44:1'PPT"@0,
M(UY0:Q.@+K$@]\QBK80;;%"XDH:/\7.%_R)K]R[RC*6[;2_]/[,9-)X>C.D?
M^/;4_1+E=-8W-<0\DW-W(YL:AS] F:<4V=[=B,57Q:[8N<<OVM'P7M_L6M?A
MLZ.<;9^$;P4WH"R3WQ@+IU+60'=TT+T=C/-K?S'7SI_&&&)[TUD0HR#Q4,ZC
M,KWI/W)-1],]DJ\D"<_F]X #EBO..*936Y[RBW+WTHY/&5G+H'\/D@61F*TU
M[F_WS>]_,@ H)_Y.&Z"$/>S^Z1&%8O@[*+SO_]&/8]9]-MRK/=^^0419ND5J
MWKA;M2&@'B^=^'Y6Z;-0CII:%Q?8[9)XIG7+8+F# U9_W]:+<4?.A6#4@.E(
M]':E%+>*7V-%V)'UTPZU%LC@PL_/(R($5\>VLP:,CH1H98L\R,AVELZ=Q%#6
MO2X,.HS.,AY<R11^DAY_BMN([1VS?&'[H5>!W(CC FUA=10!/\4U7[R.V%@R
M_BO+(5H:OPJR9>A[H96D]0U]:_GO&=>/>KP">BJ43ANGSE8!Q3<OSI!\=K0I
M!Z#\54/2;O!O^@>KKTZRYTL2#_A9#F'U\ & N:R;(R/1>K^[9L'3B&E;3/[.
MPL$U_8FWBE_:W.8\L*2\KGQ(&B':EBG?=[?23.:UE;^4U'3MZXYGQ)&W,A&H
MU^F(XINQ:H_X9]6_,7,>)4%F\[;8[Z2KVA]T%F-B1^@K#K^M/9>[+)=U9. (
MI?#LQ51[5;O,>V-1;N%SAH[C*Q_F&;+\IFD)]7#H,K/D4@?W87_8G(?AAOC2
MQB#J]P#[?J^K'V>7^Q6'JWK7H]A!-$BWN7=HFY?ZR]=I3*\'39>^W-XP^>-6
MS#PHD])$FJ:^IQ-%0E4\!I>+_EB0(Z_FL3$4=XZ02HCP!&O$!I9] ^6!7!AB
M8(C0\+15M*%9.%3488S/:1O;/O3W'Y0646-!E+_['GC&]^AS^Q4W>D&A1;SB
MR@X6Y!&*7/QKL-\%[]/S^8?G: "R#$L'Y;RN:]D8OY)GP]EY2S"]83![&K8$
M_3P@O>-[\.W1TE4N3^QKE+GKH(]LJFDED1&,PMK]\7ROK RN)*B@\*W2;G[[
M*$R8?+''$>NDV]V_\+\&%:)G5&G>ZX*4&N]URWYB4"+EXQ=%QQ$S2^^A(3P:
M0?60+R;,-#R(\J=!LXU?<'[5Z=%B(AFW+8OJ%GL,'P77F=XH_EPM7NWIXK:@
MWD#IT_?&2-5BI'M_Y'/.")J@@8!<4^?UA:45]9K^ZOY5T#$U. [0$ *<-;=&
M<^:)..?(MSTE)R, 74G[PN BQG$4"52:$#A-5]I0@_/EUC<8_^%XG[ TN/UD
M_N3?+_!.Q+2CJ0-J$JV7QA #($\ANK^O9+?JXAH>:?UH9RSU89J2L:TA"AY/
MZ%+SJP45!Q@$*G#*PF(-\*&,!4U8KM@RU^?PDX:=IV4G^%.C6@ 9T[FL;8.F
M?>DDZ4*XI:329>%Q#'9UY\Y]"^(2[N]*4\G7T]D%GP[9R49++@?X'(W;U1M\
M)2&<7?Q#Y8]/!+=52LYA+<OWOSL42HO.I<AWNU3:/+]W:AKV+CLCK,"I^K.W
M0NX"O"TR<IX63<[/*PIZJM*YA)S>K;+]2%S[LH &XMI#@_/L1(:$O:[,2X<O
M%4XV8Y;6)]X<^??RF<+TGBH*0W[]4?Q%"H4!I9K(7=_U)D0'-AO^S  ?O9HO
MOO]9FT?K/0DW_2\VC/+*&F<GILC8%['YOB \J873I)8MGP%OBMR6<D/[41HS
M>;/UBS0X$\C^U3H30XW=L9(0)34&(W\4AUN%3U[O,Q03MUDD.A=CIRU3=*3D
M*"R(K#.12(.1,OUIS#"Z!*^$VN]1\"]]H -?2S7.:.716WD$,U>X.NV'MSYV
M25R2/QY^+=IP(UP6>@5*^&M5SYZMO9[RAG6$'].B=6/#]<\4M:48S(79^@=G
MTAURI+[MOL5!X-F5SA;(OQ)>JH$H>SGF<:XT0'YXI'L\$B[SL6K8;]1T?2R8
M[5%P+ZP,^LEU)+K1!PD-5@\4)X6UL" 'K/_H:X8^7ZUUJ! X;<%Q:#V,4OW5
M<NAQ7NNCW@5>-4K:5WN(S,UPYE7XQ%LDR1D6%;B'HXJLL'8<YP5]$<Q;996F
MNS+A$^'Z(&YJ;YKKD94S88W!8J_F:>8O[V@'ME7VR]^0ZW*_S&DVA+/,_CGK
MLS9SS=.<^\%$B**BHIJFEJ)0R(6HR,B.HOIOU[PE]TA.$@UD^GM=D_>/B#@+
M#Y:7Q2T[>72WS;PYVZ1:G7PD;E B1E?^J'=]MEV-%-9&BTKUS6UJ.$-2>%X!
M[//%-M/PH:JFDYL;J_4>S0U"V'.K0:ZZ \YWSW^W6."]MWK>>N3F'P0H__O<
M/3?N\>@T\C_2NHI"[WX2,\#_I+%Q*>((<AX,C??LWMJ;D=D)QC37HP]8HT%7
MM7D"_;+RHL)A7P3!YVEY_45\FZ5I^^M")U?T8ZYRFPLDNI'6$>6+%8H!OD\S
M-0<\'69CIUD0% NR"(K+[FE&%NA:X0^'A0;+^/KK&S<JMRY^58=0,9.C3BGH
MG;X+W<>E7*26(F[TJ5X:6N1/9'(/9D>;E'Y-],XTZZ?7KFT6%2IEO]&*=39N
MT7#:FS9[3]!A 2]1VZ<R3E/()_$D:+WH1,O%WY1?Y"VMJD8UL[<MKEAYQYK3
MU?=GQ G%Q,1$1*SV",$-/U,RA0;,*WTS_KM7K$;N6;*S#T]&''EU=>_!CR=W
M<N_J84L-\<W.R+@>L1@P'V"E+U!2+Q JTG6"KWJLS?QE>=S+FC(?FQK_&\P*
M,%X;AU$E]'SM3;# +=>H=.$HZ"&BN;DLL]M&9,CUWO(J<&3<^N78U4F-KNF?
MI2)AS^W2-ZU(<1^KPD>-PZ[W\40DMZ8:L2#W6X[QGMOG=9:?/S)K8F+M<[>B
M\)-7?KNAY)_O!]"K 9MJ5KIU-5AY-=FI PP5X_<?$YIH;6O==VLJ:BL;'O<[
M.;VTRG,N69S5,G9U<]H]7]'W$L@ H_ C5YG[?6YO^@>R"[)38XHLM3;U _FP
MSIX]SR_&=D[W$):@+5^<L^CZV+,C<J\.+)+G@R5"Y'S>D_F/C77@[0:E=M)A
MG'?'FP";YO:$E.P]B@X_"7X:-NP:.GK)NK^,7C^8+DI+HD$/_>@KWO.X1;^F
M1]?(U4*LQ,EZ_%=??&QE6B7<>9!CQ\B%QSV"KQ=_(]HCE<N-;6SPV6@7=IXY
M?2ZRZC8DT 9W)_O/SS,OZ]]^]7 OT./OQ;4G\OJE61Q=?.!O"47RVY^9S36\
M,F95K69L_=E[^WNS.0.+O0SH<I[D_<JA>A9$@VEG%!Y9'.2*V=K#/V,/)#TD
M\3=B]*W3X<4ZEIKL610FZEW6K60$<IYV^/=[2KYM?#4V1&PO4H-N__WSDO;;
MQSUHJG%>3D9<3?6 D8^Y4%P5@2&A'-^H^$D4O9I'"H+.F-C#7] QPB*<AJ;<
M^3;K_?C\U"R"DY75TK+0/>%8M@4U\=H_&[!J75X<&7E3;Q7T>7_, ""AF]3X
M:8*RJOXL-4923/2AJ.I#E9CO9J7.A16NRSOK06<<O[6^H'1:M##8EBZ>=>N5
M,@?;I*6&: !^A@%8/@K?!X&M=,F#7:$P7],D[V7HO4^N*=UQS?V2(-T8<9)Q
MZ-KO5[5/Q(73$EU73LK$#5ZF@3Z]LDNOXB="5$C1@#!_.M3X&VUH5<X=<V^#
M!6E$^D4,#5FS(%?8KJ5S>JZMY_TA*_B2AJ8.;B^L]-_)_EDH&N%F+=&5'33"
M@'_M_FUL7A\\^DCGY@[<#R0YY_<WF!WA$EH;1--*J#$-"'6)U?W<X3#F'XPA
M&1K?5M,$)$K(J96<]H)C;I8!VP:GH"9M\9%V3[910Z5Y3=4,[5M7UKJ8GQ%H
MBY'D+)GJA>UU%O5;-LZP6OCAA1[J$"G[!'?'<L-F8;#FA?!!)U>JG?'))T_T
M/ZE=@H<:?!E\K@;G0.D^*]"1M%PBKX[2!GUD7CL[6>.9;!OQ!Q%QH011?M!#
M@'*F1'?.CP6QU3MLK2H=.,=!:*1'ORUY8QSQ .OCMH"+"SKRY*EG_=A8#1 3
MXW8@+>EZ\+H1YN?F(,^[AV'[V(1J6)!(YV[VT4>(\7FJJ;BF.9N:'P,H1IZ]
M)V55ZS\RKE>5K.38G)B,<ZN,#GX9X%#;V[Z,W,Q<09(+2C,/%,4TFLT*]:*0
MME9[M$4A,:L%,OE.$8>#B6MKCN/GKQMTU59@$C.L+RIF542C-X 8BF8:"W)R
M$T9; :&GCUWC'*HU]!7HENNY,HZ^-D6];=:^[!T!"%N!EE/LOTGA!QUV//T3
M>-):J+*%?UOI_@[6V=]WAHN]*U3QN[GS[?:^O(CK'U+CHF2#U!P@(W\Z59(#
MTNO1D_10?4-9\!(<JCOD4)'1@/GQ!]9)(PCX&K+E7>0MZ*@$P_LS2W3HB)F-
M4\V32'A7**>AT?4MI#4Y-,! K.3/1^QE_]13HD94TEA88@AC0'FTLC?.[5D]
MG1$N>>%\'BJ/!A@;#;ADI;.YNOH?>*)36^M RZA+P\#F#0>7"_P+4'F<0QHG
M'Q6B;NT@$EOMQ2Z.UC"+61 VVLCKH11T#3Y)-SRUC<V0AB+G2?#?= YPO+$U
M3G&^=S38C)Z&:(%3S2WSC-SMY15;'MK'^J>U[6061!HY/W?8$/%P!R$*WI9D
MH:-8F4Y\#R*/]E\LT7D\!S]E*/;1<JA_D_XH)!RU53JY,^833\_[J7>-V4%P
M]*LCA@;?QE%;PGIQVY7+\OYS,3.YW+ARF_(JA./0SJ/I:0@L+?R>F+!GMH@G
MCE(]%*G>=:SO^B]7Y(Q.W )PX4;'ZVQGL_0&&\U48IEHQMLO%'A2IN@ TR[S
MFUX= %NF,-/#E'^R(- 5T8PW3U.GX[!H J)HY@2/8KUEY;@#?"#K5PGH%6LW
MU:40D(W04$PYO!E]E"Y&_3)1?*R]80?9]&F"9>638DOV9]8"IS%8%\)P0+;C
MFLA7FDMAKO[>3%OWXU8J;_B/CI==AH1 0>NX<$A>_(KA:V??+_  9U@FW?0I
M@4?3,+GN;K)3T&9)P6@FG0!,%,-)FJ@7J/>PYVAUT4 %:_LI^,_"D@4;F_BI
M9D><\E*S9.<7X?NJ%\C<PR]NZ1EM9O:IWA*JP,I+>FF[3F"];@N? ,(>03X%
M[-S7D^/W?<=$A*TCZJ:@).,)_?8$?K\O"]+,._M$U75R3+0U^!CY7)I'EN^3
MYIJ9U\I1<44.B?DSUA;XX6ZT0,O1''4C!<DB]U,60IK(%3#H"OD*0AM,?NG;
MU39S.$_#_F\+RBS(STR"E%5G17S=)NC^/!E9RU1M@['[1OW2GHEUA=Y$O F\
M,&55&+KR)I+M>EOV_;+QH$J]5-4_ZJ,D,G3%-14VI<K?QHZUWTTO64=DPM5[
MEO=-FN/.FZ2\1*EI:ZZ'1Z8FC^I9CRQ*N>;@G[PV-HE8&?!B.[G2O>_DX2L3
M$X\;#T4HG$-GAQKX"&?T1Q:+.NFN4X.DT/DK:L=J:L?ACBJ!-C6,1@U.LT?@
M+$+^Z\&U*OVS>!,1:,2(#E:A'B L-0F8EK,@7%1IHQ71]\G7[C/%>L\U-9;X
MZB$?%;9[9!'7-(IFC@KQ^8T<^'Q0P7MM_3"=HFUROI%G]^&@YIW<L#L<^^:
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M=6[O[Z[I2)>L"^]S^>I-;^3>=A[]/?%G>7.PT$7Y8,,3\O$J 1^>&/>YXTO
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M2+Z?M:O53?\[(5M:40'4WQ,3U"%;@>2T3X;WGJ<==6N7$=ZZ%2Z6B/=#"W-
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MQ5"2D!LTW*'5+=_/)=O5<FPD\;>[.PH]E.'>C^4",?8^R*J^:,(J$7!%[Z_
M "YP@> Y#N@@,69U"^WK]8(;K\Y%(!V  %2N-KV/[9P/<>""5X/"32@4!IN?
MGZEZ5U-D$=$9YH[R?G.MZ#L+_1K'12XQ!'H8.Z&&@&&J-FCO1K5G7-6612X!
MG^B_[D: I0!7;_;.0/S2C]V+;\4C-H=>#&55-C0PES@@09Q:Z<G*4E/_AO[Y
MNL8:IL3LEZ-WE3S%0>C<JAD>ZDS+,01005_0ATV%[<)H%1\RO09U-)@#$O.F
MD+NY("UAK*6!WUM>P%!?O^2MIE)I5#8Y/W-VY_<5WSZ7X;=D5E0T:7RN9XZE
MJB^9L)H&?*8_^PQ/A( =(W!)#>KH-$81;QON<>LMI U]3\=>KC)Y4W+Q ,1N
ML9@+MUB=]U?7MD; "\*PF75(CK-?S68#5Y6'UY24B9@V3(P<C!&BM_?L,%L9
M+) =E&LUQB!A\WFH'2TI&@S#+W%AXV-4LF!UT' ^8UUX4#*%7)>*=U$.621[
M;AY#9.LZ;+<)9D;Z^BSX:Z7"?4)_1PCNF=?X>]NPZU&F W#5$<I46>:9XH &
M1B@4YK*O-<.$XC3'@#8K)C&H1+"L/J*^=.Y[2?<[658N]E --2D_GJ =^H3
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M/22!"E29+E!6+C3GDS[G9L5C61;UDBA(RV#Y9OL6@X_HZ=F=:\Q7EB^Q->6
M5,W\[$GL '^7P:JW/D:JJA2V,&#."./VTP%-8JO *G /#11]FO2 C[G:],)D
M+8P$PL1RJ$&A\,.;M^E=Y*O]H3*6HZ$>,FS5WZ6>3J5Y/[J:W72C/#;L&8HI
MH<NCO^&'2U.>^3!,7.C@^";1A:?P^, 0*V% RC!31MOEV?&_:C^>BWA9Y?)@
MAW\#IRNG>UD@XO(NHM^# 9I0$E]G8".Y2N+RJ9?E_J0IYF*33[%V$T218SBN
MQ'A65C2)(G^<RRX[\%TC1@]W1?;/_<75_K3E(0],,\*V=<O+DY7UU#,MF%]Q
M;]"@<U41?<+SF5>X)[K$2Z/C%^!,+WUZX_20H[2H&#CAC8N$N5#<!\;1;-?B
MOJSZ$O-;I4L>7FO^[EV6T"RC2$4_^>SG6]X$<CEO^Y+#)&0$:11,*>6CA<7B
M;^N;T*H?>0XVD5_[.F?MW:]Z::/]=.977XE4NU2MT)IC^_\2J(T,:\,+L <@
M,NQ#3!LZ-!XE#@@UVRSD2I#NK%E(=E#Y,Y>F*ZBGF$9Y\)Y[VY@?FDO*YGU"
M%A_3/%*H3@'3N9=7'(NTQK!C8QN7%((88X0;UQZ!2'JVS3P\$,8Q6HK.4H?E
MGG]P3>Q/+@*^)?0TJ !14F@)9LI-1J<T<$ /2>J]S,B>5179P%>("UDW5_D+
MX_T8EA>=W:6#DO<1@&_V,.BW3PB5LMPC-^94RIN4U=XHQ+8;2NE)IEW^-?@Q
M^^>7XKX:AH];[<C.M<R$BJ007V:-_4B85:;I*EJ@$I*,$J'+UN?-PBNT6P+C
M4'*5](EH?^GGB!K"9IU5Z_G*STNE6OXP-UDI^E+V1K_[G)!OC6A$>HE:7N"^
MQ6X9\DN%H_R8D?I)<#+R-(- !;?[NWQQ%P$4WR!P+4.RLA"^!@FJ-54?=G7H
M6%/*QDQ;Q..A:GM=N\HR>T?_T@_^U ,GB2^2-M5_AGEOK+.>WJOEQJ3LTS]Y
M-^ )$1NP%6CV$:+!="RK$7_KDCFT R)X0:GBA85RVY7E3^!#O'$K+K>_3 D^
M>/JYC-]8KN/@]5K"P6AZ7+QZ:(=XV&,B0R?@"$.TROGEP8$O@R71,[U!G]-E
M$>%VW;/VA2Y25D)PM>=EY:. KE;QGP&EIZM\7V0%Z!4-)J;ZI7:;GQLS[YD8
M+?1>GW8H,#5X&,SR8VRR#PTS_"P^ 5&3'%#T?8V.X#)$M&L- U5Z.^9*M>0Y
MC,QXXXM4SQ5,>/C=)6%U8^2/MT?]E2Z6D6@.3!%M"CA&<ZP>_-C>.:X5+&PA
M_-&1#'=T]3$0K7CY^G18L.H/C'53#(]G:>F2ZK>XVQH/:Z&3Q-; )R@UH)2F
M&MPQH3,PYL!0:[Q;,3Y^SOY4NM8*I;KRP2^5)=6;CI2*Z@=;=]M?*4:>A55%
MB:!2]'SB:*Y9K64:G<53X5;\0^S^SGL_1PTZI+*GUVQBQ >;W6[>1>A!]1BR
MPT<DU4N>%%X2INC>>S$4>G*M8G%TT,#3"VNNMN"5Y=9/J>;=JMWZ:"GV>6'@
M^?  V^W42EP-:P76_DX:I*\S@ZL.UZQBOXE44KYLS' VZE)2#X+SO;!+?6YZ
M+M54_^CW]A4.")N&IOO#H<M;)Z"G(M%D.>;M?YO(?QMCF>GSWL3"/J>4;?Z;
MKYN-LN. FJN0>/S4DX8W2[OUXXR\+EGR;D6U9'I"D;%ZC:9M]:C"6%4]M%;J
M^40^G"ECA[)=.?%O@YA_VO=U5HI*@TUAQEGWX7<;E[>V7#@@7F[+4\R,GY>.
M7S6E83<<MH.W^[<,Q]A;$)I-GV$A;X/#^"AY*GKB'W)#X6RKSL,OKVVCR4KH
MW-LK#BSLSB:$&U=LK4TJ'I'27$@DYE/2B_LY5CFFW1R0V?/C_^,1DU3\(@=$
MKN6 @,S,!.13MB.+/!Q(K%?.1?= F0<YH%?@IX4[^,VE_X^Z-P]+*OKB?BDK
M*U,S-<V)2LO4U"SG5+)R3LTAS9',S($4<T1%J)S2'$I3RXG*%$W1<LR1%(?,
MRI34'!%P'L$4CX)PZ7??WWWO?9_W_G7_NG\<G@>><_9AK;WV6I_O@;TW[[JS
M]:EH_%H<!W2X($GG=.LW9@NDY]AX;E.^=:99T9:"W-538UOF::Y="=M)4&5\
M,V9K%D(K]2E,!W]K71WZMY?@LC,'I ]E2=IQ0!GK+&:5ZG_/>G_T,=&# XI4
M]]CVQ%D:J7KSN61I;G KHYP^NJ"2S5\ZL_N?ZQ-ZP,MLH>XTPDQA#Y2!7AM'
MLRPMC:P_%G% !M2M2'3Z_[-3D)E<S&3O=G- '?W3E4S(UBJ$?;;X79J'!3NZ
M>_5?\V+9+!875F/\MM'HGJ/;2NR^768:%PJ*UK\NS*0]/,8#O$BC,;A&_+'A
MNOKA/XMYN44!HL@!38VV0DGKUZ,DF5R7HKJ!_H];7AP0W@>]<9)4K&BNT)6I
MO7*P;!OZ]W,M.Q(/:'+![*S))WPS?FM9</KA]LV;SPV]VJ98,=@Y6YM;/8(S
M:>R]^*\:_SU5?F9[RPM=7;F%IW_]US6W8A6^>@#=)SB@$;_(<],)Z]W__H4T
M?;EW>Q$]-8IA9:<SGTH<[3Z30);RY("\WC-U.: H#DCJGS%E(C;_;5]5=:[T
MG[GH=7?3I\970*)3=U"KD%D0!*="&*_<95[C@-X>@%3H?S#_G_>0V?K[^Y]+
M(=NG]1,:H$Q& @=TE7_G;IKJ!'KM-Y1E:68DQ0T;KD>46#&3[$C,?PR0,YEA
M5N[N/./>O[!W"\K<%.,&FZV-B1PD"P(<YH!.;N$+L.PCW&_3([2-6N*ZD"NC
M*3Y_)GA4](_88.85S<^%3&W%RI0NB=>&UJ7PFS\,MRLI('7DDH:NA;'&TI2?
M7$H.#+0RD=4!$VK\1YL"'Q%+WI5-9]94F:DVR,7]#=B9J"--COV_[M?T/XZ]
M0B_2G"VQJ0CQW0.Z<\D<4,%VJ(AJF#F,8MZSABUL9.TE#?B'K<R+=%EV3#\1
MT%84&#C HS 5+YWX==/.^EU1EZKQRVS?J-ZAGXMLSUF8-]P2/%EN_.)\Q!>P
M%O^C#[<CC[T!EX)OV-0RU>^$R=S4EHX/#]XL/5<2<JX^W$ILPQTZL^N65O!N
MM.C6] =+E7R1](7MK7M1KIL^M$B**"]XJY]MG/%M"[S5CJ9K*(LHJCNR&HMW
M/4Z$K6+N:=A^&,7!_S.:TM>9FZ?76[IW:1B6I<S-;G?TA"%7%G% SEE)TA*J
M;#<[]^=)*X-R.\H\HX/<0*[EICAKMNFS_R8KO?]D+^S&332TPL_Y'$,$/3=N
ML+94/S>14/MO]](R;HP56&PWOQ![J3/' 4E;+[YGUT3\RT?017X+(YGV-!8S
M@9N_6,R/C$STW(H[J;,48(XN*Z:#Q*_RBJMAK3N$,,C0%8>W!,'&F-GNG<\M
M^#^BMK@Q[AA\S $9%9<,/&O$[F.N5_[N:E[4]=>MK8>N[WQ@8:?]#)/KCJMU
M^[R3YH#&<=JI5T%B^A<]$Z2M/<0#,"LHC=>\#CN"<\XW0ZU+V??+TL&]8-9^
M] NJ0ZF#AHBG<Y6C<Y1?2^$N,T?H6%60[(,['%"9S=+FQJXEC" T'I9I_7+]
M4XF^B;2UZ',,F@9F:@2T;?4QL=M)R$_LV^@IM?7U=>V' L$W9\O<1CF@OT).
M(=C1=RN[;MFGQ,\U]/"N'6V)G)-$X_S&,O#[8K[.W9T.93#*F7?XZHP#C2_U
M%<&,0;9?]OS=TW4I(SF*FE0D[K\\-8;N!2MK$BUVP#JO&I-2O%:4K-20JQ=Q
M#@]OQA+#[?(RWV7;+V?VO]-\N^_<]..N/2Q:M*[#CZ8 _GG/GP>3Z?5RWKU]
M\OB6>P1AUPA?L(KI'JN@VT<UD_?R(0F/K'G_4*LSVB?EB _B=AF/RT>=U$V\
MIG<<WHJ6>9A^_9P^XC$:&:\BFBUPZ*HX2=G@4W%!3E!WU?J@3W-^6O)WM=\7
ME+M%DPD>+DE^HG3QR."'89%7W_]>)CH07<K\-/M?>NS=73X6G&;XY4I!@TY?
MG5+D]^<Z=XV7_7N^\*9.;VQ5H'X%GIUZ Y*Z6/WDX'ARDD7W:>ILTLUTE9DS
M%[Y9[;[^QK/XA5UK?K2J^504;-6D:GW=)#&YTE8E^9:%[L<4A-PP_NJ[I#C3
M,2LS#26-XOB=RN_E@J&0"_P+I)BDA?-;.C9- 2*8EP*H!T>FP]I82_G67-GP
MB%O-YI<-:!Q0( <T[V]E7]J*: RL?WFZ+GTQ'9VX_J<Q4[_(:T7>U]Z_(L)O
MFSH;XK!^2=1USD<J,WF.![_:UB<=% W#5F>DYMN'GT1^P31^EHJ&G'=4@&WU
M$5DP;-4\9,)Z=W]I>\JYXDSMHM66)FX<H%EJ,XX=#I9%#F'52[O3]21X\_PR
MWZ63]_OT'A*E'S:%\X[)8.7%YY6="/7?+YQH/,TS^.C$V)\C,@+137^Y-=JZ
MS&&WDH3>2OL;B?>R6@DRN<=P@[--@='!LAZ[ELB='BWF8IE+A*6TG&%SYR[U
M2,G\IZF@*!&=I65M*<^DB2=FHE<$\])U[*E@(QEN7<R\:\2NA4R(XGWVC#P7
M7..UP3B7$+'W)K3UQ4;<6@3YI)T;&0MWU13<G/\D+85;+OGE+(X-S9G=E1LU
MR2,1_G@6/TRF\DKK!YH$1HY)+QNJ:/,-BC6<W.CBEEY8=C6SC[VUX;=0TT?E
M@"+015ZZ@8VNS\>V';<CE#6U?1UPA^R2*I_ZV:^N/:UL#&_)-QGQ"<U2/CE6
M9\P;=O&JC,XF=(8MOE3.:I>P49'<M]NIKY8L]$1W<Y_$='EC?<T;08^8SM L
MVW,I&7DK^I_GN P @5:HW8S-')>-*JIBK^RX0 '>RY7N>GF?D\VW"OXD3>CX
M,]8&MYORC9[]D/L4GR$?$!S3%Y"+?]&MKUTQ^>7B2>030RBY*S@]LGH/\6-?
MRT,)^,XT!Q2\D[.R(G":A_G]370@B7P=HYB4E.20-I+F4(FK+"U2!.+GD,:G
MF.ONC-/5(X:;N:L_WPTYR'UJ^ZG]1?9R5/*=5%VAM;R_;LH5LVK/[>_<0:U$
M;4Y[$NMTAU7]4SZ IH6:MC?7.D,U8_DQ"7]E=Y)F<FPC<>D+ <_>?=K0B3:O
M>CA;JB-?-IM74)FY"8<]J%G7A6D]!UU[\57\S-.E/P'B<P40W?E3WO>][_=,
M'=E[\$M7^#%KZ\@Y?X,UUD&T[OR=>9*-78\,B5M,+RW1TK,5!^<SG,?<*CWO
M\X8KO);:DQ<D^( #"J?M.*Q\D@M<5Y@Z/OX^+_TRMMX:[==>9]OJI+_E27.>
MJ)E'E;%&LZN?(,<_;+6P-H9I)OBXO/%;T\P QHPE&OJV(6"Y*H"D<%*A[Y4)
M5OPF2$I C;7TMCK"Z+MP1#GR"]9WSE=%]+;4[O0#W;I+SQT+A5U90CJ]H NW
MHM*LEY+FRZ^H^K[ 9$(V(HG08^8]OOT!TQDLF>Y?'O ?DI.]D\ZUX=]K\6Y@
ME[59M*G,_J\TZYBJ<#!@A-1/#SP$&3G^6DY 9ZE;Q*Y9D ,Z#8V%+#MRAS4[
MQ_]<A3FF P/,;%?O[FU#-Y ARQ()[)S';%<.B.94KL42E64,?[NN1L^P.['^
M7$;=_XC,U>DLH>)U,_D[^F5_5?W"3#F@M5_P89E77Y=A&V-L/E4.2,%LMQ:]
M7.6'V?'MA_U5T 57;H@N=+\FQKJ9U]FD)A(MKI?C8R>R<]'Y')#&]\7Z5\,I
MM8S:B;71L@7XTEJCO_6J"9=83 ";6D@#>'<;3.:2S>E_["8*4=T)G0%V2*EK
M^$TLEYA*=[D%=NT_\[VQ6[)<0)1E<=%F&MKGR 'MQ<YP0%;->+!+=C0'A(/T
M"*W\CX8#6DK5P%MWN:<KL477\ <A][D<!9$*Z1->9!]H $*E,3$K9W^';M Q
MG6MQ$ %X>4U9:+U6Y'=G>(>@. "[V=+O;_FC1LNY);]Y)[1VXOOQ;#$A2_53
MS/V[J:V*FF% +R- 7.XH!U2+7>[JD"$MLI4_2@7'/-'O.D0OFWMM#!;2T[CQ
M4ZC4)'NLJU)?U.S;>.EOA'G25I5UUD"XV>)(OY3*69ODMP(^W\;K_+B,7;SC
MXG9996O;0H@#"E-EKN/)QL+,%VC2"[8H \+%10],JHS"4,V: !#LLHNIW0UW
MQ"SG.#PK_#=3L]J+75KJ+N(K6U]550_@Y+8N73"^?-KXSN.\E!+3[>#. O'?
M2$F*OB/!&3<4$U7BLW5Z@+)&D#E+VTI&0BZ_&K!1R:2D'5J,[$O0*',P$RE:
MS?C@/EH=D&Q^S^06D2]W!E@D.;9Y'C_[+BFO)>7V[R?/ZHA9$KG^3J3Q.H;_
MY&*%I/#5/+];Q>1#&B(3!:VK657K0[N:.C_^M_VF-/B_=APYG+1#9+V0^<V>
M1F_]F_%NQWS!E5-<P\^(!*G.<>'IL1U75&+=H6FXWE8.: @S_93QWP;/C6+&
MT]BL-%KIN<(7:*XR.HS)WM5=9T4'N&W]6X%3SN2_X67\W_:YK/UL^]_NWO8L
M_,)P-G4IZ/]3G/V_!_!XT]JN+]LTS0\=!&&N0]I3_N<-TI-TQ/YR,?)+Z3::
M6*G:/31#0B]9<Z70?VT7^;_&A_U+FZ]XKH+;;]W+SH] &=2K,+E0BDZ7_:_E
MA?]M__V[5"/6)IJFB()N+/72-QO^_^[8*MFM_JOK5G\>P6>^ZA_<D"<>,%<H
M&2DNNWMR$*<;JM#^WKFVZ!#S1- /9WIF?GY^0;T**V=YP/=?(X\^7'BT7UIL
M#Z)G7GO41.=KGU1(Z;EW^;-LG<:LT=!CH443@R4OHPM'^[(TARVO_^^VSA"Y
M%])G\-)6\5*-7W./7.D1/],]KR=L#NE-!=RQ\(P[\D>[[6?1;5MS.]N'F609
MH^^#5H[JTXUVR:=L;\G5)J4,C)^?) V5HM[UN_?1AZ<@*=PAWB?D@SI!)\S_
M)0$QA*&",U49QGAF-)X1S=IZ[I(([4WK_0S_]%HOO4$(?].1G\(ZH#2^7_XD
M3_S$D\!HPV6=/O+<S(DN*.9.X.L*ZZ2BUUZ('0TU[?.HXZY ).!W2_9JD4]?
MN<SIP%B)":OSY_\MQ.MX/&FKDBL.JM96>)GF\DFS@"BML@-Z;(JFRA"B1W<]
M&@UR 4(06996R@?]PG6+5O/A\+/%.YK%=2^VR[U@CD9G4O>C)=D_2"<,I'PF
M+PTUAY)=K/F-N#6EVT 4>$A9.<L!=<J(PD46#,[3L0FJ>G9OG-#M9_S+^RCZ
MQC_73#Y^3K?T-B&&2A__-FNA)+E[=8BQPQ>\4/\!6KB^*[.[,@N3TO?M+KB
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M9+*R(E,3U/?.2E_MQ_ZFI,.BGH7]51XW_D"_:+IRU+->-W1[>O5EB,-P.!J
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M4N(2HLZ=!_#P)DN615]T><KNC::X69DN#[YO\=KV_@(64]G@@*19>UN!PC*
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MWZ_E+BMSR+&<J$S-S*R<)]C55C-3,LLQ99>5(BDY)2I"Y8!IRBY3=YJ2.>=
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MI"Q B0=Y0QK?E.(?%3V#ZF$0_.N@*H_4#5&6</*FU(0NNPO#X@YV_2MT)8?
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M+![=Z@\]D#/M(SMX0Z4^[D[Z?T^RB,H:8:FTD^ _&\Q$.Z=HGBZ;E C=@W4
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MLBZ7A>4$'NZ)O^%[XN*YZ#KYDY[8CY81;5Y7WKW_N,S_Q%-0$K-(C5ZIPD#
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M""[=>Z[T4LF:V\YWE:\M/[3$9N7'&009H&)_WWPJ\,'ZO )WOA!_5'<'E7W
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M*/5.;\7[0!F!*=C/WP7H/.+)\A] =@B-RG LB"96F6VBA1"JCV)=N8,Z'0G
M MLAA72L2*+[N\%"EP3IKM;CF0GH;E,69O:RJ]+$SR]SQT.\8B*Z$/9(/.!&
M5\"@ D0-M\10W*<-F<Y0=;XAF,M6($!MF5&(K2"1H]J7$48-K +;G!B3;S:@
MN0DE <XOKWP!PX8Y8X-^K8SJG&'Q*FLA[_J=4\MV%"Z\ETB :@.'\/4KG75X
M+IE DL&CB.D(-3LY7M %:MJ4,&%F*MX-"$I<M?HF\4A^5(1/@',Y1FG2.P$A
M.!5(L\DG+N;?KE!>9LGAQO!;H<>P=A*#+\>&@BR@><$/8$H*IH^/X660.[6-
M. .4)"J^K'WE >[0%*U\AJ7\[GG('I3ZM.J_$^U?UP-VMP[U)*\_JO!Q#&K,
M41_TBK?/GDS_T6[&;*)N).7X6?M&,<TN^HY6:A?%O$#:FN4\F-[0G84KX3O,
MRH?-R6D_@_'[5F&J6"N N7@!%D9,$L-> =FB?\!*8.)70!TP37H1$J#1/G:5
M#@2EAJX1QLP&;AJNF+^MKC7+/7OLV-C<C?1/L&N0SZB9O@?BH[@W-LR^32GU
MD,)#@,)2I$SOP@\<Y =-;43#+YZ5%,>O86.$L!J0X,9;3S:/MS?QSI2E*UK0
MBZ\XA-^<N.Y[?N)FJ=S7W.,_<UC Q785X<U6>ALH7X?[@!8<=!$H> N5AK'Q
MD64@'0[N^X.!RHM>1"AK=JTW#V/_E!C.V/*O[O76IK[$Y2@4L<G?VZEDLN_P
M(VV84 7U1D<53!;L! DS@XLKL3-$:7&W%T)1_;SD-XD-ID'Z13"Q5'B:=V"L
MJ3*:J$*4GT-?Y=C^.+:F0J4U#J<\E2_2:YI*>:I:0_]\W?IES9-6Q)>X>3*C
M:0DWL5"98?UM*'?L@/SE?<,/#:W=+H9R#!U+6FXNLQ>O3)7DN4S7(TU_<7L+
ME<$8DYYPMDDRU(@'>8!5J  )?PZ9(90Q](X<Z*XQ_S7GI1KSG6%VAE<Y+(WQ
MR9Z2$*4OOMYNA7KM-HUJ#RJF]*BYKF&DEU")M=YW%VH#M6T")\QI]"3CC83)
M<6]?#':3&K=^P6J##U#/@_$*Y*;X!(4!(*"N[,J\$F:6XU\P5L5NU[T G-<X
MEO6\MJ6F+,<.'2[7U+,A#L!L2O4B=B_CCA,UA0< RS2[/8"8Z?^I:4JW V?"
MJZ%G"IUO;OA-^L_?6<>94(#!Y!H338_1 ]1\M^A/!_V-7%L:FK*6+-5^N6U*
M^8("_L]&'IT(FWD^;8E(R;5!B:=T=.H_7:O7,7"^#D:,0?;8J7*[VUI;_+75
MNT^\I:F(/RI.]I2W-HUD>O?N_.=BU00"E!4IM;,2<A/.'U_Y(^< Q_#7>\S+
M?XI"LLZIM$RFKP?4Q?F\GQ\(6:,XO<1W6$<Q>>)'91@(-_,IUR299B%*Q^F+
MQUF[:;HF]VI7[5VZ ]3 P%*PJ(FT#4SO6-?9WY;5*=Z?W@-5&!.:1AO3VJL_
MG_YD/'R(ER47I[ H)SAQBKV21@+.DR:<+C(;ER+/@7."Z_/TW4& W'0*&5EB
MTF7OU3$0B8^V'YT:*ZCR0SW@//W'A_;H%C]4X5_&QP\I)L=!Y'_S:!A4F2K<
MA\3+X*E-J9V())PLKA^F3K^AD!J@E=NS4CHE= 34>^%[L6=Y!JED(:QZ,C@%
MO@UE<0>V1Q/.*"N4B]-K&2XM/*LQ(5IR*O+#=SA!E3!'$)^)9\!3 O,%FBP@
MLWB5)^C%:]XR*XCD,(7Z 8?!M.EC.DJO"R<#>-I]]U?]-%W#3:CV,?D+<ML9
MY]24D!9C&ZY-HP4#:XR+E66/Y_@ZTTL;<9M2GK;!HM-/N&EE<WV/2H]$5'S3
MGTQJ*=[I/.7S#OF"XE4I4?T9]"(I]+][GS"=,"R<)WT>7'F)8Y(TQ-I-'TG
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M RZ;X\>K>B *=K$EN"&H/*F;C^0,2C!FK]W5Z!OX8B&2(?06JSW%ZE9A+>@
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M8W/38V%LS+U-*=3@^*_.0BU1!51Q&O>A]2ND865)6J%3LUVZ [<7[*] %MH
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MVL*5S)B.U8WR^X]?IQ]OW!>O+^O[Y3U1,3= P<^KCUH"X=T>>]7958OY23.
M.-[D:9(:/J@@72%=/?$ K-;7__&U-G]LE_UQ"LP&_J%%HT4?@1&T<E7Z9LH,
MS7G-@?4:[Q*!QBV.D3Y3\4U]]B*575[#OE<^$/6ZBBLDD"B&0:>75/;<9O4+
M!\_\N1M='O-1O%T!4>Y7EG[&#OT>J^ZKID_+7%-DY>#4,9[UN). ,4VVJ5J=
MUO&XQ+V*SZYW)5>G74YQM>TTEV_VM,_>4;<#Y80GWE2-7BRCC:O.!E?P?D@)
M.R>MMY\TB*(A\*)8S8B:ZJ. '>,B\R(K<9+U7,N![OP9)PODTXHF+F72N>M
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MWQ+2&$QB*! D[;P(9ANZ:?T'!W(7;-)DJBL0@"R4.O]V)RN: W%Q.O2P@ZD
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M60EAA][[S>1BI8N45O1Q$A2'GK_UK18:7'_[M?UN&O_8K,-%CX[6 TV!?4@
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M#R+RVZZTQM]B+Y,6#DCY*L]:>+)UCOYIP6._BR\M8D?^OH!A0(4YZT6R%IH
M'T6O' , [T(4 DV&:QT^!0+_PX-#,I#H=]'Q[S+"A'+YT-IX\&@OT/3X+$9=
M+_!$M@S3P=%3,DCOPBV\?#-)-JO?.-ZG$L$:/DQQNK_@)O!HH)X\^2\[L?3;
MA0KJMBAW .>T_6^;M4[?1^.P:#VRC7 #P,BR'IRX>._ZS,?^Y&!O*L@3M95)
MD:YW,P_?EN7:^I68FW\;3>RE@GS N,Q_-DNUFF?DT<"BDFJCYI10QG5W3FG\
M>21_6"*O"Z^O%#.+%?RCHJ#L50+'+QA"[S!9TD=[R7JRQ+H.LD: #PVBDS:
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MFVE$X)+O 2ZV(W'DNO1[6_1$&FG :FJ RW100;$[).+-%3% %X4H\M[1;77
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M\L;=\-BOAL]NA3FJ<I8#7Y#+/?])E%5C@Y4WFJ;_\E6PMO)DF)S9H7W)F]I
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MCN?6>JT6-R=1Y^XZMLW9&]=+Z+ZM3SS-$VKW;,T'RISX[5<D3*!B7]^G\%I
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MKN]WEBYA@8@+E2S0O)_NEV)Z4[W?[.8FL[2(49C& OVT S?#Z G;CK.H%4C
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MX@U-M7ZJOME+LP79%KX];[(M_/6^E_Q.],T/2W[Z*\G8PUF]>)H2Z$D='=O
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M+_NJ:4^F5EOHR365#>FDZ6_"?Z99N@J'7F^R]\L\;_?I9.V=2R&#SSR+=][
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MA9C*IY15#IS>C5"Q^K,K ":IP.MRL".Y;6I^)E],G32%IP5R#_%.P&:$$FC
M&-_;"/A5<GT/B\[FH+&1FK=#35-"UO=+'4E;1H*A-VF: R%+3:,G)[//UOZR
M@DU0^/("\XGH="M''G$KYF;]2QY],SC-89-TAB.:D#N_@I16E%*%'A./+@E>
M#7WQ 1-C_%*!'WOUYR;II^%]U8,AQ>G<;^<T4IE.9[U]YANJO7_/O?8)2E0(
M5708[WGU.:,0?J<OS?+7N]FQ-<AM/2;U6G\:RV]FY>\[>GD 27A0\DRZ==8I
M#,.ECX[R/L<+2KEI3ZG5WFS2B(C#?E@ 8@&B0_9_[CDQ""5<N2>8Q],T^K*K
M.-,)6"C\CM2J?(^P%6,EF8BKS>$==, 5>Q>VB:8B=@%O\]8@7[&RD4L/R]CV
M<(KUD3%P&"G(RV9@-=!"/SW K&D"334HG<G12XF^4E&9?2]2,];A%RJRCU]E
MVB2:FYL;S?P]*!@6YO19FQ &M;> Y24_<DAQ!&6\.?8^30X,GQ"]WS= H>H"
MV1,26ESAC,6U[L!Z5HBSSY]*>A<&-_V;83GFYDE]?"T+?2U/FB)I0DR4()2(
M0="':Y!:69RRWA.L+<>TWH(/!.,K;X\?^F*]'0=O0:E)=<3&3"O'VZ]!=09J
M)S6R](<P_]AP1)ZULO]^=$Y/][=JKQ';<GO\T&-;K;*+@W4&\\T=L>2LX3\O
M6][' V95/6I2GYY\Y>J\,S/L>_K;J:%OP]EF3;6L$0G\-:$3]I:2L@9!DT8\
MA"8 D4%YF*\J,&\G/T!MH"'PU\%A\_:FGM YD9R;A%P ,@0;6F0:6JOGI>F#
M.XG)1OPJ'X=ATS0WEP$3\L[QNG3R%>/,D$WE.$HB=8-H-_XJN(]'8;EQ8/,S
M7%)\-*QZI8MXSP*>8JV-Z^(-)XEC.914-M3:$!=W">!7Y4:_KD_A]!!;I19]
MD4X6W6YY^),16=FK7O01S/I1$Q+@7":ZA(^E@[W M# AKC.E0'P)1')Z$Z3J
M "R):E[LB486HE%;J4:E.$1KV*F[:17PHH8O)J-.EAZ8P7Q%PH%&DEL]+O1?
M<Q<!7<@%!0)>ZQ>\U? $>&4"L9ZTVU8 O0@TM"+C85#I]AF_0X*QYN;)/%(*
MU9.V\8M)$M6N<D9M-6WIC@FKYIM-25<L4;=B)_*DEYY?WP\N/Z;HY="01T-V
M52-"9PZTC!EX$FW?EG;RP_BALS,=([:S+)]R<PRY&E$+G9\!Y(69:Y#[_\IX
MS9G 81H,=.2PXQ#7).I<F$PYS603=RTC$G/,.[$[ZILG* JXZ\QV[>."=8.U
MY ?:ZA;T% ^WH2JQ?J$WPZAV)UKCFKO'G=3H1S@[!F6$(?0=I >31C#_@&=X
M(M1V-OX?F3)U<Q0T<(9;L"SS=NU3F9S>9*DF7AW,Y**@8T&(71$>_6(G]02:
MSNC7F>C5Q >F/F.G%UCCBOY_#\"7Y2WK#01J[V488R IJUM,'B)J4+ $-1GR
M$Z2*P_AU/,P<*HZ\O>*&]3$0U2[,B<VG^POH#J33N?^ %$G9YMP220%*[>O8
M)1\_])M@;[QPI7P/XW/%&N3&8HJ%?@=IH_@:@$V@R8LM!($,]E9PM-5/LQX,
M S MTJW L-"<A#?G8N7 #)XG((V[@E9KK@S6@*::OE/V&@Y==K)#$M]6IO50
MS1[]76F18KO[X+CPNW191"3S"CT_*105SU_]75(T??#L\TK<;/_D)%JOWI$?
MND!(PLM)\NA7[,6'9+#;#]AUP.)02M0 P7'A AD%T%.L8@K$E]\#Z8E CS'M
M!"Z.@XC'HU[@G(=M!D;;"?NJL[2L%Z;/#48JFC..CP2=9<^OJ*\.-*B1-TM[
MB=7U3P4QPE] X'Q2!2YGT0D0E@IXWJ!O%5CC5)_LZT4UY31C/!J&X";E)]4<
M8])NK4'.]DTG(AL.'4"^[M'X+_-,,ZK'A,+*Y1DGEDD_:=3GE?\HNRW:YQM+
MF8BC)T;,9/_UE+!W#._B5F5W\P"I8QL>%:/+,"[X%W."ULZ8GR]X%W*<!VO/
M@_)4$-JU,.4Q7 RWDM)^2'IP1FKTA9?</^<HH++FQ_=+OS(G6N]O(EU\5IH\
MT&54='X-4MA</'"@%9GSNC[CUTI$</<'X>_;-VX-M5\)_JQ>O-!?OO64]W1!
MQD7TF"E!AMM^JQ[H\IJEFHG%MMZOX<)R<+@2C&Y=@VR0'L6K 8$MI$WX,/"#
MP,V1Q%,A[XPDIJ"V$;;C7);+$="96[C$UGJ/\2U@827F4,E(L/J7,Z_ T"[[
MIL%-5=FJ"T_WF(\E,M@C9*&#I,QJG>@4'@L& KD=]/6U,6N0T6Y.]'RF@,B)
MG.Z08+GNF3S$-KQ#;:W *#L9OYO+][#[(K9Y@1%&U3?6DZIFSN>^4V.%F%^H
MP5PY<(ZM.P<#7%&L^VN0KG$%\"E'U!N/4*2Z3-"5YO*-'X@-P7U $V?A*9>^
M RRT;_Q"M2_#RWCL24X3!J%MW/02-:NA75H"9K#/]R^8\$__U*O5XUXG$#MA
MP'D82[^#U=O*=]UMO1M4_P=4%VQC<KL8E'7XPZ#]!#(!H7C#6L^;_95-WC-'
MD <(N:7H<5V!:@O31&(6Z^9EWF!WMB%D_[J0X)\F_0/CZ<<QXD/HXKH9##%_
M82RL?<)W$2W2C][-F;&Y\.3Y)=VM!RCS!<^]G?NQ[*D[%!K>'NB5;GU9(C:6
MO"88S"!JD%TG0Q#7B"SY-O;FVE@U+,NH()/7 L:9MQLIM<D>?E@M7RZ=UV(1
MG1B*WQ3-W<5L>3PVJU%'';*&-0YX!RTL!Q/>BK0)7>.*8)_(!B2U^\F!S[BP
MN[0_-9T)8AU)/74#T&0'9IF0=OW(H7?L!*Y+\!MB!>N=M@O@2WG'L'LP&GMR
M^.Q$/7K(CF*@+M>ENE[_9]0O81)87(;3X=DQNL>0CMKJX(I %M54"0>\.PJ]
MNL++0&9;MM1HH!;3<XQ_W"S-'TODD78@]?)">T*LH.@-!T6&/@2N) \Q4>!G
M!#A7"MA<\_:0\#/OP)0PT7:<F] '-,*$ <R_!/#X94TL!,SD%)/CJ<=Y2,5@
M=PURPG*>&78##NM9,[P,W3F"#*G8U?HNU??;7[7PH,+N[@/D%8M@-O(4PL9.
M*Z'LQ-D+G$T6D5ASAYSO&>%IY@75&??CLT<SFIJ71?+"6Z E@#@+CHHV2IGT
M]5::W#^%V23%TAW2,0WL0VM57&8'B]2^CH-5%:N /@+E-N^L<@Y)?7:5\+0B
M.%]-<,&[.7Z!O+T\N'^FH3XZBHONJ"G"(]K(7TN%)X!L!GE$&\DR]P5C9,I7
M\2C @B?+F(L!V" L:@ =N;UQ4@V!>9*5[4O<56P">\O5/FP(]19-A5E[HFY1
MJ9?[?C&[4^-1$R!\K):>%?+JP^^9*@*;7)O>)'!L@:FFUTS0H;/$K7AE+CN1
M*(^'<:")^6H N8T. 1V[++3I+W%5C#;V]@AY2ZT-_Y!]ZP7;"ZW+7FU!N0Q$
MGGPYL(!5PZFZ-]RGAU+2"(I@[ 0I(?N.7"L\R5H#]&8MB@\/RR*T):>KHS*:
MLTQ^"%\T]3WS-_"YAG<*YIH_RNARE\45C!'TO$95YI57OCW1V*L9U@/J5H1=
M'_1#.+$7Z\1K$.2!&H5MM:H6F3>GII[/_.QTS4ALWC6C:>V%>AHTG^%K+9"0
MB5=1([(0-O^,AV+]\NJS"JP(@E4KLCLHV\18 )50%Q)A*W(*-OO@CVA#J./-
M!4?29_"P0L]+.)(S;%=A?V%3 [ 87_L?WO9&UN.Y,!NYF"LB)4+[^*8OM"TX
M31XJF::!N_Z+!Y\?X5#2:.;@(A?.2K+2XI$3",9@X83D3*?V>J:5ON@4\;HO
M6KH?<(]_U<5A;T?9<C6[R3O ]Y$A'A??#D9XSK?U_,Z=((TRA"0PW+QU$B T
M<WQU;$%]SN+#<76 'B?K&K<&V6+<7(3WU4C&.\!V4/7V^AIT>8P?K:<YF7O1
MAE[>BJA$V#)#+B<PSS!U$CI*^6Q!*UZ90UP/QMF 6H+-PRT$E0&J'"#J0"@3
M-HE/@/&\WO6@WF_XRQJ DB#VX?9H7ABX_$5LD9/&Q+DS737H8IU-_WV1MG<K
MZX9?Y!MGKYC?P:P8$)\NO>*]07OU.?T<&=/+K77K^V44U6A/25ZMI:7T$0.1
M]_(-)0^97'@K*7$5U45.R=\-1O/(*M(^[[&&KB;29KPS*%\YHWVPD>0X7$N_
M>^NK)G:/>$\?U4!!HZJ!>\IJKL'\%L:<X4H'JF=:ODG=#-3.MZM^_G^Z^_)X
MJ/J^_].JA-&5(L6T$TE7MLIR4K>0F"A$,97LV:+(=BI$B@E)J4P2DRQSQ:!2
M)HVE1&,7RAC[;C#&,&?./&=<UW/?U7,]]_;Z/<_S>OW^.#-S9L[W<S[+^[-]
MYYSSW46*>>Y3L'_DV5.E*T9M2Y?+:$Q'1H+GJ3>17[B6S^%MK$("*^S])5L!
M0+,S9&*B=(*8Y+".Q?5ZJNZH:Q1D98X5,)8-8U>-L*-@$W_7W!7WSVOD'+[L
M>3$&;R0Y:#TS>:+]Y#NBHD-8A.7B:ZL#CNI9[)=;NE<&JU@AY5'N+J(@]:WA
M]=LF\O/FYE$D)+ZSPBS"4O3.'0?-.XXRK3;;DMX_*BPI?%O0]G%?M&*.A.0?
M3YF;WYYN!N^!<34J4A#>.S0&3/8W;,"*0>?!-NW.EJMH_KH._K)39_/C@PHW
M'!L\_5!FN3OQ4@$78<?S=^VW0\L#NG@TZU!-5L+P)9^;0<TL1A2%MBG)V[+G
M=J$G@6<=6ILL_=YC1:?GHPGE8_B($C1DR*NQBB+&V'R,!5YLF#7<++]#2UZ^
M:5IN][!=W?FQ8.N,5FZ\ #!JN*CML=F\>9-6$D=K-]V['IXR.!CNF&5_LH"[
M+>D@E&.=9U_7JJRR^<EH(8-X,J6%R6C3ZHX,+]G;$5J/VO1F[@"TK@"S,N!F
MN;\ D%1OIA0VD2_2UWP,1+:]>E,46^OJ?[>-'1C#EBU,NGA&,PE:4AUWJLUD
MY3)=;)?J: //-MCJ#=<9ZO:*Z5!IW%DBQB5;3)#?WZ PGW)]2M8'$"PC#T2/
MS92:,'/4#&_2;D/EVB3=PJ3T2H^G-D;Y'YW/B"6]#OL&/S!0=<3TPH[(N8JW
M+KX7&N./)3Q,''N8,O:9XY63'>+;[=5.Y[Q!H4Z\+@!^"49+^K)\[B>F0E1N
M,)XU<[P^.UB;^4Q'N^O3[([8K*Z;(9MI@3L3T^P"(D]>>]],MVN^**<W<[0Y
M^ZQL:);/95)QFP91' V1!?WA.M $ILOK.K+;;9_AS5!E&Y<U6$GY3[30%01:
MR>:;[Z\05M1<[,QG%K+\M!!Y%>6!N4=W(SR>#>;;V7^UL=/7Z*51*RGF(ZDP
M]1:UVFNEW:<';36'9UXGF'$*&JP*DUT;3 E/W]CP3H?6=^A,6)=!Z[DM78RH
M-^;=F)O4Y:,E(K#QQ+87\@F^60%49LA31.Y5Y/O7;QF<LZ8JU#8=!>:@_9QT
MF&4<^\L,(Z]8Q8\H(@ \Z6WT3M6(-]J=]' !L+: (1H E;YN3B=SE;[Y4<7<
MI4N6-TY77H,DC3MKG.UJ"U2<WULA&U^&A;YU8+;S=W\Z$=O%43F\(C7$[]SL
MMFC=.V#21-+L#>OLC.=*^?V'J\Q,*>0@-[;I,,G.7Q=[BOMV0J',?B%63 -:
M;6\?L"SXR(1(!99[J.=:&>JB[S],6$6F<WW+]+:K5;HE9<Q8U+%-MU6=,*5_
MB5=6+--\451CSV0Y<\;X: _@/+[H!+R;:SQ!L$4SWJAVF2WUYJ@.5CZ.Z>%P
M@%!N6S50T5_FX=BE(G(BVM2MPVZ1Z8,CC>G6Q77G3"+K,GZ+'V(R>J*W\_:H
M))9<F)R:W)_5;"EGJ9G1]# QH:!AU*/>W22#<+()T0UVF%@:,7&0]GJ\#"OI
M;NM<09#G0EV$\D597S/08J2R2SH"%T6D(4I-&@^^9#3%DC(^=N5<,'*\-BDI
MRV;NCY9,H4Y@.&P^N40)WE/"Q76/QX;NF)"^=C%&S; NV-C55R+2/8=+,ZBU
M6E)/P:\+H)G5C<!GNDUEZ2.%3U34RO>-Y;@8I#_XN#[!MG0'M*G.I/48@J_
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M.L.85-0R W^CA#H1$1&SM[>'FM :^'KU[VA<^X=ID%ZP2PK?2D!BB=T,9)4
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MQA!F%CR:611*4$TF$_Y$>//IY!"2 +B"@F0*'P!EM1+<L%PM%'U(-DR&57[
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M;=Y?,[8\6OWU7(_$H5]3U!!BB0BJ!C20ERK#(CUODT;2F%Z2I_2+/"IC- 2
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M F!"BCV%NF)GH  PL>DASNC-(/;4^A;,&6028IR-B>2A'59(]-?O!T!.)P5
M()XW"'&CU?\Z^%@\])7'F!5^/*7[QS!-[+@"GZ/LR]O-X*%#&29HFVK^/1\-
M=+1UNSK,5S%#>R3?<:@7_>C-F1^E^ 5Z0YSYDD,?^02-HP-#5 7 2D..(W4&
M'5DBG'5(PX%41(3,+MBKP*<+'VV.?J3]/BKM=_:+P'P5 ?!6E<^FP@;8UKL"
MH",)F<,CFV)T$ ' E:?6-_Y_+;*N>I;#P_M!D"S*\8M#*1 $8_"#;A=P/"):
M!*GB!]WOOE$B< S-'FUO(O.3SFM_^K-S9CRMSWMA_]FN97IR]W;F;K57X!H
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M4[$FPMQF;B+\&U'F[SS9^']S6R!H_0]02P,$%     @ Q:KU7$.GTSJ'E (
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M_NVO(:W3YQ44@/_<V.?M$^+%VNX42PZ]ROIPEOR6)8M=O>!@P9(_ < > >]
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M<I_F=N$.X([FOL>=QUW%W<8]P$WA7N?AX9'BT> QXX'Q7.$)Y8GG><+SFH?
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MXE>#!_@DE/1(RK0_T/Y"]J\!N_,_A.S?@?T=UP0@P,'&<AZ',  %& RU%\G
MOS+!S8WQW;+ONP\9HO/FAD-TG5)4>:>G 9@WJW,7+X:C01*O4B/NZ/7M YF
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M!:M-(!7L1R'<!L($8R3@ D3)N+ 5#AC-ZK7I11EN:NV"M.4O,"5ST'QT<9$
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MS.K<'JDN,S!/E/:4GEN?+IL.F]-YQ,@+9O%W.!?W,Z71-<2Z-C0]L-Z,!AI
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M;Z/CLHH1&626S!,9?W<R+!75#J8J("4(85%D2R0O4+W4JK'H&;7%2]!>^>+
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MB.H"D_3P$J:;9B\RU9+MAKQT=6&(>E[1";/NW!BI]Q&A2V0'&JCW'%UJA])
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M1C(G%$M,UAJZ\X^6B]X3_3E):10--&F5!LJS!5IIH)>M8\*$;=1T'C7>&W]
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M#T>LK+ F^H(.*B^)8TD!F?:93SZE+#'#6I;-KSB >3;MJLP]^4LYIN_;.^.
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MG2YXAJ6!',>[QG,B>L8*W/J4?N7QFO\<8;;K8\[3>[N.+5?5[<M,(EV1S/U
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M"",!THA/#!>Z2%B)HX'@@WP4MC$(GRT@W15VCJ@3CA3[ )N]60A,P:(M#Y*
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M::"J6O1YB@A<;*(%1<!\&4%<9I'N<)!J;A[9OL.-=JX;E4,N5VY\FK0&TR6
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MQB^J+='W&;2*Z*'<7Z*<NE1JZ)<>G_.RN[?/7,''V&<YSWZN@M=>LE;29O@
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M$4[9>?GP4+A;<R'4]W-Q@BP%*X9*3MY&S^P+M #H[!+H$HM&F[ZZK/\5MA;
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M:0HB@?^%]D-M_+?_]VDC-L'/!P%D;N$O_&M!RRU!W7V?A V_TMCPN9FWK2-
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M"7F-R?2=CAEQ(L)O3AH&=*7__OD"='D\E+=_[^CI<57/]HS$_<L'@)@'O@<
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M#8^VOYTT53;=+ZAL?!4Y'OE'C6;]S_PS;1'!V20/H/"27^.8A)DHR@3][E/
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M1W&5"8K1>HS%HNG1@'-I(-5K:2;J"?3/FFT8_Y?^\_]'4SL%<+X*UAC7-SB
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MIX#$)7QL(OC49N$4\+7K%C7:@)9N -K_G;J9<$>B*.%I_7\Z3&Y'_U47V;\
MSU$43O[K?"#3(;]+XXOHU>.$=Z,KCA_]Y\)3 '/W6E'EO7([9R<G!T?PO)/S
M GN+S5OGQ=$0G]Z$_;:6!(.<I0,;IX?QOZ7EK:\[%HW5>4VN_M^'_+^,EB#!
M)/=_2B:! VQS8(Z;N^B+?VE]FJ> 1>KH2^>PLGX4^1]AD/HJE9:]-"[XWT+<
MHMG-8DK*N?7GJMKDHH1+4+_B$PV*TK2VN GQB2S%I(1<2]O50Q&9U>F3.D&%
M4,@ SXI@,F[\$.:&]55\U#*A:1)2JC^<E>[]HD'YZUJ*OX)TL/X^Q9FPV$M3
MGX'1U4 _FJ2=6) ]<.EXLTNC@ALSE5YP475G4C)I_D93&N]A,>W[-%)VM&EA
MR._;KEKJ2PF7@P3FKF0-X'#UHF^P;^,B9+2JP^'0<E-0A:1&S5?ROT+^V)=C
M]BK]X7@GF!C^D+R/7+#W/NXTB2 JZL_N:][_#'&!=OS^U- XXX/+U^)?QDUF
M,K\3*RJIOT02,(O)O_*%G(UC36QN]_D"/>D7XIKHY*GQWCP^,/2#:6%WJ;:6
M$WM3IEDV7Z)K_$,^SO/C)"P@T<$I+]X]39(/USO'KU3LQBN:6>.7U56SB,NF
MT4G[P?YA4?.)6+-(BDVW!*%32(Y ;8<<P:7,SF^[:!"=D6@&"BA<-'UY]Q%%
M,]8JM8^PLK1BHETL$6N6,G>BCX.L-BB-MK<7\,(X",+)E*"UPWCUKNXF#[S_
M!;N='--X)!2!<4#%UKJ/_ZVHJ0TQNP))+'5:[$="7Y(VAR=QSB(6*1#S(.$%
MK@M^("WOA L_+#;6UU-EIS::LVT:_MI,SE)2\^10;N!(18H*&4&HG].;"P8S
M4Z1G1>:Z!5>@B/Z5&Q.=EEA!>["E!VJ"8ND6+M1 AQFJWK&9/&Q/4VG*7<SX
MM<AP>($VO'J1)NA"9K(@(&.:!$P,L)^KB!R.A,S]K?@FJ@UNS)I<X^_EB^\X
MV08*[,;,' #+]V1^=!=N4O,]5QP#F0P-C\43+A+^"&R2'EF Y)YU[>KIZ8'K
M-Y*[>-S\,P]U7.5?':UPU!$XMH5DF@EZ>2M=0>%8)E9A:/<8NOM6(F9%HHV8
MU?"9/&C<,E/40M3.#,1)+U;]V MYUI9 AV@83'Q^TV34D61%EJY:\&[>0B_D
MOPNMA.EFXZI?'L5VFB!_PL7'-<.U\_R+1Y%06PR_+[6[ CN7;M38,K4R]K"U
MI2Y<S]/AQQN&8X4$9=:J\0[X,'])DS-W@G0]:%ZLOJO%8[0!/H2X^!&MS4N8
M24G$L;*"L"RAYD3M>+PP,WD0TWX+ Z6 D(Y-R/B_)V-"\][FT&S+F4[+"^WD
MA"US5)MZ!\/*;F ,F[ &3N=']AIKPL'!P=\:D0&>RY4+4(M53 X,S*;IYEL*
M'=CMV1 EU+;@!1B P8D8EQL3G_7"G5W-?]>^[^=XZ";"]+>4\P)ZW/M[KD/[
M"TA]_4F:\81T@0H913(C2^/S[N-,CN*43%X8PN6]\H6GND5^MB,2*:!2:&B_
M!=GJ!S*VJ>;^_;KIZU.#<8V[$<H#0\ ?3U+-TP86I-7<H5Q9>C.G #?A-\>K
MB?Z:8$31;KY?5>7/[NM$^NC]3D><A@X 6H9Q$4KA;4R]2B[N(;5':0O.A50I
M-3=93\OON669U2\VKD#T^,R*?W[2BA98G1\XZEX."?W;@0COWGH]>J) $6B=
M:MH7]V=Q^LC* ?-LIGX**;=TF$G?!W/N_651M&HFGK_=*>_OU]*N%16K'SV0
MV:P<MZCI-[QR#!)-G\;K. ',3-?]U(:&-/&<&8^L)"W+"'H&#QIMVAU]N/ZG
MWEKG0)?&VA$E@T68UK9R"MA6G,P:FZ#IY[G2),[.#$\2$B2JK[SZWS7KU&*=
M1+$@UNH*&J?(H7TY/'N'V&2]XEG-IU]V\U4@+QZ1\@7>!&0Y//N&4A!TV51S
ML?O.5W.#/BJ=Y<0:E\KN!6<?!Z:R053N+'CEB&='5*XN#0^_ZX4\\17[-JEQ
M!P!X]V[,XNXHXBJJD;7?UQB?.@ 6HCR:WDQS)VJCPL3S4[[W33UH>KOP<[8"
ME6E879RT=\Z*^Y:PLMD20=SR&MR=./.T-'8DPUM_=SE?*I3$!G]D9 WVTO_H
M_8WJV.<GF.)?8*:(N?_Q<MH UZ<<4ZX[?\5&HB.[4W_4PDRJJ3L![0V:$#I]
MM<4>O@'H=@%<#;D(_E%["AC0UJ'&P"5A<F1ZG-NXMC;Y_N X>6?.K*4M9<QJ
M]@^YK Y5;\BDP+=?&YW1S+I)_WJ8*>S.M1H4\>XK?980;:;_BI.O06/0_?#S
M1/$:K!G;]B1]TTQP>)NL'%=0&S;C!MN8KR1@U%]!TR+?F3>]8*;A(=.WVU]*
M+_?E.=@EJ%8J5)DM3&0Z<%@F24^U!Q4#1_G*F\1&1P6&)87'._4RS#1&L-&E
M-LDR^L)\T8-8%ZG4V8 &S!,IR;XLN4@O:[25T_2._J07"*1OJHD\#B6_(QB@
M$2T&>R<$?QI/<QX.$0/F<P)O9]ER+SC_4?R9?[NQ)7_5L7GZS[_K$)M)H.W4
MRLZESOEK)0.SH=JN^HYKRRJTRZ$G-KO\0^0((A.>,VOU@I(:/V[Q42+F97Z%
MOUAF WWJB6(?Q[!O]2'_^;7^ZVFJ'Y0'JE4K4&["9&GAY$)BE/95ZN>F"&T$
MW:YR19D#%(<VY%[(COFK;R8W>V21\$/)5AWVO5].U/""H_90ZH'Q_G&!;B,Q
M]8VV*!CF]Y_>LZ7NG#93=?TN"+L8OBR%.P583J*9WO_1F^P\:HAD>^>_N4W:
M#U&^;(=[;HW0-M;YNI70>^(DQ\/BA5,XMD _#6+4GFVR!TV.>%OT#5M)65H\
M"B8R&N<X[5Q12-?A>H2_PE&1/"(($W*.R84\_>6@T.NJF*32@L%)F3RI5_\3
M8"T6BYG<,B?99>1D%-M/-O[#+Y!1/?FBU%R4:XT&MF7/ +O*34[$Y&L2F7.<
M47%;7SIH"XW9UD&^2'(WV65Q\13@>I RW?M$\VVOUS/&(7:=K])8,%G*M$P#
M:D:R) M$O(#9$M/1.<Q!T$(?]W3KZ8UI^> N#6/CL&7F]-&@2N\*I<IG_S;8
M_K4.CCJ5[8O]UQB/W(5#<N\>&_1T=/A?@&G&PO-*=XY>PH+(+=9)DJ 0=R]N
MN\:_'S(^0A#Y=FMV2=6BOA4'JP1CQ+PK1DB3*+BU'T',-]X/M^SL?$_FZM3;
M KOLA*;!LO-E6]/(BHW*._Q3^FQO[K3;]7TR6F6-QJQ#H5OSJ_5E-LD^I@J9
M<J&."H.N@8T1R?R\E3M7RWB?;#>7FF:(";FIISTR#]2X'0;7B0ZP:FU)R.+/
M@RF+"+PW+^1/K\C=;/OL%6WW4M4)+I*I'ZVI=27L1,K<^V/(+2!W#B+@%-"K
MA7JJQ4KR(M 5)&C:EMT/)4;VM[LUC<4A2ZAKA/V:;UZ!PC'!!T8#S>5?@4QQ
MI*;E <)JNYX#Z12PX$%*G*)=]?0O] P:#,+[VBSZ??1Y+>8LM3Q=MGB OG01
M2>D8T+<G?1&5I)^"JU-<)KNO0@4>$5G0_4&5(]>RVKG?BYJ+'93@?>[BQ9[$
MI?T&)4DA:P/)(-P8UZZ+*O%*&2[BY:;QLJUUJPK[KTF?[P]LFH<Q]?U":^\&
MIW24+W 4;/FSM6YQQ.8Y!%3O;*E%.8:(5/9@MZ#H-/5RD%XKMC#D:W93YE'V
MK[$X2EA*32)F.E]LYGL#TW25C>ROQP&3FX^2)98K_22?/]DN.VE'=(:F)V:Y
MEU;LK-R8\0O1,MH\M)D%@D9,-&EN_3/??GTUBOZ^Y2YW8LYQ3;GW=3\\C38J
M_.57Q10EG&@T(:YHP#6;CK4/#;L3,9>P:P7.+(&]FEC0&2ZA_0-?X ?7>^QU
M*V$:R>E$)C,%;Q7C:S3!B=JUL1^^Q$V]B!=I+%4:!Y<N+AA:V_A<8Z0*)RM?
M?YB>M);?.B2B<S<0K-*[Q,5=L:6VH6+3N%[U)"!SRD^EPR[)R@WAI:9ARKG9
MZ&OJU9SV#\Z.O3BCN:CZ><>JXF1)F;O2;PXVW"UF;&]J\ELWH_'$FN-%0@J3
M8[@=+F:!\PVOJUU1@MC\M<"BZ </G*0J*Z,!S( [DV5%"=3'5#W11J,1O;)G
MU=E#HMEO_W?5!I;V7 .\Y[5. :Q;*1$&]&^\IA_18U"-X+V\0@JHI9-H%O4D
M\@&QJ:O!T#6*P0?8RR"_[H3A&4G9T:.#3\;5.B6?M +_T==ZJK?$ B'+K."Z
M I,9GV>><M6UYL59RI9'<ZHRR6]<,R_;T$LMX5"E%HI+*0QK>.1?P:[==?""
M*\EW2EMNFP.2HS!8!MTR;DYSU'C'+^I0?:=*Y8<\PT:^2?F-S/JAZ^=29KTI
M<TG0FUENC//YED9*#5Q\9FRQ">9E*8[#()<[,9+V3;(B8&QY6^XSE";N.VM9
M<O1#M'394$KREBTKDSYOE6..N8,$3K#=WOJEAK'E^BE@WIA4V$%8WB] HX1W
M$)Z$C=X$07K;MJ>_MBT-7X@E8_8N=!7#WBCL;7)$ZS,:M6S38Q"QW1SDIK51
MX[[\FXT)IP#3F9J67H7DR?EOME1A\_J,9X.:=ZND)072[W1;O0./^965K6RK
M1Z]DECN,/"FW<P+Y!ODJ9&2M0.W?15X"Q#!76S>GW'7[R4 UHB8C/)\@%QUA
MLL00/,+W1\\I@)"R8\O.S9^<^YC#52;MSJ6#9<"OR&LC[!O6'^SF\GHTP2Z9
MWFIR;O'E5;JE]7O67D ;CD2G5OYZ+R.BR_YE*V_OX8Q222.&]353.0SV#M2G
MA2.NXCY;;,5EM_?]:KI-4G]*VB2,_"8MDHI/XE6*78:J)(0_@*]V"T&1)!BY
MDB8XK;2O^"C_^]8H86:EPY5E-K[2WFE8I&&:?P7F$,FD\&'=O;^Q\'T1I:C[
M%#!-<:TFA[H0A/?OK/W[@[R&]L)6L5Z$0>L)41,K@^Y/4\1IXTTQ\T9U]<]%
M]5\+\G@,?^9^K%U$K80#["C/";(8FW=ZPDE*O'+^G8KE"A7B(4D:V^FJ=+31
MB ;W<XQI;\EXX#\N@@'>-H[&"HV90@<M+9(AZ.;VYL(@?(=&C<Z^;?O<_"=(
MF!*DM437N$ZOH3[6/TNEHVXAVNQ/)O.#(!]1[W)=:*[F+6,.75#Y;!362P_D
M$IBL)_323VJBAK>CB4EXZ?VU[_ ;!.JU@3Q-[5LZ0W7DW"MAF:/JC[[]6K(6
MKPI7?VM90Y=@A=>4G]D>M@HRU WA*&50.3ZL@<\(TWWLX<].V*<$%;G(DTQ&
M>HMEO]VW3]MQ?"[RQ5?Y;C9(X^O*_70AS'=#)W;$C6YAVOA+TW=GZ 8&)+];
M:R(.HKM"'5KG?&5N=$=H6!'^4GX-B:9MJTBV#(FVUU^$DNH"6FT#5OZ5DQ5)
M_N23SS^U91KS\6NIR; PG*#Q_8D_C<DA+"IVTS[SCYR-(3Y/8X8U!K)49RW%
MBHRUS:W?RS[G6:WS3YR\+_Z1:(#-/,@-X6OL#5>ND"WDJ6NUE\E7_LVYJI=K
M[)/.Q]4JG48GP\7<<)FQ<6>XB<^Z@D\5QQ%5\3TJ)Z'4)<-*='MH2.IMY@9$
M2\!,FZ<GX!;KDR#F*[Z.P!Y\(+13RVMBM.)IP$R==?UP$][(_H5KEDNT%Y;(
M@=%[2B"7JJ<42)=>+*.W12,N=0-@?HGV]>0S*L-'=AW@?_$NK,8 6\#M@ XO
M&V4I>6J0(FNA.I/A=Q,8YN8Z]/3V96'V(8&!@Q2.8#_BEZ2TZ'<)[*7Q3TMJ
M[]W*)0[0P6/-2LD:) -R.'[$66502)"(&&3EF+^'/?GH*X=]X,(W63N#ZU!N
M6U5<&FC+['5S]TW<2#J/T#A2'K^\9$CW\8VQD.-;0U6?I)36T9<_U-K"[75+
MC=[#H5+LU06:-0+?S=.CQ*0LGAM=<1IM'?IM7_P'SH'!!68J)NEI^KFF?+6&
MB6FF<^3T_1B>LD-XI58QIA<;<-A>W+*("F@*E+*H&K$I51MFUZHZ"ZJ:,$(H
M+CL69GT-*?1.#/,2$5=DF?$1U)5Q/WCRTX6 )GW'DB603>*-5[S(GR</42W3
M>[(A3* TW.RO%8$J+_SU026.@?K^FPJ4ZI0D/L,=!B"E\JWA]9"%P*.7:^_>
M8B3Y=GC7_FA!CCA(C.1:&I#\F'9UVH_?&=P3>G5[=Q/4;1\<GBG[&"]C5]H&
MKB<P5C!^^&KNHL/^F%HJ!?U1.F8ZO;-8H]:TM[@+'6I"&I2FS?U.Y2?[ >OL
M3&_U]8;[7"M\\ZW-I@%MG6;G_1OQ!]<0[!A>20 SLQW5<)J#N1'*T?\_MM#]
M3[OV7Z?-=?JP4X /X@\L!/=W7^B,;;T5W*)^.05,$.<29^OFCVEQ PB.?W!#
MBO\IX,W\C]6=U8;L7A;&/K3^K"B1=3^<(/(@^SY1N:;\9S?/W&/4G/NKGS3Q
MZ<8V$503@?HGY9UWVN+M=[(YMKJ\?L(?=!IL]R\354@Z*'(> 6$P1]%8BY=!
MK)4*7X!=QG>)H'-F4!C_5S0FL@$18C"31&,D0W!F7-TUX84<XNF &??\7V.6
M4P?V#UDN_"LY!9@)<\.98.)DXAE.O=>M"-,BM&#&Z).-INR$!(CP#]PU)<DV
M/:KUT]I#RAS[+XH,?KF?#+6^[JUEG"+I4K/VM'EVP'0RB/\JB90++H=\_-ED
M L9249&-Y125BIT7>_RKYMWU5S=W:$N5B>%#)>%QY@_,#>NRDG9#(, IEZ/N
MG-WZB9<-P\@W-9;L1,Z=RN>-:B&A3G6Y8<')N)(E886L7.1R.JC@+'7Q(M8*
M=9J FTBBR%VR-#&\9Q9%;! ^!Q_6OD!\1+"-TK0OWA:^HFE-(-&.CR?UN)^+
MMP1YX QM_H6$W0H_2EMQI&LWOB?*]#MZ;!"1JM,P1N&RQ&?WM79+;.<(%1(3
M!TX!]:GH@D2=)G'D&OC*4+&7B@V-L3TOF*S)!VP:B^[4J:(8=O\.CA#';?"8
M3&"2QE%Y7W:/M280SU#SJ>B7+A^*R(@U'30+C^$$S*V8HC<9/*K8EQ.2F5*
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M=M:RK>PBM6K*W3'-?1*?^VGZ##%7SXD62RG;;#XO+Z63**=(MBG/*7K@D'M
MX@@IBYJGJ7*BM0,7(J=BNSS6P(-@LH3.X.&;]J/>CV/GO7RK,"'"5W=;?I'K
MYP8+%S$LE?<1'F<P9.;3%.-%^YK/\C?GNB@*9UZ+A,\>CZ;N31#QMN0)PAAF
MA9]:"M>$&9+O5<"'%PS0ATP+Y$2L>SQVDVC=E1JW1G0NU%;JFJ:HMPNFU.!X
M.PWR5/:RQZL&XR?2CR /J;GP"Y[-<*ZI/P51\(M3U3!6_,EJ0C=K8^.X[],6
MPA8F0M\X_I#B5:I?[(N*DRMKS_="]GCQ@_ABZ+F2L8?S]TGNA *,,QBW%0._
M0)$=[[X%&2FO1>+S%/OX39!QAXAFD31!^X)'*>=$G^\\&I%1F;I[,VM3S<W>
MN7-(Y7*I+W=B\:Y;TYQ)<*AN##V'J5(ALU7;=3ST]W2"#8DGPV<9-Z/^Q0I\
M<&@]O "AD"FBU!;46G$!V]B>\W.$YVJL<@!\WN4ZF4B@WLQ>,XL43\=VKC(<
MA AT(/CLG!P3[^-8W(^_]QG+[RWKBHZSP=I$IS;S\M>\=Q$$*^$%?RMJ-IQU
M>;N VR\8O"#U%^%U!_>"<*M7.-9%4EM]"GX!VGX*0+\E=Q\+7]LY-HN$\6"W
M?7$-Z>!(PX:VZ?7V\-2]1&AQO&OZ,<L$RATY?W9Q%>%OL'PD[?RD+5;K**Y)
M)P;B^FE15Y.E'-KD9XDY@@OTZ,Q/[5:%!@ E;V[BOXG50=+/ N#I&:&4Q^1<
M>HT%7X5_1S'\15Z!VCK.:8*PRP*6!+_L4-?BW>Y;71'&F)>E&98/5JQGVQ B
M*][)K37+O>Q&T9E&V0VF(Z:I'B76^2D[.V;%+[V;^'OQ(GS/\6*21M=2\TL=
MP=E7<O&AVJ"@OL[,K!DKEW<-E#ER[XDQ^12 +Z-<[>@7;M3N$$O)PY\"X@L:
MHIAP57GL\]5[VJLU.^-05TQV>T2EZQ[;TL)(J+H!VZ_J!0NVJ,!"\!AJL6JM
M:2P!Y2E,1P&2(["'42LW)F%LIX"+51-_S9C'B :#"T>OE<#_11W8^\L">:OG
MJ)V.6MK9#9PJLO*5E2]-Z7NTZ/$VLA%AF*]#S8'S0$=(@<2"O:X2<I QP;;O
M%, %9<((G6\8IZ@\8<G_@!W5<&INCS,IV?YIP9L_O+.U/_Z@^M48KUCFQX@P
MY<R3B_ Q%U$"3Q\+$RF6[$' DZ*)IX ^1"S\&CG$ER@_T,U8[VMK.:4)9(B9
MU6M*VR0XW-<X;,L:7S(3+E#Z?D6TASLYS.%PU/$WO/G!7*]M;<8MB98]3WW+
M=#^%3!452P/N0Q6)(15NY,6-4'?4#<1:/HK7EQ)Q\H3V54BLFVB;\/'A]"E@
M+7O<P=D99CR;)NMJ.Q?L+SR_'>J052P[BE'.R9Q9'BVIM_-F3-9:?JU/EV%(
MOUA0+_.?Q W!"D&6/'H3?-,@JBF9@^1%_A#&R5SC1I\,/+RTW%NU?-UBN"4G
MUZ_>=.=>GB_'-\L-@Y;]L3C$E]"];.+3([1Z+ 8YOX@U2#KH%"B>)X?W-7C3
MV*?6M07'&[<U=P6%#0PM&*J5=NU!:4R.T$F)W'3^\J>L:B?*\*%V_[U3P%FB
MRB0C W$QQ- S$.0Y)O@3?J/U[?;EX@6R3B^<==SR+L'VE=)7"]+1/K<Z76/V
M=WGCA8^1FD8^>$\FQ:Z#XRI'@@E*8]%ZRDS1"&HTO77/.*OD25Q>J+G*Z.&3
M2HNT7(<)-9##9)K?=Y#2!]+E]5P//M4Q\. U]^9LFMZVSIZ4SI\<=<PU@):T
M+V+=)9W65WP* !67A\/P_XJG_EO>?OR_BEDY(R*HJD?K;(,N]X2*.1_=O?Y&
M@>%ZY'AD[\70BP$&+R\<S_GGGP+2=:2!IP#6[57F4X"_V7RQ56SOBA Y$"M_
M[0?%FY :"Y2/52^<#1%.[);HGKQ)M$93K)M35#UB01/[,OXAS@JTOW\](IWR
MGJ@HOU4RG]O)"Z./I %@7&0$C@V'HJ,H$LIB-1^\\^8F'=<6E!4T>I&.FZ96
M=K*.=9= FORB_,G3:2;A5U*YDD)-1&2&?^JR@HN/*>RH[\N--K<+3:UF3"'A
M?YTFDQ<2 MYX[TNW2 R;+8."Q*HZ&"6*(@/^USH04HG<<@H0UN8]!=2=Q=3D
M2<Z?]M]FB0CB;VSJR3EAJGS;)V?;8@HNC.N,_?3]IW+P_V;_8T5J[OW<_U0P
ML)@_UOFJ/D@Q/[O7NZ.S0>T$S^EQ/OI_,OIU,PK7"3YS$(UZK0Y&^[)3:YK&
M$AT:O%H^+Y.<#+"^4L#VF;F QR.">V-NGAL*+LI9"K?#:.#ST=OCI#WM3.H3
MVA*"8(8@0TQ"0<3\ J**!:$@CJ)5:%:\_=)DY7T.,J:4_:$?\QB[&=U&[I0A
MFT<6S]OV@5;S210C7.8,Y"KK0%BC5KW:6PGR%/%C6=3[D6KRS77O75%#$+MR
MEH6L_OF1-\-/(E"W9:/I4*YKU8,BZ THC#FP4=+50STS4&E7QU7-IGROF,=<
MGTM-<B"7(ZJT:;^"*H_U"^UKE8EDR:I>O!P["K&MB1^8Z)>O- W9&=7-E9Q%
M#IE=+=3/D]"SS,UI+)#:].@+MJ;:@F:5I(>4]H- T\&^ND+B]3,RM3YRKH'H
MBH0=B?=[JGP7+N:KVT ?P[M. =0(EHB=H\S9RKGV^9J#_#&38)TGR65<JDT2
M3=]*<@(#7W[.F?C<[-41R?*#_N(53$!$'%[+#![TW:OPTGCL6^&7KW.E/42\
MTZRNOKRJH,$?\8!LP;NVGL+[5K&'3WK,24BMTF37+^$0,N^(]&WD3T@'594<
M0L1;;%^\5 M;.(04Z,&'3P$-M*83 PJ$D(J.D.*S-,XG G5XO#\IZI60G_8]
M2+?,6S_7V;;YT&'A?(GFK\K7 P:DB**?M&MDW[51'?VIXD@082RJT4ZF&ILB
M]F9ES&1R_V)@[0SCI^K;,>[7E6J-\QV!_\[(]<5X:AX*ZT3AZ"!W(>T%$%PP
MZW;(1Y% QNK9;M8Z]T2C!^[:SY[2 H&_UY_@;ROSYJ9"J6W=MT'80Y9YF,J$
M'"4/C$%US_+?<LM9-$C.J/0S_T6MJ*^^,OGHJHI'ZM8AIVIS"K_=\(SH5N10
ML915Q8 IN=JGAIZW:G[8.LS3 &[--^JYJ/,6YH5_&7*GM56W*,OQK3[41PLH
M6AS_;<<!N$4]7)7 KOW=*#,*LK'TZ!-NU!D06$U<T9X.,=S,@]TI'16+B7]L
M+*H[RZ?\L>7N#\?$M*3]?&O!NSVBMNVT07##(GG,)A)GD+ ?2[EY;#)$&ZC/
M5T#;H6(A-=\2>JKF%]4;Y.ZR#U_%>U^C=!%BL0.%1,O!=N$H'W:]YO:.!&>7
MC7.27B4].,>V$JU+KO>OW7_N_V[ZTAC]T>\^%YY)30$L51Z=(]B^L)WC7&+3
M/"$Q^#5Q!%6==D=N?P"T/5VP)<0\5$D4@L3C-)>-FOCM8BURQ?]5S V *N;U
M;1/0V,>X3&"9CE13NMF_Q*A?.?,T-[#F-Z1-LOH2[9<WD)B8%1C]\:@<.R<=
M:)9M9SDKYQ5\IVB07_\5G1YCX5UK:_-7A0:, %Y  *!?.T&:-$62??._FU=:
MD1S0$S2-UR;E8-T)_)R[;W&K591YTPP;K^Z6>[2=@*>)P?3Y&?,$#-X)6WT(
MU%P[.+GV;*TRN12VR=<KFP%8\WCW6PD96NXTHA0#Z:CX,7S8#'+S66O3N,]^
M*<SU%;T@G8YCR\3+_5, 2UEY$ZT;3(![?-X%\W0:(Y3W@7-&319&^G%(10E7
MVI<?=>NNKZF0)9H@-/]WOSI#)RI)=J;S\XJ]N;+H7MN_F7O7KYWKN/9L[JM#
MZ(]L\R;UA,XLZ4#>=H9>Q^$1Z4R1%[<#KEUE&+PWVXT?]_G3(2OU799?M;C.
MT\(05GL_'N#[;=D^)6SL.M' ;-?@,PIX=#BN?L:J(G;!W:M:+R23$KY5OZP-
M)+_1"%K=3B*:%;U=Z*:9'82"X__MGSR#CWGA3(#=HF0=LWC@*+_D!I&EM/J>
ML/74 .O"\&>N U_M4'?_#X7,GYX1_SF7>!]GQ5;80]0?UB]XMSM_"VU687.[
ME6"7T-W[]9^S54G"()USP^M^A%$V-]'YO@S'0%J_DC_GEZ\=[_!ON8)#OC)7
ME[QAK8$+P6<*+IGU(>)L57*<&^.Q8$[%G9=.A79HKS!%^<7&,X^&,#YTL1,1
M0$P,O[JT@A @,L70D#8%5S<(F4H[ ZKD"5A*GOYD<=(;&R-3EWW;2:?TF>:Q
MH=;=ZW9>IP"_QT58ON],O(4A>U4N4EGBRBZ'FL6\WT%5UNLY1V62PI7" +C\
M#]@3,N+S;B"7B<LRC]G<_A45AQTV"9NWKX+6E^7$W^A>OE%OP(O\KK-XAIJ\
MH1[@!G(#]H0S$41D'G'#/6M)7&^>_>",ZWXKQZU8#K@ZTEALBE)X,X.!#Z-X
MGY&=B>+#LZ1U-!;!:7(INT8FI8_7W5T2 @/0W=<3N:E]=RDYN4<6CJ$8$Y13
MB<8]\.N$%]7OQI[4>DWVI38JW@_@RI\\H!?U39.<51,)_"'TX2M5&KTB11OO
MPQ*M;XTFH(UX'WZ7&OI.3$R&6Q\@(5<<*E=V*OCZP\NIX;VG@*O2;N1O*&#N
M(C3,0'Y,0O<4L*]JE"PYN]YATBKFDHEWBR^:;![\?<L_ N$OEHGAR;YM\N1V
MZ]1&@KY^0YXXQ^6:.-4$,V"HHL3%_*Y+0/?_MM8IE4S<FCDLF1*9]8/=$^QP
MTK:U[XA_6O!((7+S8_QY_8/%5UY7U?C$\W HEAUM5J(V"AOAP//F%* [XZ^T
MC0]QTVG]D*5V/A?08-!LO3@7)IH&*4 NV<JD>>E]SDBO]RJK]%IT7-DF17R@
MG@)@RI*/^BV3I>HRO'"W9S)N+B0;JEE6&+WH].>OSW#C+NA>KUX?41P-"@L$
M[F]\FPL-%=4\XF'9')5^S#)I.!^J><4^_G!ZY@6O**( ,9O^>AI/.7EG:!?T
M!A5_X;<F_F_ES(+ZG_K]IFZ;D^3J-HLD$2X!/0DQWI(TD$2_:)H-2.Q9]=NF
MO_1[$40]&B_%A_"G13%SG&(SB%;O='Q31&WV'(V>.G_7OV%%!O;+^EG/ -[E
M%M8_5DB=V(]1SN<D?.ZH 6G0V31,;7K>6[KDL/;:KUSALD=F.+$7V=#-?88/
M=.!2N_S)665X9U-T#TGY]^*R_EM#H(G_:,*S=]9/4]VZ&LX(]H<?_P=[[QG5
M5-NNBT9144&1(@@"44$1:8+T%D'I @+22T1 " B(2 ]$Z1T%@5= D Y""!VD
M1?H+2"^1&A*07A)*F$!(3EQ[[+W6M[YOG[U^G#/&'GOL'_-'QLR\GWGWZ\IX
MGCNY^^K3X?@N3.LC)HMXT>9[KTOT##XY" U,5'J$NDN/^IB8ZEI+Y4)O=GZO
M8QCNV55L5.PO-_-=>&U<I'-YK:WLWKZMDUXF2_H7OX&,0V?5L8W\,W.1)U5Q
M=46O@J^=SGM[(S98*1)RXJE?NGFG9V]3OK=U*2"UJJ:NQN4SB.GU\[!;$O70
M3P^2A7_]F.D>I:V3IF ].6L]>6#-2=;*G])/$ZSA1$CH]9JL!F[L6ZM&W\W[
MG^&Q_^I%_V"!(28 RH35]524)J ^<%E&V87?OH._GYV7G,Q6,6\?F_2^WU>.
M1EJ.&%:53E%!'[XD>&0=;IN@71!AO/3 .$&H$\%$N07S=.%E'Q>5--]^Y;K/
ML"D*NUTQCG03^2SV]G!S*V=2HN1*XEFOLSSF6E>!?BKH<N=)''HEPQD;$:]H
M1C_/860,#GZ_(923&,'W)DD_K><N5E=T^V=3,A*CFP!A5;1RMF12#3.;$FFH
M_SR<Z-I8HL%@+F5?>EC3TCM%Z:95GA7L'L<(@N#H0 5U%U%FA]$K8GFT C+0
M1P4EF"Y$D!4X2-)44(Y'"16$\\1C*18&__X.5!!@]0=6IR07;AWW%4[N40Y0
M"Y/0]*FEK#WZD%4JZ,'%3%,JZ#,"A3T(^O]LL4]!VTT-@5GZV_X4I>1!ES3$
M$"]3(?GG/3\HQ8&"1LP>@T\:<Q%#4"U:Z'Y)I8)X<X]]U*F@KRU)5%"(@AA%
M"1H/)FQ ?TU3HKI05%#88 SB$*;Q+]8^;MFA)3BD>1T@F2J5T<KT0U_EK-W[
MQ;\1AZE'M+3WV4"0MN*H()5  2KHG#>4[)^P.7N=$GRD3V'<0 /[0;*(]@J$
MG?N1 !>:PJ$L0@7]SO\7*_\'TUF1OA>>G)H_0OQL*TRF@I:@ZP<GV HJ:+I!
MYN3L7A:9<Q)!7(/4_5M$08 'E530PCB ^U<V^A<K-VZ+9CF.'L^A$QP\_Z^'
M_H_P4(F'URPKA7F5GC3PL7[MW29EK&) >?#:X!'EW<$!70@T.NN?E+$VHX*"
M+8(Z=><_>QD1NHV/_8&X5VK=9($@\;]KY?V?V(E302Z'&LM/?=AFM/@SSUXP
M"NBUIO!.N&_Z-\N30Z9?.O?,$_RG*2^O(AHR)WU*CIN9)O3_P:C@?[ %V1U,
M> +]]8L1T58_3@41ZHE.)Y :003N%[JB[H0U#DH%,631NLS.2(S1%NT^F!8U
M5)#6_UYV_K^9\+][)OR?Z*$F+'Z@+J<9$U[KPF5T=JA<>\U$/UP&HT'_JIL>
MQ,W-?5^V6^K0XU^UXS'?",H%QV.V*5@F2WT(+O[;[;&W6J);<_K<0(.1,!7D
M7A]YG\6YM.(]MW.CW<7"T6@1W9-B(0O*MB[KL0V:T+KIJ9!'\%5H1OUE3-DD
M]35#9U<"HTXJ\A!#EG^&M845_IL=[#1I=JC],R./09]FA_-44'LYVD[LZ(Y_
M H4]2)#FR&2::<1^]5&B,G-IILF*1APZJ!5309)'@6&_$37K!X';?YQ[E@:[
MV\/<Q8Y2:9EO>3+[_\="RS7]D!6&LU10Q,4YZ+[H/J7NN/$_R=4@=7VDF=_U
M <W\[%ED_Q9FVK=M@[J@>T_VP61ALA$5U'</@OL%K4@]8572H-4M"!NM;O7&
M&%%@>\<,O;2ZB=DZ_K<08F>@>>5J$WK->OW$_<#G/PE.V(SCHP1/.5(812#
M/IR/]MVVDUCTRN<U"& .T%1.>8;X)P79"\FCJR2.9 H&-7N0B9&DO;DP!X5;
MR \QUH@YPFYM_X-0\#27QLG9ZD'R-0M:%@(:%)ZP8T[$\(,Q!*&*J$\%"1?]
M"]U$] \+1S?$A$Y0T,;M_Q:B9F)D69,=*JC8![6/GL7^@U1(K63"$0,L"[A?
M_2>W"0ED!0:2!"WH'6G"<8[X+(JYP;]0S2)K5[_PEXTI+=!\Y@*L1BGORJ'
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M7?N(JUY8RFQR)-;B^*D5<BVS=GC3P2M_<LFH\UFT:T\MTGXV=;]QGPQYJFA
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M;=0!V1MHIX+._#@I5F9_Y%$$4^:N!5*SI]U>-A*LD)Y%W2SA[7VYNK_G!*=
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MUCM2M/W-Z43U)%*9&16F>)&B."Z2%V-%3-AVG7C=Q\^E^.K2Y_//V(X->/U
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M(Q$DB$J6]W*^EU@2UG'OV;*1-J(I-\HC.E58TG#9)45RK:<VU[L^"[CKTU9
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M86,S179%R/)'B/>E/+SW&ZQ>;C\]WS%?LS]%+F,C_E;_RJMRYN*A0 ?O7:)
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M"A=&Y%^4A0<Q,46%R3^-DS?(8"O??W;S3.[UWL1T+:'O<U-97U^;R)<]N&.
ME'M6$H8R#"V4_BVH4C1>,)-?,O(F'MW+9J 6Y!OH^S\?A_M?NDXM0:ZA%[-<
M$-LT:G7TNA85X;(E%@O=T:]!'] 8W8FLI6E[3;4RT[$_]-.3V\2^$4B1@=I5
MU?\VI"9/(;)M04"6GD^ WHF^0JP.=<:>]Q)H;W>//9I<0&-",/!4WT)6)W;*
MO0U2>8)M$SOG*T.R0(>TRZ=D$P7:C[JCO*!1RK*4SE2KEN'2^"P:OL?UWYDZ
MW_)32D:GN&5HK>#\<&S%@WD.\E5]7%V'&)W3440'%73!-P)W$&,+,"^@XI1O
M)4J.%A+BR A&N$X18-GE#P[;+A,;.=HVBG@ZRO>]MK:^)IRM=LSVD4^?N/?4
M%):<1!9#D97J)^0C9(3>1,/)2;"=9R3/9\M_'QR\'('WRLPI]AGMOPG9&RSO
MWK\15'.8@-\&[LFT@^E\'7'=<61]@N7"0/)\ MC7L;5%L(%H/1&"\Y5$TZ_.
MR6?*2K)-&"YTK 86SS3,J"A-^;[!F+-[Z')^27RZTA) /*!<A.(.X5>/S0!/
M'"1<^<$*K7)O[!:Z6""BE:5@+72$P6@X\_SLBXF)D5W-)C.Q)H-"M>*>LDZ/
M6ZLF,DPPZ14+G;RPA^HB6+TZ1.'^HN#+:\_RQLWJK@9 3;>^YS<G+W!*_G;(
M=<U+A]@4H?H1G(A6]28ZPHMI7$U6A]@ILNV$I/Z5%2A#?",QN+MMCGNTB<>Q
MF*Q6/7)K9&NYHH7(;]$_YF,1GL\Y9OIPU,ORTNTEWTN_XG\UC(Y30?/%B+-[
M^I&9(@0I;#LT[LVJ\BE@U)8@U@UFV2"+%5C#E0G=,5*-D1M-#SP0Q1JE-6,3
MO#>_.^KP5U;4MX39^:&0KBJQWQTG3P95,Q4N<?3=JX@M2]+/A577[.BN_SJ1
MS/EP^MR%'D[.Y4S_W4$EOU4=S75+T??_G5Y:]R)Z9-,I77M4T*AF&5?C)RHH
MT4/F)&Z5"BKXJ.N^D[KX=PIA_\2@G1;1,?\^1*F,'L^#BMUZ>Q_.N2#"^B-I
M:E!DJP+/XZD:TG%EVHF4\F90OA7FY^=HRYCY0D,8P^&VSO/)5(4O7B/>'P8]
MVJT-[=DIF3J&O47YS$Z*;M8F6M39M>2@A:4@4].DC\TGX1RD2()C2 MXUK=$
M)Z3[(.@6T:9&.=<!)]@D/I_ XLREG+P 9?"U3M/5,>>5KZ[0^2*@%U#_=EU?
MO.QW?6(/<D1_],MIDJN.ZK"44%Q.H(;&"&J9N>Q7QT&#%W)FSHP_.59+X1X?
M^[UO%UX*ZUZR1.[I;]?M4T'TC^Z917NE/34\*#8J38^)7OR6'E\V-2LY7I;V
MLH;-0'/F;DXTZ,\E5$<T);^',U!!+Q:HH-7>G?KH3;(Q%70#>IH*^E5/R_<W
M306UJ85K40@VQ.;VWWC:0VK_R_-&_VE&-TH<I0<H44&WZ32HH#(?]-&3O?RJ
M/<0'KP0@EPK*Y]NZ=S>G7/[?]\V0'U2?M+3<!4)(WX!50MHQ*080(F0]!LR/
M'[424MNQ3/OH]Y K<!@>S>HDE.]K<2(F0$Q)0$VNI'!,=0[4>+FX"DT>2FN6
MSSR)?1\6:(N# H*F[4SL\(= UE=S\GV@T850A>/!=@0J=$&KI>;2<6* <9I-
M-B&G]VBWZS56A3XFGSCP&>8TY?6[X$NQ,^^5X$&3A@B'].HW&D)TL+(TBX-5
M5X7IDMI4B,9=5+\K'>6BE$!D$"<PC2^%5&QOVN;[NK0?L;_'9YVMBX2+$XY5
MDO!UX7"MXL["U2-T:)D4)/(U[,BBTT51_O=^5BQ*428 EJ-9YTKWM\FYI;<)
M@!"XM3E@OB6)"'T$Z!+;K8F7\XE3T,D&:(@-> @N6$;6*@>J&QZL$YP\+SWH
M/.!E_5[>, */Z9@H5=3U*E2[U*NXT\5B_<Z<M.Z6"5UV#/Q\E*469.%K1[FH
MAG./M+D-L!:8 P%X^C;=@$[LU9;[<"'@,P&!=WQ7O4I&X%!L<&' =TZI95@J
M\)$F,30-$O%X2JHK'0GCFHUM$:C B(AM(@T53&0XV'?)O#3\4D+F!5!X,2;S
M-5K9;5&$7R>(Q0?Q^F+P^NVH&"B'XNULP.='B\(0Y?HJ>MI&-N%Q2G='0Q>*
M\4@TOG+-0Z=XU=L[+3^6U0J&82V*U42T(Z"^I?O#JVBL^^YQEC73F#:@3^J;
M:$UM#>(U&O82L?%(RCJT@[TZO_)FSH]3;IX@D;>+J,HBLVFT@ZLAG1!&LGC"
M/-,F/2$_Z*8O?0>8K>4J,(K/"H<_R $L\1KO)*_WW_JU?L0Y0K9$NDAK&$98
MCM9<OP2Q&JF>/A@MXVM(.W\F.KDO:'PJJADH)NE.6C]0+:_C)G\;Y12%@ASI
M156VOWQ=YO9Q&#+LZ-P+]MROTJF:E9D>:V>9@55OE(WX;-#23^S14O3=G)9(
M8O G<1[Q0R9"7LZ[1DN%BSI7_!UOAJON6UWQF[?C"?!"C3%-AJARB;6E"U5=
MLXSSIQR8I*E^XQR>=-WL>_ZE]U;HJWE;RS67'2!8??RI>:0!1H"?T6M]@)[[
MQ(4$_<'U>H@"!NSTZ6VK""?O7I3$*ECREWIG1GCNG-\_RI)YD/:LN+UT36 G
M>AUEX];/ VBVP+1M=GY/':WO>(\2:TF0BW]J=M95+ZT6*5](:P,O,N YG!GG
M-;:<UK468,XWMG\<D7+?YIPZBP;LC+"R7:@7_VGU0$_*!8\BX !_KH)(UT&Y
M/R& J48P3*X>B<9XEK2Z>@:ZE\Q]OM-HYJ41Z2QRK4(SY7% %-^I'T^YKT D
M(2[NG%H+VU/Z^.7()P5X+(6E$7FK\Z $]>NM+'YD<T(:+-I.4EW@/KW(XH>:
MP0)W$.^2VL%5>G&E5H][_!:4W$V)PDV;LW0S4LDQ//4S9YN+!#/O_S0M'FPW
MB/7@3"J1S*I<3ER*3M(3N6O>9^PZFP;+FYB #%-!'!*O4M^WQ'#?3,3O9%0Q
M9RS<;Y(*;L=[F F+P%]"_UK2)?*Z1K:9EFA[E>_GWO-MN)<O.)IA;&-CGZZ_
MIQ=]%_6*"E)4_8=M?5G7@(4GA+CR!\P>14_RIGZ5V&;17__-=V+U?!_B.S_O
M@QR\LO[4%Z'1/.ZF[% ;EB:[<RK%4)S;3@#(B%W@9\SP@+(X-R#GOA?-K,D,
M#"IUA(;-6*F'M9C944$.IVZ SFD.""*E$&+&KN0:=BH(=>@'W=G,'EJG*!/!
MD?P?9FQJ:DH4V*IJ9MF<&UN>6EL&X![VN'Y?>RA']RE^;FO_[^CK,87@!]<6
M$E^T;/1>ARG%,">-IFVX*]*5F@$OF%@&[B=5-EJ$NDLSF.KV2&;8<R^6RUYL
MHJ&QR_!G<+DR->ZU1-A4R.WF >^E.Z^?O E6F6?YW@I*/+6N;[*/L6_@WQMU
M$1CMV>*1I((4D*R!<UE!$0Q*^?WI=[^'X\?3%1Y7]+%*#R?%]5[X(?>#7*+:
MW<&UE+)Z)^N;S73EFV]U$H<:/%<_I)SAQ8IQ+[4@@?<XS2;C[,\B9U2/QG7[
M\UK5[76_.[7?%5BR,<7*\DD1=\62'FB\KA2,=Q<UZQKW.M]J#T)?KW\).GH_
ME5)B'."_<81:]UK-1NP>(J >6W-,0$WI8*!M_OJ55C]27R0R;.QYI_!+4V/&
M>0<H:)].H)@[K8[8/TWA-WCGG?1FD30(<L1,E4M"(^IT/;\"20\;=/6?R)@<
ML+3]T/!Y9??1I^1YI5;U;C+=^U'D6S#WV.90%OV9F3*/KH=G8O<&SN._).J[
MK%=9+[AC!@-B CG442USZ65?1':^MY(%Z^(7NMB+[Y5D5S>?-;,'SQ;+\2AX
MD,N=P9&4JXA+ZY5:%YD+UAA'I^]#DWG^XKPU<Z'U3!7HEPA92J8-YNT[TJF)
MPS4\#/RI$^N_)T!03MY#Q<)EF*+V+-/I+PJ ^F""5I^^G+IW:CU\Y>%V2$BT
M3M7DX<;QD0\5]$ZY;+H$VH^P%-E>W-_)"ID3D^ #')_^5?TQ)4G7YX7/8ZV7
M[W7>:'M;!2N</M\!O:9XXQFB3=>.079@5HW/L/N,[4N0_?*-TQ[O,^J0OKF/
MO@$N1G%+X0$ZT]?#?']&$G]_^/A)^)R)R@>/Z6")&A)]1$T F MPO>/%6&>R
M-$<ZU^KTFZ'V"4JVSR$U>W4T.J@E<6]D\&BN]WBM67ZMP;]LZG"])) I/8C+
MMQQPMXCF7+0M6!.]U: J<2N98I8/>G/^!=V5RRJ<"VG'IWCLC=\^_WM>HC(C
MW%#BO%+K52(XMDD*$B[56,(Q-['1Y:(5Z8!EN/(L&!'U^IP&_!B#AM\A^I"Z
M_IJ26LQ:/7IQ-[(1/CHEPUS>,V-^_EY[^<77#WK)(^AOHSO8T9J(9>SNL!A@
M]XL&:AY!%-'SN3$+/ SS&2T0@F2MMW]=N)2.U%@-IV2)R*.GM4,U'#HZN04S
ML\6NRL\^YWIG@@:^_GX]"P&1Z8CN71;@3@0(KCH.URU=JZ-<(YHD%W\60Y6)
M_C454QU_=*5*DT52&G4O3/7A957&]PEK :1P@C;Y(2!.5&@+DVFIFF_V/G_*
M\%>C#N?+*GLZB(3^Q?M\N5?\TRB0-!GF3?<4J)CMC0\JOQDNO[D\K[D'T2;L
MWO,(O_7%J:C+,[@I]UIQ[[,9NVU=C<]E&E>)GN:2I8F0X:SLYLN\@[Y,L3M6
M>KJ?FOJ8TDS:[';/_P;4_EJ0B*6"1$AO5UY41$=W8 HY;7>YGL9I5R[FC<N^
MZ6*&5&]*![@S.WG7A8ITIE05/I*=H>.?J!NBGXX_-Q&M\G% I759BKQ(?D%(
M] 7C4Q,4A<M+I8_T([=-^MD6&10^6RQAW$%?:D<ZPN)Q.^^XRU\%88.ZY\3<
MN8/Z:0AA_Y!?0H]RM;S\._^6K5=^]NC6*;?%YI;=S&<5/"6[?*0=PC9)IAN&
M6C">I(&*U=1EANKJ"8I77CW?J8K?V6_DKJ<JJ07A<)>5GPX0S1YCJ[I_4V;5
M-V^;7C+\-&J H5B/EZ8^^Y(.^0EFWY'_?D= O,_E3LFB',DV:6*I"E'?@6FK
M$5* S-G.C_IH-6X7$UV\^.(O;)R]+;B8X=F3AUII)]14HI_G1-_E' +T+=+;
M,V\/*:K0O4I7GZCN5Y6^7G?*_6W2$YE[*1?76;J\@[M]Z#BE3J2=,'W%JQ;>
M.1&"@78PW]# D3IIXL!Y)8_C ?+\Y;,(T<?D4@7F0;MN/OH*U H51$),Z$<J
M,Y"EQLT_YWTGI'Q(3)%3=D765[_1?V-!E_4HC6S4I7CKK<03?YVTJQ5F6@HN
M?8890BK6;_4^S35;K@V.*"JBG"=3.%?R]9)]CZ?K]2?[9FM3C!*:?;SL-UT#
MPVD=JRUA[/_UO,M_X6(2!SJI(/YC2RHH0)]&JL)JX I0#[@MC5<%(JF@YD(:
M7VB;:N%MW5-\I\$3^?>)D!,<3-I#W_U+9R$U#V%P-__/8-)<^B&*>I&J@4[(
M"H)/G2F;' >Z3:]H-_9V/=CCPQOQV"TEO5,@UO?_X7:0$X A705R;8E&"XX=
M8I.#I*1ZX'9>T/#P=#_1I\T_H1W)URVNBVPOE/X(B5*\2FNA_F_GN#%BDCTO
MZQ+QFEO9)K8"GRQA^O>!/BKH3 S@0V28/]@@$B):(<S[V A2UAE+JU&I;6;I
MS+26&J)8FXWTF*L4(M+B<AV_J<GIV2;]XNF:R2PXT?PP@?&UQ+W/$.CK0*9%
MIS_:% :*.-0T'/I-Y\C^?M<VF)5VJ7AN?4H_V5/[06*H'_*L8)=$ZJT85^LJ
M8@DIAX:-M:8H0VAF12U\/WCA;$2HH@Q>C-&7OCVEY3HFB-L,&#4@6$&9;E:'
MZ$3@J*!(-RFDO/[Y5?]/TA\+:EP*S24/'#R60V51>N[ G3%''--F#:$<;A*(
MK05'2I[X[2?ARA0O3W!=+8@6H?2<%'1;[JJ56#WX7&H ;^4J>/8WM@A0CMB1
M?'X$_GO8QR5(?E9,!(%*K*0,M'GJ!?7O/EM>AN\<-.<Y< K9]+P9T#(7NC-2
M.41^_,?I9WR2\(71CA.F"\U?,E,#\N%\-2D\ ;CX+'P"BQ,&?6%#TL72"<Z#
M3T>^F5ANR^3!_!X>"332&-W4Z75PRESL, .[_CGIE_9AC9?SY"M<@0IB,,=#
M>!"P+%#0,).OHD0$A7D;4-D74GKH"^VAC,P6\3R>[F=+^Y""[6$)OZ)31[^O
M\"=N8L&/#KFN-]2D]AY,36./9J"3OQ[_OJTU!RL.V!W7E@@93=<I[G,QKQ[/
ML.OE+5Q#9+G1TZ-4XC]]JO_OFH\HA.:D_@]1(&W!_^'*KV?^X?\F39G^1*!U
MAQWD\DNZ(J*_O0^8>(^G&$DQ)']FF5-&?Y-U_O=G\\P^&<[_L>N?9QY>4!/]
M$[C7_JP)2MY-W50@>':A>5K TV0E0EU"*?E2[IK\;"A%(?A NV4LAU@8BH1/
MNBMR2 U\IE6-\.2"=:.3-"4;?._")H>_O[[M=[YZ3ZC&\_\N7^6J8%<I]^T@
M<Z>-#<K^M]VMZLFJ16@4%72*<INL?O)%"O4NI44 ,)]?@:OAIE%G;;!.O/3$
MTRO^,J$6<Q-8W4K"0/C<G7@7G>E3('.N[:=IO6;)C[TICC^Q&@#?$R)[#$Z7
M08-HDIWKW#"17&BQBK$(?V_KE[_JH^-PT=*RW]T.X5=D/9U2%WWS7E^ LH/I
M7=6K@Z;_(UTYT(M/8*HLAG&C3Y\"Z58?&V-= YRF85,';IM1_\$N7/_Q ^@?
MK&>-CD8O,LQ#CSG 5)">:7+'GWL85SSJ\#3 440%17L<!4.6;ONMZ[J*Z8^S
M_!D2.8W]V&&@QA;]OYR1O;<=@MUY*HDX6@Z@@O(&;>QLOA "*-KG$J@@JVW$
MWN=5'4=:/;ZQ#B9J4$':&C//#-2>OSW+%OH>,\;4\8%^2?,JT3N,"CI[_B1)
M48LHWX?C_4B4*U.T+@+Z+ %/V / M'-B[FHJGB,BOSGB&>$^$3D0P1':'8T/
M5-[M&1I D=8K& )3!*.>/E0>^;I,SQ-@;^\X8^^X^G$?%;J'  0=-\SQ3$R^
M=9W^8EU?9 P)V\&.TEQ+2)>OOM]TI"<&H\44KS.%2\+0%:=](SI3;?@J&D:1
M\ ?9/(\LORSL&O[=]CCB*W2:UE",DG!YV*LO@-2E%6F*-!44!E.. (<W&5)!
M5[X"L;8Z^01)["6,AK)T3.>Y7K-]NKR>;&3OZLB=KW\+_])]:$X*K#W,U,*Y
M3PJ04@%;8M8")%Z9'1X &-L1MA>@7<7*]UWFF(BIK4(H%M]<W:2G(V]Y^,R&
M]K#7+'P7M.)LTRY=XJ_XGJZ>O'G[2TSIVGO]#\ HY8([@ABPP!%)]B$:X3G>
M2VXSK'/I=\Z>VX-S R^#N."/@+ <N!FA%HD#;Z!C6OBJ,*BW4'85G.4ET^-'
MNFDBY^;PQU;E%6-B^0S<Y?W[PE00P0#]:V>T59XI89LB\JC02?D.$173<GVE
M?(V7@QA8&"FFB)C7N3.F:#0_C(-5\Q/9@OA&D*D2JX:K45[\^2_>W_9^ZO-G
MJYS89,%Z=\M5P ,2TZ22ZQO1=13_,0<P7.[(8H('X-"7UOU)S<\;4C[BCB%7
MUS.YRPF[+G6U R7LGXZB;0+STA]<^VX2>YTT,AOD%+03:%1;-C',7[9G8W'H
M!]OAZ&#Z14<J &H(.FV(<Q3^H#$*'?%.%B&F WJQ2870 6E]&?&8^)8*NK@U
M*;(9I.2TW#DB$%>-9H:==94*!*LBF& Q1:TN)>UN(^HW$GJDL(  :I.#4/*(
MP (7)&+?>5%!4<H")TU["5.F'7.WR@%C& X=#KE4;4NHU#\[NTK*8MK;9IZV
ML@&"AO>F=9SBRLK2J@L-60>%K/A'ZZ92T81G@[^\VSM\@CBR%B1J\V%XR%5?
MP9<AK2VR]2,U8!Y 8@O?!R6PQY0^PF%&O=!<T_HP3Q*"$68JX]^\][I'Y$LI
ML>3^ABAB/AM;:8UJUS\'-TO%6VWB:'A&#$,!^VK/,9WW[5KN]*^+)XNY^OB4
M ?*0LY8KAL W)N;5"9*,A'Z^->S^S+>OO0X+C AK<O>V",;Z^]N MSH]T.%F
M*>4@0AV9U<XXHBOK,D48.%Y0S!0":O+@=D /$877:RX$M+&/AYJL\4S1:(8<
MP,#N*X!XS!4VD\E-P :3Y1SR5?+:/0*+L7-2I;MSUHH8X?4)&RJH5:%) 4'
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M#/Z"])SZ^S["_.?.!C]^,_KG?3,7+P]D9+[N:LLW?_C@PK%%<Z"^V83[HG=
MW"/C,=1M;_XDJ=^;'9U_961:Z.6_W]!3=SG:.,EX>YXL3A#"Z46QO;CI,(]@
M*OD*"B)9GB],'@#U*296B=^ =V!VF K?*VWFU');S4P'^X<S>=8O^LQ<O[:
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MAUK,LY,ZDF+!39L?%NKI"P^7@[K!H" Y&D+YD54MULV4 *W&= V"?75(_D
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M^/B48SNX DN^&F%P\I7&/IF ]NXY^9.X:C#3'%F9Z-X!92%+TP #:U<F/["
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M [G* _L9]_,8KG4E#B,5I)JX+12G)\64;QN9OI%])\KF^:_QV[[R)-OAP'#
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MLK&_M?PB23O+K"E0@#W(KX'<U$AYQGY5-*WZ[+WBCP# 3WY1O2\6_+KF/&6
M% Z'\*\W8\DR8P=>;#!0=^C=1H)4'RIFZ6H[\9C,.@*.6KHY)0XW"PZ$P?E+
MM_X:TLL%R^A7;#G355<MI0Z?&M7K<]VGJOG#@@_AQA^WG0/2$E4-K$QRY/-'
M;Q3]:L!SNR(_5UMX'#P^&Q%0Y7N-Y&'2?=)R\XI@6#FM4+3[BPS!-RTK8=[9
M?OA)Y(.[/C(T/_F:Y?Y0$Q]:DXXKX,ZD><)N3]Z-@]&(+4+U /8%F.80' UD
ME=ME*CY++W-N34?B0EYIQO5R#2/1KGX>>IP':EKTBYK"#6DIB_R-,G=X0/W
M>,15V2K@:EZ<WSD@,?0N 8A&7 F=R 60O%=04=:2M7,!45[P2PC$"NE9RDR/
MC_6"?"%UO(>?AXUY:M].@4[C6;:=EJ.H775:0TB6M3L*N&<GB;/\T9MY4-3B
M=+OECJ88!J7>M.BSP;LLXW8R?_1=<86:*DR;X8+@59UO[S08?/S35#ZDIC8Q
MB>O^JM45/.!4L1&)=WB3XK]ZX3Y(%(=B)UN</H0_(.RDKHXRN(&NDS4^P_Z
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MF@Z/CBZO+M7K>RG,GU=>I:DD:BT ^B( /!8_J</@3J=:9&U2 ^[,Q"B.CX/
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M_2";#WJ@W_=*]TI2@+CFP](X[N07]L[W-;0OV]Q,'C4L?"<V.-)4FOIN[,(
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MS_5)IBXFON<?G[>R".KLKV:<=Q K+A0ORDI)J2M3&G$H.>!$WOM<]Y$3@Q[
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M(1E T3Y7B<*?\^?>U1J"7ABK<*; 7%&B**H]@*ST[]!@(=,A1MX!Y4 3$2,
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MD[C4<CD)$LH@=,&3I7O3#PQ\E0&+@<NVN>P&H^9[X?6-A-T3;)\A]&4&/U4
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MW,ER,VSMM:^,TC/P"86Q-)<BAZ,,D*VBXLZ49INGBRAQ]<>-+S[7\LK15J@
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M'[+"3B+2<I)E:TL&]W'SF#(N&L\;^@D!\ALZNQA50#>#E.J;CPH"_/(\Z*+
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M"8C!>%).=WT=H7-\:#!-D#;*5D@B"=TY[_()JKE4MQF?LD)_*:1:Y=2%I5Y
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M5!!4"(?CV)OOCM\#D_:"'N_',RWI'>RUA5=8&SIE)N_3:1B&GL)\[.[$)3)
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MT$]!0"OBDL 4]3ZZ#RJ(XL"43'K:"@1A.>EBR[CC\Q39H<KU!_F?J]-%(.Q
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MX[F'?HZ\WU=4DFS:"08HA$ V@#S+/GU0CYLA<$5BJ]T[B:AI+B","([%<E9
MWD$I2H-K9?3SB+U,SNJ"FG$]_W=>INZ!]P0%4;TZ9P/'[!$4'+&/)C1(\>%*
M/(6-P=0LM%.3GFKZ1I,:+@.^>J..)' T2H7UZRL[XT+X5=_<Q?V$29##)&R7
M.J8PGFV7\N!8XHK;(DXO=*"VOG'+P9/NN-/O$P G^TNO;D,]?<="=F69W<SS
MS.:O[V\*+D*R?-$5 QHY7[,;)1 WHEO 89WB8NGS?ELB3BP=&9K-$4U;Q!&"
M?22_#R^8F(C#N^QF'21J'Z(0=L\ R50AO0*\'?)R!_1H >!"E"F(4;Q'7LV4
MBDQ'GQ@Z9Z^'IAK@!K<;(](,,X6E ^]UJ] O,PF[+AA()1IV0$51ER@1X7AX
M; L8J.X0YZ1P8C57TP?MR?/%@7G+ISXL17RN>?'^2&1\[N&K1Q94RJETS.BR
MNTI.:%.#O2-YT-%[\>&VI?[55RR)^IA;!+*W&HUOS^(@15?%$UM5SPP0[AQZ
M+T946_\WTOWF\'KX8R8(UY59;KE5&YG+\6-.'T'LX^T5:\DJO[XAJII1B2B1
MZ[*9,Z45C;J0F6&KJP'$S4(Y #EB?90* \2/7.APJ$U\0TQ@:>=7<XC\7+2\
M9\O=Z<*9Y7V_7".K0E@G1;$SFF20S&=Z-"LS9*4> WEM^60B8!NQOXJI4%LK
MIZJ9'2W0E0.X3#/7"0[);#$U:XK'%1_#S<_S[_?F73RKF(&27Q)TNZ26]2)O
M)&/U.Y7W]J3QW5EL7-U1K<# A@%M,:DYA<^W<CZ/LG!=_!C6H'4Q1_?JRXL2
M3'!./ZXW@\,3ON ^V'Z!'D%/7AMNT4&ZM,-R5K@5<SFK2MJ)I2(9<:WIV?)#
MY7/9(WN=-LYB_*J90[_,'I;[^U+_3"_>Z-W7+BE2+0(%?@&APP[C1#.>:9]V
M3%32=H]I-VF2:T 6N9X.Y[]U<F2-I+3C6>S<4/;'JTS,Z,!9/0GA8%FTP >>
M<)FM%+6:04%8B56FG&1R<7AZZ(DT:&UAVF:7\D7>9>CCL%S.)Q"^HQ2>=JJF
M19KT\9_Y"!$9>879VKI$=6_B]5C!>U>2.WF]>-1G]=M*SH%*WH% 2S:+.3A/
M8WV93IG._[+L()'2_W?Q@<=8@:M+Y._2P[]\@[SK'S/_I\LC_KY7'^^?34OJ
M$Z)?BY4!?=$Q-#>LVF$2'1"SL"L21K<S)@7IS7V8K>Y"+VC?GVV:3,[3TRP%
M1R\:7-04SUT,B77X7[^U@4L)Z&2 )*B.S#P 8R;-B%J4%MSOWYCP>4_&3 S0
M<NY"$IV3#YAREISZ%ZJU8-@%!V0S6B'/"*?IDC1EBN]SM-+R*9IH'3F+ >J$
MB@.^K<D(<3:R[IM9]9E4@Z':<A,Q2]_WU5*_>>;U!R6X+QD=I7$0<H CHOMH
MU#-:-3S.^>S?V^?A*,S!)XS7AC#-+XED$T.% AN&P)4&Q60B3'1\T9D'P/D1
MRW59AVK@0HO[VO5/IM_G+]G6%;6)Z2O7<OZ>R71]P':? :K(1(,'U*M2.[J4
M1_@@GIIO$WJD!3L[6]S1L2:R2X\K4N,\L<6J4/&6$X25;#"Y&=>)B>HE87F7
M\.C2=T@'&/]B%3+U9M6P]]VF#]D3>NGS"F:]O344,U',?:[:[F^&CG5P$32'
ME_/Y:C(ZBP(G3C% <2KLY=>ZVMM5T9!?ZRHKWZ<N&,19U=0/Y#0CQGT>N!DF
MSK.&]YPNE9-Q.X<[Q,1VX'&MW9\4[)HTQ\;SEJ.>FK[M?:ST?C"[MLM,%N;+
M$VAK*&?;!I$0Z:/\77;'R;$K:+^\LA.!Y?&L>ZHP$ME%,$@U?VYCY"/U7.9-
M#AFS*D#!F@YL,T!\3BCNVFH@EXW&^XD&3^U8"28>I5S'L*!_=>[4CIX=OE&:
M8R218O KI]%T_$;X]WRM>R4]$R'CWDO@EKT_.MM#<_OKLN9^=O8]U[PU3/@\
MNQ[&Q:)_TON->XH?:2UG/AZ$3R'Z$K!L 6O^SN3>O4Y8U CZ/+DV;#E;ZI=B
MD]/[UE( 8Q9_-IUJ-SC7Y%BNB3][3LBM,5$RZ2$/G_;)%2Q>8$8E^RG]0@/0
M3VZ8:%=:X4$&TZY"$U%:_/$-J\:\*8L+%B$4[X-"4?]K&ZX?A?HE$[(OBAG3
MU.#CYV?GT\B7=XN \\7TK^G9EX'&60[8;%^TM@+5,HF'ID7UC5VE!?I)CD8%
ME*N2&"#KL,Y^PC2>M[]B>^VVO6>ZQ;S;R[6KME!/Z)C<K&06;C6B""4.6+F2
MHY[26::1 J2,IRA6(B%,<Z2R$'5M-"!4E\.E\](BE'=]#256[J7YW%#W=2C)
MSL>G=L+FF:*\CUZTJ_0%KY6/@XWC&PA:9>GV#>3JO?BY#XFWBYT555QT/6]:
M_/[],&%*?<L<E3@R3K"E9I%\$S!L3?S[1]"*0#%YKYT'*)&1)G<X[,4KBRG0
M]#A&6&OPFM/PZX''?-@AJ0I%R9*3VG4/1N.!J-VQ VQ DAC-!# L0*Y<HW Q
MHS<R^V@3I9D!:J<ZN<,^- W/AIDU#<W^VDZ 6R)K2K/\OU8'-5<G>KH.E$]!
M(+.)DY=MB87=N+&,W6%,&)T5@,QPA:4 U>W[OJMC+9R#*$/%-V1P!YC[ <IN
M_V=Y<648S7L6+K1\WH(\'Y<S-C71GC.-4O57:>[PN\HZ?M00G@O>-0%^$RMC
M"=S,40=P?Z7MC!6"WNGC0,F%=3F@<V?D0@B'42[]VNS%2]-GHIR]81;U0PQ0
M;2"UNW;@Z.><WF".F4^]OQF@<9=/<JKXT2GI_-4)>!3BSY]4>9]+9D7$D@'3
ME/4 +V-=+V_U-K\F=YE>0T>#"^M+Z^@Z0&0W T"0F*CE>,L9Y :<W-TFP@Q!
M/.>;4B"DE:Y&J8QT&7;>L+2+75*U37;J="N?[!C4%\JXL74VR*^VY4[NHH4>
MZ-M5JT-'3ET]XGK*\ CWU_//Y?Y, F>IDK000(<$>Y8M >13)=JIUSW8=LW(
MX-8>;3$,B2OJ$:;M)64]BA27Y>C<U!37\21W+#35J@8IA;4C=V2,/AAA DK#
M[Q? BS[?H!>^_814&[K]QCM*CQ'=/,IVK\7MVKT&&202Q$TN@>*+3CS-LQC&
MPK&T2P[X?73\6IM-J6VFRIV9F93;_>5")CV*CQ?,E0G03B\KK&*LMZG^_5B9
MO,?_<AI^$!,829!\J2*##)#9N4]>_]>9517<-WCJ.<?VT1U##GU>*_G_>EON
M=[HL[>]NR+90B'[3B'QMEOM-B@'.C<C$^2[MC_4L*&PQ-$,,Q]0/8><,K\VK
M1[=KJAH:&S]]_EQ?5U/S;"';[I>/[GOX:?08[IB*;XQFTBH#1 KQ/;H"YM'6
M(N-(:2.XV230HD-6W>L2Q+3PB+9<F0=/[[WZAJXP1%%OP?3T^&WCPMZ2\<Y
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MLLSH)@-4Z(P9_D\1[_]1&4CE'^<%X!E,)/2/U3@I_KV7F74TD$.KW:8*W<X
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M<6\I %H[5L/[I8XSHN>"S[B.7?M\>G?:N OX1?HS-+2/'(_YH,*$L=IZT^\
M%OAY"=M(1SO6,QL1I_KDW!;BH.*7-X=#FHO#4Y_P0%X_Y%_D.$HU=[W=J_:+
MW2B0=M\E0ZA\ZNU2\8'&U6KXK.5'G.;ZAH><B(L:^/M/_=5:MKUR\LD_@]U
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M!.%]6OO99K&!\;\[_?=7L8;2CAE%C&G/)F[?]WM1-)D]_OLCM[8_!/+-]^K
MZ(/TIJ6_H1LS2^Z<X=(+*B6_G_/CI3UY+Q\#XL$L<_*!E[@;@"-;I=._T[^7
MCDV2/YEYODY Y&*Q17%;JM"^=X\?"T:P65G<??QXL;L94-08;\94>C;/+#*_
M/JK')32J(!@1UGGJ8AE+J+N4GY,/+R@]>QM&+WF^<7&!P_T].SD9L0[Y[-Z,
MV4/20MD.::P2XL"'C"(8^*NS_1KEG%,TC1#7/$__G>JPMS]^2B@^VWMNZ74
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M<2''D61P#FR]LO#@9[#@01A+77_@C/3F-".N)0X[M1&#!B$]UT/)0 =KRQ2
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M5V1<JGI>[M(V(LCXF/? ^)U9_0V)RVV;QJFOH8ZN]T_)LRFMMU]G1N!^;O)
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MJ!KBJA9P(!=TUCT7/U-/A]5!">K=;-YL'>'3S^&_D,'DZ3CXDVZ<W 24;$"
M2BJT\Q%9=!@!^AQ0B75<&DW$:*V)?;=% M!.^P98J<] @$ ! LPGP]CWV!!7
M-XMFNX* =V'^?\J_1_E!)W1V3XMHGZC+2)M1DIOD:MA?J[78TG+U4E*Y#X.V
M;195B*:6E(W, 01HZ&50C'5 I.MG4$L#!!0    ( ,6J]5S/:S+S)98" *"Y
M @ =    ;GDR,# W-SDQ-7@Q7VQI;F5C:&%R=#!X,2YJ<&?<NG=4DUW7-QA
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M@)Y%M_"0B'_9;OW]C1A  : %, )8 5P 7H 00!P@ U $J +N [0!!@ 3@ 7
M%N $< -X _P!(8!( !CP') ,R "\!.0#B@$5@!I (Z -T GH!0P!1@%3@%G
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MR_?0G?AR[ ;4ZTP0$XNUP3-83!0X"LT*WZ,"RZRH\4*;G5-[B[5O $E8L:W
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MUU[HKORXH[_<0VR$-3598)A%[/U8F0H(S,7,Z)':]$7$![D;:AJ_#&%"#]X
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M[=8>KIRU9^(,:MW*!LHR-HK#%<*WAAGA>A=4S8/=6L E+J([:0R?AJ7YV4Z
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M-+/A'9>[+@0C%O.,U^E2EM"]IWYW458>@IY2P1CVDJ#C%'I\8M^*/+^_$&N
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MVKZMRU9K!\&]BJ,[_KU(6('#]VO257XB!=)_0,38_^LB$3S_ O1$QH":LI(
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M<' = [N@BCI>2:LURB3HN/;9Z0&!8U)ZEDJCG#;)O9,I1@_Y*ZWJ3LKV95;
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MA'E\_LUY7/8F&+)>IX^M8=TVB5%"ZE\OD,+O@DPA88QCR7L*#B9$20%T=K/
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MJ*DD>/8@Q]F:*QFJQ<<@X"C$[D\1YXEY?E3-_FMK07*0*WM (?>;RR;OF,W
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M_A,YZX.#/SL>:0S+-1OASJ#C6L-G]? (^$SL78;Q'UKEG(7=Z!1A.6]KISK
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MR8_(2CF^<ZR3/<V(-_)\!?7IS#M5 "&4A\2K?$PR-BQ*28A3Q@2G>]<9=$R
MAGTN,O%/300,>HTR&J'WAIYE'JG/!FC\<X^7R"W*6PV/'*54C\@K[[Z5"Y 8
M&HP0PT/42++6(Y\LK96?,-QQ767U7U4\,C+C3M^O#ID.MNU,L9'_OCP],;X/
M6US_8?C&568C(]Z1R41SZ3EOJ;^*FI>SRDT97:OEX@&ZQ7_"C.X8?&#@^$M!
M!'-E')4XD2WG*X;G$R+@ 9<?AO9K)&\J:\*5R/(^0)&J=NVYVFM:DQ?)[V]%
M%JCH%25G;"U^JVH760S:Y2'YAH=(JC'(WOOV-Q?I*CR5MI0;F/V.AL(^^=F
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MR8Y9/0UAUC:+;FS<F'P(3T[P!E2L.B9>*.@8,O^%*SL9[=^1PH3CQ/+:W0A
M&;CG)=Q%$$[C?A;"1HX3Q!SU6M8F"(G06L[71K"[SS#!XT7W'TL_6FPLB%?B
MTBTV)Q%D.?I7Z3;ZL=SY2JOT44;(US<RB[0&<M:*0MN,>^JHWT*FNO&51K<8
M5BT;*\LGU[\LV:3G: E< WY]55BD[V7D"4<V6<C!Q!3 1A^P"DQ3'D/VA\FR
M/2A^?XWZ;#,(!4W9FC6+T:EXK2PB)\.ZHWDW!6-I-W] (/M]J8#G;N>\U$>$
M@:-+L9S\7+IHFT#D5%M3TUPW:=/%(9KNM97GB[?>Q)[_K@$X09+>E >$?N4F
M:*_R8B9*/?OT@CU!P:34DVFY\8LZLS%VY?V/I'"=UL_@H(2U,7)F" )ZH?:[
MJW07M<BKT7>+FD#Y<+PXEB9.0:/PHVI!.ABEL\3R*%3FC'?N<Y1=XRK&V Y"
MH,'E7%)&_'D6P?>#/@!HUQ-6D(*7?QNI-/T=E]E+YV@Z(44NRVUF_E=S+WO%
MF<S44SOAJQ.QRQO0[F2L(*HE(0J+2_:8.AIEZ/[S>TLTU&%KPV2[K0.3D^AQ
M.)LKP&TZN][0H)C/A%1@DT HTQWFEFK?2D3J4[=$R:&$/ ("1_R7A#]TF_2V
MC H8K??9_S/NG7'7'#)+5R^1Z<.37541./Z;POO?(D>"*'#TF :#@M<X*12<
MPLUL(;K8R59;_IVRY610 1U>9U:$D5R#M;\1LE& G&-R3GX5'$XJM.25XWEI
MAV=YB%IF[P;?OP8XZ9,!??6B=/]TB"DGP&Q$=>N3GC0W3!XO$ZG5US='2][[
M/,CB/T ;83 DC+?8!B.7[2 K5&D]!6Q=$II0KA4I)?YQ HOE]B.!-"@P;.1%
M,Y9B9L:QBO?U5/"#,XCY>9RC2R*#.LO4-2 JF9,=DQ3Q&_AI<=,:]^'7Y7L2
M.9?4<XKNW1[.W \ 5&;9UHU+(N]38D-YB2HJU$8[QO7T2EG_K7#P0&$9$M6?
M:9'IF;!XOOB-R!H5=3O,;5F",V>]8^O0Q,K+Y;'H/P*FFQ%E.Y3H*< P%NHD
M\CWKK;9F+[#>1@B#8M/7WJW<ACFYZWQZ&K$1TV%@//4C*ARO:(R( A^<&'WU
MW147B#FZ)"?0)FTDB*9L8)>:+ 5Q'_0?JGY;RLI^2.X!M?3V/%,]B_0/&.>_
M^N\.G\= ;;3=1V7[6G(K_(NFZ>,=&[L^ M\LGKID1Y-+NJGKP70-ND OW;O4
MI*6Q =[F.;)XSUH@01.=*F6^KH-70[/CN&IWPRL)O1>^ \*2GF J @<"0ZV'
M2U-.!*/X.ULG!F.?8%Z&'?_9SO:I#/9WR9"#X#A>"3]:V'[RQ(K1X=/C&CCA
M/@ZWCM5'TR/&$J\!E JNZ#RCOA5JG',94,^76+MB2 J_(,GVV,9W[X*V"^J_
MH:V8#C_U_MXTDR0BA-^B(]:V>$R[[GKB[J+ G(L0^25!,9!ATF?0CU[/*1_H
MY+9X9S#9?:0'LR&VA2KF60;X>024ENZ^$R6R;U!BQQ9\Y.UK):%R"L85("[.
M(U0)W_4>C?A[$NT&4M@*QMH;)E,_/)F-*=3+D_M1*"#RO?#><)%AGO*2W8($
MNG&P>S6R@$[IZ>)60LT(9K8[@@,+LA1<RN$[T80IRFU@O?ZV/]29P8X.L7@_
MC3=-=.[S49_!BV-J\?0A?2O*&,H<=\S8J2DVLR\EA=IZ)T3N&O >SQM2OKW"
MAEF%'&<]UK9YNVE>C[F:*0]^5LS<&OXJZ#/QE]@!3V1]+_-) X'LCFK$C3@W
M&OT8NHGA]%A VM"0]^W=@DPL(_*X=A".DX[6O]W<JY\B)O!/8[ 22]G[3BUK
M;S!V##(6$W0RF0@96U2N,S+1M?^3<JS6JOW)KV]SHP4L.E3<F[7R+F6$S35V
MY$B'EHRFLS/LJ5^UIKH6]$=[4&L!+/5MQQ<S\7;]XPA%-*5X)1I^%R-*B341
MH>_V)R'?F%ORX2@UB_I568'3,2IG^LJ';G6HZQHN:(#NN0HIRFE5;:K#IAY=
MVA%(5V_H;XEIWFM ISS"BV#9(VNZZ$!6F+V2C:I\Y@)C;S.]&<E*\B^-<+EW
M?T_EG/^&Y:=S?<HSTVW[H1'IJA'O_CS+85W9JQ8G) I1=KT&)+B>OL.)8A#6
M5]^4Q!:6-)RK_EVP3D\W999X^#[Z%?3RG83.3*.BG?6KOY :+]B>PJ"3BT%@
M,#6)&K[HZBMWT_2-!6LCR+;C;&=FV>A3T*+]YS6KJJ177[*!F*XZNA^JBZ*9
MW.U 2%5?O6:;V-M%!^]1E94;_ABL_!._!O08*[N_ZN(9\H _8";0'4?0$Z8?
M#@9T/;X&?#R=VBG6"_W0OM*5+-+'9G=@I)>*>B)XIZSZ1&:?!K7+9I^]X2E8
MJW"7&A* /XS6/&E+-L::;][3RK.<,8\S^#Y5,;J-3? U[U<CN'X!5@^>-^DB
M<@59]J.9%7]WZ(_AR!\.I@UC)J!"S5S%D'X-,<0;;@8D=]* *NV)!YEQ.J,Q
MPO3,N-5#>Y\JJ@!CU>JC).ZV2@+V&)O?Z8,W=$%K5[8NO),;P:%EVIY0Z^W4
M\V<2GFVVK45N87GY:8'RBXLWX<M*>/?9X:]JO\\OV)QN>A>RPJZ1O><:$&G'
M '9-XAQ4KA_KO08L$!E@77)"JMV5^+"(^:YBE)4G^*%[DU40YS-()6FSXH('
MPZ4N3)?+P$E>Z2_NC$#)E-8K 82>VDX>AR<)Z,?^RY?QUI*G^_ N6)(YH9:R
M)HIVR.:,E'44R@:]RF&)$A^A'7G)/&S897&#FKP8DV8L'$]]O/,B:"8319S7
M525B88GR56]&F;19M/)OG%=LZ$)EQ[Y5C(A39(H-^.5[WG2B$?=-(,79CJRN
M@HL ?6T&$NM!6VY6(.P<4X4B2XU/WSC?D@F0W,RDQPZR.+62).0*IXQA<K53
MD+F#B.UYLX?H>IV2J7*-V 90G<-3!GPG"LNH@Y6D67IB8'#Z(TES&BH0S#^9
MI[R@OP@GD-DAQ^8R%E$'T9+_35]1?M@E@->9?-*%*7A_/((M7;1T']#VE!=,
MTMH3%O4Q\3EAADP<MS.3D^<DS*?Z<)A'^BI??5%&?E]E5Y+"!V/&>GP35^NN
M 4E*]ZCHMI@VH-]Q^<>XS$M%O22'X$>9FK5 NU<IPZT?[Q5EK)R:'=E*N9F]
M]4R^P>8G0C<]O)'0B&D>L"-1$L2%][##?'OAQ%LA;?HQC7F&S.%YKBJZSSTL
M12I]_D@NU,;X!ET%,!?;5[,JK>EE9>WM/X/=&SK2V(VZJ3G9U8\N^HA9 NM5
M'-R[FEP/R]988;, M%+')GUG>@%,T9_RA45W_1'=KX6Q;+7M)]7T^SRRFHE?
M-=!H378?H05Z=O<XG?-(0+:-1\1W>>QS7W<[UEG _$,S>,FSWJSK?<\3LB6Y
M5SYX/Q9A6/1O5'/F2X44OPR4G_O, DZ/+=5'0RCH'[EFC5%B?.SS, 2[7O/$
MVIAZK['HHZSI0EW'>M"99'9EUGIHJ2C=]D3)/;U'*:)-4/8*]?M7*9?>X!Z;
M#N9+,9!N E(?(1K3-CBHG*2N_2J8BL(M,\D3^B_3#,5=/W' "ZN?EI+?"T#/
MJ+4QF69"E[1I[E,O=;QX+KA9&P/&6.<9:>#JON%%KBJO 2YPNHBQ5<RG)4N$
M-YK\LM-XL%05+.1GN6TYD%X+#'G13OAYY&32TO4C=<N;-L/B];<P7/'IW9;Q
M_X[I_P&%W AVOO=L7S4Z)7FSM]B:G"+*.L$Z*6C-:?+C_;<$&JOT^EN)]0LB
M]JL?I?;A&/\[A$?>U*=>3;"6":M!\")!JM7\&_#[S#4 1?].7B.*UUU:N+2K
M[(^ $W)4@OW>WW"9"'94/&.-4>]<8GXI3XW]%P1MW)A]0K^Z7_\T8H2:"<8W
M_]K8748@,,JZOMUZ]#<\_I>"*E:0OA?DC2ZE2O@Q;TH$D6F@34,"V4)%;C?1
ML[[OWC!7Z!QD3JF PTRE:4^Z@G=YBDE( Q:VGU[]=]K@)OOWZ')=Q>!-,-*Z
M4=W/V*0Q!_WFP;I&)C,ELZ63+A-!N@(':M':>>(SJ[KM"48MV2-FX7/%J>@%
MNG!@X3+A$Y=^_']JV0,$^:(NVWU9<(ZGBMCE@]VK=[4U<44@3>RSPG(W=DR:
MP!#/.:P\)L9709%V_9??SQE+4-NO5'E!A% 9MM4N%HZL.VU;AB-\<;QJ!?&<
MK39^(*J6*(MD?,-R OP'7IG^Z5(F]\>*'E.U4>3=F6X9Y3KE&ZM,Y6:JC-'R
MI;&T<+MP3B]-0-5^F)4SJ2Y)[VQLRI%DX\!\]-=VO?-PD+9=/?5GY3H'4M[_
M=Z!]@"U++Q*H))-;))LLJ#BX=AC?,N^(E7R\J<W,9%SG 1%=OC$S)5Q%^<-A
M-OWYT8$#2EP;6;-)M.+Y$@54SA'L?QDUJ)W/K<59&ECC\K0Z1%E62LW,Z!-B
MI!2XK=587O3S:C6&RGW)HU"[-YG.3\@DC!4P=[!?JH.>8*0'?&\O68^@:MG<
MMBHM5-Z6988%#0^L7&IU)4M_=NR<K'7,GU@G^G%4&%#UTR1I-7F528'\4@DD
MA'7M/XAC:G C/,!XQ\&G]I_HR^VOSW^D"W.&_#BO.6'5VG_E527\.B9_V^T3
M[1#G40+A'ECRZ+^]:C2P5#J760+G*\V!6V"FG9=[KY\59?0LO.<;>J*N!VHF
MD)^V'47T,[V>+&U+T5%FZ*"4.HX*ZSZ]NVKG:1#V\UDLN(E>"]CW4="&N^U]
M=WWS3XW'B+$D5T1J51G*,7]J),],L,4 &A>48^AO/3KN+DVSLF>G>FJ!W7#4
M[G$#)IQ82DF8=1O+Y&POU0-]:V>&RM>F7&D-J2]@@E-G:"ACN!0?-%QBL[T
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M-;UTK:]M66PVV5/1Y/3Q'Z=YY8)IUG<7_;5-X3I@>_9%S\&"1I<XK,E-EGB
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M^N?"^V\@L8$GTGLW^8U8=O8:X 1?L$,.=H<K0RY"$H.N ?%R=E$G@M> !S;
MC'<"1UIV-,"9LUX>0?E[QSDM(MGS0B5=PL+3+:ZW6?B</?#O;SQ*L2V0:8U
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MQ\.*^>QB?G2@0)!C?#3/@UHR8U[U7%HYXZ*_%28!N?#*EN:]L=Q? "*ANYJ
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MT4 %3?#%;L-C5,=&)NG&IV'GS,E^K)1"&GM&ARV/_P J5%!/*ETK3N]1)]_
M]_+VH]9*R?%S4_!@Q&.,BWR_#V,_U@HM=\X;\U5$;*AA;+>JF<B.]Y<8PS"#
MUE=I52IU8-A7K=0:+$.8>=ETG\;]W?+A$O65)X1($,L-%I:;!Y47R%'*O?I$
M>-+I@MY\V6D\+\J7&GA3-.LL]N=8RDZ/5 ^70?TH]53R)&FM3@E+-?]0L+OP
M\>N$%A2$E;/F\O2_/R1_:B#!21>KNV>7XOA[6.4]?BQ1;[.$.:YH32WGM2X3
MPK#!KRT=\E&.+:UZNRUN4M,S?!'EZ0M5":?)*')-Y7\6OHJG5KV)>A]!LM>
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M9#H"$=1D..*M>/K9\9L;T]7DEFZPKZ1I&V3-JG%E3)S9-"Z*7?SJRXT_!K/
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MHGV,B/(MY/F"*F9XV5'\"=:9W,D)S^")/CP[G.^Y1P3 >MD!FNC"1!@M48Q
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MN7^-=54W9]; DFV'Z(6]N97<G]R[747"NLX4DRX/"R#5.1:9BLP0)\(1)HA
M2X/[B*%.\$1.WKHI;>K=/'B5_DQ#:[F"*&02\]#%W237D_$3:[F:C!*"16/]
MNTD5V099'Y&Q1^LB*H2YJT>1I$&B08%C4H0V-.;?_^;7TCS]*++\S1=.NY7-
MIN1,PZ[!PB;G9@K7J"&]%;=9;;+FGS" W#M>;6O,R#/.T9M81[=&]/;0M!:K
M50\L#NDG5A?82YY*!M;CK2^!8W!1<;8'<(T4?E+I_IE$GOL^AJ\33;2>R2 F
M9$MZN(Y@&Y][& $ZETSX=9P1=N?0&PUDQ2<,KJDV8&$$,3&8UMQ9QY@G_P_=
MNZX$ ?^R_369.3F*"8[)X@F_-VQ;75_U0WD_+8O<7<7"/@ W(J]).(EL%FLW
MPI$*YGTC,/!D^K->F9<&#1A0--0):65UN1GWT*IRS(8>U91./UZGSJ ]S>/Y
M<LJ8Y,.-@/Z78Q,](\"=P<X\<P9$FT2BPWE[15_Y_%IB0"8-Z##'18Q]W?N4
M']RXI=A7QF:,J-PKTJ.-?!NOP5KXH8!CA]&OXCQ:-[DR;L1O5$G#)AX^8*T>
M,_AZ[+?\[L],_F@7O:Y@6__T2C.$8=5*+D))57]B_1<()X:?NA1V"P=VXTMO
M6OTR+CYF$+?&':/=C'7#QXQAQG, .8C.U %\Q!"7B-_%5S?Y?3_/P4QFO1C_
M5R\I+E[\2S7,(AK$U9E?(9.(_4E)K7@V(4ZF!Y,ARK;>--.JPAT0,&787D;4
M&)M=Z[@_IV4<X/JZ;Z;3T'HTF2U?6-APS4O2^L=Q4)K'Y4'$HS&(BW"_XZ*N
M\FD=BU[@LP(>UH3AN7B$@J&V>56@&SXGH<!P"]?D//U6ES=5\$O\INK'+_&"
M)/_?_E^9.YW4A[LOR1X6J-Z]M[."?4+]I2TL='!)(<9H?+;6+O8-\5#O/(Z3
MY+4F69'#-[76P6#=G>$CFEXAIGFCE2%V4NJ*31?V;L/];[<_OE0EF7!%Z&GO
M6@0W]I#5;@2W5JV+]XZET2>4ZKE#0#DZGM;VN3JVY7_W1(8#8$E<+'.E+ZTF
MZS[](A&WIV)E6='/2?WG7\K$1G/>$,<4\Y:.Z-W'F6NN9=&O+7@3C\RL'>W>
M?WN(5B*;(?W@_#H],/7K43&AUOMS-S-GQ-#@&'ELJ8T(*-5RZ K-6]*-FF,P
M, R,8C!X<N=_K1E*/70,/*#Q?W)OHC%,CVSA]LGW;^@T6QDL.RI C3/N=$((
MV3IGS?BIS;'Y60FT1-)(4I$CE1YQNT!.C1^R"Q4IC?7,49@3__5EL,.]GU1$
M1(\Z_+C>Y/63G2!K6A"+]:3<UGA+$%WGC/9@@@K3$$J+=(%WA]=EK;W<L$=,
MHQ;LVMB<;QEZ+B'>HB83!XG:.'K?.R+ZJOARKQ+DP"I2/@P'9+8L9%BUR1?#
MPBI6Q@+#@@!'(LQ.P=)%#052([U_>6;B)X]?TXT=MSB3.(:@>3C^HDJKJOUM
MI@@RQ7MJ#[%WBZBSONS*3P:7KZ]X22TO#SWA?7PW$^SH;%Y]N*$E+N[%&W^/
M)Q5,)W^8:A@4T@6D>7ZBI6?H993FV2(@-&9[V*9:[=Z\I&7SN\;5XV- P1-5
M-6O8;Z4K]UDH*9;9"%.]*6ECW;66_N<%YL?PEJG-^^*'%97%'B*?(A*YVFH_
M$Y2P5OT%C^>K"8 +[P2 5.4>DY&;)6=M(D$.AFQ J:HM@]O:?FYVWA5!B#DX
MY1R]RC\,'--YRZP08M)Y:U65[^?+Q$@,1'&_=S/<X6X42PEZM TTR)6R0/AK
M0U67/?K+K6[0SEW.,"_5,#'73$LGU=UXQK0=7!G08';%/!T8*N8\NOZZ_K-
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M:16$RVDG\[N94I\2/+):""B$1:A:JYVA(".1,.\$ZQSOW+PQO*9Z;N3,[NG
M3],#?]N9O";BW][]LR(I?&"X_HI3PQU=1"1(!(^66]IIT,8^I_5AVH+[NJ(:
M+6A[-^YEA:K9U21>S8M0S4DXU_B2EG[IX^>$D[<2+Y<8_3,//LF1!Q"TM BV
M"(TK>IP]+ Q)#_Q)1[F\XJXI;0]L&3NFDEA5!.^M"L 7/'AS)J:]UKKAAHYR
MWHGM.6TL34"ZS:Z8^T$QSUG-<36BF19$')DT_%,OO,1[>_#FA(AYA=EERKF/
M)\F4ZL0E;U'YS*E>T 32(A&HTF)&'6SC;[\=%?WI3Q"?"_-T4-M[M'34O^_%
M(>_G@9"HIW60'6)\6&E''0?Q;E[QT=2LG#"S-.K9K&37C\G'SDY&FNT_/C?:
M=?\\9>(410N>BNU6MX<@WHWE)C_2*IDOC.^PSHTOY?O5-;3/\\96@M=4</73
MF]CXIUM^5\8R=5.>O"XJ#OEZ/NEHYXE_^OTX('.HQR'Q\PL*9UPE)4&XB:4[
MA&6-S2UTPY__YY(+Y@R)$?@  ?CL2JMNRJ(PS.M!X6$9O\%\!;2P8YWK-RIK
M+M]_^Z)M9X?02@54MMDB_/,*;-'<+^"#FFKALO\R!","!B+0:DS;JF("=IW8
M(*.[SV/)E$TI)*M-J?H;2#A^WG5JZLR0JM: XALZU-]V_[P1O6/MI1'GV[,"
M3]=G#R>8 U*_BZ_WY]5=?8 /\GJ-"$SM;AI8(+&ZN<)!B3,(/D9Z@!/D3(QP
MINH'NO"\-$(XZA33<)X&Z3  PRU%3 >W^%7$:6O5Q[2HTDC<K8:,.Y&_E*P*
M+0N6_J628>\>/'R3$]'DSIK<(P3 *1".P#S@QE1H=Y8<;%2B8WG1(V@>P(HN
MH]-:_UA*)X*\T:++&YM=06*PDKWZO L\M]-5..E]!>3'Q(H&[U[8PUOG$NP6
M"6)<1#R%F:L"5X/#V& &B)7RMP(U\L@"*W1D?G!5E:WWT9*PG*^)/Z(4$JH]
MN:AM>)AQV_F,U&/;08/\FJ9R,Y[ZVDA:Y/<':/8>'CP7MPFD<8XAYN" 0M<J
MGHXYX3'!.0:DT+#1&D M_?%.Q >TRNB:=#N"G@!WJ&=PWA=/4Y;)3?W-290\
M[<LP\I2]T7^GE;WE/"]UU.D5?,B AX[4U%.8N]B#RU<F(*=6GVQYC)2FWFO;
MU:VRQML)_Y'0!.F_]20]-Z6.[!9/H16YUE@97D(NM,$9Q@. O&EK C^L::CQ
M+!/>PI'&2'>X*(\OP&H8I$C_MCS/]/#.XT&Z_D'I;5X:D_TW17H]CR<5VWMO
M[/-0Y#A'*;L'4'^;J=U!+M!Y7Z%/+>VH=:A%@7FJJ=%DN\Y;Q"8(1QA[$B@1
MD&VSJ4^#9OE8.REN0R;6?0NKDRUC)V'G;=ID/U0T/B&&_F F<X[^R>$,DQBW
MJ5/[/"Q%@# OH'<#*&1(MQB*U3 *VS<$H([+]89OYIU$;ODH6;VVAZN^#RE#
MNMH14];4'B_HAG[KE2&2WRE$V)*4?,%ST2"&'2Z:)%@M.!5$WV:+:K3I8"H3
MX[1Q^5B!J659M0FU?1Z:Y+!"HJ5VQV\+[(G%":D.8M+U@YX[XK7S>GV*+=FU
MMV['\7W,\MBN[=VA;@1O-4#OM]Q/<.@I.(+<AAV[(2JO<VS/-N_2R*N4!<WY
M#>?<#Q):8\FC[&8@>_<NVVL4/#=+F-K^LCVK-MJ/+>6,.6L#9L_]:^URN'P*
M>#J'/Z(FN=@LWI29^;-I6(78YS8*;7CW@#CTFR(D#9OZ8[1CL)<)GHL",2 0
M870/N"JP!@V">\*%: Q2ZT;L,,IK4-\*XSV/-^W >N8")4$-]5DA:P?FS;*V
M^G LY+!^7,B57''L\:4%4"C Q9%#SGLXM-S?/2VVPM_>?8Q.?#'2XC: 4*F-
M81]D7O@Y+@!QBJ([(D(-\^<%A1PZ'_\W)M$^XE6?WUQ5T"9?)K2T74&>#,U4
M5F['O ,?X:K].!#C/LQ"[0#J($#BHJ] =?7>:_9!PN)V#4> <:%JGG_/SXZQ
M';5EX4U1.ZY24YCC$:2=_O UY;PV.70[=BM4[J8\*D%WW0*9H*"9,D9I)C^N
MG8'5LF6LB,JR<H*QV;J3=@D8FU:K^R+AD5)XOGNT^QUWS(KZK=Z.Q#9SHRJM
M'5Z#6/W!V&:5[_.$OW4%!)@. =ZXJ"RN0T;XHR N>=3FC*"2I6;9O2SE1LC>
MZ^T* L['N\3)4WP\./SZ#PA+X?TY=7/;:SB&#6;*;XZT>HQKQ=_*_"$#NQ>1
M-\"O@C%Q ;B(^O7"'&2(U9C\)\L[@K$0FO1NAMJ:=,-*ADW9HKR*EGUJ4.32
MJZK+2GT7-BBXDY@6Q6:=93@#2CB!:3%90WDR%E'2P[_[%/D)QQV=O5?F-XB>
M5%[?9NEWV9^PQCY'[+^3U*FA^5O1F3XR+UZ8ZU>IL44W.<=@3!)K9*]ZG\=U
M@VQ$(R6@93QD3P*\3VDV\RH*'4'!:X1HQ-E!M#P,Z/'4!XN_S_8*M,,:A%GX
MB 9MUP>K]-"^V[_[JM)SJ2W5;MLFF<-)HR*^QDX%> YW]%]YR!3^-@^-QZF!
M/P5D/S?QF3&V#I"R+ PQA.5A]*D,6VJ<U (6,T?<(44TGV?S,[%K 7.@L!U(
M5#6"#]TO*SS::/F <Z82<K"-[CV>"#KN4<^JK$DH7<:6 @G53?K$K918RHQC
MVR&7Y#? ]0*V2S-W2E,YW:#3^SR/U( +45V$R<*V>C"6S4^CRB*#( Q2AT](
M2W 6MMB[+Q])L"6-HXSF<((4#VT)CMCH^>IQ_$*ZI3Z^WNNXRX?W2CN:W*][
MBVF1:@S9->,,9IW:J\:X[O-@!7;U.",[XCCW@N7@_-X5[72=Z R+&F\!M?M8
MV\%#]04QI1?>;>0N_S?I%2A5GO'#*. A5$)D$UPYL'J0N^PQP_L\'I@(L C)
M^^]^F"UN'AX)%T"9:/69T@AA6Z"36K6)*L,]Z^,J<M"PMC;9?X;7??*2%BTU
MTQMUN80YMQW=N<TOUFYFKMB_TI1D49,%7?))Q<.ME>:\&QU_Z"+KJ!)\H]Y6
M.XUU9TJ,G_7@'11[3B<4FZCV^3<1@$UF*<L=<-V%<:.SVU /N,1$4ZQ&FV6]
M=>K1%71+"<NF#,O08)  ^]P@\?-O;PK%W:*H>N_&,EE^]'!CC,:7S9N)"1>V
M?F&!2R"VR#SK*>#'M2AI+P/\"!+!D6H$7!F(^=_PHV>9F(A&F1(XM,O-AXX0
M]Y*581Z7TNI8W4X3+RYU\#RZ:3)<_;17'R_U^@DXVU*0<PS.K#7G3O;@"H9A
MY<[$M14"!L633L:"$9PQ@@(V:7F3-H9[):50Y7-\,?+BEN3Y3#=+A)]#A,O)
MM!^J>U5<A$@%G<9X4 %%R"IQ]S%@T0D^X8^-!!T^!SQK5AHD4J@G%>(1))H
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MRB-!6%0IM3@^M3:0\JLF*Y1C O0@(Y0/ZR+-/V.+^Q,<[.(*)0>2%%75XS[
MM=/&'(*F.1-*?\YPP8/!:<554Q.X/P<.@]=@V_9Y7BSM.J%$@="Y&<$VYZO
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M3?.*1-&TIVC0<PO>%^9^_+#UZI08;U2%:-_'7EX[\/)GR788N\"BR^Z@NM,
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MIS0+V6-=JW9^[3J4ZXE_7R]QJ$F)!TZXD7=Z\-**\-MDIQZT("#[T)\S[,R
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MBV/QYZ\"M3Z_(?\O;2)]"? &+OH.PAI R:$WW3J9T %9ZZJB2(&MFK:#;+%
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M1!%K,U/H5Q\N#D5H5Z7\]1HK-)^J&BW8VJ#-%]*_H:6@K/1SY'E#,K@3"ES
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MLJLV#?1T[@%R1Z]X5#!NABZY.*OT\TN5?<.,3D.A_]>J@C*GIG%"]1E\7I]
ML:^KFC/!9-^?B<)$S:+LT?F\J5D'1<T7T>R $LT-CF:N..K0G='=S 2\I11W
M'8(X_96T=!4H<=2B\499AMR8FD-PUT^/3%W!@E6J=MB5Y$#^SJS$"=APCY/:
M2&W*P6E,"[A*HI9FQ>@D5,(V.4DA+/[SO'0KP)(XR(-*'YD&5TYS<O^U\)S^
MT_E:%-_[J6F\!*GRR%FY\]'6.>8E$<9=",L_!D^MT8'&@1DGG-G$+N0=@JH>
M!<*Y#T%>@V%'FJ0&OOFEC*Y&X7Q.-Z$\0EO#>58AX@ :,JX[N8]MQ_%Z[$,:
MW N]@UN_5(R(V)<B+4<SS!KLSQV\1K, (>05(K05&X'E@' 9(L!M\TPHMC:&
M"(!YM#UI58-O"[9^Y8W(<>@NDKR\=IW:>:X1<?42S7M@4NJGI47YO(E#>8AW
M_H^4C+6]IC*-46-T8^ZD#^'MVJZY_MW_ TG(R&EO:BP00).E<P(1E'52'CW5
MD0O 9O<5FB \\!X3NC>*!Z6>.H+):5&*QWB\LJ0H!I6^KCD>P8^@S8UC2 3I
M6M57"N,*ME4"BYB?CEI,BR(LY(&YL A86GO]9 L<-]UH?0AB&]&#?@54%YHD
MB1T2"G5 *$*OZE)&0RGKE("2*6G?."YM/*?)T_U)Q_']F3*B^TS?RG=&N&SY
M<G<[Y,K1 \;3$0?1C49'5.A$=M]\#@T+,$Y@Z@)+, 087>'$P? _R# -_'%=
MT<!"N"W VRGR8Z(2F*9U.2J0$R/W*H D/0OAJ@/'7_8W8]C>*AV"LO%3<8L^
MKVA&C($CU&5 />XJ?4RC1!%QX9BS,]]+<GSSC4@(GE'+QE'VA6,*J[65/SRW
M96#>#S?XWSQ+)OQLG$S[,WYFVG']#X/ -*W^KRTW: < ?RKJ#T'#G' <G'PU
M%P]($UK@2 ',$-/.P9$XM7) +*L,@)?^SRT"\O\56)]N?TK,_^L2;>5S"\@=
MRJ@/\,5 *)'X!156[SGE<>QB]\W1#PT!=]ZZO0$K'PD#EEG?QY3K4950"/W[
M-T=1E;:'G[_WCI&_WY&0J%'@CRZ6%O&_N"O76^HUFCQLD*EYVP)Y,_E*.W']
M8?%0&Y$H7Q=OXG5/UB*LL<BZU$)M==38Q%5+NGX^X$M3L=?3=*O,\3_T3_:V
M4]/]@7K?=DI\;[!S-R9]W6@!\=\[-F"DRW[<K!W*4J(.QH$%J_$)VIN?()SD
M8N-L.J2BGIUBK,;90+.2?*DL+&"0AK)D),N"<%(KOP-)N&Y"-)B_NM1@SW92
M9;,JX[EZ]<<HIT"EZH2$W"\GN?D48]3"+D;O?!.?"E=U/@?[?@ARA4]#'8 @
M4JA@RW3US!Q*!M:0.#3]K=EEVFIYMX\=-C$"$G[PFX5V3^:QZ^S9L[&,DYT'
M%P"5#C,>E*%D/UDX$=;RUB!(,4#746ZTU%![@&CE](3=VC<B+*S-!;C]1S(A
M01MO][.(7+TFVQM_'UI2@.+NO'^NA6Z8OD!!*<+X%I]4WRZ3B/<RL'UJ+F]:
M@XSJH^ANJ5>*F6B6Z"ZMCH;E;7H.9P2HJ,PH^-RM[?EZ?T-HZ<RUI=U?6JO6
M7M7E^Y^N'KMES>S\\X<JWI'N7FU;OGL<RCJ#L&LP^>/99.>SJ>=3W= TN!0:
MO'U@QW@Z/T#4Y[/ZMY>Z@I'@=,&TMOV!+S0P6HMBTAWVYQ 4?0@ZU<R)F8!7
MKG2I3+NW.(I7AUK3.L&5@V&Z-[ !B^NV:*C8$#1&;4989KA:S]! T0F%2-]?
MDJY^4<N-F=(I\1KH.&&EV/'R(I^ S#M_4/(&!U:Y6>$(#CJ/ -< HKB&%6%H
M,KK!9#,L&]K]( QR'-7>#6&CX!-T[1>A&_@8/'\)1LSAO@WPVP[P?*^^>]HO
M?ZI$T(2_ N7=T9I;C?H9)..Y^=ZLIIX*PP3;KLY?O7V0F5[?7#\E_9NP_(.^
MT7C45_)17Y<X.^<!Q?[.N2:B2AR8'>M)B"!4[(4=&2'P"T=!(+1H30/+VVA.
MW YCG"?7#:$O$875V/3)!_,O&NT+/%_^F'/LS&V."6"I&\VR?Y-M!"TV RYH
MM,]'8UFA"WAX!6<[(98,MZ5?(^>W$)@]FZ5' ]3E"GY-0J?Z_#S?SV>[79KS
M$'E$M5/_YI(L-J$<=>(6^ 7F'U@,9W1,3F^W1A,64K!DTT/0"W@5;G.5TD<\
M8E:,K*<"$?EBCF58#?^,"S5IHA%3AG:A4'&YA@<1)9Z6L[WI>0DUV7G?S*62
M[TZ46/R<T\&MFE'=/@/K'^G,@*TGS61M3G"" <F/0$@#Q06 _ \[P)QN&Z"V
M!ZN9YE,0NZVH!OR,,DN\&2_5[S5ZSO6ECO3>]+K9E:SZIE!(<$)SIIXBU2C0
M>I305UMOKL]_G95S4ORWOGCPT*F%;CJ?9>M\S0J.@(!.#3J2:S?B FBFC*_X
MRH$LB**G(\MPLQ(@2MS J!SD08;5\R,:]1=#S(2^]A5YS+/Y;^M8D[M>ICZY
M!HU!YHRY?>E/;\/\4[W)%)5/C09&*>X,ME!R90>X\FDV>6M^4;"K/,$"J.S0
MP'.C5<I;R8.D@2;R'">')_9TV<8C?G<*?^<WN]?UKR@&:5+!8KXSH5DW?] /
M0?8!*Y!3@#ZYF_BQ='$VL$7B!'GRA3HN%B*;UD7@5E=B,JX9W:*[DWHV255I
M'9"SJ2SCU>+6QA[.8<8]?;<I.9%NNB\F&IJVAW=KTCV/B"N1NOI[WBV]:7L<
M/EE^X^_G@PRL#V%J;R&?SF6-C9J[#,00H9STQX D30]]]> MVHAL#QLO/0^\
M/2+/@;;Y#L<3PW1^\'.)>Q2EV>UH];@XX:J_9T>SIAVT?QIOZR&4MJ3C=B>I
MG@<)]- ";*OB$<Z!IR(/08N&7?-3^&Y'(4"5_'*=H0$HE:W.\0$9Q .[KK89
MAW&ZRD%VT:K(>%YIPWW'_ESO*Q\[/R1I.G++;TH=/"]E=$(K-&(@2C-TU)&.
M<9L/FQ[L4K!?#[4 1T_CV@D<#D!I@/<-X:KQ>:LT,\^/XYOLYM4?BZ$9!785
M"M?\A*UF=LD@=Q#[NW>@RX]/FNHL'-L]_J(4*>T*P'<.0>$%&M5EI64-:VD^
M_4'XN#T"V:@\]O/4;,^1B/NGQ&X.-,W[,0V\" N[#?F:6?,)S-$J_[T==.WL
M.^Z)(XD5CD68X.@\Q=2@2N_BXI]5E%/=(=9-S:^DFQJ]L3@"#U$#]L10S+QI
MC*8[$\,CQ7/[&PUVSG #<_37L^N'H/V=?\B8![8X3^=289@CR;R,+@+NZ/@0
MEK=P"KFLTMJ*N:,-M?JK2C4XXM+_Y5D#N#9F;&=5@6S6;;W?G'TFDW\BC=7.
M2.;;[[5+LYUZ*1_,$QW*7",>2@?%7WKYK,@DE'TG>H^G-$(T9I'Y07*/KK-8
M\C-5. C5MK](?0O,>BZ$*M6BE0#[$/%#4)Q/.U[2=N+];^@0STT#@Q,QE39]
M+@;*^18GV^;?H"HS2C18275^IR.SW[K_0+#^4'JUK#YNU"YH?SE/7JC1!&7^
MVJODC'U8H;UH0E&>4%N*NJ"Z_"NS38!)>7\@U%"S Y;**4=T-XOV>Q204GBW
M;_UZ*;LZ)*!'U]HI+D%,@B>Y(=.N<<+W13H])/6T(K.OXS7U=YEV6HO^R6<Z
M7T2PL/,_[TV"!!Q[_;(%[P3PDQ=M@12*:MN^-0ZAF$K=3RC++O0ZJ24P/= V
M =>&I8P;)7QZ?\&WWHC; /,0ZM-H13Y%A..6:ALHL/#=X@R:34YMXE:_2V5&
M;^Q%'H%T)M$^GE/R80Z=L(BNDSI@9KHZV;V]X;3:_*E?(I@X;X6WKE>&?P8M
M/3@6M)*,'O$_9C6;8LC*)P%-!)"_3-X]J&LX$3T(9%SH(F>Q<;\H=4QDC81D
M.;^Q:!U(N+6PS#J:(L+G-9;+<MN\U.)N+A_QZ2[C]2#D]1LQ),>BK"L:BFM;
M 3;4O5AMT@&O+QANTH.%M2[?V]6!ICQ/7LC<3D\QEM/L])ZRN^D4<5Z*6\RW
M2R@ $<V7NO#D\9G0M?&S0J!@$%3>[A!T,Y=?J*!36BA/**\B=D1A*<F0DC<S
M8;H3W+.'M&:0<V+EGOV;"?R8H64W-8"!7>G=9A*6B@OB[#UII#D(<B_%RL')
M1[(;D./<^"<EPNEDC59X/+[:O14;!>;?G>?'3/JNS1VCP.*4U.9YITQ(*@E@
M/J3_S2^CKC>@F86KZ5GX )=8\2VEK1R;\$^HT?V6)+44"2T^W2<*DKGLQ9+'
M2THXF;ENG:7 ,X.CZ#P*C--1Q5Z"]65Y-!;&M]KTU-Q /RPV2*-M\(SN)*PV
MJ4=O_%LY57]6\;>)8M*5DRM/]4S$&\N!'8;UW[\<ZN,:JS[KN\W=1"R=2Y4Z
M?H0@%HRO6+(9.$($&@_UF)\B$ 6[X<)&)#,NNANN R(]XC\OL1:\-"<]\7"$
M1!'_-J2<,U%C)W7EXJHUSS=J:NKW*U]%5J<(18>@2 )/(Q,EJB5+&,@@UW;6
M@Q,98%2?B8ES6Y8*>7S#+C6BW/.)L:)<Z$?X]3LP@4W%RUWB9YBZUJ[*7P5L
ML*U@Z$+JP@-,*[SRC.8A*-V*V#Y4*(X(X;> I.P%M@_^L\9LO( _@]8 7(E*
MIUJRCI,CWZ4;1C2>(R9HS]\:4N-0UI)*U>%0,:FZM;FQ:6'D^NIA#/^-KYOQ
MGS^4E92DY?]99SRD,9YNU-1F#@S$RG[\S\!S0NE_/#$.V[CPKZ#B[E_CWQ\A
MN'&,!=3%(R?V^K\4,?C?:\Z:]\FF>I<.;N7]N&S "3:[LZ?>">QU!1L^0ZL6
M \7V&;VCN\6V,@'69E=^.@G;A^@$N#OL"5JDQ$I__9LA%<$\>455.**/_.8=
M1H/;F"V\U;PXII/D;7(]A5V/I3ZE:"SY:;P3\XS/G%T&\=,?"BI=Z(ZZR)MX
MTPO5VGRR%G$IM\>]32_FFW(;U<KUFALI;:$,-S4H, MR<T(^P-OJ+3W9P0F^
M4W_E%3N[[BQDX/?%^UY)$:'#\@+<;<N7A1ICA0S\?N&9&+R>\Z?1'-[$[Q;"
M?[S3&$,4@0^7!PN]!;F[)BV%1=1>=HH^9.&/O.F[Y=0T#V&CZ: DX93M6'7L
M-"^)X[-V5JW.#$KA3@.[I>&0Y&4IP9<WUYB?W+?OJ>"M<KN0ZMI^OZZ\[B[7
M>S$7Y_RA  ;\JL(.Y'C+0Z 6T@D49CFMF2>J<.B6/WNR/_FSM\[.+^'VVY+5
MVPK??[[3M[[4,9%&D7MP+J+MMV8A?!NHY8XBTFNBCBU7>XZG\C3Z-L(2WX_F
MOW6/38^_R%4()BT\T>Q%>1D3"Q-29;B]ZRY:36MUF6HX:TK)6DYFS?[--]?'
M?$U)<DBRV\[^^_7_3A7U[VTN25*W1F[U1L?:OHV^>SS,2.KE29!,\GUX&$8:
M#07>$M^@W<F+75E"E+T76Q);"EAN0/7^J*YQKIG>BY&9.7O] H\]C=3! (0?
M>\VD0-^YNC"BR&GG1/.:!B-69H@;*SCEN; %Y]T62E7\UNS.JY>H\J5!:BQP
M-!"8]P%G2@8)VC'X_08)NNE$NT W)W?'!2BIDK:[P5,P:A#E$-2Q_3W0FN*&
M"Y$NCQY=Q+;3$!!X!$:Y>JC\;%TUQ3!&E]_)N6!5!>&_76:B^.1O3 .V?7WG
M(,!:!#:,'*T=M-S ,3$F".1[\]/)Q+1$K/?@5/T>599\:H/R'A5'>B1Q&C"B
M1 Z2E(LIT(YF$<"$).YW=;Q,-V"1P.F5BA$F7V@B>=+5L7H)ST;+$%4L2"5"
M]0>/14^7@]"#)*B'G@ZU]" =PLH83K=^'DJTA\8QC@\W/FP6&W/E_?&K5G"X
M$38=.)VJF;H_-[W/]KIBC$<V=TPQHFG-4,2T )J608B 5Y2_:+R!I"@P6(UI
M$K,>>%:(NIG[8@AA>ITJ"V10<LT/PC'JW:1;DN,YE/(N<%@S.T4I9:_=NYS/
MT.\$X[-R-3'3^?H8TFYGS>2ZD(^OS)]D,O8N8%^$5B*?V&X5)9R>1Y]+;DM7
M@W-LH4^KOV"<@7!65<:.WHQKQ^4EYR?(3_>RE);F5'<\5H28\N>Z'C\$*>]-
MSZB55H["97Y@L^8CMOY,]IF9^.\&_S\2@?[_;[V0GVT@VH:KVV=CP7VKZ M3
MUH>++5NHPJ+,]I30HF-?^R06,I_?<UE4PCT*V/LP6_ISQ+%\UYX@U?)W<1&V
M*;U@%O;MTSJ/XUK]9H=Y'_*]9S9DZ),V3ZT@CY&4KWW;[9=LGY]TO$@H7BCG
MP0P'G]KD7MQF\9"X[(T[$D.CV]E-8X@L@R_:9;E?!"9$_Q+-V2\V,#_3$;AU
M-FDU[M0;_K_&BUFE)4 4*3^Q7+TA9DO9F2*0^XA[3R/YQ+L=>_OKX8K.B;+<
M5I8)7V1 6;H?Y>PT/[XZE2;_3/#QSG?B+5"2 2D89#3P6'OR+Y2$'T$F:.*B
M515K,A4AX+#'MHV%S6*I_->#?G(J=GTY@&F4"RO>68RE<J/B]>1?2\K^OO:Q
M;'Z?LT6"B3Q@_')!U<BZXQZIT<VF:'0@V[8ZY:&?HJ+D9D4OKT6VR!N;B:1L
MQU+MBOB10E$=V4.0:;W8E;N>J9]6/W<*X,4NYB5=J_TJ4,Q\'2SCWK,<W18Q
MT\KT>-UN_#=L U>\EC[9@F=Q\!KITR5G7N\5C8E+2Q\8V;E5FG$9_2U&B%O2
M_0078H%UWYHP=H9GP--7D(U,#;G!2K[GA\Y0_B:W,&V\]JG3R=,J4:)'*H5?
MQ:TDJ<H*1SQSKD_>Y<N6[VOKTC_I7]S<$UK&.KQI?XF?^>5N5UH@\LV[,S_.
MF%3].7(.L*$LS?^/JHX?X^BX[B']8JNC8+AF8OIIG?SW1V%?F./C7[U[YDVV
M;R5\FJ?S;5/] %\2?DJ'Z@7,TJ3G,=_LMHHI8H!.-U00(H&:6U]T;^=DHYM0
MSE27K]5+U8.CRI-;"%Q_."1"0RP<H-:3(H,T?;=$)=-38;/GL7/[LK5_?288
MX2:EA&*P-N,;OA(9#G6#3V40.3=:LTW\2.4GZ3* 7S9=-W*[8_A&D"])U$3Y
MZ[6@H*+IKQ=J)"V^A,1%51PW]D;]M+=Y'BE5[O'/3G6%!>B950PWV2Q*S8P%
M@-U\OEF%/(/RNU,Y7&4B/V>T7)_$H7-GE!@V,"!8E^4YK8!ROJ%8 9D=Z-B]
M=U=E[/^B$/K"P6?LH_($Z&F&"EKFX W4%3NUW*S'&,(*T#5(4+'2P3BT?L "
M.)S @3Y!C'OS2 5MMD@0[<[SBM\33']'69V&1>[6)18'20I'CE_L]NW#?"74
M#G9@H[$BS6J,GOGJ0U!KIB@U\""OF07@O DTA2").&%.,;0B$$5&PNO'U&C8
MZ"P6RDVJB.N&0/#3TKRYU>")5R53G5@G16/%Q _])VI'P34RFQ%D&%4*,,)2
MXA8O% 8M-XV71S7R+A XICC<29P=\R)K3Z+55(X#3.TOOZ9-[QW9_R_6LIOO
MC[/9V'G/K)9N.@4)_A9<@&WTT0Q0@^W@6C"=3X-:2-X!-*BI!P7_!$KSH2\!
MEF1.XW=S@S0=] GR7@3:M@B0),Y5%N9T'Q13%#KLYLK0UQ;?(HBWJC;=K$9*
MQRK,Q"LF:/2J8?OM^<$=Y^%2?WN9B;T$JO?-\ORRE4M!AZ 3P0?%?_"1&-6#
M:H@(IGTZ,!Z[D-7,/(DVX9C$20/%)S,H\UW0,^AS)?VYJ.1%>#A$K#E..44E
M;+?2N7#-W#,]LB2]+/^CG?H2[[5'%7<(C5!.=  1'RO!3$9VX$^L&96@;G0S
M!(?0KL10"W47DQM7*<IIWB6>&EZ)3/G3BLAS+W.?45)E6RZ_@D> /Z=%TT^Y
M'H)._@14[TVX?JXCUX33F.A&HXT.K$))0G\X)-L@RJ-HLX\_RI:MQG+'SS5^
MKG_^UC6D*_7"MZ1G<]LT7C.:'0!FL!R":(+8=ET4+S&_PPPG< @ZCN%D,^-
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M7N7?7^4<LR0O?<NFX5W!A:/%8M;G(7T_500P;8XZ$^A+"%(&F,LPD,)[+RC
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M25TKYB+YJOOWI0@%C?(4F/*1*+Z\=A\1T>%Z[V*UM]/.Z='\S4M!#($ ;UC
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M/:LXVE0E6$!6S-;@,..IU]2(*[:]I!DV46D"YI2V'.*4?>8M^X @%R@UQYC
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M9 8WTZOB./R7RCN";R>K$] 7L?CS1H(Q^/%%-W_[3[9HJRQCZUK;##R1)S2
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M*CX?'G"V%@:^^&+.F2N1635L;]:060M#1YT69+VS]%:$+%SK5)S_;:EU<YS
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M95YU=HW> +@9O9"AX=US>>)I\&X\CBUHI,L<V-\C1/GVPK82JI%*.U^QZ?C
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M!X@QE9%M2*ZPD&BG#.K='#F&>*GRY1"2H'IBV5RWXB6O>]4B=KZ_.D&]?L]
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MJA%KJLXR87!QQ$TTU3%QWI(51H5.H:CX&*2 "_SWTM/FZ8QX8Z7\6C;?1,C
MAQAUEMD<.-ZUL5-GD#6TW#M!N(?^"MX*VDW763T!7VI[RA7#8;Z!/7Y5\"9:
M8#=&&(82;%4'7GSUATS5 ,1N1T?\SN/8'P?._#047W0^^XB[^DZQ8XH[X2D[
M ^-F5#-M,_F4A)]M;0K$!Y[[M<KM$T_!\,*#.F,UZZ'\/YTOQ2@H'_^LC36=
M[O::YN;]4;[_Z@%T9JO7;AGJGE.KL3-<H7N.BY'*27]3(\29B0K6!7H&-;P@
M]6GRHDCH5N&8"YT8JUTBK4U$"% 'Y*SX!7S6]'T//LZH0TNMI*HBFS[4%ET/
M+BRRL=%R='3SE*4IXB:NJ'47Y=G:UZA_UGSBH!5E=,C.OLOC^S?7DE&LS<-W
M7C98\0T5LX*CYCP;188Z/QV*KB?ZG<M6?I4J2]T#:=P&L!S\D!L+[J'?Y%
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M>4+A0YQ*PI]K?[?\WP-!LI%/D-,0_!7DIYQSP(7W<_ 3ML(_20(!.)V)2M5
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ME621WAY@)K<M$Q*+4,L#BU_.9.-A2E%6+>I"DRNJ]T]L7:Q?Q#^<'O!6_^D
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MMNI:$)_6&M:H=V,UQ<]4;G"9"[,KB"S3@8>DG0V(Z!Z(D@$AU^Z!-M(T7D"
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MBLJ1)ZB,S<=(S3U0ISJJW7</M*@,/8AB'$3P[X$&N\'T 0S=&;5S):,=S+H
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MX"^9"SS%(2"=HR@Y,H%4EF@4@=_YX[/[S%(CN'$CC;#Q1YY(#4/U(=SVF',
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M_.5L_^(C]]W<G4-]0KC^$A5-?Q__T" NLP!G5S<N\?\@=O_?\!27=P#0'@,
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M(_V"F/Y>6G%3/PFOC"F"P27H&RDCGRR<'_D7VC^0_8\!>_G_"ME_ OL7KA6
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MLI,COSA]\VCPRYZL6(R'VZH3([944XB,B$#J8$B78>JO<W)-/</49)!%@S<
MC?T>*=]&A>.^&MU"[A\#?SG>--.9$/"\ WU*4.F3>4R1.BQ[)37&_?JY&H%^
MN5%%@?)B?QA);7?07:[V.>ZN+@,?AT>U 5_:.4)R<'U3=PA!A-:+?_ROJ!U^
M6F&9EVU-1!^YD4<H_%=1P@:+P(R$[!;-[$Y+!G2=>W#!G5W;.=M(*FV+[5;
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M7A2*)HN*&2JP*;QN>)TIPWY'Q*MV9S:_G'D@U\]07SN_+.L&\(GRXUS-.&M
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M:JB?6#/<WCDCNQH4S^A+,$$E\>#"-9X]80=N'P=4/59D'Y> )X@J])OD%B>
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MP3Z(_ZF2Z(/^"^0%99<&?/M4$'%*"P>4Y7R/RY4Y.'@[YY?1+4F/9"-L'T8
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M8ET"L+15QF@J&=U+3&G=OH=C>K.#>SAZM-V>>2CO(E(+2'[UD>X+Q. _V;C
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M9_TSR5'ZX:=$>SHC&E8@5U_I?_>UM]C>T\^6!?;G!*PK%[['NEZ8(2QBNR&
M-JJF&HA;WMWLJ5O?U0BN^$'$%]S;67#\._W5>VXMWJ\E+N[V]6S/N6LI?"\>
M6VI#[T3MUK:EG#6Z.08=/BOS\6I-2N],C0!NS>Y\!57!/"S=.O*R,_)S)E$O
MP6^D!)I^]Z=I2K-\6L.G)G%[OISA=S&U_G37UQ.]5\J-J;=P"BOG<6LN;UK"
MC9I'*UR(NFVV#'D(H!%YGSPF"1C^ ["9NJQ8=C$.IA36N">=RHJBBSM.5-(J
M6CO(EH'AL>B*A:_R3F;#,DLF)VW:M(>(^J@FTI+EW?"(N^%Z5^9]+TC0'>0#
M57.N"N=:]YQXG'??;9#7UBPG_&\+%R+N<V:(?,1(IR0+ 78!5T7M])VRB1*L
M *H3WR5M/1&1<,$JA(;3Y.K]6!'1\-:ZE>QVJ4>]11_>.S3W?0_L/ 3UX,Q!
M%5"&2(,BAAT[E7 04>! &^L'9TN91-ZG0-.DW2A[3H<!^YY"A;,;7HLO>.9^
MZVNDXEKLSZ@(K9C("GS\ZMZ136YVYPR6VQRXHOPIRE5GO-]?)V_#\87"*8$7
MZEBPB_Y:?X=,@J%K\Y#+TP6#FBYS<.<WE/(8I*8O^M,Y(*K*ZLDX&9\?_#Q2
M_$!J+6:L81W_+CPE)-'R@C8VP^/9M4#9_C8&C,1_/?BBQ%_,'/VDZ*.>M:5?
M>]$P;<YGM!(KEH9V 1R"E\<>E.@ +>%T08IPT?(^Z-BZDF2VTE*GE]7FX%&.
M^FS<B[4JCY30JD#?2F5EQ/4#K$QV&4N9Z8_N,D7JD\=( 9?8M1;*J,^<@[3M
M=*1I%=(#2*!;*)X*J?\#%0TS:/5IQ:3\U(P@)_!KU=<'B*;JJER,X]"D+FPM
MT9RW2<H4IX?UZ&OFX61HCC[VR(]2*8(YRS2U]_V/"15^"D0H7'QMQ""SYKE_
M4'[_=_E^<<L/)P>*'^ ''I#QFF[>;CD:O$77HHA^#PIS("*.1EE2<J[AXS6R
MW7D)W;K5;F(/;KV8^!X7FO <F_:Y/#]*2&$ ,MKL;?IQQBJM]QJ1K '.\CBZ
MH9]RB#>[QZT:)IT_V^..M9%,J<_S=*NHF;YXMF:S$D)2-A:2,3T[]_5V=/]=
MQ12=4>I _*UGQX0O?R-:?SP1'R [1C#Z0RUD&;*;"(; 3_A\'!FS.4)!8S@G
MV4]1/ "&7$%0:P#*R$]"*Q:!8<J!Z?JW ;0 !-8UP\'P8E/3APS!FL</<$W2
MHO_<""HY ?/] CS891BQ<U&:+$<Z>  BRAG?@S^,,8</F(ADFL'B*KZ&"577
ME][06S@H=.6B8,3K^:*J4XLKJ460PO$V@F"I;N,%KWQIK;J=M-:_Q2%C0I;^
M=(O1BWAT@,RPU%JBB[YX>Z7(S>* \(62G_*8=QY9P^GO:B%]+L/-CG>3-9<,
M:C.&RV6N#I^]2O]2;:^9H^Z)^Z&NKV5_[%UD=FB_8W$EGRST\QB.]XO,#:)#
MBSI4?,RB9V_R86K)9?+[J9PC'S>^[L51B9* /,V=D<ANA8:ADPK5ML!4R#R<
M NN&R"&M)P+IJ?>YCDR@QRJU,UX)DR .0X0-7,4W-Y5\!Q8Z&74)QQ_97K]S
M6=<0#&?G$,/A&?L@6?0-#$E]GH(<GT/>9K] D_T1@KV+)R9>,17B2]Z3MZ2=
MBVSI^F^M?*^U%/_3)-Q\9K6Z\/6;]:1JR1Z7,B=1==E\$>DKO!EE29].3Z2<
MU.UVQ7JOTR-=0[OUR7)K$[=[AN+K;Q2;4U,UZ1HB6;V!N"@6],4-7,-F]=E1
M1)PH)M_71;9>6JO[\L#U,TPS*4-Q&&]ZOD"'F:NZS#KB[FA1H1_;N!OZ[KH/
M]>?OG=4G.?QC^R"_2CYE*.PSE40LA'Z9[X(U!6]5,\_.(:]RD2W""<S2PW\F
M-L5L\W8M,R,L'*)[XW,P43&_UDO,N)TET/!.@;BZUT!HR D=KQJ5X@?H2^CE
M?"+.J7>;),*(Z6@%B''PMUSF)A-[(>(LG=EV.[B -R1ME?;UO?IZ-EQ60Z'^
MPU\7 AKU(TC@?N/,<Z*@VU!-D+Z4?U+_\)G^\:X@O7<<DN39Z2BE<9<GKF4.
M5Y->0(/5[,9R;_N0?,L?MMMWTQU\,D1.C-X.,W-Z0CE7 NX+TAU>=_GT[HL1
M637C00J??$9=2JVCS%#LB9VAJR?\BH/6!@D>P^M+I'#&O<_$($B2DB$P38F0
M=YG] ^/Q4-V:>5*.XZ]9TON@XFQY<]=)\<.YP9,/?K6^N6<WV DML9#B*G(-
MTHF.3=6#2P+N''XRTWF# *;SYA$JR]<;^;I^>869))+2M>!:'NOWVL]9#_WX
M(I^7!#H@N[,$:(3"@&M8#//7R0CASN'?O)TFR0_.'K54UGAP\%[O-\BG:)@R
M9Z 4%[=%KT8*L$N1QJ]0/6Y>2SU?VD667Z@/#"S1FOX(RF*1>IH1QYU$%06^
MGXF\]G@3,R_7;5_U3*'OT2W\CT!9"^$F$<TAA((!1)Q=Z\UO'!#M$8CS/V]D
MY/Z@<B2M?*O6.)I@VQ\YXD=2_5WLWO=\6D3T-:T?;#KRZV;-+8*@D=,ILEHO
M_KW,)[>HS,Y1H];/7=35 G*9C1!X<:KG_),\>^8-:C S@0P1]4,4=1>"T^ Q
MBA>Z=_?Z"X)?^P!Q7CI<D_UC\FN7PL0:*?61%Q1/.H<3_WMI_._[QAF-!_'Z
MSQY][7O\ZYX\T!UY?+=3)4:V:ZV05<\-ZR,'IA7K',VP9YL4O1R<T>YTE'@(
M7PL_QKH,V%4O:ORP@-)XO^4/]-Y:\I)X-/+ZQV>^)TZYNFW.*]&[$F %0)IY
M$?D/=YH'J!D+<2XR0V2 TJY]T =,YYC0EW4_W5(G.TTM@AK+<7:SK-#I"*SO
M[LT&WU +A0=P;>;0C7W0I8=FD3]^A'\L[_F2Y>9]Q;C26_ H(2O*I6]P]':^
M0*7L9+*"OL>&\YC$.N3-8/]TN5QNYJXJO*X_BB&B31% JL%XG\V,A4\/*>=?
M=N[I6_4XBI3O#Y;QOBA!3AE2M1=GU\AE9/VX^$)5P,6C6+>&>3-0X,VGJS<.
M.MKY(:B$<_V.4"_GT^OQ$4*=YOR=Q_]T<:[-DE.S4"<YX^#&?=#6$WH (QHX
M1V_S9I=R^#EC7D&/]T'\35GMXL&AD&PS9ZK&C@[A<3 Z7K4)]Z[Q\8T,RCF!
M]SJFZ;(9K]K(N[U0DCU#D]U(D$1]6I)%Z2)2J;O=(B0-R]GO0 (5(N]-4LMD
M:5$P(I::NU)R>=,/^846ZJ@5=]X%.DHA5C24^L4B :^F=V^(N+/ANBD'@L+5
MH][6MJM]8/R*;(),YWE<9F^^;B6,]]Q8*>L!B]-<^LZ'*X\L"8VEH:<14==+
M?,WJOA-AG"$[,CD[/UA!^5-A5V+4<IZDYZ)+MMYW8G0F>S, =/^C\;=@#.R7
M"=U!O#98X1I5\PB8'; %&X-E(6',ZZP@[MH^1<:PGQ,D.9\+FWH@J0R+HY]C
M1ZZO;LZ07HPEZ\7DC!J/W7_[,R AP2'A2DL;>V6G2Z<[/<]E66 '.U?=!\/!
M-[?_.U2DA9V-.HV,H$.V#M!V!TIY\> L"Q$Z+.?Z^WW0PP;+4ML9K3^U(P;K
ME+Z3.?:AU?DK)R_(]$;]XR[R_4I=-_ZT?T?Y)YJK#GKN\JA%F<RLZXS Y8=?
M%^RN7)6@\ALSH2&KIVO[;CH*]@G(?$6&H&N-&?(:!9*49OU@?(D737?TW9=V
MZ\/_\U"X[R)",/'4/*/K):+.+L42%4]:V40^8\5^DQACQ9K0Q_= BC3=Q+O*
MU60G[-,.QA\F#IT =6GP,D</KA/_[VQ58;N[3NIIZ>Z#/&?P@EIJMA-;:H0I
MO+GU=WE304&-$))W9FU;;:IMQ-9RNI>=:MZTJ*5FIULR\@PWRKSLQ^U"3'^D
MP#12A*[1AQ;5<^(!KB]YT;EM<!N$X!9\MPZP@HL0O)P_UK.HV3XIJ[W-,IB5
M*=FXY"FJK?+OXKPE#Z<-_6RBS;[M_38!Q*X@'&(Y ^ZOD;=HX#XX#_"$+/5$
M+2U@BJ/LL9%?2Y8' U;:00UTB0*OZ1[+T*-R#KWB-G&W?KX[<WY8V=IU_AD@
MR@Q #9?B?F92,,=8!X$MVCPE/WNYJ*T(*@U#>/<V&D8!=^RM'J\6N-HIG8G0
MG#Z1-\.YZBVKG/TMASQNAZ44=9'R\>1M0-]I4TYR>A%#'H$QR@FTTAR(9G7)
M(L("O(Y6NC:YTWRC)3W?Z?U7[[2;VR7GAV9N7\H]S#,;S P'8%S@&F=>1$WM
M.6U*!Y*)@IX(#.?(#VZ?/<:"TH9"Y'O$-5N)J7^:60YQ$2\_14C#2KNQ^M]:
M:S%-H[_PF[E$4F"H6E'DB :+P8:OO)Z"_TZ,A\1MC_^-F[_ E /.,,-1@TNX
MN,QV]V7P_5*<2/<^*$/I'.W?V6.(HAZ4&-TJI;(VM'_"6>C3<$BN9M-,_J\\
M.RR.'ALL;J(Q*JB-*L-25I>ENS%SV.72K?^.8A.=@09&G.M:!-,AO4MSJ_WC
MR-!V(/$UR1>&(%Y$\X0V_88AEK]<^KW@,TR1W4FKA^B[>J;?C_#-(&E&)5*9
ML?N@+B_H<N520]R6/1VRO-2) 4YQ-<T4J4'+[D\&IZ!.KQ7",NIOLIR5JLE;
M$%="(2E1RZNWKJ0\(?IZM_F*TMS,A?:S[HD_6RNKVN:'/SF@S$U8^R#''W^K
MES&LNFBF"WJ.B(C;![GN/JS=V\"2E3G\JO0-JLV6_CZ([R@R'.AC_H.4F8(&
M<R/AIPP<^[RQ#Q*,M4^8]UXXJ 7N*3S\N*K]\_J1@C#XIN9RVV'?WG1$T"$U
M9E.E8A'G-_O GS]L#V>KP VO4H;!D]=AQ&M3L4Z;3,_ZG!<5WHD-5]I_/6J:
MVXR(&V!D/C\BJ. ]&05%Q)7)/77_YK1%9@8BQBZPGUFHP)"F0"S3$JE-C[FU
M]CB48#C+ ;\ VX[G.@1-R%>W35426NT#6QMUN^3_:L]79M^3/4PL)A[F+,$:
MC]#1#ZU6!^!*ZU+A%',9WR]6>E>&7WLKGC]@7GR'R4=2?6%A6W:T\@OU5LU3
MJGRTJ6%C-F.+C4K=V2AC3SO#SB#X&$5PB:\(;ZM2[H(>J!QYV^5_E,1IH:W;
M*PJ3[")$5SJ(!%_+OHX&"[LH?N8&WE9_)^)R_(^[^Z!,@@:W%0NW<'V6$&)I
MH$2"5D*D\UU)E.[<<TJ+;1,ZM=L7WWK\,:[CL/Q<F4E^V;L4;WNX;AS/S>P&
M-]0)UD6:2#=<$ 8L48*SS*#+\"-KJ,M$ND@ZWM17S;XQ(5U*'E&R_M.6^COR
M5&R&S-/GJH_S1#W3)($(KG#<!\)?L]S8M>CE8C]9VF\/*VJ$P6]&.9W8D]GA
M:!PX^6<?E$8X#/QC9K7,MOXI8YOOH;GC;?L])BO]"/@$GS$=,[]-A:;N@R+!
M<TD]#"][KW".*!#'-(1N:5'9CC,42W@$74#^\?*8,,+>;WSAX>.J:C/"F=D_
M?SJ23]GA$D*7EU*.[X/N Q7__<%&AW7^;!S1:K)Z:#N\$6W)$0-6: 4#%L9T
MFQZH +#]SXQ9XO*"? ]!F:[V<*O^XTS,F CP87K;S+2NHV*\]W>H%T[T(Z.
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M2%:MF]OO1?-JI=\4,"F.@:15/S#CIVOT@J59?%4L*%!:]P.E0./+JJ+S/D'
M^^*7TA7ZRM9:';$*F$#]T7+U]EO*EY+B35JL;019*ZBQTD9T'W'.E'&87I"S
M _EBQSF-/#-.T&6%3]2;1052B4?KBQA:3A0E["&@H-_$X7MJXNL0@MB'A"2E
MEEK;IL=>\UTJ=;)'1<.0T>Q,/;0X-_QF^R#_L;D>JG ;^87W/^R7T/!,L/28
M6M=64! -?9_K"T)+SLS&R(NDR.&+*J+7.$+,&,-X_9%7?<'FWT3T;FW"B_\L
MC5FM8%>_N#5NV\_=_/FV:+XI?">>P2E&J2"]@0A:DNU$['9ZB>ZXF6SY1LGQ
M"3.-BC"YA<^-C5-F5MA+U\;_% 7WW"TH?#@T")?+:G$S)E7DH*EQ6_RT  :<
M%@,^AC)&_DO;[H$=]@TOA*9LL2Y0O!O"_;6;L LVP14>ROVY+?F_*%96UQ\8
M=>I>HO<+SOZ:9=JR$H"G%B"$($.27;US? DWN_F"2P&C<HK5:;&'S]K3EY9C
M""?:,.2!?H=C%^>WO[5-G,38TYV>3IJ78&_\AGWP\=L"7T9W67).<L:6\(9;
MV_[,$\@8 $,F\B-EV"7$8+ D@MK'V/O6-&OBGFZAQW+_P&7D!#*G*([WJ;3!
M>!A:N*SI/?W%&Q_*ZJ=V]<<?%)(G'?9!,*ACY>FMN$7&5F7A3NMD['?TQ3NS
MQ_R\N^+"]>*DFB[W145$":9F(-2L\F5?Q:KZ&0<$QL2JZ+X[OCPU_=><JTA!
M[*HB1@8[ WFF,KQ$):D/*OI?#S\&I#(2@=0ZFW/MK8PZVN(.[H5&7XIL><JZ
M/%HR1*,Z;*;[NTR)U=WBPP)V;/\JO-VN&GP#;5&4+.'\#^]_PTKSE:KVER-O
M/FTZ'E2GJM 0_79F 8J_>_'/W]2R<]8>'WWH^16C>4-:51=D9$:VW5DU6KZ2
MT?ZJ;5!['H=%Y7?L3!(*3MU>R:HD:OK48:U0A?,=^*TZS!A$C)MB7"6]MLV/
MP,!H)6WT,6O<;+M.[>*/^.D"!NK]B88IW-_%Q?6O0_F'C8]&6].WLTL,;EQ3
MN%^XM[H,X_J06D8N30\JACH*U _WHXZV$(B3QV=NEK<^,)B*:2'-7\8A?FZ1
M'_LM1JV\)UFNZ^J4_B:Q*Y&'J/GL5P2#5D"^?U9J'T1K9-T.,."(T7EJ52+J
M';MA)EKFY2'>=Z[G"9;7_WH[U()=PW*.C-"Y[%TJ^%]!B"".A_H=IP?W%I6F
M[8/$M#4)BH#WI68B7=XR%GOB 86E%^4=FA^B:MW<2BCA>: [ZIKQ#CN+J+UW
M&UF>>NMYO6M67X!.WOKRF=&GM<NUE_$W];V P@R/NX:.$O-EX,4AA0]/7Q47
M!\*_807-4)0<+?HA W*.QK#NS2?J7=>BXP$?*TT+?QO9M-YKYXXJ"6<+1/=2
MU(Y>75>?KE@CTT8KOKTJ4WS"277>O7%6H"?W$+QS1^6T8NU8.YSN3M[M:?./
MHT*E$>B>QQ%W16-]+Y(6UV/^L1?4,!^+O7L&E)QSQ/<KZ[7LQRN_6P$THQSH
MO  D]<H%;_XF>W;>&6\_Q;#0!%)/6\O_RSE!:'S2LX>4%I7*H9!F;4H0PV(%
MM>JUPDM=I1]2NXB'EX0"V_7,8)133WWM*# EWT5@S%MZ):_DU\1VKZ'A1F5!
MC,BWT"C/SK<'KLI@/Q&P23W-[6ZJ;I&C,6?]6&6-N5B]UXMC'-^ARKK@;37Q
M/1CS@OZ -41CV%7NW)V][S'K9&GEB].A@5-K[1$V"8OY$*;QVHCTZ?DB.H8C
M .$2T2-ZT^8^B+(/2BV$;:Z]#"&<HJUFF$%KUO=2T\RBR6-B:XVSYTAA_ &2
MC9GA">S,NYI1$7D_(Y6^]L?UK#1HWL<\XG03:5>WYVT8"\!.!,W1E%O#,*$(
MK!GT3?AM( /"$Q:_LO)FK5_WG;?G E!X)#!W^>Q!=^4A-UV>6\GRFS! O8 E
M?H@"W^JAEB:7Z !Q5,Q1A)_((42P.VWK9T$=R<>&D3*E+Z-_9#OBI]8AH=?O
MTH[RBL,7>>[?7P'3'#" BDT_Y,L^B('!4-5R."< &^_Q+:3JFQ_C:ZU:^&\%
M!=*%6?0//_._5=SJ$TNY3I8M.H X&KU7)<PU0X#J2(^FCYV"4(+ZGS<S_9IA
M-9! 5HAC<=&#ZJ$R\/7\0:]+')^17]O@=6#,\:F.CZ5W3^'S[[Y;;U:^%)_R
MSML'!;0:!6=?OJJS1)((X&>&7$7-7:\T:M&(/@_9<8#>V(KN-7S #2YDBY^>
MV7<RI!$6(G>GK@H(Z(YNG(J@KY'\B@NS?!IXYVL-)#-^GFPUEV>HLU_$>#^'
M%'36OET7O\\H6A(/Y];0T8;F?H6JRC?#/#=U[IU,ESAZKUD->O7-UGIT<4E)
MF0V6":VS(*IS9C[Y*$BI5YZV\[K<\YJ\/+E@]#G;"+^@-PFM\>^1Y0EZ8Z_1
M35&O*JS-OC(PXQ !"<]^$5^\M/B=L+<^IC5!X&>ICH,XGP#XLKW4@:O#X61S
ML3-?S@S];&8J^Y@>^ABJ>EM$67*1](,A96J55X=_I;YYM>G>^3?WKIWVF#MV
M>M.@^,Z S/2K%C4OO'W+=(UI&R%T<&%Q;V'C#8%8:QXOXV,@9_8,:2YWS-LZ
M^[0+QJGA2!_,*B[\Q]7PH&N=]C@#8X&_,L=IEYI7%>B?BZ\7YE^L5_GMTSQF
MY)QK;;S<=&$NU>*K*TG#E*AEEL=ARGNQ.;LK5<P0W/S'^V77C^B66!OS9)4\
MEV]958@J=9XAEI:2I#E'M,A@#%0!=9H56L!(HANF_.2<0KS:[I/V4E 2G=R.
MP UG-E-L&E.6UPVVS#16'E39]D2G:-[%_C#(V/F0Q33X&#[=&V@T>&W#K5I.
M/\SZA5S.5:J^OJ!;M;/JB,3/7'C0)K) FJ;&3_\N*%00%>3L9-1UC0[UZ;E<
MDS'@[ZKIU) '#JN^U^<?9L<T'M(^5_QR&^6]CA1B'D!U<VVZ!FT6!B16(7:=
M@?ML(L639650^SKT;,B6H/W1RYDW<$TM+2X9)P>CU48]5OZA$';G.=OLW_N@
MV6IG'Z.O06HZ?;,# >JMP-M+3S?<HAXJVJGD1NI1CVB)N66Y_)HNZ;=ZO.*C
M__3:;<TG_ J'K^2/[Q$$^07R:JV35=6TK=S%7?#Q)7^*;M>ZW8[8.)%EX;;V
M^8]?_)UOO]>Z]MQ_5W,M+HAE &32^3J7#J')/#3I#%:(WI)XV#Z(% 7 +DSI
M_ZU3;IE\<?+N\N16O=R"(L%2[[[['9W<.Z4_"&7Y1ZID<HV^]>MT'#J:D\IW
M" OO[E!2' WNF1L5,:Q,K<XH$7/)K72[DJ4V(GVXI6;040OV7&^ZXLGL503J
M^*U$87.R O4AW8@TEZBPF&URI>]SM2/^HL40WH3^-'1Z5_7N%>?X&L^VB]J?
M.!+HY7SP 0L31 #C#_O%SD("6:27*!QBHMV&70CSJF];7DBPG]2;#S73J/>V
MT>K;VLGN>)-^JMEV4K>VX+AZ<2%G2_T9SO7:\$K.RU*-U?F!CSD*$K#(Q*[:
MO#4Z6G*6LHD"*\($G?@U+:2,/":KO>IN4&5'RXNKW1>_%Z^>,8V;#5A%JM"(
M@F2H"-4(S5]$.5>(:)^H#Z(;%>N;:9:I-R/U10+EKKZ9SG3VB/F*E9HG#9[%
M]A(!+;YDI/-_J@O[@,>DMI^H ]Z?8-=RE!;6&846R8D45=R$W_"5E)^)+J-#
M_3O7)[+B2JP6IK_" FT'Q0Y]1Q(;\\3_E1'J-@A<L;>6%VKB37'B*;%3H&;0
M=;/ZJYR?^Y]3O^RJ[J^F_NAAX47'RWD&16'>_1%A=;,Q=0P%6$\,HBWUG*-"
M[_4P_]/?G[X>KTVK=LP+[99XCT!><:[VTJU6@]:^B0NC7[GMH/=\E2,.Q'(=
MK8>7_4N$??>B4OL3)UP&)4*^AQ3YW$((=]YVT?M(1.#-/RNTP^X\<JS<?="#
MQ\BS0-TR&@-K4-OJHC609VKH+N#[LZ2<5+I:EY_,A2B*QAC/_V#N/:.:BJ+]
MP5B1KE0!)4H1I"M5JJAT(?0.$1$0,"#2 L1$Z1T! :E1*:$C76JD!$1$I$N0
MDL1&3Q3"E10&WZQ9,Q_>S/S7F[7FO0_G0^Y:-\D]9]]?6?OL??S(%AF5OSY?
M#NM$0PHBBC=)R;XF]S^4?MMD-%4/?;V:^/767?R'B;\(I;LFW[!"X]KW2O[^
M:/O0G/S7^T[CIRNX/]8--WKD;F,TY@:(5:9QD=8%R(EKD]G)15Y"?7BK+%]E
M+FG";4&>>S8CYTV^3Z3+'GEQI]%1TU:G@N7JZ)60*V\Y8)K\'G(Z)E:#A%6+
MAU46IF5W"?(B/G]::1#D5(G&X5-D ^)&C.P#D _D"5IHYRP]BLC-YDXW 9(H
MD'>=[4^Z]5;T..YKCI4T5]Y24$T)8I2CM&>/SE]L,7%=V3!:&M*S^H^B$EF*
M3O<RV4*1$VXTX"Y&$2U>@>(%">7QI4&O?873FP7RO"K&RP8#0YU::$Z3_2/V
M2T91ZP.<M?>=2F[9"3&FDB<U'EEY<C[ACT6%&H$XFD6+'K[S;.4,['C>GMMG
MRL_)4UQN\4/&POANY&GXN6#W6OCK$N%Z-XYV64=M+NCN2*WJ;4_<;%WBL >S
MP;W'U;;2:BI+A<3V< "G;V1TZ6M&]B#@XZ#>3SG>S!1OR/?1OGDNF]-%I327
M\(;O883WS7RYJ1-Y'@]/5SE_AN<3,<X]K@;.S;EBSOU*F%-, ^0"MD6OWPT\
M5-#0!\7G4;6 8@J$($G-]JP&](B*,=W'0BF\YC.J*4D8P8+K*;>CS6\..,Q:
M2]P5:>M(U\H?>?SF!-<!2)KY7J\I#X=*QC8:;6:0*[8'F&H BMQ _+Z7F$WU
M(NOAH@IK,LX +K?>/C&O^.JJKX/#_2B\N_<KR==#Y46L..3<[52)['U1%W6V
MM2D6+MSOD>[XNZP@97[V+R<L!S)>/(WQ]0RU+G_^^XL6]\VIAXLCY^'BNC-Q
MHA+[;4X0Q?Z5Q\\7$0HR/7YO\5\*1!=8719NV"JU7N2/RS'\Z]=I\["(-T.F
M4WT(>/ G0+*AY.<UTK!'>?3XU34-82$U:-[=[WD_7Z@_+8&^^'G62<["-_:=
MQYK#?H[,SBOIN2JVW1J'*L.BO#^[9!8FFSPQ<'YJQ2'^,* .0&GH0X\N?  Z
MWWL:>+1,H&:4P14);77$PS#IOB\@6PZ/_#V,$V!5*/0/#.=L[?PZ+JOR,&M2
MJB#X?.3/#1^:UJ$M]**)(:</IZKO]6@9W8Y1MM4K2;^-);OUTFB,(ZJ/N:W:
M/G?KB>F?55ZK R5AVI,$;FIWJ758CM$,J [O/R9^1<QGO)*2NL-UFGMO9M5Z
M^H+5LP5](1E#973GTVCIU3U;)(O$DF+297M'3,R'JA49;PV\QL:0/[\-K_"?
M4I=UMAQI6XQ@ D9SRPXJ\5VR[%J'?7,./#AU@'CU0\<<'U%YS>DD)/_>5ZT;
M$?:\BG#A:[D"N4?K9<\[<#I#K@Q-C?Z:ZK=^[AE;]FI3)DK5NK: GG;XMNC!
M/0=[!1E/$:JOX=D#G<L)K2]VN464)D,9XE83JC=\>CK@,:O[.:VM>%:VXVD?
M#:"2SS*?S&!7TIA@BF(\DI4>T$S12U =YU@RH]U&6'1'CP\*&Y:_7G2=-P\*
M^ QUT:]V=AK1R>FOO],5)]%>R&5M:/66^:XLRLXV1])$8C/ PN2XUY=H#2&Y
M12V.(X+S5C<3^XU^!,A9*W5XX]5/GQK!7UDH*MF-5T[T]_1$&Y:S!>6BT@=(
M-=,IV,82T=JU2MRC&EP'%;+H ,&\RB2?!(N[GJS\X9A,67&-$7E&(%BG::#N
M3PX1'CI&W)65'J$)O]E_+CDJ9*)^34K6"5V,(MN9L[A1U#?D*<M&GU7<(*XS
M 3LNE]HF=_QETR#6'<8-=1+/7)R<<9*X@>JA;\-\ ;1'[\(:4K%>VX",5#\X
M%MT\WK<<S[P,7*-9Z272SY /S1CS[*R-!<!-TGJAUQ)2I\NNA6XVEI^IB/F8
MEFSV35HF>!/:G7'T;>@#/L1WTRV6MX0D4(/^TVC-Y#18_MTK"9:/KGO9G[5X
M%Q!VY_K*LSZ(EQ5.[E)P+":G%@/.,Q-)B-=T7+/&I.7RE&MFOZXT4:MTL$F)
M]>P.J-MJ*=?U'7NK?JT!ET7\F))4=>]+P5\!WHLXCT8AL;$JNP&/*T!19(V%
M]<<W5TKM0Z]88^J$)ZRB85HUR!O_3M,XURN.< 5"R:744$8)0IQDW.U!<S+P
M]:^&9]N0*YJ]6 8@\8+&64"I(^76E%.AO(ACMD46<7+8K+<S><O$_D[CW^IJ
M)()1K'L6&&:R)M!<?V&/A12#AY#*C%P]W_-2IL+@I <JYBZN">^P?#NC!LW3
M$I030VA/&=_<R-4G7R'!(54/JJE/1H7[+C<LMS1?>774>O)/DI>HA^5BO+'6
M]?=V4L=T.%4<+Y^X=UEFV^GDCO=#X"(ZZMK%#)&PS5,@D&APKV"2 *]"W7.;
M=_K?WU;>%;@:6QUL.TB4B?IRV]R4WIB5>]0JX4TL3RRZQ2;9)G,L@[Q.,TJ2
M#D**:^&&$\EGB[IHXD*F<3+P!^TR_5/?/C[RBGE4)0P@?ML%V06S_7GN/Q2J
M= !R")GE28:.,SZUDS* 2WN;([3KB-L4H[[Q)"@/U@>-]U )Y'$&A@F!\8K:
M#E5P(USN]P7K-S,[;CK>7?<O=6299Y56J]S5BF6[_0;C1&#/2 *3+=$+>2N8
M379?<L,PFNT0J_3F$TPHRO?QF,$>GD V((4HF-)M=#RH_T&+2%[4>Q4:*$4J
M7R/-7?5B&8]Z#K2SR4GPSJT7D+Q'A/C-M^NM[X8,']K%1PSYW=^,];Z]Z2$N
M0'L;\%#W;BT?F<7 /6+<HPPHMWB^?@#RMHX8<VVF*404-?)^HUXM/:=2_=A4
MA62JNB2DZ4I!R\]II99M!7TF=]K*VKQ#U;[(?PA3D$3S6Q,R-KXJMCC%-DL5
M&['*_5R0N]7TX5KS_E>E<4Z9WZ8:$<1BOD.==4;W%." ^]=M8AOO.=B)CD,8
M^1/2S%9F4[C01)<T$;NVSXK>ZL[*CTO&77(G0A9&YC8V. 3V'IEV22X+Q_WL
MI 3&:YNB5EK K-H.@O&[?Q'*@ANA)'.%0)[A,C]%PI?=DY36+B-/M::VL8H%
M:+>DEYE0@#WQUH6AM**YC;.Q+#YB5XV_)(P>R=7M8C]Y(OY15.B>R@'H<C@+
MOOSYZ5K; ,NHDVLG(X:"@#^NNQKI=D'<I\F6:;_Y,Q_)9*&Z'$,3'-/]H84&
M5KA=^X /X]/]0%3\P!U[5F_'I,J@K\ :O]>-#$V<W<?R?,B1U[/15=9UTK:!
M)2H5KUMBK<4??#MWTE)=X9&AV1GT[1B<B3G;D;N@$V\<]R2"Q@E3D\50=0QD
MM>< Q+OCTMY[ )KY_R/]&POA/2=;^HCOR2_'*R)/YHOG9=B/I T>O9$Y!C)W
M*EC*]&GXA6^+JRPUP:P[>S&S4<):AMM>5<ZC/B%)8L\FNOI4DNLQTH-*W^R+
M^8Z0\_J7 2F6#<PA5AC,83TV1=XUKZ.;AY,6<-OU<!M<9-UL1RB<J3KM,Q,:
M85ASS:PF*K'!Y\_.0F'P.2H/CN^SYL=>KXB,C<P#T'$4(_8 ='>=.SE,[Y2N
M@-NRWA"48W0%);H&/MUM4 5L6T_3V54<3H^L=$7U/#(I&1C(,GI$?*P[;=C.
MT:B]*7Y3"#K5*<V]'K5C]MN8WL%XAEU)1[U!;>A1_!V!>3(O(;VF''X LIIJ
MV'%3MJ9(I81B^1> FS>G?](,MC)7:#IWB? 0D6N%>[=<N%5<?GPU^RY@LY_2
M&EQ<JOM6B+YZ__7(@]I_58DW_\_RPWVZ'CG7?W^]X9O-?Y:VK,K 'ZXLXR0U
M [/6GRQ=?8:HU^+PKH$#.8DZU>U #AY2[\PM?@EODM785@R)3U)E#VOLCMY?
M,@O+=]<9U>GVBKE\XI'6W/?VA /02KQ><U["[B*[>PQ1<7 T)8W=[LW,RWB'
MB:QK%5-;GAWIEYUE#8(XXG6:XN[@(,<=-GOXK\9Z^4A&H=X=@!3'WV[-[:XR
MC>N\_'+5PG*M!.YO;,(V/7VNA9G!L_CDHAIM3V0$%S0;\-_0M0-Z:'+W]011
M]Z'SV=2GT]UF5:L%F(V)",K5;1/R;EUK+=XG^=#FG0*?@N*J1Y24%RK0#\QG
M&ELOC*B/*(X4_-7J!Y--MF.9I\CJFW4K#-[A$@5!<%M>:@#"@*CCMZ9EEI)Q
M]/X5686G*R@VE_?.I^@Z!$)0)2-:RE8#^_QJ<;7_;D"R(@.11<\ZO[R[/O9W
M#3%*R:;Z3C"O(#]JMF^,5@)YMI,J;@[OF,)D,R#WPQ(>9BT;R(FZ]U>]?^DA
MK"3J51GNISBWG! X0.G*%_C4REA":B\(B%F1ZUS<C2]N0*AV  ^9%Z*EO:9A
ML  5O0WHIL;*<Y$(!<_;%F(/[_J(G'T@X=!J=?U?;JOA+3VNY5 9^2/\9GM/
M 2BJ)U!(>P!,X0Y (#FZ:@6<%[?$,84\"P@.=&+2>\&KE '_X!6&V6#80[57
M&"=_801T'I_S/89]J#G+,?./N"KRE>\!B!-QHGP>0 Z-]KN#C;OERU:=19_*
M=9KGX&;SRG^%93JMJN7F!=_8.V/D>?QTF8C$B>.> :R7NI*EN0%=EX773;^P
M%>,?H></0'W*W2(D]/Q-:B$CIQXI"7\];, H1XJO@\^$HOCU/3$C-?" /7N*
M8 +B%CZL^/B3OF!?#N;Y^$7D9[,6Y9$_)__6X+LA-&$@?!![#N6%36L"NAS:
MIU%>!Z!X*)^N\/T"N;!<[]'!62@O0O$EX/S'>L9;?*R]<TJ^13\8=K[2\5O!
M#X/L4Z"&%NG2\7IT_/*<6V#7^>6?0 W2Z(,>Z !T#WN,S@\<JT..:^9\19]!
M"!%U;(C\6SV"21L/EN3MAXD*S55^^-[,<"]A$=\'G_V"G2N^R5&>;"9\0]20
MVYFL083Q># KDP/!TP:,DM*B"-L;%)JA&65XA9'>&N@9^IB YA)?L_%%L]WK
M?CP>3N@1=K,G.[J/, N>F7Q'5%?R[MY-5IMK@"BN]8=OPVSF0PX=?Q0X']J.
MHO-LKV W9RB"U!  2WSLXT0&#QZ YJ>()].(8]RX7J'VUJSMP27AJ5TMF#WM
M'5(L?>6UV_VY.?M&\T MH4M37E$);:ZN'[AKD9_ ;WX.8)\P)0 &J2=@%RF+
MT&>\8BKX8?FUH<3QL[\B;^_E^LO7]182MME\3;Y]D&_1XUBUGYCWI<A>ADU^
M6%%Y 0Z8N+Y%96+K!+\BG,BR5'ERWL8>S10Y"15E@H'T/8L)/5\XG;L*7D-P
MZRWT\"' Q(=*.*:\)L93=N);;3,56^O4(+)6L8-)$K@MH>(O)V@6R=*"NWNR
M2./_.)FI3 JT=\%'"#0C4FRX].F:3Q=\$T9(JLB-^&Y,3#OME?^UN/+EO=R[
M+"0<NWV6>=NDR:6%@%EGA?8;,(D%7^F*A4B)W+KV)A._A0D!2?3HG:?AS9>]
M+(VESO>N@J*RKOSR?X^4ION1]?K?RHTG;M][.[<K_3-%GYR;GK56(D7A_/R%
MLR+C];Q$>_L4YWO'85;CF*U'? *B!M7TAY1P7)WS=C^TN0T=J!I7UC3OORRL
MNAZ>UZ>I+)'&.2W*UYKZ=TEE%O9^*2U G'Q(LWD.OB1_OYV&>.@1NBIY/PI]
MQFT\F*28*%SFL8L&PTL@FYQA5$*!B63R)Q.^BHQRB2REELD= F=/-SN?1M!9
MSU]&G!"V'%=_Q)A["5>A^ZQOW;JY[PU.+2>LWP$H5_TVV=TK\>/7U7O)156&
MB)Q@/W)VWU10UD]'S?#49C8*<NVYJU+(MVW-5B\+6R_2,[H>,$>9)=%N#N<%
M(03(QWL?89[256;SD'ISM0K3 0>@V&S<YZ233SY92<4O#VRU-R;=B_^]PL\*
M-:)K P:'YH#@G:6".GIHK,F[S>_WU"&8+P.<,XR=MX*">WM^KW_\IOX\4A_P
M,^='R>WN5,<?/0+2J8'BC2//+CVT4%?8_&+3G]I^]MO3<7V;:?N/5_BKJF7<
MA[EJ2?'E\"G[9M/(/W9949]*GQ?.TB2GHD?>O#!-X;5!BV3L?6T$AMF^Y,DD
MGV..51J6"//8$FA%<I>M,Q3[OX]==D@_D>[SW%,AN=A%PQIR V<8_ FDE^/X
M,QW9'?HZF>C\(+(.^F-KLZ*'$=4SE"/Q4_SLRCG*WS/T7^RI.S\_@]?,-9-/
M_G>W7?U?'8C'-.0 [88K<@C;<@O<5+-D1+MN1IZ"0N)AY2-\FI_G4H\QKRM;
MV)]J)?E0,TM'+G_)8]X,/8J-!\^/']Y2"$P-@8_^RUT>/T1BDP5J]ASVON)\
M A$=K^U L:&%G5>_3FF(V50UYZ8>FNNXPCIH=Z0VFCM4<&Z7-:1'T2-Z#2_B
MNU7&??36 >@KFLXG2TVD!&Z\HIU%?L:V@)_L:$%/'WJ'O(%%&W?RC^)* Y5]
MY[7YY,G) Y!]_&)NA$J=FDL<=IKGDH._?P2?YE$W5+:;$9,]A?;(OT2#W)ZA
M>Y9^#SA&7(Y'G[C'*&(*(8S(/]((_NOO#T"'%)2&/:MPL8.2$,<4\COM,A+.
MN1T?TJ$H_/6FA#UU8I5W5+UHR]HX=]V^I9VNCB[?#VT*%:T?17;Z5_2FF->V
MKHUO29D+UF <%<HF=%^WV9=:PH^<;OT5?27D<\S[),P?CCN_3Z?.X$LKW,P>
M5ZSN->-'/'6^IY5/SUH_\VHI()[ZD8N_T2UT(?Q^43K[1?'D'GOC_[VOA<]:
M9%O>:Z?1RG7-G/ALS#N^\<=52RY?G/J%<OA&0T,E+ V%YFT%0T^\.#)R](E>
M%B1:[W?K^*;)H7UA$)89#DL\#>OUV&>0^76'26W] Q"+'7-:N"*F>K5@-E]]
M@T8@G2PM6W9>L^?=!% $R2#.[T7-+A\\'WH^DTBXE_S^B]<%%#3T"@U*1+U<
MGO^/_6'\-_Z7&F7_AJ2ASB&%F..ZQZ9[)>DN%/F&V&ZA<G,?6$3MDEP#F^L:
M;XJ_QM'K6::3YE=L+2L-G1Y=OR9:)4>47[X,>P7A9OL9),YT-GXQI)S]!)4@
M<0[YKQU1(/+BJNA%1A8BD)S1WXEL)H&%VQ.USU>M=:+B=@H;3BO&JRSJ.0AR
M5_IOETM.3.:&+IZO=3!N=C5]D7[UU>+CU!CY=%B1UQ>V;LJK))P5)K&*7<HB
M]D>.:=&X,5Z^97E$#9%WGL)OP4<0O3C^9BWM=H!+CF>0$U*TLTKC;F/+_0\A
M2FO% M73P06F5IAMZ<5>VZ*\B4>'_PNJ=R<O<<274CULV5$XVM8R5;M3Y^[2
MM=!1QAKH^R!^S&I+02(D7M+;[L_Y\*M5B^XS'BL04>:D/$NBKLQYLT,QRG8O
M>U-8O=]?J[UUAFZ%>;OL$TH1^#WS8OCXA]&'VLJ>>CF\M=Y;6RL"3U%/%6.9
MK)1QNCPT :8>2[]/8O)"V8V.6\&-!DT$OL_"1!#C"H4<OD\PBB5*5Q^>0)5S
MQX]H*N2_*+B@,J9Q/)1M)46CG054='Y>0X*DT\%/+0H:Z("<LNV;&FG,&IK!
M#377.->DEL>GVJF>LC9Y5&56X% 5<(^TU;*%E%I)2.PV)S+D]ET]\CP>?54P
MU^[50)QDX4SKM_PHF9(6\0D^0ER;+A$K%C2\0N7S$N8)9NS(&#T/2R PI 8Z
M0WLS2GUGG=USO#CL9]743AO  F&!'$AGHW-6AHE/I(=%4NYE!;OX*5UAHIZ5
MO\:JP$8Z3#I,UA9@;<OV2]MCZ$ER[.4AI5C/4P;20Z>34SW/EF6EWLTRD<@R
M<9(XQ"ZQZ/^L^][_X,&=<P""+:<M<V%]%.>-2)BAP!31T^#32# @_DYX]A51
M[XAJ3QT>/OD)KCO8*YBUM,]>(R0V6]Z1/F05$:CZ)MW>US/T!.3/*)F%U+#)
MI0*)>TA7.@#%(+HOKW#'J?=J?V;* +H_Y*'O\/YP%\>9&7D84WRXPNSE@$Y#
MDMR.?X7:7K2& JGYH@?\E9<^XPP2KW=4%8T/I[H",V1V?8IN\<KF36)#="CD
M5$.2JIN,CM^P:8RU@5E*?LOJO23O^=-WTR6,HJ\W#_61G)F( ]#A0PQ3R9\1
M1BO8)_^:<70NL_2*N2&4\RPF Y""\XYP,*Y$*Y ;\/ZMH<IYDN'@U$T!1;G<
M">G_L] ]FUEK=2WU!I]4U"K*SK^NZP $C:MR7GH<&.5BYKX4%4+G7HOO]T])
M$9%-Z0KV"=4I;YE3BXLI=$GR,"KX^I;PD4?YEN/#A4<:J@'5OA37/@_/$QL'
M(+_N^$]XV:ZZ5\BIX'/2V>,M=Q2+I2/4GH 6D]MO/_OG^ANR#U< .R_X;KG]
MT+F2MN=+B6H]1 @G'$(\KG;&3W,NMOY"Z]R#0HN>9";>[%J 9P$( =A$CHC(
M2LNF!T,=K:ZC!AC#Y(9#NBMCI&NSTXZA^@91(EAO<#Q3G**>@I!<R7@R$NI1
M#^\W<PI=S]<V(&1PK;?[ATH6!5T?X9S9:;QAQ_=7.A_TC7OK-3;S/X7N"CU_
M.F1'9'5U_\WK9)G8_T<"MQ&^_K*X]N'U_M3LS*+TR,B2Z9([ U<XCNX-NQ\A
MK98$I]]G8OFP:G&A41'E?WQ;ZQ<NF3AI]G:4_Q(0C*QHC8*5K[8IM>(6&8Q!
M@;9G-Y*=2IPJ<NSXKTOD#ELHNU^DZ%'CR9@GH8Z(BV7X-=UK0&;E4%T9G+>_
MBI-:)WTQ/T#5!#'3_%EE.7.<FMZL6MX2?TTLWD3RZ*65ENVG2ZI <Z4ST$!-
MFJD+E"-T)&\; D:$KIH,X$9+3ERNBTGW394JCEZ9&:*6Q+-% U&T;ZC(XRPA
MOEI,6PG71-H#5V:=P?J) +^9G/H<38B[PVQ9W:GMB =TA(6_E#W\=GWTQRMO
M@M+L-OGE+O&/2(TE#^)-%2XO6E9@W/WO2_>&0BPI_ZI"!*BD@646J6DZ*_ES
M=]A^^Y!+81"CO.Y6W.SO4<)29DC7/1//$!:<(*4GO?\ =#?9ET]IGYUP*,=/
M()3)?P_E:?P._*BK16 KS,;RTZO:]?W:S*$\X=Z>:C=6155STY675UT7S<5/
ML"6U\K%MA=!.M:S?:VUIC<8O<3:Z+ PT2=^-5K'3%S80ECG!QG>)"R3D6:(2
M'S'><.YG*K?'LJIJHX(5%1Y"WN&%&?)8E+7YV55+%'TK:>PTE7<ST&HC1[CZ
MSN:JG[>AW;Q2Q"<J5J<NK'+9C]D0/3#VX6RD<^NU,LK9N,!:N\I2?H[ODR$;
M=/SC)+9'L<[7V796$Y^>>P(/@%QJL;.[;@<"*8'.@KA QSYSL;3SM3@H/R^G
MF%HLN+7WTDJ:8L464L4%=A"-J0&YH[<.,;5*^K_[#-W_R@!JF&R**^ T%)_>
M73#>Y1VXN94QDS"DQX>0HUS*6:EXTRT<5AZ!TJGZLU.G;.6M[UGE-ROVTZ*Q
MZZK!MZ]?A_H=TR6@Q/;^0R#SR4AJ0S5CWHU_"62RUM%<$4?_99/ABD3PP&5Z
M%.4 A(LT2D8H$[;9EP ;IRDHL2&1[D0JOCFXYXQ*W$DS&NG)>95GU)*^XCK\
M/8E=SOH?Y+2C-UF)Z'D(]3I H]T 9/L;@7&<'AM3=%U7:B*$/1Z7@V/4WM"*
M*C:6F_VMF^\A41-56:9LI.RL+YW6W,<,:LU8$&&R;=*4Z"J ).T!PH&!0=V#
MIB^SZRH=.N+'Z5B:&MS,=#)D^\S]2"G<>1>+MN2%OI*++5W1>PZS*L:MTJ3.
M99U)YTX3R6^!?#Q-&*Q[H>RNVPZD;G?!KK7@]W9 C1MXL7T9D[<[6CX<P56(
M,:C\V*X9:Z^6N>QZX8A4MQE\=NW>$=L3N0^W7LJD*O6GYT2^Z=8ARLL.=L)Z
M7U5 '=T2XD]V)@\QQRW5U*_V9YGX!$L^GQK,.ZU\]IO; 2C"1.BL:M=M?0.^
MN9 TI\6<,_S%BU]D7DM+YK]XQF][U"D)!#+1>,EBY<Y*)E'+&45()?@<3H^3
M*8B  3#2LBAPR?<E!1K;K4CLD;6?"[D&^W8_0& /TO8V8EI?YL5/^.RM.'+3
MU:PC>YT@IH'NJ0/0ASF]5BE&X5X":A<*-\76=_[?7'[!:*#H?0Z\OX^L/0RB
M5R?X+.'']RV/&""-F;-HLGU& KHI;TCVD&3WL0-@/J#=<BJD\+SIMOU4J"R[
MB$'4MZOR33>#SV5U2429O0^K=SDFH::#HH+_'<<"*%/QG93=A'@Z9P/\ZMX[
MR_M[ZDDU2RY^9]SU:TTB.!0YVC(->3]D?;"Z@ S+N7 GVL.VXMM+C*#4V+V2
MACPBK;[A"T9(^L_O7O=UNVY/X!I.[YIDES&#^Y 31MADZG"[Y65(V,R@_80
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MCPFQ9.R HJC?G.ZUN4.C3:AT\16]\FSH<WE[/,(X/5#\:>*C$A?EHT\<OAV
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MKGL.:8B4#VFLQ@RWRLV&Y07)A>>V[9FTZIN]$,N'GV<SKN\^1[YZ9!7Z0CM
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M39O^P]J/(*[&OTPT[1;"N9N12]>G$%'S@42=A,'-2\.#X9'A&X2@FE_FI,T
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MJ&EW>]@)Y9612#VDNSHYQ0 2HPCL3/X#[&]%N=W^,N 36&.D_*M.\GO;HH6
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MVKT=\!)(D14MQ-?S%D?4!H\)=Q'9(6FI#(YF)N30$GA@^SL]!GV0,2"A0O\
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M<SK7&]'[>6.1DN6F]D/*(K._$LQPVC$;L_RRA)':K&DG $Z]H$)J'&HIU%*
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M<O2X+"XF9&"E$5,":X7NRDGL8T(^J+8P(7LN[W'LJCZ#A<&8L=RMXQQ,R*N
M!@I_^H97E^9XE\Q\:;":E6%(X>C_ZG.:_V>'ZZ/-:;HNQF#7UE-%Z:2!]/!9
M Y'8RIXS5Z(OSJ1=SGX4++7%Y]"8W$:$5S4Z(M[<C::H"#+Z894[K115Y-04
MIB7A<,S#%TS(Y"DP?-)<JDLOD5YC\RQ[^Q[TJWT7E!LS@4, YH1(3[4L&3I.
MC_O:>W<D0'H^07')+!;:]9[\\2,V0^+=3=Y/7>0,EXN(7RDI3:F.K"BGE<M=
M4*F!TCA",&E46F^_J0*@W0$#'OC13I!:NRX O>U0891QW;-D@28>,(1\>_9C
M9]?1O9[X5,YI":%S!N$;[L*["NU8(!"Z3!'$^@%S+#Z7BW*ZOT^@IJX@\^V\
MX[7>+$[3N@AZ_\EFZO;BI?GC%W#NFGZ!2[ZII"XG!KON+5^!B,;\1U:SC8V;
M:]Z(N\OT&0+69:\@AQ"3P,]2L)<)J1HJ=H<>)=PF'7-PK""/4SNAW'XN'V,3
M+[TJO;=\TB0(<#BX1*+LNG0@@/N"-/Z''2KR0";VDU\$C^DM',VZ'RR !UYH
MR4M[1I6^SW'@@2O_6!()4?+'IE(/T:]2B,$F@6N_-A;]CUN:?BO0>'VC/*5H
ML2S0==2N<6QX*IN^8^N N[?R1%/P+/Q)1M5ZGNE9_YV\,]J!O;I&_ P_9[4_
M=@EFZ6G?)%4:0^8:Y;4"WF:<_ZPG.J_A+,S#_HMKA'CX@)3RVNM$HR^%.O9?
MQ^7!(JH#DG8!3*#>9?1)7##Y4=:FE1JW=<$ET-?Q;,H.SYELF:8%B/NS3O/L
MQV4:*Y^K+!W42^;I0RP&8:F%<DDL.TT6-Y$=,,W(;!BLT\QIS-R#+G22_6((
MG#K"7CM-2F#,!.ZX8V?BQK\<?+/IE*N$K1KO^'7\[='XK75,'&'B'0:P](LJ
M"*#8KV" \RVK8V8FA093C0),B)6VB761FYMNV^HN-."TGQ<3HG&:P3L?7&D2
M6+*4=6'8]VY2S\>DFY24&I3LR\2OO6+#,L9WIY\:"W><:W>N FV [4$:";RR
M&?/BR>>/#36"#\-[*5\1]Z>3/@9>%)*T [XLCE%-FI4S*I)6ZNX[.E)U:?@+
M9_P[CBM1%64\J\8K[D=[==NNU>"N#"[7_V( M(<L]L3-<JYB Y?T>\U.\8?M
M]H=O2J./ X(OU'_.N&D'=3X\EA'$A)RCEO:SZ341I)"CC..OZ2^KLN7!AX#V
MU$Y;A].X2;A!!4"T>+A>G&EMY*IXX?KGBT(P)"_ME0.(N3PPX)82ES\J"QD5
MCWLO9/5D2.K[D<$KQI]X.OF0"S/M(CSQO\N_?:K-TWN@'\_H3J#15O T'([$
M<,?:Q)>8F2(O&(P35-]-_[+K:B]1*%O>67U#YT&VLI0 DXHY4B?ME[6+/:<I
MODP(#\I%)/F7Q5"6KH20Y36!&Y^L/^V_)$UK9+4?%PB,(W[D9 ^4-I"PC0*]
M>==XQC[M#3_W[==D[P[AM6E($Y_/NV@E\O37;_%<4]N#THGG3:0S,A)#I#=^
M9)DK]PV(/7)E0I*VRE+@^M(9!6.)OGV#6V&TO2#B')NSZM<YC+O(C<:EPB^S
MNX\4-%*&AIT>>?76Z-@P(6PA+/ V(I>_I&+Q1E$TF<); BXNDUQ1>B(#LX]?
M59WRNK_ A-P+M(5$>@8?^-PUV^1,0:SP4Q_2+F?.4FI6VJE7?Y4V-RR)<W9J
ME4?E&]_*G%PN5?;).=/\N_S(RX^BC1<N029LPGD^P=Z6G7S<VESH+N>M+K.Z
M&8H(]-%&X2=+VD;:X86Q&;S!5:>;X7WC>PKYZ[LAL[43VCA!XWZ0U=\13NB$
M2%7O0MN:5(?6'.VE!8(W?$D//QS,_!0^5JMN/3#!A+36R]I (R<SY(7ANP5-
ME_47N_U5]UL<TK?^*'[<&&<AG565W.!A%=/@:6-9]\QF.,PG+,Q2N< EOD3N
MS.\-5T91W[;<^<9341]2SXSFC. _]!"1VBTI!]53H]3@=E:/OWL.?7@O\;CT
MMR?@WE[:?.(%LJTQ^07_H4';Z+-\CR"""4L6.;@46#>T%I.:>-')I&O#]&'2
MZO0H=?3C<;T%A:QZBZ_4S(]=.VJ/?TM*-%F\F?)-*XP<YNE1;)[ONERO5,]P
M':L)&J..D6JFU>1O3>GL)6+>J '&"R:&VDUK:\<]E?)E-NZDR!7EY41??E3?
MB @N66FB>OSE?D,E/\*,-O+RG7,789EL!E,)8.YN;F?312;D\TOLM@82QH18
M5F_]2SG&3&<@V1EMO9Q,R$)\"^&+RQ26]H)57EW<PYF03:H?8K$7Z&28=#[&
M+%\#"(S?EQ6:62PZQI+1^-_+,&'Y5,UL_&RT/$Z-^MM_] X"_\8X\(6AB;*M
M $\"Z9TD 3ST*+*RPTX" HSGDN&DHZ"@B=9:3&!,F 94"Z[$9>(@%;JTR\U[
MK.Z]LM$ [!M[ A,R,;URMTO&+X+51)ACB3OMT),:)" %*=?F+'3^'.1M\CV4
M>OGAC5?U)RX(ZU#"Z2;<AR5CGQZ6W)0$]/=^7":RJ(RB"Q/2Q(<Y>;7.<73+
MGO J8TH3[;#N%&2]NS0S\(7N1(B&2K R7!<6L JSE;6,0@#7UH1!_3?"OZ6W
MZ?&!;\@U<9_W2;^2!*I?B+Y\\/7)9>"2G!14&&QE<!)8$?R-DH#U<0=L',&P
MVU*\1[-XZ;_K^.D5'A&;=-RPB]X(A5SZ''?CY?%/#[&;9Z@ZT(T.&'42TY+Z
M.9R!9'6:Z &:@I%Z?JXXK%YP4#=@^&X#PUT1P,^P,FJRU +4/-@9 VAAWD3%
MP":R"8##&K2JLXTD"/.-._5M24DC89+KJ=90Q!U-:"WOB ?/KU/E4T]FPZL"
MOYW;X(H)["7ND*6;_-H20&1-G'002?76/(&O]&WRNH7CT-!AE]\>H*T/2V1V
M[N'3O1_HK]\1VHQC9W1;K$LR(5GG,*0J)N0(>H0)Z:W3)CE:A=7Y#.30XKW>
MW"B!$Z<H"<EJM0JF6?'#!(5A=V^&.78ZCPGAV*)^S0S>=J.7-5A;*J/,@#6R
M!&X6ZV ^EM?^[;Z^3V=\;O3@ $,,L8!D]-)CFW3@+D(C *P]]H'0V5ES&>J3
M+6%VR9>8(9=_]<UI@EL-2QT>#(F3P9_G'^A24;A>T)"ZH9Q:3:\G1:)4(XN\
MR91J)[U*6UPE?69DE,$)^V+*J?)<X^,ZS,V/*$OR.%(P.F'_PN7>T2F9@'RY
MQ0>6#S^5<56A;#I(X%T<,=1OQZ@Y03 ":BB"/ !,924S2O[NEGQA*20&TI )
M0:F MF&A/ 4?X&'/-V<8VXWH-=T0Q*&9WD?)XZ,_DHACI-2M,-B7J!4H7SVC
M!U8UN4?CI]QF//+,XT59B</N8HG!K+ GQ&!VG1"+A&TX9G=2D X0)HU&?)B0
MN6>('1;;CK#^ZO\(3=E<8$#7]NCCONL?%<XX>7E[+S619N@!3,@9E2J4-1.2
MZTDOA '=8#T3DKQ)\ *+1K>]Z(48H!M9R9(,,DJP?ZW_C=*@DS[2.&\B)[6&
MZKA%;1@C3GRMT+:H:,1YXD<KG;";FZQ[\/I3KFVP5!VD6K"8;@K%CPE1>+?!
M.,V$].'1 P30C<9JK;\L,B&V:Q6C+' <)JRQ0O.(7C?K@SJG6($F2#M-Q_#3
MZ$U?&&L[=/2:YD.Z63<L#<<X2".PB@4<D\R%I5@RXDJV,UFE0X5,8MA;S=%8
MI3#W;U: -7^S@O375EAMT>PWMJD*5 +I#Q-ZMU04&5X$4+"0!EWR6\_^LZ8Z
M3$@T9M,'4;7&$,:P"-9Z'6$P=+F:"=EH4?DC$!/^!S,(T0PTR0T33&40@M-K
M&?DSV!X62]W/\DPXW8=Q0P_3#MO3P/WK9!K]HRWV>[B_U_;O9GJ8@N@=7<:M
M,B&8X=6-8-B/ALK=8E9^<\8"F#+"EZA>L) )N?HWOZ?^K_A=?H^AL$L-2Z:3
M_@4^<WNI*1AU!(US@,&U5;-[?9<)X6-"YHD$3Q+M/$.)"9D)E/A'<Q"+C?\/
MV(0BVC$POPI"/9T)0=3W_&)"K-=[9TN8D">/,,T,ECO/0&%D+%W4?D7[C\:T
MG4 KS_VS125T^Z:_UYBJ1* !,0P0 >0N@;BYE6W['0QA:2>D'KOH[$ ;Q  J
MEB!LB#1C\">$_ CYLSF8XIW_0>6_1]!?0I*-1:[8]T9I[U!_ DG"/UJ#VW+^
M.VW_'D X,@%;,X(88S AN+'954Q1B/N&+1/RJ1'V7WC__Q/>W]Y"V7QF0F)9
M\_J(98;@7R->_2,3DO*/H,1B6<!1/MK-:YE6'@>+P?\M4R;Y)=#4*3$=>_RX
MJ"K"2,UV_-.]N;9QP8]F<083.[&_X8U7\.DAKB=T'%TCKGYO$V]XF/18@>[0
M)-8J0VA=V]^L9JVOYGP<:'MH<%['NOV,1XJ"](-.20>I5V+\R#';5T_LKNOS
M#X=P8WJ%"&M$3(393=LRZTKK=ZO]5G9V=HB0-;?:NU"%_#,7 G9E-&W&@_V3
M8FVL^APTRH?#@N_)YT1_WOQ_W<WP/_6@':%GPR9*2'B59RQ8YM;5++-1+Z"_
MH(^ 7<7S:>S/4)9AY4L$[E74Z7>97([]V4/JW?.3:?P#M@&AFJ]RGG_=N"4$
M7E7DIO:N_$$#GX)PZC$:'/0!5-L);.AS-!LPG2+7JL&0'%!3B1"YFU1FG'KB
MB]*W5WYLX]G>(>\0HG%+)QR:Y=X(V3FU/\X/Q"75?-NF&[D79I7<0#=9(>*P
ME5":0,TVDOY63],36XF-:Q*EN='?H,\AGW.!ACKBE+F6A<E0THG/GW3LMB5N
M;3QWKXT)=<B?>.PDE'G2_7ZQ+V,4 SAP/2-\L%]AG\2.Y%J#4$KKE$H;20!Y
MM[NMSN(-D'ZU/_"-[ZFFVK1QT<.*OH&B89=7J=P-!=KPD/O8RQYUXTS( *<V
MD;BV/N \9OG32V%#:EN3U; FFE"=D#MM68=JZ2^9$"_L8Y/)WJ,F9'<*HJ,7
M4ABI<ZY(.IAS7W_5$@EOO.&5#_\&]Q<>.Z'MNB]M5W021Q-3HDK1KM*+%&%N
M@P"T/>'H8EUAFR@VDHA)V!I5XM 1]<?ETXAN43T^Q69%AG[%XQTO'865#C[N
M$35]'O&[H&/(RAS=B0WK/C>#61JFP%#RN!/T7#0,R;[M#,I1.*=ZVY9*8OY8
M?/+=?1A?71DGVY0E/W[AM\H/$9DGX-W=+W*>CI]?%)X^^/+MJUU6ECBXQ#*I
MF7:<]3,!G.ID0$ W8(H<]1A/B!J7Z$>9H]&2CO,O]=\M$-O;7L+5G_3C%48T
M'\<HA/1UE":>OGJ[*WB!M,FIK=D'+>>S0K S2%C@.B*<!%A:1A"-VA*B']F_
MH,&#R4[^:E!.$-K,[> $ECC7&CLN,LC]XWN+0X>7 [JO>,>,%N7?S'%Z^UY1
M_H1]'Q1IA< R(17#-#[$!&[%A"JSA*A63LA'UG\B'&VX,"[-&*NDF#\3U)-\
M']7*(98Z(),5I9&3FN5E&N<CGMLCG?YXM <="A8RCI^DIZ.XRCQ.((>W@^E%
MM)- 9]M>](@'3!AE!5#48/L7AU:TVNGYA=WOG U"0[P^G*L->,J>*6G=(_0Y
M/Z".E?P&H J#<%9FQ"W.;?(8HKPI]=LK(!N@O1T*=*Z<+O':ZXUA0)'KXOQ-
MT,(G:F:])[R=U>HHQ][7]2T'A.GU<-)S5E4C!0_)/&F5_MWM%$'WO[5W94%-
M95LT0B$"0D11%(2@@*),+8)H&$)K,8D2:5L"84@K(&! 4%I "8G*8P@(2,O0
M0$MD$F14)$$!$P,$E4%DAB ) 1&9FAL;PY7<W+S8W]U_[]6K5]4?J^I\[G/.
M6GNO7:=J'UB6E=EQ4L1%FA84#?!?(E,QBC"&W$LV%:9_R;TO2*M/YZDS@.&B
MBI@J5PWTT1"%#WFBR$OW3F7AW_>%Z9ET,QT5]TP:$YG\Y*^)A<S,TWV3!XV%
M;K R6Z9"E.019:I(ZW*.T/PEX:EB@KT)A- BTY!4I@&1M67?N_K&3(T%G":1
M6,S]=$3=UV_2V:KV<8'QBE%;X%TG["FX'M( $_=SZA/X*O9&O0\?9EIW$)*9
M2&%K\ZFHPNQ! @>MD-0XXAK9E6X;W0FT_=)P(.O,H3.N?WY74G&&05UC":0(
MM1O7-#P<_K^3X]\#.9O0)FOV.K!2Q-9XIEQL- 94(5FFGJ#%OYK/&/_(E!77
MV[V0YR!Y$X5]08JX0$O#OTV89FV;]Y<'/F;5\V,I+YO/+A:9#NLQA@--B<6A
MZ@W,TNMTAQW%V:]WFUUU(E.!DB<R_T%C&MZM<0!5!)T&<@X>0)>"B?O1,SU5
M6(>>C5<=ZITD+$P0ANL\C8%VF(MTP)DI5 )L)L2TF2,XI5)$6Y!0Y61J[RIF
MLU5=R>![U=,?GZ?&]IRY.^6\+<_@H,["2S>?B:_W)B"T%)$?7MTI1;QI>D-3
MFR3]1 !-1J'MI:)HH28;FXRFM9DKD]]<\0$+IS<^$N([)]IHV^A&)O4E+?%'
M5MJU/PS;BHEYJ?S3C*V^AF51V"M1)GN/I_+!@\GIS'W0MU2Y"/? AT$;H'EN
M!MN1+B^82PX&FMJU_2Z@U'JGNX>?#0UYF3V]JOHB5__"1]?VXVIS=RV2SHI0
MD(:/R$I29B]+2FQWRL4(T BYY =0.EA;6$U6QA@DB0SP;YDN+0^-<6(4DLIK
MP=M*9C6>OX_B^^D;B6_4>Y)F7+S+]OHU9,HV>#N;I"-Y\BT:A6!)D101CKS-
M:K#NZ..B7O+5R*A8\D<I @L$KONEN55QK*8G0W!:B5_8/MKBV#DG-J- [\?9
ME)W%O#Z6Q; YL$3G\F[PQ&/;7#M'0*V3ZSSAX.7:E8KRS(G,L0D155('VWJ1
MG&2.J$1RYPMVW$8L]W:#('B(%%\2.P%O%49I?%SIUCJI[Y5F.-;[,8DWL%W!
MVPL'U HPM]#\#J2L#@,>YNGP)GJ44$6$DY213(7$]K7H%'_(RX=X(['V2W/#
M\EV\=Z\ENN;U3KG<FI[(ARP&:UQ%-":I8H4B=6,3V"@MRM1]UBY6$%85#_[P
MQ]G'0BDBDX03O(AP&:*?ZSCTZ=#X?.3W/^>=30Y.#>_=XO4FOCB792PS %FT
MQ]A7E,U^%+:[+4KL".T16K=3-I'?%3">RC2MX@N6:*NCJ):UET9]&]&,+!&Q
MFW5$.[8^?,Z[S&OS50WES+U'MY=Z? Y?H(_'<Q<_:_C5EQ#4TNJJ+Z[U1WP2
MZ\HZ @4Y2=UE2L3*^#U8Z;[8#+(8ZIVC4L(CML8J>H&9$17NG;$01J"8-,J)
MUBK;Y9FJO=CMA__D&/G QLL,%<*+84UED%7?V6O*..&#F2JA(!LWZ-0G,75
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MBLL)"X=\G64"C8'U6AK$QPOS ^_T$2W/OS;<B5"<R^O @M;)4WWM_']AM"K
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MVC>49U?D[T'(+776>CC6_C%D-EDGFG"3L?JO/H?Y\SWG,P%6-I1QC ;0((T
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M_?]EB/S&1I(.TBGUTZ=.J6BHJ$O&!D3YG[]D])\$Y?]O_#ZCO\ZD'P, ]VT
MZ!CSB8Z(^:N,^?<7%H =X ;X 6%  I "Y $50 /0 ?2!LX Q8 '8  Z *^ %
M^ #^0 @0 <0"". &D )D '>!?* (0 %/@%J@$6@!.H%NH!<8 D: #\ TL "L
M &O %H 'B ")'I"L#%P,? S"#! &&08E!@T&709#!F.&BPQV#*X,EQG\&$(9
MHAD0#+<8,AAR&8H8RAAJ&9H9GC/T,KQA&&>88\ R;#!\9SA@9&+D9.1G%&>4
M951CU&4\QVC)Z,#HR>C'&,X8SWB;,9OQ 6,Y8P-C!V,OXPCC-.,*XQ;C'A/
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MD#/P-7ABL'KFQ!GO,V5G5@PE#2\;/C9<@1Z'>D/+H;BS4F>OGJTZ^^6<PKG
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M0'>/+K\;&>#W%YF1G8/DW^&@8N=[S3?"-Y3NJE. ;VQ J!_=_]"K ;_9LF1
MJ.3_!-/_$>?_;OQMGW_CRE&^\*B_[#/L>EQ$@)]_E*29;VRP;U24Y"5OGR#O
MB*O*DAHG3VH!D=<T-?[R*@,GG2.S+--H/V0!@#4/ "@Y-!JIC$:CT'UG6@"
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MNYJH4F13&C!:\<]:K* >#Q.EW\XJ%%4L8E?M(/T'&7*9'LN/\3;4]$T,F$.
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M8C)HA+>QFPTE:WH3-(?BD<F-Y',^OD<JXI[TQXD/9,6%^(2?:1.RJ[XK<*4
M?O?;F]"3237-E#SD-4R&'=D%#]W>):!P.U^&QI(/6+,,''U7PC)1G-TRV$0.
MG.P]_(KG)W!TN"])'A^68^#6$;]7E>\36[<14RK9/(F=/MX)=\0B3UG&9HR>
M=!'9Y4[+]W_+'W ER"%%Y*6;;KQ O4.9=>,)M*X%?VU77IV"=8C)H^.*^6(*
MU5(&J%N:[_89Q/I54]BCZGW"74./)"-&6)*'K@FG<+"F#E\Y&9?$Q^-5$NPE
MX]WL$FN1)?\<ISB= CE2AY,1L?F1E$ZJ&B9>!WGPDUA,W[((=0HJ2#T!MQ_
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MT=:1QY&'7_'$'W5U%>QUCP'Z)WV</*3T@WMUF,Q7;07NT]<Z1BE!AD"%-Y,
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M_6P#A[L/]]Z'?G-,Y[U<>*D4'C65SS7@YG'*UM-2^ZVE5NE#W*X@&/;*2X
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MA1*#Z:;VD;T&2?IDO9PA+W40[4<Z R\0M]ZUF***DUVN97AV!D6GNVBKZ-&
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MM][[1]CKAU\^:B.3KROLRW.^+F-9[#5W<&=_3*-+(A49.<>#=F;B<2UJZ+^
MC7EH0JXH:V1Y Y+/Z=W#Q6&.K[8(&,7$TD^:GC/+"S"RFF8;CU1ND"#B:"VA
M[ZVSDQ/L[!)27F +S(<5? V(YZK=Y((92S^)(X;I/P2=0GLL$)-;8+5CIB<X
M T8FE>6PQ$HT?W"1_C,B1V+Z^YY7+:N+R^:Z49K\UL(,FME7^>X%KU%=04-&
MS>O;>).K"1=_\+IT4V/AH-4QIX/44F,S69TUFY03#S(N=G23$>6#W]+=<]MN
M6H53PZA672@[VD#9+#CQ7*ZR&+Y"Z=@J7+QJ^R';V1M^W$(JUYY@>SYIQ%@)
MLG]5?'6(=C-#*]TMTABR[\ VC5)V2IF$3^CTFE\ZGZ2FL3 ^H_C!^D&\1N/G
MAP,G[8I37+]%N[5F&"J@:&JE*DIO2VF^X@5Z.5CQG =3?PZ?JVU(Z8SH$7PY
M0[D[Z])=-26;-.$L^:_N@3#:B=4#*/Q%Q3/PG=#8,4CM$OD0],<<4S\ZB /"
MB?E#%^0\%GCB3851=\=:)0;06A<MRCV154 R"2\\B;[\LS*(1!"Q\4.XD#WT
M:A)[,?KH.\RT/?"&;?D<^@'@S]B<@#-X/H$%4+:[=P#>/%2_Y0C[*MU6O@P
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MS!A;H5M??MFA38:A:!'%W1QZ<X3CS]N#4%U^M<7&&(/1GZ8);$N<TYWU&DY
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M>M2LQ:8SIN[!]"U2&F!""<3GQ>UN'H3872LT4&)?H._DQ0^.+_\<TV&:ZAI
MSC&,)(OZY.W+^V[_O?>7C]0)N_;Q0]!)8#;7+N< N^IT_EM#DI?>NX<3^\:.
M6\;%)\N7)G0OS;H&O.WD/R80=+ZO[I33RA4'1%&8W2@51P54?3L1+[(LV.+'
M;@*^^RZ8"0BY:WU@WV0*TX$192&BUZGW<#+HRP/%PZ8J/0O-[KW2FV;,X%AC
M3QE^ O_^Y<7&AH&-@BQ&7Z?*#DC< +&:#0]EDHB181RJP_X?^=3X_J=8YDTH
MH"K1AIT8X_!NY0$^E#LL1-M_@S?F/WCI A;,N2XN:U:6(N=QR0AIK&\4]&8M
M%;@SORG93T2YM(_ERM2ROEQMY[$#XN6:=PN+5O9N2)NDDWO)7_2?KT !%? _
MU #H,PB)YQ]V$+.?P\>[;X[:Y/#Q[)MC!N=.06'WH./+]!^%<IF?\$?9O'5C
M8>E XGNV%1 2$.[AZ4 ?BT9KGZCAG %R*GH++(B>;H4]*W"U@#$]GVWJ3EDS
MY1=\)+H95H[%;_>OF2<DS/7]/+-OTT]Z;/>;XX6F7KK[N\7+\I+^CZG7-M-_
MC[U&!P,;S*G="*8[^R^@O'S.KT4BZF[798E&3#0!%;.P#[=+6$5>3\&_'U^5
M:--/Z9XGM];_5% M/Y?@>0QIGGS+S-4NSR:\W.EUM)$C8]G^8:3YZ82':?AK
MJ8&#T7Q V3 3"-!5&R/H\CGZM3FI#K^K>W'FCT45TP25NLCC8D#>OB6V-9CJ
M&_QB\E1T"#.5-JL ]#(\O>U1E3I-![!VA"")H&!%_NG^8V_9B06)^9"UNVIW
M(::SQV;HAP3F=_#](._KKY<GV5RA/HX^2*9XTVT%UO9P\<8^]" /KZ' 'T2T
M[F/F9N<>N3.YQ':_*5G/VL/L*U0G^2^/:9YD:,5]KUG&A==/1;3-($VF(@R#
M.Z5W%U,7FI/]^]YIF'43=?1#\V3&BB7*DE8=DNX-+0;##V0!M805NM^"XLM[
MF$[*L@V?@7]?8SHL?J2M%2YB+CCWNC#@YHO?B'-9%JN*8EZ#2S)3'LB>1]#@
MB&#!+Z?^_;=7@%51?=&"[[N;G*6%DX^RP)$_7'X^YMY]%= UC^/][RQGJC<V
M9HX$V7#:AW-Z836'H'B8#S7!ZRPK?7-]>0$J"T2ZM;!:<A;XOQNKA804HZ#F
M+-U>>I;KZ^ZEQ6W^5+FR<\&A09*G3!_O-Q55K&\6DNOJUW^9WNUWW$86S/ZR
MFJW'8F)W,LVP@E0P=OX]C'D3_P^B.CB!;<L4Z82)F^J@>5G!;#&>3]BCL'NP
M%"KY79<9,,# /C55J!WZ<=_8)!#M0B__3=:0:&\Y6]W,G*E/V0S[KLPD4W<I
M&4]L)WVM8;1#T#7N+_&CSN=32=2X<&(T@M?T."J3(YJ;S*U900?I&O]-H1<"
M^!EB'</)+.*"'O7O28OU"3I,RO\!@%EK?V+QE&(B7LL(CFO$[P8EQ[S/Y,A4
MM]0,W9_/Z/1?<F[&%R\41^ENCS6GN  (FU%J\<X2\>#%@!U-1U_(+"18/;15
MQU]=^\J:NH/9V=B4ZQ^N?#YW_X.6T45G>RG+/Z19Q$F1W:> Y[XF6XFEWSF7
MU#B:1S\$Q6).<VDNW!-*F_R5$!R44ETV\;U.WB:6GG/):338>.8*9U)9+T/[
MI-WDXX2KLBDD10)E+]RD*('C=PCB&EC B&=7YB"'(]K!H#[=@^%@?L2XR<K:
M4[@"0/I7FZD)8)+?*O3,([L9X<["IAB+R*H@ U]5A(S[2S\J+IFQ5EVZY"=L
MV56&Z<<S'V+9(MD+$JW<N&!?_6_JMC)=.7'GP/ ;"THKIT;#1"AAL^*C&O?O
MD9JKGG=P!)F>W+LG[RNHGXB4,^^[?BYKT#5Y,3EZ/&M0L5=^;5,N9V,L,KP^
M,OA \SOGV?E*ET\M.LS_CB/Z X Q)%Y4%K<PB2ELZ'N@B^92KZ>?Y=.Q])SA
MJ3GF-JA9/$26U"#S\Q8/;08M9G3O3<[^')EY_S%&Y=4 -HL*0+$=1# *O%O(
M51)_P(+1OW&&M;_[X. =Y7$)YNL ^QX+LK[/F)-$(3M<'DTJOV#K/Z;;![$A
M1<BQO<3+# E2/0)XN6H;C(Q\8G?;4O'MB8V#".&1PFD.OH1(AUH>M&"#<!.U
MN]K_G9O!OG'PLD6#_028V]= V>X^/7B'/KZO@1E D =OU;<3>"R ^%#YYZP[
M;.E90V8#OE,Z*J,YA+NL8#]?NT'UC6V#<#(KU%W07&WF[$(5]X)O.5-4LD0*
M-K _$<%GJH#*WITXR-T&3R!V+0!_UL,%VAS3]L#V!O"\B*T%/&>,;Q^"1%$]
M"[ NP?L < (&81LQQ5^%((MI!<?HB\,%CTU[E%*HD_6#Q5#E P0"KM1U?P\9
MA$$4_ ZOR^30SQ/%#[+9H=XL[5T,H,+BMV9]@XD&4OR9M9]:SCUG7)/F1SG#
MY 0]:$_"IP B1RCF8W/P*<O*SVJKVG[6$0\G;PQ]OGWOY52&:0X#=GH%(SJ@
M"SZ]Y@ _D5G85CMK+4CN^%8J Y=5M9\<-:Q44K*\&92@'R@\_NF<=V('_2%;
M20V2TOZU=;[*]<DXY1Y4S%GTPO@M3>EWY7<O&B3L^$B'^=TLX!TI=_Y0P!>V
MH-)GI5+=J?6NX*19=^CK)&_1Z4*52^87X<Y3_N?(01,R82[_8H5@@?W1W, ;
MZ:LNL*A 93MMY==5#\I8CI"NW\NZN;%T:]4]Y5W55*NP^1>.N^VEG%+9<^*H
M9:;$!HY9VS$K53-*MJL 0NW3"Q-^73<R)58HDIAUO+'V0Z3ENH\Q9FKG IVE
MTO0^WS'WPDH@+&V/0$[_+_;>.ZJIM7L7C=N"@A!1$ 4A*DHO%IJ4Q 8("!'I
M-2(B)0*BE  A4:F"D"T(*"TJ)11#I 24%NDJ(M(E2$DB2)6$NB3MQ'O'N>/N
M_>W?N>..\9U_SN]CC$7&8*WPON]\YWSF\V2MS-D5RP?1U9BFZZ].M6=_A!NT
MO"J;2R6MA6S'OU5+=)PR,)L*^N3N):U^74[\BM^+63[(XX=<NP/O<_OR&;9!
MY,%(=Z0BUC/0_WU_'Z%JW7^V.PI,]'G5+>58P=J11IB/N)%J09C+J' ?Z5+;
MYW)I?:48-3+YYM+TPP3#@N(4PH.7E&PXH!=-IZ*U67#.O@LF+.].2C*B:DE
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MCI+H0%;,9@QUK_,%#]G7NJ?<S4Z-'@-]ZMO9[+<R<0#0;$> #2U* =T.'F0
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MM(;OXH2P7 "<0+OZLGZL.PVN+@G-ZW9L-#=),*=S69UG7[.V]\15*^5\G:V
MTSZL20R+/0Z4\;O=$Z)3H%&882:3R-+"'PJ.NK#>.L '(<'[W)"0'1QO%HRV
MPOOXH12HO3C4<*8,&&G2F]'/;"4&3@;DBA'0=8&QJ_BX![-KSPSU:O1#*'%/
M9S=?PN]<1G+FGGD9K!R+_]3Y+--S^MKWP ^_F.$R5='=JI:J*JH6\FK8N<'<
MQ$[>Y+'8&>B,K.IG0O.? F0Y0#47C]NQMVG[W7Z4RD$[70>AXP\36X;;[;JB
MBA1(Z@YZ]K;4Z8+2GIEY8-1!4G^PXJ"&1DBA#;3,?&2U,1;U S6N0MJM$602
M?F,<>?\CL\&\V.L- AF3(M<D;#?0F*'AZ RA4&0P.NA++%(B;+)26C&!)P_$
M._9"#\[KZ[QEXLPSVW3EK9@*Y,DEZE:+?D/=5VAHS8-I/;11Z6S6-96LE'LU
MPYFB=3]_(I,>],NUKC< ):PN&JEU:72TPQG>!I,&O&U8A/:>$3.>'%!EQ7*;
M'-0&QV;AHQO,]+ [D#59,;494-FZH5=K\!,SPSHE/\Q*3 _;-M4Y\4&YD%,7
M&IX=>H8=DEUD?PY#<S@"B.M>\<Z+Z*ONUX\)O^&UY:S]XV=G+R]L,9,7>;-X
MH.4[XZ!V(53TA571P=*O8>8QKU-LO>Y'/V+$I9POR&=/'=#O_W"FZ)L"A5J4
ME4;HMLFC)#MN JY].:_/Q 0]W72J5F*\P _9W>[[5,KZ7F)N.9GK7-%LS0CT
M,CE!/$=XTOM$T4J;FP?9O#W ,69D+SV$2=Q@$AX8!K(.<TR!TVQ)5"L]H(IM
MP/&J$$A,ZZ\H/$^RH,J,$26R*.T_%I_2<#*RQ/PZ:SP3&^*_:Q!;&4#>_]#6
MM7-Y^W2R7#S;'=MLJA8"3L RJPW580OQK.RKP$,ZK0CPM@@/$6B5W2CHADD?
M^H(_;1M<!"(AR%&J,W5&BT,Q#Y&1=*1RP'.[^F<#&$5BVTQSGZ]=2XQ8I?[K
MLR?VG+@6>@\DD@,ZL3TB/HZGB<*U8$4PQ] J7UZM)AD9T)OR:68-2/H1T5$@
MV_I+ R1*AUP$0%6KPM=E D7'4'_.\N0'/2P-)Q!S60HI7DW[:ZZ/T'&[!II+
M\UHES0DUK1XGKB(<TI6+;<H$9!#O:V@9<O#*B_MI+TQ%X>!=/5]+/Q>4G'\5
M<;))DW;WF4=38_IU)M[ZT\JMGT\HU2\2"Z_6R(NTV>2GMXK&=YT0"V8!G)\G
M.SVK#*T\',#GKO^(3CYPO93FM:J[L(@'O"" DE@0'G! @*I2GO%!<0^8&4&+
M"%_T[E01"QQPE-N1IIS4NHL53;],77TTEQ6!O@!/UC\XE+56H/* @PI&H6_:
MU++5G!+>)_FCW=@&V \EV.:SE(7<WVTMAAXPT]%K@:SHM@K.P49 -LRW8 ZS
M#PJK -)H[/FO)*O&R:6]QOG?9O2'.?)AKQ'G_ ,)*-+ER)T-QAZ17I&R YMR
MR>&W_#5><4;T@\Z$N';4(*V>#$3EA7().F4CUP&+79E6+Y/IA2H0-\=8*:65
MCB<O]A.4R-->.69QM%?@7=>#M @VH\R+<I#';U:N5^*D3FL<*XS/80BG%EK(
M59I=DW7L+R[ND;1JH*D$$Z38HJ\P S!9_/IE()>^"O0PD%BI43ZH^;(617@V
MHIN0&.B_%B7S+DQ.8B@D$K<+P$QI8$9> BK^%J9]-[//]A^O[57@]=0\0/H>
M<4CFLM>S^S$G_;)P;1-BO.:ZC!<OT9?Z*/ZP@T#:^KU^S$$@VXQ)2=)8#)G8
MB=K!I@4^)(>_'*B>KZ?$U6QH,C07MVCUH0)&VT[/G9X;*OB4"I[&?XHJ#&OJ
M&_WXT\#B_KWOWMOO'0OHN!W1'[.BVI"D5;HL6DXW%9N?61!SC-QK?!V /E&U
M(<:38HMF[=H&UR5/S0RT#*^S6DSVM%^)4\#5$N(=(ZH*(;YRSFL>3MH+A<*-
MMUGY4B[;'[Z[J;=[6/R0O91Z2T.H3,(<[>XMX7<-?85^O^SU:]P>;:8H0FQD
MXPA)Q<4#=B<<_;Z:=6"=DUUUEW"+2-8F@T:YQ]/VPU?R06V*S)MX.@Y04HR?
M9.VH9_;82^O[43L>LPU1.DL=R[[2&4EJN\</#?"..?D-UQYM'C8;+$@\-:M=
M<3'P%FN:2.]:1/*$M]!(\5E#+S.^8(8I%0YM8'%46 MUXJNZ5$M$3]RB!D89
ME?'#]'5#36V:R:#FU1;X =?V6^L;?:U^VD<T1^CB?-!I=G9 =W=5Z.);@S!/
MF9H?,A4=03E!.39M*SM"]YE+G]WVZ-CMST)GOQ]Z+7O_O6RIPP[K6&$)CZ3H
M7,GM*FNW@TKL*57M4P>R[I0/^ISYN.?CE+&N^GZ%JXF)T;&6B.2O=6\XH:KB
M3^P=;]T@J*!V*P39@..Z&"XJ](7Z?? MNZZ5V;S8;1R@6)B49<O]D=Y/L*&:
M5ZMZ4")Y:NB[0+J EB3"F#84$:"V<PBCPJ1$0U4Y1P>;9%%(NLZK0)XTX&G-
M_+&H2L.*S=;J9$CMF.Z_\*4C^NY=;WIXL,]1W<V+PU5SRJ%\D+8 U1]$FS%P
M$IC/B/T<&Y88.!&Q4]L>^#"9[#Q!(R7SC@&*#(=FTD/GSR^XM1[01K8Z*HO>
M:@G<GQ0@H _5@ ^Z-3ZK;_>6V?Q%,YA[ROLQH]8%^\[F6'RXQO?W=Q6<<$_#
M KI65F0G=+OQV7ED,HWK'^P6>6XH,+@+LM=Y)J(FMZ3I?KGV0I8.43+VFRZ\
MT,_,*\P+%3PZ%;]06S$R[FRUWG?I,7R?9$B=Z_'=VNC]\F#W1YA"&U$[FQ11
M95O'6QI.YX-G^2"RJ:@EW2M3^3/1U<CO2:Z7RNG"J]EEAB?E3@Q]6N8PU#_=
MUA-<Y4^K,I2];'=Y=B 6O&@X^O"NL%Z.N9/MBMK%.Z6NQ@L^'B?>IH#!B2DB
M:0<O[(LG'5('3Y!BSP_SY-;8NZM'!&2PF;>%UR/*4OV\@AGC@W9]X&8_A7-+
M%?XP'@3'=<8ESV#'#YKY\D%]E]>X"<-,#SYH&PU(HY,>09AV\ ?X?0V!X;(;
MB6A_EFI;W4^2FGA4WF?E +0L7?M!JQ5Y-[W'HE^-4=L?7*\=YF()[:-^,TBH
MA2Q!*;M9#B(VVY_=..!,U*_6"Q.Q(J@&" >U>Y[)MZR'>>URERA/LV5(8 .X
M4J==H6&M#9'9'D?T/()X1Z??/#I5)BG=]\*P[/BZ7= N<XMY[9+BH3:RLO)U
MQ:MF]=\X'P4.<(X/^I"($N%]Q"XJ\D%$6=95BB5R196W2X@/4E">U&0K\T'5
M>%YU6+LY5YO4]8,%R_R.FW559!=)\9IG^*#9-[$2UE>#(<]@S*N4A-_?;$Z&
M;L5\F:B@+,JRELP! RQ+?MV7%8A;2QI1)UL075H08+6040B8BK;<7Y-AXS(G
M'7"?4=-[U?_0M\(.TE27QY1(>%$6K!7W%;$>W2\@>XC1P'7%7JRO(.5T+KBQ
M\GZL7X$?<L%T38AB;\+B(?L-U1FDI''8 ._ /$88*XFV'. $Y3O[9$D+9B>Z
MN!9ES-&EA5_OTPRY]\ESU_8BV//?U=T5VPUP(SWKJER"0%:)H*%,7 KT*/H4
MH$V7P8F9TG%BSL@:<XWR6XNIEG<4J_/F-EHB),<&,"K#U0]FO<*\\S\'7%:1
MIFO^*%L_R*5 ]=$7!*:,Y6SYHLZQ8VMS+@'R+!$Z%H>]:0 &HW4 F4F\&(!S
M'\ (\;KKPI)YRIAA.3"K)WXU9O!6@VPQVK$ALQGI(5? D_&'N5CJ6CTLJLV(
M# ^EC/V:'6[*]IFX^=&9,%4Z[#(;]I("MZS7P5X+MC:V/F(L<45H!4*'_7+>
M>(=83ZKOX<+1OHC^6.Q)GCP?E$Y";^>#?.H;^*"!C8YTKMY5EZ[AU;,2UL8G
MA%,N77^Z/4MIZLJ=;0GE6SI.;?UC2^?!0_2"E_>+^NO\M:N<M5>@MX%Y]A%>
M-[;Z [.5$PS :)"$2D#GIT6/Z#?D_N$3;KY$@[8-G:Z0(M>OWUQ]AP.W6885
MCG5!<V_WEEG<6MA"BNBO5M]WJ:*B7XLH?[D_>/'4$+73ZG5%!9E<];JJZN'A
MZNJJV@?'$L?'J0<8B3NO7TQ1ZK66M#LK7>V@;2BW-SD"*'5TU5:S4K9QS+'4
MEWB!V%.BX6S>Z--N6UK2:>Y74/B^.OGQ//U-/*S3*_RF67+/:?1-R]0N*;5L
MI?:;CM],G)YT0:YJ5_1UG9 L@XO<0WWL37:U:>DK8$D>);CDF9T@13_GQ@5O
M__V,/A"_OMG RJE+>4'"=#M[+\SS0<(?5UI#3\^&WO9M.HUK;VU_C%P>^W![
M^$[U^5:V 5M;7#S/ S4B#F[P*4_KA(*XC12/MP(T'--=#Q]H.,D*8$_&MRV-
MQ#-^Q&)]-&.;]*J9 4F,;BAD+^ -'UAM+D1B]@\%5,]HRRHLC]J<,K3VLX\-
M4%?_E&1X[B6IQP4.R-<NAM"6J 2&Z2)R,A!0D4HT5&?),S"-OK"'FD7<ITV2
M0+YM'T>\T,W !R^*UB2ARAP&U\"[43#+UR='<A5;^:"1#*G^YATOHKR#PK:!
M(:O[C/>[U4V4LX.CJG]5C"UN:FHN7[R=W[G;NNM(UL7DO6:)I0?=;(7^+.64
MWKCF*/AM)02R/F9]N5XAY8S-X<7'DL/R+ZCO'J5T'I0\+B'B+^ Q8^Q3Z!W<
M_&I+U=8)Z::#J+N=6>ZQ):(N)I8FJMD&C:> XA3ORH'J[&Q1DYT!=!')M9=N
M(BY?^TZ&["XZ<!F33^O9 <!;I,5P-*P(<-?X"]J QH4.F_<&^VM:D:O[5[OU
M/QZ/&_K<-ZXT>#3NP(!*\4%%M;8*M0AGU?#K0:?SX6!#XW"/6?.[A>?M_,R3
ME7N</N8J*NXT#V0\N9Y35Q/<=3 I5]C1B5ZQK^5+SIQUJSG9[$J^?D:(HGE2
M&L'*QO?,QY-6\-!6@CD@0W=8D'_.,?O=%IFSC=N@#9'Y=@'+/#V):T-$ZP@2
M71%S,9GWF*Z'QA9;8-#G@HC?W)*21)*5>M1\O>7PMVN/F0BB[-ZN_? FGU<P
MTIMI+CR6,OD<7Z&0S0[A;._E@17;!)DR1G\C&J/,T0/:F7Q09X1I7#!6$BR&
MZJ%EE%.+XC:@TH/?R94#JQ]2D=D695H-%7=224M9DAE4[&<<M9XG2N?BL'X]
M8LTD( ';HLDV _+ID/O08YQ [O-@&?B^3L7V[C#CU/' !$$*" 2L&,RPF'P
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MSB36Z<XL?"SF*"J,)RS"@M'".BTOK/O"1Z0$>J$M<!OG&'.WLVX''W1_,Y2
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M'T3T*Y)';B.7I1B9"P?I!EC9F6&Y/4Q2"D\)I6K%#%P4)<Z<\MG\T7R)+&K
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M2JH&\(L71*5ZX'I-_8Y]K\@WWW-2XJ$>$C02TXHB(<U5[#5Q+0)L^JA,D;F
MY]S(0=Q):I"Q-8-35,A18+4ZRL+#Z;[P^Z<8$]1K5ZY5YAIG3S1I*OO ]NQ.
M*:ONB7)3:G"%. #I2O<X <QM"?IS69 VG!S7#,"(Q*.-9=[WZ#=G1OL'$G:-
M0+%'ER<#]%]4YI1W?TX;[0D]FGH/_!M:@O>(*\=6AP.8<E1X&_WPH+^9$OHG
M*M03KZ/INZ%R*H*1H]N>"A U_;E.TZL$7J/J<A$-5M5DA*H^+_O1[HEU(2Y"
M<VT6D%.]\B$MI=$.D7/"S<XMVV6HF58]F)J1$@$KG<J+M_KE@H7T3Q^!8OXI
M1_!**T4 .N,WFUN.;8<N*;P6@,IEH>NGD"XKA^::Y;Z<^/W>F/0%"VVP(;\?
MO-?$G(UI,1/%B+3D=[)@\1AY,SGN'G;T9"R> &F"YOEB)(6^:NXK9U=5\?1:
M6,1"H7>>MVQ6^7.E;.0+)WW>LD%PI9LS^6BEF  T/,;L23+Q9J;01!@A;5>:
M3%^BR.-R;3S=ECX@OW7=8@U;39!%!;3G_L0FM,'$?"J!, '(?@AG.:AYM,G.
M#%LZ8HY'#/<$%"2=_#32'J:9MPQ)(HGHP9+XNRK9M?C2627%?CV)O:A33' 4
MVIGQ[48083LP^29K@-C((.R>9OLX#&5Y3-<VW+=U[H9>K*JO[-?K&ID]G(\P
MO1$/>0 5T1,*.)B=.Y.*2G#B%">9'4;UP92$+)G1B"S\1)_-HGG!(='5C>&N
M&J>K*_H"_11/LH>PPE\VU*-XCK1!JHL++" DR.3]<N4B81KI1AH$:BZ-J.$6
MEHD-SADA+J3W7\>_UT[8(?)7C0[E/7KE0+PG9+QN97ZK 6;=5.-@S;+$]UW>
MX-4]50)0[_0OK(85Q!/+-3X4"9U=F!2 K#KM7W8O<B/IF*'1'GY*:NGYGPG)
M)E<X"&;//:CWXGV$J'_0& CH(B,4(?PCM@$,<?56>,<C(<J5=K*A#Q9J1L$4
MQ]P#2-F95=I@M@$Q"Q(55!7*&)6E12#:5OWRN^6KPZ^840AI7/D-'5\E<6"4
MH\Q"8Q30]@1?A-3*<6AM&=J<(;%I[+,77XSZ,PI]@DUM=3MH='*&KLB&86^D
MNIX;@KT:,2C&?W;SA7-IY85!JF]\1C&$V:^>%^R6[JASVCN+TO.R[C3X!02H
M=OK'GW/P/PPU!! ;9U')")HHTZIU<1_7 KC$)(%0<@S3S)0F&$?"]F.01'0M
M1H+KJIY4(TQ_@ X?)@.07&HX:LF!4Q=7N!;^JQIY]"N\%/OTKX-'GT5-0>]!
MJQ&MBS3PJ4%] M9-M5??ZF,3C 46]PFS*(YM,BZ=68UJ-3LV9+*O8;2["/O2
MQ\XO#Y7,.IEMSYZ8H#S6%U>;&61<UJV$F#+ PX-^QLS<=$X"$]HN(8UVX]3%
M$/?/0D6;- *8$A( A.R@ (WFVN*]&M;BX(OGV,'8 OAL&+$.PVC>6M3<+S57
M>^&3D7=8T*/F1F_34XR45M)V]$$V;S&F2=Y3OS8'P\0IH(@3Y5_BF?,K2"54
MW15.42W.*WF[Q*?\P:"1":J?S:O*BMUP;-J[;_+>/ QBJ,NIH%2M'E<?.JWI
M68H]V/ XM8Z$"0OI'45D*"592)_W#U1 <.\UV0I ;@TA_*?SL[CR*.'.0\,X
MS.S0.0&(FM,<L QR?(^HE6L;2\")8#Q[8L<DB:) 2(O16H*)/ ./:5N[R/VE
M/\@8L<LK3 X;*.[HVE\3JM<L?VW Q Z-J7I&U1O=-'2I5Y;Y[6+\TJ)C345E
M_97('((2L,+.FV2EM!+VH@_!%'WHFX5I_OD,7XZC5I'G1=M55?(9%>#61PC,
M<3Y7G=+FD%GK<.FS>2A1T_*0^$#9P^>Q\Z'2-0VD.T=*C +.^]FU+[VNSLJT
M/>%50^<9]']',A?G13CAK6'%+3FNZDI;@!-,R#TC :B-$(^0F2=N1?\"4 I0
MSNV#%U&[(M1/]TL\T"\]CM[_[+-75D]"4"G>T<UP-\4W;X?2ZG9\N1+B!@<\
M'\(&M]!/ ';L63B &W=.0C#+T\IFPB)KY!*YX*L%WK595C&!)"DG'WB_(?UG
MVVZCGHY@H\)&U)F"$-L2D_A'-IS'3QB#)$^<XBQF5S4A>DF8UD]4")5I&P:K
M=,35L 4J]FLS!X8MEG+2;S-,0]U@8L1FL>1+=3%C%_I4EN#;&0/*%5C'*UH3
M\W,"D&=*=%;P<_:E\Z\^TC]R0>R%4@8":U#QH1(.]VH@12_WB'3[E:JVZ=J5
MFM8F%%RAN.NWS:HVMW;>@5L]["W,C$"N0[\MZ]1$>A^O3@L<(^'3QXOWON@N
MO7/8N$;NPYHWW8Q65OYRJB7]KH?'@?3TF%.'Y;?L-M\BN?V$='7@M(7RLQFT
M,&XJ6Z8)0*Z> E"?;?RZ&?$6VY&;I #C!>$$(&LMC:GU#\4PW%30>0 ,X+ZD
MO"< *F#N;\5W27/%_#[,>N^8C,;R($F'-/X0LW0M]_<U)'$;U@+0K!7Z,H$*
M?\*%37P_> NW\!MB0R1?Z/"80HVQ_AAY0VB$+Q&A_,_0JLRYB9? QNH^7FX@
M(85__+[BVY77-P94<:[LTP<C=#<,VQ0,R2/A\HN1*I0[/1'%;E,-KA-%^<75
MM0V$]"!W9,07+F_C.'^ Q': ) M ^XD[ 0P%6D%Y0[J+VQ38* #MZ=JP1+63
MO) B:#CG\>!@KEAP;Q.4@1 #SJT*$UXK71FVUT=!>KV]B% \@_0M<L4W=WFW
MHV=Q)"@2%C.VEW^,WX&KQI$EAC=<T\@D>9/;;%R[&9BM]'Q7&6UKVWK-?*Y:
MKR;ZE\HW=*5&CL'3.J)BS5 ;&W/ULT^%3Y%7]/-'F"<2@"IE+F?#UHM4BR4[
MCXE&OB$I0J])/(!N@WKU))+V!@E LNB+G*.WIC(1.X@J_/?"Q ,MX>YD\_)F
MUOJX%_K1SIRH-S1D6[@ )/>@H89ZL]H4>C[Y*YUE_SH^?6Z]D==E/T';J.%?
MQOOG8.Q"8-^6B4+EU9>^<#;M"Y2&6Y7C90E -RO&IXG& .3RH#[FIU-,7V&&
MQ[7FZG*PY!Y9[W61I#E\8,\^P)IK-^Z'-!^$F(!9KCKOA!G#,0:I-=FGGWT\
MPSC;03DHXL X=!,*RL#>;SK,GF2L80-).U#@-^O;TAG('8"[1:VMJ?K)CWJV
MQ\OTFK5:A\V<\/.:/\>K;*FJ[5LR?ON>4I9W%YH$ PX5SW6)S,<)(\GF67!5
M0<.#K)NY:@+0?3=H8M.A,:\L<:T1)C(&?9OY':V-]PE^54D.F50M"Q-?7MO3
MK>,M=_3@@7F_LVZB&TJ1= &HQI$K=8<)V0GP(7M00ZMH*O=J*:#8'BDY%/VU
MN(0+YE"PR%1R&WU_W'Y:N(:7_'B_WYS?J'+]JX:Z^KXND]1/7>N^?YZ]R +3
M<EH(4<A/7".@4X0"E?(:Q&\8\_N6O*"B4&_'\.W(HV:*7+OS@;@' A!8M3K5
M(%IONFUV' G^'F-LVZSF:[W [9K^-0OR@#4SG"Y6N;?\[ V_1[T$\TEY2T6=
MC$M9#.6]#<?/'62(??\F )6:P-*-RA_?3C\\T!G@4EMSLSCAV!6LA(G%]L@5
MAH/4SQR)0]WHHST76VZK6L3VH"%,G[U>UZK$U,)/)GH^O75#0^R[Q],O3^TS
M&8/J(JGO_!N99PE;8]ZZ2>CWO&3B9B3F9C?<N$J\@B9-1L]N0+?-8 <TKKJ_
M?SE;'O)KQOYK(X$/N\SNO3CL' $_KG4@E_YU>U.S90=3'E\CJN$<>STILI#
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M G+^?(PTIO4 8^S[Y O,.!S#B9\JG1B+(U4'E[#3F%#RHAA 84!B_?A*:%L
MQT!&T16!0@\F4A311M?G9&2&ACYKGKSO5S[6%DQ7?#UP\PM[F=98-^*'[!GQ
M[$VS1,Q+SL^ND2!+_/+.M <R$]?+T[_;I\_5>'LUUETGE,+!O_SQY%#&;O8B
M]UL_E*T)!=H#+U] (IJ%U@5J-H<NK=S(_(YQC'0@U[)Q6&9]7;HR:6Q_FXZ:
M_\.DZ2,Z7T*5E6_)"W^*Z<"E7[*69KR52=]47V<YC@3>"^E4UO7;)GGRR]--
MUIM+\&\%H,%VX;M>$^:Q!)@P)R,,>8$8WO:^VM+>E0BFF?UP1%=7%UZ8?V-.
M8(#3)L8"D,F*!%<4QM>VXAY4VB\ Y89A^5N+!:"]Y?'QP2L;8RO4;POM[QHA
M]<(.#IGP#^'OD=@E /68GA* -E$%H,0+ M!V+!8SF?M< +KG+61 C3Q")L:+
M1,LTY^7HPZ+AEG@A;S$AB5^!0L[F%OXV.^?6!B6T^OAKKCL+N@LEV^7"R4P(
M.JRI9V>R/Z3=Z*P1)F;>'VERJ?PT<E%O]*"=KO5 C>@>C2G"&FFV>'(T_MSN
MA,>T"PZ-WMXO7>4P/7UC?]G/:$].R.HB.Z45&>^F#P1![ZZ,[1[F0OJ).Z:A
M>U8:(;M12+O!P U22D/O1^Y.NBA;MCA +HZO#&\/[*VMO\T 'L+GB3743'MB
M7Y"Q+_)\/]0/,NQHRU'*9R@N)IMMQ[:%.<:9F(^7CFK[(R<?H8,809Z#W)^V
ML)UL?<,YFV@RA@[\+96YK'9:SA/;40W+YNK )PEA?#,$VTP TC$M5*SIV<*<
M^U[O3M!-2N\C->^PLIW)&O5>Q+%C42'\T!DP((OC7DOYXU"Y[6%"1S16W=BX
M>R:&'%U7H(=AC-B":K3EJ-4]\PUF.0R(TQ/&NZ(\6*9N+-N^P*YY7QNJB>(+
MB;D>N;&9]:!H0G3-Q0:'9BW<BP9XW4?XML9"5/[)7J[M\\\U"PF$Z0QX1QIJ
MM2Y#,Z1HQH S>L4EV_0DO6]]I*<NX\06P^"/Y^[=356Y^4)S]G\/2;K<N7.]
MCU7F<M(2@KWUYAJL?7*[38W@Q7\JJ/P_EXZCA87LWROLW81KYF=2UWKC4IWQ
MOQ6411-$^+>'E6_EVENY)9>?5A]_,Z%NLK3&:&PU.-0Z+V(R6>,U4"44BL/"
M>H<(0'F#"6&\Q?7I[VON%^#3U,J%.NKD[-()R _K_1\-2D@/1MP1@" SB^\^
M+_ZX%4Y*&AQ$3),H Q_2X:8S5$T0!2Z1%5R_UC#!NV<S7WG3SJ44?#HY))>Y
MME:WZ^'(2(NDKJZN1_*>S<9'4NFD<'Y#9,0G?>GRN=2!VE0'Y[KB#"+AW?L?
M4-EWXW92;?!]DROL[#<"T#:3/25<+PZDO82O.C*]:EM&8;]'1;(8(3'+*=*^
MP6X'HBA9=LF$8A^CF"?EWJE3@W5PBP;7EB!DF+]D!U,TSD1XEI9S)AJE*'\!
MB&*V ]!FI4BCU%M)5<F9&^?0%OWE358,L+BOV6ZV"1_"J8M"F^?3IL+2OSP$
MTMK=Y/HCE8 \VT9%H16##2A7U]HI7FI.7?VLC73+<9X7@#:OW^P<?"Y+S6IH
MGE><W_O!P4?3V-*ZLW2IQ-=/HK?GKX<%+Z[H4#54':'N2DWL+IX-\X@A7!O:
M;>UG?,7'X2&=]F2^R#Z#[KZ%\^1 NL,9W)WC8@4.Z?^HJNY0Q\S/34VDTG7G
M'TK#B[Q_#,6=\JX%Q 3/];NSP21985^M45 C)7P"CO^$]7NWK6UHVQ5#G$J,
M<>?(W6-- 8/"LOL#WP0)ZX;23.A#\N3M2R"YBZ53 M XQM']MN/PS08M(?>N
M]_TG)65A_/<*OO87P#CT;Q+9Z]C-A_*>0?2@\;?1DH O>](!J. 8#+UAHZTY
MED]\F>**+7PP&QFEO]]! #)G\^C-S(@@CSHC2GQ-DH9#+7LUZJIG:-!M9/Y,
M5A*WP2]QMUV@\]!B)((-+6K7.E,P,5#0W#^"S+,VH"=-U3;V:IHV_E@/)B7V
M1PYAQ$W4GW-M^J@(=BZ.D\\((5L"42QDM-DQCC0M#&VLBSH"5OQ$0]MSL ^J
M4Q2]B*)]ZGV3CC!)]=7:G!>4K2, RO>BL^W.);--O(9(:=\Q6;X&5Y$S6,-(
M 0&EC,4V)!:Z:UE;K3FT%(ZJ7&-:M9*PB-V!BHT)*Q_GJA=WEE?A44LP$=1)
MR&XW.%@>,:VE9X@[GSII4ZDY2RU=JIOF&9PJM="7.SY*M,\#4M-NI]7DS9\+
MN>A=E%4SET+ _&&0P7\@9^(=CL1\$/NE\[TBM#ZGCKPH/PNWHH"WHR4X-<1"
MIJ:G>5^3/C,G@$)^H[ 8[3Z$-]$L]\X<D];+<?6HI9KMMS;->%[JUAS;V-RG
MUVW9<SG[/5\T<@R\BZ@V#94R\6,^"21@B9O8/1T(*;0<>WO_ <[*4 HWG  X
M(@:718MJV:Z4NX&S"2,\IZD0.!''Z-GZ&>ARINK]5OZ58U$;IY_4?T%VA=K]
M'8/ _!8./V)CPFZT(\1T6PZ%V'2JYP_XS#>>V?#\\3!2_ 0@'Z'W>K?^C?$A
MIXCKQDZN*.&Z4A=J8#$-#MC;H>4S=&WJ\N@-"0E?0[AE>OXP?48<C TJC:9R
M+VII/L.(PK9R.)+3CZ:'%OTHSOS1L4KQF5(G=#C;LG!RNB$97ZSV&ZVC4*O9
M,X\N*K$;TZJQ-3G]MF$"P40[I $J,YV[-\6QGWOD$0P:6[;<%1XZD5A'8%'Y
MB@A<L%D8]-L2#E:SZZ5FQ,R%R%2'4;"U,&S\]Z[@"GLQMAHL-Z6@'L_5*)LF
M'F3WQ.F5B@>0UU>30K<]+Y@U,BOQV[^04S)=-]BCVCR:/E_0Z^+\^>3\OD=G
MRHJWU7K5$82YO1R'"X9?\-:_D5LR? 6O/T*8G?Z/_%'>/^3IZE_X*H?D$D;$
MKJ]3UB8AA>TU!>Y=]18(+44O9N*O;91;I\]33)X^%6-6^TRLK7,$()=?A7[/
MUO;EF.? \@2?R&<)6>-< K=A1>CSZI3_ ]ZX<.X?[%?OZ+'VNZ?EXC_\91<&
M7@[Z/S#FCVCV^V;&T/PL&TLQZIG7]'QYQ==LN] =S@T7S]*/]*,1!-OBS]-*
MIH ? [$;M=CBI@8DC0-Z]0N$B8_5R/U<;<Y0M'I=PSW(1%.?G]:!Z&<#<Z?F
M[3;@","=$5/'(3-)+3!YKBY@[3L^@I2?4AB=C$4K,R5D?;5]#=<C4J*XFACA
MV6SZ'5UZ36ZS' <#O?3 $J>T*A_YU G#2L.'_$)$6ZDV4AWXCGFSP7V?#M<\
M?+A8T<;EG=&A]N%WL(S>).I:3IJC=W4YL? '#642%5%4IE4\G8/&L'TO PYR
M,.K*?@-GDB+J5,<>5U[U._7>Q2'RT,E9VZ%E@I9!OV8[GA_?920J'KEZ.4.E
MD%W',GC$N=0.WM>D6>1%RTT/8$.8+[F'!\L)$]6IX@&7D"! F2( T1HNCIQ9
M.E7,PU)D@Y7LQY,GYX,-856=J"L)8=-?N4T\J-)<-6-A^:N?A8T)OKH^JRK>
M]TS=2U>_/GKT?U(7%LV1:[Q [D;E?UX7_Q5L3OSSF)R7@/NIAN;44%:SCMZM
MS943,K<>6BF Q,[>D;$\%WK"Q%,FY]]P@B<*0"DQ M ="$\V_6(J'&(Q\%T(
MEN"_A1@NJ92D$4#Z*Y?L*B,]_W]EZ.ZB(WCY-=!A]C JLXVTH\FB#*V2TH;8
MQ84P(7%&5G%H+<_>($A<Y#$J6C3?SG,\U#\E=J4;:LO95?_<G "3^U3N-U^C
MUDB]6>-T%*D$02MILZM0'U@,VFQ#.(H^1#:@Z[QFOWM_KE0N&JGOV[QSR!5E
M,.[];6;5, M]9Z'S==TCF[L_J0H[?N)OWNDQXSTKZ'V]?Y8MT\]RR&;FG(YU
M:;&G7S7F_R=_?>0KCN&ZC;[>AW(G2I)O2U=DUEN>Y[SV.$H\\_;ME^O7;V<-
MELKB.-]$>(&(21LAY@4@*&1FSN=P=6--;V@HQG&Y3A_ZH,GLVX?Y_?S)+,>;
MKC\K9EG>^#E4'91Z9LO374?^9+Q=]<9F/83LF2( /5=(SOE[@;WZ^Q62"NO'
M?F34B;!>J"]FQRRT.J4-,CR(V<PU9W_&[8J4F2')Z(/CW+1ZH0P%]KG&0@#3
M;A IP]EB)N5Z\8P^/N1<G];BEE14Y7XSJ-A8MN_;ZJ13%YP]GV8(>RF3*S%=
MJ<(0D5%+2YM(ZAN@K8Y4ALT3GB^'_+";.\>VDFYVZS*'$B+E@)!+ (*YB WS
MI/1@E7X&*MB*;6X_#P2*6T)CE<38<[33:]A+?8$)3Q:;Y)@GN,;,_:+M&43P
M0-97AUZ"9[+O:WU3HZ56:"E:E07="7RSSG9E!S<6 PE647".'%:M/W 8[NNU
M,K;#-Y,OSU'+^/ 6.P\W(!7.&-G/@$Z'!*?]?$/T=48=IID/#4'TGT\WBF?[
MV/:J5WN$Z^4\]9 +]],;3)+\3^]+$/\)M!LT(7SC>R[>/[Z(;GR!'[PU=,BI
MS%'[7;;$XTTY,Z*2BD>V;WXZ^.>"+*^46)'#K'R \A1J'%)GB2F-<R0"J1%\
M9(XXP;?Z3^SL_UR64$II&]:0!+XNJHIA2!: MN DA]$G. :X\;%8)?U^M#>#
M)#8\33]4_[$,;?=RBBC-GF T<L!)_B::SV?652FQ"S?G]7@&?=\<L#8UQ&9B
MY4 ^E<<ZR\%%!^&D4,4M60[-Q6- :<LQ5.1D>Y9,4^&*^"8)F1&$&^J.JZ7F
MLY,-[>79$::/Q/C7@RO3ZD"2PNM?XI,8P]JW,KJAH93KA$/T:5>-FBX-VH89
MS?K_DH%M+=B#">XEM%%:X7BN;(!\!F._3J^)YYW8Q[CT#\?(3R,T>GT?"TN3
MM0 N$8 ^V@4%/5YS$Q)L>4?_0'XQIC<8^M]]Y/7?KF7A#?O]V7/Y?W_TW)B_
M$S,.CH5*0\=QN)K,NWP9E'.;FSX0QP1'\7^N8^.BN<J$F4AYCAO^):W3]T6!
MF_Q 8'BIYFG@/EWC!%(O0HL^ Y[G6=+'S)\D*CQ].4:1$PK3C91A169(>\H#
M84RI2KE+&B]?Y8L!=FP22R0!ZD>015\>XINBM@G#E[WP@LWVTE%I+;3)*/\O
MN3^5<>$"4'1*GD6>=^[FC_B@_1)M!@W53'J;K:]?")*7+TRZYGP)%(ZU-F>_
M<8:[GXU,1BNSN]IR30"/TFD%9!M,:69]$<L%CZ=)#S9$C\6MS"/)CL'PCG2/
M?*=A5T0$D3YN[J>G;?O"XG81?K2:E )]53<OMX&$<_UXN40)KJOPBHJ$9U&#
M>O5@>TZP+4O'8??A'?F$R%[P'E:OB:C0Y6A%!;B_4-RQ A3UXE?P 9?KJ7[S
MGM1EWD5K[8#;"IV:KL6TT<:Q@4@-QSKXN:[K*Z2)V?QO&XON*RS^#DH0A[BQ
M*L5+1T*])0!KB8X17)3;GDS*/.O0UX0.21_D#;O'Q*/QDW+>S-! Y-QPT I1
M](7XE04^O31T\L6&0_R1N-]7KH7^)@#]^P/AB<3#7#TVM@.&-=,#KK!&C^SW
M;>&;L%<+&<V8<SGF4DXS#HNBUE*[SQH&5^Y=F"MW;ZNMNV5^6^IHA;+$I&$;
M9JEF\2YI7BX$MYX+])&*=WXH/!)4,I@/WU-J4^9A@S_1;B-SN!^KPCC>6&)Y
MVU\GP4Z/%K;_^-$;$*V.J[IBV]1J)?;?:_O8\6L%RB<U/[:5R:ZYBI"(>^X@
M?B[=1^;YSNJ7YB4G;R?F4:UQL9B?N(>9N+W>N?J\)+[J;/#@6 UA[E?2=> "
M:S2,KI&-3()6%<=>S8!L\E'@X=O\Y.+0VJ53^?S=B%@C]T*N47"IAW3FS:',
MBQ3U+T@*\M,B"SS7P](,7V4*!S#(,,Y, 45A9#P/D)O?LW%\:EKM>1E7J]G!
MN=G?3YFL>R**"7F#DU+1>&F(]9><#VR4$E]--SI5I+J(A3Y#C @+,R41K<<'
M\>K,MD_KS"#D!2"/M6821P);]I,M+I[T4XVL)-H&" E4WKJHY7=3$B$)>.R_
M$>[J\ %3T>9?WM<LXE9=!8R,"T!8:"UTKN;%]'I*_ ITNS=M-+KB>I0M4#&N
M 5AT+][EGG^R0[;BQIAW-76R42DRH=RYZ^JMWB/0M._GG.,_H/5[=!,IJF_L
MF6+E>#'P^LJ;15J_2T KRD-!'B%UG5/ <LB,==EOD[F*UG[MN"\R(//JK4]&
M*T>NO?SR+F79,/8)1@)50;XB(>GN!C[TO.VW.?M]6D'1CX\A..)-SH42^,GZ
MTR];Q3T^RU,P3IFRUR\\5L[\\KJLQZCK577IQ!/HGMYVC %"@C2.AV[G:Z)=
M '?FH@)7#4@?)\0253AR,;#$,7*MV_X!OC@DB7JYHCK>5<*ECG,3L4>O>7-;
M58'A)8P/(.G)3BY\(6[HV+]X])G1'&[0C?0<#>&]--N.2FE54J7BN1?8(\RZ
M!RM(42#[=--Y-=FPPNI:A:+LP"@=IUD%^Y9;J0>NS 6).I7C"R3VZ0QQZGY_
MU+]%E6_"I^*JU=L1"8@J$6PDV(I-9AKD,R%[X<!)B"S*\TVD#H!A6MPWX"#)
MBF.;$&[>\)R4N.K%W0;YNW AQ:TFQN%;:AL>-]1FKQ(.0G-)'JZV_)W.&X=0
MN9,,JU8<;<B5O:ND"(@QA5P$5#=^\8&7%Q=?01AT.3U*8XK$!&WIDS[2EE#G
M5)/\]:.YYN/,C*]J,$=U=G@K8>?M[X0$^FY44@N2/"9];/DU(>G.'$4QOJ6_
M"Y6O&%?RF\>3]\=C"L_>L$WM+['5Z1BO*FLTP).?G*Z0$$GJ8@\KMKJ_^(KK
M#M)5@C"X9W40>]+/RAH?Z1Z\]-CS-;I8YEXA-F-_:_11@[ 7UZIV'C][0ZW9
M2/(=YU6N[(GRP\Q;H?X[:^ [=_-+H.-98*DF;W;/92#S;XLPK>!=?'![H=?;
MJA#1Q",#VY,GA8BI*;%=Q43GGJB\X;[:)0")30M U]F>\:Q[Q?SWI.J*VOK7
M6?/E3R/KAM@]&TZ1=%)=W=S\QB^10A4'"T W8<-?8=$X*;--/G(&88X=$KM0
M83# G'A4*-FN+\&27(.AR)]1/BPGP)L A"/N=KZ8?N4$//")W$<*1?[JY-\V
M0\*3A/K#2AEN;&_8E<Z$Q"*V$H\!ZB<'XO'%\4U0=P]6RDX7L/:SAR,S@RE%
M*J72G"[I#JCV5=07JSMO!S:T=%5Z.+OV-NPSSKI6&%NH,,!X>$JDO3K??B2W
M3..6/R3VUDSR ?W8^^E.KP]W'W_1.MGOF:+U7ENZZN@N]XSPFT$RCCKD<W6K
M%_.??#M^S2,F/YO:]?)<C('M[..2WD+(5:.!8TTO]4J,<+VN,L %*'>?W,9N
M.PZF!;JKVH*S4,J0D';Q-E"@M,=5:Q>@/%N-DJN,G$\IE13-W#''NSA-IUK+
M#^D;&UMK'LWSS!)IBM]Q!>/=I,F18@A R9JIWUHBC[.Q"?CK(Y4LLIM*;\U;
MIU>?2[]Z9V8>V9LRKG+LR^[M^BS6+=1<I=/Q&[^)1=I?TLXWL43 ]-XPEVB_
MS4A_MK?Y9(2:T5./*[3[L+-@JN,VMKKH:U^)"$3D4T]&P?CT8+3\AE$?>3 _
M+FEGDNM%PA&I%R_L?1$>]JV%-1.5Q@J'RL!2 .XDVS^Z1!B4LA(5'!(*1FJZ
MYR?(5R]LVV2E(-8T)/760=$7E?[U=4[?WD<%09<FW;5_.]NX(_Z]KI@#>/.]
M-XS9:YS7GUU]4#>UI$1CBH]\2CRGO@=^OO!D],[S.?"!EQ_TIJF)Q2<.%?5;
MZCS-WV[Q+B UT5WZ<^%A8TMM6X<1;Y4:OV'YK)XVR&94N&L?5[<<J/NE#VV.
MEU9P2\&4T$80]"<NE-TQ]"LR E#$S]KFKR&X0TM,N@"D&:S_'8_9,$3A5I.!
M:"2GT:4ID[$6LV)W"I9]ECW_)<30[!".'';Y&,7]Q3')PMI'(:7;FZ;FK\15
M6J.74LTD87U>'RT4+ O2DV2D*SZW'8S>^MO2.1&5%9.A+VY2MX>4.'3#I JN
M;8OT:^>H8]\']J+<<VSE+[" KA@?*ZFN7/<[3\]ZL^Z\9AZFMK!>5;0S7MFK
M6VD[84IMG XS*\R2W1^T, Y$1XLYMUTKM&Z*T++OC"ZO1]KH*Z/Z)_QO91XM
M2BON?E_??VW]4![IALF;O/A#H/_:KE=2Q)!Z?2H7+ N_9#@ZL9*D/7)&W]K;
M[\NX!MJ79CER=UUC*7OUM5#E2M%:O"QT*&/L)\"3O$K:2_!7MNW9.P9XMJ]?
M#U:2K?.MUR1570RW]8-K+.XY>$J_;?UZY17-/$74@OH53P_L8!EFO!A<*3Z1
M7LC@%"?BDP;PS9UU:0R)]M""NSV2-E=3G:';/M-L./Z?^N"?8?YSA<^SG-XU
MHN^S%L36%PQ_NA2G4V:F_M/QOK:C;D?VVICU6=>)F:G+S+WZ5'_)NZ.RU1X_
MI[Y@_R7M## %1+7HO*\R><ZQM+/2[IRTS+V*;6-Y7XU(LF$''=AKWV9T^;:X
MA;[]U1G[55W>*-+3((\O .41=PKU,Y/_%KQLBB()R6FQ70#B7YWZ/[TXBUD9
MBX).E3%(7-,)$K<O2&B7GPHIRL)1&/88LUH"T->H1;@&A\I:X\I:C>/(BCA1
M&EJ'G1D7J='YLE.%-C>TCHGE[S//F^;8/+KGE7N4_5ZNH?;Y[2<*>O>[C[H[
MO<G8Z':7W%A(V A!%3.UTHI\<-LPU\$T",5AO3VZ\"ONY6R#%98/1EW#U)[:
MUZL7)@#%!J6)K9Y-U;!ZX4Q6K7Y[NJ+*TMSD/$<BJO3:[;UGM0+$@I7%GDW
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M.$P)*'5CFV34D7:M"$!2OKFBG) 8$[M\U"G*[;>ISBBR<V^3.6-C?MOP=:?
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MJ=ZJ XP5XWK7POX$REBQU)<7*W=*RCY'"!2N9BO&/R@8VQ+PM)C47/[H$R(
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M6QN@<M]W_^/B3)TV?3\]/=TEX<B(E7A^+E'3[KJ)W6W(H=H&FB@61>G_FZ/
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MGW6[+] O\,@[&T?O2#OL0N+UNS72%2I*9Y[QD V-SG"^R*F";HP*9#*QMK%
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M.W*6I<+.] 2C/W0%ZS2F8 (9<%GTSNAR&.8\VD,U<^E.<RK#NV/LG@_#]@?
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MU6WX6J#H_-._D</P;^3Y-_BS0&P.P,LPD!J*)OBD1<Y*CQAHS&_P@)0]E?8
MMZ;AJM.C?JP(^KJ=C03.EEX5<29U7<OE_/W&S,"C<T?SFUMVW [3AWK9>HA8
M3!5G6%SN#.$X;;4))E1$B.D0'!GJD58S#E)(*?W2&/02>/CU[[,S_L%JFRN.
MO_P_XA)_$^>):TCF-<;B2SI*!'T J2^>C.$Z,")VUF",A )VY^U? TV45GR%
M-STIZ<G$--VTP:-TUH2G=&X_8?92A;MK3LYT\_77#9[GRW4&;>8>(/B7)&85
MZ5(VJ?"+*<>?#%HF=(_EG;K<^37YG,2<\L1.QL?[5[QX;8\MZ?Y=H6M'L8\Y
MYE":1 D/N9)='9I%K[W%*9*#\2G7]==):9Z3,86>M/O\F9%O:7RE4AY3QA!.
M[!ZU+G5_\>[+BQ\.;+$"LIK14=P==K[161KN-LC/#)H/92D-4=/,)X/; RQ&
M>"DTWEDPPH#/4S4AM!RGGG&[50@\@'2YGTL^-X/RK=5NIY<W=0.U46?9554L
M(W"($,X\&W%N?FM/M#11TTVJ[Z.8!=!/<8X'O2H<<U#K?OXJ2>7=>>I^#ZX]
MDD9.'G+FDB%FH-SH^I-]7(U6I_>5*YX/M626=:U>.H><4;[R1EWA18O*'/-5
M6*+6PV:2X?7ER:[Q9%_;[#K[P(#%#]]D3-WB,Z5/2?3Z7GJCR*?\ F-=]J+\
M[L5M#ZQ]UT344JG]FS?>LKD_LUJ'W:4Z(. G+0\L3:[4[R).X__0]MY136WM
MUGA4E":B]!Z5*E6EBDAL= 'IG8A(ER:@$4+BH7<4! 2$B A(E]Z)= $!Z1)J
M@HCTA!(VD/*+Y]X[[CGO'=]W[CO&]\L8^2=C9V6M]<QGSKDRGKT?(0[5FX ;
M5L.$P'#3$<+1.KV<^>K*FVA:_IT!$R[RG'L>_D3/WYLF%KPE7JV"_<7PX/J)
MC6;Y]Q[F0M>KO2,0;*.T2Q^M<:^IC 1,N=2\18=-WW&[X#1:?9/8&/DJ-O^X
M^8GA:^H>A(V5[;WML7U=J>59*2RZ1TH?\MD<D[;!ZU<,A3WK:DRM6K2[2Y+$
M>[X"0K&QQ6^61DF"HJ7-/UF9\].]*JWCGVG/%]HSPE?&='B^LL/E 8)8?+%E
MUY&N;5NQ/5R'!K>,[X#>0B&_-AZD28^-&LU>7*\;EC^[W+5/YQ'J:L1#EW'B
M)UJ(@H(8WF!][UI.-T$1)#U&&T9[?$!\J^-CAQ5109KU0. :OJGM,!JP<WKX
M)<!._5R BM 5/DQQL>U:JRT&09YXEW)?QET=!/0$%,+*5CL6OQXZ150L>$(Z
M*+RC]!U0)KM$!J ;P\-&,RF%S]1PP4_L-"U_9E+.M=R5378C)LIR2[&EGOBO
M_T8W%2PBK. 0H/=4,3:V"9WH-^_6:-C1G\@"B]6!L*B)>ZF9+3;(E#T,Q=U-
MJS#P4G"3*1.M:Q3B&&T;=E)ZS_U22Q[7&H[?6G3.1C%/6I%SQ"?GVY^L>1/X
M- $[+(L\A:O:8I]%+)&CV.6:$#.EO4[J,?CF54$][RQ_SE[KDSLD*JC_$%W:
MLAES\',:6]YC65UZ9G"1^+*A<6R7"HI2%A*9"/##Y[:]5&I9<!.U",7V6_;X
M>%9_+\6QL))$S?-J"I]Y!YS.E1UOY8?[-X^0O-WR$<.3?.IYY<#@I"T>4:3.
M ;L* .SM/E7\*#HM)S\?&9*6(";%!"=H659X9J8[_2$(#!DBH8L#P;>-[-G+
M2#> X8]S\'LH3?([<3RY/*::S#>-W4B"7\$GY*MS0RTS'8O=+\_8&X@2HB?"
M+)@\ Q9>KN#6E/+B+J7;? ;S#!;[/D4+%=@I&4;$8BT54(!Y*[N#)X'.^KD,
M06LC'UFM+V_GO$,YN]\=IE+']MPQX-A_[$%='KD[!K\A3!MBO;SYF&\1/!!E
M585?CMB[(==]& 17P&>%D.X23LXHGUN9$T_]B?%3#D?IIFJ+V0EKSCO"/)N;
M(ICE-P9'U/E)3RJK@>=G"H\T;3V4[?D(2GE%P";^-ZK_ %YACXJK,PWQU2]M
M;'E(XD+I[N7.BO'\7]'-;,]W_K@(ND6:7*1 Q\F>NYR<.TUP!6#3/S93E/RA
MS,(T#6<,RY^WI(+"]1<J/1'@HGKO"/ #9;!+!O?#$KC]NN)PE>N]*\49DQWE
M\75XN$ZB-CFG3.%:LTG1"C>*=9,;^RQTCQW?H5^9)3*N\":W\:UX[*15F!I+
M<!G#IK3R0>WGQKCC!Q3DCZ ESD4H/I1D106%)79FH$BR4^A/ 88LKAB+2)(B
M%<2TT\$/OX)CYI7.-"?<7J4@IP,B)Q9#-L6&MU*D%:B@.N]:T=+<V?70\R #
M[1/B/+V;OM/JKT'5OTLF[YA102_M\Z@@>V[4H:$HM(BOG!2R)W>(;Z:"1IY?
MZ@E815]6/T;SA?>1?6H0)_31.44P^1Y<#YI3<[!$!=&]HX)>PQ#]2.)%=\CA
M&R 5?<?U=U&%,P]T_S&$#*,9U'P<S#"*)%-FOY:1-5Z3EDXW>8\ 07DUO2Z*
MVW"[<^86]H7Z>"P5Q. 2107] E-!R4IH4F!+S!$%(HM<*Z!\23&O_5VKH>G%
M6+NY]VSE=RQD?M".3A&P1,H?5-"!O <MJS_2MD:^$[G+2@7U9D(I-^PKC)J_
M=1*T1(:U1-9[Z9YH1^VH%CZU-'JC4/*1^>J[AT7,9^D5NM8GGR/ ?[:<[:.1
MY6D"F'R""MIVGJ2"$HW^QXP>QIR8*MLF0?[L?_GF.W"G\PK42I?(H[TE\\B/
M&.L8IK/HK,+.YO/N+4AG75+?I%W]/,IX3"RFQ__)W*P.?_#[[UY:Z5,&? \T
M;]'3';\>L_N="IJ@G0'M'E)!P[&&]5005)GLCR0SC*RV@']&?BGU:-D:[>_O
M)[B\I(+:>7&00WHJZ,= .14DE$LY.W2."OH&H8+$/)' 7F 7QU_6TON_6$O1
MC/V4M=JYV3EK3,M8MEFE[<R=$S/]*4)FC7V_1G52C2HO#Z0:)6C>)'HTD=3^
M['W^%?E/@QKH8,.ZQ3(D[HTPY+!]>97N=/Y3S/GU?!T&\XL*_2]+;GY6E#FV
M/OD,^(]NGWW@LU204R((;M4Z6F,8#6:"RRP*&NJ,;OG'LMRQJJO*( J"C3.8
MX^]H!GTL<\A8UFRIKZG+WM)N>KX['?W02K3&I5<]RVF!!6I053VZ2^;"=+>W
M8YBE^/F5/M565U751)^OK:FIC;@;,8>9X]!^$,*A_3Z:2V7<Z*90A\9QTP>9
M[BO]SUQG,?T6_67SL=MJJ'_94O#?\54\(?$.,4!S+S3XS:<T_^O5C^O" ^8!
M+5SU$>M6=X5,FZ'Z=)3^6Z/(V9\;2VVVQVWB7B5XH(M=*&HFE%8H%:11>L)T
MHK&EN:E<;@TJ!5LF7<@6IH+>(2GW,%00817R]YVV*#&ZV9*Q)=?Q9Q?-YY!_
MOCI(<0X:>8"T0)AO(X$[:EI4T$TJB)1>0P4MCB'_#J5R_:8Q:84]+71K984.
M3XGW\X"314W'DCZ.]O(XGTCB2**W?HQ)S?)6X-KG"X_CYKZ.&*";?$K0]VT.
M-[QX2<1*;*Y3\KG[])L7#6KW!6(/4-BEI<F]W;H,Y#\"EK[*;@GXLVVUM_B_
M)*_6OZQP+T:"U;FI'_^?O7=/[H<'3/EGG:&K_%I;^#%Z<JB.__1DA"7%4<)\
M)@S\^JV_BIJY\K\,0>1%+LY-KBA3XHK&4M%!)/X[_N/[0>*CE=OK:,C_9D_O
MV?^?H_\_L'(I4<3W-9MVU"-? 8=9T]X+=&$W.[V?'+M@(7U3Y/2)%S?^.Y@6
M__##1='"+K")NV["3(_B[?2Z!=@B[M)5TH->SYQ:8+3]PVH_8R*^ +JB:IY3
MO/)4-1^M.-L:FC_GSI7:&%'G6S#5^Q':]L%J2.&9ZML)\[/]P<\Y7YNTU+PU
MMC,H/*[PXLS=UM&5Z?[^\K45;]5_*P1SAO^:_(G_ K/Q-8[[0O_&CDF\N_'_
M"N'C5>4P"[M&M-6#RKF0'OVH.I076DU)B:!]>21T^TM<0_>9JXR<\^/]6WN+
ME/HV*NA]:III,PKKO0.NLIO'4K3B_]^S[5^5(_D?AW^O?[I44D/!6.V,<);P
M*T'LRZ)Z'3.=*PV:%DQ8RURI8S5_7&X+=@Q0[*JIV<CKZLI]W!C"_,8Y8VK_
MZN/Z&&6W\YZK_;5F)@U6OBGGC_WW//^9OU4G#KL!W<?EGG)T;#S.2FF79Z*<
M!-[D76Z*^G$B*;&FI<@_Z=KIF"3A:L.EOH^KW=>4BM=?7A(%.^9N/%::,._F
M8?M+2DO^_X@GLLQG(+2]<6.N6 %OF1:=4WV_.RB@7\OMM-?ED8@#.QX7'I4O
M(GZ6Z'_!V/<M]"(6/4.S&AIYIA]J[:/^34.A<>7?H57+?"UI/\VD#I$G71<C
M=!X&)"F;#+_ZEN)T(UV'ON+=O\$ _P#VO%R8(;1NO'KJ9\44AW+MR)=YUUK/
MC\G"\@[.TC['5$ 9N^X5M",_^#)R4H/BSV)B8=TRZ;7V'TBT@T$ZY0+\5QQ>
M!Z7/&F)D-,V6GIJ$7A8^'QIR3/"S(OV_QJP7/=%/\RNT&-U6%/Q3RFG!1NK]
M<[Z:J'UO'A+_FCBX39H7#SQH-=_(]D[+HMC3@HV8;6JU78XY^1<KAOXGH-[F
M[]=+%X_!;&)P-E9JQ1_?U<>XR>0M[ULP\E?=$:?_\5K*![8P_N\EW5\%R>N$
M(;ZLB2N]K$TT=<JK=#WUY,Y& C&&PON(E^UEDZ-Q9P5HERY;BO]?Q@CB *_*
M4D%K;Y&'BNZEHI.]E&A*[F\#!?GRO\%+<S2;6E*CEH#[D$C2U?<7)42S9J/,
MS$"ISN=!C"),#XD>S6C6/QLW+T'^ :I9-_92RE_*ELO(Q(]&E6IT?;V<F7Z&
M(6%&>]7Y982M2-";31Z!F)I_RR58OG_QWQ/H "S:#V<3T 5VLU8']^^(# @?
M$+>J%:N_J)NFO%EZ<^;86G)74/B3#"0IN&,/<LA85E:9O39Z2$J(T4N5D=J:
M''Y:<4"+"%W(GX5S8'(**\9DEYQ+D60B*Y5_10$BK*0W!2^HH/6/B!'TX3 5
MQ"FUB\G;VH8F7:7Q=:,#>JU+CGSQ@@:'L:IA.N3QK!PQ9 +IA$S /%LO+.O!
M#F$N(B,S1DEBXT(R0K15A>5/"3=%&E8ASUI#?]4&9M>YG/P9_6$U,._#1*!!
MX4=K]R<?;6ZND?#(-I4 *" !B:&"/,CL&E#:#.I^/SW3I@-9K=6Y%8WB:-8X
MLH1-=\U)X <+\7<ZT55;(<U@%SS4, VGWH1K*@<#C4?$%_A^&!6D27")7$XP
M9' UFB^+#7)\#ZNR&+U(IHE%" IPQ$'BT+\;72=&JI]SG5,ET'>6WL&>:IT[
M.X+@A26;X5&=S%GF?7KZ-W6P@BYWDF1LCIX,SDT$30N*M=]M('#4=G0,-V:9
M^%!4X#+X?>)#(), 72!'KH\>:2#;G-2TL*R1:.;6R\ T$4.(3&@]3_+'"\-I
ML0Q'XKMWNA#L!)F4N;S<[Q@[H(G"3F9IEN?N:&(.#NSIU"E24PW>57YZOU>M
M:?Y']59Y[I3[QM+WCU/%;D&_YONW9J<\ _:1[X(%52?;P9^X$RF76 'Q@O5E
M@CSQXYAB,3A:"7U, <I%LIAH=O2\41>5&ZL_O*G(6[/%::/@O"GC[,UB8[6*
M61U@FB.WZM4V1ME5?X1(0A9RP'AK[S#468@3ZUD 2F&L(6RU"RD"6P3S25SV
M'[FP0^92B_8)Z"FX,+X 2X,HS2]RM8K9S<"2]48*[*":W^2JP6> ,\RN<8=U
M"6H..67)H@.#67Y,UZ>@^+5]>&^55_]V:P;4>VV,\JKRJJ:FEM&,2SZB&HG:
M.8BA:,(O'=U&? /7(-)ID-PF9VV@/>3B4&=V^[< D>7.Q&EZ'+@3'3;/GC_<
M*D;2!I:PL&KH*0 QV8V0^T,N0$9/#_^T6*BP'!;9D3ROV3A1$"!MO7[O<2D&
M4DGBIH).5N,3UZ=I(W\G_X%T0V&VVJ#\K:*P:6(R7K,T;]6""J)O!:_8"X]Y
MD0SQAT8?UNQ%":>RQ!JPT_J2K.PE/NY$;^?2DYV3%D(:S6<O'H<2+ QSIY?'
M_05K=ZB@/R@NKX%8BGD++8G>;],^,!GBG=Q=A';5K9L</25)T] 6A6SK1; "
M!_C0=BB'&B?6!@R(]\10A(9RX;;XEKJP9E,,.A)N4KA:]^R5V]/ VCIF-_EI
M(*%71H[EE[S^R1_.'%<N)1_I?,@Z:$'>/?\^1O*%U!?$-?@9P.WH+EQU0IV+
M9(7_*B2)?UI-3&.?NC% S IR^N@VR?@LWX-/J?S#K.7JH5)%OEUWFA)?:EJP
M1P!=C*GVL(Z(<> >9TH@AZ^".Y:@4#B98_^VT#S7^ERA;NFU M[10@.W;I_7
M-L9QR?K7%9XN-:0Z)/_DD9Z\U.-X]>NH3-?][J6#!&AT:6C/ ]\W[J^*([L<
MKL">CY9'=MXO9AC+M8[#&K]=Y+VMJR._0T]T!98)6@M;W607H@BY"&[FBTMD
M5^">$R:_H2BL$@/M,\6[R\.)S^D[K-<; VI1!88$O<_W-5.MB?W^K03.)-F&
MJ_H^._9SB.QRR89!'_GLENN+)R"Z!\K$S^3470@F% O#_[#.&PIM%8/=L:@F
M]+2A8E1US^' $?-L"DK*UF?0^;/==&O.^Q*I@;,Q7RI6K6TGSZ*WPJ[V="(Z
MT35B303T30*D0RY.5;\N!$E3ZC^4OP'*BY%_:%Y(T-?E:7>SA^#;5>X$+: $
MK2YZ6,OL-;94:^)LSB\]C-!I]98IMQ'OT;K0,U$,98T**/K!<[B3I5OSL4VU
MYLE;,_>DUP7QG]L:L$6FKPOB/FNE]P7@WQ3J[97)]#^AJ&$;6\5]!D_0ISDW
M0,?PV1+X;JO(O+!VI_KU>RL+>(& I"7 U20G'%LFUEGO4/58C.OU9?BU+C-S
MOK>7G[N<?<2C"@TPNGE^FT$X6^O&&=8?,/5=BS%4W$FC,?\698N:U'ZST?6
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MT*?YC;8%*,,50G;*$1\"8Z&*CEQ7N(Z,1K.5*+!&H&IL*68+#2UCN01_"^5
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MG?CS2_:J#-?[!MRK0PE#Z'M'>Y"O9-="2N\S*DA]A J:9Z5QZ#!1#WU 3*,
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M-NN"+9XJ_R+:@1^AS?9?&OU?DN(Z+2EN_Q<\ 0OBC\J)4D^TTU;4TPS[ND+
M9H$*VG#$+^+ G86[@C0UL6K]!C_)&JD6A/4T[$Q:4;UGH9JRF?Q^'H;2:9S(
M&)G8U!.4MG=/:OMA]668O/BW5<Z=2=U.!$Y04.+TWQ*TW-V-#/8->ZOO88>X
M!<T.'A_85!G')==F&:]6>]KYDTS&21:$I\N+DUWE\4BZ,KA3 ?P:,'1DC6B#
M,LJ0'/-A&IOTL0A^ 'FW:1BA..<Z82^%7R+5SIVM3;,.[9BD*%>-R@C7MM:,
MS>M,;)1)B[1$=D)<:0J'L;\$I&!E3+ IB=%[: $X%[D*\O@&-_9I;O!"Z;4:
M?M;0I^"JO+SQVA1LEIX9_@>%9UQ-JQ#C+B3^#<$-*\9QHJ)VXPV[GJR8MPJC
M.LTG=MJ@W[[5- ]N50UD+SN&&%S6N7!,)(%17(0]N9>VT9;"ZR,[?[2KJ(!.
MPXNNLWYY]>V520 RVF;\.;3OT'NY-F-'CVF)/\BZXB>J>M^K5,ZUZ%?6B,$3
M"^L5SG+%#VB>9N\C#<JW[(MXZ$8T@1U[JH[@-7D3[[U..%*!;1&?C.ZA(X@5
M'@08NHN+;V,K8=3HFZ+W*4&MSNQ+2;CN43W"L_" O EI?^9<OY,1B1\&)_:C
MOT-) >2<[KS%Q$C&4F!UFAB.G';IX+/HV&*2ZU@3QC9 'A6CP8#J]I'1D3:^
M.9NG!7]WGCZYVR)P.;%&1H/D\1YH'OIP"\<",:D:\=\C>Q[);$$OPG^\G.:-
M$B_D?_7B$$1_0]5!O2<@CMGJQ8V;[*#@J*,/#T"F(26G>,YJRZXU(\M1>\LC
MY# ,LJ5X2YS?/>FG9Z&&%,;(C./!-+QU\,R$.31$78+\@0KRFC\Q![\I%;0X
MQ-Z!E^I4OT%&*4II 3HYE21K()Y@O(:;05=-=NG9Q((9>[*$VR;P<*9: N=R
M9%YH^_T>'.HL),8S+V/D>2D9W04]A_;P/KDR7T-W!9C&L4;7E(=108)HAZUC
MI&MC2.P)_(_:P)YP-1ONS[&&"8?AV5GY-")D9;>!O8>> W#0<_,S6H4:"_OU
MC<GM=4*<R3I6#\B((\YO/8<*,Z=97P&+@J._?& SQTZ<-PG/6[C&M8/DQJL<
M]?CYWT0X]OL-&@0.!\RI7C]8WPU<&ZV=>]3#>EUA;<(C1;2DH?S+2EV0]U:[
M&Q4T],7/^Y(B_;?E^02D+$12$EEI1_NP.O2[Y@+BA#/]-Y_K1O]B*+7,6V@\
M@:81R_\EQ[G_V_C%++] 1)3-(\O!>]VL9(Z:<]5-YQ.K](:.?M/5>'%_4+0H
MBX#L8E^8DUD4W=UW<2\T_5X&.O)T2167F@^5O[UC/U2@-3'_,V[UO^:&WN^@
M@@@<P7_]\8( FN"H&VXB[.U=0^HA,?:JM8 C?KIG_IS7[JR)51U>+DR1"N+L
MS_V5JJR:6E$4SWZO88S]WLBZS,7LG]L4BC;;R,0<0]:/[$=&U6S]OY!_%==+
M+%E3/$JCCL+O7B-XS>CIZ[<&86()OQ5.7RG#0K\4+/74:^*IAXV=*U(%P81?
MWNC!>^[9:?9CR^/@@@0]X@SY;:OD#+#6]?1P,K+9B+;I++F.#CA(- )$D)QR
MB__8A<?,0>G7K'O:-F1EK%GX=4,,&0"N=IB7XG5P=6(>W,(#/VI'?JVFD4?Y
M CU3LW4&,<PU?YHDSMHI(]61?8(0&:&NHH=]TPQ=.&A5@8EWS2F,^3=!S]F1
MC EBX=RQ)0H#AG8$F:WX&L.S>L$E -1,-3G>'NU.$XZA0X7FMZA9]#L>K/H6
M:.,HI_*SU[4_ [FE[AOWZI+(]I,G']@89U2ZG_CVYF;>;4C-#JQY5#/9ZP$(
M]#.];W 46^S#->0\U\K2RKB?I*-IG.SGV6V1W*0N -B5D(02]5K0Y!AU#M+5
MAHGWPR1E1YR'5 ND"T6G$.6O,D)9O%=).%/GAB^'>M[IKCW98>?&U_V&(A+"
M'"TV+O?^&!L652F;B;L.CD;7V4U&^6>2I=>@-0&MA?G\;[PM#-%5D*J>S[%2
ML5FGB-L37]T;[ZJ69N<^R @O8:2K>YKFNL;9Z7>+>Z9[ K]XV?;LJ7'ZP?;X
MZ4^Y/(*@P:L<((8/7,\<P;]V?$!'E8Z)GLV!;Q^P647-?-6A 8F"0O0?/AXW
MF<B<?K4CRB,A5:]B)9*5;":[.8LQU/=DX83\[9#S=P$V^HW$R?\\\TBL!Z<D
MXHY=_!]GI ,J2.OUHW/[X'KAHUS2X>[[M<:C;_ _]7=8=)\$5SYZA?Q57922
M^]SSR4Z5")OJ>MPCJ7,O8QB^&*N<#QVR+OY+4B:Y]YM5KH;:#_T'^F-0?TU$
M\-^0//L,&LB:?(1*2\M02UR$"]$U 4:+L8;1C0D%>3"N+8W4R4Z+1D@4W YK
M=TM&/%4"%\'R['-&:C*N2:2IR2-(+WPD@(%O&^-6XJTVJ_YSDU?=G H*L5_-
M\.Q9ESE2@R'&RW!C)/8%&P@3+%9W[+&BI[+)MYI8_LS"A)2/UFM*$Y.QOBPI
M756;4N==9PTS.@40(>14_)-/!@799E"5\R$,$K?HV&@&DGSS_)\;UC^9^*I^
MD>XXNXH*78BV]+L]#CO: N1]6K3'-AAOE6D]_8 5W8+F6DL%%_R\]3>#D_@W
MJOC]+87_<AQ5+E00^#YRTI3B/__7JS@?3F"69"\\B[AK]HI1%/S.(?O=:?]-
MU;W<=-JW3R*B:2:>-&SNO5<9U(PZY#<U\[*QR15^15?"W,H03XA?U[Q< ,G2
M^LL4_F0(Q74:$"BNH510&?)"\B$3*:LN$YN=2 6=U"/D#8:6 ]D=9H2M]>02
M@+N+[P>FH),E<&04%P;AK.Y?8V5QY;87R[3 #X7M"5YOK]WVX'.)5%/*,/^#
M3D\I3RACU-:V%[)F..7U&XOVF@Q3XN?)',:9'B-*;URDNBW83HH\PQ2=,C3^
M?$H\Z8EETIKA<]FF4L_ALN*&%%VO M%JG[?.F:'>>JY9H_%C)9BFJD!Y? %1
M'X 0N-NA8#5![L]; O#KA,A(!"]ET%X9#^XTC%.",C4'8V68<>CX %8.P'CG
MLP6:7S8 PMF,YE"7.5]%4([>R_+K2'N:D? R(_N#MZ*KIYK&F63Q7P7KH<%'
M1JL()II4;B@_QZ;7A /A!-V.C@G,L]" 1 8@!,+JAF(G.3A@8S-WF\>61V5)
MUY]C^8.9%MO]K%>^N?NY>COXEK@'#N;<&,R!?!<;67^IW_PCA$%$M_/!,J_D
M$U;"J2\J='$O7/\[TWXI+3S:]@&)I J+)(F5-O[NGXPV!$1&WQ56XWXF_:P6
M#F -FIK6S'QJ%&- !;E[859._G-FS_]'9D?>H;S?(G]!6R45FX<I31[G3X$]
M,FX_JV[>>]Q)YH6I"^C1XKNB^;_FGIM8S;CW?.^IENS:7X?KMZ G:4?L>PJ)
M=$ D41H@Y "#=@%Y:#QW3');(#1RKUQ@13EPOY,?>7J-V_[<L',57F8O92CZ
M7>/XQ>B>\+U?>W(LJW57;&1S\NUZ61H+YO\F6!)<=3&TI&+X=;M>^.WBA6/=
MR+"D@GJ%@S3-5MJJ1$PCJPM4@RYU=<W)K(BD8MP;DBU&EG%:&]!%=!CT'!7D
MLC4UC[W1&HG=,.D!\U%X"D+]M^+GKN UZPI_0:J&0A7T6%E7YME(06[%_;F9
ML_PXLX@\#ZXT_+[&B.@HS;D"C0R*H<]/A6-;#!SV>N*\T!YZAK'0*J5TO%X7
M@G&\]9A[M@#!%B$^ ==?0'(""8?+^L,D>BP1WYI'X.Z,QNFK$[P#!K3G;&%>
M6]I05OUGQ7H7/897?4^X0FZJ#P0/;;J ]H[9W?J!RGQ("Y;G4NWB4INT5?[@
M1J9O7>:U+\=L)=3K&4X(%2S/]HJ7WTE'7JTK:MEM^M5J?I!>Q)IA\C/I-3EE
MYN+"2/[H4F#?JNV [K[G=3O1O( Y#GI)VV/U[R[H?.Z]WQ5%]R-<)(7G9/3/
MK'_P.?&4__ =%04@+]PABGQL:)=S;%*Y8'I&RX]?YW34.U1ZRHNCQ+$4$")@
MQ-S/K45PEVQ5HG1 B2+]+FB\207UQL!8*7V1&U)44"F88(S6+]X1IS">H(+$
M+BU CB3!U>64:F27+EFI,(B4>R L #[*YZ<T&__G@_N%/P#/*$P6A.)N=%7!
M.N^1*=P3\,613WRV5P,"\(F=JOMA)"C.[JJ=B^ZWFAHE8NJS2-T8#,%[CVW?
MWB#:,\!3]NWA3".2^,Y.P:Z1<AS9I@+Q0$= ."'NT*E%C6K:%,EP%W(AW 8W
MG3GU@YP*-SE2E/M# 0EV]P/ MF-;)/E"(%J!(U)32,AU>9(3-\:DHQZ6ZCNC
M4D^;X3<TB8-_\5D,TGGK>S$Q"5A>0#']?L"S=P<T0G4HJIJ5%0@9WB+=D'V?
M9&/540C$]*G=&(J$WR#6$KA:F*J==N,E=WES>%,@69 I>IJ5:I)%+N0@CZ%=
MAC#TQ"AR@MJ= G<46,T;O]@Y?P9Q#,XZXC\4G4$%1<H@763N+&K][B/"9Y\+
MQQ&G%Z#QN[/67=PXH3AK5\5^9D\^!\7:7(44N8!MDGV6A?>-VBU=8J#;^$H9
MQAU%@F0G'FZF\KC$:(O%7,O)4(ZP=-)(NO3PU5,=CE?UCV ?;ILM.DFL:C^X
MI;@-Z1GZKDS4(.>IB9<#-KBZ=3(^$9IFA4^+:K[@@$NG\,/XEKOFV"H),J\G
MGJ51SDXJLK+.S;BJME3I"&Z$[[UC\0[V<//AS.#DW%OBO$OAVL@YD"JET0,/
M^I$>*@Q]3)T3$%K#1;9Y)$ZM?1:2 :RPWM'@DW"+ I(:$(^#1J+/K2N0(3AD
M."FHQ(V/893F,0F<_OT>\VRVLV[G5EF*GV/*LIXY!JEM]QYJX2.QRB\0="0Y
M/'?;4#CFM! /$(0?:L=HA<+!.;=$JLHR<UQ37UE-W=Q79A7MFNW0.INZN?U3
M1]9KT]XF,UK(S2XQ=UBWOY)U[? H\2>D4XNBVHSG68<LI$W&C^U106%KW1ZC
M*@*!H&!]I $GJ0?VM_I*]._ZRMMS]NCWK&N;3!+OW_S9< GA@9B&5M$8ED%-
M"XN:%B<Z5=PZTH%S?LJ6T>NXHNM90KD!%V-G'F*#BQ$8X@TQY=FS8FB\W8]H
M:8Q7?87&,<TD=NX5_2O?5%-$7@0NUA_&G5MK6Y4:&K@ZH^X96AA:MFRP'6ZK
M+A:[U/F 8/JH(++;H8 HA5T55;GA*#I@\,')P"^NM2!4I4E^(8X*8D8Y5>._
MYS'!XKA<7O_DF'U<#.F59S)N_WEPRC<B[AWAFKUG2*$%<VP![V@IPZ!*G(PU
M3Z-*X&ZS.-&7G$/YW6R:24V.X(UM?3?ZR_Y"C5/SJ)SPD5(--O&LM?RM,L"D
MT]R XA2!?N=^23$AS^-BG':L@IB>&S:=_./L<WKA,8MM^2,HZ1JY&N($!2Z5
M)G:APTT\T(Q(9U0,S;8@.&P3V8%G)BVC% 9;=R'%!OQD!-R0-FF(5FU#LD;%
M>$#6K1K+O>)XJ'X=-R70WFTT/5LY\7"^MBV<0?)SR"UCAO-)3Q@6DY-[3KS;
M+:</KP_ESNQ7Z-\18+$5<GR%<UL@F#EQ,_%0O#UY'#^-Y;]>,>H\8AR/5]ZX
MP#,HF>4>K0X=IZ5:VD7\/O-G 9MV-;,4 I@!*'R)4\D4Z<?7?W'<L6=-@7PT
MZ_:)/+?HL[8**UD4?IYU^I34.1T'CXG2VS7W#*S2&DP*KOUZ'W.XB#__/D;B
M&,/,Y<!G^\3R[L3XQT@'R/1^&Z0Z_@7?L_6=(_>!#W N<LXYTSNY@-9B1$85
MLCT7R$*8U=JPLD^W4$'ABD'=9ZV[8DMO4ZS*O3S_(+\I1]&4'/I"B(/\4?TX
M7 \07*2[.ZH6@)TN9I;1Z[.258/@I)QMJ*#3L-0>E4<M> K:LV U=3W<:J#J
MMJ5(F<<O%>^K'4M3L05O_/K%!R1,^ZHR?&Q'8*=-WU&J#, >Y](>7KASM1TY
M9L"6\2SN0S9/S)-"@UTJ*%Y7-X^+9AQ^(/J'CVHN+AF86RPE!WT(VK[L;TYW
MV>&E10Y]_AEMM6=TH=]QK?;D"H@3B@[Q'7J,!,4[=B<9YAL6RM0V+"!YW-;J
M['X_$/V6<PL>F=!\_4FXK$R _@DS1J4'J6)-%4G[AJ\ZN9-/X5& 6,$&/0X=
M"SD98!@.X:[R.-*@]+=>S%R([)Y5_6GN,3V@UU'1+,1!:#]XH>-; -OJJ/VT
M^A23<,\Z(L>[6,]KB.T4)/>T\G'YN/W]C6^A>[R\>V5J/2=BO\@_-CCU8:3+
M"0C+L4_^66 ME5K&SWW;QK0#][$O52R,PE?MWFZCO?K9L>A;8?C7RP'BFBV\
MHYWW"P4EC8L-='44B*_%N7F[K>UTK^K;@6D\C#>8QV1VSW.J*2\BIT:)<1&"
MS,0V<NJ>#?0XW&E$J?HRL*8)XVQF)=2U4Q[[,&^=AFL/I\KH;,KD,GJ6RI ,
M64JXN1C%5_01-(O6=E>=CG0;CXJ&,](,]"ERVJ[5'A@C3/0>]9*!!RP$2Q^P
M'-VB#([,9%)! B2YL1%%[]HU:X7CRYV4DZG:RQG3%B$PSPOUS:GM*A02&:6N
M!K].SF\] V->3&LO?7C#^S,5=+::W]-;NYY'K^F:0$MKP7OWB2DYAS)7OKR6
MS?A2MVW*]I!Q94/=PWM!"9:-ILL,CCX$HUQK TXWN8.(SKP!R:=3QD7)Q9&3
M"\L%+;SR\X.?OL/U):V(=KH*GV"K":G*C/K6O,Z>_1M26 ?^.@$Q,>6NI8$/
M+;'%$8D*>+-'#T@FY-161K@KP3 2[D)@;R-X9%_ ]]UA"5^=F[,DOY^8<ZZ/
MZ#&-&71U')=^G_[CE4PYEW9/^L679M_!@2%]$QB&4L^%&&9786V'NAB5Q1B)
MQ?M1K]Y_9/KX3O)C^PO0"4[WF ,X.O+JZ>(K U7P*M&^;=*H>JG6N:R?*M)G
M^%D2!HJQA4?2-Q[W<&J^E7*4-"J F61?#! ]><FJ[#DTDC_;Y5HJO4R__.G)
M*SU.4XJ2U5??GI+CC>ITN-JG^+-H(N^/CO%"24OK '?1:]UQ#_(DNJK72[KB
M+M&Q?[Z@!3JIL@!2/1U\HW#7R+YW*<I4P*5B:"5Q)\'-HZ=5G/(-3(=@MH<]
M,P1J"![8H0Z;>:[9X-@.I>QKA(10;&S6TQ\Z' 89MGQ=>Q_2W#BJ.@1V[I:>
MEE/0$8G9OHBRB[F;SJ4]92=P2DOS3%S),7-SXSM2QQG.[Y>Z1);K9O'M29@7
M:+%OJ)=;^Q=II@3H?!SW=]>5Y.2\ILB[K;.MO]TW$+.Z(596^C79@O:R*2XM
M;_R>E)LD\MKAA?!) \TG!1\/!4XOGOKPOI+WP.B(=GIL$Z/042;M)?#H^#33
M%D +%RQR(RTJ@/4$@+RSW>R0I^/O15R=*!<L8O&:L\AZO#?I42@<X1RS.K(M
M@=4F^J, 4?!G"..*DA+T-$(4,0IFE).1+BU-NP\$$Q:[ ZW4]1MO;TI[><GY
M?P_[VOKXE8WU+2^!5QQ&/5$]$_,"5) '>&J2Z*;.9Y@PSPWGQO=Y\\S=2(SP
M)!D6UM0,EBIH7O!54,*WJ0V[$2-@YD?F61='2JPM:2(N]NI$T$8X.;70T:5P
MI>YIW>'37 _O8(=@)S4+\V>USWQ%B)/F:9>K.GP]?4]'2[-W;@A4-#9>,:<C
M"P_6%["F+A&RI>1S4Q3MK_FO&A6>%KMPV\TBG&_\DB2L2_-IW+MEJ_OHB_<-
M4\@LZI=Q$@X^!P'26YQ[MJ=MW1S,+'4YL$8['\UC8P,>9+1(/+SQP:VX2)>Q
M&N&9^+V<F('/,<+W4YAX"9@)?I]>#R>"5OL</5#(]1FAD7UD5CGJ#18^KL/H
MXI<J[GLM%XF?IC AWTT'ITXOTJ_G$5J_-LQZ$, T2P3GEBI[0C/-[1?\/KIM
M:Z\^399IO%BGLN"R2XS!%;[%2;6;$M[<RQ7\?7=$UZ.#QS,+XWF\8P41!>:Z
M>D%CDWIS'9$<SI)&*8_5#:-?0Z]F/4Z6C/?X-7HX 6:\PY4UOEF</[N)\83\
MX*8P!:)K(D-HS+N/D"-G(CCAEQK&RA0]A!>]7Q#F@;2;A*Z#-'VN#(-R3Z44
M=_]2S6M.J7:J(]L8O0U][P]Z'FE<)G=;A^GCT2[S44(,Y(S??PJ=M"*_:KT"
M"P1/'6*66MG<:=39 >6=@8L01.8N5'QS2#5D<\UXR#'A75+J[WG5='3KW9@T
M4_JIW *9;B"/DN.U+K-U.S;J_6OAXJ(!MJ\YWR+,S1"<XRE6MBQ]FJ8A3ZZ!
MP215/*ISB,E]CH60G^Q1^HNOIB+BYPA.64X@-BUD<\3UA]5&N:=3Y\3D955;
MC:O%'_Z(,.P=PVZ>ZEM5HREMLP+V7G+LXITK"?)7O_RH=R(H^+J'K2SXD9Q9
M9;Y*F7=TEW&S&"<(L]^Y6IPV^;YHH; ]_K$]._NANG!7#%R_PPIR@C!H9B./
M+3DERSD.5X*PVUSM>U0\EM'UP_>KY&0!TZ<"^VJIA8IQ H^:DS+?94MQ/68;
MYNVMMJ%I#R(W0>Q5+F""A7130:%"X$^C,LEZWTB<Y+P\N%J:?FV5QMU/G_#Y
M+>!(K\<;&VG['BRUV2\OF&OT\H!=+=VMGQ:[G<G)FY]R-^=F$*EK^=1(6ZR_
M\ 5<?=WS"Z^T?WWY$32YE!B#. N7 X**O\/HB:6 R0(D=IY^+S-L6(V>,-JE
M?F9$41#9H2^=H[#% -<;3^T_TARXY50WTFR==M9F)B5!:N7BD\TLSQX2VS+1
MGEVI 8\T!6KP8./&*W-M)7 .H [7<GP$>N5>ZA87*N"C^^'U_X^T]PYK<MO6
M1V-%141$0&E1:2("%HJT(+H  2$"(E*CH@8( >D!0B*@@%*B(+"D13I(B70%
MDE!%0(QT"24DJ'1(J)&T7SS[['/6VO=W]G/NO7]\>9X\(?,;<XXQWO&^(Y/Y
M.=W)+T[=K/PX>U/E::]'*]NVU=GAH*N,_E8T(N9,B55T>)M#QT'9NXG=Y\7N
M_;"R4[D+FTI55_UH<K$D9>;864WDW@=71+-E\]\.M%OGK$D;M8X>LM97]71(
MO%^%_)*Y</]#K[0B4+.[^LS1[WF7RBQU1[U5!.);ZR5#HIUB>U+U=CF::Q:?
M\<^SP<UYFQ:S.X[+YJWA9J0V.9P$PZG<4/LH-C"?+<C)X^J@^EP%)=>W)$>B
M:X7<_OB*#']#X=)D@#?2G/O5U@VN=H0>4[R9JO+LF_O6RTZT0K61?)H6^@Y;
MGJG'#VC7?NYQA 28(;RD3C>T&B[7URRX6CR7K<Q\$#BM?L1CK2 ?MJD:UJ&5
MGB]..#&L*B&^G5CJ+1_]\X=\DE[CU,=Y2$-IV[=C4^?>SSM;)M_<[G4<G#B
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M(3CD_;X-89$%1ZU&FC"0;4,7KZ0*[W'PV-:<C"E"Q+1):C]?+JL-\2X<<L@
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MH#^B\U]!=5+CD11,=3CHNM;XXP0/;[N+:M<2KAO;*BG41229Z<C_K/AK..>
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MR/9GFWYTY4Q]L#2X7>U:V:?BQ/IA=XK@%#9@-'4@3B1QY4/Q4, 9W[\H:)<
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M,E-@.UT/S F2@&6;T/P&VL$>D79EM&8R$.+P+-:F+(D(BQ>N06>/[M?G2(1
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M;._3*V6Z;6$Z5P=2!U+<[CA],&2M2CHLNZ9?=,].#'DH)8FF ]"_A!@B':H
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M2CFCYC[-+;V7@6S\X<IWK_W3W&H>A%H?J%56NTXTJ.M"'AR$_V;D^3<'D3[
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MN^YYS(2>["HP+([D9_SK??I]&^4N6$_#,FC 86[J!%G<V;=8\<TYH2(0=Y=
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M</R2:\()9Z2N@/1^.XN$?\JW1L#9-K2A353A]GWLY+DL)$\;;0Z[KF/!W=
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M0"TG>.T5WBME?#V@7G+NV_,9X0:@GN/,A-P30A Y!K5 -@'MW,'-46,;MY#
MY-Q1>#)X:E!5[7,(68%_EG.NS&!EHI+R$[D=':4>Y7RYOZ;B1QL=/[]189Y0
MRK^:Q0Q'QH3A-_X$;^L(Q$ 8QX6]P0B.;#MQ;];;C1O9@P&>9+M^'<,#3$J1
M-E6#,>=I?XSV?HL!ZYL !]??Z(#I<Z\(<GR@FV)GO.O[%S?/KU']F8VW M^_
M>+H<*)G+C]F]1F?$UQNV/9.@[IDPRPFB*OOD2MQV-/[%467#=[BE07>2#4TC
M!R*J?40@R"41:&D E@VR/*YZX]GV:X]R3++GWR\OOWPE3N1A/](@B?<#-]7Y
M\N6Z7YG=+ &<G'^[AWQ%_T$*&A1V8/9<?LY-_99WH-0'RO3M12J;SM@[2!JL
M8V#W"/*ALD W$QR/W8-V%8$Z,ED)9BK,;(L6Z&&\/>#!.87<[*NJW5<SZN%V
MX3-*[[Y72]O;'7#7RS27]X?QLKOOU1]QC;?K+Y:*S%E;%?:*/U22<R:99PUX
M71!D-LGS?L.8]F.L>-8S.<<$A0M\KV#"2;9$)W1=P/J)LYR,^S>T#<L1E]GI
M^4SXKO=7&<9LG:ZV43<=[/AW?13AY(O++K.[WJ]BLFZ;/CQG7X2-C$SM0C9
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M+MT7H<.Q19"&9/C:"&&!KSI;"[X*1-&>U[K1H0I^3!\%8-'&'[[(@$WWA[-
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M%KII?IJ9X>OSAN;6!("S:[K2ZWULLC_?/V@E%K+.XXGL/9%'*1, ]24E4@G
M=TP[R/=SN7?(YZTG![]+'_GA\5I41.GA1PR@^V, ^-Q&9SYHAA-VN1GYO !7
M+NO2:R:4 K\EC-L3N1$VMH5D"# [?9H'_9BO=X>+L9(B'Z$.U-35!59GCU?Q
MLP\2&+I# D#BUU\^DXF*/YV5,#2#&05#]6KX$I@E7.J)NOY@CC^GB@,$,^<B
M)7[Y^ZX+H 6F=X/(M07 K<UJ3_>?L*)W,:&F@3_KI@/7%UO\)<$AZC)=N@.D
M[S9*.TK&+Y&#R\LM\_."$TY>L2U_VW%(A+SFGHT@1 =8_'42Z5(D,5R%RRL9
M,ET>[_PB$?1292G3&)GGPOPHW+.'71*KTT-*:POG;(Q6&R&<_8%7*C+F6A4[
MBH>\L&ECF^=*UGO<?3#P0_*L),@H04Z/Z;&IF#M@(/XC/L#H(_5IDOV'DRIY
MV]_$ 0GIN?.+JY@7LR8MD]=YR[DKP8AYB"W9?1S*E!T&-23%586YOV:"1MJ:
MYI6GC#52QS+SH?#,L]TAD!H=P_-IE'">KG9F%DE9=RW<Q&;^&#FT[$/&H)9W
M5?+I;>Y9OI[^5_T#/*X=*]+6UH8'')R9U:BHQ&%Q50G7JBHKJQXGR^D,/Y'9
M?_6)S/%<Q]..C@#X]G-F!W)/'#F,>JTIRL@;X'_B0WEAKBN+5!*Q8V%FJQ/Y
M:7&*GRWT<0W>S5T ( &CJ0( 6 ;*EH4) &T^OY[XC__N0\MYEO,"&I,NY#E1
M\IIK;'AX^22+O )C1:#HW]=483Q3%^2P&T$ 4"[2O%IQ7E?GEN[E0,-#FQ='
MWXP.C04<W*P9& HXJ2:BL$H(Y6BO.EOLAK(M]I@X9]TR[]IN%V^6?4+(U$;Y
M)1FSH_AL0E\6[FVGWW>W;L@G > 3"NP^7O[OTVFQ?O=-::0>O^[WB,O&0T.Y
MJM!)_P/_WL2\_1*;PM4:E 8:OMYW$@#2:CUM+DSE%0P_A9K._1YPYVTF"I$2
M[@^GPK>C<7_/-W15C2XJ "E$)^]V_@GBZX@R >#$3&)0%ODW@Z NY>Z7B2]5
MCJQK-:M7 T3)RMQ5!I%VMV' ALIW)\F:!4:KU2OVI:145?LZTLRN4TX&=365
M6!?YH%3+]VF'9HX<*;21%XEWL"N8[%L\"3O!S]K6TD<LIW;<#5!: 7H$),TP
M:HO41[X%F.\J]1J^SK0D="\M+G--_&XO!84Z5=]V!85R\'C"T<D3S]O6+-(W
MJ#)71<_U\^;5[VBJ7U]LS_UE\9CLWU'D;^D9@9]G PG=/1>H ^G@2D(-LN*'
M * RWL5!3M(ZA'I(N.OL646S']]=/ AKEY4E1/FN:\Z_I+;E'[OM=UL "%D2
M9AUA8 &9='M2*Z*R$M?2\JJ1F$ ^?"!E3**Z]:S!EH:&W2K;+OXENEIQAV1/
M,X8IFW?Z/1>Y*4&U^=AJ) ?P/J[D;%+#2^46^(^N(!N6!8"'?2\'>FF#U#.4
M<,R[\,M_<>>_6]U_$PJO7AE]9IG&JR[5!*%*U,>5*TB:RG81S-_G3CIF+]><
M).[E(G)XB_*.CJ-:(;&'/HLGEVL?2C@RZAAS67O'WZSCIZ&Q\[+YF'F,,'I"
MR6O>7_<=NOUBIO2NVNQO'KL?;#?][FG]Z:4GY&#>+AOQ*\O9'?)?@/T ^1^\
MK[K'V^M;-YT[G (U>5=6T:Z U5$_>;:L*-=FQQ67LS%RY:*.!S/O#;Y*_2C2
M%SGV(6>2O&:9^M:OVB*QB"8_KQ.\[<@"OX]JWS<7/&VDKWQJV]Y/O@YTA[0V
M<!2$^FV&_F(V8&\RS=/ZZ4N%Y:ISV=F186%"@)))CQO4=BF>WP94GJ^ZP^WE
M/]^O^##(ZW:\D&=/?MFB]E07KIG4\4I*JIU(.4@0^RBZ\"QHMAL?WH0,"I,D
ME8K;3'=MO :^@CZQ?[5Z1NX+<#[B?E*!.L D^]F?NX')6GZ$K4 L3'9@FH3A
M]"92K'2[",MLYP,@&?9 U P9_E'IBM+]^_$!<K!GM?RUMI</$.1-YTZ*:G:V
M#S]M/][>$K&2#-^*WJ"96+\^G"6BVAS6'4@T>S0N)Z=Y_,OAE^-*]))U2\?U
M%SB$82'OV5[(FH1_&J*[<K5XV=_;UW!DZ&L6DM22?ED87P.$RSM1R_AH5;,3
MF[;]JB[P=]4?G'04N7E2*O/71.C5FIWK0%-_9W%A'$]$_GI-PE\&@/]$U8M_
M(ZB_VV(/AMUQ U+XLWQB"C<<93Z[_+Z\#;GT4X\X80RP]<4MZ+6W"-[G_4&C
M\4K'[@W'[PAZ8*2T$VH8U;[!;\'*;\(4_+B'7B]J[)7R,LD." "=TW(97.&:
M4(D=:Y7%=I!+GU:2*.[.Y'1R#RO@O[,M[ _X*OR/.;[G[(_(G(X4%)M[3[7^
MR2V0N#?!=?5[IT)M4,6I\K-*+8K&!Y-CF&-R7:6^(G<WLC:4[H  8D]G:$40
MM492/MV6PD-RG^=O+I?+W]K6\<SRTY@A943^TEOQO SAIOS._7Y_Y* >*Q(A
MA$U$[ 'P)MK'AT(L^"VL@+Y2*_%,7'S;!VCUYZTB;>MIG]?5M_S8L$&NOCE7
M*:A5>RRZ;PF.BT-N%U8>A]E1B^<^],XL&>D5I[C4=-^8NU)1VZL3W/K,[;MO
M7WJH 8ML6':JC[5(%#_RL?Q,;'"Y%0,S?'3VVQKS[VB5>NYE.<'Q2_4M=_Z\
M[?1431%/K.(>\*OW_:[(2A6C+Z+S</D?B8^6\RE@2)S:<NT]U@9^V!H M'5U
M/!OAN(I843X\3536$B)-W9>;AQL:QH&Y4BY_*D%\:/Z(+LJ?*\L!$I O_B))
M+7_Y##7]L;B 489_ ;XW]:X,8_U.TA?_#BC P9GJ2!R/RD-!)X5A]"OY20.4
MOKO0193<J"D?U?AA?RBM!]\-/Q%":L(5=L&J!B;'IWDZSJ 5Z$]_\X8TV2O
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M(8\RGN45'5^LP;L<IRP^R_@ZH(?HHUHN$0XB44,QA$IH:R>H85"982&4# *
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MEC3KUEDRF1C#]2U'.D-3[$A+=GLO>2I$%0=YPT;+PIB8;Z!&9W=9M@Y-;)K
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M8VAA<G0P>#4N:G!G[+EW5)-=MR_ZT'OO-2A=FO1.1 0$! 01!(2(U%"E2=!
M%*0W!0$%!*4C B^]$ZE149 N() $I9=$*9&$</)^WSWGVW?<?<:]^^Q]_CAC
MW,E8R61FKO6L.>=:<_[6>LZ^G:$!3DLS"S. BHH*>$_Y \YV :WK?B$1(>%^
M(?<DU)4O CJ7+:QI=IGMO<-# B,CH"'! (4X_]8%J "J__Y]AF5!6YB80*[;
MVYI97#.E# @ +%^#0X*]J2D*0<$18?;FER5N.;M(,$P##  ?P .P .<\/,/O
M ?\769B:2(13E/XQWO^@H]E__C>E=/6ZA 3P'R-.+^]P3\IP5RA\Q%W*PRE\
M!X7GO>M@;T+A/P, (ZM7D)<7 #!]H\B3??^APWSG;QW??Z,3&!D$I<@C_I8'
M>7N$4_AD"B]U-^ >1<;\[F]YV#_[OO\'_V_Z1GA[^E'DTQ0YZ_U(;\JSF-$4
M/BDJXN^^+'Y_ZWO>"_N;AU-X.4\_#XH.2SF%5_SG_/]!PG_[1H+B)"U572TM
M)34E58DH:(3?Y>LF_T&G_+_1WS'Z)R?U&@ XG@! V[AG9-C]?\IH__Z@ Y@!
M#H 7$ +$ 4E #E "U !M0!^X!)@"EH MX  X ^Z )^ '! %A0!0 !QX#B4 :
M\!3(!0J $J <J 'J@2:@'>@!^H$18!3X"LP BP :^ EL SC@""!2%B0#%1L5
M#Y40%8A*FDJ!2HU*A\J(RI3J&I4]E3/5'2I?JF"J2"HX53Q5&E4V50'5&ZH:
MJD:J3JI^JH]4$U3S5!BJ3:I?5"?4--2LU+S48M0RU"K4.M3&U%;4#M1NU+[4
MH=0/J)]09U*_H"ZE?D?=1MU//4H]0XVFWJ8^I %H6&CX:<[1*-'HT)C0V-*X
MT/C0A-'$TJ32Y-&4TM33=-&@:*9HT#0[-']HZ6EY:"5HE6CU::_2WJ3UI VE
MC:5-IRV@K:9MHQVBG:+%T.)HR71L=*)T"G1Z=!9TM^A\Z:+H$NGRZ"KI6NF&
MZ6;H?M(=T=/3\]/+TFO37Z5WIO>G?TB?3O^*OH'^/?T$_2K](0,#@Q"# H,A
M@RV#!T,$0R+#2X9W#$B&28:?# 1&%D80HQJC&:,+8S!C'&,>XUO&/L9)QG5&
M(A,GDS23'I,MDQ=3-%,64SE3%],XTT\F(C,7LRRS(;,#LS_S8^87S/7,P\S?
MF7^SL+"<9]%EL6.!LCQB><'R%\L'%@S+'U9NU@NL)JRW62-9,UFK6-^SSK/^
M9F-CDV&[Q.;"%L&6R5;#-LBVS$9@YV%79K=@]V)'L!>RM[%/LN]Q,'%(<QAS
MN',\X,CC:.88Y]CA9.*4X33A].",Y2SD[.2<XSSDXN%2Y;+E"N)*YWK+]9%K
M@YN!6X;;E-N+^PEW&?<@]RH/#8\DCPF/)T\\3SG/,,]/7GI>65X+7G_>--XZ
MWC%>'!\WGP:?(Q^,KY"OEP_-3\,OPV_!'\B?Q=_$/\M_(B F8"S@+9 B4"\P
M*7 L*")X2=!;,%6P07!&\$1(0LA4*$#HF5"[T)(PK? %83OA*.%BX6'A'1%>
M$7T13Y%4D2:1!5%JT0NB]J(/1<M$/XL>BHF+F8O=$WLI-BBV(\XO?DG<7_RY
M>)_X)H@'9 2"@IZ#D* M"3X)8XE B1<20Q*X<Z+GKIZ+//?FW-@YXGG9\S?/
MQYUO.+\DR2RI(^DC^5QR0!(G!9*REH)+U4HM2#-)ZTC[2>=+HZ2/961EG&22
M9-IE-F0%92UD'\C6RGZ78Y,#RX7*E<I-R]/+Z\@'R+^2_WJ!^H+F!;\+A1?&
M%:@5M!2@"J\4)A3I%'45@Q5+%>>46)6,E>XKU2IAE/F5KRG'*;<K[ZE(J;BH
M/%-!J9 O:EX,O%A^<5&56]52-4ZU2_67V@4U3[5"M6EU-G4S=81ZASI>0T'#
M6Z-8XYLFCZ:U9I+F@.:IEK96F%:]UJ:VE/8=[2+M.1U>G>LZZ3H?=.ET+^LB
M='MT_^AIZ47H->GMZROI!^B_U=\PD#7P-B@W6#4\;^AA^,80;21A=,?HM1$:
M? [L 2X%8R])7O*Z5'EIW5C>V-_XG?'>Y8N7PRZW7CXVT3.),7E_A>:*^974
M*V.FW*8W30M,E\W.F_F:U9KAS#7-'YJ_OTIWU>KJLZMS%F(6GA8U%CA+;<L8
MRR$K5JL;5@56V&L7KH5=Z[*FMK:TSK'^;B-M$VS3;@O86MCFV"Y=E[T>>KW;
MCM[NNEVAW9J]JCW<'G6#YP;DQML;1PZ7';(<%F_*W8R\.>#(X7C;L<;QV.F*
M4[83^I;*K9A;H\["SE#G#A<&%T>72I=#5U/77->?MS5O)]Z>=9-U@[E]=!=V
M#W3OA7! /"#-=^CN.-UY>X?D8>M1ZG%XU^)NT5V<IXEGON>VUR6OYUZ;WH;>
MV=[K/H8^V3X;OH:^.;Z;?F"_/+\=J FT (KWO^I?XG\<8!M0%7 6Z!38$,08
M=">H,Y@[."!X*$0\!!8R<4_A7N(]=*A>:&XH+LPJK#*<*MPMO"."EU)8/D?*
M129$8NX;W2^\3XARC&J&<<&"89^C+T2G1*\_,'M0\9#VH>?# ?@Y^&,X)L8X
MYDTL5>S=V &$).()XN<C\T?5CYD?!SS^$G<Q+CON(-XIONN)V)-'3U83S!-J
M$]D3PQ+GDO232I)IDZ')8RGJ*2]3R*E>J9_2+J;EI9'2/=,_9:AFO,@XR_3)
M',O2RBI^2O\T^.GL,_"SZFRN[ ?9JSG6.6W/)9ZG/C_(A>1^S-/(*\EGSH_,
M1[^X]J+CI=3+IR])!7X%,X67"QN*1(M2BHY?>;V:++Y47%\B5I)6<O(:^OK;
M&_,W;:4RI7EE]&7WR];*'<M1%3H5-97"E6F5IU7!5>AJ^^JA&NV:FK>B;[-J
MJ6LC:S??W7[WM>Y*74>]4OV;!OZ&M+^ OR+_VFJ\TSC;9-4TT*S37-\BW5+4
MRM.:VD;5%MV&:_=K1W<X=TQT6G8.=.EWM78K=U?UG.LI[.7KS>IC[GO2=X9\
M@#Q\?^_]3K]O_^H 9&!Q\-;@])#=T-BPU?"'$;.1090Q"OG!\$//1[V/G9]T
M/K6/:HVV?=;\W/I%\TOKF-98V[CV>,=7W:]=$P83?9/@R?ZI*U,CTQ;3HS,V
M,Q.S-V>_S=V>0W_S^K8Q'SB/7[B_0%Q\])WN>^H2YU+>LNARZ8K\2@-:"]V+
MN8+YC+V!75SU7-W^$?Z#]//)&MM:WCIHO69#;:-GTVSSZY;KUL_M>]O$G<1=
MKMVB/;F]EOU+^Y]QMW _\6'XLU_IOX5^5QUH' P<7C]</@HZ(AZG$H0(U7]T
M_J!.G$[6B5$D!M*+4_G3+K(5^?M9T-G9O\$DRG]CMG_AD2O>/AZ1@1$2?P,5
MDY# D,@PB1OW/#R])93^.[#[WX-3[KX$@/8$ !!<^)>,0M?_^?5/O/8/H@+^
M?:+^5S\:?DI3IXC*_R4+*04 G4.*_&DXU/<?,A-[!XE_XP<E>V\?[S#O8(JI
MCE#O*&BP+\7^8"_HWVA9 AHL\7]STW^)\?^&_C7/?V'E"&]8Q#_F&7(O.@SJ
MZQ<A<=4[*M [(D+BNH=G@$>8EZ*$VL6+&D"XC[K:/[I2L5(P,MW*V=EO&0!@
M> X IUEG9\0W9V>G%-MI%@'@?>39(F#R]SGA/T5_#_*?'8/J[#W Q4BM1_N9
MANH\0,U%1<-%=38$@"A6T/U3X;^[AHJ:AI:.GH&1B9F%HM#*"5!3T=!0T]+0
MT=%2<"Q5#.5W@):+CON<JC$]CYT'P_E07K7'S]XP2EYN[.>SG\!)J=\-BV-B
MYA<0%!*6EI&5D[^@H:FEK:.K9W+%U,S\JH7E#8>;CDZ4 'AZ>?OX^D']PR,B
M[T?!HA_$/TE(3$I.2<W.>9Z;E__B94%I67E%955US=NFYI;6MO:.SJZ!P:'A
M$=2'CY\FIZ9G9N>^S2]@L*L_?JZM;VQNX7_]/C@\.B;\.?G;+BJ YG^8_N_:
MQ46QBYJ6EH:6X6^[J*BC_E;@HJ4[ITK/;6S'X!'*<U[M,2/OY6=O&ON9)-7M
M<7QWPR:8^:4T,-+XOTW[AV7_WPR+^U^R['\8]B^[%@!6&BI*\&BX #! )LN5
MI@+_?_L_L<6%?GQ-G7HM4W=[:CGO$;,\$\ -HZF3T_UQG<J4][^VF862NGA(
MR!)+N=<<8TOA1VB\)G+W-R[GR&@JEA$V:HT#9VJ TZ/TJD96A!:L,$L<M_$J
M RN,!,CPC0T$2\1F.1&1%E$KV'.CR@0+$AP-",'T/U386%!:+JN^M769(W\?
MC"Y'ML14I8:0M9'OQQ,VB<!F26OD^,[+R-4:@W"L#MFHKPR*=X S=A F0C"Z
M&G9H%"$0R1^_:5&.".#@_?CZRLE :=XO\T60$)D!=@:,E+2A=FSQW9<:IWX2
M$#B3@956K5P\]5&,_?+LR:??V(8GL: -,KL5F_Q\<*1I9R^.7)D?YIIDQ3CA
M57*GX#Q".U+EV_C1PG3+DOF1>,E[)&OAD7G/:8LR OHP9,&M3U*J6*698!Y.
MO&Q!O 8>D"%8+KAL[>.Y##PT^KB2AE6W:C$A!'/\VZLK03ZM"FXQ-Y$< T32
M)\>IH%SR<6Q[[[N#S1B.:U-G +I\I>7F7(K&2F83B9MP$T3B.78]?5N/\&93
M1Z6MCG,B!OZX_B T1N/.CZ]:KR>L393BO"#LRF0%9ZO*5WR:COAKL>(%*RXL
MND-J)F@P03YJEZV>$(\!HSAXX;P$VW)R?PD("=7/FB_!1&5$[(O#$E=7OR36
MU,*.;Q,@N$5L2#I<*;ITD:!/YD0FQVI_[4-!R_T6WIV04RH#NJ0/\1VA4=Q_
M>K-V($2HF.2ETX2&/G&2VAF0:(R;V\W1W@4%$2T_XE65>]QB<+%S1PG(T_*(
MDB<HS.4-G#\.?A7"LSR,T6_@$3,A<^D<B'C67/'I??I^NH>!R$U>L*J('4<T
MRJ;WB9%4&T^?@WT@"RMFIZ4'B 7+.>RC&0.GU?TD!!M9:?L,$(SEA>NF8>PW
M9D_Z4E9;9P_9!,SQ>:W5D/8$L]SRV]^A:FY+[N\B($$G$)NNH)]]R R4WV+5
ME]ZZ.4A:1?[2-#ENH^$YW((H1!+%V_36P0H=9F.-3&JV%RJ.FA'\&<0;Y,EE
ML4G[W]<[LK<P&DL,EP@-E1L%AG&CDBQN*E>G=B(6Y=KZ?:&T%QKK.+Z!'&<U
MQ[_]1HM7-6P_6$_1C";Q-KH'%,O,1H(XMT^>-<T<Z@O*SK0NN:_]OCG38-K:
MHCH:4[WT??EVM,>>;-[E,:OM$,C RII9!F3*K*T+&;Z](%?Z@H[7[M+_\0UV
MO,M6Y[\L0J###PZYL+\)+P\HX!@ I0B/9;R=U\W\?6TF8IPA0+LK]@U4XH+]
MVJ<]QOH[]XPM/,T8)!RC=FGPVP.0YI5'/OBD9(^^V<-79B>+@\74./%XP6Y\
MR!!"S/^=!^XXKD>ABF;-W;^K=^W#PF6Z^E<^[7K%;Q3YM?)Y9'-@-48:_BN-
MVB/0/LUY0K21/"$>W3YB15E!;+ +LVOKUKB3 '$>O-2);'Q0I4JH=G*D$HMM
M\90Y<N9UHN!AG273GE(@-M$ON\;<5+;YOGO,[H^NMDG2-5E'Y9ORYB_'-"IT
M=>HDBI]U=[54U*:ZM/(?3)X!XY"CJEUU(O@,Z%<DTU$^K0T,B3&Q4PN4)*0+
M5\45CG2= 0-9&1#.,D(.+A[;.Y=N8%OAU]4PN&W+$.!X_FALW[F][_FFMHM-
M::2^8\*7GF=&RG7(!WUZE+%,C)C)XR[CCV)!L*HKA!H\RVI65H](T&J&-MK\
M_7Z2\!DP#$XYZA.3%X9L=[4EO!EH]'L@EDNTJLHP=^V=\NSN2KP:.!O-]3P6
MANB7!Z-?@IN&]W=RB8+P:$(6;G%$7)%05TG2Q65E*K:4I+H;$9YA$4P$DY$W
MXFMBOI<(3M@OL>O]Q4+3@3[S1L5YL:)MKDS<0KMEF:86%_:S8F4W(7^%D/C,
MCY).WR#\QND)9/!C9 OJ/>*)D0@A"#\UL,(!A^ YC'&09"-ABVI70A*F(06!
MX9B(W+TQ: [)VU*Z_]["IRWJE_,B(/0+-]=U8'GDM%'R9;-]O/?0M]!T;M"N
MS#[(OLI%Q\_Z4Z3"!=OY3S<5OHQ];ZK1%@[9J1J5;V\B^I$7$<W[NX9$B=BI
M%>Y8,;@5H1!W;$MPQA&QP2_Q[D&R@P5)\0@_\&.]O@2,F,L9X% $4Q_*.VH_
MH90L*_WH0PA;X8L?C3W32I(!KIW9\LX76[(6!]%9[Y&/($UB.=O@%H%=H565
MS!4&DB$6\J0/A#L>7'+%FN_RX"&#PDY/(H("G/'[J7##URB^NMP?PO?+H-6P
MXI.3H\GY2)'.<RT!^8XNI!5<0V(/%!_??P;@7,^ 19/+A*C5%1JX^&DETK>S
M1Q)G,EBLBLMKP-CRPZ^= 0D0G.1P%WT#7@U$Y\]9V1L Q2[9DY='!W>CJURV
MA(=;8N^T0BU\UGON@7W'F<B?P+AKKT)68[N)CK&?(4)]8K&H,X!C!2.P:X<S
MP:RDPXU]T;NN#CB!A @D-TD27Y&9@CD#>%Q7K+ ,S4T]73BG-#@X).#MPN*G
MO).,HM('NG?KZF9[[8E< 6^)-LMI;JT(ESJ2U:2]@_UZ]G-)N=.@J;2LENRX
M7!>[]23-T@KI?1U0*UGYM,<(@.N=%K4@%J*P0<<9?<(P ;<9GL$"IT1X..YX
MN(!C.,ADY(;_\0.VJL>!1H*WH>;#"TEI^ZT!(H6N;.=1-AT!'\KT$GHFH4_<
MG02(8$3_U3XJ4BRA5N!]_VNX-T$!GV6'.UQ)ZU'%K1PE$&Y@;9_T2>&1"0>_
MC%;J"$J:0P]!7*Z;^&>&IZT9J_Y:>5BKE)ULQHIG8#'X0VS)(@\6O#-Q!M#.
MG[:"H1SQ9# A<:7I>#<2"Q*'W\:-).!0UR>-I A9Z#=->([X'@;\WCYZN$@-
M<FN[X.;S62/%:0-=J%>[%M>8IHAK@'ZT5/;*1A ".Y=$J>%ER/;C';95Y'SX
MP!G U:J2B&AR[,9#L+XCX,P^64+0JFU2K,A478\'6H@D64:2^=I@$%KNI^TN
M,4<RKG$S":V'/HC)_>X2^\I?.7VC_X?#:MMQ\_VNMKRMY;D'^[^_5Z37R9OD
MV=G8LGPTB_CQ]F:"-X-C94;U+[,;3?'/SV]:%=N^=-U"BB+Z/9#>$ 98&78E
M+H*R &*_@K@-/'$*(^[2N)+A$C:X/$$6VR"^ N-'#3Q;;*M917".EY9W!;]$
MHZ)_9-D@>Y!)=M-C)=6]F3D&6@URIQP$0WP4YAA5DFC$3!C$U0[=CU4B1.-9
MC)OPL@D&)G>;RO4R\V,+2WWBL#K!0<%W[AW-Y45='XSTC62=G5,UU[")_^5)
M9FK'Q%C9XJ-(?&/KCKB]LBK$@#$QB.20;U-B-ZD<> :T1Z!P]$_^LO!0^M*#
M6"AX:#@TRMHVXB<%_7%A^&?@B0J)<^[J3 N((,.Q@Z&4$Y^:,G]^:[RCKL:2
M^\CV-61K0I\J[,3*(4#AP^N..)DV6/$W#;^ZX F-Z,OEG6;R6L7?N]R/NZR1
M.5#H2:%'[5U9>_&9X8$Z@VO9UY^+B@D?; YHA\''KA?F=-DN=5FXJ;PF&R+Z
M+Y%922R$?-G^AP@6D@]A$?_0%O>E(0-N15EXT92L"$H3E\79QN^7YXF N&&S
MAGQWITC:G@@I>Q&6A\2#Z7VLK=&X;3''\JQY,AA=@6Q:3B+J$T2.WJ4-&<G.
M&='!!K$R*3C4+7QQ"L;ZLBG!%6OHZY(_>&,4'VX^;?:JCL!A@SM.SC;D&6H7
M?A5O7;8EX&AEV&P2R?N%T(B?Z_\:.P;&V2$602AD2Q(*O%AXY$MP)9J.XQI&
M((QD5?)G+>&Q"AQQA.4UP1BN7DN@045U<0R"DZ.Z0E))2M$^"(SX7YUZ<.Y-
M;;5QT5N=R^3U\#. 61:-(O'(KG(\,0((+$<II^61X,6058[,'AHTA#%V<ID9
MSYZS"DZCI!>-PA@1.WQ?KV<H!L2XY'<&L&L0#H@EH-N$IOVK$W4_6B>"@S'(
MQ!/LK"GOC;9-??_=F?*5O&,+<@%&U%WFQI#LA8M'L4L/=9W'V+DMXW_>",^N
MKOM<9-^"Q2@IG@%>.XB \?@NY"X3%C+?;3(=:1TR$DM'N$G)GEA0<LNH8+"1
M.-P05U^GUI!T!Y^4SO;]OK!C-]95I27 1?DI[=1W/RVG!SU?0KR%1V5'4&06
M$Z(H2V&,WP(\RC8NRDBZ'?<<TJI10DV* NV,G2S-5A>(RAG)6]W)"RC_6-O1
M".$R?(3[;=69[Z#*H8;4.@,\SX#Y;NSXSA)N[NCD#(ASALV.K#N=OHY5)='A
M(4/C\>"6'.=M']1J7@(6E/@,;AC"'&"DB"P@&X)O$>SJ--L36G;/NW[C,]"_
M'\D2H'.76Z-S#MQZ'&_@1$E%S2$$6:,$HB$I MSF7D'46XS]['D4U$D06%VD
M*2/LN7&#&+ZL6ML.JQ-BI_KYC1BF&II7 [)XVY"B\@'<2PI,+VQL;BW/V2Y;
M;M8).*VM6.M%RF[/_)&\4/0"VA7Y-LR&'=%;I5/QQ 875J* U)"4M;.P+.G*
MU]X=WY4_ ^C83HL0WK8"\(LXVV$ERD$M8$6H1P&KP@N_V(PS?Q()$1M?C38
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MG"NXI$$0+X2@/@0"]:D2M-%[95BV\]%*D6D0YNWK6P)DB?:I^C>PM?9L\O*
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MS-6= A@P&=7]2B%EX?<LVE.SK(GY7]KKY"87OE,#Z'1XPR.##,\^^#C!L[@
M"\,[27-\N6/:%:C Y:CU*6;VRM5KK_R8_OR6?<!Z_5($>9&82XT7WCN,L6*>
M#M+>J*'DG *8=F>H-QM);HET@D*A0?O@F;F^4+XH62T!8J*YT ]S(H@5\8#W
M)I)BC-"M:C\!.[<T!C6VI+!?W3%3$#;HFC:#?TN#]ZQ0N:9IK.:?8J *!RDG
MKZD^GXV,ZL 7O&;-NC\77%2X09'GL7G^$L+U_*FW(L/S4X F(OA(@?PWCB:V
M\M$+]P'+IL4$C1UP,6?.<E%B8U(#6BD,5(6XFLA9#E8WAK[^6(6:YTD/-?X\
MK%3,S"R%](.K$3'L\/".$#7FE1D%3E.A]*EOX45JTEV+U139.XI-*6*@\_TC
MH.ANJW<N\0&>5@$2;J99W&EI#6[[1#+S(;=^B,C?3;H>.SM"(M0HX+ S?'WD
M;A:9 LH\4;^Q49KE#%.^?WYO^;'AO+5C%7,2,;V=HD]_NH0TMC.)?02+=9:T
MZQM&2)&+NWH]GC^W5W]&5BYP2SMC>?V6^AHD\@DM%J7Z&+/YY5N4:!X& >)R
M'<6:![H41X7#W-QVOY^@@7M9)#KKUXO%/8?=H57C0G+N9._(\L@^^;(3U#J2
M6X)YI]"J1Q_O!NF;LULB<C$#(K!L/?)!(0IAFP^/8V\+TBMT6-^YY)W<FL+
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MBT#>#?+G<^/'+HZDJ9P23ZZ"1V>3)9M1QFDJ9RP<K[RX>)[NS+'QP_V+.7"
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M;>(4\"QU5M)@5+G-C1C[DBJ53X'UEC"^?KA^5'M_ R4TOJDBDP@_[Q%Z4'R
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ML$N@@NVL]Y3ZMZOZD01A;<<'CLJD06 22D26QSZ@ZGNI9?GE!PWQ26N=_:<
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M[FCOP#+T-9+3[[Z!#Z)V=T#>2$]UX7JEL80IAY_?.?7\SU[%5&#?K7O3FZ<
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M7.J9*HC/(-<*D9&0#L>"I^J.5;).54)4B;07G.!:,/,CV@)(?[ #D@'WQ)H
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MM1_EM^=^;>K'=[E'QG_DM\DI$ L[F"6NSYRNLB&NW8-5"95U1SP<BD^.+.R
M_A>JO<H6[;FHM'\'])#<Z0T6XOMZAQ7%C$$L[I'_R_+J3@.N_V5YL:Z!WW=
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M,(]EUQQ)W"Y3S\]34_Z1@)?1L"E+F^U]Q!'7'XY/PU/['28U\*LZOYI2,F3
MDK<45;XG3]VX<63Z3J)X@GMBSU_&]&>AU^.LU*">U :<V$\:(3F29SEPZ>N:
MUIEM-VIDZ'F&B:>8GLVPEG_KB('H1'[^,5+#VX8X1&'^#_]+I8\FDT406APS
MRR%7I#U/S$:#^4# 8X+I>^DO#!4.^GCT()8> 'B6_L!^L<S[][D^NOW?6=J(
MWQR_ WK>8L@'XW= GW!^KFI,I")@2"<E$B&RJ!U0YQ8DON5D6:K?*R"ULR#G
M]9.RX([?B_+R3O<J?:RE6G8S?C.FJ%J_#/M,+QF%X?+_@[YB(K#M;M";N'%;
M1MZR!)OY85H<&H1\Z&/(SG@?/(,?Y!K0<0H_Y=KJ*XEYG5#A:1]1#5&3\5O:
M8L2<AHWL_4_R0U=F'\<IGVVZZF_\.#YMZ.F+PMEHU=&I25S)4CA.)O]ZY?4P
M@X4QBG.QG)1Z=P'![L_G0W<<AEPW"FSM(J&WN&J,U0.H54H!+)4K2U@P/\EJ
M:PW1B8 ?#'+]&A)M61W@S90Y(\,AJ+2.[+LT^=>;9M4U__ZK8Q9PW#3+9AD,
MJ)&67PF=8_7O&I95=A]M/[MA9%YA9#KV4RS0H/>D16R^P<:9C!H#5[A84NWQ
MI]57\"[6-XMMP@IMML8-_7](.EA8O_M?G>XK*+NXW>B;@Z8.K'B&X<HN 30B
M>^"T,LY!7BK?@'L92&*(W9V;IF,IF6DX$-JA'.T\MGH+'1Y&A]#B*;ER&X^@
M 0B=%->F1D+-4HD,0*#WR>D<6&P[-@K_APW.N8?(7(!\B Y,B(#]A3*Q9!T=
M[HG3QXD&R07&)V:'24T];9,>7JNVA8'3C7_)JJ0L=@;K>HC:/L-G&<T(JS=K
MQ&$.D7AQF%W<4$$_(*G3BGQE@,+IBL'* \F :SO\$/?Z=0)W'P +?[D4)4V@
M0PYP%5DM=Z%@_]$6M?" @C-5E<"P'5LG90?4T-"3[=A,:OM3!A_4L+7U%/5$
MR,LC8DQ,3%"AH5I:US.FJ%3JE$'*%(TVI7+I>=S^)WZ)1T;]4@RN6HB \+RH
M'5#BFH<8T1]9DDOMG1_JYSEP[_&'&@OZ5E?\MR^A,CF1O *!%[<+02;O@"1W
M0$%UE4"S0(D="1#,0.ZT5-LQ?J^'3-)1H$XIDS5&H9TI#7WI'I1+&ESPV?NF
M=?0HSNLKURA6&Z>(+VY]JL5SXO<9+_N<X!7Q=Z,*1.NP0LEM![BGQJZW*OU-
M17MRWA&1>X/RV-\A4JB4(4JGDNII?$<S*M[[31W5(%?-861Y!7DK( XZ-\PI
M&^0:L4G,C16)\I^0>L/V60!9@V)R2MF*&:0:[CV@C]7#,$S%!L&_;=,W'G*A
M;+^NZ(RR&>\H6U9/!UB(:\N*2B$2=OND0PWYIIF7A]'N3& '5*^MO_F"GXT-
M:,6V8S1XQ>:[@#)Z3R*\'0LVM6+!Z7>;9Z!"ERK?HF#M3:0X?9,=T %4,-5(
MQ2)6].*[NN$CQ]^>0#A*6QWQU9HF('4LHC;6U#VMAKED6R4J2E%O98F/Y45N
M[F&K\46DF-L$X(30\NBV(5>.U?^HBKN;#>Z"/\()80RY\-'#GIDKR%1S,<",
M@4LF00^TR26_O%2>_4'->EBH$RYQJH0ZX#-2Q@JM":T*QAQ%@,=ZKOS\.$Y;
M_'S[TMEKY]H5XN/;%5*XVFPP]Q!X9B )&@0>%V5$M8,/HB^S2'%M^]#![.DN
M& 1P@O.>M^DONFPH=Y;(L_?VQ7&A@^74=3&-2TTCYG\O/EXLT26Y1SPS/??\
M^^(6!A]6>>&>P4LFV7[I#UR0U&:R:L?JM[>W7I=@H[^P<"OCVS<F*P20/;$'
MGC<SQM5U[4;2OO+[?"" H=!# QZ4"4EH$6* 4[>FVR$@=$@;$!_&$"W6<QV+
MA$D'WXVFDF8N<0T1%>WT=$>5NE'Q"LGFDP"8 _#>_*(#HMO7@([MF7I^ER#H
MR2O>_MMG4%8S*TGQ7*L*K@\+'L\-9UMU0H3-#W)=!0UKDZ.N$U!)WFSM_'(X
MBM0!8:6[!1?<2J_>-XRDS5%]BZT2H#/%<&))?A77F%=(7'T$W75K!W2-\!!+
M].,/3QTLH5P6\*2^#P$?#)=<)Z3[B (G&:(:S98LJ<:$YZAM-]N85;G@+<HB
M+2\QHE<C:*W0L^K778L9&* &67%Z"4?+\0I-O=G@&;/59<BV"7_X"7^(+'XK
MHA B8-@+0 KX /H\M4V#JP,X,ZHU)IQ99PKQ@ "#1NRP3#$]][:1EG-E01Y>
M8+S[=V^?9U3R_!@\ZE;C]+ +-.KSDIVK93;UTW8OC#K_*^P'I%2)R"9P)4;\
M.+K ;C!2:!+<V^DQ&6ENPDN#!F0^PFA0T>%,;.*9K?F4R(7K[T:)+FRK]!JY
M7XB8H%K?< 0>E=O1K?7X@EQH'$W%)"KGC^SX.S*@9I;36+A]&--?$)FF@?2K
M "26SUS1S/KT@T9#%+2VMIC?Z#O^]M[M[F3_7*O<\Z(?O_S(VB)8[8 :'WGT
M]V]5+U '!M9\DF@C#A:Z_VVM\%S42CI=)QDJ:ZX*!'Z [X[< :7*83/;(..
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MO*(=T#+9>P>T2&2'HN=E!."I@]L!?:N6W0&5W\ PUX(%_]J@6_%RC0+Y.7I
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M,";TB.Y5\EI>8:+(V]3"^$F5K92/(-=Z(+&(S'$9Y@ZH8SI."<*K6INFQ7=
M)-KVH*%#;8<62D[Q<$BT:,P+[@4@BMY<_<CTE*EM*4#V^FJ?P#!3_3S;( "F
MX.&0,\/=;^U.9*-/79B#[X:&D.,@N[C^V\%V=+(XVK.-!>DAC%<S=#Y,)SQ!
MY3FP5I--@_&+YAJI%U-M1KG8*DIDZ0)CU']X59L(7C:)/6][O&"JOY_&O;@!
MWNS\Q\S*Q@-FU&W\#GWAJI(:6$HJF7.0,YKUG#482=L(L79 O[ZE'IZWJFX3
MJ:/Z$W"GZ)]R+W&V?QW)2\V_F@-?M@X8G<WU_UU5Y# 04O,V+;LJH<+T<TJU
MB#W1!A5BH'']U&W*]<!EU\5 K@2KAP6=V5AYL!VZ"**%8$7X,CKMV+BQ# =M
M56",O=Q+=R.*'?G4T+H1SSU(XY/NOC'VL@B,FC\:>:"L SJ#FVX@Q MT#4P+
MI)#E36-? GEP%B>'#DNFJ4QF/IP9UB:^)Z#]9M+#*7<ENJ0)KX(X=G^Y;CV5
M\&F>/OXHY.VG ZX2ZN=W0/+:996J.-6LO(UJO%V4(I?F.VFOOXDLS;ATO27K
MBS4GL"E%]D:*1F):KX+]8-E#7Z+M4?"MHMVP'Z?M+NH9-V#?EDB+//W=E"EA
MU_A*_=VXK_,]7W\AR>S;^(3G]%6U _KR4=FVU8<^N&F.HA)@T$[8J=*>M9,_
M@&=7G$\YWU;0O:"2X9KT*<CW;X^7T_5=C/ OX[Y^<G:^?VK.7UW9>]*MY:F7
MM[>7I>)?&Z<'E'[+CIBNJ"-_Q'W>KY9E"&8H0,:0\IC1'= ;Y(I9%*N>@5N!
M"T2!D]L S,[ _D+I?)@Z\Q80_/*+29_N:H8FT:*#MU3QE3Y Q=5ATPMT#9XO
M]41MY.RPYKK4):FVKI/Y#WLW_]IO&O]D\219>Y63:=_",Y'(F(RAGC6-O:F
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MW!?X 3>U!ZG1BFQ T0BG,/L[%J_HEJ7#LO(N4:$14*X-QO#P3/^=R.O 2JK
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M0](#57N0$Z@1M?GQZJ3"2\^EJV;R6HH[VNVEHYLQ!:'7RDXGVDG'&/V17T&
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M!EK]5>-F*N"9A?#_:&\/TH:_L+8'*5I-G5[$KP] @2OL%@6-F2[^V7N0NF^
MWAXD4Q$]1P(,R:"\6P0UC=S*'GS_D&.BD?9*9_MQ<"9T(+<V6>A>]Z,4.%^V
MR7OKKN*OPLDF-R_3D7/BAAI4Y+'26[[\VW4=E:S-&S%9"(+HXJ7!TE00;Y/N
M4>>/\16WY"H0*G'+5-^,\9P?>[]MSN[Q<N >Y."_19O/"UJ\3@M0#HU%1I'?
M?&6T-QKOC@@+L.6=#Y#5TGU8@:!?-I'Z6/M0HSU)I_K-4X^S+CWWK[#K&K+K
M%CO:37FD_-O=^]QL*'/<S!@1.9W:[/X0_;LB]4=EXMH/Y>CS:%_IRK &;OW'
MZDJF5RVB-5AA_!9LZ5L37O_ @8SU:QJHV(.DAEB.DBSO;FS2/[V]=7XF4Z*%
MQV\\3ALE>JK@^NV-\9@? XTZGZ^G5U'/ZQCU5.]!>CN0X-EMID!UB+3Z418G
MBL_=XKU/9TXWG8U<S#1=8TZ.&(U!* UE+V=$495K$; [?//(X4]L*15Z!M]\
M*_O3Y\&[NUG'';R6^GY->="9WN"Y%-L P>;VAFW!8KJ48X^"A,M?51-1_4NO
M)<_)PN<,#;E;?@@$=ZH$.=[V#7IB6Y"S]E-R8XO^B<<GP9&Z<6]!KL<X@EYN
M_L'3>3@O8]'JC>R/W3]#CE[MT-E&628/-^M8@49R]1NM)>; ?+4OPL>MP(1>
M3RG^.=[[F/]V#]J=S&O6H-I;?GR@7<3DC.%43Z7+ GD,S3KZDFT&\KN9#1H,
MRSF'@B6"/TV4,,Z]]9B.^+(KL6@.S@"\7= 3GKBS(QM<EN+XFWS,2XFF]?(:
M_;^-JFO65B0\SJS-Q'G?W:VS<+S+5*.6*+J/9N]FFY?P3POO>JM5>EHEGR]S
M>.4JF&?^.*'\B3F]PH2HI;/S"&S.FJE:B^N5I^C^/&Z&53K;*!(H@XK<2GZ$
M^:5YU\@\[S@KPY U')YG^21Q*\4G2_75$*DWUXX]NN?V(,UV#9?[-$D 6W\Z
MHJX9-N9ZDB5@7 MF* [AB,E5G(PY_?(C[E=QY;\/U,S<=OC(KJ3,KN186:HY
M;33 XO3<\7[I=U]+USIR>1\0T6M6NVY[ORDDO*;]2*GK^LU#KTQ$CT+V/1.#
M;G#EE.]!HAQ;1KW'DB=76 TKJXWDBI%=A#%+=K"CYLA H%MDV2NIO&/HB/*R
MMU+O_^2=TE_N4+5\_,K!I+T1BE__/0"G1&<!UKW<DZ*['!2-D4BLBWO\"H$^
M2/F1&C#3I-6A]! GW:S\"A2E*5B4KY\O8,^D'NL823#;I[@=.+MBX+SLG;AJ
MC4P@'1:RJ#.=R^1LKVU$1J/\52>O2+8_EDIF@I.)7@MMT WA' (8_E;^_F=?
M45F_IKJE++_&3,)W]/SR-.K5[[55[E\?K&Y], '^Z'3E2:TNS<IF.M^L3[)(
M\AGU6F6%B!@S>:ZP'_O.1'^<^TOL)*_C:[.J[VG&G83G02Z_',N_A08J-,E<
MDNI+&CDOGMLK;78KB74DG&TX5FD=BDKXL<W\0<45V?J:P1F0#-B8:BN5I:C7
MU4:,L:35>1"/7EY-NO&R)%'!O>P[CP\K[-8_SZP(]_*^W='MNCGJ&NS</38?
M+%O@=!W/!I6WD\:IF)!ET=ADQ"9:I$#V2.WE-7NRVDQ<P:G))KMO>;D!>Q#8
M>;8+1L,!Z_12W=%KGT$.'UB2BU2%W?QCIA^H)I/NIMX>-^CPTX2N4JHX\R8C
M;J#UF/YGO9^___R)96.*/=L<*C'H7C:+"*!$Y+W;+3Q4Q^H MP'\=89EV:,:
M6028]=#-^MNXM(*0K#AJ]Z![+NN,V['\M(1[:559HT[#R<E9%4VQAC/O\C:V
MZ=5^,]<#T9$5>9HSNI;4DH=%/RS3BLZ;<^OY)+U:U?R=[HO]L5:/GRW_=U1+
ME_WDO*G;9@&!##WC ']?23,?7W]Z,25NFZ^+V9!D)MOV)-'^U%JOI%HYX[L9
M&_]._+NH/AO?7^. I_X&V92I5X345QV#_!\Q0)$= ZHVF/1O4BF<3Q--I%*Y
M_QR52C21WJV_GVAC>K]RE1T)_K- 8LS4_A?.]B!&DQ[L[Y,H[$'5]]R#7!YG
M.U>4;4O6M]=XJLL>9(;=A^A=>B_K*<C][Z[0UFY601.24,KNB"E+C*WA#UW>
M@^1Z5^Y!6O^O"*,!!:;AH-R1&=*#Q=OWW= =\&???[U]!*>Z/#:93H0L7!/6
M8(57_C, 8C@\Z<*_=!^LW\TA<*ROS1[$A2*+<@?Q*A43P6Y%8Q.Y"*=M4A?Y
MXVHK7A@KL4O8@SS8@X1GG=QXW\?T =A4EB,4*TLKE=!;Y#)3G_0UZB\MV>34
M&/(K+I[4!"_Y\+VK^UA?6_D*TF=V]N3RIAF_[1P])LY%H-(R9N-Z-P"/]0&[
M/B?HB;ZVO6E-!QO,53_EYXEXELE5+@[=FCYO;A'Z]O>[/!T3HV]="!L+0_X?
M%W-BSD'^HWPPP;MP5EHY.QB>I50^OMV2L$_XT,NW%WH?)AB?S0O],S5CZMA[
M?.$$YQ6YZ_L60RU>'UAZY+[?\US.TV/_:6';-*DKK2Q!2U*^[%K7Q[LO'AE=
MDCP-&+LTO^/XCY6P:R:0%ZH7Y]_B:N%?1X4IO5%-A\&(S+.I7UCR?0W6T#"L
M?1DHU+::O7#!DS,;T]DJA+]+YXZHNG+@0N6('XJT$7*YX[896N4G1>207YK9
M^\DE8G'UEI/72*>'(?_-"__Q:K5$$:P1H-SZND$/GL"T?P>:0P5!XE5 .4)Z
MU%\TQ$"#+(Q)#*CJTU?+%Q[#C98L"O$TV BJ>*=17[:<'T=5*,7DC27?]']P
MYI9O@LD7,7HO[ARO1W626>E  &JT:@?I,_1O@^B_UY:/ 0K:T/LQBQ;TA)>4
M5<$Y"9DA%A23B.0 :9V&0Z55G%G'P'Q.>0,C-/?BRXM+.[AB@?#=Y(FQ'X+6
MH0O"QY[2XMUH6L_T]::AAYFP4:SCNWF8%A@)C9(!M,*)FZ+!7NAV']"R2]RT
MC9!M=XT6<M$]A:\UL"CP&-FU)EDJ:5_X?LM86TLSK?N#-MY;55N-&]7;@[Y5
M.>R)4(TKVR=W_<5%5RG5MV['WY_\LG;D]%-WI6?)G(4!/]H5#FCVIXR_GZE.
M,-_WY7>?RM!_9[3V:3_*\S'!)L,:RYX[@Z;]E4ZZV[;#FWJ,L*KR0;]&S7'3
M;@:C^\VU&$Y'4[N\VMHTHULQYR;'GEI=%/&SU:&P]0/HTLD2[-/WHC0&F-+A
M80U6>?:+F6)TP=C $]GO40ZP[&._[!8<O#;K];5L;!_IFJ+U;UA>^ZGZ5F12
MZ*1ZQSYU&7_1N+-VW]\%R%R8^"+^[::.6)_4X%A!2(F9H<"I%$G)RU)Q73'B
M.2?R#8VH]B_$FTWFVB#!(H=-#(T5^B]&F+R_EGMP_YIJSO&-;I5C:BN&.N)2
M-^EU=1>ZZBZXWET0-CD8_/SBB9SL!-K1-P/GLY-SM5^Z)(OGZDB>^-"6/?WT
MIP&&EH**4APR:.N_^)ZB/B#EB;A]^'$N;.S=4??"1,S]J.^);4!\9X^M32SG
MVYK7)WY!=$Y3?'N%"ZD-E;7W7C@YFE/NEZBUR^];N*QR.OC%.<ZRF30Y%04C
MH_#[\7F&MHFG%^Y?Q88]N&@J]_G@^3L'[GXT/Y+M&C\Y;6R$ <2MGZORJAYX
MMGU4[&F@Y-M[3Z7^ISV7BK*-!&LXK7R*:=#'-NB%)FTPA"-R!8NF.HI?'Y]V
M JI(L8I*RDP-V.<"HV6?@O:R,0<G)P_"HT(E2JC]V:ZBLJ&W-Z4&A]6'Q_O)
MM\91P^J#3B(>"_RV?!1"M,0!,(DCJ@Q[B#;)T3["XJ4[5U&0?&;O/"]XJLSA
M5(#I=HE&:H89Y8%@W8^74D#I;MSKM%_=T->YF++QIV8:?H.(!QF#?]^QNWKJ
M?UWWMOUCRQ0\BKU&_LC=3J5L52/XV6!I!ES%!*Y&O!L/0AE/$UN?Y6OFIUF(
M)'E<7NK<_5!]T*DZ:^L9=V_,KD:AM^*[^NAWGR-$H^QRU:W:DJXZ:-E+NH@]
M>_'IVH>Y:WKBUIURYZ86ZU"KC&J1)QY;'KN=,P4_\92J=V7^JZ",_6WFSP&\
M1\-TK7"&$<*EU]P0E^E^Q4%$)D'_VK@+&.7QY("S%__MLH3QOJI8QLUY4XP9
M9=!L.VN+YXG9UZJUACW(U&JIPSG.'8]_N\'W\SR]<VOV^!%M;6U),9ZOL# _
M8@\RD@R8D'ZR41R=H-AT&B/8/6W^K+29SGT3+)+.("[ST0LQ* MZ$Y%V%&M1
M@A+I#$_OB+PX_*.\M%?Q3RFZ<'Y;<^?-$].?LT9WR'E^-X50;B[4'F[6T5:&
M&!BP%5J[6Z">%?;(D6F=U2%":G//2VIC*7T&G+/HLL@:-BS0-). J=G;J5\<
M;!.JM-\GES58W*7.:5CYZF^7_S(.UA\]D2G$#KV/<)TPKMUW,KOY6 ,@@1,:
M@Z813V)8 S9TY5BE!N%<YA7Z0]4)L( F^!SXL^B8_J4.&L^\Q,^.N9Z8)-,^
M17_A_)3@JA2]^O0W?QB),39.*=M_MS?%R0%534Z-!__G[>>;L_\RCH9@H?[_
MCR=I$OY=C,[['P=I^*W^(R9]Z/$X\*)71(?C]*<SS>)'NC)MRW\8S\2J6WJ8
M^F5D# \$;8\6#J(>C.;6_+;5[!?X>7A([U/QVO/:DY<X:X8R+_A^E92%0Y#X
M9FW6/D^X,)[JUEO@R3//Z]AKT!MZMJ')26:U[?%WML3T%MV#5.U!W%OCEU4^
MA6)HJ(\5\G_OTO!]0?*_M2M:69S3A3,7:"R1+NT('0F8<,JMBAM2*G"K]LLW
MD_S^ELP85>29+MI=SQP\&A<O9]%^LZ2HV7B^%A6O37P^\P81OL[LE4Q!AV8B
M7W<KM2-.T.WLBY2NOZV_5="K%=EV)8DOXM6L@H&GM^_COU;3WJ5T-<J_1+E"
MF.XON@TX%?P).^- %RKAE%WI[M"+]]7T;J[,&I="=UM+_9OZI?Q:L85.UWEX
MM0(.0I_M0>YE3:335MM(4!1.#"1"&H#6GI)%Z,2(A,CGEQNB2>=1:.X>Q0Q*
M"I=2G[R4XFYJT52+T*[B=#7OU"4&7$'E>X3.K6MQE^2^\'2H)*B>,+H$O?#?
M6'OS<*CW-W[8.9V2)"$4,960O;)FF?F6(H20?9DCR19SA$R,F;(O:4Z$(J:R
MKQ-F*(:)L9R29,^(,3.5+&,^GV+ZQ,QXIK^>OW[/=3W/]?SQ_O_SN=_W_5JN
MZWW?MV:RV:#I,[1AKU#1X3/P-:4B-*PNW-2G^WG']=+(,-Z<_:^4^?E/!UWV
MMBOJ_E%H<[S-RHPX8E9.VV?RSFQ;+ 4BI%DZ#J.#TF_NB5.([)D,O#]\\QVK
MOE[[P6+J#S]#] U'4V>IS-Z)FMK $\QGEJ]<&@-(1?3?6SZ!,LGDE]49+W-H
M_/9,LQ3S6KLO&,\]CVYTGGH;5F?_Y)6*Y<YK*RXUE9F5 :<6^]P;S=A)#5KC
M78W2?4(8>%@C2<YW+"[T[AGSI(VN\:.PV\'WSRA=++6C':^Y7YU^.?P,WY,Y
M&XD=[&U=*;X2H#9Q8PVU2K+M;O=W6GX_RK[_=7G^387WE_;V/*\I;YF#6G'O
M=T67-D [>LT_I7-=/I!^=GGQ!FM]7T_Y/#EKO5_.Y45B!%#G]>(LW#!OER/V
M.+3"VR6H-):FGV,$ #^S/N?W_NRH_/JJ&IKG]L=/3\,/CAWI#)/.(*I3VTK<
M"GF^B?D["T@FBK<47=Z<ZKQUI0")E(.VQ?KN_]E[S1@=3S/O5KOR[D>#OO\]
M# +?SUS^^Q^R]H=[H->3 ]\_!?6>:ZG7OM(L?VH#>!G>[!Y=$&3]^ &3N^L?
M@T.LUF)O+LQEP?XVUB5KD(EH>_%0AZ:25>E4\2R]/"?==&^]?4EJN'OE875+
MFV,EL0#IB\<;+#@2O9/D+.*[LWLC7GTIOI!]W._NJ\\WY3V/[\U??\.BC+S&
M'>I6QMA/8&PKT08#2AK4)*:C3Z2<'[FYP\VJJGSWOJ#S_];[OQ[ZJCU'UYW"
M'Y<[=FE8N0XHLX#$X]F,#-4C@ 811 R68,XR?QF%+1:BI+L:I'1/Y&I^7*=*
M?_N*'KVK(U-L;';H%]8',N0%B/ "S3\+P4 #-R@G$92[L(5-2:KS@NS?2QUC
MNXZ3!<=X XDNM2MMVV+TA&N;UQI5/F6V*8Q_>H/2U=,J.Q^\-]I9&=U>"%;_
M]05CP71[;V9K6C-]8#$N9K6ET$*C^MTD,CCCOE;@DK/$N8\=45T^'X8U,6TI
MO=-Y#?##3&>IF'T'6*N#5J#BEDY62T<L0^J+40LFR4\#9<(>XD18&A)/3-?-
M*X7GFM\<6A!2W:^&7AA#OCC@643,M;1]6F?+VA;;-5?9(89O0I_SMG2HU+Y7
MD\=VOD^?[O/X>\$H1S4_"14EB>I"LV_7]QH39UMY\:/P$]]PDE&8H CCM>:=
M@W1+N\CCCLPD<=?<9)]0^EJEVL -LO*BG,W^OM$9!Z4+M585^;W*:S$X&;1F
M1BU3LP]C5_C/Y^:/GTR0:<\(4\*!ONF!(.W>M#U77LS<^V=C^5S<]?R^\6I=
MW2/5'G%L&[E:&'[(3">[]>VC[-NJMO@1>'UJ7Q H?SH<28\-99XD??'I\BEX
MX40^8>:6$W[OB]*/_%PSUP*[ >G5!&W)Q,RU2-:KM#&OD%SU[(L?S>T.W+&\
MJ7;_D/?!DU&IAU.2I6+@,)"1:NE>L[)IFX&Y4+YB7IU&'+\$JMPOK?'U__2-
MGC+X-<<!>G8K]+K$I%?D/%&5>_J,/+:ERE#"ODDAU\]#M?1&;/5>>>V"I7-5
MIV.7[+LN!@9JU;+4]^PO#1O(+LD]85^1E^H+OW7PAJ,].IL$;"R[]MH8]D^D
M*>57IZ4N]Z:J9SZYRCYGV&CFDE+'JO2(KE98/$[PO2!OGW1NC+X\]M:W)'2-
MF\H)BS@.#D;?U"M0BD%)JOS0/7;Q7?\?,CKIF'T1MYWVV[UW2;YY3R[?[HR3
M_?[LJ.F'BR=Z97S>NKK8M3W(=G*LJ:*[YMN93 0I:MG-5EQ]4L%S<>P\/D1R
MN7 Y^?^A<_K_CR,M8E"A9."6FO"])TR\B)=,8'K<V18[A/'?LL8.P^5!17S>
MBD^*SZ2E50/?&B"FQ%EI+/@N/_#.\>7NU?XV?<SB2CQ)[X?$Q;SN=H@0#^0(
M)7(JL"-E^P4EV+\@!(TNSK'8\L,80Z:L8?-QCVG=A7'DH'E4;23BGE[N!)TR
MG5!6&O',9_9L-:6-YS9@]^#!Q*F?Q-E.GM_4ME@$-3D!V5NZHS\!F4*,W1;+
MP>W&'N]NK/\XMVR2YX,Q!J?R6;/#)WUGWAQ^SG9K&_],:GO\B";5]V!(^_31
M&D04?L8-*:B'*T'*#H#F_56X,L8=L@!37N-4X ?0G3X?2OJZ55O P3OZ:^K-
MK:!&EOQD03\OK<X;B?1"2CH\6@OT'D.GSON>54?.V;4':]"IMD/CGV^/T][*
M1[N'CB675)X=>Q+HZ/C&J;Y17DN=:W=S12.?$F?G[P[B.>Y$-))7#^&W+,XR
MI52Y]H#S:CB5)"!F!4\0U28,-@9!1B[E2+?\RV:'6VT9E[YC=%16PD^]FS[G
M^T9-836S$?ED$\>7M^"--$/&6R;8L6YU019?ZC: XQ5,4V  NP=^$" .2B-8
MG)$^ UA8$0Q(65%44**F-U@J5T*2_<6"@N%2 AUC&\.R4K:56:9//CE-N74Z
MR1D8X9T05#IS_@!#>#F"IU@XQ@K<%LONUL8.><):^ZGI?"G@QQ4@/HTBIMBW
M.=553<R@DHSG4.Y3L2<8/EW=U(YI%,RG<Q*U5B@35M43=J-8:NL/="WU&N%C
M(N\?Q'X^O&-PM12TYJ%!81<K>,S88)6KZ,U72%R<-!H^-C*BZ*&HM#A[P'LD
M\?@#ZR\$4E\0[H3?;85<C=+\^(3$#O(/JN/NO,$)M^@X+9Q\#_8KCT?J*BXL
MD"4;A(ZY3O'RO]I/P%6P\S@YBB*X@Y<'^6]=Y^L"!B+%(\O_$]I1(9R(7L'M
MQD0V8LX!Z52@Z#)*SCO\5IX?E$$+D)^\P?=G"B)Z.PI+HJ-B-UY,\/_3;U#Y
M^PSN* XZ,<CYO0J9(($+9]Q'MHK3#'8+_]L64]C@9O"$N'2A?H32XJ!SNNI^
MJ+$N;!-YUS*"/2(9@+9P!.($Y/$(I0M3Y&=02-\TO0RO^KS9K"SQ=D%W@R@!
M]M'YGH+*;C.,#UB4I;N&5<9$"7(YB& 55,^MPNG+4/*,= XEF!A>=BS#_2I/
M9R\=E9U66:%ZOD@FP-=R;=Y-VW.H$ <X$>FM ]MB^["RPB$<29QC" P-(EI"
M>J7B7YM>':(A]I!+=[ 1_3A)OO:$;IS!'V@+EG@F"N->@_:T;R&5V(V63\?!
M]GX;JHEP6:ISF+6+,Y3PJX\M;FM'A430Y]RZNN-]]T0/UM=TM+C$N9_1/!OC
M0!<N37_]@AV:X:ZRWQ7,8CY5MX92R5R.%:C)>P]QMHPQQZ%#P/N?S&VQU146
M-^TDYG]0*QN7V?$U-0JC \)>8Q7 V^.6ALQA-9K/W/MZ]E!,+92./MJ5[P#T
M)=QZ7#487Z\GK!BEK2+;VSDN+,:,W (W5:B&UF$VX!0H%UCX7(($5G8&?7Q%
MY^E<N"-HT%?+7*!'5>J>IE^H.][2UW9.<+7Y])N.+U/&]%F18T!<+PUAVG+4
MMI#\F]T@_'']$I+4GBF4C2C6S.#H-G&(%!U%&BZ] W<7I;=A47LM(O&7L4Z)
M&NX&K[GOQ:Q9LGN(?_^V6)OMZDP#=KQ[-^3/=)3KZPA)BX+#A*.PO[ F?O/A
MM^(]FY%+C#V602B6+V<?W<+&-GG+HSV+<V/ML]Y.2L/>FB ]A[FOR*$XG"WU
MU^:Z^95HA&<CUV[ZX7)'_.>?01SUU8=)?:0,@X$*;L.3TME?TNQM,<ZV&)C#
M"P &7U-W\*, PNKP@DB,^/*20>0]W77E2"0[G<@DS'!?!^P"L(_#&L*[=4%N
MWX@"VLU^JI@W8&4S:.LH?@X0O*//DV_65_A9=7O]8F1LBRT0/7C;8G^(@!2O
MM"*4@;S9C"Q8RZU*8,2.2EA ]#_"Q .&K)WM V=6;V D6/Z:+,>I!R%QS"YI
MIPG])@X_*;(Q3'89+I]C2Z6$<O\.E4Q";44(^^F+'!460>06#G8?1%-[L)+0
M[);5,E:7T"O+=P .PV3A2NA.6IGY&(=$E4>;#JH>,BV.^\E+6I[QFO=:WKRP
MZE-8=#MJ['_WQS(R?FR+\7Y 9T#N:]P+S?XN0];PS]Y(-T\1(O43[_XS$KUE
MB/ECPO+,@D%JV=Y12M+S<!_&/>P1M/\B2,P2ZJ -;=('DIS[-JUX96HO28^6
MAOY2NC$=OY\\%%S5OBPP;IL3N&Z<.24[,(;.LHFY4CM6JQWS,,Q>3UNRT!4S
MFE?<>!L1/5A@1LK_BO\ VXF+@M$)_3BR9S8NA)J)E1+DQ^GMZ*&V=O)QTY@(
M0(=%[8.I]N^L>A:-JX3B:5+P9PNS4J='?%]-ZAWK*&9XE#@(/P"?1QI"#6IN
M&_K:I@%(X1Y/D.HK^)?ON96(21!5RQ83O\HLQZA/\@.9*U*2+)-F(M\#C,^)
M+;TNO6_6>E=:/',(L3>T6Q8,:.=UPO9]"E=5R_=OO^,5KM1&0$6@,80GU$!I
M>488DG1X6ZR5N[K(YMY%D%"O85DP"0RN">,'U0,1/$>2X,FJ4!9-'QM[3^LQ
M*3LV33EU%*B^MX:Y3"_8(%,S#N+WATU-Y<U13'AO1S2_Q8LN<X%0?'5;K,?4
MB !I+O;#% <;?:33?N*D-_"'T;[.$6I26RM%Q<("EI2B\P3]9GXH_5ZAXLD>
M=+]^V9L\9WVM['H*HN@6L?&5*WF2/,F-:ZNW.:">7:]XXLJ3)X%98T[WGG&(
MMA_'XXY55!]X-1X=[4FU*LOY2KC# -Q+8T1E=UBX W,">DYHN4^.W+(S::V&
MG! S);SL#+;B/:$"NMP9F!!JC_,-P!C:R+.PZ).3NGIK1B.0G:5.?'RY]PI@
M5?&,H][>G?\1=PTQ6\\6Y[B .J*JAN06;#.$*NB8@=_\H,B2_D,ZA]XCJ!,J
M$?Z,2&A+J5AAR,(/,*!S(W;D9C#R?8'\7&5929-E84)4:Q72-JXFQ?+4&O8]
MHH7*"0;&!^#BN"S&_FVQ:Y%!/? _QIM(X_5\(\%C1B]2H?O(KP3U 7Q%>( :
M:+R8M4;"[5D^Z<3K:*L3RH]]=G1%:[;LFAK[]NBEOSA/4O!<E!)7,!J"YT(+
MC ^T(R8)0%P&XWYF8!P!MX6F1H#+(O2?X%]XS@@UQSX $_L4L7J3L2O4?:%3
M/[.P0MBXWIING(H-74N"!#,O6W0PB/LVF[#TTVK=B;?F;WK?OLB\WF0E$?S\
M3%P)0YK\@HATL;OPX\W-^B%FRY=[9=S5P*U8?J"@D7*[\5WW3DB*24SO",F&
M'X,<^E1W9["$S0B.+?!\L2>AN_'YDBE.OEL^7%5F?'W8"N,25WD>G%E2^O*N
M.*Z)6#VOG/-1]CJQM%L<2[^%V(6[QL@HQ.T4BN>&L*8'";.:[)^O?\_=EH@S
MR)K7G%CW]QSP<>XGJ%Q@(96@:I9T3I'_U#I"8B:L0YZ;'5?OX&OQ<;WB)=YN
M--+RKHSS/P!N]=#6.70*KQ5RW+J$21+EMM+/R] 1X6EAWU3W+O[AR6XEO@W4
MA6(U'DO:,^L(C1#]H7*/9LIH;**W3;E";J7O)Q_G>JW'4G61L^_/_IYE";:5
M -),7)JE(5AM [0/<N\0R*;]!#IN8;'O(T4GKA%R'7&#"MC4@U#Z8L^\'M _
MMY&[1GP6'J ,NGPP_J5GK.Q;'AVEOUI:ONN0.YM<N!*?&(E;NC6U$N:@$O']
MO6MVP\,OJTD5XV4*[[7Y_Y9DM+ND5K[1.FLRX6-;@9;DT2$NTSFWVTA0C LG
MI,*D*(= #\2=;CW!4[@<5,*4QF\PE#!&4 :3N-.>%Z#VH2D8M$VG&+ (TN@,
M&VIBD*6GSY6V^#:-Q!R[C'^?XTJ[8;@>9T2X S>=VI+!T0*#> %0V )NIIKW
M"!SIQ:<CZ3Z>_0('+ZB1.>?+FN!M:J;SL4*%HMZV;B7DG^$!FH_TJO*$6H3^
MP@ZYGIKEMK8\THL+Z\0[U*NXW/D34!<;1;?FU4'M %=40 =1\)WHZ@7QWCEI
MIG-RW(B$Z$O#F*B#EM-E:E-[ XY-;S!DH)P^)5XYS_IV=%Q<Q,XJ0A3/XX'9
MOQ<?F7/Y<NW]'2.KIELP[!LJT&)I(9V)N$Y0%@X'Z$[Q_6*3[$AX.1I@VF=^
MJ[7!>\GDF'M72[Y?^E1$TFF'P0=Z<\\CR"?\=OU")>H7V?-F.$U=!IL/I\R'
M^R?]FHDG;*)RGG!=\2UI 5YO35W<;]_6A,4UQ6N%5TX@H@@YFUS.,Q#&^QN*
M7T#>55"@[A8A8/$M<@4_$*+5\Q$0#72C"4^.QN;&^X#M/8@]%Q8$GN= Z0R*
M3EB=8Y@:(R+Z36TXW7TCI>WQT4Q"LXA/D70'D>!LL5W]"<J)"#S'J,NV3RG^
M;NR0Z0O@_;^@;1VZNB]AOC+D*1I),\=,PUZUOYRV/%N[1$^8<U+2.?]XK=+C
MHK<SC4 FBC+\ G:J&]X^1O$%D0O[B@#DI=]K7%4@V_Y;L%W&F=1P1/J4JMQ4
M;&D27V\!E^6";C2*0'"4.:=]O2TOTB.[GQ9'54;_U>:II_2+&B6<1K3:9B B
M"#.S+-BJ@)6$<@4FJW-)0W]40?5V%]>,G2711?^;U(W[O5XL;TPR3XU29#M-
MZI1<)!5?+-P\44F^_4SND*L_B1_WW7<36<U(:L-/_3H5;>_'*Z$Y$5L]\]V^
MX'6-7-*>/OQB\@5W^T*M)MB6OQ4BG")("+6Q(ZH*@F9$R$AJ]TY G(-@U72K
MH'7Z&>)P;2AE,*&:1LU*Z'Z0U(2.Z4$>,"+(HG5ZI\9-B#O3)N],\]43:Y9N
M;1:0GDW,/OJ,2^W^ _L!UR;^FK@'UV,#/\H_)"@5&3@;Z"R0R/LL:(8?0?_T
M MO[$[D2T/A  K:(/33GV^]CVDN5"@M0F-9]_XR)E_XXE&3,S27[[YGVZ,RS
MD%*0K/(L[MX ?HKPSX/O"I4#DOW4MI!!;AIB/T5^ZS149I )_Q/ ]QJDFR\F
MK_'C05.G46ZLWHY!@NR&LPRZ)"!;:]TW8JMS"R<-77T_<JG(_66>=XC)MW^G
M'R!_+ZQ$W)A3/B^H@ROQ#04-<$4HAJG(N0OBV3@\_W;5"F,WV0HU@).B6(&$
MON*"]^TAP B2!&H4A24V+0<<Z/;7<<7)?YP+V\0V*R_3M;*.*ZS8#=9[_'0;
MFYY<(18*;VV9FBWNO5%YJ#*;9-52'9+F/FVE'3[65?L]T5W?\]WBM8WH,)7J
M?ABDA<O2IX1L&4'6"P89\+UA;502[K45@OTS#1.SY<RWFQ(>@#3]VR:C=(^]
M@-R84K[_ ]JSY:Y 3T<#C#D;:1/_^GIY&="#4B[_E]6('<<!KI$HIO@ 3*0H
M6]/3%%=G@"W6&A&(OP3U@ 9(056WA36PR$3<U2,GMH\9;8OM"O7Y^O@Y8Z7,
M"H27-_B$YTJ&^;B7YE;E5NL3,:.V\7MW>/+2!"E80_3(PF(*[KI!2L!)P9/G
M@M)86(J28L\ ,#(XDDS']^$4T.[K5NI\A'2?P0XHY2*HD!'>K:UTF?2RK6V"
M!#6LDDL.$CE1Q[SWNGR'G]@62P[&_!X7)=S#ORPH$VIC3*;@Q_EF@E**LB@4
MF^,\ A1FVF^P"^,!$.[R._'2Z)8?6Q8>XWQK)D$IK'T8?6&^-#%>7E@:HU!R
M:T6EO>2T7[%I2#QYCE/55=@^CM2907HG87]XY%-JWKR%CUPD%7BYYFY$YW74
MFE2^9;RD7UK41RPTBJI^"Q9*(-G>$4JA$P<9,H&">B/8C&D?0XIR"M08\0#*
MVMG^U@.G((<M-V9UWW^Q4"Q^/Y38M^OGQ4G,J<9Y;[I/B9Z=T_,'Y(:[PG1@
MD1.R=1Z#$#S'A<#N4,FVO=S4[KT(4D:Z4(N83G$#Z@<#=, H?!7_(H0I+#LV
MSI>.CV$A]T!![PA^@,6R^9W'>@]\W<>:(E?+EM\]SFN_ORUV%9=#.(#=@5&!
MHMGX3.IN#C]Z09J.9SISQ(G+.&GX@3? S]>&H8Q]_,0PUI*E(I.QQRM\L^#M
M7%=!.R^2F+F1N-1$U)"(J^D]&+V,;!]9+6$AZ2-,Z8QU1'J9U0O(&6QG9O2A
M)/A>D %HLRUF7^+9#J#N\4WCCAN.1 =%'#<U54BH2L'5AQ6='/CBO_;W[:!B
M,[J)HAXG0F-UONGMVV%__7;4D+._7NX]37AX?JF9RT,MGX?NU[N6/\1WN#WQ
M/.[[).B0C]W =_AYL)HOGR+</Y)"4! :?>+#@7M8Q7Q>9X<@#W%=F;L?VK!4
M9A*SS=L*T)N[ND"Y0>RIR1O!8Y9R"X[* 6,4SV@X\4;1%@FQS_&X_73\R2P-
M2&];;*?O*(J"! =?(Y0,L&+H/.X"=Y7+,J#?-% 5OL$I^K(U:8*8UV7[BR-0
M\NB C0U_@_]-\,^PYU2CKT7&KGSG*7':RG<.ETZ<O7:_RV!P6PRX1!6Q-\]
M0*!>A^V"6..]<!'_&_]V:#)89;[#A*5ZL$C!<%G4%/AT7$/$O $04'FSL/O(
M!\KMF@C5X]MBJ>6V9;^.%X_[OY2X&9SEL!X@)L +C:#Z7IB2I<26TPJC]2B
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M?G0[BV\;/V_@"X0:V&DJJ>GQEFLHH9DKPEUEYO3]N"Q1%NWDQZB:0R6@@1^
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MBJ@^8S<61;H-TSQ^M:OD.3NTUE\(6KQ%)H?\1VW;%N,?D&;'KSXF\L].J7W
M!:&%*ABK#W+])@$*$&'+!9&\+18JG6.N45I1U<K:+53E6[4!MYY5>R\O9R55
M03'.T^3D36&Y5$W*6\6KIQ@8&T&'4 MJ92%>HY(1+;!>E#AZA14_@+@SBATW
M_UH)E@PHC=RE[ 383*N%\8;ULXU^D"=-J#V] 9.#\OTGBFS&&XP$QAR.(WE2
M\*[%]_P @M!MANO1PQI#C %JV_EML7U"/?ZN5B"#4R0H3V0AY3#>D"9.I#N=
M:79QTKM,4[\"[32B_.^G$-5+'@&RP><)CEON*?[HT$]SCE4^P_&'#4V)4#Y/
M EI9&#F('=X64T9<)]X3P;LZV+JPN#I3+APJ@Y.AHH6DQ#Y1!+LU('%'_*5.
M,M5$:1_U.3KGPA0))N,U7/^M47[]Q2=:[&:2\+\R[^.H(L>"3G]&"-$7-0UV
MG"%,?ZK;(I<[E^W3LD^I>:8T[.CRD*@X[*@9GJV00_(M_8R)WM+'3F$U!258
M&9%8<D&$(K.WQ78W-<*U9K&?AIC]D":3>V")S@ZGRE,BF834^;^ ZE0CU,'&
MKJ[*J=QZJ,ASO#+'+V] BT.2J.@L<3 UX80+JHAL!)W:AP3<")#&0,F6"U\5
M"@26A=,T!+FLF9D;S]3LR_4<[%:>+)_$2G_;%J-W'YJ,Q-@Q<9(1=-LLS*GH
MR'!4U/-6"L"K1=5<T'A<\YB5)[.RB>3+#@V:CZQN;/GPCT/U6]:#+$(F@X0:
M)$H+1XNE!QQW].Q'WUKI0<IB],3OD",E744P?=98@L1K'N?[+CP]-L8A&U)I
MIC(?WV"FEW^&4("0U8@M)#J?5_U[ZW'8"-V-EP$YL[40(5UJK.J,&W!5S&DH
MJ!&-L.X@BPP "1@>S,KWG**<;5J>AFM,$(^0.J?TFK##S[V]9OK#RF<;6OS\
M' *6HX8-XIJVU"/BM\6,WK%M%8?L]QFS#[Y/.T_,:#\]T%$@Z"J)C_T4#+OV
MR[TX9PY6%F ELIH(M %/Z24XN'KW&=J4J1LBW./2@#$ R8/96"V^P_3&L/7E
M3D$CWW#! ;6:TRF0ZY?#[\-<['KUB@2E52AWFO%-F8WG?F'4@VK\3GO#/FR+
MJ4#C_71/SN^AU1.CU%!81ME.5"Y<'T=_K &*TZ2S<#*5@/0=AC7DFU3KK(&O
M"-]$I3\'^WR$&?*5!:-@U5UE=,*:0\GP_MNC%XP>F1/X<IX#T]3FHKZ1F0X:
M:S%C'0=#I_!JIK?%PI%_0*#EJ?B:;TJ*F?GL.?R@@?@W[-$/59UM'9.ZD6OK
M0_XP_\*QK_-V0<5AC3MVCYU)&OC!\X*F07'6MMBJ,SC(5NQ#I&_B<Q'7J5#
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MN_PMN:ZD^P]R)&21>GU+S&-K1QG:'^!$(H3J)U:A^#;U4YR!,L"WAUAG16+
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MS^\\"K_J7Q+9Z#"M3O\:L.9A7F-.RNZNTNO7.^3A6'"!/&3[=^KPEZ:?D\L
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M[^%Y((NOD><*/M/#6*)AC)2SW4($,K\\F+=,6;&C\3W]6)_IYUGS8Q-G(Y)
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M](0=QPZ :=90L;FW9ZPCR':9#YS^/5P0N(&A*3(__=WM?,7<;N]EL< Q%GO
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M*Z=%=8E,<, V1QZL@9]"^X3A%53F7VJJ0XY7+<C]TZF(JS1/AC9W_@,]$%>
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MY?M=\,MW3V=,5"T<3JLUS^DW1S=4G[?(%_6-076C2>*<X\',\]F)$.%-$QY
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M19Y3JBZ^#K_F@Z4$'X0$!PF^4>&CNLS^@7YZDLT4(AS;8\ 9V_.TA*L/GGD
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M+M)2^=;3P@TVKZ*79<W(E]DN:5O%:>QCTXVG CTU^SY5-9.D='$C=GO6U)"
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M+*_F%00'Z>>)"&&.;$\R)>SAG4D!L,12>0XB]FU#$IMBK(* QY, IK_UY3S
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M^S66HR*NGUUVADP>]VC #12,-U9=T'IF8+,;F6>.F+'(44LX!_2= [Z81"J
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MSZ&N$+V;J]U5I6+($@7-W?/NP"L+/<U6&=.S/=9VL(V,<!0W0I44['V(NDP
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M+\5("G$XBPZ ,&/M[&S <""D(62&W!RN/]&H/!29%>0S;.A3U90O;[QGT/!
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M*#80C(@"@A"5JC0+16E1D"8" @("0D1 "!&BTD*-@O3V"0(*0J0$I$:$$(%
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M];.\PJJDJP;5/$VQC"@PVG07;QJYTW;_2KVFO9RDX_/ 3<3X'($:Q,Z>'(2
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M)3^]Q A%&@.Y5>AV+^A==!*L46-I_C6W.[RQB:%"A_&Q:F+6:E#?A@9+FH8
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M5I/P ^=P%>_R3''6I7K.SB[KK]$K)ON27R?OK*R,<W#8X6#T"+3C$FC'(Y#
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M7M+U>T7TD^@41_@L)J!U3_&S(S]:L1GWA-ML;:$^1/<5@"O1#SM*="SDA$@
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M#V7&?[\NDE^Y,MF']5BJI!QNA7*?O"5>'5$9V+,P&8:"4X6 _ S(1AM.\6[
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ME/G&X6,Y\S!1H^O77E7>(QXK)[B]G-P#W99?5@1":!&AV02_6?$MU"._J @
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MJ-0D:PT1LT]Q7AM::@(%UBM^!"-3I?@4K(D-,IL&=K@!M/DV*643"\2R2#N
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M:3[OZ^T"T7<CXR-O=1K6\=4H_5U;G]%_Z_'#^V_S?T?7&'YH?_/VH?S-QP>
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M85&79@>I9]6/8@3^?Q, 4$L#!!0    ( ,6J]5R77A0M_7,1 "Y]NP 3
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MP#*1)T"A'P/<<7,-R(,V6\RR*1ZVY1S[0RV=X,?0>%\?*'V-X,62-@^KO\V
M2^STLR9!N>!S)D"&!UI=[U.&7-\BY!KU+X-!UR?\R^"E67 TI)61Z//F8BC1
M)_=LCZ8_2;:_M=%YGRRH==G+\)?*5+&5C<D4JI=MTS%U78 AIE48Z@4L^XP
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MF/+J,NNLRM@;E$OG%8">(P,I6A'D6@+>L]5"09J$2/[GS*_<>*N-7$O ^]J
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M.#DG$]MWQ2:5:I-H/NDT= 82TYF"473#Y.G("UMD=L((F*%B-CS<(XZ8)N*
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ME#@:[_+&OYT)N7VU9G?]I^,<7)*Y! 0=P*TF1D%*S87#,T9XZL@4M14&(N0
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M7T9=0O,/'AF]@3*TA$HI68:VB3*T5M;*T&JR#&T[96C9;&F$EIR[M)-(AZ)
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MN)<6H XB '40 "C1 RF4YR1]JHR,3?I46T(S4 B0_^*A6?99E!:R#B.0=1B
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M6PB9OL5Y6P-VJ]F.13E,#?"4*%MZ7UD9F_2^M@1_W]+!W[<"PU_VN?G23CC
MWUX(^'HN\'60$A.@A<,P^:(-$*<BS,&'&%K@/_P2IA)JJ("4-M86J23RF)ZA
MF-;<="$TLN'IF%B7=*>I#&9O\=+) 0..V(P,'5/Y289S79->85X0L^"PV%L+
MB\W]IN!OK\"PN ->X6\A</S-!4> J;EI [REP+P$M%Q!0H2[CCD;:P8^0NRL
M2I^RT BYNS[E;^O!D_/QMW)Q6_ADGY7IX/$B!(__<>&Q5JFU2/?OA>8\(LZ!
M%FAWC%SKU)#.6TZ@J>#X<Y%N3?L?Z;QED]'IT.DRA$X7(72:S77SD7DKR^N%
MI4RIO7F0RJIGD^6Q2:]K2ZCW5"=]-VWD(KNHMW,.UE4(PBYC:P9X+Y^.["OV
M-A DO:B@<%XB5FP.),(T&)L/G'96#,VBC)LRW(_C*(;+1Q("D_>1I80AO9]P
MYV5 7/O>8D2QLACX\ O\2L<Z"U[PCJI:WZ\U4]L1XM+!'WKX<^33RJ3&.B8_
M3RQ-UTM1 ]TZC(ZL6HL=5X"'JV]8&#\!$HVW(-S1?N,@ ;M+)YJF?1E;GTY2
M$"KT]_^4RUU#)=>X?56ME,OB >%Y7I_CSZ<6HS_;\*_E7'5&+6XGIA%"!L?N
M>[DA6B:^H;3TZVY9>8Q?E>D$)GE,J'Y/'^T0/Z:6=_G8M%1FE5WN5N8/GTG,
M^(#O\P="%XZY! [!=E^+^9T1+L9XV^Y/I4\GZVA[RN"E+G6K\=1%*<*Y^A-?
M=0^]L8MQZYK!RMYP-4-S-*HO345+N+]@XS3UUY+Q6*M4#@Z.JLV'Z@^[\:-:
M:9;_IC_FM]@U$\;7-I2I:<' T/YYK)DGCR2E. ]7Q)DK&_]\1RV-XM:N ?X?
MCIQ_>^_.9VSJ:M!"C_J=TLFH?7K1Q;,J._VKT;([T3Q>F#R" JM .0QGK?X*
MA)A1S5@/$+%P$/? :75;6+!"I[#2M5SS$PL/KC@X_VW'\/V_-]TA'HX@3I%I
M7PV_X]&@4>1]<Z,AOL!'@Y@[,",E,N'45J3[H+"Y XXLLQC!%J%\8TO7'T$&
M':;N\6VKB:GKYCVV%M6,"8HF[FF%;"KNC\%=Q.1=^P)7$90TRO>\0-N=J6:3
M.5_/V'YOTKG?FY2H)M !7DQN,:#,)A/X&M,&<!!S;T_.<G,&;![9L3%G@*@,
M\TO'XBUB]X[JY,K<)S6Q][;VO?OOSM"7,6\4XHT-<T&*ST6.A0U,L>^!4DC
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MLYJ7\NH'YY-"44+E9-0[3H3RH#URM>"N%AKN,@%]JZ_@YUM&*(3MU<"0Y4I
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M?=@"Q[YX+=DT_@Z+\; EG@ID+U!!-7S_'6\5 'HZH7>FY0UG?;+5GFNOD_,
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M@R ]VD3V6) <4KA!D$(';!"D1YO(?@K2T_(G#B(UB-17)U(A>EB7QG4_!&L
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M@"#[\J\QDJ1Q970G@H]<HP7LA=;$A">O7VQ'3!@:SZMA-+VC.7VTO0I*>O@
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MC%KH<,51]#YG"V("5\E(WR'F+C##\FV'STMS<)*T FT&PJO:@-Y#Q^ &/-.
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M4G5%C)K*;+V<!1TXB,X1#(.!3B;(E._J]LW>@20F#NXB9HX)V@0+4_-E\T3
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MR?>(9>P^O^\]0AG?!XS5WQ=@_Q9RPR6W19%$_]+]@+Q-_AB7=4X[^^NOYUN
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M(>U1&P!I>]07\9(U!@%K[=4WIC2M1:EKWDVN^:9M"@0KT;9SN$85GGM<?V'
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MJQP:_.G1\4G0V=AX+^$Q3[Y-76-I\TWYB.BLZ)>CZ').I*@?9T=OCAY2BG=
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MUW%I'*AVX"+W*QJY#;(\R/+>R')OY%$;?^ Q9? (N"JYNXPEF2(QQ+V:(V5
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MH9"TLFJ9IL6DH2H/=%74%$R;FL RXAE2W-#V #%8@ERA2'U!G:IA"0P:N\]
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M$7B63X&6VYUAK"+!29IB"(^GI+?Y!X"?^N=0=I*%TO->CFZ8X.OQ8*B]EW@
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M(X/??O+QZ>(_7GQ]\R7AC]C-J#"R4OTAY5.H4;9F;"F91K,A?/.BS>^ZE,I
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MXT]NRM'M&.,)WRS^=P-#>\3T0R 3IM#OPOE]>;2_CM(T36.P8H2K:87O+]B
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M&>O=)F^W\,QHL)S4*_/C79D:#W,C8 OF5+?W<J?:B/!HKM2@DB(QS2',N53
MBCM0,9J ATHJ@@-,-V0$Q#BM3&R=1E&U:RXA)^,CH>%DX1A>A\B-$.D0ZYG=
MR^_D:L/C1+#/I>GOH,\DU1;H1=-#L*27HHQ"/I9T-48X4VA'_\P,0I],@=BM
MK/11*Q5>\S9PJB%\\*!R(TE4]A]GSW;@<8.A>289&5*5F7XO)0NSS%]L(2F9
MU^BLF)DBF#=@WF5/O--N,D]50[\HUA[74%,R&"4E;3B[^6+T%XJE/;'TA;;Y
M_GO8!2?:-FM12KIF+;K80I(DEI B$.=:8?%#&7=T08RUQ,>J003*EXYJHMT;
M'<$D-8A@_JV7NREW\Y63%*)962ZVD"EE24?I*=34H3/A+0)%*7\A(8@[2;Q$
M.%&,G]221-R_/MKC<H?I'M\B[N'8(#>47,ZOK'QS[^E$[^F+S^\]G>B.G'M/
M'Z3W].7CZCU]\7QN/GV0YM,'\052;:2S._ ;=@<0JM3Q&&!B$[HC7&<)W"K/
M@#@D@0?TC\8ZU N 19"F$'87TG[V\A"E(*?<@U3B$IQR>,N9 'U*P&9%NMA"
M/BF5@WJ%8M_Z]@"\&#K&].J@CTF!UI=M5$=UJO,KDV=?24'F[=I7]K&[/&UW
M,.L5%X-5W93;P<)6E'*[R\LV[@"!V]GU<X2E-DR3Z8Z"IAZU<_ANCDPJ<$@"
M%+.R@#0$^"8.KRPL@T=D;:7:#RH%Y2@Z@7UW"]>;%2Q=-BZ+5\]=F781IJ8>
MI2 NY'0+BRPO[A^FV4&=24C.(O+(\$* (BT6G KS3QB0)Y2X'N/13=FESS<+
MMROLM(G:!JBP"21HYS:A/2Y4C/.[:<Y"Q=!0Z-?8771OL/D1&GP2*"C0!I;C
M?0-I#I[?7E<#R&!OPJ9)&2Z).34T6H :^E#4&6,$WBNMD2?9417.%)A>!$'@
MD7N>G(G&C-1^8U=A<"#T.$:!LKNKQW04V!CL\#+ ?O  5]Q307B,C'3UT1J3
MDJC+[+( $5;>H90[!#OXU];(T1*&N@VI+_SDF$+)16(B_V/N):A=,@ F$PR%
M +3*RE_8@(%,*M7@6-8FT'WGLGSTS^S7?G*^^'@/;*JU6#44SU60U&G/4GVQ
MA4RE/1!]$,RSFV%5]CP<)YUE.'6VLPQ?;"$I&1ZC[G,;9^CV=#AA-TMPZF1G
M";[80E(2/-1ZWK[!@1QL/^_RM4$H=Y@FJ@/#K*K2W+Z=+AS/ I\2A%G@+[:0
ME,"KYH@N&$QB2:>Y"NI:HK$ 'H5@)C?Z.S^?@$DP&[;V>2M]3+/<I^1AEON+
M+63*W6[-JAU*)N4%''3(B@!HB37A'PQR'74P6UO-$IPZV5F"+[:0)&86%1TP
MU>%=EM4&ZCTTJ=?UY9;01&D8WLU$\134+-:IXY[%^F(+28DUMD"YX!''6&.Y
M)>#\IDN11$ I&YE+RCUYYTOC0>HAB3(+?4H89J&_V$)20K\Q>=5OK#-=%V9;
MKJ0L;)WQ=MCU*20YCPL ?0&,#.%&86<A3QW^+.076TA*R*4L:FQHV5@IA])@
M,71]>V" ]2AYJ(E!I;XMT\%(Z-=2.[X--<OU&H%8B(?'%4DSH+&2.?W$^A>+
MM2GPG6ZA6X<ZG;K-T"-R#B%!KVF88-:HE*3-&G6QA9RC42'6$<!9,%L,:48G
M%PII%[6&N/Z'$&V+;A6JY]^:9M=4@B!0=T)NDM2H@AHFL/N@OFU 8;>(P=5B
M]G1=E4A(@#,#!%75M-!%,S?1ID5O5K&++22E8C'XGZ*JQD$OTZW:<DEPR]@1
MR&Q9T.VV^(&^)K19S-:548.,C5U( R%D69I#PWWET';4-M6_HZ'VD373W0\4
M-XFMXS$HX]9^USA+79MH?PC;"+I%T,>H"3X&3H.Z>74DBJB.Z(T$0#5Q@RI6
M@0RBA;>./,GN%-":N*=U@%"H4;^6AMM] =!7M_ ) H[J[.*@.&-8R<9C) /[
M)3?S$=,E,&D%FT#?3?2K!JU_U]KY!\W!C,/UGE2/\-=?/7\E;<SO\W:9VY#I
MV=\^5N:P>+W"3O>7SY^_7#Q1M'E_LF:]EL6=)\G_YS_'S_[3'^ Y_\GVX.D(
M]DJCK*Z'MD:Y95F3816[8?DMXW/5S*]RKJS"/"TG57YHVBWMQHOGS_[G9O%?
MS1W@GPLJV!1!BP"!>>9E_W3'$26L9@P\J%=%]I.0>GN8,V!P-EHBPT:<J7A4
M@.)ML:&$PP=MS6W908S@V'VL^@&<+4829;N]67Q?=P.CVB=:\:7;.UBZ>S/_
M,AB(^T?S*W<>%:,86F[NK')K!;K&T;X!#O3(."0M G3MB\E8YATTG</^ \8O
MT]7 7SXCC$W$<D1@2B8&QW,P+A6V;AT=JG"^%03J#B83:A]JIB!8/DZ0B'VL
M%3]<?&*X7MB5ML!N4P>TR7+ JYK4/S%T@ B_@/QUBUN=1(;WT'K1!<!8T24"
M6N*  ")SNL?=F?Q#;0B:WL'Z^?[H/ +!Y!\'J#4A,D*C[\[+.=CD_>8.# U<
M7GB9E8,T:XW 'KM>@=2YCR<I(F.! -QJ:$=:E;?&] P@IW?<S7>,X$#AN!<5
M:$P!^_K7O"OR?VIZP6NU_Q$.Z@9PY7)/I>G*>X[V?8"TP;]H4@I%VIZ%-3<V
M=(EOS69H5\R8#-VG!$!6-*O! 4!MFP*PRB%P6@F'G+()>G1GVNWHE&$F./2=
ME2OD,A-# N\]TU"="07P\O.A ":&U6<H@ >! OCBD4$!O)BA 'Y//%2.8H(8
MG>RU+:;;.PQ2EDS8:NN$B(<17!CJR]AGHIX]]3![!]D;&7_ZMD'@IY[F+6&F
MO88[O4 <\VS2@6"G!AX(EXQS?;;6<?8?@FL$G'Y3$_?'WK22S(C15U?Y0#BM
M?>/F(M'94!3 SCT/UA^30]"3>CT!-YHR GI/9'XUUTGH\^TG^2EI-N@H#@%\
M QAO%4[5@+?")P;P+S@ XMC,@1>H*'+TDU'(5IA]$\X58L"!5"]V"W'\ILS)
MP04["XY,=ZTY@]>)/3M]/B&)%L+DAO&#CQ$]])O,>$2._D14A.#% W#:PD&X
M(,YYGQ0)XY>_?T/L\>C'4R %L+\@,0*F'89B=;ABPCIWB4Z70O.N+3BNII99
M0N^^@@6Q@8\U!.'R84!5 S+[*-E&B>!@6_FB"AP^<]="F+7"K0EEU>^>=]Z#
M$)>%->3#]EPV(K@4'DV([N(G&RHV>X+EQS *]YW@HV^'RH&359531AH;AY,?
M)1KURMWOL>H*?Q+21W3 =*,@Q3!BC6)[8?>)**<I)<#)JNG,C"2B93"5*3_4
MN862H8#  <=PXKDE8STS!\:1R>4*8:/['L]WS_K#2<O?PH#Q/8]A:_+:Y:#4
MH+!D8D.S+[1#U@NO4-GKIGX&%.U5B4U^,+L,^VN?5@,-Y?.;YV,:2DQ/U_6
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MU]:IB/APJ<JMZWZL[7#$MTT+J[,NWA8I:EVR:WJ[\3+"$^Z$7M33?Z@=L\N
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MPI<^CE_,G/0) .,K':4<(SJXG5")"!@F%M A!SZI42DQ=;?':Q;D*#AO4J(
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MPO!/PF8""(H[24;CH_D"_&QI_Z!L1U $,BV/ #XM]:)$O#O!-NB&%P;VR<:
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MBOIRG3Z,1&N-KGNX>BL\567L2>QI,,<JV,<^;%3D0)F-3HXQ/00CO;2JD%*
M4TG.%B+0)V,B5(,2^G^)=J7'^YQ$FIY :.5O[-Y240I2VV4_MGB!_KOT24DB
M:C["N1D-$:?0LHZV9D"@N[C+#^08 HY^1_=AZHQ0I,4RS"T+Y[4LO'K^V2T+
M4T7UN67A05H67CRREH5OYY:%WU/+ L]<'^%X\ D#;H"E< ;;+:EJ:MV5L#?<
M!?8=,?Q2S[ZN>$P,&QP=!> NP716H71$CYWO$:5>TZTP;ON^4TEZ= ANBBM/
M$YQDS*.UP][VGC<#B^DN<0)1;)V*,WR_YLA1)(<C#.\D7_7[R^Z^T15LG8!7
MT7!4MMPW%7+XV4?4M_V&W1+7B2S.$KI(5OY<;4%*!#>+U_7!>U><Y?><1RXQ
M8K^XY2R^!\!U20T@OB[K7, YNJ'#-\!/C"I^G"2"^'R"3H>$C5)U\!92'RE$
ME\+*/3X_8S$$]D'P Z-?33'.R* &5B:DP))C)\*X2JF299!>O-Y^XS]3.[P:
M.7:C,Z#/$UAX'BH\2L3$B=*C9C1(^4KX8%^1Q74T!-!,S2<%[2]2#$P0H5$O
M%6:I]1  $QB-?W%Z<"MX=29ABGDB3[1Q3](PG<(AK)H0S*"LH8E$IJA<-57]
ML95W"/3'6[+:V%50X3S$<\N9D+"5 B>?(.&XC^<%L!0:=:=U6#0B*0 H>[0%
MQX#KJ?'AWANB;V&7/G31J&=B3!W"Y FK.1%$[>_\HZ?$)5@]X?3#H\]9N;!;
MP5*0.0UE'<TN>Q.^(DQ&SRE5\EY0!1G?%64"?E6QXZ.QIXR[9JA[I"T[(UTN
M8(:IHI ^B7BDA0Q_@=<"7PF&\K/CMO_Z0']S[F63("D\@YD-\P_I9#@M3S5*
M>.NOOZ$W&;P]B#"" E2P"?K3=&Z4KFFW^%!?%;-ZA6)ZK=>(]X=5TLN?I:*(
M4Z<XZHX =R,RH5!A@@]BYYY5@L(:,CI'%)>H-7< FV<Z*"^@:^J[B*A340FR
M\P_$BXWH8)G,-]T]%PZPTD"G+G<=S<8J(SWF;9N! V;@@$]!:F8A[3+&)>X^
MR;G(%F^M>U7V U^9[\R^M"_VYR9OB\_$:7[[[L\CG&9H]>WMQ4<N-:2K^=HI
MM[LFI%$.YF[Y;M[!I4(1Y?ARSB/;DOF) %KOO\1;X#NA=!R:$(N/HF1);B>'
MR^0?\H=RIB+'R  )O/&/K84WZBW J_#OG6^-=.&KUC(-;<CS;V67W[8&*PK2
MO<:L.BUL6X5;%'!4INH[XB^A063CW=C CUBY\5W&7PU>++G^#GZYZSELA2[I
MDK((,^:0_]AL-A^+V3SAM5AW Y%[,^EN)K_ _F&V0"7<,O^Q:CP'1Y<S+&_>
M_<VW_T!+T+XL!E4W/&)!P%3P[! ]T*HR10C2T#LL_P&NJ7TA'S#7YK9!-XL+
M0[ PF&.(O5KL2U4_-.MF2F9GW;S80M*D+"YX )IQ>S6A)EJWO!U*5R'O6\?&
M4+*0R945W.>SB*>.?A;QBRTD.;5A76(KT&OJRB7&=9@&RB1SPO&RRZ<SB(?W
M,FLEY>0GDY.):2%* RK..LC$.8\Z>?OHZ02YNF#FQW.[1Q-D]"ZS=J6D;M:N
MBRTDR1S,TT02T%#H:+7LZ+","W%FF4Z=]2S3%UM(4J9#847O73H[,>OA)MJC
MRHP+7VRH@$T B&'0F]N6)VDQD0 YUJ4A5(*J,C@NFE.C'/Q4\LJ  G';[+"3
M%+$!YQMA4JIF[;G80E+:(P/*0(]=)[A/-5(V%C]I1!7)NFE2'YLS5RLK'LC-
M@)']+0R,.<7<P9=***M]5K;T+V]^CI.E(?)@.T&\UPX5UZ-N!QLX47D*.CQX
ME'JPRYIQ[R?D=M;/BRTDI9_8_.UZQX-8Q,%,KA-CQ]R:C2 A+;76<8-Z34^(
M$%QULD]ZG49=^?+/NJP=)#/%4I1N<//)_QSL*M:E?3=A57%E9JE.!KSA4Z_?
M5<V=O#YT'?AWQRJEW@V\\=VEJW.3_=!2X_ZNZ?IG/?0<$A, 0J,_&W94G  \
M')A+HSX:_,'DXM5+S!;#?6RV&(_%8HRTPKNYH'%4/X-V9="[Z++G8ECOL1O*
M'DT#$O"=HU5I>R&:IGNQ@O>$YW+"Q[^<-Q?2R[!M]GC9SXJ7$LA9\2ZVD+3B
M\56WVC2(F8*<'55O6LA3[GW;BW2*ZI%XC\+@YOOTD/-$K^A$R=FI5L\3TI[P
M*;IH9T5*"=BL2!=;R)3/"YV!4\A_2P\)D79L?V6IGF<()V8(7WS^#.'$E-L\
M0_@@,X0O']<,X<OG\PSA@\P0/L@EFYH&G._9W_@]BYD:0IBU_VFO4"I]<&MY
MQ07VN$"8!LX1A)3>T%WM9OOU\(ENH4PZK^%%7]8.$D]WLJHA34 K0[JGT%68
M/=N4),X:=[&%G-]<J6=+[54=3)T%61?_-]@/H].MH+FEZ:8'"R'"3.H;HJ&-
M,K"S^J3$:E:?BRWD9&K3:1#6'@ :!Z\%>!P IPTUY2U-@7C>S_ R,PXHEF>A
M9C%/'?\LYA=;2'IR:8?(HT3E$1.IL2-%J.4Q&KBC[G!L[C(VBA#4&'1@2\HM
M=7[YV;]ENI4%X8D+1J^G:=USO$&</\YA3I;&T3/[K<IXF'I%G@DP9J8%U"X<
MR$[?7K.>IN1WUM.++>2X-X<$#2Y060]4'A\%+$QUVM3X_XB.DYY'F\4])0:S
MN%]L(2EQ[PRT/_(0I1-84Q>[IG27B0Q16A,.F!S0 0(.61'2^#1+^[M[AX:#
MXUI$+<WSD0%#8@RV+?] DF+6E)0$S9IRL86D-"4')@_R=$((F7.R:-R&Z7AV
M=_:ZD%:.?=E4B++"N I_@3[+GX*?^)F;+9,:\V3UEY]^?BJ]D8+%/L) U6V5
M L-"7J( L4@4%= \)^;G#XAB3EKN,"<<'%J7Q&>953HEZK-*7VPAQR9G1L%/
MJ.".)EKRUSX'CJAQR% W"WCJX&<!O]A"TL6@=*,_S;X,->"\\^REPGM&BKZ#
MNZSH:P-Z>!4/8'J=(1AG1(@B3 WFF4A>55M JVIG54F)T*PJ%UO(?51%$FD
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M#-8_!:V1N90:#U=R^=<>R,YGW1.OT^Q,ZU-Y'@,A\BGO 7>I &,#RG"% K^
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M.7'-U!UV%?N'^5YJ'$50* SS@/F9 ^9??/Z ^<0(]#Q@_B #YJ\>V8#YRWG
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M3M>SP!527T3"G7K^1QN?F@+_^\4?W9>PA(2<I0YUK3)8SOG..G;)B8+_<M2
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M!-M?+MY<X/LN3P_OEZ(_UD_P6[/TJSY07*MD%L)FI):. Z$2CX)7EWAAN2O
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ML81:K31\[*MC;';WX=JY89>F_J]D9,*]?%!>F+3_;9TUR&PALXG^+I[_6,F
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MP^JFC=J.[IQ#T8@KC'$;.&\I175T3B8=W^)PFB.'_9C&QTNC%C>KM< =4:=
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MLP=DO@L<Z"BZCE:ZWM7UEA)R<\Y7I 2P>6\;"$14+1B <8 B6(>=Z@B\6MA
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MAR@ZGM:8U(&L!F2Q"-U4I:7O67A3Z8>4IC!I*(CXN)YV+95I.=R7B-V23P>
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M94)=#*=,O@LZID19?M7'U,RVJ:ZZX-DWF]6X&>JZ$_7A;4T:I$U7%P:_<C%
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MBQN]?(<LDJE!?[\QLD)=52<C$XR-[1!V6[RQ"F>4E"TY_3\O&(.#_2$]Z"Y
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MQ#2GQ)8ZBBQ4<'UW=;VZK< ;FT'4FR(+"\_;=19_%L9&-+)H"N (6/0OT P
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M '/?SM$7>45@21@!>D5,1'"/Q\YCMA'H!@C :%FIS)XF%QD43V<QA10E2,6
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MV8>GZ'2\:>@J&126J0'36]T"8U$S<)XMZ<%(H6;!CZL[H3(G;0FZ3O\:VA#
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M+0& US@ASC*\8---Z7R:N$&7.(")DIE:D"LH,]Y56K&"\\B23J @FMG!/A.
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MG:9G@P(H<+]$+#_H/1W>C;[GC,%.W(F -# =8'ZZ20R0W6J1$A5V&)3Y%5Z
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MJF"(,P,^Q'%J_LYT(WFZD3\]>6NZD3E"C#/=R#NA&WGZ@=&-?'FF&_F8U I
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MW+AMY&!@%0HB3RX2YN3H_VRJ7XLHZ9YC0@V'' AT\ATJMSG$[^ =@<RDM!Y
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MYZ#FT-[19X6D=1+4B&]\E.'BLW]:1>6D*&90#8XKO,X:%> / *$O9_WS$@*
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M8I''>CUR^7!T0!V("A2*>FMOD8IS'$3G5IUI=7/"%[E[@<#C(OR6'B7B33Q
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M*:=L),(8PGO;!Y+CHK+[N$:T*K E%?# /&;^>!)?)V8*CV6#0C8SQGXP%,2
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M<'+/;'S^R7,?]7SVR]$$<"6"GH_S'5NFB9 Q-:*.NQ:AGT,[$'#TZ6<V),/
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MR;M,*4Y0PQ-,$F#E)L[@//$4)!DQQP7#Q,G:L9$?K,OB!^G[=3YMXR?Y'I&
MF"'>E/>4258 &J;)%2<$XTG-]90 <(JTF2 RZ21"R].TY'!/S6#*:#2RS"D(
MXT7[@T\4UYN)(=A.^UR*:#X@ L:_25@9"&G7$':R]F?LS01+!7$[^C\W)>LU
M[K^6G W)'@B/+\Q2T"9%/7X2XQ?I(6I%('6C]B&Z6Y8DDV7:&,,0&@88H;4(
M7UB3F$CBPQJ,+(:X8:PZIN[K*/MXA82T=V QQ;JWL9 B>%/:)&#'0V 2@GU\
M,$I<=M/CO\5FWW!EHOB3%MNI*@CQC0DSU(-YH?805YSQ ,?A ;YX\M9X@+F*
M]1D/\$[P $\_,#S EV<\P,>$!X!M,-]J7UYU;;EZH(.2IA#W>G;@)1@*<.>A
M1G_G[5R;62($S>[,HE1//.VS7VN=73972M@K NY+!*GWE/3TQ'OC-57Q&S2^
MJX.:WDFZXDTEOG/(X#>5'_:\%[:^8*6(G4#GGMVR5YEX\6[5B%WP1%GTF!A"
MS34,G^RC8]9<_'_2(<6K))W(M/$II.LJ9@@P;"3Y-.*^!!DB.^@E>"K?7"\Y
MWYOQ;U5.AHQ&*I],1<#?G83R!U9O>) BZC&&L_:I(4Z<SQLMS8KBA-T#*3(%
M\2.?C?&@!'-R7>W)WK1I%$QKH^Y<8!H^'E<15Y^9ZQ#1 1-[=:\X-D;L])(Z
M!E)I&XI-*@'8#G2BQ^1/;:Y'?F8FV4'@!'=7R8AO,.4!3LLD70+-G2 70!<$
MLL[%V%"Q4")RVO!7=>LS*+?@@)3+:J2&(^6@23.I"4@@VT(W 4JRX &DX+'>
MP*OZN#=G$N61R9:,+4]0,6[1:K)="O "+ LK][[M7D>FY$2)=78/,F,H\IA'
M&A[<8M-]E4TFN#Q*FES?6TTJK'S-#"50)$2:W9AOYI'0,+Q/-V(OAVB2*")M
M\*;:O.5I^UN<L"?KSKM,]?U-O4$4;AC1I/K2AO.0\<Z"U<T4Q20IZ9.;-VT$
M1$2O>DB$X3NG1\3(I0S3*P (@=3+%XZP>J=*9;-?S=F!L?&KARX?5<^:>*-)
MA2V\&^X *%L6]#K!"$_XAY66=@][[=P926!34YZ<'9JIBD (.-<7^CZ%4"'G
M:YT\'%SS6J7%,P<!O\)*6,)RC&&?W[(4 A9*0;=*XL2*L3*=W:P\26BE&,<>
M\8:'_8J9MN*?H@GXK;U</_T?K<?[5Y;#\Z-H=WD8C.NN3$0'J5Q#<0G50<3F
M( 5C+V*&*8CKIMHP--5D'XA>XKIK[Z'RX$G+.2)$-#(C* 3>9O")Y1)O#MO\
M@B$.N)[93>DKAW:8/M?)'@W'3]]14S8+]/G0IR\Y+ 0]P!>FHJ1<>B$Z)IP/
M#"] &I@3BE/,?RB8(DDS\M/L-?/,]NCXYX4YGM#Q6/WKC=^W3@Y9QJ@QVWK]
MKU3$8Y+F>G53&2XN=-YA%*0593W[]-G83MD\>I-RQ:)[.(+H^"D7S;B](I0Y
M2NPJ/K5:&?I,;#P9NWX$] 1@:*\Y#)%I@5AY*2ORR $VIS+I!6'MO@-=A*Y4
M;1X=W4L6&<H^X<3 \=GCWCJJ-4)IFB$C2FI60[7S7V'1+,M;L-8)'#2<XW".
M17G&PQ,=+D0;9<JB'(<61R&,"[79J>+,5>73Y+H]##2!W(P9*GZ#F*\'A]Z:
M[+2WF406(NYM-PCRL%*SV0*%=4I6]^0^CQ"HC5TCML1H9L(#(/?/G&2I:\DC
M((5O:-%WC@TQ1[^)H:UP32?[Y8T01J31%RX[F!HB^$E=;D=]P]:=\6#>%N0(
MU2:.E'OUZ%2]*4*Y.. _G0OV,P7[IV]?L)\I*9\+]N^D8/_LPRK8?_[D7+#_
MC0KV'U@X]Z"Z?M*(I$>92$6F]4SK<# R;@(E3BMY/C5K@.W<+TEG.6>;Z+3
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M:%K2@I($MXR[&OG5Y='RE4D+UID?=1L#FU2Y%?]._Q1QH7-/*"R?-<JVE'F
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M=</*G@9L%?)M4&S]AB;Q_)"T$];?P1V#< DG8%R@F;1/XA6_B! #RU1P4]#
MTF$8'EED6<JE&<"8U<J]NS[E(XVJ6YZ+%%%0B8:3J6HVEXPIE?>UW571N#F*
MA<D:PLO=#5OK<]A4 W>C(U&6.$091*=$KH-K+N->1CU* R;4_,SILJAJO8/E
M?8*$P0 %[]WLE\G-K$RNT@Z132]L%6LV?K+[.&IF2G="R4$&=QJ$9I(N"ET^
MY'G5$H\(#2)8&W"VDSZJJ<U$-W7+/9K")([TKL- 5^)V8]V*E1EVBBTA"[6L
MV'S[Y-D/KR0(7G9#3+]BEV^M]6 Y06)_0'&1:,I5FT>ZK(X2UN^*6'->.NCM
MS[_[OO^#2$F05>)@T=!)6;\ +>AS)XF#O9+MKL2ESW7;7#W"NMGE#SN'2IXB
M7@*:"BTHC$@V=#1O@:5RRX&;WGU08:.715^YJ.;&%+8&AWY=FAG"<2J$X_.?
M#^&8 !G,$(Y[@7!\\9%!.#Z;(1R_)0@'7S^(>EQ62JH4'<.N$^,H/"JM$=6@
MZ^1BB6]];B@OEX1B:EV"$U?VE=B4&K:PO1&%\PE.I'['&7&9)VF6!\,)$JBW
MF@*!)=A51AK)@@O')DRL@Z(7F.^;<L#6DQ@M# ?<24;B]Q&ASH31RTW>[)MP
M+K4=>_T@]^FCQ$J L@^&+D[V$CU\U/"#& P]HL2V)8R-/&D2FN.^ES%( /%@
MLGDE/HD$XE):S_@*)KK76^G^.;9JL66Q(?NPG9P#3L)I/L)$TN@N$N7D74S-
M",IBT[.3AK&KJ$$^HH<?6_77?L/3^.GTA*1+J;CX;>06JVW\ EU?*ZM;",_)
M$.)DF1O"R6]>1G"@Z0&"ZP-ISR#RB*LJS,O-+.W)?W-AVP<5MG&@4[$9HUSS
MR#T^BCD2($AX8;E/]ZMK4PZU!,-[6P.AASN'\+-%;N2Q1>GH$3-H'IRXN(('
M>X46%F@KC-;$ZNYS"L^=61)6=D13C%J<CJMY0("TU$C*:CS<(5R&X,:7!0[.
MBTNSNP5OL(.\9=> OK29J\3=Q^;3XV,Z/>CNM9'#R"ICYIP@K,CIE0HUJC9
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M%F ;KDS#"RQ%#7HL:RF#XD<UP:I=B=<>=(#M% 41#\,*J7UF5"?A'HW02RV
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M.(MZLQHL;7@P0=>^?&WGVKI4'Q-^>V5M.U8#?H)\%H:?ZZ6^3 SG8C=ZF5L
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M(M$4!BS!.2JH@5U7<"1+3L;1O7T M[LI]CY]- VU2!!S6'K:/-J'JI-&]R,
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M(/\</;"ETN0Z 0<EX#5Y)V__>AU UI3GP4KGZ'QV*$EZNB\"1VH"5DX )/D
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MR 43Y_H/(VNQ^ 1-\A ?XA3%XV_^U)-(V8T^35-^]V=:J#_]$5^41,>3;_[
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M.9J/M,O.R4]_J "R5[Z89TDK/\WRZP!?7G6%IY;[!>Q$KZ.UM BM(UPITM3
M RCBT^>-V+C_^3^>?/'XFZ>//[6;\NU?G_\MK(AUT?Y"0XW(_2[:6P%%F?<K
M9EE=+YY\_C^/[FM(6RH("STK&1P-OC %A\D3HOXB!RE#(+F%MGF2473&+)"
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MV/81*XCK-&3>;ROO%'=&&CO2##@>/VRCUT=+D#KQ7")MY_XW?/L?6]^64:G
M['&6 BC\>DPQIECDB@KEWTW%%D6XDXWK*80,M%Y/V\[ X C]!8EWLRXY[A==
M#@!BBJH.3MQPI*<%#'YC87#@SG;LVYJB@\TG#,>(6.!.2&1&RM7<AP6DV78[
MB:78OP^-]RJSGRTNP8N1$Q2A4PM;3>-GV<REOWUT7]D54IF\:>N!&YB'@O9
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M]T\_?RP>YP:$/<Q!8"=#9]W.@^%+L'[&SMKABB"#C!IM= ]<P4]#T>V01F.
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M.4'G%>,%;FFF_76UC:]\-BVPMW3VK'C 9BM6^;->^"YSA0#I>,K%/R[>7,3
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M#TB0"^%PECJ*HI?*77*5*Q@X_/=+PZEJWP*)FQ]U)NA'NRB&LLK7(N'#-Y@
MK1;#F5CEZ/:Q8 ];K,0ER^2)6/9CYW58NF,:<LTCFC4O)Y&SYIUM(J=R)9]\
MEP0\ZGAE._3.V.JKTD(YYRLG*Q"SX)]M(@<%GWO(N?"N,'DO_G'QYD*X]>E4
M%[ >>OYR3+0*^T;/%MBL#@>V[T&IPZ0,-P95=$#J:8,*"/[ ==U+;=+!7$7M
MCOLZ6HMK%O2< ,R"?K:)'#=XM'<83OI=OWC^^GMZV/-OO_M>GGD#:A0<])4T
M K=,P'&%A6T?6G2[AEMJV\#3[KKJ2@ON8.:$K*LA"E1Q.S'F:!77 D017<7%
MXX7-K8/38<4-LVA\^WYG-E'%26=OLJ6X0'7;XW'[2U2+[ KTIJ7/].1&U85R
M-H3.#-2^:S=<82Y4S6MISE4 >[CDR_"JLTE\57.'2Y3Q:/IQ=G<FM&+6_K--
M9$K[^P%)O\I6D<4)037X:@O"LFE\Y_QSL^5=Q ;3F8TIP=K"H  7"+@UQ3M4
M5LT67UY$9E4XVT1RJC#J/1>TD8R"T&EW-<'J2L]M1IN70[_K]K;(8L1.C,L/
MQN/K%]\]^NSI4UOQ<8! /.<S882S%LU:])%ID<7V3N!_EXLKTWHT\">^4GB#
MZP/!;)A9-1IY*D,WV(P-O+#KMM_A0Z0_?U@N3'-3=6T#=158<5YS!(IY;8IZ
M=QWCC34>_0_22'KXFYW#J"'%2E."$4A7'KWMXA=7M!'=P$?8'_G-M5"%-LS(
M),R@ML.H9.KHUS$?F[WZ@0^$H2U/D/*V:'U.JE4/NU;""3'2Z1&HI&7:A1'N
M]PVD*<Q$:"E='[9CU$/>M6,\TI12VHYJ05_@_<L"C-B+D6)G7VE1;=PP:&*N
MD6>T"DH3<['XO^W F9FANQ*HXXI^$HAB9VXJVFE(+CI)DD?#5EB>]V=3O#-A
ME]5PLSQ7G6UPZ6H5I5'JB=7ZKEZ>'YC2!@3,1;W<I0NZ*VN:E3;!_1-= (V5
M<Y%4_/M_T55*<K,BN7M-P_W/__'DB\??O)2!_NF/^,Z?7=O<M33UG&[=?;%X
M%L1IPMF&,(D[]O'TC4V/]O'DO8SZ?G8&Q@ )8D5+$<F HSE\\^(YF$33#J S
MM=$4M=%G]T!M-,&],U,;W0^UT><?%;71IS.UT;U0&_T;C9<<(=()E3H7BQ](
M,SA+:W[6W?1/F /_D5B N+V?TQ=?DB>X^ YVTJN&.VCC%1]P>1UI=1X4^-OF
MY*YKHD1RUPBF5GWX:\&5[,;?X NH&M/A[FA7T J\:DMQ;/7-TBTKN<1<NY^8
ME,B^3$M&RHM,>^N'8 F_6@<4#2=;O]%7 ELV6KF172N(-VW&OC[0N7[$3"RV
MS:0-<]C.?8;&&EK&YNT8K@+P1B>9)WF[,^QF=E"XQ]S'FY9&O-=F\9:^6<7H
M@(45]8 _]E(KAR78,-B^]F_MARWP&B7"HF2B!Z\X_F!ON)-%B;VEAR,'"*J;
MNB!]I>MS,)S6$&);]3BB!9B>I$TMTMN*=_1E-%IP*H:HD#M-;'_[BXG]*5L>
M%V*[#1T&PE)=0G3?\0G3TL9?%<*P38,?MJ4-YJ:CJ_S))I'?-7@6+#BY[1):
M(+9C1N.-YF_'SG+MGSBF#XYYM>6-( 2OA;Q+2UQ(1NOBEJWY=M&W%[-!?;)!
M_?D]&-03%M]L4-^/0?W%QV!0/WG\:,,7/-G43V:;^I>QJ:^?_%(GPFB=\C9V
M]I!0D=B]_2ZS[V__Z\7BNQ>O__KB]>C0S<[PZ;]IAD\^.]GR^XO3VMBTM>OP
ME^^S*W'2_']10S?CO7R@\?N6#3%KWZVNN[:AH5Z1182^TQV]L]>TEX8[-X8A
M@OTH1J]& KL2M:\M-^_-:LBTPW;L91>+5SNZS8UTB-\.'6)I$B6EF;57>#!
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M<%V0H]RS7GO/WA\[?7ZY@R66%"F*E@T>QXX,(ZEIOO"/^IW9^J*VY[Z[LEL
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MTB;,/L4WCY-V\,]N)W/NR("6LY713MR1G"J%GAP9W8^C#.OIHL4LA@=.1,.
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MNKK.5-2E.9C#YWVH6DZ(UFW%QW&H8!ISMTR/':Y:!Q"9C[L K@Z<!O7E(]C
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M<8G!WN>R,'?.8R+.158L5&V(U]PS(SC4 ((U5N)&0RRSK;UB] &1>\]$CFD
M84/]ZRET\-&X-0>-@03@J5B-JO"%:3.JHE2^3)J-F-E@]'29RJB*+'$F%O27
MX=CC)VLQF9G1>&889=^1!PFC/Q8DS) D#+B%&)/AF4="R@[9!XQA3U*;B<XF
MREB-_GUK5JKLSNO.15RC@U@F,U3@U,Q=ML.IDZ*JN_(+7V%E(*W68U4CEX$/
MRIA%@1-]%!HX\=8VLD[>CU,2U']_[HP>!>T&[T@HEV=HVJJM"74U9@.!\+>"
M\-%DZE1P*H/008-+1+5(9;K;Q;C6D^"4HK++6:32:O*D(?LPBY>FD,6KBW22
MP$G8,7(O=9#%69$+K=[&8A(W7"K.HZOB-)/6*;VM8P;'/!"#IG? 4DH*A&+G
MFA4[]<Y/K]1FY,BLSB0LM(\9IRN/P!#6Q=ZMHIQY3^\\:OXR): 19%E\)0)]
MX6@BG#J".=19G"%,L<>-P$AN+KO>RAB+;JQGR.EEL)2R:,YF=N4B'-.B3,_1
M[*_BC Z"BX9P-$A3IK=@0(<^_;X^_4<;Z-/O:20/??J;Z=,_'EJ?_L%^:-0/
MC?K!J+J%C7Q3&<:HA0YF*@S1E:9I7-:$XVX=!@T'XRPMVAHR-N<W+,YUAMJ'
M!69:=%K3$=RR$>Z>5>7)O#/OY%0XI;((+3U>J@W<>6L;N9H[_R62<5/-1EXR
MM@8<\L0Z>M$Y<TGGCP2.1=P8Z-Y'#X'N;VTC?72O)U3++F4]@KZ- .- :"\*
MU9 MU41G?D8@>!\A!(*_M8VLW<SA&^Q"^4?OA-2QR(H+>_!9S(BLUYF1^A?/
M0>#_VN6#<HCJJ3NCQJ>6U+K=^:EL_=$,WN)RB6&RFI[[(_Q,LR,:.#X9O8)=
MB5)-5%&E?;&< CO' !_L2U9L9$M[0J6"SV5\W!(;WL2U!LMX3\/>G99);N-:
MFGM36P&8R/E8D#Y#DCX8#"D:6=.@2A-:05M_OE8ULGJ2L#C/L7>&L_8;UY90
M'S'Z_XHA3:XM4&X>/J@3TIDNXC*^C;ALEU]7X-5D&-]2-I$%+Z.P8@PF#<']
M%WDN+TP'[H4>X.6<3Q=33A+,(@-!R2^!WV"+,,\9[X/&25*&  :W!><61DTE
M0-MQ[!]S&Q.5S&  +/XP/G*.H'+%"$>?8_7-DN:<P_;QJV6<?Z'LOY;^\$M9
MWCZ)..JGQI1J;E!G0OHXK=VS<39?BG@R(U@= @!RU)0;R?A:H!V*99#_1MNG
MF8XY:,@*2WD1%Z^J._9PG"=>M6S;T'L1$(7*OEQU)61?U/$7.OXY_-<Y!#Q>
M?:3N(<050YH)DB]4A8%9.;0?2GG,W,Q.)2 +V6S7\SF>.:^&018X$\>:#<E7
MV&0\ZJZU#H5#UM[A*!HW-1")A%_RG0%V0#03K@:+"I#E<9:UMA]GRRK571>*
M>HP(C,?P/5M&8C=A4U5F>B?>V)\-SNDK<CG,VDW&Z2)6KB9S!WIV=Z>O/!-G
ML@2M$PTPLG&E.)L=WI0LZP3>7?%VN+^V?),IA_KSNX\?/8D%MPCQ(_5]5!HI
MG'G2/H,U3F6 0OZ$4!HF("]0;#J(":.(4\J"JZ>*;O<,\(B%:GHD44T=.F]_
MI0%Z2N<@+\'^OI\^X*_J+AQK=EN_; ,;'_DE+4E^=Z0<C_%H2SK9\R>'V[KH
MA??3]('"$>4$?B+@WE!RFZ>O+8B=[;M"&3X-[U*[UMU)Z'[H: 3WU%,-J6FM
MJMWQ>A5X2EB7,'.':9J%C<PY^D%P":#Q:G!5E'!BO'1 5OLOYC[^>4T+S</'
M]WZQ">6CT[OEFG /]K:4V][DVB!RZA&O!Z*G><HA-:UX,,=AUTY8,AR>+66[
ME.;TJ[G V8Y5M_*ZI4$LBR:VAL(JU06T"%I>;:S_+MO%EZ;*K&U"Z;$U7+^-
M00RB&#8W%5AH1]ZTK,H5!.LF?J1^5(!NEC%!OBP]D(1/+E)V?<!.I!$4I30*
MY5=S#0,G!PE9A_' JT"#)QX\\6MZXE?[P"\T$-LK+0).E19A>U^ZO+:*Q$3I
M!UDW=<J.NY2^>]%GK^11_VO-FEI7E7.(TK;)^Y4UA_!<^#K"7I)UY.2ORC0O
MI9$Y1F$5P#DMO$ZY&[VU6QD.+\EQ;G6Q4$A2+9&C_L>KIM&R5C$?C9?E4U75
M:#(<@J\R'K9'HNX 7.JC((%V5P*U-)L!GJDJD#JJ5-PU*0PXI.8G^+<Q4;25
M.[(J5=GX(/@<CL47W/R/4]F]K#A+06B4NI$*C-<_N'N31JZ/FS*/N!W,<7%A
M05,L[\HGX'>#,: [Q.C]=KN8F6G T4]4^I,9B#T] L+N7I,BEE:2@?3;YN!^
M8.@=9VBC5WE("@<Z5VMD!8%E*UZ35<?V$?@38\QR,:?33,6Q+"\?<R4W86U4
MM4DDV$H:_H4*'?XHR[X1SH13HZ-(Y#/DYD0V9T;Q!=CZ:F2G7S I@4&MI(MT
M(;!\E?D]G:L0 ?6%*L=<OE=5HO.KP@@"+^$'!K^UC7R=SW"B25M.".K:_E:D
M@:,!P3CUD4 @]5O;B(_444_):<XVW*G44X0)Y^TC*J)I(]5<D9\5%/G6EBI/
MHDG.4:G01Y2BL* .O(J,VQ[(_]S6HK+ +3O,+90%U<@22PMWC?#$.4PBC:HZ
MG:/CQ2X0(P"K!D4-$-P-K*A4A0J"2#.)(B->EK%B**W 26C:NZ.FO>,--.WU
M=)6%IKW--.T]'ES3WD%HVAMVTUY0[#NLV-MF<)J#"4I)5C:%QS+_@EUZI.X)
M_A^A7BV+6 W.%9C;2,24*C46,99Y%B IP)A.L&:/2IP%@<)B5K7JATV6,5$T
M',:8&^88D8[VX/0?JVQ4]?:OBB(%J]I'E('Y;FTCZS"?,TH.N$?6WB%(\AD7
M.^K::71"Y=0 .85'VL^^>1PCP\R@SK! P@\U!WPW5E,!J/ #.5_HN3]S >Q$
M54$<!#+8&EC$2.LST>%BP1ZQ/9;21&4)Y9G#LY@.!8\!RR@Z45_Y4,GW#YTH
M+R(*8ADO3KF5\D&Z <;-0$QFMDTTZ >"+L.?@*J>/=J=P2-!3.RPF. 6K&J&
M^9.B*2>F.+?=0=&N3E#%NZ;ER\:I=?!\3+NCA"_B5WCEA'?FCZH VZU6R<!8
M.\Q8;?U+=FF+TUASJOGJ;DY0,8'*W!,GJCJ &IQ+.77 "A 3..SA_N'37L1;
MFKB0B*AL\HO8&+=?Q-(\&\X K?2<@,A CX6"@1[""PQV:QOITUQL+(YDB9O,
MA2MUA<9D-"Z+..%R6<:C,TXHC@V1K,<]NP8QNHL#+9/Q;(^FTQ65B*9J#U[
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MI+EN:DHNL ;BOJ]RXD5::,7X2E<]G'#5PX.U#FR ;*;RJ+ [H&KD')KNP.=
M:%>,I0-46,B#DN+>_J9DOZJ-NZN:UQ$Y9\0E[;%5,K(H4BZ$1?$\LFOQ\:%N
MQ>>I;6Y%]V-4'E-:[5ADQ<4#62NOU>4B!HW63D.MQ UBI=C=5B4R8$[W6#!\
M $NP/JQHP]E_MU0/1;3(0'Z7W!B@#E4K'/D236J@D#."#9-FIM6&1X5&EYA(
MQUZ%/;V^M**V]:R1*>ZTG+,RGL&2K4':UI=15-DXXW&VQ,0C%P6CWU78+0>Z
M^);/%=YG_7%O6UGA?1[]O<FE!#T\&H&8.7P\TJ=:HC%6,GWYZ?\^JAU0PY,8
M QE@(\0N->"%/Z!/% CJ(J]>84I<R,LA;)PZ0V2I'*^.#3A)- QFH6O!%/4D
M"LX&_MK= QH:H/6J%6L?$8&,Y".(,A,:I@DDQJ1)W3&D!4V=AK+XX&G-?*%Z
MNA/PWJBR/0'%V>('"AYC&?U<5JL8RX@M)I?<&?$>:$U%XW2/3BE09G M#<.!
M4^F\9 "RQ8#"E)VIC[I7H%A"8[QTSD=5V"OQ8G4$@&2[4JJUK$?[T7T"IX5E
MXN%+2U<IH[CHJC&\S)QZF"IQ3CA"RD2!/<VE7_[55KC"%6H+++40I&?T*-H6
M=%5DRE;R."D>K6(L+]E0+8WYV%GYN6[ZPC]7[4HI\SPL.NJ*;>S&AE]YRY5Z
MB<8IN]Y:N8=$.&W0?82_6?2CCZ8E;492W/B$)8LR%9NK.L; *DEQ]](!%6==
M(ZHG4==)GHM+WN$+K>E6&.^R,!7!NLI%478*:1#:,Z6EE(*<-%3:>/J40BNU
M3]F6[A9+&]^"K!Y\G3P3=FAP.^A#$/JG9*GKW.V>PS!N+ F\H 8(/>$"W=@5
M.ZUW:['0\KW(F&0_O&,;+:GC(<7B1RHAED]6S0WMB$UG:LIZ&IF5FX*#E]@Y
M'*%6GWK@*Z0B=QZ6HO#7%)[0Q)4(;90#9_]]HM+HYR*7X+#K6\VQEG6)K-ED
M -EK6-,K+.:ND=RW"15!DINQSA5E-,A*YRABEJY]$)Z.9*6S3PI1260(54-.
M$!GM"":^UJ);NS*>CD'A#9*S$LV AX@@Y*>EHCD'3_J*:CJY0E6_RO7L9L\+
MKN?7;^D8@NXB2_=K]C(ZQ;.$]83RT37/G:71TRXH9SA9J="<1?-CNXHL%-/U
M%=,]VT Q74^U5RBFVT@QW='^X(KICD,QW4:*Z6[7N+XB)NFMRMN4R=T*/3O*
M9 *&&3YKV;'_J$==&N,+VSP9LA7NM8B-)>RSI]H1]]56^E4FL[;-E:9T+LI:
MS5XW.*_(0[+7O5]:N-VKP^F/;I1TW<1!*YZ^-N5^FA0+X:/8$XI-P.%NJ1?\
MIFOM]7B).DN0/I D3CBA20D*DUUCAT@M-_E0QN-Z!]N1^SSR^AF=UQ,36ST@
ME '6>6AI[0&Y)TC<$QRJ)WO)[$XNRBN+25.;"(R$DGA.!0UF@[0][6KHAU31
M67$N2MT18@ KG$/0X!5V,<_]DP?NN?EBE_*%GYJQ$6-N,.K^B_[''#QQ'T.N
M2#43+##4BJE^"FLNP)J?IQ7YHB:9]J$I)[,83&GSVOOX19FBL[]OOH3C=Z-/
M^"*947N@@B-:6'6"(PN@->SLT?,/<_D5D],\%Q4%\*BV=Z$6-K&6L#!; &_)
M1@ANNW;\V]7[Q+-[X&1;>@H@'SR7A2::8$AT%NCY3:G]QXZLO+R<I>.TYO>^
M:H=(R9>EZVR_!5]R;KU#'0S7+8,*E+C/B/"D!C:0XZZ=9SN*@/5"DG1M%U'C
MEYC*S31/FJHN90&H[K!>ROII >LZ;VU=P;;@(T CP:T1$X(L^B)J1GBKVOK,
M7H6#86,GMO5>ZS+&6(H<[9+R5<M(!A72Z0I2)3(2/$5J A.($(6KAANSNBGM
M@&@"&E%.R3%2CEO(4I4/8/C^GJ &]:I)I8"L3BUMX+HS$N8XSBAVP\RXXB F
M1<DM\20SM!MNGC3A6E@.?SBB=42R04;OB1AC!8>CX/YK76M5L&S)1'+6#1L8
M3)N>Y>CTP*K5D+0ZY14! S>J_\[9N[B,$?I2SP^),T2$MLTW7HCDC4^,?K0.
MB[IVDH-S?K!W<#]^P!S<BJ;]FE:X)RR"^(3\VV3B2B8]U[5PFG38HDNILQG5
M*JV3&H?1=!TO>^]?ZC\QQ94S8GH!#)#6N@J.0V1@]Y6)TEZ>EF.XGHHD9&SU
M* /]:D'!9:CZI*TU<(4U[@J.1TZ*HBUA I<8S@B8J@;E)D.8.E_#O1HZUV&^
MV*HHLR*<59MK*2D#<@/I2NFN'B-A:U,13E&4VO],9(F#HL&-J%(<MNJEK#3.
M"IG2I@[UL%@:32V^9;.H8F&N!+NF&]E#0Z6C#MF,-(\V8UNKN$D]W>3.FHIA
M1)6_HD+AUW^#*U,(H;!=^2#=M+67TGZWK97L *(A71H]BR!&8%?#49%'5SJ4
M#(>/A)OFB$RPW&;"/4O/>UT%6V?*W 7;[FA*(]ID/%EVL@4* IF);$KVO2TB
M2+5CEM5C_>!\ /B+Q*]A+P%^)[E(%=^##&TENYW0L9;=8[HV2]F/)+%) :4B
M_[0K.;&.0&S4B"W\*MA08H$U%, [YWCX,H! 6\.@/0C%/G&XUWF7]338.#UO
MJ1_C'!.^&OE('7-1NB<+.QDYMC$'!,Z4&($/UC0[R*#?,/EW?(T#Z6O8WL%5
M!7R>L-*]7U[JM__%.9$H>DN+<;L-'HQ6W83I"\2]Z5B,?5;^>^F>N9R2QM,G
M+ 6ETWHR4;:TBH\DN_/L%7G3L#I!13!VK].('HNO4H\5_!3AJR X%_ED.8HF
MH$W3^@)-&BF+R]:PE!YA*>'75!;G$[5M(?N>RM0MKIV!6FC%9D1\%E^X=5'C
M./]2-HL:UY/F9FW3,F[06,IK]L^6G*HL=>V4%);=<Q:7"YU!HPA:*W?&E4A\
MN]+8-DA4N!U"74*S_0PMQX*E+@Z/FMBSMSK#Z/"!L'DI7"B-V,HBCKHM!F[6
M"ZROI2L<I.B3N@:OOJHX<$ M"2!:NJLEMPN6JR&E6F6%JU0YTS2B?5949 WO
M7U*Y<+[2 9%C.%<Y"1Z7H&W\@4B(1Z[9!P_]0\BJ.<THU&G!Y].5REIY.A4Q
M[5K4=:M9N@$C[;-T\N7ZZT0GN1EKAG7GJ,U%;N-U:4->%R_:@>523+%N4M$D
M]K HV\E15>I&^+C^:)(S)@]7,WEVMN>-!4OFH2$YS#V<@R6Z,._"")MU,U(.
MV.LO'$>?NG1HGWO="%S/F#E[\(,D/P[L="K$_8Z4BC_(IY-[Q\TEGKFW-MH2
MO![E"/<"F/E [="@=)O4ZQ7+.T9#2KEXZCK AUS$6(4XBN9%8BEP$ &8@Y=6
M-WU0YOPMDY+;02JS#JEJ58Q@Q;F>9%DAWW6*<2YZL\L1:_F_ZF(L#]0"O5,=
M5]BE5B8D&S2KK!XXJFOP+#@<E ;%I&%:=KJTR*L'K0_6"&[?J!8-3MR:Y=5W
M+LX!>)&"+U36J)<4I6<J8;:Z794KXJ[MX*DO^"DG)<9G9ZBA0)>?E3C@<!)7
M,X-^C"2#=A9Z6&X,.50BK%N)<+C_[94(?:GR4(FPF4J$@\%5(CP.E0A;6(GP
MU64';RA_1 +\A$'HUU&;?@7D5O/EF-CGJ5&<L?@$6FV]Q\O@U)7P==JLB7G<
M!E<8,&A])."+Q9S@>:W.:/R(T\.\GNG&Y0%+[WA@7)5G7,!<Q*HIT8FK'SU^
M>C_6(?73(K':=&C49&<A5^"/**?IRB!@+U*)4MT:"M"D<F/9Z&CF)#="6@@E
M)H-4EEE9D.X17&G7@6%)_I*S9R=KS;ED7$S7?U69+?),9'Q=PJ)65GQ1A<97
M# ]0V^-19=(C*IJ:7?W.\+.^HVYYY3J@4.3:Q--=RFWT@5;SA-?UUXDTW6'M
MM?&</-!>="*=!96]:[FM*SU$'3["J_L/]W_88V?=!.7O'ZMN52]9C_)+LECU
M+5A^DV5TPE&?=42"&T%P/#K=7>*X_>BYU,761H]7MM!(RDXQ2Z;\;"7N1BJ?
M;((1QIAOW0R>MB9J.[5M0J4D7(QG;D4IJ,A\U*DRWR/_@#O6X%;/158L5'!G
MJ03UJ@2QICQ5W:T]S5;<<H&OY4QT):C6&BS#*;4V.HFOGI>Y@>6*Z]4P$U=D
M$G+\>D7W7U=<[V\E,U) M4S%U1<9LH?5"Q8 (XWPH0ONU9FY X!E_3T"DL@<
M;%M9J6VVEBT/P9IIC4\EWN$>,E5GH.*N!8?_C&#&LGP!YR7:N2)==L\P*?0>
MBJYR;"X1DY3 .5K9"(*:QE"X*RE&LM1$>[' CZ"J)I2NDA%@:W]7NLEM@"&_
MSSM:T^$U&?KV9ZOKU-.X@=78[HQ(<]PN_43^'Z?2BQ[[:8WM2Y6IS\T*_E),
MF*.Z5'ICG;G4#)WS[F@)>7(V!+!ZI:T;L-) @7/ 42%.2+26LKAOKZNUH(Z9
M:D.>?VH6&.^V[_@M.@+_7-B_4MMY^6>#N:P/69Q?9W5H Q1+M6GNQ,38$MET
M2@/[+WMD?XCQAY UU62G*RY_U-;.KD6R'+DL=2XY2MO4X"9V+!;<,A47R49H
MLI@L_'>=%*?2%G!^.=3J](XSJ!TA9Y"TI["RHW4<BPN^3O4DJD2.^L-J54S7
MF?UE:J><O;-7XARS53B%VHK*J6@4+X8O0<WO1:_88,6A>J/KF"/N'+!288@H
MB0KG)^ X[(ZE E39!$&NI.%6E-Q0Q,0CA!;'Q(MN#X^F'B.JVZE4;BLB] !Y
MN5>TM?KV8[.YSA[:F^'2[5;)NC4$&=T),B5 ?4C0T1RG=^&P4C3=DP9Q=<Q
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M&A7 V4".503$&A.G\*?BY#RMBA(,YK2<@P85&>A2U*+.I;?%#3P'"'TNP.A
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M'K872>[8TRO'<('6;836=S$-"M_>]:;7AINHH,UN1?"'K5@#7%0T9N6;B+&
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M2AOL4 UP71O["JA6+>S7D'.7ENCD"#1CHB(&H O;MPJ\N)S-]_)R!CY'#C;
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MJPO]WM= %U^+K5@#?2!UQ$M&14QXACTT[="<G;QDM,A-@ _=(\P$UV\J?.
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M5@>\>$%N76B;> _R@ \#EG$6S 7\=9S;KL?[9#SP@4KWL700AXND00CJM8P
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M=B9/^&Z:*6PB/N"00&.Q$Q<&#16H2S4IV+8B[G M4CG&L&Y&XKO+9,*54_!
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M"5:%%1JY;9WV"&P!3B&I4.UCM=;?RH/?8[\Y=8,MW+6J(*;)CEA,34WH_#E
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M+U@KT^23;!9Y@J7^XV^XO;'[.'8O-ULF-U5:H\EQ0H$^CS#B.(K9E?&LNRT
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M'DO#F,$M5'6!RZT*$YRED(T!-6!Q@B;QC?!%RFCQ%_A8ZIX1H->D?;5(005
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M=S+RPJWX <=6T(=)T_/'!<A1F$SHT&8WNW/FP[X94$M3@R)JFS,<P;OT(I[
M18-X[-]0*XA,EX A:*+(%1G)6X:-@W\E9G)'D^]A#T"MX"H7P)A]=#RG:6E
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MUY+N)QI/FN87. "IY9<20$582D!2!,<S>PEBCG#)]/24=P$SA'.>81L9R\^
M-6J8U0\++HBBP6:4;)T'_&3Z=9+QK#2O:'L&JI*#%[;-N2IW*C]<&ZI$@+M.
M(Z<.YY\7^3,-RG>;0-.;YJI^0)-NZDLE?2VO%,E D^B@+PZ500V9\NCPBJ5O
M80-&CZC?4X--4O5-;D5JB!DV1698?9=BA#L<R/@F38:M&'V?B.Y*1!]L(!'=
MD2GM$]&;242_V,9$](]](OIA$M'?S!N]56):>:.'H>K?0U/&<VBLQHXZI,<=
M>%'3N\X$-=>H"'8AC\R,U<SGZI8N#JT*,3+B_M9E/I2CM'(D&@8O\5FNC7'&
MWK>I\_[K.SG<J9/#7%W\N=;4+CLW-:=PW1'*>OHS56Z)%XXUZ^:O7E$Z%1NJ
M;^1>[6T'I?-&ZN;ZEM6A(]B+VJ--)"1J:_)/"+,D*7Y%DF()6!<!!'\-Z1WM
M(B^_:$G]YU$@\UVTQM+;D<,8,6P)[68$%%\RI;IVGB6]FF_>Z)M11K)!K524
M4K+*B9%>L$,'OA?L1YO(_04;#[,&ZBTI?N=:GD6FV"]*'3\W49Q5LGT=<X<B
M*9(0^O/<J1J(L5ZG;*IZ%%GQHY'48BEA%9P=:HNJ%\+0X>R%\-$F<@\AG&73
M6E@M_FAR-F.*/$!S4"/"C5Q@;GLUCKG"<JFE"XIBIWO:]_4+'ZY>B!YM(O<0
M(DP55-+.S0)R,VE[:N@%=+#$Z@/1CGT\>C.91XM:_72+?/&G%=0,H\Z(UA41
M=G&%.(6'7)1[/,?4ID2FD-R_XOY]?03IT43M2>N,P]4EL"OAKAUZ!K'8QE4F
M$(!T[_P05TG\[Z#--3PD7O5OG"=^D;Q=2$NPLF:FV2^($5,AXOE](^W#>V!3
M/;*.,BP]8H:=W7,00CP?=OX9PDM<<X5\ [&X=NLSPOHJEE=OZ&M#=1'H&R;N
MN%M 0!@A&5[$*"0>"K].VB91-5EPXC*/U]%@,E0KQ ^%O<?RH'4613>K880"
MS_<,KDH\/LVP3Y]RF@:&\,1+2]60/==4FW>]D=6VZ9W4%3)=O;XR&/.)LW12
MIC6!-:?,B*LFIG]0E!$C:]F$(0UI+5('8]IFOV$W=Y L._#RU/=Q^26M80J3
MU*J<>+6__WPD)))B[CJBQKSABD9:>!.I?0*E3?4IMSA7M01T'G0MM7L=MO<V
MNFQ2,!RE;A=:^OV%9$V">F O./USX;J](0B&3!_G)H\*35]J4AW,CLEA"1M<
MBW)64["2B,J;' XZ!Z2RY/W"9RCDS\PXJM%0SH/C6;@!J,TY"#( )YQ@6%E=
MI;.I9K)S4/T$^_%1C449GF4'*5&(;%QD"H7BHK +!/PQ][>[WE-[C(G<OZA0
M<8TJ56<33-Z(Y#K=$F\<GO=9IGF<A) L*,,>$Q,Y2]Q.W=2+E^F,(?E=K'6B
MR.] KVEUI[F1&>,/5G]J7(E9&B>4''55'&;IZT)1-,,'B=A5E9;HI6(UU1$A
M"BE-(7V5PA P/O:^=91TJ'7D*A*?"DIU.Q!>MF>3629L?U?9+$40)5<[48"8
M&7\=WG"?(0>)>]$Y=\](W2;OU&3&X=E+PV]#G>LOAY69'EG[P$:Q6A3$/V#:
MAEM4Z(HT6;&=XWQR^/-E#+;!<F_UQ<6V.P[CLDO8H+"N0@,L":RY;H-M2('9
MU\?4=W#N CRVW87PXN%]@YD7:#D467-KW@;>NV2Z'38-&7$+ZKE0&+YY? %V
M>=.?M#9&Z@1"\CXB%YQ  C3'X.PUQ1+5$+O,O1:!'.JWNIYI,8<15=ARP@*R
M+AF)W^#\(01AJ)Q<=EDMN1=T+RW=DA,0T@"AV8N_U)I^<.;&8T5G!V>$3B;H
M;)P$GFYZ[DB@P=R8%HY966(Q\IR=] LF%^>0.*I,Y:OR8]3@UGI&QUVUTV0T
M=ID> I\D$ZXX0HF>1)%88T?#S,J6VPQBZP"12P-$?EBWK8<U=\&:7VP UMR!
MN^UAS9N!-;_<1ECS3SVL>2.PYHW<)D. Y/Y"^80OE,>Q!0S#ZBD)L!!=4TYL
M_!1+K*)IFB 7+\5 YUSZI1K!C>RK&9ENKH.[T0&Z$U69=0Y?.P>=2JB4<"3,
M&A(]BTA"J<#5O%'(8-B)KVJF,M7Q+QW#8;\_+^S'<9TLM^'E.JN"R\_P^>"6
M-*5=N&Y>$'R\.#G&NW1X/;N:%B */#AU4Q@8*]8J1=T;<QD:\U:M4;FX_V+_
MA46$@\6+WR!/^\U**_9?WKXX_?WAT5' &!V9]+@JH\1H;XJ_<E;'38_O<O&%
MVZFG&,^44^^F/*S2"2,!;GF%LT"=?%'$2>P17S!"0=6$EGY$A+LQJ69B?MLA
M^)SJ4G@=4P&R(J1RV\H%Z7^E2G:D:^+E.Z:]H4%,]"EX7Y?T=O@N=O@#'#T0
MC:+$;!Z8@;J4M@6TW90PGE$?!([OX.F/<Y0#"P2G^X5PMV_X"C;75'FD )(G
M:(.ZA93C9E9;#\X?2S,_K- FT\405!S;'TV954GFC:[#*'9_DT.%"E0N^D?J
MM<K4;4^$(T$X/(<3+J5EG7P'7C$7XOV.R8?@3MT+ NX$H@O[3)'^6*]0MD6A
MG%]:[7_M%$VK";"J?%S5+-@7?U6NTA__T+'HC_^C3:3K^*^ >%FM#]> 3&DD
M2:<<*$$*&I8[@+(L#WMETR]_3#;62L][8'G81&*<Q3,K_:MX'X?67)5N^*3R
M5*<IIC;A'T<P(22=\=X<G'S2S&XDIZ<OT;? +O4*1G^L5S#;I&#84"I).-1@
M0E\:^_/?G_^G>/[/FG$U*3-B$O=QP%H\/H#OR"')3XIGW'QT@(R^0Q$8BK6,
MT\[*8>XZ$%>7JN5<&$L+DD.<:,(1EJM+'+6W@W>>F*K(PWG1!.25VLQ=\=56
MZ+RLQGJMOYKH$8-.D'RY9B!IE<V1'2Q/BZ:R(]0ZQ-3-K*Z&^Q8N_?FD!R1V
MB$>O!AYM(EUJ((RLIG1FL[!9['0/G2QO%&=QM["3MYS-YVF2<1=#$W_M\K+]
MAIF]P/0"LX4"<YI>2!M;NOS!Z6Z[C91D-53BB""<3.!(F!H#9G7T6U6"7]F4
MU!T8&U*,/,+-<<?MU%P,!=&UD" R _94?]<J32E\&ML?":'?.F9(>54,RO)8
MTES3=^>]L(8.<2^LCS:1D+"R);/D,A7(J.7??BK3:4J-DSF, ZX; DP)P?ET
MZZ)OUWG79)!-5[<^E]SGDGNM]5 N1IE*,\;8ZM!'P.Y:RF)"7=E]4YXTB V_
MB//L/[%J^3ZN,G#(2SKP]M_B<(6?JD1 \5"Y7A:J,=*B@P#D<=V47MVI7>"C
M(557*EN5%]&4;\7,19Y56&/DW^+KLDFE46&)=4CD0\$G9'Y51QN^8%FS)F/O
M>&APZJK,P[Q1DMGAU@G&JZOB>1J\$&53)F1TGL/<\_B 0?IUDBYJ3[M)YY>E
MYX%T)HR1:ITQ<,&\CUP_)<4=#9)')=3& H'[C->/I=0[N  K7MJ]J-[$'AK4
MWZO97LT^E)I=IEXG\2*KX:'_$=[^]118AZAM4JD]K)X:1:RG2(\P26:,Q4B#
MKT/#* GZ?0(WV1C;UXJR0265A"^P\RS/YEDULEIMS @H)7G4^.("*YEJ*G4:
MW P%F%Q4*[=07ITD)<:3Y]*3M,B9[2^D'E4MTUK:KWNW1\MZ8:K_I-_(1+VB
M:G=;9DHG\C1GQ,P!RSRRM\0;?E]!]:TJJ%YNH(*JH\2GKZ#:3 75JVVLH/JY
MKZ#J*ZAZ-_ 1)M+M!LX%KGT[AQ#_*J[963/V0%_=Z"[E*@1=@@>][6[0,337
M5KFU#C(IP'>]PH 3A[W2TK(=$U3_3>-LAB$%SC!617L>U]3 #;,05FTY]?\V
M'<EIO6-GO]ZK&_VA-$#CA".WDL-.6Q<9M5%6<<U"^G1-8;34'XT0ZUFN_K+&
MLPV9NXXG9'68-=IU!H?DZF;9-_%U;^O<WLJ1#1][<6ZS;^K<]I&$WH3<@=6I
MVR18@K1(2V8A$D%"QCE&"MN<,D;A,S,,(2ZNTCQ&  ;I;H/'4)'5H$"Q\C0O
M98X0?B<]FAF9YD))'S8FG0D1MUGL.KO9"V,OC(]"AKN6Q3>0"I+-8D)P/9A;
MAOB,M;RL<:JP4#VXK^.(]*+P:!-999<L0Q1H0AQ'DZ:JX478JE<TO,V=BTVD
M5:DH.-E$@(5B@U4HB#)RKT4=#+$A !22(U1B$'69_C?CJ>]EK)>Q.X0/TJ]2
MH;5&E1AA:,W%2BP(I3NPS@L=-5.]Q9<VI%,NB[EOE8(RUK)4]659-!>7O>_6
M"]/V"Y/%Z4TBHDLUK/@#4;>D'C^L0JD86G&*0+U++^+)371883#B359IRB K
M:I0B?2H5:(2O40AYM:7YDABY95RJK$1^@1Q,!0@P]ZU'>O9QG'\AP]?@A4T@
MOU3[$@T0R":Q$<)A")UDYZ Y5*/*6 RV+O&*5H1WMRC;=2L=U+4XR>#L.0:C
M1HP)7"1Q $_YJI 6:8C<RWS^_:':EZZYV"EA)@#FFW"(PS\%W<K3_  /.<+Z
M(3BY$Z%C[T&:'2#-)4&)U<A-9X&\ALL]<K.W7[W]N@>D*$PZ?#NL9AB7V6'!
MGA96<QDN,[@ 3PVK&7I!<.(]5K-7K$NW[[M0K'=#:=JJ:YE6V8YD_,91FAJ1
M&9S[TT5IMA/9X7O1MJ,T>S7;J]F'QT*IAG"W@SUU:=IPTF '8$_1;1!/W>BF
MX/SO@'CB7=DTUFGI4\,HI]6(IN"4GP;*:36B*3CY'L+_+2'\KS8 X>_ F/<0
M_LU ^'_80@C_P?,>PM]#^'NW]1$FLA;-Q\-!+0.PR@ZWS8-:9G4/M.RE;HWM
MVQFI.UQQT>@AEKT0/'DA:)D>!USIY.#O#;'4T18#I RG?;837+E%S:7:_N$:
MS:7.SP-._KEI[D4+;?WL+,[;%&:P3DNIRY</NBCT:+CO8$)DXJ[*C^NC3:Q)
M=QRG'>V>=1ZR1-B_=\S2A+/&SMN*(MG"SI# 66@89_O7:86NWA./X7'8%I=@
M+=39#J8*?\&^=?1-OW'\]65*H3?Y"/;;P[L^?58[KG:;7]59H>)^P@Z\1X;5
M[H\P<N-=XW167/^MQ\TX_SVD%1W$0S<Z9;WV"5I6D))Y4S?@5RH,F&HN'0"W
MD6F\C8/1^X?;=++'W]O)3C-2V/8Q!JTM7/79U%7$%MVN#?J%Q[Q))^E\G)9<
M=W_P<A0A'[_3*&915%6&QY802A7Y*>%,&W$1)ZW>-=H^#5_KCXRBR^(ZO5+0
M8?A_6165Z&Y1]$(9RK"9LWO#QU=Q-F,@,6>9I-$K808T:M1.F<$O:4FX30Z&
M3/))M@ M,:%LBP)YRA=<[P2QV7@+#4Z?WR0FM&-A*<N(29S.H>$&U5G=8,?=
M.,+ NT&>^BOQFIYGUG3:E'@J9$U-HE$AOFD'$][YGY_ST)+XIHJ:!4':_]VD
M%6E'.5VJ+3 #U*XT@3/13!\?X3(&5P+W)DG!54.WP5!8LS=A\4)7FA<:?GA;
ME',>TMFSEP2ZY9P;'0V8X]<;\_F_PL\4>6LJ[-++^;J1\HMXSO1E^./!JXCF
MJ&-CX:WI=7^TH[I_TNM^K?M1]<?W[L2)ZE':D,4$WIUUH@OR(G\&EX$T9B6L
M.>.I\6;\)>7.VOPVT7FD0G3_TIGI=@H+D>9_%!G&&$J+!!J$_3(;9U+^(DH0
M[RCYC=*,_ +[]K36C:D7^L#!WPFA3[XWH;>D73MXY8J&G8[GYW0IE)JUE#$Z
M($1=4<?.^""V;<FF-74W0_-:3!_!OF-3# ,Y@@$;CW*3?J2C6;N"I+SFO*H5
M.UMVA$3NFKV&B794PZ3?FX99YTKI$$)8IWV>IE2_KB]6E^G,RIVGM>B=CN^'
MKQ$4010G0MP0JBHJ%% .6Y)B#+*%H6L7L1>JXA5T!6HYN<6LF(^)TZ[723FH
M<)?=>E-65L'IKU9@"@\ .D]A!=.AT^PGK->"4%(>[BTFZX,?Z?ZL7:W."VX[
M^!:<_6UNR1J/(==EUURR:8(UZMV^UL=V32E/OS>E+.K7SN,X()_U1'6<4LV^
MSL-D4_OR9!4T9^6DF2,3P"3MJ%LAH:<@V-]V4XI>]E*4?5=29$L&FA'*60IG
M!#L,RR\@OI\P+N(R0=E),L3X%V4E3!-(XE',L0ET; (=\LV@,/E>$+LW:.*X
M>WOKU;9@O^>ZA1VU9;T48AW+]R2&J\5HI()Z*$68L37AB?0JGC4Q73'P X<3
ML'I":O-)K@$C.&!?R!WTQ'!R&><= A@+X%#3V!4*VI!2,#*!4:44C=3/K#H'
M$ TD"HDMIPE"1<\<]A(:.*0[(J'?EXC:XDDE317S4>&)ASM\S2C"C*HXJ-5Y
M!B_'$CFA$C'RF]<E7M/*=,9"*P\)RRV)3?@*C**$^8Q\BO'*6JH"-:S>HO]9
M-&75Q+FNM+L-=/$U#+P7TET5TJOO2D97F]%[65$[JH/.,B<$M/4+6]$+#('7
MW<\D1YCB^(0_0"TRY11>^I6ML_Q&$@O[SZ-Q4\%5M:HXN6#0B#R.B:*FI'D]
MK('M:UV[:EU_V$"M:T<Q9E_KNIE:UQ^WL=9UOZ]U[6M=M]RKN/BNG H?7[ Z
MW-R!..@#S;UO_MT&FEDFPB'F-#K)L>";0U)G&AC#0H7?^X4<^5,G=M4?_%T]
M^-_7R3>G>-/74414,+VI(R92*1ZT'*X(14=RP=QH9->F*N_CNX&#NB-2^GV)
M*4O08T=V)8H;E-4^LMN+9Q_9?6@CJEU2;>OLF&U0,#<4QV7 ]_8$<WMLWL.)
MZ^5W):T*FQ<-.H,EBB1!&:=VS$0P/ HSNR*Z0C2Q7&%5APLS6FU\B#&)BJS(
MZBNC'QW.X"<DX+A*'5&WBR-<$O0X.FO )N/T/J*,CY!X=E:@VJEDO.BKKTF5
M9K>:6<9JQD;>S(*^C-#@X/1KBU:$A[1 A:.<!O6G*:A/;)9A(:(=3AS#?]/7
MBST5Y?1].?I6/'=]]:2^L8Z""GU6J:B@:"JU]<U4E!KQPRNIX/RUXG(TD1K4
M*C45(.[JE92>P)-14G]\;TK*%)=Y56=6KSDJ*:.Z'JHAHV121H2J#A?[R&)X
M'UDTK'AQ,BRL&+_@*M@./164<.3CGPJ[O?U2ZM[(;[WQZYH"D\#+5ZH[IDAK
M)JFZ8^)_5A"J-,P*;XC*5K1_JPO>#-O_6/700X6G&QB$)X\V0M',*^J1TO1X
MN?'+;44O<=$;/#7'\?C56$5HZ?1VW9C-<O9JB<9]W4EYDBT9.PX3_X6Z:QQ6
MTMW[!\^>I3&2H^2I@TUR3>K'IL8"0Z+<'?&"+*\\-@5^;I0+*Q+B$A8C7ESB
MIB&HN6IF=:L[07"F#4C!3+J*+;)2\^S%T8OGSV#0P<F3Y4S4G1Q/&;'"2&$X
MG6_%HP4CSR8P06HJS&? KYJV5V^T]$P9^BW=L)/CD%1"4:RW1(.LEMPS'9NJ
M+HK$"%)P_8.+<-<]\3OTA ^@NPI^E:)SX/BP8O13G:^6\]"NAA_N;KBSM_Z#
M+]^;]?<I+4P4X4'LO:4*PB'/6]M[:\#;9-O7L.-A"^#8=ELW[:*%E]T)6N[@
M]'?5FM_!<@?G3];<WG5U\5S#?H?:;C^*%;^7Q0Y+P:VMN/:"[V"Q]_KFXTR:
MS%R#25IEI:25UV'ON5"\@H4A+'26AP^\/L#6;HRDA^X-O8[Y1*ZRBE6R)-?L
MX\1L1:T]S10^18A"QG$%OZ+^9-:G8%Z3,ANS'=+]UY#L'<S3;,^%SO<U!]TU
M!S]NH.:@ Q3?UQQLIN;@IVVL.3CH:PXV4G.P1>T&@J4+ZW0<H%8*G^(;Y2A:
MSLN.=AVPO;9Y \[N(M;^+U)TPMD"H68:*"_# %;NO_;W7D4PX!G^CJ$;C@VM
MKXMP/=[J+@[1H"BY"F"Q@ W$$8S8.X4_EC>2[ $S."4!Q^ZC=E[EKT5I&*NU
MVWO6C"OD*H;/G!O&SR&^!GNI!L<!-MFT7\!-'QP.@U1GSLQM^V\Q;,5CN,^,
MHL$O0Z=2P@!;5O8E<NX9JTC5,!D6@N/X^2_[.>0=&6ZN13.&Y<<&IWD.^GV"
M%ZLDJ_#.22W(#-NJ,W^\4C0YM9=)0J,- )4&U&PULQLWT0APL$D97^=#)E4;
M' TU3.@@FH,<7%:!%6Q[;9U%ZN%3%$H2AHZ/WX?-$*57G=\9Z7ZTZYTYP20$
M#M646MNJG_Z0(];R"[=+ 1\\W]N, J9UV5'5RWNJE:[;L&D-U?OCWBL&R8D"
M=@ZA",AWH8"56+BFQXA(LG&]N\;RC=96OGP.'D[M=B)#'USA!E#C]U:UKGIU
M)K\951LZ6?9INN!>XI=*TZ[76NM;]1N[E:95'<<._QFX\QPB^E>+PS]CC!"N
M-?<M5+WG73VP%/?IG+M=I%\GZ:*6QGB(>BZYI@$D >.B%'2GWGG..:1XW64\
MFU)## ES2SS4S@R[T<\]^"42E^IE%H[N*@BY$F%!,2+)KCS0]QHOM#7A2$V5
M8J9&MEN+9/J?),5"N'F=R4NI5&* 7]2ET.:J*\HNQQ4V.B^L)>#(&3QI%E^;
M]9"X?@=*=OU7Q;RTF&21!F@CU0B- G.HE8I&VJ'X+UW+P]K"HW^(G6Y4O++3
MXLDR7*.42V-(U2"G*F8IV"5A*70O/?@!'<5G&1CI993DE>JC9;H[T-?V(A3*
M:U8KY!11VQG,"U7P.B>W%>NLA"6328- 0&I>*931AIG>D4B=<;\9R0$C&UCD
M,^Z!I]T=>@B911PK1]Y5:HTCP-G$F3^.AA!VJ!^XBPP9&(PUYWO1A\(T!RIQ
M=/&-9J2.2[THTH?(,XF<Q4G+2<:MANB3Q36FMX@(>H0>RE4V2[EBL81]3&Z6
M@0]YTHL4<XZ<XI#%UTNTZNG.W+O?M!>]9=F9%V5* H[92FKYP2D3D&!_9NL-
M@.< 1X3+I<V)0MIGD5?]9!69+TKO]*UZRU.T\&^/ Q:>+E=XYH^_+M*\6K-K
MZ!;JN*!YE[QP)28.#LY4S3=5\\UR:12=4;^S/)VTNJEV@F>#G3C=7C)T!$&9
M,D,%]G*/,VTH5<LL' $Y%B@":F2FT28<2TFHJQ%DE=V;35MR$&F3.R)75>NN
M5-KI9#6R=%&+Y.>O_UXMXEQM8^ "3\OZ)V<MHM8BD/(_>+VD-2U=X?_^5WS9
M/T;TZOW7L@G& 0GV6!1ICV_$DE3UDMWC*E/)(".!2#:#1:WLQ<Y2!<Y&98!X
M$# E8'?0U[",@#P@M-WNA7/IUG>T$1JUG3)WNG!4P%R YT.@=T&=+S^X_M2Q
M3YU$ Q-9!W.*L1G;[1JPP%V*Z"FD;M!9 VRUD$]0H>OOJX%R'Z8A_43KK9P\
M<M*J!A9</D]24A=MM=OG-KMRFS]M(+?9D7SK<YN;R6W^O(VYS1=];O.!<IO[
MW\@;5*G-H*+0\9W3]Z$ SZ^GQ\?O<6&CT^-WA^?';Z+SC]'Y;\?1^^/37X]/
MM]L-[E#@2\-<I^_/#@,+<0;&"*Z:QDKOK"-\8JI^05<DS23U87I6Y5S8/YFD
M)77W::<X^:Z-$:AB"C=A"JF8"!3UJW7"+<9M4,_,\JNTHD^+9WJDB^&BM^Q*
M4">E4GG'!(WCS;&@NCZO3AM\!<^88S6?8A5!5W#$H;E6^S6,<-'#DY&*=<#H
M+K/*Q3Z*+X[XXDF,J'/D(*DTV9#UQ!$.@_HS$"_=E)YE?Y]\/!.SP^>AS\W/
MP)=/XRN^M:H<"07?EL5OR,ORPF/\H9&)A;=CBG)-Z?)BG07H]&B)',>$+(@8
MQLXA21P(:9AD"KP1Y.GJ18!;_30EEU8M VZ^OU+%?$[.*GUB#K?U#,8YL]"X
M4F*)_B\!AQ<2<%&8:<IO9%?M!5%G%"L3<"5BM^S#M!!SKHJMZZ'&H'9F83#4
MIMDU+"EIY=ZL[AXQ!_&$6P-^G_Q1-"6E1^!W]0(1R_A2A0.@E IN84G9&M64
M#=8;UQSODU6#,ISA&N%1%1RB>]1:UYUVN5MN9814#"S6PU"1)2=$"]=7;/E&
M\;]*K=/M= L(5E6(T!IA$YX2E!FZ<.@,DLD[T>XP*%[PO11==,#ISJS7 ZJ;
M\E]S5#L@^2*.PM"RX'6Z1=J0SZ]Z1&P>6[M9,]9\<RK*CA0;"^&L";9?4)9,
MK82 3#$<ZFE\?+E\/H/1)E2M (^<XEG"$8XXKCG2YY#3EG Z8XZIJ0J &<._
MI8\&_L3Q56N1-M*H%\LG=$=Z)=02O=49'GS:>F&^+33R]Y ;#FZC\%S@,?8T
MO#IA409Z^*K@< BW.U)"!BN>E78R:JF&UKVFV\H]6)\>L/74I=HVUYJA"--8
M<(QH6+959;F;"QT!BFEI3HN\P<U@Z;=Q3B*05D*=;<W_;I,N.)AC2R87R^C/
MD=<FL7!<]IW-.=':_'>3IQQ%.G@YB@Z>'_PPZDK;<8AVN=O7CLHZH+QK;E@,
M7X!O7 A$@>SGUVS.3L+/+_ZBE4M38^J&O-.ENVG"<]YV*OOEVC8A<FV+)2>H
M OE:\"&O4S@62#8AVHI/2&?34Y@J>3*4BL:<%%HA7"S+05PZ/]O=W(O>:JIE
M\M]4O0DAB&X9*;Q]IV:&VGBT?6V5WKZ,N&H-_E>6Q+@U>3,?2W9KJ;]-[E2Q
MZ*@<,HZU4UR"OPZZSQ3$E:RDSEI*%K22G 0.=4I!4/26E+]EN_!TN."\40(M
M> :F=YNL[@.^V5EK^56LCQR^%K]H]>O*U/8U6A]UIFZ^=I7%_A+OJL;\K+*I
M5<@*!GT:X\F,VEZV>W755E]<9DHH@8Y%O5.(CS7E]X>LFW."R*> XXUPF+22
MBUV=H:L0OK(YWZ9FSVR+Y[J)&UA6% G*R%:>W\NY@9%=VAB7LXQ#',3Y3O?D
MF"]TQTI[.?,_)\#+8#SD=:+;"B7O"!)8A<^DSME9:#%;41UB[=],#-SO)R<G
M3L)9@?7@M9.AF__H3# I+YU5<)HX0 HY%*3/S3YK[(4G!FVH1I).T,]7Z*)Y
MT:!>17@=L3'RKY%VG$HX5?MKUO@+P=^B9,YF'N!&W]^#W*M=\0I$U"5#7CQR
MUQI4&7H:YL8F#U#YNU:QG_#?^1$\4* T#.\Z4^MUUJ #N&JECA"@Y>IDE#5"
MIVR]KA=OB:T$G.!A%2?GY'J<WZP0$C0-=Y8PU*4@Z17LCP]45U-$_4^(&QJJ
M#6[CYN=CS'THC]EPZ%I5C[(KK2GOJOH],7&?D4V=J(*HFKEDW?"IL^Y=B#16
MS/1(.D9+HIUM&=M@G+,[MMDQ\E413M=3T\?5?MH1.]EGW2'/8#2S%4A9"X!A
MQZ+Q"UF%R\C%OIV#TB$7-ZJM@B]MA0ZSK%M14SP/Y*/SA03&492PPSI8Y(?G
M35"$XWU$\<FM1WE89XM91I._&CYJ6'#%=B@T3%OA=&],QD[O8*UH[.TCL"O*
MCYPXK+K-=8KJ&A%'-ZAPQ^CCFA'''BJQ+E3BYPU )3IR^3U48B-0B1^?;R-4
MXF4/E7@8J,3CN7^WJ?IV4S@.H]'ZB1PW3G';0EPOM2/%3 O=(J,[V:-=!?OW
MCK6Q,CQ.I,7*SMPQOZ,3.J[Y^];)G1V]B+2]D+.E^1OO +4S-WZ-Y*HLSC(?
M?;V4S5ZW$]691NE\:Y\S&;5\V169DWAYDDME2IS,R/Z*Q$C7_BQ-@IA Y>ID
MB%T7MZ,;N)TAW$[)6C^.V_D(.YA[VP#MJJ#L:NS)[@=H45)6!F5=O/TC!VBC
M>\5F-?5_5W1V:40V&+K<7'2V6BL\VVV8UHW1=@N@$ZAM!6?;VKL/U'*E%V9%
M+PI<!:YW<I"1@0!J4J3L,\!QH;_1XODT"HM9*AH(CAB6W[!+B:A5> ;24Y8I
M&%A9[&D#<H;C4^]%R:P8\-8^:'*R,,Y6UTQ7RWDMC+(>YGGZE;74$;W?^L6;
M+:]%W']Y%[:!T_?O0C#L=WC1_+QX C#L(P7DF'ITY7>!:TE^P"L\KK%?":Q7
MLW!.6@<-I5+1[$;8'H0N'X3ASC+0J_ 7I^4VFAOJD ("DEP@.S&X'"/3WE&<
M$/X]7_$6%G6'_A",#*P:&ESUKR4?YB?2':<56>5O2 &OQ;/LOF1&X%K;TAL;
M@L78684W9IB;V@"$*V!F1_TTZK8$>CMMI)"#Y,7DB87DE:? @U.JKW=#"K3M
M_ E*3* 18=X=4R0=6 '#:UW)\FD39"R32ISO__3<;ZEW)(AHY"S>97,0@)-=
M7Q8B.XH>H"TK0H(=N'#Y8"NS81I;-O*193]O$EFVHYMA:;V0L.C+7SOKN4R3
M^0$,2ZL%H*T[I]J6J3.?8/ 15)OCHCYQY=$94[F7^FAKCU% ?3S?>_'R+_Q%
MY;CJ[; U2&?@94?7?*7_'ECI1_/?\=\A511PWY7?#B,[II>^C;JJV)^$P[X?
M\-?/.PKX=O1H?LQ)FB,3>&WW$^4@ _GP@MBU6R>L JPZ!'G*]A%X@'H=:E$P
M$98!/G)-OH[ UO_Y'V?V<_5 A(Y#V#B&&N3!D9< AMCV6Z:4R;%P]MKH+4HA
MT'><(V<M_NO'YWO/-8.P9+QP 6SW%;X\!T^X*(F?S7K!!A>&)_8!'_])/=ZB
MPL0#,%RU3*X/^%\OG*F9Y2GA8I MO'I"#O9)*$_//"?,S;TGAZ.GN57^%#@I
MB!AU>>T:=9;CN&)*+9[[W#)D2%2"8#'L+&[5<DIGCLJ_ZG!]#2Z?#V9?.@ _
MS!<^U)J/QT9WX<]F-5I/"IV"'EJS)K3FA^?WA]9T83]Z:,UFH#7[VPBM>=5#
M:[XG:(UO5EOE/A884AL6./H5U4M-X$)?:3!NJPC*-<'[SXT%OK<5#?NVCCUE
M@V8;G/N;+Y<JP3-@EK7VER(48I**+"%#P#"#IH#FU&R(0V$4R-2Z[NU>=+:4
MF '6PYC^T#+R$,9JLK6&OP=C$NZ<ZE96U!MJ!U)E:;Z3-Q)NV O&X$J@UO7I
MX,'Z0%(+M-;FR T"?O5D+^@K3J_QJ-P2B"X?N^-VOX$;_=H#[1[<2(<&X*P(
MP6O5F<.#>?RZ7A^&;W;[?W&WV__9X6G 9)_:5<&G5+S74:BYH[)P*!S&$NN4
M<Q7F+))J;A_/2?<1Q7KDQG.I>2#<"RF?OU)76H5'L5N/+663WMWX3A9/K&5@
M8UW&3S!]8@C! GYJW:F6?'O44MX@Z&-JNSH1Y4O39< #QM;+=$&1-^:R3%TF
MR[BK-)V\"OP+,D80LR]=VMU :S?6D0V8:LSHT%:%*D\ZMHTZ*+QX'DUB#-G'
M)071/3R/77OO@Z-BC//#(+ - =6IE!.&ZEIM =,ILF23@S2A?@4TXNY5&6,G
M01 \C#_I6G_D:.:RH/HRYI/X\W.8FSWPI6.5WB'\U?1*P$$Q*^4RO<I 5%E/
M.].'+1PY%4D6EE<>MO0T2;\*F-:7-%TLG3J[04W1(+FXF7@;M6:!U1(&,@E[
ML'JPFV"U"4:6O1_#?)A3<"FUD%@? 4 CQJ8Q.RT"NBV9*AL%8MM_^=(TMQ#&
M=H(/*1S:53%KYL*Z Z>T?%9,G]&YQ]*T,A.@M?WP4WAX!,\5O]# V80H@,:N
MXEXM4>7S1$(!UCIS_2TE$=S9!#Z%=C1N\2O;+^+Y.V-"@&!]B<K@!G8HU(9D
MY2E1K"Y+/L+02FD!C=U90=S!1-S84"JFV27L5;CL,H/1SYF00X>'&1]W(W Y
M;^+6@#2Q[_@FN-1/UIU<OBV^<^@G@S?B**K4SPK#M=+_8R'];=LS0"_NX@$>
M_1[R (_,W?)WB@#?VPN\?/&8+<I6+-6/ZT,??C]] NZNXJ=I(93<VQ/6_S05
M!O=-#XA[4,RW7_*LXURYP1<>XU*>(=<?)\=2G!]L3(7"GHT;I8VL0 FG,\2Q
M'B!,&-V4>\62?C]MI6(*+KBW@AL69ALKDTLP?TG*F&K..8O&HJY@^(-N]2;9
MF1FVK[?[O[EMS!)N0*(XFMI!'HP)5>#3'VL& 2$/4/$:5*:TP^1@4Y0DPBIS
M% !T$W"MW,"4#X=:JZ*@15X05YI,DBO7";NM:Z655YH7<.H%"T..FL5') @;
M:^"J#,/:>;'55;O%O682I44"SX;C?;J4XXIJGW94]"GX]?MII??Y KW://7
MY>H&;&L[IZ>.SQ]I)[KCFDL5K?/H'3^O&1OJ&HS(-5CT14?GG/HU2)1N%'W8
M.]S#FP>?"W;&N.F$W)(FQ44.:Y.8.S+I,%W%/T[K:W3!@_T8AKIAE/8%R)G<
M.3-V"XM_!,L,T@+OKNIL8F]X]1I6Q;I$>%[\N0*@[;H 6$WAK(H,!1&$?US>
M+/"D3:3W"ES\D7D-_PTSI-YP?NV*@>D)-(^(* :JP0NJNQA1PG/A:\;:GF*6
M)4( ,<O@@J1^2! 7,6O4#VBL<^X4:=DR"QDX''%OJH))CC""'9=88R0WESAW
MKH-6A:ZY[IMZ&[4BU=_H/DLJ,4ECK!(>2^#&FSL6$X/^G]R\YEOK^,9NX55S
MS2J%MJZRJX* S/0%_#/>O[A#2V;;+-HFU ;L_R]B<D7HASQ%\I*XI$XO2E_3
M -6LZ'EI^IH+K=EC=Q8@PM+F6@B *(8AOYA*F3>.^P^X_%<)BT(T8!H_+SC4
M9JN$W2K*">SS.,Z_E,VBGA LT]K>X6NF=1G?2)\N\4RP08W=A,4](73=IZ-#
MC2K5)=ZM$.L(7#G'R1H)[X/3\Y0+W35WS4A#:N'>/\YFB *1N^JH%>?,48%G
M"\-+3&X$GHDKV0/Q-ZDU'[R,]MBN:@.91"<(5H\,L_Z9_ZAW?D:(RY(ZG;;Y
MM"_+HKFXU$>.,E_E#:T:/94VTGYP+C9%?F7P/VBLO'>2H)%70I/P*AB-#,'F
MHK)YDX(FR&K$.#E6#=>$V=2]EN-$<=N,84_Y@+^F2-!5IN0PAF.5%+DJS(O)
M2HOU%B>JEOK'C@298]9;GDP/@^F"P>QO  ;3@=/H83";@<$<;",,YH<>!O,]
MP6#<.Y;XF"EY<!/IN>JRQ956TTKC-%$TV[$M[D-U_U)A5:6*$/83Y1K$21,R
M@>!JF6^"32@;ZN/ Y? (4#56F!K-,6^-=2L0W(0S GTKYS:JC!!%TW^M_ #]
M[BSWS9QXH+ZU\QC\W"Q24X+SB'\Y,OZ)!/VMFQL/$(\9,\OE8#=A&Y]1'D$G
M"^^=/$4K>BI/\W*EVH&@:';%2<B!<D-QBV#S;U0LPPH&X?H*WY"*!^&GY!-2
M8>7?O#%.H[QL?H A&%+35>]BGQI+Q]N^OG(;]L)5788WB>B$OJ3:EY!8"OMA
M.6:KP$&$22<-L@Q549YF=+8IF4956V5TT<1$;--NS=Y]-G;Q2GZ;,@Q<RT\J
M+K6C]VL?)."%D,AOQM^)IYI53J2Q':AS(01Q=:DC=W:YCM)=WE%20 5;.3 ?
M^[@"=46))_M";8U9">5 RJK5.]7?U3X-1W:P[).@QIQ8&?7XY*AE6JMZ@,$D
MGDT:YL *N.F_'AY^\M 3<,NK:BY1H<M.FL"%9OJWT$&I.22:SF85DKSF%__G
MS\__3#\OD&=3?F9WCOXI)VCYEA_0GHL3* ^&@^ :Z2AR?J ?_UZ7__!^*Q_[
M>YUXGL!!^&!%5#D!:Z9^"V/T7VQ)R8-(A&C^'U[+BK?>_-<Z63W/+9A(2&Y)
M@]V@69@0BN&GYW\9ZBP$B9T"1&K,9%MO^PJ;;]N_IO-YC!]!(Q OT@8CCJ/H
M))_L18/[Y%KHP5VU.WZ?#/#G:P+;8.H _%VX:'"T '^>@%G*:D6FEC23VM0B
M3=.T15EWQO$5MN>O]O;56XZ_@N]289S[73;!/+^--/SU_3YHBX2>06F.P*9'
MT7\WLQM^[HM]JD][R2P#<V[H!#-Z'\L'?J2_O[H_ )IWZ(SP&S1J&JNWLJ/.
M*#I_G34>DD^3CSF#:V5RP\@7ZH9M13H4F:&3L=(@C^"RN(E7)K^1K[=6[*?[
M.W<P?U;H($%%XKIWTGIN-N.4!I99WWL#X'7*HGC+_CJZA;KY$_VZ[%3(?X*_
MXBG_1V\M9/*]M;B+M<!,\"5H4/3FM<G8?[YIFZ%TN5;>0=6P0J$W"W@B.GYI
M&N8>7:JTW[][XRKM+5'0."Y74P371I"E%YR!TA'@L,+?@![SGNLKLZVU(6_@
M@&)ZS]G8'^^_<;!-EAWQ<"V;MR/XNK =H9,07)7 Z;"LT?W']"Z]B"<WT6%5
MP>VG-W)1;^1VQ,BM!K7-$'PE1QF1XR8):<77P"@T@J48;%;:/^EWO-'O:"E<
M0;,R2^9(9XV3AH:*W_G;C@K?R^]7^'X0V?OYAQ]?[9SL=62Z'+42D ?[SY2W
M,,*&AI2]0"K2H-\QM!..%[5!BF<I84ZJ# 89@\F/L8HOFS-*1T-(V%8%S63D
M63#V'TS.A!S>M4/9W'@QOZ$^05S)(<U G0':71P) I/=(ES.G9VDYEHW^ 1'
M?*%_#-KFL"<IBJ57%;VJV#E58<KHX"I73"B]BE>UIL;"J44Q^9(BCJH2J=8U
M.AE7^W5<6SO4A".";C(5)10< ZJ/LGAKO!P)P_=6?ZUUV8+KBL.VK3NX%MW"
MKG+$=M>TU4O4,76]<*2H\'H6SLLLT5F8PXQK+$>$,5[&)<Y0@&LPUG?OC@PX
MJRZH-0F.GY*]V#.+5P>O02J.BS3-LQO=_Z0:NOEVJVF7HISL'.E:&ZX:'M]$
MBD4>X6+<)<4 ^^V:MO:U=)V-X^MCKY7=C_5:^3O2RBB<!&4)*.@.66WIFS;:
M1=W1.,!D.4PXYI H[CV6%#XAJ,,_X1JJFKGO*-+AO*6ZI:A.>O4$"ZDU*4D+
MK]2NJ-&H"(X@Z,KM2ZHC1[9AX@%0M?[X&0Q2JT^E^"D&46/W4*E-MK#6-LS!
MIR[R7!)&O@M0C(ME;@AX85]0 L-LM4'#9\_C+\*R86,KG-ESO:%T/>6Z;"&!
M4E<^A,I;A=I\7PJW&U'#YC8<P862RQPZ+5>ICB<3Y]2BS(BFBNJDJ%IAAAC1
MRZ+,L%<G5ZJ%GRDO5J56-2@\_!#Q:L*O;'"8'[+V? )BO<:9.J%P%ZOBJ3*+
M/EM'H)R](>J*& MADG0O^J0BX;([NDD++*P=PI+" WE I8[A;;["!Q9?ZQP/
M9_Y2HF)F-PJ+S2CR75[= &^!!4ZJ)$!$$],*2%W:7CQ]&@M\#H+]G5EXD^#K
MNTW/T:/HUT71'VP 1=\!\^Y1])M!T;_81A3]CSV*_GM"T1?47:G)$5.NKOR6
MOB;&*-;I:"AR<-/!_<="0E#;W*,).U24_%G'ML17!4<G2M3N0J3D*'<VW'O1
M;\4UMF1GVT/]ZA:4QS4@,\WXTH+1*TXIUT"O+,<R!?AHT!)5+R#O%2@I&T?J
MU\I.H,8RN&_C%?+[U=*P:(E4\ =IH9C,B=[.AI#?:(\$9STORE3(H\ 3L1D(
MJFC0Y)01,W6PZ!ZF51T<GX>1IY[MS+%.% )ZD&QK32GW3<L3&.XB,#QLP\/M
M*_B0$;@X:9#3;$>O3$P\,E\0AKFR/32A>[(QU-R'@1@=9H:I<P1GKM8T9J[/
MB*?R0#J8F*KF8#%#&W<D?UOGPA]@&QE0Q0:=WB#J/,Y56QS34\HJ >)_ZXH0
MPXYKV.,55YFS1 %<E;,D71@K]ZI LA::J,/VIDIVJ68\*ZO::8E S["F-*(K
M3GBPJC[7#H3ZWQ^.A!$LC4)I;FP+/&->8=44&-[ES-V<(ZR&F9C5"UR%/=2_
MJF212IIDZ=[253Q ("$]>:R: <TY,N#'#[F8OK3;^DP=IEZ'X@01;I64TJ,=
MP8.1I$A%(&@V3QI\/HO/F.7T$H#NV[U>R[7#Z86%7EC!%KB)<8=6+=H#L2I4
M%7;%U"',D=BR&4-<%"(5F%RFDR\8R)^AD-,!>T;ZC!J2H[ 10V26Z"M?G"0E
MF9MIFXW&LC-PGAG5A?R)EYJ TZK>0L82OKAFG(H=J^S /(6+?F*9)M);AKM0
MC)$5ES#&U^K@V3XRN(4LVMJDDRV4I(5%!@2OF#>S.EO,2#V@HL%/_KN!FRR=
M,ONCSAI0-2!]YW#H#],J8<$W#'[A3]0%AC=R8KK0Y?FJALQB>NY:/-K)@29<
MH)J7SH<I#\DLV=)G[T5OQ6,@!T[E>I*B&=>V0G9]'3J95"H)-F/:E+2MALF@
M'?XMTUEZA9$P>XF$ ,-3=_8GPDH_$1J!.JNF\435(U 15%?S-%UF5^')C?C0
M:L[(I^WI'.K.S+ATYRXOA1P.9WMWGHK-=B3FJ FE/S(WQT8J7*(?QY_PA)&(
MP9V(G!_RBRRZX"+WNJV(MZ[[75?!Z"['(X-\,!*@-*@QCFES8VMQD.1;7A%K
M)*)JRT-?JN;]U^,R[X3+K M=3:_,&C@HM;Z("YF+]/LF$!2H:XP/P*$,*F@0
MPF;.;*5XV^8X=N@+'35;+!97"$"09*6MQA4!JOV@I?F6'@T=.HV]U#W:1-:1
M.I$031KE")W':A20,[$>S/^HA4VGX)4L&2\I*'CX\%Z4G GTHK0+H@1'0YW7
MT&&G@ZUN*_H#(X?>G?@#DTSG6"T&<QU:+8LZ-9E?9C*K@Y(4=N-&ABB8T6P6
M\YGDOJW7\F6+*K<2[&R$$8R8D6]TLV(#&'Y3+ZBA ]P+ZJ--I$-0D;%&:)+&
MV45#F _\=5&6%#0H&6"JL)LV8,4*:)C+%HF1M'1(4L6*2Y!?0_%!]ZV@F!K@
MZO+W4%!2\?0$OE2UD#GSN*Y)'LN(<C;TH;C,"-IA^+^]MSR4>@A.OE<9O<K8
M=I415TJZ34H:XRL6E P]Z;QJ2FDYHVEN43*J9OR'"*33-L0(X)GI2'/("DAJ
MV"_CO,-+/IR8JRXVF:D$9'Z!_$,DF@3&JG64<:1P[U;$F&CW[7XX\!$I7AQC
MI57UY4:5&L_BZUXX@X>V%\Y'F\AFA-/VQ[-*6 \-Y)7S-=ADPO2BB*1M>H*M
MS5%V%;8]*)L62(4[W$@#>A?JVDM3Z)3UTO1H$^GRCC$+-V,3AIE)IS$<HZ_!
MBAB(+7T0Z3V$Q!I3BN#SB>MG0:8JU?Y,I6Y53B*V<^5!B3*/6(=;NY>K7JZV
M3*[N9Z6X0U]:A<U(4?8G/G 2^A/_:!/IRBU(A:PIS-58@&#2FL[]==',$@<'
MC">,^P+I>$*IXIXZ_>W%$<+QT))?H1L3!F,6L_3"O*DC2.*D.EQ3N/?@PK@+
M&(A_ZD:B!EF /\*U%2W^;PJ3-T_C7"$D+1B1M9L(=W"6AR"A+U[]1;. 6DW*
M.+X=2E,YF5I4Q1;(@D.!RX[FB-P?1!!*U9SZ,):&\R%2WU/TZ*&@N#RWW6FL
MKRSJJBQZL8'*HH[2E[ZR:#.512^WL;+HI[ZRZ'NJ+&J#]POI>RD%U;X)J(NA
M7T *)QK^A!@\U][8W1/QHEDKF.IJNQ'P3I0-L*HFJ$PB_9I.&@576F7!6NVQ
M"M\R[7@S2[]X2O4S2TE78"?R"4(E1U:?[K+F&Y+!!CO;:/#!=DS<SYA1JBM8
M-J'YQ*Q>\UZYF"[E4)46JB1@W=(,-9GTZR(K'9"L#_.F0JZ1U'X[Z\.-LYVI
MIZJ)M@FYM-^"YH1^[=*;8JM#+#I/L4X!/ADF51WJH;LDV_ZWV[3>V*B3SK_7
M(Y"[+. (4XU4Y2YV=F<\K%3'QGYY)5U,<&NGQ1.'5'^DR]0GDX4-D@YME0)8
MOQMW6P'$LTH7AF)YX[Q IHF:>V B^\ (P3$]$MG[KX];W"UN@05L34UMJU!I
MH[XAP\&_D5[$6 PUGV,E<Y8&T< CX:+6Y9T*OU5*=9?F(IH75]B&LALBT8(W
M^^!H [;L8]^AD]9+U*--)!C[1C&X!"'B,^_RQ%]@QS#%- -^53Y2>(0;'4I1
M#9QMLE>["YUBE3&=FKKH#$NW"W:P6DN[B05[T^ DQMD5EDAJ'XN*0U&,V>5I
M<3:*J']*\SS0?P!'#,<_QUZWBL(0KP%N',E IWJ(5"_CVR[CUAW%:GRM+>-9
M+27A;U+X=5R"-*6Z0X?3D)NYNJP+G2*9N,1;=PF"KCIZV\\-"KMYUQ%6Y5)9
M&\[R**YJNC.7=(T67C*7AJQC=%D%)ZFJ3=7LVQ3O(C/N,RYEX9]S:JU-8ZNB
M-QFK'!FX<@/TKZU%X2)K& E(&C$(T$/Y4E-,AW+=BZEH'1< %8=?(*S^@V'?
M]*D(=:$P%>]PA9B4V<(K0+6TLTX.4:5D60NU&:5@T]KUT,@-K"*L]N;:<;Y\
MFPNW'-YI0U?TK_K<(@F*Z',[R2"\_F"#ZCJ>7&(B!+8>#1&X?V OOO+=^>W3
MOMZ^%YL8?=X[V],2=L*DZN?Q5V<+CC"_A&T?)ZD;7H-5^\T83MOE."KF<(4$
M^2PF7[;KEGS;0ZVB.4E631H&IF5<&@D>2:GK>.?.@DYE086EOO86=!)8T*S"
M:BR'W%ISY7OL%ZRLJ%KL<O7R,_-+A\C%6NC@T?'LILKH641+X3#Z<9Y9VAG+
M#_A)CA$XD\:/HV%2])=>H(P!L3BSBVQ:6Y]6U/X^>'84S0JPQ@2NQ6X%]#+U
M-8T EOU)$SC.7 "$6<V15YIM[:*5H68^#*H?A\>V=@>!4[$XM#SUAIE#, R6
MJN!:0;0+S%LP%]HKIC=QYA_<YP'8PG11:XJ.&7C@^ 9A9]1S@U?"1(1))&5?
MEF7L#-:LIK8EW)2(UHJ&PX2CW!PVEZHFS:$5&HW5LEIB]<0#?J-:<BL@F:(2
M)B^=!HMS(.LK_6B=B0<Z)[\67B_8&>[K J?/VB$J>TPK2QQDKQUZ%ST$W=(B
MN+/!7<59P,M'\@1I!VYXN& PBZ(2UE4]# %YZ^L1R6.6[VXZP%UV^&D<5]R2
MC>9<8 .<<R3M!(<'248T_AWS*\T,&9?<NZ =_O^C <\.U4B23CB6*G$;O,Q5
M:(#+9D8$IZ0 $NS=S?C]*ZK$R\&QG*2L F473D[/1E[13+R$+U[:<^_L]J15
MJJEST5U'6>2R!4;IV-4/209+0$QP=#P7X-KP7NV!=\-@&M<4Z>=T?5.!ZJ1Y
M,MSOZ[*(I1F3<]$FX,^$L$4MU$]L07BZ+)730%UWLZN0\ZHV:1CZ79I^(6ZP
M!1P6]C*1UPE>J(13G2GF >$SXTP<B<)*W;I!57%YFI9488D<7CGA"@O2266L
MBKGAH?1"OD:8\=54/D9=$TMT$E")F$[9<4NC>Z,)6J$[^0B[>^A;.DG9Q/6\
M'C"$_#E<B<PEO.O\#G%>2''.)%YDQ%E=$1$65^@H.BX\,8*J@C$X78WWX8-Z
M?T!S1@-M1*GL#\P@7%J(Z'I*Y8MXV9TS&Z,_Z[8AFW4ZF.Z!T6Q,BB +;_K8
M-]U=B4E63IHY9]O9\5M#3$=>VY-LOH@-#]3[%-0]&FHZ_+I#/ P0_@<;N9L9
MJ]%KQV\&,IBSXD<K,&_F^,4]N)=H@"*\O&ZO2^?<VR?%F7_K!##VOG14JED[
MK@*SYF\8?NATNFWA^G"?I7#Z<-]MPWTDY^G715P3=IW<3HQI(+,!B,)_4J8O
MF!7YQ3,,FU/6*['=)"=(UH>T0WO?G_%'FTCG&5<AI &8WR2=,B4C>D5#-.(5
M$7A.!)Q.'6SRR8TJ*J1CC@])X(H?][G9X.;WA_S1)A(ZY,SM5$6*)GV9^XF^
MAOAAF(V%]\ %(DDXE2+!MC*KOCPK=8<-NBNG%S="IZN?$$Q9@*.$%S-RR4Q8
MRSP;KWX79<S9%^6G/;!4]<#\+F#^RPT \SN0XSTP?S/ _%?;",S_N0?F;P28
MOQ%C'X+8]_;^"=O[<9Q_H2"!BA1R$SO"-A+'*5E:\'/ACQG%<*HZJ[E5:^_
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M R82R6"Y7S +!MJVJB*O]*U)U\D]R$"L$*S>(*JK9RS70H.$_,YEL"3VV]M
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MRN==)*!._IR>"LK&2?]#@807!1*6.[TVC!N0KM8X*AE:XBZA<T=%JTQHWMM
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M$O!A9@4!1^/L :QW#ZQ%C^/:^$(ES[P%/\"F+WP2.' _])31 :0NA(&^SAA
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MT_CGE#OQI,?^3A?=LX+YT3R=L\7IS/HA)C&E617H/ H ?B,]+X S_EW0"U8
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M;4QT8,!Z78-A$0MBLR4$<;MA% SX"6X V\.UHB2=O(FS9#:5F#?"B &3&#>
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MLB>VDSW1TS-[HD/9$[O)GM#*R[91AL4%ZB*WJ(N@Q[JB6^I%K%")O$*/J[Q
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M%"=+-J,UP]H!&(E+U,)HMY>:89&/IMTRAT9QK/K51A,^^R^9:0&%\]/-4I
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MT$#Q@%?' \Q6 UXO\UZ[V\U[/3@\=*"!8@2OCQ&49P"TFAVQ8*8Y1!@;FZ<
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MK\7\VCER?AT,!L/M\6LPM;SQBIVTD&V)78E=UV77[C&QZS<^!Q8#KO"! _S
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M\"L,'!]_&S!GS+RQ;URX\+_BGR[=L36!)<0A&6_0M=%NO<^8B7+"\>^?#2N
MF1X5=6\Y^>WC^>V%<7Y[J8Q'\2CS_=O">;ESY];(&)C#IB$6R_?#F9K5T)?#
M!%2-0IL%T42]:(G*5I]Y<"4/8!P>S"#\^-4-N)QWLZ,6U)C$D^H'\+(91SQ9
MSL@.Q_*)>-&YXX1PQ3?Q(@/F\*/KS=236J=_X!OB=2Z<BE5KKV;G62A/; "6
MG*5DC4>N'ZA9\7/S IARQL;8!7P&<)T'G#!W'8%D^9  Q\1'KN/.8)WD! =3
M%H!471CW'%XYXM8CD'*_$'=< CZ9LQ">L<%[/P7UB>?.EA>F63@5,'4P-IBQ
MF80CKK<WC@#@A#A!.*+L&D^Y+>C@;#0M9CCD(+BMC+]\SL4+Y-9SSVWW::/(
MX$MW] -YBP9K>XM>OC]G1V8Y<-=);KOL=H?+3M=7[-.O=S*E.Z1W6\.#95P4
MMY W-6LAKQU!'6GY5[RIO00>M;@[5%-[4]/6A]H2UJ$^T]1G6O69KNWP#M)T
M,K<51'UR"O<'L]DO3A6J7(I?6BO4IN>DJ:6?LR+DY7>(C8%<J_#]&OCN-8=E
MKBUSV!B<=?6016:ST]F*+-)^00[6\.F -I9.-!1*D$W@5[W#!Z\4$X-&UVS7
M3$S4467913E5O;4!S<G;N:@Y)F7EK#'H]VHFA;1?D+U6<M- .="!!E)0-A4-
MO<;PK&ZBH8X*R@XKG>BM"&A.'NDI6Q1&_4:O/]!+&-5?']G=>6P-% (=:%@I
M(HY:^>@VNMU-JF.N9/?7)YZH%%F=<D]R)&F1[5$%F@Z=A)+ZL)QVEDWGRGU:
M8MU[VQU]/YUXEFTOY6[UEQA0:DM+@C\U$<MO")WO($V<?22]G36[@]+HKCD8
M9 /7Y1.5^?L_3D^OG+%QPQZX80X'IZ?R"=F!WGS$WR\\SKZ?PW^2P=J<>4+&
M3G,SF28^UN RDUGZAOCI<_CF]!Z_.F43&.7/!K.?V,+/+,C4BRY7J1=J>5OS
M'^^- OI@X><_5-9_=,)&KGM\XD+<F5O& DTR2NAX]]NJR;W@\-)H>H?%TXLX
MPL'&(U]6G"+B)>&VY?#3B%[+L?"\1")Z^U+T_L(,:_SKB;-HMUJ#P9G9^V'^
MZ7?_-,W.*:9B<\<7&:I_SA_Z<#&0>NZ,IJX')/[RCL6K-"^G:4UHWZ[(8WAD
MGL6< '=D;X9C6,IN$..8>GSRZ\E?[ZXO3WZ[.[_X?&5<?S0NK[_>77V]NT5J
M?WDW+\95-+4P9& 4)UC)RU):S)CEK!86A:*AZ('3SJ[DPGH)[1F>[*N31.LE
MH[G.Z564@_PARD&^3.$&K&EXZR(]_N5,V\-E"/?7'NHGQSB?PPXA4ZK;K7:W
M(5*I;X!L9-L+RU6'#]C8G6/N.C.>/"L .!F%TY39S JFS'B#CW_-,84T::L6
M)W>,0:;BKWLSR$!0IGTQ%]Q61P<PYS[*Y7<G1EJ0R.3Z@DSZS'R4G"91R?CB
MH,@3^FKPP BH\L"+QMQS1]R7[WY FAQQ<,3C_P[A?D%7TX!5% ?'\+R%M[R
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MH8D;$!>NM2*6:A;N->> 5'P-GAZ2/'LYQ4VJ@$$D Z-5;DD;VV#QS1%I<[8
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MW@C"WO_/WILVMXTD^</OYU/@[YU]0HJ@:)&Z[/9,1\BRNEN[;LDKR=T[KR9
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M&.3T4^7_PH^H6X>C$-@* G9@:P,:7A28WD]13)JWQ[LH-3>FHFF**!ZV5&5
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M;;[?@J%_5# T\E:7(6=A??L&UO?\^(_C\XMCX=$77SZ?7*XCTG=Y]:O%^2[
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M:,1L$U5B5(96HC)&\6M"SI2J;9XD$:7'D*Y VCU0K4ZW!:*4*+ 8'.(IN4J
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MH(0;;)>C:+W\!I,0F3N']I!PCB:?M<^X1+GK+VF>BJA)19X@8&ZH+ O086Y
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MEGLOY-[GI4/Q0K=.-#R"FJ6?5SV/85;B7.#4QV3^Q!F8.#77B_HWQR@COYN
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M0?8R!(P]Q:\#G[%FY*V! =/^C4%8&ZO5<2Q7QQA:>0]!X=(@,+Y2OBWZ(.N
M?G2&R6U^L!:@_!W.0)!G'^IWL%$I?CKYSKS,*,Z;26:>T.,'J91O()'DOO^?
MO3=M;AM+TH6_]Z_ 6U,U(460M$@MMLL]'2%+LDO=7M22:OKM^^4&2((BRB#
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M%L('333&(4FXLN#WWD7/+1XCBL)[">&9&$(-!$=  4!B/F0O74FO/SI^ 8S
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MJ>SPJR0R2FYI6L)GXVT03V,>I@4LBD\FT!3,X/0)W3I#%W*/"IG5=!+>D/N
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M!J)TUJ3!%T4UFZNUQJNFC,OJCN<IZG%.CF4Y_RR_CJ\S/X#-TB>/AG-/\[3
M- M&V6:3#K?D]'&/;FL[2K(MYEY^E\]22[M*'C(^_9H?7GFESB &J@[Z;NXA
M-YJD4CE\/SL!3V_O+;^%[GN#KG)^Q9-S]]( DU6/P93%N9;00\F2"?K/((23
MOR#/ZO[!"NJ9NI(OK>FOZ6W4C$\,<9H=;1=;)]\GYK'\EYXCC#K/W,2LIV/_
M2,[$)KHH*M19-H-&C1>&>BWJXN&(SFC'.J3D%@D,!6XIE]#)$7!W(EN678;_
M:_0"/3$N#/BNZ??H1SCS)Y5GC=/23WP7&!2@\Z<;(ALPT#"9BK(HVV>PZL=L
M^4/V#F0B!R$Y38D[\3*\#9SV'&M\U R D)A&!+FL"G!E6T=53I<7> $Z'*-+
M>9'CS!&TB:Q6S*M5PFJ-[-7*([YEVG%+C<+$Q<4RKG$4)IH,(]+#;GBU##2Q
M6"P2Z1=1&"\E2PE,F>LGQ>DDR[D+0"^XP(=]B9&J J<?WD:FG85G[%)B,<E&
M\ A\!QIAR.AA!B1L!&JD)MVEGLO-M$N"YE2(,2-X KZM4U_+B5/+9*7L<$/9
M?+#H[ *7R:Z1Z,U[M;/JTD1%4_AXL\?1A>-K21C91D:' *4%$ZM1AX6D%$@?
M(9KEAV!.K36FY@[6P'KILD+Y<9L#SRK#!42'I+&TQ*:9[?B<2BZG(A]573X#
M;[F;#M!@.DS(C/D6S5.0HT,)M,8+A;>A0(3=2)+5W@9+A&Q?;YX5L5U6)X??
M%- T][1W>39$0IE2B ]X6F<A,IAU9)T!7^=_S9!E)@(,&BN+PC!=F>@)<7_1
MD-MH/QH:HS]@#)J*MZX3U_584-"?5:66 &OOZTD 4SNC9,O&)80N,S0G&Z2-
M->W^.)H3I9!>2H7B4]D+SG%P$1>6H42)3F38P]"NBPR6H8WPK9GIV6*>0G:=
MGAD#"@V$6=>K:&RTAKR99MCFZQC-Y7;CWK<;E0&9GW$M1P)#8<)16'*T==UX
M37W9,?]C19LCNLFV=4I&Y)4(HY@XC@1V1E5Q#(/FQ=;LBN+.(E*KT"6JC0 M
M>RTM5)9B(A2I<<$MEO;8HKA*6$[!XKV.O,R* /94,W0M*PXGI*7J-!Y6K_V]
M0]:3VV @EL1 ]'<>CX%H2])O,!!/@X'HKQ@&8F^#@?B1,!#._=ATX]*]K5*)
MZH)3 4%#^4\81>?JP'RKOK*YH%=1JG)4Q:HSK=TD';:\V1'R;T.IK>4+1MU>
M_HVI[])&JT.7]HS'EH/< %,8AH4A7;0X]X3M5G)UFEK0#4R'<^1%#ZXP\D\P
MC\*REQJ,-._&JX][78W3=D/.*M>R3#HKY4S]-&U6$&>)[Q'(=NA+BYUEC&+?
MXGJ8?>4[.=;,+=Z"9BOJ3O'VK/+O*.K?0KR#0^0L'>O&D<ZCE7^#3_:QNO9;
MU(015=7%X>K*(OY7T[@[XL\(S\HTNZ&?V\.]B8PVM&N!U1XO^!MF>Q_F[*SI
MR;YL0BM[KJ64L".'8"GU_B&%H@S$IL;^#2L^MS#R[2&+A\6"I+]QW8<KM(C;
M$GJ'&KI?]>C"E)'*:#23W[E+XR:UO65RO*E1EN,J92RU1E\\Z"9<\=S!@]KP
MXFNI&]5;IN)>VWS!VV@45K4JE88T5]-Y<-FNO5(53NI)=;(*F.D;X#I+0(90
M=!3DS:<B"%--M]-: ^97/:!=GU6%8MU%?2EQD7!4HCPO.<7A@A*.R(9U'8_Q
MA\(<[!:_8JAJ?(TPU5[P*6MB#FH:I^%!$4*BI@4-%9I$%8%8O7:_NZC=<Y(V
M_6[MU?A&_6Y)2C;];A\<I^H_09RJ)9"RB5,]39QJL IQJL$.Q:E>;OK=_LC]
M;E_>U^_VI=7O]N/)^?N3<UCXCV<GGRX.+T\_?W()!-:CP^WK!]C![P5:\=TO
MX:^S?L\LV);CW/7W#I7S=:*0IH<CSNJ=5TFDOA5V^X.MT;:=O&_EC" >_>@+
M>E#81U"X5CL*)2$\E#Z(S0)O.TQ)89[CJ!C,C+$3^U5IB,7NT6TTJDKA>HE'
MV'>%L^G8K%?163J!,8;Q**]/48\AI4%<(%^&U[KPM(QFX@SO#+;*;3^?>1Y=
M(?H4AWO1_8>.]U1#U4] 7-$E6S[^]+=_XIL)U*S<X[.,^B7!0IV%"UX,W"/M
MEL$HK871[L<G6J 3O4"?98'<YI%ZQ%\YW$LOA!C(DHK..+5[ZC2-\EA3VN.<
MZJ-5X^.G-HW]SIZVO>"PWF_X0OH-?^1^PV[/9PHBD*Q3M"(LOM3[>!$-<C8O
M!; N\2L_XI(Q&/[7[Z\Y[KLJEE8FYR<7GS_\]\GQKW7!4(^7:_RGO_%!E(/M
MR<@3''.&\Z>1B7A]]8%^\"%F*7Q8^U:]+NX!_XNW,M_LO"^Q8\NIA$=-_E)O
MT9(*PEN>KU(7#Y]ZNT+I2!HOCX9((4S/9^?UY'B90\'E!XUW(V4,>NJAWUUI
M/#[81AW0$)^K9HA4:=1 AX"K'0S_V"%MBYI=),'9?9 *O_V;E);?XH'Q#1$J
M]N&86+((LB$,4^%WYZ$F+]9JJ*$IBXHGP]<52I!BB"TJR5#1$"Q7QY5U'Q@+
ML$,73)EU% 2*Y96'S>U_QAWO/KD*\W%B)<VRJF0$X(0O0;W*N.PK$$%K")<]
MA%O)6&RQ- W JFT.&.+T"3QJ9Q"$R5^VAP]RC9F*$@5,B88G?*6]E =%Z\^Q
M!! 3K-3_>:4V_X%%-!/L+LI]AVP/(81'_,%=*&3#4<X+3 >5FAZ/F@+"]SDS
M4\MM1[E_S;@L=W9.C9176#<>"S$>9\IXI%(\KC3\GRK+JQDC]*.">.2H/YQL
MC=<@4<[\D:URSF0&H.B&A0@XWW7#//N"K97AZN");\54;+9MM>Y(5<&Z+(@;
MI[?UA2CG++U_)"LE2P]1))>.7FV_G.GD_?0WN(3DZC4Z&S,7\X:U]%MZKL\"
M/ICC[D_1PR-L<*8.G6Z&(8>(DU5</ILLY.*EEM+JIT6[O^IM\KO/YYX/*4C:
MY;?S^RO7/RLW==B6L7D^^:F6F*:.8VZ23LLFG09/D'1JR8ILDDY/DW3:78FD
M4Y^23J\V2:<?.>GTZKZDTRLKZ71X_/?/OY]_@DOI<I-@6CD[\=1UJ"9AG%",
MTC#B%15&2&*,T1AP$CLQKDODF(G"5<Z>V:EJAJ;,, [7G",U IBF_*6+>0)V
MJ?N-(S FD1?0_?0]@H53YX$"HB+@"<'>U!\"\P=3,&G^*BW5[C,;W22#]*Y"
ME"0G$_[(JKQN*<M/^+6-SJ=4 FBJ0[<)R<$.]M0J.C9U'[T3P6%9 GO"?&4&
M(DS-@&K[\B?MA3OW!^Q+\%5;TG.V1,@"$F1^B^R"<28XXKV2C6+BDGMC Q+<
MPRP28O3-*5A'V:^O\;/U?$\G3BR'F/_9%5TJ(,18QY8(MJD/6" YG42=IV&<
ML]^L7-"[Q,KMU<H-TEPM<N?/N;:](5J%B7++ZWY.8.9->'3MPJ.'EJY]VK"H
M"H7Z,&8_+-HX@I62G6\8#G6^0(\;1R-A5_J5=1SZ@4[@M"%^ZJRQ+F?R VZK
MO]*;N.D2<=/F(_O=]W$3+WW2>&F3.]X)3M\%GTZ.3F"ISO^]B9HN&S7=?8*H
M:4M8;Q,U?9JHZ=Y*1$T'W6%5;&*F/VS,].W;IHBIN9G$K[P(WOY^<?H)U/"*
M7#(>*O!1)I7 J4IBX+< W>0_(#*/R BPR2B1# HZV+&A"E.(*=>TY;QTU'TM
M?XI+]0%Z&O)AB?1_ZG-ZFP?(["#?9L\E$2;NP-G,J7@6B&(;CE)#!A^$"%P'
M6M+/UU%^'<.;O[N$?F5%A8LS#&' H,Z1.K.@]LE8KU_&HP#;G8^(-%T5J$O?
MLP(IRTIPUJD+BR.?DVQ42=5"/"/N0N%%2,#A+YANL8P)$TR0YS2J\FP<,44
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MXD>-W8S0FX#T7</M0N7 JL]K]8KIIF+"/3]T(VT#M_=O&ED.9R7T/G:LQ=+
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M[$:EM6L#O#=\T_K+CI\^MCO<J/YU:"PXI&S@A#"@^.?^?J].NR81= Q[\$%
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M9SV8/+L3L65ZH' P"05B<<F+""F73H$BPDZ24T>!G$[CVJ@W>RX'6=$<S=1
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MW04XE!LL3.$+CK,1#3>+JJ7P3D4/U 2.C)'>!5@[A/*'PWD %Y;2)WRW.$N
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M:6[)P!OD#%2OYADR.-SJI*2PQ7M;(X)-:@-;M1A0C1C5&M)WN>03N??B$ZW
M8!5CDYM+.9].B"_] (S(R9*BA[Y3#^K.7D 07T Q#?7Y\O^<BINZ71=E#?X*
M-+5W2\H^%Q/4R<9IC 1U+.MZFOBM:46D1%^6^@40 _,%A@1@CPI)/9I%2*)
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M45"#OS9"4C;7WA!MFB<U]UDI2AWY&(VD@;L.9C#Y%Q>1P/V_0&*'YH+Y)PK
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M/CY8FG_P=*YN:<(>>E^ND*0^D7--$II\AR7)D='5]NK OO\5*-POZ9^U/MN
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METV.-%@4 @1ZO I@6L23U^6T 3R]J.A-*\$]^!AA6#Z@+Z-Y?/+JJ[,/Q&-
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M(YCGQ)C'S\N&.[E& FAE"-P8$5$KR;1853 WMT3;VP2>*^W_:@F>:/M/UU#
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M;$N^N1.S+@R,Y4'38,?F%%M5G<(_6LN#6+I&<0-J24365ZW& >\QBC74M*]
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M_#A[C63["%Q?:PBT[S7S4TGG$ Q(E]OA+P4FAM_"(<>NSAC?);G\-DCF/WY
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MV8Z),^BQSF^_A%\F;N>2EH@(#"(O-YRQ\C4BF D#/?44^TG16?'^IL9_:#'
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MF[%BY31]?)R]@ O(V]"*/(F,Q>GOD+S%0@ENXC0EE#GS@?9!SGB9_-KHBHG
M^5ES-2+$:-[D%T-?Y3FH0\J%>D)<5,[11&GBMR<E%!\6V)CS(I0Q[UQB&I9I
MC6?.Q&*RG:[R/@SLW5DWBO?=%) F"USWPQ 0,['=L$,TI'ZBY8WA C679[KL
M%0>^I#6W+VYIT?>TL[/RV@H$M8D+'QG4C^A]%*@@:/(BR3XD:?QN%<?F^.0%
MR2.?, +6R.LT.R9CN+<@%R*1[1!X&H,%9$R3RPZ_81<DX=&<%Z2P6..[;N%=
M'5?SZJL7R7)PE664L+2)2Z]OL-FX)I?F_W$]H]O?L'UZ3-$AKO0KE.H_=_10
M/.:7I=UCT=1?,Z!AN<ONO7K^\O7]2419*9-@B0DN#U9!0:R8&43@_>()[),6
MQ=P.LTO*>"*SD%$J]TED?-ND29I"&]'2IG"511QO0[D40W+*7/ S?65_I]6K
M6&D6EIWS\[&YQ!$\(0-JG? *UMC702E^99(VPK4DO*:[L>)(>6W*7PR)6:^#
MDFQWOUDUNEHUT*! '3F;P*T$*T^Q<'#UFR2U>DKS@5S(76$GP_75=D=RGX40
M-"I->I.& 5%P#@&[6;5J2R0M1N\>;.7)-0I8?VBV4(D\9RL\OL.->GW06R?&
MX>Z3,% -A<2Y3-IYF7LP;2XZ&)2WAPA=AE4B(H8+?KQ>41F(N+)\M":! ^I:
M9[ H+BPA0][RA):.+[;S<MYKJQ<,/.XXB=NI1"FB>\I&,B37> @O2%-(J$V3
MMXC\1A.7XOW<CUHT?BNM> 4$9'>'!M#RF&\N/\_+-4>41V<BJ7H: _E^K(M'
M%\Q\#X3PSADPSB'[-E\/<'W'MO'AKOID%2?'?)97[2[O <8YW=AQ8Z%I1Z1F
M$N'^' 53@*S-ET8DQ&:_(X+59W'&2,1IMN8[0RKH03GG#/C1F?$KUX6$AAM)
MC?B^IV !JH07RFZ#FA$-?24.(99?SL*B'[(:=#4H"=HA18FP(>;O$'VE+]/L
ME*.'#O/1HB@4V]%**-8!!VE#SXL=N[CNBYE0J;7D["%GQ%=Q;RC"A9H!SA(<
M8Q)5N->=-7_CR$09&L-\Y)!7&M%4GHEJO?-6<WH;2J::W;\09L'+/';2/$2E
ME#>SW QD/0BSJ 2R;M1AVE^55.R<DY5J31<P8YPJ,7T<VP^[N'&HV ,Q+HY9
MF5C1+)Q5NAGD[E,_(5,O(4CEA\U)]VET!WFILEV10ZQI9DB=[X/%3=QQRR'9
M%VI8>!^XYWQ;H[G,<$4Y?J'K&*Q?.&1P"!7*)Q',+(9B@0&2B_$- LSKYR)B
M\2Y6 >P@!&OC.X6NN*!EV,MG^]RE\?8M<EAUX) !#G=E$CVRW$[1A?-GQDD$
M2X/7*I@E-?^V8B>&*ZHK%SSP:&P5VW2GY3CJ,^'_"#BR'? 8:\[3B>7$TIUY
MR_&'*HK%3"*IC08@BT?:[-OZ B"K2?!V@6C*$*(1S$LR YH4CB=-P]_WI@25
MEAQAJ(#H&+LU&"Q!?"3=D,9G%_G()6?R$AWG?<E+8P+J&*H<1?./CO"TJ?.Y
M&5J<@V3<G;V+Z8P]P>>85@N6X6-W"IZ_ SX,6_ LX4%4B/N9A@;"^=_-V]?<
M6(&O5/UF*K!H%_R(JO-T732LZ)>F;M0TB040RL,[K@-DP#A5\W'V-=S\=SFB
MRA--@= EWC4Y:;_0!- Q"E/+R"A]WQ!7IQ44[R3FNXP_5)RN]$,O;+X*#"=L
M(<CC[+6&H]E^2=RFX>P$LUG0'G#5-2.XQF<G7&.[08FD.6#&)T9/0'W)$> L
M-%@FM1J]Q3'+N-:E"$QQIM'F\''65YNBT^#,6B^^RZPF#H:,AJE9 H+Y#:MJ
M5J,V.;MSBT:91C'[)M<\D ?9><LE(-GO"A*(R\E,28D'>,D06#0)'^S@0]-D
MO[9FNAC^\ "4N"I0XND- "7V9/(/0(F; 4I\>KN $H\/0(D_$U#B)VAWX6^5
M6.1EET<<TS2X&^OH$6ND]4@"E['@/@)H-<UTE\P&$)+^NY+D/4!4XP.UZRX
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MC.55U*+K1;R&,X+(UIHVMN)V#]ZV )9V+[.3-^\]I9JC5!!4Q/XP&J<6)!7
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M $Z7!P1D47]0/ ?G5]LY<D\Z\8D9*B-PBYDXQL,6[VD$$Z>LD)9'<(2@O0Y
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M+M0(=\*Z0VYP)\Z:FBY@X_1A"GU3)'Z^T3)(U<VZ+,[#(J"15V ,TX)K*ZS
M6INC[SP#'BT <"3#!KHFJXXETXZM/G>5GY=2 K7U^R++69)B7-6E(C:#"JSP
MF9-L94QRCC,YQ&+:7D1S3ZP2WUV-\;"IS.LQ+)M 0]RYXH1K-/M^Z;+7(4/A
M'<6&OO+(FG V@9+M':?RU\].3UAIS4FU[P:T'LT>R(U$T3V"?H00315'6Q1O
M!<?-Y('"4D62?)0"]DW&3T]"TI$%J< C$#=:40T*D^OJ"&!/1&W0IV$/J69,
M2ZS(:B'XT&%*1<8(^:%OH)E4L 'NPQW&I<:T8^; $]<"-Q_[@)7N&2<=-$*
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M14XI[3,).5]3$Y"5:^PVL(.-=I:P1HFCDB5%\.D6Z+>V%;UA\BWF(IEA;[T
MWGMKVKY]_ZSIP/40ARZ(P_,'@#ATY.![B,.#0!R.]C8+XG#<0QR^#L1AHR)*
M=X)!M,64/N@NB#/L>,A9T"WUE5X[L#P]DK,NVBH 3> #C&O%"LWTPC(Y5]]@
M\JHG=]Z>/C/5NR]?GCH=+M%"+!)4G:)5Q\>!326_1Q,CK>%8\@+D7C1X/05]
MGHFA]291TTN$2%<*.S2WQ&XPQT]V\D0%*55II\@;8B#W #$/YX0;H7*7Z]Q6
MB794B)9_\?:_DSSS#"0$@!/"P73&,\1UAA:PF,[L]33,*V/&1MA@CDT@_$R^
M3#('"'EF;&DT[M^:0WCOMG]VXD)GOX%58<[WK;D6W#-U8PS=, R/%,J:G.:[
M+T]_;E1?[R1P!L9;;!Y TS=(^(0QR7R5S#!XWO!DW1-:U!1@Q_SG19;H[G1@
MTK:=7.ENSC8)F]LAM!K:E%*G:Z?G+ ]4(:3"-%\:5\)Y36@H\BNW%H1PWD5^
MR+ W$B 0E$-/Q$-!!OYSLJ@7!+2?%Q@$T1 #']8;=[&9[U&_/46/6C/4VU.G
M7+!S_>/1'KC]*YU@F7&-.>@\+(M?BO_;^6U+"VXYAQ$.FI2Z_,B\6")$J44^
M4?:^16S9-HW<AUAZW)CNODX9K#Y*6\&$=4-4U13!=T'>S!37FM C9DE)XI_+
M\">*RWS!I-I-T!%43H91?C%;E7,S"0+_>I447%Y/XU(:1]?.%ER*6N9 /"(;
M/":\?<?(IBMEQ,:_;0R35$M>^ _DSAI829)@3X>@V+2R!5G 1@@FI-I]:E1K
M NY)EH&BUQ+&RA%Y+5:>82J/*( & $A&+HB>B1[;UMCJKPJ3QPPCTU4'J#0T
M\V%$B!H].+$.$098Y;@KG6Q @E!KB+!LGC,];'N$W52=B]' 0AUK(?P77+.4
MED1M,RR&I'ZX57-FT&) C$;@8$MRAE .!XS!JJB9B?V]E"AYPDA 4P5L[-H*
M1;/J&/[2*%?PDW MYT*&$L@FI=D#0:$Z]HL"=D$)YZ4J,/1)YST%6PC96LUT
M-1Z]'<0C4EV6,TJ2T)&C0Q9_@QUNYMPB I]APJ)2L3')-$ /9>?N#'NW:O&]
MK:3\6ACZ2@5RHH)O*\H&U=D"_J&Q6!0UI_ 2'*3ZC%$ZCI)-5%CTO8C_1/'C
MR@$K(=JZM(&8J\G&H<9LV!@*G^V&QSA\11=K\_NZ]H9 NA]><W#U[4L=CMJ!
MW[U]^6R H*Z%TM:/*6&&FT>.0@QKZ>>8*>Z@[:QS$H\K*7DTV .;B_:VKANK
MTJNY=_Y5GM8@T,EXPH4,X@1;:\!1JPSHT;0K!@%BRSNE<%PK-/<H;&96^5?6
MO*^2BU<=DP4VC56FI##@0J1K/DF*&%N8@1Y,\XM: G(6+"4+$$S=@AOFF&5$
M8>$[*K:%=$RQTS:\;6 E..O0<HFD52_EPXZ\P/YJ*J4_++ ZECNF<P$SKC=!
MK#RJ7-,BC,N3Z?#]"[-EI9+O-!UL!T5,APWF 3R'!'R8/%C#%//!4<%ATBZM
M (]G7'U;#3ZI( J<I, C.6-Q)(EL)^/ <9",GZ\LSQ+[.-+/:IYM1+O<+S+Q
M0A>"OVWUR%]N_PR4US8,X8PF*%U#D"?Z:'K=289J&#E=NO57 CB$TV* ^KH/
MZ(YLM_[&1!+)83F ,8P1F,]+-,7]1KW,.:S@-ITV51C-41PT3818G58GX-])
MDFMI;>H8I$2\4.G*]J*XH<L89B7\5A6X C&[K2T]RT$$* .V:)PA%X,0C(^*
MA$B1Z;5B2PJ[U+>G#G1&^@3$;C=2Y[1-8R]J$Y0[(-"V)8#ZD^$O35_@#Q:.
MS;L(^ESZIXT5,5/,K,[KM&,[MDR=%NM&D[0QJA=HMPU*,,$6;YGLDXQ1E<9+
MU$9FT]HTQ3*IKG,/]I=3(1 ]FGONMQ"?;))+9H(&M[9I1FS<<[R3% _$S!>)
M]+T1T)>./. 1/04L<\UEV,<ER#D37F/WP-,BW'V,NKN1E8J<[3AE+:4_WEH<
MQ>*H3M,%CI6J]T9?5Z$]!UJ6;3FA3-<_-'RCK73!J,6$JV1#P;0=YG538X 0
MN(< 9*=Q\"Y:@WDA$-:/9I@'&DKO;8_6,S.N!2VZC^_/P#@'F8I^C+34D_;#
M?'_R AY/@-@W4A-TQ&A@Y.3.>-L7EP>?+)!<-_>\]-'CUE3.<;(8PNQP;VG.
MM4SR=J?%[*Q6^@!2&LVQTKT"6F12*2Z7>8ONC68NTX9H'>B9-Z=*ANG\0*K_
M'4>46H*]VZ_D)5KFF;*V:?$-<71C\/OEAVYXQP]<NMZ''T7O/%]3@.0&[&RI
M)B^9D26RCT2*BW1C;>1?IP,+&,28-7##((G3U<@X0]P )>%IQ:BT)"SEA?W\
MC8/1K'9Q+ MR*!D).)*PR#/I23)3-/N'VQR;*KZ?.80OW99WXF?L<MKQ+S%5
M,Y9^@.$0!<]H+P(*0KU3YID+G#45I$$G#"QPH-#=SL0[@LC#KAE'!S0*C=\A
MQ2G'2SU;44=@9T%O^QCID,"GZC$4ZV(H#O?NCZ'H2O+W&(J'P5",-@M#<=)C
M*'ZD-A%E/>?^"U@.4M5%Y@AZ,-?^K$OJL,"M&U$S_:P3PZSG*)2:E*1!?$4-
M>J%$&!P9> H4 /F)ZZF^4$EU!0<2U]! Y<P!5?T^7AF[,4T]KWMXXOL<;T$[
M"63THC_$*M)->LNZ!*IJM:!W .04-:T?#26TZ&$)V84:U=^IY_YL;5;Z9L.0
M*C>H93E5RJW8V\DPPDP)/!OM;FE=6RB\5)T*4KAV^-_!=9Q<47X479H<#@'C
MBPEG(05L2J$"[>.X6>.NH*F##G@+-Y=30U8*#I%=>V/$-;HI?UPH?0:,WC7.
M>VL\JD%M0D'<;J/=_V:2M6&;ED #MB;6$06D>!,4<PBZ9?&V+(B;I5,-F-3O
M4,0 .YG-[(P>OP'PX'T:NY/^)#K (T9EKNT:*"73 T$[& (Y9S^^3014NG'B
M0AD;WS9%3.9_,0:]#1FU6/WT#(62H?D6;!\O@U*"-$W7:=HVST;P1=2),9[#
MX?B9*A0=MI6Y[LUQG92VD(% T72*A?@#U:7JI&X)]M@!DAUKI",NI?MF5I)J
M0.,_6?,%XK9U/C_!<=BZ:HJZ.?@4[VBN?]68SM;8(],H'4F])81F,KY8D\&M
M9I//3I0LUD IDSR=)W.@$_Q$I)MW.Q5JA@!T-@F=*6Z]*NV,2;#HG'>[7G"1
M_V:\#5[Y)14(R"M"-(8^*'L6/*\6]!>=''I-CA:GGBPJTUU96YB?H!%Z8C(J
MZ#A53@]7JY*Q ,.FXN))?B4MB\ \*_&&A]KM=B6\&?L)#[K"AB/8:VIV!;>'
MMG#"(W;@ZT6E^QO9_'[4S+R[Q8L&TFD:VTAYS;;FM\\%,.G'[U)LL"*E;Z8(
MAB!3%SE'/DGRJDHYV6;J3-P&9"%#^+-M?>J_ZR/U;;U@G)3$(=FQX!JX-*XS
M;#=R4Q@'7O0[T ;FQG6QW7B/6;/EX^YHFF5>"JX(-V(F>TO3+',.-$P+2_ ;
MU34M2BJL!Z0,/S%Q[E<$'E$YRKZH2UH,-JV6'ILT4+E$@P2!4].Z+ 59D*F+
MO.*AZN&9O,=L;VR@ (SUY%)ABXZ-_5:T\!MJ\HX197?#FK)YB!P?#N:(3+-0
M0QF4<FZNQF_HYJ^LN2J3CI)CT/=!E<<OU-2YW9'4\0P'KTQG)_A20LN^RBMN
MS?N6\: ?;?^0KJ.RKV[9)=#66RQ_-X1U%'4M=(>->)UQ<,1*ET2AC)H3!^?6
M/"0P[6]=J7VC>13)6N3]C!WAWC_4C-E 1F0P"T(;J^GP&;L+6-PTH5CF@K2Y
M+F.56WU+O3.DV<AO&JW"9TI#)GAHT<><[.CW4K_\6Q/>QM>?E<!+Q>!TCD/A
M2D,/.R_??SQ[]^S&ZWH/VH*ZX4WKHF!MA)J96EYP6N^_#I ^CCH82S</\]$Y
M(-&\2EMQF/A1)W(S*[ KR'@4(]3SZ9+%,C:0-%\"^"(/;#\X\(*SPXBDUVUJ
M](&B7J?LSS9F*-8?W/8>6^B9X@BO6<&6JM.;NW!0M:O)=(:-N(2U#%NWF6&-
M=DQ4%:$NI>>[(UELPQD']=S@*JL4F5>LU8R@0)8+U@GA]7+'/72?I6W'%8@9
M B0.2NXM+@:2;I?@P/09EX,>&T?\&8#;>,[.?[U__]\^] (',22EC&$HG<&E
MRB[0:)? !"7#MI2B;].-1^D2:(:!DD$KG4,Z8-=H2 )](AU<Z*\)N!34Y/\#
M4]-I[F/ 5%;LFEY!''TJ1?P@"6)C%AJR5BI2I_2(AMCT 5>F(9LLI5X2%(+?
M@KB^CW]\*)_A!,V4DN5O3T^ER%0O+>:I(@O;'9X&C^Q\P'(/F5:JM4GX2;EK
MXY<P"$Z&%2UK4ISP-!F?H/N\,QXNQO:7)3>JH/ <)?5!P6@P'+TMV']9HFJI
MM+?OY'[$TGOK=%OEWO,V0>U>#(V/M4Z&F"!2A= ]ZJZ+, H)1CA<">8,M;ER
MD,>W/"9R@8;<AR'0(+J?5P0'5>IB=TJ.$\B ;;9P\76&ZM4=<:>;X)1,%YV[
M11L(O7T[7\#--SIM;3#.A3<8C!=#NJX7-#?/>LNH@O']0+AZE"-+I(*5+<)3
M\OE\ESJ6AO)/CB\AN_T2"+.BII'490'D-,;;V:9P]T3O)D+F>4\6$JJ+"^S#
M7,#,ENH?(F \R@7'O+GBGJK[B5 M@,UO!E)Q3008U'&24FM:/\[N=K.4;D5>
M4P*B=J==FXYS2C,^=RP-0S@:,U',R$I&-'45OIAHCX[?6P8B[2I6&TEK0N>;
M8&DE10C^>Y$^VK$KOBO+<SY1L1J@MK3JB1 -!">AL7[8)R,OBGIIJD#PT+@\
M9HV>2'ZC.[]E720]ZS IWVA9IZ>JFE_ Z>/D/"WKJ2ETR<WDYG7).%D3^@NN
MR[_\\.H89,,G^_:4P]XFTHF]@:F?-$'1,3#H?*!4R;^YQH[4GPQ$MU_#1U.&
MSI?,")RN^*_4W0Y;0YCO._*%GN:/(0VNN]% )M*M]!H=_&P3Y8A:(&7Z!__5
M<*'P V4"2*ZT-Q1LQ(=Z-$$7FF#T &B"CG1WCR9X&#3!>+/0!,][-,&/A":P
MZ5 G,Q\/9(J5,>SC5 92#<0Q<#)VB,VE+IB<AR!8="/N+TV[6LH$999>X928
MZD)Q#)<Z2R!(>^E[['92 %6%S>L4',]48 >Z[E:\+G+W<"HNOA!C>&AV,"A!
MIT5D?=JKTK5,7)>O0=,$^,8M8-"6WZN+$>,LJ]$D]';/*'19FL$*\C$Y6W"Z
M..D1E[III_28Q2(R;D;/H'(.L^G+T@6#]J:<]&P2I(-LY,X>F5-];TO%$6]L
MHQX&8#ZEXF-_]V#Q<C,[3'%&5/T)I!*T-"MSEW9DZ5Q![I5?)@4XN9SU+_6.
M0ARC9'8QX\8&<Q(D(77K1C^RP_?/3S)42"$!\?UI-2R%@O$*..F7(/JQ+E<U
MYIB)X#O8%XDS"+D&C;TTW-LT2X"O,S5*]SGJRI6P&8O(=_(N[$ _>QP&KNI.
M"J!^$FA*%S( TK"XM-04=\,O]$7#!6@!Y]3S82*)++$JY<8C=>:3;6&8=;PW
M7%]B.ITLX>C.S%34%]Y4U(8(!$]OB_U@='RMDX4M8,IIO%1>.7@VN$J <MUA
MD<%0A4 G3#G?H&C.J?240=6<9#6+%LF2>IDT23R@L!R\C5=>]F\<Z038ZVSP
MW[08>RMF^,8+&;[1T9Z4>C#_GL/S1L<_'1\<<=]7D#ZO__L%]BDEXYJ+6?,!
MM>./I VICOO 3VEL:VQ;5^,=1;@RT^VRLQTIKN7;]2-M]B"59KK^_%\GN U7
MEZ!$B)SF_!4!"+'C/2ZS)1Y;8BP\=.A)"UWGQ:=!/"VPYD7.%!>_!LFQJ<$C
M@L!V! DPP!HK2I8ZQH@$(GB0DU1",U'K'A1N?M1. &\CS<BF!!+I?\$"67*
M?I6 :$"J,,<A E=*:SL<)[N+%R:N.]VY$^8%WUQ'1O1X!\+<<#>?6T]&>BW-
M25>;YQ,=47DZVB(-!AM,F("DH0C8"<0+$K]F%)J9I%Q@P%H@/(R-S%;F7G;<
M0=[>B7#U&(7(231R*19L\YD#O%Q)0VMM]>E1[.A!V/"I;?ZM(SI^SVSN)B*]
M3@S%VUDXJ'GY5G7-?QMB@BZV],9UZD>12- !-PKP4K**J^=5<U!TJ6U9C8J
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M_OV-2O0?[/6)_A\IT1^T3S4%*6RN8K"1RCPH+TZ=).&G8_)TY:.1N+!7.#?
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MD!]8?;2W]Y^<K\(7&Z!%;% A3MTWY56VEJ9LYT,M)TK;DXHHBN-7"B_6L]-
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M+IL/I32HQ6A1[W@TDEL[$]'J?4";4^1']9EA':<NR#4&AL4(&\ZG/U+Y+A\
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MN#74ZP48\87.^;_!&41OJ&[I%,E@:[63ORT:K91*.19M2S0363K82 A'B]'
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M"Q"S/BGW'O)Z$H^%UL[!\VC\_.A9'R+:D.7U#/"-&>!X+SK8V^L98%.6US/
MM\\2C*+1WL%&&:\_4(3T"WI./A8G=A/6T#O2FQ8RVH^.CP_ZD%%/Z8^>T@^C
MHSXXVE/ZQE/ZWOW(?&<4G1P:1'/;>\)O;%:Z7CL?/T;$M,L>Q?;M:5[V0=+O
MOKR;7>3>%5Y'P@72#(YS,,NQ/WZW.-L3X?1TY^ P.AR/UQ%H^CM]?&E3EM<S
MSW=FGJ.#Z/CHN&>>;5Q>SSS?EWENXAJOC#"TUN_REM'S:/PEZ+0;#?#[=T,?
MRX %WU#?-$;I6.VF\O7C6*X12UNRWBT[WBU;;D\-_7(WCAI:E:/SPW_ 7W&Z
MB?N!#9_^TS&R[=86,B]L"YG!2SUV=Z.FU*P_&+"K-XZ=)ZPGKL]P&NW3T='P
M.;<W@G6F.-:OR@=/QV"U^;]M&_5YZYQCAC,^/=@;CAM/6^L)!\,!SBDR0^)Y
M^&@")P&'Z@Z)-Y.,_O+E8WK80J5_RHW>? 5C-PI]QUD\:SLX'7#1AAL#:[Q=
M;#Q\7ZR3\?CH?E)R S;2QD>Q);I\#B0\//$I.,F &'&N./+91&5JCA.SA"+C
M 1"C*@;8:IUG8A(CR$RMJJBG%8_@;AL>_?.].UO<)L5[=NC9X7[LL#\\;K##
MLE#3-,EP\4CEK(6,UK%2.Y@)S0.GS419XB*<) L'L3+/:=G_8)!/8(G\1;"A
M%&N4]RK+!F^2*;[5'2\-7,H3V6>#WX A@3:K/-,SR?&-M+=ED5\4\<(LN^?%
M-AKM>?&;;60-7AP/CQJ\.(<;3Y-J172?$V[/<*+F/\N15>X8A3.%C)PP7YDO
MP3.G>9:I*?ZZE1NOD^J2.!!X:9F7( 2$FYUQZ#AQFJS1GJ_:Z*WGJV^VD37X
M:A0Z1L@#EVJ!+:Q6$=!%5@.;B2&'?(;CA8L\O47G:2TTS7%$^QWXRK<<Z87,
ML<YL5AEE"RR'3_X-_G(-%!_1P?Q#%:5:]9S71I$]YWVSC:S%>4WKLKR,"[4[
M(8*?Y@OD,$]%-5B,&0*^:9RPGO3;2*(G_6^VD;5(?[_%L<KGJBSA)S"JYDIB
M#J V<#JW.Y/D9_I#3^0]D6\VD>^U658Z=.!8,S9DS6$UZZ2 W95<H7]# _74
MX.]O1\9W7\9P!G$*5E<^GY>J&DQ6K895DC6>5M;+95X03^%37YV_T$\=?G6V
M>C2I%;?GZZG7\W7KDRO=[6R[TBN'PU$SNS)Z'C" 1RCKYD9T=F5\.-SKLRL.
MZ_4*8=L40EL(ZPY63V_Q] 2^V00^&A[Z!(ZT#+\=K9-4Q!]N<W\C# \M,8QT
MI=)5Y'C#K;9/IX?<.Q#M9-:STS?;R%H.1#,;?T/*XSL8[]_,>#U9VWAMFGI-
M1ZFW[[X9F3]N?LV,>]WI\<?3:5'':6G<%73B896JK)*J+A0:?=H).8O!3559
MU;OA:[.[W\[Z#;:S?D/MK$^IG?6VNN O./VUEH,<#=[#9L"@&OR:8%9@BL(&
M[*ZCT.[*YQZ-)/;H&EES\8AU:LW-;E,!";O4SA.F8+FA28>>2U+B(UH]'DR6
MW_S:MCRZI &+*@:&8J7'W<JQ9FEZ.;A6!69&KN*TQC@7&I+UI(2OPW=![I=
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MB,)J37X8?U5^N(GV[X S>). D)SI*,%9O$0&&WQ095X7TS7#]QO%^>O;U>_
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MY;Y^RJCMPD9WO[ FGO_L[.7+5Z^^\TW=9VXMY66718YH-ZH,VZ%*LB1[YH"
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MW\3?+!T!Y[W1")ZCM9ADVI,RU<?^9E ZT$S0X>"W_!K-Z,YV(+$8IL[AMRQ
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M,&<VOWN3;W!QN"FJV/>4.995*'"^N#IZICJB]Q_?Y"?$Z< \BP'N\]%X."0
M74RU88?0&AXW1=P=,%6P3?I!%Z]?6T?M3;,4W(6U"/!K@<B^P_D:'__P>SXE
M6K]'%\#0_1_A"\N"#AZ)XGQ>(-<-?AH6>M+QK[:\Q$(^RL7B2Q:=:1%J* LQ
M.3/E:R)8@<RVYR^Z\36P#C1""]"\1Y2KIA7/U@F8?]JI9 V\B]Z+6OG__7+T
MX<W7?/'OS5'NY,5=8[*7;_QE?Q89*S]&8!KU=LQ<T<P8;N"7%:RS2(X!P/R
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M=^Q\L(74LG,5 %?>NU2ER+W42-4&:UW24)P/T?%\%2]T/'^PA51Z+.IF%[&
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M8^#PV46OK$*-86FZ+OI:($Q%)<X[]8RHZ7<*H,1:>358"4W P XK"^4B[]6
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M/'BZBVN@VD_ ;4/44R<?E88E9M=\4R:['&<J1$V]']0*CY=DDXSZN@HZ"AT
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MVO,7 _=X</KRSOU1>W%'NZFMOW[BXHCP,A_->I^361N4-&J@4>WF'[;N()M
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M+3A&$F*4=$%R6;*T9:M:M-FOB-Q.%#M1;)@H?O9BG(D*LA+-YXE(4QKYN(
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M>ZI4FKFP6JKRDZG?68KW248A/@J(D?5*Z1U$A90P^ -OS-?;:C+<=YF&MS;
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MF.4L3[EB3J1?7,:"<QY,3!:D_HJR+FH1A2R%6I!>KB3D" E9Y]\C@JH2-T@
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MMWT.@'E8;BP0483J"Z-0')HR0P2*F#A23.[.53=#$C:2[\K0,Y4%"M_(8?K
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M:++1,ON;1@Z:FZULEK'65R^T'$Q,5H:VLH%EFS,QAK\V"']U4KUK1WU,TE2
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MTQ+<\;SY$G.XE*0-52BJ4!5IDP.2Y\V7J$*5I V]HX.HT.,A>(WJ.%O4 <\
MS4:"--ONE'+:S]JE488^?["ML>W8H0TD7'LNVXBQ0R3KUK0[G\R([Y.I=A]Z
MDV^L!P;[UYR21?S@O[6+MV1F3^SPE7;S[Y4=/OTZ]G^2[F$3(AV5$W"VK7DP
M8H=LA&RD& %GVRX1V0C[N=;#VSMOSD(%U813K)P ;+6*"@H-\:H55 W0([7S
MOW9,5[P6G4Z=!#CZ^=@HCZI L,JTX> UC/.I2!OR)?*EBK3A0&'D2Q5IPYGL
MF!=1$]I0A:(*59$V')>.*K0FM*%W="[@H (;NWD>618"O)I,*/^$ =V$)VOL
MD$9@[Y43<+;@_XY ],N-!JV9^F@PPM8AR*BJ,ZJA=PSL<5,S?[2>C%K>:V\=
MJT8CI^)1!,BL]<+Y5&56S"I!-5B%&ES3NF[ME3W(3F1!-5@OK$Y59D4UB&Y+
M_=R6KFX.1[688WY>Z7OKP#M_1:2#S"?%U+ZFX^TJTX:Q@!--6QH(36;$,Y,P
M<Q7YOOE\+Z[PCCX<(>,K0!OFSYQV>'=^J"HR?Z/QSQHR/R;IJ$@;ZNG33LU&
M/:T0;9A,B7JZ)K2A(WE:1W*HMXUV,[%@]4^N%/#]O"2^%=+5TU]8 8G1W2<]
M!GR7'EVTYS8BS%,Y 1AG.H)J,?3!8!?5HBZ;5$X \NE1^-3H[A(.59=-*B<
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M(T]:6G<5\*U_\?H6!:%RVO *P%3!LV5^[#J*J8(UH0V]U+IXJ34 ENM[=O>
M$\^I4B)^\-_:Q93,[(D=OM+(OU=V^/0SI@O66P<IJF@P2HELA&RD& &8C=.$
M4ZR< $P7Q&P<5%"HH)0E -,%44&A(5ZU@JH!JE/K=$%C77FHY_($0>U2F]OT
M7SZLONF(K\JT(1I]$C2Z%Z'1NXR_JB5CJ4P;,GU=0C"U9"^5:<,LD1--CHF2
M1"X,S!*LGC;,$L0L010$U/\G03E5/7N5:<,$/DS@JPEMZ#W6Q7NL =2K_MEM
MBN?2%UY[C8BF5$[ V89SU%0CZC)*Y00@IR*GUH. L\WA.>9<;.35FJ*5JO+J
MB2!)H]7GG<3?X>Q>U+&JUAD/1 CIX#D#Y\VEF(:YC7;MES#N52-XH7("T($Z
M0I+5+I-5:X 5JIT6BJ&)ZFG#T$0CD!I5V4MEVI#UJV3]IG.7RK1A2D^UH&?3
M^4MEVC"O\\@@ZONF<Y#*M*%F1S=31=HP61.3-6M"&[J%YU(T7\^-53<R43D!
M&!JI#V*)G(J<BIRJ/@&8H7-(0# ..)O(I?5"]53ETKJ79)\WWZ)VQ?Q']0G
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M<'[#!0%ULXJTH<.LLL-<$EG8YBU&?Z#WVL:!@P'90QI[/]CA^I)#S?/=7&@
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MA,5?KFG::/+&B\/.#DT7Z\I;BI.'K+^E9M^-\SOMZ.!,P_P%N5\1\DK]7A2
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MT97!41^\(-!FOK>(("G//>Q(3S41;\7).[)GCX"\L 6Z+6-?0-[HZ9VN@:E
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MBDP9*V^/2M[FKA2P0+$CSB)WLI3D+T5'*]?4^.>M?FG" XOO+[:0A_%]G"6
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MX$V#5MN1EU<JW][JUI^>E;Y5^1[:5K(=F&YFJC@OE'*W3(WY][CT,JT[^:^
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MV8Q-4L<7"9YS+X8#=*[B:!DE )</KU@B2&SZEEZB +\>B/$J\.[@MY@Y2;:
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M,7,KCM^T_X$/Q#45:?DQ;&F21$%6L(5Y&2\,Q+LICIC>C_-AX6L&Q^?=>GY
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M5*-Y!T2(2J=.,'I92BZ_/27 ;;T.6A**QSVP("?$-I3C)A5%#E2VB1<$K$A
M,69PS3T_3],@4G'A.Y_-'';/)AE%6H3B*J@/=4) N1,1L?/&"1/^7Z_NSK?D
M.*7$*;A?!)1YEH9,J'K(-VH2^0>#Y5]Y2@N2,L_L(JD^03^L<&H)^:P<LB[&
M(_+I<\TLG"H2_$AH!3^.R>)1MVY"NLR$34&+TD-K)&3@RZ4(B*LACV+SN.$S
MCJ,,I _\.4-32X^/2&I$H) <BI/@&4[A%"-@(F$O3T3T$E7$<G$!9!YJ![D
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MT'[6*B[KIRV(8A"4>!RS:\%D]TO>V82'V+>"N@3IUT_?_B>'U!9Q;NH.'>W
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M TVB?ZL!OH _256)*FU''TS$V9U*9- F19DQ%@X!N!GU\32S&<JC$;J$THH
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M&$!=S4K1"I>ZW\2*'<?I1S<C'HG]#U%A-8FT1(7<IVMS+C;-N>CL(.>B)BG
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M$+HA7$E*!=7C^T)@)N09HZT@?5"^>!HM4WQP37/P1S0$YP.?3&W!'^"A-<W
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MO/$Y]C*8EY7/2;Y%)TK@-^\HS+%.F0:(#:-I;_,;W_+N2_"*6&BDB@VK:-[
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M?&>4DZK;5B05OBU\"UK./^$#<[P<NUT-I]4]QKW/0CR\91S![?!'X-TEB"=
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M*F>H*J4)N?6O.Y_U77\$C<5% ,*SF3E!QM>A<7 U;38":7AGB JSO4%$>K?
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M>IL:HLJFKO<:TFO(XQIBOTT-X<U$>PWI->1Q#7'>I(9@B*\X9J\BO8JL<$1
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MXHN_*<^@3<#NI#@ /Z:#-D+*/- :F3]]NI;%J9@(&5T<PBDG"C8GHC$%J7K
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M7UX8>J(Z51L Z-JU)<(?'77N]._C>PB58UM%F:(E%.IOB@>89_N>8$*?=]&
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M[KTAC6\X#:,PRY#UY2/Y!%?3UFX*- @$H)8_\7#=II*RB,\@7[$/2UWQJF#
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M^+#)B*<_TH3"EZO,$(_OBKQKM;#3YXC5JF<_07G0U4B_ Z'SCP--!/Q("]T
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MSTW+9, F>.^Q<$XALF7,W^;QH4_0=(2\'AS>(#C8JF7ZODY4BQ"BZ(SBX9'
M\@FC5-/U9SMXJX$#^)2RIAN; (?M.7Q]0\6RH6*VL*7!O@2J7:"A;]FV6RW;
MZHT^3K@VU''6TA5%5ZA%7).XNN^8"F.4D, "-%6T[;995&UPO>;1M4]P]3K;
MZ^QBG35UFP:!IS@>M8GI&XY+5<6DAJ]:-F/*:F>#GZJSIBIKYFYT6]R_3-?S
MFDSS6MP7\9&Z&DIVG+SE*-U'M*L ]0PB SLE/YFX$5L,R4H!R3^4(/9H"<,L
M[J\SRLK]=0]C?ZD9<#5PVG3-,757(]10',/4 W#>&+RT W>[94VF)FOV)LS
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M/Q]SI/VSE\O=HI;/2B[7A2;WE,N$1(%(0B6!$F.._,0-L4@2P?W0DTBXIZY
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M3^^HMZ4B59V9+"^'HHZAJ*.OL8JAJ*-OV8%GQ;%[>.*[IOC>6JW^7K[,,[V
MR5A\*.Q0[T^@X)O(^3SQ98)$$A"&HU 0$:- ^+YP,4,LZ,CW/= DI C[O7:J
MAY:<'2P+,!W$=U&PM-36A3$K\@GLZE#;\?CD#1TY3\;:Z"V/]9R\H4/EE!4,
M.]4HP6'QWIP5K^TAPALFB[)6?,X2#^& 8>D1XC&&E"41\D#&RBHY547J,::J
MGMY>>8)%%CL8)1M"'N)V,L[OA;!O3FP_2V?$8S*FV9/QV/I PX,7G)ZMVCW
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MSMGV9NH%=_;:FD^:/;KVAO@TX=P5G J,41S% :61>BOP,$.H:T+,@M=]Q#U
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M-Q&M0B\25V:W/GW5:2'@7@*45P:\M=(]-[DA6,'*(8.XA<R5HG3$=W5/R/G
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M]U?5)=[D!?3*SCGLE4BF\[]>F@;=1J&#2(0,@]B/F4PP\ETB8LP$)H@GC).
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M&49"J<141"%#;E>#I08U7'F7%_>?[R<&BO*E9:SZLPH2;C'>PF=%'6\Q@2<
M5RD7%99V,3=QZQ'71@:8P[F4)#+!A+N)FS!*9.+Y@4^QVS5P8>NU>:]%<J>5
MD<#DJQ=FO9 ?<5D0)T$4!9'+PQ"3V*4TC)1ZIXIA?.:+KA[OK9?E7:V_CKDT
MW5H1^.:8RX()B2)._$0@+*(H$8'K^RYF-(F457,0M[RI5+#Z_(U5P-NL2PF5
MXFL6IENU7SKO5JAUT\]D0V=UJ$R7O)F6*JV?]5P9$S\S7^C0D+(N?]=:[_0U
MYMY>Y;\>.<1,Z<SM;OK1.4'___>-;BY>>;068JI3J17XG^[AXVEIJD]R:6*
M&@!UJ;FA/?+#'M'56!#+E?8-?:?;'#K^:JRIIJ%@JV%&%=SS?0/6%J+=502W
M&9&%,JL*.;1]MC>^Q(5SJXR>6V4@S"/ YOGHV,S@ZEZ<"II>@XH)Z#=L/?^&
M 1\\W91[@<#T.T71^\Q N+:43JUQFMJ,1-B+L21N+#!/" E=P:C2:KY$B8<[
M4BX[S%*? [\&.R=?IO/U;E8Z[;W.K;5M+;I!CSVY7MJKWMN+#]%+G2G\33\Z
M)PS]MKA"3PP(*(1D=%NP\1Q&ME:N7,$\(^">=GGY+?@L9I &:#X#5@C:@]T
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MF/Y[=8'[:X',-^_;'IM]3D6_K0)2&[LMC=E3 8FFNB50:/Q'4$"U3^BD<H[
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M)K)A^G>V@AS!#3A.N 3M5=2/-A7U?X)X[0N(/+YL1&O?Z[),I37>ZE&DZ9V
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M+%7*K?Q0X1;5F$6P)D4!853S@7J*15@DW7P+0#S*[%._ Q]TY,PFRO.%B*@
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M)AJ-ZXEYU<@ABS"EP3;5]ZYGJ8&3!*4%(ZWF[/8(H%-[36$)UDYAV:Q+]U#
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M$OMNN!D 87-Q" F"A& I0BD2["=)(E@0>V& ?!^'ZDZG* YY@!/:__$W?.G
MRH_TOTYC TR(?;X'SGP35E5];'4N;U[*/=;_A/46T4']R^T!,V9A;;*^A, H
M3<<0J[VF19WE61X)6$S5)=)<#XI1N[;@9G#]IB/F6[EF*LQ1MJPS0[OI1_T:
MV+O_/)9=O?K-Z[+'8FX_/@7$7.G6!6W[&1BQ2[<&ZO 7))$)Q^I_*(H%BHE
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M!DO>\?'K65N! Y=A=D5AH9%W?-Q\WO)_V&K*3OZ#(^_H>/VLY?^P19''0/*
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M3?KZO;G[8L7+R<?;O/AHP=G'F93\KNU]9=;//,&?W'?<O5_U<_G7BSG]%O1
M%G,-52RPEH(J84C"F5(0*0;;AA/$( ;C?-Y#5UM8.+34C8N)=E)0RJO4_;Y#
M9%;F__'"G3[8UQ4 ]J^; 0A,EE>53\;Y[*VB-+[E>Q76KBYOUW]IK;.!I>+%
M2FLXM9B'0)%D"4(^[_Y$EO?2CJ"5!$V!7C@4!<>BX B:PK%P* J.1<$1- 5-
MX5 4'(O"(PB?SC;N$.J]UUQMM4.W)V#-TQ!W;D.R,27O>8\X_.,<M2O^]]G
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MFO18"KK(:&CY)==C2IX0&0TSP-DUY.CRX,^+O*X=QZ4X[,&*6-CD=2T_3H,
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MARI.!"4FELPD(CT1X@9H.?(5%-[>>1YA^'*[=N;@I<3Z@J!A12[I[I-USM9
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M$I+*$P'4I <1ZH9M[*!C9]2A/4B:*J\[+*)"9%2(-'6+=\8TE8 A+)I"Y%.
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MYTWIN;EJ- ](7T^*PE+U+N,BZUO5U*/U X2-YBC5W%@'!&+,N$!":V&,@-@
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MXL1'N^P0I#^.&HNXD/18GWCC;[-CC_;HJRYTM%.GC>F O#]&]0%Y*<9*&4@
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MNO%9:P^K]0KP+#=(I^X$<X!A@VM15/;8N4-FGM$R8*J)R;X K!KDMSDPUW
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M%74?"@'Y8#+PKS1X2:^ PD2#),!"_Q"9^3V=I)_-)%&_)KG'@?F?4WB*NDY
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M7D_G8S!E7\U"0%T.2F9<UH>']C5GP7B1W88ZWJ63/Q8?O:P^^<:8? VNOUV
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M^ISDL]()R:LHIHNIO('M*1;U\2(<EE>MZ0HL:&S%,?(SGQB&6G8_1Z1^A;W
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M1DA>J:IC@O*N!A@Z3M[IH?R3BW\<AO)Q-&)A=7H8X9_ZVX&.D'=Z)/SD1.!
MD!R<CO^['&/N.'FGAXSGQ_]/$TUV8&,/A8QOTLR:I(_CGAGXZZAX'X[POCMM
MD+9D<S=;M@KSU$(Y$356!XIQK! )..4!BD*#D40XUCAXH" MPM$PPNMWVD>9
MP]4%L>@"#7UX]@3(\\3AV1;AW3-&RZ/(2"0%#@0BRO5",[$2DE)E*,-&/DR,
MEN&'255Y;.%^=!KZ(&V78?6=ATL\U2#M-,GZ$.WCDW<WE'Y()_KS\\]/$J*]
M9Y/Z$[L&7A[]9UI= Z%)H(GA0EL2!5*JD,<$3DT'5 !$>!C7@* AYNN-5+_O
M8]T=(>]N;D6O2^XU\.+D#D>+2MC3X3!$&Q-R'E,4$Z(,4SH60@=62(TU;4F&
M/87#@>)HA$F?'-]5\N[FISP/;=$I%Z9J>[]Z%.'SF8^W4HE;-:<M#BD\?BWN
M8^N+1Z=A4U7M_IQXIL&+4R9_K[H==YG)\'A%MT8PHQ35A&)#"&4\5HIS'%&
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M[2WJX\<6'L^B,HP9UQI'5I! :!8+"@>$D4&1 %O[T,$$L*BM#5>?4ASAK#-
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M#[=X:2=.''^8>$M7):_CY/5W^@^&#O:<)'IL@""C. JLY6$<,R*,Y%P@:<)
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MNJPW,3ML&,TJWBU70W.Z?QP-A=YDT7;S^GPK#L.91KY( +""VX1(S(AE-J&
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M'$M" 4&)%I @3B6&6O$8D1;WW;;LVSJ@[3CC08MC"#3L%ASK5<)A54)R-(U
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MJ&5,M.8''@RZPJPA]-Y'>DY@NZU7>QU2>ZMZPA@D8@T4ES0A4)E$) 9P"IF
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M9: E/-82"*A]0U9)E8@1:Z\=]"$@XN%CRK.X24?S,'>)$;\UD\A7*#R9C*8
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M ;/&T2_"^F,S[?H&>T/R0#-G5^<8HK*=Y3FP43[^6JT:6HTAA$[Y(VG7AQ>
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M)A@EV#246-]+UC%JHR)'9V4O</)ZU7#@+.8P5(-66C.%,)/($$L1UXDEVEB
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M!50(Q3S6UC06RVLO6Q$/,&[C:'!G!3QP\GK]T^N?_>H?"S20!E&!*">8LH0
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MWX'OTS<9FNA5A?\&D8A^-2/Q5;@Y5./\=IS7TY'-WI5P< F*__=T=%>EHB
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MW6)=T_]8^^_?")U,%IH66X$[4@[6F9?N8@M;3F]3K=]E?)]C/3?8;[\0J=#
M=A"OTR7[3:C6ME)&YM=3NQ2:. AD G/3SKZC9_4K;!>?6]7.M-#,-Z@%K^'+
M*A0R<#9 +FNLP5L]NZ&2K\EDR4M0174-UXVER?-2$WB\'0UT40\#Z@\"PB8J
M^'X?9Z61%+#M!P(L"PNHH>:KZCG'2=1YT#6M-T-376W4U!CM;_("$=4;_?LS
M\%CSVRN[J)9YD_@J#J/(A!FHQR1,X9] 9=J7B0*=%PV8-VN-N; V;\+5+8#3
M@1; 07H^K9$2[%12%:PKJ?K@!K]\F"#2RE2A-4K(.RNZP7@D19AH&<<)XY'.
MO)1G8(@F'DN,2O=2596% 8.+@C!0#!%=0ITE/%3"0]_)ST["9-D"G:#:!1+_
M>@LN8(FS1S9=ADNDUUZULJQT_6[NP *GY"=WME<WVXN'4SOH \H3I^_BT*;6
MMW+$8NY-EVK^BB?7'&V>&UZHKU4';YF;&?YR@4!<H"/G[G,#&A#;?6P)U@2G
MK*)%X:;RM@JDQQ62JBUUQ0XT:Q')O(3CXE=.N)]T@CAT7;"4*BQ.U]%D[TF@
M7W]:D-#VQ%_7S.-\P+J^N]!5G1@=^14R?-?$&2:HJXC%F6PV9X'>*0%MHI!>
M8A83CCW" 7%F#!AW52VVPM/9S"=V@=U$35/M7G_':+K[U*[[4MQ?T@_V_E7\
MJQGWT-[EW?3Q[_3D=_#@UKG)X-33AH/\>2'SPDRD/(C!_3!:9SK,PF633Y8^
MY>7]Y_L[.Z+GE6.L^F_5X)/^8:KF17V86IL;.Z_*OL*J^]56<>L>:6,\:0RB
M"8 F81[BZ+ T$%J$DJ4JC =!=#:ES7L2R:TH8Y#)!PG331,BOB#=O2WD>R2+
M]@6H4@$4$1HA%T2F9"0\%8'=Y9EP6=QL([*\J_77GDA#Y!C6BL@W>R1+(I,X
MB@,3AL J,A1"*6.8\G"TE4G2!Y'E3:6"X>]OG +>A"XE-J.L(,RP:K\:O5NB
MUBV>@_/L:D^.:FH)4L+J9YJ\;=T[^X4!#6GJ#AO2>H\?F0]VJK(-PH>8*8./
M7'?1*8U$_?L-]:LO/5H+/:-<6!>(>US:\H/<6'\1#83%_JGN'&1W1%?!<L>5
M[@-ZTFV.B"=UGWS;4'#E$!?5&+Q[UV^%L0T,QE0!AG;P "LRJZEK3\"M.Y7N
M!JM+=[\AQFO;6K:MJH0=G%Y?3@CWIIKI8*MARB4L>H$ZL1L-ND6CU$Z01=:V
MDY20/>0-0O?:-LAQ 9R),S0D?4#]YGJH/:*C\LHVO#LR&JA3C!?T4/+'ME.^
MYD1BU]:ZZK9".NCZK[SYE!QZ;.?E&WK60K#TN0,'K(V*N8E4#O"X'C:P)KGU
MMG[.>_,.WND=OM(+NAJG]_WL-,9[TQYB[AE/I[[6+(N88#I5G&<JBC(!AW :
MQVNG%^UJH& 6SK[F>WQ+N\Q]SO@+5LU[6K[!RS-JJX P'R,0M5/U8!"M"42]
MTT!Y3:;+BGHI3Z8RE$F:>2IE/#!IG,1!(#(>A))KI?80>]*>SL!G4 &#5XU2
MD69QS!E+$/S(\X/X6XL](<E1R3URG&FG^KL@7G4DKM^Y';;[E.),G9B%FS18
M6HN^:H\?4W)&VSF0L[QI(';#CFQ;,>]B8KK\!,ZP)^_ (O*,;?B'/MHL@5 V
M.0Q%]4EN:194A?#Q.QF\:NP4)4UZBSA [_P&W+<+SZZLZ5O/?COP[.G:?LY6
M*9=!1%!XI,<(-6?W4X&6RR\P)F>#@;:2C2",7&\I@E$@ZA^_=V!,<]V:IFNY
MG5>3?[NVW;QT*6MXDIU]AU71>5'D7ZDNVN$H-0(V^/3^R[0;I9K>?M&@S]HI
M8Q/TI J7@:X?VH4<(.%'@E&&M]W?UI*W<@P[SHNJP;;E9SFY[KSR;#RAW:DP
M"]J0Y*!R)@X5<V8#P*7%(:GI2*!(R!+X6YW);0 YUM\187;OW4*)5?"/0^.=
M*K"2MH+A==*Z'DI8%7L^@2[9J;0P6%E:N%XM[*!+V GI$@I@;*4YX*S[6HQG
M,XVM'2Z X3+CO1C&L48ESHV*ZQL5HX<W*BYII3LW*NZE43$ZQD9%=FY4?.)&
MQ6"GPMQ@)43<L9]W6S8J;ADZI<%A: +-2UW_$4ZFC^]_[QYW[D^$]+I!&'5]
MU!2>L&WD='64\7UUF%/,J(DY]L:B9\*+M,]$H"6"YR>"AYF,XDS&.@FC;  T
M<J>QZ-'J(K.]O$J@6>2;.-4L\9EGDBP6+#5*>ZG/,.^_ITGV:UYEH%YNX8-9
MSR;?)/K=8I#-A\/#%Q\2$=V/EMJIVCOTU@1$/[J1>"^FZN=F(-YK2[*%/H),
MA3%6@R0FY2Q4B1"*&^T%2<#")&7[&'\6":G@M!>>GZ4L\[PLS"(9^YI[*O!\
MGIQ"8)1M$1C]V)Y)V-J"QYX:M%/A9[@2&&VWK3Q.I^_CLM&1E(A>6E!6(8EV
MH7CZ(.6UAJHOJP&@?Y]:()L9X?=\T--I>3_YPJ=C7K<O_J*G&D^U@M_=8\T:
M3K*DX_:7SQ]L!<LO^O:6CUZ.*<,&TC>?C240Z>U47MDOXM\)2GV&NK69DYD7
MU_ HFS(O6U\ 6L\-_&!12GO?(@1L[*#@\*_[&0)9VN"+)ICVWAPD&K4QKFH%
MJ[D<EQ5"3X/FUF"_E> Z%W2)@%<W]5 /&B9R:>-P&/B!"VE-6$A8X],AL&S9
MJK5;TKR*M83V):0LYC3K8PD#-"MTD/8UX))]!PLRU*-LEP/:]*NQ9]<3VC8!
M:PX/[=396W#:)?#?@[B?=>R23VO2X+UI+BJV*=,[$ B\PZ>H&Q9FO/P#*Q8)
M4Y3+"CRWD^\F%[T*_M5 3]WCV\(%@O3V++3V!/8V(K"H+%$;JK3T J* V:@P
M<U"%4Y%MR8 <D7]:5D"J!:'H8]O*O+28J;7,]4E6,[0$SX_8&2RI$L?S3!QJ
MK_L[:)TO6%/G9M07U!SA7GLI*7O-T72'5K02WT-=SN\PC:NUZQ GH$.T7\CB
MKBZJI_!R"Q \PQFXUQ6'PYK)X$(VP0VLGI1746A@:>(GFF0[^D(BUD2A*LIW
MLRU?Q_4\ABJX6LR=O/=%V(V8@"4]=2MFN%/Y>1BLFGA#>?VWU!D$MA3]UK&B
M5G0ZQ)&.(D\R)3D\,>3&8V!LIP@?ZPMO'^@<B3;:I%X<I6#=)VG&HR1)TRAC
M*F)>9$X"/W8;HXK(/WKK^K1>UWU:C]_I$.XVY'-E">'ZW=R!!4XI _U^>?M?
MIP:>%#=.(8,S=VH/N#YFP$()X6!3UD6W>)!.1MOZ6*')VR#$DD[#"P<L2.LE
MC5K.Q5/EE\.=R@3#U1-"US+7#AQYROEEZF-94\!&7/Q;/JWS159?.6W5Z;_0
M80KTR<#W9I&?9C(SDD5>*ID(A>?O*2*SKL3,NTJ6EYBM;LK=/-926=$=+)MU
ME8 U$(^E(&CY%RUQ?6]^=@(*!_,'*[?M#@[F2_!1=1($&78G9 %/(Q-GX*Y*
M'82;H!GOA[JKT"]FLV(LYE:O *EKQ>:HO0$6R">G<2R)VJ ?:6KBP##C1YQY
M*DFY5%$ :B!37B#-8%?L0=Z?+7W_7IROQFX]%HVZ4ZUBN'I&[5DY;J8<A4P"
MYL4<)!<'F4O!8^4EQJ2IBF.1#31@[11Y7\>^_I5_,.78Q]QZ; VI="@48Y[)
MC&*Q3+B7^7$49-Q/HEB&ZZNF'^'\V41#DH.ZH1VW&M"L@W_P -UK/!D;$4=)
MYH?,2)&!LLBTR;!M3F0J>#3*+M>]!].W>W+E=ZKP#=<A;-)LZ9<8%7O5"B2^
MIU(_D)&WA+P^_J*Q#6 1;BG,3!88[K%,& 8;FP4JDR)0AGD\T'JP879+CSXP
M098(%1J3I2Q-_,S$D60ACW7(9:CX*7CTF_OSM!V7M!^C]H8\MC._4VENN+(T
M=_U&[K#[I^3,=_#U0:/0G-!V*)]_Y3BREL]&UP6'IZK>Y);67-O>?(06H[@3
M=WVS_NB+35-40["J=BQ:1"<V79\+R_(.G5C$LFGDF)/^]+L+$>35>+N\ 4]J
MSUJGK[?'G-?K>G2;=Z?*TG!E9>EZKMY!%)[84!XN71K2<0M5W\AV+R=<_G'Y
M2=[D$PS5VSV_ SY"#KW-E9X@KU@YP"KQ-F]T0UM/Q2<[%5>%*XNKUF_Y#GSR
MU!59.\P/K"9$MG0A)G86U4,]<-.-6KZ;S_J)I]80PG:JE3(_U=SCJK"]_01K
M_]I/D"]!?^8(U3Y!P#C2ENWQAO/2 M;IE2^PJ/L+7;4T-%-"FU1ME;"T059X
M/F';(;P97#"?NO[2VE@G=7YW-W$8:_UD_, 3_GNNKFUKQ@N$A[,EUQ?8RX09
MS[PHJQ2C#2#7N6828SN8T\&C-31>>FA4)Y6L!D3CNQ46(J>YET5FL+ ,3R7:
M.U4DL97XD^NE= ?1CDY(M#^ T4%],HN=;0U"QJ!46O#!EF1V&-LFZ/$[R-6!
M]V,YO@41H!XY"S)X07_P?Z2<=0^1C\8GP3=OP)K)"TJ!MP>VDT-HHQ+4BT3%
M$3C8O,RGY"[;Q58%#B*?SRKFU7_BI(<24]HSS*);$;W+R]EE98C9FA#;:T.U
M /:A0M_P+T@LJA[MG7W65"R7-ZQ/\Z_4*EC.$09GC#=OO5R]*K U.:T(O]MJ
ME:KF8E 5+':MXU!!T'^NW@/K7E?1VI$:](E2U%V$TMW=[>;>I$5H<BM5L()E
M*$!WC615(8%+A&?6:K#FC$83XRLL3%7$N?."5_UE@U?5"JL*B;1HU/H>IMK0
MROTZ;9\$W4(.6RG@.JN =I80('77B".:-RC-M8YV.K4Y+DB96J@#@MKGM6JD
M<D^Y*I*V CKZ\34GVZG8CJTLMCMR);B;'5P/I3%6SHTF)")RJ-!K:AD?78/'
MZK!>H9V4\^*J$W9ZNG)>ME,)"EM6@M*4\])D\3>@D%^YFJB_CV<WK^!\R>'[
MRXM0F/)ED$8F]+'<6\K,EY%*4B'B+# ZWD?(*M:>CI,P\4TLF8R"-(BXU"I-
M9!K%*HB^K9#5.]" 4]>/:NL5W-X\<LR*[52 PE86H*S?R1VV_V1C5AQ,,\PV
MV#DEDVK?ZP)$>Z"!/5+245]7WG7]K^;KSTHXNW[+9]KF?9+GKE?<M6S/Z(G5
M8ZC5A@)&56GI166 7;2J1_5%!4#M)FMAGP2-%2MR-8>34\*?Q\H.(\."Q7$!
M5A@O:J?)E30.O4=3B.@6!6;7AZK5O6YS1Y(4!9[H]@_P$OU.>IS@0KW;A4;
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M6!_(XMN;6 >9-JE1&4^BB&FE,L\+311*8P*5I&)9U=E^Q#J]\(*]B/4Y0'9
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M3V12AY3L>/_Z[09 BJ2HAV7)HFR>FILK2WPT@'[\NM'=D.+QA6>@@T/0I&=
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M/6/P2%RR^;SO>]JWRJ<GQY10WU2?C>V]QJ9>7=#8TG!97HBF<(Z*';=\-IF
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MRU$\T7P^O>,\J?FFHL"V(*K@D2H_ 1_YL_%WR4P8%I^R))";2AOQ%PMYDI[
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M1(W(-6T_=.R(NJ[OTLC@-@DXM?2 F ^MU=W2J7&&]E[[H!PT7;%#-+0[*2]
MK+?(,CP",'W4VQ=+<7:AJG:)M+L:->@X>?O'Y\\NJ+$*NB]'"(:A"O/%.9C&
M;[NU?5UFL8Z3MW\@_.PD8$N,[.Q3 KH<.>XX>?O'C,<G <\33G9@8K?%C!_2
M+.)Q'YT],O374?'>"\2SA[8C5NCU?D.X2A3P5.TB%E2)]QB,6Y%M>818C(9&
MX)J.22@W VY&MFZO/]Q@)R%<.C"=Q>9L;W:/>E^\#/>!W%V"U$WZUSXZCMLB
MP!L&<RGCIJ';7A#:-G4MT^,AM3V7>0:(.@N\IPGF$GWH>7TT]SD@\X[*]E'
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M29).>:Z3;Y-K<&S?(J6G23!*,Z#P]U]8N4B3Y21MR-J7*TZ4O659#+X';@R
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M=6W"+!W#T";S=,9]J^WHF\<ID2T/QR%@\8S%\P,Z@2G[PNFW?\CSL7:'O#H
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MMC#4)K,,Q6D*<E033-$7*I=T8%?!).1SH<9W J;#IE$P: RBC>^U. DRCCH
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MLIS_@-]*]154-,)0:VHY!FH(=WKC"<)<G'^T*Z"F,F!3!7-A#4H]<9-FJ"Q
M$2X)56ZT+J<"N]7PU16@[S.6O./%Y55@:H0,C(KE1"$+J.N#>C!1.P3$X;!J
M;LL)<H]=%++31(B:L $2 [G91 4@!EB4')0Q&;T4MD(L$O8GKR&OK&W)MEFQ
MJQ& E%$Z;GB>*Y?+ID;@4<]RG,"DOL'@DQ7"/WB <N!Z]CZE:=L,EI95F\/>
MABU?LVS"/[D'59E<CUNT\#L.>"29*TL5VBFW#<8Q&&U0K@ -2J\QRM*;)UN^
M,(J(I[NA%=D6M7SN8]38LLTP!!$,VKKG='KYMC0AV\R<%QH&]4,'G$*;4L>
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M\N2B!5UUPO<*^U"5/?CEM")YU2/Q N9:C),@,FP:61'#(DC.#6:$;J@[_A$
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M.C)3IM%Q>=D6@>?RLE\&^T5>=K?1Z=@5_75IV74.XH87L4V63=G AW9%SKJ
MUQ)VTFTW^\^- G?6BW8Y:]AE<%M,$/(HGTX0'9>];1\J/):]36);2.U-2VMK
M-7;+P7/9VUOW_9T^/PGLM''2&[ZR!F M"EL.GDOU?@F3O=]\ID8!*O8>S!T^
M +? TJ3P$;N.$R8\ E[FWV^T1,P&/K?/ZL+!L*M-)(8/NHWAT+D%7AL&EQAN
M4V+X::,U7*]88C_%^$[[$9:$XJ58!T$?L>L@RZ, AV!*6 Z>\R5LW7/:>AZ#
M; ^?XC?=682T'#SG&7B9Z-MS/0,GK?W3*+J'XQCXPC(O1.< 3WR?S1,V!94A
MN&7T]=Y8(C; L+H*4(6 !VP*%=@3'(TWB1=8Y5'+GUJ"X?RTC#MQ$&I"$.N\
M!?T-@];)*IRPY?P-EB@-CLA>D,B&E>Z+M6BL?]IHK];LH66EMM%UA>VK*")S
MEGCIU$]$1=]L%N,]Q^,?#=AW&HQY,_@@7&1L<@B&D.7@E96:=?#<&6FKS$(Z
M505]I\V3@4M?L :\2GW#X?^F\5\5")XV6Y;6!QZ J^!?-&B538Y]V)I_PY1P
M1F&=>O$B2S.0S7 TVY74-G DVV1N%1H>L"UC\@_1K1(L]%:CWVF[%NXO70#@
ML'()5O;;[4:WU]JP4#-/9A3?TXDF%2=9O-&IF*?=:0Z(SQC"[W60K :D5T7\
M78+IQ#J(;#PE&V$2;/4E@*ID)]J'O\!?L9>2_L!K\F#>]GTY%_[W(LV"ZP<X
M#]D)40%O?BY\*FUK%,;C'\?721"&1T71UQ\686MW*D'3;K'\AD7T Z1=]!)'
M=]KL#6K$\M&[JRGS_#%& OWH :=)\$9:Z(\#21; 4S<X]0F[7Z&#+INR%"V!
MB.+%U!CK.HC\:!S 0V /9 P'-J9-LT&E._SJP_]X?-)>]:2,?__/\?$%&%O?
MT"SK#D^.C_D*YDZ_?<2_OT^8_^,,_I/O-F1^0AK8M'"4.O3*C6&<9NT;CG*M
MYX8=C_"K8_\:MODWSP_O_(?4N)%I4@A#B/MMS>]_\2K@@YN?WWO^(HL5K^SS
MBU><E'Y9N,<*=XKXT]'/[Y8=[GL&+Y7'VZ\^7D0DW*S:>=DG(('G@(=!Q(XE
MO$$49$ S.>OO<Y_'K[X73'X[BAXZK=9@<-H^N6__F?;^[+3ZQT!HP)%;G3_G
M-SUX$, \B\;3. 'P?OW95S<TKX=G1;R^+.$U41U]OO63P,=V?5&<S!!^^O9.
M[&H4AQ/:PS1AU[\=_>_5UW-@,6?O/U]X7S]ZYU^_7%U\N;I$:'_]>5Z-4_)8
MC[$M'Q#*4D+FK&+F!]%R3E')%ZH6G+:WQ11*YV327E]H I5\0B!%=GYYWJFX
M^>\7OW_Z/][5/RZ^GWV[^./JT_EEP_OTY;SI%=L$%X6B52=0DN9J^X WEU\_
M?_IP=G7QP;N\@O_Y'=%(H-0_+[Y??4(,^_;]XN/%]^_TS-?S_]<[^_*!-_>D
MC__X^OG#Q?=+4)0Z[<$O_ \?+CY^.O]T9:A >W)F;SY%(*SC1>I'$UB?W8\9
M9GE1H,V? 4O,TK>K;.W%%+S!RD9VU960J@J[#T,T?$&/^>VH=42?A17./QL[
M(W:Z"M_@[%M\E?"[X-\)Z27>"2 75?<M&>M]S6AH]WJO;L?H\'2:_;8#:!E
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MN\;R&Q;1CRB^BS9_=NU6$;S39J_.@7'T[FK*/'^,_1;]Z %L;SD-/8&O(R^
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M5[-@JI%RROS)2AAI(&%%Q<E.=6,?5C-=/&O,]-]$P/15D=&$H9@^$L41>VG
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M3[K-4@%O:-OI/Z\%GP4;J2+4ST2B;4_V[/W_%C&:,*1&IKP>F:P3K@5RJRU
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M2\&VE;"[PG0/XC3?^&AI6"R8K!),_Z>>)OHM 0&)[3:._X$\1)[2!1_,=\F
M47#MYA,/B@/[J(BY[ZR)K#6'%J-5<B>.AMY:KVC?BQ88^,?#D\G L30!3 3
M[/C<.I#]MH-"9\>5:$(-2L3,&I7*:A($=R)I=D?%G61<2V1A"/>&]LUO1ZTC
M^CS'<Q"?>8R8_BDN:_GI=NAX1619+ QG;D;^/,_X0!]_S9)WA6_%8[]FDT)X
ML5-]AQY-I@0ZD-\"C,47:PBY%>0[>D>9'/U?Q(F7WOQS-GE\GQ9LI(I$=&N.
MSRU<HFH*/"7GX)RS%FFP_>*M<3I_H:^36OSY"_P54?F=0^YMX\3>([>P+VLP
MNC@?E'>TBE4M4Q"A^2$8NY_,U _!ZKQ!L:^WGE(]"D03<KXX*F%IQ5%XHE0
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MJ:I?$'-29,.CJCL6_8\$X:8@P_DL9D(@=N^KO&Q1$)"P$"Q*7-N_)\8F-OQ
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M7:E8)D=)2>IBTED^5B:; JK>3 714Q^?'(TU@DZUV6-R^7PX).&ZPHX"T=^
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MGE?M1/$7Z 3-W=:<%_'$(7H0,TWRO@J)</"(B@P<5(F%><@I\"&MCH7.+Z<
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M@%+1R?.QJKA3 -PCY3 W[6S$.Z\DIBH= C65TE8R!J["-EM#QRU6.3W'+98
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M 4"]>)3Y0>3Y7AA$S(NOO7'")D'F^;-X00E3^-!/K6:;^\,!O#"(X?D4G_W
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M60[>]BVV_:.!IQESN7^WT>H\Q6'V\M;<VB.F=N#RZDRV2Y9E(2.3;5^\,3;
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M(#BD_EXEA(,/WG]9$H-06,SAKP\!@]N"J[EE\N$;0N@)KG,=)W!QL*U%@K
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M(3'V5E2@+7GH"YDAW/85%=0K,I/0<I2B D?O\W;=X3/9V5L6%3BLJ&"\6S9
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MJ;E]XH"+.9/28BONYJ;3R %KWS.<5B(,(FCB!;.,'9:RFE7/^B=J3>N]%P?
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M#)?>RK-.4!PTLVV*76F6)* U!/2V_"C.8^/B<U-4R#N50UDCGQ72!WW@6DV
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M55['64 ZV'O(]XKVE&*QCK32L;N=H5_NMRB)::4,ORJZU3:8#,_UG0,>VTN
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M8"MO$&1W^$^1I9Z(RLH\!J 47_"FRS<L(%H#8 MC23L-1OU*X@7:-+ _/ C
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MB'-I0D831=P$=J>G#MY!!1236703TBKW\FRD!V$I9@W#8P*OB.;"J]E"6TL
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M8CJ<.>]VW=HZ^_ZNYGRK3R*>4O^P3PVCK5>N.7AU]0_;T_7I10SVX4F4? ;
MFC6/,FRJWN@T.-S\[XWLJ3NQ1\[T+S6HL Z0IZ0M9>H-7E.-A>$=#=P-78E&
M=_ ::BP,33^FQF+8G9H:"PW :ZBQ,$3]N!J+L=W;K<CS<!Y8OV$33[#&HLGN
M_#=)\#"%SR4F,SZWC4[0>@ZW2P?)HYL#M0M9MC00\]@J\9$]Z(_LX62G(BV]
M]U\#&.I]$4.&FQV._JELOQ8PU+H.A@0W^@>3O?H'A@9K+7U#@VTQY\4!UGD?
MG/ *#CJ#TQR<Z M><Y[56<<.&DW_OCW$;"C'-(@Z/GB;$Z+.FGXW-X+:9W6V
MKL2A.W@;,ZG.FG8W.AM]QPC>XX.W,7/KO(EWDY<RLL<[=4O=Z*0\?62\VQU3
M\T]U9G2CN09H=661$P%WV"9@6X;;=H&;6]DM@;=EZ&T;N,)N;0N\+4-OR\ 5
MAN!QX:VUDZ0/?X%?,1(I7W!$JW&T=;CI:DFL.S$'U&/S,JT;[$?9F7LIL1:>
M'UNW=(!8M+!2N#I)H]EW*UJG?A0F[%(RM^99#&:Z@AZ\F [_L$@XATOJ([0T
M)0-[_%O>"G:7YV6\<+J3H;4FL97@+')Z$9Y%NL5WMA63!#,Y_%L2W'>%T];&
M#?#$B#W+%[/H"IRK^/83"YR<619X-)TEH5B>^XL%B4DX(\H&7)/TCI"07D)X
MOR-KC7.)Z_<2D8S?5O?\?;1:>^$]\(W;&[\&$*+5*@KY[8LHQID;2?EQZ=)+
MK:4W+[T[L8+HCN M7OB(UW4MQ%@:I5[0B"T%"P(< 86@U2?19T"2A*T J++'
M[@"Z">!-54I4/Y<^56CT.H 5=!8Q/"VG5"$,1Y,RH?7<6DJ39&+U#5GX';S=
M\#GX8-H=C!L\]HNW'SOCD3ISL1E3RM]_[70^P*Y\15DUZ#F=#GN"NM*O'_'W
M=S'QOE_"/\5J ]AS&A]8EE I0Y^??BK8;'Q#_O0U?-.YQJ\ZW@*6^8OE!7?>
M?:+LR#(N54#P_776/UY;-?#!SJ]_6%Z61KE>'+&-S[4FO;.TCS4JD_]T\?/;
M3<A]1^"E KV]>O0B(>%B\Y573R,%\ SPP ])1\#KAW[J>T&AYBEE7[Q]XUG^
M_->+\-YUG/%XVAO^Z/V1#/YPG7%GX8=AE)+$<?]8W[@#N!8@O0QGRR@&"-_\
M[.6;M&X&:4O2_K9A+-&M%_N@\S!B%*]P"?1;>5@17<8R)HM?+_YV]>4]R/C+
M=[]]L+Y\M-Y_^7SUX?/5-X3VS<_K>K(2F(5- T8)TXV\S*0%SH'>+"QJ14/=
M Y?]0\D%]@4^&O8?Q+<_>W#0TX@;@UMITF]4^WRAXM["F:<>_4LKNV#<W7X]
MU#)(DFS%%5B6\)Q5JNOJS; L$9KM70#<W_D&[ &ZJD8A=E 9X\6K:$X"L '1
MRDH ^@#4<_*+7FBKI^0ZI-7!32US4#M!@ %,6/.O%\X%_<RCR^RSLC(P+;SK
M;5B*"3?^5<P(F7W'93M_)X!<]E0.%'0=R:$5JB:.Z]')\ Q8!-\ U A0;T U
M(2ISK&#\]6)P-/^VGB1WG?C,2/#I4]:U'$NXWZX-1R1%%89R-Y\P"LES R8Q
M0 E(QB)/IZB'>Q9I27-;CL+\O^!&6!\:/%LM1<,#8TR-O##R8FO 1M/N='HX
MXCIMT;&_S%E-J4-;P S9/HUL=RH4V:C9GJK$S/"%1A_]=S_! #>AQQTDQA+<
MV$O)7AE;L]/-=H#7*'V>H3.REN1<*V;ZW<GH)ZL#FSET?SH#JM </$.TVQ'M
MV&%$.YK^I(>2/*/)G\TU;+P5!0#KSTDXW[<BU$%P:"@=]MCL7TOBJQ4!3M=Q
M]JFO#&T9VE)HZ\342MOT_FX:AYT?LVRPVRCP4C_PT_LSL!<U!^_@0J5M9%TK
M;R;@A/71GIV,NKV]:C5=Z4)S\ S9;D.VXTEW0&,'XVEWJ)L?=D[^%FS'RGI)
MLW]?G8HYJ@,,F\7 29J^PZX## UJZ%3V4 <8SI*.ICO3T4:EL/?R;1V2"2O5
M;!JD[[4 )L%/6@&E(Z)TA.DY-Z]6HD@?MBMTU*J(H#?9(>F>%A%TWGF8:X]E
M:"1,6!D!FHYA0O3*B]^AS) 6S-&@3^>:KFXFKX[PU<5DAADB<UK41U;K(+HG
M",S<AU_2*$YLA3#"*.SD5]%*N04Z:"1.>%7@;A5V=UXBU2!8+WTL$(RR!"Y(
M7IF2A!,I29@<KP%J'3SCKCLT &T""/0/!>B$:A(F2E=5DV/<A*BCTJ(*@P[)
MFLTU"9Q'3(KFUD4):N6WO 6U.].:)6I;;#&I=I(VQ19&$.X!,'>L"C^3M/[\
MM1;:$H>V@!FJ;5VI1;T*,^D^C;&'_TU"$GL!#;%X\Y4?^DD:>]@R2X1\]LKB
M>N8F: Y>DQQZALR)EK9 ;J+V%SW;';I[:=^M.<UH#IXAZ3V2=&^\4T?ZPZG:
MIFPNMV86K,;>XI-*%TE"O'BVI IU3FY)$*U70*L'T*8ZR!?]A,@N-'B:4\J:
M2/,-1B8%1 (]?&2 VZUSP:HN28UL9F0PGN(X(GS#VU,A+QU@,"2^+Q)_(GV#
MEAT-'T'AA_1KV3C&$_%?#Q"+U=7XU1R\!MN\2FW&!J\3.R49 Q+9FD<99G,T
M"AF'"YD7KNT,>W^I08-U .6J*_UI#IYACR.R1[\_W+,.WG\2]*1-XS-T9;;3
M %?(BI: VS+LM@Q</8BA5AA*'UH[J.8RP?$>]1G$-LTT9C-!LA!SF&]">.&\
M.=_YV@N\\K@4S%C.PEN28(&@:*R.*<DOW*YC\>D>-BKOV1+GL)"\F#"RKEGJ
M-']M!#8!N)8CEOR\W6B:I7O0E/GF0U[7V2$]OC?J6I]"0"6QKKP? (=6.=G;
M4]-'V.N%'P(-^$ S,5E'8,2%-]8ZB]=1@N\+HB2!;06BP#9U=,4I7;&<V,[R
MVA4J>BC''9X59'/"!O>P3'=\,5)G%()):=+>3S3M?509OJ%LYW,G=4^[SO$+
MPK0&:#+MLE*%$\I[IT1HTCT?1-11B5&%08?$N>:\=\$D)F'.)+[KFOBN"CV3
M^&XDX;X ZP^[D_[AB.NT1>*^,M^UI0YM 3-DV[[4]WHE9E+?&^,/?X_@H;#:
MO7*R9J'H=H#7*&Y,.G 347><IJ9\%V]?O!SW[<EDO)?&=9J3CN;@&<K>,V6/
MIK8SF;[20[^:?'<\)P$3*3PQ1U)#F6&2?C<)A@V)OZY Y^.3?V%SW9[[>I\Y
M>#H0F@XP&&(_'6(_I"-K<MW;:0!K#EZ3?6ZR>;>70$_)Z.6>JI U=8*M?,^K
M_6MA7:E3<_ ,\QR9>9@S?&#FV>'@=1_9\TS[ZT;Q#=#JRJ"G 6XN7UH";\O0
MVS)P-:&&6G$H?6AM_OS5DE@)?.$O0$.'J9QP'"UH,O(ZCF[]!+/C,<6YR'G.
MFX-[:1K[UQE=OX*?-!*7+^)H!8\.4S_,,*TY6I/88YGTCVD([L7$- 0_^<QH
MS1J"]YSN9&(@VMP2W.7=,TXH-]KT!-\.4<>EQA(0.B17;>@*SMG$Y%29[&A=
MLZ--6_"'\6]DX>,@<_O=:>]PY'7:0G%?^='ZDH?&D(VZPXDAW%9E2)OFX#LF
M=[W/XACV[)<=3:Y'LKAF8<B6P->H0<\XP_00!IRN^Z\]?$V*TM#GWN):3U*!
M3;EV.ZM #1#[@)[K-68QDSF=@G%R'I^&JFD7>CO-W$ZGZTX;"/'%R]YTNI>Z
M'2TH0 \@:C60(4/8FR8J='MZN&=[*[!IM7O6J+:^I5ZZEXD2VAN1FL.WFZ9[
M3!5#^XS<QRO!38,J^MW^$^L;>N-]UO'H3IG:P[>3<C:<LU%O'V[\A?N8Z2Z'
M#-NR'/,S\%D;T_5H,UL>H;5>?A6Y>:^L=R0D"S\]'?M=!R":PJS;T^&I.A&/
M4>-,J+SL3=Q]5O-H02AZ -$0=#74^DC5>?%VZ&BE ?<6M6VU9]S8VHDL""C&
MN3FYU!B^PX>'VV?ZFY-+C> [>-SX+.BS!3I0 \2:DTN=@# GEX<(VAZDD9(6
M]*('$.:<<]].W]%[(9DS47,FVE+XS)EH>\Y$#ZB7=25/[>$S!Z-M.!C5T4)H
MBO.?45MB=CHJPL!6?CIZ.L:^#D#L=BAZ/LU;3U&/&VK?[5#UG*C=J-T3;%+\
M),U[X'PD;8UVS>';K+#/W'G83F<_J6%K;^(>J]6Q[J2I/7P;M?^9L\Y6!L!3
M.&?H:-^XF%D$NE%O [3:<MN)P)LKVI; VS;\M@Y>H3W:UKQ8[41;^E110M=!
M-/O>6<1^$&QN.\N"V6ZM5R$AHOJ&+/P.>C%\#D4W[0[&#;K]XNW'SGBL)I<V
M8TKY^Z^=SH=P;GWU;H@UZ/4Z'?8$=:5?/^+O[V+B?;^$?XK5!L2+J26Q+*%2
MACYWEA5L-K[AHC!#;TCG&K_J> M8YB^6%]QY]XFR(\NXI,_Y_CKK'Z^M&OA@
MY]<_>#-AT?22;7S.*O3.TC[6\ G_Z>+GMYN0^X[ 2P5ZW7KT(B'A8O.55UUV
M 3P#//!#TA'P^J&?^EZ0+X=1-A@[GN7/?[T([UW'&8^GO>&/WA_)X _7&7<6
M?AA&*4D<]X_UC3N$:P'2RW"VC&* \,W/7KY)ZV:0MB3M;QN:==UZL>^%*=J6
M\0J74&GA19>QC,GBUXN_77UY#_[\Y;O?/EA?/EKOOWR^^O#YZAM"^^;G=3U9
M"<QVL,4W\,I&7F;28N7YX69A42L:CFH#C[ATWRHB<FG%!- Q\P.?=CH7[=07
M/'4O2;T4J"R^EUNJQUY*L&TZ7D@6"S)+_5NUISJ]0NZ9OKEENI\T-DJW+?)C
M1L <7Y,8!1SLGVF>;IJG'Z@Q.,L[,P U C3NL:"":9VNV8'T,[0+/BHQJC#H
MT'.UN7&Z8!+3:G77KN+4&M#DP,S4,#;;,?_J?NM:'S?9B"^OV<G:7OJ%Y5RO
M64"E'>#UA4=@NEQN?VHPJ#\NIP=E0WO8&QG"/CIX;L\0]OX(>T-"3%XC!1AW
M?M(JL>6,ZBP;&PJ SDU@22)H<\B^ AKY !KJU#.H9SM1AU)#/6:(J:6:I-4>
M7V/MXA4X=;.8S/TT>08%HZO)J3EXAU=+[;.(#Z"Q=-U^S<$[O)X["^IL@0K4
M +$/Z#FW2<_]_O]YJ_7KOW-==RHFI@XPG*W/=)"83&_,\X]?CMW1/I/Q=2 5
M'6 X6Z_L(.0Z$2%$0.!I!A!/T^W[#,_Q?M 4I2C&<_8YF6>SU,<O@'I7QAG4
M%CSC#!IG4%_PC#-HG$%=M%^C,_@U%EU:8G+K!1G-D3X5 U<'&(Q/N%>?L#BH
MM]UQ;Y^M5G0@%AU@,%[A/@F61S" ;%\9IU"[/6U4BU_2)8G/P$;5'#SCX#V3
MF'*=[H1'KP;] VA570E,<_","_F\:MKINB>JIENP<0V[]G[IA3?P(C^T<@?5
M\K"0U@MG>^DUKH/5K0,,QE4]S'E0WQX]:H*KUL2B PS&5=V98%_V)DS'G9)R
M:[4/NM$%+9I7A#?F-%)O\(RS:DXC]07/N)+F-%(7E=>8BY,7^B5TCI0I\SL!
MI74ZO*_U1NH P]GZ8Z>I2%KM5C4>[=$1A5(C%WQ%2%+L"RAZ K*6?V=@%&H.
MGO&HGNOX;Y@?_XW-Z9\NX!F7[;E#]4Y+2C?.:);@QR@F\-G"ZGRFEY-3,9=U
M@&$W%7M.8]6>HD?U&B*H YWI ,-N^O2$:/U"#VUF1O31-C,XHN\,K%?-P6OJ
M&6HFBFVM^YXR4FS3(#Y^2.!VZ\:4[O*68T[\TYS\-0>OJ?&IX<ZGN;A/X2:G
MNQ,S_61F!CZ* QJ@U95A3P/<W!IH";PM0V_+P,VU3]OF!1Y558VV=H'V-Y.+
M?JO@9]N97 ,SD\O,Y*IPX7,)'!F>*1,V!J!&@$:#[F#Z3!#M8(.:.5P'FL-U
M5 )48=!A#E?)<^?,8&9O/6+VUD"/RA<S>VOCD>]#9N!>^5LSEZ0=X%6$D!E,
M]&!"8J_+)(&93*270?.DB@51G;Z(HY4DL%!*_7+(^@6-3"0-!9%).6^I)#A)
M>X9EG->GFO,AHF=@,F@.WN$%B;%H2MFVX^[ V#-ZB2IY!M:)6 @ZP'"V5LJ!
M)4B_^Y@6L"V0(*=I!RV]F'2NO83,K5FT6I,PV5N[:<VM"\W!,\;/<XFNO-'@
MT#0:U$P\L5#. ?L,ZF")Z "#L89V%RDOW6EW:OJV:;1;#T_4^'V_$S4TMR$T
M!\^8.,]LXO2ZO7:8.&=43,UZ2GKS/[,D70$YFR#/T23,"967'DZ,/*&.&ERL
MWC;E*N)ZO625*97%/?F0IWF;!"#-P&M* #(%>ON4=SL5NVXI\/)B5U.@]S@.
M:(!65X8]#7!S>6-*L@Y2DG6U)-;[: 7RX-[R9C/ ;YK06BJY4:(%6 ?_X?+;
M>VL\<&Q+D3,,$/S[%\M/X>DS>.PG=O<5WLW%C?426]RXSFO^&/JI]_I5UY)@
MH%UPQJ\3*XB2Q+HF (G:L]&:16'B)P DV(,DN,><&@]D)>\?C+>Q!]).PM:?
M6>PG<W]&@[KITDOQ_C3VK[,4GL6KRE;>GU'LI_?6RYN8P%U82 ;K&SH_O1(5
M:FG>A<JB]6(^  )7WM DY42ABG_"AGNS99:0- 58M*H=VYXN/DF&%UG _B=8
MNT? )IM;=P0VQ0L""] IE^\%Y); E^$<$ N$ %>^<+JN@AQ81(!;L6VUWK!K
M?8YR".B+<S!"? :EB;4'GL'6!8"MW9._BP C[@J 2H +$-N![UW[@9_Z!#=I
M$2"5(B8PY:P@W 1IF6:AK6&W4C -E)VA##?SXO@^ HN-/3@EJW44>T#C<Q^>
M$9-P1I KTSM"0OH*>@/.J/!6*#HH-]8#AMNS\$,OG/E *C&!!Z?T1GP//(D]
M $0-GA*K LA:9_$Z2@APTS? A[\ <S),Z5%R%&(T0W!I68C,'T:8@@-&V VU
MH:8.]%3J0$?.T4)&=?#T'-WJ+O6#:#)BW@LP/1)L^.O%H.U%H90*35'H@X@Z
M+C&6@-"A+%1B@1*4G$M,A>BN%:):B@116C<Q<F(;[!DYL1&ROJO*AOU2UVD+
M#'1$3YLZ](7,T.V3Z/88C0_JU9A)'=LEL'/0(N*"VS4[!&@)?$TRZ8Q3R@YA
MR>FZ_;K#9\A3HZKY&F5X1C47C?TS/LL'$=+APR**[[QXOI<$1:T\0OTD@BF\
M:"+.%WW'[O6'>[6U#!$:(MR-"!],M9_:[NB(<\L.J=E:[>8U-XWRUC1#YK_@
MZL4D(5X\6](#Z3EF3D1K3,VWR \LD"9[U8"Z6JJZPW=PD=4^2_J1TNQ!8>8.
M[-%XKT-(=2<NW>$SQ/]LQ-_OV8/1$9LB&2=U<UPV!OT<9GLI/]'"%-<"".,/
M[%F#.G9_TC^$!C6T:FAUO[3:F]C#WN@T%=YI^JZ_$2\A>>;T_3D8P+K#9PST
M9Y!7_/AH9/>G$^.=Z@.?(?[G)/[I:'J:REK_;6O4R+\W19#3O)FO.5-ML0 Z
M&RG#70+7=IS'M/75FTRT ,+0ZIXUXL0>]1X3:FF!1CQ-]_5R-HLS+V#UOWCV
M&M^:(U8=X#-V_'-(K3%O_C/L&2=6(_@,\3\G\8_'PU:H[!-L3-JHE[^ET>R[
M%:VQ08]Q4(\G7,ZG+>GC)<@3NI*.>Z[Q; V1GS:1#P=ZZ=?S:J;K-K;XPV9L
M=;VPSL'"UAV^AEH]TT[WL8'D)\BOZ<">N(_)PFPM]>D.G^$.?;AC/+)[@\=8
ML1L5_/Z;1S-#0#>";H!66P8\$7B% &D)N&U#;]O@U8,<:@6B]*':3%QMX%KZ
M5%%+UT$T^]Y9Q'X0;.[6RIQEMU:Y2(BHOB$+OX.F#)]#]4V[@W&#MK]X^[$S
MGJB-<IHQI?S]UT[G0SBWOGHWQ!KTW$Z'/4%=Z=>/^/N[F'C?+^&?8K4!\6)J
M6RQ+J)2AS_6G@LW&-UP42ON&=*[QJXZW@&7^8GG!G7>?*#NRC,7E7*'S_776
M/UY;-?#!SJ]_\!Z\HK,^V_B<4^B=I7VLX1/^T\7/;S<A]QV!EPKT]NO1BX2$
MB\U77O73!? ,\, /24? ZX=^ZGM!OAQ&V6  >98___4BO'<=9SR>]H8_>G\D
M@S]<9]Q9^&$8I21QW#_6-^X(K@5(+\/9,HH!PC<_>_DFK9M!VI*TOVUHY77K
MQ;X7IFAMQBM<0J7!%UW&,B:+7R_^=O7E/?CPE^]^^V!]^6B]__+YZL/GJV\(
M[9N?U_5D)3#;P6;WP"L;>9E)BY7GAYN%1:UHL/;125IFH8$DK4UK:2'%3J>1
MLWX0F=;2>AXKFI:QIK5T:<WZ=]PTK:5UV3 C)XX=I34M>DUK::TA,W1K6DN?
MRNG_5JVEI;E7IK^TQO"9!KZFO[3&\!GR-/VE-5%[S<71:-)THD4G2PA+=SLY
M1U _&6 J2CMN=UJ?<[HQ-6?*$I,OWKX<V,YD_,JDBAN2?3:2[7?[]>5&VQ1"
M \'V1_U76N5]FU+HC:KQ:XR#%])[6@I-_I/YM&O(.1BNNL-GRD&?7=_V[+$[
M/(2^U97&=(?/\, S*W#7=D:C=BCP<RJ,_I(N2:Q6;4GAVY,QRK4 PA21[E.Y
MNN-NKU]SX+=#K<G+GA!'=:\I7VW<9<,4NFM;]\G5U3ORA%8*793L/5FAM]HC
MWZ5"^T"Z7E>K7W?X-A:B[D,8GIY7\B3/_"ER<FA/>OUCVP^Z$K+N\!E&>T[W
M_REL-K('?<>8)"V@D":SX]]>D'G8>,WR@B"Z\\*9F7#5+F'64HE59QK\F26I
MO[C?++2>ZD)-IK;3,[&%HP-A&&-[5?XLC#&:VN.>VWYM?N:!A,\D-8W>](3/
MM+)Z<J2@)-] 4EKS*,/N XT"SN'2ZL4FT2:8JCL8U8C175X#].+VW->FA9P^
M\!F^>W+@X.!\-ZD+^3V"[TQOND=QRHDT]VH;O'HT(SM9]+8-7CW(H58@2A^J
MO>F.JM5Z?8[$K0*>GT+PCD#)K_P0M(B5+HD5$O"4%E%L>=9M-1QJTVO>1RM0
M*_?6TDNL&_^6A IR9E&8^*"XV*UI9/EI8LVR51; -[<$U%KTW?+#6;0B-.,Z
MB)+$6D>)3T=>=*VKTAO098/_S>FKO5O/#VB#K17QPL2*%E9,9A'8*+B &E?/
MQE<%V5RLCX]K1KCH+$BD+EAT:F$..  (ER% B&^\G/SPDY3 RMF;X#T)?9+W
M X%0UIV2U3J*O?C>FOL+@ /OXD_A4+,WPX,0O'7@A13K20KO)3<^8;.X /=D
MYL%+X<\LS6(B7L9QUK4NZ;*KG56P=8*Z0=C$+(7_PY/A84%0MZ66=X-7I'2;
MPGI_&=Y9>VNT4##P8C+M.A:0<4 O@\6\&$V[X_R;.]A-W"TP:^;PY.95T'NQ
MHM[&T61K,D/"">X9;=0! JB)<1[WW%K'/I ^<!*^P,/;LR 5.&=#0!F>Z_;<
MNB$A?D/FW5+CQ".S]6AKEMZ>.);>W/I7]UO76A#DUJ &(RI?RZ-3\27>>AU'
M/P#=*>R-]:+G#KH3L=?=AQY=>ER.>-A*"B5NUSWQXL2ZQM:)E%-H^\?:M?7&
M8!J#IY$"PZ[]&)D$J!UWO5@PM8G'KY/ZG;\#AE6A@*=.*:70UW857 "6DVRV
MM)$$Q6L>6#"\8^G=HLB#AP./8;]&G!^_( HJSH3PDA30_"!9*#BO4MS([3KL
M14+"I$M/D( %?V%CR2A+K#G<D,"/8$7<+ &B_G07*5IAE+I9PC7@C;N]1T$W
M&#1"IR!D Z0,O4USC^M0V76M79$X:BVM_@L8,+:^H5X!D\/J3US*Z/U)7V'F
M3Q@ "6'#?P?%'V:(YSF80#Y@#ZR<&+4]/D#9E P??1-196Y%=R!/DJ6_MF9+
M+[SAYI-T:RZ3)+,$"[112:UCTF&W/2P^$?J()LA+=WEI&OO764KQE^%<[ ;9
M)T: TN'9DIZT$9QHL0 3@$$4):EXN&3 P1U$9=65=P]B&X3;RJ>Z%.Q,)EH#
MNPXMXD<@Q&@VRT#F^W07@/Y\5.*2\9B_77K(];TU_ GH*YI]7T8!H#\1)#P#
M8S:QAHX%*\9P%K;?74=@$P$+@"F']D$$-$]-PYB0#BH<O-:/ .AO 'T G^,L
M !SADH!G $2ZPR4V4U8?>'<U9BPP%#P8C<)Y+0ZXWEN#Z4>QBB\L[JE<GX@;
MN)%8LG:$Z1B#D>QQ,H<;<!>3I1>CSEG[*>Y'@ML(=]PM?=A]OG-1EJ(-S\DU
M3 %-)6U*191XHRJ7?.5""W :,L)3#5F;0O,TPK<M\%0JA$\-5XGX"RI6Q#AB
M.=]!";""J)'\DNSZ3Q 4^) $9(B_\&=>F#+:]KC+TE(Q*).H-YN!BYURYR\#
MDHO1<V"NBG#.8(NH'6:MP$D!%'Q'W0&\%J+II3I#P$\)<B-]'!K]@+K_TIN9
ML(F"6_S4\"+&/J0P]8'XFF""/;JFIC]<M@!:CP3_,\</Z S(P$*:1_N0RR38
M3EOA)$PQ]NZ8@ ;7,@'NP2K@W%O+7Y=ZWTF(9(?,.6./ I915T^OX8^-";!B
M*/Q)\ RI-P-;F:9!_@[0PRD*+HG:/'!:4QM8X([]:2$?W_J\3EF"'1>=($0S
M/P91"22-GB>\-_ X>)ZR!E4V<23##4T(IKX<_"_,@&D U3[3&-X<3^(1U^KB
M U"6N;00:=N4P6.R"'!Q^%I8:$+^D^'R2P(-X :8X'NV+M@)&OP1#GP!94/,
M@%-R0BG/1Q5.N$A=$U#FF$$NXZ9IU2!0@6/IYC"A%-WZ"9(B>RP5%%1(J)[!
M1_@5P62^"PG1U6TR,@LOERD[ZH.$$:X@SJ@3PH&/8@EVCB8,LV R UT'%6-(
M2]2VXQ+S5$23*H115C.1$(+PP<VHRO-U!A866#:@I%2QM(VYK[Z._("5A^R-
MURCLP$Y"&*@HR])E%-.:!!8R V>0[3N(R1E39M2+1'+);;[6[LF7T/I'%MPS
MW UDU'T)B?7.O['>$4")O\@"^ 2X>(GFK>N\_O*N3__JO7Y%8T! RC-J%U[^
M/_;>M+EM),D??C^? J/Q1L@;( V =[OM"%F6=S2/+3LL>7O_KSI L"AB# )L
M'+(TG_[)K"J<!"B2XE$ :R+&+9(XLJI^>5969LYH*2@0$@OE1$ PRPN>IG)!
M\5=D^QSV./_<IK'_D^B,Q*I%;$Q0,'FTN ,5WB!3T$@*^/,G3(S8@ (KC.77
MTJNI(N&"+(U6%$,,5)3$$F-YP67[DLKV):,=M"^IZ*\AVY?LIGU)5\CV)0/9
MOF0G[4N6'C@S]B47GBFVV]]D*TL?M)7/N 40K*5>9]V]#HH^&D"-VLC*CVJP
M_I T#<U)X+F:&@S7KO+%Y/8"& MZWLX:$\M$9YN:V4_<32$N#<*H6 V[9:$C
MX[#M/@?7%K5\SDHPE6Y'[>H#)?@K0L4\]=#%,\=H:GD^\Y3 ];?!& -O@CDB
M(,C^ "/1#T'CJ4!@$)C6+$)W+ #A$\Z8Z4'\.8C/.1@+V#T';\H.Q6"V B/*
MO/<)<^2HRI]P:Y $ENFPP,4<YG,&UJJ/,2@'!OQ$C1;F =!1H[\#E@?<SYZ4
M;FU%"S8U<[ YY]%\:<]-'_4P9)6; 6KYN*P1$7QI)L$EL)9LNK?)HCWFG'E*
MA1<HKX;M7CYTC;&C,O+@48GSC6_@R\$'&M-$2,CFBGI<N2A23:%=C.[AF+Q%
MO.,-UQ.7;5@GN*4^]&1"O4N8&@HP#-39#WGWF3H0>8\6/!(,7> .)]P[!B E
M+BN-<X2 6S"WR2/Q+1O=DYF-+JY+?L&+.%6(-+C0#KBSB=O,*GTL#Y,DMFPQ
M^A$/(@OY"0:X,S=3EQY=5=_FP48TQP$M"&P>CL'-"1HJR<>:EJ/GF7F[C\#!
M!9C1$#+>YM./*9\6.' Y/\$;XT1AS!6NQ1@+CHEOBO !,RZ@N#?2_>N81^Q@
M:8:H;(I\!'DR:/C5,H,9<(.34%CFJ<>_!S-@"HPR%/>XGMD17X]CCJ?>]-':
M/'0;S>>8+@&#IIH;U@WC2=]YL! FJ\;"8>JAB&2Y(F/<0$#;#5G65()TW"F$
M+3IV/QT[8X6+V\L<0(9=([/98[M3-#DI@R^82*!O]$J=TDP@G1E*T[5C51GX
M_2]:NZE&IHYT0'A$+<CD7["H.ZK>>(3S.0HBU$<T,06%@\6B[8NX!".-J&58
MCS]^4F048$EDP E3H?1"SJ-3WYLSMC,=BVX;L5  (R)31H)%HI?*(HL6,RNW
MV:M@!Y.\\-PX$)A"*X43A1"--)H!1VF@G%-1Y44!S$GP^K>ZSD 9W2]OQRB[
M+^9OW;[78:=MB-7K4#R*AKKLOBAB78%#=%4[*A@+1(C0G6I%]T5==E]<HRG5
M_\-\EBMJUVW8WJ@V0Y0-)D59,"D*#T997#Q1-NH[8H-)8=$A+F42M[+!9%-J
MCE1FR>2C;#3ZLENN%NSX9DWHJY(]LH_"I@A_U5%[_=%N&J,*#AK1Z9.@WB6H
M!STQ%.P)M?NH+L69VV7:M1(50JB()SED-X,J/.ZOU*"N]@?&3@MDB0 O(8B0
M&!<&XP/JO,KZF.*TVZZMS2LZ?14VN2RPMY[@>4EQO9()P/_U5*.K[T/%B@I!
MT>F3+"(@BXQ&LESD&D->O]Z>J$S8$'J3#G+U(+=NTULW>L6 0ZE S'P0K%SD
M^CGMM]%BP<I58&<^.[ <#T^)T/((F2ST3&$%GF3^BY9PS&8:Y^9&9AW+K.-3
MR_$5CR*9=2SF%HI,M9-9QX4QBY^I)+..5V/M<%)/9AU+42BS-T40&#+K^'B4
M2=S*K./:[.1NN3]PB;4G%J;->W?PNB[/E/98.A+_VX;V6J,VI42G3^9ZRK0'
M@>F3\-P%//>G/ZORWC;6GP),[#-*4G_^; ZMU32E.Q*T8$RQ-D[CW$GQ9,,F
M@#RM1,Q77=48;F1VB[W\0A A,;@I!O7>1H>\:J"Z:NWZ56JU[\LUS-*RA^#Y
MD4?>%P5=0VPG45!V)0-7LE[A*5BOHM.W=^E5/^MZ6\&VXIB#;NRQ;[W@"!.=
M/LD!->& &M@!]5V[/V@,GTQ:)@P-VS'X9,ZKOK)H+M:5YFNW5.\5JWS26J^O
M&V/5"T&$="UV=<Z0A\T&,'?R2*R$:@V@.MP.JOM7DJ?A%*^M)S%EG9;YQ_[>
M%0KR%,QHT>E;*:"D.;_YL7WL(]3N:?\E75EAZ),8%P;C*_6P/, J)ALUA%XQ
M3BPV=GKK1J\8<"@5B)D/M3W ^BG"9K\\2A9WX&-;8H56@TMQ,]:E#WLSN=A#
MD)YTS<T/;[ADF;[_1!M#)QW%6%^X?$78; ^B!78HIJW0O.>:A>$IVNK^8+*C
MSRF<K>UJPZ-%D$I/LAIM;20I6GT>NM<>=@Y$T0;F[*9'R[KRO,06CDM\%A*E
M?U%R_[837Y?C7;QC-\?EQ +SR=./F8G:0>2Y( WD"9UG)0%8:?W=,KQ@;DU-
MZ%N2"/*@PG.0;FE5>TJKDTF&[0XS?+IJ5]^FQO'^9)5,)4&!-&B,GA>"B'+1
M(G?75\F/53OLG51^]+J]9LJ/IMHZPU.P)42G;_\"Z:1LG35E57]XO(P@:>M4
M":118\P,(8B0ML[>Y,?0:*C\:*BMT]%.P980G3YIZQQ#5HWZ_5K(JA-JG7<W
M(SXQIP#EQA@;0A"QF8 YG79B6TH1'AQ^25<Q3>T,.T*)G[B'C3252B63A\T#
M8$C\+ :9+&=$G8*I(CI]55MDZV-;FE(;"<&S]YV..M2&0LFR$S*E*DNK?"9!
M\)MB(YC)CCH0BV#*"$&$M*=V*DI>V*+U'*VID18+H++W%&]Y+92X:EA'URU-
MK&\LGUQY,)V(E-;X/04#1G3Z5AM8TI!:1_J]I GF*BG'R.B4>Z>;O,7HJ%U]
M*/J11"Y*16.4JC-=HC)V0^A-!%/=#J'ECPD5/BW)M['C63];4]]VG-5G@IA)
M:I2JW\Q$++\A<G^"R'4/(4-'[>Z@0FV<O?_4&FKYHO[5,Y7[^^^MUI4[4;YA
M[8RNWFVUV!/R(_WV"7__X!/SYP7\DXX6K Z?*JE982JSU"?V9&XV*]]PEDKJ
M>](:XU<M&N;^33&=7^93D%N1F5]0%'Q]M<7C6Z6$/ECYQ2,_Z<4O[;.%3UB%
MWEE8QQ(^B4^QO'F_:G(_$'AI/+V]\NE%(.%@DY$OV[8Q\8QPQW9)*Z;7=L'>
M,YU4TO?9V;'?3<6>O#MSGPQ-&PQ&>N]1_S/H_FEH@];4=ETO)(%F_+FX-X9P
M+5!ZX5HSSP<*?W]C)HNTJ"9I36C?KCCC\&#ZMNF&:+;X<QS"TLD'.HR93Z;O
MSOYQ]_7R[/W=Q8?/5\K73\KEUYN[JYN[6Z3V]S>+<EC%,PN+!HSBABMYF4D+
M++.VS@'"I>:7RP^<&?N2"\^<6^IS:;^6*Z$/V\JE-Y_;(3LJBZ=@+^'Y8.L0
MU\+#J^N<*9UU]CI6^FC >@BT6\^.GY^P7FOXG\F]Z2C??,\B!.V[]88KX,'G
M:W:P&*2@[9K^$XBPR ^H;SB. A 8 ;P1+X"U!DOU"1[ZI(R)$D3C?Q,K9)U\
M82IRNGB13HN*$V#/&3[0Q;RGYZ-5/(R<?2P[!4VP*0U<"O].HB $<H(HL,@B
MM-&FAG<M3.1']DK^Y+9REWF.:5FLN0T>W29!:,_I46G'"VBW83N<*> #+[*D
M9\FE9'**?\T(F/^1-8OO-GV"UX[I 6.\D#T?/K5SPV?8L+P V2((/,NF--"7
MPYAA=H$HT$SLB>1Q0=P ?\?WV:X5^3Z9M)6+5>>Y\>W8?"F_-MA,&22T8L(\
M^>$3CA"_7AIENWZ\:6@;,.>U.R%SUYZ"2TS;3E_<^X0P,74B7$H-/&0F@ "J
M2R\"L"6SD$,KZCA>(S0( 5>FCV7!\Q,(V'FP _@KSVVT4-K@;;!TO3=V.*,'
MN*%'?,9'Z6,H\L.G!08MG"=:AGPZ1::D[39P)%CB ,=''HD5L8>R>@GF8@&
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M@R5C5Q1K9KKWV"E;F9JVKV#?5<*ZOB?MQ7D?\87YA/!7XV;BBF.;8[Y5SD,
MM$\E#BR$"[ W8O82SOX.MKB<!B14QD_P6K"<21"WBVUOLN3;RBI!>A#K%8*@
MK -QIZW<1N. _!7AY%X]T)YA0G7U6K_[YR?/9[U:L[UAT[YG00A?L([MK U\
MW&PS[G?-VEWG%GV=3O&\HS"\*TAGDK"9#&>@<.]GV4:;[!E]]@RD$;O2@K=F
MS7C;UU**?Q'L$1L$$9FLV0&[<\B#$L\ALKM!5^RKQX7M)[U+/]LNE1J7/IF
M;*HI-*]=;, :F7ZNW2HBX#,)05!EVK+R_L=$^6"Z/VFK6-I(&:5;W-:U %*?
M.+RA->L56YBRW -9E^)L?UC+)Q2\X 2CI8'?F;P+;$B/L<3=E5G']GQO]KB;
M_01%;D)TS%0.&QO*?$8*+)('R,;7)50M=> E)C"!&<\')QBD?C!ES\*;7%@P
M]O3<3*1OBHG&^<, ,ES,^M,N+4/3V>D:A$:\?A?I E^F6C@WA=]\;PYR!A/3
M;JAR1BGY!]/+M=4,P'Y?L$YSD?EB$>Z#F&<]GW-,\$KOM;4\W@%!"]^S")D
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M#[:G*M>NU5;.^3,ROR2WT-<"2?<^*D3^8K!VV:TJ\L;,HU[#+Y=;;_;$!N6
M=&8>F+PD?43\#FH]_YM88<S8 ?!F,#4M9K[XP'W AHG:0M% A4N@H)L">C*<
MQ7S,'YZ,7,U0G)N;7R"*E#G^%O,TGW.Z#"K[DBT)\YLB1!RVG%]WO'$W^R#R
M'^P'O-OR_(67&F7XX[QJ(=.Y ;%KX3D@-AN)QF>7J;E7TD'%'B,H&M=$I]2+
MGTR'DYL%L I\<T$B$(@!6U#^WN**H*V3>)'Q[/,Q+,^Y&=(?R'2*5#_ [<!'
MA<NS0[Y*+D2&BX>N4M&(]\!T12'8\2[&<)1@9OKT:70\B<D#!LK<PST(S_J)
M+98M)THO#YC/G+F"N0%*M/#<W)0PQSK@:Y1_Q<(G8#XA>])GJ)EGKZ E\Z:5
M3U]VZ7&^?\56 W[8Y'V<(THEYX0$EF^/T>(DCO?K-4/.F,0T< &TI)=I[ XQ
MP54C<(,;H6N')*7$%>3(,HF6Z5@1TW) IFD!9TR8I9F'=PHJ9L'"0\8VLIW%
M;0X[H'$5BUL%8S27J1F=GQ^0YD /%:,A,>=L8G'(4\^* O0=>=\)"ACT$Y2Y
MYQ"@D13G(.$7?-_<F]!A*-]O+IA)$U!#A1U:G\!T!'0T$?C$OO-$I]Y'64:G
M:0)F RCT]?2Y@(HLA1:(0[IR5'LQLXH+CF7A4*+GSFW0,[F)1K$*"%U0F6>F
MQEU&:-QF+UE6=;'[%)@.R:,SENH9/.+%.:LN-K;08F-6O[F ]7VTY_ KC/;5
M0&MK2FS/XG*?VSB('!,O4B\ ^3E]:/F T Q8@D+^<^'3$DC&#HRF-?6!KF+;
MWGS_=!Y>+UWJ3!1V^0V1^],%S7<((([:W4'%7O[9^T^M82<?EZZ>J=S??V^U
MKM"D0?G4U0>M%GM"?J3?/N'O'\"I_WD!_Z2C!;_:IYD#L\)49JE/=CURLUGY
MAN3I"_BF-<:O6N84AOF;8CJ_S*<@MR(SO[![S]=76SR^54KH@Y5?//+=%GYI
MGRU\LM5%[RRL8\D^%__I[,W[59/[@<!+X^D=ED\O @D'FXQ\>>,C)IX1[H#0
M;\7TVJZ-@>ID. S99^]_-Q5[\N[,?3(T;3 8Z;U'_<^@^Z>A#5K@TU&-JAE_
M+NX[.EP+E%Z ;^GY0.'O;\QDD1;5)*T)[=L5W2<?3-\&98ZY)!B-*O&;Z#!F
M8&>\._O'W=?+L_=W%Q\^7RE?/RF77V_NKF[N;I':W]\LRF$5SVP+C5;@E96\
MS*3%W+3=U<*B5#0<5T?QW=GU\B 3%_IY+5&0\IV<E(^U0TY3E;GTRY;<DIRG
ML8:$C'!FAMQZ9[<RO;A29XTQ%H"F"Z-_3K)!B;\B.WQ*=XO8[6."JCD*4N.0
M:6=F6\53D'L)J"P,?"5^0%;IEON:B=]C9T)F/,3"A[WTU.2GPC(I:.AG[3N8
MC<@)J<V8C!6D5!"D\:38A2M935W++F=V2<J,Y-0#NRN,9GDQ\HA8,6<E\Y1W
M"0HS]3P,<(HR.WO<&J%8\BP8E&+/YV1BLRD L"+@&5UYKPN<\%6OJ7(J<B-/
M'8QR?Z+<12B,)RPAKLI+8&YIA1]:6[OZ+AU,P;^Q'-S;XHLP]2*,?/P5F3[?
M(*# H9&, "UH[L#GEHBRQ -N2+"M!CKI,U \W"=A2T^#/ME8!NZ=P8KBEA_=
MS :O"4P<C'I8/#:;Q@54)76^<V$ %]TA9$O@XWM>SHNN.]^@4Z:VD]W4N+VZ
MQ+&613_H5@8+$+65'^A=@6GHAR9>;OM6-,=H@85+4]Q8CZ/5EA<YZ/ZFFR\P
MOPOS*3_NW";/E+#]&WW0[L5B1%V:J\H'9V/E%0].GUM;\%ZSZ*:R8G^ JM75
M.P(%.5@:'R\JCZ 8+6"JUR=HX:"JS,20S$1J)((==Y'5.,052V0[R I7&L+A
M(3N.^QH&XPUM@V#\70:F?,;^!:P7D*PJJRE4:2 >M&*23!"/[-Y\H.CAKG^X
MQARH^>@RS42(E6 :!T4#(+H'V:ET-/;2-I>X]-H9>Z\R1<&.(GT,])HLV$I#
M2!7S3W&) =\,I6WE@BI,P*CS5,BUH!HEX'$\[]Z%F63A/<HJ+$#( YV\BWJR
M%5RR^9P;^3)QD\B/-<$"EL^;8(8(?G-+%F$V+R29D;L,K71>8"DRE%+Y6=AD
M+W9]7SE=U+F.'YA=U>?'O\SN,D!3&:#I[B! 4Q%!D &:W01H1D($:(88H G-
ML=;Y<W$OHS-[BL[,]".E4L;1FE(YP4$17GZX[92L_/>K+]?_I]S]\^K[Q;>K
M'W?7E[>J<GUSV2[F)*]EA1UK I8,D&3T] A [ZW2D.'\N+GX\?'Z[NHC\L/'
MJYM;]M?MU\_7'R_PZP\7GR]N+J^4VW]>70&S-&/4#5O$<QI?\*( ?*'@M5C&
M_6!MXW[[\R'YD5'%M(X$SAUHR1URV>[LR,M/-_:7CC8>]TQ5EIY>6Q](@E81
MU.5U.<2A2+@I$HZ@;K_=/51]G-+S->7"8T;,R5J2H[RF2EI*IU;5MX?E6G"7
M9?B/"L \#<5#F:[GDN,2%@NPE^/H^0.G0B)M37LKDU3?T=4-#UO69I08VFLT
MW(4E+%9*D@]7(W3IF&*#6;'WXI.\.RK4=AJUSM=9JK6\VHL@(&&PS[Y7B1@3
MK#!'/<A;LGDVAGGSJE7MP> 6=?D%)V_)$I#HW :=^].')]3WJO)0"<_#-*FF
MVVN+1X&\=P&5U@DT%VIH*$A '2/!5%-%(KACM643J4LS8$>^+?P#\W0?3 =+
M!)V $2@X>?M71O6S4;<TI5ZMTR['Z*K:5N7[ZPHPP<G;O_YL'/X-+C%>P )Z
M=R!4!XL3ZAA5W0#9)PO3GL2%,S.M'14KYR0VQ706@8;-U._I-->I NFJQCJ]
M%S?6&76U/6AF"?*-=.SI@'R%(EW5*VWXXEYINFIH0Z$4<-Q(Y+0=Z(JRY&?O
M[[P0CU[M2PV+:IP+3E[5[N/Z4#XYWV$+O9XV6P;'8=27OK,PY%7M;TK\[UKE
MIRS04SN]GE"J6VZBOO].@M"W:=40C' WQ6X7@8:3W2S=@R)-(W!J5QM)3_?8
MGN[IH/5EGBX"5C.V 6P-M%ZM'=;*4B\+XK."_ZPS!CV?V?*FK2@@TGT5A#RY
M]7M8]U7OJOW!-F&WN@),</+DUN_!W5=@@5&OH8I<_-5;U0$&QO1$=WPQ.VO!
M2L>[)*DU]R)&$\$R%X$&Z<ON4JNRY=1U=:#WI2];1_583[2^6 <::F]4CQ#N
MQNE/C71F5R1&N9[;DKNR8I&W_Y2JQIGU+P@FOR@+I3O0I3LL"GG[S])J'-\<
M,8&KV]F&=?9G0E3M^G>:ET']3):63)(^C$;?!''-]$364ML%(0-3HTR\" MS
M5DH9C4N95[& >?901U&4;?*67D\U.M*#/WI^UNGPS;IJ6WS6Z:N=OECA],Z)
M)'+OK,349]L<VXX=VOBVRTPGNV])]^-;UJG+G90,6V&_\I92O .O\I%,;<L.
M9>$J4<DK-VDV89[F.5NR<)4HY)4;#A*=S:LW(L#$OK!PE9/J3UF]2KCP>H.V
M!67UJF/'G$\;3#70)H+[;%L6QL#&CI$;!MA5%CO:G( !*#AY,G/Y($6K,L<.
MU=%@'P>&1 68X.3)S.5#%:U*6:"C=H8=H4*M)^0$KM+-?D16%JW*.(A-,9M%
MH.%D_<"]Y%*QY>RJNKY-9JC00!&!AI/U,_=\+K>C#K1Z5'*4OFSIP=Q8.3ZI
MB;Y<># ?GGL"9K3@Y$DO][!5,71U,-A'_4=1\24X>=+)/;@ZU]7^<)OZ:H=7
MYZ=4F/ECG ?DDP?B1F1)5<O]S5H='ZJG;'E!Z8N7''08J,90)@<?7;V>#LY?
M=KSW)5#OJMU^5RCM*ZLR;U"5>3]Q9E&M<\')DZ69#UR:N:_J/>D\"T.>+,U\
M^-+,G2W/L=4@&"[^ZE6F"6=.U+A>2)(L+A7<:<?$DLU =/C4%+->!!KDUO ^
M-.Q([6JR/='1/>'3@>N+"UUU5'TKQ-9 (=;:H<U$FFUW MC]36E51I\-S>@H
M?YB^;V(*-*97?28AH#W^+MU"5LYMUW*B"0E*)D!17O747K='G_ *O(6!IDQ]
M;Y[3PN ZOSX!XUQP\N2^\V'WG7MJOR_K8 E#GMQW/OB^<W_+39X:& KB+]X*
MQ=];5O+2;:ZQWJVG='EAJZ/><!\]%R1:I=>\IQRLSE: K8$NK+73O"+ C/G4
MN ,<@JJT9N00RE)4XUEP\J1K>PCMV^&S3)?.T(VWTKD5A3SIW!Y(H1N]F =Z
M38V!B[]T6YR"PIY'WG2/AZ%$D$X-U\'UE#,OVQW657VKON!"0T4$&J2?NZ=T
M*5T=U"1=2K9!*C^&M'==*:H5+3AYL@-234XW]?IJ=R2SIH4A3[9 JL]QJ;ZF
MZEVQ"G+M[+A4#99]]9DH67.KIJ>:ZBF$MM#>Z7Y;5U>[W6W.70H-%1%HV/\A
MI'K"=3N=F2+6Z*N=H5AM?^0>\>H]XOG<#N<DSJ"VXCUC"Q2D<G[CA825 ]?[
MKV7/'E')DYO'LF>/N.3)G=U3Z;(@P,3NX##N(FEO%]#V=N>W\"H2L 6[)62B
M*A=467YXK2JOM#90K6,:E?)@.A%YJ\A>/TW0>,T1'$(OI @TG.Q&:C.U4*T=
MM4SX\OD3L+K15?5.1^T8?268F3YV&8C"F>?#ZR:*&>*,S)0OIF_-V$)W=!7>
M8/1+9D&A*NTCL<A\3/S<Y;VWBJX/X4U]U>CWXC?908#]#6A;@R@,0O@#\Y96
MO'7E&\S[>Y_<FR'F//T5V1.3UH]DNAC<48+[N:\,?:1V1MJ6+SD!6UMP\J2C
M>M (LJ%IZK"_C^0K40$F.'G2%3YT2'I[%JB!I2/^ZE5)K[+6\!/6&E[VRFV$
M(A94VDC_N8Y:K3E@JH%6.1W_&7<_/9>%>4M#N7K?4.$[_#]W>\L]Y[6<[I7N
M[T =PH=AITNO@D\Z^_2LL[W9B_#<;[ @5F@_$$<>^STZ>=(A/LBQW^3(HZQF
M)0QYTA<^D"_\,O37P& 1?^&JNP3#T#'0;3HP#?8$;!;%,A=V:#I-<0Y$H.%D
MO=T]'^SM=;9IL2HT5$2@X63]Z7V=Z!G$@-7U>E2\.*USO=7:T;*B><3J5/'H
M\ D8QH*3)\_P'D+/]MH=!H*MCR&>=[2AVM?U6-Z5O:MXSVOI'0M"GCSP>R#S
MH/="+C-&NCH:]3?B,J%LD*I3;PUL9/S,V>"@>E.Z*:Z%"#1L=E;X=/J[;F,E
MO%1X#0>J-N@<V420'+'1<>33X8@C:?2!I@Z'O?IK]-.('JQ=[T/%T\V5I[QP
MS_PP!H"H+H?@Y*TV&T[:\UG+<BA(1)A*9>)%R J5(E'CXNW5*EF82[@MRMU-
MWM+K;=FFMJZ(%IR\U5;)23/<NH:)^#S75SO]T8Z-E_PRC;U'NKQ^R;(6D3<C
M]OV,SN^ 6G%Y(T<T/JF@5E2V;@:YB1E0$WIK-KTU(S?14<>EMU0<9C[\#7[%
MUN[I!?SA?RO]M*3JQ@XX)JVI;SO.V9*6'A;UE6Z46HB9B5A^0^3^!.WK'D*=
MCMK=084% 5[;C"BF97ES4$A/F.+L>B$>:_;A:U>QX:I[GR9+^;3"<S@C 5$B
MUXPF-NX2@X<W(6[ _J(./VX>9U9B:KNF:]DTV@L_T<I7[4+)#KDVY6OSJ37L
MK3M3N;__WFI=@7O]S;PG2E<?M5KL"?F1?ON$OW_PB?GS OY)1^L0TZ>VY*PP
ME5GJDXA,;C8KWW"66E3WI#7&KUKF%(;YFV(ZO\RG(+<B,[]@T/'UU1:/;Y42
M^F#E%X]X*L!+!%6?+7PBQNB=A74LD6'\I[,W[U=-[@<"+^73:VCETXM PL$F
M(U^.#L7$,\(=VR6MF%[;M4-@FHS<'=)Y_MU4[,F[,_?)T+3!8*3W'O4_@^Z?
MAC9L :>!S-,Z?R[N#;@0R+QPK9GG WF_OS&3%5I4T[,FKF^7<$VYCGY^,'W;
MQ$,@KN?/D7[Z[2\^JK'G3.@89CZ9OCO[Q]W72Y! %Q\^7RE?/RF77V_NKF[N
M;I':W]\LRC$53VL+*^<!HZQD9"8JYJ;MKI84I7*A[($S?5]"86F>\KS7YVJX
M5$YP4(27MU\[)2O__>K+]?\I=_^\^G[Q[>K'W?7EK:I<WUP6I7!1N@@V TLQ
MEV3XU'SH+=>!JNEP?MQ<_/AX?7?U$1GBX]7-+?OK]NOGZX\7^/7M'?SG"W(*
M<LW7;["N=]=P@7)Q@U=^^?;]ZI]PV_7_7BF?O][>YFRDALP17_*&C.8<E$DX
M\Z+ ="?!Z[5&<;!8S&#MX&<9W=0(AX$Z#H8DP+Q\=Z:=T<\\0,(^YT9&U=@Z
M\IJI3?Z5SZ:=?<>M!OY.(+GHE.PIC-+/QE Z_:-M<Y;1H\<A*$E0%4$Z?3Z:
MB1B>>W?6/9HK6P[)&3$G:^$Q!\&2_>Q:G?<9ELO67186."H4\S04@\NNYY)#
M$Y9A@"*1>D4ZY,9'WI]+%Q 2<VOJ\SMP;XCR!6Z?!0HXXF2R:8W2V@RU<!I>
M2+G'M]&TH12&Z\R>%(8K".OV]H>L9@M%+)31:&@(2YC$[ LPV]N93GNI^I+%
MAE94DW<<$Y#(:MCRKJ0[Y6G!=F?K05ZYX)'E1C:%]ZL5.4D&L]6&'7V'>7R"
MXTIP\B3L#P;[_E8]<_>GID^HQ$[5JGU=$-3#[KU"'A>8&A+LM<"L0-ZJ:$+G
M! J8-#3N(9&DU !)-5 CM?;V*LO4?"<!P;@S/4,V 6_/\1:86'@"MJ7@Y.U9
M=IR,Z;NJO-: JPC=4'5-DUZ?(.1)Z!\0^CVUUSMBCY$-5'8#J[I4ZN7_(2[!
MPP*HELW)W';M($1?\&&7L5@19%!=!,WI5*[80IH81NE^W0:5*[JJ-C!VKX E
MPB7"A4&X,1!+S^ZL>EJM7>-G"JMY2S'8$S# !2>O=%=H=P6GI'^0^ <OD'=Z
M7]7WH=)%!:7@Y$F>J0//C-1A1ZQMV!,JL5JUY)^](%"FOC>/C0'/W:41((+4
M:K)H.AWYTXT+H&Q?0%+OJ9WNT>JNBX!&$6B0'"$01XQ4O:O5I*+J!@K\M#;
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M@F#UL# ,!VK,AJONL5<3%K'"N%PX(P%1(M>,)C86M[(\+,(5L+_H5C#6O,I
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MBCGW8(S_85^0QP7FZC?&'!:""&F3;VZ3KVHED?16'71V6<Y-"*P(080$[)X
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MXVP@0FV\  A+2N2U<^/_Y@,'6%A2SYU0]@OB;2;GB<.0<Q-]YR_P4>#%()D
M?0$LDSV%8>.>5/HFX F8=VM&B<K>3*93SP^#S*PJL-S@; &_X%Z8!08CG42\
M,?D0QGWD:%8)';(',V@NL "@Z> LVYZ/@\9UQYK!@!\F1RG?@7?'7TRISXV^
M="1SL)]#RG2905GFP@[Q;>8$[D$^3!8)DT)]$_ "\Q@QILR,*UW ED^ X^E8
MX&GFV'9HG<*V<O5 P#%E/)X1;/K@;8"@H>M3,H_4I0TB"T72- +2[! 9).$%
MY=>,N"H^&.[UU>SC<Y/ UQ1G#>0@7.M&A)5@CE]..PJO)T!FG;VJ8?IH<"9@
M*6SK>=6\OI3Y'P_7Y=+#R7/K+"ISH8_GPAJEP0S$50X@=)O:9SH%'^]/,O*(
MN*!1'1 6\ M9X#/Q$N @?#^P)CQ]@?VH@5]AR3#XAJQJ@B"CC, F7,5M'Y 8
MU $"?J%R"/'*8&G&(I3M?"?2+H ?@JF92%C@LYBK8L'.?#9X<.2S4N)C;G$U
M0A_.F"F! INFW,$?M*(*R":3+H#C!7%>@4ONX3N42/E67;FEYG>B2H%I@D5&
MXPS_6"1V*;[3I$"(YM1V0B$/LM,.VPK6>>.O##W@4?CME=YO]YEI _/DQ$]Y
M9>CM;O[KJ<=,GA \:0*6F1O. CQK#@_Y@OJ$7=W15<70C#Y]"OS14U'A+%#-
M@H0$=4J51SI$:A,"&#(C2TGKMH=+I.7F \G4]T!F6[F@&J;DCIR@AMF>5,PV
MWOZJHPT+LYNW-3&SQ H#IAV1)R/*?A0S.:VW$C*Y*2G )SNQ\=3 ?T'M$LKL
MTX@J110(#FJKF1("5V34$HR$"1$:I064P_S@V&)-%,[,D!E^4QPW*D 801 M
M4)ERYR$ '17KW_P$(%ICBXWK<%P($ <6'V0R1?0]^#@<8(RBW- SE1&R1DQL
M,20YK[GV/T&Q_P]HU3G\B$8,#6^I3 .C;3DFA6'27%HD*EV?.%E(3<9#OP$Q
MC_/,+9IY4KW!&X/TB W2!+N_B/.0@'?J.;"<^&S\#17#DMN542//* \V+? K
M<0("%@C01$6Q36V9QZ<W\"_E@X@9,#A-9$+YP<25B9RPR '4/>1/I:L4LL=2
M9P!>[6)@D9[0!>MM[$5L&9DJ>,I!'T577O-0+8;BP27*$YBM;.V*P^=SPEZ]
MP63\(ID1UE3??#%=<)]P/*E1ZIA4C):Y&0!8G%X. ^5<?TW7%3UB !SQ[\&C
M*$I97 N>VP86PP.UKAW3(DF>7 0@MBC[P8+&GOFWZV]7B6N>N#>J<FZ\SA8$
M=T)89BK& N6<M._;:OR@S#V^]P07@A'C^Z;+1ANHB:V0L[XS=Y'0:K]6%6"J
M\\YK&K]O*]_)E%!OY 9XF[OT.F6\N4=Y(3E !IAWPID7W>>%S#R9[P2W=*X7
M8,%0<8@>#5T!-64$UT/;*/*I898 -8DXH'P99YT%JA'IXM$@22ISTHE##YKX
M\X ;=K'EEGUN+* XG1G3@TH;$/% "!B';>4ZY]TP-X4_,6]_,$!EYCA[V]Q\
MPF' #%K,S9T0QWQ"S0IN"L%U("CK7010@ <2X!L,_X  MJE\KG!,023=^^:<
M>>S4XT'= F+1]E"XPE13 ]./E=F2HYFZMK$=&SD8'Z*H1]MX.L68!1(18ZI@
M83.9&% PE0PYF:U4EJ4SO9GPG%?Q\\2C.@@FC#S87 E42M@R7W4]B5M;07BW
MUDYQN2+@<QM+Q:(+;D[^'04AN]0G#E/TG-G JL"83SRY+#8",T4MM]CSP8M\
M7&+J(:4Q# :F^&/YO5FOB2$$_6D.IT0?*K#J]) /#49FXPSATYJA@:-%Z-=?
M8Z.MW$;S.8;H8)RW&0/Y(O5JO\%:6SA;M0N(#-:>B ]F8%/+]1M*33=D:#E!
MSIV98"B/"7&S89"B]8(Z'9ESLY (#U'\<"E1-+I/I_P"E N +C%T?K1OV\K_
M7%Q\2ZP=9&1J#YC,3:!R(G)(D(V24I>,;QW(Y*&U$U1&.TA0J<B@D DJNTE0
MZ8J8H&+(!)7])*@<3J'PA)3U#GEAM)4932ASKQZM&7J.:!1C= >U92R_;Z\N
M$\D-LMGTN8<,O&C/4ZU3V)GB>T5@W(,=[Z-72;<(F=((XC;2&$M/(^OWD<UB
M\_1Z^FNB/- 4GWHTGL3T3L:B =WC3H"N ,B?I,9A/("+V\N<ZBF]\\>";1^F
M-_U(;N):Z%.B8$N?\,&#_R3W?[JX_1 _H(Y[3^5:L+SO:6(2P$1=)B9)O2VN
M7>Q$<7\IQQDA?W2\25N99F+RT.FOF8?&&)@7A=P2=F>&D2]Y3@8/SCB,1ZTX
MVN&#E\PVFQC/CTV'!7A3&S&)/U NL[)+V6P,_TC6]S)9W\OL^GXJ%7.WZ5K7
M%^F[]"T\=PGL@0E>]YCZ8R;;%35=-TI3.@J;M]0!F#K$"M58TF,J%'?VT^B/
M2D-CV<@#;K#&&Z;L,?&&(B :XUXT.H!!>Y=@'!&]Y&3+Q[3]E(Q8X!<C1"G%
M"R^PV99BU3[8<G(3"^%%#B,UL^]4V/+;<H>NK5SRQ(E,D);^.O6\$-5MKBP8
MFRCG*=WQ2 .7^259M7^>JN<4#"F$O/Q!< ^<S##>7UKOX$+%<867H#:8T>CF
MF.[.QW+NWY'+MN'IJ#;;):%;C1[?\O<)1I79"N8&3W=GV"I^!/C-Q\3/+61O
MU=;3U':H+75'OTVGVO6 (] .PQP!:L %A2!W@MU<CE#&GX^#07Q1/)C7"4WR
M'-.(*[S/;KKL9YD55T%HSZD)6%]1SGDUB8V6 6%]KLGA-V?6+ 6-4 XP.%-A
MP+=Q@^QN$*:KFC^)0I)YIDFH01#-%SRQ@<IGMM? 0L?H1&#\*9/3EJ;09 *_
M;-<@%6]\SQH1GE:<*-ZD\&VF"4]+97FP2Y-3#):ME@9JDMU31GV<%!!OW-.J
M&9/(CS>OTQ0[UIT@R&<#@!;%N!L\*YU$6&B0$*'GTVQ#?*AOHZ>E*C0D!68?
M"!U.%GK:7A2P&ATE4^^C6'%L\L"VI\:DX-.9@<<V<M($7\OVK6B.>RP6YMA]
M()89!6SO)6)\E9)J(W10HK!M4:IWDRG,#)VE*:O8##EB^0Y4:;)=*?#O<(<R
M(ZZ2%S1;3%UF<C"^I3D8-U3S?#.?Z,+45'1=! AX;AXP<('3K@PQ[VBY3FE^
MBL_>E]OF"KA1F%5#V9*7)\B&!/#IL8.>WW4D3IQTQ!4E5>@\S[\R#T8YQV?P
MYV<O9+\NV JE;V1;K7-"8F%'128('O#F4*.K*)^H7?I@.B@SPD(F&WQ!3'@$
M^H1P,\NICID()50^5?HVO2PV%=#BR[S )]F-.#"FT77T7&X08Q'9?)H5W86G
MHN2<"[/7]&3 / [S/*]K,EJEQ":&U_MDQC.1\8VYK6(J7'"I8NF9&8M'ITG-
M9\' ]&*JN!=P73 EA.]7,GE'Y5G5PM'IX<.DTQ,G+A8RUI @/G_NDJ%%-Y=Q
M)W7!MJ68APX"+'XR\!75W[CK3D5<9JF*0YRN)IC25=RFMPB9!.FF:,!+/14?
MM(1MF@D$[@(_G<$GRX8E#<&HI#8]3":&PEAL,&&\;*+9+YJ>$F_DINH9(Q/6
M#*4**CAZ! :>#@.M0O]Y (Y1FJ R;'B [0\V;\KGC.U24T&?995X*Q_AE2 C
MR%EH> 0 L?!$N2^%C/-4L$PFA,PIEWI1&  LJXQ??(3O.9A90"77+QO]'<:3
MB2B.)3 5^SS9JI!WD.JH[E!KZ=HZ:NJC34^"1'8P0V[(KB9ER"OZIC)-Q=Z1
MAJ.Y=M1[K>YZ;R8T+8WFD"'O_9-,[I&$%L:X@/LL9M1?P?2&Z5Q]!>NQDB;.
M>92$-,P=(S5G9>?4RFJ5AIF?)AKPJ7;+JS25N1NE"JP "<L#A_<_/'NZ7$MY
M^])2.8V0V+_+ IS&=TOF+&*'])0ON&&E7)J^XX$#/^?;XGCLCS@4G3'C%([1
M8<8F=]-<4@ALK)3SL?/RP3&MGZU;:^9A6'\!S@42M/S>A$,5-\*0!@XJ<Y8P
MF)D^,_RG]B,-""D3@FEY-O,C"H*\0]^??M:UADOVRU0)WC$EV#0A'R]WG+Y'
MD\'3G&Z:S8]P3?WF@L@N''<$$0:^;L!_57Q<A#B_%*1"@ _*''M[#NL)CK/I
M**8"\X7O<8%;@*%I8JA?>F2'"19,?F1F$#=EDMM0H-ALI$M&"XHV;@;FK*?4
M)\[84=2[*#M*O&Q'R6R9M;-E1MH.LF4JTCEDMLQNLF5Z(F;+E-7TD-DRC<V6
MR=AFJ;%[-R,E7NR2[<NAYCQEK>"<),_8A,SPP[\SEEY\N"LMNI#;S8E<;PPC
M?J 6E>TN(NYA,\,[:U#G3>\2\YI5(UC B['H@L,W6LDCGA9 U8K^T./"SF\P
MQ!&4C%JOH]76WZ":W7<>Q__.O(RZI[K$QEKB- 7)3D7)GB_ZGGVMG_-R$J>1
MWY<WV]"9 N>7[<HXCCGF62J*>0^&#[-OF$?-@J(V>D,6VQW!")F#037<"HA+
MDK,,8M][ %=_Q<$8Y H;,UP*MM< N/<3A@!<=K0C?VPJ&7J0]2)CEPS#AS#'
M+7IJDW*;,B?AS /\/Y#E;5\@EV[&X^RQ/9TX\CO&L-^$+&QV>I.P!)TI\Z$2
MRN.P9 3FZ)SX;>5_4?XCI]-)G7!7-!MFR\Y 8LAB("YSNI&'$S,Y0=3)0Y?8
M>8I?2JM A+PN \SVF!WBH5M%.0G$SL>9>%(IO^[LT"_ZQ?&D)F=%/<N*8#@_
M%E/?PS-,YE-\?H2?0DWJ8A1M[NR49EV)8OQZ@DF$[&0Y?;>:1ISH[_&9/7@+
M;9#&/R8Q2':R%HUZ3(JZC\^I<'YO*W^@ZVOF$9T_%A.C&^>/>[TT-LPB'?ST
MVJKAP KPB!&9H(?TE+FO.+PXGZN 6PR11#07C*XIPR 5W9R@^-#UMHD%\>LS
M<Y/G@)49!IRLI;-8*U*$XOR8G614-%U/6:P4SL7$HR<YLL> @.\\/ 5%9W7#
M(FT"*K)K%^QF&&2* U:W@&;N7MQ^B,-B%[<_*#I:VN EL=/S.P]$-P9A65+Q
M]VSEF32L2C7F)9?>07P7J,_7ORG91]]:H-GP]"UX*6E:$?OVT@&9GX2>$?ZW
M&%=K?:"2ZL9S:?+8958?,#+,Y,U4CR<TQN3QN&Y^FXQI)Y]2PA130*G >F )
MP=F=+20HKMECY0>>"06RP[B)<,T$4?&4*]:58"8SCZ58]'RVFP3RL=ZMG=&'
M_#WQF4"?[2-DDFMCRF@(LL7>Z_*IRJG.8M@X4P/!3/0NF[]8U,5O;V?!A'*7
MT.05G)]IX2#L&%U:EVV.@? ),%F#"C"X>Y#5WG%>/4\ B0_X4ZV;N:^M7&%Q
M,,6<L*U.JJ+C+?1" #J], ]_EKR8&_^_3)"[/J_E%F<8,M.'K@(_Z(LC9%8/
M>U5"Q<2FN7!,DYBI#K&!%%@MKUS:YX+ML1H#G4?8&="J\'M^F/&BLK2U]"P!
M3%YNE9:CXG8A?DY2_PLM5@[M\K <%RK( BS66!UX_Y)4#Z"%FKBY\2DYL8[I
M2U$05->>2"<B4X6BMN>1K['"W]-ZDKJSCJ2.BU'^+;>8"@)DS V=1  /-2ZV
M\\<5$J&N4?',3*08_!G=>6'19 T_/8L"GWE&,$U#3JSTZWB#GVVNQ1*72UES
MCLE9>;Q.,YLD\:LS,LW,O#J&9C:UOQ@O]YR']"D%*A]B*M,T!$HE/T=-^8]F
MR*$RR-R7%J'*+%&:] ?K%#_'2]B2[WY9&+UG/'F)J]#2M58/_C4PW1F+22CX
M"4VWW"2PZ>)/M9<$?3PI!45&[7.'W&-".+N"6L<K!AYO0F0=(UJ?@I;V %P#
MBW ICZ+J*7':?%87#Y1+O+4<9QW"Y_$3SQ:AF3-VIG8>/644<P!.XDHE@I^Y
M9;R4*9AJF+P/@D'@@GVL]^)23<MJ9_FYB0)"P[WJ[2O5$4^2QY&D:A"!Y":O
MK1Y87L@O:[$.?WJ9YBJ6RBP1_ 5AOX+9,B)\6TE]8%5941J-U0+]Q4IKQ"JS
MP&]4 + #1M7<QO"827&*_ 6 I-8JZ<9[R'L0W4J]U&UIW?4\B''(NX'AGT7U
MQ#P$:CP$<1[$5RI OO+DW//;:!RB8F)$=0=:RT %=>UBW9A)YN;X!%ZRZ8DO
M+,F#3 J]Y"SG7/&MHAH"E%.B8IV3!HB7*H1-\*59(RD]<L'14LBJIC@*F#Q@
M0[+2^<#?V"/3: @^=J5@P+5!%BJ3"COAP^W.GL!8>+2\D)F8G,NI8T1B_;(<
ME>$'#,XJ_X^$2:#B5"3(6I8MZT]=%!S)X4,N7+XGFO,REY+$NULSVY931>7'
M1SLP[^]]<I^H/WYI\F3EBA]22.0&UJWF58=I03 0$:;M4 62.71&:RRE61&8
M-'KO^38[(9P<?#B/<S;HUYC;X6)M9%7!&JK>$V'5A^%:LR29%W,G@+U8\-N<
MX\C_$W^BVP +A^#'US(=8OUT"'T'Z1 5^_4R'6(WZ1!]$=,ANC(=XI32(;+;
MB+$]&!]@L$QNM?+<MB2?'YW_))S+$G#+#QBB?09.!^K()6\X$P'->+S/>+GL
M#+1?%5K=_)F#-:*O-+3#;!M>!)$6.D&?T6;9R/KKTB**M, RK4U96E*"&1!3
M:DD6775&,MVZ368M/=W(YQ3+?1J8?!@67X@'ZMFN:_S = V7SNL5CF-G:V.F
M'1ABYYH'H&*3.N^9LDFDE\0DNLM=5594"^!UI3<VHH]6T*^[-J=UVLHG3-KY
M7YJT\X7E\M2]X$2V8C-&X1*<E1==2).69C;Q,='C*3F0QV)L>3@53ODF1ULK
M,J$\MK,3A^=XI0I:9VB">V[L,"NKZYW$PD@Y65RZI2$EVBC%_BOB'G;,)%%H
M.W1WGA:!Y1G2K+QXYKGG+.P6!4!- /:Z4"M>KL[6:OV)'5E9"@MQ'&SL#//^
M[DP[HY]YAVGV.3<R$-_F>!V]R@P<_I7/N)!]Q^T[_DX@N=C6M>!B_4W933-J
MRAZ<8F/0+^K]W'(>HOUMEIYA>]"1!*TB2!]TVSV4V6=HTZ,C_.Y,UX[6$+@<
MEC-B3M;"9 Z&2MS0/7:PC+;>*>5CA8;WP%"*OV5W'+FY_;!<W>)<H[WV(BB(
M ,<\#;'\BA?+]5QR:,*R'%"@,N&3EZ.J.%(@7*&V8.HSBXB[-?M)EI5Q$E(J
M,'.5]T:7HN*YV9.B8@5A'8,E+NX'6\T6&)_1^^ AB$:#1%C"C&Z[OT?1>#+P
M-1J-$F$)D\)W)^CM-!HDPA(FT;L]>N^P6^3.O(L7.A+E,0=]\Q5;WDJ]O+RZ
M^O3IR$NU'";-?O%<#3P,9?^6WX'/+M4.&7R+Z3ND_!&3O HIM#ZF.4]N@6I,
MUPL)C5L3%,B_?',A M3WX#R+NOJ"DU?EGTAT2G0>GSPI.B4XA25/@G,7X-R?
MVZ#MRFT08&*?\0WTRD*!>+(LT[_]$&Z""#)#/,&P"1J?$PS-X7ZAUU$$&LKM
M<PFFVBVD"#1(P=2,=12!!HDE@4U<H]T9GDYDW*BR?K]X+GG":W^24)G"V((3
M<$L%)V\CN5&&X^9YS5MN_.3._SZ[%UDBDWMT;5_I?;77T?A)W1- H.#D;6;Q
M2PX!#NGR+?T],@D_*R^Y1!#RI!H138W$K)%]7'PQCU(.V)IM_Q+)A6*1)[E0
M-"YDQERQY$N\M)NRS?X\5Z.MZ64@Z6SJN0JPY#*\="#)L@EH:AI>VH/X@+54
M)EZ$!Z<KY8>V;V?PY %=[M9)1&_INVT$ZKV9C2>/:BFFCR.FMW:V-GF+9!O)
M-LUBF[IX1YT**,@3+[B,F5:W\MB+L.25RKA-@-V\V)#,W1:%O')O3*)3HE,$
M\J3HE. 4ECP)SGKF!)[4L9=,5Q%:;1S[Q&+IT*8$$$2@X50S@+?T6E\]'ZR3
M(3=1TNI.!ZXK]E_2?9-F0$ $&J30W$QH&B.UJVE-67T1:) (W :!8E3"VIEM
M7^M]@4JSW]",CO*'Z?NF&R:]')[^^P2<<L')V[O,J5_,8!=;H7DGPC!DEK20
MY.W?]6@<_-?-"LMS@(2_B.1)X7\ X<_CT#VUW]<E\@4A3R+_P,@7*HEK9\49
MQ%^V51Y9;]DC:THH100:]GX$[V0$"?>?1#R>>O(HWW]1A'K"?'L_2<)<0!JD
M,-^I5?@"C!MJ;SB4")<(;S;"A7*8X@-0#=G%DBFKHI"W\KB=C+?(@ZIU [3@
MY*VN=7#2#%?K<@>BXDUP\J3Z.9KZZ0S4?G<D.4$0\B0GU(X35KI[^>D;>X]T
MVOV2Z2X"8L9;DAKM 45$WBT4#;X5U(K*;<T@-Q86-2&W9K-;,W(3EZ(F]-9L
M>FM&KA0-DES!P%!J)V4^_ U^Q1/(V0M^7WKZLDWJ1PYI@5T:VJ9S5IP)+3,-
M V.]_0!N=F:N2+[SV5/-*/3*S-.L!3MD:W#V/CX8DQW6\C=TZ&#5.PY:B&"@
MOCO3SNAG;K#2SXQX^B<?:/:5G7*CF8^8/Q>^+"[W"S<JRBWS)<\$2'P>9SMS
M*89T[O][+]6OCC^R,D?H;D84AB+;M9QH L_[Q?+* L4.@HA,@%#%&X>F[2JF
MXM@N4;RI8OED8H>*.0>Y$ (^\*)76EMG6S- GF-[<'V UWXQ?6O&?NCH*JR\
MT6^_^-S7&B+@2$[H8&TG='N.SH_,=N&NLP*#=?O#)4)R$B@GE;;C]I?[J?TE
M)_6X.K"_K*\E094$Z8-NN]?%5RC 4!@">7>F:T<S"\IA.2/F9"U,EF^AITD3
MM:KS0IF??O[%%V[L.9-];)Z+$9C-VV>NYY)#$Y;E@ *5"9^\'%7/6Z)"XFXY
M3%L2ECY[_Y%89#XF?LY:Z.WLD/A.!0/O2\_V':6T>&[VI+1805CI!L[.L-5L
MF?&9/!"'X51O-$B$):P\+T7"=U/X&HU&B;"$2>&[$_1V&@T280F3Z-T>O7=>
M:#IBE*#290FJ%9'2BR @H>Q*(2YY%5+HE$LRR',JHI!7Y9](=$IT'I\\*3HE
M.(4E3X)3=J40Q#>H[DIA!C.%_!79#Z8#:#N(FR""S!!/,)Q N>N&;HD):)]+
M,-5N(46@00JF9JRC"#1(+ ELXFY<[[/6D?&*?/FS]U\\ESSAM3])J$QA;,$)
MN*6"D[?W:ESU\YKW<$Y[@Z)<K_2>VNUT9,$"0<C;?]W1QG'(EA5N-F$26>!&
M+/*D&A%-C6Q==DV$,L"BPEQP\B07BL:%S)C[6\DT*$(67BT.I%/#3A4RO'3@
MLEWK@*:FX:5CU^S:ES-X\H!>7:#T=!%=Z^JD)X]J*:9EC>N:058$&B3;'-.Z
M$=\[ZE1 09YXP67\S)OZV40>>Q&7O%(9MPFPFQ<;DKG;HI!7[HU)=$ITBD">
M%)T2G,*2)\%9SYS DSKVXKET4.@5NEX([UR83U@]]/]G[UN?V\:1?;^?OX+K
MS:E*MB1%I-Z33*H<C[,W6QD[-_;NGOMI"J(@BQN*U/!A6^>OO]T 7^!#EFS)
M BELU68LB8]&XX=^H='=E ""##2<:@;P,[W6-T\'ZU3(39:TNM.!ZX;]EW3?
MI!D0D($&)31W$YIZKZ5WNTV9?1EH4 A\#@+EJ(2U-]N^UOL"E6:_T35ZVK]Y
MBP;-CG8)UG\[ :=<<O(.+G/J%S/8QU:HZ$08ALJ2EI*\P[L>C8/_MEEAX@I0
M\)>1/"7\7T'X1W'H8<L8#Q7R)2%/(?^5D2]5$I?:B&$>V:#HD34EE"(##2J<
M4Q__Z>3!JC9A:N3NG#Q:E6C=LXVFMWKCL0*J FHM@%H+9^*T*KUM2OC"5ML
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M85DXF'^F+=G(EGQD<S:R!^I1?LIFIDW7#((7[G)%G#7H)!^^=!WMS] -Z$P
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M(C-@'YY&@0UWCC4''0M$A8X[!1S<,XV56>\]&-8J#/@< 0-L:H+H(0ZY8Q*
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MIUW/X=%P)8.ZN2!@0_A<%#J!Y]KO6HP"?!4,>1JKWA)94B8+.C$7\S9N)+C
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MY99<X[;=?<8FU?MEH8^"+S*W/+3?0:;/XF306"$)NB9GPI7LD&5T6&IAL?>
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MEB7:N):YM%@2R]FF2DW!."HI6M8[:-$R]FB8_P"FQ7SRG.LP,NZV<BO_Q:O
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M8 5_,7##0JZ[^';+P\5C>6P VRT/"5%T8R'3,\P$>6WHHP\^ H(R(=)"UBV
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MBWM/>'=A  G1Z -9,RQ=8()OQ]0\^CDS"O:!->7[&:GU;;2$:!V?'OP;1$X
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MR#AMIHUAPHCQ<S?$^,>?(0$&,YN! 8?%,WR4^9$;+TPL6Q(@%U"3,\&!3%^
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MFCY]:_B8=+:8JQULG !K^#1EI39/@#5\FK1:FR; &CYM.?.-MG5LX'OSM-G
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MGX7#;^/0=WGD_!5Y2<(#YRP,L+F#3?5JI[BVWB_B__[>R4'[=,#-KY)U?S5
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M2$9BGE4YV0O_FWA)FJB,JAM)3>4,S/LT_PP3D9?&I' 4&0TH-X?<08<=D#G
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MP^AF40%%,;S:A<O2]ZKGS4N@Q65!RZJ"2MGIA0JA;>*4.V%JX(J>/\SG'XN
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M";A23QQ+ ^'"I!S#[%F(A.NA:W@FZCTZ*EUBH'A0CWOECG^D08CS#">QOU5
M2F(::L&]?78[6-3;>E!O2^::LR/"5!X<AM-09+IF%I:82_'0H5@'TQ"=Z_>Y
M2Z;.D^(6:AOBRMY!]T-%QJE%3-4F4X7*;W OK22U_TY#4+NI5$16WH$P)M->
M]&(720-!BO9EK@4HJ%21V 1W9)DFY2NOM%-!7+X]R_'V\+6U6DIK0M8>K@M9
M>[@69.WA6LA-A^M"U@*1!V::@&_(N$8#UCZOP;QLL&N U>H M<4LIK!V\HP
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M$6T7[KT'O$LF61; >TI0>5(1I#A3\>R?0QW2+MU%/6Y9'+@$EDA!.]+^]B0
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M<R!2ZY&/<'@E:;30U03+BC^7"B=*PB_/4Q!7[V+^)B(R=_)T$]2*8.8BF:9
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M:IV30J94>R3O&GZ ]6;ZA>*]X3-8R44*QVJ)=U"30@'LF8!GK@-7WF21XQ[
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M(#QQA>+?"N/P9&HR[43T>A=C*)G>'S[)NJ1<$]"@<:#1=AN<OZ5IHY+M73"
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M@X$(]%X5/2,F$%(K8MFMGVT,X>(^%3X=.=^V.X@C]_O1'3ED%T73L98H(86
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MYTPCE>W3<>7@=Q\VX[.;MR?*9G1Z=CQ*+,6(^%3U1*!>"=SQI7;M7/QVW2[
M#4:6A2P&'>R$(#OM%/MN,KK$QE6&/SKN\G>&U#R?(#7?ZR@AI.;Y4<B)_2M^
M%3$QZ\_W:1.\AB,X06E&7OI!*,:C@]*\+YN ZCL9 YL6P>SLM%M=Y2!M0'&
M&ED3=%E7;ZF("R8,VX8+ZTS!(!C/5V69!,L(%9DI)_(JQCO6R5U:P[+C/[W"
M0H?W2'2E86>. M1TX!&D>]8RRUV5* @^R6W<YX>Z@DIQZ]O9VL'*O:&;<S9U
MUS&^48_RK L6T9)/086TA(.QV)"2M(FR7*^=!M>;MXHF0I.M:/EC5SKV1G^7
MA?6N2V#N:4GD7A=P'3<<K&UTF;OV*L/!A[\1YE*>,I[#[AC65;JF7!,A#Q@L
M[U36Z26-K[,4R?:IYQT8:V2U(7P,ZU27;/UAV!,[9.&EWH7I_USE@AH-^H!#
M7>"!R:VKR:UC_GTNIN ?6V[@_*2#,EL1Z?D-; ]E3\OA)8A=51;"D2S2XXJ*
M'I!;BRGRUV5=(X?9/.S0K#DUOJ8;=W!;5E^"=;1.N9C4.WV,@SUJU[J*MT9V
M+\KSP?\N6_+F^8TH<-O@";-HB\.>M4^U)>)&O_VZ3HL:!; Y"+BP^+";$I91
M*LVEJ:&L<BV))F:3J\H5%_!'R4U6L\A5ZZ[[KYLU&L 9]->MN\?DX5'1J/+W
M%H:>!Q2NUX>^(0V#WU,0QOJF*$'6IEQ]W%LYVS;B+<(KF/:&D=C'QF[G,W"H
M=,NA)%T233 7\,/+O&,4YNQ$E5-XE])IWZ"$FA=_=!)\LMM2WCDH]!P-$(D+
MR5S5^K[):A1?+9Q^O3<S?#T!Z+&6R>=ND/4N6JWSE+$_O7=C2V8]H02'' 77
MFS6ZMF2GP FJL[J;<4E2[/*W2/V'KN&N"9/QJR\[-./WZ."1_\BPW\<X'2?N
M?L=P8ON V!"(\T P;*"0LC+9SR#["*JD!,G[;P/6C==^M?'L%.9V,!U)5B/S
M!\=]I.F 5\'98AKIUGF*9,,'MQ4V#2E$SK/JCAH%K+""R;/=*7;>R,#>TSW[
MB'88KUSB70S^F5(H"0; EYL!*]5MPD.I3R'FCQJ4GV3E2+!,(GX8[:(Z.(ML
MI-RZ<).LTY<=FJP[.D0<]G8K^W4S2@1)X0P+%SSW2P2$J\V/S9! )K"UC+"+
MAM!DX(.4!+T:.S#^Z+?M(C(63 _KXJ?3TV!]LCH)9CCK_XL&_VMJ"0+SGBN7
MS3MP'!2XHP(75LY]%+C"!^T:1?#R#=8CFFL+@Y6%017;16WDTE5U?S"P6+9#
M8N%9TI5@:72///(XF+1(]=+HMEKP-?,K.X1=O2D(^\V 8;Z?R_PS>47=1W0]
MYJ%6TL-3F:2QONS0I/'1X>O>J02_A:WM"*F.L+Z35"29]%$=;?(0!^MRAFHF
MUU)#%"HJ/1^C/5(0PD*G11)59!8;X[DSI%6:LM")&N30:3K!81)%=9F+72OF
M+#P7+I[5S'I0I%>P1(2\EKY.R2/!B=B2R1-Z'$#J$C!9PM5TH[[\(W/QN\A>
MOWC<<JM)]NG+#DWV'1T6@V2?(Y+\X@?I&MM"195W/_3^ S1D3'Q[7?)S4S%%
M$6*TZF[+8'8^=T2B"BAT$CY=L=\AYN2P@EV1:!8(2_/<;!M)K[G(?2+ (?0U
MVNT@274+/(KLB;GN3];X?7 EB[08K-)E6FFD"?)JIFLL;439UB994U:*.%<8
M117/:*!99-R2_#[;H-4<D5?D+@_IYB1IXW@?M%_.T:1*?LZJ52^HX69*E"*U
MDX[XM,Y=J.2DD^48RFCLGL<(G0["71T_Q!P9EZL5=E$18E@=:;$:HYAJX>X\
MJ%SX2TJMH-Q#>MN)N[G'!$,RQ*!*)$/$[YOSB3L9G, "J["6J$8XNUJNUS#
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MS&6'9J<<7;+=@HX9H?&6.<T_Y%'1P5&IP!A)?2)QQ/ZTC&[OQ@]5.WD5*<3
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M0M/\?NP*ZB'>M(]V<8.^.<;S*<%[G1:^'M<$AL2[$_6R'*Z!6Q&XSF*&(R[
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M69&FJ4[)^>]!G?K?C\VI-XF(P9[7J .YGYK5IQJU7.UT/Y<&?VXIS-(DZ>D
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M?B>2>OQY<YU5B1!]2>F%$B$#JIK4LHQU! O2GYU2X3B>":W[QZ!UG]T#6G<
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M!2$U1$P*2KE=0M8(=L\S:12JM6]ME[EIZ7K',0S5/?0 ] H=[UV 0<3\:'C
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MN'UC1CXGZM PR,N(2WN$V"8&SSMKK'+JT'2"M&JL1QF9W>NP77O5JD:8KNB
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MNO6A-/7!Q\!92+\8&9]$*T0 6HWN3H)+*PCJ$^Z[O&HKAN19E9J;',*[S(@
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M  JFU/@"JAR$,:BEN,XJF)1.IJMRB)=R83#+3M(3;LYW(PDZ^3>U)%[JOYG
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MD%BFDQD=<!?XXG)A"U.K@[[ZQ#[0$N;I;?(/H%ROP$-TQE+O*++)Y*13#.V
M\KR\K7_:Y2Z&HRX3/N=AG$6]0T["5SP8GO-+JV:_4V,I_/2UARV<@#HC[_XH
MTI<G!]0Q'*!2F/<1W<Z-<X)^09VD$M=\PV4",7=)E 3:?&AS+%?A"Q&H$71F
M+;NSZ=T&X!;,?^9;:D+'&5!0OE>@GBUUE[-KL&:-PYU_MMI823/+84F4A]T1
MB^-L:[]0?2M QP++(S&&H3ED>*I_0L.=\GB ]<9[6ZRXX?B"I $:.:;'UD"'
M+?L]B2(G8T1@R='BAJYZA)Y 'FY;7 ?/]PBF&;D_/)3@Y6!HN2'T.+_I8?0#
M-9X&Q)#!W8,E)A C7$4C85SAZ7L]R*C?F&GZ(*$Z<'\;6XBDS6'@0*JXTIO8
M&J7<NP]C-"Z-'(@-@9V]&X]TF>?BJ%C?H4M\JR=3YG;Q]'WX"Y-:L)<=FUHX
M.53+7FI!GP[M6JO"" 07B21"6<%53;"6GMB>>ZY>.,+IBO#TUS'"*,7Z(@K(
M?A Y\J*:*P@1T8CNGA$G5O*:0H^0G-Q+/)O*HIK&2 O#?4-X84PEHA1%P3D/
MC=WORE*78L5W%0Z+2F,D K.P%(E)X>88YJ4/EAA/<NQ(Y5AR<G+L7OF\('"2
M+#J,7B-14Q<CX0R]W_W.RH&@$!#F38QH([I36BJR=8@ZT)QV]]LMV3X)D]?6
M1%Z[LND=$%/<SJ4"JF!NT@S-#@'C35$Q??!5;?LRL\P$@+@H[PX/0-;7O24'
M0 @\-ZDS.Z.!MK,P1V..P\_..U@B>_'@XPW^OHR8-(6KW031BC$0X4^\#-!"
M6L][!O@_5!"5;0%MY3\Y-&>=M]HP$-]H.1PLF<'*]LVE%ISZ4_-=ZJI+; G!
M^1N;F?6;M9"AY1)VI52AI\"LJ#.2I(G+J*DW;PE\@=FR-<'6[@OK33"2S7XB
M!MW/KI1>.B:PH19'T<@+PSX5N3)=QRR:12T'O +K3$J7@IZQ[3Z;7J#)?8H_
MNKN8J7W+JL*G$V5<=YD?-&AY&HQQ=P&XR)BE/C8V4V$CEO+$>R5;'*G?T10'
MCO+0,\*G>S60/W M "6F12A#\B,<^X?'*P/F^M XC-#O\@)\8YDP%1I_LV-#
M^:I))@R CDPL\_7L9ZXN>6^=8QOV<M2X@9! )P3G1TUMP#<4/PT*!2UN$! "
M!FA)%2L"D47,2@9+],$0>=@,K ,GS?Y5LJB:"BN^3V'%BWLHK!A _D^%%?=3
M6/'JARNL"%K+O+138<71%E:,M5; X"]&%;7%:6B6X(]"LTC!?@E=WVZ06LC+
M.WE"NY^#"A1Y<PE>NP9S<!P<3)7H1L_\7,95.IM#\V.E("-94X8SB;&'+WK
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M;":DD*_$Q&-L&(0P!-[LH<J!\C$B\6+LH%55KB,90 DPN7T5U&(<3S$&_P^
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M/+Y1!04,&,7$3CM^[VM&WQFQ'=\JJ^I&R\E5"^7W6KNLXINR\F2RHZKV^E"
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M7[!^F\WCCTXCPE]KA+C_3ULH+DN =.K%T]G\D'8EH:A9/5)9 (N&P[8+[4U
M>T#:HPLG]F(NGL?@WD;;ZRJE58A-[?2FRJ@L>@R#KS\K3)<=<PVZ '23161;
M=$DOVYL?FQ]DIX0C9W96PFSH<'"&W@F]J>#TO3<*$5A+OD:N'*&W8G^E]0];
M@C;@8@,;O@-M#LW-5*6"6],6F"JV>]HT0>+YKIA=KF1B*<BO8M%G]YK.=F;J
M@X9PFQA'L.6V XUY2L,=C!7S');D@V9NA!V0<@,GQ042#F7MN<-N:2#X'&$@
M8YW5N8JID 0*C_SCZQ@!Z*&RI0$8H!_:W!RE)_&C\Z=#Q[%3#?22_OO/LX]G
M;\YF\,L+?8-GCV=S+PCTZO'S\+KP1HJK95RH^M'O7W(],?V<10_P&G[A<RUA
M<VH@D6\/:U9D#7]OG7K53Y4:".3;7X#O#$9) 6;\*V9AZ!QU+'L$3P?70LL9
M)$HS[0_O'&][P7.(+(NN61,X1R8/0M!RO<EI>S04_P;'B'@>EE49 ^P<VPIB
MQ8B>(E?/S(ANLBBPD3?OR=@J!>HL@27;)IDNU)&6?R1_O*!,/XG"8G6RQ.QE
MQV:)G5SYQR>D/#-.A9"V<Q\*0S3/*8AM52^$UL*#HP_Y!LXY"6>,GBJP=CA;
M&12$/P5%"@AVJ^Z%D-JM^3NJW>!QI"H( FO@HDV[S,G*J[12(<U3J:LV9U%C
MA+X>O^2   $$Y# 8SD#=MM$6)Q:+!1J+_NWR\@^;,XW#9BBSY4"3FR1N7+X7
ME]W"J8(OK*2&A-9,*:$K0*S?(-PF] U<C8TEJ=0O[E>]TJ9F]M'_+V9-*\5#
MMZP<X[?O(@,)2<!+"RF,(03J5L75(ZBMBU/8IYV$,M@-4#9:%OH=0 8$MH$U
M=.S^@/5?ERTT.8Z-\ 8O@NN6L8<1>A)MD2-=N17KL-3.5.(R4^@NA!N%DZ7N
M!;%U8<P+:(N<8U50C>;OT+Z-!@U/MY:.UU3TK[6;D>\$ ?$TY@ZZJ _-IB::
M5+R^W"A)SZ3WA]Y$>7GK10A-6-_,,2FI(W!#38?/9K^[8BL]#+WR^@EU#L60
MF!)SNS5L^)#_(9V&X/P#J6W;N+@HW4HZ*FA^')@)YR]>UWCP6BKP6:OFVB2\
M]89+LDVN>#/=EBT4@*BNK>S-IGOKX$8?..MDTR[+\C.U\*11B<"HO=F 1PJW
M]-X0'D+VEGI5N-A'M(<S'=I_DXUB+SLV&^7DRD-ZYQNTCC[1(!9 *P"=%#ZI
M-BP"-M*@"NT-&T<Z[+>A9*&L?<Q5B"CVT"9(PJ$1)V"@9W(7H.5S2\WCQ?S\
M8C'B.!K4-3D0?R_*6RACQ/%/<-WO M=]^O@>X+H#>-()KGL_<-V+'PZN&VS6
MS$L[P77_DG!="S>RA1:I@HY,>HE,U*I;5RSKC=E>7JNXH/)T3WA_L![H[..C
M_[,CO#F@0.P D0#'S^(#,$TQ_>+\:F$I=>8Y:BM/C9T_OC0:K/=T=#:"?O.F
M*M=M?F4" ]:'-K6<J&(!Q[")BZTW]TNG8G\'BEH,,A.=I"O@G%"EG7\3JO1'
M1I6^@"4\ %7J<1%AV /Q;Y0I JPBV+7:RVL&^$"1)\.<.7;NM=NZ6ME0 2,&
M]>A!0)4@MQ)%WWL?UVG\G_#7NHD.H#ZMF=S#9S)9S>PG0VP2!3_JK#=?YXE3
M:DR/L<QOJ"K:>MY#881@#&+R>NUEQR9]3@[_]XE#7P:V5U D'&.;^L07^ -6
ML%ZQMM6:5^M'\DI-F(H0$'PTA=^Z*;7FS5AE;P!=ER4J').&8]C6-6,' %1Q
MDZE;TN@8_0>3&4.A%".E_NR"SSBYAA:U3)5\ U)AI1]61?R!&ZS] #AZ5(&T
M\##B6N6>+2,E)]D$5I"M,9JMC*CR. !+6!Q(>>M[5L!_ W$$;M<)4PI/WX7N
MAM>-UH'?"O;]*W,_81UV_2=Y9"\[-GFT.C5Y=/_6T.I.UA#6N4M?IA/B'@BF
MCP"%1!7_8) N&G9]Q)V,L8/8:NRXBR,<3"H:RV>2 D<J!:Y.30J84XA6OOX?
M%$?5V[I16*3;UX'8B2!DCG1BYA_PB""0ZYD6#,0*\RSEWP)]>,P_>207M@BM
M;L&4R!0QQ)@")ILWQMJEEKI".JN)DJ9:JBRS'!F45L&16]  YOIMYX9@:G"%
MI6V\*-ANH5:#"4-)/R+MC."\]9P2+1FA).2 R1+UBUZC_GLT^49:PD)^/U7Z
MDKS+L\>I[DJM ,[62Y4VHA<$ 7")AM$*/VRY65O*&; >O:\@012,"9$@P47P
MFH80E&&OUS+X D0F'T>$+O>&$<2 -8#BN=;P'B$"# L& S?T>R;!4/2QBZ]$
M!Y!@!Q6DKW%[4L_F!LKAL%XON :,B];OR+>Z 9WA6%FABJ[F/E%MC>5TXGT(
MZ]IEV:A-.RY#@KER(D)SN62NZBOW2Y/[_KT"KG4#2N4[9= KVVL=;V\8%BP[
M\!/>D8T<RQ:B/Z1Q[H,=(X/>8!A/X5T0BBM8L1/S,V%-/##-WV'!._":.3LM
M"+3FVR"@:$&UG24( R876AH 2F^EAN3B :+884J0T7HE4" 6!+*DKMIV?I48
M-O'+ <\_7,%O%FFPY1MWT1P7!.^F=!V-TB7\ 2-%Y,]U+$0Z+W.X&@YA.$L;
MX+>88;.=RO:PJ;5Z0R0MG$DV$0U /;56Z )I*<#(E->#]@*I:]U!>S!N5?P9
MWH\R$2I]+7P3\:,&BG.@OK0 * %^RK//"IOVA.>?0N <I34=U-ZBLYY#JE@0
M7A%IE1JL EPG+3O8;,6W[L8EL;*&/@/V,B9P9ZM*O\]HUBE;-\L3&15S ]&\
M6HI%6[T+3,/E5B$K:FD$CUQ\O5@2^S,D'+LH&9[[ 0LO.9#O#'3R04W[";?@
M+@ N:B,!^GSU91->!$A'$3T,H: /W:9W'_#DVMC+CLVUN3Y1U\;N<D[I.C7@
MMCL%_XP!/L#3Y+DTRG-IU"*43*72#3J#*FSU=WKC@4J2HG@.Z QQ#N&115G8
M/RR&P8Z""9N%@2F>(VG=H%BKF0%_#8)U("&=U=9NMPJ%JBA8I:1"IW!4F1^)
M152,/PW.W[!E6PGL0BM8#MC#+-ME0I7>*?$ AV;=YA;'"^'CMF!@;\!*80@I
MF+[=8#9O"?-Y+Z;-R/.JW$#]"IHD,?!H.?,]X1"4M?T' EG\_L2VY':"ME K
M7"9$Y52^83.THW$C6D7CVW%)7%4(IVX;8>M9"[)KG\)&V>>!7K@\./5.O=>S
MT!&:](V][-CT37:B^L:FNS'+!\>">T<XFB?+/U1? S500G@96Q;GM Y)9!^X
M<[%\=/%]CHI'IO%R(M/X5OL-R#1>GMAAVC\-=;FL%6-3WN!A< 0:]YWB>GE(
M?HO Z_^(J^2:OO_D/,P6=_'XXKE+AZ' Z'=DNT%5F[98&P6?VY[()EX) _K=
M9,3?4$9<C_-G<YUD]Z2X&;<ZGNW9X/A:&>@ D3%,6/;O@V4_OP<L^P#8>L*R
MWP^6_<D/AV4/MM/FI9VP[$>+9>];+4Z%%NJJ;#+A+'KI.%, ;G,4CA>X8\#Z
MWML\YGR:45C_,.''2XI/S]YR&JF:S9?ZM@DEJ3#MA9'(A QAPU!YZW)1+IAQ
M31V)N="+@OVR1\C!*KR>/3N#TBU+3+'_'>"+R5V_J.[ZQ<]W_6)^UR^N[_K%
MPG[1VRFPH0Z[T<8"B.9HU71++1JD*Z\4,F(;MZA>! R6ZYAC(Z/;+_ZL-_@F
MC_7/J'@"=A% H?6VWH8:)P6*%3P7Z=7D(OG_'M9%>C6Y2+M=I'\6+D3\&R-C
M,N$RO3^P3S1\]IM$V,2S9KMQHGPHZHUU^@@T(<X1V_(+W!-D=EC&.7HC];52
MS4XBCFCFW)N?0$G)V;FP>#3PU/@*,#---P_X,X_A(XPA GU&NB_$?6'B.]Z#
M0<,%ET#0MQ;X12]B#_#C[FKWBZ$'1[J7.VBHS(@ZB<R!VO24!6N<> D2)FN-
MQ-^8T1S8KK1/#3"G%:R Z=)>S6ZR,C=AY.#T?XMOH4PZ\5\3-HKS'5%'2.XQ
M)XSL2HJ9=;O7 BXIY;<G'VE7?Z"A_!O9)O=3%P*%J0E!!^^[S,&9:XN@/XI4
MP2V67]D3_M7^X8EO'"P\?SRIPLXZ/Z@J/'\\Z<*!,_,)F.A!S%TB'L[%"EFV
MC<;ARMN".QR"[KLJ2]$??=;PG:,0=5.N %0UA/S<P,)RWM/ *.FF^#WH=4 @
M#54CVC$BDHRXN,H8\&[N ,$]\V=&_"'446OC#<HE)/@#L@UHEPP"%]"#>K!^
M3+&2%$/478:SNZ2[]4(8"E6_%:'Q#KWQT4 &\I]6'8^H7L(D+0FSQ15 G5FZ
M&_'*$U$/J^@>\PX0$&$5E9F([2B /.T,&3,K6)D9#[Y9^]KX5U^9DZ[:"]$T
M6VD-0MEK"&JA2:6__5;KJ?420;^U5P3UAR7\DI=\:_E^/LGWSCH_K'P_G^3[
M@'S_H+1A_@<)Q.WKV6]&?M[)PP%Y/V-F(@60.)("1* (%0#\G CO,M#]9 ^;
M5;LVA-M$_+"U(64;+FP8#$2NW6?[:(ZA3G#@$<7% (\LE#FAH,$.#N[>V,6^
M$X/QF^%0;6B^'<1K%O8*> F J![2:R"3;W&&M6A[@\-11(IL4-DL@#<E0!UK
M!JOH]1D1O0%Z-=8HKAD>S!YOX1,=8W<:@DJ+58=Q\ #T(^=#J.U#F8!Q][ZE
MZ>+6[;(!.WIM&ATMQZHE_O2$.>4P AO1NRM*[1IS'9N%BJ9J%;=Y([@W.LLV
MRCT"GW"#=-JX%$/^UDKG8E(ZG75^6*5S<1)*Y^"&'N^T $,&\%9HGJF)Q\@K
M/PK\VLDU\;ASW.E<)-;VB#TA4M>9(E& Y520S(!6=MK1L#D&E>V[/V9SX1FE
M):1Y9T6LUV(A:S&QB!.T: 9EK@2-!@\1K;N*JI#@6\;WHGMRBSNJ!2SHVOHZ
MVS@#)N.*J8RK9_O#UD.$_AQP5T=67<10@6A]SOZ-]>#_;*NL3K-DN.<DV RM
M?N<F.$S,EZ;FPW;MLHFML<]=SWN[3!VJ[;.[1RD/W2UQ7I<S=,,1P!6)\K:A
M'B6QM&@'[%*H>%&-MTED_9'WSF!]QNW@,4.S4KS':,$I-ASU;HA++883]7>F
MK61S5U&<:J4-\162M#.Q0:ZN*#\1G/U2%5CK!G!VN/&<<JC!>W<8$>3'9D;5
MI.7L9<>FY4ZN0<+7R*WE07++5=?;@KW:4V<V-^5!6ZS7&3RZUH,S-]'2Z0/U
MP 5!HX^I*OR:W#'9)-6E7TY-75V#SX &]>H+UC)#RQOW3(Q>ZPNPN%8_$2Y,
M],*7:RP2JLM5<QN;4J?Y^0(, ?OENLQQJ<+=BPB4@4( NQ1C$X*D3!5UDY#K
M%V.3)C,^\P#;:\&.PO&V!PUX".B6"1%A,;MF]]OSBX7!]GLM,Z O<D34>?RR
M+*^>7K!R0TI*[^$6>CNUD#J-A@(H*4C8;-ER,C4RK[);RA3(&)O:V$U5 FZ8
M2KU4=9-A"-E4^(8G;U\+IN*]!>6&;462Y3DS-6 T1@2J6HJ,NX?9] /DW_6P
MJ;\%+[]9)1C4F\7@SD^@[@T/4J=>F0DR4MF<0EZ,P 271M9/^64QH\HMU5#'
M++_X&6C8"D[RUE"\1PE=8U_@T &=UN94;N\^6*KF%G+Z8WE\5JI9)3L^N/KH
MD4":GF6+<[><M#8[#Z7VMJ(<>&";&.<.D;D^G0/VH(6">SP\EEIM_G;AO]=X
M5L<YOLK0'L)UQN.M[56$^_VZ@(. Z^XVO65CDEN"."G-Z,59T+<:L&^I9U,%
M)JXY$V4EMA'?VFR'JMY/!B[.9I_&8EUHEIG;3)#W[P-YO[@'R/L )GN"O-\/
MY/WI#P=Y#[9[YJ6=(.]'"WD?HV\W%C7Z_U^)ID)[?\8&_Z"][XEW&>$:RLJ8
M]HQZR$T+B+N8G'4&?%!8:)E1CWAGMOC<[R&;@O)"_:Q,9&I058%C(08QQCO>
M[99=*[T+R(2;0=/'>H=N+?Q4;'\4D<O.RE%0GK3K1MW;2S_ R;.=K##]&YE<
ML?N3OT[:T+XR&!H$DO02<C@V>Q]KVB)65;"%:Y\C(X DHS+=]Y"M&[<,&&"
M#BD@3";Z_RW)-:M4H6[C?!']**LYT?]W_DUMIWZ4R$_R]9$?SY&PIVS_R _G
M'R3T:W> QPJC*P@\=PFC3&S$"0_7-O$:&3Q8Y"#7.-=F(0 %VW?,.X1@CN!
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MZWVDK7FQ6VYA- [BGG2@O>S8=.#)]5!#Z@A3'G)=@J</!0-8QVJ1?9' Z@D
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MM!5I;O5E('=7-<K_%I]U^JC>\=E-IFX)1U?6#1'?\U\7,!@TF;I9?2E6F"1
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M?<HW7MQ#^<9 ?<%4OG$_Y1NO?KCRC8NI?&-J@_:#FY3)J9F47H*N:PG<+>[
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M&TP<U5$YHDJ#X(]K5+R@N;J/_@G=1F(C,SR5>S?)M%=>UG699!"=G^MG S$
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MGIU-$/,A%^T-!?JL^+59ZI\YE&.]LU^A:KV3D=.W:K*<Q'RL;TE$-/ K9?E
MN< $;/RI0\ZXN[0E .@\ .'NJ8]_:?UA$.[89WGOV&ZE'C$B$T(Z69EV8KO6
M&[TG+#YL6!^*/ZC((B\H#%ZSUXXN&D(*6)8;Y^2ASNR!4L?A\<:5[&(<J)#)
M)!1-MZ\Y9YR70%0I",6Q99W*T\CQBE'N-E5YO%6I7F"V#;1+G7-W/_A16P&0
M%.WYU<#SVV*\3ULZP?D/17W5"EY>3=1.=#20<],Q7G#F\'<@2(#JS#?0Y0TM
M"7-D3,A\0W66&'6-L4V#FK$A(<+R1& NC**KLDR1J;0;P3>OP]R#DL?Z:]?9
MINY=/8A]=D%.9*L $P87M(6=HZ [][\EL:HQ5*ZT65+%.8>+D2"KK-15B3AE
M$>CMGY;P\<A^D./ACD(83Z&-9,S%(O;[V,X*Q*3W."_TK)^FM._L2-.^)X>]
MK!4H B2* WXB;8+7/GL;MFPH:PMCL5*/L\+&X.%B]AG'>Q.\(<%F]!=4W; G
MEA5&C 7%!/)("XP%=M @+F$+,\-.1@C)BG,*P]+ F<A7"Q?0-Z1[K&@VS8%(
M]+GI[59#KZ?C'-C21W&<3P[%T9B.$+$(-G7R$]2G5YQ+F5H99(1TT18\U%R#
M%N$9#)<#&4IO0 NG6I6;3L#Z>"?7*!XJE<2;K-&S^*^AG4]A+ER+KRT,;'&[
M7IJFR?"-3JMFQ.0AGW@*P(%LV<H>- R"H\7("K<4Y'=-1SNTO8_B:">G<;2Y
M,"A![&U$+5N04+ %8 : 8[2BI/)L?;+B[6Q>.AH]TM=%"J#]+7V.T.Z%P;/:
M#@S300AMAJ,X".EI' 2GX[",.#)]6.#;8,)>P4& 9DQ4N^J4CTBC$.ENTJZ7
M1 '%#<F$=4MZ\ UI):Z;'D$LU:XPE6\@Z*:,6IW.5FA_'<794J=VMDC/^ X@
MZIS^V2D"[N!^IJ304']@\X6A(@3QO$E#!7?249RBU6F<(C;5;%,^Z,\$N?ST
MACHQ0&*:%0O6R+"K0E%VC^ '@N.1+*D2)V92*8,;XB@.P]5I' :G4K@"+=]2
MWR]?M[@/UV4*H.^LHU:,PPY&F.T7-E=?9#!"?=ED7*SA93F#.@4C(J"3L'*+
M/"$36YSE6=T0CO6.*94G9^=/]L^I=%PU7!_3QQ/7PY2N(3 "!_;_V'NSYC:2
M;$WP_?Z*L+;;;60;Q!8I:BO-/# E9;6Z,U,R454Y8V/S$  <9*0"$:A82*%^
M??M9?(MP#P D2 *"IY7=*Y) A&_G^%F^\QUH@KY>XHQAN9A.PB(U2$ZH=<VA
MLPGP?J4W<E+$#.-=KE6W.8W>J81#I(Y>4@@),]W\"NZ>J-3TQ_9-J5T?FE)#
M@21Q=!3((*WGE'3 O14,9*G6U#%)-O.*M2NCMX*Z-ZPIJ#W%Y3YM0V45Q=YW
M]/="[+.#$WN-OW"P$#IPU&L2>YSH]K,H*&DNA6"4W')5O&X:XFO^JOP"E">O
M%*.$P=V,AA6:0KI++^1* -J-29+)-3!N/I-GEZOS1RZ"K#*->DUG<S251M;L
MK/:ZC@(H6JR2I'DBL ?8/MUIK6&T='-5JIF8'WAUBX6(_'+/^VHR<'"(__GR
M^?.1/!6*$H4[C.A&9&;LTY*0'JN9.=SVQU:7(=-M&(H?(=RA>0<X5VV: $$2
MFUL9>4M3(=/MG3U&.Y&/(*7S-RZ+ENLV/1MF[]?JG>#NQHGT1J7FS&IY"*S[
M#JF&R@7UE"ND1.FY>V1 68X+E ?NG33B;C$CZZS!YPPOK'6/>J<_AM: @^_-
MP%25<E9;]QHW0K9QEUIXE,6]'!%SQ!SJ0"IK'.N<"<NZUN?@OH? .W\NU@MT
M6B:?B'$3H4U13:N)[;S3D]H1I5BT]C1%:^=;*%H+5%7%HK7M%*V]VKFB-6]+
M1U[:6+2VMT5KYP-&J54(55/"<L%E9 #OJ3*@'Z&_]'\C'4UYX;CXG86T$J1\
M\Y]4;9G.V]37:47Y3A7-KE6:5+65HTOD>T;P[72"IC(9P.$O$RSI&1'%I[?
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M*7L-#PT 4#R)A5#P/SC+D^0"2=\L^U,1?E-*@GE?+? :=W"PR%SOUD<C <_
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M.H>((B_R$0JI;UG4DD X8WUO(<?4"GI<]EKH677<A@<'YD<4<Q#%_'H+*.8
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MD:JJ1R,%:]8A\W:_]-KI<[LIIB[AT>TL=(=MKU4R:ZLBJZ_1,R.@*-M$]'L
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MOIRI"S2\;C!G77:"^EI>7'<O@!BJ<V&U#-U4KF&MU'9@:)ZV:JIK1 "WAL>
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M,ZH.U#1&ZH</(D=^J*AT],?V3>F(0U0ZW,>>!>1",_=VY36*Q:&*Q>P0Q6*
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M207$//:]?LR"M%=G$>7X6&<%4(YG!R$(#XAR1/$9 CB:1E?#V$8+Q^B]]78
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M]\#9(JW2QU +7G:(\X$KP&,#@<\_)<A$KWD]=^R3/Z"ND1_&[E6.RK[(Y5\
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M8XLEWY[LUN59.LYR8!B ^VY6I>T4JXN0G ,2P'DN9XRCOK-C.++2X(;H0"\
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M[6VNO4XHT1^ZZZ_T:'>0F&016*KEG>O1C!,P_;HE4_J'SK#OV[?P&;D T%\
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M$C-1,1ZX']H'4[3)FI:SIX)F[= 3 $V9J&H!1@]:0)G=VHG>QRCF% M7Y'@
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M*- [.H"H_?=GKYY\ #]YT#Z6D>W& '[VY-!=FZ$+:5@DEW/@*8X61;PD=G0
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MB:[M7^'B1B^+I/SXWZ- 8@G%?H>./W( ]AL/3^"+,?#%LQL 7XR@ R;PQ<V
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M@NK>A 7;?6IN64>?D')&4KDRZ7.]ON^.3T^/_W82O7SS-H[>_/9JIQ!RVTO
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MCX(WPKZ0K% <4> 0^=!:G=LL1RQW>^P::U!"+V<(UY"]^@0D$MVT5*U1WW4
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M7Q"TGR0NW8P:=(9Z0"5Y/NG5Y-'L]\8 68]!-_@2XXU8&^EEU^34ZOPU6&5
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M"\&-8/W&07@Z@5FGZ%HVYKR.&&#P?9+<9DU%\=YF M$9]BXU 41T)F 5SS#
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MEW=: =<!.UI=]*!J[ZM)4J"G_0<?'^T=L&AHJWAJYYT'R+<T2'JQNP!\? N
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MOXP:?X"Z!]P\CBA*&:J=:/5V2G/MS_^%$K.QQ!3:#0GW2+O8 +#5HMC&)AJ
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M%'M3'"@G$B>4#"4_<;W1;<H:L5BU6-JL<#N[C&HNG!L1JEE3N13\'EYOQ5V
MF4:9 <L1>O)BCKCIHVMIM11):2A.3Z,/_<FYB+R04]J)%6T?;1O2567-SE.8
M:&:)H=9R0OQ0C?$SJ&UH5 KBTZ53WHG+TT>6=?09%03]M)%S_I34[:60OFS5
MI-#5QDJA.0HVV&IXC:B$TYU'+UB?*P7IB;+ U%A66D6\898H)*?B_&XQ),6/
M6?Z%U$9\*5;G9&RGP23T,&WYX@!*H@Q2:.613QA;3L+8W@(2QEHRFGS"V&(2
MQO:[EC"V[Q/&GJ:ARO.5'FY/,W,+)J4!2G!AP=A",PF@R?X_9!AA L9^1'GK
M&5I63^):<2BX,I[&!1!IR#*!8'YI.%WU3()0,4\H$:4J83Q#0+-:G0LDD)EQ
M#:2UL"YGU$AQF(IK[&"CA.D2BDJAI\211QDR4_+9-F&H_'9A.W^W5,&XRX<I
M'2X%8YLMQM3VDYI;P4E$0F'!+<B>-"][,G6%ZTS #<B'J0Z>3N**Y*]D/TS1
M[TU&)K-AH,2CGJRT:H&">U.WDL:C-"-VA3HKEMK88FFZXGTP\''X1X:^3U?2
M3U:5U!8 QS<]3,->VU)PQ"J_B4GYXIRV.C_?FS$&+WXJ,^9Z,\R8AU=%LFV8
M5)7"&%&I^RHOV7]S527<C0-(.AW>K7!NE#\+FU=-:3T=RVZ7\L+]A%;1R+H+
M2E%G&7&(#S0& CG5%>#==1R;@W#6OW;4EVP.EM9*3@RQ3"H&ITIU9JET9Q92
M73' \;VFXU,^!]Z*3AO%-=U#>ZR/>IZ"WU/-7#ZV0HPH8&H1I.HRT\QF-AIV
ML.*<5JHVUUQ%R!F=+I?*42XL=%.[&4:(C<*ENLO'B((+F(%%1PDSU:5B#1LY
MH7,J E"O\61QE28X$"GV((*-G=]:T;5!C[43/FO+]ZICN]>"X1]RQ^=9*+EK
M/BMRH5F1O68 __[,R,8:<Q.;9BJ?JBM+.8];E_@_0YF+M!7)@MH]1 C(L+\5
MK&_T=8JR%+F/S(A48@>_JE,@>W7R7V9G,PHA&X[9V?.[KUV%+&KSS85<4+B#
MQ@J0V]B$'SC !JYL2XV_OP]J\$ HT*]EO'*A<UAN"X@QSYK1_)US:"R41/)(
MR"0Z(VFQ(M!O2E'GC&9EBOTT5%EAP\\AA\9F<:&XY3#.A]48#4>L#F\53&B0
M'U8JB*;+3Q# F<K57]^/ %;N#CDXEQ>D-6?([A-':"9;EM0!RTFNG#P-S"IV
MA)/K$*( &\N]V?_8JPLU[^Y_PLD:GX]T9))01K)$OVR3AIEU^%S9UX-D"D@#
MB54N3+BS[E*%3L0:@(/G5Z\H%@K<F9& NRJ=R7"Q2JS4;*5-PF+<Q%FBJR*V
M)C<S1@FN2&W,N1B-D%20!-**^O]$ 2H@O996!3IA,C?'(02Y*VE'AV7%I5JH
M;4E><3,YW92L+BL@IV YZ>8 '/>D.E1#U7+D/5$-BZ!3(PNT6Y#)G>#8SB.7
M\D9I6Q;]3[<?,SJEF;W,6"Y4"5%=%J?6!J$U76H8IUTT/K=@G33R6E^M68=L
MU!?F0O=XJT 7S+'M'QX!8+W(;*V.-U9>K>E<LZ9O"X+;K$HBL]E,:-)6'F"X
M1Q5H=VW,CEX4-!>&Y">EJCCB"@L!U5M[*9+LEEF _K&Z1)Z)P1)81SS(-V!!
MF6R!5=-)$@ZQ&-2$*NS 6] B'1'/WBJV#>AE!EP8S2IL(!5=,2S3FGM,Q,FF
MEZ!:14,E,UQ5=JPF'RYFW/G6K-,>"Z,WZ^=!</ZY?S8X#\X&W^ _@Y.+P5'P
MX1_!Q>?C\^!P<'9Q_/'XL'\Q"."BX/S[A[\-#B^"B].@?W(4?.W_(S@]^?*/
MX,/ 6N*+L_[)^<?!V1D\ZO@D.#S]^NW+<?_D<!#\?GSQ.>@'4UW7>_#EX>FW
M?V DZ??/QX>? WC[Z4GP\?@+O!E>"./\=G9\<GC\K?\%+H(Q4=3I;/#U^._X
MZUG_V^#[Q?'A>0_>>+C*K2C9()<'WL@>(N9G-?%"*<U73QW) LUL:T_N-;DO
M!=N1P#1D1P #?2"[C4G, 2LAR)?DTZAK+-79(.>!FTFL[I9<7#N;:<[<G*8,
M03$Y D%K;<HDNZ4N0)'B[.7=5%=1]V+V463K>Z2D !9>UR$AH15)]EG_HN16
MHW=(<[@:W7P9IW:M,UU=KD 5%B\ON$(, > YYA,F]>*$J 84KD"+\;Y5IP[5
M$E;JXW5O:5YOW HFBWCD/'[-PFL&IEYE+H 0+E1;6.=.62T+F:0R=+L,2;3F
MRI%!.C;>8E* <HJXB:U)_ZVML^L&RL@<P 0< @DB]6BL^Z'9=>3"<,(V9#2.
M-R;U3!+>NO$4TNMQESB(+2)%/N3PQ+-3)'?&N:5E,/"XO,Q2OV]P>GQ< 'H0
M1G90!^=BYZCI@]XL?@Z3JL"OK<Q5&H/Y0F9RJI1_$MZ2HY7R6Y6Q:E0EL<'"
MTJDLGY\*]72MO,/\T+DBIDJ;- <T37R&,F[3#(P:=QI-OR@<DRL;SPZ770=U
M3918N8I_@AU%RY;\VC=AG+ )SHJPRH,!13."^:)7@,>B+LB&H%=;Q:>X9#O/
M>AH=03XE=(<4]QAK6/J35D?DLE,!JO]#-'+H*- ^HDV,'B[4?J=X!O%@>DZ=
MJ,+J._+88ZZT2@^$4ZEZ0$=MAUBS%HIK)[(1N! _<''B](\JU8"!YD'TD, V
M2.#^ B"!+9@U#PE<#"3P5=<@@:\\)' =(8&SZI-K[HHOD.Q>"082!M3/K2XZ
M07(/E28QHHH/[+FU!(04!#/: K-<ESR>#)$1MT>1 R!-DIQX)&OP:BW8"MGY
MCV06>F@88J) *E2\^5R69);9*27U"PP).O5'E<=%Q.[ '@^/+5)\7!3%JOC<
ME,8"W[&(G](_&CJU%F(@ZZ0Z@[I60Z,Q58W;D$P7?.5EAJ6SBPK4>Z/ZI?2P
MR2KF8ZKM866$CEPJFQFD8H-A6LN1#DK+]1B7M0)%P5-6GZC(D2Y:8LAE.TCF
M)**Z!'J3AJ2U=QD6<4/)US-ASV]32S*65VL_7 \%79*N04CH9R@1KY,\-IYF
MFS^NO5ME*^#8J2RRX\4%FS1<NGQU;M64"QM>7M.WJA ITW5223<A91.=!;+(
M"(^A%]1]2YO'HX<;-T%#M2PMD'*P92K$VU;==\P;Q\U6Y=RYJRI([*MKFGJS
M:+>JX,4&*LP(MQ&^G%QC6 V#5UCU6T9R&V5U"I$D=L[V=.Q3S)&?7Q?&-18C
M;,R=.)8LO__H96?\BYX\YOY3F%(:\:3DAU0"EZQY<K;S\ZT%:(=!<QT9FLW4
MP'JU2P]FB)JK++96+]-<T&RTH4P71&_*0X'^,,,SP4ZT^(99M!Y$"6>/I9WA
M;&0!Q+X,X@ZH%#2S75LB3-+*?GQ&:IZ]. O+4(%$GB45M5F@:)'ON,YN@1/E
MS5?HT+>UN,W9-ZI(8!R6SBT%$G'[*C@2"1^:0@.W+++6F0^*\&N>P@):HHHT
MQ-O '_68V\CRYG9SA-ISH7W:I.3,R1Y"OLYFKA@(E>8\%P,UGU_SZWM*VS)L
MY9H8GNS7S,X:?"5#0/1Z%;(NM[%B1:_VLY+\O+K"Z"V&\,9@!)42/2=#N;O_
M2YW=&AUVSP"S/ 8YQHR,Q8SM<LA:N)UF)D]4G[;W<$"*LT9(SU9M2+V"=XPG
M6*$<Q9C29EE"X]Z@?^<6&'8%5(<+&X&I:U,DA];1PZ;*L^C27<U#LVTM)YP=
M4 NFU%!X(XI%J>+9ZO?TNYSON1?B2N%]B]O?P^,YKJ!Y=QO::&K"Z\456WHS
MI#*.QEY6T'<53^%<+?.X$5NC>B\S&.-M6"L#-;+2/HIV0>NQ$*4*:TO/ _53
M)WP/>NY!(:=C?Q(64?AO-LF8XQ@0FE2A-@V]4Z%QB6;2^\=>BP60Q5>4K.2R
MM2SI8?@;F32;9+3*.O]W%4G3VIS5H6C&F9/*7@NRRP#*N/G9,.-&JL+=H@I.
M]"@<8KLNJNAQS9H7B5MRK-?=C;C] HW8P&$4M2Q2E#=C+HH)6>EZ-QHT0AJ]
M0N_CM5$.1F2BF2DLNQ;7#G@'ZWRK3"7WQMQ:/#CP)49";C(^P23";#_(5$37
M!7NA@&[/"/9RL(KCO:N]KJV.+_):)6$\[LG,3,PPN%/*( &C\KBH8:D-#FQU
MVW:^1-M%5_AHV88;WRP1<^Z #V[1E_!6&U[D1*/47WCA+1RF6J(S=$]#4K-T
M!)R<G'#T -!2TF$\212L-1NM\DX>GP3]DW\$_<.+X].3X/0L^'9V>C@8'!V?
M? H^#"Y^'PQ."#?T_>1H<'9^_.ED<-1#3!%^=WHR"#[W3^ +^!_;K.F?G_<_
M#7H26@2/Q9><?L3;CL\0 75^?'3</SL>G-=/0P"2>M[9\3F.X/3[!=X%]Y\-
MOO0O\*N+4T95.=!/@_[A9_D2>[QR. 2WHA']A;HP'I^=#7X[/>Q_^/(/^NG[
MR>'IR=$QKD3_"WP'GQ#*=4X_PIB_'L/?]/Y!,/C[X9?OY\>_V9BMOWV'@1\=
M\V+B7;\-3KX/U)@.3[^?T7P./R..ZTRM2'!^@=@P^' $L_P=,6*G9[WZ3>C_
MA_?#Y/@)1Z>#\^#D] (6Z[<:3O:U?W$!"V@.H<=/__YM<'8,:ZC?W_9.N7+'
MB%ZCW\^#H^/SBS-XFKSYH[Q(?WWZT5H ]3#N;4A[ TOVN7\1P(H&AU_ZQU_/
M$<UV-CC_-J#;>6).^CO_C#=] "(;],^.:#V/!C#'K\>PJ_4.P$XA%1\>GIX=
MU?@X(I)O_3,80__;9[J9\6^#0WZZ_HUZ_C'T^O<^/.^<B956%0<%^_"E_P^\
MA7=3'AE[W#;YUW. B^N=.^=V?>ZWX"(9EQ)4L'^"0+S3$WCQ,1(!+/_WK[A*
M1Z<U 5A$=_K;@ \;3._B'SUJYV=NP_%'O!&!?[ \GV <^(;@][-C/%P]7CJU
M.9( K:,DO^L?'<%5YY*8K,D;EP?G QHS/%,><OR^?_$=IO8-#N0Y[.S9X.*4
M&,C4N]6II=,/AW;JY?73^Q]@WCWXXNPWB6FD+8!KOG\[E3M "^+>/"?1#3Y^
MQ*V!!=XZWH;W?#\+/@"]G>!3C_K_@ WZB.?MPP#NLA8 >0:"/\\&G^"4#!"_
MB8>/4: #!'P>?T'.",N !^%P</SM O[[_W\?P-7(K4[A['TB4OW6/X8OMHYA
M ,ALS?>;K^=7>O3 O.B!5PM #[2$MSUZ8#'H@8.NH0<./'I@P] #OQWW@SXB
M^K_S<H+@ G'Q^_'1@*3LR?&GSZP6'0,?5J+GTW=0*V#-B2V?@.YFB0:+@8.N
M!-+E#(0TB ?@\<#D?_\\J$4"".C^X?\Y.?W]R^#H$PJ&8Y:AA_USVML!"Q(4
MG5L?;6U6:AAX]1D-$R7GV7'_"\HET!?^L<HF2XOQ*0MI:^P]!NC0Y1AB3X<*
M>3_BBQ&S*/-P"/!@QSJ5:2G1GU3N@WWW&F:J;JS;1:B$'X1H*J<<A=?J)!F&
M)N@4?*H>PG$[/=SI"6V1.[@>N15FV;;".A(N[/ (PE4B$4.PP]-X"&L4)XV<
M7!O=45^*]X?4.VJ(=G9=2??[SOE.,!(1K>P %3I.MQT%P#U?]A"E0DD,@_I9
M)D09+V9WI''!N7I9(8&3:+P7=AJOX5$%BQVV<>=JI_> ]/;;V]L=3&S"B>T,
ML['T05/:DS%O\H<I/RSLP,XDLM.^. ^_II6B0M]T++AB _J%I#M7HMFE'Z&.
M-@#)1+&1,]!14/9]Z>QO=PY:5:PMO:$LSS]2'>5B>X[<Y99<4Z_,MBFS!PM0
M9ENT+:_,+D:9?=TU9?:U5V8W0IF5Y<Y^O9*>-;GR9PEWS;-23*[RJYSWEK_[
MM<)BC5W+?N+](G=4SVH6W5*GA31,57UL?Q]W$@\[RIK__/.K>\MPF7M!5/"_
M_]^WN^]>O7]403#7V%XW:<R/IMZWO?UG&L^?7-6&YJAR9U!4L^(=T5P@SU8M
M&W?VWRZB%-YRF-#+N3E0?XB5M20\D;3<Z($U]E9DHA]J .^'. .;/1WN_.51
M)V'I1[$K ^#C_X@CQ'=TX13ANF"\Z1E8DKV&!^8*LLJ^\W)W+3C3+ZQI=VE]
MZ0/8VWW]!*2RTB>PNYNU] $T6+.GEN?GUWL[N_LKQ:]_6<%:'W5*6<-J#].,
M/-4KPO;GISAYD)O3A:<&U&^A=JHMGRP7+1B6ML=/QX#>O'X<7^\( _(JP--S
MCL>22G=4@%\45R?A6*R/P.J@DKD^%+8"2J;G\9M] M?<*?"+//X"T^P\D_>>
M!,_D5V5-NWL ECZ =6?RGEH\O^XDOYX;/+!>W'MQB )$**\GJH#QW1?8;&,B
M*MC%0B(+'M>1L"M,9.D#\%S,:YU>C_!:IZ>6U1B Y]=+Y]<>;[!:1\;C#3S>
MX$GW^.D8D,<;=).==)!SK$\T^#%X ^\5\("#U=0R/3.?FM)&G+09:N JG2@/
M(%CZ &:Y!E:)E!;-G!^?0KTG4\X-)K[<W.#&@):?K-SU 3&;[=20_(#NW;3E
M9KT;'_X$OV+5"/.")<K7_9V]1Y3 \ 6%W 6%_MDHW51FT]6I_C5OR:'-7LK!
MB]<+J,W44CS(UV9:3&VF-UVKS?3&UV;RM9DVMS93!U34[E9 ZM9H]EY-G;HG
M&L]BW(X-+Y,/)'7!7[/T 3 5KX5#_Q?=C[]A&ZHRKY*[X"ZK\J*W[)/I@8*=
M/2U+'T#CN'KHES^#3\<9O^5Q6@884\=2W=3-53;#W3I.80)Q5(7)MH_<^)/]
M=#3X3VJ%_?K]OSQ'\%*YJP-8][/;2:F\,F?M5U/\HB@71>'%ZY,?T4T^B@L'
M1G3!A=GUH';'LA':=I*/S"/2"#8V.'_PJ!B(CRC[X/R3!^??+" XWQ(]]L'Y
MQ03GWW8M./_6!^=]<-X'YYLW^W!XYT8C@_//W.3J29P>WL?8!?_!$@8PHR*6
M#]K[H+T_NJLR@+U7/CJP*GNU] 'LO?34XAGV\A$>@[2,RSN/[O BH%O@CN[N
M\=('X$6'%QU>??.,WA/+B@S ,^P.,.Q-*>7I\61+XO,/KMRYNC3FR\5V15SX
M<K'U6CZ90/&E6;MY=+LG&3:Z;&9W]VKI W"S]/6AEN>JX_OT9H/GYE-3VH@#
MVJYRK=(Y]$3Q7(KX*E'%<Q7LG<F=?0:2'Y#DLYT:4>>6J',#8C;HT[]\;5:?
M_K5:2SEX\78!Z5\M^4D^_6LQZ5_ONI;^]<ZG?SU-^M?U[E-QA*EU<J>#.9G$
M7S'[P-K62 RS/"SC#"X#XA8YDA9<>7[X>7#T'9;[^*__@3?]5[,/M2.1K#N+
M,"68]0J0HG+P?DUF<YBEPRK/X6/P,4[#%#/I@C,!7*\047!^'>8PD'GF]FQZ
MU)M?5Z*"1:0J2B'!KYX.B*F0F<Q4;+^ I=STSRN;"OE</1GF&\V[Y5M&YG!4
M\8?[J*-S(^[.@/8/ND5A2^U!XC["UR*,YCJ_QA2Z4<NE=8COG&&OO8>&O;J.
M9'@[KQ2W!,*N0U63PL_(VUC$-LS+OSI.38UI='24S.D\T3\L C&/*KN0W>D,
M <V4#"LXGSF% -'%WD*0NUT_(0N/TWH^_HRC;/#Q!='MBC#WA9-N=_C4)O/=
M-B":Y[LS5]+SW6<<I8OO/IYN/=]=]H8OCN]VE:MN)*"TV[[1+KA#Y^!KJP0Q
M7#1W6CKO67P@I1L,]P&AEE4:\*HK8W/,:16&+-G9*HVX,^-ULB/C0\? CZ]W
MVB$E_SP?7HNH2D1P_"^/>YP;K/=N 6"]%C29!^LM!*SW^F4GP'H'#-8;_??D
M:M>#]38 K$?Z3$T19?_D[Q\=&]]'JF!%_&/'(%XSI,7'T[.O0!2_ K][WJRI
M6>#!8$6'CR?Q^.03',;@M_Z7[X/@[/C3YXOSH/_I;##X"E^OZ+Q6?%L^#"Y^
M'PQ.5G3T*[[XW_KGY_U/@^##\6DO.#XYW%G1>:SX-H1IM*(C7_&%U_5:>T%8
M!&>H>Q1!_PI^7M$)K?A^'(6EB' KLE&@]\;;U7/:U1]?[#[>KFXS_+Q=O1B[
M>K=K=O6>MZLWP*[63&)J!;LE&YX]0VH4I^O1S&WY]2:ZFU#5K=&\>MNIX71K
M<3HVF@-_K%9E-,_& 9WQR\4DM=G5V6J<W]XJ%4IL28U91>1,=P= 0L132O<W
M:OD#./!,945VR@'1Z4"5]L603]>QYW,G=+HC*>C=>08XN.ZA^V;*9-VW)(($
MV+YS;M[NSJL'[MVT[^OP<##X^'')F_;.Z5N>RW]0>Y9&_9._]_N[?_ZO_MG%
M\>&70; ;' T^'I\<7QR?GD@/TZ(.]R^LX[,QGFZ.S5FP>&ZRE@?T%P@[N+V.
M2T%.'8%L^#8/EYV], >U[T_#3]KIW2J(I1:3G_-JAS,&/K[85R6P'G8.?I7!
MS;'Y+]\L@J<M?RO73G?ID$'T4%*YCT]TDQEX"GI"0\F3T.KMX+('\#AYM3$4
MU'GEH-,&S^(3I+NI^7=Y;$^C;7!YB0Z3WF)L[?-=,#[.Q1 +[S(I[^[L>CM[
MK;6?#:'J(S$B,%:6%IZ@UUD7VUC'$9&Y]QPM=2^]T;8:NIRGE/6BE*?5D3RU
MK!>U>&?0D\K[AX;"-\ SM*!0^%X="M\+6O*FO76SSLQE8ZT;I/VYC)O7WKCI
MC@CIK@ZP] %XXV9%-FKY _#&S0IMUK('X(V;]9#WG;9G?*1[^6/SD>['Q 3W
MFI'N/1_I7OK8?*1[ 53]F?KS4:F>P]_.BO=!?S+)XK3$KO7XI55-R5/\&BMK
M&^LLHG/@O45+W4MOU:V&LK=\2EF4[-N;TNCV%BG?-IL U]T)M4 B/,G@,7F8
M%B.18]TK3X2KH2ZMNTZTZ1&T3AN WJ.V_+%YC]JC1-_^E/ZU[_T+ZZRU;0I5
MGV3!(:[ "-:@%.^#,W$5%Z#A(:G;GX)LY)@W_KN0"N'[X/ Z3*\$>N+Z492+
MPN>C>"?<>BJ<^QNN<"Y_+[T3;C7TP^53RJ+$Y:LI)?"5]W^LACJW5D3X+;RC
M@.>W/!N*J (]RY/A:BA,ZZX5O9I3*WJSIEI1IZU&[X9;_MB\&^Y1PN]@2@,[
M\!Z&==;;-H6J3[+@MZR$M>H%1_%-'(DT*H(L#XYQ=40!#X(K!O^NXO(.OF[Q
MPYW>IB(OKN.)OLT?CG76)C?8_78PIZ+Y=DT5S>7OI7>_K89>N'Q*6928?#VE
M_+WV?H_54./6B@C[EW&">EB9!?W+,(VR%),1/"FNAM*T[IK1ZPW7C#IM,7H7
MW/+'MJ$N.$]Z'1C;YOK*//DM?VS>&[5990.7O\0+J@VX7]<&W \N/JMR@$$?
M*P1ZPVLU^$,WF<#":OC-"PCU=M<2=MEK'\L?F[>[UGI[.STV;W>M_19W>&S>
M[EK[BH8KN:K=M426/@ ?C[\WTK3?K#*XO]@J@YM-@#X>/S<18OYR&*?!457&
M,(0PC8(S44RRM(@I4A_[_)A5T66ZJ; L+#B_/V_I/N\D6L(V>U-I^6/;4"?1
MHJ1ALTS@_F++!':5:CH]MLWU/2V0JI6.)PL\^U+/G1J;=W ]D;XX;UG#=VNJ
M+RY_+[U;;374N^53RJ*D7;/4X/YB2PUN-@%ZM]K<1'@F"KB$2_^Q3VV<W83)
M5,^-\VHX%$61Y9Y*5T.?6G>E:382Z^7._K[4FG9WUU1MZK15Z-ULRQ^;=[,]
M2CHV"P'N+[808%>IIM-C\VZV!5!U'U2Y21FF0Z[A;"AZEW=/H^AUEIXZ/#;O
M;GLBS7%V^<)-T!R7OYO>X;8:BIZGE/6BE'7WC'EJ61T5I)MZQMKG"V^ E=-_
M5:<2OPH.3W\;G/1/+LX#;]*L,S_96),&R1VLE8>"P+R9XM6)9QV -U-69*.6
M/P!OIJS09BU[ -Y,60]YWVG+Q >TES\V']!^3.CO53.5]]5B4WF[2C6='IL/
M:"^ JK_$!8$4/V=))'+?CMB[>;JDJBTL<HVD[OT\JZ#<+9TUK*F:MGQ*6934
M:N;POEIL#N]F$^"ZNX\62(2#T2C+2U\Z9464GW77</;64\/IM"'F/5O+'YOW
M;#U*D#6S:5\M-INVJU33Z;%YS]8"J/I;GEW'ER#SHZ!/].V=6]ZYM9ZJW_YZ
MJG[+WR+OW%H-36WYE+(HP=7,G'VUV,S9S29 []R:FPC[5127LH;<CJ? U5"!
MUEW/8;#V0^W3SNLYG;;(O(MK^6/;4!>7)[T.C&US?5&>_)8_-N\RVJP,V^4O
M\8+2: _J--J#H/]U<'($_[_@/-JE<XTU9@W=//\+2WL]($OJH:XE;TEY?6*U
MQ^8MJ;7>WDZ/S5M2:[_%'1Z;MZ36/@EX)5>UNP;&T@?@X^7WAH0.FHFY![['
M[JJH+&M%A/VQ2",L!%T$O\?E=5:5P6&6%K(%B,RN#;+\R=JR;3:E>F?0(^+J
M![O>&_3LN^=MHN6/;4.]08L2>\U$W /?3'?I8]M<)],"J=I0YFY!F7-H<I[.
MUUG?6SEOUN)4P;WU5 67OT7>-;8:FMOR*651@JR9V7O@^^2NBJ*U5D0X&(V
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M>]9^BSL\-N_M\6'U3FFK\X;5W]1A]3?!U^/SP\&7+_V3P>EW7ZMQ5;A#-UG
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M1.0YG;X@O,QN<%%+5$K'55D!R=S!XVY$&I(((DV #FL/)IK+UV? T/!A(.Y
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M"V@\H-F@UBD_H2J<PYF#;>GI#\@R[GIX)8T,OA^/LU3]S&.@#33?MA-\A!M
M:YYDJ*\1+<32FB$VU5.6I7R.FADIW<2GVB?'TV>5++N%=\*O/ =F*6$*&K/V
M54PR8)$Q#P+':2V$6BWW@I -0+,JK_.LNF(+#VWFO+B.)_C$FXP.6"&&51Z3
M88+S!AM%7R-]&<9M,?E6"K0Q+N6B@XYJ>3UZ6L5E?FDO%FZ06C"\KO&KB-2/
MQ&:!M'*1A%C@0;/;CAVC:6?]]#&2.)V'N[E"8$!3CAQ)0^K'X-MUF(_#X#Q+
M*I*BO>#+E\..K=(3,QN]%N<E_'Z%'B6@4>>RX5F,LF&E_'55^2(;O9ADPQ_
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M"3JVD4][8FPWU%,)P68(B 3AFXXM]!.?&)-,V]?9(?#<0LY:Z?L$WMP2KIK
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MK.KZ@RA"1&]/"J2>K<1:&F?/UD5)$ O4ZB(L#HL!\;@!"MWFZ@79:,2N;VH
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MO)%>6B.$$W&%3;J5C*:F]3W)VZ=^H$*F58X93[FN8S<U$CQK)=&>/A)F2J<
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MA<8:]Z"#H]*J,F9E-5M'(AYFK#DK\*I[9#7=[3IG)V]Q$6*^ [7^;&R6D>:
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M.3@\?(?OVC\^.L'__?+;*<[XRW%T?/AQ__3P'3WBKT?P\ _'AX>?0"7A'W%
MI\?[GT_V#TZ/OGP^877UZ2M_A4>X%>$:="P 3O[O>NH'A[ 2[X]H!C#Z@__\
M_.6/CX?O/L O3O^Z?QH-CH;1YR\PHJ_'AR<P@OU3F&X,(Y+1[)^>?CG^?/AW
M'#G.[@L,[UB_8O_$?O'P71P=_C_\X016#;Y)G_SCZ.0PYC>=_(:[YGS]CR^_
M?7P'+S^-<>EPVH>_TUO?1Q^/3H\^[./TP0HX//Q/7*G#S^^_'!\<X@<[)@Y_
M/_SP!9>:SU<,LX/IT7'Q%N6WS[C=I[ BO"PX$5CEDR/X-6X+#.4(%OSH@(:
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MT59:G(VXXLT9NU<V$FUS>LBM8ONY1:;)=WPJK5AZZ+S]V.;IPYX;J.O^=)3
M-(UHS2KG-(ML,W1DBT"L6"/%4\G#$RR<\S[!:[I&M#@VR><( 5;!A $:U@FS
MDDF>!D;6JM>YB@CH.IQ^K%\]HO]CYCMK21P6N,'I^XQ#. M"'/-,$D)>T?9A
M.P=F8I)B-0$)ZWH#81O1<&6O*P4AB<N:@0G$\5&#)N)>22L;8GG!CJ_,_73S
M)5Q/2E][6=VO#D8=QX.*NAB+G.K\B"R0V ++AM;"EXC.PMX7YXH603=1Q7U
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MJ2/6.!Y2>FD]].#L V!%O[$3FN'!W;MRS41;/)HE"Y=#6*Q%<):V(ER7@2,
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MOT8;6:_2K-)=,;4F<C\9++5H,.-7K:E5#@ET'$P%8^M*@314P]!*= CFN7S
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MT>\G-(Q?3S_][@YL_5M:JR4%=9Z$IV/8>QH]#FP[GL;GI5BB:-^3#:_=CCC
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MRT:Z3#+XP6""G0U3YY7M-UYE">AR^$Y#-STX_9Q6$ZX5J"M,_6)D@:PB;*(
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M8@;M]["4['XL;$T8#L? 0CZ"(M/!AY_9U0-2$&@]L<#3AYA#$OO"\T8/,O.
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MM$";!<+;N3'U8(I;X"R_(JNC\U4R71VU',.<''WRDR"H<:/@](5#P]-TILH
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MBUH_WT6GH6\]V67J'1?H(Y33GTY(;_U"32*Q5QQ([2XO@LB!Q190;K;573*
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M"T,N1F##Z4H[P;P'L9-V"Z.R9/7>]J"@AP$%O=D"**@#M=*#@K8""MI_]MA
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MOF7LI((QETD^^Z1=;NU!_Q59C\.MQ?%>Z[;F0,JDR6]-CM0KX63J(U4QGHS
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M5K<0AJI0LY8/9D8,5:']/+K],R.>3LW>("P/;D8\'6'YEA+B;\M[]66#'WT
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MM5GGZ,U!"^F/;9D6^CAHH0?30@,*_5%0Z*\V@$+O@$D/*/3-H-#?]@V%_FI
MH3\,#>[WRS1V8]?#%X%E(Z;+ZN55QAB-O.MDG!1CTON%\2W=-+AM48+YU>0+
MS4.Q2DP*_XQ14,S:Q"HZ97 C9%.*XPP#*M(;L"P)$ !#U5.ZRN:METLHZJX
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MX4<H?SR^2FIQODW)6C)& )7"LY-V1JN#Y</9AIHUTVWH,NH2?I/90H%PCD)
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M2BPVF04UIKHLRTDT3=#Z4?D0##-5.E>I0N7=R>\[0 9#+<8CQ:?>;B ^U1%
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MNC5EFAS0L%(XYCC(D3*X'BK9BSD(K3111[7ZA'A&)#=(8"1ZCT$=^)!'"X/
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M#@!1DC9S[*Y519>,M<^N)$I6W>;Z!&N7EV1Q4_+*F_"IV40?TN!LHO*V$1U
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MK=)7 1J6UB\_G?+EWT[.CXX_?3H\/?[\^U/O_[/_XF&*E$_+0/,?U=OXV-1
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M*PVFR$#]SC_Y-Q RM]@MI3E'I3K3J<-D^F.RW@D,4J' M"$ZE:[06 E^!5/
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MOR3*PEX][B;Q\:LV38U$S8_!I88GIQC_KTUW  K6XW=,].*JS";ILW+Z#'Z
MCDP!IR#7#9%5K$><70,JMRL\30B,AM+HTO=VPK,UP&])\+X(1<@1K.,S-$9"
M\75EAVOY.S0BYR5*50.O842Y6*-?4A6=4B6Y[7@\1GDXPR3.@_!BJ_!ES9!_
M^M=<DKNJT9%5::0B>-;W0!U:W0KL3A^Y9@6FWPY"2M9G@S9IM8E:-=7?60>0
M ETWW(5J_513F"PMS;<>8XHB#>'K,#I;J+Y#>\^/G^VI(SU2_34.)XV^X[BW
M!JV/+M?SYHY$TXM<&J9@B(]6C=@,'-09QQ1;<RJ2OR@28O?B^98.[!=A*KG
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M/#^*D:=SU,[<W>ZMZW0W/[8/R][NZSZN9@JX^6XZ'/PCAL^%_73"?U/9G!!
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MCB&!+A5G#N'@FS8G0P3L@4RK!"DN%)8$D#' C7Z>\5WME.9++\/!&Z2-J&F
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ME9GU6#O_2-%*8GZ.0-P(J43ZC@S<-O+:+)8(0C9P-,&VI*3>_6>TGZ-3<+3
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M]M8N3M(\QS5\+::Z-,(S#IT*)KKL:RY@<E9IC(47JJ9.B)RG;3C<T#2^45A
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M\(!M";DJ_*IZ!^3OEM"#9H^;ND27Q4L6RO6!_RT7#9=W&:2_$T<QFE\G?"S
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M%9H==-$Z"YS796"5LV5WC8G&D;4ED4"/VR3N+ KOH%O@:XO#52G6GYL LL.
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MF(52;YH8":HQ$M&>@S=>Z<[$L3'5HNGQR^##D/6$G55!6]BDK+C R6I;01'
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MEM4GY"T,U^";G8@GJOF?L,X-,3,[R1<UE:#AB+@ #T:1@ :70?CTFGI<;OM
M8;"[C;CW#'Y/.N(X\S=8_:YI297,/6O;MHG1=4^,[N\3?A(AH)A'_^MW+]8G
M$?CT=]GZCD;V[:F3I!YP,(V3Y9)HB9EOI-.$6N[T_N[W7Y,[;1"_??B#70#/
MC?#*GGP 6XD+9.X/L?'*R0=$UO[AT:"#MIN^O_MR,X*]#PBQK>_)>?(!A.*&
MCQ>5M3C/7ZVT?#$=T!5IW]_=._BJ=, #=?+;V\V) RN?1^UA41)/R)JIDL=+
MG*@2?[KPU*@N\RPQ!75/+Y9]*YOUV^/U')5G?VXE;Y75_(*W3!AB^:W<,J?Q
M+/WQ/C;_]J+IXZ)YK-!M^''_RO;XR44_?*?T)&1K($(/38';*1C4=/]>B^B&
MVIE-OUNHT]SF.#%K>XU\32?Y:PQQK.\ ENG]#9>*I=JY=PS2P=.G =<=\;-F
MIME2,-EC[.;MTGXM$OG$R7+K'VT,VI;CK9/C[8<>.-XZ2,BV'&_]<+S]L&X<
M;_O/MQQOWP#'&^'H4"16;U\IS245!<UZ$Z&]N@\1VN'/9Z/1KR,#V5@ZJ:\%
MX'Q_%K2.KLYM4C*G%"+0&8P:RN';G!?XO7NMSH&KH6&?3IQ>+Q$G0OR %CK9
M&%[$GT>GH[/#=QMU&O9V[]^$YJ1&GGC&Q+=*OX--X9$*VCD[&3PB;?&!*7YI
M!]GN]$T1,#J1NC&?=(O:OX6:YT8R1%Z/)-EQQ-3]$PQ6$"]\RCT2]#]KTV1=
MT?\'1SG&QJN72")7\5D.%4X4\4SS;?O4X5U/Y8:S!0AG^?LS&$5%'1MFU-<D
M-/RLY@65EK3VGTSK'6HX0T1XS)BO7H*="JHDYA8(S56[(<[0[]&$[0'!O ([
MB)2HUY'>K/D8^<2Y/2W/$_[LS#]/+U.LA-"MO*E2Q&UU(ZU<VDO%G0>#"T4C
M9FFP_D)CPEJ(";?+D@81X2=[]'9Z!KHB8GT;\CQ>)3RH(8_0WPD!^X4J]K%(
M+EDG=! -=J]]D%K0._;!;O=<<\(<?7A$;(H^Z;+K4/*YW:.%JA]_5=1XR(O)
MK=.US*I7LE\_](N=Y)NJGU53E?FZW^LM8&/[5M^<:_T3V+TGIS\/HY_>G_TT
M.KGX>#:*#D^/H]'YT=G[WS;J:.\_X+:7XO&.,ZS.K2A\Z@8#ET#'Z7XT/><G
M>G28DU1N,KJR67-<2]U[+77O01-!=314#62FV Y8M%C,;[*[X)C&AJKW360/
MRK01FDP6LT4>^RMAW8ZAGU.?:VKD',-_2ABS\V=JEFV>O*MV<Z-D]/[7ST]E
M-4TS+$\U+> \71ZPS9Q]Z6BUXW;+'+:[DV>S69IDL!DY]ZO$N-,L;L23G/+
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M-; 9BJ_-RSI3-KT/I_!P(PI?V;$*NB^+1FR$(!I!=)M"@10+A(;!G*[++ D
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M"@7D2_B=!-J"PL'U^SK97;NCYZ?Y,*Q=3%BO%$A?1D%D V==9$I@S""?BOY
M^FHG2^>!7<QA"9"SH*'%(/8"O_1V>,=\T:S LX\ZN2DW3;9?W3_3"A>\B@!;
MZH05)7[,#/)[KZ(/9!QJL7?V%]0?ZBUJ\:ZJ]SA6KEN].ZQ0K>KL5FF B[KW
MQR+/&GV>7,4%F%V'$R&@"NOE85?$K9/1QXG[81XG80HN$+C<K)BS!L[!H-^8
MY4P_8Q8(T=;50L.L5IB47Q%)FERIBC-XE/KQ^-G!(-*D*CI1,Y43*4-1)@)E
M*]PQ@1I;Z6H)GV2O/F/56X<1I5W+M&F'\_7]F3^*!K;1++=SY72;(,M4KR=0
MJ?#XLCH<L#&9-0LI)$AY (:6QM.B>([J!;J-::)XIK)*?M8PAI'SDQ;02_2R
M>F8+$=QFCVF7'*CC.<,$:T7#+Z>;)C#?WS\+HC?J/!5,9Y@:2O%^M4MB;%WM
M$?GZLJ3+JW*^BLD]N8:)"".G>9[6JFI4T;0J9T.MA^4):**;A]"_IJ$G23Y:
M/!^VJ[F^!D6:<Y>E'(X*?7TD*C8/J4.XON5SW331^N$1A@*:@Z'P%-=CM1TJ
M_(U+@VMA,? V /6!,$A5%%593%*2<+^*J=)<'&GE6*,>= 1R@C@ !%"0-\VT
MDQP*LC&6 J=%'=92/9SV)\H#+'RZU1!?"R]BQ Z^3J\D;0HF,BRPBXJE*1:>
MW\\<&[BRMR*6EU4\&[+9D(B?D.;3(?/>T;# N*AW.XK*:+9^5=DE&,\5S'M1
MU.CPIHHDHJS\.;=@PS)[_KY4,(HMKM?$@ I"VOFK (_?.R?]_"&I3-B*(Q%#
M7/C1;)Z7M\Y=#E^Z$CRSKY,ZKOBV)E:GB!PIES+NUN!<\#R AZ4)(5,:#)$8
M">]?N#;'PG*KPXG!7$&<4XD/F]&U,GUO8E\B_0L>9<G&2 MCK0M\D@)/HCRN
M4HS;<OR2@IH4'N.02)+58#-7E[PTDHEG"T9F5GOT?I'07A)>RF4[A('$35WB
M3374,U3,$50UK,G_W&B,&9R._!F $P6$NVG^NHK*B,;"6G_/-MJX,W9_X,<1
M:JNT0FWNAF2<(\/\88K\*_&OH[+@D$M9H7HW#[1+;<<LUE*-0!4[55EDDXBS
M' MD*+&\1M>!&C(O$/R824_\"!VZQ!FL6YQK6D7]W::\3.E&45S*RD+'43/^
MBTV48TX!R!CU9.T9T9]<MU6-/L*\G4[KV%3H)A$P5%BTW7DR51 T].9B< WK
M":8X$WJ.54QLK12VC,#D0\R3=SCN$WOP"+?D!$YP$JU!KG8._K!>GM\OJ6KX
MGTC]WQ9FL3+,8K\'F$4'#F +L^@'9K&_=C"+@RW,XAOH76755OUZ\@\LT3@[
M_##Z>'%R=#Z,3DZ/-@;RVSF__>?[KZ+1WS]BX1A\ ,*#Y64?WAV>KO=4]WZX
M3UNNCZ<G%]'/9X>G%]'I>YC]:*-,W_NWY^K$+E.?' 2/N!;PHVG5[:?YQ)?M
MIF 6F">=*8?S+)UEG]$XK^)YNH 'P>J>%!,EPO]=8,@//L#X\;5$3Y!/6*<2
MBN0OXFY210P&$=M$[OA2^(P=Y\?,V&KBHF=*S9\Z9O'H)1:OSWOG9CEY/MT#
M-;4RB.NYY:/G&14K$8OTXUA<+9?9WU _#:B/#[HD]:3*QA9FO]\3=7;^T2?F
M':[4!B@0OK;:\G3,QTY_-DV,S4'0[VJ/W!NEM'KD3*/J]_CXR?M)+;,":-(:
M[Y?Q,U8/HZQ0[I^S&V,WEV'Z&ZV79W@W;%2(8T*'GIH=PQV9Y]AX'?3L7[][
M_AW]6UK5\[_MF36?8:_'JQA^;'[+1Q7O%7\FWH>\$X;L-W]V_M%?LWA2-:K!
M^(L7OF'J;*<C?5^H#[8]GJ?ORKV^HSD@I_/)&H0K ;Q[\(YL17*&C$^_>]#J
M",8NXC5"A<$J4Y_"T5XRW3^8%^ .WV(EY6/=ES\^2CR>7#[790!\)AXA8_R+
M=1 S7!>T!9[ZG+(3N?M\;WMXG</+9M$Q&$O;L_LESFY/<K<]T-L#O=J!/N6B
M+0P]@,>X/=3;0[T]U$^TJOT=:FDPB[&P&<8I*#"SO;2WY_MK/M_?\#D^EV[+
MV^/[Q8_OUW1,'RA5_[J@DGA) '(& HOEKK,$T<Q$<FN54/R[+RWP^*#MON3H
MURANZPWIZ8.EZSZ@)P[@6O_X$_P5DQYKPOOQR-SGV]M@X82!8%*JTVL6C(>\
M#K1!&B-B2Y%%N,Q.?NUCZJ8'.YH^./TJ[&)*/]76>DZ[\HMK%ZYBAK;.D<!^
M44@%?CDF:C2J2TP4[!SAG76:&S9+!G[J-LHT &?^UF"F"P1($"J82E!K*3SS
MZGU6GY"W, P^-SO!+9XQ>RH5S$/,SD[R14U@5AP10WEA% EH\%HU%W;9&_2X
MW"[Q4@U]&S&-/S.=4I\!9_Z&UJMK6E+\N;8HV6TN]&'YM7VBNOP.@9R8.O_K
M=R_6)_?W]'?9^HYF_T4+7/F%QG,/&^\JC9/EDFB)F7=T6!!;[O3^[O=?DSMM
M<+M]^(-=,,V-\,J>? !\A+82YR3K#Y'>^.0#0F/_\&C0@:,!:.3[NR\W(]C[
M@!#;^IZ<)Q_ 'MM9/8O*6ISGK;1\:46_E98OJ+"[TB+[NWL'7Y7"?N %^O9V
M<X+VRD%5>UB45"6]9GK_\1(G)]F?+CP5NXMDB:EA?'JQ[/MF6+\]7L]1A>Z0
MK>3=L9I?\)9YW1$M^#9NF=-X9GK'/4JNMQ=-<%3AB^:Q0K?AQ_TKV^,G%_WP
MG=*3D*V!"#T4KV#GRU#3_7LM0E%J9S;];B'6^<UQ8M;V&OF:3O(V'O5'Z?T-
MEXJEVKEWP-C!T^=LUQV>M6:F61?RC_7H(^SF[=)^+1+YQ,@&ZQ]MP."65J^3
M5N^@!UJ]#MZW+:U>/[1Z!VM'J_=B2ZOW#=#J$>@116+U9A722D)1!&T:]]SA
MSV>CT:\C [)9.K.O!9)^?^(Y@R=V[N V!9Q3O!(@,2<.>7R;\P*_<X_5+&#-
M&]#O/U\B4X?2@OYD8_@H?QZ=CLX.WZW5:7B]NZPO:_=YD##:WD,:SU,IEM3F
M$_;_&*NT4O@?2&AX'>=V3_IU6JRVZMB_G^[8B0>R7)VD?DA&A^OB-KAU%(?#
M BX%$?3[*$$2?Z_?7/I%6"VQ[KK%NCA"QG88O6DQ5YNF!C@C:2Y+/.S4/HR4
MFG2(+.>-U4E'%@<[WDB##2IZB>LKMU$>S%':A\#?0/O!DBQIN-?5$40U4U$D
M@@G6EF3CA1H1-77@?F<E=NR]5;V=\ \X*)#P)LNYL@@[).R IL:&" .SH_2B
M:^J(N^X$E?<5ZW%0K+D(B"33EV>W"XJSH5C))'($NQG2#=1^ AR1K, &#[3Z
MB7P+VZUD"7=*&V-E$UKM.;?5N@+YQ98?L&OEHM&=]W0;.^PB2JU_03O102*'
MR#I!Q_0A#$677)&HJ,895ELV/ ,9"6*38\<-&/ TI=8PBN2?6ERDG^<9O-OM
M#$B'*#1KK!2C5KFV"%N'BAIKF*_#?Q:I$E'J&[=TR;""2O72I"5QVW3244$6
MV7&>U;A0=8KB"5,/#75<EK__GJ;4,#F>4".":"=^E-H)O>:0'^T3E*)XI%VK
M2,2@U*B'%FS)8Z,=U<-$=5<:J$Y(UE:K9=1*@>2!I(F^J567W@9:?5SS==<"
M]U,">[O[]S8%3C1-J>C9"U65:3$)LR"RL5"Y%9VK4+\N:[^JRABY'I#I4[/:
M94^5%EKC6XLAU6T-)YN+ORIJ9. M)K=VGQJ[EM1MX>D5HLHW5=>2IBKS39.1
M^[<+_ZC[<7VHRAFHS8!86#:DJTN-/<FKBDV,X#\-+8)6XZRG22*TY8)VAVD%
MIKL+F:9HJM<9-1-C7FVC+W6ELNHJIAJ2K;7KLIH_MCD.V:?1^<7)Z<]OHI_>
MG_TT.KGX>#:*#D^/H_/1Q<6[S8M<[#_ 61.R%E@B-F'@-+3/'QTMM&SILD<K
MX](WZ?!L7 OQ2RW$+T'_1#4*DW:;<++BB;'"R;*BO]V4B]QN%S96MK7N% 5C
M6<P6>:PZ\IE1TI&]N4JIPQB8A6RP4>] \YNVD@\Q$5Q([S09X;FTA9,&:<XJ
M<+.T(2F@12&#->N7S69@E<";<VY:AE'H6=Q(2 F[*,8%%FO+;+1)J7NKQ;6U
M'$G*7=U237C@ELR7E>FY1IW65&?Q[HYK;I>\Q&V&'G+AG=E[;727V5WC.,>I
M#NP=JW %K#GC7FDC;,@, +:,P0^F6F+5[8J[['=?E(YA'::@->H[K,4!/!3E
M9D4=_P<WUGIH?&?_ 4;=N;Y-M:98IQ7I,8BS-(#5)?$=!DJ'](]3=L_@C)KX
M WD0$C7Q#0Z)HF 8I.3_QN;@@YM(S191I;+[8GQ<?7*F 6]V&(W)#\) ">M#
MZOQ';6;K['-S&^V\>CX W^>VMAX)/]3C4H]']\AU>$'QXZ'4#CG^$LYN>ED2
M3XC=!Q.;$B9PS&YI197'I7@]'-.>+@G[MZQ^84*W1CG6<HU<9R6>W58/=Q/4
M26,0;]1$VMU?_ER*ZU/S;M,!_%8W@'?FCP%]ZI(IW=UE-+B+.ZB:Z4I%D6#=
M=8$O7( 7?Y9>+N1[YRG=D=+;?O?%\Q\.G^WOC <[KP<[6388#(VR[QCZ.(7I
M7<O >8EUXVB0ND6N*&O@GIJ7=:8N/+A[\+IIXL]I+1OA# :'LFGG7T>[3K1)
MDM7ZF%*(TO/]M<M/6^A9!4XC8+ZB,-;R7Z0MPX]^BK,J^C6N?@=']I,.ZJCX
M:2%!J%O'@)AC4$B?)CLT 6;-M".L9DV"=0U/H]!DNJ*!]$3\P8<>ZD[&F?I_
M%V#RD1],27\0SJ2\42V0HB+%ES5BH-&KA^HLK6 ]2&!&FS]]K^*V%^7*H)D7
M/8!F.E =6]!,/Z"9%VL'FGFY!<U\ Z"90'1I<\)+%X?_.+PX>7]*,27X1_3;
MR<4OO[Q_=WQR^O.:FT3WLX@.'A!8.E.!5OJ;]A3M((.=12X[&[Z3H=_)RDAF
M2BAP0Y9&_)D(%>NR8L,7/\ @/M@K&.<W_)",65!1#W"EBIK#4C4%ZM/9G.-,
M8FP$N!*[L] 9#C>_I<@8F#I@=X YPJZ &AL^ BUQICET4R#8V)$H;2-J]&BO
M:NTETR..2N&GV*T/5%"Q:DQZ'2@.[XQ6'#P@6G$!6_X;" EFAV$+-CUDX>-.
M##P#98R#!^SLH[SY9\ZD/X9T),$$:H*G:QIG.0;>X$OB>5+.)3=.>\"SU0DP
M2:C=F&WAH\J<GN1DE6 H<%Q8_Y2B,2#AP6!,7 ?'F>;R%,P"P<3J*6,%Y* @
M"ZO!I#A+X0^.\H/,/RK^@O&RB;U5A6]TB#:KZP6%&@PO*:F939,][2X[ >0)
MNB=YFEQ2S,%3X: 2%SD(#+EASK+G&8>M8'O1^<2$*_Z;XNV8V*,X1'G#4>U.
M*5&*/"0JX(VFE[ ->5K72A(E!1%0I>>+<9V!OUB!XH]_5S@2RR^F*PKDPY87
M<XQD[BC9:<>(G>DOD_%=V&)&0MGC+-H#G=% 633MZP(?3++8<."*UT&),QUV
M&_;DSZICP8EYG2)Y5FS>0E#91]?>D\Y$KGP/ 3YT3S=P<O/4Q"=<X(K::CW_
M#.:>E!QU*V>SC#4?1@'X'!:EG>5%O=!4BPFE$>[4,H3&21;,))SF&:6&TJ#F
MP=5#8<[RK+E=\[PPNZ'+[?9/&V.VOT<JTNC#V?M/)^=@O9^ON3J^GS9^\1#
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MO\NLJ <'MO^[99I;'?IYT /TLP.;N(5^]@/]_&'=H)\OMM#/C89^KG()])$
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M#./V@_7J6-&.C:Y$-BS!4=.N@IWRXK+1^;D6'E[ O/8:^PQPFG@=B=*?U<2
MP+21;S9IU<;=J^8IU9UZ8),6+X'/KM<"]<AA3?7,\>=LMI@M]]2-U^-1@8;K
M(9?<%R*K&C"MJ%<)!FMQQIJ676'[0]]D^R^'L,)JT#NHW.4-FBBJ.S;@7RC6
M<RW'G40)D[V<#/#IJ@U%BO.FE[LOX3EY>3/8-/E)E/P$6M>&2>51E,3:<Y>/
MK!W"%J#YXYU0#B$I 5T2DV;U%Y#5Y?(9*AL;;J&+*T,77_0 7>S UFVAB[U
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MR\^D.;/KC+%I%0JEO *N&85W7.IPYR3,1C6C?@JCD)^+0NZDM?-Z;^A!M$%
MQ^:*G=+R3OHI'/*'#;D*,DENA)!C<!33\'9JG1I7/%!0G/I92-B/]V_BU93
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M=8E<]ZZ T):V"Z%65*E:T6;^T=_^<V3==!@-XZN!-;OAD'@N.\ZQ!E/TZ[<
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M#L&SBA6_SMZ;I<N*$06(D^]#/%41*@"L_**?BC&V:-6].[%-A_R,J*/7'^H
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MR4+S3<]?6SU26SVR@K9V=>4-;?7(:JI'>FM6/=(VM6MD]<A)W943WMY"<S?
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M]9)3YQHC9B'GX5T!BQG:Q6]R\9',W,+Z,QBJK=DC$-'%*NE1Y/!]R>@'ZR
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MKDBQG^P=GBC%?K"W+Q6[CKITNW]KK?)-4<V;*\\?TV1'H7/?BOI?5'(LR0G
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MAUF1<$,,TGSG#=)2F[M=,U31H5)%AZUAM3%*97-%T= <[Z-D& ;GN\&;,$K
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M[\UY![.5V&\BL2])9&\09S="P85>9Y)?K!5>SQ9N@/#^[07)[F4R1):HG(M
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MO^/SO,^RV]8%;5W09Y?+U@5M7=#6!6U=4#Y.YWIJ?=!FG<;6L6A]T%94GF$
MK0_JKE+K@SZ;#_J691F+X^!SFA5+M0-N7=!E!M.ZH*T+^MR#:5W0U@7=L'VP
M;Z<6C=O$(]DZ%ZT?VHK*,PR@]4/=56K]T.?S0],X3(+K-!F.H]8+76,O=&-4
M0.MMKJFL+>QM-DW4UMVK;-IZFW>*H!?:),-MYH;;B]U/'_AA&RS4E%P>O-[N
M\2$LG248SZ.Q:H;T_)WHUWU =&VOU9#6;HW6;D!X_SV; C%^^ O_:]B/F?Z
M>/A?O#]55'P_3@=?=D99%,?N'7]P=.+JZ6[/^ U<+Z2ZC86HOJ%,OB3I??(]
MKI'3W8/CVIOD\G+GV&XG4;]2UK__S\[.13(,/H>W+#@Z/MK9^?M?S$_\1?SS
MYU?]=/@(_QT7D_CO_Q]02P,$%     @ Q:KU7!,7X1\440( L-P" !@   !N
M>3(P,#<W.3$U>#%?=&%B;&4P,2YJ<&?LNG=4TU_3+QIZ%^E*5[H(*-)!(B)=
M0$!ZB0A(B8!2(R515'I1%% 0(EUJ% AH*)&N(-*)!"4D*$A/E/*5A'#B[SGO
M^[SO6F>M>\\]]_YWA[7Y3B:S=V9F[SWSF94<?CE< !VU-K<R!S$Q,8'>,_Y
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M!J=<?PX"M3T$@8[A_RUCT)5_/?Z%U_XA)M#_FIC_/8]%E#'.,405_Y:%EX%
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M$$C\R5$Y_+!E8E<:!7I16G&FY1N+XR'H(:+1P\-G%LC?LYW:.H%IFI2S-9_
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MB448&L'4LA>G72\J'O^QIK58]%6SV1L:_D#]H)BQ7[F$8W0>1+<Z-@3Y!>I
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MH?'0^,WQ9"7^G+J=EF)8O)<:])5=N6.#>8.2V03N:V2UBBYWR"G[:(WF^]0
M1+<Y&(K\,ME#:(I=7Z/(D!#K*\1PO,3BCT-0FK:,9$+<9(+ 8G$\$=>#NC]S
M8W[X(D6A^K[Z8L>T=H[PH%8;),CFK48+KLCR%-YO\,[RW"T($V*A%2Q@Q+7
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MIZMJYW^]\-KR1ZJG_!ZGPF'+=.X BNFN_T$F_1S\"Z:M.Q&ZL#RH@=<EHOK
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MIC2^]I8V(]0 /;VSGO UB&C%E-?>!6/3]U)>EFI2X3KS;P\7?W]JH7HSXM<
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M5C)\KSXER$7NZT&N50A]6*:U\'8AY'B)#$$HT<)3[.:=;>>Y$!YDRMG&K^Q
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MC(C5?ZME(G<?<:,SE2_]/Z^7WUH _P/8_QK6?\/MPEHV,")J_DX H\2?]RX
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M"D#D!.Z-I2G$DF@"?-%WW)ULLG2%%_'[J<,OE83X34?U<4/9F+.3PI94^N%
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M#D+$>]'$FOCO7[_V&#CY\#*>]QG@MG[Y^C77M6[/[-!JHR%*';@'UP K>;;
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MXWW*3856M \NV1P9%F(05H._;PL/U6H.2]D56B./B,!XT.&A\JN_LOWB)FA
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M!["2:G5"1@O4=_-;8DT?61ZM+O;H?1ZJ6DT5.A2N%&3 IP;2H\$76[[SY2?
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M1N][61:2XA7VM=M%G&DI)FP$IFL,OT>,2RMJL,2)65\TS^^T,=FV*?P[O)O
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M-B?&BR-7WZVCL]2#P$76$6WLA^&/LU5*<6#%2[3O8[2%+\)1\>7LB !$,!2
MR$*W)X7X N/J]+*%5/GB(@'0Z12 %M7Q@#?IFYT =#(;QO3.$8!F[?T0+$4
MSK_KN7R >7]6 'I)1$SB$@2@<$^ ) "=0JV8$X">)$\V\=/)\!EG%FOXDP $
MC1*  O#\?7AUU.(<BO,-Q[+@!0I -7F4J[2EW<8"4& >0@"*6?[+9#ML'67N
M3*QPW+2E"$"[6P6@33-! M"8"$P JK*&0);"Y_DD&".9+XRSU>Y= &Q$64<8
M138DEM/-Q?AZXIK3<#3'Y6\<FI+X 5OY'##7 G=9 &).HKZ0^&%FN(%)(24.
ME<'H7;0"%&]SNG#9+J( ],$+5^M/ARVM:!:^UU*LB?^B$I?7#&3!(G!SEDPP
M?#'L<P5EPF2(S_[_G$+P#S+HR5=I9M!X4A4B[?RKGD3(4LPBK)+0\(CT=M>C
MF\>4.7U%R0$S&=>_5ATZO>6]ZIN?CN^:M5Y8':V#/>F]36B"0_FB+ASI&!RC
M4QA&8)3P<C'C.'H7KL"8(P"MDWI0?S!_<M_!Z1S?0"I1JCF:10LY*+EM[\#W
M.HLW^2XM[S J-CF<ZQS;)1O(,5P1OL[E3;:'%:AJ#T&[2Z-[/*,SWF(-L4]?
MOC>;>Z=A_7MN]<?UEP]$#@7>/62L?^#-NZ%'C^H]VJP-Z^N=OGP]\J%J<+4O
M],FJE8^B/1'4AT+AM>/7(0D0^HD&0H45@GK\2O( @^L< Z<^"G]-8)X%?ZG6
MW$L1V[7NRU>9VOZ=YV]YMGIOA)VU&KYDQ!!').UAOKEY5AD77A:E=K-R^JS>
M\*I8.]7#9+4[2Q@\&X<FQ'WR=U<92'Q]P86CT]V1GY%FW-$46UI6FE]RH:0=
M%HN\YA32<J!Z,5!N\,@VSWOWVD7>#CAK=7>7/0U9=W\%?S]3[D! B+]W0_Y1
M?I8(=XLR^_"*8P!"9>WQ\Q@XPZ!]VQ9>IN@VKX4EBV#A1ESX#>]O$]:/F"</
MH=-JNQOTKKFF1?L[9F#5".=K1SXUQIW5DO-?N!ULTORL*J=;]_9LDW\_/YX7
MNV-)R:/?O/&5\S95,]5NEVV6R&G.D>[N"E+>7$F>F_L\+&'LM'B#LBSHH?C!
MNWZ#SY6)^D5WD7?DKEQ#]+_<[@B:GM"(UN"&PL_P$ZG+/R/<;3@\"/C<>JJT
MDK\9M^7AFX:SD[*3S<=T'?/=A?"O^L:+;0$#I 1E:,I>UH%!60'H>?8H#7_3
M:G"1&M)=?VWBR-79!95&LW/I.=4'*V*![#9OJ9(S387NO=B,>/2*NC>[WG[7
M"SV9L!_IF+& 6"DYU6\[0X./Y-<Q5.\=^6!VD*2WS?GUE #4I?5VI5&PXBU.
M7\,YOQ0='-2704D77FU :.T*TQW%F.Q1%@L6MI66YGI3Y_L[$?U]C=AWB,*O
MCJX8Z&/'(\JU.IP#NT:/ZH3N4GPJ(JL8MQB/' !+.[Y]MJUA>W!G3 [B4)*#
M6X5J&:*I%&^'6K#!!6\['G3!XN#;BQUFY<&7S,YUM9ZB6Y3ZT5XMXG0/CQR.
MO.I=!=I4/"_;< P.<+SSHS]<_B)V"73ZTO#I"?T&$HF4R@\T9XOSGEZX15Z5
M[/5!  H*M1]5I*'><?4GVK UB*)K3F< >5Q" 6M-F>'!: *J>3"90QU9Q+?"
M\:Q\]Z,S8B<F^SSBKTC=R9W!;+EC.7O'?PQ?\H[IX!1R?B3GGMNN],K2W=VJ
M2.[:_,3=O1^YHD4W-/@5VF[O-AYI)MU4# @H<[<K]G_SQ!O$K1"O1(.<)_E2
MG&I* >3;MV3E^\.G)HN1B=.>DX0I\+CE%K8ZC[#E"#/@@[*<&A'IUJZ_$K%1
MATULTB ^%[+;TZ#T,>=D42F5[Y[-"K6/7V5\)%2\O&(!O1[_2G&BJT<7['RW
M<8*>)F69"]EJ?USE5 DJN#$FKAQAEX<1@-9+GP2A'CYNV+6B.576851RYA"5
M,R, 80C\/11O&#V*# KNT=MQ"R0+9NEU^?L'E$O2 $?$7<2<"ES(+I7. E!L
MCI#V&,>X5J9O1LF*1D_[+P&?]R0G%YO2)BKC>R:( 7#'1V/)7W-C3%_>2#"]
M,B$<%#68I(\E?"$=T90%H+"T/_R;V ?YZ_(OA2Y:"U@M )UX+  !NEVX11T\
M\! N31D+H#?S)5FP!-Z));[BU:'O."_8H@1B?!RP&[$5BHP -"/4CMK6/_Z'
M.IW /4A\!UF2S!*2?7^1D.P[<#7RW)\$H-0S.*[")(S[S(A[6CD",0=EC@KY
M$DUHXJ<&X"0._#^SO+6MQO>:'?N?-KX>OC=^]]CGM:,MCQ(Y5/9&P#N/AC&*
M8&BX+$@O*89=R;4.(%N'V_7W3\1+N.XHOH,YNST2]<;+TB*.2WE\7^1K%Z%@
MX9V)R1-WJRJRYXG)G0V>V1,^!XI4&L-VI$R<?J8S;7ABJ]X<,573?J4Q<RHJ
M,^&%M<VXGW?,VH'"@M+HGK6MYE=?&4EWGC^B/'P4&K=$O8\X$;U[@+#QMKOF
M(';W^X.RZEMKZ=_UB,KT'NN)MEIG6=NYG"LLZT@'ES.;4T_$9DB9/5OK?^:5
M7@4KPFU<MLK([FW_."7DPXV8\'"*5L8=4FE2DN:%4[BT=Y(73H'^^-)JO/=]
MVT\6_O-70>/ML522+9 TB*@VA1B$C-;+GR7]))IH(M:T1^/29Y2>\2!J'5*;
M6G#6WO)(:['UDQ.23P:-Y=9>&IT*V^(W]1GJ='-0+WN5QZ.O%B9YT"[VX9 )
MV?P=UZUN7(\TWJJSK;[.^M'CJZ>/-,//,(\$*J6E#(R>\,A8;[&WT1>KG@%S
MV:^X.\??.B<;>2T]MC@^LF%3:$98FEF<M8I*5</%%/;L] O>U7*E]U QM/KW
MZGY)I()E1T__!F=$>939X,<-:U)S+M%JMGM=E4ABASP.T>TDN!RY@#C";X?J
M%C+!=8AUIL[,T7=^"Y&:R_=8+K:JA8AQ3[/V$+)<%568UXE,VFGF5'U2QMCM
MK]60>H+0CE3#?7DYJ_-3;RP<K,\>61TS/CD3;/9\?>2*%G61LQX?WHW?ZWF+
MV@QLJ>H_F&1*J%.4:YE?+ ZI<#OD9G6VI#*QB6/89:)P0M?W>E1Z]-9)XVND
MRGO6!CY;5J4<_4E=OT)343%8?MWMF(PSDAWI,WM29>L.]T\WM6<?K#DAZ7(^
ML$1GWZ;,&,M(E]Y'IVSVOIS-L5'U*EB<S.6WPM9CE;FZ@ ?S.SL(V"(3K7>!
MM;4JT3E\=/D'T2NK^I69[ *IA)H\98;:=.HVGP7;Z.!5"^O=+[=Y-74KO9'/
M".Q]S^[*@"29'P,*.-!N0,0.L!E =;>?? TX@2.A*EQ-F,268X O74+$E8H0
M+5:=V0+4J6..9MN[8!4+"LMB>C:HFIJ>V#O\MC/?8= B]%S[?O=Y34Z"-7"%
M*0 YD%Z7=%8HT,O'BN/;>DVVC$L'?X,57-P37]JV<]<C(V?930;KW1\^\!0S
M;"G:$6@!F#)IB-<$$RI&@JYO9?J6FH\QUX^CA<YUNXVP%";=R5V9X:<5=G40
M[XKYWVET+C??>>G#_MMEEA/P\D*7]&*K!3^'/D6R_TZG,UEDQKCVWC?]Y\_=
MCG!E)>=.)X[T3TS9ZX)7:D\9<0X#"=6)^K0'Y-6G(#6T8)V01Q)!=A=;L0J3
M0D\;@;3UJ9J$12RY, E!N?-NYA?;A#)=<<2MV%^W4KU182GRX*>,^)9!?I?"
M_V+OS:*:RMYOT5B*B(A105 0HJ6 2%=*IW0I&T! 0+$ !2&B(H08(M(%"(F*
M@("0$@1*$*(T1MHH$% (B1 :E0*DER"$!)$V9D<A;$EWXO^..^ZY_W,?[LL9
M=]PQ?@\[#WF8:^VUOV]^<^Z]FHY1G@IP JX!)G85Z8-V\<]Q)P"/-LP>D"A5
M569#L==%YX=P^SG^-FV:1=4<4R6094#K04<Y"B9:"HL>D_VUM#*\^RY24X._
M/\W%/*<9B.QP^P',?=Q);H9&J[T.T5>@4QU5,8%P*YG_WH<4]D#/ %^:P@KT
M_W[>?=I?P[E^\.D@Y[=-1OE?/^QMB(&&62N -D!+)$_+&;,.]':S8;(*%C6U
MG^1;E/Z-C$O_,&@Q7.Q2N^D+<I<Z9 ECHFM0NRM'PZQN>()=N3"8$#?NA^,/
M!#K6>]<DUJ5[C(U-*MVRTWF2$=_\?3EX5O\^7A<O+R@#]2B"^J]#3;<L,Q2P
M"'G,/>;T;09C_@03IN0.Y+C],PXBF<7/+&@_AZQC?6*!5NVLI,X'"I-5]P<Z
MS \SHZ(PP78]/,JP,;<O:8W2P4C1S,ND[\ 2G,&4J&M[ 6*[&[ZK;8W6Y%@6
MMRK\&_1H*SI"35LC\)HK+U@H?1E<XIM_'[&R4CUE4I)U97*9K23=0R]/J':=
MHBB[52SX/FAJ61$WJ1?J]O166A)C.?/4W0>P?E9U<SZK^0X=[WY#9=@O?&5Q
M9M)BSJOG >D<>CH\)<R<LA$;W890<HB")O?4Y&&@0G.?@?=VW$\[_3\^_II3
M>O5-P^&KVS**3@SW\E#O)RPJJ8-4?B6=%5W[>7"LY\/WOUAN%B%ENKKUE*"!
M!5&UD2CNZ)[L)[,PR0W/?H?K8359S<V;#Q;?(4%^[<&-M\1=!FWD8W5'':%
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M]L8Q+--_J)34]YJ@*8.TF<+O&T>*TFWT!JM,C+Q^-S2(D=B!(@&YE5W'EA=
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M2?WP*3)C]PH!U ON@C[(GRS@_%J\/8:H>UXP)8*EXG?FOUO0T?%C[$;I:-*
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MF=A[(]]I&MM^/JPS?;Q!0#/;Q^PX9.MYZ%UF>ACC,>R3OO"-I(!PA0WJS6;
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MX8S+58#.AC=@SA1&!5FD/1@E4>>WL\(>[_QL51ZELNS-HK9;EB./E!P[K)C
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MQBNG".WPW2K61TLU%>^*[3!<$H^XG?TX./']8/U(4X.566?? 7PH.NU,#F6
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M'2<IB=<_E_:Q881@_CV2_!>Z4:S$H(&+4WY0119(F>Y;DCS[_'ZJY:I32ZU
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MB0G<OSQ4$9>%IK22B<]+5>\-EJBWE_>KQE]B&A)UG9WN=S%EF$;L#RC8I%=
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MKXB00F1<ZW#DS\&39=F6[Z*6ZFD+$YF\VH5$<XX-HM6!&O!3HI2>T$11TCX
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M5)XPH!)V%5#6I[;+%UV3GD+VG%.CA5-+SX8E[4.B[A<6I($A"?H-.U%';$_
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MCV8^.AG]=*2<.L;V3$%WG'W:\Z%*Z>SU+Z)5SQJE7]W;<>=(V&B8L]-?0+>
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M(I.W1A& :*9PGKG;O_<SWW8-A?_:H1]/OO96 ,*:P'EB"0)0;/Z"(?SG3(
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MFITN_'#:V<+/JD$[$ER4,&#?8'=_OB\^L5!];U>UO(%WOLWBK2ZS'$($^)4
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MI,HPH:1F)4IIW3(1LINW?^,I"B, ;68 <5R5N4PF&SIIU $5 [08Y_IY817
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M2-'6O4$_W;_W+"< U@2UX^M@FL\+'X1_A!$C;>&AV)+)NBLICZD$<+Q^X Y
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MYYHS%^NW!2E\W7=LY#Z_RY)#VGB,E@B OTW=2.+=88_8 NX,O+PERX9!;!6
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M1"Q_QT4FJ4<GH/HRU>U<Y YT[+SR]J+=;+'R/4^\]A#A[4W>=H#(W8\ZW2\
M^3,5)^5B2;^A[@*]K+%.>)5<2V],?2?O #GE+N\HN[A5-PXLCO5(0VA=Z$>0
M-%"&-2.-,@P)Z.4H1)H$W 4F$3YVL?'WXTM2.F:JS>"W]K$$<-*O1?^]/*T-
MK*DCZQ$=VV)KSR$(V3Q>'.CLS'))0MFRN.Y  VU -*HW+H2;L@=(7FHS)L8W
MGG[K_O6KKUL&<6H"GGHO:+?:6R.F6EB&M+Z6$NO]R*$;]]5*II&?-9?R6L''
M#$0ELYZ?W/[D:WS-FXY"ZXX]B5'[-A%47EYEYPI .!,*?ZYI"8>/:%\F(LB7
MSAYYDOAT\"ON>(_'"Y6R.SF5M#$7YZI;7:.H0]18M.Y&&L1DO@K3?/-J%>N,
M)P?'"HQ:#KP?=,5__; LWY#\9@,;(KF%VJF8L*;6_ZJ&K=X6'F&+L[RJ%O;S
MTMYGSS&60CYK(V1F > J8NNX. /<LO3K@&C+*)XD?0GDGRO'1@A 42%FMHLH
M WJDB7G]\&$=U'X\,N9\IBTI=]OTP([,5 _3[0K3_<,66R%YH)WW=[QX$08A
MNYW>-+=I_7Z$%"\.?#K2UCITP[1ZFB< B93IT[?6=AP,<N\J+)\>=IN8-?Q:
M48.@='WA!6XDX##^Y%'/5@I\(1V'_J"BP=:,UI=,]C B#@A ONY&G>C?8MXI
M8%LDE9!C;2K&$)/APS,C8DG%[*+L+?7!-CF;3'5K!""'!^H!?U1X_IP&M-K@
MPEF(8:N31&S86G3-3OROR^PCN:$ F$%MAR:HJ .S>5=0\EBZ7!3:T+]^.#.$
M1:4OH$\\,@\(D/S-_E5'_27(COYJA.9"UL,SLOG:74[\EQ\.\G?\L+_I]</>
M8P:GF2F_/]'?U6+/VX<GY^_?V^?SPD=^1K[,X5L5LSK+V6/I;&,:EXG[Y/(H
M(?'JS,'3.UF/\V6?X1"(CVL.SK=LERIGIL"/H#[@Q'K[: &(5ED?LOK0)WZ&
MDPK$L*5A@*:B?[V>I/QLE@"TL$0';YG-W&4,)W,NU+'ML)BB/U9J!G@9]OH%
MH0M>*LJL25H@4YM[5)@EY 'F-2X$F3VY'=#B;._'>&,2R)*-B@SL9E> 2E]*
M6%CDF3"Z$;>&3%T89HJM;L/)J_5.U)B5_84!2<?K#,..9L<^+.>O[OW\</M!
ML1+*D8B@=ITVD4URQ$TG9Q/#@]]U%FTQWJZ$KR0NA4RLCJ%3$*8K!Z\YW/%K
M/^[>_J/81_.>B?[ 4$TEMCCP'9FBR@D%^MB>G)0-+/EFH"*_![S7 *?J+IP!
MR4<"D"QD.TH#6+E&MX^#;BVREYD R,T>OU<-!T,5D>(GV0_G+'X@M#KJ;<EQ
M-P@UF5QC3L^BHFW;F) G1Y:[ RX<^UI DWL490'8>M-[@0/%,20SGAN+W$:-
M"[=/;OP?[+T)4%/;MC8:&T1%1!2D)PH* @(V-$J7K0@(B @H*%VV(D*( 9$N
M0$@4I!>R!8$M"%$0D"9$A,"6)I%>9"-](J$)"2+2)S1A 6E>W.?=_[[_GG/?
MO^M5O:KWOSJS6%6K*JN^RASC&]\8(\PUIR]?X3UKL3'?CRZM/W9OJYVODVHU
MI+2:F'.ABA*P=HY;<+3:!V."GA[SN'6S>67<5IK88+O561R2*CM89VGX:5Y2
MJCX_I77[Y8Z(]V]..>_>_='[?FKL@]W'?#(F30/;=,T:E\+R4]:X$;?J[Y<;
M(9&6CF%/I]1[=/R"-PC'TB,L(!%C_NEUUL>] 6'.%E$ ;K-W,)4K@R)9,1PX
M,!7)GFP2@,2(N]';T8.0G21UI,)'JJ<"._/#6[V>B26%I@J@JH4:-KZ/V-BO
M%V5UXSVE&G,89DCS+RMK*8)Q7)^LN-MM8EEY$G*N7$.6='$K_'==TE%7I&JS
M <F$7'TZQXTN-_+#P %9-#O:(G5 SU!^%MHMUK+/H>&,I</V!?7>Z)+.$Z]J
MQR<.1NR_>I[APM]P^.H8>^/+T [3!Z O9ZE@)_.P&0*A^"K!UJ-FX0=\K_^A
MAX[]UFKE1&M?DOUT_H:VE,/E02T<5?]R<"[$87#*8GFUWK9K)A=K=@-?O>ZX
M,#&1\>3MQ,O?3(-Z78XR&W6BH+^P]V?M/KIFJGO]7>(?LIE+]G71!L8)DU^>
M;>O<H?A-YR;,^N*-(Z5NS[[L=1G)^*+!%W_ADG&YKTQ3PZ@TXY9CLO7*]12-
MS]E58RMOAT-";8. $5X%&4Y01@^@(6P1?B%^[O#XCNK!101*A@&'S^68RHOO
M$HN%:\TMG'>WB"KS?*S=2@U[1FK-EGT5)_W$?T-\2<?S6/*?DO-'EF)1Q;]N
M YUV6MD?].G;HTB72+83(SZ)+PFLMPJKZP:/XI[;94CHS;H^]D/5Y 4*YXV8
MUMRE@V>Z$)&^M[/W:--NXL*OAS[X;,+X:L6O.CW]^MFM;9Q]'[='/>[Q/$=8
M=5%I\O[C2K%VBW?PJ<JF#I&X#)&X%*/?7OI8'@RZH9)3TJ,VI6&P\68DLYC;
MC8QM5?3Z^2?+/]=V[P8R\U:>0::/[>D,7Y<FE^*$EWZ_%L27J*_9R,((WK;B
M=I89)RQ/1T\1OZU40*9GI_D"D+YR2 >7YRX T;^_-?E!GB['K-,$H!3E8.@*
M!;*U@&EOQ)8)0 .Q E!TE@"D.K6Q[M,6:8TQ(;/4^6CXDOK?!_JO.+<7CG.7
M!:"/N(T-0@/NRQ\"$*X,M\4=#*>"5]:"!"!,]JN5? $H3UAXTN%\O? ^3,]-
M 6B)^',C>8( =%6&OQ?*Q69-C\579ZT(F^[MF.GOI&6,T20?78%96G&8=L?T
M#/7P^'XQ7Y+Y$1T"4!0!Z)NV$(!,O00@$I7KNTGFG8,"&IAE,R@N5+D?VJ/+
MW2/\$ME;G=PY[,;F!P&(W'TE#_YL^[L/N0FYEO*6JHMK.Q_NGC5ZRGG+_<\9
MGBST'-MNK7#XY:][5+](AQ_SW[ R.?3H06 OY<:/=BDMF^""G26VX\^E;BR,
M%8Z0,:=+TV?.0PMS_'DGB?5#;E9U:@/'0I]=>=J?FQIX,OU,R8TC&6(G[RKN
M_Y;Z*%J+5JUU64XU".%#OEN,&5X_UV3>8O+4^ORWRCOAW_:Y),^\^URU\T38
MR:#MNQ3 6F$[4R.#>OS6Q4%3=^PJ%.ZV/']P!E4Y6"'!&#Q@"0<@'9AUE+E#
M:L7[)\]ER+YM)X*.+[VI>.Y/R:PUWPQHVC.XV2;[F6.3O%Y0FEXBJO:&>B8-
MT2@?&.;W97Y-6YEVX,ZV W=_9<I22WKN^Z1.XRI$(OR35#= *6C6SE]_G1#V
M"-4<V6^/?\"_!&,;P35GJ4\E5OB!GMA\+7^'U">5WX+5%2/69BCDSA[I.>?\
M2IC-=?=&8IIG=TVA[=WG;GY"3O!T)D2[U]QLG)Q3EC3L_/&1M<,CO6L(-?U1
MFQ8$]]R]5"^U!^>/N>_\]$WBMZ<AHMD++8H2:;IUY.9QW)( E)[-U'MQ[>">
M\Y_SI+&R2J?V8_8N2,> K-9=*I4J1_=/4#>H[2OQG-+OG-//9YG'U>=_E QF
MC#S,>?#]98Z_X_.<AP'9=HWV<U?!#S=SIA["-$.'JJM3$ST[U?#>Q')\B>8?
MHM]E9>>4I:O6,*>\!A&=:XK4UUPCH&Q2-TY^(97(P#O#D0L5K[/7KX;>>S^(
MF,RXFTG[#NI25ONE3\[!V<+E^$U#_6F;PB\R<DTFO^T2_7 $381?'5@*B9RS
M.WNU)GMYDS^KH&#KJPH[ECW+H)R[?6V78;T1PUKQ0(=8=[B[:<[T"^60C'LF
M9[$=4\-3)E<.WW+2;'5N9IX^AX7;IN]__>2Y64VQRW#S=>^]I3:H5&V;GG''
MLGMXM0Q<2_?GH?*A@:J!HNE5.&NIC9)GQ I]S*R73/8(LH_>U-,E?SYTQ.=I
MY8W.5$=VGNCN,[OL0M>^T7>B5(,F[..4)5AML]*- WK)R(!=#M%C>G#MYAV'
M/CTYMJ"24NX2??VWAU'WR#]:8N'W;N8I?#I]OEO7*X?:^9[V(5==V<4>[+3'
MYN8?>OV!@173,KNRCN.]X=I*F\/&6L.W/#]O!E,8%E(NO;M/Y">!_NX5_1VJ
MIJJV9_?UW\Y^$LU[Q%FT%'5$$KHP(S)7!* G.:UU=P^XYU8!N[;L,)H!9TXL
M:?-U42?/=.HY5*9\1=P_:J]_ZC-XWP6>!2GQ.S'[W*!QPWUIZVMB"./P.Z!I
MQ>F8GD9T$,H3\&!")&;7LX>XVZ<MZG"M9RT>IBJ?*Z+RCP&B3OWE8S?&,L:5
MC)9O.+Y6/8U>\=*[S=VWE< >/6N9Z1W7/-AZK5B/G1Z-^@,%T?-RQCOG;VAH
M/LPR&7GZ*T'#^N:&I]YGK[P''&.MYS['$U*,_SBO]ERS.>!R];<%Y9)EKJT#
MO2IK09RMX,HNX)YAXZOEISZREK F=_6YVKF?F_*YUA241M&/Z"]C!\$G;LZP
MNSAI5Q;JX25'<P4@8_)$,5T&<S^'#IP@S-MN'?]Y4F2U60GKT$5@@S77;C<I
M?K7E<G]( N+.NT']#_KBH>,#CM69,/TN;;&K?\2;&ZP[QXE?IEU1BQVTP;W'
M5!%B5[^B3H>46A?2,##< 63-<,#3 \F5/H:)ND11HLRV2_GCMF6):KXQX??N
M]$O^\9UDSBOER_(_'^#3<%7Q"[IL+V9>%8. Q>Q 2Z-N4/@R*)TJB@D$YC5)
MV#?C;!0#O&V,>UW84^)G]%P4B@S.\8"X5,+K?^^]F.5 \]3D6=SW5SB3LL]9
M/J:E':\9]#8'GN?HD)Z;FV8G &E.1>E5MK6$>P8^9G#-) RZR[Z?RW)].4-]
MF6LT^*#O>L%:N'/,#<WN<Y\=\0YUZ=\1/[!MF!',I/T"9LN0Z\S+@4S\SE?F
M%9']H+*O 7LF)HE^6-@T0)X(0/N. 1E;-@"'ZLZV3_9F<9XQRO;H_U@J+V_0
MV/58/+4R'$$0P\Z'?T_[-N8ZDFN$;F%@%U*$%9L(RX=[:(F_5P]]HH=-OS"$
M\8'L0X:Y\5Y@?"$IX+TZ)#FN QL;NX;WJ-YZBS(OHNN\+O)$IK<D>_OW7]4)
M4=C"+KQPW?P^D> ->8LCNLRO;XD+0$WFJ+,L."=Q".,KAY9$UGY<KPD5@,2%
MD,)R6)JKP="51_JON%?6# :8@3V .,P"XO3B5++#C9R6]5)]8ZVR%]FM(XU_
M=NGHX^;#ME20+AQ7WL_-O\F*?!I=DHLIX+I3"GI)NL *<[T#MP=([\@[S#:H
M/]XX%?<,ID;PEHCGJI="*W(;]=)?MVFS4[YGJI\N4TDN]E[4-[O^(2<=6V;W
M1UF$F^WX9EXUZP\"(BFMXN5YGWD92O; \/'=?ZQHT:PCJ8B:\6*F2UN/DG ^
M3A ?W3C,.\,%R!L^?5, PG+MMY TI#J#4S!A+X6$7!9&L02#SCV)D?#-)L0*
MFZF+K33$(B'?;<X2X>+NH6Y;A[OYR#:0DV,M/TYB\W(:W+9\T)\PK.O& M#7
M=&;/@@^30$MF"!NVX?AVB+)V" X\<_H" ;!JRW[H=S(QWYI3UE+\M>TMS/5Y
M("RSJN.-64Z8G^K PG2-,Z$.?8S? :W$M?=LXW?0JRK*MLRELS@G<AC3*2;;
MBGRADF@P3AH9W<%8BJF&Z>6:MX>>^3JJD**&V3=C$#'%^X(KG@DDY09ISQN>
MOM5):G1QY+V$W---)!,Y,5N1,V3Y+!<V)A[BTR//U2"^8PE J2@)#(O'W:E+
ME.7:,9.QFE^6' U=CU/><<)<7[JNNE[-U1KIB/2U;BF:5,N)*"OSJ[;3TLN^
MRCOTH_:'T3GYOA*;6F+V2Y_'SC=+JZ)CGBKK9I]YRP@_;VTPV2U;Z"-=.TF>
MKV+7<UIY^9B)E+\(C@!SW@R9*7)1P&DVG$E]&HP!^ZFV9!O&K0D+5Z1T"H\>
MC8(%\&(,?J<9$,2[^VKSC(]_P#J[B?=WB75)D5H$H)U8'O'G<8N !K6#+(="
ML:U:@UCD"=S')5&D5E/BEC'2;]HJ#ZJ,LJ)P38ZQU5O!TMW:+VEU@,>2\^+T
M+S6U?Q!CU=W$=F4S;<66B.MFLL**, K=G)TU7Q6VM0>IRR$ )9&L,%M>OHD'
M >5NOQ]U 0CS*8>CC[[[N5P!B/\(E0PYL2H6C/W8V_+:<]SZ<-9MI:[1&8)>
M[>FF0ML@Q)I+,_CK"D>5I;X0."%!2Q=VE$U%7#,V--E,7K?E+N#&ZFKGBR8S
M.MK)8DC'K[X&ZT;8^(.TY?56>6P\Y/WJFE%<_-L./9>Z?=IG$[.Y'AK&;P;3
MAPRC#)RY"G9CL^OVMF-&LJFH[1DV@07Q A#RB68DL;C+ERA;G?;TI;>W?T!L
MF2_Z#XV3AA&/?EGE1@Z\S:\T[?VYBOEO7-O>/%3H!;>3O'BOR%[8X1Q.*;%_
M 6W*/<;J:3T?K/]"S\/%(2Y20A)V8/0=O QQMI6FMQF6<!*O\U)KS/5"R7%B
M2VE#G_%;_=4U*0R4Q>M\[J45=&Q^L8+@,\HB[.;_B:L2@!Z1I&9Q.QJ.LI(_
M1D@T>X39DOJXYA-:$OMAE<C(UE C_+.!-6^V$F[X$W51'W[VVVQ6=KVGQZP8
MCMA].FQLQ!.E"02^]0#V;ZXWF<G7-0#N2^HMR26KR7+J+&-2&NT0)/8;TM:W
M//B>D?_<(;&H!-Y+L-94!3\I+.KKAZ/<RJUZ-^ZSY7),I>@\3J9C#P2VFR^"
M@D!3#MH&1*#\]8PQ-3I5<"/W"\R;Y;N-+BEK6WM9"B6A0LD,<J!F:*Q$J=3R
M$OT=>#XPD/T;"I/#B0#N__Q=8#!$G7V>Q2M]0QO^8%O)=$N1O(&"!#(+\TZ\
M@4K9%W82M-JD8JZM'$T<F)?7P+1P*3W?S"YC-+<:(9W*& %H;QFCAT-_BK(6
M@':[Q&%J24=G7$/C)QMO5-OI+Z&\"F"'J36N]S*8L#?$>Y35.053RV4*I<O1
MT*!WQ-UVNZ7*L[X&!09X7GM+'=V#5F.KIY+V<"58ABT$>>"9+C.GE::<J>#8
M?V=(]:;./%>/2@@#QZZ^N''GS(]Q,/9*_]V;1ZVU3?[X39>JYV17E,<)HWK6
M"D#Q,E7QRX1,''9ME/_@CC!*++B1@\$+MA/K"<=Y:4=9BZ^9*Y,YY!$O*R"0
M:< C3C?F,*^##_@75%+]=7;WFUB''.Q^A9.TF-1*EKU?^#!;?/",]3V,HU O
M->!Y)KPZ_EY^/_IX':N!M)V',Q-#4IO)$O..[2[LQJ56<L)F;-$+IJF/^Z"G
MKB94 D82[_\U^3(1EG>=0LR]REK=(*WFORR:@@^[U8S)#PQ!J4Z:2%<IQOR@
M&]8HMV@4?Z*^3=CN:0V%SZX-;I1QF@!S)@2+>X];$&&9-[MD>^8P<4E"6W,1
M$]IBURAO_DBV'E@+D/H1%G&C<&&UYC</]PX$S+3_2\_.@Y^C3SE8@[!F/U?1
MWY88QG'\,UO:T=L ?=9*,_WPDLE1!D^TC72.]3U6I'&J;:$HWNLV/E>D0K(G
M7F_!;WG<=L&RQ3+>MF;(YYG_FA8\^>6Y+=<DW!Q?H;*L^*JCXW.5*:G^=.OJ
M/ &(VN7UJ-=,FGN>5?&X NG40MK+HJ0PL(?\T"J4!G/& L3J76U?"-ZEC>HB
M,ZY!'EQMK3T<EF6FTE!?]X%2F">#L($G9L]_/O8K2HQA/Z^ZI<8584LDH> L
MIXGX1R0Y)+V5L\XR3&XP?NV*@0-HTXL#\U5N2 N"\W?P'IC=>[G"W@9#Y8S\
M,;L L=&OGZ[);RX+0V8\)UST&"0C:APWQ?/ ?=G_3"C 2<"/^^7H_?!,7"43
M:6['#B&DZ)+O+Z@R>A)4>55<^S"95@OV>,%#6G8GO!B(;(\87-#)B&(:0Z6A
M,YD<4F#R+VD:;;_Q'P5+Q'F"6%/TI_IV$LT1RKDE7,N&FB&3J+=-1:X6D9-V
M-G3+FMZC@R;VIV*A-^L]E/OI]F>@>ZQK$F][#V>8+DAYK(^8&]WTT[O^7(4W
M<]ZX9BVJWHVT5.;3"16'W 8/[YA8?QHB >8:"MDECW1I-^2K*&MB6P\K*U9%
MF5M2G&G+W=ZLZBR-<ZS<TI%9F1]ZPKJF(NMV3E>6P=3W4#-R".OLQ,)2'#=\
M8HL0E[<7UTR6"O&P]0!2&#,FQH4USR:C?&YN03@5Q<Q(\/L-^3;.:XYM '%T
M_$W_G[=37B2?N#T[Z!#&PT Q09Y_1;K,M[1SPV;*@ HBK#E/+:>9ICA^A*4=
M5U*(-+R595>=[L@BY>)'7&_-<ER5)B_YZ\TA;/J;/].6%6"2ZM$4V9=2OVB]
MST\R=W#HU]"JGZ$'=!X1"K:L"SA(F,B;#-%GB$!R$ .Q'ZH\+,R 337H,U$&
M0PW6<(9MMZ6VZU(+9;,R8:RM8,SO@7F4:?3EFN4QRW0][T')KPZ6S3!]G]+Y
M<$/N"4P,A/5X'*4-V8<Z*#3'FK@K(G3]8P]C3+M!.ZA\%"X L3+L2[KSB965
M:9L!!T4HWSX@KPB;T[',E;C9']7TN/$=?5P7)E0)YGFP-WA)#NBR[],C2 /Y
M/;95M503\R*DOUA]@,17O\TGUPK;UBI21-9&(X+/UA>6]AQ).'%'(L#"F+2T
M)/.3<6-X/G1H^)NK^D?=:))B+:NQ*(95]3'"HCC:Q Z/[&FBU(7%!ML:8\20
M5:WW@+EQ%=:J <5!+;G,;]IIT(XWGEW3[ZXP@CUK=AMO"I]8:J9+(J<M@!<5
MR!W-\K6MD/V^M*SX8 D%/S-P_Y*)4\$/H^9/V3788GC5B%DAK&C6]F3^\A>%
MY]%>JE5JZZ$!-C_?)US:?WGUJ4O70%'NLPXDA+$>35(&H#8LJ\<H[5> <1--
MJ9H2 8GEZA<._Z =SH$'FE!=#G,BO)^>HEV06G<Y-/KE66N9WHKMR=>T6V(6
M$Y@X_D[ AY$#%>&:L2H2)^A[OG:7CMY"AK5DAU1DO''MP<]FU5$(VHVQ;QQ&
M6C?C\&\]9V6N/,,:S'Z'2=!5ZOU.U"_R!:"Y]_LOSR#Q)HT&'@;0 3/]/O)$
M'J[2(&;2%,/<E;MUAJNB?)(-3KAO<B.J9 R V P>'F@U0K0:AF87Q7AA1+KC
MX_PS%\>U/N2TU-3]6E?G%!2LEIMM'CD9,"^SI<+ORSO31SJ*\@$4)GH4D2.7
M4G=K-]A%P4U3RR)A?G]2:.A&L_3 VP+0'IV<^_U7$-5+!W0*?>ZKO]">2#J_
MUX7ZW'$&H4W[/%Y#XT=%) ^W;'BM1V"RUD+1I]!#D'>0-IP,-^(#T,8J8 A
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M+Z@-S2\NZA>S1>@<RBM:LMQD3@]*?,L430'+"T!^X&AR-7G!HX@K!\!\ML[
M<(>K"7$8"3,)(+F59/R!'5?+MK5XQVHO9BX= @J@_:@SV<XYNY+O8 N!.R.V
M@SK.F\Z1W7;2%RGOW^)TDB/7B?,-> 2B,<U5L:_85%':HJ@4-MSV>7&<D^*;
MR5]8A=_8&)N0$,HJ471^N!09Y#"$,-.#HJX KUEWH-N1T\V0ZJN5S$3N>29F
M1"= <ISN@1Q@1,Y55<3DH^2! (8DDR#+O<*&Q./L $P1]WP_]SQ"9-2H]9$[
MNIG?A&,5K](?9];)M(!3LG4[%OQ:7(>(A&3<03WR 2N"!Q++S$K6H4/9GE51
M"IZ>'C #E\V4;P4MV>8VE&Q,/+YZ2T$T3<S;9UDW ?QN/07C"R?0BMN@<ER7
MUS-Y>L +U@I3?5X VC*M>(8(8RK)3&":HT)['/N9[$O7QCU@W[<ZH))J6?94
M%.H^U?[N0'FYB98XE^+@(5</_MK"N0+$LF3:,3)FJEP["EK!FH"R84$_0N(I
MXW* 2[X?+2!V=4QK0CUF#2HV0SKRH8[2D#.'#VN3*+?37\@?+JS %L/J+#-$
M%@N4/F17]87480 9VW&:'\?>8JI,6O;.;4?W[L$GA8NUWIU2F35#!N/U5I'K
M <^ ]"THOX]T%AAA.TWTS'NS@ACDUA=D'RWR'G,VH0TL33KBYRG6M[@F !WZ
M<0;(IS.PCU[WKHI'S 8<3A%9W:H?BW3?4HMYTUWBVJ0GXY9;ME+,><TK-+FQ
MA1" 6O -%QCVT7F'V?;-]&2,(E]E%%G T&V%)+K(A\;CN?; #08NP4QY" U&
M]M.ZFN3'7Y0C,<UF1WN%BF?'WE?CFI):4C)3<X$+D9(Y\(4>#K1P_'D5)%%T
M+UW93!?=@6?9MY&4>&7Z8-&Y/ B+WFYGWLH'UP/>;)D63SG[W> $UUVO7]V"
M@UDO?+-HVIDYINO1][ 70\COMU.OIVI]\$ZM;>D!U$AE+'H+_9UH?# NT=DU
MF_^)+L4_@7)E<XK?SAA>ZV'O:!72GJ[@B<R'2+B:!YYTW8\3UB#QJ?IBW09?
M9N'IWOD7 GPX)=]3LAUG.U&;QGYYV2$N9-S%EUJ=G2O6D91A1/ 0L?%#6./B
M:G\WA,R%EP+%#$*36XHYH^=1@^I;9%8S7VI@HI<K\19)HG[DBPZ0.A&(@.,9
MU.3%X.3?@['B/YQG5'.:\A?A6L=OED_ MG=LU++@G%$@@YT(\8,.3TXJ8UG6
MI&-<$UZ>/B2)@C;DY:*/V;%E&*%DAJ[,"%#_R[L!U?I&8HQ3?X-#OH?OTQ#;
MR.3$?J;8EM8GU=I4"\LM"0Z;EVL"W7)$=Z.U@ L34"E8GCQ[5T$98.411V_5
M>&O-T)5S13JUU@4DZ)+ 0,^6IB_Q& N7HAV\H:?]T.U"X,G0K"OM_8NG.,NH
MPBTS?C-=6@^2")$CZ0/KEP$)%L81(&^=^LKOJ8&(FHG"(IZ,'V =R[Y:4#%V
M<W9=627K*FL6F7F+05%)Y3%8B]E]A1G$PNKW;;LSTJ)T"R(6I@;6MNJRK]_(
MO?FPS.+8E-98+?PA[0LE-*QQ_7V4V44>=@UA@WD*85GNGAHD[CFXQ=\SPWXX
MRSO66/<[U#U%C)&^9ZEAYJ[AV9/]UF>Z3\,NE4\I:FA BX5*0U]P8!LR)%+X
M(MQ=P![62 O](-J4WU=K!K'?H9Z*LH8\X2LA72P V"LW9$P;28.=6N+E_7:6
M6L,Y3*VY1O.-T'_O)Y_1UG0];YLD?0JW0P#Z%2K#/<&NG3_*Q%MUC"L/3?#2
M(/<"%%%[V4J%>3DE;IW,;FB;L^?!FAIJ\+ULQY/56RXL7F?V^%+P8M6%2NG:
MYXN0^YCAZ4E",E\3_05:39^GEP"[YIC%\Z,"D-1]52"(;81PLV5!6[%[N2XL
M?NZKN4V[GL3@RR%BPH+6CR+^YBL4)I_0%^)V&_*[#D-#,3(OUS!4 !H)F(H,
MND^(JICWX0_(A^B&3GK&I&1,S3N^FELN@ZL-N1VOCP@]RS^&PO"J40HLMZ8(
M8D<S>3CY(U@F@)@"O<2F%+*])A<HCUD^ESPT+ZOVKV'VSTDB_4PQ[LH&V(6P
M[*N)8?M?O/4]]?'.T)L/=RK&C84B(&([%#^/84!HQGPI#W(B*H" [O^-_SD-
M9<#"M(X)<XSYH)E*%WN_ ,2(K:D5=O4RKM?E/02@)VL821K-XZ;[Z*T+WV"N
MSQ^ZC^E1YJMN<X-XZ9#[NLDD+5XNWP3HNL)[@3Z#N@"XFJG<A&- #<*N<4]H
M#DOK<GK[9L4S]5ANT*M9F3I,DDY(CR+W3%^Y_^J,/L*^F7,6&6>\556H)'7F
M(K4:"JAE8<L%H'M8$%>J <!.W&5+Q$'\<1)\ZF9>R2L ZM#'U>9AO=B!?'4H
M(-&RJ3X2<&S@Z0%[M<3"L?#HWC<'1AL;RVQ5\H<7$(<Y]+&P2)UU-\2/E^J>
M_JY7-5R_P)EUR8V9V?"0R.(Z&L_^B0 T\9HN:29/1P^-R_.JT-)(>P8Y@7S/
M/B847'VW+JN9(.TW;LCJ22))SQ6W6O8W]ZW925@-,M@N\?[5>_1,0YWN!W>-
M7?1N&,@T/@)_PU)?P&S=0&(^>FH ZUMVZ!ZH.$F9"XIA&":0]&!UA,=F)T>1
M]1UYHBQ.(B,RX. ,7Y[->1S)P.MTN5*YYG[KN[2MFM;38:Y7*A4BO]T5"]'!
M=1"^[H)B,8?(?E!))+8]<Q/S&..[-'RXBP.+4K]:G8LR?TUO*06P#CFM]SA>
MVL\I/EOWQNY4VP89ZSG%A8P^'76)%8!\P".VS)XFK!S_3USUEUJ6>@MT]W=
MADEX/,.TC[V&+'!F8UHC<ZU:LC%Q#?KL_9-7V3LC/'$LOKA\FZZ.OL3>IB"F
MP2!1*6;+<KR;<BXW8PN/*'69)8S8&44)F6+W8S4@RV/-.> ]W&V>;Y7'_;D=
M*8Y[D0UMDWBT:=@.%D&!>DE@-$6&$F'51 %LV;,=3$RK??RXRB *',[D'6J!
MR*&T PIFEBT"F5K:9HNR^KDB*@-Z=M9'^]9"W,K*PA4(?9")UP*00H/=A#UM
M!R=Z .*C9#; B>#E!1-2(W3>!C3 PM1;>Q(Q!_B2<%H>3@&YXTHEBT?)D'E<
M<7^UMF9P+>I6:L&NVN-3Q(R447F[KNY^]"=P%7U!BU5V@^7RV$P')<M+=6FB
M[T6=+00B[8 YUJ+254B2,@1GT6?YS*M<_4E%@P)"-";$%JOV.2J""97UPQYO
M'H]*TLB<.AXSAM[#_X([9 ;B?Z$?,%-"0EL]1=B05CMXAP DB\(PZGLD8:Z#
MGGO2 A+&S2A<C]OYR*3/X[-SUR,OWP]Q*)IU.>PM "'O9M*^MI;)'73UX"L[
M].&=*+QTI<I#3]+2DP-A^CY=:FEVZHTY_CW]TSVA\EGMF)$.CA*PQEA*EG?Y
M**ZIFP057WO,JOJY9:&9YAQ4$F4HTOZZT!Z/?(#,FZF&2'C,Y!UA^1-AC+G&
MZS.UA@;4E;.MO]U\8R_2,X1Y%]:N0,"2*^GS,^P I[K(A: V 4C,1%<WD7 L
M105.D)XQL'V-S ]4#&Q1#.PBS&3'M"8>%$E\]B P?:.,08ZA'X;<[HF%U$(7
M8B9U=Z' @%T),, X=A#IQKD/[-!-1MFQ2#U,RZ=Y1][U<V^]/99MD"5-3S([
M@L1Z]NKQ+!K.,G*5FSNLGV)@8B_2)J]!BB#O>IHB<<.3'$L>SDQ\]I2"![P)
MLP]U'L[4NI?KCR)(T6D5E<PWMD].IE\D'1DD<+,L-;TTSP1:T_IJ?3 >F;3@
ML('2T0:C'/\;,DOGCXKJI%]#?' K0- _\T+,"/E)&DH7+*2N;;O5WW;67J$,
MD>+J,>G_<)?!]C-GOQ@K4E*D8/A^6!%Q96ZV]I!+K:T>_WMNHW)/9]6W)2RX
M<OHCA&:CE\7TB7G5,'1?Q<T8>A#F6/.,J7#B()08E4V_46-/5'C8?X#U:6F7
MLEUE6=7Y#0_(Q#/P>T5<?;H5F\O6N66 9+)_N3]I[-E_8>#(I&@1?.U>TN9)
M&9E 2[<+MQ^87,AAO.MU+KZ8:52NX9BRU'7U-#S3L/Y]Z!#N9:!$S+@T^]YM
M)WUFP'[@K-F?91@%I>P''&ARFW.MYE6\7W6A9FJ?0\-&;IK+>ZLI>Z[1#HZQ
M /0:PY3ARQB"N80"OM*V+24!J)?,%J8IL1PLWX4Z2Y0>X#<&XGC2<M-\Q4HS
MZ.I*I[($UY;P2 !:]>$:"4"M]B>6!:"W >KK&^ ,".N'Q-<EOE!9$J" ^RAF
MF80%@D7GPP2@B\(G=;DZ_I -*+1TT.&_8HK^_PZR()V_9\>6XDLM7\R!P7VY
M!>W48\NGT(&^\<^^[F/3GZ+Q#G:!=+DR :C=(>]6\6%R=:51,;PX IL/'5K4
M+:A]+!:P&V62O*0L]?G0C !TK<<*3Z%M@)]?$X":P *0U^\W&UPAK>=>QNV[
MQVZ;T[JKC/O1E+PO/<T>/=1'PS1I8+P5[))%XE/;>YLNL L9C'=7]]2HUT10
M9X:D5S[D&<KD:IRD'W([XV1G.Y<>,IKN7I..TQ^JKD48F):3FW![S\2*9  A
M3<-AJ@WHXM^\ ;1+B%;'L$.\%JF6.DZ-$H#.:PM3Y._0*I%B#:_)&S.M>=H-
M0:L"T/7&>-E-2@.894<?;AZN4JI-WO3ZSC[V;4WT[9.@W\S(7:L'DX#[+B#6
MO?,?O,[Y'&_]X-$Y]+$_)XRX%D;<G"$XS3W@:K2<LY".^_2P3K%FBG/3Z!0Q
M&W-O+Z<FEVAVN%:8/]#<[34"D)-HTL7E[37DLX]GMYWV2>^<CFF#8UIV<\4G
MU]'')[8)0$=G(A] IC*BBBU0>:H?,;O8(1XHE[B7"IY5S]_,#G:>>I_S$-'Y
M06\$43,261LT6F"3J;Q7"M;^_*"UI612D@W%^L2/C.J%'^6HZP+0.^S'^7WJ
MB1VJBW/OTP'^7'$)P1$(W-)'G0!N1^B;[K@4F>)L$BZ?6JDQ2-!^A&!H>_\N
MZ5_X,70Y0[9FC]=CZ(4^CQ?JT>.'6-]AMD:?N*8,DRK] FGY<_-J=K'%"6_2
MZX*G.W6L9$J?.Z:%PL:T[G\?O1ZACLZ9*>USI?3Z;I-Y_.C\QQ^F\5>+<25Z
MC$^BE"2MU6_XF?>VE[(L$.2*5A$IARO_Z\/*__/:J;X#8C_M;IC*/0Z;S-WK
ML7W3^G6<;8X8P4CBI W>*RH@(AIR^M:9_E\>_QY]PS"C!7%[S,$=*-=7O*=<
M(R,IXABGDF&C7])U\TONY>7/VEK&^I%SA-^RGQ:<Z S2@/D$XX=@C9_EHV(K
M<B6C*7J)AF??=\A;QGZ=&O$#&9Y]V%%VT#X(>A85RON]FIR2I\7*2L:U99%D
M2;TF1]E:'^7+G3=W)>(["( Q,S.K>&:3GU<U2UFV+_ [C"UT=9]QK<%ICKK&
MDQZU'0NK<)I-TD(62A4HJ61I6@<[UX[=?FC9>>M8;O_"S%?N*EL XAZ:9%!3
MRE$[Q+&):SAQ.LKD'8OS[+8!#K8OPK_$JQ!P1Y[UC J[W+>D9S$8P+5EK-G"
MEJ8;8<$C"6F1YSR8*:KC@Y@[8+&1&1=.GC@;08_5SQ& DO*,@.R0F09M1H 4
M$Y*0:67-EHG#V;)WX<+@@?N,#$9,15WKTCR@MF&13\(A_2HYBS2--?+: +?.
M[TJ)4YJ?0U]]O4'>S"+Q!_HNX,;?LUEFF!*L*\>]T)##:"\L]\-\59;O#1[3
MM:56W%_DB_N"=_]*(4*5813Y@,3YD$/%+17NMJ]A,LXT/P\SG'YN6V.#]OV1
M;!?NH?66;(,G>B.ZB:Y#)&(%C'^&5=M*/Z03CP@O15T$(B<_H2#>3-U]H[EN
M3D/'>T-L4PR;T?*5R6WR=M21:[!VKWM+QI.K?DEA&&H7E^1:>'?X^8/GJI$7
MYG@;X>$;(77+-=@)S$%^L_(!MF<9WJQD,NJAKK@GUY)"4O,E*0[H*8G:XBY3
M&JQ9(VY 6-G(.)Q"N2?4R<-I2@BNN7_V4^UCAN\4;$O\\;JZJ$7R55X6T6&2
M\$3Y/)5_8G1\#B>&"+$UWB)+(%4OLHR!(=T*@OK[ZL'T%JKS9E1%LK?X=+I:
M*D4^ECC*)G+M?*+.=D+O]ET,)>.X8M!&?&&WQPECWXPW><GOB8U*:RN#$+R4
MP^7>O[.&;\66D*PL45U75Y6&N-_C8SS2/85T:TUO(QD$8W1\5XN2[DHHO$V3
M0>;(N?QZH50 8M5R%00@TQ AO8ZA[ 6@STEKXC&F]@-/(T-[Y,YU+@9E&T@X
M;6)BC2OHZ0MCX6A3 FK#>XBO6[?BB0DK\(0*<RNFB;Q"%=XT_]P(EONV@'_X
MYTXKTQ5D85N%312 -AP\7[^+P UP3WPUM9_A2T&[EH6#&^7_D-Q%7D=Q<6,S
M ;H"4"QY@KXQ1Q!V9JI,#/^ZPS\C$Z[] ^"^<K%0G??J3@D]&8XVJST/G:)O
MD=#VBZNU6<*'Z:P [AI5.+5G;(@ I'GBGZ!=WOZ?"/^8FLPRMZ&A@0QV>TE8
M7N+1(>KK$6Y=PF<# $-^Q)P !%P&< )0AA3FOR)K#?X#0$&TA =I3MY >WIZ
M0K'X+RX;8?PE7/I6H_;4OS(PY+\B2\_^ R$E9I"/8UAPR;K"T4&9UN+6"T!A
M/9V\\4QA<A8&E[@ E%<G /$/FJD+0%,6X'_IO)\8EDVS&'M6/A^:)1R3<T$9
M?&&/6S_]C;]D&X[Y^:[:+@&HQP,C;%[!AP2@Y7SL/X-'Q/V%4?#K&J08<,#H
M=@D'>^W#9P%(1P :6UG&A!4VD/_9U5;_ KW1_!\@_R !.6M*.(#-T2E,%F9Q
M8P-2WS_^;QK]FT;_IM&_:?0/1_\N ,F82*OMZ"2<$CT"W@W@Y-K/8N>?*C=N
M*D=02^;_K];:,[+Y'].D"JV$6%GFZLT$:"8S>QXO3%Y^Q1^)/L90B6\:/YZJ
MI\AZFVU4FFH/VG\5ML .:D)T61,.GA/E2X(/?4-#AN4(CO^S/WDP(;]X\*",
M&8S.)F)Z[J<?)-IZ1"1CU$A6Q5P5SQ,=DP+0P3P8G57;(#?03=WTXEN #^5)
M!&SL#"8X_&MR:.O@5V>%D^<M085\=3?319X*SOI/3@E :Z&ON)ZLV^?/P%M3
MA>Y* '"03=__#NT\%/I7%*W]=&X'<SUF_UFUAL !LP-L"-@>>.[XS_3[OR>)
M'7K!R*T+VR;TR+,8'7*, .2(3>Q8[C\!EFF0/7=P[F.$Q&[@)691I='J7X=B
MUM303XX4D4-S_S7;S-F13?'E=>Q-P*IU6@ *E)XU_E^2K84=T'3E(=13G=\&
ME@H]DIIM]59QR^F?0^*_(^[):BJ"&($RK&V<JPVP#0\'R!/]I[RIGP2@RG]8
M_8TP)ALGOF B"<L/,4RAH=2QFT\B]ZXI_3?LA6X%X ACQ;;A85SMI5W[L(;0
MZ6,"4-MQ9@R5 !D^OS!0J/L7JY\)/VD_+0"I9"5!<!Q+^+^V?9O,7[8G"'5'
M,XO9\7C:7%$ &GG8'O@\O8FO%OSK_E^\$8IE^QX]N* 87"+:1M^U/PW>8I8G
MR8:\4L2T%CR.W;%CQV//@O])TS8'A#*[^3_,^-_[X_^#T?_?)Y'2MH2HIWW1
MMS[*?7LEYT0EV(W5L:JA70C./P2\?*AA/G-KJRZ@WJ^K?J2P8?+OI97Z#?]+
M1_-NJ:1*N3<LEE?JCJOK0'T_[B@+ZXE@?@=>3^S^AI1I'S^PPC2^EP25G#E5
M???!!?&PE].5H+75Z<M.)0[$JR]GW="7;:P1]=]J2&0\N\PS5:GMCI;CJVF6
M)?[F1:=:+51ET/>,NF&8?V9_\=^;LM""8E8?R:OG 6$RVIL+%H#2A.H06S !
MW53DR@COKF(%H,X;Q4.!D%4)MV)N/1HZQB?,H?@?A%'[J@%BOQ'10&X4^ER\
M\-7?R68EPL]\ 1E^/$1$>.=4(/Q:-\"L:I28 &2.BQ92IZ1/:$!-;"D3\T.Y
MUGXCE$NNYT$IT]13F%69^!D!2-<E:[V!S*BN_A=,^&>60;C:X.T"4._T!)FK
M&8SAVPCS-/8QYD<0"\J7-A(JU7&'-7=[W@Z*$%F'GK6.*=L<W?PNP8]F\2!3
ML\O\]2RN06;,WW-P\3_;[3JFN8^ER]N/%DZON=A* /I6:E8F!'@5,0:9&EGF
M+ZUAW'#N33^/WP 7<QL]H>-"TL?U]_Y3TOWG='[C#9 [D7@L]43#[8F-J8P^
MU53=0S_FYQ=_V5NJTV5\\.*C@F,3V]*V+?[ZTO[ <RG-CCCS[T=W;C\U&UJ[
M4S'FJ7-0H6.Z3>%YIP!_Y#)G":S;45%+R?"[4?%V*-9%P<,I2Y_0-2P 98YG
MKO3\K2!<G7@U,7WDZ98 Y*DQ\E=D5_V'7-/]__<K#?Y=8?Z[POPWC?Y-H[]H
M-//G[SO\K3^!XS$VRST)8*E@W3B20DZ;F69=:H?-^S\&\$N%;I')+P[;V=\:
MJ%:XFZ00&BYF]KK458TI=T.LZO;U=W4/<JU/-.LX(HYEY-#6B02$TOCGS362
M;-+J@V!-9N6-$@;K:X03WK/QUK)CH<WSZ\7GNSLM-8Z-C=A>S7:%_CW]E?6?
MS+55(8&^+#RU/"]W9%],AO^9!\;K9>KYS[[,'VJ2%7W6]$TQI-O6SI4-IXR[
MFAH*0&9U])M;E"G81M'FP[DZ?F:N]G?RW[+'TU,?%*=?+?6N@=WW:]RP!5D:
M!>5U"$!#:V]HGI$(GY&N)0$HOO%$(P2/YRWIY#9J?X?^+=R1W>N;(7SH=.]J
MJ6OL6M$+GQ!,N.XSN!<\,#Q$2^.V=&.UG=[R@5.A;?)9]WV.!";96"]LAH=!
MAWC^#[OL1@8L0I<6-P0@YYG"AJV_%T$-+1QGWCNR#WW$ZN-F3ZO],+U#8Q*[
M%\"TUL4_T<]I*9REZ7_!,<7U[Z1]_QPI?N_SYWFM"X$BK8?*$5)LFXJG%PC%
M-ZX_G89D@3V);OXU53-34]2UM8:FDL(3G38ZE+2P9(J692$"/"4LXK'_#_3!
M\3^">OS#_^Y!]&\M_G]-BYVRF )0],:8#GE! )+")D&*GGGF_@6C<?'Q@-Y_
M=&D+:D0>*FV1NQF\6JO%H,O_,#N1S117L;LP14PY_MSS!ZTFT\!Z'54[>!_O
MZ'@V[F;R>\P!:8KC@3VB?WR!2&*G;"^3H7.LO_[1[RFR9<?O-9/C_<[?"W1,
M0I+T\-!69[0LUK:VGZO-8-P?5V5C$E$7RK[^4)9E%<=[U6=JA8>0#\ C,E)S
MBUNT2JNKO%E)K9$#AT=?23Q?.S?3C5;!-%FC(MDXH8Y4]\P3MPSX/631<CX$
MF<S(?&VX$,YV8>01)L<,&:$9;WW1>P?OL.C-^@UL=&/1;)W(T#LV;VPZ84D/
M4ME32N:J&KDGU+ _+VE;J UQYGBW!* 66::FT?7"$^V.6<,.R3GU_=P2@_Y&
MFH?9RAJ8$PSP)GIH5A,N+62LV>[417H+Y(#):013=G5D6/O;X*H8?=P<#P2Y
MG/K4JU/):'0=%X LAR9CQV5#Q,1^[QN6O@D(0.V0$:T6C#A?!]T%$3?1A^4#
MG!Y. E#%A,1&5'S(1Z;;UYN)DOI0$N7 ^_'(A/MWZZ(C7TSW9_9'BN4DWV(^
M_I:MGW9!41@T0D8)0 MG604<(9VCR_A=)%W G;X=K8K=-X>I%LZ$'I\MVJH$
M[G "(B<P[3Q[A^1)7R"*B=E'\S6@FC>MP- ZE%4[]4O]VH35;64S%"?ML57*
MBGM(WFD6;OXX T(C\/>("D#['ANVQ+)SYK*<-S-P+;G._3/ZT%TC*.6A"JYQ
M*=>RLO<;S@[7-E<V?N7((''F5^IDE%7KZ4/'W]5O&;S\[<= _8!'9K*'!V'S
M*[/DZ=N2,:NTPG<<IY0<3L;DU>+Z8WF_U2-T0V>&;_*H/#S9KT><WPW98::-
MNO:._Y$=GVPF SS4E;1FL;G6L-OELX?C;U8.>,.T%\;GKM<\,0_28[LKJ%GY
M]MW*-/3QQ)-,W+\BZ]OE Q)(RG S,!#. ,=&&+92 $(8$[S;+*;<KD1_-(M_
MX%WO;4I\XL):E IEW#AN4%_)8,"J,7-6"ZZP,7U&10#2AAP(QGT=<1::%<J]
MRR[^^7:C*'EAIHP; "27(#G3#I065$#\9$9MNQVT!<]843SH#CSGFE6Q3![
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ME#<I((\\ZD"@S\)P!U$05E [E.5&3\S39 EKF5;R/L"P%2)!Q$DB1:]LTVV
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MD(/<.RS<(V*)SAHN&BRIRY='MHN1WS57S66')A? :V4V]\1M3A$1.^8CQM[
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M:'Q6)K6"I +DM]*2YTA*#>$4O>XFZ:X?%>40/*PRO6,)-K ;(^V2WLP<WSM
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MGT H2MH/PK+3CHW$S+?[LQTW059*>^$\+[U'J;[LK$V04S7[8GXK>++"<!1
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MZ8Z^RDC;974=D4DAJD7X*H\;$3(6M ;-VO.[M^OH$1/[6_?$=N#)C#P\;L,
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MY'!F601/<T);S$_G C.0>S9TK@FE5M.C3O-;BTHUC)@_3K*29MJ<+2"$^XW
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M&@E#%4P)>L&WP_C EZF2NXB$O=':'OSR4/)6@,PT(;=QX3L0QQB85NP#TEX
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M181E#^,W)HXW98</"K%("9AZ;)L(AN7&#N-XHER8H@GF^U!@YGH< 2]N#^H
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M:3P%K]AVR[E\C^(QI=X%)S^$GAO1N34B='[*4:JN(^USCW#:+X$"$X \9Y:
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M%65X3%&>T>Z*,RV2VN=08NN,%U+ODRXM__)<37ULGN5<8QN9;C73I5&IO@.
M!QPIIOV0+,NRU;:Z-KNNG_7^=)B-CO5)M<^3]J<&7I("09-3<X=0D#%P '!*
MH8TOP0!VG]9:8(+;?3 ?#;T$XOI0RUFDU8FRJSN QT"G<1PN L2V:=(:[A9]
MPC5Z,/!6R^Y4!2*DX:X)?DF[]L4-&]EZ#Y)+[",5];V'=ST$=)WCK>?J,];I
M(@QK*IX>/6O$!5-)BDLS0';B;(K;>&>!2,LI-M"]9L34G4&BZ:1GI A#ZJ3O
M?I8&+,#,$+:-:71]G#Y>*X2:H<$<YJ7N * D">1TDR7'G#]HD -Y3 H>B#W;
MCF *_45\<6N8&T5M+/= 1M%V .WS-_[,3<K7( 9Q%^<NSP_JCY &!0E@<A)X
MKK]C]DW !.I7)5'XV'[-?;(NM,-)V<3G=](S;/,CLJT:6#N "0^BNK680V2J
M3W+YH:NA;>[MWE[Z9?$5QQ3OV]9I5#D*I6;8V[M<??IN<_D4C7G$^>[CW.;+
M73;!.9BH?^&3(]*_>(5V<1KGN^[*_C#Z=/S&@[O1S.%*]\]MH>52Y_75>WQU
MO?6'\&I#FUXX4?O2O'SLN_]>,'0]\/]QWI5WLM-,R[H>9V0D)VO&28KXSV;<
MD%1*_00;QUQA#?*R,($#,6."*US&W@>KX(]#Q'!\U;XY186/1..JW#,,2&N_
MQDJ'DAAY\WXI">M%8H(2X^-";S@[%4&)6(T36G?Y'2-VAS55KE2_>C'J![V'
M/=-5G/FTQ?!^L(VFTCW-<T=?59\L)=N'Y'U>OJBOK&[3XJEI[I8Q-EFZ_G9X
MIGD5H[T#.'J35V)^Y,]HP!@<NCM?E:QWH G*%/THCZ>',N9LV;Y\K?%P[3#J
M5J?"5"YBTKM-:1=I7&\:U)'M-5_T-3CL*[1^+,VF9)J=(^&OE4[Z1\\4-H?]
M2J*IT05$96]Z+LMRD*L2/0<464GOI '%N.8,?#:<"CGHBU(<A7.-J, G^2KD
M56IM;*?VVZ7^$XLYJ[7()/WA3>M&Z>IL ;TK^U'_:%Z"<)E\8$99^:IW7T;(
MQI=SU?5/2^\1G0^VRLECX@DB)T]B;8<(_3JGUTJ;WR?;DW&5?N^;W@\41-S)
MJKYTZGUVV/WT3W+% U^\A9-9Z?"@O 9857/$;_A4=;?I8?GY%+?7<[:Z+H2-
M$E>WV.2M^]Y9:P.7*O'EW,>HBTS(:H4H5WR+1FDK2/8]-JP/GFH9F$OH2$3!
M7D'8 7"7.5.@_#K_['+#_'C''I9W5 K&CJ$U<RAI9H'LDX-$G6@X9L!ZLY9_
M16B#!3HXB2S@'SK-<5IJ6(^G1_ D7 2'[H4Z^4[:N"M-NKPX6*9\#B37@X!_
MITS9^T6$*G8X#1QSP&G=O>^RUZ6Z@K7%%Z,?#C:4;U@ROAL\[M;VY8>KO?FT
MODFR):>>#*F\N'99AGT"FE3&>.1U:XP293</REE4@1I0)\]T/OY[\ZMLNLPK
MK<_F :J]]]9:O#=79GC&WM9W4@]IW,EY>:SHT+5QK?L0;?71Q_<+]#X0< 8;
M7I/3""Z>+7R-[5.%:54FW=16H!):1!N9B 1,D.C7F@$:/X]J!]<%BT%]-0GL
MPE+[:%$L?%49ZU0W?K/>-2I1O]-[GJB!&M"QG*:S6L[QGG&%F'[\0P5%Z$FW
M_ -DOA:;V&U<CWN-[XB6"JD#*Z(.%5#O9=]DC'53#\&RW-US"'<@4RO2XDLS
MDK_693H#%JC:374Q%W@B7Y&0]IS+C3X@BV%")ZD);O4[G*, .]DT E187[,D
MA!Y<]PY>:\R.:#WPL"?NJH03HRP^(ID.=AXEB"BXC(2_N++MPRHLG9CQ6:I]
M=JW_9ECHX0PON_B;+4(I+0$_]GY?&%MWHT? 3>"1/\?[JE)N%A<Y: 0/EAV"
M&J[UGHU):,JB5_C@MMP&^= =0,"? 359A<P*_H'IV?5)E8_:^&"^&"^);T;Y
MMFAN-@BNTT'I1P7-[,?L@_*5":/B"Z)LFW#M(T@<WI[QW*!L5X[LXV>7%I]Q
M+R6S_-E.?SK,#J-,&-W43DK,;?!LN7SD(ZY"(-.Q77P9O,?\L"?[AP,[+#J:
MJ09AS">F6C*(\?I]4].A,G;I8]/ZR6\6HE)TOI[KY!DJ:/JIALD^[Q.GI[IL
MS5D0[UI-^[FKEUK:%_96S=XYZ[MB30;AUBK7;\,1VJ"TN>:ZAAB37-C[[Q>.
M)8;M[5,-*^K:K?NI4@[MMC?4<KB^BI_\VT\&M_G EW]OL"2^AG#=+PJE3:$^
M=8ELGK2)H%?<YCOJ3U\TB[07',<4*=X4RN#0?),K,:VF*&"$6F++ ?9NS"[N
M628PV;L=(K]:]H'!RMY?1Q,&B@7?&W.:\H"P$^Q'$"F?O+VA:CE_[R:5"( C
M1B:9%<+>AS#U/QD[2VS[ZI]D.3G4A!8:S!QZ_C2FLJF\U?G,7RI[QE?#%66N
MU&(=R81&884#\*Q>8063R]J5U-HKCPE)8[+#>^NO7O:XA/9PNR%S>&+D\K#^
M@8<:ZKNNA5\% '9]!0  =TQ"[7N7M$/JO+Q]9"*WUJ9?7+O#_Q+L<+WGXK7A
MNPM;_DZCRW6$$O^J,8H5^A0[BG9RJQ4B (%6&%][BFLR@E:WGT5(H,XS]0L>
MPK5]W9EOER"UX/B3T6).A2]"M$\=6'ESHOV.VVB(V,TLI_GQ7G"M88HV^B2:
ML@.HMDXE."KRO^0;?"#Q\M%Z'LAR3  H;A(;PU6>5<9#T:+,(P6S0 EDE5F8
M.V%\':=*R(D"BR[7/] AEC6G=!5J/Q6;MDKA:>?:W;W^&_;"0Z^,7>*_[UHC
MCZ5Q9-2DYNUNT6?[*O- [4J*@VES0WKV(.NXM5--2+U&8;L#OLO1"U'QJ6.R
MS_L-?BWT;/T3I_K][PIZ].TU@O<TN'-[*AQ?[2+ZA5:D<[FT9*UW&&ZK&WG/
MICRBX8&)]MH.((LG1(4\,A5 X%X/7CTJ A@?3A%&KG06B&&@0?H#2GF'9L R
M/<$4@AGE\6VR\VBZ*/W>T$T&KZ0T%^-7ZE@#%S]HF5>Y%9:92^3EZI-$T(,0
M.;0AZAH#GT0*(!WB1C&PJW9SCK$%!]!'N**,\0Y%38_1B9,C^#DV[@%%W%P.
M93JJM$$8DU=+V, >;H]Z$S0901\MK8M4=5[/V,I@O>'E-($XU[AB3,-6A-@*
M_R3#/YX4_6K%H.44(WSLZDJ#] =JP=$EOH SF,"B'?J<AC;U$ES)-Z+RSGF2
MU\.G%KTN-=0_R]3\WK*7EUPURYZ816 A<GQ#Y(^Y[*=\"3:F8T:)[0FM0L(^
M\H486['%S.AW9)0=3:48J6 Q-.[#U,$5[2KJ>Q/LTE_:&K@#4#+V:6)GZ4?[
M35BJM2PU-G-,<(HSJVU(!%I#K.S3<W&OLL91O=%\8G/>-!?;2?E*_"B@C.@S
M* />PR;0#D#$B6/.%J8A6N&8CP_X>8RRB^P3+7*\DC]E;YZ*RSMV+J.O*W*[
MH,.[_PXQD4IDAB3,I;BX,/ 3=0CENI,[@,L_^Z*Z5Z=O<D#LJ"X(PWT@CB*F
M+[H7=69DDY2R Y#VI88WJ]D/FRL'0?9L(F+0>X8CUB78=H)K5=[TUXQL;?J/
M:PVI/M)=*S893JE7F7:JZ17\WZT"O7AH*GA<Z3B1L9"PGW0OQ@1W3T2C5_'6
M_*Y;%>8EQS3O:Y0':-1<Z2W)!?P]6D3M!RQGP!*LR$=J0P-Y!>:5M^$D0NF[
M;ZM:?Y-^\D=8P<-&WF[//Y8D>K3JHU@V",3:$AF2W+L#^![\;OPJJ<;>.ON%
M95F(JV+5EL.7-1:LT7K.D2L!I+UD0:2X& XHJ('R$9(*%N6+<X^QH>7(<ZP,
MMB@5!CG\S3=(-*P2&67%CF"B-0_J$#R;H@)A)>9U0*[*5G_(\9QEN(4C>3W$
MUI >=RNH19ZQ%3\;!1$-RG%+@*D.?^N!%T-9#1%-V1+5T+)TA<N%*0N9B5!5
M#<\OAA)UH40!IW=<"IG:?) [6+9:_C;D^K=&@S5Z2>;6O>:,!ZN23I8JWE4K
MVSN ! C2R5)RWW@$#]..;[+BX HN8I0A<10@VIBKRGNY YBM]I5GQS&)70WN
M[:3]OG^:_.E''^KKR-F(]'/\,.;8+59>_V)O?1;1V6P.RLKPE74UE%7650+@
MI\5UST2-:J88="TFO*^+#W!Z.'PI_<S*4)YGPLS-AZ&_#(^1'0:BX,,\E[5&
MS,>S> ?7XQ].2IWOU4U.;PK)F3Z52X'A!N9_S<VA''EO3$T$.&3#JR(%X@6:
MMYOJF H.7'\D^,U< 3;.EQ\+GX;,N3_B*ZU,=B>A]=C=;6BE9JS-> 3X\'4D
M"#)J:O0Z0R23\D119S\V<K!S#;.//)N0PC^.DF;C&;]8Q;P";B!M/0%<B^^"
MJWS$[-L!!)(>WP,?0472L/N7T0 R0H>K/6>D8WX<]L/J/>-I3L"+B)*OR-?M
MUL:13\K>>YY*M:G*(17ZQZ@/7DHJEZ_J3/$[].C.-77+709QLX#&!Z$?\6>8
M":V0!/.S#.L.R&X?),)A6 ^;I"3-!#WF^H11^S3MA5U']"A24)D&G0H5R->I
M3J-FF,E24_*+I_C#;48NAY."O^76!$]7YC0V1%+P\ <H:[61R>?+QBW#SC8_
MP??$TC/20VT=L];L38CA68U%OP/_T !D]^R?X9:* J^9-\G,%<BC>_./-+,E
M O'+?(! ]86UDL17T1K<8"8IE:M9?@$4MPEWZ=P!' D7!4 ?S,3BEA\D,G47
M9_29X7QM9DC:R:WXJIMU:7\CZL#^"&&D)G6]E<+6C.SF%#Q2DF/GS?%$6>]X
M5>NWAB,&1+R_P91,AYH,7UE$EB O!SN648(M+)J3G4?#6Z5S]Z;U^Y=30!GA
MY*/H,0:8*_$ KC3.NL? IF*@H#_?"TKR^] J#.LDM#37=+3I-&.\/:T%QYB[
M4F#'4&&7=>;+,W )3R(XF,.=)P1W4G$Z9J8?<:R!Q'J<C@"6V<#WVO9(:HI_
MZE?-/:I^7_&OP#N2,O< _E,_U,J[I4Q4B>@<U%F["GKIUO2RY)F?M6&LT)?H
M@U;:GL6O<QT<6+;C"QM>W_@^X$!0DB%0 H/ LM4"D[6X"$&^R_4:Y^_E1HXT
MW:0*" &6BEN/,35B\.VCJ%_R*I;,]S/KWS>LU2%PR\:6&S)'O1?E"X?JX/(_
MOU+Z2[PL(R5(O;YG1DD!!>R(J@S&5*<\(A:/"4E18%4.U8&!B^/FQ^3+NG@J
MM#@BW;ULFCW0D:]-JB>OZWLK>)H*:]W+]E4;T9%I=Z]WF8#FH+9D$/["F+]S
MW.-19H560T$-IS*+NWY]^]8 ;?"O2V_N_X[3'UFM9UK)PQ)]OF=9]376BM_M
M5L^796QXY<W4*B66G*K&'#;8FGP+S2HO][VPA_"L/0+U+KGBR>O(>ZE&)>'8
ML+VNAS^^)RH4MYS"%]$5ZW[Z$A?U'Z=#FRYF@\R>S_5+EU*CRDRF[]8WKT3U
M>ZK\?B,(N114)-:%B>%*@JDZ%3<Y^ER982Z0(62;W![)-V.[1,R!!$*?4/:D
M*92QXFH@4W!D4^5M4&I6BWR>-NHLW""CE%TZ=V'L%G_D0_KPC%RATH?2&:XD
M([(3SU;!I)@;>;*%K1(Z2-7=R7J*%IU@,;T45>MR=M< U;I5#@4*Q*WPC[^[
ME.$3/X^?8[!' ^-_(TH:DJ\DJF6Y(B@K^"-!AI.9^;5114O9#UI>9G26+6<;
MPPG;*8_=563.>OKV25R?[+P#D.C>6UW\ZI;E#0<(ADH7=8N9H;@.A],=A$V>
MA."4234QRYK>R7=Q"'U"6-?*WG>Z%1:J%Y1.N:KW7KOA7-O24 '#7QMW'>[=
M-JB<BJP.;;>W'Y@Z;4 ;AA:_]*'A/F_874IWKPG\M8=CO]CPI42(*YU6-!@Q
M#6M-1P]1JMVJF6H.@P2Z[XKKF+GPDKD8&U/.O6QL^L K.;D/R=6&O;%Y<\!Y
M>7KC?82L?]SH.W3&B*D%QY#KPON \>NW8\EC=BW?F]G#5F!^F9M+2#27"JKW
M:YUT;TT):WW@@XU!2=%64O9/#M@3F4HE-#:NA+&06WYVE(!?Q5V^[N4M-Q6Y
M3OE*?_C\@-_NNZA9/S>)W8V7,VW3CFOL3I]-?W5:=9?G VM!M+TZV>$EB)^@
M(=_K?5'WE3)+)Y=Z(B+/R60MS'IUBO>'JJ3WZSTJ5GUYIJ<DVJ66G.T-6R-L
M8$S $+.#U&O?7I;MG5?O65PO_CW\]'FV1E;_W<:*K0:^,U>*@6@UEQ<$T2FT
M %_%-R )QKZ)S+#+["U&1I<;7Y]L:H: S4TACH+IKN:)]W$&Q'WEHW[Y<Q<^
MY/3.VFG5E]^,T*W<=>@,OY:FVBEGFB$O'I9O^_07)7\3LBJ-=FYE(9L>'R\V
MD>F]B&OV].L:]4?5O)-S,WD>WUH1GE>)BQ;W*JYW(VUNY3J]+O?]EL1,V@HG
M:=,Q#C"=^@?O7B>=5IB.A(QSC3EM2>JO=!KQ*WS%Z!]S%*ZD7=N]?'U>K0 K
M,UOD1S?*(R!'8!3Q'4"PF5#'LP,GT\?L@=Z\O$U[\[6QGY>'QF8T/RT$$7OJ
M5"W3=U.:)BE'T/T-HEVD)T!YU$F.$,KV3Y>'5VR8@,5^8H(['(&PEK,CN'E^
M!SNWS%ZQC=\YEF7H+B.3+9\1I"0U6I<7Z<$)/Y/V!FEAUU*7)7VT&T*6?&:A
MV?73*I61%>3S$"2A2P](:?EY3EG=\_))N],F'K%'Z^+^3K_T%U9G[].W'UOV
MCVI9NUT]@]_*SJO4#;N3D8R(;H A(@3\+!W?A_MBR_88S7GS]KQ)543XG+-F
MYIN6ONGDE7%[QWG([)=J**./)23P&(CKSIS B+(5J-ETOS=V3*$.XY*F+):2
M\##*L1*%&(0W6="$^U..9+QJC0Z%2\T4WO\^-87[+*(ZI)D>G4P;[\ <Y 8R
M#+DRB&Z2""C$U&F6%SF+;8-KML^HO!O>5-\8D+2G#CQ6TAO4]Z:(7'>$'1TG
M_%/79\?3G7(C[^N,V^Q/F?*\?OUB3" _97U#&WB-'$*(MK.O)@TC;J9/KE]I
MK(Y9:%N8N4J[K*.UD$+_$<?MGI:L;KKM8)M^SDUY>(.M;?G4[1YSHE(SI+Y\
MMW7(.PW9,:"J^M..-[:/-:[MMC(J>C%##_<QL=0V( <&4*I>IRH%GXW!R4A)
M*7F;.2<EC>=M;N%"$B,#9[OCYMAJC"W6%B^-"V'B;=E15!Z()L.5P+;/B#(0
MB:9AKQ?MH#3@4WE#;(N\CP?4P+BT/&B1;UC#^'5[F-M3-.K6FE(7^T][%TD/
M/=T7&,C1$*#W=41$Q7WRI1U _!:O($3_4I1)-B<@R9OEG>"2JN[G\:,AE3:T
MCOO.D; Y)W0CCXAQV$Y]5+A,NF5<A2U=3KC2D,IQX _5$%L,9-[%>^"U^*/'
M2 $-B3Z9.LH3&J<GJ_8#?L^Q:GC_H$ <+Y3T./H0L@PRWJ3]FIW0D;^+J;^
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M]F'G7K7CY-K=T8=;M]N7>7O_[K@/^DEI(^U!&0YC AP39DZ-M)QA2[ "1_5
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M=.:BOLG[68GE$^HVB=(+-O5=MAMJ,C+60RI1@5C[=S9Z&P99.CGAP:RKMK=
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MWH-? &D=4#!T]0[P]G?U]N$_+W4.4+JLK4>Q3F?L[.]])S# S=L+ "^6P[4
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M^MW]-4=Y^(T*H .8@1, %\ '" "B@"0@"R@"JL!%0 /0 0P 4\ "L 4< 5?
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M'XAN)L!0UI.>!X[K(0/[NT5'RF'-OX^U<<3,@]6VCX\$_-R%T?T7A!%.6T-
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M9BJ59#=-=ID #X=7]BG>V(;&+W]4;-[0*P(Q8)SX>:TQN?Y0G>':"HC1F]&
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M*MME7<$G?RR/-8G$5DZH"TZ'%UOW-/@\\"G<,=<?EEL_TSUP?5CBSC8!:O!
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M."W66R<1J&T>1)_JPW^FQH[V?1C<[4]ZE7#IBJ1W+.@("?\WI%\;GD F.PM
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M67..&[Y[2[O85,HSQ,DD(VOQ@TW6]<$ ;6NQ*=40?[N!J;,C>/KT(XX*]P)
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M&\^3?&?V.,Y=EQ5+?<^"XFDS48>G)9BP)T9@^M6[Z^9&]CNTI]S&W2=.E0M
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MF9VX(W%6).!K.G$,X?HU*[:HU'<)[?W.HG>6 C@2$W :X&Z6&YZY$B64X-\
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M7OHM>HY.HX&]J&#T*1W[=HUGURJ2+^'R0VI)Q$$>LL^L)/!/ZS#N%*;A?VR
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MR;)C6!PPQT&/G9$&[P$NK'>N(_9)U$2:XC\E)SKYN^1DO#"-U_M#6FS9?4I
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M2'H%=-'G%]I]=>/J#- =$K71%G.VSM#:96,Q_#Q?I?A@1*2/./N[E\_Y*=5
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MZ6PWFZ$RK[*WE'QQQS6;"XF9E*!QP3EQCK=-?XL%8QON0($455TJ%:O'XAX
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M+=8A0%_FY#W$E&ZRS- J21J#<CFUT#0Q7:[U.FO<5XZ&3D3(8G?R ]LM^O[
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MOTGY;; Z%XFOF)SL1&IHVTQ/38??VNW^C\A(:"G2!2[".DBJ6&G E3?^ :$
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M7D<A>"2$FFABH'CC;8+S((FE</+RD9::=_'LTT>.QMU5<WWT2T;&\ITZQB_
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M_).3@V/%.N97KG_I7]-3/?T\[<KX"RU:OT<.*I8\]7(#5A4:3]?V(7J/B+=
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M#Z2:;[M@&WKK3R47N[O:;V'RJ #AF"@'B2'',Y3$>TB?X+3H.$Z?'-$3B&:
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ML'U".<BCG&A/AQYPD3$4!:(V#YMD=.(;6F8^ZKW$WD]K\0<"<G<-A634U#2
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M]?6^!R$2M)%W)[C9FJE'5_$G')FTMS\W8'_5(^60&/;G,O%.AD"?:"G*^'T
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MV)PN='SWH?6!TW'BQ[6FU%"'"]:A#_!WL \>A1X_A\7@C7K^'3CISJF/-,[
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M\[&%P4/,1_ F'?L]12$93@,M1E<+ IN>E]J?3'_Y)?7Y1'F6P\\H_F/1<T8
M>ZS80?0683G'WEQ)5R64\:2B)97'( HM+=XR1S< ?"IX:HRMPCVB5WHD;4)G
M)]URJ!;G@]XZRO;1CJ6]J<7M8K>K5C KXUY=O-036F)[EWV7- +?O '#H%1(
MPS[;H29@B_W @D&SGD!!/$390S3A583QK/&RT .>=G((/":4(J-GA#O,Q^#Q
M./VE%=VF!GV%BXR!"M[;.X,>%_YN0_:3 8#]&2U)C#*2'+FE6'C=<DN*,+M
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M8?5;B6 G(9/PR+B5&"\J.1D<ZQ+D^[X<(>@>I!VVI@U$_M@5,4P(.N0@!.W
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ME&=R;>0(A>ZM&;>M\4ZOX8,/:>$."9+6GXV-K6N54Y,KHTOV3B[(R2=H3\Q
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MD$87W&7[G\MV(L!:AIL-2SMN7K_>;'/U5LO/49 SBGH4I:3@$ );[_R8^:\
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M@&(HK%7+@BZ0ACDV)EUG]C.3KGX(P+B\J8TK+S\12KAY\(C1=-G-!Y&H8%$
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M_B* ,*]ZX;DKKXC+0G=W:O$(E-LVOAU\27"6I;PPT4-6J\Z\/D ^A(&VDX^
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M9-\K$$6??=SL1E\?Y)K'K#4X=6UJIYM$KKZ'6-YR97ZR/O[@[8YDV>;Z=BB
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M_SM?K?V?NT$/DWAK]V@.?L2"'0OEQ\BC$?7/?N*'>GHW7TLL:7;P$S\>F1=
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MU7FHC%REP<9U *LY"Q&+/<'NAE[@&1=*(-*/:$QG!J!?6)N;&*PRYM8++K'
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M$+Z_L*90Q='I[C^W,XPV?U0"T;.30M&"E)]V\ZHE$#<\ISNR#RDOIB.^!K$
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MH,=7!)6!]1TU2"4L(ICGT$DU^8 U,'V 5>; 4Q#;&P-Y(=+XICU8\!I;$.H
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M8J=I,L6G3ZP%;I]M^_H3#Q5"=Y\>ZK>^R@C,/FG8<P+?BQQN%<NY\HZA<G>
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MG\D<W^ _3&V60*+K,C-%I]9$XP]$U=)JO6]?%I[=%==(F_&;%"\>77#79Y/
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M[BJX=QC .VC*N7"URQ^',8$N_578>9,NRWYR4I,+:DC<=4'=JHG2\])T[K/
M"=_L(S[V!;$>IW=%^/T4J#O3$HB<A0$*KXCUOV]@L1N+C.H<\H+PFFH>5W;S
M/=6Y;:Y#OX(UK%9F6ICZG?G0NUGUA>1*\U-)N,@OR*T2"&I>3[SYJ31[MTD?
M=@W7AX#BM-$2B ;B)C&:R8K%*6+$G<U:AP:6OQ\,M_$.I7L;O>45&.A6V[]P
MB)+C<XIN:%18\Y)23W2L \;&'@ENU7U825!NQGO#P2#9EK&C?'>>7B+MJO\(
M$\:,>V-"W$A!;@69O6RU>05$[%Z0R_XH/!E0ALD:'W* M?[>_;SXD8'/ #=F
M>1.Y^.4Z^S3-4L'N*R_).>D#Z155S^Y4-MCWEO>-4>O5K97<!EJ+O0JN?[$:
MNE16MNTRP7__8$I^7%GV0[NS6?<(!Y.<0B?Q%5KFTFY%X9MML(&"8-P@[57<
MW%.@BZ]/ UAS'\S7!023A)$\M;9>^=GP0N(C<U/OLA:GV9]XIU&9JUN134+[
MC+6;#YMO913^T7_T[3V<BC2U[E#UI/9Y!9]WY+ERH',"]C#N.*Z+N$,/A'(,
MCK*1B092=^=[\(KJ"F=KQ!L90M/@<DRF_1#6.V\<'+%]"8SGL_$RZ' )) D^
MOQ)IZO0A [/XPX@PC0L%=5B__&4C+^!$ O7/9O,(S=3CP& _Y@1;IG/N&^^>
M%6=LO?4'(:H4LVVHQ\_##C/>V9IK_*JV@3ZW>XC<\+ATT[QW72S3SN+KJ?O$
M$'SSY@4*<HMP'9@NV"G%Y6SR8A1^!_XF*_XKR@O^.HK=W1,G'722#QO/1;72
M5,G=UU?M//7:<7O4U/?'71BJ,*RRM=[XH,(],NL$R'U@+*,Q;*HJJU/MZDCS
M](\(7U-,.1]\WEJ[;*!0[E5G2XZ-CI/AQ9D>E>=SHB>7#IP^8&\PD%HNHYV5
MMHJ7HM$U&C-VBM\BRC'?R>N8?<,D_%+,Z/<T6[0=,"0G6 U5YUGY%V/R9KH<
MZ,%-4O[>R@\9/QCGT<<!5A/O&C2Z%IID .@,E]4SL6L+I9=1]2'I_GP[PY8N
M._)2E:%%US6T3 Z-"==+G5G ZXX?XRY5515E3'(\&Z9RW733LZQOF:+5T%\J
M&KRD)&_!V2EYS\[>7-\#Y[!EYOVV;O?+"T,KJ^;'OB\L^I=WA_^?WPUN%>;S
MX;]ZZ.#_]2W,B :SD#E5VI77RRMF&YG]H9:*HJ..",\"V/!G9M'.QHTU1SY:
MO#+,;TQDNV\V\-IC=KY2>?<]EZ9;M#3:,-Y5%)\]@>_$*V O2M,_&+/(?PPV
ME>#ZD)25![SB:-JU:?&^7DY2BC77E9#W(:A;G]N6NTT@DSX??60$]:ZTBS.K
M"I"!.^@&W6J-NX<G&QC6JGD-0Q)(.JT<W>WU/ZA[LZBFLNA]D*IR1D100$&(
MRB0RI)1)!I-"!42$""A3A)2E#"&&%#)%"$FIS&,) @I"5":9!1(B$!(A# HB
M$B8)0DBB()/<"(0K)*&I?NK?ZE[_U?W2J_LI:YV'K'O/WOO;WW?N/GNWE)RP
M/1$-E.L//7J1VQ#&]EWP'\\BV[Y V)$\+\Z>U'K8_.Y(<DVFYDY[NU^R!QYE
M^_UIX[[M_JZC#YVWJ.,8J1O5N-1>^PNQ&P(X]\O6WK,^M6&+9C;8-0D'!;H9
MTC-I)+X?N9T9-RO4= -HK-J$G"C[>/KYY]?Q_5VBG#4SF"JCJ4EHFY-5[ 42
MWAU93\C?8\A,A -N*(X5;XT%/P+>[(+M!T-YT%32-GA0@;$H4O*,>.J;= ^8
M+[2:*F-Q?\5,RN3S56(95K7_6.N:BW79LQIZ]?D7/Y)9:ZKUW;R)( G9;3CO
MHVW6P\EW9;,QM9A%6@GWH:P:XN&EO\L1$\[7!]9NNF4:%QCYC[9NAT:YNB2T
MP*.$F:@6R\*&XL ZI%/57'-PEMRB)"<[P*@L!G-#:;+\Y?M&#C$?JSU49["V
MMK;WE9=7AR]_SM_S6;K]L<OFTN. -'=[WTA9S;?U<&KV8N&3NR&D\C&O-G1Y
M$!2C02[[W!MB'=(63=)>S?3B7'IW=G#2NTJAY?HY"$!VE]00'(3YHBC0EE^K
M_IG8 Z=<C=@B%KBQ2-YHK/080;]U-!R^,ZC9N570JNRDV=V WS??00*R"2?
M:IYC2M,(5 Y/OCI\K('>Z-C=.&1@1"A:AL=2N2E$>9"TE1I/"G4[K3)B(8?H
MACO%2N=YN/@#;>MK_XA=Y)KQ["6^^<)8F;R2;00AQKBS-!"FSOB8W\[9?RZ,
M>3"0Q!E5&5W'OADH"HE;">:4K(T+M[0N\KUP(-DU]<B+V0]EINROJ<?T?)$3
MYLI9"6='*F9+22X'/00)Z5OP\!RE1%0FG)4T$_3Y_?+X<QNB7%!>2&9!]F[*
M!'#WS.;YEV&+")?9S,#'*R=(?HO>RPCRM<PY$;(OP&/$!*&2(F<WH)/?EM<!
MU!0<$2H!B%0RL!40R98J7;6IFS(["59"A"@$='PI[5.>5 ;*DI#\VG9NNL:9
M9G!6&"1H6X],MD:6X3W%9^X:, Z!:L[D*PT#% G*@]SI_;7SZY?<WRY%ZQ_3
M;A?=^;'*V/">6'J?7&@EO[VJ8 GCI5,25=[9=*;3P=+49'K#S.-.,NGC-:7E
M_H4"X11QD-F0T,;-"&C/J[U70]3%:SH(=8JF)$%JCZGR<G/+71\QJN?S6Z*1
M*2G19YUE7U?A;C7^P_4R;.5F'WI\=%WU>:592V"XG<O3FV=:ND)<4Y8.:PV.
M-M^P/7CERO_3LY'_4=F4]S\._?_WENY_Y?0/2.T[F( SY*<Q_ %YM;\;LEYO
MC4+][<':4B7_Y]6R0M+;&;--F;H<JTT9UZ#"G;LW9=X9LDBB8SWP553"GA.E
MS3EV5]['93^R%-S)W+6W:5NP;]'1U'0;I:_D/^Z\$_3_]HZ?9"T/2:6?D)K$
M_Q(.C3W0X7T>_T+?[="CZ^^>&?*&,W]34-R=]]'NYK$U[-$1:#+Q=X(68%9J
M@E CN(+A4Q*_ZA>M/IJ=,'.@/V'5.,#JXK\^*7)(-TJSV:"UL99;(KU<54])
M/?EW2/_2XNC&:9 D<AYDR(/C;>3MULQ?\0&B C!4V"NZMX6<*3Z80E6AQ^+Y
MJ8V,_>(_8^Q1C?2&9):-D)PH/O92'7D)@-6%:+1&/L='OK',/P^)-3U!^0O"
M "<VH,2/BD0VJA&W>(,/_<04G9!4$=7F<C9EY*'$_XK@*#MJ2^<W911*0230
MPBNAYY4^ !@L5Q C0.S#>[B,K+8P%8,8J*35-$5#>]<FJHJ"=AX+SSFABXNV
M;QPO4\*N3XHF# =FZ#Z>/7]G[RC9?3X_ES/D$LMSO=YGEVORZ+J%Q52!A0/'
M./BTXYJT1]3KVD ="IMO\3F/8-#BO_>L]_#U*ZUZ'1-'D-&5R,<:%XT,9Y)&
M//WC)BUN^H7YNV\3S!%_!W*2<#4^\S ]8/HAAI=H&$QP#"V?C_*+8R94USYJ
M3>MJ,AT><IG]W?>H(<9P ]G]]S.*P90__>:4?%=&//D TV\I'J5.5 DLYW'C
MB,=!QV+\>#OQ<"-[(<P/F(E_]G'[D(9:RL7!7V?S0CX^I\8<\9Q]XXFDDK/]
MG9J[,,*$2Z"ND"5JW;*#UW4\\PWQ$!"03C0F3I UK%6$R_S5A S"I>:=\:;P
MN'YAEJ-P1_Y4S'GWPGZWEDV96 \6:C==FT?>CE[7+DA;?:^*&[?-COOZI;[[
MSB-<- -IJAYEMLK,=%B=?*<VU''FY<:9:"_GN$M"EV!VZD&#HL!W-(NK][T)
MYM'%Y*6 6*(>X31X+_1NP!0\<7*;D#I9L"W2,JXVEH#B;<HH7O\T[G0L63_E
MK0GVG @9J/WHD"#'[^+D'RZ>KXXW?Z(ZG8XYMWSQ@4M=_K7!ZH7OJW*G]5ON
MFLJJ^=C6>"":Z/4.JM,CDS^K:I4_H/D7O^>QO_SQX<_<@"_F"R7EWH0CDB+I
M,6F/Y18!2MK0(O8P*>8IL&W7Q1X@3F@E0@(U:5 6-[%PUR!U";2K6;"^J-(&
MWV?M;XKX#=^X[-C*!*25!]!YU(*/+8.XQ2\_QQ]M[2:!8"+,8$''N=(]?CR4
MFA@I#.C"J4_@H:(S(W1;H5KG ,?S.@J3MQ9/-)YTPCW[IOI7S1,>?#=:_K@7
M&,I2#7B"*_'\XWE9<TO.]%QHKGU-CV%X*\>#O8YA;\K,G.IHLM0[)V47SSI[
M=[H^.J9WYW7?R71$-G+"Y2OA\PAU4^86A:2,1W:8YW45_+=](.GZD+55A,FF
MS'[/;^L?"LHG SV^&,L:_C72,WUWI;=>(;&Q]:+.,<_8-V?RH(K@'8$C<V1J
M=,6!XF/DY*R.\$BY5I?E.%@Z$% X[I6\*7/%@</^X*0SS9GFNCDF%6%V+\XD
M?[/5<CVY*7,*LI>@LG&.V 6(C1UQ#W1YT&XOQJ]@B\AAF'%TCB95S.L6%4F*
MQ9'"G0AA-FWQE]-X-\_A\ PET(H'_\?:6*C"7TNVCA3NZ[TT:G!TJ!CH'WL_
M.JA-?$%L(ZEMI22<!L$"Z%]X,K640%8TP>US!$XB$GT/##&@>(Q-8YVD1'H
M_\#W-="=RC >4[?R'2VCPZR$$75F3?PTJZY&7PVA4R_8/NY*_]A)7:8XM??,
M3EIB,3]G(W^@8*D?TLTY#N?")-EVY!9=:/K'D+2GQZ6#KG=<AFTZ+YD>[Q]*
MU+T_MRL86YK,Y_!/S-!>W[^0MWOJR;:'3GOK<M(]2]*R!0\//QQXH'?2IARS
MC)+N3N(OHAD'Q8&@;"UJ,JA!^A9%Z>_,&.MFK9<6&7]&31*L@(5U1 KQ4%NX
M25QQ-@7R*[[W/%!\Y^V2UBN0:('\9<ACUO9"=C[RYQJR;-D7-UP05A'M_7=Y
ML,>)4OY::N,CPL];>4SD]?_NZMW[7][-4P(BQ0=K,"])M^0AU26BHK)6;A+C
M('KP,]H[390==9L*3V;(O6+2MJSK])K:2D.VZ"<MEF*B$PM>9 _]WG==L_],
MNV@ZTX.Z2&QL9D[Z^=:^>NY-@YK7EUD^I=',M:Y71UOYCK06M!@OJ>K_8/(S
MVC-V$=^2#_XWE.@(86>+T#RVOX.4UNS1+I_H^PM=N)9*<.)EJ(/FG;[*0M/5
MR:+0(CRK0_6SNW?W_>^4%-1^+TS>3<]W&)S<9^\'?3=-DNG0!Z2I9YLRRO0;
MPO.\V@?5+T##F!+Q+2$BG;#SA0T/)R=V$RHQ61G[9XGJ0KM:GB-YO]CW@=L#
M'JJCY*X8?I"H_5$L&U+B>U[]\Z;,F/=3X2>'2*/DV.)'SX:R4J(VJKU:*C'4
M_-8%4>N*A<8-YZ<%ED)1>$RQWLOVH&*_124C^\,.;E$]E./\J>+\.PVE3_L_
M5>@+97FZBR@AET=>Z-[01S?/I##DN7@FGQ1OC>/#P<O6/L_%".$T,[3X6U3!
M(U58$A9@MA&UF&"V '<PJ#F]I!Q1"3)ZIEGM'.VXDK2G(L1+WS\R-W:VRX_C
M!-Q%:)E8'^AOZ]\I/@DP.V*B>?9I,#WQ^2&&%@><7&ZW)&@H@FG10"/K'-"=
M0.ES9$EUDI<[I$<'OZ_JD'V&UD"DXS^<.3/+G.?'9:RMAR?33SH;>=0/4",F
M1QOJN;TWW-X#RU_2*DY2]0;+5:TKW()#BHQL _S9M<X_(AXX477?P5##'/UE
MV@5)-=&HM7_1L 3?S5M[(-;G(^Y!&NP?,'[7N8<KGP#OJ72KCL:),97SECO*
MJV<YSUX-T\]B7X+>$V&S*R\I\X,WPD]>_YQ?,J'RB-@//\!$<U-(&E(C/-E9
MJ-O>:T7:+^TA-T#3Q%#>V5 [X2HW@6#!ES^"+OQ]6%-?CI8FDSZ\&DA=6IPU
M>):\<75PE/5[9P@VI!2%(&;O]G9V/N62G%.S-OVUGBW1R8\.[,6O.U^]L>O:
MTTKG8D67KR%7)15/BTOY*P6Z&C[:$0551,J [UDALTT5T0&)RUN*%]\0]$7R
M^N/S#*VN"G.3Q'JUMCRK;$"4$(FKG%^_S3C>Y*4[8*+^UX</,7"O5FI3P]"-
M@>]&<34E 18J>C\#IG!I4?(+2\_$$6 WT+](5),4$K7GX?NDJM(>F#I8(C#T
MA\CA!7S*P_D<F";XO!@%"JX5;K23=YLJ9?:Z-P\%KZI%^T3; 8PBOKK1B?PK
M=<C./<[%R!3"N^(BK#K'(105\;2@:B4VO_XDP_!*^:ZAY*M?=SN[S5P'7%*?
M%L_>X3XTW671I#]4Z:S@FE6W@;0E*HKW2EX:$G=*NYBTG6DXAD7@ILPAQE%0
M5]#?*0=G39Z Z0Q2^Q=Q!_'3D'V!Q-^&JJI6YN?;RL#S+D+LU^$/";A;L#:-
MAV63U5F7&CWVU1%[-V6HOOF .6_GXEV@^PWW &4I(X_V1CXN:<.& !5"$U>=
M<%=3.LWR^F/=$:KXT*O-K:_KADNHP*9,IYSFM==Y9XQ>1*MK=JE>=KB3]&5A
M<&Z04ATAT%;Z3BDA.K:T5LVHH<+&V2,61?E76I5,GB\&#E5J59R[4SI5\9J5
M8QXZG:[!;)5]V:.03I^MG5C7_X$1Z"X^W[@L_2#5$(:A#EBK  BDL&#M33XS
MC;0WMRT3SX;(>WW^!K, =L82'*=P:J7558XOYUS'.X4[G5O8=*\73B_&N&>K
MV4[/.0^/W DF?IQ4 L3$?0,P7>+HY+%A0KA0WA.8X-XC'B3\!JK4X 7MDQ A
M))U:.5[@9O<:T(VOH@H%<J'\W^OS>IU'K!TJYFDPC8^4@I,Q48;F?U!4,H=.
M0NUU'MU:5%%Z_V6XMJ>FD5%-R7[2T-VVX=DN7YAZT[*B0?1[V>'&Y_WZ3LM.
M.KQ#Y^Y$IK&G[>><E, 68(.GDBHUQ#-=0(L--Y#9R:E-E&Z7=L/WA.N?,(&J
M@RDVS>PM7YIW!=-T&@3OJ+A]<\WH43&2UPO=AR?]01T-EV\<4TLSF@:1ATUE
ML\R-*]Y-<9-0]3-MT#2(JBDS!:6X*1-(3H/_0H=,+=V'[**;"F(PK.:T[HX4
M0S-)#3UZJE6M727*F(.:5QGEV">*L8(,Q7?E:)@&.VS"8E.&CPI>]N:.OO*@
MG5U-9ILCGO@:PFXUW<7I.;PNSDE[4M7N;#W)RA26:U5<<\%\ZCDXU_7B2G[J
ML%=7P8G!:W[N3FBYC,_)^C]_"*_E+NX4[NR"'!%K"J&L*&ZGSTV1&[@;<.[U
M%"KG"OM]P/,A6P3F (IP*K>3 1/.L%*<=MH.A6TMB2\/K59&S[=:N0MC]W_;
MCPQT5XT8=KHDU=Q( C"=JK@TA@+!2)B>5C&W/IW-STA@R(VN2 (Z](.:I97H
M"C :T9IP9=2]2Q:C/1+,O@%[V1@!>,O./$6>/V*UW_;2]228GSXUVKM'Z)K2
M.CYB-#<;3EW QG497)Z!^)TDT$?<FK/"YBYE7QA,SFAQ-6NU&'(/N1."O;"2
M=^)%O=7_)ZK &?Z2K$T9_PWH6  OO@Y@LSHCB:<>N(.5PDC^@Z#1YENJES\Z
M"6_RE9F"V95P*JVYQ3[!-LL'>UJ-=;)U(:+]ZQ0-?5EOI8]XB_B&";B2=A,Y
MDZ<ESV#*0;YR63Q<)^(>64&,YH$$P[N5[RI8 FZ\5%V84S=5;<R/C%L*-ND[
MMA3VD]JJN'%1*%= ;1TB0D9<U2QP92I_6[E.4ZH;TU%$,OG\X0^I&!<W]+6\
M<E5S1N7G[(N5T31"7=3<XO=5^QKI *I>F2ITX_?_0PJL?8!2#>\?6Q;=!^1C
M36OCA7@N LA(@!W#AW8RY:QM*I#SN0Q98>U]:\073E!.A/<$4]05]](SR-NY
MK'A.1<75/M0D]'%N-P4'ZJ*2Z"I3AK92=>D(2<7:<.,"6"9P+A'.\Q'=8RNH
M/7,C3"7"S2I\C+5>-*]?0ZR%P4!_"^+NK:);;2\D\YC;+^2\XY4;&$)7)AR@
ML<O]BY#ZI<4,'C,=U5#3L'&>8)?0SMU.-W]&< +[I]2]9SI\3]=GL/*PY/:,
M9*(>B-O1]!*?[TW[:% 5WUBHGN*6*1N;;J57*Y=W_7IBSEW8$V"I4SZ> 04P
M!%N W '9!N;SUL=])LW3K>'\ZBUH2N9X[C0?=>*?A:T++B*CCQV)_^Y/5QA?
MP)EFH5ET05GO+3&[M4#\,*\DOF+8MK(<$LB\>V966VE1<[OV.RM;7=>3I[]]
MK82;$LPW9;;5#2P8F!;@.C9E#J]"%0E>PNY%IPVX= BB2 @M%5L"&?<)5K5!
MI(:^50KC(!"0(#T"NJQ(9-LYUT0%VW+R"BE&U)@HT?HT%NG6/%0VOG]2"!4?
M\,<&;\J(<MD+1*N@=1P+RC$7_0/>V+C\&53%_?(M=VU2#BR9PBD3S(201*,P
MKHJ<:_^5X3#H(6^"Z6!8R<"JK*W/+[6Z#,KKYK ?VANL-YLRZHQ=8J?"#^,\
M9I=\O :\:>AV.!:!H &H#((A/ZF6,K%CKJO[^I#A\0%3Q]'7]0-+X6<M!]V:
MDWQE9?,W3A@5Z@4_]ZCD]7-4IB"I!)<J4+,=I494!(NZB$>2UTG[\0@65X&@
M607F7DBX;-#\B-.84!:T9EE(5BY\VQNU%C%@6.Y^X/';HT<&6U?9_=>BO4>B
MJLT&9Z:US^_B%P6>Z7T"G;RT/.,Z[7PI,C_OY><LW)-W#A-CM4]@OV_*M,&E
M$/%?DGKB-NGH.C,YO,#\"FA5W(:N(5A2&N(1>\5.(P1]:!)NZW$R.@:I/0[*
M)4"MN[ VA6JXNXCZ&E,>CN<W91][U>CR06PCB6,<[Q1B^&N=B+%<4:4P8^'C
MI@S%*G"-JV9]Z@:PUH92I,1@.J.,DB#Q6.DQ_#&Q[PO!&PV+9F!!V=N_Y.6G
MQJ(25..34M3G;[4Q_@UFB'8(>&(M;BLA(':2E0B'V5OVO8\U%C5EB>X(80D5
MXF# */?E+'%O2E<4+<Z0J.<57##JT2QT:LR(K '5VMS/.3EV-O[9_6)BDG+Z
M+6PY@]_?/D:0#1>>@R9I;,OB52>C'*.%.^#*WZ!3^6=6^L[YZ+IDSG?J$\,N
M*K*NWL>:"4L8UQH9R8X.R<YIAZ"FMS:\]'5+!JG4N7_M#EVJ<(VKUCOY_>]'
MY9/.1])#GE[W7@LNZV&OD<WJ(R/;^V4Z 1JO_SY#_3R?= @_;'V8UZK/FNG<
MTKD$F[O\6C5\H8_EB-5=*O<@_KXD;^;J"-4A>PGZ'7G+_^Z3H_&'E,]D,6H-
MA;K=D/N3<D+[!+H"?RF%N9=N*("K&,CS4+OQ*=U$E0&"(_]"TY\Y_<\#H]++
ML>5SO7]_T9*[@3WS)-&S]T#RZE&;PSN/_MCUS;[:D;%4PRB[?-?U:XI[7-&M
MI5Z_%S'N!:O_]4:T^?]!*Y7,KBQ[+==?;V9KF,MD:ZM?>K6W^'1F<6KYMO!M
M&NB5T3\3/XQQDM]'E/NWWW<>ON*5OG//LTR\3-Z/_F=PG9I-F:G'L&,C)E#0
MA:@EJ8'IXS-$1AHPA#IM8:8"Q+738,=;J0E=#_A*-!;VIJ!JUCR#BHH32?6N
M_AN8=1Q3'_B*]<R1'S HX$3+)Y( 1&VB:D8*PPP!($0,L #0Y44NZK]LK!56
M\G*>\" [P8EQ=P:PF!M+L*T0:PL34HZ3/4&W:#YJ'WHDHOG^I[9J3V_4N>;2
MAS?+?&X><6[:E-FN @Y,C1&,A4B^_$+!W2G4&*(+I1&&^Z<0(DQ((L2$%!.B
MHKF*^$6I*HCA;^W+FS[[MIS2\;;FI61WJQ2U;<(PAAY.=L(;_!<-19](;X8D
M<VG=75AX%YERF]3 7>@K$V- CPW(9YU<X7R794;G&>L#_*W@4(8IUPE'4\3J
MP(-V)I",&9DT'*4?YJDC$/3A?:TU^+\^S'LTJZH_JOV[,'1VHW<EAMA7BY^4
M6-0(HN=_!.03]J2P*V@GW3U+W!Z>*TJ.8^)?;IBZ]BB7!&/T*<1_".;@^2EH
M+'<W01,X_X9S$@W91U"8JK9ZHZ$Q8/WSNQ,S?F7B5-ACP[+F@LGI.3[RFF%D
MI'5M2'B(%NW 1?;;]R0#Z0YB-^R8T&.!6B[MD)X1RG?*QTX:2M(9<!AUXRPA
M%.BLRAGT 7&7A#J5 N8]7\L!(U-]!X*V($4?MPM,QOU*^ .(68D4G?)!<QJS
M*I!>O4;Y420/QB&"'4#K7$K0V 963J4(RO'F?/-8 EQ VHNB^*LT?Z0[E7C/
MJ]YB;V4>D]/4DL^^88AEVZ/X\6Q3 >17)MK'7!!.Z]J44>6@W2UWMC&W($J!
MX :LM6_]UJZ^[&.F,WG>51Q<QY)*%12[/2>;IR[;V1C%3*"D(3;L5DT3*>J.
M'C?1_J(7%YY6&S67U8A'ZP<F%R=*FU<Y_:5_/[=P\7 /F]EE9W4I)?76@B#@
M4&?[HT>#EZ Y>I.!R]Q_X'5+B3 -\2TA9%%7."J(;_FOJ&>$L!L-E%T08I<>
MT"T ;OOD=M /74E+U 'Z8ZUE>?Z%[2-+/J.7@AC:HU19B;WKL"ZMX;YR75VC
MX_EOFS)R3/]>: **TKVHNV'/XO>VNBZ+4C["=G^+9"CE.M[GC+:SID:R^)*3
MD].C5QV;_(<^T L-T&7)&$>7OT0V-Z/CGOY$G21^X )N.'GI1ZX\_/92BJ\:
M:"7\5="VQ>Y3C4R@.]#>^PI>SG,58.;?=O*Z$^C16_1Y/XAKJYN-6(M  86V
MM6-]4RVV^5=\[%G-Z6FUUZ\C[:,-E#?@>YC8_M1YH8"'>$/FI(@B/C+V8,@0
MZ9$M[8IJ1Y)WB*]NRL05A*#1P(]1NR$Q@@=-RD."\/8L$-G1Z.W>ZF<=&74[
M;R:A!O><SA8,Q;UWI(<4,I)GD;=>+&0NADVT7N9Y["IR?$@[?/5.G%W%.\O,
M1R^7G8L0WIG!"N':2RUW)K1QI72;#?-O4E-0O"FC1H^L_8PO[+8#':L(>N!=
M0!ICJ1:CTJ8 3B[T"L]WADS*/BD;MG808,VZ60P-).W^VV]1^[(B;P3ZJTYL
MD/.9 4N?:KI%%X9KB$;X7'Y9&LR80U"6D*F0>UM80# K_(V-#<_XE: P0'TM
MOBT]E#S:'C%J2>L@J7-[7P1Z6T?-4JF,H>JP%'U]GV-0:&UIRU=X  34^P-L
M@&7PY9-)>U>8L:@]#!UI_^0923E#%K]J'<;0LBQK(R=,'ATT(>WO%T(<L_X8
M\&CSU<^X+-R90'#8EWLCFF]XMLI4-D5Y:-3E%;YT8TN =9*2X,JD@!BH0)9@
M3 %R4^D!O+3(+HU?P=":^5$7![,T B=NC:5/4@DB?9J%)ZR2#N )WU2D6O4)
M3DS8H=9A(\HJUK9J;Y9\X<G^@.#Q($K4>/7B:,PY>5E?E_+M?:;]+C#O9 =.
MUO0CG]KPA1(G)Z\2%<2%:CX*<&8^D!J# <#Y3@U3D%SLQ%M*YE)H7? D.(79
M 96[7NY(WA,$.4"]"&%I[*>G99HGN (TED2S756C0?9EX&JEH0-RNB]FT5=V
MPY@0O:7W%Z$ JAVB$J8FF[;/*3"( T^VUH\YD>L&(#*LM:NX(+*[<,\PJO=>
M_A6 EKR2AK3/<[\O3]6NBDS:&W+=CKIT[73KQ#!UG/9PP.:<"?KDG>D$K;NW
MUC*#Q/U8/V+ B^'6_2ZV!]/^E_J*GB7(;2/MDGY$[5U=BO/];YRFM07_,"4Z
MOY*Y-^B!W2C6B*+NST*QOU,6+X[[I'@MKIXU8_\Y/7DY5O_>TPQD%6H_/N,/
MH##K;BV>[,T6PU]\NK#L.Y?7N<H@W\0>"60;.X:&:X7H?4IOBU2)*3Y>QW^*
M=#HSX6 R3&,Z*IQI__OIR1,]3XM.]#GR0C(I68P<]!CY%!XN,@5#>$NJLZ3]
M!"\!/!5^6.S&FS#V9M-U(X5DOOI2FH$8LC-Q938LC2A@>5^.B'+/+IN+:LRR
MYOA-5HR$SAUO1V.?-<5;E'A,$R ;OVUE$W\:0/.H%P9T^;@/3I$3_4:E!T!4
M!TH12B7M!@\'&YBJGXQ1N3B@4W_1;X#K/#13AUC4@ZXB,9Y3-,HPEF=GOWY.
M/@V^VXCNR)/?,4YP 'SZD^FDTCG5[OL$.(YO>!KKT>GMF[UW3;5 %!>@Q')\
MV5;6A@W1%B K)05_/NY1Z8FI UD"7#LT87VX.\$:*]1LFU0>7;36+,>OS]N-
MK(ZKR5WBMEF:9.RKY)=7ZV;[9YP;_)I^H67(:SO%4&TII*ZNS!3#66ZMR2:S
M*IK=QSTB*)&1$T\G6;]F9L7)NI$[=56",L;Z0AT:/[?VG+[DQ+SS-)>ES,"P
M27]"8AE'$MKU>2B-K?Q4,'/?9%/F(#Z4U<Q,(&I_1G,ZR_X1>U5\FH]*8$4P
M?(SLL]HBHJCW48$C<7;5)9\1H=J-KTJOC9F1-WXA' #6$N@JS_$07[ !^+[V
MQKWPS( 8SM\21H1S#+9UP'^]=#O@"GU\IB)H?&U4A])J.9J@._(E7?3!T'5R
MWJWN]99TI@TKKSB%FP][+W5DR( W65&H5(*- +(/K:$T\MW$T4FM0X5#?:KJ
M7!W.]WKV@"7B8.<=OW 157VAOZ+KO"FU>#_$L>M'1C/'B)_@]1^*^%3 -'?Q
M%Z!0T-E7[<3K!'Z H[8^%^<!G[.IG#/WOC_:8NLE"[A K/%,3,GE8WL?NX:Z
MHRESII58GVIH]+K/I$3\+NST.E;/7FZW@]TIUT>:^O" GF?Y3C[LLF"D5;L9
MZ/(U:D9\8&9*IZQL_!O'<*EC2>;;'?'I>M"&'Z/V!KZ?ZO-K=[?TM\'BX8!Z
MMOA.G_K7:5JH4E=+5;_1RUSWJ.S98>A?S*;FQB?/:OHO23*(ZB#.)>L:0$J1
M&N!/2@53,['279/7\1[=\B6M,W'T/;00T-$CF]G@'TCW><XBD>0*6P*QS/#H
M.PW>O72EM?Y$B )])U#&4BDT ;/XB[^]D2H.SM0WM@I5DJCZ6-V+U-=#P2_J
M7MW'C)>E'\SY\0./K?[8..O_4/,/KW]JSP+VB_ -*X*#SUWZ;UL$L38%$;>2
MDD;J<'@.TBXR\NT_+@Q\:1E>FDK^TK<C/RAQ,23JG0C_A^1+\L5MTU7\B6E!
M0Q1U,))FR_3[8G[^%^<7*?$:!4C?4_1C,-1=7SU3;?4 H)A*ONM+RF#*B(]M
MV(D-AHC[P25/87H!S\=WYN+K85T@A]ZL0WUIE!*NOD@M613G> @_?[KNT[9M
M393E33=/VXLY_7A-\Q;!5/+4V@H0C5]Y-4R/%)[G2W/O*I.5<AX**SOR<!DF
MM?)RI@'I*L#7V.8=9%R)@Y9Q_EV.5@Q@N_>2@MM.<Q:\,6"A2' V\B+0';OE
M!/"X+>*VCQF](_]%X#HBU:1R7.(NG;V/]/8<9UF=[5BNDU6T.]1TYG!MJ9ZY
MJ\(7PD *MGC0N\6GLE8[.L(D]G=JV6+YQLFLU)M.'PZXK5W[?-/(RX0]DW7)
M@V:,B2#DEDD[X;^&5;OVN[T:H%I=I8#+T1OVL&Q<= "NB"N^^+HNIQ\18]?#
M=4I8](4 7S(+'%E1FI=>H:->E'#>Z?DD%$CJX;<DQJ+[ #35%+7WW&W&::3X
M(+@EVM[0 MQ5C1Y4>(NO @M1/I-) N7T]I_?*5>'#"@2N^$!91\SD7)+POO/
M0CAGZ$J%TZ73T]C.V9CHP(TRS.\Y!^1.7CNQ<>+$-?#17UG-X*T"<JORHQ?K
M#K[C7%X+[I,:;T<1#Z[T3<-\5'H2_+$ITU6X;0!V9'*>80P^B.$[A;8S]K!-
MJS6WB">0B-=T;6WXS6X@V%1RX'(+,Q,9W8=PE_;72]G,)K./C]=KDYEUS'M2
M_?^H9Y=51A)$C2XGR-@#FHIW/_,56P@7-(XT#IK(IF2%OS0LJ.Z*JXC)W'#_
M]T)S]6K5OXB8[50JY?V?<3=K7Y@B$HG;!J"KU<9>PL@$2O5Y5I[[PQJ,*"^^
M,@!MEE&,?W"EB4UQLK_B]151SPGB%!0,QY--2MSGOJO08BG/]-AL:P]>-<E-
MJ)/R M/L6UZ)A[LTL@EN99Z3YT/N\B3.R\[4X44#TT!-_VC]RC2C]0_20_Y[
MEC"A>WOV7"QFHCV(Z/5Y[%7<5_^FF&LM6:NWU:X7?LBICT_N<;Y:8M&^:*I[
MPF$H<XYL/%O6*S61I&R%]*R);,'-;JX:EN!4@E><X<6W"JH/\&TG,P2(1*;\
M]Z7OJWITJ%#>N^&5#5]6(9)$$(WN'T>O%R32FY&R\S="C,20_<0VDFPX'(+F
M*M"A@DV9-.Z>U3X5GN@>T'">"OH(YDE[OZVKW".8W0M;_,V^(?^/H:^#B[Y_
M&.&D_7?27EZ/S5OH&;!M6)P[><T[!=TS[KWNU<(91SHE;[F ;J2=W.3IUJJ?
M1<4^@\[SK=_7(@.Z&>:2).DAO&@UW,FM"WYH9>*F&P!+ P1\Y5I>?^+HNG*1
M,*%M?7_![;#^9#<OSDDPV4U]NF@;I^1IE%V%J+GPN7]N'>?Z(8^YQ0.V;+KY
MBUD-]8]5V)76 S;L!1,?M<L4&_6:@A)T1)WGK,AL(%V31J'<5\.[@3?3/*A!
M'G*UXLM@- ^GC+=_4Z@E)">8P _C?Z[N$BOQ"MRN41I&Z&XZV3LY5*V/"[H/
M=8<T>KAK--G@])N7%2T./BVSTOE<78$<TZZL7\A]=US@'*>BU_5[Z;3@L..%
M+^,4-URDGB/VJX7/I/-2TPLZMY-[B*@$[D0V *-IQ*-X1+OTV) UO :LZ;XP
M0JW45W==8OD>HN:M=5@NMCYB5W<T^Z:A<2$A+WVU_-7PS[(G_DD31KJ"SX$9
M>\"VMJ/:K4MZZ!5((F&*)S^!/3->=1DL6F/SRLC(NM9(5'G^0JY>)>(N>A_Y
MB\.QEAR^UC]6EO>;_,J:5P<"5W&W6KAOF6@G"]TSOGN6KP_0%1UHVJ1PK[)(
MK&J,R\0 ZDS_QI_$7G>&83.@SNW>DA'*A:?K1FNLH=&\7J9J8".GI"QQ$8IR
M:AHPPLXTI[:5C\\IM#YJS,S.LRKY_702S'M-_@"^C%6X]Z,I5 E?BQRT/LMK
MU9@(7G4*]6B)[[W\JA&M&1?03'^2<^@OM%_R[]_;'-\F[_-T"\E$GWEG7H\N
ME9B,?CDQ7&*JNX<R_5SX^L/I*]3Q:31536NM\?WDBZ8T2!=#0;BCB8_8^XVH
M-4#%[0>M9S4[+0WC)*T?2GC+M5[JCK:JU&+G0<]-F:!/^KZ>/^?(:-H.3]K1
MOE!SE"I,T1-__II0LM9!WCZ&UST_8@J7GY.>I N5GV">H]>_I[UT+)[+._NA
MY&Q'Q+OR3W-_.]T(N3FM]J@E:>K'^V3W7(,66 &$ Q*E!>OR'!O]IC9]!^X3
M[X\1^:VB!VQ4STI$0.F [UU@GC_*@J0T^TTV *QNQD'A]R=E$_EJ&_VRF C+
MC@B5Y^<E.:!7GR;'^4J"9XVB>9C5D-)TLY-5IZ_J\&J_ A[C.&K2>KY#0P&K
M9XTH\O8];U;TK+'I5KBZ>CCRPDW#)T,+O[34'S@I>?'Y\,W/](^#'LU!XQ/8
M^?'PM31G19=' 2J'9Y6+\[(:(E*<^R],Y@[ NB1*]XKQE:PH:1%?7=-V9*7/
MS0W(*=KQD(^157M=8T0Q=)[NXKK17@T?2TL9FW JF^!,VN]M\ZF>2;ZRY[7)
M!*ZS\# PL91@,D'R95.B-V4.8719#.6&(=R?U-?"'<TF\Y+KLZJ779NIWY]+
M<DOFS#=E_/ZQ9MZJ;\H/?OOT_@=1 Q.#H8I61C]:%&&6[4:IWZN)P4@49CFZ
MD9OO]"$^N4,(22+ >7(:\QT:)T:V .9"'>9JRW X\F55%79R_8<<[(-%L.ZM
MM%LMC.;&!MJY2*=0Z]^[5!V4$/]T;P00W['Q<?033(I]N[90%:,(QJS<M<:]
M.']7@R8G0/^8O:-%NZC9FOY38V JP@,9=VK_$04G.U</ERS'B"S,TL4GPR5.
M):XE9\SKGPJ4OR]4%0]_7QDL7^E36NY.VY3!H,9R>;0DJOP._(:@E@7=!38X
M(-V'Q&=KP%K'P57,=@8U6?1^PJO/LG=7$Z50[;'YR^5CV5K7*W_S'>3A#H*A
M79/J V(D3QWC+(3$$VQN[BO;R@JV0Y'-_I5EG^4^^GKYM'OK+7[]3>_X*7=U
MN7VG'<P/:XFP)N2BZ-@@]M.275?++.SF7%(%>K9E_L596*]OW[,+XU</NJLD
MT1$\[HY 2W*RM5<UFJ$.?$\+-J)B<9XM\=U.@]6I2;L*OW^/N/AG8J]!2$+$
M;]$5,UI7E^JPQ?E8K2PL[5;F<.-DDG:+>6!1[:43A_[?N'OJL:P'.$ZI=*C;
MBZZ\DM3! ZR4<1RRR$E2 \>B%$#<A50366$9;]_SC0N@1'I2O'U4_5IA-$HY
M4#:R F_+42L=).!N%'_VZCZ8&^I,'O2QN9U3?AAI>^_XLK:!88YIQ@?TH?<7
M$[<O[RU)+19WG>N4WA[NNEY>Z;L(SVP=]'%S?C]3FY!VU[;'Z<Y@N1(N^?2C
M\DNFQY>*RWOR,/81PRO-I"[HO5JZHX#Y:5-&NGM6F. R8L*,AS<\(([!&V?2
M&3K@ _YHN_IY@3D+D>"K)\SME$]48>ZD9J1NRLC=WK+&KADVI<!NPY,M&#7U
M\0F#[\%GS@U>9:2QSTS$(#P!NX)*PN^2E]+C>#5^%9R"6ABM( YQZP(2X4%.
MT"GSA7=5X@,2LBDS7F/'\.J8U#P(M9<B@?/-.^+ ;$-12N04FO@[,YXB,7:*
M[V8I]^O/RX5&B9BC!]TYT9Q6BID(YZ=YJ=[FX!73RH:+7>'XAY<O]QDMG_#3
M>M="ZLL3;E'B[0924X+!$$S=&[\ITPW?&9SO.A!>NP]<YODW6I_BX_9BUO>5
M["LI\?'^/6UEPKD=^3BNL9(G\64OVX\LZ+ZN8U ?:N_-J:A6JJJI'9UH7:-^
MI],9!'G#(,,*!OM2ZE\U91KH[KVOUJ&WRT^&.CYIOY)3GSG=X SO[T^$&1"[
M51,65X40/F(A&MCX ZSC22#2W1X;MI.@P :4#PCE0>7%;@PV 0=\F]78!W35
M\6+,V(>MKYJXZ*25!Q4>B1=<9=]D#!IJ[Y!R9,-^DGC<#O@.,$N $ROF+;^Q
M[%^(N8$IDG[44/CX!;R[82 ^(GR!@>P6Z_%KXV&F'[\35(3Y FY*>"/9==1T
MQ^L'K/6R6-.E?5YS4EVA7$U1U=NWZZ$Q#>LP"1E^$Y,1RU2B+F60#L+,\*.B
M6'"P MP!C_-&I%C_%W,@Y#R 8SVH1>*+K@ S<=;R4X;Z#H"4;,3DJZF;7Q,J
M-YA$6N:4PY[\&>]Y])\M\AK078I^=?_8X,)?.T+"+D3\>]3\Y!W:-H.;QN5:
M21E+OWP;LDP*K%D\F,6L6<LHJ"V[2HE4?7.M'/WAZJSYM:&_T[2JT>Q,6D-U
M$;%_TCE<,Z(D^!9)G[M;GC5Q@!=_#QBW;P!&4H16;1#@>I\E#H*W1[ 75FH/
M!L(T1F%G\>P-WA!G,5:Y<?3A-]KZT4)!>\/EZK\XI,=ATYYW](?$UX#QCA$2
MM3:1-/7(W7M',6P/X8;DI?CL!I[ZP]L*C!@5^5]K%HYV(N+S.TC^%,IK21'!
MXOFW5YY)OS9F\;MIRJ7C'QYNRI3(O_+\60O_5&W]\U:RE\Z&">QV9MO#;;4Z
M?4M:1Q\>J#/4<&XW=CMTS%CVP5X[WLU3!M,FR[&7V_).&9DGCCTZ]<>XH\S%
MMSMR*0N,M=&)AH$P]/CHTNB<FN\+]S#^3_1X7JI;ZJS5N[%K&2?S44'FES[T
M@ILR8.VS;QSS#CBH!]\264&(#/@VJ2)^G@_IAB1Y-*O$,@R)7<VT;D0Z1($A
M'R2*:"1OJ]VR!O1(IY#4ENO]WIN8:&"RM!/$M:M>,->0%YH50MQ>.Z32]F_*
MN'(;8&G5^$A1!*CV#)^"$B*2P_O4>.;_F$RX=1 M/B+;)TU&OB^(3Y7:Z)3P
MN7*,ZEJ'Y_C,^3]SD>R2D56OJG#E)EK^E>8<\R>2'(R:?M+SUZ\;J(71H?EW
MIVG)7L]@KWJ^]2NLV;FY5_C!;F4W1LZ.&27!"I#LGNG7MX^SALI-8<'1)6)'
MCMLCKKFI5V?+N_E=-J@GXY/H@RZV-I_^[TR!^A\3H>2ZQ=']FS+7_39E/JJ6
M_A^N*@T)FE=1CTL:5D@/__L>G""]W#\U(PD5=DNK,E1&/RL!FS+_%ZNS,^0?
M%GW,!;_T39FAO+)[[:0?CG]S)8EW,B0>O/8G^J?M-8NQ^L>M#"Y=-4FMN)CF
MN/_YTW^>U>W9??CHK<%OM0;KO_TLE#02K:0?4%2-[*F,1+(L92E)*K<I<[^(
MH UV3RUM<?$M,$33'4.$!]H9QD!_Y\655A=Q $ -#H<D1,+W45$[/V,XTB*A
M!E*G#K6'ZXWR C.MQC'1MJL0>>( :A_S+Y=-F>TPT%#X8SUF)Y_6B4@C'Y!:
M$Q2!1WDZE=&58N)'J9GX&.">Q&M5X<6:->9"@"=!C85F@+1\:EZBZWPW.*RR
M)'72P.R#/^J;0G659@NRB];@.&O_;Z[30?W(XW&Z[[QZDIYN<R6\ZL"ZAMQ#
MY'U@\ST#"D<XZ,7'5/J@S<',\;JYCV_G^@\<V?NX)RMYL,![)(+K41'IW.ND
M6>0^&B%.EZ^X.IUMZ[VGJNIIMIJ=P[F_[SQ5LNUSOS[;$^2"&&NWIE=T=Y'K
M^MLSU EJDGO$7PG'1E_DL?CV]YD!T+UXG%O#77<'2NTAVZDORQ2NF3$U/:OR
M\FV%AXW\X8A&&=.?+@""A^ON3X<#%[F?EG@J"ZL\[B[,NO;WRI 2XC!148CK
MP+KQ=!KXK?+M,&/A9?(!V!$.6-K=YFO1/% J9'9@]"B;,JK]9DF&7Z0'8VY>
M>M";Y;WA5[;BX;L;0$V9)Q!W8)B' X (VDM2.U08P'=^+@P$E?E6-L6@9J?T
M)"T=H?$9C/"\/V%?AA_O^+V/WSL!F[JK'+4JJ@WQ/X?J27RTAHO4UFZMK=Z4
ML:I$8D5&>%^<W[8OY=WR;O(Z>6XNP2DI:UE.\)OO3/B#;L/>,P+(@J,0)QAM
M(R>3 7>F&E@I\AX@U<$T"$X +MFT/X&TC:@+3Q>[^/&ANZ7OMSS ("PC 2*W
MHK8IDP#;62]TS]*]9["X^G:U(?+9]3%N$>C-8JD^L-E7%(IJAQE)GA)/;LJT
M783[H]+AK^R3"#9;8OB(V(4"_LMM+,LF\9E*>,=VTHY5B*Q#^6P4*?V%,'1R
MG'!22"5WV X:; D>^7V,A/"S[7,YS?&IG)BF$,F><35=XSY_K&>OSOP3;*J!
MWQ.%F^]_V&;^T HJ?[+;S_8:[X]?K<Z8?+HPB 8^=32\[0\Q?!KQ3>>)P^2@
MM<QN+5?GZ3N>BG>B!F<\@CF4[)H%R7A0P1)VA-$\=Z[MG=U3=;\S[0TU3\O/
M<_2B ZY%6]BT_]Z<50:_X]#)N'9P@2@GOBA)(AZ8Y6I0X&.54V>9Z83S?D5B
M\R'8,<*6!$0)U.T["O>!/AOPV<*369U,>:9?;4*$BG(YA@>1$T>![XIGO=,;
M2AQ#8UXZ;&$!KXM:6OV&74:E.4%!'4@7-QD&!_MXB_N6!?8=N-2\".:&-I)P
M3E)&@1R9?'>WC+!=4C'.OU:83CR"CT;$J"$0";?#O A>98Y ^\YD63GC]O6(
M:G7Z76,4<0$Z=I#*B2EP>AOG_97P+.#*I?'*R_"1?V[I[S)X<W@7@AZ:P#^[
M8^8:P$U:2?OM&FG7O*HTJV+,&T]V>M7PFC% =3K7A7'$$O61V<JT4<XMMOW=
M;9'/>7F>BA:L"UX.BT9Y06O>9J*HB3%#*J/ M;7K55#!Q>$2V(7\X*>:O8=M
M3OPX!Y-D-]W*S\P,JOIY]>PX$4MJ@^:@^1*Z:8%5"*#<LN5,<I+G.!CDS$WM
MZBZR7\!4P8'.2,O;%8J33C!$HC<JY8KDR:]&)<HET_2&)]>EQ:/_$K:!NE/<
ML5&>RGV8'+A'_R&/NQWMY)_+>5#%:6RM1/E\#F(<$\*:[B3?7_(5PI@QY1A.
MW\CP@3GON-Z*"B7;U?4G)E\XXV**V#EY?[:E"4\_],2DP^T2G:]:C<TI6%V_
ML*P])UX4?_I?=K!_3SPEU@0BNQ$)&MJ@EV#> 4K0Y?<&&JPF&DK?T[!8I<\J
MSHVYYLIK.EU\F]WWH(ONAN?Z_.Y6&54'C^@G2BP;3*MQ=L!D-JD6G^ ^:&(H
M?ZDQ<^WJB&G^O(^QX^!MGEI),W,(ZG>?S>8<>Y_UV?%(H(7_P4%TF=J$R3"M
M=856(-()B>6=&')H=PD*0LFFN&=FKS1XM*[4@:<V7,3*;-A_8R5_0?*TT[ZX
M2M]RZZ>9PHPVY0')DW#9-/DW3%6ZH6Y&6'Y./97B=,XGDI=3+7 Z?K<T]G.0
M2J396E[JJ+D_,LER*3XKD*G.Q-7&H2CJDBK5I5BB-:@FH@"1]P1#QU54(ZH!
M<Q[C"1#=QCGBY&?Y^.L@P8&?7YLXJ8VR/!J\0'!0GOKSQR-BIVTIP4!8SQ$[
MWA]\(]5/N0*D%ST;P\]M&S"MC.;^%O2C>J2R! DFPREM(;P".TQ8X?J(%6VP
MYE:L];<NZR0*) $E%Q8+8)?BZ8>G));P;8&1ZY!_:BA8E4N-&>U2]9&<MW/>
MJ'B=AGMNCNSP"X,KHI;&P3PU3!LZB%U5>/56F.3&G>*AIB'M?9A*C@>NGX^6
MK ?=U3>4+#\]Z7K5SS=>VS75I]:&G6:A0]9OW354NH*6SJ/"Q*\E>3#9H%P2
M)2.=L0O/^N_(]-&6GGA@*E%Q!V5YCM^^Z[:JTCHE.Q"*>'=!9Z[Y:0?E"MC>
M0(=R? !OX\S=HQGN,>?^RG57MH4=)U\6=C#KY+O473=E^+D+&RJLLP<$ 5TD
MQ3FR[&K&7MM2L:]0+B%^4R:P7P$367AX@'&\EY\RPJ8[\AU3#F!XE>/0;52Q
MXL28-\?R<OL*R;908U *V:+'U='MC9.*,!WAWN8 L4YS36RSV[PEG7.V<G;]
M#Z'Z1!*FI<EDW%B[('%(G</Y3-F_<+D:/T?L@]>;D06>U$>@+J QR-^[7L70
MC%^E'YAZ*78S:PCY>VT0XY);IYI*6_9QT![GGD 71J+?Q[T+"NGPHFD;JEMH
MO<BC!\^$33[]D95[>M@JT.ER77.0R<QV/'^VR6(H[;GO58&-K[GH(6N@Q#FS
M2.>YZ<'\"68^<^I%[GIAW<8Q/-0-D.:B<55SY,.;,GZRBP=LA;=S73Q9Y5R"
M'T@**9TE:N>,Z+=\6BQJSE%S^LL1;Q2<>>KO 5N3YRZO24E<&9@E/D?02=(@
MFG4"QFT/"=J2PBW0C&9I' :/J20MU8@1H5M)9ELO^J4/OJ7#5X=MHN=QB5U-
M^9KK.&"P8*1I^92,RYLY575M/9I/D@61G<VWHG I*X8'.BQM"XM*,'5CF!'E
MJ+3_Q-K\1LQ-N^$<V4]?[^M/0%P;&H>JH+]6-7I$?)PX)^Q5?'UG D1V60:7
ME=I'/@/)#BV-KP=-4PX%WS9-44M!OKU%:ZX;.IKLF.BK]ECCHC^MX%*OFN7I
M;"WWD K!P1?4F:?Y0=*%H>-L+$?D9#8L653_4/%8VYUZ*>LEI\# 6M,)YKEQ
MV;K2V3CSTJ+>U=2B@^RUF"\#/TD;\AR"9P(/OM 762D.ECPV$A^"'2%8;[&&
M F!H3'P!:R&&_IGC?8%X(I?OQX8F/O>G)4^+P9#4-86^!D12\55$@*2&8,^_
M"K[;T!.;#4K-YS=E?A/K"JU08%$9R/($%K_?*YGS%A,A@,4H!?MKK[MP7\%+
MSJS'FG=<#7;I1E+PB$(D+K!]CJ^,NC7(O(4:TV\W'X'IL+?$ /F>],B0]=EP
M;.4LYVL9JW_7;*2JZ33Y]'5.D!GG/OH5-544VGT$^%Q<1U$\WMQ<?U\'[-LX
M@Y<7T%*E^T%F=QW:<E,F7JK<)T#.TM5JOD7Y,GE,97L!9*_9_;3RFI)IFSWH
M;=T5G,O_7O;FGW@;>#])K_G?;%LSKK[;I()[L-'(I3DG,RH1&9;(JQQLJY#-
M'DH%*N85?*]_C/.&C2QGIEVT'8R5?&H*_%*UU+,I8\K0(-P&JX7F_)WWI;_@
M&T3I0MUXXF%O<$WT>" ,E9%WL% %F$F%F8V)M4;HVGY3FS+RYP5JK<HH.;4^
M(\A^_#U3B3TK*IPBU=-0N'OSUM4A#@K:)'E.0LL?0@:NZ^0+(SLG3?]K^V2*
MR&B&<J2JX#B/U,Y,WI11%.M-08Y\"M0X '(#*L!YFT8P1KC3=J"*? 7XWL#K
MD_?\:%=4_:F1%HX[&_?Y-K.QF=D&>0#3!MS3@"4DB 36O$'2LY2(K3]_L"36
M?NZ+OVFOS&.\7[=[:)@U*]IA^E!,:XC73()L2[@]*H2\@=^30C\2K'BD@^)C
M()8O+P?:J,+W?/.F/;"&QQ2#=\RNV6=<J'O]*AI[6D]!R2_]PQG7*Y73^G_^
ME1V%YHY5KZ[=E"Q%.R.;0O6+^;DGJ2,I>G^><C:"(W,J8#_*KYGEOI)PZ7-V
MIQZ4F!]^/?1TV+TT:^;1IHS2%JI!DM;+NKD/X >_+S)T\3\0O_5MF$A9*$7*
MA+,/W!Z -97/36J#B_QJ^0[+_D23<4>K?">8DX.!0;ACKZQ5DDF*C[W#*SJ[
M9&//CM=K,1B!>0<YEF$)M@HU9OBH1&KM VX#<_$4D-6.4E@,US.97QEB[,5O
MRDRA_J%;E8.Y'BT-@S?)+BU ?QK!OH1POF5HF/78X[]#FX%;Z6,DUU5H+%=V
M->5L &*8J(&'NKP2JL13:G=@1CP*5=E&AJ89NP-#?3X',@X/51=3 H-7#'6B
M-\8H$T:WHJWT@LLR)P]Q/'1.P/833C8":XETS9TL\G9;'D[%<PQ=>!+X@<<X
MJ)HGKDC,;>N!:;)?]2SWUH91&=;O&;J9F(:1^^*FI8K-KGX:],I&]<3\X/"=
MZ&9MY:(708_\ DH;8ZO8WCU+-[;"BG^U2?JJM3I+E%L9><;Z:GFY?<&RFUNM
M4X]B%AW]>JXX3^P_"K.0#A&UFB3DL"9K>\$BW%Y2_!P<%W(XHZQ):Q #-'28
M32HUCH:EX+;>=T7^$,%F\.L@9=X0\L;#7>/TR$K*&?G$54SKI6_O[AC>7AJ&
MV\+_(B=R#\)TI!^4&<>%C-IG^,JN/%(B\2@^P%YXQ+LKO](+G][-LI06%8,1
M:QV6HW%A&]@]R]=D<1H%_+/V[:),M(='HX='\Y_A3VY"+N"[>;KMW$2B^B!=
M4\!,(.X1)L11(JA83=:D%C#RL"IPW<WKG&'5N/,K!B6/TS&.?$F+Y70KI,L<
MOVYG-HI\'F@)B5N)L6)-J@ZL]/UFPS;\JXY-P:IVC3NQ5\;/>-QV;S13#CF/
MP>!4@8?G%8^+C@Q=K=QM8^OF@IZ<-:Q9KPS.0]@"U=[U2!Z0_6TTVX$?=*UT
M]L?+'J>-SX_^XNJ[NV=;],$"JKVT#XTU23'2OKRUQ9*8C6O$ 4M21ZLY[QRH
MT8\$KS..T@;I/D+$E?J/V!DPTN"C?&Q$WI86,@S#4!@MRLOX\@"LW@%7]">U
M)]<.TP.D>\[SSJ(ZX)2RA54^5-;&M#N=L9]P".0*N]^$("T<OEL[ D4=Y+T$
MI"1;8]=G:]LBSR"I:H[9YPSEFHV'P$'I!X=(]%Z1B/UYO#/\[K0D9]+A17IT
MT:^X_ 6A\6[='S=9O5\K[Z*7S53R.IA PO_&W)M%-95&;Y]4.8N(@(""$"=$
M1*!4!F5**0("!I09(J04%4(,*64*$))29 8I0* $(2)#9 @I)0&9$B$!1 H1
M D&"0 9!F<]1#*=("$W];WKU6KVZOYMO=5_D[ESD[/=]]_-[SMKOWHEFB#@$
MZ$H1]JFN*W *S8NJOZYZM\54^GT*Y8?EUFW?6E\Y&JK*&3'G:;U@-,@_,-(\
MD^;/:Y9D3=5MYS'L;3VINP-]Y]?>(W#4PA^O%A?Y5?<C?ZEG.[?.AH]X%3OG
MW\N27N <[^KQZ^JQ;ZM A]!1*<3]X+%<Z47B!+P>OF"W37:Y=3^HZ ^- P7"
MWYM2BI0<A3CVT@-^O)SZ0M'EK^Z_FI<X6?OPTX."/E532:S18W>'@6YMBQK9
M/D@E3G_!1S0Y2D:"AS'P^N#Y)]5XC/A+!REYY!3"J .?+%J2]'4G6)^JN^;<
MMV5=X:'MKEE+6'JDR>:/9Z,T8^5_KN@E)Y^\0"S"![V9W(KUZ<@G*@$L]HM<
M8<YLE: %M1O-A&UZ4T/;@8W, V26$230+=/W)&\UY142U;"0?T[VSR\Z>>1$
MZU,4*-T/C$Q.7HZ#[X72^EVXC'4%%22:]_><?U]2LH0UC[%Q<W^DU]+6,"B?
MC)-L-];+L7)C?(K961*^6.73C#Z60^E1CUR4]G6NOG!VGJLMKJT-=C-&=T7J
M[WCO2ZOE/?9\7FUP?>9"A6'@XM.7>]'#5W+174^/&(Y29! T<A&4U$C/$<?O
MD#4V3GZQHG"*M;!?>FW6O_^/UNL"Z5WPC-_+ :8)E.XY;(K5[_8I,2A1@GF#
MIT<;R,+X"_!-DP%HGX+\>Z,G"[+;[Y'+R8Q'C=M2X8(BIC6HU)!=%:+!__*F
M?T<H;U7WU=(Q:EG["T=AS8N(/F<_4HS1C\?WJ(Q_7EV?*K3(?G/[,#.M=>TQ
M_+:-7:=FB05KC<S</8EG7>$M$EQ((F1_,E&]B4<CG(^)6EGQ'YXHL\U?L="J
MZ%O.BK&9?V7#:33FMB9=\&^+1@ZT&HB5#'T 4HKIN"*GT*RSU;SP2Q+#*D['
MO0/I%^6&PU;-^"B:'MMO75ZXO>ZWCR*SG%\N/#@PU^5..5I<>M4S]CBK/K(L
M>DP4V[;%Q:1JIV_:O:J]LT)O+2/G"I=O4N_*?^=G:!/P<8]6#:K55Z(/P?H#
M*\0H6/)NC:$MH'#<DDJVU3=F2>X%$&&Z!"M>:_C=%P'PCAZM=P&V6,,NIBK"
M<M\AU?(!A/I<_Y&:VC^K[^">P(,3&[@$'ZGA)T+4D+55/+#(E3Q>:SU)^Q%P
M88#>K] GM7<2SR3?C[3J5?+^MH+@WFSA'@)79(=49ANC?30L'_?CL/''2O5:
M>J3]I5!X>W,4303? T4[ C\JFT3:Z8HX]3E+^^*'L?DO(X5S'A1TP^K4CVK%
M])YEC+YYU,O M]]\QQJSM;J2L3?&"7I00+PPP./-"&NW3#U:T(?S&(JD!G4T
M!F[HDS6\:DZK3=9<654]B3[-M\E\7_8BU*./%!UWTBC<YO.K:TY'G#O?^292
MQ3?%V\>/5QEZ1(Q-#S30\),#8[_'W"G*&$:^,[NK'G/K1 Y%WT?;17/[MW-G
M.XESHWU=%M'-;;6RX#<KK/KX[@4K< M1IZVBO^M?HB9TBZDWCK_Z8X?L-%.3
M,6)<!E!9J17<H[CM^AF<1DUL905_7:'#<T)7.4G^]I$9["?"C0'F05_"?WT,
MBPA( -9%@A'.#!.5"190@)BZR1Y( 6:_\I?2"(: Q570**\[7<0S17B+_0>F
M$98ZA^.5C$_.3PS&-15%CK6;PJI+-(#H=MK]50^T[AY@A<U*]'>@1.J-??S*
MTX4!\25E^+1T/4[V6,6#P$\.&6F#\**C(>^:O YZ/];5A()$-22M 'Y(R4Y0
MG<*Q\AP@D,(QP66S#?)3]8S!(H<L%_#BAZ/@W!7DUT:C2FKE<VYM+&'ZX\$'
MB"1U^_U-<8/I&4>61AO*CEN4-3N]H.<W-/N8USS,"[V;D&?IX67H16Q_7^A>
MY4Q7<\\H.^?D7!M\3MJZ<.Y>)[W@\ZW)[LETVX-00C6T>T544@.(.TBJ\%"W
M9-M-(_)#(6"(MU;6 YE5%;%7K@VE,36!1=J+F6A_8G*\F+1/\R6#9W8\;)&:
MCTE'G!.7Q)$,^TT66[&@MD@_P5;+2>H(C75)B-LW0IQ%ZM@DF$SCC=BJM(%1
M"<(:U&@PA]]05HI>S2Q)XF\N9&2.3]-*)S"GT:?'U]KJ?IRN>G&=^R-8[#/?
M)UQ72"U1:@.Z'X:UG@,FL$A.(3S5^I(C&[<9SV4'GL-J7D)LY3J#2XG6CI4]
M&-H,,!.U2C#WT1AI#GQ9V9!;&9_@^4 [:/.3R?JE^5R!\OT26,G@K ZLBZG/
MA!+#00?2GD]X.)MX@+N,TNP5]I*V^?4+<(I?&U(KH-/=3D#QJQ"M"/_P7N*=
MRC;,@K-$M#KK9^Y5=;SI:)U(5-:K2<UQQW;?I+^*K2MLN>>R*:W8EUOL]*Z@
MP:O":[@PJSYC2$[;YU A/UI>*=3<']#E9*\/PA^V.HK)*;:G&6NYK;?$_\T]
M)C]<5[BS=HL"ZJ=VD2W2<+;*!!4 ER W0TN8^BV#\W3(3"-99-PHR-JE@Z >
M+%SD34\HYD>'DP]!*D"0)!OZ5WH4/R;4O5\N[VO6[,"EL%18:)KB-;R4,P!U
M!T)5%6A+<O=2:CY_N@(C?$NW(BGUUGW\Q%B2'<EAI? 4[VJ0XVQ'!R]I2M@(
M*%R@H\UI3LZ@D[= 00@PK.98J3E%A-11<V6,F$P-YSIG>>8O>22-F^CG7LVZ
M,.#^XW->X8QI\;G;QB<%*G/X\ ZY-D#,;X8EFAKILV-/!\X6ILW$ZB4V/*'4
ME5)G?6+?OXQMR,_N5&@>-HN3CKO*?R^Y-?YCO'-H_COB"#TN(J]T<['0R#OM
M[O1T7NZXM"T_RRZRX)SK#XSS%0D^S<C!K7B@^NLW]_"<QTW7]WDBJ@P"T54A
MH]"*P&T7P6F A&9MG/7_1K83?R'L!%R+_BN\)^P>"-,4^]S?6/5#O'(N<1OD
M_5[)>1#"KW3 @^\_^T/QA;PW<GK"-.??F17#)>4LH@&8_&!=(<@D36X"?$E;
M?B*+%J(>Z!KP3EH'";2/UT;@(*<(DM*XZ^I($ET<374,"M995KWFQ[=9+)/X
M#MGK<:;V]Z/%J-%<23"4*+)Q^^\JE.TVV4&0E$;+_P>C>P2$WY>=JIGS<<'A
M=(JS)$D5+WP1T<?3>/NH5,*_KA]O7"KK.'AUMD0'@"<0#@DQ;IL@9,<$#%A)
MN'/G"W=>9E@V8^ZM"VOXNQGM/_U.YQA_WWP0XS5Z^LRO?V^O.-W3YBIY5^S;
MTX$P%PDCA'L+,VX4NKLN2MH*1U</?Q6>X#XZ3#Z=$;H6G%..\7Y<ME#]_B[Q
MG=.%W3MC7[LN="+CX4=(:!P_N3OVEJ0*#;#$.VLE,,#5+16F6;%!.7'N V;7
MKX,[1P* 7;K[P(JAJXZ1JI-&# E5HD?6:/S%Z?>+NY(C8[H7O*IDWE"T /<(
MM2N2E$ZT@-C"25WB!A:^OL65D?23"[\CH/L5! > F7J/8!%7%M)L&FN>6.<_
MMT/MZZ#><#[9C!X^]FKKG["1 &U)Z%H)P0I3[1<"WVRK'L(KG,BNADB^C5SK
M;<*:XPR$8D#^8'RP \LEWO)4=,7LO1G)Z<"/""9/2#7Z)QNF9R[92'-H8(3S
MZ!M$;M?=PRMO!D# HZ?V:VS W"=\(&8,^RL44+@X87<LT[@T&!VSEIL;NN+]
M ?'YR6$'?Z^J[NSC%N\6QZXBYC0:HKT;"G\P_@G^@S,D6<0_\O/*"-K>$1E@
MB<FY4CB%=2" .2Q3H\@X_:!OAU&99%T90I!*;46 J$[23E*(#4HR#/D!"2(<
M>V$[=&\. 9T1H%0","I?8TWN![5P?QC"5+Y.F !%_+F[^)4KCW[(SM>DEB<9
MF@["ZTM?BI33)O<3%$&K3GB];:GT5ZC?#=@\R=!DXY+#99'@&?P-7(KN-L Q
MD[EYEJS&$FKJ&KS^<..#@ 4Z/HJH<=L&Q7&TF'E&TV1<';6XE19K=,R-M^ B
M#&8C@CF.G?S&/PB'JO 5%&"M%Y^TPN8'O'^U8JOVNJ49:&//GAXSX[H)YXKF
M1I?]_#V.%1D-L_FF1H;Y-329*>1&,TF-H*E!1]XTOX9RC1Z7&')_M"E>;-O8
M+OSXK>\,XVT1-WB2";NZ_K*/2#N=\H(==_42Z2K_(E0=RO7\->5:Z,Z97EB4
M3]++P05[^U$+ZMK"6 1P-MU$4O7=X.CG6:] 7J&D(&/H9ME^WKV$FA-H_ZMA
MA6E7,C9DVU&*(%R!MHF54VP/MT+=(E(Z7 %^>RE#8KL%5$XW0T<8N<>3'*%&
MX&IDO 6[1)]'L*D8Y6/\&]FH='UVPR\8%;;20DFQB#6_$.A7V7#2^CN;1"<M
M>.@_($0#Y$ZXJLP)!V(DH=!YZ05"$-0N*HIS<7$9=QCCD)5:X77R?GX\MRVC
MH48IOTH,5VO5^) RL;'KT:;",K_#N1*Y\@/6=B/"#I,.*2Y)]Z=&Z*[UP"<W
MP26"_G-'X;G%P\QDCT>B^"TGDXI,9UX@QR9J!\=:G\]NITQ..V3 J'A#H7J&
MW'#8VDY(4_CXB7!IL+;51(RP\^'2#9T(V#*TI,#;DGA?I%CT5HR-ZAA\)_\V
M..+:%O?7]<:6DN,BSR?#A32W8">+BN(R:FW=()(^:YX[U9)4,O/TE<PC-DAO
MG^UM<;_7M^^-^ML;;8*VN2CNO)<S?<6WN*W%1<BZW]S=2=Y*_$#>)#,0D3(#
MST%5SV1WUPH('J!=9RPNLPP0T@>MXX29*&%*LA=PQ_]8<GG/,[1/5,F9X3M?
M/CQ<R0^\%N6>($G9-4@L\%&[^UQF/1#IIH09B8U^&%$<?&G0F* G-/*?UCG6
M?86[C+"GSQBW6CV;<#Y<HF3Y8YEJ,,T]>7./*T_C\H>7C0]ICB1J"-\S_^_9
MPH8GE;UQ^KFWU-?6J$\+[N4HI T;ZV76'>W9=//\V-%=]PSW]R Z7XQ^&QW5
M^X<;)O$G&)ED?[T^8ZGR]-;5OG-5#M\>/_6@N!I9F$^VN9\ID:S,9UJ>V%]G
MM) 7*,)C!Z;2-L=47,J;+N8=O^Z=_=BT_E+O@:L/ AUO7=R2HFYV.R+Q?U<C
M3.)U4OO1ND4:Z5;_OK[HR+LQI^4\>,-F6^P_WSXYO[23VD'RLS>4S[34WG6H
MSN[:[OFKNN>NG6LVM)Y,N,1DK=YV,V924P:7ZA*Y\&VMFH"+V(*3I4WP).V4
M!4&GZO#?NV#;K7U DRM%OF K6?''DA(TUQ&+D#\)KPL(F(NUS1,':/LT<,,J
M-/X)._B]!)/9=+/(B8FT(&8%Y"Z1LON0)68APYGG/#.N>ZMF'#B76U0N-G2]
M@B N4*C#7$;=2"?KE>-" )@K2)X?E9[!*PKUV9F;1.L*F>L*Z*RQ1LD,Y'>C
MQ Q\5"%LLV*GEQ(0T(S8RD0E<$Y#HM7'#HFU"CGU"9,/^ 5,PI21*+OG_/ZJ
MML?ZP9*6M;^)!R&6)&R-8JM%'+#5!E =;FFD5\$+!M)]+ YLC\P2)-93":=X
MUHKB_C3;G\'*=%&;IM](1)\RQY*PYRNOL)B20N\+;#_:D#]0?+1P0G BG@O\
M5P/65TG0X[)^(RGCM;M?382L*[S\PF&EP]1:KU=!9-<S4):H.Y5H FT2.22*
M^H+[N%,/V/:L(6LTJ"KEO/KUPS5_)'H@\]B([N73)59BDDP-@]K(#NL*&_B!
M*A#I)_XV2$(OI9!?+F5@(Q ^'2O-3RTU"J2FH86WEE),L5BM-2PC"[K\[&7^
M!*=SE[GD\&\F-YH1;_B/S]6M6DV\7W4V7QJ <X1Y!T+9+QP6I&9.@V%%E07#
M%FUEYO+ZD,9^QOQC9+!%U;I"^V49J5;>0Z8W+O0 O4+]1,:ZPN@7X3S_]A.I
M94\M5+@ZTK6N<*"R?D-L(>7.0,/AY?2SY<EO2C1;ADR^)+3'!M9Z=$930TP8
M:U8.#4U)GR2QJ(5QL$4([S(Z(EQ9R +2A10V^7\^8>IWHK+DFT!8!UEW3GZ6
M"<CS (S#2Q#^R%H-5.V^!HPD;P3@85H_VX<:CZW!WW;IVSG[;1"S_>CCG@/B
M8JA@76'S!S"JHH(X"M]%5)%Y "/WF3\1>0C!4HK&NH*2&4YIMC"#I$BT0@?:
M OVIK>$B\O:VI(K@8.S&$ZNW_^#.V>Y_M)W?VYFE445!*&44>-^+UP97)"8)
MXB_=DP_(:@1'D9$-81.P(F M* +A7<Q=&,7Z:JC^,K0@U+'H\%&;*:1'&^(J
MZHK0F*CO.Q;J;O[5OR>Q[.8-GT6IH:ETW/\4&H=IC)@,_,HM@)5-%UC'I]UM
MTW.^AT^M_NX?+C6S[[B2.52VMZ#-]K;<?Q N*"73)8D"T@,2?:3+9+1;V)W
MNDG.FC@%Q0BI.]<5SD,%M7,D;5N-K^1]D1@C96'R(^9Q?-@<VUM7M6D@$FOG
M-:#-L<0E1LZU>; U"CFGKZ6GGEP*2O\#JE]7V$("-3M,$D@_$Z[3"(<^4* "
M$8J/$9F\V=ACRNW>A8L4XR(@JP.^I=7#-@$,[I;X_]'X?>G0 'W!I3UVNDCW
MV<NQ:V-0_G9_QZC4K.=?68#K)-\1":#:8:,U8MB"H<!MO_PM2\$:#7SOU-J:
M]4QF-+0,RV2I1;@EK';F-P'=;UA[6P,B1>,N'=LN#M#H;?LCQ]85%"&?R\/6
M;MBRL<XHR6# 1-^Q @X.T@LK O4E&6LUMB?G4'M.%@DG%[8!FMUP98(!P$?L
M]",) PA>4$T97OL\E LZ:+,81A7@R(*M!L&FQ65O0YK(QLZ%65P'Y]XZS1J?
M]*2/C$^/N>A'UT03^@/:+N7\$P.//I&&N*#,E^X.Z:LXP=#4;Q8\W7N0'EUE
M$>:E$2R[NV$S'\M\ +<,0G29[#"D)W1+Y6LD2V_+E-?29?NC26+%)>5^L3(,
MO_*FD)9&/#+>\*S!HCFL.%B@<\-M]]>?42?$$3TB..,"UX_?J3^(JG=<L (I
M&]Q.W[:QL)@-BQ4.++63U>7[\6IO4!H1\=%"S?3(=04-_*9.EC+S8*CE8BKZ
MI<RK%$]"#;;:/YLCZK;^/6P45IM)_7RO/>8WD>IY4#EY70% L-0@*TG$6A93
M-12EOLQ2(?P**4M]\&Z2.J@;U%VYP#Q-0('4RC*Q35#7/21RC7YM9H0_M93V
MK)%+B]Q1Q^MW&Q0DX6]:1:T%"_M'63X?UA6PY-1)QDWF<6Z8J1N,V#^YF[C+
M'[*UL9PQ"["Z CAFM/J)THOOB3TQ^?22=W*8BAUZR].H*NO38RY'<RTMCQ?T
MH(U,7?L#L&]S9QGTHC6EF5J4V;GW[M>X"54N*ZY[,H3N'IE#GN4S/=P'.?FM
MC3ZN/JN\M..U[X'_OS?15C_ M</M:M14[=Z\Q_$HM\^P]J[=+N= IUO9;R\^
M,O6.CCKD=?[VP9]#G?_AT;%G./[F5.%:V'L;.X>1B-XU;9^__WJ=)+T\M'#K
M%:O^<1?X]D@3H\3WYJGFLSYZ.LC-,<$?8.]7.G$9+)4-D8.-]<MW? ?'?@6/
MO7PN?^?-8O0_8BH1E($?K8/^Z'6%_90/Q,V$F\U0 CCFV?BS01T!OL',I@"I
M0WPNAWL%D#^IA2KYIW B;8-R>:8AR!9ER520DHN@9A;K=I8*X11T2VB2'*@.
MG0.=OW?!]UB?*"1S7-ZV1@O5!&Y[H;C+0,F?[*X+L-VV9!$6>1'<.>Y_] 2
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M5UB8DUX*D:N"O[:"YKG8<GRHM%WWP*#9Y_MW6F/ >TNNK0!_[DS?W;@8Z4^
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M8LKGB'I2>(+,:5UA^W.(N3C'[A>=E2L[">/BX==: #X_TT'G(#_Y=7;N5:>
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M>;K*8PO]<%$5N62*XS-I"002,4V#A. =]8*8.*>G5Z__3;/Z6DL>7'[:Q,"
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M*R(7>Q<OE9B5])2JE9:6G2U+*J<O#RA?K[A7\:7R1F5SE6Q5;C5?==Q[X'W
M^XV:/VJF:HUKN^K4ZZKJQ>O?-O TQ#;2-3YIQ#:Y-2TUVS2/?C#ZT-5RI:6A
M5:ZUN.U<6U8[;WM2!WM'1 <5&8P\^/CHXU:G:^=R%Z1KKMNZ>Z+G3L]PKW'O
MGWUZ?=W]U_J1?VK]V39P>>##)_5/38.J@XV?53XW#*D,-0RK#C>.J(TT?]'X
MTC*J.=HQ!A[K'+\QWC=A.#$X>6MR=,IBZNOTO>FEK\Y?O\\\G,'-!LX2YY[.
M,\W'+IQ82%\\NYB'DD)5+ZDNM:-OH#]CS#%SRT[+F]_\OI%6(E8Y5]/70&NE
MWQ6_MZWKK7_9L-M8V7RT2=R*VN;>?OOCPH_ZG:L[G['6V!7<8QQU-W[OS%[Q
MOO)^U\'M@T6\%YYX&$LX0RCYJ?ZS_\CJ:(T81&(AO29+D5LHQI1YJA>5^A\T
MB=POS?8//7+#Y8%CP$-_D5]"1<?GH4_ 8Q'S1XY.+B*R_R;L_M_1*??? $!3
M) "<GOW'&*W=_MO+W_3:7XT.^'VC_\=U#'RTAQ)MJ. ?8SYY *!^0!M_Z>?N
M^M>8CME=D?_ @ZR9RP.7QR[>-*B6[BY![MZN-/S>SNZ_U+*(N[?(_XFF_Q+P
M_Z']8Y__T,K^+E#_O_;I\^C)8W=7-W\1 Y>@AR[^_B*W'9T\'1\[7Q11O'1)
M&?![H*3XUZ5TQV@:F0E%I>Y)  !+*@"0DZA48BZ52J9A9Y@#@(\!U#E YU>=
M\+_4?BWRO[H&'?4CP,U*I\?XB8'N/$#/3<? 34?M 4 T%$Q_F_!OU-#1,S R
M,;.PLK%ST"8TG #HZ1@8Z!D9F)@8:3J6+HSV/L#(S73RG,(U9IX[CBSG?4\I
M/GN5RRIZO::3UVP4*Z9T_W$X&SL?_^DS N(2DA>DI)555-74-2[KW-#5TS<P
M-#*_:V%I13. D[/+ U<W=P\__X# (.B3X.<1D5'1,2]BDU-2T](S7K_)S,LO
M*"PJ+BDMJZVK;VAL:O[0TM7=T]O7_^? I['QB<FIZ:\SLVC,\K>5U;7OZQNX
MW;W] _PAX>?1+UQT ,._0_\M+FX:+GI&1@9&EE^XZ.B#?DW@9F0ZI\!\\MH=
M%D=?GO.*SUA/77^56]/))JIDAN6]_WB4G4],&2V.^P7M+V3_]X"%_S]"]N_
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M*K4]:)Y$*W0[Y<$N(W,A2U;;:3ACS&+VLB<XWE9M.X&H1Y#O1)UL4\#Q]':
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M-8GG<(FE<^3$.J3^,$;SB<L[SQ900D,!=F4@PZ8-9T&)S']#TBE%539LX].
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M%2>T$Q$JA8;P?9TS*2)<,4[J(@:<J?K6EFJK72[40*K5.DB\N(4.QW\SK<V
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M=IQKB_X<"_UA)J,E/;:XNKC@G;PB#=M/S4ZU4LZ<-JYL(W]SU_2W/ZME>R)
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MU-STS#3=#+T0FJ"C?LM)?E*^N:D6'T(+9XMD<8\Y _+=5"FN!%J 0R:)LK7
MZXQ6>G\/[EG+#A'?,:,S(KT2#A-QH8PXI-]FG"A_%'1_YVB=.\RRME%WF@G,
MSG7L/AH1JY&L*MN'^%!!=;V.?0@%MF32#8]UP!_DZ4UR'$8:7.<JX7CTTLN
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M+"7NK,=1#K$MD&6-@G89"3$<8[?(WKAD"JX3*>X!IKK+F<-$UI[<IQ1=7EV
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M/AG$ !>36,KX7SDV%@ZS)A.?)^7K)]3/(G+4-6W3+E<%/1\R"Y/RU_WI%5X
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M:VTLKO2[XS8/W0YK<?ZIVYK%<@5$WZ %6!'?,)>;?XV0#3#2!*WIJ$J?.JP
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M>;<AH:>T]F82T-BC&?=HX_+0<F2\/</HI?RMZ7.TAO'[80XI)0S!41RK$,P
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M7M;C!<W9@Y&Q'@L;/^8_C;[09,PNPGC.XZ21Q!JA%RJ(1M#Q$/"?3^XKOAX
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M<0^#ZXP'# U:$3?"/;(].'8"G2EJ96 [Z>>(I[F[FS\+W+@?8TFAELX3%3_
MTB\W[NXMZPWAO(\]>J5T,L(WZ9FG'T*72B^_/ALG5A)"N(1D2B#/D 96H&A)
M:2$>INAZ(K6]T:Q7:%4X*=[!NQ>Q&[[A3I[>$">D8, LH_],>.)+1/>!:IN
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M"$7\N=F?+=II\(1&65&VI0Q+<S9!8S'QH12N T(@[5YP6LE\IX,U=S"F05R
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MG:%S_6:C+?T7"KF(^)G\W')3CO'LR><*X5=6;3,R,KAC>N.^^YXNZCN/;P&
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M( LP-0X.F$?>G--C([Y&S,S5CBFU ;/HS[-/Z87+4:]$\M#*.%'K$UL1$="
MX3H<:NK189'"QKG;4'-UZH#",R]\-YDJ6DJ5@!(*9C()<QRT!(23*D<6ZLLL
M/U_4@+/$[A25"O<*]'!=$M SWQJ.%CLY?**,H0D))4%-@PAR/_7-KT.H^&#<
MIT8\?+B-%2'7=<T= HT7J(D>:I$N V60G?/4D5'^#5$==#O6KHH[W$Y]:^L
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MI#OH&K5DGNK6!Z;5TVWS7I AZQ5KY^?1.!(3LP?[I/RG]R2OQH$G/]D]S/R
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MF<L]<O=Q)TWI)1DWY:]1DWT)/I/\D?YVKR=/IVU)3[B7ANY=N^:Y0$]Z5(>
MG)6%3N%YOI 0OR4*.HC_[G,]X[4SH3<E4_"S*P%\^>^VMT;VSB5\NBG,1N*^
M",%@W$0H)*]DUK(D-F1 -0%\A2:(^V@ID#6[0YCQZ2< 0NB]SO]_?JRH77!
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M.%INS&6=W77U_=OT1+T_[B3_D>AT)_?4+V][%<A/"3=(H^A6=/7T6^).7A1
MC ]=%O4QT1S >1:-^N"/1!M8W1Q";X=ZW &OA4Q$P;C[YT<-39^TM!8;2^,]
M_'4.74F--^4]A,R F XT8(-)0M:BVGH3")3.10F@'G.'1.EM(XRT,I%WJ>(\
MJP$J' IFW<P!\I3$HE#*?J.RN7?I[?7KB6L:,>43:@EY371ONM-HI\+=$%G2
M4\'/T#A(9]%^L-N=S[FG<!IUT&NRNZ"/L8_FB]R%NS1,\%[T;#%1@.HFX:(\
M(R@-A+L-\K2!X7:J]B#EQS 09["I64Z\S*0$$Z7\T#=J]Z-,1]O"PK<E&KJ$
MZ#.,2JO3W(DN3%'#-=OW7@HM@8^HY&-GXJV''LW;Q:F)Q1<N%4Q9KY1J("+>
M=)U^E,>FO4[\/L]YQB_"*^*[T#O6,,EPZ1M#@3K95J@+P' \3Y<5H%M-4\#.
M=U#5!SSZ>.I,XG8?W^.(4BBMS:"\S:'&@1JRQU0^E[/"'NT>8F,W84)Z[=$+
M^?7&DFI(,3RI0IX\O])D'[X'_@,LO0)A/B0F^(Q6I,KB7*A )]'(T"<K,Y;G
M"71OPBY!F>Q>I7;/EUV[LB02=3H2EZT>!%B+ 8><)KF();5V35?FQ), Y@S^
MU 3/B$(9Q$6SR@W?VN NI)VU]%].J$0=ITI2@);Y[P_0"KH#MN;/BK)V5QPQ
M5^R<=M#=;51IR;92*^+,40+0T=ENUB]#I]QCS=NC=K9WY\QU7'N=GC?0_]37
MXK?U-,=D+7I2U>7OVIQH/BV$ED22S^/G"H[Q?H;HW.,\GZ%&N5!0Z6VN./3!
MF^7\*Y3$_&#@<V (PU-C([9!26WU.ANU\1-?MP\WZD<%>97Y?FJX/+32*=X<
MO[J71AJ_*C$*9R[S9(HY+F#M8B89*\5>2@"KSD)]@#_'M@XZ'U""U;.&E,IK
M4O22<9=P7LSQ %U-L_9U=W7@P4/_YUWLST:7/%[5?7L\4_/)Z&?DC&A"09U+
MGX7Z6O724.9PL3O589>J2[J,S^#MV_G.]/5)>;NI/XO/U+W +ZU,!YSQ84Z&
M%+]_:"IMM]_#5/K*3_\O/R)?O7DRX0*K5M8T/X>V\' 35CK<O+;AC7Y" NP9
MW_4DXDF<L$U8I9F C!89GLVQA0X+U/%7]$LV84W7D?-#2M\J_M6D2^8K21Y_
M G<&V@D,=\#E\,>A4DL \[N16-[$_,3!X5#_Q^6LN_W=LH]<73H/ES+\,ON/
M.<^ZN+U(7;<=4*M]717G^F0RI4F+*B_T9+&\/9 KZ,GQ@IK9F/L3DJ] ?"%
M8G9V,.0@4<V;E@TY:N= 9\B3;1B%D4S9]44<?F4HA+)MU771NGLE0'%J]-ME
M?]=*-7&546M.@/O8DZ%'+(N"DA=U'9KM5M7[9=9J:BR6NH>K*\BA:V8MQ 23
M_5 7T,E:;B?O$#^+4P>UFW,5049<1_FM#)?'GWCV!2[^D4X#QR=SIS0Q)NU1
M$J._6B8,J8?G]1QPZQ1Q@L:8*8<GS6+P/WW/RBT!#W>8[ $1;=OH.MDZ#=5
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MI'_DH_4L:D,9PY)B17CI/F[]RG1;&6H_94\KW!O<^$#S0T-'.]^21C+M1B*
M8(X;A$/Z+R<9J"1-^PJ.0SDOYVO==T);6!_<#S2K4( _.;E:X*3+M;*:8;TP
M%UOSK43IVV>OO4:Y5G<7C*\-^ON'!ZB&?],?OW6YY&-_K$&/-  D>RX>^%ZW
M[]K3.E<[]I0^)2THN2PC_@M5DI_/$V'3$I3A$$HS/@FG.DF4Y2GWX?6PCI?
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MSS,;IJ5*2?-=>0EA1=^E1OV_B0A$1X#S+"&D/Y,X3Z$GDY@=OH*C8'P+>H3
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MJ,$_G.#C6.:959ZFWE5NWIXV3CJ#7><NEB**(ZZT.7V16AWZ-D"OV,C@> A
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M'LU#1IP;3M;>X#0&;1;Z8*7[H0 T\7A\"WK/2P#2? F(8SU"*P-8SG5SCB,
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MFOC8CQ\*5:J<3D(4EF!<(^ZHBUNV6*X7GJB>L_;J\%X@=4TE+4A*5%WY%W>
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MEL3!*?V@FQQRXLA+F\*7B+NAY["*4*8DW]ELT2"-+R']%K]YC+('RQP)TA>
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MC\':(X-L[.PB<CRP4L3KA*[_VS:@ODQBOX.*6 ,A@]Q;0?Y.# N6Y\9NKYS
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MJM:5FMSY*JN!JHC_R;4J^$%X.#(1JE#-B# '#8(*0K]5>EEA-<@3/DGW>]8
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M[0*H2]V"B9.2)_C#K(CG6Z0T'C35UH.4:K)LA4R)FWH97,$&DQ"J[MS,$Z+
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M'W!F/)FW5D5= V^ KGHD8;K.^!9*YUNMVL#45+5R#7I%O)WQC<S2H>7EVGV
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MA9CO5M;;@@[:^$=02W#I3 JAZJF__T)32$=^-&"C:7'B+:>EFV,C5JL2HL%
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M;!H4<$?<(5B".0(;+I*)O0NM[UX:BA&T1[>"8QSBN S"O09:R/%QM]65VZQ
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M+R;+<O/\$C[7T]X6[6RT\G?SCJH<+?8^E]K'&A6>&2Y?TJYX5[IG)$/][,M
M6]JQ[*QL\B>$6&V1.YN"WR1"$,89M2Z9<FWL!FY^@C\^0B--* CC0)0@:,*Q
M=BRJ;SNX($:1-58##> JX1M3&5$)-MW8G<5E_N>0,TKHQ?%2VLVWK_#S<C1^
M!!#E(^@K(=6G+X_W\5R6JC@J=]3D@7YHTDP4V'"0=^T]>$H!?TH-P7O1H</1
MF5H=&U?(D1I=3\P,ZLY15!\WA''O/;B?+^& --&/> >P4722T,>N_R1LYK*5
MQ!Z2(HP86P+&+;:OQP52DM-:S'D2TZA68COA:)(,XL8@G^YGP8_.#!KK%,+B
MT2]G"@W-3I>W!VV1:W?K>:CBJFN+D5PLK$A:I-K@,5IK/+)>/K%@QJ"/"R L
M('(]?!?]1_S;VZ&;ENY$6"F]GB6<?_"AKL[.0K-\:R$K'4\IU]*/JEZBL1,"
M/U\&_OS3,\NMU#]*[[#Z)[>6L#-1BSW*WHJ^G]Q^NA\^]-'MP[-$UT#_=7[;
M]+*\BKTE:5)=W*7NKB;S#-C/C5TJ.WH%3%=)H;V'^2NXFM@?/+Z30@E$!T%
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M@;'Q0#>7G?QQK,7B>@7*EG^_P;:H]-&B5/?;]L/@8;FOI2J"V4Y-ST?%-MS
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M727T$8X-1J,9XRK"NM'5ODS-]2)5P?VBW0*%9,)^7$[]A$H& 9)3W[R(50U
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M"7>YX;?IF)?"Q8=''PU7>W0GX[T$UKL(IGB;EH$=/14!Y]_CFEU@5OVT0Y2
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M@FI?@4W>& A,DT*\](46N5U;K.W[A6[0FFE3PM&GCS^L.1Y96IJ/*QT7[0^
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M.*?T'UUX]\G1Z7<%CRE2B$_6=\T(*>1F)^/#*[O:N!68N:W,'@,T*-O"U[8
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ME7LNG[N83;2.B,PA;0T=)G@\UCGJ2?!4WN)Q\/'C\R=?N[K:+VB-$(3X$DP
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MRV27_9Z18I:?1YC]X"=[F.4"1HL?QT+PQH6Z'R334!7[W9C81C!)>% 4 =H
MJSWVZX$TT+D$<S"G<WK7H"PO)@@YT-1P,DZ1E&5NIH;V='M>G]0S.&^O,=SH
M<_-[.Q"5S;1[S10WB*Q@76%N@FW@/ NO*M+GIRZL QJX4DC[!:HZYB<0\<21
MG75Y\CS_+@Q($<ET'AN;'FW]M>TJEP?M*JAXJ=L:P@HS.PX,U!'+X$=;1Z.@
MSQM[7^Z+0D[4:BW?:*LIRIT,'0NU;(V_F]"<=NZ3@=-C?XVG%D_8H1F%YZY\
MUC?\=HZ[\]P#@KY':TSRD\('@<+SK!\$"\Q_*CKQ#K.GUD+P$BCKC=&&\"59
M/Q[<>52QF4I=%;-K;W9<G C-:XH<N/0TF%%75/VE8* 47CYO'?;1.S:,]\;O
M]9IC@F\_-H(% XWM*E*?A.-.@E*(4.$BF,/97G0=%FF582\O.NNNW#%M2,N*
M+OV 5T WG %>3Q_(CGOX2WUC]([WDT\E!*\;7LU!*E((G>\Q[1RE<8_8Z*YC
M&!7DX=565*M/CIY^]L"/9T0H_?$"\KWHC;@"^VD_%#A%6UL6/Y-!E*O?^&Q1
MPK6$8=A2M@*HBQ#')KS'KA%,YI??/OU']<U_Z6J^YWL)F_;=K:\')CP 3T:L
MM=GO&6]"=PF<ARE^PC#,?G'#%3Z9ET< JEE$G+U\!\M\\$E!GT\3O[>NH*9@
M@3&/(/0\9D1N3#;V]"@R/>:-?!C] %6\(')X@HZ3;)WE6X9A+PXN'PG'_H9-
MON_77Q,:[7O%\R_\;NJ>PWW;\AO:G[<8;/LK^=&YQ%\W6?QHX"=WF$T3JT#7
M8]G>3Z20I7A+1JP=6T6\6RDXX^ =[GF/ >==7B%62%?5EZQE9,C^A>7H47.,
M&S NV2(N%QT5IU)-)3V_BTZ-D/T/<RA8:""^;Q@=/C8FA3A!M2RD$&5DOJ[)
M1CLOO[@N]C#'J3DU@1!NH1BL@WU^J_<(2)<YO>.(Q=%:VB6[(#:1)T<2F8/Y
M0GG0&'/T'24$*H-Z>301#B:S:N&=5"A S#2OC>G2Z.'T$>AU$^A8961<X-.W
MC"-M;4N77[RP7/620DIH0(.]S-N#QP!GB6JL@A2B-_BO5NY>6AQMR^/Y+/.&
MPUOS@/?7RM0W!!\O.L*XX7& <&2D(N>L^PV/@]DQ,RW3X\XS5FDTUD,J#*#?
MM3>=EKQF-O7U,"=BV+@^*41U/N$H6"LCE-1M@-X]\Q<R3MNTKD>R!_0F@:7O
M0J60;5%0Q9)L9'.]9/S>M'AL:>B(UV83KJ#(3+)EGF6V%<0)=HU0-+E8U0O!
MB&="D4/\IE-\S5<<7B3'F+9#I'J+;><A[-$V'#%[TMH\TC.ZTMMJ,=#V6/#M
M@^N8Y5BTFLO/#H)4D3$]10I9/HU1E$*2 V0H_6H9V_GF1U6CXZ8.*'C^"TR$
M=V[$8TWRD:&\NJ* \AI=5<L1]9Y=^^?<>TTM]OD81D1&$-7/*CXNV[#S%>%-
MP3O 74YPX=D[*20,IBUY/\O5[,]R[H/]9&L$F")^MKR_/MHZBI1BZQ_):>3O
MCF51D9F9F7V/?2P?,S!G.M."U,^J*1)?2RQEJ3,8;,)F(30E>T5*XGK[ PET
M*42!%JH5,-X-;=3KI&T&@]K75D7[&:)8V]B-Q%JT0F^QSC I"IO24DPK=VIJ
MJ9TI#*JBORQ JC=DVS@@UYS_-9;0?PGXT$QV#.T$V>5+;9A&4Y[OUXL >*N<
MH/74]6E$U1$7CY J%U>ENVT?&0]0KX=#JH.QME)(8\R"D56'EK)D\W>A-GH3
M9[7;?0=:7? G^ YSE$_J](VZ5\2%RC$1(*Q/8C=H@7J.Z.-HJ5T91I%WFA?.
MN__F[P.FPE/FIGF!0DRBV<B/[_;E:6 8W[.7U@CE_<1?[<63K7@_<:00"/1.
M7H(-WSE%9,%R7]?.E)M>(1O1MX+0]F*5M%D-A_E87$X\1SZ PY$(S[YH2G,*
M^R6N,MQ^%*9$U3CHA8*B=SW:H@_/:/SY])_'#-TEY_X\N?^W/T]^"6'^BQN&
MH_8/>3<TN,_&Q,3SHE;GOQTB)G4-5QE\S2$LE-#M72,(3BJ_O=S]04^_TFK7
M:],S,\]C+XHJ *A(*=(+0'5B[T#712DPDKH3C$"$T%XRRE2@A<"2K)V( +U3
M8-V<?!.W'FE_8)QDKQ%J/9WSU!>65BLZ5@G6T,W2%\/VM@[[_D6H>/CN8IJ)
MD/9#_5IAXH@B+["9;R1P%]=+]"6O"F)X6VJM,A(LT>NZBK< 5MVPK<AI\Q<-
M2>XCHENL%Q3$=5,)%.SSJV\^5CU7<'-5L)I?K?7M0LU]IZ3E.(E:4!=V3=]^
MLQ3223HFA7Q<@[&O8:RDD-(D%DYDN R5P,L8<-IT#N\3-=-?(K!(ZM2OU+]1
MN;3T8O0I477G"QV-#**M]_[')KOVL[X'I.L EOE2R/H>T).U"$GX"RHOT4;3
MNJG0=[2K"CBN(#7_[/@O23WV>F #UVT>JJJ73L)<K76/J/AN34I?P:KZSZTR
M:FMKZB<W7QY>:/QR?6A#\PHT U&OEV)ODC!:8,4SX<!WSO$GWLNXZ@[8M39/
MM@1_;<SMZ1?$#O(M"RUG1%)/4VQN4U5YJ-HS=PL"Q2LZQ3%2ZX/W.S?ML;6R
M_P5C"723Q6IWA-L\;66X!*F0XI;KF9B1:Z!?P8LU<,K+)Y?L)(05^!*C$]S?
MRX*A2XFH"=&&@';\),$,2.?C!' 0P:')H\LZL>LH+BQ2:E. ;AM\?6C3&BW)
MUHYKEJ46K<!54 JV-AFH473;;5G@1(A'KM_11/@I,R[A)9K9$; 3Q+'HJA@[
M?L5]F32#]4YKC=D:<.*5@(/DT9OR<7"\V^C-[X)#+^[-]<X$^]S/.Z'P<M?%
MG_5E%OTS5/T-GAUUF6AN&G/Q61UB?+$^IW_F[&G78==#GQ\_M=I94;9QSA65
M;7C65?V3=[1O S^N#P8XH=*T;4 W8L) "TVDHLZM75R@L\*<NV*DD"U4Y3GJ
M9F##RGC*$R"E@3B7H/Z.$L0MO'"3KB@Z 7Q.":MA]/\Z1-H_Z/7VQ-#7K[IM
MUN=.NZ^0^NCOH;WVMN+2C^)*6A"-D=_'?+[8 U<2V0U1542G\5W3VX"@;KMU
M?=-;WY$^TP9W?@DXW)0][L#WNK=ZV)&(3IFJ&]I)(>2XYU^?QD[A_U?2%"S$
M<C%!K$HF+Y/)SQ,J!WX#[KOK6PPLK A&;Y4MO!07W!$3[2PV'*VL/$+8=60R
M][VH'4@5*:UCJV4*CX@"Q46V<+X?!Y?)!G.%3M.288DZV&S"*\[G)[%I/8$H
M]BMSG/ILL7ZZ*<\"IA*R-I9D28JIIN82&:%ZWK3G&HY%]7?-2D6_B!/M#6>A
M&E1M49BX@A8&S80V2FJ!4+I/,^C"UJ1O13NSG6\W:CD'##$=1VP].6UR[7\I
MX##GS%]IR]DY7&C)>/WV&K*RL2NB?GB1!/K@Y:60+T_ ?5+(UK9-4DC.%UF4
M'P%,289"(@RH?H?];I__?S'WWE%-96^_>,:&@HA2I69&*2(E%HH")F,!1 0$
ME"ID&$4(&#(J2)"0C"(@3490$! BT@0,42$@+1D(@5%$I 5)A) @2 LD"N%(
MV@W?]W?O;[TSWG?I^[UWK?L'+)*0??9^]O-\RMGG[&-7L,1ZB:AC()XSF(I!
M>Y[]=NE&1HV[^XF2 ;^;#]@]:E"_!YD1IP0I9PEU3W[#U0[]B=N"'0#72$$T
MRO R+:^P]!& X[!N1&5LF-%Z\T?V\["\ P-%X.#!BSM:4L*=(B*9[[@+OR9R
M]JL20.DI&T8I&V9A/!>P7IA$$]C$J<(QI*!.['9Q-2P$MR4<"^(E<0^Q(4E0
M^;[\=IP"*?66)E9;=!CPO+R2D6!WACVK'6[RP\5/@;XS:SU(6D\;-?;]5;[8
M] TE6W3"R=?6A!4\Y-@X4^^OX9$@_WSR,=%H>]M,"8>K*3Q.ZMK%.(5OV53E
MJDCV-6D2Y0@-)>U75Z^E3B<;B2* ='Y\![X6Q37@9_8?[6V.YF=T:D4DL<>5
M;HKV7(A;VPJ5Y^$2"6.]F)_8SIH?8U]&"A$0(S)YV_N1T>-!R2K< -R)@.@C
M]%K'7$*_;U^4KG&UVKKT-3/J5_PLNC1WZSY2T=CH>U1-_KB<9<\_]<17BK1Z
M =N(U8[KN,MVO7OPIV#=P.>7D2_KC4]X1'C<S8_PR+J,K&.&W,+2\#5J&7.7
MA)88*_&#Q06- &"^A_U>[\=$B!H<L6<JVH8H6$Z)(JK8.I4R1V?V^HESE[)K
M3]5GQ22O>76BYNY9_+MR@4N_%'0.=3-/%MP"VXX<LEW]$-9,Y Y4KG1+TC<D
M63;+I*>=^Q6.4VUP33UY8&>FKD$U]*4NNR"09YQ+X"YOS)F"?TLFYF=%-P%Y
M*/LJ?]SQ^WW%2L&O,@6J([L#/R\C2.O&R8V>B=4+1S_%<AQ%RCOZV[UAI(5$
MJ";V+?DGP(EG*WC+A]RP0_!A8Z.Y8_DNX<Y]=F<>A>==J!H?\6QMI +YSEE'
MW5+JZ,KO@,+>R.%B-Y)<0DD=J>YYQM*CV3^QJLT\M4ZJ\6*X-<^^YV8)SR)O
M;5OZ+Z,:68XV*@C##1OVAXNSL2\G[C$G,"]HA[])&%V.&(I%+AM0'L$O63P.
MFFIHO)06,UBZ8$7HL7E0835PKL?C\D2*\RCI22;\MJR:6L&BF!*9)[E#UL,<
M%-=B?,<R5"4TLA50Q%&*QRL; 2YLBEH8/5 #N/&<B< J4?HL*<KDW*N%6_O-
M(VH+8)YWC^>H*Z+63-<YAVS4^S(&EE&/0,(;NHT!<\#;9>V[-_N.+VR:"C1Z
MNX13!O3&!>< IX>MXXIRK@.$ZB74YA["-",M9^6DS42:Y_3S,*_CRU[.ER.0
M@Z7)/XBW_&.R,OXYHS,M)8W#7U[06@*$T9*Z.O?6H%^&C&H3[JH5)1,W4D(V
M'M'I33^CZ:<ZKOW2BO-D/N,U_A:.YZ*4PLA))EOZB;3$C9*](FW 6&B/3FV7
MD7\5+PRW'JW"039K9:2?"\?I&%%AV]'TT8\^0&PP1QL1L<;G*.J)[[2U2@P#
MLZU3QVMZQ9KG.+9\0PH*8=V$*4HVBFSJ6FIYUFT]<E/8C;Q:K7OC,UHI4RN*
M=[V\B#C,3'I4[+Z."XT/'+5>VF5:7#J6<"Z \BV)FI45UCT]E?UJ"&E2'U$]
M63MUJO2@JWQ?9MC\Y<PT_\E+-^X^0-"ZO+?OHM76]OK7/WKQE6#]L]62T=E&
M82^S]^S7ROT?F/!S0#3\FNTUDUO?,C-3"M6S"XXH^TO_3-.O,.$/42-Q4X"2
M1+Y)"C)D\SY+WK $QZ6@P=FQ%?%^XDLI"-B=DR':A!/:8*")G1VCVUIR8>'@
M81LVA\0W3+^TPY^)N<1+&U)Y;G]M[FFKO%W-B9^//W+(=#CMX3CM]L^Q+;F-
M90"E7WZ>+!NB/],BLH,:JY?>C*9P_BDQ_PGS667_C9A]@MR&K2%OQ_;BMRRY
M); T[ [8.;'-7!><!Y4/0)9T-7QZ25QYB:[GSWRC1-'AX@"?V4!=OEY"!?-P
M7,FLC3VW=*F$SP[>ZV3A$?E/(_"5>&X:'HD@'<G1?S1N[NO@5&$_7%:8;K&(
M(/1^P-5\G,/S8@6(G(X\/)7IIAY&A@#I,:6CZ&6.43M.!UW.\6Y??9CN+XRN
MX(>^L] ]_-OEE3.?IJ^IE7QN+4&<<D&5^YK1VN_X;RK/=EQQ_;9$RT<VU3'G
MEWZ]B>A/25/]22W6P<K9^^I<8QT3=96)\OS6?+WC'3 T>OL;)VK-ZCQ]D8*D
MH/6GI*!,9Z$5;E@BH<%6FFKEQ=;$ESW ;J.,9H7'F%WB!^>>\LMO+IR/%RR)
MTR!&SF[;II8ABJ7$#L(&__P*+^W.U:5>K^R8]QN+TIW_>O4P3VSZC[[]__?,
MA,\>2/?F\<3>USJ_-?^=>E<+@#M[ ZC@#;7A-;%::"$;<IMKCA*I\2%M>C_Q
MK%--GQ"K(YE-%"4TWKFA=RDV%GFD>[SQ>6&X=L-XRLQ(7ZCNS3M/HS:4?5-U
MNKZ9C:I4F<B\E&/B8M%?XV)Y(6\FKS=/)BD2DW@RY):H\8P2?\D;HA9NYLVG
MLY$;&)S)\)?<Q3@YM_J^Q7>&32]"7C1FF]CZ>#@G%TSDWGVY<_\S(S8R5G!J
M4 IB/X9"P]6SK8?@,I+A$GE09JL4I =[:G<"LY\#WX@YR5/'7V$'*+3G67:3
M!JL?FV%_%!WD;REB=WLLV^\+T_(BL)'J7#XR3K]."KKX3=ID((_B7Q5.]&<-
M6N0^F.[+NQE <'6BF?CZF6^QBC[[_&;I!@+O):/;D P&#LEL8#L@Q]OQ\4\<
MCT#>@1W4LHKGC0J=FWGUUTO$CZ&0  RT+O5XDS,3:;C0ZH&^%:K1J%IC[#^B
M%6OXM"71J:@A\?CD'7]X.XMW,F-8FU:XGP].(<$V J]T-3I&+3(XUAE0901<
ME?S3-'BM7<SX7_.$!28M$ + RH$4I;6S?@6#XE*"H%AGY<2[L/KLM^_#KGI?
M-CXG^ I0_1-0W IQKR52T&S]QY$_GKZP5UM_Y$8*XO&GH_<L&JZ2R&JOA 3=
MWD_UR>1U0!<GA$OBU7,H*9%5AS3&*',D7G^[$R^%KLT\&,+/Z "G_I:^EJ;W
M(]Z9E,MRZH-J W+'XJDKRH&'49:2XG%D1*@J8_IMD[CUVY#.J8GYW,OYLW"$
M:7DS2,Y:@^#4\+*.E&/Z2Y-^\4:'30:U9^;G6=]:#SOFFX@M8+P4Q//L^:*.
M.X<7'H?,E4I!%:4T;/[0!Y9(M:MS=!V9-S3W>QW4DG=OW!_+HCRG3;0Q@ R'
M%WO\_(%7[/+&^T>O39J@-2;S0I@ZSI]M=TU2G'%_!X[_N?@D8X)+-H3'4?"N
MG=_,GM.-\^3%JTL?<1I0=0 VCFM;N 67P_XX/!*FMP' CTE!6]$:-+J5]Y!6
M\,3')(Q;V5F$#8E45Q3Z,BK8CN[MJ1^]QZ9+X8^IHS]X_Z-?7P$TE9K&D;";
M7_0?!+\:U^]W[;88S NO#'=()RH 5T[(K$ SC&VV1=-L$;XY-,\[J?:689YS
M;E"_1?AVB]F-I2]R\Q ?;M,9^C&E%S*]UH^D[K7DV;&>NY:#N3\(O4*'M**6
M6'-=P@C1WF=D(!^2A#DUNIVO<0.Z!QWMG,064,1Y=$]&^*9@/IS-%128-I)O
M][N5SD(5FC3()\*M/E&8W\1+EH;5] 51/X70=]ZUP"9%WJM6EW./$*)YQ!TQ
M<N"5\EV_NC<SLB(U &"R(GT-;..9+_]Y660+9 A/3^<946,)YN-MHQL;Q8^Q
M$):L2.MZ)WR?+,82USMS]CZ$AQ[\.<?&C):/6/ZMIO72NCM..ZP2ZV7M=(CO
M6$I!FK.!QA1>4IKG8;[C;15.2"I4Z9W,420$\;1IN*T>GW2=FOTYD/BKA3^E
M_IE76'ZI@LF<\7[:5:*X_Q3EAFV54"'W\ 6AR3?8OO(>V&1<?;10 A\<SJ,&
MJ9X^HR5O/.*8J>[ZROH$W3O%:?G$FZDO<%] 9=PM&5P/OBZQ +I.UO9!MV%?
M4Q0LNY7&"M*BL[TUH*9 !1]].(2_ML/:2KWFKQ6'G#'\^E ;QYL8F.*'K0&C
M+'1&>X[[NN?UO[\74[ZQ2.OF&@V"Q3$MOD]^DL<(HJ,,/QHRFK+<4Q@O=[7M
MO>GAY[![.1KUS70<+:/CC-]A8R7P3[*IOX&5@AA'H.NEH&E\I^4*$IZ%Y[GC
MP6CE93_Q]71\.L;@JHPV9?VYOIQS@=E^S8Y#[S,#=W#\J[+4QF^9/3)]Y#3!
M5%8/>+UO_XKO/W/'$S@G^S8VQ-*0_"QE$.58*07A0[Z98/O_@V _X#)@SR!_
MLAC:'7F.[7B-\G:8O.A8G]W>Z+%SX_B;%-7F&!Z>IM5Y'47$U4:(-#AFGG\R
M)C,,F]@-D*Y ^Z#'3[B(*_HUOBX7/S6@'GY+U2)JY_/=_DKNN'?\TT":D79Y
MEZ6F27GDW'QU8<7B;M%NX Q/.)9!E8(V8TP!;W:<;2MY#>]JH05+"8AU]G5I
M*6C(=DZ>R([-#6DFDUN:"F.YCNZ4%PV4 52U.005$=)0Z.O_ ;41^SI:HB0N
MP87Y.R]LG"+O$>=0+L+D$846_#<9CWO*6^J3)'NF\TZ#E9JO%(?9K)NT)7@?
M!FK&$M\N><:$UACF/P'\?6XOO[*AI=T3@+\EDXX@X3W10Y$+V&6GK-V1I7/T
M9(_H&^EW/3[<L];SO_SB@!.M@UY'1UA^PK<N $;1<UT\YTZH*G"=G0[NE/Q$
M)^L@&+?O\/*Z.-XTW"V\LN@@+]IYD-#7<^HYX,_NT022O/OL=.JU,)<0O\ZZ
MD808K;/AY?X!U)!&]9?DU84'[%_+,GRM%L5!XNT\U6Z7C@-8DUFPO!E6'SW/
M'',E\:$*)92,SKSZUOM1$SRUA5M;BE7][O88I@NT"T[L6IB_>*$)?D"<\"VV
MNO_CO877"^&!\P+XT,?W^"KVZ=-QZ5M\NG)E->WQ/+V/E#61$IALE@GU:0:T
MQW&W*/6NR?S93K\H<@Z/(H@"W"H!DS&7#.838H3(DZ_ >5\7#5,5X:)"D/J9
MH70HF$=/8/>L!;"C7W92FAH;^/:?'!6OUV1^YLY\D\YUJ0]?] I,_"/MIS?]
M]"M1^DR7!HN<]\7;.TQ*?LUN*FA1:_\F!96Z2F98.=S7;U<@4( #"QU8)3KE
M_,+O?X2.FO+H!#LPR?%FA&'2R:'(IB]!]? DEK)[>;:M?T7@@3,CVTJC-FH.
M.@?_#ONK7E"8+P4=U@:+%&1P/'Y/;#36SM8#OQXHWUZ?_[+46)^[9&?>6(O+
MAY_,.[,;B*?.%QP<<$X(+6-O<C$2E]\/?>]9,XB8#'ST6 I"3%,6MSV3@OYL
MPDD..OZM8:%2G4PCP!!2T-@E*6C_%Z69=_@5.:(L72IQGZ#A"Q#O ; ,R<(7
MTBCK,;I7> O4/K0*+?"'_'9W-+FGE:)*UD4[<D*2%F%JG?),_#;@:B<M[T*1
M.*G*;8VCVH! ^5B.LZH#NB#KTA='H9N+%/0P/4.RGBD%\5_!:A=9*QO?R8X<
M0)&"=*HQ+J9;]N4\HW4JWBKMUA3:C+ZYY!G??.$N$>%8<B^OR6FXIO<5?WC2
M.<7G??&V^Q/O*"$V,)_6QL7=)])/WSOA^9MSX3VWZ+P'7XH,'[WW=P_O)^\2
M>:RN,NG.2D'*$B-TYF<:UI)OV1ZM1:Y!9_-J"X]M8S#\&,/#5%1P^;3 Z@\J
M(JC\';,5@4"J_D95KOR\N)PJ!84R42HB)?']J&X36F/]30H",@SWIO T$A<6
MA>$?7M#)ZJG]G(4DR<[^I<=!2*M.;R"NNH[([B)8+66ZN#D-+%84^=^?6RA&
MW92"_O. B_\6CXXZ%4B5CC[LBNMV3;B2:WZQUJ4RWM*>&FICA'D^=8 Z6&#L
M,>'NG.D^<??'<6;\F\\BG<\IE>C7]AC!W7/W?]T+T?!4\][FMH=ZH7;_=LZ9
MX[_NO,_^O-E,Q\74O\*XP>9I9:4'T4M%:,TA<GN$AT6!O*1;(B6.HF>KGN[;
M9E35NW I:)L,1ZBX#2+;0;+!K-_9Q'&W >R/X5#UOEJQ8WN-WVAMWLU+ 6_J
M"(]/+%_V;V[5C(;@QHIPI/7+B1&+QLUN;(LA$GB]$97@QB'54XGK_3%A Z*M
MV;/!4M#&"2F(YF,1R;\H0)4[JN>;3GZ)VO1DQW&#9HP&3 'W7^9HRJOG!O*1
M]+5FITK=!\N5SB5-I#OMOG0WL^Y3^NY5$=17JDYPE3]$3#LP?X:_O;S=[CA_
M^Q.[/:09<:Q.N:>2ZYERU_PP[$S"22_#$IV#P5KWF\_8&]BYQ)P66I\!:&,+
M\I*.0K 8WZR ,Z_BL%+ *N5 /;_?(\YF\I6N%G@CTX5-3(0I732/X([;5+9N
MSB.F6\8*#^H_2_GL_>SI#<<\!1[TYTH8XQI*O.XBCF?.DH)NNXO+9:;RK4.G
M%+2&*P4!$U'LBJ#?4B@U59K.VY()*82# _$/9NCAT6IJ7:X/$&]+".C>4E>S
ME[277PZ6V>[OGKB^TJ%U>GJBX8*"<>NIHB.UH6_;QL8DV]^<,>#N]<E[D79U
MM^O5BC0:9_<1"_:!_H29W1G_.6AW_W-( Z",')&X7*8C.D4])G^K<>BT[,]?
M<:].4'[%"7<W=DH>0G<3%UV(GPME[X>$7S/+$:G&"R#D9KI%D[,)/.5:S4A@
M0)AZMJ#NK]%U_",F/9=,7ZKN?O,JI<\F\:K\)GUY*>C(5Q8U9K_ :;D.9X-N
M7<K,7,E6\*D=XGF?*9*4Q*GLW(W=%G3.PUQ9,OH&;]J?6E-UXDU?3<W4RK<B
M\=*77/'^_U KGX6<))%*R)@<#7X;:B9^M 11P[[%*@&$\3BE8[S.6S)9FP@&
M2PPP!VZ/4POU;NR*),@K0.1G_3#JC2>5[0633V^:/6F\.Z1U\X[EP*<3K.!O
M8H+^2X-6^#L%)R+##;2>EKL;&QM8:AH81.:Y"JXBX36A78 CK]X!L!QS,6%+
MKG.4] #\R3Y]<K9B" =^V\Z>KT%;=L%%FWVH>@P0:=Z,Q)HXG7TG>WUIA[H<
M$1?O,'^N4 TK9FN#WUUC>0[AD+CASYU:#E4QPAU8NM]H/K^2L="&A>#;\E9O
M=-^!SJWEPL:-J%]*^A;,2+-Q8)JW9/M;NW-!L>7%B&4KQE#*HJ+3>)H?+6IE
M_;=0^=N209;WX$*DS('0)1=S>XLM7<T<L_,NI7E#3&X^G'Z5[V+!WM5T8&ZN
M":SSKXM@+V.T /O'H1I89:!8Z W%LPL,/Q[IQ9A42P;@VRU[-O@A/*=RH.#$
M=K2K%-2>&9J!+)M>/C;MQ0W]I;^:,#>/+'9"!IFTBE8OEG"1=+,V7K0HT&#7
MM[LQ^EM'=7JC$*0JB$(HC(3J0$*H,(;&M:R9E9LU4]EZ!O5/\4+/4]GA!6ZO
M;Y%$6:^'S'8>;Y=<_[;UU"\?13T+$DK5\ODX[XT-N$M'1RB0!O!547U='CQ3
MHTY4*02; / Q[W2,F_ 2\%'P $@OIY8"Y]CE;03K,>NYV1)%UR&/AH%(UK;W
MP\ 09ZA=?,(DQDCR5_-0U)U'@+;CTUS. .XY9F?<8[C##KKI>"IWY=O$"FO>
M>7[UAC;1/')C&]ZRX/U'XY=U^9>S9NON.#F8E)Q3Z_OX?2<)UF 9L$]H',\9
M)82PM&!+!<U7X&5GOAP6!@,RO(B&D3Z*5-9,LCI&MQ6.4L>'.IR(Y4GM>19/
MAZF0N2_CX>C2QGL07[/QS)B=B=:Y=P*]CP_D_*(T_;6Z=&-GB%N^/%CT$[QH
M\>87#>+>6J[]YG,%4_]QKF \T 10X+$Z*)I855$,?TMN7 Q?>ZSZSGB+!IN[
M,C/$F\YS*6]/U;5UX9^N"7WVRF)VEMFEN&^4/BJ8U"A\HU[P8Y2*9=0W>6V-
M\) (O'E;YLU,CXE,UWU.PZ6[7IZ !#[+]'"+[ L_?76)1YE;$D*!XC$<#<:@
M_/D4L;=+:(=!\=-8NAC%*I^P.OJ09#N?U5Y@+=08M_Z][.EM-,G?WY>4KM79
M"=4>?,*VDJFL-O?*Z0X?\\B_TCOIL&_IEL5<WA2=8A0I]IX19NUJ\[B9[UW&
M3'6)>_SB%:39+SJ\,77J"GP=5$YD(R[$;D/;CD53=7?$[6</78_,+]#XN2_*
M1$@(8YNB(,0H$Q)YP%+3J'% O[%Y &58Z%Q^]8_7K[ _JV)JBG"M>RGG44H
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M^A_:&7_K\HM'Y,B_UE^ G'%'D<JL( +X.,[:BCG!M\KGR[6-FO/)">6 /R=
M=F!**GBK1-U?Y,7KR-')7KD:SX>X\AQO6<2"-7S]?+NA^,V-Z4UAF\IZS LA
MV(YC)DO?9)-=K.J0UVRQQUQ5*\W][MSD%/1E>CA5554MU83WDFJ"66O1X#:8
MHITNFY@D^8$GR&'#U@.V#D]YRXEVUH^89F4YCZ88YS<A@X."UWP\?ZH]Q7J_
M7>9!1'",0?15P(WM-A<7S&Y:8"H(HH'D,1?MCM4M2#KQ.J.84%X40<QMZBP/
MAZF..V'-,%8M?>P7=8.U [TB5%$G?VV;GR!OAP^,;8XF$,U( 2H]^:O2[ANF
M/\&0&-)"7IS/^_SY\_E7!<8O AP&!HI5&V+.&LEM\KQ$>J!%&@\/W!NW[;-1
MJQ3T3D40">SG3-O%EB%&#P'7Q[<W_Q3'6S[&E^L@ID / ;18-@0T$^3MP4/=
MU.A<F:]'LKD*'LD[ZP=^?5KO3#A"MR2U-!6^KW7I0J^5;"H0&HBL^3GQ(O^'
M@'='/1VL:'<TFL-*@"F*W/F>'*,4R5:,,=_R0XX*M)ZWP+[:PC%9D ,B5AC^
M3146]?7]^AG',J/CM&PW;/2<<_N6P>(M2,N%E3W>]8O)*V3M$7$W.*H>?%EO
M-L*,5);^@E8O?B=P[()MDFQ TY<%K8!8Z(7QZ$<NIN;C-P/A @RPJ<CQ,6/F
MBDR3RMF971[=S8>D+FF:?BP<[3H-9/&53K<T93B_>O\.C:)B=0*.'%C:5/TH
ME<OX1MM/.=^B[.7P1YIQV2.)\9O+R++WY4:&K.YAL[L>SL>^=97,?K5 H&N_
M?M6S-_8MU%BF,U?OW^&YJ+ZU<WPXFX$,$?YBV1:ZTH&O:%8P:CU^#+EO^*QK
M[R;YIT=_/#7A8VS@"CL=5BK M5$\"Q-)E[)E!7M?"IK14Q6= U*%5J*UXF+8
MV!.R72_9%K.39T1#FOPL3H!NGVDT2TJO53@4P709J,9:B@X_+URAV]X-TGU=
M=Z>TQJ7KB_S.=49J2]8B&Z9DTY 4Y! BA$E!;+*,8H#!WT9E4'RW&>,I!=6L
M \Y(057]'%TDMI_%\\A(8-7(=7#E!+$#4$5)'TP3:R0SATIR-.TXI3$CZD;R
M#J<0]@_5 >AKSN(CVT6'RP*9MZ),X+LO^!]$<C34F\J5]AQV<6IRD((V!^0
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M4UB%_HOF\Q9*RJ)S/'(&<5JY9XU)2R*Q=.3L._C/KB^Y99%!?^U<U/[ZP5]
M@-T+HOPD:H_0%C<L\Q7>Q/C9Q3<5]:](.-5&\MN#[$1J7%BC0/5B1=!<RUW3
MZMD19DYT<#2=\;W8[>X9/2*>F_HWF<U>0T:/U)D7J/\/4Z6@O[Y@XX9Y;E_]
M?S!O%@48P<6:^+G5^4P4.DI!XV>629?UH,#U,51"X=8A[(^8U5U/FQ7&,C:O
M/KAM*YI(\R-E)S^<5B\\_]N3(<8]T5O_GPT*?9 /';)>OVC(TPY5=IJX;04Q
M7UCXA??N='[D+OU[S,CIDLS!.L9S)S/_S^0Y8/P[('[%>ZR3NY[G*$CFB9=3
MR!M$'CQOFME:YX$M694S>HI#IDM1?5&'M5Y;B/U&-82!N5=Y^WI4-7C^+RTV
M&R8'[M!J24S\4(LL'Z[;Q>9EGG O2KH;6.E>[NI4/5W2S_QO)_6_R]3N]JSH
MY:=_FVRL[/"MCI2Q0KS,L%%[$N$@$F2MI N^7F2&(V(9JZ<"XBWS6S1:_0+N
MKN0D8+SYT?9]&*>'@4ZJOW27SOI=_#0<9D6X/V_V(?3]UO#%G5^/<K-0(B_+
M"_T<P469MQ*+4W!+T:%J*ZC3S D_2DH /'3[487$%5K4TC6KTU.^L;M\ P8I
MP[/!V(^ML*^ERVG<5\;M/3IP>D0F9*W_GTCG2[BMDIV '-LHGD2Y!5<1G6-3
M0 "8>K4KNAH@TO):LI.*$+\Y65SED4:+<1;J_!;:Z[=,_Z/-W5%1%E9T_DN[
M9QVT#P+4:C[[E(W(;])G1A189/K5,;V<#*ZR"E;P>M\U^2=%6L 7GK\@D3<X
ME :5$[GR0FA@Q7<S^Z:U$JO&N!']WDDG!X/2#;-<!G=<[WZ3B_DIVYA.ERC$
MC&[:6;#M4=25V5IK@V(DM/N9H]+-NZ>+CRKM(J%?64R_,HM$E/3[1=0/_7<Q
M]MS_G>D"9$"]7D8"-ZYAJ1(03PJ:(UP:(PZ'C%$2C?@P+D5H">QOWS<U*M]O
MBO?AE=]J]CU4W<06"E+V1%@0O$:.6=,S+QB/_Q!P? WER-<M3P_E:QM55R(_
M=7H+&LD?#]E9:<]NOS>W:WBW>N K=>\THN#:,+SA.]-(S5HVNC<9E6S*E%Z2
M1#Y)"MHY\64YY/O*PGT5Y:'_KLY7Y._DH*@]\:.*=.P.S&D^,9&L!VA3WW9"
M21R*1KBZGUY2N?YG1V1$O<;R)RHH;V;2AX T&\SCS,O^X#[*1FS;WMQ$:8FG
M!NUX4'KDAE- O6N>DQD3Z6MFB9(Q])'OS)Y"P);/'&-QY=@(3#C/D0./)^]"
M^['<\<>;Z!A=PO"L.EV+]+Q3?R6P)/N3YN*(PZ[2E)#GE,31#T=-/6,"3S_F
MSJK^SY16O)GID;[9[M'@0+%KODNTBV%>__]K*"T9E0W=S>U=[)^-E#DGI7@I
M*!A_0Z*=VH&K5VKM60\0+/#K$=GA1,#-JZ_YG'DY6WS*?KO0*R?.H+3F/</I
M?FGH#M--AS/>?I7O/LL._[7=D<]8?3E7)0R 7RG,UMX\R_$LLB^9&I:A,Y8+
MFYA97OC\G7GX+WBV^;<3\08&*:Z A;@--U@X  M\/'NAK<'N> 2.#:[E)]V:
MB^QV]'4^1$&^Z(^LOT/2[G(VFQ9T_646V/>V,36YV+1!):O7BG7^76E2:YNY
M9W'2S3-$XR,/?JT[P2VIKQ.*AL?PWSZDX5%Y/B6>K(_V/L;OI$I!JE-ZECQ4
M\L5S \TP3H;"#-UO,O[)NQ.^'K.N@Q;3U:;S;'.BML6^NI?NG+CG.Q\GXO0
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MVCY:"OI[;J'!L]XR.=GK6"@#!A9X0@IRUSL^_E]'<.YQL1"\2PHJ\O*7#?0
M7'+F WE,"O)[@9>DV"W+X@)(09"56Y\<>V$\-]@-V$9,G!"'_4NRCE].Q<NC
M\UO))D!6)4*BSZ,_*Z7%EH1[N:,A[='/_&;4KZC?YJ@VU=T8<QA'9.I?D M5
M$P]\E?N\^>ZKMQ=)07?O866_!6>B,L0_8\[ I_+AK_5VGRI.X# 6GPX@@J9-
M]3951AJWW;,84;M:Y.)@3*X>BG-;[)DB^M6%L!VTU7+/5-W_-3#V03\Z#>G$
MJ7IQA&!^W(8T<N+VWJ%L<Z_5C1"^#\E,/J]*]I!%W+^U6+ 0]B<?GM)L.8;:
M/"O9S\]N*D6?:\.J]2XI;45GM5^;F-.ZFE$TE>?RI+XQNZ*"];[YJB#;R^N/
MKDN7[-Y4Z(2^[DSY#Z?_XG0U;U'9KV[ZR$MSHIN93/7SO\X&_QMUO26A&J%G
MU&N1H8S&N=?2+71Q)Y_1(P/\VLX4=GGVD6Q]B)'B(V^BOEP@-=?FF=PR@&<?
M+_'2T>ILX7^,MUC0"H5O06&<2_R!A?85PP9.@%P;*@8LF"]G+RB>15S-$]2C
MRBL0,@.]V-6"<B(UM-SQ&(E <0ETAUS!FD^KC.#5IH]_6A1R/K_<M;M)/SMO
MA#&R,(E!?A?/)2FUP]><14N$[#.4U$A-B3ZB4/T9GUPZ=I^D'6/G%,16=/-L
MZJU=V!:(")V<9#J1!R]"+IJ93QZ[S9FD<PZD;L?_ *2.'>:OQZJ"U:=@O.?X
M-I?QUK&@"G^\BM(&\R<6.SG1?4?S'R]ZT9WZ=Y+1]$TH]>,[+Z!+Y ,#6'&C
M([0EC)'H"U5TED(MYT-JZFEE3-D88KYK#!EC"V# A+-9:ZGS!L:]&%T(40"*
M_7ENR5ONQ*HQIZ#FO(DV9GBASB#GZ.3T"CG7I%.0;U*2$IP2'IO@5?_BAJ_-
MRFI"G/.Y:.)4J:HU-6B#A!4T_Q];%^2I")[+QA(CH9+5Q164L0>CVWD?YVIX
M< ?><CLX':]N@=*>6L'=J.T*5U)%^'G_2=&8S4,FDE Z01#"15*L;8##J&:\
M?O0IQUV::BL*7P_-63!7U@LCF<%;)_OTN9@O>^7+[+1<"3[-G+A-Y$;%O=[%
M_FUT2$W2XWCBK?/RJ=ZXP'A)X(J(]?V.V47F,&IP_Y:G'/P++>R4; )\QUC;
M1$>!#$Z!2BMT R\QYQ(!G4\+U!\P6VQ1.=;'_7E_X(S&D/D?K<K9I\\^BPE&
MLY,#??^7$?1 OGV8Z8WL+\MT]F*&O=0GH=X(:\:_.CM?1Y)YI-&9_J@1B M]
M,989YWR<'BD\Y'UB *FOS&!--R8T1U^UKNLC=IFU#-;VNFU.I7;N>#I&WZQW
MB!<\=-L2G%A'-NPSQ\05 U=<^%@">Q=D9[Y_GVC_$Q9K^IH#Z?&P@Y^SB:[W
M*1D4!%CYXTVX?8@AU@5E0@E7,R8:%ZM4%10IIBE>%8\<BFRLRYLB3A(G,:CO
MFHLK92)W(.H)YA@?TN9BTE&H,X U1%NORNYF[[%8,U?&>'NA+F\A>1["Q1RJ
M"M>ZZ-K_SB]<!9$S^\N0@O99LZ;C*;^&CO2WXU0E.FC'CL"U0 P'IP5<.<H?
MHFU:8N*2L,H#4<[A<;@.#^#<29O.6P[7RVS%5:<"M)W7++MG;G_M]?2Y9H#?
M,:_H[*%[PO#9+V&0*K89[EQ2O;69N,#VRI5=GT99&I;%R"^U(^^^@+^GFL#4
M0"@/GD:";9\BJ_.M[E2'24%*S4?(JGQR3OE(IZ5,T&$<#;/*9GL16B,/=\0J
M=*5K^/0M^9_/58N(% K#JZYF:IZ9)9:N1EJ+&A18F;"!Y'UZNL6SQC\RK.?-
M]-+_N7/Z6\6EL+%"V-./2;"+%,#(^Z8%9/C<6-T]-NX6=)^XY(D(^7 8;>0<
M?Y)O3TS"KIE9F4_84!-VY];"N3[2K5\'+GJ=:AOEJI^G7H%COD[G/WU]Q]+_
M=:IHLY7F(&TT0:/KU@UX8V+JS'U?W]@6)JJ%=>7[:'5WA S "O[N-+[W/$;5
M)"4-5V<]1Q1"T:G.O(R.G@R6 E837>Y3D^'^C"<%I6+\RQ!Y38C+/8)04GC5
M)D-KK:MWS#J",LX,G"/UCQZ[H_[A_GL35[=C'UC!5T]._3)=C>BE'MG=E?=;
MN1HVY9-3.*JP97B<\NUP\W[%JZITMO$"GA":EW[[6?$,W8N1?:]R.OHW^'1C
M-CY6_JPORP?N]]*,-%(PV'RG!WD%9?I'MTK)G::=:]#=SIP>JIGV63XJ<0FG
MA_9VIHO6L[7!8/0H]13]R9,/O*0;2P>C0B,75-#9SLGGXH_U+L"/T+%=,8^[
M4#J]T]']#GXFB( SJUX0I7C3*R)1UZ@F<GJV=+$_0$VL$M>3*2OG[XEO%& L
M],9VXVLQ*USBG_ATEJ)D]RCZ@FW,DA"\ <"[#I(4S?NXN6:0^2<[[@::YZ*G
M7B(J317+1_;=JV_XXX8)I!57YS97SM?FR+*\%;\&^Q:_">/+=W-M&)B;MU,L
M H;L*4,E+;W6.*2OCQ\ULJLR,%2H+Z'7]NLWO>C'-&"9.GIG\^$4(JU,.#W[
M+L$9-*"5N*V"[&.IY>+JQ,R&(&RK+*H7H@:_TW%GL&$R%N^\##Q2DD/C'?@Z
MDDU\U^(QO 9SVOO.V??H<%KC,:^:&:@>_:'G1\1**8G$O=?O]WZ'+2/0+X V
MZ7^6:K*T2)3Q^(54Q82PF80-3961C'[7$3H%MO__@-]NS]# OI2":N!S;!FW
M[Y8-ZTJ@2 [8R9ME'_J8'"D%,485L1__E.@\?SLQR.XGRV<_NRTF;,.^K4N/
MB?Q%*4NS,*!$;@<%.?MYOR!7ILS_P+7NDX)F^P54*6C0& 4OBYQ8O5K-8\_3
MA(/C.S=V;/.YS]CK9( Q5&LR*".,X//TOG)Q&7JT2@HR9O/PXN)4N*P=)BKP
MY=]W_J3CN-8R.!,"Q?Q403EOF1O"<Q,T\R%SO?RUQP!9']:;_]2+50;<.'9:
M^,1)OLM02G59)EPU/'L/T^E2K%G)A0-S^I'^!I$-:T+2_!!6^<\C.<0+2Q/Q
MTU-73J@9.#5&CCAYO@X^T[;OYOEQ^>Y7;TJ*%)C%F78PB3PU/+@,(W/E-TZC
MFZA[?#OYB6!F5EN@)H\[T;!U=@BN1.K6$F/U$:GZ>TF#;VXRKODX53 /AEM\
MWHDXM2DW:3TOA(HGP42JT6?$I5 K/PF#I4FY -\$K!7\#E3Q]H]!J+ ;S]"_
M=A[I)6"WS6XJ JN+/..]^BT56#IAT!V#OX9W=:O/S[3133:$$O13Z)/K,F;A
MU_$\5^>%C2(T;X%[4'A2T@]3H80OI$-_Z+,L4&%?*!I/5Z!B-_*,J JHK?8"
M9+@[+X/*4OBR@JR_1=*V&SX[F^,]M/^^MK'RR3^<E2"<!< P(\,"=PNVO=E=
M:(IEP-4IP? -DK>!!@,8)/\<&Y^(T1QCZ4QEH5EPGW&^8ZI$+PQK&!OGS.YH
MXAQXVX6[5(8+M=<5IC;Y_.2#Y'+"W-W=&QOA*JGAWE>?]$^'Q[;H#>V(W*M2
M8=-7[-Y7Y9F']HMBNQ*;'%2G!QZ,>Z@R/=(:BK2Z=U5>=O7(,/XRQ($SUPHF
M@&&A+K:+LM7/+=T+J_)6 A&% L[""(R3.+79Y!&0.GZLAY?E-6!GQ,:I PI'
MF^H:):]YQ%3+ "ND-XV1D3@7@G<.WLJP5TQ+1AUD$X%=K%2L'+8=5K=,@R12
M2/;+7&04C^@!A)2*E/N@^P"C=JR>N$RB/ -76R+L;[U '<<G+&7( TX8-T0Q
MD.H3X-G&R"YLO*GU'+%L$R IVA;\K%9L3*>,Y>AM7MUJ9+CG3WP-K(.5@JL)
M29."@K^('*_PECD7?E^)3JL6'87=7I<Q_A$H8A^*G1L%\X?Y<1^6_;(?1GB[
MQ?K/YOJU<KD^C#RRFBS1O#!0NMU!H4LYUY;OWP&K[6S',;K:1G5YCC(??(M1
MG<1>2#(K1\-;/0ZQ;IAB%-BH39U6N>Q\RN89RH4A,])!\RCGJO3 5WV<<Q^*
MF4XG3C>6!IL,.W17!V.SAZ/]$!%?3*U^S:N=X :"[PS>\^\_HZXR7*[G2V,Q
M&:[[J2[6URH?(0]CSV*@P*PP#&,&)/' -,D/3;*>$42Q@Y:L9+VM;V&AJ#78
M/OSS;GHJ+\2;!TZ%)"2ERO2:TV+<K@#1GF:>_Z@C82J;OFR=K?+.ET0044+2
M"?.PASU,C7;)CSRWN1RA"[JS[5K+<I+(G0W_':\NLF=W1SO?9X;Y6344HU4"
M!BQ:/-K8A_<$^@0R6Z.0N]9U6AP?T_&F0;?(.H(0N6?1P'(X-D8R"M8A0S$&
MP"8.$DR3R2NHR@Q4DX?_?<AS"&-*!-\TA^X"F&V?P5LQQY.H_+M!2)Q>OGKY
MI>WYIU0<]7G.*\9\"OLN6(N\6>0-'(JJZF8+42FX+9@0GF \H+XFX]2+WB)^
M1A))2:FK\G"0J>#9:-<O>?$!CN$&W8VN_(UYH?=2;UU.LM B97GWE^4=4N.&
M]$^N1 6%_FK<V^Z [3W8,3#N47)^H"7?U3V,$*QF[#OK,>_4W6$FXY0"EJHH
M5%P%.T\!#%EM* 9G05  3/"9XYW<U#+L&];F13-M>&\D7 ,XRG9HX5_7\$6I
M82P 5/ET=G1C9^IBQJ9W@=-6ZM<2"6BR&?\T/?I:&L1L_(@%=@WF-W$U=CNV
MEU*S1(Q7D<BG\WO8Y>U@#28 %J3TX2ZBACL^'^'A$R*1%]ZPD5!3M':'343.
M6O1/=@>)J4<K@<N\]U.?IS2\(0:,E^=4,H;@ZM@_*0J2G=AV[%IQ,O:G</)/
M=#MKWO*?+,5F2S;K5N.V5*J>16_S&5YUS\F,-MPVC W_9<7A(B#);<#B!6EC
MD#+<?UW>1[?<:F3(75BV:+]L"C$8CSJ Q"OG)'&-A4C1+^*RBY+USC&/,;MY
MNE+039$)C])&+]S1U'^A-XL6>,A-[KU;%%\[\%F_4::MYE(,TJRH,2;B0VUN
M::95-=K/SVP"%8UNVL7H<LB<KSOY,5ME>^6I#_=<CU,5*ZMP(1[[)]MM;D<1
MS:/H>PAO6CJ*5/-%H[R%)%PXD;D@^%E<(@4A=^&02BG@31-\.9&%80$/-Z:4
M0, 80C=-412A>FX<RD9B EE_*H<1/+&0'$519R!LD@3D%F@Q(JZH.Q89C5!Q
M#M?9MDAYODPC)H^J\!U%6[79CDD8%$=1@STDJ]QAA7&#A7;X!L1R]Y;KX]H]
M&S#Z0'0L.V:I:T\I"GRDF=+<T.][R^K3^^-=RW_!?- 4R29;8C-,4Z(GTA#7
M8/=BY,1Y6&@X=C<?T@[^74^6X_%13.U#(9U[WX,UJ6-@G1FAW>$QW!9TV0RJ
M-ARJ][2^,>5,MF"T[],;V]?4]^@:R:;D]0MMX'>=;?@ML%"X-L8(Z!5N00=A
MC'GX<?)UMHN<#_Y4GZ72YFFR&C\"ST&!PJ-KIABW<SD%UB=JK-6-O!1#3.$&
M _SF9W]]F9[)=[&::\"JO>I#N5P<66PBC]!TK':;[Q><T?4YDD'*;[=_<HR=
M6N1755;@\+#2(^%8L8&K.;_<8#MM_T<6PT30!=0+#TGZ<3Q/W:O4=C_\+=F,
MRPFT ##?A$VA$KSX9;S;Z7RE=L9"N]ENY$7$G^79C(0!&].\E^ET_RZ3=3?W
MX<V2X+Q^08BXKAE<C.W!U1JP1*K^M%$3/B[5$O9#.%Y/HBL*R:%Z@4%V]FRX
M#L-W!)W:1I&O#5"B]HX ^]L;@UJ<W7X8908>;[SW85M<_5^W)WW\!Z'J,I."
ML6:S-%>?V0>P^=1.?&U9A= ?H\9CM2FE*XX7:#N\A7MJJ?4D#R[AE7!M!^V\
M K?W)Z973S.LXMD%^]V.-T,M-EK^5#GCE[[T>CR'AQ,I4VG;1D7:O)R.#.;1
M<:/.C.$A 8;OEM0,YQ''W)*;C<=82AV6\+4O8$J_ JG\M4?<B:)C_1CU"B4!
M,H%;F*/V.IM.1)^_;9CH-)GD<.\N"@W/W46S(-9,NBRZ3K..VCNJ3G1[W/,U
M=BVI:#MPS^W="9_<-_LKV1Y]KFD/,V]4_56T&W-[?[3H#\"1C;HEDU_+;4H
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M'L1V?LT*]YNU;:2.1*Z>EJJVO).!JCY=X_^BVK,TC#Z#G ;5"Y,5$[#'>+L
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M+/RN):PL&YO,EF7.=TAOBWA;A%YC]N-YAG3HAT(]H+#*J(I?KYQ<;Y+;X*U
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M<M=8][DE.5<;^_?82.S(])?X:<"1P%430B*H_%"I**H]\BN24RV$9'T6J>(
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MZT-]RT;,KM[[=*C!?HJOUKVP]H8$:GFOQ')/\QP:0'-@C155A&);GQO2W\B
MOA%8 )KW!<K(+4'!>:4\#D[:#_V51H$*)HS_=BA7EE;6^@=[G&8Q!]-6"K3@
MLE \>3IG'VC'-N^FBO/.LQ6[$$ A[SC=GQ9D/-AB"<2RNM-6UYW"(YG-Q@81
ME/T EECF>*"Q4,OU:7.FB>T[ X@3-A84Z\8IXV9$:A-PE4[*@W?!DP3B?+R1
MB$<UI3-0@B-@+O-Z^6RX132[FV74GU;_X^ UE7[II>M!^P"17\Z!)Z^'U!=R
MO8:JR3^^OO%K,CUFI-+N#T&?$*(DA$3@1>'=*,V3#^KF8/@9ZGQB?88[Y_F
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MGQVR)93L-3Y#1E@;C&H7)L:\WMX3[W]^\C^)-50I G6^0UN(0#4403IT/1*
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MF;6T].<X[#J]17WP\M+/A4=N3ZFETK2A4U6,G]9H28PJB679:>3VCC6U&&7
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M>LH_(P(-06V(O<0QOW/]4 0M%<MV(2JA[6O>#1]?;=0Q7?*Y^9NQY/*IU4N
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M_)5,F:BS7HPL_):>#T?Q0QTNS>(<F^; \4Z(XD@W-ZKUH3VF'27&X58F]:^
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MW9SDF3/M*?!BYA6BQ(O9M>]+[M)G/VD]*3DS]5;IR-O,>]?>P(WTE8&E,#,
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M7!=!R7&,$K[=L_>A6&OZC0J=)2V5AJF:[.$%?]SG')F(JX&&O\!);<57OD;
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M:$B'VZ#!JX;!,'-SKPN.5$H0VVO,^T..2<[5,TSFNT?79E+B)VU<)M^/$]6
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MYX'MW, V&6"7HK9[ *^_,*X3:!"[B?1ZH6.]<&^(".3#6/80@=XP":/S^BZ
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M7C*$7"'5VT7UDL[-*6&P'"Q?%L?E _5(GB7*G.6W7,7N;0?OQ]Y)2P%+"+4
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M[(QV[$_80 8=T^O(GGWUOVV1?%W=&8&1!CINWBP%P-.XQV$T1G3A %+I^G7
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MN543$#H,B3+Y,J>;C@S7N6Z8>:MHS[I3HGW]#;'Q6<?/(I>+1""M>+'UU8I
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MBW2&6/C7["CK 8H/['G:7B75R!R\PW^K\+_:PCX<*0+Q#S&X)SGVY!3\DT)
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M7YSM'WSDHI^_=\2-<-E?1,4$?@,>$2KK<-/;QT]6[=^(W?\[/.7Z,P!HBP<
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MYDMMN48\_IU\W"(#\'=;EGIP.^(9.QIZ7OR>3D"8SW<>NIPU>8(!F/43^AD
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M)&*IPGDD1?(&7EH*SW02A"N@)0=2< P-9,L XDI7%>]I08[J),.JW!;*FU]
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M=_MFVHQ[&A5VYCM]F>F?J[W0?$=E,K]Z)G6F(T ,JCK8WJ7=&6R<\G?DDI2
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M%OE=(-3BP+EZV?/&GOFQDC5%B9/EHFORN]!*_]QOA2GNJO-H>2HK>9H0:4(
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M[@GS3Y0YO2S*3=-S0KJC=ZI'3>INI6FK[(D9B[0O=3^)[&T\[#RO! *G/!"
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M*Q%%YQNTHLSZ,M:M8&51RO56"?FQ79.ET&<=U.#T,;60[XXO%G1VV]WU-W=
M+?G;PB )@:@._NRL3 V@PA'E]Q*KS3IXQEUH.2,Y_A!Z'_= 0"%_M(F=7[#H
MJ1 ZCH3))]P)K533.+[X)<J\:D6GW-#,)/:EPFUEN=HW-75MXT$%;;K8<'=T
MA[Z1!/(,RX:$?I G_:N]!E<&P#$5T.)3"UCA:S^T$F*4=(9[(\9M[&AC_1@A
M^J+E6$412V7.33M\,[9_@=R3?GVVE1C'^%WN1*T =,'HUX=@ )06H)J!6XZ<
MH^Q ]+H"6<S!WJ:@% '(EYCH9L)^T@1]@ N5D"0CL*0")TO.V_6GFXXS@PFA
MW0H>+:\WCY? ?16-V>'JZ^ G1&H9M)K"4%)]*,Q2$\(X",)P;[)())12]9!.
M<A3M:U=2LE@'_XC'Q?>(O%6KI&[/@]E1!S1]FQKCK,=#>:YK\\V9(Q>7WMH>
M,[ KB#<W.3EE79Y>T&INF959E&$1WF3EGCT,XZ1\';-]7YLP%N9MH/^B^CG2
MSPZG:"QND?@B>#\8;J"L,655^B/*R/]I*L'[+6-M=;F((\E_*P#MA?@)0-/3
MU"7 C ;NE<! ]W!=BTTX>L@C (LN0V#6EU!M]B'L+5G>Z5M6M7EN&LXN^)8)
M%2:_KDSS605TH69!'SFPXXE^[L"G3Y .X@.C7:RO7-GI#HBXD3:_4WDK+W?-
MG.@;)#<CS!0[C]4S5Y.-]B/JNK)OZ)=WL-0[S[K":@ ?=@\B4$-[VK>N'E:A
M(RX7@JA>U#" _1QFAK#+?@&Z\.NT>SGW'B^IQ9GNKG6 ZY[62]R%%>:ME,_#
M+<;,YLZ3OKX!7E2=R:.3+5IHC8S*[AP*?F*RULP@JV&?P>$CYL=YUWG)D$ V
MKQE-K03OY%H5 @K0N+:M@#?'D.O$A#P(U;!QY']BG6*?=2%#H?YM1\>=0T.@
M,RWA3WOA>QK,X>+%&VTMC4UO_LPXZKD;C\4W5"-'TRMA:G<MTS(+W/H8)=OI
M*V.4&TS"=_+JMLLY'9U0,G[>4OQRUL5R"T13*GS?TLW#=LH?TA(?%7CT%#IX
MJ9V^KR$Q%?-KIPZ"/T&4%_HI\:.\,2_)0)W)IM!P<<@0+^IJ\CGSO3B6F<NO
MS=HA-*NH+GUL_*W1GOP"SV3_Q6GGX<J>UHB;AJGOBJUNUPM WQ)^8$B01^C:
MP65)H>[@#J'A04\@H!85CB/W!M#*"NK&[C50>87\+0'<01;'Q"%MYB 2[=A;
MK37CRW=(KES(N$[.S&^P"+?<\=FBG;E!(4%PB8$1@,C?7<<YC1H@[H/X)WM1
MS9:#]!Z@_2G[@32Z"(DBQ;T2UQ4>@MBY:CMLX%RY@&:F3R\4?UZ4"W@]ZVY&
MCW8W'0VU4C.TO]%)\7<6DZ) WF+K(K@R1-K>7([6#?Y;:/U@N[@7.PYP+D84
MV+$B'A*"Q.'L3=4D;2M+YPD=)13[9$F> &2:>?+EA$ZRSTJOZP@AYV)WPWC@
MVG0.C,%^"[.O&O67C4[+D%<++%JT'D:NG/W:E)1FW6>QH%?<YYO4[W7>/N\H
MB%6=_^?E%,WS>@<UE4/*+1?OEMM\O-<X6K1[V"[47RT09MZWD?41JV@$X@M5
MD3)*"MUA" E$/P)O0UYDNHW2-Q@7F?TT<#<XANQ15 "H>M0V TFE@*_K0ZLC
ML^3IJZGGPR1$_>NQ\(;197GWH?4K5A8#)0FNJ"96&)$K/=W^ZW=ZJW-L<0+O
M 5]F<81KAZ]N8@5U&1I?&^YNB".T!K6?121=&>5*T-)N&B@H)^Q-+NEJ>D$V
MG(BY%]:\L'J3D.U2V-+$?<![2:2^GMT+Q)3S^Z![VW9SI9H!'8X:OQ\JW2+.
M4K4$PO:6^Z+I.%DH8.-!&'>9_5#;E@4[=5VWMOZD9O[K@:@R_TFWMLHR[;1=
M =\-?OU2= B(HA,!-4@L)"C))LY(C\#4BRMD-M] 2"VNDK[VR(OE(_6Q'<X[
M%>/#1+5/CWH,L#_*6:Z#?3Q2]2VF+RW#WTR5E:J%?3JR:.37<+[)-CV]=4$E
MR@-?'R7UPZ I]\J"I8A::H]W<+?C9J%AKMO=0MJ?S@6B(_ZY%XCAUF<>S<R?
MP$4]Y\?P>\"UD.68E_QA"O,Z-#: "GTD ,D;Z2-/ %GEB"AV *##6NK:.MJ9
M71*3.86CNB2O8,MZRZ FT?="X3PSCJK[6&B_I;@^+9]@R4F::@S:CNKB2_"*
M!"#J:P4)$CH96L-_SCD&N+=CM_9V@161"LQ W,T(*CJQJ3B&+EU$AK?)LT0>
M!^ 9FC9[X'H*_#3?LN+TFTV]<;A3N"(\\4VC T RXS5 ?E\]@/3F%:-."$=:
M:]8ED7"."P5&*#)&BDM\958L[C$RC&HEBQ\P&@(\.;8C2,O\.V9MM6FVF59Z
M3DT/?9HS1:Q>*]M8L"A<N?[NS3A&%K.?G0A$,ZLTI&G83@$HSBVN4Q'Z>/;P
MI/MUED22@0@.ZNJOSVW:2+B5.*^A,Z6EW7KDJ[F?LWU#38Y% DYU+/L[:ZH)
MD77R>]F+D8+ R+X^*7:PYYQ]W9>,U0$A*?W$.A[TM%)P..J&@'I9G@E)WF.H
M'.$4TSV>I7O\',FTT%'?6EP-D?BTW"I*SRQ_<XH%YXNRJ) G6&'!"PO0HHLL
MGV2:L:^/&8C2HM%=1)"1"E*3A7VT+K%O\8>??GAYE)< )%H+0*UJ=>%J"VPH
MF7T_9DD?R<[.Z"2I45Q51M'R[9^WWG\JCAKG>@GM1\WV5&=BNG,PCRG5@UW1
MTO2&+K3$TH2;$T&H9D*LJ!01!.8&(4^6I9S\TAVH<ZFMC3Z[0B.(15E!+M<]
MIONERLD--PISEJS9I=FFTT]+=PV20\K?D,]]&[-+<RYWG&I=&6E[^SV$:[JW
M]=JY3IZG7:Q^8J7%7N["@+[%JQ0)D1TG-&\WWE3M&TG/29XRD7%VI?YE5X\9
M,^X^+[XMC4KDG*#(0-:/I1)]U%E8_JXS M ))A/*2P]*!&^FFD/K9+]_Q&UD
M"T#K;/2F/23P'?&S?:8 ]'&OD-*OM?/=(-3Y(. [+Y6XM$&G\-,0RL0,?WX9
M^B_>W;@+7L$+0(Q5WDGL\V!G+N9,WI]HGEFA4 J&@PW^61S^[X\PA"70GU\"
M8OQ>]*]3"<8ESJVH3Y3OD5B"%B\+FR  ;68NAE&)_P/_E,,_A5[Z1%Q[K10L
M  67"D W0]%K R'S_B=>X2](?'/FB[J*9S1PI:/XNXFE"Z/2=',CV44YO1KU
M+Y;1LD;RB#5RW^NM+?"[D_>'(O8:\]*1!7T_>;Y\42^691=Z.Y&:1FF =.-$
M2(56],&X6?4QKA4MK6IAV)_L7=QZDP85T\THM2JQOJ)W=B&B<F^17ZU24B0\
MZ.A6:9$Y"G!DM1?\F"_+&F1(",6)#PL:UW* .<G.!\[@ "</='=3,?85(G"P
MJ\DSJYSLWE'FWU0X42\'?PV$>++V.%5&1@3MV9A@UY\8\?!T[Z%((Z!L C#)
MN<B5Y^6CO;3V> (B3H O"]+E]@4S%W 5Q@(>\A?=19(NO2$R,8G: S>U*<N\
MRQ2S^KP)1L"Z):S NQ&?=;L#LWW!HG!I=+XIPTTVFG%4#69BI3K+3*W/0D>N
MO[D3?4I37JT[Y#SGE!SL :IO)-?@6LG)D?2"T)'L2M'2S:FHDK4+9?Q9,/X:
MA&FJL8U-R.ER.Y[/,7$#)J @%Z[U6(O&2P__3>^42I8X]T)4!2P3.L5:T'4;
M:]J7TE&<V$5^>\LR@7'\*>BBQ),A+";OB%!,*"/A0"RU.2@!NH\;AEL8!7H4
M+0VU;#R\M5 '%_+.C1'ZIR.N!GB2.N^W/>7KZ+L^N\--,K28F)W)9D@1GT<1
MI^WG#+\N)\,X,GT&1X@[3W$=\K3,CPZ5*)].L\?<0.\KM%NJ+-,IK57(^9EG
M![-]?\ODT2>9F>85[)0B?[>%#B897*,5"X'GVIL/&6U!]4GYGP&.>C*='E1\
M7-+WJ6T3?</$Q89!#GK LE,*7L/=5 J20L=?CH1RO)][PX(8FFNKA.D7);$O
M9+[N,G$KBM2$)DU9YUQ/).2MNA2W/!\V,RR(S]V]_XF)\X&;9[.EPAC+F><D
MDHOLI3T+B^=E[P=/X$?OF9\LSL#,X%*(]3T/.%J]'#^@O ?;L$H2@!+NIY04
M 7$D- CB&[3#3UDFC@[N6 6;>:-+%MP\YA;N+9)?#!;Y%\\:7O[1M7GG_ITS
M9//7GK4?6"[]/V%"094WIH4,X,BA.UQ6# +ND;L;XMN4H$",9\O8(Q]#XR[]
MN#_XQZ">LY_Z^JIY973&S3?>6WY+\SJ"ZX>^YFOSB.A;8MI ,QV:C"7(+W=P
M?D.>G%P+<(/L0>YG:K5SGK<=_<1K?!!C/HZ\%$(/DE2-7UFI_%'2.CX;0W-W
MJ3IN9?K]>Z>B[S1 8E+HQ,[!*1)?5)1CW/L20>R40GKPZE G*0#4! @N1F#-
MQUM<:1*/GWG49S8HJS#74XJ,\O/-Y&.%["+=*SZ^K+MTBOPE 6,XXS!OH35E
MH9:>_M590CE"V>'G#<7:Z\631Y)"D)4>,_7KAGL"$&9*%LT]MN5QG=00MZJ'
M%8L.<81'^?(7#)Q4+*<_X&%##S/T]IME:J<[9M'47I2EC;V&%.DGJD]!]'=S
M[-G- M"SHVPE :CN#!/#K])*)K \HDLY'@+0VV><O0+0U)^ F0#D+-]#_@#M
M^M6K00!:.+&4SV<D"Y6)! ^RC=[TBWRV_LO.'O_>4X^G2"$PIK7CVC/@+H65
M9R7PI]%9[J-KK5#;T>6PG(!4$W: VX>1+XK1%I2^3)?W>C6#X*Q3"0WPZO/X
MZ]KD"*N2JM*IQ8IUCPG,6V%9OOV_Q[R_GK]L],06@&(%H/F#V /$929?6&@O
M%@&]T'U.H1OE A 4S'^VK4Z>216 EO>"-\.K;4UD\WO^:[D?836VKJ' GW08
M7E?DJ3K4I-MXE\(BLO11^;ZGG6QUBAB%U9^F+62?7WG:ER+[9V#'H9%7?UB5
MA"Y/E%:.KD#'UCWLW8F-XV&5EM<G="Q[I3S]W2H9'PI>>[R5])+R\)RUU!GH
M>B"YSV"D>;OC]?#76V-E;.O;IP/J5V8K6Z=7.O&AE5#G(5S^V)JAL]UPV,5H
MBN]8:!*G59<OONC(S>D_^7MCTOW4ROFWS>E/[ZGK)V[1S8;A1YO@IME3)<,%
MA9-<[SD)N>@7B/+NMA.L\WC-B8(NU.'Q]<%:_(,KCZ<Y=M]7WVK*&O]9+[<[
MO^Y!2F#B"7,-J=KEQ]-I@5;O6J<#&D:=UJ=_>Y5X8M^_.#*W!=]VC*7@EXKP
M-KA45?*XJ%&^%@C3B38)/1"T33WIG;9WHP)\9J?CS;L3/;_W%1HY2":9R(C7
M,\)G,C)FEC/?A5L*K2NSZ]]J4?(_<SWG_UC7*2^ -WV-TYH;1UZL].>#QX^D
MN+P2FMUZX^K8K43O*>U@"NS'],RQ$-5W:J?R;]MDD+1D,TRV615G!^B4P:9*
M9G1J-+J[-D(&P\(,)O6<SUD&AX0$JP\&!P>?PZ?9&(S4F6N/7ATX5OMVX%C*
M^Y7W76FR,M?_6S>U?_O9QGDMS"![T'T&!D+QXJU(C^,7ICHO=_]JP=RQ$S*O
MK"PF -4FLXP%(#MS=?:M-G=9_@\HOVU0 ++P94SI<1/O43A;A!IVX4]PVJ_^
MD:O \0\-PD 6;0 @>Y-9[I; +8K85]:CT?HB&APGE?P[XI7&3FV7V*J:(D5C
MGU ?3>B@M%CL-M_,")0%NDLG3T\ *JAB-O 59IP%H)S=? S$S[PX$2SV9W'F
M$>_QD'D+UDJGRUQXSXTYU0,?S@9/M/ER E:Y?"&[4*\)0-Q[]44)..L77KM?
MU#C7?DYJ:(V>Q7U=J#M?TZCIF-0UUG7K;MX$_N>%KXRE3F[U(Z^5SL);E?N+
M7DU&5*X"PF'OFT!0^"G-G10 '@;EW_G5C1IN("0H,P]:$%>G2>@4NK(<<_8T
MY2=72'/MSP4@8!X<T"H 8?N)7%&L )3BA+W1C1Y<Y99(:"WQE5Y@%[\(R>XW
MB1)N]ZT6XL)J&F?J/^9[;-??.W/Y E#?W>]\(NTCNOPYF <RPOZ03?QU]T";
MS:HOG<(U=IU#;^JOBJ%IE>/HG]4%_,,5+")/*2*6R)Q8)'(_.C-4IX/07[^O
M"D!;?06@N?3H^@T^6E.(XW$T_X+9Y!GH#XX =)+4ORDL4F[RJVZCUT";Z/=.
MZOW\O)^05FP2FB7N*Z3M;TLM&@+0XP9' >A+)P9X7-<C *V%S<H)0"3W,@'H
MQTTH'ON/H_^GJ?U+F\5M-CX3@(:V+0A 9UQP6IM1G_GL7_>;_FOG@- 5!A4%
MH.%)A+L )!XH9-J!6-3(/\[AG^87(BL 08C?7Q@0<4 X^#\U."EM0MO$W#6
MYR,P)/(REF#V6-/^RF1H]$U&&NUQN>(-S:S7TU"\V&%6R"[RS4"OO8X/,S]=
MZE$?0AD*8[^-?QH88#70>[O+;<A>I&SQABYLO/))%EY!HY<4;;T9K0:17-QP
M>P7[/FM&+P]MBK*]=Q@VLLO)+K;+;^_P9GG)K*?2Y7;%_EKQ]9>'/GVXM)-N
M\%#ONW@ ,+'"0'K0'=W+,QPGU@^5-4BKO9:W^V-K'&C+1] .K4IZ9!J;/%7.
M.1^ : !P6(^I5S1NAGTHO_"GTM6!WJ7SV$3)>6O^!,?:8K*^ 8;'D&S^PMW,
M_MFX.+)-_:P -#A/X6\74E?OB7\D#>P_&M,'_1>.@4=3R41%R1B.$^" ,6;6
M.1[];G2Z2.@;_MQ ?=3X?Q)G/RG"572<^]T<3 B*O61X%7 M^\RSX1X_H,.Q
M_%_>X?^2C5K[Y[2X^]2[B3)K6G^0#1L8*K29 VWB7,GA-BD/&SU2I04K;#I7
MJR=/G^4%OWL$\6J;U_9AH/.B2NVSJF-F-9%/EE5=YGAG_]%?FB5D/68JLQZR
M9VY4K8J0SP6\^3/0JWSIM[J;/5_:MP6_:]]V?FO6!$NC>'&QGO=)N\E\DU%'
M056,7-AIN=_A83OAP.L07 4]>E[4I*C2'1<)-6V^6(Z-_0\B4TC5+>+7#;Y]
M7-:Z +3WO5#'O,?P_P#;_$SLCD2/4E0WZEA!_VQZVW_E".KL-$8#\<?/" 'H
M@5 +L/J,IJ.$WI2%!J0A M#!@J4_<3]Y E Z;9Z')E4+]?Q9R"8H&O)%779>
M +)!8F<'NXG_ 9&)^8?)D'@WW@H-M&5- /JSPCF+9_@='041?OA?A ;X+XQ)
MA/W3)/YIAHV)0JM2?EHK0R>Y%R760XX*0"]%1OFW:CRA:QOO>,N_[FKX5ZE
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MS[-!Y ;^6]4N"L^$H  /6R2>TQ\HTW$+T+$NL+JH/>9NI5,&6QZ,,9)"Z@I
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M!;>\*A_+.NK6YFUA%0+S7>$/(O?R6M ^@V3IW@V*6,LV.E;2%?D;81B3<,=
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MCH!T&)V<X 85P\/)L<7/H_,]@9V4:\IJ#1.AG)SIB+::-"O70WAT@]0=UAF
M--?+,&>57.=5$P:GO&C.W1)_8&M7L%1BC.<!((L>E Q6-# $)ZP/'KA4\:FV
M^Q4@9C)F8$F=D?I"NN3T;!VV+N[C]-!A[%C"K>^[&]X3F59$LF(G9!M*3$C=
MEFV&0HPP!<C?F)@8B#\QWDB+R/KZ*!31HI>/-"6VC2P;#90!ZB1;BK]NTV4A
M)=G!98="WP2M'HICL(,5WU'C!HL"#-9^SFR&$:.^K3&:N]\YA_[,7R:B7LSO
M /NJG;&+"*Q+'PO[&IA^6..@3^4JZ@52R @/_^ /0L'\$_Z0G5P) 4@,8@G$
M%0&75WLCFB0P;3*(T7:[;EK.Q7B-VV.60)I5W?5:F^"#X64<\6G1'8W/"FYZ
M5C)_L%\"$)895>DK0X/*@]NW )9>!8A>S\:)P#4-:Y(=QHJIU%,>0#<WC0O>
MO6BE@F_2 ![*/GH77GK@@?N +72_</876S0"ROPH^]!^JXEY6DQHO- "9'Q#
M"M*>5JG>M:E;5\;5!L)V-((E^%(+3J?]]>['9F)IAG)1>A.O)(V3/:F7D)6Z
MV(.5++WE$LYOR , 7"B8[@.Y5(P2UY39\-@@F.8AP<X X!6(HP[C 3=9+SS/
M3^H,*IH5(,(IG:],)P-Q!+WQBMB7#SOH89'>,"G%J(0CYJJ39=#H51YJRT''
MJV7W*A:Z'0H2*G*LY1SFS3[V..=86.>:6Q0&A8YG-+JC*_A'>,*(\M':A50%
M3K*(W2BC+!)V#PKR_BG7@&54F>_/GAA9&0K3DC(@KT&\HW*W[@]M/;X^'_4M
M/2<]94(V._*5T\]I.H:!9F*$GFJT$WD)B.!<0=X Q&G]%'(_;96T?[6R;2]\
M>!$JS;U4.OT.[<6D. YSG;V+9F&H/:RP)\P9R)/,V:_6#_=/OJ]O1)+ 7R:(
M^=_X1WE"L?S(320^M%_)UV0<(JP9=._GI96Z=T>6+,KA"N H[\KYBKZA3].6
M^%/5?3B9\O0P[V/@(3"@?JL,$<56W%66"*'F@^M>;W$XL<6^^^I+$&B+HZ-,
MJ..6WT!;+L_<?\J2+;&NP-;9QI[2;K3+3LOU#UVTI"1??=.C:?U.';\\F\V+
M8/U@4WBY0OL(0'+?VK8 "70/U(]>\DJ67KQ&BSA58@>BG*Z56-&BMZW)AF[E
M9<I\_+SLQH+"P0"9-ZW$?9']>W!!!_L53W-'>.E&!C"(#%<(\(Y$ $,;3/$\
M-LJ7GS83,H(D0I$>GMA4DG ;",@G=@A BAZ> *Y367K<\^C.4MK"'0@>2WHX
MT1F5['[5RHB]:V7?HS7<PSP=IE[G*J"&9:P9:0-II#PQEMD3KBC3\@9@7X68
M=JP9.K4.C6W2BPL\-%G!U2N'1^AF8G;FEJNDP77#4Q].ZD=WK52=4D7PKP.B
M='0<7[M:&%9L1 /M-CE@DO1K5($;#LS9@@(7W9R"Q8DZ[@&@NN%^3X9H \$5
MS[.W3]EDD_G[3=H*TZ+;9N8?TU3",_(FB1H<_U'&]^-AB]9%%RZ,6NC4/'7(
MTO;'>9FVR)2HV*UF]X5?QYSRW5D4[;V92X.05ZG0]L&I'#:4U= M &'<!I.0
M%UA!YD,M$!HF&:7#)$S$1,\%6$#%_955@B01),O:E"\0T9QD=<OFS,\>_2<2
MZ><KKVU$A"2H++>)H&:)=38,,=;.59HO:546\7BZ]]FW>P#6@KF:8B Z)Q&W
M,:O.[-H>.7N8>1_1?'6$2#LR\LI4^IU&RD+F9/14S/*PU2ETBJ?^R-I $/M7
MCR3I!84/6.^R!;<XAB0',@U=:$K&ZV7JU0_2/*#O&YH)N<J*\<?:I4S4# +/
M>Q^BMVWR*BH8&FAJ(99Y+=J)/*L8;>H*\6N5<G_K=;7JV(@(*>;\:-Z5W0,^
M:1??/I7R2OY\+[%H^J0Z'_*0N/Y=\WPB66>9]T+E03%]3N_"*9O:1]B+I04Q
MI>]Q!RX<&\N=&7R).H?NN"R4#0]0%\91BD!S-^K$!->;5GY"!W+@VZ^++I6!
M4?H9IEQNB,*@^-?D%:Y*@7^XYT'3>N^FTY0;&O^%LC>/2FK]^X8YS65&ICFF
ME*:6IIYR*@<X96KF,5)+4U-.F2F2<DI-3(3**34E-;4TI7(>D!S0''&V\IBS
M)@X(G'+6C>-.IH?NY[G?M=[?NM>SWO>/_0=L]@6;?7T_PS5\O_\^S$'JE%MQ
M*P2VP#3;^(E0%Z?62I82*N$R;+G13\W<\MJ+<:%MKF8=&&6K+PZ?&XQ+ LZ;
MZ1]/W7R89F\1[!TD,UQ]U>*^3")UM9FG.<8/Z1/J",<G#PV(('ZP)R)(!99D
MO6C/U18_S*=P/;P\L/P<;\\F'YA;M41$XKV\V<A#>!O@(B,ZG&J MBM]G<>8
M39,UN;CGYOC.(;48HJU83-M!6;L7+'G'QFW$AI@1RJ*WZ455B2 R9M[4<?SM
M@6,#]=K 2I<C=SJ.34/M\QD>5CG.O4OV]O-D8V(,NFPQYK=QD1-C%SXT216@
M YEVY@Y$\OHD *;3[HYSY.V_%XWYOW$WOG(_UH$P^2 UX>;2M<(3-NJ# O7W
MV5$W2E5C<<=M;F49I"MX_L7MDBE2.2?UY%AB7TK*DV,OGQZ0M+FT_-\%%4RU
MB3\U&=6">(:>,)WFRL&45XL@26'%Q&\3[T60V>+KI49/&H3V_!?V5[Z!7SLZ
M;RZ>[2R]?^DWS\@=Y#_V(EZ\O6!_1:MK,R5M;H_P]N,2JPMEVPLA+Q"*$+__
MR@>0>P-RZ:A*Q-/?ME36(#9-.Y)[#]CP3_QV(O=H^-,]\(B_A-<.>_&^.)N?
MV=,S_<=>RY,[@G;<S[(Z:PXU+SCZ_(Y4EI6U_9RYC_CS6DW;KCU^=.@ M'<M
MYS_&:+5WMWEH 9T1IVX-\MW8=MM;MOS:!:DIV *0=&.@TE1AW>[R+;]\](>)
MN6"CJA7FG-S^#RXN.?'W@TY+G3^2<*%7,K?XH?MHP_^N1I](!:/_ /)(!;BX
M=L4?8JD,G35:#"Z:KQ7F>V7[,+S>'U29OSIDJ+!8<H_26QZ5_@.7[= DNR-V
MNU_W(RT)MV+,&"9T3/N9[L+RT:BY_J7A&TLZI11_-1?*DM]T3-;)J2PYFUOI
MFC[?XX?Z7M^0-O^?=SDR<-+""PRR(+912P09T!FZ'_2?[VQ/F!\B>,M9_G_9
MGIA)*ZO#^*TW=T[W/TYHU2JQ+G"P_K$38A2[1^WI[V&2_^\AZ?_A^&V#VJSW
M\^ ]XKP(XBB"].=1W:C'07411%62)"#.$;>N#<T'/1=JKO 3)Z!/Q7#W+RE#
MS''K*K(B2&EMM?#)+=1IYP%Z)6*+)$$<<7<30?[X0'U5? FO/?VS(I7*55\1
M-WK5WO(6F-%6NSO<S)0"5K<_:DAXPB)+HH,9D_12WP!*568.6M&O/NU15';8
MW\Q31E6I?39F*]5[%?554JQ"_?WM;TY'U:-8) 6<XT5N3V30A#$*(,88F,*D
M?52.#^C*<FR&^(C"4>N"V:V&E'[6W;+ZLE33 @UYJ$3QU-WZ04(_ZC<EEF1G
M)XN+:=:<HF2[J_>T,1>?B2 LJ<B%H,]FA@])A8NCC="#EAH),S+TL=ZFHN[G
M$366VC66NL[:590OE! L4%S<D#(T6;#!T/Y!BF16H19RN=0V>]":9;VX$ZCH
M]-#*,DX=:TV'Q=Z[,TQ5BS5*=2H;\%><G!-!OL2HN,A^/<DXV_=OT#6G6VL-
MORE8^0(O[U Q[87:&[5^-T]0C]3]2KHY*X+(^<%_0^&O ]?S.XIY>VBF>E'.
MBD/U<-VZ#UGMZV=UC_8SH4<SKL3:?LMVTK?QC3>Q\E0J'J9B[ZV-F3987ZVM
M+OOP@?:QH;&A-N4HK;*"%C-=4UN3Y72#55T=99R*ON-UB6,5_%>1W7:'N(8<
MLK:O$WJ4,E#5'82\YO*^WKB96-FS(. JL9AQ!!U06HQM3_ N0%<3<0P&O 8Y
M%X??U0/+4<0/!M_6XWWF-K]L8T@:7T[7N?!O+<OON,W+\M\UN\U^C76W39X;
M+L&;LI",N*FO5,J<0^<N<C[U^1KO)-;[]5.+G15S=MX[!BXO%,J</)ED=<S^
MQHL]%L4V#R9S#;\F1T[#0HSO<*CU&7VN6S-AH98!DR>XV,AZ*=8$LGWR-%<E
MAH65\*F*)Q:#<6V*F5G)[V>K,,_')WV=!RPP.RZ6%QDDD4Y/J)$":@M7$!%T
MFO4"DSM];=  $8Y2(AS!VPQ7%@?7#QH0]X&I75>'_$K826=S&OQ,\<%)+M:G
M^JPV$RW4R^O+"E_*W8P\UVQC^47+ ;S][TOR>__E?TEAXI [49-/_&2-%$&H
M\PC!B81J,S\11"TZAKYPKE ,J3=IT?_7TY6U5.N?;6%RQ?SW#];L+4__5V*5
MP[8.@VN+2LC&H?7X"UV7^RN[7)9I.DB'VJ>=R($%RFUT*58/JYL3.SD\/"D3
MXIT5<NA$ME-PT%4[O "8WJ +4H5ZN"_(:+*$$([7XS(3U!(V[%DD25Q1J\.0
M=]P5JU2AVPG5L-J(AR^RN^^KAX_G_)W]YS]J#DWJ7Z5\S[QT3$V\8G,._MDX
MN/;;EHD8=-_^ I;_F*P:478GQ8H@G*YFU(:F*W&6X_86@WY$*. 4_)], (=C
MV$C)&973@)#&0A[VV2(^,S-DFY]9M1JIU'%EF';K._<'[5%A\*[0*U\9.!NE
M/5PQTV]5?9EDY'4KW"WPJJ1&NN_LS,!HZ3\_K5L0'\@+7E,Z_CUM65!!FG"/
MC^(&60OI633*-P=X[J,]2OX)H2ZZ]Z8/(I5N9:<?+;=J.O/[7WNVO-UZ*Y&'
M9A5)T7S+''3Z1G@QP_96T4QM>WQI;JZODW[I9XI>)>]3'JVV*H7@'(7+,E)V
M?N):>?7/6WLTLO>TFP_>3@HSM#F^!@\ 0WA'A5V(O7@D+!ZN(.RA[S639'_[
M<Q'+1A[ J5D,T#(L'I"4F\L:8P=Z/NA;'T_\=&]2LJ^N@V"E%017%W:1*Z([
M4 =GA3H@%3!F$=L0,NB_6[&>;*@L:&HU'(3SH[QI:*A N3/J5\?^6.B6I+5V
M[PA]==Q7/GQ99B0P7L5&P>'L4.;$I^L7K[J\?C6E5?341A.RS6[;1N!@R/6S
M)R;Y]8G?Z:&N(WT83%:H9@LBLA\D-67I$:,GI50T053NW"-8:Z:_N00R2@1I
MVC*B>:ED%J,]Y%+E/14-(P41IUW&&:.GKC:4[[FPXY/9YC.Z-_:)BBZ8^ Y_
MBVO= HU.WVQ'[C=_W@@#PXMP;I=KN?[)NJ^$=S,,\VCJ-?4VE;/PT+WIUDF?
MGV;<C?/E?#?7%NX+Y>G/,ZS;B8=]'B+D:5@(7A58CN/;E?"O5(+.%&HK2=H%
M5'(L[S>S])["RDX@L;>H<ZF,2/[!L=%N0;K>A1Z=DO[V'0GT %"NPU6O#;4#
MM.@4*F'R@<UXOOX[L,(",T\L]ZA*9"N?&7,:B)\H_0GO?N"GRUJ=6CV^DCN>
MP?1G,S#$^:V:@YG[:B]<F_-#!*>B)+X[NDUVJROH?OGZB=OMN?&'((5_GF/N
MQM:MX9GQ58;J@ZC6H2HT=K$(\AONT;3+$**2\ITVJ-%0E]2>'EK<%?(CEKW>
M7/_2]EA(UVG/429^%ZA=.(N KDG:LKR?!$E"6=<CMIQ;PU1YK>E!/S*F*&?F
MS\-E:P?XYE[W=Z1NA:5T1N_MTZQ*0&BX&\N6JUE!5&C7L=1C PM4O24)B5 E
MM[C/7W0W#XY=7+U\W4KB]XM^Q5E7=C]R2RT<<*X\6I,YD:WL/E WX!R8R;R6
M-;."B$154)NP3RHPQHC=<"C?%/0.8LLZC>CRY5CNFN?KAK89K<6NS'4P3GZO
MMOZ-0SLCX3.^^]+U*-\5_![PM,H3KF9+'_]WP $7P)$M*\&%L_.>U4J^&" <
MQ60=33A!ZW9K=WJ/T'.F#WE&J3?4U$"/3[JFFD;-_2/(@B/P"$&^4 KTYGBW
M3 _G -9Q_F:6?CG5SP+;^]:)QBU"]2&^9E$<Y9P_U0E2VQB-K_KWYB>-JH,]
M*R$9<HP9F<,G+^BFA^>?6+5(T756*)YP<>V_(D1G!;/U(LC[\6[ "BRB40.
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MJ3C5)]\7$4,6VR)_XF@=N_,YX8BPFRC?N WGJ^R]\4:04N\I1J"V2;E^M<'
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MU8=)AX'.\-R& 4/CL[+!P0GEM?7'83? ,$"N,Y4)7&6.;6=OQIFI*?$5P1H
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M@O+O ,A(O@U1D)B#8WSI/VD@9D^<D?L=?NV?6\.OC]]EK#A=DG U+$FZZ.^
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M=?/#_[5?@M2_'2BW#\\X-CY6:6>MHZ&N-99X7==S[>NSDBG?7IIO&>;Q,,Q
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MC9>ACZ9<\!J#,#72NWVQ67[=/Q9<>^\DYXLR^&H7CZ6^;%JAIWHV>J<48/_
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M!SPIX(=LC?4C\:@.;Y6UPKE8)E0$<'5H51&>Z,(SZQT%JIFTC#M>KD-KC -
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M@.00F*,?IIKN"G2#++*^MG+>Y]XQ+[JEQ1LOWO>A6EOECTE',_; J0\3HCA
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MW48 D^'W5:'21L9/VAO@2J3[RP*M:;F\!4.[):U:_^N(B&"7QN'IT0#6^<!
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M2)'*]N\KL!'&(?2.ZROW,A?^>]LU(Z\)WU5&Q:"EBUPOT:.(JO1_W/-\7W1
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M[YZZZ97GPNZ<>./ZU@*V LDD-/%R.#F]$%E;\!QD4\=10:"P7*0KL*D%_I)
M45-W. X<(*F;ZTDZ:7O6#%92IO4[QI!M!Y@#-L8^%E@(_^9H!)(LYPA[E3V8
M63))-6<LT?BQ& M ^$+"5QW3K/?.4B<8LY#7ZNK(<-9ZEW&F2@SV 0LJ"P1L
M=*X9&.^=6(B)^_(UG038?AT^J>4?[=9\M.^9GG;F_I;Z@MD?]9< -H?&.R_)
MOA(TC4<"F"^F)9![35B+NXJ[KP+9*K*=!F)[3 !UES&,*2^F3:3(U=A G \
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MPHOFNRW5=#'.R[EXQ;7][')U1=[[K[K9]$BPNF+SE23H7PR.]PU8-^%C(8@
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MS&3-->]-@Z*[+)^Y6+T64[5^$ASCR80 OW\S]\8")8OY<DQ'/.=),SC=0Y4
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M#NB5=\4.J/3>Q[V*_W;A&<IX!]1]Y?L.B&P(\ B3;X#S7,MN_2#2DX.A,'9
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M+#@RD!%/"V 8,:]PGJ/D4>_Q?"< ?C):8+50TN0L:CP'@X97AG4,,H-7N+)
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M_4RN.$-F\Z)T@)8,$L&X,(4M\W5H_XQ=IM<V^4>+GU!0'))^<H"3\I*;C$>
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MZGSRC[BU\LOC9;DID[414N9O&"F8!TUT(RX..)9A$V\GEK*7 #++D82:)C5
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MN+_8+MT-X)<[>J(0I0LR(96:]YSF/I^L[;Z5K(P)4.)=*@_+?CG3A,!:Z=+
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MM,[5!#T6%A^=8[R1OO]7UFQKGO/+9?LPR;RR ;5<I-U%NWHK8W#]]\R(>JO
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ML@&X$6U7?((*3I/"4BRIEHF$"*ID:'6P_,?(Y82C+JYF]SPE)Y3B646JK'1
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MBCW]NUXB#C6L%9WYK!ZIZ7O9[>//[#(!]@G,U[F3W+=&<@N>UI1.>17 G2E
MA:4@.^303H W;8G0/&DD1QL\H,D:+)_:WSB^IGE+1:HIZ4!QG[O[OZ7U,7W5
MJE^W?D_\US*TEYA3'$D@F*E(@_41GDPO$.GF3$,W8(%I=K4A6!D?H[GU<Z,0
M=<'7R7]=<U/]Q*+!2V8&F)6R.-2 .!=>:40L;##TG-[9!4&\2@$_IYMG/Q*X
M12F+H85KTXL/$NN27]Y;E$A/SG-R$OP3LLX^-"+PD^',39C$[: F5U-K^GNQ
MS,5Y//M8-6236?U%MZ$=<C-X_ \A A13;IZ1?0EFEF?"K2PC<8SUH]O<V9<!
MY_DA7)RBS'.F;D?K:]1GI+CG2I/W6LXU YU)A%P[,:O<YA%)N:?QN6GE.=P=
M^RO'8OP&/^$'="^M(A^J9/R:_8&YP?NX"V+87N7F$^]!4F -QDM)F^V15!Y!
M-=&7B^/)3Z=8+0+.JKTB7J0>L(1*-OGG9SEU: %OIV_Z^NCBB*9FP9+EP^S?
MU9[BL^U8*G3-NQQ WN1VT#&G4/'F$VV*;%_@UPV2SBKLB)QY&/8(RL>)<;+@
M2'OCQ/2-6@+!$Z%4 &_U+AO$WA&_=#WGP"P52OQ1%D$IA$5P)+&.9[S]KYA;
M2-GG6R=X$H8<+L;@(]Y\RTB$FDND3X%CYL[O@IZ$\KM$GYN!)-X>@K$* &4X
M(Z2+=Q)V!"7J/,H1H[5BY8$%JQ'"):01F$I)S$WY%)&+C=^T5;GDC3!%'B2O
M&A243CKII=LUK@:?H]S[L]&H:'(8DFS)4@ FD#2\L.5KS"#Q<)L?8[OWT=6!
M2A&?GD?Q3]N4"X%'?;N@[@+/Y&R%C^KY>@_7^RK"?(S"Z=(9<CW)R^ ?!R2\
M=D$3K=CG%SI'4JI*Z6L.WRLNNWI_?^.0^#WHXT7WJ.J'-=/(7_!N;!V.+LG(
M8/4#O<SN>5(/-,:&@62E,U6[\<?0?S-RTMH@M,IA\ \2YM"HZ@B2"D1%%5G)
M)YPG(30U[Z8N>#8WV>I%QN[]2$=(UF"\N(60NUH2?RK:UO)[L*B'I\P$QX>M
MPLBBO>"C'1=1#Z;-/&W]OC3(>0U:-\;;D/)NU#<DL;W.%N9]EHF<<WEZU2XG
MZ*>1/6;!"5-9O.S&RHLL@N?>S:_VW\EJRWZ4FE'IZA[H=O=UP$5Z[N1.%^ML
MM2:]!)9]35,A7?7DQ>>FC\J6?Q&( _O?9L[<S4A_P/JLGY'IK<9,+Q]'UH=D
M-B/A37!U=T;]>V+M,#V/?97W81<$XNU#L5DI@*?^VFL:+AY\T,B*)C0-W@_/
M)H*W('M%CZ"0O7I8P:46<<@3V>MCI5)D'1-5*Y\)S88\6;V.L:7G08CU#H I
MNO:\:@XS#:O'T\]2N?!N-U@W_C'_ZIQ@1B#TX/66%TS)0>"Q>4>T7N;(U$")
MG+I=[6$1RK06??UQ[/ZC=DIWT]8-;6QL348GN[HFR7U]?7-"ANKJEQ0(#?4-
MC0E_-Q((C8\5X^;(<Q+7_GXB<>UU@OBE$?N_I,X@B(#@+/'#_:[1)\Y+F3FU
MVR67!WC47XZ)#S("Q3(>+';4V&TW_[:9ITQILX:Y.5OXIW.RW&<FFFA0WKQ?
M&N\4*HWFE3&/33.19HZ3M[LUL'WZIML]C_SB=+'[K70,-N*+.\#PVKJ).)QR
MK0JH,YGD#"FB"(=2GCZR_ >M789V95K$+D"?LB9%_TS5)+1=>&5#Q8H&YA:3
M(O1/C&R>V""<6#MWCN[;-#8O+5WOX5%=-NWWLZ09I;AQIG";UR[]P]/@? G&
M4E=6Y]726=.SK>0+B/)*.J?RVI0_6INJ->7<6R#/;2 &P,B!2SUS)W%=1%F,
M, <"P%\!CV;#S&@:BK<8^?BI+1$SYXM3EB6[(#\/B92JCMZHL%#JC,<5Y&)%
M3AXW#^)#E$&+<Y^$0:>T/)BPV+"T$S# >4'S28'JJ+2+O'3J$LVN@M9*5[O+
M#L(A*O,B#X6MWAJ_-I9<Z!)TH"KBD,)#K&EYX<9/CHYIJGSFG6\9K:SM;1RG
MQTY2C?LSQHUWLZH)HA)&!%33>H+91IA>&>G')FHH6">N86G-MG1YH5/>*.?:
M^-9PO,FI9IQ-TRC'DSH; DT7$GG(T:*I1]JXY'Y7OTE,O"0;%GVB5C1L071J
MD#4&+/(I,QM ,K<7M#H/;Q&3(4+*0!1CNXLB@E:FI:A3*8^WK-SH&T;V-:@,
MC\2EOMS%R3I?0E,+(<W:QE:3/(+I18;II&MCLNW-*5M<K-OV;9= :]:2]8T;
MF3>_%2G+!&9Z%.:7*-N>F:V^Z1/YKA?_"9^,>[O1DR:-EN0FW\,<YUQCX*-W
M0?[(KW7]U)DY0:9%>\E*2U,W3GP%<X*ADC1/E%B6H6=5!<.? Y$]ATL.T]=?
M-429'C?M52YL6__R-QK"38$$>IKQ[\6<[8/Y I'I.(YJNL&P[*8DR.\?Q\BC
M]G5C3GWA#S1<2R(@;M"TGG&.7*4OD_HN?<XST "?&(:3F T@C7YF9;<$X5@V
MH3>Y-PN3VMNQ8D8:\KZ&MI<^9JZ5Z4H;&'5\=DCY[7NFW,*@+#1K+$#WMR(5
M\A7':@-.U*!A ):MP_L"$VP[P;Z$]@42:+"GI1!I0+5'9KN7$DWB&;ZT75 '
MQY6241SERFYUD1T)GE)KHZTF5BW$Y]SSZ]LOK^,8UR$)Y_^KB!'QZ^=!FO.3
M,J93!I-'H;697!B/?WIG)*CMLA_3:ZG_Z->Y-H.+*TC:Y08KA2?KUS9[QZ;=
MM-6NGTN<=:8K2WARAR"MMS$EID.Z>B_5'.S#5!8$PSP\J(>:W0Z_4W?UU#A6
MEP@36X74+242M*;_/'RBAT@G&!F"H]M.LPU0>?,3&['?;*$\\:3V"'>F.EQO
MI[I2(R] \5KBU*>0%_B%]F/_U)+;_(;D9=FF'! 3]@]&D3=#(6PRM5*-E!>(
M7WLXNJ.\$X#)JFLMD!;U!F5C.:$RCD[ZNEFQ5D4CQOW5$C69KUE2;DK]AKB<
MJV.%=2P_=?3*"8$GHJ;&(M+8'"H< QO3R99_F5D=NF@_T<$JIZ[]KMH,L%QK
M!]_$*A"%V\)*,)]Q]9;=&ZE\." B-J:@?43Y-FT&I>L\*G(^D#=($2; $@WZ
M:N52LEZ"#^7UR1Q(?<',C7IPR -XM $;IZ>[!FF4O,MV02RZO^'A3<"K;ML)
M1@+S>#%4Y16D$ KGQ<B)U\6)H7R_!<"ZR=\KBJ;F5EH4/U ]IVTZ"B*E- NO
MOS?[Y[?D"Q]&!M7N!1XGN4P4QL@MSYW5UNUD:J0]06O[T?89/I$)J79??KYB
M<7?_>N;,1M :_(M_$->0Q17_.BP4ERV_//X]34GA5;Y%<V'5"B3 H<@AO6XQ
M[9P#+&"E0XV;"KD+D<0,D?CJ=I&2:&1.G8W"7.:-%D  TBO5^+Y268LO1NY*
MXBX!!@/C5??B64-O+:6?],RZ5 C^W987/-6#BF 9 SFOT0^Y+1V:RQ!)OE,^
MT$2WI4) /V!'PG9!@F1/"FJ06D"@B@I84;\SY5_[5KI.^^>$3 =ZV;TN<R/#
M9I4_'1J9&? ]O1\3QT_N;QVK[C\MDD2M+#+OT2T<,HV754HNC4='V.JOCV>U
MZN5.*#(7:)"U/YOX@+BE:&5?AB(+QRTQV>?! ;5,;,KBP2N0PYB30(XY0&!J
M6S"^5_M5D0-DTEACV*ZS5,MQK5"V*W)]\ZRFT]EG1DY-1U\3<KY"^*@033M8
MR2SJI!# :PE,1U- E;G:-7>( /C6? 7ZN[>]E $?)H3**E#P5/V+69(24UG9
M:?+LV?OL1X3B")*INLW^%(VR^C@FUNI'(5\$SAH@5WT?8"K,*T(BK:SM1 MN
M!5H7>ZJJ0K.#/$:^/<AP"EQW^$[4)O82]YB >=.3E*,J3#S=C-E/E:^G3D-%
MO7[L0+J0C^<.3H:F"0V^F1L.7.B5V4YL\SG-U-W:2I;ZZ?YUN9$U.2F6UWPW
MW,\3KY?%O@3D6'!;VH+9KIY 6K?-?-I1S&>R:->UT+T[R1C%NDD=B"2VRS*B
MRJNMT:K(LE!6]T)Q0H4Q>2A#H^I^12;WQ?7L,V6)UU13+[_.U4_T]S5//WO[
MN;651.V[.^F7Q5[(R5FWI%<=4K*/VG2KQ,"^N;T^<+QT2=/J3<+G!YG-HP%Z
MTX^4>)+^-4\! 98 T,^L7."FT?<Q8?WD]M(*!M(36."C/,LKW5@ .J*YCCF&
M"OR^:LF;\JM_(IL/M9G8NB2T+)-:J=S+G0DG.>^]2LB>4E]+2Z"(;H*3P$>,
M'C*Z>\]K_*$<P*S'2V2R\(ZK=ADJS;IEM.:.^7WGST\,BXR$'UHMI(S'W;"\
M5;+LYA5?YNJ_HY)7]F/'(@\I69!?$N 43@[/\PX0C(F;_-CW^1("H?&:KSE.
M)5XJNB%Y=$\B\=J;^\&EKR\;I [9.1#;ODUGIS065=HG!8W4M=;^CN=[FEEN
M# ?+EE^&B85!DXEB1L9,1YIETCQ#_\DF4LQ?O;*])HF11XV+"87L1WGBW,<:
M!HO?-24&%!/CA"+J/^G%:@9YNO8)/.';>OPTA.4UB5% P5E_ <V,O<C''<;,
MI:<=BLLFAX!?5*0<%(^^2$+#PK705\H /V?&U?1>FHB@31?)*?O1A[&2IS'1
MGQW\FG%;08D1DSO&+>%-O]V_?+SD=B'VDEF!8(Z^4M'ELS41#^><VS+GZAQ:
M$*KP8M(2MI\X9;D0T4_9R_O0*'\1R)D7<:1IO<>3P=3MON$$C$H3@U5+31,%
M:H:[TE>UR@,P1[]4'VDW3J%&VQ,:QIQOM27.41'RWUGKDU9MM<L0,/$N10+M
MR2WB"Y)DLAZ1RM4RY;XT\F,>Z^DX,QIVI2+?QZN1F?;D+J,/AZ1NU$YYN,HF
MN0_LWR:2(YPN"-UP$\C]^S3$9\2<L@3\&&1)4'3'T.O)Q3/%TZ$G?6T;9S>#
M;;>RVTC-O[?92IQ ?DB1%BCT:)H0/;#_%O=?(\D%KC05^S[!>T2G597(5(U>
MJT%@U%8,,/7PX^.Z7!F-L.I[/L2.=\V$=);ATX9A!4/WI].;XO4Z4<<L&%LQ
MC[P>%P<\DG\AG#%X)*]HF97K&^,P"U4>&G_N.F5VH.V!Q\R@1L_Z\[C<AW=R
M34<-+XP5WSIC?=0^<V;QH=4 Y:'5QX]T\@7B.>=KQ7^6S'[Y7V9@:_[76=J#
MV[\M?_XI$7&J,/$,Z/_2]BU!R"36/TDL5VX^Y@PZ*J_K)S *B=O1*.!__U";
M09T_M,IXG5#J7SN]"X*WQY4WJJ4'P@V'N+CP\*L?WF;_;=E;P8?#DT 1@P:+
MP9SF5A#O()#S.9V4Y)W^."-#*BY9_@301$4FR1Q,J$:-3JH/"YLO>"K:CA@9
M5@&8?L<G-[JV!UI_AEO+'$3Y7MW8!<W7O-@%Q8=@QB^=@##B?UR2NXBE&C#P
M)_ 9!%@TI!%"GV+DL1" +M-Q?OL?B!]Q:K K!W((';4 E23VVFK3H&D8I1\=
MA[Y4:1H9%Z'<NWDGQ\0'N]5K#MJDV$4]XADF2;X0UWE1K=387IR54U.S4U(Z
M6+-19+1F[K8JIA;JZ_C"OL@@=,'*[MC+E?'D]H;9RP;W%Q.WVTL,71NFOVQM
MD"UY@OO8KKPA*7):0IL/>]\5_>X<X'DQYQ(#GTSCEG*.*#$UMA/#ED,A!SV;
MXJO:P!6!N:; XVRA!(4VX=QK__9'/2APO[R.#F$'848A!TSVHN\#R^PKF+[#
MC(Y!JM-S:N6&R(]P7(- -">(9]Q!,K)$OO):II>C(KHOZL<Y7G,?M)EL:WT[
M+K[E>]Y,_*).= '?/O>!(+[0O7O>@PD1:Y]!FV#&6X7>,!C#9=22<ZR5]4SM
M8K<MH\+^Y9TT,."WS[CNOO9TM2#9GQ"^NKCT72T=;[L@TS,1&"=+[KH8)S_S
M,S9BP^U)AOW]I,26B<B9@8:0X#_[4/#.</0G,6+#;"?>@-OP>V+L+DA6=U@4
MY=X%EC8R9,*[*%)H[1(@K;=QQ!,5V-^7+>.40J7#NK-WJD)4LQY-DA)CK@E?
M__N=2SA&%]MYG2/+ +,H#.>U^ 5</#FE+![M_AJEQOJU<(,I?+80!?, 8J-J
M C!2HX3V/9MH]V42N30Y6[2J@RB=I3N/?:LC-?H!@V$*="*G95DKC/BU:<;@
M@F@G/W3^5)5:VV!L>P"N3.W>EE'.S3&,"FH71/.0/S1"5V7,I5"KU;O=[KE%
MQ"'"8.>A%3.K$<MA_G6QJ9?)$]7(\QUZF&%Y"2X_K.>+8(V03E%)M6EW5!/O
M,)];__%W:X/S,JA8J0"*A"Y\0PB5 _T[HC>D</6HV\Q=/>?L<0]WJ<.&-](G
M=T$Z!4F^D:NS[3M'5VB_I>M?+@ZY9098MY\9>[D+BK@\7G:&K19>NGB\3_>R
MHM8C6[W"/*X.,,VVZ68@%[!K%8R[T$-6^ &V'=#=SSL6WW.X6N5EP1&3 XQ\
M8J+,CNVEY:9X=YD<LM0 8G3;AJTY^4X;VJ/[2Y7.3]L#)@R^C:Y8\3KVQ40&
M&%MP3FE3KT 94&BV^/B%%L8N*-I$^BM LS7DB34R<]*T=%)LKC>1PE813GV_
M3!ES^0'E%"^WSTW2Z0%O=1Y8_>Z=%R6+]N*D>1!^%&ATG.!XNY[[4ZDM@Q7+
M+<0<YMP?"\*%3;#P5$I,2Q0QK@UY3$HKK P@=4^R6M(#(2L;86<(5J]5#B;D
MK<, C92L_*8UQ07UI$@;>"0?GI)@!U2)!<<5$N%3-&9-2H $Z4%?XK:V.7R_
MU,B MF%)V_FN*H4$20>W8C:^H/5WZ<U:735J;=B/\6\L9.[)+TF9BB<UU-*C
MH>:Z3@X.(8Z+#45\PEGN[]5*-#D(:/%OMH<B@5%:?0Z$=)H<?6MKZ3GQC=#6
M 4?=;6ZJ)<3-]=LUM1")[1W$UH:W;^OJ&@N^K__\+H3R\7LF"&RS]+FM5"[>
M1 GSQ6M__/QP"D^LEV$-C?_UM:GG\D(=$Y:PB7WZ"%/_QI^<73F_6)L*$QC4
MS"N9#CP?0#*HJ0Q1SJZXMZWR.31])HH9YNM7[I[GSK:!K][UOP./'$35_!V@
ML9A*.RQSXOF"UGZFN9'FS09'RY/EMT9<,':\?O#/]&% #<^-@?A2N$X[0X*3
M4:-<9RB@ZNEZ,^6>_KG1,H/T&.K'O)QU]9NV0XVC=B_O%6;,_0R8PC0Z?]P%
M->;0M<%KC_EN9WIAK4 DHY\?O4^]4 Y]6H+F-:KQLHZX7A.U$8[6$?I=6VT7
M=QU"AI-[$W)M.D.AZ[9@+*=GIY!XEI\!A%@2[_ (\W41]*(Y4Z!+_/GZX?;^
M7OS!+-.E6.&O#CU'FP<$CK\.)+V15WE0%H]W.#(:*Y.>5!>>^3<Y/*#L+OYN
M;I2C'@([_PHL82*'8E.U8K%PR)29&W" "DF55QIK.\8?(EKJ8Z9[%U&*<[)
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MI!_]YM% ON_&KE;)L-MNS[-MG*GYC0]'BU;RB1J"D5W=!;W-SF ?6BU0(Q'
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M.X*1027U[!!CJG1@"411$Q7SBA^-3LZD$ K:B.3HT3#Z+>YWNF3#>+$9,L0
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M@4;C;8H"D=H+%S\T]#N-I'B:]^)69RSOIZ^I*A9"'.NC?<V8DAFERP3P6/U
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M-%>#!UH2JW(J#LL*]U9Y]O7) GS]JD,CZ9OU)$?3>XFNYS(<6JW1>WUHT]K
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MJ=@+CJ5*DM25G)2J8IFBE;&Q7]OIOJA"K_% COR0_**BR5%IJ4HBC4%&O_-
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M-^><2AV'HL5/+PN5RX99AC5)+']DQB4E*=VOZ8$/W/U(/Q)W3%"3Z#<+/1!
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M@#MVDP%EBY';>2!9HPO<4;  ^C8X+=*F5*D3!\C/ES*EHW+#[<4N9W41P9Y
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MWIHNRY9UN"S7-\EE3?K1WK[10_LVIRE3,K6WH9U$A@MVXO%53CI7%FD [*M
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MV/;)G.8]D)QJ_J!*3[M@9#[TIDSWA)N[/SPK<XT6FU>Z*!7/E4=>9OKDX<L
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M;IG^+7WB'4FEJ,-2_V9B<)<-9O75W%R3DL-84;&EA,RU87S+8-]F9#<VTA/
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MA+-*.!5WV8<*W0$I^S'4)?]"Y[%J=93L! #NVKZ3J#B0NHS(USR<).418V"
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MUQ4T(<SB&Q0SP?X=Z*1A *]9+4",@9W#)!<S<WL2O2E1/)"<*^!+&4S5T3R
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M4MUYE6W$>*N<VV*UL72WSBAF\YWT8@S1]=4=5'[XETZ_!*_GOO#4]RI1 NV
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MUWX)Z!\'K?_/,^YI9*_R/^=WXC\7<8 -KEWNJ!(<$G>S5'"'ZQ,)*1(0VPN
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M;=9SWY.C,"<K :W7  :X6N)-JF%<O&N?4-%RMI1M3;SIH]>6?BED[YP-@OT
M9X-<YN<B4@(8"45\K\5TO;8ZKGW4YMQ0&M+P&CN];6J_.%\\@-!<1 \3^#%
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MZ!^+L$JW"*S/@!N"\Y)[FJWAPU^8P+9GQ C^@L*W9:O$MC]$I<UU[!2/Z-F
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M"/B,@>/LJR6R?MYD\<$?^[\_!ZRFFA-_DD,>MFW=XEIM$[ZOLUG5[;L@ZF4
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MY&Z%<1Q=;%- ZA\[,0 $& 9WH":<@9 QL%(.UD\7?_^+47RGXF\0 7E7./9
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M6H!_181>%_2(U9 79']A$VAT%UT\Z45(606-.8SE %BQBQYT8QY3J=C,6"Z
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MW9YI2'.%7E""BXE@H8$8)L9TW$(&=*%!PU9E-2@,N ;E(+G<//%1YCU4;M.
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M*(!:J8DU2LJ(/?5S:,OACN:H=6Q-I:R#FU:VA]?(9"+!;SSHP$&#JA#O/W
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MVM'9*L?T<Y*B(([^C5;_P#'=IGXD!J"!V_ODF ETED89^:DM\3E:XY1FJ/;
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M&*$%&M[+$=Y.\XGG&"*TRJZ)ZBA/--YUOVZ=//0  VY?:PS0?M(P4947CA
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M.9=05.3+S?-CO?GPM E2E)61A]7Y_A*M$7$1AK52E#JQUS]NIYFA3TM7(ZZ
M7(9,GS,#O'?W3"NYY]6K:N<X*>HJ+H/KJPI=&._<\;O,#&H:>G()-!@[WM\8
M>PHW:%7$B+YE9:P 5L47=P,TGW<' XQ:7\;9E]^UYIVZ!PZ8[[S1YJ=.CG("
M:4LB1DZYL$TG;730QFO^N$-H8IA6VMBUS\TQ*77 A>^\Y*%4 5L09IJJ9N\F
M J7:VU]NNQA#V%03PVS7WE!EZ$AUB'>%K4'2^%31Q<J:MPTO80:]+8"Y*ZAP
MMBUS@:O,_IR^Q4LS_(DN-]V<@&1U&Q&ONG49[+<HWSR@)&$CRC+9!FC6R'K:
M@NFN7=B92MMP5>2N!+(UKMPD*+9$H@-^1-MM<!YA^KY;L$-%'H7931+*5D5P
MU^&"".AZ@EC45XTIWI1&'JZ98UY,H?<F<%*&6_U>B(@)<_?KDI'!?K7)\A.U
M:?+XV&V\!$_8,>SR%.4.?2E_Z8NHU$=\@M'OXRN@)S0:_PA"*'(GML :0'"&
MT"?LVRWF'764L6=%G' Z28ZZ^IU.#"EBH4V@,J#L^[;H0XI#A%;9-5$8Y8E>
M<*1QB<,:WC\=@+8_5IN3M9\J.%1%!>$"0-1W+8$FY;EFO^&2WO8<G!4!FC9
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M6$/F3IB(-T*)# #E&4)D&.^=#DB806 [*!%'A<UPXBY,?);G&_0I2']'^75
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M59->Q&OE:=^CLE!@J) @*!P'*!-_>(1]KQ_WZW44(K'IA6V:4QEVF],P.T1
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MMR1BI.8+V]16XK292/J]=6ABF%;8J?FVN*$(YG#A._5Z*%7 %H29.J79N[F
MJ]K;7VJ_&$/85!-M^#&'*N_-J@[QKK U?!UFHNABI?[;AI<P\=\6P-P]W])B
MA/K+9>+9>81IYENP0T4>A?0-$!EJP%V'@ %T]?78@N8Z@XU4TWF408V#'K
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MN^MQ9]LR%YCP\(BR/,@1_?^(Z'+3S0E(5K<1\:I;V=^_1?GF 24)&U&6R39
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MT=_PC,_'+):%J=C18479\27S?<KN3/3JE2'B#M5_HNWZ)^]^!G>]'' &7]8
M4XN=T,3GB./])%]7:TV9-.+;%&74J[^2P1TD6R$6!RR9!FFLLC2+]6(:JIQJ
M,IY5(0W?KI_PVO)KJ8*;^N'"Z2PPFGPY7V64^5J6&H=V/J7U1EG2>M'Q]XR&
M^Z6WBO&.[[5TQQW/-6G&718% SN=TJ0?2%)/ZK_,;U)WUS=/CH(G/V"9T296
M.J4)W1>DGL]_7>X/R'*/E_L#R_T!.E5^6>X/+/<'EOL#R_V!Y?[ <G]@N3^P
MW!^8P?T!5K;VX]-G7J5&>=MCC491VZEN.@WO$JAH:(S[!!)^/-\IJ+SD1[3#
M:1XEKWXO"?28H2?T21B1(5[ICN(:I_?$9PWH3P\I7D?Y+<ZR:P*JNN,SOB![
M;!Q'*UJ"?[!U:CX+;D=IO@NN1O&Q0#7)U)4TU*VNN>SK5MZP5H^HH:]UR3$N
ML()Z.NN2&[[HTB3BQ[>#*"R>RTEL5^H#*63L/WW</2AUE#82/H&L^?;?)"5[
M.6!5[ 4KH_P> *NGN)$@"V;.=WIQ>31QAQ/<2%I5IF8_0 5K7&M:UGB^R%12
MTTB E/'D._'U#N451U2DOCO)^JWQ(+N_S1=4(B6,Y2=V63#,9^2\K<U;.6^#
M%YR2OSZBF#)6 [</%<W>DJ\JM_=\X6:F2,]?62Z3AMEPBI!]WD3IZB%(\SV]
M@0"%*J>7!**#7N\/FF+%>8;D@#G#'"Y%*+*CFD!$BCM+@,GK_/[P"5*C9YCR
M>#3,4%)$ZR7:I2B,JL@[^7%+Y?^W"F0!%"2X%5)X?^"%*]0S@H6,MK.')A@B
M4@L-J86$WB-HO>ZXI4PUH?4??:'Q+,O(CFZ["Z*4RG)!UO[7P8Y*W*A)6.,T
MFB_D0&H9"6D\7AJ ^7M4D!B(BG&?/)=/J96K\/WZ%@7#M0[0M%GHA$WG"SD%
M%8VUQ DY:N#G[4#FOAOK9$06!2V:*#:KQ7PQ)E?(6/%J%B,-HG1/2SC;$/;Y
M(BS@J-57>.;\#H.-)DKT>@8M"S1^T#U/44*J.,ZHU$>(S'<48]11FE<D\N*+
M'RP?S[!'!X47=;H*\?C^0HL&*O2*3DE8\8/E QDV$_"HHG9_(5S?:4315)E>
M@0N))G[P=@]?F!BGDA2ID@SY_K#J-8PH8:G!H+>[XP=1Z\V_6-"L*RGKTK@]
M@@<TFQ,<]YKX&$"WK.319H,YW\V4.8T[Y$\Y89T.?UYD1!-9ULC&N%,.:MO<
M3!&W]7KGW"(ZL9I6VC VYZ*\K2@>W??]BIH;]LU9UF_=BTW^+VS#K(O%TG16
M+Q'!TJ)=0B=CP>&E92\V9-TVUC.B\-JPFADMW/\5Y+CD4?@)K:*0\E$/R[S5
M"VK;.NX7M/7KHP^OXZJ(QO ECO=H)80\WZ,M7C+T1T$=]#>*-;_W:+O,#/S
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M#WJSH5P_A;6GJ9@BSAW=-U)+(<RB)^N?%]@@CMM1-R"ZFY#0A3AG0ST^=-%
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MV<;:G"#8N/&6CGW0AA(=2-'IBP6>PLO#HB^@Y^]F]@-HBQXU7Z'_R-%T1'I
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M&,>LU*.T(@5GTGW(EO=6]>/ %F/0L\2J"P9F(F?HV4@8V, Z8;V>B=AIW>\
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MY#4*J6'N"<);GJZ'B557C,U)PC"TG0#P 7?_&CT3,=1Q[!1(-S60:B)T^N*
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M<F:24WYZ0JES SL0I6\#R(A<J<8.]9U3>6.W%_CTG4&/*@U ?;I.3J^VA1G
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MQKOKG>!OA4XVBO+>RFY3&8"Y3]6AW!<*_+K,J7Y2[QS9%E_!S1/'BQ,;[V@
MEIC\X+[,&]NAS6^[6Y/BC[18::>\]9PRKZGBA#8C?2M!%A_M]%K9FT(2]\B'
M:J'LH 9:=BDB,SD#R*@LT1AQ,MN4"U":;!QX]1L-]'J!0*N*'8?"GHP-G;U&
M*-O$&G \QQ29Z#\&US2PS=[TO_4=2OGJ \[Q.JM*?E#Q [NKK4O ;E76A3!
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M=T&'ZZ0G"W*_J=?Q'4#<N%,S-)?X3A6<-/] CP4^8;,265W(E10\1(0^7@&
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M$N1.\A[[KSS9>P0V@8 1=]@$>"MPBKBMD",:-_NT%K" "V<R 0,NV^*X9/%
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M%C.YW5 .<TH#-(9G+S*YH0&S8)5&@EO>=" 1F(X=&;"UI(&9'P>NH>/%Y 9
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MTK>F87NU/37M_5G44"./-M4*LK2JFEYE5U6SY5K6" %ZMC4)&[5U562:]B6
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M"IH!ST!+DOK"7)',%A0Y/'FU]J8B"&V,:&N^EMBU/UL,BM;YX$'HNDJG_PT
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M3Y)J,>@=$C40.!.BH8HM& F$P#(-#;3 N9!880:0"BL6>$.I<YT!HV\"44)
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M&8B'M8D)<^A&C86>=YL7]XN!O/\=EMN(QJ=MD/JU6@%N5-+:,='B(-T!47"
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M4Y2D##J! U0S2!#;'AN:I!9Y:W8&PF9!(4Q0:"3.'7\TN.-M5ZAMO>)9\)P
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M4+%EZ?(87RFVJZ[F$=\LQNA1Q1Y5_.L)Z<52PA<3(!'+CAY9I 9U9X[:HN9
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M2$6AH904U'8EDOP'A&KA^L:KXE6'@2OM.' %$P=68>"FIUUUPW=/OZ4%@#K
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M2$Z*">:QD8:N9 =V/$;8ITHP!C2VJZ9FI%V0O5#H_OS]+S]\*.!+?^%CE_W
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MJ6 GA=SC--\01>*[#:U +U*UZXWPP#R<.\Y3"/H$ZG3F&@3L/IW [ASQBPB
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M8C\,C^QR$6(_@B'V(QAB/\X+8FS!1X#8C\/CL=R(:5%;&>%ARP=.1PC;;O4
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M24R[AI.'AQ(G4>XV]!W?&_I,5C%LLG^@F'IM/O?<;TIUZB3_L#H^X$Q'?&7
M 1NID>?A@<1=_HI2T.0'*%D;,5%)'[ %%U7=A(E(USBR<5!@UH91%;SBN!ML
M(BS#LE&G,C[@!B+>,!MT(EICQ4.??7L:KU_-BT[/0-*'Z]F)MW2J,I=6LJJN
M^%6.;PHVN+Q%7_.G+RA^0Y_('O^5';NL3T;@@X&1L394M=#!<=-H:*P]M%68
MX7ER8$QXF6$(*NY_HR!]^H(U,=ZIK0CM8^W9(IJMGVF ?&S;R\N/2E*2-B'1
M$Z#Z.A@NZ\\;Q0P=38CCLG6/;T;!Y+S"^^Y]4-WJ&C@NJ\\:Q@P-38?BLG']
M,'-?0!SU4K/K5M<!<60UI?LD(.YK:$(01XW4\!J^8/N>%*BTJPW9R0\$-).&
M(JH[-&8+;9&NIL%WAX-YQ<&S!-9$M2:09XQ=*W =$OF>XSR(747HYV0=92'>
M)SE:7WX-2='5EOY+!:XR&A#L\FG,"\A 78V(:CX'&K'SOY803] +#0QTSA-_
M #G=#QWE<TMY!T68O,/ QFU#/PC?D9= M6-%E$YS!L:.R-JJ79)&[T)8[X1>
M%B&U-#=*682DI V[&295;L!Z_8>K3_D#4&V*?/7-ZE6G\R .OS^^@#A>@^V1
M3Z/TEX>E#*T8J#*%BX5F >8ZH2S@X%"6RB$;P2P"7I[4_BM((VIW>#W._5XI
MBO'=P?Z622'K;D9]3\\UV;W,TXO;O:K;F_U>U+G38-F%T;9 OZ'HY96^*DD3
MD;Z@BVH[^T"VH.Q+BKK5F78>4MU!_ S4@=H< 2%O+0?4N&CL9WGI/JNM6QV"
M1F9UW] HU\$@-#+)^YL&JBUK[0/HW[*0EF/BJU7.>2#QI5)#3(N.R;,I.QO5
M=GJ,9<_XOG.T\(:24DJ6[OCA9&#1V!^RG+]3#YMSO-U&>6$"5LF:WC\GE@$E
M882R<QS'Y7,_M*_JJ\1V7_@6L$N77C'.]BGO'H)6W0H4BG6MC-CC&_.-CGM#
MJS2E[]K6K-]B EOVYR?R5T;8IRDP6*^.C]= ;3E&:,#>DR,-OA@OJPC+M)X:
MZ96QDY^ZVP<!6^W,YT<T:Q\S72O6-ICG?5M8T_(QA9P>_-)'%<C4\]HVCLGZ
M)B)[O4;&A=^B_/4>)0E;'X;)UHHR1M;:G*V+%#R:4MO+ 47^BDP*QOAR[4WA
MAC(HJQ_1=AN<19C>E@UV:)]'848623*+ *[:-P> JEXB65\YP]&JU/88#RY,
MV$?B21@/G;C:G<%LK*-R6"/^/I0TXA(2P]94[3XQS\_IC:L>'UX>)!K0RPWG
MO:8Q2!^W:R9)FYLQV5OJ,BKQ/CA0 -VC]#[%ZWV8GP?).EJ3!<,53A_(D/J$
M$TSVG%%(=IP%EK+/.T*%##/T5F;YVCSN4!AM2 GR2XR+%RL_13%9=N"DNYMS
M@95^;UE@Q9HQ' 7_V+8Z!=;6I,#4SMH5U+75N)XVIC<ATUN*Q2!,W4\NCGN]
MX>U,_E6VT(\!8?C(=7V85RD!-%Q!%(3#3T+AG0PG%3W:&!X2_JP]I,=+-XR3
M![39)VO*WNJ%2$'OW5PAE/5&^#49X&$A; ?P@VC428CU:,P.]"9T.2[L-3ET
M[H&^IAB?=Z17DWP [-4HL$ /I3!OR&OI<4+ 0_FS%OT%@;N$>[J":RS6@IBW
M,3%+E#4H!A"=]S@QI>T)A\X EJTE<^"=R(5AND?K"Z*&C"ARGQ;"G>]3BHGN
M$1RD;'WF)BX[.TBKZ&9<I$HX&9"KP78V$9QEISBJ0R%G$*_(?CU-#^3'?P5Q
M/Y6(2ITZF!)69W80UM'5N% &<F3M74..37W,<?C'=9;145B\'G5?/ KUB'*B
ML]*3=!/ET0MK*:Y5MXZ&4ZL[.P /T=VX0%;DS+4G&COC\/&5=&U6^(G69X<+
MPA]9%O73XBA58MM>;J7985=+6Y-:7RY+UIY\!#PH^D3?7,C+)RO/<+*O\OET
M PM4JC >$N57F1U.-30U+DIA#(WR#N-LPJ!&C*N9(GK*+/N>1RCJW5G!$US6
MZ-H!!3Z+-=0(_'F:8H?J#B?%HM+JW:K+?^^C_,"Y/,7^6&&A^]'N]:="DV>'
M\YCH6GR/B5NR=R&)4=+2K<PL6D=!>J#'N15;C-M%TG*GNYJ\<E;$.S%Q&VSI
M$N TR"\PO<O>E1-<H1884,&@.S;/7]&G(/T#Y5=!6"0+/)['LZ]%@"O4CEE
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M$>Z8ZN=NGV<Y?:@A>:D6 J71R'HBJXVL 0W !IA6 ^]CG W7O87AIL6T:UF
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M(@/F=X=@!F;<TW:ZUTZ?SF/1H#ILS!I_A5X=;3T!U(#A&40L^>RC6;B!L<R
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MNGZ*8B^3+EUN=S$^(/2(TK<H1.PYZQ8G;Z4#@^([>\)Y$#>_4[W>XOR_4?Z
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MXDV4US<>*J:S)WR.DPS'T9K>Q&4%H9LC>#R:'4[06E0J9>ELGQ&;EV4UAXP
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MQB=)#)LU>'%+IOBA'<KAP\M;&@;T<L.YSS$&:<EJ5(^TN1GS\XZ, [J?*78
M5]0?&*+HC;&<!)2L9!66M#;21^E<K**7]D@WR0\=XT(^7+NE?Y_B$*%U1M]^
M(,(^H,T^65-6Z4M@I03WP:%01S\(3;7F*1P-7G-V,-77V[BP5>++M1.)TV"[
MV-/[Z%SC*2]8W\P6%)P=)L%:&1>"(C9<.YUH#I?'5YSF-'+N)(# 6 I*,PPD
ML_3L *BFG^D,(9,7UTXY:*[*-H\R(PBN4!M#0(7985)92R,;1P [ PY 1LH!
M53Q*1L1J#JK/.YS0;$3E+2NRP49I'D3)V3XC\F;9IRA&68Z3WJF<(6K'C>!
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M-C=!LC[R5\6%!"^]=\$@91L]+BCK"P*@XFHA0D#<W]B+DV!<]'"AXALNS('
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M2>(7M8PD2DE?A$/K7XKYSZJ3T%*3,_DISDX_')'-OB6DG!\J(LZDOR:AM[2
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M;.\]&X_'EX8O*3H5H+;K;:?GVTY=\]1.8]7S7]W /+^")?YH:ULG!<1TJR<
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MQ%)M.X0%;?TMAE0F0S7B1DM7?TB\* F&BCQ\5TX#(5^>QXL_9\AFF1\.%6]
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M7W)E9'=O;V0N:G!G4$L! A0#%     @ Q:KU7+2DT PV'P( 66(" !T
M         ( !&38! &YY,C P-S<Y,35X,5]B87)C:&%R=# Q>#(N:G!G4$L!
M A0#%     @ Q:KU7!5AG\!KE $  =L! !T              ( !BE4# &YY
M,C P-S<Y,35X,5]B87)C:&%R=# R>#$N:G!G4$L! A0#%     @ Q:KU7#6*
MQZGCB@( /]<" !L              ( !,.H$ &YY,C P-S<Y,35X,5]C:&%R
M=',P,7@Q+FIP9U!+ 0(4 Q0    ( ,6J]5P63:%YO ,# *Q> P ;
M      "  4QU!P!N>3(P,#<W.3$U>#%?8VAA<G1S,#)X,BYJ<&=02P$"% ,4
M    " #%JO5<9F8,_#"C P##Z@, &P              @ %!>0H ;GDR,# W
M-SDQ-7@Q7V-H87)T<S S>#(N:G!G4$L! A0#%     @ Q:KU7%0"5:6WK (
M&=T" !L              ( !JAP. &YY,C P-S<Y,35X,5]C:&%R=',P-'@R
M+FIP9U!+ 0(4 Q0    ( ,6J]5QY"QP)3W$  +>B @ 8              "
M 9K)$ !N>3(P,#<W.3$U>#%?97@Q,"TR-BYH=&U02P$"% ,4    " #%JO5<
M?*E:U:0[  ! 0P$ &               @ $?.Q$ ;GDR,# W-SDQ-7@Q7V5X
M,3 M,CDN:'1M4$L! A0#%     @ Q:KU7#;I3=F.BP$ A\,( !@
M     ( !^781 &YY,C P-S<Y,35X,5]E>#$P+3,P+FAT;5!+ 0(4 Q0    (
M ,6J]5RH*H/Y$P(! -Q_!@ 8              "  ;T"$P!N>3(P,#<W.3$U
M>#%?97@Q,"TS,2YH=&U02P$"% ,4    " #%JO5<ZE3C?_@-  !C-0  &
M            @ $&!10 ;GDR,# W-SDQ-7@Q7V5X,3 M,S(N:'1M4$L! A0#
M%     @ Q:KU7/W88\B7'@  BI\  !@              ( !-!,4 &YY,C P
M-S<Y,35X,5]E>#$P+3,S+FAT;5!+ 0(4 Q0    ( ,6J]5S6H(+5QA8  'AA
M   8              "  0$R% !N>3(P,#<W.3$U>#%?97@Q,"TS-"YH=&U0
M2P$"% ,4    " #%JO5<^E9_S! _  !N80$ &               @ ']2!0
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M,2YH=&U02P$"% ,4    " #%JO5</KLT;)$"  !,!@  %P
M@ &^I10 ;GDR,# W-SDQ-7@Q7V5X,C,M,BYH=&U02P$"% ,4    " #%JO5<
MM-.I]/D#  "%#0  &               @ &$J!0 ;GDR,# W-SDQ-7@Q7V5X
M.3DM,3 N:'1M4$L! A0#%     @ Q:KU7*$%[O5H!   S L  !<
M     ( !LZP4 &YY,C P-S<Y,35X,5]E>#DY+30N:'1M4$L! A0#%     @
MQ:KU7*=$"Y7= P  B@P  !<              ( !4+$4 &YY,C P-S<Y,35X
M,5]E>#DY+34N:'1M4$L! A0#%     @ Q:KU7'.6$0\%!   ^@T  !<
M         ( !8K44 &YY,C P-S<Y,35X,5]E>#DY+38N:'1M4$L! A0#%
M  @ Q:KU7$5Z@C, !   [@T  !<              ( !G+D4 &YY,C P-S<Y
M,35X,5]E>#DY+3<N:'1M4$L! A0#%     @ Q:KU7 5M?O;T P  ? T  !<
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M'@!N>3(P,#<W.3$U>#%?9W)A<&AI8S Q+FIP9U!+ 0(4 Q0    ( ,6J]5R
M^MYFGW4" "V3 @ :              "  3.'( !N>3(P,#<W.3$U>#%?9W)A
M<&AI8S R+FIP9U!+ 0(4 Q0    ( ,6J]5P0EC\X^O," /HG P :
M      "  0K](@!N>3(P,#<W.3$U>#%?9W)A<&AI8S S+FIP9U!+ 0(4 Q0
M   ( ,6J]5Q#I],ZAY0" +?6 @ <              "  3SQ)0!N>3(P,#<W
M.3$U>#%?9W)A<&AI8S T>#$N:G!G4$L! A0#%     @ Q:KU7,]K,O,EE@(
MH+D" !T              ( !_84H &YY,C P-S<Y,35X,5]L:6YE8VAA<G0P
M>#$N:G!G4$L! A0#%     @ Q:KU7/9T-W%)#P$ BC4! !T
M ( !71PK &YY,C P-S<Y,35X,5]L:6YE8VAA<G0P>#(N:G!G4$L! A0#%
M  @ Q:KU7#*NAW8>AP( ;N(" !T              ( !X2LL &YY,C P-S<Y
M,35X,5]L:6YE8VAA<G0P>#0N:G!G4$L! A0#%     @ Q:KU7*ME]K1UBP(
M#[P" !T              ( !.K,N &YY,C P-S<Y,35X,5]L:6YE8VAA<G0P
M>#4N:G!G4$L! A0#%     @ Q:KU7)=>%"W]<Q$ +GV[ !,
M ( !ZCXQ &YY,C P-S<Y,35X,5]S-"YH=&U02P$"% ,4    " #%JO5<$Q?A
M'Q11 @"PW ( &               @ $8LT( ;GDR,# W-SDQ-7@Q7W1A8FQE
M,#$N:G!G4$L! A0#%     @ Q:KU7#"MT?N*W ( 9E4# !H
M ( !8@1% &YY,C P-S<Y,35X,5]T86)L93 R>#$N:G!G4$L! A0#%     @
MQ:KU7"0$PV9LD@( &5,# !H              ( !).%' &YY,C P-S<Y,35X
M,5]T86)L93 S>#(N:G!G4$L! A0#%     @ Q:KU7'3JA&PY@0( HA # !H
M             ( !R'-* &YY,C P-S<Y,35X,5]T86)L93 T>#$N:G!G4$L!
M A0#%     @ Q:KU7#0(#0#,&   'TD! !$              ( !.?5, '!A
M<V<M,C R-C W,C$N>'-D4$L! A0#%     @ Q:KU7):Y4ZWX%0  'F\! !4
M             ( !- Y- '!A<V<M,C R-C W,C%?8V%L+GAM;%!+ 0(4 Q0
M   ( ,6J]5QH@(CJ[UX  *^7!@ 5              "  5\D30!P87-G+3(P
M,C8P-S(Q7V1E9BYX;6Q02P$"% ,4    " #%JO5<4^;)YT79   W#0X %0
M            @ &!@TT <&%S9RTR,#(V,#<R,5]L86(N>&UL4$L! A0#%
M  @ Q:KU7+RX:YKPE@  4FL+ !4              ( !^5Q. '!A<V<M,C R
C-C W,C%?<')E+GAM;%!+!08     ,0 Q ((-   <]$X    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>ny20077915x1_s4_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pasg="http://passagebio.com/20260721"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pasg-20260721.xsd" xlink:type="simple"/>
    <context id="c20260101to20260331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20260331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20250101to20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20260331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20250331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentAndCertainOtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:PropertyPlantAndEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">pasg:LaboratoryEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260131_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">pasg:LaboratoryEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250714to20250714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2025-07-14</startDate>
            <endDate>2025-07-14</endDate>
        </period>
    </context>
    <context id="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_CashAndCashEquivalentsAxis_DemandDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CashAndCashEquivalentsAxis_DemandDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FinancialInstrumentAxis_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_DisposalGroupClassificationAxis_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongLivedAssetsHeldForSaleByAssetTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-31</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-04</instant>
        </period>
    </context>
    <context id="c20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-07</instant>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:MarketStreetSubleaseAgreement1835Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-20</instant>
        </period>
    </context>
    <context id="c20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-29</instant>
        </period>
    </context>
    <context id="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-29</startDate>
            <endDate>2023-09-29</endDate>
        </period>
    </context>
    <context id="c20240220to20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:MarketStreetSubleaseAgreement1835Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-20</startDate>
            <endDate>2024-02-20</endDate>
        </period>
    </context>
    <context id="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-07</startDate>
            <endDate>2023-08-07</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-04</startDate>
            <endDate>2024-09-04</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:SubleaseAgreementCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20200201to20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="c20251231_PlanNameAxis_EquityInducementPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250131_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260131_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EquityInducementPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="c20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20260501to20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-01</startDate>
            <endDate>2026-05-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_IncomeTaxAuthorityAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_IncomeTaxAuthorityAxis_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_TaxCreditCarryforwardAxis_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20241231_TaxCreditCarryforwardAxis_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_OrphanDrugMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">pasg:OrphanDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c20260331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">pasg:AttheMarketFacilityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20250101to20250331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentAndCertainOtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260214to20260214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2026-02-14</startDate>
            <endDate>2026-02-14</endDate>
        </period>
    </context>
    <context id="c20260304to20260304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2026-03-04</startDate>
            <endDate>2026-03-04</endDate>
        </period>
    </context>
    <context id="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:ArrangementWithGemmaBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260331_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PlanNameAxis_EquityInducementPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260331_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_PlanNameAxis_EquityInducementPlan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pasg:GeneticMedicinesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c20260428to20260428_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-28</startDate>
            <endDate>2026-04-28</endDate>
        </period>
    </context>
    <context id="c20260428_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-04-28</instant>
        </period>
    </context>
    <context id="c20260522to20260522_PropertyPlantAndEquipmentByTypeAxis_MarketStreetLeaseAgreement2005Member_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:MarketStreetLeaseAgreement2005Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-22</startDate>
            <endDate>2026-05-22</endDate>
        </period>
    </context>
    <context id="c20260624to20260624_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-06-24</startDate>
            <endDate>2026-06-24</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U002">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U003">
        <measure>shares</measure>
    </unit>
    <unit id="U004">
        <measure>pure</measure>
    </unit>
    <unit id="U005">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U006">
        <measure>pasg:item</measure>
    </unit>
    <unit id="U007">
        <measure>pasg:plan</measure>
    </unit>
    <unit id="U008">
        <measure>pasg:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20260101to20260331"
      id="Fact_723110b0c7b24db4b051c4943c1e8143">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20260101to20260331"
      id="Fact_9946e5eddb1a49729ff626a6ca5e08e2">0001787297</dei:EntityCentralIndexKey>
    <dei:EntityFilerCategory
      contextRef="c20260101to20260331"
      id="Fact_369a8940b23142559db48644f0c7b55d">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20250714to20250714"
      decimals="2"
      id="Fact_87ff84423c1d4358a1dd1652b1ad4132"
      unitRef="U004">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c20250714to20250714"
      decimals="2"
      id="Fact_9c4ae5c452f740698340777ae9877470"
      unitRef="U004">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:IncomeTaxExaminationDescription
      contextRef="c20250101to20251231"
      id="Fact_bf46da9b45834552bfbf43a7fff05a75">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December 31, 2025, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statement of operations. Tax years from 2022 and after remain subject to examination by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:IncomeTaxExaminationYearUnderExamination
      contextRef="c20250101to20251231"
      id="Fact_76a8a6c10938470cb53d52e197480e2e">2021 2022 2023 2024 2025</us-gaap:IncomeTaxExaminationYearUnderExamination>
    <us-gaap:NumberOfReportableSegments
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_6fcb045ac6ef441986cb7c4046a9cae6"
      unitRef="U008">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_54f55c66f3b44146b30493895e843cea"
      unitRef="U008">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20251231"
      id="Fact_ddc4c321df544d6ab525cd8234db36c3"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20241231"
      id="Fact_3ede8ec3df2f4c6594e8b1e4cf743bf7"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c20251231"
      id="Fact_84393bbafad4493585cb473ec6ceb36d"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c20241231"
      id="Fact_37943eae796244c0bb11517d9e8ac664"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20260331"
      id="Fact_b0ea0c10802147e1aace77035d2e4588"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20251231"
      id="Fact_aae3abcfe7c54022ae82a6d996c01274"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c20260331"
      id="Fact_6cc7532afaff475eb890c1213316a0a2"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c20251231"
      id="Fact_fc17000e5373490cbae15a0831b04236"
      unitRef="U001"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="c20260101to20260331"
      id="Fact_ffd8b3e949cd48aba981e97fd7327022">S-4</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="c20260101to20260331"
      id="Fact_a1fdc0d923ce49cba4f21e91dd7488c9">PASSAGE BIO, INC.</dei:EntityRegistrantName>
    <dei:EntitySmallBusiness
      contextRef="c20260101to20260331"
      id="Fact_8a5466b72b744501b30bfdec44f2379c">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20260101to20260331"
      id="Fact_b69d9f57028d411898fbb83f8f542477">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20251231"
      decimals="-3"
      id="Fact_1608a05412ea4dcfa782e814b07711c0"
      unitRef="U001">46303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c887f241d20b42e4842fde32f15fdeec"
      unitRef="U001">37573000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_932e5c244e184316a00d9a8c5f1bb417"
      unitRef="U001">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_a9efeb9bd03544468507e2bbfec71a9c"
      unitRef="U001">39183000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_7595bec57fbd4f2aa92ef3b52ec406cb"
      unitRef="U001">629000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_08aecb5c3ddb49c487d64df757f3f8ab"
      unitRef="U001">838000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_d0ad8120e42f4be0941f0367112106ff"
      unitRef="U001">830000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ceb698037e264f56ae704c081c1ce251"
      unitRef="U001">1221000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_bd5b616bc58f44e0a45f8c10668f61db"
      unitRef="U001">47762000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_dd563fcc23564cc79daacd759eeb53d1"
      unitRef="U001">78815000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_627e3a4a24ce4afe83400c10dc3e8513"
      unitRef="U001">4107000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_96e9dab067a54115ba48e73f570cba11"
      unitRef="U001">9331000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20251231"
      decimals="-3"
      id="Fact_cdbe7d439ca645639ee2df2f1c8bd1cb"
      unitRef="U001">10168000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1a518e77be6446a1bf351fa4bd6dafa7"
      unitRef="U001">13803000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_85ea212a26e748698778280f5b9bebe4"
      unitRef="U001">244000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_10fe436b128d42af999dd28f6f10275f"
      unitRef="U001">463000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="c20251231"
      decimals="-3"
      id="Fact_0d661250bf4b42709dc40fe9672039f0"
      unitRef="U001">62281000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c0177b115ed84e48be6b7af8450e9114"
      unitRef="U001">102412000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_204590269fdb45e6a6a42eb1aa1585c4"
      unitRef="U001">1113000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_7df1eab2688047f5aa99b51b2ecf7751"
      unitRef="U001">742000</us-gaap:AccountsPayableCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_81c9a7f2a8d4476cbcd3040f5efb00af"
      unitRef="U001">4653000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ecef7056e5554435a6c65d1c01c976f6"
      unitRef="U001">6707000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_13fbfe7cebc7454ca44bf6e069d34e16"
      unitRef="U001">13750000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_abba2b3cb12f422a9654eb314307cd69"
      unitRef="U001">8226000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4127d285dab44e44a70da091b2148f77"
      unitRef="U001">3567000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_02900ee9c22b462fa2b245226ceac11b"
      unitRef="U001">3688000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_88cf06fcc7f7480b8e75088ece7312a0"
      unitRef="U001">23083000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_03eb1fcb731942a29b52fc50291980c2"
      unitRef="U001">19363000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_77a1daa8c1794d9b930c47cc58e2b005"
      unitRef="U001">20443000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_7a7f3494f7c148999a09e2e49a1527dd"
      unitRef="U001">21788000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_5d8722bf4ee54a89b635aa6b6e42c71c"
      unitRef="U001">43526000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4d807a3bc80a4eea969da57ecacf918f"
      unitRef="U001">41151000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="INF"
      id="Fact_7756d5f9acf4477a8751ae833c6643ec"
      unitRef="U002">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20251231"
      decimals="INF"
      id="Fact_ec60ab55909d4a1d82221e0ddb202020"
      unitRef="U002">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_6f5eb69035b4453ca3f0e5a7e537783e"
      unitRef="U003">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20251231"
      decimals="0"
      id="Fact_27a28f3217ac44a184949dba4d25804b"
      unitRef="U003">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20241231"
      decimals="INF"
      id="Fact_c73212cfb0024bf7bf71b8623aa0cc83"
      unitRef="U003">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20241231"
      decimals="INF"
      id="Fact_899857c6492a47bfb90aae6d82ea51f4"
      unitRef="U003">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20251231"
      decimals="INF"
      id="Fact_5c21a44574fb4ed8aa123d628d3fab54"
      unitRef="U003">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20251231"
      decimals="INF"
      id="Fact_036609dd09fe44dd8bfa8fa9b114633a"
      unitRef="U003">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="INF"
      id="Fact_21ba0d99aa1b45e9a1eea27dbf435633"
      unitRef="U002">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20251231"
      decimals="INF"
      id="Fact_141128e9599e4fdd96a48127d0ffcdce"
      unitRef="U002">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_c22dc72a100e40b1b25e1a54924d9d39"
      unitRef="U003">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20251231"
      decimals="0"
      id="Fact_48a92c530fd14870a3ea35c1ae1153af"
      unitRef="U003">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20251231"
      decimals="0"
      id="Fact_b7d573a085364ca0a22275f13b77b180"
      unitRef="U003">3182810</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20251231"
      decimals="0"
      id="Fact_04d21bdb2dc14b7085638353903eb339"
      unitRef="U003">3182810</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20241231"
      decimals="0"
      id="Fact_ff08e3e4c29749aa9c2a1e842e40492e"
      unitRef="U003">3161503</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_b8709531b8b645c1aaae1bc0cebd42c3"
      unitRef="U003">3161503</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20251231"
      decimals="-3"
      id="Fact_63230078ab2b43d28995e3f09acaab9a"
      unitRef="U001">723512000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ac81376ed19a46a8a1fbb2dc7b0c1e2d"
      unitRef="U001">720488000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ca7de7b76f14427a99a6590bd8e9b770"
      unitRef="U001">8000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20251231"
      decimals="-3"
      id="Fact_2bc83809162c4c0a9ea547e234dcdd8b"
      unitRef="U001">-704757000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20241231"
      decimals="-3"
      id="Fact_8176dd341744403ea8aa1f7d4eaa2330"
      unitRef="U001">-659235000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_8730030a74b64b3d960eea44f723102c"
      unitRef="U001">18755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_638affc09ca846d59ba106a5d178ee04"
      unitRef="U001">61261000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_b274b32963b24a509563feeaeb248fba"
      unitRef="U001">62281000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_252cf0467897495f952826583b0c7bb4"
      unitRef="U001">102412000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_152b9f8606e3451da90114ba61b9c824"
      unitRef="U001">23276000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_cf5cc5abdbe248a68680d95ce80edf07"
      unitRef="U001">40179000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_ad5478d6f1ec458689aba63a402c2b93"
      unitRef="U001">19875000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_107e8dc38be4437e80aa6092b76d72b0"
      unitRef="U001">24988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_2b550ea33ac34914bb0b26b232e55242"
      unitRef="U001">6145000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_194cf261268c421b8e086fef65ef1dad"
      unitRef="U001">5233000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_f7afedf0f469436898bcbbda7258cb15"
      unitRef="U001">-49296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f34738da80d54c50920d17d3eed093dc"
      unitRef="U001">-70400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7ca418cbf4164f679473fefcde6d7453"
      unitRef="U001">3774000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b683c0823d2946dea0db014a6fb9936f"
      unitRef="U001">5633000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_adf4a316455f4aa99e1bab94fb47a632"
      unitRef="U001">-45522000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1f95564c1cc04578954b9ea6380dffe0"
      unitRef="U001">-64767000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_444734cc52454f7eb7131f3c321288c3"
      unitRef="U002">-14.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_10e43fef19104c41b83c347cb26e465f"
      unitRef="U002">-14.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_7dfe283d90164b1d80b51eebea8a1387"
      unitRef="U002">-21.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_2583a5c42d0f4733b579cce8ed584519"
      unitRef="U002">-21.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_b30d5e9d70c04ba899076b0be6d0f3fa"
      unitRef="U003">3172870</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_2b4da21d98874ff7af659a0cdf31f0d7"
      unitRef="U003">3172870</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_89157f08401b4345bacd39daeb5d4f76"
      unitRef="U003">3078665</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_5f842b8a289947de888145d47b6afe89"
      unitRef="U003">3078665</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_e23c12f7454a4a9390b302cf54bcedfc"
      unitRef="U001">-45522000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_39f73fe0e5f4468d8984a46d75addf5a"
      unitRef="U001">-64767000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_0b2376cfa19a4fe69448001379f72ea1"
      unitRef="U001">-8000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_6ab96f57709b4d27979374478f317ba0"
      unitRef="U001">51000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_4f1f79b7febe409586084ca60b899653"
      unitRef="U001">-45530000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_af1b4475a9744533b51ffac3384b901c"
      unitRef="U001">-64716000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a34defea973d4aa68f42f4eaf5e73d07"
      unitRef="U003">2805618</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_65496520abe94d8abf0286bab1029424"
      unitRef="U001">705794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_50bf9694df9a4c4e80385630d7e6e2d0"
      unitRef="U001">-43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_60391dabfafb4c9989f1c6c69dfa057b"
      unitRef="U001">-594468000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_e6aa24ad461a4aadb5feaa808bbaf4b7"
      unitRef="U001">111283000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_1f667ded66324aeb85e18433a62f827b"
      unitRef="U003">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_fc1ce62aa5a0487db42ff7c8a7da6974"
      unitRef="U001">8742000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f94f436125ea49d08fe82e361ad8a679"
      unitRef="U001">8742000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_452d01bc1f9e45f499ce72828cf6e6f5"
      unitRef="U003">45649</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6fe5c5a475894cd0af807450ef5e9f41"
      unitRef="U001">35000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_15320d855b9c4a3a9a94dc82c08e87a8"
      unitRef="U001">35000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9373b5469599456fb38a52263a12e19a"
      unitRef="U003">10236</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_65f5932f1cb442c5a80b0edabed5c971"
      unitRef="U001">97000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c66ef19f593b404baf66ca2659aadb7a"
      unitRef="U001">97000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_0be72dfdd3324caf9485065ba8eedb7b"
      unitRef="U001">51000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_12b414ab1883475685dab18aa25839c1"
      unitRef="U001">51000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7334c3efca9f482c81f7c7cc0c72efcd"
      unitRef="U001">5820000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c5e40ed208f64f8e84ac6e8cb3c7d189"
      unitRef="U001">5820000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c1c30a57d58f4f3eac7cc34c6a75e746"
      unitRef="U001">-64767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_84e429571b1e4de9944a5837bc90d96d"
      unitRef="U001">-64767000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_89918d7417c042689bc54daef89e6352"
      unitRef="U003">3161503</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_71ecde895d9c4d7da56053511dc8eeaa"
      unitRef="U001">720488000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_d868233e309743c4a1896e9e635a5b42"
      unitRef="U001">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2449be1a21224d3cb4682503a8359ca8"
      unitRef="U001">-659235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_74103f990f3449c984e237a86d71acf9"
      unitRef="U001">61261000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b14fe65c2cbd41f6be807c9e12575aa7"
      unitRef="U003">3161503</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3b73ad9b2e664aaeb020262d34088a9e"
      unitRef="U001">720488000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a6bae5f10dd14a768c564e731dd3b5f2"
      unitRef="U001">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_964b441779c5454b9304903f2c4d1bdf"
      unitRef="U001">-659235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_2c9af7fc267a430f9f6ccc6b31767dcf"
      unitRef="U001">61261000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fb70c5bc997a4e05afd5d1712f86c739"
      unitRef="U003">16825</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fc67e7011e4a4e5cb70b104a2cab3f32"
      unitRef="U003">4482</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_db5811826d7c47dca294259a5925cbed"
      unitRef="U001">23000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_31111d30bf744add98f7897032f27001"
      unitRef="U001">23000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_051efc7b99c84e4abe5dd9a09d8c87d2"
      unitRef="U001">-8000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_b0e331e67d6647fc92d05f71ea53867a"
      unitRef="U001">-8000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a58377578ff94c1c84013c6c00a2ab59"
      unitRef="U001">3001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_4ba3e4e3451b4fe1b77caf3e96907f5e"
      unitRef="U001">3001000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d70dd6b7e100432f8f93335e200e3a46"
      unitRef="U001">-45522000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_b875eb6a46f44d32b064ebbed261f3e0"
      unitRef="U001">-45522000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2f449928750144d5a4c4477853b5d8fe"
      unitRef="U003">3182810</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7eee63aa4df94b019d12d82b4bae5ce1"
      unitRef="U001">723512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_1cfa13f645044718adfcf7db6303f68a"
      unitRef="U001">-704757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_07b47e8838354d66b93583d808a45592"
      unitRef="U001">18755000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_cb4f4c506f794cf3873d8c0208fd4179"
      unitRef="U001">-45522000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_ab27a0316591466ebdce43df513aa4ae"
      unitRef="U001">-64767000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_6569275f3381453c8966ffaf82489b57"
      unitRef="U001">728000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1335e44ed8c34a779b7ac363b0bf4681"
      unitRef="U001">3081000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_96cb8cbe4d0746a2bdb8910559ccdb5b"
      unitRef="U001">3001000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_93a7e33dfc574f9892c2ae1de1ae7dcc"
      unitRef="U001">5820000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_b6ea1a19e0054b039dd59ca6aaae4cf1"
      unitRef="U001">129000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_792a54745cd640b2af8653609bdf8825"
      unitRef="U001">-1527000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7d23d03bbb8e402d8dde73fd57ec8acf"
      unitRef="U001">6145000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_90bea641633149b09db39bb2238357f8"
      unitRef="U001">5233000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherNoncashExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_6912bfc5ba794f86a384bf0e9c3e2d84"
      unitRef="U001">14000</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_64e8208d53334d408177a6f428325a35"
      unitRef="U001">-228000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_881435f1a7b84965a4febb2659f490c0"
      unitRef="U001">-255000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_86f0714dce8a48178802f0cabf119338"
      unitRef="U001">-391000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_0db1f77eaf284505a5e8a00fdcc6b471"
      unitRef="U001">-1521000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_a6a6856d609b40469d4529cc26907148"
      unitRef="U001">4015000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d9438c1b68674fc38e12611de7ada864"
      unitRef="U001">8226000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_73538a4e663a4df8819aa51be0bc7ab4"
      unitRef="U001">464000</pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities>
    <pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_22f4d662f62842d884d754c7b252eb1b"
      unitRef="U001">279000</pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_69f7b75d3f2f4657b4f780c7fe1fa517"
      unitRef="U001">1880000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_6ed04e427b6040078b6acfbc61f3ae0c"
      unitRef="U001">-556000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_72c767f143cf470380294b05cb793b37"
      unitRef="U001">-2054000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c704a975ea5b4e1f928a26e2ae335a6e"
      unitRef="U001">-4963000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_df41db104f0f4bb8a6074da2f2b6a2a4"
      unitRef="U001">-31509000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d94245b660ea4885b885556d04719692"
      unitRef="U001">-47956000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_49d805c50d4a44aaa7d7a6c4dc36bccb"
      unitRef="U001">88170000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_c28d788ac38846cab526a5da130015ec"
      unitRef="U001">39046000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f8c72b78f63f461492437d072cbe9791"
      unitRef="U001">143150000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_60d4f77aec614d5f86059003f182ef4f"
      unitRef="U001">34000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_ecd268bca1cd4506b093957a06d7fb27"
      unitRef="U001">1170000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_5747e2f331ef4f0c96d9eb9ea4958e08"
      unitRef="U001">40216000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f98dca241c8247a08116c3e606423f4c"
      unitRef="U001">54946000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_2db2fb3eb58c476e8e935e22e04c3c57"
      unitRef="U001">8742000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b3e2dcb1345c4f1881cc3dec6d5f9024"
      unitRef="U001">35000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_0cd0c1044c254467a99ca91631c9466b"
      unitRef="U001">23000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_98fb95edf9574e62b758f13e2e607ee5"
      unitRef="U001">97000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_944d7f84956441dfa90e21431440f18a"
      unitRef="U001">23000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d3ba1b87ca4946d8b341f5c4d8b43e34"
      unitRef="U001">8874000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_c368a82784ba4993ba587171a1b4c85c"
      unitRef="U001">8730000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_844ec8b1e4eb4ba4924c19ccf57c5a93"
      unitRef="U001">15864000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3c721680743e4495bbf4f8bcda77b31c"
      unitRef="U001">37573000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5ae862670ac148cca4413db950840f6e"
      unitRef="U001">21709000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20251231"
      decimals="-3"
      id="Fact_aa676b4407c845dfb10172a8f108b345"
      unitRef="U001">46303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="-3"
      id="Fact_9179363e8d6446cca876933ff661e101"
      unitRef="U001">37573000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_970b25ce13e9477cafb094a4ed97725b"
      unitRef="U001">-8000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_81e4e0f180b0406d99e1905ae83bf1ce"
      unitRef="U001">51000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9311ef85c6e14343acaa11187fb3a4fc"
      unitRef="U001">422000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <pasg:OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7e116678a10c4814a0d0cdc8e72141df"
      unitRef="U001">422000</pasg:OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard>
    <us-gaap:NatureOfOperations
      contextRef="c20250101to20251231"
      id="Text_e1ee21d341264b828ba139f91408ccd2">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"&gt;1. Nature of Operations &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#x2019;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#x2019;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-&lt;span style="font-style: italic;"&gt;GRN&lt;/span&gt;,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. &lt;/div&gt;
</us-gaap:NatureOfOperations>
    <pasg:RisksAndLiquidityTextBlock
      contextRef="c20250101to20251231"
      id="Text_f57d5e5afeca418eb7fd8408a6796027">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"&gt;2. Risks and Liquidity &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $704.8 million as of December 31, 2025. The Company anticipates
            incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop
            its product candidates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company&#x2019;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            issued 300,000 shares of its common stock under the ATM Facility, resulting in net proceeds of $8.7 million, after deducting offering costs of $0.3
            million in March&#160;2024. The Company is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on
            March&#160;5, 2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company plans to seek additional funding through public or private equity
            offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances
            or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding or prospects of funding are unfavorable,
            the Company could be required to further delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In accordance with the Financial Accounting Standards Board&#x2019;s, or FASB,
            Accounting Standards Codification, or ASC, Topic 205-40, &lt;span style="font-style: italic;"&gt;Presentation of Financial Statements &#x2013; Going Concern&lt;/span&gt;, the Company has evaluated whether there are certain conditions and events, considered in
            the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company
            expects that its cash and cash equivalents will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these financial statements. &lt;/div&gt;
</pasg:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20251231"
      decimals="-5"
      id="Fact_6cba1d7c84034023918e592f1853c1a1"
      unitRef="U001">-704800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_7b54d3222ec14b829d5c16a073d7a766"
      unitRef="U001">125000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="0"
      id="Fact_82abdd0edae4439795aa7abd514c3334"
      unitRef="U003">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_928b13df4d8e4c63bbf38e4d4a9112f6"
      unitRef="U001">8700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_6732f9d7795f4da9ac65de4ef7065a4f"
      unitRef="U001">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20250101to20251231"
      id="Text_9cb80479c5684973813880a1aaf5bb69">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;3. Summary of Significant Accounting Policies &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Basis of Presentation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accompanying financial statements have been prepared in accordance with
            generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP&#160;as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;14, 2025, the Company effected a &lt;span style="-sec-ix-hidden:Fact_87ff84423c1d4358a1dd1652b1ad4132"&gt;1&lt;/span&gt;-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of shares of Common
            Stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity, have been adjusted
            retroactively to reflect the Reverse Stock Split for all periods presented. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;Use of Estimates &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;Fair Value of Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"&gt;Concentration of Credit Risk &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which dictates the allocation of funds within its portfolio of money market funds. The Company has
            not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money market funds. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"&gt;Cash and Cash Equivalents &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of December 31, 2025 consisted of money market funds. Cash consists of cash deposits at banking institutions. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"&gt;Marketable Securities &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. The Company held no marketable securities as of December 31, 2025. Marketable
            securities as of December 31, 2024 consisted of various securities as described in Note&#160;4. Marketable securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other
            comprehensive income (loss) within stockholders&#x2019; equity. Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable
            securities sold are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund
            operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;Property and Equipment, Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years for office
            equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. The Company recognized de minimis losses on disposals of property and equipment for the year ended
            December 31, 2025. The Company did not recognize any losses on disposals of property and equipment for the year ended December 31,
            2024. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company recognized impairment expenses for property and equipment of $3.5 million for the year ended December 31, 2025, $2.5
            million of which was for lab equipment, $0.9 of which was for leasehold improvements, and $0.1 million of which was for certain other assets. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As a result of the Company&#x2019;s January&#160;2025 announcement to reduce its overall
            workforce and cease its lab operations, the Company reassessed asset groups at its lab in Hopewell, New Jersey, and evaluated such asset groups for impairment under FASB ASC Topic 360, &lt;span style="font-style: italic;"&gt;Long-lived assets:
              Impairment or disposal of long-lived assets&lt;/span&gt;. The Company determined the laboratory equipment was a separate asset group based on management&#x2019;s implemented plans to sell the laboratory equipment and estimated the fair value of the
            laboratory equipment based on the estimated future cash flows from the sale of such equipment, resulting in impairment of laboratory equipment and certain other assets of $2.6 million. Subsequent to recording the impairment, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement and an estimated market participant subtenant borrowing rate and compared that to the carrying value of the asset group, resulting in impairment to leasehold improvements of $0.9 million. The impairment expense for the leasehold improvements relate to the proportional allocation of total impairment recognized for the asset group subject to
            impairment testing. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recognized impairment expenses for property and equipment and
            certain other assets of $2.7 million for the year ended December&#160;31, 2024, which primarily relates to the proportional allocation of
            total impairments recognized for asset groups subject to impairment testing as further described in Note&#160;10. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"&gt;Leasing &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of December 31, 2025, the Company has classified all leases with terms greater than one year, as operating leases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company recognized impairment expenses for ROU assets of $2.6 million and $2.5 million in the years ended December 31, 2025 and 2024,
            respectively. These impairment expenses include the proportional allocation of total impairments recognized for the asset groups subject to impairment testing as further described in Note&#160;10. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Research and Development &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#x2019;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#x2019;s external accrued research and development expenses, which primarily relates to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#x2019;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Other Income (Expense), Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, income from subleases, and the sale of certain tax credits. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $3.8 million to other income (expense), net for the year ended December 31, 2025, which consisted of $2.3 million attributable to interest income and the amortization of premium and discount on the Company&#x2019;s marketable securities and $1.5 million from sublease income. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $5.6 million to other income (expense), net for the year ended December 31, 2024, which consisted of $4.3 million attributable to interest income and the amortization of premium and discount on the Company&#x2019;s marketable securities, $1.0 million from sublease income, and $0.3 million related to the sale of
            certain tax credits. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Share-Based Compensation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option
            awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application
            of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The expected term of the stock options is estimated using the &#x201c;simplified
            method,&#x201d; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the
            midpoint between the vesting period and the contractual term of the option. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For stock price volatility, the Company uses a composite of comparable public
            company data as a basis for its expected volatility and considers the historic volatility of its common stock from its initial public offering to date to calculate the fair value of option grants. The selection of comparable public company data
            requires the application of management&#x2019;s judgement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company accounts for forfeitures of RSUs and stock option awards as they
            occur. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;License and Other Revenue &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company may enter into license agreements and transition services
            agreements (see Note&#160;8) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company applies FASB ASC Topic 606, &lt;span style="font-style: italic;"&gt;Revenue







              from Contracts with Customers&lt;/span&gt;, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#x2019;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#x2019;s balance sheet when the Company&#x2019;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#x2019;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Income Taxes &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Income taxes are accounted for under the asset-and-liability method as
            required by FASB ASC Topic 740, &lt;span style="font-style: italic;"&gt;Income Taxes&lt;/span&gt;, or ASC 740. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
            carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
            the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;corresponding to the enactment date. Under ASC 740, a valuation allowance is
            required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;FASB ASC Subtopic 740-10, &lt;span style="font-style: italic;"&gt;Accounting for
              Uncertainty of Income Taxes&lt;/span&gt;, or ASC 740-10, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The
            Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax
            position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.
            In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income,
            net, within other income (expense), net. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Net Loss Per Share &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;658,973&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;577,581&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;50,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;7,093&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Employee stock purchase plan&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;696&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,636&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;709,669&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;587,310&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;Recently Issued Accounting Pronouncements
            Not Yet Adopted &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In November&#160;2024, the FASB issued ASU No. 2024-03, &lt;span style="font-style: italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income&#160;&#x2013;&#160;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses&lt;/span&gt;, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#x2019;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In September&#160;2025, the FASB issued ASU No. 2025-06, &lt;span style="font-style: italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed, and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2025, the FASB issued ASU No. 2025-11, &lt;span style="font-style: italic;"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/span&gt;, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;periods. ASU 2025-11 is effective for the Company for interim periods within
            annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement
            disclosures. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2023, the FASB issued ASU No. 2023-09, &lt;span style="font-style: italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;, or ASU 2023-09, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and
            income taxes paid. The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU&#160;are effective for annual periods beginning after December&#160;15, 2024 with
            early adoption permitted. The Company adopted this new accounting pronouncement retrospectively during the year ended December&#160;31, 2025. Refer to Note&#160;14 for additional disclosures. &lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <pasg:BasisOfPresentationPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_ce43ed643c64417cbffdfc18a128623c">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Basis of Presentation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accompanying financial statements have been prepared in accordance with
            generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP&#160;as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;14, 2025, the Company effected a &lt;span style="-sec-ix-hidden:Fact_87ff84423c1d4358a1dd1652b1ad4132"&gt;1&lt;/span&gt;-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of shares of Common
            Stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity, have been adjusted
            retroactively to reflect the Reverse Stock Split for all periods presented. &lt;/div&gt;
</pasg:BasisOfPresentationPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c20250714to20250714"
      decimals="0"
      id="Fact_419ff5da80084795bfee3f8abba8b05d"
      unitRef="U003">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:UseOfEstimates
      contextRef="c20250101to20251231"
      id="Text_336ce045db334f54b2124a91e296d99b">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;Use of Estimates &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. &lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20250101to20251231"
      id="Text_5c0187fade50459fb24e02190d3ceef2">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;Fair Value of Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/div&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20250101to20251231"
      id="Text_d4d0fe9c4ed84af6beaa831961870d13">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"&gt;Concentration of Credit Risk &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which dictates the allocation of funds within its portfolio of money market funds. The Company has
            not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money market funds. &lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_e8f6a9cafd72470984a70fe4b7f6b488">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"&gt;Cash and Cash Equivalents &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of December 31, 2025 consisted of money market funds. Cash consists of cash deposits at banking institutions. &lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="c20250101to20251231"
      id="Text_8255baa722d944b49918c420a2872198">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"&gt;Marketable Securities &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. The Company held no marketable securities as of December 31, 2025. Marketable
            securities as of December 31, 2024 consisted of various securities as described in Note&#160;4. Marketable securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other
            comprehensive income (loss) within stockholders&#x2019; equity. Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable
            securities sold are recognized as a component of other income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund
            operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet. &lt;/div&gt;
</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_ebef65929cfb43208e94ce483dbcd85a"
      unitRef="U001">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_42dd64e891964538aa09f73b8715a6d2">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;Property and Equipment, Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years for office
            equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. The Company recognized de minimis losses on disposals of property and equipment for the year ended
            December 31, 2025. The Company did not recognize any losses on disposals of property and equipment for the year ended December 31,
            2024. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company recognized impairment expenses for property and equipment of $3.5 million for the year ended December 31, 2025, $2.5
            million of which was for lab equipment, $0.9 of which was for leasehold improvements, and $0.1 million of which was for certain other assets. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As a result of the Company&#x2019;s January&#160;2025 announcement to reduce its overall
            workforce and cease its lab operations, the Company reassessed asset groups at its lab in Hopewell, New Jersey, and evaluated such asset groups for impairment under FASB ASC Topic 360, &lt;span style="font-style: italic;"&gt;Long-lived assets:
              Impairment or disposal of long-lived assets&lt;/span&gt;. The Company determined the laboratory equipment was a separate asset group based on management&#x2019;s implemented plans to sell the laboratory equipment and estimated the fair value of the
            laboratory equipment based on the estimated future cash flows from the sale of such equipment, resulting in impairment of laboratory equipment and certain other assets of $2.6 million. Subsequent to recording the impairment, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement and an estimated market participant subtenant borrowing rate and compared that to the carrying value of the asset group, resulting in impairment to leasehold improvements of $0.9 million. The impairment expense for the leasehold improvements relate to the proportional allocation of total impairment recognized for the asset group subject to
            impairment testing. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recognized impairment expenses for property and equipment and
            certain other assets of $2.7 million for the year ended December&#160;31, 2024, which primarily relates to the proportional allocation of
            total impairments recognized for asset groups subject to impairment testing as further described in Note&#160;10. &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"
      id="Fact_474247f28f1d460d8ec86fcd1e76c30c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      id="Fact_f54daa09bbfb48d0b0bca8fb1252a407">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"
      id="Fact_3d8577570d664890aa67c4aa76c2c2e9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      id="Fact_348877d82be34e77be502204cab78717">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_3874194f809e4db8860eca77b2f3b14a"
      unitRef="U001">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_2ac3d5614881474a9ec01ca06c7c8f23"
      unitRef="U001">3500000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"
      decimals="-5"
      id="Fact_292fc42baece40d3939aa7de9d46cdcf"
      unitRef="U001">2500000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"
      decimals="-5"
      id="Fact_fd01ce4d433044e09d336faa10531aff"
      unitRef="U001">900000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember"
      decimals="-5"
      id="Fact_f3616a53216e424ca8c88038595c16f9"
      unitRef="U001">100000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20251231_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember"
      decimals="-5"
      id="Fact_d56e2fee856e44d1b52e2db326cd1cbd"
      unitRef="U001">2600000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c20260101to20260131_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_f94b37ce674245cba7f909c88351333e"
      unitRef="U001">1200000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"
      decimals="-5"
      id="Fact_865d0ec7e9c74958929153b0bc133c2b"
      unitRef="U001">900000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentAndCertainOtherAssetsMember"
      decimals="-5"
      id="Fact_d738b25b96e04d4b846f823b6400d717"
      unitRef="U001">2700000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_c8a01f07e1be44beb46247ce73c79d59">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"&gt;Leasing &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of December 31, 2025, the Company has classified all leases with terms greater than one year, as operating leases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company recognized impairment expenses for ROU assets of $2.6 million and $2.5 million in the years ended December 31, 2025 and 2024,
            respectively. These impairment expenses include the proportional allocation of total impairments recognized for the asset groups subject to impairment testing as further described in Note&#160;10. &lt;/div&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_23f6859a3fc345c0b43818d2955e1eb3"
      unitRef="U001">2600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_87d6ae83626d4885a57f2786ec3447bc"
      unitRef="U001">2500000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20250101to20251231"
      id="Text_93ac640af2c6454ba76a29c750a58c17">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Research and Development &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#x2019;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#x2019;s external accrued research and development expenses, which primarily relates to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#x2019;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. &lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pasg:OtherIncomeAndOtherExpensePolicyPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_2f702f06a54542a98f070865d1766077">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Other Income (Expense), Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, income from subleases, and the sale of certain tax credits. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $3.8 million to other income (expense), net for the year ended December 31, 2025, which consisted of $2.3 million attributable to interest income and the amortization of premium and discount on the Company&#x2019;s marketable securities and $1.5 million from sublease income. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $5.6 million to other income (expense), net for the year ended December 31, 2024, which consisted of $4.3 million attributable to interest income and the amortization of premium and discount on the Company&#x2019;s marketable securities, $1.0 million from sublease income, and $0.3 million related to the sale of
            certain tax credits. &lt;/div&gt;
</pasg:OtherIncomeAndOtherExpensePolicyPolicyTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_f8d2d4098fea460fa3682f74e3de06f5"
      unitRef="U001">3800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_2f46959b3ad94ae380462b8a0ec6e98d"
      unitRef="U001">2300000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:SubleaseIncome
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_d78f0a2470c442709a74eb4c4e134243"
      unitRef="U001">1500000</us-gaap:SubleaseIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_a502ec31a7a84cd28b0a8415ebcf6ec9"
      unitRef="U001">5600000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_2a225adab2e34ccab3772e95498e2378"
      unitRef="U001">4300000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:SubleaseIncome
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_ca17523a8a6d4b30b60955350abbe144"
      unitRef="U001">1000000</us-gaap:SubleaseIncome>
    <pasg:GainLossOnSaleOfTaxCredits
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_df4731bbc440490a81147559be1e19ad"
      unitRef="U001">300000</pasg:GainLossOnSaleOfTaxCredits>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20250101to20251231"
      id="Text_35a88f9995fb4176ab5854ea155965b1">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Share-Based Compensation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option
            awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application
            of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The expected term of the stock options is estimated using the &#x201c;simplified
            method,&#x201d; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the
            midpoint between the vesting period and the contractual term of the option. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For stock price volatility, the Company uses a composite of comparable public
            company data as a basis for its expected volatility and considers the historic volatility of its common stock from its initial public offering to date to calculate the fair value of option grants. The selection of comparable public company data
            requires the application of management&#x2019;s judgement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company accounts for forfeitures of RSUs and stock option awards as they
            occur. &lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_47115dbd2f2840328a5778ab75c9966d">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;License and Other Revenue &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company may enter into license agreements and transition services
            agreements (see Note&#160;8) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties, and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company applies FASB ASC Topic 606, &lt;span style="font-style: italic;"&gt;Revenue







              from Contracts with Customers&lt;/span&gt;, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#x2019;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#x2019;s balance sheet when the Company&#x2019;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#x2019;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. &lt;/div&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_631b0384b8b6447c896c5fdfef6402e2">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Income Taxes &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Income taxes are accounted for under the asset-and-liability method as
            required by FASB ASC Topic 740, &lt;span style="font-style: italic;"&gt;Income Taxes&lt;/span&gt;, or ASC 740. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement
            carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
            the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;corresponding to the enactment date. Under ASC 740, a valuation allowance is
            required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;FASB ASC Subtopic 740-10, &lt;span style="font-style: italic;"&gt;Accounting for
              Uncertainty of Income Taxes&lt;/span&gt;, or ASC 740-10, defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The
            Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax
            position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.
            In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income,
            net, within other income (expense), net. &lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_9a2490101f8e4e2cb8f6b23776bffbac">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Net Loss Per Share &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;658,973&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;577,581&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;50,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;7,093&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Employee stock purchase plan&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;696&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,636&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;709,669&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;587,310&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20250101to20251231"
      id="Text_8ef8738e0bf44e4b9375fd93779f1b49">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 95.28pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;658,973&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;577,581&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;50,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;7,093&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Employee stock purchase plan&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;696&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,636&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;709,669&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;587,310&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"
      decimals="0"
      id="Fact_da6fd82c1f3b448498c155ac2f69157b"
      unitRef="U003">658973</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"
      decimals="0"
      id="Fact_35444f43d93643288fa4cfc5cb99f803"
      unitRef="U003">577581</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_cc9c246d952c460aa3a2075eef3e1d3e"
      unitRef="U003">50000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_988d3413b97b41daa83c3686b35e9e5f"
      unitRef="U003">7093</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20251231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"
      decimals="0"
      id="Fact_8c4f9c012f8743cd89eeeafe78fabcca"
      unitRef="U003">696</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"
      decimals="0"
      id="Fact_8d29dd197eb44968a4a7bd48d225284a"
      unitRef="U003">2636</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_f355596633e145ef949ce883936b5eff"
      unitRef="U003">709669</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_ff1f335ee6c44a5e871baaa89ab64454"
      unitRef="U003">587310</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20250101to20251231"
      id="Text_debea71f797f4c758a06b1580069d248">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;Recently Issued Accounting Pronouncements
            Not Yet Adopted &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In November&#160;2024, the FASB issued ASU No. 2024-03, &lt;span style="font-style: italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income&#160;&#x2013;&#160;Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses&lt;/span&gt;, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#x2019;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In September&#160;2025, the FASB issued ASU No. 2025-06, &lt;span style="font-style: italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed, and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2025, the FASB issued ASU No. 2025-11, &lt;span style="font-style: italic;"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/span&gt;, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;periods. ASU 2025-11 is effective for the Company for interim periods within
            annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement
            disclosures. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2023, the FASB issued ASU No. 2023-09, &lt;span style="font-style: italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;, or ASU 2023-09, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and
            income taxes paid. The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU&#160;are effective for annual periods beginning after December&#160;15, 2024 with
            early adoption permitted. The Company adopted this new accounting pronouncement retrospectively during the year ended December&#160;31, 2025. Refer to Note&#160;14 for additional disclosures. &lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="c20250101to20251231"
      id="Text_0ebc5bbd31f14b0cb567f764a589206e">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;4. Cash, Cash Equivalents, and Marketable Securities &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;The following table provides details regarding the Company&#x2019;s portfolio of cash
            and cash equivalents: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 240pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 51.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 56.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 58.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 34.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Cost or &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amortized cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized gains&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized losses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2025: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Cash accounts in banking institutions&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;2,500&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;2,500 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;43,803 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;43,803 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$46,303&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$46,303 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2024: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Cash accounts in banking institutions&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;3,527&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;3,527 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;29,058 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;29,058 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$37,573&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$37,573&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.74pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 56.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 58.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 34.74pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"&gt;The following table provides details regarding the Company&#x2019;s portfolio of
            marketable securities: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 240pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 51.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 56.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 58.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 34.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amortized cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized gains&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized losses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2025: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Certificates of deposit&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 17.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Corporate debt securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;U.S. government securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2024: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Certificates of deposit&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;5,970&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;1&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;5,971 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,433 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;6 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,439&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Corporate debt securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,864 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,865 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;U.S. government securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,908 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(1) &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,908 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$39,175&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;9&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 1.67pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$39,183&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 240pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 56.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 58.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 34.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As of December 31, 2025, all of the Company&#x2019;s marketable securities matured
            and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#x2019;s balance sheet. &lt;/div&gt;
</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_5024e8bfbd4444379e398e3a6e7def8c">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 240pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 51.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 56.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 58.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 34.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Cost or &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amortized cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized gains&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized losses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2025: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Cash accounts in banking institutions&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;2,500&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;2,500 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;43,803 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;43,803 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$46,303&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$46,303 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2024: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Cash accounts in banking institutions&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;3,527&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;3,527 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;29,058 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;29,058 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$37,573&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$37,573&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 240pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.74pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 56.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 58.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 34.74pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20251231_CashAndCashEquivalentsAxis_DemandDepositsMember"
      decimals="-3"
      id="Fact_a05bcf81049748999d8031ba613e1167"
      unitRef="U001">2500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20251231_CashAndCashEquivalentsAxis_DemandDepositsMember"
      decimals="-3"
      id="Fact_e5c57736c32440c48ab37bcd654a067e"
      unitRef="U001">2500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact_a6dc6c79dd6b4c44ba5664f05a4acb7d"
      unitRef="U001">43803000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact_406fce4119f341cdb62e134aea895fa2"
      unitRef="U001">43803000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20251231"
      decimals="-3"
      id="Fact_f434cdf1cce145ba927efbe3c3f2a2d6"
      unitRef="U001">46303000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20251231"
      decimals="-3"
      id="Fact_12c7e5164c214fde842ea44566e28142"
      unitRef="U001">46303000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20241231_CashAndCashEquivalentsAxis_DemandDepositsMember"
      decimals="-3"
      id="Fact_8ea2e8a91e2542f9924bec00fa76d020"
      unitRef="U001">3527000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_CashAndCashEquivalentsAxis_DemandDepositsMember"
      decimals="-3"
      id="Fact_585c2f7f6b504ee28711325e28a23301"
      unitRef="U001">3527000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact_7fdf9dbd73d042e9a45238ff23fac95e"
      unitRef="U001">29058000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember"
      decimals="-3"
      id="Fact_19992400100445018c90b7b98c8c0f35"
      unitRef="U001">29058000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember"
      decimals="-3"
      id="Fact_3b203f93fa314d64baef6248c838c80b"
      unitRef="U001">4988000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember"
      decimals="-3"
      id="Fact_cf836b247437409283182761a1485421"
      unitRef="U001">4988000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_741c8f6707ad4ce6b47b947d5381a070"
      unitRef="U001">37573000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4ae10ababb2e46b4bc960eb6fa78fcdf"
      unitRef="U001">37573000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_240290ae2d0b4ecb8dbf65a9dd23d926">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 240pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 51.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 56.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 58.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 34.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 240pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amortized cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized gains&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Unrealized losses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2025: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Certificates of deposit&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 17.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Corporate debt securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;U.S. government securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2024: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Certificates of deposit&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;5,970&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;1&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;5,971 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,433 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;6 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,439&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Corporate debt securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,864 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,865 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;U.S. government securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,908 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(1) &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,908 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 240pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.63pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$39,175&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 56.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.98pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;9&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.65pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 1.67pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;(1)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 34.74pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 1.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$39,183&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 240pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 56.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 58.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 34.74pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact_84d7be86d2f040d08e01cf83ba4ff3e8"
      unitRef="U001">5970000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact_35e4035a7c414230aaa0b16097ecfd3d"
      unitRef="U001">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FinancialInstrumentAxis_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact_3b7e22efb5ba4e7baaeda0d664a34d55"
      unitRef="U001">5971000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20241231_FinancialInstrumentAxis_CommercialPaperMember"
      decimals="-3"
      id="Fact_9c79dd73331d419681ae2b8aca19ef9e"
      unitRef="U001">25433000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20241231_FinancialInstrumentAxis_CommercialPaperMember"
      decimals="-3"
      id="Fact_c8bfddd6d6fd45289dfaa9d736ad083e"
      unitRef="U001">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FinancialInstrumentAxis_CommercialPaperMember"
      decimals="-3"
      id="Fact_5160440ec6764c9a9deebfa9be5e8804"
      unitRef="U001">25439000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_4d4236fbcf2c4b35b62f1d85573dc05c"
      unitRef="U001">1864000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_1dc170488b4f4d5497b265a1be6d0cde"
      unitRef="U001">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_71fbdeba7ba24be8bca6d5001179ace9"
      unitRef="U001">1865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="Fact_f90153813c7f48c2a425952a10810047"
      unitRef="U001">5908000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="Fact_ae7da0a15f3f4853b78283b89d4bd1b6"
      unitRef="U001">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4d052f75045f46acb6dee4fc417c6b20"
      unitRef="U001">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="Fact_5894d76495c84415911f2a689cec9db5"
      unitRef="U001">5908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1399264646ef4220a58d68b83c53595d"
      unitRef="U001">39175000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1e8a48a281e140d6998d4a7c6db848f7"
      unitRef="U001">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20241231_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="Fact_946bff7e976b434497b3e148945c3ca3"
      unitRef="U001">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c074c9e30e7a498c98fc18375376fb0b"
      unitRef="U001">39183000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20250101to20251231"
      id="Text_824aeb4535e54b93929ad1a7732d02e8">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;5. Fair Value of Financial Instruments and Non-Financial
            Instruments &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, &lt;span style="font-style: italic;"&gt;Fair Value Measurement&lt;/span&gt;, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-style: italic;"&gt;Level&#160;1:&lt;/span&gt; Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-style: italic;"&gt;Level&#160;2:&lt;/span&gt; Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-style: italic;"&gt;Level&#160;3:&lt;/span&gt; Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following fair value hierarchy table presents information about the
            Company&#x2019;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="height: 6pt; width: 147.47pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="width: 147.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair value measurement at &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;reporting date using &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Quoted prices &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;in active &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;markets for &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;identical &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;assets &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;(Level&#160;1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Significant &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;other &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;observable &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Inputs &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;(Level&#160;2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Significant &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;unobservable &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Inputs &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;(Level&#160;3) &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2025: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Assets &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Cash equivalents: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;$43,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;$&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;43,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total financial assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$43,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2024: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Assets &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Cash equivalents: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;$29,058&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;$&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;$&#x2014; &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;29,058&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Marketable securities: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Certificates of deposit&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;5,971&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,439&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Corporate debt securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,865&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;U.S. government securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,908&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total marketable securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;39,183&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total financial assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$29,058&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$44,171&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 47.77pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 36.89pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 45.77pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;Non-Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;inputs is determined by estimating the amount and timing of net future cash
            flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest. Significant increases or decreases in actual cash flows may result in valuation changes. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following long-lived assets were measured at fair value, on a nonrecurring
            basis, during the years ended December 31, 2025 and 2024. Assets remeasured in 2024 or sold in 2025 are not included in the fair value presented as of December&#160;31, 2025. The significant assumptions utilized are further described in Notes 3 and
            10: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="height: 6pt; width: 189.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="width: 189.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair Value Measurements as of December&#160;31, 2025 of &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;assets remeasured during 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year ended &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;1&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;3&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Impairment Losses &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;3,155&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;$3,373 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Right of use assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;9,489&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,633 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;139 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$12,644&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$6,145&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 53.59pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 53.59pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 61.43pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="height: 6pt; width: 189.54pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="width: 189.54pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair Value Measurements as of December&#160;31, 2024 of &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;assets remeasured during 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year ended &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;1&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;3&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Impairment Losses &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;$1,668&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;$2,279 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Right of use assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,516 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;200&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;438 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$3,510&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 55.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 55.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 58.1pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_19ce8f64c3a34ac995c24f97422a318e">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="height: 6pt; width: 147.47pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="width: 147.47pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair value measurement at &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;reporting date using &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Quoted prices &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;in active &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;markets for &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;identical &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;assets &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;(Level&#160;1)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Significant &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;other &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;observable &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Inputs &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;(Level&#160;2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Significant &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;unobservable &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Inputs &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;(Level&#160;3) &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2025: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Assets &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Cash equivalents: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;$43,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;$&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;43,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total financial assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$43,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;December&#160;31, 2024: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 3.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Assets &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Cash equivalents: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Money market funds&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;$29,058&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;$&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;$&#x2014; &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total cash equivalents&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;29,058&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Marketable securities: &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Certificates of deposit&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;5,971&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Commercial paper&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,439&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;Corporate debt securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,865&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 30pt; text-align: left;"&gt;U.S. government securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,908&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total marketable securities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;39,183&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total financial assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 47.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 7.64pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$29,058&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.89pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.2pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$44,171&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 45.77pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.38pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 47.77pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 36.89pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 4.26pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 45.77pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20251231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_cbffef4cb6d64b2bbd5ddaa722db3b21"
      unitRef="U001">43803000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1ff3ab7f713d4971a6f8ff96efae279d"
      unitRef="U001">43803000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_4f2530a0a3fe4a7e9b201e08c0d44533"
      unitRef="U001">43803000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_CashAndCashEquivalentsAxis_MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_1b4c44a90a6f4a488dd5675ce76a97d6"
      unitRef="U001">29058000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_CashAndCashEquivalentsAxis_CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_39260886795d4a9996c4f2e5b840488a"
      unitRef="U001">4988000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_7b9156c059094770a41897feae27260d"
      unitRef="U001">29058000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_49c78d1a02f242c0a27102236a612ad9"
      unitRef="U001">4988000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CertificatesOfDepositMember"
      decimals="-3"
      id="Fact_d80cbbe85c1f4994aa5f87b7d387cfe8"
      unitRef="U001">5971000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CommercialPaperMember"
      decimals="-3"
      id="Fact_f554fcdc0d8148658f3f8ca34e96bc82"
      unitRef="U001">25439000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_4d7e4cedfa2649cb915cd22d01a90f45"
      unitRef="U001">1865000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentDebtSecuritiesMember"
      decimals="-3"
      id="Fact_d98b9e36867a4bc09da28d98cea0e7bd"
      unitRef="U001">5908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_9bd539657f60458ea687d697b4f130ba"
      unitRef="U001">39183000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_dbd7584135444309a40296f688d86ded"
      unitRef="U001">29058000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_e16656888d16415e829f76c4f06d4728"
      unitRef="U001">44171000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock
      contextRef="c20250101to20251231"
      id="Text_c695bc53ec3f4490b8ca4743f7d255d3">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="height: 6pt; width: 189.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="width: 189.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair Value Measurements as of December&#160;31, 2025 of &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;assets remeasured during 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year ended &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;1&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;3&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Impairment Losses &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;3,155&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;$3,373 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Right of use assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;9,489&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,633 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;139 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 53.59pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.3pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 61.43pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.47pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$12,644&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$6,145&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 53.59pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 53.59pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 61.43pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="height: 6pt; width: 189.54pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="7" style="width: 189.54pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Fair Value Measurements as of December&#160;31, 2024 of &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;assets remeasured during 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year ended &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 192pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;1&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;2&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Level&#160;3&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Impairment Losses &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;$&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;$1,668&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;$2,279 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Right of use assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,516 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;200&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;438 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 192pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 55.26pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.13pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 58.1pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.29pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$3,510&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 65.53pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 19.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 192pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 55.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 55.26pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 58.1pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.23pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 65.53pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_c9117365900644a98aeda30f601680fb"
      unitRef="U001">3155000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_0a1af8f2a4ae47c58da333ccc5e9aaeb"
      unitRef="U001">3373000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <pasg:RightOfUseAssetsFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_139fae85d2fe43149bf58fca7ef4eefa"
      unitRef="U001">9489000</pasg:RightOfUseAssetsFairValueDisclosure>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7668576fcf57451e963f6716772e227f"
      unitRef="U001">2633000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_62929a5d62514c34a2d05b86f0c9f5b7"
      unitRef="U001">139000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20251231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_0d5d6c69164e415e9edd06cd62b4beb8"
      unitRef="U001">12644000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_2fdb4a2b04504beba7a7deceb2373949"
      unitRef="U001">6145000</us-gaap:AssetImpairmentCharges>
    <us-gaap:PropertyPlantAndEquipmentFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_c8c12e334815498faad3a8ae2e575849"
      unitRef="U001">1668000</us-gaap:PropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_242ef526ec1748f1b87d225acf5df6ea"
      unitRef="U001">2279000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <pasg:RightOfUseAssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_161717718d0d44eaa1314bd75c62f320"
      unitRef="U001">1642000</pasg:RightOfUseAssetsFairValueDisclosure>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_55ac05c4e573494396724c34e8d652f6"
      unitRef="U001">2516000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_a493bd27150643dfb3ce5ebf682c30e8"
      unitRef="U001">200000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9079a3be7b3142c9b216f4003628dfdd"
      unitRef="U001">438000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20241231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-3"
      id="Fact_619390e3bf834028866053368dc6fce6"
      unitRef="U001">3510000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7602d219fb9a4113855eb3b0e8ac667c"
      unitRef="U001">5233000</us-gaap:AssetImpairmentCharges>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_0db423afdcc64514b58b1bad8522d337">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"&gt;6. Property and Equipment, Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;"&gt;Property and equipment, net, consists of the following: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;$&lt;span style="padding-left: 15.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;$10,020 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Office equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 17.87pt;"&gt;119&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Computer hardware and software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 10.74pt;"&gt;1,111&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;419&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;419&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,510&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;7,386&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total property and equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;8,024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;19,055&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Accumulated depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,917)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(9,724)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;4,107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;9,331&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In connection with the Company&#x2019;s January&#160;2025 announcement to reduce its
            overall workforce by 55% and cease its lab operations in Hopewell, New Jersey, management implemented plans to sell substantially
            all the laboratory equipment and certain other assets and estimated the fair value of the assets based on the estimated future cash flows from the sale of such assets. Subsequent to recording the impairment of $2.6 million, the Company sold substantially all the laboratory equipment and certain other assets for $1.2 million. As a result, the Company did not record any
            depreciation on the impaired and disposed laboratory equipment during the year ended December&#160;31, 2025 as the equipment was considered held-for-sale in January&#160;2025. Neither laboratory equipment nor accumulated depreciation related to such
            equipment are recorded on the balance sheet as of December&#160;31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Depreciation and amortization expense was $0.7 million and $3.1 million for the
            years ended December 31, 2025 and 2024, respectively. &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20250101to20251231"
      id="Text_00a755d3d1f648259f0a45c4ab434de2">
&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;$&lt;span style="padding-left: 15.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;$10,020 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Office equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 17.87pt;"&gt;119&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Computer hardware and software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 10.74pt;"&gt;1,111&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;419&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;419&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,510&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;7,386&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total property and equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;8,024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;19,055&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Accumulated depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,917)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(9,724)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;4,107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;9,331&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"
      decimals="-3"
      id="Fact_95ba2779709c422a92652b2696b5cb94"
      unitRef="U001">10020000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_bdb296821c7f40bebafe7f0401eabaed"
      unitRef="U001">107000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_a4dc1c758a20468c9f4e0a9a648a5d25"
      unitRef="U001">119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      id="Fact_47659c04fd0e475f9591a37ab1045740"
      unitRef="U001">988000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      id="Fact_a2cbd7ad71764989a29cf17238cce67c"
      unitRef="U001">1111000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_84746eb22c5a40ab8c779cb1f968223d"
      unitRef="U001">419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_d8f2350fc07f41c1b61c85e81f1aa9a6"
      unitRef="U001">419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_5351e41ed87f484a8c5cec877b703d5c"
      unitRef="U001">6510000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_ccdfbfd88b6b474788262d9c71172c2a"
      unitRef="U001">7386000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231"
      decimals="-3"
      id="Fact_662f0311873741b28c6154f4011e8c6e"
      unitRef="U001">8024000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_36ef555e66074d32990d9cbcc5fdc11a"
      unitRef="U001">19055000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20251231"
      decimals="-3"
      id="Fact_5d0d071fa09b45ae87b021eb9bcf9d9b"
      unitRef="U001">3917000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d4b407797e9547bea184f72d6249b4c5"
      unitRef="U001">9724000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_c0acffe08f5f4f93bb748697dd7be168"
      unitRef="U001">4107000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f196ed8b6c704e49888368bf48243143"
      unitRef="U001">9331000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="2"
      id="Fact_35a4892984ed409395c4035e056c13f6"
      unitRef="U004">0.55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20251231_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember"
      decimals="-5"
      id="Fact_edc63f19a99f41718523833f6501430e"
      unitRef="U001">2600000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c20260101to20260131_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_b5d1deb63dd6448d8523ff6dad1a04a6"
      unitRef="U001">1200000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="c20250101to20251231_DisposalGroupClassificationAxis_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_LongLivedAssetsHeldForSaleByAssetTypeAxis_LaboratoryEquipmentMember"
      decimals="0"
      id="Fact_3181b42a5fee45ec85553b8389521bec"
      unitRef="U001">0</us-gaap:Depreciation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_f001388c831c43e4bc166b8e3621c02f"
      unitRef="U001">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_51a029c2c40d4bf68b6e25fbb9902667"
      unitRef="U001">3100000</us-gaap:DepreciationDepletionAndAmortization>
    <pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_fea37eaf2402449ab3beebffb24f16c5">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;7. Accrued Expenses and Other Current Liabilities &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Professional fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;347&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;406 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Compensation and related benefits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,740&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;4,405&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt;"&gt;642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,896&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Divestiture fee due to Catalent&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;924&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$4,653&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$6,707&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
    <pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_1fbbc0625e634c3fb40cf744aac6f484">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Professional fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;347&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;406 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Compensation and related benefits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,740&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;4,405&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt;"&gt;642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,896&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Divestiture fee due to Catalent&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;924&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$4,653&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$6,707&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 3.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_0061632e9afe4eba96fb166c5db30013"
      unitRef="U001">347000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c728b099a7444d75aa3d48ba45bbef7a"
      unitRef="U001">406000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_e113660ef9ef46e39194a35d869f94ae"
      unitRef="U001">2740000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_5eb48edd151e426fb662d70508a6e180"
      unitRef="U001">4405000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="c20251231"
      decimals="-3"
      id="Fact_cf513611705548818f5b287744d44943"
      unitRef="U001">642000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="c20241231"
      decimals="-3"
      id="Fact_796093cede2d4b14944b85c45248de32"
      unitRef="U001">1896000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedDivestitureFeesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_dec777de22784b4bb24fecf85b1f0980"
      unitRef="U001">924000</pasg:AccruedDivestitureFeesCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_1bd1f4380fb44b549d32d996de6e0719"
      unitRef="U001">4653000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_af2e0205b4154320bc6f79f3e38d4923"
      unitRef="U001">6707000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_4f81f5d8c94a4dcfb4a40fd153d8c63e">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;"&gt;8. Gemma License Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $15.0 million in
            initial payments for licenses and clinical product supply, of which $7.5 million was previously received, $2.5 million of which was due in May&#160;2025, and $5.0
            million of which is due in March&#160;2026; (ii) an additional $5.0 million contingent on Gemma completing certain business milestones;
            (iii) up to an additional $114.0 million in development and commercial milestone payments; and (iv) single digit royalties as a
            percentage of annual worldwide net sales, in exchange for sublicenses to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will
            be responsible for all payments due to the Trustees of the University of Pennsylvania&#x2019;s, or Penn, under the Company&#x2019;s research, collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs.
            On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which,
            the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. As of
            December 31, 2025, the Company has collected $7.5 million in initial payments, $4.8 million in transition services payments, and applied $1.5
            million in amounts owed to Gemma for the Huntington&#x2019;s disease program against amounts due to the Company for transition services under these agreements. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of December 31, 2025, the Company has received initial payments of $7.5 million associated with the aggregate $15.0 million of
            initial payments to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $4.8 million associated
            with the Transition Services Agreement and applied $1.5 million in amounts owed to Gemma for the Huntington&#x2019;s disease program against
            amounts due to the Company for transition services under these agreements. The Company recorded these amounts ($13.8 million) as
            non-refundable sublicense and transition services payments on the balance sheet as of December 31, 2025, as the criteria set forth above have not yet been met. &lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <pasg:UpfrontLicenseFeeReceivable
      contextRef="c20240731"
      decimals="-5"
      id="Fact_6893b3cd8a104d1c9aca44f4fa057f77"
      unitRef="U001">15000000</pasg:UpfrontLicenseFeeReceivable>
    <pasg:ProceedsFromNonRefundableSublicensePayments
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_fac334603d5a4e5788a3e21ef5d1f2aa"
      unitRef="U001">7500000</pasg:ProceedsFromNonRefundableSublicensePayments>
    <pasg:ShortTermLicenseFeeDueAndReceivable
      contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_9a1f6325fd2c4cce8061d1554bf5e4e1"
      unitRef="U001">2500000</pasg:ShortTermLicenseFeeDueAndReceivable>
    <pasg:LongTermLicenseFeeDueAndReceivable
      contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_309fc47be1b9427fbe1ae0db2c5663e2"
      unitRef="U001">5000000</pasg:LongTermLicenseFeeDueAndReceivable>
    <pasg:ContingentProceedsFromUponCompletionOfCertainBusinessMilestones
      contextRef="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_ad7eb28ff5824ec4a711a19c60c9dc4f"
      unitRef="U001">5000000</pasg:ContingentProceedsFromUponCompletionOfCertainBusinessMilestones>
    <pasg:MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable
      contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_69ba06ed5f814a1d9f9af963b74af3b5"
      unitRef="U001">114000000</pasg:MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable>
    <pasg:ProceedsFromNonRefundableSublicensePayments
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_a2731203382c411f8c743ea377b8cade"
      unitRef="U001">7500000</pasg:ProceedsFromNonRefundableSublicensePayments>
    <pasg:ProceedsFromNonRefundableTransitionServicesPayments
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_853c821bd68d44b5865057d3a32e7640"
      unitRef="U001">4800000</pasg:ProceedsFromNonRefundableTransitionServicesPayments>
    <pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments
      contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_92371728ffbd46d5866b80d3e44b1ed5"
      unitRef="U001">1500000</pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments>
    <pasg:ProceedsFromNonRefundableSublicensePayments
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_448ba42fe6f5449bb08894427debb023"
      unitRef="U001">7500000</pasg:ProceedsFromNonRefundableSublicensePayments>
    <pasg:UpfrontLicenseFeeReceivable
      contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_6934c7d0abe4406baac9ec6483d368a2"
      unitRef="U001">15000000</pasg:UpfrontLicenseFeeReceivable>
    <pasg:ProceedsFromNonRefundableTransitionServicesPayments
      contextRef="c20250101to20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_c5f687a1f0aa4e238d64b6a175a7351c"
      unitRef="U001">4800000</pasg:ProceedsFromNonRefundableTransitionServicesPayments>
    <pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments
      contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_6ffe3eaaafd8440ab4256a5f287e1514"
      unitRef="U001">1500000</pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_d93ea224c4e24e839852b20ed48f13fb"
      unitRef="U001">13800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_5680eb51727a433c96bb9b204e0e295a">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;"&gt;9. Severance &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately 55%.
          &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In accordance with ASC 420, &lt;span style="font-style: italic;"&gt;Exit and
              Disposal Activities&lt;/span&gt;, the Company recorded severance and termination-related costs of $0.4 million in general and
            administrative expenses and $1.3 million in research and development expenses for the year ended December 31, 2025. During the year
            ended December 31, 2024, the Company recorded no severance and termination-related costs. As of December 31, 2025, there were no unpaid severance and termination-related costs. &lt;/div&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="2"
      id="Fact_6607b0e795e349c6985707181d26b5a7"
      unitRef="U004">0.55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="-5"
      id="Fact_2fd1851e266346be9b8dd78571e52d62"
      unitRef="U001">400000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="-5"
      id="Fact_1e54d4050021494b833ad11dcaee9dce"
      unitRef="U001">1300000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="c20240101to20241231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="0"
      id="Fact_c78d97c07cd946f891e3554399406966"
      unitRef="U001">0</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserve
      contextRef="c20251231_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="0"
      id="Fact_e50ba9b12fd6446c995e15cfeda3d70f"
      unitRef="U001">0</us-gaap:RestructuringReserve>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20250101to20251231"
      id="Text_3b508a4265244397a68a874ae16f7a8e">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;10. Leases &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;2005 Market Street Lease Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately 37,000
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to extend the term of the 2005 Market Street Lease Agreement by two additional terms of five years each. The Company has an option to early terminate
            the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than fifteen months prior
            to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#x2019;s measurement of the ROU asset and operating lease liability as of December 31, 2025. During 2023 the Company subleased all of the space at
            2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Sublease Agreement A &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately 8,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to extend the sublease agreement through November&#160;30, 2031. The base sublease rent is $0.1 million per year and increases by 2.75% annually through
            the expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses, and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Pursuant to ASC Topic 842, &lt;span style="font-style: italic;"&gt;Leases&lt;/span&gt;,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Sublease Agreement B &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately 29,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024, and continues through August&#160;2026. Sublessee B has an option to extend the
            term of the sublease agreement through March&#160;31, 2029. The base sublease rent is $0.9 million per year for the entire term of the
            sublease. Additionally, Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005
            Market Street Lease Agreement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;1835 Market Street Sublease Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On February&#160;20, 2024, the Company entered into a sublease agreement with a
            counterparty, or the 1835 Market Street Sublease Agreement. Under the 1835 Market Street Sublease Agreement, the Company subleased approximately 16,000
            square feet of office space in Philadelphia, Pennsylvania. The sublease term began on March&#160;26, 2024 and expired on September&#160;30, 2025. The Company had the option but did not elect to extend the term of the sublease agreement through February&#160;28, 2029. The base sublease rent was $0.3 million per year for the original 18-month term of the
            sublease. Additionally, the Company was required to pay utility costs associated with the subleased premises. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Laboratory Lease Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company is also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and is expected to expire in March&#160;2036. The &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;Company has an option to early terminate the Laboratory Lease Agreement as of March&#160;2032 given notice is provided to the landlord no less than twelve months prior to March&#160;2032. The Company has an option to extend the term of the Laboratory Lease Agreement by up to&#160;two five-year terms. These options were not recognized as
            part of the Company&#x2019;s measurement of the ROU asset and operating lease liability as of December 31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In January&#160;2025, the Company implemented a restructuring plan which included
            ceasing lab operations. As a result, the Company is no longer using any of the space covered by the Laboratory Lease Agreement and is actively pursuing opportunities to sublease all remaining space in the Laboratory Lease Agreement as well as
            discussing with the landlord potential alternatives. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Hopewell Sublease Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately 3,200 square feet, or 5% of its approximately 62,000 square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and expires on December&#160;31, 2029. Sublessee C has the option to extend the term of the sublease through
            December&#160;2032. The base sublease rent is $0.1 million per year and increases by 2.5% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C is required to pay the portion of the common area maintenance expenses,
            operating expenses, and use and occupancy taxes that the Company is required to pay under the Laboratory Lease Agreement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the Laboratory Lease Agreement. The Company continues to account for the Laboratory Lease Agreement as a lessee and in the same manner as prior to the execution of the Hopewell
            Sublease Agreement. The Company accounted for the Hopewell Sublease Agreement as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In 2024, the Company determined triggering events were present and reassessed
            the asset groups related to its laboratory space under the Laboratory Lease Agreement, which resulted in changes to the Company&#x2019;s identified asset groups. The Company determined whether an impairment indicator was present for each of the new
            asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying values, which includes ROU assets, leasehold improvements, and other property and equipment allocable to the
            laboratory space for those asset groups. The Company concluded the carrying values of certain asset groups were not recoverable as they exceeded the estimated undiscounted cash flows. The Company calculated the amount of impairment on those
            asset groups using a discounted cash flow model to calculate the fair value of the asset group which incorporated the net identifiable cash flows for the term of the Hopewell Sublease Agreement, including an estimate for cash flows in the
            residual period, and an estimated borrowing rate of a market participant subtenant. As a result, certain asset groups were impaired and the Company recognized impairment expense of $5.2 million, including $2.5 million for the ROU assets, $2.3 million for the property and equipment, net, and $0.4
            million for certain other assets during the year ended December&#160;31, 2024. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In connection with the January&#160;2025 announcement to reduce its overall
            workforce by 55% and cease its lab operations in Hopewell, New Jersey, the Company determined triggering events were present and
            reassessed its asset groups related to its laboratory space under the Laboratory Lease Agreement. Laboratory equipment was separated from the ROU assets and leasehold improvements allocable to the laboratory space as the equipment was no longer
            being used in operations and the Company had implemented a plan to sell those assets. For the ROU assets and allocable leasehold improvements, the Company compared the estimated undiscounted cash flows from subleasing to the carrying value and
            determined there was no impairment. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2025, the Company determined triggering events were present based
            on rental market activity. The Company determined whether an impairment indicator was present for each of the asset groups. Where an impairment indicator was present, the Company compared the estimated undiscounted cash flows to the carrying
            values, which includes ROU assets and leasehold improvements allocable to the laboratory space for those asset groups. The Company concluded the carrying value of one asset group was not recoverable as it exceeded the estimated undiscounted
            cash flows. With support from a valuation specialist, the Company estimated the fair value of that asset group by creating a discounted cash flow model which incorporated the net identifiable estimated cash flows for the remaining term of the
            Laboratory Lease Agreement based upon sublease market activity and an estimated market &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;participant subtenant borrowing rate and compared that to the carrying value
            of the asset group. As a result, the Company recognized impairment expense of $3.5 million, including $2.6 million for the ROU assets and $0.9
            million for the leasehold improvements during the year ended December 31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following table summarizes future minimum lease payments for the Company&#x2019;s
            lessee operating leases, which comprises of the 2005 Market Street Lease Agreement and the Laboratory Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A, Sublease Agreement B, and the
            Hopewell Sublease Agreement as the Company was not relieved of its primary obligation under the 2005 Market Street Lease Agreement and Laboratory Lease Agreement: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 408pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 35.83pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$&lt;span style="padding-left: 8.33pt;"&gt;3,757 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;3,863&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2028&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;3,973&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;4,085&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2030&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;4,200&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;17,421&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total undiscounted lease payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;37,299&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(13,289)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;24,010&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following table summarizes lease expense by lease type that was recognized
            during the years ended December&#160;31, 2025 and 2024: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 142.48pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Operating lease cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$3,419&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$3,505 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Variable lease cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,103&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,127&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,522&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,632&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 142.48pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average discount rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;"&gt;9.7% &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;9.7% &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average remaining lease term (years)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;"&gt;9.3 &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"&gt;10.2 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The cash paid for amounts included in the measurement of the Company&#x2019;s
            operating lease liabilities for the years ended December&#160;31, 2025 and 2024 were $3.9 million and $3.8 million, respectively, recorded in operating cash flows. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following table summarizes sublease income that was recognized in other
            income (expense), net during the years ended December 31, 2025 and 2024: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 142.48pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Sublease rental income&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$1,467&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.25pt; text-align: left;"&gt;$987&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      decimals="0"
      id="Fact_c4ab2e1a31bd4bebadcee4036a9835e8"
      unitRef="U005">37000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_e4e497d21a4a4b89be2334b08a2d66e1">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      decimals="0"
      id="Fact_57ba9d62f9364166a2e80973a574379a"
      unitRef="U006">2</pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_8f2cae5e68934b998459e9418b77770b">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_9f888cc6f6f341808ceaa5c472ce2e8d">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_f58e1ae79bbe4671bbfbee8ea428ed44">P15M</pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease>
    <us-gaap:AreaOfLand
      contextRef="c20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      decimals="0"
      id="Fact_2b9cd9ea26854127b269a9f086090870"
      unitRef="U005">8000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      id="Fact_0b4b22fb0b664f07883c8cbc7add1e0c">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:SubleaseIncome
      contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      decimals="-5"
      id="Fact_8a9d0c97bcdd4596a93e9ab95ec7ba0b"
      unitRef="U001">100000</us-gaap:SubleaseIncome>
    <pasg:PercentageOfAnnualIncreaseInSubleaseRent
      contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      decimals="4"
      id="Fact_5bea738f5e3c40ee8447201ab92e1da8"
      unitRef="U004">0.0275</pasg:PercentageOfAnnualIncreaseInSubleaseRent>
    <us-gaap:AreaOfLand
      contextRef="c20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"
      decimals="0"
      id="Fact_9abc0e3faf90493f9af45cedff960fd3"
      unitRef="U005">29000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"
      id="Fact_84906cd581804c97ba2c43fb95bef060">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:SubleaseIncome
      contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"
      decimals="-5"
      id="Fact_2b40ab65489a4419be239c96d168e124"
      unitRef="U001">900000</us-gaap:SubleaseIncome>
    <us-gaap:AreaOfLand
      contextRef="c20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member"
      decimals="0"
      id="Fact_4c5837a1527e4d799018e512ad943948"
      unitRef="U005">16000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="c20240220to20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member"
      id="Fact_45b6c202eb5a4a3cae4f988fc4f50da0">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:SubleaseIncome
      contextRef="c20240220to20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member"
      decimals="-5"
      id="Fact_56ebaadcbc314fa49860135f09c52940"
      unitRef="U001">300000</us-gaap:SubleaseIncome>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20240220_PropertyPlantAndEquipmentByTypeAxis_MarketStreetSubleaseAgreement1835Member"
      id="Fact_61eab1a6d29f496fa620b102181bf567">P18M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember"
      id="Fact_d9e208f2913343f2a253acf7fc7a515d">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember"
      id="Fact_da4da20e455149c9877a4ca10bef4fc2">P12M</pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease>
    <pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_2136f8a98b844994a3f5a2455286938e"
      unitRef="U006">2</pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions>
    <pasg:NewLeaseAgreementOperatingLeaseRenewalTerm
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"
      id="Fact_c0366e3a9fdc42dea8c511cd64fcc915">P5Y</pasg:NewLeaseAgreementOperatingLeaseRenewalTerm>
    <pasg:AreaSubleased
      contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="0"
      id="Fact_f0cf17f4750e4ee5bc7284ae78a09bfa"
      unitRef="U005">3200</pasg:AreaSubleased>
    <pasg:AreaOfLandSubleasedPercentage
      contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="2"
      id="Fact_dea06821f8ff4360922ddb914db50f9f"
      unitRef="U004">0.05</pasg:AreaOfLandSubleasedPercentage>
    <us-gaap:AreaOfLand
      contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="0"
      id="Fact_cd3cf65e93c84402ae5ac72df2cd9910"
      unitRef="U005">62000</us-gaap:AreaOfLand>
    <us-gaap:SubleaseIncome
      contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_59d3791e2e68498abcb42d2f8cecce06"
      unitRef="U001">100000</us-gaap:SubleaseIncome>
    <pasg:PercentageOfAnnualIncreaseInSubleaseRent
      contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="3"
      id="Fact_def797da785c4a05b7f77d5ed80ae2a5"
      unitRef="U004">0.025</pasg:PercentageOfAnnualIncreaseInSubleaseRent>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_12fa6df3d2a04613884170f6ec411b77"
      unitRef="U001">5200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_241534d11f754be8b4f92c003d8720eb"
      unitRef="U001">2500000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_82a1ba97743141bfb2fb02edb0270f18"
      unitRef="U001">2300000</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="c20240101to20241231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_b753048cf5c34e02ac1fffdce873f77d"
      unitRef="U001">400000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="2"
      id="Fact_44daeb3f54984e53b821f5a444665808"
      unitRef="U004">0.55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_616990bd921a4fd2bc283b81336d3d8d"
      unitRef="U001">3500000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_50fc5d51c350470c91b262a944a2a79e"
      unitRef="U001">2600000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold
      contextRef="c20250101to20251231_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_f3bfda529c78425bb3feff116b9a3a5d"
      unitRef="U001">900000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_bf968286b91a4b78bfd0f780bf688228">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 408pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 35.83pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 408pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$&lt;span style="padding-left: 8.33pt;"&gt;3,757 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;3,863&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2028&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;3,973&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;4,085&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2030&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;4,200&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;17,421&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total undiscounted lease payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;37,299&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(13,289)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 408pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;24,010&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 408pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.09pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 35.83pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20251231"
      decimals="-3"
      id="Fact_f4e71201efa1462c89992eefe27ec609"
      unitRef="U001">3757000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20251231"
      decimals="-3"
      id="Fact_17fdd0550d964e578c2295e154e9d31a"
      unitRef="U001">3863000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4e4f23db07674f63a619a9d295b1b38e"
      unitRef="U001">3973000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20251231"
      decimals="-3"
      id="Fact_5298105745ac4bacb3d48f7727555f02"
      unitRef="U001">4085000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c20251231"
      decimals="-3"
      id="Fact_fc73701c558c4d758e36a774cfdf0d93"
      unitRef="U001">4200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c20251231"
      decimals="-3"
      id="Fact_46d3443eff654f03b09e83b6618694a2"
      unitRef="U001">17421000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20251231"
      decimals="-3"
      id="Fact_3e43248efd7348af968de60a6366a5ee"
      unitRef="U001">37299000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20251231"
      decimals="-3"
      id="Fact_f5f6706f1bc24457bfc34a2cf1675aa0"
      unitRef="U001">13289000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20251231"
      decimals="-3"
      id="Fact_11373ac715fb4b0382ff8881b9637ec4"
      unitRef="U001">24010000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_3d5d856da87441e2abf02d2dd296ec6e">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 142.48pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Operating lease cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$3,419&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$3,505 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Variable lease cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,103&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,127&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,522&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,632&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 142.48pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average discount rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;"&gt;9.7% &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;9.7% &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average remaining lease term (years)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 26pt; text-align: left;"&gt;9.3 &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 23.5pt; text-align: left;"&gt;10.2 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.75pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 142.48pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 142.48pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Sublease rental income&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$1,467&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 22.25pt; text-align: left;"&gt;$987&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.75pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7c3ae0119e7f40c6a7f5ccc1cbed5477"
      unitRef="U001">3419000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1e82f8a729b84953b25adc94acd23f6a"
      unitRef="U001">3505000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_6d31e17f62474dc8afb6a21a904e8670"
      unitRef="U001">2103000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_cc1641009a70479ba6bbe76b602cd603"
      unitRef="U001">2127000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_d5bdce0728034a44bb4c99b22a8d0f89"
      unitRef="U001">5522000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e5c668418cae4a5a93c5d7079eb4b601"
      unitRef="U001">5632000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20251231"
      decimals="3"
      id="Fact_0c3847f98fc045dbb81514880ef5d40f"
      unitRef="U004">0.097</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20241231"
      decimals="3"
      id="Fact_936dd2aae7cd46ed8fdfd61a6f796ba4"
      unitRef="U004">0.097</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20251231"
      id="Fact_9ac06680dc194f0b9749214fa2666d81">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20241231"
      id="Fact_019dcb92d12f49879e8383b7e1c89088">P10Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_744ddf2613744807b0e7fc1d858d2a45"
      unitRef="U001">3900000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_1629a6b4c77e439a9e269d21052cf1ad"
      unitRef="U001">3800000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:SubleaseIncome
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_1fd2bcc3a4f14c79bebdd23fabea1872"
      unitRef="U001">1467000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_99935ac63ed2490ab09337e30981a3aa"
      unitRef="U001">987000</us-gaap:SubleaseIncome>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_528cb9f8536842b3a82c8a9b13e46873">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;11. Commitments and Contingencies &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Amended and Restated Research, Collaboration
            and License Arrangement with Penn &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;(i)&#160;terminated the funding of discovery research programs; (ii) terminated the
            research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS, indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate
            transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe, and MLD and certain platform technologies resulting from the discovery programs that it funded. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For the Company&#x2019;s licensed programs in FTD, GM1, Krabbe, and MLD, the Penn
            License Agreement requires that it make payments of up to $16.5 million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications, and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $55.0 million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"&gt;Gemma - Research, Collaboration and
            License Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New
            Drug-enabling work for the Company&#x2019;s active research program in Huntington&#x2019;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and (ii)
            Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $16.5 million per product candidate in the aggregate for Huntington&#x2019;s disease and any future CNS indications available to the
            Company under its four options and (ii) $39.0 million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $1.0 million per product indication, with $0.5 million due upfront and another $0.5
            million fee owed upon a further developmental milestone. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;8. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"&gt;Catalent Agreements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#x2019;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#x2019;s gene therapy product candidates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#x2019;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements, is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $0.9 million to Catalent which has been accrued as of and during the year ended December&#160;31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"&gt;Litigation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of December 31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#x2019;s initial
            public offering in February&#160;2020, he was promised 150,000 shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to 33,836 shares (1,692 shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it
            agreed with the Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the
            initial public offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#x2019;s favor, finding that no binding agreement was reached and that the plaintiff
            was not entitled to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate court affirmed the entry of judgment in favor of the Company and on
            October&#160;7, 2025, the plaintiff filed an Application for Reargument to the Superior Court &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;of Pennsylvania. In December 2025, the Superior Court of Pennsylvania denied the Application for Reargument. In December 2025,&lt;/span&gt; the plaintiff petitioned for review of their appeal to the Pennsylvania
            Supreme Court which is currently pending. The Company intends to continue to defend against this claim. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: justify;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Other than the above, we are not presently a party to any legal proceedings
              that, in the opinion of management, would, if decided against us, have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management
              resources, negative publicity and reputational harm, and other factors. &lt;/span&gt;&lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Employment Agreements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to 150% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. &lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone
      contextRef="c20251231_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember"
      decimals="-5"
      id="Fact_aaf759282d1a4fe0a9c5759de8d59689"
      unitRef="U001">16500000</pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementSalesMilestonePaymentsPayable
      contextRef="c20251231_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember"
      decimals="-5"
      id="Fact_f61799dbeb364d88adec6a5c8c3a8f23"
      unitRef="U001">55000000</pasg:CollaborationAgreementSalesMilestonePaymentsPayable>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone
      contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_4db0797560ec49e8b9686cc2bcdb54b2"
      unitRef="U001">16500000</pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone
      contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_07c2926a68de4aab8aa64d3998e591a0"
      unitRef="U001">39000000</pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementSalesMilestonePaymentsPayable
      contextRef="c20251231_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_b81775e259974eab990d4c7c4c54c8e7"
      unitRef="U001">55000000</pasg:CollaborationAgreementSalesMilestonePaymentsPayable>
    <pasg:NonRefundableAggregateFeesPayablePerProductIndication
      contextRef="c20251231"
      decimals="-5"
      id="Fact_e9571fae85e24a75bf0fce469a649604"
      unitRef="U001">1000000</pasg:NonRefundableAggregateFeesPayablePerProductIndication>
    <pasg:NonRefundableUpfrontFeesPayablePerProductIndication
      contextRef="c20251231"
      decimals="-5"
      id="Fact_1627cec58d8e4ac5b326d5ebb72f211f"
      unitRef="U001">500000</pasg:NonRefundableUpfrontFeesPayablePerProductIndication>
    <pasg:NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone
      contextRef="c20251231"
      decimals="-5"
      id="Fact_b057ade5794e4649adf988deb16170c9"
      unitRef="U001">500000</pasg:NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone>
    <pasg:AccruedDivestitureFeesCurrent
      contextRef="c20251231"
      decimals="-5"
      id="Fact_1cdebbde6e9546849c22f52be49fcde0"
      unitRef="U001">900000</pasg:AccruedDivestitureFeesCurrent>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="c20251231"
      decimals="-5"
      id="Fact_939ab66caae941a3b0cfdef429d8d983"
      unitRef="U001">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <pasg:StockIssuedDuringPeriodSettlementOfLitigation
      contextRef="c20200201to20200229"
      decimals="0"
      id="Fact_5b4770cc238746feae94c8d8864cbd5b"
      unitRef="U003">150000</pasg:StockIssuedDuringPeriodSettlementOfLitigation>
    <pasg:LossContingencySharesAgreedByDefendant
      contextRef="c20200201to20200229"
      decimals="0"
      id="Fact_a202af6bb36b42faa336d2a4707c15fc"
      unitRef="U003">33836</pasg:LossContingencySharesAgreedByDefendant>
    <pasg:LossContingencySharesAgreedByDefendant
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_8fd59443fffc4c69b3979d0ac5f27a0c"
      unitRef="U003">1692</pasg:LossContingencySharesAgreedByDefendant>
    <pasg:PercentageOfTargetAnnualBonusAmounts
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_892b2c23c98341e7bb6f5ce264e114b2"
      unitRef="U004">1.50</pasg:PercentageOfTargetAnnualBonusAmounts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_f564bf0f512b48abaec4658c5e728db2">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"&gt;12. Common Stock &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            issued 300,000 shares of common stock under the ATM Facility, resulting in net proceeds of $8.7 million, after deducting offering costs of $0.3 million
            in March&#160;2024. The Company is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on March&#160;5,
            2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;14, 2025, the Company effected the Reverse Stock Split. The Reverse
            Stock Split did not reduce the number of authorized shares of the common stock and did not change the par value of the common stock. In addition, proportionate adjustments were made to the number of shares of common stock available for issuance
            under the Company&#x2019;s equity inducement and incentive plans; the number of shares underlying, and the exercise prices of outstanding equity awards under such plans. All share information in these financial statements has been adjusted for this
            Reverse Stock Split. &lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_b759239f388b4887811c1e3f86e753fc"
      unitRef="U001">125000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20250101to20251231_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="0"
      id="Fact_4fb68306e6e74e238b627c5a362ea8e3"
      unitRef="U003">300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_8b21952e8b92480bbdb8aa56ce2a2d82"
      unitRef="U001">8700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20240101to20240331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_e64ccddae1b344a0ada9dbe1f9e8b078"
      unitRef="U001">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20250101to20251231"
      id="Text_b280b2bae9534450a605d9beab9f0e1b">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"&gt;13. Share-Based Compensation &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Equity Incentive Plan &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020&#160;Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The total number of shares authorized under the Incentive Plan as of December
            31, 2025 was 947,598. Additionally, 204,732
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of December 31, 2025, 433,624
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January 1st of each
            year, commencing on January 1, 2021 and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 159,141 and 155,155 shares in January&#160;2026 and 2025,
            respectively. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Inducement Plan was approved by the Company&#x2019;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of December 31, 2025 was 125,000. Of this amount, 87,166 shares were &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt; available for future grants as of December 31, 2025. The Inducement Plan
            provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options awarded to date under the Inducement Plan vest
            based on requisite service period and have a term of ten years. The Company&#x2019;s restricted stock units awarded to date under the
            Inducement Plan vest based on requisite service period and have a term based on each award agreement. &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 107.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$2,529 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,159&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;3,291&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$3,001&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,820&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;"&gt;The following table summarizes stock option activity for the year ended
            December 31, 2025: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 300pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;exercise price&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;per share&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;remaining&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;contractual&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;term (years) &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at January&#160;1, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;577,581&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;77.56&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.5&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;248,208&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt;"&gt;7.78&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;(125,526)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;82.56&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(41,290)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;175.24&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;658,973&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;44.20&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.1&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested and exercisable at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;357,766&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;78.82&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;5.6&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested or expected to vest at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;658,973&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;44.20&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.1&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 300pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The weighted-average grant date fair value of options granted was $6.07 and $20.20 for the years ended
            December 31, 2025 and 2024, respectively. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The aggregate intrinsic value of options outstanding was $0.9 million at December 31, 2025 and was de minimis at December 31, 2024. The aggregate intrinsic value of options exercisable was $0.2 million at December 31, 2025 and was de minimis at December 31, 2024. There were no options exercised during the year ended December 31, 2025 and the aggregate intrinsic value of options exercised during the year ended December 31, 2024 was de minimis.
          &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As of December 31, 2025, the total unrecognized compensation expense related
            to unvested stock option awards was $3.0 million, which the Company expects to recognize over a weighted-average period of 2.2 years. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 95.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;93.7%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;88.4%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;4.1%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;4.2%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;5.9 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;6.0 years &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;Restricted Stock Units &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company issues restricted stock units, or RSUs, to employees that vest
              over periods of time as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#x2019;s common stock on the date of grant.
              Compensation expense is recognized on a straight-line basis over the vesting period of the RSUs. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;"&gt;The following table summarizes activity related to RSU awards during the year
            ended December 31, 2025: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 60.58pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 69.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted average &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;grant date fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at January&#160;1, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;7,093&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$44.80 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;60,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5.37pt;"&gt;11.70&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;(16,825)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;27.92&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(268)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;90.40&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;50,000&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$10.52&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As of December 31, 2025, the total unrecognized expense related to all RSUs
            was $0.3 million, which the Company expects to recognize over a weighted-average period of 1.0 years. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"&gt;Employee Stock Purchase Plan &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to 99,088 shares of the Company&#x2019;s common stock. Of this amount, 59,103 were available for future grants as of December 31, 2025. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January&#160;1st of each year and continuing for ten years, in an amount
            equal to one percent of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP was not increased. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Under the ESPP, eligible employees can purchase the Company&#x2019;s common stock
            through accumulated payroll deductions at such times as are established by the board of director&#x2019;s Compensation Committee. Eligible employees may purchase the Company&#x2019;s common stock at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000
            worth of the Company&#x2019;s common stock for each calendar year in which such right is outstanding or purchase more than 200 shares of
            the Company&#x2019;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from 200 shares to 2,000 shares in any single offering period, not to exceed $25,000 in any calendar year. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In accordance with the guidance in ASC Topic 718-50,&lt;span style="font-style: italic;"&gt; Compensation &#x2013; Stock Compensation&lt;/span&gt;, the ability to purchase shares of the Company&#x2019;s common stock at 85% of the
            lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and&lt;span style="font-weight: bold;"&gt;, &lt;/span&gt;therefore, the ESPP is a compensatory plan under this
            guidance. Accordingly, share-based compensation expense is determined based on the option&#x2019;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. No share-based compensation expense related to the ESPP was recorded during the years ended December 31, 2025 and 2024. &lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pasg:NumberOfEquityIncentivePlans
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_8a4422aa0db54255bd0e752dc5131602"
      unitRef="U007">3</pasg:NumberOfEquityIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_91aa82385f444dd6be5198c42aed083b"
      unitRef="U003">947598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_5bf7fce0581a4e5cbd6152936038a8e0"
      unitRef="U003">204732</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="0"
      id="Fact_ac49e5e2f9294cc6bb4b4db936dbd6f2"
      unitRef="U003">433624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      id="Fact_2c7df563d86c4eb58ee9af3730b23a3f">P10Y</pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      decimals="2"
      id="Fact_8acec2b7c36c43b791c8162048c4bc9d"
      unitRef="U004">0.05</pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="c20260101to20260131_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_f166fa3c87cc4ffcbbc973b98f83be6a"
      unitRef="U003">159141</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="c20250101to20250131_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_1e67ddab33ca4a8d997159821e11b4fd"
      unitRef="U003">155155</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      id="Fact_7f0ce76302b749aca94ae32edf65845e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm
      contextRef="c20250101to20251231_PlanNameAxis_EquityIncentivePlan2020Member"
      id="Fact_363e6eac101d4b6889f8ffb289129d7f">P10Y</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20251231_PlanNameAxis_EquityInducementPlan2021Member"
      decimals="0"
      id="Fact_5122329a0e1d40728f439bbde26c7e46"
      unitRef="U003">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20251231_PlanNameAxis_EquityInducementPlan2021Member"
      decimals="0"
      id="Fact_20409e4c49304194a291c6532e8fc625"
      unitRef="U003">87166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm
      contextRef="c20250101to20251231_PlanNameAxis_EquityInducementPlan2021Member"
      id="Fact_1e39c8a1c89f4e508bacabde2ed9e1b8">P10Y</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20250101to20251231"
      id="Text_d72cd2c19b0341ed9849ce7fcfb1e0a0">
&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: justify;"&gt;The
            Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense
            categories in its accompanying statements of operations and comprehensive loss for the period presented:&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 107.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$2,529 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,159&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;3,291&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$3,001&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$5,820&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_d2b104b3f140419894ac38499e64a502"
      unitRef="U001">842000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_f2066bf12ea04470bdae85076816fb37"
      unitRef="U001">2529000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_1f408cfee014428981935b46448ba157"
      unitRef="U001">2159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_6384068b3afd4a26ab7a128b90073cb6"
      unitRef="U001">3291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_7a656d1779cd4b4f8c58d4f592cde7fa"
      unitRef="U001">3001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9ee7f83ffadb439090af56039355155a"
      unitRef="U001">5820000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_898291d9d77a4cde8a80adf92addc91e">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 300pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 300pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;exercise price&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;per share&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;remaining&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;contractual&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;term (years) &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at January&#160;1, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;577,581&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;77.56&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.5&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;248,208&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt;"&gt;7.78&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;(125,526)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;82.56&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(41,290)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;175.24&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;658,973&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;44.20&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.1&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested and exercisable at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;357,766&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;78.82&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;5.6&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 300pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested or expected to vest at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0.56pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;658,973&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 6.89pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;44.20&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.1&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 300pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20241231"
      decimals="0"
      id="Fact_45b065f0a57c4191abd6fa3153d460fa"
      unitRef="U003">577581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20241231"
      decimals="2"
      id="Fact_ac7e4eb9ea744e0abb5bf5d570288bcf"
      unitRef="U002">77.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231"
      id="Fact_af6cec3c43d44fbfb0090ad82f6edd4f">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_c098e8952a7146b4affb5bc0e99dce83"
      unitRef="U003">248208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_27a47536a72c4a47a7d2b165e9ee1096"
      unitRef="U002">7.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_56efd0c892c1409690153e21b127d203"
      unitRef="U003">125526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_955eb1ba20a14cadb4e7cab66ce682eb"
      unitRef="U002">82.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_5ad40d4e9adf450bbc3974aced06a512"
      unitRef="U003">41290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_e4dee399761744ce8cd7aad0fabd2d6f"
      unitRef="U002">175.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20251231"
      decimals="0"
      id="Fact_ea8ecc6d462e446897cc9925644c5333"
      unitRef="U003">658973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20251231"
      decimals="2"
      id="Fact_c1c423c453204155a78ac3bc0d28e5ae"
      unitRef="U002">44.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20250101to20251231"
      id="Fact_a38a64d2ab204fdfa21fb5fd5655e16b">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20251231"
      decimals="0"
      id="Fact_b82ed796f0f04403bda23f40111ed0e7"
      unitRef="U003">357766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20251231"
      decimals="2"
      id="Fact_946c0a7b27e04de5bd6c9f307c52b7c8"
      unitRef="U002">78.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20250101to20251231"
      id="Fact_5097ffe2eae54528a658a01d129233c2">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20251231"
      decimals="0"
      id="Fact_8ba460f28b744c8b9a541fe9b9514312"
      unitRef="U003">658973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20251231"
      decimals="2"
      id="Fact_efcd13e7d2444f56894f962096307251"
      unitRef="U002">44.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20250101to20251231"
      id="Fact_c134529c866248abaa4e5584b3f1c57e">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231"
      decimals="2"
      id="Fact_b136cc86df1f47388ef4e4ee297941cb"
      unitRef="U002">6.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_71ab0f8898d449ceac898ba1a75f3359"
      unitRef="U002">20.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20251231"
      decimals="-5"
      id="Fact_df8aa066a5084113af97a409f74d04ee"
      unitRef="U001">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20251231"
      decimals="-5"
      id="Fact_e1d292e9947143c9996e2fab60da3a1d"
      unitRef="U001">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20250101to20251231"
      decimals="INF"
      id="Fact_49b0fff8399f4c74b3c689455349da50"
      unitRef="U003">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20251231"
      decimals="-5"
      id="Fact_5eb2d7d37f794fc99b9188c97d4f615c"
      unitRef="U001">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20250101to20251231"
      id="Fact_bacc2541ad344e3da35501471eb22ebc">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_9e392f53478042f5bb5d184ec076e0a0">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 95.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 95.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;93.7%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;88.4%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;4.1%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;4.2%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;5.9 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;6.0 years &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_4c266c34c0f94bef86947be24f2ea533"
      unitRef="U004">0.937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_eb2d393bd1cc4bb195058c00266f2cd5"
      unitRef="U004">0.884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_ecc965bd11234b28b9b394489b8a4e38"
      unitRef="U004">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_bf0248a0f04a4423a77f38f8843d33f3"
      unitRef="U004">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20250101to20251231"
      id="Fact_1ac58e93742a4c4cb5eb3081e26cca90">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231"
      id="Fact_35400f2d0d014f7da6f9ac048cbd36ef">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_5a0dc34f8e9b4eecb2853a5bcca387bd"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_b0186d6b23d34501a355109da4e967ba"
      unitRef="U004">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_dcbfd101faef4ecb8bfc6b4460abb94e">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 60.58pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 69.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted average &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;grant date fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at January&#160;1, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;7,093&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$44.80 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;60,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5.37pt;"&gt;11.70&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;(16,825)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;27.92&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(268)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;90.40&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at December&#160;31, 2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;50,000&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$10.52&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_13f6639f0522449487b4f2a70845a20d"
      unitRef="U003">7093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_26b9c824cfe148c2a134d4beb0ab95bf"
      unitRef="U002">44.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_abaf8b269954426c8fc2a3a25c8fd7d9"
      unitRef="U003">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_e238b71526164e96ad10587979cff368"
      unitRef="U002">11.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_7b52f661896d47cf9c54668eeadd2983"
      unitRef="U003">16825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_88d69d1b0d7740e6a15aa71251957b0a"
      unitRef="U002">27.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_2820809321754b06b322326f97a95cf1"
      unitRef="U003">268</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_269339ade09545b5abd66e7f99dabc4e"
      unitRef="U002">90.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_799b94c51ff447e89f9f49e2a69b7e83"
      unitRef="U003">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_806a8eed7f3041f7b48004719bfb6f49"
      unitRef="U002">10.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_96cf1445405645c8ade283f8537e9735"
      unitRef="U001">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="c20250101to20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      id="Fact_c230c76de13d4da3b28ac3a16ef04a29">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_0afe79a01adb4bd69f905ffa0a81c755"
      unitRef="U003">99088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20251231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_614c1d5ca57140f49f936aebf4069924"
      unitRef="U003">59103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      id="Fact_fa9d02b9390644cd98b2233904fdb5ab">P10Y</pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_dc3e48ec26df470c88655f5a53a97cbe"
      unitRef="U004">0.01</pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding>
    <pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact_a4e4f275cd634469bf47a710ea2122c9"
      unitRef="U004">0.85</pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage>
    <pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_473de1307fea4d14aefff4877e86b76b"
      unitRef="U004">0.15</pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage>
    <pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased
      contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_c8a02dd939e4413a8dd5b7f081e012f5"
      unitRef="U001">25000</pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_513a3dd570af45e78e6679b3818903f9"
      unitRef="U003">200</pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_dc3ed54840894071b3134b6ce56d0140"
      unitRef="U003">200</pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased
      contextRef="c20260501to20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_a5f5a4e533e641679c988bb8388956e8"
      unitRef="U003">2000</pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased
      contextRef="c20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_8d4dc96fac544b9e9938f2d15a1422b8"
      unitRef="U001">25000</pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="Fact_ed866bcdd2d04d8584451b9a18b745b9"
      unitRef="U004">0.85</pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="Fact_f199ba375c0c45c8a7f7d23743d18fbc"
      unitRef="U001">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20251231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="Fact_dbecac16ef614fb0bf59ce3c0f411f71"
      unitRef="U001">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_3822bad715044d959d44a011b4f19698">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"&gt;14. Income Taxes &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The tax effects of temporary differences that gave rise to significant
            portions of the deferred tax assets and liabilities were as follows: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 89pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Deferred tax assets:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Net operating loss carryforwards&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$105,425&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$94,923 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Research and development credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;55,020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;50,842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Collaboration and license agreement&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt;"&gt;2,832&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;3,422&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 32.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="margin-top: 11.25pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 89pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Capitalized research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;46,041&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;59,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;4,329&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;5,863&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Accrued expenses and other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;4,581&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;1,404&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Operating lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;6,520&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;7,560&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,048&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;461&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total gross deferred tax assets before valuation allowance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;225,796&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;224,278&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Valuation allowance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: justify;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(222,752)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(219,833)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Net deferred tax assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;3,044&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,445&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Deferred tax liabilities:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Right of use assets - operating leases&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,044)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(4,445)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total deferred tax liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,044)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(4,445)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Net deferred taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 32.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In assessing the need for a valuation allowance, management must determine
            that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined the deferred tax assets do not meet the more-likely-than-not
            threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#x2019;s net deferred tax assets as of December 31, 2025 and 2024. The valuation allowance increased by $2.9 million and $19.1 million during
            the years ended December 31, 2025 and 2024, respectively. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;During the year ended December&#160;31, 2025, the Company adopted ASU No. 2023-09,
            &lt;span style="font-style: italic;"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt; retrospectively. A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 288pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="10" style="height: 6pt; width: 165.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="10" style="width: 165.09pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 73.44pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 76.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Percent&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Percent &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;US federal statutory tax rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$&lt;span style="padding-left: 1.67pt;"&gt;(9,560)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;21.0%&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$(13,601)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;21.0%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Federal:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Tax credits:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Research and development tax credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 14.17pt;"&gt;(175)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;0.4&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;(626)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Orphan drug tax credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt;"&gt;(4,003)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;8.8&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;(4,896)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;7.6&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Changes in valuation allowances&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;12,334&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;(27.2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;17,422&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;(27.0)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Nontaxable or nondeductible items:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Share-based payment awards&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;241&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(0.5)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;459&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(0.7)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Expiration of share-based payment awards&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,159&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(2.5)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;1,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(1.9)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 27.5pt;"&gt;4&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;0.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 30.83pt;"&gt;9&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;0.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;State and local income taxes, net of federal income tax effect&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Effective tax rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;span style="padding-bottom: 0.5pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;span style="padding-bottom: 0.5pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 288pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 32.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 26.06pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 35.83pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 26.06pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_rule-partial" style="height: 0pt; width: 72pt; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-right: auto; margin-left: 0pt; margin-top: 13.25pt;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic;"&gt;1&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; text-align: justify;"&gt;In 2025 and 2024, state and local income taxes in Pennsylvania and Philadelphia comprise the majority of
                    the state and local income taxes, net of federal income tax effect category.&lt;span style="font-style: normal;"&gt; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;During the years ended December&#160;31, 2025 and 2024, the Company made no income tax payments. Additionally, the Company generated no foreign pre-tax income or losses during these periods, as all operations were conducted within the United States. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: justify;"&gt;The following table summarizes carryforwards of federal, state and local net
            operating losses, or NOL, and research and development and orphan drug tax credits: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 91.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 91.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$398,039&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$339,055 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;398,035&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;339,051&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Local&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;277,828&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;218,844&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research tax credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;55,020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;50,842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For federal income tax purposes, $0.3 million of NOL carryforwards expire in 2037. The remaining federal NOL carryforwards were generated subsequent to January&#160;1, 2018, and therefore, are able to be carried
            forward indefinitely. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;"&gt;For state income tax purposes, NOL carryforwards begin expiring in 2037, and
            expire through 2045. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For local income tax purposes related to the city of Philadelphia, NOL
            carryforwards begin expiring in 2042, and expire through 2045. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As of December 31, 2025, the Company also had $11.6 million of federal research and development and $43.4
            million orphan drug tax credit carryforwards that will begin to expire in 2038 and 2040, respectively, unless previously utilized. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The NOL and tax credit carryforwards are subject to review and possible
            adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders
            over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually
            to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in
            future years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOL carryforwards may also be limited, including Pennsylvania, which limits NOL utilization as a
            percentage of apportioned taxable income. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;&lt;span style="-sec-ix-hidden:Fact_bf46da9b45834552bfbf43a7fff05a75"&gt;The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net.&lt;/span&gt; As of December 31, 2025, the Company had no accrued interest or penalties related to uncertain tax positions and no
            amounts have been recognized in the Company&#x2019;s statement of operations. &lt;span style="-sec-ix-hidden:Fact_76a8a6c10938470cb53d52e197480e2e"&gt;Tax years from 2022&lt;/span&gt; and after remain subject to examination
            by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized. &lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_18cdc19081024323b420349013328872">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 89pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Deferred tax assets:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Net operating loss carryforwards&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$105,425&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$94,923 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Research and development credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;55,020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;50,842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Collaboration and license agreement&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt;"&gt;2,832&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;3,422&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 32.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="margin-top: 11.25pt; width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 89pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 89pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Capitalized research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;46,041&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;59,803&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;4,329&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;5,863&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Accrued expenses and other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;4,581&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;1,404&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Operating lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;6,520&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt;"&gt;7,560&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,048&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;461&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total gross deferred tax assets before valuation allowance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;225,796&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;224,278&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Valuation allowance&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: justify;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(222,752)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: justify;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(219,833)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Net deferred tax assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;3,044&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 18.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,445&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Deferred tax liabilities:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Right of use assets - operating leases&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,044)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(4,445)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Total deferred tax liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,044)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="padding-left: 15pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(4,445)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Net deferred taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -3.33pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -8.33pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 9.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 32.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20251231"
      decimals="-3"
      id="Fact_8323423f0e8f41de86b48269e4216f6d"
      unitRef="U001">105425000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20241231"
      decimals="-3"
      id="Fact_91aebc5f5e12450fade0c59d32372140"
      unitRef="U001">94923000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="c20251231"
      decimals="-3"
      id="Fact_6da378c7f2c940279ae42027ba57fa1f"
      unitRef="U001">55020000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_8f1044e9d70d46089f53f95e2671e8c0"
      unitRef="U001">50842000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement
      contextRef="c20251231"
      decimals="-3"
      id="Fact_d02d92cf76dc467aa4567e78ae3854e0"
      unitRef="U001">2832000</pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement>
    <pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement
      contextRef="c20241231"
      decimals="-3"
      id="Fact_9cd0150bfd46424996f62befa2d4e522"
      unitRef="U001">3422000</pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement>
    <pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="c20251231"
      decimals="-3"
      id="Fact_9eba2b4c6b1b4b138f7a40f925a67ed8"
      unitRef="U001">46041000</pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_760c017e982349deaefd9db5a984799f"
      unitRef="U001">59803000</pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20251231"
      decimals="-3"
      id="Fact_3fbe55c454074507b13eb69fd44ec3d9"
      unitRef="U001">4329000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3397f2a69e194c85bf6d007acf272508"
      unitRef="U001">5863000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="c20251231"
      decimals="-3"
      id="Fact_edd047796804445ea1b1b9dfc1bf686a"
      unitRef="U001">4581000</pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3df4e946f78e429dad911ea71e5f46ee"
      unitRef="U001">1404000</pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <pasg:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_97c4932987cc49e0b076e5de243f2605"
      unitRef="U001">6520000</pasg:DeferredTaxAssetsOperatingLeaseLiabilities>
    <pasg:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_719945a60519400d8bc5d11a12fbd24b"
      unitRef="U001">7560000</pasg:DeferredTaxAssetsOperatingLeaseLiabilities>
    <pasg:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="c20251231"
      decimals="-3"
      id="Fact_2a4219c63a904b228a285b98e3749773"
      unitRef="U001">1048000</pasg:DeferredTaxAssetsDepreciationAndAmortization>
    <pasg:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c48edbf799c94712b48437aa37b56560"
      unitRef="U001">461000</pasg:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20251231"
      decimals="-3"
      id="Fact_a83fd552a95a487483e82e4ca4d6ac3b"
      unitRef="U001">225796000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ad526a50fa9140aeb6f71c1545645796"
      unitRef="U001">224278000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20251231"
      decimals="-3"
      id="Fact_06020a90aec0443fa72eef6dcd1406c5"
      unitRef="U001">222752000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4b951fb4635341dcaa9e595cbe74854d"
      unitRef="U001">219833000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_25395b998d364a7fb9c143541d30639d"
      unitRef="U001">3044000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c86a8657c65e487f909a4af078cea44f"
      unitRef="U001">4445000</us-gaap:DeferredTaxAssetsNet>
    <pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="c20251231"
      decimals="-3"
      id="Fact_ac89ef03169048a495414cba3bb11f00"
      unitRef="U001">3044000</pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3b19f29d9ce94bdd9a13d74964a10962"
      unitRef="U001">4445000</pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_9c5e362b4a4e4f888cd6372d303dfb20"
      unitRef="U001">3044000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_527ce2e7d616412e871264b2807c329b"
      unitRef="U001">4445000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_bdac3f41a6a047bf831c18c8f1daa73e"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_76ae474e54b049d49d4e737ef1aa0a95"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_4c5c8bdcb49e491588b899b1b6017381"
      unitRef="U001">2900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_65a12505bffc4211a69831f785ce5dbe"
      unitRef="U001">19100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="c20250101to20251231"
      id="Text_67b5e1f66f7c4acdb597df2538091232">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 288pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="10" style="height: 6pt; width: 165.09pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 288pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="10" style="width: 165.09pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 73.44pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 76.77pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 288pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Percent&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Amount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Percent &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;US federal statutory tax rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$&lt;span style="padding-left: 1.67pt;"&gt;(9,560)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;21.0%&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$(13,601)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;21.0%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Federal:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Tax credits:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Research and development tax credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 14.17pt;"&gt;(175)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;0.4&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;(626)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Orphan drug tax credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt;"&gt;(4,003)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;8.8&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;(4,896)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;7.6&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Changes in valuation allowances&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;12,334&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;(27.2)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;17,422&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;(27.0)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Nontaxable or nondeductible items:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Share-based payment awards&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;241&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(0.5)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;459&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(0.7)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Expiration of share-based payment awards&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;1,159&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(2.5)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;1,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;(1.9)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-align: left;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 27.5pt;"&gt;4&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;0.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 30.83pt;"&gt;9&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;0.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;State and local income taxes, net of federal income tax effect&lt;sup&gt;1&lt;/sup&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 288pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Effective tax rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 32.5pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.61pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;span style="padding-bottom: 0.5pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 35.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 26.06pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.62pt; text-align: left;"&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;span style="padding-bottom: 0.5pt;"&gt;%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 288pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 32.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 26.06pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 35.83pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.44pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 26.06pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 3pt; margin-left: 0pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic;"&gt;1&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-style: italic; text-align: justify;"&gt;In 2025 and 2024, state and local income taxes in Pennsylvania and Philadelphia comprise the majority of
                    the state and local income taxes, net of federal income tax effect category.&lt;span style="font-style: normal;"&gt; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_fdcd6efca63e4a5e9257ddb5c3f41701"
      unitRef="U001">-9560000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_c05dd176c0ae41f9b288c6269e729664"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d861656a247c46e987f3515461d229ff"
      unitRef="U001">-13601000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_8b483eede7b747c19be8706024a32a16"
      unitRef="U004">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_ad7f4d71827c4438a2acd3149b84c768"
      unitRef="U001">175000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_15a3c7540a7548d290f25136237c3498"
      unitRef="U004">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d1a26b11e4a74db5b9fee6b8410356ca"
      unitRef="U001">626000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_e88b9e3b8e0945aab7f90976998699b8"
      unitRef="U004">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_82aaa4a9221843b6916924e73c581722"
      unitRef="U001">4003000</pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_e294a6ebffb240e59c2d4741c13f89c3"
      unitRef="U004">-0.088</pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
    <pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_be58a5acf8b64bfd9c47a5db645bce56"
      unitRef="U001">4896000</pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount>
    <pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_9ae53492f60746bfbac71bbdeef1e12d"
      unitRef="U004">-0.076</pasg:EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_f9ba5a37e0494569999b58d99cc0ccee"
      unitRef="U001">12334000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_0f40f26e8f6d46e2b17673a2bfce5eda"
      unitRef="U004">-0.272</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_fff59c56d7824dc5bc13694f48c14a4f"
      unitRef="U001">17422000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_082289dd25fa40ad87a6add21e15a0f2"
      unitRef="U004">-0.27</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_0e133f5c507e4b3da83e962354139c03"
      unitRef="U001">241000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_1d8046d6cc234a5593f9cdcb7f921475"
      unitRef="U004">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1755d38c70c444e0a775784e4a512390"
      unitRef="U001">459000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_a96bbee22d19486092a3a3dbac2b3c61"
      unitRef="U004">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_1e2f04a60938463884065ee477fa41a2"
      unitRef="U001">1159000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_61e3b64dd42d4b8684f562c185892a20"
      unitRef="U004">-0.025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b5750ff937784aeb99a1be30b220933d"
      unitRef="U001">1233000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_421cc73fc425446ea2c3589f400f1cc6"
      unitRef="U004">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_fbbbb487c0394a22a886c6921af84307"
      unitRef="U001">4000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20250101to20251231"
      decimals="3"
      id="Fact_dc693fb67ad94b9db60d9b03a3f2027f"
      unitRef="U004">-0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_99243719aeb440f1bfbcf0aacf6a0f92"
      unitRef="U001">9000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20240101to20241231"
      decimals="3"
      id="Fact_9016768f60194f26b3f0ebebe4a5a516"
      unitRef="U004">-0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_873120e2011d48d989606558a7b10414"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20250101to20251231"
      decimals="0"
      id="Fact_f96dedb2b0e14ef89481beb35364b697"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a4a50b54568f409ba68599f459819ef6"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_9addc95db57c40d395969e6264800fd9"
      unitRef="U004">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_cf781248de6748e9be75c34c717e6e8a"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_3585b94c69714555aeb8f1589728d43b"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c20250101to20251231"
      decimals="-3"
      id="Fact_a9d2b67203404d1a821eaca2a80ac225"
      unitRef="U001">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_095107ebd20b45c0bee1e104a36f3b88"
      unitRef="U001">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="c20250101to20251231"
      id="Text_5e0d470cf8e643c39f279ec97ffdae31">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 91.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 91.5pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 360pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; border-bottom: none;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Federal&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$398,039&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;$339,055 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;State&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;398,035&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;339,051&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Local&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;277,828&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;218,844&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 360pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research tax credits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;55,020&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 37.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;50,842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 360pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.25pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 37.5pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20251231_IncomeTaxAuthorityAxis_US"
      decimals="-3"
      id="Fact_f99fec03bceb44d69b320638e3110176"
      unitRef="U001">398039000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_US"
      decimals="-3"
      id="Fact_7c88dfeca3024284bfac89a78119d3ec"
      unitRef="U001">339055000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20251231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember"
      decimals="-3"
      id="Fact_2bb492ec56c1499e8b6412b5d3f2c233"
      unitRef="U001">398035000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_StateTaxAuthorityMember"
      decimals="-3"
      id="Fact_f3516b2362894cc1b233da5a89a068c3"
      unitRef="U001">339051000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20251231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember"
      decimals="-3"
      id="Fact_618b9b6af59a4b8094803769a0527625"
      unitRef="U001">277828000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_LocalTaxAuthoritiesMember"
      decimals="-3"
      id="Fact_f7180588a5f74b1f98448d7528675ac5"
      unitRef="U001">218844000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20251231_TaxCreditCarryforwardAxis_ResearchMember"
      decimals="-3"
      id="Fact_3d596e912cc14fa9babd3d4afa18e38e"
      unitRef="U001">55020000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20241231_TaxCreditCarryforwardAxis_ResearchMember"
      decimals="-3"
      id="Fact_5546a465f4e643189210239552794a79"
      unitRef="U001">50842000</us-gaap:TaxCreditCarryforwardAmount>
    <pasg:OperatingLossCarryforwardSubjectToExpiration
      contextRef="c20251231_IncomeTaxAuthorityAxis_DomesticCountryMember"
      decimals="-5"
      id="Fact_deadf62dfb2544d2bb68c0fd647b9979"
      unitRef="U001">300000</pasg:OperatingLossCarryforwardSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_ResearchMember"
      decimals="-5"
      id="Fact_ba68e86d28e640fa8f94b364f6f95062"
      unitRef="U001">11600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20251231_IncomeTaxAuthorityAxis_US_TaxCreditCarryforwardAxis_OrphanDrugMember"
      decimals="-5"
      id="Fact_97b3030478ab48b68834ea68376d1c23"
      unitRef="U001">43400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="c20251231"
      decimals="-5"
      id="Fact_0c019b42a10f465d94a7eefa03ac3f66"
      unitRef="U001">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="c20250101to20251231"
      decimals="-5"
      id="Fact_d987024a26fa4143a993c02b9513e960"
      unitRef="U001">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20250101to20251231"
      id="Text_9742994bf92f4ad7a6f30665c90e0a45">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"&gt;15. Segment Reporting &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a &lt;span style="-sec-ix-hidden:Fact_6fcb045ac6ef441986cb7c4046a9cae6"&gt;single&lt;/span&gt; reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies. The Company&#x2019;s CODM is its chief executive officer. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The measure of segment assets is reported on the balance sheet as total
            assets. All assets are located within the United&#160;States. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt; The CODM uses net loss as reported on the Company&#x2019;s statement of operations
            to assess the Company&#x2019;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses
            exclude certain non-cash items such as share-based compensation and depreciation and amortization expenses. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;"&gt;The following table summarizes significant segment expenses: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 107.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;7,462&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;$12,265 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;14,532&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;22,691&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;2,529&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;440&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,694&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total research and development expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;23,276&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;40,179&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;7,784&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;9,255&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;9,644&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;12,055&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;2,159&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;3,291&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;288&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;387&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total general and administrative expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;19,875&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;24,988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Impairment of long-lived assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,145&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;49,296&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;70,400&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other (income) expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,774)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(5,633)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$45,522&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$64,767&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;"&gt;The components of Other (income) expense, net are further described in note 3
            to the financial statements.&lt;/div&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="c20250101to20251231"
      id="Text_3506ba8ede0c40ecabbea17553c3c669">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 107.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 107.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Year Ended December&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2024 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;$&lt;span style="padding-left: 5pt;"&gt;7,462&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;$12,265 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;14,532&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;22,691&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;842&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;2,529&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;440&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;2,694&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total research and development expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;23,276&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;40,179&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;7,784&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;9,255&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;9,644&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;12,055&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;2,159&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;3,291&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;288&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;387&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total general and administrative expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;19,875&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;24,988&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Impairment of long-lived assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,145&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;5,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;49,296&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;70,400&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other (income) expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,774)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(5,633)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$45,522&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.28pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 4.39pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$64,767&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 12.36pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <pasg:ResearchAndDevelopmentLaborAndRelatedExpenses
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_3fd6f1cd904042d3b20e6c667e4b0c19"
      unitRef="U001">7462000</pasg:ResearchAndDevelopmentLaborAndRelatedExpenses>
    <pasg:ResearchAndDevelopmentLaborAndRelatedExpenses
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_81abfc315ce34662a68b7a26ff77e986"
      unitRef="U001">12265000</pasg:ResearchAndDevelopmentLaborAndRelatedExpenses>
    <pasg:ResearchAndDevelopmentThirdPartyCosts
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_961359f9bb6d46aba24ac633cea6baf4"
      unitRef="U001">14532000</pasg:ResearchAndDevelopmentThirdPartyCosts>
    <pasg:ResearchAndDevelopmentThirdPartyCosts
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_29d962d9a1e84b5d8e1e43fbbb8c3d97"
      unitRef="U001">22691000</pasg:ResearchAndDevelopmentThirdPartyCosts>
    <pasg:ResearchAndDevelopmentShareBasedCompensation
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_776044df752b4242ae4ca60ec7ed1b7f"
      unitRef="U001">842000</pasg:ResearchAndDevelopmentShareBasedCompensation>
    <pasg:ResearchAndDevelopmentShareBasedCompensation
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_c7d0394254a5495ca03213022dbd1394"
      unitRef="U001">2529000</pasg:ResearchAndDevelopmentShareBasedCompensation>
    <pasg:ResearchAndDevelopmentDepreciationAndAmortization
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_e9f3c02413df48259cda1695b10802cb"
      unitRef="U001">440000</pasg:ResearchAndDevelopmentDepreciationAndAmortization>
    <pasg:ResearchAndDevelopmentDepreciationAndAmortization
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_121e637bb4384ac2ac7fa5be75e964ae"
      unitRef="U001">2694000</pasg:ResearchAndDevelopmentDepreciationAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_f55f1fcb81ce404abaecf92524b1d2ca"
      unitRef="U001">23276000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_f85e68dccde24bde84b7937d67a417c4"
      unitRef="U001">40179000</us-gaap:ResearchAndDevelopmentExpense>
    <pasg:GeneralAndAdministrativeLaborAndRelatedExpenses
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_74f5e6a8136f483499d1a04e9127d1c2"
      unitRef="U001">7784000</pasg:GeneralAndAdministrativeLaborAndRelatedExpenses>
    <pasg:GeneralAndAdministrativeLaborAndRelatedExpenses
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_0d3e5dec0cec46e88c8541ca1f9f3576"
      unitRef="U001">9255000</pasg:GeneralAndAdministrativeLaborAndRelatedExpenses>
    <pasg:GeneralAndAdministrativeThirdPartyCosts
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_d80159027deb457a94f193cac6cd75b4"
      unitRef="U001">9644000</pasg:GeneralAndAdministrativeThirdPartyCosts>
    <pasg:GeneralAndAdministrativeThirdPartyCosts
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_cb1eb4de7bf4448f8d53e61308ccd85e"
      unitRef="U001">12055000</pasg:GeneralAndAdministrativeThirdPartyCosts>
    <pasg:GeneralAndAdministrativeShareBasedCompensation
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_c21bbc4fa24549b99ba6b0775469992f"
      unitRef="U001">2159000</pasg:GeneralAndAdministrativeShareBasedCompensation>
    <pasg:GeneralAndAdministrativeShareBasedCompensation
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_86a4508f02a2428e8b7fd056ca562c30"
      unitRef="U001">3291000</pasg:GeneralAndAdministrativeShareBasedCompensation>
    <pasg:GeneralAndAdministrativeDepreciationAndAmortization
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_e7f24888938b4e48b0fc35d979a67aee"
      unitRef="U001">288000</pasg:GeneralAndAdministrativeDepreciationAndAmortization>
    <pasg:GeneralAndAdministrativeDepreciationAndAmortization
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_b5472040dc934ae0a1ca2a2ae682cb9e"
      unitRef="U001">387000</pasg:GeneralAndAdministrativeDepreciationAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_3ef49bde238e4ab6ab5dff3788a4758b"
      unitRef="U001">19875000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_564cb9ae79324daa813af94cbb5a146a"
      unitRef="U001">24988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_4b71f524ce4140c9bd40eb5e592cf74e"
      unitRef="U001">6145000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_a2891305c71c48b19d1a66322374b040"
      unitRef="U001">5233000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_7055b6997b9a458ba417af2d593d1de7"
      unitRef="U001">-49296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_2149e04d80cf4dc98150f94f92a01532"
      unitRef="U001">-70400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_9ae7c6fcdf01448e84aa36d6b238ed34"
      unitRef="U001">3774000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_0b3e33bc765b468d958947c564a637bb"
      unitRef="U001">5633000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20251231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_43ceea284e014699a2e74661cde072d8"
      unitRef="U001">-45522000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_50e14a6f3ed64720ba6dc11d107bb709"
      unitRef="U001">-64767000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20250101to20251231"
      id="Text_6863ed48a63d44b0a8696795a5d8cb8c">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;"&gt;16. Subsequent Events &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;"&gt;None. &lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20260331"
      decimals="-3"
      id="Fact_baca7cafd3794351a910e440dbfedef2"
      unitRef="U001">33336000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20251231"
      decimals="-3"
      id="Fact_737a2058fd6c4e0a9ab5fb9a8609b5ed"
      unitRef="U001">46303000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_e3d66196cdb14bce9ebe46aa9b3cb7f3"
      unitRef="U001">682000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_dd157cec4eff437898738a757d7e227f"
      unitRef="U001">629000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_04c70b6c419f4520a32ade088d36aade"
      unitRef="U001">723000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_b51f2dd458cb4b79a4b7de229183f33f"
      unitRef="U001">830000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_c54f1af76c4c413689ca95cb42199b43"
      unitRef="U001">34741000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_8bd48b9bcc85499db52e307b224f577a"
      unitRef="U001">47762000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20260331"
      decimals="-3"
      id="Fact_6fd229ebc8e540529b8d6bfd0c4ea0ea"
      unitRef="U001">826000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_2758f48ba9914fe89b03129424133708"
      unitRef="U001">4107000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20260331"
      decimals="-3"
      id="Fact_a1aa9d4a02d4458f9f4c23e558e91cc2"
      unitRef="U001">651000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20251231"
      decimals="-3"
      id="Fact_43f6e99446c04ba499ce589b826597f7"
      unitRef="U001">10168000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_2d627cfc67744369a47a3d8c12bcfe5e"
      unitRef="U001">244000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_4b32cbcbc4ee47e293a34a5961da7196"
      unitRef="U001">244000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="c20260331"
      decimals="-3"
      id="Fact_f9e856ab45e04451ac139ef129503527"
      unitRef="U001">36462000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20251231"
      decimals="-3"
      id="Fact_ef531f1ee8be4287ab60da189e0375f4"
      unitRef="U001">62281000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_d54f371363e9488f9fd51c48b341649b"
      unitRef="U001">1310000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_d09400df388b4c1ead8ce6f5a20d3b14"
      unitRef="U001">1113000</us-gaap:AccountsPayableCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20260331"
      decimals="-3"
      id="Fact_3cbb6ccdf0e74d9598eba256c7790387"
      unitRef="U001">3895000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_65d3409b7cab43b6a94a7ccb412d0085"
      unitRef="U001">4653000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_8f7ffdf4390d4f508bcb004bed6b0cfd"
      unitRef="U001">13750000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_2a111f91023b4a0f8249c367561cf0b3"
      unitRef="U001">13750000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_6d50bcbbff8a4b6f9c48fe3323073a9d"
      unitRef="U001">1149000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_45052f4ba9334c5d9f085bea8aea5fcd"
      unitRef="U001">3567000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_b75a68170c024705bbc13608802bf93a"
      unitRef="U001">20104000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_82c405676db041f68e156add2e64ff09"
      unitRef="U001">23083000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_74195e706c40453da7b3ef1a31f8d95b"
      unitRef="U001">4606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_5039b200ac9e43b9873143cc3aa65c6b"
      unitRef="U001">20443000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20260331"
      decimals="-3"
      id="Fact_39d42c322055480a90b5d08992997ebe"
      unitRef="U001">24710000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_d047bfc1332741c2b8b52d968625fd96"
      unitRef="U001">43526000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20260331"
      decimals="INF"
      id="Fact_be731cf726cf4132abea5f891ddbed01"
      unitRef="U002">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20251231"
      decimals="INF"
      id="Fact_559697deb2af486e9814bd17aeca554b"
      unitRef="U002">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20260331"
      decimals="0"
      id="Fact_d0dec8ea1db7456c94780bf9a19c0f9a"
      unitRef="U003">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20251231"
      decimals="0"
      id="Fact_4aa32106aa6f4e12b74c83dc07f7d959"
      unitRef="U003">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20260331"
      decimals="INF"
      id="Fact_3f2dfde085a348c7ae3bf0939f35d1f8"
      unitRef="U003">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20251231"
      decimals="INF"
      id="Fact_259a4b6c1c1742a3b021f20e9400afff"
      unitRef="U003">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20251231"
      decimals="INF"
      id="Fact_198c6ce0d4cb42b3a6eca4aac61d53e4"
      unitRef="U003">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20260331"
      decimals="INF"
      id="Fact_05169ecaafac4626a0a3545e253d9165"
      unitRef="U003">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20260331"
      decimals="INF"
      id="Fact_a5e1a6f3ad78467f8445bb6560b4e7b3"
      unitRef="U002">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20251231"
      decimals="INF"
      id="Fact_1ed9b55a8c6d4939bec0bb1c0b0dacc7"
      unitRef="U002">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20251231"
      decimals="0"
      id="Fact_39194d1243a84f82bf9265d568bdc7e1"
      unitRef="U003">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20260331"
      decimals="0"
      id="Fact_320e8d1703394f169b12212f1fee6443"
      unitRef="U003">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20260331"
      decimals="0"
      id="Fact_e53fc8338b134444adcba5cf45a9e5e1"
      unitRef="U003">3207810</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20260331"
      decimals="0"
      id="Fact_880532351558425a8f586df286f6801d"
      unitRef="U003">3207810</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20251231"
      decimals="0"
      id="Fact_d1f634250a4843e19223b1afb4a32537"
      unitRef="U003">3182810</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20251231"
      decimals="0"
      id="Fact_183b90fa5d754215a77a690896c8c055"
      unitRef="U003">3182810</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20260331"
      decimals="-3"
      id="Fact_7b1bd9c7572c46a7aca3f826243ecfa6"
      unitRef="U001">724068000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20251231"
      decimals="-3"
      id="Fact_3f7f8f53f47e440f97702e8e3fc6f206"
      unitRef="U001">723512000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20260331"
      decimals="-3"
      id="Fact_a965e46c82ea4ee59cfab93e59bfbaaa"
      unitRef="U001">-712316000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20251231"
      decimals="-3"
      id="Fact_8c5b8394d9414efa9a55aae9cfe7812b"
      unitRef="U001">-704757000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20260331"
      decimals="-3"
      id="Fact_531d66ecf4d540369b1efe4b06d02939"
      unitRef="U001">11752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_a0e117115a0c425383c397ed154a9eea"
      unitRef="U001">18755000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20260331"
      decimals="-3"
      id="Fact_34daa57d15c846e4a055a03ae1f2523f"
      unitRef="U001">36462000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_97a8f5030e1842f6bf566114e5fc3991"
      unitRef="U001">62281000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_73964263e3a0417bb5eac10cc1b4e019"
      unitRef="U001">4093000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_3bb671550ef8455d84276a7546ddcaed"
      unitRef="U001">7737000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_6f268f3daf5b45aa9b56ebe4bba94586"
      unitRef="U001">4787000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_dda45b9342724a429816cbd58cc1d079"
      unitRef="U001">6085000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_4971bd6e20844486a18d73e5347bb07b"
      unitRef="U001">2637000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_23e0ad2e78b14a1cbab9a6857bbfa19b"
      unitRef="U001">633000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_5131882999e94245950ae08c3c019f17"
      unitRef="U001">-8247000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_8610e6090c06424088644082f5e57d8e"
      unitRef="U001">-16459000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_5144dc288c4a4ff0b791f46c6d063b59"
      unitRef="U001">688000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_8358688a84534310801b8cdecc92981d"
      unitRef="U001">1054000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_f578e337b450429da14285b31dc8724b"
      unitRef="U001">-7559000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_4a3cfab7aed24869b72750468d4e55f4"
      unitRef="U001">-15405000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20260101to20260331"
      decimals="2"
      id="Fact_510a6e6e2dbe4a0496a4181240e7645c"
      unitRef="U002">-2.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20260101to20260331"
      decimals="2"
      id="Fact_0a5849c24c3540f780a4accb1db74dd8"
      unitRef="U002">-2.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20250101to20250331"
      decimals="2"
      id="Fact_ee2a7d0c8b5941ce9a9e08516a151a01"
      unitRef="U002">-4.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20250101to20250331"
      decimals="2"
      id="Fact_e203fd703e0f43aeb36f3eb9309baaf3"
      unitRef="U002">-4.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_fe3ab6034f19452684f52e26e3170402"
      unitRef="U003">3205866</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_e5d22873e84244fb89d7dd630ea2a0a9"
      unitRef="U003">3205866</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_e16fb4b85bbf45bf92f69cc765915ed4"
      unitRef="U003">3163914</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_dc8c42d10306473da164228a33c1660e"
      unitRef="U003">3163914</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_54c74b94447440ca99ede9283666a28a"
      unitRef="U001">-7559000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_3b0c88e6d23840499d7334b272bc644b"
      unitRef="U001">-15405000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_ef0ff808302943adac208a2b5cc0973e"
      unitRef="U001">-8000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_5261cea89f454636a5b2eb42c318f96b"
      unitRef="U001">-7559000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_1565b40a52b8441cbb7e3cd6414ed5e2"
      unitRef="U001">-15413000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="c20251231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9f4674a68da948b58e065dfbfc5d1f79"
      unitRef="U003">3182810</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20251231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_09cc79da126e462789c8ba6c547e7ec8"
      unitRef="U001">723512000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_72cd475cad4d47c597d8db01d3cc5ca1"
      unitRef="U001">-704757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20251231"
      decimals="-3"
      id="Fact_467f3ceefb9046b7bd74f1b74f752bea"
      unitRef="U001">18755000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20260101to20260331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_1babbc723d5a488e951e86b80dc67300"
      unitRef="U003">25000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20260101to20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0418d71e8d874401a1bfa09676769d1b"
      unitRef="U001">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_13eac2d0ce1f487db0a1d0250b5ca726"
      unitRef="U001">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20260101to20260331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c2c27d2dc7a148dfb937266a8b92a69a"
      unitRef="U001">-7559000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_b2c8311489b146028601c0e527afe016"
      unitRef="U001">-7559000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20260331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_635730bd39b74254abbcd213e935960c"
      unitRef="U003">3207810</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20260331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_8f5b135425ed4374b8d7841529914ede"
      unitRef="U001">724068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20260331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_081a74f81f3148fda55d099edf0497f6"
      unitRef="U001">-712316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20260331"
      decimals="-3"
      id="Fact_8db4feafaff44f968d1d4f667697d1ff"
      unitRef="U001">11752000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_e96612d5ce0a4d18937e33aaab4e5db0"
      unitRef="U003">3161503</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2a9e83f0dff54dd9baa1da2b1487382f"
      unitRef="U001">720488000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_94060ce6eda4403b9273727dc2327338"
      unitRef="U001">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0c9164c371dd43e5816eee6d87d61592"
      unitRef="U001">-659235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_035b67ac3de64fc79eb91922b2dd8a9a"
      unitRef="U001">61261000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0daf2d6f528145da903fde531c071b26"
      unitRef="U003">4325</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_8b4f0b52c0c041a4a6f790fb233e1dbd"
      unitRef="U001">-8000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_bdc564e0e6264adf85be233ab162d80c"
      unitRef="U001">-8000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_71f698419a424dcc9db060f2d6ca426b"
      unitRef="U001">858000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_ebbf29a6202a4358b57ef7fd382a3678"
      unitRef="U001">858000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6fd23e64b787436f8121ddbb67789687"
      unitRef="U001">-15405000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_cf7b5bfd952a45318d6219ca20666c7c"
      unitRef="U001">-15405000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20250331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f1dc144d556f47cc8b19eecd305dd8a4"
      unitRef="U003">3165828</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20250331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bedb26746b31452092c7687b97bdbc66"
      unitRef="U001">721346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20250331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a53661cae021489fae0606c3afa62522"
      unitRef="U001">-674640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20250331"
      decimals="-3"
      id="Fact_4f5a87ba13c74076adb082be3adab9f4"
      unitRef="U001">46706000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_06866935a11a4f48800dcc7c1fdb05f9"
      unitRef="U001">-7559000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_167ada6afb344bc6bda428923e19f334"
      unitRef="U001">-15405000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_a3234483f678475494db6cc9e900eb40"
      unitRef="U001">129000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_d4b25415761441318de8d5a2623b5675"
      unitRef="U001">201000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_d96961153a1f43fb86b853c514c9ff4e"
      unitRef="U001">556000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_d44b4f3ae98f4d278f7f53205af6c5fc"
      unitRef="U001">858000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_13ba4a5c43ee466591edd34ccc667e9e"
      unitRef="U001">129000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_35c859b89a2e4d8cbb7661c17b4f96b9"
      unitRef="U001">633000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_f3022c33b8e445a89c00789cc1b02ef1"
      unitRef="U001">2637000</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_7829b53d3b084b31ad103cc58699e240"
      unitRef="U001">53000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_20a9320556ac4cef80f07a618b6768ea"
      unitRef="U001">709000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_9f613d07bfae41e4ae406e1ff86b3629"
      unitRef="U001">-107000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_8e67b90ee6ab42e2959944b780f3a99e"
      unitRef="U001">-30000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_0d153bfd4e744c318c208c7e96b687db"
      unitRef="U001">506000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_3dc16583a93948b0aca59381fc730a72"
      unitRef="U001">4973000</pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities>
    <pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_023592fceb0b49d58120f79d664b1d1f"
      unitRef="U001">97000</pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_5695fc21fd89498e89a4b30e9491d873"
      unitRef="U001">197000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_b5eb567c66904b50bf633c52c1b003bb"
      unitRef="U001">716000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_71831830d3444369a2ba6a0978df2fa0"
      unitRef="U001">-758000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_ac1e0e411dd54fe4a3fb4e7a3db25068"
      unitRef="U001">-2713000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_e69530fa2728495b9f0c7e889fbe7810"
      unitRef="U001">-12987000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_54304b9b5000432cad36dbf7e5260c93"
      unitRef="U001">-13847000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_3c5a83ed15c14e6982b33034792fa602"
      unitRef="U001">39046000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_bdcef3ed5f0a4d5f85903010343293e1"
      unitRef="U001">20000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_dcdd6c236b2e4f528d9f4def02ce5c9e"
      unitRef="U001">585000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_5f895841a48d48a2b0a5e5ca1e71c525"
      unitRef="U001">20000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_7b36403e56e44f5d849a01601e8a3d88"
      unitRef="U001">39631000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_d66fc2ee5f8c4bbe8172094d1acfb4ea"
      unitRef="U001">-12967000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_496d609746574e3ca0c5dd54fbe1a56d"
      unitRef="U001">25784000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20251231"
      decimals="-3"
      id="Fact_84b136414fac42688b06ccb6856dcbba"
      unitRef="U001">46303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="-3"
      id="Fact_186eee3260a74e2fa11ba4e57c32c901"
      unitRef="U001">37573000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20260331"
      decimals="-3"
      id="Fact_db9d6ada9ece4cf7bcd1a1c22787dfe0"
      unitRef="U001">33336000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20250331"
      decimals="-3"
      id="Fact_f0d0be25a2584356940ed59cb33ed8b3"
      unitRef="U001">63357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_50249c6099854b3ebb62b1ce7b0a25a8"
      unitRef="U001">-8000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <pasg:DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_46b186032a174035918e77db7595a21f"
      unitRef="U001">-585000</pasg:DeferredProceedsReceivableFromSaleOfEquipmentInOtherCurrentAssets>
    <us-gaap:NatureOfOperations
      contextRef="c20260101to20260331"
      id="Text_2b766c4664334617b6188ccc87e1d49e">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;"&gt;1. Nature of Operations &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Passage Bio, Inc., or the Company, a Delaware corporation incorporated in
            July&#160;2017, is a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. The Company&#x2019;s primary focus is the development and advancement of cutting-edge, one-time therapies designed to
            target critical underlying pathology in these conditions. The Company&#x2019;s lead clinical product candidate is PBFT02 for the treatment of frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-&lt;span style="font-style: italic;"&gt;GRN&lt;/span&gt;,
            which seeks to elevate progranulin levels to restore lysosomal function and slow disease progression. &lt;/div&gt;
</us-gaap:NatureOfOperations>
    <pasg:RisksAndLiquidityTextBlock
      contextRef="c20260101to20260331"
      id="Text_f1cc5cc1bd44436c89eb346335870528">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"&gt;2. Risks, Liquidity, and Going Concern &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has incurred recurring losses and negative cash flows from
            operations since inception and had an accumulated deficit of $712.3 million as of March 31, 2026. The Company anticipates incurring
            additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its
            product candidates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company&#x2019;s operations have consisted primarily of conducting preclinical
            studies, developing licensed technology, conducting clinical trials, and the development and manufacturing of clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product
            candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These
            efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its regulatory objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key
            members of management. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On March&#160;5, 2021, the Company entered into a Sales Agreement, or the Sales
            Agreement, with Cowen and Company, LLC, or Cowen, relating to the applicable terms of at-the-market equity offerings, or the ATM Facility, pursuant to which the Company may, but is not obligated to, offer and sell, from time to time, shares of
            its common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent in the ATM Facility. The Company
            is currently limited in its capacity to offer and sell shares of its common stock under the Sales Agreement pursuant to the prospectus supplement to its shelf registration statement on Form&#160;S-3, filed on March&#160;4, 2024. As of March 31, 2026, $15.8 million of capacity remains available to be sold under the ATM Facility. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;These financial statements have been prepared in accordance with U.S.
            generally accepted accounting principles, or GAAP, assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. In
            accordance with the Financial Accounting Standards Board&#x2019;s, or FASB, Accounting Standards Codification, or ASC, Subtopic 205-40, &lt;span style="font-style: italic;"&gt;Presentation of Financial Statements - Going Concern&lt;/span&gt;, the Company has
            evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are
            issued. The Company incurred net losses of approximately $7.6 million and $15.4 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, the Company had cash and cash equivalents totaling $33.3 million, which the Company does not expect to be sufficient to meet the Company&#x2019;s capital requirements over the next 12 months. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As a result, there is substantial doubt about the Company&#x2019;s ability to
            continue as a going concern within one year after the date that these financial statements are issued. The financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported
            expenses that may be necessary if the Company were unable to continue as a going concern. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On April&#160;20, 2026, the Company announced that it has initiated a review of
            strategic alternatives to maximize shareholder value (see Note&#160;13). These strategic alternatives may include, but are not limited to, merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships,
            licensing opportunities, or other potential paths. The Company does not intend to provide updates on the strategic review until the board of directors approves a specific action or otherwise determines that disclosure is appropriate or
            required. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;or other arrangements on favorable terms, or at all. The terms of any
            financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, or prospects of funding are unfavorable, the Company could be required to further delay, reduce or eliminate
            research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. &lt;/div&gt;
</pasg:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20260331"
      decimals="-5"
      id="Fact_acf14738350f429b9539927e18bf46fb"
      unitRef="U001">-712300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20210305to20210305_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_b44f4ce92ada4ee3ba025445c5b9524a"
      unitRef="U001">125000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <pasg:RemainingCapacityOfValueOfSharesAvailableToBeSold
      contextRef="c20260331_SubsidiarySaleOfStockAxis_AttheMarketFacilityAgreementMember"
      decimals="-5"
      id="Fact_6e47240646da4623aa5e81f6c0a07c8a"
      unitRef="U001">15800000</pasg:RemainingCapacityOfValueOfSharesAvailableToBeSold>
    <us-gaap:NetIncomeLoss
      contextRef="c20260101to20260331"
      decimals="-5"
      id="Fact_61ed3feee4df487bb06b3b6b41896579"
      unitRef="U001">-7600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_cd8f78fac37d4f3fafb4eba11fba9e5c"
      unitRef="U001">-15400000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20260331"
      decimals="-5"
      id="Fact_f509dc230d6e4435be02bcd0dea85b8a"
      unitRef="U001">33300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20260101to20260331"
      id="Text_5c335827d7c942fe803d9f1d6483992c">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"&gt;3. Summary of Significant Accounting Policies &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company&#x2019;s complete summary of significant accounting policies can be found
            in &#x201c;Note&#160;3. Summary of Significant Accounting Policies&#x201d; in the audited financial statements included in the Company&#x2019;s Annual Report filed on Form&#160;10-K for the year ended December 31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"&gt;Basis of Presentation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accompanying unaudited financial statements have been prepared in
            accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;14, 2025, the Company effected a &lt;span style="-sec-ix-hidden:Fact_9c4ae5c452f740698340777ae9877470"&gt;1&lt;/span&gt;-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of
            shares of common stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity,
            have been adjusted retroactively to reflect the Reverse Stock Split for all periods presented. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Interim Financial Statements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accompanying unaudited interim financial statements have been prepared
            from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the SEC, which permits reduced disclosures for interim periods. All adjustments, consisting only
            of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets, statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows have been made. Although these interim financial
            statements do not include all of the information and notes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of
            operations and cash flows are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and notes should be read in conjunction with the audited financial statements and notes
            included in the Company&#x2019;s 2025 Annual Report filed on Form&#160;10-K. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Use of Estimates &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Fair Value of Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Concentration of Credit Risk &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;dictates the allocation of funds within its portfolio of money market
            funds. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money
            market funds.
          &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Cash and Cash Equivalents &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2026 consisted of money market funds. Cash consists of cash deposits at banking institutions. As of March&#160;31, 2025, all of the Company&#x2019;s marketable
            securities matured and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#x2019;s balance sheet. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company had cash and cash equivalents of $33.3 million and $46.3 million as of
            March 31, 2026 and December 31, 2025, respectively. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Marketable Securities &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#x2019; equity.
            Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable securities sold are recognized as a component of other
            income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all
            marketable securities as current assets within the balance sheet. As of March 31, 2026, the Company had no marketable securities. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"&gt;Property and Equipment, Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years
            for office equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company did not recognize any impairment expenses for long-lived assets for the three months ended March 31, 2026. The
            Company recognized impairment expenses for laboratory equipment and certain other assets of $2.6 million for the three months ended
            March 31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"&gt;Leasing &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of March 31, 2026, the Company has classified all leases with terms greater than one year, as operating leases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;When assets and liabilities for operating leases are written off, the balances
            are removed from the respective accounts, with any resulting gain or loss recognized concurrently. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company did not
            recognize any impairment expenses for ROU assets for the three months ended March 31, 2026 or 2025. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"&gt;Research and Development &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#x2019;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#x2019;s external accrued research and development expenses, which primarily relate to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#x2019;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"&gt;Other Income (Expense), Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, and income from subleases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $0.7 million to other income (expense), net for the three months ended March 31, 2026, which consisted of $0.3 million attributable to interest income and $0.4 million
            related to income from subleases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $1.1 million to other income (expense), net for the three months ended March&#160;31, 2025, which consisted of $0.7 million attributable to interest income and the amortization of premium and discount on the Company&#x2019;s marketable securities and $0.4 million related to income from subleases. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Share-Based Compensation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option
            awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application
            of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Prior to 2026, the Company estimated the expected term of the stock options
            using the &#x201c;simplified method,&#x201d; as the Company had limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The
            Company now has sufficient historical exercise data and has determined it is no longer appropriate to use the &#x201c;simplified method&#x201d;. Additionally, the Company no longer uses comparable public company data to estimate expected volatility and
            instead bases its expected volatility assumption on the historical volatility of its own stock price. The Company will apply this methodology prospectively and the change in estimates did not have a material impact for the three months ended
            March 31, 2026. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company accounts for forfeitures of RSUs and stock option awards as they
            occur.
          &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;License and Other Revenue &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company may enter into license agreements and transition services
            agreements (see Note&#160;7) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;The Company applies FASB ASC Topic 606, &lt;span style="font-style: italic;"&gt;Revenue





































              from Contracts with Customer&lt;/span&gt;s, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#x2019;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#x2019;s balance sheet when the Company&#x2019;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#x2019;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Net Loss Per Share &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;846,107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;704,699&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;62,500&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Employee stock purchase plan&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,593&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;848&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;872,700 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;768,047 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"&gt;Recently Issued Accounting Pronouncements
          &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In November&#160;2024, the FASB issued ASU No. 2024-03, &lt;span style="font-style: italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#x2019;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In September&#160;2025, the FASB issued ASU No. 2025-06, &lt;span style="font-style: italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2025, the FASB issued ASU No. 2025-11, &lt;span style="font-style: italic;"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/span&gt;, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim periods. ASU 2025-11 is effective for the Company for interim periods within annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be
            applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement disclosures. &lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <pasg:BasisOfPresentationPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_9900b853e4fd4930834c30cb1f722ae7">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 18.5pt; margin-left: 0pt; text-align: left;"&gt;Basis of Presentation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accompanying unaudited financial statements have been prepared in
            accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the ASC and Accounting Standard Updates, or ASUs, promulgated by the FASB. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;14, 2025, the Company effected a &lt;span style="-sec-ix-hidden:Fact_9c4ae5c452f740698340777ae9877470"&gt;1&lt;/span&gt;-for-20 reverse stock split of its common stock, or the Reverse Stock Split. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who were otherwise entitled to receive fractional shares received the number of
            shares of common stock as rounded up to the nearest whole share. All share and per share amounts in these financial statements and notes thereto, including the stock options, restricted stock units, and employee stock purchase plan activity,
            have been adjusted retroactively to reflect the Reverse Stock Split for all periods presented. &lt;/div&gt;
</pasg:BasisOfPresentationPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="c20250714to20250714"
      decimals="INF"
      id="Fact_1f617be7dfb8470bad4fc64b6a7a284b"
      unitRef="U003">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <pasg:InterimFinancialStatementsPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_2db19ac0e23642d3b7c93a3baef523da">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Interim Financial Statements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accompanying unaudited interim financial statements have been prepared
            from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the SEC, which permits reduced disclosures for interim periods. All adjustments, consisting only
            of normal recurring adjustments, necessary for a fair presentation of the accompanying balance sheets, statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows have been made. Although these interim financial
            statements do not include all of the information and notes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. Unaudited interim results of
            operations and cash flows are not necessarily indicative of the results that may be expected for the full year. Unaudited interim financial statements and notes should be read in conjunction with the audited financial statements and notes
            included in the Company&#x2019;s 2025 Annual Report filed on Form&#160;10-K. &lt;/div&gt;
</pasg:InterimFinancialStatementsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20260101to20260331"
      id="Text_44216349385c4476a0266584440beed9">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Use of Estimates &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The preparation of financial statements in conformity with GAAP requires
            management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues
            and expenses during the reporting period. Actual results could differ from those estimates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimates and assumptions are periodically reviewed, and the effects of the
            revisions are reflected in the accompanying financial statements in the period they are determined to be necessary. &lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20260101to20260331"
      id="Text_e2a059f2461946b0a2a2bee09b46e5cb">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Fair Value of Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial
            instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/div&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20260101to20260331"
      id="Text_8a987435b0fc463490f745ee4e7b931a">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Concentration of Credit Risk &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Financial instruments that potentially subject the Company to significant
            concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains a deposit account in a federally insured financial institution in excess of federally insured limits. The Company also maintains a portfolio of
            money market funds, which is diversified to limit exposure related to counterparty and industry risks. The Company maintains an investment policy which &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;dictates the allocation of funds within its portfolio of money market
            funds. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents beyond the normal credit risk associated with commercial banking relationships and money
            market funds.
          &lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_fdfdf5e9710c425799a4c30f0db20294">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Cash and Cash Equivalents &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company considers all highly-liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents as of March 31, 2026 consisted of money market funds. Cash consists of cash deposits at banking institutions. As of March&#160;31, 2025, all of the Company&#x2019;s marketable
            securities matured and the proceeds were invested into money market funds, which are included in cash and cash equivalents on the Company&#x2019;s balance sheet. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company had cash and cash equivalents of $33.3 million and $46.3 million as of
            March 31, 2026 and December 31, 2025, respectively. &lt;/div&gt;
</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20260331"
      decimals="-5"
      id="Fact_53fee346efe74341884f2ff80d1000bc"
      unitRef="U001">33300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20251231"
      decimals="-5"
      id="Fact_5b6e91543c464b98823663a6ce8b1a95"
      unitRef="U001">46300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="c20260101to20260331"
      id="Text_44153f8fe9a7480b9c1c656d00ed3f4e">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;"&gt;Marketable Securities &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company classifies its marketable securities with original maturities of
            greater than three months as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#x2019; equity.
            Any premium or discount arising at purchase of debt securities is amortized and/or accreted over the term of the security to other income (expense), net. Gains or losses on marketable securities sold are recognized as a component of other
            income (expense), net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all
            marketable securities as current assets within the balance sheet. As of March 31, 2026, the Company had no marketable securities. &lt;/div&gt;
</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_71d6355f396247388882d9e1c7dbff55"
      unitRef="U001">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_2a5cb37ec6674a5e908a9ce87047fd8b">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"&gt;Property and Equipment, Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Property and equipment, net consists of laboratory equipment, office
            equipment, computer hardware and software, furniture and fixtures, and leasehold improvements and is initially recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred.
            Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset-by-asset basis, which generally consists of three years for computer hardware and software, five years
            for office equipment, five years for laboratory equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;When property and equipment are retired or otherwise disposed of, the costs
            and accumulated depreciation and amortization are removed from the respective accounts, with any resulting gain or loss recognized concurrently. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as property and equipment, for
            impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. The Company did not recognize any impairment expenses for long-lived assets for the three months ended March 31, 2026. The
            Company recognized impairment expenses for laboratory equipment and certain other assets of $2.6 million for the three months ended
            March 31, 2025. &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember"
      id="Fact_4001efaf22034039b8a26f19fee9e393">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      id="Fact_f0cffa7a259340d493482beb3c48d367">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentMember"
      id="Fact_e1b93eb40dbe4fc6b9dc5b0d54730f3c">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      id="Fact_7c76562f330d4c3bbddff4d0b952f78c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20250101to20250331_PropertyPlantAndEquipmentByTypeAxis_LaboratoryEquipmentAndCertainOtherAssetsMember"
      decimals="-5"
      id="Fact_a0f0e81ee4954b4e8daa9d559b4d0866"
      unitRef="U001">2600000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_0c8c3c7890d84a2f867622b9a23caedd">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-align: left;"&gt;Leasing &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company evaluates leases at their inception to determine if they are an
            operating lease or a finance lease. As of March 31, 2026, the Company has classified all leases with terms greater than one year, as operating leases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recognizes assets and liabilities for operating leases at their
            inception, based on the present value of all payments due under the lease agreement. The Company uses its incremental borrowing rate to determine the present value of operating leases, which is determined by referencing collateralized borrowing
            rates for debt instruments with terms similar to the respective lease. The Company utilizes the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition
            requirement to leases with a term of 12 months or less. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;When assets and liabilities for operating leases are written off, the balances
            are removed from the respective accounts, with any resulting gain or loss recognized concurrently. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;The Company reviews long-lived assets, such as right of use assets, or ROU
            assets, for impairment when events or changes indicate the carrying amount of the ROU assets may not be recoverable. The Company did not
            recognize any impairment expenses for ROU assets for the three months ended March 31, 2026 or 2025. &lt;/div&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_9b05e14b2ecc4527ba39c569c6e73599"
      unitRef="U001">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="c20260101to20260331"
      decimals="-5"
      id="Fact_2e451f68e47140f796b48fde0814a26f"
      unitRef="U001">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20260101to20260331"
      id="Text_9d3640017f8a43d7bbdafe027243784c">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"&gt;Research and Development &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Research and development costs are expensed as incurred and consist primarily
            of expenses incurred with the University of Pennsylvania&#x2019;s Gene Therapy Program, or GTP, and Gemma Biotherapeutics, Inc., or Gemma, contract research organizations, contract manufacturing organizations, internal analytical and testing
            activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#x2019;s external accrued research and development expenses, which primarily relate to contract research
            organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at
            that time. The Company determines the estimates by reviewing contracts, vendor agreements, change orders, and through discussions with the Company&#x2019;s internal clinical personnel and external service providers as to the progress to completion of
            services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. &lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <pasg:OtherIncomeAndOtherExpensePolicyPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_265e550c4dca4673af040818b46e1b04">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"&gt;Other Income (Expense), Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Other income (expense), net consists of interest earned on cash equivalents
            and marketable securities, amortization of premium and discount on marketable securities, and income from subleases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $0.7 million to other income (expense), net for the three months ended March 31, 2026, which consisted of $0.3 million attributable to interest income and $0.4 million
            related to income from subleases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company recorded $1.1 million to other income (expense), net for the three months ended March&#160;31, 2025, which consisted of $0.7 million attributable to interest income and the amortization of premium and discount on the Company&#x2019;s marketable securities and $0.4 million related to income from subleases. &lt;/div&gt;
</pasg:OtherIncomeAndOtherExpensePolicyPolicyTextBlock>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20260101to20260331"
      decimals="-5"
      id="Fact_40e3889a964045189c9fc4508c4b3b01"
      unitRef="U001">700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="c20260101to20260331"
      decimals="-5"
      id="Fact_f41ccb0e7229473092a85f69093ce23a"
      unitRef="U001">300000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:SubleaseIncome
      contextRef="c20260101to20260331"
      decimals="-5"
      id="Fact_588f62f4f15a40d78acd524ec9d02cf5"
      unitRef="U001">400000</us-gaap:SubleaseIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_bc72406a730e4fdcba6d07ff88d66b97"
      unitRef="U001">1100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_de3bd440f9fd46c7a0916529a1756c36"
      unitRef="U001">700000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:SubleaseIncome
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_f0c6fb6579134fcb944e9ef90dbeb9d2"
      unitRef="U001">400000</us-gaap:SubleaseIncome>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20260101to20260331"
      id="Text_39f92fa049bf434f92d9cb2df40a2ee3">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;Share-Based Compensation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company measures share-based awards at grant-date fair value and records
            compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option
            awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Estimating the fair value of stock option awards requires the input of
            assumptions, including the expected term of stock options and stock price volatility. The assumptions used in estimating the fair value of share-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application
            of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Prior to 2026, the Company estimated the expected term of the stock options
            using the &#x201c;simplified method,&#x201d; as the Company had limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The
            Company now has sufficient historical exercise data and has determined it is no longer appropriate to use the &#x201c;simplified method&#x201d;. Additionally, the Company no longer uses comparable public company data to estimate expected volatility and
            instead bases its expected volatility assumption on the historical volatility of its own stock price. The Company will apply this methodology prospectively and the change in estimates did not have a material impact for the three months ended
            March 31, 2026. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The Company accounts for forfeitures of RSUs and stock option awards as they
            occur.
          &lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_4d1c285f316b48cc91c5d78bb692fe63">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;"&gt;License and Other Revenue &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company may enter into license agreements and transition services
            agreements (see Note&#160;7) under which it may license rights to research, develop, manufacture, and commercialize its product candidates to third parties and provide transition services for such licenses. Payments under these arrangements may
            include non-refundable, upfront fees, reimbursement of certain costs, payments upon the achievement of certain milestones, and royalties on product sales. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;The Company applies FASB ASC Topic 606, &lt;span style="font-style: italic;"&gt;Revenue





































              from Contracts with Customer&lt;/span&gt;s, or ASC 606, when all of the following criteria are met, to determine a valid contract exists: (i) the parties have approved the contract and are committed to perform their respective obligations; (ii) the
            Company can identify each party&#x2019;s rights regarding the goods or services to be transferred; (iii) the Company can identify the payment terms for the goods or services to be transferred; (iv) the contract has commercial substance; and (v) the
            Company will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Once it is determined that a valid contract exists, the Company performs
            the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the
            contract; (iii) measurement of the transaction price, including consideration of the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations on a relative stand-alone selling price basis;
            and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use its judgment to determine the number of performance obligations, the
            transaction price, the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price, the contract term and pattern of satisfaction of the performance obligations. The Company uses
            judgment to determine whether milestones or other variable consideration, except for certain sales-based milestone payments and royalties, should be included in the transaction price as described further below. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;At the inception of each arrangement that includes milestone payments, the
            Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method set forth in ASC 606. If it is probable that a significant
            revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as those subject to regulatory approvals, are not
            considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making
            this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
            achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the statements of operations and comprehensive
            loss in the period of adjustment. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For customer contracts in the scope of ASC 606, amounts due to the Company are
            recorded as accounts receivable on the Company&#x2019;s balance sheet when the Company&#x2019;s right to consideration is unconditional. Amounts received prior to satisfying the related performance obligations are classified on the Company&#x2019;s balance sheet as
            current deferred revenue if expected to be recognized as revenue within 12 months following the balance sheet date and as deferred revenue, net of current portion, if amounts are not expected to be recognized as revenue within the 12 months
            following the balance sheet date. The Company does not evaluate a contract for a significant financing component if payment is expected within one year or less from the transfer of promised items to the customer. &lt;/div&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_891e5895b38441af8b347814ac8a1699">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Net Loss Per Share &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Basic net loss per share of common stock is computed by dividing net loss by
            the weighted average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which
            would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists,
            dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following potentially dilutive securities have been excluded from the
            computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;846,107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;704,699&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;62,500&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Employee stock purchase plan&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,593&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;848&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;872,700 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;768,047 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20260101to20260331"
      id="Text_95d493bcef2e46fe984f118665f28ecd">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Stock options&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;846,107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;704,699&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested restricted stock units&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;25,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;62,500&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Employee stock purchase plan&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,593&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;848&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;872,700 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.67pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;768,047 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"
      decimals="0"
      id="Fact_ba3d6fba1c3d4f9ea5267cc145ea5b8a"
      unitRef="U003">846107</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_StockOptionsIncludingSharesSubjectToRepurchaseMember"
      decimals="0"
      id="Fact_4ea5f3f6b2fd44e1b96091136deedb84"
      unitRef="U003">704699</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_d80f0ff5d19f4fffbd8dae3f738975ae"
      unitRef="U003">25000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_bb62a3b2d44f4af9a1e9559827956d18"
      unitRef="U003">62500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20260101to20260331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"
      decimals="0"
      id="Fact_2695fb3b335242f29426ef55c24f6f96"
      unitRef="U003">1593</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20250331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockMember"
      decimals="0"
      id="Fact_e01e9331415d4ec6b6da19db465a8b14"
      unitRef="U003">848</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_03bf821f130448d584801821d9a3bd41"
      unitRef="U003">872700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20250101to20250331"
      decimals="0"
      id="Fact_a840ec7de3c647f1ae318928c25f8bea"
      unitRef="U003">768047</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20260101to20260331"
      id="Text_481db3a20a0c4a8b9f5e0999cc91663c">
&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"&gt;Recently Issued Accounting Pronouncements
          &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In November&#160;2024, the FASB issued ASU No. 2024-03, &lt;span style="font-style: italic;"&gt;Income Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;, or ASU 2024-03, which requires entities to provide disclosures to
            disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for the Company&#x2019;s first
            fiscal year beginning after December&#160;15, 2026, and for interim periods within the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. The
            Company is currently evaluating the impact of this guidance on its disclosures. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In September&#160;2025, the FASB issued ASU No. 2025-06, &lt;span style="font-style: italic;"&gt;Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software&lt;/span&gt;, or ASU 2025-06. ASU 2025-06 is intended to increase the operability of the accounting
            for internal-use software costs by removing all references to software development project stages. ASU 2025-06 requires capitalization of software costs to start when management has authorized and committed to funding the software project, it
            is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for the Company&#x2019;s first fiscal year beginning after December&#160;15, 2027, and for interim periods within that
            year with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In December&#160;2025, the FASB issued ASU No. 2025-11, &lt;span style="font-style: italic;"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements&lt;/span&gt;, or ASU 2025-11. The amendments reorganize and clarify the interim disclosure requirements in U.S. GAAP and establish a single, principles based framework for
            determining the information that should be disclosed in interim periods. ASU 2025-11 is effective for the Company for interim periods within annual periods beginning after December&#160;15, 2027, with early adoption permitted. The guidance can be
            applied prospectively or retrospectively. The Company is currently evaluating the impact of ASU 2025-11 on its interim financial statement disclosures. &lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="c20260101to20260331"
      id="Text_f605d606d39849ce93545310d0b767f3">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"&gt;4. Fair Value of Financial Instruments and Non-Financial
            Instruments &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Fair value is the price that could be received to sell an asset or paid to
            transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on
            a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities,
            various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including prepaid expenses and accounts payable are shown at cost, which approximates fair
            value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, &lt;span style="font-style: italic;"&gt;Fair Value Measurement&lt;/span&gt;, for financial assets and liabilities measured on a recurring
            basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories: &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-style: italic;"&gt;Level 1: &lt;/span&gt;Unadjusted quoted prices in active markets that are accessible at the
                    measurement date for identical, unrestricted assets or liabilities. &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-style: italic;"&gt;Level 2: &lt;/span&gt;Quoted prices in markets that are not active, or inputs which are
                    observable, either directly or indirectly, for substantially the full term of the asset or liabilities. &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 20pt; text-align: left; vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2022;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top;"&gt;
                  &lt;div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;"&gt;&lt;span style="font-style: italic;"&gt;Level 3: &lt;/span&gt;Prices or valuation techniques that require inputs that are both
                    significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company considers all highly liquid investments that have maturities of
            three months or less when acquired to be cash equivalents. Cash equivalents include money market funds that are carried at cost, which approximates their fair value. The fair values are based on quoted market prices in active markets for
            identical assets and therefore are classified within Level&#160;1 of the fair value hierarchy. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 15.5pt; margin-left: 0pt; text-align: left;"&gt;Non-Financial Instruments &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Long-lived non-financial assets are measured at fair value on a nonrecurring
            basis for purposes of calculating impairment using Level&#160;3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level&#160;3 inputs is determined by estimating the amount and timing of net future cash flows (which
            are unobservable inputs) and &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;discounting them using a risk-adjusted rate of interest. Significant
            increases or decreases in actual cash flows may result in valuation changes. There were no assets remeasured in the three months ended March 31, 2026. Assets remeasured in the three months ended March 31, 2025 included laboratory equipment and
            certain other assets which were sold prior to March&#160;31, 2025 and were not included in the balance sheet as of March&#160;31, 2025. The impairment related to the remeasurement of $2.6 million is included in the statement of operations for the three months ended March&#160;31, 2025. &lt;/div&gt;
</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="c20260101to20260331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsNonrecurringMember"
      decimals="-5"
      id="Fact_c39ea8a1ab284c6eaffbe359f155aa7c"
      unitRef="U001">2600000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20260101to20260331"
      id="Text_aecfc78749574a559761528a9cc29a16">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16pt; margin-left: 0pt; text-align: left;"&gt;5. Property and Equipment, Net &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Property and equipment, net, consists of the following: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 52.96pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Office equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;$&lt;span style="padding-left: 15.83pt;"&gt;55&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;$&lt;span style="padding-left: 10.83pt;"&gt;107 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Computer hardware and software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;959 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;988 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;306&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;419&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,564&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,510&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total property and equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;2,884 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;8,024 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Accumulated depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(2,058) &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,917) &lt;/span&gt;&lt;span style="padding-bottom: 1.5pt;"&gt; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;826&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;4,107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On March&#160;4, 2026, the Company entered into the Hopewell Lease Termination
            Agreement. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $4.8
            million as well as accrued rent through February&#160;14, 2026. As a result of the Hopewell Lease Termination Agreement, the Company recognized a net gain of $0.6 million on the lease termination for the three months ended March 31, 2026. The net gain is comprised of a $3.8
            million gain on the write-off of assets and liabilities for operating leases offset by a $3.2 million net loss on disposal of
            property and equipment. The assets disposed of as part of the termination included office equipment, leasehold improvements, furniture and fixtures, and computer hardware and software. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Depreciation and amortization expense was $0.1 million and $0.2 million for the
            three months ended March 31, 2026 and 2025, respectively. &lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20260101to20260331"
      id="Text_2cb494f093514aad82c29480d2bd18db">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 52.96pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Office equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;$&lt;span style="padding-left: 15.83pt;"&gt;55&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;$&lt;span style="padding-left: 10.83pt;"&gt;107 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Computer hardware and software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;959 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;988 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;306&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;419&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,564&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,510&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total property and equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;2,884 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;8,024 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Accumulated depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(2,058) &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(3,917) &lt;/span&gt;&lt;span style="padding-bottom: 1.5pt;"&gt; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 11.06pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 10.83pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;826&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.84pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;4,107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_eea6129bbe944886b987d2390b6107e8"
      unitRef="U001">55000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_d66246b73a664b19abdd0ee5df61f840"
      unitRef="U001">107000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      id="Fact_c51a37cede0143289da28b6957d7c8e0"
      unitRef="U001">959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_ComputerHardwareAndSoftwareMember"
      decimals="-3"
      id="Fact_bf6091ad5db849cf9162face7abe5189"
      unitRef="U001">988000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_7c738874ea844270b7428215e0eb755c"
      unitRef="U001">306000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_c67c9f915a2f4d48a706531d5ee63afa"
      unitRef="U001">419000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_6a582bd3327b41cf9d45a483c040f81f"
      unitRef="U001">1564000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdsAndLeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_8da914b34e874cf8b1714d2d361adc46"
      unitRef="U001">6510000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20260331"
      decimals="-3"
      id="Fact_c39f8a4639b846e8ae47084564f8d504"
      unitRef="U001">2884000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20251231"
      decimals="-3"
      id="Fact_29ef8fd9a7554edd9003f53cff2d78b0"
      unitRef="U001">8024000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20260331"
      decimals="-3"
      id="Fact_1def950e44a14cfb8e8bbf08195b4b06"
      unitRef="U001">2058000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20251231"
      decimals="-3"
      id="Fact_5b484891f1a34d3c8b93faa5fe58be2b"
      unitRef="U001">3917000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20260331"
      decimals="-3"
      id="Fact_e96c8ae250be475788b57f77120ef5fd"
      unitRef="U001">826000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20251231"
      decimals="-3"
      id="Fact_fad700a15569499b86eb1769716d8972"
      unitRef="U001">4107000</us-gaap:PropertyPlantAndEquipmentNet>
    <pasg:EarlyLeaseTerminationFee
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_e2f987609c6a46c6a69dd67b70ad7b41"
      unitRef="U001">4800000</pasg:EarlyLeaseTerminationFee>
    <pasg:EarlyLeaseTerminationFee
      contextRef="c20260214to20260214"
      decimals="-5"
      id="Fact_8858bd784a2e40fbbbadc93e6a778ce8"
      unitRef="U001">4800000</pasg:EarlyLeaseTerminationFee>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_d9acabbd87b14ddd9406338998e469d7"
      unitRef="U001">600000</us-gaap:GainLossOnTerminationOfLease>
    <pasg:GainLossOnWriteOffOfOperatingLeases
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_5b1d818f89b54a4bb763e9c70d104378"
      unitRef="U001">3800000</pasg:GainLossOnWriteOffOfOperatingLeases>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_b6104c3bb9d54706a258c8a273fff0af"
      unitRef="U001">3200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20260101to20260331"
      decimals="-5"
      id="Fact_0c8bc34da66d4a17a100ad85665c318b"
      unitRef="U001">100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_5c7ad5c5b522465eb0b1df55f0905e9a"
      unitRef="U001">200000</us-gaap:DepreciationDepletionAndAmortization>
    <pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock
      contextRef="c20260101to20260331"
      id="Text_61818a45ed0f4be4bdea6f0a9863e926">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 16.5pt; margin-left: 0pt; text-align: left;"&gt;6. Accrued Expenses and Other Current Liabilities &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Accrued expenses and other current liabilities consisted of the following: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 52.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Professional fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;500&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;347 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Compensation and related benefits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,297&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,740&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,174&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt;"&gt;642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Divestiture fee due to Catalent&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;924&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;924&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$3,895&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$4,653&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
    <pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="c20260101to20260331"
      id="Text_079b562fb0f34a1799d1ed43f83dcbde">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 324pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 52.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 64.49pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 324pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;December&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Professional fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;500&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;347 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Compensation and related benefits&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,297&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;2,740&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;1,174&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt;"&gt;642&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Divestiture fee due to Catalent&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;924&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;924&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 324pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.72pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$3,895&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 64.49pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 18.5pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$4,653&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 324pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.64pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 64.49pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_1907e8ab81af45db8b2809a920076dbd"
      unitRef="U001">500000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_85ec014f58054d2987da1305c85debfa"
      unitRef="U001">347000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_cca50877b1f74c4cacd32d032514a019"
      unitRef="U001">1297000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_d87ce4b868bc4d889800b4049512c7b3"
      unitRef="U001">2740000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="c20260331"
      decimals="-3"
      id="Fact_1bff2efaa92448c19471ab49fbb6214b"
      unitRef="U001">1174000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="c20251231"
      decimals="-3"
      id="Fact_e76c86f3baf24424b81fb5e698977bb7"
      unitRef="U001">642000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedDivestitureFeesCurrent
      contextRef="c20260331"
      decimals="-3"
      id="Fact_b2ee8e67c6514b00af86fc3195e37629"
      unitRef="U001">924000</pasg:AccruedDivestitureFeesCurrent>
    <pasg:AccruedDivestitureFeesCurrent
      contextRef="c20251231"
      decimals="-3"
      id="Fact_2bd32c3e7841485d9fbcdb265812911b"
      unitRef="U001">924000</pasg:AccruedDivestitureFeesCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20260331"
      decimals="-3"
      id="Fact_366d793b61cc4f068ae36e01912f8ba1"
      unitRef="U001">3895000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="c20251231"
      decimals="-3"
      id="Fact_62ee0f1c7c454397bc5b3a900cdd0f12"
      unitRef="U001">4653000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="c20260101to20260331"
      id="Text_6740f125cb9846df93081ba6e95823ee">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;"&gt;7. Gemma License Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;31, 2024, the Company entered into a series of sublicense agreements
            with Gemma in connection with the outlicense of PBGM01 for the treatment of GM1 gangliosidosis, or GM1, PBKR03 for the treatment of Krabbe disease, or Krabbe, and PBML04 for the treatment of metachromatic leukodystrophy, or MLD, collectively
            the Outlicensed Programs, and such agreements, the Gemma Sublicenses. On May&#160;7, 2025, the Company agreed to amend each of the Gemma Sublicenses to revise certain financial terms related to the Outlicensed Programs, or the Amended Gemma
            Sublicenses. Pursuant to the Amended Gemma Sublicenses, the Company is entitled to receive (i) an aggregate total of $15.0 million in
            initial payments for licenses and clinical product supply, of which $5.0 million was previously received, $5.0 million of which was due in May&#160;2025, of which $2.5
            million has been received, and $5.0 million of which was due in March&#160;2026, and has not yet been received; (ii) an additional $5.0 million contingent on Gemma completing certain business milestones; (iii) up to an additional $114.0 million in development and commercial milestone payments; and (iv) single digit royalties as a percentage of annual worldwide net sales, in exchange for sublicenses
            to relevant intellectual property, transfer of regulatory dossiers and transfer of clinical trial materials and product supply related to the Outlicensed Programs. Gemma will be responsible for all payments due to the Trustees of &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;the University of Pennsylvania&#x2019;s, or Penn, under the Company&#x2019;s research,
            collaboration and licensing agreement with Penn, or the Penn License Agreement, related to the Outlicensed Programs. On July&#160;31, 2024, the Company also entered into a transition services agreement with Gemma, or the Transition Services
            Agreement, as amended by the First Amendment to the Transition Services Agreement, dated January&#160;31, 2025, pursuant to which, the Company provided transitional services at cost to Gemma through May&#160;31, 2025, and is entitled to reimbursement for
            transitional services performed retroactively from March&#160;1, 2024, related to the transfer of the Outlicensed Programs. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As Gemma has a limited history of operations, the Company will not recognize
            revenue under ASC 606 until the Company either (i) has received payment and there are no remaining obligations to transfer goods and services under the Amended Gemma Sublicenses and Transition Services Agreement (as payments received by Gemma
            are nonrefundable), or (ii) concludes that substantially all of the transaction price is collectible. As of March 31, 2026, the Company has received initial payments of $7.5 million associated with the aggregate $15.0 million of initial payments
            to be made under the Amended Gemma Sublicenses for licenses and clinical product supply and $4.8 million associated with the
            Transition Services Agreement and applied $1.5 million in amounts owed to Gemma for the Huntington&#x2019;s disease program against amounts
            due to the Company for transition services under these agreements. The Company recorded these amounts ($13.8 million) as
            non-refundable sublicense and transition services payments on the balance sheet as of March 31, 2026, as the criteria set forth above have not yet been met. &lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <pasg:UpfrontLicenseFeeReceivable
      contextRef="c20240731"
      decimals="-5"
      id="Fact_d721e387add64a879c7f51dae06e3c87"
      unitRef="U001">15000000</pasg:UpfrontLicenseFeeReceivable>
    <pasg:ProceedsFromNonRefundableSublicensePayments
      contextRef="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_47a55d363a9d4a5fa1df902812153907"
      unitRef="U001">5000000</pasg:ProceedsFromNonRefundableSublicensePayments>
    <pasg:LicenseFeeDueAndReceivable
      contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_ddb0b3a132c747f9919aede502cf26b2"
      unitRef="U001">5000000</pasg:LicenseFeeDueAndReceivable>
    <pasg:ProceedsFromShortTermLicenseFee
      contextRef="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_6e9eec9c1bee47899933c74e8c9ef125"
      unitRef="U001">2500000</pasg:ProceedsFromShortTermLicenseFee>
    <pasg:LongTermLicenseFeeDueAndReceivable
      contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_990cffc51caa4950a9e9b408211e54c9"
      unitRef="U001">5000000</pasg:LongTermLicenseFeeDueAndReceivable>
    <pasg:ContingentProceedsFromUponCompletionOfCertainBusinessMilestones
      contextRef="c20240731to20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_c3f5e81fc2d54bec92ca01906daf3f46"
      unitRef="U001">5000000</pasg:ContingentProceedsFromUponCompletionOfCertainBusinessMilestones>
    <pasg:MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable
      contextRef="c20240731_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_1f1af82c259a460099e800234e577b27"
      unitRef="U001">114000000</pasg:MaximumAdditionalAmountInDevelopmentAndCommercialMilestonePaymentsReceivable>
    <pasg:ProceedsFromNonRefundableSublicensePayments
      contextRef="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_2f610da5d1c84b9dba7f4638ab4f43b5"
      unitRef="U001">7500000</pasg:ProceedsFromNonRefundableSublicensePayments>
    <pasg:UpfrontLicenseFeeReceivable
      contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_769fadbb18274ef48374baffc5ce0550"
      unitRef="U001">15000000</pasg:UpfrontLicenseFeeReceivable>
    <pasg:ProceedsFromNonRefundableTransitionServicesPayments
      contextRef="c20260101to20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_34269150cf894e5b9aae1b2ff4b6d377"
      unitRef="U001">4800000</pasg:ProceedsFromNonRefundableTransitionServicesPayments>
    <pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments
      contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_d77c0d9d2b1946e38c03d9f3600fd988"
      unitRef="U001">1500000</pasg:PayableDecreaseFromAmountsReceivedTransitionServicesPayments>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_4bc309b0b56c495788390beb7d775d06"
      unitRef="U001">13800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="c20260101to20260331"
      id="Text_be025be6753c4d5e84fc6c429f004662">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;8. Severance &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;During the three months ended March 31, 2026, the Company did not record any severance and termination-related costs (see Note&#160;13). &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In January&#160;2025, the Company announced a workforce reduction to reduce
            operating expenses and to extend its cash runway. In connection with the announcement, the Company reduced headcount by approximately 55%.





            In accordance with ASC 420, &lt;span style="font-style: italic;"&gt;Exit and Disposal Activities&lt;/span&gt;, the Company recorded severance and termination-related costs of $0.4 million in general and administrative expenses and $1.3 million in
            research and development expenses for the three months ended March 31, 2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;As of March 31, 2026, there were no unpaid severance and termination-related costs. &lt;/div&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="c20260101to20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="-6"
      id="Fact_aee9ab359d934fa78a5c7d85071b3a9a"
      unitRef="U001">0</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="c20250101to20250131_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="2"
      id="Fact_767f6686be7e4cc9951951297fa245c2"
      unitRef="U004">0.55</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="-5"
      id="Fact_b4f0c40e22514232bcd8e94fe96ebb1a"
      unitRef="U001">400000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="-5"
      id="Fact_6c2700fb88dc4672aae472eefb71b003"
      unitRef="U001">1300000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserve
      contextRef="c20260331_RestructuringCostAndReserveAxis_EmployeeSeveranceMember"
      decimals="-6"
      id="Fact_f62e1f40e4d44e0cbb7491123707e518"
      unitRef="U001">0</us-gaap:RestructuringReserve>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20260101to20260331"
      id="Text_9197aad69ea541df9f9604e168bbb26c">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;9. Leases &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;2005 Market Street Lease Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company is party to a lease agreement for office space, or the 2005 Market
            Street Lease Agreement, in Philadelphia, Pennsylvania. Under the 2005 Market Street Lease Agreement, the Company leased approximately 37,000
            square feet. The 2005 Market Street Lease Agreement commenced in February&#160;2021 and is expected to expire in December&#160;2031. The Company has an option to extend the term of the 2005 Market Street Lease Agreement by two
            additional terms of five years each. The Company has an option to early terminate the 2005 Market Street Lease Agreement as of April&#160;2029, given notice is provided to the landlord no less than fifteen months prior to April&#160;2029. The optional extension and termination terms were not recognized as part of the Company&#x2019;s measurement of the ROU asset and operating lease liability
            as of March 31, 2026. During 2023, the Company subleased all of the space at 2005 Market Street as further described in Sublease Agreement A and Sublease Agreement B below. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Sublease Agreement A &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On August&#160;7, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee A, to sublease approximately 8,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement A. This sublease term began on November&#160;1, 2023, and continues through March&#160;31, 2029. In the event the Company does not elect its early termination option under the 2005 Market Street Lease Agreement, Sublessee A has an option to extend the sublease agreement through November&#160;30, 2031. The base sublease rent is $0.1 million per year and increases by 2.75% annually through the
            expiration of the agreement. Additionally, Sublessee A is required to pay the portion of the common area maintenance expenses, operating expenses and use and occupancy taxes which the Company is required to pay under the 2005 Market Street
            Lease Agreement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Pursuant to ASC Topic 842, &lt;span style="font-style: italic;"&gt;Leases&lt;/span&gt;,
            or ASC 842, the Company concluded the sublease is a separate lease, as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease
            Agreement as a lessee and in the same manner as prior to the execution of Sublease Agreement A. The Company accounted for Sublease Agreement A as the lessor, and concluded the lease qualified as an operating lease, as it did not meet the
            criteria of a sales-type or direct financing lease. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"&gt;Sublease Agreement B &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On September&#160;29, 2023, the Company entered into a sublease agreement with a
            counterparty, or Sublessee B, to sublease approximately 29,000 square feet of the 2005 Market Street Lease Agreement, or Sublease
            Agreement B. This sublease term began on March&#160;1, 2024 and Sublessee B has elected the option to extend the term of the sublease
            agreement through March&#160;31, 2029. The base sublease rent is $0.9 million per year for the entire term of the sublease. Additionally,
            Sublessee B is required to pay applicable use and occupancy taxes but is not obligated to make payments for operating expenses and common area maintenance expenses which the Company is required to pay under the 2005 Market Street Lease
            Agreement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Pursuant to ASC 842, the Company concluded the sublease is a separate lease,
            as the Company was not relieved of the primary obligation under the 2005 Market Street Lease Agreement. The Company continues to account for the 2005 Market Street Lease Agreement as a lessee and in the same manner as prior to the execution of
            the Sublease Agreement B. The Company accounted for Sublease Agreement B as the lessor and concluded the lease qualified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;"&gt;Laboratory Lease Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company was also party to a lease agreement for laboratory space, or the
            Laboratory Lease Agreement, in Hopewell, New Jersey. The Laboratory Lease Agreement commenced in March&#160;2021 and was expected to expire in March&#160;2036 with an option to extend the term of the Laboratory Lease Agreement by up to&#160;two five-year terms. On March&#160;4,
            2026, the Company entered into the Hopewell Lease Termination Agreement with the Landlord. Pursuant to the Hopewell Lease Termination Agreement, the Company agreed to pay the Landlord a termination fee of $4.8 million as well as accrued rent through February&#160;14, 2026. The Company has no further obligations under the Laboratory Lease Agreement
            subsequent to the effective date of the Hopewell Lease Termination Agreement. As of March&#160;4, 2026, the Company recognized a net gain of $0.6
            million on the lease termination comprised of a $3.8 million gain on the write-off of assets and liabilities for operating leases
            offset by a $3.2 million net loss on disposal of property and equipment, which was primarily leasehold improvements. As a result of
            the Hopewell Lease Termination Agreement, ROU assets decreased $9.4 million and lease liabilities for operating leases decreased $18.0 million during the three months ended March 31, 2026. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;"&gt;Hopewell Sublease Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On September&#160;4, 2024, the Company entered into a sublease agreement with a
            counterparty, or Sublessee C, to sublease approximately 3,200 square feet, or 5% of its approximately 62,000 square feet of leased
            laboratory space under the Laboratory Lease Agreement, or Hopewell Sublease Agreement. This sublease term began on September&#160;11, 2024 and was scheduled to expire on December&#160;31, 2029, with an option for Sublessee C to extend the term of the
            sublease through December&#160;2032. The base sublease rent was $0.1 million per year and increased by 2.5% annually through the expiration of the Hopewell Sublease Agreement. Additionally, Sublessee C was required to pay the portion of the common
            area maintenance expenses, operating expenses, and use and occupancy taxes that the Company was required to pay under the Laboratory Lease Agreement. In connection with the Hopewell Lease Termination Agreement on March&#160;4, 2026, the Hopewell
            Sublease Agreement was concurrently terminated. The Company has no ongoing sublease arrangements related to the Hopewell, New Jersey laboratory space. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following table summarizes future minimum lease payments for the Company&#x2019;s
            lessee operating lease, which comprises of the 2005 Market Street Lease Agreement. The below table does not include expected cash inflows related to Sublease Agreement A and Sublease Agreement B, as the Company was not relieved of its primary
            obligation under the 2005 Market Street Lease Agreement: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 420pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 30.83pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 420pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$&lt;span style="padding-left: 10.83pt;"&gt;900 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2028&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,270&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,308&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2030&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,348&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,388&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total undiscounted lease payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;7,447&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(1,692)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;5,755&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 420pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 30.83pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;The following table summarizes lease expense by lease type that was
            recognized during the three months ended March&#160;31, 2026 and 2025: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 118.96pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March 31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March 31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Operating lease expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;$476&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;880 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Variable lease expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 1.5pt;"&gt;326 &lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;538 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$802&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$1,418&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following table shows the weighted average discount rate and weighted
            average remaining lease term of the operating leases: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 118.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average discount rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;"&gt;9.0% &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;9.7% &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average remaining lease term (years)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;"&gt;5.8 &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"&gt;10.0 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The cash paid for amounts included in the measurement of the Company&#x2019;s
            operating lease liabilities for the three months ended March 31, 2026 and 2025 were $0.6 million and $1.0 million, respectively, recorded in operating cash flows. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The following table summarizes sublease income that was recognized in other
            income (expense), net during the three months ended March 31, 2026 and 2025: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 118.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Sublease rental income&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;$356&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;$367&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      decimals="0"
      id="Fact_b8db6bbe266d4815bbaa92aa9209bca3"
      unitRef="U005">37000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_3287ce56016d49cd9671859453abefec">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      decimals="0"
      id="Fact_0bee9a223a464a819bf749d6c47753d1"
      unitRef="U006">2</pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_182333cf5b64412582167b938bf83e1a">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_615a49a6c10b4490b4c22b851f5622a1">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease
      contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForOfficeSpaceMember"
      id="Fact_9c7a58674cc541c3a790492419d6de9b">P15M</pasg:LesseeOperatingLeaseNoticePeriodForTerminationOfLease>
    <us-gaap:AreaOfLand
      contextRef="c20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      decimals="0"
      id="Fact_530297f723c342daabc6164f17fc18c2"
      unitRef="U005">8000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      id="Fact_7b97529228e84a30a70fa0bf22ebefe8">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:SubleaseIncome
      contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      decimals="-5"
      id="Fact_c16a229e9f1f426eae79626ab2ea1f03"
      unitRef="U001">100000</us-gaap:SubleaseIncome>
    <pasg:PercentageOfAnnualIncreaseInSubleaseRent
      contextRef="c20230807to20230807_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementaMember"
      decimals="4"
      id="Fact_dca8a11809904b2fa366f34207f44221"
      unitRef="U004">0.0275</pasg:PercentageOfAnnualIncreaseInSubleaseRent>
    <us-gaap:AreaOfLand
      contextRef="c20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"
      decimals="0"
      id="Fact_7ec0bd04eff1479b827738a6630d064e"
      unitRef="U005">29000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"
      id="Fact_3ead746fc9b44234adb809338ac3de15">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:SubleaseIncome
      contextRef="c20230929to20230929_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementBMember"
      decimals="-5"
      id="Fact_ec13e867913345c7ac44700f0eb85e82"
      unitRef="U001">900000</us-gaap:SubleaseIncome>
    <pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions
      contextRef="c20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"
      decimals="0"
      id="Fact_040e5881400c45a4a27a053d62db93e1"
      unitRef="U006">2</pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions>
    <pasg:NewLeaseAgreementOperatingLeaseRenewalTerm
      contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember_RangeAxis_MaximumMember"
      id="Fact_8c9afa3885474ef3ab8fc3e2129bff4c">P5Y</pasg:NewLeaseAgreementOperatingLeaseRenewalTerm>
    <pasg:EarlyLeaseTerminationFee
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_5dfb43c1248e461d8842fe34064e24dc"
      unitRef="U001">4800000</pasg:EarlyLeaseTerminationFee>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_d830beb8dee94e6dafa72baa6d4547d9"
      unitRef="U001">600000</us-gaap:GainLossOnTerminationOfLease>
    <pasg:GainLossOnWriteOffOfOperatingLeases
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_3c8e9fe1a5c54e10ac1b99dcbfa26b6e"
      unitRef="U001">3800000</pasg:GainLossOnWriteOffOfOperatingLeases>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c20260304to20260304"
      decimals="-5"
      id="Fact_44b86cd44fe3413dac35002b57cb70fe"
      unitRef="U001">3200000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <pasg:RightOfUsePeriodDecreaseDueToLeaseTermination
      contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember"
      decimals="-5"
      id="Fact_3776b3e8fec2446faa427fff6937e18b"
      unitRef="U001">9400000</pasg:RightOfUsePeriodDecreaseDueToLeaseTermination>
    <pasg:LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination
      contextRef="c20260101to20260331_PropertyPlantAndEquipmentByTypeAxis_OperatingLeasesForLaboratorySpaceMember"
      decimals="-5"
      id="Fact_c160bcb70aee4989bd8d6dfeae9f3cea"
      unitRef="U001">18000000</pasg:LeaseLiabilityForOperatingLeasePeriodDecreaseDueToLeaseTermination>
    <pasg:AreaSubleased
      contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="0"
      id="Fact_4cf1e4cc4ba641bfb5ad26d9d29c1fb2"
      unitRef="U005">3200</pasg:AreaSubleased>
    <pasg:AreaOfLandSubleasedPercentage
      contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="2"
      id="Fact_e4dd28c9f08946eba9251c0781e96303"
      unitRef="U004">0.05</pasg:AreaOfLandSubleasedPercentage>
    <us-gaap:AreaOfLand
      contextRef="c20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="0"
      id="Fact_3eea5202f60d4290b8ad1d8c712c5e80"
      unitRef="U005">62000</us-gaap:AreaOfLand>
    <us-gaap:SubleaseIncome
      contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="-5"
      id="Fact_e2363683c0944824b71c3add3d072e81"
      unitRef="U001">100000</us-gaap:SubleaseIncome>
    <pasg:PercentageOfAnnualIncreaseInSubleaseRent
      contextRef="c20240904to20240904_PropertyPlantAndEquipmentByTypeAxis_SubleaseAgreementCMember"
      decimals="3"
      id="Fact_14a3452b86f641cb928be1c244b97b92"
      unitRef="U004">0.025</pasg:PercentageOfAnnualIncreaseInSubleaseRent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20260101to20260331"
      id="Text_13cd0d9e70eb49e6b37b6f379fb4b961">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 420pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 30.83pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 420pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;$&lt;span style="padding-left: 10.83pt;"&gt;900 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,233&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2028&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,270&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,308&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;2030&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,348&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,388&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total undiscounted lease payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;7,447&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(1,692)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 420pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total lease liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 8.59pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 30.83pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$&lt;/span&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;5,755&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 420pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 8.59pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 30.83pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20260331"
      decimals="-3"
      id="Fact_4b1e94dcaad448a2aa54b9a0ce83c085"
      unitRef="U001">900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20260331"
      decimals="-3"
      id="Fact_7647b0e7bd4e4027addd8406bba979c4"
      unitRef="U001">1233000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20260331"
      decimals="-3"
      id="Fact_28dba370fd474cd491304d997d8a61a4"
      unitRef="U001">1270000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20260331"
      decimals="-3"
      id="Fact_c19c0c4de1e94b30af9df827bad56223"
      unitRef="U001">1308000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20260331"
      decimals="-3"
      id="Fact_f0cce44f040644929acaf3b328aa54e3"
      unitRef="U001">1348000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <pasg:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="c20260331"
      decimals="-3"
      id="Fact_11940c42ca184781a12113f65f4abe25"
      unitRef="U001">1388000</pasg:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20260331"
      decimals="-3"
      id="Fact_7b416108109f441da01142339a1d3470"
      unitRef="U001">7447000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20260331"
      decimals="-3"
      id="Fact_4808fa4eca574b519fe5422173f34179"
      unitRef="U001">1692000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20260331"
      decimals="-3"
      id="Fact_828336aa6e554776b52a970921cc22b1"
      unitRef="U001">5755000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="c20260101to20260331"
      id="Text_fd8bf6aaa04c42f1b6386cd7317328e1">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 118.96pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March 31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March 31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Operating lease expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;$476&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"&gt;$&lt;span style="padding-left: 7.5pt;"&gt;880 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Variable lease expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid rgb(0, 0, 0); padding-bottom: 1.5pt;"&gt;326 &lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;538 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$802&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 12.73pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$1,418&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 118.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average discount rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;"&gt;9.0% &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;9.7% &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Weighted-average remaining lease term (years)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20.23pt; text-align: left;"&gt;5.8 &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 17.73pt; text-align: left;"&gt;10.0 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.52pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 118.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 118.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;March&#160;31, 2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Sublease rental income&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;$356&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.52pt; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 52.96pt; padding-top: 2.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 16.48pt; text-align: left;"&gt;$367&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.52pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 52.96pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_3bdc1dc74dbc4be28233ab8093e88b20"
      unitRef="U001">476000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_2e489b19bda541a28b240741d82b11ee"
      unitRef="U001">880000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_e4c39687eabd4a54ab7e13601eab3491"
      unitRef="U001">326000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_b79439e5e0ce417a839c5a5d23f15e91"
      unitRef="U001">538000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_023a2bb8d1b44382a3f0f7dc6cace75c"
      unitRef="U001">802000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_f94787c4bb90451f944051bdaf1653b8"
      unitRef="U001">1418000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20260331"
      decimals="3"
      id="Fact_2f1ba15a7db44d27804f7879a7d616ae"
      unitRef="U004">0.09</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20250331"
      decimals="3"
      id="Fact_9da1647fab19446f84156846e8b04a22"
      unitRef="U004">0.097</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20260331"
      id="Fact_edfd780a8c2a49258f6538a5f55c1a1f">P5Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20250331"
      id="Fact_b2b03d86cc0141f9a69bc39ef14524f5">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="c20260101to20260331"
      decimals="-5"
      id="Fact_ea47e46017bc42bba0ac08183a289cd8"
      unitRef="U001">600000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="c20250101to20250331"
      decimals="-5"
      id="Fact_5c81ea4924ed48c49fd7b3f8c13b6b7f"
      unitRef="U001">1000000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:SubleaseIncome
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_e479181a948b4296807e7d5b742daddf"
      unitRef="U001">356000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_fe6c4dfd9e8246f88c3d38a48c7b4830"
      unitRef="U001">367000</us-gaap:SubleaseIncome>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20260101to20260331"
      id="Text_fe20e307efce454ea5e2c2713bf1b014">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;"&gt;10. Commitments and Contingencies &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 7pt; margin-left: 0pt; text-align: left;"&gt;Amended and Restated Research, Collaboration
            and License Arrangement with Penn &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In connection with the transfer of the Outlicensed Programs (GM1, Krabbe, and
            MLD), the Company restructured its research, collaboration and license agreement with Penn, as amended, previously the Penn Agreement and now referred to as the Penn License Agreement. Pursuant to the Penn License Agreement, as of July&#160;31,
            2024, the Company (i)&#160;terminated the funding of discovery research programs; (ii) terminated the research and exploratory research programs; (iii) terminated the remaining eight options it had for future central nervous system, or CNS,
            indications; (iv)&#160;terminated the transaction fee payable to Penn in the event of certain corporate transactions; and (v) retained its current exclusive and non-exclusive licenses to its programs in FTD, GM1, Krabbe and MLD and certain platform
            technologies resulting from the discovery programs that it funded. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;For the Company&#x2019;s licensed programs in FTD, GM1, Krabbe and MLD, the Penn
            License Agreement requires that it make payments of up to $16.5 million per product candidate. Each payment will be due upon the
            achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications.
            In addition, on a product-by-product basis, the Company is obligated to make up to $55.0 million in sales milestone payments on each
            licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, other than the Amended Gemma Sublicenses, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn
            License Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such
            licensed product in such country, and (ii) the expiration of the royalty period. Pursuant to the Amended Gemma Sublicenses, Gemma is responsible for the payments to Penn related to the Outlicensed Programs. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"&gt;Gemma - Research, Collaboration and
            License Agreement &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In connection with the transfer of the Outlicensed Programs, on July&#160;31, 2024,
            the Company entered into a research, collaboration and license agreement with Gemma, or the Gemma Collaboration Agreement. Pursuant to the Gemma Collaboration Agreement, (i) Gemma will conduct certain preclinical and Investigational New Drug,
            or IND, enabling work for the Company&#x2019;s active research program in Huntington&#x2019;s disease and a currently paused research program in Temporal Lobe Epilepsy, or TLE, which were previously being conducted by Penn under the Penn Agreement and
            (ii)&#160;Gemma will grant the Company options to conduct mutually-agreed research programs in four new CNS indications. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Gemma Collaboration Agreement requires the Company to make payments of up
            to (i) $16.5 million per product candidate in the aggregate for Huntington&#x2019;s disease and any future CNS indications available to the
            Company under its four options and (ii) $39.0 million per product candidate in the aggregate arising from the research program for
            TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development
            milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0
            million in sales milestone payments on each licensed product based on annual worldwide net sales of the licensed product in excess of defined thresholds. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Upon successful commercialization of a product using the licensed technology,
            the Company is obligated to pay to Gemma, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits percentage on annual worldwide net sales of such
            licensed product. In addition, the Company is obligated to pay to Gemma a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Gemma Collaboration Agreement. The agreement will
            expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i) the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and
            (ii) the expiration of the royalty period. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;If the Company was to exercise any of the four options under the Gemma
            Collaboration Agreement, it would owe Gemma a non-refundable aggregate fee of $1.0 million per product indication, with $0.5 million due upfront and another $0.5
            million fee owed upon a further developmental milestone. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has also entered into the Amended Gemma Sublicenses and Transition
            Services Agreement as described in Note&#160;7. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Amended Gemma Sublicenses, the Transition Services Agreement, and the
            Gemma Collaboration Agreement are collectively referred to as the Outlicense Transaction Agreements. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"&gt;Catalent Agreements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has entered into a collaboration agreement, and a development
            services and clinical supply agreement, or the Amended Catalent Agreements, with Catalent Maryland, a unit of Catalent, Inc. acquired by Novo Holdings A/S, or Catalent, to secure clinical scale manufacturing capacity for batches of active
            pharmaceutical ingredients for the Company&#x2019;s gene therapy product candidates. Under the terms of the Amended Catalent Agreements, Catalent agreed to manufacture batches of drug product for the Company&#x2019;s gene therapy product candidates. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Amended Catalent Agreements remain in effect until November&#160;6, 2030, and
            establish a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company&#x2019;s adeno-associated virus delivery therapeutic product candidates for the treatment of FTD
            and GM1. The limited exclusive relationship under the Amended Catalent Agreements converts to a non-exclusive relationship (i) in the event Catalent fails to meet certain performance standards and (ii) following certain conditional events
            related to the divestiture by the Company of either FTD or GM1, in which case, if such events occur, the Company would pay Catalent certain fees. In the event of certain transactions, the Company may terminate the Amended Catalent Agreements
            for convenience with respect to such products, in which case, the Company would pay Catalent a certain termination fee. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The outlicense and completed transition of GM1 to Gemma under the Outlicense
            Transaction Agreements is deemed by Catalent to be a divestiture under the Amended Catalent Agreements. As such, the Company is required to make payment of $0.9 million to Catalent which is accrued as of March 31, 2026. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"&gt;Litigation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In the normal course of business, the Company from time to time is named as a
            party to legal claims and actions. The Company records a loss contingency reserve for a legal proceeding when the potential loss is considered probable and can be reasonably estimated. The Company has not recorded any amounts for loss contingencies as of March 31, 2026. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company is the defendant in litigation with a former employee, who filed a
            lawsuit in the Court of Common Pleas of Philadelphia County asserting claims for breach of contract and violation of the Pennsylvania Wage Payment and Collection Law. The plaintiff, who was terminated from their employment in 2019, contended
            that the Company entered into a binding settlement agreement in February&#160;2020 under which he was to receive shares of company stock and additional compensation. Specifically, he contended that before the announcement of the Company&#x2019;s initial
            public offering in February&#160;2020, he was promised 150,000 shares of stock as part of the settlement, and that those shares were not
            subject to the reverse stock split that was implemented for all shareholders. The Company responded that the shares offered in settlement negotiations in 2020 were to be subject to the reverse split, and that had the settlement been finalized,
            the plaintiff would have been entitled to 33,836 shares (1,692 shares adjusted for the Reverse Stock Split effected in 2025). A trial in this case was held in October&#160;2024. The jury found that an agreement was reached, but it agreed with the
            Company that any shares to be awarded to the plaintiff were subject to the reverse split. The jury awarded damages in an amount that was roughly equal to what the Company contended had been offered to the plaintiff before the initial public
            offering. Both sides then challenged the verdict, and on December&#160;12, 2024, the judge who presided over the trial delivered a judgment in the Company&#x2019;s favor, finding that no binding agreement was reached and that the plaintiff was not entitled
            to recover any damages. On December&#160;23, 2024, the plaintiff filed an appeal with the Superior Court of Pennsylvania. On September&#160;25, 2025, the appellate co&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;urt affirmed the entry of judgment in favor of the Company and on October&#160;7, 2025, the plaintiff filed an Application for Reargument to the
              Superior Court of Pennsylvania. In December&#160;2025, the plaintiff petitioned for review of their appeal to the Pennsylvania Supreme Court. The Company intends to continue to defend against this claim. &lt;/span&gt;&lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Other than the above, the Company is not presently a party to any legal
            proceedings that, in the opinion of management, would, if decided against the Company, have a material adverse effect on the Company&#x2019;s business. Regardless of outcome, litigation can have an adverse impact on the Company due to defense and
            settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 13.5pt; margin-left: 0pt; text-align: left;"&gt;Employment Agreements &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has employment agreements with certain key personnel providing for
            up to 18 months of salary continuation, up to 150% of target annual bonus amounts, and acceleration of vesting in stock-based
            compensation awards in certain circumstances. &lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone
      contextRef="c20260331_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember"
      decimals="-5"
      id="Fact_feac6bc678d642e1ad4f073912607e1c"
      unitRef="U001">16500000</pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementSalesMilestonePaymentsPayable
      contextRef="c20260331_TypeOfArrangementAxis_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember"
      decimals="-5"
      id="Fact_9a22ab6d6d8b428e8aa0bd36d8b24559"
      unitRef="U001">55000000</pasg:CollaborationAgreementSalesMilestonePaymentsPayable>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone
      contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_3d5a6dd3557346adaf511f6e73a1d121"
      unitRef="U001">16500000</pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone
      contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_2f288be71db6437e912ad1cd2e6b8b2d"
      unitRef="U001">39000000</pasg:CollaborationAgreementAmountPayablePerProductCandidateUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementSalesMilestonePaymentsPayable
      contextRef="c20260331_TypeOfArrangementAxis_ArrangementWithGemmaBiotherapeuticsIncMember"
      decimals="-5"
      id="Fact_33dadb7e92b3424ca778bcac7d87f5a2"
      unitRef="U001">55000000</pasg:CollaborationAgreementSalesMilestonePaymentsPayable>
    <pasg:NonRefundableAggregateFeesPayablePerProductIndication
      contextRef="c20260331"
      decimals="-5"
      id="Fact_4aaaf0040153465c984bb7e12f3dbec4"
      unitRef="U001">1000000</pasg:NonRefundableAggregateFeesPayablePerProductIndication>
    <pasg:NonRefundableUpfrontFeesPayablePerProductIndication
      contextRef="c20260331"
      decimals="-5"
      id="Fact_d5cccc6390d34574872145dabde45655"
      unitRef="U001">500000</pasg:NonRefundableUpfrontFeesPayablePerProductIndication>
    <pasg:NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone
      contextRef="c20260331"
      decimals="-5"
      id="Fact_7b2fc4a170604f31902119b897be6bd6"
      unitRef="U001">500000</pasg:NonRefundableFeesPayablePerProductIndicationUponDevelopmentalMilestone>
    <pasg:AccruedDivestitureFeesCurrent
      contextRef="c20260331"
      decimals="-5"
      id="Fact_60a7f80684d24054b0ad1c65b357994b"
      unitRef="U001">900000</pasg:AccruedDivestitureFeesCurrent>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="c20260331"
      decimals="-6"
      id="Fact_ff1c236195c24eafb1e1916b77dc5813"
      unitRef="U001">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <pasg:StockIssuedDuringPeriodSettlementOfLitigation
      contextRef="c20200201to20200229"
      decimals="0"
      id="Fact_9d8cd52857db497d8beb5565e79b3065"
      unitRef="U003">150000</pasg:StockIssuedDuringPeriodSettlementOfLitigation>
    <pasg:LossContingencySharesAgreedByDefendant
      contextRef="c20200201to20200229"
      decimals="0"
      id="Fact_d10ca8f024ea4f9793496d0d26f8d831"
      unitRef="U003">33836</pasg:LossContingencySharesAgreedByDefendant>
    <pasg:LossContingencySharesAgreedByDefendant
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_2d59f3fb9bfb401d924f566e722a5698"
      unitRef="U003">1692</pasg:LossContingencySharesAgreedByDefendant>
    <pasg:PercentageOfTargetAnnualBonusAmounts
      contextRef="c20260101to20260331"
      decimals="2"
      id="Fact_80298b39b5f04a53aa113e7d5c78251a"
      unitRef="U004">1.50</pasg:PercentageOfTargetAnnualBonusAmounts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="c20260101to20260331"
      id="Text_ad515e99e2e146ed801f2975eb7781c0">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;"&gt;11. Stockholder&#x2019;s Equity and Share-Based Compensation &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On July&#160;14, 2025, the Company effected the Reverse Stock Split. The Reverse
            Stock Split did not reduce the number of authorized shares of the common stock and did not change the par value of the common stock. In addition, proportionate adjustments were made to the number of shares of common stock available for issuance
            under the Company&#x2019;s equity inducement and incentive plans; the number of shares underlying, and the exercise prices of outstanding equity awards under such plans. All share information in these financial statements has been adjusted for this
            Reverse Stock Split. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 17pt; margin-left: 0pt; text-align: left;"&gt;Equity Incentive Plan &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity
            Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The total number of shares authorized under the Incentive Plan as of March 31,
            2026 was 1,106,739. Additionally, 204,732
            shares previously issued under the 2018 Plan which were forfeited are available for issuance under the Incentive Plan. As of March 31, 2026, 405,163
            shares were available for future grants under the Incentive Plan. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January&#160;1st of each
            year, commencing on January&#160;1, 2021 and continuing for ten years, in an amount equal to five percent of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31st of the preceding calendar year, subject to the discretion of the board
            of directors to determine a lesser number of shares shall be added for such year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 159,141 and 155,155 shares in January&#160;2026 and 2025,
            respectively. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Incentive Plan provides for the granting of common stock, incentive stock
            options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options awarded to date under the
            Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Inducement Plan was approved by the Company&#x2019;s board of directors in
            July&#160;2021. The total number of shares authorized under the Inducement Plan as of March 31, 2026 was 125,000. Of this amount, 87,634 shares were available for future grants as of March 31, 2026. The Inducement Plan provides for the granting of nonqualified stock options and
            restricted stock awards to employees hired by the Company, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options awarded to date under the Inducement Plan vest based on requisite service period and have a term of ten years. The Company&#x2019;s restricted stock units awarded to date under the Inducement Plan vest based on requisite service period and have a term
            based on each award agreement. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company measures share-based awards at their grant-date fair value and
            records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations and
            comprehensive loss for the period presented:&lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;$142&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;$244 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;414&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;614&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$556&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$858&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.5pt; margin-left: 0pt; text-align: left;"&gt;The following table summarizes stock option activity for the three months ended
            March 31, 2026: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;exercise price&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;per share&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;remaining&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;contractual&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;term (years) &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at January&#160;1, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;658,973&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$44.20&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.1&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;191,510&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;7.64&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt;"&gt;(4,376)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;10.99&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;846,107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$40.13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.5&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested and exercisable at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;387,675&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$74.20&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;5.6&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested or expected to vest at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;846,107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$40.13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.5&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The weighted average grant date fair value of options granted was $5.81 and $6.20 for the three months
            ended March&#160;31, 2026 and 2025, respectively. As of March 31, 2026, the total unrecognized compensation expense related to unvested stock option awards was $3.6 million, which the Company expects to recognize over a weighted average period of 2.6
            years. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The aggregate intrinsic value of options outstanding was $0.1 million at March 31, 2026 and was de minimis at March&#160;31, 2025. The aggregate intrinsic value of options exercised and options exercisable were
            each de minimis during the three months ended March 31, 2026 and 2025. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;The fair value of each option was estimated on the date of grant using the
            weighted average assumptions in the table below: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;92.4%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;93.8%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;3.9%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;4.1%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;5.8 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;6.0 years &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Restricted Stock Units &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company issues RSUs to employees that vest over periods of time as
            determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value of the RSUs is equal to the fair market value of the Company&#x2019;s common stock on the date of grant. Compensation expense is
            recognized on a straight-line basis over the vesting period of the RSUs. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The following table summarizes activity related to RSU awards during the three
            months ended March 31, 2026: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 60.58pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 69.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted average &lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;grant date fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at January&#160;1, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;50,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$10.52 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;(25,000)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5.37pt;"&gt;11.70&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;25,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$11.70&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;As of March 31, 2026, the total unrecognized expense related to all RSUs was $0.2 million, which the Company expects to recognize over a weighted-average period of 0.8 years. &lt;/div&gt;

&lt;div class="BRDSX_h3" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;"&gt;Employee Stock Purchase Plan &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective
            on February&#160;28, 2020. The ESPP authorizes the issuance of up to 99,088 shares of the Company&#x2019;s common stock. Of this amount, 59,103 were available for future grants as of March 31, 2026. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to
            rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for ten years, in an amount
            equal to one percent of the total number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding
            calendar year, subject to the discretion of the board of directors to determine a lesser number of shares shall be added for such year. As a result, on January&#160;1, 2026 and 2025, subject to the discretion of the board of directors, the shares
            authorized for issuance under the ESPP were not increased. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Under the ESPP, eligible employees can purchase the Company&#x2019;s common stock
            through accumulated payroll deductions at such times as are established by the board of directors&#x2019; Compensation Committee. Eligible employees may purchase the Company&#x2019;s common stock at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first day of the offering period or on the last day of the offering period. The offering
            periods under the ESPP have a duration of six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000
            worth of the Company&#x2019;s common stock for each calendar year in which such right is outstanding or purchase more than 200 shares of
            the Company&#x2019;s common stock in any single offering period. Beginning in May&#160;2026, the limit will increase from 200 shares to 2,000 shares in any single offering period, not to exceed $25,000 in any calendar year. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;In accordance with the guidance in ASC Topic 718-50,&lt;span style="font-style: italic;"&gt; Compensation &#x2013; Stock Compensation&lt;/span&gt;, the ability to purchase shares of the Company&#x2019;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the
            purchase date) represents an option and&lt;span style="font-weight: bold;"&gt;, &lt;/span&gt;therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#x2019;s grant-date fair
            value as estimated by applying the Black-Scholes option-pricing model and is recognized over the withholding period. No
            share-based compensation expense related to the ESPP was recorded during the three months ended March&#160;31, 2026 and 2025. &lt;/div&gt;
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pasg:NumberOfEquityIncentivePlans
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_2a58113f0b1349ba92b432995f065c62"
      unitRef="U007">3</pasg:NumberOfEquityIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20260331_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_e99b45a98fbf4f1d8ac73b95c5b38dde"
      unitRef="U003">1106739</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20260331_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_71fac20ef33b4ae8a73f1caca75e6c9e"
      unitRef="U003">204732</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20260331_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_5e5cebfad00541098d44e01b71b03b64"
      unitRef="U003">405163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_34166b18522e4978a9533c7294886e47">P10Y</pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease
      contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember"
      decimals="2"
      id="Fact_825535d307514b1483afa0b767ba9a9b"
      unitRef="U004">0.05</pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="c20260101to20260131_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_7d26f85d3e994537aafe1ae6ede70f43"
      unitRef="U003">159141</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="c20250101to20250131_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_2b33ccb23d7d49609915e4d28a2e5ef1"
      unitRef="U003">155155</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_2685e68de1a949c28bb3e55ba79ef614">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm
      contextRef="c20260101to20260331_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_18f02e80074e474bac3d4c0059d3924e">P10Y</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20260331_PlanNameAxis_EquityInducementPlan2021Member"
      decimals="0"
      id="Fact_88f7c0964749400cba81dfed0c08f92f"
      unitRef="U003">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20260331_PlanNameAxis_EquityInducementPlan2021Member"
      decimals="0"
      id="Fact_5c4ca4b6a9bf4c0cb0596a55ce504018"
      unitRef="U003">87634</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm
      contextRef="c20260101to20260331_PlanNameAxis_EquityInducementPlan2021Member"
      id="Fact_f73b5682026941038fa437674c858847">P10Y</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20260101to20260331"
      id="Text_0b3ff716410e4f2a9b3c18c24982954e">
&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;$142&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;$244 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;414&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;614&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$556&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 15.92pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$858&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.85pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.84pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20260101to20260331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_0e48072e30c0457d991f10fb38395128"
      unitRef="U001">142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20250331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_41df688023ea410eadebe79e4b0a0cc0"
      unitRef="U001">244000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20260101to20260331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_3ecfcf4ffd374fa4b1c8c0684528fd8b"
      unitRef="U001">414000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20250331_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact_f075694dec9c434bad6680e58bd73c3b"
      unitRef="U001">614000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20260101to20260331"
      decimals="-3"
      id="Fact_ed2ecf6d19c74e378c1f900c75899ba5"
      unitRef="U001">556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20250331"
      decimals="-3"
      id="Fact_d72d1fdff783451ea3b1f3d1d56fdb28"
      unitRef="U001">858000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20260101to20260331"
      id="Text_c08f539b44794ae0be2ad8207fcae901">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;exercise price&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;per share&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;average&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;remaining&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;contractual&lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;term (years) &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at January&#160;1, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;658,973&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$44.20&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.1&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;191,510&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 10pt;"&gt;7.64&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Exercised&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="padding-left: 6.67pt;"&gt;(4,376)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt;"&gt;10.99&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="padding-left: 22.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Outstanding at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;846,107&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$40.13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 2.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.5&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested and exercisable at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;387,675&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$74.20&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; padding-bottom: 3.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;5.6&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 3.26pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested or expected to vest at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 36.95pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 2.23pt; text-align: left;"&gt;846,107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 46.28pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.39pt; text-align: left;"&gt;$40.13&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 41.96pt; padding-top: 3.26pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.74pt; text-align: left;"&gt;7.5&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 36.95pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.14pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 46.28pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 5.13pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 41.96pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20251231"
      decimals="0"
      id="Fact_47d5665cbf3c419da30c30823d8ea926"
      unitRef="U003">658973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20251231"
      decimals="2"
      id="Fact_716c2ea03f9040d19e4dff99ec7a1175"
      unitRef="U002">44.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20250101to20251231"
      id="Fact_3ebdc1ee5a6245c1a4f3ef70abf31622">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_09eb3b98306a4ae1934a1b34afe56e4f"
      unitRef="U003">191510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20260101to20260331"
      decimals="2"
      id="Fact_f42f836bd76f488b84f2e61ce450c135"
      unitRef="U002">7.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c20260101to20260331"
      decimals="0"
      id="Fact_2ae5f659115a4d2c837314e3ce3f6068"
      unitRef="U003">4376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20260101to20260331"
      decimals="2"
      id="Fact_4ae32069cd6648539ed4698a924d2ac9"
      unitRef="U002">10.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20260331"
      decimals="0"
      id="Fact_8d4bb9ab37d64555b9b57b01efac95a3"
      unitRef="U003">846107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20260331"
      decimals="2"
      id="Fact_2d5585421a6644ffad761fe8023c6e0e"
      unitRef="U002">40.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20260101to20260331"
      id="Fact_e27bcd744be141c78b55a3a70602b810">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20260331"
      decimals="0"
      id="Fact_d1b0ff019f0e4689ada4032fba084354"
      unitRef="U003">387675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20260331"
      decimals="2"
      id="Fact_d2394f763baf4108a8f9e78b78371c2e"
      unitRef="U002">74.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20260101to20260331"
      id="Fact_74fbc1efca2e4391ba22c08ccf89c8b6">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20260331"
      decimals="0"
      id="Fact_9f24968af9bb4b4880fc4a55db82e9e4"
      unitRef="U003">846107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20260331"
      decimals="2"
      id="Fact_5d2776ad0f1d4142acbe21cfd12c2fcd"
      unitRef="U002">40.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20260101to20260331"
      id="Fact_4a85db7c7b5c47a4911c43b5b45eae20">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20260101to20260331"
      decimals="2"
      id="Fact_a4a73941316e419aa44a4bef1bc0dfc1"
      unitRef="U002">5.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20250101to20250331"
      decimals="2"
      id="Fact_62ecb9cb986a406cbf885986634cebf8"
      unitRef="U002">6.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20260331"
      decimals="-5"
      id="Fact_95890eea2e4342f79b29844136bb7404"
      unitRef="U001">3600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20260101to20260331"
      id="Fact_08c0ae6b9b754b7d904fa264db0e44b2">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20260101to20260331"
      id="Fact_57577a0471e242aa8f1a194eb44c4f7c">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20260331"
      decimals="-5"
      id="Fact_ceded439fb6c47ca99e586c59efd40dd"
      unitRef="U001">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20260101to20260331"
      id="Text_9e91f614c71d4b6cb3438a13756da5f9">
&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;92.4%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;93.8%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;3.9%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;4.1%&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;5.8 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;6.0 years &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Expected dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.85pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 51.84pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;"&gt;&#x2014;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 51.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_994ec3ae968141ebb9db854f723c5ac2"
      unitRef="U004">0.924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_4e5353bf9a3549f8b945862c878f00eb"
      unitRef="U004">0.938</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_737afc3b303b46bb9b6ea9068f5dd39f"
      unitRef="U004">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_83855d5969ed45d5bc7c438749a9ef4c"
      unitRef="U004">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20260101to20260331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_1bd70ae9e4914bd498db52766bcf52d5">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20250101to20250331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_4aed6500676b44e79ac1d6cc9296c884">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="c20260101to20260331"
      id="Text_d87b4b9f2e004776a61a102db1ddc619">
&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 312pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 60.58pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 69.84pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 312pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Number of shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Weighted average &lt;br/&gt;
                  &lt;/div&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;grant date fair value &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at January&#160;1, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt;"&gt;50,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$10.52 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;(25,000)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 5.37pt;"&gt;11.70&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;&lt;span style="padding-left: 17.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 312pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Unvested balance at March&#160;31, 2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 60.58pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 14.87pt; text-align: left;"&gt;&lt;span style="padding-left: 3.33pt; border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;25,000&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 69.84pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 21.17pt; text-align: left;"&gt;$11.70&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 312pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.4pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 60.58pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 6.39pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 69.84pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_c57921ca7f5a465cbb337557cbd0b319"
      unitRef="U003">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20251231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_b741a79e011d4861a50c0953a90aeb58"
      unitRef="U002">10.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_dbd3f842b47541a881e2aefec0f659ef"
      unitRef="U003">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_c66a157d3ee34ed3a4adaa470bdaec9d"
      unitRef="U002">11.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_bd1fae84ce08459aa6a2484b5a4956ff"
      unitRef="U003">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_e8ee539028a3470d82efb3d6228d6baa"
      unitRef="U002">11.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_f54ee35392674129a6fe5dd5b67e8bec"
      unitRef="U001">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20260101to20260331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      id="Fact_01f8a434997945efa8f1b7ecebefe9df">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_ba4c74a37d6f4c71989cac83c8d04b3f"
      unitRef="U003">99088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20260331_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_6776f1af908f4bd4919070c16fbb6052"
      unitRef="U003">59103</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      id="Fact_9c911b0cd506418d9ae319d90989df88">P10Y</pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_4e54c823e31d43018f6f953e601476c1"
      unitRef="U004">0.01</pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding>
    <pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_8799123dba9249fcad58511d4a3a3788"
      unitRef="U004">0.85</pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage>
    <pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_aaa2d91a2e134f9cb72db425c35cd487"
      unitRef="U004">0.15</pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage>
    <pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased
      contextRef="c20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_2da43c57fdac48bcad3511dc17ed9185"
      unitRef="U001">25000</pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_642c949577c34b2a9575d957b46bc896"
      unitRef="U003">200</pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased
      contextRef="c20200228to20200228_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_dff1908d5f6545bebcebe563ddc57c19"
      unitRef="U003">200</pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased
      contextRef="c20260501to20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_9d224bd754c64472bd774ac4de059739"
      unitRef="U003">2000</pasg:EmployeeStockPurchasePlanThresholdNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased
      contextRef="c20260531_PlanNameAxis_EmployeeStockPurchasePlanMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_e9cdbc14166241cdb74bbd44a790d0a1"
      unitRef="U001">25000</pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20250101to20250331_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="Fact_8a044c6ae3b24f599b612a0d35aaa128"
      unitRef="U001">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20260101to20260331_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="Fact_4aa2144f0fa2412081929b93ffad0840"
      unitRef="U001">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20260101to20260331"
      id="Text_b3d57ceda17f4e5fb5f3483971688bcc">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;"&gt;12. Segment Reporting &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;Operating segments are defined as components of an enterprise which engages in
            business activities from which it may recognize revenues and incur expenses about which separate discrete information is available for evaluation by the chief operating decision maker, or CODM, in deciding how to allocate resources and in
            assessing performance. The Company operates in a &lt;span style="-sec-ix-hidden:Fact_54f55c66f3b44146b30493895e843cea"&gt;single&lt;/span&gt; reportable segment, developing and advancing genetic medicines designed to
            target critical underlying pathology of neurodegenerative diseases. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The accounting policies of the single segment are the same as those described
            in the summary of significant accounting policies in the Company&#x2019;s 2025 Annual Report filed on Form&#160;10-K. The Company&#x2019;s CODM is its chief executive officer. The measure of segment assets is reported on the balance sheet as total assets. All
            assets are located within the United States. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;The CODM uses net loss as reported on the Company&#x2019;s statement of operations to
            assess the Company&#x2019;s performance. The CODM also uses cash forecasts in deciding where to invest or expand operations within the business. In these cash forecasts, research and development expenses and general and administrative expenses exclude
            certain non-cash items such as share-based compensation and depreciation and amortization expenses. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt;The following table summarizes significant segment expenses: &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"&gt; &lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;$&lt;span style="padding-left: 3.33pt;"&gt;1,458&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;$&lt;span style="padding-left: 8.33pt;"&gt;3,589 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;2,432&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;3,794 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;142&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;244 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;61&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;110 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total research and development expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,093&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;7,737 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,891&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;2,790 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;2,415&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;2,603 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;414&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;614 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;67&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;78 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total general and administrative expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,787&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,085 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Impairment of long-lived assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;2,637 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Net gain on lease termination&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(633)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(8,247)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(16,459)&lt;/span&gt;&lt;span style="padding-bottom: 1.5pt;"&gt; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other income (expense), net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;688&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,054 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$(7,559)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$(15,405)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 49.35pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 54.34pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"&gt;The components of Other (income) expense, net are further described in Note&#160;3 to
            the financial statements. &lt;/div&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="c20260101to20260331"
      id="Text_4d9727421a81487994f3e25bd39a759f">
&lt;table cellpadding="0" cellspacing="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto; border-spacing: 0;"&gt;


  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 6pt; width: 336pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 6pt; width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="height: 6pt; width: 117.85pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="4" style="width: 117.85pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;Three Months Ended March&#160;31, &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_header"&gt;

    &lt;td style="width: 336pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;(in thousands)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2026&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; border-bottom: none; white-space: nowrap;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.08pt; padding-bottom: 2.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;"&gt;2025 &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Research and development &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;$&lt;span style="padding-left: 3.33pt;"&gt;1,458&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;$&lt;span style="padding-left: 8.33pt;"&gt;3,589 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;2,432&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;3,794 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;142&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;244 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;61&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 21.2pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;110 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total research and development expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,093&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;7,737 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;General and administrative &lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Wages, benefits, and other payroll&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;1,891&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;2,790 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Third-party costs&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt;"&gt;2,415&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;2,603 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Share-based compensation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt;"&gt;414&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;614 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;"&gt;Depreciation and amortization&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;67&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;78 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Total general and administrative expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 8.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;4,787&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;6,085 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Impairment of long-lived assets&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 20.83pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt;"&gt;2,637 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Net gain on lease termination&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 12.5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(633)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 1.01pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 25.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;&#x2014; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Loss from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(8,247)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 5pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;(16,459)&lt;/span&gt;&lt;span style="padding-bottom: 1.5pt;"&gt; &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: left; vertical-align: bottom;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Other income (expense), net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 15.83pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;688&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; padding-bottom: 2.63pt; text-align: center; vertical-align: bottom; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="padding-left: 13.33pt; border-bottom: 1pt solid #000000; padding-bottom: 1.5pt;"&gt;1,054 &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="width: 336pt; padding-top: 2.26pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"&gt;Net loss&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 49.35pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$(7,559)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="width: 54.34pt; padding-top: 2.26pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"&gt;
                  &lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 9.25pt; text-align: left;"&gt;&lt;span style="border-bottom: 3pt double #000000; padding-bottom: 0.5pt;"&gt;$(15,405)&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr class="BRDSX_boxspacer"&gt;

    &lt;td style="height: 2.75pt; width: 336pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 49.35pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 7.08pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="height: 2.75pt; width: 54.34pt; background-color: #CCEEFF;"&gt;
                  &lt;div style="font-size: 1pt;"&gt;&#x2002;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <pasg:ResearchAndDevelopmentLaborAndRelatedExpenses
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_6fcdf625ea22434c9d0aaaa8241c009f"
      unitRef="U001">1458000</pasg:ResearchAndDevelopmentLaborAndRelatedExpenses>
    <pasg:ResearchAndDevelopmentLaborAndRelatedExpenses
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_e13382fd4c0d43a7b6562457929dcd84"
      unitRef="U001">3589000</pasg:ResearchAndDevelopmentLaborAndRelatedExpenses>
    <pasg:ResearchAndDevelopmentThirdPartyCosts
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_e43f6b3435304cb1aabcfd6d84fa65a7"
      unitRef="U001">2432000</pasg:ResearchAndDevelopmentThirdPartyCosts>
    <pasg:ResearchAndDevelopmentThirdPartyCosts
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_5dc5ea02ee3a4fe69fed6bc3a3276d66"
      unitRef="U001">3794000</pasg:ResearchAndDevelopmentThirdPartyCosts>
    <pasg:ResearchAndDevelopmentShareBasedCompensation
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_88b71e25afe042a8960f21aa2397edb2"
      unitRef="U001">142000</pasg:ResearchAndDevelopmentShareBasedCompensation>
    <pasg:ResearchAndDevelopmentShareBasedCompensation
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_9c8338005f004ae7b218924f44f645b5"
      unitRef="U001">244000</pasg:ResearchAndDevelopmentShareBasedCompensation>
    <pasg:ResearchAndDevelopmentDepreciationAndAmortization
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_fca85ae1cf264f5fabf87ee2a2d8d07b"
      unitRef="U001">61000</pasg:ResearchAndDevelopmentDepreciationAndAmortization>
    <pasg:ResearchAndDevelopmentDepreciationAndAmortization
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_3cf0fa17fae04539a7c908b689ab5687"
      unitRef="U001">110000</pasg:ResearchAndDevelopmentDepreciationAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_2fd3ed61081743b98a47fa54afd70657"
      unitRef="U001">4093000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_5dea6130f5b14247a20b8146ed7566a8"
      unitRef="U001">7737000</us-gaap:ResearchAndDevelopmentExpense>
    <pasg:GeneralAndAdministrativeLaborAndRelatedExpenses
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_32df42db8ac24025a09c7efafe972bbb"
      unitRef="U001">1891000</pasg:GeneralAndAdministrativeLaborAndRelatedExpenses>
    <pasg:GeneralAndAdministrativeLaborAndRelatedExpenses
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_a40c9f42fbc143f7b2d2639b41de1fd5"
      unitRef="U001">2790000</pasg:GeneralAndAdministrativeLaborAndRelatedExpenses>
    <pasg:GeneralAndAdministrativeThirdPartyCosts
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_d5ccbb0d01764bc79b955410e38a5183"
      unitRef="U001">2415000</pasg:GeneralAndAdministrativeThirdPartyCosts>
    <pasg:GeneralAndAdministrativeThirdPartyCosts
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_0ab2dd98645142f9bc0c5c3aff8ee60a"
      unitRef="U001">2603000</pasg:GeneralAndAdministrativeThirdPartyCosts>
    <pasg:GeneralAndAdministrativeShareBasedCompensation
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_448b761a506d469a927d27e0bb0b5a72"
      unitRef="U001">414000</pasg:GeneralAndAdministrativeShareBasedCompensation>
    <pasg:GeneralAndAdministrativeShareBasedCompensation
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_ba029c30b0b442f7b7cabe770196280b"
      unitRef="U001">614000</pasg:GeneralAndAdministrativeShareBasedCompensation>
    <pasg:GeneralAndAdministrativeDepreciationAndAmortization
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_bb4af7102c284069b880326d7e082044"
      unitRef="U001">67000</pasg:GeneralAndAdministrativeDepreciationAndAmortization>
    <pasg:GeneralAndAdministrativeDepreciationAndAmortization
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_f33ad63c13f54e23ba65542c3ef97fb7"
      unitRef="U001">78000</pasg:GeneralAndAdministrativeDepreciationAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_faefffcf7db94fb88ebbaa377b65707b"
      unitRef="U001">4787000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_65818292169d4f8aa9dd143fba695759"
      unitRef="U001">6085000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_c97de7d39c784d0c9fcfddb7d5337d2d"
      unitRef="U001">2637000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_e9465e41853b469a88855d93fdd40ffd"
      unitRef="U001">-633000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_c901f272c7124cf0888e95a7b8aebdf0"
      unitRef="U001">8247000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_e47337846f3e4ebfab6dae21f58abd15"
      unitRef="U001">16459000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_44e02b34bef94b7b9079cb0434a42c71"
      unitRef="U001">-688000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_aaddde2c00a749bba3ceed1c6ff9f724"
      unitRef="U001">-1054000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20260101to20260331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_9bde39fc75ea4532b7d31484d9c3ba31"
      unitRef="U001">7559000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20250101to20250331_StatementBusinessSegmentsAxis_GeneticMedicinesSegmentMember"
      decimals="-3"
      id="Fact_7810d7d4369340ca93681f129b71e5d4"
      unitRef="U001">15405000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20260101to20260331"
      id="Text_bccb8136b6c74517a91af1fb6892a0ce">
&lt;div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;"&gt;13. Subsequent Events &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On April&#160;20, 2026, the Company announced it has initiated a review of
            strategic alternatives to maximize shareholder value. These strategic alternatives may include merger or acquisition transactions, a reverse merger, a sale of assets of the Company, strategic partnerships, licensing opportunities, or other
            potential paths. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On April&#160;28, 2026, in connection with the Company&#x2019;s review of strategic
            alternatives, the Company announced a restructuring of its workforce, or the Restructuring Plan, to decrease operating expenses by reducing the workforce by approximately 75%. The implementation of the Restructuring Plan should be substantially complete in the second and third quarters of 2026. The Company estimates the aggregate severance and related
            costs for the Restructuring Plan will be approximately $3.3 million, which will be recorded primarily in the second quarter of 2026.
            These estimates are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with,
            the Restructuring Plan as well as the Company&#x2019;s review of strategic alternatives. &lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;"&gt;On May 21, 2026, the Company provided written notice to Gemma to terminate
            the Gemma Collaboration Agreement, which termination will become effective in accordance with the terms of the Gemma Collaboration Agreement. Following the effectiveness of the termination, the Company will no longer have any rights to the
            research programs or the options for new CNS indications previously available to it under the Gemma Collaboration Agreement.&lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On May 22, 2026, the Company and the landlord entered into a lease termination
            agreement pursuant to which the 2005 Market Street Lease Agreement was terminated and the Company paid a termination fee of $2.3
            million.&lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On June 23, 2026, the Company delivered written notice to Penn to terminate
            the Penn License Agreement, pursuant to Section 10.2 thereof, solely with respect to the Company&#x2019;s product candidate referred to as PBFT02 for all indications licensed to the Company thereunder for such product candidate, including
            frontotemporal dementia with granulin mutations, or the &lt;span style="font-style: italic; font-weight: bold;"&gt;PBFT02 Termination&lt;/span&gt;. The PBFT02 Termination will become effective on the date that is 90 days following Penn&#x2019;s receipt of the
            notice, after which the Company will no longer have any rights under the Penn License Agreement to develop or commercialize PBFT02. The Penn License Agreement will remain in effect with respect to all non-terminated licensed products.&lt;/div&gt;

&lt;div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;"&gt;On June 23, 2026, the Company delivered written notice to Catalent to
            terminate, pursuant to Section 20.1(b)(ii) thereof, the amended and restated development services and clinical supply agreement, dated November 9, 2023 (one of the Amended Catalent Agreements), in its entirety, effective as of June 23, 2026.
            The Company determined to terminate this agreement in connection with the wind-down of our gene therapy programs and the proposed Merger (as defined below), and the Company was not obligated to pay Catalent any termination fee in connection &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;with the termination.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 24, 2026, the Company entered into
              an Agreement and Plan of Merger and Reorganization, or the Merger Agreement, with Remix Therapeutics, Inc., a Delaware corporation, or Remix, and Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company, or Merger
              Sub. Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Remix, with Remix continuing as a wholly-owned subsidiary of the Company and the surviving
              corporation of the merger. Upon termination of the Merger Agreement under specified circumstances the Company will be required to make a payment to Remix equal to $1.5 million in cash.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; In July 2026, the Pennsylvania Supreme
              Court denied the petition for review with respect to the plaintiff&#x2019;s challenge to the post-trial rulings in favor of Passage Bio, but it agreed to hear the question of whether certain communications between lawyers and the mediator were
              appropriately excluded from evidence at trial under Pennsylvania&#x2019;s mediation privilege. The Pennsylvania Supreme Court timing for this hearing is currently pending.&lt;br/&gt;
            &lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <pasg:RestructuringPlanReductionInWorkforcePercentage
      contextRef="c20260428to20260428_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="2"
      id="Fact_9eb8286cf3d84c4d9c9bab64602e5a63"
      unitRef="U004">0.75</pasg:RestructuringPlanReductionInWorkforcePercentage>
    <pasg:EstimatedSeveranceAndRelatedCosts
      contextRef="c20260428_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_938ee3f34987438b823136167661ab2e"
      unitRef="U001">3300000</pasg:EstimatedSeveranceAndRelatedCosts>
    <pasg:PaymentOfLeaseTerminationFee
      contextRef="c20260522to20260522_PropertyPlantAndEquipmentByTypeAxis_MarketStreetLeaseAgreement2005Member_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_239b7988048f48318dd830e290a2461d"
      unitRef="U001">2300000</pasg:PaymentOfLeaseTerminationFee>
    <pasg:MergerAgreementTerminationPaymentAmount
      contextRef="c20260624to20260624_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_46d381260a5647aa85af78b2f5861409"
      unitRef="U001">1500000</pasg:MergerAgreementTerminationPaymentAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>ny20077915x1_ex107_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2026-07-21</startDate>
            <endDate>2026-07-21</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-21</startDate>
            <endDate>2026-07-21</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-21</startDate>
            <endDate>2026-07-21</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-21</startDate>
            <endDate>2026-07-21</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c0" id="ixv-195">S-4</ffd:SubmissnTp>
    <ffd:FormTp contextRef="c0" id="ixv-196">S-4</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-25">PASSAGE BIO, INC.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c1" id="ixv-197">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c1" id="ixv-198">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c1" id="ixv-77">Common Stock, par value $0.0001 per share</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c1" id="ixv-199">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c1"
      decimals="INF"
      id="ixv-200"
      unitRef="shares">42605021</ffd:AmtSctiesRegd>
    <ffd:MaxAggtOfferingPric contextRef="c1" decimals="INF" id="ixv-201" unitRef="usd">8190.12</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c1" decimals="INF" id="ixv-202" unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c1" decimals="2" id="ixv-203" unitRef="usd">1.14</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c2" id="ixv-204">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c2" id="ixv-205">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c2" id="ixv-92">Warrants to purchase Common Stock</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c2" id="ixv-206">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c2"
      decimals="INF"
      id="ixv-207"
      unitRef="shares">24891</ffd:AmtSctiesRegd>
    <ffd:FeeAmt contextRef="c2" decimals="2" id="ixv-208" unitRef="usd">0</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="c3" id="ixv-209">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c3" id="ixv-210">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c3" id="ixv-109">Options to purchase Common Stock</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c3" id="ixv-211">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="c3"
      decimals="INF"
      id="ixv-212"
      unitRef="shares">3058476</ffd:AmtSctiesRegd>
    <ffd:FeeAmt contextRef="c3" decimals="2" id="ixv-213" unitRef="usd">0</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="c0" decimals="INF" id="ixv-214" unitRef="usd">8190.12</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="c0" decimals="2" id="ixv-215" unitRef="usd">1.14</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="c0" decimals="0" id="ixv-216" unitRef="usd">0</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="c0" decimals="0" id="ixv-217" unitRef="usd">0</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="c0" decimals="2" id="ixv-218" unitRef="usd">1.14</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c1" id="ixv-155">&lt;table style="font-size: 12pt; width:100%;"&gt;&lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%; vertical-align: top; font-size: 10pt;"&gt;(1)&lt;/td&gt;&lt;td style="width: 1%; vertical-align: top; font-size: 10pt;"&gt;(a)&lt;/td&gt;&lt;td style="width: 98%; font-size: 10pt; text-align: left;"&gt;Represents the maximum
number of shares of Common Stock, par value $0.0001 per share (&#x201c;Passage Bio
Common Stock&#x201d;), of Passage Bio, Inc. (&#x201c;Passage Bio&#x201d;), that are expected to be
issued (or become issuable) to securityholders of Remix Therapeutics, Inc. (&#x201c;Remix&#x201d;)
pursuant to the merger and related transactions contemplated by the Agreement
and Plan of Merger, dated as of June&#160;24, 2026 (&#x201c;Merger Agreement&#x201d;), by and
among Passage Bio, Merger Sub, Inc., and Remix, with Remix continuing as a
wholly-owned subsidiary of Passage Bio and the surviving corporation of the
merger. The number of shares of Passage Bio Common Stock to be registered on
this registration statement (&#x201c;Registration Statement&#x201d;) consists of (i) the
estimated number of shares of Passage Bio Common Stock that are expected to be
issued in exchange for shares of Remix Common Stock (the &#x201c;Remix Common Stock&#x201d;)
outstanding immediately prior to the Effective Time (as defined in the Merger
Agreement), including the shares of Remix Common Stock to be issued in the PIPE
Financing, after giving effect to (A) the conversion of all outstanding shares
of Remix preferred stock into shares of Remix Common Stock, (B) the conversion
of the 2025 Convertible Notes (as defined in the Registration Statement) and
the associated warrants into shares of Remix Common Stock, and (C) the
conversion of the 2026 Convertible Notes into shares of Remix Common Stock,
each without taking into account the effect of a reverse stock split of Passage
Bio Common Stock and assuming a maximum pre-split exchange ratio of
approximately 0.1734 shares of Passage Bio Common Stock for each outstanding
share of Remix Common Stock (which is subject to adjustment prior to the
closing of the Merger), and (ii) shares of Passage Bio Common Stock issuable
upon exercise of warrants issued in the merger in exchange for Remix warrants,
without taking into account the effect of a reverse stock split of Passage Bio
Common Stock and assuming a maximum pre-split exchange ratio of approximately
0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix
Common Stock (which is subject to adjustment prior to the closing of the
Merger), and (iii) options to purchase shares of Passage Bio Common Stock in
exchange for options to purchase shares of Remix Common Stock outstanding under
the Remix 2019 Plan, without taking into account the effect of a reverse stock
split of Passage Bio Common Stock and assuming a maximum pre-split exchange
ratio of approximately 0.1734 shares of Passage Bio Common Stock for each
outstanding share of Remix Common Stock (which is subject to adjustment prior
to the closing of the Merger).&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; vertical-align: top;"&gt;(b)&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;Estimated solely for the
purpose of calculating the registration fee under Rule 457(f)(2) under the
Securities Act of 1933, as amended. Remix is a private company, no market
exists for its securities, and Remix has an accumulated capital deficit.
Therefore, the proposed maximum aggregate offering price is calculated based on
an aggregate offering amount equal to one-third of the aggregate par value of
the Remix Common Stock that will be exchanged in the merger.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; vertical-align: top;"&gt;(c)&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;In accordance with Rule 416
under the Securities Act of 1933, as amended, this registration statement shall
be deemed to cover any securities that may from time to time be offered or
issued resulting from forward or reverse stock splits, stock dividends or
similar transactions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c2" id="ixv-171">&lt;table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"&gt; &lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 99%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt; &lt;td style="padding: 0px 0pt; font-size: 10pt;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; (2) &lt;/div&gt; &lt;/td&gt; &lt;td style="padding: 0px 5.4pt; font-size: 10pt; text-align: left;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; Consists of Passage Bio warrants issued in the merger in exchange for Remix warrants, without taking into account the effect of a reverse stock split of Passage Bio Common Stock and assuming a maximum pre-split exchange ratio of approximately 0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix Common Stock (which is subject to adjustment prior to the closing of the Merger). The registration fee with respect to the warrants has been allocated to the underlying shares of Passage Bio Common Stock issuable upon exercise of such Passage Bio warrants, as described in footnote (1). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="c3" id="ixv-181">&lt;table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"&gt; &lt;tr style="height: 0px; font-size: 0px;"&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 99%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt; &lt;td style="padding: 0px 0pt; font-size: 10pt;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; (3) &lt;/div&gt; &lt;/td&gt; &lt;td style="padding: 0px 5.4pt; font-size: 10pt; text-align: left;"&gt; &lt;div style="margin-bottom: 4pt;"&gt; Consists of Passage Bio stock options to purchase shares of Passage Bio Common Stock issued in exchange for Remix stock options to purchase shares of Remix Common Stock, without taking into account the effect of a reverse stock split of Passage Bio Common Stock and assuming a maximum pre-split exchange ratio of approximately 0.1734 shares of Passage Bio Common Stock for each outstanding share of Remix Common Stock (which is subject to adjustment prior to the closing of the Merger). The registration fee with respect to the options to purchase shares of Passage Bio Common Stock has been allocated to the underlying shares of Passage Bio Common Stock issuable upon exercise of such options, as described in footnote (1). &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</ffd:OfferingNote>
    <ffd:CombinedProspectusTableNa contextRef="c0" id="ixv-221">N/A</ffd:CombinedProspectusTableNa>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-222">0001787297</dei:EntityCentralIndexKey>
    <ffd:FeeExhibitTp contextRef="c0" id="ixv-223">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:OffsetTableNa contextRef="c0" id="ixv-224">N/A</ffd:OffsetTableNa>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
